Microstructured O 
, O 
functional O 
PVA B-ABBREVIATION 
hydrogels O 
through O 
bioconjugation O 
with O 
oligopeptides O 
under O 
physiological O 
conditions O 
. O 

this O 
work O 
, O 
bioconjugation O 
techniques O 
are O 
developed O 
to O 
achieve O 
peptide O 
functionalization O 
of O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
PVA B-ABBREVIATION 
, O 
as O 
both O 
a O 
polymer O 
in O 
solution O 
and O 
within O 
microstructured O 
physical O 
hydrogels O 
, O 
in O 
both O 
cases O 
under O 
physiological O 
conditions O 
. O 
PVA B-ABBREVIATION 
is O 
unique O 
in O 
that O 
it O 
is O 
one O 
of O 
very O 
few O 
polymers O 
with O 
excellent O 
biocompatibility O 
and O 
safety O 
and O 
has O 
FDA O 
approval O 
for O 
clinical O 
uses O 
in O 
humans O 
. O 
However O 
, O 
decades O 
of O 
development O 
have O 
documented O 
only O 
scant O 
opportunities O 
in O 
bioconjugation O 
with O 
PVA B-ABBREVIATION 
. O 
As O 
such O 
, O 
materials O 
derived O 
thereof O 
fail O 
to O 
answer O 
the O 
call O 
for O 
functional O 
biomaterials O 
for O 
advanced O 
cell O 
culture O 
and O 
tissue O 
engineering O 
applications O 
. O 
To O 
address O 
these O 
limitations O 
, O 
PVA B-ABBREVIATION 
is O 
synthesized O 
with O 
terminal O 
thiol B-FAMILY 
groups O 
and O 
conjugated O 
with O 
thiolated O 
peptides O 
using O 
PVA B-ABBREVIATION 
in O 
solution O 
. O 
Further O 
, O 
microstructured O 
, O 
surface O 
- O 
adhered O 
PVA B-ABBREVIATION 
physical O 
hydrogels O 
are O 
assembled O 
, O 
the O 
available O 
conjugation O 
sites O 
within O 
the O 
hydrogels O 
are O 
quantified O 
, O 
and O 
quantitative O 
kinetic O 
data O 
are O 
collected O 
on O 
peptide O 
conjugation O 
to O 
the O 
hydrogels O 
. O 
The O 
success O 
of O 
bioconjugation O 
in O 
the O 
gel O 
phase O 
is O 
quantified O 
through O 
the O 
use O 
of O 
a O 
cell O 
- O 
adhesive O 
peptide O 
and O 
visualization O 
of O 
cell O 
adhesion O 
on O 
PVA B-ABBREVIATION 
hydrogels O 
as O 
cell O 
culture O 
substrates O 
. O 
Taken O 
together O 
, O 
the O 
presented O 
data O 
establish O 
a O 
novel O 
paradigm O 
in O 
bioconjugation O 
and O 
functionalization O 
of O 
PVA B-ABBREVIATION 
physical O 
hydrogels O 
. O 
Coupled O 
with O 
an O 
excellent O 
safety O 
profile O 
of O 
PVA B-ABBREVIATION 
, O 
these O 
results O 
deliver O 
a O 
superior O 
biomaterial O 
for O 
diverse O 
biomedical O 
applications O 
. O 

1 O 
. O 
Organic O 
anion O 
transporting O 
polypeptides O 
( O 
OATPs O 
) O 
are O 
a O 
family O 
of O 
transporter O 
proteins O 
that O 
have O 
been O 
extensively O 
recognized O 
as O 
key O 
determinants O 
of O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
and O 
excretion O 
of O 
various O 
drugs O 
. O 
Human O 
OATP1A2 O 
has O 
been O 
demonstrated O 
to O 
transport O 
wide O 
spectrum O 
of O 
endogenous O 
and O 
exogenous O 
compounds O 
. O 
Study O 
on O 
OATP1A2 O 
orthologues O 
of O 
other O 
species O 
, O 
however O 
, O 
is O 
still O 
limited O 
. O 
2 O 
. O 
Here O 
, O 
we O 
described O 
the O 
cloning O 
and O 
functional O 
characterization O 
of O 
a O 
member O 
of O 
the O 
OATP O 
/ O 
Oatp O 
family O 
member O 
obtained O 
from O 
pig O 
( O 
Sus O 
scrofa O 
) O 
liver O 
. O 
Sequence O 
analysis O 
suggested O 
that O 
it O 
has O 
a O 
high O 
homology O 
with O 
human O 
OATP1A2 O 
and O 
bovine O 
Oatp1a2 O 
. O 
Prototypic O 
substrates O 
estrone-3-sulfate B-SYSTEMATIC 
( O 
E-3-S B-SYSTEMATIC 
) O 
and O 
taurocholic B-TRIVIAL 
acid I-TRIVIAL 
were O 
transported O 
by O 
the O 
protein O 
. O 
The O 
transport O 
of O 
these O 
two O 
substrates O 
is O 
pH-dependent O 
, O 
with O 
lower O 
pH O 
showing O 
higher O 
uptake O 
function O 
. O 
Kinetic O 
study O 
showed O 
the O 
transport O 
of O 
these O 
two O 
substrates O 
have O 
a O 
K(m) O 
of O 
42.5 O 
± O 
12.1 O 
and O 
33.1 O 
± O 
8.7 O 
µM O 
, O 
respectively O 
. O 
Pig O 
Slco1a2 O 
has O 
the O 
highest O 
expression O 
level O 
in O 
the O 
liver O 
, O 
and O 
to O 
a O 
less O 
extend O 
in O 
the O 
brain O 
and O 
small O 
intestine O 
. O 
3 O 
. O 
In O 
conclusion O 
, O 
an O 
OATP O 
member O 
was O 
cloned O 
from O 
pig O 
liver O 
. O 
Sequence O 
analysis O 
and O 
phylogenic O 
study O 
revealed O 
it O 
as O 
an O 
orthologue O 
of O 
human O 
OATP1A2 O 
. O 
Its O 
kinetic O 
characteristic O 
for O 
prototypic O 
substrates O 
and O 
organ O 
distribution O 
are O 
similar O 
with O 
that O 
of O 
OATP1A2 O 
. O 

1 O 
( O 
MUC1 O 
) O 
is O 
a O 
heterodimeric O 
protein O 
formed O 
by O 
two O 
subunits O 
that O 
is O 
aberrantly O 
overexpressed O 
in O 
human O 
breast O 
cancer O 
and O 
other O 
cancers O 
. O 
Historically O 
, O 
much O 
of O 
the O 
early O 
work O 
on O 
MUC1 O 
focused O 
on O 
the O 
shed O 
mucin O 
subunit O 
. O 
However O 
, O 
more O 
recent O 
studies O 
have O 
been O 
directed O 
at O 
the O 
transmembrane O 
MUC1-C O 
- O 
terminal O 
subunit O 
( O 
MUC1-C O 
) O 
that O 
functions O 
as O 
an O 
oncoprotein O 
. O 
MUC1-C O 
interacts O 
with O 
EGFR O 
( O 
epidermal O 
growth O 
factor O 
receptor O 
) O 
, O 
ErbB2 O 
and O 
other O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
at O 
the O 
cell O 
membrane O 
and O 
contributes O 
to O 
activation O 
of O 
the O 
PI3KAKT O 
and O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
kinase O 
(MEK)extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
pathways O 
. O 
MUC1-C O 
also O 
localizes O 
to O 
the O 
nucleus O 
where O 
it O 
activates O 
the O 
Wnt O 
/ O 
β-catenin O 
, O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
( O 
STAT O 
) O 
and O 
NF O 
( O 
nuclear O 
factor)-κB O 
RelA O 
pathways O 
. O 
These O 
findings O 
and O 
the O 
demonstration O 
that O 
MUC1-C O 
is O 
a O 
druggable O 
target O 
have O 
provided O 
the O 
experimental O 
basis O 
for O 
designing O 
agents O 
that O 
block O 
MUC1-C O 
function O 
. O 
Notably O 
, O 
inhibitors O 
of O 
the O 
MUC1-C O 
subunit O 
have O 
been O 
developed O 
that O 
directly O 
block O 
its O 
oncogenic O 
function O 
and O 
induce O 
death O 
of O 
breast O 
cancer O 
cells O 
in O 
vitro O 
and O 
in O 
xenograft O 
models O 
. O 
On O 
the O 
basis O 
of O 
these O 
findings O 
, O 
a O 
first O 
- O 
in O 
- O 
class O 
MUC1-C O 
inhibitor O 
has O 
entered O 
phase O 
I O 
evaluation O 
as O 
a O 
potential O 
agent O 
for O 
the O 
treatment O 
of O 
patients O 
with O 
breast O 
cancers O 
who O 
express O 
this O 
oncoprotein O 
. O 

- O 
dependent O 
interaction O 
of O 
DOPC B-ABBREVIATION 
liposomes O 
with O 
an O 
octadecanol B-SYSTEMATIC 
-covered O 
Au(111) B-FORMULA 
surface O 
investigated O 
using O 
electrochemical O 
methods O 
coupled O 
with O 
in O 
situ O 
fluorescence O 
microscopy O 
. O 

potential O 
- O 
controlled O 
incorporation O 
of O 
DOPC B-ABBREVIATION 
liposomes O 
( O 
100 O 
nm O 
diameter O 
) O 
into O 
an O 
adsorbed O 
octadecanol B-SYSTEMATIC 
layer O 
on O 
Au(111) B-FORMULA 
was O 
studied O 
using O 
electrochemical O 
and O 
in O 
situ O 
fluorescence O 
microscopy O 
. O 
The O 
adsorbed O 
layer O 
of O 
octadecanol B-SYSTEMATIC 
included O 
a O 
small O 
amount O 
of O 
a O 
lipophilic O 
fluorophore- O 
octadecanol B-SYSTEMATIC 
modified O 
with O 
BODIPY B-ABBREVIATION 
-to O 
enable O 
fluorescence O 
imaging O 
. O 
The O 
deposited O 
octadecanol B-SYSTEMATIC 
layer O 
was O 
found O 
not O 
to O 
allow O 
liposomes O 
to O 
interact O 
unless O 
the O 
potential O 
was O 
less O 
than O 
-0.4 O 
V O 
/ O 
SCE O 
, O 
which O 
introduces O 
defects O 
into O 
the O 
adsorbed O 
layer O 
. O 
Small O 
increases O 
in O 
the O 
capacitance O 
of O 
the O 
adsorbed O 
layer O 
were O 
measured O 
after O 
introducing O 
the O 
defects O 
, O 
allowing O 
the O 
liposomes O 
to O 
interact O 
with O 
the O 
defects O 
and O 
then O 
annealing O 
the O 
defects O 
at O 
0 O 
V O 
/ O 
SCE O 
. O 
A O 
change O 
in O 
the O 
adsorbed O 
layer O 
was O 
also O 
signified O 
by O 
a O 
more O 
positive O 
desorption O 
potential O 
for O 
the O 
liposome O 
- O 
modified O 
adsorbed O 
layer O 
as O 
compared O 
to O 
that O 
for O 
an O 
adsorbed O 
layer O 
that O 
was O 
porated O 
in O 
a O 
similar O 
fashion O 
but O 
without O 
liposomes O 
present O 
in O 
the O 
electrolyte O 
. O 
These O 
subtle O 
changes O 
in O 
capacitance O 
are O 
difficult O 
to O 
interpret O 
, O 
so O 
an O 
in O 
situ O 
spectroscopic O 
study O 
was O 
performed O 
to O 
provide O 
a O 
more O 
direct O 
measure O 
of O 
the O 
interaction O 
. O 
The O 
incorporation O 
of O 
liposomes O 
should O 
result O 
in O 
an O 
increase O 
in O 
the O 
fluorescence O 
measured O 
because O 
the O 
fluorophore O 
should O 
become O 
further O 
separated O 
from O 
the O 
gold O 
surface O 
, O 
reducing O 
the O 
efficiency O 
of O 
fluorescence O 
quenching O 
. O 
No O 
significant O 
increase O 
in O 
the O 
fluorescence O 
of O 
the O 
adsorbed O 
layer O 
was O 
observed O 
during O 
the O 
potential O 
pulses O 
used O 
in O 
the O 
poration O 
procedure O 
in O 
the O 
absence O 
of O 
liposomes O 
. O 
In O 
the O 
presence O 
of O 
liposomes O 
, O 
the O 
fluorescence O 
intensity O 
was O 
found O 
to O 
depend O 
on O 
the O 
potential O 
and O 
time O 
used O 
for O 
poration O 
. O 
At O 
0 O 
V O 
/ O 
SCE O 
, O 
no O 
significant O 
change O 
in O 
the O 
fluorescence O 
was O 
observed O 
for O 
defect O 
- O 
free O 
adsorbed O 
layers O 
. O 
Changing O 
the O 
poration O 
potential O 
to O 
-0.4 O 
V O 
/ O 
SCE O 
caused O 
significant O 
increases O 
in O 
the O 
fluorescence O 
and O 
the O 
appearance O 
of O 
new O 
structural O 
features O 
in O 
the O 
adsorbed O 
layers O 
that O 
were O 
more O 
easily O 
observed O 
during O 
the O 
desorption O 
procedure O 
. O 
The O 
extent O 
of O 
fluorescence O 
changes O 
was O 
found O 
to O 
be O 
strongly O 
dependent O 
on O 
the O 
nature O 
of O 
the O 
adsorbed O 
layer O 
under O 
investigation O 
, O 
which O 
suggests O 
that O 
the O 
poration O 
and O 
liposome O 
interaction O 
are O 
dependent O 
on O 
the O 
quality O 
of O 
the O 
adsorbed O 
layer O 
and O 
its O 
ease O 
of O 
poration O 
through O 
changes O 
in O 
the O 
electrode O 
potential O 
. O 

metabolites O 
, O 
but O 
not O 
other O 
phenolics B-FAMILY 
derived O 
from O 
grape O 
seed O 
phenolic O 
extract O 
, O 
are O 
transported O 
through O 
differentiated O 
Caco-2 O 
cell O 
monolayers O 
. O 

seed O 
phenolic O 
extract O 
( O 
GSE O 
) O 
is O 
predicted O 
to O 
have O 
health O 
benefits O 
, O 
even O 
though O 
its O 
bioavailability O 
, O 
including O 
digestibility O 
, O 
permeability O 
and O 
ultimate O 
metabolism O 
, O 
are O 
still O 
poorly O 
understood O 
. O 
In O 
vitro O 
gastric O 
and O 
pancreatic O 
digestion O 
and O 
in O 
vitro O 
ileal O 
and O 
faecal O 
fermentation O 
were O 
combined O 
with O 
Caco-2 O 
cell O 
permeability O 
studies O 
for O 
GSE O 
samples O 
. O 
Qualitatively O 
, O 
there O 
was O 
no O 
change O 
in O 
type O 
/ O 
number O 
of O 
GSE O 
compounds O 
following O 
gastric O 
and O 
pancreatic O 
digestion O 
and O 
LC-MS O 
analysis O 
. O 
However O 
, O 
the O 
monomers O 
were O 
significantly O 
( O 
P O 
< O 
0.05 O 
) O 
increased O 
after O 
gastric O 
digestion O 
, O 
along O 
with O 
a O 
significant O 
( O 
P O 
< O 
0.05 O 
) O 
decrease O 
in O 
polymers O 
. O 
In O 
addition O 
, O 
all O 
forms O 
of O 
phenolic B-FAMILY 
compounds O 
decreased O 
following O 
pancreatic O 
digestion O 
. O 
However O 
, O 
none O 
of O 
the O 
original O 
GSE O 
phenolic B-FAMILY 
compounds O 
passed O 
the O 
Caco-2 O 
cell O 
monolayer O 
, O 
since O 
all O 
were O 
recovered O 
in O 
the O 
apical O 
compartment O 
. O 
In O 
contrast O 
, O 
the O 
two O 
intestinal O 
microbiota O 
metabolites O 
with O 
deprotonated O 
molecular O 
weights O 
of O 
[M-H]-165 O 
/ O 
121 O 
and O 
193 O 
/ O 
175 O 
, O 
that O 
were O 
found O 
both O 
in O 
the O 
ileal O 
and O 
faecal O 
fermented O 
samples O 
, O 
passed O 
the O 
Caco-2 O 
cell O 
monolayer O 
. O 

Reticulatae O 
Pericarpium O 
( O 
CRP O 
) O 
is O 
one O 
of O 
the O 
most O 
commonly O 
used O 
traditional O 
Chinese O 
medicines O 
with O 
great O 
medicinal O 
and O 
dietary O 
values O 
. O 
In O 
this O 
work O 
, O 
we O 
developed O 
an O 
approach O 
utilising O 
rapid O 
resolution O 
liquid O 
chromatography O 
/ O 
electrospray O 
ionisation O 
tandem O 
mass O 
spectrometry O 
( O 
RRLC-ESI-MS O 
/ O 
MS O 
) O 
for O 
the O 
identification O 
and O 
profiling O 
of O 
chemical O 
composition O 
in O 
CRP O 
. O 
On O 
the O 
basis O 
of O 
RRLC O 
retention O 
times O 
, O 
cochromatography O 
with O 
available O 
authentic O 
standards O 
, O 
mass O 
spectral O 
fragmentation O 
patterns O 
and O 
literature O 
information O 
, O 
a O 
total O 
of O 
41 O 
chemical O 
compounds O 
, O 
including O 
4 O 
flavone-C-glycosides B-FAMILY 
, O 
7 O 
flavonoid-O-glycosides B-FAMILY 
and O 
19 O 
polymethoxyflavones B-FAMILY 
were O 
unambiguously O 
identified O 
or O 
tentatively O 
characterised O 
in O 
CRP O 
. O 
The O 
occurrence O 
of O 
1 O 
flavone-C-glycoside B-FAMILY 
and O 
3 O 
cyclic O 
peptides O 
in O 
particular O 
has O 
not O 
yet O 
been O 
described O 
. O 
The O 
results O 
indicated O 
that O 
the O 
developed O 
method O 
could O 
serve O 
as O 
a O 
rapid O 
, O 
effective O 
tool O 
for O 
structural O 
characterisation O 
of O 
chemical O 
constituents O 
in O 
CRP O 
. O 

surface O 
properties O 
of O 
commercial O 
crystalline O 
telmisartan B-TRIVIAL 
samples O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
differences O 
in O 
surface O 
chemistry O 
of O 
commercially O 
available O 
telmisartan B-TRIVIAL 
( O 
TMS B-ABBREVIATION 
) O 
samples O 
in O 
Indian O 
market O 
and O 
to O 
correlate O 
them O 
to O 
the O 
surface O 
molecular O 
environment O 
. O 
Comprehensive O 
characterization O 
of O 
material O 
properties O 
of O 
four O 
TMS B-ABBREVIATION 
samples O 
from O 
different O 
sources O 
showed O 
that O 
all O 
samples O 
exhibited O 
same O 
polymorphic O 
form O 
, O 
but O 
different O 
particle O 
shape O 
, O 
particle O 
size O 
distribution O 
, O 
surface O 
energetics O 
and O 
surface O 
chemistry O 
. O 
Wettability O 
and O 
surface O 
free O 
energy O 
were O 
determined O 
using O 
sessile O 
drop O 
contact O 
angle O 
technique O 
. O 
TMS B-ABBREVIATION 
samples O 
exhibited O 
significant O 
variations O 
in O 
their O 
wetting O 
behavior O 
. O 
The O 
role O 
of O 
crystal O 
shape O 
, O 
particle O 
size O 
distribution O 
, O 
surface O 
energetics O 
and O 
surface O 
chemistry O 
in O 
controlling O 
TMS B-ABBREVIATION 
powder O 
wettability O 
was O 
collectively O 
explored O 
by O 
contact O 
angle O 
experiments O 
. O 
Evaluation O 
of O 
work O 
of O 
adhesion O 
( O 
Wa O 
) O 
, O 
immersion O 
( O 
Wi O 
) O 
and O 
spreading O 
( O 
Ws O 
) O 
indicated O 
that O 
samples O 
had O 
differential O 
wetting O 
behavior O 
. O 
The O 
surface O 
chemistry O 
was O 
elucidated O 
by O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
. O 
The O 
surface O 
polarity O 
index O 
was O 
determined O 
by O 
XPS O 
and O 
expressed O 
as O 
( O 
oxygen B-SYSTEMATIC 
+ O 
nitrogen B-SYSTEMATIC 
)-to-( O 
carbon B-SYSTEMATIC 
) O 
atomic O 
concentration O 
ratio O 
. O 
It O 
was O 
found O 
to O 
be O 
different O 
for O 
all O 
four O 
TMS B-ABBREVIATION 
samples O 
. O 
Crystal O 
morphology O 
of O 
TMS B-ABBREVIATION 
polymorph O 
A O 
was O 
predicted O 
using O 
Bravais-Friedel O 
Donnay-Harker O 
( O 
BFDH O 
) O 
method O 
. O 
Molecular O 
lipophilic O 
surface O 
potential O 
( O 
MLSP O 
) O 
data O 
for O 
TMS B-ABBREVIATION 
showed O 
the O 
varied O 
surface O 
lipophilic O 
environment O 
throughout O 
the O 
molecule O 
. O 
Hence O 
it O 
can O 
be O 
concluded O 
that O 
the O 
differential O 
abundance O 
of O 
surface O 
elements O 
play O 
an O 
important O 
role O 
in O 
controlling O 
the O 
biopharmaceutical O 
performance O 
of O 
TMS B-ABBREVIATION 
powder O 
samples O 
. O 

pyrazole B-SYSTEMATIC 
derivatives O 
containing O 
1,2,4-triazoles B-FAMILY 
and O 
benzoxazoles B-FAMILY 
as O 
potent O 
antimicrobial O 
and O 
analgesic O 
agents O 
. O 

class O 
of O 
compounds O 
are O 
well O 
known O 
for O 
their O 
excellent O 
therapeutic O 
properties O 
. O 
Present O 
paper O 
describes O 
about O 
the O 
synthesis O 
of O 
three O 
series O 
of O 
new O 
1,2,4-triazole B-SYSTEMATIC 
and O 
benzoxazole B-SYSTEMATIC 
derivatives O 
containing O 
substituted O 
pyrazole B-SYSTEMATIC 
moiety O 
( O 
11a-d O 
, O 
12a-d O 
and O 
13a-d O 
) O 
. O 
The O 
newly O 
synthesized O 
compounds O 
were O 
characterized O 
by O 
spectral O 
studies O 
and O 
also O 
by O 
C B-FORMULA 
, O 
H B-FORMULA 
, O 
N B-FORMULA 
analyses O 
. O 
All O 
the O 
synthesized O 
compounds O 
were O 
screened O 
for O 
their O 
analgesic O 
activity O 
by O 
the O 
tail O 
flick O 
method O 
. O 
The O 
antimicrobial O 
activity O 
of O 
the O 
new O 
derivatives O 
was O 
also O 
performed O 
by O 
Minimum O 
Inhibitory O 
Concentration O 
( O 
MIC O 
) O 
by O 
the O 
serial O 
dilution O 
method O 
. O 
The O 
results O 
revealed O 
that O 
the O 
compound O 
11c O 
having O 
2,5-dichlorothiophene B-SYSTEMATIC 
substituent O 
on O 
pyrazole B-SYSTEMATIC 
moiety O 
and O 
a O 
triazole B-FAMILY 
ring O 
showed O 
significant O 
analgesic O 
and O 
antimicrobial O 
activity O 
. O 

mechanisms O 
underlying O 
the O 
response O 
of O 
embryonic O 
cells O 
to O 
Doxorubicin B-TRIVIAL 
. O 

involvement O 
of O 
NF-κB O 
in O 
the O 
regulation O 
of O 
teratogen O 
- O 
induced O 
apoptosis O 
has O 
not O 
been O 
established O 
yet O 
. O 
Therefore O 
, O 
we O 
tried O 
to O 
assess O 
the O 
involvement O 
of O 
the O 
p65 O 
subunit O 
of O 
NF-κB O 
in O 
the O 
embryonic O 
response O 
to O 
the O 
anti-cancer O 
drug O 
Doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
. O 
Thus O 
, O 
exposure O 
of O 
p65 O 
knockout O 
( O 
p65(- O 
/ O 
- O 
) O 
) O 
or O 
wild O 
type O 
( O 
WT O 
) O 
mouse O 
embryonic O 
fibroblasts O 
( O 
MEFs O 
) O 
to O 
DOX B-ABBREVIATION 
resulted O 
in O 
a O 
decrease O 
in O 
cell O 
survival O 
, O 
culture O 
density O 
and O 
cell O 
proliferation O 
, O 
which O 
was O 
found O 
to O 
be O 
more O 
prominent O 
in O 
p65(- O 
/ O 
- O 
) O 
MEFs O 
. O 
Those O 
phenomena O 
were O 
accompanied O 
by O 
a O 
DOX B-ABBREVIATION 
-induced O 
increase O 
in O 
the O 
proportion O 
of O 
apoptotic O 
cells O 
, O 
which O 
was O 
demonstrated O 
only O 
in O 
p65(- O 
/ O 
- O 
) O 
cells O 
and O 
a O 
G2 O 
/ O 
M O 
arrest O 
, O 
which O 
was O 
found O 
to O 
be O 
more O 
prominent O 
in O 
WT O 
cells O 
. O 
Furthermore O 
, O 
DOX B-ABBREVIATION 
-treated O 
WT O 
and O 
p65(- O 
/ O 
- O 
) O 
MEFs O 
differed O 
in O 
their O 
expression O 
of O 
various O 
apoptosis O 
- O 
associated O 
molecules O 
, O 
when O 
the O 
former O 
demonstrated O 
a O 
decrease O 
in O 
the O 
percentage O 
of O 
p65-positive O 
and O 
a O 
more O 
prominent O 
decrease O 
in O 
the O 
percentage O 
of O 
p53-positive O 
cells O 
, O 
while O 
a O 
decreased O 
percentage O 
of O 
IκBα-positive O 
and O 
a O 
more O 
prominent O 
decrease O 
in O 
the O 
percentage O 
of O 
bcl-2-positive O 
cells O 
was O 
detected O 
among O 
the O 
latter O 
. O 
The O 
fact O 
that O 
the O 
response O 
of O 
the O 
cells O 
to O 
the O 
teratogen O 
was O 
clearly O 
p65-dependent O 
implicates O 
this O 
molecule O 
to O 
be O 
involved O 
in O 
the O 
response O 
of O 
the O 
embryonic O 
cells O 
to O 
DOX B-ABBREVIATION 
. O 

of O 
nitrogen B-SYSTEMATIC 
supply O 
on O 
the O 
production O 
of O 
higher O 
alcohols B-FAMILY 
/ O 
esters B-FAMILY 
and O 
expression O 
of O 
flavour O 
- O 
related O 
genes O 
in O 
cachaça O 
fermentation O 
. O 

study O 
provides O 
the O 
first O 
attempt O 
to O 
analyse O 
the O 
influence O 
of O 
ammonium B-SYSTEMATIC 
supplements O 
on O 
sugar B-FAMILY 
-cane O 
juice O 
fermentation O 
and O 
the O 
flavour O 
profile O 
in O 
a O 
cachaça O 
industrial O 
process O 
. O 
The O 
objective O 
was O 
to O 
find O 
a O 
relationship O 
between O 
higher O 
alcohol B-FAMILY 
/ O 
ester B-FAMILY 
content O 
and O 
the O 
transcription O 
levels O 
of O 
the O 
main O 
genes O 
involved O 
in O 
production O 
of O 
these O 
compounds O 
under O 
cachaça O 
fermentation O 
. O 
Sugar B-FAMILY 
-cane O 
juice O 
with O 
a O 
low O 
amount O 
of O 
assimilable O 
nitrogen B-SYSTEMATIC 
( O 
81 O 
mg O 
N O 
/ O 
L O 
) O 
, O 
was O 
further O 
supplemented O 
with O 
mid O 
- O 
range O 
or O 
high O 
concentrations O 
of O 
ammonium B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
. O 
Overall O 
, O 
higher O 
alcohol B-FAMILY 
production O 
was O 
reduced O 
by O 
ammonium B-SYSTEMATIC 
supplementation O 
, O 
and O 
this O 
can O 
be O 
correlated O 
with O 
a O 
general O 
downregulation O 
of O 
genes O 
encoding O 
decarboxylases O 
and O 
dehydrogenases O 
of O 
the O 
Ehrlich O 
pathway O 
. O 
The O 
production O 
of O 
acetate B-FAMILY 
esters I-FAMILY 
was O 
enhanced O 
by O 
mid O 
- O 
range O 
ammonium B-SYSTEMATIC 
supplementation O 
and O 
the O 
production O 
of O 
acyl B-FAMILY 
esters I-FAMILY 
by O 
high O 
ammonium B-SYSTEMATIC 
supplementation O 
. O 
The O 
acyl B-FAMILY 
esters I-FAMILY 
could O 
be O 
correlated O 
with O 
expression O 
of O 
alcohol B-FAMILY 
acyl B-FAMILY 
-transferase O 
EEB1 O 
and O 
the O 
acyl B-FAMILY 
esterase O 
IAH1 O 
. O 

alcohol B-FAMILY 
dehydrogenases O 
make O 
yeast O 
fitter O 
for O 
growth O 
in O 
the O 
presence O 
of O 
allyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
. O 

studies O 
showed O 
that O 
fitter O 
yeast O 
( O 
Saccharomyces O 
cerevisiae O 
) O 
that O 
can O 
grow O 
by O 
fermenting O 
glucose B-TRIVIAL 
in O 
the O 
presence O 
of O 
allyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
, O 
which O 
is O 
oxidized O 
by O 
alcohol B-FAMILY 
dehydrogenase O 
I O 
( O 
ADH1 O 
) O 
to O 
toxic O 
acrolein B-TRIVIAL 
, O 
had O 
mutations O 
in O 
the O 
ADH1 O 
gene O 
that O 
led O 
to O 
decreased O 
ADH O 
activity O 
. O 
These O 
yeast O 
may O 
grow O 
more O 
slowly O 
due O 
to O 
slower O 
reduction O 
of O 
acetaldehyde B-SYSTEMATIC 
and O 
a O 
higher O 
NADH B-ABBREVIATION 
/ O 
NAD(+) B-ABBREVIATION 
ratio O 
, O 
which O 
should O 
decrease O 
the O 
oxidation O 
of O 
allyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
. O 
We O 
determined O 
steady O 
- O 
state O 
kinetic O 
constants O 
for O 
three O 
yeast O 
ADHs O 
with O 
new O 
site O 
- O 
directed O 
substitutions O 
and O 
examined O 
the O 
correlation O 
between O 
catalytic O 
efficiency O 
and O 
growth O 
on O 
selective O 
media O 
of O 
yeast O 
expressing O 
six O 
different O 
ADHs O 
. O 
The O 
H15R O 
substitution O 
( O 
a O 
test O 
for O 
electrostatic O 
effects O 
) O 
is O 
on O 
the O 
surface O 
of O 
ADH O 
and O 
has O 
small O 
effects O 
on O 
the O 
kinetics O 
. O 
The O 
H44R O 
substitution O 
( O 
affecting O 
interactions O 
with O 
the O 
coenzyme O 
pyrophosphate B-SYSTEMATIC 
) O 
was O 
previously O 
shown O 
to O 
decrease O 
affinity O 
for O 
coenzymes O 
2-4-fold O 
and O 
turnover O 
numbers O 
( O 
V O 
/ O 
Et O 
) O 
by O 
4-6-fold O 
. O 
The O 
W82R O 
substitution O 
is O 
distant O 
from O 
the O 
active O 
site O 
, O 
but O 
decreases O 
turnover O 
numbers O 
by O 
5-6-fold O 
, O 
perhaps O 
by O 
effects O 
on O 
protein O 
dynamics O 
. O 
The O 
E67Q O 
substitution O 
near O 
the O 
catalytic O 
zinc B-SYSTEMATIC 
was O 
shown O 
previously O 
to O 
increase O 
the O 
Michaelis O 
constant O 
for O 
acetaldehyde B-SYSTEMATIC 
and O 
to O 
decrease O 
turnover O 
for O 
ethanol B-SYSTEMATIC 
oxidation O 
. O 
The O 
W54R O 
substitution O 
, O 
in O 
the O 
substrate O 
binding O 
site O 
, O 
increases O 
kinetic O 
constants O 
( O 
Ks O 
, O 
by O 
> O 
10-fold O 
) O 
while O 
decreasing O 
turnover O 
numbers O 
by O 
2-7-fold O 
. O 
Growth O 
of O 
yeast O 
expressing O 
the O 
different O 
ADHs O 
on O 
YPD O 
plates O 
( O 
yeast O 
extract O 
, O 
peptone O 
and O 
dextrose B-TRIVIAL 
) O 
plus O 
antimycin B-FAMILY 
to O 
require O 
fermentation O 
, O 
was O 
positively O 
correlated O 
with O 
the O 
log O 
of O 
catalytic O 
efficiency O 
for O 
the O 
sequential O 
bi O 
reaction O 
( O 
V1 O 
/ O 
KiaKb=KeqV2 O 
/ O 
KpKiq O 
, O 
varying O 
over O 
4 O 
orders O 
of O 
magnitude O 
, O 
adjusted O 
for O 
different O 
levels O 
of O 
ADH O 
expression O 
) O 
in O 
the O 
order O 
: O 
WT≈H15R O 
> O 
H44R O 
> O 
W82R O 
> O 
E67Q O 
> O 
W54R O 
. O 
Growth O 
on O 
YPD O 
plus O 
10mM O 
allyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
was O 
inversely O 
correlated O 
with O 
catalytic O 
efficiency O 
. O 
The O 
fitter O 
yeast O 
are O 
" O 
bradytrophs O 
" O 
( O 
slow O 
growing O 
) O 
because O 
the O 
ADHs O 
have O 
decreased O 
catalytic O 
efficiency O 
. O 

of O 
sulforaphane B-TRIVIAL 
for O 
topical O 
formulation O 
. O 

Context O 
: O 
Sulforaphane B-TRIVIAL 
( O 
SFN B-ABBREVIATION 
) O 
is O 
a O 
natural O 
compound O 
that O 
has O 
been O 
investigated O 
as O 
a O 
chemopreventive O 
agent O 
. O 
SFN B-ABBREVIATION 
has O 
been O 
shown O 
to O 
inhibit O 
the O 
activator O 
- O 
protein-1 O 
( O 
AP-1 O 
) O 
transcription O 
factor O 
and O 
may O 
be O 
effective O 
for O 
inhibition O 
of O 
ultraviolet O 
( O 
UV O 
) O 
induced O 
skin O 
carcinogenesis O 
. O 
This O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
stability O 
of O 
SFN B-ABBREVIATION 
as O 
a O 
function O 
of O 
pH O 
, O 
temperature O 
and O 
in O 
various O 
solvents O 
and O 
formulations O 
. O 
Materials O 
and O 
methods O 
: O 
Stability O 
was O 
analyzed O 
using O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 
A O 
potential O 
lead O 
formulation O 
was O 
identified O 
and O 
evaluated O 
in O 
vivo O 
. O 
Results O 
: O 
SFN B-ABBREVIATION 
was O 
determined O 
to O 
undergo O 
apparent O 
first O 
- O 
order O 
degradation O 
kinetics O 
for O 
the O 
conditions O 
explored O 
. O 
It O 
was O 
observed O 
that O 
SFN B-ABBREVIATION 
undergoes O 
base O 
catalyzed O 
degradation O 
. O 
Buffer O 
species O 
and O 
solvent O 
type O 
impacts O 
stability O 
as O 
well O 
. O 
SFN B-ABBREVIATION 
was O 
found O 
to O 
be O 
very O 
sensitive O 
to O 
temperature O 
with O 
degradation O 
rate O 
changing O 
by O 
a O 
factor O 
of O 
nearly O 
3.1 O 
for O 
every O 
10 O 
°C O 
change O 
in O 
temperature O 
( O 
at O 
pH O 
4 O 
) O 
. O 
SFN B-ABBREVIATION 
completely O 
degraded O 
after O 
30 O 
days O 
in O 
a O 
conventional O 
pharmaceutical O 
cream O 
formulation O 
. O 
Improved O 
stability O 
was O 
observed O 
in O 
organic O 
formulation O 
components O 
. O 
Stability O 
studies O 
were O 
conducted O 
on O 
two O 
nonaqueous O 
topical O 
formulations O 
: O 
a O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
ointment O 
base O 
and O 
an O 
organic O 
oleaginous O 
base O 
. O 
Conclusion O 
: O 
Topically O 
applied O 
SFN B-ABBREVIATION 
in O 
the O 
PEG B-ABBREVIATION 
base O 
formulation O 
significantly O 
reduced O 
AP-1 O 
activation O 
after O 
UV O 
stimulation O 
in O 
the O 
skin O 
of O 
a O 
transgenic O 
mouse O 
model O 
, O 
indicating O 
that O 
SFN B-ABBREVIATION 
in O 
this O 
formulation O 
retains O 
efficacy O 
in O 
vivo O 
. O 

investigate O 
temperature O 
- O 
dependence O 
of O 
free O 
energetics O 
with O 
two O 
single O 
halide B-FAMILY 
anions O 
, O 
I B-FORMULA 
- O 
and O 
Cl B-FORMULA 
- O 
, O 
crossing O 
the O 
aqueous O 
liquid O 
- O 
vapor O 
interface O 
through O 
molecular O 
dynamics O 
simulations O 
. O 
The O 
result O 
shows O 
that O 
I B-FORMULA 
- O 
has O 
a O 
modest O 
surface O 
stability O 
of O 
0.5 O 
kcal O 
/ O 
mol O 
at O 
300 O 
K O 
and O 
the O 
stability O 
decreases O 
as O 
the O 
temperature O 
increases O 
, O 
indicating O 
the O 
surface O 
adsorption O 
process O 
for O 
the O 
anion O 
is O 
entropically O 
disfavored O 
. O 
In O 
contrast O 
, O 
Cl B-FORMULA 
- O 
shows O 
no O 
such O 
surface O 
state O 
at O 
all O 
temperatures O 
. O 
Decomposition O 
of O 
free O 
energetics O 
reveals O 
that O 
water O 
- O 
water O 
interactions O 
provide O 
a O 
favorable O 
enthalpic O 
contribution O 
, O 
while O 
the O 
desolvation O 
of O 
ion O 
induces O 
an O 
increase O 
in O 
free O 
energy O 
. O 
Calculations O 
of O 
surface O 
fluctuations O 
demonstrate O 
that O 
I B-FORMULA 
- O 
generates O 
significantly O 
greater O 
interfacial O 
fluctuations O 
compared O 
to O 
Cl B-FORMULA 
- O 
. O 
The O 
fluctuation O 
is O 
attributed O 
to O 
the O 
malleability O 
of O 
the O 
solvation O 
shells O 
, O 
which O 
allows O 
for O 
more O 
long O 
- O 
ranged O 
perturbations O 
and O 
solvent O 
density O 
redistribution O 
induced O 
by O 
I B-FORMULA 
- O 
as O 
the O 
anion O 
approaches O 
the O 
liquid O 
- O 
vapor O 
interface O 
. O 
The O 
increase O 
in O 
temperature O 
of O 
the O 
solvent O 
enhances O 
the O 
inherent O 
thermally O 
- O 
excited O 
fluctuations O 
and O 
consequently O 
reduces O 
the O 
relative O 
contribution O 
from O 
anion O 
to O 
surface O 
fluctuations O 
, O 
which O 
is O 
consistent O 
with O 
the O 
decrease O 
in O 
surface O 
- O 
stability O 
of O 
I B-FORMULA 
- O 
. O 
Our O 
results O 
indicate O 
a O 
strong O 
correlation O 
with O 
induced O 
interfacial O 
fluctuations O 
and O 
anion O 
surface O 
stability O 
; O 
moreover O 
, O 
resulting O 
temperature O 
dependent O 
behavior O 
of O 
induced O 
fluctuations O 
suggests O 
the O 
possibility O 
of O 
a O 
critical O 
level O 
of O 
induced O 
fluctuations O 
associated O 
with O 
surface O 
stability O 
. O 

lignans I-FAMILY 
and O 
norlignans B-FAMILY 
from O 
fruits O 
of O 
Schisandra O 
wilsoniana O 
. O 

new O 
dibenzocyclooctadiene B-FAMILY 
lignans I-FAMILY 
, O 
marlignans B-MULTIPLE 
M-S I-MULTIPLE 
( O 
1-7 O 
) O 
, O 
four O 
new O 
norlignans B-FAMILY 
, O 
marphenols B-MULTIPLE 
C-F I-MULTIPLE 
( O 
8-11 O 
) O 
, O 
and O 
21 O 
known O 
compounds O 
( O 
12-32 O 
) O 
were O 
isolated O 
from O 
the O 
fruits O 
of O 
Schisandra O 
wilsoniana O 
. O 
The O 
structures O 
of O 
1-11 O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
including O 
1D- O 
and O 
2D-NMR O 
techniques O 
and O 
CD O 
experiments O 
. O 
Compounds O 
1-11 O 
were O 
evaluated O 
for O 
their O 
anti-HIV O 
activities O 
and O 
showed O 
EC(50) O 
values O 
in O 
the O 
range O 
2.97-6.18 O 
μg O 
/ O 
mL O 
and O 
therapeutic O 
index O 
values O 
of O 
5.33-29.13 O 
. O 

miserable O 
targeting O 
performance O 
of O 
nanocarriers O 
for O 
cancer O 
therapy O 
arises O 
largely O 
from O 
the O 
rapid O 
clearance O 
from O 
blood O 
circulation O 
and O 
the O 
major O 
accumulation O 
in O 
the O 
organs O 
of O 
the O 
reticuloendothelial O 
system O 
( O 
RES O 
) O 
, O 
leading O 
to O 
inefficient O 
enhanced O 
permeability O 
and O 
retention O 
( O 
EPR O 
) O 
effect O 
after O 
intravenous O 
injection O 
( O 
i.v O 
. O 
) O 
. O 
Herein O 
, O 
we O 
reported O 
an O 
efficient O 
method O 
to O 
prolong O 
the O 
blood O 
circulation O 
of O 
nanoparticles O 
and O 
decrease O 
their O 
deposition O 
in O 
liver O 
and O 
spleen O 
. O 
In O 
this O 
work O 
, O 
we O 
fabricated O 
a O 
series O 
of O 
mixed O 
shell O 
micelles O 
( O 
MSMs O 
) O 
with O 
approximately O 
the O 
same O 
size O 
, O 
charge O 
and O 
core O 
composition O 
but O 
with O 
varied O 
hydrophilic O 
/ O 
hydrophobic O 
ratios O 
in O 
the O 
shell O 
through O 
spontaneously O 
self O 
- O 
assembly O 
of O 
block O 
copolymers O 
poly(ethylene B-FAMILY 
glycol)-block-poly(l-lysine I-FAMILY 
) I-FAMILY 
( O 
PEG-b-PLys B-ABBREVIATION 
) O 
and O 
poly(N-isopropylacrylamide)-block-poly(aspartic B-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PNIPAM-b-PAsp B-ABBREVIATION 
) O 
in O 
aqueous O 
medium O 
. O 
The O 
effect O 
of O 
the O 
surface O 
heterogeneity O 
on O 
the O 
in O 
vivo O 
biodistribution O 
was O 
systematically O 
investigated O 
through O 
in O 
vivo O 
tracking O 
of O 
the O 
(125)I B-FORMULA 
-labeled O 
MSMs O 
determined O 
by O 
Gamma O 
counter O 
. O 
Compared O 
with O 
single O 
PEGylated O 
micelles O 
, O 
some O 
MSMs O 
were O 
proved O 
to O 
be O 
significantly O 
efficient O 
with O 
more O 
than O 
3 O 
times O 
lower O 
accumulation O 
in O 
liver O 
and O 
spleen O 
and O 
about O 
6 O 
times O 
higher O 
concentration O 
in O 
blood O 
at O 
1 O 
h O 
after O 
i.v O 
. O 
. O 
The O 
results O 
provide O 
us O 
a O 
novel O 
strategy O 
for O 
future O 
development O 
of O 
long O 
- O 
circulating O 
nanocarriers O 
for O 
efficient O 
cancer O 
therapy O 
. O 

studies O 
of O 
diabetes O 
have O 
examined O 
risk O 
factors O 
at O 
the O 
time O 
of O 
diabetes O 
diagnosis O 
instead O 
of O 
considering O 
the O 
lifetime O 
burden O 
of O 
adverse O 
risk O 
factor O 
levels O 
. O 
We O 
examined O 
the O 
30-year O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
risk O 
factor O 
burden O 
that O 
participants O 
have O 
up O 
to O 
the O 
time O 
of O 
diabetes O 
diagnosis.RESEARCH O 
DESIGN O 
AND O 
METHODSAmong O 
participants O 
free O 
of O 
CVD O 
, O 
incident O 
diabetes O 
cases O 
( O 
fasting O 
plasma O 
glucose B-TRIVIAL 
≥ O 
126 O 
mg O 
/ O 
dL O 
or O 
treatment O 
) O 
occurring O 
at O 
examinations O 
2 O 
through O 
8 O 
( O 
1979-2008 O 
) O 
of O 
the O 
Framingham O 
Heart O 
Study O 
Offspring O 
cohort O 
were O 
age- O 
and O 
sex O 
- O 
matched O 
1 O 
: O 
2 O 
to O 
controls O 
. O 
CVD O 
risk O 
factors O 
( O 
hypertension O 
, O 
high O 
LDL O 
cholesterol B-TRIVIAL 
, O 
low O 
HDL O 
cholesterol B-TRIVIAL 
, O 
high O 
triglycerides B-FAMILY 
, O 
obesity O 
) O 
were O 
measured O 
at O 
the O 
time O 
of O 
diabetes O 
diagnosis O 
and O 
at O 
time O 
points O 
10 O 
, O 
20 O 
, O 
and O 
30 O 
years O 
prior O 
. O 
Conditional O 
logistic O 
regression O 
was O 
used O 
to O 
compare O 
risk O 
factor O 
levels O 
at O 
each O 
time O 
point O 
between O 
diabetes O 
cases O 
and O 
controls.RESULTSWe O 
identified O 
525 O 
participants O 
with O 
new O 
- O 
onset O 
diabetes O 
who O 
were O 
matched O 
to O 
1049 O 
controls O 
( O 
mean O 
age O 
, O 
60 O 
years O 
; O 
40% O 
women O 
) O 
. O 
Compared O 
with O 
those O 
without O 
diabetes O 
, O 
individuals O 
who O 
eventually O 
developed O 
diabetes O 
had O 
higher O 
levels O 
of O 
hypertension O 
( O 
odds O 
ratio O 
[ O 
OR O 
] O 
, O 
2.2 O 
; O 
P O 
= O 
0.003 O 
) O 
, O 
high O 
LDL O 
( O 
OR O 
, O 
1.5 O 
; O 
P O 
= O 
0.04 O 
) O 
, O 
low O 
HDL O 
( O 
OR O 
, O 
2.1 O 
; O 
P O 
= O 
0.0001 O 
) O 
, O 
high O 
triglycerides B-FAMILY 
( O 
OR O 
, O 
1.7 O 
; O 
P O 
= O 
0.04 O 
) O 
, O 
and O 
obesity O 
( O 
OR O 
, O 
3.3 O 
; O 
P O 
< O 
0.0001 O 
) O 
at O 
time O 
points O 
30 O 
years O 
before O 
diabetes O 
diagnosis O 
. O 
After O 
further O 
adjustment O 
for O 
BMI O 
, O 
the O 
ORs O 
for O 
hypertension O 
( O 
OR O 
, O 
1.9 O 
; O 
P O 
= O 
0.02 O 
) O 
and O 
low O 
HDL O 
( O 
OR O 
, O 
1.7 O 
; O 
P O 
= O 
0.01 O 
) O 
remained O 
statistically O 
significant.CONCLUSIONSCVD O 
risk O 
factors O 
are O 
increased O 
up O 
to O 
30 O 
years O 
before O 
diagnosis O 
of O 
diabetes O 
. O 
These O 
findings O 
highlight O 
the O 
importance O 
of O 
a O 
life O 
course O 
approach O 
to O 
CVD O 
risk O 
factor O 
identification O 
among O 
individuals O 
at O 
risk O 
for O 
diabetes O 
. O 

Acute O 
Recovery O 
from O 
Alcohol B-SYSTEMATIC 
Impairment O 
in O 
Adults O 
with O 
ADHD O 
. O 

: O 
Prior O 
research O 
has O 
found O 
that O 
adults O 
with O 
attention O 
- O 
deficit O 
/ O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
show O 
increased O 
sensitivity O 
to O 
the O 
impairing O 
effects O 
of O 
alcohol B-FAMILY 
( O 
Weafer O 
et O 
al O 
. O 
, O 
Exp O 
Clin O 
Psychopharmacol O 
17 O 
: O 
113-121 O 
, O 
2009 O 
) O 
. O 
However O 
, O 
these O 
studies O 
have O 
focused O 
exclusively O 
on O 
the O 
ascending O 
limb O 
of O 
the O 
blood O 
alcohol B-FAMILY 
concentration O 
( O 
BAC O 
) O 
curve O 
, O 
and O 
it O 
is O 
unclear O 
whether O 
these O 
adults O 
continue O 
to O 
show O 
increased O 
sensitivity O 
during O 
the O 
later O 
phase O 
of O 
the O 
dose O 
as O 
BAC O 
is O 
declining O 
. O 
OBJECTIVE O 
: O 
This O 
study O 
tested O 
the O 
hypothesis O 
that O 
those O 
with O 
ADHD O 
would O 
display O 
increased O 
response O 
to O 
alcohol B-FAMILY 
during O 
the O 
ascending O 
limb O 
of O 
the O 
BAC O 
curve O 
and O 
less O 
recovery O 
from O 
the O 
impairing O 
effects O 
during O 
the O 
descending O 
limb O 
. O 
METHODS O 
: O 
Adult O 
social O 
drinkers O 
with O 
ADHD O 
and O 
control O 
adults O 
completed O 
measures O 
of O 
motor O 
coordination O 
, O 
reaction O 
time O 
( O 
RT O 
) O 
, O 
and O 
subjective O 
intoxication O 
twice O 
following O 
0.64 O 
g O 
/ O 
kg O 
alcohol B-FAMILY 
and O 
placebo O 
. O 
The O 
measures O 
were O 
administered O 
during O 
the O 
ascending O 
limb O 
of O 
the O 
BAC O 
curve O 
and O 
again O 
during O 
the O 
descending O 
limb O 
. O 
RESULTS O 
: O 
During O 
the O 
ascending O 
limb O 
, O 
alcohol B-FAMILY 
reduced O 
motor O 
coordination O 
, O 
slowed O 
RT O 
, O 
and O 
increased O 
self O 
- O 
reports O 
of O 
subjective O 
intoxication O 
. O 
Those O 
with O 
ADHD O 
displayed O 
greater O 
impairment O 
of O 
motor O 
coordination O 
compared O 
with O 
controls O 
. O 
During O 
the O 
descending O 
limb O 
, O 
controls O 
reported O 
diminished O 
subjective O 
intoxication O 
and O 
showed O 
recovery O 
from O 
the O 
impairing O 
effects O 
of O 
alcohol B-FAMILY 
on O 
both O 
their O 
motor O 
coordination O 
and O 
their O 
RT O 
. O 
Those O 
with O 
ADHD O 
showed O 
reduced O 
subjective O 
intoxication O 
and O 
faster O 
RT O 
during O 
this O 
time O 
, O 
but O 
they O 
did O 
not O 
recover O 
motor O 
control O 
. O 
CONCLUSIONS O 
: O 
The O 
protracted O 
time O 
course O 
of O 
motor O 
impairment O 
in O 
adults O 
with O 
ADHD O 
despite O 
reductions O 
in O 
subjective O 
intoxication O 
may O 
contribute O 
to O 
poor O 
decision O 
making O 
and O 
diminished O 
behavioral O 
control O 
in O 
this O 
group O 
. O 

infectious O 
diseases O 
continue O 
to O 
be O 
one O 
of O 
the O 
leading O 
causes O 
of O 
morbidity O 
and O 
mortality O 
. O 
It O 
has O 
been O 
estimated O 
that O 
microbial O 
species O 
comprise O 
about O 
60% O 
of O 
the O 
Earth's O 
biomass O 
. O 
This O 
, O 
together O 
with O 
the O 
fact O 
that O 
their O 
genetic O 
, O 
metabolic O 
and O 
physiological O 
diversity O 
is O 
extraordinary O 
, O 
makes O 
them O 
a O 
major O 
threat O 
to O 
the O 
health O 
and O 
development O 
of O 
populations O 
across O 
the O 
world O 
. O 
Widespread O 
antibiotic O 
resistance O 
, O 
the O 
emergence O 
of O 
new O 
pathogens O 
in O 
addition O 
to O 
the O 
resurgence O 
of O 
old O 
ones O 
, O 
and O 
the O 
lack O 
of O 
effective O 
new O 
therapeutics O 
exacerbate O 
the O 
problems O 
. O 
Thus O 
, O 
the O 
need O 
to O 
discover O 
and O 
develop O 
new O 
antimicrobial O 
agents O 
is O 
critical O 
to O 
improve O 
mankind's O 
future O 
health O 
. O 
Plant O 
secondary O 
metabolites O 
( O 
PSMs O 
) O 
offer O 
particular O 
promise O 
in O 
this O 
sense O 
. O 
Plant O 
Kingdom O 
could O 
be O 
considered O 
a O 
rich O 
source O 
of O 
the O 
most O 
diverse O 
structures O 
( O 
e.g O 
. O 
there O 
are O 
more O 
than O 
12000 O 
known O 
alkaloids O 
, O 
more O 
than O 
8000 O 
phenolic B-FAMILY 
compounds O 
and O 
over O 
25000 O 
different O 
terpenoids B-FAMILY 
) O 
, O 
many O 
of O 
which O 
were O 
proven O 
to O 
possess O 
strong O 
antimicrobial O 
properties O 
( O 
e.g O 
. O 
thymol B-TRIVIAL 
, O 
eurabienol B-TRIVIAL 
, O 
etc O 
. O 
) O 
. O 
In O 
many O 
instances O 
, O 
PSMs O 
can O 
be O 
easily O 
isolated O 
from O 
the O 
plant O 
matrix O 
, O 
either O 
in O 
pure O 
state O 
or O 
in O 
the O 
form O 
of O 
mixtures O 
of O 
chemically O 
related O 
compounds O 
. O 
What O 
is O 
also O 
important O 
is O 
that O 
the O 
development O 
of O 
bacterial O 
resistance O 
toward O 
natural O 
plant O 
products O 
( O 
that O 
are O 
generally O 
regarded O 
as O 
eco O 
- O 
friendly O 
) O 
has O 
been O 
thus O 
far O 
documented O 
in O 
a O 
very O 
limited O 
number O 
of O 
cases O 
( O 
e.g O 
. O 
for O 
reserpine B-TRIVIAL 
) O 
. O 
Having O 
all O 
of O 
the O 
mentioned O 
advantages O 
of O 
PSMs O 
as O 
potential O 
antimicrobials O 
in O 
mind O 
, O 
a O 
major O 
question O 
arises O 
: O 
why O 
is O 
it O 
that O 
there O 
are O 
still O 
no O 
commercially O 
available O 
or O 
commonly O 
used O 
antibiotics O 
of O 
plant O 
origin O 
? O 
This O 
review O 
tries O 
to O 
give O 
a O 
critical O 
answer O 
to O 
this O 
question O 
by O 
considering O 
potential O 
mechanisms O 
of O 
antimicrobial O 
action O 
of O 
PSMs O 
( O 
inhibition O 
of O 
cell O 
wall O 
or O 
protein O 
synthesis O 
, O 
inducing O 
leakage O 
from O 
the O 
cells O 
by O 
tampering O 
with O 
the O 
function O 
of O 
the O 
membranes O 
, O 
interfering O 
with O 
intermediary O 
metabolisms O 
or O 
DNA O 
/ O 
RNA O 
synthesis O 
/ O 
function O 
) O 
, O 
as O 
well O 
as O 
their O 
physical O 
and O 
chemical O 
properties O 
( O 
e.g O 
. O 
hydrophilicity O 
/ O 
lipophilicity O 
, O 
chemical O 
stability O 
) O 
. O 
To O 
address O 
the O 
possible O 
synergistic O 
/ O 
antagonistic O 
effects O 
between O 
PSMs O 
and O 
with O 
standard O 
antibiotics O 
, O 
special O 
attention O 
has O 
been O 
given O 
to O 
the O 
antimicrobial O 
activity O 
of O 
PSM-mixtures O 
( O 
e.g O 
. O 
essential O 
oils O 
, O 
plant O 
extracts O 
) O 
. O 
Moreover O 
, O 
possible O 
ways O 
of O 
overcoming O 
some O 
of O 
PSMs O 
molecular O 
limitations O 
in O 
respect O 
to O 
their O 
usage O 
as O 
potential O 
antibiotics O 
were O 
also O 
discussed O 
( O 
e.g O 
. O 
derivatization O 
that O 
would O 
enable O 
fine O 
tuning O 
of O 
certain O 
molecular O 
characteristics O 
) O 
. O 

wall O 
material O 
from O 
potato O 
pulp O 
by O 
- O 
product O 
was O 
used O 
for O 
the O 
extraction O 
of O 
galactan O 
- O 
rich O 
rhamnogalacturonan O 
I O 
( O 
RG-I O 
) O 
type O 
pectic O 
polysaccharides O 
using O 
alkaline O 
( O 
NaOH B-FORMULA 
and O 
KOH B-FORMULA 
) O 
and O 
enzymatic O 
( O 
endopolygalacturonase O 
from O 
Aspergillus O 
niger O 
) O 
methods O 
. O 
The O 
extraction O 
yield O 
increased O 
as O 
the O 
concentration O 
of O 
alkaline O 
solution O 
was O 
increased O 
from O 
0.5M O 
( O 
22-24% O 
) O 
to O 
2M O 
( O 
53-56% O 
) O 
. O 
The O 
yield O 
of O 
38% O 
obtained O 
upon O 
the O 
enzymatic O 
treatment O 
was O 
similar O 
to O 
those O 
observed O 
with O 
1M O 
alkaline O 
solutions O 
. O 
The O 
results O 
reveal O 
the O 
high O 
debranching O 
of O 
arabinan O 
side O 
chains O 
of O 
RG O 
I O 
as O 
compared O 
to O 
the O 
galactan O 
ones O 
under O 
harsh O 
alkaline O 
conditions O 
. O 
The O 
molecular O 
weight O 
distribution O 
shows O 
that O 
the O 
enzymatic O 
extraction O 
led O 
to O 
the O 
highest O 
proportion O 
of O 
high O 
- O 
molecular O 
weight O 
polysaccharides O 
( O 
> O 
500kDa O 
; O 
62.2% O 
) O 
. O 
According O 
to O 
monosaccharide O 
pattern O 
, O 
the O 
weak O 
acidic O 
fractions O 
of O 
high O 
alkaline O 
( O 
1-2M O 
) O 
- O 
based O 
polysaccharide O 
extracts O 
was O 
the O 
most O 
enriched O 
with O 
galactan O 
- O 
rich O 
RG O 
I O 
. O 
Using O 
milder O 
conditions O 
( O 
enzyme O 
and O 
weak O 
alkaline O 
) O 
, O 
two O 
RG O 
I O 
populations O 
with O 
low O 
and O 
high O 
linked O 
homogalacturonan O 
fragments O 
were O 
recovered O 
in O 
the O 
weak O 
and O 
strong O 
acidic O 
fractions O 
, O 
respectively O 
. O 
The O 
structure O 
of O 
galactan O 
- O 
rich O 
RG O 
I O 
was O 
confirmed O 
by O 
H(1) B-FORMULA 
NMR O 
spectroscopy O 
analysis O 
. O 

-type O 
diterpenoids B-FAMILY 
from O 
the O 
fruits O 
of O 
Vitex O 
trifolia O 
. O 

new O 
labdane B-TRIVIAL 
-type O 
diterpenoids B-FAMILY 
, O 
vitextrifolins B-MULTIPLE 
A-G I-MULTIPLE 
( O 
1-7 O 
) O 
, O 
along O 
with O 
eight O 
previously O 
reported O 
analogues O 
, O 
were O 
isolated O 
from O 
the O 
fruits O 
of O 
Vitex O 
trifolia O 
. O 
The O 
structures O 
of O 
1-7 O 
were O 
elucidated O 
by O 
spectroscopic O 
data O 
interpretation O 
. O 
The O 
isolates O 
were O 
evaluated O 
for O 
their O 
cytotoxicity O 
against O 
four O 
human O 
cancer O 
cell O 
lines O 
( O 
A549 O 
, O 
HCT116 O 
, O 
HL-60 O 
, O 
and O 
ZR-75-30 O 
) O 
, O 
but O 
all O 
were O 
inactive O 
( O 
IC(50) O 
< O 
5 O 
μg O 
/ O 
mL O 
) O 
. O 

present O 
study O 
was O 
designed O 
to O 
evaluate O 
the O 
effects O 
of O 
chronic O 
fluorosis O 
on O 
the O 
dynamics O 
( O 
including O 
fusion O 
and O 
fission O 
proteins O 
) O 
, O 
fragmentation O 
, O 
and O 
distribution O 
of O 
mitochondria O 
in O 
the O 
cortical O 
neurons O 
of O 
the O 
rat O 
brain O 
in O 
an O 
attempt O 
to O 
elucidate O 
molecular O 
mechanisms O 
underlying O 
the O 
brain O 
damage O 
associated O 
with O 
excess O 
accumulation O 
of O 
fluoride B-SYSTEMATIC 
. O 
Sixty O 
Sprague-Dawley O 
rats O 
were O 
divided O 
randomly O 
into O 
three O 
groups O 
of O 
20 O 
each O 
, O 
that O 
is O 
, O 
the O 
untreated O 
control O 
group O 
( O 
drinking O 
water O 
naturally O 
containing O 
< O 
0.5 O 
mg O 
fluoride B-SYSTEMATIC 
/l O 
, O 
NaF B-FORMULA 
) O 
, O 
the O 
low- O 
fluoride B-SYSTEMATIC 
group O 
( O 
whose O 
drinking O 
water O 
was O 
supplemented O 
with O 
10 O 
mg O 
fluoride B-SYSTEMATIC 
/l O 
) O 
and O 
the O 
high- O 
fluoride B-SYSTEMATIC 
group O 
( O 
50 O 
mg O 
fluoride B-SYSTEMATIC 
/l O 
) O 
. O 
After O 
6 O 
months O 
of O 
exposure O 
, O 
the O 
expression O 
of O 
mitofusin-1 O 
( O 
Mfn1 O 
) O 
, O 
fission-1 O 
( O 
Fis1 O 
) O 
, O 
and O 
dynamin O 
- O 
related O 
protein-1 O 
( O 
Drp1 O 
) O 
at O 
both O 
the O 
protein O 
and O 
mRNA O 
levels O 
were O 
detected O 
by O 
Western O 
blotting O 
, O 
immunohistochemistry O 
, O 
and O 
real O 
- O 
time O 
PCR O 
, O 
respectively O 
. O 
Moreover O 
, O 
mitochondrial O 
morphology O 
and O 
distribution O 
in O 
neurons O 
were O 
observed O 
by O 
transmission O 
electron O 
or O 
fluorescence O 
microscopy O 
. O 
In O 
the O 
cortices O 
of O 
the O 
brains O 
of O 
rats O 
with O 
chronic O 
fluorosis O 
, O 
the O 
level O 
of O 
Mfn1 O 
protein O 
was O 
clearly O 
reduced O 
, O 
whereas O 
the O 
levels O 
of O 
Fis1 O 
and O 
Drp1 O 
were O 
elevated O 
. O 
The O 
alternations O 
of O 
expression O 
of O 
the O 
mRNAs O 
encoding O 
all O 
three O 
of O 
these O 
proteins O 
were O 
almost O 
the O 
same O 
as O 
the O 
corresponding O 
changes O 
at O 
the O 
protein O 
levels O 
. O 
The O 
mitochondria O 
were O 
fragmented O 
and O 
the O 
redistributed O 
away O 
from O 
the O 
axons O 
of O 
the O 
cortical O 
neurons O 
. O 
These O 
findings O 
indicate O 
that O 
chronic O 
fluorosis O 
induces O 
abnormal O 
mitochondrial O 
dynamics O 
, O 
which O 
might O 
in O 
turn O 
result O 
in O 
a O 
high O 
level O 
of O 
oxidative O 
stress O 
. O 

exposure O 
to O 
dietary O 
zearalenone B-TRIVIAL 
, O 
a O 
mycotoxin O 
, O 
promotes O 
premature O 
onset O 
of O 
puberty O 
and O 
disrupts O 
early O 
pregnancy O 
events O 
in O 
female O 
mice O 
. O 

( O 
ZEA B-ABBREVIATION 
) O 
is O 
a O 
mycotoxin O 
commonly O 
found O 
in O 
contaminated O 
livestock O 
feed O 
and O 
human O 
food O 
with O 
levels O 
in O 
the O 
range O 
of O 
ppb O 
and O 
low O 
ppm O 
. O 
It O 
was O 
hypothesized O 
that O 
ZEA B-ABBREVIATION 
, O 
an O 
endocrine O 
disruptor O 
, O 
could O 
affect O 
puberty O 
and O 
early O 
pregnancy O 
. O 
To O 
test O 
this O 
hypothesis O 
, O 
newly O 
weaned O 
( O 
3 O 
weeks O 
old O 
) O 
C57BL O 
/ O 
6J O 
female O 
mice O 
were O 
exposed O 
to O 
0 O 
, O 
0.002 O 
, O 
4 O 
, O 
10 O 
, O 
and O 
40 O 
ppm O 
ZEA B-ABBREVIATION 
and O 
0.05 O 
ppm O 
diethylstilbestrol B-SYSTEMATIC 
( O 
positive O 
control O 
) O 
in O 
phytoestrogen O 
- O 
free O 
AIN-93G O 
diet O 
. O 
Females O 
exposed O 
to O 
10 O 
and O 
40 O 
ppm O 
ZEA B-ABBREVIATION 
diets O 
showed O 
earlier O 
onset O 
of O 
vaginal O 
opening O 
. O 
Those O 
treated O 
with O 
40 O 
ppm O 
ZEA B-ABBREVIATION 
diet O 
also O 
had O 
earlier O 
first O 
copulation O 
plug O 
and O 
irregular O 
estrous O 
cyclicity O 
. O 
At O 
8 O 
weeks O 
old O 
, O 
all O 
females O 
were O 
mated O 
with O 
untreated O 
stud O 
males O 
on O 
AIN-93G O 
diet O 
during O 
mating O 
. O 
Treatment O 
resumed O 
upon O 
identification O 
of O 
a O 
vaginal O 
plug O 
on O 
gestation O 
day O 
0.5 O 
( O 
D0.5 O 
) O 
. O 
Embryo O 
implantation O 
was O 
assessed O 
on O 
D4.5 O 
. O 
Exposure O 
to O 
40 O 
ppm O 
ZEA B-ABBREVIATION 
diet O 
resulted O 
in O 
reduced O 
percentage O 
of O 
plugged O 
mice O 
with O 
implantation O 
sites O 
, O 
distended O 
uterine O 
appearance O 
, O 
and O 
retained O 
expression O 
of O 
progesterone B-TRIVIAL 
receptor O 
in O 
D4.5 O 
uterine O 
epithelium O 
. O 
To O 
determine O 
the O 
exposure O 
timing O 
and O 
mechanisms O 
of O 
disrupted O 
embryo O 
implantation O 
, O 
four O 
groups O 
of O 
females O 
were O 
fed O 
with O 
0 O 
or O 
40 O 
ppm O 
ZEA B-ABBREVIATION 
diets O 
during O 
premating O 
( O 
weaning O 
to O 
mating O 
) O 
and O 
postmating O 
( O 
D0.5-D4.5 O 
) O 
, O 
respectively O 
. O 
Premating O 
exposure O 
to O 
40 O 
ppm O 
ZEA B-ABBREVIATION 
diet O 
reduced O 
fertilization O 
rate O 
, O 
whereas O 
postmating O 
exposure O 
to O 
40 O 
ppm O 
ZEA B-ABBREVIATION 
diet O 
delayed O 
embryo O 
transport O 
and O 
preimplantation O 
embryo O 
development O 
, O 
which O 
subsequently O 
affected O 
embryo O 
implantation O 
. O 
These O 
data O 
demonstrate O 
that O 
postweaning O 
exposure O 
to O 
dietary O 
ZEA B-ABBREVIATION 
can O 
promote O 
premature O 
onset O 
of O 
puberty O 
and O 
disrupt O 
early O 
pregnancy O 
events O 
. O 

properties O 
of O 
D2 O 
and O 
D3 O 
dopamine B-TRIVIAL 
receptors O 
agonists O 
and O 
cocaine B-TRIVIAL 
, O 
but O 
not O 
with O 
D1 O 
dopamine B-TRIVIAL 
receptors O 
agonist O 
and O 
l-dopa B-ABBREVIATION 
, O 
in O 
bilateral O 
6-OHDA B-SYSTEMATIC 
-lesioned O 
rat O 
. O 

dysregulation O 
syndrome O 
in O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
has O 
been O 
attributed O 
to O 
dopamine B-TRIVIAL 
replacement O 
therapy O 
( O 
DRT O 
) O 
. O 
We O 
hypothesize O 
that O 
DRT O 
can O 
induce O 
a O 
potential O 
rewarding O 
effect O 
in O 
an O 
animal O 
model O 
of O 
PD O 
. O 
Using O 
the O 
conditioned O 
place O 
preference O 
( O 
CPP O 
) O 
paradigm O 
, O 
we O 
investigated O 
the O 
motivational O 
effects O 
of O 
l-dopa B-ABBREVIATION 
, O 
dopamine B-TRIVIAL 
receptor O 
agonists O 
( O 
DRAs O 
) O 
, O 
and O 
cocaine B-TRIVIAL 
in O 
rat O 
with O 
a O 
bilateral O 
6-OHDA B-SYSTEMATIC 
lesion O 
of O 
the O 
nigrostriatal O 
dopaminergic O 
pathway O 
. O 
In O 
6-OHDA B-SYSTEMATIC 
animals O 
, O 
D1 O 
receptors O 
agonist O 
( O 
SKF81297 B-IDENTIFIER 
) O 
revealed O 
significantly O 
a O 
conditioned O 
place O 
aversion O 
( O 
CPA O 
) O 
at O 
3 O 
mg O 
/ O 
kg O 
and O 
9 O 
mg O 
/ O 
kg O 
doses O 
. O 
D2 O 
receptors O 
agonist O 
( O 
bromocriptine B-TRIVIAL 
) O 
induced O 
both O 
CPP O 
and O 
CPA O 
at O 
1 O 
mg O 
/ O 
kg O 
and O 
10 O 
mg O 
/ O 
kg O 
doses O 
respectively O 
. O 
D3 O 
receptors O 
agonist O 
( O 
PD128907 B-IDENTIFIER 
) O 
induced O 
a O 
CPP O 
only O 
at O 
1 O 
mg O 
/ O 
kg O 
, O 
comparable O 
to O 
that O 
of O 
cocaine B-TRIVIAL 
. O 
Sham O 
animals O 
revealed O 
biphasic O 
CPP O 
curves O 
, O 
with O 
significant O 
dose O 
effect O 
, O 
for O 
the O 
intermediate O 
dose O 
of O 
the O 
3 O 
DRAs O 
. O 
However O 
, O 
l-dopa B-ABBREVIATION 
induced O 
no O 
significant O 
effect O 
while O 
cocaine B-TRIVIAL 
induced O 
CPP O 
in O 
both O 
lesioned O 
and O 
sham O 
animals O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
confirms O 
the O 
predominant O 
roles O 
of O 
D2R O 
class O 
, O 
and O 
most O 
specifically O 
D3R O 
subtypes O 
, O 
in O 
rewarding O 
properties O 
of O 
DRT O 
. O 

extract O 
and O 
zingerone B-TRIVIAL 
ameliorated O 
trinitrobenzene B-SYSTEMATIC 
sulphonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
colitis O 
in O 
mice O 
via O 
modulation O 
of O 
nuclear O 
factor-κB O 
activity O 
and O 
interleukin-1β O 
signalling O 
pathway O 
. O 

is O 
a O 
commonly O 
used O 
spice O 
with O 
anti-inflammatory O 
potential O 
. O 
Colitis O 
is O 
the O 
common O 
pathological O 
lesion O 
of O 
inflammatory O 
bowel O 
diseases O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
therapeutic O 
effects O 
of O 
ginger O 
and O 
its O 
component O 
zingerone B-TRIVIAL 
in O 
mice O 
with O 
2,4,6-trinitrobenzene B-SYSTEMATIC 
sulphonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
TNBS B-ABBREVIATION 
)-induced O 
colitis O 
. O 
Ginger O 
and O 
zingerone B-TRIVIAL 
ameliorated O 
TNBS B-ABBREVIATION 
-induced O 
colonic O 
injury O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Pathway O 
analysis O 
of O 
ginger- O 
and O 
zingerone B-TRIVIAL 
-regulated O 
gene O 
expression O 
profiles O 
showed O 
that O 
ginger O 
and O 
zingerone B-TRIVIAL 
significantly O 
regulated O 
cytokine O 
- O 
related O 
pathways O 
. O 
Network O 
analysis O 
showed O 
that O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
and O 
interleukin-1β O 
( O 
IL-1β O 
) O 
were O 
key O 
molecules O 
involved O 
in O 
the O 
expression O 
of O 
ginger- O 
and O 
zingerone B-TRIVIAL 
-affected O 
genes O 
. O 
Ex O 
vivo O 
imaging O 
and O 
immunohistochemical O 
staining O 
further O 
verified O 
that O 
ginger O 
and O 
zingerone B-TRIVIAL 
suppressed O 
TNBS B-ABBREVIATION 
-induced O 
NF-κB O 
activation O 
and O 
IL-1β O 
protein O 
level O 
in O 
the O 
colon O 
. O 
In O 
conclusion O 
, O 
ginger O 
improved O 
TNBS B-ABBREVIATION 
-induced O 
colitis O 
via O 
modulation O 
of O 
NF-κB O 
activity O 
and O 
IL-1β O 
signalling O 
pathway O 
. O 
Moreover O 
, O 
zingerone B-TRIVIAL 
might O 
be O 
the O 
active O 
component O 
of O 
ginger O 
responsible O 
for O 
the O 
amelioration O 
of O 
colitis O 
induced O 
by O 
TNBS B-ABBREVIATION 
. O 

receptor O 
- O 
selective O 
dicarboxylic B-SYSTEMATIC 
ester I-SYSTEMATIC 
-derived O 
salvinorin B-TRIVIAL 
A I-TRIVIAL 
ligands O 
. O 

A I-TRIVIAL 
, O 
the O 
active O 
ingredient O 
of O 
the O 
hallucinogenic O 
plant O 
Salvia O 
divinorum O 
is O 
the O 
most O 
potent O 
known O 
naturally O 
occurring O 
hallucinogen O 
and O 
is O 
a O 
selective O 
κ-opioid O 
receptor O 
agonist O 
. O 
To O 
better O 
understand O 
the O 
ligand O 
- O 
receptor O 
interactions O 
, O 
a O 
series O 
of O 
dicarboxylic B-SYSTEMATIC 
ester I-SYSTEMATIC 
-type O 
of O 
salvinorin B-TRIVIAL 
A I-TRIVIAL 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
binding O 
affinity O 
at O 
κ- O 
, O 
δ- O 
and O 
μ-opioid O 
receptors O 
. O 
Most O 
of O 
the O 
analogues O 
show O 
high O 
affinity O 
to O 
the O 
κ-opioid O 
receptor O 
. O 
Methyl B-SYSTEMATIC 
malonyl I-SYSTEMATIC 
derivative O 
4 O 
shows O 
the O 
highest O 
binding O 
affinity O 
( O 
Ki=2nM O 
) O 
, O 
analogues O 
5 O 
, O 
7 O 
, O 
and O 
14 O 
exhibit O 
significant O 
affinity O 
for O 
the O 
κ-receptor O 
( O 
Ki=21 O 
, O 
36 O 
and O 
39nM O 
) O 
. O 

quantum O 
- O 
chemical O 
calculations O 
on O 
a O 
complete O 
set O 
of O 
rotameric O 
families O 
of O 
the O 
DNA O 
sugar B-FAMILY 
- O 
phosphate B-SYSTEMATIC 
backbone O 
and O 
their O 
comparison O 
with O 
modern O 
density O 
functional O 
theory O 
. O 

DNA O 
sugar B-FAMILY 
- O 
phosphate B-SYSTEMATIC 
backbone O 
has O 
a O 
substantial O 
influence O 
on O 
the O 
DNA O 
structural O 
dynamics O 
. O 
Structural O 
biology O 
and O 
bioinformatics O 
studies O 
revealed O 
that O 
the O 
DNA O 
backbone O 
in O 
experimental O 
structures O 
samples O 
a O 
wide O 
range O 
of O 
distinct O 
conformational O 
substates O 
, O 
known O 
as O 
rotameric O 
DNA O 
backbone O 
conformational O 
families O 
. O 
Their O 
correct O 
description O 
is O 
essential O 
for O 
methods O 
used O 
to O 
model O 
nucleic O 
acids O 
and O 
is O 
known O 
to O 
be O 
the O 
Achilles O 
heel O 
of O 
force O 
field O 
computations O 
. O 
In O 
this O 
study O 
we O 
report O 
the O 
benchmark O 
database O 
of O 
MP2 O 
calculations O 
extrapolated O 
to O 
the O 
complete O 
basis O 
set O 
of O 
atomic O 
orbitals O 
with O 
aug-cc-pVTZ O 
and O 
aug-cc-pVQZ O 
basis O 
sets O 
, O 
MP2(T,Q) O 
, O 
augmented O 
by O 
ΔCCSD(T) O 
/ O 
aug-cc-pVDZ O 
corrections O 
. O 
The O 
calculations O 
are O 
performed O 
in O 
the O 
gas O 
phase O 
as O 
well O 
as O 
using O 
a O 
COSMO O 
solvent O 
model O 
. O 
This O 
study O 
includes O 
a O 
complete O 
set O 
of O 
18 O 
established O 
and O 
biochemically O 
most O 
important O 
families O 
of O 
DNA O 
backbone O 
conformations O 
and O 
several O 
other O 
salient O 
conformations O 
that O 
we O 
identified O 
in O 
experimental O 
structures O 
. O 
We O 
utilize O 
an O 
electronically O 
sufficiently O 
complete O 
DNA O 
sugar B-FAMILY 
- O 
phosphate B-SYSTEMATIC 
- O 
sugar B-FAMILY 
() O 
backbone O 
model O 
system O 
truncated O 
to O 
prevent O 
undesired O 
intramolecular O 
interactions O 
. O 
The O 
calculations O 
are O 
then O 
compared O 
with O 
other O 
QM O 
methods O 
. O 
The O 
BLYP O 
and O 
TPSS O 
functionals O 
supplemented O 
with O 
Grimme's O 
D3(BJ) O 
dispersion O 
term O 
provide O 
the O 
best O 
tradeoff O 
between O 
computational O 
demands O 
and O 
accuracy O 
and O 
can O 
be O 
recommended O 
for O 
preliminary O 
conformational O 
searches O 
as O 
well O 
as O 
calculations O 
on O 
large O 
model O 
systems O 
. O 
Among O 
the O 
tested O 
methods O 
, O 
the O 
best O 
agreement O 
with O 
the O 
benchmark O 
database O 
has O 
been O 
obtained O 
for O 
the O 
double O 
- O 
hybrid O 
DSD-BLYP O 
functional O 
in O 
combination O 
with O 
a O 
quadruple-ζ O 
basis O 
set O 
, O 
which O 
is O 
, O 
however O 
, O 
computationally O 
very O 
demanding O 
. O 
The O 
new O 
hybrid O 
density O 
functionals O 
PW6B95-D3 O 
and O 
MPW1B95-D3 O 
yield O 
outstanding O 
results O 
and O 
even O 
slightly O 
outperform O 
the O 
computationally O 
more O 
demanding O 
PWPB95 O 
double O 
- O 
hybrid O 
functional O 
. O 
B3LYP-D3 O 
is O 
somewhat O 
less O 
accurate O 
compared O 
to O 
the O 
other O 
hybrids O 
. O 
Extrapolated O 
MP2(D,T) O 
calculations O 
are O 
not O 
as O 
accurate O 
as O 
the O 
less O 
demanding O 
DFT-D3 O 
methods O 
. O 
Preliminary O 
force O 
field O 
tests O 
using O 
several O 
charge O 
sets O 
reveal O 
an O 
almost O 
order O 
of O 
magnitude O 
larger O 
deviations O 
from O 
the O 
reference O 
QM O 
data O 
compared O 
to O 
modern O 
DFT-D3 O 
, O 
underlining O 
the O 
challenges O 
facing O 
force O 
field O 
simulations O 
of O 
nucleic O 
acids O 
. O 
As O 
expected O 
, O 
inclusion O 
of O 
the O 
solvent O 
environment O 
approximated O 
by O 
a O 
continuum O 
approach O 
has O 
a O 
large O 
impact O 
on O 
the O 
relative O 
stabilities O 
of O 
different O 
backbone O 
substates O 
and O 
is O 
important O 
when O 
comparing O 
the O 
QM O 
data O 
with O 
structural O 
bioinformatics O 
and O 
other O 
experimental O 
data O 
. O 

dietary O 
exposure O 
to O 
chlorpyrifos B-TRIVIAL 
causes O 
behavioral O 
impairments O 
, O 
low O 
activity O 
of O 
brain O 
membrane O 
- O 
bound O 
acetylcholinesterase O 
, O 
and O 
increased O 
brain O 
acetylcholinesterase-R O 
mRNA O 
. O 

( O 
CPF B-ABBREVIATION 
) O 
is O 
an O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
insecticide O 
that O 
is O 
metabolically O 
activated O 
to O 
the O 
highly O 
toxic O 
chlorpyrifos B-TRIVIAL 
oxon I-TRIVIAL 
. O 
Dietary O 
exposure O 
is O 
the O 
main O 
route O 
of O 
intoxication O 
for O 
non-occupational O 
exposures O 
. O 
However O 
, O 
only O 
limited O 
behavioral O 
effects O 
of O 
chronic O 
dietary O 
exposure O 
have O 
been O 
investigated O 
. O 
Therefore O 
, O 
male O 
Wistar O 
rats O 
were O 
fed O 
a O 
dose O 
of O 
5mg O 
/ O 
kg O 
/ O 
day O 
of O 
CPF B-ABBREVIATION 
for O 
thirty O 
- O 
one O 
weeks O 
. O 
Animals O 
were O 
evaluated O 
in O 
spatial O 
learning O 
and O 
impulsivity O 
tasks O 
after O 
21 O 
weeks O 
of O 
CPF B-ABBREVIATION 
dietary O 
exposure O 
and O 
one O 
week O 
after O 
exposure O 
ended O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
the O 
degree O 
of O 
inhibition O 
of O 
brain O 
acetylcholinesterase O 
( O 
AChE O 
) O 
was O 
evaluated O 
for O 
both O 
the O 
soluble O 
and O 
particulate O 
forms O 
of O 
the O 
enzyme O 
, O 
as O 
well O 
as O 
AChE O 
gene O 
expression O 
. O 
Also O 
, O 
brain O 
acylpeptide O 
hydrolase O 
( O 
APH O 
) O 
was O 
investigated O 
as O 
an O 
alternative O 
target O 
for O 
OP O 
- O 
mediated O 
effects O 
. O 
All O 
variables O 
were O 
evaluated O 
at O 
various O 
time O 
points O 
in O 
response O 
to O 
CPF B-ABBREVIATION 
diet O 
and O 
after O 
exposure O 
ended O 
. O 
Results O 
from O 
behavioral O 
procedures O 
suggest O 
cognitive O 
and O 
emotional O 
disorders O 
. O 
Moreover O 
, O 
low O 
levels O 
of O 
activity O 
representing O 
membrane O 
- O 
bound O 
oligomeric O 
forms O 
( O 
tetramers O 
) O 
were O 
also O 
observed O 
. O 
In O 
addition O 
, O 
increased O 
brain O 
AChE-R O 
mRNA O 
levels O 
were O 
detected O 
after O 
four O 
weeks O 
of O 
CPF B-ABBREVIATION 
dietary O 
exposure O 
. O 
However O 
, O 
no O 
changes O 
in O 
levels O 
of O 
brain O 
APH O 
were O 
observed O 
among O 
groups O 
. O 
In O 
conclusion O 
, O 
our O 
data O 
point O 
to O 
a O 
relationship O 
between O 
cognitive O 
impairments O 
and O 
changes O 
in O 
AChE O 
forms O 
, O 
specifically O 
to O 
a O 
high O 
inhibition O 
of O 
the O 
particulate O 
form O 
and O 
a O 
modification O 
of O 
alternative O 
splicing O 
of O 
mRNA O 
during O 
CPF B-ABBREVIATION 
dietary O 
exposure O 
. O 

about O 
400 O 
living O 
species O 
and O 
82 O 
genera O 
, O 
rodents O 
of O 
the O 
subfamily O 
Sigmodontinae O 
comprise O 
one O 
of O 
the O 
most O 
diverse O 
and O 
more O 
broadly O 
distributed O 
Neotropical O 
mammalian O 
clades O 
. O 
There O 
has O 
been O 
much O 
debate O 
on O 
the O 
origin O 
of O 
the O 
lineage O 
or O 
the O 
lineages O 
of O 
sigmodontines O 
that O 
entered O 
South O 
America O 
, O 
the O 
timing O 
of O 
entrance O 
and O 
different O 
aspects O 
of O 
further O 
diversification O 
within O 
South O 
America O 
. O 
The O 
ages O 
of O 
divergence O 
of O 
the O 
main O 
lineages O 
and O 
the O 
crown O 
age O 
of O 
the O 
subfamily O 
were O 
estimated O 
by O 
using O 
sequences O 
of O 
the O 
interphotoreceptor O 
retinoid B-FAMILY 
binding O 
protein O 
and O 
cytochrome O 
b O 
genes O 
for O 
a O 
dense O 
sigmodontine O 
and O 
muroid O 
sampling O 
. O 
Bayesian O 
inference O 
using O 
three O 
fossil O 
calibration O 
points O 
and O 
a O 
relaxed O 
molecular O 
clock O 
estimated O 
a O 
middle O 
Miocene O 
origin O 
for O 
Sigmodontinae O 
( O 
∼12Ma O 
) O 
, O 
with O 
most O 
tribes O 
diversifying O 
throughout O 
the O 
Late O 
Miocene O 
( O 
6.9-9.4Ma O 
) O 
. O 
These O 
estimates O 
together O 
results O 
of O 
analyses O 
of O 
ancestral O 
area O 
reconstructions O 
suggest O 
a O 
distribution O 
for O 
the O 
most O 
recent O 
common O 
ancestor O 
of O 
Sigmodontinae O 
in O 
Central-South O 
America O 
and O 
a O 
South O 
American O 
distribution O 
for O 
the O 
most O 
recent O 
common O 
ancestor O 
of O 
Oryzomyalia O 
. O 

attenuates O 
bleomycin B-FAMILY 
-induced O 
pulmonary O 
fibrosis O 
in O 
rats O 
through O 
inhibition O 
of O 
miR-21 O 
. O 

, O 
there O 
is O 
no O 
satisfactory O 
treatment O 
for O 
pulmonary O 
fibrosis O 
, O 
and O 
effective O 
agents O 
urgently O 
need O 
to O 
be O 
developed O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
baicalein B-TRIVIAL 
on O 
bleomycin B-FAMILY 
-induced O 
pulmonary O 
fibrosis O 
, O 
and O 
the O 
novel O 
mechanisms O 
involved O 
in O 
the O 
anti-fibrosis O 
effects O 
. O 
Pulmonary O 
fibrosis O 
was O 
induced O 
by O 
a O 
single O 
intratracheal O 
instillation O 
of O 
5 O 
mg O 
/ O 
kg O 
bleomycin B-FAMILY 
. O 
Two O 
bleomycin B-FAMILY 
-treated O 
groups O 
were O 
orally O 
administered O 
daily O 
with O 
50 O 
and O 
100 O 
mg O 
/ O 
kg O 
of O 
baicalein B-TRIVIAL 
from O 
day O 
1 O 
to O 
28 O 
. O 
The O 
results O 
showed O 
baicalein B-TRIVIAL 
decreased O 
hydroxyproline B-SYSTEMATIC 
content O 
and O 
α-SMA O 
levels O 
and O 
increased O 
lung O 
index O 
. O 
Histopathological O 
examinations O 
demonstrated O 
baicalein B-TRIVIAL 
could O 
obviously O 
lower O 
the O 
degree O 
of O 
alveolitis O 
and O 
lung O 
fibrosis O 
. O 
The O 
total O 
antioxidant O 
capacity O 
in O 
bleomycin B-FAMILY 
-treated O 
rats O 
with O 
baicalein B-TRIVIAL 
was O 
also O 
remarkably O 
higher O 
than O 
in O 
those O 
without O 
baicalein B-TRIVIAL 
. O 
Baicalein B-TRIVIAL 
remarkably O 
decreased O 
miR-21 O 
levels O 
and O 
inhibited O 
the O 
increased O 
expression O 
of O 
TGF-β1 O 
and O 
p-Smad-2 O 
/ O 
3 O 
in O 
bleomycin B-FAMILY 
-treated O 
rats O 
. O 
Baicalein B-TRIVIAL 
can O 
attenuate O 
bleomycin B-FAMILY 
-induced O 
pulmonary O 
fibrosis O 
. O 
The O 
attenuation O 
is O 
partly O 
achieved O 
by O 
improving O 
antioxidant O 
activity O 
, O 
alleviating O 
inflammation O 
, O 
repressing O 
miR-21 O 
, O 
and O 
inhibiting O 
TGF-β O 
/ O 
Smad O 
signaling O 
. O 

of O 
phenylpropanoids B-FAMILY 
with O 
5-fluorouracil B-SYSTEMATIC 
as O 
anti-cancer O 
agents O 
against O 
human O 
cervical O 
cancer O 
( O 
HeLa O 
) O 
cell O 
line O 
. O 

therapy O 
is O 
the O 
most O 
effective O 
treatment O 
strategy O 
in O 
cancer O 
to O 
overcome O 
drug O 
toxicity O 
and O 
drug O 
induced O 
resistance O 
. O 
The O 
effect O 
of O 
eight O 
phenylpropanoids B-FAMILY 
in O 
combination O 
with O 
5-fluorouracil B-SYSTEMATIC 
against O 
the O 
cervical O 
cancer O 
cells O 
( O 
HeLa O 
) O 
is O 
reported O 
here O 
. O 
The O 
cytotoxic O 
activity O 
of O 
these O 
phenylpropanoids B-FAMILY 
against O 
HeLa O 
cells O 
is O 
in O 
the O 
order O 
of O 
eugenol B-TRIVIAL 
> O 
ferulic B-TRIVIAL 
> O 
cinnamic B-TRIVIAL 
> O 
caffeic B-FAMILY 
> O 
chlorogenic B-FAMILY 
> O 
p-coumaric B-TRIVIAL 
> O 
3,4-dimethoxycinnamic B-TRIVIAL 
> O 
2,4,5-trimethoxycinnamic B-FAMILY 
acids I-FAMILY 
. O 
Eugenol B-TRIVIAL 
, O 
ferulic B-MULTIPLE 
and I-MULTIPLE 
caffeic I-MULTIPLE 
acids I-MULTIPLE 
interacted O 
synergistically O 
with O 
the O 
drug O 
, O 
in O 
bringing O 
about O 
a O 
reduction O 
in O 
the O 
amount O 
of O 
the O 
latter O 
. O 
Flow O 
cytometry O 
results O 
indicated O 
that O 
the O 
combination O 
of O 
eugenol B-TRIVIAL 
and O 
5-fluorouracil B-SYSTEMATIC 
increased O 
the O 
number O 
of O 
cells O 
in O 
the O 
S O 
and O 
G2 O 
/ O 
M O 
phases O 
when O 
compared O 
to O 
treatment O 
with O 
the O 
individual O 
compounds O 
alone O 
. O 
This O 
indicates O 
that O 
they O 
possess O 
different O 
cell O 
cycle O 
targets O 
and O 
induce O 
apoptosis O 
in O 
the O 
cancer O 
cells O 
. O 
In O 
vitro O 
hemolytic O 
activity O 
of O 
phenylpropanoids B-FAMILY 
on O 
human O 
erythrocytes O 
showed O 
that O 
the O 
compounds O 
possessed O 
minimum O 
amount O 
of O 
hemolytic O 
activity O 
, O 
indicating O 
that O 
they O 
can O 
be O 
used O 
as O 
drugs O 
without O 
causing O 
adverse O 
toxicity O 
. O 
3D-quantitative O 
structure O 
activity O 
relationship O 
studies O 
indicate O 
the O 
importance O 
of O 
electrostatic O 
region O 
near O 
the O 
substitutions O 
present O 
in O 
the O 
benzene B-SYSTEMATIC 
ring O 
and O 
near O 
the O 
double O 
bond O 
of O 
the O 
compounds O 
for O 
anticancer O 
and O 
hemolytic O 
activities O 
, O 
respectively O 
. O 
The O 
models O 
derived O 
had O 
good O 
statistical O 
predictive O 
capability O 
. O 

reports O 
have O 
identified O 
a O 
role O 
for O 
the O 
tyrosine B-TRIVIAL 
kinase O 
receptor O 
EphB4 O 
and O 
its O 
ligand O 
, O 
ephrinB2 O 
, O 
as O 
potential O 
mediators O 
of O 
both O 
bone O 
formation O 
by O 
osteoblasts O 
and O 
bone O 
resorption O 
by O 
osteoclasts O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
role O 
of O 
EphB4 O 
during O 
bone O 
repair O 
after O 
traumatic O 
injury O 
. O 
We O 
performed O 
femoral O 
fractures O 
with O 
internal O 
fixation O 
in O 
transgenic O 
mice O 
that O 
overexpress O 
EphB4 O 
under O 
the O 
collagen O 
type O 
1 O 
promoter O 
( O 
Col1-EphB4 O 
) O 
and O 
investigated O 
the O 
bone O 
repair O 
process O 
up O 
to O 
12 O 
weeks O 
postfracture O 
. O 
The O 
data O 
indicated O 
that O 
Col1-EphB4 O 
mice O 
exhibited O 
stiffer O 
and O 
stronger O 
bones O 
after O 
fracture O 
compared O 
with O 
wild O 
- O 
type O 
mice O 
. O 
The O 
fractured O 
bones O 
of O 
Col1-EphB4 O 
transgenic O 
mice O 
displayed O 
significantly O 
greater O 
tissue O 
and O 
bone O 
volume O 
2 O 
weeks O 
postfracture O 
compared O 
with O 
that O 
of O 
wild O 
- O 
type O 
mice O 
. O 
These O 
findings O 
correlated O 
with O 
increased O 
chondrogenesis O 
and O 
mineral O 
formation O 
within O 
the O 
callus O 
site O 
at O 
2 O 
weeks O 
postfracture O 
, O 
as O 
demonstrated O 
by O 
increased O 
safranin B-TRIVIAL 
O I-TRIVIAL 
and O 
von O 
Kossa O 
staining O 
, O 
respectively O 
. O 
Interestingly O 
, O 
Col1-EphB4 O 
mice O 
were O 
found O 
to O 
possess O 
significantly O 
greater O 
numbers O 
of O 
clonogenic O 
mesenchymal O 
stromal O 
progenitor O 
cells O 
( O 
CFU-F O 
) O 
, O 
with O 
an O 
increased O 
capacity O 
to O 
form O 
mineralized O 
nodules O 
in O 
vitro O 
under O 
osteogenic O 
conditions O 
, O 
when O 
compared O 
with O 
those O 
of O 
the O 
wild O 
- O 
type O 
control O 
mice O 
. O 
Furthermore O 
, O 
Col1-EphB4 O 
mice O 
had O 
significantly O 
lower O 
numbers O 
of O 
TRAP-positive O 
multinucleated O 
osteoclasts O 
within O 
the O 
callus O 
site O 
. O 
Taken O 
together O 
, O 
these O 
observations O 
suggest O 
that O 
EphB4 O 
promotes O 
endochondral O 
ossification O 
while O 
inhibiting O 
osteoclast O 
development O 
during O 
callus O 
formation O 
and O 
may O 
represent O 
a O 
novel O 
drug O 
target O 
for O 
the O 
repair O 
of O 
fractured O 
bones O 
. O 

activation O 
of O 
alveolar O 
macrophages O 
by O 
ambient O 
particles O 
can O 
be O 
facilitated O 
via O 
Toll O 
- O 
like O 
receptors O 
( O 
TLR O 
) O 
. O 
The O 
action O 
of O 
TLR O 
agonists O 
and O 
antagonists O 
has O 
been O 
reported O 
to O 
depend O 
on O 
the O 
formation O 
of O 
nanoparticulate O 
structures O 
. O 
Aim O 
of O 
the O 
present O 
study O 
was O 
to O 
identify O 
the O 
signaling O 
pathways O 
induced O 
by O 
nanoparticulate O 
structures O 
in O 
human O 
macrophages O 
, O 
which O 
might O 
be O 
critical O 
for O 
inflammatory O 
cell O 
activation O 
. O 
METHODS O 
: O 
Studies O 
were O 
performed O 
in O 
primary O 
human O 
alveolar O 
macrophages O 
or O 
in O 
differentiated O 
THP-1 O 
macrophages O 
. O 
Silica B-TRIVIAL 
nanoparticles O 
were O 
prepared O 
by O 
Stöber O 
synthesis O 
and O 
characterized O 
by O 
dynamic O 
light O 
scattering O 
and O 
scanning O 
electron O 
microscopy O 
. O 
Mycobacterial O 
DNA O 
was O 
isolated O 
from O 
Mycobacterium O 
bovis O 
BCG O 
, O 
and O 
nanoparticle O 
formation O 
was O 
assessed O 
by O 
atomic O 
force O 
microscopy O 
and O 
dynamic O 
light O 
scattering O 
. O 
Actin O 
polymerization O 
was O 
measured O 
by O 
phalloidin B-TRIVIAL 
- O 
TRITC B-ABBREVIATION 
staining O 
, O 
and O 
cell O 
activation O 
was O 
determined O 
by O 
reverse O 
transcription O 
quantitative O 
PCR O 
analysis O 
, O 
L929 O 
cytotoxicity O 
assay O 
( O 
cytokine O 
induction O 
) O 
, O 
and O 
pull O 
- O 
down O 
assays O 
( O 
Rho O 
GTPases O 
) O 
. O 
RESULTS O 
: O 
In O 
contrast O 
to O 
immune O 
stimulatory O 
sequence O 
ISS O 
1018 O 
, O 
BCG O 
DNA O 
spontaneously O 
formed O 
nanoparticulate O 
structures O 
and O 
induced O 
actin O 
polymerization O 
as O 
did O 
synthetic O 
silica B-TRIVIAL 
nanoparticles O 
. O 
Co-incubation O 
with O 
silica B-TRIVIAL 
nanoparticles O 
amplified O 
the O 
responsiveness O 
of O 
macrophages O 
toward O 
the O 
TLR9 O 
ligand O 
ISS O 
1018 O 
. O 
The O 
activation O 
of O 
Rac1 O 
was O 
induced O 
by O 
silica B-TRIVIAL 
nanoparticles O 
as O 
well O 
as O 
BCG O 
DNA O 
and O 
is O 
suggested O 
as O 
the O 
critical O 
signaling O 
event O 
inducing O 
both O 
cytoskeleton O 
changes O 
as O 
well O 
as O 
inflammatory O 
cell O 
activation O 
. O 
CONCLUSION O 
: O 
Nanoparticles O 
can O 
induce O 
signaling O 
pathways O 
, O 
which O 
amplify O 
an O 
inflammatory O 
response O 
in O 
macrophages O 
. O 

and O 
Biological O 
Evaluation O 
of O 
a O 
New O 
Series O 
of O 
Hexahydro-2H-pyrano[3,2-c]quinolines B-FAMILY 
as O 
Novel O 
Selective O 
σ1 O 
Receptor O 
Ligands O 
. O 

synthesis O 
and O 
pharmacological O 
activity O 
of O 
a O 
new O 
series O 
of O 
hexahydro-2H-pyrano[3,2-c]quinoline B-SYSTEMATIC 
derivatives O 
as O 
potent O 
σ1 O 
receptor O 
( O 
σ1R O 
) O 
ligands O 
are O 
reported O 
. O 
This O 
family O 
, O 
which O 
does O 
not O 
contain O 
the O 
highly O 
basic O 
amino B-FAMILY 
group O 
usually O 
present O 
in O 
other O 
σ1R O 
ligands O 
, O 
showed O 
high O 
selectivity O 
over O 
the O 
σ2 O 
receptor O 
( O 
σ2R O 
) O 
. O 
The O 
activity O 
was O 
shown O 
to O 
reside O 
in O 
only O 
one O 
of O 
the O 
four O 
possible O 
diastereoisomers O 
, O 
which O 
exhibited O 
a O 
perfect O 
match O 
with O 
known O 
σ1R O 
pharmacophores O 
. O 
A O 
hit O 
to O 
lead O 
program O 
based O 
on O 
a O 
high O 
- O 
throughput O 
screening O 
hit O 
( O 
8a O 
) O 
led O 
to O 
the O 
identification O 
of O 
compound O 
32c O 
, O 
with O 
substantially O 
improved O 
activity O 
and O 
physicochemical O 
properties O 
. O 
Compound O 
32c O 
also O 
exhibited O 
a O 
good O 
ADMET O 
( O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
, O 
excretion O 
, O 
toxicity O 
) O 
profile O 
and O 
was O 
identified O 
as O 
a O 
σ1R O 
antagonist O 
on O 
the O 
basis O 
of O 
its O 
analgesic O 
activity O 
in O 
the O 
mouse O 
capsaicin B-TRIVIAL 
and O 
formalin B-TRIVIAL 
models O 
of O 
neurogenic O 
pain O 
. O 

( O 
http O 
: O 
/ O 
/ O 
tga.nig.ac.jp O 
/ O 
h2db/ O 
) O 
, O 
an O 
annotation O 
database O 
of O 
genetic O 
heritability O 
estimates O 
for O 
humans O 
and O 
other O 
species O 
, O 
has O 
been O 
developed O 
as O 
a O 
knowledge O 
database O 
to O 
connect O 
trait O 
- O 
associated O 
genomic O 
loci O 
. O 
Heritability O 
estimates O 
have O 
been O 
investigated O 
for O 
individual O 
species O 
, O 
particularly O 
in O 
human O 
twin O 
studies O 
and O 
plant O 
/ O 
animal O 
breeding O 
studies O 
. O 
However O 
, O 
there O 
appears O 
to O 
be O 
no O 
comprehensive O 
heritability O 
database O 
for O 
both O 
humans O 
and O 
other O 
species O 
. O 
Here O 
, O 
we O 
introduce O 
an O 
annotation O 
database O 
for O 
genetic O 
heritabilities O 
of O 
various O 
species O 
that O 
was O 
annotated O 
by O 
manually O 
curating O 
online O 
public O 
resources O 
in O 
PUBMED O 
abstracts O 
and O 
journal O 
contents O 
. O 
The O 
proposed O 
heritability O 
database O 
contains O 
attribute O 
information O 
for O 
trait O 
descriptions O 
, O 
experimental O 
conditions O 
, O 
trait O 
- O 
associated O 
genomic O 
loci O 
and O 
broad- O 
and O 
narrow O 
- O 
sense O 
heritability O 
specifications O 
. O 
Annotated O 
trait O 
- O 
associated O 
genomic O 
loci O 
, O 
for O 
which O 
most O 
are O 
single- O 
nucleotide B-FAMILY 
polymorphisms O 
derived O 
from O 
genome O 
- O 
wide O 
association O 
studies O 
, O 
may O 
be O 
valuable O 
resources O 
for O 
experimental O 
scientists O 
. O 
In O 
addition O 
, O 
we O 
assigned O 
phenotype O 
ontologies O 
to O 
the O 
annotated O 
traits O 
for O 
the O 
purposes O 
of O 
discussing O 
heritability O 
distributions O 
based O 
on O 
phenotypic O 
classifications O 
. O 

magnetoresistance O 
switching O 
in O 
exchange O 
- O 
coupled O 
CoFe₂O₄ B-FORMULA 
-- O 
Fe₃O₄ B-FORMULA 
binary O 
nanocrystal O 
superlattices O 
by O 
self O 
- O 
assembly O 
and O 
thermal O 
annealing O 
. O 

- O 
assembly O 
of O 
multicomponent O 
nanocrystal O 
superlattices O 
provides O 
a O 
modular O 
approach O 
to O 
the O 
design O 
of O 
metamaterials O 
by O 
choosing O 
constituent O 
nanocrystal O 
building O 
blocks O 
with O 
desired O 
physical O 
properties O 
and O 
engineering O 
the O 
interparticle O 
coupling O 
. O 
In O 
this O 
work O 
, O 
we O 
report O 
the O 
self O 
- O 
assembly O 
of O 
binary O 
nanocrystal O 
superlattices O 
composed O 
of O 
magnetically O 
hard O 
CoFe₂O₄ B-FORMULA 
nanocrystals O 
and O 
magnetically O 
soft O 
Fe₃O₄ B-FORMULA 
nanocrystals O 
. O 
Both O 
NaZn₁₃ B-FORMULA 
- O 
and O 
MgZn₂ B-FORMULA 
-type O 
CoFe₂O₄ B-FORMULA 
-- O 
Fe₃O₄ B-FORMULA 
binary O 
nanocrystal O 
superlattices O 
have O 
been O 
formed O 
by O 
the O 
liquid O 
- O 
air O 
interfacial O 
assembly O 
approach O 
. O 
Exchange O 
coupling O 
is O 
achieved O 
in O 
both O 
types O 
of O 
binary O 
superlattices O 
after O 
thermal O 
annealing O 
under O 
vacuum O 
at O 
400 O 
°C O 
. O 
The O 
exchange O 
- O 
coupled O 
CoFe₂O₄ B-FORMULA 
-- O 
Fe₃O₄ B-FORMULA 
binary O 
nanocrystal O 
superlattices O 
show O 
single O 
- O 
phase O 
magnetization O 
switching O 
behavior O 
and O 
magnetoresistance O 
switching O 
behavior O 
below O 
200 O 
K O 
. O 
The O 
NaZn₁₃ B-FORMULA 
-type O 
CoFe₂O₄ B-FORMULA 
-- O 
Fe₃O₄ B-FORMULA 
binary O 
nanocrystal O 
superlattices O 
annealed O 
at O 
500 O 
°C O 
even O 
exhibit O 
bistable O 
magnetoresistance O 
switching O 
behavior O 
at O 
room O 
temperature O 
constituting O 
a O 
simple O 
nonvolatile O 
memory O 
function O 
. O 

role O 
of O 
L-carnitine B-TRIVIAL 
and O 
vitamin B-FAMILY 
E I-FAMILY 
on O 
the O 
testis O 
of O 
atherosclerotic O 
rats O 
. O 

is O 
a O 
condition O 
caused O 
by O 
lipid O 
build O 
- O 
up O 
and O 
inflammation O 
in O 
the O 
arteries O 
, O 
so O 
hyperlipidemia O 
is O 
the O 
major O 
reason O 
for O 
atherosclerosis O 
. O 
Testis O 
was O 
found O 
to O 
be O 
negatively O 
affected O 
by O 
hyperlipidemia O 
which O 
leads O 
to O 
its O 
impaired O 
functions O 
. O 
Vitamin B-FAMILY 
E I-FAMILY 
and O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
have O 
well O 
- O 
known O 
lipid O 
- O 
lowering O 
and O 
antioxidative O 
activities O 
. O 
Triton B-FAMILY 
WR I-FAMILY 
1339 I-FAMILY 
is O 
a O 
non-ionic O 
detergent O 
, O 
which O 
induces O 
severe O 
hyperlipidemia O 
by O 
inhibition O 
of O 
lipoprotein O 
lipase O 
. O 
The O 
present O 
study O 
evaluates O 
the O 
protective O 
role O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
on O 
the O 
testis O 
in O 
atherosclerosis O 
and O 
detects O 
the O 
most O 
effective O 
choice O 
for O 
protection O 
against O 
atherosclerosis O 
; O 
vitamin B-FAMILY 
E I-FAMILY 
, O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
or O 
a O 
combination O 
of O 
both O 
. O 
A O 
total O 
of O 
80 O 
albino O 
male O 
rats O 
were O 
divided O 
into O 
eight O 
groups O 
( O 
10 O 
rats O 
for O 
each O 
group O 
) O 
: O 
control O 
(G(1)) O 
, O 
triton B-FAMILY 
(G(2)) O 
, O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
(G(3)) O 
, O 
triton B-FAMILY 
+ O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
(G(4)) O 
, O 
vitamin B-FAMILY 
E I-FAMILY 
(G(5)) O 
, O 
triton B-FAMILY 
+ O 
vitamin B-FAMILY 
E I-FAMILY 
(G(6)) O 
, O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
+ O 
vitamin B-FAMILY 
E I-FAMILY 
(G(7)) O 
and O 
triton B-FAMILY 
+ O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
+ O 
vitamin B-FAMILY 
E I-FAMILY 
(G(8)) O 
. O 
Data O 
showed O 
a O 
significant O 
increase O 
in O 
the O 
levels O 
of O 
total O 
cholesterol B-TRIVIAL 
( O 
TC O 
) O 
, O 
triglycerides B-FAMILY 
( O 
TGs O 
) O 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
, O 
17 B-FAMILY 
beta I-FAMILY 
hydroxysteroid I-FAMILY 
dehydrogenase O 
( O 
17 O 
β O 
HSD O 
) O 
, O 
testicular O 
catalase O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
in O 
G(2) O 
when O 
compared O 
with O 
G(1) O 
, O 
whereas O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
, O 
serum O 
testosterone B-TRIVIAL 
, O 
testicular O 
17 O 
ketosteroid B-FAMILY 
reductase O 
( O 
17 O 
KSR O 
) O 
, O 
total O 
thiol B-FAMILY 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
data O 
showed O 
a O 
significant O 
decrease O 
in O 
G(2) O 
when O 
compared O 
with O 
G(1) O 
. O 
Treatment O 
with O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
or O 
/ O 
and O 
vitamin B-FAMILY 
E I-FAMILY 
helps O 
in O 
improving O 
the O 
adverse O 
effect O 
of O 
triton B-FAMILY 
; O 
also O 
the O 
histological O 
changes O 
confirm O 
this O 
finding O 
. O 
So O 
the O 
present O 
study O 
recommends O 
all O 
people O 
to O 
include O 
< B-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
l I-TRIVIAL 
< I-TRIVIAL 
/ I-TRIVIAL 
sc I-TRIVIAL 
> I-TRIVIAL 
-carnitine I-TRIVIAL 
and O 
vitamin B-FAMILY 
E I-FAMILY 
in O 
their O 
diet O 
to O 
be O 
protected O 
against O 
atherosclerosis O 
. O 

hyperinsulinism O 
causes O 
persistent O 
hypoglycemia O 
in O 
neonates O 
and O 
infants O 
. O 
Most O 
often O 
, O 
uncontrolled O 
insulin O 
secretion O 
( O 
IS O 
) O 
results O 
from O 
a O 
lack O 
of O 
functional O 
KATP B-FORMULA 
channels O 
in O 
all O 
β-cells O 
or O 
only O 
in O 
β-cells O 
within O 
a O 
resectable O 
focal O 
lesion O 
. O 
In O 
more O 
rare O 
cases O 
, O 
without O 
KATP B-FORMULA 
channel O 
mutations O 
, O 
hyperfunctional O 
islets O 
are O 
confined O 
within O 
few O 
lobules O 
, O 
whereas O 
hypofunctional O 
islets O 
are O 
present O 
throughout O 
the O 
pancreas O 
. O 
They O 
also O 
can O 
be O 
cured O 
by O 
selective O 
partial O 
pancreatectomy O 
; O 
however O 
, O 
unlike O 
those O 
with O 
a O 
KATP B-FORMULA 
focal O 
lesion O 
, O 
they O 
show O 
clinical O 
sensitivity O 
to O 
diazoxide B-SYSTEMATIC 
. O 
Here O 
, O 
we O 
characterized O 
in O 
vitro O 
IS O 
by O 
fragments O 
of O 
pathological O 
and O 
adjacent O 
normal O 
pancreas O 
from O 
six O 
such O 
cases O 
. O 
Responses O 
of O 
normal O 
pancreas O 
were O 
unremarkable O 
. O 
In O 
pathological O 
region O 
, O 
IS O 
was O 
elevated O 
at O 
1 O 
mmol O 
/ O 
L O 
and O 
was O 
further O 
increased O 
by O 
15 O 
mmol O 
/ O 
L O 
glucose B-TRIVIAL 
. O 
Diazoxide B-TRIVIAL 
suppressed O 
IS O 
and O 
tolbutamide B-TRIVIAL 
antagonized O 
the O 
inhibition O 
. O 
The O 
most O 
conspicuous O 
anomaly O 
was O 
a O 
large O 
stimulation O 
of O 
IS O 
by O 
1 O 
mmol O 
/ O 
L O 
glucose B-TRIVIAL 
. O 
In O 
five O 
of O 
six O 
cases O 
, O 
immunohistochemistry O 
revealed O 
undue O 
presence O 
of O 
low-Km O 
hexokinase-I O 
in O 
β-cells O 
of O 
hyperfunctional O 
islets O 
only O 
. O 
In O 
one O 
case O 
, O 
an O 
activating O 
mutation O 
of O 
glucokinase O 
( O 
I211F O 
) O 
was O 
found O 
in O 
pathological O 
islets O 
only O 
. O 
Both O 
abnormalities O 
, O 
attributed O 
to O 
somatic O 
genetic O 
events O 
, O 
may O 
account O 
for O 
inappropriate O 
IS O 
at O 
low O 
glucose B-TRIVIAL 
levels O 
by O 
a O 
subset O 
of O 
β-cells O 
. O 
They O 
represent O 
a O 
novel O 
cause O 
of O 
focal O 
congenital O 
hyperinsulinism O 
. O 

and O 
PDGFR O 
tyrosine B-TRIVIAL 
kinases O 
are O 
important O 
targets O 
for O 
therapy O 
of O 
different O 
types O 
of O 
leukemia O 
. O 
Several O 
FLT3 O 
/ O 
PDGFR O 
inhibitors O 
are O 
currently O 
under O 
clinical O 
investigation O 
for O 
combination O 
with O 
standard O 
therapy O 
for O 
treatment O 
of O 
acute O 
myeloid O 
leukemia O 
( O 
AML O 
) O 
, O 
however O 
these O 
agents O 
only O 
induce O 
partial O 
remission O 
and O 
development O 
of O 
resistance O 
has O 
been O 
reported O 
. O 
In O 
this O 
work O 
we O 
describe O 
the O 
identification O 
of O 
potent O 
and O 
novel O 
dual O 
FLT3 O 
/ O 
PDGFR O 
inhibitors O 
that O 
resulted O 
from O 
our O 
efforts O 
to O 
screen O 
a O 
library O 
of O 
25607 O 
small O 
molecules O 
against O 
the O 
FLT3 O 
dependent O 
cell O 
line O 
MOLM-13 O 
and O 
the O 
PDGFR O 
dependent O 
cell O 
line O 
EOL-1 O 
. O 
This O 
effort O 
led O 
to O 
the O 
identification O 
of O 
five O 
compounds O 
that O 
were O 
confirmed O 
to O 
be O 
active O 
on O 
additional O 
FLT3 O 
dependent O 
cell O 
lines O 
( O 
cellular O 
EC50 O 
values O 
between O 
35 O 
and O 
700 O 
nM O 
) O 
, O 
while O 
having O 
no O 
significant O 
effect O 
on O 
24 O 
other O 
tyrosine B-TRIVIAL 
kinases O 
. O 

( O 
NNK B-TRIVIAL 
) O 
metabolism O 
- O 
related O 
enzymes O 
gene O 
polymorphisms O 
, O 
NNK B-TRIVIAL 
metabolites O 
levels O 
and O 
urothelial O 
carcinoma O 
. O 

polymorphisms O 
of O 
the O 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone B-SYSTEMATIC 
( O 
NNK B-TRIVIAL 
) O 
metabolism O 
- O 
related O 
enzymes O 
- O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
monooxygenase O 
2A13 O 
( O 
CYP2A13 O 
) O 
and O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
(UGT)-2B7 O 
could O 
contribute O 
to O 
the O 
levels O 
of O 
NNK B-TRIVIAL 
-related O 
metabolites O 
in O 
urine O 
, O 
thereby O 
increasing O 
the O 
susceptibility O 
to O 
urothelial O 
carcinoma O 
( O 
UC O 
) O 
. O 
Therefore O 
, O 
our O 
study O 
aimed O 
to O 
evaluate O 
the O 
roles O 
of O 
two O 
gene O 
polymorphisms O 
( O 
CYP2A13 O 
and O 
UGT2B7 O 
) O 
of O 
NNK B-TRIVIAL 
metabolism O 
- O 
related O 
enzymes O 
in O 
the O 
carcinogenesis O 
of O 
UC O 
in O 
Taiwan O 
. O 
A O 
hospital O 
- O 
based O 
pilot O 
case O 
- O 
control O 
study O 
was O 
conducted O 
. O 
There O 
were O 
121 O 
UC O 
cases O 
and O 
121 O 
age- O 
and O 
sex O 
- O 
matched O 
healthy O 
participants O 
recruited O 
from O 
March O 
2007 O 
to O 
April O 
2009 O 
. O 
Urine O 
samples O 
were O 
analyzed O 
for O 
NNK B-TRIVIAL 
-related O 
metabolites O 
using O 
the O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
method O 
. O 
Genotyping O 
was O 
conducted O 
using O 
a O 
polymerase O 
chain O 
reaction O 
- O 
restriction O 
fragment O 
length O 
polymorphism O 
technique O 
. O 
ANCOVA O 
and O 
multivariate O 
logistic O 
regression O 
were O 
applied O 
for O 
data O 
analyses O 
. O 
In O 
healthy O 
controls O 
, O 
former O 
smokers O 
had O 
significantly O 
higher O 
total O 
NNAL B-ABBREVIATION 
and O 
higher O 
NNAL-Gluc B-ABBREVIATION 
than O 
never O 
smokers O 
or O 
current O 
smokers O 
. O 
Subjects O 
carrying O 
the O 
UGT2B7 O 
268 O 
His B-FORMULA 
/ O 
Tyr B-FORMULA 
or O 
Tyr B-FORMULA 
/ O 
Tyr B-FORMULA 
genotype O 
had O 
significantly O 
lower O 
total O 
NNAL B-ABBREVIATION 
than O 
those O 
carrying O 
His B-FORMULA 
/ O 
His B-FORMULA 
genotype O 
. O 
However O 
, O 
no O 
association O 
was O 
seen O 
between O 
gene O 
polymorphisms O 
of O 
CYP2A13 O 
and O 
UGT2B7 O 
and O 
UC O 
risk O 
after O 
adjustment O 
for O 
age O 
and O 
sex O 
. O 
Significant O 
dose O 
-response O 
associations O 
between O 
total O 
NNAL B-ABBREVIATION 
, O 
free O 
NNAL B-ABBREVIATION 
, O 
the O 
ratios O 
of O 
free O 
NNAL B-ABBREVIATION 
/ O 
total O 
NNAL B-ABBREVIATION 
and O 
NNAL-Gluc B-ABBREVIATION 
/ O 
total O 
NNAL B-ABBREVIATION 
and O 
UC O 
risk O 
were O 
observed O 
. O 
In O 
the O 
future O 
, O 
large O 
- O 
scale O 
studies O 
will O 
be O 
required O 
to O 
verify O 
the O 
association O 
between O 
the O 
single O 
nucleotide B-FAMILY 
polymorphisms O 
of O 
NNK B-TRIVIAL 
metabolism O 
- O 
related O 
enzymes O 
and O 
UC O 
risk O 
. O 

of O 
coadministration O 
of O 
artemether B-TRIVIAL 
and O 
lumefantrine B-TRIVIAL 
on O 
selected O 
plasma O 
biochemical O 
and O 
erythrocyte O 
oxidative O 
stress O 
indices O 
in O 
female O 
Wistar O 
rats O 
. O 

the O 
artemisinin B-TRIVIAL 
-based O 
combination O 
therapy O 
( O 
ACT O 
) O 
regimens O 
, O 
artemisinin B-TRIVIAL 
derivative O 
, O 
artemether B-TRIVIAL 
in O 
combination O 
with O 
lumefantrine B-TRIVIAL 
( O 
artemether B-TRIVIAL 
- O 
lumefantrine B-TRIVIAL 
, O 
AL O 
) O 
has O 
achieved O 
excellent O 
results O 
in O 
the O 
fight O 
against O 
malarial O 
scourge O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
toxic O 
potential O 
of O 
these O 
drugs O 
at O 
the O 
therapeutic O 
doses O 
in O 
female O 
Wistar O 
rats O 
. O 
Animals O 
were O 
randomly O 
divided O 
into O 
four O 
groups O 
: O 
those O 
administered O 
1% O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
( O 
control O 
) O 
, O 
those O 
administered O 
artemether B-TRIVIAL 
( O 
4 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
, O 
those O 
administered O 
lumefantrine B-TRIVIAL 
( O 
24 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
, O 
and O 
those O 
coadministered O 
artemether B-TRIVIAL 
( O 
4 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
and O 
lumefantrine B-TRIVIAL 
( O 
24 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
. O 
The O 
drugs O 
were O 
orally O 
administered O 
twice O 
daily O 
for O 
3 O 
days O 
by O 
gastric O 
intubation O 
after O 
which O 
selected O 
plasma O 
biochemical O 
indices O 
, O 
and O 
erythrocytes O 
antioxidant O 
defence O 
and O 
lipid O 
peroxidation O 
markers O 
were O 
evaluated O 
. O 
Coadministration O 
of O 
artemether B-TRIVIAL 
and O 
lumefantrine B-TRIVIAL 
raised O 
liver O 
and O 
renal O 
function O 
markers O 
and O 
increased O 
atherogenic O 
index O 
. O 
While O 
reduced O 
glutathione B-TRIVIAL 
, O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
( O 
G6PD O 
) O 
and O 
catalase O 
activities O 
were O 
reduced O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
glutathione B-TRIVIAL 
-s-transferase O 
activities O 
increased O 
in O 
all O 
the O 
treated O 
groups O 
compared O 
to O 
the O 
control O 
group O 
. O 
The O 
drugs O 
caused O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
elevation O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
compared O 
to O 
the O 
control O 
group O 
. O 
These O 
results O 
imply O 
that O 
coadministration O 
of O 
artemether B-TRIVIAL 
and O 
lumefantrine B-TRIVIAL 
may O 
increase O 
the O 
risks O 
of O 
atherosclerosis O 
as O 
well O 
as O 
liver O 
and O 
renal O 
function O 
impairments O 
in O 
the O 
users O 
. O 
In O 
addition O 
, O 
the O 
drugs O 
may O 
also O 
promote O 
oxidative O 
stress O 
in O 
the O 
erythrocytes O 
. O 

chloroquine I-TRIVIAL 
analogues O 
as O 
dual O 
- O 
stage O 
antimalarial O 
leads O 
. O 

control O 
of O 
malaria O 
is O 
challenged O 
by O 
drug O 
resistance O 
, O 
and O 
new O 
antimalarial O 
drugs O 
are O 
needed O 
. O 
New O 
drug O 
discovery O 
efforts O 
include O 
consideration O 
of O 
hybrid O 
compounds O 
as O 
potential O 
multitarget O 
antimalarials O 
. O 
Previous O 
work O 
from O 
our O 
group O 
has O 
demonstrated O 
that O 
hybrid O 
structures O 
resulting O 
from O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
conjugation O 
with O 
heterocyclic O 
moieties O 
from O 
well O 
- O 
known O 
antimalarials O 
present O 
improved O 
antimalarial O 
activity O 
. O 
Now O 
, O 
we O 
report O 
the O 
synthesis O 
and O 
SAR O 
analysis O 
of O 
an O 
expanded O 
series O 
of O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
displaying O 
remarkably O 
high O 
activities O 
against O 
both O 
blood- O 
and O 
liver O 
- O 
stage O 
malaria O 
parasites O 
. O 
Two O 
compounds O 
judged O 
most O 
promising O 
, O 
based O 
on O 
their O 
in O 
vitro O 
activity O 
and O 
druglikeness O 
according O 
to O 
the O 
Lipinski O 
rules O 
and O 
Veber O 
filter O 
, O 
were O 
active O 
in O 
vivo O 
against O 
blood O 
- O 
stage O 
rodent O 
malaria O 
parasites O 
. O 
Therefore O 
, O 
the O 
compounds O 
reported O 
represent O 
a O 
new O 
entry O 
as O 
promising O 
dual O 
- O 
stage O 
antimalarial O 
leads O 
. O 

is O 
a O 
novel O 
target O 
gene O 
of O 
caveolin-1 O 
promoting O 
chemoresistance O 
to O 
epirubicin B-TRIVIAL 
in O 
human O 
gastric O 
cancer O 
cells O 
. O 

to O 
chemotherapy O 
is O 
a O 
major O 
obstacle O 
for O 
curative O 
treatment O 
of O 
human O 
gastric O 
cancer O 
( O 
GC O 
) O 
. O 
However O 
, O 
the O 
underlying O 
molecular O 
mechanisms O 
are O 
largely O 
unknown O 
. O 
Wingless O 
- O 
type O 
MMTV O 
integration O 
site O 
family O 
members O 
( O 
WNTs O 
) O 
are O 
secreted O 
glycoproteins O 
involved O 
in O 
embryogenesis O 
and O 
, O 
on O 
inappropriate O 
expression O 
in O 
the O 
adult O 
, O 
in O 
cancer O 
. O 
Here O 
, O 
we O 
show O 
expression O 
of O 
WNT6 O 
in O 
GC O 
patient O 
specimens O 
, O 
human O 
GC O 
cell O 
lines O 
and O 
in O 
a O 
mouse O 
model O 
of O 
GC O 
. O 
In O 
human O 
GC O 
cells O 
, O 
WNT6 O 
expression O 
was O 
enhanced O 
by O 
caveolin-1 O 
( O 
Cav1 O 
) O 
, O 
a O 
scaffold O 
protein O 
of O 
plasma O 
membrane O 
caveolae O 
. O 
WNT6 O 
knock O 
- O 
down O 
and O 
overexpression O 
experiments O 
demonstrated O 
that O 
WNT6 O 
increased O 
the O 
resistance O 
to O 
apoptotic O 
cell O 
death O 
induced O 
by O 
the O 
anthracycline B-FAMILY 
chemotherapeutics O 
epirubicin B-TRIVIAL 
( O 
Epi B-ABBREVIATION 
) O 
and O 
doxorubicin B-TRIVIAL 
( O 
Dox B-ABBREVIATION 
) O 
. O 
Epi B-ABBREVIATION 
increased O 
the O 
activity O 
of O 
the O 
human O 
WNT6 O 
promoter O 
through O 
Cav1-dependent O 
binding O 
of O 
β-catenin O 
to O 
the O 
proximal O 
WNT6 O 
promoter O 
. O 
Epi B-ABBREVIATION 
increased O 
both O 
WNT6 O 
/ O 
Wnt6 O 
and O 
Cav1 O 
expression O 
in O 
human O 
GC O 
cells O 
and O 
within O 
the O 
tumor O 
area O 
of O 
a O 
murine O 
model O 
of O 
GC O 
( O 
CEA424-SV40 O 
TAg O 
) O 
. O 
In O 
GC O 
patients O 
, O 
WNT6 O 
expression O 
was O 
positively O 
associated O 
with O 
the O 
tumor O 
stage O 
and O 
the O 
nodal O 
status O 
, O 
and O 
inversely O 
correlated O 
with O 
the O 
response O 
to O 
ECF O 
( O 
Epi B-ABBREVIATION 
, O 
cisplatin B-TRIVIAL 
, O 
5-fluorouracil B-SYSTEMATIC 
) O 
chemotherapy O 
. O 
These O 
results O 
showed O 
that O 
WNT6 O 
and O 
Cav1 O 
are O 
upregulated O 
by O 
chemotherapeutics O 
and O 
enhance O 
the O 
resistance O 
of O 
GC O 
cells O 
to O 
anthracycline B-FAMILY 
drugs O 
. O 
Understanding O 
the O 
molecular O 
mechanisms O 
driving O 
WNT6 O 
/ O 
Cav1-induced O 
drug O 
resistance O 
will O 
provide O 
benefits O 
in O 
developing O 
new O 
therapies O 
for O 
GC O 
. O 

is O 
a O 
multidomain O 
Arf O 
GAP O 
( O 
ADP B-ABBREVIATION 
ribosylation O 
factor O 
- O 
directed O 
GTPase O 
- O 
activating O 
protein O 
) O 
that O 
was O 
shown O 
to O 
promote O 
the O 
fast O 
- O 
recycling O 
of O 
transferrin O 
receptors O 
. O 
Here O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
AGAP2 O 
regulates O 
trafficking O 
of O 
β2-adrenergic O 
receptors O 
. O 
We O 
found O 
that O 
AGAP2 O 
formed O 
a O 
complex O 
with O 
βArrestin1 O 
and O 
βArrestin2 O 
, O 
proteins O 
that O 
are O 
known O 
to O 
regulate O 
β2-adrenergic O 
receptor O 
signaling O 
and O 
trafficking O 
. O 
AGAP2 O 
colocalized O 
with O 
βArrestin2 O 
on O 
the O 
plasma O 
membrane O 
, O 
and O 
knockdown O 
of O 
AGAP2 O 
expression O 
reduced O 
plasma O 
membrane O 
association O 
of O 
βArrestin2 O 
upon O 
β2-adrenergic O 
receptor O 
activation O 
. O 
AGAP2 O 
also O 
colocalized O 
with O 
internalized O 
β2-adrenergic O 
receptors O 
on O 
endosomes O 
, O 
and O 
overexpression O 
of O 
AGAP2 O 
slowed O 
accumulation O 
of O 
β2-adrenergic O 
receptor O 
in O 
the O 
perinuclear O 
recycling O 
endosomes O 
. O 
On O 
the O 
contrary O 
, O 
knockdown O 
of O 
AGAP2 O 
expression O 
prevented O 
recycling O 
of O 
β2-adrenergic O 
receptor O 
back O 
to O 
the O 
plasma O 
membrane O 
. O 
In O 
addition O 
, O 
AGAP2 O 
formed O 
a O 
complex O 
with O 
endogenous O 
Erk O 
and O 
overexpression O 
of O 
AGAP2 O 
potentiated O 
Erk O 
phosphorylation O 
induced O 
by O 
β2-adrenergic O 
receptors O 
. O 
Taken O 
together O 
, O 
these O 
results O 
support O 
the O 
hypothesis O 
that O 
AGAP2 O 
plays O 
a O 
role O 
in O 
the O 
signaling O 
and O 
recycling O 
of O 
β2-adrenergic O 
receptors O 
. O 

practical O 
protocol O 
to O 
obtain O 
accurate O 
heat O 
capacity O 
values O 
of O 
pharmaceutical O 
compounds O 
using O 
modulated O 
- O 
temperature O 
differential O 
scanning O 
calorimetry O 
was O 
established O 
. O 
Three O 
pharmaceutical O 
compounds O 
, O 
acetaminophen B-TRIVIAL 
, O 
indomethacin B-TRIVIAL 
, O 
and O 
tri-O-methyl-β-cyclodextrin B-SYSTEMATIC 
were O 
used O 
as O 
model O 
compounds O 
. O 
Powder O 
samples O 
did O 
not O 
produce O 
reproducible O 
results O 
, O 
presumably O 
due O 
to O 
inclusion O 
of O 
gas O 
in O 
gap O 
of O 
powders O 
that O 
influenced O 
the O 
measured O 
heat O 
capacity O 
and O 
thermal O 
homogeneity O 
in O 
the O 
sample O 
. O 
Thus O 
, O 
the O 
amorphous O 
characteristics O 
were O 
evaluated O 
using O 
quench O 
- O 
cooled O 
samples O 
. O 
Crystalline O 
samples O 
were O 
obtained O 
by O 
partially O 
melting O 
the O 
sample O 
to O 
allow O 
recrystallization O 
using O 
the O 
residual O 
crystal O 
as O 
a O 
template O 
. O 
Optimum O 
sample O 
mass O 
was O 
about O 
10 O 
mg O 
. O 
Use O 
of O 
too O 
small O 
sample O 
size O 
resulted O 
in O 
poor O 
reproducibility O 
due O 
to O 
localization O 
of O 
the O 
sample O 
in O 
the O 
pan O 
, O 
while O 
too O 
large O 
size O 
resulted O 
in O 
low O 
heat O 
capacity O 
values O 
probably O 
because O 
of O 
heterogeneity O 
of O 
the O 
sample O 
temperature O 
. O 
The O 
optimum O 
modulation O 
period O 
was O 
in O 
the O 
range O 
of O 
60 O 
s O 
and O 
90 O 
s O 
, O 
to O 
which O 
the O 
ramp O 
rates O 
of O 
2°C O 
/ O 
min O 
and O 
1°C O 
/ O 
min O 
, O 
respectively O 
, O 
were O 
applied O 
. O 
The O 
ramp O 
amplitude O 
was O 
less O 
significant O 
in O 
the O 
evaluation O 
. O 
This O 
information O 
should O 
help O 
in O 
comprehending O 
basic O 
characteristics O 
of O 
pharmaceutical O 
compounds O 
. O 

and O 
interindividual O 
variabilities O 
in O 
endogenous O 
cortisol B-TRIVIAL 
6β-hydroxylation O 
clearance O 
as O 
an O 
index O 
for O 
in O 
vivo O 
CYP3A O 
phenotyping O 
in O 
humans O 
. O 

study O 
was O 
designed O 
to O 
evaluate O 
the O 
in O 
vivo O 
activity O 
of O 
cytochrome O 
P450 O 
3A O 
( O 
CYP3A O 
) O 
in O 
49 O 
healthy O 
Japanese O 
subjects O 
aged O 
22-58 O 
years O 
using O 
endogenous O 
cortisol B-TRIVIAL 
6β-hydroxylation O 
clearance O 
[CLm(6β)] O 
, O 
a O 
novel O 
biomarker O 
for O 
CYP3A O 
phenotyping O 
. O 
CLm(6β) O 
in O 
the O 
49 O 
healthy O 
subjects O 
was O 
2.4 O 
± O 
0.79 O 
ml O 
/ O 
min O 
with O 
an O 
approximately O 
4-fold O 
interindividual O 
variability O 
of O 
CYP3A O 
activity O 
. O 
The O 
mean O 
clearance O 
in O 
the O 
24 O 
women O 
was O 
2.5 O 
± O 
0.89 O 
ml O 
/ O 
min O 
; O 
the O 
value O 
in O 
the O 
women O 
was O 
higher O 
than O 
in O 
the O 
25 O 
men O 
( O 
2.3 O 
± O 
0.69 O 
ml O 
/ O 
min O 
) O 
by O 
approximately O 
9% O 
. O 
We O 
also O 
measured O 
the O 
change O 
of O 
CLm(6β) O 
in O 
14 O 
healthy O 
subjects O 
in O 
the O 
morning O 
at O 
10 O 
: O 
00-12 O 
: O 
0 O 
every O 
2 O 
or O 
3 O 
days O 
over O 
a O 
period O 
of O 
36-53 O 
days O 
and O 
observed O 
a O 
1.5-fold O 
to O 
3.4-fold O 
day O 
- O 
to O 
- O 
day O 
intraindividual O 
variability O 
in O 
the O 
CYP3A O 
activity O 
. O 
The O 
mean O 
value O 
for O 
CLm(6β) O 
in O 
each O 
subject O 
for O 
36-53 O 
days O 
was O 
2.54 O 
± O 
0.76 O 
ml O 
/ O 
min O 
( O 
n O 
= O 
14 O 
) O 
. O 
We O 
also O 
evaluated O 
the O 
CLm(6β) O 
every O 
2 O 
hours O 
from O 
8 O 
: O 
00-20 O 
: O 
0 O 
in O 
26 O 
healthy O 
subjects O 
. O 
The O 
within O 
- O 
day O 
intraindividual O 
clearance O 
variability O 
was O 
1.1-fold O 
to O 
2.5-fold O 
( O 
2.45 O 
± O 
0.91 O 
ml O 
/ O 
min O 
, O 
n O 
= O 
26 O 
) O 
. O 
No O 
characteristic O 
diurnal O 
rhythms O 
were O 
observed O 
in O 
the O 
in O 
vivo O 
activity O 
of O 
CYP3A O 
. O 

probable O 
clinically O 
significant O 
interaction O 
between O 
warfarin B-TRIVIAL 
and O 
cloxacillin B-TRIVIAL 
: O 
three O 
case O 
reports O 
. O 

: O 
Three O 
patients O 
were O 
admitted O 
to O 
the O 
Imam O 
Hospital O 
, O 
Tehran O 
, O 
Iran O 
with O 
a O 
diagnosis O 
of O 
bacterial O 
endocarditis O 
. O 
The O 
patients O 
had O 
indications O 
for O 
valve O 
replacement O 
surgery O 
and O 
anticoagulant O 
therapy O 
. O 
The O 
administration O 
of O 
cloxacillin B-TRIVIAL 
reduced O 
the O 
effect O 
of O 
warfarin B-TRIVIAL 
, O 
and O 
subsequent O 
increases O 
in O 
warfarin B-TRIVIAL 
doses O 
were O 
unable O 
to O 
overcome O 
this O 
effect O 
. O 
CONCLUSION O 
: O 
A O 
decrease O 
in O 
warfarin B-TRIVIAL 
anticoagulation O 
effects O 
was O 
detected O 
in O 
our O 
three O 
patients O 
following O 
cloxacillin B-TRIVIAL 
therapy O 
for O 
infective O 
endocarditis O 
. O 
Penicillinase O 
- O 
resistant O 
penicillins B-FAMILY 
remain O 
essential O 
antibiotics O 
in O 
the O 
treatment O 
of O 
severe O 
infections O 
caused O 
by O 
Staphylococcus O 
aureus O 
due O 
to O 
their O 
bactericidal O 
activity O 
, O 
safety O 
, O 
and O 
cost O 
. O 
Thus O 
, O 
in O 
situations O 
where O 
anticoagulants O 
are O 
indicated O 
in O 
patients O 
with O 
infective O 
endocarditis O 
, O 
it O 
would O 
be O 
better O 
to O 
replace O 
warfarin B-TRIVIAL 
with O 
low O 
- O 
molecular O 
- O 
weight O 
or O 
unfractionated O 
heparin O 
. O 

protects O 
osteoblast O 
function O 
via O 
its O 
antioxidant O 
activity O 
in O 
MC3T3-E1 O 
cells O 
. O 

- O 
related O 
osteoblast O 
dysfunction O 
is O 
the O 
main O 
cause O 
of O 
age O 
- O 
related O 
bone O 
loss O 
in O 
both O 
men O 
and O 
women O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
effect O 
of O 
sciadopitysin B-TRIVIAL 
, O 
a O 
type O 
of O 
biflavonoids B-FAMILY 
, O 
on O 
osteoblast O 
function O 
was O 
investigated O 
in O 
osteoblastic O 
MC3T3-E1 O 
cells O 
. O 
Sciadopitysin B-TRIVIAL 
caused O 
a O 
significant O 
elevation O 
of O 
alkaline O 
phosphatase O 
activity O 
, O 
collagen O 
synthesis O 
, O 
osteocalcin O 
production O 
, O 
mineralization O 
, O 
and O 
glutathione B-TRIVIAL 
content O 
in O 
the O 
cells O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Sciadopitysin B-TRIVIAL 
also O 
decreased O 
the O 
production O 
of O 
tumor O 
necrosis O 
factor-a O 
( O 
TNF-α O 
) O 
induced O 
by O 
antimycin B-TRIVIAL 
A I-TRIVIAL 
, O 
a O 
mitochondrial O 
electron O 
transport O 
inhibitor O 
. O 
We O 
investigated O 
the O 
protective O 
effects O 
of O 
sciadopitysin B-TRIVIAL 
on O 
antimycin B-TRIVIAL 
A I-TRIVIAL 
-induced O 
toxicity O 
in O 
osteoblastic O 
MC3T3-E1 O 
cells O 
. O 
Exposure O 
of O 
MC3T3-E1 O 
cells O 
to O 
antimycin B-TRIVIAL 
A I-TRIVIAL 
caused O 
a O 
significant O 
reduction O 
in O 
osteoblast O 
dysfunction O 
. O 
However O 
, O 
pretreatment O 
with O 
sciadopitysin B-TRIVIAL 
prior O 
to O 
antimycin B-TRIVIAL 
A I-TRIVIAL 
exposure O 
significantly O 
reduced O 
antimycin B-TRIVIAL 
A I-TRIVIAL 
-induced O 
cell O 
damage O 
by O 
preventing O 
mitochondrial O 
membrane O 
potential O 
dissipation O 
, O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
loss O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
release O 
, O 
and O 
nitrotyrosine B-SYSTEMATIC 
increase O 
, O 
suggesting O 
that O 
sciadopitysin B-TRIVIAL 
may O 
be O 
useful O 
for O 
protecting O 
mitochondria O 
against O 
a O 
burst O 
of O 
oxidative O 
stress O 
. O 
Moreover O 
, O 
sciadopitysin B-TRIVIAL 
increased O 
phosphorylation O 
of O 
cAMP B-ABBREVIATION 
-response O 
element O 
- O 
binding O 
protein O 
( O 
CREB O 
) O 
inhibited O 
by O 
antimycin B-TRIVIAL 
A I-TRIVIAL 
. O 
Our O 
results O 
demonstrate O 
that O 
sciadopitysin B-TRIVIAL 
may O 
reduce O 
or O 
prevent O 
osteoblasts O 
degeneration O 
. O 

hypocholesterolemic O 
effects O 
of O 
two O 
low O 
calorie O 
structured O 
lipids O 
( O 
SL1 O 
and O 
SL2 O 
) O 
containing O 
essential O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
prepared O 
by O 
lipase O 
catalysed O 
interesterification O 
of O 
ethyl B-SYSTEMATIC 
behenate I-SYSTEMATIC 
respectively O 
with O 
sunflower O 
and O 
soybean O 
oils O 
were O 
studied O 
in O 
rats O 
and O 
rabbits O 
. O 
The O 
feeding O 
experiment O 
conducted O 
on O 
rats O 
as O 
well O 
as O 
rabbits O 
, O 
fed O 
on O 
normal O 
and O 
atherogenic O 
diet O 
containing O 
10% O 
of O 
SL1 O 
and O 
SL2 O 
( O 
experimental O 
) O 
and O 
sunflower O 
oil O 
( O 
control O 
) O 
indicated O 
no O 
adverse O 
effects O 
on O 
growth O 
and O 
food O 
intake O 
. O 
However O 
, O 
the O 
structured O 
lipids O 
beneficially O 
lowered O 
serum O 
and O 
liver O 
lipids O 
, O 
particularly O 
cholesterol B-TRIVIAL 
, O 
LDL O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
and O 
also O 
maintains O 
the O 
essential O 
fatty B-FAMILY 
acid I-FAMILY 
status O 
in O 
serum O 
and O 
liver O 
. O 
The O 
lipid O 
deposition O 
observed O 
in O 
the O 
arteries O 
of O 
rabbits O 
fed O 
on O 
atherogenic O 
diets O 
was O 
significantly O 
reduced O 
when O 
structured O 
lipids O 
were O 
included O 
in O 
the O 
diet O 
. O 
These O 
observations O 
coincided O 
with O 
reduced O 
levels O 
of O 
serum O 
cholesterol B-TRIVIAL 
particularly O 
LDL O 
cholesterol B-TRIVIAL 
observed O 
in O 
experimental O 
groups O 
. O 
Therefore O 
the O 
structured O 
lipids O 
, O 
designed O 
to O 
have O 
low O 
calorific O 
value O 
also O 
beneficially O 
lower O 
serum O 
lipids O 
and O 
lipid O 
deposition O 
in O 
animals O 
fed O 
on O 
atherogenic O 
diets O 
. O 

ethanol B-SYSTEMATIC 
consumption O 
under O 
exposure O 
to O 
lead O 
intensifies O 
disorders O 
in O 
bone O 
metabolism O 
: O 
A O 
study O 
in O 
a O 
rat O 
model O 
. O 

was O 
investigated O 
whether O 
ethanol B-SYSTEMATIC 
( O 
Et O 
) O 
modifies O 
the O 
damaging O 
impact O 
of O 
lead O 
( O 
Pb B-FORMULA 
) O 
on O 
bone O 
metabolism O 
in O 
a O 
rat O 
model O 
reflecting O 
excessive O 
alcohol B-FAMILY 
consumption O 
by O 
humans O 
exposed O 
to O 
relatively O 
high O 
levels O 
of O 
this O 
metal O 
. O 
For O 
this O 
purpose O 
, O 
markers O 
of O 
bone O 
formation O 
( O 
osteocalcin O 
, O 
procollagen O 
I O 
, O 
osteoprotegerin O 
, O 
alkaline O 
phosphatase O 
) O 
and O 
resorption O 
( O 
telopeptides O 
of O 
collagen O 
I O 
, O 
soluble O 
receptor O 
activator O 
of O 
nuclear O 
factor-κB O 
ligand O 
) O 
, O 
calciotropic O 
hormones O 
( O 
parathormone O 
, O 
calcitonin O 
, O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
and O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
) O 
in O 
the O 
serum O 
, O 
and O 
the O 
femur O 
content O 
of O 
mineral O 
( O 
including O 
calcium B-SYSTEMATIC 
- O 
Ca B-FORMULA 
and O 
inorganic O 
phosphorus B-SYSTEMATIC 
- O 
Pi O 
) O 
and O 
organic O 
components O 
were O 
estimated O 
in O 
the O 
rats O 
exposed O 
to O 
500mg O 
Pb B-FORMULA 
/l O 
( O 
in O 
drinking O 
water O 
) O 
or O 
/ O 
and O 
Et O 
( O 
5g O 
/ O 
kg O 
b.wt O 
. O 
/ O 
24h O 
, O 
by O 
oral O 
gavage O 
) O 
for O 
12weeks O 
. O 
Moreover O 
, O 
Ca B-FORMULA 
and O 
Pi O 
in O 
the O 
serum O 
and O 
urine O 
, O 
alkaline O 
phosphatase O 
in O 
the O 
bone O 
tissue O 
and O 
Pb B-FORMULA 
in O 
the O 
blood O 
and O 
femur O 
were O 
determined O 
. O 
The O 
exposure O 
to O 
Pb B-FORMULA 
or O 
/ O 
and O 
Et O 
decreased O 
bone O 
formation O 
and O 
increased O 
its O 
resorption O 
resulting O 
in O 
the O 
bone O 
demineralization O 
. O 
These O 
effects O 
were O 
accompanied O 
by O 
destroying O 
the O 
hormonal O 
regulation O 
of O 
mineral O 
metabolism O 
, O 
and O 
Ca B-FORMULA 
and O 
Pi O 
imbalance O 
. O 
The O 
co O 
- O 
exposure O 
to O 
Pb B-FORMULA 
and O 
Et-induced O 
disorders O 
in O 
bone O 
metabolism O 
were O 
more O 
advanced O 
than O 
those O 
caused O 
by O 
Pb B-FORMULA 
alone O 
. O 
Et O 
co O 
- O 
administration O 
increased O 
Pb B-FORMULA 
concentration O 
in O 
the O 
blood O 
and O 
decreased O 
its O 
accumulation O 
in O 
the O 
bone O 
. O 
This O 
paper O 
is O 
the O 
first O 
report O 
providing O 
evidence O 
that O 
consumption O 
of O 
Et O 
under O 
exposure O 
to O 
Pb B-FORMULA 
intensifies O 
disorders O 
in O 
bone O 
metabolism O 
and O 
that O 
destroying O 
of O 
the O 
receptor O 
activator O 
nuclear O 
factor-κB O 
( O 
RANK O 
) O 
/ O 
RANK O 
ligand O 
/ O 
osteoprotegerin O 
system O 
is O 
involved O 
in O 
the O 
mechanisms O 
of O 
interactive O 
action O 
of O 
these O 
xenobiotics O 
on O 
the O 
skeleton O 
. O 
The O 
modifying O 
impact O 
of O 
Et O 
may O 
be O 
an O 
effect O 
of O 
its O 
independent O 
osteotropic O 
action O 
and O 
interaction O 
with O 
Pb B-FORMULA 
. O 
Based O 
on O 
the O 
results O 
it O 
can O 
be O 
concluded O 
that O 
alcohol B-FAMILY 
abuse O 
by O 
subjects O 
excessively O 
exposed O 
to O 
Pb B-FORMULA 
considerably O 
increases O 
the O 
risk O 
of O 
bone O 
damage O 
. O 

on O 
real O 
- O 
time O 
observation O 
on O 
dynamic O 
growth O 
/ O 
dissolution O 
of O 
conductive O 
filaments O 
in O 
oxide B-SYSTEMATIC 
-electrolyte- O 
based O 
ReRAM O 
. O 

formation O 
and O 
dissolution O 
in O 
the O 
system O 
Ag(Cu) B-FORMULA 
/ O 
ZrO(2) B-FORMULA 
/ O 
Pt B-FORMULA 
were O 
observed O 
by O 
Liu O 
et O 
al O 
. O 
[ O 
Adv O 
. O 
Mater O 
. O 
2012 O 
, O 
24 O 
, O 
1844 O 
] O 
. O 
Their O 
explanation O 
of O 
the O 
phenomena O 
is O 
shown O 
here O 
to O 
be O 
inappropriate O 
. O 
Various O 
situations O 
, O 
including O 
the O 
" O 
bipolar O 
electrode O 
" O 
shown O 
in O 
the O 
figure O 
, O 
are O 
considered O 
and O 
the O 
difference O 
between O 
the O 
behavior O 
in O 
electrochemical O 
metallization O 
memories O 
( O 
ECMs O 
) O 
and O 
valence O 
change O 
memories O 
( O 
VCMs O 
) O 
outlined O 
. O 
Of O 
crucial O 
importance O 
for O 
distinguishing O 
ECM O 
from O 
VCM O 
behavior O 
, O 
that O 
is O 
, O 
the O 
effects O 
of O 
cation O 
and O 
anion O 
migration O 
, O 
is O 
the O 
choice O 
of O 
the O 
solid O 
materials O 
used O 
to O 
transport O 
metal O 
cations O 
. O 
A O 
possible O 
explanation O 
of O 
the O 
phenomena O 
is O 
proposed O 
. O 

study O 
of O 
Growth B-TRIVIAL 
Hormone-Releasing I-TRIVIAL 
Peptide I-TRIVIAL 
6 I-TRIVIAL 
( O 
GHRP-6 B-ABBREVIATION 
) O 
in O 
nine O 
male O 
healthy O 
volunteers O 
. O 

is O 
a O 
growth O 
hormone O 
secretagogue O 
that O 
also O 
enhances O 
tissue O 
viability O 
in O 
different O 
organs O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
studied O 
the O 
pharmacokinetics O 
of O 
this O 
short O 
therapeutic O 
hexapeptide O 
( O 
His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) B-FORMULA 
MW=872.44 O 
Da O 
) O 
in O 
nine O 
male O 
healthy O 
volunteers O 
after O 
a O 
single O 
intravenous O 
bolus O 
administration O 
of O 
100 O 
, O 
200 O 
and O 
400 O 
μg O 
/ O 
kg O 
of O 
body O 
weight O 
. O 
GHRP-6 B-ABBREVIATION 
was O 
quantified O 
in O 
human O 
plasma O 
by O 
a O 
specific O 
LC-MS O 
method O 
, O 
previously O 
developed O 
and O 
validated O 
following O 
FDA O 
guidelines O 
, O 
using O 
(13)C(3)Ala-GHRP-6 B-FORMULA 
as O 
internal O 
standard O 
( O 
Gil O 
et O 
al O 
. O 
, O 
2012 O 
, O 
J O 
. O 
Pharm O 
. O 
Biomed O 
. O 
Anal O 
. O 
60 O 
, O 
19-25 O 
) O 
. O 
The O 
Lower O 
Limit O 
of O 
Quantification O 
( O 
5 O 
ng O 
/ O 
mL O 
) O 
was O 
reached O 
in O 
all O 
subjects O 
at O 
12h O 
post O 
- O 
administration O 
, O 
which O 
was O 
sufficient O 
for O 
modeling O 
a O 
pharmacokinetic O 
profile O 
including O 
over O 
85% O 
of O 
the O 
Area O 
under O 
the O 
Curve O 
( O 
AUC O 
) O 
. O 
Disposition O 
of O 
GHRP-6 B-ABBREVIATION 
best O 
fitted O 
a O 
bi O 
- O 
exponential O 
function O 
with O 
R(2) O 
higher O 
than O 
0.99 O 
, O 
according O 
to O 
a O 
mathematic O 
modeling O 
and O 
confirmed O 
by O 
an O 
Akaike O 
index O 
( O 
AIC O 
) O 
lower O 
than O 
that O 
of O 
the O 
corresponding O 
one O 
- O 
compartment O 
model O 
for O 
all O 
subjects O 
. O 
Averaging O 
all O 
three O 
dose O 
levels O 
, O 
the O 
distribution O 
and O 
elimination O 
half O 
- O 
life O 
of O 
GHRP-6 B-ABBREVIATION 
were O 
7.6 O 
± O 
1.9 O 
min O 
and O 
2.5 O 
± O 
1.1h O 
, O 
respectively O 
. O 
These O 
values O 
are O 
coherent O 
with O 
existing O 
data O 
for O 
other O 
drugs O 
whose O 
disposition O 
also O 
fits O 
this O 
model O 
. O 
Dose O 
dependence O 
analysis O 
revealed O 
a O 
noticeable O 
trend O 
for O 
AUC O 
to O 
increase O 
proportionally O 
with O 
administered O 
dose O 
. O 
Atypical O 
GHRP-6 B-ABBREVIATION 
concentration O 
spikes O 
were O 
observed O 
during O 
the O 
elimination O 
phase O 
in O 
four O 
out O 
of O 
the O 
nine O 
subjects O 
studied O 
. O 

use O 
of O 
bacterial O 
viruses O 
for O 
antibacterial O 
treatment O 
( O 
bacteriophage O 
therapy O 
) O 
is O 
currently O 
being O 
reevaluated O 
. O 
In O 
this O 
study O 
, O 
we O 
analyze O 
the O 
potential O 
of O 
processing O 
bacteriophages O 
in O 
a O 
dry O 
powder O 
formulation O 
, O 
using O 
a O 
laboratory O 
spray O 
dryer O 
. O 
The O 
phages O 
were O 
dried O 
in O 
the O 
presence O 
of O 
lactose B-TRIVIAL 
, O 
trehalose B-TRIVIAL 
or O 
dextran O 
35 O 
, O 
serving O 
as O 
an O 
excipient O 
to O 
give O 
the O 
resulting O 
powder O 
the O 
necessary O 
bulk O 
mass O 
and O 
offer O 
protection O 
to O 
the O 
delicate O 
phage O 
structure O 
. O 
Out O 
of O 
the O 
three O 
excipients O 
tested O 
, O 
trehalose B-TRIVIAL 
was O 
found O 
to O 
be O 
the O 
most O 
efficient O 
in O 
protecting O 
the O 
phages O 
from O 
temperature O 
and O 
shear O 
stress O 
throughout O 
the O 
spray O 
drying O 
process O 
. O 
A O 
low O 
inlet O 
air O 
temperature O 
and O 
atomizing O 
force O 
appeared O 
to O 
be O 
the O 
best O 
parameter O 
conditions O 
for O 
phage O 
survival O 
. O 
Pseudomonas O 
podovirus O 
LUZ19 O 
was O 
remarkably O 
stable O 
, O 
suffering O 
less O 
than O 
1 O 
logarithmic O 
unit O 
reduction O 
in O 
phage O 
titer O 
. O 
The O 
phage O 
titer O 
of O 
Staphyloccus O 
phage O 
Romulus O 
- O 
containing O 
powders O 
, O 
a O 
member O 
of O 
the O 
Myoviridae O 
family O 
, O 
showed O 
more O 
than O 
2.5 O 
logarithmic O 
units O 
reduction O 
. O 
On O 
the O 
other O 
hand O 
, O 
Romulus O 
- O 
containing O 
powders O 
showed O 
more O 
favorable O 
characteristics O 
for O 
pulmonary O 
delivery O 
, O 
with O 
a O 
high O 
percentage O 
of O 
dry O 
powder O 
particles O 
in O 
the O 
pulmonary O 
deposition O 
fraction O 
( O 
1-5μm O 
particle O 
diameter O 
) O 
. O 
Even O 
though O 
the O 
parameters O 
for O 
spray O 
drying O 
all O 
phages O 
were O 
not O 
optimized O 
, O 
it O 
was O 
demonstrated O 
that O 
spray O 
drying O 
phages O 
with O 
this O 
industrial O 
relevant O 
and O 
scalable O 
set O 
up O 
was O 
possible O 
. O 
The O 
resulting O 
powders O 
had O 
desirable O 
size O 
ranges O 
for O 
pulmonary O 
delivery O 
of O 
phages O 
with O 
dry O 
powder O 
inhalers O 
( O 
DPIs O 
) O 
. O 

airway O 
distensibility O 
due O 
to O 
increased O 
airway O 
stiffness O 
is O 
a O 
characteristic O 
of O 
asthma O 
. O 
Airway O 
stiffness O 
is O 
determined O 
by O 
the O 
property O 
and O 
structural O 
organization O 
of O 
the O 
various O 
elements O 
of O 
the O 
airway O 
wall O 
, O 
and O 
is O 
often O 
divided O 
into O 
active O 
and O 
passive O 
components O 
. O 
Active O 
stiffness O 
is O 
thought O 
to O 
be O 
associated O 
with O 
activation O 
of O 
muscle O 
cells O 
in O 
the O 
airway O 
wall O 
. O 
This O 
component O 
of O 
stiffness O 
can O 
be O 
inhibited O 
when O 
active O 
force O 
produced O 
by O 
the O 
muscle O 
is O 
abolished O 
. O 
Passive O 
stiffness O 
, O 
on O 
the O 
other O 
hand O 
, O 
is O 
thought O 
to O 
stem O 
from O 
non-muscle O 
component O 
of O 
the O 
airway O 
wall O 
, O 
especially O 
the O 
collagen O 
/ O 
elastin O 
fibrous O 
network O 
of O 
the O 
extracellular O 
matrix O 
within O 
which O 
the O 
muscle O 
cells O 
are O 
embedded O 
. O 
In O 
this O 
brief O 
review O 
, O 
the O 
notion O 
that O 
passive O 
stiffness O 
is O 
exclusively O 
extracellular O 
in O 
origin O 
is O 
challenged O 
. O 
Recent O 
evidence O 
suggests O 
that O 
a O 
substantial O 
portion O 
of O 
the O 
passive O 
stiffness O 
of O 
an O 
in O 
vitro O 
preparation O 
of O 
tracheal O 
smooth O 
muscle O 
is O 
calcium B-SYSTEMATIC 
sensitive O 
and O 
is O 
regulated O 
by O 
Rho-kinase O 
, O 
although O 
the O 
underlying O 
mechanism O 
and O 
the O 
details O 
of O 
regulation O 
for O 
the O 
development O 
of O 
this O 
intracellular O 
passive O 
stiffness O 
are O 
still O 
largely O 
unknown O 
. O 
To O 
reduce O 
airway O 
stiffness O 
different O 
lines O 
of O 
attack O 
must O 
be O 
tailored O 
to O 
different O 
components O 
of O 
the O 
stiffness O 
. O 
The O 
regulatable O 
passive O 
stiffness O 
is O 
distinct O 
from O 
the O 
relatively O 
permanent O 
stiffness O 
of O 
the O 
extracellular O 
matrix O 
and O 
the O 
stiffness O 
associated O 
with O 
active O 
muscle O 
contraction O 
. O 
To O 
improve O 
airway O 
distensibility O 
during O 
asthma O 
exacerbation O 
, O 
a O 
comprehensive O 
approach O 
to O 
reduce O 
overall O 
airway O 
stiffness O 
should O 
therefore O 
include O 
a O 
strategy O 
for O 
targeting O 
the O 
regulatable O 
passive O 
stiffness O 
. O 

was O 
determined O 
to O 
be O 
a O 
new O 
inhibitor O 
of O 
lactoperoxidase O 
( O 
LPO O 
) O 
with O 
an O 
IC(50) O 
of O 
0.848.10(-5)M O 
. O 
The O 
K O 
(i) O 
for O 
sulphanilamide B-TRIVIAL 
was O 
determined O 
to O 
be O 
3.57.10(-5)M O 
and O 
sulphanilamide B-TRIVIAL 
showed O 
competitive O 
inhibition O 
, O 
which O 
makes O 
it O 
a O 
suitable O 
ligand O 
for O 
constructing O 
a O 
Sepharose B-TRIVIAL 
4B I-TRIVIAL 
- O 
L-tyrosine B-TRIVIAL 
affinity O 
matrix O 
. O 
The O 
affinity O 
matrix O 
was O 
synthesised O 
by O 
coupling O 
sulphanilamide B-TRIVIAL 
as O 
the O 
ligand O 
and O 
L-tyrosine B-TRIVIAL 
as O 
the O 
spacer O 
arm O 
to O 
a O 
cyanogen B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
CNBr B-FORMULA 
)-activated- O 
Sepharose B-TRIVIAL 
4B I-TRIVIAL 
matrix O 
. O 
Lactoperoxidase O 
was O 
purified O 
409-fold O 
from O 
the O 
synthesized O 
affinity O 
matrix O 
in O 
a O 
single O 
step O 
, O 
with O 
a O 
yield O 
of O 
62.3% O 
and O 
a O 
specific O 
activity O 
of O 
40.9 O 
EU O 
/ O 
mg O 
protein O 
. O 
The O 
enzyme O 
activity O 
was O 
measured O 
using O 
ABTS B-ABBREVIATION 
as O 
a O 
chromogenic O 
substrate O 
( O 
pH O 
6 O 
) O 
. O 
The O 
degree O 
of O 
LPO O 
purification O 
was O 
monitored O 
by O 
SDS B-ABBREVIATION 
-PAGE O 
and O 
its O 
R(z) O 
( O 
A(412) O 
/ O 
A(280) O 
) O 
value O 
. O 
The O 
R(z) O 
value O 
for O 
the O 
purified O 
LPO O 
was O 
found O 
to O 
be O 
0.7 O 
. O 
Maximum O 
binding O 
was O 
achieved O 
and O 
K(m) O 
and O 
V(max) O 
values O 
were O 
determined O 
. O 

of O 
the O 
natively O 
α-helical O 
prion O 
protein O 
into O 
a O 
β-sheet O 
rich O 
isoform O 
is O 
related O 
to O 
various O 
human O 
diseases O 
such O 
as O 
Creutzfeldt-Jakob O 
disease O 
and O 
Gerstmann-Sträussler-Scheinker O 
syndrome O 
. O 
In O 
humans O 
, O 
the O 
disease O 
phenotype O 
is O 
modified O 
by O 
a O 
methionine B-TRIVIAL 
/ O 
valine B-TRIVIAL 
polymorphism O 
at O 
codon O 
129 O 
of O 
the O 
prion O 
protein O 
gene O 
. O 
Using O 
a O 
combination O 
of O 
hydrogen B-SYSTEMATIC 
/ O 
deuterium B-SYSTEMATIC 
exchange O 
coupled O 
to O 
NMR O 
spectroscopy O 
, O 
hydroxyl B-SYSTEMATIC 
radical O 
probing O 
detected O 
by O 
mass O 
spectrometry O 
, O 
and O 
site O 
- O 
directed O 
mutagenesis O 
, O 
we O 
demonstrate O 
that O 
stop O 
mutants O 
of O 
the O 
human O 
prion O 
protein O 
have O 
a O 
conserved O 
amyloid O 
core O 
. O 
The O 
129 O 
residue O 
is O 
deeply O 
buried O 
in O 
the O 
amyloid O 
core O 
structure O 
, O 
and O 
its O 
mutation O 
strongly O 
impacts O 
aggregation O 
. O 
Taken O 
together O 
the O 
data O 
support O 
a O 
critical O 
role O 
of O 
the O 
polymorphic O 
residue O 
129 O 
of O 
the O 
human O 
prion O 
protein O 
in O 
aggregation O 
and O 
disease O 
. O 

- O 
bound O 
polyphenoloxidase O 
( O 
mPPO O 
) O 
an O 
oxidative O 
enzyme O 
which O 
is O 
responsible O 
for O 
the O 
undesirable O 
browning O 
reaction O 
in O 
Snake O 
fruit O 
( O 
Salacca O 
zalacca O 
( O 
Gaertn O 
. O 
) O 
Voss O 
) O 
was O 
investigated O 
. O 
The O 
enzyme O 
was O 
extracted O 
using O 
a O 
non-ionic O 
detergent O 
( O 
Triton B-FAMILY 
X-114 I-FAMILY 
) O 
, O 
followed O 
by O 
temperature O 
- O 
induced O 
phase O 
partitioning O 
technique O 
which O 
resulted O 
in O 
two O 
separate O 
layers O 
( O 
detergent-poor O 
phase O 
at O 
the O 
upper O 
layer O 
and O 
detergent-rich O 
phase O 
at O 
the O 
lower O 
layer O 
) O 
. O 
The O 
upper O 
detergent-poor O 
phase O 
extract O 
was O 
subsequently O 
fractionated O 
by O 
40-80% O 
ammonium B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
and O 
chromatographed O 
on O 
HiTrap O 
Phenyl B-SYSTEMATIC 
Sepharose O 
and O 
Superdex O 
200 O 
HR O 
10 O 
/ O 
30 O 
. O 
The O 
mPPO O 
was O 
purified O 
to O 
14.1 O 
folds O 
with O 
a O 
recovery O 
of O 
12.35% O 
. O 
A O 
single O 
prominent O 
protein O 
band O 
appeared O 
on O 
native-PAGE O 
and O 
SDS B-ABBREVIATION 
-PAGE O 
implying O 
that O 
the O 
mPPO O 
is O 
a O 
monomeric O 
protein O 
with O 
estimated O 
molecular O 
weight O 
of O 
38kDa O 
. O 
Characterization O 
study O 
showed O 
that O 
mPPO O 
from O 
Snake O 
fruit O 
was O 
optimally O 
active O 
at O 
pH O 
6.5 O 
, O 
temperature O 
30°C O 
and O 
active O 
towards O 
diphenols B-FAMILY 
as O 
substrates O 
. O 
The O 
K(m) O 
and O 
V(max) O 
values O 
were O 
calculated O 
to O 
be O 
5.46 O 
mM O 
and O 
0.98 O 
U O 
/ O 
ml O 
/ O 
min O 
, O 
respectively O 
, O 
when O 
catechol B-TRIVIAL 
was O 
used O 
as O 
substrate O 
. O 
Among O 
the O 
chemical O 
inhibitors O 
tested O 
, O 
l-cysteine B-TRIVIAL 
showed O 
the O 
best O 
inhibitory O 
effect O 
, O 
with O 
an O 
IC(50) O 
of O 
1.3 O 
± O 
0.002 O 
mM O 
followed O 
by O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1.5 O 
± O 
0.06 O 
mM O 
) O 
, O 
glutathione B-TRIVIAL 
( O 
1.5 O 
± O 
0.07 O 
mM O 
) O 
, O 
EDTA B-ABBREVIATION 
( O 
100 O 
± O 
0.02 O 
mM O 
) O 
and O 
citric B-TRIVIAL 
acid I-TRIVIAL 
( O 
186 O 
± O 
0.16 O 
mM O 
) O 
. O 

reigns O 
as O 
to O 
how O 
protein O 
binding O 
changes O 
alter O 
the O 
time O 
course O 
of O 
unbound O 
drug O 
concentrations O 
in O 
patients O 
. O 
Given O 
that O 
the O 
unbound O 
concentration O 
is O 
responsible O 
for O 
drug O 
efficacy O 
and O 
potential O 
drug O 
toxicity O 
, O 
this O 
area O 
is O 
of O 
significant O 
interest O 
to O 
clinicians O 
and O 
academics O 
worldwide O 
. O 
The O 
present O 
uncertainty O 
means O 
that O 
many O 
questions O 
relating O 
to O 
this O 
area O 
exist O 
, O 
including O 
" O 
How O 
important O 
is O 
protein O 
binding O 
? O 
" O 
, O 
" O 
Is O 
protein O 
binding O 
always O 
constant O 
? O 
" O 
, O 
" O 
Do O 
pH O 
and O 
temperature O 
changes O 
alter O 
binding O 
? O 
" O 
and O 
" O 
How O 
do O 
protein O 
binding O 
changes O 
affect O 
dosing O 
requirements O 
? O 
" O 
. O 
In O 
this O 
paper O 
, O 
we O 
seek O 
to O 
address O 
these O 
questions O 
and O 
consider O 
the O 
data O 
associated O 
with O 
altered O 
pharmacokinetics O 
in O 
the O 
presence O 
of O 
changes O 
in O 
protein O 
binding O 
and O 
the O 
clinical O 
consequences O 
that O 
these O 
may O 
have O 
on O 
therapy O 
, O 
using O 
examples O 
from O 
the O 
critical O 
care O 
area O 
. O 
The O 
published O 
literature O 
consistently O 
indicates O 
that O 
a O 
change O 
in O 
the O 
protein O 
binding O 
and O 
unbound O 
concentrations O 
of O 
some O 
drugs O 
are O 
common O 
in O 
certain O 
specific O 
patient O 
groups O 
such O 
as O 
the O 
critically O 
ill O 
. O 
Changes O 
in O 
pharmacokinetic O 
parameters O 
, O 
including O 
clearance O 
and O 
apparent O 
volume O 
of O 
distribution O 
(V(d)) O 
, O 
may O 
be O 
dramatic O 
. O 
Drugs O 
with O 
high O 
protein O 
binding O 
, O 
high O 
intrinsic O 
clearance O 
( O 
e.g O 
. O 
clearance O 
by O 
glomerular O 
filtration O 
) O 
and O 
where O 
dosing O 
is O 
not O 
titrated O 
to O 
effect O 
are O 
most O 
likely O 
to O 
be O 
affected O 
in O 
a O 
clinical O 
context O 
. O 
Drugs O 
such O 
as O 
highly O 
protein O 
bound O 
antibacterials O 
with O 
multiple O 
half O 
- O 
lives O 
within O 
a O 
dosing O 
interval O 
and O 
that O 
have O 
some O 
level O 
of O 
renal O 
clearance O 
, O 
such O 
a O 
s B-TRIVIAL 
ertapen I-TRIVIAL 
em O 
, B-FAMILY 
teicoplan I-FAMILY 
in O 
, B-TRIVIAL 
ceftriaxo I-TRIVIAL 
ne O 
an O 
d B-TRIVIAL 
flucloxacill I-TRIVIAL 
in O 
, O 
are O 
commonly O 
affected O 
. O 
In O 
response O 
to O 
these O 
challenges O 
, O 
clinicians O 
need O 
to O 
adapt O 
dosing O 
regimens O 
rationally O 
based O 
on O 
the O 
pharmacokinetic O 
/ O 
pharmacodynamic O 
characteristics O 
of O 
the O 
drug O 
. O 
We O 
propose O 
that O 
further O 
pharmacokinetic O 
modelling O 
- O 
based O 
research O 
is O 
required O 
to O 
enable O 
the O 
design O 
of O 
robust O 
dosing O 
regimens O 
for O 
drugs O 
affected O 
by O 
altered O 
protein O 
binding O 
. O 

of O 
solid O 
lipid O 
nanoparticles O 
based O 
controlled O 
release O 
system O 
for O 
topical O 
delivery O 
of O 
terbinafine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
. O 

study O 
describes O 
the O 
development O 
and O 
evaluation O 
of O 
solid O 
lipid O 
nanoparticles O 
( O 
SLNs O 
) O 
of O 
terbinafine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
TH O 
) O 
for O 
sustained O 
release O 
and O 
skin O 
targeting O 
. O 
TH-loaded O 
SLNs O 
were O 
prepared O 
by O 
solvent-injection O 
technique O 
and O 
optimized O 
using O 
3(3) O 
full O 
- O 
factorial O 
design O 
. O 
Effect O 
of O 
drug O 
: O 
lipid O 
ratio O 
, O 
surfactant O 
concentration O 
and O 
volume O 
of O 
organic O 
solvent O 
were O 
studied O 
on O 
% O 
entrapment O 
efficiency O 
( O 
%EE O 
) O 
and O 
particle O 
size O 
( O 
PS O 
) O 
. O 
The O 
optimum O 
formulation O 
based O 
on O 
desirability O 
( O 
0.945 O 
) O 
exhibited O 
%EE O 
of O 
73.74% O 
and O 
PS O 
of O 
300nm O 
. O 
Optimized O 
SLNs O 
were O 
incorporated O 
into O 
Carbopol B-TRIVIAL 
gel O 
and O 
evaluated O 
for O 
drug O 
content O 
, O 
pH O 
, O 
in O 
vitro O 
release O 
, O 
ex O 
vivo O 
retention O 
, O 
in O 
vivo O 
pharmacodynamic O 
and O 
stability O 
studies O 
. O 
Drug O 
release O 
from O 
SLNs O 
dispersion O 
followed O 
Korsmeyer-Peppas O 
model O 
, O 
indicating O 
Fickian O 
drug O 
release O 
, O 
while O 
that O 
from O 
the O 
gel O 
followed O 
Higuchi O 
model O 
. O 
The O 
ex O 
vivo O 
studies O 
through O 
rat O 
abdominal O 
skin O 
indicated O 
skin O 
retention O 
ability O 
of O 
SLNs O 
as O 
compared O 
to O 
commercial O 
product O 
. O 
In O 
vivo O 
pharmacodynamic O 
studies O 
showed O 
that O 
the O 
SLNs O 
based O 
gel O 
reduced O 
fungal O 
burden O 
of O 
Candida O 
albicans O 
in O 
rats O 
as O 
compared O 
to O 
commercial O 
product O 
in O 
shorter O 
duration O 
of O 
time O 
. O 
The O 
SLNs O 
dispersion O 
and O 
gel O 
exhibited O 
physicochemical O 
stability O 
under O 
refrigeration O 
upto O 
3months O 
. O 
It O 
was O 
concluded O 
that O 
SLNs O 
incorporated O 
Carbopol B-TRIVIAL 
gel O 
had O 
skin O 
targeting O 
ability O 
and O 
may O 
serve O 
as O 
a O 
promising O 
carrier O 
in O 
treatment O 
of O 
fungal O 
skin O 
infections O 
. O 

human O 
genome O 
codes O 
for O 
13 O 
members O 
of O 
a O 
family O 
of O 
filament O 
- O 
forming O 
GTP B-ABBREVIATION 
-binding O 
proteins O 
known O 
as O 
septins O 
. O 
These O 
have O 
been O 
divided O 
into O 
four O 
different O 
subgroups O 
on O 
the O 
basis O 
of O 
sequence O 
similarity O 
. O 
The O 
differences O 
between O 
the O 
subgroups O 
are O 
believed O 
to O 
control O 
their O 
correct O 
assembly O 
into O 
heterofilaments O 
which O 
have O 
specific O 
roles O 
in O 
membrane O 
remodelling O 
events O 
. O 
Many O 
different O 
combinations O 
of O 
the O 
13 O 
proteins O 
are O 
theoretically O 
possible O 
and O 
it O 
is O 
therefore O 
important O 
to O 
understand O 
the O 
structural O 
basis O 
of O 
specific O 
filament O 
assembly O 
. O 
However O 
, O 
three O 
- O 
dimensional O 
structures O 
are O 
currently O 
available O 
for O 
only O 
three O 
of O 
the O 
four O 
subgroups O 
. O 
In O 
the O 
present O 
study O 
we O 
describe O 
the O 
crystal O 
structure O 
of O 
a O 
construct O 
of O 
human O 
SEPT3 O 
which O 
belongs O 
to O 
the O 
outstanding O 
subgroup O 
. O 
This O 
construct O 
( O 
SEPT3-GC O 
) O 
, O 
which O 
includes O 
the O 
GTP B-ABBREVIATION 
-binding O 
and O 
C B-FORMULA 
-terminal O 
domains O 
, O 
purifies O 
as O 
a O 
nucleotide B-FAMILY 
-free O 
monomer O 
, O 
allowing O 
for O 
its O 
characterization O 
in O 
terms O 
of O 
GTP B-ABBREVIATION 
-binding O 
and O 
hydrolysis O 
. O 
In O 
the O 
crystal O 
structure O 
, O 
SEPT3-GC O 
forms O 
foreshortened O 
filaments O 
which O 
employ O 
the O 
same O 
NC O 
and O 
G O 
interfaces O 
observed O 
in O 
the O 
heterotrimeric O 
complex O 
of O 
human O 
septins O 
2 O 
, O 
6 O 
and O 
7 O 
, O 
reinforcing O 
the O 
notion O 
of O 
' O 
promiscuous O 
' O 
interactions O 
described O 
previously O 
. O 
In O 
the O 
present O 
study O 
we O 
describe O 
these O 
two O 
interfaces O 
and O 
relate O 
the O 
structure O 
to O 
its O 
tendency O 
to O 
form O 
monomers O 
and O 
its O 
efficiency O 
in O 
the O 
hydrolysis O 
of O 
GTP B-ABBREVIATION 
. O 
The O 
relevance O 
of O 
these O 
results O 
is O 
emphasized O 
by O 
the O 
fact O 
that O 
septins O 
from O 
the O 
SEPT3 O 
subgroup O 
may O 
be O 
important O 
determinants O 
of O 
polymerization O 
by O 
occupying O 
the O 
terminal O 
position O 
in O 
octameric O 
units O 
which O 
themselves O 
form O 
the O 
building O 
blocks O 
of O 
at O 
least O 
some O 
heterofilaments O 
. O 

Deficiency O 
Impairs O 
Secretory O 
Vesicle O 
Biogenesis O 
and O 
Leads O 
to O 
Growth O 
Retardation O 
and O 
Decreased O 
Glucose B-TRIVIAL 
Tolerance O 
. O 

vesicles O 
in O 
endocrine O 
cells O 
store O 
hormones O 
such O 
as O 
growth O 
hormone O 
( O 
GH O 
) O 
and O 
insulin O 
before O 
their O 
release O 
into O 
the O 
bloodstream O 
. O 
The O 
molecular O 
mechanisms O 
governing O 
budding O 
of O 
immature O 
secretory O 
vesicles O 
from O 
the O 
trans-Golgi O 
network O 
( O 
TGN O 
) O 
and O 
their O 
subsequent O 
maturation O 
remain O 
unclear O 
. O 
Here O 
, O 
we O 
identify O 
the O 
lipid O 
binding O 
BAR O 
( O 
Bin O 
/ O 
amphiphysin O 
/ O 
Rvs O 
) O 
domain O 
protein O 
PICK1 O 
( O 
protein O 
interacting O 
with O 
C O 
kinase O 
1 O 
) O 
as O 
a O 
key O 
component O 
early O 
in O 
the O 
biogenesis O 
of O 
secretory O 
vesicles O 
in O 
GH-producing O 
cells O 
. O 
Both O 
PICK1-deficient O 
Drosophila O 
and O 
mice O 
displayed O 
somatic O 
growth O 
retardation O 
. O 
Growth O 
retardation O 
was O 
rescued O 
in O 
flies O 
by O 
reintroducing O 
PICK1 O 
in O 
neurosecretory O 
cells O 
producing O 
somatotropic O 
peptides O 
. O 
PICK1-deficient O 
mice O 
were O 
characterized O 
by O 
decreased O 
body O 
weight O 
and O 
length O 
, O 
increased O 
fat O 
accumulation O 
, O 
impaired O 
GH O 
secretion O 
, O 
and O 
decreased O 
storage O 
of O 
GH O 
in O 
the O 
pituitary O 
. O 
Decreased O 
GH O 
storage O 
was O 
supported O 
by O 
electron O 
microscopy O 
showing O 
prominent O 
reduction O 
in O 
secretory O 
vesicle O 
number O 
. O 
Evidence O 
was O 
also O 
obtained O 
for O 
impaired O 
insulin O 
secretion O 
associated O 
with O 
decreased O 
glucose B-TRIVIAL 
tolerance O 
. O 
PICK1 O 
localized O 
in O 
cells O 
to O 
immature O 
secretory O 
vesicles O 
, O 
and O 
the O 
PICK1 O 
BAR O 
domain O 
was O 
shown O 
by O 
live O 
imaging O 
to O 
associate O 
with O 
vesicles O 
budding O 
from O 
the O 
TGN O 
and O 
to O 
possess O 
membrane O 
- O 
sculpting O 
properties O 
in O 
vitro O 
. O 
In O 
mouse O 
pituitary O 
, O 
PICK1 O 
co O 
- O 
localized O 
with O 
the O 
BAR O 
domain O 
protein O 
ICA69 O 
, O 
and O 
PICK1 O 
deficiency O 
abolished O 
ICA69 O 
protein O 
expression O 
. O 
In O 
the O 
Drosophila O 
brain O 
, O 
PICK1 O 
and O 
ICA69 O 
co O 
- O 
immunoprecipitated O 
and O 
showed O 
mutually O 
dependent O 
expression O 
. O 
Finally O 
, O 
both O 
in O 
a O 
Drosophila O 
model O 
of O 
type O 
2 O 
diabetes O 
and O 
in O 
high O 
- O 
fat O 
- O 
diet O 
- O 
induced O 
obese O 
mice O 
, O 
we O 
observed O 
up O 
- O 
regulation O 
of O 
PICK1 O 
mRNA O 
expression O 
. O 
Our O 
findings O 
suggest O 
that O 
PICK1 O 
, O 
together O 
with O 
ICA69 O 
, O 
is O 
critical O 
during O 
budding O 
of O 
immature O 
secretory O 
vesicles O 
from O 
the O 
TGN O 
and O 
thus O 
for O 
vesicular O 
storage O 
of O 
GH O 
and O 
possibly O 
other O 
hormones O 
. O 
The O 
data O 
link O 
two O 
BAR O 
domain O 
proteins O 
to O 
membrane O 
remodeling O 
processes O 
in O 
the O 
secretory O 
pathway O 
of O 
peptidergic O 
endocrine O 
cells O 
and O 
support O 
an O 
important O 
role O 
of O 
PICK1 O 
/ O 
ICA69 O 
in O 
maintenance O 
of O 
metabolic O 
homeostasis O 
. O 

conjugated O 
oligothiophenes B-FAMILY 
for O 
sensitive O 
fluorescent O 
assignment O 
of O 
protein O 
inclusion O 
bodies O 
. O 

hydrophobic O 
ligands O 
identifying O 
intracellular O 
protein O 
deposits O 
are O 
of O 
great O 
interest O 
, O 
as O 
protein O 
inclusion O 
bodies O 
are O 
the O 
pathological O 
hallmark O 
of O 
several O 
degenerative O 
diseases O 
. O 
Here O 
we O 
report O 
that O 
fluorescent O 
amyloid O 
ligands O 
, O 
termed O 
luminescent O 
conjugated O 
oligothiophenes B-FAMILY 
( O 
LCOs O 
) O 
, O 
rapidly O 
and O 
with O 
high O 
sensitivity O 
detect O 
protein O 
inclusion O 
bodies O 
in O 
skeletal O 
muscle O 
tissue O 
from O 
patients O 
with O 
sporadic O 
inclusion O 
body O 
myositis O 
( O 
s-IBM O 
) O 
. O 
LCOs O 
having O 
a O 
conjugated O 
backbone O 
of O 
at O 
least O 
five O 
thiophene B-SYSTEMATIC 
units O 
emitted O 
strong O 
fluorescence O 
upon O 
binding O 
, O 
and O 
showed O 
co O 
- O 
localization O 
with O 
proteins O 
reported O 
to O 
accumulate O 
in O 
s-IBM O 
protein O 
inclusion O 
bodies O 
. O 
Compared O 
with O 
conventional O 
amyloid O 
ligands O 
, O 
LCOs O 
identified O 
a O 
larger O 
fraction O 
of O 
immunopositive O 
inclusion O 
bodies O 
. O 
When O 
the O 
conjugated O 
thiophene B-SYSTEMATIC 
backbone O 
was O 
extended O 
with O 
terminal O 
carboxyl B-SYSTEMATIC 
groups O 
, O 
the O 
LCO O 
revealed O 
striking O 
spectral O 
differences O 
between O 
distinct O 
protein O 
inclusion O 
bodies O 
. O 
We O 
conclude O 
that O 
1 O 
) O 
LCOs O 
are O 
sensitive O 
, O 
rapid O 
and O 
powerful O 
tools O 
for O 
identifying O 
protein O 
inclusion O 
bodies O 
and O 
2 O 
) O 
LCOs O 
identify O 
a O 
wider O 
range O 
of O 
protein O 
inclusion O 
bodies O 
than O 
conventional O 
amyloid O 
ligands O 
. O 

- O 
up O 
approach O 
to O 
creating O 
three O 
- O 
dimensional O 
nanoring O 
arrays O 
composed O 
of O 
Au B-FORMULA 
nanoparticles O 
. O 

bottom O 
- O 
up O 
approach O 
to O 
creating O 
3D O 
assemblies O 
of O 
Au B-FORMULA 
nanorings O 
by O 
drying O 
aqueous O 
dispersions O 
of O 
PS O 
colloidal O 
particles O 
and O 
Au B-FORMULA 
NPs O 
is O 
shown O 
. O 
The O 
evaporation O 
of O 
water O 
from O 
the O 
dispersion O 
allowed O 
for O 
the O 
formation O 
of O 
hexagonally O 
assembled O 
colloidal O 
crystals O 
and O 
nanorings O 
composed O 
of O 
Au B-FORMULA 
nanoparticles O 
among O 
the O 
PS O 
colloidal O 
particles O 
. O 
The O 
size O 
of O 
the O 
nanorings O 
could O 
be O 
controlled O 
on O 
a O 
scale O 
of O 
tens O 
to O 
hundreds O 
of O 
nanometers O 
. O 
After O 
sintering O 
, O 
the O 
Au B-FORMULA 
NPs O 
formed O 
Au B-FORMULA 
nanorings O 
. O 
This O 
simple O 
approach O 
supplies O 
a O 
potentially O 
useful O 
path O 
to O 
novel O 
plasmonic O 
materials O 
and O 
unique O 
metamaterials O 
for O 
the O 
visible O 
light O 
region O 
. O 

of O 
Ibuprofen B-SYSTEMATIC 
Sodium I-SYSTEMATIC 
using O 
compressed O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
as O 
antisolvent O 
. O 

with O 
compressed O 
antisolvent O 
( O 
PCA O 
) O 
process O 
was O 
used O 
to O 
produce O 
fine O 
particles O 
of O 
Ibuprofen B-SYSTEMATIC 
Sodium I-SYSTEMATIC 
with O 
the O 
ultimate O 
goal O 
of O 
obtaining O 
controlled O 
particle O 
size O 
and O 
size O 
distribution O 
of O 
this O 
non-steroidal O 
anti-inflammatory O 
drug O 
. O 
This O 
systematic O 
investigation O 
shows O 
that O 
particle O 
size O 
and O 
size O 
distribution O 
of O 
the O 
final O 
product O 
can O 
be O 
controlled O 
reproducibly O 
by O 
varying O 
a O 
number O 
operating O 
parameters O 
such O 
as O 
antisolvent O 
addition O 
rate O 
, O 
temperature O 
, O 
concentration O 
, O 
and O 
solution O 
addition O 
rate O 
. O 
The O 
mechanisms O 
that O 
control O 
particle O 
size O 
and O 
particle O 
size O 
distribution O 
were O 
explained O 
by O 
invoking O 
the O 
differences O 
in O 
the O 
relative O 
weight O 
of O 
primary O 
, O 
secondary O 
nucleation O 
and O 
growth O 
kinetic O 
phenomena O 
. O 
A O 
number O 
of O 
techniques O 
were O 
used O 
for O 
the O 
characterization O 
of O 
the O 
generated O 
particles O 
. O 
In O 
addition O 
to O 
scanning O 
electron O 
microscope O 
( O 
SEM O 
) O 
, O 
dynamic O 
light O 
scattering O 
measurements O 
were O 
conducted O 
to O 
determine O 
the O 
size O 
of O 
the O 
particles O 
in O 
terms O 
of O 
number O 
- O 
weighted O 
size O 
distribution O 
. O 
The O 
influence O 
of O 
process O 
parameters O 
on O 
the O 
Ibuprofen B-SYSTEMATIC 
Sodium I-SYSTEMATIC 
crystallinity O 
was O 
investigated O 
using O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
. O 
Moreover O 
, O 
the O 
' O 
' O 
in O 
vitro O 
' O 
' O 
drug O 
performance O 
was O 
tested O 
. O 
The O 
results O 
showed O 
an O 
improvement O 
of O 
the O 
PCA O 
processed O 
Ibuprofen B-SYSTEMATIC 
Sodium I-SYSTEMATIC 
' O 
' O 
in O 
vitro O 
' O 
' O 
drug O 
activity O 
. O 
In O 
addition O 
, O 
dissolution O 
investigations O 
demonstrated O 
that O 
the O 
flow O 
rate O 
, O 
in O 
combination O 
with O 
the O 
particle O 
size O 
distribution O 
, O 
substantially O 
influence O 
the O 
drug O 
" O 
in O 
vitro O 
" O 
dissolution O 
. O 

of O 
lysosomal O 
exocytosis O 
in O 
the O 
excretion O 
of O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
and O 
enhancement O 
of O 
the O 
drug O 
delivery O 
effect O 
by O 
exocytosis O 
inhibition O 
. O 

exocytosis O 
of O 
phosphonate B-SYSTEMATIC 
modified O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
( O 
P-MSNs O 
) O 
is O 
demonstrated O 
and O 
lysosomal O 
exocytosis O 
is O 
identified O 
as O 
the O 
mechanism O 
responsible O 
for O 
this O 
event O 
. O 
Regulation O 
of O 
P-MSN O 
exocytosis O 
can O 
be O 
achieved O 
by O 
inhibiting O 
or O 
accelerating O 
lysosomal O 
exocytosis O 
. O 
Slowing O 
down O 
P-MSN O 
exocytosis O 
enhances O 
the O 
drug O 
delivery O 
effect O 
of O 
CPT B-ABBREVIATION 
-loaded O 
P-MSNs O 
by O 
improving O 
cell O 
killing O 
. O 

: O 
a O 
biological O 
review O 
. O 

is O 
an O 
important O 
five O 
membered O 
nitrogen B-SYSTEMATIC 
heterocycle O 
, O 
which O 
has O 
been O 
extensively O 
researched O 
upon O 
. O 
The O 
ring O 
is O 
quite O 
stable O 
and O 
has O 
inspired O 
chemists O 
to O 
carry O 
out O 
various O 
structural O 
variations O 
in O 
the O 
ring O 
. O 
This O 
has O 
propelled O 
the O 
development O 
of O 
distinct O 
pyrazolines B-FAMILY 
with O 
an O 
array O 
of O 
pharmacological O 
activities O 
viz O 
. O 
anti-inflammatory O 
, O 
analgesic O 
, O 
antimicrobial O 
, O 
anticancer O 
, O 
antidepressant O 
etc O 
. O 
The O 
review O 
aims O 
at O 
highlighting O 
this O 
pharmacological O 
diversity O 
of O 
pyrazolines B-FAMILY 
. O 
The O 
review O 
is O 
a O 
gist O 
of O 
latest O 
work O 
done O 
describing O 
the O 
pharmacological O 
aspects O 
and O 
potential O 
of O 
pyrazoline B-SYSTEMATIC 
ring O 
. O 

and O 
Metabolism O 
of O 
GSK2251052 B-IDENTIFIER 
in O 
Humans O 
: O 
A O 
Novel O 
Boron B-SYSTEMATIC 
-Containing O 
Antibiotic O 
. O 

( O 
GSK2251052 B-IDENTIFIER 
) O 
is O 
a O 
novel O 
boron B-SYSTEMATIC 
-containing O 
antibiotic O 
that O 
inhibits O 
bacterial O 
leucyl B-TRIVIAL 
tRNA O 
synthetase O 
, O 
and O 
that O 
has O 
been O 
in O 
development O 
for O 
the O 
treatment O 
of O 
serious O 
Gram O 
- O 
negative O 
infections O 
. O 
In O 
this O 
study O 
, O 
six O 
healthy O 
adult O 
male O 
subjects O 
received O 
a O 
single O 
i.v O 
. O 
dose O 
of O 
[(14)C]GSK2251052 B-SYSTEMATIC 
, O 
1500 O 
mg O 
infused O 
over O 
1 O 
hour O 
. O 
Blood O 
, O 
urine O 
, O 
and O 
feces O 
were O 
collected O 
over O 
an O 
extended O 
period O 
of O 
14 O 
days O 
, O 
and O 
accelerator O 
mass O 
spectrometry O 
was O 
used O 
to O 
quantify O 
low O 
levels O 
of O 
radioactivity O 
in O 
plasma O 
at O 
later O 
time O 
points O 
to O 
supplement O 
the O 
less O 
- O 
sensitive O 
liquid O 
scintillation O 
counting O 
technique O 
. O 
An O 
excellent O 
mass O 
balance O 
recovery O 
was O 
achieved O 
representing O 
a O 
mean O 
total O 
of O 
98.2% O 
of O 
the O 
dose O 
, O 
including O 
90.5% O 
recovered O 
in O 
the O 
urine O 
. O 
Pharmacokinetic O 
analysis O 
demonstrated O 
that O 
radioactivity O 
was O 
moderately O 
associated O 
with O 
the O 
blood O 
cellular O 
components O 
, O 
and O 
together O 
with O 
GSK2251052 B-IDENTIFIER 
, O 
both O 
were O 
highly O 
distributed O 
into O 
tissues O 
. O 
The O 
parent O 
compound O 
had O 
a O 
much O 
shorter O 
half O 
- O 
life O 
than O 
total O 
radioactivity O 
in O 
plasma O 
, O 
approximately O 
11.6 O 
hours O 
compared O 
with O 
96 O 
hours O 
. O 
GSK2251052 B-IDENTIFIER 
and O 
its O 
major O 
metabolite O 
M3 O 
, O 
which O 
resulted O 
from O 
oxidation O 
of O 
the O 
propanol B-SYSTEMATIC 
side O 
chain O 
to O 
the O 
corresponding O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
comprised O 
the O 
majority O 
of O 
the O 
plasma O 
radioactivity O 
, O 
37 O 
and O 
53% O 
of O 
the O 
area O 
under O 
the O 
plasma O 
versus O 
time O 
concentration O 
curve O 
from O 
time O 
zero O 
to O 
infinity O 
, O 
respectively O 
. O 
Additionally O 
, O 
M3 O 
was O 
eliminated O 
renally O 
, O 
and O 
was O 
demonstrated O 
to O 
be O 
responsible O 
for O 
the O 
long O 
plasma O 
radioactivity O 
elimination O 
half O 
- O 
life O 
. O 
A O 
combination O 
of O 
in O 
vitro O 
metabolism O 
experiments O 
and O 
a O 
pharmacokinetic O 
study O 
in O 
monkeys O 
with O 
the O 
inhibitor O 
4-methylpyrazole B-SYSTEMATIC 
provided O 
strong O 
evidence O 
that O 
alcohol B-FAMILY 
dehydrogenase O 
, O 
potentially O 
in O 
association O 
with O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
, O 
is O 
the O 
primary O 
enzyme O 
involved O 
in O 
the O 
formation O 
of O 
the O 
M3 O 
metabolite O 
. O 

evidence O 
for O 
4-isobutyl-3-isopropylbicyclophosphorothionate B-SYSTEMATIC 
as O 
a O 
selective O 
blocker O 
of O 
insect O 
GABA B-ABBREVIATION 
-gated O 
chloride B-SYSTEMATIC 
channels O 
. O 

γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
)-gated O 
chloride B-SYSTEMATIC 
channels O 
( O 
GABACls O 
) O 
and O 
glutamate B-TRIVIAL 
-gated O 
chloride B-SYSTEMATIC 
channels O 
( O 
GluCls O 
) O 
, O 
which O 
function O 
as O 
inhibitory O 
neurotransmitter O 
receptors O 
, O 
are O 
important O 
targets O 
of O 
insecticides O 
and O 
antiparasitic O 
agents O 
. O 
The O 
antagonism O 
of O 
GABACls O 
and O 
GluCls O 
by O 
4-isobutyl-3-isopropylbicyclophosphorothionate B-SYSTEMATIC 
( O 
PS-14 B-IDENTIFIER 
) O 
was O 
examined O 
in O 
cultured O 
cockroach O 
and O 
rat O 
neurons O 
using O 
a O 
whole O 
- O 
cell O 
patch O 
- O 
clamp O 
method O 
. O 
The O 
results O 
indicated O 
that O 
PS-14 B-IDENTIFIER 
selectively O 
blocks O 
cockroach O 
GABACls O 
relative O 
to O 
cockroach O 
GluCls O 
and O 
rat O 
GABACls O 
. O 
PS-14 B-IDENTIFIER 
represents O 
a O 
useful O 
probe O 
for O 
the O 
study O 
of O 
insect O 
GABA B-ABBREVIATION 
receptors O 
. O 

of O 
PPARγ O 
is O 
required O 
for O 
hydroxysafflor B-SYSTEMATIC 
yellow I-SYSTEMATIC 
A I-SYSTEMATIC 
of O 
Carthamus O 
tinctorius O 
to O 
attenuate O 
hepatic O 
fibrosis O 
induced O 
by O 
oxidative O 
stress O 
. O 

stress O 
caused O 
hepatic O 
fibrosis O 
by O 
activating O 
hepatic O 
stellate O 
cells O 
( O 
HSCs O 
) O 
, O 
which O 
were O 
implemented O 
by O 
depressing O 
PPARγ O 
activation O 
. O 
Hydroxysafflor B-SYSTEMATIC 
yellow I-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
HSYA B-ABBREVIATION 
) O 
as O 
a O 
nature O 
active O 
ingredient O 
with O 
antioxidant O 
capacity O 
was O 
able O 
to O 
effectively O 
attenuate O 
oxidative O 
stress O 
mediated O 
injury O 
. O 
So O 
it O 
will O 
be O 
very O 
interesting O 
to O 
study O 
effect O 
of O 
HSYA B-ABBREVIATION 
on O 
HSCs O 
activation O 
and O 
liver O 
fibrosis O 
, O 
and O 
reveal O 
the O 
role O 
of O 
PPARγ· O 
CCl4 B-FORMULA 
and O 
H2O2 B-FORMULA 
were O 
used O 
to O 
mimic O 
oxidative O 
stress O 
mediated O 
hepatic O 
injury O 
in O 
vitro O 
and O 
in O 
vivo O 
respectively O 
. O 
The O 
anti-fibrosis O 
effects O 
of O 
HSYA B-ABBREVIATION 
were O 
evaluated O 
and O 
its O 
mechanisms O 
were O 
disclosed O 
by O 
applying O 
western O 
blot O 
, O 
histopathological O 
analysis O 
, O 
flow O 
cytometry O 
, O 
RT-PCR O 
and O 
ELISA O 
. O 
Our O 
results O 
showed O 
that O 
HSCs O 
activation O 
and O 
proliferation O 
could O 
be O 
induced O 
by O 
oxidative O 
stress O 
, O 
and O 
the O 
expressive O 
levels O 
of O 
TGF-β1 O 
and O 
TIMP-1 O 
, O 
the O 
serum O 
levels O 
of O 
ALT O 
, O 
AST O 
, O 
HA O 
, O 
LN O 
, O 
III-C O 
and O 
IV-C O 
were O 
also O 
enhanced O 
by O 
oxidative O 
stress O 
, O 
which O 
is O 
correlated O 
with O 
liver O 
fibrosis O 
( O 
p O 
< O 
0.05 O 
or O 
p O 
< O 
0.01 O 
) O 
. O 
HSYA B-ABBREVIATION 
was O 
able O 
to O 
effectively O 
inhibit O 
oxidative O 
stress O 
mediated O 
hepatic O 
injury O 
by O 
increasing O 
the O 
activities O 
of O 
antioxidant O 
enzymes O 
, O 
up O 
regulating O 
the O 
expression O 
of O 
PPARγ O 
and O 
MMP-2 O 
, O 
and O 
down O 
regulating O 
the O 
expression O 
of O 
TGF-β1 O 
and O 
TIMP-1 O 
, O 
and O 
reducing O 
α-SMA O 
level O 
. O 
The O 
protective O 
effect O 
of O 
HSYA B-ABBREVIATION 
can O 
be O 
significantly O 
attenuated O 
by O 
GW9662 B-IDENTIFIER 
via O 
blocking O 
PPARγ O 
( O 
p O 
< O 
0.05 O 
or O 
p O 
< O 
0.01 O 
) O 
. O 
Taken O 
together O 
, O 
these O 
results O 
demonstrate O 
that O 
HSYA B-ABBREVIATION 
is O 
able O 
to O 
significantly O 
protect O 
the O 
liver O 
from O 
oxidative O 
stress O 
, O 
which O 
requires O 
for O 
HSYA B-ABBREVIATION 
to O 
stimulate O 
PPARγ O 
activity O 
, O 
reduce O 
cell O 
proliferation O 
and O 
suppress O 
ECM O 
synthesis O 
. O 

-induced O 
transcriptomic O 
responses O 
in O 
primary O 
hepatocytes O 
and O 
in O 
vivo O 
liver O 
: O 
toxicokinetics O 
is O 
essential O 
for O 
in O 
vivo O 
- O 
in O 
vitro O 
comparisons O 
. O 

traditional O 
2-year O 
cancer O 
bioassay O 
needs O 
replacement O 
by O 
more O 
cost O 
- O 
effective O 
and O 
predictive O 
tests O 
. O 
The O 
use O 
of O 
toxicogenomics O 
in O 
an O 
in O 
vitro O 
system O 
may O 
provide O 
a O 
more O 
high O 
- O 
throughput O 
method O 
to O 
investigate O 
early O 
alterations O 
induced O 
by O 
carcinogens O 
. O 
Recently O 
, O 
the O 
differential O 
gene O 
expression O 
response O 
in O 
wild O 
- O 
type O 
and O 
cancer O 
- O 
prone O 
Xpa O 
( O 
- O 
/ O 
- O 
) O 
p53 O 
( O 
+ O 
/ O 
- O 
) O 
primary O 
mouse O 
hepatocytes O 
after O 
exposure O 
to O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
B[a]P B-ABBREVIATION 
) O 
revealed O 
downregulation O 
of O 
cancer O 
- O 
related O 
pathways O 
in O 
Xpa O 
( O 
- O 
/ O 
- O 
) O 
p53 O 
( O 
+ O 
/ O 
- O 
) O 
hepatocytes O 
only O 
. O 
Here O 
, O 
we O 
investigated O 
pathway O 
regulation O 
upon O 
in O 
vivo O 
B[a]P B-ABBREVIATION 
exposure O 
of O 
wild O 
- O 
type O 
and O 
Xpa O 
( O 
- O 
/ O 
- O 
) O 
p53 O 
( O 
+ O 
/ O 
- O 
) O 
mice O 
. O 
In O 
vivo O 
transcriptomics O 
analysis O 
revealed O 
a O 
limited O 
gene O 
expression O 
response O 
in O 
mouse O 
livers O 
, O 
but O 
with O 
a O 
significant O 
induction O 
of O 
DNA O 
replication O 
and O 
apoptotic O 
/ O 
anti-apoptotic O 
cellular O 
responses O 
in O 
Xpa O 
( O 
- O 
/ O 
- O 
) O 
p53 O 
( O 
+ O 
/ O 
- O 
) O 
livers O 
only O 
. O 
In O 
order O 
to O 
be O 
able O 
to O 
make O 
a O 
meaningful O 
in O 
vivo O 
- O 
in O 
vitro O 
comparison O 
we O 
estimated O 
internal O 
in O 
vivo O 
B[a]P B-ABBREVIATION 
concentrations O 
using O 
DNA O 
adduct O 
levels O 
and O 
physiologically O 
based O 
kinetic O 
modeling O 
. O 
Based O 
on O 
these O 
results O 
, O 
the O 
in O 
vitro O 
concentration O 
that O 
corresponded O 
best O 
with O 
the O 
internal O 
in O 
vivo O 
dose O 
was O 
chosen O 
. O 
Comparison O 
of O 
in O 
vivo O 
and O 
in O 
vitro O 
data O 
demonstrated O 
similarities O 
in O 
transcriptomics O 
response O 
: O 
xenobiotic O 
metabolism O 
, O 
lipid O 
metabolism O 
and O 
oxidative O 
stress O 
. O 
However O 
, O 
we O 
were O 
unable O 
to O 
detect O 
cancer O 
- O 
related O 
pathways O 
in O 
either O 
wild O 
- O 
type O 
or O 
Xpa O 
( O 
- O 
/ O 
- O 
) O 
p53 O 
( O 
+ O 
/ O 
- O 
) O 
exposed O 
livers O 
, O 
which O 
were O 
previously O 
found O 
to O 
be O 
induced O 
by O 
B[a]P B-ABBREVIATION 
in O 
Xpa O 
( O 
- O 
/ O 
- O 
) O 
p53 O 
( O 
+ O 
/ O 
- O 
) O 
primary O 
hepatocytes O 
. O 
In O 
conclusion O 
, O 
we O 
showed O 
parallels O 
in O 
gene O 
expression O 
responses O 
between O 
livers O 
and O 
primary O 
hepatocytes O 
upon O 
exposure O 
to O 
equivalent O 
concentrations O 
of O 
B[a]P B-ABBREVIATION 
. O 
Furthermore O 
, O 
we O 
recommend O 
considering O 
toxicokinetics O 
when O 
modeling O 
a O 
complex O 
in O 
vivo O 
endpoint O 
with O 
in O 
vitro O 
models O 
. O 

by O 
Australian O 
copperheads O 
results O 
mainly O 
in O 
muscle O 
paralysis O 
largely O 
attributed O 
to O 
the O 
presence O 
of O 
postsynaptic O 
α-neurotoxins O 
. O 
However O 
, O 
poorly O 
reversible O 
neurotoxic O 
effects O 
suggest O 
that O 
these O 
venoms O 
may O 
contain O 
snake O 
presynaptic O 
phospholipase O 
A2 O 
neurotoxins O 
( O 
SPANs O 
) O 
that O 
irreversibly O 
inhibit O 
neurotransmitter O 
release O 
. O 
Using O 
size O 
- O 
exclusion O 
liquid O 
chromatography O 
, O 
the O 
present O 
study O 
isolated O 
the O 
first O 
multimeric O 
SPAN O 
complex O 
from O 
the O 
venom O 
of O 
the O 
Australian O 
common O 
copperhead O 
, O 
Austrelaps O 
superbus O 
. O 
The O 
multimeric O 
SPAN O 
P-elapitoxin-As1a O 
( O 
P-EPTX-As1a O 
) O 
along O 
with O 
two O 
novel O 
monomeric O 
SPANs O 
and O 
a O 
new O 
postsynaptic O 
α-neurotoxin O 
were O 
then O 
pharmacologically O 
characterized O 
using O 
the O 
chick O 
biventer O 
cervicis O 
nerve O 
- O 
muscle O 
preparation O 
. O 
All O 
SPANs O 
inhibited O 
nerve O 
- O 
evoked O 
twitch O 
contractions O 
at O 
the O 
neuromuscular O 
junction O 
without O 
inhibiting O 
contractile O 
responses O 
to O 
cholinergic O 
agonists O 
or O 
KCl B-FORMULA 
. O 
These O 
actions O 
are O 
consistent O 
with O 
a O 
prejunctional O 
action O 
to O 
inhibit O 
neurotransmitter O 
release O 
, O 
without O 
direct O 
myotoxicity O 
. O 
Furthermore O 
, O 
the O 
multimeric O 
P-EPTX-As1a O 
caused O 
tetanic O 
' O 
fade O 
' O 
in O 
muscle O 
tension O 
under O 
high O 
frequency O 
nerve O 
stimulation O 
, O 
and O 
produced O 
a O 
triphasic O 
alteration O 
to O 
neurotransmitter O 
release O 
. O 
These O 
actions O 
have O 
been O 
previously O 
noted O 
with O 
other O 
multimeric O 
SPAN O 
complexes O 
such O 
as O 
taipoxin O 
. O 
Moreover O 
, O 
the O 
neurotoxic O 
α-subunit O 
of O 
P-EPTX-As1a O 
shows O 
high O 
homology O 
to O 
taipoxin O 
α-chain O 
. O 
Several O 
other O 
coagulopathic O 
and O 
myotoxic O 
high O 
mass O 
proteins O 
including O 
a O 
class O 
PIII O 
snake O 
venom O 
metalloproteinase O 
, O 
C- O 
type O 
lectin O 
, O 
l-amino B-FAMILY 
acid I-FAMILY 
oxidase O 
, O 
acetylcholinesterase O 
and O 
phospholipase O 
B O 
were O 
also O 
identified O 
that O 
may O 
contribute O 
to O 
the O 
overall O 
toxicity O 
of O 
A O 
. O 
superbus O 
venom O 
. O 
In O 
conclusion O 
, O 
clinicians O 
should O 
be O 
aware O 
that O 
early O 
antivenom O 
intervention O 
might O 
be O 
necessary O 
to O 
prevent O 
the O 
onset O 
of O 
irreversible O 
presynaptic O 
neurotoxicity O 
caused O 
by O 
multimeric O 
and O 
monomeric O 
SPANs O 
and O 
that O 
A O 
. O 
superbus O 
venom O 
is O 
potentially O 
capable O 
of O 
producing O 
coagulopathic O 
and O 
myotoxic O 
effects O 
. O 

of O 
A(1) O 
adenosine B-TRIVIAL 
receptor O 
attenuates O 
alpha-naphthylisothiocyanate B-SYSTEMATIC 
-induced O 
cholestatic O 
liver O 
injury O 
in O 
mice O 
. O 

has O 
limited O 
therapeutic O 
options O 
and O 
is O 
associated O 
with O 
high O 
morbidity O 
and O 
mortality O 
. O 
The O 
A(1) O 
adenosine B-TRIVIAL 
receptor O 
( O 
A(1)AR O 
) O 
was O 
postulated O 
to O 
participate O 
in O 
the O 
pathogenesis O 
of O 
hepatic O 
fibrosis O 
induced O 
by O 
experimental O 
extrahepatic O 
cholestasis O 
; O 
however O 
, O 
the O 
contribution O 
of O 
A(1)AR O 
to O 
intrahepatic O 
cholestatic O 
liver O 
injury O 
remains O 
unknown O 
. O 
Here O 
, O 
we O 
found O 
that O 
mice O 
lacking O 
A(1)AR O 
were O 
resistant O 
to O 
alpha-naphthyl B-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
( O 
ANIT B-ABBREVIATION 
)-induced O 
liver O 
injury O 
, O 
as O 
evidenced O 
by O 
lower O 
serum O 
liver O 
enzyme O 
levels O 
and O 
reduced O 
extent O 
of O 
histological O 
necrosis O 
. O 
Bile B-FAMILY 
acid I-FAMILY 
accumulation O 
in O 
liver O 
and O 
serum O 
was O 
markedly O 
diminished O 
in O 
A(1)AR(- O 
/ O 
- O 
) O 
mice O 
compared O 
with O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mice O 
. O 
However O 
, O 
biliary O 
and O 
urinary O 
outputs O 
of O 
bile B-FAMILY 
acids I-FAMILY 
were O 
significantly O 
enhanced O 
in O 
A(1)AR(- O 
/ O 
- O 
) O 
mice O 
. O 
In O 
the O 
liver O 
, O 
mRNA O 
expression O 
of O 
genes O 
related O 
to O 
bile B-FAMILY 
acid I-FAMILY 
transport O 
( O 
Bsep O 
and O 
Mdr2 O 
) O 
and O 
hydroxylation O 
( O 
Cyp3a11 O 
) O 
was O 
increased O 
in O 
A(1)AR(- O 
/ O 
- O 
) O 
mice O 
. O 
In O 
the O 
kidney O 
, O 
A(1)AR O 
deficiency O 
prevented O 
the O 
decrease O 
of O 
glomerular O 
filtration O 
rate O 
caused O 
by O 
ANIT B-ABBREVIATION 
. O 
Treatment O 
of O 
WT O 
mice O 
with O 
A(1)AR O 
antagonist O 
DPCPX B-ABBREVIATION 
also O 
protected O 
against O 
ANIT B-ABBREVIATION 
hepatotoxicity O 
. O 
Our O 
results O 
indicated O 
that O 
lack O 
of O 
A(1)AR O 
gene O 
protects O 
mice O 
from O 
ANIT B-ABBREVIATION 
-induced O 
cholestasis O 
by O 
enhancing O 
toxic O 
biliary O 
constituents O 
efflux O 
through O 
biliary O 
excretory O 
route O 
and O 
renal O 
elimination O 
system O 
and O 
suggested O 
a O 
potential O 
role O 
of O 
A(1)AR O 
as O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
intrahepatic O 
cholestasis O 
. O 

the O 
binding O 
interactions O 
of O 
galantamine B-TRIVIAL 
with O 
β-amyloid O 
peptide O 
. O 

anti-Alzheimer's O 
agent O 
galantamine B-TRIVIAL 
is O 
known O 
to O 
possess O 
anti-amyloid O 
properties O 
. O 
However O 
the O 
exact O 
mechanisms O 
are O 
not O 
clear O 
. O 
We O 
studied O 
the O 
binding O 
interactions O 
of O 
galantamine B-TRIVIAL 
with O 
amyloid O 
peptide O 
dimer O 
(Aβ(1-40)) O 
through O 
molecular O 
docking O 
and O 
molecular O 
dynamics O 
simulations O 
. O 
Galantamine B-TRIVIAL 
' O 
s O 
binding O 
site O 
within O 
the O 
amyloid O 
peptide O 
dimer O 
was O 
identified O 
by O 
docking O 
experiments O 
and O 
the O 
most O 
stable O 
complex O 
was O 
analyzed O 
by O 
molecular O 
dynamics O 
simulation O 
. O 
These O 
studies O 
show O 
that O 
galantamine B-TRIVIAL 
was O 
interacting O 
with O 
the O 
central O 
region O 
of O 
the O 
amyloid O 
dimer O 
( O 
Lys B-FORMULA 
16- O 
Ala B-FORMULA 
21 O 
) O 
and O 
the O 
C B-FORMULA 
-terminal O 
region O 
( O 
Ile B-FORMULA 
31- O 
Val B-ABBREVIATION 
36 O 
) O 
with O 
minimum O 
structural O 
drift O 
of O 
Cα O 
atom O 
in O 
those O 
regions O 
. O 
Strikingly O 
, O 
a O 
significant O 
drift O 
was O 
observed O 
at O 
the O 
turn O 
region O 
from O 
Asp B-FORMULA 
23- O 
Gly B-FORMULA 
29 O 
( O 
Cα O 
atom O 
RMSD=9.2 O 
Å O 
and O 
11.6 O 
Å O 
at O 
50 O 
fs O 
and O 
100 O 
fs O 
respectively O 
) O 
. O 
Furthermore O 
, O 
galantamine B-TRIVIAL 
' O 
s O 
binding O 
mode O 
disrupts O 
the O 
key O 
pi-pi O 
stacking O 
interaction O 
between O 
aromatic O 
rings O 
of O 
Phe B-FORMULA 
19 O 
( O 
chain O 
A O 
) O 
and O 
Phe B-FORMULA 
19 O 
( O 
chain O 
B O 
) O 
and O 
intermolecular O 
hydrogen B-SYSTEMATIC 
bonds O 
seen O 
in O 
unbound O 
peptide O 
dimer O 
. O 
Noticeably O 
, O 
the O 
azepine B-SYSTEMATIC 
tertiary O 
nitrogen B-SYSTEMATIC 
of O 
galantamine B-TRIVIAL 
was O 
in O 
close O 
proximity O 
to O 
backbone O 
CO B-FORMULA 
of O 
Leu B-FORMULA 
34 O 
( O 
distance O 
< O 
3.5 O 
Å O 
) O 
to O 
stabilize O 
the O 
dimer O 
conformation O 
. O 
In O 
summary O 
, O 
the O 
results O 
indicate O 
that O 
galantamine B-TRIVIAL 
binding O 
to O 
amyloid O 
peptide O 
dimer O 
leads O 
to O 
a O 
significant O 
conformational O 
change O 
at O 
the O 
turn O 
region O 
( O 
Asp B-FORMULA 
23- O 
Gly B-FORMULA 
29 O 
) O 
that O 
disrupts O 
interactions O 
between O 
individual O 
β-strands O 
and O 
promotes O 
a O 
nontoxic O 
conformation O 
of O 
Aβ(1-40) O 
to O 
prevent O 
the O 
formation O 
of O 
neurotoxic O 
oligomers O 
. O 

of O 
nNOS O 
/ O 
NO O 
/ O 
sGC O 
/ O 
cGMP O 
signaling O 
pathway O 
in O 
cocaine B-TRIVIAL 
sensitization O 
and O 
in O 
the O 
associated O 
hippocampal O 
alterations O 
: O 
does O 
phosphodiesterase O 
5 O 
inhibition O 
help O 
to O 
drug O 
vulnerability O 
? O 

: O 
Repeated O 
cocaine B-TRIVIAL 
administration O 
induces O 
behavioral O 
sensitization O 
in O 
about O 
50 O 
% O 
of O 
treated O 
animals O 
. O 
Nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
could O 
be O 
involved O 
in O 
the O 
acquisition O 
and O 
maintenance O 
of O 
behavioral O 
cocaine B-TRIVIAL 
effects O 
, O 
probably O 
by O 
activation O 
of O 
neuronal O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
(nNOS)/ O 
NO B-FORMULA 
/ O 
soluble O 
guanylyl B-TRIVIAL 
cyclase O 
(sGC)/ O 
cyclic B-SYSTEMATIC 
guanosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
( O 
cGMP B-ABBREVIATION 
) O 
signaling O 
pathway O 
, O 
since O 
inhibition O 
of O 
the O 
nNOS O 
enzyme O 
attenuates O 
development O 
of O 
sensitization O 
in O 
rats O 
. O 
On O 
the O 
other O 
hand O 
, O 
increased O 
cGMP B-ABBREVIATION 
availability O 
by O 
phosphodiesterase O 
5 O 
inhibitors O 
has O 
been O 
correlated O 
to O 
the O 
misuse O 
and O 
recreational O 
use O 
of O 
these O 
agents O 
and O 
also O 
to O 
the O 
concomitant O 
use O 
with O 
illicit O 
drugs O 
in O 
humans O 
. O 
Hippocampus O 
is O 
an O 
important O 
brain O 
region O 
for O 
conditioning O 
to O 
general O 
context O 
previously O 
associated O 
to O 
drug O 
availability O 
, O 
influencing O 
drug O 
- O 
seeking O 
behavior O 
and O 
sensitization O 
. O 
Moreover O 
, O 
cocaine B-TRIVIAL 
and O 
other O 
drugs O 
of O 
abuse O 
can O 
affect O 
the O 
strength O 
of O 
glutamate B-TRIVIAL 
synapses O 
in O 
this O 
structure O 
, O 
lastly O 
modifying O 
neuronal O 
activity O 
in O 
main O 
regions O 
of O 
the O 
reward O 
circuitry O 
. O 
OBJECTIVE O 
: O 
The O 
objective O 
of O 
this O 
study O 
is O 
to O 
determine O 
whether O 
the O 
pharmacological O 
manipulation O 
of O 
nNOS/ O 
NO B-FORMULA 
/ O 
sGC/ O 
cGMP B-ABBREVIATION 
signaling O 
pathway O 
altered O 
changes O 
induced O 
by O 
repeated O 
cocaine B-TRIVIAL 
exposure O 
. O 
RESULTS O 
: O 
The O 
present O 
investigation O 
showed O 
a O 
relationship O 
between O 
behavioral O 
cocaine B-TRIVIAL 
sensitization O 
, O 
reduced O 
threshold O 
to O 
generate O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
in O 
hippocampal O 
dentate O 
gyrus O 
, O 
and O 
increased O 
nNOS O 
activity O 
in O 
this O 
structure O 
. O 
However O 
, O 
when O 
nNOS O 
or O 
sGC O 
were O 
inhibited O 
, O 
the O 
number O 
of O 
sensitized O 
animals O 
was O 
reduced O 
, O 
and O 
the O 
threshold O 
to O 
generate O 
LTP O 
was O 
increased O 
. O 
The O 
opposite O 
occurred O 
when O 
cGMP B-ABBREVIATION 
availability O 
was O 
increased O 
. O 
CONCLUSION O 
: O 
We O 
demonstrate O 
a O 
key O 
role O 
of O 
the O 
nNOS O 
activity O 
and O 
NO B-FORMULA 
/ O 
sGC/ O 
cGMP B-ABBREVIATION 
signaling O 
pathway O 
in O 
the O 
development O 
of O 
cocaine B-TRIVIAL 
sensitization O 
and O 
in O 
the O 
associated O 
enhancement O 
of O 
hippocampal O 
synaptic O 
transmission O 
. O 

induces O 
JNK-dependent O 
apoptosis O 
through O 
the O 
mitochondrial O 
pathway O 
in O 
HL60 O 
cells O 
. O 

, O 
a O 
natural O 
sesquiterpenol B-FAMILY 
present O 
in O 
a O 
variety O 
of O 
Chinese O 
herbs O 
, O 
is O 
known O 
to O 
inhibit O 
the O 
proliferation O 
of O 
human O 
tumor O 
cells O 
. O 
However O 
, O 
the O 
molecular O 
mechanisms O 
of O 
the O 
effect O 
of O 
β-eudesmol B-TRIVIAL 
on O 
human O 
tumor O 
cells O 
are O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
report O 
the O 
cytotoxic O 
effect O 
of O 
β-eudesmol B-TRIVIAL 
on O 
the O 
human O 
leukemia O 
HL60 O 
cells O 
and O 
its O 
molecular O 
mechanisms O 
. O 
The O 
cytotoxic O 
effect O 
of O 
β-eudesmol B-TRIVIAL 
on O 
HL60 O 
cells O 
was O 
associated O 
with O 
apoptosis O 
, O 
which O 
was O 
characterized O 
by O 
the O 
presence O 
of O 
DNA O 
fragmentation O 
. O 
β-eudesmol B-TRIVIAL 
-induced O 
apoptosis O 
was O 
accompanied O 
by O 
cleavage O 
of O 
caspase-3 O 
, O 
caspase-9 O 
, O 
and O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
; O 
downregulation O 
of O 
Bcl-2 O 
expression O 
; O 
release O 
of O 
cytochrome O 
c O 
from O 
mitochondria O 
; O 
and O 
decrease O 
in O 
mitochondrial O 
membrane O 
potential O 
( O 
MMP O 
) O 
. O 
Activation O 
of O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinases O 
( O 
JNK O 
) O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
was O 
observed O 
in O 
β-eudesmol B-TRIVIAL 
-treated O 
HL60 O 
cells O 
, O 
and O 
the O 
inhibitor O 
of O 
JNK O 
blocked O 
the O 
β-eudesmol B-TRIVIAL 
-induced O 
apoptosis O 
, O 
downregulation O 
of O 
Bcl-2 O 
, O 
and O 
the O 
loss O 
of O 
MMP O 
. O 
These O 
data O 
suggest O 
that O 
β-eudesmol B-TRIVIAL 
induces O 
apoptosis O 
in O 
HL60 O 
cells O 
via O 
the O 
mitochondrial O 
apoptotic O 
pathway O 
, O 
which O 
is O 
controlled O 
through O 
JNK O 
signaling O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
Src O 
/ O 
ERK O 
and O 
GSK-3 O 
/ O 
β-catenin O 
signaling O 
by O 
pinosylvin B-TRIVIAL 
inhibits O 
the O 
growth O 
of O 
human O 
colorectal O 
cancer O 
cells O 
. O 

, O 
a O 
naturally O 
occurring O 
trans-stilbenoid B-TRIVIAL 
mainly O 
found O 
in O 
Pinus O 
species O 
, O 
has O 
exhibited O 
a O 
potential O 
cancer O 
chemopreventive O 
activity O 
. O 
However O 
, O 
the O 
growth O 
inhibitory O 
activity O 
against O 
cancer O 
cells O 
and O 
the O 
underlying O 
molecular O 
mechanisms O 
remain O 
to O 
be O 
elucidated O 
. O 
Therefore O 
, O 
the O 
anti-proliferative O 
activity O 
of O 
pinosylvin B-TRIVIAL 
was O 
investigated O 
in O 
human O 
colorectal O 
HCT O 
116 O 
cancer O 
cells O 
. O 
Pinosylvin B-TRIVIAL 
inhibited O 
the O 
proliferation O 
of O 
HCT O 
116 O 
cells O 
by O 
arresting O 
transition O 
of O 
cell O 
cycle O 
from O 
G1 O 
to O 
S O 
phase O 
along O 
with O 
the O 
downregulation O 
of O 
cyclin O 
D1 O 
, O 
cyclin O 
E O 
, O 
cyclin O 
A O 
, O 
cyclin O 
dependent O 
kinase O 
2 O 
( O 
CDK2 O 
) O 
, O 
CDK4 O 
, O 
c-Myc O 
, O 
and O 
retinoblastoma O 
protein O 
( O 
pRb O 
) O 
, O 
and O 
the O 
upregulation O 
of O 
p21(WAF1 O 
/ O 
CIP1 O 
) O 
and O 
p53 O 
. O 
Pinosylvin B-TRIVIAL 
was O 
also O 
found O 
to O 
attenuate O 
the O 
activation O 
of O 
proteins O 
involved O 
in O 
focal O 
adhesion O 
kinase O 
( O 
FAK O 
) O 
/ O 
c-Src O 
/ O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
signaling O 
, O 
and O 
phosphoinositide B-FAMILY 
3-kinase O 
( O 
PI3K O 
) O 
/ O 
Akt/ O 
glycogen O 
synthase O 
kinase O 
3β O 
( O 
GSK-3β O 
) O 
signaling O 
pathway O 
. O 
Subsequently O 
, O 
pinosylvin B-TRIVIAL 
suppressed O 
the O 
nuclear O 
translocation O 
of O 
β-catenin O 
, O 
one O 
of O 
downstream O 
molecules O 
of O 
PI3K O 
/ O 
Akt O 
/ O 
GSK-3β O 
signaling O 
, O 
and O 
these O 
events O 
led O 
to O 
the O 
sequential O 
downregulation O 
of O 
β-catenin- O 
mediated O 
transcription O 
of O 
target O 
genes O 
including O 
BMP4 O 
, O 
ID2 O 
, O 
survivin O 
, O 
cyclin O 
D1 O 
, O 
MMP7 O 
, O 
and O 
c-Myc O 
. O 
These O 
findings O 
demonstrate O 
that O 
the O 
anti-proliferative O 
activity O 
of O 
pinosylvin B-TRIVIAL 
might O 
be O 
associated O 
with O 
the O 
cell O 
cycle O 
arrest O 
and O 
downregulation O 
of O 
cell O 
proliferation O 
regulating O 
signaling O 
pathways O 
in O 
human O 
colorectal O 
cancer O 
cells O 
. O 

exercise O 
does O 
not O 
ameliorate O 
spatial O 
learning O 
and O 
memory O 
deficits O 
induced O 
by O 
chronic O 
administration O 
of O 
nandrolone B-SYSTEMATIC 
decanoate I-SYSTEMATIC 
in O 
rats O 
. O 

exposure O 
to O 
the O 
anabolic O 
androgenic O 
steroids B-FAMILY 
( O 
AAS O 
) O 
nandrolone B-SYSTEMATIC 
decanoate I-SYSTEMATIC 
( O 
ND O 
) O 
in O 
supra O 
- O 
physiological O 
doses O 
is O 
associated O 
with O 
learning O 
and O 
memory O 
impairments O 
. O 
Given O 
the O 
well O 
- O 
known O 
beneficial O 
effects O 
of O 
voluntary O 
exercise O 
on O 
cognitive O 
functions O 
, O 
we O 
examined O 
whether O 
voluntary O 
exercise O 
would O 
improve O 
the O 
cognitive O 
deficits O 
induced O 
by O 
chronic O 
administration O 
of O 
ND O 
. O 
We O 
also O 
investigated O 
the O 
effects O 
of O 
ND O 
and O 
voluntary O 
exercise O 
on O 
hippocampal O 
BDNF O 
levels O 
. O 
The O 
rats O 
were O 
randomly O 
distributed O 
into O 
4 O 
experimental O 
groups O 
: O 
the O 
vehicle O 
- O 
sedentary O 
group O 
, O 
the O 
ND-sedentary O 
group O 
, O 
the O 
vehicle O 
- O 
exercise O 
group O 
, O 
and O 
the O 
ND-exercise O 
group O 
. O 
The O 
vehicle O 
- O 
exercise O 
and O 
the O 
ND-exercise O 
groups O 
were O 
allowed O 
to O 
freely O 
exercise O 
in O 
a O 
running O 
wheel O 
for O 
15 O 
days O 
. O 
The O 
vehicle O 
- O 
sedentary O 
and O 
the O 
ND-sedentary O 
groups O 
were O 
kept O 
sedentary O 
for O 
the O 
same O 
period O 
. O 
Vehicle O 
or O 
ND O 
injections O 
were O 
started O 
14 O 
days O 
prior O 
to O 
the O 
voluntary O 
exercise O 
and O 
continued O 
throughout O 
the O 
15 O 
days O 
of O 
voluntary O 
exercise O 
. O 
After O 
the O 
15-day O 
period O 
, O 
the O 
rats O 
were O 
trained O 
and O 
tested O 
on O 
a O 
water O 
maze O 
spatial O 
task O 
using O 
four O 
trials O 
per O 
day O 
for O 
5 O 
consecutive O 
days O 
followed O 
by O 
a O 
probe O 
trial O 
two O 
days O 
later O 
. O 
Exercise O 
significantly O 
improved O 
performance O 
during O 
both O 
the O 
training O 
and O 
retention O 
of O 
the O 
water O 
maze O 
task O 
, O 
and O 
enhanced O 
hippocampal O 
BDNF O 
. O 
ND O 
impaired O 
spatial O 
learning O 
and O 
memory O 
, O 
and O 
this O 
effect O 
was O 
not O 
rescued O 
by O 
exercise O 
. O 
ND O 
also O 
potentiated O 
the O 
exercise O 
- O 
induced O 
increase O 
in O 
hippocampal O 
BDNF O 
levels O 
. O 
These O 
results O 
seem O 
to O 
indicate O 
that O 
voluntary O 
exercise O 
is O 
unable O 
to O 
improve O 
the O 
disruption O 
of O 
cognitive O 
functions O 
by O 
chronic O 
ND O 
. O 
Moreover O 
, O 
increased O 
levels O 
of O 
BDNF O 
may O 
play O 
a O 
role O 
in O 
ND-induced O 
impairments O 
in O 
learning O 
and O 
memory O 
. O 
The O 
harmful O 
effects O 
of O 
ND O 
and O 
other O 
AAS O 
on O 
learning O 
and O 
memory O 
should O 
be O 
taken O 
into O 
account O 
when O 
athletes O 
decide O 
to O 
use O 
AAS O 
for O 
performance O 
or O 
body O 
image O 
improvement O 
. O 

- O 
assisted O 
cobalt B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticle O 
formation O 
. O 

formation O 
of O 
Co(3)O(4) B-FORMULA 
nano O 
- O 
scale O 
colloid O 
particles O 
by O 
gamma O 
irradiation O 
of O 
CoSO(4) B-FORMULA 
solutions O 
was O 
investigated O 
. O 
Solutions O 
of O 
0.2-0.3 O 
mM O 
CoSO(4) B-FORMULA 
at O 
pH O 
6 O 
and O 
10.6 O 
( O 
air O 
- O 
saturated O 
and O 
Ar-purged O 
) O 
were O 
irradiated O 
at O 
an O 
absorbed O 
dose O 
rate O 
of O 
5.5 O 
kGy O 
h(-1) O 
. O 
The O 
resulting O 
concentrations O 
of O 
H(2) B-FORMULA 
, O 
H(2)O(2) B-FORMULA 
, O 
Co B-FORMULA 
(II) I-FORMULA 
and O 
Co B-FORMULA 
(III) I-FORMULA 
species O 
in O 
solution O 
and O 
the O 
chemical O 
composition O 
and O 
sizes O 
of O 
particles O 
that O 
were O 
formed O 
were O 
measured O 
as O 
a O 
function O 
of O 
irradiation O 
time O 
. O 
Particle O 
formation O 
was O 
observed O 
only O 
for O 
initially O 
air O 
- O 
saturated O 
CoSO(4) B-FORMULA 
solutions O 
at O 
pH O 
10.6 O 
. O 
Analysis O 
of O 
the O 
particle O 
formation O 
as O 
a O 
function O 
of O 
irradiation O 
time O 
shows O 
that O 
the O 
particles O 
evolve O 
from O 
Co(OH)(2) B-FORMULA 
to O 
CoOOH B-FORMULA 
and O 
then O 
to O 
Co(3)O(4) B-FORMULA 
. O 
The O 
radiolytic O 
oxidation O 
of O 
Co B-FORMULA 
(II) I-FORMULA 
to O 
Co B-FORMULA 
(III) I-FORMULA 
was O 
completed O 
in O 
100 O 
min O 
and O 
the O 
chemical O 
composition O 
of O 
the O 
final O 
particles O 
was O 
identified O 
as O 
Co(3)O(4) B-FORMULA 
by O 
XPS O 
, O 
Raman O 
and O 
UV-Vis O 
spectroscopy O 
. O 
Transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
images O 
show O 
the O 
final O 
particles O 
are O 
approximately O 
uniform O 
in O 
size O 
, O 
ranging O 
from O 
8 O 
to O 
20 O 
nm O 
. O 
A O 
mechanism O 
is O 
proposed O 
to O 
explain O 
the O 
particle O 
formation O 
. O 
A O 
key O 
factor O 
is O 
the O 
low O 
solubility O 
of O 
Co(OH)(2) B-FORMULA 
in O 
air O 
- O 
saturated O 
solutions O 
at O 
high O 
pH O 
. O 
This O 
mechanism O 
for O 
particle O 
formation O 
is O 
compared O 
with O 
the O 
mechanism O 
previously O 
reported O 
for O 
the O 
radiolytic O 
formation O 
of O 
γ-FeOOH B-FORMULA 
nanoparticles O 
. O 

: O 
A O 
New O 
Boost O 
for O 
the O 
Treatment O 
of O 
Human O 
Immunodeficiency O 
Virus O 
Infection O 
. O 

is O 
commonly O 
used O 
as O 
a O 
pharmacokinetic O 
booster O 
for O 
antiretroviral O 
regimens O 
in O 
the O 
management O 
of O 
human O 
immunodeficiency O 
virus O 
infections O 
. O 
Limitations O 
to O 
ritonavir B-TRIVIAL 
boosting O 
include O 
increased O 
pill O 
burden O 
, O 
adverse O 
effects O 
, O 
and O 
a O 
wide O 
range O 
of O 
clinically O 
significant O 
drug O 
- O 
drug O 
interactions O 
. O 
Cobicistat B-TRIVIAL 
is O 
a O 
new O 
pharmacokinetic O 
booster O 
that O 
is O 
a O 
selective O 
inhibitor O 
of O 
cytochrome O 
P450 O 
3A O 
, O 
the O 
main O 
metabolizing O 
pathway O 
of O 
several O 
antiretrovirals O 
. O 
Cobicistat B-TRIVIAL 
has O 
been O 
studied O 
as O 
a O 
booster O 
for O 
elvitegravir B-TRIVIAL 
, O 
a O 
second O 
- O 
generation O 
integrase O 
inhibitor O 
, O 
and O 
protease O 
inhibitors O 
. O 
Based O 
on O 
successful O 
clinical O 
trials O 
, O 
a O 
new O 
single O 
- O 
tablet O 
regimen O 
of O 
elvitegravir B-TRIVIAL 
, O 
cobicistat B-TRIVIAL 
, O 
emtricitabine B-TRIVIAL 
, O 
and O 
tenofovir B-TRIVIAL 
has O 
been O 
approved O 
for O 
the O 
management O 
of O 
treatment-naïve O 
patients O 
. O 
Additional O 
studies O 
are O 
underway O 
investigating O 
the O 
safety O 
and O 
efficacy O 
of O 
cobicistat B-TRIVIAL 
-boosted O 
protease O 
inhibitor O 
regimens O 
for O 
both O 
treatment-naïve O 
and O 
treatment-experienced O 
patients O 
. O 
Cobicistat B-TRIVIAL 
is O 
well O 
tolerated O 
and O 
may O 
become O 
a O 
preferred O 
booster O 
for O 
antiretroviral O 
regimens O 
, O 
as O 
it O 
can O 
be O 
coformulated O 
with O 
several O 
agents O 
to O 
create O 
simpler O 
regimens O 
. O 

simple O 
method O 
for O 
fabricating O 
patterned O 
curvilinear O 
microstructures O 
in O 
poly(dimethylsiloxane) B-SYSTEMATIC 
by O 
selective O 
wetting O 
. O 

fabrication O 
of O 
patterned O 
microstructures O 
in O 
poly(dimethylsiloxane) B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
is O 
a O 
prerequisite O 
for O 
soft O 
lithography O 
. O 
Herein O 
, O 
curvilinear O 
surface O 
relief O 
microstructures O 
in O 
PDMS B-ABBREVIATION 
are O 
fabricated O 
through O 
a O 
simple O 
three O 
- O 
stage O 
approach O 
combining O 
microcontact O 
printing O 
( O 
μCP O 
) O 
, O 
selective O 
surface O 
wetting O 
/ O 
dewetting O 
and O 
replica O 
molding O 
( O 
REM O 
) O 
. O 
First O 
, O 
using O 
an O 
original O 
PDMS B-ABBREVIATION 
stamp O 
( O 
first O 
- O 
generation O 
stamp O 
) O 
with O 
linear O 
relief O 
features O 
, O 
a O 
chemical O 
pattern O 
on O 
gold O 
substrate O 
is O 
generated O 
by O 
μCP O 
using O 
hexadecanethiol B-SYSTEMATIC 
( O 
HDT B-ABBREVIATION 
) O 
as O 
an O 
ink O 
. O 
Then O 
, O 
by O 
a O 
dip O 
- O 
coating O 
process O 
, O 
an O 
ordered O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
polymer O 
- O 
dot O 
array O 
forms O 
on O 
the O 
HDT B-ABBREVIATION 
-patterned O 
gold O 
substrate O 
. O 
Finally O 
, O 
based O 
on O 
a O 
REM O 
process O 
, O 
the O 
PEG B-ABBREVIATION 
-dot O 
array O 
on O 
gold O 
substrate O 
is O 
used O 
to O 
fabricate O 
a O 
second O 
- O 
generation O 
PDMS B-ABBREVIATION 
stamp O 
with O 
microcavity O 
array O 
, O 
and O 
the O 
second O 
- O 
generation O 
PDMS B-ABBREVIATION 
stamp O 
is O 
used O 
to O 
generate O 
third O 
- O 
generation O 
PDMS B-ABBREVIATION 
stamp O 
with O 
microbump O 
array O 
. O 
These O 
fabricated O 
new O 
- O 
generation O 
stamps O 
are O 
utilized O 
in O 
μCP O 
and O 
in O 
micromolding O 
in O 
capillaries O 
( O 
MIMIC O 
) O 
, O 
allowing O 
the O 
generation O 
of O 
surface O 
micropatterns O 
which O 
cannot O 
be O 
obtained O 
using O 
the O 
original O 
PDMS B-ABBREVIATION 
stamp O 
. O 
The O 
method O 
will O 
be O 
useful O 
in O 
producing O 
new O 
- O 
generation O 
PDMS B-ABBREVIATION 
stamps O 
, O 
especially O 
for O 
those O 
who O 
want O 
to O 
use O 
soft O 
lithography O 
in O 
their O 
studies O 
but O 
have O 
no O 
access O 
to O 
the O 
microfabrication O 
facilities O 
. O 

C B-FORMULA 
-Terminal O 
Region O 
of O 
Cytoplasmic O 
Polyadenylation O 
Element O 
Binding O 
Protein O 
Is O 
a O 
ZZ O 
Domain O 
with O 
Potential O 
for O 
Protein O 
- O 
Protein O 
Interactions O 
. O 

polyadenylation O 
element O 
binding O 
protein O 
( O 
CPEB O 
) O 
provides O 
temporal O 
and O 
spatial O 
control O 
of O 
protein O 
synthesis O 
required O 
for O 
early O 
development O 
and O 
neuronal O 
synaptic O 
plasticity O 
. O 
CPEB O 
regulates O 
protein O 
expression O 
by O 
inhibiting O 
polyadenylation O 
of O 
selected O 
mRNA O 
transcripts O 
, O 
which O 
prevents O 
binding O 
of O 
the O 
ribosome O 
for O 
protein O 
synthesis O 
. O 
Two O 
RNA O 
recognition O 
motif O 
domains O 
and O 
a O 
C B-FORMULA 
-terminal O 
binuclear O 
zinc B-SYSTEMATIC 
-binding O 
domain O 
are O 
required O 
for O 
mRNA O 
binding O 
, O 
but O 
the O 
zinc B-SYSTEMATIC 
-binding O 
domain O 
is O 
not O 
required O 
for O 
sequence O 
- O 
specific O 
recognition O 
of O 
the O 
targeted O 
mRNA O 
transcript O 
. O 
The O 
structure O 
and O 
function O 
of O 
the O 
zinc B-SYSTEMATIC 
-binding O 
domain O 
of O 
CPEB O 
are O 
unknown O 
. O 
The O 
C B-FORMULA 
-terminal O 
region O 
of O 
CPEB O 
may O 
participate O 
in O 
assembly O 
of O 
the O 
ribonucleoprotein O 
complex O 
that O 
includes O 
the O 
scaffold O 
protein O 
, O 
Symplekin O 
, O 
and O 
the O 
cleavage O 
and O 
polyadenylation O 
specificity O 
factor O 
. O 
Sumoylation O 
of O 
Symplekin O 
is O 
required O 
for O 
polyadenylation O 
, O 
and O 
both O 
cleavage O 
and O 
polyadenylation O 
specificity O 
factor O 
and O 
poly(A) O 
polymerase O 
are O 
sumoylated O 
. O 
The O 
foreshortened O 
poly(A) O 
tail O 
is O 
maintained O 
by O 
poly(A) O 
ribonuclease O 
, O 
which O 
associates O 
with O 
CPEB O 
. O 
While O 
zinc B-SYSTEMATIC 
-binding O 
domains O 
are O 
renowned O 
for O 
nucleic O 
acid O 
recognition O 
, O 
binuclear O 
zinc B-SYSTEMATIC 
-binding O 
structural O 
motifs O 
, O 
such O 
as O 
LIM O 
( O 
Lin-11 O 
, O 
Isl-1 O 
, O 
Mec-3 O 
) O 
, O 
RING O 
( O 
really O 
interesting O 
new O 
gene O 
) O 
, O 
PHD O 
( O 
plant O 
homeodomain O 
) O 
and O 
ZZ O 
( O 
ZZ O 
- O 
type O 
zinc B-SYSTEMATIC 
finger O 
) O 
domains O 
, O 
participate O 
in O 
protein O 
- O 
protein O 
interactions O 
. O 
Here O 
, O 
we O 
report O 
the O 
solution O 
structure O 
of O 
the O 
C B-FORMULA 
-terminal O 
zinc B-SYSTEMATIC 
-binding O 
domain O 
of O 
CPEB1 O 
( O 
CPEB1-ZZ O 
) O 
, O 
which O 
has O 
a O 
cross O 
- O 
braced O 
zinc B-SYSTEMATIC 
binding O 
topology O 
. O 
The O 
structural O 
similarity O 
to O 
other O 
ZZ O 
domains O 
suggests O 
that O 
the O 
CPEB1-ZZ O 
domain O 
recruits O 
sumoylated O 
proteins O 
during O 
assembly O 
of O 
the O 
ribonucleoprotein O 
complex O 
prior O 
to O 
mRNA O 
export O 
from O 
the O 
nucleus O 
. O 

chemicals O 
lyral B-TRIVIAL 
and O 
lilial B-TRIVIAL 
decrease O 
viability O 
of O 
HaCat O 
cells O 
' O 
by O 
increasing O 
free O 
radical O 
production O 
and O 
lowering O 
intracellular O 
ATP B-ABBREVIATION 
level O 
: O 
protection O 
by O 
antioxidants O 
. O 

investigate O 
in O 
this O 
study O 
the O 
biochemical O 
effects O 
on O 
cells O 
in O 
culture O 
of O 
two O 
commonly O 
used O 
fragrance O 
chemicals O 
: O 
lyral B-TRIVIAL 
and O 
lilial B-TRIVIAL 
. O 
Whereas O 
both O 
chemicals O 
exerted O 
a O 
significant O 
effect O 
on O 
primary O 
keratinocyte(s) O 
, O 
HaCat O 
cells O 
, O 
no O 
effect O 
was O 
obtained O 
with O 
any O 
of O 
HepG2 O 
, O 
Hek293 O 
, O 
Caco2 O 
, O 
NIH3T3 O 
, O 
and O 
MCF7 O 
cells O 
. O 
Lyral B-TRIVIAL 
and O 
lilial B-TRIVIAL 
: O 
( O 
a O 
) O 
decreased O 
the O 
viability O 
of O 
HaCat O 
cells O 
with O 
a O 
50% O 
cell O 
death O 
at O 
100 O 
and O 
60 O 
nM O 
respectively O 
; O 
( O 
b O 
) O 
decreased O 
significantly O 
in O 
a O 
dose O 
dependant O 
manner O 
the O 
intracellular O 
ATP B-ABBREVIATION 
level O 
following O 
12-h O 
of O 
treatment O 
; O 
( O 
c O 
) O 
inhibited O 
complexes O 
I O 
and O 
II O 
of O 
electron O 
transport O 
chain O 
in O 
liver O 
sub O 
- O 
mitochondrial O 
particles O 
; O 
and O 
( O 
d O 
) O 
increased O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
generation O 
that O 
was O 
reversed O 
by O 
N-acetyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
and O 
trolox B-TRIVIAL 
and O 
the O 
natural O 
antioxidant O 
lipoic B-TRIVIAL 
acid I-TRIVIAL 
, O 
without O 
influencing O 
the O 
level O 
of O 
free O 
and O 
/ O 
or O 
oxidized O 
glutathione B-TRIVIAL 
. O 
Lipoic B-TRIVIAL 
acid I-TRIVIAL 
protected O 
HaCat O 
cells O 
against O 
the O 
decrease O 
in O 
viability O 
induced O 
by O 
either O 
compound O 
. O 
Dehydrogenation O 
of O 
lyral B-TRIVIAL 
and O 
lilial B-TRIVIAL 
produce O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
aldehydes I-FAMILY 
, O 
that O 
reacts O 
with O 
lipoic B-TRIVIAL 
acid I-TRIVIAL 
requiring O 
proteins O 
resulting O 
in O 
their O 
inhibition O 
. O 
We O 
propose O 
lyral B-TRIVIAL 
and O 
lilial B-TRIVIAL 
as O 
toxic O 
to O 
mitochondria O 
that O 
have O 
a O 
direct O 
effect O 
on O 
electron O 
transport O 
chain O 
, O 
increase O 
ROS O 
production O 
, O 
derange O 
mitochondrial O 
membrane O 
potential O 
, O 
and O 
decrease O 
cellular O 
ATP B-ABBREVIATION 
level O 
, O 
leading O 
thus O 
to O 
cell O 
death O 
. O 

organic O 
electronics O 
rests O 
on O 
the O 
use O 
of O 
bottom O 
- O 
up O 
chemical O 
self O 
- O 
assembly O 
processes O 
in O 
order O 
to O 
design O 
conducting O 
components O 
on O 
the O 
5-100 O 
nm O 
scale O 
. O 
The O 
challenges O 
in O 
this O 
field O 
are O 
both O 
the O 
construction O 
of O 
1D-nanostructures O 
displaying O 
optimized O 
transport O 
properties O 
and O 
their O 
precise O 
connections O 
to O 
electrodes O 
. O 
The O 
present O 
Research O 
News O 
highlights O 
important O 
advances O 
in O 
such O 
materials O 
regarding O 
their O 
electrical O 
performances O 
, O 
from O 
semiconductors O 
to O 
organic O 
metals O 
, O 
but O 
also O 
regarding O 
their O 
processability O 
. O 
In O 
particular O 
, O 
by O 
externally O 
controlling O 
light O 
- O 
responsive O 
supramolecular O 
polymerization O 
processes O 
, O 
and O 
by O 
using O 
appropriate O 
methods O 
of O 
casting O 
with O 
an O 
applied O 
electric O 
field O 
, O 
it O 
becomes O 
possible O 
to O 
pre O 
- O 
determine O 
the O 
accurate O 
positioning O 
of O 
organic O 
interconnects O 
within O 
patterned O 
nano O 
- O 
circuitry O 
. O 
These O 
strategies O 
using O 
external O 
stimuli O 
to O 
obtain O 
addressability O 
, O 
thus O 
hold O 
promising O 
alternatives O 
to O 
other O 
conducting O 
materials O 
such O 
as O 
carbon B-SYSTEMATIC 
nanotubes O 
for O 
further O 
technological O 
applications O 
in O 
nanosciences O 
. O 

male O 
rats O 
are O 
less O 
sensitive O 
than O 
adults O 
to O 
the O 
anxiogenic O 
and O 
serotonin B-TRIVIAL 
-releasing O 
effects O 
of O 
fenfluramine B-TRIVIAL 
. O 

taking O 
behavior O 
increases O 
during O 
adolescence O 
, O 
which O 
is O 
also O 
a O 
critical O 
period O 
for O 
the O 
onset O 
of O 
drug O 
abuse O 
. O 
The O 
central O 
serotonergic O 
system O 
matures O 
during O 
the O 
adolescent O 
period O 
, O 
and O 
its O 
immaturity O 
during O 
early O 
adolescence O 
may O 
contribute O 
to O 
adolescent O 
risk O 
taking O 
, O 
as O 
deficits O 
in O 
central O 
serotonergic O 
function O 
have O 
been O 
associated O 
with O 
impulsivity O 
, O 
aggression O 
, O 
and O 
risk O 
taking O 
. O 
We O 
investigated O 
serotonergic O 
modulation O 
of O 
behavior O 
and O 
presynaptic O 
serotonergic O 
function O 
in O 
adult O 
( O 
67-74 O 
days O 
old O 
) O 
and O 
adolescent O 
( O 
28-34 O 
days O 
old O 
) O 
male O 
rats O 
. O 
Fenfluramine B-TRIVIAL 
( O 
2 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
produced O 
greater O 
anxiogenic O 
effects O 
in O 
adult O 
rats O 
in O 
both O 
the O 
light O 
/ O 
dark O 
and O 
elevated O 
plus O 
maze O 
tests O 
for O 
anxiety O 
- O 
like O 
behavior O 
, O 
and O 
stimulated O 
greater O 
increases O 
in O 
extracellular O 
serotonin B-TRIVIAL 
in O 
the O 
adult O 
medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
( O 
1 O 
, O 
2.5 O 
, O 
and O 
10 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
. O 
Local O 
infusion O 
of O 
100 O 
mM O 
potassium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
into O 
the O 
mPFC O 
also O 
stimulated O 
greater O 
serotonin B-TRIVIAL 
efflux O 
in O 
adult O 
rats O 
. O 
Adult O 
rats O 
had O 
higher O 
tissue O 
serotonin B-TRIVIAL 
content O 
than O 
adolescents O 
in O 
the O 
prefrontal O 
cortex O 
, O 
amygdala O 
, O 
and O 
hippocampus O 
, O 
but O 
the O 
rate O 
of O 
serotonin B-TRIVIAL 
synthesis O 
was O 
similar O 
between O 
age O 
groups O 
. O 
Serotonin B-TRIVIAL 
transporter O 
( O 
SERT O 
) O 
immunoreactivity O 
and O 
SERT O 
radioligand O 
binding O 
were O 
comparable O 
between O 
age O 
groups O 
in O 
all O 
three O 
brain O 
regions O 
. O 
These O 
data O 
suggest O 
that O 
lower O 
tissue O 
serotonin B-TRIVIAL 
stores O 
in O 
adolescents O 
limit O 
fenfluramine B-TRIVIAL 
-stimulated O 
serotonin B-TRIVIAL 
release O 
and O 
so O 
contribute O 
to O 
the O 
lesser O 
anxiogenic O 
effects O 
of O 
fenfluramine B-TRIVIAL 
. O 

accuracy O 
and O 
performance O 
of O 
implicit O 
solvent O 
methods O 
for O 
solvation O 
free O 
energy O 
calculations O 
were O 
assessed O 
on O 
a O 
set O 
of O 
20 O 
neutral O 
drug O 
molecules O 
. O 
Molecular O 
dynamics O 
( O 
MD O 
) O 
provided O 
ensembles O 
of O 
conformations O 
in O 
water O 
and O 
water O 
- O 
saturated O 
octanol B-SYSTEMATIC 
. O 
The O 
solvation O 
free O 
energies O 
were O 
calculated O 
by O 
popular O 
implicit O 
solvent O 
models O 
based O 
on O 
quantum O 
mechanical O 
( O 
QM O 
) O 
electronic O 
densities O 
( O 
COSMO-RS O 
, O 
MST O 
, O 
SMD O 
) O 
as O 
well O 
as O 
on O 
molecular O 
mechanical O 
( O 
MM O 
) O 
point O 
- O 
charge O 
models O 
( O 
GB O 
, O 
PB O 
) O 
. O 
The O 
performance O 
of O 
the O 
implicit O 
models O 
was O 
tested O 
by O 
a O 
comparison O 
with O 
experimental O 
water- O 
octanol B-SYSTEMATIC 
transfer O 
free O 
energies O 
( O 
ΔGow O 
) O 
by O 
using O 
single- O 
and O 
multiconformation O 
approaches O 
. O 
MD O 
simulations O 
revealed O 
difficulties O 
in O 
a O 
priori O 
estimation O 
of O 
the O 
flexibility O 
features O 
of O 
the O 
solutes O 
from O 
simple O 
structural O 
descriptors O 
, O 
such O 
as O 
the O 
number O 
of O 
rotatable O 
bonds O 
. O 
An O 
increasing O 
accuracy O 
of O 
the O 
calculated O 
ΔGow O 
was O 
observed O 
in O 
the O 
following O 
order O 
: O 
GB1 O 
∼ O 
PB O 
< O 
GB7 O 
≪ O 
MST O 
< O 
SMD O 
∼ O 
COSMO-RS O 
with O 
a O 
clear O 
distinction O 
identified O 
between O 
MM- O 
and O 
QM O 
- O 
based O 
models O 
, O 
although O 
for O 
the O 
set O 
excluding O 
three O 
largest O 
molecules O 
, O 
the O 
differences O 
among O 
COSMO-RS O 
, O 
MST O 
, O 
and O 
SMD O 
were O 
negligible O 
. O 
It O 
was O 
shown O 
that O 
the O 
single O 
- O 
conformation O 
approach O 
applied O 
to O 
crystal O 
geometries O 
provides O 
a O 
rather O 
accurate O 
estimate O 
of O 
ΔGow O 
for O 
rigid O 
molecules O 
yet O 
fails O 
completely O 
for O 
the O 
flexible O 
ones O 
. O 
The O 
multiconformation O 
approaches O 
improved O 
the O 
performance O 
, O 
but O 
only O 
when O 
the O 
deformation O 
contribution O 
was O 
ignored O 
. O 
It O 
was O 
revealed O 
that O 
for O 
large O 
- O 
scale O 
calculations O 
on O 
small O 
molecules O 
a O 
recent O 
GB O 
model O 
, O 
GB7 O 
, O 
provided O 
a O 
reasonable O 
accuracy O 
/ O 
speed O 
ratio O 
. O 
In O 
conclusion O 
, O 
the O 
study O 
contributes O 
to O 
the O 
understanding O 
of O 
solvation O 
free O 
energy O 
calculations O 
for O 
physical O 
and O 
medicinal O 
chemistry O 
applications O 
. O 

immunomodulation O 
effect O 
of O 
aronia O 
extract O 
lacks O 
association O 
with O 
its O 
antioxidant O 
anthocyanins B-FAMILY 
. O 

Polyphenols B-FAMILY 
comprise O 
a O 
diverse O 
group O 
of O 
molecules O 
with O 
antioxidative O 
and O 
anti-inflammatory O 
activities O 
. O 
To O 
compare O 
the O 
antioxidative O 
and O 
anti-inflammatory O 
capacity O 
of O 
Aronia O 
melanocarpa O 
berries O 
( O 
chokeberries O 
) O 
, O 
recognized O 
for O 
their O 
high O 
content O 
of O 
anthocyanins B-FAMILY 
, O 
a O 
noncytotoxic O 
isolation O 
method O 
was O 
developed O 
to O 
obtain O 
high O 
- O 
purity O 
anthocyanins B-FAMILY 
in O 
the O 
extract O 
. O 
The O 
antioxidative O 
activity O 
of O 
the O 
extract O 
, O 
the O 
anthocyanin B-FAMILY 
-rich O 
fraction O 
( O 
AF O 
) O 
was O 
determined O 
by O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
radical O 
and O 
ferric B-SYSTEMATIC 
-reducing O 
ability O 
of O 
plasma O 
along O 
with O 
resveratrol B-TRIVIAL 
as O 
a O 
reference O 
. O 
The O 
immunomodulation O 
properties O 
were O 
assessed O 
in O 
lipopolysaccharide O 
(LPS)-stimulated O 
human O 
monocytes O 
mono O 
mac O 
6 O 
. O 
The O 
isolated O 
AF O 
, O 
containing O 
six O 
different O 
anthocyanins B-FAMILY 
, O 
exhibited O 
a O 
stronger O 
antioxidative O 
capacity O 
compared O 
to O 
resveratrol B-TRIVIAL 
. O 
Resveratrol B-TRIVIAL 
enhanced O 
tumor O 
necrosis O 
factor-α O 
and O 
reduced O 
interleukin-10 O 
( O 
IL-10 O 
) O 
production O 
by O 
LPS O 
, O 
whereas O 
AF O 
only O 
had O 
a O 
slight O 
effect O 
in O 
reducing O 
IL-10 O 
. O 
These O 
results O 
demonstrated O 
that O 
there O 
was O 
no O 
major O 
relationship O 
between O 
the O 
antioxidative O 
effect O 
and O 
immunomodulation O 
capacities O 
of O 
AF O 
and O 
resveratrol B-TRIVIAL 
. O 
The O 
immunomodulatory O 
activity O 
of O 
the O 
extract O 
is O 
associated O 
with O 
bioactive O 
compounds O 
in O 
Aronia O 
other O 
than O 
its O 
anthocyanins B-FAMILY 
. O 

and O 
evaluation O 
of O 
[ O 
¹¹C-carbonyl B-SYSTEMATIC 
]-labeled O 
carbamates B-FAMILY 
as O 
fatty B-FAMILY 
acid I-FAMILY 
amide B-FAMILY 
hydrolase O 
radiotracers O 
for O 
positron O 
emission O 
tomography O 
. O 

acid I-FAMILY 
amide B-FAMILY 
hydrolase O 
( O 
FAAH O 
) O 
plays O 
a O 
key O 
role O 
in O 
regulating O 
the O 
tone O 
of O 
the O 
endocannabinoid O 
system O 
. O 
Radiotracers O 
are O 
required O 
to O 
image O 
and O 
quantify O 
FAAH O 
activity O 
in O 
vivo O 
. O 
We O 
have O 
synthesized O 
a O 
series O 
of O 
potent O 
FAAH O 
inhibitors O 
encompassing O 
two O 
classes O 
of O 
N-alkyl-O-arylcarbamates B-FAMILY 
and O 
radiolabeled O 
eight O 
of O 
them O 
with O 
carbon-11 B-SYSTEMATIC 
. O 
The O 
[ O 
¹¹C-carbonyl B-SYSTEMATIC 
]-radiotracers O 
were O 
evaluated O 
in O 
vitro O 
and O 
ex O 
vivo O 
in O 
rats O 
as O 
potential O 
FAAH O 
imaging O 
agents O 
for O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
. O 
Both O 
sets O 
of O 
[¹¹C]O-arylcarbamates B-FAMILY 
showed O 
good O 
to O 
excellent O 
brain O 
penetration O 
and O 
an O 
appropriate O 
regional O 
distribution O 
. O 
Pretreatments O 
with O 
a O 
FAAH O 
inhibitor O 
demonstrated O 
that O 
80-95% O 
of O 
brain O 
uptake O 
of O 
radioactivity O 
constituted O 
binding O 
of O 
the O 
radiotracers O 
to O 
FAAH O 
. O 
Brain O 
extraction O 
measurements O 
showed O 
that O 
binding O 
to O 
FAAH O 
was O 
irreversible O 
and O 
kinetically O 
different O 
for O 
the O 
two O 
classes O 
of O 
carbamates B-FAMILY 
. O 
These O 
promising O 
results O 
are O 
discussed O 
in O 
terms O 
of O 
the O 
requirements O 
of O 
a O 
suitable O 
radiotracer O 
for O 
the O 
in O 
vivo O 
imaging O 
of O 
FAAH O 
using O 
PET O 
. O 

has O 
been O 
significant O 
progress O 
in O 
our O 
basic O 
understanding O 
of O 
drugs O 
and O 
targets O 
in O 
the O 
management O 
of O 
breast O 
cancer O 
. O 
Recent O 
breast O 
cancer O 
clinical O 
trials O 
have O 
examined O 
whether O 
combinations O 
of O 
drugs O 
targeting O 
transmembrane O 
receptors O 
or O 
their O 
downstream O 
effectors O 
involved O 
in O 
cell O 
signal O 
transduction O 
can O 
increase O 
response O 
rates O 
and O 
overcome O 
acquired O 
and O 
/ O 
or O 
de O 
novo O 
drug O 
resistance O 
compared O 
to O 
a O 
single O 
targeted O 
agent O 
with O 
or O 
without O 
systemic O 
chemotherapy O 
. O 
We O 
reviewed O 
published O 
clinical O 
trials O 
and O 
conference O 
proceedings O 
examining O 
combinations O 
of O 
targeted O 
therapies O 
across O 
different O 
breast O 
cancer O 
subtypes O 
. O 
Improvements O 
in O 
pathological O 
complete O 
response O 
( O 
pCR O 
) O 
rates O 
and O 
progression O 
free O 
survival O 
( O 
PFS O 
) O 
in O 
preoperatively O 
treated O 
and O 
metastatic O 
human O 
epidermal O 
growth O 
factor O 
2 O 
(HER2)-positive O 
breast O 
cancer O 
, O 
respectively O 
, O 
have O 
been O 
observed O 
with O 
combinations O 
of O 
anti-HER2 O 
therapies O 
given O 
concomitantly O 
. O 
Promising O 
results O 
were O 
also O 
observed O 
in O 
estrogen B-FAMILY 
receptor O 
(ER)-positive O 
, O 
HER2-negative O 
breast O 
cancer O 
using O 
a O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
inhibitor O 
with O 
tamoxifen B-TRIVIAL 
or O 
an O 
aromatase O 
inhibitor O 
( O 
AI O 
) O 
in O 
the O 
preoperative O 
setting O 
and O 
for O 
patients O 
with O 
metastatic O 
breast O 
cancer O 
that O 
had O 
previously O 
progressed O 
on O 
endocrine O 
therapy O 
alone O 
. O 
A O 
recent O 
phase O 
II O 
trial O 
reported O 
a O 
statistically O 
significant O 
improvement O 
in O 
PFS O 
with O 
the O 
addition O 
of O 
an O 
oral O 
inhibitor O 
of O 
cyclin O 
- O 
dependent O 
kinase O 
4 O 
/ O 
6 O 
to O 
letrozole B-TRIVIAL 
compared O 
to O 
letrozole B-TRIVIAL 
alone O 
( O 
26.1 O 
versus O 
7.5 O 
months O 
) O 
. O 
A O 
phase O 
III O 
study O 
is O 
planned O 
for O 
early O 
2013 O 
. O 
On O 
the O 
basis O 
of O 
preclinical O 
data O 
, O 
clinical O 
trials O 
have O 
examined O 
combinations O 
of O 
hormonal O 
agents O 
such O 
as O 
fulvestrant B-TRIVIAL 
with O 
an O 
AI O 
. O 
However O 
, O 
the O 
results O 
are O 
conflicting O 
. O 
Early O 
data O 
indicated O 
that O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
( O 
PARP O 
) O 
inhibitors O 
exploiting O 
the O 
concept O 
of O 
synthetic O 
lethality O 
would O 
offer O 
improved O 
outcomes O 
for O 
patients O 
with O 
ER-negative O 
, O 
progesterone B-TRIVIAL 
receptor O 
(PR)-negative O 
, O 
HER2-negative O 
breast O 
cancer O 
often O 
referred O 
to O 
as O 
triple O 
negative O 
breast O 
cancer O 
( O 
TNBC O 
) O 
; O 
however O 
, O 
data O 
in O 
the O 
phase O 
III O 
setting O 
failed O 
to O 
confirm O 
these O 
findings O 
but O 
this O 
may O 
be O 
because O 
the O 
drug O 
was O 
not O 
a O 
true O 
PARP O 
inhibitor O 
. O 
Chemotherapy O 
continues O 
to O 
be O 
the O 
mainstay O 
of O 
treatment O 
for O 
TNBC O 
until O 
specific O 
drugs O 
and O 
their O 
associated O 
targets O 
are O 
identified O 
. O 
As O 
advances O 
in O 
medical O 
technologies O 
continue O 
to O 
identify O 
multiple O 
molecularly O 
distinct O 
breast O 
cancer O 
subgroups O 
that O 
are O 
predicted O 
to O 
respond O 
to O 
combinations O 
of O 
targeted O 
agents O 
new O 
challenges O 
have O 
arisen O 
. O 
In O 
particular O 
, O 
how O 
do O 
we O 
evaluate O 
the O 
safety O 
and O 
efficacy O 
of O 
these O 
new O 
drug O 
combinations O 
in O 
relatively O 
small O 
subgroups O 
of O 
patients O 
? O 
Novel O 
clinical O 
trial O 
designs O 
will O 
be O 
required O 
and O 
increasingly O 
regulatory O 
agencies O 
will O 
require O 
companion O 
diagnostic O 
tests O 
that O 
can O 
identify O 
the O 
subgroups O 
likely O 
to O 
respond O 
to O 
these O 
therapies O 
. O 
The O 
US O 
Food O 
and O 
Drug O 
Administration O 
is O 
assessing O 
the O 
role O 
of O 
pCR O 
in O 
breast O 
cancer O 
studies O 
as O 
a O 
surrogate O 
endpoint O 
to O 
predict O 
clinical O 
benefit O 
in O 
the O 
accelerated O 
drug O 
approval O 
process O 
. O 

is O 
a O 
powerful O 
tool O 
to O 
study O 
the O 
dynamics O 
of O 
dendrimers O 
. O 
By O 
analogy O 
to O 
linear O 
polymers O 
, O 
shorter O 
T(1) O 
relaxation O 
times O 
have O 
been O 
traditionally O 
associated O 
to O 
less O 
mobile O 
nuclei O 
and O 
hence O 
, O 
dendrimers O 
described O 
with O 
reduced O 
local O 
motions O 
at O 
either O 
the O 
core O 
or O 
the O 
periphery O 
. O 
Herein O 
we O 
report O 
a O 
NMR O 
relaxation O 
study O 
[ O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
T(1) O 
, O 
T(2) O 
; O 
(13)C B-FORMULA 
{ O 
(1)H B-FORMULA 
}NOE O 
; O 
various O 
fields O 
and O 
temperatures O 
] O 
which O 
reveals O 
profound O 
differences O 
between O 
the O 
relaxation O 
behavior O 
of O 
dendrimers O 
and O 
linear O 
polymers O 
. O 
Dendrimers O 
show O 
slower O 
dynamics O 
at O 
internal O 
layers O 
and O 
on O 
increasing O 
generation O 
and O 
may O 
display O 
internal O 
nuclei O 
in O 
the O 
slow O 
motional O 
regime O 
with O 
larger O 
T(1) O 
values O 
than O 
the O 
periphery O 
. O 
In O 
contrast O 
to O 
the O 
relaxation O 
properties O 
of O 
linear O 
polymers O 
, O 
these O 
T(1) O 
increments O 
should O 
not O 
be O 
interpreted O 
as O 
resulting O 
from O 
faster O 
dynamics O 
. O 
Only O 
the O 
recording O 
of O 
T(1) O 
data O 
at O 
various O 
temperatures O 
( O 
alternatively O 
, O 
T(2) O 
or O 
NOE O 
at O 
one O 
temperature O 
) O 
ensures O 
the O 
correct O 
interpretation O 
of O 
dendrimer O 
dynamics O 
. O 

dahurica O 
is O 
used O 
in O 
functional O 
foods O 
for O 
the O 
prevention O 
and O 
treatment O 
of O 
various O 
diseases O 
, O 
such O 
as O 
inflammation O 
and O 
cancer O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
effect O 
of O 
A O 
. O 
dahurica O 
polysaccharide O 
( O 
ADP O 
) O 
on O 
dendritic O 
cell O 
( O 
DC O 
) O 
maturation O 
. O 
ADP O 
increased O 
the O 
expressions O 
of O 
CD86 O 
and O 
MHC-II O 
molecules O 
, O 
the O 
production O 
of O 
IL-12 O 
, O 
IL-1β O 
, O 
and O 
TNF-α O 
, O 
and O 
allogeneic O 
T O 
cell O 
activation O 
ability O 
of O 
DCs O 
, O 
and O 
reduced O 
DC O 
endocytosis O 
. O 
As O 
a O 
mechanism O 
of O 
action O 
, O 
the O 
knockdown O 
of O 
TLR4 O 
with O 
small O 
interfering O 
RNA O 
decreased O 
the O 
ADP-induced O 
production O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
IL-12 O 
by O 
DCs O 
, O 
suggesting O 
the O 
membrane O 
receptor O 
candidate O 
of O 
ADP O 
. O 
After O 
binding O 
to O 
TLR4 O 
, O 
ADP O 
increased O 
the O 
phosphorylation O 
of O 
ERK O 
, O 
JNK O 
, O 
and O 
p38 O 
MAPKs O 
, O 
and O 
the O 
nuclear O 
translocation O 
of O 
NF-κB O 
p50 O 
/ O 
p65 O 
. O 
These O 
results O 
indicate O 
that O 
ADP O 
activates O 
DCs O 
through O 
TLR4 O 
and O 
downstream O 
signalings O 
. O 

and O 
dose O 
- O 
dependent O 
effects O 
of O 
developmental O 
exposure O 
to O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
on O 
anxiety O 
and O 
spatial O 
learning O 
in O 
deer O 
mice O 
( O 
Peromyscus O 
maniculatus O 
bairdii O 
) O 
offspring O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
a O 
widely O 
produced O 
, O 
endocrine O 
disrupting O 
compound O 
that O 
is O 
pervasive O 
in O 
the O 
environment O 
. O 
Data O 
suggest O 
that O 
developmental O 
exposure O 
to O 
BPA B-ABBREVIATION 
during O 
sexual O 
differentiation O 
of O 
the O 
brain O 
leads O 
to O 
later O 
behavioral O 
consequences O 
in O 
offspring O 
. O 
Outbred O 
deer O 
mice O 
( O 
Peromyscus O 
maniculatus O 
bairdii O 
) O 
are O 
an O 
excellent O 
animal O 
model O 
for O 
such O 
studies O 
as O 
they O 
exhibit O 
well O 
- O 
defined O 
sex- O 
and O 
steroid B-FAMILY 
-dependent O 
behaviors O 
. O 
Here O 
, O 
dams O 
during O 
gestation O 
and O 
lactation O 
were O 
fed O 
with O 
a O 
phytoestrogen O 
- O 
free O 
control O 
diet O 
, O 
the O 
same O 
diet O 
supplemented O 
with O 
either O 
ethinyl B-TRIVIAL 
estradiol I-TRIVIAL 
( O 
0.1 O 
ppb O 
) O 
, O 
or O 
one O 
of O 
the O 
three O 
doses O 
of O 
BPA B-ABBREVIATION 
( O 
50 O 
mg O 
, O 
5 O 
mg O 
, O 
50 O 
μg O 
/ O 
kg O 
feed O 
weight O 
) O 
. O 
After O 
weaning O 
, O 
the O 
pups O 
were O 
maintained O 
on O 
control O 
diet O 
until O 
they O 
reached O 
sexual O 
maturity O 
and O 
then O 
assessed O 
for O 
both O 
spatial O 
learning O 
capabilities O 
and O 
anxiety O 
- O 
like O 
and O 
exploratory O 
behaviors O 
. O 
Relative O 
to O 
controls O 
, O 
males O 
exposed O 
to O 
the O 
two O 
upper O 
but O 
not O 
the O 
lowest O 
dose O 
of O 
BPA B-ABBREVIATION 
demonstrated O 
similar O 
impairments O 
in O 
spatial O 
learning O 
, O 
increased O 
anxiety O 
and O 
reduced O 
exploratory O 
behaviors O 
as O 
ethinyl B-TRIVIAL 
estradiol I-TRIVIAL 
-exposed O 
males O 
, O 
while O 
females O 
exposed O 
to O 
ethinyl B-TRIVIAL 
estradiol I-TRIVIAL 
, O 
but O 
not O 
to O 
BPA B-ABBREVIATION 
, O 
consistently O 
exhibited O 
masculinized O 
spatial O 
abilities O 
. O 
We O 
also O 
determined O 
whether O 
dams O 
maintained O 
chronically O 
on O 
the O 
upper O 
dose O 
of O 
BPA B-ABBREVIATION 
contained O 
environmentally O 
relevant O 
concentrations O 
of O 
BPA B-ABBREVIATION 
in O 
their O 
blood O 
. O 
While O 
serum O 
concentrations O 
of O 
unconjugated O 
BPA B-ABBREVIATION 
in O 
controls O 
were O 
below O 
the O 
minimum O 
level O 
of O 
detection O 
, O 
those O 
from O 
dams O 
on O 
the O 
BPA B-ABBREVIATION 
diet O 
were O 
comparable O 
( O 
5.48±2.07 O 
ng O 
/ O 
ml O 
) O 
to O 
concentrations O 
that O 
have O 
been O 
observed O 
in O 
humans O 
. O 
Together O 
, O 
these O 
studies O 
demonstrate O 
that O 
developmental O 
exposure O 
to O 
environmentally O 
relevant O 
concentrations O 
of O 
BPA B-ABBREVIATION 
can O 
disrupt O 
adult O 
behaviors O 
in O 
a O 
dose- O 
and O 
sex O 
- O 
dependent O 
manner O 
. O 

generates O 
the O 
same O 
xylose B-TRIVIAL 
- O 
and O 
glucuronic B-TRIVIAL 
acid I-TRIVIAL 
-containing O 
glycan O 
structures O 
as O 
LARGE O 
. O 

( O 
like O 
- O 
glycosyltransferase O 
) O 
and O 
LARGE2 O 
( O 
glycosyltransferase O 
- O 
like O 
1B O 
( O 
GYLTL1B O 
) O 
) O 
are O 
homologous O 
Golgi O 
glycosyltransferases O 
possessing O 
two O 
catalytic O 
domains O 
with O 
homology O 
to O 
members O 
of O 
glycosyltransferase O 
families O 
GT8 O 
and O 
GT49 O 
. O 
Mutations O 
in O 
human O 
and O 
mouse O 
Large O 
result O 
in O 
muscular O 
dystrophy O 
due O 
to O 
underglycosylation O 
of O 
dystroglycan O 
. O 
The O 
systemic O 
function O 
of O 
LARGE2 O 
is O 
unknown O 
, O 
but O 
at O 
a O 
cellular O 
level O 
the O 
enzyme O 
can O 
substitute O 
for O 
LARGE O 
in O 
glycosylating O 
dystroglycan O 
. O 
Here O 
, O 
we O 
show O 
that O 
LARGE2 O 
catalyzes O 
the O 
same O 
glycosylation O 
reaction O 
as O 
LARGE O 
. O 
It O 
is O 
a O 
bifunctional O 
glycosyltransferase O 
using O 
uridine B-SYSTEMATIC 
diphosphate I-SYSTEMATIC 
( O 
UDP B-ABBREVIATION 
)- O 
xylose B-TRIVIAL 
( O 
Xyl B-ABBREVIATION 
) O 
and O 
UDP B-ABBREVIATION 
- O 
glucuronic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GlcA B-ABBREVIATION 
) O 
as O 
donor O 
sugars B-FAMILY 
to O 
produce O 
a O 
xyloglucuronan O 
with O 
alternating O 
Xyl B-ABBREVIATION 
and O 
GlcA B-ABBREVIATION 
residues O 
. O 

NMR O 
spectra O 
of O 
ethane-1,2-diol B-SYSTEMATIC 
and O 
other O 
vicinal B-FAMILY 
diols I-FAMILY 
in O 
benzene B-SYSTEMATIC 
: O 
GIAO O 
/ O 
DFT O 
shift O 
calculations O 
. O 

proton O 
NMR O 
spectra O 
of O 
several O 
1,2-diols B-FAMILY 
in O 
benzene B-SYSTEMATIC 
have O 
been O 
analysed O 
so O 
as O 
to O 
associate O 
each O 
magnetically O 
nonequivalent O 
proton O 
with O 
its O 
chemical O 
shift O 
. O 
The O 
shifts O 
and O 
coupling O 
constants O 
of O 
the O 
OH B-FORMULA 
and O 
methylene B-SYSTEMATIC 
protons O 
of O 
ethane-1,2-diol B-SYSTEMATIC 
have O 
been O 
determined O 
in O 
a O 
wide O 
range O 
of O 
solvents O 
. O 
The O 
conformer O 
distribution O 
and O 
the O 
proton O 
NMR O 
shifts O 
of O 
these O 
1,2-diols B-FAMILY 
in O 
benzene B-SYSTEMATIC 
have O 
been O 
computed O 
on O 
the O 
basis O 
of O 
density O 
functional O 
theory O 
. O 
The O 
solvent O 
is O 
included O 
using O 
the O 
integral O 
- O 
equation O 
- O 
formalism O 
polarizable O 
continuum O 
model O 
implemented O 
in O 
Gaussian O 
9 O 
. O 
Relative O 
Gibbs O 
energies O 
for O 
all O 
stable O 
conformers O 
are O 
calculated O 
at O 
the O 
Perdew O 
, O 
Burke O 
and O 
Enzerhof O 
(PBE)0 O 
/ O 
6-311 O 
+ O 
G(d,p) O 
level O 
, O 
and O 
shifts O 
are O 
calculated O 
using O 
the O 
gauge O 
- O 
including O 
atomic O 
orbital O 
method O 
with O 
the O 
PBE0 O 
/ O 
6-311 O 
+ O 
G(d,p) O 
geometry O 
but O 
using O 
the O 
cc-pVTZ O 
basis O 
set O 
. O 
Previous O 
calculations O 
on O 
ethane-1,2-diol B-SYSTEMATIC 
and O 
propane-1,2-diol B-SYSTEMATIC 
have O 
been O 
corrected O 
and O 
extended O 
. O 
New O 
calculations O 
on O 
tert-butylethane-1,2-diol B-SYSTEMATIC 
, O 
phenylethane-1,2-diol B-SYSTEMATIC 
, O 
butane-2,3-diols B-FAMILY 
( O 
dl O 
and O 
meso O 
) O 
and O 
cyclohexane-1,2-diols B-FAMILY 
( O 
cis O 
and O 
trans O 
) O 
are O 
presented O 
. O 
Overall O 
, O 
the O 
computed O 
NMR O 
shifts O 
are O 
in O 
good O 
agreement O 
with O 
experimental O 
values O 
for O 
the O 
OH B-FORMULA 
protons O 
but O 
remain O 
systematically O 
high O 
for O 
CH B-FORMULA 
protons O 
. O 
Some O 
results O 
based O 
on O 
the O 
Gaussian O 
3 O 
solvation O 
model O 
are O 
included O 
for O 
comparison O 
. O 

of O 
4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole B-SYSTEMATIC 
( O 
AZ20 B-IDENTIFIER 
) O 
: O 
a O 
potent O 
and O 
selective O 
inhibitor O 
of O 
ATR O 
protein O 
kinase O 
with O 
monotherapy O 
in O 
vivo O 
antitumor O 
activity O 
. O 

is O 
an O 
attractive O 
new O 
anticancer O 
drug O 
target O 
whose O 
inhibitors O 
have O 
potential O 
as O 
chemo- O 
or O 
radiation O 
sensitizers O 
or O 
as O 
monotherapy O 
in O 
tumors O 
addicted O 
to O 
particular O 
DNA-repair O 
pathways O 
. O 
We O 
describe O 
the O 
discovery O 
and O 
synthesis O 
of O 
a O 
series O 
of O 
sulfonylmorpholinopyrimidines B-FAMILY 
that O 
show O 
potent O 
and O 
selective O 
ATR O 
inhibition O 
. O 
Optimization O 
from O 
a O 
high O 
quality O 
screening O 
hit O 
within O 
tight O 
SAR O 
space O 
led O 
to O 
compound O 
6 O 
( O 
AZ20 B-IDENTIFIER 
) O 
which O 
inhibits O 
ATR O 
immunoprecipitated O 
from O 
HeLa O 
nuclear O 
extracts O 
with O 
an O 
IC50 O 
of O 
5 O 
nM O 
and O 
ATR O 
mediated O 
phosphorylation O 
of O 
Chk1 O 
in O 
HT29 O 
colorectal O 
adenocarcinoma O 
tumor O 
cells O 
with O 
an O 
IC50 O 
of O 
50 O 
nM O 
. O 
Compound O 
6 O 
potently O 
inhibits O 
the O 
growth O 
of O 
LoVo O 
colorectal O 
adenocarcinoma O 
tumor O 
cells O 
in O 
vitro O 
and O 
has O 
high O 
free O 
exposure O 
in O 
mouse O 
following O 
moderate O 
oral O 
doses O 
. O 
At O 
well O 
tolerated O 
doses O 
6 O 
leads O 
to O 
significant O 
growth O 
inhibition O 
of O 
LoVo O 
xenografts O 
grown O 
in O 
nude O 
mice O 
. O 
Compound O 
6 O 
is O 
a O 
useful O 
compound O 
to O 
explore O 
ATR O 
pharmacology O 
in O 
vivo O 
. O 

and O 
antibacterial O 
evaluation O 
of O 
a O 
novel O 
tricyclic B-FAMILY 
oxaborole I-FAMILY 
-fused O 
fluoroquinolone B-SYSTEMATIC 
. O 

have O 
designed O 
and O 
synthesized O 
a O 
novel O 
class O 
of O 
compounds O 
based O 
on O 
fluoroquinolone B-SYSTEMATIC 
antibacterial O 
prototype O 
. O 
The O 
design O 
concept O 
involved O 
the O 
replacement O 
of O 
the O 
3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
ciprofloxacin B-TRIVIAL 
with O 
an O 
oxaborole B-SYSTEMATIC 
-fused O 
ring O 
as O 
an O 
acid O 
- O 
mimicking O 
group O 
. O 
The O 
synthetic O 
method O 
employed O 
in O 
this O 
work O 
provides O 
a O 
good O 
example O 
of O 
incorporating O 
boron B-SYSTEMATIC 
atom O 
in O 
complex O 
molecules O 
with O 
multiple O 
functional O 
groups O 
. O 
The O 
antibacterial O 
activity O 
of O 
the O 
newly O 
synthesized O 
compounds O 
has O 
been O 
evaluated O 
. O 

of O 
chronic O 
ethanol B-SYSTEMATIC 
treatment O 
on O 
μ-opioid O 
receptor O 
function O 
, O 
interacting O 
proteins O 
and O 
morphine B-TRIVIAL 
-induced O 
place O 
preference O 
. O 

: O 
Both O 
the O 
acute O 
and O 
chronic O 
consumption O 
of O 
ethanol B-SYSTEMATIC 
have O 
been O 
reported O 
to O 
modify O 
several O 
molecular O 
events O 
in O 
the O 
central O 
nervous O 
system O 
, O 
and O 
the O 
endogenous O 
μ-opioid O 
receptor O 
system O 
is O 
involved O 
in O 
the O 
reinforcing O 
/ O 
rewarding O 
effects O 
of O 
ethanol B-SYSTEMATIC 
. O 
OBJECTIVES O 
: O 
The O 
present O 
study O 
was O 
designed O 
to O 
clarify O 
the O 
effects O 
of O 
chronic O 
ethanol B-SYSTEMATIC 
treatment O 
on O 
cellular O 
processes O 
involving O 
μ-opioid O 
receptor O 
and O 
the O 
development O 
of O 
morphine B-TRIVIAL 
-induced O 
rewarding O 
effects O 
. O 
METHODS O 
: O 
Male O 
C57BL O 
/ O 
6J O 
mice O 
were O 
continuously O 
treated O 
with O 
a O 
liquid O 
diet O 
containing O 
3 O 
w O 
/ O 
v O 
ethanol B-SYSTEMATIC 
. O 
The O 
direct O 
involvement O 
of O 
μ-opioid O 
receptor O 
functions O 
in O 
the O 
activation O 
of O 
G O 
- O 
proteins O 
and O 
changes O 
in O 
protein O 
levels O 
in O 
the O 
lower O 
midbrain O 
of O 
mice O 
after O 
chronic O 
treatment O 
with O 
ethanol B-SYSTEMATIC 
were O 
investigated O 
by O 
a O 
[ B-FORMULA 
(35)S I-FORMULA 
] I-FORMULA 
GTPγS I-FORMULA 
binding O 
assay O 
and O 
Western O 
blotting O 
, O 
respectively O 
. O 
The O 
rewarding O 
effects O 
of O 
morphine B-TRIVIAL 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
under O 
treatment O 
with O 
ethanol B-SYSTEMATIC 
were O 
measured O 
by O 
the O 
conditioned O 
place O 
preference O 
paradigm O 
. O 
RESULTS O 
: O 
The O 
function O 
of O 
μ-opioid O 
receptor O 
was O 
increased O 
by O 
treatment O 
with O 
ethanol B-SYSTEMATIC 
in O 
the O 
lower O 
midbrain O 
using O 
[ B-FORMULA 
(35)S I-FORMULA 
] I-FORMULA 
GTPγS I-FORMULA 
binding O 
assay O 
. O 
Furthermore O 
, O 
the O 
GRK2 O 
protein O 
level O 
was O 
significantly O 
increased O 
by O 
treatment O 
with O 
ethanol B-SYSTEMATIC 
. O 
Chronic O 
treatment O 
with O 
ethanol B-SYSTEMATIC 
enhanced O 
the O 
rewarding O 
effects O 
of O 
morphine B-TRIVIAL 
. O 
On O 
the O 
other O 
hand O 
, O 
this O 
enhancement O 
of O 
the O 
rewarding O 
effects O 
of O 
morphine B-TRIVIAL 
by O 
ethanol B-SYSTEMATIC 
treatment O 
was O 
significantly O 
inhibited O 
by O 
the O 
GRK2 O 
inhibitor O 
β-adrenergic O 
receptor O 
kinase O 
1 O 
inhibitor O 
. O 
CONCLUSIONS O 
: O 
The O 
present O 
study O 
demonstrated O 
that O 
chronic O 
treatment O 
with O 
ethanol B-SYSTEMATIC 
enhanced O 
the O 
rewarding O 
effects O 
of O 
morphine B-TRIVIAL 
by O 
up O 
- O 
regulating O 
functional O 
changes O 
in O 
μ-opioid O 
receptor O 
, O 
mediated O 
by O 
GRK2 O 
. O 

high O 
- O 
fat O 
( O 
HF O 
) O 
diet O 
can O 
alter O 
offspring O 
metabolism O 
via O 
perinatal O 
developmental O 
programming O 
. O 
This O 
study O 
tests O 
the O 
hypothesis O 
that O 
maternal O 
HF O 
diet O 
also O 
induces O 
perinatal O 
programming O 
of O 
offspring O 
bone O 
mass O 
and O 
strength O 
. O 
We O 
compared O 
skeletal O 
acquisition O 
in O 
pups O 
from O 
C57Bl O 
/ O 
6J O 
mice O 
fed O 
HF O 
or O 
normal O 
diet O 
from O 
preconception O 
through O 
lactation O 
. O 
Three O 
- O 
week O 
- O 
old O 
male O 
and O 
female O 
pups O 
from O 
HF O 
( O 
HF-N O 
) O 
and O 
normal O 
mothers O 
( O 
N-N O 
) O 
were O 
weaned O 
onto O 
normal O 
diet O 
. O 
Outcomes O 
at O 
14 O 
and O 
26 O 
weeks O 
of O 
age O 
included O 
body O 
mass O 
, O 
body O 
composition O 
, O 
whole O 
- O 
body O 
bone O 
mineral O 
content O 
( O 
WBBMC O 
) O 
via O 
peripheral O 
dual O 
- O 
energy O 
X-ray O 
absorptiometry O 
, O 
femoral O 
cortical O 
and O 
trabecular O 
architecture O 
via O 
microcomputed O 
tomography O 
, O 
and O 
glucose B-TRIVIAL 
tolerance O 
. O 
Female O 
HF-N O 
had O 
normal O 
body O 
mass O 
and O 
glucose B-TRIVIAL 
tolerance O 
, O 
with O 
lower O 
body O 
fat O 
( O 
% O 
) O 
but O 
higher O 
serum O 
leptin O 
at O 
14 O 
weeks O 
vs O 
. O 
N-N O 
( O 
P O 
< O 
0.05 O 
for O 
both O 
) O 
. O 
WBBMC O 
was O 
12% O 
lower O 
at O 
14 O 
weeks O 
and O 
5% O 
lower O 
at O 
26 O 
weeks O 
, O 
but O 
trabecular O 
bone O 
volume O 
fraction O 
was O 
20% O 
higher O 
at O 
14 O 
weeks O 
in O 
female O 
HF-N O 
vs O 
. O 
N-N O 
( O 
P O 
< O 
0.05 O 
for O 
all O 
) O 
. O 
Male O 
HF-N O 
had O 
normal O 
body O 
mass O 
and O 
mildly O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
, O 
with O 
lower O 
body O 
fat O 
( O 
% O 
) O 
at O 
14 O 
weeks O 
and O 
lower O 
serum O 
leptin O 
at O 
26 O 
weeks O 
vs O 
. O 
N-N O 
( O 
P O 
< O 
0.05 O 
for O 
both O 
) O 
. O 
Serum O 
insulin O 
was O 
higher O 
at O 
14 O 
weeks O 
and O 
lower O 
at O 
26 O 
weeks O 
in O 
HF-N O 
vs O 
. O 
N-N O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Trabecular O 
BV O 
/ O 
TV O 
was O 
34% O 
higher O 
and O 
cortical O 
bone O 
area O 
was O 
6% O 
higher O 
at O 
14 O 
weeks O 
vs O 
. O 
N-N O 
( O 
P O 
< O 
0.05 O 
for O 
both O 
) O 
. O 
These O 
data O 
suggest O 
that O 
maternal O 
HF O 
diet O 
has O 
complex O 
effects O 
on O 
offspring O 
bone O 
, O 
supporting O 
the O 
hypothesis O 
that O 
maternal O 
diet O 
alters O 
postnatal O 
skeletal O 
homeostasis O 
. O 

Sub-10 O 
nm O 
Atomic O 
Layer O 
Deposited O 
Oxide B-SYSTEMATIC 
Nanostructures O 
on O 
Graphene B-TRIVIAL 
via O 
One-Dimensional O 
Organic O 
Self-Assembled O 
Monolayers O 
. O 

- O 
scale O 
control O 
over O 
the O 
integration O 
of O 
disparate O 
materials O 
on O 
graphene B-TRIVIAL 
is O 
a O 
critical O 
step O 
in O 
the O 
development O 
of O 
graphene B-TRIVIAL 
-based O 
electronics O 
and O 
sensors O 
. O 
Here O 
, O 
we O 
report O 
that O 
self O 
- O 
assembled O 
monolayers O 
of O 
10,12-pentacosadiynoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PCDA B-ABBREVIATION 
) O 
on O 
epitaxial O 
graphene B-TRIVIAL 
can O 
be O 
used O 
to O 
template O 
the O 
reaction O 
and O 
directed O 
growth O 
of O 
atomic O 
layer O 
deposited O 
( O 
ALD O 
) O 
oxide B-SYSTEMATIC 
nanostructures O 
with O 
sub-10 O 
nm O 
lateral O 
resolution O 
. O 
PCDA B-ABBREVIATION 
spontaneously O 
assembles O 
into O 
well O 
- O 
ordered O 
domains O 
consisting O 
of O 
one O 
- O 
dimensional O 
molecular O 
chains O 
that O 
coat O 
the O 
entire O 
graphene B-TRIVIAL 
surface O 
in O 
a O 
manner O 
consistent O 
with O 
the O 
symmetry O 
of O 
the O 
underlying O 
graphene B-TRIVIAL 
lattice O 
. O 
Subsequently O 
, O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
alumina B-TRIVIAL 
ALD O 
precursors O 
are O 
shown O 
to O 
preferentially O 
react O 
with O 
the O 
functional O 
moieties O 
of O 
PCDA B-ABBREVIATION 
, O 
resulting O 
in O 
templated O 
oxide B-SYSTEMATIC 
nanostructures O 
. O 
The O 
retention O 
of O 
the O 
original O 
one O 
- O 
dimensional O 
molecular O 
ordering O 
following O 
ALD O 
is O 
dependent O 
on O 
the O 
chemical O 
reaction O 
pathway O 
and O 
the O 
stability O 
of O 
the O 
monolayer O 
, O 
which O 
can O 
be O 
enhanced O 
via O 
ultraviolet O 
- O 
induced O 
molecular O 
cross O 
- O 
linking O 
. O 

Effect O 
on O 
the O 
Photoluminescence O 
of O 
MoS2 B-FORMULA 
Monolayers O 
. O 

effect O 
of O 
surrounding O 
solvents O 
on O 
the O 
photoluminescence O 
( O 
PL O 
) O 
of O 
MoS2 B-FORMULA 
monolayers O 
on O 
Si B-FORMULA 
/ O 
SiO2 B-FORMULA 
substrates O 
is O 
studied O 
. O 
A O 
redshift O 
( O 
up O 
to O 
-60 O 
meV O 
) O 
is O 
observed O 
for O 
MoS2 B-FORMULA 
monolayers O 
with O 
nonhalogenated O 
solvent O 
surroundings O 
. O 
A O 
blueshift O 
( O 
up O 
to O 
60 O 
meV O 
) O 
and O 
intensity O 
increase O 
( O 
2-50 O 
times O 
) O 
are O 
observed O 
for O 
monolayers O 
with O 
halogenated O 
solvent O 
surroundings O 
. O 

distillation O 
technique O 
was O 
used O 
for O 
the O 
total O 
dealcoholization O 
of O 
a O 
red O 
wine O 
( O 
Aglianico O 
grape O 
variety O 
) O 
up O 
to O 
0.19vol.% O 
. O 
The O 
dealcoholization O 
process O 
was O 
performed O 
in O 
subsequent O 
cycles O 
which O 
gave O 
rise O 
wine O 
samples O 
at O 
different O 
alcoholic O 
degrees O 
. O 
The O 
effect O 
of O 
processing O 
on O 
the O 
main O 
chemical O 
and O 
physical O 
properties O 
of O 
Aglianico O 
wine O 
was O 
evaluated O 
. O 
Among O 
wine O 
samples O 
, O 
no O 
significant O 
differences O 
( O 
p O 
< O 
0.05 O 
) O 
of O 
oenological O 
parameters O 
such O 
as O 
pH O 
, O 
total O 
acidity O 
were O 
found O 
. O 
Similarly O 
, O 
the O 
total O 
phenolic B-FAMILY 
, O 
flavonoids B-FAMILY 
and O 
tartaric B-FAMILY 
esters I-FAMILY 
content O 
and O 
the O 
composition O 
of O 
organic O 
acids O 
did O 
not O 
show O 
significant O 
differences O 
( O 
p O 
< O 
0.05 O 
) O 
during O 
the O 
process O 
. O 
On O 
the O 
contrary O 
, O 
colour O 
intensity O 
and O 
tonality O 
of O 
wine O 
samples O 
changed O 
significantly O 
when O 
the O 
alcohol B-FAMILY 
reduction O 
was O 
over O 
the O 
6.5vol.% O 
. O 
Finally O 
, O 
the O 
total O 
dealcoholized O 
wine O 
showed O 
properties O 
similar O 
to O 
Aglianico O 
wine O 
except O 
for O 
the O 
volatile O 
compounds O 
, O 
which O 
decreased O 
over O 
98% O 
. O 
Hence O 
, O 
flavour O 
enrichment O 
may O 
be O 
required O 
to O 
produce O 
a O 
pleasurable O 
and O 
delicious O 
non O 
alcoholic O 
beverage O 
from O 
wine O 
. O 

of O 
novel O 
2-amino-4-(5'- B-FAMILY 
substituted I-FAMILY 
2'-phenyl-1H-indol-3'-yl)-6-aryl-4H-pyran-3-carbonitrile I-FAMILY 
derivatives O 
as O 
antimicrobial O 
and O 
antioxidant O 
agents O 
. O 

a O 
part O 
of O 
systematic O 
investigation O 
of O 
synthesis O 
and O 
biological O 
activities O 
of O 
indole B-SYSTEMATIC 
analogues O 
linked O 
to O 
various O 
heterocyclic O 
systems O 
, O 
we O 
have O 
synthesized O 
new O 
compounds O 
viz O 
. O 
, O 
2-amino-4-(5'- B-FAMILY 
substituted I-FAMILY 
2'-phenyl-1H-indol-3'-yl)-6-aryl-4H-pyran-3-carbonitriles I-FAMILY 
( O 
2a-i O 
) O 
, O 
4,5-diamino-6-(5'- B-FAMILY 
substituted I-FAMILY 
2'-phenyl-1H-indol-3'-yl)-8-aryl-2-oxo-2,6-dihydrodipyrano I-FAMILY 
[2,3-b:3,2-e]pyridine-3-carbonitriles I-FAMILY 
( O 
3a-i O 
) O 
, O 
4-amino-5-(5'- B-FAMILY 
substituted I-FAMILY 
2'-phenyl-1H-indol-3-yl)-7-aryl-1H-pyrano[2,3-d]pyrimidin-2(5H)-ones I-FAMILY 
( O 
4a-i O 
) O 
, O 
4-amino-5-(5'- B-FAMILY 
substituted I-FAMILY 
2'-phenyl-1H-indol-3'-yl)-7-aryl-1H-pyrano[2,3-d]pyrimidin-2(5H)-thiones I-FAMILY 
( O 
5a-i O 
) O 
, O 
4-(5'-subtituted B-FAMILY 
2'-phenyl-1H-indol-3'-yl)-6-aryl-1,4-dihydropyrano[2,3-c]pyrazol-3-amines I-FAMILY 
( O 
6a-i O 
) O 
and O 
5-(5'- B-FAMILY 
substituted I-FAMILY 
2'-phenyl-1H-indol-3'-yl)-7-aryl-3H-pyrano[2,3-d]pyrimidin-4(5H)-ones I-FAMILY 
( O 
7a-i O 
) O 
. O 
Antibacterial O 
activity O 
results O 
revealed O 
that O 
, O 
compound O 
6a O 
showed O 
promising O 
activity O 
versus O 
Escherichia O 
coli O 
, O 
Staphylococcus O 
aureus O 
and O 
Klebsiella O 
pneumoniae O 
. O 
Compound O 
6d O 
exhibited O 
good O 
activity O 
against O 
S O 
. O 
aureus O 
, O 
K O 
. O 
pneumoniae O 
and O 
Pseudomonas O 
aeruginosa O 
. O 
Antifungal O 
activity O 
results O 
indicated O 
that O 
, O 
compound O 
4d O 
exhibited O 
maximum O 
zone O 
of O 
inhibition O 
against O 
Aspergillus O 
oryzae O 
and O 
Aspergillus O 
flavus O 
. O 
In O 
case O 
of O 
antioxidant O 
activity O 
, O 
compound O 
4a O 
showed O 
promising O 
radical O 
scavenging O 
activity O 
, O 
ferric B-SYSTEMATIC 
ions O 
( O 
Fe(3+) B-FORMULA 
) O 
reducing O 
antioxidant O 
power O 
( O 
FRAP O 
) O 
and O 
metal O 
chelating O 
activity O 
. O 

- O 
Like O 
Growth O 
Factor O 
Binding O 
Protein O 
2 O 
( O 
IGFBP-2 O 
) O 
Promotes O 
Growth O 
and O 
Survival O 
of O 
Breast O 
Epithelial O 
Cells O 
: O 
Novel O 
Regulation O 
of O 
the O 
Estrogen B-FAMILY 
Receptor O 
. O 

breast O 
tumors O 
IGF O 
binding O 
protein-2 O 
( O 
IGFBP-2 O 
) O 
is O 
elevated O 
, O 
and O 
the O 
presence O 
of O 
IGFBP-2 O 
has O 
been O 
shown O 
to O 
correlate O 
with O 
malignancy O 
. O 
However O 
, O 
how O 
IGFBP-2 O 
contributes O 
to O 
the O 
malignant O 
state O 
is O 
still O 
unclear O 
. O 
Silencing O 
IGFBP-2 O 
blocked O 
cell O 
proliferation O 
and O 
in O 
MCF-7 O 
cells O 
increased O 
cell O 
death O 
, O 
indicating O 
that O 
IGFBP-2 O 
was O 
acting O 
in O 
both O 
a O 
mitogenic O 
and O 
a O 
survival O 
capacity O 
. O 
Exogenous O 
IGFBP-2 O 
acting O 
via O 
integrin O 
receptors O 
to O 
reduce O 
phosphatase O 
and O 
tensin O 
homolog O 
deleted O 
from O 
chromosome O 
10 O 
( O 
PTEN O 
) O 
levels O 
protected O 
these O 
cells O 
against O 
death O 
induced O 
by O 
various O 
chemotherapeutic O 
agents O 
. O 
This O 
was O 
dependent O 
on O 
a O 
functional O 
estrogen B-FAMILY 
receptor O 
(ER)-α O 
because O 
silencing O 
ER-α O 
blocked O 
the O 
ability O 
of O 
IGFBP-2 O 
to O 
confer O 
cell O 
survival O 
. O 
Loss O 
of O 
IGFBP-2 O 
increased O 
levels O 
of O 
PTEN O 
and O 
improved O 
chemosensitivity O 
of O 
the O 
cells O 
, O 
confirming O 
its O 
role O 
as O 
a O 
survival O 
factor O 
. O 
Silencing O 
IGFBP-2 O 
had O 
no O 
effect O 
on O 
the O 
response O 
to O 
IGF-II O 
, O 
but O 
responses O 
to O 
estrogen B-FAMILY 
and O 
tamoxifen B-TRIVIAL 
were O 
no O 
longer O 
observed O 
due O 
to O 
loss O 
of O 
ER-α O 
, O 
which O 
could O 
be O 
prevented O 
by O 
the O 
inhibition O 
of O 
PTEN O 
. O 
Conversely O 
, O 
exogenous O 
IGFBP-2 O 
increased O 
ER-α O 
mRNA O 
and O 
protein O 
in O 
both O 
normal O 
and O 
cancer O 
cells O 
via O 
its O 
interaction O 
with O 
integrin O 
receptors O 
. O 
These O 
actions O 
of O 
IGFBP-2 O 
on O 
ER-α O 
involved O 
the O 
IGF-I O 
receptor O 
and O 
activation O 
of O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
in O 
the O 
cancer O 
cells O 
but O 
were O 
independent O 
of O 
this O 
in O 
normal O 
breast O 
cells O 
. O 
The O 
production O 
of O 
IGFBP-2 O 
by O 
breast O 
cancer O 
cells O 
enhances O 
their O 
proliferative O 
potential O 
, O 
increases O 
their O 
survival O 
, O 
and O 
protects O 
them O 
against O 
chemotherapy O 
- O 
induced O 
death O 
. O 
IGFBP-2 O 
not O 
only O 
modulates O 
IGFs O 
and O 
directly O 
regulates O 
PTEN O 
but O 
also O 
has O 
a O 
role O 
in O 
maintaining O 
ER-α O 
expression O 
. O 

family O 
proteins O 
constitute O 
a O 
group O 
of O 
> O 
12 O 
0 O 
transcriptional O 
regulators O 
encoded O 
in O 
bacterial O 
and O 
archaeal O 
genomes O 
that O 
control O 
gene O 
expression O 
in O 
metabolism O 
, O 
stress O 
responses O 
, O 
virulence O 
and O 
multi O 
- O 
drug O 
resistance O 
. O 
There O 
is O 
much O 
interest O 
in O 
defining O 
the O 
molecular O 
mechanism O 
by O 
which O 
ligand O 
binding O 
attenuates O 
the O 
DNA O 
- O 
binding O 
activities O 
of O 
these O 
proteins O 
. O 
Here O 
, O 
we O 
describe O 
how O 
PcaV O 
, O 
a O 
MarR O 
family O 
regulator O 
in O 
Streptomyces O 
coelicolor O 
, O 
controls O 
transcription O 
of O 
genes O 
encoding O 
β-ketoadipate O 
pathway O 
enzymes O 
through O 
its O 
interaction O 
with O 
the O 
pathway O 
substrate O 
, O 
protocatechuate B-TRIVIAL 
. O 
This O 
transcriptional O 
repressor O 
is O 
the O 
only O 
MarR O 
protein O 
known O 
to O 
regulate O 
this O 
essential O 
pathway O 
for O 
aromatic O 
catabolism O 
. O 
In O 
in O 
vitro O 
assays O 
, O 
protocatechuate B-TRIVIAL 
and O 
other O 
phenolic B-FAMILY 
compounds O 
disrupt O 
the O 
PcaV-DNA O 
complex O 
. O 
We O 
show O 
that O 
PcaV O 
binds O 
protocatechuate B-TRIVIAL 
in O 
a O 
1 O 
: O 
1 O 
stoichiometry O 
with O 
the O 
highest O 
affinity O 
of O 
any O 
MarR O 
family O 
member O 
. O 
Moreover O 
, O 
we O 
report O 
structures O 
of O 
PcaV O 
in O 
its O 
apo O 
form O 
and O 
in O 
complex O 
with O 
protocatechuate B-TRIVIAL 
. O 
We O 
identify O 
an O 
arginine B-TRIVIAL 
residue O 
that O 
is O 
critical O 
for O 
ligand O 
coordination O 
and O 
demonstrate O 
that O 
it O 
is O 
also O 
required O 
for O 
binding O 
DNA O 
. O 
We O 
propose O 
that O 
interaction O 
of O 
ligand O 
with O 
this O 
arginine B-TRIVIAL 
residue O 
dictates O 
conformational O 
changes O 
that O 
modulate O 
DNA O 
binding O 
. O 
Our O 
results O 
provide O 
new O 
insights O 
into O 
the O 
molecular O 
mechanism O 
by O 
which O 
ligands O 
attenuate O 
DNA O 
binding O 
in O 
this O 
large O 
family O 
of O 
transcription O 
factors O 
. O 

of O 
a O 
novel O 
bioerodible O 
dexamethasone B-TRIVIAL 
implant O 
for O 
uveitis O 
and O 
postoperative O 
cataract O 
inflammation O 
. O 

of O 
anti-inflammatory O 
steroids B-FAMILY 
concurrently O 
to O 
both O 
anterior O 
and O 
posterior O 
segments O 
of O 
the O 
eye O 
is O 
a O 
challenge O 
. O 
The O 
anterior O 
ocular O 
structures O 
limit O 
topical O 
delivery O 
. O 
Injection O 
can O 
be O 
disproportionately O 
and O 
repeatedly O 
invasive O 
and O 
selective O 
for O 
only O 
one O 
ocular O 
hemisphere O 
. O 
We O 
developed O 
a O 
novel O 
implant O 
that O 
can O 
compensate O 
for O 
the O 
limited O 
conveyance O 
of O 
topical O 
medicine O 
and O 
reduce O 
the O 
repetitive O 
invasiveness O 
of O 
injection O 
from O 
the O 
capsular O 
bag O 
allowing O 
dexamethasone B-TRIVIAL 
( O 
DXM B-ABBREVIATION 
) O 
delivery O 
to O 
both O 
the O 
anterior O 
and O 
posterior O 
chambers O 
. O 
To O 
establish O 
proof O 
of O 
concept O 
, O 
microparticles O 
were O 
prepared O 
with O 
PLGA B-ABBREVIATION 
[ O 
poly(d,l-lactide-co-glycolide) B-FAMILY 
, O 
50 O 
: O 
50 O 
, O 
MW O 
. O 
7000-17000 O 
] O 
, O 
hydroxypropyl B-SYSTEMATIC 
methyl I-SYSTEMATIC 
cellulose O 
( O 
HPMC O 
) O 
, O 
and O 
DXM B-ABBREVIATION 
by O 
oil O 
- O 
in O 
- O 
water O 
emulsion O 
/ O 
solvent O 
evaporation O 
technique O 
. O 
Zeatsizer O 
Nano O 
and O 
SEM O 
( O 
scanning O 
electron O 
microscopy O 
) O 
results O 
showed O 
microspheres O 
in O 
the O 
range O 
of O 
8±1µm O 
. O 
The O 
target O 
load O 
of O 
DXM B-ABBREVIATION 
in O 
the O 
microparticles O 
was O 
~20.0% O 
with O 
a O 
% O 
recovery O 
of O 
99.9% O 
( O 
w O 
/ O 
w O 
) O 
. O 
Dose O 
related O 
pharmacokinetics O 
with O 
near O 
zero O 
order O 
kinetics O 
was O 
observed O 
for O 
up O 
to O 
6 O 
weeks O 
in O 
rabbits O 
with O 
intracapsular O 
bag O 
implants O 
. O 
DXM B-ABBREVIATION 
flow O 
was O 
bidirectional O 
from O 
the O 
endocapsular O 
space O 
and O 
significant O 
concentrations O 
were O 
found O 
in O 
the O 
anterior O 
and O 
posterior O 
chambers O 
after O 
up O 
to O 
6 O 
weeks O 
. O 
Whereas O 
, O 
with O 
topical O 
drops O 
the O 
exposure O 
was O 
minimal O 
in O 
all O 
the O 
ocular O 
tissues O 
with O 
greater O 
systemic O 
exposure O 
. O 
Intraocular O 
pressure O 
was O 
normal O 
in O 
all O 
of O 
the O 
study O 
groups O 
; O 
slit O 
lamp O 
biomicroscopy O 
examinations O 
revealed O 
that O 
no O 
cells O 
or O 
fibrin O 
formation O 
in O 
the O 
anterior O 
and O 
posterior O 
chamber O 
with O 
implants O 
but O 
flare O 
, O 
cells O 
and O 
fibrin O 
was O 
present O 
in O 
the O 
topical O 
drops O 
group O 
. O 
Histological O 
examination O 
revealed O 
normal O 
tissues O 
and O 
no O 
signs O 
of O 
inflammation O 
in O 
all O 
the O 
groups O 
. O 
The O 
implant O 
did O 
not O 
migrate O 
to O 
the O 
center O 
of O 
the O 
eye O 
or O 
obstruct O 
the O 
visual O 
axis O 
. O 
We O 
believe O 
these O 
findings O 
demonstrate O 
the O 
feasibility O 
of O 
drug O 
delivery O 
from O 
the O 
capsular O 
bag O 
to O 
the O 
anterior O 
and O 
posterior O 
segments O 
effectively O 
compared O 
to O 
topical O 
alternatives O 
. O 

effects O 
of O 
4A-DNT B-SYSTEMATIC 
( O 
4-amino-2,6-dinitrotoluene B-SYSTEMATIC 
) O 
and O 
RDX B-TRIVIAL 
( O 
1,3,5-trinitro-1,3,5-triazine B-SYSTEMATIC 
) O 
in O 
Japanese O 
quail O 
, O 
Northern O 
bobwhite O 
, O 
and O 
Zebra O 
finch O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
assess O 
the O 
toxicological O 
effects O 
of O 
two O 
munition O 
compounds O 
, O 
4-amino-2,6-dinitrotoluene B-SYSTEMATIC 
( O 
4A-DNT B-SYSTEMATIC 
) O 
and O 
1,3,5-trinitro-1,3,5-triazine B-SYSTEMATIC 
( O 
RDX B-TRIVIAL 
) O 
, O 
on O 
three O 
different O 
bird O 
species O 
: O 
two O 
common O 
toxicological O 
model O 
species O 
- O 
the O 
Northern O 
Bobwhite O 
( O 
Colinus O 
virginianus O 
) O 
and O 
the O 
Japanese O 
Quail O 
( O 
Coturnix O 
japonica O 
) O 
, O 
and O 
a O 
representative O 
passerine O 
- O 
the O 
Zebra O 
Finch O 
( O 
Taeniopygia O 
guttata O 
) O 
. O 
Bobwhite O 
were O 
exposed O 
to O 
4A-DNT B-SYSTEMATIC 
at O 
0 O 
, O 
8 O 
, O 
15 O 
, O 
30 O 
, O 
60 O 
, O 
or O 
150 O 
mg O 
/ O 
kg O 
body O 
weight O 
( O 
bw O 
) O 
d O 
by O 
oral O 
gavage O 
for O 
seven O 
days O 
; O 
because O 
the O 
high O 
dose O 
of O 
4A-DNT B-SYSTEMATIC 
was O 
lethal O 
to O 
bobwhite O 
, O 
the O 
maximum O 
dose O 
was O 
changed O 
to O 
100 O 
mg O 
/ O 
kg O 
bw O 
d O 
for O 
Japanese O 
quail O 
and O 
finches O 
to O 
ensure O 
tissue O 
could O 
be O 
used O 
for O 
future O 
toxicogenomic O 
work O 
. O 
RDX B-TRIVIAL 
was O 
similarly O 
administered O 
at O 
0 O 
, O 
0.5 O 
, O 
1.5 O 
, O 
3 O 
, O 
6 O 
, O 
or O 
12 O 
mg O 
/ O 
kg O 
bw O 
d O 
. O 
Blood O 
was O 
drawn O 
prior O 
to O 
euthanasia O 
for O 
blood O 
cellularity O 
and O 
chemistry O 
analyses O 
. O 
Finches O 
were O 
clearly O 
least O 
affected O 
by O 
4A-DNT B-SYSTEMATIC 
as O 
evidenced O 
by O 
a O 
lack O 
of O 
observable O 
effects O 
. O 
Bobwhite O 
appeared O 
to O 
be O 
the O 
most O 
sensitive O 
species O 
to O 
4A-DNT B-SYSTEMATIC 
as O 
observed O 
through O 
changes O 
in O 
blood O 
cellularity O 
and O 
plasma O 
chemistry O 
effects O 
. O 
Bobwhite O 
appeared O 
to O 
be O 
more O 
sensitive O 
to O 
RDX B-TRIVIAL 
than O 
Japanese O 
Quail O 
due O 
to O 
increased O 
effects O 
on O 
measures O 
of O 
plasma O 
chemistries O 
. O 
Finches O 
exhibited O 
the O 
greatest O 
sensitivity O 
to O 
RDX B-TRIVIAL 
through O 
increased O 
mortality O 
and O 
seizure O 
activity O 
. O 
This O 
study O 
suggests O 
that O 
sensitivity O 
among O 
species O 
is O 
chemical O 
- O 
specific O 
and O 
provides O 
data O 
that O 
could O 
be O 
used O 
to O 
refine O 
current O 
avian O 
sensitivity O 
models O 
used O 
in O 
ecological O 
risk O 
assessments O 
. O 

of O 
the O 
redox O 
- O 
cycling O 
herbicide O 
diquat B-TRIVIAL 
on O 
transcript O 
expression O 
and O 
antioxidant O 
enzymatic O 
activities O 
of O 
the O 
freshwater O 
snail O 
Lymnaea O 
stagnalis O 
. O 

presence O 
of O 
pesticides O 
in O 
the O 
environment O 
results O 
in O 
potential O 
unwanted O 
effects O 
on O 
non-target O 
species O 
. O 
Freshwater O 
organisms O 
inhabiting O 
water O 
bodies O 
adjacent O 
to O 
agricultural O 
areas O 
, O 
such O 
as O 
ditches O 
, O 
ponds O 
and O 
marshes O 
, O 
are O 
good O 
models O 
to O 
test O 
such O 
effects O 
as O 
various O 
pesticides O 
may O 
reach O 
these O 
habitats O 
through O 
several O 
ways O 
, O 
including O 
aerial O 
drift O 
, O 
run O 
- O 
off O 
, O 
and O 
drainage O 
. O 
Diquat B-TRIVIAL 
is O 
a O 
non-selective O 
herbicide O 
used O 
for O 
crop O 
protection O 
or O 
for O 
weed O 
control O 
in O 
such O 
water O 
bodies O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
diquat B-TRIVIAL 
on O 
a O 
widely O 
spread O 
aquatic O 
invertebrate O 
, O 
the O 
holarctic O 
freshwater O 
snail O 
Lymnaea O 
stagnalis O 
. O 
Due O 
to O 
the O 
known O 
redox O 
- O 
cycling O 
properties O 
of O 
diquat B-TRIVIAL 
, O 
we O 
studied O 
transcript O 
expression O 
and O 
enzymatic O 
activities O 
relative O 
to O 
oxidative O 
and O 
general O 
stress O 
in O 
the O 
haemolymph O 
and O 
gonado O 
- O 
digestive O 
complex O 
( O 
GDC O 
) O 
. O 
As O 
diquat B-TRIVIAL 
is O 
not O 
persistent O 
, O 
snails O 
were O 
exposed O 
for O 
short O 
times O 
( O 
5 O 
, O 
24 O 
, O 
and O 
48 O 
h O 
) O 
to O 
ecologically O 
relevant O 
concentrations O 
( O 
22.2 O 
, O 
44.4 O 
, O 
and O 
222.2 O 
μg O 
l(-1) O 
) O 
of O 
diquat B-SYSTEMATIC 
dibromide I-SYSTEMATIC 
. O 
RT-qPCR O 
was O 
used O 
to O 
quantify O 
the O 
transcription O 
of O 
genes O 
encoding O 
catalase O 
( O 
cat O 
) O 
, O 
a O 
cytosolic O 
superoxide B-TRIVIAL 
dismutase O 
( O 
Cu B-FORMULA 
/ O 
Zn B-FORMULA 
-sod O 
) O 
, O 
a O 
selenium B-SYSTEMATIC 
-dependent O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
gpx O 
) O 
, O 
a O 
glutathione B-TRIVIAL 
reductase O 
( O 
gred O 
) O 
, O 
the O 
retinoid B-FAMILY 
X O 
receptor O 
( O 
rxr O 
) O 
, O 
two O 
heat O 
shock O 
proteins O 
( O 
hsp40 O 
and O 
hsp70 O 
) O 
, O 
cortactin O 
( O 
cor O 
) O 
and O 
the O 
two O 
ribosomal O 
genes O 
r18S O 
and O 
r28s O 
. O 
Enzymatic O 
activities O 
of O 
SOD O 
, O 
Gpx O 
, O 
Gred O 
and O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
were O 
investigated O 
in O 
the O 
GDC O 
using O 
spectrophoto O 
/ O 
fluorometric O 
methods O 
. O 
Opposite O 
trends O 
were O 
obtained O 
in O 
the O 
haemolymph O 
depending O 
on O 
the O 
herbicide O 
concentration O 
. O 
At O 
the O 
lowest O 
concentration O 
, O 
effects O 
were O 
mainly O 
observed O 
after O 
24 O 
h O 
of O 
exposure O 
, O 
with O 
over O 
- O 
transcription O 
of O 
cor O 
, O 
hsp40 O 
, O 
rxr O 
, O 
and O 
sod O 
, O 
whereas O 
higher O 
concentrations O 
down O 
- O 
regulated O 
the O 
expression O 
of O 
most O 
of O 
the O 
studied O 
transcripts O 
, O 
especially O 
after O 
48 O 
h O 
of O 
exposure O 
. O 
In O 
the O 
GDC O 
, O 
earlier O 
responses O 
were O 
observed O 
and O 
the O 
fold O 
- O 
change O 
magnitude O 
was O 
generally O 
much O 
higher O 
: O 
transcription O 
of O 
all O 
target O 
genes O 
increased O 
significantly O 
( O 
or O 
non-significantly O 
for O 
cat O 
) O 
after O 
5 O 
h O 
of O 
exposure O 
, O 
and O 
went O 
back O 
to O 
control O 
levels O 
afterwards O 
, O 
suggesting O 
the O 
onset O 
of O 
an O 
early O 
response O 
to O 
oxidative O 
stress O 
associated O 
to O 
the O 
unbalance O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
in O 
hepatocytes O 
. O 
Although O 
increases O 
obtained O 
for O 
Gred O 
and O 
SOD O 
activities O 
were O 
globally O 
consistent O 
with O 
their O 
respective O 
transcript O 
expressions O 
, O 
up O 
- O 
regulation O 
of O 
transcription O 
was O 
not O 
always O 
correlated O 
with O 
increase O 
of O 
enzymatic O 
activity O 
, O 
indicating O 
that O 
diquat B-TRIVIAL 
might O 
affect O 
steps O 
downstream O 
of O 
transcription O 
. O 
However O 
, O 
constitutive O 
levels O 
of O 
enzymatic O 
activities O 
were O 
at O 
least O 
maintained O 
. O 
In O 
conclusion O 
, O 
diquat B-TRIVIAL 
was O 
shown O 
to O 
affect O 
expression O 
of O 
the O 
whole O 
set O 
of O 
studied O 
transcripts O 
, O 
reflecting O 
their O 
suitability O 
as O 
markers O 
of O 
early O 
response O 
to O 
oxidative O 
stress O 
in O 
L O 
. O 
stagnalis O 
. O 

profile O 
of O 
bacopasides B-FAMILY 
from O 
Bacopa O 
monnieri O 
( O 
BM O 
) O 
as O 
an O 
emerging O 
class O 
of O 
therapeutics O 
for O 
management O 
of O 
chronic O 
pains O 
. O 

pains O 
management O 
costs O 
billions O 
of O 
dollars O 
in O 
medical O 
exchequer O 
to O 
the O 
world O 
population O 
. O 
Additionally O 
, O 
77% O 
of O 
people O 
with O 
chronic O 
pains O 
also O 
have O 
a O 
degree O 
of O 
medically O 
treatable O 
depression O 
. O 
Opioids O 
have O 
a O 
narrower O 
safety O 
index O 
due O 
to O 
their O 
side O 
effects O 
associated O 
with O 
its O 
tolerance O 
, O 
hyperalgesia O 
and O 
subsequent O 
dependence O 
. O 
Likewise O 
, O 
non O 
steroidal B-FAMILY 
anti-inflammatory O 
drugs O 
and O 
anticonvulsants O 
, O 
also O 
have O 
limited O 
safety O 
and O 
tolerability O 
profile O 
in O 
the O 
management O 
of O 
chronic O 
pains O 
. O 
Bacopa O 
monnieri O 
, O 
a O 
renowned O 
ayurvedic O 
medicine O 
has O 
a O 
strong O 
antidepressant O 
effect O 
and O 
significant O 
antinociceptive O 
effect O 
, O 
which O 
is O 
comparable O 
to O 
the O 
effect O 
of O 
morphine B-TRIVIAL 
via O 
adenosinergic O 
, O 
opioidergic O 
, O 
and O 
adrenergic O 
mechanisms O 
. O 
BM O 
has O 
been O 
also O 
reported O 
to O 
be O 
effective O 
in O 
neuropathic O 
pains O 
. O 
Additionally O 
, O 
it O 
has O 
a O 
strong O 
anti-inflammatory O 
effect O 
mediated O 
via O 
COX-2 O 
inhibitory O 
mechanism O 
. O 
Apart O 
from O 
its O 
effect O 
of O 
augmenting O 
morphine B-TRIVIAL 
analgesia O 
, O 
BM O 
also O 
inhibits O 
opioid O 
- O 
withdrawal O 
induced O 
hyperalgesia O 
, O 
and O 
acquisition O 
and O 
expression O 
of O 
morphine B-TRIVIAL 
tolerance O 
. O 
BM O 
is O 
reported O 
to O 
have O 
a O 
strong O 
protective O 
effect O 
against O 
toxic O 
effects O 
of O 
opiates O 
on O 
major O 
organs O 
like O 
brain O 
, O 
kidneys O 
and O 
heart O 
. O 
BM O 
is O 
well O 
documented O 
to O 
be O 
safe O 
and O 
well O 
tolerated O 
herbal O 
therapy O 
in O 
multiple O 
clinical O 
trials O 
including O 
various O 
age O 
groups O 
. O 
This O 
minireview O 
evaluated O 
the O 
preclinical O 
data O 
that O 
highlights O 
potential O 
of O 
BM O 
as O 
a O 
future O 
candidate O 
for O 
clinical O 
management O 
of O 
chronic O 
pains O 
. O 

properties O 
of O 
Aβ1-42 O 
, O 
Aβ11-42 O 
, O 
and O 
[Pyr¹¹]Aβ11-42 O 
generated O 
from O 
O-acyl B-FAMILY 
isopeptides O 
. O 

use O 
of O 
water O 
- O 
soluble O 
O-acyl B-FAMILY 
isopeptides O 
enabled O 
us O 
to O 
investigate O 
the O 
biochemical O 
properties O 
of O 
Aβ11-42 O 
species O 
, O 
by O 
preparing O 
highly O 
concentrated O 
stock O 
solutions O 
after O 
a O 
pretreatment O 
. O 
Aβ11-42 O 
and O 
[ O 
Pyr B-FORMULA 
(11)]Aβ11-42 O 
showed O 
comparable O 
aggregation O 
capability O 
and O 
cytotoxicity O 
, O 
suggesting O 
that O 
the O 
pyroglutamate B-TRIVIAL 
modification O 
at O 
Glu B-FORMULA 
( O 
11 O 
) O 
does O 
not O 
have O 
a O 
crucial O 
role O 
in O 
these O 
events O 
. O 
However O 
, O 
given O 
that O 
Aβ11-42 O 
is O 
converted O 
to O 
[ O 
Pyr B-FORMULA 
(11)]Aβ11-42 O 
by O 
a O 
glutamyl B-TRIVIAL 
cyclase O 
in O 
vivo O 
, O 
the O 
potential O 
aggregative O 
and O 
cytotoxic O 
nature O 
of O 
[ O 
Pyr B-FORMULA 
(11)]Aβ11-42 O 
that O 
was O 
observed O 
in O 
the O 
present O 
study O 
provides O 
valuable O 
insights O 
into O 
the O 
pathological O 
functions O 
of O 
pyroglutamate B-TRIVIAL 
-modified O 
Aβ O 
species O 
in O 
Alzheimer's O 
disease O 
. O 

of O 
mechanisms O 
involved O 
in O 
the O 
antinociception O 
of O 
the O 
ethanol B-SYSTEMATIC 
extract O 
from O 
the O 
inner O 
bark O 
of O 
Caesalpinia O 
pyramidalis O 
in O 
mice O 
. O 

RELEVANCE O 
: O 
Caesalpinia O 
pyramidalis O 
Tul O 
. O 
( O 
Fabaceae O 
) O 
is O 
an O 
endemic O 
tree O 
of O 
the O 
Northeast O 
region O 
of O 
Brazil O 
, O 
mainly O 
in O 
the O 
Caatinga O 
region O 
. O 
More O 
commonly O 
, O 
inner O 
bark O 
or O 
flowers O 
are O 
traditionally O 
used O 
to O 
treat O 
many O 
painful O 
and O 
inflammatory O 
processes O 
. O 
A O 
common O 
use O 
of O 
this O 
plant O 
is O 
made O 
by O 
macerating O 
a O 
handful O 
of O 
its O 
stem O 
bark O 
in O 
a O 
liter O 
of O 
wine O 
or O 
sugarcane O 
brandy O 
. O 
It O 
is O 
drunk O 
against O 
stomachache O 
, O 
dysenteries O 
, O 
and O 
diarrheas O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Caesalpinia O 
pyramidalis O 
inner O 
bark O 
was O 
used O 
in O 
mice O 
via O 
oral O 
route O 
, O 
at O 
the O 
doses O 
of O 
10 O 
, O 
30 O 
, O 
and O 
100mg O 
/ O 
kg O 
, O 
in O 
behavioral O 
models O 
of O 
nociception O 
and O 
investigates O 
some O 
of O 
the O 
mechanisms O 
underlying O 
this O 
effect O 
. O 
RESULTS O 
: O 
The O 
ethanol B-SYSTEMATIC 
extract O 
( O 
30 O 
and O 
100mg O 
/ O 
kg O 
, O 
P O 
< O 
0.001 O 
) O 
, O 
given O 
orally O 
, O 
produced O 
dose O 
dependent O 
inhibition O 
of O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
visceral O 
pain O 
. O 
The O 
ethanol B-SYSTEMATIC 
extract O 
also O 
caused O 
significant O 
and O 
dose O 
- O 
dependent O 
inhibition O 
of O 
capsaicin B-TRIVIAL 
-(100mg O 
/ O 
kg O 
, O 
P O 
< O 
0.001 O 
) O 
and O 
glutamate B-TRIVIAL 
-(10 O 
, O 
30 O 
, O 
and O 
100mg O 
/ O 
kg O 
, O 
P O 
< O 
0.01 O 
) O 
induced O 
pain O 
. O 
The O 
antinociception O 
caused O 
by O 
the O 
ethanol B-SYSTEMATIC 
extract O 
( O 
30mg O 
/ O 
kg O 
) O 
in O 
the O 
abdominal O 
constriction O 
test O 
was O 
significantly O 
attenuated O 
( O 
P O 
< O 
0.001 O 
) O 
by O 
intraperitoneal O 
treatment O 
of O 
mice O 
with O 
l-arginine B-TRIVIAL 
( O 
600mg O 
/ O 
kg O 
) O 
. O 
CONCLUSIONS O 
: O 
Collectively O 
, O 
the O 
present O 
results O 
suggest O 
that O 
the O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Caesalpinia O 
pyramidalis O 
produced O 
dose O 
- O 
related O 
antinociception O 
in O 
several O 
models O 
of O 
pain O 
through O 
mechanisms O 
that O 
involved O 
both O 
glutamatergic O 
system O 
and O 
/ O 
or O 
the O 
l-arginine B-SYSTEMATIC 
- I-SYSTEMATIC 
nitric I-SYSTEMATIC 
oxide I-SYSTEMATIC 
pathway O 
, O 
supporting O 
the O 
folkloric O 
usage O 
of O 
the O 
plant O 
to O 
treat O 
various O 
painful O 
processes O 
. O 

chemotherapy O 
resistance O 
of O 
ovarian O 
cancer O 
cells O 
by O 
liposomal O 
cisplatin B-TRIVIAL 
: O 
molecular O 
mechanisms O 
unveiled O 
by O 
gene O 
expression O 
profiling O 
. O 

we O 
reported O 
that O 
liposomal O 
cisplatin B-TRIVIAL 
( O 
CDDP B-ABBREVIATION 
) O 
overcomes O 
CDDP B-ABBREVIATION 
resistance O 
of O 
ovarian O 
A2780cis O 
cancer O 
cells O 
( O 
Krieger O 
et O 
al O 
. O 
, O 
Int O 
. O 
J O 
. O 
Pharm O 
. O 
389 O 
, O 
2010 O 
, O 
10-17 O 
) O 
. O 
Here O 
we O 
find O 
that O 
the O 
cytotoxic O 
activity O 
of O 
liposomal O 
CDDP B-ABBREVIATION 
is O 
not O 
associated O 
with O 
detectable O 
DNA O 
platination O 
in O 
resistant O 
ovarian O 
cancer O 
cells O 
. O 
This O 
suggests O 
that O 
the O 
mode O 
of O 
action O 
of O 
liposomal O 
CDDP B-ABBREVIATION 
is O 
different O 
from O 
the O 
free O 
drug O 
. O 
To O 
gain O 
insight O 
into O 
mechanisms O 
of O 
liposomal O 
CDDP B-ABBREVIATION 
activity O 
, O 
we O 
performed O 
a O 
transcriptome O 
analysis O 
of O 
untreated O 
A2780cis O 
cells O 
, O 
and O 
A2780cis O 
cells O 
in O 
response O 
to O 
exposure O 
with O 
IC50 O 
values O 
of O 
free O 
or O 
liposomal O 
CDDP B-ABBREVIATION 
. O 
A O 
process O 
network O 
analysis O 
of O 
upregulated O 
genes O 
showed O 
that O 
liposomal O 
CDDP B-ABBREVIATION 
induced O 
a O 
highly O 
different O 
gene O 
expression O 
profile O 
in O 
comparison O 
to O 
the O 
free O 
drug O 
. O 
p53 O 
was O 
identified O 
as O 
a O 
key O 
player O 
directing O 
transcriptional O 
responses O 
to O 
free O 
or O 
liposomal O 
CDDP B-ABBREVIATION 
. O 
The O 
free O 
drug O 
induced O 
expression O 
of O 
essential O 
genes O 
of O 
the O 
intrinsic O 
( O 
mitochondrial O 
) O 
apoptosis O 
pathway O 
( O 
BAX O 
, O 
BID O 
, O 
CASP9 O 
) O 
most O 
likely O 
through O 
p38MAPK O 
activation O 
. O 
In O 
contrast O 
, O 
liposomal O 
CDDP B-ABBREVIATION 
induced O 
expression O 
of O 
genes O 
from O 
DNA O 
damage O 
pathways O 
and O 
several O 
genes O 
of O 
the O 
extrinsic O 
pathway O 
of O 
apoptosis O 
( O 
TNFRSF10B-DR5 O 
, O 
CD70-TNFSF7 O 
) O 
. O 
It O 
thus O 
appears O 
that O 
liposomal O 
CDDP B-ABBREVIATION 
overcomes O 
CDDP B-ABBREVIATION 
resistance O 
by O 
inducing O 
DNA O 
damage O 
and O 
in O 
consequence O 
programmed O 
cell O 
death O 
by O 
the O 
extrinsic O 
pathway O 
. O 
Predictions O 
from O 
gene O 
expression O 
data O 
with O 
respect O 
to O 
apoptosis O 
activation O 
were O 
confirmed O 
at O 
the O 
protein O 
level O 
by O 
an O 
apoptosis O 
antibody O 
array O 
. O 
This O 
sheds O 
new O 
light O 
on O 
liposomal O 
drug O 
carrier O 
approaches O 
in O 
cancer O 
and O 
suggests O 
liposomal O 
CDDP B-ABBREVIATION 
as O 
promising O 
strategy O 
for O 
the O 
treatment O 
of O 
CDDP B-ABBREVIATION 
resistant O 
ovarian O 
carcinomas O 
. O 

-induced O 
inflammatory O 
activation O 
is O 
mediated O 
by O 
intracellular O 
free O 
calcium B-SYSTEMATIC 
in O 
microglial O 
cells O 
. O 

( O 
TCDD B-ABBREVIATION 
) O 
has O 
been O 
known O 
to O 
induce O 
inflammatory O 
signaling O 
in O 
a O 
number O 
of O 
cell O 
types O 
and O 
tissues O 
. O 
However O 
, O 
the O 
adverse O 
effects O 
of O 
TCDD B-ABBREVIATION 
on O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
have O 
not O 
been O 
entirely O 
elucidated O 
. O 
In O 
this O 
study O 
, O 
using O 
reverse O 
transcriptase O 
PCR O 
( O 
RT-PCR O 
) O 
and O 
ELISA O 
, O 
we O 
showed O 
that O 
TCDD B-ABBREVIATION 
up O 
- O 
regulated O 
the O 
expression O 
and O 
secretion O 
of O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
in O 
a O 
time O 
- O 
dependent O 
manner O 
in O 
cultured O 
HAPI O 
microglial O 
cells O 
. O 
TCDD B-ABBREVIATION 
also O 
caused O 
a O 
fast O 
( O 
within O 
30min O 
as O 
judged O 
by O 
the O 
increase O 
in O 
its O 
mRNA O 
level O 
) O 
activation O 
of O 
cytosolic O 
phospholipase O 
A2 O 
( O 
cPLA2 O 
) O 
. O 
This O 
initial O 
action O 
was O 
accompanied O 
by O 
up O 
- O 
regulation O 
of O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
an O 
important O 
inflammation O 
marker O 
within O 
1h O 
after O 
TCDD B-ABBREVIATION 
treatment O 
. O 
These O 
pro O 
- O 
inflammatory O 
responses O 
were O 
inhibited O 
by O 
two O 
types O 
of O 
Ca(2+) B-FORMULA 
blockers O 
, O 
bis-(o-aminophenoxy) B-SYSTEMATIC 
ethane-N,N,N',N'-tetra I-SYSTEMATIC 
- I-SYSTEMATIC 
acetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
acetoxymethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
BAPTA-AM B-ABBREVIATION 
) O 
and O 
nifedipine B-TRIVIAL 
, O 
thus O 
, O 
indicating O 
that O 
the O 
effects O 
are O 
triggered O 
by O 
initial O 
increase O 
in O 
the O 
intracellular O 
concentration O 
of O 
free O 
Ca(2+) B-FORMULA 
( O 
[ O 
Ca(2+) B-FORMULA 
]i O 
) O 
. O 
Further O 
, O 
TCDD B-ABBREVIATION 
exposure O 
could O 
induce O 
phosphorylation- O 
and O 
ubiquitination O 
- O 
dependent O 
degradation O 
of O 
IкBα O 
, O 
and O 
the O 
translocation O 
of O 
NF-κB O 
p65 O 
from O 
the O 
cytosol O 
to O 
the O 
nucleus O 
in O 
this O 
microglial O 
cell O 
line O 
. O 
Thus O 
, O 
the O 
NF-κB O 
signaling O 
pathway O 
can O 
be O 
activated O 
after O 
TCDD B-ABBREVIATION 
treatment O 
. O 
However O 
, O 
Ca(2+) B-FORMULA 
blockers O 
also O 
obviously O 
attenuated O 
NF-κB O 
activation O 
and O 
transnuclear O 
transport O 
induced O 
by O 
TCDD B-ABBREVIATION 
. O 
In O 
concert O 
with O 
these O 
results O 
, O 
we O 
highlighted O 
that O 
the O 
secretion O 
of O 
pro O 
- O 
inflammatory O 
cytokine O 
and O 
NF-κB O 
activation O 
induced O 
by O 
TCDD B-ABBREVIATION 
can O 
be O 
mediated O 
by O 
elevation O 
of O 
[ O 
Ca(2+) B-FORMULA 
]i O 
in O 
HAPI O 
microglial O 
cells O 
. O 

of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
on O 
growth O 
and O 
nitrogen B-SYSTEMATIC 
nutrition O 
of O 
roots O 
of O 
soybean O 
seedlings O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
an O 
environmental O 
endocrine O 
disruptor O 
that O 
seriously O 
threatens O 
ecological O 
systems O 
. O 
Plants O 
are O 
the O 
primary O 
producers O 
in O 
ecological O 
systems O 
, O 
but O 
little O 
information O 
is O 
available O 
concerning O 
the O 
toxic O 
effect O 
of O 
BPA B-ABBREVIATION 
on O 
plants O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
effects O 
of O 
BPA B-ABBREVIATION 
on O 
the O 
growth O 
and O 
nitrogen B-SYSTEMATIC 
nutrition O 
of O 
roots O 
of O 
soybean O 
seedlings O 
were O 
investigated O 
by O 
using O 
a O 
root O 
automatic O 
scan O 
apparatus O 
and O 
biochemical O 
methods O 
. O 
It O 
was O 
found O 
that O 
when O 
soybean O 
seedlings O 
were O 
treated O 
with O 
1.5 O 
mg O 
/ O 
L O 
BPA B-ABBREVIATION 
, O 
the O 
growth O 
of O 
roots O 
was O 
improved O 
, O 
the O 
content O 
of O 
nitrate B-SYSTEMATIC 
in O 
roots O 
was O 
increased O 
, O 
the O 
content O 
of O 
ammonium B-SYSTEMATIC 
in O 
roots O 
was O 
decreased O 
, O 
and O 
the O 
activities O 
of O 
nitrate B-SYSTEMATIC 
reductase O 
and O 
nitrite B-SYSTEMATIC 
reductase O 
in O 
roots O 
were O 
not O 
changed O 
. O 
The O 
opposite O 
effects O 
were O 
observed O 
in O 
roots O 
treated O 
with O 
17.2 O 
mg O 
/ O 
L O 
and O 
50 O 
mg O 
/ O 
L O 
BPA B-ABBREVIATION 
, O 
except O 
for O 
an O 
increase O 
in O 
the O 
content O 
of O 
nitrate B-SYSTEMATIC 
in O 
roots O 
treated O 
with O 
17.2 O 
mg O 
/ O 
L O 
BPA B-ABBREVIATION 
and O 
a O 
decrease O 
in O 
the O 
activities O 
of O 
nitrate B-SYSTEMATIC 
reductase O 
and O 
nitrite B-SYSTEMATIC 
reductase O 
in O 
roots O 
of O 
soybeans O 
seedlings O 
. O 
Statistical O 
analysis O 
indicated O 
that O 
the O 
change O 
in O 
the O 
nitrogen B-SYSTEMATIC 
nutrition O 
of O 
roots O 
of O 
soybean O 
seedlings O 
treated O 
with O 
BPA B-ABBREVIATION 
was O 
one O 
reason O 
why O 
the O 
growth O 
of O 
roots O 
was O 
changed O 
. O 
The O 
authors O 
suggest O 
that O 
the O 
potential O 
environmental O 
and O 
ecological O 
risk O 
of O 
BPA B-ABBREVIATION 
to O 
plants O 
should O 
receive O 
more O 
consideration O 
. O 

UDP B-ABBREVIATION 
-glucuronosyltransferase O 
and O 
sulfotransferase O 
expression O 
and O 
function O 
during O 
progressive O 
stages O 
of O 
human O 
nonalcoholic O 
fatty O 
liver O 
disease O 
. O 

UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGTs O 
) O 
and O 
sulfotransferases O 
( O 
SULTs O 
) O 
represent O 
major O 
phase O 
II O 
drug O 
- O 
metabolizing O 
enzymes O 
that O 
are O 
also O 
responsible O 
for O 
maintaining O 
cellular O 
homeostasis O 
by O 
metabolism O 
of O 
several O 
endogenous O 
molecules O 
. O 
Perturbations O 
in O 
the O 
expression O 
or O 
function O 
of O 
these O 
enzymes O 
can O 
lead O 
to O 
metabolic O 
disorders O 
and O 
improper O 
management O 
of O 
xenobiotics O 
and O 
endobiotics O 
. O 
Nonalcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
represents O 
a O 
spectrum O 
of O 
liver O 
damage O 
ranging O 
from O 
steatosis O 
to O 
nonalcoholic O 
steatohepatitis O 
( O 
NASH O 
) O 
and O 
cirrhosis O 
. O 
Because O 
the O 
liver O 
plays O 
a O 
central O 
role O 
in O 
the O 
metabolism O 
of O 
xenobiotics O 
, O 
the O 
purpose O 
of O 
the O 
current O 
study O 
was O 
to O 
determine O 
the O 
effect O 
of O 
human O 
NAFLD O 
progression O 
on O 
the O 
expression O 
and O 
function O 
of O 
UGTs O 
and O 
SULTs O 
in O 
normal O 
, O 
steatosis O 
, O 
NASH O 
( O 
fatty O 
) O 
, O 
and O 
NASH O 
( O 
not O 
fatty O 
/ O 
cirrhosis O 
) O 
samples O 
. O 
We O 
identified O 
upregulation O 
of O 
UGT1A9 O 
, O 
2B10 O 
, O 
and O 
3A1 O 
and O 
SULT1C4 O 
mRNA O 
in O 
both O 
stages O 
of O 
NASH O 
, O 
whereas O 
UGT2A3 O 
, O 
2B15 O 
, O 
and O 
2B28 O 
and O 
SULT1A1 O 
, O 
2B1 O 
, O 
and O 
4A1 O 
as O 
well O 
as O 
3'-phosphoadenosine-5'-phosphosulfate B-SYSTEMATIC 
synthase O 
1 O 
were O 
increased O 
in O 
NASH O 
( O 
not O 
fatty O 
/ O 
cirrhosis O 
) O 
only O 
. O 
UGT1A9 O 
and O 
1A6 O 
and O 
SULT1A1 O 
and O 
2A1 O 
protein O 
levels O 
were O 
decreased O 
in O 
NASH O 
; O 
however O 
, O 
SULT1C4 O 
was O 
increased O 
. O 
Measurement O 
of O 
the O 
glucuronidation O 
and O 
sulfonation O 
of O 
acetaminophen B-TRIVIAL 
( O 
APAP B-ABBREVIATION 
) O 
revealed O 
no O 
alterations O 
in O 
glucuronidation O 
; O 
however O 
, O 
SULT O 
activity O 
was O 
increased O 
in O 
steatosis O 
compared O 
with O 
normal O 
samples O 
, O 
but O 
then O 
decreased O 
in O 
NASH O 
compared O 
with O 
steatosis O 
. O 
In O 
conclusion O 
, O 
the O 
expression O 
of O 
specific O 
UGT O 
and O 
SULT O 
isoforms O 
appears O 
to O 
be O 
differentially O 
regulated O 
, O 
whereas O 
sulfonation O 
of O 
APAP B-ABBREVIATION 
is O 
disrupted O 
during O 
progression O 
of O 
NAFLD O 
. O 

of O 
aqueous O 
media O 
properties O 
on O 
aggregation O 
and O 
solubility O 
of O 
four O 
structurally O 
related O 
meso-porphyrin B-FAMILY 
photosensitizers O 
evaluated O 
by O 
spectrophotometric O 
measurements O 
. O 

photosensitizers O 
tend O 
to O 
aggregate O 
in O 
aqueous O 
solutions O 
even O 
in O 
the O 
micromolar O 
concentration O 
range O 
. O 
This O 
is O 
a O 
challenge O 
during O 
formulation O 
of O 
e.g O 
. O 
, O 
parenteral O 
preparations O 
for O 
photodynamic O 
cancer O 
therapy O 
, O 
or O 
preparations O 
for O 
local O 
or O 
topical O 
administration O 
in O 
antimicrobial O 
photodynamic O 
therapy O 
. O 
Monomerization O 
is O 
essential O 
to O 
achieve O 
biocompatible O 
drug O 
formulations O 
of O 
high O 
bioavailability O 
and O 
physiological O 
response O 
( O 
i.e O 
. O 
, O 
photoreactivity O 
) O 
and O 
low O 
toxicity O 
. O 
The O 
aggregation O 
and O 
solubilization O 
of O 
four O 
structurally O 
related O 
meso-tetraphenyl B-SYSTEMATIC 
porphyrin I-SYSTEMATIC 
photosensitizers O 
with O 
nonionic O 
( O 
4-hydroxy B-SYSTEMATIC 
) O 
, O 
anionic O 
( O 
4-sulphonate B-SYSTEMATIC 
; O 
4-carboxy B-SYSTEMATIC 
) O 
and O 
cationic O 
( O 
4-trimethylanilinium B-SYSTEMATIC 
) O 
substituents O 
were O 
evaluated O 
in O 
various O 
vehicles O 
by O 
use O 
of O 
UV-Vis O 
spectroscopy O 
. O 
Substituents O 
, O 
overall O 
charge O 
and O 
charge O 
distribution O 
influenced O 
the O 
pKa-values O 
and O 
interaction O 
of O 
the O 
porphyrins B-FAMILY 
with O 
different O 
solvents O 
, O 
excipients O 
and O 
impurities O 
. O 
Modification O 
of O 
medium O 
polarity O 
and O 
solubilization O 
by O 
the O 
nonionic O 
surfactant O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
adjusted O 
the O 
acid O 
- O 
base O 
equilibria O 
and O 
increased O 
the O 
solubility O 
by O 
reduction O 
of O 
porphyrin B-FAMILY 
aggregation O 
. O 
The O 
selected O 
porphyrins B-FAMILY 
were O 
sensitive O 
towards O 
ionic O 
strength O 
, O 
temperature O 
and O 
inorganic O 
impurities O 
to O 
various O 
extents O 
. O 
The O 
results O 
will O 
be O 
further O 
used O 
during O 
development O 
of O 
parenteral O 
and O 
topical O 
formulations O 
of O 
porphyrin B-FAMILY 
photosensitizers O 
for O 
use O 
in O 
photodynamic O 
therapy O 
of O 
cancer O 
and O 
bacterial O 
infections O 
. O 

and O 
selected O 
immunological O 
properties O 
of O 
substituted O 
quino[3,2-b]benzo[1,4]thiazines B-FAMILY 
. O 

new O 
type O 
of O 
azaphenothiazines B-FAMILY 
- O 
tetracyclic B-FAMILY 
quino[3,2-b]benzo[1,4]thiazines I-FAMILY 
, O 
possessing O 
common O 
substituents O 
( O 
H B-FORMULA 
, O 
CH3 B-FORMULA 
, O 
Cl B-FORMULA 
, O 
Br B-FORMULA 
, O 
F B-FORMULA 
, O 
CF3 B-FORMULA 
, O 
SCH3 B-FORMULA 
) O 
in O 
positions O 
8-10 O 
and O 
pharmacophoric O 
aminoalkyl B-FAMILY 
substituents O 
in O 
position O 
6 O 
, O 
were O 
obtained O 
from O 
diquinodithiin B-SYSTEMATIC 
and O 
2,2'-dichloro-3,3'-diquinolinyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
in O 
several O 
- O 
step O 
syntheses O 
. O 
Sixty O 
one O 
compounds O 
, O 
grouped O 
as O 
the O 
6H O 
, O 
6-dialkylaminoalkyl B-FAMILY 
, O 
6-acylaminoalkyl B-FAMILY 
and O 
sulfonylaminoalkyl B-FAMILY 
derivatives O 
, O 
were O 
tested O 
for O 
cytotoxicity O 
, O 
their O 
effects O 
on O 
phytohemagglutin O 
A O 
(PHA)-induced O 
proliferative O 
response O 
of O 
human O 
peripheral O 
blood O 
mononuclear O 
cells O 
( O 
PBMC O 
) O 
and O 
lipopolysaccharide O 
(LPS)-induced O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNF-α O 
) O 
production O 
by O 
these O 
cells O 
. O 
The O 
compounds O 
exhibited O 
differential O 
inhibitory O 
activities O 
in O 
these O 
tests O 
and O 
significantly O 
varied O 
in O 
terms O 
of O 
cytotoxicity O 
. O 
The O 
most O 
promising O 
compounds O 
were O 
tested O 
for O 
growth O 
inhibition O 
of O 
leukemia O 
L-1210 O 
cells O 
, O 
colon O 
cancer O 
SV-948 O 
cells O 
and O 
epidermal O 
carcinoma O 
A-341 O 
cells O 
. O 
The O 
most O 
active O 
compounds O 
exhibited O 
anticancer O 
activity O 
against O 
these O 
cell O 
lines O 
comparable O 
to O 
that O 
of O 
cisplatin B-TRIVIAL 
. O 
The O 
structure O 
- O 
activity O 
relationship O 
of O 
the O 
compounds O 
were O 
discussed O 
. O 

putative O 
JAK-STAT O 
inhibitor O 
AG490 B-TRIVIAL 
exacerbates O 
LPS-fever O 
, O 
reduces O 
sickness O 
behavior O 
, O 
and O 
alters O 
the O 
expression O 
of O 
pro- O 
and O 
anti-inflammatory O 
genes O 
in O 
the O 
rat O 
brain O 
. O 

functional O 
significance O 
for O 
activation O 
of O 
inflammatory O 
transcription O 
factors O 
, O 
such O 
as O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
( O 
STAT3 O 
) O 
, O 
nuclear O 
factor O 
(NF)κB O 
or O 
NF-interleukin O 
(IL)6 O 
and O 
their O 
contribution O 
to O 
the O 
induction O 
of O 
brain O 
controlled O 
sickness O 
responses O 
, O 
such O 
as O 
fever O 
, O 
during O 
infection O 
and O 
inflammation O 
is O 
unknown O 
. O 
Using O 
AG490 B-TRIVIAL 
, O 
previously O 
shown O 
to O 
inhibit O 
the O 
STAT3- O 
and O 
NF-IL6-signaling O 
pathway O 
, O 
we O 
therefore O 
investigated O 
the O 
central O 
involvement O 
of O 
these O 
two O 
signaling O 
pathways O 
in O 
mediating O 
sickness O 
behavior O 
, O 
fever O 
and O 
accompanying O 
brain O 
inflammation O 
induced O 
by O 
peripheral O 
lipopolysaccharide O 
(LPS)-stimulation O 
. O 
Rats O 
pre O 
- O 
treated O 
i.c.v O 
. O 
with O 
AG490 B-TRIVIAL 
1 O 
h O 
before O 
the O 
i.p O 
. O 
LPS-challenge O 
( O 
100 O 
μg O 
/ O 
kg O 
) O 
showed O 
a O 
modestly O 
exaggerated O 
fever O 
, O 
attenuated O 
adipsia O 
and O 
almost O 
unimpaired O 
locomotor O 
activity O 
compared O 
to O 
LPS-controls O 
receiving O 
vehicle O 
( O 
i.c.v O 
. O 
) O 
. O 
The O 
LPS-induced O 
anorexia O 
was O 
not O 
altered O 
and O 
AG490 B-TRIVIAL 
did O 
not O 
have O 
any O 
effect O 
on O 
rats O 
receiving O 
PBS O 
( O 
i.p O 
. O 
) O 
. O 
We O 
did O 
observe O 
effects O 
of O 
AG490 B-TRIVIAL 
on O 
STAT3-signaling O 
at O 
4 O 
h O 
, O 
while O 
AG490 B-TRIVIAL 
-mediated O 
changes O 
in O 
brain O 
activity O 
of O 
inflammatory O 
transcription O 
factors O 
at O 
8 O 
h O 
were O 
not O 
significant O 
. O 
Increased O 
NF-IL6 O 
and O 
suppressor O 
of O 
cytokines O 
3 O 
mRNA-expression O 
in O 
AG490 B-TRIVIAL 
/ O 
LPS O 
- O 
treated O 
rats O 
were O 
indicative O 
of O 
a O 
compensative O 
activation O 
at O 
24 O 
h O 
. O 
Moreover O 
, O 
a O 
significant O 
decrease O 
in O 
hypothalamic O 
anti-inflammatory O 
IL-10-expression O 
and O 
an O 
increase O 
in O 
inflammatory O 
microsomal O 
prostaglandin B-FAMILY 
E I-FAMILY 
synthase O 
( O 
mPGES O 
) O 
mRNA-expression O 
8 O 
h O 
after O 
LPS-injection O 
was O 
revealed O 
in O 
AG490 B-TRIVIAL 
pre O 
- O 
treated O 
animals O 
compared O 
to O 
solvent O 
- O 
treated O 
LPS-controls O 
. O 
In O 
summary O 
, O 
we O 
have O 
shown O 
a O 
dissociation O 
between O 
the O 
effects O 
of O 
central O 
AG490 B-TRIVIAL 
treatment O 
on O 
fever O 
and O 
components O 
of O 
sickness O 
behavior O 
, O 
which O 
appears O 
to O 
be O 
related O 
to O 
reduced O 
IL-10 O 
and O 
increased O 
mPGES-expression O 
in O 
the O 
brain O 
. O 
Thus O 
, O 
AG490 B-TRIVIAL 
might O 
have O 
therapeutic O 
potential O 
to O 
reduce O 
sickness O 
behavior O 
. O 

- O 
specific O 
and O 
Far-Red O 
Light-Activatable O 
Prodrug O 
of O 
Combretastain B-TRIVIAL 
A-4 I-TRIVIAL 
Using O 
Photo-Unclick O 
Chemistry O 
. O 

tissue O 
- O 
penetrable O 
light O 
( O 
red O 
and O 
NIR O 
) O 
has O 
a O 
great O 
potential O 
for O 
spatiotemporally O 
controlled O 
release O 
of O 
therapeutic O 
agents O 
, O 
it O 
has O 
been O 
hampered O 
because O 
of O 
the O 
lack O 
of O 
chemistry O 
translating O 
the O 
photonic O 
energy O 
to O 
a O 
cleavage O 
of O 
a O 
chemical O 
bond O 
. O 
Recently O 
, O 
we O 
discovered O 
that O 
an O 
aminoacrylate B-SYSTEMATIC 
group O 
could O 
be O 
cleaved O 
to O 
release O 
parent O 
drugs O 
after O 
oxidation O 
by O 
SO O 
, O 
and O 
have O 
called O 
this O 
" O 
photo O 
- O 
unclick O 
chemistry O 
" O 
. O 
We O 
demonstrate O 
its O 
application O 
to O 
far O 
- O 
red O 
light O 
- O 
activated O 
prodrugs O 
. O 
A O 
prodrug O 
of O 
combretastatin B-TRIVIAL 
A-4 I-TRIVIAL 
( O 
CA4 B-ABBREVIATION 
) O 
was O 
prepared O 
, O 
CMP-L-CA4 B-ABBREVIATION 
: O 
CMP B-ABBREVIATION 
( O 
dithiaporphyrin B-SYSTEMATIC 
, O 
a O 
photosensitizer O 
) O 
and O 
L O 
( O 
aminoacrylate B-SYSTEMATIC 
linker O 
) O 
. O 
Upon O 
irradiation O 
with O 
690 O 
nm O 
diode O 
laser O 
, O 
the O 
aminoacrylate B-SYSTEMATIC 
linker O 
of O 
the O 
prodrug O 
was O 
cleaved O 
rapidly O 
releasing O 
CA4 B-ABBREVIATION 
( O 
> O 
80% O 
in O 
10 O 
min O 
) O 
in O 
CDCl3 B-FORMULA 
. O 
In O 
the O 
tissue O 
culture O 
, O 
it O 
showed O 
about O 
a O 
6-fold O 
increase O 
in O 
its O 
IC50 O 
in O 
MCF-7 O 
after O 
the O 
irradiation O 
, O 
most O 
likely O 
, O 
because O 
of O 
the O 
released O 
CA4 B-ABBREVIATION 
. O 
Most O 
significantly O 
, O 
CMP-L-CA4 B-ABBREVIATION 
had O 
better O 
antitumor O 
efficacy O 
in O 
vivo O 
than O 
its O 
non-cleavable O 
( O 
NC O 
) O 
analog O 
, O 
CMP-NCL-CA4 B-ABBREVIATION 
. O 
This O 
is O 
the O 
first O 
demonstration O 
of O 
the O 
in O 
vivo O 
efficacy O 
of O 
the O 
novel O 
low O 
- O 
energy O 
light O 
- O 
activatable O 
prodrug O 
using O 
the O 
photo O 
- O 
unclick O 
chemistry O 
. O 

and O 
Strain O 
Fields O 
inside O 
a O 
Ag B-FORMULA 
/ O 
Au B-FORMULA 
Core-Shell O 
Nanowire O 
Studied O 
by O 
Coherent O 
X-ray O 
Diffraction O 
. O 

- O 
dimensional O 
coherent O 
diffraction O 
patterns O 
of O 
an O 
isolated O 
, O 
single O 
- O 
crystalline O 
Ag B-FORMULA 
/ O 
Au B-FORMULA 
core O 
- O 
shell O 
nanowire O 
were O 
recorded O 
at O 
different O 
X-ray O 
beam O 
energies O 
close O 
to O 
the O 
Au B-FORMULA 
LIII O 
absorption O 
edge O 
. O 
Two O 
- O 
dimensional O 
slices O 
of O 
the O 
three O 
- O 
dimensional O 
diffraction O 
pattern O 
, O 
with O 
the O 
diffraction O 
vector O 
oriented O 
perpendicular O 
to O 
the O 
wire O 
axis O 
, O 
were O 
investigated O 
in O 
detail O 
. O 
In O 
reciprocal O 
space O 
, O 
facet O 
streaks O 
with O 
thickness O 
fringes O 
were O 
clearly O 
observed O 
in O 
the O 
two O 
- O 
dimensional O 
diffraction O 
patterns O 
, O 
from O 
which O 
the O 
shape O 
and O 
size O 
of O 
the O 
corresponding O 
cross O 
sections O 
of O 
the O 
nanowire O 
could O 
be O 
revealed O 
. O 
Comparison O 
with O 
simulated O 
diffraction O 
patterns O 
exhibited O 
the O 
coherency O 
strain O 
field O 
in O 
the O 
nanowire O 
. O 
During O 
in O 
situ O 
annealing O 
at O 
temperatures O 
which O 
would O 
lead O 
to O 
significant O 
intermixing O 
by O 
volume O 
diffusion O 
in O 
bulk O 
material O 
, O 
according O 
to O 
literature O 
data O 
, O 
a O 
core O 
- O 
shell O 
morphology O 
was O 
preserved O 
; O 
that O 
is O 
, O 
intermixing O 
in O 
the O 
nanowire O 
was O 
pronouncedly O 
decelerated O 
compared O 
to O 
bulk O 
diffusion O 
. O 

- O 
stage O 
metal O 
- O 
catalyst O 
- O 
free O 
growth O 
of O 
high O 
- O 
quality O 
polycrystalline O 
graphene B-TRIVIAL 
films O 
on O 
silicon B-SYSTEMATIC 
nitride I-SYSTEMATIC 
substrates O 
. O 

using O 
two O 
- O 
stage O 
, O 
metal O 
- O 
catalyst O 
- O 
free O 
chemical O 
vapor O 
deposition O 
( O 
CVD O 
) O 
, O 
it O 
is O 
demonstrated O 
that O 
high O 
- O 
quality O 
polycrystalline O 
graphene B-TRIVIAL 
films O 
can O 
directly O 
grow O 
on O 
silicon B-SYSTEMATIC 
nitride I-SYSTEMATIC 
substrates O 
. O 
The O 
carrier O 
mobility O 
can O 
reach O 
about O 
1500 O 
cm(2) O 
V(-1) O 
s(-1) O 
, O 
which O 
is O 
about O 
three O 
times O 
the O 
value O 
of O 
those O 
grown O 
on O 
SiO(2) B-FORMULA 
/ O 
Si B-FORMULA 
substrates O 
, O 
and O 
also O 
is O 
better O 
than O 
some O 
examples O 
of O 
metal O 
- O 
catalyzed O 
graphene B-TRIVIAL 
, O 
reflecting O 
the O 
good O 
quality O 
of O 
the O 
graphene B-TRIVIAL 
lattice O 
. O 

@ O 
Au B-FORMULA 
core O 
- O 
shell O 
nanospheres O 
self O 
- O 
assemble O 
to O 
form O 
colloidal O 
crystals O 
that O 
can O 
be O 
sintered O 
and O 
surface O 
modified O 
to O 
produce O 
pH-controlled O 
membranes O 
. O 

prepared O 
colloidal O 
crystals O 
by O 
self O 
- O 
assembly O 
of O 
gold O 
- O 
coated O 
silica B-TRIVIAL 
nanospheres O 
, O 
and O 
free O 
- O 
standing O 
nanoporous O 
membranes O 
by O 
sintering O 
these O 
colloidal O 
crystals O 
. O 
We O 
modified O 
the O 
nanopore O 
surface O 
with O 
ionizable O 
functional O 
groups O 
, O 
by O 
forming O 
a O 
monolayer O 
of O 
L-cysteine B-TRIVIAL 
or O 
by O 
surface O 
- O 
initiated O 
polymerization O 
of O 
methacrylic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Diffusion O 
experiments O 
for O 
the O 
cationic O 
dye O 
Rhodamine B-TRIVIAL 
B I-TRIVIAL 
through O 
L-cysteine B-TRIVIAL 
-modified O 
membranes O 
showed O 
a O 
decrease O 
in O 
flux O 
upon O 
addition O 
of O 
an O 
acid O 
due O 
to O 
the O 
nanopore O 
surface O 
becoming O 
positively O 
charged O 
. O 
Diffusion O 
experiments O 
for O 
the O 
neutral O 
dye O 
, O 
ferrocenecarboxaldehyde B-SYSTEMATIC 
, O 
through O 
the O 
PMAA B-ABBREVIATION 
-modified O 
membranes O 
showed O 
a O 
13-fold O 
increase O 
in O 
flux O 
upon O 
addition O 
of O 
an O 
acid O 
resulting O 
from O 
the O 
protonated O 
polymer O 
collapsing O 
onto O 
the O 
nanopore O 
surface O 
leading O 
to O 
larger O 
pore O 
size O 
. O 
Our O 
results O 
demonstrate O 
that O 
SiO2 B-FORMULA 
@ O 
Au B-FORMULA 
core O 
- O 
shell O 
nanospheres O 
can O 
self O 
- O 
assemble O 
into O 
colloidal O 
crystals O 
and O 
that O 
transport O 
through O 
the O 
corresponding O 
surface O 
- O 
modified O 
Au B-FORMULA 
-coated O 
colloidal O 
membranes O 
can O 
be O 
controlled O 
by O 
pH O 
. O 

work O 
aimed O 
to O 
evaluate O 
and O 
compare O 
the O 
phenolic O 
profile O 
and O 
some O 
biological O 
properties O 
of O 
the O 
ripe O 
" O 
berries O 
" O 
methanol B-SYSTEMATIC 
extracts O 
of O 
Juniperus O 
oxycedrus O 
L O 
. O 
subsp O 
. O 
oxycedrus O 
( O 
Joo O 
) O 
and O 
Juniperus O 
oxycedrus O 
L O 
. O 
subsp O 
. O 
macrocarpa O 
( O 
Sibth O 
. O 
& O 
Sm O 
. O 
) O 
Ball O 
. O 
( O 
Jom O 
) O 
from O 
Turkey O 
. O 
The O 
total O 
phenolic B-FAMILY 
content O 
resulted O 
about O 
3-fold O 
higher O 
in O 
Jom O 
( O 
17.89±0.23mg O 
GAE O 
/ O 
g O 
extract O 
) O 
than O 
in O 
Joo O 
( O 
5.14±0.06mg O 
GAE O 
/ O 
g O 
extract O 
) O 
. O 
The O 
HPLC-DAD-ESI-MS O 
analysis O 
revealed O 
a O 
similar O 
flavonoid B-FAMILY 
fingerprint O 
in O 
Joo O 
and O 
Jom O 
, O 
whereas O 
a O 
difference O 
in O 
their O 
quantitative O 
content O 
was O 
found O 
( O 
4632μg O 
/ O 
g O 
extract O 
and O 
12,644μg O 
/ O 
g O 
extract O 
) O 
. O 
In O 
addition O 
, O 
three O 
phenolic B-FAMILY 
acids I-FAMILY 
were O 
detected O 
in O 
Jom O 
only O 
( O 
5765μg O 
/ O 
g O 
extract O 
) O 
, O 
and O 
protocatechuic B-TRIVIAL 
acid I-TRIVIAL 
was O 
the O 
most O 
abundant O 
one O 
. O 
The O 
antioxidant O 
capacity O 
of O 
the O 
extracts O 
was O 
evaluated O 
by O 
different O 
in O 
vitro O 
assays O 
: O 
in O 
the O 
DPPH B-ABBREVIATION 
and O 
in O 
the O 
TBA B-ABBREVIATION 
tests O 
a O 
stronger O 
activity O 
in O 
Jom O 
was O 
highlighted O 
, O 
while O 
Joo O 
exhibited O 
higher O 
reducing O 
power O 
and O 
metal O 
chelating O 
activity O 
. O 
Joo O 
and O 
Jom O 
did O 
not O 
affect O 
HepG2 O 
cell O 
viability O 
and O 
both O 
extracts O 
resulted O 
virtually O 
non-toxic O 
against O 
Artemia O 
salina O 
. O 
The O 
extracts O 
were O 
also O 
studied O 
for O 
their O 
antimicrobial O 
potential O 
, O 
displaying O 
efficacy O 
against O 
Gram O 
- O 
positive O 
bacteria O 
. O 

- O 
template O 
molecularly O 
imprinted O 
solid O 
phase O 
extraction O 
for O 
selective O 
analysis O 
of O 
ractopamine B-TRIVIAL 
in O 
pork O 
. O 

imprinted O 
polymers O 
( O 
MIPs O 
) O 
for O 
selective O 
adsorption O 
of O 
ractopamine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
RAC B-ABBREVIATION 
) O 
were O 
synthesised O 
by O 
an O 
in O 
situ O 
method O 
, O 
in O 
which O 
salbutamol B-TRIVIAL 
( O 
SAL B-ABBREVIATION 
) O 
was O 
used O 
as O 
the O 
dummy O 
- O 
template O 
to O 
avoid O 
the O 
template O 
leakage O 
. O 
Scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
, O 
mercury O 
porosimerty O 
and O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FTIR O 
) O 
were O 
used O 
to O 
investigate O 
the O 
physical O 
and O 
morphological O 
characteristics O 
of O 
the O 
dummy O 
- O 
template O 
MIPs O 
. O 
The O 
test O 
of O 
adsorption O 
selectivity O 
indicated O 
that O 
the O 
dummy O 
- O 
template O 
MIPs O 
exhibited O 
high O 
selectivity O 
to O 
RAC B-ABBREVIATION 
. O 
The O 
saturated O 
adsorption O 
capacity O 
for O 
RAC B-ABBREVIATION 
on O 
dummy O 
- O 
template O 
MIPs O 
was O 
90.9μgg(-1) O 
. O 
Based O 
on O 
the O 
dummy O 
- O 
template O 
polymers O 
, O 
a O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
LC-MS O 
) O 
method O 
was O 
developed O 
for O 
the O 
selective O 
analysis O 
of O 
RAC B-ABBREVIATION 
in O 
real O 
pork O 
samples O 
. O 
The O 
averages O 
of O 
intra- O 
and O 
inter O 
- O 
day O 
accuracy O 
ranged O 
from O 
78.9% O 
to O 
92.2% O 
and O 
from O 
90.7% O 
to O 
93.1% O 
, O 
respectively O 
. O 
The O 
RSD% O 
of O 
repeatability O 
ranged O 
from O 
1.9% O 
to O 
6.3% O 
, O 
and O 
the O 
RSD% O 
of O 
intermediate O 
precision O 
ranged O 
from O 
3.5% O 
to O 
9.2% O 
, O 
while O 
the O 
limit O 
of O 
detection O 
( O 
LOD O 
) O 
was O 
0.02μgkg(-1) O 
. O 

study O 
focuses O 
on O 
changes O 
in O 
starch O 
content O 
and O 
expected O 
glycemic O 
index O 
( O 
eGI O 
) O 
caused O 
by O 
different O 
sprouting O 
methods O 
of O 
lentil O 
. O 
On O 
germination O 
, O 
a O 
decrease O 
was O 
observed O 
in O 
total O 
starch O 
content O 
( O 
TS O 
) O 
, O 
α-amylase O 
inhibitors O 
activity O 
( O 
αAI O 
) O 
and O 
eGI O 
values O 
. O 
After O 
elicitation O 
, O 
the O 
highest O 
TS O 
content O 
was O 
determined O 
in O 
3-day- O 
old O 
control O 
sprouts O 
( O 
100.9 O 
mg O 
/ O 
gf.m O 
. O 
) O 
, O 
whereas O 
the O 
lowest O 
was O 
in O 
4-day- O 
old O 
sprouts O 
induced O 
with O 
300 O 
mM O 
NaC B-FORMULA 
l O 
( O 
57.8 O 
mg O 
/ O 
gf.m O 
. O 
) O 
. O 
Resistant O 
starch O 
( O 
RS O 
) O 
content O 
was O 
most O 
effectively O 
increased O 
by O 
induction O 
with O 
600 O 
mM O 
mannito B-TRIVIAL 
l O 
. O 
The O 
highest O 
eGI O 
values O 
were O 
determined O 
for O 
3-day- O 
old O 
sprouts O 
induced O 
with O 
300 O 
mM O 
NaC B-FORMULA 
l O 
, O 
whereas O 
the O 
lowest O 
were O 
for O 
6-day- O 
old O 
sprouts O 
induced O 
with O 
100mM O 
NaC B-FORMULA 
l O 
. O 
In O 
treated O 
sprouts O 
starch O 
digestibility O 
was O 
connected O 
with O 
αAI O 
activity O 
and O 
RS O 
content O 
. O 
Sprouting O 
conditions O 
can O 
modify O 
starch O 
content O 
, O 
its O 
potential O 
bioavailability O 
and O 
eGI O 
values O 
. O 
Optimization O 
of O 
this O 
process O 
will O 
allow O 
for O 
the O 
maximum O 
nutritional O 
benefit O 
. O 

study O 
was O 
conducted O 
to O 
investigate O 
the O 
potential O 
of O 
bambangan O 
( O 
Mangifera O 
pajang O 
) O 
fruit O 
extracts O 
in O 
the O 
protection O 
against O 
oxidative O 
damage O 
caused O 
by O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
in O 
the O 
human O 
hepatocellular O 
HepG2 O 
cell O 
line O 
. O 
Proteins O 
which O 
might O 
be O 
involved O 
in O 
the O 
cytoprotective O 
mechanism O 
were O 
investigated O 
using O 
western O 
blotting O 
technique O 
. O 
Quercetin B-TRIVIAL 
was O 
used O 
as O 
a O 
positive O 
control O 
. O 
The O 
results O 
showed O 
that O 
only O 
the O 
kernel O 
extract O 
of O 
M O 
. O 
pajang O 
and O 
quercetin B-TRIVIAL 
displayed O 
cytoprotective O 
activity O 
in O 
HepG2 O 
cells O 
, O 
with O 
EC(50) O 
values O 
of O 
1.2 O 
and O 
5.3μg O 
/ O 
ml O 
, O 
respectively O 
. O 
Expression O 
of O 
quinone B-FAMILY 
reductase O 
, O 
glutathione B-TRIVIAL 
reductase O 
and O 
methionine B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
reductase O 
A O 
proteins O 
were O 
significantly O 
up O 
- O 
regulated O 
by O 
quercetin B-TRIVIAL 
, O 
suggesting O 
their O 
involvement O 
in O 
the O 
cytoprotective O 
activity O 
of O 
quercetin B-TRIVIAL 
. O 
However O 
, O 
expressions O 
of O 
only O 
glutathione B-TRIVIAL 
reductase O 
and O 
methionine B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
reductase O 
A O 
proteins O 
were O 
significantly O 
up O 
- O 
regulated O 
by O 
the O 
kernel O 
extract O 
, O 
again O 
suggesting O 
their O 
involvement O 
in O 
the O 
cytoprotective O 
activity O 
of O 
bambangan O 
kernel O 
extract O 
. O 
Future O 
study O 
is O 
needed O 
to O 
investigate O 
the O 
involvement O 
of O 
other O 
cytoprotective O 
proteins O 
in O 
the O 
cytoprotection O 
mechanism O 
. O 

activity O 
of O 
hexane B-SYSTEMATIC 
extracts O 
from O 
bones O 
and O 
internal O 
organs O 
of O 
Anguilla O 
japonica O 
suppresses O 
cyclooxygenase-2-dependent O 
prostaglandin B-TRIVIAL 
D2 I-TRIVIAL 
generation O 
in O 
mast O 
cells O 
and O 
anaphylaxis O 
in O 
mice O 
. O 

purpose O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
effects O 
of O 
n-hexane B-SYSTEMATIC 
extracts O 
from O 
bones O 
and O 
internal O 
organs O 
of O 
Japanese O 
eel O 
, O 
Anguilla O 
japonica O 
( O 
HEE O 
) O 
, O 
on O 
cyclooxygenase-2 O 
(COX-2)-dependent O 
prostaglandin B-TRIVIAL 
D2 I-TRIVIAL 
( O 
PGD2 B-ABBREVIATION 
) O 
generation O 
in O 
stem O 
cell O 
factor O 
( O 
SCF O 
) O 
, O 
IL-10 O 
, O 
plus O 
LPS-induced O 
mouse O 
bone O 
marrow O 
- O 
derived O 
mast O 
cells O 
( O 
BMMCs O 
) O 
and O 
on O 
passive O 
cutaneous O 
anaphylaxis O 
( O 
PCA O 
) O 
in O 
mice O 
. O 
HEE O 
suppressed O 
SCF O 
/ O 
IL-10 O 
/ O 
LPS-induced O 
PGD2 B-ABBREVIATION 
generation O 
, O 
and O 
concomitantly O 
reduced O 
COX-2 O 
protein O 
expression O 
dose O 
- O 
dependently O 
. O 
To O 
understand O 
the O 
mechanistic O 
basis O 
for O 
the O 
inhibition O 
of O 
PGD2 B-ABBREVIATION 
generation O 
by O 
HEE O 
, O 
we O 
examined O 
the O 
effects O 
of O 
HEE O 
on O 
upstream O 
signaling O 
pathways O 
essential O 
for O 
COX-2 O 
induction O 
. O 
HEE O 
was O 
found O 
to O 
inhibit O 
the O 
translocation O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
p65 O 
subunit O 
to O 
the O 
nucleus O 
and O 
its O 
DNA O 
- O 
binding O 
ability O 
through O 
the O 
inhibition O 
of O 
TAK1 O 
, O 
IKK O 
and O 
IκB O 
phosphorylation O 
. O 
Furthermore O 
, O 
HEE O 
also O 
attenuated O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
- O 
mediated O 
regulation O 
of O 
DNA O 
binding O 
of O 
activator O 
protein-1 O 
( O 
AP-1 O 
) O 
. O 
Moreover O 
, O 
oral O 
administration O 
of O 
HEE O 
inhibited O 
anti- O 
dinitrophenyl B-SYSTEMATIC 
( O 
DNP B-ABBREVIATION 
) O 
IgE-induced O 
PCA O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
Taken O 
together O 
, O 
the O 
present O 
study O 
provides O 
new O 
insights O 
into O 
the O 
anti-inflammatory O 
activity O 
of O 
HEE O 
, O 
which O 
could O 
be O 
a O 
promising O 
candidate O 
to O 
be O 
used O 
for O 
an O 
inflammatory O 
therapy O 
. O 

formulations O 
with O 
sugar B-FAMILY 
-derived O 
surfactants O 
: O 
a O 
new O 
approach O 
for O 
photoprotection O 
and O 
controlled O 
release O 
of O 
promethazine B-TRIVIAL 
. O 

of O 
a O 
novel O 
phenolic B-FAMILY 
compound O 
in O 
litchi O 
( O 
Litchi O 
chinensis O 
Sonn O 
. O 
) O 
pericarp O 
and O 
bioactivity O 
evaluation O 
. O 

( O 
Litchi O 
chinensis O 
Sonn O 
. O 
) O 
is O 
a O 
delicious O 
fruit O 
widely O 
accepted O 
by O 
consumers O 
all O 
over O 
the O 
world O 
. O 
In O 
this O 
work O 
, O 
phytochemical O 
investigation O 
of O 
litchi O 
pericarp O 
methanol B-SYSTEMATIC 
extracts O 
led O 
to O 
the O 
isolation O 
of O 
a O 
novel O 
phenolic B-FAMILY 
, O 
2-(2-hydroxyl-5-(methoxycarbonyl) B-SYSTEMATIC 
phenoxy I-SYSTEMATIC 
) I-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
together O 
with O 
kaempferol B-TRIVIAL 
, O 
isolariciresinol B-TRIVIAL 
, O 
stigmasterol B-TRIVIAL 
, O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
, O 
3,4-dihydroxyl B-SYSTEMATIC 
benzoate I-SYSTEMATIC 
, O 
methyl B-SYSTEMATIC 
shikimate I-SYSTEMATIC 
and O 
ethyl B-SYSTEMATIC 
shikimate I-SYSTEMATIC 
. O 
Most O 
were O 
found O 
in O 
litchi O 
pericarp O 
for O 
the O 
first O 
time O 
. O 
Their O 
structures O 
were O 
mainly O 
elucidated O 
by O 
NMR O 
and O 
MS O 
evidences O 
. O 
Antioxidant O 
activities O 
of O 
the O 
eight O 
compounds O 
were O 
determined O 
by O 
a O 
DPPH B-ABBREVIATION 
radical O 
scavenging O 
assay O 
and O 
the O 
results O 
showed O 
that O 
2-(2-hydroxy-5-(methoxycarbonyl) B-SYSTEMATIC 
phenoxy)benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
kaempferol B-TRIVIAL 
, O 
isolariciresinol B-TRIVIAL 
, O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
and O 
3,4-dihydroxy B-SYSTEMATIC 
benzoate I-SYSTEMATIC 
exhibited O 
good O 
antioxidant O 
activities O 
. O 
An O 
interesting O 
finding O 
was O 
that O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
was O 
detected O 
as O 
a O 
natural O 
antioxidant O 
in O 
this O 
work O 
, O 
which O 
was O 
usually O 
taken O 
as O 
a O 
synthesized O 
antioxidant O 
. O 
Furthermore O 
, O 
the O 
novel O 
compound O 
exhibited O 
no O 
inhibitory O 
effects O 
against O 
tyrosinase O 
and O 
α-glucosidase O 
activities O 
. O 

and O 
synthesis O 
of O 
cyclopropylamide B-SYSTEMATIC 
analogues O 
of O 
combretastatin-A4 B-TRIVIAL 
as O 
novel O 
microtubule O 
- O 
stabilizing O 
agents O 
. O 

series O 
of O 
novel O 
cyclopropylamide B-SYSTEMATIC 
analogues O 
of O 
combretastatin-A4 B-TRIVIAL 
( O 
CA-4 B-ABBREVIATION 
) O 
were O 
designed O 
and O 
synthesized O 
. O 
Most O 
of O 
them O 
had O 
significant O 
in O 
vitro O 
antiproliferative O 
activities O 
, O 
particularly O 
for O 
compounds O 
7i4 O 
, O 
7c4 O 
, O 
8a4 O 
, O 
and O 
8c4 O 
. O 
Moreover O 
, O 
compound O 
8c4 O 
was O 
also O 
equally O 
potent O 
against O 
paclitaxel B-TRIVIAL 
resistant O 
cancer O 
cells O 
. O 
Interestingly O 
, O 
the O 
novel O 
cyclopropylamide B-SYSTEMATIC 
analogues O 
had O 
different O 
binding O 
mechanisms O 
from O 
CA-4 B-ABBREVIATION 
. O 
Instead O 
of O 
inhibiting O 
tubulin O 
polymerization O 
, O 
these O 
CA-4 B-ABBREVIATION 
derivatives O 
were O 
able O 
to O 
stimulate O 
tubulin O 
polymerization O 
. O 
Flow O 
cytometry O 
revealed O 
that O 
compound O 
8c4 O 
arrested O 
A549 O 
cancer O 
cells O 
in O 
the O 
G2 O 
/ O 
M O 
phase O 
and O 
resulted O 
in O 
cellular O 
apoptosis O 
. O 
Further O 
immunofluorescence O 
assays O 
revealed O 
that O 
compound O 
8c4 O 
induced O 
mitotic O 
arrest O 
in O 
A549 O 
cells O 
through O 
disrupting O 
microtubule O 
dynamics O 
. O 
In O 
addition O 
, O 
compound O 
8c4 O 
also O 
effectively O 
inhibited O 
the O 
tumor O 
growth O 
in O 
the O 
A549 O 
xenograft O 
model O 
without O 
causing O 
significant O 
loss O 
of O 
body O 
weight O 
. O 
Compound O 
8c4 O 
represents O 
a O 
novel O 
class O 
of O 
microtubule O 
- O 
stabilizing O 
agent O 
and O 
can O 
be O 
used O 
as O 
a O 
promising O 
lead O 
for O 
the O 
development O 
of O 
new O 
antitumor O 
agents O 
. O 

thermo O 
- O 
sensitive O 
pluronic B-FAMILY 
/ O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
in O 
situ O 
hydrogels O 
for O 
sustained O 
release O 
of O 
an O 
anticancer O 
drug O 
. O 

this O 
study O 
, O 
we O 
developed O 
oral O 
in O 
situ O 
gelling O 
formulations O 
composed O 
of O 
pluronic B-FAMILY 
( O 
Plu B-ABBREVIATION 
) O 
and O 
polyacrylic B-FAMILY 
acid I-FAMILY 
( O 
PAA B-ABBREVIATION 
) O 
for O 
the O 
delivery O 
of O 
an O 
anticancer O 
drug O 
, O 
epirubicin B-TRIVIAL 
( O 
Epi B-ABBREVIATION 
) O 
. O 
We O 
investigated O 
various O 
Plu B-ABBREVIATION 
/ O 
PAA B-ABBREVIATION 
/ O 
Epi B-ABBREVIATION 
formulations O 
for O 
their O 
physicochemical O 
properties O 
and O 
in O 
vitro O 
permeation O 
and O 
accumulation O 
, O 
as O 
well O 
as O 
for O 
in O 
vivo O 
pharmacokinetic O 
and O 
antitumor O 
efficacy O 
. O 
A O 
scanning O 
electron O 
microscopic O 
( O 
SEM O 
) O 
image O 
of O 
Plu B-ABBREVIATION 
14%/ O 
PAA B-ABBREVIATION 
0.75%/ O 
Epi B-ABBREVIATION 
hydrogel O 
showed O 
a O 
sponge O 
- O 
like O 
structure O 
. O 
This O 
formulation O 
has O 
suitable O 
gelation O 
time O 
, O 
water O 
content O 
, O 
bioadhesive O 
force O 
, O 
structural O 
stability O 
, O 
and O 
a O 
high O 
permeation O 
percentage O 
of O 
Epi B-ABBREVIATION 
, O 
with O 
sustained O 
drug O 
release O 
characteristics O 
for O 
96 O 
h O 
. O 
This O 
hydrogel O 
was O 
retained O 
at O 
the O 
end O 
of O 
the O 
ileum O 
near O 
the O 
colon O 
of O 
Sprague-Dawley O 
( O 
SD O 
) O 
rats O 
for O 
at O 
least O 
12 O 
h O 
. O 
An O 
in O 
vivo O 
pharmacokinetic O 
study O 
using O 
SD O 
rats O 
showed O 
that O 
after O 
oral O 
administration O 
in O 
this O 
formulation O 
, O 
Epi B-ABBREVIATION 
had O 
prolonged O 
half O 
- O 
life O 
, O 
greater O 
area O 
under O 
the O 
curve O 
, O 
and O 
higher O 
relative O 
bioavailability O 
than O 
in O 
an O 
oral O 
Epi B-ABBREVIATION 
solution O 
. O 
In O 
vivo O 
tumor O 
growth O 
inhibition O 
of O 
Epi B-ABBREVIATION 
in O 
this O 
formulation O 
was O 
more O 
pronounced O 
compared O 
with O 
oral O 
Epi B-ABBREVIATION 
and O 
intravenous O 
Epi B-ABBREVIATION 
solutions O 
in O 
CT-26 O 
mouse O 
colon O 
adenocarcinoma O 
bearing O 
Balb O 
/ O 
c O 
mice O 
. O 
This O 
study O 
highlights O 
the O 
advantages O 
of O 
using O 
oral O 
in O 
situ O 
temperature- O 
and O 
pH-sensitive O 
hydrogels O 
for O 
future O 
cancer O 
therapy O 
. O 

transplantation O 
is O 
an O 
attractive O 
strategy O 
to O 
treat O 
severe O 
diabetic O 
conditions O 
in O 
patients O 
suffering O 
from O 
autoimmune O 
derived O 
diabetes O 
, O 
and O 
it O 
has O 
currently O 
been O 
considered O 
a O 
forefront O 
research O 
arena O 
in O 
diabetes O 
. O 
Major O 
aim O 
of O 
islet O 
transplantation O 
is O 
to O 
achieve O 
successful O 
insulin O 
independent O 
disease O 
free O 
survival O 
. O 
The O 
key O 
challenges O 
in O 
transplanted O 
islets O 
are O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
associated O 
oxidative O 
stress O 
, O 
pro O 
- O 
inflammatory O 
cytokine O 
- O 
( O 
TNFα O 
) O 
mediated O 
apoptotic O 
induction O 
, O 
attack O 
by O 
immune O 
cells O 
, O 
and O 
achieving O 
revascularization O 
with O 
minimal O 
hypoxic O 
microenvironment O 
. O 
Free O 
radicals O 
and O 
their O 
derivatives O 
are O 
constantly O 
produced O 
in O 
living O 
systems O 
, O 
but O 
at O 
relatively O 
low O 
level O 
, O 
and O 
in O 
a O 
balanced O 
state O 
. O 
Oxidative O 
stress O 
, O 
which O 
occurs O 
as O 
a O 
result O 
of O 
an O 
imbalance O 
between O 
the O 
intracellular O 
free O 
radicals O 
production O 
and O 
the O 
cellular O 
antioxidant O 
defense O 
mechanisms O 
in O 
the O 
transplanted O 
islets O 
, O 
can O 
lead O 
to O 
cell O 
death O 
. O 
The O 
balance O 
between O 
oxidants O 
and O 
antioxidants O 
in O 
a O 
cell O 
can O 
be O 
easily O 
disturbed O 
by O 
increase O 
in O 
ROS O 
production O 
or O 
reduction O 
in O 
the O 
level O 
of O 
cellular O 
antioxidant O 
defensive O 
substances O 
, O 
which O 
can O 
cause O 
many O 
metabolic O 
complications O 
, O 
including O 
pancreatic O 
β-cell O 
damage O 
. O 
Antioxidants O 
function O 
as O 
blockers O 
of O 
radical O 
processes O 
by O 
eliminating O 
harmful O 
ROS O 
produced O 
during O 
normal O 
cellular O 
metabolism O 
. O 
A O 
complex O 
antioxidant O 
defense O 
mechanism O 
has O 
been O 
developed O 
by O 
nature O 
in O 
cells O 
to O 
protect O 
the O 
cellular O 
homeostasis O 
. O 
This O 
system O 
mainly O 
includes O 
antioxidant O 
enzymes O 
, O 
vitamins O 
and O 
minerals O 
. O 
As O 
transplanted O 
islet O 
survival O 
is O 
crucial O 
for O 
achieving O 
successful O 
therapy O 
, O 
most O 
of O 
these O 
antioxidants O 
can O 
be O 
used O 
as O 
a O 
supplement O 
to O 
scavenge O 
the O 
local O 
ROS O 
thereby O 
improving O 
the O 
survival O 
of O 
transplanted O 
islets O 
. O 
Currently O 
, O 
very O 
few O 
techniques O 
have O 
been O 
routinely O 
used O 
to O 
qualitatively O 
and O 
quantitatively O 
assess O 
the O 
survival O 
and O 
function O 
of O 
islet O 
grafts O 
, O 
especially O 
to O 
confirm O 
the O 
success O 
of O 
treatment O 
, O 
which O 
includes O 
metabolic O 
parameters O 
such O 
as O 
blood O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
C- O 
peptide O 
levels O 
. O 
These O 
biochemical O 
measurements O 
provide O 
markers O 
at O 
only O 
the O 
late O 
stages O 
of O 
islet O 
rejection O 
. O 
Use O 
of O 
molecular O 
imaging O 
techniques O 
has O 
the O 
potential O 
for O 
real O 
- O 
time O 
non-invasive O 
monitoring O 
of O 
the O 
functional O 
status O 
and O 
viability O 
of O 
transplanted O 
islet O 
grafts O 
in O 
living O 
animals O 
. O 
This O 
review O 
mainly O 
focuses O 
on O 
the O 
current O 
status O 
of O 
islet O 
transplantations O 
, O 
potential O 
preventive O 
strategies O 
used O 
to O 
reduce O 
oxidative O 
stress O 
- O 
mediated O 
toxicity O 
in O 
islet O 
grafts O 
, O 
and O 
use O 
of O 
molecular O 
imaging O 
as O 
a O 
tool O 
to O 
quantitatively O 
evaluate O 
the O 
functional O 
status O 
of O 
the O 
transplanted O 
islets O 
in O 
living O 
animals O 
. O 

of O 
terpenes B-FAMILY 
on O 
fibroblast O 
cells O 
compared O 
to O 
their O 
hemolytic O 
potential O 
and O 
increase O 
in O 
erythrocyte O 
membrane O 
fluidity O 
. O 

are O 
considered O 
potent O 
skin O 
permeation O 
enhancers O 
with O 
low O 
toxicity O 
. O 
Electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
spectroscopy O 
of O 
the O 
spin O 
label O 
5-doxyl B-SYSTEMATIC 
stearic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
5-DSA B-SYSTEMATIC 
) O 
was O 
used O 
to O 
monitor O 
the O 
effect O 
of O 
sesquiterpene B-FAMILY 
nerolidol B-TRIVIAL 
and O 
various O 
monoterpenes B-FAMILY 
on O 
membrane O 
fluidity O 
in O 
erythrocyte O 
and O 
fibroblast O 
cells O 
. O 
In O 
addition O 
, O 
the O 
hemolytic O 
levels O 
and O 
cytotoxic O 
effects O 
on O 
cultured O 
fibroblast O 
cells O 
were O 
also O 
measured O 
to O 
investigate O 
possible O 
relationships O 
between O 
the O 
cellular O 
irritation O 
potentials O 
of O 
terpenes B-FAMILY 
and O 
the O 
ability O 
to O 
modify O 
membrane O 
fluidity O 
. O 
All O 
terpenes B-FAMILY 
increased O 
cell O 
membrane O 
fluidity O 
with O 
no O 
significant O 
differences O 
between O 
the O 
monoterpenes B-FAMILY 
, O 
but O 
the O 
effect O 
of O 
sesquiterpene B-FAMILY 
was O 
significantly O 
greater O 
than O 
that O 
of O 
the O 
monoterpenes B-FAMILY 
. O 
The O 
IC(50) O 
values O 
for O 
the O 
terpenes B-FAMILY 
in O 
the O 
cytotoxicity O 
assay O 
indicated O 
that O 
1,8-cineole B-SYSTEMATIC 
showed O 
lower O 
cytotoxicity O 
and O 
α-terpineol B-TRIVIAL 
and O 
nerolidol B-TRIVIAL 
showed O 
higher O 
cytotoxicity O 
. O 
The O 
correlation O 
between O 
the O 
hemolytic O 
effect O 
and O 
the O 
IC(50) O 
values O 
for O 
fibroblast O 
viability O 
was O 
low O 
( O 
R=0.61 O 
) O 
; O 
however O 
, O 
in O 
both O 
tests O 
, O 
nerolidol B-TRIVIAL 
was O 
among O 
the O 
most O 
aggressive O 
of O 
terpenes B-FAMILY 
and O 
1,8-cineole B-SYSTEMATIC 
was O 
among O 
the O 
least O 
aggressive O 
. O 
Obtaining O 
information O 
concerning O 
the O 
toxicity O 
and O 
potency O 
of O 
terpenes B-FAMILY 
could O 
aid O 
in O 
the O 
design O 
of O 
topical O 
formulations O 
optimized O 
to O 
facilitate O 
drug O 
absorption O 
for O 
the O 
treatment O 
of O 
many O 
skin O 
diseases O 
. O 

methanol B-SYSTEMATIC 
extract O 
of O 
the O 
tubers O 
of O 
Polygonum O 
perfoliatum O 
L O 
. O 
afforded O 
a O 
new O 
lignan B-FAMILY 
: O 
8-oxo- B-SYSTEMATIC 
pinoresinol I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
and O 
five O 
known O 
compounds O 
3',5-dihydroxy-3,4',5',7-tetramethoxy-flavone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
catechin B-TRIVIAL 
( O 
3 O 
) O 
, O 
quercetin B-TRIVIAL 
( O 
4 O 
) O 
, O 
quercetin-3-O-β-D-glucuronide B-SYSTEMATIC 
( O 
5 O 
) O 
and O 
rutin B-TRIVIAL 
( O 
6 O 
) O 
. O 
Their O 
structures O 
were O 
established O 
by O 
MS O 
, O 
one- O 
and O 
two O 
- O 
dimensional O 
NMR O 
experiments O 
. O 
Compound O 
1 O 
showed O 
cytotoxicity O 
against O 
human O 
mammary O 
carcinoma O 
( O 
Bcap-37 O 
) O 
, O 
human O 
colon O 
carcinoma O 
( O 
RKO O 
) O 
, O 
human O 
hepatocellular O 
carcinoma O 
( O 
SMMC-7721 O 
) O 
, O 
human O 
prostate O 
carcinoma O 
( O 
PC3 O 
) O 
and O 
human O 
erythroleukaemia O 
( O 
K562 O 
) O 
cells O 
. O 

-mediated O 
changes O 
in O 
adipose O 
triacylglycerol B-FAMILY 
metabolism O 
are O 
exaggerated O 
, O 
not O 
diminished O 
, O 
in O 
the O 
absence O 
of O 
a O 
functional O 
GR O 
dimerization O 
domain O 
. O 

glucocorticoid O 
( O 
GC O 
) O 
receptor O 
( O 
GR O 
) O 
has O 
multiple O 
effector O 
mechanisms O 
, O 
including O 
dimerization O 
- O 
mediated O 
transactivation O 
of O 
target O 
genes O 
via O 
DNA O 
binding O 
and O 
transcriptional O 
repression O 
mediated O 
by O 
protein O 
- O 
protein O 
interactions O 
. O 
Much O 
attention O 
has O 
been O 
focused O 
on O 
developing O 
selective O 
GR O 
modulators O 
that O 
would O 
dissociate O 
adverse O 
effects O 
from O 
therapeutic O 
anti-inflammatory O 
effects O 
. O 
The O 
GR(dim O 
/ O 
dim O 
) O 
mouse O 
has O 
a O 
mutation O 
in O 
the O 
dimerization O 
domain O 
of O 
GR O 
and O 
has O 
been O 
shown O 
to O 
have O 
attenuated O 
transactivation O 
with O 
intact O 
repression O 
. O 
To O 
understand O 
the O 
role O 
of O 
GR O 
dimerization O 
- O 
dependent O 
targets O 
in O 
multiple O 
tissues O 
, O 
we O 
measured O 
metabolic O 
fluxes O 
through O 
several O 
disease O 
- O 
relevant O 
GC O 
target O 
pathways O 
using O 
heavy O 
water O 
labeling O 
and O 
mass O 
spectrometry O 
in O 
wild O 
- O 
type O 
and O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
administered O 
the O 
potent O 
GC O 
dexamethasone B-TRIVIAL 
( O 
DEX B-ABBREVIATION 
) O 
. O 
Absolute O 
triglyceride B-FAMILY 
synthesis O 
was O 
increased O 
in O 
both O 
wild O 
- O 
type O 
and O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
by O 
DEX B-ABBREVIATION 
in O 
the O 
inguinal O 
and O 
epididymal O 
fat O 
depots O 
. O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
showed O 
an O 
exaggerated O 
response O 
to O 
DEX B-ABBREVIATION 
in O 
both O 
depots O 
. O 
De O 
novo O 
lipogenesis O 
was O 
also O 
greatly O 
increased O 
in O 
both O 
depots O 
in O 
response O 
to O 
DEX B-ABBREVIATION 
in O 
GR(dim O 
/ O 
dim O 
) O 
, O 
but O 
not O 
wild O 
- O 
type O 
mice O 
. O 
In O 
contrast O 
, O 
the O 
inhibitory O 
effect O 
of O 
DEX B-ABBREVIATION 
on O 
bone O 
and O 
skin O 
collagen O 
synthesis O 
rates O 
was O 
greater O 
in O 
wild O 
- O 
type O 
compared O 
with O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
. O 
Wild O 
- O 
type O 
mice O 
were O 
more O 
sensitive O 
to O 
DEX B-ABBREVIATION 
-dependent O 
decreases O 
in O 
insulin O 
sensitivity O 
than O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
. O 
Wild O 
- O 
type O 
and O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
were O 
equally O 
sensitive O 
to O 
DEX B-ABBREVIATION 
-dependent O 
decreases O 
in O 
muscle O 
protein O 
synthesis O 
. O 
Chronic O 
elevation O 
of O 
GCs O 
in O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
results O 
in O 
severe O 
runting O 
and O 
lethality O 
. O 
In O 
conclusion O 
, O 
some O 
metabolic O 
effects O 
of O 
GC O 
treatment O 
are O 
exaggerated O 
in O 
adipose O 
tissue O 
of O 
GR(dim O 
/ O 
dim O 
) O 
mice O 
, O 
suggesting O 
that O 
selective O 
GR O 
modulators O 
based O 
on O 
dissociating O 
GR O 
transactivation O 
from O 
repression O 
should O 
be O 
evaluated O 
carefully O 
. O 

of O 
a O 
new O 
series O 
of O 
[1,2,4]triazolo[4,3-a]quinoxalines B-FAMILY 
as O 
dual O 
phosphodiesterase O 
2 O 
/ O 
phosphodiesterase O 
10 O 
( O 
PDE2 O 
/ O 
PDE10 O 
) O 
inhibitors O 
. O 

synthesis O 
, O 
preliminary O 
evaluation O 
and O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
of O 
a O 
series O 
of O 
1-aryl-4-methyl[1,2,4]triazolo[4,3-a]quinoxalines B-FAMILY 
as O 
dual O 
phosphodiesterase O 
2 O 
/ O 
phosphodiesterase O 
10 O 
( O 
PDE2 O 
/ O 
PDE10 O 
) O 
inhibitors O 
are O 
described O 
. O 
From O 
this O 
investigation O 
compound O 
31 O 
was O 
identified O 
, O 
showing O 
good O 
combined O 
potency O 
, O 
acceptable O 
brain O 
uptake O 
and O 
high O 
selectivity O 
for O 
both O 
PDE2 O 
and O 
PDE10 O 
enzymes O 
. O 
Compound O 
31 O 
was O 
subjected O 
to O 
a O 
microdosing O 
experiment O 
in O 
rats O 
, O 
showing O 
preferential O 
distribution O 
in O 
brain O 
areas O 
where O 
both O 
PDE2 O 
and O 
PDE10 O 
are O 
highly O 
expressed O 
. O 
These O 
promising O 
results O 
may O 
drive O 
the O 
further O 
development O 
of O 
highly O 
potent O 
combined O 
PDE2 O 
/ O 
PDE10 O 
inhibitors O 
, O 
or O 
even O 
of O 
selective O 
inhibitors O 
of O 
PDE2 O 
and O 
/ O 
or O 
PDE10 O 
. O 

Modified O 
Poly(ethylene B-FAMILY 
imine I-FAMILY 
) I-FAMILY 
Glycopolymers O 
: O 
Physicochemical O 
Properties O 
and O 
First O 
In O 
Vitro O 
Study O 
of O 
Polyplexes O 
Formed O 
with O 
HIV O 
- O 
Derived O 
Peptides O 
. O 

delivery O 
entities O 
are O 
desirable O 
in O 
immunotherapies O 
in O 
which O 
polyplexes O 
are O 
widely O 
formed O 
by O 
electrostatic O 
interactions O 
to O 
induce O 
cellular O 
uptake O 
processes O 
for O 
bioactive O 
molecules O 
. O 
In O 
our O 
study O 
, O 
biocompatible O 
Ni(II)-nitrilo(triacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
-modified O 
poly(ethylene B-FAMILY 
imine)-maltose I-FAMILY 
( O 
Ni-NTA-DG B-FORMULA 
) O 
is O 
realized O 
and O 
evaluated O 
as O 
complexation O 
agent O 
against O 
His B-FORMULA 
-tagged O 
peptides O 
using O 
fluorescence O 
polarization O 
and O 
dynamic O 
light O 
scattering O 
. O 
The O 
polyplexes O 
are O 
stable O 
until O 
a O 
pH O 
of O 
6.5-6.0 O 
, O 
and O 
also O 
up O 
to O 
50 O 
mM O 
of O 
imidazole B-SYSTEMATIC 
. O 
A O 
first O 
uptake O 
approach O 
shows O 
that O 
polyplexes O 
lead O 
to O 
an O 
increase O 
in O 
peptide O 
uptake O 
in O 
monocyte O 
- O 
derived O 
immature O 
dendritic O 
cells O 
. O 
In O 
summary O 
, O 
Ni-NTA-DG B-FORMULA 
represents O 
a O 
promising O 
( O 
delivery O 
) O 
platform O 
for O 
forthcoming O 
in O 
vitro O 
applications O 
. O 

study O 
proposes O 
an O 
investigation O 
strategy O 
to O 
identify O 
sensitive O 
, O 
robust O 
and O 
reliable O 
chemical O 
markers O 
of O 
hazelnut O 
roasting O 
. O 
A O 
fully O 
- O 
automated O 
and O 
validated O 
analytical O 
method O 
, O 
based O 
on O 
Headspace O 
Solid O 
Phase O 
Microextraction O 
( O 
HS-SPME O 
) O 
coupled O 
with O 
Gas O 
Chromatography-Mass O 
Spectrometric O 
detection O 
( O 
GC-MS O 
) O 
, O 
for O 
effective O 
off O 
- O 
line O 
monitoring O 
of O 
changes O 
in O 
the O 
volatile O 
profile O 
of O 
high O 
- O 
quality O 
hazelnuts O 
was O 
developed O 
. O 
Samples O 
from O 
two O 
different O 
harvests O 
were O 
submitted O 
to O 
roasting O 
, O 
following O 
different O 
time O 
/ O 
temperature O 
protocols O 
and O 
different O 
technologies O 
, O 
enabling O 
chemical O 
changes O 
to O 
be O 
correlated O 
with O 
technological O 
processing O 
and O 
sensory O 
quality O 
. O 
Chemical O 
indices O 
, O 
expressed O 
as O 
analyte O 
response O 
ratio O 
, O 
were O 
defined O 
and O 
their O 
trend O 
observed O 
across O 
roasting O 
profiles O 
. O 
Reliability O 
and O 
robustness O 
of O 
chemical O 
indices O 
were O 
also O 
evaluated O 
, O 
in O 
view O 
of O 
their O 
application O 
to O 
on O 
- O 
line O 
monitoring O 
with O 
Mass O 
Spectrometry O 
- O 
based O 
electronic O 
nose O 
technology O 
( O 
MS-nose O 
) O 
. O 
Experiments O 
, O 
simulating O 
on O 
- O 
line O 
chemical O 
characterisation O 
of O 
the O 
volatile O 
fraction O 
, O 
were O 
performed O 
through O 
a O 
fully O 
- O 
automated O 
system O 
. O 
The O 
results O 
confirmed O 
: O 
( O 
a O 
) O 
the O 
effectiveness O 
of O 
single O 
process O 
indicators O 
of O 
roasting O 
selected O 
by O 
the O 
separative O 
method O 
( O 
5-methylfurfural B-SYSTEMATIC 
, O 
1(H)-pyrrole B-SYSTEMATIC 
, O 
furfuryl B-TRIVIAL 
alcohol I-TRIVIAL 
, O 
1(H)-pyrrole-2-carboxaldehyde B-SYSTEMATIC 
, O 
1-hydroxy-2-propanone B-SYSTEMATIC 
, O 
dihydro-2(3H)-furanone B-SYSTEMATIC 
, O 
5-methyl-(E)-2-hepten-4-one B-SYSTEMATIC 
, O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
pyridine B-SYSTEMATIC 
, O 
furfural B-TRIVIAL 
, O 
pyrazine B-SYSTEMATIC 
, O 
and O 
several O 
alkyl-pyrazines B-FAMILY 
) O 
; O 
and O 
, O 
( O 
b O 
) O 
the O 
reliability O 
of O 
proposed O 
chemical O 
indices O 
: O 
5-methylfurfural B-SYSTEMATIC 
/ O 
2,5-dimethylpyrazine B-SYSTEMATIC 
, O 
5-methylfurfural B-SYSTEMATIC 
/ O 
2-methylpyrazine B-SYSTEMATIC 
, O 
2,5-dimethylpyrazine B-SYSTEMATIC 
/ O 
2,3-dimethylpyrazine B-SYSTEMATIC 
; O 
these O 
maintained O 
a O 
consistent O 
trend O 
versus O 
harvest O 
and O 
sampling O 
/ O 
analysis O 
technology O 
. O 

RELEVANCE O 
: O 
Five O 
herbs O 
, O 
Curcuma O 
longa O 
L O 
. O 
( O 
CL O 
) O 
, O 
Scutellaria O 
baicalensis O 
Georgi O 
( O 
SBC O 
) O 
, O 
Scutellaria O 
barbata O 
D O 
. O 
Don O 
( O 
SBB O 
) O 
, O 
Hedyotis O 
diffusa O 
Willd O 
. O 
( O 
HD O 
) O 
and O 
Solanum O 
nigrum O 
L O 
. O 
( O 
SN O 
) O 
, O 
are O 
often O 
prescribed O 
in O 
the O 
polyherbal O 
formulas O 
for O 
cancer O 
treatment O 
by O 
traditional O 
Chinese O 
medicine O 
( O 
TCM O 
) O 
practitioners O 
. O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
identify O 
important O 
anticancer O 
herbs O 
used O 
in O 
TCM O 
and O 
carry O 
out O 
bioactivity O 
- O 
directed O 
fractionation O 
and O 
isolation O 
( O 
BDFI O 
) O 
using O 
six O 
cancer O 
cell O 
lines O 
as O 
well O 
as O 
peripheral O 
blood O 
mononuclear O 
cells O 
( O 
PBMCs O 
) O 
, O 
to O 
identify O 
constituents O 
with O 
anticancer O 
activity O 
but O 
devoid O 
of O 
toxic O 
effects O 
against O 
healthy O 
immune O 
cells O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Of O 
243 O 
document O 
anticancer O 
TCM O 
treatments O 
, O 
199 O 
anticancer O 
TCM O 
herbs O 
were O 
ranked O 
by O 
the O 
number O 
of O 
literature O 
reports O 
for O 
each O 
herb O 
. O 
Five O 
herbs O 
were O 
identified O 
from O 
the O 
top O 
50 O 
ranked O 
herbs O 
by O 
at O 
least O 
two O 
out O 
of O 
three O 
TCM O 
practitioners O 
as O 
frequently O 
used O 
in O 
the O 
TCM O 
treatment O 
of O 
cancer O 
. O 
BDFI O 
using O 
MTS B-ABBREVIATION 
assay O 
was O 
applied O 
to O 
determine O 
the O 
active O 
anticancer O 
extracts O 
, O 
fractions O 
, O 
and O 
finally O 
discrete O 
compounds O 
. O 
RESULTS O 
: O 
Five O 
herbs O 
were O 
selected O 
for O 
study O 
of O 
their O 
anticancer O 
activities O 
. O 
The O 
extracts O 
of O 
Curcuma O 
longa O 
L O 
. O 
, O 
Scutellaria O 
barbata O 
D O 
. O 
Don O 
, O 
and O 
Hedyotis O 
diffusa O 
showed O 
antiproliferative O 
activity O 
to O 
various O 
extents O 
, O 
extracts O 
of O 
Scutellaria O 
baicalensis O 
Georgi O 
and O 
Solanum O 
nigrum O 
L O 
. O 
showed O 
little O 
anticancer O 
activity O 
. O 
Seven O 
out O 
of O 
the O 
21 O 
fractions O 
obtained O 
from O 
Hedyotis O 
diffusa O 
showed O 
anticancer O 
activity O 
. O 
One O 
new O 
compound O 
, O 
ethyl B-SYSTEMATIC 
13(2) I-SYSTEMATIC 
(S)-hydroxy-chlorophyllide I-SYSTEMATIC 
a I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
along O 
with O 
10 O 
known O 
compounds O 
, O 
i.e O 
. O 
2-methyl-3-methoxyanthraquinone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
2-hydroxymethylanthraquinone B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
2-hydroxy-3-methylanthraquinone B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
2-hydroxymethy-1-hydroxyanthraquinone B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
1-methoxy-2-hydroxyanthraquinone B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
2-hydroxy-3-methyl-1-methoxyanthraquinone B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
8 O 
) O 
, O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
9 O 
) O 
, O 
stigmasterol B-TRIVIAL 
( O 
10 O 
) O 
and O 
docosanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
11 O 
) O 
, O 
were O 
isolated O 
and O 
identified O 
. O 
Compounds O 
2-6 O 
, O 
8 O 
and O 
9 O 
dose O 
- O 
dependently O 
inhibited O 
the O 
cell O 
viability O 
of O 
cancer O 
cells O 
within O 
a O 
concentration O 
range O 
of O 
1-200µM O 
. O 
Furthermore O 
, O 
compounds O 
2 O 
, O 
3 O 
, O 
5 O 
and O 
9 O 
showed O 
significantly O 
stronger O 
inhibition O 
of O 
tested O 
cancer O 
cell O 
lines O 
than O 
on O 
that O 
of O 
PBMCs O 
. O 
CONCLUSION O 
: O 
This O 
study O 
identified O 
anticancer O 
herbs O 
, O 
extracts O 
, O 
fractions O 
and O 
eventually O 
compounds O 
from O 
the O 
documented O 
anticancer O 
TCM O 
herbs O 
by O 
using O 
BDFI O 
. O 
It O 
also O 
determined O 
the O 
antiproliferative O 
activity O 
in O 
cancer O 
and O 
healthy O 
immune O 
cells O 
of O 
the O 
isolated O 
compounds O 
from O 
Hedyotis O 
diffusa O 
. O 
The O 
results O 
will O 
be O 
useful O 
in O 
the O 
validation O 
of O 
the O 
clinical O 
application O 
of O 
these O 
herbs O 
and O 
the O 
development O 
of O 
novel O 
anticancer O 
therapeutics O 
. O 

behavior O 
of O 
malonic B-TRIVIAL 
acid I-TRIVIAL 
adsorption O 
at O 
the O 
air O 
/ O 
water O 
interface O 
. O 

presence O 
of O 
organic O 
materials O 
adsorbed O 
to O 
the O 
surfaces O 
of O 
aerosol O 
particles O 
has O 
been O 
demonstrated O 
to O 
be O 
a O 
determining O 
factor O 
in O 
relevant O 
atmospheric O 
processes O 
. O 
Malonic B-TRIVIAL 
acid I-TRIVIAL 
is O 
a O 
small O 
, O 
water O 
- O 
soluble O 
organic O 
acid O 
that O 
is O 
common O 
in O 
aerosols O 
and O 
is O 
surface O 
- O 
active O 
. O 
A O 
comprehensive O 
investigation O 
of O 
the O 
adsorption O 
of O 
malonic B-TRIVIAL 
acid I-TRIVIAL 
to O 
the O 
air O 
/ O 
water O 
interface O 
was O 
accomplished O 
using O 
vibrational O 
sum O 
frequency O 
spectroscopy O 
( O 
VSFS O 
) O 
and O 
surface O 
tension O 
measurements O 
as O 
functions O 
of O 
concentration O 
and O 
pH O 
. O 
Malonic B-TRIVIAL 
acid I-TRIVIAL 
was O 
found O 
to O 
be O 
weakly O 
solvated O 
at O 
the O 
air O 
/ O 
water O 
interface O 
, O 
and O 
its O 
orientation O 
as O 
a O 
function O 
of O 
concentration O 
was O 
explored O 
through O 
different O 
VSFS O 
polarization O 
schemes O 
. O 
pH-dependent O 
experiments O 
revealed O 
that O 
the O 
surface O 
- O 
active O 
species O 
is O 
the O 
fully O 
protonated O 
species O 
. O 
Computational O 
analyses O 
were O 
used O 
to O 
obtain O 
depth O 
- O 
specific O 
geometries O 
of O 
malonic B-TRIVIAL 
acid I-TRIVIAL 
at O 
the O 
air O 
/ O 
water O 
interface O 
that O 
confirm O 
and O 
enrich O 
the O 
experimental O 
results O 
. O 

impressive O 
specific O 
capacitance O 
and O 
high O 
- O 
rate O 
performance O 
reported O 
for O 
many O 
nanometric O 
charge O 
- O 
storing O 
films O 
on O 
planar O 
substrates O 
cannot O 
impact O 
a O 
technology O 
space O 
beyond O 
microdevices O 
unless O 
such O 
performance O 
translates O 
into O 
a O 
macroscale O 
form O 
factor O 
. O 
In O 
this O 
report O 
, O 
we O 
explore O 
how O 
the O 
nanoscale O 
- O 
to O 
- O 
macroscale O 
properties O 
of O 
the O 
electrode O 
architecture O 
( O 
pore O 
size O 
/ O 
distribution O 
, O 
void O 
volume O 
, O 
thickness O 
) O 
define O 
energy O 
and O 
power O 
performance O 
when O 
scaled O 
to O 
technologically O 
relevant O 
dimensions O 
. O 
Our O 
test O 
bed O 
is O 
a O 
device O 
- O 
ready O 
electrode O 
architecture O 
in O 
which O 
scalable O 
, O 
manufacturable O 
carbon B-SYSTEMATIC 
nanofoam O 
papers O 
with O 
tunable O 
pore O 
sizes O 
( O 
5-200 O 
nm O 
) O 
and O 
thickness O 
( O 
100-300 O 
μm O 
) O 
are O 
painted O 
with O 
~10 O 
nm O 
coatings O 
of O 
manganese B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
MnOx B-FORMULA 
) O 
. O 
The O 
quantity O 
of O 
capacitance O 
and O 
the O 
rate O 
at O 
which O 
it O 
is O 
delivered O 
for O 
four O 
different O 
MnOx B-FORMULA 
- O 
C B-FORMULA 
variants O 
was O 
assessed O 
by O 
fabricating O 
symmetric O 
electrochemical O 
capacitors O 
using O 
a O 
concentrated O 
aqueous O 
electrolyte O 
. O 
Carbon B-SYSTEMATIC 
nanofoam O 
papers O 
containing O 
primarily O 
10-20 O 
nm O 
mesopores O 
support O 
high O 
MnOx B-FORMULA 
loadings O 
( O 
60 O 
wt% O 
) O 
and O 
device O 
- O 
level O 
capacitance O 
( O 
30 O 
F O 
g(-1) O 
) O 
, O 
but O 
the O 
small O 
mesoporous O 
network O 
hinders O 
electrolyte O 
transport O 
and O 
the O 
low O 
void O 
volume O 
restricts O 
the O 
quantity O 
of O 
charge O 
- O 
compensating O 
ions O 
within O 
the O 
electrode O 
, O 
making O 
the O 
full O 
capacitance O 
only O 
accessible O 
at O 
slow O 
rates O 
( O 
5 O 
mV O 
s(-1) O 
) O 
. O 
Carbon B-SYSTEMATIC 
nanofoam O 
papers O 
with O 
macropores O 
( O 
100-200 O 
nm O 
) O 
facilitate O 
high O 
rate O 
operation O 
( O 
50 O 
mV O 
s(-1) O 
) O 
, O 
but O 
deliver O 
significantly O 
lower O 
device O 
capacitance O 
( O 
13 O 
F O 
g(-1) O 
) O 
as O 
a O 
result O 
of O 
lower O 
MnOx B-FORMULA 
loadings O 
( O 
41 O 
wt% O 
) O 
. O 
Devices O 
comprising O 
MnOx B-FORMULA 
- O 
carbon B-SYSTEMATIC 
nanofoams O 
with O 
interconnecting O 
networks O 
of O 
meso- O 
and O 
macropores O 
balance O 
capacitance O 
and O 
rate O 
performance O 
, O 
delivering O 
33 O 
F O 
g(-1) O 
at O 
5 O 
mV O 
s(-1) O 
and O 
23 O 
F O 
g(-1) O 
at O 
50 O 
mV O 
s(-1) O 
. O 
The O 
use O 
of O 
carbon B-SYSTEMATIC 
nanofoam O 
papers O 
with O 
size O 
- O 
tunable O 
pore O 
structures O 
and O 
thickness O 
provides O 
the O 
opportunity O 
to O 
engineer O 
the O 
electrode O 
architecture O 
to O 
deliver O 
scalable O 
quantities O 
of O 
capacitance O 
( O 
F O 
cm(-2) O 
) O 
in O 
tens O 
of O 
seconds O 
with O 
a O 
single O 
device O 
. O 

association O 
of O 
serum O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
and O 
vertebral O 
fractures O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 

D I-FAMILY 
is O 
an O 
important O 
regulator O 
of O 
bone O 
health O 
. O 
Previous O 
studies O 
examining O 
the O 
association O 
between O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
and O 
osteoporotic O 
fractures O 
have O 
reported O 
conflicting O 
results O 
. O 
The O 
relationship O 
between O 
vitamin B-FAMILY 
D I-FAMILY 
status O 
and O 
risk O 
of O 
vertebral O 
fractures O 
in O 
diabetic O 
patients O 
is O 
unknown O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
examine O 
whether O 
low O 
serum O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
[ O 
25(OH)D B-SYSTEMATIC 
] O 
levels O 
were O 
associated O 
with O 
vertebral O 
fractures O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 
This O 
cross O 
- O 
sectional O 
study O 
was O 
conducted O 
among O 
161 O 
postmenopausal O 
women O 
and O 
180 O 
men O 
with O 
type O 
2 O 
diabetes O 
. O 
Serum O 
concentrations O 
of O 
25(OH)D B-SYSTEMATIC 
were O 
measured O 
and O 
the O 
presence O 
of O 
vertebral O 
fracture O 
was O 
assessed O 
using O 
lateral O 
plain O 
radiographs O 
of O 
the O 
thoracolumbar O 
spine O 
. O 
Women O 
had O 
lower O 
25(OH)D B-SYSTEMATIC 
levels O 
than O 
men O 
( O 
31.3 O 
± O 
17.7 O 
vs O 
. O 
41.3 O 
± O 
26.5 O 
ng O 
/ O 
mL O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Vertebral O 
fractures O 
were O 
found O 
in O 
16% O 
of O 
patients O 
. O 
Men O 
with O 
a O 
serum O 
25(OH)D B-SYSTEMATIC 
concentration O 
greater O 
than O 
30 O 
ng O 
/ O 
mL O 
showed O 
a O 
lower O 
prevalence O 
of O 
vertebral O 
fractures O 
compared O 
to O 
those O 
with O 
20-29.9 O 
ng O 
/ O 
mL O 
or O 
those O 
with O 
less O 
than O 
20 O 
ng O 
/ O 
mL O 
( O 
9.4% O 
vs O 
. O 
17.9% O 
vs O 
. O 
21.7% O 
, O 
p O 
for O 
trend=0.036 O 
) O 
. O 
However O 
, O 
there O 
was O 
no O 
significant O 
association O 
between O 
vitamin B-FAMILY 
D I-FAMILY 
status O 
and O 
the O 
prevalence O 
of O 
vertebral O 
fractures O 
in O 
women O 
( O 
14.4% O 
vs O 
. O 
19.2% O 
vs O 
. O 
26.6% O 
, O 
p O 
for O 
trend=0.111 O 
) O 
. O 
After O 
adjusting O 
for O 
multiple O 
confounding O 
factors O 
, O 
men O 
with O 
a O 
serum O 
25(OH)D B-SYSTEMATIC 
concentration O 
of O 
less O 
than O 
20 O 
ng O 
/ O 
mL O 
were O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
vertebral O 
fractures O 
( O 
OR O 
7.87 O 
; O 
95% O 
CI O 
1.69-36.71 O 
) O 
, O 
but O 
not O 
women O 
. O 
In O 
conclusion O 
, O 
serum O 
25(OH)D B-SYSTEMATIC 
levels O 
below O 
20 O 
ng O 
/ O 
mL O 
were O 
associated O 
with O 
an O 
increased O 
vertebral O 
fracture O 
risk O 
in O 
men O 
with O 
type O 
2 O 
diabetes O 
. O 

synthase O 
: O 
a O 
molecular O 
therapeutic O 
drug O 
target O 
for O 
antimicrobial O 
and O 
antitumor O 
peptides O 
. O 

this O 
review O 
we O 
discuss O 
the O 
role O 
of O 
ATP B-ABBREVIATION 
synthase O 
as O 
a O 
molecular O 
drug O 
target O 
for O 
natural O 
and O 
synthetic O 
antimicrobial/ O 
antitumor O 
peptides O 
. O 
We O 
start O 
with O 
an O 
introduction O 
of O 
the O 
universal O 
nature O 
of O 
the O 
ATP B-ABBREVIATION 
synthase O 
enzyme O 
and O 
its O 
role O 
as O 
a O 
biological O 
nanomotor O 
. O 
Significant O 
structural O 
features O 
required O 
for O 
catalytic O 
activity O 
and O 
motor O 
functions O 
of O 
ATP B-ABBREVIATION 
synthase O 
are O 
described O 
. O 
Relevant O 
details O 
regarding O 
the O 
presence O 
of O 
ATP B-ABBREVIATION 
synthase O 
on O 
the O 
surface O 
of O 
several O 
animal O 
cell O 
types O 
, O 
where O 
it O 
is O 
associated O 
with O 
multiple O 
cellular O 
processes O 
making O 
it O 
a O 
potential O 
drug O 
target O 
with O 
respect O 
to O 
antimicrobial O 
peptides O 
and O 
other O 
inhibitors O 
such O 
as O 
dietary O 
polyphenols B-FAMILY 
, O 
is O 
also O 
reviewed O 
. O 
ATP B-ABBREVIATION 
synthase O 
is O 
known O 
to O 
have O 
about O 
twelve O 
discrete O 
inhibitor O 
binding O 
sites O 
including O 
peptides O 
and O 
other O 
inhibitors O 
located O 
at O 
the O 
interface O 
of O 
α O 
/ O 
β O 
subunits O 
on O 
the O 
F1 O 
sector O 
of O 
the O 
enzyme O 
. O 
Molecular O 
interaction O 
of O 
peptides O 
at O 
the O 
β O 
DEELSEED O 
site O 
on O 
ATP B-ABBREVIATION 
synthase O 
is O 
discussed O 
with O 
specific O 
examples O 
. O 
An O 
inhibitory O 
effect O 
of O 
other O 
natural O 
/ O 
synthetic O 
inhibitors O 
on O 
ATP B-ABBREVIATION 
is O 
highlighted O 
to O 
explore O 
the O 
therapeutic O 
roles O 
played O 
by O 
peptides O 
and O 
other O 
inhibitors O 
. O 
Lastly O 
, O 
the O 
effect O 
of O 
peptides O 
on O 
the O 
inhibition O 
of O 
the O 
Escherichia O 
coli O 
model O 
system O 
through O 
their O 
action O 
on O 
ATP B-ABBREVIATION 
synthase O 
is O 
presented O 
. O 

new O 
method O 
for O 
the O 
detection O 
of O 
alternariol B-TRIVIAL 
( O 
AOH B-FORMULA 
) O 
, O 
alternariol B-SYSTEMATIC 
monomethyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
AME B-ABBREVIATION 
) O 
, O 
altenuene B-TRIVIAL 
( O 
ALT B-ABBREVIATION 
) O 
, O 
tentoxin B-TRIVIAL 
( O 
TEN B-ABBREVIATION 
) O 
, O 
and O 
tenuazonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
TeA B-ABBREVIATION 
) O 
, O 
five O 
alternaria O 
toxins O 
( O 
ATs O 
) O 
was O 
developed O 
by O 
liquid O 
chromatography O 
- O 
triple O 
quadrupole O 
mass O 
spectrometry O 
equipped O 
with O 
atmospheric O 
pressure O 
chemical O 
ionisation O 
( O 
APCI O 
) O 
. O 
A O 
single O 
extraction O 
was O 
used O 
to O 
recover O 
the O 
five O 
ATs O 
by O 
apple O 
juices O 
, O 
beers O 
, O 
tomato O 
sauces O 
, O 
olives O 
and O 
dried O 
basil O 
. O 
Different O 
Solid O 
Phase O 
Extractions O 
( O 
SPE O 
) O 
and O 
clean O 
- O 
up O 
were O 
selected O 
to O 
optimise O 
the O 
purification O 
step O 
for O 
each O 
food O 
matrix O 
. O 
Limits O 
of O 
detection O 
and O 
quantification O 
were O 
, O 
respectively O 
, O 
in O 
the O 
range O 
0.16-12.31 O 
and O 
0.54-41.04ngg(-1) O 
. O 
Recovery O 
rates O 
were O 
generally O 
above O 
70% O 
, O 
except O 
for O 
dried O 
basil O 
and O 
olives O 
. O 
Thirty O 
out O 
of O 
70 O 
samples O 
analysed O 
( O 
7 O 
apple O 
juices O 
, O 
14 O 
beers O 
and O 
9 O 
tomato O 
sauces O 
) O 
resulted O 
positive O 
to O 
at O 
least O 
one O 
alternaria O 
toxin O 
investigated O 
. O 
AOH B-FORMULA 
was O 
the O 
most O 
common O 
AT O 
( O 
14 O 
samples O 
) O 
, O 
followed O 
by O 
ALT B-ABBREVIATION 
( O 
10 O 
samples O 
) O 
. O 
The O 
highest O 
concentration O 
of O 
ATs O 
was O 
found O 
in O 
commercial O 
apple O 
juices O 
(35.33ngg(-1)) O 
. O 

heterocycles O 
as O 
potential O 
inhibitors O 
of O 
SIRT1 O 
: O 
Pd B-FORMULA 
/ O 
C B-FORMULA 
-mediated O 
synthesis O 
of O 
novel O 
N-indolylmethyl B-FAMILY 
spiroindoline-3,2'-quinazolines I-FAMILY 
. O 

N-indolylmethyl B-FAMILY 
substituted I-FAMILY 
spiroindoline-3,2'-quinazolines I-FAMILY 
were O 
designed O 
as O 
potential O 
inhibitiors O 
of O 
SIRT1 O 
. O 
These O 
compounds O 
were O 
synthesized O 
in O 
good O 
yields O 
by O 
using O 
Pd B-FORMULA 
/ O 
C-Cu B-FORMULA 
mediated O 
coupling O 
- O 
cyclization O 
strategy O 
as O 
a O 
key O 
step O 
involving O 
the O 
reaction O 
of O 
1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione B-SYSTEMATIC 
with O 
2-iodoanilides B-FAMILY 
. O 
Some O 
of O 
the O 
compounds O 
synthesized O 
have O 
shown O 
encouraging O 
inhibition O 
of O 
Sir O 
2 O 
protein O 
( O 
a O 
yeast O 
homologue O 
of O 
mammalian O 
SIRT1 O 
) O 
in O 
vitro O 
and O 
three O 
of O 
them O 
showed O 
dose O 
dependent O 
inhibition O 
of O 
Sir O 
2 O 
. O 
The O 
docking O 
results O 
suggested O 
that O 
the O 
benzene B-SYSTEMATIC 
ring O 
of O 
1,2,3,4-tetrahydroquinazolin B-SYSTEMATIC 
ring O 
system O 
of O 
these O 
molecules O 
occupied O 
the O 
deep O 
hydrophobic O 
pocket O 
of O 
the O 
protein O 
and O 
one O 
of O 
the O 
NH B-FORMULA 
along O 
with O 
the O 
sulfonyl B-SYSTEMATIC 
group O 
participated O 
in O 
strong O 
H B-FORMULA 
-bonding O 
interaction O 
with O 
the O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
. O 

of O 
p-cymene B-TRIVIAL 
antinociceptive O 
and O 
anti-inflammatory O 
effects O 
by O 
inclusion O 
in O 
β-cyclodextrin B-TRIVIAL 
. O 

, O 
we O 
have O 
demonstrated O 
the O 
analgesic O 
- O 
like O 
property O 
of O 
p-cymene B-TRIVIAL 
in O 
rodents O 
. O 
Short O 
half O 
- O 
life O 
is O 
a O 
limitation O 
for O 
p-cymene B-TRIVIAL 
application O 
and O 
several O 
approaches O 
have O 
been O 
used O 
to O 
improve O 
pharmaceutical O 
properties O 
of O 
monoterpenes B-FAMILY 
, O 
including O 
the O 
employment O 
of O 
drug O 
- O 
delivery O 
systems O 
. O 
Here O 
, O 
we O 
used O 
p-cymene B-TRIVIAL 
/ O 
β-cyclodextrin B-TRIVIAL 
( O 
β-CD B-ABBREVIATION 
) O 
complex O 
and O 
p-cymene B-TRIVIAL 
( O 
PC O 
) O 
isolated O 
to O 
evaluated O 
whether O 
the O 
complex O 
formulation O 
is O 
able O 
to O 
improve O 
the O 
antinociceptive O 
activity O 
of O 
this O 
monoterpene B-FAMILY 
. O 
Male O 
mice O 
( O 
26-30g O 
) O 
were O 
pretreated O 
with O 
PC/ O 
β-CD B-ABBREVIATION 
( O 
20 O 
or O 
40mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
, O 
PC O 
( O 
20 O 
or O 
40mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
or O 
vehicle O 
( O 
distilled O 
water O 
) O 
, O 
0.5h O 
before O 
painful O 
tests O 
and O 
antinociceptive O 
effect O 
was O 
evaluated O 
at O 
times O 
: O 
0.5 O 
, O 
1 O 
, O 
2 O 
, O 
4 O 
, O 
8 O 
, O 
and O 
16h O 
after O 
treatment O 
. O 
We O 
evaluated O 
the O 
analgesic O 
- O 
like O 
effect O 
of O 
PC O 
/ B-ABBREVIATION 
β-C I-ABBREVIATION 
D O 
and O 
PC O 
in O 
acetic B-SYSTEMATIC 
aci I-SYSTEMATIC 
d-induced O 
abdominal O 
writhes O 
, O 
hot O 
- O 
plate O 
, O 
carrageenan O 
- O 
induced O 
paw O 
edema O 
and O 
in O 
rota O 
- O 
rod O 
apparatus O 
. O 
Our O 
results O 
demonstrated O 
that O 
acute O 
treatment O 
with O 
complex O 
PC O 
/ B-ABBREVIATION 
β-C I-ABBREVIATION 
D O 
produced O 
an O 
antinocicepitve O 
effect O 
( O 
p O 
< O 
0.01 O 
or O 
p O 
< O 
0.001 O 
) O 
for O 
8h O 
followed O 
whereas O 
isolated O 
PC O 
produced O 
the O 
same O 
effect O 
for O 
2h O 
. O 
Similar O 
results O 
were O 
obtained O 
in O 
hot O 
- O 
plate O 
test O 
, O 
PC O 
/ B-ABBREVIATION 
β-C I-ABBREVIATION 
D O 
, O 
in O 
all O 
doses O 
, O 
significantly O 
reduces O 
( O 
p O 
< O 
0.01 O 
or O 
p O 
< O 
0.001 O 
) O 
nociceptive O 
behavior O 
for O 
8h O 
while O 
isolated O 
PC O 
for O 
1h O 
, O 
did O 
so O 
only O 
in O 
higher O 
dose O 
. O 
Such O 
results O 
were O 
unlikely O 
to O 
be O 
caused O 
by O 
motor O 
abnormality O 
. O 
Systemic O 
pretreatment O 
with O 
PC O 
/ B-ABBREVIATION 
β-C I-ABBREVIATION 
D O 
and O 
PC O 
inhibited O 
the O 
development O 
paw O 
edema O 
by O 
carrageenan O 
1% O 
, O 
but O 
PC O 
/ B-ABBREVIATION 
β-C I-ABBREVIATION 
D O 
did O 
so O 
during O 
a O 
longer O 
period O 
when O 
compared O 
with O 
isolated O 
monoterpen B-FAMILY 
e O 
alone O 
. O 
Our O 
results O 
provide O 
evidence O 
to O 
propose O 
that O 
the O 
complex O 
with O 
β-C B-ABBREVIATION 
D O 
improved O 
analgesic O 
and O 
anti-inflammatory O 
effects O 
of O 
p-cymen B-TRIVIAL 
e O 
. O 

of O 
α-tocopherol B-TRIVIAL 
and O 
α-tocopheryl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
from O 
the O 
cuticle O 
of O 
soybean O 
pods O 
armyworm O 
( O 
Spodoptera O 
cosmioides O 
) O 
. O 

chemical O 
composition O 
of O 
the O 
soybean O 
pods O 
armyworm O 
Spodoptera O 
cosmioides O 
( O 
Walker O 
, O 
1858 O 
) O 
( O 
Lepidoptera O 
: O 
Noctuidae O 
) O 
and O 
Anticarsia O 
gemmatalis O 
Hübner O 
, O 
1818 O 
( O 
Lepidoptera O 
: O 
Erebidae O 
) O 
larval O 
cuticles O 
was O 
evaluated O 
using O 
gas O 
chromatography O 
coupled O 
to O 
a O 
mass O 
detector O 
( O 
GC-MS O 
) O 
. O 
Among O 
the O 
usual O 
lipids O 
found O 
in O 
the O 
insect O 
cuticle O 
, O 
α-tocopherol B-TRIVIAL 
and O 
α-tocopheryl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
were O 
also O 
isolated O 
from O 
S O 
. O 
cosmioides O 
. O 
On O 
the O 
other O 
hand O 
, O 
no O 
vitamin B-FAMILY 
E I-FAMILY 
derivative O 
was O 
found O 
in O 
A O 
. O 
gemmatalis O 
exuvia O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
occurrence O 
in O 
the O 
insect's O 
cuticle O 
. O 

of O 
matrix O 
metalloproteinase-9 O 
expression O 
by O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
mediated O 
by O 
heme B-FAMILY 
oxygenase O 
1 O 
in O 
12-O-tetradecanoylphorbol-13-acetate B-SYSTEMATIC 
-induced O 
MCF-7 O 
human O 
breast O 
cancer O 
cells O 
. O 

metalloproteinase-9 O 
( O 
MMP-9 O 
) O 
plays O 
a O 
crucial O 
role O 
in O 
tumor O 
metastasis O 
. O 
Previous O 
studies O 
showed O 
that O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
exhibit O 
an O 
anti-cancer O 
effect O 
in O 
various O 
human O 
carcinoma O 
cells O 
, O 
but O 
the O 
effect O 
of O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
and O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LA O 
) O 
on O 
metastasis O 
of O 
breast O 
cancer O 
cells O 
is O 
not O 
fully O 
clarified O 
. O 
We O 
studied O 
the O 
anti-metastasis O 
potential O 
of O 
DHA B-ABBREVIATION 
and O 
LA O 
in O 
12-O-tetradecanoylphorbol-13-acetate B-SYSTEMATIC 
( O 
TPA B-ABBREVIATION 
)-induced O 
MCF-7 O 
cells O 
. O 
We O 
found O 
that O 
TPA B-ABBREVIATION 
( O 
100 O 
ng O 
/ O 
ml O 
) O 
induced O 
MMP-9 O 
enzyme O 
activity O 
both O 
dose- O 
and O 
time O 
- O 
dependently O 
, O 
and O 
200 O 
μM O 
DHA B-ABBREVIATION 
and O 
LA O 
significantly O 
inhibited O 
MMP-9 O 
mRNA O 
and O 
protein O 
expression O 
, O 
enzyme O 
activity O 
, O 
cell O 
migration O 
, O 
and O 
invasion O 
. O 
Treatment O 
with O 
PD98059 B-IDENTIFIER 
( O 
10 O 
μM O 
) O 
, O 
wortmannin B-TRIVIAL 
( O 
10 O 
μM O 
) O 
, O 
and O 
GF109203X B-IDENTIFIER 
( O 
0.5 O 
μM O 
) O 
decreased O 
TPA B-ABBREVIATION 
-induced O 
MMP-9 O 
protein O 
expression O 
and O 
enzyme O 
activity O 
. O 
TPA B-ABBREVIATION 
-induced O 
activation O 
of O 
ERK1 O 
, O 
Akt O 
, O 
and O 
PKCδ O 
was O 
attenuated O 
by O 
DHA B-ABBREVIATION 
, O 
whereas O 
LA O 
attenuated O 
only O 
ERK1 O 
activation O 
. O 
GF109203X B-IDENTIFIER 
also O 
suppressed O 
ERK1 O 
activation O 
. O 
EMSA O 
showed O 
that O 
DHA B-ABBREVIATION 
, O 
LA O 
, O 
PD98059 B-IDENTIFIER 
, O 
and O 
wortmannin B-TRIVIAL 
decreased O 
TPA B-ABBREVIATION 
-induced O 
NF-κB O 
and O 
AP-1 O 
DNA O 
- O 
binding O 
activity O 
. O 
Furthermore O 
, O 
DHA B-ABBREVIATION 
rather O 
than O 
LA O 
dose O 
- O 
dependently O 
increased O 
HO-1 O 
expression O 
. O 
HO-1 O 
siRNA O 
alleviated O 
the O 
inhibition O 
by O 
DHA B-ABBREVIATION 
of O 
TPA B-ABBREVIATION 
-induced O 
MMP-9 O 
protein O 
expression O 
and O 
enzyme O 
activity O 
in O 
MCF-7 O 
cells O 
, O 
and O 
HO-1 O 
knockdown O 
reversed O 
the O 
DHA B-ABBREVIATION 
inhibition O 
of O 
cell O 
migration O 
. O 
These O 
results O 
suggest O 
that O 
DHA B-ABBREVIATION 
and O 
LA O 
have O 
both O 
similar O 
and O 
divergent O 
signaling O 
pathways O 
in O 
the O 
suppression O 
of O 
TPA B-ABBREVIATION 
-induced O 
MCF-7 O 
metastasis O 
. O 

Governing O 
Role O 
of O 
Surface O 
Hydration O 
in O 
Ion O 
Specific O 
Adsorption O 
to O 
Silica B-TRIVIAL 
- O 
an O 
AFM O 
Based O 
Account O 
of O 
the O 
Hofmeister O 
Universality O 
and O 
its O 
Reversal O 
. O 

measurements O 
of O 
the O 
force O 
acting O 
between O 
silica B-TRIVIAL 
surfaces O 
in O 
the O 
presence O 
of O 
varied O 
alkali B-FAMILY 
- I-FAMILY 
chloride I-FAMILY 
salts O 
and O 
pH's O 
elucidate O 
the O 
origin O 
of O 
the O 
Hofmeister O 
adsorption O 
series O 
and O 
its O 
reversal O 
. O 
At O 
low O 
pH O 
, O 
electrostatics O 
is O 
shown O 
to O 
be O 
insignificant O 
. O 
The O 
preferential O 
adsorption O 
of O 
Cs+ B-FORMULA 
to O 
the O 
silica B-TRIVIAL 
surface O 
is O 
traced O 
to O 
the O 
weak O 
hydration O 
of O 
neutral O 
silanols B-FAMILY 
and O 
the O 
resulting O 
hydrophobic O 
expulsion O 
of O 
weakly O 
hydrated O 
ions O 
from O 
bulk O 
solution O 
to O 
the O 
interface O 
. O 
The O 
same O 
interactions O 
keep O 
the O 
strongly O 
hydrated O 
Li+ B-FORMULA 
and O 
Na+ B-FORMULA 
in O 
solution O 
. O 
As O 
pH O 
is O 
increased O 
, O 
a O 
tightly O 
bound O 
hydration O 
layer O 
forms O 
on O 
deprotonating O 
silanols B-FAMILY 
. O 
Cs+ B-FORMULA 
is O 
correspondingly O 
expelled O 
from O 
the O 
surface O 
and O 
adsorption O 
of O 
small O 
ions O 
is O 
encouraged O 
. O 
The O 
deduced O 
role O 
of O 
surface O 
hydration O 
is O 
corroborated O 
by O 
hydration O 
repulsion O 
observed O 
at O 
high O 
pH O 
, O 
surface O 
over O 
- O 
charging O 
at O 
low O 
pH O 
, O 
and O 
data O 
in O 
other O 
oxides B-FAMILY 
. O 

specific O 
ligand O 
targeting O 
the O 
immunodominant O 
region O 
of O 
hepatitis O 
B O 
virus O 
( O 
HBV O 
) O 
is O 
desired O 
in O 
neutralizing O 
the O 
infectivity O 
of O 
the O 
virus O 
. O 
In O 
a O 
previous O 
study O 
, O 
a O 
disulfide B-SYSTEMATIC 
constrained O 
cyclic O 
peptide O 
cyclo B-FORMULA 
S(1) I-FORMULA 
,S(9) I-FORMULA 
Cys-Glu-Thr-Gly-Ala-Lys-Pro-His-Cys I-FORMULA 
( O 
S(1) O 
, O 
S(9) O 
-cyclo-CETGAKPHC O 
) O 
was O 
isolated O 
from O 
a O 
phage O 
displayed O 
cyclic O 
peptide O 
library O 
using O 
an O 
affinity O 
selection O 
method O 
against O 
HBV O 
surface O 
antigen O 
( O 
HBsAg O 
) O 
. O 
The O 
cyclic O 
peptide O 
binds O 
tightly O 
to O 
HBsAg O 
with O 
a O 
relative O 
dissociation O 
constant O 
( O 
K(D) O 
( O 
rel O 
) O 
) O 
of O 
2.9 O 
nM O 
. O 
The O 
binding O 
site O 
of O 
the O 
peptide O 
was O 
located O 
at O 
the O 
immunodominant O 
region O 
on O 
HBsAg O 
. O 
Consequently O 
, O 
this O 
study O 
was O 
aimed O 
to O 
elucidate O 
the O 
structure O 
of O 
the O 
cyclic O 
peptide O 
and O 
its O 
interaction O 
with O 
HBsAg O 
in O 
silico O 
. O 
The O 
solution O 
structure O 
of O 
this O 
cyclic O 
peptide O 
was O 
solved O 
using O 
( B-FORMULA 
1 I-FORMULA 
) I-FORMULA 
H I-FORMULA 
, O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
and O 
( B-FORMULA 
15 I-FORMULA 
) I-FORMULA 
N I-FORMULA 
NMR O 
spectroscopy O 
and O 
molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
with O 
NMR O 
- O 
derived O 
distance O 
and O 
torsion O 
angle O 
restraints O 
. O 
The O 
cyclic O 
peptide O 
adopted O 
two O 
distinct O 
conformations O 
due O 
to O 
the O 
isomerization O 
of O 
the O 
Pro B-FORMULA 
residue O 
with O 
one O 
structured O 
region O 
in O 
the O 
ETGA O 
sequence O 
. O 
Docking O 
studies O 
of O 
the O 
peptide O 
ensemble O 
with O 
a O 
model O 
structure O 
of O 
HBsAg O 
revealed O 
that O 
the O 
cyclic O 
peptide O 
can O 
potentially O 
be O 
developed O 
as O 
a O 
therapeutic O 
drug O 
that O 
inhibits O 
the O 
virus O 
- O 
host O 
interactions O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

on O 
background O 
concentrations O 
of O 
elements O 
in O 
soils O 
and O 
the O 
sixth O 
population O 
census O 
data O 
of O 
China O 
, O 
this O 
study O 
discussed O 
the O 
distribution O 
characteristics O 
of O 
soil O 
elements O 
and O 
longevity O 
population O 
at O 
province O 
level O 
in O 
China O 
. O 
Percentages O 
of O 
the O 
aging O 
population O 
are O 
high O 
in O 
Southwest O 
China O 
and O 
the O 
eastern O 
coastal O 
region O 
but O 
low O 
in O 
western O 
and O 
northwestern O 
regions O 
. O 
Provinces O 
in O 
South O 
and O 
Southwest O 
China O 
gain O 
a O 
high O 
level O 
of O 
longevity O 
, O 
while O 
the O 
northern O 
part O 
of O 
China O 
has O 
a O 
low O 
level O 
of O 
longevity O 
. O 
The O 
background O 
concentration O 
of O 
Se B-FORMULA 
in O 
soil O 
has O 
a O 
significant O 
positive O 
correlation O 
with O 
longevity O 
index O 
, O 
while O 
Ba B-FORMULA 
and O 
Ni B-FORMULA 
have O 
a O 
significant O 
negative O 
correlation O 
with O 
longevity O 
indexes O 
. O 
By O 
regression O 
analysis O 
, O 
longevity O 
index O 
C O 
/ O 
100000 O 
can O 
be O 
expressed O 
as O 
C O 
/ O 
100000 O 
= O 
1.679-0.205 O 
Ni B-FORMULA 
+ O 
0.413 O 
Co B-FORMULA 
+ O 
0.006 O 
Se B-FORMULA 
( O 
with O 
R O 
(2) O 
= O 
0.402 O 
and O 
p O 
< O 
0.01 O 
) O 
, O 
C O 
/ O 
65+ O 
can O 
be O 
expressed O 
as O 
C O 
/ O 
65 O 
+ O 
= O 
3.425-0.262 O 
Ni B-FORMULA 
+ O 
0.435 O 
Co B-FORMULA 
+ O 
0.006 O 
Se B-FORMULA 
( O 
with O 
R O 
(2) O 
= O 
0.369 O 
and O 
p O 
< O 
0.01 O 
) O 
. O 

effect O 
of O 
starter O 
culture O 
and O 
temperature O 
on O 
phenolic B-FAMILY 
compounds O 
during O 
fermentation O 
of O 
Taggiasca O 
black O 
olives O 
. O 

influence O 
of O 
two O 
operative O 
parameters O 
on O 
the O 
fermentation O 
process O 
of O 
table O 
olives O 
from O 
Taggiasca O 
cultivar O 
were O 
investigated O 
. O 
Laboratory O 
scale O 
fermentations O 
were O 
performed O 
using O 
Lactobacillus O 
plantarum O 
as O 
the O 
only O 
starter O 
and O 
in O 
combination O 
with O 
Saccharomyces O 
cerevisiae O 
at O 
three O 
different O 
temperatures O 
( O 
23 O 
, O 
30 O 
and O 
37°C O 
) O 
. O 
Control O 
tests O 
used O 
for O 
each O 
trial O 
were O 
fermented O 
only O 
by O 
indigenous O 
microflora O 
. O 
pH O 
and O 
phenolic B-FAMILY 
compounds O 
were O 
monitored O 
in O 
the O 
brine O 
and O 
olive O 
flesh O 
during O 
the O 
fermentation O 
. O 
Higher O 
temperatures O 
( O 
37°C O 
) O 
enhanced O 
notably O 
the O 
release O 
of O 
phenolic B-FAMILY 
compounds O 
in O 
the O 
brine O 
. O 
High O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
analysis O 
of O 
brines O 
evidenced O 
the O 
complete O 
hydrolysis O 
of O 
oleuropein B-TRIVIAL 
after O 
100 O 
days O 
of O 
fermentation O 
at O 
37°C O 
for O 
all O 
treatments O 
. O 
The O 
antioxidant O 
power O 
of O 
the O 
extracts O 
was O 
linearly O 
correlated O 
to O 
their O 
polyphenol B-FAMILY 
contents O 
. O 
The O 
results O 
confirmed O 
the O 
efficiency O 
of O 
treatments O 
compared O 
with O 
the O 
control O 
tests O 
for O 
debittering O 
process O 
of O 
table O 
black O 
olives O 
. O 
Phenolic B-FAMILY 
compounds O 
in O 
the O 
brines O 
can O 
be O 
then O 
extracted O 
and O 
used O 
in O 
food O 
, O 
cosmetic O 
and O 
pharmaceutical O 
industries O 
. O 

nanoparticles O 
enhance O 
Pseudomonas O 
aeruginosa O 
PAO1 O 
biofilm O 
detachment O 
. O 

Objectives O 
: O 
Silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
with O 
a O 
size O 
ranging O 
from O 
7 O 
to O 
70 O 
nm O 
were O 
synthesized O 
using O 
the O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
- O 
citrate B-FAMILY 
seed O 
- O 
mediated O 
growth O 
approach O 
at O 
room O 
temperature O 
. O 
Methods O 
: O 
The O 
8 O 
nm O 
silver B-SYSTEMATIC 
particles O 
were O 
prepared O 
using O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
in O 
alkaline O 
conditions O 
and O 
used O 
as O 
seed O 
to O 
prepare O 
AgNPs O 
. O 
Results O 
: O 
The O 
presence O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
citrate B-FAMILY 
allows O 
the O 
regulation O 
of O 
size O 
and O 
size O 
distribution O 
of O 
the O 
nanoparticles O 
. O 
The O 
increase O 
in O 
free O 
silver B-SYSTEMATIC 
ion O 
- O 
to O 
- O 
seed O 
ratio O 
( O 
Ag(+) B-FORMULA 
/ O 
Ag(0) B-FORMULA 
) O 
resulted O 
in O 
changes O 
of O 
particle O 
shape O 
from O 
spherical O 
to O 
pseudo O 
- O 
spherical O 
and O 
minor O 
cylindrical O 
shape O 
. O 
Further O 
, O 
a O 
repetitive O 
seeding O 
approach O 
resulted O 
in O 
the O 
formation O 
of O 
pseudo O 
- O 
spherical O 
particles O 
with O 
higher O 
polydispersity O 
index O 
and O 
minor O 
distributions O 
of O 
tetrahedral O 
particles O 
. O 
Citrate B-TRIVIAL 
-capped O 
AgNPs O 
were O 
stable O 
and O 
did O 
not O 
agglomerate O 
upon O 
centrifugation O 
. O 
The O 
effect O 
of O 
AgNPs O 
on O 
biofilm O 
reduction O 
was O 
evaluated O 
using O 
static O 
culture O 
on O 
96-well O 
microtiter O 
plates O 
. O 
Results O 
showed O 
that O 
AgNPs O 
with O 
the O 
smallest O 
average O 
diameter O 
were O 
most O 
effective O 
in O 
the O 
reduction O 
of O 
Pseudomonas O 
aeruginosa O 
biofilm O 
colonies O 
, O 
which O 
accounted O 
for O 
90% O 
of O 
removal O 
. O 
Conclusion O 
: O 
The O 
biofilm O 
removal O 
activities O 
of O 
the O 
nanoparticles O 
were O 
found O 
to O 
be O 
concentration O 
- O 
independent O 
particularly O 
for O 
the O 
concentration O 
within O 
the O 
range O 
of O 
80-200 O 
µg O 
/ O 
mL O 
. O 

and O 
its O 
synthetic O 
analogues O 
: O 
Antioxidant O 
activity O 
and O 
toxicity O 
evaluation O 
. O 

( O 
1 O 
) O 
is O 
a O 
secondary O 
metabolite O 
of O 
plants O 
and O 
is O 
described O 
as O 
a O 
promising O 
anti-inflammatory O 
, O 
antimalarial O 
, O 
antiulcerogenic O 
, O 
analgesic O 
and O 
cytotoxic O 
compound O 
possibly O 
due O 
to O 
its O 
antioxidant O 
profile O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
pharmacologic O 
activity O 
and O 
the O 
antioxidant O 
and O 
toxicological O 
profiles O 
of O 
compound O 
( O 
1 O 
) O 
and O 
its O 
synthetic O 
analogues O 
( O 
2-6 O 
) O 
. O 
The O 
synthetic O 
analogues O 
were O 
designed O 
from O 
the O 
lead O 
compound O 
, O 
( O 
1 O 
) O 
, O 
using O 
a O 
molecular O 
- O 
simplification O 
strategy O 
. O 
Compound O 
5 O 
showed O 
, O 
by O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
and O 
β-carotene B-TRIVIAL 
systems O 
, O 
similar O 
antioxidant O 
activity O 
when O 
compared O 
to O 
compound O 
( O 
1 O 
) O 
. O 
The O 
oxidative O 
stress O 
in O 
erythrocyte O 
membrane O 
demonstrated O 
the O 
highly O 
protective O 
effect O 
of O 
compounds O 
( O 
4 O 
) O 
, O 
( O 
5 O 
) O 
and O 
( O 
6 O 
) O 
and O 
high O 
antioxidant O 
/ O 
pro O 
- O 
oxidant O 
activity O 
in O 
relation O 
to O 
the O 
concentrations O 
of O 
compounds O 
( O 
1 O 
) O 
and O 
( O 
3 O 
) O 
. O 
Compounds O 
( O 
2 O 
) O 
, O 
( O 
4 O 
) O 
, O 
( O 
5 O 
) O 
and O 
( O 
6 O 
) O 
were O 
haemobiocompatible O 
. O 
All O 
compounds O 
( O 
1-6 O 
) O 
showed O 
cytotoxic O 
effects O 
in O 
3T3 O 
cells O 
, O 
but O 
compounds O 
( O 
2 O 
) O 
and O 
( O 
6 O 
) O 
were O 
highly O 
cytotoxic O 
in O 
this O 
lineage O 
when O 
compared O 
to O 
compound O 
( O 
1 O 
) O 
. O 
Compound O 
( O 
5 O 
) O 
had O 
a O 
lower O 
myelosuppressive O 
effect O 
in O 
haematopoietic O 
progenitor O 
cells O 
compared O 
to O 
( O 
1 O 
) O 
. O 
Both O 
compounds O 
, O 
( O 
1 O 
) O 
and O 
( O 
5 O 
) O 
, O 
showed O 
low O 
genotoxic O 
effects O 
in O 
vitro O 
, O 
on O 
human O 
lymphocyte O 
cells O 
. O 
In O 
addition O 
, O 
these O 
compounds O 
also O 
showed O 
low O 
- O 
toxicity O 
in O 
vivo O 
as O 
defined O 
a O 
LD50 O 
> O 
2000 O 
mg O 
/ O 
kg O 
. O 
In O 
this O 
assay O 
, O 
we O 
did O 
not O 
observe O 
death O 
in O 
the O 
animals O 
exposed O 
to O 
treatment O 
with O 
( O 
1 O 
) O 
and O 
( O 
5 O 
) O 
compound O 
. O 
In O 
conclusion O 
, O 
the O 
structural O 
design O 
of O 
the O 
analogues O 
as O 
validated O 
once O 
compound O 
( O 
5 O 
) O 
was O 
found O 
to O 
have O 
an O 
antioxidant O 
profile O 
that O 
was O 
as O 
potent O 
as O 
the O 
lead O 
compound O 
( O 
1 O 
) O 
. O 
In O 
addition O 
, O 
considering O 
the O 
safety O 
profile O 
, O 
these O 
compounds O 
are O 
promising O 
as O 
preventive O 
and O 
/ O 
or O 
therapeutic O 
agents O 
against O 
oxidative O 
damage O 
. O 

Rhizoma O 
inhibits O 
the O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
-induced O 
reduction O 
in O 
nigrostriatal O 
dopaminergenic O 
neurons O 
in O 
estrogen B-FAMILY 
-deprived O 
mice O 
. O 

RELEVANCE O 
: O 
Cyperi O 
Rhizoma O 
has O 
commonly O 
been O 
used O 
for O 
the O 
treatment O 
of O 
gynecological O 
and O 
neuropsychiatric O 
disorders O 
in O 
traditional O 
medicine O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
estrogenic O 
properties O 
and O 
neuroprotective O 
effects O 
of O 
Cyperi O 
Rhizoma O 
under O 
estrogen B-FAMILY 
-deprived O 
condition O 
in O 
female O 
mice O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
To O 
determine O 
the O 
estrogen B-FAMILY 
-like O 
effect O 
of O 
Cyperi O 
Rhizoma O 
extract O 
( O 
CRE O 
) O 
, O 
we O 
measured O 
luciferase O 
expression O 
after O 
transfection O 
of O 
a O 
promoter O 
construct O 
containing O 
an O 
estrogen B-FAMILY 
response O 
element O 
( O 
ERE O 
) O 
and O 
treatment O 
of O 
CRE O 
. O 
To O 
evaluate O 
the O 
neuroprotective O 
effect O 
of O 
CRE O 
, O 
we O 
measured O 
striatal O 
dopamine B-TRIVIAL 
, O 
movement O 
ability O 
, O 
tyrosine B-TRIVIAL 
hydroxylase O 
( O 
TH O 
) O 
immunoreactivity O 
, O 
and O 
apoptosis O 
- O 
related O 
protein O 
expression O 
levels O 
after O 
treatment O 
of O 
CRE O 
either O 
with O 
or O 
without O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
( O 
MPTP B-ABBREVIATION 
) O 
in O 
ovariectomized O 
female O 
mice O 
. O 
RESULTS O 
: O 
CRE O 
significantly O 
induced O 
the O 
luciferase O 
expression O 
driven O 
by O 
an O 
ERE O 
in O 
PC12 O 
cells O 
, O 
a O 
dopaminergic O 
cell O 
line O 
, O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
mice O 
, O 
MPTP B-ABBREVIATION 
significantly O 
decreased O 
the O 
levels O 
of O 
dopamine B-TRIVIAL 
in O 
the O 
striatum O 
and O 
behavior O 
performance O 
; O 
in O 
contrast O 
, O 
both O 
CRE O 
and O 
17β-estradiol B-SYSTEMATIC 
benzoate I-SYSTEMATIC 
( O 
EB O 
) O 
recovered O 
these O 
parameters O 
to O 
normal O 
levels O 
. O 
CRE O 
and O 
EB O 
treatment O 
also O 
recovered O 
TH O 
immunopositive O 
fibers O 
and O 
cells O 
, O 
respectively O 
, O 
from O 
MPTP B-ABBREVIATION 
toxicity O 
. O 
Additionally O 
, O 
MPTP B-ABBREVIATION 
significantly O 
down O 
- O 
regulated O 
Bcl-2 O 
expression O 
in O 
the O 
mitochondria O 
of O 
dopaminergic O 
cells O 
in O 
the O 
SN O 
, O 
followed O 
by O 
an O 
increase O 
in O 
Bax O 
expression O 
, O 
cytochrome O 
C O 
translocation O 
to O 
the O 
cytosol O 
, O 
andcleaved-caspase-3 O 
expression O 
, O 
whereas O 
these O 
were O 
inhibited O 
by O 
CRE O 
or O 
EB O 
treatment O 
. O 
CONCLUSIONS O 
: O 
These O 
findings O 
provide O 
the O 
first O 
evidence O 
that O 
CRE O 
has O 
estrogen B-FAMILY 
-like O 
and O 
neuroprotective O 
effects O 
on O 
dopaminergic O 
neurons O 
in O 
estrogen B-FAMILY 
-deprived O 
mice O 
treated O 
with O 
MPTP B-ABBREVIATION 
-toxin O 
. O 

blood O 
mononuclear O 
cells O 
( O 
MNCs O 
) O 
are O 
accessible O 
through O 
blood O 
collection O 
and O 
represent O 
a O 
useful O 
source O 
for O 
investigations O 
on O 
disease O 
mechanisms O 
and O 
treatment O 
response O 
. O 
Aiming O 
to O 
build O 
a O 
reference O 
proteome O 
database O 
, O 
we O 
generated O 
three O 
proteome O 
data O 
sets O 
from O 
MNCs O 
using O 
a O 
combination O 
of O 
SDS B-ABBREVIATION 
-PAGE O 
and O 
nanoflow O 
LC-MS O 
. O 
Experiments O 
were O 
performed O 
in O 
triplicates O 
and O 
514 O 
unique O 
proteins O 
were O 
identified O 
by O 
at O 
least O 
two O 
non-redundant O 
peptides O 
with O 
95% O 
confidence O 
for O 
all O 
replicates O 
. O 
Identified O 
proteins O 
are O 
associated O 
with O 
a O 
range O 
of O 
dermatologic O 
, O 
inflammatory O 
and O 
neurological O 
conditions O 
as O 
well O 
as O 
molecular O 
processes O 
, O 
such O 
as O 
free O 
radical O 
scavenging O 
and O 
cellular O 
growth O 
and O 
proliferation O 
. O 
Mapping O 
the O 
MNC O 
proteome O 
provides O 
a O 
valuable O 
resource O 
for O 
studies O 
on O 
disease O 
pathogenesis O 
and O 
the O 
identification O 
of O 
therapeutic O 
targets O 
. O 

-loaded O 
lipid O 
nanocapsules O 
as O 
oxygen B-SYSTEMATIC 
sensors O 
for O 
tumor O 
tissue O 
pO(2) O 
assessment O 
. O 

assessment O 
of O 
tumor O 
oxygenation O 
is O 
a O 
crucial O 
factor O 
in O 
cancer O 
therapy O 
and O 
may O 
be O 
carried O 
out O 
using O 
fluorine B-SYSTEMATIC 
MRI O 
once O 
fluorine B-SYSTEMATIC 
probes O 
have O 
been O 
distributed O 
within O 
the O 
tumor O 
. O 
However O 
, O 
the O 
deposit O 
of O 
those O 
highly O 
fluorinated O 
compounds O 
often O 
jeopardizes O 
anatomical O 
image O 
quality O 
and O 
requires O 
emulsification O 
of O 
the O 
probes O 
. O 
Due O 
to O 
the O 
high O 
density O 
and O 
the O 
high O 
lipophilicity O 
of O 
perfluorocarbons B-FAMILY 
, O 
nanoemulsion O 
of O 
these O 
molecules O 
usually O 
requires O 
high O 
- O 
energy O 
processes O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
discuss O 
the O 
synthesis O 
and O 
the O 
physico O 
- O 
chemical O 
characterization O 
of O 
perfluorocarbon B-SYSTEMATIC 
nanocapsules O 
using O 
a O 
low O 
- O 
energy O 
phase O 
- O 
inversion O 
process O 
. O 
The O 
nanocapsules O 
were O 
tested O 
on O 
a O 
mouse O 
tumor O 
brain O 
model O 
to O 
assess O 
oxygenation O 
. O 

serum O 
- O 
resistant O 
lipopolyplexes O 
targeted O 
to O 
the O 
folate B-TRIVIAL 
receptor O 
. O 

this O 
work O 
, O 
we O 
have O 
developed O 
and O 
evaluated O 
a O 
new O 
targeted O 
lipopolyplex O 
( O 
LPP O 
) O 
, O 
by O 
combining O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
, O 
1,2-dioleoyl-3-(trimethylammonium) B-SYSTEMATIC 
propane I-SYSTEMATIC 
( O 
DOTAP B-ABBREVIATION 
) O 
/ O 
Chol O 
liposomes O 
, O 
the O 
plasmids O 
pCMVLuc O 
/ O 
pCMVIL-12 O 
, O 
and O 
the O 
ligand O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
, O 
able O 
to O 
transfect O 
HeLa O 
and O 
B16-F10 O 
cells O 
in O 
the O 
presence O 
of O 
very O 
high O 
concentration O 
of O 
serum O 
( O 
60% O 
FBS O 
) O 
. O 
These O 
complexes O 
( O 
Fol-LPP O 
) O 
have O 
a O 
net O 
positive O 
surface O 
charge O 
. O 
The O 
combination O 
of O 
folic B-TRIVIAL 
acid I-TRIVIAL 
with O 
lipopolyplexes O 
also O 
enhanced O 
significantly O 
the O 
transfection O 
activity O 
of O 
the O 
therapeutic O 
gene O 
interleukin-12 O 
( O 
IL-12 O 
) O 
, O 
without O 
any O 
significant O 
cytotoxicity O 
. O 
The O 
specificity O 
of O 
the O 
folate B-TRIVIAL 
receptor O 
( O 
FR O 
) O 
- O 
mediated O 
gene O 
transfer O 
was O 
corroborated O 
by O 
employing O 
a O 
folate B-TRIVIAL 
receptor O 
deficient O 
cell O 
line O 
( O 
HepG2 O 
) O 
. O 
This O 
formulation O 
improved O 
gene O 
delivery O 
showed O 
by O 
conventional O 
lipoplexes O 
or O 
polyplexes O 
resulting O 
an O 
efficient O 
, O 
simple O 
, O 
and O 
nontoxic O 
method O 
for O 
gene O 
delivery O 
of O 
therapeutic O 
genes O 
in O 
vitro O 
and O 
very O 
probably O 
in O 
vivo O 
. O 

of O 
a O 
liquid O 
chromatography O 
- O 
electrospray O 
mass O 
spectrometry O 
( O 
LC O 
/ O 
MS O 
) O 
method O 
to O 
the O 
biodistribution O 
and O 
excretion O 
studies O 
of O 
novel O 
5'-chloro-2 B-SYSTEMATIC 
, I-SYSTEMATIC 
3-didehydroindolo I-SYSTEMATIC 
( I-SYSTEMATIC 
2 I-SYSTEMATIC 
' I-SYSTEMATIC 
, I-SYSTEMATIC 
3 I-SYSTEMATIC 
' I-SYSTEMATIC 
: I-SYSTEMATIC 
2 I-SYSTEMATIC 
, I-SYSTEMATIC 
3 I-SYSTEMATIC 
) I-SYSTEMATIC 
betulinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DRF-4012 B-IDENTIFIER 
) O 
in O 
tumour O 
- O 
bearing O 
mice O 
. O 

betulinic B-TRIVIAL 
acid I-TRIVIAL 
derivative O 
5'-chloro-2 B-SYSTEMATIC 
, I-SYSTEMATIC 
3-didehydroindolo I-SYSTEMATIC 
[ I-SYSTEMATIC 
2 I-SYSTEMATIC 
' I-SYSTEMATIC 
, I-SYSTEMATIC 
3 I-SYSTEMATIC 
' I-SYSTEMATIC 
: I-SYSTEMATIC 
2 I-SYSTEMATIC 
, I-SYSTEMATIC 
3 I-SYSTEMATIC 
] I-SYSTEMATIC 
betulinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DRF-4012 B-IDENTIFIER 
) O 
is O 
a O 
new O 
effective O 
lupane B-TRIVIAL 
type O 
triterpenes B-FAMILY 
with O 
greater O 
anticancer O 
activity O 
and O 
efficacy O 
than O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
currently O 
under O 
advanced O 
preclinical O 
investigation O 
phase O 
. O 
In O 
this O 
study O 
, O 
a O 
sensitive O 
and O 
rapid O 
liquid O 
chromatography O 
- O 
electrospray O 
mass O 
spectrometric O 
( O 
LC O 
/ O 
MS O 
) O 
method O 
has O 
been O 
developed O 
for O 
the O 
determination O 
of O 
DRF-4012 B-IDENTIFIER 
in O 
tumour O 
- O 
bearing O 
mice O 
plasma O 
, O 
urine O 
, O 
feces O 
and O 
tissues O 
( O 
liver O 
, O 
brain O 
, O 
lungs O 
, O 
heart O 
, O 
spleen O 
, O 
stomach O 
, O 
thigh O 
muscle O 
, O 
kidneys O 
, O 
urinary O 
bladder O 
, O 
small O 
intestine O 
and O 
tumour O 
) O 
. O 
Biodistribution O 
and O 
excretion O 
studies O 
were O 
performed O 
for O 
DRF-4012 B-IDENTIFIER 
nanoparticle O 
( O 
30 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
after O 
intravenous O 
( O 
i.v O 
. O 
) O 
injection O 
in O 
tumour O 
- O 
bearing O 
mice O 
. O 
DRF-4012 B-IDENTIFIER 
rapidly O 
distributed O 
throughout O 
the O 
body O 
. O 
After O 
0.5 O 
h O 
, O 
tumour O 
showed O 
the O 
second O 
highest O 
concentration O 
, O 
which O 
was O 
nearly O 
half O 
of O 
the O 
liver O 
. O 
After O 
4 O 
and O 
24 O 
h O 
, O 
the O 
highest O 
concentration O 
of O 
DRF-4012 B-IDENTIFIER 
was O 
found O 
in O 
tumour O 
indicating O 
its O 
retention O 
in O 
tumour O 
site O 
for O 
a O 
longer O 
time O 
. O 
Excretion O 
studies O 
revealed O 
that O 
very O 
low O 
amount O 
of O 
unchanged O 
DRF-4012 B-IDENTIFIER 
was O 
observed O 
in O 
urine O 
and O 
primarily O 
excreted O 
through O 
fecal O 
route O 
. O 
This O 
study O 
may O 
be O 
useful O 
to O 
explain O 
the O 
manner O 
in O 
which O 
DRF-4012 B-IDENTIFIER 
can O 
inhibit O 
tumour O 
growth O 
without O 
apparent O 
toxicity O 
and O 
preclinical O 
/ O 
clinical O 
evaluation O 
of O 
this O 
potential O 
antitumour O 
agent O 
. O 

as O 
a O 
Tool O 
for O 
Better O 
Characterization O 
of O 
Ionic O 
Liquids O 
: O 
A O 
Comparative O 
Study O 
of O 
1-Alkyl-3-methylimidazolium B-FAMILY 
Bis[(trifluoromethyl)sulfonyl]imide I-FAMILY 
Room-Temperature O 
Ionic O 
Liquids O 
. O 

properties O 
of O 
three O 
( O 
1-ethyl B-SYSTEMATIC 
- O 
, O 
1-butyl B-SYSTEMATIC 
- O 
, O 
and O 
1-octyl B-SYSTEMATIC 
- O 
) O 
1-alkyl-3-methylimidazolium B-FAMILY 
bis[(trifluoromethyl)sulfonyl] I-FAMILY 
imide I-FAMILY 
room O 
- O 
temperature O 
ionic O 
liquids O 
are O 
reported O 
and O 
discussed O 
. O 
The O 
speeds O 
of O 
sound O 
in O 
RTILs O 
were O 
measured O 
as O 
a O 
function O 
of O 
temperature O 
in O 
the O 
range O 
288-323 O 
K O 
by O 
means O 
of O 
a O 
sing O 
around O 
method O 
. O 
The O 
densities O 
and O 
isobaric O 
heat O 
capacities O 
were O 
determined O 
from O 
288.15 O 
to O 
363.15 O 
K O 
and O 
from O 
293.15 O 
to O 
323.15 O 
K O 
, O 
respectively O 
. O 
The O 
related O 
properties O 
, O 
like O 
isentropic O 
and O 
isothermal O 
compressibilities O 
, O 
isobaric O 
coefficients O 
of O 
thermal O 
expansion O 
, O 
molar O 
isochoric O 
heat O 
capacities O 
, O 
and O 
internal O 
pressures O 
, O 
were O 
calculated O 
. O 
It O 
was O 
found O 
that O 
for O 
some O 
ionic O 
liquids O 
, O 
temperature O 
dependence O 
of O 
isobaric O 
coefficients O 
of O 
thermal O 
expansion O 
is O 
small O 
and O 
negative O 
. O 
All O 
investigations O 
were O 
completed O 
by O 
the O 
ultrasound O 
absorption O 
coefficient O 
measurements O 
in O 
1-ethyl- B-MULTIPLE 
and I-MULTIPLE 
1-octyl-3-methylimidazolium I-MULTIPLE 
bis[(trifluoromethyl)sulfonyl] I-MULTIPLE 
imide I-MULTIPLE 
as O 
a O 
function O 
of O 
frequency O 
from O 
10 O 
to O 
300 O 
MHz O 
at O 
temperatures O 
293.15-298.15 O 
K O 
. O 
The O 
ultrasound O 
absorption O 
spectra O 
indicate O 
relaxation O 
frequencies O 
in O 
the O 
megahertz O 
range O 
. O 

of O 
a O 
synthetic O 
Aminopeptidase O 
N O 
inhibitor O 
LB-4b B-TRIVIAL 
as O 
a O 
potential O 
anticancer O 
agent O 
. O 

inhibitors O 
have O 
been O 
considered O 
as O 
potential O 
anticancer O 
agents O 
for O 
years O 
. O 
LB-4b B-TRIVIAL 
is O 
the O 
first O 
synthetic O 
APN O 
inhibitor O 
to O 
be O 
evaluated O 
for O 
both O 
of O 
its O 
anti-invasion O 
and O 
anti-angiogenesis O 
effects O 
. O 
As O 
a O 
potent O 
synthetic O 
APN O 
inhibitor O 
( O 
IC50=850nM O 
, O 
versus O 
bestatin B-TRIVIAL 
of O 
8.1μM O 
) O 
, O 
LB-4b B-TRIVIAL 
was O 
determined O 
to O 
have O 
more O 
significant O 
block O 
effects O 
to O 
cancer O 
cell O 
invasion O 
and O 
angiogenesis O 
than O 
bestatin B-TRIVIAL 
. O 
Besides O 
, O 
it O 
is O 
able O 
to O 
be O 
easily O 
synthesized O 
with O 
a O 
high O 
total O 
yield O 
, O 
while O 
the O 
reported O 
synthetic O 
methods O 
of O 
bestatin B-TRIVIAL 
are O 
much O 
more O 
complex O 
. O 

potassium B-SYSTEMATIC 
channel O 
blocker O 
venom O 
peptides O 
from O 
Mesobuthus O 
gibbosus O 
( O 
Scorpiones O 
: O 
Buthidae O 
) O 
. O 

the O 
present O 
study O 
, O 
we O 
report O 
for O 
the O 
first O 
time O 
, O 
the O 
molecular O 
, O 
biochemical O 
and O 
electrophysiological O 
characterization O 
of O 
the O 
components O 
present O 
in O 
the O 
soluble O 
venom O 
from O 
Mesobuthus O 
gibbosus O 
( O 
Brullé O 
, O 
1832 O 
) O 
. O 
According O 
to O 
the O 
epidemiological O 
and O 
clinical O 
situation O 
of O 
scorpion O 
envenomation O 
cases O 
M O 
. O 
gibbosus O 
scorpion O 
is O 
one O 
of O 
the O 
most O 
important O 
health O 
- O 
threatening O 
species O 
of O 
Turkey O 
. O 
Despite O 
the O 
medical O 
importance O 
reported O 
for O 
M O 
. O 
gibbosus O 
, O 
there O 
is O 
no O 
additional O 
information O 
on O 
toxin O 
peptides O 
and O 
venom O 
components O 
to O 
clarify O 
the O 
toxic O 
effect O 
of O 
the O 
M O 
. O 
gibbosus O 
sting O 
. O 
Biochemical O 
characterization O 
of O 
the O 
venom O 
was O 
performed O 
using O 
different O 
protocols O 
and O 
techniques O 
following O 
a O 
bioassay O 
- O 
guided O 
strategy O 
( O 
HPLC O 
, O 
mass O 
spectrometry O 
and O 
Edman O 
degradation O 
sequencing O 
) O 
. O 
Venom O 
fractions O 
were O 
tested O 
in O 
electrophysiological O 
assays O 
on O 
a O 
panel O 
of O 
six O 
K(+) B-FORMULA 
channels O 
( O 
K B-FORMULA 
(v)1.1-1.6 O 
) O 
by O 
using O 
the O 
two O 
- O 
electrode O 
voltage O 
clamp O 
technique O 
. O 
Three O 
new O 
α-KTx O 
peptides O 
were O 
found O 
and O 
called O 
MegKTx1 O 
, O 
MegKTx2 O 
and O 
MegKTx3 O 
( O 
M O 
. O 
gibbosus O 
, O 
K(+) B-FORMULA 
channel O 
toxin O 
number O 
1-3 O 
) O 
. O 
A O 
cDNA O 
library O 
from O 
the O 
telson O 
was O 
constructed O 
and O 
specific O 
screening O 
of O 
transcripts O 
was O 
performed O 
. O 
Biochemical O 
and O 
molecular O 
characterization O 
of O 
MegKTx O 
peptides O 
and O 
transcripts O 
shows O 
a O 
relation O 
with O 
toxins O 
of O 
three O 
different O 
α-KTx O 
subfamilies O 
( O 
α-KTx3.x O 
, O 
α-KTx9.x O 
and O 
α-KTx16.x O 
) O 
. O 

analysis O 
of O 
Drosophila O 
Cys B-FORMULA 
2- O 
His B-FORMULA 
2 O 
zinc B-SYSTEMATIC 
finger O 
proteins O 
reveals O 
a O 
multitude O 
of O 
novel O 
recognition O 
motifs O 
and O 
binding O 
determinants O 
. O 

zinc B-SYSTEMATIC 
finger O 
proteins O 
( O 
ZFPs O 
) O 
are O 
the O 
largest O 
group O 
of O 
transcription O 
factors O 
in O 
higher O 
metazoans O 
. O 
A O 
complete O 
characterization O 
of O 
these O 
ZFPs O 
and O 
their O 
associated O 
target O 
sequences O 
is O 
pivotal O 
to O 
fully O 
annotate O 
transcriptional O 
regulatory O 
networks O 
in O 
metazoan O 
genomes O 
. O 
As O 
a O 
first O 
step O 
in O 
this O 
process O 
, O 
we O 
have O 
characterized O 
the O 
DNA O 
- O 
binding O 
specificities O 
of O 
129 O 
zinc B-SYSTEMATIC 
finger O 
sets O 
from O 
Drosophila O 
using O 
a O 
bacterial O 
one O 
- O 
hybrid O 
system O 
. O 
This O 
data O 
set O 
contains O 
the O 
DNA O 
- O 
binding O 
specificities O 
for O 
at O 
least O 
one O 
encoded O 
ZFP O 
from O 
70 O 
unique O 
genes O 
and O 
23 O 
alternate O 
splice O 
isoforms O 
representing O 
the O 
largest O 
set O 
of O 
characterized O 
ZFPs O 
from O 
any O 
organism O 
described O 
to O 
date O 
. O 
These O 
recognition O 
motifs O 
can O 
be O 
used O 
to O 
predict O 
genomic O 
binding O 
sites O 
for O 
these O 
factors O 
within O 
the O 
fruit O 
fly O 
genome O 
. O 
Subsets O 
of O 
fingers O 
from O 
these O 
ZFPs O 
were O 
characterized O 
to O 
define O 
their O 
orientation O 
and O 
register O 
on O 
their O 
recognition O 
sequences O 
, O 
thereby O 
allowing O 
us O 
to O 
define O 
the O 
recognition O 
diversity O 
within O 
this O 
finger O 
set O 
. O 
We O 
find O 
that O 
the O 
characterized O 
fingers O 
can O 
specify O 
47 O 
of O 
the O 
64 O 
possible O 
DNA O 
triplets O 
. O 
To O 
confirm O 
the O 
utility O 
of O 
our O 
finger O 
recognition O 
models O 
, O 
we O 
employed O 
subsets O 
of O 
Drosophila O 
fingers O 
in O 
combination O 
with O 
an O 
existing O 
archive O 
of O 
artificial O 
zinc B-SYSTEMATIC 
finger O 
modules O 
to O 
create O 
ZFPs O 
with O 
novel O 
DNA O 
- O 
binding O 
specificity O 
. O 
These O 
hybrids O 
of O 
natural O 
and O 
artificial O 
fingers O 
can O 
be O 
used O 
to O 
create O 
functional O 
zinc B-SYSTEMATIC 
finger O 
nucleases O 
for O 
editing O 
vertebrate O 
genomes O 
. O 

of O 
Scutellaria O 
baicalensis O 
reduced O 
body O 
weight O 
and O 
blood O 
triglyceride B-FAMILY 
in O 
db O 
/ O 
db O 
Mice O 
. O 

baicalensis O 
has O 
been O 
extensively O 
employed O 
for O 
the O 
clinical O 
treatment O 
of O 
hyperlipidemia O 
, O 
atherosclerosis O 
, O 
hypertension O 
, O 
dysentery O 
, O 
inflammatory O 
diseases O 
, O 
and O 
the O 
common O 
cold O 
. O 
The O 
present O 
study O 
was O 
performed O 
to O 
investigate O 
the O 
anti-obesity O 
and O 
anti-dyslipidemia O 
effect O 
of O 
Scutellaria O 
baicalensis O 
extracts O 
( O 
SBE O 
) O 
in O 
type O 
2 O 
diabetic O 
db O 
/ O 
db O 
mice O 
. O 
Male O 
db O 
/ O 
db O 
mice O 
were O 
divided O 
into O 
three O 
groups O 
( O 
n O 
= O 
5 O 
) O 
and O 
orally O 
administrated O 
vehicle O 
( O 
control O 
) O 
, O 
SBE O 
10 O 
, O 
and O 
100 O 
mg O 
/ O 
kg O 
body O 
weight O 
/ O 
day O 
for O 
4 O 
weeks O 
everyday O 
. O 
Administration O 
of O 
SBE O 
improves O 
weight O 
gain O 
, O 
hypertriglyceridemia O 
, O 
and O 
hyperinsulinemia O 
in O 
db O 
/ O 
db O 
mice O 
. O 
In O 
obese O 
db O 
/ O 
db O 
mice O 
, O 
SBE O 
treatment O 
also O 
reduced O 
plasma O 
alanine B-TRIVIAL 
aminotransferase O 
levels O 
. O 
In O 
the O 
livers O 
of O 
db O 
/ O 
db O 
mice O 
, O 
SBE O 
promoted O 
5 B-SYSTEMATIC 
' I-SYSTEMATIC 
AMP I-SYSTEMATIC 
-activated O 
protein O 
kinase O 
activity O 
and O 
restored O 
metabolic O 
process O 
and O 
insulin O 
signaling O 
pathways O 
. O 
Our O 
data O 
demonstrate O 
that O 
SBE O 
exerts O 
potent O 
anti-obesity O 
and O 
anti-hypertriglyceride O 
effects O 
suggesting O 
its O 
useful O 
potential O 
function O 
as O 
adjuvant O 
therapeutic O 
agent O 
for O 
the O 
treatment O 
of O 
weight O 
gain O 
and O 
hypertriglyceridemia O 
. O 

of O 
chromium B-SYSTEMATIC 
in O 
edible O 
mushrooms O 
: O 
influence O 
of O 
environmental O 
and O 
genetic O 
factors O 
. O 

concentrations O 
were O 
determined O 
in O 
167 O 
samples O 
of O 
wild O 
edible O 
mushrooms O 
, O 
collected O 
from O 
three O 
different O 
sites O 
( O 
urban O 
, O 
traffic O 
and O 
pastureland O 
areas O 
) O 
in O 
Lugo O 
( O 
NW O 
Spain O 
) O 
. O 
The O 
hymenophore O 
( O 
H O 
) O 
and O 
the O 
rest O 
of O 
the O 
fruiting O 
body O 
( O 
RFB O 
) O 
were O 
analysed O 
separately O 
. O 
The O 
analyses O 
were O 
performed O 
using O 
inductively O 
coupled O 
plasma O 
optical O 
emission O 
spectrometry O 
( O 
ICP-OES O 
) O 
. O 
The O 
highest O 
mean O 
chromium B-SYSTEMATIC 
levels O 
( O 
mg O 
/ O 
kg O 
dry O 
weight O 
) O 
of O 
3.5 O 
and O 
8 O 
, O 
4.5 O 
and O 
6.2 O 
, O 
and O 
6.2 O 
and O 
4.3 O 
were O 
found O 
in O 
Lycoperdon O 
utriforme O 
, O 
Coprinus O 
comatus O 
and O 
Agaricus O 
campestris O 
in O 
H O 
and O 
RFB O 
, O 
respectively O 
. O 
The O 
highest O 
concentrations O 
of O 
chromium B-SYSTEMATIC 
were O 
observed O 
in O 
terrestrial O 
saprophytic O 
species O 
in O 
relation O 
to O 
mycorrhizal O 
species O 
. O 
With O 
respect O 
to O 
the O 
underlying O 
substrates O 
, O 
chromium B-SYSTEMATIC 
concentration O 
was O 
lowest O 
in O 
the O 
pastureland O 
area O 
( O 
24.6 O 
mg O 
/ O 
kg O 
dw O 
) O 
. O 
All O 
mushroom O 
species O 
were O 
bioexclusors O 
of O 
chromium B-SYSTEMATIC 
( O 
BCF O 
< O 
1 O 
) O 
with O 
statistically O 
significant O 
differences O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
The O 
consumption O 
of O 
mushrooms O 
harvested O 
from O 
the O 
areas O 
investigated O 
poses O 
no O 
toxicological O 
risk O 
to O 
human O 
health O 
due O 
to O 
chromium B-SYSTEMATIC 
. O 

1 O 
( O 
Top1 O 
) O 
resolves O 
transcription O 
- O 
associated O 
supercoils O 
by O 
generating O 
transient O 
single O 
- O 
strand O 
breaks O 
in O 
DNA O 
. O 
Top1 O 
activity O 
in O 
yeast O 
is O 
a O 
major O 
source O 
of O 
transcription O 
- O 
associated O 
mutagenesis O 
, O 
generating O 
a O 
distinctive O 
mutation O 
signature O 
characterized O 
by O 
deletions O 
in O 
short O 
, O 
tandem O 
repeats O 
. O 
A O 
similar O 
signature O 
is O 
associated O 
with O 
the O 
persistence O 
of O 
ribonucleoside B-FAMILY 
monophosphates I-FAMILY 
( O 
rNMPs B-FAMILY 
) O 
in O 
DNA O 
, O 
and O 
it O 
also O 
depends O 
on O 
Top1 O 
activity O 
. O 
There O 
is O 
only O 
partial O 
overlap O 
, O 
however O 
, O 
between O 
Top1-dependent O 
deletion O 
hotspots O 
identified O 
in O 
highly O 
transcribed O 
DNA O 
and O 
those O 
associated O 
with O 
rNMPs B-FAMILY 
, O 
suggesting O 
the O 
existence O 
of O 
both O 
rNMP B-ABBREVIATION 
-dependent O 
and O 
rNMP B-ABBREVIATION 
-independent O 
events O 
. O 
Here O 
, O 
we O 
present O 
genetic O 
studies O 
confirming O 
that O 
there O 
are O 
two O 
distinct O 
types O 
of O 
hotspots O 
. O 
Data O 
suggest O 
a O 
novel O 
model O 
in O 
which O 
rNMP B-ABBREVIATION 
-dependent O 
hotspots O 
are O 
generated O 
by O 
sequential O 
Top1 O 
reactions O 
and O 
are O 
consistent O 
with O 
rNMP B-ABBREVIATION 
-independent O 
hotspots O 
reflecting O 
processing O 
of O 
a O 
trapped O 
Top1 O 
cleavage O 
complex O 
. O 

- O 
state O 
dependent O 
dissolution O 
and O 
oral O 
bioavailability O 
of O 
piroxicam B-TRIVIAL 
in O 
rats O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
gain O 
understanding O 
about O 
the O 
effects O 
of O 
different O 
solid O 
- O 
state O 
forms O 
of O 
a O 
poorly O 
water O 
- O 
soluble O 
piroxicam B-TRIVIAL 
on O 
drug O 
dissolution O 
and O 
oral O 
bioavailability O 
in O 
rats O 
. O 
Three O 
different O 
solid O 
- O 
state O 
forms O 
of O 
piroxicam B-TRIVIAL 
were O 
studied O 
: O 
anhydrate O 
I O 
( O 
AH O 
) O 
, O 
monohydrate O 
( O 
MH O 
) O 
, O 
and O 
amorphous O 
form O 
in O 
solid O 
dispersion O 
( O 
SD O 
) O 
. O 
In O 
addition O 
, O 
the O 
effect O 
of O 
a O 
new O 
polymeric O 
excipient O 
Soluplus B-TRIVIAL 
® O 
( O 
polyvinyl B-FAMILY 
caprolactam I-FAMILY 
- I-FAMILY 
polyvinyl I-FAMILY 
acetate I-FAMILY 
- I-FAMILY 
polyethylene I-FAMILY 
glycol I-FAMILY 
graft I-FAMILY 
copolymer I-FAMILY 
) O 
on O 
oral O 
bioavailability O 
of O 
piroxicam B-TRIVIAL 
was O 
investigated O 
. O 
Significant O 
differences O 
in O 
the O 
dissolution O 
and O 
oral O 
bioavailability O 
were O 
found O 
between O 
the O 
solid O 
- O 
state O 
forms O 
of O 
piroxicam B-TRIVIAL 
. O 
Amorphous O 
piroxicam B-TRIVIAL 
in O 
SD O 
showed O 
the O 
fastest O 
dissolution O 
in O 
vitro O 
and O 
a O 
solid O 
- O 
state O 
transformation O 
to O 
MH O 
in O 
the O 
dissolution O 
medium O 
. O 
Despite O 
the O 
presence O 
of O 
solid O 
- O 
state O 
transformation O 
, O 
SD O 
exhibited O 
the O 
highest O 
rate O 
and O 
extent O 
of O 
oral O 
absorption O 
in O 
rats O 
. O 
Oral O 
bioavailability O 
of O 
other O 
two O 
solid O 
- O 
state O 
forms O 
decreased O 
in O 
the O 
order O 
AH O 
and O 
MH O 
. O 
The O 
use O 
of O 
Soluplus B-TRIVIAL 
® O 
was O 
found O 
to O 
enhance O 
the O 
dissolution O 
and O 
oral O 
bioavailability O 
of O 
piroxicam B-TRIVIAL 
in O 
rats O 
. O 
The O 
present O 
study O 
shows O 
the O 
importance O 
of O 
solid O 
- O 
state O 
form O 
selection O 
for O 
oral O 
bioavailability O 
of O 
a O 
poorly O 
water O 
- O 
soluble O 
drug O 
. O 

Smilacis O 
Glabrae O 
( O 
RSG O 
) O 
and O 
Rhizoma O 
Smilacis O 
Chinae O 
( O 
RSC O 
) O 
are O 
two O 
herbal O 
materials O 
that O 
belong O 
to O 
the O 
same O 
genera O 
and O 
are O 
both O 
listed O 
in O 
the O 
Chinese O 
Pharmacopoeia O 
. O 
Chemical O 
constituents O 
in O 
the O 
two O 
species O 
were O 
compared O 
by O 
HPLC-DAD-MS O 
/ O 
MS O 
. O 
Many O 
common O 
constituents O 
were O 
found O 
in O 
both O 
species O 
, O 
including O 
shikimic B-TRIVIAL 
acid I-TRIVIAL 
, O 
5-O-caffeoylshikimic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
trans-resveratrol B-TRIVIAL 
, O 
taxifolin B-TRIVIAL 
, O 
astilbin B-TRIVIAL 
and O 
its O 
three O 
stereoisomers O 
, O 
engeletin B-TRIVIAL 
and O 
isoengeletin B-TRIVIAL 
. O 
However O 
, O 
syringic B-TRIVIAL 
acid I-TRIVIAL 
was O 
found O 
only O 
in O 
RSG O 
, O 
while O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
was O 
found O 
only O 
in O 
RSC O 
. O 

cordifolia O 
is O 
a O 
well O 
reported O 
plant O 
possessing O 
numerous O 
medicinal O 
values O 
including O 
anti-diabetic O 
property O 
. O 
Aim O 
of O 
the O 
present O 
study O 
is O 
to O 
study O 
the O 
mechanism O 
of O 
action O 
of O 
Tinospora O 
cordifolia O 
and O 
its O 
active O 
compound O 
in O 
differentiated O 
myocytes O 
, O 
L6 O 
cells O 
. O 
Key O 
marker O 
of O 
diabetes O 
in O 
cells O 
is O 
the O 
insulin O 
dependent O 
glucose B-TRIVIAL 
transporter-4 O 
( O 
Glut-4 O 
) O 
which O 
also O 
responds O 
to O 
exogenous O 
chemicals O 
, O 
and O 
is O 
over O 
expressed O 
up O 
to O 
5- O 
and O 
4-fold O 
, O 
by O 
Tinospora O 
cordifolia O 
and O 
palmatine B-TRIVIAL 
, O 
respectively O 
. O 
Next O 
to O 
Glut-4 O 
, O 
the O 
predominant O 
protein O 
influencing O 
glucose B-TRIVIAL 
metabolism O 
is O 
PPARα O 
and O 
γ O 
whose O 
expressions O 
were O 
also O 
positively O 
modulated O 
. O 
Further O 
, O 
the O 
inhibitors O 
of O 
insulin O 
pathway O 
prevented O 
glucose B-TRIVIAL 
uptake O 
mediated O 
by O 
Tinospora O 
cordifolia O 
and O 
palmatine B-TRIVIAL 
which O 
shows O 
that O 
the O 
activity O 
is O 
majorly O 
mediated O 
through O 
insulin O 
pathway O 
. O 

/ O 
HYPOTHESIS O 
: O 
Precise O 
estimates O 
of O 
progression O 
rates O 
from O 
' O 
prediabetes O 
' O 
to O 
type O 
2 O 
diabetes O 
are O 
needed O 
to O 
optimise O 
prevention O 
strategies O 
for O 
high O 
- O 
risk O 
individuals O 
. O 
There O 
is O 
acceptance O 
of O 
prediabetes O 
defined O 
by O 
impaired O 
fasting O 
glucose B-TRIVIAL 
( O 
IFG O 
) O 
and O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
( O 
IGT O 
) O 
, O 
but O 
there O 
is O 
some O 
controversy O 
surrounding O 
HbA1c-defined O 
prediabetes O 
ranges O 
, O 
with O 
some O 
favouring O 
6.0-6.4% O 
( O 
42-46 O 
mmol O 
/ O 
mol O 
) O 
. O 
Comparing O 
progression O 
rates O 
between O 
groups O 
might O 
aid O 
this O 
issue O 
, O 
thus O 
we O 
aimed O 
to O 
accurately O 
estimate O 
progression O 
rates O 
to O 
diabetes O 
from O 
different O 
prediabetes O 
categories O 
. O 
METHODS O 
: O 
Meta-analysis O 
of O 
prospective O 
observational O 
studies O 
in O 
which O 
participants O 
had O 
prediabetes O 
at O 
baseline O 
( O 
ADA-defined O 
IFG O 
[ O 
5.6-6.9 O 
mmol O 
/ O 
l O 
] O 
, O 
WHO-defined O 
IFG O 
[ O 
6.1-6.9 O 
mmol O 
/ O 
l O 
] O 
, O 
IGT O 
( O 
7.8-11.0 O 
mmol O 
/ O 
l O 
) O 
or O 
raised O 
HbA1c O 
[ O 
6.0-6.4% O 
/ O 
42-46 O 
mmol O 
/ O 
mol O 
] O 
) O 
and O 
were O 
followed O 
up O 
for O 
incident O 
diabetes O 
. O 
Incidence O 
rates O 
were O 
combined O 
using O 
Bayesian O 
random O 
effects O 
models O 
. O 
RESULTS O 
: O 
Overall O 
, O 
70 O 
studies O 
met O 
the O 
inclusion O 
criteria O 
. O 
In O 
the O 
six O 
studies O 
that O 
used O 
raised O 
HbA1c O 
, O 
the O 
pooled O 
incidence O 
rate O 
( O 
95% O 
credible O 
interval O 
) O 
of O 
diabetes O 
was O 
35.6 O 
( O 
15.1 O 
, O 
83 O 
) O 
per O 
1000 O 
person O 
- O 
years O 
. O 
This O 
rate O 
was O 
most O 
similar O 
to O 
that O 
for O 
ADA-defined O 
IFG O 
( O 
11 O 
studies O 
; O 
35.5 O 
[ O 
26.6 O 
, O 
48 O 
] O 
) O 
and O 
was O 
non-significantly O 
lower O 
than O 
WHO-defined O 
IFG O 
( O 
34 O 
studies O 
; O 
47.4 O 
[ O 
37.4 O 
, O 
59.8 O 
] O 
) O 
, O 
IGT O 
( O 
46 O 
studies O 
, O 
45.5 O 
[ O 
37.8 O 
, O 
54.5 O 
] O 
) O 
and O 
IFG O 
plus O 
IGT O 
( O 
15 O 
studies O 
, O 
70.4 O 
[ O 
53.8 O 
, O 
89.7 O 
] O 
) O 
. O 
Similar O 
results O 
were O 
seen O 
when O 
the O 
data O 
were O 
analysed O 
by O 
the O 
criteria O 
used O 
to O 
diagnose O 
diabetes O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
This O 
study O 
provides O 
evidence O 
that O 
progression O 
rates O 
differ O 
by O 
prediabetes O 
definition O 
, O 
which O 
has O 
implications O 
for O 
the O 
planning O 
and O 
implementation O 
of O 
diabetes O 
prevention O 
programmes O 
. O 
HbA1c O 
6.0-6.4% O 
might O 
identify O 
people O 
at O 
a O 
lower O 
diabetes O 
risk O 
than O 
other O 
prediabetes O 
definitions O 
, O 
but O 
further O 
research O 
is O 
needed O 
. O 

epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
has O 
an O 
essential O 
role O 
in O 
multiple O 
signaling O 
pathways O 
, O 
including O 
cell O 
proliferation O 
and O 
migration O 
, O 
through O 
extracellular O 
ligand O 
binding O 
and O 
subsequent O 
activation O 
of O 
its O 
intracellular O 
tyrosine B-TRIVIAL 
kinase O 
( O 
TK O 
) O 
domain O 
. O 
The O 
non-small O 
cell O 
lung O 
cancer O 
(NSCLC)-associated O 
EGFR O 
mutants O 
, O 
L858R O 
and O 
G719S O 
, O 
are O 
constitutively O 
active O 
and O 
oncogenic O 
. O 
They O 
display O 
sensitivity O 
to O 
TK O 
inhibitors O 
, O 
including O 
gefitinib B-TRIVIAL 
and O 
erlotinib B-TRIVIAL 
. O 
In O 
contrast O 
, O 
the O 
secondary O 
mutation O 
of O 
the O 
gatekeeper O 
residue O 
, O 
T790M O 
, O 
reportedly O 
confers O 
inhibitor O 
resistance O 
on O 
the O 
oncogenic O 
EGFR O 
mutants O 
. O 
In O 
this O 
study O 
, O 
our O 
biochemical O 
analyses O 
revealed O 
that O 
the O 
introduction O 
of O 
the O 
T790M O 
mutation O 
confers O 
gefitinib B-TRIVIAL 
resistance O 
on O 
the O 
G719S O 
mutant O 
. O 
The O 
G719S O 
/ O 
T790M O 
double O 
mutant O 
has O 
enhanced O 
activity O 
and O 
retains O 
high O 
gefitinib B-TRIVIAL 
-binding O 
affinity O 
. O 
The O 
T790M O 
mutation O 
increases O 
the O 
ATP B-ABBREVIATION 
affinity O 
of O 
the O 
G719S O 
mutant O 
, O 
explaining O 
the O 
acquired O 
drug O 
resistance O 
of O 
the O 
double O 
mutant O 
. O 
Structural O 
analyses O 
of O 
the O 
G719S O 
/ O 
T790M O 
double O 
mutant O 
, O 
as O 
well O 
as O 
the O 
wild O 
type O 
and O 
the O 
G719S O 
and O 
L858R O 
mutants O 
, O 
revealed O 
that O 
the O 
T790M O 
mutation O 
stabilizes O 
the O 
hydrophobic O 
spine O 
of O 
the O 
active O 
EGFR-TK O 
conformation O 
. O 
The O 
Met B-FORMULA 
790 O 
side O 
chain O 
of O 
the O 
G719S O 
/ O 
T790M O 
double O 
mutant O 
, O 
in O 
the O 
apo O 
form O 
and O 
gefitinib B-TRIVIAL 
- O 
and O 
AMPPNP O 
- O 
bound O 
forms O 
, O 
adopts O 
different O 
conformations O 
that O 
explain O 
the O 
accommodation O 
of O 
these O 
ligands O 
. O 
In O 
the O 
L858R O 
mutant O 
structure O 
, O 
the O 
active O 
- O 
site O 
cleft O 
is O 
expanded O 
by O 
the O 
repositioning O 
of O 
Phe B-FORMULA 
723 O 
within O 
the O 
P-loop O 
. O 
Notably O 
, O 
the O 
introduction O 
of O 
the O 
F723A O 
mutation O 
greatly O 
enhanced O 
the O 
gefitinib B-TRIVIAL 
sensitivity O 
of O 
the O 
wild O 
- O 
type O 
EGFR O 
in O 
vivo O 
, O 
supporting O 
our O 
hypothesis O 
that O 
the O 
expansion O 
of O 
the O 
active O 
- O 
site O 
cleft O 
results O 
in O 
enhanced O 
gefitinib B-TRIVIAL 
sensitivity O 
. O 
Taken O 
together O 
, O 
our O 
results O 
provide O 
a O 
structural O 
basis O 
for O 
the O 
altered O 
drug O 
sensitivities O 
caused O 
by O 
distinct O 
NSCLC-associated O 
EGFR O 
mutations O 
. O 

chemopreventive O 
activity O 
of O 
hydroxytyrosol B-SYSTEMATIC 
on O 
HL60 O 
and O 
HL60R O 
cells O 
by O 
chemical O 
conversion O 
into O 
thio B-SYSTEMATIC 
derivatives O 
. O 

derivatives O 
of O 
hydroxytyrosol B-SYSTEMATIC 
containing O 
thiol B-FAMILY 
, O 
thioacetate B-SYSTEMATIC 
and O 
disulfide B-SYSTEMATIC 
functionalities O 
were O 
synthesized O 
from O 
natural O 
hydroxytyrosol B-SYSTEMATIC 
( O 
3,4-DHPEA B-SYSTEMATIC 
) O 
via O 
3,4-dihydroxyphenethyl B-FAMILY 
halides I-FAMILY 
. O 
These O 
compounds O 
, O 
containing O 
the O 
combination O 
of O 
catechol B-TRIVIAL 
moiety O 
and O 
divalent O 
sulfur B-SYSTEMATIC 
functions O 
, O 
were O 
tested O 
for O 
the O 
pro O 
- O 
apoptotic O 
and O 
anti-proliferative O 
activities O 
on O 
both O 
parental O 
HL60 O 
and O 
multi O 
- O 
drug O 
resistant O 
HL60R O 
cells O 
. O 
It O 
was O 
found O 
that O 
all O 
synthesized O 
compounds O 
were O 
more O 
effective O 
than O 
3,4-DHPEA B-SYSTEMATIC 
in O 
inducing O 
apoptosis O 
on O 
HL60R O 
cells O 
, O 
and O 
that O 
the O 
hydroxytyrosol B-SYSTEMATIC 
disulfide B-SYSTEMATIC 
was O 
the O 
most O 
active O 
pro O 
- O 
apoptotic O 
and O 
anti-proliferative O 
compound O 
on O 
both O 
HL60 O 
and O 
HL60R O 
cells O 
. O 
Different O 
from O 
3,4-DHPEA B-SYSTEMATIC 
, O 
all O 
thio O 
derivatives O 
of O 
hydroxytyrosol B-SYSTEMATIC 
induced O 
apoptosis O 
by O 
a O 
mechanism O 
not O 
involving O 
the O 
release O 
of O 
H(2)O(2) B-FORMULA 
in O 
the O 
culture O 
medium O 
. O 
The O 
data O 
on O 
HL60R O 
cells O 
suggest O 
that O 
these O 
compounds O 
could O 
be O 
able O 
to O 
reverse O 
the O 
resistance O 
toward O 
the O 
most O 
common O 
drugs O 
in O 
cancer O 
therapy O 
. O 

of O 
a O 
novel O 
series O 
of O 
quinolone B-FAMILY 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
agonists O 
. O 

throughput O 
screening O 
led O 
to O 
the O 
identification O 
of O 
a O 
novel O 
series O 
of O 
quinolone B-FAMILY 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
agonists O 
. O 
Optimization O 
of O 
an O 
HTS O 
hit O 
( O 
1 O 
) O 
led O 
to O 
4-phenyl-1-(quinuclidin-3-ylmethyl)quinolin-2(1H)-one B-SYSTEMATIC 
, O 
which O 
was O 
found O 
to O 
be O 
potent O 
and O 
selective O 
. O 
Poor O 
brain O 
penetrance O 
in O 
this O 
series O 
was O 
attributed O 
to O 
transporter O 
- O 
mediated O 
efflux O 
, O 
which O 
was O 
in O 
turn O 
due O 
to O 
high O 
pKa O 
. O 
A O 
novel O 
4-fluoroquinuclidine B-SYSTEMATIC 
significantly O 
lowered O 
the O 
pKa O 
of O 
the O 
quinuclidine B-TRIVIAL 
moiety O 
, O 
reducing O 
efflux O 
as O 
measured O 
by O 
a O 
Caco-2 O 
assay O 
. O 

phototoxicity O 
of O 
cosmetic O 
formulations O 
containing O 
photounstable O 
and O 
photostable O 
UV-filters O 
and O 
vitamin B-FAMILY 
A I-FAMILY 
palmitate I-FAMILY 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
in O 
vitro O 
skin O 
phototoxicity O 
of O 
cosmetic O 
formulations O 
containing O 
photounstable O 
and O 
photostable O 
UV-filters O 
and O 
vitamin B-FAMILY 
A I-FAMILY 
palmitate I-FAMILY 
, O 
assessed O 
by O 
two O 
in O 
vitro O 
techniques O 
: O 
3T3 O 
Neutral O 
Red O 
Uptake O 
Phototoxicity O 
Test O 
and O 
Human O 
3-D O 
Skin O 
Model O 
In O 
Vitro O 
Phototoxicity O 
Test O 
. O 
For O 
this O 
, O 
four O 
different O 
formulations O 
containing O 
vitamin B-FAMILY 
A I-FAMILY 
palmitate I-FAMILY 
and O 
different O 
UV-filters O 
combinations O 
, O 
two O 
of O 
them O 
considered O 
photostable O 
and O 
two O 
of O 
them O 
considered O 
photounstable O 
, O 
were O 
prepared O 
. O 
Solutions O 
of O 
each O 
UV-filter O 
and O 
vitamin O 
under O 
study O 
and O 
solutions O 
of O 
four O 
different O 
combinations O 
under O 
study O 
were O 
also O 
prepared O 
. O 
The O 
phototoxicity O 
was O 
assessed O 
in O 
vitro O 
by O 
the O 
3T3 O 
NRU O 
phototoxicity O 
test O 
( O 
3T3-NRU-PT O 
) O 
and O 
subsequently O 
in O 
a O 
phototoxicity O 
test O 
on O 
reconstructed O 
human O 
skin O 
model O 
( O 
H3D-PT O 
) O 
. O 
Avobenzone B-TRIVIAL 
presented O 
a O 
pronounced O 
phototoxicity O 
and O 
vitamin B-FAMILY 
A I-FAMILY 
presented O 
a O 
tendency O 
to O 
a O 
weak O 
phototoxic O 
potential O 
. O 
A O 
synergistic O 
effect O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
palmitate I-FAMILY 
on O 
the O 
phototoxicity O 
of O 
combinations O 
containing O 
avobenzone B-TRIVIAL 
was O 
observed O 
. O 
H3D-PT O 
results O 
did O 
not O 
confirm O 
the O 
positive O 
3T3-NRU-PT O 
results O 
. O 
However O 
, O 
despite O 
the O 
four O 
formulations O 
studied O 
did O 
not O 
present O 
any O 
acute O 
phototoxicity O 
potential O 
, O 
the O 
combination O 
2 O 
containing O 
octyl B-SYSTEMATIC 
methoxycinnamate I-SYSTEMATIC 
( O 
OMC B-ABBREVIATION 
) O 
, O 
avobenzone B-TRIVIAL 
( O 
AVB B-ABBREVIATION 
) O 
and O 
4-methylbenzilidene B-SYSTEMATIC 
camphor I-SYSTEMATIC 
( O 
MBC B-ABBREVIATION 
) O 
presented O 
an O 
indication O 
of O 
phototoxicity O 
that O 
should O 
be O 
better O 
investigated O 
in O 
terms O 
of O 
the O 
frequency O 
of O 
photoallergic O 
or O 
chronic O 
phototoxicity O 
in O 
humans O 
, O 
once O 
these O 
tests O 
are O 
scientifically O 
validated O 
only O 
to O 
detect O 
phototoxic O 
potential O 
with O 
the O 
aim O 
of O 
preventing O 
phototoxic O 
reactions O 
in O 
the O 
general O 
population O 
, O 
and O 
positive O 
results O 
cannot O 
predict O 
the O 
exact O 
incidence O 
of O 
phototoxic O 
reactions O 
in O 
humans O 
. O 

carbocyclic I-FAMILY 
adenosine I-FAMILY 
phosphoramidate I-FAMILY 
( O 
FMCAP B-ABBREVIATION 
) O 
prodrug O 
: O 
in O 
vitro O 
anti-HBV O 
activity O 
against O 
the O 
lamivudine B-TRIVIAL 
- O 
entecavir B-TRIVIAL 
resistant O 
triple O 
mutant O 
and O 
its O 
mechanism O 
of O 
action O 
. O 

2'-fluoro-6'-methylene- B-FAMILY 
carbocyclic I-FAMILY 
adenosine I-FAMILY 
( O 
FMCA B-ABBREVIATION 
) O 
monophosphate B-SYSTEMATIC 
prodrug O 
( O 
FMCAP B-ABBREVIATION 
) O 
was O 
synthesized O 
and O 
evaluated O 
for O 
its O 
in O 
vitro O 
anti-HBV O 
potency O 
against O 
a O 
lamivudine B-TRIVIAL 
- O 
entecavir B-TRIVIAL 
resistant O 
clone O 
( O 
L180M O 
+ O 
M204V O 
+ O 
S202G O 
) O 
. O 
FMCA B-ABBREVIATION 
demonstrated O 
significant O 
antiviral O 
activity O 
against O 
wild O 
- O 
type O 
as O 
well O 
as O 
lamivudine B-TRIVIAL 
- O 
entecavir B-TRIVIAL 
resistant O 
triple O 
mutant O 
( O 
L180M O 
+ O 
M204V O 
+ O 
S202G O 
) O 
. O 
The O 
monophosphate B-SYSTEMATIC 
prodrug O 
( O 
FMCAP B-ABBREVIATION 
) O 
demonstrated O 
greater O 
than O 
12-fold O 
( O 
12× O 
) O 
increase O 
in O 
anti-HBV O 
activity O 
without O 
increased O 
cellular O 
toxicity O 
. O 
Mitochondrial O 
and O 
cellular O 
toxicity O 
studies O 
of O 
FMCA B-ABBREVIATION 
indicated O 
that O 
there O 
is O 
no O 
significant O 
toxicity O 
up O 
to O 
100 O 
μM O 
. O 
Mode O 
of O 
action O 
studies O 
by O 
molecular O 
modeling O 
indicate O 
that O 
the O 
2'-fluoro B-SYSTEMATIC 
moiety O 
by O 
hydrogen B-SYSTEMATIC 
bond O 
as O 
well O 
as O 
the O 
Van O 
der O 
Waals O 
interaction O 
of O 
the O 
carbocyclic B-FAMILY 
ring O 
with O 
the O 
phenylalanine B-TRIVIAL 
moiety O 
of O 
the O 
polymerase O 
promote O 
the O 
positive O 
binding O 
, O 
even O 
in O 
the O 
drug O 
- O 
resistant O 
mutants O 
. O 

on O 
contemporary O 
recognition O 
and O 
sensing O 
of O 
fluoride B-SYSTEMATIC 
anion O 
in O 
solution O 
and O 
in O 
the O 
solid O 
state O 
. O 

fluoride B-SYSTEMATIC 
anion O 
has O 
recently O 
gained O 
well O 
deserved O 
attention O 
among O 
the O 
scientific O 
community O 
for O 
its O 
importance O 
in O 
many O 
fields O 
of O 
human O 
activities O 
, O 
but O 
also O 
for O 
concerns O 
on O 
its O 
effect O 
on O 
health O 
and O 
the O 
environment O 
. O 
Although O 
surprisingly O 
overlooked O 
in O 
systematic O 
studies O 
in O 
the O 
past O 
, O 
fluoride B-SYSTEMATIC 
has O 
nowadays O 
become O 
a O 
topical O 
target O 
in O 
the O 
field O 
of O 
anion O 
recognition O 
. O 
A O 
multitude O 
of O 
scientific O 
reports O 
are O 
published O 
every O 
year O 
where O 
the O 
establishment O 
of O 
efficient O 
and O 
specific O 
interaction O 
with O 
fluoride B-SYSTEMATIC 
is O 
sought O 
in O 
polar O 
and O 
aqueous O 
media O 
. O 
Here O 
, O 
the O 
emphasis O 
is O 
directed O 
to O 
a O 
detailed O 
description O 
of O 
the O 
most O 
interesting O 
contemporary O 
studies O 
in O 
the O 
field O 
, O 
with O 
a O 
particular O 
focus O 
given O 
to O 
those O 
published O 
in O 
the O 
last O 
few O 
years O 
. O 

glycosides I-FAMILY 
from O 
the O 
flower O 
buds O 
of O 
Lonicera O 
japonica O 
. O 

new O 
glycosides O 
( O 
1-6 O 
) O 
have O 
been O 
isolated O 
from O 
the O 
flower O 
buds O 
of O 
Lonicera O 
japonica O 
. O 
Their O 
structures O 
including O 
the O 
absolute O 
configurations O 
were O 
determined O 
by O 
spectroscopic O 
and O 
chemical O 
methods O 
as O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-2-hydroxy-5-methoxybenzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
2-O-β-d-(6-O-benzoyl)-glucopyranoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-4-hydroxy-3,5-dimethoxybenzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
4-O-β-d-(6-O-benzoyl)-glucopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-(E)-3,5-dimethoxyphenylpropenoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
4-O-β-d-(6-O-benzoyl)-glucopyranoside I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-(7S,8R)-(4-hydroxyphenylglycerol I-SYSTEMATIC 
9-O-β-d-[6-O-(E)-4-hydroxy-3,5-dimethoxyphenylpropenoyl]-glucopyranoside I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-(7S,8R)-(4-hydroxy-3-methoxyphenylglycerol I-SYSTEMATIC 
9-O-β-d-[6-O-(E)-4-hydroxy-3,5-dimethoxyphenylpropenoyl]-glucopyranoside I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
and O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-4-hydroxy-3-methoxyphenol I-SYSTEMATIC 
β-d-{6-O-[4-O-(7S,8R)-(4-hydroxy-3-methoxyphenylglycerol-8-yl)-3-methoxybenzoyl]}-glucopyranoside I-SYSTEMATIC 
( O 
6 O 
) O 
, O 
respectively O 
. O 

on O 
a O 
rhein B-TRIVIAL 
-producing O 
endophytic O 
fungus O 
isolated O 
from O 
Rheum O 
palmatum O 
L O 
. O 

palmatum O 
L O 
. O 
( O 
Chinese O 
rhubarb O 
) O 
is O 
a O 
highly O 
regarded O 
medicinal O 
plant O 
. O 
Its O 
dominant O 
active O 
constituents O 
are O 
anthraquinones B-FAMILY 
including O 
emodin B-TRIVIAL 
, O 
aloe B-TRIVIAL 
- I-TRIVIAL 
emodin I-TRIVIAL 
, O 
rhein B-TRIVIAL 
, O 
etc O 
. O 
Rhein B-TRIVIAL 
naturally O 
occurs O 
in O 
anthraquinone B-SYSTEMATIC 
( O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
3 I-SYSTEMATIC 
, I-SYSTEMATIC 
8-trihydroxy-6-methyl I-SYSTEMATIC 
anthraquinone I-SYSTEMATIC 
) O 
, O 
which O 
is O 
found O 
in O 
R O 
. O 
palmatum O 
L O 
. O 
and O 
related O 
plants O 
such O 
as O 
rhubarb O 
. O 
It O 
has O 
good O 
antitumor O 
, O 
anti-inflammatory O 
, O 
anticancer O 
, O 
antimicrobial O 
and O 
hemostatic O 
properties O 
. O 
In O 
this O 
study O 
, O 
a O 
total O 
of O 
14 O 
strains O 
of O 
endophytic O 
fungi O 
were O 
isolated O 
from O 
R O 
. O 
palmatum O 
L O 
. O 
All O 
fungal O 
isolates O 
were O 
fermented O 
in O 
liquid O 
PDA O 
medium O 
and O 
their O 
extracts O 
were O 
preliminarily O 
analyzed O 
by O 
antibacterial O 
reactions O 
, O 
magnesium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
- O 
methanol B-SYSTEMATIC 
reagent O 
and O 
Borntraiger's O 
reaction O 
, O 
and O 
the O 
strain O 
reselection O 
was O 
made O 
by O 
thin O 
- O 
layer O 
chromatography O 
( O 
TLC O 
) O 
, O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
and O 
LC-MS O 
to O 
identify O 
the O 
fermentation O 
products O 
of O 
the O 
selected O 
strains O 
and O 
confirmed O 
through O 
a O 
comparison O 
with O 
authentic O 
standards O 
. O 
Extract O 
from O 
one O 
strain O 
, O 
R13 O 
, O 
showed O 
positive O 
reactions O 
with O 
both O 
reagents O 
. O 
The O 
strain O 
R13 O 
had O 
a O 
component O 
with O 
the O 
same O 
TLC O 
( O 
Rf O 
) O 
value O 
and O 
HPLC O 
, O 
LC-MS O 
retention O 
time O 
as O 
authentic O 
rhein B-TRIVIAL 
standards O 
. O 
The O 
yield O 
of O 
rhein B-TRIVIAL 
in O 
R13 O 
can O 
reach O 
5.672mgl(-1) O 
. O 
The O 
fungi O 
were O 
identified O 
as O 
Fusarium O 
solani O 
by O 
using O 
both O 
ITS O 
rDNA O 
sequencing O 
and O 
spore O 
morphology O 
. O 

RELEVANCE O 
: O 
Rokumi O 
- O 
jio O 
- O 
gan O 
- O 
containing O 
prescriptions O 
, O 
traditional O 
medicine O 
, O 
are O 
widely O 
used O 
to O 
treat O 
renal O 
dysfunction O 
in O 
Japan O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
The O 
present O 
study O 
was O 
conducted O 
to O 
examine O 
whether O 
two O 
Rokumi-jio- O 
gan O 
- O 
containing O 
prescriptions O 
( O 
Hachimi O 
- O 
jio O 
- O 
gan O 
and O 
Bakumi O 
- O 
jio O 
- O 
gan O 
) O 
have O 
an O 
ameliorative O 
effect O 
on O 
dyslipidemia O 
in O 
nephrectomized O 
rats O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Each O 
prescription O 
was O 
orally O 
administered O 
to O 
nephrectomized O 
rats O 
at O 
150mg O 
/ O 
kg O 
body O 
weight O 
per O 
day O 
for O 
10 O 
weeks O 
, O 
and O 
its O 
effect O 
was O 
compared O 
with O 
vehicle O 
- O 
treated O 
nephrectomized O 
rats O 
. O 
RESULTS O 
: O 
Rats O 
given O 
Hachimi O 
- O 
jio O 
- O 
gan O 
and O 
Bakumi O 
- O 
jio O 
- O 
gan O 
showed O 
an O 
improvement O 
of O 
renal O 
functional O 
parameters O 
such O 
as O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
, O 
creatinine B-TRIVIAL 
, O 
creatinine B-TRIVIAL 
clearance O 
, O 
and O 
urinary O 
protein O 
. O 
The O 
increased O 
triglyceride B-FAMILY 
, O 
total O 
cholesterol B-TRIVIAL 
, O 
non-esterified O 
fatty B-FAMILY 
acid I-FAMILY 
, O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
, O 
and O 
very O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
/ O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
levels O 
in O 
serum O 
, O 
and O 
triglyceride B-FAMILY 
and O 
total O 
cholesterol B-TRIVIAL 
contents O 
in O 
the O 
kidney O 
of O 
nephrectomized O 
rats O 
were O 
significantly O 
decreased O 
by O 
Hachimi O 
- O 
jio O 
- O 
gan O 
and O 
Bakumi O 
- O 
jio O 
- O 
gan O 
administration O 
. O 
Furthermore O 
, O 
Hachimi O 
- O 
jio O 
- O 
gan O 
acts O 
as O 
a O 
regulator O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
, O 
sterol B-FAMILY 
regulatory O 
element O 
binding O 
protein O 
(SREBP)-1 O 
, O 
and O 
SREBP-2 O 
. O 
On O 
the O 
contrary O 
, O 
the O 
increased O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substance O 
were O 
decreased O 
, O 
while O 
superoxide B-TRIVIAL 
dismutase O 
and O 
the O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
/ O 
oxidized B-TRIVIAL 
glutathione I-TRIVIAL 
ratio O 
were O 
augmented O 
by O 
Hachimi O 
- O 
jio O 
- O 
gan O 
rather O 
than O 
Bakumi O 
- O 
jio O 
- O 
gan O 
. O 
The O 
improvement O 
of O 
nuclear O 
factor O 
- O 
kappa O 
Bp65 O 
, O 
cyclooxygenase-2 O 
, O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
, O 
NF-E2 O 
- O 
related O 
factor O 
2 O 
, O 
and O 
heme B-FAMILY 
oxygenase-1 O 
was O 
marked O 
in O 
the O 
group O 
administered O 
Bakumi O 
- O 
jio O 
- O 
gan O 
. O 
However O 
, O 
oil B-TRIVIAL 
red I-TRIVIAL 
O I-TRIVIAL 
staining O 
showed O 
that O 
the O 
increased O 
lipid O 
deposition O 
in O 
the O 
kidney O 
of O 
nephrectomized O 
rats O 
improved O 
on O 
Hachimi O 
- O 
jio O 
- O 
gan O 
and O 
Bakumi O 
- O 
jio O 
- O 
gan O 
administration O 
. O 
CONCLUSION O 
: O 
This O 
study O 
provides O 
scientific O 
evidence O 
that O 
two O 
Rokumi O 
- O 
jio O 
- O 
gan O 
- O 
containing O 
prescriptions O 
( O 
Hachimi O 
- O 
jio O 
- O 
gan O 
and O 
Bakumi O 
- O 
jio O 
- O 
gan O 
) O 
improves O 
oxidative O 
stress O 
via O 
dyslipidemia O 
in O 
the O 
remnant O 
kidney O 
of O 
nephrectomized O 
rats O 
. O 

whole O 
zebrafish O 
embryo O 
model O 
( O 
ZFE O 
) O 
has O 
proven O 
its O 
applicability O 
in O 
developmental O 
toxicity O 
testing O 
. O 
Since O 
functional O 
hepatocytes O 
are O 
already O 
present O 
from O 
36 O 
h O 
post O 
fertilization O 
onwards O 
, O 
whole O 
ZFE O 
have O 
been O 
proposed O 
as O 
an O 
attractive O 
alternative O 
to O 
mammalian O 
in O 
vivo O 
models O 
in O 
hepatotoxicity O 
testing O 
. O 
The O 
goal O 
of O 
the O 
present O 
study O 
is O 
to O 
further O 
underpin O 
the O 
applicability O 
of O 
whole O 
ZFE O 
for O 
hepatotoxicity O 
testing O 
by O 
combining O 
histopathology O 
and O 
next O 
- O 
generation O 
sequencing O 
- O 
based O 
gene O 
expression O 
profiling O 
. O 
To O 
this O 
aim O 
, O 
whole O 
ZFE O 
and O 
adult O 
zebrafish O 
were O 
exposed O 
to O 
a O 
set O 
of O 
hepatotoxic O 
reference O 
compounds O 
. O 
Histopathology O 
revealed O 
compound O 
and O 
life O 
- O 
stage O 
- O 
specific O 
effects O 
indicative O 
of O 
toxic O 
injury O 
in O 
livers O 
of O 
whole O 
ZFE O 
and O 
adult O 
zebrafish O 
. O 
Next O 
- O 
generation O 
sequencing O 
( O 
NGS O 
) O 
was O 
used O 
to O 
compare O 
transcript O 
profiles O 
in O 
pooled O 
individual O 
RNA O 
samples O 
of O 
whole O 
ZFE O 
and O 
livers O 
of O 
adult O 
zebrafish O 
. O 
This O 
revealed O 
that O 
hepatotoxicity O 
- O 
associated O 
expression O 
can O 
be O 
detected O 
beyond O 
the O 
overall O 
transcription O 
noise O 
in O 
the O 
whole O 
embryo O 
. O 
In O 
situ O 
hybridization O 
verified O 
liver O 
specificity O 
of O 
selected O 
highly O 
expressed O 
markers O 
in O 
whole O 
ZFE O 
. O 
Finally O 
, O 
cyclosporine B-TRIVIAL 
A I-TRIVIAL 
( O 
CsA B-ABBREVIATION 
) O 
was O 
used O 
as O 
an O 
illustrative O 
case O 
to O 
support O 
applicability O 
of O 
ZFE O 
in O 
hepatotoxicity O 
testing O 
by O 
comparing O 
CsA B-ABBREVIATION 
-induced O 
gene O 
expression O 
between O 
ZFE O 
, O 
in O 
vivo O 
mouse O 
liver O 
and O 
HepaRG O 
cells O 
on O 
the O 
levels O 
of O 
single O 
genes O 
, O 
pathways O 
and O 
transcription O 
factors O 
. O 
While O 
there O 
was O 
no O 
clear O 
overlap O 
on O 
single O 
gene O 
level O 
between O 
the O 
whole O 
ZFE O 
and O 
in O 
vivo O 
mouse O 
liver O 
, O 
strong O 
similarities O 
were O 
observed O 
between O 
whole O 
ZFE O 
and O 
in O 
vivo O 
mouse O 
liver O 
in O 
regulated O 
pathways O 
related O 
to O 
hepatotoxicity O 
, O 
as O 
well O 
as O 
in O 
relevant O 
overrepresented O 
transcription O 
factors O 
. O 
In O 
conclusion O 
, O 
both O 
the O 
use O 
of O 
NGS O 
of O 
pooled O 
RNA O 
extracts O 
analysis O 
combined O 
with O 
histopathology O 
and O 
traditional O 
microarray O 
in O 
single O 
case O 
showed O 
the O 
potential O 
to O 
detect O 
liver O 
- O 
related O 
genes O 
and O 
processes O 
within O 
the O 
transcriptome O 
of O 
a O 
whole O 
zebrafish O 
embryo O 
. O 
This O 
supports O 
the O 
applicability O 
of O 
the O 
whole O 
ZFE O 
model O 
for O 
compound O 
- O 
induced O 
hepatotoxicity O 
screening O 
. O 

is O 
one O 
of O 
the O 
most O 
prevalent O 
diseases O 
in O 
the O 
world O 
, O 
for O 
which O 
the O 
mainstay O 
treatment O 
has O 
been O 
inhaled O 
glucocorticoids O 
( O 
GCs O 
) O 
. O 
Despite O 
the O 
widespread O 
use O 
of O 
these O 
drugs O 
, O 
approximately O 
30% O 
of O 
asthma O 
sufferers O 
exhibit O 
some O 
degree O 
of O 
steroid B-FAMILY 
insensitivity O 
or O 
are O 
refractory O 
to O 
inhaled O 
GCs O 
. O 
One O 
hypothesis O 
to O 
explain O 
this O 
phenomenon O 
is O 
interpatient O 
variability O 
in O 
the O 
clearance O 
of O 
these O 
compounds O 
. O 
The O 
objective O 
of O 
this O 
research O 
is O 
to O 
determine O 
how O 
metabolism O 
of O 
GCs O 
by O 
the O 
CYP3A O 
family O 
of O 
enzymes O 
could O 
affect O 
their O 
effectiveness O 
in O 
asthmatic O 
patients O 
. O 
In O 
this O 
work O 
, O 
the O 
metabolism O 
of O 
four O 
frequently O 
prescribed O 
inhaled O 
GCs O 
, O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
, O 
flunisolide B-TRIVIAL 
, O 
budesonide B-TRIVIAL 
, O 
and O 
fluticasone B-SYSTEMATIC 
propionate I-SYSTEMATIC 
, O 
by O 
the O 
CYP3A O 
family O 
of O 
enzymes O 
was O 
studied O 
to O 
identify O 
differences O 
in O 
their O 
rates O 
of O 
clearance O 
and O 
to O 
identify O 
their O 
metabolites O 
. O 
Both O 
interenzyme O 
and O 
interdrug O 
variability O 
in O 
rates O 
of O 
metabolism O 
and O 
metabolic O 
fate O 
were O 
observed O 
. O 
CYP3A4 O 
was O 
the O 
most O 
efficient O 
metabolic O 
catalyst O 
for O 
all O 
the O 
compounds O 
, O 
and O 
CYP3A7 O 
had O 
the O 
slowest O 
rates O 
. O 
CYP3A5 O 
, O 
which O 
is O 
particularly O 
relevant O 
to O 
GC O 
metabolism O 
in O 
the O 
lungs O 
, O 
was O 
also O 
shown O 
to O 
efficiently O 
metabolize O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
, O 
budesonide B-TRIVIAL 
, O 
and O 
fluticasone B-SYSTEMATIC 
propionate I-SYSTEMATIC 
. O 
In O 
contrast O 
, O 
flunisolide B-TRIVIAL 
was O 
only O 
metabolized O 
via O 
CYP3A4 O 
, O 
with O 
no O 
significant O 
turnover O 
by O 
CYP3A5 O 
or O 
CYP3A7 O 
. O 
Common O 
metabolites O 
included O 
6β-hydroxylation O 
and O 
Δ(6)-dehydrogenation O 
for O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
, O 
budesonide B-TRIVIAL 
, O 
and O 
flunisolide B-TRIVIAL 
. O 
The O 
structure O 
of O 
Δ(6)-flunisolide B-SYSTEMATIC 
was O 
unambiguously O 
established O 
by O 
NMR O 
analysis O 
. O 
Metabolism O 
also O 
occurred O 
on O 
the O 
D-ring O 
substituents O 
, O 
including O 
the O 
21-carboxy B-SYSTEMATIC 
metabolites O 
for O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
and O 
flunisolide B-TRIVIAL 
. O 
The O 
novel O 
metabolite O 
21-nortriamcinolone B-SYSTEMATIC 
acetonide I-SYSTEMATIC 
was O 
also O 
identified O 
by O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
and O 
NMR O 
analysis O 
. O 

of O 
paraoxonase O 
1 O 
192 O 
Q O 
/ O 
R O 
polymorphism O 
on O 
paraoxonase O 
and O 
acetylcholinesterase O 
enzyme O 
activities O 
in O 
Turkish O 
population O 
exposed O 
to O 
organophosphate B-FAMILY 
. O 

( O 
OP O 
) O 
compounds O 
are O 
the O 
most O 
commonly O 
used O 
pesticide O 
groups O 
and O 
they O 
are O 
commercially O 
used O 
in O 
the O 
market O 
for O 
local O 
and O 
industrial O 
purposes O 
. O 
Paraoxonase O 
1 O 
( O 
PON1 O 
) O 
enzyme O 
plays O 
an O 
important O 
role O 
in O 
biotransformation O 
of O 
OP O 
compounds O 
, O 
which O 
shows O 
toxic O 
effects O 
via O 
inhibiting O 
the O 
acetylcholinesterase O 
( O 
AChE O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
effects O 
of O 
PON1 O 
gene O 
polymorphism O 
and O 
its O 
effects O 
on O 
PON O 
and O 
AChE O 
enzyme O 
activities O 
in O 
individuals O 
who O 
were O 
exposed O 
to O 
organophosphorus B-FAMILY 
insecticides O 
due O 
to O 
occupational O 
reasons O 
, O 
and O 
to O 
profile O 
the O 
probability O 
of O 
susceptibility O 
to O 
organophosphorus B-FAMILY 
compounds O 
. O 
For O 
this O 
purpose O 
, O 
54 O 
individuals O 
who O 
were O 
exposed O 
to O 
OPs O 
and O 
54 O 
healthy O 
unrelated O 
controls O 
were O 
studied O 
. O 
First O 
, O 
PON1 O 
and O 
AChE O 
enzyme O 
activities O 
were O 
measured O 
. O 
Second O 
, O 
PON1 O 
192 O 
Q O 
/ O 
R O 
polymorphism O 
was O 
determined O 
by O 
standard O 
polymerase O 
chain O 
reaction O 
- O 
restriction O 
fragment O 
length O 
polymorphism O 
technique O 
. O 
When O 
the O 
PON1 O 
192 O 
Q O 
/ O 
R O 
polymorphism O 
was O 
compared O 
with O 
PON1 O 
enzyme O 
activities O 
, O 
statistically O 
significant O 
association O 
was O 
found O 
in O 
both O 
OP-exposed O 
and O 
control O 
groups O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
PON1 O 
192 O 
R(+) O 
( O 
QR O 
+ O 
RR O 
genotypes O 
) O 
genotype O 
carriers O 
had O 
higher O 
PON1 O 
activities O 
than O 
192 O 
R(-) O 
( O 
QQ O 
) O 
genotype O 
carriers O 
. O 
On O 
the O 
other O 
hand O 
, O 
results O 
were O 
statistically O 
analyzed O 
in O 
terms O 
of O 
AChE O 
enzyme O 
activities O 
and O 
there O 
were O 
statistically O 
significant O 
differences O 
only O 
in O 
the O 
OP-exposed O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
mean O 
AChE O 
concentration O 
in O 
the O 
OP-exposed O 
group O 
was O 
determined O 
as O 
33.79 O 
± O 
6.84 O 
U O 
/ O 
g O 
haemoglobin O 
( O 
Hb O 
) O 
for O 
PON1 O 
192 O 
R(+) O 
carriers O 
and O 
30.37 O 
± O 
7.62 O 
U O 
/ O 
g O 
Hb O 
for O 
PON1 O 
192 O 
R(+) O 
carriers O 
. O 
As O 
a O 
conclusion O 
, O 
PON1 O 
and O 
AChE O 
activities O 
were O 
increasing O 
according O 
to O 
the O 
genotypes O 
found O 
in O 
individuals O 
having O 
been O 
exposed O 
to O 
OPs O 
at O 
a O 
chronic O 
level O 
; O 
192 O 
R(+) O 
> O 
192 O 
R(-) O 
, O 
respectively O 
. O 

recently O 
discovered O 
pleckstrin O 
homology O 
( O 
PH O 
) O 
domain O 
leucine B-TRIVIAL 
-rich O 
repeat O 
protein O 
phosphatase O 
( O 
PHLPP O 
) O 
family O 
is O 
emerging O 
as O 
a O 
central O 
component O 
in O 
suppressing O 
cell O 
survival O 
pathways O 
. O 
Originally O 
discovered O 
in O 
a O 
rational O 
search O 
for O 
a O 
phosphatase O 
that O 
directly O 
dephosphorylates O 
and O 
inactivates O 
Akt O 
, O 
PHLPP O 
is O 
now O 
known O 
to O 
potently O 
suppress O 
cell O 
survival O 
both O 
by O 
inhibiting O 
proliferative O 
pathways O 
and O 
by O 
promoting O 
apoptotic O 
pathways O 
. O 
In O 
the O 
first O 
instance O 
, O 
PHLPP O 
directly O 
dephosphorylates O 
a O 
conserved O 
regulatory O 
site O 
( O 
termed O 
the O 
hydrophobic O 
motif O 
) O 
on O 
Akt O 
, O 
protein O 
kinase O 
C O 
and O 
S6 O 
kinase O 
, O 
thereby O 
terminating O 
signalling O 
by O 
these O 
pro O 
- O 
survival O 
kinases O 
. O 
In O 
the O 
second O 
instance O 
, O 
PHLPP O 
dephosphorylates O 
and O 
thus O 
activates O 
the O 
pro O 
- O 
apoptotic O 
kinase O 
Mst1 O 
, O 
thereby O 
promoting O 
apoptosis O 
. O 
PHLPP O 
is O 
deleted O 
in O 
a O 
large O 
number O 
of O 
cancers O 
and O 
the O 
genetic O 
deletion O 
of O 
one O 
isozyme O 
in O 
a O 
PTEN O 
( O 
phosphatase O 
and O 
tensin O 
homologue O 
located O 
on O 
chromosome O 
1 O 
) O 
+ O 
/ O 
- O 
( O 
or O 
heterozygous O 
) O 
prostate O 
cancer O 
model O 
results O 
in O 
increased O 
tumourigenesis O 
, O 
underscoring O 
the O 
role O 
of O 
PHLPP O 
as O 
a O 
tumour O 
suppressor O 
. O 
This O 
review O 
summarizes O 
the O 
targets O 
and O 
cellular O 
actions O 
of O 
PHLPP O 
, O 
with O 
emphasis O 
on O 
its O 
role O 
as O 
a O 
tumour O 
suppressor O 
in O 
the O 
oncogenic O 
phosphoinositide B-FAMILY 
3-kinase O 
( O 
PI3K O 
) O 
/ O 
Akt O 
signalling O 
cascade O 
. O 

chemistry O 
, O 
material O 
processing O 
and O 
fundamental O 
understanding O 
of O 
colloidal O 
semiconductor O 
nanocrystals O 
( O 
quantum O 
dots O 
) O 
are O 
advancing O 
at O 
an O 
astounding O 
rate O 
, O 
bringing O 
the O 
prospects O 
of O 
widespread O 
commercialization O 
of O 
these O 
novel O 
and O 
exciting O 
materials O 
ever O 
closer O 
. O 
Interest O 
in O 
narrow O 
bandgap O 
nanocrystals O 
in O 
particular O 
has O 
intensified O 
in O 
recent O 
years O 
, O 
and O 
the O 
results O 
of O 
research O 
worldwide O 
point O 
to O 
the O 
realistic O 
prospects O 
of O 
applications O 
for O 
these O 
materials O 
in O 
solar O 
cells O 
, O 
infrared O 
optoelectronics O 
( O 
e.g O 
. O 
lasers O 
, O 
optical O 
modulators O 
, O 
photodetectors O 
and O 
photoimaging O 
devices O 
) O 
, O 
low O 
cost O 
/ O 
large O 
format O 
microelectronics O 
, O 
and O 
in O 
biological O 
imaging O 
and O 
biosensor O 
systems O 
to O 
name O 
only O 
some O 
technologies O 
. O 
Improvements O 
in O 
fundamental O 
understanding O 
and O 
material O 
quality O 
are O 
built O 
on O 
a O 
vast O 
body O 
of O 
experience O 
spread O 
over O 
many O 
different O 
methods O 
of O 
colloidal O 
synthetic O 
growth O 
, O 
each O 
with O 
their O 
own O 
strengths O 
and O 
weaknesses O 
for O 
different O 
materials O 
and O 
sometimes O 
with O 
regard O 
to O 
particular O 
applications O 
. O 
The O 
nanocrystal O 
growth O 
expertise O 
is O 
matched O 
by O 
a O 
rapidly O 
expanding O 
, O 
and O 
highly O 
interdisciplinary O 
, O 
understanding O 
of O 
how O 
best O 
to O 
assemble O 
these O 
materials O 
into O 
films O 
or O 
hybrid O 
composites O 
and O 
thereby O 
into O 
useful O 
devices O 
, O 
and O 
again O 
there O 
are O 
many O 
different O 
strategies O 
that O 
can O 
be O 
adopted O 
. O 
In O 
this O 
review O 
we O 
have O 
attempted O 
to O 
survey O 
and O 
compare O 
the O 
recent O 
work O 
on O 
colloidal O 
synthesis O 
, O 
film O 
and O 
nanocrystal O 
composite O 
material O 
fabrication O 
, O 
concentrating O 
on O 
narrow O 
bandgap O 
chalcogenide B-FAMILY 
materials O 
and O 
some O 
of O 
their O 
topical O 
applications O 
in O 
the O 
solar O 
energy O 
and O 
biological O 
fields O 
. O 
Since O 
these O 
applications O 
are O 
attracting O 
rising O 
interest O 
across O 
a O 
wide O 
range O 
of O 
disciplines O 
, O 
from O 
the O 
biological O 
sciences O 
, O 
device O 
engineering O 
, O 
and O 
materials O 
processing O 
fields O 
as O 
well O 
as O 
the O 
physics O 
and O 
synthetic O 
chemistry O 
communities O 
, O 
we O 
have O 
endeavoured O 
to O 
make O 
the O 
review O 
of O 
these O 
narrow O 
bandgap O 
nanomaterials O 
both O 
comprehensive O 
and O 
accessible O 
to O 
newcomers O 
to O 
the O 
area O 
. O 

of O 
quercetin B-TRIVIAL 
in O 
cadmium B-SYSTEMATIC 
-induced O 
oxidative O 
stress O 
, O 
neuronal O 
damage O 
, O 
and O 
apoptosis O 
in O 
rats O 
. O 

present O 
study O 
was O 
carried O 
out O 
to O 
evaluate O 
the O 
neuroprotective O 
effect O 
of O 
quercetin B-TRIVIAL 
( O 
QE O 
) O 
in O 
protecting O 
the O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
)-induced O 
neuronal O 
injury O 
in O 
frontal O 
cortex O 
of O 
rats O 
. O 
A O 
total O 
of O 
30 O 
adult O 
male O 
Sprague-Dawley O 
rats O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
of O 
10 O 
animals O 
each O 
: O 
control O 
, O 
Cd B-FORMULA 
treated O 
and O 
Cd B-FORMULA 
treated O 
with O 
QE O 
. O 
The O 
Cd B-FORMULA 
-treated O 
group O 
was O 
injected O 
subcutaneously O 
with O 
cadmium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
CdCl2 B-FORMULA 
) O 
dissolved O 
in O 
saline O 
at O 
a O 
dose O 
of O 
2 O 
ml O 
/ O 
kg O 
/ O 
day O 
for O 
30 O 
days O 
, O 
resulting O 
in O 
a O 
dosage O 
of O 
1 O 
mg O 
/ O 
kg O 
Cd B-FORMULA 
. O 
The O 
rats O 
in O 
QE O 
- O 
treated O 
groups O 
were O 
given O 
QE O 
( O 
15 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
once O 
a O 
day O 
intraperitoneally O 
starting O 
2 O 
days O 
prior O 
to O 
Cd B-FORMULA 
injection O 
, O 
during O 
the O 
study O 
period O 
. O 
Rats O 
were O 
sacrificed O 
at O 
the O 
end O 
of O 
the O 
study O 
and O 
the O 
frontal O 
cortex O 
tissues O 
were O 
removed O 
for O 
biochemical O 
and O 
histopathological O 
investigation O 
. O 
To O 
date O 
, O 
there O 
is O 
no O 
available O 
information O 
on O 
the O 
effect O 
of O 
QE O 
on O 
neuronal O 
injury O 
after O 
Cd B-FORMULA 
exposure O 
. O 
Rats O 
intoxicated O 
with O 
Cd B-FORMULA 
for O 
30 O 
days O 
, O 
significantly O 
increased O 
tissue O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
and O 
significantly O 
decreased O 
enzymatic O 
antioxidants O 
superoxide B-TRIVIAL 
dismutase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
catalase O 
in O 
the O 
frontal O 
cortex O 
tissue O 
. O 
Administration O 
of O 
QE O 
with O 
Cd B-FORMULA 
significantly O 
diminished O 
the O 
levels O 
of O 
MDA B-ABBREVIATION 
and O 
significantly O 
elevated O 
the O 
levels O 
of O 
enzymatic O 
antioxidants O 
in O 
the O 
frontal O 
cortex O 
tissue O 
. O 
The O 
histopathological O 
studies O 
in O 
the O 
brain O 
of O 
rats O 
also O 
supported O 
that O 
QE O 
markedly O 
reduced O 
the O 
Cd B-FORMULA 
-induced O 
histopathological O 
changes O 
and O 
well O 
preserved O 
the O 
normal O 
histological O 
architecture O 
of O 
the O 
frontal O 
cortex O 
tissue O 
. O 
The O 
caspase-3 O 
immunopositivity O 
was O 
increased O 
in O 
degenerating O 
neurons O 
of O 
the O 
Cd B-FORMULA 
group O 
. O 
Treatment O 
with O 
QE O 
markedly O 
reduced O 
the O 
immunoreactivity O 
of O 
degenerating O 
neurons O 
. O 
In O 
conclusion O 
, O 
the O 
results O 
of O 
the O 
current O 
study O 
suggest O 
that O 
QE O 
may O 
be O 
beneficial O 
in O 
combating O 
the O 
Cd B-FORMULA 
-induced O 
neurotoxicity O 
in O 
the O 
brain O 
of O 
rats O 
. O 
We O 
believe O 
that O 
further O 
preclinical O 
research O 
into O 
the O 
utility O 
of O 
QE O 
may O 
indicate O 
its O 
usefulness O 
as O 
a O 
potential O 
treatment O 
for O 
neurodegeneration O 
after O 
Cd B-FORMULA 
exposure O 
in O 
rats O 
. O 

, O 
Synthesis O 
, O 
and O 
Structure-Activity O 
Relationship O 
Studies O 
of O 
Novel O 
3-Alkylindole B-FAMILY 
Derivatives O 
as O 
Selective O 
and O 
Highly O 
Potent O 
Myeloperoxidase O 
Inhibitors O 
. O 

to O 
its O 
production O 
of O 
potent O 
antimicrobial O 
oxidants O 
including O 
hypochlorous B-TRIVIAL 
acid I-TRIVIAL 
, O 
human O 
myeloperoxidase O 
( O 
MPO O 
) O 
plays O 
a O 
critical O 
role O 
in O 
innate O 
immunity O 
and O 
inflammatory O 
diseases O 
. O 
Thus O 
MPO O 
is O 
an O 
attractive O 
target O 
in O 
drug O 
design O 
. O 
(Aminoalkyl)fluoroindole B-FAMILY 
derivatives O 
were O 
detected O 
to O 
be O 
very O 
potent O 
MPO O 
inhibitors O 
; O 
however O 
, O 
they O 
also O 
promote O 
inhibition O 
of O 
the O 
serotonin B-TRIVIAL 
reuptake O 
transporter O 
( O 
SERT O 
) O 
at O 
the O 
same O 
concentration O 
range O 
. O 
Via O 
structure O 
- O 
based O 
drug O 
design O 
, O 
a O 
new O 
series O 
of O 
MPO O 
inhibitors O 
derived O 
from O 
3-alkylindole B-FAMILY 
were O 
synthesized O 
and O 
their O 
effects O 
were O 
assessed O 
on O 
MPO O 
- O 
mediated O 
taurine B-TRIVIAL 
chlorination O 
and O 
low O 
- O 
density O 
lipoprotein O 
oxidation O 
as O 
well O 
as O 
on O 
inhibition O 
of O 
SERT O 
. O 
The O 
fluoroindole B-SYSTEMATIC 
compound O 
with O 
three O 
carbons B-FAMILY 
in O 
the O 
side O 
chain O 
and O 
one O 
amide B-FAMILY 
group O 
exhibited O 
a O 
selectivity O 
index O 
of O 
35 O 
( O 
Ki O 
/ O 
IC50 O 
) O 
with O 
high O 
inhibition O 
of O 
MPO O 
activity O 
( O 
IC50 O 
= O 
18 O 
nM O 
) O 
, O 
whereas O 
its O 
effect O 
on O 
SERT O 
was O 
in O 
the O 
micromolar O 
range O 
. O 
Structure O 
- O 
function O 
relationships O 
, O 
mechanism O 
of O 
action O 
, O 
and O 
safety O 
of O 
the O 
molecule O 
are O 
discussed O 
. O 

has O 
been O 
identified O 
as O 
an O 
oncogene O 
in O 
human O 
tumors O 
. O 
By O 
use O 
of O 
rational O 
drug O 
design O 
, O 
a O 
targeted O 
covalent O 
inhibitor O 
3 O 
( O 
CNX-1351 B-IDENTIFIER 
) O 
was O 
created O 
that O 
potently O 
and O 
specifically O 
inhibits O 
PI3Kα O 
. O 
We O 
demonstrate O 
, O 
using O 
mass O 
spectrometry O 
and O 
X-ray O 
crystallography O 
, O 
that O 
the O 
selective O 
inhibitor O 
covalently O 
modifies O 
PI3Kα O 
on O 
cysteine B-TRIVIAL 
862 O 
( O 
C862 O 
) O 
, O 
an O 
amino B-FAMILY 
acid I-FAMILY 
unique O 
to O 
the O 
α O 
isoform O 
, O 
and O 
that O 
PI3Kβ O 
, O 
-γ O 
, O 
and O 
-δ O 
are O 
not O 
covalently O 
modified O 
. O 
3 O 
is O 
able O 
to O 
potently O 
( O 
EC(50) O 
< O 
100 O 
nM O 
) O 
and O 
specifically O 
inhibit O 
signaling O 
in O 
PI3Kα-dependent O 
cancer O 
cell O 
lines O 
, O 
and O 
this O 
leads O 
to O 
a O 
potent O 
antiproliferative O 
effect O 
( O 
GI(50) O 
< O 
100 O 
nM O 
) O 
. O 
A O 
covalent O 
probe O 
, O 
8 O 
( O 
CNX-1220 B-IDENTIFIER 
) O 
, O 
which O 
selectively O 
bonds O 
to O 
PI3Kα O 
, O 
was O 
used O 
to O 
investigate O 
the O 
duration O 
of O 
occupancy O 
of O 
3 O 
with O 
PI3Kα O 
in O 
vivo O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
a O 
PI3Kα-selective O 
inhibitor O 
, O 
and O 
these O 
data O 
demonstrate O 
the O 
biological O 
impact O 
of O 
selectively O 
targeting O 
PI3Kα O 
. O 

of O 
nicotine B-TRIVIAL 
, O 
its O 
metabolites O 
and O 
tobacco O 
extracts O 
on O 
human O 
platelet O 
function O 
in O 
vitro O 
. O 

smoking O 
is O 
a O 
leading O 
cause O 
of O 
cardiovascular O 
disease O 
. O 
The O 
cardiovascular O 
effects O 
of O 
smoking O 
are O 
probably O 
multifactorial O 
, O 
including O 
effects O 
on O 
platelets O 
. O 
Previous O 
reports O 
investigating O 
the O 
effects O 
of O 
nicotine B-TRIVIAL 
and O 
tobacco O 
on O 
platelet O 
function O 
are O 
inconsistent O 
. O 
The O 
present O 
study O 
investigated O 
in O 
vitro O 
effects O 
of O 
nicotine B-TRIVIAL 
, O 
its O 
major O 
metabolites O 
, O 
tobacco O 
extracts O 
and O 
extract O 
of O 
tobacco O 
- O 
free O 
snuff O 
on O 
human O 
platelets O 
. O 
None O 
of O 
the O 
metabolites O 
cotinine B-TRIVIAL 
, O 
cotinine-N-oxide B-SYSTEMATIC 
, O 
nicotine-1'-N-oxide B-SYSTEMATIC 
or O 
trans-3'-hydroxycotinine B-SYSTEMATIC 
( O 
0.1-10 O 
μM O 
) O 
affected O 
platelet O 
aggregation O 
or O 
P-selectin O 
expression O 
. O 
Nicotine B-TRIVIAL 
( O 
10 O 
μM O 
) O 
weakly O 
increased O 
platelet O 
aggregation O 
, O 
whereas O 
trans-3'-hydroxycotinine B-SYSTEMATIC 
( O 
0.1 O 
μM O 
) O 
and O 
nicotine-1'-N-oxide B-SYSTEMATIC 
( O 
1-10 O 
μM O 
) O 
weakly O 
inhibited O 
adhesion O 
to O 
fibrinogen O 
. O 
To O 
elucidate O 
the O 
influence O 
of O 
other O 
tobacco O 
compounds O 
, O 
we O 
investigated O 
the O 
impact O 
of O 
moist O 
tobacco O 
and O 
smoke O 
extracts O 
on O 
platelet O 
function O 
. O 
Filtered O 
extracts O 
of O 
oral O 
snuff O 
, O 
cigarette O 
smoke O 
and O 
tobacco O 
free O 
snuff O 
inhibited O 
platelet O 
adhesion O 
concentration O 
- O 
dependently O 
. O 
The O 
inhibitory O 
effects O 
of O 
tobacco O 
extracts O 
on O 
platelet O 
adhesion O 
were O 
independent O 
of O 
nicotine B-TRIVIAL 
content O 
and O 
the O 
nitric B-SYSTEMATIC 
- I-SYSTEMATIC 
oxide I-SYSTEMATIC 
-pathway O 
and O 
not O 
mediated O 
through O 
a O 
platelet- O 
nicotine B-TRIVIAL 
-receptor O 
. O 
Taken O 
together O 
, O 
tobacco O 
extracts O 
inhibit O 
platelet O 
activation O 
during O 
short O 
- O 
term O 
in O 
vitro O 
challenge O 
. O 
As O 
only O 
limited O 
effects O 
of O 
nicotine B-TRIVIAL 
and O 
nicotine B-TRIVIAL 
metabolites O 
were O 
seen O 
, O 
the O 
tobacco O 
- O 
induced O 
platelet O 
inhibition O 
are O 
likely O 
induced O 
by O 
other O 
compounds O 
present O 
in O 
tobacco O 
and O 
tobacco O 
free O 
snuff O 
. O 

pollution O 
exposure O 
in O 
industrialized O 
cities O 
is O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
morbidity O 
and O 
mortality O 
attributed O 
to O 
cardiovascular O 
diseases O 
. O 
Combustion O 
exhausts O 
emitted O 
from O 
motor O 
vehicles O 
and O 
industries O 
represent O 
a O 
major O 
source O 
of O 
nanoparticles O 
in O 
the O 
atmosphere O 
. O 
Flame O 
- O 
generated O 
organic O 
carbon B-SYSTEMATIC 
nanoparticles O 
( O 
OC O 
NPs O 
) O 
provide O 
interesting O 
model O 
nanoparticles O 
that O 
simulate O 
fresh O 
combustion O 
emissions O 
near O 
roadways O 
or O 
combustion O 
sources O 
. O 
These O 
model O 
nanoparticles O 
can O 
be O 
produced O 
by O 
controlling O 
flame O 
operating O 
conditions O 
and O 
used O 
to O 
test O 
possible O 
toxicological O 
mechanisms O 
responsible O 
for O 
the O 
observed O 
health O 
effects O 
. O 
OC O 
NPs O 
were O 
used O 
to O 
investigate O 
their O 
possible O 
effect O 
on O 
endothelial O 
cells O 
( O 
EC O 
) O 
growth O 
and O 
production O 
of O 
proinflammatory O 
lipid O 
mediators O 
. O 
Results O 
indicated O 
a O 
dose O 
and O 
time O 
- O 
dependent O 
reduction O 
in O 
cell O 
viability O 
following O 
incubation O 
of O 
EC O 
with O 
OC O 
NPs O 
for O 
24 O 
and O 
48h O 
. O 
Fluorescence O 
- O 
activated O 
cell O 
sorting O 
revealed O 
that O 
EC O 
treated O 
with O 
OC O 
NPs O 
showed O 
a O 
cell O 
proliferation O 
index O 
significantly O 
lower O 
than O 
that O 
of O 
control O 
cells O 
and O 
an O 
increased O 
apoptotic O 
cell O 
death O 
. O 
The O 
annexin O 
assay O 
confirmed O 
the O 
increased O 
apoptotic O 
cell O 
death O 
. O 
Moreover O 
, O 
OC O 
NPs O 
also O 
induced O 
a O 
time O 
- O 
dependent O 
increase O 
of O 
proinflammatory O 
lysophospholipid O 
production O 
. O 
These O 
results O 
, O 
establishing O 
that O 
OC O 
NPs O 
induce O 
EC O 
proinflammatory O 
lysophosholipid O 
production O 
and O 
apoptotic O 
cell O 
death O 
, O 
provide O 
the O 
first O 
evidence O 
of O 
the O 
detrimental O 
effect O 
of O 
OC O 
NPs O 
on O 
EC O 
. O 

capacity O 
of O 
anthocyanins B-FAMILY 
from O 
Rhodomyrtus O 
tomentosa O 
( O 
Ait O 
. O 
) O 
and O 
identification O 
of O 
the O 
major O 
anthocyanins B-FAMILY 
. O 

anthocyanins B-FAMILY 
in O 
the O 
fruits O 
of O 
Rhodomyrtus O 
tomentosa O 
( O 
ACN O 
) O 
were O 
extracted O 
by O 
1% O 
TFA B-ABBREVIATION 
in O 
methanol B-SYSTEMATIC 
, O 
and O 
then O 
purified O 
by O 
X-5 O 
resin O 
column O 
and O 
C18 O 
( O 
SPE O 
) O 
cartridges O 
. O 
The O 
purified O 
anthocyanin B-FAMILY 
extract O 
( O 
ART O 
) O 
from O 
the O 
fruits O 
of O 
R O 
. O 
tomentosa O 
showed O 
strong O 
antioxidant O 
activities O 
, O 
including O 
DPPH B-ABBREVIATION 
radical O 
- O 
scavenging O 
capacity O 
, O 
ABTS B-ABBREVIATION 
radical O 
scavenging O 
capacity O 
, O 
reducing O 
power O 
and O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
( O 
ORAC O 
) O 
. O 
The O 
purified O 
anthocyanin B-FAMILY 
extract O 
was O 
analyzed O 
by O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
. O 
The O 
major O 
anthocyanins B-FAMILY 
were O 
purified O 
by O 
semi-preparative O 
HPLC O 
and O 
Sephadex O 
LH-20 O 
column O 
chromatography O 
, O 
and O 
were O 
identified O 
as O 
cyanidin-3-O-glucoside B-SYSTEMATIC 
, O 
peonidin-3-O-glucoside B-SYSTEMATIC 
, O 
malvidin-3-O-glucoside B-SYSTEMATIC 
, O 
petunidin-3-O-glucoside B-SYSTEMATIC 
, O 
delphinidin-3-O-glucoside B-SYSTEMATIC 
and O 
pelargonidin-3-glucoside B-SYSTEMATIC 
by O 
HPLC-ESI O 
/ O 
MS O 
and O 
nuclear O 
magnetic O 
resonance O 
spectroscopy O 
( O 
NMR O 
) O 
. O 
Cyanidin-3-O-glucoside B-SYSTEMATIC 
was O 
considered O 
as O 
the O 
most O 
abundant O 
anthocyanin B-FAMILY 
, O 
which O 
was O 
29.4mg O 
/ O 
100g O 
dry O 
weight O 
of O 
R O 
. O 
tomentosa O 
fruits O 
. O 
Additionally O 
, O 
all O 
the O 
major O 
anthocyanins B-FAMILY 
were O 
identified O 
from O 
R O 
. O 
tomentosa O 
fruit O 
for O 
the O 
first O 
time O 
. O 

of O 
crizotinib B-TRIVIAL 
- O 
midazolam B-TRIVIAL 
interaction O 
using O 
the O 
Simcyp O 
population O 
- O 
based O 
simulator O 
: O 
comparison O 
of O 
CYP3A O 
time O 
- O 
dependent O 
inhibition O 
between O 
human O 
liver O 
microsomes O 
versus O 
hepatocytes O 
. O 

( O 
Xalkori B-TRIVIAL 
) O 
is O 
an O 
orally O 
available O 
potent O 
inhibitor O 
of O 
multiple O 
tyrosine B-TRIVIAL 
kinases O 
, O 
including O 
anaplastic O 
lymphoma O 
kinase O 
and O 
mesenchymal O 
- O 
epithelial O 
transition O 
factor O 
. O 
Objectives O 
of O 
the O 
present O 
study O 
were O 
as O 
follows O 
: O 
1 O 
) O 
to O 
characterize O 
crizotinib B-TRIVIAL 
time O 
- O 
dependent O 
inhibition O 
( O 
TDI O 
) O 
potency O 
for O 
CYP3A O 
in O 
human O 
liver O 
microsomes O 
( O 
HLM O 
) O 
and O 
cryopreserved O 
human O 
hepatocytes O 
suspended O 
in O 
human O 
plasma O 
( O 
HSP O 
) O 
; O 
2 O 
) O 
to O 
characterize O 
crizotinib B-TRIVIAL 
enzyme O 
induction O 
potency O 
on O 
CYP3A4 O 
in O 
cryopreserved O 
human O 
hepatocytes O 
; O 
3 O 
) O 
to O 
predict O 
crizotinib B-TRIVIAL 
steady O 
- O 
state O 
plasma O 
concentrations O 
in O 
patients O 
( O 
e.g O 
. O 
, O 
autoinhibition O 
and O 
autoinduction O 
) O 
using O 
the O 
mechanistic O 
dynamic O 
model O 
, O 
Simcyp O 
population O 
- O 
based O 
simulator O 
; O 
and O 
4 O 
) O 
to O 
predict O 
a O 
clinical O 
crizotinib B-TRIVIAL 
- O 
midazolam B-TRIVIAL 
interaction O 
using O 
the O 
dynamic O 
model O 
as O 
well O 
as O 
the O 
static O 
mathematical O 
model O 
. O 
Crizotinib B-TRIVIAL 
inactivation O 
constant O 
(K(I)) O 
and O 
maximum O 
inactivation O 
rate O 
constant O 
(k(inact)) O 
for O 
TDI O 
were O 
estimated O 
as O 
, O 
respectively O 
, O 
0.37 O 
µM O 
and O 
6.9 O 
h(-1) O 
in O 
HLM O 
and O 
0.89 O 
µM O 
and O 
0.78 O 
h(-1) O 
in O 
HSP O 
. O 
Thus O 
, O 
crizotinib B-TRIVIAL 
inactivation O 
efficiency O 
( O 
k(inact) O 
/ O 
K O 
(I) O 
) O 
was O 
∼20-fold O 
lower O 
in O 
HSP O 
relative O 
to O 
HLM O 
. O 
Crizotinib B-TRIVIAL 
E(max) O 
and O 
EC(50) O 
for O 
CYP3A4 O 
induction O 
( O 
measured O 
as O 
mRNA O 
expression O 
) O 
were O 
estimated O 
as O 
6.4- O 
to O 
29-fold O 
and O 
0.47 O 
to O 
3.1 O 
µM O 
, O 
respectively O 
. O 
Based O 
on O 
these O 
in O 
vitro O 
parameters O 
, O 
the O 
predicted O 
crizotinib B-TRIVIAL 
steady O 
- O 
state O 
area O 
under O 
plasma O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
with O 
HLM-TDI O 
was O 
2.1-fold O 
higher O 
than O 
the O 
observed O 
AUC O 
, O 
whereas O 
that O 
with O 
HSP-TDI O 
was O 
consistent O 
with O 
the O 
observed O 
result O 
( O 
≤ O 
1.1-fold O 
) O 
. O 
The O 
increase O 
in O 
midazolam B-TRIVIAL 
AUC O 
with O 
coadministration O 
of O 
crizotinib B-TRIVIAL 
( O 
21-fold O 
) O 
was O 
significantly O 
overpredicted O 
using O 
HLM-TDI O 
, O 
whereas O 
the O 
prediction O 
using O 
HSP-TDI O 
( O 
3.6-fold O 
) O 
was O 
consistent O 
with O 
the O 
observed O 
result O 
( O 
3.7-fold O 
) O 
. O 
Collectively O 
, O 
the O 
present O 
study O 
demonstrated O 
the O 
value O 
of O 
HSP O 
to O 
predict O 
in O 
vivo O 
CYP3A O 
- O 
mediated O 
drug O 
- O 
drug O 
interaction O 
. O 

of O 
15N B-FORMULA 
- O 
1H B-FORMULA 
NMR O 
relaxation O 
in O 
proteins O 
by O 
a O 
combined O 
experimental O 
and O 
molecular O 
dynamics O 
simulation O 
approach O 
: O 
picosecond O 
- O 
nanosecond O 
dynamics O 
of O 
the O 
Rho O 
GTPase O 
binding O 
domain O 
of O 
plexin-B1 O 
in O 
the O 
dimeric O 
state O 
indicates O 
allosteric O 
pathways O 
. O 

investigate O 
picosecond O 
– O 
nanosecond O 
dynamics O 
of O 
the O 
Rho-GTPase O 
Binding O 
Domain O 
( O 
RBD O 
) O 
of O 
plexin-B1 O 
, O 
which O 
plays O 
a O 
key O 
role O 
in O 
plexin O 
- O 
mediated O 
cell O 
signaling O 
. O 
Backbone O 
15N B-FORMULA 
relaxation O 
data O 
of O 
the O 
dimeric O 
RBD O 
are O 
analyzed O 
with O 
the O 
model O 
- O 
free O 
( O 
MF O 
) O 
method O 
, O 
and O 
with O 
the O 
slowly O 
relaxing O 
local O 
structure O 
/ O 
molecular O 
dynamics O 
( O 
SRLS-MD O 
) O 
approach O 
. O 
Independent O 
analysis O 
of O 
the O 
MD O 
trajectories O 
, O 
based O 
on O 
the O 
MF O 
paradigm O 
, O 
is O 
also O 
carried O 
out O 
. O 
MF O 
is O 
a O 
widely O 
popular O 
and O 
simple O 
method O 
, O 
SRLS O 
is O 
a O 
general O 
approach O 
, O 
and O 
SRLS-MD O 
is O 
an O 
integrated O 
approach O 
we O 
developed O 
recently O 
. O 
Corresponding O 
parameters O 
from O 
the O 
RBD O 
dimer O 
, O 
a O 
previously O 
studied O 
RBD O 
monomer O 
mutant O 
, O 
and O 
the O 
previously O 
studied O 
complex O 
of O 
the O 
latter O 
with O 
the O 
GTPase O 
Rac1 O 
, O 
are O 
compared O 
. O 
The O 
L2 O 
, O 
L3 O 
, O 
and O 
L4 O 
loops O 
of O 
the O 
plexin-B1 O 
RBD O 
are O 
involved O 
in O 
interactions O 
with O 
other O 
plexin O 
domains O 
, O 
GTPase O 
binding O 
, O 
and O 
RBD O 
dimerization O 
, O 
respectively O 
. O 
Peptide O 
groups O 
in O 
the O 
loops O 
of O 
both O 
the O 
monomeric O 
and O 
dimeric O 
RBD O 
are O 
found O 
to O 
experience O 
weak O 
and O 
moderately O 
asymmetric O 
local O 
ordering O 
centered O 
approximately O 
at O 
the O 
C(i–1)(α) O 
– O 
C(i)(α) O 
axes O 
, O 
and O 
nanosecond O 
backbone O 
motion O 
. O 
Peptide O 
groups O 
in O 
the O 
α-helices O 
and O 
the O 
β-strands O 
of O 
the O 
dimer O 
( O 
the O 
β-strands O 
of O 
the O 
monomer O 
) O 
experience O 
strong O 
and O 
highly O 
asymmetric O 
local O 
ordering O 
centered O 
approximately O 
at O 
the O 
C(i–1)(α) O 
– O 
C(i)(α) O 
axes O 
( O 
N–H B-FORMULA 
bonds O 
) O 
. O 
N–H B-FORMULA 
fluctuations O 
occur O 
on O 
the O 
picosecond O 
time O 
scale O 
. O 
An O 
allosteric O 
pathway O 
for O 
GTPase O 
binding O 
, O 
providing O 
new O 
insights O 
into O 
plexin O 
function O 
, O 
is O 
delineated O 
. O 

fragment O 
indole-6-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1F1 O 
) O 
, O 
previously O 
identified O 
as O 
a O 
flap O 
site O 
binder O 
in O 
a O 
fragment O 
- O 
based O 
screen O 
against O 
HIV O 
protease O 
( O 
PR O 
) O 
, O 
has O 
been O 
cocrystallized O 
with O 
pepstatin B-FAMILY 
-inhibited O 
PR O 
and O 
with O 
apo-PR O 
. O 
Another O 
fragment O 
, O 
3-indolepropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1F1-N O 
) O 
, O 
predicted O 
by O 
AutoDock O 
calculations O 
and O 
confirmed O 
in O 
a O 
novel O 
inhibition O 
of O 
nucleation O 
crystallization O 
assay O 
, O 
exploits O 
the O 
same O 
interactions O 
in O 
the O 
flap O 
site O 
in O 
two O 
crystal O 
structures O 
. O 
Both O 
1F1 O 
and O 
1F1-N O 
bind O 
to O 
the O 
closed O 
form O 
of O 
apo-PR O 
and O 
to O 
pepstatin B-FAMILY 
: O 
PR O 
. O 
In O 
solution O 
, O 
1F1 O 
and O 
1F1-N O 
raise O 
the O 
Tm O 
of O 
apo-PR O 
by O 
3.5-5 O 
°C O 
as O 
assayed O 
by O 
differential O 
scanning O 
fluorimetry O 
( O 
DSF O 
) O 
and O 
show O 
equivalent O 
low O 
- O 
micromolar O 
binding O 
constants O 
to O 
both O 
apo-PR O 
and O 
pepstatin B-FAMILY 
: O 
PR O 
, O 
assayed O 
by O 
backscattering O 
interferometry O 
( O 
BSI O 
) O 
. O 
The O 
observed O 
signal O 
intensities O 
in O 
BSI O 
are O 
greater O 
for O 
each O 
fragment O 
upon O 
binding O 
to O 
apo-PR O 
than O 
to O 
pepstatin B-FAMILY 
-bound O 
PR O 
, O 
consistent O 
with O 
greater O 
conformational O 
change O 
in O 
the O 
former O 
binding O 
event O 
. O 
Together O 
, O 
these O 
data O 
indicate O 
that O 
fragment O 
binding O 
in O 
the O 
flap O 
site O 
favors O 
a O 
closed O 
conformation O 
of O 
HIV O 
PR O 
. O 

novel O 
one O 
- O 
step O 
microbial O 
transformation O 
of O 
betulin B-TRIVIAL 
to O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
catalysed O 
by O 
Cunninghamella O 
blakesleeana O 
. O 

acid I-TRIVIAL 
and O 
its O 
derivatives O 
are O 
potential O 
bioactive O 
compounds O 
present O 
in O 
nature O 
. O 
This O 
study O 
investigated O 
the O 
biotransformation O 
of O 
betulin B-TRIVIAL 
to O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
by O 
Cunninghamella O 
blakesleeana O 
cells O 
. O 
LC-MS O 
analysis O 
demonstrated O 
that O 
betulin B-TRIVIAL 
could O 
be O 
transformed O 
into O 
at O 
least O 
five O 
products O 
from O 
cultured O 
C O 
. O 
blakesleeana O 
cells O 
, O 
among O 
which O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
was O 
the O 
most O 
important O 
. O 
The O 
presented O 
method O 
provides O 
an O 
attractive O 
alternative O 
approach O 
to O 
chemical O 
synthesis O 
, O 
because O 
is O 
less O 
time O 
- O 
consuming O 
and O 
more O 
environmentally O 
friendly O 
. O 
C O 
. O 
blakesleeana O 
can O 
transform O 
betulin B-TRIVIAL 
into O 
potent O 
derivatives O 
with O 
high O 
pharmacological O 
activities O 
. O 

completion O 
of O 
the O 
human O 
genome O 
project O 
and O 
the O 
subsequent O 
advent O 
of O 
DNA O 
microarray O 
and O 
high O 
- O 
throughput O 
sequencing O 
technologies O 
have O 
led O 
to O 
a O 
renaissance O 
in O 
molecular O 
toxicology O 
. O 
Toxicogenomic O 
data O 
sets O 
, O 
from O 
both O 
in O 
vivo O 
and O 
in O 
vitro O 
studies O 
, O 
are O 
growing O 
exponentially O 
, O 
providing O 
a O 
wealth O 
of O 
information O 
on O 
regulation O 
of O 
stress O 
pathways O 
at O 
the O 
transcriptome O 
level O 
. O 
Through O 
such O 
studies O 
, O 
we O 
are O 
now O 
beginning O 
to O 
appreciate O 
the O 
diversity O 
and O 
complexity O 
of O 
biological O 
responses O 
to O 
xenobiotics O 
. O 
In O 
this O 
review O 
, O 
we O 
aim O 
to O 
consolidate O 
and O 
summarise O 
the O 
major O 
toxicologically O 
relevant O 
transcription O 
factor O 
- O 
governed O 
molecular O 
pathways O 
. O 
It O 
is O 
becoming O 
clear O 
that O 
different O 
chemical O 
entities O 
can O 
cause O 
oxidative O 
, O 
genotoxic O 
and O 
proteotoxic O 
stress O 
, O 
which O 
induce O 
cellular O 
responses O 
in O 
an O 
effort O 
to O 
restore O 
homoeostasis O 
. O 
Primary O 
among O 
the O 
response O 
pathways O 
involved O 
are O 
NFE2L2 O 
( O 
Nrf2 O 
) O 
, O 
NFE2L1 O 
( O 
Nrf1 O 
) O 
, O 
p53 O 
, O 
heat O 
shock O 
factor O 
and O 
the O 
unfolded O 
protein O 
response O 
. O 
Additionally O 
, O 
more O 
specific O 
mechanisms O 
exist O 
where O 
xenobiotics O 
act O 
as O 
ligands O 
, O 
including O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
, O 
metal O 
- O 
responsive O 
transcription O 
factor-1 O 
and O 
the O 
nuclear O 
receptor O 
family O 
of O 
transcription O 
factors O 
. O 
Other O 
pathways O 
including O 
the O 
immunomodulatory O 
transcription O 
factors O 
NF-κB O 
and O 
STAT O 
together O 
with O 
the O 
hypoxia O 
- O 
inducible O 
transcription O 
factor O 
HIF O 
are O 
also O 
implicated O 
in O 
cellular O 
responses O 
to O 
xenobiotic O 
exposure O 
. O 
A O 
less O 
specific O 
but O 
equally O 
important O 
aspect O 
to O 
cellular O 
injury O 
controlled O 
by O 
transcriptional O 
activity O 
is O 
loss O 
of O 
tissue O 
- O 
specific O 
gene O 
expression O 
, O 
resulting O 
in O 
dedifferentiation O 
of O 
target O 
cells O 
and O 
compromise O 
of O 
tissue O 
function O 
. O 
Here O 
, O 
we O 
review O 
these O 
pathways O 
and O 
the O 
genes O 
they O 
regulate O 
in O 
order O 
to O 
provide O 
an O 
overview O 
of O 
this O 
growing O 
field O 
of O 
molecular O 
toxicology O 
. O 

of O 
the O 
effect O 
of O 
gelatine O 
, O 
egg O 
albumin O 
and O 
cross O 
- O 
flow O 
microfiltration O 
on O 
the O 
phenolic B-FAMILY 
composition O 
of O 
Pinotage O 
wine O 
. O 

effect O 
of O 
fining O 
and O 
cross O 
- O 
flow O 
microfiltration O 
on O 
the O 
phenolic B-FAMILY 
composition O 
of O 
red O 
wine O 
was O 
investigated O 
. O 
Both O 
gelatine O 
( O 
G O 
) O 
and O 
egg O 
albumin O 
( O 
EA O 
) O 
fining O 
decreased O 
the O 
mean O 
degree O 
of O 
polymerisation O 
( O 
mDP O 
) O 
of O 
tannin B-FAMILY 
significantly O 
by O 
26.4% O 
and O 
25.2% O 
, O 
respectively O 
, O 
compared O 
to O 
the O 
control O 
( O 
C O 
) O 
. O 
Cross O 
- O 
flow O 
microfiltration O 
( O 
CF O 
) O 
also O 
decreased O 
the O 
mDP O 
significantly O 
by O 
25% O 
. O 
Thus O 
, O 
the O 
fining O 
agents O 
and O 
cross O 
- O 
flow O 
microfiltration O 
selectively O 
removed O 
the O 
highly O 
polymerised O 
phenols B-FAMILY 
. O 
After O 
3.5 O 
months O 
of O 
bottle O 
ageing O 
, O 
differences O 
between O 
the O 
different O 
treatments O 
and O 
the O 
control O 
decreased O 
. O 
CF O 
had O 
the O 
most O 
significant O 
effect O 
on O 
the O 
flavan-3-ol B-FAMILY 
and O 
polymeric B-FAMILY 
phenol I-FAMILY 
( O 
tannin B-FAMILY 
) O 
content O 
of O 
the O 
wines O 
compared O 
to O 
the O 
control O 
followed O 
by O 
G O 
fining O 
. O 
CF O 
and O 
EA O 
treatments O 
significantly O 
decreased O 
the O 
total O 
pigment O 
content O 
compared O 
to O 
C O 
. O 
CF O 
was O 
also O 
the O 
only O 
treatment O 
that O 
could O 
be O 
distinguished O 
from O 
the O 
other O 
treatments O 
by O 
sensory O 
analysis O 
. O 
All O 
treatments O 
improved O 
clarity O 
of O 
the O 
wines O 
with O 
cross O 
- O 
flow O 
microfiltration O 
having O 
the O 
largest O 
effect O 
. O 

tegmental O 
area O 
α6β2 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
modulate O 
phasic O 
dopamine B-TRIVIAL 
release O 
in O 
the O 
nucleus O 
accumbens O 
core O 
. O 

: O 
Phasic O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
signaling O 
underlies O 
reward O 
learning O 
. O 
Cholinergic O 
and O 
glutamatergic O 
inputs O 
into O 
the O 
ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
are O 
crucial O 
for O 
modulating O 
burst O 
firing O 
activity O 
and O 
subsequent O 
phasic O 
DA O 
release O 
in O 
the O 
nucleus O 
accumbens O 
( O 
NAc O 
) O 
, O 
but O 
the O 
specific O 
VTA O 
nicotinic O 
receptor O 
subtypes O 
that O 
regulate O 
phasic O 
DA O 
release O 
have O 
not O 
been O 
identified O 
. O 
OBJECTIVE O 
: O 
The O 
goal O 
was O 
to O 
determine O 
the O 
role O 
of O 
VTA O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptors O 
( O 
NMDARs O 
) O 
and O 
specific O 
subtypes O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
in O 
regulating O 
phasic O 
DA O 
release O 
in O 
the O 
NAc O 
core O 
. O 
METHODS O 
: O 
Fast O 
- O 
scan O 
cyclic O 
voltammetry O 
in O 
anesthetized O 
rats O 
was O 
combined O 
with O 
intra-VTA O 
micro O 
- O 
infusion O 
to O 
evaluate O 
the O 
ability O 
of O 
glutamatergic O 
and O 
cholinergic O 
drugs O 
to O 
modulate O 
stimulated O 
phasic O 
DA O 
release O 
in O 
the O 
NAc O 
core O 
. O 
RESULTS O 
: O 
VTA O 
NMDAR O 
blockade O 
with O 
AP-5 B-IDENTIFIER 
decreased O 
, O 
while O 
VTA O 
NMDAR O 
activation O 
with O 
NMDA B-ABBREVIATION 
increased O 
NAc O 
peak O 
phasic O 
DA O 
release O 
. O 
Intra-VTA O 
administration O 
of O 
the O 
nonspecific O 
nAChR O 
antagonist O 
mecamylamine B-TRIVIAL 
produced O 
a O 
persistent O 
decrease O 
in O 
phasic O 
DA O 
release O 
. O 
Infusion O 
of O 
the O 
α6-selective O 
antagonist O 
α-conotoxin O 
MII O 
( O 
α-ctx O 
MII O 
) O 
produced O 
a O 
robust O 
, O 
but O 
transient O 
decrease O 
in O 
phasic O 
DA O 
, O 
whereas O 
infusion O 
of O 
selective O 
doses O 
of O 
either O 
the O 
α4β2-selective O 
antagonist O 
, O 
dihydro-beta-erythroidine B-SYSTEMATIC 
, O 
or O 
the O 
α7 O 
antagonist O 
, O 
methyllycaconitine B-TRIVIAL 
, O 
had O 
no O 
effect O 
. O 
Co-infusion O 
of O 
AP-5 B-IDENTIFIER 
and O 
α-ctx O 
MII O 
produced O 
a O 
similar O 
phasic O 
DA O 
decrease O 
as O 
either O 
drug O 
alone O 
, O 
with O 
no O 
additive O 
effect O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
suggest O 
that O 
VTA O 
α6β2 O 
nAChRs O 
, O 
but O 
not O 
α4β2 O 
or O 
α7 O 
nAChRs O 
, O 
regulate O 
phasic O 
DA O 
release O 
in O 
the O 
NAc O 
core O 
and O 
that O 
VTA O 
α6β2 O 
nAChRs O 
and O 
NMDA B-ABBREVIATION 
receptors O 
act O 
at O 
a O 
common O 
site O 
or O 
target O 
to O 
regulate O 
NAc O 
phasic O 
DA O 
signaling O 
. O 

suppresses O 
renal O 
carcinogenesis O 
via O 
amelioration O 
of O 
hyperproliferation O 
, O 
oxidative O 
stress O 
and O 
inflammation O 
: O 
plausible O 
role O 
of O 
NF-κB O 
. O 

family O 
is O 
a O 
rich O 
source O 
of O 
polyphenolic B-FAMILY 
compounds O 
and O 
hence O 
possess O 
strong O 
antioxidant O 
and O 
anti O 
inflammatory O 
properties O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
efficacy O 
of O 
chrysin B-TRIVIAL 
; O 
a O 
bio O 
- O 
active O 
flavonoid B-FAMILY 
as O 
an O 
anticancer O 
agent O 
. O 
Renal O 
cancer O 
was O 
initiated O 
by O 
single O 
intraperitoneal O 
( O 
i.p O 
. O 
) O 
injection O 
of O 
N-nitrosodiethylamine B-SYSTEMATIC 
( O 
DEN B-ABBREVIATION 
200 O 
mg O 
/ O 
kg O 
BW O 
body O 
weight O 
) O 
and O 
promoted O 
by O 
twice O 
weekly O 
administration O 
of O 
ferric B-SYSTEMATIC 
nitrilotriacetate I-SYSTEMATIC 
( O 
Fe-NTA B-FORMULA 
) O 
9 O 
mg O 
Fe B-FORMULA 
/ O 
kg O 
BW O 
for O 
16 O 
wk O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
report O 
the O 
chemopreventive O 
effects O 
of O 
chrysin B-TRIVIAL 
against O 
( O 
Fe-NTA B-FORMULA 
) O 
induced O 
renal O 
oxidative O 
stress O 
, O 
inflammation O 
, O 
hyperproliferative O 
response O 
, O 
and O 
two O 
- O 
stage O 
renal O 
carcinogenesis O 
. O 
To O 
ascertain O 
the O 
molecular O 
mechanism O 
implicated O 
in O 
the O 
antitumor O 
promoting O 
activity O 
of O 
chrysin B-TRIVIAL 
, O 
its O 
effect O 
was O 
investigated O 
on O 
markers O 
of O 
tumor O 
promotion O 
and O 
inflammation O 
: O 
ornithine B-TRIVIAL 
decarboxylase O 
( O 
ODC O 
) O 
activity O 
, O 
proliferating O 
cell O 
nuclear O 
antigen O 
( O 
PCNA O 
) O 
, O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
cyclo-oxygenase-2 O 
( O 
COX-2 O 
) O 
expression O 
, O 
and O 
on O 
levels O 
of O 
proinflammatory O 
cytokines O 
interleukin-6 O 
( O 
IL-6 O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
and O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
. O 
Pretreatment O 
of O 
animals O 
with O 
chrysin B-TRIVIAL 
at O 
both O 
doses O 
( O 
20 O 
and O 
40 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
markedly O 
inhibited O 
all O 
. O 
Further O 
, O 
Fe-NTA B-FORMULA 
enhances O 
renal O 
lipid O 
peroxidation O 
, O 
with O 
concomitant O 
reduction O 
in O 
reduced O 
glutathione B-TRIVIAL 
content O 
( O 
GSH B-ABBREVIATION 
) O 
, O 
antioxidant O 
enzymes O 
, O 
and O 
phase O 
II O 
metabolizing O 
enzymes O 
. O 
It O 
induces O 
serum O 
toxicity O 
markers O 
, O 
viz O 
. O 
, O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
, O 
creatinine B-TRIVIAL 
and O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
. O 
Prophylactic O 
treatment O 
of O 
animals O 
with O 
chrysin B-TRIVIAL 
before O 
the O 
administration O 
of O 
Fe-NTA B-FORMULA 
was O 
effective O 
in O 
modulating O 
oxidative O 
and O 
renal O 
injury O 
markers O 
and O 
resulted O 
in O 
the O 
diminution O 
of O 
Fe-NTA B-FORMULA 
mediated O 
injury O 
. O 
These O 
results O 
suggest O 
chrysin B-TRIVIAL 
as O 
an O 
effective O 
chemopreventive O 
agent O 
having O 
the O 
capability O 
to O 
obstruct O 
DEN B-ABBREVIATION 
initiated O 
and O 
Fe-NTA B-FORMULA 
promoted O 
renal O 
cancer O 
in O 
the O 
rat O 
model O 
. O 

: O 
a O 
unique O 
class O 
of O 
chemokine O 
receptor O 
type O 
4 O 
inhibitors O 
. O 

interaction O 
of O 
CXCR4 O 
with O 
CXCL12 O 
( O 
SDF-1 O 
) O 
plays O 
a O 
critical O 
role O 
in O 
cancer O 
metastasis O 
by O 
facilitating O 
the O 
homing O 
of O 
tumor O 
cells O 
to O 
metastatic O 
sites O 
. O 
Based O 
on O 
our O 
previously O 
published O 
work O 
on O 
CXCR4 O 
antagonists O 
, O 
we O 
have O 
synthesized O 
a O 
series O 
of O 
aryl B-FAMILY 
sulfonamides I-FAMILY 
that O 
inhibit O 
the O 
CXCR4 O 
/ O 
CXCL12 O 
interaction O 
. O 
Analogue O 
bioactivities O 
were O 
assessed O 
with O 
binding O 
affinity O 
and O 
Matrigel O 
invasion O 
assays O 
. O 
Computer O 
modeling O 
was O 
employed O 
to O 
evaluate O 
a O 
selection O 
of O 
the O 
new O 
analogues O 
docked O 
into O 
the O 
CXCR4 O 
X-ray O 
structure O 
and O 
to O 
rationalize O 
discrepancies O 
between O 
the O 
affinity O 
and O 
Matrigel O 
in O 
vitro O 
assays O 
. O 
A O 
lead O 
compound O 
displays O 
nanomolar O 
potency O 
in O 
the O 
binding O 
affinity O 
assay O 
( O 
IC(50)=8.0 O 
nM O 
) O 
and O 
the O 
Matrigel O 
invasion O 
assay O 
( O 
100 O 
% O 
blockade O 
of O 
invasion O 
at O 
10 O 
nM O 
) O 
. O 
These O 
data O 
demonstrate O 
that O 
benzenesulfonamides B-FAMILY 
are O 
a O 
unique O 
class O 
of O 
CXCR4 O 
inhibitors O 
with O 
high O 
potency O 
. O 

-initiated O 
polyethers B-FAMILY 
: O 
multifunctional O 
hydrophilic O 
ligands O 
for O 
PEGylation O 
and O 
functionalization O 
of O 
metal B-FAMILY 
oxide I-FAMILY 
nanoparticles O 
. O 

CA- O 
PEG B-ABBREVIATION 
( O 
catechol B-TRIVIAL 
- O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
) O 
and O 
multifunctional O 
CA- O 
PEG B-ABBREVIATION 
- O 
PGA B-ABBREVIATION 
/ O 
PEVGE B-ABBREVIATION 
( O 
poly(glycidyl B-FAMILY 
amine I-FAMILY 
) I-FAMILY 
/ O 
poly(ethylene B-FAMILY 
glycol I-FAMILY 
vinyl I-FAMILY 
glycidyl I-FAMILY 
ether I-FAMILY 
) I-FAMILY 
) O 
ligands O 
for O 
the O 
functionalization O 
and O 
solubilization O 
of O 
nanoparticles O 
are O 
introduced O 
. O 
Tunable O 
polymers O 
with O 
polydispersities O 
< O 
1.25 O 
and O 
molecular O 
weights O 
in O 
the O 
range O 
500-7700 O 
g O 
mol(-1) O 
containing O 
a O 
catechol B-TRIVIAL 
moiety O 
for O 
conjugation O 
to O 
metal B-FAMILY 
oxide I-FAMILY 
nanoparticles O 
were O 
prepared O 
. O 
The O 
functional O 
PEG B-ABBREVIATION 
ligands O 
were O 
synthesized O 
starting O 
from O 
the O 
acetonide B-SYSTEMATIC 
-protected O 
catechol B-TRIVIAL 
initiator O 
2,2-dimethyl-1,3-benzodioxole-5-propanol B-SYSTEMATIC 
( O 
CA- O 
OH B-FORMULA 
) O 
for O 
oxyanionic O 
polymerization O 
. O 
CA- O 
OH B-FORMULA 
was O 
used O 
both O 
for O 
homopolymerization O 
of O 
ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
EO O 
) O 
as O 
well O 
as O 
copolymerization O 
with O 
functional O 
epoxides B-FAMILY 
N,N-diallyl B-SYSTEMATIC 
glycidyl I-SYSTEMATIC 
amine I-SYSTEMATIC 
( O 
DAGA B-ABBREVIATION 
) O 
, O 
releasing O 
primary B-FAMILY 
amino I-FAMILY 
groups O 
and O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
vinyl I-SYSTEMATIC 
glycidyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
EVGE B-ABBREVIATION 
) O 
, O 
exhibiting O 
a O 
double O 
bond O 
for O 
click O 
- O 
type O 
reactions O 
, O 
to O 
generate O 
CA- O 
PEG B-ABBREVIATION 
and O 
CA- O 
PEG B-ABBREVIATION 
- O 
PGA B-ABBREVIATION 
/ O 
PEVGE B-ABBREVIATION 
. O 
We O 
demonstrate O 
the O 
potential O 
of O 
the O 
functional O 
ligands O 
by O 
binding O 
to O 
MnO B-FORMULA 
nanoparticles O 
, O 
rendering O 
the O 
PEGylated O 
nanoparticles O 
highly O 
stable O 
in O 
aqueous O 
environment O 
. O 
Furthermore O 
, O 
addressability O 
of O 
the O 
functional O 
groups O 
has O 
been O 
proven O 
, O 
for O 
example O 
, O 
by O 
coupling O 
with O 
fluoresceine B-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
( O 
FITC B-ABBREVIATION 
) O 
, O 
to O 
allow O 
for O 
optical O 
monitoring O 
of O 
the O 
nanoparticle O 
fate O 
in O 
biological O 
systems O 
. O 

kavalactone B-FAMILY 
derivative O 
inhibits O 
lipopolysaccharide-stimulated O 
iNOS O 
induction O 
and O 
NO B-FORMULA 
production O 
through O 
activation O 
of O 
Nrf2 O 
signaling O 
in O 
BV2 O 
microglial O 
cells O 
. O 

and O 
oxidative O 
stress O 
are O 
involved O 
in O 
the O 
pathogenesis O 
of O 
neurodegenerative O 
diseases O 
such O 
as O 
Alzheimer's O 
diseases O 
and O 
Parkinson's O 
disease O 
. O 
Naturally O 
derived O 
kavalactones B-FAMILY 
isolated O 
from O 
Piper O 
methysticum O 
( O 
Piperaceae O 
) O 
have O 
been O 
shown O 
to O 
exhibit O 
neuroprotective O 
effects O 
. O 
We O 
have O 
previously O 
reported O 
that O 
a O 
chemically O 
synthesized O 
kavalactone B-FAMILY 
derivative O 
, O 
2',6'-dichloro-5-methoxymethyl-5,6-dehydrokawain B-SYSTEMATIC 
( O 
compound O 
1 O 
) O 
protects O 
against O 
oxidative O 
stress O 
- O 
induced O 
neuronal O 
cell O 
death O 
through O 
activation O 
of O 
Nrf2 O 
signaling O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
effect O 
of O 
compound O 
1 O 
on O 
neuroinflammation O 
. O 
In O 
BV2 O 
microglial O 
cells O 
, O 
compound O 
1 O 
strongly O 
inhibited O 
LPS-stimulated O 
iNOS O 
induction O 
and O 
NO B-FORMULA 
production O 
, O 
but O 
did O 
not O 
affect O 
LPS-stimulated O 
induction O 
of O 
COX2 O 
. O 
At O 
6h O 
after O 
LPS O 
challenge O 
, O 
when O 
iNOS O 
induction O 
was O 
not O 
clearly O 
seen O 
, O 
treatment O 
with O 
LPS O 
or O 
compound O 
1 O 
alone O 
increased O 
expression O 
of O 
heme B-FAMILY 
oxygenase O 
1 O 
( O 
HO-1 O 
) O 
whose O 
transcription O 
is O 
regulated O 
by O 
Nrf2 O 
. O 
When O 
treated O 
with O 
both O 
, O 
compound O 
1 O 
enhanced O 
LPS-stimulated O 
HO-1 O 
induction O 
, O 
which O 
was O 
more O 
evident O 
at O 
24h O 
after O 
LPS O 
treatment O 
. O 
Furthermore O 
, O 
LPS-stimulated O 
activation O 
of O 
Nrf2 O 
signaling O 
and O 
nuclear O 
translocation O 
of O 
Nrf2 O 
were O 
potentiated O 
by O 
compound O 
1 O 
. O 
The O 
mechanism O 
by O 
which O 
compound O 
1 O 
activated O 
Nrf2 O 
signaling O 
was O 
supposed O 
to O 
be O 
a O 
covalent O 
modification O 
of O 
the O 
sulfhydryl B-FAMILY 
groups O 
of O 
Keap1 O 
by O 
an O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
group O 
present O 
in O 
the O 
compound O 
1 O 
. O 
Treatment O 
with O 
hemin B-TRIVIAL 
, O 
a O 
HO-1 O 
inducer O 
, O 
and O 
with O 
[Ru(CO)3Cl2]2 B-FORMULA 
, O 
a O 
CO B-FORMULA 
donor O 
, O 
decreased O 
LPS-stimulated O 
iNOS O 
induction O 
and O 
NO B-FORMULA 
production O 
. O 
In O 
contrast O 
, O 
siRNA O 
- O 
mediated O 
knockdown O 
of O 
HO-1 O 
expression O 
reduced O 
the O 
inhibitory O 
effect O 
of O 
compound O 
1 O 
on O 
LPS-stimulated O 
iNOS O 
induction O 
and O 
NO B-FORMULA 
production O 
. O 
The O 
compound O 
1 O 
inhibited O 
LPS-stimulated O 
ERK O 
phosphorylation O 
after O 
LPS O 
treatment O 
. O 
Finally O 
, O 
compound O 
1 O 
suppressed O 
LPS O 
/ O 
IFN-γ-stimulated O 
NO B-FORMULA 
production O 
in O 
primary O 
microglial O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
compound O 
1 O 
is O 
capable O 
of O 
inhibiting O 
LPS-stimulated O 
iNOS O 
induction O 
and O 
NO B-FORMULA 
production O 
via O 
activation O 
of O 
Nrf2 O 
signaling O 
and O 
HO-1 O 
induction O 
in O 
microglial O 
cells O 
. O 
Taken O 
together O 
, O 
compound O 
1 O 
has O 
a O 
potential O 
to O 
reduce O 
neuroinflammation O 
as O 
well O 
as O 
oxidative O 
stress O 
in O 
neurodegenerative O 
diseases O 
through O 
activation O 
of O 
Nrf2 O 
signaling O 
. O 

/ O 
Enhancer O 
- O 
binding O 
protein O 
- O 
homologous O 
protein O 
sensitizes O 
to O 
SU5416 B-IDENTIFIER 
by O 
modulating O 
p21 O 
and O 
PI3K O 
/ O 
Akt O 
signal O 
pathway O 
in O 
FRO O 
anaplastic O 
thyroid O 
carcinoma O 
cells O 
. O 

, O 
vascular O 
endothelial O 
cell O 
growth O 
factor O 
receptor O 
inhibitor O 
, O 
suppresses O 
hypoxia O 
- O 
induced O 
angiogenesis O 
, O 
growth O 
, O 
proliferation O 
, O 
and O 
metastasis O 
in O 
cancer O 
cells O 
. O 
CCAAT O 
/ O 
enhancer O 
- O 
binding O 
protein O 
- O 
homologous O 
protein O 
( O 
CHOP O 
) O 
has O 
pivotal O 
roles O 
in O 
regulation O 
of O 
growth O 
and O 
survival O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
effects O 
of O 
SU5416 B-IDENTIFIER 
on O 
cell O 
survival O 
, O 
p21 O 
, O 
and O 
PI3K O 
/ O 
Akt O 
signal O 
pathway O 
in O 
FRO O 
anaplastic O 
thyroid O 
carcinoma O 
( O 
ATC O 
) O 
cells O 
. O 
Moreover O 
, O 
we O 
investigated O 
the O 
roles O 
of O 
CHOP O 
in O 
cell O 
survival O 
under O 
condition O 
of O 
SU5416 B-IDENTIFIER 
treatment O 
in O 
FRO O 
ATC O 
cells O 
. O 
After O 
SU5416 B-IDENTIFIER 
treatment O 
, O 
cell O 
viability O 
, O 
PARP-1 O 
, O 
and O 
caspase-3 O 
protein O 
levels O 
were O 
not O 
changed O 
. O 
p53 O 
and O 
p27 O 
protein O 
levels O 
decreased O 
while O 
p21 O 
protein O 
levels O 
increased O 
. O 
Phospho B-SYSTEMATIC 
-Akt O 
protein O 
levels O 
were O 
not O 
altered O 
. O 
In O 
SU5416 B-IDENTIFIER 
-treated O 
situation O 
, O 
cell O 
viability O 
was O 
not O 
different O 
before O 
and O 
after O 
administration O 
of O 
either O 
p21 O 
siRNA O 
or O 
LY294002 B-IDENTIFIER 
whereas O 
it O 
was O 
lessened O 
after O 
co O 
- O 
administration O 
of O 
p21 O 
siRNA O 
and O 
LY294002 B-IDENTIFIER 
. O 
Compared O 
to O 
SU5416 B-IDENTIFIER 
treatment O 
alone O 
, O 
cell O 
viability O 
was O 
reduced O 
with O 
CHOP O 
plasmid O 
but O 
it O 
was O 
unchanged O 
with O 
CHOP O 
siRNA O 
. O 
PARP-1 O 
and O 
caspase-3 O 
protein O 
levels O 
with O 
CHOP O 
plasmid O 
were O 
elevated O 
whereas O 
the O 
protein O 
levels O 
with O 
CHOP O 
siRNA O 
were O 
similar O 
. O 
While O 
CHOP O 
plasmid O 
transfection O 
diminished O 
p21 O 
and O 
phospho B-SYSTEMATIC 
-Akt O 
protein O 
levels O 
, O 
CHOP O 
siRNA O 
transfection O 
did O 
not O 
alter O 
the O 
protein O 
levels O 
. O 
In O 
conclusion O 
, O 
these O 
results O 
suggest O 
that O 
CHOP O 
may O 
sensitize O 
FRO O 
ATC O 
cells O 
to O 
SU5416 B-IDENTIFIER 
thereby O 
inhibiting O 
cell O 
survival O 
by O 
modulating O 
p21 O 
and O 
PI3K O 
/ O 
Akt O 
signal O 
pathway O 
. O 
Furthermore O 
, O 
these O 
findings O 
imply O 
that O 
CHOP O 
may O 
be O 
a O 
possible O 
candidate O 
as O 
the O 
chemosensitizing O 
factor O 
for O 
induction O 
of O 
cytotoxicity O 
in O 
ATC O 
cells O 
exposed O 
to O 
SU5416 B-IDENTIFIER 
. O 

and O 
optivanin B-TRIVIAL 
new O 
constituents O 
from O 
the O 
stem O 
bark O 
of O 
Grewia O 
optiva O 
Drummond O 
ex O 
Burret O 
( O 
Tiliaceae O 
) O 
. O 

on O 
the O 
chemical O 
constituents O 
from O 
the O 
stem O 
bark O 
of O 
Grewia O 
optiva O 
have O 
led O 
to O 
the O 
isolation O 
of O 
two O 
new O 
compounds O 
, O 
grewialin B-TRIVIAL 
( O 
1 O 
) O 
and O 
optivanin B-TRIVIAL 
( O 
2 O 
) O 
, O 
along O 
with O 
three O 
known O 
constituents O 
which O 
were O 
hitherto O 
unreported O 
from O 
this O 
species O 
. O 
The O 
structures O 
of O 
the O 
new O 
constituents O 
have O 
been O 
elucidated O 
by O 
spectral O 
studies O 
including O 
1D O 
and O 
2D O 
NMR O 
experiments O 
( O 
HSQC O 
, O 
HMBC O 
, O 
COSY O 
, O 
NOESY O 
and O 
J-resolved O 
) O 
as O 
well O 
as O 
HR O 
EI-MS O 
spectroscopic O 
data O 
analysis O 
, O 
as O 
2S*-(3-hydroxy-4-methoxyphenyl)-3R*-methyl-2H-[1,4]-dioxin B-SYSTEMATIC 
[2,3]-chromen-7(3H)-one I-SYSTEMATIC 
( O 
1 O 
) O 
; O 
a O 
coumarinolignan B-FAMILY 
and O 
3-hydroxy-1-(3-hydroxy-4-methoxyphenyl) B-SYSTEMATIC 
propan-1-one I-SYSTEMATIC 
( O 
2 O 
) O 
. O 
The O 
known O 
compounds O 
were O 
identified O 
as O 
β-sitosterol B-TRIVIAL 
, O 
stigmasterol B-TRIVIAL 
and O 
lupeol B-TRIVIAL 
by O 
comparing O 
their O 
spectral O 
data O 
with O 
those O 
reported O 
in O 
the O 
literature O 
. O 

paper O 
investigates O 
whether O 
moisture O 
diffusion O 
can O 
be O 
predicted O 
for O 
food O 
materials O 
. O 
We O 
focus O 
especially O 
on O 
mixtures O 
of O 
glucose B-TRIVIAL 
homopolymers O 
and O 
water O 
. O 
The O 
predictions O 
are O 
based O 
on O 
three O 
theories O 
: O 
( O 
1 O 
) O 
the O 
Darken O 
relation O 
, O 
linking O 
the O 
mutual O 
diffusivity O 
to O 
the O 
self O 
diffusivities O 
, O 
( O 
2 O 
) O 
the O 
generalised O 
Stokes-Einstein O 
relation O 
for O 
the O 
solute O 
self O 
diffusivity O 
, O 
and O 
( O 
3 O 
) O 
the O 
free O 
volume O 
theory O 
for O 
water O 
self O 
diffusivity O 
. O 
Using O 
literature O 
data O 
obtained O 
for O 
the O 
whole O 
class O 
of O 
glucose B-TRIVIAL 
homopolymer O 
, O 
we O 
show O 
that O 
these O 
theories O 
predict O 
the O 
moisture O 
diffusivity O 
for O 
the O 
whole O 
range O 
of O 
volume O 
fractions O 
, O 
from O 
zero O 
to O 
one O 
, O 
and O 
a O 
broad O 
range O 
of O 
temperatures O 
. O 
Furthermore O 
, O 
we O 
show O 
that O 
the O 
theories O 
equally O 
holds O 
for O 
other O 
hydrophilic O 
biopolymers O 
one O 
finds O 
in O 
food O 
. O 
In O 
the O 
concentrated O 
regime O 
, O 
all O 
experimental O 
data O 
collapse O 
to O 
a O 
single O 
curve O 
. O 
This O 
universal O 
behaviour O 
arises O 
because O 
these O 
biopolymers O 
form O 
a O 
hydrogen B-SYSTEMATIC 
bonded O 
network O 
, O 
where O 
water O 
molecules O 
move O 
via O 
rearrangement O 
of O 
the O 
free O 
volume O 
. O 

characterization O 
and O 
constitutional O 
and O 
rotational O 
isomerism O 
of O 
ClC(O)SCN B-FORMULA 
and O 
ClC(O)NCS B-FORMULA 
. O 

and I-MULTIPLE 
isothiocyanate I-MULTIPLE 
( O 
ClC(O)SCN B-FORMULA 
and O 
ClC(O)NCS B-FORMULA 
) O 
have O 
been O 
isolated O 
and O 
characterized O 
by O 
IR O 
( O 
Ar B-FORMULA 
matrix O 
, O 
gas O 
) O 
, O 
Raman O 
( O 
liquid O 
) O 
, O 
(13)C B-FORMULA 
NMR O 
and O 
UV-visible O 
spectroscopies O 
. O 
Vibrational O 
and O 
quantum O 
chemical O 
studies O 
suggest O 
the O 
presence O 
of O 
the O 
syn O 
and O 
anti O 
conformers O 
( O 
SCN B-FORMULA 
group O 
with O 
respect O 
to O 
the O 
C═O B-FORMULA 
bond O 
) O 
in O 
the O 
gas O 
phase O 
for O 
both O 
constitutional O 
isomers O 
. O 
syn-ClC(O)SCN B-FORMULA 
is O 
preferred O 
by O 
ΔH° O 
( O 
anti O 
/ O 
syn O 
) O 
= O 
1.3(0.3) O 
kcal O 
mol(-1) O 
. O 
The O 
solid O 
- O 
state O 
structure O 
of O 
ClC(O)SCN B-FORMULA 
has O 
been O 
determined O 
by O 
single O 
crystal O 
X-ray O 
diffraction O 
analysis O 
at O 
low O 
temperature O 
. O 
The O 
crystalline O 
solid O 
consists O 
exclusively O 
of O 
molecules O 
in O 
the O 
syn O 
conformation O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
anti O 
form O 
is O 
more O 
stable O 
for O 
the O 
ClC(O)NCS B-FORMULA 
isomer O 
. O 
The O 
structure O 
of O 
ClC(O)NCS B-FORMULA 
and O 
its O 
conformational O 
composition O 
were O 
determined O 
by O 
gas O 
electron O 
diffraction O 
. O 
An O 
unusual O 
low O 
syn O 
→ O 
anti O 
interconversion O 
energy O 
barrier O 
of O 
0.98 O 
( O 
0.15 O 
) O 
kcal O 
mol(-1) O 
was O 
detected O 
for O 
ClC(O)NCS B-FORMULA 
at O 
cryogenic O 
temperatures O 
. O 
The O 
photochemistry O 
of O 
both O 
constitutional O 
isomers O 
isolated O 
in O 
solid O 
argon B-SYSTEMATIC 
at O 
15 O 
K O 
was O 
studied O 
. O 
Rearrangement O 
of O 
ClC(O)SCN B-FORMULA 
to O 
ClC(O)NCS B-FORMULA 
was O 
observed O 
in O 
the O 
neat O 
liquid O 
and O 
under O 
UV-vis O 
irradiation O 
of O 
ClC(O)SCN B-FORMULA 
isolated O 
in O 
solid O 
argon B-SYSTEMATIC 
. O 
Properties O 
have O 
been O 
discussed O 
in O 
terms O 
of O 
the O 
valence O 
electronic O 
structure O 
, O 
including O 
the O 
analysis O 
of O 
the O 
He B-FORMULA 
(I) I-FORMULA 
photoelectron O 
spectrum O 
of O 
ClC(O)SCN B-FORMULA 
. O 

induction O 
of O 
mitochondria O 
- O 
mediated O 
apoptosis O 
in O 
cancer O 
cells O 
by O 
ruthenium B-SYSTEMATIC 
(ii) I-SYSTEMATIC 
asymmetric O 
complexes O 
. O 

ruthenium B-SYSTEMATIC 
(ii) I-SYSTEMATIC 
asymmetric O 
complexes O 
, O 
[Ru(bpy)2(PAIDH)](2+) B-FORMULA 
( O 
bpy B-ABBREVIATION 
= O 
2,2'-bipyridine B-SYSTEMATIC 
, O 
PAIDH B-ABBREVIATION 
= O 
2-pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione B-SYSTEMATIC 
, O 
) O 
, O 
[Ru(phen)2(PAIDH)](2+) B-FORMULA 
( O 
phen B-ABBREVIATION 
= O 
1,10-phenanthroline B-SYSTEMATIC 
, O 
) O 
, O 
[Ru(dmp)2(PAIDH)](2+) B-FORMULA 
( O 
dmp B-ABBREVIATION 
= O 
4,7-dimethyl-1,10-phenanthroline B-SYSTEMATIC 
, O 
) O 
and O 
[Ru(dip)2(PAIDH)](2+) B-FORMULA 
( O 
dip B-ABBREVIATION 
= O 
4,7-diphenyl-1,10-phenanthroline B-SYSTEMATIC 
, O 
) O 
, O 
have O 
been O 
synthesized O 
and O 
characterized O 
. O 
These O 
complexes O 
displayed O 
potent O 
anti-proliferation O 
activity O 
against O 
various O 
cancer O 
cell O 
lines O 
and O 
had O 
high O 
selectivity O 
between O 
tumor O 
cells O 
and O 
normal O 
cells O 
. O 
HeLa O 
cells O 
exhibited O 
the O 
highest O 
sensitivity O 
to O 
complex O 
, O 
accounting O 
for O 
the O 
greatest O 
cellular O 
uptake O 
. O 
Complex O 
was O 
shown O 
to O 
accumulate O 
preferentially O 
in O 
the O 
mitochondria O 
of O 
HeLa O 
cells O 
and O 
induced O 
apoptosis O 
via O 
the O 
mitochondrial O 
pathway O 
, O 
which O 
involved O 
ROS O 
generation O 
, O 
mitochondrial O 
membrane O 
potential O 
depolarisation O 
, O 
and O 
Bcl-2 O 
and O 
caspase O 
family O 
members O 
activation O 
. O 
These O 
results O 
demonstrated O 
that O 
complex O 
induced O 
cancer O 
cell O 
apoptosis O 
by O 
acting O 
on O 
mitochondrial O 
pathways O 
. O 

anion O 
mediates O 
the O 
L-selectin O 
down O 
- O 
regulation O 
induced O 
by O 
non-steroidal O 
anti-inflammatory O 
drugs O 
in O 
human O 
neutrophils O 
. O 

anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
induce O 
the O 
shedding O 
of O 
L-selectin O 
in O 
human O 
neutrophils O 
through O 
a O 
mechanism O 
still O 
not O 
well O 
understood O 
. O 
In O 
this O 
work O 
we O 
studied O 
both O 
the O 
functional O 
effect O 
of O 
NSAIDs O 
on O 
the O 
neutrophils O 
/ O 
endothelial O 
cells O 
dynamic O 
interaction O 
, O 
and O 
the O 
potential O 
involvement O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
in O 
the O 
NSAIDs O 
- O 
mediated O 
down O 
- O 
regulation O 
of O 
L-selectin O 
. O 
When O 
human O 
neutrophils O 
were O 
incubated O 
with O 
diclofenac B-TRIVIAL 
, O 
a O 
significant O 
reduction O 
in O 
the O 
number O 
of O 
cells O 
that O 
rolled O 
on O 
activated O 
endothelial O 
cells O 
was O 
observed O 
. O 
Different O 
NSAIDs O 
( O 
flufenamic B-TRIVIAL 
acid I-TRIVIAL 
, O 
meclofenamic B-TRIVIAL 
acid I-TRIVIAL 
, O 
diclofenac B-TRIVIAL 
, O 
indomethacin B-TRIVIAL 
, O 
nimesulide B-TRIVIAL 
, O 
flurbiprofen B-TRIVIAL 
, O 
meloxicam B-TRIVIAL 
, O 
phenylbutazone B-TRIVIAL 
, O 
piroxicam B-TRIVIAL 
, O 
ketoprofen B-TRIVIAL 
and O 
aspirin B-TRIVIAL 
) O 
caused O 
variable O 
increase O 
in O 
neutrophil O 
intracellular O 
ROS O 
concentration O 
, O 
which O 
was O 
inversely O 
proportional O 
to O 
the O 
change O 
produced O 
in O 
L-selectin O 
surface O 
expression O 
. O 
Pre O 
- O 
incubation O 
of O 
neutrophils O 
with O 
superoxide B-TRIVIAL 
dismutase O 
, O 
but O 
not O 
with O 
catalase O 
, O 
showed O 
both O 
a O 
significant O 
protective O 
effect O 
on O 
the O 
L-selectin O 
down O 
- O 
regulation O 
induced O 
by O 
several O 
NSAIDs O 
and O 
a O 
diminished O 
effect O 
of O 
diclofenac B-TRIVIAL 
on O 
neutrophil O 
rolling O 
. O 
Interestingly O 
, O 
diclofenac B-TRIVIAL 
and O 
flufenamic B-TRIVIAL 
acid I-TRIVIAL 
but O 
not O 
piroxicam B-TRIVIAL 
significantly O 
increased O 
the O 
extracellular O 
superoxide B-TRIVIAL 
anion O 
production O 
by O 
neutrophils O 
, O 
and O 
inhibition O 
of O 
nicotinamide B-SYSTEMATIC 
adenine I-SYSTEMATIC 
dinucleotide I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
NADPH B-ABBREVIATION 
)-oxidase O 
activity O 
with O 
diphenyleneiodonium B-TRIVIAL 
prevented O 
the O 
down O 
- O 
regulation O 
of O 
L-selectin O 
by O 
diclofenac B-TRIVIAL 
. O 
In O 
accordance O 
with O 
these O 
results O 
, O 
neutrophils O 
from O 
patients O 
with O 
chronic O 
granulomatous O 
disease O 
, O 
a O 
hereditary O 
disease O 
in O 
which O 
neutrophils O 
show O 
a O 
reduced O 
capacity O 
to O 
form O 
superoxide B-TRIVIAL 
radicals O 
, O 
exhibited O 
a O 
lower O 
down O 
- O 
regulation O 
of O 
L-selectin O 
( O 
IC50 O 
: O 
15.3 O 
μg O 
/ O 
ml O 
) O 
compared O 
to O 
normal O 
controls O 
( O 
IC50 O 
: O 
5.6 O 
μg O 
/ O 
ml O 
) O 
in O 
response O 
to O 
diclofenac B-TRIVIAL 
. O 
CONCLUSION O 
: O 
A O 
group O 
of O 
NSAIDs O 
is O 
capable O 
of O 
interfering O 
with O 
the O 
ability O 
of O 
neutrophils O 
to O 
interact O 
with O 
endothelial O 
cells O 
by O 
triggering O 
L-selectin- O 
shedding O 
through O 
the O 
NADPH B-ABBREVIATION 
-oxidase O 
- O 
dependent O 
generation O 
of O 
superoxide B-TRIVIAL 
anion O 
at O 
the O 
plasma O 
membrane O 
. O 

chose O 
promoters O 
responsive O 
to O 
sonication O 
in O 
LNCap O 
cells O 
, O 
a O 
prostate O 
cancer O 
cell O 
line O 
, O 
out O 
of O 
a O 
library O 
composed O 
of O 
DNA O 
fragments O 
constructed O 
by O 
linking O 
the O 
TATA O 
box O 
sequence O 
to O 
randomly O 
combined O 
cis-acting O 
elements O 
of O 
transcription O 
factors O 
activated O 
in O 
response O 
to O 
radiation O 
in O 
prostate O 
cancer O 
cells O 
. O 
When O 
a O 
plasmid O 
containing O 
the O 
luciferase O 
gene O 
under O 
control O 
of O 
a O 
promoter O 
was O 
transfected O 
into O 
LNCap O 
cells O 
and O 
sonicated O 
with O 
1 O 
MHz O 
ultrasound O 
at O 
0.5 O 
W O 
/ O 
cm(2) O 
, O 
10% O 
DF O 
for O 
60s O 
, O 
13 O 
promoters O 
showed O 
more O 
than O 
10-fold O 
enhancement O 
compared O 
with O 
their O 
counterparts O 
without O 
sonication O 
12h O 
after O 
sonication O 
. O 
As O 
to O 
their O 
responsiveness O 
to O 
sonication O 
, O 
the O 
best O 
two O 
promoters O 
were O 
then O 
compared O 
to O 
clone O 
880-8 O 
, O 
a O 
derivative O 
from O 
clone O 
880 O 
that O 
was O 
created O 
by O 
random O 
introduction O 
of O 
point O 
mutations O 
and O 
was O 
shown O 
to O 
have O 
an O 
improved O 
response O 
to O 
X-ray O 
irradiation O 
. O 
We O 
then O 
took O 
clone O 
880-8 O 
for O 
further O 
analyses O 
since O 
it O 
showed O 
the O 
highest O 
enhancement O 
to O 
sonication O 
, O 
though O 
not O 
statistically O 
significant O 
from O 
the O 
others O 
. O 
Next O 
, O 
we O 
employed O 
a O 
retrovirus O 
vector O 
and O 
stably O 
introduced O 
the O 
luciferase O 
gene O 
under O 
control O 
of O 
clone O 
880-8 O 
into O 
LNCap O 
cells O 
to O 
establish O 
a O 
cell O 
line O 
. O 
When O 
the O 
cell O 
line O 
was O 
sonicated O 
with O 
1 O 
MHz O 
ultrasound O 
at O 
0.5 O 
W O 
/ O 
cm(2) O 
, O 
10% O 
DF O 
for O 
60s O 
, O 
luciferase O 
expression O 
was O 
enhanced O 
up O 
to O 
14.8-fold O 
12h O 
after O 
sonication O 
. O 
We O 
then O 
established O 
another O 
cell O 
line O 
by O 
replacing O 
the O 
luciferase O 
gene O 
with O 
the O 
fcy O 
: O 
: O 
fur O 
gene O 
, O 
a O 
suicide O 
gene O 
, O 
and O 
when O 
the O 
cell O 
line O 
was O 
sonicated O 
with O 
1 O 
MHz O 
ultrasound O 
at O 
0.5 O 
W O 
/ O 
cm(2) O 
, O 
10% O 
DF O 
for O 
60s O 
, O 
expression O 
of O 
the O 
gene O 
was O 
enhanced O 
, O 
showing O 
the O 
maximum O 
expression O 
12-24h O 
after O 
sonication O 
. O 
When O 
the O 
cells O 
were O 
incubated O 
in O 
medium O 
containing O 
5-fluorocytosine B-SYSTEMATIC 
, O 
cell O 
survival O 
ratio O 
decreased O 
dose O 
dependently O 
with O 
5-fluorocytosine B-SYSTEMATIC 
only O 
after O 
sonication O 
treatment O 
, O 
suggesting O 
this O 
promoter O 
could O 
be O 
utilized O 
for O 
gene O 
expression O 
control O 
with O 
ultrasound O 
. O 

cycle O 
regulation O 
by O 
glucosamine B-TRIVIAL 
in O 
human O 
pulmonary O 
epithelial O 
cells O 
. O 

epithelial O 
cells O 
play O 
an O 
important O 
role O 
against O 
intruding O 
pathogens O 
. O 
Glucosamine B-TRIVIAL 
, O 
a O 
commonly O 
used O 
supplemental O 
compound O 
, O 
has O 
recently O 
begun O 
to O 
be O 
regarded O 
as O 
a O 
potential O 
anti-inflammatory O 
molecule O 
. O 
This O 
study O 
aimed O 
to O 
uncover O 
how O 
glucosamine B-TRIVIAL 
impacts O 
on O 
cellular O 
proliferation O 
in O 
human O 
alveolar O 
epithelial O 
cells O 
( O 
A549 O 
) O 
and O 
bronchial O 
epithelial O 
cells O 
( O 
HBECs O 
) O 
. O 
With O 
trypan B-TRIVIAL 
blue I-TRIVIAL 
-exclusion O 
assay O 
, O 
we O 
observed O 
that O 
glucosamine B-TRIVIAL 
( O 
10 O 
, O 
20 O 
, O 
50 O 
mM O 
) O 
caused O 
a O 
decrease O 
in O 
cell O 
number O 
at O 
24 O 
and O 
48 O 
h O 
; O 
with O 
a O 
flow O 
cytometric O 
analysis O 
, O 
we O 
also O 
noted O 
an O 
enhanced O 
cell O 
accumulation O 
within O 
the O 
G(0) O 
/ O 
G(1) O 
phase O 
at O 
24 O 
h O 
and O 
induction O 
of O 
late O 
apoptosis O 
at O 
24 O 
and O 
48 O 
h O 
by O 
glucosamine B-TRIVIAL 
( O 
10 O 
, O 
20 O 
, O 
50 O 
mM O 
) O 
in O 
A549 O 
cells O 
and O 
HBECs O 
. O 
Examination O 
of O 
phosphorylation O 
in O 
retinoblastoma O 
( O 
Rb O 
) O 
protein O 
, O 
we O 
found O 
an O 
inhibitory O 
effect O 
by O 
glucosamine B-TRIVIAL 
at O 
20 O 
and O 
50 O 
mM O 
. O 
Glucosamine B-TRIVIAL 
at O 
50 O 
mM O 
was O 
demonstrated O 
to O 
elevate O 
both O 
the O 
mRNA O 
and O 
protein O 
expression O 
of O 
p53 O 
and O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
, O 
but O 
also O 
caused O 
a O 
reduction O 
in O 
p21 O 
protein O 
expression O 
. O 
In O 
addition O 
, O 
glucosamine B-TRIVIAL 
attenuated O 
p21 O 
protein O 
stability O 
via O 
the O 
proteasomal O 
proteolytic O 
pathway O 
, O 
as O 
well O 
as O 
inducing O 
p21 O 
nuclear O 
accumulation O 
. O 
Altogether O 
, O 
our O 
results O 
suggest O 
that O 
a O 
high O 
dose O 
of O 
glucosamine B-TRIVIAL 
may O 
inhibit O 
cell O 
proliferation O 
through O 
apoptosis O 
and O 
disturb O 
cell O 
cycle O 
progression O 
with O 
a O 
halt O 
at O 
G(0) O 
/ O 
G(1) O 
phase O 
, O 
and O 
that O 
this O 
occurs O 
, O 
at O 
least O 
in O 
part O 
, O 
by O 
a O 
reduction O 
in O 
Rb O 
phosphorylation O 
together O 
with O 
modulation O 
of O 
p21 O 
, O 
p53 O 
and O 
HO-1 O 
expression O 
, O 
and O 
nuclear O 
p21 O 
accumulation O 
. O 

and I-MULTIPLE 
imidazo I-MULTIPLE 
dihydropyrazolopyrimidine I-MULTIPLE 
potassium B-SYSTEMATIC 
channel O 
antagonists O 
. O 

disclosed O 
C6 O 
amido B-MULTIPLE 
and I-MULTIPLE 
benzimidazole I-MULTIPLE 
dihydropyrazolopyrimidines I-MULTIPLE 
were O 
potent O 
and O 
selective O 
blockers O 
of O 
IKur O 
current O 
. O 
Syntheses O 
and O 
SAR O 
for O 
C6 O 
triazolo B-MULTIPLE 
and I-MULTIPLE 
imidazo I-MULTIPLE 
dihydropyrazolopyrimidines I-MULTIPLE 
series O 
are O 
described O 
. O 
Trifluoromethylcyclohexyl B-SYSTEMATIC 
N(1) I-SYSTEMATIC 
triazole I-SYSTEMATIC 
, O 
compound O 
51 O 
, O 
was O 
identified O 
as O 
a O 
potent O 
and O 
selective O 
Kv1.5 O 
inhibitor O 
with O 
an O 
acceptable O 
PK O 
and O 
liability O 
profile O 
. O 

analysis O 
of O 
the O 
triterpenoids B-FAMILY 
with O 
cytotoxicity O 
and O 
QR O 
inducing O 
properties O 
from O 
the O 
total O 
tea O 
seed O 
saponin B-FAMILY 
of O 
Camellia O 
sinensis O 
. O 

tea O 
seed O 
triterpene B-FAMILY 
saponin I-FAMILY 
( O 
TS O 
) O 
from O 
Camellia O 
sinensis O 
was O 
found O 
to O 
exhibit O 
better O 
antitumor O 
activity O 
in O 
vivo O 
in O 
S180 O 
implanted O 
ICR O 
mice O 
and O 
QR O 
inducing O 
activity O 
for O 
hepa O 
lclc7 O 
cells O 
respectively O 
compared O 
with O 
the O 
total O 
tea O 
seed O 
saponin B-FAMILY 
( O 
TTS O 
) O 
, O 
hydrolysate O 
of O 
the O 
TTS O 
and O 
tea O 
seed O 
flavonoid B-FAMILY 
glycosides I-FAMILY 
( O 
TF O 
) O 
. O 
By O 
bioassay O 
- O 
guided O 
isolation O 
, O 
the O 
TS O 
fraction O 
was O 
separated O 
and O 
seven O 
major O 
components O 
were O 
purified O 
and O 
identified O 
as O 
theasaponin B-TRIVIAL 
E1 I-TRIVIAL 
( O 
1 O 
) O 
, O 
theasaponin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
2 O 
) O 
, O 
theasaponin B-TRIVIAL 
C1 I-TRIVIAL 
( O 
3 O 
) O 
, O 
assamsaponin B-TRIVIAL 
C I-TRIVIAL 
( O 
4 O 
) O 
, O 
theasaponin B-TRIVIAL 
H1 I-TRIVIAL 
( O 
5 O 
) O 
, O 
theasaponin B-TRIVIAL 
A9 I-TRIVIAL 
( O 
6 O 
) O 
, O 
and O 
theasaponin B-TRIVIAL 
A8 I-TRIVIAL 
( O 
7 O 
) O 
, O 
among O 
which O 
compounds O 
4 O 
and O 
5 O 
were O 
isolated O 
from O 
this O 
genus O 
for O 
the O 
first O 
time O 
. O 
The O 
antitumor O 
bioassay O 
of O 
the O 
isolated O 
compounds O 
showed O 
that O 
compounds O 
1 O 
, O 
2 O 
and O 
3 O 
exhibited O 
potential O 
activities O 
against O 
the O 
human O 
tumor O 
cell O 
lines O 
K562 O 
and O 
HL60 O 
. O 
Furthermore O 
, O 
compound O 
1 O 
( O 
the O 
major O 
constituent O 
with O 
a O 
mass O 
content O 
of O 
over O 
1% O 
) O 
showed O 
significant O 
QR O 
inducing O 
activity O 
with O 
an O 
IR O 
value O 
of O 
4.2 O 
at O 
4μg O 
/ O 
ml O 
. O 
So O 
it O 
can O 
be O 
concluded O 
that O 
tea O 
seed O 
especially O 
the O 
compound O 
1 O 
( O 
theasaponin B-TRIVIAL 
E1 I-TRIVIAL 
) O 
could O 
be O 
used O 
as O 
an O 
antitumor O 
agent O 
and O 
a O 
chemoprevention O 
agent O 
of O 
cancer O 
. O 
The O 
preliminary O 
structure O 
- O 
activity O 
relationship O 
in O 
the O 
anti-tumor O 
activity O 
and O 
QR O 
inducing O 
activity O 
of O 
tea O 
saponins B-FAMILY 
was O 
discussed O 
briefly O 
. O 

is O 
widely O 
accepted O 
that O 
insufficient O 
insulin O 
- O 
stimulated O 
activation O 
of O 
muscle O 
glycogen O 
synthesis O 
is O 
one O 
of O 
the O 
major O 
components O 
of O 
non-insulin O 
- O 
dependent O 
( O 
type O 
2 O 
) O 
diabetes O 
mellitus O 
. O 
Glycogen O 
synthase O 
, O 
a O 
key O 
enzyme O 
in O 
muscle O 
glycogen O 
synthesis O 
, O 
is O 
extensively O 
regulated O 
, O 
both O 
allosterically O 
( O 
by O 
glucose-6-phosphate B-SYSTEMATIC 
, O 
ATP B-ABBREVIATION 
, O 
and O 
others O 
) O 
and O 
covalently O 
( O 
by O 
phosphorylation O 
) O 
. O 
Although O 
glycogen O 
synthase O 
has O 
been O 
a O 
topic O 
of O 
intense O 
study O 
for O 
more O 
than O 
50 O 
years O 
, O 
its O 
kinetic O 
characterization O 
has O 
been O 
confounded O 
by O 
its O 
large O 
number O 
of O 
phosphorylation O 
states O 
. O 
Questions O 
remain O 
regarding O 
the O 
function O 
of O 
glycogen O 
synthase O 
regulation O 
and O 
the O 
relative O 
importance O 
of O 
allosteric O 
and O 
covalent O 
modification O 
in O 
fulfilling O 
this O 
function O 
. O 
In O 
this O 
review O 
, O 
we O 
consider O 
both O 
earlier O 
kinetic O 
studies O 
and O 
more O 
recent O 
site O 
- O 
directed O 
mutagenesis O 
and O 
crystal O 
structure O 
studies O 
in O 
a O 
detailed O 
qualitative O 
discussion O 
of O 
the O 
effects O 
of O 
regulation O 
on O 
the O 
kinetics O 
of O 
glycogen O 
synthase O 
. O 
We O 
propose O 
that O 
both O 
allosteric O 
and O 
covalent O 
modification O 
of O 
glycogen O 
synthase O 
may O 
be O 
described O 
by O 
a O 
Monod-Wyman-Changeux O 
model O 
in O 
terms O 
of O 
apparent O 
changes O 
to O 
L O 
, O 
the O 
equilibrium O 
constant O 
for O 
transition O 
between O 
the O 
T O 
and O 
R O 
conformers O 
. O 
As O 
, O 
with O 
the O 
exception O 
of O 
L O 
, O 
all O 
parameters O 
of O 
this O 
model O 
are O 
independent O 
of O 
the O 
glycogen O 
synthase O 
phosphorylation O 
state O 
, O 
the O 
need O 
to O 
determine O 
kinetic O 
parameters O 
for O 
all O 
possible O 
states O 
is O 
eliminated O 
; O 
only O 
the O 
relationship O 
between O 
a O 
particular O 
state O 
and O 
L O 
must O 
be O 
established O 
. O 
We O 
conclude O 
by O 
suggesting O 
that O 
renewed O 
efforts O 
to O 
characterize O 
the O 
relationship O 
between O 
phosphorylation O 
and O 
the O 
kinetics O 
of O 
glycogen O 
synthase O 
are O 
essential O 
in O 
order O 
to O 
obtain O 
a O 
better O 
quantitative O 
understanding O 
of O 
the O 
function O 
of O 
glycogen O 
synthesis O 
regulation O 
. O 
The O 
model O 
we O 
propose O 
may O 
prove O 
useful O 
in O 
this O 
regard O 
. O 

influence O 
of O 
pH O 
on O 
phosphatidylethanolamine B-SYSTEMATIC 
monolayer O 
at O 
the O 
air O 
/ O 
aqueous O 
solution O 
interface O 
. O 

dependence O 
of O 
the O 
interfacial O 
tension O 
of O 
a O 
phosphatidylethanolamine B-SYSTEMATIC 
( O 
PE O 
) O 
monolayer O 
on O 
the O 
pH O 
of O 
the O 
aqueous O 
solution O 
has O 
been O 
studied O 
. O 
A O 
theoretical O 
equation O 
is O 
derived O 
to O 
describe O 
this O 
dependence O 
. O 
A O 
simple O 
model O 
of O 
the O 
influence O 
of O 
pH O 
on O 
the O 
phosphatidylethanolamine B-SYSTEMATIC 
monolayer O 
at O 
the O 
air O 
/ O 
hydrophobic O 
chains O 
of O 
PE O 
is O 
presented O 
. O 
The O 
contributions O 
of O 
additive O 
phosphatidylethanolamine B-SYSTEMATIC 
forms O 
( O 
both O 
interfacial O 
tension O 
values O 
and O 
molecular O 
area O 
values O 
) O 
depend O 
on O 
pH O 
. O 
The O 
interfacial O 
tension O 
values O 
and O 
the O 
molecular O 
area O 
values O 
for O 
PEH(+) B-ABBREVIATION 
and O 
PEOH(-) B-ABBREVIATION 
forms O 
of O 
phosphatidylethanolamine B-SYSTEMATIC 
were O 
calculated O 
. O 
The O 
assumed O 
model O 
was O 
verified O 
experimentally O 
. O 
The O 
experimental O 
results O 
agreed O 
with O 
those O 
derived O 
from O 
the O 
theoretical O 
equation O 
in O 
a O 
whole O 
range O 
of O 
pH O 
values O 
. O 

of O 
rat O 
aortic O 
smooth O 
muscle O 
( O 
A7r5 O 
) O 
and O 
human O 
osteosarcoma O 
( O 
U2OS O 
) O 
cells O 
on O 
photo O 
- O 
cross O 
- O 
linked O 
polyelectrolyte O 
multilayers O 
( O 
PEMUs O 
) O 
with O 
uniform O 
, O 
or O 
gradients O 
of O 
, O 
moduli O 
were O 
investigated O 
. O 
The O 
PEMUs O 
were O 
built O 
layer O 
- O 
by O 
- O 
layer O 
with O 
the O 
polycation O 
poly(allylamine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAH B-ABBREVIATION 
) O 
and O 
a O 
polyanion O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAA B-ABBREVIATION 
) O 
that O 
was O 
modified O 
with O 
photoreactive O 
4-(2-hydroxyethoxy) B-SYSTEMATIC 
benzophenone I-SYSTEMATIC 
( O 
PAABp O 
) O 
. O 
PEMUs O 
with O 
different O 
uniform O 
and O 
gradients O 
of O 
modulus O 
were O 
generated O 
by O 
varying O 
the O 
time O 
of O 
uniform O 
ultraviolet O 
light O 
exposure O 
and O 
by O 
exposure O 
through O 
optical O 
density O 
gradient O 
filters O 
. O 
Analysis O 
of O 
adhesion O 
, O 
morphology O 
, O 
cytoskeletal O 
organization O 
, O 
and O 
motility O 
of O 
the O 
cells O 
on O 
the O 
PEMUs O 
revealed O 
that O 
A7r5 O 
cells O 
established O 
a O 
polarized O 
orientation O 
toward O 
increasing O 
modulus O 
on O 
shallow O 
modulus O 
gradients O 
( O 
approximately O 
4.7 O 
MPa O 
mm(-1) O 
) O 
and O 
durotaxed O 
toward O 
stiffer O 
regions O 
on O 
steeper O 
gradients O 
( O 
approximately O 
55 O 
MPa O 
mm(-1) O 
) O 
. O 
In O 
contrast O 
, O 
U2OS O 
cells O 
exhibited O 
little O 
orientation O 
or O 
durotaxis O 
on O 
modulus O 
gradients O 
. O 
These O 
results O 
demonstrate O 
the O 
utility O 
of O 
photo O 
- O 
cross O 
- O 
linked O 
PEMUs O 
to O 
direct O 
vascular O 
and O 
osteoblast O 
cell O 
behavior O 
, O 
a O 
potential O 
application O 
for O 
PEMU O 
coatings O 
on O 
biomedical O 
implants O 
. O 

deacetylase O 
inhibitors O 
( O 
HDACi O 
) O 
have O 
been O 
enthusiastically O 
investigated O 
as O 
a O 
novel O 
generation O 
of O 
chemotherapeutics O 
for O 
cancers O 
usually O 
called O 
as O 
epigenetic O 
therapeutics O 
. O 
Histone O 
deacetylases O 
have O 
been O 
found O 
to O 
influence O 
cellular O 
function O 
by O 
catalyzing O 
the O 
removal O 
of O 
acetyl B-SYSTEMATIC 
groups O 
from O 
ε-N-acetylated B-TRIVIAL 
lysine I-TRIVIAL 
residues O 
of O 
several O 
protein O 
substrates O 
including O 
histones O 
, O 
transcription O 
factors O 
, O 
α-tubulin O 
, O 
and O 
nuclear O 
importers O 
. O 
Cyclic O 
peptides O 
represent O 
the O 
most O 
structurally O 
complicated O 
and O 
diverse O 
class O 
of O 
histone O 
deacetylase O 
inhibitors O 
. O 
Each O 
subtype O 
of O 
the O 
Histone O 
Deacetylase O 
( O 
HDAC O 
) O 
family O 
perform O 
a O 
distinct O 
role O 
in O 
the O 
gene O 
expression O 
and O 
cyclic O 
peptides O 
with O 
their O 
plentiful O 
set O 
of O 
surface O 
contacts O 
, O 
zinc B-SYSTEMATIC 
binding O 
group O 
and O 
macrocyclic O 
cap O 
, O 
can O 
target O 
enzyme O 
precisely O 
through O 
adequate O 
modulation O 
of O 
the O 
amino B-FAMILY 
acid I-FAMILY 
configurational O 
and O 
structural O 
assortment O 
. O 
The O 
present O 
article O 
summarizes O 
current O 
status O 
of O 
different O 
peptide O 
based O 
macrocyclic O 
compounds O 
being O 
developed O 
as O 
HDACi O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 

saligenin I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
makes O 
multiple O 
adducts O 
on O 
free O 
histidine B-TRIVIAL 
, O 
but O 
does O 
not O 
form O 
an O 
adduct O 
on O 
histidine B-TRIVIAL 
438 O 
of O 
human O 
butyrylcholinesterase O 
. O 

saligenin I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
CBDP B-ABBREVIATION 
) O 
is O 
a O 
suspected O 
causative O 
agent O 
of O 
" O 
aerotoxic O 
syndrome O 
" O 
, O 
affecting O 
pilots O 
, O 
crew O 
members O 
and O 
passengers O 
. O 
CBDP B-ABBREVIATION 
is O 
produced O 
in O 
vivo O 
from O 
ortho- O 
containing O 
isomers O 
of O 
tricresyl B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
TCP B-ABBREVIATION 
) O 
, O 
a O 
component O 
of O 
jet O 
engine O 
lubricants O 
and O 
hydraulic O 
fluids O 
. O 
CBDP B-ABBREVIATION 
irreversibly O 
inhibits O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
in O 
human O 
plasma O 
by O 
forming O 
adducts O 
on O 
the O 
active O 
site O 
serine B-TRIVIAL 
( O 
Ser B-FORMULA 
-198 O 
) O 
. O 
Inhibited O 
BChE O 
undergoes O 
aging O 
to O 
release O 
saligenin B-TRIVIAL 
and O 
o-cresol B-TRIVIAL 
. O 
The O 
active O 
site O 
histidine B-TRIVIAL 
( O 
His B-FORMULA 
-438 O 
) O 
was O 
hypothesized O 
to O 
abstract O 
o-hydroxybenzyl B-SYSTEMATIC 
moiety O 
from O 
the O 
initial O 
adduct O 
on O 
Ser B-FORMULA 
-198 O 
. O 
Our O 
goal O 
was O 
to O 
test O 
this O 
hypothesis O 
. O 
Mass O 
spectral O 
analysis O 
of O 
CBDP B-ABBREVIATION 
-inhibited O 
BChE O 
digested O 
with O 
Glu B-FORMULA 
-C O 
showed O 
an O 
o-hydroxybenzyl B-SYSTEMATIC 
adduct O 
( O 
+ O 
106amu O 
) O 
on O 
lysine B-TRIVIAL 
499 O 
, O 
a O 
residue O 
far O 
from O 
the O 
active O 
site O 
, O 
but O 
not O 
on O 
His B-FORMULA 
-438 O 
. O 
Nevertheless O 
, O 
the O 
nitrogen B-SYSTEMATIC 
of O 
the O 
imidazole B-SYSTEMATIC 
ring O 
of O 
free O 
l-histidine B-TRIVIAL 
formed O 
a O 
variety O 
of O 
adducts O 
upon O 
reaction O 
with O 
CBDP B-ABBREVIATION 
, O 
including O 
the O 
o-hydroxybenzyl B-SYSTEMATIC 
adduct O 
, O 
suggesting O 
that O 
histidine B-TRIVIAL 
- O 
CBDP B-ABBREVIATION 
adducts O 
may O 
form O 
on O 
other O 
proteins O 
. O 

Background O 
and O 
objective O 
: O 
To O 
evaluate O 
the O 
effects O 
of O 
ischemia O 
and O 
reperfusion O 
( O 
IR O 
) O 
and O 
ischemic O 
preconditioning O 
( O 
IPC O 
) O 
on O 
the O 
metabolic O 
activities O 
of O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
isozymes O 
in O 
rats O 
by O 
a O 
five O 
- O 
drug O 
cocktail O 
approach O 
. O 
Methods O 
: O 
Cocktail O 
approach O 
was O 
used O 
to O 
evaluate O 
the O 
influence O 
of O 
IR O 
and O 
IPC O 
on O 
the O 
activities O 
of O 
CYP1A2 O 
, O 
CYP2C9 O 
, O 
CYP2E1 O 
, O 
CYP2D6 O 
and O 
CYP3A4 O 
, O 
which O 
were O 
reflected O 
by O 
the O 
changes O 
of O 
pharmacokinetic O 
parameters O 
of O 
five O 
specific O 
probe O 
drugs O 
: O 
caffeine B-TRIVIAL 
, O 
chlorzoxazone B-SYSTEMATIC 
, O 
tolbutamide B-TRIVIAL 
, O 
metoprolol B-TRIVIAL 
and O 
midazolam B-TRIVIAL 
, O 
respectively O 
. O 
Rats O 
were O 
randomly O 
divided O 
into O 
IR O 
, O 
IPC O 
and O 
sham O 
groups O 
, O 
and O 
then O 
injected O 
the O 
mixture O 
of O 
five O 
probe O 
drugs O 
. O 
Blood O 
samples O 
were O 
collected O 
at O 
a O 
series O 
of O 
time O 
- O 
points O 
and O 
the O 
concentrations O 
of O 
probe O 
drugs O 
in O 
plasma O 
were O 
determined O 
by O 
a O 
HPLC O 
method O 
with O 
UV O 
detection O 
. O 
The O 
pharmacokinetic O 
parameters O 
were O 
calculated O 
by O 
the O 
software O 
of O 
DAS O 
2 O 
. O 
Results O 
: O 
The O 
parameters O 
including O 
t(1 O 
/ O 
2β O 
) O 
, O 
CLs O 
, O 
AUC O 
, O 
MRT O 
and O 
K(10) O 
exhibited O 
a O 
similar O 
tendency O 
for O 
both O 
IR O 
and O 
IPC O 
groups O 
. O 
Compared O 
with O 
sham O 
group O 
, O 
CLs O 
and O 
K(10) O 
of O 
five O 
probe O 
drugs O 
were O 
significantly O 
lower O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
AUC O 
and O 
t(1 O 
/ O 
2β O 
) O 
of O 
five O 
or O 
some O 
probe O 
drugs O 
were O 
significantly O 
increased O 
in O 
IR O 
and O 
IPC O 
groups O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Compared O 
with O 
IPC O 
group O 
, O 
CLs O 
of O 
five O 
probe O 
drugs O 
were O 
decreased O 
and O 
AUC O 
were O 
significantly O 
increased O 
in O 
the O 
IR O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Conclusion O 
: O 
IR O 
can O 
variably O 
decrease O 
the O 
activities O 
of O 
CYP O 
isozymes O 
in O 
rats O 
and O 
this O 
decrease O 
can O 
be O 
attenuated O 
by O 
IPC O 
. O 

of O 
a O 
mixed O 
valence O 
diiron B-SYSTEMATIC 
hydride I-SYSTEMATIC 
: O 
evidence O 
for O 
a O 
spectator O 
hydride B-SYSTEMATIC 
in O 
hydrogen B-SYSTEMATIC 
evolution O 
catalysis O 
. O 

mixed O 
- O 
valence O 
diiron B-SYSTEMATIC 
hydrido B-SYSTEMATIC 
complex O 
(μ-H)Fe2(pdt)(CO)2(dppv)2 B-FORMULA 
( O 
[ O 
H1 B-FORMULA 
](0 O 
) O 
, O 
where O 
pdt B-ABBREVIATION 
= O 
1,3-propanedithiolate B-SYSTEMATIC 
and O 
dppv B-ABBREVIATION 
= O 
cis-1,2-C2H2(PPh2)2 B-SYSTEMATIC 
) O 
, O 
was O 
generated O 
by O 
reduction O 
of O 
the O 
differous O 
hydride B-SYSTEMATIC 
[H1](+) B-FORMULA 
using O 
decamethylcobaltocene B-SYSTEMATIC 
. O 
Crystallographic O 
analysis O 
shows O 
that O 
[ O 
H1 B-FORMULA 
](0 O 
) O 
retains O 
the O 
stereochemistry O 
of O 
its O 
precursor O 
, O 
where O 
one O 
dppv B-ABBREVIATION 
ligand O 
spans O 
two O 
basal O 
sites O 
and O 
the O 
other O 
spans O 
apical O 
and O 
basal O 
positions O 
. O 
The O 
Fe B-FORMULA 
-- I-FORMULA 
-Fe I-FORMULA 
bond O 
elongates O 
to O 
2.8 O 
from O 
2.66 O 
Å O 
, O 
but O 
the O 
Fe-P B-FORMULA 
bonds O 
only O 
change O 
subtly O 
. O 
Although O 
the O 
Fe-H B-FORMULA 
distances O 
are O 
indistinguishable O 
in O 
the O 
precursor O 
, O 
they O 
differ O 
by O 
0.2 O 
Å O 
in O 
[ O 
H1 B-FORMULA 
](0 O 
) O 
. O 
The O 
X-band O 
electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
spectrum O 
reveals O 
the O 
presence O 
of O 
two O 
stereoisomers O 
, O 
the O 
one O 
characterized O 
crystallographically O 
and O 
a O 
contribution O 
of O 
about O 
10% O 
from O 
a O 
second O 
symmetrical O 
( O 
sym O 
) O 
isomer O 
wherein O 
both O 
dppv B-ABBREVIATION 
ligands O 
occupy O 
apical O 
- O 
basal O 
sites O 
. O 
The O 
unsymmetrical O 
( O 
unsym O 
) O 
arrangement O 
of O 
the O 
dppv B-ABBREVIATION 
ligands O 
is O 
reflected O 
in O 
the O 
values O 
of O 
A( O 
(31)P B-FORMULA 
) O 
, O 
which O 
range O 
from O 
31 O 
MHz O 
for O 
the O 
basal O 
phosphines B-FAMILY 
to O 
284 O 
MHz O 
for O 
the O 
apical O 
phosphine B-SYSTEMATIC 
. O 
Density O 
functional O 
theory O 
calculations O 
were O 
employed O 
to O 
rationalize O 
the O 
electronic O 
structure O 
of O 
[ O 
H1 B-FORMULA 
](0 O 
) O 
and O 
to O 
facilitate O 
spectral O 
simulation O 
and O 
assignment O 
of O 
EPR O 
parameters O 
including O 
(1)H B-FORMULA 
and O 
(31)P B-FORMULA 
hyperfine O 
couplings O 
. O 
The O 
EPR O 
spectra O 
of O 
[ O 
H1 B-FORMULA 
](0 O 
) O 
and O 
[D1](0) O 
demonstrate O 
that O 
the O 
singly O 
occupied O 
molecular O 
orbital O 
is O 
primarily O 
localized O 
on O 
the O 
Fe B-FORMULA 
center O 
with O 
the O 
longer O 
bond O 
to O 
H B-FORMULA 
, O 
that O 
is O 
, O 
Fe(II)-H B-FORMULA 
··· O 
Fe B-FORMULA 
(I) I-FORMULA 
. O 
The O 
coupling O 
to O 
the O 
hydride B-SYSTEMATIC 
is O 
A( O 
(1)H B-FORMULA 
) O 
= O 
55 O 
and O 
74 O 
MHz O 
for O 
unsym- O 
amd O 
sym-[ O 
H1 B-FORMULA 
](0 O 
) O 
, O 
respectively O 
. O 
Treatment O 
of O 
[ O 
H1 B-FORMULA 
](0 O 
) O 
with O 
H(+) B-FORMULA 
gives O 
0.5 O 
equiv O 
of O 
H2 B-FORMULA 
and O 
[H1](+) B-FORMULA 
. O 
Reduction O 
of O 
D(+) B-FORMULA 
affords O 
D2 B-FORMULA 
, O 
leaving O 
the O 
hydride B-SYSTEMATIC 
ligand O 
intact O 
. O 
These O 
experiments O 
demonstrate O 
that O 
the O 
bridging O 
hydride B-SYSTEMATIC 
ligand O 
in O 
this O 
complex O 
is O 
a O 
spectator O 
in O 
the O 
hydrogen B-SYSTEMATIC 
evolution O 
reaction O 
. O 

of O 
in O 
vitro O 
metabolites O 
of O 
luotonin B-TRIVIAL 
A I-TRIVIAL 
in O 
human O 
liver O 
microsomes O 
using O 
electrospray O 
/ O 
tandem O 
mass O 
spectrometry O 
. O 

. O 
The O 
pharmacological O 
activity O 
of O 
luotonin B-TRIVIAL 
A I-TRIVIAL 
varies O 
, O 
depending O 
on O 
the O 
type O 
of O 
functional O 
group O 
and O 
the O 
site O 
of O 
derivatization O 
. O 
To O 
understand O 
the O 
in O 
vivo O 
efficacy O 
of O 
luotonin B-TRIVIAL 
A I-TRIVIAL 
, O 
the O 
in O 
vitro O 
metabolism O 
of O 
luotonin B-TRIVIAL 
A I-TRIVIAL 
was O 
investigated O 
in O 
human O 
liver O 
microsomes O 
and O 
recombinant O 
cDNA-expressed O 
cytochromeP450 O 
( O 
CYP O 
) O 
. O 
2 O 
. O 
Incubation O 
of O 
luotonin B-TRIVIAL 
A I-TRIVIAL 
with O 
pooled O 
human O 
liver O 
microsomes O 
in O 
the O 
presence O 
of O 
NADPH B-ABBREVIATION 
-generating O 
system O 
resulted O 
in O 
the O 
formation O 
of O 
four O 
metabolites O 
and O 
the O 
structures O 
of O 
each O 
metabolite O 
were O 
tentatively O 
characterized O 
on O 
the O 
basis O 
of O 
electrospray O 
tandem O 
mass O 
spectra O 
. O 
3 O 
. O 
The O 
main O 
metabolic O 
pathway O 
of O 
luotonin B-TRIVIAL 
A I-TRIVIAL 
in O 
human O 
liver O 
microsomes O 
was O 
hydroxylation O 
, O 
resulting O 
in O 
the O 
generation O 
of O 
two O 
mono-hydroxyl B-SYSTEMATIC 
metabolites O 
( O 
M1 O 
and O 
M2 O 
) O 
and O 
two O 
di B-SYSTEMATIC 
- I-SYSTEMATIC 
hydroxyl I-SYSTEMATIC 
metabolites O 
( O 
M3 O 
and O 
M4 O 
) O 
. O 
CYP1A2 O 
was O 
primarily O 
involved O 
in O 
hydroxylation O 
of O 
the O 
quinolone B-FAMILY 
moiety O 
( O 
M1 O 
andM3 O 
) O 
, O 
while O 
CYP3A4 O 
was O 
mainly O 
responsible O 
for O 
hydroxylation O 
of O 
the O 
quinazoline B-SYSTEMATIC 
moiety O 
of O 
luotonin B-TRIVIAL 
A I-TRIVIAL 
( O 
M2 O 
and O 
M4 O 
) O 
in O 
human O 
liver O 
microsomes O 
. O 

this O 
work O 
we O 
report O 
on O 
the O 
preparation O 
, O 
characterization O 
, O 
and O 
properties O 
of O 
a O 
thermally O 
treated O 
lignin O 
- O 
derived O 
, O 
phenolic O 
- O 
rich O 
fraction O 
( O 
PRF O 
) O 
of O 
wood O 
pyrolysis O 
bio O 
- O 
oil O 
obtained O 
by O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extraction O 
. O 
The O 
PRF O 
was O 
characterized O 
for O 
viscoelastic O 
and O 
rheological O 
behavior O 
using O 
dynamic O 
mechanical O 
analysis O 
( O 
DMA O 
) O 
and O 
cone O 
and O 
plate O 
rheology O 
. O 
A O 
unique O 
thermoplastic O 
behavior O 
was O 
evidenced O 
. O 
Heat O 
- O 
treated O 
PRFs O 
acquire O 
high O 
modulus O 
but O 
show O 
low O 
temperatures O 
of O 
thermal O 
flow O 
which O 
can O 
be O 
systematically O 
manipulated O 
through O 
the O 
thermal O 
pretreatment O 
. O 
Loss O 
of O 
volatiles O 
, O 
changes O 
in O 
molecular O 
weight O 
, O 
and O 
glass O 
transition O 
temperature O 
( O 
Tg O 
) O 
were O 
investigated O 
using O 
thermogravimetric O 
analysis O 
( O 
TGA O 
) O 
, O 
mass O 
spectrometry O 
( O 
MS O 
) O 
, O 
and O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
respectively O 
. O 
Underlying O 
mechanisms O 
for O 
the O 
thermal O 
and O 
rheological O 
behavior O 
are O 
discussed O 
with O 
regard O 
to O 
interactions O 
between O 
pyrolytic O 
lignin O 
nanoparticles O 
present O 
in O 
the O 
system O 
and O 
the O 
role O 
of O 
volatile O 
materials O 
on O 
determining O 
the O 
properties O 
of O 
the O 
material O 
resembling O 
in O 
several O 
aspects O 
to O 
colloidal O 
suspension O 
systems O 
. O 
Low O 
thermal O 
flow O 
temperatures O 
and O 
reversible O 
thermal O 
effects O 
can O 
be O 
attributed O 
to O 
association O 
of O 
pyrolytic O 
lignin O 
particles O 
due O 
to O 
intermolecular O 
interactions O 
that O 
are O 
easily O 
ruptured O 
at O 
higher O 
temperatures O 
. O 
The O 
thermoplastic O 
behavior O 
of O 
PRF O 
and O 
its O 
low O 
Tg O 
is O 
of O 
particular O 
interest O 
, O 
as O 
it O 
gives O 
opportunities O 
for O 
application O 
of O 
this O 
fraction O 
in O 
several O 
melt O 
processing O 
and O 
adhesive O 
technologies O 
. O 

properties O 
of O 
natural O 
actomyosin O 
( O 
NAM O 
) O 
containing O 
2% O 
or O 
8% O 
fish O 
protein O 
hydrolysate O 
( O 
FPH-2 O 
, O 
FPH-8 O 
) O 
or O 
8% O 
sucrose B-TRIVIAL 
- O 
sorbitol B-TRIVIAL 
blend O 
( O 
SuSo B-ABBREVIATION 
) O 
were O 
compared O 
to O 
control O 
NAM O 
before O 
and O 
after O 
freeze O 
- O 
thaw O 
treatment O 
. O 
Surface O 
hydrophobicity O 
of O 
control O 
and O 
FPH-2 O 
increased O 
after O 
freeze O 
- O 
thaw O 
treatment O 
, O 
while O 
that O 
of O 
FPH-8 O 
did O 
not O 
change O 
, O 
which O 
may O 
be O 
related O 
to O 
greater O 
thermostability O 
of O 
actin O 
and O 
myosin O 
in O 
FPH-8 O 
as O 
observed O 
by O 
differential O 
scanning O 
calorimetry O 
. O 
The O 
cooked O 
gel O 
of O 
freeze O 
- O 
thawed O 
control O 
had O 
39% O 
expressible O 
moisture O 
after O 
an O 
8.5% O 
cook O 
loss O 
, O 
whereas O 
gels O 
of O 
freeze O 
- O 
thawed O 
SuSo B-ABBREVIATION 
, O 
FPH-2 O 
and O 
FPH-8 O 
had O 
significantly O 
lower O 
expressible O 
moisture O 
( O 
15-22% O 
) O 
and O 
no O 
cook O 
loss O 
. O 
Gels O 
of O 
freeze O 
- O 
thawed O 
FPH-2 O 
and O 
FPH-8 O 
were O 
similar O 
to O 
unfrozen O 
control O 
gel O 
in O 
hardness O 
, O 
cohesiveness O 
and O 
gumminess O 
. O 
This O 
study O 
demonstrates O 
that O 
FPH O 
effectively O 
stabilised O 
NAM O 
protein O 
structure O 
and O 
function O 
during O 
freeze O 
- O 
thaw O 
treatment O 
. O 

INCREASES O 
HEPATIC O 
IRON B-SYSTEMATIC 
LEVELS O 
IN O 
MICE O 
FED O 
A O 
HIGH-FAT O 
DIET O 
. O 

evidence O 
suggests O 
that O 
ezetimibe B-TRIVIAL 
may O 
be O 
a O 
promising O 
agent O 
for O 
treatment O 
of O 
non-alcoholic O 
fatty O 
liver O 
disease O 
and O 
steatohepatitis O 
( O 
NAFLD O 
/ O 
NASH O 
) O 
. O 
Phlebotomy O 
and O 
dietary O 
iron B-SYSTEMATIC 
restriction O 
reduces O 
serum O 
transaminase O 
in O 
NAFLD O 
/ O 
NASH O 
patients O 
. O 
Recent O 
studies O 
showed O 
that O 
mutual O 
effects O 
exist O 
between O 
lipid O 
metabolism O 
and O 
iron B-SYSTEMATIC 
metabolism O 
. O 
Accordingly O 
, O 
the O 
effects O 
of O 
ezetimibe B-TRIVIAL 
on O 
iron B-SYSTEMATIC 
metabolism O 
were O 
examined O 
in O 
mice O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
with O 
or O 
without O 
iron B-SYSTEMATIC 
. O 
C57BL O 
/ O 
6 O 
mice O 
were O 
fed O 
the O 
following O 
diets O 
for O 
12 O 
weeks O 
. O 
Experiment O 
1 O 
: O 
1 O 
) O 
a O 
control O 
diet O 
; O 
C O 
2 O 
) O 
C O 
plus O 
ezetimibe B-TRIVIAL 
( O 
0.3mg O 
/ O 
day O 
; O 
4 O 
weeks O 
) O 
; O 
CE O 
3 O 
) O 
a O 
high O 
- O 
fat O 
diet O 
; O 
H O 
4 O 
) O 
H O 
plus O 
ezetimibe B-TRIVIAL 
; O 
HE O 
. O 
Experiment O 
2 O 
: O 
1 O 
) O 
C O 
containing O 
carbonyl B-SYSTEMATIC 
iron I-SYSTEMATIC 
( O 
average O 
; O 
22.4mg O 
/ O 
day O 
; O 
6 O 
weeks O 
) O 
; O 
CI O 
2 O 
) O 
CI O 
plus O 
ezetimibe B-TRIVIAL 
; O 
CIE O 
3 O 
) O 
H O 
containing O 
carbonyl B-SYSTEMATIC 
iron I-SYSTEMATIC 
; O 
HI O 
4 O 
) O 
HI O 
plus O 
ezetimibe B-TRIVIAL 
; O 
HIE O 
. O 
Blood O 
, O 
livers O 
, O 
and O 
duodenum O 
were O 
removed O 
after O 
12 O 
weeks O 
. O 
In O 
Experiment O 
1 O 
, O 
hepatic O 
iron B-SYSTEMATIC 
levels O 
were O 
higher O 
in O 
HE O 
than O 
H O 
, O 
whereas O 
there O 
was O 
no O 
difference O 
between O 
C O 
and O 
CE O 
. O 
Hepatic O 
mRNA O 
expression O 
of O 
transferrin O 
receptor O 
1 O 
and O 
2 O 
, O 
ferritins O 
, O 
and O 
hepcidin O 
were O 
increased O 
more O 
in O 
CE O 
than O 
C O 
, O 
and O 
in O 
HE O 
than O 
H O 
. O 
In O 
duodenum O 
, O 
DMT1 O 
, O 
ferritinH O 
, O 
and O 
hephaestin O 
mRNA O 
levels O 
were O 
increased O 
in O 
CE O 
compared O 
to O 
C O 
. O 
In O 
Experiment O 
2 O 
, O 
hepatic O 
iron B-SYSTEMATIC 
concentrations O 
were O 
higher O 
in O 
HIE O 
than O 
HI O 
. O 
Hepatic O 
mRNA O 
expression O 
of O 
ferritinL O 
and O 
hepcidin O 
were O 
increased O 
in O 
HIE O 
compared O 
to O 
HI O 
. O 
In O 
duodenum O 
, O 
ferritinL O 
mRNA O 
was O 
increased O 
in O 
HIE O 
compared O 
to O 
CIE O 
. O 
Ezetimibe B-TRIVIAL 
induced O 
hepatic O 
iron B-SYSTEMATIC 
uptake O 
transporter O 
expression O 
in O 
mice O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
, O 
causing O 
increased O 
hepatic O 
iron B-SYSTEMATIC 
concentrations O 
. O 

delivery O 
of O 
growth O 
factors O 
( O 
GFs O 
) O 
can O 
accelerate O 
regeneration O 
of O 
injured O 
tissue O 
, O 
but O 
for O 
many O 
medical O 
applications O 
, O 
injectable O 
GF O 
delivery O 
systems O 
are O 
required O 
for O 
clinical O 
success O 
. O 
Viscoelastic O 
, O 
injectable O 
aggregates O 
of O 
micrometer O 
- O 
sized O 
hydrogel O 
particles O 
made O 
of O 
multiarmed O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
starPEG O 
) O 
and O 
heparin O 
were O 
prepared O 
and O 
tested O 
for O 
site O 
- O 
specific O 
paracrine O 
stimulation O 
of O 
tissue O 
regeneration O 
. O 
Heparin O 
was O 
used O 
as O 
it O 
binds O 
, O 
protects O 
and O 
releases O 
numerous O 
GFs O 
. O 
Hydrogel O 
based O 
delivery O 
of O 
basic O 
fibroblast O 
growth O 
factor O 
( O 
bFGF O 
) O 
and O 
murine O 
epidermal O 
growth O 
factor O 
( O 
EGF O 
) O 
was O 
monitored O 
utilizing O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
ELISA O 
) O 
. O 
bFGF O 
was O 
released O 
slowly O 
because O 
of O 
its O 
high O 
affinity O 
to O 
the O 
heparin O 
while O 
the O 
significantly O 
higher O 
release O 
of O 
the O 
non-specific O 
binding O 
EGF O 
was O 
controlled O 
by O 
diffusion O 
only O 
. O 
To O 
investigate O 
GF O 
delivery O 
in O 
vivo O 
, O 
a O 
hydrogel O 
loaded O 
with O 
murine O 
EGF O 
or O 
bFGF O 
was O 
injected O 
subcapsularly O 
into O 
the O 
left O 
kidney O 
of O 
mice O 
with O 
experimental O 
acute O 
kidney O 
injury O 
caused O 
by O 
glycerol B-TRIVIAL 
induced O 
rhabdomyolysis O 
. O 
Visual O 
examination O 
confirmed O 
sustained O 
stability O 
of O 
the O 
injected O 
gel O 
aggregates O 
during O 
the O 
timescale O 
of O 
the O 
experiment O 
. O 
The O 
number O 
of O 
proliferating O 
kidney O 
tubular O 
epithelial O 
cells O 
was O 
quantified O 
both O 
in O 
the O 
injected O 
kidney O 
and O 
the O 
non-injected O 
contralateral O 
kidney O 
. O 
bFGF O 
delivery O 
from O 
hydrogels O 
induced O 
a O 
significant O 
increase O 
in O 
cell O 
proliferation O 
in O 
the O 
injected O 
kidney O 
, O 
although O 
small O 
effects O 
were O 
also O 
seen O 
in O 
the O 
non-injected O 
kidney O 
due O 
to O 
a O 
systemic O 
effect O 
. O 
EGF O 
delivery O 
strongly O 
increased O 
cell O 
proliferation O 
for O 
both O 
kidneys O 
, O 
but O 
also O 
showed O 
a O 
local O 
effect O 
on O 
the O 
injected O 
kidney O 
. O 
The O 
hydrogel O 
without O 
loaded O 
GFs O 
was O 
used O 
as O 
a O 
control O 
and O 
showed O 
no O 
increase O 
in O 
cell O 
proliferation O 
. O 
Our O 
results O 
suggest O 
that O 
this O 
novel O 
starPEG-heparin O 
hydrogel O 
system O 
can O 
be O 
an O 
effective O 
approach O 
to O 
deliver O 
GFs O 
locally O 
. O 

, O 
extraversion O 
and O 
working O 
memory O 
. O 

has O 
shown O 
that O 
extraverts O 
performing O 
a O 
working O 
memory O 
task O 
benefit O 
more O 
from O 
caffeine B-TRIVIAL 
than O 
do O 
introverts O 
. O 
The O 
present O 
study O 
aimed O 
to O 
replicate O 
this O 
and O 
extend O 
our O 
knowledge O 
by O 
using O 
a O 
lower O 
dose O 
of O 
caffeine B-TRIVIAL 
( O 
65 O 
mg O 
) O 
and O 
a O 
range O 
of O 
tasks O 
related O 
to O 
different O 
components O 
of O 
working O 
memory O 
. O 
In O 
addition O 
, O 
tasks O 
assessing O 
psychomotor O 
speed O 
and O 
the O 
encoding O 
of O 
new O 
information O 
were O 
included O 
to O 
determine O 
whether O 
caffeine B-TRIVIAL 
-extraversion O 
interactions O 
were O 
restricted O 
to O 
working O 
memory O 
tasks O 
. O 
A O 
double O 
- O 
blind O 
design O 
was O 
used O 
, O 
with O 
128 O 
participants O 
being O 
randomly O 
assigned O 
to O 
caffeinated O 
or O 
de-caffeinated O 
coffee O 
conditions O 
. O 
The O 
results O 
showed O 
that O 
caffeine B-TRIVIAL 
interacted O 
with O 
extraversion O 
in O 
the O 
predicted O 
direction O 
for O 
serial O 
recall O 
and O 
running O 
memory O 
tasks O 
. O 
Caffeine B-TRIVIAL 
improved O 
simple O 
reaction O 
time O 
and O 
the O 
speed O 
of O 
encoding O 
of O 
new O 
information O 
, O 
effects O 
which O 
were O 
not O 
modified O 
by O 
extraversion O 
. O 
These O 
results O 
suggest O 
possible O 
biological O 
mechanisms O 
underlying O 
effects O 
of O 
caffeine B-TRIVIAL 
on O 
cognitive O 
performance O 
. O 

developed O 
a O 
hybrid O 
method O 
for O 
predicting O 
plasma O 
concentration O 
- O 
time O 
curves O 
in O 
humans O 
by O 
integrating O 
species O 
differences O 
in O 
in O 
vitro O 
intrinsic O 
clearance O 
(CL(int)) O 
into O 
the O 
Dedrick O 
approach O 
based O 
on O 
the O 
allometry O 
concept O 
. O 
With O 
prediction O 
of O 
clearance O 
( O 
CL O 
) O 
by O 
allometric O 
scaling O 
, O 
taking O 
in O 
vitro O 
CL(int) O 
into O 
consideration O 
improved O 
the O 
accuracy O 
and O 
reduced O 
the O 
average O 
fold O 
error O 
from O 
2.72 O 
to O 
1.99 O 
. O 
With O 
the O 
hybrid O 
approach O 
of O 
applying O 
the O 
same O 
concept O 
to O 
the O 
Dedrick O 
approach O 
, O 
the O 
predictability O 
of O 
plasma O 
concentration O 
profiles O 
was O 
compared O 
with O 
the O 
results O 
of O 
the O 
conventional O 
Dedrick O 
approach O 
and O 
the O 
physiologically O 
based O 
pharmacokinetic O 
model O 
using O 
15 O 
compounds O 
with O 
widely O 
ranging O 
physicochemical O 
and O 
pharmacokinetic O 
profiles O 
. O 
The O 
hybrid O 
approach O 
showed O 
the O 
highest O 
predictability O 
among O 
the O 
examined O 
methods O 
. O 
For O 
CL O 
and O 
the O 
apparent O 
volume O 
of O 
distribution O 
at O 
the O 
steady O 
state O 
(V(ss)) O 
, O 
the O 
relationship O 
between O 
the O 
exponent O 
of O 
allometric O 
equation O 
and O 
fold O 
error O 
was O 
also O 
evaluated O 
with O 
the O 
hybrid O 
approach O 
. O 
The O 
relationship O 
appeared O 
to O 
be O 
a O 
horseshoe O 
curve O 
. O 
Six O 
compounds O 
with O 
exponents O 
ranging O 
from O 
0.7 O 
to O 
1.1 O 
for O 
both O 
CL O 
and O 
V(ss) O 
[ O 
antipyrine B-TRIVIAL 
, O 
caffeine B-TRIVIAL 
, O 
epiroprim B-TRIVIAL 
, O 
propafenone B-TRIVIAL 
, O 
theophylline B-TRIVIAL 
, O 
and O 
verapamil B-TRIVIAL 
] O 
displayed O 
higher O 
predictability O 
. O 
Three O 
compounds O 
with O 
an O 
exponent O 
ranging O 
from O 
0.7 O 
to O 
1.1 O 
for O 
CL O 
showed O 
better O 
predictability O 
for O 
CL O 
, O 
and O 
the O 
other O 
four O 
compounds O 
appeared O 
to O 
display O 
similar O 
relationship O 
between O 
the O 
exponent O 
and O 
predictability O 
for O 
V(ss) O 
. O 
These O 
findings O 
indicated O 
that O 
the O 
exponent O 
becomes O 
a O 
preliminary O 
index O 
to O 
speculate O 
on O 
predictability O 
. O 
Combination O 
of O 
the O 
hybrid O 
approach O 
and O 
exponent O 
allows O 
us O 
to O 
prospectively O 
draw O 
human O 
plasma O 
concentration O 
- O 
time O 
curves O 
, O 
with O 
the O 
implication O 
of O 
possible O 
prediction O 
accuracy O 
prior O 
to O 
clinical O 
studies O 
. O 

, O 
an O 
E3 O 
ubiquitin O 
ligase O 
, O 
interacts O 
with O 
and O 
ubiquinates O 
the O 
human O 
pregnane B-TRIVIAL 
X O 
receptor O 
. O 

pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
, O 
NR1I2 O 
) O 
plays O 
a O 
pivotal O 
role O 
in O 
the O 
disposition O 
and O 
detoxification O 
of O 
numerous O 
foreign O 
and O 
endogenous O 
chemicals O 
by O 
increasing O 
transcription O 
of O 
numerous O 
target O 
genes O 
, O 
including O 
phase O 
I O 
and O 
II O 
drug O 
- O 
metabolizing O 
enzymes O 
and O 
transporters O 
. O 
In O 
the O 
present O 
study O 
, O 
yeast O 
two O 
- O 
hybrid O 
screening O 
identified O 
an O 
E3 O 
ubiquitin O 
ligase O 
, O 
RBCK1 O 
( O 
Ring-B-box O 
- O 
coiled O 
- O 
coil O 
protein O 
interacting O 
with O 
protein O 
kinase O 
C-1 O 
) O 
, O 
as O 
a O 
human O 
pregnane B-TRIVIAL 
X O 
receptor O 
(hPXR)-interacting O 
protein O 
. O 
Coimmunoprecipitation O 
studies O 
confirmed O 
the O 
interaction O 
between O 
RBCK1 O 
and O 
hPXR O 
when O 
both O 
were O 
ectopically O 
expressed O 
in O 
AD-293 O 
cells O 
. O 
Domain O 
mapping O 
studies O 
showed O 
that O 
the O 
interaction O 
between O 
RBCK1 O 
and O 
hPXR O 
involves O 
all O 
RBCK1 O 
domains O 
. O 
We O 
further O 
demonstrate O 
that O 
RBCK1 O 
ubiquitinates O 
hPXR O 
, O 
and O 
this O 
may O 
target O 
hPXR O 
for O 
degradation O 
by O 
the O 
ubiquitin O 
- O 
proteasome O 
pathway O 
. O 
Simultaneous O 
ectopic O 
overexpression O 
of O 
RBCK1 O 
and O 
PXR O 
decreased O 
PXR O 
levels O 
in O 
AD-293 O 
cells O 
, O 
and O 
this O 
decrease O 
was O 
inhibited O 
by O 
the O 
proteasomal O 
inhibitor O 
MG-132 B-IDENTIFIER 
( O 
carbobenzoxy-Leu-Leu B-TRIVIAL 
- I-TRIVIAL 
leucinal I-TRIVIAL 
) O 
. O 
Furthermore O 
, O 
overexpression O 
of O 
RBCK1 O 
decreased O 
endogenous O 
levels O 
of O 
PXR O 
in O 
HepG2 O 
cells O 
. O 
Of O 
importance O 
, O 
ectopic O 
overexpression O 
and O 
silencing O 
of O 
endogenous O 
RBCK1 O 
in O 
primary O 
human O 
hepatocytes O 
resulted O 
in O 
a O 
decrease O 
and O 
increase O 
, O 
respectively O 
, O 
in O 
endogenous O 
PXR O 
protein O 
levels O 
and O 
in O 
the O 
induction O 
of O 
PXR O 
target O 
genes O 
by O 
rifampicin B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
RBCK1 O 
is O 
important O 
for O 
the O 
ubiquitination O 
of O 
PXR O 
and O 
may O 
play O 
a O 
role O 
in O 
its O 
proteasomal O 
degradation O 
. O 

experimental O 
measurement O 
of O 
the O 
slip O 
length O 
of O 
air O 
flow O 
close O 
to O 
three O 
different O 
solid O 
surfaces O 
is O 
presented O 
. O 
The O 
substrate O 
was O 
driven O 
by O 
a O 
nanopositioner O 
moving O 
toward O 
an O 
oscillating O 
glass O 
sphere O 
glued O 
to O 
an O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
cantilever O 
. O 
A O 
large O 
separation O 
distance O 
was O 
used O 
to O 
get O 
more O 
effective O 
data O 
. O 
The O 
slip O 
length O 
value O 
was O 
obtained O 
by O 
analyzing O 
the O 
amplitude O 
and O 
phase O 
data O 
of O 
the O 
cantilever O 
. O 
The O 
measurements O 
show O 
that O 
the O 
slip O 
length O 
does O 
not O 
depend O 
on O 
the O 
oscillation O 
amplitude O 
of O 
the O 
cantilever O 
. O 
Because O 
of O 
the O 
small O 
difference O 
among O 
the O 
slip O 
lengths O 
of O 
the O 
three O 
surfaces O 
, O 
a O 
simplified O 
analysis O 
method O 
was O 
used O 
. O 
The O 
results O 
show O 
that O 
on O 
glass O 
, O 
graphite B-TRIVIAL 
, O 
and O 
mica B-TRIVIAL 
surfaces O 
the O 
slip O 
lengths O 
are O 
98 O 
, O 
234 O 
, O 
and O 
110 O 
nm O 
, O 
respectively O 
. O 

A O 
non-destructive O 
method O 
for O 
monitoring O 
creaming O 
of O 
emulsion O 
- O 
based O 
formulations O 
is O 
in O 
great O 
demand O 
because O 
it O 
allows O 
us O 
to O 
understand O 
fully O 
their O 
instability O 
mechanisms O 
. O 
This O 
study O 
was O 
aimed O 
at O 
demonstrating O 
the O 
usefulness O 
of O 
magnetic O 
resonance O 
( O 
MR O 
) O 
techniques O 
, O 
including O 
MR O 
imaging O 
( O 
MRI O 
) O 
and O 
MR O 
spectroscopy O 
( O 
MRS O 
) O 
, O 
for O 
evaluating O 
the O 
physicochemical O 
stability O 
of O 
emulsion O 
- O 
based O 
formulations O 
. O 
Emulsions O 
that O 
are O 
applicable O 
as O 
the O 
base O 
of O 
practical O 
skin O 
creams O 
were O 
used O 
as O 
test O 
samples O 
. O 
Substantial O 
creaming O 
was O 
developed O 
by O 
centrifugation O 
, O 
which O 
was O 
then O 
monitored O 
by O 
MRI O 
. O 
The O 
creaming O 
oil O 
droplet O 
layer O 
and O 
aqueous O 
phase O 
were O 
clearly O 
distinguished O 
by O 
quantitative O 
MRI O 
by O 
measuring O 
T1 O 
and O 
the O 
apparent O 
diffusion O 
coefficient O 
. O 
Components O 
in O 
a O 
selected O 
volume O 
in O 
the O 
emulsions O 
could O 
be O 
analyzed O 
using O 
MRS O 
. O 
Then O 
, O 
model O 
emulsions O 
having O 
different O 
hydrophilic O 
- O 
lipophilic O 
balance O 
( O 
HLB O 
) O 
values O 
were O 
tested O 
, O 
and O 
the O 
optimal O 
HLB O 
value O 
for O 
a O 
stable O 
dispersion O 
was O 
determined O 
. O 
In O 
addition O 
, O 
the O 
MRI O 
examination O 
enables O 
the O 
detection O 
of O 
creaming O 
occurring O 
in O 
a O 
polyethylene B-SYSTEMATIC 
tube O 
, O 
which O 
is O 
commonly O 
used O 
for O 
commercial O 
products O 
, O 
without O 
losing O 
any O 
image O 
quality O 
. O 
These O 
findings O 
strongly O 
indicate O 
that O 
MR O 
techniques O 
are O 
powerful O 
tools O 
to O 
evaluate O 
the O 
physicochemical O 
stability O 
of O 
emulsion O 
- O 
based O 
formulations O 
. O 
This O 
study O 
will O 
make O 
a O 
great O 
contribution O 
to O 
the O 
development O 
and O 
quality O 
control O 
of O 
emulsion O 
- O 
based O 
formulations O 
. O 

food O 
fortification O 
with O 
folic B-TRIVIAL 
acid I-TRIVIAL 
in O 
Spain O 
: O 
Predicted O 
contribution O 
to O 
children's O 
dietary O 
intakes O 
as O 
assessed O 
with O 
new O 
food O 
folate B-TRIVIAL 
composition O 
data O 
. O 

Spanish O 
market O 
offers O 
a O 
significant O 
number O 
of O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
voluntarily O 
fortified O 
foods O 
. O 
We O 
analysed O 
FA O 
and O 
(6S)-5-methyltetrahydrofolic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
(6S)-5-CH3-H4PteGlu B-SYSTEMATIC 
) O 
content O 
in O 
ready O 
- O 
to O 
- O 
eat O 
cereals O 
( O 
RTEC O 
) O 
( O 
n=68 O 
) O 
and O 
cow's O 
milk O 
( O 
n=25 O 
) O 
by O 
a O 
previously O 
validated O 
affinity O 
chromatography-HPLC O 
method O 
. O 
Contribution O 
to O 
potential O 
FA O 
intakes O 
for O 
children O 
aged O 
2-13years O 
, O 
was O 
assessed O 
using O 
food O 
consumption O 
data O 
from O 
a O 
representative O 
nationwide O 
study O 
, O 
folate B-TRIVIAL 
Recommended O 
Dietary O 
Intakes O 
( O 
RDI O 
) O 
, O 
and O 
Upper O 
Levels O 
( O 
UL O 
) O 
. O 
Results O 
showed O 
that O 
at O 
all O 
food O 
fortification O 
levels O 
obtained O 
, O 
fortified O 
products O 
provided O 
more O 
than O 
tenfold O 
FA O 
than O 
(6S)-5-CH3-H4PteGlu B-SYSTEMATIC 
. O 
For O 
RTEC O 
, O 
the O 
high O 
fortification O 
level O 
provided O 
6-21% O 
, O 
per O 
serving O 
, O 
of O 
RDI O 
and O 
⩽32% O 
of O 
ULs O 
at O 
90th O 
percentile O 
of O 
RTEC O 
consumption O 
( O 
P90 O 
) O 
. O 
Milk O 
products O 
fortified O 
at O 
the O 
higher O 
level O 
reached O 
on O 
average O 
54-136% O 
of O 
RDI O 
per O 
serving O 
and O 
only O 
exceeded O 
UL O 
at O 
P90 O 
of O 
milk O 
consumption O 
in O 
children O 
aged O 
2-5years O 
. O 

acid I-TRIVIAL 
induces O 
Nrf2 O 
nuclear O 
translocation O 
in O 
vivo O 
and O 
attenuates O 
renal O 
damage O 
and O 
apoptosis O 
in O 
the O 
ischemia O 
and O 
reperfusion O 
model O 
. O 

has O 
been O 
shown O 
that O 
the O 
pretreatment O 
with O 
nordihydroguaiaretic B-TRIVIAL 
acid I-TRIVIAL 
( O 
NDGA B-ABBREVIATION 
) O 
, O 
a O 
lignan O 
with O 
direct O 
and O 
indirect O 
antioxidant O 
properties O 
, O 
protects O 
against O 
the O 
ischemia O 
- O 
reperfusion O 
( O 
I O 
/ O 
R)-induced O 
renal O 
oxidant O 
damage O 
. O 
Although O 
it O 
has O 
been O 
shown O 
that O 
NDGA B-ABBREVIATION 
induces O 
Nrf2 O 
nuclear O 
translocation O 
in O 
renal O 
epithelial O 
LLC-PK1 O 
cells O 
in O 
culture O 
, O 
it O 
is O 
unknown O 
if O 
NDGA B-ABBREVIATION 
may O 
induce O 
Nrf2 O 
translocation O 
in O 
vivo O 
. O 
In O 
this O 
work O 
was O 
explored O 
if O 
NDGA B-ABBREVIATION 
is O 
able O 
to O 
induce O 
in O 
vivo O 
Nrf2 O 
nuclear O 
translocation O 
in O 
kidneys O 
of O 
rats O 
submitted O 
to O 
uni O 
- O 
nephrectomy O 
( O 
U-NX O 
) O 
or O 
I O 
/ O 
R O 
injury O 
. O 
Four O 
groups O 
of O 
male O 
Wistar O 
rats O 
were O 
used O 
: O 
U-NX O 
, O 
NDGA B-ABBREVIATION 
, O 
I O 
/ O 
R O 
, O 
and O 
I O 
/ O 
R+ O 
NDGA B-ABBREVIATION 
. O 
NDGA B-ABBREVIATION 
was O 
injected O 
i.p O 
. O 
( O 
10mg O 
/ O 
kg O 
/ O 
day O 
) O 
starting O 
48h O 
before O 
I O 
/ O 
R O 
. O 
Kidney O 
samples O 
were O 
obtained O 
at O 
3h O 
of O 
reperfusion O 
after O 
to O 
measure O 
Nrf2 O 
translocation O 
. O 
Additional O 
groups O 
of O 
rats O 
were O 
studied O 
at O 
24h O 
of O 
reperfusion O 
to O 
measure O 
histological O 
damage O 
and O 
apoptosis O 
. O 
NDGA B-ABBREVIATION 
was O 
able O 
to O 
induce O 
Nrf2 O 
translocation O 
in O 
vivo O 
in O 
kidneys O 
of O 
rats O 
submitted O 
to O 
both O 
U-NX O 
and O 
I O 
/ O 
R O 
injury O 
and O 
to O 
protect O 
against O 
renal O 
histological O 
damage O 
and O 
apoptosis O 
. O 
It O 
is O 
concluded O 
that O 
the O 
pretreatment O 
of O 
NDGA B-ABBREVIATION 
is O 
able O 
to O 
induce O 
in O 
vivo O 
nuclear O 
Nrf2 O 
translocation O 
in O 
kidney O 
of O 
rats O 
suggesting O 
that O 
this O 
may O 
be O 
involved O 
in O 
the O 
renoprotection O 
against O 
I O 
/ O 
R O 
. O 

studies O 
of O 
ionic O 
hydration O 
and O 
interactions O 
for O 
amino B-FAMILY 
acid I-FAMILY 
ionic O 
liquids O 
in O 
aqueous O 
solutions O 
at O 
298.15 O 
K O 
. O 

acid I-FAMILY 
ionic O 
liquids O 
are O 
a O 
special O 
class O 
of O 
ionic O 
liquids O 
due O 
to O 
their O 
unique O 
acid O 
- O 
base O 
behavior O 
, O 
biological O 
significance O 
, O 
and O 
applications O 
in O 
different O 
fields O 
such O 
as O 
templates O 
in O 
synthetic O 
chemistry O 
, O 
stabilizers O 
for O 
biological O 
macromolecules O 
, O 
etc O 
. O 
The O 
physicochemical O 
properties O 
of O 
these O 
ionic O 
liquids O 
can O 
easily O 
be O 
altered O 
by O 
making O 
the O 
different O 
combinations O 
of O 
amino B-FAMILY 
acids I-FAMILY 
as O 
anion O 
along O 
with O 
possible O 
cation O 
modification O 
which O 
makes O 
amino B-FAMILY 
acid I-FAMILY 
ionic O 
liquids O 
more O 
suitable O 
to O 
understand O 
the O 
different O 
kinds O 
of O 
molecular O 
and O 
ionic O 
interactions O 
with O 
sufficient O 
depth O 
so O 
that O 
they O 
can O 
provide O 
fruitful O 
information O 
for O 
a O 
molecular O 
level O 
understanding O 
of O 
more O 
complicated O 
biological O 
processes O 
. O 
In O 
this O 
context O 
, O 
volumetric O 
and O 
osmotic O 
coefficient O 
measurements O 
for O 
aqueous O 
solutions O 
containing O 
1-ethyl-3-methylimidazolium B-SYSTEMATIC 
( O 
[ O 
Emim B-ABBREVIATION 
] O 
) O 
based O 
amino B-FAMILY 
acid I-FAMILY 
ionic O 
liquids O 
of O 
glycine B-TRIVIAL 
, O 
alanine B-TRIVIAL 
, O 
valine B-TRIVIAL 
, O 
leucine B-TRIVIAL 
, O 
and O 
isoleucine B-TRIVIAL 
are O 
reported O 
at O 
298.15 O 
K O 
. O 
From O 
experimental O 
osmotic O 
coefficient O 
data O 
, O 
mean O 
molal O 
activity O 
coefficients O 
of O 
ionic O 
liquids O 
were O 
estimated O 
and O 
analyzed O 
using O 
the O 
Debye-Hückel O 
and O 
Pitzer O 
models O 
. O 
The O 
hydration O 
numbers O 
of O 
ionic O 
liquids O 
in O 
aqueous O 
solutions O 
were O 
obtained O 
using O 
activity O 
data O 
. O 
Pitzer O 
ion O 
interaction O 
parameters O 
are O 
estimated O 
and O 
compared O 
with O 
other O 
electrolytes O 
reported O 
in O 
the O 
literature O 
. O 
The O 
nonelectrolyte O 
contribution O 
to O 
the O 
aqueous O 
solutions O 
containing O 
ionic O 
liquids O 
was O 
studied O 
by O 
calculating O 
the O 
osmotic O 
second O 
virial O 
coefficient O 
through O 
an O 
application O 
of O 
the O 
McMillan-Mayer O 
theory O 
of O 
solution O 
. O 
It O 
has O 
been O 
found O 
that O 
the O 
second O 
osmotic O 
virial O 
coefficient O 
which O 
includes O 
volume O 
effects O 
correlates O 
linearly O 
with O 
the O 
Pitzer O 
ion O 
interaction O 
parameter O 
estimated O 
independently O 
from O 
osmotic O 
data O 
as O 
well O 
as O 
the O 
hydrophobicity O 
of O 
ionic O 
liquids O 
. O 
The O 
enthalpy O 
- O 
entropy O 
compensation O 
effect O 
, O 
explained O 
using O 
the O 
Starikov-Nordén O 
model O 
of O 
enthalpy O 
- O 
entropy O 
compensation O 
, O 
and O 
partial O 
molar O 
entropy O 
analysis O 
for O 
aqueous O 
[ O 
Emim B-ABBREVIATION 
][ O 
Gly B-FORMULA 
] O 
solutions O 
are O 
made O 
by O 
using O 
experimental O 
Gibb's O 
free O 
energy O 
data O 
and O 
literature O 
enthalpy O 
data O 
. O 
This O 
study O 
highlights O 
that O 
the O 
hydrophobic O 
interaction O 
persists O 
even O 
in O 
the O 
limit O 
of O 
infinite O 
dilution O 
where O 
the O 
hydration O 
effects O 
are O 
usually O 
dominant O 
, O 
implying O 
importance O 
of O 
hydrophobic O 
hydration O 
. O 
Analysis O 
of O 
the O 
results O 
further O 
shows O 
that O 
the O 
hydration O 
of O 
amino B-FAMILY 
acid I-FAMILY 
ionic O 
liquids O 
occurs O 
through O 
the O 
cooperative O 
H B-FORMULA 
-bond O 
formation O 
with O 
the O 
kosmotropic O 
effect O 
in O 
contrast O 
to O 
the O 
usual O 
inorganic O 
salts O 
or O 
hydrophobic O 
salts O 
like O 
tetraalkylammonium B-FAMILY 
halides I-FAMILY 
. O 

Detailed O 
Experimental O 
and O 
Theoretical O 
Study O 
into O 
the O 
Properties O 
of O 
C60 B-TRIVIAL 
Dumbbell O 
Junctions O 
. O 

combined O 
experimental O 
and O 
theoretical O 
investigation O 
is O 
carried O 
out O 
into O 
the O 
electrical O 
transport O 
across O 
a O 
fullerene B-TRIVIAL 
dumbbell O 
one O 
- O 
molecule O 
junction O 
. O 
The O 
newly O 
designed O 
molecule O 
comprises O 
two O 
C60 B-TRIVIAL 
s O 
connected O 
to O 
a O 
fluorene B-SYSTEMATIC 
backbone O 
via O 
cyclopropyl B-SYSTEMATIC 
groups O 
. O 
It O 
is O 
wired O 
between O 
gold O 
electrodes O 
under O 
ambient O 
conditions O 
by O 
pressing O 
the O 
tip O 
of O 
a O 
scanning O 
tunnelling O 
microscope O 
( O 
STM O 
) O 
onto O 
one O 
of O 
the O 
C60 B-TRIVIAL 
groups O 
. O 
The O 
STM O 
allows O 
us O 
to O 
identify O 
a O 
single O 
molecule O 
before O 
the O 
junction O 
is O 
formed O 
through O 
imaging O 
, O 
which O 
means O 
unambiguously O 
that O 
only O 
one O 
molecule O 
is O 
wired O 
. O 
Once O 
lifted O 
, O 
the O 
same O 
molecule O 
could O 
be O 
wired O 
many O 
times O 
as O 
it O 
was O 
strongly O 
fixed O 
to O 
the O 
tip O 
, O 
and O 
a O 
high O 
conductance O 
state O 
close O 
to O 
10(-2) O 
G0 O 
is O 
found O 
. O 
The O 
results O 
also O 
suggest O 
that O 
the O 
relative O 
conductance O 
fluctuations O 
are O 
low O 
as O 
a O 
result O 
of O 
the O 
low O 
mobility O 
of O 
the O 
molecule O 
. O 
Theoretical O 
analysis O 
indicates O 
that O 
the O 
molecule O 
is O 
connected O 
directly O 
to O 
one O 
electrode O 
through O 
the O 
central O 
fluorene B-SYSTEMATIC 
, O 
and O 
that O 
to O 
bind O 
it O 
to O 
the O 
gold O 
fully O 
it O 
has O 
to O 
be O 
pushed O 
through O 
a O 
layer O 
of O 
adsorbates O 
naturally O 
present O 
in O 
the O 
experiment O 
. O 

1 O 
. O 
Organic O 
anion O 
transporting O 
polypeptide O 
1B1 O 
plays O 
a O 
pivotal O 
role O 
in O 
the O 
disposition O 
of O 
many O 
anionic O 
drugs O 
. O 
Significant O 
overlap O 
in O 
substrate O 
specificity O 
between O 
individual O 
OATP O 
isoforms O 
has O 
hampered O 
the O 
identification O 
of O 
the O 
relative O 
importance O 
of O 
individual O 
isoforms O 
for O 
hepatic O 
uptake O 
of O 
xenobiotics O 
. O 
2 O 
. O 
The O 
present O 
study O 
focused O 
on O 
the O 
use O 
of O 
siRNA O 
technology O 
to O 
decrease O 
OATP1B1 O 
selectively O 
in O 
human O 
hepatocytes O 
. O 
Following O 
delivery O 
of O 
siRNA O 
by O 
the O 
novel O 
lipid O 
, O 
AtuFECT01 O 
, O 
mRNA O 
expression O 
of O 
OATP1B1 O 
was O 
reduced O 
by O 
94%-98% O 
with O 
no O 
significant O 
toxicity O 
. O 
Off O 
- O 
target O 
effects O 
were O 
also O 
shown O 
to O 
be O 
minimal O 
as O 
evidenced O 
by O 
the O 
expression O 
of O 
common O 
drug O 
metabolizing O 
enzymes O 
, O 
transporters O 
, O 
nuclear O 
receptors O 
and O 
associated O 
co O 
- O 
regulators O 
. O 
Uptake O 
of O 
estrone-3-sulfate B-SYSTEMATIC 
( O 
5 O 
nM O 
) O 
by O 
OATP1B1 O 
was O 
reduced O 
by O 
82%-95% O 
. O 
This O 
methodology O 
was O 
subsequently O 
used O 
to O 
assess O 
the O 
relative O 
contribution O 
of O 
OATP1B1 O 
uptake O 
in O 
human O 
hepatocytes O 
for O 
olmesartan B-TRIVIAL 
( O 
42%-62% O 
) O 
, O 
valsartan B-TRIVIAL 
( O 
28%-81% O 
) O 
, O 
rosuvastatin B-TRIVIAL 
( O 
64%-72% O 
) O 
, O 
pitavastatin B-TRIVIAL 
( O 
84%-98% O 
) O 
and O 
lopinavir B-TRIVIAL 
( O 
64%-89% O 
) O 
. O 
These O 
data O 
are O 
consistent O 
with O 
previous O 
values O 
obtained O 
using O 
a O 
relative O 
activity O 
factor O 
approach O 
. O 
3 O 
. O 
The O 
siRNA O 
approach O 
provides O 
a O 
robust O 
and O 
reproducible O 
method O 
for O 
assessing O 
the O 
relative O 
contribution O 
of O 
OATP1B1 O 
to O 
hepatic O 
uptake O 
of O 
new O 
chemical O 
entities O 
. O 
The O 
technique O 
also O 
has O 
potential O 
utility O 
in O 
facilitating O 
detailed O 
characterization O 
of O 
drug O 
- O 
drug O 
interactions O 
involving O 
hepatic O 
drug O 
transporters O 
. O 

grafting O 
of O 
crystalline O 
and O 
ultrafine O 
cellulose O 
nanofibrils O 
with O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
chains O 
via O 
ionic O 
bonds O 
was O 
achieved O 
by O 
a O 
simple O 
ion O 
- O 
exchange O 
treatment O 
. O 
The O 
PEG B-ABBREVIATION 
-grafted O 
cellulose O 
nanofibrils O 
exhibited O 
nanodispersibility O 
in O 
organic O 
solvents O 
such O 
as O 
chloroform B-TRIVIAL 
, O 
toluene B-TRIVIAL 
, O 
and O 
tetrahydrofuran B-SYSTEMATIC 
. O 
Then O 
, O 
the O 
PEG B-ABBREVIATION 
-grafted O 
cellulose O 
nanofibril/ O 
chloroform B-TRIVIAL 
dispersion O 
and O 
poly(l-lactide) B-SYSTEMATIC 
( O 
PLLA B-ABBREVIATION 
)/ O 
chloroform B-TRIVIAL 
solution O 
were O 
mixed O 
, O 
and O 
the O 
PEG B-ABBREVIATION 
-grafted O 
cellulose O 
nanofibril/ O 
PLLA B-ABBREVIATION 
composite O 
films O 
with O 
various O 
blend O 
ratios O 
were O 
prepared O 
by O 
casting O 
the O 
mixtures O 
on O 
a O 
plate O 
and O 
drying O 
. O 
The O 
tensile O 
strength O 
, O 
Young's O 
modulus O 
, O 
and O 
work O 
of O 
fracture O 
of O 
the O 
composite O 
films O 
were O 
remarkably O 
improved O 
, O 
despite O 
low O 
cellulose O 
addition O 
levels O 
( O 
< O 
1 O 
wt O 
% O 
) O 
. O 
The O 
highly O 
efficient O 
nanocomposite O 
effect O 
was O 
explained O 
in O 
terms O 
of O 
achievement O 
of O 
nanodispersion O 
states O 
of O 
the O 
PEG B-ABBREVIATION 
-grafted O 
cellulose O 
nanofibrils O 
in O 
the O 
PLLA B-ABBREVIATION 
matrix O 
. O 
Moreover O 
, O 
some O 
attractive O 
interactions O 
mediated O 
by O 
the O 
PEG B-ABBREVIATION 
chains O 
were O 
likely O 
to O 
be O 
formed O 
between O 
the O 
cellulose O 
nanofibrils O 
and O 
PLLA B-ABBREVIATION 
molecules O 
in O 
the O 
composites O 
, O 
additionally O 
enhancing O 
the O 
efficient O 
nanocomposite O 
effect O 
. O 

leverage O 
genomic O 
and O 
biochemical O 
data O 
to O 
identify O 
synergistic O 
drug O 
regimens O 
for O 
breast O 
cancer O 
. O 
In O 
order O 
to O 
study O 
the O 
mechanism O 
of O 
the O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitors O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VPA B-ABBREVIATION 
) O 
and O 
suberoylanilide B-TRIVIAL 
hydroxamic I-TRIVIAL 
acid I-TRIVIAL 
( O 
SAHA B-ABBREVIATION 
) O 
in O 
breast O 
cancer O 
, O 
we O 
generated O 
and O 
validated O 
genomic O 
profiles O 
of O 
drug O 
response O 
using O 
a O 
series O 
of O 
breast O 
cancer O 
cell O 
lines O 
sensitive O 
to O 
each O 
drug O 
. O 
These O 
genomic O 
profiles O 
were O 
then O 
used O 
to O 
model O 
drug O 
response O 
in O 
human O 
breast O 
tumors O 
and O 
show O 
significant O 
correlation O 
between O 
VPA B-ABBREVIATION 
and O 
SAHA B-ABBREVIATION 
response O 
profiles O 
in O 
multiple O 
breast O 
tumor O 
data O 
sets O 
, O 
highlighting O 
their O 
similar O 
mechanism O 
of O 
action O 
. O 
The O 
genes O 
deregulated O 
by O 
VPA B-ABBREVIATION 
and O 
SAHA B-ABBREVIATION 
converge O 
on O 
the O 
cell O 
cycle O 
pathway O 
( O 
Bayes O 
factor O 
5.21 O 
and O 
5.94 O 
, O 
respectively O 
; O 
P-value O 
10(-8.6) O 
and O 
10(-9) O 
, O 
respectively O 
) O 
. O 
In O 
particular O 
, O 
VPA B-ABBREVIATION 
and O 
SAHA B-ABBREVIATION 
upregulate O 
key O 
cyclin O 
- O 
dependent O 
kinase O 
( O 
CDK O 
) O 
inhibitors O 
. O 
In O 
two O 
independent O 
datasets O 
, O 
cancer O 
cells O 
treated O 
with O 
CDK O 
inhibitors O 
have O 
similar O 
gene O 
expression O 
profile O 
changes O 
to O 
the O 
cellular O 
response O 
to O 
HDAC O 
inhibitors O 
. O 
Together O 
, O 
these O 
results O 
led O 
us O 
to O 
hypothesize O 
that O 
VPA B-ABBREVIATION 
and O 
SAHA B-ABBREVIATION 
may O 
interact O 
synergistically O 
with O 
CDK O 
inhibitors O 
such O 
as O 
PD-033299 B-IDENTIFIER 
. O 
Experiments O 
show O 
that O 
HDAC O 
and O 
CDK O 
inhibitors O 
have O 
statistically O 
significant O 
synergy O 
in O 
both O 
breast O 
cancer O 
cell O 
lines O 
and O 
primary O 
3-dimensional O 
cultures O 
of O 
cells O 
from O 
pleural O 
effusions O 
of O 
patients O 
. O 
Therefore O 
, O 
synergistic O 
relationships O 
between O 
HDAC O 
and O 
CDK O 
inhibitors O 
may O 
provide O 
an O 
effective O 
combinatorial O 
regimen O 
for O 
breast O 
cancer O 
. O 
Importantly O 
, O 
these O 
studies O 
provide O 
an O 
example O 
of O 
how O 
genomic O 
analysis O 
of O 
drug O 
- O 
response O 
profiles O 
can O 
be O 
used O 
to O 
design O 
rational O 
drug O 
combinations O 
for O 
cancer O 
treatment O 
. O 

of O 
various O 
pressing O 
programs O 
and O 
yields O 
on O 
the O 
antioxidant O 
activity O 
, O 
antimicrobial O 
activity O 
, O 
phenolic B-FAMILY 
content O 
and O 
colour O 
of O 
pomegranate O 
juices O 
. O 

juice O 
( O 
PJ O 
) O 
samples O 
were O 
produced O 
with O 
three O 
different O 
pressing O 
programs O 
: O 
( O 
1 O 
) O 
1.2-4.8 O 
bar O 
for O 
25 O 
min O 
, O 
( O 
2 O 
) O 
1.2-2.4 O 
bar O 
for O 
15 O 
min O 
and O 
( O 
3 O 
) O 
1.2-1.8 O 
bar O 
for O 
5.5 O 
min O 
. O 
Respective O 
juice O 
yields O 
were O 
39.2% O 
, O 
33.2% O 
and O 
27.2% O 
. O 
Effects O 
of O 
pressing O 
pressure O 
- O 
time O 
and O 
yield O 
on O 
total O 
phenolic B-FAMILY 
( O 
TP O 
) O 
content O 
, O 
condensed O 
tannin B-FAMILY 
( O 
CT O 
) O 
content O 
, O 
monomeric O 
anthocyanin B-FAMILY 
( O 
MA O 
) O 
content O 
, O 
antioxidant O 
activity O 
( O 
AOA O 
) O 
and O 
antimicrobial O 
activity O 
( O 
AMA O 
) O 
of O 
the O 
samples O 
were O 
determined O 
. O 
Strong O 
positive O 
linear O 
correlations O 
were O 
found O 
between O 
the O 
pressing O 
pressure O 
with O 
AOA O 
( O 
r=0.973 O 
) O 
and O 
TP O 
content O 
( O 
r=0.979 O 
) O 
, O 
while O 
negative O 
logarithmic O 
correlations O 
were O 
found O 
between O 
pressing O 
pressure O 
with O 
the O 
contents O 
of O 
CT O 
( O 
r=-0.778 O 
) O 
and O 
MA O 
( O 
r=-0.955 O 
) O 
. O 
Among O 
12 O 
microorganisms O 
tested O 
, O 
Bacillus O 
megaterium O 
, O 
Bacillus O 
subtilis O 
, O 
Staphyloccocus O 
aureus O 
and O 
Pseudomonas O 
sp O 
. O 
were O 
found O 
to O 
be O 
sensitive O 
to O 
juice O 
samples O 
. O 
However O 
, O 
increasing O 
pressing O 
pressure O 
and O 
yield O 
did O 
not O 
lead O 
to O 
a O 
significant O 
change O 
on O 
the O 
AMAs O 
of O 
the O 
juices O 
. O 

hydrogels O 
are O 
very O 
important O 
biomaterials O 
used O 
in O 
drug O 
delivery O 
systems O 
( O 
DDSs O 
) O 
, O 
which O 
gained O 
increasing O 
attention O 
of O 
researchers O 
. O 
Thermosensitive O 
hydrogels O 
have O 
great O 
potential O 
in O 
various O 
applications O 
, O 
such O 
as O 
drug O 
delivery O 
, O 
cell O 
encapsulation O 
, O 
tissue O 
engineering O 
, O 
and O 
etc O 
. O 
Especially O 
, O 
injectable O 
thermosensitive O 
hydrogels O 
with O 
lower O 
sol O 
- O 
gel O 
transition O 
temperature O 
around O 
physiological O 
temperature O 
have O 
been O 
extensively O 
studied O 
. O 
By O 
in O 
vivo O 
injection O 
, O 
the O 
hydrogels O 
formed O 
non-flowing O 
gel O 
at O 
body O 
temperature O 
. O 
Upon O 
incorporation O 
of O 
pharmaceutical O 
agents O 
, O 
the O 
hydrogel O 
systems O 
could O 
act O 
as O 
sustained O 
drug O 
release O 
depot O 
in O 
situ O 
. O 
Injectable O 
thermosensitive O 
hydrogel O 
systems O 
have O 
a O 
number O 
of O 
advantages O 
, O 
including O 
simplicity O 
of O 
drug O 
formulation O 
, O 
protective O 
environment O 
for O 
drugs O 
, O 
prolonged O 
and O 
localized O 
drug O 
delivery O 
, O 
and O 
ease O 
of O 
application O 
. O 
The O 
objective O 
of O 
this O 
review O 
is O 
to O 
summarize O 
fundamentals O 
, O 
applications O 
, O 
and O 
recent O 
advances O 
of O 
injectable O 
thermosensitive O 
hydrogel O 
as O 
DDSs O 
, O 
including O 
chitosan O 
and O 
related O 
derivatives O 
, O 
poly(N-isopropylacrylamide) B-SYSTEMATIC 
-based O 
( O 
PNIPAAM B-ABBREVIATION 
) O 
copolymers O 
, O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
/ O 
poly(propylene B-FAMILY 
oxide I-FAMILY 
) I-FAMILY 
( O 
PEO B-ABBREVIATION 
/ O 
PPO B-ABBREVIATION 
) O 
copolymers O 
and O 
its O 
derivatives O 
, O 
and O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
/ O 
biodegradable O 
polyester B-FAMILY 
copolymers O 
. O 

mannose B-SYSTEMATIC 
6-phosphate I-SYSTEMATIC 
-binding O 
sites O 
of O 
M6P B-SYSTEMATIC 
/ O 
IGF2R O 
determine O 
its O 
capacity O 
to O 
suppress O 
matrix O 
invasion O 
by O 
squamous O 
cell O 
carcinoma O 
cells O 
. O 

M6P B-SYSTEMATIC 
( O 
mannose B-SYSTEMATIC 
6-phosphate I-SYSTEMATIC 
) O 
/ O 
IGF2R O 
( O 
insulin O 
- O 
like O 
growth O 
factor O 
II O 
receptor O 
) O 
interacts O 
with O 
a O 
variety O 
of O 
factors O 
that O 
impinge O 
on O 
tumour O 
invasion O 
and O 
metastasis O 
. O 
It O 
has O 
been O 
shown O 
that O 
expression O 
of O 
wild O 
- O 
type O 
M6P B-SYSTEMATIC 
/ O 
IGF2R O 
reduces O 
the O 
tumorigenic O 
and O 
invasive O 
properties O 
of O 
receptor O 
- O 
deficient O 
SCC-VII O 
squamous O 
cell O 
carcinoma O 
cells O 
. O 
We O 
have O 
now O 
used O 
mutant O 
forms O 
of O 
M6P B-SYSTEMATIC 
/ O 
IGF2R O 
to O 
assess O 
the O 
relevance O 
of O 
the O 
different O 
ligand O 
- O 
binding O 
sites O 
of O 
the O 
receptor O 
for O 
its O 
biological O 
activities O 
in O 
this O 
cellular O 
system O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
demonstrate O 
that O 
M6P B-SYSTEMATIC 
/ O 
IGF2R O 
does O 
not O 
require O 
a O 
functional O 
binding O 
site O 
for O 
insulin O 
- O 
like O 
growth O 
factor O 
II O 
for O 
inhibition O 
of O 
anchorage O 
- O 
independent O 
growth O 
and O 
matrix O 
invasion O 
by O 
SCC-VII O 
cells O 
. O 
In O 
contrast O 
, O 
the O 
simultaneous O 
mutation O 
of O 
both O 
M6P B-SYSTEMATIC 
-binding O 
sites O 
is O 
sufficient O 
to O 
impair O 
all O 
cellular O 
functions O 
of O 
the O 
receptor O 
tested O 
. O 
These O 
findings O 
highlight O 
that O 
the O 
interaction O 
between O 
M6P B-SYSTEMATIC 
/ O 
IGF2R O 
and O 
M6P B-SYSTEMATIC 
-modified O 
ligands O 
is O 
not O 
only O 
important O 
for O 
intracellular O 
accumulation O 
of O 
lysosomal O 
enzymes O 
and O 
formation O 
of O 
dense O 
lysosomes O 
, O 
but O 
is O 
also O 
crucial O 
for O 
the O 
ability O 
of O 
the O 
receptor O 
to O 
suppress O 
SCC-VII O 
growth O 
and O 
invasion O 
. O 
The O 
present O 
study O 
also O 
shows O 
that O 
some O 
of O 
the O 
biological O 
activities O 
of O 
M6P B-SYSTEMATIC 
/ O 
IGF2R O 
in O 
SCC-VII O 
cells O 
strongly O 
depend O 
on O 
a O 
functional O 
M6P B-SYSTEMATIC 
-binding O 
site O 
within O 
domain O 
3 O 
, O 
thus O 
providing O 
further O 
evidence O 
for O 
the O 
non-redundant O 
cellular O 
functions O 
of O 
the O 
individual O 
carbohydrate B-FAMILY 
-binding O 
domains O 
of O 
the O 
receptor O 
. O 

, O 
a O 
common O 
form O 
of O 
inflammatory O 
arthritis O 
, O 
is O 
strongly O 
associated O 
with O 
elevated O 
uric B-TRIVIAL 
acid I-TRIVIAL 
concentrations O 
in O 
the O 
blood O 
( O 
hyperuricemia O 
) O 
. O 
A O 
recent O 
study O 
in O 
Icelanders O 
identified O 
a O 
rare O 
missense O 
single O 
nucleotide B-FAMILY 
polymorphism O 
( O 
SNP O 
) O 
in O 
the O 
ALDH16A1 O 
gene O 
, O 
ALDH16A1*2 O 
, O 
to O 
be O 
associated O 
with O 
gout O 
and O 
serum O 
uric B-TRIVIAL 
acid I-TRIVIAL 
levels O 
. O 
ALDH16A1 O 
is O 
a O 
novel O 
and O 
rather O 
unique O 
member O 
of O 
the O 
ALDH O 
superfamily O 
in O 
relation O 
to O 
its O 
gene O 
and O 
protein O 
structures O 
. O 
ALDH16 O 
genes O 
are O 
present O 
in O 
fish O 
, O 
amphibians O 
, O 
protista O 
, O 
bacteria O 
but O 
absent O 
from O 
archaea O 
, O 
fungi O 
and O 
plants O 
. O 
In O 
most O 
mammalian O 
species O 
, O 
two O 
ALDH16A1 O 
spliced O 
variants O 
( O 
ALDH16A1 O 
, O 
long O 
form O 
and O 
ALDH16A1_v2 O 
, O 
short O 
form O 
) O 
have O 
been O 
identified O 
and O 
both O 
are O 
expressed O 
in O 
HepG-2 O 
, O 
HK-2 O 
and O 
HK-293 O 
human O 
cell O 
lines O 
. O 
The O 
ALDH16 O 
proteins O 
contain O 
two O 
ALDH O 
domains O 
( O 
as O 
opposed O 
to O 
one O 
in O 
the O 
other O 
members O 
of O 
the O 
superfamily O 
) O 
, O 
four O 
transmembrane O 
and O 
one O 
coiled O 
- O 
coil O 
domains O 
. O 
The O 
active O 
site O 
of O 
ALDH16 O 
proteins O 
from O 
bacterial O 
, O 
frog O 
and O 
lower O 
animals O 
contain O 
the O 
catalytically O 
important O 
cysteine B-TRIVIAL 
residue O 
( O 
Cys B-FORMULA 
-302 O 
) O 
; O 
this O 
residue O 
is O 
absent O 
from O 
the O 
mammalian O 
and O 
fish O 
orthologs O 
. O 
Molecular O 
modeling O 
predicts O 
that O 
both O 
the O 
short O 
and O 
long O 
forms O 
of O 
human O 
ALDH16A1 O 
protein O 
would O 
lack O 
catalytic O 
activity O 
but O 
may O 
interact O 
with O 
the O 
hypoxanthine B-TRIVIAL 
- O 
guanine B-TRIVIAL 
phosphoribosyltransferase O 
( O 
HPRT1 O 
) O 
protein O 
, O 
a O 
key O 
enzyme O 
involved O 
in O 
uric B-TRIVIAL 
acid I-TRIVIAL 
metabolism O 
and O 
gout O 
. O 
Interestingly O 
, O 
such O 
protein O 
- O 
protein O 
interactions O 
with O 
HPRT1 O 
are O 
predicted O 
to O 
be O 
impaired O 
for O 
the O 
long O 
or O 
short O 
forms O 
of O 
ALDH16A1*2 O 
. O 
These O 
results O 
lead O 
to O 
the O 
intriguing O 
possibility O 
that O 
association O 
between O 
ALDH16A1 O 
and O 
HPRT1 O 
may O 
be O 
required O 
for O 
optimal O 
HPRT O 
activity O 
with O 
disruption O 
of O 
this O 
interaction O 
possibly O 
contributing O 
to O 
the O 
hyperuricemia O 
seen O 
in O 
ALDH16A1*2 O 
carriers O 
. O 

Cholesterol B-TRIVIAL 
Goals O 
in O 
High-Risk O 
Patients O 
: O 
How O 
Low O 
Do O 
We O 
Go O 
and O 
How O 
Do O 
We O 
Get O 
There O 
? O 

is O 
widely O 
recognised O 
that O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
is O 
one O 
of O 
the O 
most O 
important O 
and O 
modifiable O 
risk O 
factors O 
for O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
. O 
Statins O 
( O 
HMG-CoA B-ABBREVIATION 
reductase O 
inhibitors O 
) O 
have O 
consistently O 
been O 
shown O 
to O 
decrease O 
both O 
LDL-C O 
and O 
CVD O 
risk O 
in O 
almost O 
all O 
patient O 
categories O 
, O 
with O 
the O 
exception O 
of O 
heart O 
and O 
kidney O 
failure O 
as O 
well O 
as O 
advanced O 
aortic O 
stenosis O 
. O 
As O 
a O 
consequence O 
, O 
statins O 
have O 
become O 
the O 
cornerstone O 
in O 
current O 
prevention O 
guidelines O 
. O 
In O 
patients O 
who O 
do O 
not O 
reach O 
the O 
LDL-C O 
target O 
, O 
combination O 
therapy O 
with O 
additional O 
LDL-C O 
lowering O 
drugs O 
( O 
e.g O 
. O 
ezetimibe B-TRIVIAL 
, O 
bile B-FAMILY 
acid I-FAMILY 
sequestrants O 
or O 
fibrates B-FAMILY 
) O 
should O 
be O 
considered O 
. O 
Guidelines O 
provide O 
different O 
LDL-C O 
levels O 
to O 
strive O 
for O 
, O 
depending O 
on O 
the O 
CVD O 
risk O 
. O 
In O 
this O 
review O 
, O 
we O 
describe O 
the O 
rationale O 
for O 
these O 
LDL-C O 
targets O 
and O 
how O 
these O 
goals O 
might O 
be O 
reached O 
by O 
current O 
and O 
future O 
therapies O 
. O 

effects O 
of O 
neolignans B-FAMILY 
isolated O 
from O 
Magnoliae O 
Cortex O 
against O 
glutamate B-TRIVIAL 
-induced O 
apoptotic O 
stimuli O 
in O 
HT22 O 
cells O 
. O 

the O 
course O 
of O 
screening O 
for O 
neuroprotective O 
natural O 
products O 
, O 
Magnoliae O 
Cortex O 
showed O 
potent O 
inhibition O 
of O 
hippocampal O 
neuronal O 
HT22 O 
cell O 
death O 
. O 
Obovatol B-TRIVIAL 
, O 
honokiol B-TRIVIAL 
, O 
and O 
magnolol B-TRIVIAL 
were O 
isolated O 
from O 
the O 
ethanolic O 
extract O 
of O 
Magnoliae O 
Cortex O 
. O 
Isolated O 
compounds O 
obovatol B-TRIVIAL 
, O 
honokiol B-TRIVIAL 
, O 
and O 
magnolol B-TRIVIAL 
were O 
protective O 
against O 
5mM O 
glutamate B-TRIVIAL 
-induced O 
cell O 
death O 
. O 
When O 
cells O 
were O 
stressed O 
using O 
glutamate B-TRIVIAL 
, O 
cell O 
viability O 
decreased O 
to O 
16.98±4.58% O 
over O 
the O 
control O 
( O 
100.00±10.15% O 
) O 
. O 
In O 
contrast O 
, O 
10μM O 
obovatol B-TRIVIAL 
, O 
10μM O 
honokiol B-TRIVIAL 
, O 
and O 
50μM O 
magnolol B-TRIVIAL 
increased O 
cell O 
viability O 
to O 
91.80±1.70% O 
, O 
93.59±1.93% O 
, O 
and O 
85.36±7.40% O 
, O 
respectively O 
. O 
The O 
neuroprotective O 
effects O 
of O 
obovatol B-TRIVIAL 
and O 
honokiol B-TRIVIAL 
were O 
attributable O 
to O 
the O 
inhibition O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
, O 
followed O 
by O 
protection O 
of O 
the O 
mitochondrial O 
membrane O 
potential O 
( O 
ΔΨm O 
) O 
, O 
recovery O 
of O 
Bcl-2 O 
and O 
Bid O 
levels O 
, O 
inhibition O 
of O 
apoptosis O 
- O 
inducing O 
factor O 
expression O 
, O 
and O 
phosphorylation O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
such O 
as O 
p38 O 
kinases O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
, O 
and O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinases O 
. O 
On O 
the O 
contrary O 
, O 
magnolol B-TRIVIAL 
did O 
not O 
show O 
any O 
significant O 
effect O 
on O 
the O 
ΔΨm O 
and O 
apoptotic O 
factors O 
. O 
Among O 
three O 
compounds O 
, O 
obovatol B-TRIVIAL 
most O 
strongly O 
scavenged O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
radicals O 
and O 
inhibited O 
the O 
elevation O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
levels O 
in O 
glutamate B-TRIVIAL 
-stressed O 
HT22 O 
cells O 
. O 
These O 
data O 
suggest O 
that O 
obovatol B-TRIVIAL 
and O 
honokiol B-TRIVIAL 
may O 
have O 
clinical O 
applications O 
for O 
preventing O 
neurodegenerative O 
disorders O 
. O 

molecular O 
structure O 
of O 
the O 
blue O 
mussel O 
Mytilus O 
edulis O 
whole O 
anchoring O 
threads O 
was O 
studied O 
by O 
two O 
- O 
dimensional O 
(13)C B-FORMULA 
solid O 
- O 
state O 
NMR O 
on O 
fully O 
labeled O 
fibers O 
. O 
This O 
unique O 
material O 
proves O 
to O 
be O 
well O 
ordered O 
at O 
a O 
molecular O 
level O 
despite O 
its O 
heterogeneous O 
composition O 
as O 
evidenced O 
by O 
the O 
narrow O 
measured O 
linewidths O 
below O 
1.5 O 
ppm O 
. O 
The O 
spectra O 
are O 
dominated O 
by O 
residues O 
in O 
collagen O 
environments O 
, O 
as O 
determined O 
from O 
chemical O 
shift O 
analysis O 
, O 
and O 
a O 
complete O 
two O 
- O 
dimensional O 
assignment O 
( O 
including O 
minor O 
amino B-FAMILY 
acids I-FAMILY 
) O 
was O 
possible O 
. O 
The O 
best O 
agreement O 
between O 
predicted O 
and O 
experimental O 
backbone O 
chemical O 
shifts O 
was O 
obtained O 
for O 
collagen O 
helices O 
with O 
torsion O 
angles O 
( O 
-75° O 
, O 
+ O 
150° O 
) O 
. O 
The O 
abundant O 
glycine B-TRIVIAL 
and O 
alanine B-TRIVIAL 
residues O 
can O 
be O 
resolved O 
in O 
up O 
to O 
five O 
different O 
structural O 
environments O 
. O 
Alanine B-TRIVIAL 
peaks O 
could O 
be O 
assigned O 
to O 
collagen O 
triple O 
- O 
helices O 
, O 
β-sheets O 
( O 
parallel O 
and O 
antiparallel O 
) O 
, O 
β-turns O 
, O 
and O 
unordered O 
structures O 
. O 
The O 
use O 
of O 
ATR-FTIR O 
microscopy O 
confirmed O 
the O 
presence O 
of O 
these O 
structural O 
environments O 
and O 
enabled O 
their O 
location O 
in O 
the O 
core O 
of O 
the O 
thread O 
( O 
collagen O 
helices O 
and O 
antiparallel O 
β-sheets O 
) O 
or O 
its O 
cuticle O 
( O 
unordered O 
structures O 
) O 
. O 
The O 
approach O 
should O 
enable O 
characterization O 
at O 
the O 
molecular O 
level O 
of O 
a O 
wide O 
range O 
of O 
byssus O 
macroscopic O 
properties O 
. O 

selective O 
once O 
- O 
daily O 
prandial O 
glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
receptor O 
agonist O 
lixisenatide O 
(Lyxumia(®)) O 
is O 
under O 
development O 
with O 
Sanofi O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
Lixisenatide O 
belongs O 
to O 
a O 
class O 
of O 
GLP-1 O 
compounds O 
designed O 
to O 
mimic O 
the O 
endogenous O 
hormone O 
GLP-1 O 
. O 
Native O 
GLP-1 O 
stimulates O 
insulin O 
secretion O 
in O 
a O 
glucose B-TRIVIAL 
-dependent O 
manner O 
, O 
as O 
well O 
as O 
suppressing O 
glucagon O 
production O 
and O 
slowing O 
gastric O 
emptying O 
. O 
A O 
once O 
- O 
daily O 
subcutaneous O 
formulation O 
of O 
lixisenatide O 
has O 
been O 
approved O 
in O 
the O 
EU O 
, O 
Iceland O 
, O 
Liechtenstein O 
, O 
Norway O 
and O 
Mexico O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
, O 
and O 
is O 
under O 
regulatory O 
review O 
in O 
the O 
USA O 
, O 
Switzerland O 
, O 
Brazil O 
, O 
Canada O 
, O 
Ukraine O 
, O 
South O 
Africa O 
, O 
Japan O 
and O 
Australia O 
. O 
This O 
article O 
summarizes O 
the O 
milestones O 
in O 
the O 
development O 
of O 
lixisenatide O 
, O 
leading O 
to O 
this O 
first O 
approval O 
for O 
use O 
in O 
adults O 
with O 
type O 
2 O 
diabetes O 
. O 

1 O 
is O 
required O 
for O 
vesicular O 
Ca(2+) B-FORMULA 
/ O 
H(+) B-FORMULA 
-antiport O 
activity O 
. O 

low O 
- O 
affinity O 
Ca(2+) B-FORMULA 
/ O 
H(+) B-FORMULA 
-antiport O 
was O 
described O 
in O 
the O 
membrane O 
of O 
mammalian O 
brain O 
synaptic O 
vesicles O 
. O 
Electrophysiological O 
studies O 
showed O 
that O 
this O 
antiport O 
contributes O 
to O 
the O 
extreme O 
brevity O 
of O 
excitation O 
- O 
release O 
coupling O 
in O 
rapid O 
synapses O 
. O 
Synaptotagmin-1 O 
, O 
a O 
vesicular O 
protein O 
interacting O 
with O 
membranes O 
upon O 
low O 
- O 
affinity O 
Ca(2+) B-FORMULA 
-binding O 
, O 
plays O 
a O 
major O 
role O 
in O 
excitation O 
- O 
release O 
coupling O 
, O 
by O 
synchronizing O 
calcium B-SYSTEMATIC 
entry O 
with O 
fast O 
neurotransmitter O 
release O 
. O 
Here O 
, O 
we O 
report O 
that O 
synaptotagmin-1 O 
is O 
necessary O 
for O 
expression O 
of O 
the O 
vesicular O 
Ca(2+) B-FORMULA 
/ O 
H(+) B-FORMULA 
-antiport O 
. O 
We O 
measured O 
Ca(2+) B-FORMULA 
/ O 
H(+) B-FORMULA 
-antiport O 
activity O 
in O 
vesicles O 
and O 
granules O 
of O 
pheochromocytoma O 
PC12 O 
cells O 
by O 
three O 
methods O 
: O 
( O 
1 O 
) O 
Ca(2+) B-FORMULA 
-induced O 
dissipation O 
of O 
the O 
vesicular O 
H(+) B-FORMULA 
-gradient O 
; O 
( O 
2 O 
) O 
bafilomycin B-FAMILY 
-sensitive O 
calcium B-SYSTEMATIC 
accumulation O 
and O 
( O 
3 O 
) O 
pH-jump O 
- O 
induced O 
calcium B-SYSTEMATIC 
accumulation O 
. O 
The O 
results O 
were O 
congruent O 
and O 
highly O 
significant O 
: O 
Ca(2+) B-FORMULA 
/ O 
H(+) B-FORMULA 
-antiport O 
activity O 
is O 
detectable O 
only O 
in O 
acidic O 
organelles O 
expressing O 
functional O 
synaptotagmin-1 O 
. O 
In O 
contrast O 
, O 
synaptotagmin-1-deficient O 
cells O 
- O 
and O 
cells O 
where O 
transgenically O 
encoded O 
synaptotagmin-1 O 
was O 
acutely O 
photo O 
- O 
inactivated O 
- O 
were O 
devoid O 
of O 
any O 
Ca(2+) B-FORMULA 
/ O 
H(+) B-FORMULA 
-antiport O 
activity O 
. O 
Therefore O 
, O 
in O 
addition O 
to O 
its O 
previously O 
described O 
functions O 
, O 
synaptotagmin-1 O 
is O 
involved O 
in O 
a O 
rapid O 
vesicular O 
Ca(2+) B-FORMULA 
sequestration O 
through O 
a O 
Ca(2+) B-FORMULA 
/ O 
H(+) B-FORMULA 
antiport O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

™ O 
mussels O 
( O 
Perna O 
canaliculus O 
) O 
were O 
dry O 
- O 
stored O 
at O 
6.44±0.54°C O 
for O 
8 O 
days O 
during O 
which O 
time O 
volatile O 
organic O 
compounds O 
( O 
VOCs O 
) O 
were O 
monitored O 
using O 
SPME O 
GC-MS O 
. O 
Thirty O 
- O 
four O 
VOCs O 
were O 
identified O 
in O 
homogenised O 
mussel O 
meat O 
and O 
29 O 
in O 
the O 
mussel O 
liquor O 
( O 
i.e O 
. O 
the O 
seawater O 
enclosed O 
in O 
the O 
mantle O 
cavity O 
) O 
. O 
Of O 
the O 
34 O 
VOCs O 
identified O 
20 O 
were O 
reliably O 
identified O 
throughout O 
the O 
storage O 
treatment O 
and O 
9 O 
were O 
found O 
to O 
change O 
in O 
relative O 
concentration O 
in O 
homogenised O 
mussel O 
meat O 
. O 
Dimethyl B-SYSTEMATIC 
sulphide I-SYSTEMATIC 
, O 
1-penten-3-ol B-SYSTEMATIC 
, O 
1-hexen-3-ol B-SYSTEMATIC 
and O 
1-octen-3-ol B-SYSTEMATIC 
increased O 
during O 
storage O 
, O 
whereas O 
pentanal B-SYSTEMATIC 
, O 
hexanal B-SYSTEMATIC 
, O 
heptanal B-SYSTEMATIC 
, O 
octanal B-SYSTEMATIC 
and O 
3-undecen-2-one B-SYSTEMATIC 
decreased O 
. O 
In O 
the O 
mussel O 
liquor O 
, O 
dimethyl B-SYSTEMATIC 
sulphide I-SYSTEMATIC 
was O 
undetectable O 
pre O 
- O 
storage O 
, O 
becoming O 
detectable O 
after O 
2 O 
days O 
, O 
and O 
a O 
large O 
increase O 
was O 
noted O 
after O 
6 O 
days O 
. O 
SPME O 
GC-MS O 
was O 
a O 
useful O 
tool O 
for O 
monitoring O 
VOC O 
profiles O 
of O 
Greenshell O 
™ O 
mussels O 
and O 
could O 
aid O 
in O 
the O 
development O 
of O 
technologies O 
that O 
monitor O 
and O 
improve O 
product O 
quality O 
and O 
consistency O 
. O 

casein O 
fraction O 
of O 
13 O 
Portuguese O 
PDO O 
cheeses O 
were O 
analysed O 
using O 
Urea B-TRIVIAL 
-PAGE O 
and O 
reverse O 
phase O 
- O 
high O 
performance O 
liquid O 
chromatography O 
( O 
RP-HPLC O 
) O 
and O 
then O 
subjected O 
to O 
chemometric O 
evaluation O 
. O 
The O 
chemometric O 
techniques O 
of O 
cluster O 
analysis O 
( O 
CA O 
) O 
and O 
principal O 
component O 
analysis O 
( O 
PCA O 
) O 
were O 
used O 
for O 
the O 
classification O 
studies O 
. O 
Peptide O 
mapping O 
using O 
Urea B-TRIVIAL 
-PAGE O 
followed O 
by O 
CA O 
revealed O 
two O 
major O 
clusters O 
according O 
to O 
the O 
similarity O 
of O 
the O 
proteolytic O 
profile O 
of O 
the O 
cheeses O 
. O 
PCA O 
results O 
were O 
in O 
accordance O 
with O 
the O 
grouping O 
performed O 
using O 
CA O 
. O 
CA O 
of O 
RP-HPLC O 
results O 
of O 
the O 
matured O 
cheeses O 
revealed O 
the O 
presence O 
of O 
one O 
major O 
cluster O 
comprising O 
samples O 
manufactured O 
with O 
only O 
ovine O 
milk O 
or O 
milk O 
admixtures O 
. O 
When O 
the O 
results O 
of O 
CA O 
technique O 
were O 
compared O 
with O 
the O 
two O 
PCA O 
approaches O 
performed O 
, O 
it O 
was O 
found O 
that O 
the O 
grouping O 
of O 
the O 
samples O 
was O 
similar O 
. O 
Both O 
approaches O 
, O 
revealed O 
the O 
potential O 
of O 
proteolytic O 
profiles O 
( O 
which O 
is O 
an O 
essential O 
aspect O 
of O 
cheese O 
maturation O 
) O 
as O 
markers O 
of O 
authenticity O 
of O 
PDO O 
cheeses O 
in O 
terms O 
of O 
ripening O 
time O 
and O 
milk O 
admixtures O 
not O 
mentioned O 
on O 
the O 
label O 
. O 

mellitus O 
is O 
a O 
chronic O 
progressive O 
metabolic O 
disorder O 
that O 
has O 
profound O 
consequences O 
for O 
individuals O 
, O 
families O 
, O 
and O 
society O 
. O 
To O 
date O 
, O 
main O 
available O 
oral O 
antidiabetic O 
medications O 
target O 
either O 
insulin O 
resistance O 
( O 
metformin B-TRIVIAL 
, O 
glitazones B-FAMILY 
) O 
, O 
or O 
insulin O 
deficiency O 
( O 
sulfonylureas B-FAMILY 
, O 
glinides B-FAMILY 
) O 
, O 
but O 
leading O 
to O 
shortfalls O 
in O 
medication O 
. O 
Advancement O 
in O 
modern O 
oral O 
hypoglycemic O 
agents O 
may O 
be O 
encouraged O 
with O 
or O 
in O 
place O 
of O 
traditional O 
therapies O 
. O 
The O 
lower O 
risk O 
for O 
hypoglycemic O 
events O 
as O 
compared O 
with O 
other O 
insulinotropic O 
or O 
insulin O 
- O 
sensitizing O 
agents O 
make O 
DPP-4 O 
inhibitors O 
very O 
promising O 
candidates O 
for O 
a O 
more O 
physiological O 
treatment O 
of O 
type-2 O 
diabetes O 
. O 
Only O 
some O 
DPP-4 O 
inhibitors O 
are O 
currently O 
used O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
( O 
T2DM O 
) O 
and O 
various O 
inhibitors O 
currently O 
undergoing O 
animal O 
and O 
human O 
testing O 
. O 
A O 
number O 
of O 
catalytically O 
active O 
DPPs O 
distinct O 
from O 
DPP-4 O 
( O 
DPP O 
II O 
, O 
FAP O 
, O 
DPP-8 O 
, O 
and O 
DPP-9 O 
) O 
have O 
been O 
described O 
that O 
is O 
associated O 
with O 
side-effect O 
and O 
toxicity O 
. O 
To O 
discover O 
potent O 
and O 
selective O 
and O 
safer O 
drugs O 
in O 
a O 
shorter O 
time O 
frame O 
and O 
with O 
reduced O 
cost O 
it O 
requires O 
using O 
an O 
innovative O 
approach O 
for O 
designing O 
novel O 
inhibitors O 
. O 
This O 
review O 
article O 
focuses O 
on O 
the O 
status O 
of O 
advanced O 
lead O 
candidates O 
of O 
DPP O 
group O 
and O 
their O 
binding O 
affinity O 
with O 
the O 
active O 
site O 
residue O 
of O 
target O 
structure O 
which O 
help O 
in O 
discovery O 
of O 
potent O 
and O 
selective O 
DPP-4 O 
inhibitors O 
by O 
lead O 
optimization O 
approach O 
. O 

of O 
pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-ones B-FAMILY 
as O 
potential O 
antimicrobial O 
agents O 
. O 

of O 
new O 
derivatives O 
of O 
pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one B-SYSTEMATIC 
via O 
reaction O 
of O 
7-(4-bromophenyl)-1,2-dihydro-5-(4-fluorophenyl)-2-thioxopyrido[2,3-d] B-SYSTEMATIC 
pyrimidin-4(3H)-one I-SYSTEMATIC 
with O 
hydrazonoyl B-FAMILY 
chlorides I-FAMILY 
or O 
reaction O 
of O 
2-hydrazino-pyrido[2,3-d]pyrimidin-4(3H)-one B-SYSTEMATIC 
with O 
different O 
aldehydes B-FAMILY 
followed O 
by O 
cyclization O 
of O 
the O 
products O 
. O 
All O 
the O 
newly O 
synthesized O 
compounds O 
were O 
evaluated O 
for O 
their O 
antimicrobial O 
activities O 
and O 
also O 
their O 
minimum O 
inhibitory O 
concentration O 
against O 
most O 
of O 
test O 
organisms O 
was O 
performed O 
. O 
Amongst O 
the O 
tested O 
compounds O 
displayed O 
excellent O 
activity O 
against O 
all O 
the O 
tested O 
microorganisms O 
except O 
SR O 
and O 
PA O 
. O 

of O 
superconductivity O 
from O 
the O 
dynamically O 
heterogeneous O 
insulating O 
state O 
in O 
La(2-x)Sr(x)CuO4 B-FAMILY 
. O 

central O 
issue O 
for O 
copper B-FAMILY 
oxides I-FAMILY 
is O 
the O 
nature O 
of O 
the O 
insulating O 
ground O 
state O 
at O 
low O 
carrier O 
densities O 
and O 
the O 
emergence O 
of O 
high O 
- O 
temperature O 
superconductivity O 
from O 
that O 
state O 
with O 
doping O 
. O 
Even O 
though O 
this O 
superconductor O 
- O 
insulator O 
transition O 
( O 
SIT O 
) O 
is O 
a O 
zero O 
- O 
temperature O 
transition O 
, O 
measurements O 
are O 
not O 
usually O 
carried O 
out O 
at O 
low O 
temperatures O 
. O 
Here O 
we O 
use O 
magnetoresistance O 
to O 
probe O 
both O 
the O 
insulating O 
state O 
at O 
very O 
low O 
temperatures O 
and O 
the O 
presence O 
of O 
superconducting O 
fluctuations O 
in O 
La(2-x)Sr(x)CuO(4) B-FAMILY 
films O 
, O 
for O 
doping O 
levels O 
that O 
range O 
from O 
the O 
insulator O 
to O 
the O 
superconductor O 
( O 
x O 
= O 
0.03-0.08 O 
) O 
. O 
We O 
observe O 
that O 
the O 
charge O 
glass O 
behaviour O 
, O 
characteristic O 
of O 
the O 
insulating O 
state O 
, O 
is O 
suppressed O 
with O 
doping O 
, O 
but O 
it O 
coexists O 
with O 
superconducting O 
fluctuations O 
that O 
emerge O 
already O 
on O 
the O 
insulating O 
side O 
of O 
the O 
SIT O 
. O 
The O 
unexpected O 
quenching O 
of O 
the O 
superconducting O 
fluctuations O 
by O 
the O 
competing O 
charge O 
order O 
at O 
low O 
temperatures O 
provides O 
a O 
new O 
perspective O 
on O 
the O 
mechanism O 
for O 
the O 
SIT O 
. O 

modulates O 
renin O 
- O 
angiotensin O 
system O 
associated O 
with O 
reducing O 
oxidative O 
stress O 
and O 
attenuating O 
neuronal O 
apoptosis O 
in O 
the O 
brain O 
of O 
hypertensive O 
rats O 
. O 

[ O 
Ang-(1-7) B-ABBREVIATION 
] O 
has O 
beneficial O 
effects O 
against O 
hypertension O 
- O 
induced O 
damage O 
in O 
heart O 
and O 
kidney O 
, O 
but O 
its O 
effects O 
in O 
brain O 
are O 
not O 
clear O 
as O 
yet O 
. O 
The O 
present O 
study O 
aimed O 
to O 
investigate O 
the O 
protective O 
effects O 
of O 
Ang-(1-7) B-ABBREVIATION 
on O 
the O 
physiopathologic O 
changes O 
caused O 
by O 
hypertension O 
in O 
brain O 
of O 
spontaneously O 
hypertensive O 
rats O 
( O 
SHRs O 
) O 
. O 
Wistar-Kyoto O 
rats O 
received O 
intracerebroventricular O 
( O 
I.C.V O 
. O 
) O 
infusion O 
of O 
artificial O 
cerebrospinal O 
fluid O 
( O 
aCSF O 
) O 
while O 
SHRs O 
received O 
I.C.V O 
. O 
infusion O 
of O 
Ang-(1-7) B-ABBREVIATION 
, O 
Mas O 
receptor O 
antagonist O 
A-779 O 
and O 
aCSF O 
for O 
4 O 
weeks O 
. O 
Brain O 
tissues O 
were O 
collected O 
and O 
analyzed O 
by O 
western O 
blot O 
, O 
enzyme O 
immunoassay O 
, O 
spectrophotometric O 
assays O 
and O 
terminal O 
deoxynucleotidyl B-FAMILY 
transferase O 
- O 
mediated O 
dUTP B-ABBREVIATION 
end O 
- O 
labeling O 
( O 
TUNEL O 
) O 
staining O 
. O 
Our O 
study O 
showed O 
that O 
infusion O 
of O 
Ang-(1-7) B-ABBREVIATION 
for O 
4 O 
weeks O 
significantly O 
reduced O 
the O 
expression O 
of O 
Angiotensin B-TRIVIAL 
II I-TRIVIAL 
and O 
Angiotensin B-TRIVIAL 
II I-TRIVIAL 
type O 
1 O 
receptors O 
in O 
SHR O 
brain O 
. O 
Additionally O 
, O 
it O 
decreased O 
the O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
and O 
elevated O 
total O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
, O 
which O 
was O 
accompanied O 
by O 
reductions O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
subunit O 
gp91(phox) O 
and O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
in O 
the O 
brain O 
of O 
SHR O 
. O 
The O 
increases O 
of O 
the O 
percentage O 
of O 
TUNEL-positive O 
neurons O 
and O 
Bax O 
to O 
Bcl-2 O 
ratio O 
in O 
SHR O 
brain O 
were O 
also O 
attenuated O 
by O 
Ang-(1-7) B-ABBREVIATION 
. O 
The O 
anti-oxidative O 
and O 
anti-apoptosis O 
effects O 
of O 
Ang-(1-7) B-ABBREVIATION 
are O 
independent O 
of O 
blood O 
pressure O 
reduction O 
and O 
can O 
be O 
partially O 
abolished O 
by O 
A-779 O 
. O 
These O 
findings O 
suggest O 
that O 
chronic O 
treatment O 
with O 
Ang-(1-7) B-ABBREVIATION 
is O 
beneficial O 
to O 
attenuate O 
hypertension O 
- O 
induced O 
physiopathologic O 
changes O 
in O 
brain O 
and O 
may O 
be O 
helpful O 
to O 
prevent O 
hypertension O 
- O 
related O 
cerebrovascular O 
diseases O 
. O 

in O 
the O 
ripe O 
fruits O 
of O 
Rubus O 
coreanus O 
Miquel O 
and O 
their O 
protective O 
effect O 
on O 
neuronal O 
PC-12 O 
cells O 
. O 

of O 
the O 
fresh O 
ripe O 
fruits O 
of O 
Rubus O 
coreanus O 
Miquel O 
were O 
extracted O 
and O 
separated O 
into O 
anthocyanin B-FAMILY 
and O 
the O 
non- O 
anthocyanin B-FAMILY 
fractions O 
, O 
which O 
were O 
used O 
for O 
the O 
evaluation O 
for O 
antioxidant O 
capacity O 
and O 
neuroprotective O 
effects O 
. O 
The O 
anthocyanin B-FAMILY 
fraction O 
accounted O 
for O 
approximately O 
47-55% O 
of O 
the O 
total O 
antioxidant O 
capacity O 
of O 
the O 
whole O 
extract O 
and O 
had O 
significantly O 
higher O 
free O 
radical O 
- O 
scavenging O 
capacity O 
than O 
the O 
non- O 
anthocyanin B-FAMILY 
fraction O 
. O 
Furthermore O 
, O 
the O 
anthocyanins B-FAMILY 
alleviated O 
intracellular O 
oxidative O 
stress O 
, O 
as O 
assayed O 
by O 
in O 
vitro O 
fluorescent O 
measurements O 
. O 
The O 
anthocyanins B-FAMILY 
showed O 
neuroprotective O 
effects O 
on O 
PC-12 O 
cells O 
in O 
vitro O 
against O 
oxidative O 
stress O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Triple O 
quadrupole O 
LC O 
/ O 
MS O 
and O 
Q-TOF O 
LC O 
/ O 
MS O 
analyses O 
revealed O 
four O 
major O 
anthocyanins B-FAMILY 
; O 
cyanidin B-SYSTEMATIC 
3-O-sambubioside I-SYSTEMATIC 
, O 
cyanidin B-SYSTEMATIC 
3-O-glucoside I-SYSTEMATIC 
, O 
cyanidin B-SYSTEMATIC 
3-O-xylosylrutinoside I-SYSTEMATIC 
, O 
and O 
cyanidin B-SYSTEMATIC 
3-O-rutinoside I-SYSTEMATIC 
in O 
increasing O 
order O 
of O 
amounts O 
. O 
These O 
results O 
demonstrated O 
that O 
anthocyanins B-FAMILY 
are O 
the O 
major O 
components O 
and O 
contributors O 
to O 
the O 
antioxidant O 
capacity O 
of O 
ripe O 
R O 
. O 
coreanus O 
Miquel O 
fruits O 
. O 
Further O 
studies O 
are O 
warranted O 
to O 
determine O 
whether O 
consumption O 
of O 
the O 
fruits O 
reduces O 
oxidative O 
stress O 
in O 
the O 
brain O 
and O 
promotes O 
health O 
. O 

polymerase O 
minor O 
groove O 
interactions O 
modulate O 
mutagenic O 
bypass O 
of O 
a O 
templating O 
8-oxoguanine B-SYSTEMATIC 
lesion O 
. O 

major O 
base O 
lesion O 
resulting O 
from O 
oxidative O 
stress O 
is O 
8-oxo-7,8-dihydro-2'-deoxyguanosine B-SYSTEMATIC 
( O 
8-oxoG B-SYSTEMATIC 
) O 
that O 
has O 
ambiguous O 
coding O 
potential O 
. O 
Error O 
- O 
free O 
DNA O 
synthesis O 
involves O 
8-oxoG B-SYSTEMATIC 
adopting O 
an O 
anti-conformation O 
to O 
base O 
pair O 
with O 
cytosine B-TRIVIAL 
whereas O 
mutagenic O 
bypass O 
involves O 
8-oxoG B-SYSTEMATIC 
adopting O 
a O 
syn-conformation O 
to O 
base O 
pair O 
with O 
adenine B-TRIVIAL 
. O 
Left O 
unrepaired O 
the O 
syn-8-oxoG B-SYSTEMATIC 
/ O 
dAMP B-ABBREVIATION 
base O 
pair O 
results O 
in O 
a O 
G-C O 
to O 
T-A O 
transversion O 
. O 
During O 
base O 
excision O 
repair O 
of O 
this O 
mispair O 
, O 
DNA O 
polymerase O 
( O 
pol O 
) O 
β O 
is O 
confronted O 
with O 
gap O 
filling O 
opposite O 
8-oxoG B-SYSTEMATIC 
. O 
To O 
determine O 
how O 
pol O 
β O 
discriminates O 
between O 
anti- B-MULTIPLE 
and I-MULTIPLE 
syn-8-oxoG I-MULTIPLE 
, O 
we O 
introduced O 
a O 
point O 
mutation O 
( O 
R283K O 
) O 
to O 
alter O 
insertion O 
specificity O 
. O 
Kinetic O 
studies O 
demonstrate O 
that O 
this O 
substitution O 
results O 
in O 
an O 
increased O 
fidelity O 
opposite O 
8-oxoG B-SYSTEMATIC 
. O 
Structural O 
studies O 
with O 
R283K O 
pol O 
β O 
show O 
that O 
the O 
binary O 
DNA O 
complex O 
has O 
8-oxoG B-SYSTEMATIC 
in O 
equilibrium O 
between O 
anti- O 
and O 
syn- O 
forms O 
. O 
Ternary O 
complexes O 
with O 
incoming O 
dCTP B-ABBREVIATION 
resemble O 
the O 
wild O 
- O 
type O 
enzyme O 
, O 
with O 
templating O 
anti-8-oxoG B-SYSTEMATIC 
base O 
pairing O 
with O 
incoming O 
cytosine B-TRIVIAL 
. O 
In O 
contrast O 
to O 
wild O 
- O 
type O 
pol O 
β O 
, O 
the O 
ternary O 
complex O 
of O 
the O 
R283K O 
mutant O 
with O 
an O 
incoming O 
dATP B-ABBREVIATION 
-analogue O 
and O 
templating O 
8-oxoG B-SYSTEMATIC 
resembles O 
a O 
G-A O 
mismatched O 
structure O 
with O 
8-oxoG B-SYSTEMATIC 
adopting O 
an O 
anti-conformation O 
. O 
These O 
results O 
demonstrate O 
that O 
the O 
incoming O 
nucleotide B-FAMILY 
is O 
unable O 
to O 
induce O 
a O 
syn-8-oxoG B-SYSTEMATIC 
conformation O 
without O 
minor O 
groove O 
DNA O 
polymerase O 
interactions O 
that O 
influence O 
templating O 
( O 
anti- O 
/ O 
syn-equilibrium O 
) O 
of O 
8-oxoG B-SYSTEMATIC 
while O 
modulating O 
fidelity O 
. O 

evaluated O 
the O 
antioxidant O 
, O 
antibacterial O 
, O 
and O 
anti-inflammatory O 
activities O 
of O 
honey O 
made O 
from O 
different O 
floral O 
sources O 
, O 
including O 
the O 
medicinal O 
herb O 
Bidens O 
pilosa O 
, O 
fruit O 
trees O 
, O 
Dimocarpus O 
longan O 
, O 
Litchi O 
chinensis O 
, O 
and O 
Citrus O 
maxima O 
, O 
the O 
Taiwanese O 
endemic O 
plant O 
Aglaia O 
formosana O 
, O 
and O 
a O 
multifloral O 
forest O 
. O 
The O 
total O 
phenolic B-FAMILY 
and O 
flavonoid B-FAMILY 
contents O 
of O 
the O 
honey O 
made O 
from O 
B O 
. O 
pilosa O 
were O 
significantly O 
higher O 
than O 
those O 
of O 
the O 
other O 
honeys O 
. O 
The O 
honey O 
from O 
B O 
. O 
pilosa O 
also O 
had O 
significantly O 
greater O 
scavenging O 
activities O 
for O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH· B-ABBREVIATION 
) O 
and O 
hydroxyl B-SYSTEMATIC 
radical O 
, O 
and O 
substantially O 
more O 
reducing O 
power O 
. O 
In O 
addition O 
, O 
the O 
honey O 
from O 
B O 
. O 
pilosa O 
showed O 
greater O 
antibacterial O 
activity O 
against O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
However O 
, O 
B O 
. O 
pilosa O 
honey O 
showed O 
little O 
inhibitory O 
activity O 
against O 
IL-8 O 
secretion O 
, O 
whereas O 
the O 
other O 
honeys O 
did O 
. O 
These O 
findings O 
suggest O 
that O 
the O 
levels O 
of O 
antioxidant O 
and O 
antibacterial O 
activities O 
are O 
attributable O 
to O 
the O 
total O 
phenolic B-FAMILY 
and O 
flavonoid B-FAMILY 
contents O 
of O 
honeys O 
, O 
while O 
the O 
IL-8 O 
inhibition O 
is O 
attributable O 
to O 
components O 
other O 
than O 
phenols B-FAMILY 
. O 

spontaneous O 
one O 
- O 
step O 
synthesis O 
of O 
hollow O 
nanocages O 
and O 
nanotubes O 
from O 
spherical O 
and O 
cylindrical O 
micelles O 
based O 
on O 
poly(acrylic B-FAMILY 
acid)-b-polylactide I-FAMILY 
( O 
P(AA)-b-P(LA) B-ABBREVIATION 
) O 
block O 
copolymers O 
( O 
BCPs O 
) O 
has O 
been O 
achieved O 
. O 
This O 
structural O 
reorganization O 
, O 
which O 
occurs O 
simply O 
upon O 
drying O 
of O 
the O 
samples O 
, O 
was O 
elucidated O 
by O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
. O 
We O 
show O 
that O 
it O 
was O 
necessary O 
to O 
use O 
stain O 
- O 
free O 
imaging O 
to O 
examine O 
these O 
nanoscale O 
assemblies O 
, O 
as O 
the O 
hollow O 
nature O 
of O 
the O 
particles O 
was O 
obscured O 
by O 
application O 
of O 
a O 
heavy O 
metal O 
stain O 
. O 
Additionally O 
, O 
the O 
internal O 
topology O 
of O 
the O 
P(AA)-b-P(LA) B-ABBREVIATION 
particles O 
could O 
be O 
tuned O 
by O 
manipulating O 
the O 
drying O 
conditions O 
to O 
give O 
solid O 
or O 
compartmentalized O 
structures O 
. O 
Upon O 
resuspension O 
, O 
these O 
reorganized O 
nanoparticles O 
retain O 
their O 
hollow O 
structure O 
and O 
display O 
significantly O 
enhanced O 
loading O 
of O 
a O 
hydrophobic O 
dye O 
compared O 
to O 
the O 
original O 
solid O 
cylinders O 
. O 

of O 
histidine B-TRIVIAL 
incorporation O 
on O 
buffer O 
capacity O 
and O 
gene O 
transfection O 
efficiency O 
of O 
HPMA B-ABBREVIATION 
-co O 
- O 
oligolysine O 
brush O 
polymers O 
. O 

of O 
the O 
major O 
intracellular O 
barriers O 
to O 
non-viral O 
gene O 
delivery O 
is O 
efficient O 
endosomal O 
escape O 
. O 
The O 
incorporation O 
of O 
histidine B-TRIVIAL 
residues O 
into O 
polymeric O 
constructs O 
has O 
been O 
found O 
to O 
increase O 
endosomal O 
escape O 
via O 
the O 
proton O 
sponge O 
effect O 
. O 
Statistical O 
and O 
diblock O 
copolymers O 
of O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
, O 
oligolysine O 
, O 
and O 
oligohistidine O 
were O 
synthesized O 
via O 
reversible O 
- O 
addition O 
fragmentation O 
chain O 
transfer O 
( O 
RAFT O 
) O 
polymerization O 
, O 
and O 
tested O 
for O 
in O 
vitro O 
transfection O 
efficiency O 
, O 
buffering O 
ability O 
, O 
and O 
polyplex O 
uptake O 
mechanism O 
via O 
the O 
use O 
of O 
chemical O 
endocytic O 
inhibitors O 
. O 
Interestingly O 
, O 
histidine B-TRIVIAL 
-containing O 
statistical O 
and O 
diblock O 
polymers O 
exhibited O 
increased O 
buffer O 
capacity O 
in O 
different O 
endosomal O 
pH O 
ranges O 
. O 
Statistical O 
copolymers O 
transfected O 
better O 
than O 
block O 
copolymers O 
that O 
contained O 
similar O 
amounts O 
of O 
histidine B-TRIVIAL 
. O 
In O 
addition O 
, O 
only O 
the O 
polymer O 
containing O 
the O 
highest O 
incorporation O 
of O 
oligohistidine O 
residues O 
led O 
to O 
increases O 
in O 
transfection O 
efficiency O 
over O 
the O 
HPMA B-ABBREVIATION 
-oligolysine O 
base O 
polymer O 
. O 
Thus O 
, O 
for O 
these O 
polymer O 
architectures O 
, O 
high O 
histidine B-TRIVIAL 
incorporation O 
may O 
be O 
required O 
for O 
efficient O 
endosomal O 
escape O 
. O 
Furthermore O 
, O 
uptake O 
studies O 
indicate O 
that O 
non-acidified O 
caveolae O 
- O 
mediated O 
endocytosis O 
may O 
be O 
the O 
primary O 
route O 
of O 
transfection O 
for O 
these O 
copolymers O 
, O 
suggesting O 
that O 
alternative O 
approaches O 
for O 
increasing O 
endosomal O 
escape O 
may O 
be O 
beneficial O 
for O 
enhancing O 
transfection O 
efficiency O 
with O 
these O 
HPMA B-ABBREVIATION 
-oligolysine O 
copolymers O 
. O 

exposure O 
of O 
juvenile O 
female O 
mice O 
to O 
polyhalogenated O 
seafood O 
contaminants O 
( O 
HBCD B-ABBREVIATION 
, O 
BDE-47 B-ABBREVIATION 
, O 
PCB-153 B-ABBREVIATION 
, O 
TCDD B-ABBREVIATION 
) O 
: O 
Comparative O 
assessment O 
of O 
effects O 
in O 
potential O 
target O 
tissues O 
. O 

represents O 
source O 
of O 
nutrients O 
and O 
major O 
dietary O 
vehicle O 
of O 
lipophilic O 
persistent O 
contaminants O 
. O 
The O 
study O 
compared O 
the O 
effects O 
of O 
two O 
legacy O 
and O 
two O 
emerging O 
fish O 
pollutants O 
( O 
Hexabromocyclododecane B-SYSTEMATIC 
HBCD B-ABBREVIATION 
; O 
2,2',4,4'-Tetrabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
BDE-47 B-ABBREVIATION 
; O 
2,2',4,4',5,5'-Hexachlorobiphenyl B-SYSTEMATIC 
PCB-153 B-ABBREVIATION 
; O 
2,3,7,8-Tetrachlorodibenzo-p-doxin B-SYSTEMATIC 
TCDD B-ABBREVIATION 
) O 
in O 
juvenile O 
female O 
mice O 
exposed O 
through O 
a O 
salmon O 
based O 
rodent O 
diet O 
for O 
28days O 
( O 
dietary O 
doses O 
: O 
HBCD B-ABBREVIATION 
199mg O 
/ O 
kg O 
bw O 
/ O 
day O 
; O 
BDE-47 B-ABBREVIATION 
450μg O 
/ O 
kg O 
bw O 
/ O 
day O 
; O 
PCB-153 B-ABBREVIATION 
195μg O 
/ O 
kg O 
bw O 
/ O 
day O 
; O 
TCDD B-ABBREVIATION 
90ng O 
/ O 
kg O 
bw O 
/ O 
day O 
) O 
. O 
Dose O 
levels O 
were O 
comparable O 
to O 
previously O 
reported O 
developmental O 
Lowest O 
Observed O 
Adverse O 
Effect O 
Levels O 
. O 
None O 
of O 
the O 
treatments O 
elicited O 
signs O 
of O 
overt O 
toxicity O 
, O 
but O 
HBCD B-ABBREVIATION 
increased O 
relative O 
liver O 
weight O 
. O 
All O 
compounds O 
caused O 
changes O 
in O 
liver O 
, O 
thymus O 
and O 
thyroid O 
; O 
spleen O 
was O 
affected O 
by O 
BDE-47 B-ABBREVIATION 
and O 
PCB-153 B-ABBREVIATION 
; O 
no O 
effects O 
were O 
seen O 
in O 
uterus O 
and O 
adrenals O 
. O 
Strongest O 
effects O 
in O 
thyroid O 
follicles O 
were O 
elicited O 
by O 
PCB-153 B-ABBREVIATION 
, O 
in O 
thymus O 
and O 
liver O 
by O 
BDE-47 B-ABBREVIATION 
. O 
HBCD B-ABBREVIATION 
and O 
BDE-47 B-ABBREVIATION 
induced O 
liver O 
fatty O 
changes O 
, O 
but O 
appeared O 
to O 
be O 
less O 
potent O 
in O 
the O 
other O 
tissues O 
. O 
HBCD B-ABBREVIATION 
, O 
BDE-47 B-ABBREVIATION 
and O 
TCDD B-ABBREVIATION 
increased O 
serum O 
testosterone B-TRIVIAL 
levels O 
and O 
the O 
testosterone B-TRIVIAL 
/ O 
estradiol B-TRIVIAL 
ratio O 
, O 
suggesting O 
a O 
potential O 
involvement O 
of O 
pathways O 
related O 
to O 
sex O 
steroid B-FAMILY 
biosynthesis O 
and O 
/ O 
or O 
metabolism O 
. O 
The O 
results O 
support O 
the O 
role O 
of O 
toxicological O 
studies O 
on O 
juvenile O 
rodents O 
in O 
the O 
hazard O 
characterization O 
of O 
chemicals O 
, O 
due O 
to O 
endocrine O 
and O 
/ O 
or O 
immune O 
effects O 
. O 

carbazole B-FAMILY 
alkaloids I-FAMILY 
from O 
Murraya O 
koenigii O 
( O 
L O 
. O 
) O 
Spreng O 
. O 

new O 
carbazole B-FAMILY 
alkaloids I-FAMILY 
( O 
1-4 O 
) O 
and O 
fourteen O 
known O 
carbazole B-FAMILY 
alkaloids I-FAMILY 
( O 
5-18 O 
) O 
were O 
isolated O 
from O 
Murraya O 
koenigii O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
. O 
Compounds O 
4 O 
, O 
6 O 
, O 
16 O 
, O 
and O 
17 O 
( O 
10μM O 
) O 
had O 
moderate O 
hepatoprotective O 
activities O 
against O 
d-galactosamine B-TRIVIAL 
-induced O 
HL-7702 O 
cell O 
damage O 
. O 
Compounds O 
11 O 
, O 
12 O 
and O 
18 O 
showed O 
significant O 
PTP1B O 
inhibitory O 
activity O 
with O 
IC50 O 
values O 
of O 
1.773 O 
, O 
1.875 O 
and O 
2.286μM O 
, O 
respectively O 
. O 

effects O 
of O 
an O 
environmentally O 
relevant O 
58-congener O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
( O 
PCB B-ABBREVIATION 
) O 
mixture O 
on O 
cardiac O 
development O 
in O 
the O 
chick O 
embryo O 
. O 

( O 
Gallus O 
domesticus O 
) O 
embryonic O 
exposure O 
in O 
ovo O 
to O 
a O 
58-congener O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
( O 
PCB B-ABBREVIATION 
) O 
mixture O 
resulted O 
in O 
teratogenic O 
heart O 
defects O 
in O 
chick O 
embryos O 
at O 
critical O 
heart O 
developmental O 
stages O 
Hamburger-Hamilton O 
( O 
HH O 
) O 
stages O 
10 O 
, O 
16 O 
, O 
and O 
20 O 
. O 
The O 
58-congener O 
mixture O 
contained O 
relative O 
proportions O 
of O 
primary O 
congeners O 
measured O 
in O 
belted O 
sandpiper O 
( O 
Megaceryle O 
alcyon O 
) O 
and O 
spotted O 
sandpiper O 
( O 
Actitis O 
macularia O 
) O 
eggs O 
collected O 
along O 
the O 
upper O 
Hudson O 
River O 
, O 
New O 
York O 
, O 
USA O 
, O 
and O 
chicken O 
doses O 
were O 
well O 
below O 
observed O 
environmental O 
exposure O 
levels O 
. O 
Embryos O 
were O 
injected O 
with O 
0.08 O 
µg O 
PCBs B-ABBREVIATION 
/g O 
egg O 
weight O 
and O 
0.5 O 
µg O 
PCBs B-ABBREVIATION 
/g O 
egg O 
weight O 
( O 
0.01 O 
and O 
0.064 O 
ng O 
toxic O 
equivalent O 
/ O 
g O 
, O 
respectively O 
) O 
at O 
embryonic O 
day O 
0 O 
, O 
prior O 
to O 
incubation O 
. O 
Mortality O 
of O 
exposed O 
embryos O 
was O 
increased O 
at O 
all O 
developmental O 
stages O 
, O 
with O 
a O 
marked O 
rise O 
in O 
cardiomyopathies O 
at O 
HH16 O 
and O 
HH20 O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Heart O 
abnormalities O 
occurred O 
across O 
all O 
treatments O 
, O 
including O 
abnormal O 
elongation O 
and O 
expansion O 
of O 
the O 
heart O 
tube O 
at O 
HH10 O 
, O 
improper O 
looping O 
and O 
orientation O 
, O 
indentations O 
in O 
the O 
emerging O 
ventricular O 
wall O 
( O 
HH16 O 
and O 
HH20 O 
) O 
, O 
and O 
irregularities O 
in O 
overall O 
heart O 
shape O 
( O 
HH10 O 
, O 
HH16 O 
, O 
and O 
HH20 O 
) O 
. O 
Histology O 
was O 
conducted O 
on O 
2 O 
cardiac O 
proteins O 
critical O 
to O 
embryonic O 
heart O 
development O 
, O 
ventricular O 
myosin O 
heavy O 
chain O 
and O 
titin O 
, O 
to O 
investigate O 
potential O 
mechanistic O 
effects O 
of O 
PCBs B-ABBREVIATION 
on O 
heart O 
development O 
, O 
but O 
no O 
difference O 
was O 
observed O 
in O 
spatiotemporal O 
expression O 
. O 
Similarly O 
, O 
cellular O 
apoptosis O 
in O 
the O 
developing O 
heart O 
was O 
not O 
affected O 
by O 
exposure O 
to O 
the O 
PCB B-ABBREVIATION 
mixture O 
. O 
Conversely O 
, O 
cardiomyocyte O 
proliferation O 
rates O 
dramatically O 
declined O 
( O 
p O 
< O 
0.01 O 
) O 
at O 
HH16 O 
and O 
HH20 O 
as O 
PCB B-ABBREVIATION 
exposure O 
concentrations O 
increased O 
. O 
Early O 
embryonic O 
cardiomyocyte O 
proliferation O 
contributes O 
to O 
proper O 
formation O 
of O 
the O 
morphology O 
and O 
overall O 
thickness O 
of O 
the O 
ventricular O 
wall O 
. O 
Therefore O 
, O 
in O 
ovo O 
exposure O 
to O 
this O 
58-congener O 
PCB B-ABBREVIATION 
mixture O 
at O 
critical O 
stages O 
adversely O 
affects O 
embryonic O 
heart O 
development O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1317-1324 O 
. O 
© O 
2013 O 
SETAC O 
. O 

the O 
present O 
study O 
a O 
new O 
method O 
has O 
been O 
developed O 
and O 
validated O 
for O 
detecting O 
free O 
microcystins B-FAMILY 
( O 
MCs O 
) O 
( O 
MC-RR B-ABBREVIATION 
, O 
MC-LR B-ABBREVIATION 
and O 
MC-YR B-ABBREVIATION 
) O 
by O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
LC-MS O 
) O 
in O 
the O 
cyprinid O 
Tinca O 
tinca O 
and O 
in O 
the O 
crayfish O 
Procambarus O 
clarkii O 
collected O 
from O 
three O 
ponds O 
in O 
Extremadura O 
( O 
Spain O 
) O 
where O 
the O 
presence O 
of O 
the O 
cyanobacteria O 
species O 
Microcystis O 
aeruginosa O 
and O 
Anabaena O 
spiroides O 
has O 
been O 
confirmed O 
. O 
Once O 
the O 
method O 
had O 
been O 
validated O 
, O 
free O 
MCs O 
were O 
determined O 
in O 
fish O 
( O 
tench O 
, O 
T O 
. O 
tinca O 
) O 
and O 
crayfish O 
from O 
different O 
ponds O 
in O 
order O 
to O 
understand O 
how O 
they O 
are O 
bioaccumulated O 
through O 
the O 
food O 
web O 
. O 
MCs O 
were O 
not O 
detected O 
in O 
any O 
of O 
the O 
fish O 
samples O 
analyzed O 
. O 
It O 
was O 
confirmed O 
that O 
P O 
. O 
clarkii O 
accumulated O 
MCs O 
in O 
their O 
tissues O 
without O 
losing O 
their O 
organoleptic O 
characteristics O 
, O 
with O 
MC-LR B-ABBREVIATION 
( O 
2.3-18.1μg O 
MC-LR B-ABBREVIATION 
/g O 
body O 
weight O 
) O 
being O 
the O 
predominant O 
MC O 
variant O 
detected O 
in O 
all O 
the O 
crayfish O 
samples O 
. O 
MC-RR B-ABBREVIATION 
was O 
measured O 
in O 
50% O 
of O 
the O 
samples O 
analyzed O 
, O 
ranging O 
between O 
1.4 O 
and O 
7.8μg O 
MC-RR B-ABBREVIATION 
/g O 
body O 
weight O 
and O 
no O 
MC-YR B-ABBREVIATION 
was O 
detected O 
. O 
The O 
results O 
indicated O 
that O 
crayfish O 
can O 
accumulate O 
free O 
MCs O 
in O 
higher O 
quantities O 
than O 
tench O 
that O 
live O 
in O 
ponds O 
contaminated O 
by O 
toxic O 
cyanobacteria O 
species O 
, O 
and O 
emphasized O 
the O 
need O 
for O 
regular O 
monitoring O 
if O 
the O 
health O 
risks O 
associated O 
with O 
their O 
consumption O 
are O 
to O 
be O 
avoided O 
. O 

evaluation O 
of O 
oral O 
and O 
dermal O 
cypermethrin B-TRIVIAL 
exposure O 
on O 
antioxidant O 
profile O 
in O 
Bubalus O 
bubalis O 
. O 

, O 
a O 
type O 
II O 
synthetic O 
pyrethroid B-FAMILY 
insecticide O 
, O 
@ O 
0.5mg O 
/ O 
kg O 
/ O 
day O 
for O 
14 O 
consecutive O 
weeks O 
produced O 
mild O 
signs O 
of O 
toxicity O 
in O 
buffalo O 
calves O 
. O 
Significant O 
changes O 
were O 
observed O 
in O 
various O 
antioxidant O 
parameters O 
in O 
blood O 
. O 
There O 
was O 
a O 
marked O 
increase O 
in O 
the O 
extent O 
of O 
lipid O 
peroxidation O 
( O 
33.9% O 
) O 
and O 
enzymic O 
activity O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
6.7% O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
35.0% O 
) O 
, O 
catalase O 
( O 
43.7% O 
) O 
, O 
glutathione B-TRIVIAL 
-S-transferase O 
( O 
64.4% O 
) O 
, O 
glutathione B-TRIVIAL 
reductase O 
( O 
36.7% O 
) O 
and O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
( O 
32.1% O 
) O 
. O 
A O 
significant O 
decrease O 
in O 
blood O 
glutathione B-TRIVIAL 
( O 
16.7% O 
) O 
, O 
total O 
antioxidant O 
activity O 
( O 
45.4% O 
) O 
and O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
40.8% O 
) O 
was O 
observed O 
and O 
no O 
significant O 
effect O 
was O 
found O 
on O 
blood O 
selenium B-SYSTEMATIC 
levels O 
. O 
However O 
, O 
the O 
extent O 
of O 
lipid O 
peroxidation O 
( O 
42% O 
) O 
and O 
the O 
depletion O 
of O 
glutathione B-TRIVIAL 
( O 
28.8% O 
) O 
was O 
greater O 
after O 
dermal O 
sub O 
- O 
acute O 
toxicity O 
of O 
cypermethrin B-TRIVIAL 
( O 
0.25% O 
) O 
for O 
14 O 
consecutive O 
days O 
. O 
Similarly O 
, O 
it O 
was O 
observed O 
that O 
the O 
incline O 
in O 
the O 
enzymic O 
activity O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
29.7% O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
38.3% O 
) O 
and O 
glutathione B-TRIVIAL 
reductase O 
( O 
38.3% O 
) O 
was O 
higher O 
in O 
dermally O 
cypermethrin B-TRIVIAL 
exposed O 
animals O 
. O 
Thus O 
, O 
the O 
present O 
investigation O 
contemplates O 
that O 
oxidative O 
stress O 
is O 
the O 
important O 
mechanisms O 
involved O 
in O 
cypermethrin B-TRIVIAL 
-induced O 
toxicity O 
and O 
the O 
oxidative O 
insult O 
produced O 
by O 
dermal O 
route O 
is O 
more O 
severe O 
as O 
compared O 
to O 
oral O 
intoxication O 
. O 

of O 
cytotoxicity O 
of O 
nickel B-SYSTEMATIC 
by O 
quercetin B-TRIVIAL 
: O 
the O 
role O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
histone O 
acetylation O 
. O 

exposure O 
to O 
nickel B-SYSTEMATIC 
may O 
cause O 
health O 
effects O 
on O 
the O 
blood O 
, O 
lung O 
, O 
nose O 
, O 
kidney O 
, O 
reproductive O 
system O 
, O 
skin O 
and O 
the O 
unborn O 
child O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
found O 
that O 
Ni(2+) B-FORMULA 
exposure O 
led O 
to O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
proliferation O 
arrest O 
and O 
death O 
in O 
human O 
leukemia O 
HL-60 O 
cells O 
. O 
In O 
the O 
presence O 
of O 
1 O 
mM O 
Ni(2+) B-FORMULA 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
( O 
indicated O 
by O 
the O 
level O 
of O 
malondialdehyde B-TRIVIAL 
) O 
increased O 
to O 
323% O 
and O 
histone O 
acetylation O 
decreased O 
to O 
32% O 
. O 
Interestingly O 
, O 
quercetin B-TRIVIAL 
( O 
QU O 
) O 
dose O 
dependently O 
prevented O 
Ni(2+) B-FORMULA 
-induced O 
cell O 
proliferation O 
arrest O 
and O 
death O 
from O 
0 O 
to O 
80 O 
μM O 
but O 
showed O 
similar O 
activity O 
of O 
scavenging O 
ROS O 
at O 
the O 
concentrations O 
of O 
20 O 
, O 
40 O 
and O 
80 O 
µM O 
. O 
When O 
the O 
effect O 
of O 
QU O 
on O 
histone O 
acetylation O 
was O 
studied O 
, O 
QU O 
significantly O 
prevented O 
Ni(2+) B-FORMULA 
-induced O 
histone O 
hypoacetylation O 
at O 
40 O 
or O 
80 O 
µM O 
. O 
Moreover O 
, O 
increase O 
in O 
histone O 
acetylation O 
by O 
trichostatin B-TRIVIAL 
A I-TRIVIAL 
could O 
also O 
significantly O 
enhance O 
the O 
protection O 
effect O 
of O 
QU O 
at O 
10 O 
or O 
20 O 
µM O 
but O 
not O 
at O 
higher O 
concentrations O 
. O 
Thus O 
, O 
our O 
results O 
further O 
confirmed O 
the O 
critical O 
role O 
of O 
ROS O 
and O 
histone O 
hypoacetylation O 
in O 
the O 
cytotoxicity O 
of O 
Ni(2+) B-FORMULA 
exposure O 
and O 
proved O 
that O 
QU O 
is O 
a O 
potentially O 
useful O 
native O 
dietary O 
compound O 
to O 
efficiently O 
prevent O 
Ni(2+) B-FORMULA 
-caused O 
cytotoxicity O 
through O 
both O 
diminishing O 
ROS O 
generation O 
and O 
increasing O 
histone O 
acetylation O 
. O 

the O 
roles O 
of O 
the O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-flanking O 
residues O 
of O 
acetyllysine B-SYSTEMATIC 
substrates O 
for O 
SIRT1 O 
activity O 
. O 

specificity O 
: O 
The O 
multispecific O 
SIRT1 O 
enzyme O 
catalyzes O 
the O 
deacetylation O 
of O 
acetyllysine B-SYSTEMATIC 
residues O 
within O 
protein O 
targets O 
. O 
However O 
, O 
little O 
is O 
known O 
regarding O 
the O 
molecular O 
basis O 
for O 
SIRT1 O 
substrate O 
recognition O 
. O 
Kinetic O 
analysis O 
of O 
SIRT1 O 
with O 
a O 
panel O 
of O 
peptide O 
substrates O 
shows O 
the O 
high O 
importance O 
of O 
the O 
region O 
N B-FORMULA 
-flanking O 
the O 
target O 
acetyllysine B-SYSTEMATIC 
and O 
its O 
high O 
conservation O 
through O 
evolution O 
. O 

from O 
Incarvillea O 
arguta O 
. O 

new O 
monoterpenoid B-FAMILY 
, O 
(+)-argutoid B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
three O 
new O 
iridoids B-FAMILY 
, O 
( B-TRIVIAL 
- I-TRIVIAL 
)-incarvoid I-TRIVIAL 
A I-TRIVIAL 
( O 
2 O 
) O 
, O 
(+)-incarvoid B-TRIVIAL 
B I-TRIVIAL 
( O 
3 O 
) O 
, O 
and O 
incarvoid B-TRIVIAL 
C I-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
five O 
known O 
compounds O 
were O 
isolated O 
from O 
Incarvillea O 
arguta O 
. O 
Their O 
structures O 
were O 
characterized O 
by O 
means O 
of O 
spectroscopic O 
methods O 
. O 

disruptive O 
potential O 
of O 
endosulfan B-TRIVIAL 
on O 
the O 
reproductive O 
axis O 
of O 
Cichlasoma O 
dimerus O 
( O 
Perciformes O 
, O 
Cichlidae O 
) O 
. O 

( O 
ES O 
) O 
, O 
a O 
persistent O 
organochlorine B-FAMILY 
pesticide O 
, O 
is O 
widely O 
used O 
despite O 
its O 
toxicity O 
to O 
non-target O 
animals O 
. O 
Upon O 
reaching O 
water O 
bodies O 
, O 
ES O 
can O 
cause O 
negative O 
effects O 
on O 
aquatic O 
animals O 
, O 
including O 
disruption O 
of O 
hormonal O 
systems O 
. O 
However O 
, O 
the O 
action O 
of O 
ES O 
on O 
fish O 
reproductive O 
axis O 
has O 
been O 
hardly O 
studied O 
thus O 
far O 
. O 
The O 
aim O 
of O 
the O 
present O 
work O 
was O 
to O 
assess O 
the O 
endocrine O 
disruptive O 
potential O 
of O 
endosulfan B-TRIVIAL 
on O 
the O 
pituitary O 
gonadotropins O 
levels O 
and O 
on O 
the O 
testes O 
function O 
due O 
to O 
ES O 
in O 
the O 
South O 
American O 
freshwater O 
fish O 
Cichlasoma O 
dimerus O 
, O 
using O 
in O 
vitro O 
and O 
in O 
vivo O 
approaches O 
. O 
In O 
vitro O 
experiments O 
showed O 
that O 
ES O 
inhibited O 
the O 
LH-stimulated O 
steroidogenesis O 
in O 
gonads O 
; O 
no O 
change O 
was O 
observed O 
in O 
gonadotropins O 
release O 
from O 
pituitaries O 
in O 
culture O 
. O 
Laboratory O 
waterborne O 
ES O 
( O 
0.1 O 
, O 
0.3 O 
and O 
1 O 
μg O 
/ O 
L O 
) O 
exposure O 
for O 
two O 
months O 
caused O 
decrease O 
in O 
βFSH O 
pituitary O 
content O 
and O 
γGT O 
activity O 
in O 
the O 
testes O 
( O 
Sertoli O 
cell O 
function O 
marker O 
) O 
. O 
Testicular O 
histology O 
revealed O 
pathologies O 
such O 
as O 
scarce O 
intermediate O 
stages O 
of O 
spermatogenesis O 
, O 
release O 
of O 
immature O 
germ O 
cells O 
into O 
the O 
lobular O 
lumen O 
, O 
presence O 
of O 
foam O 
cells O 
and O 
interstitial O 
fibrosis O 
. O 
As O 
FSH O 
and O 
FSH O 
- O 
mediated O 
steroidogenesis O 
regulate O 
spermatogenesis O 
and O 
Sertoli O 
cell O 
function O 
, O 
the O 
effect O 
of O 
ES O 
on O 
FSH O 
could O 
be O 
responsible O 
for O 
the O 
morphological O 
alterations O 
observed O 
in O 
testes O 
. O 
In O 
vitro O 
, O 
ES O 
disrupted O 
steroidogenesis O 
in O 
gonads O 
, O 
therefore O 
similar O 
effects O 
in O 
vivo O 
cannot O 
be O 
ruled O 
out O 
. O 
Based O 
on O 
this O 
evidence O 
, O 
ES O 
exhibits O 
an O 
endocrine O 
disruptive O 
action O 
on O 
the O 
reproductive O 
axis O 
of O 
C O 
. O 
dimerus O 
, O 
causing O 
disruption O 
at O 
the O 
pituitary O 
and O 
/ O 
or O 
at O 
the O 
gonad O 
level O 
. O 
These O 
effects O 
could O 
acquire O 
ecological O 
significance O 
under O 
prolonged O 
exposure O 
to O 
the O 
pesticide O 
in O 
nature O 
. O 

the O 
pharmacokinetics O 
of O 
doxylamine B-TRIVIAL 
/ O 
pyridoxine B-TRIVIAL 
delayed O 
- O 
release O 
combination O 
in O 
nonpregnant O 
women O 
of O 
reproductive O 
age O 
and O 
women O 
in O 
the O 
first O 
trimester O 
of O 
pregnancy O 
. O 

Diclectin B-TRIVIAL 
( O 
doxylamine B-TRIVIAL 
/ O 
pyridoxine B-TRIVIAL 
delayed O 
- O 
released O 
combination O 
) O 
is O 
widely O 
used O 
in O 
Canada O 
, O 
its O 
pharmacokinetics O 
( O 
PK O 
) O 
during O 
pregnancy O 
has O 
never O 
been O 
described O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
compare O 
the O 
PK O 
of O 
doxylamine B-TRIVIAL 
/ O 
pyridoxine B-TRIVIAL 
delayed O 
- O 
released O 
combination O 
in O 
pregnant O 
versus O 
nonpregnant O 
women O 
. O 
The O 
apparent O 
clearances O 
( O 
CL O 
) O 
of O 
doxylamine B-TRIVIAL 
and O 
pyridoxal B-SYSTEMATIC 
5'-phosphate I-SYSTEMATIC 
( O 
PLP B-ABBREVIATION 
; O 
the O 
active O 
metabolite O 
of O 
vitamin B-TRIVIAL 
B(6) I-TRIVIAL 
) O 
during O 
the O 
first O 
- O 
trimester O 
pregnancy O 
in O 
women O 
who O 
participated O 
in O 
a O 
Diclectin B-TRIVIAL 
randomized O 
trial O 
were O 
compared O 
with O 
those O 
of O 
healthy O 
, O 
adult O 
, O 
nonpregnant O 
women O 
who O 
participated O 
in O 
a O 
voluntary O 
PK O 
trial O 
. O 
Eighteen O 
nonpregnant O 
women O 
were O 
compared O 
with O 
50 O 
pregnant O 
women O 
who O 
were O 
treated O 
with O 
Diclectin B-TRIVIAL 
. O 
There O 
was O 
no O 
difference O 
in O 
the O 
apparent O 
CL O 
of O 
doxylamine B-TRIVIAL 
in O 
women O 
in O 
their O 
first O 
trimester O 
of O 
pregnancy O 
when O 
compared O 
with O 
nonpregnant O 
women O 
on O 
day O 
4 O 
( O 
median O 
= O 
196.7 O 
vs O 
249.5 O 
mL O 
/ O 
h O 
/ O 
kg O 
, O 
respectively O 
, O 
P O 
= O 
0.065 O 
) O 
, O 
day O 
8 O 
( O 
median O 
= O 
248.4 O 
vs O 
249.5 O 
mL O 
/ O 
h O 
/ O 
kg O 
, O 
respectively O 
, O 
P O 
= O 
0.82 O 
) O 
, O 
and O 
day O 
15 O 
( O 
median O 
= O 
200.9 O 
vs O 
249.5 O 
mL O 
/ O 
h O 
/ O 
kg O 
, O 
respectively O 
, O 
P O 
= O 
0.55 O 
) O 
. O 
No O 
difference O 
was O 
found O 
in O 
the O 
apparent O 
CL O 
of O 
PLP O 
on O 
day O 
15 O 
( O 
median O 
= O 
342.3 O 
vs O 
314.7 O 
mL O 
/ O 
h O 
/ O 
kg O 
, O 
respectively O 
, O 
P O 
= O 
0.92 O 
) O 
. O 
There O 
was O 
no O 
pregnancy O 
- O 
induced O 
effect O 
in O 
the O 
apparent O 
CL O 
of O 
either O 
doxylamine B-TRIVIAL 
or O 
PLP B-ABBREVIATION 
in O 
women O 
during O 
the O 
first O 
trimester O 
of O 
pregnancy O 
despite O 
the O 
existence O 
of O 
morning O 
sickness O 
. O 

Mechanisms O 
in O 
the O 
Pyrolysis O 
of O 
Unsaturated B-FAMILY 
Chlorinated I-FAMILY 
Hydrocarbons I-FAMILY 
: O 
Formation O 
of O 
Benzene B-SYSTEMATIC 
Rings O 
Part O 
II O 
- O 
Experimental O 
and O 
Kinetic O 
Modeling O 
Studies O 
. O 

mechanism O 
of O 
formation O 
of O 
benzene B-SYSTEMATIC 
rings O 
during O 
the O 
pyrolysis O 
of O 
dichloro- B-MULTIPLE 
and I-MULTIPLE 
trichloroethylene I-MULTIPLE 
has O 
been O 
investigated O 
by O 
the O 
method O 
of O 
Laser O 
Powered O 
Homogeneous O 
Pyrolysis O 
coupled O 
with O 
product O 
analysis O 
by O 
gas O 
chromatography O 
. O 
Additionally O 
, O 
selected O 
(co)-pyrolyses O 
between O 
the O 
chlorinated B-FAMILY 
ethylenes I-FAMILY 
, O 
CH2Cl2 B-FORMULA 
, O 
C4Cl4 B-FORMULA 
, O 
C4Cl6 B-FORMULA 
, O 
and O 
C2H2 B-FORMULA 
have O 
been O 
performed O 
to O 
explicitly O 
probe O 
the O 
roles O 
of O 
2C3 B-FORMULA 
and O 
C4 B-FORMULA 
/ O 
C2 B-FORMULA 
reaction O 
pairs O 
in O 
aromatic O 
growth O 
. O 
The O 
presence O 
of O 
odd- O 
carbon B-SYSTEMATIC 
products O 
in O 
neat O 
C4Cl6 B-FORMULA 
pyrolyses O 
indicates O 
2C3 B-FORMULA 
processes O 
are O 
operative O 
in O 
these O 
systems O 
; O 
however O 
, O 
comparison O 
with O 
product O 
yields O 
from O 
C2HCl3 B-FORMULA 
suggests O 
C4 B-FORMULA 
/ O 
C2 B-FORMULA 
processes O 
dominate O 
most O 
other O 
systems O 
. O 
This O 
is O 
further O 
evidenced O 
by O 
an O 
absence O 
of O 
C3 B-FORMULA 
and O 
other O 
odd- O 
carbon B-SYSTEMATIC 
species O 
in O 
(co)-pyrolyses O 
with O 
dichloromethane B-SYSTEMATIC 
which O 
should O 
seed O 
C3 B-FORMULA 
-based O 
growth O 
. O 
The O 
reactions O 
of O 
perchlorinated B-FORMULA 
C4 I-FORMULA 
species O 
C4Cl5 B-FORMULA 
, O 
C4Cl3 B-FORMULA 
, O 
and O 
C4Cl4 B-FORMULA 
with O 
C2Cl2 B-FORMULA 
were O 
subsequently O 
explored O 
through O 
extensive O 
kinetic O 
simulations O 
of O 
the O 
possible O 
reaction O 
pathways O 
based O 
on O 
previous O 
kinetic O 
models O 
and O 
the O 
exhaustive O 
quantum O 
chemical O 
investigations O 
of O 
our O 
preceding O 
work O 
. O 
The O 
experimental O 
and O 
theoretical O 
results O 
strongly O 
suggest O 
that O 
, O 
at O 
moderate O 
temperatures O 
, O 
aromatic O 
ring O 
formation O 
from O 
chlorinated B-FAMILY 
ethylenes I-FAMILY 
normally O 
follows O 
a O 
Diels-Alder O 
coupling O 
of O 
C4 B-FORMULA 
and O 
C2 B-FORMULA 
molecular O 
units O 
followed O 
by O 
internal O 
shifts O 
; O 
the O 
one O 
exception O 
is O 
the O 
C4Cl4 B-FORMULA 
+ O 
C2Cl2 B-FORMULA 
system O 
, O 
where O 
steric O 
factors O 
lead O 
to O 
the O 
formation O 
of O 
non-aromatic O 
products O 
. O 
There O 
is O 
little O 
evidence O 
for O 
radical O 
- O 
based O 
routes O 
in O 
these O 
systems O 
. O 

mutations O 
of O 
the O 
critical O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
for O 
the O 
sweetness O 
of O 
the O 
sweet O 
- O 
tasting O 
protein O 
, O 
brazzein O 
. O 

have O 
previously O 
identified O 
critical O 
residues O 
important O 
for O 
sweetness O 
of O 
the O 
sweet O 
protein O 
brazzein O 
by O 
site O 
- O 
directed O 
mutagenesis O 
( O 
Yoon O 
, O 
Kong O 
, O 
Jo O 
, O 
& O 
Kong O 
, O 
2011 O 
) O 
. O 
In O 
order O 
to O 
elucidate O 
the O 
interaction O 
mechanisms O 
of O 
brazzein O 
with O 
the O 
sweet O 
taste O 
receptor O 
, O 
we O 
made O 
multiple O 
mutations O 
of O 
three O 
residues O 
( O 
His B-FORMULA 
31 O 
in O 
loop O 
30-33 O 
, O 
Glu B-FORMULA 
36 O 
in O 
β-strand O 
III O 
, O 
and O 
Glu B-FORMULA 
41 O 
in O 
loop O 
40-43 O 
) O 
. O 
We O 
found O 
that O 
all O 
double O 
mutations O 
( O 
H31R O 
/ O 
E36D O 
, O 
H31R O 
/ O 
E41A O 
and O 
E36D O 
/ O 
E41A O 
) O 
made O 
the O 
molecules O 
sweeter O 
than O 
des-pE1M-brazzein O 
and O 
three O 
single O 
mutants O 
. O 
Moreover O 
, O 
the O 
triple O 
mutation O 
( O 
H31R O 
/ O 
E36D O 
/ O 
E41A O 
) O 
made O 
the O 
molecule O 
significantly O 
sweeter O 
than O 
three O 
double O 
mutants O 
. O 
These O 
results O 
strongly O 
support O 
the O 
hypothesis O 
that O 
brazzein O 
binds O 
to O 
the O 
multisite O 
surface O 
of O 
the O 
sweet O 
taste O 
receptor O 
. O 
Our O 
findings O 
also O 
suggest O 
that O 
mutations O 
reducing O 
the O 
overall O 
negative O 
charge O 
and O 
/ O 
or O 
increasing O 
the O 
positive O 
charge O 
favour O 
sweet O 
- O 
tasting O 
protein O 
potency O 
. O 

of O 
glycogen O 
synthase O 
kinase-3 O 
ameliorates O 
β-amyloid O 
pathology O 
and O 
restores O 
lysosomal O 
acidification O 
and O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
activity O 
in O 
the O 
Alzheimer O 
disease O 
mouse O 
model O 
: O 
in O 
vivo O 
and O 
in O 
vitro O 
studies O 
. O 

of O 
β-amyloid O 
( O 
Aβ O 
) O 
deposits O 
is O 
a O 
primary O 
pathological O 
feature O 
of O 
Alzheimer O 
disease O 
that O 
is O 
correlated O 
with O 
neurotoxicity O 
and O 
cognitive O 
decline O 
. O 
The O 
role O 
of O 
glycogen O 
synthase O 
kinase-3 O 
( O 
GSK-3 O 
) O 
in O 
Alzheimer O 
disease O 
pathogenesis O 
has O 
been O 
debated O 
. O 
To O 
study O 
the O 
role O 
of O 
GSK-3 O 
in O 
Aβ O 
pathology O 
, O 
we O 
used O 
5XFAD O 
mice O 
co O 
- O 
expressing O 
mutated O 
amyloid O 
precursor O 
protein O 
and O 
presenilin-1 O 
that O 
develop O 
massive O 
cerebral O 
Aβ O 
loads O 
. O 
Both O 
GSK-3 O 
isozymes O 
( O 
α O 
/ O 
β O 
) O 
were O 
hyperactive O 
in O 
this O 
model O 
. O 
Nasal O 
treatment O 
of O 
5XFAD O 
mice O 
with O 
a O 
novel O 
substrate O 
competitive O 
GSK-3 O 
inhibitor O 
, O 
L803-mts O 
, O 
reduced O 
Aβ O 
deposits O 
and O 
ameliorated O 
cognitive O 
deficits O 
. O 
Analyses O 
of O 
5XFAD O 
hemi O 
- O 
brain O 
samples O 
indicated O 
that O 
L803-mts O 
restored O 
the O 
activity O 
of O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
and O 
inhibited O 
autophagy O 
. O 
Lysosomal O 
acidification O 
was O 
impaired O 
in O 
the O 
5XFAD O 
brains O 
as O 
indicated O 
by O 
reduced O 
cathepsin O 
D O 
activity O 
and O 
decreased O 
N B-FORMULA 
-glycoyslation O 
of O 
the O 
vacuolar O 
ATPase O 
subunit O 
V0a1 O 
, O 
a O 
modification O 
required O 
for O 
lysosomal O 
acidification O 
. O 
Treatment O 
with O 
L803-mts O 
restored O 
lysosomal O 
acidification O 
in O 
5XFAD O 
brains O 
. O 
Studies O 
in O 
SH-SY5Y O 
cells O 
confirmed O 
that O 
GSK-3α O 
and O 
GSK-3β O 
impair O 
lysosomal O 
acidification O 
and O 
that O 
treatment O 
with O 
L803-mts O 
enhanced O 
the O 
acidic O 
lysosomal O 
pool O 
as O 
demonstrated O 
in O 
LysoTracker O 
Red O 
- O 
stained O 
cells O 
. O 
Furthermore O 
, O 
L803-mts O 
restored O 
impaired O 
lysosomal O 
acidification O 
caused O 
by O 
dysfunctional O 
presenilin-1 O 
. O 
We O 
provide O 
evidence O 
that O 
mTOR O 
is O 
a O 
target O 
activated O 
by O 
GSK-3 O 
but O 
inhibited O 
by O 
impaired O 
lysosomal O 
acidification O 
and O 
elevation O 
in O 
amyloid O 
precursor O 
protein O 
/ O 
Aβ O 
loads O 
. O 
Taken O 
together O 
, O 
our O 
data O 
indicate O 
that O 
GSK-3 O 
is O 
a O 
player O 
in O 
Aβ O 
pathology O 
. O 
Inhibition O 
of O 
GSK-3 O 
restores O 
lysosomal O 
acidification O 
that O 
in O 
turn O 
enables O 
clearance O 
of O 
Aβ O 
burdens O 
and O 
reactivation O 
of O 
mTOR O 
. O 
These O 
changes O 
facilitate O 
amelioration O 
in O 
cognitive O 
function O 
. O 

Dieckmann O 
cyclization O 
reactions O 
may O 
be O 
used O 
on O 
oxazolidine B-SYSTEMATIC 
and O 
thiazolidine B-SYSTEMATIC 
templates O 
derived O 
from O 
various O 
aldehydes B-FAMILY 
to O 
access O 
bicyclic O 
tetramates O 
, O 
which O 
have O 
potential O 
as O 
templates O 
for O 
chemical O 
library O 
construction O 
. O 
Bioassay O 
against O 
Staphylococcus O 
aureus O 
and O 
Escherichia O 
coli O 
showed O 
that O 
these O 
systems O 
have O 
little O 
or O 
no O 
intrinsic O 
antibacterial O 
bioactivity O 
. O 

Interactions O 
of O 
C B-FORMULA 
-Terminal O 
Peptides O 
from O 
Human O 
Thrombin O 
. O 

with O 
bacterial O 
lipopolysaccharide O 
( O 
LPS O 
) O 
, O 
both O 
in O 
aqueous O 
solution O 
and O 
in O 
lipid O 
membranes O 
, O 
were O 
investigated O 
for O 
a O 
series O 
of O 
amphiphilic O 
peptides O 
derived O 
from O 
the O 
C B-FORMULA 
-terminal O 
region O 
of O 
human O 
thrombin O 
, O 
using O 
ellipsometry O 
, O 
dual O 
polarization O 
interferometry O 
, O 
fluorescence O 
spectroscopy O 
, O 
circular O 
dichroism O 
( O 
CD O 
) O 
, O 
dynamic O 
light O 
scattering O 
, O 
and O 
z-potential O 
measurements O 
. O 
The O 
ability O 
of O 
these O 
peptides O 
to O 
block O 
endotoxic O 
effects O 
caused O 
by O 
LPS O 
, O 
monitored O 
through O 
NO B-FORMULA 
production O 
in O 
macrophages O 
, O 
was O 
compared O 
to O 
peptide O 
binding O 
to O 
LPS O 
and O 
its O 
endotoxic O 
component O 
lipid O 
A O 
, O 
and O 
to O 
size O 
, O 
charge O 
, O 
and O 
secondary O 
structure O 
of O 
peptide O 
/ O 
LPS O 
complexes O 
. O 
While O 
the O 
antiendotoxic O 
peptide O 
GKY25 O 
( O 
GKYGFYTHVFRLKKWIQKVIDQFGE O 
) O 
displayed O 
significant O 
binding O 
to O 
both O 
LPS O 
and O 
lipid O 
A O 
, O 
so O 
did O 
two O 
control O 
peptides O 
with O 
either O 
selected O 
D-amino B-FAMILY 
acid I-FAMILY 
substitutions O 
or O 
with O 
maintained O 
composition O 
but O 
scrambled O 
sequence O 
, O 
both O 
displaying O 
strongly O 
attenuated O 
antiendotoxic O 
effects O 
. O 
Hence O 
, O 
the O 
extent O 
of O 
LPS O 
or O 
lipid O 
A O 
binding O 
is O 
not O 
the O 
sole O 
discriminant O 
for O 
the O 
antiendotoxic O 
effect O 
of O 
these O 
peptides O 
. O 
In O 
contrast O 
, O 
helix O 
formation O 
in O 
peptide O 
/ O 
LPS O 
complexes O 
correlates O 
to O 
the O 
antiendotoxic O 
effect O 
of O 
these O 
peptides O 
and O 
is O 
potentially O 
linked O 
to O 
this O 
functionality O 
. O 
Preferential O 
binding O 
to O 
LPS O 
over O 
lipid O 
membrane O 
was O 
furthermore O 
demonstrated O 
for O 
these O 
peptides O 
and O 
preferential O 
binding O 
to O 
the O 
lipid O 
A O 
moiety O 
within O 
LPS O 
inferred O 
. O 

diarylheptanoids B-FAMILY 
from O 
Alnus O 
hirsuta O 
f O 
. O 
sibirica O 
on O 
3T3-L1 O 
cells O 
. O 

new O 
diarylheptanoid B-FAMILY 
, O 
(5S)-hydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-hepta-1E-en-3-one B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
was O 
isolated O 
along O 
with O 
seventeen O 
known O 
diarylheptanoids B-FAMILY 
( O 
2-18 O 
) O 
from O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
Alnus O 
hirsuta O 
f O 
. O 
sibirica O 
leaves O 
using O 
bioactivity O 
- O 
guided O 
fractionation O 
. O 
Among O 
the O 
isolated O 
compounds O 
, O 
compounds O 
1 O 
and O 
2 O 
and O 
4-12 O 
reduced O 
lipid O 
accumulation O 
dose O 
- O 
dependently O 
in O 
3T3-L1 O 
preadipocytes O 
. O 
Of O 
the O 
compounds O 
active O 
in O 
the O 
present O 
assay O 
system O 
, O 
the O 
most O 
potent O 
compound O 
7 O 
, O 
platyphyllonol-5-O-β-d-xylopyranoside B-SYSTEMATIC 
, O 
significantly O 
suppressed O 
the O 
induction O 
of O 
peroxisome O 
proliferator O 
activated O 
receptor O 
γ O 
( O 
PPARγ O 
and O 
CCAAT O 
/ O 
enhancer O 
binding O 
protein O 
α O 
( O 
C O 
/ O 
EBPα O 
) O 
protein O 
expression O 
, O 
and O 
inhibited O 
adipocyte O 
differentiation O 
induced O 
by O 
troglitazone B-TRIVIAL 
, O 
a O 
PPARγ O 
agonist O 
. O 
It O 
was O 
demonstrated O 
that O 
compound O 
7 O 
has O 
anti-adipogenic O 
activity O 
mediated O 
by O 
the O 
regulation O 
of O 
PPARγ O 
dependent O 
pathways O 
. O 

C B-FORMULA 
-terminal O 
extended O 
serine B-TRIVIAL 
residue O 
is O 
absolutely O 
required O 
in O 
nosiheptide B-TRIVIAL 
maturation O 
. O 

qua O 
non O 
: O 
Substitution O 
of O 
the O 
extended O 
Ser B-FORMULA 
13 O 
in O 
the O 
core O 
peptide O 
of O 
nosiheptide B-TRIVIAL 
by O 
analogous O 
amino B-FAMILY 
acids I-FAMILY 
prevented O 
enamide B-SYSTEMATIC 
dealkylation O 
of O 
the O 
terminal O 
residue O 
for O 
nosiheptide B-TRIVIAL 
maturation O 
. O 

promote O 
prostate O 
cancer O 
cell O 
growth O 
through O 
induction O 
of O 
autophagy O 
. O 

regulate O 
both O 
the O 
physiological O 
development O 
of O 
the O 
prostate O 
and O 
the O 
pathology O 
of O 
prostatic O 
diseases O 
. O 
However O 
, O 
the O 
mechanisms O 
by O 
which O 
androgens B-FAMILY 
exert O 
their O 
regulatory O 
activities O 
on O 
these O 
processes O 
are O 
poorly O 
understood O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
determined O 
that O 
androgens B-FAMILY 
regulate O 
overall O 
cell O 
metabolism O 
and O 
cell O 
growth O 
, O 
in O 
part O 
, O 
by O 
increasing O 
autophagy O 
in O 
prostate O 
cancer O 
cells O 
. O 
Importantly O 
, O 
inhibition O 
of O 
autophagy O 
using O 
either O 
pharmacological O 
or O 
molecular O 
inhibitors O 
significantly O 
abrogated O 
androgen B-FAMILY 
-induced O 
prostate O 
cancer O 
cell O 
growth O 
. O 
Mechanistically O 
, O 
androgen B-FAMILY 
-mediated O 
autophagy O 
appears O 
to O 
promote O 
cell O 
growth O 
by O 
augmenting O 
intracellular O 
lipid O 
accumulation O 
, O 
an O 
effect O 
previously O 
demonstrated O 
to O 
be O 
necessary O 
for O 
prostate O 
cancer O 
cell O 
growth O 
. O 
Further O 
, O 
autophagy O 
and O 
subsequent O 
cell O 
growth O 
is O 
potentiated O 
, O 
in O 
part O 
, O 
by O 
androgen B-FAMILY 
-mediated O 
increases O 
in O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
These O 
findings O 
demonstrate O 
a O 
role O 
for O 
increased O 
fat O 
metabolism O 
and O 
autophagy O 
in O 
prostatic O 
neoplasias O 
and O 
highlight O 
the O 
potential O 
of O 
targeting O 
underexplored O 
metabolic O 
pathways O 
for O 
the O 
development O 
of O 
novel O 
therapeutics O 
. O 

Investigations O 
of O 
Substituted O 
Triarylamines B-FAMILY 
and O 
Their O 
Applications O 
as O 
Fluorescent O 
pH O 
Sensors O 
. O 

triphenylamine B-SYSTEMATIC 
derivatives O 
functionalized O 
with O 
fluorophenyl B-SYSTEMATIC 
, O 
methoxyphenyl B-SYSTEMATIC 
, O 
and O 
pyridinyl B-SYSTEMATIC 
groups O 
as O 
respective O 
donors O 
and O 
acceptors O 
were O 
synthesized O 
and O 
characterized O 
. O 
Their O 
photophysical O 
properties O 
were O 
systematically O 
investigated O 
in O 
various O 
solvents O 
with O 
different O 
polarities O 
. O 
The O 
solvent-dependent O 
Stokes O 
shifts O 
of O 
these O 
compounds O 
were O 
observed O 
and O 
analyzed O 
by O 
the O 
Lippert-Mataga O 
equation O 
. O 
The O 
synthesized O 
compounds O 
, O 
especially O 
tris(4-(pyridin-4-yl)phenyl) B-SYSTEMATIC 
amine I-SYSTEMATIC 
, O 
presented O 
pH-dependent O 
absorptions O 
and O 
emissions O 
, O 
indicating O 
that O 
these O 
compounds O 
might O 
be O 
used O 
as O 
pH O 
sensors O 
. O 

factors O 
of O 
sensitivity O 
to O 
elisidepsin B-TRIVIAL 
, O 
a O 
novel O 
kahalalide B-TRIVIAL 
f I-TRIVIAL 
-derived O 
marine O 
compound O 
. O 

( O 
PM02734 B-IDENTIFIER 
, O 
Irvalec B-TRIVIAL 
® O 
) O 
is O 
a O 
synthetic O 
marine O 
- O 
derived O 
cyclic O 
peptide O 
of O 
the O 
Kahalalide B-TRIVIAL 
F I-TRIVIAL 
family O 
currently O 
in O 
phase O 
II O 
clinical O 
development O 
. O 
Elisidepsin B-TRIVIAL 
was O 
shown O 
to O 
induce O 
rapid O 
oncosis O 
in O 
ErbB3-expressing O 
cells O 
. O 
Other O 
predictive O 
factors O 
of O 
elisidepsin B-TRIVIAL 
sensitivity O 
remained O 
unknown O 
. O 
A O 
panel O 
of O 
23 O 
cancer O 
cell O 
lines O 
of O 
different O 
origin O 
was O 
assessed O 
for O 
elisidepsin B-TRIVIAL 
cytotoxicity O 
and O 
correlated O 
with O 
mutational O 
state O 
, O 
mRNA O 
and O 
protein O 
expression O 
of O 
selected O 
genes O 
. O 
Elisidepsin B-TRIVIAL 
showed O 
potent O 
and O 
broad O 
cytotoxic O 
effects O 
in O 
our O 
cancer O 
cell O 
line O 
panel O 
, O 
being O 
active O 
at O 
concentrations O 
ranging O 
from O 
0.4 O 
to O 
2 O 
μM O 
that O 
may O 
be O 
relevant O 
for O 
clinical O 
settings O 
. O 
We O 
have O 
shown O 
that O 
elisidepsin B-TRIVIAL 
is O 
more O 
active O 
in O 
cells O 
harboring O 
epithelial O 
phenotype O 
with O 
high O 
E-cadherin O 
and O 
low O 
vimentin O 
expression O 
. O 
In O 
addition O 
, O 
high O 
ErbB3 O 
and O 
Muc1 O 
expression O 
was O 
correlated O 
with O 
sensitivity O 
to O 
elisidepsin B-TRIVIAL 
, O 
whereas O 
the O 
presence O 
of O 
KRAS O 
activating O 
mutations O 
was O 
associated O 
with O 
resistance O 
. O 
In O 
DU-PM O 
cells O 
with O 
acquired O 
resistance O 
to O 
elisidepsin B-TRIVIAL 
, O 
ErbB3 O 
expression O 
was O 
decreased O 
, O 
while O 
Bcl2 O 
was O 
increased O 
. O 
DU-PM O 
cells O 
displayed O 
higher O 
sensitivity O 
to O 
ErbB1-inhibitors O 
suggesting O 
possible O 
cross O 
- O 
talk O 
of O 
ErbB1 O 
and O 
ErbB3 O 
signaling O 
pathways O 
. O 
Combinations O 
of O 
elisidepsin B-TRIVIAL 
with O 
lapatinib B-TRIVIAL 
and O 
several O 
chemotherapies O 
including O 
5-FU B-SYSTEMATIC 
and O 
oxaliplatin B-TRIVIAL 
resulted O 
in O 
synergistic O 
effects O 
that O 
offer O 
the O 
potential O 
of O 
clinical O 
use O 
of O 
elisidepsin B-TRIVIAL 
in O 
combination O 
settings O 
. O 

imidazopyridazines B-FAMILY 
are O 
potent O 
and O 
selective O 
inhibitors O 
of O 
Plasmodium O 
falciparum O 
calcium B-SYSTEMATIC 
-dependent O 
protein O 
kinase O 
1 O 
( O 
PfCDPK1 O 
) O 
. O 

series O 
of O 
imidazopyridazines B-FAMILY 
which O 
are O 
potent O 
inhibitors O 
of O 
Plasmodium O 
falciparum O 
calcium B-SYSTEMATIC 
-dependent O 
protein O 
kinase O 
1 O 
( O 
PfCDPK1 O 
) O 
was O 
identified O 
from O 
a O 
high O 
- O 
throughput O 
screen O 
against O 
the O 
isolated O 
enzyme O 
. O 
Subsequent O 
exploration O 
of O 
the O 
SAR O 
and O 
optimisation O 
has O 
yielded O 
leading O 
members O 
which O 
show O 
promising O 
in O 
vitro O 
anti-parasite O 
activity O 
along O 
with O 
good O 
in O 
vitro O 
ADME O 
and O 
selectivity O 
against O 
human O 
kinases O 
. O 
Initial O 
in O 
vivo O 
testing O 
has O 
revealed O 
good O 
oral O 
bioavailability O 
in O 
a O 
mouse O 
PK O 
study O 
and O 
modest O 
in O 
vivo O 
efficacy O 
in O 
a O 
Plasmodium O 
berghei O 
mouse O 
model O 
of O 
malaria O 
. O 

catalyzed O 
palm O 
oil O 
hydrolysis O 
under O 
ultrasound O 
irradiation O 
: O 
diacylglycerol B-FAMILY 
synthesis O 
. O 

( O 
DAG B-ABBREVIATION 
) O 
rich O 
oils O 
have O 
an O 
organoleptic O 
property O 
like O 
that O 
of O 
regular O 
edible O 
oils O 
, O 
but O 
these O 
oils O 
do O 
not O 
tend O 
to O 
be O 
accumulated O 
as O 
fat O 
. O 
Palm O 
oil O 
ranks O 
first O 
in O 
the O 
world O 
in O 
terms O 
of O 
edible O 
oil O 
production O 
owing O 
to O 
its O 
low O 
cost O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
propose O 
a O 
new O 
methodology O 
to O 
produce O 
diacylglycerol B-FAMILY 
by O 
hydrolysis O 
of O 
palm O 
oil O 
using O 
Lipozyme O 
RM O 
IM O 
commercial O 
lipase O 
as O 
a O 
catalyst O 
under O 
ultrasound O 
irradiation O 
. O 
The O 
reactions O 
were O 
carried O 
out O 
at O 
55 O 
°C O 
with O 
two O 
different O 
methods O 
. O 
First O 
, O 
the O 
reaction O 
system O 
was O 
exposed O 
to O 
ultrasonic O 
waves O 
for O 
the O 
whole O 
reaction O 
time O 
, O 
which O 
led O 
to O 
enzymatic O 
inactivation O 
and O 
water O 
evaporation O 
. O 
Ultrasound O 
was O 
then O 
used O 
to O 
promote O 
emulsification O 
of O 
the O 
water O 
/ O 
oil O 
system O 
before O 
the O 
hydrolysis O 
reaction O 
, O 
avoiding O 
contact O 
between O 
the O 
probe O 
and O 
the O 
enzymes O 
. O 
An O 
experimental O 
design O 
was O 
used O 
to O 
optimize O 
the O 
ultrasound O 
- O 
related O 
parameters O 
and O 
maximize O 
the O 
hydrolysis O 
rate O 
, O 
and O 
in O 
these O 
conditions O 
, O 
with O 
a O 
change O 
in O 
equilibrium O 
, O 
DAG B-ABBREVIATION 
production O 
was O 
evaluated O 
. O 
Better O 
reaction O 
conditions O 
were O 
achieved O 
for O 
the O 
second O 
method O 
: O 
11.2 O 
wt.% O 
( O 
water O 
+ O 
oil O 
mass O 
) O 
water O 
content O 
, O 
1.36 O 
wt.% O 
( O 
water O 
+ O 
oil O 
mass O 
) O 
enzyme O 
load O 
, O 
12 O 
h O 
of O 
reaction O 
time O 
, O 
1.2 O 
min O 
and O 
200 O 
W O 
of O 
exposure O 
to O 
ultrasound O 
. O 
In O 
these O 
conditions O 
diacylglycerol B-FAMILY 
yield O 
was O 
34.17 O 
wt.% O 
. O 

of O 
long O 
- O 
term O 
co O 
- O 
administration O 
of O 
Wuzhi O 
tablet O 
( O 
Schisandra O 
sphenanthera O 
extract O 
) O 
and O 
prednisone B-TRIVIAL 
on O 
the O 
pharmacokinetics O 
of O 
tacrolimus B-TRIVIAL 
. O 

( O 
TAC B-ABBREVIATION 
) O 
is O 
an O 
immunosuppressant O 
that O 
has O 
been O 
widely O 
used O 
alone O 
or O 
in O 
combination O 
with O 
prednisone B-TRIVIAL 
( O 
PRED B-ABBREVIATION 
) O 
to O 
prevent O 
acute O 
rejection O 
after O 
organ O 
transplantation O 
. O 
Wuzhi O 
tablet O 
( O 
WZ O 
, O 
Schisandra O 
sphenanthera O 
extract O 
) O 
is O 
often O 
prescribed O 
with O 
TAC B-ABBREVIATION 
to O 
prevent O 
drug O 
- O 
induced O 
hepatitis O 
. O 
We O 
recently O 
reported O 
that O 
WZ O 
could O 
significantly O 
increase O 
TAC B-ABBREVIATION 
blood O 
exposure O 
by O 
inhibiting O 
P-gp O 
- O 
mediated O 
efflux O 
and O 
CYP3A O 
- O 
mediated O 
metabolism O 
of O 
TAC B-ABBREVIATION 
. O 
PRED B-ABBREVIATION 
is O 
also O 
a O 
substrate O 
of O 
P-gp O 
and O 
is O 
a O 
weak O 
inducer O 
of O 
CYP3A O 
, O 
and O 
drug O 
- O 
drug O 
interactions O 
within O 
this O 
combination O 
therapy O 
might O 
occur O 
. O 
Therefore O 
, O 
the O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
long O 
- O 
term O 
treatment O 
of O 
WZ O 
and O 
PRED B-ABBREVIATION 
on O 
the O 
pharmacokinetics O 
of O 
TAC B-ABBREVIATION 
in O 
rats O 
. O 
After O 
14 O 
days O 
of O 
co O 
- O 
administration O 
of O 
WZ O 
and O 
PRED B-ABBREVIATION 
, O 
the O 
AUC(0-24h) O 
of O 
oral O 
TAC B-ABBREVIATION 
was O 
increased O 
( O 
from O 
59.6±37.3 O 
to O 
95.3±39.4 O 
ng O 
h O 
/ O 
ml O 
, O 
p=0.18 O 
) O 
and O 
the O 
clearance O 
was O 
decreased O 
( O 
from O 
38.4±28.4 O 
to O 
17.7±6.4 O 
l O 
/ O 
h O 
/ O 
kg O 
, O 
p=0.15 O 
) O 
. O 
When O 
only O 
co O 
- O 
administered O 
with O 
WZ O 
, O 
AUC(0-24h) O 
of O 
TAC B-ABBREVIATION 
was O 
demonstrated O 
a O 
significantly O 
increase O 
( O 
from O 
59.6±37.3 O 
to O 
135.9±34.8 O 
ng O 
h O 
/ O 
ml O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
concomitant O 
administration O 
of O 
PRED B-ABBREVIATION 
resulted O 
in O 
a O 
reduction O 
in O 
the O 
systemic O 
exposure O 
of O 
TAC B-ABBREVIATION 
and O 
an O 
increase O 
in O 
its O 
clearance O 
, O 
though O 
neither O 
was O 
statistically O 
significant O 
. O 
Thus O 
, O 
our O 
study O 
suggested O 
that O 
the O 
presence O 
of O 
WZ O 
and O 
PRED B-ABBREVIATION 
still O 
could O 
increase O 
the O 
systemic O 
exposure O 
of O 
TAC B-ABBREVIATION 
in O 
rats O 
. O 
The O 
drug O 
- O 
drug O 
interactions O 
among O 
this O 
combination O 
therapy O 
should O 
still O 
be O 
taken O 
into O 
consideration O 
in O 
clinical O 
practice O 
. O 

and O 
assessment O 
of O 
a O 
microfluidic O 
network O 
system O 
for O 
oxygen B-SYSTEMATIC 
transport O 
in O 
engineered O 
tissue O 
. O 

and O 
nutrients O 
cannot O 
be O 
delivered O 
to O 
cells O 
residing O 
in O 
the O 
interior O 
of O 
large O 
- O 
volume O 
scaffolds O 
via O 
diffusion O 
alone O 
. O 
Several O 
efforts O 
have O 
been O 
made O 
to O 
meet O 
the O 
metabolic O 
needs O 
of O 
cells O 
in O 
a O 
scaffold O 
by O 
constructing O 
mass O 
transport O 
channels O 
, O 
particularly O 
in O 
the O 
form O 
of O 
bifurcated O 
networks O 
. O 
In O 
contrast O 
to O 
progress O 
in O 
fabrication O 
technologies O 
, O 
however O 
, O 
an O 
approach O 
to O 
designing O 
an O 
optimal O 
network O 
based O 
on O 
experimental O 
evaluation O 
has O 
not O 
been O 
actively O 
reported O 
. O 
The O 
main O 
objective O 
of O 
this O 
study O 
was O 
to O 
establish O 
a O 
procedure O 
for O 
designing O 
an O 
effective O 
microfluidic O 
network O 
system O 
for O 
a O 
cell O 
- O 
seeded O 
scaffold O 
and O 
to O 
develop O 
an O 
experimental O 
model O 
to O 
evaluate O 
the O 
design O 
. O 
We O 
proposed O 
a O 
process O 
to O 
design O 
a O 
microfluidic O 
network O 
by O 
combining O 
an O 
oxygen B-SYSTEMATIC 
transport O 
simulation O 
with O 
biomimetic O 
principles O 
governing O 
biological O 
vascular O 
trees O 
. O 
The O 
simulation O 
was O 
performed O 
with O 
the O 
effective O 
diffusion O 
coefficient O 
(D(e,s)) O 
, O 
which O 
was O 
experimentally O 
measured O 
in O 
our O 
previous O 
study O 
. O 
Porous O 
scaffolds O 
containing O 
an O 
embedded O 
microfluidic O 
network O 
were O 
fabricated O 
using O 
the O 
lost O 
mold O 
shape O 
- O 
forming O 
process O 
and O 
salt O 
leaching O 
method O 
. O 
The O 
reliability O 
of O 
the O 
procedure O 
was O 
demonstrated O 
by O 
experiments O 
using O 
the O 
scaffolds O 
. O 
This O 
approach O 
established O 
a O 
practical O 
basis O 
for O 
designing O 
an O 
effective O 
microfluidic O 
network O 
in O 
a O 
cell O 
- O 
seeded O 
scaffold O 
. O 

- O 
oligosaccharides O 
( O 
GOS O 
) O 
, O 
an O 
important O 
class O 
of O 
functional O 
food O 
, O 
are O 
commonly O 
produced O 
from O 
lactose B-TRIVIAL 
using O 
β-galactosidase O 
. O 
In O 
the O 
present O 
study O 
, O 
β-galactosidase O 
( O 
LacS O 
) O 
from O 
Sulfolobus O 
solfataricus O 
P2 O 
was O 
cloned O 
and O 
site O 
- O 
directed O 
mutagenesis O 
was O 
performed O 
to O 
obtain O 
two O 
mutants O 
, O 
F359Q O 
and O 
F441Y O 
. O 
All O 
of O 
the O 
wild O 
- O 
type O 
enzyme O 
and O 
mutants O 
were O 
expressed O 
in O 
Escherichia O 
coli O 
BL21(DE3) O 
and O 
purified O 
to O 
homogeneity O 
. O 
The O 
enzymatic O 
properties O 
and O 
optimal O 
condition O 
for O 
transglycosylation O 
reaction O 
of O 
the O 
enzymes O 
were O 
investigated O 
in O 
detail O 
. O 
Under O 
their O 
individual O 
optimal O 
conditions O 
, O 
yields O 
of O 
GOS O 
could O 
reach O 
50.9% O 
for O 
wild O 
- O 
type O 
enzyme O 
, O 
58.3% O 
for O 
F359Q O 
, O 
and O 
61.7% O 
for O 
F441Y O 
. O 
In O 
addition O 
, O 
the O 
potential O 
mechanism O 
for O 
this O 
enhancement O 
was O 
analysed O 
. O 

CRF(1) O 
receptor O 
antagonist O 
SSR125543 B-IDENTIFIER 
prevents O 
stress O 
- O 
induced O 
cognitive O 
deficit O 
associated O 
with O 
hippocampal O 
dysfunction O 
: O 
Comparison O 
with O 
paroxetine B-TRIVIAL 
and O 
D-cycloserine B-TRIVIAL 
. O 

: O 
The O 
selective O 
CRF(1) O 
( O 
corticotropin O 
releasing O 
factor O 
type O 
1 O 
) O 
receptor O 
antagonist O 
SSR125543 B-IDENTIFIER 
has O 
been O 
previously O 
shown O 
to O 
attenuate O 
the O 
long O 
- O 
term O 
cognitive O 
deficit O 
produced O 
by O 
traumatic O 
stress O 
exposure O 
. O 
Memory O 
disturbances O 
described O 
in O 
post O 
- O 
traumatic O 
stress O 
disorder O 
( O 
PTSD O 
) O 
patients O 
are O 
believed O 
to O 
be O 
associated O 
with O 
changes O 
in O 
neuronal O 
activity O 
, O 
in O 
particular O 
at O 
the O 
level O 
of O 
the O 
hippocampus O 
. O 
OBJECTIVES O 
: O 
The O 
present O 
study O 
aims O 
at O 
investigating O 
whether O 
the O 
effects O 
of O 
SSR125543 B-IDENTIFIER 
( O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
2 O 
weeks O 
) O 
on O 
cognitive O 
impairment O 
induced O 
by O 
traumatic O 
stress O 
exposure O 
are O 
associated O 
with O 
changes O 
in O 
hippocampal O 
excitability O 
. O 
Effects O 
of O 
SSR125543 B-IDENTIFIER 
were O 
compared O 
to O 
those O 
of O 
the O 
5-HT B-SYSTEMATIC 
reuptake O 
inhibitor O 
, O 
paroxetine B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
, O 
and O 
the O 
partial O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptor O 
agonist O 
, O 
D-cycloserine B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
, O 
two O 
compounds O 
which O 
have O 
demonstrated O 
clinical O 
efficacy O 
against O 
PTSD O 
. O 
METHODS O 
: O 
Mice O 
received O 
two O 
unavoidable O 
electric O 
foot O 
- O 
shocks O 
. O 
Then O 
, O 
1 O 
or O 
16 O 
days O 
after O 
stress O 
, O 
they O 
were O 
tested O 
for O 
their O 
memory O 
performance O 
using O 
the O 
object O 
recognition O 
test O 
. O 
Neuronal O 
excitability O 
was O 
recorded O 
during O 
the O 
third O 
week O 
post O 
- O 
stress O 
in O 
the O 
CA1 O 
area O 
of O 
the O 
hippocampus O 
. O 
Drugs O 
were O 
administered O 
from O 
day O 
1 O 
post O 
- O 
stress O 
to O 
the O 
day O 
preceding O 
the O 
electrophysiological O 
study O 
. O 
RESULTS O 
: O 
Application O 
of O 
electric O 
shocks O 
produced O 
cognitive O 
impairment O 
16 O 
, O 
but O 
not O 
1 O 
day O 
after O 
stress O 
, O 
an O 
effect O 
which O 
was O 
associated O 
with O 
a O 
decrease O 
in O 
hippocampal O 
neuronal O 
excitability O 
. O 
Both O 
stress O 
- O 
induced O 
effects O 
were O 
prevented O 
by O 
repeated O 
administration O 
of O 
SSR125543 B-IDENTIFIER 
, O 
paroxetine B-TRIVIAL 
and O 
D-cycloserine B-TRIVIAL 
. O 
CONCLUSIONS O 
: O 
These O 
findings O 
confirm O 
that O 
the O 
CRF(1) O 
receptor O 
antagonist O 
SSR125543 B-IDENTIFIER 
is O 
able O 
to O 
attenuate O 
the O 
behavioral O 
effects O 
of O 
traumatic O 
stress O 
exposure O 
and O 
indicate O 
that O 
these O 
effects O 
are O 
associated O 
with O 
a O 
normalization O 
of O 
hippocampal O 
neuronal O 
excitability O 
impaired O 
by O 
stress O 
. O 

Determinants O 
of O 
Agonist O 
Efficacy O 
at O 
the O 
Glutamate B-TRIVIAL 
Binding O 
Site O 
of O 
NMDA B-ABBREVIATION 
Receptors O 
. O 

receptors O 
are O 
ligand O 
- O 
gated O 
ion O 
channels O 
assembled O 
from O 
GluN1 O 
and O 
GluN2 O 
subunits O 
. O 
We O 
utilized O 
a O 
series O 
of O 
N-hydroxypyrazole-5-glycine B-SYSTEMATIC 
( O 
NHP5G B-SYSTEMATIC 
) O 
partial O 
agonists O 
at O 
the O 
GluN2 O 
glutamate B-TRIVIAL 
binding O 
site O 
as O 
tools O 
to O 
study O 
activation O 
of O 
GluN1 O 
/ O 
GluN2A O 
and O 
GluN1 O 
/ O 
GluN2D O 
NMDA B-ABBREVIATION 
receptor O 
subtypes O 
. O 
We O 
show O 
using O 
two O 
- O 
electrode O 
voltage O 
- O 
clamp O 
electrophysiology O 
, O 
fast O 
- O 
application O 
patch O 
- O 
clamp O 
, O 
and O 
single O 
channel O 
recordings O 
that O 
propyl- B-MULTIPLE 
and I-MULTIPLE 
ethyl I-MULTIPLE 
- I-MULTIPLE 
substituted I-MULTIPLE 
NHP5G I-MULTIPLE 
agonists O 
have O 
a O 
broad O 
range O 
of O 
agonist O 
efficacies O 
relative O 
to O 
the O 
full O 
agonist O 
glutamate B-TRIVIAL 
( O 
< O 
1%-72% O 
) O 
. O 
Crystal O 
structures O 
of O 
the O 
agonist O 
binding O 
domains O 
( O 
ABDs O 
) O 
of O 
GluN2A O 
and O 
GluN2D O 
do O 
not O 
reveal O 
any O 
differences O 
in O 
the O 
overall O 
domain O 
conformation O 
induced O 
by O 
binding O 
of O 
the O 
full O 
agonist O 
glutamate B-TRIVIAL 
or O 
the O 
partial O 
agonist O 
propyl-NHP5G B-SYSTEMATIC 
, O 
which O 
is O 
strikingly O 
different O 
from O 
ABD O 
structures O 
of O 
AMPA B-ABBREVIATION 
and O 
kainate B-TRIVIAL 
receptors O 
bound O 
to O 
full O 
and O 
partial O 
agonists O 
. O 
Subsequent O 
evaluation O 
of O 
relative O 
NHP5G B-SYSTEMATIC 
agonist O 
efficacy O 
at O 
GluN2A-GluN2D O 
chimeric O 
subunits O 
implicates O 
the O 
amino B-FAMILY 
-terminal O 
domain O 
( O 
ATD O 
) O 
as O 
a O 
strong O 
determinant O 
of O 
agonist O 
efficacy O 
, O 
suggesting O 
that O 
interdomain O 
interactions O 
between O 
the O 
ABD O 
and O 
the O 
ATD O 
may O 
be O 
a O 
central O 
element O 
in O 
controlling O 
the O 
manner O 
by O 
which O 
agonist O 
binding O 
leads O 
to O 
channel O 
opening O 
. O 
We O 
propose O 
that O 
variation O 
in O 
the O 
overall O 
receptor O 
conformation O 
, O 
which O 
is O 
strongly O 
influenced O 
by O 
the O 
nature O 
of O 
interdomain O 
interactions O 
in O 
resting O 
and O 
active O 
states O 
, O 
mediates O 
differences O 
in O 
agonist O 
efficacy O 
and O 
partial O 
agonism O 
at O 
the O 
GluN2 O 
subunits O 
. O 

-based O 
formulation O 
- O 
induced O 
genotoxicity O 
and O 
cytotoxicity O 
in O 
the O 
fresh O 
water O 
fish O 
Cnesterodon O 
decemmaculatus O 
( O 
Jenyns O 
, O 
1842 O 
) O 
( O 
Pisces O 
, O 
Poeciliidae O 
) O 
. O 

analyzed O 
the O 
aspects O 
of O 
lethality O 
, O 
genotoxicity O 
, O 
and O 
cytotoxicity O 
in O 
the O 
ten O 
spotted O 
live O 
- O 
bearer O 
exposed O 
under O 
laboratory O 
conditions O 
to O 
the O 
pirimicarb B-TRIVIAL 
-based O 
formulation O 
Patton O 
Flow(®) O 
( O 
50% O 
active O 
ingredient O 
( O 
a.i O 
. O 
) O 
) O 
. O 
Acute O 
effects O 
were O 
evaluated O 
using O 
different O 
end O 
points O 
for O 
lethality O 
, O 
genotoxicity O 
, O 
and O 
cytotoxicity O 
. O 
Median O 
lethal O 
concentration O 
( O 
LC50 O 
) O 
estimation O 
was O 
employed O 
as O 
a O 
bioassay O 
for O 
lethality O 
, O 
whereas O 
micronucleus O 
( O 
MN O 
) O 
induction O 
and O 
alterations O 
in O 
erythrocyte O 
/ O 
erythroblast O 
frequency O 
were O 
used O 
as O 
end O 
points O 
for O 
genotoxicity O 
and O 
cytotoxicity O 
, O 
respectively O 
. O 
Results O 
demonstrated O 
an O 
LC5096h O 
value O 
of O 
88 O 
mg O 
/ O 
L O 
. O 
Patton O 
Flow(®) O 
increased O 
the O 
MN O 
frequency O 
in O 
fish O 
erythrocytes O 
after O 
48 O 
h O 
of O 
exposure O 
at O 
a O 
concentration O 
of O 
66 O 
mg O 
/ O 
L O 
, O 
whereas O 
a O 
concentration O 
range O 
of O 
22-66 O 
mg O 
/ O 
L O 
was O 
able O 
to O 
exert O 
the O 
same O 
genotoxic O 
effect O 
at O 
96 O 
h O 
of O 
treatment O 
. O 
Furthermore O 
, O 
cytotoxicity O 
was O 
also O 
observed O 
by O 
alterations O 
in O 
erythrocyte O 
/ O 
erythroblast O 
frequencies O 
within O 
the O 
concentration O 
range O 
of O 
22-66 O 
mg O 
/ O 
L O 
, O 
regardless O 
of O 
the O 
exposure O 
time O 
. O 
Our O 
current O 
observations O 
provide O 
evidence O 
that O 
Patton O 
Flow(®) O 
( O 
50% O 
a.i O 
. O 
) O 
should O 
be O 
considered O 
a O 
clear O 
lethal O 
, O 
cytotoxic O 
, O 
and O 
genotoxic O 
agent O 
on O 
Cnesterodon O 
decemmaculatus O 
. O 
Thus O 
, O 
repeated O 
applications O 
of O 
this O 
carbamic B-SYSTEMATIC 
insecticide O 
can O 
enter O 
the O 
aquatic O 
environment O 
and O 
exert O 
deleterious O 
effects O 
on O 
aquatic O 
organisms O 
other O 
than O 
the O 
evaluated O 
species O 
C O 
. O 
decemmaculatus O 
. O 

- O 
term O 
heating O 
reduces O 
the O 
anti-inflammatory O 
effects O 
of O 
fresh O 
raw O 
garlic O 
extracts O 
on O 
the O 
LPS-induced O 
production O 
of O 
NO B-FORMULA 
and O 
pro O 
- O 
inflammatory O 
cytokines O 
by O 
downregulating O 
allicin B-TRIVIAL 
activity O 
in O 
RAW O 
264.7 O 
macrophages O 
. O 

has O 
a O 
variety O 
of O 
biologic O 
activities O 
, O 
including O 
anti-inflammatory O 
properties O 
. O 
Although O 
garlic O 
has O 
several O 
biologic O 
activities O 
, O 
some O 
people O 
dislike O 
eating O 
fresh O 
raw O 
garlic O 
because O 
of O 
its O 
strong O 
taste O 
and O 
smell O 
. O 
Therefore O 
, O 
garlic O 
formulations O 
involving O 
heating O 
procedures O 
have O 
been O 
developed O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
whether O 
short O 
- O 
term O 
heating O 
affects O 
the O 
anti-inflammatory O 
properties O 
of O 
garlic O 
. O 
Fresh O 
and O 
heated O 
raw O 
garlic O 
extracts O 
( O 
FRGE O 
and O 
HRGE O 
) O 
were O 
prepared O 
with O 
incubation O 
at O 
25°C O 
and O 
95°C O 
, O 
respectively O 
, O 
for O 
2h O 
. O 
Treatment O 
with O 
FRGE O 
and O 
HRGE O 
significantly O 
reduced O 
the O 
LPS-induced O 
increase O 
in O 
the O 
pro O 
- O 
inflammatory O 
cytokine O 
concentration O 
( O 
TNF-α O 
, O 
IL-1β O 
, O 
and O 
IL-6 O 
) O 
and O 
NO B-FORMULA 
through O 
HO-1 O 
upregulation O 
in O 
RAW O 
264.7 O 
macrophages O 
. O 
The O 
anti-inflammatory O 
effect O 
was O 
greater O 
in O 
FRGE O 
than O 
in O 
HRGE O 
. O 
The O 
allicin B-TRIVIAL 
concentration O 
was O 
higher O 
in O 
FRGE O 
than O 
in O 
HRGE O 
. O 
Allicin B-TRIVIAL 
treatment O 
showed O 
reduced O 
production O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
and O 
NO B-FORMULA 
and O 
increased O 
HO-1 O 
activity O 
. O 
The O 
results O 
show O 
that O 
the O 
decrease O 
in O 
LPS-induced O 
NO B-FORMULA 
and O 
pro O 
- O 
inflammatory O 
cytokines O 
in O 
RAW O 
264.7 O 
macrophages O 
through O 
HO-1 O 
induction O 
was O 
greater O 
for O 
FRGE O 
compared O 
with O 
HRGE O 
. O 
Additionally O 
, O 
the O 
results O 
indicate O 
that O 
allicin B-TRIVIAL 
is O 
responsible O 
for O 
the O 
anti-inflammatory O 
effect O 
of O 
FRGE O 
. O 
Our O 
results O 
suggest O 
a O 
potential O 
therapeutic O 
use O 
of O 
allicin B-TRIVIAL 
in O 
the O 
treatment O 
of O 
chronic O 
inflammatory O 
disease O 
. O 

of O 
ethyl B-SYSTEMATIC 
carbamate I-SYSTEMATIC 
in O 
cachaça O 
produced O 
from O 
copper B-SYSTEMATIC 
stills O 
by O 
HPLC O 
. O 

carbamate I-SYSTEMATIC 
( O 
EC O 
) O 
is O 
a O 
common O 
substance O 
in O 
fermented O 
foods O 
and O 
drinks O 
, O 
and O 
its O 
quantification O 
is O 
important O 
because O 
of O 
its O 
carcinogenic O 
nature O 
and O 
its O 
usually O 
presence O 
in O 
alcoholic O 
beverages O 
. O 
The O 
present O 
work O 
involved O 
the O 
development O 
and O 
validation O 
of O 
an O 
analytical O 
method O 
for O 
the O 
evaluation O 
of O 
EC O 
in O 
cachaça O 
by O 
HPLC-FLD O 
after O 
previous O 
derivatization O 
with O 
xanthydrol B-TRIVIAL 
. O 
The O 
method O 
presented O 
a O 
mean O 
recovery O 
of O 
94.88% O 
, O 
an O 
intra O 
- O 
day O 
precision O 
of O 
4.19% O 
( O 
30 O 
μgL(-1) O 
) O 
and O 
3.32% O 
( O 
75 O 
μgL(-1) O 
) O 
, O 
a O 
coefficient O 
of O 
determination O 
(r(2)) O 
equal O 
to O 
0.9985 O 
, O 
and O 
limits O 
of O 
detection O 
and O 
quantification O 
equal O 
to O 
6.39 O 
and O 
21.32 O 
μgL(-1) O 
, O 
respectively O 
. O 
The O 
results O 
show O 
that O 
the O 
analytical O 
method O 
is O 
accurate O 
, O 
reproducible O 
and O 
linear O 
over O 
the O 
concentration O 
range O 
from O 
5 O 
to O 
160 O 
μg O 
of O 
EC O 
per O 
litre O 
. O 
The O 
method O 
was O 
applied O 
to O 
the O 
analysis O 
of O 
EC O 
in O 
cachaça O 
, O 
the O 
analyses O 
being O 
rapid O 
and O 
efficient O 
. O 

and O 
Bcl-xL O 
suppress O 
glucose B-TRIVIAL 
signaling O 
in O 
pancreatic O 
β-cells O 
. O 

lymphoma O 
2 O 
( O 
Bcl-2 O 
) O 
family O 
proteins O 
are O 
established O 
regulators O 
of O 
cell O 
survival O 
, O 
but O 
their O 
involvement O 
in O 
the O 
normal O 
function O 
of O 
primary O 
cells O 
has O 
only O 
recently O 
begun O 
to O 
receive O 
attention O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrate O 
that O 
chemical O 
and O 
genetic O 
loss O 
- O 
of O 
- O 
function O 
of O 
antiapoptotic O 
Bcl-2 O 
and O 
Bcl-x(L) O 
significantly O 
augments O 
glucose B-TRIVIAL 
-dependent O 
metabolic O 
and O 
Ca(2+) B-FORMULA 
signals O 
in O 
primary O 
pancreatic O 
β-cells O 
. O 
Antagonism O 
of O 
Bcl-2 O 
/ O 
Bcl-x(L) O 
by O 
two O 
distinct O 
small O 
- O 
molecule O 
compounds O 
rapidly O 
hyperpolarized O 
β-cell O 
mitochondria O 
, O 
increased O 
cytosolic O 
Ca(2+) B-FORMULA 
, O 
and O 
stimulated O 
insulin O 
release O 
via O 
the O 
ATP B-ABBREVIATION 
-dependent O 
pathway O 
in O 
β-cell O 
under O 
substimulatory O 
glucose B-TRIVIAL 
conditions O 
. O 
Experiments O 
with O 
single O 
and O 
double O 
Bax-Bak O 
knockout O 
β-cells O 
established O 
that O 
this O 
occurred O 
independently O 
of O 
these O 
proapoptotic O 
binding O 
partners O 
. O 
Pancreatic O 
β-cells O 
from O 
Bcl-2(- O 
/ O 
- O 
) O 
mice O 
responded O 
to O 
glucose B-TRIVIAL 
with O 
significantly O 
increased O 
NAD(P)H B-ABBREVIATION 
levels O 
and O 
cytosolic O 
Ca(2+) B-FORMULA 
signals O 
, O 
as O 
well O 
as O 
significantly O 
augmented O 
insulin O 
secretion O 
. O 
Inducible O 
deletion O 
of O 
Bcl-x(L) O 
in O 
adult O 
mouse O 
β-cells O 
also O 
increased O 
glucose B-TRIVIAL 
-stimulated O 
NAD(P)H B-ABBREVIATION 
and O 
Ca(2+) B-FORMULA 
responses O 
and O 
resulted O 
in O 
an O 
improvement O 
of O 
in O 
vivo O 
glucose B-TRIVIAL 
tolerance O 
in O 
the O 
conditional O 
Bcl-x(L) O 
knockout O 
animals O 
. O 
Our O 
work O 
suggests O 
that O 
prosurvival O 
Bcl O 
proteins O 
normally O 
dampen O 
the O 
β-cell O 
response O 
to O 
glucose B-TRIVIAL 
and O 
thus O 
reveals O 
these O 
core O 
apoptosis O 
proteins O 
as O 
integrators O 
of O 
cell O 
death O 
and O 
physiology O 
in O 
pancreatic O 
β-cells O 
. O 

reverse O 
- O 
transcriptase O 
inhibitor O 
( O 
NRTI O 
) O 
drugs O 
are O 
a O 
major O 
component O 
of O 
highly O 
- O 
active O 
antiretroviral O 
therapy O 
( O 
HAART O 
) O 
. O 
NRTI O 
combinations O 
have O 
been O 
demonstrated O 
as O 
producing O 
a O 
sustained O 
reduction O 
in O 
plasma O 
viremia O 
with O 
an O 
increased O 
CD4 O 
count O 
, O 
thereby O 
showing O 
clear O 
clinical O 
benefits O 
. O 
Therefore O 
, O 
the O 
secondary O 
effects O 
caused O 
by O 
the O 
combination O 
of O 
two O 
NRTIs O 
, O 
mainly O 
those O 
related O 
to O 
amplification O 
of O 
genotoxic O 
effects O 
, O 
due O 
to O 
increased O 
risk O 
of O 
DNA O 
damage O 
caused O 
by O 
these O 
drugs O 
, O 
should O 
be O 
carefully O 
examined O 
. O 
We O 
employed O 
the O 
standard O 
version O 
of O 
the O 
wing O 
SMART O 
in O 
Drosophila O 
melanogaster O 
to O 
obtain O 
more O 
detailed O 
knowledge O 
about O 
the O 
genotoxic O 
profile O 
of O 
NRTI O 
combinations O 
of O 
AZT B-ABBREVIATION 
+ O 
ddI B-ABBREVIATION 
, O 
AZT B-ABBREVIATION 
+ O 
3TC B-SYSTEMATIC 
and O 
AZT B-ABBREVIATION 
+ O 
d4T B-ABBREVIATION 
. O 
Our O 
results O 
showed O 
that O 
all O 
combinations O 
increased O 
the O 
frequencies O 
of O 
induction O 
of O 
mutant O 
spots O 
. O 
The O 
combinations O 
AZT B-ABBREVIATION 
+ O 
ddI B-ABBREVIATION 
and O 
AZT B-ABBREVIATION 
+ O 
3TC B-SYSTEMATIC 
were O 
shown O 
to O 
induce O 
recombination O 
rates O 
ranging O 
from O 
86.38% O 
to O 
98.36% O 
while O 
AZT B-ABBREVIATION 
+ O 
d4T B-ABBREVIATION 
showed O 
a O 
large O 
discrepancy O 
between O 
recombination O 
and O 
mutation O 
percentages O 
. O 
The O 
combination O 
index O 
demonstrated O 
that O 
3TC B-SYSTEMATIC 
and O 
d4T B-ABBREVIATION 
produced O 
antagonism O 
while O 
ddI B-ABBREVIATION 
showed O 
synergistic O 
effects O 
in O 
combination O 
with O 
AZT B-ABBREVIATION 
. O 

exposure O 
to O 
BDE-99 B-ABBREVIATION 
causes O 
learning O 
disorders O 
and O 
decreases O 
serum O 
thyroid B-FAMILY 
hormone I-FAMILY 
levels O 
and O 
BDNF O 
gene O 
expression O 
in O 
hippocampus O 
in O 
rat O 
offspring O 
. O 

of O 
pregnant O 
women O 
to O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
may O 
mean O 
serious O 
health O 
risks O 
. O 
The O 
main O 
goal O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
the O 
neurobehavioral O 
changes O 
in O 
rat O 
offspring O 
that O 
were O 
perinatally O 
exposed O 
to O 
one O 
of O 
the O 
most O 
prevalent O 
PBDEs B-ABBREVIATION 
congeners O 
found O 
in O 
humans O 
, O 
2,2',4,4',5-pentaBDE B-SYSTEMATIC 
( O 
BDE-99 B-ABBREVIATION 
) O 
. O 
Rat O 
dams O 
were O 
exposed O 
to O 
0 O 
, O 
1 O 
and O 
2mg O 
/ O 
kg O 
/ O 
day O 
of O 
BDE-99 B-ABBREVIATION 
from O 
gestation O 
day O 
6 O 
to O 
post O 
- O 
natal O 
day O 
21 O 
. O 
When O 
pups O 
were O 
weaning O 
, O 
cortex O 
and O 
hippocampal O 
gene O 
expressions O 
of O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
of O 
the O 
different O 
isoforms O 
of O 
the O 
thyroid B-FAMILY 
hormone I-FAMILY 
( O 
TH O 
) O 
receptors O 
( O 
TRs O 
) O 
were O 
evaluated O 
. O 
Serum O 
TH O 
levels O 
were O 
also O 
determined O 
. O 
The O 
remaining O 
pups O 
were O 
assessed O 
by O 
neurobehavioral O 
testing O 
for O 
learning O 
and O 
memory O 
function O 
. O 
The O 
results O 
showed O 
that O 
maternal O 
transference O 
of O 
BDE-99 B-ABBREVIATION 
produced O 
a O 
delay O 
in O 
the O 
spatial O 
learning O 
task O 
in O 
the O 
water O 
maze O 
test O 
. O 
Moreover O 
, O 
the O 
open O 
- O 
field O 
test O 
revealed O 
a O 
significant O 
dose O 
- O 
response O 
anxiolytic O 
effect O 
. O 
It O 
was O 
also O 
found O 
that O 
the O 
serum O 
levels O 
of O 
triiodothyronine B-TRIVIAL 
( O 
T3 O 
) O 
, O 
tetraiiodothyronine B-SYSTEMATIC 
( O 
T4 O 
) O 
and O 
free-T4 O 
( O 
FT4 O 
) O 
decreased O 
. O 
Although O 
no O 
effect O 
on O 
the O 
gene O 
expression O 
of O 
the O 
different O 
isoforms O 
of O 
TRs O 
was O 
observed O 
, O 
the O 
expression O 
of O 
the O 
TH O 
- O 
mediated O 
gene O 
BDNF O 
was O 
down O 
- O 
regulated O 
in O 
the O 
hippocampus O 
. O 
These O 
results O 
indicate O 
a O 
clear O 
signal O 
disruption O 
of O 
TH O 
and O 
reinforce O 
previous O 
studies O 
in O 
which O 
neurotoxic O 
effects O 
of O 
PBDEs B-ABBREVIATION 
in O 
animal O 
research O 
were O 
observed O 
at O 
levels O 
comparable O 
to O 
those O 
found O 
in O 
humans O 
. O 

attenuation O 
of O 
the O 
inflammatory O 
response O 
in O 
H9c2 O 
cardiomyocytes O 
involves O 
inhibition O 
of O 
NF-κB O 
and O 
MAPKs O 
activation O 
via O 
the O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
signaling O 
. O 

phenolic B-FAMILY 
glucoside I-FAMILY 
gastrodin B-TRIVIAL 
, O 
a O 
main O 
constituent O 
of O 
a O 
Chinese O 
traditional O 
herbal O 
medicine O 
, O 
has O 
been O 
known O 
to O 
display O 
several O 
biological O 
and O 
pharmacological O 
properties O 
. O 
However O 
, O 
the O 
role O 
and O 
precise O 
molecular O 
mechanisms O 
explaining O 
how O 
gastrodin B-TRIVIAL 
suppresses O 
the O 
inflammatory O 
response O 
in O 
septic O 
cardiac O 
dysfunction O 
are O 
unknown O 
. O 
To O 
study O 
this O 
, O 
rat O 
H9c2 O 
cardiomyocytes O 
were O 
treated O 
with O 
gastrodin B-TRIVIAL 
and O 
/ O 
or O 
lipopolysaccharide O 
( O 
LPS O 
) O 
. O 
Our O 
results O 
showed O 
that O 
gastrodin B-TRIVIAL 
treatment O 
strongly O 
suppressed O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
and O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
family O 
activation O 
and O 
upregulation O 
of O 
the O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
and O 
interleukin-6 O 
( O 
IL-6 O 
) O 
in O 
LPS-stimulated O 
H9c2 O 
cardiomyocytes O 
. O 
Simultaneously O 
, O 
gastrodin B-TRIVIAL 
obviously O 
upregulated O 
the O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
( O 
PI3-K O 
) O 
/ O 
Akt O 
signaling O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
However O 
, O 
wortmannin B-TRIVIAL 
, O 
a O 
specific O 
PI3-K O 
inhibitor O 
, O 
blocked O 
the O 
inhibitory O 
effects O 
of O 
gastrodin B-TRIVIAL 
on O 
LPS-stimulated O 
H9c2 O 
cardiomyocytes O 
. O 
Furthermore O 
, O 
PI3-K O 
/ O 
Akt O 
inhibition O 
partially O 
abolished O 
the O 
inhibitory O 
effects O 
of O 
gastrodin B-TRIVIAL 
on O 
the O 
phosphorylation O 
of O 
inhibitor O 
κB-α O 
( O 
IκB-α O 
) O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
1 O 
/ O 
2 O 
( O 
ERK1 O 
/ O 
2 O 
) O 
, O 
c-Jun O 
N B-FORMULA 
-terminal O 
protein O 
kinase O 
( O 
JNK O 
) O 
, O 
and O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
p38 O 
MAPK O 
) O 
, O 
and O 
activity O 
of O 
NF-κB O 
. O 
Here O 
we O 
report O 
activation O 
of O 
the O 
PI3-K O 
/ O 
Akt O 
signaling O 
by O 
gastrodin B-TRIVIAL 
and O 
that O 
inhibition O 
of O 
this O 
pathway O 
reverses O 
the O 
inhibitory O 
effects O 
of O 
gastrodin B-TRIVIAL 
on O 
NF-κB O 
and O 
MAPKs O 
activation O 
in O 
H9c2 O 
cardiomyocytes O 
. O 

silicon B-SYSTEMATIC 
networks O 
as O 
anodes O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 

silicon B-SYSTEMATIC 
( O 
Si B-FORMULA 
) O 
networks O 
with O 
controllable O 
porosity O 
and O 
thickness O 
are O 
fabricated O 
by O 
a O 
simple O 
and O 
scalable O 
electrochemical O 
process O 
, O 
and O 
then O 
released O 
from O 
Si B-FORMULA 
wafers O 
and O 
transferred O 
to O 
flexible O 
and O 
conductive O 
substrates O 
. O 
These O 
nanoporous O 
Si B-FORMULA 
networks O 
serve O 
as O 
high O 
performance O 
Li B-FORMULA 
-ion O 
battery O 
electrodes O 
, O 
with O 
an O 
initial O 
discharge O 
capacity O 
of O 
2570 O 
mA O 
h O 
g(-1) O 
, O 
above O 
1000 O 
mA O 
h O 
g(-1) O 
after O 
200 O 
cycles O 
without O 
any O 
electrolyte O 
additives O 
. O 

and O 
aversion O 
in O 
a O 
heterogeneous O 
midbrain O 
dopamine B-TRIVIAL 
system O 
. O 

ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
is O 
a O 
heterogeneous O 
brain O 
structure O 
that O 
serves O 
a O 
central O 
role O 
in O 
motivation O 
and O 
reward O 
processing O 
. O 
Abnormalities O 
in O 
the O 
function O 
of O 
VTA O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
neurons O 
and O 
the O 
targets O 
they O 
influence O 
are O 
implicated O 
in O 
several O 
prominent O 
neuropsychiatric O 
disorders O 
including O 
addiction O 
and O 
depression O 
. O 
Recent O 
studies O 
suggest O 
that O 
the O 
midbrain O 
DA O 
system O 
is O 
composed O 
of O 
anatomically O 
and O 
functionally O 
heterogeneous O 
DA O 
subpopulations O 
with O 
different O 
axonal O 
projections O 
. O 
These O 
findings O 
may O 
explain O 
a O 
number O 
of O 
previously O 
confusing O 
observations O 
that O 
suggested O 
a O 
role O 
for O 
DA O 
in O 
processing O 
both O 
rewarding O 
as O 
well O 
as O 
aversive O 
events O 
. O 
Here O 
we O 
will O 
focus O 
on O 
recent O 
advances O 
in O 
understanding O 
the O 
neural O 
circuits O 
mediating O 
reward O 
and O 
aversion O 
in O 
the O 
VTA O 
and O 
how O 
stress O 
as O 
well O 
as O 
drugs O 
of O 
abuse O 
, O 
in O 
particular O 
cocaine B-TRIVIAL 
, O 
alter O 
circuit O 
function O 
within O 
a O 
heterogeneous O 
midbrain O 
DA O 
system O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
NIDA O 
40th O 
Anniversary O 
Issue O 
' O 
. O 

vitro O 
evaluation O 
of O 
(99m)Tc-EDDA B-MULTIPLE 
/ I-MULTIPLE 
tricine-HYNIC-Q-Litorin I-MULTIPLE 
in O 
gastrin O 
- O 
releasing O 
peptide O 
receptor O 
positive O 
tumor O 
cell O 
lines O 
. O 

Bombesin B-TRIVIAL 
and O 
its O 
derivatives O 
exhibit O 
a O 
high O 
affinity O 
for O 
gastrin O 
- O 
releasing O 
peptide O 
receptor O 
( O 
GRPr O 
) O 
, O 
which O 
is O 
over O 
- O 
expressed O 
in O 
a O 
variety O 
of O 
human O 
cancers O 
( O 
prostate O 
, O 
pancreatic O 
, O 
lung O 
, O 
etc O 
. O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
in O 
vitro O 
potential O 
of O 
the O 
hydrazinonicotinamide B-SYSTEMATIC 
( O 
HYNIC B-ABBREVIATION 
)-Q- O 
Litorin B-TRIVIAL 
. O 
(99m)Tc B-FORMULA 
labeling O 
was O 
performed O 
by O 
using O 
different O 
co O 
- O 
ligands O 
: O 
tricine B-TRIVIAL 
and O 
ethylenediamine B-SYSTEMATIC 
diacetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EDDA B-ABBREVIATION 
) O 
. O 
The O 
radiochemical O 
stability O 
of O 
radiolabeled O 
peptide O 
conjugates O 
was O 
checked O 
at O 
room O 
temperature O 
and O 
in O 
cysteine B-TRIVIAL 
solution O 
up O 
to O 
24 O 
h O 
. O 
The O 
in O 
vitro O 
cell O 
uptake O 
of O 
(99m)Tc-EDDA-HYNIC-Q-Litorin B-SYSTEMATIC 
and O 
(99m)Tc-tricine-HYNIC-Q-Litorin B-SYSTEMATIC 
were O 
evaluated O 
on O 
pancreatic O 
tumor O 
and O 
control O 
cell O 
lines O 
. O 
Optimum O 
specific O 
activity O 
and O 
incubation O 
time O 
were O 
determined O 
for O 
all O 
the O 
cell O 
lines O 
. O 
The O 
results O 
showed O 
that O 
the O 
cell O 
uptake O 
of O 
the O 
radiolabeled O 
peptide O 
conjugates O 
in O 
tumor O 
cell O 
lines O 
were O 
higher O 
than O 
in O 
the O 
control O 
cell O 
line O 
. O 
The O 
findings O 
of O 
this O 
study O 
indicated O 
the O 
need O 
for O 
further O 
development O 
of O 
in O 
vivo O 
study O 
as O 
a O 
radiopharmaceutical O 
for O 
pancreatic O 
tumor O 
imaging O 
. O 

omics O 
based O 
assessment O 
of O 
cadmium B-SYSTEMATIC 
toxicity O 
in O 
the O 
green O 
alga O 
Chlamydomonas O 
reinhardtii O 
. O 

effects O 
of O 
cadmium B-SYSTEMATIC 
were O 
assessed O 
in O 
the O 
freshwater O 
alga O 
Chlamydomonas O 
reinhardtii O 
. O 
Algae O 
were O 
exposed O 
to O 
concentrations O 
of O 
0 O 
, O 
8.1 O 
or O 
114.8 O 
μM O 
of O 
cadmium B-SYSTEMATIC 
and O 
growth O 
rates O 
, O 
gene O 
transcription O 
and O 
metabolite O 
profiles O 
were O 
examined O 
after O 
48 O 
and O 
72 O 
h O 
of O 
exposure O 
. O 
In O 
algae O 
exposed O 
to O 
8.1 O 
μM O 
Cd B-FORMULA 
, O 
several O 
genes O 
were O 
differentially O 
transcribed O 
after O 
48 O 
h O 
but O 
no O 
adverse O 
growth O 
related O 
effects O 
were O 
detected O 
. O 
A O 
transient O 
effect O 
on O 
both O 
gene O 
transcription O 
patterns O 
and O 
metabolite O 
profiles O 
could O 
be O 
discerned O 
after O 
48 O 
h O 
of O 
exposure O 
but O 
the O 
majority O 
of O 
these O 
changes O 
disappeared O 
after O 
72 O 
h O 
. O 
In O 
contrast O 
, O 
all O 
effects O 
were O 
more O 
pronounced O 
at O 
the O 
114.8 O 
μM O 
cadmium B-SYSTEMATIC 
exposure O 
. O 
Here O 
growth O 
was O 
clearly O 
reduced O 
and O 
transcription O 
of O 
a O 
large O 
number O 
of O 
genes O 
involved O 
in O 
oxidative O 
stress O 
defense O 
mechanisms O 
was O 
differentially O 
increased O 
. O 
Metabolites O 
involved O 
in O 
the O 
glutathione B-TRIVIAL 
synthesis O 
pathway O 
( O 
an O 
important O 
antioxidant O 
defense O 
) O 
were O 
also O 
affected O 
but O 
the O 
effects O 
of O 
cadmium B-SYSTEMATIC 
were O 
found O 
to O 
be O 
more O 
pronounced O 
at O 
the O 
transcript O 
level O 
than O 
in O 
the O 
metabolome O 
, O 
suggesting O 
that O 
the O 
former O 
exhibits O 
greater O 
sensitivity O 
toward O 
cadmium B-SYSTEMATIC 
exposure O 
. O 

new O 
coumarinolignoids B-FAMILY 
from O 
seeds O 
of O 
Solanum O 
indicum O 
. O 

- O 
guided O 
fractionation O 
of O 
seeds O 
of O 
Solanum O 
indicum O 
for O 
anti-HBV O 
activity O 
led O 
to O 
the O 
isolation O 
of O 
two O 
novel O 
coumarinolignoid B-FAMILY 
alkaloids I-FAMILY 
( O 
indicumines B-MULTIPLE 
A-B I-MULTIPLE 
, O 
1-2 O 
) O 
and O 
two O 
new O 
coumarinolignoids B-FAMILY 
( O 
indicumines B-MULTIPLE 
C-D I-MULTIPLE 
, O 
3-4 O 
) O 
, O 
together O 
with O 
four O 
known O 
coumarins B-FAMILY 
( O 
5-8 O 
) O 
. O 
Their O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
. O 
The O 
two O 
novel O 
coumarinolignoid B-FAMILY 
alkaloids I-FAMILY 
shows O 
anti-HBV O 
activities O 
through O 
specifically O 
inhibiting O 
the O 
secretion O 
of O 
HBsAg O 
in O 
HepG2.2.15 O 
. O 

optimization O 
of O 
2,5-thiophene B-FAMILY 
amides I-FAMILY 
as O 
highly O 
potent O 
and O 
selective O 
17β-hydroxysteroid B-SYSTEMATIC 
dehydrogenase O 
type O 
2 O 
inhibitors O 
for O 
the O 
treatment O 
of O 
osteoporosis O 
. O 

of O 
17β-HSD2 O 
is O 
an O 
attractive O 
mechanism O 
for O 
the O 
treatment O 
of O 
osteoporosis O 
. O 
We O 
report O 
here O 
the O 
optimization O 
of O 
human O 
17β-HSD2 O 
inhibitors O 
in O 
the O 
2,5-thiophene B-FAMILY 
amide I-FAMILY 
class O 
by O 
varying O 
the O 
size O 
of O 
the O 
linker O 
( O 
n O 
equals O 
0 O 
and O 
2 O 
) O 
between O 
the O 
amide B-FAMILY 
moiety O 
and O 
the O 
phenyl B-SYSTEMATIC 
group O 
. O 
While O 
none O 
of O 
the O 
phenethylamides B-FAMILY 
( O 
n O 
= O 
2 O 
) O 
were O 
active O 
, O 
most O 
of O 
the O 
anilides B-FAMILY 
( O 
n O 
= O 
0 O 
) O 
turned O 
out O 
to O 
moderately O 
or O 
strongly O 
inhibit O 
17β-HSD2 O 
. O 
The O 
four O 
most O 
active O 
compounds O 
showed O 
an O 
IC₅₀ O 
of O 
around O 
60 O 
nM O 
and O 
a O 
very O 
good O 
selectivity O 
toward O 
17β-HSD1 O 
, O 
17β-HSD4 O 
, O 
17β-HSD5 O 
, O 
11β-HSD1 O 
, O 
11β-HSD2 O 
and O 
the O 
estrogen B-FAMILY 
receptors O 
α O 
and O 
β O 
. O 
The O 
investigated O 
compounds O 
inhibited O 
monkey O 
17β-HSD2 O 
moderately O 
, O 
and O 
one O 
of O 
them O 
showed O 
good O 
inhibitory O 
activity O 
on O 
mouse O 
17β-HSD2 O 
. O 
SAR O 
studies O 
allowed O 
a O 
first O 
characterization O 
of O 
the O 
human O 
17β-HSD2 O 
active O 
site O 
, O 
which O 
is O 
predicted O 
to O 
be O 
considerably O 
larger O 
than O 
that O 
of O 
17β-HSD1 O 
. O 

effect O 
of O 
secoisolariciresinol B-TRIVIAL 
diglucoside I-TRIVIAL 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
. O 

mellitus O 
is O 
a O 
chronic O 
metabolic O 
disorder O 
characterized O 
by O 
hyperglycaemia O 
. O 
Its O 
complications O 
such O 
as O 
neuropathy O 
, O 
cardiopathy O 
, O 
nephropathy O 
, O 
and O 
micro O 
and O 
macro O 
vascular O 
diseases O 
are O 
believed O 
to O 
be O 
due O 
to O 
the O 
increase O 
in O 
oxidative O 
stress O 
and O 
decrease O 
in O 
the O 
level O 
of O 
antioxidants O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
antihyperglycemic O 
activity O 
of O 
synthetic O 
Secoisolariciresinol B-TRIVIAL 
diglucoside I-TRIVIAL 
( O 
SDG B-ABBREVIATION 
) O 
in O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
)-induced O 
diabetic O 
rats O 
. O 
The O 
synthetic O 
SDG B-ABBREVIATION 
in O 
a O 
single O 
- O 
dose O 
( O 
20 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
two O 
- O 
day O 
study O 
showed O 
dose O 
- O 
dependent O 
reduction O 
in O 
glucose B-TRIVIAL 
levels O 
with O 
maximum O 
effect O 
of O 
64.62% O 
at O 
48 O 
h O 
post O 
drug O 
treatment O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
which O 
is O 
comparable O 
to O 
that O 
of O 
the O 
standard O 
drug O 
tolbutamide B-TRIVIAL 
( O 
20 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
. O 
In O 
a O 
multi O 
- O 
dose O 
fourteen O 
- O 
day O 
study O 
, O 
lower O 
doses O 
of O 
SDG B-ABBREVIATION 
( O 
5 O 
and O 
10 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
exhibited O 
moderate O 
reduction O 
in O 
glucose B-TRIVIAL 
levels O 
, O 
lipid O 
profile O 
, O 
restoration O 
of O 
antioxidant O 
enzymes O 
and O 
improvement O 
of O 
the O 
insulin O 
and O 
c O 
- O 
peptide O 
levels O 
which O 
shows O 
the O 
regeneration O 
of O 
β-cell O 
which O 
secretes O 
insulin O 
. O 
Altered O 
levels O 
of O 
lipids O 
and O 
enzymatic O 
antioxidants O 
were O 
also O 
restored O 
by O 
the O 
SDG B-ABBREVIATION 
to O 
the O 
considerable O 
levels O 
in O 
diabetic O 
rats O 
. O 
Results O 
of O 
the O 
present O 
investigation O 
suggest O 
that O 
diabetes O 
is O 
associated O 
with O 
an O 
increase O 
in O 
oxidative O 
stress O 
as O 
shown O 
by O 
increase O 
in O 
serum O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
decreased O 
levels O 
of O 
catalase O 
( O 
CAT O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
. O 
Also O 
, O 
diabetes O 
is O 
associated O 
with O 
an O 
increase O 
in O 
serum O 
total O 
cholesterol B-TRIVIAL 
as O 
well O 
as O 
triglycerides B-FAMILY 
levels O 
and O 
decrease O 
in O 
insulin O 
and O 
c O 
- O 
peptide O 
levels O 
. O 
SDG B-ABBREVIATION 
is O 
effective O 
in O 
retarding O 
the O 
development O 
of O 
diabetic O 
complications O 
. O 
We O 
propose O 
that O 
synthetic O 
SDG B-ABBREVIATION 
exerts O 
anti O 
hyperglycemic O 
effect O 
by O 
preventing O 
the O 
liver O 
from O 
peroxidation O 
damage O 
through O 
inhibition O 
of O 
ROS O 
level O 
mediated O 
increased O 
level O 
of O 
enzymatic O 
and O 
non-enzymatic O 
antioxidants O 
. O 
And O 
, O 
also O 
maintaining O 
tissue O 
function O 
which O 
results O 
in O 
improving O 
the O 
sensitivity O 
and O 
response O 
of O 
target O 
cells O 
in O 
STZ B-ABBREVIATION 
-induced O 
diabetic O 
rats O 
to O 
insulin O 
. O 

/ O 
iodide B-SYSTEMATIC 
symporter O 
is O 
expressed O 
in O 
the O 
majority O 
of O 
seminomas O 
and O 
embryonal O 
testicular O 
carcinomas O 
. O 

cancer O 
is O 
the O 
most O 
frequent O 
cancer O 
in O 
young O 
men O 
. O 
The O 
large O 
majority O 
of O 
patients O 
have O 
a O 
good O 
prognosis O 
, O 
but O 
in O 
a O 
small O 
group O 
of O 
tumors O 
, O 
the O 
current O 
treatments O 
are O 
not O 
effective O 
. O 
Radioiodine B-SYSTEMATIC 
is O 
routinely O 
used O 
in O 
the O 
treatment O 
of O 
thyroid O 
cancer O 
and O 
is O 
currently O 
investigated O 
as O 
a O 
potential O 
therapeutic O 
tool O 
even O 
for O 
extra O 
- O 
thyroid O 
tumors O 
able O 
to O 
concentrate O 
this O 
radioisotope O 
. O 
Expression O 
of O 
Na(+) B-FORMULA 
/ O 
I(-) B-FORMULA 
symporter O 
( O 
NIS O 
( O 
SLC5A5 O 
) O 
) O 
, O 
the O 
glycoprotein O 
responsible O 
for O 
iodide B-SYSTEMATIC 
transport O 
, O 
has O 
been O 
demonstrated O 
in O 
normal O 
testicular O 
tissue O 
. O 
In O 
this O 
study O 
, O 
we O 
analyzed O 
NIS O 
expression O 
in O 
a O 
large O 
series O 
of O 
testicular O 
carcinomas O 
. O 
Our O 
retrospective O 
series O 
included O 
107 O 
patients O 
operated O 
for O 
testicular O 
tumors O 
: O 
98 O 
typical O 
seminomas O 
, O 
six O 
embryonal O 
carcinomas O 
, O 
one O 
mixed O 
embryonal O 
choriocarcinoma O 
, O 
and O 
two O 
Leydig O 
cells O 
tumors O 
. O 
Expression O 
and O 
regulation O 
of O 
NIS O 
mRNA O 
and O 
protein O 
levels O 
were O 
also O 
investigated O 
in O 
human O 
embryonal O 
testicular O 
carcinoma O 
cells O 
( O 
NTERA O 
) O 
by O 
real O 
- O 
time O 
RT-PCR O 
and O 
western O 
blotting O 
respectively O 
. O 
Immunohistochemical O 
analysis O 
showed O 
the O 
presence O 
of O 
NIS O 
in O 
the O 
large O 
majority O 
of O 
seminomas O 
( O 
90 O 
/ O 
98 O 
) O 
and O 
embryonal O 
carcinomas O 
( O 
5 O 
/ O 
7 O 
) O 
of O 
the O 
testis O 
but O 
not O 
in O 
Leydig O 
cell O 
carcinomas O 
. O 
Expression O 
of O 
NIS O 
protein O 
was O 
significantly O 
associated O 
with O 
lymphovascular O 
invasion O 
. O 
In O 
NTERA O 
cells O 
treated O 
with O 
the O 
histone O 
deacetylase O 
inhibitors O 
SAHA B-ABBREVIATION 
and O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
significant O 
increase O 
in O 
NIS O 
mRNA O 
( O 
about O 
60- O 
and O 
30-fold O 
vs O 
control O 
, O 
P O 
< O 
0.001 O 
and O 
P O 
< O 
0.01 O 
respectively O 
) O 
and O 
protein O 
levels O 
, O 
resulting O 
in O 
enhanced O 
ability O 
to O 
uptake O 
radioiodine B-SYSTEMATIC 
, O 
was O 
observed O 
. O 
Finally O 
, O 
NIS O 
expression O 
in O 
testicular O 
tumors O 
with O 
the O 
more O 
aggressive O 
behavior O 
is O 
of O 
interest O 
for O 
the O 
potential O 
use O 
of O 
targeting O 
NIS O 
to O 
deliver O 
radioiodine B-SYSTEMATIC 
in O 
malignant O 
cells O 
. O 

II O 
enzymes O 
, O 
including O 
Ugts O 
, O 
Sults O 
, O 
and O 
Gsts O 
, O 
are O 
critical O 
for O 
the O 
disposition O 
and O 
detoxification O 
of O 
endo- O 
and O 
xenobiotics O 
. O 
In O 
this O 
study O 
, O 
the O 
mRNA O 
and O 
protein O 
expression O 
of O 
major O 
phase O 
II O 
enzymes O 
, O 
as O 
well O 
as O 
key O 
regulatory O 
transcription O 
factors O 
, O 
were O 
quantified O 
in O 
livers O 
of O 
time O 
- O 
matched O 
pregnant O 
and O 
virgin O 
control O 
C57BL O 
/ O 
6 O 
mice O 
on O 
gestation O 
days O 
( O 
GD O 
) O 
7 O 
, O 
11 O 
, O 
14 O 
, O 
17 O 
, O 
and O 
postnatal O 
days O 
( O 
PND O 
) O 
1 O 
, O 
15 O 
, O 
and O 
30 O 
. O 
Compared O 
with O 
virgin O 
controls O 
, O 
the O 
mRNA O 
expression O 
of O 
Ugt1a1 O 
, O 
1a6 O 
, O 
1a9 O 
, O 
2a3 O 
, O 
2b1 O 
, O 
2b34 O 
, O 
and O 
2b35 O 
decreased O 
40 O 
to O 
80% O 
in O 
pregnant O 
dams O 
. O 
Protein O 
expression O 
of O 
Ugt1a6 O 
also O 
decreased O 
and O 
corresponded O 
with O 
reduced O 
in O 
vitro O 
glucuronidation O 
of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
in O 
S9 O 
fractions O 
from O 
livers O 
of O 
pregnant O 
mice O 
. O 
Similar O 
to O 
Ugts O 
levels O 
, O 
Gsta1 O 
and O 
a4 O 
mRNAs O 
were O 
reduced O 
in O 
pregnant O 
dams O 
in O 
mid O 
to O 
late O 
gestation O 
; O 
however O 
no O 
change O 
in O 
protein O 
expression O 
was O 
observed O 
. O 
Conversely O 
, O 
Sult1a1 O 
, O 
2a1 O 
/ O 
2 O 
, O 
and O 
3a1 O 
mRNAs O 
increased O 
100 O 
to O 
500% O 
at O 
various O 
time O 
points O 
in O 
pregnant O 
and O 
lactating O 
mice O 
and O 
corresponded O 
with O 
enhanced O 
in O 
vitro O 
sulfation O 
of O 
acetaminophen B-TRIVIAL 
in O 
liver O 
S9 O 
fractions O 
. O 
Coinciding O 
with O 
maximal O 
decreases O 
in O 
Ugts O 
as O 
well O 
as O 
increases O 
in O 
Sults O 
, O 
the O 
expression O 
of O 
transcription O 
factors O 
CAR O 
, O 
PPARα O 
, O 
and O 
PXR O 
and O 
their O 
target O 
genes O 
were O 
downregulated O 
, O 
whereas O 
ERα O 
mRNA O 
was O 
upregulated O 
. O 
Collectively O 
, O 
these O 
data O 
demonstrate O 
altered O 
regulation O 
of O 
hepatic O 
phase O 
II O 
metabolism O 
in O 
mice O 
during O 
pregnancy O 
and O 
suggest O 
that O 
CAR O 
, O 
PPARα O 
, O 
PXR O 
, O 
and O 
ERα O 
signaling O 
pathways O 
may O 
be O 
candidate O 
signaling O 
pathways O 
responsible O 
for O 
these O 
changes O 
. O 

Permeability O 
Surface O 
Area O 
for O 
Glucose B-TRIVIAL 
in O 
Obese O 
Women O 
with O 
Postprandial O 
Hyperglycemia O 
: O 
No O 
Effect O 
of O 
Phosphodiesterase-5 O 
( O 
PDE-5 O 
) O 
Inhibition O 
. O 

- O 
mediated O 
microvascular O 
recruitment O 
is O 
recognized O 
as O 
a O 
potential O 
mechanism O 
contributing O 
to O 
insulin O 
resistance O 
. O 
In O 
this O 
study O 
, O 
we O 
compared O 
a O 
marker O 
of O 
microvascular O 
function O 
, O 
the O 
permeability O 
surface O 
area O 
for O 
glucose B-TRIVIAL 
( O 
PSglu O 
) O 
, O 
and O 
forearm O 
glucose B-TRIVIAL 
uptake O 
after O 
an O 
OGTT O 
in O 
obese O 
women O 
with O 
impaired O 
glucose B-TRIVIAL 
metabolism O 
and O 
healthy O 
lean O 
nondiabetic O 
women O 
, O 
with O 
the O 
aim O 
to O 
characterize O 
whether O 
decreased O 
permeability O 
surface O 
area O 
for O 
glucose B-TRIVIAL 
or O 
decreased O 
glucose B-TRIVIAL 
uptake O 
may O 
contribute O 
to O 
postprandial O 
hyperglycemia O 
in O 
the O 
obese O 
group O 
. O 
In O 
addition O 
, O 
we O 
evaluated O 
whether O 
the O 
phosphodiesterase-5 O 
( O 
PDE-5 O 
) O 
inhibitor O 
tadalafil B-TRIVIAL 
, O 
in O 
a O 
randomized O 
double O 
blind O 
placebo O 
controlled O 
design O 
, O 
might O 
attenuate O 
postprandial O 
glucose B-TRIVIAL 
levels O 
in O 
obese O 
women O 
. O 
For O 
these O 
purposes O 
, O 
intramuscular O 
microdialysis O 
, O 
blood O 
sampling O 
from O 
arterial O 
and O 
venous O 
blood O 
of O 
the O 
forearm O 
, O 
and O 
measurements O 
of O 
forearm O 
blood O 
flow O 
were O 
performed O 
. O 
The O 
results O 
showed O 
an O 
impaired O 
permeability O 
surface O 
area O 
for O 
glucose B-TRIVIAL 
( O 
IAUC O 
PSglu O 
31±13 O 
vs O 
. O 
124±31 O 
; O 
p O 
< O 
0.05 O 
) O 
in O 
obese O 
when O 
compared O 
with O 
lean O 
participants O 
, O 
but O 
no O 
differences O 
in O 
forearm O 
glucose B-TRIVIAL 
uptake O 
appeared O 
between O 
the O 
groups O 
. O 
Furthermore O 
, O 
a O 
single O 
dose O 
of O 
tadalafil B-TRIVIAL 
10 O 
mg O 
showed O 
no O 
improvement O 
of O 
the O 
permeability O 
surface O 
area O 
for O 
glucose B-TRIVIAL 
, O 
glucose B-TRIVIAL 
uptake O 
, O 
or O 
circulating O 
glucose B-TRIVIAL 
levels O 
in O 
obese O 
participants O 
. O 
In O 
conclusion O 
, O 
the O 
postprandial O 
PSglu O 
response O 
was O 
impaired O 
in O 
obese O 
women O 
showing O 
postprandial O 
hyperglycemia O 
, O 
indicating O 
a O 
compromised O 
microcirculation O 
. O 
However O 
, O 
we O 
were O 
unable O 
to O 
demonstrate O 
any O 
acute O 
effect O 
on O 
either O 
vascular O 
function O 
or O 
glucose B-TRIVIAL 
uptake O 
of O 
the O 
phosphodiesterase-5 O 
( O 
PDE-5 O 
) O 
inhibitor O 
tadalafil B-TRIVIAL 
. O 

D I-TRIVIAL 
attenuates O 
bile O 
duct O 
ligation O 
- O 
induced O 
hepatic O 
injury O 
and O 
fibrosis O 
in O 
mice O 
. O 

D I-TRIVIAL 
( O 
PD O 
) O 
is O 
the O 
major O 
triterpene B-FAMILY 
saponin I-FAMILY 
in O 
the O 
root O 
of O 
Platycodon O 
grandiflorum O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
protective O 
effects O 
of O 
PD O 
on O 
bile O 
duct O 
ligation O 
(BDL)-induced O 
cholestasis O 
in O 
mice O 
. O 
Mice O 
were O 
allocated O 
to O 
five O 
groups O 
: O 
sham O 
, O 
BDL O 
alone O 
, O 
and O 
BDL O 
with O 
PD O 
treatment O 
at O 
1 O 
, O 
2 O 
, O 
and O 
4mg O 
/ O 
kg O 
. O 
PD O 
was O 
administered O 
to O 
the O 
mice O 
for O 
28 O 
consecutive O 
days O 
after O 
the O 
BDL O 
operation O 
. O 
PD O 
treatment O 
of O 
BDL-operated O 
mice O 
decreased O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
serum O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
and O 
total O 
bilirubin B-TRIVIAL 
levels O 
by O 
up O 
to O 
37% O 
, O 
31% O 
, O 
and O 
41% O 
, O 
respectively O 
, O 
in O 
comparison O 
with O 
the O 
levels O 
in O 
mice O 
that O 
underwent O 
BDL O 
alone O 
. O 
PD O 
treatment O 
attenuated O 
oxidative O 
stress O 
, O 
as O 
evidenced O 
by O 
an O 
increase O 
in O 
anti-oxidative O 
enzyme O 
levels O 
glutathione B-TRIVIAL 
and O 
superoxide B-TRIVIAL 
dismutase O 
together O 
with O 
a O 
decrease O 
in O 
lipid O 
peroxidation O 
and O 
oxidative O 
stress O 
indices O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 
Histopathological O 
studies O 
further O 
confirmed O 
the O 
protective O 
effects O 
of O 
PD O 
on O 
cholestasis O 
- O 
induced O 
hepatic O 
injury O 
and O 
liver O 
fibrosis O 
in O 
mice O 
. O 
In O 
addition O 
, O 
nuclear O 
factor O 
- O 
kappa O 
B O 
and O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
levels O 
significantly O 
decreased O 
after O 
PD O 
treatment O 
, O 
as O 
did O 
the O 
levels O 
of O 
hepatocyte O 
apoptosis O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
PD O 
treatment O 
might O 
be O 
beneficial O 
in O 
cholestasis O 
- O 
induced O 
hepatotoxicity O 
. O 

surface O 
- O 
enhanced O 
Raman O 
scattering O 
platforms O 
: O 
composite O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
microspheres O 
coated O 
with O 
astralen O 
and O 
silver B-SYSTEMATIC 
nanoparticles O 
. O 

- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
microspectroscopy O 
is O 
a O 
very O 
promising O 
label O 
- O 
free O 
, O 
noncontact O 
, O 
and O 
nondestructive O 
method O 
for O 
real O 
- O 
time O 
monitoring O 
of O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
development O 
and O 
cell O 
integration O 
in O 
scaffolds O 
for O 
tissue O 
engineering O 
. O 
Here O 
, O 
we O 
prepare O 
a O 
new O 
type O 
of O 
micrometer O 
- O 
sized O 
SERS O 
substrate O 
, O 
core O 
- O 
shell O 
microparticles O 
composed O 
of O 
solid O 
carbonate B-FAMILY 
core O 
coated O 
with O 
silver B-SYSTEMATIC 
nanoparticles O 
and O 
polyhedral O 
multishell O 
fullerene B-TRIVIAL 
-like O 
structure O 
, O 
astralen O 
. O 
Astralen O 
has O 
been O 
assembled O 
with O 
polyallylamine B-FAMILY 
hydrochloride I-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
by O 
the O 
layer O 
- O 
by O 
- O 
layer O 
manner O 
followed O 
by O 
Ag B-FORMULA 
nanoparticle O 
formation O 
by O 
means O 
of O 
a O 
silver B-SYSTEMATIC 
mirror O 
reaction O 
, O 
giving O 
the O 
final O 
structure O 
of O 
composite O 
particles O 
CaCO3 B-FORMULA 
( O 
PAH B-ABBREVIATION 
/ O 
astralen)x/ O 
Ag B-FORMULA 
, O 
where O 
x O 
= O 
1-3 O 
. O 
The O 
components O 
of O 
the O 
microparticle O 
carry O 
multiple O 
functionalities O 
: O 
(i) O 
an O 
easy O 
identification O 
by O 
Raman O 
imaging O 
( O 
photostable O 
astralen O 
) O 
and O 
(ii) O 
SERS O 
due O 
to O 
a O 
rough O 
surface O 
of O 
Ag B-FORMULA 
nanoparticles O 
. O 
A O 
combination O 
of O 
Ag B-FORMULA 
and O 
astralen O 
nanoparticles O 
provides O 
an O 
enhancement O 
of O 
astralen O 
Raman O 
signal O 
by O 
more O 
than O 
1 O 
order O 
of O 
magnitude O 
. O 
Raman O 
signals O 
of O 
commonly O 
used O 
scaffold O 
components O 
such O 
as O 
polylactide B-FAMILY 
and O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
as O 
well O 
as O 
ECM O 
component O 
( O 
hyaluronic O 
acid O 
) O 
are O 
significantly O 
enhanced O 
. O 
Thus O 
, O 
we O 
demonstrate O 
that O 
new O 
mechanically O 
robust O 
and O 
easily O 
detectable O 
( O 
by O 
astralen O 
signal O 
or O 
optically O 
) O 
core O 
- O 
shell O 
microspheres O 
based O 
on O 
biocompatible O 
CaCO3 B-FORMULA 
can O 
be O 
used O 
as O 
SERS O 
platform O 
. O 
Particle O 
design O 
opens O 
many O 
future O 
perspectives O 
for O 
fabrication O 
of O 
SERS O 
platforms O 
with O 
multiple O 
functions O 
for O 
biomedical O 
applications O 
, O 
for O 
example O 
, O 
for O 
theranostic O 
. O 

a O 
free O 
- O 
living O 
nematode O 
, O 
C O 
. O 
elegans O 
is O 
exposed O 
to O 
various O 
pesticides O 
used O 
in O 
agriculture O 
, O 
as O 
well O 
as O 
to O 
persistent O 
organic O 
residues O 
which O 
may O 
contaminate O 
the O 
soil O 
for O 
long O 
periods O 
. O 
Following O 
on O 
from O 
our O 
previous O 
study O 
of O 
metal O 
effects O 
on O 
24 O 
GFP-reporter O 
strains O 
representing O 
four O 
different O 
stress O 
- O 
response O 
pathways O 
in O 
C O 
. O 
elegans O 
( O 
Anbalagan O 
et O 
al O 
. O 
Ecotoxicology O 
21 O 
: O 
439-455 O 
, O 
2012 O 
) O 
, O 
we O 
now O 
present O 
parallel O 
data O 
on O 
the O 
responses O 
of O 
these O 
same O 
strains O 
to O 
several O 
commonly O 
used O 
pesticides O 
. O 
Some O 
of O 
these O 
, O 
like O 
dichlorvos B-TRIVIAL 
, O 
induced O 
multiple O 
stress O 
genes O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Unusually O 
, O 
endosulfan B-TRIVIAL 
induced O 
only O 
one O 
gene O 
( O 
cyp-34A9 O 
) O 
to O 
very O 
high O 
levels O 
( O 
8-10-fold O 
) O 
even O 
at O 
the O 
lowest O 
test O 
concentration O 
, O 
with O 
a O 
clear O 
plateau O 
at O 
higher O 
doses O 
. O 
Other O 
pesticides O 
, O 
like O 
diuron B-TRIVIAL 
, O 
did O 
not O 
alter O 
reporter O 
gene O 
expression O 
detectably O 
even O 
at O 
the O 
highest O 
test O 
concentration O 
attainable O 
, O 
while O 
others O 
( O 
such O 
as O 
glyphosate B-TRIVIAL 
) O 
did O 
so O 
only O 
at O 
very O 
high O 
concentrations O 
. O 
We O 
have O 
also O 
used O 
five O 
responsive O 
GFP O 
reporters O 
to O 
investigate O 
the O 
toxicity O 
of O 
soil O 
pore O 
water O 
from O 
two O 
agricultural O 
sites O 
in O 
south O 
- O 
east O 
Spain O 
, O 
designated O 
P74 O 
( O 
used O 
for O 
cauliflower O 
production O 
, O 
but O 
significantly O 
metal O 
contaminated O 
) O 
and O 
P73 O 
( O 
used O 
for O 
growing O 
lettuce O 
, O 
but O 
with O 
only O 
background O 
levels O 
of O 
metals O 
) O 
. O 
Both O 
soil O 
pore O 
water O 
samples O 
induced O 
all O 
five O 
test O 
genes O 
to O 
varying O 
extents O 
, O 
yet O 
artificial O 
mixtures O 
containing O 
all O 
major O 
metals O 
present O 
had O 
essentially O 
no O 
effect O 
on O 
these O 
same O 
transgenes O 
. O 
Soluble O 
organic O 
contaminants O 
present O 
in O 
the O 
pore O 
water O 
were O 
extracted O 
with O 
acetone B-SYSTEMATIC 
and O 
dichloromethane B-SYSTEMATIC 
, O 
then O 
after O 
evaporation O 
of O 
the O 
solvents O 
, O 
the O 
organic O 
residues O 
were O 
redissolved O 
in O 
ultrapure O 
water O 
to O 
reconstitute O 
the O 
soluble O 
organic O 
components O 
of O 
the O 
original O 
soil O 
pore O 
water O 
. O 
These O 
organic O 
extracts O 
induced O 
transgene O 
expression O 
at O 
similar O 
or O 
higher O 
levels O 
than O 
the O 
original O 
pore O 
water O 
. O 
Addition O 
of O 
the O 
corresponding O 
metal O 
mixtures O 
had O 
either O 
no O 
effect O 
, O 
or O 
reduced O 
transgene O 
expression O 
towards O 
the O 
levels O 
seen O 
with O 
soil O 
pore O 
water O 
only O 
. O 
We O 
conclude O 
that O 
the O 
main O 
toxicants O 
present O 
in O 
these O 
soil O 
pore O 
water O 
samples O 
are O 
organic O 
rather O 
than O 
metallic O 
in O 
nature O 
. O 
Organic O 
extracts O 
from O 
a O 
control O 
standard O 
soil O 
( O 
Lufa O 
2.2 O 
) O 
had O 
negligible O 
effects O 
on O 
expression O 
of O 
these O 
genes O 
, O 
and O 
similarly O 
several O 
pesticides O 
had O 
little O 
effect O 
on O 
the O 
expression O 
of O 
a O 
constitutive O 
myo-3 O 
: O 
: O 
GFP O 
transgene O 
. O 
Both O 
the O 
P73 O 
and O 
P74 O 
sites O 
have O 
been O 
treated O 
regularly O 
with O 
( O 
undisclosed O 
) O 
pesticides O 
, O 
as O 
permitted O 
under O 
EU O 
regulations O 
, O 
though O 
other O 
( O 
e.g O 
. O 
industrial O 
) O 
organic O 
residues O 
may O 
also O 
be O 
present O 
. O 

disorders O 
have O 
long O 
and O 
dominantly O 
been O 
regarded O 
to O 
be O 
induced O 
by O 
disturbances O 
of O 
neuronal O 
networks O 
including O 
synapses O 
and O 
neurotransmitters O 
. O 
Thus O 
, O 
the O 
effects O 
of O 
psychotropic O 
drugs O 
such O 
as O 
antipsychotics O 
and O 
antidepressants O 
have O 
been O 
understood O 
to O 
modulate O 
synaptic O 
regulation O 
via O 
receptors O 
and O 
transporters O 
of O 
neurotransmitters O 
such O 
as O 
dopamine B-TRIVIAL 
and O 
serotonin B-TRIVIAL 
. O 
Recently O 
, O 
microglia O 
, O 
immunological O 
/ O 
inflammatory O 
cells O 
in O 
the O 
brain O 
, O 
have O 
been O 
indicated O 
to O 
have O 
positive O 
links O 
to O 
psychiatric O 
disorders O 
. O 
Positron O 
emission O 
tomography O 
( O 
PET O 
) O 
imaging O 
and O 
postmortem O 
studies O 
have O 
revealed O 
microglial O 
activation O 
in O 
the O 
brain O 
of O 
neuropsychiatric O 
disorders O 
such O 
as O 
schizophrenia O 
, O 
depression O 
and O 
autism O 
. O 
Animal O 
models O 
of O 
neuropsychiatric O 
disorders O 
have O 
revealed O 
the O 
underlying O 
microglial O 
pathologies O 
. O 
In O 
addition O 
, O 
various O 
psychotropic O 
drugs O 
have O 
been O 
suggested O 
to O 
have O 
direct O 
effects O 
on O 
microglia O 
. O 
Until O 
now O 
, O 
the O 
relationship O 
between O 
microglia O 
, O 
neurotransmitters O 
and O 
psychiatric O 
disorders O 
has O 
not O 
been O 
well O 
understood O 
. O 
Therefore O 
, O 
in O 
this O 
review O 
, O 
at O 
first O 
, O 
we O 
summarize O 
recent O 
findings O 
of O 
interaction O 
between O 
microglia O 
and O 
neurotransmitters O 
such O 
as O 
dopamine B-TRIVIAL 
, O 
serotonin B-TRIVIAL 
, O 
norepinephrine B-TRIVIAL 
, O 
acetylcholine B-SYSTEMATIC 
and O 
glutamate B-TRIVIAL 
. O 
Next O 
, O 
we O 
introduce O 
up O 
- O 
to O 
- O 
date O 
knowledge O 
of O 
the O 
effects O 
of O 
psychotropic O 
drugs O 
such O 
as O 
antipsychotics O 
, O 
antidepressants O 
and O 
antiepileptics O 
on O 
microglial O 
modulation O 
. O 
Finally O 
, O 
we O 
propose O 
the O 
possibility O 
that O 
modulating O 
microglia O 
may O 
be O 
a O 
key O 
target O 
in O 
the O 
treatment O 
of O 
various O 
psychiatric O 
disorders O 
. O 
Further O 
investigations O 
and O 
clinical O 
trials O 
should O 
be O 
conducted O 
to O 
clarify O 
this O 
perspective O 
, O 
using O 
animal O 
in O 
vivo O 
studies O 
and O 
imaging O 
studies O 
with O 
human O 
subjects O 
. O 

of O 
selenolate B-SYSTEMATIC 
-protected O 
Au18(SeC6H5)14 B-FORMULA 
nanoclusters O 
. O 

work O 
reports O 
the O 
first O 
synthesis O 
of O 
selenophenolate B-SYSTEMATIC 
-protected O 
Au(18)(SePh)(14) B-FORMULA 
nanoclusters O 
. O 
This O 
cluster O 
exhibits O 
distinct O 
differences O 
from O 
its O 
thiolate O 
analogue O 
in O 
terms O 
of O 
optical O 
absorption O 
properties O 
. O 
The O 
Au(18)(SePh)(14) B-FORMULA 
nanoclusters O 
were O 
obtained O 
via O 
a O 
controlled O 
reaction O 
of O 
Au(25)(SCH(2)CH(2)Ph)(18) B-FORMULA 
with O 
selenophenol B-SYSTEMATIC 
. O 
Electrospray O 
ionization O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
ESI-TOF-MS O 
) O 
revealed O 
the O 
crude O 
product O 
to O 
contain O 
predominantly O 
Au(18)(SePh)(14) B-FORMULA 
nanoclusters O 
, O 
and O 
side O 
products O 
include O 
Au(15)(SePh)(13) B-FORMULA 
, O 
Au(19)(SePh)(15) B-FORMULA 
and O 
Au(20)(SePh)(16) B-FORMULA 
. O 
High O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
was O 
employed O 
to O 
isolate O 
Au(18)(SePh)(14) B-FORMULA 
nanoclusters O 
. O 
The O 
results O 
of O 
thermogravimetric O 
analysis O 
( O 
TGA O 
) O 
, O 
elemental O 
analysis O 
( O 
EA O 
) O 
, O 
and O 
(1)H B-FORMULA 
/ O 
(13)C B-FORMULA 
NMR O 
spectroscopy O 
confirmed O 
the O 
cluster O 
composition O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
of O 
selenolate B-SYSTEMATIC 
-protected O 
Au(18) B-FORMULA 
nanoclusters O 
. O 
Future O 
theoretical O 
and O 
X-ray O 
crystallographic O 
work O 
will O 
reveal O 
the O 
geometric O 
structure O 
and O 
the O 
nature O 
of O 
selenolate B-SYSTEMATIC 
-gold O 
bonding O 
in O 
the O 
nanocluster O 
. O 

chamomile O 
, O 
Chamaemelum O 
nobile O 
L O 
. O 
( O 
Asteraceae O 
) O 
, O 
has O 
been O 
used O 
for O 
medicinal O 
applications O 
, O 
mainly O 
through O 
oral O 
dosage O 
forms O 
( O 
decoctions O 
and O 
infusions O 
) O 
. O 
Herein O 
, O 
the O 
nutritional O 
characterisation O 
of O 
C O 
. O 
nobile O 
was O 
performed O 
, O 
and O 
herbal O 
material O 
and O 
its O 
decoction O 
and O 
infusion O 
were O 
submitted O 
to O 
an O 
analysis O 
of O 
phytochemicals O 
and O 
bioactivity O 
evaluation O 
. O 
The O 
antioxidant O 
activity O 
was O 
determined O 
by O 
free O 
radicals O 
scavenging O 
activity O 
, O 
reducing O 
power O 
and O 
inhibition O 
of O 
lipid O 
peroxidation O 
, O 
the O 
antitumour O 
potential O 
was O 
tested O 
in O 
human O 
tumour O 
cell O 
lines O 
( O 
breast O 
, O 
lung O 
, O 
colon O 
, O 
cervical O 
and O 
hepatocellular O 
carcinomas O 
) O 
, O 
and O 
the O 
hepatotoxicity O 
was O 
evaluated O 
using O 
a O 
porcine O 
liver O 
primary O 
cell O 
culture O 
. O 
C O 
. O 
nobile O 
proved O 
to O 
be O 
an O 
equilibrated O 
valuable O 
herb O 
rich O 
in O 
carbohydrates B-FAMILY 
and O 
proteins O 
, O 
and O 
poor O 
in O 
fat O 
, O 
providing O 
tocopherols B-FAMILY 
, O 
carotenoids O 
and O 
essential O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
C18 O 
: O 
2n6 O 
and O 
C18 O 
: O 
3n3 O 
) O 
. O 
Moreover O 
, O 
the O 
herb O 
and O 
its O 
infusion O 
are O 
a O 
source O 
of O 
phenolic B-FAMILY 
compounds O 
( O 
flavonoids B-FAMILY 
such O 
as O 
flavonols B-FAMILY 
and O 
flavones B-FAMILY 
, O 
phenolic B-FAMILY 
acids I-FAMILY 
and O 
derivatives O 
) O 
and O 
organic O 
acids O 
( O 
oxalic B-MULTIPLE 
, I-MULTIPLE 
quinic I-MULTIPLE 
, I-MULTIPLE 
malic I-MULTIPLE 
, I-MULTIPLE 
citric I-MULTIPLE 
and I-MULTIPLE 
fumaric I-MULTIPLE 
acids I-MULTIPLE 
) O 
that O 
showed O 
antioxidant O 
and O 
antitumour O 
activities O 
, O 
without O 
hepatotoxicity O 
. O 
The O 
most O 
abundant O 
compounds O 
in O 
the O 
plant O 
extract O 
and O 
infusion O 
were O 
5-O-caffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
an O 
apigenin B-TRIVIAL 
derivative O 
. O 
These O 
, O 
as O 
well O 
as O 
other O 
bioactive O 
compounds O 
, O 
are O 
affected O 
in O 
C O 
. O 
nobile O 
decoction O 
, O 
leading O 
to O 
a O 
lower O 
antioxidant O 
potential O 
and O 
absence O 
of O 
antitumour O 
potential O 
. O 
The O 
plant O 
bioactivity O 
could O 
be O 
explored O 
in O 
the O 
medicine O 
, O 
food O 
, O 
and O 
cosmetic O 
industries O 
. O 

anion O 
- O 
transporting O 
polypeptides O 
( O 
OATP O 
) O 
1B1 O 
, O 
1B3 O 
, O 
and O 
2B1 O 
can O 
serve O 
as O 
the O 
loci O 
of O 
drug O 
- O 
drug O 
interactions O 
( O 
DDIs O 
) O 
. O 
In O 
the O 
present O 
work O 
, O 
the O 
cynomolgus O 
monkey O 
was O 
evaluated O 
as O 
a O 
potential O 
model O 
for O 
studying O 
OATP O 
- O 
mediated O 
DDIs O 
. O 
Three O 
cynomolgus O 
monkey O 
OATPs O 
( O 
cOATPs O 
) O 
, O 
with O 
a O 
high O 
degree O 
of O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
identity O 
( O 
91.9 O 
, O 
93.5 O 
, O 
and O 
96.6% O 
for O 
OATP1B1 O 
, O 
1B3 O 
, O 
and O 
2B1 O 
, O 
respectively O 
) O 
to O 
their O 
human O 
counterparts O 
, O 
were O 
cloned O 
, O 
expressed O 
, O 
and O 
characterized O 
. O 
The O 
cOATPs O 
were O 
stably O 
transfected O 
in O 
human O 
embryonic O 
kidney O 
cells O 
and O 
were O 
functionally O 
similar O 
to O 
the O 
corresponding O 
human O 
OATPs O 
( O 
hOATPs O 
) O 
, O 
as O 
evident O 
from O 
the O 
similar O 
uptake O 
rate O 
of O 
typical O 
substrates O 
( O 
estradiol-17β-d-glucuronide B-SYSTEMATIC 
, O 
cholecystokinin O 
octapeptide O 
, O 
and O 
estrone-3-sulfate B-SYSTEMATIC 
) O 
. O 
Moreover O 
, O 
six O 
known O 
hOATP O 
inhibitors O 
exhibited O 
similar O 
IC(50) O 
values O 
against O 
cOATPs O 
. O 
To O 
further O 
evaluate O 
the O 
appropriateness O 
of O 
the O 
cynomolgus O 
monkey O 
as O 
a O 
model O 
, O 
a O 
known O 
hOATP O 
substrate O 
[ O 
rosuvastatin B-TRIVIAL 
( O 
RSV B-ABBREVIATION 
)]-inhibitor O 
[ O 
rifampicin B-TRIVIAL 
( O 
RIF B-ABBREVIATION 
) O 
] O 
pair O 
was O 
examined O 
in O 
vitro O 
; O 
the O 
monkey O 
- O 
derived O 
parameters O 
( O 
RSV B-ABBREVIATION 
K(m) O 
and O 
RIF B-ABBREVIATION 
IC(50) O 
) O 
were O 
similar O 
( O 
within O 
3.5-fold O 
) O 
to O 
those O 
obtained O 
with O 
hOATPs O 
and O 
human O 
primary O 
hepatocytes O 
. O 
In O 
vivo O 
, O 
the O 
area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
of O 
RSV B-ABBREVIATION 
( O 
3 O 
mg O 
/ O 
kg O 
, O 
oral O 
) O 
given O 
1 O 
hour O 
after O 
a O 
single O 
RIF B-ABBREVIATION 
dose O 
( O 
15 O 
mg O 
/ O 
kg O 
, O 
oral O 
) O 
was O 
increased O 
2.9-fold O 
in O 
cynomolgus O 
monkeys O 
, O 
consistent O 
with O 
the O 
value O 
( O 
3.0-fold O 
) O 
reported O 
in O 
humans O 
. O 
A O 
number O 
of O 
in O 
vitro O 
- O 
in O 
vivo O 
extrapolation O 
approaches O 
, O 
considering O 
the O 
fraction O 
of O 
the O 
pathways O 
affected O 
and O 
free O 
versus O 
total O 
inhibitor O 
concentrations O 
, O 
were O 
also O 
explored O 
. O 
It O 
is O 
concluded O 
that O 
the O 
cynomolgus O 
monkey O 
has O 
the O 
potential O 
to O 
serve O 
as O 
a O 
useful O 
model O 
for O 
the O 
assessment O 
of O 
OATP O 
- O 
mediated O 
DDIs O 
in O 
a O 
nonclinical O 
setting O 
. O 

mechanism O 
of O 
Piper O 
gaudichaudianum O 
Kunth O 
essential O 
oil O 
and O 
its O 
major O 
compound O 
nerolidol B-TRIVIAL 
. O 

gaudichaudianum O 
Kunth O 
is O 
used O 
in O 
popular O 
medicine O 
as O 
anti-inflamatory O 
and O 
against O 
liver O 
disorders O 
. O 
One O 
of O 
the O 
most O 
studied O 
components O 
of O 
the O 
plant O 
is O 
the O 
essential O 
oil O 
for O 
which O 
chemical O 
analysis O 
revealed O 
(E)-nerolidol B-TRIVIAL 
as O 
major O 
compound O 
. O 
Recently O 
, O 
we O 
have O 
shown O 
that O 
P O 
. O 
gaudichaudianum O 
essential O 
oil O 
possesses O 
strong O 
cytotoxic O 
effects O 
in O 
mammalian O 
V79 O 
cells O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
analyze O 
the O 
cytotoxicity O 
and O 
mutagenicity O 
of O 
P O 
. O 
gaudichaudianum O 
essential O 
oil O 
and O 
nerolidol B-TRIVIAL 
using O 
Saccharomyces O 
cerevisiae O 
as O 
model O 
study O 
. O 
Treatment O 
of O 
the O 
XV185-14c O 
and O 
N123 O 
strains O 
with O 
essential O 
oil O 
and O 
nerolidol B-TRIVIAL 
led O 
to O 
cytotoxicity O 
but O 
did O 
not O 
induce O 
mutagenicity O 
. O 
Our O 
results O 
revealed O 
an O 
important O 
role O 
of O 
base O 
excision O 
repair O 
( O 
BER O 
) O 
as O 
the O 
ntg1 O 
, O 
ntg2 O 
, O 
apn1 O 
and O 
apn2 O 
mutants O 
showed O 
pronounced O 
sensitivity O 
to O 
essential O 
oil O 
and O 
nerolidol B-TRIVIAL 
. O 
In O 
the O 
absence O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
in O 
sod1Δ O 
mutant O 
strain O 
) O 
sensitivity O 
to O 
the O 
essential O 
oil O 
and O 
nerolidol B-TRIVIAL 
increased O 
indicating O 
that O 
this O 
oil O 
and O 
nerolidol B-TRIVIAL 
are O 
generating O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
The O 
ROS O 
production O 
was O 
confirmed O 
by O 
DCF-DA B-ABBREVIATION 
probing O 
assay O 
in O 
Sod O 
- O 
deficient O 
strains O 
. O 
From O 
this O 
, O 
we O 
conclude O 
that O 
the O 
observed O 
cytotoxicity O 
to O 
P O 
. O 
gaudichaudianum O 
essential O 
oil O 
and O 
nerolidol B-TRIVIAL 
is O 
mainly O 
related O 
to O 
ROS O 
and O 
DNA O 
single O 
strand O 
breaks O 
generated O 
by O 
the O 
presence O 
of O 
oxidative O 
lesions O 
. O 

role O 
of O 
native O 
salinity O 
regime O 
on O 
grass O 
shrimp O 
( O 
Palaemonetes O 
pugio O 
) O 
sensitivity O 
to O 
cadmium B-SYSTEMATIC 
. O 

euryhaline O 
crustaceans O 
, O 
sensitivity O 
to O 
toxic O 
trace O 
metals O 
may O 
be O 
linked O 
to O 
osmoregulation O 
and O 
salinity O 
conditions O 
. O 
This O 
study O 
investigated O 
if O 
grass O 
shrimp O 
( O 
Palaemonetes O 
pugio O 
) O 
populations O 
from O 
different O 
salinity O 
regimes O 
differed O 
in O 
sensitivity O 
to O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
. O 
Grass O 
shrimp O 
were O 
collected O 
in O 
May O 
2011 O 
from O 
two O 
marsh O 
sites O 
with O 
average O 
salinities O 
of O 
~3.0 O 
ppt O 
and O 
24 O 
ppt O 
. O 
Groups O 
were O 
acclimated O 
for O 
3-32 O 
weeks O 
in O 
either O 
their O 
respective O 
native O 
salinity O 
( O 
3 O 
ppt O 
→ O 
3 O 
ppt O 
and O 
24 O 
ppt O 
→ O 
24 O 
ppt O 
) O 
, O 
or O 
the O 
average O 
of O 
the O 
salinities O 
of O 
the O 
two O 
collection O 
sites O 
( O 
3 O 
ppt O 
→ O 
13.5 O 
ppt O 
and O 
24 O 
ppt O 
→ O 
13.5 O 
ppt O 
) O 
. O 
After O 
acclimation O 
, O 
groups O 
were O 
exposed O 
to O 
equivalent O 
free O 
- O 
ion O 
Cd B-FORMULA 
concentration O 
( O 
4.8 O 
± O 
0.3 O 
mg O 
/ O 
L O 
, O 
Cd(2+) B-FORMULA 
) O 
in O 
their O 
respective O 
acclimated O 
salinity O 
to O 
compare O 
survival O 
among O 
salinity O 
treatments O 
. O 
Results O 
of O 
Kaplan-Meier O 
survival O 
analysis O 
indicated O 
that O 
3 O 
ppt O 
→ O 
3 O 
ppt O 
shrimp O 
were O 
more O 
sensitive O 
to O 
Cd(2+) B-FORMULA 
than O 
any O 
other O 
group O 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
Additionally O 
, O 
3 O 
ppt O 
→ O 
13.5 O 
ppt O 
shrimp O 
were O 
less O 
sensitive O 
to O 
Cd(2+) B-FORMULA 
than O 
were O 
24 O 
ppt O 
→ O 
13.5 O 
ppt O 
shrimp O 
( O 
p O 
= O 
0.0013 O 
) O 
. O 
These O 
results O 
suggest O 
that O 
sensitivity O 
of O 
grass O 
shrimp O 
to O 
Cd B-FORMULA 
is O 
dependent O 
upon O 
the O 
salinity O 
during O 
exposure O 
, O 
and O 
the O 
salinity O 
regime O 
from O 
which O 
the O 
tested O 
population O 
originated O 
. O 
The O 
implication O 
is O 
that O 
toxicity O 
studies O 
and O 
risk O 
assessments O 
using O 
euryhaline O 
crustaceans O 
should O 
consider O 
the O 
salinity O 
of O 
test O 
population O 
collection O 
sites O 
when O 
interpreting O 
and O 
comparing O 
results O 
. O 

agonists O 
mediate O 
enhancement O 
of O 
β1-adrenergic O 
receptor O 
N B-FORMULA 
-terminal O 
cleavage O 
and O 
stabilization O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 

β(1)-adrenergic O 
receptor O 
( O 
β(1)AR O 
) O 
is O 
the O 
predominant O 
βAR O 
in O 
the O 
heart O 
and O 
is O 
the O 
main O 
target O 
for O 
β-adrenergic O 
antagonists O 
, O 
widely O 
used O 
in O 
the O 
treatment O 
of O 
cardiovascular O 
diseases O 
. O 
Previously O 
, O 
we O 
have O 
shown O 
that O 
the O 
human O 
( O 
h O 
) O 
β(1)AR O 
is O 
cleaved O 
in O 
its O 
N B-FORMULA 
terminus O 
by O 
a O 
metalloproteinase O 
, O 
both O 
constitutively O 
and O 
in O 
a O 
receptor O 
activation O 
- O 
dependent O 
manner O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
specific O 
events O 
involved O 
in O 
β(1)AR O 
regulation O 
, O 
focusing O 
on O 
the O 
effects O 
of O 
long O 
- O 
term O 
treatment O 
with O 
β-adrenergic O 
ligands O 
on O 
receptor O 
processing O 
in O 
stably O 
transfected O 
human O 
embryonic O 
kidney O 
293 O 
(i) O 
cells O 
. O 
The O 
key O 
findings O 
were O 
verified O 
using O 
the O 
transiently O 
transfected O 
hβ(1)AR O 
and O 
the O 
endogenously O 
expressed O 
receptor O 
in O 
neonatal O 
rat O 
cardiomyocytes O 
. O 
By O 
using O 
flow O 
cytometry O 
and O 
Western O 
blotting O 
, O 
we O 
demonstrated O 
that O 
isoproterenol B-TRIVIAL 
, O 
S-propranolol B-TRIVIAL 
, O 
CGP-12177 B-IDENTIFIER 
[ O 
4-[3-[(1,1-dimethylethyl)amino]2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one B-SYSTEMATIC 
] O 
, O 
pindolol B-TRIVIAL 
, O 
and O 
timolol B-TRIVIAL 
, O 
which O 
displayed O 
agonistic O 
properties O 
toward O 
the O 
β(1)AR O 
in O 
either O 
the O 
adenylyl B-TRIVIAL 
cyclase O 
or O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
signaling O 
pathways O 
, O 
induced O 
cleavage O 
of O 
the O 
mature O 
cell O 
- O 
surface O 
receptor O 
. O 
In O 
contrast O 
, O 
metoprolol B-TRIVIAL 
, O 
bisoprolol B-TRIVIAL 
, O 
and O 
CGP-20712 B-IDENTIFIER 
[ O 
1-[2-((3-carbamoyl-4-hydroxy)phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol B-SYSTEMATIC 
] O 
, O 
which O 
showed O 
no O 
agonistic O 
activity O 
, O 
had O 
only O 
a O 
marginal O 
or O 
no O 
effect O 
. O 
Importantly O 
, O 
the O 
agonists O 
also O 
stabilized O 
intracellular O 
receptor O 
precursors O 
, O 
possibly O 
via O 
their O 
pharmacological O 
chaperone O 
action O 
, O 
and O 
they O 
stabilized O 
the O 
receptor O 
in O 
vitro O 
. O 
The O 
opposing O 
effects O 
on O 
the O 
two O 
receptor O 
forms O 
thus O 
led O 
to O 
an O 
increase O 
in O 
the O 
amount O 
of O 
cleaved O 
receptor O 
fragments O 
at O 
the O 
plasma O 
membrane O 
. O 
The O 
results O 
underscore O 
the O 
pluridimensionality O 
of O 
β-adrenergic O 
ligands O 
and O 
extend O 
this O 
property O 
from O 
receptor O 
activation O 
and O 
signaling O 
to O 
the O 
regulation O 
of O 
β(1)AR O 
levels O 
. O 
This O 
phenomenon O 
may O 
contribute O 
to O 
the O 
exceptional O 
resistance O 
of O 
β(1)ARs O 
to O 
downregulation O 
and O 
tendency O 
toward O 
upregulation O 
following O 
long O 
- O 
term O 
ligand O 
treatments O 
. O 

and O 
validation O 
of O 
an O 
HPLC O 
method O 
for O 
the O 
determination O 
of O 
six O 
penicillin B-FAMILY 
and O 
three O 
amphenicol B-FAMILY 
antibiotics O 
in O 
gilthead O 
seabream O 
( O 
Sparus O 
Aurata O 
) O 
tissue O 
according O 
to O 
the O 
European O 
Union O 
Decision O 
2002 O 
/ O 
657 O 
/ O 
EC O 
. O 

confirmatory O 
high O 
performance O 
liquid O 
chromatography O 
method O 
for O 
the O 
determination O 
of O 
six O 
penicillin B-FAMILY 
antibiotics O 
and O 
three O 
amphenicol B-FAMILY 
antibiotics O 
in O 
gilthead O 
seabream O 
( O 
Sparus O 
Aurata O 
) O 
tissue O 
was O 
developed O 
. O 
Ampicillin B-TRIVIAL 
( O 
AMP B-ABBREVIATION 
) O 
, O 
penicillin B-TRIVIAL 
G I-TRIVIAL 
( O 
PG O 
) O 
, O 
penicillin B-TRIVIAL 
V I-TRIVIAL 
( O 
PV O 
) O 
, O 
oxacillin B-TRIVIAL 
( O 
OXA B-ABBREVIATION 
) O 
, O 
cloxacillin B-TRIVIAL 
( O 
CLO B-ABBREVIATION 
) O 
, O 
dicloxacillin B-TRIVIAL 
( O 
DICLO B-ABBREVIATION 
) O 
, O 
thiamphenicol B-TRIVIAL 
( O 
TAP B-ABBREVIATION 
) O 
, O 
florfenicol B-TRIVIAL 
( O 
FFC B-ABBREVIATION 
) O 
and O 
chloramphenicol B-TRIVIAL 
( O 
CAP B-ABBREVIATION 
) O 
were O 
separated O 
on O 
an O 
Inertsil O 
, O 
C(8) O 
( O 
250×4 O 
mm O 
, O 
5 O 
μm O 
) O 
column O 
by O 
gradient O 
elution O 
with O 
a O 
mobile O 
phase O 
consisting O 
of O 
ammonium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
0.05 O 
M O 
and O 
acetonitrile B-SYSTEMATIC 
at O 
25°C O 
. O 
Diode O 
array O 
detection O 
with O 
monitoring O 
at O 
225 O 
nm O 
( O 
for O 
the O 
determination O 
of O 
AMP B-ABBREVIATION 
, O 
PG O 
, O 
PV O 
, O 
TAP B-ABBREVIATION 
and O 
FFC B-ABBREVIATION 
) O 
, O 
240 O 
nm O 
( O 
for O 
OXA B-ABBREVIATION 
, O 
CLO B-ABBREVIATION 
and O 
DICLO B-ABBREVIATION 
) O 
and O 
278 O 
nm O 
( O 
for O 
CAP B-ABBREVIATION 
) O 
was O 
applied O 
. O 
Examined O 
antibiotics O 
were O 
isolated O 
from O 
gilthead O 
seabream O 
tissue O 
by O 
liquid O 
- O 
liquid O 
extraction O 
and O 
further O 
clean O 
- O 
up O 
was O 
performed O 
by O 
solid O 
phase O 
extraction O 
using O 
Oasis O 
HLB O 
( O 
200 O 
mg O 
/ O 
6 O 
mL O 
) O 
cartridges O 
. O 
The O 
developed O 
method O 
was O 
fully O 
validated O 
in O 
terms O 
of O 
selectivity O 
, O 
linearity O 
, O 
accuracy O 
, O 
precision O 
, O 
stability O 
and O 
sensitivity O 
according O 
to O 
the O 
European O 
Union O 
Decision O 
2002 O 
/ O 
657 O 
/ O 
EC O 
. O 

Americans O 
have O 
used O 
Phytolacca O 
americana O 
to O 
treat O 
breast O 
ailments O 
, O 
gastrointestinal O 
disorders O 
, O 
rashes O 
, O 
and O 
inflammation O 
. O 
Some O 
anti-cancer O 
and O 
anti-viral O 
research O 
has O 
been O 
reported O 
on O 
this O 
perennial O 
herb O 
, O 
but O 
none O 
has O 
been O 
published O 
concerning O 
the O 
effects O 
of O 
its O 
extracts O 
on O 
cancer O 
cell O 
genes O 
. O 
In O 
this O 
study O 
, O 
changes O 
in O 
gene O 
expression O 
at O 
the O 
transcription O 
level O 
were O 
evaluated O 
in O 
HCT-116 O 
colon O 
cancer O 
cells O 
after O 
exposure O 
to O 
P O 
. O 
americana O 
ethanol B-SYSTEMATIC 
extract O 
and O 
its O 
water O 
fraction O 
using O 
the O 
Human O 
Cancer O 
Pathway O 
Finder O 
PCR O 
Array O 
. O 
Of O 
the O 
genes O 
significantly O 
affected O 
in O 
HCT-116 O 
cells O 
exposed O 
to O 
the O 
ethanol B-SYSTEMATIC 
extract O 
at O 
3200 O 
µg O 
/ O 
ml O 
, O 
changes O 
in O 
expression O 
of O 
MYC O 
, O 
PLAU O 
, O 
and O 
TEK O 
may O 
benefit O 
the O 
treatment O 
of O 
colon O 
cancer O 
. O 
Exposing O 
the O 
cells O 
to O 
1600 O 
µg O 
/ O 
ml O 
of O 
the O 
water O 
fraction O 
resulted O 
in O 
several O 
gene O 
changes O 
that O 
may O 
also O 
be O 
beneficial O 
in O 
the O 
treatment O 
of O 
colon O 
cancer O 
: O 
NME4 O 
, O 
TEK O 
, O 
and O 
THBS1 O 
. O 
A O 
few O 
genes O 
on O 
this O 
array O 
that O 
are O 
known O 
to O 
play O 
a O 
specific O 
role O 
in O 
colon O 
cancer O 
had O 
activities O 
changed O 
in O 
a O 
way O 
that O 
may O 
be O 
detrimental O 
in O 
the O 
treatment O 
of O 
colon O 
cancer O 
. O 
Further O 
studies O 
should O 
be O 
performed O 
to O 
understand O 
how O 
these O 
changes O 
would O 
impact O 
colon O 
cancer O 
treatment O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

cleavage O 
site O 
prediction O 
of O 
protein O 
antigen O 
using O 
BP O 
neural O 
network O 
based O 
on O 
a O 
new O 
set O 
of O 
amino B-FAMILY 
acid I-FAMILY 
descriptor O 
. O 

accurate O 
identification O 
of O 
cytotoxic O 
T O 
lymphocyte O 
epitopes O 
is O 
becoming O 
increasingly O 
important O 
in O 
peptide O 
vaccine O 
design O 
. O 
The O 
ubiquitin O 
- O 
proteasome O 
system O 
plays O 
a O 
key O 
role O 
in O 
processing O 
and O 
presenting O 
major O 
histocompatibility O 
complex O 
class O 
I O 
restricted O 
epitopes O 
by O 
degrading O 
the O 
antigenic O 
protein O 
. O 
To O 
enhance O 
the O 
specificity O 
and O 
efficiency O 
of O 
epitope O 
prediction O 
and O 
identification O 
, O 
the O 
recognition O 
mode O 
between O 
the O 
ubiquitin O 
- O 
proteasome O 
complex O 
and O 
the O 
protein O 
antigen O 
must O 
be O 
considered O 
. O 
Hence O 
, O 
a O 
model O 
that O 
accurately O 
predicts O 
proteasomal O 
cleavage O 
must O 
be O 
established O 
. O 
This O 
study O 
proposes O 
a O 
new O 
set O 
of O 
parameters O 
to O 
characterize O 
the O 
cleavage O 
window O 
and O 
uses O 
a O 
backpropagation O 
neural O 
network O 
algorithm O 
to O 
build O 
a O 
model O 
that O 
accurately O 
predicts O 
proteasomal O 
cleavage O 
. O 
The O 
accuracy O 
of O 
the O 
prediction O 
model O 
, O 
which O 
depends O 
on O 
the O 
window O 
sizes O 
of O 
the O 
cleavage O 
, O 
reaches O 
95.454 O 
% O 
for O 
the O 
N B-FORMULA 
-terminus O 
and O 
95.011 O 
% O 
for O 
the O 
C B-FORMULA 
-terminus O 
. O 
The O 
results O 
show O 
that O 
the O 
identification O 
of O 
proteasomal O 
cleavage O 
sites O 
depends O 
on O 
the O 
sequence O 
next O 
to O 
it O 
and O 
that O 
the O 
prediction O 
performance O 
of O 
the O 
C B-FORMULA 
-terminus O 
is O 
better O 
than O 
that O 
of O 
the O 
N B-FORMULA 
-terminus O 
on O 
average O 
. O 
Thus O 
, O 
models O 
based O 
on O 
the O 
properties O 
of O 
amino B-FAMILY 
acids I-FAMILY 
can O 
be O 
highly O 
reliable O 
and O 
reflect O 
the O 
structural O 
features O 
of O 
interactions O 
between O 
proteasomes O 
and O 
peptide O 
sequences O 
. O 

, O 
a O 
DPP-4 O 
inhibitor O 
, O 
suppresses O 
proliferation O 
of O 
vascular O 
smooth O 
muscles O 
and O 
monocyte O 
inflammatory O 
reaction O 
and O 
attenuates O 
atherosclerosis O 
in O 
male O 
apo O 
E-deficient O 
mice O 
. O 

peptidase-4 O 
( O 
DPP-4 O 
) O 
inhibitors O 
modulate O 
the O 
progression O 
of O 
atherosclerosis O 
. O 
To O 
gain O 
insights O 
into O 
their O 
mechanism O 
of O 
action O 
, O 
9-wk- O 
old O 
male O 
apolipoprotein O 
E O 
(apoE)-deficient O 
mice O 
were O 
fed O 
a O 
DPP-4 O 
inhibitor O 
, O 
anagliptin B-TRIVIAL 
-containing O 
diet O 
. O 
The O 
effects O 
of O 
anagliptin B-TRIVIAL 
were O 
investigated O 
in O 
, O 
a O 
monocyte O 
cell O 
line O 
, O 
human O 
THP-1 O 
cells O 
, O 
and O 
rat O 
smooth O 
muscle O 
cells O 
( O 
SMCs O 
) O 
. O 
Treatment O 
with O 
anagliptin B-TRIVIAL 
for O 
16 O 
wk O 
significantly O 
reduced O 
accumulation O 
of O 
monocytes O 
and O 
macrophages O 
in O 
the O 
vascular O 
wall O 
, O 
SMC O 
content O 
in O 
plaque O 
areas O 
, O 
and O 
oil B-TRIVIAL 
red I-TRIVIAL 
O I-TRIVIAL 
-stained O 
area O 
around O 
the O 
aortic O 
valve O 
without O 
affecting O 
glucose B-TRIVIAL 
tolerance O 
or O 
body O 
weight O 
. O 
Serum O 
DPP-4 O 
concentrations O 
were O 
significantly O 
higher O 
in O 
apoE-deficient O 
mice O 
than O 
control O 
mice O 
, O 
and O 
the O 
levels O 
increased O 
with O 
aging O 
, O 
suggesting O 
the O 
involvement O 
of O 
DPP-4 O 
in O 
the O 
progression O 
of O 
atherosclerosis O 
. O 
Indeed O 
, O 
soluble O 
DPP-4 O 
augmented O 
cultured O 
SMC O 
proliferation O 
, O 
and O 
anagliptin B-TRIVIAL 
suppressed O 
the O 
proliferation O 
by O 
inhibiting O 
ERK O 
phosphorylation O 
. O 
In O 
THP-1 O 
cells O 
, O 
anagliptin B-TRIVIAL 
reduced O 
lipopolysaccharide-induced O 
TNF-α O 
production O 
with O 
inhibiting O 
ERK O 
phosphorylation O 
and O 
nuclear O 
translocation O 
of O 
nuclear O 
factor-κB O 
. O 
Quantitative O 
analysis O 
also O 
showed O 
that O 
anagliptin B-TRIVIAL 
reduced O 
the O 
area O 
of O 
atherosclerotic O 
lesion O 
in O 
apoE-deficient O 
mice O 
. O 
These O 
results O 
indicated O 
that O 
the O 
anti-atherosclerotic O 
effect O 
of O 
anagliptin B-TRIVIAL 
is O 
mediated O 
, O 
at O 
least O 
in O 
part O 
, O 
through O 
its O 
direct O 
inhibition O 
of O 
SMC O 
proliferation O 
and O 
inflammatory O 
reaction O 
of O 
monocytes O 
. O 

, O 
biological O 
evaluation O 
of O 
new O 
oxazolidino B-FAMILY 
- I-FAMILY 
sulfonamides I-FAMILY 
as O 
potential O 
antimicrobial O 
agents O 
. O 

number O 
of O 
linezolid B-TRIVIAL 
-like O 
oxazolidino B-FAMILY 
- I-FAMILY 
sulfonamides I-FAMILY 
( O 
7a-y O 
and O 
8a-b O 
) O 
were O 
designed O 
and O 
synthesized O 
with O 
a O 
view O 
to O 
develop O 
antimicrobial O 
agents O 
with O 
improved O 
properties O 
. O 
Most O 
of O 
the O 
synthesized O 
compounds O 
showed O 
good O 
to O 
moderate O 
activity O 
against O 
a O 
panel O 
of O 
standard O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
and O 
fungal O 
strains O 
. O 
The O 
compounds O 
7i O 
and O 
7v O 
exhibited O 
significant O 
activity O 
, O 
with O 
a O 
MIC O 
value O 
of O 
2.0-6.0 O 
μg O 
/ O 
mL O 
against O 
a O 
panel O 
of O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
These O 
compounds O 
also O 
showed O 
activity O 
against O 
Candida O 
albicans O 
, O 
with O 
a O 
MIC O 
value O 
of O 
4 O 
μg O 
/ O 
mL O 
. O 
A O 
correlation O 
of O 
the O 
antimicrobial O 
activity O 
with O 
calculated O 
lipophilicity O 
values O 
( O 
C O 
log O 
P O 
) O 
is O 
also O 
presented O 
. O 

and O 
NO B-FORMULA 
production O 
inhibition O 
activities O 
of O 
epi-aleuritolic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
. O 

epi-aleuritolic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
for O 
anti-HIV O 
activity O 
in O 
293 O 
T O 
cells O 
and O 
NO B-FORMULA 
production O 
inhibition O 
activity O 
. O 
Of O 
the O 
derivatives O 
, O 
1 O 
, O 
2 O 
, O 
3 O 
, O 
4 O 
, O 
11 O 
, O 
and O 
13 O 
showed O 
relatively O 
potent O 
anti-HIV O 
activity O 
with O 
EC50 O 
values O 
ranging O 
from O 
5.8 O 
to O 
13.3 O 
μM O 
. O 
The O 
most O 
potent O 
compound O 
, O 
3α-2',2'-dimethylsuccinic B-FAMILY 
acyl I-FAMILY 
epi-aleuritolic I-FAMILY 
acid I-FAMILY 
( O 
11 O 
) O 
, O 
displayed O 
significant O 
anti-HIV O 
activity O 
with O 
an O 
EC50 O 
value O 
of O 
5.8 O 
μM O 
. O 
Compounds O 
1 O 
, O 
3 O 
, O 
4 O 
, O 
and O 
11 O 
showed O 
NO B-FORMULA 
inhibition O 
activity O 
, O 
with O 
IC50 O 
values O 
ranging O 
from O 
3.4 O 
to O 
7.1 O 
μM O 
and O 
compound O 
1 O 
inhibited O 
NO B-FORMULA 
production O 
with O 
an O 
IC50 O 
value O 
of O 
3.4 O 
μM O 
. O 

mammary O 
microcalcifications O 
are O 
routinely O 
used O 
for O 
the O 
early O 
detection O 
of O 
breast O 
cancer O 
, O 
however O 
the O 
mechanisms O 
by O 
which O 
they O 
form O 
remain O 
unclear O 
. O 
Two O 
species O 
of O 
mammary O 
microcalcifications O 
have O 
been O 
identified O 
; O 
calcium B-SYSTEMATIC 
oxalate I-SYSTEMATIC 
and O 
hydroxyapatite B-TRIVIAL 
. O 
Calcium B-SYSTEMATIC 
oxalate I-SYSTEMATIC 
is O 
mostly O 
associated O 
with O 
benign O 
lesions O 
of O 
the O 
breast O 
, O 
whereas O 
hydroxyapatite B-TRIVIAL 
is O 
associated O 
with O 
both O 
benign O 
and O 
malignant O 
tumors O 
. O 
The O 
way O 
in O 
which O 
hydroxyapatite B-TRIVIAL 
forms O 
within O 
mammary O 
tissue O 
remains O 
largely O 
unexplored O 
, O 
however O 
lessons O 
can O 
be O 
learned O 
from O 
the O 
process O 
of O 
physiological O 
mineralization O 
. O 
Normal O 
physiological O 
mineralization O 
by O 
osteoblasts O 
results O 
in O 
hydroxyapatite B-TRIVIAL 
deposition O 
in O 
bone O 
. O 
This O 
review O 
brings O 
together O 
existing O 
knowledge O 
from O 
the O 
field O 
of O 
physiological O 
mineralization O 
and O 
juxtaposes O 
it O 
with O 
our O 
current O 
understanding O 
of O 
the O 
genesis O 
of O 
mammary O 
microcalcifications O 
. O 
As O 
an O 
increasing O 
number O 
of O 
breast O 
cancers O 
are O 
being O 
detected O 
in O 
their O 
non-palpable O 
stage O 
through O 
mammographic O 
microcalcifications O 
, O 
it O 
is O 
important O 
that O 
future O 
studies O 
investigate O 
the O 
underlying O 
mechanisms O 
of O 
their O 
formation O 
in O 
order O 
to O 
fully O 
understand O 
the O 
significance O 
of O 
this O 
unique O 
early O 
marker O 
of O 
breast O 
cancer O 
. O 

CYP3A O 
is O 
the O 
most O 
abundant O 
P450 O 
isozyme O 
present O 
in O 
the O 
human O 
liver O 
and O 
small O 
intestine O 
, O 
and O 
metabolizes O 
around O 
50% O 
of O 
medical O 
drugs O 
on O 
the O 
market O 
. O 
The O 
human O 
CYP3A O 
subfamily O 
comprises O 
four O 
members O 
( O 
CYP3A4 O 
, O 
CYP3A5 O 
, O 
CYP3A7 O 
, O 
CYP3A43 O 
) O 
encoded O 
on O 
human O 
chromosome O 
7 O 
. O 
However O 
, O 
transgenic O 
mouse O 
lines O 
carrying O 
the O 
entire O 
human O 
CYP3A O 
cluster O 
have O 
not O 
been O 
constructed O 
because O 
of O 
limitations O 
in O 
conventional O 
cloning O 
techniques O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
introduction O 
of O 
a O 
human O 
artificial O 
chromosome O 
( O 
HAC O 
) O 
containing O 
the O 
entire O 
genomic O 
human O 
CYP3A O 
locus O 
recapitulates O 
tissue- O 
and O 
stage O 
- O 
specific O 
expression O 
of O 
human O 
CYP3A O 
genes O 
and O 
xenobiotic O 
metabolism O 
in O 
mice O 
. O 
About O 
700 O 
kb O 
of O 
the O 
entire O 
CYP3A O 
genomic O 
segment O 
was O 
cloned O 
into O 
a O 
HAC O 
( O 
CYP3A-HAC O 
) O 
, O 
and O 
trans-chromosomic O 
( O 
Tc O 
) O 
mice O 
carrying O 
a O 
single O 
copy O 
of O 
germline O 
- O 
transmittable O 
CYP3A-HAC O 
were O 
generated O 
via O 
a O 
chromosome O 
- O 
engineering O 
technique O 
. O 
The O 
tissue- O 
and O 
stage O 
- O 
specific O 
expression O 
profiles O 
of O 
CYP3A O 
genes O 
were O 
consistent O 
with O 
those O 
seen O 
in O 
humans O 
. O 
We O 
further O 
generated O 
mice O 
carrying O 
the O 
CYP3A-HAC O 
in O 
the O 
background O 
homozygous O 
for O 
targeted O 
deletion O 
of O 
most O 
endogenous O 
Cyp3a O 
genes O 
. O 
In O 
this O 
mouse O 
strain O 
with O 
' O 
fully O 
humanized O 
' O 
CYP3A O 
genes O 
, O 
the O 
kinetics O 
of O 
triazolam B-TRIVIAL 
metabolism O 
, O 
CYP3A O 
- O 
mediated O 
mechanism O 
- O 
based O 
inactivation O 
effects O 
and O 
formation O 
of O 
fetal O 
- O 
specific O 
metabolites O 
of O 
dehydroepiandrosterone B-TRIVIAL 
observed O 
in O 
humans O 
were O 
well O 
reproduced O 
. O 
Thus O 
, O 
these O 
mice O 
are O 
likely O 
to O 
be O 
valuable O 
in O 
evaluating O 
novel O 
drugs O 
metabolized O 
by O 
CYP3A O 
enzymes O 
and O 
in O 
studying O 
the O 
regulation O 
of O 
human O 
CYP3A O 
gene O 
expression O 
. O 
Furthermore O 
, O 
this O 
system O 
can O 
also O 
be O 
used O 
for O 
generating O 
Tc O 
mice O 
carrying O 
other O 
human O 
metabolic O 
genes O 
. O 

of O 
palmitate B-TRIVIAL 
-induced O 
insulin O 
resistance O 
in O 
C2C12 O 
muscle O 
cells O 
by O 
rooibos O 
( O 
Aspalathus O 
linearis O 
) O 
. O 

levels O 
of O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
FFAs B-FAMILY 
) O 
, O 
specifically O 
saturated B-FAMILY 
free I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
such O 
as O 
palmitate B-TRIVIAL 
are O 
associated O 
with O 
insulin O 
resistance O 
of O 
muscle O 
, O 
fat O 
and O 
liver O 
. O 
Skeletal O 
muscle O 
, O 
responsible O 
for O 
up O 
to O 
80% O 
of O 
the O 
glucose B-TRIVIAL 
disposal O 
from O 
the O 
peripheral O 
circulation O 
, O 
is O 
particularly O 
vulnerable O 
to O 
increased O 
levels O 
of O 
saturated O 
FFAs B-FAMILY 
. O 
Rooibos O 
( O 
Aspalathus O 
linearis O 
) O 
and O 
its O 
unique O 
dihydrochalcone B-SYSTEMATIC 
C-glucoside I-SYSTEMATIC 
, O 
aspalathin B-TRIVIAL 
, O 
shown O 
to O 
reduce O 
hyperglycemia O 
in O 
diabetic O 
rats O 
, O 
could O 
play O 
a O 
role O 
in O 
preventing O 
or O 
ameliorating O 
the O 
development O 
of O 
insulin O 
resistance O 
. O 
This O 
study O 
aims O 
to O 
establish O 
whether O 
rooibos O 
can O 
ameliorate O 
experimentally O 
- O 
induced O 
insulin O 
- O 
resistance O 
in O 
C2C12 O 
skeletal O 
muscle O 
cells O 
. O 
Palmitate B-TRIVIAL 
-induced O 
insulin O 
resistant O 
C2C12 O 
cells O 
were O 
treated O 
with O 
an O 
aspalathin B-TRIVIAL 
-enriched O 
green O 
( O 
unfermented O 
) O 
rooibos O 
extract O 
( O 
GRE O 
) O 
, O 
previously O 
shown O 
for O 
its O 
blood O 
glucose B-TRIVIAL 
lowering O 
effect O 
in O 
vitro O 
and O 
in O 
vivo O 
or O 
an O 
aqueous O 
extract O 
of O 
fermented O 
rooibos O 
( O 
FRE O 
) O 
. O 
Glucose B-TRIVIAL 
uptake O 
and O 
mitochondrial O 
activity O 
were O 
measured O 
using O 
2-deoxy-[(3)H]-d-glucose B-SYSTEMATIC 
, O 
MTT B-ABBREVIATION 
and O 
ATP B-ABBREVIATION 
assays O 
, O 
respectively O 
. O 
Expression O 
of O 
proteins O 
relevant O 
to O 
glucose B-TRIVIAL 
metabolism O 
was O 
analysed O 
by O 
Western O 
blot O 
. O 
GRE O 
contained O 
higher O 
levels O 
of O 
all O 
compounds O 
, O 
except O 
the O 
enolic O 
phenylpyruvic B-SYSTEMATIC 
acid-2-O-glucoside I-SYSTEMATIC 
and O 
luteolin-7-O-glucoside B-SYSTEMATIC 
. O 
Both O 
rooibos O 
extracts O 
increased O 
glucose B-TRIVIAL 
uptake O 
, O 
mitochondrial O 
activity O 
and O 
ATP B-ABBREVIATION 
production O 
. O 
Compared O 
to O 
FRE O 
, O 
GRE O 
was O 
more O 
effective O 
at O 
increasing O 
glucose B-TRIVIAL 
uptake O 
and O 
ATP B-ABBREVIATION 
production O 
. O 
At O 
a O 
mechanistic O 
level O 
both O 
extracts O 
down O 
- O 
regulated O 
PKC O 
θ O 
activation O 
, O 
which O 
is O 
associated O 
with O 
palmitate B-TRIVIAL 
-induced O 
insulin O 
resistance O 
. O 
Furthermore O 
, O 
the O 
extracts O 
increased O 
activation O 
of O 
key O 
regulatory O 
proteins O 
( O 
AKT O 
and O 
AMPK O 
) O 
involved O 
in O 
insulin O 
- O 
dependent O 
and O 
non-insulin O 
regulated O 
signalling O 
pathways O 
. O 
Protein O 
levels O 
of O 
the O 
glucose B-TRIVIAL 
transporter O 
( O 
GLUT4 O 
) O 
involved O 
in O 
glucose B-TRIVIAL 
transport O 
via O 
these O 
two O 
pathways O 
were O 
also O 
increased O 
. O 
This O 
in O 
vitro O 
study O 
therefore O 
confirms O 
that O 
rooibos O 
can O 
ameliorate O 
palmitate B-TRIVIAL 
-induced O 
insulin O 
resistance O 
in O 
C2C12 O 
skeletal O 
muscle O 
cells O 
. O 
Inhibition O 
of O 
PKC O 
θ O 
activation O 
and O 
increased O 
activation O 
of O 
AMPK O 
and O 
AKT O 
offer O 
a O 
plausible O 
mechanistic O 
explanation O 
for O 
this O 
ameliorative O 
effect O 
. O 

of O 
the O 
abuse O 
liability O 
of O 
ABT-288 B-NO_CLASS 
, O 
a O 
novel O 
histamine B-TRIVIAL 
H3 O 
receptor O 
antagonist O 
. O 

: O 
Histamine B-TRIVIAL 
H3 O 
receptor O 
antagonists O 
, O 
such O 
as O 
ABT-288 B-NO_CLASS 
, O 
have O 
been O 
shown O 
to O 
possess O 
cognitive O 
- O 
enhancing O 
and O 
wakefulness O 
- O 
promoting O 
effects O 
. O 
On O 
the O 
surface O 
, O 
this O 
might O 
suggest O 
that O 
H3 O 
antagonists O 
possess O 
psychomotor O 
stimulant O 
- O 
like O 
effects O 
and O 
, O 
as O 
such O 
, O 
may O 
have O 
the O 
potential O 
for O 
abuse O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
further O 
characterize O 
whether O 
ABT-288 B-NO_CLASS 
possesses O 
stimulant O 
- O 
like O 
properties O 
and O 
whether O 
its O 
pharmacology O 
gives O 
rise O 
to O 
abuse O 
liability O 
. O 
METHODS O 
: O 
The O 
locomotor O 
- O 
stimulant O 
effects O 
of O 
ABT-288 B-NO_CLASS 
were O 
measured O 
in O 
mice O 
and O 
rats O 
, O 
and O 
potential O 
development O 
of O 
sensitization O 
was O 
addressed O 
. O 
Drug O 
discrimination O 
was O 
used O 
to O 
assess O 
amphetamine B-TRIVIAL 
-like O 
stimulus O 
properties O 
, O 
and O 
drug O 
self O 
- O 
administration O 
was O 
used O 
to O 
evaluate O 
reinforcing O 
effects O 
of O 
ABT-288 B-NO_CLASS 
. O 
The O 
potential O 
development O 
of O 
physical O 
dependence O 
was O 
also O 
studied O 
. O 
RESULTS O 
: O 
ABT-288 B-NO_CLASS 
lacked O 
locomotor O 
- O 
stimulant O 
effects O 
in O 
both O 
rats O 
and O 
mice O 
. O 
Repeated O 
administration O 
of O 
ABT-288 B-NO_CLASS 
did O 
not O 
result O 
in O 
cross O 
- O 
sensitization O 
to O 
the O 
stimulant O 
effects O 
of O 
d-amphetamine B-TRIVIAL 
in O 
mice O 
, O 
suggesting O 
that O 
there O 
is O 
little O 
overlap O 
in O 
circuitries O 
upon O 
which O 
the O 
two O 
drugs O 
interact O 
for O 
motor O 
activity O 
. O 
ABT-288 B-NO_CLASS 
did O 
not O 
produce O 
amphetamine B-TRIVIAL 
-like O 
discriminative O 
stimulus O 
effects O 
in O 
drug O 
discrimination O 
studies O 
nor O 
was O 
it O 
self O 
- O 
administered O 
by O 
rats O 
trained O 
to O 
self O 
- O 
administer O 
cocaine B-TRIVIAL 
. O 
There O 
were O 
no O 
signs O 
of O 
physical O 
dependence O 
upon O 
termination O 
of O 
repeated O 
administration O 
of O 
ABT-288 B-NO_CLASS 
for O 
30 O 
days O 
. O 
CONCLUSIONS O 
: O 
The O 
sum O 
of O 
these O 
preclinical O 
data O 
, O 
the O 
first O 
of O 
their O 
kind O 
applied O 
to O 
H3 O 
antagonists O 
, O 
indicates O 
that O 
ABT-288 B-NO_CLASS 
is O 
unlikely O 
to O 
possess O 
a O 
high O 
potential O 
for O 
abuse O 
in O 
the O 
human O 
population O 
and O 
suggests O 
that O 
H3 O 
antagonists O 
, O 
as O 
a O 
class O 
, O 
are O 
similar O 
in O 
this O 
regard O 
. O 

effects O 
of O 
(-)-epicatechin-3-gallate B-SYSTEMATIC 
, O 
a O 
novel O 
sodium B-SYSTEMATIC 
channel O 
agonist O 
in O 
cultured O 
neonatal O 
rat O 
ventricular O 
myocytes O 
. O 

( O 
ECG B-ABBREVIATION 
) O 
, O 
a O 
polyphenol B-FAMILY 
extracted O 
from O 
green O 
tea O 
, O 
has O 
been O 
proposed O 
as O 
an O 
effective O 
compound O 
for O 
improving O 
cardiac O 
contractility O 
. O 
However O 
, O 
the O 
therapeutic O 
potential O 
of O 
ECG B-ABBREVIATION 
on O 
the O 
treatment O 
of O 
arrhythmia O 
remains O 
unknown O 
. O 
We O 
investigated O 
the O 
direct O 
actions O 
of O 
ECG B-ABBREVIATION 
on O 
the O 
modulation O 
of O 
ion O 
currents O 
and O 
cardiac O 
cell O 
excitability O 
in O 
the O 
primary O 
culture O 
of O 
neonatal O 
rat O 
ventricular O 
myocyte O 
( O 
NRVM O 
) O 
, O 
which O 
is O 
considered O 
a O 
hypertrophic O 
model O 
for O 
analysis O 
of O 
myocardial O 
arrhythmias O 
. O 
By O 
using O 
the O 
whole O 
- O 
cell O 
patch O 
- O 
clamp O 
configurations O 
, O 
we O 
found O 
ECG B-ABBREVIATION 
enhanced O 
the O 
slowly O 
inactivating O 
component O 
of O 
voltage O 
- O 
gated O 
Na(+) B-FORMULA 
currents O 
( O 
I( O 
Na B-FORMULA 
) O 
) O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
( O 
0.1-100 O 
μM O 
) O 
with O 
an O 
EC(50) O 
value O 
of O 
3.8 O 
μM O 
. O 
ECG B-ABBREVIATION 
not O 
only O 
shifted O 
the O 
current-voltage O 
relationship O 
of O 
peak O 
I( O 
Na B-FORMULA 
) O 
to O 
the O 
hyperpolarizing O 
direction O 
but O 
also O 
accelerated O 
I( O 
Na B-FORMULA 
) O 
recovery O 
kinetics O 
. O 
Working O 
at O 
a O 
concentration O 
level O 
of O 
I( O 
Na B-FORMULA 
) O 
enhancement O 
, O 
ECG B-ABBREVIATION 
has O 
no O 
notable O 
effect O 
on O 
voltage O 
- O 
gated O 
K(+) B-FORMULA 
currents O 
and O 
L- O 
type O 
Ca(2+) B-FORMULA 
currents O 
. O 
With O 
culture O 
time O 
increment O 
, O 
the O 
firing O 
rate O 
of O 
spontaneous O 
action O 
potential O 
( O 
sAP O 
) O 
in O 
NRVMs O 
was O 
gradually O 
decreased O 
until O 
spontaneous O 
early O 
after O 
- O 
depolarization O 
( O 
EAD O 
) O 
was O 
observed O 
after O 
about O 
one O 
week O 
culture O 
. O 
ECG B-ABBREVIATION 
increased O 
the O 
firing O 
rate O 
of O 
normal O 
sAP O 
about O 
two O 
- O 
fold O 
without O 
waveform O 
alteration O 
. O 
Interestingly O 
, O 
the O 
bradycardia O 
- O 
dependent O 
EAD O 
could O 
be O 
significantly O 
restored O 
by O 
ECG B-ABBREVIATION 
in O 
fast O 
firing O 
rate O 
to O 
normal O 
sAP O 
waveform O 
. O 
The O 
expression O 
of O 
dominant O 
cardiac O 
sodium B-SYSTEMATIC 
channel O 
subunit O 
, O 
Nav1.5 O 
, O 
was O 
consistently O 
detected O 
throughout O 
the O 
culture O 
periods O 
. O 
Our O 
results O 
reveal O 
how O 
ECG B-ABBREVIATION 
, O 
the O 
novel O 
I( O 
Na B-FORMULA 
) O 
agonist O 
, O 
may O 
act O 
as O 
a O 
promising O 
candidate O 
in O 
clinical O 
applications O 
on O 
cardiac O 
arrhythmias O 
. O 

7-Amino-5-thio-thiazolo[4,5-d]pyrimidines B-FAMILY 
as O 
Potent O 
and O 
Selective O 
Antagonists O 
of O 
the O 
Fractalkine O 
Receptor O 
( O 
CX3CR1 O 
) O 
. O 

have O 
developed O 
two O 
parallel O 
series O 
, O 
A O 
and O 
B O 
, O 
of O 
CX3CR1 O 
antagonists O 
for O 
the O 
treatment O 
of O 
multiple O 
sclerosis O 
. O 
By O 
modifying O 
the O 
substituents O 
on O 
the O 
7-amino-5-thio-thiazolo[4,5-d]pyrimidine B-SYSTEMATIC 
core O 
structure O 
, O 
we O 
were O 
able O 
to O 
achieve O 
compounds O 
with O 
high O 
selectivity O 
for O 
CX3CR1 O 
over O 
the O 
closely O 
related O 
CXCR2 O 
receptor O 
. O 
The O 
structure O 
- O 
activity O 
relationships O 
showed O 
that O 
a O 
leucinol B-TRIVIAL 
moiety O 
attached O 
to O 
the O 
core O 
- O 
structure O 
in O 
the O 
7- O 
position O 
together O 
with O 
α-methyl B-SYSTEMATIC 
branched O 
benzyl B-SYSTEMATIC 
derivatives O 
in O 
the O 
5- O 
position O 
displayed O 
promising O 
affinity O 
, O 
and O 
selectivity O 
as O 
well O 
as O 
physicochemical O 
properties O 
, O 
as O 
exemplified O 
by O 
compounds O 
18a O 
and O 
24h O 
. O 
We O 
show O 
the O 
preparation O 
of O 
the O 
first O 
potent O 
and O 
selective O 
orally O 
available O 
CX3CR1 O 
antagonists O 
. O 

exposure O 
to O 
ultraviolet O 
( O 
UV O 
) O 
radiation O 
causes O 
pro O 
- O 
inflammatory O 
responses O 
via O 
diverse O 
mechanisms O 
including O 
oxidative O 
stress O 
. O 
Codium O 
fragile O 
is O 
a O 
green O 
alga O 
of O 
Codiales O 
family O 
and O 
has O 
been O 
reported O 
to O 
exhibit O 
anti-edema O 
, O 
anti-allergic O 
, O 
anti-protozoal O 
and O 
anti-mycobacterial O 
activities O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
investigated O 
a O 
novel O 
anti-inflammatory O 
potential O 
of O 
C O 
. O 
fragile O 
using O 
in O 
vitro O 
cell O 
culture O 
as O 
well O 
as O 
in O 
vivo O 
animal O 
models O 
. O 
In O 
HaCaT O 
cells O 
, O 
buthanol B-SYSTEMATIC 
and O 
ethylacetate B-SYSTEMATIC 
fractions O 
of O 
80% O 
methanol B-SYSTEMATIC 
C O 
. O 
fragile O 
extract O 
( O 
CFB O 
or O 
CFE O 
) O 
and O 
a O 
single O 
compound O 
, O 
clerosterol B-TRIVIAL 
( O 
CLS B-ABBREVIATION 
) O 
isolated O 
from O 
CFE O 
attenuated O 
UVB O 
( O 
60mJ O 
/ O 
cm(2))-induced O 
cytotoxicity O 
and O 
reduced O 
expression O 
of O 
pro O 
- O 
inflammatory O 
proteins O 
including O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
and O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF- O 
α O 
) O 
. O 
Moreover O 
, O 
CFB O 
, O 
CFE O 
and O 
CLS B-ABBREVIATION 
effectively O 
suppressed O 
UVB-induced O 
production O 
of O 
pro O 
- O 
inflammatory O 
mediators O 
such O 
as O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
. O 
In O 
another O 
experiment O 
, O 
topical O 
application O 
of O 
CFB O 
, O 
CFE O 
or O 
CLS B-ABBREVIATION 
prior O 
to O 
UVB O 
irradiation O 
( O 
200mJ O 
/ O 
cm(2) O 
) O 
on O 
BALB O 
/ O 
c O 
mice O 
, O 
inhibited O 
the O 
UVB-elevated O 
protein O 
levels O 
of O 
COX-2 O 
, O 
iNOS O 
, O 
and O 
TNF-α O 
. O 
Furthermore O 
, O 
CFB O 
, O 
CFE O 
and O 
CLS B-ABBREVIATION 
suppressed O 
oxidative O 
damages O 
caused O 
by O 
UVB O 
irradiation O 
for O 
example O 
lipid O 
peroxidation O 
and O 
/ O 
or O 
protein O 
carbonylation O 
, O 
which O 
seemed O 
to O 
be O 
mediated O 
by O 
up O 
- O 
regulation O 
of O 
antioxidant O 
defense O 
enzymes O 
. O 
These O 
results O 
suggest O 
that O 
C O 
. O 
fragile O 
could O 
be O 
an O 
effective O 
therapeutic O 
agent O 
providing O 
protection O 
against O 
UVB-induced O 
inflammatory O 
and O 
oxidative O 
skin O 
damages O 
. O 

redox O 
- O 
active O 
phospholipid O 
polymer O 
with O 
a O 
phospholipid O 
- O 
mimicking O 
structure O 
( O 
2-methacryloyloxyethyl B-SYSTEMATIC 
phosphorylcholine I-SYSTEMATIC 
; O 
MPC B-ABBREVIATION 
) O 
was O 
synthesized O 
to O 
construct O 
a O 
biocompatible O 
electron O 
mediator O 
between O 
bacteria O 
and O 
an O 
electrode O 
. O 
In O 
this O 
study O 
, O 
a O 
copolymer O 
of O 
MPC B-ABBREVIATION 
and O 
vinylferrocene B-SYSTEMATIC 
[ O 
VF O 
; O 
poly(MPC-co-VF) B-FAMILY 
] O 
( O 
PMF B-ABBREVIATION 
) O 
is O 
synthesized O 
. O 
When O 
PMF B-ABBREVIATION 
is O 
added O 
to O 
cultures O 
of O 
the O 
bacterial O 
species O 
Escherichia O 
coli O 
( O 
Gram O 
negative O 
) O 
and O 
Lactobacillus O 
plantarum O 
( O 
Gram O 
positive O 
) O 
, O 
which O 
have O 
different O 
cell O 
wall O 
structures O 
, O 
a O 
catalytic O 
current O 
mediated O 
by O 
PMF B-ABBREVIATION 
is O 
observed O 
. O 
In O 
addition O 
, O 
growth O 
curves O 
and O 
live O 
/ O 
dead O 
assays O 
indicate O 
that O 
PMF B-ABBREVIATION 
does O 
not O 
decrease O 
metabolic O 
activity O 
or O 
cell O 
viability O 
. O 
These O 
results O 
indicate O 
that O 
PMF B-ABBREVIATION 
mediates O 
extracellular O 
electron O 
transfer O 
across O 
bacterial O 
cell O 
membranes O 
without O 
associated O 
cytotoxicity O 
. O 

increases O 
the O 
expression O 
of O 
the O 
pro O 
- O 
apoptotic O 
gene O 
FAS O 
by O 
epigenetic O 
mechanisms O 
in O 
tumor O 
cells O 
. O 

is O 
growing O 
evidence O 
that O 
aminobisphosphonates B-FAMILY 
like O 
ibandronate B-TRIVIAL 
show O 
anticancer O 
activity O 
by O 
an O 
unknown O 
mechanism O 
. O 
Biochemically O 
, O 
they O 
prevent O 
posttranslational O 
isoprenylation O 
of O 
small O 
GTPases O 
, O 
thus O 
inhibiting O 
their O 
activity O 
. O 
In O 
tumor O 
cells O 
, O 
activated O 
RAS-GTPase O 
, O 
the O 
founding O 
member O 
of O 
the O 
gene O 
family O 
, O 
down O 
- O 
regulates O 
the O 
expression O 
of O 
the O 
pro O 
- O 
apoptotic O 
gene O 
FAS O 
via O 
epigenetic O 
DNA-methylation O 
by O 
DNMT1 O 
. O 
We O 
compared O 
ibandronate B-TRIVIAL 
treatment O 
in O 
neoplastic O 
human O 
U-2 O 
osteosarcoma O 
and O 
in O 
mouse O 
CCL-51 O 
breast O 
cancer O 
cells O 
as O 
well O 
as O 
in O 
the O 
immortalized O 
non-neoplastic O 
MC3T3-E1 O 
osteoblastic O 
cells O 
. O 
Ibandronate B-TRIVIAL 
attenuated O 
cell O 
proliferation O 
in O 
all O 
cell O 
lines O 
tested O 
. O 
In O 
the O 
neoplastic O 
cells O 
we O 
found O 
up O 
- O 
regulation O 
of O 
caspases O 
suggesting O 
apoptosis O 
. O 
Further O 
we O 
found O 
stimulation O 
of O 
FAS-expression O 
as O 
a O 
result O 
of O 
epigenetic O 
DNA O 
demethylation O 
that O 
was O 
due O 
to O 
down O 
- O 
regulation O 
of O 
DNMT1 O 
, O 
which O 
was O 
rescued O 
by O 
re O 
- O 
isoprenylation O 
by O 
both O 
geranylgeranyl-pyrophosphate B-SYSTEMATIC 
and O 
farnesylpyrophosphate B-SYSTEMATIC 
. O 
In O 
contrast O 
, O 
ibandronate B-TRIVIAL 
did O 
not O 
affect O 
FAS O 
and O 
DNMT1 O 
expression O 
in O 
MC3T3-E1 O 
non-neoplastic O 
cells O 
. O 
Data O 
suggest O 
that O 
bisphosphonates B-FAMILY 
via O 
modulation O 
of O 
the O 
activity O 
of O 
small-GTPases O 
induce O 
apoptosis O 
in O 
neoplastic O 
cells O 
by O 
DNA- O 
CpG B-ABBREVIATION 
-demethylation O 
and O 
stimulation O 
of O 
FAS-expression O 
. O 
In O 
conclusion O 
the O 
shown O 
epigenetic O 
mechanism O 
underlying O 
the O 
anti-neoplastic O 
activity O 
of O 
farnesyl B-TRIVIAL 
-transferase O 
- O 
inhibition O 
, O 
also O 
explains O 
the O 
clinical O 
success O 
of O 
other O 
drugs O 
, O 
which O 
target O 
this O 
pathway O 
. O 

of O 
Primary O 
Chronic O 
Glomerulonephritis O 
with O 
Rehmannia O 
Glutinosa O 
Acteosides B-FAMILY 
in O 
Combination O 
with O 
the O 
Angiotensin O 
Receptor O 
Blocker O 
Irbesartan B-TRIVIAL 
: O 
A O 
Randomized O 
Controlled O 
Trial O 
. O 

study O 
aims O 
to O 
assess O 
the O 
efficacy O 
and O 
safety O 
of O 
Rehmannia O 
glutinosa O 
acteosides B-FAMILY 
used O 
in O 
combination O 
with O 
the O 
angiotensin O 
receptor O 
blocker O 
irbesartan B-TRIVIAL 
to O 
treat O 
primary O 
chronic O 
glomerulonephritis O 
. O 
A O 
total O 
of O 
479 O 
patients O 
diagnosed O 
with O 
primary O 
chronic O 
glomerulonephritis O 
were O 
recruited O 
from O 
outpatient O 
clinics O 
and O 
were O 
randomly O 
assigned O 
to O 
the O 
treatment O 
group O 
( O 
Rehmannia O 
glutinosa O 
acteosides B-FAMILY 
, O 
two O 
200-mg O 
capsules O 
, O 
bid O 
; O 
and O 
irbesartan B-TRIVIAL 
, O 
one O 
150-mg O 
tablet O 
, O 
qd O 
) O 
or O 
the O 
control O 
group O 
( O 
irbesartan B-TRIVIAL 
, O 
one O 
150-mg O 
tablet O 
, O 
qd O 
) O 
. O 
The O 
primary O 
outcome O 
was O 
24-h O 
urinary O 
protein O 
. O 
Secondary O 
outcome O 
measures O 
included O 
blood O 
pressure O 
, O 
estimated O 
glomerular O 
filtration O 
rate O 
, O 
erythrocyturia O 
, O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
aspartate B-TRIVIAL 
transaminase O 
and O 
electrolytes O 
. O 
After O 
8 O 
weeks O 
of O 
treatment O 
, O 
the O 
treatment O 
group O 
showed O 
a O 
mean O 
reduction O 
in O 
24-h O 
proteinuria O 
of O 
36.42% O 
compared O 
to O 
baseline O 
, O 
which O 
was O 
significantly O 
higher O 
than O 
the O 
mean O 
reduction O 
from O 
baseline O 
of O 
27.97% O 
in O 
the O 
control O 
group O 
(P O 
= O 
0.0278).Adverse O 
drug O 
reactions O 
occurred O 
at O 
a O 
similarly O 
low O 
rate O 
in O 
the O 
treatment O 
group O 
( O 
0.4% O 
) O 
and O 
control O 
group O 
( O 
1.2% O 
, O 
P O 
= O 
0.3724 O 
) O 
. O 
In O 
the O 
treatment O 
of O 
chronic O 
glomerulonephritis O 
, O 
the O 
combination O 
of O 
Rehmannia O 
glutinosa O 
acteosides B-FAMILY 
and O 
irbesartan B-TRIVIAL 
can O 
reduce O 
proteinuria O 
more O 
effectively O 
than O 
irbesartan B-TRIVIAL 
alone O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

memantine B-TRIVIAL 
induced O 
concurrent O 
functional O 
disconnectivity O 
and O 
altered O 
ultra O 
- O 
structural O 
tissue O 
integrity O 
in O 
the O 
rodent O 
brain O 
: O 
revealed O 
by O 
multimodal O 
MRI O 
. O 

: O 
An O 
effective O 
NMDA B-ABBREVIATION 
antagonist O 
imaging O 
model O 
may O 
find O 
key O 
utility O 
in O 
advancing O 
schizophrenia O 
drug O 
discovery O 
research O 
. O 
We O 
investigated O 
effects O 
of O 
subchronic O 
treatment O 
with O 
the O 
NMDA B-ABBREVIATION 
antagonist O 
memantine B-TRIVIAL 
by O 
using O 
behavioural O 
observation O 
and O 
multimodal O 
MRI O 
. O 
METHODS O 
: O 
Pharmacological O 
MRI O 
( O 
phMRI O 
) O 
was O 
used O 
to O 
map O 
the O 
neuroanatomical O 
binding O 
sites O 
of O 
memantine B-TRIVIAL 
after O 
acute O 
and O 
subchronic O 
treatment O 
. O 
Resting O 
state O 
fMRI O 
( O 
rs-fMRI O 
) O 
and O 
diffusion O 
MRI O 
were O 
used O 
to O 
study O 
the O 
changes O 
in O 
functional O 
connectivity O 
( O 
FC O 
) O 
and O 
ultra O 
- O 
structural O 
tissue O 
integrity O 
before O 
and O 
after O 
subchronic O 
memantine B-TRIVIAL 
treatment O 
. O 
Further O 
corroborating O 
behavioural O 
evidences O 
were O 
documented O 
. O 
RESULTS O 
: O 
Dose O 
- O 
dependent O 
phMRI O 
activation O 
was O 
observed O 
in O 
the O 
prelimbic O 
cortex O 
following O 
acute O 
doses O 
of O 
memantine B-TRIVIAL 
. O 
Subchronic O 
treatment O 
revealed O 
significant O 
effects O 
in O 
the O 
hippocampus O 
, O 
cingulate O 
, O 
prelimbic O 
and O 
retrosplenial O 
cortices O 
. O 
Decreases O 
in O 
FC O 
amongst O 
the O 
hippocampal O 
and O 
frontal O 
cortical O 
structures O 
( O 
prelimbic O 
, O 
cingulate O 
) O 
were O 
apparent O 
through O 
rs-fMRI O 
investigation O 
, O 
indicating O 
a O 
loss O 
of O 
connectivity O 
. O 
Diffusion O 
kurtosis O 
MRI O 
showed O 
decreases O 
in O 
fractional O 
anisotropy O 
and O 
mean O 
diffusivity O 
changes O 
, O 
suggesting O 
ultra O 
- O 
structural O 
changes O 
in O 
the O 
hippocampus O 
and O 
cingulate O 
cortex O 
. O 
Limited O 
behavioural O 
assessment O 
suggested O 
that O 
memantine B-TRIVIAL 
induced O 
behavioural O 
effects O 
comparable O 
to O 
other O 
NMDA B-ABBREVIATION 
antagonists O 
as O 
measured O 
by O 
locomotor O 
hyperactivity O 
and O 
that O 
the O 
effects O 
could O 
be O 
reversed O 
by O 
antipsychotic O 
drugs O 
. O 
CONCLUSION O 
: O 
Our O 
findings O 
substantiate O 
the O 
hypothesis O 
that O 
repeated O 
NMDA B-ABBREVIATION 
receptor O 
blockade O 
with O 
nonspecific O 
, O 
noncompetitive O 
NMDA B-ABBREVIATION 
antagonists O 
may O 
lead O 
to O 
functional O 
and O 
ultra O 
- O 
structural O 
alterations O 
, O 
particularly O 
in O 
the O 
hippocampus O 
and O 
cingulate O 
cortex O 
. O 
These O 
changes O 
may O 
underlie O 
the O 
behavioural O 
effects O 
. O 
Furthermore O 
, O 
the O 
present O 
findings O 
underscore O 
the O 
utility O 
and O 
the O 
translational O 
potential O 
of O 
multimodal O 
MR O 
imaging O 
and O 
acute O 
/ O 
subchronic O 
memantine B-TRIVIAL 
model O 
in O 
the O 
search O 
for O 
novel O 
disease O 
- O 
modifying O 
treatments O 
for O 
schizophrenia O 
. O 

, O 
isolated O 
from O 
dietary O 
mugwort O 
( O 
Artemisia O 
princeps O 
) O 
, O 
induces O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
by O 
inactivating O 
cdc25C-cdc2 O 
via O 
ATM-Chk1 O 
/ O 
2 O 
activation O 
. O 

, O 
a O 
flavonoid B-FAMILY 
derived O 
from O 
Artemisia O 
princeps O 
( O 
Japanese O 
mugwort O 
) O 
, O 
has O 
been O 
shown O 
to O 
inhibit O 
the O 
growth O 
of O 
several O 
human O 
cancer O 
cells O 
, O 
However O 
, O 
the O 
exact O 
mechanism O 
for O 
the O 
cytotoxic O 
effect O 
of O 
jaceosidin B-TRIVIAL 
is O 
not O 
completely O 
understood O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
molecular O 
mechanism O 
involved O 
in O 
the O 
antiproliferative O 
effect O 
of O 
jaceosidin B-TRIVIAL 
in O 
human O 
endometrial O 
cancer O 
cells O 
. O 
We O 
demonstrated O 
that O 
jaceosidin B-TRIVIAL 
is O 
a O 
more O 
potent O 
inhibitor O 
of O 
cell O 
growth O 
than O 
cisplatin B-TRIVIAL 
in O 
human O 
endometrial O 
cancer O 
cells O 
. O 
In O 
contrast O 
, O 
jaceosidin B-TRIVIAL 
-induced O 
cytotoxicity O 
in O 
normal O 
endometrial O 
cells O 
was O 
lower O 
than O 
that O 
observed O 
for O 
cisplatin B-TRIVIAL 
. O 
Jaceosidin B-TRIVIAL 
induced O 
G2 O 
/ O 
M O 
phase O 
cell O 
cycle O 
arrest O 
and O 
modulated O 
the O 
levels O 
of O 
cyclin O 
B O 
and O 
p-Cdc2 O 
in O 
Hec1A O 
cells O 
. O 
Knockdown O 
of O 
p21 O 
using O 
specific O 
siRNAs O 
partially O 
abrogated O 
jaceosidin B-TRIVIAL 
-induced O 
cell O 
growth O 
inhibition O 
. O 
Additional O 
mechanistic O 
studies O 
revealed O 
that O 
jaceosidin B-TRIVIAL 
treatment O 
resulted O 
in O 
an O 
increase O 
in O 
phosphorylation O 
of O 
Cdc25C O 
and O 
ATM-Chk1 O 
/ O 
2 O 
. O 
Ku55933 O 
, O 
an O 
ATM O 
inhibitor O 
, O 
reversed O 
jaceosidin B-TRIVIAL 
-induced O 
cell O 
growth O 
inhibition O 
, O 
in O 
part O 
. O 
Moreover O 
, O 
jaceosidin B-TRIVIAL 
treatment O 
resulted O 
in O 
phosphorylation O 
of O 
ERK O 
, O 
and O 
pretreatment O 
with O 
the O 
ERK O 
inhibitor O 
, O 
PD98059 B-IDENTIFIER 
, O 
attenuated O 
cell O 
growth O 
inhibition O 
by O 
jaceosidin B-TRIVIAL 
. O 
These O 
data O 
suggest O 
that O 
jaceosidin B-TRIVIAL 
, O 
isolated O 
from O 
Japanese O 
mugwort O 
, O 
modulates O 
the O 
ERK O 
/ O 
ATM O 
/ O 
Chk1 O 
/ O 
2 O 
pathway O 
, O 
leading O 
to O 
inactivation O 
of O 
the O 
Cdc2-cyclin O 
B1 O 
complex O 
, O 
followed O 
by O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
in O 
endometrial O 
cancer O 
cells O 
. O 

shed O 
light O 
on O 
islet O 
cell O 
molecular O 
phenotype O 
in O 
human O 
type O 
2 O 
diabetes O 
( O 
T2D O 
) O 
, O 
we O 
studied O 
the O 
transcriptome O 
of O 
non-diabetic O 
( O 
ND O 
) O 
and O 
T2D O 
islets O 
to O 
then O 
focus O 
on O 
the O 
ubiquitin O 
- O 
proteasome O 
system O 
( O 
UPS O 
) O 
, O 
the O 
major O 
protein O 
degradation O 
pathway O 
. O 
We O 
assessed O 
gene O 
expression O 
, O 
amount O 
of O 
ubiquitinated O 
proteins O 
, O 
proteasome O 
activity O 
, O 
and O 
the O 
effects O 
of O 
proteasome O 
inhibition O 
and O 
prolonged O 
exposure O 
to O 
palmitate B-TRIVIAL 
. O 
Microarray O 
analysis O 
identified O 
more O 
than O 
one O 
thousand O 
genes O 
differently O 
expressed O 
in O 
T2D O 
islets O 
, O 
involved O 
in O 
many O 
structures O 
and O 
functions O 
, O 
with O 
consistent O 
alterations O 
of O 
the O 
UPS O 
. O 
Quantitative O 
RT-PCR O 
demonstrated O 
downregulation O 
of O 
selected O 
UPS O 
genes O 
in O 
T2D O 
islets O 
and O 
beta O 
cell O 
fractions O 
, O 
with O 
greater O 
ubiquitin O 
accumulation O 
and O 
reduced O 
proteasome O 
activity O 
. O 
Chemically O 
induced O 
reduction O 
of O 
proteasome O 
activity O 
was O 
associated O 
with O 
lower O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
, O 
which O 
was O 
partly O 
reproduced O 
by O 
palmitate B-TRIVIAL 
exposure O 
. O 
These O 
results O 
show O 
the O 
presence O 
of O 
many O 
changes O 
in O 
islet O 
transcriptome O 
in O 
T2D O 
islets O 
and O 
underline O 
the O 
importance O 
of O 
the O 
association O 
between O 
UPS O 
alterations O 
and O 
beta O 
cell O 
dysfunction O 
in O 
human O 
T2D O 
. O 

deacetylases O 
are O 
able O 
to O 
catalyze O 
the O 
hydrolysis O 
of O 
N-acetyl B-SYSTEMATIC 
lysine I-SYSTEMATIC 
residues O 
of O 
histones O 
which O 
package O 
chromosomal O 
DNA O 
. O 
Therefore O 
they O 
play O 
an O 
important O 
role O 
in O 
mediating O 
gene O 
expression O 
and O 
cell O 
proliferation O 
. O 
HDAC O 
inhibitors O 
have O 
not O 
only O 
shown O 
promise O 
as O 
antiparasitic O 
, O 
antineurodegenerative O 
, O 
antirheumatologic O 
agents O 
and O 
immunosuppressant O 
, O 
but O 
as O 
potent O 
anticancer O 
agents O 
by O 
inducing O 
cell O 
cycle O 
arrest O 
, O 
differentiation O 
and O 
apoptosis O 
. O 
This O 
review O 
highlights O 
recent O 
development O 
in O 
design O 
, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
HDAC O 
inhibitors O 
for O 
cancer O 
therapy O 
. O 

Inhibits O 
Rosiglitazone B-TRIVIAL 
-Induced O 
Adipogenesis O 
in O 
3T3-L1 O 
Adipocytes O 
. O 

investigated O 
the O 
effects O 
of O 
6-gingerol B-SYSTEMATIC 
( O 
(S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone B-SYSTEMATIC 
) O 
on O 
the O 
inhibition O 
of O 
rosiglitazone B-TRIVIAL 
( O 
RGZ B-ABBREVIATION 
)-induced O 
adipogenesis O 
in O 
3T3-L1 O 
cells O 
. O 
The O 
morphological O 
changes O 
were O 
photographed O 
based O 
on O 
staining O 
lipid O 
accumulation O 
by O 
Oil-Red B-TRIVIAL 
O I-TRIVIAL 
in O 
RGZ B-ABBREVIATION 
( O 
1 O 
µmol O 
/ O 
l O 
) O 
- O 
treated O 
3T3-L1 O 
cells O 
without O 
or O 
with O 
various O 
concentrations O 
of O 
6-gingerol B-SYSTEMATIC 
on O 
differentiation O 
day O 
8 O 
. O 
Quantitation O 
of O 
triglycerides B-FAMILY 
content O 
was O 
performed O 
in O 
cells O 
on O 
day O 
8 O 
after O 
differentiation O 
induction O 
. O 
Differentiated O 
cells O 
were O 
lysed O 
to O 
detect O 
mRNA O 
and O 
protein O 
levels O 
of O 
adipocyte O 
- O 
specific O 
transcription O 
factors O 
by O 
real O 
- O 
time O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
and O 
Western O 
blot O 
analysis O 
, O 
respectively O 
. O 
6-gingerol B-SYSTEMATIC 
( O 
50 O 
µmol O 
/ O 
l O 
) O 
effectively O 
suppressed O 
oil O 
droplet O 
accumulation O 
and O 
reduced O 
the O 
sizes O 
of O 
the O 
droplets O 
in O 
RGZ B-ABBREVIATION 
-induced O 
adipocyte O 
differentiation O 
in O 
3T3-L1 O 
cells O 
. O 
The O 
triglyceride B-FAMILY 
accumulation O 
induced O 
by O 
RGZ B-ABBREVIATION 
in O 
differentiated O 
3T3-L1 O 
cells O 
was O 
also O 
reduced O 
by O 
6-gingerol B-SYSTEMATIC 
( O 
50 O 
µmol O 
/ O 
l O 
) O 
. O 
Treatment O 
of O 
differentiated O 
3T3-L1 O 
cells O 
with O 
6-gingerol B-SYSTEMATIC 
( O 
50 O 
µmol O 
/ O 
l O 
) O 
antagonized O 
RGZ B-ABBREVIATION 
-induced O 
gene O 
expression O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
(PPAR)γ O 
and O 
CCAAT O 
/ O 
enhancer O 
- O 
binding O 
protein O 
α O 
. O 
Additionally O 
, O 
the O 
increased O 
levels O 
of O 
mRNA O 
and O 
protein O 
in O 
adipocyte O 
- O 
specific O 
fatty B-FAMILY 
acid I-FAMILY 
binding O 
protein O 
4 O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
induced O 
by O 
RGZ B-ABBREVIATION 
in O 
3T3-L1 O 
cells O 
were O 
decreased O 
upon O 
treatment O 
with O 
6-gingerol B-SYSTEMATIC 
. O 
Our O 
data O 
suggests O 
that O 
6-gingerol B-SYSTEMATIC 
may O 
be O 
beneficial O 
in O 
obesity O 
, O 
by O 
reducing O 
adipogenesis O 
partly O 
through O 
the O 
down O 
- O 
regulating O 
PPARγ O 
activity O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

between O 
bufadienolides B-FAMILY 
derived O 
from O 
toad O 
venom O 
and O 
verapamil B-TRIVIAL 
in O 
langendorff O 
- O 
perfused O 
guinea O 
- O 
pig O 
hearts O 
. O 

toxicity O 
may O 
occur O 
due O 
to O 
dangerous O 
drug O 
combination O 
. O 
We O 
aimed O 
to O 
investigate O 
the O 
influence O 
of O 
verapamil B-TRIVIAL 
( O 
a O 
P-gp O 
inhibitor)-- O 
bufadienolides B-FAMILY 
interaction O 
on O 
cardiotoxicity O 
and O 
bufadienolide B-TRIVIAL 
uptake O 
by O 
the O 
isolated O 
heart O 
. O 
The O 
study O 
was O 
performed O 
in O 
Langendorff O 
isolated O 
perfused O 
guinea O 
- O 
pig O 
hearts O 
by O 
bufadienolides B-FAMILY 
infusion O 
in O 
the O 
absence O 
and O 
presence O 
of O 
verapamil B-TRIVIAL 
( O 
250 O 
, O 
500ng O 
/ O 
ml O 
) O 
. O 
Arrhythmia O 
parameters O 
were O 
evaluated O 
by O 
ECG O 
and O 
the O 
content O 
of O 
bufadienolides B-FAMILY 
in O 
heart O 
were O 
measured O 
by O 
ultra O 
- O 
performance O 
liquid O 
chromatography O 
tandem O 
mass O 
spectrometry O 
( O 
UPLC-MS O 
) O 
. O 
In O 
the O 
present O 
of O 
verapamil B-TRIVIAL 
, O 
the O 
wide O 
QRS O 
duration O 
and O 
lightly O 
rapid O 
heart O 
rate O 
( O 
HR O 
) O 
were O 
markedly O 
reduced O 
in O 
the O 
early O 
stage O 
of O 
bufadienolide B-TRIVIAL 
intoxication O 
. O 
However O 
, O 
the O 
ECG O 
changes O 
characterized O 
by O 
prolonged O 
P-R O 
interval O 
, O 
and O 
slow O 
heart O 
rate O 
and O 
low O 
QRS O 
amplitude O 
in O 
the O 
late O 
stage O 
of O 
bufadienolide B-TRIVIAL 
intoxication O 
were O 
significantly O 
enhanced O 
. O 
Furthermore O 
, O 
the O 
contents O 
of O 
a O 
variety O 
of O 
bufadienolide B-TRIVIAL 
compounds O 
in O 
the O 
verapamil B-TRIVIAL 
+ O 
bufadienolide B-TRIVIAL 
group O 
were O 
significantly O 
higher O 
when O 
cardiac O 
arrest O 
occurred O 
. O 
Although O 
verapamil B-TRIVIAL 
reduced O 
the O 
bufadienolide B-TRIVIAL 
-induced O 
ventricular O 
arrhythmias O 
, O 
verapamil B-TRIVIAL 
worsened O 
heart O 
block O 
and O 
lethal O 
bradycardia O 
of O 
bufadienolides B-FAMILY 
partly O 
via O 
increasing O 
the O 
uptake O 
of O 
bufadienolides B-FAMILY 
in O 
heart O 
tissue O 
, O 
which O 
could O 
compromise O 
the O 
protective O 
effects O 
of O 
verapamil B-TRIVIAL 
against O 
bufadienolide B-TRIVIAL 
intoxication O 
. O 
These O 
results O 
suggested O 
that O 
the O 
verapamil B-TRIVIAL 
may O 
produce O 
dangerous O 
interactions O 
with O 
drugs O 
containing O 
bufadienolides B-FAMILY 
. O 

- O 
dried O 
casein O 
- O 
based O 
micelles O 
as O 
a O 
vehicle O 
for O 
solubilization O 
and O 
controlled O 
delivery O 
of O 
flutamide B-TRIVIAL 
: O 
Formulation O 
, O 
characterization O 
, O 
and O 
in O 
vivo O 
pharmacokinetics O 
. O 

casein O 
( O 
CAS O 
) O 
- O 
based O 
micelles O 
loaded O 
with O 
the O 
poorly O 
soluble O 
anti-cancer O 
drug O 
, O 
flutamide B-TRIVIAL 
( O 
FLT B-ABBREVIATION 
) O 
, O 
were O 
successfully O 
developed O 
in O 
a O 
powdered O 
form O 
via O 
spray O 
- O 
drying O 
technique O 
. O 
Genipin B-TRIVIAL 
( O 
GNP B-ABBREVIATION 
) O 
was O 
used O 
to O 
crosslink O 
CAS O 
micelles O 
as O 
demonstrated O 
by O 
color O 
variation O 
of O 
the O 
micelles O 
. O 
Drug O 
solubilization O 
was O 
enhanced O 
by O 
incorporation O 
within O 
the O 
hydrophobic O 
micellar O 
core O 
which O 
was O 
confirmed O 
by O 
solubility O 
study O 
and O 
UV O 
spectra O 
. O 
Spherical O 
core O 
- O 
shell O 
micelles O 
were O 
obtained O 
with O 
a O 
particle O 
size O 
below O 
100nm O 
and O 
zeta O 
potential O 
around O 
-30mV O 
. O 
At O 
low O 
drug O 
loading O 
, O 
FLT B-ABBREVIATION 
was O 
totally O 
incorporated O 
within O 
micellar O 
core O 
as O 
revealed O 
by O 
thermal O 
analysis O 
. O 
However O 
, O 
at O 
higher O 
loading O 
, O 
excess O 
non-incorporated O 
drug O 
at O 
micelle O 
surface O 
caused O 
a O 
significant O 
reduction O 
in O 
the O 
surface O 
charge O 
density O 
. O 
Turbidity O 
measurements O 
demonstrated O 
the O 
high O 
physical O 
stability O 
of O 
micelles O 
for O 
2weeks O 
dependent O 
on O 
GNP B-ABBREVIATION 
-crosslinking O 
degree O 
. O 
In O 
a O 
dry O 
powdered O 
form O 
, O 
the O 
micelles O 
were O 
stable O 
for O 
6months O 
with O 
no O 
significant O 
changes O 
in O 
drug O 
content O 
or O 
particle O 
size O 
. O 
A O 
sustained O 
drug O 
release O 
from O 
CAS O 
micelles O 
up O 
to O 
5days O 
was O 
observed O 
. O 
After O 
i.v O 
. O 
administration O 
into O 
rats O 
, O 
CAS O 
micelles O 
exhibited O 
a O 
prolonged O 
plasma O 
circulation O 
of O 
FLT B-ABBREVIATION 
compared O 
to O 
drug O 
solution O 
. O 
Furthermore O 
, O 
a O 
more O 
prolonged O 
drug O 
systemic O 
circulation O 
was O 
observed O 
for O 
GNP B-ABBREVIATION 
-crosslinked O 
micelles O 
. O 
Overall O 
, O 
this O 
study O 
reports O 
the O 
application O 
of O 
spray O 
- O 
dried O 
natural O 
protein O 
- O 
based O 
micelles O 
for O 
i.v O 
. O 
delivery O 
of O 
hydrophobic O 
anti-cancer O 
drugs O 
such O 
as O 
FLT B-ABBREVIATION 
. O 

death O 
of O 
osteocytes O 
was O 
recognized O 
over O 
15years O 
ago O 
, O 
but O 
its O 
significance O 
for O 
bone O 
homeostasis O 
has O 
remained O 
elusive O 
. O 
A O 
new O 
paradigm O 
has O 
emerged O 
that O 
invokes O 
osteocyte O 
apoptosis O 
as O 
a O 
critical O 
event O 
in O 
the O 
recruitment O 
of O 
osteoclasts O 
to O 
a O 
specific O 
site O 
in O 
response O 
to O 
skeletal O 
unloading O 
, O 
fatigue O 
damage O 
, O 
estrogen B-FAMILY 
deficiency O 
and O 
perhaps O 
in O 
other O 
states O 
where O 
bone O 
must O 
be O 
removed O 
. O 
This O 
is O 
accomplished O 
by O 
yet O 
to O 
be O 
defined O 
signals O 
emanating O 
from O 
dying O 
osteocytes O 
, O 
which O 
stimulate O 
neighboring O 
viable O 
osteocytes O 
to O 
produce O 
osteoclastogenic O 
cytokines O 
. O 
The O 
osteocyte O 
apoptosis O 
caused O 
by O 
chronic O 
glucocorticoid O 
administration O 
does O 
not O 
increase O 
osteoclasts O 
; O 
however O 
, O 
it O 
does O 
negatively O 
impact O 
maintenance O 
of O 
bone O 
hydration O 
, O 
vascularity O 
, O 
and O 
strength O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
" O 
The O 
Osteocyte O 
" O 
. O 

- O 
dimensional O 
penning O 
ionization O 
electron O 
spectroscopy O 
of O 
open O 
- O 
shell O 
metallocenes B-FAMILY 
: O 
outer O 
valence O 
ionic O 
States O 
of O 
vanadocene B-TRIVIAL 
and O 
nickelocene B-TRIVIAL 
. O 

order O 
to O 
investigate O 
outer O 
valence O 
ionic O 
states O 
of O 
open O 
- O 
shell O 
metallocenes B-FAMILY 
, O 
we O 
have O 
applied O 
two O 
- O 
dimensional O 
collision O 
- O 
energy O 
/ O 
electron O 
- O 
energy O 
- O 
resolved O 
Penning O 
ionization O 
electron O 
spectroscopy O 
( O 
2D-PIES O 
) O 
upon O 
collision O 
with O 
metastable O 
He B-FORMULA 
*(2(3)S) O 
excited O 
atoms O 
as O 
well O 
as O 
a O 
high O 
level O 
ab O 
initio O 
molecular O 
orbital O 
calculation O 
( O 
the O 
partial O 
third O 
- O 
order O 
quasiparticle O 
theory O 
of O 
the O 
electron O 
propagator O 
( O 
P3 O 
) O 
) O 
to O 
ionization O 
from O 
neutral O 
ground O 
states O 
of O 
vanadocene B-TRIVIAL 
( O 
(4)A2g O 
) O 
and O 
nickelocene B-TRIVIAL 
( O 
(3)A2g O 
) O 
. O 
Assignments O 
of O 
observed O 
Penning O 
ionization O 
electron/ O 
He B-FORMULA 
I O 
ultraviolet O 
photoelectron O 
spectra O 
were O 
consistent O 
with O 
the O 
P3 O 
calculation O 
results O 
for O 
ionization O 
of O 
α O 
and O 
β O 
spin O 
electrons O 
except O 
for O 
electron O 
correlation O 
bands O 
observed O 
by O 
PIES O 
. O 
Negative O 
collision O 
energy O 
dependence O 
of O 
partial O 
Penning O 
ionization O 
cross O 
- O 
sections O 
( O 
CEDPICS O 
) O 
indicate O 
attractive O 
interaction O 
with O 
He B-FORMULA 
*(2(3)S) O 
around O 
the O 
molecule O 
. O 
Results O 
by O 
model O 
potential O 
calculation O 
utilizing O 
Li B-FORMULA 
( O 
2(2)S O 
) O 
instead O 
of O 
He B-FORMULA 
*(2(3)S) O 
for O 
interaction O 
between O 
He B-FORMULA 
*(2(3)S) O 
and O 
open O 
- O 
shell O 
metallocenes B-FAMILY 
do O 
not O 
explain O 
the O 
strong O 
negative O 
CEDPICS O 
of O 
the O 
bands O 
observed O 
in O 
PIES O 
. O 

of O 
amlodipine B-TRIVIAL 
on O 
the O 
oral O 
bioavailability O 
of O 
cephalexin B-TRIVIAL 
and O 
cefuroxime B-TRIVIAL 
axetil I-TRIVIAL 
in O 
healthy O 
volunteers O 
. O 

this O 
study O 
, O 
the O 
authors O 
compared O 
the O 
effects O 
of O 
amlodipine B-TRIVIAL 
( O 
AML B-ABBREVIATION 
) O 
on O 
the O 
bioavailability O 
of O 
cephalexin B-TRIVIAL 
( O 
LEX B-ABBREVIATION 
) O 
and O 
cefuroxime B-TRIVIAL 
axetil I-TRIVIAL 
( O 
CXM B-ABBREVIATION 
) O 
. O 
Twenty O 
- O 
four O 
healthy O 
men O 
were O 
randomized O 
to O 
4 O 
treatments O 
according O 
to O 
a O 
crossover O 
design O 
with O 
a O 
14-day O 
washout O 
. O 
After O 
an O 
overnight O 
fast O 
, O 
they O 
were O 
administered O 
orally O 
LEX B-ABBREVIATION 
500 O 
mg O 
alone O 
, O 
LEX B-ABBREVIATION 
500 O 
mg O 
2 O 
hours O 
after O 
oral O 
administration O 
of O 
AML B-ABBREVIATION 
5 O 
mg O 
, O 
CXM B-ABBREVIATION 
500 O 
mg O 
alone O 
, O 
and O 
CXM B-ABBREVIATION 
500 O 
mg O 
2 O 
hours O 
after O 
oral O 
administration O 
of O 
AML B-ABBREVIATION 
5 O 
mg O 
. O 
All O 
participants O 
completed O 
the O 
whole O 
study O 
without O 
side O 
effects O 
being O 
observed O 
. O 
Pharmacokinetic O 
data O 
were O 
analyzed O 
by O 
noncompartmental O 
modeling O 
with O 
WinNonlin O 
software O 
. O 
The O 
geometric O 
mean O 
( O 
GM O 
) O 
ratios O 
were O 
1.38 O 
( O 
90% O 
confidence O 
interval O 
[ O 
CI O 
] O 
, O 
1.32-1.45 O 
) O 
for O 
the O 
area O 
under O 
the O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
for O 
LEX B-ABBREVIATION 
and O 
1.27 O 
( O 
1.18-1.36 O 
) O 
for O 
the O 
maximum O 
concentration O 
of O 
drug O 
in O 
serum O 
(C(max)) O 
for O 
LEX B-ABBREVIATION 
followed O 
by O 
AML B-ABBREVIATION 
versus O 
alone O 
. O 
In O 
contrast O 
, O 
no O 
significant O 
differences O 
were O 
found O 
in O 
the O 
pharmacokinetic O 
parameters O 
of O 
CXM B-ABBREVIATION 
between O 
treatments O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
They O 
authors O 
conclude O 
that O 
AML B-ABBREVIATION 
possesses O 
an O 
enhancement O 
effect O 
in O 
β-lactam B-TRIVIAL 
antibiotic O 
bioavailability O 
( O 
in O 
this O 
case O 
, O 
LEX B-ABBREVIATION 
) O 
, O 
and O 
this O 
interaction O 
may O 
be O 
specific O 
to O 
the O 
peptidomimetic O 
β-lactam B-TRIVIAL 
antibiotics O 
. O 

derived O 
from O 
the O 
C B-FORMULA 
-terminal O 
heptad O 
repeat O 
( O 
C O 
peptides O 
) O 
of O 
HIV-1 O 
gp41 O 
are O 
potent O 
inhibitors O 
against O 
virus O 
entry O 
. O 
However O 
, O 
development O 
of O 
a O 
short O 
C O 
peptide O 
possessing O 
high O 
anti-HIV O 
potency O 
is O 
considered O 
a O 
daunting O 
challenge O 
. O 
We O 
recently O 
discovered O 
that O 
the O 
residues O 
Met B-FORMULA 
626 O 
and O 
Thr B-FORMULA 
627 O 
preceding O 
the O 
pocket O 
- O 
binding O 
domain O 
of O 
the O 
C O 
peptide O 
adopt O 
a O 
unique O 
M-T O 
hook O 
structure O 
that O 
is O 
crucial O 
for O 
the O 
design O 
of O 
HIV-1 O 
fusion O 
inhibitors O 
. O 
In O 
this O 
study O 
, O 
we O 
first O 
presented O 
a O 
proof O 
- O 
of O 
- O 
concept O 
prototype O 
that O 
the O 
M-T O 
hook O 
residues O 
can O 
dramatically O 
improve O 
the O 
antiviral O 
activity O 
and O 
thermostability O 
of O 
a O 
short O 
C O 
peptide O 
. O 
We O 
then O 
generated O 
a O 
24-mer O 
peptide O 
termed O 
MT-SC22EK O 
by O 
incorporating O 
the O 
M-T O 
hook O 
structure O 
to O 
the O 
N B-FORMULA 
terminus O 
of O 
the O 
poorly O 
active O 
short O 
C O 
peptide O 
SC22EK O 
. O 
Amazingly O 
, O 
MT-SC22EK O 
inhibited O 
HIV-1 O 
- O 
mediated O 
cell O 
fusion O 
and O 
infection O 
at O 
a O 
level O 
comparable O 
to O 
C34 O 
, O 
T1249 O 
, O 
SC29EK O 
, O 
and O 
sifuvirtide O 
, O 
and O 
it O 
was O 
highly O 
active O 
against O 
diverse O 
HIV-1 O 
subtypes O 
and O 
variants O 
, O 
including O 
those O 
T20 O 
( O 
enfuvirtide O 
) O 
and O 
SC29EK-resistant O 
viruses O 
. O 
The O 
high O 
- O 
resolution O 
crystal O 
structure O 
of O 
MT-SC22EK O 
reveals O 
the O 
N B-FORMULA 
-terminal O 
M-T O 
hook O 
conformation O 
folded O 
by O 
incorporated O 
Met B-FORMULA 
626 O 
and O 
Thr B-FORMULA 
627 O 
and O 
identifies O 
the O 
C B-FORMULA 
-terminal O 
boundary O 
critical O 
for O 
the O 
anti-HIV O 
activity O 
. O 
Collectively O 
, O 
our O 
studies O 
provide O 
new O 
insights O 
into O 
the O 
mechanisms O 
of O 
HIV-1 O 
fusion O 
and O 
its O 
inhibition O 
. O 

functional O 
conformational O 
study O 
of O 
2-O-sulfated B-SYSTEMATIC 
3,6 I-SYSTEMATIC 
anhydro-α-D-galactose I-SYSTEMATIC 
and O 
of O 
neo-κ- B-MULTIPLE 
and I-MULTIPLE 
ι-carrabiose I-MULTIPLE 
molecules O 
in O 
gas O 
phase O 
and O 
water O 
. O 

examined O 
the O 
conformational O 
preferences O 
of O 
the O 
2-O-sulfated-3,6-α-D-anhydrogalactose B-SYSTEMATIC 
( O 
compound O 
I O 
) O 
and O 
two O 
1,3 O 
linked O 
disaccharides B-FAMILY 
constituting-κ O 
or O 
ι-carrageenans O 
using O 
density O 
functional O 
and O 
ab O 
initio O 
methods O 
in O 
gas O 
phase O 
and O 
aqueous O 
solution O 
. O 
Systematic O 
modifications O 
of O 
two O 
torsion O 
angles O 
leading O 
to O 
324 O 
and O 
144 O 
starting O 
geometries O 
for O 
the O 
compound O 
I O 
and O 
each O 
disaccharide B-FAMILY 
were O 
used O 
to O 
generate O 
adiabatic O 
maps O 
using O 
B3LYP O 
/ O 
6-31G(d) O 
. O 
The O 
lower O 
energy O 
conformers O 
were O 
then O 
fully O 
optimized O 
using O 
B3LYP O 
, O 
B3PW91 O 
and O 
MP2 O 
with O 
several O 
basis O 
sets O 
. O 
Overall O 
, O 
we O 
discuss O 
the O 
impact O 
of O 
full O 
relaxation O 
on O 
the O 
energy O 
and O 
structure O 
of O 
the O 
dominant O 
conformations O 
, O 
present O 
the O 
performance O 
comparison O 
with O 
previous O 
molecular O 
mechanics O 
calculations O 
if O 
available O 
, O 
and O 
determine O 
whether O 
our O 
results O 
are O 
impacted O 
, O 
when O 
polarization O 
and O 
diffuse O 
functions O 
are O 
added O 
to O 
the O 
6-31G(d) O 
basis O 
set O 
, O 
or O 
when O 
the O 
MP2 O 
level O 
of O 
theory O 
is O 
used O 
. O 

aldo O 
- O 
keto O 
reductase O 
superfamily O 
contains O 
173 O 
proteins O 
which O 
are O 
present O 
in O 
all O 
phyla O 
. O 
Examination O 
of O 
the O 
human O 
and O 
mouse O 
genomes O 
has O 
identified O 
that O 
in O 
some O 
instances O 
a O 
single O 
AKR O 
gene O 
can O 
give O 
rise O 
to O 
alternatively O 
spliced O 
mRNA O 
variants O 
which O 
in O 
some O 
cases O 
can O 
give O 
rise O 
to O 
more O 
than O 
one O 
protein O 
isoform O 
. O 
This O 
is O 
currently O 
well O 
documented O 
in O 
the O 
AKR6A O 
subfamily O 
which O 
contains O 
the O 
β-subunits O 
of O 
the O 
voltage O 
- O 
gated O 
potassium B-SYSTEMATIC 
ion O 
channels O 
. O 
With O 
the O 
emergence O 
of O 
second O 
generation O 
sequencing O 
it O 
is O 
likely O 
that O 
the O 
occurrence O 
of O 
transcript O 
variants O 
and O 
protein O 
isoforms O 
from O 
a O 
single O 
AKR O 
gene O 
may O 
become O 
common O 
place O 
. O 
To O 
deal O 
with O 
this O 
issue O 
we O 
recommend O 
that O 
the O 
Ensembl O 
data O 
- O 
base O 
nomenclature O 
be O 
used O 
to O 
annotate O 
the O 
transcript O 
variants O 
from O 
a O 
single O 
AKR O 
gene O 
. O 
However O 
, O 
since O 
multiple O 
transcript O 
variants O 
could O 
give O 
rise O 
to O 
either O 
the O 
same O 
or O 
multiple O 
protein O 
isoforms O 
from O 
the O 
same O 
AKR O 
gene O 
we O 
also O 
propose O 
to O 
expand O 
the O 
nomenclature O 
of O 
the O 
AKR O 
protein O 
superfamily O 
, O 
so O 
that O 
when O 
a O 
protein O 
isoform O 
is O 
shown O 
to O 
be O 
expressed O 
and O 
is O 
functional O 
it O 
would O 
be O 
assigned O 
the O 
standard O 
AKR O 
name O 
followed O 
by O 
a O 
" O 
period O 
or O 
full O 
- O 
stop O 
" O 
and O 
a O 
number O 
for O 
that O 
unique O 
isoform O 
. O 
Numbers O 
will O 
be O 
assigned O 
chronologically O 
and O 
linked O 
to O 
the O 
respective O 
transcripts O 
annotated O 
in O 
Ensembl O 
e.g O 
. O 
AKR6A5.1 O 
( O 
Kvβ2.1 O 
) O 
( O 
AKR6A5-001 O 
, O 
-6 O 
and O 
-201 O 
) O 
, O 
followed O 
by O 
AKR6A5.2 O 
( O 
Kvβ2.2 O 
) O 
( O 
AKR6A5-002,-202 O 
) O 
. O 
This O 
nomenclature O 
is O 
expandable O 
and O 
it O 
enables O 
multiple O 
protein O 
isoforms O 
to O 
be O 
assigned O 
to O 
their O 
respective O 
transcripts O 
when O 
they O 
arise O 
from O 
the O 
same O 
AKR O 
gene O 
or O 
for O 
a O 
single O 
protein O 
isoform O 
to O 
be O 
assigned O 
to O 
multiple O 
transcripts O 
when O 
the O 
transcripts O 
encode O 
the O 
same O 
AKR O 
protein O 
. O 

AT2 O 
receptor O 
activates O 
the O 
cyclic-AMP B-TRIVIAL 
signaling O 
pathway O 
in O 
eel O 
. O 

unique O 
angiotensin O 
type O 
2 O 
receptor O 
( O 
AT2 O 
) O 
that O 
induces O 
a O 
cAMP B-ABBREVIATION 
signaling O 
pathway O 
was O 
cloned O 
and O 
characterized O 
for O 
the O 
first O 
time O 
in O 
fish O 
, O 
Anguilla O 
japonica O 
. O 
Phylogeny O 
and O 
synteny O 
results O 
showed O 
that O 
the O 
AT2s O 
among O 
fishes O 
and O 
tetrapods O 
share O 
the O 
same O 
origin O 
despite O 
a O 
sub O 
- O 
cluster O 
formation O 
among O 
eel O 
, O 
salmon O 
, O 
and O 
zebrafish O 
. O 
The O 
eel O 
AT2 O 
was O 
expressed O 
abundantly O 
in O 
the O 
spleen O 
and O 
localized O 
at O 
straight O 
arterioles O 
and O 
ellipsoid O 
regions O 
prior O 
to O 
the O 
sinusoid O 
, O 
suggesting O 
a O 
role O 
in O 
the O 
regulation O 
of O 
microcirculation O 
and O 
/ O 
or O 
immune O 
response O 
. O 
Various O 
angiotensin O 
( O 
Ang O 
) O 
peptides O 
, O 
including O 
Ang O 
II O 
, O 
Ang O 
III O 
, O 
and O 
Ang O 
IV O 
, O 
were O 
detected O 
in O 
the O 
spleen O 
by O 
a O 
radioimmunoassay O 
coupled O 
with O 
HPLC O 
separation O 
, O 
and O 
these O 
endogenous O 
peptides O 
stimulated O 
a O 
cAMP B-ABBREVIATION 
signaling O 
, O 
which O 
has O 
no O 
crosstalk O 
with O 
cGMP B-ABBREVIATION 
pathway O 
. O 
The O 
common O 
and O 
contrasting O 
features O 
of O 
AT2 O 
between O 
fishes O 
and O 
mammals O 
imply O 
some O 
ancestral O 
characters O 
of O 
AT2 O 
, O 
which O 
are O 
important O 
information O 
for O 
receptor O 
binding O 
and O 
evolutionary O 
studies O 
. O 

of O 
phosphate B-SYSTEMATIC 
buffer O 
in O 
parenteral O 
drugs O 
on O 
particle O 
formation O 
from O 
glass O 
vials O 
. O 

characteristics O 
of O 
inorganic O 
particles O 
generated O 
in O 
glass O 
vials O 
filled O 
with O 
phosphate B-SYSTEMATIC 
buffer O 
solutions O 
were O 
investigated O 
. O 
During O 
storage O 
, O 
particles O 
were O 
visually O 
detected O 
in O 
the O 
phosphate B-SYSTEMATIC 
buffer O 
solution O 
in O 
particular O 
glass O 
vials O 
which O 
pass O 
compendial O 
tests O 
of O 
containers O 
for O 
injectable O 
drugs O 
. O 
These O 
particles O 
were O 
considered O 
to O 
be O 
different O 
from O 
ordinal O 
glass O 
delamination O 
, O 
which O 
has O 
been O 
reported O 
in O 
a O 
number O 
of O 
papers O 
because O 
the O 
particles O 
were O 
mainly O 
composed O 
of O 
Al B-FORMULA 
, O 
P B-FORMULA 
and O 
O B-FORMULA 
, O 
but O 
not O 
Si B-FORMULA 
. O 
The O 
formation O 
of O 
the O 
particles O 
accelerated O 
at O 
higher O 
storage O 
temperatures O 
. O 
Among O 
the O 
surface O 
treatments O 
tested O 
for O 
the O 
glass O 
vials O 
, O 
sulfur B-SYSTEMATIC 
treatment O 
showed O 
a O 
protective O 
effect O 
on O 
the O 
particle O 
formation O 
in O 
the O 
vials O 
, O 
whereas O 
the O 
SiO2 B-FORMULA 
coating O 
did O 
not O 
have O 
any O 
protective O 
effects O 
. O 
It O 
was O 
found O 
that O 
the O 
elution O 
ratio O 
of O 
Al B-FORMULA 
and O 
Si B-FORMULA 
in O 
the O 
solution O 
stored O 
in O 
the O 
glass O 
vials O 
after O 
the O 
heating O 
was O 
similar O 
to O 
the O 
ratio O 
of O 
Al B-FORMULA 
and O 
Si B-FORMULA 
in O 
borosilicate B-SYSTEMATIC 
glass O 
. O 
However O 
, O 
the O 
Al B-FORMULA 
concentration O 
decreased O 
during O 
storage O 
( O 
5°C O 
, O 
6 O 
months O 
) O 
, O 
and O 
consequently O 
, O 
particle O 
formation O 
was O 
observed O 
in O 
the O 
solution O 
. O 
Adding O 
citrate B-FAMILY 
, O 
which O 
is O 
a O 
chelating O 
agent O 
for O 
Al B-FORMULA 
, O 
effectively O 
suppressed O 
the O 
particle O 
formation O 
in O 
the O 
heated O 
solution O 
. O 
When O 
50 O 
ppb O 
and O 
higher O 
concentrations O 
of O 
Al B-FORMULA 
ion O 
were O 
added O 
to O 
the O 
phosphate B-SYSTEMATIC 
buffer O 
solution O 
, O 
the O 
formation O 
of O 
white O 
particles O 
containing O 
Al B-FORMULA 
, O 
P B-FORMULA 
and O 
O B-FORMULA 
was O 
detected O 
. O 
It O 
is O 
suggested O 
that O 
a O 
phosphate B-SYSTEMATIC 
buffer O 
solution O 
in O 
a O 
borosilicate B-SYSTEMATIC 
glass O 
vial O 
has O 
the O 
ability O 
to O 
form O 
particles O 
due O 
to O 
interactions O 
with O 
the O 
Al B-FORMULA 
that O 
is O 
eluted O 
from O 
the O 
glass O 
during O 
storage O 
. O 

DNA O 
damage O 
corresponds O 
to O 
the O 
long O 
term O 
survival O 
of O 
human O 
cells O 
treated O 
with O 
silver B-SYSTEMATIC 
nanoparticles O 
. O 

examined O 
the O 
relation O 
between O 
DNA O 
damage O 
and O 
the O 
clonogenic O 
potential O 
of O 
3 O 
human O 
cell O 
lines O 
, O 
HepG2 O 
, O 
HT29 O 
and O 
A549 O 
, O 
treated O 
with O 
bare O 
20nm O 
or O 
200nm O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
. O 
The O 
endpoints O 
examined O 
were O 
the O 
DNA O 
breakage O 
estimated O 
by O 
the O 
comet O 
assay O 
, O 
the O 
oxidative O 
base O 
damage O 
recognized O 
by O 
formamido B-SYSTEMATIC 
- I-SYSTEMATIC 
pyrimidine I-SYSTEMATIC 
glycosylase O 
( O 
FPG O 
) O 
and O 
estimated O 
with O 
the O 
FPG O 
+ O 
comet O 
assay O 
, O 
and O 
the O 
frequencies O 
of O 
histone O 
γH2AX O 
foci O 
and O 
micronuclei O 
. O 
Each O 
cell O 
line O 
studied O 
had O 
a O 
different O 
pattern O 
of O 
DNA O 
breakage O 
and O 
base O 
damage O 
versus O 
the O 
NPs O 
concentration O 
and O 
time O 
of O 
treatment O 
. O 
The O 
overall O 
pattern O 
of O 
DNA O 
breakage O 
and O 
base O 
damage O 
induction O 
corresponded O 
to O 
the O 
intracellular O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
There O 
was O 
no O 
increase O 
in O 
the O 
frequencies O 
of O 
histone O 
γH2AX O 
foci O 
and O 
micronuclei O 
as O 
compared O 
to O 
those O 
in O 
the O 
untreated O 
cells O 
. O 
The O 
reported O 
experiments O 
suggest O 
that O 
only O 
the O 
oxidative O 
DNA O 
damage O 
corresponds O 
to O 
the O 
loss O 
of O 
the O 
clonogenic O 
ability O 
of O 
cells O 
treated O 
with O 
AgNPs O 
. O 

for O 
the O 
Use O 
of O 
Prolonged-Release O 
Fampridine B-TRIVIAL 
in O 
Patients O 
with O 
Multiple O 
Sclerosis O 
( O 
MS O 
) O 
. O 

- O 
release O 
fampridine B-TRIVIAL 
( O 
fampridine B-TRIVIAL 
PR I-TRIVIAL 
) O 
is O 
a O 
potassium B-SYSTEMATIC 
channel O 
blocker O 
that O 
improves O 
conductivity O 
of O 
signal O 
on O 
demyelinated O 
axons O 
in O 
central O 
nervous O 
system O 
. O 
Fampridine B-TRIVIAL 
PR I-TRIVIAL 
has O 
been O 
approved O 
to O 
improve O 
speed O 
of O 
walking O 
in O 
patients O 
with O 
multiple O 
sclerosis O 
. O 
This O 
statement O 
provides O 
a O 
brief O 
summary O 
of O 
data O 
on O 
fampridine B-TRIVIAL 
PR I-TRIVIAL 
and O 
recommendations O 
on O 
practical O 
use O 
of O 
the O 
medication O 
in O 
clinical O 
practice O 
, O 
prediction O 
, O 
and O 
evaluation O 
of O 
response O 
to O 
treatment O 
and O 
patient O 
management O 
. O 

of O 
designer O 
steroid B-FAMILY 
methylstenbolone B-SYSTEMATIC 
in O 
" O 
nutritional O 
supplement O 
" O 
using O 
gas O 
chromatography O 
and O 
tandem O 
mass O 
spectrometry O 
: O 
elucidation O 
of O 
its O 
urinary O 
metabolites O 
. O 

use O 
of O 
" O 
nutritional O 
supplements O 
" O 
containing O 
unapproved O 
substances O 
has O 
become O 
a O 
regular O 
practice O 
in O 
amateur O 
and O 
professional O 
athletes O 
. O 
This O 
represents O 
a O 
dangerous O 
habit O 
for O 
their O 
health O 
once O 
no O 
data O 
about O 
toxicological O 
or O 
pharmacological O 
effects O 
of O 
these O 
supplements O 
are O 
available O 
. O 
Most O 
of O 
them O 
are O 
freely O 
commercialized O 
online O 
and O 
any O 
person O 
can O 
buy O 
them O 
without O 
medical O 
surveillance O 
. O 
Usually O 
, O 
the O 
steroids B-FAMILY 
intentionally O 
added O 
to O 
the O 
" O 
nutritional O 
supplements O 
" O 
are O 
testosterone B-TRIVIAL 
analogues O 
with O 
some O 
structural O 
modifications O 
. O 
In O 
this O 
study O 
, O 
the O 
analyzed O 
product O 
was O 
bought O 
online O 
and O 
a O 
new O 
anabolic O 
steroid B-FAMILY 
known O 
as O 
methylstenbolone B-SYSTEMATIC 
( O 
2,17α-dimethyl-17β-hydroxy-5α-androst-1-en-3-one B-SYSTEMATIC 
) O 
was O 
detected O 
, O 
as O 
described O 
on O 
label O 
. O 
Generally O 
, O 
anabolic O 
steroids B-FAMILY 
are O 
extensively O 
metabolized O 
, O 
thus O 
in O 
- O 
depth O 
knowledge O 
of O 
their O 
metabolism O 
is O 
mandatory O 
for O 
doping O 
control O 
purposes O 
. O 
For O 
this O 
reason O 
, O 
a O 
human O 
excretion O 
study O 
was O 
carried O 
out O 
with O 
four O 
volunteers O 
after O 
a O 
single O 
oral O 
dose O 
to O 
determine O 
the O 
urinary O 
metabolites O 
of O 
the O 
steroid B-FAMILY 
. O 
Urine O 
samples O 
were O 
submitted O 
to O 
enzymatic O 
hydrolysis O 
of O 
glucuconjugated O 
metabolites O 
followed O 
by O 
liquid O 
- O 
liquid O 
extraction O 
and O 
analysis O 
of O 
the O 
trimethylsilyl B-SYSTEMATIC 
derivatives O 
by O 
gas O 
chromatography O 
coupled O 
to O 
tandem O 
mass O 
spectrometry O 
. O 
Mass O 
spectrometric O 
data O 
allowed O 
the O 
proposal O 
of O 
two O 
plausible O 
metabolites O 
: O 
2,17α-dimethyl-16ξ,17β-dihydroxy-5α-androst-1-en-3-one B-SYSTEMATIC 
( O 
S1 O 
) O 
, O 
2,17α-dimethyl-3α,16ξ,17β-trihydroxy-5α-androst-1-ene B-SYSTEMATIC 
( O 
S2 O 
) O 
. O 
Their O 
electron O 
impact O 
mass O 
spectra O 
are O 
compatible O 
with O 
16-hydroxylated B-FAMILY 
steroids I-FAMILY 
O-TMS I-FAMILY 
derivatives O 
presenting O 
diagnostic O 
ions O 
such O 
as O 
m O 
/ O 
z O 
231 O 
and O 
m O 
/ O 
z O 
218 O 
. O 
These O 
metabolites O 
were O 
detectable O 
after O 
one O 
week O 
post O 
administration O 
while O 
unchanged O 
methylstenbolone B-SYSTEMATIC 
was O 
only O 
detectable O 
in O 
a O 
brief O 
period O 
of O 
45 O 
h O 
. O 

stress O 
and O 
MAPK O 
involved O 
into O 
ATF2 O 
expression O 
in O 
immortalized O 
human O 
urothelial O 
cells O 
treated O 
by O 
arsenic B-SYSTEMATIC 
. O 

is O 
a O 
subfamily O 
member O 
of O 
AP-1 O 
and O 
has O 
an O 
important O 
role O 
in O 
cellular O 
stress O 
responses O 
. O 
ATF2 O 
has O 
been O 
implicated O 
in O 
a O 
transcriptional O 
response O 
leading O 
to O 
cell O 
migration O 
and O 
malignant O 
tumor O 
progression O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
effect O 
of O 
arsenic B-SYSTEMATIC 
on O 
expression O 
of O 
ATF2 O 
and O 
regulatory O 
pathways O 
in O 
human O 
urothelial O 
cells O 
. O 
In O 
this O 
study O 
, O 
ATF2 O 
expression O 
was O 
measured O 
in O 
NaAsO2 B-FORMULA 
-treated O 
human O 
uroepithelial O 
cell O 
line O 
( O 
SV-HUC-1 O 
) O 
with O 
1 O 
, O 
2 O 
, O 
4 O 
, O 
8 O 
and O 
10 O 
μM O 
concentrations O 
in O 
order O 
to O 
provide O 
some O 
basis O 
data O 
for O 
the O 
study O 
on O 
mechanism O 
of O 
bladder O 
cancer O 
induced O 
by O 
arsenic B-SYSTEMATIC 
. O 
We O 
found O 
that O 
ATF2 O 
expression O 
levels O 
at O 
2 O 
, O 
4 O 
, O 
8 O 
and O 
10 O 
μM O 
arsenic B-SYSTEMATIC 
-treated O 
cells O 
were O 
significantly O 
higher O 
than O 
those O 
of O 
control O 
cells O 
, O 
and O 
the O 
strongest O 
expression O 
occurred O 
in O 
4 O 
μM O 
NaAsO2 B-FORMULA 
-treated O 
cells O 
. O 
Antioxidants O 
( O 
melatonin B-TRIVIAL 
) O 
and O 
JNK O 
or O 
p38 O 
inhibitors O 
decreased O 
significantly O 
arsenic B-SYSTEMATIC 
-induced O 
ATF2 O 
expression O 
. O 
Taken O 
together O 
, O 
these O 
data O 
indicated O 
that O 
the O 
increasing O 
of O 
ATF2 O 
expression O 
is O 
mediated O 
via O 
oxidative O 
stress O 
induced O 
by O 
arsenic B-SYSTEMATIC 
in O 
SV-HUC-1 O 
cells O 
, O 
and O 
JNK O 
or O 
p38 O 
rather O 
than O 
ERK O 
is O 
responsible O 
for O 
arsenic B-SYSTEMATIC 
-induced O 
ATF2 O 
expression O 
. O 
ROS O 
were O 
also O 
involved O 
in O 
arsenic B-SYSTEMATIC 
induced O 
the O 
activation O 
of O 
JNK O 
and O 
p38 O 
MAPK O 
signaling O 
pathway O 
. O 

medicine O 
for O 
targeted O 
and O 
platinum B-SYSTEMATIC 
-based O 
chemotherapy O 
of O 
lung O 
and O 
bladder O 
cancer O 
. O 

personalized O 
medicine O 
revolution O 
is O 
occurring O 
for O 
cancer O 
chemotherapy O 
. O 
Biomarkers O 
are O 
increasingly O 
capable O 
of O 
distinguishing O 
genotypic O 
or O 
phenotypic O 
traits O 
of O 
individual O 
tumors O 
, O 
and O 
are O 
being O 
linked O 
to O 
the O 
selection O 
of O 
treatment O 
protocols O 
. O 
This O 
review O 
covers O 
the O 
molecular O 
basis O 
for O 
biomarkers O 
of O 
response O 
to O 
targeted O 
and O 
cytotoxic O 
lung O 
and O 
bladder O 
cancer O 
treatment O 
with O 
an O 
emphasis O 
on O 
platinum B-SYSTEMATIC 
-based O 
chemotherapy O 
. O 
Platinum B-SYSTEMATIC 
derivatives O 
are O 
a O 
class O 
of O 
drugs O 
commonly O 
employed O 
against O 
solid O 
tumors O 
that O 
kill O 
cells O 
by O 
covalent O 
attachment O 
to O 
DNA O 
. O 
Platinum B-SYSTEMATIC 
-DNA O 
adduct O 
levels O 
in O 
patient O 
tissues O 
have O 
been O 
correlated O 
to O 
response O 
and O 
survival O 
. O 
The O 
sensitivity O 
and O 
precision O 
of O 
adduct O 
detection O 
has O 
increased O 
to O 
the O 
point O 
of O 
enabling O 
subtherapeutic O 
dosing O 
for O 
diagnostics O 
applications O 
, O 
termed O 
diagnostic O 
microdosing O 
, O 
prior O 
to O 
the O 
initiation O 
of O 
full O 
- O 
dose O 
therapy O 
. O 
The O 
clinical O 
status O 
of O 
this O 
unique O 
phenotypic O 
marker O 
for O 
lung O 
and O 
bladder O 
cancer O 
applications O 
is O 
detailed O 
along O 
with O 
discussion O 
of O 
future O 
applications O 
. O 

intensive O 
studies O 
of O 
the O 
secretase O 
- O 
mediated O 
processing O 
of O 
the O 
amyloid O 
precursor O 
protein O 
( O 
APP O 
) O 
to O 
form O 
the O 
amyloid O 
β- O 
peptide O 
( O 
Aβ O 
) O 
, O 
in O 
relation O 
to O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
, O 
no O 
new O 
therapeutic O 
agents O 
have O 
reached O 
the O 
clinics O 
based O 
on O 
reducing O 
Aβ O 
levels O 
through O 
the O 
use O 
of O 
secretase O 
inhibitors O 
or O 
immunotherapy O 
. O 
Furthermore O 
, O 
the O 
normal O 
neuronal O 
functions O 
of O 
APP O 
and O 
its O 
various O 
metabolites O 
still O 
remain O 
under O 
- O 
investigated O 
and O 
unclear O 
. O 
Here O 
, O 
we O 
highlight O 
emerging O 
areas O 
of O 
APP O 
function O 
that O 
may O 
provide O 
new O 
insights O 
into O 
synaptic O 
development O 
, O 
cognition O 
, O 
and O 
gene O 
regulation O 
. O 
By O 
modulating O 
expression O 
levels O 
of O 
endogenous O 
APP O 
in O 
primary O 
cortical O 
neurons O 
, O 
the O 
frequency O 
and O 
amplitude O 
of O 
calcium B-SYSTEMATIC 
oscillations O 
is O 
modified O 
, O 
implying O 
a O 
key O 
role O 
for O 
APP O 
in O 
maintaining O 
neuronal O 
calcium B-SYSTEMATIC 
homeostasis O 
essential O 
for O 
synaptic O 
transmission O 
. O 
Disruption O 
of O 
this O 
homeostatic O 
mechanism O 
predisposes O 
to O 
aging O 
and O 
AD O 
. O 
Synaptic O 
spine O 
loss O 
is O 
a O 
feature O 
of O 
neurogeneration O 
resulting O 
in O 
learning O 
and O 
memory O 
deficits O 
, O 
and O 
emerging O 
evidence O 
indicates O 
a O 
role O 
for O 
APP O 
, O 
probably O 
mediated O 
via O 
one O 
or O 
more O 
of O 
its O 
metabolites O 
, O 
in O 
spine O 
structure O 
and O 
functions O 
. O 
The O 
intracellular O 
domain O 
of O 
APP O 
( O 
AICD O 
) O 
has O 
also O 
emerged O 
as O 
a O 
key O 
epigenetic O 
regulator O 
of O 
gene O 
expression O 
controlling O 
a O 
diverse O 
range O 
of O 
genes O 
, O 
including O 
APP O 
itself O 
, O 
the O 
amyloid O 
- O 
degrading O 
enzyme O 
neprilysin O 
, O 
and O 
aquaporin-1 O 
. O 
A O 
fuller O 
understanding O 
of O 
the O 
physiological O 
and O 
pathological O 
actions O 
of O 
APP O 
and O 
its O 
metabolic O 
network O 
could O 
provide O 
new O 
opportunities O 
for O 
therapeutic O 
intervention O 
in O 
AD O 
. O 

characterization O 
of O 
X-ray O 
absorption O 
, O 
emission O 
, O 
and O 
photoelectron O 
spectra O 
of O 
nitrogen B-SYSTEMATIC 
doped O 
along O 
graphene B-TRIVIAL 
edges O 
. O 

X-ray O 
absorption O 
( O 
XAS O 
) O 
, O 
emission O 
( O 
XES O 
) O 
, O 
and O 
photoelectron O 
( O 
XPS O 
) O 
spectra O 
of O 
nitrogen B-SYSTEMATIC 
doped O 
along O 
graphene B-TRIVIAL 
edges O 
are O 
systematically O 
investigated O 
by O 
using O 
first O 
- O 
principles O 
methods O 
. O 
In O 
this O 
study O 
we O 
considered O 
pyridinium B-SYSTEMATIC 
-like O 
, O 
pyridine B-SYSTEMATIC 
-like O 
, O 
cyanide B-SYSTEMATIC 
-like O 
, O 
and O 
amine B-SYSTEMATIC 
-like O 
nitrogens B-FAMILY 
at O 
armchair O 
and O 
zigzag O 
edges O 
and O 
pyrrole B-SYSTEMATIC 
-like O 
nitrogen B-SYSTEMATIC 
at O 
armchair O 
edge O 
as O 
well O 
as O 
graphite B-TRIVIAL 
-like O 
nitrogen B-SYSTEMATIC 
at O 
graphene B-TRIVIAL 
interior O 
site O 
. O 
Our O 
results O 
indicate O 
that O 
nitrogen B-SYSTEMATIC 
configuration O 
and O 
its O 
location O 
( O 
armchair O 
or O 
zigzag O 
edge O 
) O 
in O 
nitrogen B-TRIVIAL 
- I-TRIVIAL 
doped I-TRIVIAL 
graphene I-TRIVIAL 
can O 
be O 
identified O 
via O 
the O 
spectral O 
analysis O 
. O 
Furthermore O 
, O 
some O 
controversial O 
spectral O 
features O 
observed O 
in O 
experiment O 
for O 
N-doped B-TRIVIAL 
graphene I-TRIVIAL 
-like O 
materials O 
are O 
unambiguously O 
assigned O 
. O 
The O 
present O 
analysis O 
gives O 
an O 
explanation O 
to O 
the O 
reason O 
why O 
the O 
peak O 
assignment O 
is O 
usually O 
made O 
differently O 
between O 
XPS O 
and O 
XAS O 
. O 

the O 
Conformational O 
Preference O 
of O 
the O 
Carbon B-SYSTEMATIC 
-Bonded O 
Covalent O 
Adduct O 
Formed O 
upon O 
Exposure O 
of O 
2'-Deoxyguanosine B-SYSTEMATIC 
to O 
Ochratoxin B-TRIVIAL 
A I-TRIVIAL 
. O 

conformational O 
flexibility O 
of O 
the O 
C8- O 
linked O 
guanine B-TRIVIAL 
adduct O 
formed O 
from O 
attachment O 
of O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
( O 
OTA B-ABBREVIATION 
) O 
was O 
analyzed O 
using O 
a O 
systematic O 
computational O 
approach O 
and O 
models O 
ranging O 
from O 
the O 
nucleobase B-FAMILY 
to O 
the O 
adducted O 
DNA O 
helix O 
. O 
A O 
focus O 
was O 
placed O 
on O 
the O 
influence O 
of O 
the O 
C8-modification O 
of O 
2'-deoxyguanosine B-SYSTEMATIC 
( O 
dG O 
) O 
on O 
the O 
preferred O 
relative O 
arrangement O 
of O 
the O 
nucleobase B-FAMILY 
and O 
the O 
C8- O 
substituent O 
and O 
, O 
more O 
importantly O 
, O 
the O 
anti O 
/ O 
syn O 
conformational O 
preference O 
with O 
respect O 
to O 
the O 
glycosidic O 
bond O 
. O 
Although O 
OTA B-ABBREVIATION 
is O 
twisted O 
with O 
respect O 
to O 
the O 
base O 
in O 
the O 
nucleobase B-FAMILY 
model O 
, O 
addition O 
of O 
the O 
deoxyribose B-TRIVIAL 
sugar I-TRIVIAL 
induces O 
a O 
further O 
twist O 
and O 
restricts O 
rotation O 
about O 
the O 
C-C B-FORMULA 
linkage O 
due O 
to O 
close O 
contacts O 
between O 
OTA B-ABBREVIATION 
and O 
the O 
sugar O 
. O 
The O 
nucleoside B-FAMILY 
model O 
preferentially O 
adpots O 
a O 
syn O 
orientation O 
( O 
by O 
10-20 O 
kJ O 
mol(-1) O 
depending O 
on O 
the O 
OTA B-ABBREVIATION 
conformation O 
) O 
due O 
to O 
the O 
presence O 
of O 
an O 
O5'- O 
H B-FORMULA 
···N3 O 
interaction O 
. O 
However O 
, O 
when O 
this O 
hydrogen B-SYSTEMATIC 
bond O 
is O 
eliminated O 
, O 
which O 
better O 
mimics O 
the O 
DNA O 
environment O 
, O 
a O 
small O 
( O 
< O 
5 O 
kJ O 
mol(-1) O 
) O 
anti O 
/ O 
syn O 
energy O 
difference O 
is O 
predicted O 
. O 
Inclusion O 
of O 
the O 
5'-monophosphate B-SYSTEMATIC 
group O 
leads O 
to O 
an O 
up O 
to O 
20 O 
kJ O 
mol(-1) O 
preference O 
for O 
the O 
syn B-FAMILY 
( I-FAMILY 
nucleotide I-FAMILY 
) I-FAMILY 
conformation O 
due O 
to O 
stabilizing O 
base- O 
phosphate B-SYSTEMATIC 
interactions O 
involving O 
the O 
amino B-FAMILY 
group O 
of O 
guanine B-TRIVIAL 
. O 
Nevertheless O 
, O 
MD O 
simulations O 
and O 
free O 
energy O 
analysis O 
predict O 
that O 
both O 
syn- O 
and O 
anti-conformations O 
of O 
OTB-dG B-ABBREVIATION 
are O 
equally O 
stable O 
in O 
helices O 
when O 
paired O 
opposite O 
cytosine B-TRIVIAL 
. O 
These O 
results O 
indicate O 
that O 
the O 
adduct O 
will O 
likely O 
adopt O 
a O 
syn O 
conformation O 
in O 
an O 
isolated O 
nucleoside B-FAMILY 
and O 
nucleotide B-FAMILY 
, O 
while O 
a O 
mixture O 
of O 
syn O 
and O 
anti O 
conformations O 
will O 
be O 
observed O 
in O 
DNA O 
duplexes O 
. O 
Since O 
the O 
syn O 
conformation O 
could O 
stabilize O 
base O 
mismatches O 
upon O 
DNA O 
replication O 
or O 
Z-DNA O 
structures O 
with O 
varied O 
biological O 
outcomes O 
, O 
future O 
computational O 
and O 
experimental O 
work O 
should O 
elucidate O 
the O 
consequences O 
of O 
the O 
conformational O 
preference O 
of O 
this O 
potentially O 
harmful O 
DNA O 
lesion O 
. O 

is O 
a O 
key O 
process O 
in O 
cellular O 
delivery O 
of O 
macromolecules O 
by O 
molecular O 
transporters O 
, O 
although O 
the O 
mechanism O 
of O 
internalization O 
remains O 
unclear O 
. O 
Here O 
, O 
we O 
probe O 
the O 
cellular O 
uptake O 
of O 
streptavidin O 
using O 
biotinylated B-TRIVIAL 
guanidinoneomycin I-TRIVIAL 
( O 
biotinGNeo B-TRIVIAL 
) O 
, O 
a O 
low O 
molecular O 
weight O 
guanidinium B-SYSTEMATIC 
-rich O 
molecular O 
transporter O 
. O 
Two O 
distinct O 
modes O 
were O 
explored O 
: O 
(i) O 
incubation O 
of O 
cells O 
with O 
a O 
preformed O 
tetravalent O 
streptavidin-( O 
biotinGNeo B-TRIVIAL 
)4 O 
conjugate O 
and O 
(ii) O 
preincubation O 
of O 
cells O 
with O 
the O 
biotinGNeo B-TRIVIAL 
before O 
exposure O 
to O 
streptavidin O 
. O 
A O 
significant O 
enhancement O 
in O 
uptake O 
was O 
observed O 
after O 
preincubation O 
with O 
biotinGNeo B-TRIVIAL 
. O 
FRET O 
studies O 
showed O 
that O 
the O 
enhanced O 
uptake O 
was O 
accompanied O 
by O 
extensive O 
aggregation O 
of O 
streptavidin O 
on O 
the O 
cell O 
surface O 
. O 
Because O 
guanidinylated B-TRIVIAL 
neomycin I-TRIVIAL 
was O 
previously O 
found O 
to O 
exclusively O 
bind O 
to O 
heparan O 
sulfate O 
, O 
our O 
observations O 
suggest O 
that O 
heparan O 
sulfate O 
proteoglycan O 
aggregation O 
is O 
a O 
pivotal O 
step O 
for O 
endocytic O 
entry O 
into O 
cells O 
by O 
guanidinoglycosides B-FAMILY 
. O 
These O 
observations O 
put O 
forward O 
a O 
practical O 
and O 
general O 
pathway O 
for O 
the O 
cellular O 
delivery O 
of O 
diverse O 
macromolecules O 
. O 

molecular O 
signature O 
for O 
the O 
early O 
detection O 
and O 
prediction O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
in O 
rat O 
liver O 
. O 

of O 
toxicity O 
are O 
central O 
for O 
the O 
assessment O 
of O 
chemical O 
toxicity O 
, O 
and O 
the O 
effects O 
of O 
environmental O 
toxic O 
compounds O 
are O 
still O 
a O 
major O 
issue O 
for O 
predicting O 
potential O 
human O 
health O 
risks O 
. O 
Among O 
the O 
various O 
environmental O 
toxicants O 
, O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
are O 
an O 
important O 
class O 
of O 
environmental O 
pollutant O 
, O 
and O 
many O 
PAHs B-ABBREVIATION 
are O 
known O 
or O 
suspected O 
carcinogens O 
. O 
In O 
the O 
present O 
study O 
, O 
to O 
investigate O 
whether O 
characteristic O 
expression O 
profiles O 
of O 
PAHs B-ABBREVIATION 
exist O 
in O 
rat O 
liver O 
and O 
whether O 
a O 
characteristic O 
molecular O 
signature O 
can O 
discriminate O 
and O 
predict O 
among O 
different O 
PAHs B-ABBREVIATION 
at O 
an O 
early O 
exposure O 
time O 
, O 
we O 
analyzed O 
the O 
genome O 
- O 
wide O 
expression O 
profiles O 
of O 
rat O 
livers O 
exposed O 
to O 
PAHs B-ABBREVIATION 
[ O 
benzo[a]anthracene B-SYSTEMATIC 
( O 
BA O 
) O 
, O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
BP O 
) O 
, O 
phenanthrene B-SYSTEMATIC 
( O 
PA O 
) O 
and O 
naphthalene B-SYSTEMATIC 
( O 
NT O 
) O 
] O 
. O 
At O 
early O 
time O 
- O 
point O 
PAH B-ABBREVIATION 
exposure O 
, O 
large O 
- O 
scale O 
gene O 
expression O 
analysis O 
resulted O 
in O 
characteristic O 
molecular O 
signatures O 
for O 
each O 
PAH B-ABBREVIATION 
, O 
and O 
supervised O 
analysis O 
identified O 
1183 O 
outlier O 
genes O 
as O 
a O 
distinct O 
molecular O 
signature O 
discerning O 
PAHs B-ABBREVIATION 
from O 
the O 
normal O 
control O 
group O 
. O 
We O 
identified O 
158 O 
outlier O 
genes O 
as O 
early O 
predictive O 
and O 
surrogate O 
markers O 
for O 
predicting O 
each O 
tested O 
PAH B-ABBREVIATION 
by O 
combination O 
of O 
two O 
different O 
multi O 
- O 
classification O 
algorithms O 
with O 
100% O 
accuracy O 
through O 
a O 
leave O 
- O 
one O 
out O 
cross O 
- O 
validation O 
method O 
. O 
In O 
conclusion O 
, O 
the O 
characteristic O 
gene O 
expression O 
signatures O 
from O 
a O 
rat O 
model O 
system O 
could O 
be O 
used O 
as O 
predictable O 
and O 
discernible O 
gene O 
- O 
based O 
biomarkers O 
for O 
the O 
detection O 
and O 
prediction O 
of O 
PAHs B-ABBREVIATION 
, O 
and O 
these O 
molecular O 
markers O 
may O 
provide O 
insights O 
into O 
the O 
underlying O 
mechanisms O 
for O 
genotoxicity O 
of O 
exposure O 
to O 
PAHs B-ABBREVIATION 
from O 
environmental O 
aspect O 
. O 

problem O 
of O 
targeted O 
delivery O 
of O 
antisense O 
and O 
siRNA O 
oligonucleotides O 
can O 
be O 
resolved O 
into O 
two O 
distinct O 
aspects O 
. O 
The O 
first O 
concerns O 
devising O 
ligand O 
- O 
oligonucleotide O 
or O 
ligand O 
- O 
carrier O 
moieties O 
that O 
bind O 
with O 
high O 
selectivity O 
to O 
receptors O 
on O 
the O 
cell O 
type O 
of O 
interest O 
and O 
that O 
are O 
efficiently O 
internalized O 
by O 
endocytosis O 
. O 
The O 
second O 
concerns O 
releasing O 
oligonucleotides O 
from O 
pharmacologically O 
inert O 
endomembrane O 
compartments O 
so O 
that O 
they O 
can O 
access O 
RNA O 
in O 
the O 
cytosol O 
or O 
nucleus O 
. O 
In O 
this O 
review O 
, O 
we O 
will O 
address O 
both O 
of O 
these O 
aspects O 
. O 
Thus O 
, O 
we O 
present O 
information O 
on O 
three O 
important O 
receptor O 
families O 
, O 
the O 
integrins O 
, O 
the O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
, O 
and O 
the O 
G O 
protein O 
- O 
coupled O 
receptors O 
in O 
terms O 
of O 
their O 
suitability O 
for O 
targeted O 
delivery O 
of O 
oligonucleotides O 
. O 
This O 
includes O 
discussion O 
of O 
receptor O 
abundance O 
, O 
internalization O 
and O 
trafficking O 
pathways O 
, O 
and O 
the O 
availability O 
of O 
suitable O 
high O 
affinity O 
ligands O 
. O 
We O 
also O 
consider O 
the O 
process O 
of O 
oligonucleotide O 
uptake O 
and O 
intracellular O 
trafficking O 
and O 
discuss O 
approaches O 
to O 
modulating O 
these O 
processes O 
in O 
a O 
pharmacologically O 
productive O 
manner O 
. O 
Hopefully O 
, O 
the O 
basic O 
information O 
presented O 
in O 
this O 
review O 
will O 
be O 
of O 
value O 
to O 
investigators O 
involved O 
in O 
designing O 
delivery O 
approaches O 
for O 
oligonucleotides O 
. O 

benefits O 
of O 
seafood O 
; O 
Is O 
it O 
just O 
the O 
fatty B-FAMILY 
acids I-FAMILY 
? O 

is O 
a O 
considerable O 
body O 
of O 
literature O 
suggesting O 
a O 
wide O 
range O 
of O 
health O 
benefits O 
associated O 
with O 
diets O 
high O 
in O 
seafood O 
. O 
However O 
, O 
the O 
demand O 
for O 
seafood O 
across O 
the O 
world O 
now O 
exceeds O 
that O 
available O 
from O 
capture O 
fisheries O 
. O 
This O 
has O 
created O 
a O 
rapidly O 
increasing O 
market O 
for O 
aquaculture O 
products O 
, O 
the O 
nutrient O 
composition O 
of O 
which O 
is O 
dependent O 
on O 
feed O 
composition O 
. O 
The O 
use O 
of O 
fishmeal O 
in O 
this O 
food O 
chain O 
does O 
little O 
to O 
counteract O 
the O 
environmental O 
impact O 
of O 
fisheries O 
and O 
so O 
the O 
on O 
- O 
going O 
development O 
of O 
alternative O 
sources O 
is O 
to O 
be O 
welcomed O 
. O 
Nevertheless O 
, O 
an O 
in O 
- O 
depth O 
understanding O 
as O 
to O 
which O 
nutrients O 
in O 
seafood O 
provide O 
benefit O 
is O 
required O 
to O 
permit O 
the O 
production O 
of O 
foods O 
of O 
maximal O 
health O 
benefit O 
to O 
humans O 
. O 
This O 
paper O 
reviews O 
our O 
current O 
knowledge O 
of O 
the O 
beneficial O 
nutrient O 
composition O 
of O 
seafood O 
, O 
in O 
particular O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
selenium B-SYSTEMATIC 
, O 
taurine B-TRIVIAL 
, O 
vitamins B-MULTIPLE 
D I-MULTIPLE 
and I-MULTIPLE 
B12 I-MULTIPLE 
, O 
in O 
the O 
context O 
of O 
the O 
development O 
of O 
environmentally O 
sustainable O 
aquaculture O 
. O 

is O 
a O 
powerful O 
research O 
tool O 
because O 
it O 
enables O 
high O 
- O 
resolution O 
optical O 
control O 
of O 
neuronal O 
activity O 
. O 
However O 
, O 
current O 
optogenetic O 
approaches O 
are O 
limited O 
to O 
transgenic O 
systems O 
expressing O 
microbial O 
opsins O 
and O 
other O 
exogenous O 
photoreceptors O 
. O 
Here O 
, O 
we O 
identify O 
optovin B-TRIVIAL 
, O 
a O 
small O 
molecule O 
that O 
enables O 
repeated O 
photoactivation O 
of O 
motor O 
behaviors O 
in O 
wild O 
- O 
type O 
zebrafish O 
and O 
mice O 
. O 
To O 
our O 
surprise O 
, O 
optovin B-TRIVIAL 
' O 
s O 
behavioral O 
effects O 
are O 
not O 
visually O 
mediated O 
. O 
Rather O 
, O 
photodetection O 
is O 
performed O 
by O 
sensory O 
neurons O 
expressing O 
the O 
cation O 
channel O 
TRPA1 O 
. O 
TRPA1 O 
is O 
both O 
necessary O 
and O 
sufficient O 
for O 
the O 
optovin B-TRIVIAL 
response O 
. O 
Optovin B-TRIVIAL 
activates O 
human O 
TRPA1 O 
via O 
structure O 
- O 
dependent O 
photochemical O 
reactions O 
with O 
redox O 
- O 
sensitive O 
cysteine B-TRIVIAL 
residues O 
. O 
In O 
animals O 
with O 
severed O 
spinal O 
cords O 
, O 
optovin B-TRIVIAL 
treatment O 
enables O 
control O 
of O 
motor O 
activity O 
in O 
the O 
paralyzed O 
extremities O 
by O 
localized O 
illumination O 
. O 
These O 
studies O 
identify O 
a O 
light O 
- O 
based O 
strategy O 
for O 
controlling O 
endogenous O 
TRPA1 O 
receptors O 
in O 
vivo O 
, O 
with O 
potential O 
clinical O 
and O 
research O 
applications O 
in O 
nontransgenic O 
animals O 
, O 
including O 
humans O 
. O 

profiles O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
α-tocopherol B-TRIVIAL 
were O 
analysed O 
at O 
three O 
ripening O 
stages O 
in O 
the O 
seed O 
oils O 
of O 
Primula O 
and O 
Echium O 
species O 
. O 
Total O 
seed O 
oils O 
were O 
increased O 
considerably O 
with O 
maturation O 
, O 
while O 
α-tocopherol B-TRIVIAL 
contents O 
decreased O 
in O 
both O 
species O 
. O 
Increased O 
levels O 
of O 
ALA B-ABBREVIATION 
and O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
decrease O 
in O 
linoleic B-MULTIPLE 
and I-MULTIPLE 
palmitic I-MULTIPLE 
acids I-MULTIPLE 
at O 
late O 
ripening O 
stages O 
of O 
Primula O 
sibthorpii O 
, O 
and O 
slightly O 
fluctuations O 
of O 
all O 
examined O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
Echium O 
italicum O 
were O 
observed O 
. O 
Considerable O 
amounts O 
of O 
α-tocopherol B-TRIVIAL 
( O 
27.4 O 
mg O 
/ O 
100 O 
g O 
) O 
, O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
42.76% O 
) O 
and O 
ALA B-ABBREVIATION 
( O 
25.46% O 
) O 
and O 
GLA B-ABBREVIATION 
( O 
4.11% O 
) O 
were O 
detected O 
in O 
Ribes O 
alpinum O 
. O 
Typical O 
accumulation O 
patterns O 
of O 
the O 
examined O 
parameters O 
may O 
be O 
useful O 
for O 
species O 
characterisation O 
and O 
biochemical O 
monitoring O 
of O 
seed O 
development O 
in O 
natural O 
conditions O 
. O 

on O 
adenylyl B-TRIVIAL 
cyclase O 
VII O 
required O 
for O 
selective O 
regulation O 
by O 
the O 
G13 O 
pathway O 
. O 

of O 
multiple O 
adenylyl B-TRIVIAL 
cyclases O 
( O 
AC O 
) O 
provides O 
unique O 
inputs O 
to O 
mediate O 
the O 
synthesis O 
of O 
cAMP B-ABBREVIATION 
, O 
a O 
ubiquitous O 
second O 
messenger O 
that O 
controls O 
many O 
aspects O 
of O 
cellular O 
function O 
. O 
On O 
stimulation O 
by O 
G(s) O 
, O 
the O 
activities O 
of O 
ACs O 
can O 
be O 
further O 
selectively O 
modulated O 
by O 
other O 
pathways O 
to O 
ensure O 
precise O 
control O 
of O 
intracellular O 
cAMP B-ABBREVIATION 
responses O 
to O 
specific O 
stimuli O 
. O 
Recently O 
, O 
we O 
reported O 
that O 
one O 
of O 
the O 
AC O 
isoforms O 
, O 
AC7 O 
, O 
is O 
uniquely O 
regulated O 
by O 
the O 
G(13) O 
pathway O 
. O 
To O 
understand O 
more O 
fully O 
the O 
molecular O 
mechanism O 
of O 
this O 
regulation O 
, O 
we O 
compared O 
the O 
regulation O 
of O 
AC7 O 
with O 
that O 
of O 
AC2 O 
in O 
bone O 
marrow O 
- O 
derived O 
macrophages O 
devoid O 
of O 
AC7 O 
. O 
Although O 
both O 
enzymes O 
could O 
fully O 
restore O 
regulation O 
of O 
cAMP B-ABBREVIATION 
by O 
Gβγ O 
, O 
activation O 
of O 
the O 
G(13) O 
pathway O 
preferentially O 
synergized O 
with O 
AC7 O 
. O 
Exchange O 
of O 
domains O 
between O 
the O 
two O 
isoforms O 
indicates O 
that O 
the O 
C1b O 
domain O 
and O 
the O 
N B-FORMULA 
-terminus O 
of O 
the O 
C1a O 
domain O 
are O 
important O 
for O 
directing O 
selective O 
regulation O 
of O 
AC7 O 
by O 
the O 
G(13) O 
pathway O 
. O 
A O 
mutagenesis O 
screen O 
identified O 
more O 
specific O 
regions O 
of O 
AC7 O 
that O 
differentially O 
mediate O 
its O 
regulation O 
by O 
distinct O 
pathways O 
. O 

and O 
Structure-Activity O 
Relationships O 
of O 
5,6,7- B-FAMILY 
Substituted I-FAMILY 
Pyrazolopyrimidines I-FAMILY 
: O 
Discovery O 
of O 
a O 
Novel O 
TSPO O 
PET O 
Ligand O 
for O 
Cancer O 
Imaging O 
. O 

library O 
synthesis O 
and O 
structure O 
- O 
activity O 
relationship O 
development O 
of O 
5,6,7- B-FAMILY 
substituted I-FAMILY 
pyrazolopyrimidines I-FAMILY 
led O 
to O 
the O 
discovery O 
of O 
2-(5,7-diethyl-2-(4-(2-fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide B-SYSTEMATIC 
( O 
6b O 
) O 
, O 
a O 
novel O 
translocator O 
protein O 
( O 
TSPO O 
) O 
ligand O 
exhibiting O 
a O 
36-fold O 
enhancement O 
in O 
affinity O 
compared O 
to O 
another O 
pyrazolopyrimidine B-SYSTEMATIC 
-based O 
TSPO O 
ligand O 
, O 
6a O 
( O 
DPA-714 B-IDENTIFIER 
) O 
. O 
Radiolabeling O 
with O 
fluorine-18 B-SYSTEMATIC 
( O 
(18)F B-FORMULA 
) O 
facilitated O 
production O 
of O 
2-(5,7-diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide B-SYSTEMATIC 
( O 
(18)F B-FORMULA 
-6b O 
) O 
in O 
high O 
radiochemical O 
yield O 
and O 
specific O 
activity O 
. O 
In O 
vivo O 
studies O 
of O 
(18)F B-FORMULA 
-6b O 
were O 
performed O 
which O 
illuminated O 
this O 
agent O 
as O 
an O 
improved O 
probe O 
for O 
molecular O 
imaging O 
of O 
TSPO-expressing O 
cancers O 
. O 

aldosteronism O 
( O 
PA O 
) O 
is O 
one O 
of O 
the O 
commonest O 
forms O 
of O 
curable O 
hypertension O 
, O 
and O 
use O 
of O 
the O 
plasma O 
aldosterone B-TRIVIAL 
-to O 
- O 
renin O 
ratio O 
as O 
a O 
screening O 
test O 
has O 
led O 
to O 
a O 
more O 
efficient O 
identification O 
of O 
this O 
condition O 
. O 
Both O 
animal O 
and O 
human O 
studies O 
have O 
indicated O 
that O 
PA O 
is O 
associated O 
with O 
a O 
variety O 
of O 
cardiovascular O 
and O 
renal O 
complications O 
that O 
reflect O 
the O 
capability O 
of O 
elevated O 
aldosterone B-TRIVIAL 
to O 
induce O 
tissue O 
damage O 
exceeding O 
that O 
induced O 
by O 
hypertension O 
itself O 
. O 
Involvement O 
of O 
the O 
kidney O 
in O 
PA O 
is O 
highly O 
relevant O 
because O 
structural O 
renal O 
damage O 
is O 
associated O 
with O 
less O 
favorable O 
outcome O 
, O 
both O 
in O 
terms O 
of O 
blood O 
pressure O 
response O 
to O 
treatment O 
and O 
possibility O 
to O 
develop O 
progressive O 
renal O 
failure O 
. O 
However O 
, O 
early O 
involvement O 
of O 
the O 
kidney O 
in O 
PA O 
is O 
characterized O 
by O 
functional O 
changes O 
that O 
are O 
largely O 
reversible O 
with O 
treatment O 
. O 
Unilateral O 
adrenalectomy O 
or O 
administration O 
of O 
mineralocorticoid O 
receptor O 
antagonists O 
are O 
the O 
current O 
options O 
for O 
treating O 
an O 
aldosterone B-TRIVIAL 
-producing O 
adenoma O 
or O 
idiopathic O 
adrenal O 
hyperplasia O 
. O 
Both O 
treatments O 
are O 
effective O 
in O 
correcting O 
hypertension O 
and O 
hypokalemia O 
, O 
and O 
currently O 
available O 
information O 
on O 
their O 
capability O 
to O 
prevent O 
deterioration O 
of O 
renal O 
function O 
indicates O 
that O 
both O 
surgery O 
and O 
medical O 
treatment O 
are O 
of O 
considerable O 
value O 
. O 

this O 
study O 
, O 
we O 
reported O 
the O 
phytochemical O 
composition O 
of O 
the O 
aerial O 
parts O 
of O 
Atriplex O 
halimus O 
L O 
. O 
collected O 
from O 
Sardinia O 
. O 
This O 
species O 
is O 
a O 
halophytic O 
shrub O 
, O 
typical O 
of O 
the O 
Mediterranean O 
Basin O 
. O 
Four O 
new O 
glycosylated B-FAMILY 
flavonoids I-FAMILY 
were O 
isolated O 
and O 
their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
1D O 
, O 
2D O 
NMR O 
and O 
MS O 
spectra O 
as O 
3',5'-dimethoxymyricetin-3-O-β-d-xylopyranosyl-7-O-fucopyranosyl-(1 B-SYSTEMATIC 
→ I-SYSTEMATIC 
3)-β-d-glucopyranoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
3'-methoxyquercetin-7-O-β-d-fucopyranosyl-(1 B-SYSTEMATIC 
→ I-SYSTEMATIC 
3)-β-d-glucopyranosyl-3-O-β-xylopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
4)-β-xylopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
3'-methoxyquercetin-7-O-α-l-rhamnopyranosyl-3-O-α-arabinofuranosyl-(1 B-SYSTEMATIC 
→ I-SYSTEMATIC 
6)-β-d-glucopyranoside I-SYSTEMATIC 
( O 
3 O 
) O 
and O 
3',5'-dimethoxymyricetin-7-O-fucopyranosyl-(1 B-SYSTEMATIC 
→ I-SYSTEMATIC 
3)-β-d-glucopyranoside I-SYSTEMATIC 
( O 
4 O 
) O 
. O 
LC-MS O 
( O 
n O 
) O 
analysis O 
on O 
the O 
extract O 
revealed O 
the O 
presence O 
of O 
other O 
myricetin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
isorhamnetin B-FAMILY 
glycosides I-FAMILY 
, O 
simple O 
phenolic B-FAMILY 
acids I-FAMILY 
and O 
esters B-FAMILY 
. O 

of O 
Ketoconazole B-TRIVIAL 
on O 
the O 
Pharmacokinetics O 
of O 
the O 
11β-Hydroxysteroid B-FAMILY 
Dehydrogenase O 
Type O 
1 O 
Inhibitor O 
ABT-384 B-IDENTIFIER 
and O 
Its O 
Two O 
Active O 
Metabolites O 
in O 
Healthy O 
Volunteers O 
: O 
Population O 
Analysis O 
of O 
Data O 
from O 
a O 
Drug-Drug O 
Interaction O 
Study O 
. O 

[ O 
1-piperazineacetamide B-SYSTEMATIC 
, I-SYSTEMATIC 
N-[5-(aminocarbonyl) I-SYSTEMATIC 
tricyclo[3.3.1.13,7]dec-2-yl]-α,α-dimethyl-4-[5-(trifluoromethyl)-2-pyridinyl I-SYSTEMATIC 
] I-SYSTEMATIC 
-,stereoisomer O 
] O 
is O 
a O 
potent O 
and O 
selective O 
inhibitor O 
of O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
( O 
HSD-1 O 
) O 
. O 
ABT-384 B-IDENTIFIER 
has O 
been O 
shown O 
to O 
be O 
safe O 
and O 
well O 
tolerated O 
in O 
humans O 
at O 
doses O 
up O 
to O 
100 O 
mg O 
daily O 
, O 
and O 
to O 
fully O 
inhibit O 
both O 
peripheral O 
and O 
brain O 
HSD-1 O 
at O 
a O 
dose O 
of O 
2 O 
mg O 
daily O 
. O 
The O 
effect O 
of O 
ketoconazole B-TRIVIAL 
on O 
the O 
pharmacokinetics O 
of O 
ABT-384 B-IDENTIFIER 
and O 
its O 
two O 
active O 
metabolites O 
, O 
A-1331480 B-IDENTIFIER 
and O 
A-847082 B-IDENTIFIER 
, O 
was O 
investigated O 
in O 
healthy O 
volunteers O 
. O 
When O 
10 O 
mg O 
of O 
ABT-384 B-IDENTIFIER 
was O 
coadministered O 
with O 
ketoconazole B-TRIVIAL 
, O 
ABT-384 B-IDENTIFIER 
exposures O 
increased O 
18-fold O 
for O 
area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
from O 
time O 
0 O 
to O 
infinity O 
and O 
3.5-fold O 
for O 
Cmax O 
. O 
The O 
results O 
suggest O 
that O 
ABT-384 B-IDENTIFIER 
is O 
a O 
sensitive O 
substrate O 
of O 
CYP3A O 
. O 
After O 
ketoconazole B-TRIVIAL 
coadministration O 
, O 
exposures O 
of O 
A-1331480 B-IDENTIFIER 
and O 
A-847082 B-IDENTIFIER 
were O 
also O 
greatly O 
increased O 
. O 
A O 
population O 
pharmacokinetic O 
model O 
was O 
constructed O 
for O 
ABT-384 B-IDENTIFIER 
and O 
its O 
metabolites O 
using O 
NonMEM O 
. O 
A O 
two O 
- O 
compartment O 
model O 
with O 
three O 
transit O 
absorption O 
compartments O 
best O 
described O 
ABT-384 B-IDENTIFIER 
data O 
. O 
The O 
model O 
predicted O 
a O 
69.3% O 
decrease O 
in O 
ABT-384 B-IDENTIFIER 
clearance O 
and O 
91.1% O 
increase O 
in O 
the O 
volume O 
of O 
distribution O 
of O 
ABT-384 B-IDENTIFIER 
in O 
the O 
presence O 
of O 
ketoconazole B-TRIVIAL 
. O 
A-1331480 B-IDENTIFIER 
was O 
shown O 
to O 
be O 
formation O 
rate O 
- O 
limited O 
and O 
A-847082 B-IDENTIFIER 
was O 
elimination O 
rate O 
- O 
limited O 
. O 
Both O 
metabolites O 
were O 
characterized O 
by O 
a O 
one O 
- O 
compartment O 
model O 
with O 
first O 
- O 
order O 
rate O 
constants O 
of O 
formation O 
and O 
elimination O 
. O 
Overall O 
the O 
model O 
adequately O 
captured O 
the O 
concentration O 
- O 
time O 
profiles O 
of O 
ABT-384 B-IDENTIFIER 
, O 
A-1331480 B-IDENTIFIER 
, O 
and O 
A-847082 B-IDENTIFIER 
in O 
both O 
ABT-384 B-IDENTIFIER 
-alone O 
and O 
ketoconazole B-TRIVIAL 
-coadministration O 
conditions O 
. O 
Although O 
ABT-384 B-IDENTIFIER 
exposures O 
were O 
greatly O 
increased O 
in O 
the O 
presence O 
of O 
ketoconazole B-TRIVIAL 
, O 
coadministration O 
of O 
ABT-384 B-IDENTIFIER 
with O 
ketoconazole B-TRIVIAL 
or O 
other O 
strong O 
/ O 
moderate O 
CYP3A O 
inhibitors O 
is O 
not O 
expected O 
to O 
contribute O 
to O 
any O 
major O 
clinical O 
safety O 
issues O 
considering O 
the O 
favorable O 
safety O 
profile O 
of O 
ABT-384 B-IDENTIFIER 
. O 

determinants O 
of O 
substrate O 
specificity O 
in O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
. O 

the O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
) O 
superfamily O 
, O 
proteins O 
belonging O 
to O 
the O 
ALDH9 O 
, O 
ALDH10 O 
, O 
ALDH25 O 
, O 
ALDH26 O 
and O 
ALDH27 O 
families O 
display O 
activity O 
as O 
ω-aminoaldehyde B-SYSTEMATIC 
dehydrogenases O 
( O 
AMADHs O 
) O 
. O 
These O 
enzymes O 
participate O 
in O 
polyamine B-FAMILY 
, O 
choline B-FAMILY 
and O 
arginine B-TRIVIAL 
catabolism O 
, O 
as O 
well O 
as O 
in O 
synthesis O 
of O 
several O 
osmoprotectants O 
and O 
carnitine B-TRIVIAL 
. O 
Active O 
site O 
aromatic O 
and O 
acidic O 
residues O 
are O 
involved O 
in O 
binding O 
the O 
ω-aminoaldehydes B-FAMILY 
in O 
plant O 
ALDH10 O 
enzymes O 
. O 
In O 
order O 
to O 
ascertain O 
the O 
degree O 
of O 
conservation O 
of O 
these O 
residues O 
among O 
AMADHs O 
and O 
to O 
evaluate O 
their O 
possible O 
relevance O 
in O 
determining O 
the O 
aminoaldehyde B-SYSTEMATIC 
specificity O 
, O 
we O 
compared O 
the O 
known O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
of O 
every O 
ALDH O 
family O 
that O 
have O 
at O 
least O 
one O 
member O 
with O 
known O 
crystal O 
structure O 
, O 
as O 
well O 
as O 
the O 
electrostatic O 
potential O 
surface O 
of O 
the O 
aldehyde B-SYSTEMATIC 
binding O 
sites O 
of O 
these O 
structures O 
. O 
Our O 
analyses O 
showed O 
that O 
four O 
or O 
three O 
aromatic O 
residues O 
form O 
a O 
similar O 
" O 
aromatic O 
box O 
" O 
in O 
the O 
active O 
site O 
of O 
the O 
AMADH O 
enzymes O 
, O 
being O 
the O 
equivalents O 
to O 
Phe B-FORMULA 
170 O 
and O 
Trp B-FORMULA 
177 O 
( O 
human O 
ALDH2 O 
numbering O 
) O 
strictly O 
conserved O 
in O 
all O 
of O 
them O 
, O 
which O 
supports O 
their O 
relevance O 
in O 
binding O 
the O 
aminoaldehyde B-SYSTEMATIC 
by O 
cation-π O 
interactions O 
. O 
In O 
addition O 
, O 
all O 
AMADHs O 
exhibit O 
a O 
negative O 
electrostatic O 
potential O 
surface O 
in O 
the O 
aldehyde B-SYSTEMATIC 
-entrance O 
tunnel O 
, O 
due O 
to O 
side-chain O 
carboxyl B-SYSTEMATIC 
and O 
hydroxyl B-SYSTEMATIC 
groups O 
or O 
main O 
- O 
chain O 
carbonyl B-FAMILY 
groups O 
. O 
In O 
contrast O 
, O 
ALDHs O 
that O 
have O 
non-polar O 
or O 
negatively O 
charged O 
substrates O 
exhibit O 
neutral O 
or O 
positive O 
electrostatic O 
potential O 
surfaces O 
, O 
respectively O 
. O 
Finally O 
, O 
our O 
comparative O 
sequence O 
analyses O 
revealed O 
that O 
the O 
residues O 
equivalent O 
to O 
Asp B-FORMULA 
121 O 
and O 
Phe B-FORMULA 
170 O 
are O 
highly O 
conserved O 
in O 
many O 
ALDH O 
families O 
irrespective O 
of O 
their O 
substrate O 
specificity O 
- O 
suggesting O 
that O 
they O 
perform O 
a O 
role O 
in O 
catalysis O 
additional O 
or O 
different O 
to O 
binding O 
of O 
the O 
substrate O 
- O 
and O 
that O 
the O 
positions O 
Met B-FORMULA 
124 O 
, O 
Cys B-FORMULA 
301 O 
, O 
and O 
Cys B-FORMULA 
303 O 
are O 
hot O 
spots O 
changed O 
during O 
evolution O 
to O 
confer O 
aldehyde B-SYSTEMATIC 
specificity O 
to O 
several O 
ALDH O 
families O 
. O 

nanodiamond O 
( O 
ND O 
) O 
is O 
a O 
suitable O 
source O 
material O 
to O 
produce O 
unique O 
samples O 
consisting O 
of O 
almost O 
uniform O 
diamond B-TRIVIAL 
nanocrystals O 
( O 
d O 
= O 
3-5 O 
nm O 
) O 
. O 
Such O 
samples O 
exist O 
in O 
the O 
form O 
of O 
long O 
stable O 
aqueous O 
dispersions O 
with O 
narrow O 
size O 
distribution O 
of O 
diamond B-TRIVIAL 
particles O 
. O 
The O 
material O 
is O 
finding O 
ever O 
increasing O 
application O 
in O 
biomedicine O 
. O 
The O 
major O 
problem O 
in O 
producing O 
monodispersed O 
diamond B-TRIVIAL 
colloids O 
lies O 
in O 
the O 
necessity O 
of O 
deagglomeration O 
of O 
detonation O 
soot O 
and O 
/ O 
or O 
removing O 
of O 
clusters O 
formed O 
by O 
already O 
isolated O 
core O 
particles O 
in O 
dry O 
powders O 
. O 
To O 
do O 
this O 
one O 
must O 
have O 
an O 
effective O 
method O 
to O 
monitor O 
the O 
aggregation O 
state O 
or O 
dispersity O 
of O 
powders O 
and O 
gels O 
prior O 
to O 
the O 
preparation O 
of O 
aqueous O 
dispersions O 
. O 
In O 
the O 
absence O 
of O 
dispersity O 
control O 
at O 
various O 
stages O 
of O 
preparation O 
the O 
reproducibility O 
of O 
properties O 
of O 
existing O 
ND O 
materials O 
is O 
poor O 
. O 
In O 
this O 
paper O 
we O 
introduce O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
as O 
a O 
new O 
tool O 
capable O 
to O 
distinguish O 
the O 
state O 
of O 
aggregation O 
in O 
dry O 
and O 
wetted O 
ND O 
materials O 
and O 
to O 
follow O 
changes O 
in O 
this O 
state O 
under O 
different O 
types O 
of O 
treatment O 
. O 
Samples O 
with O 
identical O 
X-ray O 
diffraction O 
patterns O 
( O 
XRD O 
) O 
and O 
high O 
resolution O 
transmission O 
electron O 
microscopy O 
( O 
HRTEM O 
) O 
images O 
gave O 
visibly O 
different O 
DSC O 
traces O 
. O 
Strong O 
correlation O 
was O 
found O 
between O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
data O 
for O 
colloids O 
and O 
DSC O 
parameters O 
for O 
gels O 
and O 
powders O 
of O 
the O 
same O 
material O 
. O 
Based O 
on O 
DSC O 
data O 
we O 
improved O 
dispersity O 
of O 
existing O 
ND O 
materials O 
and O 
isolated O 
samples O 
with O 
the O 
best O 
possible O 
DSC O 
parameters O 
. O 
These O 
were O 
true O 
monodispersed O 
easily O 
dispersible O 
fractions O 
of O 
ND O 
particles O 
with O 
diameters O 
of O 
ca O 
. O 
3 O 
nm O 
. O 

diseases O 
are O 
complex O 
disorders O 
with O 
several O 
pathoetiological O 
pathways O 
leading O 
to O 
cell O 
death O 
. O 
Rationally O 
designed O 
multi O 
- O 
targeted O 
agents O 
, O 
or O 
" O 
multi O 
- O 
targeted O 
designed O 
drugs O 
" O 
( O 
MTDD O 
) O 
show O 
significant O 
promise O 
in O 
preclinical O 
studies O 
as O 
neuroprotective O 
and O 
disease O 
- O 
modifying O 
agents O 
. O 
In O 
this O 
review O 
, O 
we O 
highlight O 
the O 
use O 
of O 
chemical O 
scaffolds O 
that O 
lend O 
themselves O 
exquisitely O 
to O 
the O 
development O 
of O 
MTDDs O 
in O 
neurodegeneration O 
. O 
Notably O 
, O 
synthetic O 
polycyclic O 
cage O 
compounds O 
have O 
served O 
as O 
scaffolds O 
for O 
novel O 
voltage O 
- O 
gated O 
calcium B-SYSTEMATIC 
channel O 
blockers O 
, O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
, O 
and O 
sigma-receptor O 
ligands O 
- O 
attractive O 
targets O 
in O 
neurodegeneration O 
. O 
In O 
an O 
entirely O 
different O 
approach O 
, O 
compounds O 
containing O 
the O 
thiazolidinedione B-FAMILY 
moiety O 
( O 
referred O 
to O 
as O 
glitazones B-FAMILY 
) O 
alter O 
mitochondrial O 
function O 
through O 
the O 
mitochondrial O 
protein O 
mitoNEET O 
, O 
an O 
attractive O 
new O 
drug O 
target O 
for O 
the O 
treatment O 
of O 
neurodegenerative O 
diseases O 
. O 
The O 
design O 
strategy O 
for O 
yet O 
another O 
agent O 
, O 
ladostigil B-TRIVIAL 
, O 
employed O 
the O 
amalgamation O 
of O 
active O 
chemical O 
moieties O 
of O 
the O 
AChE O 
inhibitor O 
rivastigmine B-TRIVIAL 
, O 
and O 
the O 
monoamine B-FAMILY 
oxidase-B O 
( O 
MAO-B O 
) O 
inhibitor O 
rasagiline B-TRIVIAL 
, O 
leading O 
to O 
a O 
single O 
compound O 
that O 
targets O 
both O 
enzymes O 
simultaneously O 
. O 
Natural O 
products O 
have O 
also O 
served O 
as O 
design O 
templates O 
for O 
several O 
MTDD O 
design O 
studies O 
. O 
In O 
particular O 
, O 
the O 
stilbene B-TRIVIAL 
scaffold O 
has O 
become O 
popular O 
in O 
particular O 
due O 
to O 
the O 
neuroprotective O 
effects O 
of O 
the O 
non- O 
flavonoid B-FAMILY 
natural O 
product O 
resveratrol B-TRIVIAL 
. O 
Recently O 
, O 
stilbene B-TRIVIAL 
scaffold O 
- O 
based O 
compounds O 
were O 
developed O 
to O 
reduce O 
- O 
through O 
chelation O 
with O 
metal O 
ions O 
that O 
interact O 
with O 
beta-amyloid O 
- O 
both O 
metal O 
- O 
induced O 
beta-amyloid O 
protein O 
aggregation O 
, O 
and O 
ROS O 
generated O 
from O 
this O 
aggregate O 
. O 
Other O 
subtle O 
modifications O 
of O 
the O 
stilbene B-TRIVIAL 
motif O 
led O 
to O 
the O 
creation O 
of O 
reversible O 
, O 
non-competitive O 
MAO O 
inhibitors O 
. O 
Finally O 
, O 
compounds O 
derived O 
from O 
the O 
xanthine B-TRIVIAL 
scaffold O 
afford O 
neuroprotection O 
in O 
Parkinson's O 
disease O 
through O 
mechanisms O 
that O 
include O 
dual O 
adenosine B-TRIVIAL 
A2A O 
receptor O 
antagonism O 
and O 
MAO-B O 
inhibition O 
. O 

of O 
the O 
importance O 
of O 
the O 
Wnt O 
pathway O 
in O 
the O 
development O 
and O 
maintenance O 
of O 
both O 
adipose O 
and O 
bone O 
tissue O 
, O 
we O 
wanted O 
to O 
evaluate O 
the O 
involvement O 
of O 
WNT10B O 
, O 
a O 
Wnt O 
pathway O 
activator O 
, O 
in O 
adipogenesis O 
and O 
osteoblastogenesis O 
in O 
humans O 
. O 
Genetic O 
association O 
between O 
WNT10B O 
polymorphisms O 
and O 
adiposity O 
parameters O 
as O 
well O 
as O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
measurements O 
was O 
analysed O 
in O 
two O 
independent O 
populations O 
. O 
The O 
first O 
is O 
a O 
population O 
of O 
1228 O 
Danish O 
men O 
( O 
702 O 
aged O 
20-29 O 
years O 
; O 
532 O 
aged O 
60-74 O 
years O 
) O 
from O 
the O 
Odense O 
Androgen B-FAMILY 
Study O 
( O 
OAS O 
) O 
, O 
which O 
was O 
designed O 
as O 
a O 
cross O 
- O 
sectional O 
, O 
population O 
- O 
based O 
study O 
. O 
The O 
second O 
population O 
, O 
called O 
SIBLOS O 
, O 
includes O 
922 O 
Belgian O 
men O 
( O 
34 O 
± O 
5 O 
years O 
old O 
) O 
and O 
contains O 
siblings O 
selected O 
from O 
over O 
500 O 
families O 
. O 
Four O 
tagSNPs O 
( O 
rs833840 O 
, O 
rs833841 O 
, O 
rs10875902 O 
and O 
rs4018511 O 
) O 
that O 
capture O 
variation O 
of O 
ten O 
SNPs O 
( O 
MAF O 
> O 
5 O 
% O 
) O 
in O 
a O 
15.2 O 
kb O 
region O 
spanning O 
the O 
WNT10B O 
gene O 
and O 
its O 
flanking O 
regions O 
were O 
genotyped O 
. O 
Although O 
no O 
association O 
with O 
body O 
mass O 
index O 
was O 
found O 
, O 
we O 
found O 
all O 
tagSNPs O 
to O 
be O 
associated O 
with O 
BMD O 
parameters O 
( O 
BMD O 
whole O 
body O 
, O 
total O 
hip O 
and O 
femoral O 
neck O 
) O 
and O 
height O 
in O 
the O 
OAS O 
population O 
. O 
The O 
association O 
of O 
rs10875902 O 
was O 
most O 
prominent O 
( O 
nominal O 
p O 
= O 
0.012 O 
) O 
and O 
confirmed O 
a O 
previously O 
shown O 
negative O 
effect O 
on O 
BMD O 
. O 
No O 
significant O 
associations O 
were O 
observed O 
in O 
the O 
SIBLOS O 
population O 
. O 
In O 
the O 
present O 
study O 
, O 
no O 
association O 
between O 
WNT10B O 
polymorphisms O 
and O 
adiposity O 
parameters O 
was O 
found O 
. O 
However O 
, O 
our O 
results O 
clearly O 
illustrate O 
a O 
role O 
for O 
WNT10B O 
variants O 
in O 
determining O 
human O 
BMD O 
. O 
The O 
effect O 
of O 
WNT10B O 
polymorphisms O 
on O 
height O 
should O 
be O 
evaluated O 
in O 
additional O 
populations O 
. O 

polymers O 
are O 
used O 
extensively O 
in O 
biology O 
to O 
disrupt O 
cell O 
membranes O 
and O 
thus O 
enhance O 
the O 
transport O 
of O 
materials O 
into O 
the O 
cell O 
. O 
We O 
report O 
the O 
bindings O 
of O 
several O 
lipids O 
cholesterol B-TRIVIAL 
( O 
Chol B-ABBREVIATION 
) O 
, O 
1,2-dioleoyl-3-trimethylammonium- B-SYSTEMATIC 
propane I-SYSTEMATIC 
( O 
DOTAP B-ABBREVIATION 
) O 
, O 
dioctadecyldimethylammoniumbromide B-SYSTEMATIC 
( O 
DDAB B-ABBREVIATION 
) O 
, O 
and O 
dioleoylphosphatidylethanolamine B-SYSTEMATIC 
( O 
DOPE B-ABBREVIATION 
) O 
to O 
dendrimers O 
of O 
different O 
compositions O 
such O 
as O 
mPEG-PAMAM B-ABBREVIATION 
( O 
G3 O 
) O 
, O 
mPEG-PAMAM B-ABBREVIATION 
( O 
G4 O 
) O 
, O 
and O 
PAMAM B-ABBREVIATION 
( O 
G4 O 
) O 
under O 
physiological O 
conditions O 
. O 
FTIR O 
, O 
UV-visible O 
spectroscopic O 
, O 
methods O 
and O 
molecular O 
modeling O 
were O 
used O 
to O 
analyze O 
the O 
lipid O 
binding O 
mode O 
, O 
the O 
binding O 
constant O 
, O 
and O 
the O 
effects O 
of O 
lipid O 
complexation O 
on O 
the O 
dendrimer O 
structure O 
. O 
The O 
structural O 
analysis O 
showed O 
that O 
lipids O 
bind O 
dendrimers O 
through O 
both O 
hydrophilic O 
and O 
hydrophobic O 
contacts O 
with O 
overall O 
binding O 
constants O 
of O 
K( O 
chol-mPEG-G3 B-ABBREVIATION 
) O 
= O 
1.7 O 
× O 
10(3) O 
M(-1) O 
, O 
K( O 
chol-mPEG-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
2.7 O 
× O 
10(3) O 
M(-1) O 
, O 
K( O 
chol-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
1 O 
× O 
10(3) O 
M(-1) O 
, O 
K( O 
DOPE-mPEG-G3 B-ABBREVIATION 
) O 
= O 
1.5 O 
× O 
10(3) O 
M(-1) O 
, O 
K( O 
DOPE-mPEG-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
1.6 O 
× O 
10(3) O 
M(-1) O 
, O 
K( O 
DOPE-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
5.3 O 
× O 
10(2) O 
M(-1) O 
, O 
K( O 
DDAB-mPEG-G3 B-ABBREVIATION 
) O 
= O 
1.5 O 
× O 
10(3) O 
M(-1) O 
, O 
K( O 
DDAB-mPEG-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
1.9 O 
× O 
10(2) O 
M(-1) O 
, O 
K( O 
DDAB-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
7 O 
× O 
10(2) O 
M(-1) O 
, O 
K( O 
DOTAP-mPEG-G3 B-ABBREVIATION 
) O 
= O 
1.9 O 
× O 
10(3) O 
M(-1) O 
, O 
K( O 
DOTAP-mPEG-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
1.5 O 
× O 
10(3) O 
M(-1) O 
, O 
and O 
K( O 
DOTAP-PAMAM-G4 B-ABBREVIATION 
) O 
= O 
5.7 O 
× O 
10(2) O 
M(-1) O 
. O 
Weaker O 
interaction O 
was O 
observed O 
as O 
dendrimer O 
cationic O 
charges O 
increased O 
. O 
The O 
free O 
binding O 
energies O 
from O 
docking O 
were O 
-5.15 O 
( O 
cholesterol B-TRIVIAL 
) O 
, O 
-5.79 O 
( O 
DDAB B-ABBREVIATION 
) O 
, O 
and O 
-5.36 O 
kcal O 
/ O 
mol O 
( O 
DOTAP B-ABBREVIATION 
) O 
with O 
the O 
order O 
of O 
stability O 
DDAB-PAMAM-G-4 B-ABBREVIATION 
> O 
DOTAP-PAMAM-G4 B-ABBREVIATION 
> O 
cholesterol B-TRIVIAL 
- O 
PAMAM-G4 B-ABBREVIATION 
, O 
consistent O 
with O 
the O 
spectroscopic O 
results O 
. O 
Dendrimers O 
might O 
act O 
as O 
carriers O 
to O 
transport O 
lipids O 
in O 
vitro O 
. O 

this O 
Letter O 
we O 
report O 
on O 
the O 
advances O 
in O 
our O 
NPBWR1 O 
antagonist O 
program O 
aimed O 
at O 
optimizing O 
the O 
5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one B-SYSTEMATIC 
lead O 
molecule O 
previously O 
obtained O 
from O 
a O 
high O 
- O 
throughput O 
screening O 
( O 
HTS O 
) O 
- O 
derived O 
hit O 
. O 
Synthesis O 
and O 
structure O 
- O 
activity O 
relationships O 
( O 
SAR O 
) O 
studies O 
around O 
the O 
3,5-dimethylphenyl B-SYSTEMATIC 
and O 
4-methoxyphenyl B-SYSTEMATIC 
regions O 
resulted O 
in O 
the O 
identification O 
of O 
a O 
novel O 
series O 
of O 
non-peptidic O 
submicromolar O 
NPBWR1 O 
antagonists O 
based O 
on O 
a O 
5-chloro-4-(4-alkoxyphenoxy)-2-(benzyl)pyridazin-3(2H)-one B-SYSTEMATIC 
chemotype O 
. O 
Amongst O 
them O 
, O 
5-chloro-2-(9H-fluoren-9-yl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one B-SYSTEMATIC 
9h O 
( O 
CYM50769 B-IDENTIFIER 
) O 
inhibited O 
NPW O 
activation O 
of O 
NPBWR1 O 
with O 
a O 
submicromolar O 
IC(50) O 
, O 
and O 
displayed O 
high O 
selectivity O 
against O 
a O 
broad O 
array O 
of O 
off O 
- O 
targets O 
with O 
pharmaceutical O 
relevance O 
. O 
Our O 
medicinal O 
chemistry O 
study O 
provides O 
innovative O 
non-peptidic O 
selective O 
NPBWR1 O 
antagonists O 
that O 
may O 
enable O 
to O 
clarify O 
the O 
biological O 
role O 
and O 
therapeutic O 
utility O 
of O 
the O 
target O 
receptor O 
in O 
the O 
regulation O 
of O 
feeding O 
behavior O 
, O 
pain O 
, O 
stress O 
, O 
and O 
neuroendocrine O 
function O 
. O 

an O 
atypical O 
wake O 
- O 
promoting O 
agent O 
to O 
potent O 
histamine B-TRIVIAL 
-3 O 
receptor O 
inverse O 
agonists O 
. O 

atypical O 
wake O 
- O 
promoting O 
agent O 
modafinil B-TRIVIAL 
( O 
inactive O 
in O 
both O 
rH(3) O 
and O 
hH(3) O 
binding O 
assays O 
) O 
as O 
a O 
launching O 
pad O 
, O 
a O 
series O 
of O 
sulfinyl B-SYSTEMATIC 
- O 
and O 
sulfone B-SYSTEMATIC 
-derived O 
H(3) O 
receptor O 
inverse O 
agonists O 
were O 
developed O 
. O 
Brain O 
- O 
permeable O 
compound O 
27 O 
, O 
a O 
potent O 
member O 
of O 
the O 
series O 
displayed O 
excellent O 
selectivity O 
against O 
related O 
family O 
members O 
( O 
H(1) O 
, O 
H(2) O 
, O 
and O 
H(4) O 
receptors O 
) O 
. O 

E2 I-TRIVIAL 
acts O 
via O 
bone O 
marrow O 
macrophages O 
to O 
block O 
PTH-stimulated O 
osteoblast O 
differentiation O 
in O 
vitro O 
. O 

PTH O 
is O 
the O 
major O 
anabolic O 
therapy O 
for O 
osteoporosis O 
while O 
continuous O 
PTH O 
causes O 
bone O 
loss O 
. O 
PTH O 
acts O 
on O 
the O 
osteoblast O 
( O 
OB O 
) O 
lineage O 
to O 
regulate O 
bone O 
resorption O 
and O 
formation O 
. O 
PTH O 
also O 
induces O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
producing O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
, O 
that O 
can O 
act O 
on O 
both O 
OBs O 
and O 
osteoclasts O 
( O 
OCs O 
) O 
. O 
Because O 
intermittent O 
PTH O 
is O 
more O 
anabolic O 
in O 
Cox-2 O 
knockout O 
( O 
KO O 
) O 
than O 
wild O 
type O 
( O 
WT O 
) O 
mice O 
, O 
we O 
hypothesized O 
COX-2 O 
might O 
contribute O 
to O 
the O 
effects O 
of O 
continuous O 
PTH O 
by O 
suppressing O 
PTH-stimulated O 
differentiation O 
of O 
mesenchymal O 
stem O 
cells O 
into O 
OBs O 
. O 
We O 
compared O 
effects O 
of O 
continuous O 
PTH O 
on O 
bone O 
marrow O 
stromal O 
cells O 
( O 
BMSCs O 
) O 
and O 
primary O 
OBs O 
( O 
POBs O 
) O 
from O 
Cox-2 O 
KO O 
mice O 
, O 
mice O 
with O 
deletion O 
of O 
PGE2 B-ABBREVIATION 
receptors O 
( O 
Ptger4 O 
and O 
Ptger2 O 
KO O 
mice O 
) O 
, O 
and O 
WT O 
controls O 
. O 
PTH O 
increased O 
OB O 
differentiation O 
in O 
BMSCs O 
only O 
in O 
the O 
absence O 
of O 
COX-2 O 
expression O 
or O 
activity O 
. O 
In O 
the O 
absence O 
of O 
COX-2 O 
, O 
PTH O 
stimulated O 
differentiation O 
if O 
added O 
during O 
the O 
first O 
week O 
of O 
culture O 
. O 
In O 
Cox-2 O 
KO O 
BMSCs O 
, O 
PTH-stimulated O 
differentiation O 
was O 
prevented O 
by O 
adding O 
PGE2 B-ABBREVIATION 
to O 
cultures O 
. O 
Co-culture O 
of O 
POBs O 
with O 
M-CSF-expanded O 
bone O 
marrow O 
macrophages O 
( O 
BMMs O 
) O 
showed O 
that O 
the O 
inhibition O 
of O 
PTH-stimulated O 
OB O 
differentiation O 
required O 
not O 
only O 
COX-2 O 
or O 
PGE2 B-ABBREVIATION 
but O 
also O 
BMMs O 
. O 
Sufficient O 
PGE2 B-ABBREVIATION 
to O 
mediate O 
the O 
inhibitory O 
effect O 
was O 
made O 
by O 
either O 
WT O 
POBs O 
or O 
WT O 
BMMs O 
. O 
The O 
inhibitory O 
effect O 
mediated O 
by O 
COX-2/ O 
PGE2 B-ABBREVIATION 
was O 
transferred O 
by O 
conditioned O 
media O 
from O 
RANKL O 
- O 
treated O 
BMMs O 
and O 
could O 
be O 
blocked O 
by O 
osteoprotegerin O 
, O 
which O 
interferes O 
with O 
RANKL O 
binding O 
to O 
its O 
receptor O 
on O 
OC O 
lineage O 
cells O 
. O 
Deletion O 
of O 
Ptger4 O 
, O 
but O 
not O 
Ptger2 O 
, O 
in O 
BMMs O 
prevented O 
the O 
inhibition O 
of O 
PTH-stimulated O 
OB O 
differentiation O 
. O 
As O 
expected O 
, O 
PGE2 B-ABBREVIATION 
also O 
stimulated O 
OB O 
differentiation O 
, O 
but O 
when O 
given O 
in O 
combination O 
with O 
PTH O 
, O 
the O 
stimulatory O 
effects O 
of O 
both O 
were O 
abrogated O 
. O 
These O 
data O 
suggest O 
that O 
PGE2 B-ABBREVIATION 
, O 
acting O 
via O 
EP4R O 
on O 
BMMs O 
committed O 
to O 
the O 
OC O 
lineage O 
, O 
stimulated O 
secretion O 
of O 
a O 
factor O 
or O 
factors O 
that O 
acted O 
to O 
suppress O 
PTH-stimulated O 
OB O 
differentiation O 
. O 
This O 
suppression O 
of O 
OB O 
differentiation O 
could O 
contribute O 
to O 
the O 
bone O 
loss O 
seen O 
with O 
continuous O 
PTH O 
in O 
vivo O 
. O 

chain O 
amino B-FAMILY 
acids I-FAMILY 
are O 
novel O 
biomarkers O 
for O 
discrimination O 
of O 
metabolic O 
wellness O 
. O 

: O 
To O 
identify O 
novel O 
biomarkers O 
through O 
metabolomic O 
profiles O 
that O 
distinguish O 
metabolically O 
well O 
( O 
MW O 
) O 
from O 
metabolically O 
unwell O 
( O 
MUW O 
) O 
individuals O 
, O 
independent O 
of O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
. O 
MATERIALS O 
/ O 
METHODS O 
: O 
This O 
study O 
was O 
conducted O 
as O 
part O 
of O 
the O 
Measurement O 
to O 
Understand O 
the O 
Reclassification O 
of O 
Disease O 
of O 
Cabarrus O 
/ O 
Kannapolis O 
( O 
MURDOCK O 
) O 
project O 
. O 
Individuals O 
from O 
3 O 
cohorts O 
were O 
classified O 
as O 
lean O 
( O 
BMI O 
< O 
25kg O 
/ O 
m(2) O 
) O 
, O 
overweight O 
( O 
BMI≥25kg O 
/ O 
m(2) O 
, O 
BMI O 
< O 
30kg O 
/ O 
m(2) O 
) O 
or O 
obese O 
( O 
BMI≥30kg O 
/ O 
m(2) O 
) O 
. O 
Cardiometabolic O 
abnormalities O 
were O 
defined O 
as O 
: O 
( O 
1 O 
) O 
impaired O 
fasting O 
glucose B-TRIVIAL 
( O 
≥ O 
100mg O 
/ O 
dL O 
and O 
≤ O 
126mg O 
/ O 
dL O 
) O 
; O 
( O 
2 O 
) O 
hypertension O 
; O 
( O 
3 O 
) O 
triglycerides B-FAMILY 
≥ O 
150mg O 
/ O 
dL O 
; O 
( O 
4 O 
) O 
HDL-C O 
< O 
40mg O 
/ O 
dL O 
in O 
men O 
, O 
< O 
50mg O 
/ O 
dL O 
in O 
women O 
; O 
and O 
( O 
5 O 
) O 
insulin O 
resistance O 
( O 
calculated O 
Homeostatic O 
Model O 
Assessment O 
( O 
HOMA-IR O 
) O 
index O 
of O 
> O 
5.13 O 
) O 
. O 
MW O 
individuals O 
were O 
defined O 
as O 
having O 
< O 
2 O 
cardiometabolic O 
abnormalities O 
and O 
MUW O 
individuals O 
had≥two O 
cardiometabolic O 
abnormalities O 
. O 
Targeted O 
profiling O 
of O 
55 O 
metabolites O 
used O 
mass O 
- O 
spectroscopy O 
- O 
based O 
methods O 
. O 
Principal O 
components O 
analysis O 
( O 
PCA O 
) O 
was O 
used O 
to O 
reduce O 
the O 
large O 
number O 
of O 
correlated O 
metabolites O 
into O 
clusters O 
of O 
fewer O 
uncorrelated O 
factors O 
. O 
RESULTS O 
: O 
Of O 
1872 O 
individuals O 
, O 
410 O 
were O 
lean O 
, O 
610 O 
were O 
overweight O 
, O 
and O 
852 O 
were O 
obese O 
. O 
Of O 
lean O 
individuals O 
, O 
67% O 
were O 
categorized O 
as O 
MUW O 
, O 
whereas O 
80% O 
of O 
overweight O 
and O 
87% O 
of O 
obese O 
individuals O 
were O 
MUW O 
. O 
PCA O 
- O 
derived O 
factors O 
with O 
levels O 
that O 
differed O 
the O 
most O 
between O 
MW O 
and O 
MUW O 
groups O 
were O 
factors O 
4 O 
( O 
branched O 
chain O 
amino B-FAMILY 
acids I-FAMILY 
[ O 
BCAA O 
] O 
) O 
[ O 
p O 
< O 
0.0001 O 
] O 
, O 
8 O 
( O 
various O 
metabolites O 
) O 
[ O 
p O 
< O 
0.0001 O 
] O 
, O 
9 O 
( O 
C4 B-MULTIPLE 
/ I-MULTIPLE 
Ci4 I-MULTIPLE 
, I-MULTIPLE 
C3 I-MULTIPLE 
, I-MULTIPLE 
C5 I-MULTIPLE 
acylcarnitines I-MULTIPLE 
) O 
[ O 
p O 
< O 
0.0001 O 
] O 
and O 
10 O 
( O 
amino B-FAMILY 
acids I-FAMILY 
) O 
[ O 
p O 
< O 
0.0002 O 
] O 
. O 
Further O 
, O 
Factor O 
4 O 
, O 
distinguishes O 
MW O 
from O 
MUW O 
individuals O 
independent O 
of O 
BMI O 
. O 
CONCLUSION O 
: O 
BCAA O 
and O 
related O 
metabolites O 
are O 
promising O 
biomarkers O 
that O 
may O 
aid O 
in O 
understanding O 
cardiometabolic O 
health O 
independent O 
of O 
BMI O 
category O 
. O 

and O 
mass O 
isotopomer O 
analysis O 
as O 
a O 
strategy O 
for O 
pathway O 
discovery O 
: O 
pyrrolyl B-SYSTEMATIC 
and O 
cyclopentenyl B-SYSTEMATIC 
derivatives O 
of O 
the O 
pro O 
- O 
drug O 
of O 
abuse O 
, O 
levulinate B-TRIVIAL 
. O 

recently O 
reported O 
that O 
levulinate B-TRIVIAL 
( O 
4-ketopentanoate B-SYSTEMATIC 
) O 
is O 
converted O 
in O 
the O 
liver O 
to O 
4-hydroxypentanoate B-SYSTEMATIC 
, O 
a O 
drug O 
of O 
abuse O 
, O 
and O 
that O 
the O 
formation O 
of O 
4-hydroxypentanoate B-SYSTEMATIC 
is O 
stimulated O 
by O 
ethanol B-SYSTEMATIC 
oxidation O 
. O 
We O 
also O 
identified O 
3 O 
parallel O 
β-oxidation O 
pathways O 
by O 
which O 
levulinate B-TRIVIAL 
and O 
4-hydroxypentanoate B-SYSTEMATIC 
are O 
catabolized O 
to O 
propionyl-CoA B-SYSTEMATIC 
and O 
acetyl-CoA B-SYSTEMATIC 
. O 
We O 
now O 
report O 
that O 
levulinate B-TRIVIAL 
forms O 
three O 
seven- O 
carbon B-SYSTEMATIC 
cyclical O 
CoA O 
esters O 
by O 
processes O 
starting O 
with O 
the O 
elongation O 
of O 
levulinyl-CoA B-TRIVIAL 
by O 
acetyl-CoA B-SYSTEMATIC 
to O 
3,6-diketoheptanoyl-CoA B-SYSTEMATIC 
. O 
The O 
latter O 
γ-diketo B-FAMILY 
CoA I-FAMILY 
ester I-FAMILY 
undergoes O 
two O 
parallel O 
cyclization O 
processes O 
. O 
One O 
process O 
yields O 
a O 
mixture O 
of O 
tautomers O 
, O 
i.e O 
. O 
, O 
cyclopentenyl- B-MULTIPLE 
and I-MULTIPLE 
cyclopentadienyl-acyl-CoAs I-MULTIPLE 
. O 
The O 
second O 
cyclization O 
process O 
yields O 
a O 
methyl-pyrrolyl-acetyl-CoA B-SYSTEMATIC 
containing O 
a O 
nitrogen B-SYSTEMATIC 
atom O 
derived O 
from O 
the O 
ε-nitrogen B-SYSTEMATIC 
of O 
lysine B-TRIVIAL 
but O 
without O 
carbons B-FAMILY 
from O 
lysine B-TRIVIAL 
. O 
The O 
cyclic B-FAMILY 
CoA I-FAMILY 
esters I-FAMILY 
were O 
identified O 
in O 
rat O 
livers O 
perfused O 
with O 
levulinate B-TRIVIAL 
and O 
in O 
livers O 
and O 
brains O 
from O 
rats O 
gavaged O 
with O 
calcium B-SYSTEMATIC 
levulinate I-SYSTEMATIC 
± O 
ethanol B-SYSTEMATIC 
. O 
Lastly O 
, O 
3,6-diketoheptanoyl-CoA B-SYSTEMATIC 
, O 
like O 
2,5-diketohexane B-SYSTEMATIC 
, O 
pyrrolates B-FAMILY 
free O 
lysine B-TRIVIAL 
and O 
, O 
presumably O 
, O 
lysine B-TRIVIAL 
residues O 
from O 
proteins O 
. O 
This O 
may O 
represent O 
a O 
new O 
pathway O 
for O 
protein O 
pyrrolation O 
. O 
The O 
cyclic B-FAMILY 
CoA I-FAMILY 
esters I-FAMILY 
and O 
related O 
pyrrolation O 
processes O 
may O 
play O 
a O 
role O 
in O 
the O 
toxic O 
effects O 
of O 
4-hydroxypentanoate B-SYSTEMATIC 
. O 

essential O 
oil O 
of O 
46 O 
spontaneous O 
plants O 
of O 
Calamintha O 
nepeta O 
( O 
L O 
. O 
) O 
Savi O 
subsp O 
. O 
nepeta O 
growing O 
wild O 
in O 
Sud O 
, O 
Italy O 
( O 
Salento O 
, O 
Apulia O 
) O 
, O 
were O 
investigated O 
by O 
GC O 
/ O 
MS O 
. O 
Fifty O 
- O 
seven O 
components O 
were O 
identified O 
in O 
the O 
oil O 
representing O 
over O 
the O 
98% O 
of O 
the O 
total O 
oil O 
composition O 
. O 
Four O 
chemotypes O 
were O 
identified O 
: O 
piperitone B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
piperitenone B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
piperitone B-TRIVIAL 
- O 
menthone B-TRIVIAL 
and O 
pulegone B-TRIVIAL 
. O 

leading O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
therapeutics O 
to O 
date O 
involves O 
inhibitors O 
of O 
acetylcholinesterase O 
( O 
AChE O 
) O 
, O 
which O 
should O 
, O 
in O 
principle O 
, O 
elevate O 
cholinergic O 
signaling O 
and O 
limit O 
inflammation O 
. O 
In O 
spite O 
of O 
the O 
effectiveness O 
in O 
20%-30% O 
of O 
AD O 
patients O 
, O 
more O 
attention O 
has O 
been O 
paid O 
to O 
find O 
new O 
anti-AChE O 
agents O 
from O 
medicinal O 
plants O 
. O 
Galanthamine B-TRIVIAL 
, O 
contained O 
in O 
the O 
bulbs O 
and O 
flowers O 
of O 
Galanthus O 
and O 
related O 
genera O 
like O 
Narcissus O 
, O 
represents O 
a O 
good O 
example O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
review O 
the O 
role O 
of O 
possible O 
AChE O 
inhibitors O 
( O 
AChEI O 
) O 
present O 
in O 
plants O 
traditionally O 
used O 
in O 
European O 
medicine O 
for O 
improving O 
memory O 
. O 
Starting O 
from O 
Galanthamine B-TRIVIAL 
, O 
properties O 
of O 
Melissa O 
species O 
, O 
Salvia O 
officinalis O 
, O 
Arnica O 
chamissonis O 
and O 
Ruta O 
graveolens O 
are O 
discussed O 
to O 
point O 
to O 
the O 
role O 
of O 
these O 
plants O 
as O 
potential O 
sources O 
for O 
the O 
development O 
of O 
therapeutic O 
agents O 
for O 
AD O 
. O 

new O 
di-O-prenylated B-TRIVIAL 
flavone I-TRIVIAL 
from O 
an O 
actinomycete O 
Streptomyces O 
sp O 
. O 
MA-12 O 
. O 

new O 
di-O-prenylated B-TRIVIAL 
flavone I-TRIVIAL 
, O 
named O 
7,3'-di-(γ,γ-dimethylallyloxy)-5-hydroxy-4'-methoxyflavone B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
culture O 
broth O 
of O 
the O 
endophytic O 
actinomycete O 
Streptomyces O 
sp O 
. O 
MA-12 O 
isolated O 
from O 
the O 
root O 
of O 
the O 
semi-mangrove O 
plant O 
Myoporum O 
bontioides O 
A O 
. O 
Gray O 
. O 
The O 
structure O 
of O 
1 O 
was O 
determined O 
by O 
comprehensive O 
spectroscopic O 
methods O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
experiments O 
( O 
COSY O 
, O 
HMQC O 
, O 
and O 
HMBC O 
) O 
. O 
Primary O 
bioassays O 
showed O 
that O 
1 O 
at O 
concentration O 
of O 
0.25 O 
mM O 
had O 
moderate O 
inhibitory O 
activity O 
against O 
three O 
plant O 
pathogenic O 
fungi O 
including O 
Colletotrichum O 
musae O 
, O 
Gibberella O 
zeae O 
( O 
Schweinitz O 
) O 
Petch O 
, O 
and O 
Penicillium O 
citrinum O 
Thom O 
. O 

alkyl I-FAMILY 
ether I-FAMILY 
derivatives O 
inhibit O 
platelet O 
activation O 
after O 
oral O 
administration O 
to O 
rats O 
. O 

low O 
lipophilicity O 
of O 
hydroxytyrosol B-SYSTEMATIC 
( O 
HT O 
) O 
has O 
motivated O 
efforts O 
to O 
synthesize O 
homologous O 
series O 
with O 
better O 
lipid O 
solubility O 
, O 
such O 
as O 
the O 
ethers B-FAMILY 
, O 
which O 
are O 
more O 
lipophilic O 
than O 
HT O 
. O 
Because O 
HT O 
inhibits O 
platelet O 
aggregation O 
, O 
the O 
aim O 
of O 
the O 
study O 
was O 
to O 
assess O 
the O 
possible O 
anti-platelet O 
effect O 
of O 
five O 
HT O 
ether B-SYSTEMATIC 
derivatives O 
( O 
ethyl B-SYSTEMATIC 
, O 
butyl B-SYSTEMATIC 
, O 
hexyl B-SYSTEMATIC 
, O 
octyl B-SYSTEMATIC 
and O 
dodecyl B-SYSTEMATIC 
) O 
after O 
oral O 
administration O 
to O 
rats O 
. O 
Whole O 
blood O 
collagen O 
- O 
induced O 
platelet O 
aggregation O 
and O 
calcium B-SYSTEMATIC 
-induced O 
thromboxane B-TRIVIAL 
B2 I-TRIVIAL 
( O 
TxB2 B-ABBREVIATION 
) O 
, O 
aortic O 
6-keto-prostaglandin B-SYSTEMATIC 
F1α I-SYSTEMATIC 
( O 
6-keto-PGF1α B-SYSTEMATIC 
) O 
and O 
nitrites B-FAMILY 
+ O 
nitrates B-FAMILY 
, O 
plasma O 
concentration O 
of O 
lipid O 
peroxides B-FAMILY 
( O 
TBARS O 
) O 
and O 
red O 
blood O 
cell O 
content O 
of O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
were O 
measured O 
. O 
The O 
administration O 
of O 
20 O 
mg O 
/ O 
kg O 
/ O 
day O 
inhibited O 
platelet O 
aggregation O 
, O 
TxB2 B-ABBREVIATION 
and O 
TBARS O 
in O 
a O 
non-linear O 
manner O 
related O 
to O 
the O 
length O 
of O 
the O 
carbon B-SYSTEMATIC 
chain O 
, O 
with O 
a O 
cut O 
- O 
off O 
effect O 
in O 
the O 
hexyl B-SYSTEMATIC 
derivative O 
. O 
Aortic O 
nitrite B-SYSTEMATIC 
and O 
red O 
blood O 
cell O 
GSH B-ABBREVIATION 
production O 
were O 
also O 
increased O 
. O 
The O 
aortic O 
production O 
of O 
6-keto-PGF1α B-SYSTEMATIC 
was O 
unaltered O 
except O 
in O 
the O 
group O 
treated O 
with O 
the O 
dodecyl B-SYSTEMATIC 
derivative O 
. O 
The O 
administration O 
of O 
50 O 
mg O 
/ O 
kg O 
/ O 
day O 
showed O 
a O 
similar O 
pharmacodynamic O 
profile O 
but O 
without O 
the O 
non-linear O 
effect O 
. O 
In O 
conclusion O 
, O 
HT O 
ethers B-FAMILY 
, O 
especially O 
the O 
hexyl B-SYSTEMATIC 
derivative O 
, O 
are O 
a O 
potential O 
alternative O 
to O 
hydroxytyrosol B-SYSTEMATIC 
, O 
and O 
their O 
effect O 
merits O 
additional O 
research O 
to O 
determine O 
their O 
role O 
in O 
the O 
prophylaxis O 
of O 
vascular O 
disease O 
. O 

mechanisms O 
of O 
the O 
cytotoxic O 
effects O 
of O 
the O 
zearalenone B-TRIVIAL 
metabolites O 
α-zearalenol B-TRIVIAL 
and O 
β-zearalenol B-TRIVIAL 
on O 
RAW264.7 O 
macrophages O 
. O 

( O 
ZEN B-ABBREVIATION 
) O 
and O 
its O 
metabolites O 
are O 
commonly O 
found O 
in O 
many O 
food O 
commodities O 
and O 
are O 
known O 
to O 
cause O 
reproductive O 
disorders O 
and O 
genotoxic O 
effects O 
. O 
The O 
major O 
ZEN B-ABBREVIATION 
metabolites O 
are O 
α-zearalenol B-TRIVIAL 
( O 
α-ZOL B-ABBREVIATION 
) O 
and O 
β-zearalenol B-TRIVIAL 
( O 
β-ZOL B-ABBREVIATION 
) O 
. O 
Although O 
many O 
studies O 
have O 
demonstrated O 
the O 
cytotoxic O 
effects O 
of O 
these O 
metabolites O 
, O 
the O 
mechanisms O 
by O 
which O 
α-ZOL B-ABBREVIATION 
or O 
β-ZOL B-ABBREVIATION 
mediates O 
their O 
cytotoxic O 
effects O 
appear O 
to O 
differ O 
according O 
to O 
cell O 
type O 
and O 
the O 
exposed O 
toxins O 
. O 
We O 
evaluated O 
the O 
toxicity O 
of O 
α-ZOL B-ABBREVIATION 
and O 
β-ZOL B-ABBREVIATION 
on O 
RAW264.7 O 
macrophages O 
and O 
investigated O 
the O 
underlying O 
mechanisms O 
. O 
β-ZOL B-ABBREVIATION 
not O 
only O 
more O 
strongly O 
reduced O 
the O 
viability O 
of O 
cells O 
than O 
did O 
α-ZOL B-ABBREVIATION 
, O 
but O 
it O 
also O 
induced O 
cell O 
death O 
mainly O 
by O 
apoptosis O 
rather O 
than O 
necrosis O 
. O 
The O 
ZEN B-ABBREVIATION 
metabolites O 
induced O 
loss O 
of O 
mitochondrial O 
membrane O 
potential O 
( O 
MMP O 
) O 
, O 
mitochondrial O 
changes O 
in O 
Bcl-2 O 
and O 
Bax O 
proteins O 
, O 
and O 
cytoplasmic O 
release O 
of O 
cytochrome O 
c O 
and O 
apoptosis O 
- O 
inducing O 
factor O 
( O 
AIF O 
) O 
. O 
Use O 
of O 
an O 
inhibitor O 
specific O 
to O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
, O 
p38 O 
kinase O 
or O 
p53 O 
, O 
but O 
not O 
pan O 
- O 
caspase O 
or O 
caspase-8 O 
, O 
decreased O 
the O 
toxin O 
- O 
induced O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
also O 
attenuated O 
the O 
α-ZOL B-ABBREVIATION 
- O 
or O 
β-ZOL B-ABBREVIATION 
-induced O 
decrease O 
of O 
cell O 
viability O 
. O 
Antioxidative O 
enzyme O 
or O 
compounds O 
such O 
as O 
catalase O 
, O 
acteoside B-TRIVIAL 
, O 
and O 
(E)-1-(3,4-dihydroxyphenethyl)-3-(4-hydroxystyryl)urea B-SYSTEMATIC 
suppressed O 
the O 
ZEN B-ABBREVIATION 
metabolite O 
- O 
mediated O 
reduction O 
of O 
cell O 
viability O 
. O 
Further O 
, O 
knockdown O 
of O 
AIF O 
via O 
siRNA O 
transfection O 
diminished O 
the O 
ZEN B-ABBREVIATION 
metabolite O 
- O 
induced O 
cell O 
death O 
. O 
Collectively O 
, O 
these O 
results O 
suggest O 
that O 
the O 
activation O 
of O 
p53 O 
, O 
JNK O 
or O 
p38 O 
kinase O 
by O 
ZEN B-ABBREVIATION 
metabolites O 
is O 
the O 
main O 
upstream O 
signal O 
required O 
for O 
the O 
mitochondrial O 
alteration O 
of O 
Bcl-2 O 
/ O 
Bax O 
signaling O 
pathways O 
and O 
intracellular O 
ROS O 
generation O 
, O 
while O 
MMP O 
loss O 
and O 
nuclear O 
translocation O 
of O 
AIF O 
are O 
the O 
critical O 
downstream O 
events O 
for O 
ZEN B-ABBREVIATION 
metabolite O 
- O 
mediated O 
apoptosis O 
in O 
macrophages O 
. O 

interaction O 
between O 
mGluR1 O 
and O 
the O 
calcium B-SYSTEMATIC 
channel O 
Cav₂.₁ O 
preserves O 
coupling O 
in O 
the O 
presence O 
of O 
long O 
Homer O 
proteins O 
. O 

I O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGluR1 O 
and O 
5 O 
) O 
are O 
G O 
protein O 
coupled O 
receptors O 
that O 
regulate O 
neuronal O 
activity O 
in O 
a O 
number O 
of O 
ways O 
. O 
Some O 
of O 
the O 
most O 
well O 
studied O 
functions O 
of O 
group O 
I O 
mGluRs O 
, O 
such O 
as O 
initiation O 
of O 
multiple O 
forms O 
of O 
mGluR-dependent O 
long O 
- O 
term O 
depression O 
, O 
require O 
receptor O 
localization O 
near O 
the O 
post O 
- O 
synaptic O 
density O 
( O 
PSD O 
) O 
. O 
This O 
localization O 
is O 
in O 
turn O 
dependent O 
on O 
the O 
Homer O 
family O 
of O 
scaffolding O 
proteins O 
which O 
bind O 
to O 
a O 
small O 
motif O 
on O 
the O 
distal O 
C B-FORMULA 
-termini O 
of O 
mGluR1 O 
and O 
5 O 
, O 
localize O 
the O 
receptors O 
near O 
the O 
PSD O 
, O 
strengthen O 
coupling O 
to O 
post O 
- O 
synaptic O 
effectors O 
and O 
simultaneously O 
uncouple O 
the O 
mGluRs O 
from O 
extra O 
- O 
synaptic O 
effectors O 
such O 
as O 
voltage O 
dependent O 
ion O 
channels O 
. O 
Here O 
the O 
selectivity O 
of O 
this O 
uncoupling O 
process O 
was O 
examined O 
by O 
testing O 
the O 
ability O 
of O 
Homer-2b O 
to O 
uncouple O 
mGluR1 O 
from O 
multiple O 
voltage O 
dependent O 
calcium B-SYSTEMATIC 
channels O 
including O 
Ca B-FORMULA 
( O 
V2.2 O 
) O 
( O 
N- O 
type O 
) O 
, O 
Ca B-FORMULA 
( O 
V3.2 O 
) O 
( O 
T O 
- O 
type O 
) O 
, O 
and O 
Ca B-FORMULA 
( O 
V2.1 O 
) O 
( O 
P O 
/ O 
Q O 
- O 
type O 
) O 
expressed O 
in O 
rat O 
sympathetic O 
neurons O 
from O 
the O 
superior O 
cervical O 
ganglion O 
( O 
SCG O 
) O 
. O 
Of O 
these O 
, O 
only O 
the O 
mGluR1-Ca(V2.1) O 
modulatory O 
pathway O 
was O 
insensitive O 
to O 
Homer-2b O 
expression O 
. O 
Uncoupling O 
from O 
this O 
channel O 
was O 
achieved O 
by O 
co O 
- O 
expression O 
of O 
an O 
mGluR1 O 
C B-FORMULA 
-terminal O 
protein O 
designed O 
to O 
disrupt O 
a O 
previously O 
described O 
direct O 
interaction O 
between O 
these O 
two O 
proteins O 
, O 
suggesting O 
that O 
this O 
interaction O 
allows O 
incorporation O 
of O 
Ca B-FORMULA 
( O 
V2.1 O 
) O 
into O 
the O 
mGluR1 O 
/ O 
Homer O 
signaling O 
complex O 
, O 
thereby O 
preserving O 
modulation O 
in O 
the O 
presence O 
of O 
scaffolding O 
Homer O 
proteins O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

of O 
anoctamin-6 O 
/ O 
Tmem16f O 
, O 
a O 
regulator O 
of O 
phosphatidylserine B-FAMILY 
scrambling O 
in O 
osteoblasts O 
, O 
leads O 
to O 
decreased O 
mineral O 
deposition O 
in O 
skeletal O 
tissues O 
. O 

vertebrate O 
skeletal O 
development O 
, O 
osteoblasts O 
produce O 
a O 
mineralized O 
bone O 
matrix O 
by O 
deposition O 
of O 
hydroxyapatite B-TRIVIAL 
crystals O 
in O 
the O 
extracellular O 
matrix O 
. O 
Anoctamin6 O 
/ O 
Tmem16F O 
( O 
Ano6 O 
) O 
belongs O 
to O 
a O 
conserved O 
family O 
of O 
transmembrane O 
proteins O 
with O 
chloride B-SYSTEMATIC 
channel O 
properties O 
. O 
In O 
addition O 
, O 
Ano6 O 
has O 
been O 
linked O 
to O 
phosphatidylserine B-FAMILY 
( O 
PS O 
) O 
scrambling O 
in O 
the O 
plasma O 
membrane O 
. O 
During O 
skeletogenesis O 
, O 
Ano6 O 
mRNA O 
is O 
expressed O 
in O 
differentiating O 
and O 
mature O 
osteoblasts O 
. O 
Deletion O 
of O 
Ano6 O 
in O 
mice O 
results O 
in O 
reduced O 
skeleton O 
size O 
and O 
skeletal O 
deformities O 
. O 
Molecular O 
analysis O 
revealed O 
that O 
chondrocyte O 
and O 
osteoblast O 
differentiation O 
are O 
not O 
disturbed O 
. O 
However O 
, O 
mutant O 
mice O 
display O 
increased O 
regions O 
of O 
nonmineralized O 
, O 
Ibsp O 
- O 
expressing O 
osteoblasts O 
in O 
the O 
periosteum O 
during O 
embryonic O 
development O 
and O 
increased O 
areas O 
of O 
uncalcified O 
osteoid O 
postnatally O 
. O 
In O 
primary O 
Ano6(- O 
/ O 
- O 
) O 
osteoblasts O 
, O 
mineralization O 
is O 
delayed O 
, O 
indicating O 
a O 
cell O 
autonomous O 
function O 
of O 
Ano6 O 
. O 
Furthermore O 
, O 
we O 
demonstrate O 
that O 
calcium B-SYSTEMATIC 
-dependent O 
PS O 
scrambling O 
is O 
impaired O 
in O 
osteoblasts O 
. O 
Our O 
study O 
is O 
the O 
first O 
to O 
our O 
knowledge O 
to O 
reveal O 
the O 
requirement O 
of O 
Ano6 O 
in O 
PS O 
scrambling O 
in O 
osteoblasts O 
, O 
supporting O 
a O 
function O 
of O 
PS O 
exposure O 
in O 
the O 
deposition O 
of O 
hydroxyapatite B-TRIVIAL 
. O 

-based O 
inhibitors O 
of O 
acyl B-FAMILY 
protein O 
thioesterases O 
1 O 
and O 
2 O 
. O 

proteins O 
are O 
of O 
importance O 
in O 
cell O 
proliferation O 
, O 
and O 
hence O 
their O 
mutated O 
forms O 
play O 
causative O 
roles O 
in O 
many O 
kinds O 
of O 
cancer O 
in O 
different O 
tissues O 
. O 
Inhibition O 
of O 
the O 
Ras-depalmitoylating O 
enzyme O 
acyl B-FAMILY 
protein O 
thioesterases O 
APT1 O 
and O 
-2 O 
is O 
a O 
new O 
approach O 
to O 
modulating O 
the O 
Ras O 
cycle O 
. O 
Here O 
we O 
present O 
boronic B-SYSTEMATIC 
and O 
borinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
as O 
a O 
new O 
class O 
of O 
potent O 
and O 
nontoxic O 
APT O 
inhibitors O 
. O 
These O 
compounds O 
were O 
detected O 
by O 
extensive O 
library O 
screening O 
using O 
chemical O 
arrays O 
and O 
turned O 
out O 
to O 
inhibit O 
human O 
APT1 O 
and O 
-2 O 
in O 
a O 
competitive O 
mode O 
. O 
Furthermore O 
, O 
one O 
of O 
the O 
molecules O 
was O 
demonstrated O 
to O 
inhibit O 
Erk1 O 
/ O 
2 O 
phosphorylation O 
significantly O 
. O 

phases O 
of O 
amphiphiles O 
are O 
a O 
prototypical O 
example O 
of O 
self O 
- O 
assemblies O 
. O 
Their O 
structure O 
is O 
generally O 
determined O 
by O 
amphiphile O 
shape O 
and O 
their O 
phase O 
transitions O 
are O 
primarily O 
governed O 
by O 
composition O 
. O 
In O 
this O 
paper O 
, O 
we O 
demonstrate O 
a O 
new O 
paradigm O 
for O 
membrane O 
shape O 
control O 
where O 
the O 
electrostatic O 
coupling O 
of O 
charged O 
membranes O 
to O 
short O 
DNA O 
( O 
sDNA O 
) O 
, O 
with O 
tunable O 
temperature O 
- O 
dependent O 
end O 
- O 
to O 
- O 
end O 
stacking O 
interactions O 
, O 
enables O 
switching O 
between O 
the O 
inverted O 
gyroid O 
cubic O 
structure O 
( O 
QII O 
( O 
G O 
) O 
) O 
and O 
the O 
inverted O 
hexagonal O 
phase O 
( O 
HII O 
( O 
C O 
) O 
) O 
. O 
We O 
investigated O 
the O 
structural O 
shape O 
transitions O 
induced O 
in O 
the O 
QII O 
( O 
G O 
) O 
phase O 
upon O 
complexation O 
with O 
a O 
series O 
of O 
sDNAs O 
( O 
5 O 
, O 
11 O 
, O 
24 O 
, O 
and O 
48 O 
bp O 
) O 
with O 
three O 
types O 
of O 
end O 
structure O 
( O 
" O 
sticky O 
" O 
adenine B-TRIVIAL 
(A)- O 
thymine B-TRIVIAL 
( O 
T O 
) O 
( O 
dAdT O 
) O 
overhangs O 
, O 
no O 
overhang O 
( O 
blunt O 
) O 
, O 
and O 
" O 
nonsticky O 
" O 
dTdT O 
overhangs O 
) O 
using O 
synchrotron O 
small O 
- O 
angle O 
X-ray O 
scattering O 
. O 
Very O 
short O 
5 O 
bp O 
sDNA O 
with O 
dAdT O 
overhangs O 
and O 
blunt O 
ends O 
induce O 
coexistence O 
of O 
the O 
QII O 
( O 
G O 
) O 
and O 
the O 
HII O 
( O 
C O 
) O 
phase O 
, O 
with O 
the O 
fraction O 
of O 
QII O 
( O 
G O 
) O 
increasing O 
with O 
temperature O 
. O 
Phase O 
coexistence O 
for O 
blunt O 
5 O 
bp O 
sDNA O 
is O 
observed O 
from O 
27 O 
°C O 
to O 
about O 
65 O 
°C O 
, O 
where O 
the O 
HII O 
( O 
C O 
) O 
phase O 
disappears O 
and O 
the O 
temperature O 
dependence O 
of O 
the O 
lattice O 
spacing O 
of O 
the O 
QII O 
( O 
G O 
) O 
phase O 
indicates O 
that O 
the O 
sDNA O 
duplexes O 
melt O 
into O 
single O 
strands O 
. O 
The O 
only O 
other O 
sDNA O 
for O 
which O 
melting O 
is O 
observed O 
is O 
5 O 
bp O 
sDNA O 
with O 
dTdT O 
overhangs O 
, O 
which O 
forms O 
the O 
QII O 
( O 
G O 
) O 
phase O 
throughout O 
the O 
studied O 
range O 
of O 
temperature O 
( O 
27 O 
°C O 
to O 
85.2 O 
°C O 
) O 
. O 
The O 
longer O 
11 O 
bp O 
sDNA O 
forms O 
coexisting O 
QII O 
( O 
G O 
) O 
and O 
HII O 
( O 
C O 
) O 
phases O 
( O 
with O 
the O 
fraction O 
of O 
QII O 
( O 
G O 
) O 
again O 
increasing O 
with O 
temperature O 
) O 
only O 
for O 
" O 
nonsticky O 
" O 
dTdT O 
overhangs O 
, O 
while O 
dAdT O 
overhangs O 
and O 
blunt O 
ends O 
exclusively O 
template O 
the O 
HII O 
( O 
C O 
) O 
phase O 
. O 
For O 
24 O 
and O 
48 O 
bp O 
sDNAs O 
the O 
HII O 
( O 
C O 
) O 
phase O 
replaces O 
the O 
QII O 
( O 
G O 
) O 
phase O 
at O 
all O 
investigated O 
temperatures O 
, O 
independent O 
of O 
sDNA O 
end O 
structure O 
. O 
Our O 
work O 
demonstrates O 
how O 
the O 
combined O 
effects O 
of O 
sDNA O 
length O 
and O 
end O 
structure O 
( O 
which O 
determine O 
the O 
temperature O 
- O 
dependent O 
stacking O 
length O 
) O 
tune O 
the O 
phase O 
behavior O 
of O 
the O 
complexes O 
. O 
These O 
findings O 
are O 
consistent O 
with O 
the O 
hypothesis O 
that O 
sDNAs O 
and O 
sDNA O 
stacks O 
with O 
lengths O 
comparable O 
to O 
or O 
larger O 
than O 
the O 
cubic O 
unit O 
cell O 
length O 
disfavor O 
the O 
highly O 
curved O 
channels O 
present O 
in O 
the O 
QII O 
( O 
G O 
) O 
phase O 
, O 
thus O 
driving O 
the O 
QII O 
(G)-to-HII O 
( O 
C O 
) O 
phase O 
transition O 
. O 
As O 
the O 
temperature O 
is O 
increased O 
, O 
the O 
breaking O 
of O 
stacks O 
due O 
to O 
thermal O 
fluctuations O 
restores O 
increasing O 
percentages O 
of O 
the O 
QII O 
( O 
G O 
) O 
phase O 
. O 

, O 
characterization O 
, O 
in O 
vivo O 
biodistribution O 
and O 
pharmacokinetic O 
studies O 
of O 
donepezil B-TRIVIAL 
-loaded O 
PLGA B-ABBREVIATION 
nanoparticles O 
for O 
brain O 
targeting O 
. O 

Objective O 
: O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
is O 
a O 
progressive O 
neurodegenerative O 
disorder O 
manifested O 
by O 
cognitive O 
, O 
memory O 
deterioration O 
and O 
variety O 
of O 
neuropsychiatric O 
symptoms O 
. O 
Donepezil B-TRIVIAL 
is O 
a O 
reversible O 
cholinesterase O 
inhibitor O 
used O 
for O 
the O 
treatment O 
of O 
AD O 
. O 
The O 
purpose O 
of O 
this O 
work O 
is O 
to O 
prepare O 
a O 
nanoparticulate O 
drug O 
delivery O 
system O 
of O 
donepezil B-TRIVIAL 
using O 
poly(lactic B-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
for O 
sustained O 
release O 
and O 
efficient O 
brain O 
targeting O 
. O 
Materials O 
and O 
methods O 
: O 
PLGA B-ABBREVIATION 
nanoparticles O 
( O 
NPs O 
) O 
were O 
prepared O 
by O 
the O 
solvent O 
emulsification O 
diffusion O 
- O 
evaporation O 
technique O 
and O 
characterized O 
for O 
particle O 
size O 
, O 
particle O 
- O 
size O 
distribution O 
, O 
zeta O 
potential O 
, O 
entrapment O 
efficiency O 
, O 
drug O 
loading O 
and O 
interaction O 
studies O 
and O 
in O 
vivo O 
studies O 
using O 
gamma O 
scintigraphy O 
techniques O 
. O 
Results O 
and O 
discussion O 
: O 
The O 
size O 
of O 
drug O 
- O 
loaded O 
NPs O 
( O 
drug O 
polymer O 
ratio O 
1 O 
: O 
1 O 
) O 
was O 
found O 
to O 
be O 
89.67 O 
± O 
6.43 O 
nm O 
. O 
The O 
TEM O 
and O 
SEM O 
images O 
of O 
the O 
formulation O 
suggested O 
that O 
particle O 
size O 
was O 
within O 
20-100 O 
nm O 
and O 
spherical O 
in O 
shape O 
, O 
smooth O 
morphology O 
and O 
coating O 
of O 
Tween-80 B-TRIVIAL 
on O 
the O 
NPs O 
was O 
clearly O 
observed O 
. O 
The O 
release O 
behavior O 
of O 
donepezil B-TRIVIAL 
exhibited O 
a O 
biphasic O 
pattern O 
characterized O 
by O 
an O 
initial O 
burst O 
release O 
followed O 
by O 
a O 
slower O 
and O 
continuous O 
sustained O 
release O 
. O 
The O 
biodistribution O 
studies O 
of O 
donepezil B-TRIVIAL 
-loaded O 
PLGA B-ABBREVIATION 
NPs O 
and O 
drug O 
solution O 
via O 
intravenous O 
route O 
revealed O 
higher O 
percentage O 
of O 
radioactivity O 
per O 
gram O 
in O 
the O 
brain O 
for O 
the O 
nanoparticulate O 
formulation O 
as O 
compared O 
with O 
the O 
drug O 
solution O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Conclusion O 
: O 
The O 
high O 
concentrations O 
of O 
donepezil B-TRIVIAL 
uptake O 
in O 
brain O 
due O 
to O 
coated O 
NPs O 
may O 
help O 
in O 
a O 
significant O 
improvement O 
for O 
treating O 
AD O 
. O 
But O 
further O 
, O 
more O 
extensive O 
clinical O 
studies O 
are O 
needed O 
to O 
check O 
and O 
confirm O 
the O 
efficacy O 
of O 
the O 
prepared O 
drug O 
delivery O 
system O 
. O 

-alkylation O 
of O 
highly O 
quaternized O 
chitosan O 
derivatives O 
affects O 
the O 
paracellular O 
permeation O 
enhancement O 
in O 
bronchial O 
epithelia O 
in O 
vitro O 
. O 

study O 
describes O 
the O 
structure O 
- O 
activity O 
relationship O 
for O 
carefully O 
characterized O 
N-alkyl B-FAMILY 
- O 
N B-FORMULA 
-quaternary O 
chitosan O 
derivatives O 
as O 
permeation O 
enhancers O 
for O 
drugs O 
that O 
are O 
mainly O 
absorbed O 
through O 
the O 
paracellular O 
pathway O 
, O 
such O 
as O 
macromolecular O 
drugs O 
and O 
hydrophilic O 
drugs O 
, O 
in O 
a O 
well O 
defined O 
bronchial O 
epithelial O 
cell O 
line O 
. O 
The O 
O-methyl B-SYSTEMATIC 
free O 
derivatives O 
used O 
in O 
the O 
study O 
were O 
fully O 
trimethylated O 
( O 
100% O 
) O 
N,N,N-trimethyl B-SYSTEMATIC 
chitosan O 
( O 
TMC O 
) O 
and O 
N-propyl-(QuatPropyl) B-SYSTEMATIC 
, O 
N-butyl-(QuatButyl) B-SYSTEMATIC 
and O 
N-hexyl B-SYSTEMATIC 
(QuatHexyl)-N,N-dimethyl I-SYSTEMATIC 
chitosan O 
, O 
with O 
85-91% O 
degree O 
of O 
quaternization O 
. O 
The O 
fully O 
trimethylated O 
TMC O 
, O 
from O 
0.25mg O 
/ O 
ml O 
, O 
decreased O 
transepithelial O 
electrical O 
resistance O 
( O 
TER O 
) O 
in O 
a O 
reversible O 
manner O 
and O 
enhanced O 
the O 
permeation O 
of O 
the O 
macromolecule O 
FITC-dextran O 
4kDa O 
( O 
FD4 O 
) O 
2-5 O 
fold O 
. O 
TMC O 
did O 
not O 
cause O 
any O 
alterations O 
in O 
the O 
tight O 
junction O 
( O 
TJ O 
) O 
protein O 
claudin-4 O 
or O 
in O 
F-actin O 
architecture O 
. O 
QuatHexyl B-SYSTEMATIC 
was O 
the O 
most O 
effective O 
polymer O 
to O 
produce O 
enhanced O 
permeation O 
and O 
decreased O 
TER O 
from O 
0.016mg O 
/ O 
ml O 
. O 
Nevertheless O 
, O 
this O 
enhanced O 
permeation O 
was O 
accompanied O 
by O 
reduced O 
viability O 
and O 
dissociation O 
of O 
F-actin O 
and O 
claudin-4 O 
proteins O 
. O 
The O 
structure O 
- O 
activity O 
relationship O 
suggests O 
that O 
more O 
lipophilic O 
derivatives O 
show O 
more O 
permeation O 
enhancement O 
, O 
TJ O 
disassembly O 
, O 
and O 
less O 
viability O 
in O 
the O 
order O 
of O 
hexyl B-SYSTEMATIC 
≈ O 
butyl B-SYSTEMATIC 
> O 
propyl B-SYSTEMATIC 
> O 
methyl B-SYSTEMATIC 
and O 
demonstrates O 
that O 
the O 
permeation O 
effect O 
is O 
not O 
only O 
mediated O 
by O 
permanent O 
positive O 
charge O 
but O 
also O 
through O 
by O 
the O 
extent O 
of O 
N B-FORMULA 
-alkylation O 
. O 
These O 
results O 
are O 
relevant O 
to O 
elucidate O 
the O 
structural O 
factors O 
contributing O 
to O 
the O 
permeation O 
enhancement O 
of O 
chitosan O 
derivatives O 
and O 
for O 
potential O 
use O 
in O 
pulmonary O 
applications O 
. O 

present O 
study O 
used O 
an O 
intensive O 
longitudinal O 
design O 
to O 
examine O 
whether O 
mental O 
rotation O 
performance O 
varies O 
according O 
to O 
a O 
monthly O 
cycle O 
in O 
both O 
males O 
and O 
females O 
and O 
whether O 
these O 
variations O 
are O 
related O 
to O 
variations O 
in O 
progesterone B-TRIVIAL 
, O 
estradiol B-TRIVIAL 
, O 
and O 
testosterone B-TRIVIAL 
levels O 
. O 
We O 
collected O 
reaction O 
time O 
and O 
accuracy O 
data O 
for O 
10 O 
males O 
and O 
seven O 
females O 
each O 
workday O 
over O 
eight O 
weeks O 
using O 
136 O 
pairs O 
of O 
mental O 
rotation O 
stimuli O 
/ O 
day O 
, O 
and O 
measured O 
sexual O 
hormones O 
concentrations O 
in O 
the O 
saliva O 
twice O 
a O 
week O 
. O 
A O 
mixed O 
linear O 
model O 
statistical O 
analysis O 
revealed O 
that O 
all O 
females O 
and O 
seven O 
males O 
showed O 
significant O 
cycle O 
effects O 
in O 
mental O 
rotation O 
performance O 
. O 
The O 
female O 
cycle O 
showed O 
an O 
amplitude O 
that O 
was O 
twice O 
as O 
large O 
compared O 
with O 
the O 
amplitude O 
found O 
in O 
males O 
. O 
For O 
males O 
and O 
females O 
, O 
estradiol B-TRIVIAL 
and O 
testosterone B-TRIVIAL 
were O 
significantly O 
linearly O 
and O 
quadratically O 
related O 
to O 
interindividual O 
variation O 
in O 
performance O 
at O 
the O 
beginning O 
of O 
the O 
study O 
( O 
progesterone B-TRIVIAL 
was O 
linearly O 
related O 
to O 
performance O 
for O 
females O 
) O 
. O 
The O 
association O 
between O 
testosterone B-TRIVIAL 
and O 
performance O 
differed O 
across O 
sexes O 
: O 
for O 
males O 
, O 
it O 
had O 
an O 
inverse O 
U-shape O 
, O 
for O 
females O 
it O 
was O 
U O 
- O 
shaped O 
. O 
Towards O 
the O 
end O 
of O 
the O 
study O 
, O 
none O 
of O 
the O 
hormones O 
were O 
significantly O 
related O 
to O 
performance O 
anymore O 
. O 
Thus O 
, O 
the O 
relationship O 
between O 
hormones O 
and O 
mental O 
rotation O 
performance O 
disappeared O 
with O 
repeated O 
testing O 
. O 
Only O 
estradiol B-TRIVIAL 
levels O 
were O 
significantly O 
elevated O 
at O 
the O 
lowest O 
point O 
of O 
the O 
cycle O 
in O 
mental O 
rotation O 
performance O 
in O 
females O 
. O 
In O 
conclusion O 
, O 
in O 
this O 
intensive O 
longitudinal O 
study O 
spanning O 
two O 
months O 
, O 
a O 
monthly O 
cycle O 
in O 
mental O 
rotation O 
performance O 
was O 
found O 
among O 
both O 
males O 
and O 
females O 
, O 
with O 
a O 
larger O 
cycle's O 
amplitude O 
for O 
females O 
. O 

efficacy O 
of O 
chitosan-g- O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
nanocapsules O 
containing O 
docetaxel B-TRIVIAL 
: O 
anti-TMEFF-2 O 
functionalized O 
nanocapsules O 
vs O 
. O 
non-functionalized O 
nanocapsules O 
. O 

development O 
and O 
evaluation O 
of O 
PEGylated O 
chitosan O 
( O 
CS O 
) O 
nanocapsules O 
( O 
NCs O 
) O 
conjugated O 
to O 
a O 
monoclonal O 
antibody O 
anti-TMEFF-2 O 
( O 
CS- O 
PEG B-ABBREVIATION 
-anti-TMEFF-2 O 
mAb O 
NCs O 
) O 
for O 
targeted O 
delivery O 
of O 
docetaxel B-TRIVIAL 
( O 
DCX B-ABBREVIATION 
) O 
is O 
presented O 
. O 
CS- O 
PEG B-ABBREVIATION 
- O 
Biotin B-TRIVIAL 
NCs O 
, O 
displaying O 
biotin B-TRIVIAL 
tags O 
at O 
their O 
surface O 
, O 
were O 
obtained O 
and O 
efficiently O 
functionalized O 
with O 
an O 
anti-TMEFF-2 O 
mAb O 
through O 
a O 
convenient O 
avidin- O 
biotin B-TRIVIAL 
approach O 
. O 
Cell O 
cycle O 
analysis O 
after O 
treatment O 
with O 
different O 
DCX B-ABBREVIATION 
-loaded O 
CS- O 
PEG B-ABBREVIATION 
NC O 
formulations O 
indicated O 
that O 
the O 
encapsulated O 
drug O 
remained O 
fully O 
active O 
, O 
showing O 
a O 
similar O 
functional O 
behavior O 
to O 
free O 
DCX B-ABBREVIATION 
. O 
In O 
vivo O 
efficacy O 
studies O 
using O 
a O 
non-small O 
cell O 
lung O 
carcinoma O 
xenograft O 
revealed O 
that O 
CS- O 
PEG B-ABBREVIATION 
-anti-TMEFF-2 O 
NCs O 
resulted O 
as O 
effective O 
as O 
free O 
DCX B-ABBREVIATION 
( O 
Taxotere B-TRIVIAL 
® O 
) O 
. O 
Interestingly O 
, O 
differences O 
on O 
the O 
pharmacodynamic O 
behavior O 
among O 
the O 
different O 
DCX B-ABBREVIATION 
formulations O 
were O 
observed O 
. O 
Thus O 
, O 
while O 
free O 
DCX B-ABBREVIATION 
exhibited O 
a O 
fast O 
and O 
short O 
effect O 
on O 
tumor O 
volume O 
reduction O 
, O 
CS- O 
PEG B-ABBREVIATION 
-anti-TMEFF-2 O 
mAb O 
NCs O 
showed O 
a O 
delayed O 
and O 
prolonged O 
action O 
, O 
with O 
no O 
significant O 
side O 
effects O 
of O 
treatments O 
. O 

of O 
group O 
I O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
potentiates O 
heteromeric O 
kainate B-TRIVIAL 
receptors O 
. O 

receptors O 
( O 
KARs O 
) O 
, O 
a O 
family O 
of O 
ionotropic O 
glutamate B-TRIVIAL 
receptors O 
, O 
are O 
widely O 
expressed O 
in O 
the O 
central O 
nervous O 
system O 
and O 
are O 
critically O 
involved O 
in O 
synaptic O 
transmission O 
. O 
KAR O 
activation O 
is O 
influenced O 
by O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
( O 
mGlu O 
) O 
signaling O 
, O 
but O 
the O 
underlying O 
mechanisms O 
are O 
not O 
understood O 
. O 
We O 
undertook O 
studies O 
to O 
examine O 
how O 
mGlu O 
modulation O 
affects O 
activation O 
of O 
KARs O 
. O 
Confocal O 
immunohistochemistry O 
of O 
rat O 
hippocampus O 
and O 
cultured O 
rat O 
cortex O 
revealed O 
colocalization O 
of O 
the O 
high O 
- O 
affinity O 
KAR O 
subunits O 
with O 
group O 
I O 
mGlu O 
receptors O 
. O 
In O 
hippocampal O 
and O 
cortical O 
cultures O 
, O 
the O 
calcium B-SYSTEMATIC 
signal O 
caused O 
by O 
activation O 
of O 
native O 
KARs O 
was O 
potentiated O 
by O 
activation O 
of O 
group O 
I O 
mGlu O 
receptors O 
. O 
In O 
Xenopus O 
laevis O 
oocytes O 
, O 
activation O 
of O 
group O 
I O 
mGlu O 
receptors O 
potentiated O 
heteromeric O 
but O 
not O 
homomeric O 
KAR O 
- O 
mediated O 
currents O 
, O 
with O 
no O 
change O 
in O 
agonist O 
potency O 
. O 
The O 
potentiation O 
of O 
heteromeric O 
KARs O 
by O 
mGlu1 O 
activation O 
was O 
attenuated O 
by O 
GDPβS O 
, O 
blocked O 
by O 
an O 
inhibitor O 
of O 
phospholipase O 
C O 
or O 
the O 
calcium B-SYSTEMATIC 
chelator O 
1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
BAPTA B-ABBREVIATION 
) O 
, O 
prolonged O 
by O 
the O 
phosphatase O 
inhibitor O 
okadaic B-TRIVIAL 
acid I-TRIVIAL 
, O 
but O 
unaffected O 
by O 
the O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
lavendustin B-TRIVIAL 
A I-TRIVIAL 
. O 
Protein O 
kinase O 
C O 
( O 
PKC O 
) O 
inhibition O 
reduced O 
the O 
potentiation O 
by O 
mGlu1 O 
of O 
GluK2 O 
/ O 
GluK5 O 
, O 
and O 
conversely O 
, O 
direct O 
activation O 
of O 
PKC O 
by O 
phorbol B-SYSTEMATIC 
12-myristate,13-acetate I-SYSTEMATIC 
potentiated O 
GluK2 O 
/ O 
GluK5 O 
. O 
Using O 
site O 
- O 
directed O 
mutagenesis O 
, O 
we O 
identified O 
three O 
serines B-FAMILY 
( O 
Ser B-FORMULA 
833 O 
, O 
Ser B-FORMULA 
836 O 
, O 
and O 
Ser B-FORMULA 
840 O 
) O 
within O 
the O 
membrane O 
proximal O 
region O 
of O 
the O 
GluK5 O 
C B-FORMULA 
-terminal O 
domain O 
that O 
, O 
in O 
combination O 
, O 
are O 
required O 
for O 
mGlu1 O 
- O 
mediated O 
potentiation O 
of O 
KARs O 
. O 
Together O 
, O 
these O 
data O 
suggest O 
that O 
phosphorylation O 
of O 
key O 
residues O 
in O 
the O 
C B-FORMULA 
-terminal O 
domain O 
changes O 
the O 
overall O 
charge O 
of O 
this O 
domain O 
, O 
resulting O 
in O 
potentiated O 
agonist O 
responses O 
. O 

of O 
in O 
situ O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbon I-FAMILY 
degradation O 
by O 
functional O 
metaproteomics O 
( O 
protein-SIP O 
) O 
. O 

knowledge O 
of O 
the O 
physiology O 
and O 
phylogeny O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbon I-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
degrading O 
bacteria O 
often O 
relies O 
on O 
laboratory O 
enrichments O 
and O 
isolations O 
. O 
In O 
the O 
present O 
study O 
, O 
in O 
situ O 
microcosms O 
consisting O 
of O 
activated O 
carbon B-SYSTEMATIC 
pellets O 
( O 
BACTRAP®s O 
) O 
were O 
loaded O 
with O 
either O 
( B-SYSTEMATIC 
13 I-SYSTEMATIC 
) I-SYSTEMATIC 
C-naphthalene I-SYSTEMATIC 
or O 
( B-SYSTEMATIC 
13 I-SYSTEMATIC 
) I-SYSTEMATIC 
C-fluorene I-SYSTEMATIC 
and O 
were O 
subsequently O 
exposed O 
in O 
the O 
contaminant O 
source O 
and O 
plume O 
fringe O 
region O 
of O 
an O 
PAH B-ABBREVIATION 
contaminated O 
aquifer O 
. O 
Metaproteomic O 
analysis O 
and O 
protein-SIP O 
revealed O 
Burkholderiales O 
, O 
Actinomycetales O 
and O 
Rhizobiales O 
as O 
the O 
most O 
active O 
microorganisms O 
in O 
the O 
groundwater O 
communities O 
. O 
Proteins O 
identified O 
of O 
the O 
naphthalene B-SYSTEMATIC 
degradation O 
pathway O 
showed O 
a O 
relative O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
isotope O 
abundance O 
of O 
approximately O 
50 O 
atom% O 
demonstrating O 
that O 
the O 
identified O 
naphthalene B-SYSTEMATIC 
degrading O 
bacteria O 
gained O 
at O 
least O 
80% O 
of O 
their O 
carbon B-SYSTEMATIC 
by O 
PAH B-ABBREVIATION 
degradation O 
. O 
Although O 
the O 
microbial O 
community O 
grown O 
on O 
the O 
fluorene B-SYSTEMATIC 
-BACTRAPs O 
showed O 
a O 
structure O 
similar O 
to O 
the O 
naphthalene B-SYSTEMATIC 
-BACTRAPs O 
, O 
the O 
identification O 
of O 
fluorene B-SYSTEMATIC 
degraders O 
and O 
degradation O 
pathways O 
failed O 
in O 
situ O 
. O 
In O 
complementary O 
laboratory O 
microcosms O 
, O 
a O 
clear O 
enrichment O 
in O 
proteins O 
related O 
to O 
Rhodococcus O 
and O 
possible O 
fluorene B-SYSTEMATIC 
degradation O 
enzymes O 
was O 
observed O 
. O 
This O 
result O 
demonstrates O 
the O 
impact O 
of O 
laboratory O 
conditions O 
on O 
microbial O 
community O 
structure O 
and O 
activity O 
of O 
certain O 
species O 
and O 
underlines O 
the O 
need O 
on O 
in O 
situ O 
exploration O 
of O 
microbial O 
community O 
functions O 
. O 
In O 
situ O 
microcosms O 
in O 
combination O 
with O 
protein-SIP O 
may O 
be O 
a O 
significant O 
tool O 
for O 
in O 
situ O 
identification O 
of O 
metabolic O 
key O 
players O 
as O 
well O 
as O 
degradation O 
pathways O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

drug O 
penetration O 
is O 
an O 
obstacle O 
that O 
is O 
often O 
encountered O 
in O 
treatment O 
of O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
diseases O 
including O 
pain O 
and O 
cerebral O 
hypoxia O 
. O 
Over O 
the O 
past O 
several O 
years O 
, O 
biochemical O 
characteristics O 
of O 
the O 
brain O 
( O 
i.e O 
. O 
, O 
tight O 
junction O 
protein O 
complexes O 
at O 
brain O 
barrier O 
sites O 
, O 
expression O 
of O 
influx O 
and O 
efflux O 
transporters O 
) O 
have O 
been O 
shown O 
to O 
be O 
directly O 
involved O 
in O 
determining O 
CNS O 
permeation O 
of O 
therapeutic O 
agents O 
; O 
however O 
, O 
the O 
vast O 
majority O 
of O 
these O 
studies O 
have O 
focused O 
on O 
understanding O 
those O 
mechanisms O 
that O 
prevent O 
drugs O 
from O 
entering O 
the O 
CNS O 
. O 
Recently O 
, O 
this O 
paradigm O 
has O 
shifted O 
toward O 
identifying O 
and O 
characterizing O 
brain O 
targets O 
that O 
facilitate O 
CNS O 
drug O 
delivery O 
. O 
Such O 
targets O 
include O 
the O 
organic O 
anion O 
- O 
transporting O 
polypeptides O 
( O 
OATPs O 
in O 
humans O 
; O 
Oatps O 
in O 
rodents O 
) O 
, O 
a O 
family O 
of O 
sodium B-SYSTEMATIC 
-independent O 
transporters O 
that O 
are O 
endogenously O 
expressed O 
in O 
the O 
brain O 
and O 
are O 
involved O 
in O 
drug O 
uptake O 
. O 
OATP O 
/ O 
Oatp O 
substrates O 
include O 
drugs O 
that O 
are O 
efficacious O 
in O 
treatment O 
of O 
pain O 
and O 
/ O 
or O 
cerebral O 
hypoxia O 
( O 
i.e O 
. O 
, O 
opioid O 
analgesic O 
peptides O 
, O 
3-hydroxy-3-methylglutaryl B-SYSTEMATIC 
coenzyme I-SYSTEMATIC 
A I-SYSTEMATIC 
reductase O 
inhibitors O 
) O 
. O 
This O 
clearly O 
suggests O 
that O 
OATP O 
/ O 
Oatp O 
isoforms O 
are O 
viable O 
transporter O 
targets O 
that O 
can O 
be O 
exploited O 
for O 
optimization O 
of O 
drug O 
delivery O 
to O 
the O 
brain O 
and O 
, O 
therefore O 
, O 
improved O 
treatment O 
of O 
CNS O 
diseases O 
. O 
This O 
review O 
summarizes O 
recent O 
knowledge O 
in O 
this O 
area O 
and O 
emphasizes O 
the O 
potential O 
that O 
therapeutic O 
targeting O 
of O 
OATP O 
/ O 
Oatp O 
isoforms O 
may O 
have O 
in O 
facilitating O 
CNS O 
drug O 
delivery O 
and O 
distribution O 
. O 
Additionally O 
, O 
information O 
presented O 
in O 
this O 
review O 
will O 
point O 
to O 
novel O 
strategies O 
that O 
can O 
be O 
used O 
for O 
treatment O 
of O 
pain O 
and O 
cerebral O 
hypoxia O 
. O 

of O 
Korean O 
red O 
ginseng O 
extracts O 
on O 
neural O 
tube O 
defects O 
and O 
impairment O 
of O 
social O 
interaction O 
induced O 
by O 
prenatal O 
exposure O 
to O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
. O 

is O 
one O 
of O 
the O 
most O 
widely O 
used O 
medicinal O 
plants O 
, O 
which O 
belongs O 
to O 
the O 
genus O 
Panax O 
. O 
Compared O 
to O 
uncured O 
white O 
ginseng O 
, O 
red O 
ginseng O 
has O 
been O 
generally O 
regarded O 
to O 
produce O 
superior O 
pharmacological O 
effects O 
with O 
lesser O 
side O 
/ O 
adverse O 
effects O 
, O 
which O 
made O 
it O 
popular O 
in O 
a O 
variety O 
of O 
formulation O 
from O 
tea O 
to O 
oriental O 
medicine O 
. O 
Using O 
the O 
prenatal O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VPA B-ABBREVIATION 
)-injection O 
model O 
of O 
autism O 
spectrum O 
disorder O 
( O 
ASD O 
) O 
in O 
rats O 
, O 
which O 
produces O 
social O 
impairrment O 
and O 
altered O 
seizure O 
susceptibility O 
as O 
in O 
human O 
ASD O 
patients O 
as O 
well O 
as O 
mild O 
neural O 
tube O 
defects O 
like O 
crooked O 
tail O 
phenotype O 
, O 
we O 
examined O 
whether O 
chronic O 
administration O 
of O 
red O 
ginseng O 
extract O 
may O 
rescue O 
the O 
social O 
impairment O 
and O 
crooked O 
tail O 
phenotype O 
in O 
prenatally O 
VPA B-ABBREVIATION 
-exposed O 
rat O 
offspring O 
. O 
VPA B-ABBREVIATION 
-induced O 
impairment O 
in O 
social O 
interactions O 
tested O 
using O 
sociability O 
and O 
social O 
preference O 
paradigms O 
as O 
well O 
as O 
crooked O 
tail O 
phenotypes O 
were O 
significantly O 
improved O 
by O 
administration O 
of O 
Korean O 
red O 
ginseng O 
( O 
KRG O 
) O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
Rat O 
offspring O 
prenatally O 
exposed O 
to O 
VPA B-ABBREVIATION 
showed O 
higher O 
sensitivity O 
to O 
electric O 
shock O 
seizure O 
and O 
increased O 
locomotor O 
activity O 
in O 
open O 
- O 
field O 
test O 
. O 
KRG O 
treatment O 
reversed O 
abnormal O 
locomotor O 
activity O 
and O 
sensitivity O 
to O 
electric O 
shock O 
to O 
control O 
level O 
. O 
These O 
results O 
suggest O 
that O 
KRG O 
may O 
modulate O 
neurobehavioral O 
and O 
structural O 
organization O 
of O 
nervous O 
system O 
adversely O 
affected O 
by O 
prenatal O 
exposure O 
to O 
VPA B-ABBREVIATION 
. O 

determination O 
of O 
lead O 
, O 
cadmium B-SYSTEMATIC 
and O 
nickel B-SYSTEMATIC 
in O 
soil O 
, O 
water O 
, O 
vegetable O 
and O 
fruit O 
samples O 
using O 
STAT-FAAS O 
after O 
preconcentration O 
with O 
activated O 
carbon B-SYSTEMATIC 
. O 

this O 
study O 
, O 
lead O 
( O 
Pb B-FORMULA 
) O 
, O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
and O 
nickel B-SYSTEMATIC 
( O 
Ni B-FORMULA 
) O 
were O 
determined O 
in O 
soil O 
, O 
water O 
, O 
vegetable O 
and O 
fruit O 
samples O 
taken O 
from O 
around O 
oil O 
refinery O 
region O 
in O 
Batman O 
, O 
Turkey O 
. O 
Digestion O 
procedures O 
for O 
samples O 
were O 
optimized O 
and O 
all O 
optimum O 
parameters O 
were O 
used O 
both O 
in O 
digestion O 
and O 
in O 
determination O 
steps O 
. O 
In O 
order O 
to O 
determine O 
Pb B-FORMULA 
and O 
Cd B-FORMULA 
, O 
slotted O 
tube O 
atom O 
trap O 
( O 
STAT O 
) O 
was O 
used O 
to O 
increase O 
the O 
sensitivity O 
in O 
atomic O 
absorption O 
spectrophotometry O 
. O 
Preconcentration O 
procedure O 
under O 
the O 
optimum O 
conditions O 
was O 
applied O 
to O 
water O 
, O 
vegetable O 
and O 
fruit O 
samples O 
to O 
determine O 
Pb B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Ni B-FORMULA 
in O 
trace O 
levels O 
. O 
In O 
soil O 
samples O 
, O 
concentrations O 
of O 
analytes O 
were O 
found O 
in O 
the O 
range O 
of O 
4 O 
± O 
0.2-12,000 O 
± O 
60 O 
mg O 
/ O 
kg O 
for O 
Pb B-FORMULA 
, O 
0.15 O 
± O 
0.01-3.0 O 
± O 
0.1 O 
mg O 
/ O 
kg O 
for O 
Cd B-FORMULA 
and O 
21 O 
± O 
1-65 O 
± O 
3.4 O 
mg O 
/ O 
kg O 
for O 
Ni B-FORMULA 
. O 
In O 
all O 
water O 
samples O 
, O 
concentration O 
of O 
Ni B-FORMULA 
was O 
expressed O 
as O 
nanogram O 
per O 
milliliter O 
( O 
ng O 
/ O 
mL O 
) O 
and O 
found O 
to O 
be O 
higher O 
than O 
Pb B-FORMULA 
and O 
Cd B-FORMULA 
levels O 
. O 
It O 
was O 
observed O 
that O 
Pb B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Ni B-FORMULA 
concentrations O 
varied O 
from O 
both O 
plant O 
to O 
plant O 
and O 
in O 
same O 
plants O 
at O 
different O 
experimental O 
sites O 
. O 
Pb B-FORMULA 
concentrations O 
in O 
vegetable O 
and O 
fruit O 
samples O 
interested O 
varied O 
between O 
20 O 
± O 
2 O 
and O 
160 O 
± O 
12 O 
ng O 
/ O 
g O 
, O 
and O 
the O 
highest O 
level O 
of O 
Pb B-FORMULA 
was O 
found O 
to O 
be O 
in O 
green O 
pepper O 
taken O 
from O 
1000 O 
m O 
away O 
from O 
refinery O 
. O 

new O 
isobenzofuranone B-SYSTEMATIC 
from O 
the O 
mangrove O 
endophytic O 
fungus O 
Penicillium O 
sp O 
. O 
( O 
ZH58 O 
) O 
. O 

new O 
isobenzofuranone B-SYSTEMATIC 
, O 
4-(methoxymethyl)-7-methoxy-6-methyl-1(3H)-isobenzofuranone B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
together O 
with O 
seven O 
known O 
compounds O 
, O 
dilation B-NO_CLASS 
( O 
2 O 
) O 
, O 
lumichrome B-TRIVIAL 
( O 
3 O 
) O 
, O 
curvulari B-NO_CLASS 
( O 
4 O 
) O 
, O 
5,5'-oxy-dimethylene-bis(2-furaldehyde) B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
chromone B-TRIVIAL 
( O 
6 O 
) O 
, O 
harman(1-methyl-β-carboline) B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
N9-methyl-1methyl-β-carboline B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
mangrove O 
endophytic O 
fungus O 
, O 
Penicillium O 
sp O 
. O 
ZH58 O 
obtained O 
from O 
the O 
South O 
China O 
Sea O 
coast O 
. O 
Their O 
structures O 
were O 
determined O 
by O 
analysis O 
of O 
spectroscopic O 
data O 
. O 
Compound O 
1 O 
exhibited O 
cytotoxicity O 
against O 
KB O 
and O 
KBV200 O 
cells O 
with O 
IC50 O 
values O 
of O 
6 O 
and O 
10 O 
μg O 
/ O 
mL O 
, O 
respectively O 
. O 

single O 
- O 
molecule O 
signal O 
transduction O 
in O 
carbon B-SYSTEMATIC 
nanotube O 
circuits O 
with O 
protein O 
engineering O 
. O 

- O 
molecule O 
experimental O 
methods O 
have O 
provided O 
new O 
insights O 
into O 
biomolecular O 
function O 
, O 
dynamic O 
disorder O 
, O 
and O 
transient O 
states O 
that O 
are O 
all O 
invisible O 
to O 
conventional O 
measurements O 
. O 
A O 
novel O 
, O 
nonfluorescent O 
single O 
- O 
molecule O 
technique O 
involves O 
attaching O 
single O 
molecules O 
to O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
field O 
- O 
effective O 
transistors O 
( O 
SWNT O 
FETs O 
) O 
. O 
These O 
ultrasensitive O 
electronic O 
devices O 
provide O 
long O 
- O 
duration O 
, O 
label O 
- O 
free O 
monitoring O 
of O 
biomolecules O 
and O 
their O 
dynamic O 
motions O 
. O 
However O 
, O 
generalization O 
of O 
the O 
SWNT O 
FET O 
technique O 
first O 
requires O 
design O 
rules O 
that O 
can O 
predict O 
the O 
success O 
and O 
applicability O 
of O 
these O 
devices O 
. O 
Here O 
, O 
we O 
report O 
on O 
the O 
transduction O 
mechanism O 
linking O 
enzymatic O 
processivity O 
to O 
electrical O 
signal O 
generation O 
by O 
a O 
SWNT O 
FET O 
. O 
The O 
interaction O 
between O 
SWNT O 
FETs O 
and O 
the O 
enzyme O 
lysozyme O 
was O 
systematically O 
dissected O 
using O 
eight O 
different O 
lysozyme O 
variants O 
synthesized O 
by O 
protein O 
engineering O 
. O 
The O 
data O 
prove O 
that O 
effective O 
signal O 
generation O 
can O 
be O 
accomplished O 
using O 
a O 
single O 
charged O 
amino B-FAMILY 
acid I-FAMILY 
, O 
when O 
appropriately O 
located O 
, O 
providing O 
a O 
foundation O 
to O 
widely O 
apply O 
SWNT O 
FET O 
sensitivity O 
to O 
other O 
biomolecular O 
systems O 
. O 

constituents O 
were O 
isolated O 
from O 
the O 
stems O 
of O 
Lawsonia O 
alba O 
Lam O 
. O 
, O 
following O 
an O 
activity O 
- O 
guided O 
isolation O 
, O 
which O 
include O 
two O 
new O 
constituents O 
, O 
namely O 
lawsorosemarinol B-TRIVIAL 
( O 
1 O 
) O 
and O 
lawsofructose B-TRIVIAL 
( O 
2 O 
) O 
, O 
one O 
known O 
compound O 
2-(β-d-glucopyranosyloxy)-1 B-SYSTEMATIC 
, I-SYSTEMATIC 
4-naphthoquinone I-SYSTEMATIC 
( O 
3 O 
) O 
and O 
four O 
compounds O 
, O 
4-hydroxy B-SYSTEMATIC 
coumarine I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
3-(4-hyroxyphenyl)-triacontyl-(Z)-propenoate B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
3-(4-hydroxy-3-methoxyphenyl)-triacontyl-(Z)-propenoate B-SYSTEMATIC 
( O 
6 O 
) O 
and O 
7-hydroxy-4-methyl B-SYSTEMATIC 
coumarin I-SYSTEMATIC 
( O 
7 O 
) O 
first O 
time O 
isolated O 
from O 
Lawsonia O 
alba O 
. O 
Their O 
structure O 
elucidation O 
was O 
based O 
on O 
spectroscopic O 
data O 
analyses O 
. O 
Compounds O 
3 O 
and O 
7 O 
showed O 
a O 
moderate O 
inhibition O 
of O 
urease O 
activity O 
, O 
while O 
rest O 
of O 
them O 
showed O 
less O 
than O 
50% O 
inhibition O 
. O 
These O 
compounds O 
did O 
not O 
show O 
any O 
significant O 
inhibition O 
against O 
α-chymotrypsin O 
. O 

silver B-SYSTEMATIC 
and O 
NaCl B-FORMULA 
toxicity O 
in O 
Daphnia O 
magna O 
: O 
a O 
comparative O 
study O 
of O 
standardized O 
chronic O 
endpoints O 
and O 
progeny O 
phototaxis O 
. O 

bioassays O 
with O 
the O 
model O 
freshwater O 
cladoceran O 
Daphnia O 
magna O 
have O 
the O 
potential O 
to O 
serve O 
as O 
nontraditional O 
but O 
sensitive O 
endpoints O 
of O 
sublethal O 
stress O 
. O 
However O 
, O 
few O 
studies O 
have O 
examined O 
the O 
comparative O 
sensitivity O 
of O 
neonate O 
phototaxis O 
perturbations O 
to O 
standardized O 
endpoints O 
commonly O 
employed O 
in O 
chronic O 
toxicity O 
testing O 
protocols O 
. O 
Even O 
less O 
understood O 
are O 
the O 
consequences O 
of O 
prenatal O 
exposure O 
on O 
neonate O 
phototactic O 
behavior O 
. O 
Here O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
D O 
. O 
magna O 
neonate O 
phototaxis O 
is O 
a O 
more O 
sensitive O 
endpoint O 
over O 
a O 
chronic O 
study O 
period O 
than O 
mortality O 
and O 
reproduction O 
. O 
D O 
. O 
magna O 
21 O 
day O 
studies O 
were O 
conducted O 
with O 
model O 
stressors O 
of O 
sodium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
and O 
dissolved O 
silver B-SYSTEMATIC 
. O 
Phototaxis O 
assays O 
of O 
progeny O 
response O 
to O 
relative O 
light O 
changes O 
in O 
small O 
water O 
columns O 
were O 
conducted O 
for O 
each O 
brood O 
. O 
Significant O 
differences O 
in O 
neonate O 
phototactic O 
behavior O 
were O 
observed O 
among O 
treatment O 
level O 
broods O 
, O 
suggesting O 
that O 
maternal O 
exposure O 
to O 
sublethal O 
levels O 
of O 
NaCl B-FORMULA 
and O 
Ag+ B-FORMULA 
impacted O 
offspring O 
. O 
In O 
fact O 
, O 
progeny O 
phototactic O 
response O 
was O 
significantly O 
affected O 
at O 
or O 
below O 
21-day O 
LOEC O 
thresholds O 
for O 
fecundity O 
in O 
broods O 
2 O 
, O 
3 O 
, O 
5 O 
and O 
6 O 
of O 
the O 
NaCl B-FORMULA 
experiment O 
and O 
in O 
broods O 
2 O 
, O 
4 O 
, O 
5 O 
and O 
6 O 
of O 
the O 
dissolved O 
Ag+ B-FORMULA 
study O 
. O 
Because O 
neonate O 
phototaxis O 
was O 
generally O 
more O 
sensitive O 
than O 
standardized O 
fecundity O 
thresholds O 
, O 
we O 
suggest O 
employing O 
neonate O 
phototaxis O 
as O 
an O 
ecologically O 
important O 
endpoint O 
in O 
future O 
ecological O 
risk O 
assessments O 
. O 

vitro O 
effect O 
of O 
N-acetylcysteine B-SYSTEMATIC 
on O 
hepatocyte O 
injury O 
caused O 
by O 
dichlorodiphenyltrichloroethane B-SYSTEMATIC 
and O 
its O 
metabolites O 
. O 

organochlorine B-FAMILY 
pesticide O 
, O 
dichlorodiphenyltrichloroethane B-SYSTEMATIC 
( O 
DDT B-ABBREVIATION 
) O 
, O 
is O 
still O 
used O 
to O 
combat O 
the O 
spread O 
of O 
malaria O 
in O 
several O 
developing O 
countries O 
despite O 
its O 
accumulation O 
and O 
known O 
hepatotoxic O 
effects O 
that O 
have O 
been O 
demonstrated O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
N-Acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
is O 
a O 
recognized O 
hepatoprotective O 
agent O 
that O 
has O 
been O 
reported O 
to O 
reduce O 
hepatotoxicity O 
initiated O 
by O 
many O 
different O 
compounds O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
NAC B-ABBREVIATION 
could O 
counter O 
in O 
vitro O 
hepatocyte O 
injury O 
induced O 
by O 
DDT B-ABBREVIATION 
or O 
its O 
two O 
major O 
metabolites O 
, O 
dichlorodiphenyldichloroethylene B-SYSTEMATIC 
and O 
dichlorodiphenyldichloroethane B-SYSTEMATIC 
. O 
HepG2 O 
cell O 
cultures O 
were O 
used O 
to O 
assess O 
the O 
following O 
parameters O 
of O 
toxicity O 
: O 
cellular O 
viability O 
, O 
intracellular O 
levels O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
mitochondrial O 
membrane O 
potential O 
and O 
initiation O 
of O 
apoptosis O 
. O 
None O 
of O 
the O 
three O 
test O 
compounds O 
induced O 
ROS O 
generation O 
, O 
yet O 
exposure O 
to O 
any O 
of O 
the O 
three O 
compounds O 
produced O 
mitochondrial O 
hyperpolarization O 
, O 
which O 
was O 
countered O 
by O 
NAC B-ABBREVIATION 
pretreatment O 
. O 
All O 
three O 
test O 
compounds O 
also O 
induced O 
apoptotic O 
cell O 
death O 
, O 
which O 
was O 
inhibited O 
by O 
NAC B-ABBREVIATION 
. O 
Despite O 
NAC B-ABBREVIATION 
counteracting O 
some O 
adverse O 
intracellular O 
changes O 
due O 
to O 
organochlorine B-FAMILY 
exposure O 
, O 
it O 
appeared O 
to O 
aggravate O 
the O 
cytotoxic O 
effects O 
of O 
the O 
organochlorine B-FAMILY 
compounds O 
at O 
low O 
test O 
concentrations O 
. O 
As O 
the O 
same O 
outcome O 
may O 
also O 
occur O 
in O 
vivo O 
, O 
results O 
from O 
the O 
present O 
study O 
raise O 
concern O 
about O 
the O 
use O 
of O 
NAC B-ABBREVIATION 
as O 
treatment O 
for O 
DDT B-ABBREVIATION 
-induced O 
hepatotoxicity O 
. O 

developmental O 
neurotoxicity O 
tests O 
performed O 
in O 
vivo O 
are O 
costly O 
, O 
time O 
- O 
consuming O 
and O 
utilize O 
a O 
large O 
number O 
of O 
animals O 
. O 
In O 
order O 
to O 
address O 
these O 
inefficiencies O 
, O 
in O 
vitro O 
models O 
of O 
neuronal O 
development O 
have O 
been O 
used O 
in O 
a O 
first O 
tier O 
screening O 
approach O 
for O 
developmental O 
neurotoxicity O 
hazard O 
identification O 
. O 
One O 
commonly O 
used O 
endpoint O 
for O 
assessing O 
developmental O 
neurotoxicity O 
in O 
vitro O 
is O 
measurement O 
of O 
neurite O 
outgrowth O 
. O 
This O 
biological O 
process O 
is O 
amenable O 
to O 
high O 
- O 
throughput O 
measurement O 
using O 
high O 
content O 
imaging O 
( O 
HCI O 
) O 
based O 
methodologies O 
. O 
To O 
date O 
, O 
a O 
majority O 
of O 
HCI O 
studies O 
of O 
neurite O 
outgrowth O 
have O 
focused O 
on O 
measurements O 
of O 
total O 
neurite O 
outgrowth O 
without O 
examining O 
whether O 
stereotypic O 
neuronal O 
growth O 
patterns O 
are O 
disrupted O 
or O 
whether O 
specific O 
sub O 
- O 
populations O 
of O 
neurites O 
( O 
i.e O 
. O 
axons O 
or O 
dendrites O 
) O 
are O 
selectively O 
affected O 
. O 
The O 
present O 
study O 
describes O 
the O 
development O 
and O 
implementation O 
of O 
two O 
HCI O 
based O 
analysis O 
methods O 
for O 
assessing O 
chemical O 
effects O 
on O 
neuronal O 
maturation O 
. O 
These O 
methods O 
utilize O 
the O 
stereotypical O 
growth O 
pattern O 
of O 
primary O 
rat O 
cortical O 
neurons O 
in O 
culture O 
( O 
i.e O 
. O 
the O 
Staging O 
Method O 
) O 
, O 
as O 
well O 
as O 
the O 
differential O 
cytoplasmic O 
distribution O 
of O 
β(III)-tubulin O 
and O 
MAP2 O 
( O 
i.e O 
. O 
the O 
Subtraction O 
Method O 
) O 
, O 
to O 
quantify O 
inhibition O 
of O 
neurite O 
initiation O 
, O 
axon O 
outgrowth O 
and O 
secondary O 
neurite O 
( O 
or O 
dendrite O 
) O 
outgrowth O 
in O 
response O 
to O 
chemical O 
exposure O 
. O 
Results O 
demonstrate O 
that O 
these O 
distinct O 
maturational O 
processes O 
are O 
differentially O 
affected O 
by O 
pharmacological O 
compounds O 
( O 
K252a B-IDENTIFIER 
, O 
Na(3)VO(4) B-FORMULA 
, O 
Bis-1 B-NO_CLASS 
) O 
known O 
to O 
inhibit O 
neurite O 
outgrowth O 
. O 
Furthermore O 
, O 
a O 
group O 
of O 
known O 
developmental O 
neurotoxicants O 
also O 
differentially O 
affected O 
the O 
growth O 
of O 
axons O 
and O 
secondary O 
neurites O 
in O 
primary O 
cortical O 
culture O 
. O 
This O 
work O 
improves O 
upon O 
previous O 
HCI O 
methods O 
by O 
providing O 
a O 
means O 
in O 
which O 
to O 
rapidly O 
and O 
specifically O 
quantify O 
chemical O 
effects O 
on O 
the O 
growth O 
of O 
axons O 
and O 
dendrites O 
in O 
vitro O 
. O 

, O 
synthesis O 
and O 
SAR O 
of O 
piperidyl-oxadiazoles B-FAMILY 
as O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
1 O 
inhibitors O 
. O 

potential O 
roles O 
of O 
11β-HSD1 O 
inhibitors O 
in O 
metabolic O 
syndrome O 
, O 
T2D O 
and O 
obesity O 
were O 
well O 
established O 
and O 
currently O 
several O 
classes O 
of O 
11β-HSD1 O 
inhibitors O 
have O 
been O 
developed O 
as O 
promising O 
agents O 
against O 
metabolic O 
diseases O 
. O 
To O 
find O 
potent O 
compounds O 
with O 
good O 
pharmacokinetics O 
, O 
we O 
used O 
the O 
bioisosterism O 
approach O 
, O 
and O 
designed O 
the O 
compound O 
2 O 
and O 
3 O 
bearing O 
an O 
1,2,4-oxadiazole B-SYSTEMATIC 
ring O 
to O 
replace O 
the O 
amide B-FAMILY 
group O 
in O 
compound O 
1 O 
. O 
Guided O 
by O 
docking O 
study O 
, O 
we O 
then O 
transformed O 
compound O 
3 O 
into O 
a O 
potent O 
lead O 
compound O 
4a O 
by O 
changing O 
sulfonamide B-SYSTEMATIC 
group O 
to O 
amide B-FAMILY 
. O 
To O 
elaborate O 
this O 
series O 
of O 
piperidyl-oxadiazole B-SYSTEMATIC 
derivatives O 
as O 
human O 
11β-HSD1 O 
inhibitors O 
, O 
we O 
explored O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
several O 
parts O 
of O 
the O 
lead O 
compound O 
. O 
Based O 
on O 
their O 
potency O 
toward O 
human O 
11β-HSD1 O 
two O 
compounds O 
4h O 
and O 
4q O 
were O 
advanced O 
to O 
pharmacokinetic O 
study O 
. O 
It O 
was O 
found O 
that O 
4h O 
and O 
4q O 
are O 
potent O 
and O 
selective O 
human O 
11β-HSD1 O 
inhibitors O 
with O 
better O 
pharmacokinetic O 
properties O 
than O 
those O 
of O 
the O 
original O 
piperidine-3-carboxamide B-SYSTEMATIC 
compound O 
1 O 
, O 
and O 
suitable O 
for O 
further O 
in O 
vivo O 
preclinical O 
study O 
in O 
primate O 
model O 
. O 

trioxide I-SYSTEMATIC 
-induced O 
hERG O 
K(+) B-FORMULA 
channel O 
deficiency O 
can O 
be O 
rescued O 
by O 
matrine B-TRIVIAL 
and O 
oxymatrine B-TRIVIAL 
through O 
up O 
- O 
regulating O 
transcription O 
factor O 
Sp1 O 
expression O 
. O 

human O 
ether B-SYSTEMATIC 
-a-go O 
- O 
go O 
- O 
related O 
gene O 
( O 
hERG O 
) O 
encodes O 
the O 
rapidly O 
activating O 
, O 
delayed O 
rectifier O 
potassium B-SYSTEMATIC 
channel O 
( O 
IKr O 
) O 
important O 
for O 
cardiac O 
repolarization O 
. O 
Dysfunction O 
of O 
the O 
hERG O 
channel O 
can O 
cause O 
Long O 
QT O 
Syndrome O 
( O 
LQTS O 
) O 
. O 
A O 
wide O 
variety O 
of O 
structurally O 
diverse O 
therapeutic O 
compounds O 
reduce O 
the O 
hERG O 
current O 
by O 
acute O 
direct O 
inhibition O 
of O 
the O 
hERG O 
current O 
or O 
/ O 
and O 
selective O 
disruption O 
of O 
hERG O 
protein O 
expression O 
. O 
Arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
( O 
As(2)O(3) B-FORMULA 
) O 
, O 
which O 
is O 
used O 
to O 
treat O 
acute O 
promyelocytic O 
leukemia O 
, O 
can O 
cause O 
LQTS O 
type O 
2 O 
( O 
LQT2 O 
) O 
by O 
reducing O 
the O 
hERG O 
current O 
through O 
the O 
diversion O 
of O 
hERG O 
trafficking O 
to O 
the O 
cytoplasmic O 
membrane O 
. O 
This O 
cardiotoxicity O 
limits O 
its O 
clinical O 
applications O 
. O 
Our O 
aim O 
was O 
to O 
develop O 
cardioprotective O 
agents O 
to O 
decrease O 
As(2)O(3) B-FORMULA 
-induced O 
cardiotoxicity O 
. O 
We O 
reported O 
that O 
superfusion O 
of O 
hERG-expressing O 
HEK293 O 
( O 
hERG-HEK O 
) O 
cells O 
with O 
matrine B-TRIVIAL 
( O 
1 O 
, O 
10 O 
μM O 
) O 
increased O 
the O 
hERG O 
current O 
by O 
promoting O 
hERG O 
channel O 
activation O 
. O 
Long O 
- O 
term O 
treatment O 
with O 
1 O 
μM O 
matrine B-TRIVIAL 
or O 
oxymatrine B-TRIVIAL 
increased O 
expression O 
of O 
the O 
hERG O 
protein O 
and O 
rescued O 
the O 
hERG O 
surface O 
expression O 
disrupted O 
by O 
As(2)O(3) B-FORMULA 
. O 
In O 
addition O 
, O 
Matrine B-TRIVIAL 
and O 
oxymatrine B-TRIVIAL 
significantly O 
shortened O 
action O 
potential O 
duration O 
prolonged O 
by O 
As(2)O(3) B-FORMULA 
in O 
guinea O 
pig O 
ventricular O 
myocytes O 
. O 
These O 
results O 
were O 
ascribed O 
to O 
the O 
up O 
- O 
regulation O 
of O 
hERG O 
at O 
both O 
mRNA O 
and O 
protein O 
levels O 
via O 
an O 
increase O 
in O 
the O 
expression O 
of O 
transcription O 
factor O 
Sp1 O 
, O 
an O 
established O 
transactivator O 
of O 
the O 
hERG O 
gene O 
. O 
Therefore O 
, O 
matrine B-TRIVIAL 
and O 
oxymatrine B-TRIVIAL 
may O 
have O 
the O 
potential O 
to O 
cure O 
LQT2 O 
as O 
a O 
potassium B-SYSTEMATIC 
channel O 
activator O 
by O 
promoting O 
hERG O 
channel O 
activation O 
and O 
increasing O 
hERG O 
channel O 
expression O 
. O 

and O 
synthesis O 
of O 
potent O 
inhibitor O 
of O 
apoptosis O 
( O 
IAP O 
) O 
proteins O 
antagonists O 
bearing O 
an O 
octahydropyrrolo[1,2-a]pyrazine B-SYSTEMATIC 
scaffold O 
as O 
a O 
novel O 
proline B-TRIVIAL 
mimetic O 
. O 

develop O 
novel O 
inhibitor O 
of O 
apoptosis O 
( O 
IAP O 
) O 
proteins O 
antagonists O 
, O 
we O 
designed O 
a O 
bicyclic B-SYSTEMATIC 
octahydropyrrolo[1,2-a]pyrazine I-SYSTEMATIC 
scaffold O 
as O 
a O 
novel O 
proline B-TRIVIAL 
bioisostere O 
. O 
This O 
design O 
was O 
based O 
on O 
the O 
X-ray O 
co O 
- O 
crystal O 
structure O 
of O 
four O 
N B-FORMULA 
-terminal O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
( O 
AVPI O 
) O 
of O 
the O 
second O 
mitochondria O 
- O 
derived O 
activator O 
of O 
caspase O 
( O 
Smac O 
) O 
with O 
the O 
X-chromosome O 
- O 
linked O 
IAP O 
( O 
XIAP O 
) O 
protein O 
. O 
Lead O 
optimization O 
of O 
this O 
scaffold O 
to O 
improve O 
oral O 
absorption O 
yielded O 
compound O 
45 O 
, O 
which O 
showed O 
potent O 
cellular O 
IAP1 O 
( O 
cIAP1 O 
IC(50) O 
: O 
1.3 O 
nM O 
) O 
and O 
XIAP O 
( O 
IC(50) O 
: O 
200 O 
nM O 
) O 
inhibitory O 
activity O 
, O 
in O 
addition O 
to O 
potent O 
tumor O 
growth O 
inhibitory O 
activity O 
( O 
GI(50) O 
: O 
1.8 O 
nM O 
) O 
in O 
MDA-MB-231 O 
breast O 
cancer O 
cells O 
. O 
X-ray O 
crystallographic O 
analysis O 
of O 
compound O 
45 O 
bound O 
to O 
XIAP O 
and O 
to O 
cIAP1 O 
was O 
achieved O 
, O 
revealing O 
the O 
various O 
key O 
interactions O 
that O 
contribute O 
to O 
the O 
higher O 
cIAPI O 
affinity O 
of O 
compound O 
45 O 
over O 
XIAP O 
. O 
Because O 
of O 
its O 
potent O 
IAP O 
inhibitory O 
activities O 
, O 
compound O 
45 O 
( O 
T-3256336 B-IDENTIFIER 
) O 
caused O 
tumor O 
regression O 
in O 
a O 
MDA-MB-231 O 
tumor O 
xenograft O 
model O 
( O 
T O 
/ O 
C O 
: O 
-53% O 
at O 
30 O 
mg O 
/ O 
kg O 
) O 
. O 

diseases O 
remain O 
the O 
leading O 
cause O 
of O 
morbidity O 
and O 
mortality O 
worldwide O 
. O 
Heart O 
functions O 
are O 
regulated O 
by O 
autonomic O 
nervous O 
systems O 
through O 
their O 
transmitters O 
and O 
modulators O 
, O 
binding O 
to O 
cell O 
surface O 
receptors O 
. O 
Among O 
them O 
, O 
the O 
cardiac O 
M(3) O 
muscarinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
M(3)-mAChR O 
) O 
has O 
been O 
studied O 
for O 
more O 
than O 
2 O 
decades O 
since O 
its O 
first O 
discovery O 
in O 
mammalian O 
heart O 
in O 
1990s O 
. O 
The O 
location O 
and O 
pathophysiological O 
role O 
of O 
M(3)-mAChR O 
in O 
the O 
cardiovascular O 
system O 
have O 
been O 
extensively O 
studied O 
and O 
many O 
pathways O 
involved O 
have O 
been O 
uncovered O 
. O 
Gain- O 
and O 
loss O 
- O 
of O 
- O 
function O 
studies O 
have O 
revealed O 
the O 
ubiquitous O 
roles O 
of O 
M(3)-mAChR O 
in O 
physiological O 
and O 
pathological O 
conditions O 
. O 
Recently O 
, O 
many O 
new O 
findings O 
have O 
been O 
uncovered O 
about O 
the O 
relationship O 
between O 
M(3)-mAChR O 
and O 
cardiac O 
diseases O 
, O 
including O 
cardiac O 
ischemia O 
, O 
pathological O 
cardiac O 
hypertrophy O 
, O 
cardiac O 
arrhythmias O 
, O 
cardiac O 
conduction O 
and O 
heart O 
failure O 
. O 
Furthermore O 
, O 
the O 
novel O 
potential O 
cardioprotective O 
role O 
of O 
M(3)-mAChR O 
against O 
heart O 
injury O 
by O 
regulation O 
of O 
microRNAs O 
( O 
miRNAs O 
) O 
has O 
been O 
revealed O 
in O 
the O 
most O 
updated O 
research O 
. O 
In O 
this O 
review O 
, O 
the O 
current O 
new O 
findings O 
on O 
the O 
role O 
of O 
M(3)-mAChR O 
in O 
heart O 
diseases O 
are O 
updated O 
, O 
the O 
downstream O 
signaling O 
pathways O 
are O 
summarized O 
, O 
perspectives O 
and O 
challenges O 
of O 
M(3)-mAChR O 
as O 
therapeutic O 
targets O 
are O 
discussed O 
. O 

of O 
proline B-TRIVIAL 
analogues O 
as O 
potent O 
and O 
selective O 
cathepsin O 
S O 
inhibitors O 
. O 

S O 
is O 
a O 
potential O 
target O 
of O 
autoimmune O 
disease O 
. O 
A O 
series O 
of O 
proline B-TRIVIAL 
derived O 
compounds O 
were O 
synthesized O 
and O 
evaluated O 
as O 
cathepsin O 
S O 
inhibitors O 
. O 
We O 
discovered O 
potent O 
cathepsin O 
S O 
inhibitors O 
through O 
structure O 
- O 
activity O 
relationship O 
studies O 
of O 
proline B-TRIVIAL 
analogues O 
. O 
In O 
particular O 
, O 
compound O 
19-(S) O 
showed O 
promising O 
in O 
vitro O 
/ O 
vivo O 
pharmacological O 
activities O 
and O 
properties O 
as O 
a O 
selective O 
cathepsin O 
S O 
inhibitor O 
. O 

: O 
The O 
dynorphin O 
( O 
DYN O 
) O 
/ O 
kappa O 
opioid O 
receptor O 
( O 
KOR O 
) O 
system O 
is O 
involved O 
in O 
the O 
dysphoric O 
properties O 
of O 
drugs O 
of O 
abuse O 
. O 
Given O 
that O 
adolescents O 
show O 
reduced O 
sensitivity O 
to O 
aversive O 
effects O 
of O 
many O 
drugs O 
, O 
alterations O 
in O 
the O 
DYN O 
/ O 
KOR O 
system O 
may O 
contribute O 
to O 
the O 
prevalence O 
of O 
drug O 
use O 
during O 
adolescence O 
. O 
OBJECTIVES O 
: O 
The O 
present O 
study O 
was O 
designed O 
to O 
assess O 
dysphoric O 
properties O 
of O 
a O 
selective O 
kappa O 
agonist O 
, O 
U62,066 B-IDENTIFIER 
, O 
in O 
adolescent O 
and O 
adult O 
rats O 
using O 
both O 
conditioned O 
taste O 
aversion O 
( O 
CTA O 
) O 
and O 
conditioned O 
place O 
aversion O 
( O 
CPA O 
) O 
paradigms O 
. O 
METHODS O 
: O 
For O 
CTA O 
, O 
water O 
- O 
restricted O 
rats O 
were O 
administered O 
U62,066 B-IDENTIFIER 
following O 
30 O 
min O 
access O 
to O 
a O 
saccharin B-TRIVIAL 
solution O 
, O 
with O 
subsequent O 
saccharin B-TRIVIAL 
consumption O 
used O 
to O 
index O 
aversion O 
. O 
For O 
CPA O 
, O 
animals O 
were O 
allowed O 
access O 
to O 
both O 
compartments O 
of O 
a O 
two O 
- O 
compartment O 
chamber O 
for O 
a O 
15-min O 
pre- O 
and O 
post O 
- O 
conditioning O 
test O 
. O 
For O 
conditioning O 
, O 
subjects O 
were O 
administered O 
U62,066 B-IDENTIFIER 
prior O 
to O 
confinement O 
to O 
one O 
side O 
of O 
the O 
chamber O 
and O 
saline O 
prior O 
to O 
confinement O 
to O 
the O 
other O 
side O 
for O 
a O 
total O 
of O 
four O 
pairings O 
. O 
RESULTS O 
: O 
Overall O 
, O 
adolescents O 
displayed O 
reduced O 
sensitivity O 
to O 
the O 
kappa O 
agonist O 
relative O 
to O 
adults O 
. O 
Adults O 
demonstrated O 
taste O 
aversions O 
to O 
the O 
0.2 O 
and O 
0.3 O 
mg O 
/ O 
kg O 
doses O 
of O 
U62,066 B-IDENTIFIER 
, O 
whereas O 
adolescents O 
did O 
not O 
display O 
aversions O 
to O 
any O 
tested O 
doses O 
. O 
Adults O 
demonstrated O 
a O 
place O 
aversion O 
to O 
the O 
0.1 O 
and O 
0.2 O 
mg O 
/ O 
kg O 
dose O 
of O 
U62,066 B-IDENTIFIER 
when O 
paired O 
with O 
the O 
preferred O 
side O 
of O 
the O 
conditioning O 
chamber O 
. O 
Adolescents O 
did O 
not O 
display O 
aversions O 
to O 
any O 
of O 
the O 
doses O 
tested O 
. O 
CONCLUSIONS O 
: O 
Reduced O 
sensitivity O 
to O 
DYN O 
/ O 
KOR O 
system O 
activation O 
during O 
adolescence O 
may O 
be O 
a O 
contributing O 
factor O 
to O 
the O 
age O 
- O 
typical O 
insensitivity O 
to O 
aversive O 
properties O 
of O 
drugs O 
commonly O 
abused O 
by O 
adolescents O 
. O 

pneumoniae O 
endonuclease O 
IV O 
prefers O 
to O 
remove O 
mismatched O 
3 B-FAMILY 
' I-FAMILY 
ribonucleotides I-FAMILY 
: O 
implication O 
in O 
proofreading O 
mismatched O 
3'- O 
terminal O 
nucleotides B-FAMILY 
in O 
short O 
- O 
patch O 
repair O 
synthesis O 
. O 

polymerase O 
I O 
( O 
DNApolI O 
) O 
catalyzes O 
DNA O 
synthesis O 
during O 
Okazaki O 
fragment O 
maturation O 
, O 
base O 
excision O 
repair O 
, O 
and O 
nucleotide B-FAMILY 
excision O 
repair O 
. O 
Some O 
bacterial O 
DNApolIs O 
are O 
deficient O 
in O 
3'-5 O 
' O 
exonuclease O 
, O 
which O 
is O 
required O 
for O 
removing O 
an O 
incorrectly O 
incorporated O 
3'- O 
terminal O 
nucleotide B-FAMILY 
during O 
DNA O 
elongation O 
by O 
DNA O 
polymerase O 
activity O 
. O 
The O 
key O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
in O 
the O 
exonuclease O 
center O 
of O 
Chlamydophila O 
pneumoniae O 
DNApolI O 
( O 
CpDNApolI O 
) O 
are O 
naturally O 
mutated O 
, O 
resulting O 
in O 
the O 
loss O 
of O 
3'-5 O 
' O 
exonuclease O 
. O 
Hence O 
, O 
the O 
manner O 
by O 
which O 
CpDNApolI O 
proofreads O 
the O 
incorrectly O 
incorporated O 
nucleotide B-FAMILY 
during O 
DNA O 
synthesis O 
warrants O 
clarification O 
. O 
C O 
. O 
pneumoniae O 
encodes O 
three O 
3'-5 O 
' O 
exonuclease O 
activities O 
: O 
one O 
endonuclease O 
IV O 
and O 
two O 
homologs O 
of O 
the O 
epsilon O 
subunit O 
of O 
replicative O 
DNA O 
polymerase O 
III O 
. O 
The O 
three O 
proteins O 
were O 
biochemically O 
characterized O 
using O 
single- O 
and O 
double O 
- O 
stranded O 
DNA O 
substrate O 
. O 
Among O 
them O 
, O 
C O 
. O 
pneumoniae O 
endonuclease O 
IV O 
( O 
CpendoIV O 
) O 
possesses O 
3'-5 O 
' O 
exonuclease O 
activity O 
that O 
prefers O 
to O 
remove O 
mismatched O 
3'- O 
terminal O 
nucleotides B-FAMILY 
in O 
the O 
nick O 
, O 
gap O 
, O 
and O 
3 O 
' O 
recess O 
of O 
a O 
double O 
- O 
stranded O 
DNA O 
( O 
dsDNA O 
) O 
. O 
Finally O 
, O 
we O 
reconstituted O 
the O 
proofreading O 
reaction O 
of O 
the O 
mismatched O 
3'- O 
terminal O 
nucleotide B-FAMILY 
using O 
the O 
dsDNA O 
with O 
a O 
nick O 
or O 
3 O 
' O 
recess O 
as O 
substrate O 
. O 
Upon O 
proofreading O 
of O 
the O 
mismatched O 
3'- O 
terminal O 
nucleotide B-FAMILY 
by O 
CpendoIV O 
, O 
CpDNApolI O 
can O 
correctly O 
reincorporate O 
the O 
matched O 
nucleotide B-FAMILY 
and O 
the O 
nick O 
is O 
further O 
sealed O 
by O 
DNA O 
ligase O 
. O 
Based O 
on O 
our O 
biochemical O 
results O 
, O 
we O 
proposed O 
that O 
CpendoIV O 
was O 
responsible O 
for O 
proofreading O 
the O 
replication O 
errors O 
of O 
CpDNApolI O 
. O 

compound O 
esterase O 
profiles O 
as O 
predictors O 
of O 
therapeutic O 
and O 
toxic O 
effects O 
. O 

organophosphorus B-FAMILY 
compounds O 
( O 
OPCs O 
) O 
inhibit O 
various O 
serine B-TRIVIAL 
esterases O 
( O 
EOHs O 
) O 
via O 
phosphorylation O 
of O 
their O 
active O 
site O 
serines B-FAMILY 
. O 
We O 
focused O 
on O 
4 O 
EOHs O 
of O 
particular O 
toxicological O 
interest O 
: O 
acetylcholinesterase O 
( O 
AChE O 
: O 
acute O 
neurotoxicity O 
; O 
cognition O 
enhancement O 
) O 
, O 
butyrylcholinesterase O 
( O 
BChE O 
: O 
inhibition O 
of O 
drug O 
metabolism O 
and O 
/ O 
or O 
stoichiometric O 
scavenging O 
of O 
EOH O 
inhibitors O 
; O 
cognition O 
enhancement O 
) O 
, O 
carboxylesterase O 
( O 
CaE O 
: O 
inhibition O 
of O 
drug O 
metabolism O 
and O 
/ O 
or O 
stoichiometric O 
scavenging O 
of O 
EOH O 
inhibitors O 
) O 
, O 
and O 
neuropathy O 
target O 
esterase O 
( O 
NTE O 
: O 
delayed O 
neurotoxicity O 
, O 
OPIDN O 
) O 
. O 
The O 
relative O 
degree O 
of O 
inhibition O 
of O 
these O 
EOHs O 
constitutes O 
the O 
" O 
esterase O 
profile O 
" O 
of O 
an O 
OPC O 
and O 
serves O 
as O 
a O 
major O 
determinant O 
of O 
its O 
net O 
physiological O 
effects O 
. O 
Thus O 
, O 
understanding O 
and O 
controlling O 
the O 
esterase O 
profile O 
of O 
OPC O 
activity O 
and O 
selectivity O 
toward O 
these O 
4 O 
target O 
enzymes O 
is O 
a O 
significant O 
undertaking O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
analyzed O 
the O 
inhibitor O 
properties O 
of O 
52 O 
OPCs O 
against O 
the O 
4 O 
EOHs O 
, O 
along O 
with O 
pairwise O 
and O 
multitarget O 
selectivities O 
between O 
them O 
, O 
using O 
2 O 
QSAR O 
approaches O 
: O 
Hansch O 
modeling O 
and O 
Molecular O 
Field O 
Topology O 
Analysis O 
( O 
MFTA O 
) O 
. O 
The O 
general O 
formula O 
of O 
the O 
OPCs O 
was O 
(RO)2P(O)X B-FAMILY 
, O 
where O 
R= O 
alkyl B-FAMILY 
, O 
X=- O 
SCH(Hal)COOEt B-FAMILY 
( O 
Hal B-ABBREVIATION 
= O 
Cl B-FORMULA 
, O 
Br B-FORMULA 
) O 
, O 
- O 
SCHCl2 B-FORMULA 
, O 
- O 
SCH2Br B-FORMULA 
, O 
- O 
OCH(CF3)R(1) B-FAMILY 
( O 
R(1)= O 
C6H5 B-FORMULA 
, O 
CF3 B-FORMULA 
, O 
COOEt B-FORMULA 
, O 
COOMe B-FORMULA 
) O 
. O 
The O 
Hansch O 
model O 
showed O 
that O 
increasing O 
neuropathic O 
potential O 
correlated O 
with O 
rising O 
R O 
hydrophobicity O 
; O 
moreover O 
, O 
OPC O 
binding O 
to O 
scavenger O 
EOHs O 
( O 
BChE O 
and O 
CaE O 
) O 
had O 
different O 
effects O 
on O 
potential O 
acute O 
and O 
delayed O 
neurotoxicity O 
. O 
Predicted O 
protective O 
roles O 
of O 
BChE O 
and O 
CaE O 
against O 
acute O 
toxicity O 
were O 
enhanced O 
with O 
increasing O 
hydrophobicity O 
, O 
but O 
projected O 
protection O 
against O 
OPIDN O 
was O 
decreased O 
. O 
Next O 
, O 
Molecular O 
Field O 
Topology O 
Analysis O 
( O 
MFTA O 
) O 
models O 
were O 
built O 
, O 
considering O 
atomic O 
descriptors O 
, O 
e.g O 
. O 
, O 
effective O 
charge O 
, O 
van O 
der O 
Waals O 
radius O 
of O 
environment O 
, O 
and O 
group O 
lipophilicity O 
. O 
Activity O 
/ O 
selectivity O 
maps O 
confirmed O 
predictions O 
from O 
Hansch O 
models O 
and O 
revealed O 
other O 
structural O 
factors O 
affecting O 
activity O 
and O 
selectivity O 
. O 
Virtual O 
screening O 
based O 
on O 
multitarget O 
selectivity O 
MFTA O 
models O 
was O 
used O 
to O 
design O 
libraries O 
of O 
OPCs O 
with O 
favorable O 
esterase O 
profiles O 
for O 
potential O 
application O 
as O 
selective O 
inhibitors O 
of O 
CaE O 
without O 
untoward O 
side O 
effects O 
. O 

activity O 
and O 
nutritional O 
quality O 
of O 
traditional O 
red O 
- O 
grained O 
rice O 
varieties O 
containing O 
proanthocyanidins B-FAMILY 
. O 

-containing O 
rice O 
varieties O 
have O 
been O 
rarely O 
reported O 
. O 
Antioxidant O 
capacity O 
, O 
major O 
antioxidant O 
components O 
, O 
and O 
nutritional O 
parameters O 
of O 
eight O 
traditional O 
red O 
- O 
grained O 
rice O 
varieties O 
containing O 
proanthocyanidins B-FAMILY 
grown O 
in O 
Sri O 
Lanka O 
were O 
investigated O 
. O 
The O 
tested O 
traditional O 
red O 
varieties O 
, O 
on O 
the O 
average O 
, O 
had O 
over O 
sevenfold O 
higher O 
both O 
total O 
antioxidant O 
capacity O 
and O 
phenolic O 
content O 
than O 
three O 
light O 
brown O 
- O 
grained O 
new O 
- O 
improved O 
rice O 
varieties O 
. O 
Major O 
antioxidant O 
phenolic B-FAMILY 
compounds O 
identified O 
in O 
this O 
study O 
included O 
proanthocyanidins B-FAMILY 
, O 
phenolic B-FAMILY 
acids I-FAMILY 
and O 
γ-oryzanols B-FAMILY 
( O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
) O 
. O 
Proanthocyanidins B-FAMILY 
were O 
detected O 
only O 
in O 
the O 
traditional O 
red O 
varieties O 
, O 
but O 
not O 
found O 
in O 
new O 
- O 
improved O 
ones O 
. O 
Most O 
traditional O 
red O 
varieties O 
also O 
contained O 
significantly O 
higher O 
levels O 
of O 
protein O 
with O 
well O 
balanced O 
amino B-FAMILY 
acids I-FAMILY 
and O 
higher O 
contents O 
of O 
fat O 
, O 
fibre O 
and O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
tocopherols B-FAMILY 
and O 
tocotrienols B-FAMILY 
) O 
than O 
the O 
new O 
- O 
improved O 
ones O 
. O 
Great O 
variations O 
in O 
antioxidant O 
capacity O 
, O 
major O 
phenolics B-FAMILY 
, O 
and O 
nutritional O 
parameters O 
were O 
observed O 
among O 
different O 
rice O 
varieties O 
. O 
These O 
Sri O 
Lankan O 
traditional O 
red O 
- O 
grained O 
rice O 
varieties O 
containing O 
proanthocyanidins B-FAMILY 
may O 
be O 
used O 
as O 
important O 
genetic O 
sources O 
for O 
rice O 
breeding O 
. O 

lateral O 
sclerosis O 
( O 
ALS O 
) O 
is O 
a O 
neurodegenerative O 
progressive O 
currently O 
untreatable O 
disease O 
, O 
characterized O 
by O 
selective O 
motor O 
neuron O 
degeneration O 
; O 
the O 
incidence O 
and O 
prevalence O 
of O 
ALS O 
are O 
greater O 
in O 
men O 
than O 
in O 
women O 
. O 
Although O 
some O 
important O 
mechanisms O 
that O 
might O 
contribute O 
to O 
the O 
death O 
of O 
motor O 
neurons O 
have O 
been O 
identified O 
, O 
the O 
mechanisms O 
underlying O 
disease O 
pathophysiology O 
are O 
still O 
uncertain O 
. O 
In O 
particular O 
, O 
the O 
mechanisms O 
underlying O 
the O 
role O 
of O 
gender O 
in O 
ALS O 
and O 
whether O 
treatments O 
should O 
take O 
into O 
account O 
sexual O 
dimorphism O 
remain O 
only O 
partially O 
understood O 
. O 
Recently O 
, O 
the O 
P2X7 O 
receptor O 
for O 
ATP B-ABBREVIATION 
was O 
reported O 
to O 
display O 
neurotoxic O 
potential O 
in O 
motor O 
neuron O 
disorders O 
, O 
and O 
antagonism O 
of O 
the O 
receptor O 
has O 
been O 
suggested O 
to O 
be O 
helpful O 
in O 
these O 
disorders O 
. O 
Studying O 
transgenic O 
mice O 
with O 
superoxide B-TRIVIAL 
dismutase O 
1 O 
gene O 
mutations O 
, O 
widely O 
used O 
as O 
model O 
for O 
ALS O 
, O 
may O 
provide O 
a O 
better O 
understanding O 
of O 
pathogenic O 
mechanisms O 
and O 
of O 
toxicity O 
towards O 
motor O 
neurons O 
, O 
also O 
possibly O 
helping O 
to O 
understand O 
whether O 
treatments O 
for O 
ALS O 
should O 
take O 
into O 
account O 
sexual O 
dimorphism O 
. O 
The O 
aim O 
of O 
the O 
work O 
was O 
( O 
1 O 
) O 
investigating O 
on O 
gender O 
- O 
dependence O 
of O 
disease O 
progression O 
in O 
the O 
standard O 
model O 
for O 
ALS O 
- O 
the O 
transgenic O 
mouse O 
bearing O 
superoxide B-TRIVIAL 
dismutase O 
1 O 
gene O 
mutations O 
- O 
and O 
( O 
2 O 
) O 
assessing O 
if O 
a O 
P2X7 O 
receptor O 
antagonist O 
treatment O 
should O 
take O 
into O 
account O 
sexual O 
dimorphism O 
. O 
We O 
evaluated O 
if O 
gender O 
affect O 
the O 
disease O 
course O 
, O 
the O 
motor O 
performance O 
, O 
the O 
weight O 
loss O 
and O 
the O 
lifespan O 
in O 
mice O 
overexpressing O 
mutant O 
superoxide B-TRIVIAL 
dismutase O 
1 O 
. O 
We O 
measured O 
motor O 
impairment O 
, O 
motor O 
strength O 
and O 
coordination O 
by O 
rotarod O 
and O 
grip O 
strength O 
testing O 
. O 
Further O 
, O 
we O 
assessed O 
if O 
a O 
treatment O 
with O 
the O 
P2X7 O 
receptor O 
antagonist O 
Brilliant B-TRIVIAL 
Blue I-TRIVIAL 
G I-TRIVIAL 
- O 
a O 
dye O 
that O 
can O 
cross O 
the O 
blood O 
- O 
brain O 
barrier O 
, O 
has O 
low O 
toxicity O 
, O 
and O 
has O 
exhibited O 
therapeutic O 
effects O 
in O 
animal O 
models O 
of O 
neurodegenerative O 
diseases O 
- O 
impact O 
on O 
the O 
disease O 
progression O 
, O 
in O 
male O 
and O 
female O 
ALS O 
mice O 
. O 
We O 
found O 
that O 
( O 
1 O 
) O 
the O 
onset O 
and O 
the O 
disease O 
progression O 
, O 
and O 
the O 
survival O 
were O 
dependent O 
on O 
gender O 
: O 
male O 
performed O 
worst O 
than O 
female O 
, O 
lost O 
body O 
weight O 
and O 
died O 
before O 
; O 
( O 
2 O 
) O 
treatment O 
with O 
the O 
P2X7 O 
receptor O 
antagonist O 
Brilliant B-TRIVIAL 
Blue I-TRIVIAL 
G I-TRIVIAL 
ameliorated O 
the O 
disease O 
progression O 
. O 
The O 
treatment O 
effect O 
was O 
gender O 
- O 
dependent O 
: O 
amelioration O 
was O 
greater O 
in O 
male O 
than O 
in O 
female O 
. O 
In O 
conclusions O 
, O 
we O 
suggest O 
that O 
not O 
only O 
pathogenetic O 
mechanism O 
of O 
motor O 
neuron O 
toxicity O 
but O 
also O 
the O 
drug O 
treatment O 
effectiveness O 
may O 
depend O 
on O 
gender O 
; O 
sexual O 
dimorphism O 
should O 
be O 
considered O 
when O 
investigating O 
on O 
ALS O 
treatment O 
efficacy O 
in O 
the O 
ALS O 
animal O 
model O 
. O 
Our O 
findings O 
also O 
point O 
on O 
the O 
potential O 
relevance O 
of O 
P2X7 O 
receptor O 
antagonism O 
for O 
ALS O 
treatment O 
, O 
and O 
highlight O 
the O 
importance O 
of O 
adopting O 
a O 
sex O 
- O 
specific O 
approach O 
to O 
searching O 
for O 
treatment O 
of O 
ALS O 
. O 

radicals O 
: O 
free O 
radical O 
reactions O 
in O 
two O 
dimensions O 
: O 
a O 
case O 
study O 
on O 
photochlorination O 
of O 
graphene B-TRIVIAL 
( O 
small O 
8 O 
/ O 
2013 O 
) O 
. O 

is O 
a O 
2D O 
giant O 
polycyclic O 
aromatic O 
molecule O 
that O 
provides O 
opportunities O 
for O 
studying O 
chemical O 
reactions O 
in O 
two O 
dimensions O 
. O 
H O 
. O 
Peng O 
, O 
Z O 
. O 
Liu O 
, O 
and O 
co O 
- O 
workers O 
have O 
systematically O 
investigated O 
the O 
influence O 
of O 
specific O 
features O 
of O 
2D O 
molecules O 
, O 
such O 
as O 
their O 
thickness O 
, O 
stacking O 
order O 
, O 
single- O 
and O 
double O 
- O 
side O 
upon O 
graphene B-TRIVIAL 
' O 
s O 
radical O 
reactivity O 
by O 
utilizing O 
a O 
free O 
radical O 
photochlorination O 
as O 
a O 
probe O 
. O 
The O 
result O 
, O 
described O 
on O 
page O 
1388 O 
, O 
can O 
contribute O 
to O 
a O 
deeper O 
understanding O 
of O 
dimensionality O 
effects O 
for O 
the O 
chemistry O 
of O 
2D O 
graphene B-TRIVIAL 
. O 

E I-TRIVIAL 
, O 
a O 
new O 
bioactive O 
C-methylated B-FAMILY 
biflavonoid I-FAMILY 
from O 
the O 
roots O 
of O 
Baeckea O 
frutescens O 
. O 

phytochemical O 
study O 
of O 
Baeckea O 
frutescens O 
afforded O 
a O 
new O 
biflavonoid B-FAMILY 
named O 
as O 
baeckein B-TRIVIAL 
E I-TRIVIAL 
( O 
1 O 
) O 
, O 
along O 
with O 
four O 
known O 
C-methylated B-FAMILY 
flavonols I-FAMILY 
, O 
baeckeins B-NO_CLASS 
A I-NO_CLASS 
( O 
2 O 
) O 
and O 
B O 
( O 
3 O 
) O 
, O 
6-methylquercetin B-SYSTEMATIC 
( O 
6 O 
) O 
and O 
6-methylquercetin-4'-O-β-d-glucopyranoside B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
and O 
two O 
known O 
biflavonoids O 
baeckeins B-NO_CLASS 
C I-NO_CLASS 
( O 
4 O 
) O 
and O 
D O 
( O 
5 O 
) O 
. O 
The O 
structure O 
of O 
compound O 
1 O 
was O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
analysis O 
, O 
including O 
HR-ESI-MS O 
, O 
1D O 
and O 
2D O 
NMR O 
spectra O 
, O 
and O 
the O 
absolute O 
configurations O 
of O 
C-2 O 
and O 
C-3 O 
for O 
compound O 
1 O 
were O 
assigned O 
by O 
circular O 
dichroism O 
spectrometry O 
combined O 
with O 
quantum O 
chemical O 
calculations O 
. O 
The O 
antioxidant O 
and O 
cytoprotective O 
activities O 
of O 
compounds O 
1-7 O 
were O 
also O 
investigated O 
. O 

Graphene B-TRIVIAL 
Foams O 
Cross O 
- O 
linked O 
with O 
Pre O 
- O 
encapsulated O 
Fe3 B-FORMULA 
O4 I-FORMULA 
Nanospheres O 
for O 
Enhanced O 
Lithium B-SYSTEMATIC 
Storage O 
. O 

assembly O 
between O 
Fe3 B-FORMULA 
O4 I-FORMULA 
nanospheres O 
and O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
and O 
subsequent O 
hydrothermal O 
assembly O 
with O 
additional O 
graphene B-TRIVIAL 
sheets O 
, O 
leads O 
to O 
Fe3 B-FORMULA 
O4 I-FORMULA 
nanospheres O 
encapsulated O 
in O 
the O 
graphene B-TRIVIAL 
shells O 
and O 
interconnected O 
by O 
the O 
graphene B-TRIVIAL 
networks O 
. O 
Such O 
3D O 
Fe3 B-FORMULA 
O4 I-FORMULA 
/ O 
graphene B-TRIVIAL 
foams O 
exhibit O 
enhanced O 
lithium B-SYSTEMATIC 
storage O 
with O 
excellent O 
cycling O 
performance O 
and O 
rate O 
capability O 
. O 

induces O 
programmed O 
necrosis O 
- O 
like O 
cell O 
death O 
through O 
the O 
formation O 
of O 
receptor O 
interacting O 
protein O 
1 O 
and O 
3 O 
complex O 
. O 

alternative O 
cell O 
demise O 
programmed O 
necrosis O 
has O 
also O 
been O 
proposed O 
when O 
apoptotic O 
machinery O 
is O 
impaired O 
or O 
blocked O 
during O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNFα O 
) O 
stimulation O 
. O 
Shikonin B-TRIVIAL 
( O 
SKN B-ABBREVIATION 
) O 
, O 
an O 
herbal O 
extract O 
from O 
the O 
Chinese O 
plant O 
, O 
has O 
been O 
reported O 
to O 
induce O 
either O 
apoptosis O 
or O 
necrosis O 
depending O 
on O 
cell O 
types O 
or O 
its O 
concentrations O 
. O 
In O 
this O 
presentation O 
, O 
SKN B-ABBREVIATION 
caused O 
cell O 
death O 
of O 
NIH3T3 O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Intriguingly O 
, O 
SKN B-ABBREVIATION 
-mediated O 
cell O 
death O 
was O 
in O 
part O 
protected O 
by O 
necrostatin-1 B-TRIVIAL 
( O 
Nec-1 B-ABBREVIATION 
) O 
, O 
a O 
specific O 
inhibitor O 
of O 
programmed O 
necrosis O 
, O 
but O 
not O 
zVAD O 
a O 
pan O 
- O 
caspase O 
inhibitor O 
. O 
SKN B-ABBREVIATION 
directly O 
mediated O 
cell O 
death O 
via O 
receptor O 
interacting O 
protein1 O 
and O 
3 O 
( O 
RIP1-RIP3 O 
) O 
complex O 
formation O 
, O 
which O 
is O 
required O 
for O 
TNFα O 
- O 
mediated O 
programmed O 
necrosis O 
. O 
Additionally O 
, O 
SKN B-ABBREVIATION 
-caused O 
cell O 
death O 
was O 
reversed O 
by O 
a O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
scavenger O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
whereas O 
TNFα O 
- O 
mediated O 
necrosis O 
was O 
successfully O 
protected O 
by O 
butylated B-SYSTEMATIC 
hydroxyanisole I-SYSTEMATIC 
( O 
BHA B-ABBREVIATION 
) O 
, O 
implying O 
that O 
ROS O 
may O 
be O 
differentially O 
derived O 
from O 
death O 
inducing O 
agents O 
. O 
Concurrently O 
with O 
the O 
protective O 
effect O 
of O 
the O 
ROS O 
scavenger O 
or O 
Nec-1 B-ABBREVIATION 
on O 
TNFα O 
or O 
SKN O 
, O 
the O 
RIP1-RIP3 O 
complex O 
was O 
significantly O 
affected O 
in O 
the O 
presence O 
of O 
those O 
agents O 
. O 
Here O 
, O 
it O 
is O 
highlighted O 
that O 
SKN B-ABBREVIATION 
as O 
well O 
as O 
TNFα O 
can O 
directly O 
mediate O 
cell O 
death O 
via O 
a O 
pronecrotic O 
complex O 
, O 
but O 
ROS O 
were O 
generated O 
via O 
different O 
routes O 
depending O 
on O 
cell O 
death O 
- O 
inducing O 
agents O 
. O 

of O 
neuraminidase O 
inhibitory O 
polyphenols B-FAMILY 
from O 
the O 
seeds O 
of O 
Paeonia O 
lactiflora O 
. O 

neuraminidase O 
( O 
nan O 
) O 
is O 
a O 
lynch O 
pin O 
enzyme O 
in O 
the O 
formation O 
of O 
biofilms O 
. O 
Thus O 
nan O 
continues O 
to O 
be O 
one O 
of O 
the O 
key O 
enzymes O 
targeted O 
by O 
bacterial O 
infection O 
. O 
The O 
purpose O 
of O 
this O 
manuscript O 
is O 
to O 
communicate O 
four O 
new O 
naturally O 
derived O 
inhibitors O 
of O 
neuraminidase O 
( O 
IC50s O 
3.7-24.4μM O 
) O 
. O 
All O 
these O 
active O 
species O 
( O 
1-4 O 
) O 
contained O 
a O 
resveratrol B-TRIVIAL 
chemotype O 
, O 
however O 
resveratrol B-TRIVIAL 
itself O 
was O 
inactive O 
( O 
IC50 O 
> O 
100μM O 
) O 
. O 
1-4 O 
were O 
isolated O 
from O 
the O 
60% O 
aqueous O 
ethanol B-SYSTEMATIC 
extract O 
of O 
seeds O 
of O 
Paeonia O 
lactiflora O 
, O 
which O 
exhibited O 
potent O 
neuraminidase O 
inhibition O 
. O 
Purification O 
of O 
the O 
extracts O 
yielded O 
four O 
chiral O 
polyphenols B-FAMILY 
, O 
suffruticosol B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
suffruticosol B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
trans-ε-viniferin B-TRIVIAL 
( O 
3 O 
) O 
, O 
and O 
trans-gnetin B-TRIVIAL 
H I-TRIVIAL 
( O 
4 O 
) O 
. O 
Mechanistic O 
analysis O 
of O 
1-4's O 
inhibition O 
showed O 
that O 
they O 
were O 
all O 
reversible O 
, O 
noncompetitive O 
inhibitors O 
. O 
Trans-ε-viniferin B-TRIVIAL 
( O 
3 O 
) O 
underwent O 
trans-cis O 
isomerization O 
, O 
which O 
led O 
to O 
a O 
reduction O 
in O 
inhibition O 
potency O 
. O 
This O 
correlates O 
with O 
the O 
fact O 
that O 
the O 
cis- O 
isomer O 
is O 
a O 
weaker O 
inhibitor O 
of O 
neuraminidase O 
than O 
the O 
trans- O 
isomer O 
. O 
Importantly O 
, O 
significantly O 
different O 
optical O 
rotations O 
( O 
[α]D O 
) O 
compared O 
to O 
previous O 
reports O 
were O 
found O 
for O 
suffruticosols B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
+ I-MULTIPLE 
95 I-MULTIPLE 
vs I-MULTIPLE 
-34 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
+ O 
136 O 
vs O 
+ O 
13 O 
) O 
. O 
These O 
two O 
species O 
are O 
the O 
most O 
important O 
standard O 
metabolites O 
in O 
the O 
whole O 
paeoniaceae O 
family O 
and O 
therefore O 
correction O 
of O 
this O 
error O 
is O 
important O 
. O 

linker O 
system O 
enhancing O 
the O 
aqueous O 
solubility O 
of O 
a O 
molecular O 
probe O 
and O 
its O 
efficiency O 
in O 
affinity O 
labeling O 
of O 
a O 
target O 
protein O 
for O 
jasmonate B-TRIVIAL 
glucoside I-TRIVIAL 
. O 

methods O 
employing O 
molecular O 
probes O 
to O 
explore O 
the O 
targets O 
of O 
bioactive O 
small O 
molecules O 
, O 
long O 
or O 
rigid O 
linker O 
moieties O 
are O 
thought O 
to O 
be O 
critical O 
factors O 
for O 
efficient O 
tagging O 
of O 
target O 
protein O 
. O 
We O 
previously O 
reported O 
the O 
synthesis O 
of O 
a O 
jasmonate B-TRIVIAL 
glucoside I-TRIVIAL 
probe O 
with O 
a O 
highly O 
rigid O 
linker O 
consisting O 
of O 
a O 
triazoyl-phenyl B-SYSTEMATIC 
( O 
TAzP B-ABBREVIATION 
) O 
moiety O 
, O 
and O 
this O 
probe O 
demonstrated O 
effective O 
target O 
tagging O 
. O 
Here O 
we O 
compare O 
the O 
TAzP B-ABBREVIATION 
probe O 
with O 
other O 
rigid O 
or O 
flexible O 
probes O 
with O 
respect O 
to O 
target O 
tagging O 
efficiency O 
, O 
hydrophobic O 
parameters O 
, O 
aqueous O 
solubility O 
, O 
and O 
dihedral O 
angles O 
around O 
the O 
biaryl B-FAMILY 
linkage O 
by O 
a O 
combination O 
of O 
empirical O 
and O 
calculation O 
methods O 
. O 
The O 
rigid O 
biaryl B-FAMILY 
linkage O 
of O 
the O 
TAzP B-ABBREVIATION 
probe O 
has O 
a O 
skewed O 
conformation O 
that O 
influences O 
its O 
aqueous O 
solubility O 
. O 
Such O 
features O 
that O 
include O 
rigidness O 
and O 
good O 
aqueous O 
solubility O 
resulted O 
in O 
highly O 
efficient O 
target O 
tagging O 
. O 
These O 
findings O 
provide O 
a O 
promising O 
guideline O 
toward O 
designing O 
of O 
better O 
linkers O 
for O 
improving O 
molecular O 
probe O 
performance O 
. O 

B O 
virus O 
and O 
anti-cancer O 
activities O 
of O 
novel O 
isoflavone B-FAMILY 
analogs O 
. O 

have O 
synthesized O 
a O 
series O 
of O 
novel O 
isoflavone B-FAMILY 
analogs O 
and O 
evaluated O 
their O 
anti-HBV O 
and O 
anti-cancer O 
activities O 
in O 
vitro O 
. O 
The O 
bioassays O 
showed O 
that O 
the O 
majority O 
of O 
the O 
resultant O 
compounds O 
exerted O 
inhibitory O 
effects O 
on O 
HBsAg O 
and O 
HBeAg O 
levels O 
, O 
HBV O 
DNA O 
replication O 
, O 
as O 
well O 
as O 
the O 
growth O 
of O 
four O 
human O 
cancer O 
cell O 
lines O 
to O 
various O 
extents O 
, O 
which O 
supported O 
the O 
rationale O 
of O 
the O 
design O 
. O 
In O 
particular O 
, O 
compound O 
8f O 
showed O 
the O 
highest O 
activity O 
against O 
HBV O 
infection O 
and O 
HBV O 
- O 
related O 
liver O 
cancer O 
. O 
Compound O 
7l O 
( O 
IC50 O 
= O 
0.47 O 
μM O 
) O 
also O 
exerted O 
remarkable O 
inhibitory O 
effect O 
on O 
the O 
growth O 
lung O 
cancer O 
cell O 
line O 
A-549 O 
. O 

studies O 
indicate O 
that O 
an O 
oil O 
extract O 
from O 
Salvia O 
sclarea O 
may O 
provide O 
clinical O 
benefits O 
in O 
various O 
pathological O 
conditions O 
. O 
In O 
comparison O 
to O 
extracts O 
from O 
other O 
Salvia O 
species O 
, O 
S O 
. O 
sclarea O 
oil O 
contains O 
twice O 
as O 
much O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
which O 
are O 
involved O 
in O 
eicosanoid B-FAMILY 
synthesis O 
pathways O 
, O 
and O 
has O 
been O 
found O 
to O 
contain O 
significant O 
levels O 
of O 
the O 
psychoactive O 
monoterpane O 
linalool B-TRIVIAL 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
mood O 
stabilizing O 
and O 
anxiolytic O 
- O 
like O 
effects O 
of O 
chronic O 
food O 
administration O 
of O 
S O 
. O 
sclarea O 
oil O 
extract O 
on O 
behavioral O 
and O 
physiological O 
parameters O 
of O 
mice O 
with O 
prominent O 
dominant O 
and O 
submissive O 
features O 
in O 
behavioral O 
assays O 
used O 
to O 
test O 
mood O 
stabilizing O 
and O 
antidepressant O 
drugs O 
. O 
Experimental O 
animals O 
received O 
oil O 
supplemented O 
food O 
from O 
the O 
age O 
of O 
4 O 
weeks O 
or O 
from O 
conception O 
via O 
their O 
pregnant O 
dams O 
. O 
Each O 
age O 
group O 
received O 
either O 
S O 
. O 
sclarea O 
oil- O 
or O 
sunflower O 
oil O 
- O 
enriched O 
feed O 
. O 
Dominant O 
animals O 
, O 
whose O 
pregnant O 
mothers O 
received O 
S O 
. O 
sclarea O 
oil O 
- O 
enriched O 
feed O 
from O 
the O 
date O 
of O 
conception O 
, O 
showed O 
a O 
significant O 
reduction O 
of O 
dominant O 
and O 
anxiety O 
- O 
like O 
behavior O 
, O 
in O 
comparison O 
to O 
their O 
sunflower O 
oil O 
- O 
treated O 
counterparts O 
. O 
S O 
. O 
sclarea O 
oil O 
- O 
treated O 
submissive O 
animals O 
exhibited O 
a O 
similar O 
tendency O 
, O 
and O 
showed O 
a O 
significant O 
reduction O 
in O 
blood O 
corticosterone B-TRIVIAL 
levels O 
. O 
These O 
findings O 
enforce O 
the O 
hypothesis O 
that O 
S O 
. O 
sclarea O 
oil O 
possesses O 
anxiolytic O 
properties O 
. O 

case O 
- O 
based O 
approach O 
to O 
the O 
practical O 
application O 
of O 
dexmedetomidine B-TRIVIAL 
in O 
critically O 
ill O 
adults O 
. O 

is O 
a O 
selective O 
α(2) O 
-adrenoceptor O 
agonist O 
that O 
offers O 
unique O 
sedation O 
because O 
patients O 
are O 
readily O 
awakened O 
while O 
administration O 
continues O 
and O 
the O 
drug O 
does O 
not O 
suppress O 
the O 
respiratory O 
center O 
. O 
Limitations O 
of O 
use O 
include O 
higher O 
acquisition O 
cost O 
, O 
inability O 
to O 
produce O 
deep O 
sedation O 
, O 
and O 
bradycardia O 
and O 
hypotension O 
. O 
Using O 
a O 
case O 
- O 
based O 
approach O 
, O 
the O 
purpose O 
of O 
this O 
review O 
was O 
to O 
qualitatively O 
assess O 
the O 
role O 
of O 
dexmedetomidine B-TRIVIAL 
in O 
the O 
care O 
of O 
the O 
critically O 
ill O 
and O 
in O 
the O 
management O 
of O 
alcohol B-FAMILY 
withdrawal O 
, O 
and O 
to O 
formulate O 
recommendations O 
regarding O 
its O 
clinical O 
application O 
. O 
Sixty O 
- O 
six O 
studies O 
were O 
identified O 
that O 
investigated O 
dexmedetomidine B-TRIVIAL 
for O 
the O 
provision O 
of O 
sedation O 
. O 
These O 
studies O 
were O 
heterogeneous O 
in O 
design O 
and O 
patient O 
populations O 
; O 
most O 
investigated O 
patients O 
did O 
not O 
require O 
heavy O 
sedation O 
, O 
and O 
few O 
used O 
propofol B-TRIVIAL 
as O 
the O 
comparator O 
. O 
In O 
general O 
, O 
though O 
, O 
the O 
aggregate O 
results O 
of O 
all O 
studies O 
demonstrate O 
that O 
dexmedetomidine B-TRIVIAL 
provides O 
comfort O 
, O 
possibly O 
shortens O 
the O 
duration O 
of O 
mechanical O 
ventilation O 
to O 
facilitate O 
extubation O 
, O 
reduces O 
the O 
occurrence O 
of O 
acute O 
brain O 
dysfunction O 
, O 
and O 
facilitates O 
communication O 
, O 
but O 
the O 
drug O 
is O 
associated O 
with O 
hemodynamic O 
instability O 
and O 
requires O 
the O 
supplemental O 
use O 
of O 
traditional O 
sedative O 
and O 
analgesic O 
agents O 
. O 
These O 
outcomes O 
need O 
to O 
be O 
substantiated O 
in O 
additional O 
studies O 
that O 
include O 
assessments O 
of O 
cost O 
- O 
effectiveness O 
. O 
Dexmedetomidine B-TRIVIAL 
should O 
be O 
considered O 
when O 
patients O 
require O 
mild O 
to O 
moderate O 
levels O 
of O 
sedation O 
of O 
short O 
to O 
intermediate O 
time O 
frames O 
, O 
and O 
they O 
qualify O 
for O 
daily O 
awakenings O 
with O 
traditional O 
sedative O 
therapies O 
. O 
The O 
data O 
for O 
dexmedetomidine B-TRIVIAL 
in O 
relation O 
to O 
alcohol B-FAMILY 
withdrawal O 
are O 
limited O 
to O 
12 O 
retrospective O 
reports O 
representing O 
a O 
total O 
of O 
127 O 
patients O 
. O 
Its O 
role O 
for O 
this O 
indication O 
requires O 
further O 
study O 
, O 
but O 
it O 
may O 
be O 
considered O 
as O 
adjunctive O 
therapy O 
when O 
clinicians O 
are O 
concerned O 
about O 
respiratory O 
suppression O 
associated O 
with O 
escalating O 
doses O 
of O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
agonists O 
. O 
Regardless O 
of O 
the O 
indication O 
for O 
dexmedetomidine B-TRIVIAL 
, O 
the O 
practitioner O 
must O 
closely O 
monitor O 
patient O 
comfort O 
and O 
the O 
occurrence O 
of O 
hemodynamic O 
deviations O 
with O 
the O 
realization O 
that O 
as-needed O 
administration O 
of O 
traditional O 
sedatives O 
and O 
analgesics O 
will O 
be O 
required O 
and O 
some O 
degree O 
of O 
bradycardia O 
and O 
hypotension O 
expected O 
but O 
intervention O 
rarely O 
required O 
. O 

research O 
has O 
shown O 
that O 
high O 
frequency O 
ultrasound O 
( O 
0.4-3 O 
MHz O 
) O 
, O 
can O 
enhance O 
milkfat O 
separation O 
in O 
small O 
scale O 
systems O 
able O 
to O 
treat O 
only O 
a O 
few O 
milliliters O 
of O 
sample O 
. O 
In O 
this O 
work O 
, O 
the O 
effect O 
of O 
ultrasonic O 
standing O 
waves O 
on O 
milkfat O 
creaming O 
was O 
studied O 
in O 
a O 
6L O 
reactor O 
and O 
the O 
influence O 
of O 
different O 
frequencies O 
and O 
transducer O 
configurations O 
in O 
direct O 
contact O 
with O 
the O 
fluid O 
was O 
investigated O 
. O 
A O 
recombined O 
coarse O 
milk O 
emulsion O 
with O 
fat O 
globules O 
stained O 
with O 
oil-red-O B-TRIVIAL 
dye O 
was O 
selected O 
for O 
the O 
separation O 
trials O 
. O 
Runs O 
were O 
performed O 
with O 
one O 
or O 
two O 
transducers O 
placed O 
in O 
vertical O 
( O 
parallel O 
or O 
perpendicular O 
) O 
and O 
horizontal O 
positions O 
( O 
at O 
the O 
reactor O 
base O 
) O 
at O 
0.4 O 
, O 
1 O 
and O 
/ O 
or O 
2 O 
MHz O 
( O 
specific O 
energy O 
8.5 O 
± O 
0.6 O 
kJ O 
/ O 
kg O 
per O 
transducer O 
) O 
. O 
Creaming O 
behavior O 
was O 
assessed O 
by O 
measuring O 
the O 
thickness O 
of O 
the O 
separated O 
cream O 
layer O 
. O 
Other O 
methods O 
supporting O 
this O 
assessment O 
included O 
the O 
measurement O 
of O 
fat O 
content O 
, O 
backscattering O 
, O 
particle O 
size O 
distribution O 
, O 
and O 
microscopy O 
of O 
samples O 
taken O 
at O 
the O 
bottom O 
and O 
top O 
of O 
the O 
reactor O 
. O 
Most O 
efficient O 
creaming O 
was O 
found O 
after O 
treatment O 
at O 
0.4 O 
MHz O 
in O 
single O 
and O 
double O 
vertical O 
transducer O 
configurations O 
. O 
Among O 
these O 
configurations O 
, O 
a O 
higher O 
separation O 
rate O 
was O 
obtained O 
when O 
sonicating O 
at O 
0.4 O 
MHz O 
in O 
a O 
vertical O 
perpendicular O 
double O 
transducer O 
setup O 
. O 
The O 
horizontal O 
transducer O 
configuration O 
promoted O 
creaming O 
at O 
2 O 
MHz O 
only O 
. O 
Fat O 
globule O 
size O 
increase O 
was O 
observed O 
when O 
creaming O 
occurred O 
. O 
This O 
research O 
highlights O 
the O 
potential O 
for O 
enhanced O 
separation O 
of O 
milkfat O 
in O 
larger O 
scale O 
systems O 
from O 
selected O 
transducer O 
configurations O 
in O 
contact O 
with O 
a O 
dairy O 
emulsion O 
, O 
or O 
emulsion O 
splitting O 
in O 
general O 
. O 

uptake O 
and O 
distribution O 
of O 
selenium B-SYSTEMATIC 
in O 
three O 
aquatic O 
plants O 
grown O 
in O 
Se B-FORMULA 
(IV) I-FORMULA 
solution O 
. O 

uptake O 
of O 
Se B-FORMULA 
(IV) I-FORMULA 
by O 
Myriophyllum O 
spicatum O 
, O 
Ceratophyllum O 
demersum O 
and O 
Potamogeton O 
perfoliatus O 
, O 
and O 
the O 
effects O 
of O 
Se B-FORMULA 
(IV) I-FORMULA 
on O 
their O 
physiological O 
and O 
biochemical O 
characteristics O 
were O 
studied O 
. O 
Plants O 
were O 
cultivated O 
outdoors O 
under O 
semi-controlled O 
conditions O 
in O 
water O 
solution O 
containing O 
Na B-SYSTEMATIC 
selenite I-SYSTEMATIC 
( O 
20 O 
μg O 
Se B-FORMULA 
L(-1) O 
and O 
10 O 
mg O 
Se B-FORMULA 
L(-1) O 
) O 
. O 
The O 
higher O 
concentration O 
of O 
Se B-FORMULA 
lowered O 
the O 
photochemical O 
efficiency O 
of O 
PSII O 
in O 
all O 
species O 
studied O 
, O 
while O 
the O 
lower O 
concentration O 
had O 
no O 
effect O 
on O 
any O 
species O 
. O 
The O 
higher O 
concentration O 
of O 
Se B-FORMULA 
lowered O 
respiratory O 
potential O 
in O 
M O 
. O 
spicatum O 
. O 
The O 
response O 
of O 
M O 
. O 
spicatum O 
and O 
C O 
. O 
demersum O 
to O 
Se B-FORMULA 
(IV) I-FORMULA 
regarding O 
chlorophylls B-FAMILY 
was O 
variable O 
, O 
however O 
in O 
the O 
majority O 
of O 
cases O 
, O 
there O 
was O 
a O 
trend O 
of O 
increasing O 
the O 
amount O 
of O 
chlorophylls B-FAMILY 
, O 
while O 
in O 
P O 
. O 
perfoliatus O 
the O 
amount O 
of O 
chlorophyll B-TRIVIAL 
a I-TRIVIAL 
decreased O 
. O 
The O 
concentration O 
of O 
Se B-FORMULA 
in O 
plants O 
cultured O 
in O 
10 O 
mg O 
Se B-FORMULA 
(IV) I-FORMULA 
L(-1) O 
ranged O 
from O 
436 O 
to O 
839 O 
μg O 
Se B-FORMULA 
g(-1) O 
DM O 
in O 
M O 
. O 
spicatum O 
, O 
319 O 
to O 
988 O 
μg O 
Se B-FORMULA 
g(-1) O 
DM O 
in O 
C O 
. O 
demersum O 
and O 
310 O 
to O 
661 O 
μg O 
Se B-FORMULA 
g(-1) O 
DM O 
in O 
P O 
. O 
perfoliatus O 
. O 
The O 
amount O 
of O 
soluble O 
Se B-FORMULA 
compounds O 
in O 
enzyme O 
extracts O 
of O 
high O 
Se B-FORMULA 
treatment O 
was O 
27% O 
in O 
M O 
. O 
spicatum O 
, O 
41% O 
in O 
C O 
. O 
demersum O 
and O 
35% O 
in O 
P O 
. O 
perfoliatus O 
. O 
Se B-FORMULA 
compounds O 
were O 
determined O 
using O 
HPLC-ICP-MS O 
. O 
It O 
was O 
observed O 
that O 
the O 
applied O 
Se B-FORMULA 
(IV) I-FORMULA 
was O 
mainly O 
transformed O 
to O 
insoluble O 
Se B-FORMULA 
. O 

-based O 
inhibitors O 
of O 
geranylgeranyltransferase O 
II O 
. O 

small O 
set O 
of O 
triazole B-FAMILY 
bisphosphonates I-FAMILY 
has O 
been O 
prepared O 
and O 
tested O 
for O 
the O 
ability O 
to O 
inhibit O 
geranylgeranyltransferase O 
II O 
( O 
GGTase O 
II O 
) O 
. O 
The O 
compounds O 
were O 
prepared O 
through O 
use O 
of O 
click O 
chemistry O 
to O 
assemble O 
a O 
central O 
triazole B-FAMILY 
that O 
links O 
a O 
polar O 
head O 
group O 
to O 
a O 
hydrophobic O 
tail O 
. O 
The O 
resulting O 
compounds O 
were O 
tested O 
for O 
their O 
ability O 
to O 
inhibit O 
GGTase O 
II O 
in O 
an O 
in O 
vitro O 
enzyme O 
assay O 
and O 
also O 
were O 
tested O 
for O 
cytotoxic O 
activity O 
in O 
an O 
MTT B-ABBREVIATION 
assay O 
with O 
the O 
human O 
myeloma O 
RPMI-8226 O 
cell O 
line O 
. O 
The O 
most O 
potent O 
enzyme O 
inhibitor O 
was O 
the O 
triazole B-FAMILY 
with O 
a O 
geranylgeranyl B-TRIVIAL 
tail O 
, O 
which O 
suggests O 
that O 
inhibitors O 
that O 
can O 
access O 
the O 
enzyme O 
region O 
that O 
holds O 
the O 
isoprenoid B-FAMILY 
tail O 
will O 
display O 
greater O 
activity O 
. O 

chemistry O 
, O 
toxicology O 
, O 
epidemiology O 
and O 
health O 
impact O 
assessment O 
of O 
melamine B-TRIVIAL 
in O 
infant O 
formula O 
: O 
Recent O 
progress O 
and O 
developments O 
. O 

review O 
summarizes O 
the O 
most O 
recent O 
scientific O 
literature O 
and O 
regulations O 
regarding O 
analytical O 
chemistry O 
, O 
toxicology O 
, O 
epidemiology O 
, O 
exposure O 
, O 
and O 
risk O 
assessment O 
of O 
melamine B-TRIVIAL 
in O 
infant O 
formula O 
. O 
For O 
analyses O 
, O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
, O 
high O 
- O 
performance O 
liquid O 
chromatography O 
, O 
capillary O 
electrophoresis O 
, O 
gas O 
chromatography O 
coupled O 
with O 
mass O 
spectrometry O 
and O 
liquid O 
chromatography O 
coupled O 
with O 
tandem O 
mass O 
spectrometry O 
have O 
commonly O 
been O 
used O 
. O 
Organization O 
of O 
proficiency O 
test O 
programs O 
provided O 
good O 
evidence O 
to O 
facilitate O 
granting O 
laboratories O 
accreditation O 
and O 
to O 
ascertain O 
the O 
measurement O 
reliability O 
of O 
melamine B-TRIVIAL 
methods O 
. O 
Metabolic O 
studies O 
demonstrated O 
that O 
melamine B-TRIVIAL 
is O 
predominantly O 
restricted O 
to O 
blood O 
or O 
extracellular O 
fluid O 
and O 
is O 
not O 
extensively O 
distributed O 
to O 
organs O 
and O 
tissues O 
. O 
Studies O 
of O 
human O 
renal O 
histopathology O 
and O 
clinical O 
diagnoses O 
indicated O 
that O 
melamine B-TRIVIAL 
-related O 
obstructive O 
nephropathy O 
derives O 
from O 
melamine B-TRIVIAL 
precipitation O 
in O 
the O 
lower O 
urinary O 
tract O 
, O 
with O 
stones O 
that O 
are O 
thought O 
to O 
be O 
melamine B-TRIVIAL 
- O 
uric B-TRIVIAL 
acid I-TRIVIAL 
complexes O 
. O 
Epidemiologic O 
studies O 
showed O 
that O 
the O 
occurrence O 
of O 
melamine B-TRIVIAL 
-related O 
urolithiasis O 
is O 
related O 
to O 
both O 
the O 
concentration O 
of O 
melamine B-TRIVIAL 
in O 
ingested O 
milk O 
products O 
and O 
the O 
duration O 
of O 
ingestion O 
. O 
Long O 
- O 
term O 
follow O 
- O 
up O 
cohort O 
studies O 
should O 
be O 
continued O 
to O 
further O 
investigate O 
the O 
epidemic O 
and O 
chronic O 
hazard O 
of O 
melamine B-TRIVIAL 
-induced O 
nephrotoxicity O 
. O 
The O 
World O 
Health O 
Organization O 
set O 
a O 
tolerable O 
daily O 
intake O 
of O 
0.2mg O 
/ O 
kgbw O 
/ O 
day O 
to O 
be O 
applied O 
to O 
" O 
the O 
whole O 
population O 
including O 
infants O 
" O 
. O 
Other O 
authorities O 
and O 
research O 
institutes O 
have O 
set O 
/ O 
proposed O 
lower O 
values O 
. O 

impulsive O 
choice O 
for O 
saccharin B-TRIVIAL 
during O 
PCP B-ABBREVIATION 
withdrawal O 
in O 
female O 
monkeys O 
: O 
influence O 
of O 
menstrual O 
cycle O 
phase O 
. O 

: O 
In O 
previous O 
studies O 
with O 
male O 
and O 
female O 
rhesus O 
monkeys O 
, O 
withdrawal O 
of O 
access O 
to O 
oral O 
phencyclidine B-TRIVIAL 
( O 
PCP B-ABBREVIATION 
) O 
self O 
- O 
administration O 
reduced O 
responding O 
for O 
food O 
under O 
a O 
high O 
fixed O 
- O 
ratio O 
( O 
FR O 
) O 
schedule O 
more O 
in O 
males O 
than O 
females O 
, O 
and O 
with O 
a O 
delay O 
discounting O 
( O 
DD O 
) O 
task O 
with O 
saccharin B-TRIVIAL 
( O 
SACC B-ABBREVIATION 
) O 
as O 
the O 
reinforcer O 
impulsive O 
choice O 
for O 
SACC B-ABBREVIATION 
increased O 
during O 
PCP B-ABBREVIATION 
withdrawal O 
more O 
in O 
males O 
than O 
females O 
. O 
OBJECTIVES O 
: O 
The O 
goal O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
the O 
effect O 
of O 
PCP B-ABBREVIATION 
( O 
0.25 O 
or O 
0.5 O 
mg O 
/ O 
ml O 
) O 
withdrawal O 
on O 
impulsive O 
choice O 
for O 
SACC B-ABBREVIATION 
in O 
females O 
during O 
the O 
follicular O 
and O 
luteal O 
phases O 
of O 
the O 
menstrual O 
cycle O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
In O 
component O 
1 O 
, O 
PCP B-ABBREVIATION 
and O 
water O 
were O 
available O 
from O 
two O 
drinking O 
spouts O 
for O 
1.5 O 
h O 
sessions O 
under O 
concurrent O 
FR O 
16 O 
schedules O 
. O 
In O 
component O 
2 O 
, O 
a O 
SACC B-ABBREVIATION 
solution O 
was O 
available O 
for O 
45 O 
min O 
under O 
a O 
DD O 
schedule O 
. O 
Monkeys O 
had O 
a O 
choice O 
of O 
one O 
immediate O 
SACC B-ABBREVIATION 
delivery O 
( O 
0.6 O 
ml O 
) O 
or O 
six O 
delayed O 
SACC B-ABBREVIATION 
deliveries O 
, O 
and O 
the O 
delay O 
was O 
increased O 
by O 
1 O 
s O 
after O 
a O 
response O 
on O 
the O 
delayed O 
lever O 
and O 
decreased O 
by O 
1 O 
s O 
after O 
a O 
response O 
on O 
the O 
immediate O 
lever O 
. O 
There O 
was O 
then O 
a O 
10-day O 
water O 
substitution O 
phase O 
, O 
or O 
PCP B-ABBREVIATION 
withdrawal O 
, O 
that O 
occurred O 
during O 
the O 
mid O 
- O 
follicular O 
phase O 
( O 
days O 
7-11 O 
) O 
or O 
the O 
late O 
luteal O 
phase O 
( O 
days O 
24-28 O 
) O 
of O 
the O 
menstrual O 
cycle O 
. O 
Access O 
to O 
PCP B-ABBREVIATION 
and O 
concurrent O 
water O 
was O 
then O 
restored O 
, O 
and O 
the O 
PCP B-ABBREVIATION 
withdrawal O 
procedure O 
was O 
repeated O 
over O 
several O 
follicular O 
and O 
luteal O 
menstrual O 
phases O 
. O 
RESULTS O 
: O 
PCP B-ABBREVIATION 
deliveries O 
were O 
higher O 
during O 
the O 
luteal O 
( O 
vs O 
follicular O 
) O 
phase O 
. O 
Impulsive O 
choice O 
was O 
greater O 
during O 
the O 
luteal O 
( O 
vs O 
follicular O 
) O 
phase O 
during O 
withdrawal O 
of O 
the O 
higher O 
PCP B-ABBREVIATION 
concentration O 
. O 
CONCLUSIONS O 
: O 
PCP B-ABBREVIATION 
withdrawal O 
was O 
associated O 
with O 
elevated O 
impulsive O 
choice O 
for O 
SACC B-ABBREVIATION 
, O 
especially O 
in O 
the O 
luteal O 
( O 
vs O 
follicular O 
) O 
phase O 
of O 
the O 
menstrual O 
cycle O 
in O 
female O 
monkeys O 
. O 

orbitopathy O 
( O 
GO O 
) O 
is O 
an O 
autoimmune O 
disorder O 
and O 
the O 
main O 
extrathyroidal O 
expression O 
of O 
Graves' O 
disease O 
. O 
There O 
is O 
a O 
spectrum O 
of O 
ocular O 
involvement O 
in O 
Graves' O 
disease O 
, O 
from O 
complete O 
absence O 
of O 
symptoms O 
and O 
signs O 
to O 
sight O 
- O 
threatening O 
conditions O 
. O 
The O 
prevalence O 
of O 
GO O 
varies O 
in O 
different O 
published O 
series O 
of O 
Graves' O 
patients O 
, O 
due O 
to O 
confounding O 
factors O 
( O 
new O 
diagnosis O 
vs O 
. O 
long O 
- O 
lasting O 
disease O 
, O 
way O 
of O 
defining O 
and O 
assessing O 
ocular O 
involvement O 
, O 
treatment O 
of O 
hyperthyroidism O 
with O 
potentially O 
GO-modifying O 
treatments O 
, O 
such O 
as O 
radioiodine B-SYSTEMATIC 
) O 
. O 
Recent O 
studies O 
, O 
however O 
, O 
suggest O 
that O 
most O 
Graves' O 
patients O 
have O 
mild O 
or O 
no O 
GO O 
at O 
presentation O 
, O 
while O 
moderate O 
- O 
to O 
- O 
severe O 
GO O 
is O 
rare O 
, O 
and O 
sight O 
- O 
threatening O 
GO O 
( O 
mostly O 
due O 
to O 
dysthyroid O 
optic O 
neuropathy O 
) O 
is O 
exceptional O 
in O 
non-tertiary O 
referral O 
centers O 
. O 
The O 
natural O 
course O 
of O 
GO O 
is O 
incompletely O 
defined O 
, O 
particularly O 
in O 
patients O 
with O 
moderate-to12 O 
severe O 
GO O 
, O 
because O 
these O 
patients O 
require O 
prompt O 
and O 
disease O 
- O 
modifying O 
therapies O 
for O 
orbital O 
disease O 
. O 
In O 
patients O 
with O 
mild O 
GO O 
at O 
presentation O 
, O 
progression O 
to O 
severe O 
forms O 
is O 
rare O 
, O 
while O 
partial O 
or O 
complete O 
remission O 
is O 
frequent O 
. O 
Progression O 
of O 
preexisting O 
GO O 
or O 
de O 
novo O 
occurrence O 
of O 
GO O 
is O 
more O 
likely O 
in O 
smokers O 
. O 
There O 
seems O 
to O 
be O 
a O 
trend O 
towards O 
a O 
decline O 
in O 
progression O 
of O 
GO O 
, O 
possibly O 
due O 
to O 
a O 
better O 
control O 
of O 
risk O 
factors O 
( O 
cigarette O 
smoking O 
, O 
thyroid O 
dysfunction O 
, O 
etc O 
. O 
) O 
and O 
a O 
closer O 
interaction O 
between O 
endocrinologists O 
and O 
ophthalmologists O 
allowing O 
an O 
improved O 
integrated O 
management O 
of O 
thyroid O 
and O 
orbital O 
disease O 
. O 

mushroom O 
species O 
have O 
been O 
pointed O 
out O 
as O 
sources O 
of O 
antioxidant O 
compounds O 
, O 
in O 
addition O 
to O 
their O 
important O 
nutritional O 
value O 
. O 
Agaricus O 
blazei O 
and O 
Lentinus O 
edodes O 
are O 
among O 
the O 
most O 
studied O 
species O 
all O 
over O 
the O 
world O 
, O 
but O 
those O 
studies O 
focused O 
on O 
their O 
fruiting O 
bodies O 
instead O 
of O 
other O 
presentations O 
, O 
such O 
as O 
powdered O 
preparations O 
, O 
used O 
as O 
supplements O 
. O 
In O 
the O 
present O 
work O 
the O 
chemical O 
composition O 
( O 
nutrients O 
and O 
bioactive O 
compounds O 
) O 
and O 
antioxidant O 
activity O 
( O 
free O 
radical O 
scavenging O 
activity O 
, O 
reducing O 
power O 
and O 
lipid O 
peroxidation O 
inhibition O 
) O 
of O 
dried O 
powder O 
formulations O 
of O 
the O 
mentioned O 
mushroom O 
species O 
( O 
APF O 
and O 
LPF O 
, O 
respectively O 
) O 
were O 
evaluated O 
. O 
Powder O 
formulations O 
of O 
both O 
species O 
revealed O 
the O 
presence O 
of O 
essential O 
nutrients O 
, O 
such O 
as O 
proteins O 
, O 
carbohydrates B-FAMILY 
and O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
. O 
Furthermore O 
, O 
they O 
present O 
a O 
low O 
fat O 
content O 
( O 
< O 
2g O 
/ O 
100g O 
) O 
and O 
can O 
be O 
used O 
in O 
low O 
- O 
calorie O 
diets O 
, O 
just O 
like O 
the O 
mushrooms O 
fruiting O 
bodies O 
. O 
APF O 
showed O 
higher O 
antioxidant O 
activity O 
and O 
higher O 
content O 
of O 
tocopherols B-FAMILY 
and O 
phenolic B-FAMILY 
compounds O 
( O 
124 O 
and O 
770 O 
μg O 
/ O 
100g O 
, O 
respectively O 
) O 
than O 
LPF O 
( O 
32 O 
and O 
690 O 
μg O 
/ O 
100g O 
) O 
. O 
Both O 
formulations O 
could O 
be O 
used O 
as O 
antioxidant O 
sources O 
to O 
prevent O 
diseases O 
related O 
to O 
oxidative O 
stress O 
. O 

E I-FAMILY 
deficiency O 
impairs O 
the O 
somatostatinergic O 
receptor O 
- O 
effector O 
system O 
and O 
leads O 
to O 
phosphotyrosine B-SYSTEMATIC 
phosphatase O 
overactivation O 
and O 
cell O 
death O 
in O 
the O 
rat O 
hippocampus O 
. O 

E I-FAMILY 
plays O 
an O 
essential O 
role O 
in O 
maintaining O 
the O 
structure O 
and O 
function O 
of O 
the O 
nervous O 
system O 
, O 
and O 
its O 
deficiency O 
, O 
commonly O 
associated O 
with O 
fat O 
malabsorption O 
diseases O 
, O 
may O 
reduce O 
neuronal O 
survival O 
. O 
We O 
previously O 
demonstrated O 
that O 
the O 
somatostatinergic O 
system O 
, O 
implicated O 
in O 
neuronal O 
survival O 
control O 
, O 
can O 
be O 
modulated O 
by O 
α-tocopherol B-TRIVIAL 
in O 
the O 
rat O 
dentate O 
gyrus O 
, O 
increasing O 
cyclic B-SYSTEMATIC 
adenosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
response O 
element O 
binding O 
protein O 
phosphorylation O 
. O 
To O 
gain O 
a O 
better O 
understanding O 
of O 
the O 
molecular O 
actions O 
of O 
tocopherols B-FAMILY 
and O 
examine O 
the O 
link O 
among O 
vitamin B-FAMILY 
E I-FAMILY 
, O 
somatostatin B-TRIVIAL 
and O 
neuronal O 
survival O 
, O 
we O 
have O 
investigated O 
the O 
effects O 
of O 
a O 
deficiency O 
and O 
subsequent O 
administration O 
of O 
tocopherol B-FAMILY 
on O 
the O 
somatostatin B-TRIVIAL 
signaling O 
pathway O 
and O 
neuronal O 
survival O 
in O 
the O 
rat O 
hippocampus O 
. O 
No O 
changes O 
in O 
somatostatin B-TRIVIAL 
expression O 
were O 
detected O 
in O 
vitamin-E B-FAMILY 
-deficient O 
rats O 
. O 
These O 
rats O 
, O 
however O 
, O 
showed O 
a O 
significant O 
increase O 
in O 
the O 
somatostatin B-TRIVIAL 
receptor O 
density O 
and O 
dissociation O 
constant O 
, O 
which O 
correlated O 
with O 
a O 
significant O 
increase O 
in O 
the O 
protein O 
levels O 
of O 
somatostatin B-TRIVIAL 
receptors O 
. O 
Nevertheless O 
, O 
vitamin B-FAMILY 
E I-FAMILY 
deficiency O 
impaired O 
the O 
ability O 
of O 
the O 
somatostatin B-TRIVIAL 
receptors O 
to O 
couple O 
to O 
the O 
effectors O 
adenylyl B-TRIVIAL 
cyclase O 
and O 
phosphotyrosine B-SYSTEMATIC 
phosphatase O 
by O 
diminishing O 
Gi O 
protein O 
functionality O 
. O 
Furthermore O 
, O 
vitamin B-FAMILY 
E I-FAMILY 
deficiency O 
significantly O 
increased O 
phosphotyrosine B-SYSTEMATIC 
phosphatase O 
activity O 
and O 
PTPη O 
expression O 
, O 
as O 
well O 
as O 
PKCδ O 
activation O 
, O 
and O 
decreased O 
extracellular O 
- O 
signal O 
- O 
regulated O 
kinase O 
phosphorylation O 
. O 
All O 
these O 
changes O 
were O 
accompanied O 
by O 
an O 
increase O 
in O 
neuronal O 
cell O 
death O 
. O 
Subsequent O 
α-tocopherol B-TRIVIAL 
administration O 
partially O 
or O 
completely O 
reversed O 
all O 
these O 
values O 
to O 
control O 
levels O 
. O 
Altogether O 
, O 
our O 
results O 
prove O 
the O 
importance O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
homeostasis O 
in O 
the O 
somatostatin B-TRIVIAL 
receptor O 
- O 
effector O 
system O 
and O 
suggest O 
a O 
possible O 
mechanism O 
by O 
which O 
this O 
vitamin O 
may O 
regulate O 
the O 
neuronal O 
cell O 
survival O 
in O 
the O 
adult O 
hippocampus O 
. O 

role O 
of O 
methyl B-SYSTEMATIC 
- O 
CpG B-ABBREVIATION 
binding O 
protein O 
2 O 
in O 
liver O 
fibrosis O 
. O 

injure O 
is O 
induced O 
by O 
various O 
insults O 
such O 
as O 
alcohol B-FAMILY 
abuse O 
, O 
if O 
insults O 
persistent O 
, O 
may O 
result O 
in O 
the O 
formation O 
of O 
liver O 
fibrosis O 
. O 
Hepatic O 
stellate O 
cell O 
( O 
HSC O 
) O 
activation O 
and O 
transdifferentiation O 
into O 
hepatic O 
myofibroblast O 
, O 
accompanied O 
with O 
potent O 
pro O 
- O 
inflammatory O 
and O 
pro O 
- O 
fibrogenic O 
activities O 
and O 
the O 
down O 
- O 
regulation O 
of O 
anti-inflammatory O 
anti-fibrogenic O 
in O 
gene O 
expression O 
in O 
coordination O 
with O 
epigenetic O 
modifications O 
at O 
the O 
level O 
of O 
the O 
chromatin O 
structure O 
, O 
are O 
pivotal O 
events O 
in O 
liver O 
fibrogenesis O 
. O 
In O 
this O 
review O 
we O 
focus O 
on O 
the O 
role O 
of O 
the O 
methyl B-SYSTEMATIC 
- O 
CpG B-ABBREVIATION 
binding O 
protein O 
2 O 
( O 
MeCP2 O 
) O 
transcriptional O 
regulation O 
of O 
different O 
target O 
genes O 
and O 
the O 
interaction O 
MeCP2 O 
with O 
microRNAs O 
( O 
miRNAs O 
) O 
during O 
liver O 
fibrosis O 
. O 
In O 
addition O 
, O 
we O 
address O 
different O 
signaling O 
pathways O 
interacted O 
with O 
MeCP2 O 
regulated O 
HSC O 
activation O 
. O 
Such O 
approaches O 
provide O 
valuable O 
insights O 
into O 
the O 
potential O 
targets O 
of O 
liver O 
fibrosis O 
, O 
and O 
are O 
useful O 
pointers O 
for O 
the O 
development O 
of O 
future O 
therapeutic O 
strategies O 
. O 

crystal O 
structure O 
of O 
human O 
telomeric O 
DNA O 
complexed O 
with O 
berberine B-TRIVIAL 
: O 
an O 
interesting O 
case O 
of O 
stacked O 
ligand O 
to O 
G-tetrad O 
ratio O 
higher O 
than O 
1 O 
: O 
1 O 
. O 

first O 
crystal O 
structure O 
of O 
human O 
telomeric O 
DNA O 
in O 
complex O 
with O 
the O 
natural O 
alkaloid O 
berberine B-TRIVIAL 
, O 
produced O 
by O 
different O 
plant O 
families O 
and O 
used O 
in O 
folk O 
medicine O 
for O 
millennia O 
, O 
was O 
solved O 
by O 
X-ray O 
diffraction O 
method O 
. O 
The O 
G-quadruplex O 
unit O 
features O 
all O 
- O 
parallel O 
strands O 
. O 
The O 
overall O 
folding O 
assumed O 
by O 
DNA O 
is O 
the O 
same O 
found O 
in O 
previously O 
reported O 
crystal O 
structures O 
. O 
Similarly O 
to O 
previously O 
reported O 
structures O 
the O 
ligand O 
molecules O 
were O 
found O 
to O 
be O 
stacked O 
onto O 
the O 
external O 
5 O 
' O 
and O 
3'-end O 
G-tetrads O 
. O 
However O 
, O 
the O 
present O 
crystal O 
structure O 
highlighted O 
for O 
the O 
first O 
time O 
, O 
the O 
presence O 
of O 
two O 
berberine B-TRIVIAL 
molecules O 
in O 
the O 
two O 
binding O 
sites O 
, O 
directly O 
interacting O 
with O 
each O 
tetrad O 
. O 
As O 
a O 
consequence O 
, O 
our O 
structural O 
data O 
point O 
out O 
a O 
2 O 
: O 
1 O 
ligand O 
to O 
G-tetrad O 
molar O 
ratio O 
, O 
which O 
has O 
never O 
been O 
reported O 
before O 
in O 
a O 
telomeric O 
intramolecular O 
quadruplex O 
structure O 
. O 

suppression O 
of O 
GH-dependent O 
isoforms O 
of O 
cytochrome O 
P450 O 
by O 
the O 
somatostatin B-TRIVIAL 
analog O 
octreotide B-TRIVIAL 
. O 

is O 
a O 
potent O 
somatostatin B-TRIVIAL 
analog O 
therapeutically O 
used O 
to O 
treat O 
several O 
conditions O 
including O 
hyper O 
GH O 
secretion O 
in O 
patients O 
with O 
acromegaly O 
. O 
We O 
infused O 
, O 
over O 
30 O 
s O 
, O 
octreotide B-TRIVIAL 
into O 
male O 
rats O 
every O 
12 O 
h O 
for O 
6 O 
days O 
at O 
levels O 
considerably O 
greater O 
than O 
typical O 
human O 
therapeutic O 
doses O 
. O 
Unexpectedly O 
, O 
resulting O 
circulating O 
GH O 
profile O 
was O 
characterized O 
by O 
pulses O 
of O 
higher O 
amplitudes O 
, O 
longer O 
durations O 
, O 
and O 
greater O 
total O 
content O 
than O 
normal O 
, O 
but O 
still O 
contained O 
an O 
otherwise O 
male O 
- O 
like O 
episodic O 
secretory O 
profiles O 
. O 
In O 
apparent O 
disaccord O 
, O 
the O 
normally O 
elevated O 
masculine O 
expression O 
levels O 
( O 
protein O 
and O 
/ O 
or O 
mRNA O 
) O 
of O 
CYP2C11 O 
( O 
accounting O 
for O 
> O 
50% O 
of O 
the O 
total O 
hepatic O 
cytochrome O 
P450 O 
content O 
) O 
, O 
CYP3A2 O 
, O 
CYP2C7 O 
, O 
and O 
IGF1 O 
, O 
dependent O 
on O 
the O 
episodic O 
GH O 
profile O 
, O 
were O 
considerably O 
downregulated O 
. O 
We O 
explain O 
this O 
contradiction O 
by O 
proposing O 
that O 
the O 
requisite O 
minimal O 
GH-devoid O 
interpulse O 
durations O 
in O 
the O 
masculine O 
profile O 
that O 
solely O 
regulate O 
expression O 
of O 
at O 
least O 
CYP2C11 O 
and O 
IGF1 O 
may O 
be O 
sufficiently O 
reduced O 
to O 
suppress O 
transcription O 
of O 
the O 
hepatic O 
genes O 
. O 
Alternatively O 
, O 
we O 
observed O 
that O 
octreotide B-TRIVIAL 
infusion O 
may O 
have O 
acted O 
directly O 
on O 
the O 
hepatocytes O 
to O 
induce O 
expression O 
of O 
immune O 
response O 
factors O 
postulated O 
to O 
suppress O 
CYP O 
transcription O 
and O 
/ O 
or O 
upregulate O 
expression O 
of O 
several O 
negative O 
regulators O 
( O 
e.g O 
. O 
phosphatases O 
and O 
SOCS O 
proteins O 
) O 
of O 
the O 
JAK2 O 
/ O 
STAT5B O 
signaling O 
pathway O 
that O 
normally O 
mediates O 
the O 
upregulation O 
of O 
CYP2C11 O 
and O 
IGF1 O 
by O 
the O 
masculine O 
episodic O 
GH O 
profile O 
. O 

, O 
synthesis O 
and O 
spectroscopic O 
characterisation O 
of O 
a O 
focused O 
library O 
based O 
on O 
the O 
polyandrocarpamine B-FAMILY 
natural O 
product O 
scaffold O 
. O 

focused O 
library O 
based O 
on O 
the O 
marine O 
natural O 
products O 
polyandrocarpamines B-NO_CLASS 
A I-NO_CLASS 
( O 
1 O 
) O 
and O 
B O 
( O 
2 O 
) O 
has O 
been O 
designed O 
and O 
synthesised O 
using O 
parallel O 
solution O 
- O 
phase O 
chemistry O 
. O 
In O 
silico O 
physicochemical O 
property O 
calculations O 
were O 
performed O 
on O 
synthetic O 
candidates O 
in O 
order O 
to O 
optimise O 
the O 
library O 
for O 
drug O 
discovery O 
and O 
chemical O 
biology O 
. O 
A O 
library O 
of O 
ten O 
2-aminoimidazolone B-SYSTEMATIC 
products O 
( O 
3-12 O 
) O 
was O 
prepared O 
by O 
coupling O 
glycocyamidine B-TRIVIAL 
and O 
a O 
variety O 
of O 
aldehydes B-FAMILY 
using O 
a O 
one O 
- O 
step O 
stereoselective O 
aldol O 
condensation O 
reaction O 
under O 
microwave O 
conditions O 
. O 
All O 
analogues O 
were O 
characterised O 
by O 
NMR O 
, O 
UV O 
, O 
IR O 
and O 
MS O 
. O 
The O 
library O 
was O 
evaluated O 
for O 
cytotoxicity O 
towards O 
the O 
prostate O 
cancer O 
cell O 
lines O 
, O 
LNCaP O 
, O 
PC-3 O 
and O 
22Rv1 O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
asenapine B-TRIVIAL 
in O 
clinical O 
practice O 
for O 
the O 
management O 
of O 
bipolar O 
mania O 
. O 

disorder O 
is O 
a O 
chronic O 
mental O 
illness O 
associated O 
with O 
high O 
levels O 
of O 
somatic O 
morbidity O 
, O 
comorbidity O 
and O 
mortality O 
. O 
Treatment O 
guidelines O 
for O 
bipolar O 
mania O 
generally O 
recommend O 
initiating O 
first O 
- O 
line O 
therapy O 
with O 
a O 
second O 
- O 
generation O 
antipsychotic O 
or O 
mood O 
stabiliser O 
, O 
either O 
alone O 
or O 
in O 
combination O 
. O 
Asenapine B-TRIVIAL 
is O 
a O 
second O 
- O 
generation O 
antipsychotic O 
with O 
a O 
unique O 
receptor O 
binding O 
profile O 
, O 
licensed O 
for O 
the O 
treatment O 
of O 
manic O 
episodes O 
in O 
adults O 
with O 
bipolar O 
I O 
disorder O 
. O 
' O 
Real O 
- O 
world O 
' O 
data O 
are O 
needed O 
to O 
complement O 
evidence O 
from O 
clinical O 
trials O 
, O 
in O 
order O 
to O 
provide O 
clinicians O 
with O 
pragmatic O 
information O 
regarding O 
the O 
likely O 
risks O 
and O 
benefits O 
of O 
using O 
a O 
new O 
agent O 
in O 
clinical O 
practice O 
. O 
Evidence O 
from O 
real O 
- O 
world O 
case O 
reports O 
demonstrates O 
that O 
- O 
as O 
in O 
clinical O 
trials O 
- O 
asenapine B-TRIVIAL 
is O 
effective O 
in O 
treating O 
mania O 
and O 
mixed O 
episodes O 
associated O 
with O 
bipolar O 
I O 
disorder O 
, O 
whether O 
used O 
as O 
monotherapy O 
or O 
in O 
combination O 
with O 
a O 
mood O 
stabiliser O 
. O 
It O 
has O 
a O 
rapid O 
onset O 
of O 
antimanic O 
effect O 
and O 
an O 
early O 
improvement O 
is O 
associated O 
with O 
treatment O 
outcome O 
. O 
Asenapine B-TRIVIAL 
also O 
shows O 
promise O 
in O 
controlling O 
depressive O 
symptoms O 
and O 
clinically O 
challenging O 
mixed O 
states O 
. O 
Asenapine B-TRIVIAL 
has O 
a O 
favourable O 
tolerability O 
profile O 
, O 
compared O 
with O 
other O 
first O 
- O 
line O 
agents O 
, O 
having O 
a O 
minimal O 
impact O 
on O 
weight O 
and O 
metabolic O 
parameters O 
. O 
Asenapine B-TRIVIAL 
should O 
be O 
considered O 
a O 
first O 
- O 
line O 
treatment O 
option O 
for O 
adults O 
with O 
bipolar O 
I O 
disorder O 
. O 

and O 
Cobalt B-SYSTEMATIC 
-Catalyzed O 
Coupling O 
of O 
Alkyl B-FAMILY 
Halides I-FAMILY 
with O 
Alkenes B-FAMILY 
via O 
Heck O 
Reactions O 
and O 
Radical O 
Conjugate O 
Addition O 
. O 

- O 
coupling O 
of O 
alkyl B-FAMILY 
halides I-FAMILY 
with O 
alkenes B-FAMILY 
leading O 
to O 
Heck O 
- O 
type O 
and O 
addition O 
products O 
is O 
summarized O 
. O 
The O 
development O 
of O 
Heck O 
reaction O 
with O 
aliphatic B-FAMILY 
halides I-FAMILY 
although O 
has O 
made O 
significant O 
progress O 
in O 
the O 
past O 
decade O 
and O 
particularly O 
recently O 
, O 
it O 
was O 
much O 
less O 
explored O 
in O 
comparison O 
with O 
the O 
aryl B-FAMILY 
halides I-FAMILY 
. O 
The O 
use O 
of O 
Ni B-FORMULA 
- O 
and O 
Co B-FORMULA 
-catalyzed O 
protocols O 
allowed O 
efficient O 
Heck O 
coupling O 
of O 
activated O 
and O 
unactivated O 
alkenes B-FAMILY 
with O 
1 O 
(o) O 
, O 
2 O 
(o) O 
and O 
3 O 
(o) O 
alkyl B-FAMILY 
halides I-FAMILY 
. O 
In O 
addition O 
, O 
radical O 
conjugate O 
addition O 
to O 
activated O 
alkenes B-FAMILY 
has O 
become O 
a O 
well O 
- O 
established O 
method O 
that O 
has O 
led O 
to O 
efficient O 
construction O 
of O 
many O 
natural O 
products O 
. O 
The O 
utilization O 
of O 
Ni B-FORMULA 
- O 
and O 
Co B-FORMULA 
-catalyzed O 
strategies O 
would O 
avoid O 
toxic O 
tin O 
reagents O 
, O 
and O 
therefore O 
worth O 
exploring O 
. O 
The O 
recent O 
development O 
of O 
Ni B-FORMULA 
- O 
and O 
Co B-FORMULA 
-catalyzed O 
addition O 
of O 
alkyl B-FAMILY 
halides I-FAMILY 
to O 
alkenes B-FAMILY 
displays O 
much O 
improved O 
reactivity O 
and O 
functional O 
group O 
tolerance O 
. O 
In O 
this O 
mini O 
- O 
review O 
, O 
we O 
also O 
attempt O 
to O 
overview O 
the O 
mechanisms O 
that O 
are O 
proposed O 
in O 
the O 
reactions O 
, O 
aiming O 
at O 
providing O 
insight O 
into O 
the O 
nickel B-SYSTEMATIC 
and O 
cobalt B-SYSTEMATIC 
-catalyzed O 
coupling O 
of O 
alkyl B-FAMILY 
halides I-FAMILY 
with O 
alkenes B-FAMILY 
. O 

goal O 
of O 
the O 
study O 
was O 
to O 
develop O 
an O 
effective O 
screening O 
strategy O 
to O 
select O 
new O 
agents O 
for O 
brain O 
tumor O 
chemotherapy O 
from O 
a O 
series O 
of O 
low O 
molecular O 
weight O 
anticancer O 
agents O 
[ O 
ON123x B-FAMILY 
] O 
by O 
the O 
combined O 
use O 
of O 
in O 
silico O 
, O 
in O 
vitro O 
cytotoxicity O 
, O 
and O 
in O 
vitro O 
ADME O 
profiling O 
studies O 
. O 
The O 
results O 
of O 
these O 
studies O 
were O 
cast O 
into O 
a O 
pipeline O 
of O 
tier O 
1 O 
and O 
tier O 
2 O 
procedures O 
that O 
resulted O 
in O 
the O 
identification O 
of O 
ON123300 B-IDENTIFIER 
as O 
the O 
lead O 
compound O 
. O 
Of O 
the O 
154 O 
ON123xx B-FAMILY 
compounds O 
, O 
13 O 
met O 
tier O 
1 O 
screening O 
criteria O 
based O 
on O 
physicochemical O 
properties O 
[ O 
i.e O 
. O 
, O 
MW O 
< O 
450 O 
Da O 
, O 
predicted O 
log O 
P O 
between O 
2 O 
and O 
3.5 O 
] O 
and O 
in O 
vitro O 
glioma O 
cell O 
cytotoxicity O 
[ O 
i.e O 
. O 
, O 
IC50 O 
< O 
10 O 
μM O 
] O 
and O 
were O 
further O 
tested O 
in O 
tier O 
2 O 
assays O 
. O 
The O 
tier O 
2 O 
profiling O 
studies O 
consisted O 
of O 
metabolic O 
stability O 
, O 
MDCK-MDR1 O 
cell O 
permeability O 
and O 
plasma O 
and O 
brain O 
protein O 
binding O 
that O 
were O 
combined O 
to O 
globally O 
assess O 
whether O 
favorable O 
pharmacokinetic O 
properties O 
and O 
brain O 
penetration O 
could O 
be O 
achieved O 
in O 
vivo O 
. O 
In O 
vivo O 
cassette O 
dosing O 
studies O 
were O 
conducted O 
in O 
mice O 
for O 
12 O 
compounds O 
that O 
permitted O 
examination O 
of O 
in O 
vitro O 
/ O 
in O 
vivo O 
relationships O 
that O 
confirmed O 
the O 
suitability O 
of O 
the O 
in O 
vitro O 
assays O 
. O 
A O 
parameter O 
derived O 
from O 
the O 
in O 
vitro O 
assays O 
accurately O 
predicted O 
the O 
extent O 
of O 
drug O 
accumulation O 
in O 
the O 
brain O 
based O 
on O 
the O 
area O 
under O 
the O 
drug O 
concentration O 
- O 
time O 
curve O 
in O 
brain O 
measured O 
in O 
the O 
cassette O 
dosing O 
study O 
( O 
r O 
( O 
2 O 
) O 
= O 
0.92 O 
) O 
. O 
Overall O 
, O 
the O 
current O 
studies O 
demonstrated O 
the O 
value O 
of O 
an O 
integrated O 
pharmacokinetic O 
- O 
driven O 
approach O 
to O 
identify O 
potentially O 
efficacious O 
agents O 
for O 
brain O 
tumor O 
chemotherapy O 
. O 

organic O 
cation O 
transporter O 
3 O 
( O 
OCT3 O 
and O 
SLC22A3 O 
) O 
mediates O 
the O 
uptake O 
of O 
many O 
important O 
endogenous O 
amines B-FAMILY 
and O 
basic O 
drugs O 
in O 
a O 
variety O 
of O 
tissues O 
. O 
OCT3 O 
is O 
identified O 
as O 
one O 
of O 
the O 
important O 
risk O 
loci O 
for O 
prostate O 
cancer O 
, O 
and O 
is O 
markedly O 
underexpressed O 
in O 
aggressive O 
prostate O 
cancers O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
identify O 
genetic O 
and O 
epigenetic O 
factors O 
in O 
the O 
promoter O 
region O 
that O 
influence O 
the O 
expression O 
level O 
of O 
OCT3 O 
. O 
Haplotypes O 
that O 
contained O 
the O 
common O 
variants O 
, O 
g.-81G O 
> O 
delGA O 
( O 
rs60515630 O 
) O 
( O 
minor O 
allele O 
frequency O 
11.5% O 
in O 
African O 
American O 
) O 
and O 
g.-2G O 
> O 
A O 
( O 
rs555754 O 
) O 
( O 
minor O 
allele O 
frequency O 
> O 
30% O 
in O 
all O 
ethnic O 
groups O 
) O 
showed O 
significant O 
increases O 
in O 
luciferase O 
reporter O 
activities O 
and O 
exhibited O 
stronger O 
transcription O 
factor O 
- O 
binding O 
affinity O 
than O 
the O 
haplotypes O 
that O 
contained O 
the O 
major O 
alleles O 
. O 
Consistent O 
with O 
the O 
reporter O 
assays O 
, O 
OCT3 O 
messenger O 
RNA O 
expression O 
levels O 
were O 
significantly O 
higher O 
in O 
Asian O 
( O 
P O 
< O 
0.001 O 
) O 
and O 
Caucasian O 
( O 
P O 
< O 
0.05 O 
) O 
liver O 
samples O 
from O 
individuals O 
who O 
were O 
homozygous O 
for O 
g.-2A O 
/ O 
A O 
in O 
comparison O 
with O 
those O 
homozygous O 
for O 
the O 
g.-2G O 
/ O 
G O 
allele O 
. O 
Studies O 
revealed O 
that O 
the O 
methylation O 
level O 
in O 
the O 
basal O 
promoter O 
region O 
of O 
OCT3 O 
was O 
associated O 
with O 
OCT3 O 
expression O 
level O 
and O 
tumorigenesis O 
capability O 
in O 
various O 
prostate O 
cancer O 
cell O 
lines O 
. O 
The O 
methylation O 
level O 
of O 
the O 
OCT3 O 
promoter O 
was O 
higher O 
in O 
62% O 
of O 
prostate O 
tumor O 
samples O 
compared O 
with O 
matched O 
normal O 
samples O 
. O 
Our O 
studies O 
demonstrate O 
that O 
genetic O 
polymorphisms O 
in O 
the O 
proximal O 
promoter O 
region O 
of O 
OCT3 O 
alter O 
the O 
transcription O 
rate O 
of O 
the O 
gene O 
and O 
may O 
be O 
associated O 
with O 
altered O 
expression O 
levels O 
of O 
OCT3 O 
in O 
human O 
liver O 
. O 
Aberrant O 
methylation O 
contributes O 
to O 
the O 
reduced O 
expression O 
of O 
OCT3 O 
in O 
prostate O 
cancer O 
. O 

many O 
functions O 
and O 
targets O 
have O 
been O 
attributed O 
to O 
the O 
histone O 
and O 
protein O 
deacetylase O 
SIRT1 O 
, O 
a O 
comprehensive O 
analysis O 
of O 
SIRT1 O 
binding O 
proteins O 
yielding O 
a O 
high O 
- O 
confidence O 
interaction O 
map O 
has O 
not O 
been O 
established O 
. O 
Using O 
a O 
comparative O 
statistical O 
analysis O 
of O 
binding O 
partners O 
, O 
we O 
have O 
assembled O 
a O 
high O 
- O 
confidence O 
SIRT1 O 
interactome O 
. O 
Employing O 
this O 
method O 
, O 
we O 
identified O 
the O 
deubiquitinating O 
enzyme O 
ubiquitin O 
- O 
specific O 
protease O 
22 O 
( O 
USP22 O 
) O 
, O 
a O 
component O 
of O 
the O 
deubiquitinating O 
module O 
( O 
DUBm O 
) O 
of O 
the O 
SAGA O 
transcriptional O 
coactivating O 
complex O 
, O 
as O 
a O 
SIRT1-interacting O 
partner O 
. O 
We O 
found O 
that O 
this O 
interaction O 
is O 
highly O 
specific O 
, O 
requires O 
the O 
ZnF B-FORMULA 
-UBP O 
domain O 
of O 
USP22 O 
, O 
and O 
is O 
disrupted O 
by O 
the O 
inactivating O 
H363Y O 
mutation O 
within O 
SIRT1 O 
. O 
Moreover O 
, O 
we O 
show O 
that O 
USP22 O 
is O 
acetylated O 
on O 
multiple O 
lysine B-TRIVIAL 
residues O 
and O 
that O 
alteration O 
of O 
a O 
single O 
lysine B-TRIVIAL 
( O 
K129 O 
) O 
within O 
the O 
ZnF B-FORMULA 
-UBP O 
domain O 
is O 
sufficient O 
to O 
alter O 
interaction O 
of O 
the O 
DUBm O 
with O 
the O 
core O 
SAGA O 
complex O 
. O 
Furthermore O 
, O 
USP22 O 
- O 
mediated O 
recruitment O 
of O 
SIRT1 O 
activity O 
promotes O 
the O 
deacetylation O 
of O 
individual O 
SAGA O 
complex O 
components O 
. O 
Our O 
results O 
indicate O 
an O 
important O 
role O 
of O 
SIRT1 O 
- O 
mediated O 
deacetylation O 
in O 
regulating O 
the O 
formation O 
of O 
DUBm O 
subcomplexes O 
within O 
the O 
larger O 
SAGA O 
complex O 
. O 

recent O 
years O 
, O 
due O 
to O 
the O 
specific O 
health O 
benefits O 
associated O 
with O 
bioactive O 
peptides O 
and O 
the O 
reduction O 
of O 
protein O 
allergenicity O 
by O 
enzymatic O 
hydrolysis O 
, O 
the O 
utilisation O 
of O 
protein O 
hydrolysates O 
in O 
the O 
intermediate O 
- O 
moisture O 
food O 
( O 
IMF O 
) O 
market O 
, O 
such O 
as O 
high O 
protein O 
nutrition O 
bars O 
( O 
HPNB O 
) O 
, O 
has O 
significantly O 
increased O 
. O 
Currently O 
, O 
no O 
reported O 
study O 
is O 
related O 
to O 
the O 
storage O 
stability O 
of O 
dried O 
hen O 
egg O 
white O 
( O 
DEW O 
) O 
and O 
its O 
hydrolysates O 
( O 
HEW O 
) O 
in O 
an O 
IMF O 
matrix O 
. O 
Therefore O 
, O 
three O 
DEW O 
/ O 
HEW O 
dough O 
model O 
systems O 
( O 
100%HEW O 
+ O 
0%DEW O 
, O 
75%HEW O 
+ O 
25%DEW O 
and O 
50%HEW O 
+ O 
50%DEW O 
) O 
were O 
established O 
using O 
two O 
commercial O 
spray O 
- O 
dried O 
egg O 
white O 
powders O 
to O 
study O 
the O 
effect O 
of O 
temperature O 
and O 
fraction O 
of O 
HEW O 
on O 
these O 
IMF O 
models O 
( O 
water O 
activity O 
(a(w)) O 
: O 
∼0.8 O 
) O 
. O 
During O 
storage O 
at O 
three O 
different O 
temperatures O 
( O 
23 O 
, O 
35 O 
and O 
45°C O 
) O 
for O 
70 O 
days O 
, O 
the O 
selected O 
physicochemical O 
properties O 
of O 
the O 
dough O 
systems O 
were O 
compared O 
. O 
Overall O 
, O 
kinetic O 
analysis O 
showed O 
an O 
apparent O 
zero O 
- O 
order O 
model O 
fit O 
for O 
the O 
change O 
in O 
the O 
colour O 
(L(∗)) O 
, O 
fluorescence O 
intensity O 
( O 
FI O 
) O 
and O 
hardness O 
, O 
as O 
a O 
function O 
of O 
time O 
, O 
for O 
different O 
dough O 
model O 
systems O 
. O 
As O 
expected O 
, O 
the O 
L(∗) O 
, O 
FI O 
and O 
hardness O 
increased O 
as O 
a O 
function O 
of O 
time O 
mainly O 
due O 
to O 
the O 
Maillard O 
reaction O 
. O 
The O 
amount O 
of O 
free O 
amino B-FAMILY 
groups O 
decreased O 
, O 
with O 
an O 
increase O 
in O 
rate O 
of O 
loss O 
, O 
as O 
temperature O 
increased O 
in O 
the O 
100%HEW O 
+ O 
0%DEW O 
model O 
. O 
When O 
DEW O 
was O 
substituted O 
for O 
some O 
HEW O 
, O 
the O 
regeneration O 
of O 
the O 
free O 
amino B-FAMILY 
groups O 
after O 
loss O 
was O 
observed O 
as O 
a O 
function O 
of O 
time O 
. O 
Furthermore O 
, O 
when O 
the O 
percentage O 
of O 
HEW O 
was O 
decreased O 
, O 
the O 
incidence O 
of O 
mouldy O 
samples O 
occurred O 
sooner O 
, O 
which O 
indicates O 
that O 
HEW O 
has O 
some O 
antimicrobial O 
ability O 
, O 
especially O 
in O 
the O 
100%HEW O 
+ O 
0%DEW O 
system O 
where O 
mould O 
growth O 
did O 
not O 
occur O 
. O 

production O 
and O 
use O 
of O 
engineered O 
nanomaterials O 
( O 
ENMs O 
) O 
are O 
increasing O 
rapidly O 
, O 
and O 
therefore O 
, O 
the O 
need O 
to O 
assess O 
their O 
environmental O 
exposure O 
and O 
associated O 
risks O 
has O 
become O 
increasingly O 
important O 
. O 
Only O 
a O 
handful O 
of O 
studies O 
have O 
quantified O 
the O 
release O 
and O 
environmental O 
concentrations O 
of O 
ENMs O 
, O 
but O 
much O 
work O 
has O 
been O 
done O 
to O 
investigate O 
the O 
effects O 
of O 
these O 
materials O 
on O 
organisms O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
quantify O 
probabilistically O 
the O 
environmental O 
risks O 
of O 
ENMs O 
, O 
producing O 
species O 
sensitivity O 
distributions O 
that O 
were O 
then O 
compared O 
with O 
probability O 
distributions O 
of O 
predicted O 
environmental O 
concentrations O 
. O 
Five O 
nanomaterials O 
( O 
nano- O 
Ag B-FORMULA 
, O 
nano- O 
TiO2 B-FORMULA 
, O 
nano- O 
ZnO B-FORMULA 
, O 
carbon B-SYSTEMATIC 
nanotubes O 
[ O 
CNTs O 
] O 
, O 
and O 
fullerenes B-FAMILY 
) O 
and O 
4 O 
environmental O 
compartments O 
( O 
surface O 
water O 
, O 
sewage O 
treatment O 
plant O 
effluents O 
, O 
soils O 
, O 
and O 
sludge O 
- O 
treated O 
soils O 
) O 
were O 
considered O 
. O 
From O 
60 O 
ecotoxicological O 
studies O 
, O 
the O 
authors O 
extracted O 
112 O 
single O 
values O 
to O 
work O 
with O 
( O 
25 O 
values O 
in O 
13 O 
studies O 
for O 
nano- O 
Ag B-FORMULA 
, O 
17 O 
values O 
in O 
10 O 
studies O 
for O 
CNTs O 
, O 
7 O 
values O 
in O 
7 O 
studies O 
for O 
fullerenes B-FAMILY 
, O 
34 O 
values O 
in O 
23 O 
studies O 
for O 
nano- O 
TiO2 B-FORMULA 
, O 
and O 
29 O 
values O 
in O 
17 O 
studies O 
for O 
nano- O 
ZnO B-FORMULA 
) O 
. O 
The O 
results O 
indicate O 
there O 
is O 
only O 
a O 
marginal O 
risk O 
for O 
these O 
metal O 
- O 
based O 
nanomaterials O 
in O 
surface O 
water O 
( O 
0.7% O 
risk O 
for O 
nano- O 
Ag B-FORMULA 
and O 
< O 
0.1% O 
for O 
nano- O 
TiO2 B-FORMULA 
) O 
and O 
some O 
risk O 
in O 
sewage O 
treatment O 
plant O 
effluents O 
( O 
nano- O 
Ag B-FORMULA 
39.7% O 
, O 
nano- O 
TiO2 B-FORMULA 
18.7% O 
, O 
and O 
nano- O 
ZnO B-FORMULA 
1.1% O 
) O 
. O 
Apart O 
from O 
a O 
marginal O 
value O 
of O 
< O 
0.1% O 
for O 
nano- O 
TiO2 B-FORMULA 
in O 
sludge O 
- O 
treated O 
soils O 
, O 
no O 
risk O 
from O 
the O 
other O 
evaluated O 
ENMs O 
in O 
terrestrial O 
compartments O 
is O 
currently O 
predicted O 
. O 
The O 
discussion O 
of O 
the O 
results O 
considers O 
the O 
influence O 
of O 
the O 
effects O 
of O 
different O 
forms O 
of O 
1 O 
ENM O 
( O 
coating O 
, O 
agglomeration O 
state O 
, O 
and O 
mineralogy O 
) O 
, O 
the O 
test O 
conditions O 
( O 
dissolution O 
and O 
agglomeration O 
) O 
, O 
and O 
transformation O 
reactions O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1278-1287 O 
. O 
© O 
2013 O 
SETAC O 
. O 

impact O 
of O 
catechin B-TRIVIAL 
and O 
epicatechin B-TRIVIAL 
, O 
total O 
phenols B-FAMILY 
and O 
PPO O 
activity O 
on O 
the O 
Mal O 
d O 
1 O 
content O 
in O 
apple O 
fruit O 
. O 

most O 
important O 
apple O 
allergen O 
in O 
Central O 
Europe O 
and O 
North O 
America O 
is O 
Mal O 
d O 
1 O 
. O 
Apples O 
are O 
a O 
very O 
important O 
source O 
of O 
secondary O 
plant O 
metabolites O 
like O 
polyphenols B-FAMILY 
in O 
human O 
nutrition O 
. O 
It O 
is O 
known O 
that O 
oxidised B-FAMILY 
phenols I-FAMILY 
can O 
bind O 
proteins O 
. O 
These O 
irreversible O 
bindings O 
can O 
lead O 
to O 
a O 
reduced O 
allergenicity O 
. O 
The O 
most O 
important O 
phenols B-FAMILY 
in O 
apple O 
are O 
epicatechin B-TRIVIAL 
, O 
catechin B-TRIVIAL 
and O 
their O 
polymeric O 
structures O 
, O 
which O 
have O 
been O 
identified O 
as O 
substrates O 
of O 
the O 
polyphenoloxidase O 
( O 
PPO O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
analyse O 
the O 
influence O 
of O 
naturally O 
occurring O 
catechin B-TRIVIAL 
and O 
epicatechin B-TRIVIAL 
contents O 
in O 
apple O 
on O 
the O 
allergenicity O 
of O 
apple O 
fruits O 
. O 
Fruits O 
of O 
the O 
cultivars O 
' O 
Elstar O 
' O 
, O 
' O 
Diwa O 
' O 
and O 
' O 
Boskoop O 
' O 
were O 
harvested O 
and O 
stored O 
for O 
8 O 
and O 
12weeks O 
in O 
a O 
cold O 
- O 
chamber O 
at O 
2°C O 
. O 
Mal O 
d O 
1- O 
, O 
catechin B-TRIVIAL 
- O 
, O 
epicatechin B-TRIVIAL 
- O 
and O 
total O 
phenol B-SYSTEMATIC 
content O 
as O 
well O 
as O 
the O 
activity O 
of O 
PPO O 
were O 
determined O 
. O 
Correlation O 
analysis O 
showed O 
that O 
naturally O 
occurring O 
catechin B-TRIVIAL 
as O 
well O 
as O 
epicatechin B-TRIVIAL 
has O 
no O 
impact O 
on O 
the O 
Mal O 
d O 
1 O 
content O 
of O 
the O 
tested O 
cultivars O 
: O 
correlation O 
coefficient O 
ranged O 
from O 
-0.203 O 
to O 
0.501 O 
for O 
the O 
correlation O 
between O 
Mal O 
d O 
1 O 
and O 
catechin B-TRIVIAL 
. O 
The O 
results O 
further O 
indicated O 
that O 
the O 
activity O 
of O 
PPO O 
is O 
more O 
important O 
than O 
the O 
content O 
of O 
total O 
phenols B-FAMILY 
to O 
reduce O 
the O 
Mal O 
d O 
1 O 
level O 
. O 
If O 
there O 
is O 
a O 
high O 
PPO O 
activity O 
, O 
Mal O 
d O 
1 O 
could O 
be O 
reduced O 
even O 
if O 
the O 
total O 
phenol B-SYSTEMATIC 
concentration O 
is O 
low O 
. O 

CpG B-ABBREVIATION 
methylation O 
and O 
activation O 
- O 
induced O 
deaminase O 
are O 
required O 
for O 
the O 
fragility O 
of O 
the O 
human O 
bcl-2 O 
major O 
breakpoint O 
region O 
: O 
implications O 
for O 
the O 
timing O 
of O 
the O 
breaks O 
in O 
the O 
t(14;18) O 
translocation O 
. O 

t(14;18) O 
chromosomal O 
translocation O 
typically O 
involves O 
breakage O 
at O 
the O 
bcl-2 O 
major O 
breakpoint O 
region O 
( O 
MBR O 
) O 
to O 
cause O 
human O 
follicular O 
lymphoma O 
. O 
A O 
theory O 
to O 
explain O 
the O 
striking O 
propensity O 
of O 
the O 
MBR O 
breaks O 
at O 
three O 
CpG B-ABBREVIATION 
clusters O 
within O 
the O 
175-bp O 
MBR O 
region O 
invoked O 
activation O 
- O 
induced O 
deaminase O 
( O 
AID O 
) O 
. O 
In O 
a O 
test O 
of O 
that O 
theory O 
, O 
we O 
used O 
here O 
minichromosomal O 
substrates O 
in O 
human O 
pre-B O 
cell O 
lines O 
. O 
Consistent O 
with O 
the O 
essential O 
elements O 
of O 
the O 
theory O 
, O 
we O 
found O 
that O 
the O 
MBR O 
breakage O 
process O 
is O 
indeed O 
highly O 
dependent O 
on O 
DNA O 
methylation O 
at O 
the O 
CpG B-ABBREVIATION 
sites O 
and O 
highly O 
dependent O 
on O 
the O 
AID O 
enzyme O 
to O 
create O 
lesions O 
at O 
peak O 
locations O 
within O 
the O 
MBR O 
. O 
Interestingly O 
, O 
breakage O 
of O 
the O 
phosphodiester B-SYSTEMATIC 
bonds O 
at O 
the O 
AID O 
- O 
initiated O 
MBR O 
lesions O 
is O 
RAG O 
dependent O 
, O 
but O 
, O 
unexpectedly O 
, O 
most O 
are O 
also O 
dependent O 
on O 
Artemis O 
. O 
We O 
found O 
that O 
Artemis O 
is O 
capable O 
of O 
nicking O 
small O 
heteroduplex O 
structures O 
and O 
is O 
even O 
able O 
to O 
nick O 
single O 
- O 
base O 
mismatches O 
. O 
This O 
raises O 
the O 
possibility O 
that O 
activated O 
Artemis O 
, O 
derived O 
from O 
the O 
unjoined O 
D O 
to O 
J(H) O 
DNA O 
ends O 
at O 
the O 
IgH O 
locus O 
on O 
chromosome O 
14 O 
, O 
nicks O 
AID-generated O 
TG O 
mismatches O 
at O 
methyl O 
CpG B-ABBREVIATION 
sites O 
, O 
and O 
this O 
would O 
explain O 
why O 
the O 
breaks O 
at O 
the O 
chromosome O 
18 O 
MBR O 
occur O 
within O 
the O 
same O 
time O 
window O 
as O 
those O 
on O 
chromosome O 
14 O 
. O 

nanoparticle O 
based O 
highly O 
efficient O 
CdS B-FORMULA 
/ O 
CdSe B-FORMULA 
quantum O 
dot O 
- O 
sensitized O 
solar O 
cells O 
. O 

nm O 
ZnO B-FORMULA 
nanoparticles O 
are O 
used O 
to O 
fabricate O 
the O 
mesoporous O 
photoanode O 
of O 
the O 
CdS B-FORMULA 
/ O 
CdSe B-FORMULA 
quantum O 
dot O 
- O 
sensitized O 
solar O 
cells O 
by O 
the O 
simple O 
doctor O 
blade O 
method O 
. O 
A O 
maximum O 
power O 
conversion O 
efficiency O 
of O 
4.46% O 
has O 
been O 
achieved O 
, O 
which O 
indicated O 
exciting O 
prospects O 
for O 
ZnO B-FORMULA 
nanoparticle O 
based O 
quantum O 
dot O 
- O 
sensitized O 
solar O 
cells O 
. O 

- O 
principles O 
calculations O 
of O 
lithium B-SYSTEMATIC 
-ion O 
migration O 
at O 
a O 
coherent O 
grain O 
boundary O 
in O 
a O 
cathode O 
material O 
, O 
LiCoO(2) B-FORMULA 
. O 

of O 
theoretical O 
calculations O 
are O 
reported O 
, O 
examining O 
the O 
effect O 
of O 
a O 
coherent O 
twin O 
boundary O 
on O 
the O 
electrical O 
properties O 
of O 
LiCoO(2) B-FORMULA 
. O 
This O 
study O 
suggests O 
that O 
internal O 
interfaces O 
in O 
LiCoO(2) B-FORMULA 
strongly O 
affect O 
the O 
battery O 
voltage O 
, O 
battery O 
capacity O 
, O 
and O 
power O 
density O 
of O 
this O 
material O 
, O 
which O 
is O 
of O 
particular O 
concern O 
if O 
it O 
is O 
used O 
in O 
all O 
- O 
solid O 
- O 
state O 
Li B-FORMULA 
-ion O 
batteries O 
. O 

starch O 
and O 
lecithin O 
complex O 
as O 
matrix O 
for O 
targeted O 
drug O 
delivery O 
: O 
I O 
. O 
Monolithic O 
Mesalamine B-TRIVIAL 
forms O 
for O 
colon O 
delivery O 
. O 

drugs O 
expected O 
to O 
act O 
locally O 
in O 
the O 
colon O 
, O 
and O 
for O 
successful O 
treatment O 
, O 
a O 
delivery O 
device O 
is O 
necessary O 
, O 
in O 
order O 
to O 
limit O 
the O 
systemic O 
absorption O 
which O 
decreases O 
effectiveness O 
and O 
causes O 
important O 
side O 
effects O 
. O 
Various O 
delayed O 
release O 
systems O 
are O 
currently O 
commercialized O 
; O 
most O 
of O 
them O 
based O 
on O 
pH-dependent O 
release O 
which O 
is O 
sensitive O 
to O 
gastrointestinal O 
pH O 
variation O 
. O 
This O 
study O 
proposes O 
a O 
novel O 
excipient O 
for O 
colon O 
delivery O 
. O 
This O 
new O 
preparation O 
consists O 
in O 
the O 
complexation O 
between O 
carboxymethyl B-SYSTEMATIC 
starch O 
( O 
CMS O 
) O 
and O 
Lecithin O 
( O 
L O 
) O 
. O 
As O 
opposed O 
to O 
existing O 
excipients O 
, O 
the O 
new O 
complex O 
is O 
pH O 
- O 
independent O 
, O 
inexpensive O 
, O 
and O 
easy O 
to O 
manufacture O 
and O 
allows O 
a O 
high O 
drug O 
loading O 
. O 
FTIR O 
, O 
X-ray O 
, O 
and O 
SEM O 
structural O 
analysis O 
all O 
support O 
the O 
hypothesis O 
of O 
the O 
formation O 
of O 
a O 
complex O 
. O 
By O 
minor O 
variation O 
of O 
the O 
excipient O 
content O 
within O 
the O 
tablet O 
, O 
it O 
is O 
possible O 
to O 
modulate O 
the O 
release O 
time O 
and O 
delivery O 
at O 
specific O 
sites O 
of O 
the O 
gastrointestinal O 
tract O 
. O 
This O 
study O 
opens O 
the O 
door O 
to O 
a O 
new O 
pH O 
- O 
independent O 
delivery O 
system O 
for O 
mesalamine B-TRIVIAL 
targeted O 
administration O 
. O 
Our O 
novel O 
formulation O 
fits O 
well O 
with O 
the O 
posology O 
of O 
mesalamine B-TRIVIAL 
, O 
used O 
in O 
the O 
treatment O 
of O 
Inflammatory O 
Bowel O 
Disease O 
( O 
IBD O 
) O 
, O 
which O 
requires O 
repeated O 
administrations O 
( O 
1g O 
orally O 
four O 
times O 
a O 
day O 
) O 
to O 
maintain O 
a O 
good O 
quality O 
of O 
life O 
. O 

irritation O 
evaluation O 
is O 
an O 
important O 
endpoint O 
for O 
the O 
safety O 
assessment O 
of O 
cosmetic O 
ingredients O 
required O 
by O 
various O 
regulatory O 
authorities O 
for O 
notification O 
and O 
/ O 
or O 
import O 
of O 
test O 
substances O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
to O 
investigate O 
possible O 
protocol O 
adaptations O 
of O 
the O 
currently O 
validated O 
in O 
vitro O 
skin O 
irritation O 
test O 
methods O 
based O 
on O 
reconstructed O 
human O 
epidermis O 
( O 
RhE O 
) O 
for O 
the O 
testing O 
of O 
plant O 
extracts O 
and O 
natural O 
botanicals O 
. O 
Due O 
to O 
their O 
specific O 
physico O 
- O 
chemical O 
properties O 
, O 
such O 
as O 
lipophilicity O 
, O 
sticky O 
/ O 
buttery O 
- O 
like O 
texture O 
, O 
waxy O 
/ O 
creamy O 
foam O 
characteristics O 
, O 
normal O 
washing O 
procedures O 
can O 
lead O 
to O 
an O 
incomplete O 
removal O 
of O 
these O 
materials O 
and O 
/ O 
or O 
to O 
mechanical O 
damage O 
to O 
the O 
tissues O 
, O 
resulting O 
in O 
an O 
impaired O 
prediction O 
of O 
the O 
true O 
skin O 
irritation O 
potential O 
of O 
the O 
materials O 
. O 
For O 
this O 
reason O 
different O 
refined O 
washing O 
procedures O 
were O 
evaluated O 
for O 
their O 
ability O 
to O 
ensure O 
appropriate O 
removal O 
of O 
greasy O 
and O 
sticky O 
substances O 
while O 
not O 
altering O 
the O 
normal O 
responses O 
of O 
the O 
validated O 
RhE O 
test O 
method O 
. O 
Amongst O 
the O 
different O 
procedures O 
evaluated O 
, O 
the O 
use O 
of O 
a O 
SDS B-ABBREVIATION 
0.1% O 
PBS O 
solution O 
to O 
remove O 
the O 
sticky O 
and O 
greasy O 
test O 
material O 
prior O 
to O 
the O 
normal O 
washing O 
procedures O 
was O 
found O 
to O 
be O 
the O 
most O 
suitable O 
adaptation O 
to O 
ensure O 
efficient O 
removal O 
of O 
greasy O 
and O 
sticky O 
in O 
- O 
house O 
controls O 
without O 
affecting O 
the O 
results O 
of O 
the O 
negative O 
control O 
. O 
The O 
predictive O 
capacity O 
of O 
the O 
refined O 
SDS B-ABBREVIATION 
0.1% O 
washing O 
procedure O 
, O 
was O 
investigated O 
by O 
using O 
twelve O 
oily O 
and O 
viscous O 
compounds O 
having O 
known O 
skin O 
irritation O 
effects O 
supported O 
by O 
raw O 
and O 
/ O 
or O 
peer O 
reviewed O 
in O 
vivo O 
data O 
. O 
The O 
normal O 
washing O 
procedure O 
resulted O 
in O 
8 O 
out O 
of O 
10 O 
correctly O 
predicted O 
compounds O 
as O 
compared O 
to O 
9 O 
out O 
of O 
10 O 
with O 
the O 
refined O 
washing O 
procedures O 
, O 
showing O 
an O 
increase O 
in O 
the O 
predictive O 
ability O 
of O 
the O 
assay O 
. O 
The O 
refined O 
washing O 
procedure O 
allowed O 
to O 
correctly O 
identify O 
all O 
in O 
vivo O 
skin O 
irritant O 
materials O 
showing O 
the O 
same O 
sensitivity O 
as O 
the O 
normal O 
washing O 
procedures O 
, O 
and O 
further O 
increased O 
the O 
specificity O 
of O 
the O 
assay O 
from O 
5 O 
to O 
6 O 
correct O 
predictions O 
out O 
of O 
7 O 
non O 
irritants O 
as O 
compared O 
to O 
the O 
normal O 
washing O 
procedures O 
. O 
In O 
addition O 
, O 
when O 
exposed O 
to O 
non-irritant O 
oily O 
and O 
viscous O 
materials O 
, O 
tissues O 
rinsed O 
with O 
0.1% O 
SDS B-ABBREVIATION 
generally O 
showed O 
increased O 
viabilities O 
accompanied O 
by O 
decreased O 
variabilities O 
as O 
compared O 
to O 
the O 
normal O 
washing O 
procedures O 
. O 
Similar O 
results O 
were O 
obtained O 
when O 
testing O 
typical O 
in O 
- O 
house O 
natural O 
botanical O 
ingredients O 
. O 
In O 
conclusion O 
, O 
the O 
use O 
of O 
a O 
refined O 
washing O 
procedure O 
making O 
use O 
of O 
SDS B-ABBREVIATION 
0.1% O 
in O 
PBS O 
was O 
found O 
a O 
suitable O 
procedure O 
to O 
ensure O 
efficient O 
removal O 
of O 
greasy O 
and O 
sticky O 
materials O 
, O 
leading O 
to O 
an O 
increased O 
predictive O 
capacity O 
and O 
decreased O 
variability O 
of O 
the O 
tissue O 
responses O 
while O 
maintaining O 
its O 
sensitivity O 
and O 
not O 
affecting O 
untreated O 
tissues O 
morphology O 
and O 
viability O 
. O 

- O 
sensitive O 
two O 
- O 
dimensional O 
magneto O 
- O 
fingerprint O 
in O 
mesoscopic O 
Bi2Se3 B-FORMULA 
channels O 
. O 

Aharonov-Bohm O 
and O 
Altshuler-Aronov-Spivak O 
oscillations O 
have O 
traditionally O 
been O 
observed O 
in O 
lateral O 
transport O 
through O 
patterned O 
mesoscopic O 
loops O 
of O 
diffusive O 
conductors O 
. O 
However O 
, O 
our O 
studies O 
of O 
perpendicular O 
- O 
to O 
- O 
plane O 
magnetotransport O 
in O 
straight O 
- O 
channel O 
, O 
diffusive O 
devices O 
of O 
epitaxial O 
Bi2Se3 B-FORMULA 
surprisingly O 
reveal O 
signatures O 
of O 
Aharonov-Bohm O 
orbits O 
-- O 
periodic O 
conductance O 
fluctuation O 
magneto O 
- O 
fingerprints O 
-- O 
even O 
though O 
the O 
devices O 
are O 
not O 
explicitly O 
patterned O 
into O 
loops O 
. O 
We O 
show O 
that O 
the O 
length O 
scale O 
of O 
these O 
orbits O 
corresponds O 
to O 
the O 
typical O 
perimeter O 
of O 
triangular O 
terraces O 
found O 
on O 
the O 
surface O 
of O 
these O 
thin O 
film O 
devices O 
, O 
strongly O 
suggesting O 
that O 
the O 
periodic O 
magneto O 
- O 
fingerprint O 
arises O 
from O 
coherent O 
scattering O 
of O 
electron O 
waves O 
from O 
the O 
step O 
- O 
edges O 
. O 
Our O 
interpretation O 
is O 
bolstered O 
by O 
control O 
measurements O 
in O 
devices O 
without O 
such O 
surface O 
morphology O 
which O 
only O 
show O 
a O 
conventional O 
, O 
aperiodic O 
magneto O 
- O 
fingerprint O 
. O 
These O 
results O 
show O 
that O 
lithographically O 
patterned O 
Bi2Se3 B-FORMULA 
devices O 
provide O 
a O 
novel O 
class O 
of O 
mesoscopic O 
physical O 
systems O 
for O 
systematic O 
studies O 
of O 
coherent O 
surface O 
sensitive O 
transport O 
. O 

functionalization O 
of O 
the O 
internal O 
and O 
the O 
external O 
surfaces O 
of O 
mesoporous O 
silicon B-SYSTEMATIC 
by O 
liquid O 
masking O 
. O 

general O 
approach O 
for O 
selective O 
, O 
differential O 
functionalization O 
of O 
the O 
interior O 
and O 
exterior O 
surfaces O 
of O 
mesoporous O 
Si B-FORMULA 
is O 
reported O 
. O 
The O 
method O 
employs O 
two O 
immiscible O 
liquids O 
, O 
one O 
inert O 
and O 
the O 
other O 
chemically O 
reactive O 
with O 
the O 
porous O 
Si B-FORMULA 
nanostructure O 
. O 
First O 
, O 
a O 
porous O 
Si B-FORMULA 
sample O 
is O 
prepared O 
by O 
electrochemical O 
etch O 
and O 
then O 
it O 
is O 
mildly O 
oxidized O 
, O 
which O 
places O 
a O 
thin O 
layer O 
of O 
silicon B-SYSTEMATIC 
oxide I-SYSTEMATIC 
at O 
the O 
surface O 
. O 
The O 
inner O 
pore O 
walls O 
of O 
the O 
partially O 
oxidized O 
porous O 
Si B-FORMULA 
film O 
are O 
then O 
infiltrated O 
with O 
an O 
inert O 
liquid O 
( O 
octane B-SYSTEMATIC 
) O 
. O 
The O 
sample O 
is O 
then O 
immersed O 
in O 
aqueous O 
solution O 
containing O 
hydrogen B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
( O 
HF B-FORMULA 
) O 
, O 
which O 
serves O 
as O 
the O 
reactive O 
liquid O 
. O 
The O 
hydrophobic O 
phase O 
is O 
retained O 
in O 
the O 
interior O 
of O 
the O 
porous O 
nanostructure O 
, O 
and O 
HF B-FORMULA 
( O 
aq O 
) O 
attacks O 
only O 
the O 
exposed O 
surfaces O 
of O 
the O 
oxidized O 
porous O 
Si B-FORMULA 
sample O 
, O 
generating O 
a O 
hydrophobic O 
, O 
hydrogen B-SYSTEMATIC 
-terminated O 
( O 
Si-H B-FORMULA 
) O 
outer O 
layer O 
. O 
The O 
reaction O 
is O 
self O 
- O 
limiting O 
due O 
to O 
the O 
immiscibility O 
of O 
octane B-SYSTEMATIC 
and O 
water O 
, O 
and O 
the O 
extent O 
of O 
penetration O 
of O 
the O 
Si-H B-FORMULA 
surface O 
into O 
the O 
porous O 
layer O 
is O 
dependent O 
on O 
the O 
time O 
of O 
exposure O 
to O 
HF B-FORMULA 
( O 
aq O 
) O 
. O 
The O 
Si-H B-FORMULA 
surface O 
can O 
then O 
be O 
modified O 
by O 
thermal O 
hydrosilylation O 
( O 
1-dodecene B-SYSTEMATIC 
or O 
10-bromo-1-decene B-SYSTEMATIC 
) O 
in O 
a O 
subsequent O 
step O 
, O 
resulting O 
in O 
a O 
bifunctional O 
porous O 
Si B-FORMULA 
film O 
containing O 
hydrophobic O 
pore O 
entrances O 
to O 
hydrophilic O 
inner O 
pores O 
. O 
The O 
hydrophobic O 
dodecyl B-SYSTEMATIC 
species O 
at O 
the O 
mouths O 
of O 
the O 
pores O 
is O 
found O 
to O 
form O 
a O 
barrier O 
for O 
molecular O 
transport O 
; O 
it O 
decreases O 
the O 
rate O 
of O 
leaching O 
( O 
into O 
water O 
) O 
of O 
a O 
rhodamine B-TRIVIAL 
test O 
molecule O 
that O 
is O 
preloaded O 
into O 
the O 
sample O 
by O 
> O 
8 O 
fold O 
. O 

bioaccessibility O 
and O 
speciation O 
in O 
biofortified O 
Pleurotus O 
mushrooms O 
grown O 
on O 
selenium B-SYSTEMATIC 
-rich O 
agricultural O 
residues O 
. O 

of O 
saprophytic O 
fungi O 
on O 
selenium B-SYSTEMATIC 
-rich O 
substrates O 
can O 
be O 
an O 
effective O 
means O 
to O 
produce O 
selenium B-SYSTEMATIC 
-fortified O 
food O 
. O 
Pleurotus O 
florida O 
, O 
an O 
edible O 
species O 
of O 
oyster O 
mushrooms O 
, O 
was O 
grown O 
on O 
wheat O 
straw O 
from O 
the O 
seleniferous O 
belt O 
of O 
Punjab O 
( O 
India O 
) O 
and O 
its O 
potential O 
to O 
mobilize O 
and O 
accumulate O 
selenium B-SYSTEMATIC 
from O 
the O 
growth O 
substrate O 
was O 
studied O 
. O 
Selenium B-SYSTEMATIC 
concentration O 
in O 
biofortified O 
mushrooms O 
was O 
800 O 
times O 
higher O 
compared O 
with O 
control O 
samples O 
grown O 
on O 
wheat O 
straw O 
from O 
non O 
selenium B-SYSTEMATIC 
-rich O 
areas O 
( O 
141 O 
vs O 
0.17μg O 
Se B-FORMULA 
g(-1) O 
dry O 
weight O 
) O 
. O 
Seventy O 
- O 
five O 
percent O 
of O 
the O 
selenium B-SYSTEMATIC 
was O 
extracted O 
after O 
in O 
vitro O 
simulated O 
gastrointestinal O 
digestion O 
and O 
investigation O 
of O 
the O 
selenium B-SYSTEMATIC 
molecular O 
fractions O 
by O 
size O 
exclusion O 
HPLC-ICP-MS O 
revealed O 
that O 
proteins O 
and O 
any O 
other O 
high O 
molecular O 
weight O 
selenium B-SYSTEMATIC 
-containing O 
molecule O 
were O 
hydrolyzed O 
to O 
peptides O 
and O 
low O 
molecular O 
weight O 
selenocompounds O 
. O 
Analysis O 
of O 
the O 
gastrointestinal O 
hydrolysates O 
by O 
anion O 
exchange O 
HPLC-ICP-MS O 
showed O 
that O 
the O 
bioaccessible O 
selenium B-SYSTEMATIC 
was O 
mainly O 
present O 
as O 
selenomethionine B-SYSTEMATIC 
, O 
a O 
good O 
bioavailable O 
source O 
of O 
selenium B-SYSTEMATIC 
, O 
which O 
accounted O 
for O 
73% O 
of O 
the O 
sum O 
of O 
the O 
detected O 
species O 
. O 
This O 
study O 
demonstrates O 
the O 
feasibility O 
of O 
producing O 
selenium B-SYSTEMATIC 
-biofortified O 
edible O 
mushrooms O 
using O 
selenium B-SYSTEMATIC 
-rich O 
agricultural O 
by O 
- O 
products O 
as O 
growth O 
substrates O 
. O 
The O 
proposed O 
approach O 
can O 
be O 
used O 
to O 
evaluate O 
whether O 
selenium B-SYSTEMATIC 
-contaminated O 
plant O 
waste O 
materials O 
harvested O 
from O 
high- O 
selenium B-SYSTEMATIC 
areas O 
may O 
be O 
used O 
to O 
produce O 
selenium B-SYSTEMATIC 
-biofortified O 
edible O 
mushrooms O 
based O 
on O 
the O 
concentration O 
, O 
bioaccessibility O 
and O 
speciation O 
of O 
selenium B-SYSTEMATIC 
in O 
the O 
mushrooms O 
. O 

Chemometric O 
Approach O 
to O 
Distribution O 
of O 
Selenium B-SYSTEMATIC 
in O 
Medicinal O 
Plants O 
Cultivated O 
in O 
Poland O 
. O 

The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
level O 
of O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
in O 
common O 
raw O 
plant O 
materials O 
( O 
herbs O 
, O 
leaves O 
, O 
flowers O 
, O 
fruits O 
, O 
and O 
roots O 
) O 
obtained O 
from O 
medicinal O 
plants O 
cultivated O 
in O 
Poland O 
. O 
Furthermore O 
, O 
the O 
relationship O 
between O 
the O 
morphological O 
part O 
of O 
a O 
plant O 
and O 
its O 
species O 
was O 
examined O 
, O 
and O 
the O 
concentration O 
of O 
Se B-FORMULA 
in O 
it O 
was O 
measured O 
. O 
Spectrofluorimetric O 
determination O 
of O 
Se B-FORMULA 
in O 
148 O 
samples O 
of O 
44 O 
plant O 
species O 
revealed O 
that O 
the O 
majority O 
of O 
the O 
plants O 
contained O 
Se B-FORMULA 
at O 
a O 
level O 
from O 
several O 
to O 
several O 
tens O 
of O 
μg O 
/ O 
kg O 
dry O 
weight O 
( O 
d.w O 
. O 
) O 
. O 
A O 
relatively O 
high O 
Se B-FORMULA 
concentration O 
, O 
in O 
the O 
order O 
of O 
50 O 
μg O 
/ O 
kg O 
d.w O 
. O 
, O 
was O 
found O 
in O 
Majoranae O 
herba O 
, O 
Crataegi O 
fructus O 
, O 
and O 
Lini O 
semen O 
. O 
An O 
especially O 
high O 
Se B-FORMULA 
level O 
, O 
> O 
100 O 
μg O 
/ O 
kg O 
d.w O 
. O 
, O 
was O 
found O 
in O 
only O 
three O 
plants-Equiseti O 
herba O 
, O 
Farfarae O 
folium O 
, O 
and O 
Cichorii O 
radix O 
. O 
Application O 
of O 
a O 
nonparametric O 
Kruskal-Wallis O 
analysis O 
of O 
variance O 
test O 
indicates O 
that O 
the O 
morphological O 
variable O 
influences O 
the O 
level O 
of O 
Se B-FORMULA 
in O 
the O 
studied O 
groups O 
of O 
raw O 
plant O 
materials O 
. O 
The O 
mean O 
concentration O 
of O 
Se B-FORMULA 
in O 
fruits O 
differs O 
significantly O 
from O 
that O 
found O 
in O 
flowers O 
and O 
roots O 
. O 
However O 
, O 
there O 
was O 
no O 
statistically O 
significant O 
difference O 
between O 
the O 
Se B-FORMULA 
content O 
in O 
herbs O 
and O 
leaves O 
and O 
its O 
levels O 
in O 
fruits O 
, O 
flowers O 
, O 
and O 
roots O 
. O 
Cluster O 
analysis O 
and O 
principal O 
component O 
analysis O 
calculations O 
show O 
that O 
it O 
is O 
possible O 
to O 
relate O 
the O 
Se B-FORMULA 
concentration O 
in O 
plant O 
material O 
to O 
the O 
plant O 
species O 
and O 
botanical O 
family O 
of O 
the O 
medicinal O 
plant O 
in O 
only O 
a O 
few O 
cases O 
. O 
Analysis O 
of O 
average O 
Se B-FORMULA 
levels O 
in O 
the O 
plant O 
species O 
showed O 
that O 
the O 
plants O 
belonging O 
to O 
the O 
Apiaceae O 
and O 
Labiatae O 
are O 
more O 
Se B-FORMULA 
-rich O 
than O 
those O 
belonging O 
to O 
Rosaceae O 
botanical O 
families O 
. O 

of O 
Bacillus O 
subtilis O 
to O 
mercury B-SYSTEMATIC 
induces O 
accumulation O 
of O 
shorter O 
tRNA O 
Cys B-FORMULA 
species O 
. O 

processing O 
is O 
an O 
essential O 
pathway O 
in O 
the O 
regulation O 
of O 
genetic O 
expression O 
in O 
the O 
cell O 
. O 
In O 
this O 
work O 
, O 
Bacillus O 
subtilis O 
was O 
used O 
to O 
understand O 
the O 
effects O 
of O 
mercury B-SYSTEMATIC 
on O 
the O 
mechanism O 
of O 
tRNA O 
metabolism O 
. O 
The O 
CVAAS O 
( O 
cold O 
vapor O 
atomic O 
absorption O 
spectroscopy O 
) O 
method O 
revealed O 
that O 
from O 
the O 
addition O 
of O 
HgCl2 B-FORMULA 
( O 
0.75 O 
μg O 
ml(-1) O 
) O 
during O 
the O 
bacterial O 
exponential O 
phase O 
, O 
ca O 
. O 
48% O 
of O 
the O 
added O 
mercury B-SYSTEMATIC 
was O 
taken O 
up O 
by O 
the O 
cells O 
. O 
This O 
led O 
to O 
an O 
immediate O 
reduction O 
in O 
the O 
rate O 
of O 
cell O 
division O 
. O 
During O 
this O 
response O 
, O 
we O 
observed O 
accumulation O 
of O 
species O 
shorter O 
than O 
mature O 
tRNA( O 
Cys B-FORMULA 
) O 
over O 
a O 
10 O 
h O 
period O 
. O 
We O 
did O 
not O 
observe O 
this O 
accumulation O 
for O 
another O 
five O 
tRNAs O 
analyzed O 
. O 
tRNA O 
processing O 
is O 
largely O 
dependent O 
on O 
RNase O 
R O 
and O 
PNPase O 
in O 
B O 
. O 
subtilis O 
. O 
Thus O 
, O 
when O 
the O 
exonuclease O 
PNPase O 
was O 
absent O 
, O 
we O 
found O 
that O 
the O 
shorter O 
tRNA( O 
Cys B-FORMULA 
) O 
species O 
increased O 
and O 
mature O 
tRNA( O 
Cys B-FORMULA 
) O 
decreased O 
after O 
mercury B-SYSTEMATIC 
addition O 
, O 
but O 
this O 
proportion O 
changed O 
during O 
the O 
time O 
analyzed O 
. O 
However O 
, O 
in O 
the O 
absence O 
of O 
RNase O 
R O 
and O 
PNPase O 
the O 
accumulation O 
of O 
the O 
shorter O 
tRNA( O 
Cys B-FORMULA 
) O 
was O 
more O 
pronounced O 
and O 
the O 
mature O 
form O 
was O 
not O 
recovered O 
. O 
In O 
the O 
single O 
rnr O 
mutant O 
strain O 
the O 
shorter O 
tRNA( O 
Cys B-FORMULA 
) O 
was O 
not O 
observed O 
. O 
All O 
together O 
, O 
we O 
provide O 
in O 
vivo O 
evidence O 
that O 
PNPase O 
and O 
RNase O 
R O 
are O 
indispensable O 
in O 
controlling O 
tRNA( O 
Cys B-FORMULA 
) O 
quality O 
in O 
the O 
presence O 
of O 
mercury B-SYSTEMATIC 
. O 

- O 
polarized O 
transport O 
through O 
single O 
- O 
molecule O 
magnet O 
Mn6 B-FORMULA 
complexes O 
. O 

coherent O 
transport O 
properties O 
of O 
a O 
device O 
, O 
constructed O 
by O 
sandwiching O 
a O 
Mn6 B-FORMULA 
single O 
- O 
molecule O 
magnet O 
between O 
two O 
gold O 
surfaces O 
, O 
are O 
studied O 
theoretically O 
by O 
using O 
the O 
non-equilibrium O 
Green's O 
function O 
approach O 
combined O 
with O 
density O 
functional O 
theory O 
. O 
Two O 
spin O 
states O 
of O 
such O 
Mn6 B-FORMULA 
complexes O 
are O 
explored O 
, O 
namely O 
the O 
ferromagnetically O 
coupled O 
configuration O 
of O 
the O 
six O 
Mn B-FORMULA 
(III) I-FORMULA 
cations O 
, O 
leading O 
to O 
the O 
S O 
= O 
12 O 
ground O 
state O 
, O 
and O 
the O 
low O 
S O 
= O 
4 O 
spin O 
state O 
. O 
For O 
voltages O 
up O 
to O 
1 O 
volt O 
the O 
S O 
= O 
12 O 
ground O 
state O 
shows O 
a O 
current O 
one O 
order O 
of O 
magnitude O 
larger O 
than O 
that O 
of O 
the O 
S O 
= O 
4 O 
state O 
. O 
Furthermore O 
this O 
is O 
almost O 
completely O 
spin O 
- O 
polarized O 
, O 
since O 
the O 
Mn6 B-FORMULA 
frontier O 
molecular O 
orbitals O 
for O 
S O 
= O 
12 O 
belong O 
to O 
the O 
same O 
spin O 
manifold O 
. O 
As O 
such O 
the O 
high O 
- O 
anisotropy O 
Mn6 B-FORMULA 
molecule O 
appears O 
as O 
a O 
promising O 
candidate O 
for O 
implementing O 
, O 
at O 
the O 
single O 
molecular O 
level O 
, O 
both O 
spin O 
- O 
switches O 
and O 
low O 
- O 
temperature O 
spin O 
- O 
valves O 
. O 

Conjugation O 
to O 
Polymeric O 
Micelles O 
via O 
Boronic B-SYSTEMATIC 
Acid I-SYSTEMATIC 
Ester I-SYSTEMATIC 
to O 
Deliver O 
Platinum B-SYSTEMATIC 
Drugs O 
to O 
Ovarian O 
Cancer O 
Cell O 
Lines O 
. O 

this O 
study O 
, O 
a O 
novel O 
technique O 
was O 
used O 
for O 
the O 
reversible O 
attachment O 
of O 
folic B-TRIVIAL 
acid I-TRIVIAL 
on O 
the O 
surface O 
of O 
polymeric O 
micelles O 
for O 
a O 
tumor O 
- O 
specific O 
drug O 
delivery O 
system O 
. O 
The O 
reversible O 
conjugation O 
is O 
based O 
on O 
the O 
interaction O 
between O 
phenylboronic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PBA B-ABBREVIATION 
) O 
and O 
dopamine B-TRIVIAL 
to O 
form O 
a O 
borate B-SYSTEMATIC 
ester I-SYSTEMATIC 
. O 
The O 
conjugation O 
is O 
fast O 
and O 
efficient O 
and O 
in O 
vitro O 
experiments O 
via O 
confocal O 
fluorescent O 
microscopy O 
show O 
that O 
the O 
linker O 
is O 
stable O 
in O 
for O 
several O 
hours O 
. O 
Reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
( O 
RAFT O 
) O 
polymerization O 
was O 
used O 
to O 
synthesize O 
two O 
various O 
sized O 
water O 
- O 
soluble O 
block O 
copolymer O 
of O 
oligoethylene B-FAMILY 
glycol I-FAMILY 
methylether I-FAMILY 
methacylate I-FAMILY 
and O 
methyl B-SYSTEMATIC 
acrylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
POEGMEMA35-b-PMAA200 B-ABBREVIATION 
and O 
POEGMEMA26-b-PMAA90 B-ABBREVIATION 
) O 
. O 
The O 
platinum B-SYSTEMATIC 
drug O 
, O 
oxoplatin B-TRIVIAL 
, O 
was O 
then O 
subsequently O 
attached O 
to O 
the O 
polymer O 
via O 
ester O 
formation O 
leading O 
to O 
platinum B-SYSTEMATIC 
loading O 
of O 
12 O 
wt O 
% O 
as O 
determined O 
by O 
TGA O 
. O 
The O 
platinum B-SYSTEMATIC 
-induced O 
amphiphilic O 
block O 
copolymers O 
that O 
consequently O 
led O 
to O 
the O 
formation O 
of O 
micelles O 
of O 
sizes O 
150 O 
and O 
20 O 
nm O 
in O 
an O 
aqueous O 
environment O 
with O 
the O 
longer O 
PMAA B-ABBREVIATION 
block O 
forming O 
larger O 
micelles O 
. O 
The O 
small O 
micelles O 
were O 
in O 
addition O 
cross O 
- O 
linked O 
using O 
1,8-diaminooctane B-SYSTEMATIC 
to O 
further O 
stabilize O 
their O 
structure O 
. O 
The O 
targeting O 
ability O 
of O 
folate B-TRIVIAL 
conjugated O 
polymeric O 
micelles O 
was O 
investigated O 
against O 
two O 
types O 
of O 
tumor O 
cell O 
lines O 
: O 
A549 O 
( O 
-FR O 
) O 
and O 
OVCAR-3 O 
( O 
+ O 
FR O 
) O 
. O 
The O 
cell O 
line O 
growth O 
inhibitory O 
efficacy O 
of O 
material O 
synthesized O 
was O 
evaluated O 
by O 
using O 
SRB O 
method O 
. O 
The O 
results O 
revealed O 
that O 
folate B-TRIVIAL 
conjugated O 
micelles O 
showed O 
higher O 
activity O 
in O 
FR O 
+ O 
OVCAR-3 O 
cells O 
but O 
not O 
in O 
FR O 
- O 
A549 O 
cells O 
. O 
Similar O 
results O 
were O 
obtained O 
for O 
both O 
small O 
and O 
large O 
micelles O 
without O 
the O 
conjugation O 
of O 
folate B-TRIVIAL 
. O 
Comparing O 
large O 
and O 
small O 
micelles O 
it O 
can O 
be O 
observed O 
that O 
larger O 
micelles O 
are O 
more O 
efficient O 
, O 
which O 
has O 
been O 
attributed O 
to O 
the O 
lower O 
stability O 
of O 
the O 
smaller O 
micelles O 
. O 
Micelle O 
stabilization O 
via O 
cross O 
- O 
linking O 
could O 
indeed O 
increase O 
the O 
toxicity O 
of O 
the O 
drug O 
carrier O 
. O 

activity O 
of O 
2,3- B-FAMILY 
disubstituted I-FAMILY 
indoles I-FAMILY 
toward O 
apoptosis O 
- O 
resistant O 
cancers O 
cells O 
. O 

types O 
of O 
cancer O 
, O 
including O 
glioma O 
, O 
melanoma O 
, O 
NSCLC O 
, O 
among O 
others O 
, O 
are O 
resistant O 
to O 
apoptosis O 
induction O 
and O 
poorly O 
responsive O 
to O 
current O 
therapies O 
with O 
propaptotic O 
agents O 
. O 
We O 
describe O 
a O 
series O 
of O 
2,3- B-FAMILY 
disubstituted I-FAMILY 
indoles I-FAMILY 
, O 
which O 
display O 
cytostatic O 
rather O 
than O 
cytotoxic O 
effects O 
in O 
cancer O 
cells O 
, O 
and O 
serve O 
as O 
a O 
new O 
chemical O 
scaffold O 
to O 
develop O 
anticancer O 
agents O 
capable O 
of O 
combating O 
apoptosis O 
- O 
resistant O 
cancers O 
associated O 
with O 
dismal O 
prognoses O 
. O 

chemistry O 
of O 
atmospheric O 
amines B-FAMILY 
. O 

reactions O 
of O 
amines B-FAMILY 
have O 
been O 
recently O 
shown O 
to O 
play O 
an O 
important O 
role O 
in O 
the O 
formation O 
and O 
transformation O 
of O 
atmospheric O 
aerosols O 
. O 
This O 
perspective O 
summarizes O 
the O 
latest O 
laboratory O 
progress O 
in O 
the O 
multiphase O 
chemistry O 
of O 
amines B-FAMILY 
. O 
Particular O 
emphasis O 
is O 
given O 
to O 
the O 
contributions O 
of O 
amines B-FAMILY 
to O 
new O 
particle O 
formation O 
, O 
growth O 
of O 
submicron O 
particles O 
, O 
and O 
alteration O 
in O 
the O 
physiochemical O 
properties O 
of O 
pre O 
- O 
existing O 
particles O 
, O 
including O 
hygroscopicity O 
, O 
thermostability O 
, O 
density O 
, O 
phase O 
, O 
and O 
optical O 
properties O 
, O 
from O 
exposure O 
to O 
gaseous O 
amines B-FAMILY 
. O 
The O 
atmospheric O 
implications O 
of O 
the O 
multiphase O 
reactions O 
of O 
amines B-FAMILY 
, O 
including O 
the O 
potential O 
impact O 
on O 
direct O 
and O 
indirect O 
climate O 
forcing O 
of O 
aerosols O 
, O 
and O 
future O 
research O 
directions O 
are O 
discussed O 
. O 

, O 
characterization O 
and O 
organic O 
field O 
effect O 
transistor O 
performance O 
of O 
a O 
diketopyrrolopyrrole B-FAMILY 
- O 
fluorenone B-SYSTEMATIC 
copolymer O 
. O 

diketopyrrolopyrrole B-FAMILY 
( O 
DPP B-ABBREVIATION 
) O 
with O 
fluorenone B-SYSTEMATIC 
( O 
FN O 
) O 
based O 
low O 
band O 
gap O 
alternating O 
copolymer O 
( O 
PDPPT-alt-FN B-ABBREVIATION 
) O 
has O 
been O 
synthesized O 
via O 
Suzuki O 
coupling O 
. O 
PDPPT-alt-FN B-ABBREVIATION 
exhibits O 
a O 
deep O 
HOMO O 
level O 
with O 
a O 
lower O 
band O 
gap O 
. O 
Fabricated O 
organic O 
thin O 
film O 
transistors O 
using O 
PDPPT-alt-FN B-ABBREVIATION 
as O 
a O 
channel O 
semiconductor O 
show O 
p-channel O 
behaviour O 
with O 
the O 
highest O 
hole O 
mobility O 
of O 
0.083 O 
cm(2) O 
V(-1) O 
s(-1) O 
measured O 
in O 
air O 
. O 

therapy O 
following O 
percutaneous O 
coronary O 
intervention O 
aims O 
at O 
preventing O 
first O 
, O 
coronary O 
disease O 
progression O 
and O 
its O 
clinical O 
manifestations O 
, O 
and O 
finally O 
, O 
the O 
two O 
main O 
complications O 
of O 
coronary O 
stenting O 
, O 
stent O 
thrombosis O 
and O 
restenosis O 
. O 
Prevention O 
of O 
in O 
- O 
stent O 
restenosis O 
is O 
restricted O 
to O 
local O 
drug O 
delivery O 
in O 
the O 
form O 
of O 
drug O 
eluting O 
stents O 
( O 
DES O 
) O 
. O 
Second O 
generation O 
DES O 
have O 
improved O 
their O 
efficacy O 
and O 
safety O 
profile O 
by O 
innovations O 
in O 
drug O 
coating O 
, O 
the O 
polymer O 
drug O 
- O 
delivery O 
system O 
and O 
stent O 
design O 
. O 
The O 
mainstay O 
of O 
stent O 
thrombosis O 
prevention O 
remains O 
dual O 
anti-platelet O 
therapy O 
with O 
acetylsalicylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
a O 
platelet O 
ADP B-ABBREVIATION 
-receptor O 
blocker O 
, O 
traditionally O 
clopidogrel B-TRIVIAL 
. O 
Two O 
new O 
drugs O 
, O 
prasugrel B-TRIVIAL 
and O 
ticagrelor B-TRIVIAL 
, O 
provide O 
faster O 
, O 
greater O 
, O 
and O 
more O 
consistent O 
platelet O 
inhibition O 
than O 
clopidogrel B-TRIVIAL 
, O 
and O 
have O 
been O 
shown O 
to O 
be O 
more O 
efficacious O 
in O 
preventing O 
ischemic O 
events O 
after O 
PCI O 
in O 
acute O 
coronary O 
syndrome O 
patients O 
. O 

1A O 
polymorphisms O 
may O 
influence O 
urine O 
uric B-TRIVIAL 
acid I-TRIVIAL 
and O 
N-acetyl B-SYSTEMATIC 
-beta-d-glucosaminidase O 
( O 
NAG O 
) O 
excretion O 
in O 
chronic O 
lead O 
- O 
exposed O 
workers O 
. O 

is O 
a O 
renal O 
toxin O 
, O 
and O 
susceptibility O 
to O 
lead O 
varies O 
between O 
individuals O 
. O 
Metallothionein O 
( O 
MT O 
) O 
is O 
known O 
for O 
its O 
metal O 
scavenging O 
role O 
. O 
The O 
aim O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
association O 
of O 
blood O 
lead O 
levels O 
, O 
urinary O 
uric B-TRIVIAL 
acid I-TRIVIAL 
( O 
UA O 
) O 
and O 
N-acetyl B-SYSTEMATIC 
-beta-d-glucosaminidase O 
( O 
NAG O 
) O 
in O 
chronic O 
occupational O 
lead O 
- O 
exposed O 
workers O 
, O 
and O 
to O 
study O 
whether O 
the O 
association O 
was O 
influenced O 
by O 
MT1A O 
gene O 
polymorphisms O 
. O 
In O 
this O 
cross O 
- O 
sectional O 
study O 
, O 
412 O 
lead O 
- O 
exposed O 
workers O 
participated O 
. O 
Their O 
annual O 
health O 
examination O 
data O 
and O 
renal O 
function O 
markers O 
were O 
collected O 
after O 
the O 
Institutional O 
Review O 
Broad O 
of O 
Kaohsiung O 
Medical O 
University O 
Hospital O 
approved O 
the O 
study O 
and O 
consent O 
letters O 
were O 
obtained O 
. O 
From O 
the O 
blood O 
samples O 
, O 
DNA O 
was O 
extracted O 
and O 
used O 
for O 
real O 
- O 
time O 
PCR O 
typing O 
of O 
2 O 
MT1A O 
single O 
nucleotide O 
polymorphisms O 
( O 
SNPs O 
) O 
: O 
rs11640851 O 
and O 
rs8052394 O 
on O 
exons O 
2 O 
and O 
3 O 
. O 
Descriptive O 
analysis O 
, O 
one O 
- O 
way O 
ANOVA O 
, O 
and O 
multiple O 
linear O 
regressions O 
were O 
performed O 
. O 
There O 
was O 
a O 
significant O 
inverted O 
relationship O 
of O 
creatinine B-TRIVIAL 
-adjusted O 
urine O 
UA O 
concentrations O 
and O 
the O 
time O 
- O 
weighted O 
index O 
of O 
cumulative O 
blood O 
lead O 
levels O 
( O 
TWICL O 
) O 
that O 
may O 
be O 
significantly O 
influenced O 
by O 
the O 
AC O 
genotypes O 
of O 
rs11640851 O 
in O 
exon O 
2 O 
and O 
rs8052394 O 
in O 
exon O 
3 O 
. O 
After O 
controlling O 
for O 
potential O 
confounding O 
factors O 
, O 
the O 
creatinine B-TRIVIAL 
-adjusted O 
urine O 
NAG O 
concentrations O 
were O 
shown O 
to O 
be O 
influenced O 
by O 
the O 
GG O 
genotype O 
of O 
rs8052394 O 
in O 
exon O 
3 O 
, O 
and O 
were O 
weakly O 
increased O 
with O 
TWICL O 
. O 
Therefore O 
, O 
we O 
concluded O 
that O 
the O 
variations O 
of O 
MT1A O 
SNPs O 
may O 
influence O 
urine O 
UA O 
and O 
NAG O 
excretion O 
in O 
chronic O 
lead O 
- O 
exposed O 
workers O 
, O 
and O 
urine O 
creatinine B-TRIVIAL 
-adjusted O 
urine O 
UA O 
as O 
a O 
biomarker O 
of O 
lead O 
toxicity O 
should O 
be O 
considered O 
. O 

II-diabetes O 
mellitus O 
( O 
TII-DM O 
) O 
has O 
been O 
regarded O 
as O 
one O 
of O 
the O 
most O 
important O 
public O 
health O 
problems O 
in O 
all O 
nations O 
in O 
the O 
21st O 
century O 
. O 
Although O 
allopathic O 
therapies O 
remain O 
the O 
most O 
important O 
for O 
the O 
initial O 
management O 
of O 
TII-DM O 
, O 
herbal O 
remedies O 
have O 
gained O 
wide O 
acceptance O 
for O 
treating O 
this O 
condition O 
. O 
These O 
alternative O 
therapies O 
are O 
particularly O 
valued O 
in O 
countries O 
such O 
as O 
Mexico O 
, O 
rich O 
in O 
medicinal O 
plants O 
strongly O 
attached O 
to O 
the O 
cultural O 
values O 
of O 
the O 
population O 
. O 
Medicinal O 
plants O 
are O 
prized O 
sources O 
of O 
α-glucosidase O 
inhibitors O 
, O 
which O 
delay O 
the O 
liberation O 
of O 
glucose B-TRIVIAL 
from O 
complex O 
carbohydrates B-FAMILY 
, O 
retarding O 
glucose B-TRIVIAL 
absorption O 
, O 
and O 
thus O 
controlling O 
the O 
characteristic O 
hyperglycemia O 
of O 
TII-DM O 
. O 
Among O 
the O 
plant O 
species O 
used O 
for O 
treating O 
diabetes O 
in O 
Mexico O 
only O 
38 O 
have O 
been O 
analyzed O 
for O 
their O 
inhibitory O 
activity O 
of O 
α-glucosidases O 
. O 
Most O 
of O 
these O 
studies O 
, O 
reviewed O 
in O 
the O 
present O 
work O 
, O 
have O 
focused O 
on O 
the O 
evaluation O 
of O 
different O 
types O 
of O 
extracts O 
on O 
the O 
activity O 
of O 
α-glucosidases O 
from O 
diverse O 
sources O 
. O 
Four O 
species O 
have O 
been O 
thoroughly O 
analyzed O 
in O 
order O 
to O 
discover O 
novel O 
α-glucosidase O 
inhibitors O 
, O 
namely O 
, O 
Hintonia O 
latiflora O 
and O 
Hintonia O 
standleyana O 
( O 
Rubiaceae O 
) O 
, O 
Ligusticum O 
porteri O 
( O 
Apiaceae O 
) O 
, O 
and O 
Brickellia O 
cavanillesii O 
( O 
Asteraceae O 
) O 
. O 
Their O 
ethnomedical O 
uses O 
, O 
pharmacological O 
and O 
toxicological O 
studies O 
, O 
chemical O 
composition O 
, O 
and O 
antihyperglycemic O 
principles O 
with O 
α-glucosidase O 
inhibitory O 
activity O 
are O 
summarized O 
. O 

sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
affects O 
hormone O 
receptor O 
activity O 
, O 
steroidogenesis O 
, O 
and O 
expression O 
of O 
endocrine O 
- O 
related O 
genes O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
is O 
a O 
widespread O 
and O 
persistent O 
chemical O 
in O 
the O 
environment O 
. O 
We O 
investigated O 
the O 
endocrine O 
- O 
disrupting O 
effects O 
of O 
PFOS B-ABBREVIATION 
using O 
a O 
combination O 
of O 
in O 
vitro O 
and O 
in O 
vivo O 
assays O 
. O 
Reporter O 
gene O 
assays O 
were O 
used O 
to O 
detect O 
receptor O 
- O 
mediated O 
(anti-)estrogenic O 
, O 
(anti-)androgenic O 
, O 
and O 
( O 
anti- O 
) O 
thyroid B-FAMILY 
hormone I-FAMILY 
activities O 
. O 
The O 
effect O 
of O 
PFOS B-ABBREVIATION 
on O 
steroidogenesis O 
was O 
assessed O 
both O 
at O 
hormone O 
levels O 
in O 
the O 
supernatant O 
and O 
at O 
expression O 
levels O 
of O 
hormone O 
- O 
induced O 
genes O 
in O 
the O 
H295R O 
cell O 
. O 
A O 
zebrafish O 
- O 
based O 
short O 
- O 
term O 
screening O 
method O 
was O 
developed O 
to O 
detect O 
the O 
effect O 
of O 
PFOS B-ABBREVIATION 
on O 
endocrine O 
function O 
in O 
vivo O 
. O 
The O 
results O 
indicate O 
that O 
PFOS B-ABBREVIATION 
can O 
act O 
as O 
an O 
estrogen B-FAMILY 
receptor O 
agonist O 
and O 
thyroid B-FAMILY 
hormone I-FAMILY 
receptor O 
antagonist O 
. O 
Exposure O 
to O 
PFOS B-ABBREVIATION 
decreased O 
supernatant O 
testosterone B-TRIVIAL 
( O 
T O 
) O 
, O 
increased O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
concentrations O 
in O 
H295R O 
cell O 
medium O 
and O 
altered O 
the O 
expression O 
of O 
several O 
genes O 
involved O 
in O 
steroidogenesis O 
. O 
In O 
addition O 
, O 
PFOS B-ABBREVIATION 
increased O 
early O 
thyroid O 
development O 
gene O 
( O 
hhex O 
and O 
pax8 O 
) O 
expression O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
, O 
decreased O 
steroidogenic O 
enzyme O 
gene O 
( O 
CYP17 O 
, O 
CYP19a O 
, O 
CYP19b O 
) O 
expression O 
, O 
and O 
changed O 
the O 
expression O 
pattern O 
of O 
estrogen B-FAMILY 
receptor O 
production O 
genes O 
( O 
esr1 O 
, O 
esr2b O 
) O 
after O 
500 O 
µg O 
/ O 
L O 
PFOS B-ABBREVIATION 
treatment O 
in O 
zebrafish O 
embryos O 
. O 
These O 
results O 
indicate O 
that O 
PFOS B-ABBREVIATION 
has O 
the O 
ability O 
to O 
act O 
as O 
an O 
endocrine O 
disruptor O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
by O 
disrupting O 
the O 
function O 
of O 
nuclear O 
hormone O 
receptors O 
, O 
interfering O 
with O 
steroidogenesis O 
, O 
and O 
altering O 
the O 
expression O 
of O 
endocrine O 
- O 
related O 
genes O 
in O 
zebrafish O 
embryo O 
. O 

oil O 
extracted O 
from O 
aerial O 
parts O 
of O 
Artemisia O 
nilagirica O 
was O 
analysed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectroscopy O 
. O 
Forty O 
- O 
three O 
constituents O 
amounting O 
to O 
98.16% O 
of O 
the O 
total O 
essential O 
oil O 
contents O 
were O 
identified O 
. O 
The O 
essential O 
oil O 
contained O 
approximately O 
79.91% O 
monoterpenoids B-FAMILY 
and O 
18.25% O 
sesquiterpenoids B-FAMILY 
. O 
α-Thujone B-TRIVIAL 
( O 
36.35% O 
) O 
, O 
β-thujone B-TRIVIAL 
( O 
9.37% O 
) O 
, O 
germacrene B-TRIVIAL 
D I-TRIVIAL 
( O 
6.32% O 
) O 
, O 
4-terpineol B-SYSTEMATIC 
( O 
6.31% O 
) O 
, O 
β-caryophyllene B-TRIVIAL 
( O 
5.43% O 
) O 
, O 
camphene B-TRIVIAL 
( O 
5.47% O 
) O 
and O 
borneol B-TRIVIAL 
( O 
4.12% O 
) O 
were O 
identified O 
as O 
the O 
major O 
constituents O 
. O 
The O 
essential O 
oil O 
exhibited O 
significant O 
antifungal O 
activity O 
against O 
Rhizoctonia O 
solani O 
( O 
ED(50) O 
, O 
85.75 O 
mg O 
L(-1) O 
) O 
, O 
Sclerotium O 
rolfsii O 
( O 
ED(50) O 
, O 
87.63 O 
mg O 
L(-1) O 
) O 
and O 
Macrophomina O 
phaseolina O 
( O 
ED(50) O 
, O 
93.23 O 
mg O 
L(-1) O 
) O 
. O 
This O 
study O 
indicated O 
that O 
A O 
. O 
nilagirica O 
essential O 
oil O 
can O 
be O 
used O 
to O 
control O 
phytopathogenic O 
fungi O 
infesting O 
agricultural O 
crops O 
and O 
commodities O 
. O 

to O 
their O 
crucial O 
role O 
in O 
the O 
modulation O 
of O 
cell O 
pathways O 
, O 
protein O 
kinases O 
are O 
important O 
targets O 
for O 
several O 
human O 
diseases O 
, O 
including O 
but O 
not O 
limited O 
to O 
cancer O 
. O 
The O 
classic O 
approach O 
of O 
targeting O 
the O 
ATP B-ABBREVIATION 
active O 
site O 
has O 
recently O 
come O 
up O 
against O 
selectivity O 
issues O 
, O 
which O 
can O 
be O 
considerably O 
reduced O 
by O 
following O 
an O 
allosteric O 
modulation O 
approach O 
. O 
Being O 
closely O 
related O 
to O 
protein O 
kinase O 
inactivation O 
, O 
allosteric O 
targeting O 
via O 
displacement O 
of O 
the O 
conserved O 
structural O 
αC O 
helix O 
enables O 
a O 
direct O 
and O 
specific O 
modulation O 
mechanism O 
. O 
A O 
structure O 
- O 
based O 
survey O 
of O 
the O 
allosteric O 
regulation O 
of O 
αC O 
helix O 
conformation O 
in O 
various O 
kinase O 
families O 
is O 
provided O 
, O 
highlighting O 
key O 
allosteric O 
pockets O 
and O 
modulation O 
mechanisms O 
that O 
appear O 
to O 
be O 
more O 
broadly O 
conserved O 
than O 
was O 
previously O 
thought O 
. O 

comprehensive O 
biological O 
, O 
sediment O 
, O 
and O 
water O 
quality O 
study O 
of O 
the O 
lower O 
Little O 
Scioto O 
River O 
near O 
Marion O 
, O 
Ohio O 
, O 
USA O 
, O 
was O 
undertaken O 
to O 
evaluate O 
the O 
changes O 
or O 
improvements O 
in O 
biotic O 
measurements O 
following O 
the O 
removal O 
of O 
creosote O 
- O 
contaminated O 
sediment O 
. O 
The O 
study O 
area O 
covered O 
7.5 O 
river O 
miles O 
( O 
RMs O 
) O 
, O 
including O 
a O 
remediated O 
section O 
between O 
RMs O 
6 O 
and O 
6.8 O 
. O 
Fish O 
and O 
macroinvertebrate O 
assemblages O 
, O 
fish O 
biomarkers O 
( O 
i.e O 
. O 
, O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbon I-FAMILY 
[ O 
PAH B-ABBREVIATION 
] O 
metabolite O 
levels O 
in O 
white O 
sucker O 
[ O 
Castostomus O 
commersoni O 
] O 
and O 
common O 
carp O 
[ O 
Cyprinus O 
carpio O 
] O 
bile O 
and O 
DNA O 
damage O 
) O 
, O 
sediment O 
chemistry O 
, O 
and O 
water O 
quality O 
were O 
assessed O 
at O 
five O 
locations O 
relative O 
to O 
the O 
primary O 
source O 
of O 
historical O 
PAH B-ABBREVIATION 
contamination O 
- O 
upstream O 
( O 
RM O 
9.2 O 
) O 
, O 
adjacent O 
( O 
RM O 
6.5 O 
) O 
, O 
and O 
downstream O 
( O 
RMs O 
5.7 O 
, O 
4.4 O 
, O 
and O 
2.7 O 
) O 
. O 
Overall O 
, O 
the O 
biomarker O 
results O 
were O 
consistent O 
with O 
the O 
sediment O 
PAH B-ABBREVIATION 
results O 
, O 
showing O 
a O 
pattern O 
of O 
low O 
levels O 
of O 
PAH B-ABBREVIATION 
bile O 
metabolites O 
and O 
DNA O 
damage O 
at O 
the O 
upstream O 
( O 
reference O 
or O 
background O 
location O 
) O 
, O 
as O 
well O 
as O 
the O 
remediated O 
section O 
, O 
high O 
levels O 
at O 
the O 
two O 
immediate O 
downstream O 
sites O 
, O 
and O 
somewhat O 
lower O 
levels O 
at O 
the O 
furthest O 
downstream O 
site O 
. O 
Results O 
show O 
that O 
remediation O 
was O 
effective O 
in O 
reducing O 
sediment O 
contaminant O 
concentrations O 
and O 
exposure O 
of O 
fish O 
to O 
PAHs B-ABBREVIATION 
and O 
in O 
improving O 
fish O 
assemblages O 
( O 
60% O 
increase O 
in O 
index O 
of O 
biotic O 
integrity O 
scores O 
) O 
in O 
remediated O 
river O 
sections O 
. O 
Additional O 
remedial O 
investigation O 
and O 
potentially O 
further O 
remediation O 
is O 
needed O 
to O 
improve O 
the O 
downstream O 
benthic O 
fish O 
community O 
, O 
which O 
is O 
still O 
heavily O 
exposed O 
to O 
PAH B-ABBREVIATION 
contaminants O 
. O 

: O 
Synthetic O 
Methodologies O 
and O 
Pharmaceutical O 
Applications O 
as O 
Serine B-TRIVIAL 
and O 
Cysteine B-TRIVIAL 
Protease O 
Inhibitors O 
. O 

are O 
interesting O 
scaffolds O 
bearing O 
( O 
at O 
least O 
) O 
two O 
sequential O 
electrophilic O 
carbons B-FAMILY 
that O 
by O 
interacting O 
with O 
the O 
nucleophilic O 
moieties O 
of O 
several O 
enzymes O 
, O 
represent O 
the O 
ideal O 
candidates O 
for O 
in O 
vivo O 
and O 
in O 
vitro O 
inhibition O 
studies O 
. O 
In O 
this O 
work O 
a O 
summary O 
of O 
their O 
use O 
as O 
optimal O 
inhibitors O 
of O 
physiologically O 
relevant O 
serine B-TRIVIAL 
and O 
cysteine B-TRIVIAL 
proteases O 
is O 
given O 
with O 
a O 
particular O 
emphasis O 
on O 
recently O 
established O 
SAR O 
studies O 
. O 
A O 
brief O 
survey O 
of O 
the O 
most O 
relevant O 
synthetic O 
processes O 
for O 
their O 
obtainment O 
and O 
the O 
importance O 
they O 
possess O 
in O 
synthetic O 
medicinal O 
chemistry O 
is O 
reported O 
. O 

Overexpression O 
of O 
Hypomethylated O 
miR-663 O 
Induces O 
Chemotherapy O 
Resistance O 
in O 
Human O 
Breast O 
Cancer O 
Cells O 
by O 
Targeting O 
Heparin O 
Sulfate B-SYSTEMATIC 
Proteoglycan O 
2 O 
( O 
HSPG2 O 
) O 
. O 

are O 
involved O 
in O 
regulating O 
the O 
biology O 
of O 
cancer O 
cells O 
, O 
but O 
their O 
involvement O 
in O 
chemoresistance O 
is O 
not O 
fully O 
understood O 
. O 
We O 
found O 
that O 
miR-663 O 
was O 
up O 
- O 
regulated O 
in O 
our O 
induced O 
multidrug O 
- O 
resistant O 
MDA-MB-231 O 
/ O 
ADM O 
cell O 
line O 
and O 
that O 
this O 
up O 
- O 
regulation O 
was O 
closely O 
related O 
to O 
chemosensitivity O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
aimed O 
to O 
clarify O 
the O 
role O 
of O 
miR-663 O 
in O 
regulating O 
the O 
chemoresistance O 
of O 
breast O 
cancer O 
. O 
MicroRNA O 
microarray O 
and O 
quantitative O 
RT-PCR O 
assays O 
were O 
used O 
to O 
identify O 
differentially O 
expressed O 
microRNAs O 
. O 
Cell O 
apoptosis O 
was O 
evaluated O 
by O 
annexin O 
V/ O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
staining O 
, O 
TUNEL O 
, O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
generation O 
analysis O 
. O 
The O 
expression O 
of O 
miR-663 O 
and O 
HSPG2 O 
in O 
breast O 
cancer O 
tissues O 
was O 
detected O 
by O 
in O 
situ O 
hybridization O 
and O 
immunohistochemistry O 
. O 
The O 
potential O 
targets O 
of O 
miR-663 O 
were O 
defined O 
by O 
a O 
luciferase O 
reporter O 
assay O 
. O 
Bisulfite B-SYSTEMATIC 
sequencing O 
PCR O 
was O 
used O 
to O 
analyze O 
the O 
methylation O 
status O 
. O 
We O 
found O 
that O 
miR-663 O 
was O 
significantly O 
elevated O 
in O 
MDA-MB-231 O 
/ O 
ADM O 
cells O 
, O 
and O 
the O 
down O 
- O 
regulation O 
of O 
miR-663 O 
sensitized O 
MDA-MB-231 O 
/ O 
ADM O 
cells O 
to O 
both O 
cyclophosphamide B-TRIVIAL 
and O 
docetaxel B-TRIVIAL 
. O 
The O 
overexpression O 
of O 
miR-663 O 
in O 
breast O 
tumor O 
tissues O 
was O 
associated O 
with O 
chemoresistance O 
; O 
in O 
MDA-MB-231 O 
cells O 
, O 
this O 
chemoresistance O 
was O 
accompanied O 
by O 
the O 
down O 
- O 
regulation O 
of O 
HSPG2 O 
, O 
which O 
was O 
identified O 
as O 
a O 
target O 
of O 
miR-663 O 
. O 
MDA-MB-231 O 
/ O 
ADM O 
contained O 
fewer O 
methylated O 
CpG B-ABBREVIATION 
sites O 
than O 
its O 
parental O 
cell O 
line O 
, O 
and O 
miR-663 O 
expression O 
in O 
MDA-MB-231 O 
cells O 
was O 
reactivated O 
by O 
5-aza-29-deoxycytidine B-SYSTEMATIC 
treatment O 
, O 
indicating O 
that O 
DNA O 
methylation O 
may O 
play O 
a O 
functional O 
role O 
in O 
the O 
expression O 
of O 
miR-663 O 
. O 
Our O 
findings O 
suggest O 
that O 
the O 
overexpression O 
of O 
hypomethylated O 
miR-663 O 
induced O 
chemoresistance O 
in O 
breast O 
cancer O 
cells O 
by O 
down O 
- O 
regulating O 
HSPG2 O 
, O 
thus O 
providing O 
a O 
potential O 
target O 
for O 
the O 
development O 
of O 
an O 
microRNA O 
- O 
based O 
approach O 
for O 
breast O 
cancer O 
therapy O 
. O 

of O 
vtg O 
, O 
ERs O 
and O 
PPARs O 
as O 
endpoint O 
for O 
the O 
rapid O 
in O 
vitro O 
screening O 
of O 
the O 
harmful O 
effect O 
of O 
Di-(2-ethylhexyl)-phthalate B-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
and O 
phthalic B-TRIVIAL 
acid I-TRIVIAL 
( O 
PA O 
) O 
in O 
zebrafish O 
primary O 
hepatocyte O 
cultures O 
. O 

the O 
last O 
years O 
the O 
concern O 
about O 
the O 
negative O 
effects O 
of O 
phthalates B-FAMILY 
on O 
reproduction O 
significantly O 
increased O 
. O 
Considering O 
that O 
, O 
at O 
date O 
data O 
available O 
dealing O 
with O 
the O 
adverse O 
outcome O 
of O 
Di-(2-ethylhexyl)-phthalate B-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
on O 
the O 
reproduction O 
of O 
several O 
species O 
are O 
still O 
contrasting O 
, O 
in O 
this O 
study O 
, O 
the O 
effects O 
induced O 
by O 
DEHP B-ABBREVIATION 
( O 
0.05 O 
, O 
0.1 O 
, O 
1 O 
, O 
10 O 
and O 
100 O 
nM O 
) O 
and O 
its O 
active O 
metabolite O 
, O 
phthalic B-TRIVIAL 
acid I-TRIVIAL 
( O 
PA O 
) O 
( O 
0.01 O 
, O 
0.1 O 
, O 
1 O 
and O 
10 O 
μM O 
) O 
, O 
were O 
analyzed O 
in O 
zebrafish O 
, O 
Danio O 
rerio O 
, O 
primary O 
hepatocyte O 
cultures O 
, O 
using O 
target O 
molecules O 
involved O 
in O 
fish O 
reproduction O 
( O 
vitellogenin O 
-- O 
vtg O 
and O 
estrogen B-FAMILY 
receptors O 
-- O 
ERα O 
, O 
β1 O 
and O 
β2 O 
) O 
and O 
metabolism O 
( O 
peroxisome O 
proliferators O 
activated O 
receptors O 
-- O 
PPAR O 
α O 
, O 
β O 
, O 
γ O 
) O 
. O 
The O 
use O 
of O 
in O 
vitro O 
culture O 
, O 
in O 
fact O 
, O 
has O 
the O 
potential O 
to O 
significantly O 
reduce O 
the O 
number O 
of O 
animals O 
sacrificed O 
for O 
research O 
allowing O 
a O 
precise O 
control O 
of O 
the O 
physical O 
and O 
chemical O 
parameters O 
that O 
is O 
often O 
not O 
possible O 
in O 
vivo O 
. O 
Moreover O 
, O 
since O 
many O 
toxicological O 
studies O 
revealed O 
a O 
sex O 
specific O 
response O 
to O 
toxicants O 
, O 
male O 
and O 
female O 
primary O 
hepatocyte O 
cultures O 
were O 
set O 
up O 
to O 
elucidate O 
the O 
possible O 
gender O 
specific O 
effects O 
of O 
two O 
common O 
environmental O 
phthalates B-FAMILY 
. O 
The O 
increase O 
of O 
vtg O 
levels O 
observed O 
in O 
the O 
culture O 
media O 
of O 
male O 
or O 
female O 
hepatocytes O 
strongly O 
evidenced O 
the O 
phthalates B-FAMILY 
E2 O 
- O 
like O 
action O 
. O 
Moreover O 
, O 
the O 
data O 
obtained O 
suggested O 
that O 
the O 
observed O 
different O 
ERs O 
isoforms O 
modulation O 
is O 
otherwise O 
associated O 
with O 
the O 
vtg O 
increase O 
, O 
depending O 
on O 
fish O 
gender O 
. O 
Regarding O 
PPARs O 
, O 
a O 
similar O 
trend O 
of O 
expression O 
was O 
found O 
in O 
both O 
males O 
and O 
females O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
enforces O 
the O 
role O 
of O 
vtg O 
as O 
biomarker O 
for O 
evaluate O 
the O 
presence O 
of O 
environmental O 
doses O 
of O 
DEHP B-ABBREVIATION 
and O 
PA O 
. O 
Considering O 
the O 
similar O 
gender O 
modulation O 
observed O 
for O 
vtg O 
and O 
PPARs O 
, O 
these O 
molecules O 
could O 
be O 
used O 
for O 
the O 
rapid O 
screening O 
of O 
the O 
presence O 
of O 
DEHP B-ABBREVIATION 
and O 
PA O 
. O 
Noteworthy O 
the O 
gender O 
specific O 
modulation O 
observed O 
for O 
ERs O 
opens O 
a O 
debate O 
on O 
the O 
estrogenic O 
mechanism O 
of O 
action O 
of O 
DEHP B-ABBREVIATION 
and O 
PA O 
and O 
their O 
role O 
on O 
vtg O 
induction O 
. O 

European O 
eel O 
illustrates O 
an O 
example O 
of O 
a O 
critically O 
endangered O 
fish O 
species O 
strongly O 
affected O 
by O 
human O 
stressors O 
throughout O 
its O 
life O 
cycle O 
, O 
in O 
which O 
pollution O 
is O 
considered O 
to O 
be O 
one O 
of O 
the O 
factors O 
responsible O 
for O 
the O 
decline O 
of O 
the O 
stock O 
. O 
The O 
objective O 
of O 
our O 
study O 
was O 
to O 
better O 
understand O 
the O 
transcriptional O 
response O 
of O 
European O 
eels O 
chronically O 
exposed O 
to O 
pollutants O 
in O 
their O 
natural O 
environment O 
. O 
A O 
total O 
of O 
42 O 
pre O 
- O 
migrating O 
( O 
silver O 
) O 
female O 
eels O 
from O 
lowly O 
, O 
highly O 
and O 
extremely O 
polluted O 
environments O 
in O 
Belgium O 
and O 
, O 
for O 
comparative O 
purposes O 
, O 
a O 
lowly O 
polluted O 
habitat O 
in O 
Italy O 
were O 
measured O 
for O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
, O 
organochlorine B-FAMILY 
pesticides O 
( O 
OCPs O 
) O 
and O 
brominated O 
flame O 
retardants O 
( O 
BFRs O 
) O 
. O 
Multipollutant O 
level O 
of O 
bioaccumulation O 
was O 
linked O 
to O 
their O 
genome O 
- O 
wide O 
gene O 
transcription O 
using O 
an O 
eel O 
- O 
specific O 
array O 
of O 
14913 O 
annotated O 
cDNAs O 
. O 
Shared O 
responses O 
to O 
pollutant O 
exposure O 
were O 
observed O 
when O 
comparing O 
the O 
highly O 
polluted O 
site O 
in O 
Belgium O 
with O 
the O 
relatively O 
clean O 
sites O 
in O 
Belgium O 
and O 
Italy O 
. O 
First O 
, O 
an O 
altered O 
pattern O 
of O 
transcription O 
of O 
genes O 
was O 
associated O 
with O 
detoxification O 
, O 
with O 
a O 
novel O 
European O 
eel O 
CYP3A O 
gene O 
and O 
gluthatione B-TRIVIAL 
S B-FORMULA 
-transferase O 
transcriptionally O 
up O 
- O 
regulated O 
. O 
Second O 
, O 
an O 
altered O 
pattern O 
of O 
transcription O 
of O 
genes O 
associated O 
with O 
the O 
oxidative O 
phosphorylation O 
pathway O 
, O 
with O 
the O 
following O 
genes O 
involved O 
in O 
the O 
generation O 
of O 
ATP B-ABBREVIATION 
being O 
transcriptionally O 
down O 
- O 
regulated O 
in O 
individuals O 
from O 
the O 
highly O 
polluted O 
site O 
: O 
NADH B-ABBREVIATION 
dehydrogenase O 
, O 
succinate B-TRIVIAL 
dehydrogenase O 
, O 
ubiquinol B-TRIVIAL 
-cytochrome O 
c O 
reductase O 
, O 
cytochrome O 
c O 
oxidase O 
and O 
ATP B-ABBREVIATION 
synthase O 
. O 
Although O 
we O 
did O 
not O 
measure O 
metabolism O 
directly O 
, O 
seeing O 
that O 
the O 
transcription O 
level O 
of O 
many O 
genes O 
encoding O 
enzymes O 
involved O 
in O 
the O 
mitochondrial O 
respiratory O 
chain O 
and O 
oxidative O 
phosphorylation O 
were O 
down O 
- O 
regulated O 
in O 
the O 
highly O 
polluted O 
site O 
suggests O 
that O 
pollutants O 
may O 
have O 
a O 
significant O 
effect O 
on O 
energy O 
metabolism O 
in O 
these O 
fish O 
. O 

, O 
antiapoptotic O 
, O 
and O 
proliferative O 
effect O 
of O 
curcumin B-TRIVIAL 
on O 
liver O 
regeneration O 
after O 
partial O 
hepatectomy O 
in O 
rats O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
assess O 
the O 
influence O 
of O 
curcumin B-TRIVIAL 
on O 
liver O 
regeneration O 
after O 
partial O 
hepatectomy O 
( O 
PH O 
) O 
in O 
rats O 
. O 
A O 
total O 
of O 
24 O 
male O 
Sprague O 
Dawley O 
rats O 
were O 
divided O 
into O 
three O 
groups O 
: O 
sham O 
- O 
operated O 
( O 
SH O 
) O 
, O 
PH O 
, O 
and O 
PH O 
+ O 
curcumin B-TRIVIAL 
; O 
each O 
group O 
contains O 
eight O 
animals O 
. O 
The O 
rats O 
in O 
curcumin B-TRIVIAL 
-treated O 
groups O 
were O 
given O 
curcumin B-TRIVIAL 
( O 
in O 
a O 
dose O 
of O 
100 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
once O 
a O 
day O 
orally O 
for O 
7 O 
days O 
, O 
starting O 
3 O 
days O 
prior O 
to O 
hepatectomy O 
operation O 
. O 
At O 
7 O 
days O 
after O 
resection O 
, O 
liver O 
samples O 
were O 
collected O 
. O 
The O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
were O 
estimated O 
in O 
liver O 
homogenates O 
. O 
Moreover O 
, O 
histopathological O 
examination O 
, O 
mitotic O 
index O 
( O 
MI O 
) O 
, O 
proliferating O 
cell O 
nuclear O 
antigen O 
labeling O 
, O 
proliferation O 
index O 
( O 
PI O 
) O 
, O 
transferase O 
- O 
mediated O 
2'-deoxyuridine B-SYSTEMATIC 
, O 
5'-triphosphate B-SYSTEMATIC 
nick O 
end O 
- O 
labeling O 
assay O 
, O 
and O 
apoptotic O 
index O 
( O 
AI O 
) O 
were O 
evaluated O 
at O 
7 O 
days O 
after O 
hepatectomy O 
. O 
As O 
a O 
result O 
, O 
curcumin B-TRIVIAL 
significantly O 
increased O 
MI O 
and O 
PI O 
and O 
significantly O 
decreased O 
AI O 
in O 
PH O 
rats O 
. O 
Additionally O 
, O 
curcumin B-TRIVIAL 
remarkably O 
inhibited O 
MDA B-ABBREVIATION 
elevation O 
, O 
restored O 
impaired O 
antioxidant O 
SOD O 
activity O 
and O 
GSH B-ABBREVIATION 
level O 
and O 
also O 
attenuated O 
hepatic O 
vacuolar O 
degeneration O 
and O 
sinusoidal O 
congestion O 
. O 
These O 
results O 
suggested O 
that O 
curcumin B-TRIVIAL 
treatment O 
had O 
a O 
beneficial O 
effect O 
on O 
liver O 
regenerative O 
capacity O 
of O 
the O 
remnant O 
liver O 
tissue O 
after O 
hepatectomy O 
, O 
probably O 
due O 
to O 
its O 
antioxidative O 
, O 
antiapoptotic O 
, O 
and O 
proliferative O 
properties O 
. O 

, O 
stabilizing O 
and O 
promoting O 
cellular O 
uptake O 
of O 
siRNA O 
are O 
all O 
critical O 
efforts O 
in O 
creating O 
matrices O 
for O 
the O 
localized O 
delivery O 
of O 
siRNA O 
molecules O 
to O 
target O 
cells O 
. O 
In O 
this O 
study O 
, O 
we O 
describe O 
the O 
generation O 
of O 
chitosan O 
imidazole B-SYSTEMATIC 
/ O 
siRNA O 
nanoplexes O 
( O 
NPs O 
) O 
embedded O 
in O 
nano O 
scope O 
polyelectrolyte O 
multilayers O 
( O 
PEMs O 
) O 
composed O 
of O 
hyaluronic O 
acid O 
and O 
chitosan O 
for O 
sustained O 
and O 
localized O 
drug O 
delivery O 
. O 
Regular O 
PEM O 
build O 
- O 
up O 
, O 
successful O 
integration O 
of O 
NPs O 
and O 
controlled O 
release O 
under O 
physiological O 
conditions O 
were O 
shown O 
. O 
Biological O 
efficacy O 
was O 
evaluated O 
in O 
neuronal O 
cell O 
culture O 
concerning O 
cell O 
adhesion O 
, O 
viability O 
, O 
NPs O 
uptake O 
and O 
gene O 
silencing O 
. O 
The O 
additionally O 
shown O 
biological O 
functionalization O 
of O 
neuronal O 
implants O 
possesses O 
potential O 
for O 
future O 
applications O 
in O 
the O 
field O 
of O 
regenerative O 
medicine O 
and O 
treatment O 
of O 
spinal O 
cord O 
injuries O 
. O 

silver B-SYSTEMATIC 
nanoparticles O 
for O 
wound O 
healing O 
. O 

this O 
preliminary O 
study O 
, O 
the O 
silver B-SYSTEMATIC 
nanoparticle O 
( O 
Ag B-FORMULA 
NP O 
) O 
- O 
based O 
dressing O 
, O 
Acticoat O 
™ O 
Flex O 
3 O 
, O 
has O 
been O 
applied O 
to O 
a O 
3D O 
fibroblast O 
cell O 
culture O 
in O 
vitro O 
and O 
to O 
a O 
real O 
partial O 
thickness O 
burn O 
patient O 
. O 
The O 
in O 
vitro O 
results O 
show O 
that O 
Ag B-FORMULA 
NPs O 
greatly O 
reduce O 
mitochondrial O 
activity O 
, O 
while O 
cellular O 
staining O 
techniques O 
show O 
that O 
nuclear O 
integrity O 
is O 
maintained O 
, O 
with O 
no O 
signs O 
of O 
cell O 
death O 
. O 
For O 
the O 
first O 
time O 
, O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
and O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometry O 
( O 
ICP-MS O 
) O 
analyses O 
were O 
carried O 
out O 
on O 
skin O 
biopsies O 
taken O 
from O 
a O 
single O 
patient O 
during O 
treatment O 
. O 
The O 
results O 
show O 
that O 
Ag B-FORMULA 
NPs O 
are O 
released O 
as O 
aggregates O 
and O 
are O 
localized O 
in O 
the O 
cytoplasm O 
of O 
fibroblasts O 
. O 
No O 
signs O 
of O 
cell O 
death O 
were O 
observed O 
, O 
and O 
the O 
nanoparticles O 
had O 
different O 
distributions O 
within O 
the O 
cells O 
of O 
the O 
upper O 
and O 
lower O 
dermis O 
. O 
Depth O 
profiles O 
of O 
the O 
Ag B-FORMULA 
concentrations O 
were O 
determined O 
along O 
the O 
skin O 
biopsies O 
. O 
In O 
the O 
healed O 
sample O 
, O 
most O 
of O 
the O 
silver B-SYSTEMATIC 
remained O 
in O 
the O 
surface O 
layers O 
, O 
whereas O 
in O 
the O 
unhealed O 
sample O 
, O 
the O 
silver B-SYSTEMATIC 
penetrated O 
more O 
deeply O 
. O 
The O 
Ag B-FORMULA 
concentrations O 
in O 
the O 
cell O 
cultures O 
were O 
also O 
determined O 
. O 
Clinical O 
observations O 
and O 
experimental O 
data O 
collected O 
here O 
are O 
consistent O 
with O 
previously O 
published O 
articles O 
and O 
support O 
the O 
safety O 
of O 
Ag B-FORMULA 
NP O 
- O 
based O 
dressing O 
in O 
wound O 
treatment O 
. O 

ZnO B-FORMULA 
core O 
- O 
shell O 
nanocables O 
for O 
flexible O 
supercapacitors O 
and O 
self O 
- O 
powered O 
systems O 
. O 

MnO2 B-FORMULA 
is O 
a O 
promising O 
material O 
for O 
supercapacitors O 
( O 
SCs O 
) O 
due O 
to O 
its O 
excellent O 
electrochemical O 
performance O 
and O 
natural O 
abundance O 
, O 
its O 
wide O 
application O 
is O 
limited O 
by O 
poor O 
electrical O 
conductivity O 
. O 
Inspired O 
by O 
our O 
results O 
that O 
the O 
electrochemical O 
activity O 
and O 
electrical O 
conductivity O 
of O 
ZnO B-FORMULA 
nanowires O 
were O 
greatly O 
improved O 
after O 
hydrogenation O 
, O 
we O 
designed O 
and O 
fabricated O 
hydrogenated O 
single O 
- O 
crystal O 
ZnO B-FORMULA 
@amorphous O 
ZnO-doped B-FORMULA 
MnO2 I-FORMULA 
core O 
- O 
shell O 
nanocables O 
( O 
HZM O 
) O 
on O 
carbon B-SYSTEMATIC 
cloth O 
as O 
SC O 
electrodes O 
, O 
showing O 
excellent O 
performance O 
such O 
as O 
areal O 
capacitance O 
of O 
138.7 O 
mF O 
/ O 
cm(2) O 
and O 
specific O 
capacitance O 
of O 
1260.9 O 
F O 
/ O 
g O 
. O 
Highly O 
flexible O 
all O 
- O 
solid O 
- O 
state O 
SCs O 
were O 
subsequently O 
assembled O 
with O 
these O 
novel O 
HZM O 
electrodes O 
using O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
/ O 
LiCl B-FORMULA 
electrolyte O 
. O 
The O 
working O 
devices O 
achieved O 
very O 
high O 
total O 
areal O 
capacitance O 
of O 
26 O 
mF O 
/ O 
cm(2) O 
and O 
retained O 
87.5% O 
of O 
the O 
original O 
capacitance O 
even O 
after O 
10 O 
0 O 
charge O 
/ O 
discharge O 
cycles O 
. O 
An O 
integrated O 
power O 
pack O 
incorporating O 
series O 
- O 
wound O 
SCs O 
and O 
dye O 
- O 
sensitized O 
solar O 
cells O 
was O 
demonstrated O 
for O 
stand O 
- O 
alone O 
self O 
- O 
powered O 
systems O 
. O 

A I-TRIVIAL 
activates O 
the O 
Nrf1 O 
/ O 
2-antioxidant O 
response O 
element O 
pathway O 
in O 
HEK O 
293 O 
cells O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
used O 
in O 
the O 
production O 
of O 
polycarbonate B-FAMILY 
plastics O 
and O 
epoxy O 
resins O 
for O 
baby O 
bottles O 
, O 
liners O 
of O 
canned O 
food O 
, O 
and O 
many O 
other O 
consumer O 
products O 
. O 
Previously O 
, O 
BPA B-ABBREVIATION 
has O 
been O 
shown O 
to O 
reduce O 
the O 
activity O 
of O 
several O 
antioxidant O 
enzymes O 
, O 
which O 
may O 
contribute O 
to O 
oxidative O 
stress O 
. O 
However O 
, O 
the O 
underlying O 
mechanism O 
of O 
the O 
BPA B-ABBREVIATION 
-mediated O 
effect O 
upon O 
antioxidant O 
enzyme O 
activity O 
is O 
unknown O 
. O 
Antioxidant O 
and O 
phase O 
II O 
metabolizing O 
enzymes O 
protect O 
cells O 
from O 
oxidative O 
stress O 
and O 
are O 
transcriptionally O 
activated O 
by O 
Nrf1 O 
and O 
Nrf2 O 
factors O 
through O 
their O 
cis-regulatory O 
antioxidant O 
response O 
elements O 
( O 
AREs O 
) O 
. O 
In O 
this O 
work O 
, O 
we O 
have O 
assessed O 
the O 
effect O 
of O 
BPA B-ABBREVIATION 
on O 
the O 
Nrf1 O 
/ O 
2-ARE O 
pathway O 
in O 
cultured O 
human O 
embryonic O 
kidney O 
( O 
HEK O 
) O 
293 O 
cells O 
. O 
Surprisingly O 
, O 
glutathione B-TRIVIAL 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
assays O 
revealed O 
that O 
BPA B-ABBREVIATION 
application O 
created O 
a O 
more O 
reduced O 
intracellular O 
environment O 
in O 
cultured O 
HEK O 
293 O 
cells O 
. O 
Furthermore O 
, O 
BPA B-ABBREVIATION 
increased O 
the O 
transactivation O 
activity O 
of O 
ectopic O 
Nrf1 O 
and O 
Nrf2 O 
and O 
increased O 
the O 
expression O 
of O 
ARE-target O 
genes O 
ho-1 O 
and O 
nqo1 O 
at O 
high O 
( O 
100-200 O 
μM O 
) O 
BPA B-ABBREVIATION 
concentrations O 
only O 
. O 
Our O 
study O 
suggests O 
that O 
BPA B-ABBREVIATION 
activates O 
the O 
Nrf1 O 
/ O 
2-ARE O 
pathway O 
at O 
high O 
( O 
> O 
10 O 
μM O 
) O 
micromolar O 
concentrations O 
. O 

reduces O 
NK O 
cell O 
activities O 
by O 
enhancing O 
metallothionein O 
expression O 
, O 
which O 
is O 
prevented O 
by O 
selenium B-SYSTEMATIC 
. O 

aquilinum O 
, O 
one O 
of O 
the O 
most O 
important O 
poisonous O 
plants O 
in O 
the O 
world O 
, O 
is O 
known O 
to O 
be O 
carcinogenic O 
to O 
animals O 
and O 
humans O 
. O 
Moreover O 
, O 
our O 
previous O 
studies O 
showed O 
that O 
the O 
immunosuppressive O 
effects O 
of O 
ptaquiloside B-TRIVIAL 
, O 
its O 
main O 
toxic O 
agent O 
, O 
were O 
prevented O 
by O 
selenium B-SYSTEMATIC 
in O 
mouse O 
natural O 
killer O 
( O 
NK O 
) O 
cells O 
. O 
We O 
also O 
verified O 
that O 
this O 
immunosuppression O 
facilitated O 
development O 
of O 
cancer O 
. O 
Here O 
, O 
we O 
performed O 
gene O 
expression O 
microarray O 
analysis O 
in O 
splenic O 
NK O 
cells O 
from O 
mice O 
treated O 
for O 
14 O 
days O 
with O 
ptaquiloside B-TRIVIAL 
( O 
5.3 O 
mg O 
/ O 
kg O 
) O 
and O 
/ O 
or O 
selenium B-SYSTEMATIC 
( O 
1.3 O 
mg O 
/ O 
kg O 
) O 
to O 
identify O 
gene O 
transcripts O 
altered O 
by O 
ptaquiloside B-TRIVIAL 
that O 
could O 
be O 
linked O 
to O 
the O 
immunosuppression O 
and O 
that O 
would O 
be O 
prevented O 
by O 
selenium B-SYSTEMATIC 
. O 
Transcriptome O 
analysis O 
of O 
ptaquiloside B-TRIVIAL 
samples O 
revealed O 
that O 
872 O 
transcripts O 
were O 
expressed O 
differentially O 
( O 
fold O 
change O 
> O 
2 O 
and O 
p O 
< O 
0.05 O 
) O 
, O 
including O 
77 O 
up O 
- O 
regulated O 
and O 
795 O 
down O 
- O 
regulated O 
transcripts O 
. O 
Gene O 
ontology O 
analysis O 
mapped O 
these O 
up O 
- O 
regulated O 
transcripts O 
to O 
three O 
main O 
biological O 
processes O 
( O 
cellular O 
ion O 
homeostasis O 
, O 
negative O 
regulation O 
of O 
apoptosis O 
and O 
regulation O 
of O 
transcription O 
) O 
. O 
Considering O 
the O 
immunosuppressive O 
effect O 
of O 
ptaquiloside B-TRIVIAL 
, O 
we O 
hypothesized O 
that O 
two O 
genes O 
involved O 
in O 
cellular O 
ion O 
homeostasis O 
, O 
metallothionein O 
1 O 
( O 
Mt1 O 
) O 
and O 
metallothionein O 
2 O 
( O 
Mt2 O 
) O 
, O 
could O 
be O 
implicated O 
because O 
Mt1 O 
and O 
Mt2 O 
are O 
responsible O 
for O 
zinc B-SYSTEMATIC 
homeostasis O 
, O 
and O 
a O 
reduction O 
of O 
free O 
intracellular O 
zinc B-SYSTEMATIC 
impairs O 
NK O 
functions O 
. O 
We O 
confirm O 
these O 
hypotheses O 
and O 
show O 
increased O 
expression O 
of O 
metallothionein O 
in O 
splenic O 
NK O 
cells O 
and O 
reduction O 
in O 
free O 
intracellular O 
zinc B-SYSTEMATIC 
following O 
treatment O 
with O 
ptaquiloside B-TRIVIAL 
that O 
were O 
completely O 
prevented O 
by O 
selenium B-SYSTEMATIC 
co O 
- O 
treatment O 
. O 
These O 
findings O 
could O 
help O 
avoid O 
the O 
higher O 
susceptibility O 
to O 
cancer O 
that O 
is O 
induced O 
by O 
P O 
. O 
aquilinum O 
- O 
mediated O 
immunosuppressive O 
effects O 
. O 

on O 
oral O 
absorption O 
of O 
paclitaxel B-TRIVIAL 
by O 
multifunctional O 
pluronic O 
micelles O 
. O 

aim O 
of O 
the O 
present O 
study O 
is O 
to O 
synthesize O 
Pluronic B-FAMILY 
F127-polyethylenimine I-FAMILY 
- I-FAMILY 
folate I-FAMILY 
( O 
PF127-PEI-FA B-ABBREVIATION 
) O 
copolymer O 
, O 
construct O 
a O 
mixed O 
micelle O 
system O 
with O 
PF127-PEI-FA B-ABBREVIATION 
copolymer O 
and O 
Pluronic B-TRIVIAL 
P123 I-TRIVIAL 
( O 
PP123 B-ABBREVIATION 
) O 
and O 
to O 
evaluate O 
the O 
potential O 
of O 
these O 
mixed O 
micelles O 
as O 
an O 
oral O 
drug O 
delivery O 
system O 
for O 
paclitaxel B-TRIVIAL 
( O 
PTX B-ABBREVIATION 
) O 
. O 
The O 
results O 
of O 
intestinal O 
absorption O 
revealed O 
that O 
the O 
PTX B-ABBREVIATION 
-loaded O 
micelles O 
displayed O 
superior O 
permeability O 
across O 
intestinal O 
barrier O 
than O 
free O 
drug O 
and O 
PF127-PEI-FA B-ABBREVIATION 
/ O 
PP123 B-ABBREVIATION 
mixed O 
micelles O 
exhibited O 
the O 
strongest O 
permeability O 
across O 
intestinal O 
barrier O 
. O 
These O 
results O 
were O 
also O 
proved O 
by O 
the O 
studies O 
on O 
cytotoxicity O 
and O 
cell O 
uptake O 
tests O 
. O 
The O 
mechanism O 
was O 
demonstrated O 
in O 
connection O 
with O 
inhibition O 
of O 
the O 
efflux O 
mediated O 
by O 
intestinal O 
P-glycoprotein O 
( O 
P-gp O 
) O 
and O 
enhancement O 
of O 
the O 
electrostatic O 
interaction O 
of O 
positive O 
micelles O 
with O 
the O 
negative O 
intestinal O 
epithelial O 
cells O 
, O 
thereby O 
promoting O 
the O 
permeation O 
across O 
the O 
intestinal O 
wall O 
. O 
The O 
presence O 
of O 
verapamil B-TRIVIAL 
and O 
Pluronic B-FAMILY 
both O 
improved O 
the O 
intestinal O 
absorption O 
of O 
PTX B-ABBREVIATION 
, O 
which O 
further O 
certified O 
the O 
effect O 
of O 
Pluronic B-FAMILY 
on O 
P-gp O 
inhibition O 
. O 
Pharmacokinetic O 
study O 
demonstrated O 
that O 
the O 
area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
( O 
AUC(0→36 O 
h O 
) O 
) O 
of O 
PTX B-ABBREVIATION 
-loaded O 
micelles O 
was O 
three O 
times O 
greater O 
than O 
the O 
PTX B-ABBREVIATION 
solution O 
( O 
dissolved O 
in O 
a O 
50 O 
/ O 
50 O 
( O 
vol O 
/ O 
vol O 
) O 
mixture O 
of O 
Cremophore O 
EL O 
/ O 
dehydrated O 
ethanol B-SYSTEMATIC 
) O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
In O 
general O 
PF127-PEI-FA B-ABBREVIATION 
/ O 
PP123 B-ABBREVIATION 
mixed O 
micelles O 
were O 
proved O 
to O 
be O 
potential O 
oral O 
drug O 
delivery O 
system O 
for O 
PTX B-ABBREVIATION 
. O 

adsorption O 
and O 
interfacial O 
tension O 
investigations O 
on O 
cyclopentane B-SYSTEMATIC 
hydrate I-SYSTEMATIC 
. O 

hydrates O 
represent O 
an O 
unconventional O 
methane B-SYSTEMATIC 
resource O 
and O 
a O 
production O 
/ O 
safety O 
risk O 
to O 
traditional O 
oil O 
and O 
gas O 
flowlines O 
. O 
In O 
both O 
systems O 
, O 
hydrate O 
may O 
share O 
interfaces O 
with O 
both O 
aqueous O 
and O 
hydrocarbon B-FAMILY 
fluids O 
. O 
To O 
accurately O 
model O 
macroscopic O 
properties O 
, O 
such O 
as O 
relative O 
permeability O 
in O 
unconventional O 
systems O 
or O 
dispersion O 
viscosity O 
in O 
traditional O 
systems O 
, O 
knowledge O 
of O 
hydrate O 
interfacial O 
properties O 
is O 
required O 
. O 
This O 
work O 
presents O 
hydrate O 
cohesive O 
force O 
results O 
measured O 
on O 
a O 
micromechanical O 
force O 
apparatus O 
, O 
and O 
complementary O 
water- O 
hydrocarbon B-FAMILY 
interfacial O 
tension O 
data O 
. O 
By O 
combining O 
a O 
revised O 
cohesive O 
force O 
model O 
with O 
experimental O 
data O 
, O 
two O 
interfacial O 
properties O 
of O 
cyclopentane B-SYSTEMATIC 
hydrate I-SYSTEMATIC 
were O 
estimated O 
: O 
hydrate O 
- O 
water O 
and O 
hydrate- O 
cyclopentane B-SYSTEMATIC 
interfacial O 
tension O 
values O 
at O 
0.32 O 
± O 
0.05 O 
mN O 
/ O 
m O 
and O 
47 O 
± O 
5 O 
mN O 
/ O 
m O 
, O 
respectively O 
. O 
These O 
fundamental O 
physiochemical O 
properties O 
have O 
not O 
been O 
estimated O 
or O 
measured O 
for O 
cyclopentane B-SYSTEMATIC 
hydrate I-SYSTEMATIC 
to O 
date O 
. O 
The O 
addition O 
of O 
surfactants O 
in O 
the O 
cyclopentane B-SYSTEMATIC 
phase O 
significantly O 
reduced O 
the O 
cyclopentane B-SYSTEMATIC 
hydrate I-SYSTEMATIC 
cohesive O 
force O 
; O 
we O 
hypothesize O 
this O 
behavior O 
to O 
be O 
the O 
result O 
of O 
surfactant O 
adsorption O 
on O 
the O 
hydrate O 
- O 
oil O 
interface O 
. O 
Surface O 
excess O 
quantities O 
were O 
estimated O 
for O 
hydrate O 
- O 
oil O 
and O 
water O 
- O 
oil O 
interfaces O 
using O 
four O 
carboxylic B-MULTIPLE 
and I-MULTIPLE 
sulfonic I-MULTIPLE 
acids I-MULTIPLE 
. O 
The O 
results O 
suggest O 
the O 
density O 
of O 
adsorbed O 
surfactant O 
may O 
be O 
2× O 
larger O 
for O 
the O 
hydrate O 
- O 
oil O 
interface O 
than O 
the O 
water O 
- O 
oil O 
interface O 
. O 
Additionally O 
, O 
hydrate O 
- O 
oil O 
interfacial O 
tension O 
was O 
observed O 
to O 
begin O 
decreasing O 
from O 
the O 
baseline O 
value O 
at O 
significantly O 
lower O 
surfactant O 
concentrations O 
( O 
1-3 O 
orders O 
of O 
magnitude O 
) O 
than O 
those O 
for O 
the O 
water O 
- O 
oil O 
interfacial O 
tension O 
. O 

- O 
efficiency O 
photocatalysts O 
based O 
on O 
mesoporous O 
Pt B-FORMULA 
- O 
WO3 B-FORMULA 
nanohybrids O 
. O 

reliable O 
nanocasting O 
method O 
has O 
been O 
developed O 
to O 
synthesize O 
mesoporous O 
hybrids O 
of O 
platinum B-SYSTEMATIC 
( O 
Pt B-FORMULA 
) O 
nanoparticles O 
decorating O 
tungsten B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
( O 
WO3 B-FORMULA 
) O 
. O 
The O 
process O 
began O 
with O 
modification O 
of O 
the O 
SBA B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
template O 
with O 
carbon B-SYSTEMATIC 
polymers O 
and O 
Pt B-FORMULA 
nanoparticles O 
accompanied O 
by O 
adsorption O 
of O 
W(6+) B-FORMULA 
, O 
which O 
was O 
then O 
converted O 
into O 
m-Pt-WO3 B-FORMULA 
composites O 
by O 
heat O 
treatment O 
and O 
subsequent O 
template O 
removal O 
. O 
The O 
synthetic O 
strategy O 
can O 
be O 
easily O 
extended O 
to O 
prepare O 
other O 
mesoporous O 
nanohybrids O 
with O 
metal B-FAMILY 
oxide I-FAMILY 
loaded O 
precious O 
metal O 
composites O 
. O 
Comprehensive O 
characterizations O 
suggest O 
that O 
the O 
as-developed O 
m-Pt-WO3 B-FORMULA 
nanohybrid O 
exhibits O 
unique O 
properties O 
with O 
mesoporous O 
structure O 
, O 
excellent O 
crystalline O 
structure O 
, O 
and O 
high O 
surface O 
area O 
. O 
When O 
the O 
photocatalytic O 
properties O 
of O 
m-Pt-WO3 B-FORMULA 
nanohybrids O 
were O 
systematically O 
investigated O 
, O 
it O 
was O 
revealed O 
that O 
the O 
m-Pt-WO3 B-FORMULA 
nanohybrids O 
showed O 
great O 
promise O 
for O 
degrading O 
the O 
organic O 
dye O 
under O 
visible O 
light O 
irradiation O 
, O 
which O 
shows O 
an O 
excellent O 
photocatalytic O 
activity O 
that O 
far O 
exceeded O 
those O 
of O 
pure O 
phase O 
mesoporous O 
WO3 B-FORMULA 
and O 
commercial O 
TiO2 B-FORMULA 
( O 
P25 O 
) O 
, O 
and O 
was O 
10-fold O 
more O 
active O 
than O 
that O 
of O 
the O 
bulk O 
Pt B-FORMULA 
- O 
WO3 B-FORMULA 
catalyst O 
. O 
The O 
as-developed O 
synthetic O 
route O 
opens O 
up O 
a O 
new O 
avenue O 
for O 
designing O 
mesoporous O 
hybrid O 
materials O 
for O 
various O 
applications O 
benefiting O 
from O 
the O 
unique O 
porous O 
structure O 
, O 
high O 
surface O 
area O 
, O 
and O 
synergistic O 
effects O 
among O 
constituents O 
. O 

of O 
EPA B-ABBREVIATION 
- O 
DHA B-ABBREVIATION 
from O 
lipids O 
recovered O 
from O 
fish O 
processing O 
wastes O 
through O 
biotechnological O 
approaches O 
. O 

effect O 
of O 
fish O 
oil O 
recovered O 
from O 
fish O 
visceral O 
waste O 
( O 
FVW-FO O 
) O 
on O 
serum O 
and O 
liver O 
lipids O 
, O 
activity O 
of O 
HMG-CoA B-ABBREVIATION 
reductase O 
in O 
liver O 
microsomes O 
and O 
EPA B-ABBREVIATION 
+ O 
DHA B-ABBREVIATION 
incorporation O 
in O 
liver O 
, O 
heart O 
and O 
brain O 
were O 
evaluated O 
. O 
Rats O 
were O 
fed O 
different O 
concentrations O 
of O 
FVW-FO O 
providing O 
1.25% O 
, O 
2.50% O 
, O 
5.0% O 
EPA B-ABBREVIATION 
+ O 
DHA B-ABBREVIATION 
recovered O 
by O 
either O 
fermentation O 
or O 
enzymatic O 
hydrolysis O 
for O 
8weeks O 
. O 
Feeding O 
FVW-FO O 
reduce O 
triacylglycerols B-FAMILY 
( O 
5.96-20.3% O 
) O 
, O 
total O 
cholesterol B-TRIVIAL 
( O 
7.9-21.5% O 
) O 
and O 
LDL O 
( O 
7.39-21.7% O 
) O 
cholesterol B-TRIVIAL 
levels O 
in O 
serum O 
compared O 
to O 
group O 
fed O 
on O 
a O 
control O 
diet O 
( O 
groundnut O 
oil O 
) O 
. O 
The O 
activity O 
of O 
HMG-CoA B-ABBREVIATION 
reductase O 
was O 
reduced O 
( O 
p O 
< O 
0.05 O 
) O 
in O 
the O 
FVW-FO O 
fed O 
groups O 
compared O 
to O 
the O 
control O 
. O 
EPA B-ABBREVIATION 
+ O 
DHA B-ABBREVIATION 
level O 
in O 
serum O 
, O 
liver O 
, O 
brain O 
and O 
heart O 
increased O 
with O 
increments O 
in O 
dietary O 
EPA B-ABBREVIATION 
+ O 
DHA B-ABBREVIATION 
. O 
Results O 
show O 
the O 
hypolipidemic O 
property O 
of O 
FVW-FO O 
and O 
reduced O 
HMG-CoA B-ABBREVIATION 
reductase O 
activity O 
which O 
is O 
proportional O 
to O 
the O 
incorporation O 
of O 
EPA B-ABBREVIATION 
+ O 
DHA B-ABBREVIATION 
. O 
Recovery O 
of O 
FVW-FO O 
will O 
address O 
the O 
increasing O 
demand O 
for O 
fish O 
oil O 
and O 
reduce O 
pollution O 
problems O 
. O 

acid I-TRIVIAL 
, O 
a O 
brominated B-FAMILY 
acetylenic I-FAMILY 
acid I-FAMILY 
from O 
the O 
marine O 
sponge O 
Theonella O 
swinhoei O 
. O 

new O 
brominated B-FAMILY 
C(17) I-FAMILY 
acetylenic I-FAMILY 
acid I-FAMILY 
( O 
1 O 
) O 
designated O 
as O 
bromotheoynic B-TRIVIAL 
acid I-TRIVIAL 
has O 
been O 
isolated O 
from O 
the O 
marine O 
sponge O 
Theonella O 
swinhoei O 
, O 
collected O 
off O 
the O 
coast O 
of O 
Tanegashima O 
, O 
Kagoshima O 
Prefecture O 
, O 
Japan O 
. O 
The O 
structure O 
was O 
determined O 
on O 
the O 
basis O 
of O 
the O 
analysis O 
of O 
its O 
extensive O 
2D O 
NMR O 
spectroscopic O 
data O 
as O 
well O 
as O 
HRMS O 
. O 
Bromotheoynic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1 O 
) O 
inhibited O 
maturation O 
of O 
starfish O 
oocytes O 
and O 
cell O 
division O 
of O 
fertilised O 
starfish O 
eggs O 
. O 
Bromotheoynic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1 O 
) O 
also O 
inhibited O 
proliferation O 
of O 
human O 
leukaemia O 
U937 O 
and O 
HL60 O 
cells O 
, O 
human O 
lung O 
cancer O 
A549 O 
and O 
H1299 O 
cells O 
, O 
and O 
human O 
embryonic O 
kidney O 
293 O 
( O 
HEK293 O 
) O 
cells O 
. O 

Structures O 
of O 
a O 
Glycoside O 
Hydrolase O 
Family O 
20 O 
Lacto- O 
N B-FORMULA 
-biosidase O 
from O 
Bifidobacterium O 
bifidum O 
. O 

milk O 
oligosaccharides O 
contain O 
a O 
large O 
variety O 
of O 
oligosaccharides O 
, O 
of O 
which O 
lacto-N-biose B-TRIVIAL 
I I-TRIVIAL 
( O 
Gal-β1,3-GlcNAc B-SYSTEMATIC 
; O 
LNB B-ABBREVIATION 
) O 
predominates O 
as O 
a O 
major O 
core O 
structure O 
. O 
A O 
unique O 
metabolic O 
pathway O 
specific O 
for O 
LNB B-ABBREVIATION 
has O 
recently O 
been O 
identified O 
in O 
the O 
human O 
commensal O 
bifidobacteria O 
. O 
Several O 
strains O 
of O 
infant O 
gut O 
- O 
associated O 
bifidobacteria O 
possess O 
lacto- O 
N B-FORMULA 
-biosidase O 
, O 
a O 
membrane O 
- O 
anchored O 
extracellular O 
enzyme O 
, O 
that O 
liberates O 
LNB B-ABBREVIATION 
from O 
the O 
nonreducing O 
end O 
of O 
human O 
milk O 
oligosaccharides O 
and O 
plays O 
a O 
key O 
role O 
in O 
the O 
metabolic O 
pathway O 
of O 
these O 
compounds O 
. O 
Lacto- O 
N B-FORMULA 
-biosidase O 
belongs O 
to O 
the O 
glycoside O 
hydrolase O 
family O 
20 O 
, O 
and O 
its O 
reaction O 
proceeds O 
via O 
a O 
substrate O 
- O 
assisted O 
catalytic O 
mechanism O 
. O 
Several O 
crystal O 
structures O 
of O 
GH20 O 
β- O 
N B-FORMULA 
-acetylhexosaminidases O 
, O 
which O 
release O 
monosaccharide B-FAMILY 
GlcNAc B-FORMULA 
from O 
its O 
substrate O 
, O 
have O 
been O 
determined O 
, O 
but O 
to O 
date O 
, O 
a O 
structure O 
of O 
lacto- O 
N B-FORMULA 
-biosidase O 
is O 
unknown O 
. O 
Here O 
, O 
we O 
have O 
determined O 
the O 
first O 
three O 
- O 
dimensional O 
structures O 
of O 
lacto- O 
N B-FORMULA 
-biosidase O 
from O 
Bifidobacterium O 
bifidum O 
JCM1254 O 
in O 
complex O 
with O 
LNB B-ABBREVIATION 
and O 
LNB-thiazoline B-SYSTEMATIC 
( O 
Gal-β1,3-GlcNAc-thiazoline B-SYSTEMATIC 
) O 
at O 
1.8-Å O 
resolution O 
. O 
Lacto- O 
N B-FORMULA 
-biosidase O 
consists O 
of O 
three O 
domains O 
, O 
and O 
the O 
C B-FORMULA 
-terminal O 
domain O 
has O 
a O 
unique O 
β-trefoil- O 
like O 
fold O 
. O 
Compared O 
with O 
other O 
β- O 
N B-FORMULA 
-acetylhexosaminidases O 
, O 
lacto- O 
N B-FORMULA 
-biosidase O 
has O 
a O 
wide O 
substrate O 
- O 
binding O 
pocket O 
with O 
a O 
-2 O 
subsite O 
specific O 
for O 
β-1,3- O 
linked O 
Gal B-ABBREVIATION 
, O 
and O 
the O 
residues O 
responsible O 
for O 
Gal B-ABBREVIATION 
recognition O 
were O 
identified O 
. O 
The O 
bound O 
ligands O 
are O 
recognized O 
by O 
extensive O 
hydrogen B-SYSTEMATIC 
bonds O 
at O 
all O 
of O 
their O 
hydroxyls B-FAMILY 
consistent O 
with O 
the O 
enzyme's O 
strict O 
substrate O 
specificity O 
for O 
the O 
LNB B-ABBREVIATION 
moiety O 
. O 
The O 
GlcNAc B-FORMULA 
sugar B-FAMILY 
ring O 
of O 
LNB B-ABBREVIATION 
is O 
in O 
a O 
distorted O 
conformation O 
near O 
(4)E O 
, O 
whereas O 
that O 
of O 
LNB B-ABBREVIATION 
- O 
thiazoline B-SYSTEMATIC 
is O 
in O 
a O 
(4)C1 O 
conformation O 
. O 
A O 
possible O 
conformational O 
pathway O 
for O 
the O 
lacto- O 
N B-FORMULA 
-biosidase O 
reaction O 
is O 
discussed O 
. O 

is O 
one O 
of O 
the O 
key O 
risk O 
factors O 
for O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
in O 
diabetes O 
mellitus O 
. O 
Despite O 
the O 
mounting O 
clinical O 
trial O 
data O 
, O 
the O 
management O 
of O 
dyslipidemia O 
other O 
than O 
lowering O 
the O 
low O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-c O 
) O 
continues O 
to O 
be O 
controversial O 
. O 
The O 
characteristic O 
features O 
of O 
diabetic O 
dyslipidemia O 
are O 
high O 
plasma O 
triglyceride B-FAMILY 
concentration O 
, O 
reduced O 
high O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
HDL-c O 
) O 
concentration O 
, O 
and O 
increased O 
concentration O 
of O 
small O 
dense O 
LDL O 
particles O 
. O 
These O 
changes O 
are O 
caused O 
by O 
increased O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
flux O 
secondary O 
to O 
insulin O 
resistance O 
and O 
aggravated O 
by O 
increased O 
inflammatory O 
adipokines O 
. O 
The O 
availability O 
of O 
several O 
lipid O 
- O 
lowering O 
drugs O 
and O 
nutritional O 
supplements O 
offers O 
novel O 
and O 
effective O 
options O 
for O 
achieving O 
target O 
lipid O 
levels O 
in O 
people O 
with O 
diabetes O 
. O 
While O 
initiation O 
of O 
drug O 
therapy O 
based O 
on O 
differences O 
in O 
the O 
lipid O 
profile O 
is O 
an O 
option O 
, O 
most O 
practice O 
guidelines O 
recommend O 
statins O 
as O 
first O 
- O 
line O 
therapy O 
. O 
Although O 
the O 
evidence O 
for O 
clinical O 
utility O 
of O 
combination O 
of O 
statins O 
with O 
fibrates B-FAMILY 
or O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
in O 
reducing O 
cardiovascular O 
events O 
remains O 
inconclusive O 
, O 
the O 
preponderance O 
of O 
evidence O 
suggests O 
that O 
a O 
subgroup O 
who O 
have O 
high O 
triglycerides B-FAMILY 
and O 
low O 
HDL-c O 
levels O 
may O 
benefit O 
from O 
combination O 
therapy O 
of O 
statins O 
and O 
fibrates B-FAMILY 
. O 
The O 
goal O 
of O 
therapy O 
is O 
to O 
achieve O 
at O 
least O 
30-40 O 
% O 
reduction O 
in O 
LDL-c O 
levels O 
. O 
Preferably O 
the O 
LDL-c O 
should O 
be O 
less O 
than O 
100 O 
mg O 
/ O 
dL O 
in O 
low O 
- O 
risk O 
people O 
and O 
less O 
than O 
70 O 
mg O 
/ O 
dL O 
in O 
those O 
at O 
high O 
risk O 
, O 
including O 
people O 
with O 
established O 
CVD O 
. O 

-mediated O 
cyclooxygenase-2 O 
expression O 
via O 
epidermal O 
growth O 
factor O 
receptor O 
/ O 
HuR O 
interaction O 
enhances O 
the O 
aggressiveness O 
of O 
triple O 
- O 
negative O 
breast O 
cancer O 
cells O 
. O 

, O 
a O 
dual O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
/ O 
human O 
epidermal O 
growth O 
factor O 
receptor O 
2 O 
( O 
HER2 O 
) O 
kinase O 
inhibitor O 
, O 
showed O 
clinical O 
benefits O 
in O 
advanced O 
HER2-positive O 
breast O 
cancer O 
patients O 
. O 
Because O 
some O 
triple O 
- O 
negative O 
breast O 
cancers O 
( O 
TNBCs O 
) O 
frequently O 
overexpress O 
EGFR O 
, O 
the O 
antitumor O 
activity O 
of O 
lapatinib B-TRIVIAL 
in O 
such O 
diseases O 
was O 
also O 
tested O 
. O 
However O 
, O 
the O 
results O 
showed O 
a O 
worse O 
event-free O 
survival O 
rate O 
. O 
It O 
remains O 
unknown O 
whether O 
and O 
how O 
lapatinib B-TRIVIAL 
elicits O 
the O 
aggressiveness O 
of O 
such O 
cancer O 
cells O 
. O 
In O 
this O 
study O 
, O 
our O 
results O 
demonstrated O 
that O 
lapatinib B-TRIVIAL 
facilitated O 
axillary O 
and O 
lung O 
metastases O 
of O 
triple O 
- O 
negative O 
MDA-MB-231 O 
breast O 
cancer O 
cells O 
without O 
affecting O 
their O 
viability O 
, O 
leading O 
to O 
worse O 
survival O 
in O 
orthotopic O 
xenograft O 
mice O 
. O 
The O 
lapatinib B-TRIVIAL 
-increased O 
motility O 
was O 
attributed O 
by O 
the O 
elevation O 
of O 
EGFR O 
through O 
the O 
downregulation O 
of O 
microRNA-7 O 
and O 
by O 
the O 
subsequent O 
overexpression O 
of O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
. O 
Strikingly O 
, O 
independent O 
of O 
its O 
kinase O 
activity O 
, O 
the O 
elevated O 
EGFR O 
at O 
least O 
partly O 
stabilized O 
COX-2 O 
expression O 
by O 
enhancing O 
the O 
binding O 
of O 
HuR O 
to O 
COX-2 O 
mRNA O 
. O 
Our O 
results O 
suggest O 
that O 
lapatinib B-TRIVIAL 
may O 
increase O 
the O 
migration O 
and O 
invasion O 
of O 
MDA-MB-231 O 
cells O 
by O 
upregulating O 
EGFR O 
and O 
COX-2 O 
through O 
the O 
downregulation O 
of O 
microRNA-7 O 
, O 
providing O 
a O 
potential O 
explanation O 
for O 
the O 
worse O 
clinical O 
outcome O 
of O 
TNBC O 
patients O 
who O 
receive O 
lapatinib B-TRIVIAL 
-based O 
treatment O 
. O 
These O 
findings O 
also O 
shed O 
new O 
light O 
on O 
the O 
molecular O 
mechanism O 
of O 
COX-2 O 
mRNA O 
stabilization O 
by O 
EGFR O 
in O 
a O 
kinase O 
- O 
independent O 
manner O 
. O 

is O 
an O 
important O 
regulatory O 
protein O 
that O 
helps O 
activating O 
a O 
large O 
number O 
of O 
genes O 
for O 
the O 
anoxic O 
and O 
microoxic O 
, O 
endosymbiotic O 
and O 
nitrogen B-SYSTEMATIC 
-fixing O 
life O 
styles O 
of O 
the O 
α-proteobacterium O 
Bradyrhizobium O 
japonicum O 
. O 
FixK2 O 
belongs O 
to O 
the O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
receptor O 
protein O 
( O 
CRP O 
) O 
superfamily O 
. O 
While O 
most O 
CRP-family O 
members O 
are O 
co O 
- O 
regulated O 
by O 
effector O 
molecules O 
, O 
the O 
activity O 
of O 
FixK2 O 
is O 
negatively O 
controlled O 
by O 
oxidation O 
of O 
its O 
single O 
cysteine B-TRIVIAL 
( O 
C183 O 
) O 
located O 
next O 
to O 
the O 
DNA O 
binding O 
domain O 
, O 
and O 
possibly O 
also O 
by O 
proteolysis O 
. O 
Here O 
we O 
report O 
the O 
three O 
- O 
dimensional O 
X-ray O 
structure O 
of O 
FixK2 O 
, O 
a O 
representative O 
of O 
the O 
FixK O 
subgroup O 
of O 
the O 
CRP O 
superfamily O 
. O 
Crystallization O 
succeeded O 
only O 
(i) O 
when O 
an O 
oxidation- O 
and O 
protease O 
- O 
insensitive O 
protein O 
variant O 
( O 
C183S-FixK2His6 O 
) O 
was O 
used O 
, O 
in O 
which O 
C183 O 
was O 
replaced O 
by O 
serine B-TRIVIAL 
and O 
the O 
C B-FORMULA 
-terminus O 
fused O 
with O 
a O 
hexa B-TRIVIAL 
- I-TRIVIAL 
histidine I-TRIVIAL 
tag O 
, O 
and O 
(ii) O 
when O 
this O 
protein O 
was O 
allowed O 
to O 
form O 
a O 
complex O 
with O 
a O 
30mer O 
double O 
- O 
strand O 
target O 
DNA O 
. O 
The O 
structure O 
of O 
the O 
FixK2-DNA O 
complex O 
was O 
solved O 
at O 
a O 
resolution O 
of O 
1.77 O 
Å O 
in O 
which O 
the O 
protein O 
formed O 
a O 
homodimer O 
. O 
The O 
precise O 
protein-DNA O 
contacts O 
were O 
identified O 
which O 
led O 
to O 
an O 
affirmation O 
of O 
the O 
canonical O 
target O 
sequence O 
, O 
the O 
so O 
- O 
called O 
FixK2 O 
box O 
. O 
The O 
C B-FORMULA 
-terminus O 
is O 
surface O 
- O 
exposed O 
which O 
might O 
explain O 
its O 
sensitivity O 
to O 
specific O 
cleavage O 
and O 
degradation O 
. O 
The O 
oxidation O 
- O 
sensitive O 
C183 O 
is O 
also O 
surface O 
- O 
exposed O 
and O 
in O 
close O 
proximity O 
to O 
DNA O 
. O 
Therefore O 
, O 
we O 
propose O 
a O 
mechanism O 
whereby O 
the O 
oxo B-FAMILY 
- I-FAMILY 
acids I-FAMILY 
generated O 
after O 
oxidation O 
of O 
the O 
cysteine B-SYSTEMATIC 
thiol I-SYSTEMATIC 
cause O 
an O 
electrostatic O 
repulsion O 
, O 
thus O 
preventing O 
specific O 
DNA O 
binding O 
. O 

kinase O 
inhibitor O 
design O 
by O 
targeting O 
the O 
Asp-Phe-Gly B-FORMULA 
( O 
DFG O 
) O 
motif O 
: O 
the O 
role O 
of O 
the O 
DFG O 
motif O 
in O 
the O 
design O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
inhibitors O 
. O 

Asp-Phe-Gly B-FORMULA 
( O 
DFG O 
) O 
motif O 
plays O 
an O 
important O 
role O 
in O 
the O 
regulation O 
of O 
kinase O 
activity O 
. O 
Structure O 
- O 
based O 
drug O 
design O 
was O 
performed O 
to O 
design O 
compounds O 
able O 
to O 
interact O 
with O 
the O 
DFG O 
motif O 
; O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
was O 
selected O 
as O 
an O 
example O 
. O 
Structural O 
insights O 
obtained O 
from O 
the O 
EGFR O 
/ O 
2a O 
complex O 
suggested O 
that O 
an O 
extension O 
from O 
the O 
meta- O 
position O 
on O 
the O 
phenyl B-SYSTEMATIC 
group O 
( O 
ring-5 O 
) O 
would O 
improve O 
interactions O 
with O 
the O 
DFG O 
motif O 
. O 
Indeed O 
, O 
introduction O 
of O 
an O 
N,N-dimethylamino B-SYSTEMATIC 
tail O 
resulted O 
in O 
4b O 
, O 
which O 
showed O 
almost O 
50-fold O 
improvement O 
in O 
inhibition O 
compared O 
to O 
2a O 
. O 
Structural O 
studies O 
confirmed O 
this O 
N,N-dimethylamino B-SYSTEMATIC 
tail O 
moved O 
towards O 
the O 
DFG O 
motif O 
to O 
form O 
a O 
salt O 
bridge O 
with O 
the O 
side O 
chain O 
of O 
Asp831 O 
. O 
That O 
the O 
interactions O 
with O 
the O 
DFG O 
motif O 
greatly O 
contribute O 
to O 
the O 
potency O 
of O 
4b O 
is O 
strongly O 
evidenced O 
by O 
synthesizing O 
and O 
testing O 
compounds O 
2a O 
, O 
3g O 
and O 
4f O 
: O 
when O 
the O 
charge O 
interactions O 
are O 
absent O 
, O 
the O 
inhibitory O 
activity O 
decreased O 
significantly O 
. O 

pharmacokinetics O 
of O 
the O 
two O 
structurally O 
similar O 
dammarane B-FAMILY 
sapogenins I-FAMILY 
, O 
protopanaxatriol B-TRIVIAL 
and O 
protopanaxadiol B-TRIVIAL 
, O 
in O 
rats O 
. O 

Sapogenins I-FAMILY 
( O 
DS O 
) O 
, O 
with O 
main O 
ingredients O 
of O 
protopanaxatriol B-TRIVIAL 
( O 
PPT B-ABBREVIATION 
, O 
33% O 
) O 
and O 
protopanaxadiol B-TRIVIAL 
( O 
PPD B-ABBREVIATION 
, O 
16% O 
) O 
, O 
is O 
an O 
alkaline O 
hydrolyzed O 
product O 
of O 
ginsenosides B-FAMILY 
and O 
had O 
significant O 
activities O 
in O 
improving O 
learning O 
and O 
memory O 
and O 
decreasing O 
chemotherapy O 
- O 
induced O 
myelosuppression O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
pharmacokinetics O 
and O 
oral O 
bioavailabilities O 
of O 
PPT B-ABBREVIATION 
and O 
PPD B-ABBREVIATION 
were O 
investigated O 
when O 
a O 
single O 
dose O 
of O 
DS O 
was O 
administrated O 
orally O 
( O 
75mg O 
/ O 
kg O 
) O 
and O 
intravenously O 
( O 
i.v O 
. O 
, O 
30mg O 
/ O 
kg O 
) O 
to O 
rats O 
. O 
Their O 
in O 
vitro O 
stabilities O 
in O 
the O 
GI O 
tract O 
were O 
also O 
investigated O 
. O 
PPT B-ABBREVIATION 
and O 
PPD B-ABBREVIATION 
concentrations O 
were O 
measured O 
by O 
LC-MS O 
. O 
The O 
results O 
showed O 
that O 
PPT B-ABBREVIATION 
was O 
eliminated O 
rapidly O 
from O 
the O 
body O 
with O 
an O 
average O 
t1 O 
/ O 
2 O 
, O 
λz O 
value O 
of O 
0.80h O 
and O 
CL O 
of O 
4.27l O 
/ O 
h O 
/ O 
kg O 
after O 
i.v O 
. O 
administration O 
, O 
while O 
PPD B-ABBREVIATION 
was O 
eliminated O 
relatively O 
slowly O 
with O 
a O 
t1 O 
/ O 
2 O 
, O 
λz O 
of O 
6.25h O 
and O 
CL O 
of O 
0.98l O 
/ O 
h O 
/ O 
kg O 
. O 
After O 
oral O 
administration O 
, O 
both O 
PPD B-ABBREVIATION 
and O 
PPT B-ABBREVIATION 
could O 
be O 
absorbed O 
into O 
the O 
body O 
, O 
but O 
their O 
systemic O 
exposures O 
were O 
quite O 
different O 
. O 
PPT B-ABBREVIATION 
was O 
absorbed O 
into O 
the O 
body O 
quickly O 
, O 
with O 
a O 
Tmax O 
of O 
0.58h O 
and O 
a O 
Cmax O 
of O 
0.13μg O 
/ O 
ml O 
, O 
while O 
PPD B-ABBREVIATION 
was O 
absorbed O 
relatively O 
slowly O 
with O 
a O 
Tmax O 
of O 
1.82h O 
and O 
a O 
Cmax O 
of O 
1.04μg O 
/ O 
ml O 
. O 
The O 
absolute O 
bioavailabilities O 
of O 
PPT B-ABBREVIATION 
and O 
PPD B-ABBREVIATION 
were O 
estimated O 
as O 
3.69% O 
and O 
48.12% O 
, O 
respectively O 
. O 
The O 
stability O 
test O 
found O 
that O 
PPT B-ABBREVIATION 
was O 
instable O 
in O 
the O 
stomach O 
with O 
40% O 
degradation O 
after O 
4h O 
incubation O 
at O 
37°C O 
, O 
both O 
in O 
pH1.2 O 
buffer O 
and O 
in O 
the O 
stomach O 
content O 
solution O 
. O 
The O 
instability O 
in O 
the O 
stomach O 
might O 
be O 
one O 
of O 
the O 
reasons O 
for O 
PPT B-ABBREVIATION 
' O 
s O 
poor O 
bioavailability O 
. O 

of O 
the O 
dorsal O 
raphe O 
nucleus O 
- O 
prefrontal O 
cortex O 
serotonin B-TRIVIAL 
system O 
by O 
chronic O 
treatment O 
with O 
escitalopram B-TRIVIAL 
in O 
hyposerotonergic O 
Wistar-Kyoto O 
rats O 
. O 

( O 
WKY O 
) O 
rats O 
are O 
sensitive O 
to O 
chronic O 
stressors O 
and O 
exhibit O 
depression O 
- O 
like O 
behavior O 
. O 
Dorsal O 
raphe O 
nucleus O 
( O 
DRN O 
) O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
neurons O 
projecting O 
to O 
the O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
comprise O 
the O 
important O 
neurocircuitry O 
underlying O 
the O 
pathophysiology O 
of O 
depression O 
. O 
To O 
evaluate O 
the O 
DRN-PFC O 
5-HT B-SYSTEMATIC 
system O 
in O 
WKY O 
rats O 
, O 
we O 
examined O 
the O 
effects O 
of O 
escitalopram B-TRIVIAL 
( O 
ESCIT B-ABBREVIATION 
) O 
on O 
the O 
extracellular O 
5-HT B-SYSTEMATIC 
level O 
in O 
comparison O 
with O 
Wistar O 
rats O 
using O 
dual O 
- O 
probe O 
microdialysis O 
. O 
The O 
basal O 
levels O 
of O 
5-HT B-SYSTEMATIC 
in O 
the O 
DRN O 
, O 
but O 
not O 
in O 
the O 
PFC O 
, O 
in O 
WKY O 
rats O 
was O 
reduced O 
as O 
low O 
as O 
30% O 
of O 
Wistar O 
rats O 
. O 
Responses O 
of O 
5-HT B-SYSTEMATIC 
in O 
the O 
DRN O 
and O 
PFC O 
to O 
ESCIT B-ABBREVIATION 
administered O 
systemically O 
and O 
locally O 
were O 
attenuated O 
in O 
WKY O 
rats O 
. O 
Feedback O 
inhibition O 
of O 
DRN O 
5-HT B-SYSTEMATIC 
release O 
induced O 
by O 
ESCIT B-ABBREVIATION 
into O 
the O 
PFC O 
was O 
also O 
attenuated O 
in O 
WKY O 
rats O 
. O 
Chronic O 
ESCIT B-ABBREVIATION 
induced O 
upregulation O 
of O 
the O 
DRN-PFC O 
5-HT B-SYSTEMATIC 
system O 
in O 
WKY O 
rats O 
, O 
with O 
increases O 
in O 
basal O 
5-HT B-SYSTEMATIC 
in O 
the O 
DRN O 
, O 
responsiveness O 
to O 
ESCIT B-ABBREVIATION 
in O 
the O 
DRN O 
and O 
PFC O 
, O 
and O 
feedback O 
inhibition O 
, O 
whereas O 
downregulation O 
of O 
these O 
effects O 
was O 
induced O 
in O 
Wistar O 
rats O 
. O 
Thus O 
, O 
the O 
WKY O 
rat O 
is O 
an O 
animal O 
model O 
of O 
depression O 
with O 
low O 
activity O 
of O 
the O 
DRN-PFC O 
5HT B-SYSTEMATIC 
system O 
. O 
The O 
finding O 
that O 
chronic O 
ESCIT B-ABBREVIATION 
upregulates O 
the O 
5-HT B-SYSTEMATIC 
system O 
in O 
hyposerotonergic O 
WKY O 
rats O 
may O 
contribute O 
to O 
improved O 
understanding O 
of O 
mechanisms O 
of O 
action O 
of O 
antidepressants O 
, O 
especially O 
in O 
depression O 
with O 
5-HT B-SYSTEMATIC 
deficiency O 
. O 

of O 
chiral O 
derivatives O 
of O 
xanthones B-FAMILY 
on O 
(S,S)-Whelk-O1 O 
and O 
L-phenylglycine B-TRIVIAL 
stationary O 
phases O 
and O 
chiral O 
recognition O 
mechanism O 
by O 
docking O 
approach O 
for O 
(S,S)-Whelk-O1 O 
. O 

resolution O 
of O 
seven O 
enantiomeric O 
pairs O 
of O 
chiral O 
derivatives O 
of O 
xanthones B-FAMILY 
( O 
CDXs O 
) O 
on O 
(S,S)-Whelk-O1 O 
and O 
L-phenylglycine B-TRIVIAL 
chiral O 
stationary O 
phases O 
( O 
CSPs O 
) O 
was O 
systematically O 
investigated O 
using O 
multimodal O 
elution O 
conditions O 
( O 
normal O 
- O 
phase O 
, O 
polar O 
- O 
organic O 
, O 
and O 
reversed O 
- O 
phase O 
) O 
. O 
The O 
(S,S)-Whelk-O1 O 
CSP O 
, O 
under O 
polar O 
- O 
organic O 
conditions O 
, O 
demonstrated O 
a O 
very O 
good O 
power O 
of O 
resolution O 
for O 
the O 
CDXs O 
possessing O 
an O 
aromatic O 
moiety O 
linked O 
to O 
the O 
stereogenic O 
center O 
with O 
separation O 
factor O 
and O 
resolution O 
factor O 
ranging O 
from O 
1.91 O 
to O 
7.55 O 
and O 
from O 
6.71 O 
to O 
24.16 O 
, O 
respectively O 
. O 
The O 
chiral O 
recognition O 
mechanisms O 
were O 
also O 
investigated O 
for O 
(S,S)-Whelk-O1 O 
CSP O 
by O 
molecular O 
docking O 
technique O 
. O 
Data O 
regarding O 
the O 
CSP-CDX O 
molecular O 
conformations O 
and O 
interactions O 
were O 
retrieved O 
. O 
These O 
results O 
were O 
in O 
accordance O 
with O 
the O 
experimental O 
chromatographic O 
parameters O 
regarding O 
enantioselectivity O 
and O 
enantiomer O 
elution O 
order O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
fulfilled O 
the O 
initial O 
objectives O 
of O 
enantioselective O 
studies O 
of O 
CDXs O 
and O 
elucidation O 
of O 
intermolecular O 
CSP-CDX O 
interactions O 
. O 

- O 
based O 
discovery O 
of O 
novel O 
and O 
selective O 
mPGES-1 O 
inhibitors O 
Part O 
1 O 
: O 
identification O 
of O 
sulfonamido-1,2,3-triazole-4,5-dicarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 

prostaglandin B-FAMILY 
E I-FAMILY 
synthase-1 O 
( O 
mPGES-1 O 
) O 
is O 
an O 
inducible O 
prostaglandin B-FAMILY 
E I-FAMILY 
synthase O 
that O 
catalyzes O 
the O 
conversion O 
of O 
prostaglandin B-FAMILY 
PGH(2) B-ABBREVIATION 
to O 
PGE(2) B-ABBREVIATION 
and O 
represents O 
a O 
novel O 
target O 
for O 
therapeutic O 
treatment O 
of O 
inflammatory O 
disorders O 
. O 
It O 
is O 
essential O 
to O 
identify O 
mPGES-1 O 
inhibitor O 
with O 
novel O 
scaffold O 
as O 
new O 
hit O 
or O 
lead O 
compound O 
for O 
the O 
purpose O 
of O 
the O 
next O 
- O 
generation O 
anti-inflammatory O 
drugs O 
. O 
Herein O 
we O 
report O 
the O 
discovery O 
of O 
sulfonamido-1,2,3-triazole-4,5-dicarboxylic B-SYSTEMATIC 
derivatives O 
as O 
a O 
novel O 
class O 
of O 
mPGES-1 O 
inhibitors O 
identified O 
through O 
fragment O 
- O 
based O 
virtual O 
screening O 
and O 
in O 
vitro O 
assays O 
on O 
the O 
inhibitory O 
activity O 
of O 
the O 
actual O 
compounds O 
. O 
1-[2-(N-Phenylbenzenesulfonamido)ethyl]-1H-1,2,3-triazole-4,5-dicarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
6f O 
) O 
inhibits O 
human O 
mPGES-1 O 
( O 
IC(50) O 
of O 
1.1 O 
μM O 
) O 
with O 
high O 
selectivity O 
( O 
ca.1000-fold O 
) O 
over O 
both O 
COX-1 O 
and O 
COX-2 O 
in O 
a O 
cell O 
- O 
free O 
assay O 
. O 
In O 
addition O 
, O 
the O 
activity O 
of O 
compound O 
6f O 
was O 
again O 
tested O 
at O 
10 O 
μM O 
concentration O 
in O 
presence O 
of O 
0.1% O 
Triton B-TRIVIAL 
X-100 I-TRIVIAL 
and O 
found O 
to O 
be O 
reduced O 
to O 
1 O 
/ O 
4 O 
of O 
its O 
original O 
activity O 
without O 
this O 
detergent O 
. O 
Compared O 
to O 
the O 
complete O 
loss O 
of O 
activity O 
of O 
nuisance O 
inhibitor O 
with O 
the O 
detergent O 
, O 
therefore O 
, O 
compound O 
6f O 
would O 
be O 
regarded O 
as O 
a O 
partial O 
nuisance O 
inhibitor O 
of O 
mPGES-1 O 
with O 
a O 
novel O 
scaffold O 
for O 
the O 
optimal O 
design O 
of O 
more O 
potent O 
mPGES-1 O 
inhibitors O 
. O 

new O 
antitumour O 
cassane B-TRIVIAL 
-type O 
diterpene B-FAMILY 
from O 
Caesalpinia O 
crista O 
. O 

, I-SYSTEMATIC 
7β-dihydroxycassa-11,13(15)-diene-16,12-lactone I-SYSTEMATIC 
, O 
a O 
new O 
cassane B-TRIVIAL 
-type O 
diterpene B-FAMILY 
was O 
isolated O 
from O 
Caesalpinia O 
crista O 
. O 
The O 
structure O 
of O 
this O 
compound O 
was O 
elucidated O 
by O 
analysis O 
of O 
NMR O 
spectra O 
, O 
and O 
the O 
relative O 
configuration O 
was O 
established O 
by O 
NOE O 
experiment O 
. O 
The O 
new O 
compound O 
was O 
evaluated O 
for O 
antitumour O 
activity O 
against O 
T47D O 
, O 
DU145 O 
and O 
showed O 
significant O 
inhibitory O 
activities O 
. O 

TiO2 B-FORMULA 
photoanodes O 
in O 
dye O 
- O 
sensitized O 
solar O 
cells O 
( O 
DSCs O 
) O 
are O 
fabricated O 
by O 
the O 
soft O 
lithographic O 
technique O 
for O 
efficient O 
light O 
trapping O 
. O 
An O 
extended O 
strategy O 
to O 
the O 
construction O 
of O 
randomized O 
pyramid O 
structure O 
is O 
developed O 
by O 
the O 
conventional O 
wet O 
- O 
etching O 
of O 
a O 
silicon B-SYSTEMATIC 
wafer O 
for O 
low O 
- O 
cost O 
fabrication O 
. O 
Moreover O 
, O 
the O 
futher O 
enhancement O 
of O 
light O 
absorption O 
resulting O 
in O 
photocurrent O 
increase O 
is O 
achieved O 
by O 
combining O 
the O 
3D O 
photoanode O 
with O 
a O 
conventional O 
scattering O 
layer O 
. O 

and O 
antibacterial O 
activity O 
of O 
9-oxime B-SYSTEMATIC 
ether B-SYSTEMATIC 
non- O 
ketolides B-FAMILY 
, O 
and O 
novel O 
binding O 
mode O 
of O 
alkylides B-FAMILY 
with O 
bacterial O 
rRNA O 
. O 

report O 
a O 
series O 
of O 
new O 
9-oxime B-SYSTEMATIC 
ether B-SYSTEMATIC 
non- O 
ketolides B-FAMILY 
, O 
including O 
3-hydroxyl B-MULTIPLE 
, I-MULTIPLE 
3-O-acyl I-MULTIPLE 
and I-MULTIPLE 
3-O-alkyl I-MULTIPLE 
clarithromycin I-MULTIPLE 
derivatives O 
, O 
and O 
thiophene B-SYSTEMATIC 
-containing O 
ketolides B-FAMILY 
1b-1d O 
. O 
Unlike O 
previously O 
reported O 
ketolide B-FAMILY 
1a O 
, O 
none O 
of O 
them O 
is O 
comparable O 
to O 
telithromycin B-TRIVIAL 
. O 
A O 
molecular O 
modeling O 
study O 
was O 
performed O 
to O 
gain O 
insight O 
into O 
the O 
binding O 
mode O 
of O 
alkylides B-FAMILY 
17-20 O 
with O 
bacterial O 
rRNA O 
and O 
to O 
rationalize O 
the O 
great O 
disparity O 
of O 
their O 
SAR O 
. O 
The O 
3- O 
O B-FORMULA 
-sidechains O 
of O 
19 O 
and O 
20 O 
point O 
to O 
the O 
so O 
- O 
called O 
hydrophilic O 
side O 
of O 
the O 
macrolide B-FAMILY 
ring O 
, O 
as O 
seen O 
in O 
clarithromycin B-TRIVIAL 
. O 
In O 
contrast O 
, O 
the O 
3- O 
O B-FORMULA 
-sidechains O 
of O 
17 O 
and O 
18 O 
bend O 
to O 
the O 
backside O 
, O 
the O 
so O 
- O 
called O 
hydrophobic O 
side O 
of O 
the O 
macrolide O 
ring O 
. O 
The O 
results O 
clearly O 
indicated O 
the O 
alkylides B-FAMILY 
with O 
improved O 
antibacterial O 
activity O 
might O 
possess O 
a O 
novel O 
binding O 
mode O 
, O 
which O 
is O 
different O 
from O 
clarithromycin B-TRIVIAL 
and O 
the O 
alkylides B-FAMILY 
with O 
poor O 
activity O 
. O 

agonists O 
increase O 
the O 
interaction O 
between O 
β-Arrestin O 
2 O 
and O 
ERK1 O 
/ O 
2 O 
and O 
upregulate O 
β-Arrestin O 
2 O 
and O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
receptors O 
. O 

have O 
recently O 
reported O 
that O 
selective O 
cannabinoid O 
2 O 
(CB(2)) O 
receptor O 
agonists O 
upregulate O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
receptors O 
by O 
enhancing O 
ERK1 O 
/ O 
2 O 
signaling O 
in O 
prefrontal O 
cortex O 
( O 
PFCx O 
) O 
. O 
Increased O 
activity O 
of O 
cortical O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
receptors O 
has O 
been O 
associated O 
with O 
several O 
neuropsychiatric O 
disorders O 
such O 
as O 
anxiety O 
and O 
schizophrenia O 
. O 
Here O 
we O 
examine O 
the O 
mechanisms O 
involved O 
in O 
this O 
enhanced O 
ERK1 O 
/ O 
2 O 
activation O 
in O 
rat O 
PFCx O 
and O 
in O 
a O 
neuronal O 
cell O 
model O 
. O 
Sprague-Dawley O 
rats O 
treated O 
with O 
a O 
non-selective O 
cannabinoid O 
agonist O 
( O 
CP55940 B-IDENTIFIER 
, O 
50μg O 
/ O 
kg O 
, O 
7 O 
days O 
, O 
i.p O 
. O 
) O 
showed O 
enhanced O 
co O 
- O 
immunoprecipitation O 
of O 
β-Arrestin O 
2 O 
and O 
ERK1 O 
/ O 
2 O 
, O 
enhanced O 
pERK O 
protein O 
levels O 
, O 
and O 
enhanced O 
expression O 
of O 
β-Arrestin O 
2 O 
mRNA O 
and O 
protein O 
levels O 
in O 
PFCx O 
. O 
In O 
a O 
neuronal O 
cell O 
line O 
, O 
we O 
found O 
that O 
selective O 
CB(2) O 
receptor O 
agonists O 
upregulate O 
β-Arrestin O 
2 O 
, O 
an O 
effect O 
that O 
was O 
prevented O 
by O 
selective O 
CB(2) O 
receptor O 
antagonist O 
JTE-907 B-IDENTIFIER 
and O 
CB(2) O 
shRNA O 
lentiviral O 
particles O 
. O 
Additionally O 
, O 
inhibition O 
of O 
clathrin O 
- O 
mediated O 
endocytosis O 
, O 
ERK1 O 
/ O 
2 O 
, O 
and O 
the O 
AP-1 O 
transcription O 
factor O 
also O 
prevented O 
the O 
cannabinoid O 
receptor O 
- O 
induced O 
upregulation O 
of O 
β-Arrestin O 
2 O 
. O 
Our O 
results O 
suggest O 
that O 
sustained O 
activation O 
of O 
CB(2) O 
receptors O 
would O 
enhance O 
β-Arrestin O 
2 O 
expression O 
possibly O 
contributing O 
to O 
its O 
increased O 
interaction O 
with O 
ERK1 O 
/ O 
2 O 
, O 
thereby O 
driving O 
the O 
upregulation O 
of O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
receptors O 
. O 
The O 
CB(2) O 
receptor O 
- O 
mediated O 
upregulation O 
of O 
β-Arrestin O 
2 O 
would O 
be O 
mediated O 
, O 
at O 
least O 
in O 
part O 
, O 
by O 
an O 
ERK1 O 
/ O 
2-dependent O 
activation O 
of O 
AP-1 O 
. O 
These O 
data O 
could O 
provide O 
the O 
rationale O 
for O 
some O 
of O 
the O 
adverse O 
effects O 
associated O 
with O 
repeated O 
cannabinoid O 
exposure O 
and O 
shed O 
light O 
on O 
some O 
CB(2) O 
receptor O 
agonists O 
that O 
could O 
represent O 
an O 
alternative O 
therapeutic O 
because O 
of O 
their O 
minimal O 
effect O 
on O 
serotonergic O 
neurotransmission O 
. O 

attenuates O 
acquisition O 
but O 
not O 
the O 
expression O 
of O 
ethanol B-SYSTEMATIC 
conditioned O 
place O 
preference O 
in O 
mice O 
: O 
a O 
role O 
for O 
imidazoline B-SYSTEMATIC 
receptors O 
. O 

present O 
study O 
investigated O 
the O 
effect O 
of O 
agmatine B-TRIVIAL 
on O 
acquisition O 
and O 
expression O 
of O 
ethanol B-SYSTEMATIC 
conditioned O 
place O 
preference O 
( O 
CPP O 
) O 
and O 
its O 
modulation O 
by O 
imidazoline B-SYSTEMATIC 
agents O 
. O 
Swiss O 
albino O 
mice O 
were O 
treated O 
intraperitoneally O 
with O 
saline O 
or O 
agmatine B-TRIVIAL 
( O 
20-40 O 
mg O 
/ O 
kg O 
) O 
before O 
injection O 
of O 
ethanol B-SYSTEMATIC 
( O 
1.25 O 
mg O 
/ O 
kg O 
) O 
during O 
conditioning O 
days O 
or O 
on O 
a O 
test O 
day O 
( O 
20-120 O 
mg O 
/ O 
kg O 
) O 
, O 
to O 
observe O 
the O 
effect O 
on O 
acquisition O 
or O 
expression O 
of O 
CPP O 
, O 
respectively O 
. O 
Agmatine B-TRIVIAL 
inhibited O 
the O 
acquisition O 
but O 
not O 
the O 
expression O 
of O 
ethanol B-SYSTEMATIC 
CPP O 
. O 
Furthermore O 
, O 
both O 
the O 
I(1) O 
receptor O 
antagonist O 
, O 
efaroxan B-TRIVIAL 
( O 
9 O 
mg O 
/ O 
kg O 
) O 
and O 
the O 
I(2) O 
receptor O 
antagonist O 
, O 
BU224 B-IDENTIFIER 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
attenuated O 
the O 
agmatine B-TRIVIAL 
-induced O 
inhibition O 
of O 
the O 
ethanol B-SYSTEMATIC 
CPP O 
acquisition O 
. O 
In O 
contrast O 
, O 
the O 
I(2) O 
receptor O 
agonist O 
, O 
2-BFI B-SYSTEMATIC 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
and O 
I(1) O 
receptor O 
agonist O 
, O 
moxonidine B-TRIVIAL 
( O 
0.4 O 
mg O 
/ O 
kg O 
) O 
alone O 
, O 
or O 
a O 
combination O 
of O 
their O 
subeffective O 
doses O 
, O 
significantly O 
attenuated O 
the O 
effect O 
of O 
agmatine B-TRIVIAL 
( O 
20 O 
mg O 
/ O 
kg O 
) O 
on O 
acquisition O 
of O 
ethanol B-SYSTEMATIC 
CPP O 
. O 
Agmatine B-TRIVIAL 
or O 
imidazoline B-SYSTEMATIC 
agents O 
alone O 
produced O 
neither O 
place O 
preference O 
nor O 
aversion O 
, O 
and O 
at O 
the O 
doses O 
used O 
in O 
the O 
present O 
study O 
did O 
not O 
affect O 
locomotor O 
activity O 
. O 
Thus O 
, O 
agmatine B-TRIVIAL 
attenuates O 
the O 
acquisition O 
of O 
ethanol B-SYSTEMATIC 
CPP O 
at O 
least O 
in O 
part O 
by O 
imidazoline B-SYSTEMATIC 
( O 
I(1) O 
or O 
I(2) O 
) O 
receptors O 
. O 
In O 
future O 
studies O 
, O 
agmatine B-TRIVIAL 
or O 
agents O 
acting O 
at O 
the O 
imidazoline B-SYSTEMATIC 
receptors O 
could O 
be O 
explored O 
for O 
their O 
therapeutic O 
potential O 
in O 
ethanol B-SYSTEMATIC 
dependence O 
. O 

: O 
Two O 
clinical O 
trials O 
have O 
shown O 
that O 
users O 
of O 
5α-reductase O 
inhibitors O 
finasteride B-TRIVIAL 
and O 
dutasteride B-TRIVIAL 
( O 
5-ARIs O 
) O 
have O 
reduced O 
overall O 
prostate O 
cancer O 
risk O 
, O 
while O 
the O 
proportion O 
of O 
high O 
- O 
grade O 
tumors O 
is O 
increased O 
. O 
We O 
studied O 
tumor O 
characteristics O 
, O 
risk O 
of O 
biochemical O 
recurrence O 
and O 
mortality O 
after O 
radical O 
prostatectomy O 
in O 
5-ARI O 
and O 
alpha-blocker O 
users O 
. O 
METHODS O 
: O 
The O 
study O 
cohort O 
consisted O 
of O 
1315 O 
men O 
who O 
underwent O 
radical O 
prostatectomy O 
at O 
the O 
Tampere O 
University O 
Hospital O 
during O 
1995-2009 O 
. O 
Biochemical O 
relapse O 
was O 
defined O 
as O 
serum O 
PSA O 
≥ O 
0.2 O 
ng O 
/ O 
ml O 
after O 
the O 
operation O 
. O 
Information O 
on O 
mortality O 
and O 
medication O 
purchases O 
was O 
obtained O 
from O 
national O 
registries O 
. O 
Cox O 
proportional O 
regression O 
was O 
used O 
to O 
analyze O 
hazard O 
ratios O 
( O 
HRs O 
) O 
and O 
95% O 
confidence O 
intervals O 
( O 
95% O 
CI O 
) O 
of O 
biochemical O 
relapse O 
and O 
death O 
. O 
RESULTS O 
: O 
The O 
proportion O 
of O 
high O 
- O 
grade O 
( O 
Gleason O 
7-10 O 
) O 
tumors O 
was O 
significantly O 
elevated O 
among O 
men O 
who O 
had O 
used O 
5-ARIs O 
for O 
4 O 
years O 
or O 
longer O 
compared O 
to O 
the O 
non-users O 
( O 
83.3% O 
vs O 
. O 
53.3% O 
, O 
respectively O 
) O 
. O 
Survival O 
curves O 
for O 
biochemical O 
relapse O 
- O 
free O 
survival O 
differed O 
between O 
long O 
- O 
term O 
and O 
short O 
- O 
term O 
5-ARI O 
users O 
, O 
but O 
the O 
hazard O 
ratio O 
remained O 
statistically O 
non-significant O 
. O 
Risk O 
of O 
biochemical O 
recurrence O 
was O 
elevated O 
among O 
alpha-blocker O 
users O 
( O 
HR O 
1.68 O 
, O 
95% O 
CI O 
1.37-2.06 O 
) O 
, O 
but O 
in O 
sensitivity O 
analyses O 
this O 
was O 
evident O 
only O 
in O 
men O 
using O 
alpha-blockers O 
after O 
prostatectomy O 
. O 
Mortality O 
was O 
not O 
associated O 
with O 
medication O 
usage O 
. O 
CONCLUSIONS O 
: O 
Long O 
- O 
term O 
users O 
of O 
finasteride B-TRIVIAL 
or O 
dutasteride B-TRIVIAL 
had O 
more O 
often O 
high O 
- O 
grade O 
prostate O 
cancer O 
. O 
Our O 
results O 
suggest O 
also O 
worse O 
progression O 
- O 
free O 
survival O 
. O 
The O 
association O 
between O 
risk O 
of O 
biochemical O 
recurrence O 
and O 
post O 
- O 
operative O 
alpha-blocker O 
usage O 
suggests O 
that O 
voiding O 
or O 
storage O 
symptoms O 
after O 
prostatectomy O 
may O 
predict O 
biochemical O 
relapse O 
. O 
Prostate O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

, O 
( O 
Avena O 
sativa O 
) O 
is O 
an O 
excellent O 
source O 
of O 
mixed O 
linkage O 
β-glucans O 
( O 
(1→3)(1→4)-β-D-glucan O 
) O 
, O 
a O 
dietary O 
fibre O 
with O 
cholesterol B-TRIVIAL 
lowering O 
properties O 
. O 
Using O 
a O 
mutagenized O 
oat O 
- O 
population O 
we O 
screened O 
1700 O 
different O 
lines O 
and O 
identified O 
ten O 
lines O 
that O 
displayed O 
β-glucan O 
levels O 
above O 
6.7% O 
and O 
10 O 
below O 
3.6%.The O 
extreme O 
values O 
were O 
1.8% O 
and O 
7.5% O 
. O 
We O 
chose O 
six O 
lines O 
with O 
an O 
increased- O 
and O 
four O 
lines O 
with O 
a O 
reduced O 
β-glucan O 
content O 
for O 
further O 
study O 
. O 
By O 
longitudinal- O 
and O 
cross O 
- O 
sections O 
of O 
seeds O 
it O 
was O 
shown O 
that O 
localization O 
of O 
β-glucan O 
varied O 
between O 
the O 
different O 
lines O 
. O 
In O 
addition O 
, O 
β-glucan O 
quality O 
parameters O 
like O 
molecular O 
weight O 
and O 
solubility O 
were O 
also O 
determined O 
. O 
Although O 
the O 
selection O 
was O 
designed O 
for O 
quantitative O 
differences O 
, O 
qualitative O 
differences O 
between O 
the O 
β-glucans O 
from O 
the O 
different O 
lines O 
were O 
found O 
. O 
The O 
high O 
and O 
low O 
β-glucan O 
lines O 
will O 
now O 
be O 
used O 
as O 
a O 
model O 
system O 
to O 
study O 
molecular O 
regulation O 
of O 
β-glucan O 
biosynthesis O 
as O 
well O 
as O 
possible O 
links O 
between O 
fibre O 
quality O 
and O 
biological O 
activity O 
. O 

significant O 
dose O 
- O 
dependent O 
relationship O 
between O 
mercury B-SYSTEMATIC 
exposure O 
from O 
dental O 
amalgams O 
and O 
kidney O 
integrity O 
biomarkers O 
: O 
A O 
further O 
assessment O 
of O 
the O 
Casa O 
Pia O 
children's O 
dental O 
amalgam O 
trial O 
. O 

amalgams O 
are O 
a O 
commonly O 
used O 
dental O 
restorative O 
material O 
. O 
Amalgams O 
are O 
about O 
50% O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
, O 
and O 
Hg B-FORMULA 
is O 
known O 
to O 
significantly O 
accumulate O 
in O 
the O 
kidney O 
. O 
It O 
was O 
hypothesized O 
that O 
because O 
Hg B-FORMULA 
accumulates O 
in O 
the O 
proximal O 
tubules O 
( O 
PTs O 
) O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferases O 
(GST)-α O 
( O 
suggestive O 
of O 
kidney O 
damage O 
at O 
the O 
level O 
of O 
PT O 
) O 
would O 
be O 
expected O 
to O 
be O 
more O 
related O 
to O 
Hg B-FORMULA 
exposure O 
than O 
GST-π O 
( O 
suggestive O 
of O 
kidney O 
damage O 
at O 
the O 
level O 
of O 
the O 
distal O 
tubules O 
) O 
. O 
Urinary O 
biomarkers O 
of O 
kidney O 
integrity O 
were O 
examined O 
in O 
children O 
of O 
8-18 O 
years O 
old O 
, O 
with O 
and O 
without O 
dental O 
amalgam O 
fillings O 
, O 
from O 
a O 
completed O 
clinical O 
trial O 
( O 
parent O 
study O 
) O 
. O 
Our O 
study O 
determined O 
whether O 
there O 
was O 
a O 
significant O 
dose O 
- O 
dependent O 
correlation O 
between O 
increasing O 
Hg B-FORMULA 
exposure O 
from O 
dental O 
amalgams O 
and O 
GST-α O 
and O 
GST-π O 
as O 
biomarkers O 
of O 
kidney O 
integrity O 
. O 
Overall O 
, O 
the O 
present O 
study O 
, O 
using O 
a O 
different O 
and O 
more O 
sensitive O 
statistical O 
model O 
than O 
the O 
parent O 
study O 
, O 
revealed O 
a O 
statistically O 
significant O 
dose O 
- O 
dependent O 
correlation O 
between O 
cumulative O 
exposure O 
to O 
Hg B-FORMULA 
from O 
dental O 
amalgams O 
and O 
urinary O 
levels O 
of O 
GST-α O 
, O 
after O 
covariate O 
adjustment O 
; O 
where O 
as O 
, O 
a O 
nonsignificant O 
relationship O 
was O 
observed O 
with O 
urinary O 
levels O 
of O 
GST-π O 
. O 
Furthermore O 
, O 
it O 
was O 
observed O 
that O 
urinary O 
GST-α O 
levels O 
increased O 
by O 
about O 
10% O 
over O 
the O 
8-year O 
course O 
of O 
the O 
study O 
among O 
individuals O 
with O 
an O 
average O 
exposure O 
to O 
amalgams O 
among O 
the O 
study O 
subjects O 
from O 
the O 
amalgam O 
group O 
, O 
in O 
comparison O 
with O 
study O 
subjects O 
with O 
no O 
exposure O 
to O 
dental O 
amalgams O 
. O 
The O 
results O 
of O 
our O 
study O 
suggest O 
that O 
dental O 
amalgams O 
contribute O 
to O 
ongoing O 
kidney O 
damage O 
at O 
the O 
level O 
of O 
the O 
PTs O 
in O 
a O 
dose O 
- O 
dependent O 
fashion O 
. O 

Driven O 
Self-Assembly O 
of O 
SPR O 
Active O 
Silver B-SYSTEMATIC 
-Gold O 
Nanohybrids O 
. O 

fourth O 
generation O 
PAMAM B-ABBREVIATION 
dendrimer O 
has O 
been O 
successfully O 
employed O 
for O 
the O 
development O 
of O 
a O 
single O 
step O 
synthesis O 
strategy O 
for O 
self O 
- O 
assembled O 
Ag B-FORMULA 
- O 
Au B-FORMULA 
nanohybrid O 
structures O 
. O 
The O 
surface O 
plasmon O 
resonance O 
properties O 
and O 
the O 
degree O 
of O 
self O 
- O 
assembly O 
of O 
the O 
nanohybrid O 
are O 
strongly O 
correlated O 
with O 
the O 
stoichiometry O 
of O 
the O 
metals O 
which O 
gives O 
rise O 
to O 
enhanced O 
plasmonic O 
properties O 
. O 
The O 
enhanced O 
plasmonic O 
response O 
of O 
the O 
nanohybrids O 
is O 
modeled O 
and O 
is O 
validated O 
experimentally O 
in O 
a O 
model O 
HRP O 
( O 
horseradish O 
peroxidise O 
) O 
bioassay O 
carried O 
out O 
on O 
an O 
SPR O 
- O 
based O 
biochip O 
platform O 
. O 

of O 
novel O 
estrogen B-FAMILY 
receptor O 
antagonists O 
using O 
metal O 
- O 
catalyzed O 
coupling O 
reactions O 
and O 
characterization O 
of O 
their O 
biological O 
activity O 
. O 

receptor O 
( O 
ER O 
) O 
antagonists O 
are O 
valuable O 
in O 
the O 
treatment O 
of O 
ER-positive O 
human O 
breast O 
cancer O 
. O 
In O 
this O 
study O 
, O 
we O 
designed O 
and O 
synthesized O 
nine O 
new O 
derivatives O 
of O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
with O 
a O 
bulky O 
side O 
chain O 
attached O 
to O 
its O 
C-7α O 
position O 
, O 
and O 
determined O 
their O 
ER O 
antagonistic O 
activity O 
using O 
in O 
vitro O 
bioassays O 
. O 
Four O 
of O 
the O 
derivatives O 
showed O 
a O 
strong O 
inhibition O 
of O 
ERα O 
transactivation O 
activity O 
in O 
a O 
luciferase O 
reporter O 
assay O 
and O 
blocked O 
ERα O 
interactions O 
with O 
coactivators O 
. O 
Similarly O 
, O 
these O 
derivatives O 
also O 
strongly O 
inhibited O 
the O 
growth O 
of O 
the O 
ERα-positive O 
human O 
breast O 
cancer O 
cells O 
. O 
Computational O 
docking O 
analysis O 
was O 
conducted O 
to O 
model O 
the O 
interaction O 
of O 
these O 
antagonists O 
with O 
the O 
human O 
ERα O 
and O 
showed O 
that O 
they O 
could O 
tightly O 
bind O 
to O 
the O 
ERα O 
in O 
a O 
manner O 
similar O 
to O 
that O 
of O 
ICI-182,780 B-IDENTIFIER 
, O 
a O 
pure O 
ER O 
antagonist O 
. O 
These O 
results O 
provide O 
an O 
example O 
that O 
attachment O 
of O 
a O 
bulky O 
side O 
chain O 
to O 
the O 
C-7α O 
position O 
of O 
E2 O 
can O 
produce O 
ER O 
antagonists O 
with O 
ER O 
affinity O 
comparable O 
to O 
that O 
of O 
ICI-182,780 B-IDENTIFIER 
. O 

conserved O 
C B-FORMULA 
-terminal O 
amino B-FAMILY 
acids I-FAMILY 
of O 
Caenorhabditis O 
elegans O 
HMP-1 O 
/ O 
α-catenin O 
modulate O 
F-actin O 
binding O 
independently O 
of O 
vinculin O 
. O 

intercellular O 
adhesions O 
formed O 
through O 
the O 
cadherin O 
- O 
catenin O 
complex O 
are O 
important O 
determinants O 
of O 
proper O 
tissue O 
architecture O 
and O 
help O 
maintain O 
tissue O 
integrity O 
during O 
morphogenetic O 
movements O 
in O 
developing O 
embryos O 
. O 
A O 
key O 
regulator O 
of O 
this O 
stability O 
is O 
α-catenin O 
, O 
which O 
connects O 
the O 
cadherin O 
- O 
catenin O 
complex O 
to O 
the O 
actin O 
cytoskeleton O 
. O 
Although O 
the O 
C B-FORMULA 
-terminal O 
F-actin O 
- O 
binding O 
domain O 
of O 
α-catenin O 
has O 
been O 
shown O 
to O 
be O 
crucial O 
for O 
its O 
function O 
, O 
a O 
more O 
detailed O 
in O 
vivo O 
analysis O 
of O 
discrete O 
regions O 
and O 
residues O 
required O 
for O 
actin O 
binding O 
has O 
not O 
been O 
performed O 
. O 
Using O 
Caenorhabditis O 
elegans O 
as O 
a O 
model O 
system O 
, O 
we O 
have O 
characterized O 
mutations O 
in O 
hmp-1 O 
/ O 
α-catenin O 
that O 
identify O 
HMP-1 O 
residues O 
687-742 O 
and O 
826-927 O 
, O 
as O 
well O 
as O 
amino B-FAMILY 
acid I-FAMILY 
802 O 
, O 
as O 
critical O 
to O 
the O 
localization O 
of O 
junctional O 
proximal O 
actin O 
during O 
epidermal O 
morphogenesis O 
. O 
We O 
also O 
find O 
that O 
the O 
S823F O 
transition O 
in O 
a O 
hypomorphic O 
allele O 
, O 
hmp-1(fe4) O 
, O 
decreases O 
actin O 
binding O 
in O 
vitro O 
. O 
Using O 
hmp-1(fe4) O 
animals O 
in O 
a O 
mutagenesis O 
screen O 
, O 
we O 
were O 
then O 
able O 
to O 
identify O 
11 O 
intragenic O 
suppressors O 
of O 
hmp-1(fe4) O 
that O 
revert O 
actin O 
binding O 
to O 
wild O 
- O 
type O 
levels O 
. O 
Using O 
homology O 
modeling O 
, O 
we O 
show O 
that O 
these O 
amino B-FAMILY 
acids I-FAMILY 
are O 
positioned O 
at O 
key O 
conserved O 
sites O 
within O 
predicted O 
α-helices O 
in O 
the O 
C B-FORMULA 
terminus O 
. O 
Through O 
the O 
use O 
of O 
transgenic O 
animals O 
, O 
we O 
also O 
demonstrate O 
that O 
HMP-1 O 
residues O 
315-494 O 
, O 
which O 
correspond O 
to O 
a O 
putative O 
mechanotransduction O 
domain O 
that O 
binds O 
vinculin O 
in O 
vertebrate O 
αE-catenin O 
, O 
are O 
not O 
required O 
during O 
epidermal O 
morphogenesis O 
but O 
may O 
aid O 
efficient O 
recruitment O 
of O 
HMP-1 O 
to O 
the O 
junction O 
. O 
Our O 
studies O 
are O 
the O 
first O 
to O 
identify O 
key O 
conserved O 
amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
C B-FORMULA 
terminus O 
of O 
α-catenin O 
that O 
modulate O 
F-actin O 
binding O 
in O 
living O 
embryos O 
of O 
a O 
simple O 
metazoan O 
. O 

Africa O 
, O 
Sutherlandia O 
frutescens O 
is O 
a O 
popular O 
medicinal O 
herb O 
widely O 
consumed O 
by O 
people O 
living O 
with O 
human O 
immunodeficiency O 
virus O 
/ O 
AIDS O 
. O 
Concomitant O 
use O 
with O 
antiretroviral O 
drugs O 
has O 
generated O 
concerns O 
of O 
herb O 
- O 
drug O 
interaction O 
( O 
HDI O 
) O 
. O 
This O 
study O 
investigated O 
the O 
inhibitory O 
effects O 
of O 
the O 
crude O 
extracts O 
of O 
S O 
. O 
frutescens O 
on O 
the O 
major O 
cytochrome O 
P450 O 
isozymes O 
with O 
the O 
use O 
of O 
pooled O 
human O 
liver O 
microsomes O 
. O 
Its O 
effect O 
on O 
the O 
metabolic O 
clearance O 
of O 
midazolam B-TRIVIAL 
using O 
cryopreserved O 
hepatocytes O 
was O 
also O 
monitored O 
. O 
The O 
potential O 
of O 
S O 
. O 
frutescens O 
to O 
inhibit O 
human O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporters O 
( O 
P-gp O 
and O 
BCRP O 
) O 
and O 
the O 
human O 
organic O 
anion O 
transporting O 
polypeptide O 
( O 
OATP1B1 O 
and O 
OATP1B3 O 
) O 
activity O 
was O 
assessed O 
using O 
cell O 
lines O 
overexpressing O 
the O 
transporter O 
proteins O 
. O 
S O 
. O 
frutescens O 
showed O 
inhibitory O 
potency O 
for O 
CYP1A2 O 
( O 
IC(50) O 
= O 
41 O 
µg O 
/ O 
ml O 
) O 
, O 
CYP2A6 O 
( O 
IC(50) O 
= O 
160 O 
µg O 
/ O 
ml O 
) O 
, O 
CYP2B6 O 
( O 
IC(50) O 
= O 
20 O 
µg O 
/ O 
ml O 
) O 
, O 
CYP2C8 O 
( O 
IC(50) O 
= O 
22.4 O 
µg O 
/ O 
ml O 
) O 
, O 
CYP2C9 O 
( O 
IC(50) O 
= O 
23 O 
µg O 
/ O 
ml O 
) O 
, O 
CYP2C19 O 
( O 
IC(50) O 
= O 
35.9 O 
µg O 
/ O 
ml O 
) O 
, O 
and O 
CYP3A4 O 
/ O 
5 O 
( O 
IC(50) O 
= O 
17.5 O 
µg O 
/ O 
ml O 
[ O 
with O 
midazolam B-TRIVIAL 
1'-hydroxylation O 
] O 
; O 
IC(50) O 
= O 
28.3 O 
µg O 
/ O 
ml O 
[ O 
with O 
testosterone B-TRIVIAL 
6β-hydroxylation O 
] O 
) O 
. O 
Time O 
- O 
dependent O 
( O 
irreversible O 
) O 
inhibition O 
by O 
S O 
. O 
frutescens O 
was O 
observed O 
for O 
CYP3A4 O 
/ O 
5 O 
( O 
K O 
(I) O 
= O 
296 O 
µg O 
/ O 
ml O 
, O 
k(inact) O 
= O 
0.063 O 
min(-1) O 
) O 
under O 
the O 
conditions O 
of O 
this O 
study O 
. O 
S O 
. O 
frutescens O 
also O 
delays O 
the O 
production O 
of O 
midazolam B-TRIVIAL 
metabolites O 
in O 
the O 
hepatocytes O 
, O 
decreasing O 
its O 
clearance O 
by O 
40% O 
. O 
Furthermore O 
, O 
S O 
. O 
frutescens O 
inhibited O 
P-gp O 
( O 
IC(50) O 
= O 
324.8 O 
µg O 
/ O 
ml O 
) O 
, O 
OATP1B1 O 
( O 
IC(50) O 
= O 
10.4 O 
µg O 
/ O 
ml O 
) O 
, O 
and O 
OATP1B3 O 
( O 
IC(50) O 
= O 
6.6 O 
µg O 
/ O 
ml O 
) O 
. O 
The O 
result O 
indicates O 
the O 
potential O 
for O 
HDI O 
between O 
S O 
. O 
frutescens O 
and O 
the O 
substrates O 
of O 
the O 
affected O 
enzymes O 
, O 
if O 
sufficient O 
in O 
vivo O 
concentration O 
of O 
the O 
extract O 
is O 
attained O 
. O 

by O 
substituted O 
cysteine B-TRIVIAL 
scanning O 
mutagenesis O 
of O 
the O 
fourth O 
transmembrane O 
domain O 
of O 
the O 
CXCR4 O 
receptor O 
in O 
its O 
inactive O 
and O 
active O 
state O 
. O 

chemokine O 
SDF-1 O 
( O 
CXCL12 O 
) O 
selectively O 
binds O 
to O 
CXCR4 O 
, O 
a O 
member O 
of O 
the O 
G O 
protein O 
- O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
superfamily O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
the O 
substituted- O 
cysteine B-TRIVIAL 
accessibility O 
method O 
( O 
SCAM O 
) O 
to O 
identify O 
specific O 
residues O 
of O 
the O 
fourth O 
transmembrane O 
domain O 
( O 
TM4 O 
) O 
that O 
contribute O 
to O 
the O 
formation O 
of O 
the O 
binding O 
pocket O 
of O 
CXCR4 O 
in O 
its O 
inactive O 
and O 
active O 
state O 
. O 
We O 
successively O 
substituted O 
each O 
residue O 
from O 
E179((4.68)) O 
to O 
K154((4.43)) O 
with O 
cysteine B-TRIVIAL 
and O 
expressed O 
the O 
mutants O 
in O 
COS-7 O 
cells O 
. O 
Mutant O 
receptors O 
were O 
then O 
alkylated O 
with O 
methanethiosulfonate B-SYSTEMATIC 
- I-SYSTEMATIC 
ethylammonium I-SYSTEMATIC 
( O 
MTSEA B-ABBREVIATION 
) O 
, O 
and O 
binding O 
inhibition O 
was O 
monitored O 
using O 
the O 
CXCR4 O 
antagonist O 
FC131 B-IDENTIFIER 
[ O 
cyclo(-D-Tyr(1)-Arg(2)-Arg(3)-Nal(4)-Gly(5)-) B-FORMULA 
] O 
, O 
which O 
displays O 
anti-HIV O 
activity O 
. O 
MTSEA B-ABBREVIATION 
treatment O 
resulted O 
in O 
a O 
significant O 
reduction O 
of O 
FC131 B-IDENTIFIER 
binding O 
to O 
D171C((4.60)) O 
and O 
P170C((4.59)) O 
. O 
To O 
assess O 
TM4 O 
accessibility O 
in O 
an O 
active O 
state O 
of O 
CXCR4 O 
, O 
TM4 O 
cysteine B-TRIVIAL 
mutants O 
were O 
transposed O 
within O 
the O 
constitutively O 
active O 
mutant O 
N119S((3.35)) O 
. O 
MTSEA B-ABBREVIATION 
treatment O 
of O 
TM4 O 
mutants O 
N119S-S178C((4.67)) O 
, O 
N119S-V177C((4.66)) O 
and O 
N119S-I173C((4.62)) O 
resulted O 
in O 
a O 
significant O 
reduction O 
in O 
FC131 B-IDENTIFIER 
binding O 
. O 
Protection O 
assays O 
using O 
FC131 B-IDENTIFIER 
prior O 
to O 
MTSEA B-ABBREVIATION 
treatment O 
significantly O 
reduced O 
the O 
alkylation O 
of O 
all O 
MTSEA B-ABBREVIATION 
-sensitive O 
mutants O 
. O 
The O 
accessibility O 
of O 
the O 
D171C((4.60)) O 
and O 
P170C((4.59)) O 
residues O 
suggests O 
that O 
they O 
are O 
oriented O 
towards O 
a O 
water O 
- O 
accessible O 
area O 
of O 
the O 
binding O 
pocket O 
of O 
CXCR4 O 
. O 
S178C((4.67)) O 
, O 
V177C((4.66)) O 
and O 
I173C((4.62)) O 
showed O 
binding O 
inhibition O 
only O 
in O 
an O 
N119S((3.35)) O 
background O 
. O 
Taken O 
together O 
our O 
results O 
suggest O 
that O 
TM4 O 
and O 
ECL2 O 
undergo O 
conformational O 
changes O 
during O 
CXCR4 O 
activation O 
and O 
also O 
demonstrate O 
how O 
TM4 O 
is O 
an O 
important O 
feature O 
for O 
the O 
binding O 
of O 
anti-HIV O 
compounds O 
. O 

regulates O 
mammary O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
homeostasis O 
and O 
the O 
mammary O 
microenvironment O 
. O 

retinol B-TRIVIAL 
-binding O 
protein O 
, O 
type O 
I O 
( O 
CrbpI O 
) O 
, O 
encoded O 
by O 
retinol B-TRIVIAL 
-binding O 
protein O 
, O 
type O 
1 O 
( O 
Rbp1 O 
) O 
, O 
is O 
a O 
chaperone O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
( O 
retinol B-TRIVIAL 
) O 
that O 
is O 
epigenetically O 
silenced O 
in O 
∼25% O 
of O 
human O 
breast O 
cancers O 
. O 
CrbpI O 
delivers O 
vitamin B-FAMILY 
A I-FAMILY 
to O 
enzymes O 
for O 
metabolism O 
into O 
an O 
active O 
metabolite O 
, O 
all B-TRIVIAL 
- I-TRIVIAL 
trans I-TRIVIAL 
retinoic I-TRIVIAL 
acid I-TRIVIAL 
( O 
atRA B-ABBREVIATION 
) O 
, O 
where O 
atRA B-ABBREVIATION 
is O 
essential O 
to O 
cell O 
proliferation O 
, O 
apoptosis O 
, O 
differentiation O 
, O 
and O 
migration O 
. O 
Here O 
, O 
we O 
show O 
the O 
effect O 
of O 
CrbpI O 
loss O 
on O 
mammary O 
atRA B-ABBREVIATION 
homeostasis O 
using O 
the O 
Rbp1(- O 
/ O 
- O 
) O 
mouse O 
model O 
. O 
Rbp1(- O 
/ O 
- O 
) O 
mouse O 
mammary O 
tissue O 
has O 
disrupted O 
retinoid B-FAMILY 
homeostasis O 
that O 
results O 
in O 
40% O 
depleted O 
endogenous O 
atRA B-ABBREVIATION 
. O 
CrbpI O 
loss O 
and O 
atRA B-ABBREVIATION 
depletion O 
precede O 
defects O 
in O 
atRA B-ABBREVIATION 
biosynthesis O 
enzyme O 
expression O 
. O 
Compensation O 
by O 
CrbpIII O 
as O 
a O 
retinoid B-FAMILY 
chaperone O 
does O 
not O 
functionally O 
replace O 
CrbpI O 
. O 
Mammary O 
subcellular O 
fractions O 
isolated O 
from O 
Rbp1(- O 
/ O 
- O 
) O 
mice O 
have O 
altered O 
retinol B-TRIVIAL 
dehydrogenase O 
/ O 
reductase O 
( O 
Rdh O 
) O 
enzyme O 
activity O 
that O 
results O 
in O 
24-42% O 
less O 
atRA B-ABBREVIATION 
production O 
. O 
Rbp1(- O 
/ O 
- O 
) O 
mammary O 
tissue O 
has O 
epithelial O 
hyperplasia O 
, O 
stromal O 
hypercellularity O 
, O 
increased O 
collagen O 
, O 
and O 
increased O 
oxidative O 
stress O 
characteristic O 
of O 
atRA B-ABBREVIATION 
deficiency O 
and O 
early O 
tissue O 
dysfunction O 
that O 
precedes O 
tumor O 
formation O 
. O 
Consistent O 
with O 
the O 
findings O 
from O 
the O 
Rbp1(- O 
/ O 
- O 
) O 
mouse O 
, O 
tumorigenic O 
epithelial O 
cells O 
lacking O 
CrbpI O 
expression O 
produce O 
51% O 
less O 
atRA B-ABBREVIATION 
. O 
Together O 
, O 
these O 
data O 
show O 
that O 
CrbpI O 
loss O 
disrupts O 
atRA B-ABBREVIATION 
homeostasis O 
in O 
mammary O 
tissue O 
, O 
resulting O 
in O 
microenvironmental O 
defects O 
similar O 
to O 
those O 
observed O 
at O 
the O 
early O 
stages O 
of O 
tumorigenesis.-Pierzchalski O 
, O 
K O 
. O 
, O 
Yu O 
, O 
J O 
. O 
, O 
Norman O 
, O 
V O 
. O 
, O 
Kane O 
, O 
M O 
. O 
A O 
. O 
CrbpI O 
regulates O 
mammary O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
homeostasis O 
and O 
the O 
mammary O 
microenvironment O 
. O 

( O 
e.g O 
. O 
, O 
ampelopsin B-TRIVIAL 
F I-TRIVIAL 
, O 
viniferin B-TRIVIAL 
, O 
pallidol B-TRIVIAL 
) O 
result O 
from O 
homogeneous O 
or O 
heterogeneous O 
coupling O 
of O 
monomeric O 
stilbenoid B-FAMILY 
units O 
, O 
leading O 
to O 
various O 
chemical O 
structures O 
. O 
Oligostilbenoid O 
synthesis O 
is O 
regio- O 
and O 
stereocontrolled O 
. O 
To O 
tackle O 
this O 
regio- O 
and O 
stereocontrol O 
, O 
a O 
supramolecular O 
chemistry O 
approach O 
is O 
required O 
that O 
can O 
be O 
achieved O 
by O 
quantum O 
chemistry O 
. O 
The O 
stability O 
of O 
noncovalent O 
π-stacks O 
, O 
formed O 
between O 
two O 
stilbenoid B-FAMILY 
units O 
prior O 
to O 
oxidation O 
, O 
is O 
accurately O 
evaluated O 
with O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
including O 
dispersive O 
effects O 
( O 
within O 
the O 
DFT-D O 
formalism O 
) O 
. O 
These O 
noncovalent O 
arrangements O 
drive O 
the O 
regiocontrol O 
. O 
The O 
rest O 
of O 
the O 
chemical O 
pathway O 
is O 
a O 
succession O 
of O 
dearomatization O 
and O 
rearomatization O 
stages O 
. O 
The O 
thermodynamics O 
and O 
kinetics O 
of O 
the O 
processes O 
are O 
calculated O 
with O 
classical O 
hybrid O 
functionals O 
. O 
This O 
study O 
allows O 
discrimination O 
between O 
the O 
two O 
main O 
possible O 
chemical O 
pathways O 
, O 
namely O 
, O 
radical O 
- O 
neutral O 
and O 
radical O 
- O 
radical O 
reactions O 
. O 
The O 
former O 
appears O 
more O 
likely O 
, O 
thermodynamics O 
and O 
kinetics O 
being O 
in O 
perfect O 
agreement O 
with O 
the O 
experimental O 
1 O 
: O 
2 O 
ratio O 
obtained O 
for O 
ampelopsin B-TRIVIAL 
F I-TRIVIAL 
: O 
pallidol B-TRIVIAL 
analogues O 
, O 
respectively O 
. O 

the O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptor O 
5 O 
( O 
mGlu5 O 
) O 
Positive O 
Allosteric O 
Modulator O 
( O 
PAM O 
) O 
Binding O 
Pocket O 
: O 
Discovery O 
of O 
Point O 
Mutations O 
That O 
Engender O 
a O 
" O 
Molecular O 
Switch O 
" O 
in O 
PAM O 
Pharmacology O 
. O 

allosteric O 
modulation O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
subtype O 
5 O 
( O 
mGlu5 O 
) O 
is O 
a O 
promising O 
novel O 
approach O 
for O 
the O 
treatment O 
of O 
schizophrenia O 
and O 
cognitive O 
disorders O 
. O 
Allosteric O 
binding O 
sites O 
are O 
topographically O 
distinct O 
from O 
the O 
endogenous O 
ligand O 
( O 
orthosteric O 
) O 
binding O 
site O 
, O 
allowing O 
for O 
co O 
- O 
occupation O 
of O 
a O 
single O 
receptor O 
with O 
the O 
endogenous O 
ligand O 
and O 
an O 
allosteric O 
modulator O 
. O 
Negative O 
allosteric O 
modulators O 
( O 
NAMs O 
) O 
inhibit O 
and O 
positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
enhance O 
the O 
affinity O 
and O 
/ O 
or O 
efficacy O 
of O 
the O 
orthosteric O 
agonist O 
. O 
The O 
molecular O 
determinants O 
that O 
govern O 
mGlu5 O 
modulator O 
affinity O 
versus O 
cooperativity O 
are O 
not O 
well O 
understood O 
. O 
Focusing O 
on O 
the O 
modulators O 
based O 
on O 
the O 
acetylene B-SYSTEMATIC 
scaffold O 
, O 
we O 
sought O 
to O 
determine O 
the O 
molecular O 
interactions O 
that O 
contribute O 
to O 
PAM O 
versus O 
NAM O 
pharmacology O 
. O 
Generation O 
of O 
a O 
comparative O 
model O 
of O 
the O 
transmembrane O 
- O 
spanning O 
region O 
of O 
mGlu5 O 
served O 
as O 
a O 
tool O 
to O 
predict O 
and O 
interpret O 
the O 
impact O 
of O 
mutations O 
in O 
this O 
region O 
. O 
Application O 
of O 
an O 
operational O 
model O 
of O 
allosterism O 
allowed O 
for O 
determination O 
of O 
PAM O 
and O 
NAM O 
affinity O 
estimates O 
at O 
receptor O 
constructs O 
that O 
possessed O 
no O 
detectable O 
radioligand O 
binding O 
as O 
well O 
as O 
delineation O 
of O 
effects O 
on O 
affinity O 
versus O 
cooperativity O 
. O 
Novel O 
mutations O 
within O 
the O 
transmembrane O 
domain O 
( O 
TM O 
) O 
regions O 
were O 
identified O 
that O 
had O 
differential O 
effects O 
on O 
acetylene B-SYSTEMATIC 
PAMs O 
versus O 
2-methyl-6-(phenylethynyl)-pyridine B-SYSTEMATIC 
, O 
a O 
prototypical O 
NAM O 
. O 
Three O 
conserved O 
amino B-FAMILY 
acids I-FAMILY 
( O 
Y658 O 
, O 
T780 O 
, O 
and O 
S808 O 
) O 
and O 
two O 
nonconserved O 
residues O 
( O 
P654 O 
and O 
A809 O 
) O 
were O 
identified O 
as O 
key O 
determinants O 
of O 
PAM O 
activity O 
. O 
Interestingly O 
, O 
we O 
identified O 
two O 
point O 
mutations O 
in O 
TMs O 
6 O 
and O 
7 O 
that O 
, O 
when O 
mutated O 
, O 
engender O 
a O 
mode O 
switch O 
in O 
the O 
pharmacology O 
of O 
certain O 
PAMs O 
. O 

rapid O 
determination O 
method O 
for O 
ethylenethiourea B-SYSTEMATIC 
in O 
potato O 
and O 
cucumber O 
by O 
modified O 
QuEChERS O 
- O 
high O 
performance O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 

rapid O 
and O 
sensitive O 
analytical O 
method O 
for O 
the O 
determination O 
of O 
ethylenethiourea B-SYSTEMATIC 
( O 
ETU B-ABBREVIATION 
) O 
in O 
potatoes O 
and O 
cucumbers O 
is O 
developed O 
. O 
This O 
method O 
employs O 
modified O 
QuEChERS O 
followed O 
by O 
high O 
performance O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
/ O 
MS O 
) O 
analysis O 
. O 
ETU B-ABBREVIATION 
was O 
extracted O 
by O 
alkaline O 
acetonitrile B-SYSTEMATIC 
( O 
containing O 
1% O 
NH(3).H(2)0 B-FORMULA 
) O 
, O 
separated O 
on O 
a O 
ZIC-pHILIC O 
column O 
, O 
confirmed O 
by O 
multiple O 
reaction O 
monitoring O 
( O 
MRM O 
) O 
mode O 
with O 
electrospray O 
ionisation O 
source O 
. O 
This O 
modified O 
procedure O 
showed O 
satisfactory O 
recovery O 
( O 
90.6-103.5% O 
) O 
fortified O 
at O 
the O 
range O 
of O 
0.005-0.05 O 
mg O 
kg(-1) O 
with O 
relative O 
standard O 
deviation O 
( O 
RSD O 
) O 
< O 
7% O 
. O 
The O 
limits O 
of O 
detection O 
( O 
LOD O 
) O 
and O 
the O 
limits O 
of O 
quantification O 
( O 
LOQ O 
) O 
were O 
0.002 O 
mg O 
kg(-1) O 
and O 
0.005 O 
mg O 
kg(-1) O 
, O 
respectively O 
. O 
Matrix O 
effect O 
and O 
HILIC O 
retention O 
mechanism O 
were O 
also O 
evaluated O 
. O 
The O 
method O 
was O 
finally O 
applied O 
to O 
detect O 
ETU B-ABBREVIATION 
in O 
potato O 
and O 
cucumber O 
samples O 
collected O 
at O 
harvest O 
period O 
. O 
Residues O 
of O 
ETU B-ABBREVIATION 
were O 
detected O 
in O 
four O 
cucumber O 
samples O 
with O 
the O 
level O 
lower O 
than O 
LOQ O 
. O 

Communication O 
presents O 
the O 
development O 
of O 
a O 
novel O 
strategy O 
for O 
the O 
easy O 
conjugation O 
of O 
biomolecules O 
to O 
hydrophobic O 
magnetic O 
microparticles O 
via O 
reversible O 
coating O 
with O 
previously O 
functionalized O 
lipase O 
molecules O 
. O 
First O 
, O 
the O 
ability O 
of O 
lipase O 
to O 
be O 
strongly O 
adsorbed O 
onto O 
hydrophobic O 
surfaces O 
was O 
exploited O 
for O 
the O 
stabilization O 
of O 
microparticles O 
in O 
aqueous O 
medium O 
by O 
the O 
creation O 
of O 
a O 
hydrophilic O 
surface O 
. O 
Second O 
, O 
the O 
surface O 
amino B-FAMILY 
acids I-FAMILY 
of O 
lipase O 
can O 
be O 
tailored O 
to O 
suit O 
biomolecule O 
conjugation O 
. O 
This O 
approach O 
has O 
been O 
demonstrated O 
by O 
amino B-FAMILY 
- O 
epoxy B-SYSTEMATIC 
activation O 
of O 
lipase O 
, O 
enabling O 
the O 
conjugation O 
of O 
different O 
biomolecules O 
to O 
the O 
magnetic O 
particle's O 
surface O 
. O 
For O 
example O 
, O 
it O 
was O 
possible O 
to O 
immobilize O 
70% O 
of O 
Escherichia O 
coli O 
proteins O 
on O 
the O 
recovered O 
particles O 
. O 
Furthermore O 
, O 
this O 
strategy O 
could O 
be O 
extended O 
to O 
other O 
lipase O 
chemical O 
modification O 
protocols O 
, O 
enabling O 
fine O 
control O 
of O 
biomolecule O 
coupling O 
. O 
These O 
conjugation O 
techniques O 
constitute O 
a O 
modular O 
methodology O 
that O 
also O 
permits O 
the O 
recycling O 
of O 
the O 
magnetic O 
carrier O 
following O 
use O 
. O 

new O 
compounds O 
; O 
epi-mukulin B-TRIVIAL 
, O 
(Z)-Δ(1,2) B-SYSTEMATIC 
dehydroguggulsterone I-SYSTEMATIC 
and O 
Δ(6,7)dehydro-20-hydroxygugglsterone B-SYSTEMATIC 
were O 
isolated O 
from O 
the O 
n-hexane B-SYSTEMATIC 
-soluble O 
fraction O 
( O 
HSF O 
) O 
of O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
guggul O 
, O 
the O 
oleogum O 
resin O 
of O 
Commiphora O 
wightii O 
together O 
with O 
six O 
known O 
compounds O 
: O 
diasesartemin B-TRIVIAL 
, O 
(+)-epi-magnolin B-TRIVIAL 
, O 
(+)-diayangambin B-TRIVIAL 
, O 
gugglsterol B-TRIVIAL 
I I-TRIVIAL 
, O 
(E)-guggulsterone B-TRIVIAL 
and O 
(Z)-guggulsterone B-TRIVIAL 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
different O 
spectroscopic O 
data O 
. O 
α-Glucosidase O 
inhibitory O 
effects O 
of O 
HSF O 
and O 
the O 
isolated O 
compounds O 
were O 
evaluated O 
calorimetrically O 
. O 
The O 
HSF O 
showed O 
significant O 
α-glucosidase O 
inhibitory O 
effect O 
[ O 
IC(50) O 
value O 
of O 
140 O 
µg O 
mL(-1) O 
( O 
p O 
< O 
0.05 O 
) O 
] O 
. O 
Under O 
the O 
assay O 
conditions O 
, O 
diasesartemin B-TRIVIAL 
( O 
IC(50) O 
= O 
60.6 O 
± O 
0.01 O 
µM O 
) O 
was O 
found O 
to O 
be O 
more O 
potent O 
than O 
the O 
positive O 
control O 
, O 
acarbose B-TRIVIAL 
( O 
IC(50) O 
= O 
92.94 O 
± O 
0.01 O 
µM O 
) O 
; O 
a O 
known O 
α-glucosidase O 
inhibitor O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
IC(50) O 
values O 
of O 
epi-mukulin B-TRIVIAL 
and O 
(Z)-guggulsterone B-TRIVIAL 
were O 
found O 
to O 
be O 
159.33 O 
and O 
132.14 O 
µM O 
, O 
respectively O 
. O 
Other O 
compounds O 
showed O 
weak O 
α-glucosidase O 
inhibitory O 
effects O 
, O 
< O 
30% O 
inhibition O 
of O 
the O 
enzyme O 
activity O 
at O 
0.1 O 
mg O 
mL(-1) O 
. O 

molecule O 
mediated O 
proliferation O 
of O 
primary O 
retinal B-TRIVIAL 
pigment O 
epithelial O 
cells O 
. O 

pigment O 
epithelial O 
( O 
RPE O 
) O 
cells O 
form O 
a O 
monolayer O 
adjacent O 
to O 
the O 
retina O 
and O 
play O 
a O 
critical O 
role O 
in O 
the O 
visual O 
light O 
cycle O 
. O 
Degeneration O 
of O 
this O 
layer O 
results O 
in O 
vision O 
loss O 
, O 
causing O 
retinal O 
disorders O 
such O 
as O 
age O 
- O 
related O 
macular O 
degeneration O 
. O 
Cell O 
transplant O 
therapies O 
exist O 
to O 
restore O 
vision O 
loss O 
; O 
however O 
, O 
risks O 
associated O 
with O 
and O 
an O 
inadequate O 
supply O 
of O 
donor O 
cells O 
have O 
limited O 
their O 
therapeutic O 
success O 
. O 
The O 
identification O 
of O 
factors O 
that O 
proliferate O 
RPE O 
cells O 
ex O 
vivo O 
could O 
provide O 
a O 
renewable O 
source O 
of O 
cells O 
for O 
the O 
treatment O 
of O 
such O 
disorders O 
. O 
We O 
show O 
that O 
a O 
small O 
molecule O 
( O 
WS3 O 
) O 
can O 
reversibly O 
proliferate O 
primary O 
RPE O 
cells O 
isolated O 
from O 
fetal O 
and O 
adult O 
human O 
donors O 
. O 
Following O 
withdrawal O 
of O 
WS3 O 
, O 
RPE O 
cells O 
differentiate O 
into O 
a O 
functional O 
monolayer O 
, O 
as O 
exhibited O 
by O 
their O 
expression O 
of O 
mature O 
RPE O 
genes O 
and O 
phagocytosis O 
of O 
photoreceptor O 
outer O 
segments O 
. O 
Furthermore O 
, O 
chemically O 
expanded O 
RPE O 
cells O 
preserve O 
vision O 
when O 
transplanted O 
into O 
dystrophic O 
Royal O 
College O 
of O 
Surgeons O 
( O 
RCS O 
) O 
rats O 
, O 
a O 
well O 
- O 
established O 
model O 
of O 
retinal O 
degeneration O 
. O 

medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
serves O 
executive O 
cognitive O 
functions O 
such O 
as O 
decision O 
- O 
making O 
that O 
are O 
impaired O 
in O 
neuropsychiatric O 
disorders O 
and O 
pain O 
. O 
We O 
showed O 
previously O 
that O 
amygdala O 
- O 
driven O 
abnormal O 
inhibition O 
and O 
decreased O 
output O 
of O 
mPFC O 
pyramidal O 
cells O 
contribute O 
to O 
pain O 
- O 
related O 
impaired O 
decision O 
- O 
making O 
( O 
Ji O 
et O 
al O 
. O 
, O 
2010 O 
) O 
. O 
Therefore O 
, O 
modulating O 
pyramidal O 
output O 
is O 
desirable O 
therapeutic O 
goal O 
. O 
Targeting O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
subtype O 
mGluR5 O 
has O 
emerged O 
as O 
a O 
cognitive O 
- O 
enhancing O 
strategy O 
in O 
neuropsychiatric O 
disorders O 
, O 
but O 
synaptic O 
and O 
cellular O 
actions O 
of O 
mGluR5 O 
in O 
the O 
mPFC O 
remain O 
to O 
be O 
determined O 
. O 
The O 
present O 
study O 
determined O 
synaptic O 
and O 
cellular O 
actions O 
of O 
mGluR5 O 
to O 
test O 
the O 
hypothesis O 
that O 
increasing O 
mGluR5 O 
function O 
can O 
enhance O 
pyramidal O 
cell O 
output O 
. O 
Whole O 
- O 
cell O 
voltage- O 
and O 
current-clamp O 
recordings O 
were O 
made O 
from O 
visually O 
identified O 
pyramidal O 
neurons O 
in O 
layer O 
V O 
of O 
the O 
mPFC O 
in O 
rat O 
brain O 
slices O 
. O 
Both O 
the O 
prototypical O 
mGluR5 O 
agonist O 
CHPG B-ABBREVIATION 
and O 
a O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
for O 
mGluR5 O 
( O 
VU0360172 B-IDENTIFIER 
) O 
increased O 
synaptically O 
evoked O 
spiking O 
( O 
E-S O 
coupling O 
) O 
in O 
mPFC O 
pyramidal O 
cells O 
. O 
The O 
facilitatory O 
effects O 
of O 
CHPG B-ABBREVIATION 
and O 
VU0360172 B-IDENTIFIER 
were O 
inhibited O 
by O 
an O 
mGluR5 O 
antagonist O 
( O 
MTEP B-ABBREVIATION 
) O 
. O 
CHPG B-ABBREVIATION 
, O 
but O 
not O 
VU0360172 B-IDENTIFIER 
, O 
increased O 
neuronal O 
excitability O 
( O 
frequency O 
- O 
current O 
[ O 
F-I O 
] O 
function O 
) O 
. O 
VU0360172 B-IDENTIFIER 
, O 
but O 
not O 
CHPG B-ABBREVIATION 
, O 
increased O 
evoked O 
excitatory O 
synaptic O 
currents O 
( O 
EPSCs O 
) O 
and O 
amplitude O 
, O 
but O 
not O 
frequency O 
, O 
of O 
miniature O 
EPSCs O 
, O 
indicating O 
a O 
postsynaptic O 
action O 
. O 
VU0360172 B-IDENTIFIER 
, O 
but O 
not O 
CHPG B-ABBREVIATION 
, O 
decreased O 
evoked O 
inhibitory O 
synaptic O 
currents O 
( O 
IPSCs O 
) O 
through O 
an O 
action O 
that O 
involved O 
cannabinoid O 
receptor O 
CB1 O 
, O 
because O 
a O 
CB1 O 
receptor O 
antagonist O 
( O 
AM281 B-IDENTIFIER 
) O 
blocked O 
the O 
inhibitory O 
effect O 
of O 
VU0360172 B-IDENTIFIER 
on O 
synaptic O 
inhibition O 
. O 
VU0360172 B-IDENTIFIER 
also O 
increased O 
and O 
prolonged O 
CB1 O 
- O 
mediated O 
depolarization O 
- O 
induced O 
suppression O 
of O 
synaptic O 
inhibition O 
( O 
DSI O 
) O 
. O 
Activation O 
of O 
CB1 O 
with O 
ACEA B-ABBREVIATION 
decreased O 
inhibitory O 
transmission O 
through O 
a O 
presynaptic O 
mechanism O 
. O 
The O 
results O 
show O 
that O 
increasing O 
mGluR5 O 
function O 
enhances O 
mPFC O 
output O 
. O 
This O 
effect O 
can O 
be O 
accomplished O 
by O 
increasing O 
excitability O 
with O 
an O 
orthosteric O 
agonist O 
( O 
CHPG B-ABBREVIATION 
) O 
or O 
by O 
increasing O 
excitatory O 
synaptic O 
drive O 
and O 
CB1 O 
- O 
mediated O 
presynaptic O 
suppression O 
of O 
synaptic O 
inhibition O 
( O 
" O 
dis O 
- O 
inhibition O 
" O 
) O 
with O 
a O 
PAM O 
( O 
VU0360172 B-IDENTIFIER 
) O 
. O 
Therefore O 
, O 
mGluR5 O 
may O 
be O 
a O 
useful O 
target O 
in O 
conditions O 
of O 
impaired O 
mPFC O 
output O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

allosteric O 
modulator O 
of O 
alpha O 
7 O 
nicotinic- O 
acetylcholine B-SYSTEMATIC 
receptors O 
, O 
PNU-120596 B-IDENTIFIER 
augments O 
the O 
effects O 
of O 
donepezil B-TRIVIAL 
on O 
learning O 
and O 
memory O 
in O 
aged O 
rodents O 
and O 
non-human O 
primates O 
. O 

development O 
of O 
novel O 
therapeutic O 
agents O 
for O 
disorders O 
of O 
cognition O 
such O 
as O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
is O 
of O 
paramount O 
importance O 
given O 
the O 
ever O 
- O 
increasing O 
elderly O 
population O 
, O 
however O 
; O 
there O 
is O 
also O 
considerable O 
interest O 
in O 
any O 
strategy O 
that O 
might O 
enhance O 
the O 
clinical O 
efficacy O 
of O 
currently O 
available O 
treatments O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
an O 
adjunctive O 
treatment O 
strategy O 
to O 
memory O 
enhancement O 
, O 
namely O 
combining O 
the O 
commonly O 
prescribed O 
acetylcholinesterase O 
inhibitor O 
( O 
AChEI O 
) O 
donepezil B-TRIVIAL 
, O 
with O 
a O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
of O 
α7 O 
nicotinic- O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
α7-nAChRs O 
) O 
, O 
PNU-120596 B-IDENTIFIER 
. O 
The O 
treatment O 
strategy O 
was O 
evaluated O 
in O 
a O 
( O 
non-spatial O 
) O 
spontaneous O 
novel O 
object O 
recognition O 
( O 
NOR O 
) O 
task O 
in O 
young O 
rats O 
; O 
a O 
water O 
maze O 
spatial O 
learning O 
and O 
recall O 
procedure O 
in O 
aged O 
, O 
cognitively O 
- O 
impaired O 
rats O 
, O 
and O 
a O 
delayed O 
match O 
to O 
sample O 
( O 
working O 
/ O 
short O 
term O 
memory O 
) O 
task O 
in O 
aged O 
rhesus O 
monkeys O 
. O 
In O 
all O 
three O 
experiments O 
a O 
similar O 
drug O 
response O 
was O 
observed O 
, O 
namely O 
that O 
donepezil B-TRIVIAL 
administered O 
alone O 
improved O 
task O 
performance O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
; O 
that O 
PNU-120596 B-IDENTIFIER 
administered O 
alone O 
was O 
without O 
significant O 
effect O 
, O 
but O 
that O 
the O 
combination O 
of O 
PNU-120596 B-IDENTIFIER 
with O 
a O 
subthreshold O 
dose O 
of O 
donepezil B-TRIVIAL 
was O 
effective O 
. O 
The O 
positive O 
effect O 
of O 
the O 
drug O 
combination O 
appeared O 
to O 
be O 
α7-nAChR O 
mediated O 
given O 
that O 
it O 
was O 
blocked O 
in O 
the O 
NOR O 
task O 
by O 
the O 
selective O 
α7-nAChR O 
antagonist O 
methyllycaconitine B-TRIVIAL 
( O 
MLA B-ABBREVIATION 
) O 
. O 
Collectively O 
, O 
these O 
data O 
indicate O 
that O 
PNU-120596 B-IDENTIFIER 
increases O 
the O 
effective O 
dose O 
range O 
of O 
donepezil B-TRIVIAL 
in O 
learning O 
/ O 
memory O 
- O 
related O 
tasks O 
in O 
young O 
and O 
age O 
- O 
impaired O 
animal O 
models O 
. O 
The O 
results O 
suggest O 
that O 
α7-nAChR-selective O 
PAMs O 
like O 
PNU-120596 B-IDENTIFIER 
have O 
potential O 
as O 
adjunctive O 
treatments O 
with O 
acetylcholinesterase O 
inhibitors O 
( O 
e.g O 
. O 
, O 
donepezil B-TRIVIAL 
) O 
for O 
age O 
- O 
related O 
illnesses O 
such O 
as O 
AD O 
as O 
well O 
memory O 
disorders O 
not O 
necessarily O 
associated O 
with O 
advanced O 
age O 
. O 

bioavailable O 
and O 
brain O 
- O 
penetrant O 
pyridazine B-SYSTEMATIC 
and O 
pyridine B-SYSTEMATIC 
-derived O 
γ-secretase O 
modulators O 
reduced O 
amyloidogenic O 
Aβ O 
peptides O 
in O 
vivo O 
. O 

of O 
amyloid O 
β O 
( O 
Aβ O 
) O 
in O 
brain O 
is O 
a O 
pathological O 
hallmark O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
Aβ O 
is O 
generated O 
after O 
sequential O 
cleavage O 
of O 
its O 
parental O 
molecule O 
, O 
amyloid O 
precursor O 
protein O 
( O 
APP O 
) O 
, O 
by O 
β- O 
and O 
γ-secretases O 
. O 
Inhibition O 
of O 
γ-secretase O 
activity O 
is O 
an O 
effective O 
approach O 
for O 
the O 
reduction O 
of O 
Aβ O 
levels O 
. O 
Since O 
γ-secretase O 
targets O 
many O 
different O 
substrates O 
, O 
selective O 
inhibition O 
of O 
its O 
cleavage O 
of O 
APP O 
is O 
believed O 
to O 
be O 
critical O 
in O 
order O 
to O 
avoid O 
undesirable O 
side O 
effects O 
. O 
γ-Secretase O 
modulator O 
( O 
GSM O 
) O 
shifts O 
the O 
cleavage O 
site O 
on O 
APP O 
and O 
production O 
of O 
amyloidogenic O 
to O 
non-amyloidogenic O 
Aβ O 
fragments O 
. O 
Since O 
GSMs O 
only O 
modulate O 
and O 
do O 
not O 
block O 
cleavage O 
of O 
γ-secretase O 
substrates O 
, O 
they O 
are O 
believed O 
less O 
likely O 
to O 
produce O 
untoward O 
adverse O 
reactions O 
. O 
Here O 
, O 
we O 
report O 
in O 
vivo O 
Aβ-lowering O 
profiles O 
of O 
a O 
pyridazine B-SYSTEMATIC 
and O 
a O 
pyridine B-SYSTEMATIC 
-derived O 
GSM O 
: O 
GSM-C O 
( O 
Wan O 
et O 
al O 
. O 
, O 
2011a O 
) O 
and O 
GSM-D O 
( O 
Wan O 
et O 
al O 
. O 
, O 
2011b O 
) O 
. O 
Both O 
compounds O 
reduced O 
Aβ40 O 
and O 
Aβ42 O 
productions O 
, O 
increased O 
shorter O 
Aβ O 
fragments O 
, O 
and O 
had O 
little O 
effect O 
on O 
Notch O 
signaling O 
( O 
∼100-fold O 
selective O 
) O 
. O 
They O 
had O 
excellent O 
oral O 
bioavailability O 
( O 
97.8% O 
for O 
GSM-C O 
, O 
∼100% O 
for O 
GSM-D O 
) O 
and O 
good O 
brain O 
permeability O 
( O 
free O 
brain O 
to O 
free O 
blood O 
AUC O 
ratio O 
of O 
0.41 O 
and O 
1.1 O 
for O 
GSM-C O 
and O 
GSM-D O 
, O 
respectively O 
) O 
. O 
Oral O 
administration O 
of O 
these O 
compounds O 
in O 
both O 
acute O 
and O 
sub O 
- O 
chronic O 
conditions O 
reduced O 
Aβ O 
levels O 
in O 
plasma O 
and O 
brain O 
in O 
rats O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
Therefore O 
, O 
GSM-C O 
and O 
GSM-D O 
represent O 
two O 
GSMs O 
that O 
are O 
orally O 
bioavailable O 
and O 
brain O 
- O 
permeable O 
. O 
They O 
could O 
serve O 
as O 
excellent O 
tools O 
in O 
the O 
investigation O 
of O 
the O 
role O 
of O 
Aβ O 
peptides O 
in O 
AD O 
pathogenesis O 
. O 

disease O 
( O 
AD O 
) O 
is O 
one O 
of O 
the O 
most O 
threatening O 
diseases O 
affecting O 
the O 
aged O 
with O 
high O 
incidence O 
. O 
Though O 
AD O 
has O 
been O 
defined O 
for O 
more O 
than O 
100 O 
years O 
, O 
it O 
is O 
still O 
incurable O 
. O 
The O 
drugs O 
clinically O 
used O 
for O 
the O 
treatment O 
of O 
this O 
disease O 
, O 
such O 
as O 
acetylcholinesterase O 
inhibitors O 
( O 
AChEIs O 
) O 
and O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptor O 
antagonist O 
, O 
can O 
only O 
provide O 
a O 
limited O 
therapeutic O 
effect O 
. O 
The O 
need O 
of O 
effective O 
drugs O 
has O 
stimulated O 
the O 
search O 
for O 
new O 
compounds O 
with O 
potential O 
clinical O 
utility O 
. O 
Natural O 
products O 
are O 
rich O 
and O 
unexplored O 
sources O 
for O 
discovering O 
novel O 
leading O 
compounds O 
. O 
Currently O 
, O 
a O 
great O 
number O 
of O 
natural O 
products O 
have O 
been O 
found O 
possessing O 
anti-AD O 
property O 
counteracting O 
different O 
etiological O 
factors O 
of O 
AD O 
. O 
This O 
review O 
will O 
give O 
an O 
update O 
demonstration O 
on O 
the O 
novel O 
anti-AD O 
natural O 
products O 
and O 
their O 
derivatives O 
/ O 
analogues O 
, O 
which O 
have O 
been O 
divided O 
into O 
five O 
subgroups O 
according O 
to O 
their O 
different O 
action O 
mechanisms O 
: O 
AChEIs O 
, O 
antioxidants O 
, O 
neuroprotective O 
agents O 
, O 
monoamine B-FAMILY 
oxidase O 
( O 
MAO O 
) O 
inhibitors O 
, O 
and O 
tau O 
hyperphosphorylation O 
inhibitors O 
. O 
We O 
put O 
special O 
emphasis O 
on O 
the O 
findings O 
in O 
the O 
past O 
5 O 
years O 
. O 
Besides O 
, O 
the O 
drug O 
design O 
strategy O 
as O 
well O 
as O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
the O 
relevant O 
compounds O 
is O 
also O 
discussed O 
when O 
it O 
is O 
possible O 
. O 

behavior O 
of O 
charge O 
transfer O 
complexes O 
of O 
tetrakis(dimethylamino)ethene B-SYSTEMATIC 
with O 
acceptor O 
molecules O 
: O 
a O 
theoretical O 
study O 
. O 

effect O 
of O 
electric O 
field O 
induced O 
electron O 
transfer O 
on O 
the O 
rectification O 
properties O 
of O 
molecular O 
rectifiers O 
based O 
on O 
charge O 
transfer O 
complexes O 
of O 
tetrakis(dimethylamino)ethane B-SYSTEMATIC 
( O 
TDAE B-ABBREVIATION 
) O 
with O 
acceptor O 
molecules O 
was O 
explored O 
. O 
The O 
current-voltage O 
curves O 
and O 
the O 
rectification O 
ratios O 
( O 
RR O 
) O 
for O 
two O 
different O 
molecular O 
rectifiers O 
were O 
obtained O 
using O 
a O 
direct O 
ab O 
initio O 
method O 
at O 
M06 O 
/ O 
LACVP(d) O 
level O 
of O 
theory O 
in O 
the O 
range O 
from O 
-2 O 
to O 
+ O 
2 O 
V O 
. O 
The O 
highest O 
RR O 
of O 
25.7 O 
was O 
determined O 
for O 
the O 
complex O 
of O 
TDAE B-ABBREVIATION 
with O 
2-nitropyrene-4,5,9,10-tetraone B-SYSTEMATIC 
at O 
0.5 O 
V O 
( O 
D1 O 
) O 
, O 
while O 
another O 
rectifier O 
[ O 
complex O 
of O 
TDAE B-ABBREVIATION 
with O 
2,7-dimethyl B-SYSTEMATIC 
nitropyrene-4,5,9,10-tetraone I-SYSTEMATIC 
( O 
D2 O 
) O 
] O 
showed O 
a O 
maximum O 
RR O 
of O 
only O 
2.9 O 
at O 
0.3 O 
V O 
. O 
The O 
electric O 
field O 
induced O 
electron O 
transfer O 
occurring O 
in O 
D1 O 
creates O 
a O 
one O 
- O 
way O 
conducting O 
channel O 
consisting O 
of O 
two O 
SOMOs O 
involving O 
the O 
entire O 
D1 O 
complex O 
. O 
In O 
the O 
case O 
of O 
D2 O 
, O 
no O 
electron O 
transfer O 
occurs O 
at O 
the O 
applied O 
bias O 
voltages O 
due O 
to O 
the O 
relatively O 
high O 
energy O 
difference O 
between O 
HOMO O 
and O 
LUMO O 
. O 

addiction O 
continues O 
to O 
be O 
an O 
important O 
public O 
health O 
problem O 
, O 
with O 
an O 
estimated O 
22.6 O 
million O 
current O 
illicit O 
drug O 
users O 
in O 
the O 
United O 
States O 
alone O 
. O 
For O 
many O 
addictions O 
, O 
including O 
cocaine B-TRIVIAL 
, O 
methamphetamine B-TRIVIAL 
, O 
and O 
marijuana O 
addiction O 
, O 
there O 
are O 
no O 
approved O 
pharmacological O 
treatments O 
. O 
Behavioral O 
treatments O 
are O 
effective O 
but O 
effects O 
vary O 
widely O 
across O 
individuals O 
. O 
Treatments O 
that O 
are O 
effective O 
across O 
multiple O 
addictions O 
are O 
greatly O 
needed O 
, O 
and O 
accumulating O 
evidence O 
suggests O 
that O 
one O 
such O 
approach O 
may O 
be O 
pharmacological O 
or O 
behavioral O 
interventions O 
that O 
enhance O 
executive O 
inhibitory O 
control O 
in O 
addicts O 
. O 
Current O 
evidence O 
indicates O 
that O 
most O 
forms O 
of O 
chronic O 
drug O 
use O 
may O 
be O 
associated O 
with O 
significant O 
cognitive O 
impairments O 
, O 
especially O 
in O 
attention O 
, O 
working O 
memory O 
, O 
and O 
response O 
inhibition O 
functions O 
. O 
In O 
some O 
studies O 
, O 
these O 
impairments O 
predict O 
poor O 
treatment O 
retention O 
and O 
outcome O 
. O 
A O 
number O 
of O 
cognitive O 
enhancing O 
agents O 
, O 
including O 
galantamine B-TRIVIAL 
, O 
modafinil B-TRIVIAL 
, O 
atomoxetine B-TRIVIAL 
, O 
methylphenidate B-SYSTEMATIC 
, O 
and O 
guanfacine B-TRIVIAL 
, O 
have O 
shown O 
promising O 
findings O 
in O 
human O 
studies O 
. O 
Specific O 
behavioral O 
interventions O 
, O 
including O 
cognitive O 
remediation O 
, O 
also O 
show O 
promise O 
. O 
However O 
, O 
whether O 
improvement O 
of O 
selective O 
cognitive O 
functions O 
reduces O 
drug O 
use O 
behavior O 
remains O 
to O 
be O 
determined O 
. O 
Cognitive O 
enhancement O 
to O 
improve O 
treatment O 
outcomes O 
is O 
a O 
novel O 
strategy O 
worthy O 
of O 
future O 
research O 
, O 
as O 
are O 
related O 
questions O 
such O 
as O 
whether O 
these O 
approaches O 
may O 
be O 
broadly O 
beneficial O 
to O 
most O 
addicts O 
or O 
best O 
reserved O 
for O 
substance O 
users O 
with O 
specific O 
demonstrated O 
cognitive O 
impairments O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

the O 
structure O 
of O 
aspongopusin B-TRIVIAL 
recently O 
isolated O 
from O 
Aspongopus O 
chinensis O 
. O 

2,5- B-FAMILY 
disubstituted I-FAMILY 
oxazole I-FAMILY 
recently O 
proposed O 
for O 
aspongopusin B-TRIVIAL 
, O 
a O 
natural O 
product O 
isolated O 
from O 
Aspongopus O 
chinensis O 
, O 
was O 
synthesized O 
through O 
an O 
unambiguous O 
route O 
. O 
The O 
synthetic O 
sample O 
showed O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
entirely O 
different O 
from O 
those O 
in O 
the O 
literature O 
, O 
revealing O 
that O 
the O 
initially O 
assigned O 
structure O 
was O 
incorrect O 
. O 
The O 
spectroscopic O 
data O 
for O 
the O 
given O 
structure O 
are O 
thus O 
made O 
available O 
for O 
the O 
first O 
time O 
. O 

( O 
ACV B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
drugs O 
of O 
choice O 
for O 
the O 
treatment O 
of O 
epidermal O 
, O 
ocular O 
or O 
systemic O 
herpetic O 
infections O 
. O 
Nevertheless O 
, O 
its O 
trans-mucosal O 
limited O 
absorption O 
and O 
the O 
scarce O 
contact O 
time O 
of O 
the O 
formulation O 
with O 
the O 
mucosal O 
surface O 
- O 
especially O 
in O 
the O 
ocular O 
mucosa O 
- O 
constitute O 
a O 
big O 
limitation O 
of O 
the O 
antiviral O 
efficiency O 
. O 
The O 
most O 
effective O 
way O 
to O 
solve O 
these O 
problems O 
is O 
to O 
increase O 
the O 
quantity O 
and O 
the O 
residence O 
time O 
of O 
the O 
drug O 
over O 
the O 
ocular O 
surface O 
. O 
In O 
order O 
to O 
cope O 
with O 
all O 
these O 
requirements O 
, O 
micro O 
- O 
particles O 
( O 
MPs O 
) O 
and O 
nano O 
- O 
particles O 
( O 
NPs O 
) O 
containing O 
ACV B-ABBREVIATION 
have O 
been O 
developed O 
using O 
cross O 
- O 
linked O 
chitosan O 
with O 
tripolyphosphate B-SYSTEMATIC 
( O 
TPP B-ABBREVIATION 
) O 
due O 
to O 
the O 
biocompatibility O 
, O 
bio O 
- O 
adhesion O 
ability O 
and O 
the O 
potential O 
power O 
as O 
penetration O 
enhancer O 
of O 
this O 
polymer O 
. O 
Particles O 
were O 
characterized O 
by O 
Fourier O 
- O 
transformed O 
infrared O 
( O 
FTIR O 
) O 
spectroscopy O 
, O 
X-ray O 
diffraction O 
, O 
SEM O 
, O 
Zeta O 
potential O 
and O 
particle O 
size O 
. O 
Encapsulation O 
efficiency O 
and O 
release O 
profiles O 
in O 
flow O 
through O 
diffusion O 
cells O 
were O 
also O 
determined O 
. O 
Besides O 
the O 
Slug O 
Mucosal O 
Irritation O 
( O 
SMI O 
) O 
assay O 
has O 
been O 
applied O 
as O 
an O 
alternative O 
to O 
the O 
Draize O 
test O 
to O 
predict O 
the O 
mucosal O 
irritation O 
of O 
the O 
selected O 
formulation O 
. O 
FTIR O 
and O 
X-ray O 
results O 
suggested O 
an O 
electrostatic O 
interaction O 
ACV B-ABBREVIATION 
-Chitosan O 
that O 
made O 
ACV B-ABBREVIATION 
be O 
molecularly O 
dispersed O 
within O 
the O 
polymer O 
matrix O 
. O 
Encapsulation O 
efficiency O 
was O 
75% O 
for O 
MP O 
and O 
16% O 
for O 
NP O 
. O 
Release O 
profiles O 
in O 
flow O 
through O 
diffusion O 
cells O 
were O 
also O 
determined O 
. O 
From O 
the O 
diffusion O 
profiles O 
, O 
it O 
was O 
found O 
that O 
the O 
amounts O 
of O 
ACV B-ABBREVIATION 
effectively O 
diffused O 
in O 
24h O 
were O 
30 O 
, O 
430 O 
and O 
80 O 
μg O 
for O 
the O 
ACV B-ABBREVIATION 
solution O 
, O 
MP O 
and O 
NP O 
respectively O 
. O 
SMI O 
results O 
showed O 
that O 
chitosan O 
- O 
based O 
particles O 
induced O 
moderate O 
irritation O 
and O 
mild O 
tissue O 
damage O 
, O 
what O 
supposes O 
that O 
ACV B-ABBREVIATION 
-MP O 
constitute O 
a O 
promising O 
alternative O 
for O 
further O 
development O 
of O 
an O 
antiviral O 
formulation O 
. O 

RELEVANCE O 
: O 
Casearia O 
sylvestris O 
Sw O 
. O 
is O 
widely O 
used O 
in O 
popular O 
medicine O 
to O 
treat O 
inflammatory O 
conditions O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
investigate O 
the O 
anti-inflammatory O 
and O 
antioxidant O 
properties O 
of O 
hydroalcoholic O 
crude O 
extract O 
( O 
HCE O 
) O 
taken O 
from O 
Casearia O 
sylvestris O 
Sw O 
. O 
( O 
Salicaceae O 
) O 
. O 
METHODS O 
AND O 
RESULTS O 
: O 
The O 
effect O 
of O 
the O 
HCE O 
from O 
this O 
plant O 
( O 
3-300mg O 
/ O 
kg O 
) O 
on O 
the O 
reduction O 
of O 
inflammatory O 
response O 
to O 
carrageenan O 
was O 
investigated O 
in O 
pleurisy O 
in O 
rats O 
( O 
intrapleural O 
, O 
2% O 
in O 
0.2mL O 
) O 
or O 
paw O 
edema O 
in O 
mice O 
( O 
intraplantar O 
, O 
300μg O 
/ O 
20μL O 
, O 
right O 
hind O 
paw O 
) O 
. O 
The O 
plant O 
anti-inflammatory O 
action O 
was O 
assessed O 
by O 
its O 
capability O 
in O 
inhibiting O 
cell O 
migration O 
, O 
enzymatic O 
activity O 
of O 
myeloperoxidase O 
( O 
MPO O 
) O 
and O 
production O 
of O 
nitrite B-SYSTEMATIC 
/ O 
nitrate B-SYSTEMATIC 
or O 
edema O 
. O 
The O 
in O 
vitro O 
antioxidant O 
activity O 
of O 
this O 
extract O 
against O 
lipid O 
peroxidation O 
and O 
damage O 
to O 
proteins O 
was O 
assessed O 
as O 
possible O 
pathways O 
to O 
contribute O 
as O 
anti-inflammatory O 
mechanisms O 
. O 
Carrageenan O 
- O 
induced O 
hind O 
paw O 
edema O 
( O 
739.3±11.9μm O 
) O 
was O 
reduced O 
by O 
HCE O 
( O 
30mg O 
/ O 
kg O 
: O 
462.8±28.38μm O 
) O 
to O 
similar O 
extents O 
as O 
dexametasone B-TRIVIAL 
( O 
365.1±16.7 O 
) O 
. O 
In O 
pleurisy O 
, O 
treatment O 
of O 
the O 
animals O 
with O 
HCE O 
( O 
100mg O 
/ O 
kg O 
: O 
0.010±0.001mU O 
/ O 
mg O 
of O 
protein O 
) O 
also O 
reduced O 
MPO O 
activity O 
augmented O 
by O 
carrageenan O 
( O 
0.020±0.001mU O 
/ O 
mg O 
of O 
protein O 
) O 
as O 
well O 
as O 
leukocytes O 
migration O 
( O 
carrageenan O 
: O 
17.8890±2.3900leukocytes O 
/ O 
mL O 
, O 
HCE O 
100mg O 
/ O 
kg O 
: O 
7.0880±9631leukocytes O 
/ O 
mL O 
) O 
. O 
Significant O 
effects O 
were O 
also O 
observed O 
in O 
animals O 
treated O 
with O 
different O 
doses O 
of O 
HCE O 
in O 
biochemical O 
tests O 
for O 
oxidative O 
stress O 
analysis O 
. O 
CONCLUSION O 
: O 
The O 
anti-inflammatory O 
and O 
antioxidant O 
effects O 
of O 
HCE O 
from O 
Casearia O 
sylvestris O 
Sw O 
. O 
suggests O 
a O 
potential O 
therapeutic O 
benefit O 
of O 
this O 
plant O 
in O 
treatment O 
of O 
inflammatory O 
conditions O 
. O 

deregulation O 
of O 
oncogenic O 
signaling O 
pathways O 
which O 
provide O 
survival O 
advantages O 
to O 
tumor O 
cells O 
is O 
mediated O 
by O 
multiple O 
cellular O 
networks O 
. O 
Among O 
them O 
, O 
the O 
PI3K-Akt-mTOR O 
axis O 
, O 
in O 
particular O 
the O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
Akt O 
, O 
is O 
recognized O 
as O 
a O 
key O 
player O 
. O 
The O 
kinase O 
is O 
hyperactivated O 
due O 
to O 
a O 
variety O 
of O 
mechanisms O 
including O 
loss O 
of O 
PTEN O 
, O 
mutations O 
in O 
the O 
PI3K O 
catalytic O 
subunit O 
, O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
and O 
Ras O 
activation O 
. O 
Indeed O 
, O 
inappropriate O 
activation O 
of O 
the O 
Akt O 
kinase O 
is O 
a O 
common O 
event O 
in O 
human O 
tumors O 
and O 
Akt O 
appears O 
to O 
be O 
a O 
critical O 
player O 
in O 
cell O 
survival O 
that O 
may O 
also O 
account O 
for O 
the O 
therapeutic O 
resistance O 
and O 
the O 
invasive O 
phenotype O 
of O 
tumors O 
. O 
Inhibition O 
of O 
Akt O 
signalling O 
results O 
in O 
apoptosis O 
and O 
growth O 
inhibition O 
of O 
tumour O 
cells O 
with O 
elevated O 
Akt O 
activity O 
. O 
A O 
functional O 
role O 
in O 
drug O 
resistance O 
is O 
supported O 
by O 
evidence O 
that O 
tumor O 
cells O 
with O 
acquired O 
resistance O 
to O 
antitumor O 
agents O 
may O 
display O 
increased O 
Akt O 
activation O 
and O 
that O 
treatment O 
with O 
molecularly O 
targeted O 
agents O 
can O 
activate O 
feed O 
- O 
back O 
loops O 
involving O 
Akt O 
. O 
This O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
may O 
therefore O 
represent O 
an O 
amenable O 
target O 
for O 
modulation O 
of O 
sensitivity O 
to O 
compounds O 
with O 
different O 
molecular O 
features O 
due O 
to O 
its O 
pleiotropic O 
role O 
in O 
cell O 
survival O 
. O 
Different O 
types O 
of O 
Akt O 
inhibitors O 
[ O 
i.e O 
. O 
, O 
ATP B-ABBREVIATION 
mimetics O 
and O 
pleckstrin O 
- O 
homology O 
( O 
PH O 
) O 
domain O 
binders O 
] O 
have O 
been O 
generated O 
and O 
some O 
of O 
them O 
have O 
reached O 
the O 
clinical O 
setting O 
. O 
The O 
present O 
review O 
focuses O 
on O 
the O 
i O 
) O 
mechanisms O 
implicating O 
Akt O 
in O 
increased O 
survival O 
and O 
invasive O 
potential O 
of O 
tumor O 
cells O 
of O 
different O 
tumor O 
types O 
and O 
ii O 
) O 
on O 
the O 
development O 
of O 
Akt O 
inhibitors O 
as O 
modulators O 
of O 
drug O 
resistance O 
. O 

child O 
exposed O 
to O 
primidone B-TRIVIAL 
not O 
prescribed O 
for O 
her O 
. O 

7.5-year O 
- O 
old O 
girl O 
who O 
was O 
treated O 
with O 
phenobarbital B-TRIVIAL 
( O 
PHB B-ABBREVIATION 
) O 
for O 
epilepsy O 
was O 
admitted O 
with O 
decreased O 
levels O 
of O 
consciousness O 
. O 
She O 
had O 
been O 
known O 
to O 
have O 
high O 
PHB B-ABBREVIATION 
levels O 
of O 
unknown O 
cause O 
, O 
without O 
symptoms O 
. O 
Her O 
PHB B-ABBREVIATION 
levels O 
were O 
very O 
high O 
, O 
as O 
expected O 
, O 
but O 
primidone B-TRIVIAL 
levels O 
were O 
also O 
detected O 
although O 
she O 
and O 
her O 
parents O 
denied O 
history O 
of O 
primidone B-TRIVIAL 
administration O 
. O 
We O 
wished O 
to O 
rule O 
out O 
intentional O 
unprescribed O 
use O 
of O 
primidone B-TRIVIAL 
. O 
Our O 
retrospective O 
review O 
showed O 
3 O 
other O 
children O 
with O 
high O 
PHB B-ABBREVIATION 
concentrations O 
where O 
primidone B-TRIVIAL 
was O 
also O 
detected O 
when O 
PHB B-ABBREVIATION 
levels O 
were O 
over O 
130 O 
μmol O 
/ O 
L O 
. O 
Complementary O 
studies O 
confirmed O 
that O 
high O 
- O 
dose O 
PHB B-ABBREVIATION 
can O 
convert O 
to O 
its O 
prodrug O 
primidone B-TRIVIAL 
, O 
which O 
has O 
not O 
been O 
reported O 
previously O 
. O 

of O 
non-polar O 
dimers O 
formed O 
during O 
thermo O 
- O 
oxidative O 
degradation O 
of O 
β-sitosterol B-TRIVIAL 
. O 

- O 
oxidative O 
degradation O 
of O 
sterols B-FAMILY 
at O 
temperature O 
typical O 
for O 
frying O 
leads O 
to O 
the O 
formation O 
of O 
oxidised O 
derivatives O 
, O 
fragmented O 
sterols B-FAMILY 
and O 
oligomers O 
. O 
Recent O 
research O 
on O 
sterol B-FAMILY 
oxidation O 
focuses O 
mainly O 
on O 
the O 
oxysterol B-FAMILY 
derivatives O 
formation O 
to O 
the O 
exclusion O 
of O 
compounds O 
with O 
high O 
molecular O 
mass O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
decipher O 
the O 
chemical O 
structure O 
of O 
non-polar O 
dimers O 
formed O 
during O 
β-sitosterol B-TRIVIAL 
oxidation O 
at O 
180°C O 
in O 
the O 
presence O 
of O 
oxygen B-SYSTEMATIC 
. O 
The O 
dimer O 
fraction O 
was O 
separated O 
by O 
size O 
- O 
exclusion O 
chromatography O 
( O 
SEC O 
) O 
after O 
pre O 
- O 
fractionation O 
on O 
silica B-TRIVIAL 
gel I-TRIVIAL 
. O 
The O 
chemical O 
structure O 
of O 
the O 
dimers O 
was O 
assessed O 
by O 
1D O 
and O 
2D O 
NMR O 
, O 
IR O 
, O 
Raman O 
and O 
MS O 
spectroscopies O 
. O 
NMR O 
data O 
confirmed O 
that O 
the O 
predominant O 
non-polar O 
dimer O 
formed O 
during O 
β-sitosterol B-TRIVIAL 
oxidative O 
degradation O 
has O 
a O 
configuration O 
of O 
3β,3β'-disitosteryl B-SYSTEMATIC 
ether I-SYSTEMATIC 
. O 
Data O 
from O 
IR O 
and O 
Raman O 
spectroscopies O 
further O 
proved O 
it O 
chemical O 
structure O 
. O 
Applied O 
analytical O 
techniques O 
also O 
confirmed O 
presence O 
of O 
dimers O 
with O 
different O 
configuration O 
than O 
disteryl B-FAMILY 
ethers I-FAMILY 
. O 

probes O 
of O 
a O 
trisubstituted O 
pyrrole B-SYSTEMATIC 
to O 
identify O 
its O 
protein O 
target(s) O 
in O 
Plasmodium O 
sporozoites O 
. O 

is O 
a O 
disease O 
that O 
has O 
a O 
major O 
impact O 
in O 
many O 
developing O 
nations O 
, O 
especially O 
on O 
the O 
African O 
continent O 
. O 
There O 
is O 
a O 
need O 
to O 
develop O 
new O 
therapeutics O 
and O 
prophylactic O 
treatments O 
against O 
it O 
. O 
A O 
trisubstituted O 
pyrrole B-SYSTEMATIC 
was O 
recently O 
found O 
to O 
inhibit O 
infection O 
of O 
mammalian O 
hepatocytes O 
by O 
Plasmodium O 
sporozoites O 
, O 
but O 
the O 
target O 
of O 
this O 
agent O 
is O 
not O 
known O 
. O 
In O 
this O 
study O 
trisubstituted O 
pyrrole B-SYSTEMATIC 
derivatives O 
with O 
different O 
substituents O 
on O 
a O 
piperidinyl B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
were O 
prepared O 
. O 
We O 
determined O 
if O 
modifications O 
of O 
the O 
piperidinyl B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
would O 
accommodate O 
a O 
drug- O 
biotin B-TRIVIAL 
linking O 
strategy O 
for O 
affinity O 
purification O 
of O 
the O 
trisubstituted O 
pyrrole B-SYSTEMATIC 
' O 
s O 
target O 
protein(s) O 
. O 

tetraterpene B-FAMILY 
glycosides I-FAMILY 
from O 
the O 
fruits O 
of O 
Lycium O 
chinense O 
. O 

new O 
compounds O 
lyciumtetraterpenic B-TRIVIAL 
hexaarabinoside I-TRIVIAL 
( O 
1 O 
) O 
and O 
tetraterpenyl B-TRIVIAL 
hexaarabinoside I-TRIVIAL 
( O 
2 O 
) O 
, O 
along O 
with O 
two O 
known O 
compounds O 
, O 
were O 
isolated O 
from O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
the O 
fruits O 
of O 
Lycium O 
chinense O 
Miller O 
( O 
Solanaceae O 
) O 
, O 
and O 
their O 
structures O 
have O 
been O 
elucidated O 
as O 
6-(1,1,5-trimethyl-5α-hydroxycyclohexanyl)-6'-(1',1',5'-trimethyl-2'β-hydroxycyclohexanyl)-9,13,9',13'-tetramethyloctadec-7,9,11,13,15,7',9',11',13'-nonene-5α-D-arabinopyranosyl(2a B-SYSTEMATIC 
→ I-SYSTEMATIC 
1b)-β-D-arabinopyranosyl-(2b I-SYSTEMATIC 
→ I-SYSTEMATIC 
1c)-β-D-arabinopyranosyl-2'-β-D-arabinopyranosyl-(2d I-SYSTEMATIC 
→ I-SYSTEMATIC 
1e)-α-D-arabinopyranosyl-(2e I-SYSTEMATIC 
→ I-SYSTEMATIC 
1f)-α-D-arabinopyranoside I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
1(6),11(12),13(14),1'(6'),11'(12'),13'(14')-dodecahydro-β-caroten-4β,4'β-diol-4β-L-arabinopyranosyl-(2a B-SYSTEMATIC 
→ I-SYSTEMATIC 
1b)-β-L-arabinopyranosyl-(2b I-SYSTEMATIC 
→ I-SYSTEMATIC 
1c)-β-D-arabinopyranosido-4'β-L-arabinopyranosyl-(2d I-SYSTEMATIC 
→ I-SYSTEMATIC 
1e)-β-L-arabinopyranosyl-(2e I-SYSTEMATIC 
→ I-SYSTEMATIC 
1f)-β-D-arabinopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
on O 
the O 
basis O 
of O 
spectral O 
data O 
analysis O 
and O 
chemical O 
reactions O 
. O 

effect O 
of O 
sulforaphane B-TRIVIAL 
in O 
6-hydroxydopamine B-SYSTEMATIC 
-lesioned O 
mouse O 
model O 
of O 
Parkinson's O 
disease O 
. O 

disease O 
( O 
PD O 
) O 
is O 
characterized O 
by O 
the O 
selective O 
loss O 
of O 
dopaminergic O 
nigrostriatal O 
neurons O 
, O 
which O 
leads O 
to O 
disabling O 
motor O 
disturbances O 
. O 
Sulforaphane B-TRIVIAL 
( O 
SFN B-ABBREVIATION 
) O 
, O 
found O 
in O 
cruciferous O 
vegetables O 
, O 
is O 
a O 
potent O 
indirect O 
antioxidant O 
and O 
recent O 
advances O 
have O 
shown O 
its O 
neuroprotective O 
activity O 
in O 
various O 
experimental O 
models O 
of O 
neurodegeneration O 
. O 
This O 
study O 
was O 
undertaken O 
to O 
examine O 
the O 
effects O 
of O 
SFN B-ABBREVIATION 
on O 
behavioral O 
changes O 
and O 
dopaminergic O 
neurotoxicity O 
in O 
mice O 
exposed O 
to O 
6-hydroxydopamine B-SYSTEMATIC 
( O 
6-OHDA B-SYSTEMATIC 
) O 
. O 
For O 
this O 
purpose O 
, O 
mice O 
were O 
treated O 
with O 
SFN B-ABBREVIATION 
( O 
5mg O 
/ O 
kg O 
twice O 
a O 
week O 
) O 
for O 
four O 
weeks O 
after O 
the O 
unilateral O 
intrastriatal O 
injection O 
of O 
6-OHDA B-SYSTEMATIC 
. O 
The O 
increase O 
in O 
6-OHDA B-SYSTEMATIC 
-induced O 
rotations O 
and O 
deficits O 
in O 
motor O 
coordination O 
were O 
ameliorated O 
significantly O 
by O 
SFN B-ABBREVIATION 
treatment O 
. O 
In O 
addition O 
, O 
SFN B-ABBREVIATION 
protected O 
6-OHDA B-SYSTEMATIC 
-induced O 
apoptosis O 
via O 
blocking O 
DNA O 
fragmentation O 
and O 
caspase-3 O 
activation O 
. O 
These O 
results O 
were O 
further O 
supported O 
by O 
immunohistochemical O 
findings O 
in O 
the O 
substantia O 
nigra O 
that O 
showed O 
that O 
SFN B-ABBREVIATION 
protected O 
neurons O 
from O 
neurotoxic O 
effects O 
of O 
6-OHDA B-SYSTEMATIC 
. O 
The O 
neuroprotective O 
effect O 
of O 
SFN B-ABBREVIATION 
may O 
be O 
attributed O 
to O 
its O 
ability O 
to O 
enhance O 
glutathione B-TRIVIAL 
levels O 
and O 
its O 
dependent O 
enzymes O 
( O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
and O 
glutathione B-TRIVIAL 
reductase O 
) O 
and O 
to O 
modulate O 
neuronal O 
survival O 
pathways O 
, O 
such O 
as O 
ERK1 O 
/ O 
2 O 
, O 
in O 
the O 
brain O 
of O 
mice O 
. O 
These O 
results O 
suggest O 
that O 
SFN B-ABBREVIATION 
may O 
potentially O 
be O 
effective O 
in O 
slowing O 
down O 
the O 
progression O 
of O 
idiopathic O 
PD O 
by O 
the O 
modulation O 
of O 
oxidative O 
stress O 
and O 
apoptotic O 
machinery O 
. O 

intraocular O 
pressure O 
( O 
IOP O 
) O 
is O 
a O 
major O 
risk O 
factor O 
for O 
glaucomatous O 
damage O 
and O 
reducing O 
IOP O 
improves O 
prognosis O 
. O 
Nevertheless O 
, O 
there O 
is O 
little O 
doubt O 
that O 
other O 
risk O 
factors O 
besides O 
IOP O 
such O 
as O 
unstable O 
ocular O 
perfusion O 
are O 
involved O 
. O 
Blood O 
flow O 
is O 
unstable O 
if O 
either O 
the O 
IOP O 
fluctuates O 
at O 
a O 
high O 
level O 
( O 
or O 
blood O 
pressure O 
fluctuates O 
at O 
a O 
low O 
level O 
) O 
or O 
if O 
the O 
autoregulation O 
of O 
blood O 
flow O 
disturbed O 
. O 
A O 
common O 
cause O 
for O 
a O 
disturbed O 
OBF O 
autoregulation O 
is O 
a O 
primary O 
vascular O 
dysregulation O 
( O 
PVD O 
) O 
frequently O 
observed O 
in O 
normal O 
tension O 
glaucoma O 
patients O 
. O 
An O 
unstable O 
blood O 
flow O 
leads O 
to O 
recurrent O 
mild O 
reperfusion O 
injury O 
( O 
chronic O 
oxidative O 
stress O 
) O 
affecting O 
particularly O 
the O 
mitochondria O 
of O 
the O 
optic O 
nerve O 
head O 
. O 
OBF O 
regulation O 
can O 
be O 
improved O 
by O 
magnesium B-SYSTEMATIC 
, O 
calcium B-SYSTEMATIC 
channel O 
blockers O 
as O 
well O 
as O 
with O 
carbonic O 
anhydrase O 
inhibitors O 
. O 

auriculatum O 
and O 
Cynanchum O 
wilfordii O 
are O 
widely O 
used O 
as O 
folk O 
medicine O 
in O 
Eastern O 
Asia O 
. O 
However O 
, O 
the O 
indeterminacy O 
in O 
the O 
authentic O 
original O 
plant O 
material O 
has O 
resulted O 
in O 
the O 
same O 
appellative O 
name O 
being O 
given O 
to O 
the O 
two O 
plants O 
, O 
and O 
they O 
are O 
commonly O 
misused O 
. O 
Therefore O 
, O 
it O 
is O 
necessary O 
to O 
establish O 
an O 
analytical O 
method O 
for O 
discrimination O 
as O 
well O 
as O 
quality O 
control O 
of O 
the O 
two O 
species O 
. O 
This O 
study O 
was O 
to O 
develop O 
HPLC-UV O 
methods O 
for O 
quality O 
assessment O 
of O 
C O 
. O 
auriculatum O 
and O 
C O 
. O 
wilfordii O 
and O 
discrimination O 
between O 
the O 
two O 
species O 
. O 
Two O 
HPLC O 
methods O 
to O 
analyze O 
eight O 
marker O 
compounds O 
were O 
established O 
and O 
validated O 
. O 
The O 
first O 
method O 
analyzed O 
seven O 
marker O 
compounds O 
simultaneously O 
on O 
a O 
reversed O 
- O 
phase O 
column O 
, O 
while O 
the O 
second O 
method O 
analyzed O 
a O 
single O 
marker O 
compound O 
, O 
conduritol B-TRIVIAL 
F I-TRIVIAL 
, O 
which O 
exists O 
only O 
in O 
C O 
. O 
wilfordii O 
, O 
on O 
a O 
Si B-FORMULA 
-column O 
. O 
Thirty O 
- O 
nine O 
batches O 
of O 
C O 
. O 
auriculatum O 
and O 
nineteen O 
batches O 
of O 
C O 
. O 
wilfordii O 
that O 
were O 
collected O 
from O 
different O 
geographical O 
regions O 
of O 
South O 
Korea O 
were O 
analyzed O 
by O 
these O 
methods O 
. O 
The O 
constructed O 
data O 
matrix O 
was O 
subjected O 
to O 
principal O 
components O 
analysis O 
and O 
hierarchical O 
cluster O 
analysis O 
in O 
order O 
to O 
classify O 
the O 
samples O 
. O 
The O 
established O 
methods O 
offer O 
a O 
potential O 
strategy O 
for O 
authentication O 
and O 
differentiation O 
of O 
the O 
two O 
species O 
. O 

1 O 
. O 
To O 
date O 
, O 
no O 
information O 
has O 
been O 
available O 
on O 
the O 
modulation O 
of O 
cytochrome O 
P450 O 
enzymes O 
( O 
CYPs O 
) O 
following O 
the O 
administration O 
of O 
a O 
hyperlipidemic O 
diet O 
in O 
pigs O 
. O 
2 O 
. O 
We O 
investigated O 
the O 
potential O 
modulation O 
of O 
xenobiotic O 
- O 
metabolizing O 
CYPs O 
in O 
liver O 
, O 
heart O 
and O 
duodenum O 
of O 
pigs O 
subjected O 
to O 
a O 
high O 
- O 
fat O 
/ O 
high- O 
cholesterol B-TRIVIAL 
diet O 
for O 
2 O 
months O 
continuously O 
( O 
C-HFD O 
) O 
or O 
on O 
alternate O 
weeks O 
( O 
A-HFD O 
) O 
. O 
3 O 
. O 
The O 
administration O 
of O 
the O 
high O 
- O 
fat O 
diet O 
resulted O 
in O 
considerably O 
increased O 
plasma O 
cholesterol B-TRIVIAL 
levels O 
although O 
the O 
animals O 
were O 
still O 
able O 
to O 
manage O 
the O 
lipid O 
overload O 
efficiently O 
, O 
and O 
no O 
sign O 
of O 
effective O 
tissue O 
inflammation O 
occurred O 
in O 
livers O 
. O 
Plasma O 
lipid O 
profile O 
and O 
liver O 
histology O 
indicated O 
a O 
better O 
adaptive O 
response O 
of O 
the O 
A-HFD O 
pigs O 
compared O 
to O 
the O 
C-HFD O 
group O 
. O 
We O 
showed O 
a O 
post O 
- O 
transcriptional O 
induction O 
of O 
hepatic O 
CYP2E1 O 
activity O 
in O 
C-HFD O 
pigs O 
and O 
a O 
transcriptional O 
induction O 
of O 
hepatic O 
CYP3As O 
- O 
especially O 
in O 
the O 
A-HFD O 
group O 
. O 
No O 
further O 
CYP O 
modulation O 
was O 
observed O 
in O 
either O 
liver O 
or O 
extra O 
- O 
hepatic O 
tissues O 
. O 
4 O 
. O 
In O 
conclusion O 
, O 
the O 
administration O 
of O 
a O 
high O 
- O 
fat O 
diet O 
in O 
pigs O 
resulted O 
in O 
limited O 
effects O 
on O 
the O 
drug O 
metabolism O 
system O 
. O 
The O 
better O 
adaptive O 
response O 
of O 
A-HFD O 
pigs O 
compared O 
to O 
C-HFD O 
pigs O 
is O 
a O 
very O 
interesting O 
observation O 
since O 
the O 
intermittent O 
administration O 
of O 
the O 
diet O 
reflects O 
the O 
mode O 
of O 
human O 
behavior O 
more O 
closely O 
. O 

- O 
flame O 
synthesis O 
: O 
a O 
general O 
strategy O 
to O 
decorate O 
nanowires O 
with O 
metal B-FAMILY 
oxide I-FAMILY 
/ O 
noble O 
metal O 
nanoparticles O 
. O 

hybrid O 
structure O 
of O 
nanoparticle O 
- O 
decorated O 
nanowires O 
( O 
NP@NW O 
) O 
combines O 
the O 
merits O 
of O 
large O 
specific O 
surface O 
areas O 
for O 
NPs O 
and O 
anisotropic O 
properties O 
for O 
NWs O 
and O 
is O 
a O 
desirable O 
structure O 
for O 
applications O 
including O 
batteries O 
, O 
dye O 
- O 
sensitized O 
solar O 
cells O 
, O 
photoelectrochemical O 
water O 
splitting O 
, O 
and O 
catalysis O 
. O 
Here O 
, O 
we O 
report O 
a O 
novel O 
sol O 
- O 
flame O 
method O 
to O 
synthesize O 
the O 
NP@NW O 
hybrid O 
structure O 
with O 
two O 
unique O 
characteristics O 
: O 
( O 
1 O 
) O 
large O 
loading O 
of O 
NPs O 
per O 
NW O 
with O 
the O 
morphology O 
of O 
NP O 
chains O 
fanning O 
radially O 
from O 
the O 
NW O 
core O 
and O 
( O 
2 O 
) O 
intimate O 
contact O 
between O 
NPs O 
and O 
NWs O 
. O 
Both O 
features O 
are O 
advantageous O 
for O 
the O 
above O 
applications O 
that O 
involve O 
both O 
surface O 
reactions O 
and O 
charge O 
transport O 
processes O 
. O 
Moreover O 
, O 
the O 
sol O 
- O 
flame O 
method O 
is O 
simple O 
and O 
general O 
, O 
with O 
which O 
we O 
have O 
successfully O 
decorated O 
various O 
NWs O 
with O 
binary O 
/ O 
ternary O 
metal B-FAMILY 
oxide I-FAMILY 
and O 
even O 
noble O 
metal O 
NPs O 
. O 
The O 
unique O 
aspects O 
of O 
the O 
sol O 
- O 
flame O 
method O 
arise O 
from O 
the O 
ultrafast O 
heating O 
rate O 
and O 
the O 
high O 
temperature O 
of O 
flame O 
, O 
which O 
enables O 
rapid O 
solvent O 
evaporation O 
and O 
combustion O 
, O 
and O 
the O 
combustion O 
gaseous O 
products O 
blow O 
out O 
NPs O 
as O 
they O 
nucleate O 
, O 
forming O 
the O 
NP O 
chains O 
around O 
NWs O 
. O 

profiles O 
, O 
antioxidant O 
, O 
acetylcholinesterase O 
inhibition O 
activities O 
of O 
extract O 
from O 
Dryoathyrium O 
boryanum O 
( O 
Willd O 
. O 
) O 
Ching O 
. O 

profiles O 
and O 
bioactivities O 
of O 
flavonoids B-FAMILY 
extracted O 
from O 
Dryoathyrium O 
boryanum O 
( O 
Willd O 
. O 
) O 
Ching O 
were O 
investigated O 
. O 
The O 
total O 
flavonoids B-FAMILY 
content O 
in O 
extract O 
from O 
D O 
. O 
boryanum O 
is O 
about O 
145.8mg O 
/ O 
g O 
. O 
By O 
means O 
of O 
HPLC-DAD-ESI-MS O 
, O 
the O 
main O 
flavonoids B-FAMILY 
in O 
D O 
. O 
boryanum O 
were O 
tentatively O 
identified O 
as O 
3-hydroxyphloretin B-SYSTEMATIC 
6'-O-hexoside I-SYSTEMATIC 
, O 
quercetin-7-hexoside B-SYSTEMATIC 
, O 
apigenin7-O-glucoside B-SYSTEMATIC 
, O 
luteolin B-SYSTEMATIC 
7-O-glucoside I-SYSTEMATIC 
, O 
apigenin B-SYSTEMATIC 
7-O-galactoside I-SYSTEMATIC 
, O 
acacetin B-SYSTEMATIC 
7-O-(α-D-apio-furanosyl) I-SYSTEMATIC 
(1→6)-β-d-glucoside I-SYSTEMATIC 
, O 
3-hydroxy B-SYSTEMATIC 
phloretin I-SYSTEMATIC 
6-O-hexoside I-SYSTEMATIC 
, O 
luteolin-6-C-glucoside B-SYSTEMATIC 
. O 
0.21mg O 
/ O 
ml O 
flavonoids B-FAMILY 
extract O 
from O 
D O 
. O 
boryanum O 
showed O 
very O 
strong O 
superoxide B-TRIVIAL 
anion O 
radical O 
scavenging O 
potential O 
, O 
which O 
is O 
higher O 
than O 
that O 
of O 
rutin B-TRIVIAL 
( O 
0.25mg O 
/ O 
ml O 
) O 
. O 
The O 
extract O 
( O 
0.21mg O 
/ O 
ml O 
of O 
flavonoids B-FAMILY 
) O 
from O 
D O 
. O 
boryanum O 
exhibited O 
similar O 
DPPH B-ABBREVIATION 
scavenging O 
potential O 
with O 
that O 
of O 
rutin B-TRIVIAL 
( O 
0.25mg O 
/ O 
ml O 
) O 
. O 
However O 
, O 
rutin B-TRIVIAL 
( O 
0.25mg O 
/ O 
ml O 
) O 
showed O 
a O 
significantly O 
higher O 
reducing O 
power O 
and O 
ABTS B-ABBREVIATION 
scavenging O 
potential O 
than O 
that O 
of O 
0.21mg O 
/ O 
ml O 
flavonoids B-FAMILY 
extract O 
from O 
D O 
. O 
boryanum O 
. O 
It O 
had O 
no O 
effect O 
on O 
acetylcholinesterase O 
. O 
D O 
. O 
boryanum O 
can O 
be O 
considered O 
as O 
a O 
medicinal O 
plant O 
and O 
the O 
flavonoids B-FAMILY 
from O 
D O 
. O 
boryanum O 
are O 
excellent O 
antioxidants O 
. O 

oxidase O 
importance O 
in O 
vivo O 
in O 
xenobiotic O 
metabolism O 
: O 
imidacloprid B-TRIVIAL 
nitroreduction O 
in O 
mice O 
. O 

oxidase O 
( O 
AOX O 
) O 
metabolizes O 
many O 
xenobiotics O 
in O 
vitro O 
, O 
but O 
its O 
importance O 
in O 
vivo O 
is O 
usually O 
unknown O 
relative O 
to O 
cytochrome O 
P450s O 
( O 
CYPs O 
) O 
and O 
other O 
detoxification O 
systems O 
. O 
Currently O 
, O 
the O 
most O 
important O 
insecticides O 
are O 
neonicotinoids B-FAMILY 
, O 
which O 
are O 
metabolized O 
in O 
vitro O 
by O 
AOX O 
on O 
reduction O 
of O 
the O 
nitroimino B-SYSTEMATIC 
group O 
and O 
by O 
CYPs O 
via O 
oxidation O 
reactions O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
establish O 
the O 
relative O 
importance O 
of O 
AOX O 
and O 
CYPs O 
in O 
vivo O 
using O 
the O 
mouse O 
model O 
. O 
The O 
procedure O 
was O 
to O 
reduce O 
liver O 
AOX O 
activity O 
by O 
providing O 
tungsten B-SYSTEMATIC 
or O 
hydralazine B-SYSTEMATIC 
in O 
the O 
drinking O 
water O 
or O 
to O 
use O 
the O 
AOX-deficient O 
DBA O 
/ O 
2 O 
mouse O 
strain O 
. O 
None O 
of O 
these O 
approaches O 
reduced O 
CYP O 
activity O 
measured O 
in O 
vitro O 
with O 
an O 
isozyme O 
nonspecific O 
substrate O 
. O 
Liver O 
AOX O 
activity O 
was O 
reduced O 
by O 
45% O 
with O 
tungsten B-SYSTEMATIC 
and O 
61% O 
with O 
hydralazine B-SYSTEMATIC 
and O 
81% O 
in O 
AOX-deficient O 
mice O 
relative O 
to O 
controls O 
. O 
When O 
mice O 
were O 
treated O 
ip O 
with O 
the O 
major O 
neonicotinoid O 
imidacloprid B-TRIVIAL 
( O 
IMI B-ABBREVIATION 
) O 
, O 
metabolism O 
by O 
CYP O 
oxidation O 
reactions O 
was O 
not O 
appreciably O 
affected O 
, O 
whereas O 
the O 
AOX-generated O 
nitrosoguanidine B-SYSTEMATIC 
metabolite O 
was O 
decreased O 
by O 
30% O 
with O 
tungsten B-SYSTEMATIC 
and O 
56% O 
with O 
hydralazine B-SYSTEMATIC 
and O 
86% O 
in O 
the O 
AOX-deficient O 
mice O 
. O 
The O 
other O 
IMI B-ABBREVIATION 
nitroreduction O 
metabolite O 
, O 
desnitro- O 
IMI B-ABBREVIATION 
, O 
was O 
decreased O 
by O 
55% O 
, O 
65% O 
, O 
and O 
81% O 
with O 
tungsten B-SYSTEMATIC 
, O 
hydralazine B-SYSTEMATIC 
, O 
and O 
in O 
the O 
AOX-deficient O 
mice O 
, O 
respectively O 
. O 
Thus O 
, O 
decreasing O 
liver O 
AOX O 
activity O 
by O 
three O 
quite O 
different O 
procedures O 
gave O 
a O 
corresponding O 
decrease O 
for O 
in O 
vivo O 
reductive O 
metabolites O 
in O 
the O 
liver O 
of O 
IMI B-ABBREVIATION 
-treated O 
mice O 
. O 
Possible O 
AOX O 
involvement O 
in O 
IMI B-ABBREVIATION 
metabolism O 
in O 
insects O 
was O 
evaluated O 
using O 
AOX-expressing O 
and O 
AOX-deficient O 
Drosophila O 
, O 
but O 
no O 
differences O 
were O 
found O 
in O 
IMI B-ABBREVIATION 
nitroreduction O 
or O 
sensitivity O 
between O 
the O 
two O 
strains O 
. O 
This O 
is O 
the O 
first O 
study O 
to O 
establish O 
the O 
in O 
vivo O 
relevance O 
of O 
AOX O 
in O 
neonicotinoid B-FAMILY 
metabolism O 
in O 
mammals O 
and O 
one O 
of O 
the O 
first O 
for O 
xenobiotics O 
in O 
general O 
. O 

hypertrophic O 
cardiomyopathy O 
( O 
FHC O 
) O 
is O 
a O 
major O 
cause O 
of O 
sudden O 
cardiac O 
death O 
in O 
young O 
athletes O 
. O 
The O 
discovery O 
in O 
1990 O 
that O 
a O 
point O 
mutation O 
at O 
residue O 
403 O 
( O 
R403Q O 
) O 
in O 
the O 
β-myosin O 
heavy O 
chain O 
( O 
MHC O 
) O 
caused O 
a O 
severe O 
form O 
of O 
FHC O 
was O 
the O 
first O 
of O 
many O 
demonstrations O 
linking O 
FHC O 
to O 
mutations O 
in O 
muscle O 
proteins O 
. O 
A O 
mouse O 
model O 
for O 
FHC O 
has O 
been O 
widely O 
used O 
to O 
study O 
the O 
mechanochemical O 
properties O 
of O 
mutated O 
cardiac O 
myosin O 
, O 
but O 
mouse O 
hearts O 
express O 
α-MHC O 
, O 
whereas O 
the O 
ventricles O 
of O 
larger O 
mammals O 
express O 
predominantly O 
β-MHC O 
. O 
To O 
address O 
the O 
role O 
of O 
the O 
isoform O 
backbone O 
on O 
function O 
, O 
we O 
generated O 
a O 
transgenic O 
mouse O 
in O 
which O 
the O 
endogenous O 
α-MHC O 
was O 
partially O 
replaced O 
with O 
transgenically O 
encoded O 
β-MHC O 
or O 
α-MHC O 
. O 
A O 
His B-FORMULA 
-tag O 
was O 
cloned O 
at O 
the O 
N B-FORMULA 
-terminus O 
, O 
along O 
with O 
R403Q O 
, O 
to O 
facilitate O 
isolation O 
of O 
myosin O 
subfragment-1 O 
( O 
S1 O 
) O 
. O 
Stopped O 
- O 
flow O 
kinetics O 
were O 
used O 
to O 
measure O 
the O 
equilibrium O 
constants O 
and O 
rates O 
of O 
nucleotide B-FAMILY 
binding O 
and O 
release O 
for O 
the O 
mouse O 
S1 O 
isoforms O 
bound O 
to O 
actin O 
. O 
For O 
the O 
wildtype O 
isoforms O 
, O 
we O 
found O 
that O 
the O 
affinity O 
of O 
MgADP B-FORMULA 
for O 
α-S1 O 
( O 
100 O 
μM O 
) O 
is O 
~ O 
4-fold O 
weaker O 
than O 
for O 
β-S1 O 
( O 
25 O 
μM O 
) O 
. O 
Correspondingly O 
, O 
the O 
MgADP B-FORMULA 
release O 
rate O 
for O 
α-S1 O 
( O 
350 O 
s-1 O 
) O 
is O 
~ O 
3-fold O 
greater O 
than O 
for O 
β-S1 O 
( O 
120 O 
s-1 O 
) O 
. O 
Introducing O 
the O 
R403Q O 
mutation O 
caused O 
only O 
a O 
minor O 
reduction O 
in O 
kinetics O 
for O 
β-S1 O 
, O 
but O 
R403Q O 
in O 
α-S1 O 
caused O 
the O 
ADP B-ABBREVIATION 
release O 
rate O 
to O 
increase O 
by O 
20% O 
( O 
430 O 
s-1 O 
) O 
. O 
These O 
transient O 
kinetic O 
studies O 
on O 
mouse O 
cardiac O 
myosins O 
provide O 
strong O 
evidence O 
that O 
the O 
functional O 
impact O 
of O 
an O 
FHC O 
mutation O 
on O 
myosin O 
depends O 
on O 
the O 
isoform O 
backbone O 
. O 

glycol)-block-poly(ε-caprolactone I-FAMILY 
) I-FAMILY 
micelles O 
for O 
combination O 
drug O 
delivery O 
: O 
evaluation O 
of O 
paclitaxel B-TRIVIAL 
, O 
cyclopamine B-TRIVIAL 
and O 
gossypol B-TRIVIAL 
in O 
intraperitoneal O 
xenograft O 
models O 
of O 
ovarian O 
cancer O 
. O 

cancer O 
is O 
the O 
most O 
lethal O 
gynecological O 
malignancy O 
, O 
characterized O 
by O 
a O 
high O 
rate O 
of O 
chemoresistance O 
. O 
Current O 
treatment O 
strategies O 
for O 
ovarian O 
cancer O 
focus O 
on O 
novel O 
drug O 
combinations O 
of O 
cytotoxic O 
agents O 
and O 
molecular O 
targeted O 
agents O 
or O 
novel O 
drug O 
delivery O 
strategies O 
that O 
often O 
involve O 
intraperitoneal O 
( O 
IP O 
) O 
injection O 
. O 
Poly(ethylene B-FAMILY 
glycol)-block-poly(ε-caprolactone I-FAMILY 
) I-FAMILY 
( O 
PEG-b-PCL B-ABBREVIATION 
) O 
micelles O 
were O 
loaded O 
with O 
paclitaxel B-TRIVIAL 
( O 
cytotoxic O 
agent O 
) O 
, O 
cyclopamine B-TRIVIAL 
( O 
hedgehog O 
inhibitor O 
) O 
, O 
and O 
gossypol B-TRIVIAL 
( O 
Bcl-2 O 
inhibitor O 
) O 
. O 
After O 
physicochemical O 
studies O 
focusing O 
on O 
combination O 
drug O 
solubilization O 
, O 
3-drug O 
PEG-b-PCL B-ABBREVIATION 
micelles O 
were O 
evaluated O 
in O 
vitro O 
in O 
2-D O 
and O 
3-D O 
cell O 
culture O 
and O 
in O 
vivo O 
in O 
xenograft O 
models O 
of O 
ovarian O 
cancer O 
, O 
tracking O 
bioluminescence O 
signals O 
from O 
ES-2 O 
and O 
SKOV3 O 
human O 
ovarian O 
cancer O 
cell O 
lines O 
after O 
IP O 
injection O 
. O 
3-Drug O 
PEG-b-PCL B-ABBREVIATION 
micelles O 
were O 
not O 
significantly O 
more O 
potent O 
in O 
2-D O 
cell O 
culture O 
in O 
comparison O 
to O 
paclitaxel B-TRIVIAL 
; O 
however O 
, O 
they O 
disaggregated O 
ES-2 O 
tumor O 
spheroids O 
, O 
whereas O 
single O 
drugs O 
or O 
2-drug O 
combinations O 
only O 
slowed O 
growth O 
of O 
ES-2 O 
tumor O 
spheroids O 
or O 
had O 
no O 
noticeable O 
effects O 
. O 
In O 
ES-2 O 
and O 
SKOV3 O 
xenograft O 
models O 
, O 
3-drug O 
PEG-b-PCL B-ABBREVIATION 
micelles O 
had O 
significantly O 
less O 
tumor O 
burden O 
than O 
paclitaxel B-TRIVIAL 
based O 
on O 
bioluminescence O 
imaging O 
, O 
3'-deoxy-3'-(18)F-fluorothymidine B-SYSTEMATIC 
( O 
(18)F-FLT B-SYSTEMATIC 
) O 
PET O 
imaging O 
, O 
and O 
overall O 
survival O 
. O 
(18)F-FLT B-SYSTEMATIC 
-PET O 
images O 
clearly O 
showed O 
that O 
3-drug O 
PEG-b-PCL B-ABBREVIATION 
micelles O 
dramatically O 
reduce O 
tumor O 
volumes O 
over O 
paclitaxel B-TRIVIAL 
and O 
vehicle O 
controls O 
. O 
In O 
summary O 
, O 
PEG-b-PCL B-ABBREVIATION 
micelles O 
enable O 
the O 
IP O 
combination O 
drug O 
delivery O 
of O 
paclitaxel B-TRIVIAL 
, O 
cyclopamine B-TRIVIAL 
and O 
gossypol B-TRIVIAL 
, O 
resulting O 
in O 
tumor O 
growth O 
inhibition O 
and O 
prolonged O 
survival O 
over O 
paclitaxel B-TRIVIAL 
alone O 
. O 
These O 
results O 
validate O 
a O 
novel O 
treatment O 
strategy O 
for O 
ovarian O 
cancer O 
based O 
on O 
drug O 
combinations O 
of O 
cytotoxic O 
agents O 
and O 
molecular O 
targeted O 
agents O 
, O 
delivered O 
concurrently O 
by O 
a O 
nanoscale O 
drug O 
delivery O 
system O 
, O 
e.g O 
. O 
PEG-b-PCL B-ABBREVIATION 
micelles O 
. O 

study O 
of O 
a O 
patch O 
containing O 
propranolol B-TRIVIAL 
by O 
design O 
of O 
experiments O 
. O 

Objective O 
: O 
To O 
evaluate O 
the O 
feasibility O 
of O 
a O 
transdermal O 
patch O 
containing O 
propranolol B-TRIVIAL 
( O 
PR O 
) O 
. O 
Method O 
: O 
Skin O 
penetration O 
enhancers O 
( O 
SPEs O 
) O 
able O 
to O 
improve O 
the O 
skin O 
permeability O 
of O 
PR O 
were O 
selected O 
and O 
a O 
quality O 
by O 
design O 
approach O 
was O 
applied O 
to O 
the O 
development O 
of O 
the O 
patch O 
by O 
a O 
2(4) O 
full O 
factorial O 
design O 
. O 
The O 
permeation O 
profile O 
of O 
PR O 
from O 
the O 
formulations O 
was O 
assessed O 
in O 
in O 
vitro O 
permeation O 
studies O 
performed O 
by O 
using O 
Franz O 
diffusion O 
cells O 
and O 
human O 
epidermis O 
as O 
membrane O 
. O 
Finally O 
, O 
skin O 
irritation O 
was O 
evaluated O 
by O 
the O 
Draize O 
test O 
. O 
Results O 
: O 
N-methyl B-SYSTEMATIC 
pyrrolidone I-SYSTEMATIC 
( O 
NMP B-ABBREVIATION 
) O 
resulted O 
as O 
the O 
best O 
SPE O 
: O 
in O 
addition O 
, O 
the O 
critical O 
factors O 
influencing O 
the O 
PR O 
diffusion O 
through O 
the O 
human O 
epidermis O 
when O 
loaded O 
in O 
the O 
patch O 
resulted O 
in O 
the O 
matrix O 
thickness O 
( O 
X(1) O 
, O 
p O 
= O 
0.0957 O 
) O 
and O 
PR O 
content O 
( O 
X(3) O 
, O 
p O 
= O 
0.0004 O 
) O 
which O 
improved O 
the O 
flux O 
; O 
conversely O 
, O 
NMP B-ABBREVIATION 
lacked O 
its O 
enhancement O 
effect O 
when O 
loaded O 
in O 
the O 
patch O 
and O 
the O 
increase O 
in O 
its O 
concentration O 
( O 
X(4) O 
, O 
p O 
= O 
0.006 O 
) O 
affected O 
the O 
drug O 
permeation O 
through O 
human O 
epidermis O 
. O 
The O 
flux O 
of O 
optimal O 
formulation O 
was O 
12.7 O 
μg O 
/ O 
cm(2) O 
/ O 
h O 
. O 
On O 
the O 
basis O 
of O 
the O 
steady O 
- O 
state O 
concentration O 
and O 
clearance O 
of O 
PR O 
, O 
the O 
estimated O 
patch O 
surface O 
was O 
100-120 O 
cm(2) O 
, O 
since O 
the O 
activity O 
of O 
PR O 
is O 
related O 
to O 
its O 
Senantiomer O 
and O 
no O 
in O 
vivo O 
bioconversion O 
occurs O 
. O 
Conclusion O 
: O 
A O 
patch O 
containing O 
(S)-PR B-ABBREVIATION 
was O 
prepared O 
and O 
the O 
(S)-PR B-ABBREVIATION 
flux O 
( O 
13.3 O 
μg O 
/ O 
cm(2) O 
/ O 
h O 
) O 
permitted O 
to O 
confirm O 
the O 
suitability O 
of O 
a O 
transdermal O 
administration O 
of O 
PR O 
. O 
In O 
particular O 
, O 
the O 
use O 
of O 
a O 
50 O 
μm O 
thick O 
methacrylic B-TRIVIAL 
matrix O 
containing O 
8% O 
(S)-PR B-ABBREVIATION 
and O 
15% O 
NMP B-ABBREVIATION 
can O 
allow O 
to O 
develop O 
a O 
patch O 
non-irritating O 
to O 
the O 
skin O 
, O 
in O 
order O 
to O 
ensure O 
a O 
constant O 
permeation O 
flux O 
of O 
PR O 
over O 
48 O 
h O 
. O 

new O 
sesquiterpenoids B-FAMILY 
from O 
the O 
rhizomes O 
of O 
Nardostachys O 
jatamansi O 
. O 

investigation O 
of O 
CHCl(3) B-FORMULA 
: O 
MeOH B-FORMULA 
( O 
1 O 
: O 
1 O 
) O 
extract O 
from O 
the O 
rhizomes O 
of O 
Nardostachys O 
jatamansi O 
led O 
to O 
the O 
isolation O 
of O 
two O 
new O 
sesquiterpenoids B-FAMILY 
( O 
5 O 
and O 
6 O 
) O 
, O 
along O 
with O 
six O 
known O 
compounds O 
( O 
1-4 O 
, O 
7 O 
, O 
and O 
8 O 
) O 
. O 
The O 
structures O 
of O 
two O 
new O 
compounds O 
were O 
established O 
using O 
IR O 
, O 
MS O 
, O 
1D O 
, O 
and O 
2D O 
NMR O 
techniques O 
. O 
In O 
addition O 
, O 
all O 
the O 
isolates O 
were O 
tested O 
for O 
their O 
cytotoxicities O 
against O 
the O 
A549 O 
( O 
lung O 
cancer O 
) O 
, O 
DU-145 O 
( O 
prostate O 
cancer O 
) O 
, O 
MCF-7 O 
( O 
breast O 
cancer O 
) O 
, O 
and O 
SK-N-SH O 
( O 
neuroblastoma O 
) O 
. O 

of O 
adulteration O 
in O 
honey O 
samples O 
added O 
various O 
sugar B-FAMILY 
syrups O 
with O 
13C B-FORMULA 
/ O 
12C B-FORMULA 
isotope O 
ratio O 
analysis O 
method O 
. O 

can O 
be O 
adulterated O 
in O 
various O 
ways O 
. O 
One O 
of O 
the O 
adulteration O 
methods O 
is O 
the O 
addition O 
of O 
different O 
sugar B-FAMILY 
syrups O 
during O 
or O 
after O 
honey O 
production O 
. O 
Starch O 
- O 
based O 
sugar B-FAMILY 
syrups O 
, O 
high O 
fructose B-TRIVIAL 
corn O 
syrup O 
( O 
HFCS O 
) O 
, O 
glucose B-TRIVIAL 
syrup O 
( O 
GS O 
) O 
and O 
saccharose B-TRIVIAL 
syrups O 
( O 
SS O 
) O 
, O 
which O 
are O 
produced O 
from O 
beet O 
or O 
canes O 
, O 
can O 
be O 
used O 
for O 
adulterating O 
honey O 
. O 
In O 
this O 
study O 
, O 
adulterated O 
honey O 
samples O 
were O 
prepared O 
with O 
the O 
addition O 
of O 
HFCS O 
, O 
GS O 
and O 
SS O 
( O 
beet O 
sugar B-FAMILY 
) O 
at O 
a O 
ratio O 
of O 
0% O 
, O 
10% O 
, O 
20% O 
, O 
40% O 
and O 
50% O 
by O 
weight O 
. O 
(13)C B-FORMULA 
/ O 
(12)C B-FORMULA 
analysis O 
was O 
conducted O 
on O 
these O 
adulterated O 
honey O 
samples O 
using O 
an O 
isotope O 
ratio O 
mass O 
spectrometer O 
in O 
combination O 
with O 
an O 
elemental O 
analyser O 
( O 
EA-IRMS O 
) O 
. O 
As O 
a O 
result O 
, O 
adulteration O 
using O 
C(4) O 
sugar B-FAMILY 
syrups O 
( O 
HFCS O 
and O 
GS O 
) O 
could O 
be O 
detected O 
to O 
a O 
certain O 
extent O 
while O 
adulteration O 
of O 
honey O 
using O 
C(3) O 
sugar B-FAMILY 
syrups O 
( O 
beet O 
sugar B-FAMILY 
) O 
could O 
not O 
be O 
detected O 
. O 
Adulteration O 
by O 
using O 
SS O 
( O 
beet O 
sugar B-FAMILY 
) O 
still O 
has O 
a O 
serious O 
detection O 
problem O 
, O 
especially O 
in O 
countries O 
in O 
which O 
beet O 
is O 
used O 
in O 
manufacturing O 
sugar B-FAMILY 
. O 
For O 
this O 
reason O 
, O 
practice O 
and O 
analysis O 
methods O 
are O 
needed O 
to O 
meet O 
this O 
deficit O 
and O 
to O 
detect O 
the O 
adulterations O 
precisely O 
in O 
the O 
studies O 
that O 
will O 
be O 
conducted O 
. O 

are O 
estimated O 
to O 
be O 
more O 
than O 
20000 O 
species O 
of O 
plants O 
in O 
Venezuela O 
, O 
of O 
which O 
more O 
than O 
1500 O 
are O 
used O 
for O 
medicinal O 
purposes O 
by O 
indigenous O 
and O 
local O 
communities O 
. O 
Only O 
a O 
relatively O 
small O 
proportion O 
of O 
these O 
have O 
been O 
evaluated O 
in O 
terms O 
of O 
their O 
potential O 
as O 
antitumor O 
agents O 
. O 
In O 
this O 
study O 
, O 
we O 
screened O 
308 O 
extracts O 
from O 
102 O 
species O 
for O 
cytostatic O 
and O 
cytotoxic O 
activity O 
against O 
a O 
panel O 
of O 
six O 
tumor O 
cell O 
lines O 
using O 
a O 
24-h O 
sulphorhodamine B-TRIVIAL 
B I-TRIVIAL 
assay O 
. O 
Extracts O 
from O 
Clavija O 
lancifolia O 
, O 
Hamelia O 
patens O 
, O 
Piper O 
san O 
- O 
vicentense O 
, O 
Physalis O 
cordata O 
, O 
Jacaranda O 
copaia O 
, O 
Heliotropium O 
indicum O 
, O 
and O 
Annona O 
squamosa O 
were O 
the O 
most O 
cytotoxic O 
, O 
whereas O 
other O 
extracts O 
from O 
Calotropis O 
gigantea O 
, O 
Hyptis O 
dilatata O 
, O 
Chromolaena O 
odorata O 
, O 
Siparuna O 
guianensis O 
, O 
Jacaranda O 
obtusifolia O 
, O 
Tapirira O 
guianensis O 
, O 
Xylopia O 
aromatica O 
, O 
Protium O 
heptaphyllum O 
, O 
and O 
Piper O 
arboreum O 
showed O 
the O 
greatest O 
cytostatic O 
activity O 
. O 
These O 
results O 
confirm O 
previous O 
reports O 
on O 
the O 
cytotoxic O 
activities O 
of O 
the O 
abovementioned O 
plants O 
as O 
well O 
as O 
prompting O 
further O 
studies O 
on O 
others O 
such O 
as O 
C O 
. O 
lancifolia O 
and O 
H O 
. O 
dilatata O 
that O 
have O 
not O 
been O 
so O 
extensively O 
studied O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

the O 
binding O 
mechanism O 
of O 
Alzheimer's O 
Aβ₁-₄₂ O 
to O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
based O 
on O 
similarity O 
with O 
snake O 
α-neurotoxins O 
. O 

over O 
a O 
decade O 
, O 
it O 
has O 
been O 
known O 
that O 
amyloid O 
β O 
( O 
Aβ O 
) O 
peptides O 
of O 
Alzheimer's O 
disease O 
bind O 
to O 
the O 
nicotinic O 
α7 O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
AChR O 
) O 
with O 
picomolar O 
affinity O 
, O 
and O 
that O 
snake O 
α-neurotoxins O 
competitively O 
inhibit O 
this O 
binding O 
. O 
Here O 
we O 
propose O 
a O 
model O 
of O 
the O 
binding O 
mechanism O 
of O 
Aβ O 
peptides O 
to O 
α7-AChR O 
at O 
atomic O 
level O 
. O 
The O 
binding O 
mechanism O 
is O 
based O 
on O 
sequence O 
and O 
structure O 
similarities O 
of O 
Aβ O 
residues O 
with O 
functional O 
residues O 
of O 
snake O 
α-neurotoxins O 
( O 
ATX O 
) O 
in O 
complex O 
with O 
AChR O 
. O 
The O 
binding O 
mechanism O 
involves O 
residue O 
(Aβ)K28 O 
( O 
similar O 
to O 
(ATX)R32 O 
) O 
which O 
forms O 
cation O 
/ O 
π O 
interactions O 
in O 
the O 
acetylcholine B-SYSTEMATIC 
binding O 
site O 
, O 
and O 
residues O 
(Aβ)G29-(Aβ)I32 O 
[ O 
GAII O 
] O 
( O 
similar O 
to O 
(ATX)G33-(ATX)I36 O 
[ O 
GTII O 
] O 
) O 
which O 
form O 
an O 
intermolecular O 
β-sheet O 
with O 
residues O 
(α7)F189-(α7)E191 O 
of O 
AChR O 
. O 
Through O 
these O 
interactions O 
, O 
we O 
propose O 
that O 
the O 
AChR O 
serves O 
as O 
a O 
chaperone O 
for O 
Aβ O 
conformational O 
changes O 
from O 
α- O 
to O 
β-hairpin O 
. O 
The O 
interactions O 
which O 
block O 
channel O 
opening O 
provide O 
fundamental O 
insight O 
into O 
Aβ O 
neurotoxicity O 
and O 
cognition O 
impairment O 
, O 
that O 
could O 
contribute O 
to O 
pathogenic O 
processes O 
in O 
Alzheimer's O 
disease O 
, O 
thus O 
paving O 
the O 
way O 
for O 
structure O 
based O 
therapies O 
. O 

1 O 
. O 
Prediction O 
of O 
biliary O 
excretion O 
is O 
a O 
challenge O 
due O 
to O 
the O 
lack O 
of O 
in O 
vitro O 
assays O 
. O 
Our O 
laboratory O 
previously O 
demonstrated O 
a O 
highly O 
significant O 
correlation O 
between O 
in O 
vitro O 
IC(50) O 
values O 
against O 
mrp2 O 
using O 
rat O 
canalicular O 
liver O 
plasma O 
membrane O 
vesicles O 
and O 
in O 
vivo O 
biliary O 
excretion O 
( O 
Colombo O 
et O 
al O 
. O 
, O 
2012 O 
) O 
. O 
This O 
study O 
explores O 
the O 
possibility O 
of O 
predicting O 
in O 
vivo O 
biliary O 
excretion O 
in O 
human O 
using O 
membrane O 
vesicles O 
prepared O 
from O 
MDCKII O 
cells O 
transfected O 
with O 
human O 
ABCC2 O 
. O 
2 O 
. O 
In O 
vitro O 
MRP2 O 
activity O 
was O 
determined O 
by O 
measuring O 
the O 
ATP B-ABBREVIATION 
-dependent O 
uptake O 
of O 
5(6)-carboxy-2',7'-dichlorofluorescein B-SYSTEMATIC 
( O 
CDCF B-ABBREVIATION 
) O 
in O 
inside-out O 
membrane O 
vesicles O 
isolated O 
from O 
MDCK-ABCC2 O 
cells O 
. O 
CDCF B-ABBREVIATION 
uptake O 
was O 
time- O 
and O 
concentration O 
- O 
dependent O 
( O 
K(m) O 
of O 
4 O 
± O 
1.2 O 
µM O 
and O 
a O 
V(max) O 
of O 
7.8 O 
± O 
0.9 O 
pmol O 
/ O 
mg O 
/ O 
min O 
) O 
and O 
inhibited O 
by O 
benzbromarone B-TRIVIAL 
and O 
MK-571 B-IDENTIFIER 
with O 
IC(50) O 
values O 
of O 
1.2 O 
and O 
7.6 O 
µM O 
, O 
respectively O 
. O 
3 O 
. O 
A O 
significant O 
linear O 
correlation O 
( O 
r(2 O 
)= O 
0.79 O 
) O 
between O 
the O 
in O 
vitro O 
IC(50) O 
values O 
from O 
the O 
described O 
MRP2 O 
assay O 
and O 
in O 
vivo O 
biliary O 
excretion O 
in O 
humans O 
was O 
observed O 
using O 
11 O 
well O 
- O 
documented O 
drugs O 
covering O 
low O 
to O 
high O 
biliary O 
excretions O 
. O 
4 O 
. O 
This O 
study O 
demonstrates O 
, O 
for O 
the O 
first O 
time O 
, O 
that O 
inhibition O 
of O 
CDCF B-ABBREVIATION 
uptake O 
in O 
MDCKII-ABCC2 O 
vesicles O 
not O 
only O 
provides O 
a O 
screening O 
assay O 
to O 
assess O 
MRP2 O 
drug O 
- O 
drug O 
interaction O 
potential O 
, O 
but O 
is O 
also O 
predictive O 
of O 
human O 
MRP2 O 
- O 
mediated O 
biliary O 
excretion O 
. O 

increasing O 
prevalence O 
of O 
drug O 
- O 
resistant O 
tuberculosis O 
, O 
which O 
is O 
resistant O 
to O 
effective O 
multiple O 
antibiotic O 
, O 
presents O 
a O 
major O 
global O 
health O 
threat O 
. O 
The O 
thymidine B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
kinase O 
( O 
TMPK O 
) O 
of O 
Mycobacterium O 
tuberculosis O 
( O 
M. O 
tuberculosis O 
) O 
, O 
which O 
is O 
an O 
essential O 
enzyme O 
for O 
the O 
maintenance O 
of O 
the O 
thymidine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
pools O 
, O 
is O 
considered O 
an O 
attractive O 
target O 
for O 
the O 
development O 
of O 
effective O 
antibiotics O 
against O 
tuberculosis O 
. O 
In O 
this O 
study O 
, O 
we O 
attempted O 
to O 
identify O 
novel O 
chemical O 
compounds O 
that O 
specifically O 
target O 
the O 
M. O 
tuberculosis O 
TMPK O 
( O 
mtTMPK O 
) O 
. O 
We O 
performed O 
in O 
silico O 
structure O 
- O 
based O 
drug O 
screening O 
using O 
the O 
crystal O 
structure O 
data O 
of O 
mtTMPK O 
and O 
a O 
large O 
- O 
scale O 
virtual O 
compound O 
library O 
, O 
which O 
is O 
composed O 
of O 
6192930 O 
chemicals O 
. O 
Through O 
a O 
three O 
- O 
step O 
screening O 
method O 
using O 
the O 
DOCK O 
and O 
GOLD O 
, O 
we O 
identified O 
ten O 
chemical O 
compounds O 
that O 
were O 
predicted O 
to O 
have O 
high O 
binding O 
affinity O 
to O 
the O 
active O 
site O 
cleft O 
of O 
the O 
mtTMPK O 
. O 
We O 
then O 
evaluated O 
the O 
antibiotic O 
effects O 
of O 
these O 
chemical O 
compounds O 
on O 
model O 
mycobacteria O 
strains O 
. O 
As O 
a O 
result O 
, O 
we O 
found O 
that O 
a O 
chemical O 
compound O 
, O 
K10 O 
, O 
completely O 
inhibited O 
the O 
growth O 
of O 
Mycobacterium O 
vanbaalenii O 
( O 
M. O 
vanbaalenii O 
) O 
and O 
Mycobacterium O 
smegmatis O 
( O 
M. O 
smegmatis O 
) O 
. O 
Moreover O 
, O 
K10 O 
does O 
not O 
exhibit O 
any O 
toxic O 
effects O 
on O 
the O 
growth O 
of O 
enterobacteria O 
and O 
mammalian O 
cells O 
. O 
The O 
structural O 
and O 
experimental O 
information O 
regarding O 
this O 
novel O 
chemical O 
compound O 
, O 
K10 O 
, O 
is O 
likely O 
to O 
be O 
useful O 
for O 
the O 
hit O 
- O 
to O 
- O 
lead O 
optimization O 
of O 
new O 
antibiotics O 
for O 
the O 
treatment O 
of O 
tuberculosis O 
. O 

anhydrase O 
( O 
CA O 
) O 
is O 
a O 
widely O 
distributed O 
enzyme O 
and O 
has O 
a O 
crucial O 
role O 
in O 
the O 
cells O 
, O 
tissues O 
and O 
organs O 
of O 
living O 
organisms O 
. O 
It O 
is O 
found O 
that O 
CA-II O 
is O 
one O 
of O 
the O 
most O 
abundant O 
CA O 
isoenzymes O 
in O 
the O 
gastrointestinal O 
system O 
. O 
It O 
plays O 
an O 
important O 
role O 
in O 
the O 
gastric O 
acid O 
secretion O 
in O 
stomach O 
. O 
In O 
this O 
study O 
, O 
we O 
purified O 
CA-II O 
isoenzyme O 
from O 
sheep O 
stomach O 
with O 
a O 
615.2 O 
purification O 
fold O 
, O 
78% O 
purification O 
yield O 
and O 
5562.02 O 
specific O 
activity O 
. O 
Moreover O 
, O 
the O 
in O 
vitro O 
effects O 
of O 
some O 
commonly O 
used O 
pesticides O 
including O 
chlorpyrifos B-TRIVIAL 
, O 
cypermethrin B-TRIVIAL 
, O 
dichlorvos B-TRIVIAL 
, O 
glyphosate B-SYSTEMATIC 
isopropylamine I-SYSTEMATIC 
and O 
lambda B-FAMILY 
cyhalomethrin I-FAMILY 
on O 
the O 
enzyme O 
activity O 
were O 
investigated O 
. O 
Of O 
these O 
compounds O 
, O 
glyphosate B-SYSTEMATIC 
isopropylamine I-SYSTEMATIC 
and O 
dichlorvos B-TRIVIAL 
showed O 
an O 
inhibition O 
on O 
CA-II O 
esterase O 
activity O 
. O 
They O 
have O 
IC(50) O 
values O 
of O 
0.155 O 
µM O 
and O 
2.69 O 
µM O 
and O 
K O 
(i) O 
values O 
of O 
0.329 O 
µM O 
and O 
3.654 O 
µM O 
, O 
respectively O 
. O 
Both O 
glyphosate B-SYSTEMATIC 
isopropylamine I-SYSTEMATIC 
and O 
dichlorvos B-TRIVIAL 
inhibited O 
CA-II O 
isoenzyme O 
in O 
a O 
noncompetitive O 
manner O 
. O 

receptor O 
CAR O 
specifically O 
activates O 
the O 
two O 
- O 
pore O 
K+ B-FORMULA 
channel O 
Kcnk1 O 
gene O 
in O 
male O 
mouse O 
livers O 
, O 
which O 
attenuates O 
phenobarbital B-TRIVIAL 
-induced O 
hepatic O 
hyperplasia O 
. O 

, O 
a O 
member O 
of O 
the O 
family O 
of O 
two O 
- O 
pore O 
K(+) B-FORMULA 
ion O 
channels O 
, O 
is O 
specifically O 
induced O 
in O 
the O 
livers O 
of O 
male O 
mice O 
after O 
phenobarbital B-TRIVIAL 
treatment O 
. O 
Here O 
, O 
we O 
have O 
determined O 
the O 
molecular O 
mechanism O 
of O 
this O 
male O 
- O 
specific O 
activation O 
of O 
the O 
Kcnk1 O 
gene O 
and O 
characterized O 
KCNK1 O 
as O 
a O 
phenobarbital B-TRIVIAL 
-inducible O 
antihyperplasia O 
factor O 
. O 
Upon O 
activation O 
by O 
phenobarbital B-TRIVIAL 
, O 
nuclear O 
receptor O 
CAR O 
binds O 
the O 
97-bp O 
response O 
element O 
( O 
-2441 O 
/ O 
-2345 O 
) O 
within O 
the O 
Kcnk1 O 
promoter O 
. O 
This O 
binding O 
is O 
observed O 
in O 
the O 
livers O 
of O 
male O 
mice O 
, O 
but O 
not O 
in O 
the O 
livers O 
of O 
female O 
mice O 
and O 
requires O 
the O 
pituitary O 
gland O 
, O 
because O 
hypophysectomy O 
abrogates O 
it O 
. O 
Hyperplasia O 
further O 
progressed O 
in O 
the O 
livers O 
of O 
Kcnk1 O 
( O 
- O 
/ O 
- O 
) O 
male O 
mice O 
compared O 
with O 
those O 
of O 
Kcnk1 O 
( O 
+ O 
/ O 
+ O 
) O 
males O 
after O 
phenobarbital B-TRIVIAL 
treatment O 
. O 
Thus O 
, O 
KCNK1 O 
suppresses O 
phenobarbital B-TRIVIAL 
-induced O 
hyperplasia O 
. O 
These O 
results O 
indicate O 
that O 
phenobarbital B-TRIVIAL 
treatment O 
induces O 
KCNK1 O 
to O 
elicit O 
a O 
male O 
- O 
specific O 
and O 
growth O 
- O 
suppressing O 
signal O 
. O 
Thus O 
, O 
KCNK1 O 
and O 
Kcnk1 O 
( O 
- O 
/ O 
- O 
) O 
mice O 
provide O 
an O 
experimental O 
tool O 
for O 
further O 
investigation O 
into O 
the O 
molecular O 
mechanism O 
of O 
CAR O 
- O 
mediated O 
promotion O 
of O 
the O 
development O 
of O 
hepatocellular O 
carcinoma O 
in O 
mice O 
. O 

protein O 
- O 
protein O 
interactions O 
within O 
the O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
signaling O 
system O 
as O 
a O 
therapeutic O 
strategy O 
for O 
cardiovascular O 
disease O 
. O 

cAMP B-ABBREVIATION 
signaling O 
system O 
can O 
trigger O 
precise O 
physiological O 
cellular O 
responses O 
that O 
depend O 
on O 
the O 
fidelity O 
of O 
many O 
protein O 
- O 
protein O 
interactions O 
, O 
which O 
act O 
to O 
bring O 
together O 
signaling O 
intermediates O 
at O 
defined O 
locations O 
within O 
cells O 
. O 
In O 
the O 
heart O 
, O 
cAMP B-ABBREVIATION 
participates O 
in O 
the O 
fine O 
control O 
of O 
excitation O 
- O 
contraction O 
coupling O 
, O 
hence O 
, O 
any O 
disregulation O 
of O 
this O 
signaling O 
cascade O 
can O 
lead O 
to O 
cardiac O 
disease O 
. O 
Due O 
to O 
the O 
ubiquitous O 
nature O 
of O 
the O 
cAMP B-ABBREVIATION 
pathway O 
, O 
general O 
inhibitors O 
of O 
cAMP B-ABBREVIATION 
signaling O 
proteins O 
such O 
as O 
PKA O 
, O 
EPAC O 
and O 
PDEs O 
would O 
act O 
non-specifically O 
and O 
universally O 
, O 
increasing O 
the O 
likelihood O 
of O 
serious O 
' O 
off O 
target O 
' O 
effects O 
. O 
Recent O 
advances O 
in O 
the O 
discovery O 
of O 
peptides O 
and O 
small O 
molecules O 
that O 
disrupt O 
the O 
protein O 
- O 
protein O 
interactions O 
that O 
underpin O 
cellular O 
targeting O 
of O 
cAMP B-ABBREVIATION 
signaling O 
proteins O 
are O 
described O 
and O 
discussed O 
. O 

pyrimidines I-FAMILY 
as O 
VLA-4 O 
antagonists O 
. O 

series O 
of O 
(S)-2-(2-(diethylamino)-5-(N-alkyl-N-sulfonamido)pyrimidin-4-ylamino)-3-(4-(carbamoyloxy)phenyl)propanoic B-FAMILY 
acid I-FAMILY 
is O 
discovered O 
as O 
orally O 
available O 
VLA-4 O 
antagonists O 
. O 
Representative O 
compounds O 
11b O 
and O 
11p O 
showed O 
efficacy O 
in O 
multiple O 
in O 
vivo O 
animal O 
models O 
. O 
The O 
in O 
vitro O 
selectivity O 
of O 
11p O 
is O 
also O 
described O 
. O 

salicylate B-SYSTEMATIC 
1,2-dioxygenase O 
as O 
a O 
model O 
for O 
a O 
conventional O 
gentisate B-TRIVIAL 
1,2-dioxygenase O 
: O 
crystal O 
structures O 
of O 
the O 
G106A O 
mutant O 
and O 
its O 
adducts O 
with O 
gentisate B-TRIVIAL 
and O 
salicylate B-SYSTEMATIC 
. O 

salicylate B-SYSTEMATIC 
1,2-dioxygenase O 
( O 
SDO O 
) O 
from O 
the O 
bacterium O 
Pseudaminobacter O 
salicylatoxidans O 
BN12 O 
is O 
a O 
versatile O 
gentisate B-TRIVIAL 
1,2-dioxygenase O 
( O 
GDO O 
) O 
that O 
converts O 
both O 
gentisate B-TRIVIAL 
( O 
2,5-dihydroxybenzoate B-SYSTEMATIC 
) O 
and O 
various O 
monohydroxylated O 
substrates O 
. O 
Several O 
variants O 
of O 
this O 
enzyme O 
were O 
rationally O 
designed O 
based O 
on O 
the O 
previously O 
determined O 
enzyme O 
structure O 
and O 
sequence O 
differences O 
between O 
the O 
SDO O 
and O 
the O 
' O 
conventional O 
' O 
GDO O 
from O 
Corynebacterium O 
glutamicum O 
. O 
This O 
was O 
undertaken O 
in O 
order O 
to O 
define O 
the O 
structural O 
elements O 
that O 
give O 
the O 
SDO O 
its O 
unique O 
ability O 
to O 
dioxygenolytically O 
cleave O 
( O 
substituted O 
) O 
salicylates B-FAMILY 
. O 
SDO O 
variants O 
M103L O 
, O 
G106A O 
, O 
G111A O 
, O 
R113G O 
, O 
S147R O 
and O 
F159Y O 
were O 
constructed O 
and O 
it O 
was O 
found O 
that O 
G106A O 
oxidized O 
only O 
gentisate B-TRIVIAL 
; O 
1-hydroxy-2-naphthoate B-SYSTEMATIC 
and O 
salicylate B-SYSTEMATIC 
were O 
not O 
converted O 
. O 
This O 
indicated O 
that O 
this O 
enzyme O 
variant O 
behaves O 
like O 
previously O 
known O 
' O 
conventional O 
' O 
GDOs O 
. O 
Crystals O 
of O 
the O 
G106A O 
SDO O 
variant O 
and O 
its O 
complexes O 
with O 
salicylate B-SYSTEMATIC 
and O 
gentisate B-TRIVIAL 
were O 
obtained O 
under O 
anaerobic O 
conditions O 
, O 
and O 
the O 
structures O 
were O 
solved O 
and O 
analyzed O 
. O 
The O 
amino B-FAMILY 
acid I-FAMILY 
residue O 
Gly B-FORMULA 
106 O 
is O 
located O 
inside O 
the O 
SDO O 
active O 
site O 
cavity O 
but O 
does O 
not O 
directly O 
interact O 
with O 
the O 
substrates O 
. O 
Crystal O 
structures O 
of O 
G106A O 
SDO O 
complexes O 
with O 
gentisate B-TRIVIAL 
and O 
salicylate B-SYSTEMATIC 
showed O 
a O 
different O 
binding O 
mode O 
for O 
salicylate B-SYSTEMATIC 
when O 
compared O 
with O 
the O 
wild O 
- O 
type O 
enzyme O 
. O 
Thus O 
, O 
salicylate B-SYSTEMATIC 
coordinated O 
in O 
the O 
G106A O 
variant O 
with O 
the O 
catalytically O 
active O 
Fe B-FORMULA 
(II) I-FORMULA 
ion O 
in O 
an O 
unusual O 
and O 
unproductive O 
manner O 
because O 
of O 
the O 
inability O 
of O 
salicylate B-SYSTEMATIC 
to O 
displace O 
a O 
hydrogen B-SYSTEMATIC 
bond O 
that O 
was O 
formed O 
between O 
Trp B-FORMULA 
104 O 
and O 
Asp B-FORMULA 
174 O 
in O 
the O 
G106A O 
variant O 
. O 
It O 
is O 
proposed O 
that O 
this O 
type O 
of O 
unproductive O 
substrate O 
binding O 
might O 
generally O 
limit O 
the O 
substrate O 
spectrum O 
of O 
' O 
conventional O 
' O 
GDOs O 
. O 
DATABASE O 
: O 
Structural O 
data O 
are O 
available O 
in O 
the O 
Protein O 
Data O 
Bank O 
databases O 
under O 
the O 
accession O 
numbers O 
3NST O 
, O 
3NWA O 
, O 
3NVC O 
. O 

is O 
a O 
prominent O 
feature O 
of O 
many O 
diseases O 
, O 
such O 
as O 
infection O 
, O 
inflammation O 
and O 
trauma O 
. O 
In O 
the O 
clinic O 
, O 
fever O 
can O 
be O 
easily O 
judged O 
by O 
measuring O 
the O 
body O 
temperature O 
; O 
however O 
, O 
the O 
pathogenesis O 
of O 
fever O 
is O 
still O 
not O 
fully O 
understood O 
. O 
A O 
febrile O 
response O 
is O 
a O 
systemic O 
pathological O 
process O 
that O 
can O 
cause O 
metabolic O 
disorders O 
. O 
Metabonomics O 
can O 
provide O 
powerful O 
tools O 
to O 
reveal O 
the O 
pathological O 
mechanisms O 
for O 
such O 
a O 
systemic O 
disease O 
. O 
Thus O 
, O 
to O 
reveal O 
subtle O 
metabolic O 
changes O 
under O 
the O 
condition O 
of O 
fever O 
and O 
to O 
explore O 
its O 
mechanism O 
, O 
an O 
ultra O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
a O 
quadrupole O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
metabonomics O 
approach O 
was O 
employed O 
to O 
investigate O 
the O 
urine O 
biochemical O 
characteristics O 
of O 
yeast O 
- O 
induced O 
pyrexia O 
rats O 
. O 
The O 
acquired O 
data O 
were O 
subjected O 
to O 
principal O 
component O 
analysis O 
for O 
differentiating O 
the O 
pyrexia O 
rats O 
from O 
the O 
control O 
rats O 
. O 
Potential O 
biomarkers O 
were O 
screened O 
by O 
using O 
orthogonal O 
partial O 
least O 
- O 
squares O 
- O 
discriminant O 
analysis O 
and O 
were O 
identified O 
by O 
accurate O 
mass O 
, O 
database O 
, O 
and O 
MS O 
/ O 
MS O 
fragment O 
information O 
obtained O 
from O 
the O 
MS(E) O 
technique O 
. O 
Sixteen O 
metabolites O 
in O 
rat O 
urine O 
were O 
identified O 
as O 
potential O 
biomarkers O 
. O 
The O 
relative O 
intensities O 
of O 
the O 
15 O 
potential O 
biomarkers O 
were O 
calculated O 
. O 
The O 
thermoregulatory O 
circuitry O 
of O 
" O 
endogenous O 
pyrogen O 
( O 
EP O 
) O 
↑-hypothalamus O 
Na(+) B-MULTIPLE 
/ I-MULTIPLE 
Ca(2+)-cAMP I-MULTIPLE 
↑ O 
" O 
was O 
partially O 
confirmed O 
in O 
this O 
study O 
. O 
The O 
results O 
suggested O 
that O 
UPLC O 
/ O 
MS O 
- O 
based O 
metabolic O 
profiling O 
of O 
rat O 
urine O 
identifies O 
impaired O 
tryptophan B-TRIVIAL 
metabolism O 
as O 
the O 
mechanism O 
of O 
yeast O 
- O 
induced O 
fever O 
. O 
This O 
research O 
provided O 
informative O 
data O 
that O 
the O 
impaired O 
tryptophan B-TRIVIAL 
metabolism O 
might O 
be O 
one O 
of O 
the O 
important O 
reasons O 
in O 
elucidating O 
the O 
biochemical O 
basis O 
of O 
the O 
febrile O 
response O 
. O 

new O 
vinblastine B-TRIVIAL 
-type O 
N-oxide B-FAMILY 
alkaloids I-FAMILY 
from O 
Catharanthus O 
roseus O 
. O 

new O 
vinblastine B-TRIVIAL 
-type O 
N-oxide B-FAMILY 
alkaloids I-FAMILY 
, O 
17-desacetoxyvinblastine B-SYSTEMATIC 
[ O 
Formula O 
: O 
see O 
text]- O 
oxide B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
20'-deoxyvinblastine B-SYSTEMATIC 
[ O 
Formula O 
: O 
see O 
text]- O 
oxide B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Catharanthus O 
roseus O 
. O 
The O 
structures O 
of O 
1 O 
and O 
2 O 
were O 
established O 
by O 
the O 
analysis O 
of O 
their O 
nuclear O 
magnetic O 
resonance O 
and O 
HR-ESI-MS O 
spectroscopic O 
data O 
. O 
All O 
alkaloids O 
were O 
evaluated O 
for O 
their O 
cytotoxic O 
activities O 
against O 
the O 
human O 
hepatocellular O 
carcinoma O 
( O 
HepG2 O 
) O 
cell O 
line O 
, O 
human O 
colorectal O 
carcinoma O 
( O 
Lovo O 
) O 
cell O 
line O 
and O 
human O 
breast O 
carcinoma O 
( O 
MCF-7 O 
) O 
cell O 
line O 
by O 
the O 
MTT B-ABBREVIATION 
method O 
in O 
vitro O 
, O 
respectively O 
. O 
The O 
results O 
showed O 
that O 
cytotoxic O 
activities O 
of O 
alkaloids O 
1 O 
and O 
2 O 
exhibited O 
moderate O 
inhibitory O 
activity O 
on O 
the O 
proliferation O 
of O 
three O 
cancer O 
cells O 
. O 

addition O 
to O 
the O 
well O 
known O 
regulating O 
effects O 
of O 
leptin O 
on O 
energy O 
balance O 
and O 
glucose B-TRIVIAL 
homeostasis O 
through O 
the O 
central O 
nervous O 
system O 
, O 
circulating O 
leptin O 
has O 
a O 
direct O 
effect O 
on O 
pancreatic O 
islet O 
and O 
insulin O 
secretion O 
through O 
its O 
receptor O 
( O 
OBRb O 
) O 
. O 
The O 
LIM-homeodomain O 
transcription O 
factor O 
Isl-1 O 
is O 
expressed O 
in O 
all O 
classes O 
of O 
pancreatic O 
endocrine O 
cells O 
and O 
is O 
involved O 
in O 
regulating O 
both O 
islet O 
development O 
and O 
insulin O 
secretion O 
. O 
Both O 
OBRb O 
and O 
Isl-1 O 
mutations O 
result O 
in O 
obesity O 
- O 
related O 
diabetes O 
. O 
However O 
, O 
the O 
interactions O 
and O 
physiological O 
significance O 
of O 
leptin O 
and O 
Isl-1 O 
in O 
pancreatic O 
islets O 
remain O 
to O 
be O 
established O 
. O 
Here O 
, O 
we O 
show O 
that O 
most O 
of O 
leptin O 
target O 
cells O 
in O 
pancreatic O 
islets O 
and O 
NIT O 
beta O 
cells O 
express O 
Isl-1 O 
. O 
Both O 
in O 
vivo O 
and O 
in O 
vitro O 
results O 
demonstrate O 
that O 
leptin O 
suppresses O 
Isl-1 O 
expression O 
and O 
insulin O 
secretion O 
in O 
islet O 
in O 
physiological O 
and O 
pathophysiological O 
conditions O 
, O 
e.g O 
. O 
high O 
fat O 
diet O 
. O 
This O 
effect O 
of O 
leptin O 
on O 
insulin O 
secretion O 
is O 
lost O 
in O 
leptin O 
receptor O 
- O 
defective O 
db O 
/ O 
db O 
and O 
Isl-1-inducible O 
knock O 
- O 
out O 
mice O 
. O 
We O 
conclude O 
that O 
the O 
action O 
of O 
leptin O 
on O 
insulin O 
secretion O 
is O 
at O 
least O 
partly O 
mediated O 
by O 
Isl-1 O 
. O 
Another O 
new O 
finding O 
of O 
this O 
study O 
is O 
that O 
Isl-1 O 
acts O 
as O 
a O 
direct O 
downstream O 
target O 
of O 
leptin O 
signaling O 
molecule O 
STAT3 O 
to O 
influence O 
the O 
effect O 
of O 
leptin O 
on O 
insulin O 
secretion O 
, O 
whereas O 
inversely O 
, O 
insulin O 
has O 
feedback O 
regulating O 
effects O 
on O 
Isl-1 O 
expression O 
through O 
JAK-STAT3 O 
pathway O 
. O 
These O 
findings O 
are O 
crucial O 
for O 
understanding O 
the O 
mechanisms O 
regulating O 
insulin O 
secretion O 
and O 
metabolism O 
in O 
related O 
diseases O 
, O 
such O 
as O 
obesity O 
and O 
type O 
2 O 
diabetes O 
. O 

are O 
liposomes O 
encapsulating O 
emulsions O 
and O 
therapeutics O 
for O 
targeted O 
delivery O 
. O 
By O 
applying O 
ultrasound O 
to O 
eLiposomes O 
, O 
emulsion O 
droplets O 
can O 
transform O 
from O 
liquid O 
to O 
gas O 
and O 
rupture O 
the O 
lipid O 
bilayer O 
of O 
the O 
eLiposome O 
to O 
release O 
a O 
drug O 
or O 
plasmid O 
. O 
In O 
this O 
study O 
, O 
perfluoropentane B-SYSTEMATIC 
( O 
PFC5 B-FORMULA 
) O 
emulsions O 
were O 
encapsulated O 
inside O 
folated O 
eLiposomes O 
carrying O 
a O 
model O 
drug O 
( O 
calcein B-TRIVIAL 
) O 
or O 
a O 
model O 
GFP O 
plasmid O 
to O 
examine O 
the O 
effects O 
of O 
a O 
folate B-TRIVIAL 
ligand O 
, O 
PFC5 B-FORMULA 
emulsion O 
and O 
various O 
ultrasonic O 
acoustic O 
parameters O 
in O 
drug O 
delivery O 
and O 
gene O 
transfection O 
into O 
HeLa O 
cells O 
. O 
Confocal O 
microscopy O 
was O 
used O 
to O 
quantify O 
drug O 
delivery O 
and O 
the O 
level O 
of O 
plasmid O 
transfection O 
into O 
HeLa O 
cells O 
. O 
The O 
results O 
showed O 
that O 
drug O 
delivery O 
or O 
transfection O 
was O 
minimal O 
without O 
incorporation O 
of O 
internal O 
PFC5 B-FORMULA 
emulsions O 
and O 
folate B-TRIVIAL 
ligand O 
on O 
the O 
eLiposome O 
surface O 
. O 
It O 
was O 
also O 
shown O 
that O 
application O 
of O 
ultrasound O 
greatly O 
enhanced O 
the O 
drug O 
delivery O 
and O 
plasmid O 
transfection O 
. O 
Delivery O 
of O 
these O 
therapeutics O 
appears O 
to O 
be O 
to O 
the O 
cytosol O 
, O 
indicating O 
that O 
the O 
expansion O 
of O 
the O 
emulsion O 
droplets O 
disrupted O 
both O 
the O 
eLiposomes O 
and O 
the O 
endosomes O 
. O 

and O 
mercury B-SYSTEMATIC 
molar O 
ratios O 
in O 
commercial O 
fish O 
from O 
New O 
Jersey O 
and O 
Illinois O 
: O 
Variation O 
within O 
species O 
and O 
relevance O 
to O 
risk O 
communication O 
. O 

is O 
an O 
emerging O 
consensus O 
that O 
people O 
consuming O 
large O 
amounts O 
of O 
fish O 
with O 
selenium B-SYSTEMATIC 
: O 
mercury B-SYSTEMATIC 
ratios O 
below O 
1 O 
are O 
at O 
higher O 
risk O 
from O 
mercury B-SYSTEMATIC 
toxicity O 
. O 
As O 
the O 
relative O 
amount O 
of O 
selenium B-SYSTEMATIC 
increases O 
compared O 
to O 
mercury B-SYSTEMATIC 
, O 
risk O 
may O 
be O 
lowered O 
, O 
but O 
it O 
is O 
unclear O 
how O 
much O 
excess O 
selenium B-SYSTEMATIC 
is O 
required O 
. O 
It O 
would O 
be O 
useful O 
if O 
the O 
selenium B-SYSTEMATIC 
: O 
mercury B-SYSTEMATIC 
ratio O 
was O 
relatively O 
consistent O 
within O 
a O 
species O 
, O 
but O 
this O 
has O 
not O 
been O 
the O 
case O 
in O 
our O 
studies O 
of O 
wild O 
- O 
caught O 
fish O 
. O 
Since O 
most O 
people O 
in O 
developed O 
countries O 
and O 
urban O 
areas O 
obtain O 
their O 
fish O 
and O 
other O 
seafood O 
commercially O 
, O 
we O 
examined O 
selenium B-SYSTEMATIC 
: O 
mercury B-SYSTEMATIC 
molar O 
ratios O 
in O 
commercial O 
fish O 
purchased O 
in O 
stores O 
and O 
fish O 
markets O 
in O 
central O 
New O 
Jersey O 
and O 
Chicago O 
. O 
There O 
was O 
substantial O 
interspecific O 
and O 
intraspecific O 
variation O 
in O 
molar O 
ratios O 
. O 
Across O 
species O 
the O 
selenium B-SYSTEMATIC 
: O 
mercury B-SYSTEMATIC 
molar O 
ratio O 
decreased O 
with O 
increasing O 
mean O 
mercury B-SYSTEMATIC 
levels O 
, O 
but O 
selenium B-SYSTEMATIC 
variation O 
also O 
contributed O 
to O 
the O 
ratio O 
. O 
Few O 
samples O 
had O 
selenium B-SYSTEMATIC 
: O 
mercury B-SYSTEMATIC 
molar O 
ratios O 
below O 
1 O 
, O 
but O 
there O 
was O 
a O 
wide O 
range O 
in O 
ratios O 
, O 
complicating O 
the O 
interpretation O 
for O 
use O 
in O 
risk O 
management O 
and O 
communication O 
. O 
Before O 
ratios O 
can O 
be O 
used O 
in O 
risk O 
management O 
, O 
more O 
information O 
is O 
needed O 
on O 
mercury B-SYSTEMATIC 
: O 
selenium B-SYSTEMATIC 
interactions O 
and O 
mutual O 
bioavailability O 
, O 
and O 
on O 
the O 
relationship O 
between O 
molar O 
ratios O 
and O 
health O 
outcomes O 
. O 
Further O 
, O 
people O 
who O 
are O 
selenium B-SYSTEMATIC 
deficient O 
may O 
be O 
more O 
at O 
risk O 
from O 
mercury B-SYSTEMATIC 
toxicity O 
than O 
others O 
. O 

Site-Selective O 
Insertions O 
of O 
Noncanonical O 
Amino B-FAMILY 
Acids I-FAMILY 
into O 
Sequence-Repetitive O 
Polypeptides O 
. O 

simple O 
and O 
efficient O 
method O 
is O 
described O 
for O 
the O 
introduction O 
of O 
noncanonical O 
amino B-FAMILY 
acids I-FAMILY 
at O 
multiple O 
, O 
defined O 
sites O 
within O 
recombinant O 
polypeptide O 
sequences O 
. O 
Escherichia O 
coli O 
MRA30 O 
, O 
a O 
bacterial O 
host O 
strain O 
with O 
attenuated O 
activity O 
of O 
release O 
factor O 
1 O 
( O 
RF1 O 
) O 
, O 
was O 
assessed O 
for O 
its O 
ability O 
to O 
support O 
incorporation O 
of O 
a O 
diverse O 
range O 
of O 
noncanonical O 
amino B-FAMILY 
acids I-FAMILY 
in O 
response O 
to O 
multiple O 
encoded O 
amber O 
( O 
TAG O 
) O 
codons O 
within O 
genes O 
derived O 
from O 
superfolder O 
GFP O 
and O 
an O 
elastin O 
- O 
mimetic O 
protein O 
polymer O 
. O 
Suppression O 
efficiency O 
and O 
protein O 
yield O 
depended O 
on O 
the O 
identity O 
of O 
the O 
orthogonal O 
aminoacyl B-SYSTEMATIC 
-tRNA O 
synthetase O 
/ O 
tRNA(CUA) O 
pair O 
and O 
the O 
noncanonical O 
amino B-FAMILY 
acid I-FAMILY 
. O 
Elastin O 
- O 
mimetic O 
protein O 
polymers O 
were O 
prepared O 
in O 
which O 
noncanonical O 
amino B-FAMILY 
acid I-FAMILY 
derivatives O 
were O 
incorporated O 
at O 
up O 
to O 
22 O 
specific O 
sites O 
within O 
the O 
polypeptide O 
sequence O 
with O 
high O 
substitution O 
efficiency O 
. O 
The O 
identities O 
and O 
positions O 
of O 
the O 
variant O 
residues O 
were O 
confirmed O 
by O 
mass O 
spectrometric O 
analysis O 
of O 
the O 
full O 
- O 
length O 
polypeptides O 
and O 
proteolytic O 
cleavage O 
fragments O 
from O 
thermolysin O 
digestion O 
. O 
The O 
data O 
suggest O 
that O 
this O 
multisite O 
suppression O 
approach O 
permits O 
the O 
preparation O 
of O 
protein O 
- O 
based O 
materials O 
in O 
which O 
novel O 
chemical O 
functionalities O 
can O 
be O 
introduced O 
at O 
precisely O 
defined O 
positions O 
within O 
the O 
polypeptide O 
sequence O 
. O 

into O 
the O 
adsorption O 
and O 
energy O 
transfer O 
of O 
Ag B-FORMULA 
clusters O 
on O 
the O 
AgCl B-FORMULA 
( O 
100 O 
) O 
surface O 
. O 

is O 
fundamental O 
to O 
uncover O 
the O 
real O 
adsorption O 
properties O 
of O 
Ag B-FORMULA 
clusters O 
on O 
an O 
AgCl B-FORMULA 
surface O 
and O 
the O 
energy O 
transfer O 
mechanisms O 
at O 
the O 
interface O 
to O 
understand O 
the O 
highly O 
active O 
photocatalytic O 
performance O 
and O 
the O 
stability O 
of O 
the O 
plasmonic O 
photocatalyst O 
Ag B-FORMULA 
@ O 
AgCl B-FORMULA 
. O 
Based O 
on O 
density O 
functional O 
theory O 
calculations O 
we O 
provide O 
valuable O 
insights O 
into O 
the O 
binding O 
nature O 
of O 
Ag B-FORMULA 
clusters O 
on O 
AgCl B-FORMULA 
surface O 
, O 
where O 
the O 
binding O 
between O 
Ag B-FORMULA 
atoms O 
in O 
the O 
cluster O 
and O 
on O 
the O 
surface O 
plays O 
a O 
decisive O 
role O 
in O 
determining O 
the O 
most O 
stable O 
adsorption O 
configurations O 
. O 
Our O 
results O 
demonstrate O 
that O 
there O 
is O 
energy O 
transfer O 
from O 
the O 
plasmonic O 
metals O 
to O 
substrate O 
. O 
The O 
hot O 
holes O 
excited O 
by O 
the O 
decay O 
of O 
surface O 
plasmon O 
resonance O 
on O 
the O 
metals O 
can O 
diffuse O 
into O 
the O 
Cl B-FORMULA 
ions O 
in O 
the O 
outermost O 
two O 
layers O 
of O 
the O 
surface O 
producing O 
highly O 
oxidative O 
Cl B-FORMULA 
atoms O 
. O 
The O 
dipole O 
- O 
dipole O 
interaction O 
between O 
the O 
plasmonic O 
metal O 
clusters O 
and O 
substrate O 
Cl B-FORMULA 
ions O 
can O 
also O 
generate O 
electron O 
- O 
hole O 
pairs O 
in O 
the O 
surface O 
layers O 
. O 
It O 
is O 
deduced O 
that O 
the O 
positively O 
charged O 
nature O 
of O 
adsorbed O 
clusters O 
acting O 
as O 
electron O 
trapping O 
centers O 
and O 
reduction O 
sites O 
plays O 
a O 
crucial O 
role O 
in O 
keeping O 
the O 
stability O 
of O 
the O 
Ag B-FORMULA 
@ O 
AgCl B-FORMULA 
system O 
during O 
the O 
photocatalytic O 
process O 
. O 
Finally O 
, O 
the O 
validity O 
of O 
the O 
cluster O 
adsorption O 
model O 
for O 
energy O 
transfer O 
is O 
verified O 
with O 
respect O 
to O 
the O 
nucleation O 
and O 
aggregation O 
process O 
of O 
Ag B-FORMULA 
atoms O 
on O 
the O 
AgCl B-FORMULA 
surface O 
and O 
a O 
detailed O 
description O 
of O 
the O 
formation O 
and O 
evolution O 
of O 
Ag B-FORMULA 
nanoparticles O 
on O 
an O 
AgCl B-FORMULA 
surface O 
is O 
provided O 
. O 
The O 
present O 
study O 
may O 
be O 
helpful O 
for O 
understanding O 
and O 
designing O 
this O 
novel O 
plasmonic O 
photocatalyst O 
and O 
can O 
be O 
useful O 
for O 
investigating O 
other O 
relevant O 
photocatalysts O 
as O 
well O 
. O 

taking O 
advantage O 
of O 
a O 
natural O 
and O 
abundant O 
polymer O 
as O 
well O 
as O 
a O 
straightforward O 
film O 
formation O 
technique O 
, O 
this O 
paper O 
focuses O 
on O 
the O 
conception O 
and O 
use O 
of O 
a O 
new O 
alternative O 
tool O 
for O 
thermo O 
- O 
controlled O 
cell O 
detachment O 
. O 
Thermoresponsive O 
xyloglucan O 
was O 
produced O 
after O 
partial O 
galactose B-TRIVIAL 
removal O 
by O 
a O 
24 O 
h O 
reaction O 
with O 
β-galactosidase O 
. O 
The O 
obtained O 
polymer O 
( O 
T24 O 
) O 
was O 
then O 
activated O 
by O 
reaction O 
with O 
4-nitrophenyl B-SYSTEMATIC 
chloroformate I-SYSTEMATIC 
( O 
NPC B-ABBREVIATION 
) O 
in O 
order O 
to O 
graft O 
a O 
cyclic O 
peptide O 
presenting O 
an O 
arginine B-TRIVIAL 
- O 
glycine B-TRIVIAL 
- O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RGD O 
) O 
motif O 
. O 
The O 
effect O 
of O 
RGD O 
grafting O 
on O 
the O 
sol O 
- O 
gel O 
transition O 
temperature O 
of O 
T24 O 
is O 
evaluated O 
by O 
rheological O 
measurements O 
. O 
Solvent-casted O 
films O 
of O 
T24-RGD O 
successfully O 
promoted O 
cell O 
adhesion O 
, O 
proliferation O 
, O 
and O 
thermo O 
- O 
controlled O 
detachment O 
. O 
The O 
presented O 
approach O 
is O 
a O 
new O 
alternative O 
for O 
cells O 
sensitive O 
to O 
the O 
proteolytic O 
treatment O 
routinely O 
used O 
for O 
cell O 
detachment O 
. O 
Because O 
the O 
RGD O 
sequence O 
used O 
herein O 
is O 
widely O 
recognized O 
by O 
different O 
cell O 
types O 
, O 
this O 
protocol O 
may O 
be O 
extended O 
to O 
other O 
cells O 
. O 
Besides O 
, O 
the O 
presented O 
chemical O 
route O 
can O 
be O 
applied O 
to O 
different O 
peptide O 
sequences O 
. O 

next O 
generation O 
of O 
novel O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
-lowering O 
agents O 
: O 
Proprotein O 
convertase O 
subtilisin O 
/ O 
kexin O 
9 O 
inhibitors O 
. O 

convertase O 
subtilisin O 
/ O 
kexin O 
9 O 
( O 
PCSK9 O 
) O 
has O 
been O 
shown O 
to O 
degrade O 
hepatic O 
low O 
- O 
density O 
lipoprotein O 
receptors O 
( O 
LDLR O 
) O 
. O 
Gain O 
- O 
of O 
- O 
function O 
mutations O 
promote O 
the O 
development O 
of O 
familial O 
hypercholesterolemia O 
, O 
whereas O 
loss O 
- O 
of O 
- O 
function O 
mutations O 
are O 
associated O 
with O 
lower O 
levels O 
of O 
circulating O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
and O 
significant O 
protection O 
against O 
coronary O 
heart O 
disease O 
. O 
The O 
major O 
classes O 
of O 
commonly O 
prescribed O 
lipid O 
- O 
lowering O 
medications O 
, O 
such O 
as O 
statins O 
, O 
increase O 
serum O 
PCSK9 O 
levels O 
, O 
thus O 
PCSK9 O 
inhibition O 
would O 
increase O 
the O 
efficacy O 
of O 
statins O 
on O 
LDL-C O 
lowering O 
. O 
Therefore O 
, O 
PCSK9 O 
is O 
an O 
attractive O 
therapeutic O 
target O 
for O 
the O 
new O 
generation O 
of O 
cholesterol B-TRIVIAL 
-lowering O 
drugs O 
. O 
Here O 
, O 
we O 
present O 
a O 
brief O 
overview O 
of O 
the O 
development O 
of O 
PCSK9 O 
inhibitors O 
and O 
highlight O 
the O 
effect O 
of O 
currently O 
prescribed O 
LDL-C-lowering O 
drugs O 
on O 
PCSK9 O 
, O 
and O 
the O 
strategies O 
that O 
are O 
being O 
explored O 
for O 
its O 
therapeutic O 
inhibition O 
. O 
Current O 
research O 
and O 
clinical O 
trial O 
results O 
indicate O 
that O 
a O 
PCSK9 O 
inhibitor O 
may O 
be O 
an O 
exciting O 
new O 
therapeutic O 
drug O 
for O 
the O 
treatment O 
of O 
dyslipidemia O 
and O 
relevant O 
cardiovascular O 
diseases O 
. O 

effect O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
epicatechin B-TRIVIAL 
against O 
nicotine B-TRIVIAL 
-induced O 
oxidative O 
stress O 
in O 
rats O 
. O 

is O 
a O 
major O 
pharmacologically O 
active O 
and O 
addictive O 
component O 
of O 
tobacco O 
smoke O 
, O 
which O 
is O 
regarded O 
to O 
be O 
a O 
primary O 
risk O 
factor O 
in O 
the O 
development O 
of O 
cardiovascular O 
and O 
pulmonary O 
diseases O 
. O 
Epicatechin B-TRIVIAL 
is O 
one O 
of O 
the O 
most O 
potent O 
antioxidants O 
present O 
in O 
the O 
human O 
diet O 
. O 
Particularly O 
high O 
levels O 
of O 
this O 
compound O 
are O 
found O 
in O 
tea O 
, O 
apples O 
and O 
chocolate O 
. O 
It O 
has O 
been O 
reported O 
that O 
tea O 
extracts O 
and O 
/ O 
or O 
its O 
constituents O 
have O 
antibacterial O 
, O 
antiviral O 
, O 
antioxidative O 
, O 
antitumor O 
and O 
antimutagenic O 
activities O 
. O 
Vitamin B-FAMILY 
E I-FAMILY 
is O 
a O 
major O 
lipid O 
- O 
soluble O 
antioxidant O 
vitamin O 
and O 
free O 
radical O 
scavenger O 
, O 
presents O 
as O 
an O 
integral O 
component O 
of O 
cellular O 
membranes O 
and O 
has O 
important O 
biological O 
functions O 
. O 
The O 
primary O 
mechanism O 
by O 
which O 
vitamin B-FAMILY 
E I-FAMILY 
is O 
proposed O 
to O 
prevent O 
cancer O 
is O 
through O 
their O 
antioxidant O 
properties O 
. O 
The O 
goal O 
of O 
this O 
study O 
is O 
to O 
evaluate O 
the O 
effect O 
of O 
epicatechin B-TRIVIAL 
alone O 
or O 
combined O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
in O 
inhibiting O 
the O 
oxidative O 
stress O 
induced O 
by O 
nicotine B-TRIVIAL 
in O 
rats O 
. O 
Results O 
obtained O 
indicated O 
that O 
there O 
was O 
a O 
significant O 
elevation O 
in O 
the O 
levels O 
of O 
malondialdhyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
in O 
nicotine B-TRIVIAL 
injected O 
rats O 
. O 
The O 
combined O 
treatment O 
( O 
epicatechin B-TRIVIAL 
+ O 
Vit B-ABBREVIATION 
E I-ABBREVIATION 
) O 
group O 
showed O 
a O 
potential O 
reduction O 
of O 
these O 
parameters O 
more O 
than O 
individual O 
treatment O 
. O 
The O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
were O 
found O 
significantly O 
higher O 
in O 
combined O 
treated O 
than O 
untreated O 
rats O 
. O 
In O 
nicotine B-TRIVIAL 
group O 
, O 
a O 
negative O 
significant O 
correlation O 
between O 
reduced O 
glutathione B-TRIVIAL 
and O 
MDA B-ABBREVIATION 
( O 
r O 
= O 
-0.92 O 
) O 
was O 
observed O 
. O 
In O 
conclusion O 
, O 
these O 
results O 
suggested O 
that O 
the O 
supplementation O 
of O 
diet O 
with O 
epicatechin B-TRIVIAL 
and O 
vitamin B-FAMILY 
E I-FAMILY 
provided O 
antioxidant O 
defense O 
with O 
strong O 
chemopreventive O 
activity O 
against O 
nicotine B-TRIVIAL 
-induced O 
carcinogenesis O 
. O 

interactions O 
in O 
1-butanol B-SYSTEMATIC 
+ O 
IL O 
solutions O 
by O 
measuring O 
and O 
modeling O 
activity O 
coefficients O 
. O 

interactions O 
in O 
1-butanol B-SYSTEMATIC 
+ O 
ionic O 
liquid O 
( O 
IL O 
) O 
solutions O 
have O 
been O 
investigated O 
by O 
measuring O 
and O 
modeling O 
activity O 
- O 
coefficient O 
data O 
. O 
The O 
activity O 
coefficients O 
in O 
binary O 
solutions O 
containing O 
1-butanol B-SYSTEMATIC 
and O 
an O 
IL O 
were O 
determined O 
experimentally O 
: O 
the O 
ILs O 
studied O 
were O 
1-decyl-3-methyl-imidazolium B-SYSTEMATIC 
tetracyanoborate I-SYSTEMATIC 
( O 
[ O 
Im10.1](+)[ O 
tcb B-ABBREVIATION 
](- O 
) O 
) O 
, O 
4-decyl-4-methyl-morpholinium B-SYSTEMATIC 
tetracyanoborate I-SYSTEMATIC 
( O 
[ O 
Mo10.1](+)[ O 
tcb B-ABBREVIATION 
](- O 
) O 
) O 
, O 
1-decyl-3-methyl-imidazolium B-SYSTEMATIC 
bis(trifluoromethylsulfonyl)imide I-SYSTEMATIC 
( O 
[ O 
Im10.1](+)[ O 
ntf2 B-ABBREVIATION 
](- O 
) O 
) O 
, O 
and O 
4-decyl-4-methyl-morpholinium B-SYSTEMATIC 
bis(trifluoromethylsulfonyl)imide I-SYSTEMATIC 
( O 
[ O 
Mo10.1](+)[ O 
ntf2 B-ABBREVIATION 
](- O 
) O 
) O 
. O 
The O 
methods O 
used O 
to O 
determine O 
the O 
activity O 
coefficients O 
included O 
vapor O 
- O 
pressure O 
osmometry O 
, O 
headspace O 
- O 
gas O 
chromatography O 
, O 
and O 
gas-liquid O 
chromatography O 
. O 
The O 
results O 
from O 
all O 
of O 
these O 
techniques O 
were O 
combined O 
to O 
obtain O 
activity O 
- O 
coefficient O 
data O 
over O 
the O 
entire O 
IL O 
concentration O 
range O 
, O 
and O 
the O 
ion O 
- O 
specific O 
interactions O 
of O 
the O 
ILs O 
investigated O 
were O 
identified O 
with O 
1-butanol B-SYSTEMATIC 
. O 
The O 
highest O 
( O 
1-butanol B-SYSTEMATIC 
)-IL O 
interactions O 
of O 
the O 
ILs O 
considered O 
in O 
this O 
work O 
were O 
found O 
for O 
[Im10.1](+)[tcb](-) O 
; O 
thus O 
, O 
[Im10.1](+)[tcb](-) O 
showed O 
the O 
highest O 
affinity O 
for O 
1-butanol B-SYSTEMATIC 
in O 
a O 
binary O 
mixture O 
. O 
The O 
experimental O 
data O 
were O 
modeled O 
with O 
the O 
Perturbed-Chain O 
Statistical O 
Associating O 
Fluid O 
Theory O 
( O 
PC-SAFT O 
) O 
. O 
PC-SAFT O 
was O 
able O 
to O 
accurately O 
describe O 
the O 
pure O 
IL O 
and O 
( O 
1-butanol B-SYSTEMATIC 
)-IL O 
data O 
. O 
Moreover O 
, O 
the O 
model O 
was O 
shown O 
to O 
be O 
predictive O 
and O 
extrapolative O 
with O 
respect O 
to O 
concentration O 
and O 
temperature O 
. O 

exposure O 
alters O 
postembryonic O 
development O 
in O 
a O 
Pacific O 
tree O 
frog O 
( O 
Pseudacris O 
regilla O 
) O 
Amphibian O 
Metamorphosis O 
Assay O 
( O 
TREEMA O 
) O 
. O 

Amphibian O 
Metamorphosis O 
Assay O 
( O 
AMA O 
) O 
, O 
developed O 
for O 
Xenopus O 
laevis O 
, O 
is O 
designed O 
to O 
identify O 
chemicals O 
that O 
disrupt O 
thyroid B-FAMILY 
hormone I-FAMILY 
( O 
TH O 
) O 
- O 
mediated O 
biological O 
processes O 
. O 
We O 
adapted O 
the O 
AMA O 
for O 
use O 
on O 
an O 
ecologically O 
- O 
relevant O 
North O 
American O 
species O 
, O 
the O 
Pacific O 
tree O 
frog O 
( O 
Pseudacris O 
regilla O 
) O 
, O 
and O 
applied O 
molecular O 
endpoints O 
to O 
evaluate O 
the O 
effects O 
of O 
the O 
antibacterial O 
agent O 
, O 
triclosan B-TRIVIAL 
( O 
TCS B-ABBREVIATION 
) O 
. O 
Premetamorphic O 
( O 
Gosner O 
stage O 
26-28 O 
) O 
tadpoles O 
were O 
immersed O 
for O 
21 O 
days O 
in O 
solvent O 
control O 
, O 
1.5 O 
μg O 
/ O 
L O 
thyroxine B-TRIVIAL 
(T(4)) O 
, O 
0.3 O 
, O 
3 O 
and O 
30 O 
μg O 
/ O 
L O 
( O 
nominal O 
) O 
TCS B-ABBREVIATION 
, O 
or O 
combined O 
T(4)/ O 
TCS B-ABBREVIATION 
treatments O 
. O 
Exposure O 
effects O 
were O 
scored O 
by O 
morphometric O 
( O 
developmental O 
stage O 
, O 
wet O 
weight O 
, O 
and O 
body O 
, O 
snout O 
- O 
vent O 
and O 
hindlimb O 
lengths O 
) O 
and O 
molecular O 
( O 
mRNA O 
abundance O 
using O 
quantitative O 
real O 
time O 
polymerase O 
chain O 
reaction O 
) O 
criteria O 
. O 
T(4) O 
treatment O 
alone O 
accelerated O 
development O 
concomitant O 
with O 
altered O 
levels O 
of O 
TH O 
receptors O 
α O 
and O 
β O 
, O 
proliferating O 
cell O 
nuclear O 
antigen O 
, O 
and O 
gelatinase O 
B O 
mRNAs O 
in O 
the O 
brain O 
and O 
tail O 
. O 
We O 
observed O 
TCS B-ABBREVIATION 
-induced O 
perturbations O 
in O 
all O 
of O 
the O 
molecular O 
and O 
morphological O 
endpoints O 
indicating O 
that O 
TCS B-ABBREVIATION 
exposure O 
disrupts O 
coordination O 
of O 
postembryonic O 
tadpole O 
development O 
. O 
Clear O 
alterations O 
in O 
molecular O 
endpoints O 
were O 
evident O 
at O 
day O 
2 O 
whereas O 
the O 
earliest O 
morphological O 
effects O 
appeared O 
at O 
day O 
4 O 
and O 
were O 
most O 
evident O 
at O 
day O 
21 O 
. O 
Although O 
TCS B-ABBREVIATION 
alone O 
( O 
3 O 
and O 
30 O 
μg O 
/ O 
L O 
) O 
was O 
protective O 
against O 
tadpole O 
mortality O 
, O 
this O 
protection O 
was O 
lost O 
in O 
the O 
presence O 
of O 
T(4) O 
. O 
The O 
Pacific O 
tree O 
frog O 
is O 
the O 
most O 
sensitive O 
species O 
examined O 
to O 
date O 
displaying O 
disruption O 
of O 
TH O 
- O 
mediated O 
development O 
by O 
a O 
common O 
antimicrobial O 
agent O 
. O 

initio O 
molecular O 
dynamics O 
simulation O 
on O 
the O 
formation O 
process O 
of O 
He B-FORMULA 
@ O 
C₆₀ B-TRIVIAL 
synthesized O 
by O 
explosion O 
. O 

applications O 
of O 
endohedral O 
non-metallic O 
fullerenes B-FAMILY 
are O 
limited O 
by O 
their O 
low O 
production O 
rate O 
. O 
Recently O 
, O 
an O 
explosive O 
method O 
developed O 
in O 
our O 
group O 
shows O 
promise O 
to O 
prepare O 
He B-FORMULA 
@ O 
C₆₀ B-TRIVIAL 
at O 
fairly O 
high O 
yield O 
, O 
but O 
the O 
mechanism O 
of O 
He B-FORMULA 
inserting O 
into O 
C₆₀ B-TRIVIAL 
cage O 
at O 
explosive O 
conditions O 
was O 
not O 
clear O 
. O 
Here O 
, O 
ab O 
initio O 
molecular O 
dynamics O 
analysis O 
has O 
been O 
used O 
to O 
simulate O 
the O 
collision O 
between O 
C₆₀ B-TRIVIAL 
molecules O 
at O 
high O 
- O 
temperature O 
and O 
high O 
- O 
pressure O 
induced O 
by O 
explosion O 
. O 
The O 
results O 
show O 
that O 
defects O 
formed O 
on O 
the O 
fullerene B-TRIVIAL 
cage O 
by O 
collidsion O 
can O 
effectively O 
decrease O 
the O 
reaction O 
barrier O 
for O 
the O 
insertion O 
of O 
He B-FORMULA 
into O 
C₆₀ B-TRIVIAL 
, O 
and O 
the O 
self O 
- O 
healing O 
capability O 
of O 
the O 
defects O 
was O 
also O 
observed O 
. O 

spectroscopy O 
of O 
PTCDA B-ABBREVIATION 
molecules O 
on O 
the O 
KCl B-FORMULA 
( O 
100 O 
) O 
surface O 
in O 
the O 
limit O 
of O 
low O 
coverages O 
: O 
site O 
selection O 
and O 
diffusion O 
. O 

performed O 
fluorescence O 
( O 
FL O 
) O 
and O 
fluorescence O 
excitation O 
( O 
FLE O 
) O 
spectroscopy O 
on O 
the O 
model O 
molecule O 
perylene-3,4,9,10-tetracarboxyl B-SYSTEMATIC 
acid I-SYSTEMATIC 
dianhydride I-SYSTEMATIC 
( O 
PTCDA B-ABBREVIATION 
) O 
for O 
very O 
low O 
coverages O 
( O 
below O 
1% O 
of O 
a O 
monolayer O 
) O 
on O 
thin O 
( O 
100 O 
) O 
oriented O 
KCl B-FORMULA 
films O 
. O 
Two O 
different O 
states O 
of O 
PTCDA B-ABBREVIATION 
molecules O 
can O 
be O 
distinguished O 
in O 
the O 
spectra O 
: O 
an O 
initial O 
state O 
, O 
which O 
is O 
observed O 
directly O 
after O 
deposition O 
of O 
the O 
molecules O 
onto O 
the O 
cold O 
sample O 
at O 
20 O 
K O 
, O 
and O 
a O 
final O 
state O 
, O 
which O 
is O 
found O 
after O 
intensive O 
optical O 
excitation O 
or O 
thermal O 
annealing O 
of O 
the O 
sample O 
. O 
The O 
spectrum O 
of O 
the O 
final O 
state O 
is O 
blue O 
- O 
shifted O 
with O 
respect O 
to O 
that O 
of O 
the O 
initial O 
state O 
by O 
130 O 
± O 
15 O 
cm(-1) O 
and O 
exhibits O 
lines O 
with O 
significantly O 
reduced O 
widths O 
. O 
This O 
can O 
be O 
explained O 
by O 
diffusion O 
of O 
molecules O 
from O 
initially O 
populated O 
terrace O 
sites O 
to O 
energetically O 
favoured O 
step O 
edge O 
sites O 
. O 
Polarization O 
dependent O 
spectroscopy O 
reveals O 
the O 
same O 
azimuthal O 
orientation O 
of O 
the O 
molecules O 
on O 
both O 
adsorption O 
sites O 
and O 
leads O 
to O 
a O 
model O 
of O 
the O 
adsorption O 
geometry O 
of O 
PTCDA B-ABBREVIATION 
at O 
the O 
KCl B-FORMULA 
step O 
sites O 
. O 
Our O 
experiment O 
demonstrates O 
how O 
optical O 
spectroscopy O 
can O 
be O 
used O 
to O 
investigate O 
kinetic O 
processes O 
of O 
fluorescent O 
molecules O 
on O 
surfaces O 
. O 

on O 
the O 
Himbert O 
Intramolecular O 
Arene B-FAMILY 
/ O 
Allene B-SYSTEMATIC 
Diels-Alder O 
Cycloaddition O 
. O 
Mechanistic O 
Studies O 
and O 
Expansion O 
of O 
Scope O 
to O 
All- O 
Carbon B-SYSTEMATIC 
Tethers O 
. O 

unusual O 
intramolecular O 
arene B-FAMILY 
/ O 
allene B-SYSTEMATIC 
cycloaddition O 
described O 
30 O 
years O 
ago O 
by O 
Himbert O 
permits O 
rapid O 
access O 
to O 
strained O 
polycyclic O 
compounds O 
that O 
offer O 
great O 
potential O 
for O 
the O 
synthesis O 
of O 
complex O 
scaffolds O 
. O 
To O 
more O 
fully O 
understand O 
the O 
mechanism O 
of O 
this O 
cycloaddition O 
reaction O 
, O 
and O 
to O 
guide O 
efforts O 
to O 
extend O 
its O 
scope O 
to O 
new O 
substrates O 
, O 
quantum O 
mechanical O 
computational O 
methods O 
were O 
employed O 
in O 
concert O 
with O 
laboratory O 
experiments O 
. O 
These O 
studies O 
indicated O 
that O 
the O 
cycloadditions O 
likely O 
proceed O 
via O 
concerted O 
processes O 
; O 
a O 
stepwise O 
biradical O 
mechanism O 
was O 
shown O 
to O 
be O 
higher O 
in O 
energy O 
in O 
the O 
cases O 
studied O 
. O 
The O 
original O 
Himbert O 
cycloaddition O 
chemistry O 
is O 
also O 
extended O 
from O 
heterocyclic O 
to O 
carbocyclic O 
systems O 
, O 
with O 
computational O 
guidance O 
used O 
to O 
predict O 
thermodynamically O 
favorable O 
cases O 
. O 
Complex O 
polycyclic O 
scaffolds O 
result O 
from O 
the O 
combination O 
of O 
the O 
cycloaddition O 
and O 
subsequent O 
ring O 
- O 
rearrangement O 
metathesis O 
reactions O 
. O 

esters I-FAMILY 
of O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
as O 
anticancer O 
agents O 
: O 
a O 
review O 
. O 

current O 
review O 
presents O 
the O 
antitumoral O 
properties O 
of O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
and O 
its O 
ester B-FAMILY 
derivatives O 
. O 
Numerous O 
studies O 
have O 
indicated O 
that O 
the O 
alkyl B-FAMILY 
esters I-FAMILY 
are O 
more O 
effective O 
against O 
tumor O 
cell O 
lines O 
than O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
that O 
this O 
activity O 
is O 
related O 
to O 
their O 
hydrophobic O 
moiety O 
. O 
All O 
related O 
studies O 
have O 
shown O 
that O 
the O 
antitumor O 
activity O 
is O 
interconnected O 
to O 
the O 
induction O 
of O 
apoptosis O 
by O 
different O 
mechanisms O 
and O 
it O 
depends O 
on O 
the O 
cell O 
type O 
. O 
The O 
results O 
presented O 
in O 
this O 
review O 
may O 
help O 
to O 
emphasize O 
that O 
these O 
compounds O 
could O 
be O 
promising O 
as O 
a O 
new O 
alternative O 
for O 
the O 
treatment O 
of O 
cancer O 
, O 
either O 
alone O 
or O 
in O 
combination O 
with O 
other O 
antitumor O 
drugs O 
to O 
potentiate O 
their O 
effects O 
. O 

A I-TRIVIAL 
, O 
a O 
Prostaglandin B-FAMILY 
Release O 
Inhibitor O 
from O 
Saccharothrix O 
sp O 
. O 

A I-TRIVIAL 
( O 
1 O 
) O 
was O 
isolated O 
from O 
the O 
fermentation O 
broth O 
of O 
strain O 
Saccharothrix O 
sp O 
. O 
MI559-46F5 O 
. O 
The O 
structure O 
was O 
determined O 
as O 
a O 
new O 
naphthoquinone B-FAMILY 
derivative O 
with O 
an O 
acetylhydrazino B-SYSTEMATIC 
moiety O 
by O 
a O 
combination O 
of O 
NMR O 
, O 
MS O 
spectral O 
analyses O 
, O 
and O 
chemical O 
degradation O 
. O 
Compound O 
1 O 
showed O 
inhibitory O 
activity O 
of O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
release O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
from O 
human O 
synovial O 
sarcoma O 
cells O 
, O 
SW982 O 
, O 
with O 
an O 
IC50 O 
value O 
of O 
1 O 
μM O 
, O 
but O 
had O 
no O 
effect O 
on O 
cell O 
growth O 
up O 
to O 
30 O 
μM O 
. O 

uterine O 
bleeding O 
( O 
AUB O 
) O 
, O 
which O 
is O 
defined O 
as O 
excessively O 
heavy O 
, O 
prolonged O 
and O 
/ O 
or O 
frequent O 
bleeding O 
of O 
uterine O 
origin O 
, O 
is O 
a O 
frequent O 
cause O 
of O 
visits O 
to O 
the O 
Emergency O 
Department O 
and O 
/ O 
or O 
health O 
care O 
provider O 
. O 
While O 
there O 
are O 
many O 
etiologies O 
of O 
AUB O 
, O 
the O 
one O 
most O 
likely O 
among O 
otherwise O 
healthy O 
adolescents O 
is O 
dysfunctional O 
uterine O 
bleeding O 
( O 
DUB O 
) O 
, O 
which O 
is O 
characterizing O 
any O 
AUB O 
when O 
all O 
possible O 
underlying O 
pathologic O 
causes O 
have O 
been O 
previously O 
excluded O 
. O 
The O 
most O 
common O 
cause O 
of O 
DUB O 
in O 
adolescence O 
is O 
anovulation O 
, O 
which O 
is O 
very O 
frequent O 
in O 
the O 
first O 
2-3 O 
post O 
- O 
menarchal O 
years O 
and O 
is O 
associated O 
with O 
immaturity O 
of O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
ovarian O 
axis O 
. O 
Management O 
of O 
AUB O 
is O 
based O 
on O 
the O 
underlying O 
etiology O 
and O 
the O 
severity O 
of O 
the O 
bleeding O 
and O 
primary O 
goals O 
are O 
prevention O 
of O 
complications O 
, O 
such O 
as O 
anemia O 
and O 
reestablishment O 
of O 
regular O 
cyclical O 
bleeding O 
, O 
while O 
the O 
management O 
of O 
DUB O 
can O 
in O 
part O 
be O 
directed O 
by O 
the O 
amount O 
of O 
flow O 
, O 
the O 
degree O 
of O 
associated O 
anemia O 
, O 
as O 
well O 
as O 
patient O 
and O 
family O 
comfort O 
with O 
different O 
treatment O 
modalities O 
. O 
Treatment O 
options O 
for O 
DUB O 
are O 
: O 
combined O 
oral O 
contraceptives O 
( O 
COCs O 
) O 
, O 
progestogens B-FAMILY 
, O 
non O 
steroidal O 
anti O 
inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
, O 
tranexamic B-TRIVIAL 
acid I-TRIVIAL 
( O 
anti-fibrinolytic O 
) O 
, O 
GnRH B-ABBREVIATION 
analogues O 
, O 
Danazol B-TRIVIAL 
and O 
Levonorgestrel B-TRIVIAL 
releasing O 
intra O 
uterine O 
system O 
( O 
LNG O 
IUS O 
) O 
. O 

influence O 
of O 
study O 
design O 
and O 
sex O 
- O 
differences O 
on O 
results O 
from O 
developmental O 
neurotoxicity O 
studies O 
of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
, O 
implications O 
for O 
toxicity O 
testing O 
. O 

neurotoxicity O 
( O 
DNT O 
) O 
of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
has O 
been O 
investigated O 
in O 
a O 
large O 
number O 
of O 
studies O 
. O 
However O 
, O 
there O 
are O 
discrepancies O 
in O 
the O 
results O 
reported O 
between O 
the O 
studies O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
identify O 
and O 
analyze O 
factors O 
that O 
may O 
contribute O 
to O 
these O 
differences O 
and O 
to O 
assess O 
whether O 
there O 
are O 
sex O 
- O 
differences O 
in O 
the O 
sensitivity O 
of O 
certain O 
endpoints O 
or O 
tests O 
used O 
in O 
DNT-studies O 
. O 
Forty O 
- O 
four O 
DNT O 
studies O 
of O 
BPA B-ABBREVIATION 
were O 
identified O 
from O 
the O 
open O 
literature O 
. O 
Details O 
about O 
study O 
design O 
and O 
results O 
from O 
each O 
study O 
, O 
as O 
well O 
as O 
the O 
criteria O 
for O 
DNT O 
testing O 
according O 
to O 
the O 
standardized O 
OECD O 
test O 
guideline O 
( O 
TG O 
) O 
426 O 
, O 
were O 
collected O 
in O 
a O 
database O 
. O 
This O 
enabled O 
systematic O 
and O 
detailed O 
comparisons O 
between O 
studies O 
as O 
well O 
as O 
to O 
the O 
criteria O 
and O 
recommendations O 
stated O 
in O 
TG O 
426 O 
. O 
Multivariate O 
analyses O 
were O 
also O 
used O 
to O 
investigate O 
how O 
different O 
factors O 
of O 
the O 
study O 
design O 
contributed O 
to O 
differences O 
in O 
study O 
results O 
. O 
The O 
analyses O 
showed O 
behavioral O 
effects O 
were O 
often O 
observed O 
for O 
endpoints O 
that O 
are O 
not O 
required O 
according O 
to O 
OECD O 
TG O 
426 O 
, O 
such O 
as O 
anxiety O 
- O 
related O 
, O 
social O 
and O 
sexual O 
behaviors O 
, O 
especially O 
at O 
very O 
low O 
doses O 
and O 
in O 
female O 
offspring O 
. O 
On O 
the O 
other O 
hand O 
relatively O 
few O 
studies O 
observed O 
any O 
effects O 
on O 
motor O 
activity O 
, O 
which O 
is O 
commonly O 
used O 
in O 
screening O 
for O 
neurotoxic O 
effects O 
in O 
regulatory O 
testing O 
. O 
However O 
, O 
varied O 
and O 
to O 
some O 
extent O 
seemingly O 
contradictory O 
results O 
have O 
been O 
reported O 
in O 
these O 
studies O 
, O 
especially O 
for O 
endpoints O 
related O 
to O 
motor O 
activity O 
and O 
anxiety O 
and O 
exploration O 
. O 
Many O 
studies O 
were O 
also O 
poorly O 
reported O 
, O 
limiting O 
these O 
analyses O 
. O 
No O 
strong O 
conclusions O 
could O 
be O 
drawn O 
from O 
the O 
multivariate O 
analyses O 
. O 
A O 
few O 
factors O 
of O 
study O 
design O 
, O 
such O 
as O 
the O 
size O 
of O 
the O 
dose O 
and O 
number O 
of O 
dose O 
levels O 
used O 
and O 
the O 
use O 
of O 
litter O 
or O 
individual O 
pup O 
as O 
statistical O 
unit O 
seemed O 
to O 
have O 
some O 
influence O 
on O 
study O 
results O 
. O 
In O 
conclusion O 
, O 
this O 
analysis O 
suggests O 
that O 
DNT-studies O 
conducted O 
according O 
to O 
the O 
standardized O 
OECD O 
TG O 
426 O 
may O 
overlook O 
sensitive O 
effects O 
of O 
BPA B-ABBREVIATION 
, O 
and O 
possibly O 
other O 
potential O 
endocrine O 
disruptors O 
, O 
especially O 
in O 
female O 
offspring O 
. O 

to O 
the O 
complex O 
chemical O 
compositions O 
and O 
pharmacological O 
effects O 
of O 
traditional O 
Chinese O 
medicines O 
, O 
we O 
developed O 
a O 
strategy O 
based O 
on O 
fishing O 
and O 
knockout O 
of O 
bioactive O 
compounds O 
using O 
a O 
combination O 
of O 
high O 
- O 
speed O 
counter O 
- O 
current O 
chromatography O 
( O 
HSCCC O 
) O 
and O 
preparative O 
HPLC O 
for O 
evaluating O 
the O 
holistic O 
activity O 
and O 
interaction O 
of O 
the O 
components O 
of O 
Herba O 
Epimedii O 
. O 
First O 
, O 
osteoblast O 
target O 
cell O 
extraction O 
was O 
used O 
for O 
preliminary O 
screening O 
of O 
the O 
potential O 
bioactive O 
compounds O 
of O 
Herba O 
Epimedii O 
. O 
Second O 
, O 
the O 
bioactive O 
compounds O 
identified O 
( O 
epimedin B-TRIVIAL 
A I-TRIVIAL 
, O 
epimedin B-TRIVIAL 
B I-TRIVIAL 
, O 
epimedin B-TRIVIAL 
C I-TRIVIAL 
and O 
icariin B-TRIVIAL 
) O 
were O 
fished O 
and O 
knocked O 
out O 
using O 
high O 
- O 
speed O 
counter O 
- O 
current O 
chromatography O 
and O 
preparative O 
HPLC O 
. O 
Third O 
, O 
the O 
bioactivity O 
of O 
resulting O 
fractions O 
was O 
assessed O 
by O 
determining O 
their O 
influence O 
on O 
cell O 
proliferation O 
and O 
differentiation O 
, O 
thereby O 
allowing O 
for O 
an O 
evaluation O 
of O 
their O 
interaction.The O 
pharmacodynamic O 
contribution O 
ratio O 
of O 
each O 
bioactive O 
compound O 
to O 
the O 
efficacy O 
of O 
the O 
herbal O 
medicine O 
could O 
then O 
be O 
comprehensively O 
and O 
intuitively O 
determined O 
based O 
on O 
the O 
spectra O 
- O 
activity O 
correlations O 
( O 
VIP O 
values O 
) O 
of O 
the O 
tested O 
compositions O 
using O 
partial O 
least O 
- O 
squares O 
regression O 
( O 
PLS-R O 
) O 
, O 
through O 
which O 
the O 
reliability O 
of O 
the O 
screening O 
and O 
isolation O 
of O 
bioactive O 
compounds O 
by O 
the O 
target O 
cell O 
extraction O 
technique O 
were O 
verified O 
. O 
The O 
proposed O 
strategy O 
is O 
a O 
useful O 
approach O 
with O 
potential O 
application O 
in O 
other O 
traditional O 
Chinese O 
medicines O 
. O 

hyaluronic O 
acid- O 
tyramine B-TRIVIAL 
hydrogels O 
incorporating O 
interferon-α2a O 
for O 
liver O 
cancer O 
therapy O 
. O 

report O 
an O 
injectable O 
hydrogel O 
system O 
that O 
incorporates O 
interferon-α2a O 
( O 
IFN-α2a O 
) O 
for O 
liver O 
cancer O 
therapy O 
. O 
IFN-α2a O 
was O 
incorporated O 
in O 
hydrogels O 
composed O 
of O 
hyaluronic O 
acid- O 
tyramine B-TRIVIAL 
( O 
HA- O 
Tyr B-FORMULA 
) O 
conjugates O 
through O 
the O 
oxidative O 
coupling O 
of O 
Tyr B-FORMULA 
moieties O 
with O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
and O 
horseradish O 
peroxidase O 
( O 
HRP O 
) O 
. O 
IFN-α2a-incorporated O 
HA- O 
Tyr B-FORMULA 
hydrogels O 
of O 
varying O 
stiffness O 
were O 
formed O 
by O 
changing O 
the O 
H2O2 B-FORMULA 
concentration O 
. O 
The O 
incorporation O 
of O 
IFN-α2a O 
did O 
not O 
affect O 
the O 
rheological O 
properties O 
of O 
the O 
hydrogels O 
. O 
The O 
activity O 
of O 
IFN-α2a O 
was O 
furthermore O 
well O 
- O 
maintained O 
in O 
the O 
hydrogels O 
with O 
lower O 
stiffness O 
. O 
Through O 
the O 
caspase-3 O 
/ O 
7 O 
pathway O 
in O 
vitro O 
, O 
IFN-α2a O 
released O 
from O 
HA- O 
Tyr B-FORMULA 
hydrogels O 
inhibited O 
the O 
proliferation O 
of O 
liver O 
cancer O 
cells O 
and O 
induced O 
apoptosis O 
. O 
In O 
the O 
study O 
of O 
the O 
pharmacokinetics O 
, O 
a O 
higher O 
concentration O 
of O 
IFN-α2a O 
was O 
shown O 
in O 
the O 
plasma O 
of O 
mice O 
treated O 
with O 
IFN-α2a-incorporated O 
hydrogels O 
after O 
4h O 
post O 
injection O 
, O 
with O 
a O 
much O 
higher O 
amount O 
of O 
IFN-α2a O 
delivered O 
at O 
the O 
tumor O 
tissue O 
comparing O 
to O 
that O 
of O 
injecting O 
an O 
IFN-α2a O 
solution O 
. O 
The O 
tumor O 
regression O 
study O 
revealed O 
that O 
IFN-α2a-incorporated O 
HA- O 
Tyr B-FORMULA 
hydrogels O 
effectively O 
inhibited O 
tumor O 
growth O 
, O 
while O 
the O 
injection O 
of O 
an O 
IFN-α2a O 
solution O 
did O 
not O 
demonstrate O 
antitumor O 
efficacy O 
. O 
Histological O 
studies O 
confirmed O 
that O 
tumor O 
tissues O 
in O 
mice O 
treated O 
with O 
IFN-α2a-incorporated O 
HA- O 
Tyr B-FORMULA 
hydrogels O 
showed O 
lower O 
cell O 
density O 
, O 
with O 
more O 
apoptotic O 
and O 
less O 
proliferating O 
cells O 
compared O 
with O 
tissues O 
treated O 
with O 
an O 
IFN-α2a O 
solution O 
. O 
In O 
addition O 
, O 
the O 
IFN-α2a-incorporated O 
hydrogel O 
treatment O 
greatly O 
inhibited O 
the O 
angiogenesis O 
of O 
tumor O 
tissues O 
. O 

microdosing O 
for O 
protein O 
and O 
peptide O 
drug O 
development O 
: O 
erythropoietin O 
as O 
a O 
case O 
study O 
. O 

: O 
Microdosing O 
is O 
a O 
technique O 
for O 
studying O 
the O 
behavior O 
of O 
compounds O 
in O 
vivo O 
at O 
1 O 
/ O 
100th O 
of O 
the O 
dose O 
of O 
a O 
test O 
substance O 
calculated O 
, O 
based O 
on O 
animal O 
data O 
, O 
to O 
yield O 
a O 
pharmacologic O 
effect O 
. O 
In O 
microdosing O 
, O 
use O 
is O 
made O 
of O 
accelerator O 
MS O 
( O 
AMS O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
whether O 
(129)I B-FORMULA 
-labeling O 
of O 
proteins O 
with O 
subsequent O 
AMS O 
measurements O 
is O 
a O 
suitable O 
method O 
to O 
perform O 
microdose O 
studies O 
with O 
therapeutic O 
proteins O 
. O 
We O 
used O 
erythropoietin O 
( O 
EPO O 
) O 
as O 
a O 
case O 
study O 
. O 
RESULTS O 
: O 
In O 
an O 
animal O 
study O 
with O 
(129)I B-FORMULA 
-labeled O 
EPO O 
in O 
Han-Wistar O 
rats O 
, O 
an O 
increase O 
of O 
(129)I B-FORMULA 
-EPO O 
is O 
observed O 
after O 
dose O 
administration O 
. O 
The O 
half O 
- O 
life O 
was O 
found O 
to O 
be O 
2 O 
and O 
5.5 O 
h O 
for O 
two O 
different O 
EPOs O 
. O 
These O 
results O 
are O 
in O 
accordance O 
with O 
expected O 
values O 
. O 
CoNCLUSION O 
: O 
Although O 
further O 
research O 
is O 
required O 
, O 
(129)I B-FORMULA 
-labeling O 
of O 
proteins O 
seems O 
a O 
feasible O 
method O 
for O 
AMS O 
microdose O 
studies O 
with O 
peptide O 
and O 
protein O 
drugs O 
, O 
such O 
as O 
biosimilars O 
. O 

dose O 
prediction O 
in O 
children O 
using O 
pharmacometric O 
bridging O 
- O 
comparison O 
with O 
published O 
pharmacogenetic O 
dosing O 
algorithms O 
. O 

: O 
Numerous O 
studies O 
have O 
investigated O 
causes O 
of O 
warfarin B-TRIVIAL 
dose O 
variability O 
in O 
adults O 
, O 
whereas O 
studies O 
in O 
children O 
are O 
limited O 
both O 
in O 
numbers O 
and O 
size O 
. O 
Mechanism O 
- O 
based O 
population O 
modelling O 
provides O 
an O 
opportunity O 
to O 
condense O 
and O 
propagate O 
prior O 
knowledge O 
from O 
one O 
population O 
to O 
another O 
. O 
The O 
main O 
objectives O 
with O 
this O 
study O 
were O 
to O 
evaluate O 
the O 
predictive O 
performance O 
of O 
a O 
theoretically O 
bridged O 
adult O 
warfarin B-TRIVIAL 
model O 
in O 
children O 
, O 
and O 
to O 
compare O 
accuracy O 
in O 
dose O 
prediction O 
relative O 
to O 
published O 
warfarin B-TRIVIAL 
algorithms O 
for O 
children O 
. O 
METHOD O 
: O 
An O 
adult O 
population O 
pharmacokinetic O 
/ O 
pharmacodynamic O 
( O 
PK O 
/ O 
PD O 
) O 
model O 
for O 
warfarin B-TRIVIAL 
, O 
with O 
CYP2C9 O 
and O 
VKORC1 O 
genotype O 
, O 
age O 
and O 
target O 
international O 
normalized O 
ratio O 
( O 
INR O 
) O 
as O 
dose O 
predictors O 
, O 
was O 
bridged O 
to O 
children O 
using O 
allometric O 
scaling O 
methods O 
. O 
Its O 
predictive O 
properties O 
were O 
evaluated O 
in O 
an O 
external O 
data O 
set O 
of O 
children O 
0-18 O 
years O 
old O 
, O 
including O 
comparison O 
of O 
dose O 
prediction O 
accuracy O 
with O 
three O 
pharmacogenetics O 
- O 
based O 
algorithms O 
for O 
children O 
. O 
RESULTS O 
: O 
Overall O 
, O 
the O 
bridged O 
model O 
predicted O 
INR O 
response O 
well O 
in O 
64 O 
warfarin B-TRIVIAL 
-treated O 
Swedish O 
children O 
( O 
median O 
age O 
4.3 O 
years O 
) O 
, O 
but O 
with O 
a O 
tendency O 
to O 
overpredict O 
INR O 
in O 
children O 
≤ O 
2 O 
years O 
old O 
. O 
The O 
bridged O 
model O 
predicted O 
20 O 
of O 
49 O 
children O 
( O 
41 O 
% O 
) O 
within O 
± O 
20 O 
% O 
of O 
actual O 
maintenance O 
dose O 
( O 
median O 
age O 
7.2 O 
years O 
) O 
. O 
In O 
comparison O 
, O 
the O 
published O 
dosing O 
algorithms O 
predicted O 
33-41 O 
% O 
of O 
the O 
children O 
within O 
±20 O 
% O 
of O 
actual O 
dose O 
. O 
Dose O 
optimization O 
with O 
the O 
bridged O 
model O 
based O 
on O 
up O 
to O 
three O 
individual O 
INR O 
observations O 
increased O 
the O 
proportion O 
within O 
±20 O 
% O 
of O 
actual O 
dose O 
to O 
70 O 
% O 
. O 
CONCLUSION O 
: O 
A O 
mechanism O 
- O 
based O 
population O 
model O 
developed O 
on O 
adult O 
data O 
provides O 
a O 
promising O 
first O 
step O 
towards O 
more O 
individualized O 
warfarin B-TRIVIAL 
therapy O 
in O 
children O 
. O 

self O 
- O 
assembly O 
of O 
short O 
amino B-FAMILY 
acid I-FAMILY 
chains O 
appears O 
to O 
be O 
one O 
of O 
the O 
most O 
promising O 
strategies O 
for O 
the O 
fabrication O 
of O 
nanostructures O 
. O 
Their O 
solubility O 
in O 
water O 
and O 
the O 
possibility O 
of O 
chemical O 
modification O 
by O 
targeting O 
the O 
amino B-FAMILY 
or O 
carboxyl B-SYSTEMATIC 
terminus O 
give O 
peptide O 
- O 
based O 
nanostructures O 
several O 
advantages O 
over O 
carbon B-SYSTEMATIC 
nanotube O 
nanostructures O 
. O 
However O 
, O 
because O 
these O 
systems O 
are O 
synthesized O 
in O 
aqueous O 
solution O 
, O 
a O 
deeper O 
understanding O 
is O 
needed O 
on O 
the O 
effects O 
of O 
water O 
especially O 
with O 
respect O 
to O 
the O 
electronic O 
, O 
structural O 
and O 
transport O 
properties O 
. O 
In O 
this O 
work O 
, O 
the O 
electronic O 
properties O 
of O 
l-diphenylalanine B-SYSTEMATIC 
nanotubes O 
( O 
FF-NTs O 
) O 
have O 
been O 
studied O 
using O 
the O 
Self-Consistent O 
Charge O 
Density-Functional O 
- O 
based O 
Tight O 
- O 
Binding O 
method O 
augmented O 
with O 
dispersion O 
interaction O 
. O 
The O 
presence O 
of O 
water O 
molecules O 
in O 
the O 
central O 
hydrophilic O 
channel O 
and O 
their O 
interaction O 
with O 
the O 
nanostructures O 
are O 
addressed O 
. O 
We O 
demonstrate O 
that O 
the O 
presence O 
of O 
water O 
leads O 
to O 
significant O 
changes O 
in O 
the O 
electronic O 
properties O 
of O 
these O 
systems O 
decreasing O 
the O 
band O 
gap O 
which O 
can O 
lead O 
to O 
an O 
increase O 
in O 
the O 
hopping O 
probability O 
and O 
the O 
conductivity O 
. O 

of O 
CIP2A O 
determines O 
erlotinib B-TRIVIAL 
-induced O 
apoptosis O 
in O 
hepatocellular O 
carcinoma O 
. O 

is O 
a O 
small O 
- O 
molecular O 
inhibitor O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
. O 
Here O 
, O 
we O 
identify O 
that O 
cancerous O 
inhibitor O 
of O 
protein O 
phosphatase O 
2A O 
( O 
CIP2A O 
) O 
is O 
a O 
major O 
determinant O 
mediating O 
erlotinib B-TRIVIAL 
-induced O 
apoptosis O 
in O 
hepatocellular O 
carcinoma O 
( O 
HCC O 
) O 
. O 
Erlotinib B-TRIVIAL 
showed O 
differential O 
effects O 
on O 
apoptosis O 
in O 
4 O 
human O 
HCC O 
cell O 
lines O 
. O 
Erlotinib B-TRIVIAL 
induced O 
significant O 
apoptosis O 
in O 
Hep3B O 
and O 
PLC5 O 
cell O 
lines O 
; O 
however O 
, O 
Huh-7 O 
and O 
HA59T O 
cell O 
lines O 
showed O 
resistance O 
to O 
erlotinib B-TRIVIAL 
-induced O 
apoptosis O 
at O 
all O 
tested O 
doses O 
. O 
Down O 
- O 
regulation O 
of O 
CIP2A O 
, O 
a O 
cellular O 
inhibitor O 
of O 
protein O 
phosphatase O 
2A O 
( O 
PP2A O 
) O 
, O 
mediated O 
the O 
apoptotic O 
effect O 
of O 
erlotinib B-TRIVIAL 
in O 
HCC O 
. O 
Erlotinib B-TRIVIAL 
inhibited O 
CIP2A O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
in O 
all O 
sensitive O 
HCC O 
cells O 
whereas O 
no O 
alterations O 
in O 
CIP2A O 
were O 
found O 
in O 
resistant O 
cells O 
. O 
Overexpression O 
of O 
CIP2A O 
upregulated O 
phospho B-SYSTEMATIC 
-Akt O 
and O 
protected O 
Hep3B O 
cells O 
from O 
erlotinib B-TRIVIAL 
-induced O 
apoptosis O 
. O 
In O 
addition O 
, O 
silencing O 
CIP2A O 
by O 
siRNA O 
restored O 
the O 
effects O 
of O 
erlotinib B-TRIVIAL 
in O 
Huh-7 O 
cells O 
. O 
Moreover O 
, O 
adding O 
okadaic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
PP2A O 
inhibitor O 
, O 
abolished O 
the O 
effects O 
of O 
erlotinib B-TRIVIAL 
on O 
apoptosis O 
in O 
Hep3B O 
cells O 
; O 
and O 
forskolin B-TRIVIAL 
, O 
a O 
PP2A O 
agonist O 
enhanced O 
the O 
effect O 
of O 
erlotinib B-TRIVIAL 
in O 
resistant O 
HA59T O 
cells O 
. O 
Combining O 
Akt O 
inhibitor O 
MK-2206 B-IDENTIFIER 
with O 
erlotinib B-TRIVIAL 
restored O 
the O 
sensitivity O 
of O 
HA59T O 
cells O 
to O 
erlotinib B-TRIVIAL 
. O 
Furthermore O 
, O 
in O 
vivo O 
xenograft O 
data O 
showed O 
that O 
erlotinib B-TRIVIAL 
inhibited O 
the O 
growth O 
of O 
PLC5 O 
tumor O 
but O 
had O 
no O 
effect O 
on O 
Huh-7 O 
tumor O 
. O 
Erlotinib B-TRIVIAL 
downregulated O 
CIP2A O 
and O 
upregulated O 
PP2A O 
activity O 
in O 
PLC5 O 
tumors O 
, O 
but O 
not O 
in O 
Huh-7 O 
tumors O 
. O 
In O 
conclusion O 
, O 
inhibition O 
of O 
CIP2A O 
determines O 
the O 
effects O 
of O 
erlotinib B-TRIVIAL 
on O 
apoptosis O 
in O 
HCC O 
. O 
CIP2A O 
may O 
be O 
useful O 
as O 
a O 
therapeutic O 
biomarker O 
for O 
predicting O 
clinical O 
response O 
to O 
erlotinib B-TRIVIAL 
in O 
HCC O 
treatment O 
. O 

of O 
the O 
scale O 
formation O 
mechanism O 
on O 
gold O 
modified O 
with O 
an O 
alkanethiol B-FAMILY 
monolayer O 
. O 

is O 
a O 
problem O 
in O 
many O 
industrial O 
processes O 
. O 
To O 
control O 
and O 
minimize O 
it O 
, O 
it O 
is O 
important O 
to O 
understand O 
the O 
dynamics O 
of O 
the O 
scale O 
formation O 
. O 
In O 
this O 
paper O 
, O 
the O 
scale O 
formation O 
was O 
examined O 
on O 
two O 
kinds O 
of O 
gold O 
surfaces O 
. O 
One O 
was O 
a O 
pure O 
metallic O 
gold O 
surface O 
, O 
and O 
the O 
other O 
was O 
a O 
gold O 
surface O 
modified O 
with O 
an O 
alkanethiol B-FAMILY 
self O 
- O 
assembled O 
monolayer O 
. O 
A O 
series O 
of O 
surface O 
characterization O 
experiments O 
were O 
performed O 
to O 
ensure O 
a O 
good O 
understanding O 
of O 
the O 
gold B-SYSTEMATIC 
- I-SYSTEMATIC 
thiol I-SYSTEMATIC 
bond O 
stability O 
in O 
a O 
caustic O 
solution O 
. O 

magnetic O 
stimulation O 
( O 
TMS O 
) O 
is O 
a O 
very O 
popular O 
tool O 
used O 
within O 
neuroscience O 
. O 
This O 
and O 
other O 
associated O 
techniques O 
allow O 
the O 
in O 
vivo O 
investigation O 
of O 
cortical O 
excitability O 
, O 
cortical O 
connectivity O 
and O 
cortical O 
plasticity O 
. O 
Schizophrenia O 
is O 
a O 
brain O 
disorder O 
and O 
various O 
theories O 
other O 
than O 
the O 
dopamine B-TRIVIAL 
hypothesis O 
have O 
been O 
developed O 
to O 
describe O 
its O 
underlying O 
neurobiology O 
. O 
Supported O 
by O 
animal O 
and O 
post O 
mortem O 
studies O 
, O 
findings O 
from O 
TMS O 
studies O 
indicate O 
that O 
schizophrenia O 
is O 
a O 
disease O 
of O 
reduced O 
cortical O 
inhibition O 
and O 
impaired O 
intra- O 
and O 
intercortical O 
connectivity O 
. O 
Further O 
studies O 
using O 
repetitive O 
TMS O 
and O 
other O 
plasticity O 
- O 
inducing O 
techniques O 
have O 
shown O 
that O 
cortical O 
plasticity O 
is O 
altered O 
in O 
schizophrenia O 
patients O 
, O 
supporting O 
the O 
recently O 
discussed O 
plasticity O 
deficiency O 
theory O 
of O 
schizophrenia O 
. O 
This O 
review O 
gives O 
an O 
introduction O 
to O 
the O 
most O 
frequently O 
applied O 
techniques O 
, O 
describes O 
findings O 
in O 
schizophrenia O 
patients O 
and O 
discusses O 
these O 
findings O 
with O 
regard O 
to O 
the O 
neurotransmitters O 
and O 
associated O 
receptors O 
involved O 
. O 
In O 
summary O 
, O 
there O 
is O 
emerging O 
evidence O 
of O 
an O 
important O 
pathophysiological O 
interplay O 
between O 
reduced O 
inhibition O 
, O 
impaired O 
connectivity O 
and O 
reduced O 
plasticity O 
in O 
schizophrenia O 
patients O 
. O 
Gamma-aminobutyric B-SYSTEMATIC 
- I-SYSTEMATIC 
acid I-SYSTEMATIC 
-receptors O 
and O 
glutamtergic O 
N-Methyl-D-aspartic- B-SYSTEMATIC 
acid I-SYSTEMATIC 
-receptors O 
are O 
most O 
likely O 
to O 
be O 
involved O 
in O 
this O 
complex O 
interplay O 
, O 
which O 
may O 
reflect O 
a O 
disturbed O 
signal O 
- O 
to O 
- O 
noise O 
ratio O 
in O 
schizophrenia O 
patients O 
. O 
This O 
review O 
will O 
discuss O 
this O 
issue O 
with O 
regard O 
to O 
the O 
available O 
treatment O 
options O 
and O 
will O 
give O 
implications O 
for O 
future O 
research O 
and O 
therapeutic O 
strategies O 
regarding O 
disinhibition O 
and O 
neuroplasticity O 
in O 
schizophrenia O 
. O 

glycaemic O 
control O 
is O 
essential O 
in O 
pregnancy O 
to O 
optimise O 
maternal O 
and O 
foetal O 
outcomes O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
assess O 
the O 
efficacy O 
and O 
safety O 
of O 
insulin O 
analogues O 
in O 
pregnancy O 
. O 
Insulin O 
lispro O 
and O 
insulin O 
aspart O 
are O 
safe O 
in O 
pregnancy O 
and O 
may O 
improve O 
post O 
- O 
prandial O 
glycaemic O 
control O 
in O 
women O 
with O 
type O 
1 O 
diabetes O 
. O 
However O 
, O 
a O 
lack O 
of O 
data O 
indicating O 
improved O 
foetal O 
outcomes O 
would O 
suggest O 
that O 
there O 
is O 
no O 
imperative O 
to O 
switch O 
to O 
a O 
short O 
- O 
acting O 
analogue O 
where O 
the O 
woman's O 
diabetes O 
is O 
well O 
controlled O 
with O 
human O 
insulin O 
. O 
There O 
are O 
no O 
reports O 
of O 
the O 
use O 
of O 
insulin O 
glulisine O 
in O 
pregnancy O 
and O 
so O 
its O 
use O 
cannot O 
be O 
recommended O 
. O 
Most O 
studies O 
of O 
insulin O 
glargine O 
in O 
pregnancy O 
are O 
small O 
, O 
retrospective O 
and O 
include O 
women O 
with O 
pre O 
- O 
existing O 
diabetes O 
and O 
gestational O 
diabetes O 
. O 
There O 
appear O 
to O 
be O 
no O 
major O 
safety O 
concerns O 
and O 
so O 
it O 
seems O 
reasonable O 
to O 
continue O 
insulin O 
glargine O 
if O 
required O 
to O 
achieve O 
excellent O 
glycaemic O 
control O 
. O 
A O 
head O 
- O 
to O 
- O 
head O 
comparison O 
between O 
insulin O 
detemir O 
and O 
NPH O 
insulin O 
in O 
women O 
with O 
type O 
1 O 
diabetes O 
showed O 
that O 
while O 
foetal O 
outcomes O 
did O 
not O 
differ O 
, O 
fasting O 
plasma O 
glucose B-TRIVIAL 
improved O 
with O 
insulin O 
detemir O 
without O 
an O 
increased O 
incidence O 
of O 
hypoglycaemia O 
. O 
The O 
greater O 
evidence O 
base O 
supports O 
the O 
use O 
of O 
insulin O 
detemir O 
as O 
the O 
first O 
line O 
long O 
- O 
acting O 
analogue O 
in O 
pregnancy O 
but O 
the O 
lack O 
of O 
definitive O 
foetal O 
benefits O 
means O 
that O 
there O 
is O 
no O 
strong O 
need O 
to O 
switch O 
a O 
woman O 
who O 
is O 
well O 
controlled O 
on O 
NPH O 
insulin O 
. O 
There O 
seems O 
little O 
justification O 
in O 
using O 
long O 
acting O 
insulin O 
analogues O 
in O 
women O 
with O 
gestational O 
diabetes O 
or O 
type O 
2 O 
diabetes O 
where O 
the O 
risk O 
of O 
hypoglycaemia O 
is O 
low O 
. O 

and O 
renal O 
Bcrp O 
transporter O 
expression O 
in O 
mice O 
treated O 
with O 
perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 

breast O 
cancer O 
resistance O 
protein O 
( O 
Bcrp O 
) O 
is O 
an O 
efflux O 
transporter O 
that O 
participates O 
in O 
the O 
biliary O 
and O 
renal O 
excretion O 
of O 
drugs O 
and O 
environmental O 
chemicals O 
. O 
Recent O 
evidence O 
suggests O 
that O 
pharmacological O 
activation O 
of O 
the O 
peroxisome O 
proliferator O 
activated O 
receptor O 
alpha O 
( O 
PPARα O 
) O 
can O 
up O 
- O 
regulate O 
the O 
hepatic O 
expression O 
of O 
Bcrp O 
. O 
The O 
current O 
study O 
investigated O 
the O 
regulation O 
of O 
hepatic O 
and O 
renal O 
Bcrp O 
mRNA O 
and O 
protein O 
in O 
mice O 
treated O 
with O 
the O 
PPARα O 
agonist O 
perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
and O 
the O 
ability O 
of O 
PFOA B-ABBREVIATION 
to O 
alter O 
human O 
BCRP O 
function O 
in O 
vitro O 
. O 
Bcrp O 
mRNA O 
and O 
protein O 
expression O 
were O 
quantified O 
in O 
the O 
livers O 
and O 
kidneys O 
of O 
male O 
C57BL O 
/ O 
6 O 
mice O 
treated O 
with O 
vehicle O 
or O 
PFOA B-ABBREVIATION 
( O 
1 O 
or O 
3mg O 
/ O 
kg O 
/ O 
day O 
oral O 
gavage O 
) O 
for O 
7 O 
days O 
. O 
PFOA B-ABBREVIATION 
treatment O 
increased O 
liver O 
weights O 
as O 
well O 
as O 
the O 
hepatic O 
mRNA O 
and O 
protein O 
expression O 
of O 
the O 
PPARα O 
target O 
gene O 
, O 
cytochrome O 
P450 O 
4a14 O 
. O 
Compared O 
to O 
vehicle O 
- O 
treated O 
control O 
mice O 
, O 
PFOA B-ABBREVIATION 
increased O 
hepatic O 
Bcrp O 
mRNA O 
and O 
protein O 
between O 
1.5- O 
and O 
3-fold O 
. O 
Immunofluorescent O 
staining O 
confirmed O 
enhanced O 
canalicular O 
Bcrp O 
staining O 
in O 
liver O 
sections O 
from O 
PFOA B-ABBREVIATION 
-treated O 
mice O 
. O 
The O 
kidney O 
expression O 
of O 
cytochrome O 
P450 O 
4a14 O 
mRNA O 
, O 
but O 
not O 
Bcrp O 
, O 
was O 
increased O 
in O 
mice O 
treated O 
with O 
PFOA B-ABBREVIATION 
. O 
Micromolar O 
concentrations O 
of O 
PFOA B-ABBREVIATION 
decreased O 
human O 
BCRP O 
ATPase O 
activity O 
and O 
inhibited O 
BCRP O 
- O 
mediated O 
transport O 
in O 
inverted O 
membrane O 
vesicles O 
. O 
Together O 
, O 
these O 
studies O 
demonstrate O 
that O 
PFOA B-ABBREVIATION 
induces O 
hepatic O 
Bcrp O 
expression O 
in O 
mice O 
and O 
may O 
inhibit O 
human O 
BCRP O 
transporter O 
function O 
at O 
concentrations O 
that O 
exceed O 
levels O 
observed O 
in O 
humans O 
. O 

deposition O 
of O 
metals O 
represents O 
an O 
important O 
approach O 
in O 
the O 
bottom O 
- O 
up O 
fabrication O 
of O 
nanostructures O 
and O 
microstructures O 
. O 
We O 
have O 
used O 
this O 
approach O 
to O 
generate O 
high O 
- O 
performance O 
chip O 
- O 
based O 
biosensors O 
using O 
silicon B-SYSTEMATIC 
as O 
a O 
platform O 
for O 
the O 
generation O 
of O 
sensor O 
arrays O 
. O 
Here O 
, O 
we O 
explore O 
the O 
applicability O 
of O 
different O 
materials O 
to O 
support O 
the O 
electrodeposition O 
and O 
identify O 
the O 
parameters O 
that O 
are O 
essential O 
for O 
robust O 
sensor O 
growth O 
. O 
We O 
show O 
that O 
inexpensive O 
materials O 
can O 
be O 
used O 
as O 
templates O 
for O 
electrodeposition O 
, O 
and O 
demonstrate O 
that O 
these O 
low O 
- O 
cost O 
sensors O 
exhibit O 
clinically O 
- O 
relevant O 
levels O 
of O 
sensitivity O 
and O 
specificity O 
. O 
In O 
particular O 
, O 
we O 
prove O 
herein O 
that O 
the O 
glass O 
- O 
based O 
sensors O 
successfully O 
detect O 
E O 
. O 
coli O 
in O 
urine O 
, O 
when O 
present O 
at O 
the O 
100 O 
cfu O 
μL(-1) O 
levels O 
found O 
typically O 
in O 
samples O 
of O 
patients O 
with O 
urinary O 
tract O 
infections O 
. O 

is O 
directly O 
related O 
with O 
physiological O 
alterations O 
occurring O 
at O 
a O 
cell O 
and O 
subcellular O 
level O 
. O 
However O 
, O 
the O 
role O 
of O 
diet O 
manipulation O 
on O 
mitochondrial O 
physiology O 
is O 
still O 
largely O 
unexplored O 
. O 
Aiming O 
at O 
correlating O 
diet O 
with O 
alterations O 
of O 
mitochondrial O 
membrane O 
composition O 
and O 
bioenergetics O 
, O 
Wistar-Han O 
male O 
rats O 
were O 
fed O 
for O 
11 O 
, O 
22 O 
and O 
33 O 
days O 
with O 
a O 
rapeseed O 
oil O 
- O 
based O 
diet O 
and O 
mitochondrial O 
bioenergetics O 
, O 
and O 
membrane O 
composition O 
were O 
compared O 
at O 
each O 
time O 
point O 
with O 
a O 
standard O 
diet O 
group O 
. O 
Considerable O 
differences O 
were O 
noticed O 
in O 
mitochondrial O 
membrane O 
lipid O 
composition O 
, O 
namely O 
in O 
terms O 
of O 
fatty B-FAMILY 
acyl I-FAMILY 
chains O 
and O 
relative O 
proportions O 
of O 
phospholipid O 
classes O 
, O 
the O 
modified O 
diet O 
inducing O 
a O 
decrease O 
in O 
the O 
saturated O 
to O 
unsaturated O 
molar O 
ratio O 
and O 
an O 
increase O 
in O 
the O 
phosphatidylcholine B-FAMILY 
to O 
phosphatidylethanolamine B-SYSTEMATIC 
molar O 
ratio O 
. O 
Mass O 
spectrometry O 
lipid O 
analysis O 
showed O 
significant O 
differences O 
in O 
the O 
major O 
species O 
of O 
cardiolipin B-TRIVIAL 
, O 
with O 
an O 
apparent O 
increased O 
incorporation O 
of O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
as O 
a O 
result O 
of O 
exposure O 
to O 
the O 
modified O 
diet O 
. O 
Rats O 
fed O 
the O 
modified O 
diet O 
during O 
22 O 
days O 
showed O 
decreased O 
hepatic O 
mitochondrial O 
state O 
3 O 
respiration O 
and O 
were O 
more O 
susceptible O 
to O 
Ca(2+) B-FORMULA 
-induced O 
transition O 
pore O 
opening O 
. O 
Rapeseed O 
oil O 
- O 
enriched O 
diet O 
also O 
appeared O 
to O 
promote O 
a O 
decrease O 
in O 
hydroperoxide B-FAMILY 
production O 
by O 
the O 
respiratory O 
chain O 
, O 
although O 
a O 
simultaneous O 
decrease O 
in O 
vitamin B-FAMILY 
E I-FAMILY 
content O 
was O 
detected O 
. O 
In O 
conclusion O 
, O 
our O 
data O 
indicate O 
that O 
the O 
rapeseed O 
oil O 
diet O 
causes O 
negative O 
alterations O 
on O 
hepatic O 
mitochondrial O 
bioenergetics O 
, O 
which O 
may O 
result O 
from O 
membrane O 
remodeling O 
. O 
Such O 
alterations O 
may O 
have O 
an O 
impact O 
not O 
only O 
on O 
energy O 
supply O 
to O 
the O 
cell O 
, O 
but O 
also O 
on O 
drug O 
- O 
induced O 
hepatic O 
mitochondrial O 
liabilities O 
. O 

we O 
report O 
comparative O 
binding O 
energy O 
( O 
COMBINE O 
) O 
analyses O 
to O 
derive O 
quantitative O 
structure O 
- O 
activity O 
relationship O 
( O 
QSAR O 
) O 
models O 
that O 
help O 
rationalize O 
the O 
determinants O 
of O 
binding O 
affinity O 
for O 
inhibitors O 
of O 
type O 
II O 
dehydroquinase O 
( O 
DHQ2 O 
) O 
, O 
the O 
third O 
enzyme O 
of O 
the O 
shikimic B-TRIVIAL 
acid I-TRIVIAL 
pathway O 
. O 
Independent O 
COMBINE O 
models O 
were O 
derived O 
for O 
Helicobacter O 
pylori O 
and O 
Mycobacterium O 
tuberculosis O 
DHQ2 O 
, O 
which O 
is O 
an O 
essential O 
enzyme O 
in O 
both O 
these O 
pathogenic O 
bacteria O 
that O 
has O 
no O 
counterpart O 
in O 
human O 
cells O 
. O 
These O 
studies O 
quantify O 
the O 
importance O 
of O 
the O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
between O 
the O 
ligands O 
and O 
the O 
water O 
molecule O 
involved O 
in O 
the O 
DHQ2 O 
reaction O 
mechanism O 
. O 
They O 
also O 
highlight O 
important O 
differences O 
in O 
the O 
ligand O 
interactions O 
with O 
the O 
interface O 
pocket O 
close O 
to O 
the O 
active O 
site O 
that O 
could O 
provide O 
guides O 
for O 
future O 
inhibitor O 
design O 
. O 

acid I-FAMILY 
residues O 
at O 
the O 
N- O 
and O 
C-termini O 
are O 
essential O 
for O 
the O 
folding O 
of O 
active O 
human O 
butyrylcholinesterase O 
polypeptide O 
. O 

serum O 
butyrylcholinesterase O 
( O 
HuBChE O 
) O 
is O 
currently O 
the O 
most O 
suitable O 
bioscavenger O 
for O 
the O 
prophylaxis O 
of O 
highly O 
toxic O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
nerve O 
agents O 
. O 
A O 
dose O 
of O 
200mg O 
of O 
HuBChE O 
is O 
envisioned O 
as O 
a O 
prophylactic O 
treatment O 
that O 
can O 
protect O 
humans O 
from O 
an O 
exposure O 
of O 
up O 
to O 
2×LD50 O 
of O 
soman O 
. O 
The O 
limited O 
availability O 
and O 
administration O 
of O 
multiple O 
doses O 
of O 
this O 
stoichiometric O 
bioscavenger O 
make O 
this O 
pretreatment O 
difficult O 
. O 
Thus O 
, O 
the O 
goal O 
of O 
this O 
study O 
was O 
to O 
produce O 
a O 
smaller O 
enzymatically O 
active O 
HuBChE O 
polypeptide O 
( O 
HBP O 
) O 
that O 
could O 
bind O 
to O 
nerve O 
agents O 
with O 
high O 
affinity O 
thereby O 
reducing O 
the O 
dose O 
of O 
enzyme O 
. O 
Studies O 
have O 
indicated O 
that O 
the O 
three O 
- O 
dimensional O 
structure O 
and O 
the O 
domains O 
of O 
HuBChE O 
( O 
acyl B-FAMILY 
pocket O 
, O 
lip O 
of O 
the O 
active O 
center O 
gorge O 
, O 
and O 
the O 
anionic O 
substrate O 
- O 
binding O 
domain O 
) O 
that O 
are O 
critical O 
for O 
the O 
binding O 
of O 
substrate O 
are O 
also O 
essential O 
for O 
the O 
selectivity O 
and O 
binding O 
of O 
inhibitors O 
including O 
OPs O 
. O 
Therefore O 
, O 
we O 
designed O 
three O 
HBPs O 
by O 
deleting O 
some O 
N- O 
and O 
C- O 
terminal O 
residues O 
of O 
HuBChE O 
by O 
maintaining O 
the O 
folds O 
of O 
the O 
active O 
site O 
core O 
that O 
includes O 
the O 
three O 
active O 
site O 
residues O 
( O 
S198 O 
, O 
E325 O 
, O 
and O 
H438 O 
) O 
. O 
HBP-4 O 
that O 
lacks O 
45 O 
residues O 
from O 
C-terminus O 
but O 
known O 
to O 
have O 
BChE O 
activity O 
was O 
used O 
as O 
a O 
control O 
. O 
The O 
cDNAs O 
for O 
the O 
HBPs O 
containing O 
signal O 
sequences O 
were O 
synthesized O 
, O 
cloned O 
into O 
different O 
mammalian O 
expression O 
vectors O 
, O 
and O 
recombinant O 
polypeptides O 
were O 
transiently O 
expressed O 
in O 
different O 
cell O 
lines O 
. O 
No O 
BChE O 
activity O 
was O 
detected O 
in O 
the O 
culture O 
media O 
of O 
cells O 
transfected O 
with O 
any O 
of O 
the O 
newly O 
designed O 
HBPs O 
, O 
and O 
the O 
inactive O 
polypeptides O 
remained O 
inside O 
the O 
cells O 
. O 
Only O 
enzymatically O 
active O 
HBP-4 O 
was O 
secreted O 
into O 
the O 
culture O 
medium O 
. O 
These O 
results O 
suggest O 
that O 
residues O 
at O 
the O 
N- O 
and O 
C-termini O 
are O 
required O 
for O 
the O 
folding O 
and O 
/ O 
or O 
maintenance O 
of O 
HBP O 
into O 
an O 
active O 
stable O 
, O 
conformation O 
. O 

- O 
inspired O 
adhesive O 
binders O 
for O 
high O 
- O 
performance O 
silicon B-SYSTEMATIC 
nanoparticle O 
anodes O 
in O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 

of O 
mussel O 
- O 
inspired O 
catechol B-TRIVIAL 
groups O 
to O 
various O 
polymer O 
backbones O 
results O 
in O 
materials O 
suitable O 
as O 
silicon B-SYSTEMATIC 
anode O 
binders O 
. O 
The O 
unique O 
wetness O 
- O 
resistant O 
adhesion O 
provided O 
by O 
the O 
catechol B-TRIVIAL 
groups O 
allows O 
the O 
silicon B-SYSTEMATIC 
nanoparticle O 
electrodes O 
to O 
maintain O 
their O 
structure O 
throughout O 
the O 
repeated O 
volume O 
expansion O 
and O 
shrinkage O 
during O 
lithiation O 
cycling O 
, O 
thus O 
facilitating O 
substantially O 
improved O 
specific O 
capacities O 
and O 
cycle O 
lives O 
of O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 

of O 
A O 
- O 
type O 
K(+) B-FORMULA 
channels O 
by O 
the O 
short O 
- O 
chain O 
cobrotoxin O 
through O 
the O 
protein O 
kinase O 
C-delta O 
isoform O 
decreases O 
membrane O 
excitability O 
in O 
dorsal O 
root O 
ganglion O 
neurons O 
. O 

- O 
type O 
K(+) B-FORMULA 
channels O 
are O 
crucial O 
in O 
controlling O 
neuronal O 
excitability O 
, O 
and O 
their O 
regulation O 
in O 
sensory O 
neurons O 
may O 
alter O 
pain O 
sensation O 
. O 
In O 
this O 
study O 
, O 
we O 
identified O 
the O 
functional O 
role O 
of O 
cobrotoxin O 
, O 
the O 
short O 
- O 
chain O 
α-neurotoxin O 
isolated O 
from O 
Naja O 
atra O 
venom O 
, O 
which O 
acts O 
in O 
the O 
regulation O 
of O 
the O 
transient O 
A O 
- O 
type O 
K(+) B-FORMULA 
currents O 
( O 
IA O 
) O 
and O 
membrane O 
excitability O 
in O 
dorsal O 
root O 
ganglion O 
( O 
DRG O 
) O 
neurons O 
via O 
the O 
activation O 
of O 
the O 
muscarinic O 
M3 O 
receptor O 
( O 
M3R O 
) O 
. O 
Our O 
results O 
showed O 
that O 
cobrotoxin O 
increased O 
IA O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
, O 
whereas O 
the O 
sustained O 
delayed O 
rectifier O 
K(+) B-FORMULA 
currents O 
( O 
IDR O 
) O 
were O 
not O 
affected O 
. O 
Cobrotoxin O 
did O 
not O 
affect O 
the O 
activation O 
of O 
IA O 
markedly O 
, O 
however O 
, O 
it O 
shifted O 
the O 
inactivation O 
curve O 
significantly O 
in O 
the O 
depolarizing O 
direction O 
. O 
The O 
cobrotoxin O 
- O 
induced O 
IA O 
response O 
was O 
blocked O 
by O 
the O 
M3R-selective O 
antagonists O 
DAU-5884 B-IDENTIFIER 
and O 
4-DAMP B-SYSTEMATIC 
. O 
An O 
siRNA O 
targeting O 
the O 
M3R O 
in O 
small O 
DRG O 
neurons O 
abolished O 
the O 
cobrotoxin O 
- O 
induced O 
IA O 
increase O 
. O 
In O 
addition O 
, O 
dialysis O 
of O 
the O 
cells O 
with O 
the O 
novel O 
protein O 
kinase O 
C-delta O 
isoform O 
( O 
PKC-δ O 
) O 
inhibitor O 
δv1-1 O 
or O 
an O 
siRNA O 
targeting O 
PKC-δ O 
abolished O 
the O 
cobrotoxin O 
- O 
induced O 
IA O 
response O 
, O 
whereas O 
inhibition O 
of O 
PKA O 
or O 
classic O 
PKC O 
activity O 
elicited O 
no O 
such O 
effects O 
. O 
Moreover O 
, O 
we O 
observed O 
a O 
significant O 
decrease O 
in O 
the O 
firing O 
rate O 
of O 
the O 
neuronal O 
action O 
potential O 
induced O 
by O 
M3R O 
activation O 
. O 
Pretreatment O 
of O 
the O 
cells O 
with O 
4-aminopyridine B-SYSTEMATIC 
, O 
a O 
selective O 
blocker O 
of O 
IA O 
, O 
abolished O 
this O 
effect O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
the O 
short O 
- O 
chain O 
cobrotoxin O 
selectively O 
enhances O 
IA O 
via O 
a O 
novel O 
PKC-δ-dependent O 
pathway O 
. O 
This O 
effect O 
occurred O 
via O 
the O 
activation O 
of O 
M3R O 
and O 
might O 
contribute O 
to O 
its O 
neuronal O 
hypoexcitability O 
in O 
small O 
DRG O 
neurons O 
. O 

, O 
synthesis O 
, O 
inhibition O 
studies O 
, O 
and O 
molecular O 
modeling O 
of O 
pepstatin B-TRIVIAL 
analogues O 
addressing O 
different O 
secreted O 
aspartic O 
proteinases O 
of O 
Candida O 
albicans O 
. O 

family O 
of O 
secreted O 
aspartic O 
proteinases O 
is O 
known O 
as O 
an O 
important O 
virulence O 
factor O 
of O 
yeast O 
infections O 
by O 
Candida O 
albicans O 
in O 
particular O 
, O 
which O 
is O 
the O 
most O 
common O 
fungal O 
pathogen O 
for O 
humans O 
with O 
respect O 
to O 
systemic O 
disease O 
. O 
Due O 
to O 
the O 
continuing O 
increase O 
of O 
drug O 
resistant O 
strains O 
, O 
these O 
proteinases O 
are O 
currently O 
considered O 
as O 
promising O 
drug O 
target O 
candidates O 
. O 
Based O 
on O 
the O 
known O 
Sap2-substrate O 
specificity O 
data O 
and O 
X-ray O 
analyses O 
of O 
Sap O 
/ O 
inhibitor O 
complexes O 
, O 
three O 
libraries O 
of O 
inhibitors O 
were O 
designed O 
and O 
synthesized O 
by O 
modifying O 
the O 
structure O 
of O 
pepstatin B-TRIVIAL 
A I-TRIVIAL 
, O 
a O 
common O 
non-selective O 
aspartic O 
proteinase O 
inhibitor O 
, O 
at O 
the O 
P3 O 
, O 
P2 O 
, O 
or O 
P2 O 
' O 
position O 
. O 
These O 
novel O 
inhibitors O 
showed O 
high O 
inhibitory O 
potencies O 
for O 
the O 
isoenzymes O 
Sap1 O 
, O 
Sap3 O 
, O 
Sap5 O 
and O 
Sap6 O 
. O 
Then O 
, O 
the O 
affinity O 
and O 
selectivity O 
of O 
the O 
peptide O 
ligands O 
were O 
investigated O 
by O 
molecular O 
modeling O 
, O 
highlighting O 
new O 
key O 
structural O 
information O 
for O 
the O 
design O 
of O 
potent O 
and O 
selective O 
anti-virulence O 
agents O 
targeting O 
Candida O 
albicans O 
. O 

with O 
viral O 
infections O 
of O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
may O 
present O 
with O 
a O 
variety O 
of O 
neurological O 
symptoms O 
, O 
most O 
commonly O 
dominated O 
by O 
either O 
encephalitis O 
or O 
meningitis O 
. O 
The O 
aetiological O 
panorama O 
varies O 
in O 
different O 
parts O 
of O 
the O 
world O 
as O 
well O 
as O 
over O 
time O 
. O 
Thus O 
, O 
virological O 
first O 
- O 
line O 
diagnostics O 
must O 
be O 
adapted O 
to O 
the O 
current O 
epidemiological O 
situation O 
and O 
to O 
the O 
individual O 
patient O 
history O 
, O 
including O 
recent O 
travels O 
. O 
This O 
review O 
focuses O 
on O 
the O 
diagnostics O 
and O 
treatment O 
of O 
viral O 
CNS O 
infections O 
in O 
the O 
immunocompetent O 
host O 
from O 
a O 
Northern O 
European O 
perspective O 
. O 
Effective O 
vaccines O 
are O 
available O 
for O 
viruses O 
such O 
as O 
poliovirus O 
and O 
tick O 
- O 
borne O 
encephalitis O 
virus O 
( O 
TBEV O 
) O 
and O 
for O 
the O 
childhood O 
diseases O 
morbilli O 
( O 
measles O 
) O 
, O 
rubella O 
( O 
German O 
measles O 
) O 
, O 
parotitis O 
( O 
mumps O 
) O 
and O 
varicella O 
( O 
chickenpox O 
) O 
. O 
However O 
, O 
cases O 
do O 
appear O 
due O 
to O 
suboptimal O 
immunization O 
rates O 
. O 
In O 
viral O 
CNS O 
infections O 
, O 
epidemiological O 
surveillance O 
is O 
essential O 
for O 
establishing O 
preventive O 
strategies O 
and O 
for O 
detecting O 
emerging O 
viruses O 
. O 
Knowledge O 
of O 
the O 
possibilities O 
and O 
limitations O 
of O 
diagnostic O 
methods O 
for O 
specific O 
viral O 
CNS O 
infections O 
is O 
vital O 
. O 
A O 
positive O 
cerebral O 
spinal O 
fluid O 
( O 
CSF O 
) O 
polymerase O 
chain O 
reaction O 
( O 
PCR O 
) O 
finding O 
is O 
usually O 
reliable O 
for O 
aetiological O 
diagnosis O 
. O 
The O 
demonstration O 
of O 
intrathecal O 
antibody O 
synthesis O 
is O 
useful O 
for O 
confirming O 
the O 
aetiology O 
in O 
a O 
later O 
stage O 
of O 
disease O 
, O 
hitherto O 
sufficiently O 
evaluated O 
in O 
herpes O 
simplex O 
encephalitis O 
( O 
HSE O 
) O 
and O 
tick O 
- O 
borne O 
encephalitis O 
( O 
TBE O 
) O 
. O 
Despite O 
improved O 
virological O 
and O 
differential O 
diagnostic O 
methods O 
, O 
aetiology O 
remains O 
unknown O 
in O 
about O 
half O 
of O 
the O 
cases O 
with O 
suspected O 
viral O 
encephalitis O 
. O 
Antiviral O 
treatment O 
is O 
available O 
chiefly O 
for O 
infections O 
caused O 
by O 
herpesviruses O 
, O 
and O 
acyclovir B-TRIVIAL 
( O 
aciclovir B-TRIVIAL 
) O 
is O 
the O 
drug O 
of O 
choice O 
for O 
empirical O 
therapy O 
in O 
suspected O 
viral O 
encephalitis O 
. O 
However O 
, O 
randomized O 
, O 
controlled O 
antiviral O 
trials O 
have O 
only O 
been O 
conducted O 
for O 
HSE O 
, O 
while O 
such O 
studies O 
are O 
lacking O 
in O 
other O 
viral O 
CNS O 
infections O 
. O 
Viral O 
cytolysis O 
and O 
immune O 
- O 
mediated O 
mechanisms O 
may O 
contribute O 
to O 
varying O 
extents O 
to O 
neurological O 
damage O 
. O 
Although O 
the O 
brain O 
damage O 
is O 
believed O 
to O 
depend O 
, O 
to O 
a O 
varying O 
degree O 
, O 
on O 
the O 
intrathecal O 
host O 
immune O 
response O 
, O 
the O 
use O 
of O 
corticosteroids B-FAMILY 
in O 
viral O 
CNS O 
infections O 
is O 
scarcely O 
studied O 
, O 
as O 
is O 
specific O 
treatment O 
for O 
neuroinflammation O 
. O 
Improved O 
antiviral O 
and O 
immunomodulating O 
treatment O 
is O 
desirable O 
. O 
Since O 
neurological O 
sequelae O 
are O 
still O 
abundant O 
, O 
follow O 
- O 
up O 
after O 
severe O 
viral O 
CNS O 
disease O 
must O 
include O 
a O 
neuropsychological O 
assessment O 
and O 
an O 
individually O 
adapted O 
rehabilitation O 
plan O 
. O 

Ordered O 
Hollow O 
Oxide B-SYSTEMATIC 
Nanostructures O 
: O 
The O 
Kirkendall O 
Effect O 
at O 
the O 
Nanoscale O 
. O 

ordered O 
ultra O 
- O 
long O 
oxide B-SYSTEMATIC 
nanotubes O 
are O 
fabricated O 
by O 
a O 
simple O 
two O 
- O 
step O 
strategy O 
involving O 
the O 
growth O 
of O 
copper B-SYSTEMATIC 
nanowires O 
on O 
nanopatterned O 
template O 
substrates O 
by O 
magnetron O 
sputtering O 
, O 
followed O 
by O 
thermal O 
annealing O 
in O 
air O 
. O 
The O 
formation O 
of O 
such O 
tubular O 
nanostructures O 
is O 
explained O 
according O 
to O 
the O 
nanoscale O 
Kirkendall O 
effect O 
. O 
The O 
concept O 
of O 
this O 
new O 
fabrication O 
route O 
is O 
also O 
extendable O 
to O 
create O 
periodic O 
zero O 
- O 
dimensional O 
hollow O 
nanostructures O 
. O 

and O 
Rapid O 
Synthesis O 
of O 
Magnetite B-TRIVIAL 
/ O 
Hydroxyapatite B-TRIVIAL 
Composites O 
for O 
Hyperthermia O 
Treatments O 
via O 
a O 
Mechanochemical O 
Route O 
. O 

paper O 
presents O 
a O 
simple O 
method O 
for O 
the O 
rapid O 
synthesis O 
of O 
magnetite B-TRIVIAL 
/ O 
hydroxyapatite B-TRIVIAL 
composite O 
particles O 
. O 
In O 
this O 
method O 
, O 
superparamagnetic O 
magnetite B-TRIVIAL 
nanoparticles O 
are O 
first O 
synthesized O 
by O 
coprecipitation O 
using O 
ferrous B-SYSTEMATIC 
chloride I-SYSTEMATIC 
and O 
ferric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
. O 
Immediately O 
following O 
the O 
synthesis O 
, O 
carbonate B-FAMILY 
-substituted O 
( O 
B O 
- O 
type O 
) O 
hydroxyapatite B-TRIVIAL 
particles O 
are O 
mechanochemically O 
synthesized O 
by O 
wet O 
milling O 
dicalcium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
dihydrate I-SYSTEMATIC 
and O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
in O 
a O 
dispersed O 
suspension O 
of O 
magnetite B-TRIVIAL 
nanoparticles O 
, O 
during O 
which O 
the O 
magnetite B-TRIVIAL 
nanoparticles O 
are O 
incorporated O 
into O 
the O 
hydroxyapatite B-TRIVIAL 
matrix O 
. O 
We O 
observed O 
that O 
the O 
resultant O 
magnetite B-TRIVIAL 
/ O 
hydroxyapatite B-TRIVIAL 
composites O 
possessed O 
a O 
homogeneous O 
dispersion O 
of O 
magnetite B-TRIVIAL 
nanoparticles O 
, O 
characterized O 
by O 
an O 
absence O 
of O 
large O 
aggregates O 
. O 
When O 
this O 
material O 
was O 
subjected O 
to O 
an O 
alternating O 
magnetic O 
field O 
, O 
the O 
heat O 
generated O 
increased O 
with O 
increasing O 
magnetite B-TRIVIAL 
concentration O 
. O 
For O 
a O 
magnetite B-TRIVIAL 
concentration O 
of O 
30 O 
mass% O 
, O 
a O 
temperature O 
increase O 
greater O 
than O 
20 O 
K O 
was O 
achieved O 
in O 
less O 
than O 
50 O 
s O 
. O 
These O 
results O 
suggest O 
that O 
our O 
composites O 
exhibit O 
good O 
hyperthermia O 
properties O 
and O 
are O 
promising O 
candidates O 
for O 
hyperthermia O 
treatments O 
. O 

as O 
agents O 
that O 
prevent O 
formation O 
of O 
cataract O 
: O 
nobiletin B-TRIVIAL 
congeners O 
show O 
potent O 
growth O 
inhibitory O 
effects O 
in O 
human O 
lens O 
epithelial O 
cells O 
. O 

capsular O 
opacification O 
( O 
PCO O 
) O 
is O 
the O 
most O 
frequent O 
complication O 
and O 
the O 
primary O 
reason O 
for O 
visual O 
decrease O 
after O 
extracapsular O 
cataract O 
surgery O 
. O 
The O 
proliferation O 
and O 
migration O 
of O 
leftover O 
lens O 
epithelial O 
cells O 
( O 
LECs O 
) O 
after O 
surgery O 
may O 
contribute O 
to O 
the O 
development O 
of O 
PCO O 
. O 
To O 
prevent O 
PCO O 
, O 
a O 
rational O 
approach O 
would O 
be O 
to O 
inhibit O 
both O 
the O 
proliferation O 
and O 
the O 
migration O 
of O 
LECs O 
using O 
nontoxic O 
xenobiotics O 
. O 
Nobiletin B-TRIVIAL 
, O 
one O 
of O 
the O 
most O 
abundant O 
polymethoxyflavones B-FAMILY 
( O 
PMFs B-FAMILY 
) O 
in O 
citrus O 
peel O 
, O 
and O 
its O 
synthetic O 
congeners O 
displayed O 
a O 
potent O 
inhibition O 
of O 
LEC O 
proliferation O 
. O 
Structural O 
features O 
which O 
enhance O 
anti-proliferative O 
activity O 
have O 
also O 
been O 
discussed O 
. O 

Phosphorylation O 
and O 
Ubiquitination O 
Sites O 
Regulate O 
Reactive O 
Oxygen B-SYSTEMATIC 
Species O 
- O 
dependent O 
Degradation O 
of O 
Anti-apoptotic O 
c-FLIP O 
Protein O 
. O 

cytosolic O 
protein O 
c-FLIP O 
( O 
cellular O 
Fas-associated O 
death O 
domain O 
- O 
like O 
interleukin O 
1β-converting O 
enzyme O 
inhibitory O 
protein O 
) O 
is O 
an O 
inhibitor O 
of O 
death O 
receptor O 
- O 
mediated O 
apoptosis O 
that O 
is O 
up O 
- O 
regulated O 
in O 
a O 
variety O 
of O 
cancers O 
, O 
contributing O 
to O 
apoptosis O 
resistance O 
. O 
Several O 
compounds O 
found O 
to O 
restore O 
sensitivity O 
of O 
cancer O 
cells O 
to O 
TRAIL O 
, O 
a O 
TNF O 
family O 
death O 
ligand O 
with O 
promising O 
therapeutic O 
potential O 
, O 
act O 
by O 
targeting O 
c-FLIP O 
ubiquitination O 
and O 
degradation O 
by O 
the O 
proteasome O 
. O 
The O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
has O 
been O 
implicated O 
in O 
c-FLIP O 
protein O 
degradation O 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
ROS O 
post O 
- O 
transcriptionally O 
regulate O 
c-FLIP O 
protein O 
levels O 
is O 
not O 
well O 
understood O 
. O 
We O 
show O 
here O 
that O 
treatment O 
of O 
prostate O 
cancer O 
PPC-1 O 
cells O 
with O 
the O 
superoxide B-TRIVIAL 
generators O 
menadione B-TRIVIAL 
, O 
paraquat B-TRIVIAL 
, O 
or O 
buthionine B-SYSTEMATIC 
sulfoximine I-SYSTEMATIC 
down O 
- O 
regulates O 
c-FLIP O 
long O 
( O 
c-FLIPL O 
) O 
protein O 
levels O 
, O 
which O 
is O 
prevented O 
by O 
the O 
proteasome O 
inhibitor O 
MG132 B-IDENTIFIER 
. O 
Furthermore O 
, O 
pretreatment O 
of O 
PPC-1 O 
cells O 
with O 
a O 
ROS O 
scavenger O 
prevented O 
ubiquitination O 
and O 
loss O 
of O 
c-FLIPL O 
protein O 
induced O 
by O 
menadione B-TRIVIAL 
or O 
paraquat B-TRIVIAL 
. O 
We O 
identified O 
lysine B-TRIVIAL 
167 O 
as O 
a O 
novel O 
ubiquitination O 
site O 
of O 
c-FLIPL O 
important O 
for O 
ROS-dependent O 
degradation O 
. O 
We O 
also O 
identified O 
threonine B-TRIVIAL 
166 O 
as O 
a O 
novel O 
phosphorylation O 
site O 
and O 
demonstrate O 
that O 
Thr B-FORMULA 
-166 O 
phosphorylation O 
is O 
required O 
for O 
ROS-induced O 
Lys B-FORMULA 
-167 O 
ubiquitination O 
. O 
The O 
mutation O 
of O 
either O 
Thr B-FORMULA 
-166 O 
or O 
Lys B-FORMULA 
-167 O 
was O 
sufficient O 
to O 
stabilize O 
c-FLIP O 
protein O 
levels O 
in O 
PPC-1 O 
, O 
HEK293T O 
, O 
and O 
HeLa O 
cancer O 
cells O 
treated O 
with O 
menadione B-TRIVIAL 
or O 
paraquat B-TRIVIAL 
. O 
Accordingly O 
, O 
expression O 
of O 
c-FLIP O 
T166A O 
or O 
K167R O 
mutants O 
protected O 
cells O 
from O 
ROS O 
- O 
mediated O 
sensitization O 
to O 
TRAIL-induced O 
cell O 
death O 
. O 
Our O 
findings O 
reveal O 
novel O 
ROS-dependent O 
post O 
- O 
translational O 
modifications O 
of O 
the O 
c-FLIP O 
protein O 
that O 
regulate O 
its O 
stability O 
, O 
thus O 
impacting O 
sensitivity O 
of O 
cancer O 
cells O 
to O 
TRAIL O 
. O 

sensitive O 
fluorescent O 
and O 
colorimetric O 
pH O 
sensor O 
based O 
on O 
polyethylenimine B-SYSTEMATIC 
-capped O 
silver B-SYSTEMATIC 
nanoclusters O 
. O 

nanoclusters O 
capped O 
by O 
hyperbranched O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
have O 
been O 
developed O 
as O 
a O 
highly O 
sensitive O 
fluorescent O 
and O 
colorimetric O 
pH O 
sensor O 
. O 
The O 
probe O 
responds O 
rapidly O 
to O 
pH O 
fluctuations O 
and O 
has O 
such O 
absorption O 
characteristics O 
that O 
the O 
color O 
changes O 
from O 
the O 
colorless O 
or O 
a O 
nearly O 
colorless O 
state O 
to O 
a O 
colored O 
state O 
with O 
increasing O 
acidity O 
, O 
so O 
PEI B-ABBREVIATION 
-capped O 
Ag B-FORMULA 
nanoclusters O 
could O 
be O 
used O 
as O 
a O 
color O 
indicator O 
for O 
colorimetric O 
pH O 
detection O 
. O 
Quantitatively O 
, O 
the O 
fluorescence O 
intensity O 
of O 
PEI B-ABBREVIATION 
-capped O 
Ag B-FORMULA 
nanoclusters O 
exhibits O 
a O 
linear O 
fashion O 
over O 
the O 
pH O 
range O 
of O 
5.02-7.96 O 
and O 
increases O 
by O 
around O 
10-fold O 
approximately O 
with O 
greater O 
fluorescence O 
at O 
higher O 
pH O 
values O 
. O 
The O 
repulsion O 
development O 
and O 
conformational O 
change O 
of O 
PEI B-ABBREVIATION 
with O 
decreasing O 
pH O 
induce O 
the O 
aggregation O 
of O 
Ag B-FORMULA 
nanoclusters O 
, O 
leading O 
to O 
an O 
obvious O 
color O 
change O 
and O 
fluorescence O 
quenching O 
of O 
Ag B-FORMULA 
nanoclusters O 
at O 
low O 
pH O 
values O 
. O 
As O 
expected O 
, O 
the O 
pH O 
probe O 
is O 
also O 
sensitive O 
to O 
the O 
different O 
buffer O 
solutions O 
, O 
except O 
for O 
those O 
containing O 
some O 
anions O 
that O 
could O 
react O 
with O 
Ag B-FORMULA 
nanoclusters O 
. O 
Besides O 
, O 
the O 
ionic O 
strength O 
of O 
the O 
buffers O 
has O 
a O 
little O 
influence O 
on O 
the O 
pH-responsive O 
behavior O 
. O 
Our O 
pH O 
sensor O 
with O 
nanoscaled O 
physical O 
dimensions O 
would O 
be O 
a O 
promising O 
candidate O 
in O 
the O 
applications O 
in O 
biological O 
, O 
medical O 
, O 
and O 
pharmaceutical O 
fields O 
. O 

photoinduced O 
charge O 
transfer O 
composite O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
ferrocene B-TRIVIAL 
. O 

demonstrate O 
the O 
formation O 
of O 
a O 
photoinduced O 
charge O 
transfer O 
composite O 
with O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
and O 
ferrocene B-TRIVIAL 
( O 
Fc O 
) O 
molecules O 
. O 
Derived O 
insulating O 
GO O 
was O 
partially O 
reduced O 
to O 
improve O 
the O 
conductivity O 
and O 
modified O 
with O 
the O 
Fc O 
molecules O 
. O 
Transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
, O 
elemental O 
mapping O 
, O 
X-ray O 
photoelectron O 
and O 
UV-visible O 
spectroscopy O 
studies O 
confirm O 
that O 
the O 
Fc O 
molecules O 
were O 
well O 
grafted O 
to O 
the O 
surface O 
of O 
a O 
GO O 
sheet O 
. O 
Photoresponsivity O 
of O 
the O 
prepared O 
GO-Fc B-ABBREVIATION 
composite O 
was O 
investigated O 
by O 
fabricating O 
a O 
metal/ O 
GO-Fc B-ABBREVIATION 
/ O 
metal O 
device O 
. O 
The O 
fabricated O 
device O 
shows O 
enhanced O 
current O 
density O 
under O 
light O 
illumination O 
, O 
suggesting O 
a O 
photo O 
- O 
induced O 
charge O 
transfer O 
process O 
in O 
the O 
developed O 
GO-Fc B-ABBREVIATION 
composite O 
. O 

a O 
recent O 
paper O 
, O 
Xu O 
et O 
al O 
. O 
[ O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
A2012 O 
, O 
116 O 
, O 
11668 O 
] O 
emphasized O 
the O 
importance O 
of O 
core O 
- O 
electron O 
correlation O 
effects O 
to O 
describe O 
the O 
Si2H6BH3 B-FORMULA 
complex O 
and O 
related O 
systems O 
properly O 
. O 
Unexpected O 
large O 
energy O 
differences O 
between O 
a O 
frozen O 
core O 
and O 
all O 
electron O 
treatment O 
were O 
observed O 
. O 
In O 
the O 
present O 
study O 
, O 
it O 
will O 
be O 
shown O 
that O 
these O 
energy O 
differences O 
are O 
an O 
artifact O 
of O 
an O 
insufficient O 
choice O 
of O 
basis O 
set O 
and O 
can O 
be O 
attributed O 
to O 
an O 
intramolecular O 
basis O 
set O 
superposition O 
error O 
( O 
BSSE O 
) O 
. O 
Although O 
the O 
general O 
problem O 
is O 
known O 
, O 
systematic O 
studies O 
on O 
the O 
effect O 
are O 
scarce O 
. O 
Therefore O 
, O 
the O 
BSSE O 
in O 
related O 
systems O 
is O 
investigated O 
. O 
This O 
study O 
shows O 
that O 
the O 
problem O 
of O 
BSSE O 
for O 
core O 
- O 
electron O 
correlation O 
is O 
quite O 
common O 
if O 
inadequate O 
basis O 
sets O 
are O 
applied O 
and O 
that O 
it O 
amounts O 
to O 
2 O 
kcal O 
mol(-1) O 
on O 
average O 
in O 
binding O 
energies O 
for O 
the O 
given O 
test O 
set O 
( O 
with O 
a O 
maximum O 
of O 
5.8 O 
kcal O 
mol(-1) O 
) O 
. O 

and O 
lanosterol B-TRIVIAL 
from O 
Garcinia O 
prainiana O 
stimulated O 
glucose B-TRIVIAL 
uptake O 
and O 
adipocytes O 
differentiation O 
in O 
3T3-L1 O 
adipocytes O 
. O 

and O 
lanosterol B-TRIVIAL 
have O 
been O 
isolated O 
from O 
twigs O 
of O 
Garcinia O 
prainiana O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
. O 
The O 
compounds O 
were O 
examined O 
for O 
their O 
effects O 
on O 
3T3-L1 O 
adipocytes O 
. O 
In O 
the O 
MTT B-ABBREVIATION 
assay O 
, O 
it O 
was O 
found O 
that O 
the O 
compounds O 
had O 
no O 
cytotoxic O 
effects O 
up O 
to O 
25 O 
µM O 
. O 
Adipocyte O 
differentiation O 
analysis O 
was O 
carried O 
out O 
by O 
Oil B-TRIVIAL 
Red I-TRIVIAL 
O I-TRIVIAL 
staining O 
method O 
. O 
In O 
the O 
presence O 
of O 
adipogenic O 
cocktail O 
( O 
MDI O 
) O 
, O 
it O 
was O 
found O 
that O 
friedelin B-TRIVIAL 
and O 
lanosterol B-TRIVIAL 
enhanced O 
intracellular O 
fat O 
accumulation O 
by O 
2.02 O 
and O 
2.18-fold O 
, O 
respectively O 
, O 
compared O 
with O 
the O 
vehicle O 
- O 
treated O 
cells O 
. O 
Deoxyglucose B-SYSTEMATIC 
uptake O 
assay O 
was O 
used O 
to O 
examine O 
the O 
insulin O 
sensitivity O 
of O 
adipocytes O 
in O 
the O 
presence O 
of O 
the O 
compounds O 
. O 
It O 
was O 
found O 
that O 
friedelin B-TRIVIAL 
was O 
able O 
to O 
stimulate O 
glucose B-TRIVIAL 
uptake O 
up O 
to O 
1.8-fold O 
compared O 
with O 
insulin O 
- O 
treated O 
cells O 
. O 
It O 
was O 
suggested O 
that O 
friedelin B-TRIVIAL 
and O 
lanosterol B-TRIVIAL 
may O 
be O 
beneficial O 
to O 
mimic O 
insulin O 
action O 
that O 
would O 
be O 
useful O 
in O 
the O 
treatment O 
of O 
diabetes O 
type O 
2 O 
patients O 
. O 

of O 
Escherichia O 
coli O 
by O 
sonoelectrocatalytic O 
disinfection O 
using O 
TiO2 B-FORMULA 
as O 
electrode O 
. O 

is O 
the O 
first O 
study O 
to O 
demonstrate O 
sonoelectrocatalytic O 
disinfection O 
using O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO(2) B-FORMULA 
) O 
as O 
an O 
anode O 
for O 
effective O 
inactivation O 
of O 
Escherichia O 
coli O 
. O 
In O 
brief O 
, O 
a O 
non-woven O 
TiO(2) B-FORMULA 
fabric O 
used O 
as O 
an O 
anode O 
and O 
a O 
platinum B-SYSTEMATIC 
cathode O 
were O 
immersed O 
in O 
an O 
E O 
. O 
coli O 
suspension O 
in O 
which O 
a O 
positive O 
potential O 
was O 
applied O 
to O 
TiO(2) B-FORMULA 
concomitant O 
with O 
ultrasound O 
( O 
US O 
) O 
irradiation O 
. O 
Two O 
control O 
experiments O 
were O 
performed O 
using O 
E O 
. O 
coli O 
suspensions O 
to O 
exhibit O 
the O 
effects O 
of O 
the O 
sonoelectrocatalytic O 
disinfection O 
. O 
One O 
was O 
disinfection O 
by O 
applying O 
a O 
positive O 
potential O 
to O 
a O 
TiO(2) B-FORMULA 
electrode O 
, O 
but O 
without O 
US O 
irradiation O 
( O 
electrochemical O 
disinfection O 
) O 
. O 
The O 
other O 
was O 
disinfection O 
without O 
applying O 
a O 
potential O 
, O 
but O 
with O 
US O 
irradiation O 
in O 
the O 
presence O 
of O 
TiO(2) B-FORMULA 
( O 
sonocatalytic O 
disinfection O 
) O 
. O 
The O 
cell O 
inactivation O 
rate O 
in O 
sonoelectrocatalytic O 
disinfection O 
was O 
synergistically O 
much O 
more O 
enhanced O 
than O 
the O 
combined O 
inactivation O 
rates O 
in O 
electrochemical O 
disinfection O 
and O 
sonocatalytic O 
disinfection O 
. O 
This O 
synergistically O 
enhanced O 
inactivation O 
rate O 
of O 
E O 
. O 
coli O 
cells O 
was O 
attributable O 
to O 
effective O 
reaction O 
of O 
the O 
sonocatalytically O 
generated O 
OH B-FORMULA 
radicals O 
with O 
E O 
. O 
coli O 
cells O 
at O 
the O 
surface O 
of O 
the O 
TiO(2) B-FORMULA 
anode O 
, O 
which O 
resulted O 
from O 
the O 
electroadsorption O 
of O 
E O 
. O 
coli O 
cells O 
toward O 
the O 
TiO(2) B-FORMULA 
anode O 
. O 

of O 
17α-ethynylestradiol B-SYSTEMATIC 
-induced O 
cholestasis O 
on O 
the O 
pharmacokinetics O 
of O 
doxorubicin B-TRIVIAL 
in O 
rats O 
: O 
reduced O 
biliary O 
excretion O 
and O 
hepatic O 
metabolism O 
of O 
doxorubicin B-TRIVIAL 
. O 

1 O 
. O 
Since O 
the O 
prevalent O 
hormonal O 
combination O 
therapy O 
with O 
estrogen B-FAMILY 
analogues O 
in O 
cancer O 
patients O 
has O 
frequency O 
and O 
possibility O 
to O 
induce O 
the O 
cholestasis O 
, O 
the O 
frequent O 
combination O 
therapy O 
with O 
17α-ethynylestradiol B-SYSTEMATIC 
( O 
EE O 
, O 
an O 
oral O 
contraceptive O 
) O 
and O 
doxorubicin B-TRIVIAL 
( O 
an O 
anticancer O 
drug O 
) O 
might O 
be O 
monitored O 
in O 
aspect O 
of O 
efficacy O 
and O 
safety O 
. O 
Doxorubicin B-TRIVIAL 
is O 
mainly O 
excreted O 
into O 
the O 
bile O 
via O 
P-glycoprotein O 
( O 
P-gp O 
) O 
and O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2 O 
( O 
Mrp2 O 
) O 
in O 
hepatobiliary O 
route O 
and O 
metabolized O 
via O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
3A O 
subfamily O 
. O 
Also O 
the O 
hepatic O 
Mrp2 O 
( O 
not O 
P-gp O 
) O 
and O 
CYP3A O 
subfamily O 
levels O 
were O 
reduced O 
in O 
EE-induced O 
cholestatic O 
( O 
EEC O 
) O 
rats O 
. O 
Thus O 
, O 
we O 
herein O 
report O 
the O 
pharmacokinetic O 
changes O 
of O 
doxorubicin B-TRIVIAL 
with O 
respect O 
to O 
the O 
changes O 
in O 
its O 
biliary O 
excretion O 
and O 
hepatic O 
metabolism O 
in O 
EEC O 
rats O 
. O 
2 O 
. O 
The O 
pharmacokinetic O 
study O 
of O 
doxorubicin B-TRIVIAL 
after O 
intravenous O 
administration O 
of O 
its O 
hydrochloride B-FAMILY 
was O 
conducted O 
along O 
with O 
the O 
investigation O 
of O 
bile O 
flow O 
rate O 
and O 
hepatobiliary O 
excretion O 
of O 
doxorubicin B-TRIVIAL 
in O 
control O 
and O 
EEC O 
rats O 
. O 
3 O 
. O 
The O 
significantly O 
greater O 
AUC O 
( O 
58.7% O 
increase O 
) O 
of O 
doxorubicin B-TRIVIAL 
in O 
EEC O 
rats O 
was O 
due O 
to O 
the O 
slower O 
CL O 
( O 
32.9% O 
decrease O 
) O 
. O 
The O 
slower O 
CL O 
was O 
due O 
to O 
the O 
reduction O 
of O 
hepatic O 
biliary O 
excretion O 
( O 
67.0% O 
decrease O 
) O 
and O 
hepatic O 
CYP3A O 
subfamily O 
- O 
mediated O 
metabolism O 
( O 
21.9% O 
decrease O 
) O 
of O 
doxorubicin B-TRIVIAL 
. O 
These O 
results O 
might O 
have O 
broader O 
implications O 
to O 
understand O 
the O 
altered O 
pharmacokinetics O 
and O 
/ O 
or O 
pharmacologic O 
effects O 
of O 
doxorubicin B-TRIVIAL 
via O 
biliary O 
excretion O 
and O 
hepatic O 
metabolism O 
in O 
experimental O 
and O 
clinical O 
estrogen B-FAMILY 
-induced O 
cholestasis O 
. O 

series O 
of O 
compounds O 
incorporating O 
an O 
aromatic O 
scaffold O 
based O 
on O 
isoxazolines B-FAMILY 
were O 
prepared O 
in O 
the O 
patent O 
application O 
( O 
WO2012151158 O 
) O 
. O 
The O 
new O 
compounds O 
from O 
the O 
patent O 
are O 
defined O 
to O 
be O 
biologically O 
active O 
metabolites O 
, O 
prodrugs O 
, O 
isomers O 
, O 
stereoisomers O 
, O 
solvates O 
, O 
hydrates O 
and O 
pharmaceutically O 
acceptable O 
salts O 
, O 
they O 
are O 
claimed O 
to O 
be O 
useful O 
for O 
treating O 
immunological O 
conditions O 
because O 
of O 
their O 
inhibitory O 
activities O 
on O 
matrix O 
metalloproteinase O 
( O 
MMP-13 O 
) O 
, O 
although O 
no O 
specific O 
MMP-13 O 
inhibition O 
data O 
or O 
other O 
rationale O 
to O 
explain O 
their O 
biological O 
effects O 
is O 
provided O 
. O 
The O 
compounds O 
have O 
a O 
broad O 
potential O 
utility O 
with O 
osteoarthritis O 
, O 
rheumatoid O 
arthritis O 
, O 
juvenile O 
arthritis O 
, O 
psoriatic O 
arthritis O 
, O 
degenerative O 
joint O 
disease O 
or O 
systemic O 
lupus O 
erythematosus O 
among O 
the O 
likely O 
preferred O 
indications O 
. O 

acid I-TRIVIAL 
modified O 
cationic O 
γ-cyclodextrin B-TRIVIAL 
- O 
oligoethylenimine B-FAMILY 
star O 
polymer O 
with O 
bioreducible O 
disulfide B-SYSTEMATIC 
linker O 
for O 
efficient O 
targeted O 
gene O 
delivery O 
. O 

an O 
efficient O 
folate B-TRIVIAL 
-targeted O 
delivery O 
, O 
while O 
the O 
interaction O 
between O 
the O 
folate B-TRIVIAL 
on O 
the O 
carriers O 
and O 
the O 
folate B-TRIVIAL 
receptor O 
( O 
FR O 
) O 
on O 
the O 
cells O 
is O 
necessary O 
, O 
the O 
recovering O 
and O 
recycling O 
of O 
FR O 
to O 
maintain O 
a O 
high O 
density O 
level O 
of O 
FR O 
on O 
the O 
cellular O 
membrane O 
is O 
also O 
important O 
. O 
Herein O 
, O 
we O 
demonstrate O 
a O 
design O 
and O 
synthesis O 
of O 
a O 
new O 
star O 
- O 
shaped O 
cationic O 
polymer O 
containing O 
a O 
γ-cyclodextrin B-TRIVIAL 
( O 
γ-CD B-ABBREVIATION 
) O 
core O 
and O 
multiple O 
oligoethylenimine B-FAMILY 
( O 
OEI B-ABBREVIATION 
) O 
arms O 
with O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
linked O 
by O 
a O 
bioreducible O 
disulfide B-SYSTEMATIC 
bond O 
for O 
efficient O 
targeted O 
gene O 
delivery O 
. O 
The O 
newly O 
synthesized O 
cationic O 
polymer O 
, O 
named O 
γ-CD-OEI-SS-FA B-ABBREVIATION 
, O 
could O 
be O 
cleaved O 
efficiently O 
, O 
and O 
FA O 
was O 
readily O 
released O 
under O 
reductive O 
condition O 
similar O 
to O 
intracellular O 
environment O 
. O 
The O 
γ-CD-OEI-SS-FA B-ABBREVIATION 
polymer O 
was O 
well O 
- O 
characterized O 
and O 
studied O 
in O 
terms O 
of O 
its O 
gene O 
delivery O 
properties O 
in O 
FR-positive O 
KB O 
cells O 
and O 
FR-negative O 
A549 O 
cells O 
under O 
various O 
conditions O 
, O 
in O 
comparison O 
with O 
cationic O 
polymers O 
such O 
as O 
high O 
molecular O 
weight O 
branched O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
, O 
γ-CD-OEI B-ABBREVIATION 
star O 
- O 
shaped O 
cationic O 
polymer O 
, O 
γ-CD-OEI-FA B-ABBREVIATION 
polymer O 
where O 
FA O 
was O 
directed O 
linked O 
to O 
the O 
star O 
polymer O 
without O 
disulfide B-SYSTEMATIC 
linker O 
. O 
Our O 
data O 
have O 
demonstrated O 
that O 
the O 
new O 
γ-CD-OEI-SS-FA B-ABBREVIATION 
gene O 
carrier O 
had O 
low O 
cytotoxicity O 
and O 
possessed O 
capacity O 
to O 
target O 
and O 
deliver O 
DNA O 
to O 
specific O 
tumor O 
cells O 
that O 
overexpress O 
FRs O 
, O 
as O 
well O 
as O 
functions O 
to O 
recover O 
and O 
recycle O 
FRs O 
onto O 
cellular O 
membranes O 
to O 
facilitate O 
continuous O 
FR O 
- O 
mediated O 
endocytosis O 
to O 
achieve O 
very O 
high O 
levels O 
of O 
gene O 
expression O 
. O 
This O 
study O 
has O 
expanded O 
the O 
strategy O 
of O 
FA-targeted O 
delivery O 
by O 
combining O 
the O 
smart O 
FR-recycling O 
function O 
to O 
achieve O 
the O 
significant O 
enhancement O 
of O 
gene O 
expression O 
. O 
The O 
new O 
FA-targeted O 
and O 
bioreducible O 
carrier O 
may O 
be O 
a O 
promising O 
efficient O 
gene O 
delivery O 
system O 
for O 
potential O 
cancer O 
gene O 
therapy O 
. O 

determination O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
chain O 
composition O 
in O 
pork O 
meat O 
products O 
by O 
high O 
resolution O 
1H B-FORMULA 
NMR O 
spectroscopy O 
. O 

resolution O 
(1)H B-FORMULA 
NMR O 
spectroscopy O 
was O 
proposed O 
for O 
the O 
determination O 
of O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
chain O 
profile O 
of O 
lipids O 
in O 
pork O 
meat O 
products O 
during O 
ripening O 
. O 
Two O 
typical O 
Mediterranean O 
PDO O 
salami O 
produced O 
in O 
Calabria O 
, O 
a O 
region O 
in O 
the O 
Southern O 
Italy O 
, O 
were O 
chosen O 
as O 
a O 
case O 
of O 
study O 
. O 
Quantitative O 
NMR O 
analysis O 
provided O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
chain O 
profiles O 
of O 
total O 
lipid O 
extracts O 
. O 
The O 
transesterification O 
of O 
total O 
lipid O 
extracts O 
furnished O 
FAME B-ABBREVIATION 
mixtures O 
that O 
enabled O 
quantitation O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
acyl I-FAMILY 
chains O 
in O 
the O 
acylglycerol B-FAMILY 
and O 
FFA O 
portions O 
. O 
In O 
all O 
cases O 
, O 
oleyl B-TRIVIAL 
chains O 
were O 
predominant O 
, O 
and O 
high O 
amounts O 
of O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
chains O 
were O 
observed O 
. O 
The O 
proposed O 
spectroscopic O 
method O 
allowed O 
also O 
the O 
estimation O 
of O 
the O 
most O 
important O 
nutritional O 
parameters O 
of O 
dry O 
fermented O 
meat O 
products O 
. O 

tumor O 
suppressor O 
p53 O 
plays O 
a O 
critical O 
role O 
in O 
the O 
regulation O 
of O 
proper O 
DNA O 
damage O 
response O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
found O 
for O 
the O 
first O 
time O 
that O 
Runt O 
- O 
related O 
transcription O 
factor O 
1 O 
( O 
RUNX1 O 
) O 
contributes O 
to O 
p53-dependent O 
DNA O 
damage O 
response O 
. O 
Upon O 
adriamycin B-TRIVIAL 
( O 
ADR B-ABBREVIATION 
) O 
exposure O 
, O 
p53 O 
as O 
well O 
as O 
RUNX1 O 
were O 
strongly O 
induced O 
in O 
p53-proficient O 
HCT116 O 
and O 
U2OS O 
cells O 
, O 
which O 
were O 
closely O 
associated O 
with O 
significant O 
transactivation O 
of O 
p53 O 
target O 
genes O 
, O 
such O 
as O 
p21(WAF)(1) O 
, O 
BAX O 
, O 
NOXA O 
, O 
and O 
PUMA O 
. O 
RUNX1 O 
was O 
exclusively O 
expressed O 
in O 
the O 
cell O 
nucleus O 
and O 
formed O 
a O 
complex O 
with O 
p53 O 
in O 
response O 
to O 
ADR B-ABBREVIATION 
. O 
Chromatin O 
immunoprecipitation O 
assay O 
demonstrated O 
that O 
p53 O 
together O 
with O 
RUNX1 O 
are O 
efficiently O 
recruited O 
onto O 
p53 O 
target O 
gene O 
promoters O 
following O 
ADR B-ABBREVIATION 
exposure O 
, O 
indicating O 
that O 
RUNX1 O 
is O 
involved O 
in O 
p53 O 
- O 
mediated O 
transcriptional O 
regulation O 
. O 
Indeed O 
, O 
forced O 
expression O 
of O 
RUNX1 O 
stimulated O 
the O 
transcriptional O 
activity O 
of O 
p53 O 
in O 
response O 
to O 
ADR B-ABBREVIATION 
. O 
Consistent O 
with O 
these O 
observations O 
, O 
knockdown O 
of O 
RUNX1 O 
attenuated O 
ADR B-ABBREVIATION 
-mediated O 
induction O 
of O 
p53 O 
target O 
genes O 
and O 
suppressed O 
ADR B-ABBREVIATION 
-dependent O 
apoptosis O 
. O 
Furthermore O 
, O 
RUNX1 O 
was O 
associated O 
with O 
p300 O 
histone O 
acetyltransferase O 
, O 
and O 
ADR B-ABBREVIATION 
-dependent O 
acetylation O 
of O 
p53 O 
at O 
Lys B-FORMULA 
-373 O 
/ O 
382 O 
was O 
markedly O 
inhibited O 
in O 
RUNX1 O 
knockdown O 
cells O 
. O 
In O 
addition O 
, O 
knockdown O 
of O 
RUNX1 O 
resulted O 
in O 
a O 
significant O 
decrease O 
in O 
the O 
amount O 
of O 
p53-p300 O 
complex O 
following O 
ADR B-ABBREVIATION 
exposure O 
. O 
Taken O 
together O 
, O 
our O 
present O 
results O 
strongly O 
suggest O 
that O 
RUNX1 O 
is O 
required O 
for O 
the O 
stimulation O 
of O 
p53 O 
in O 
response O 
to O 
DNA O 
damage O 
and O 
also O 
provide O 
novel O 
insight O 
into O 
understanding O 
the O 
molecular O 
mechanisms O 
behind O 
p53-dependent O 
DNA O 
damage O 
response O 
. O 

pregnant O 
women O 
, O 
the O 
diabetic O 
condition O 
results O 
in O 
a O 
three- O 
to O 
fivefold O 
increased O 
risk O 
for O 
fetal O 
cardiac O 
malformations O 
as O 
a O 
result O 
of O 
elevated O 
glucose B-TRIVIAL 
concentrations O 
and O 
the O 
resultant O 
osmotic O 
stress O 
in O 
the O 
developing O 
embryo O 
and O 
fetus O 
. O 
Heart O 
development O 
before O 
septation O 
in O 
the O 
chick O 
embryo O 
was O 
studied O 
under O 
two O 
hyperglycemic O 
conditions O 
. O 
Pulsed O 
hyperglycemia O 
induced O 
by O 
daily O 
administration O 
of O 
glucose B-TRIVIAL 
during O 
3 O 
days O 
of O 
development O 
caused O 
daily O 
spikes O 
in O 
plasma O 
glucose B-TRIVIAL 
concentration O 
. O 
In O 
a O 
second O 
model O 
, O 
sustained O 
hyperglycemia O 
was O 
induced O 
with O 
a O 
single O 
injection O 
of O 
glucose B-TRIVIAL 
into O 
the O 
yolk O 
on O 
day O 
0 O 
. O 
The O 
sustained O 
model O 
raised O 
the O 
average O 
plasma O 
glucose B-TRIVIAL 
concentration O 
from O 
70 O 
mg O 
/ O 
dL O 
to O 
180 O 
mg O 
/ O 
dL O 
and O 
led O 
to O 
decreased O 
gene O 
expression O 
of O 
glucose B-TRIVIAL 
transporter O 
GLUT1 O 
. O 
Both O 
models O 
of O 
hyperglycemia O 
reduced O 
embryo O 
size O 
, O 
increased O 
mortality O 
, O 
and O 
delayed O 
development O 
. O 
Within O 
the O 
heart O 
outflow O 
tract O 
, O 
reduced O 
proliferation O 
of O 
myocardial O 
and O 
endocardial O 
cells O 
resulted O 
from O 
the O 
sustained O 
hyperglycemia O 
and O 
hyperosmolarity O 
. O 
The O 
cell O 
cycle O 
inhibitor O 
p21 O 
was O 
significantly O 
increased O 
, O 
whereas O 
cyclin O 
D1 O 
, O 
a O 
cell O 
cycle O 
promoter O 
, O 
decreased O 
in O 
sustained O 
hyperglycemia O 
compared O 
with O 
controls O 
. O 
The O 
evidence O 
suggests O 
that O 
hyperglycemia O 
- O 
induced O 
developmental O 
delays O 
are O 
associated O 
with O 
slowed O 
cell O 
cycle O 
progression O 
, O 
leading O 
to O 
reduced O 
cellular O 
proliferation O 
. O 
The O 
suppression O 
of O 
critical O 
developmental O 
steps O 
may O 
underlie O 
the O 
cardiac O 
defects O 
observed O 
during O 
late O 
gestation O 
under O 
hyperglycemic O 
conditions O 
. O 

Mechanism O 
of O 
Li B-FORMULA 
/ O 
SeSx B-FAMILY 
( O 
x O 
= O 
0-7 O 
) O 
Batteries O 
Determined O 
by O 
In-situ O 
Synchrotron O 
X-ray O 
Diffraction O 
and O 
X-ray O 
Absorption O 
Spectroscopy O 
. O 

energy O 
storage O 
for O 
transportation O 
has O 
going O 
beyond O 
the O 
limit O 
of O 
converntional O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
currently O 
. O 
New O 
material O 
or O 
new O 
battery O 
system O 
development O 
is O 
an O 
alternative O 
approach O 
to O 
achieve O 
the O 
goal O 
of O 
new O 
high O 
energy O 
storage O 
system O 
with O 
energy O 
densities O 
five O 
times O 
or O 
more O 
greater O 
. O 
A O 
series O 
of O 
SeSx B-FAMILY 
- O 
carbon B-SYSTEMATIC 
( O 
x O 
= O 
0-7 O 
) O 
composite O 
materials O 
has O 
been O 
prepared O 
and O 
evaluated O 
as O 
the O 
positive O 
electrodes O 
in O 
secondary O 
lithium B-SYSTEMATIC 
cells O 
with O 
ether B-SYSTEMATIC 
-based O 
electrolyte O 
. O 
In-situ O 
synchrotron O 
high O 
energy O 
X-ray O 
diffraction O 
was O 
utilized O 
to O 
investigate O 
the O 
crystalline O 
phase O 
transition O 
during O 
cell O 
cycling O 
. O 
Complementary O 
, O 
in O 
- O 
situ O 
Se B-FORMULA 
K-edge O 
X-ray O 
absorption O 
near O 
edge O 
structure O 
analysis O 
was O 
used O 
to O 
track O 
the O 
evolution O 
of O 
the O 
Se B-FORMULA 
valence O 
state O 
for O 
both O 
crystalline O 
and O 
non-crystalline O 
phases O 
, O 
including O 
amorphous O 
and O 
electrolyte O 
- O 
dissolved O 
phases O 
in O 
the O 
(de)lithiation O 
process O 
. O 
On O 
the O 
basis O 
of O 
these O 
reuslts O 
, O 
a O 
mechanism O 
for O 
the O 
(de)lithiation O 
process O 
is O 
proposed O 
, O 
where O 
Se B-FORMULA 
is O 
reduced O 
to O 
the O 
polyselenides B-FAMILY 
, O 
Li2Sen B-FAMILY 
( O 
n≥4 O 
) O 
, O 
Li2Se2 B-FORMULA 
, O 
and O 
Li2Se B-FORMULA 
sequentially O 
during O 
the O 
lithiation O 
, O 
and O 
Li2Se B-FORMULA 
is O 
oxidized O 
to O 
Se B-FORMULA 
through O 
Li2Sen B-FAMILY 
( O 
n≥4 O 
) O 
during O 
the O 
delithiation O 
. O 
In O 
addition O 
, O 
X-ray O 
photoelectron O 
spectroscopy O 
and O 
electrochemical O 
impedance O 
spectroscopy O 
demonstrated O 
the O 
reversibility O 
of O 
the O 
Li B-FORMULA 
/ O 
Se B-FORMULA 
system O 
in O 
ether B-SYSTEMATIC 
-based O 
electrolyte O 
and O 
the O 
presence O 
of O 
side O 
products O 
in O 
the O 
carbonate B-FAMILY 
-based O 
electrolytes O 
. O 
For O 
Li B-FORMULA 
/ O 
SeS2 B-FORMULA 
and O 
Li B-FORMULA 
/ O 
SeS7 B-FORMULA 
cells O 
, O 
Li2Se B-FORMULA 
and O 
Li2S B-FORMULA 
are O 
the O 
discharged O 
products O 
with O 
the O 
presence O 
of O 
Se B-FORMULA 
only O 
as O 
the O 
crystalline O 
phase O 
in O 
the O 
end O 
of O 
charge O 
. O 

of O 
angiogenesis O 
and O 
invasion O 
by O 
DMBT B-ABBREVIATION 
is O 
mediated O 
by O 
downregulation O 
of O 
VEGF O 
and O 
MMP-9 O 
through O 
Akt O 
pathway O 
in O 
MDA-MB-231 O 
breast O 
cancer O 
cells O 
. O 

, O 
either O 
directly O 
or O 
via O 
metastasis O 
formation O 
, O 
is O 
the O 
main O 
cause O 
of O 
death O 
in O 
cancer O 
patients O 
, O 
development O 
of O 
efficient O 
anti-invasive O 
agents O 
is O 
an O 
important O 
research O 
challenge O 
. O 
In O 
order O 
to O 
obtain O 
more O 
potent O 
inhibitors O 
, O 
a O 
series O 
of O 
brartemicin B-TRIVIAL 
analogs O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
inhibitory O 
activity O 
against O 
invasion O 
. O 
Among O 
the O 
synthetic O 
analogs O 
tested O 
, O 
DMBT B-ABBREVIATION 
, O 
6,6'-bis B-SYSTEMATIC 
(2,3-dimethoxybenzoyl)-a,a-d-trehalose I-SYSTEMATIC 
, O 
was O 
found O 
to O 
be O 
the O 
most O 
potent O 
anti-invasive O 
agent O 
. O 
But O 
the O 
effects O 
of O 
DMBT B-ABBREVIATION 
on O 
breast O 
cancer O 
cells O 
were O 
not O 
known O 
. O 
In O 
this O 
study O 
, O 
the O 
effects O 
of O 
DMBT B-ABBREVIATION 
on O 
invasion O 
and O 
metastasis O 
in O 
MDA-MB-231 O 
cells O 
were O 
investigated O 
. O 
MTT B-ABBREVIATION 
assay O 
showed O 
that O 
no O 
obvious O 
inhibitory O 
or O 
cytotoxic O 
effect O 
of O 
DMBT B-ABBREVIATION 
was O 
found O 
. O 
DMBT B-ABBREVIATION 
could O 
inhibit O 
invasion O 
, O 
migration O 
and O 
tube O 
formation O 
of O 
HUVECs O 
. O 
Gelatin O 
zymography O 
showed O 
that O 
DMBT B-ABBREVIATION 
inhibited O 
secretion O 
and O 
activity O 
of O 
MMP-9 O 
. O 
Western O 
blotting O 
demonstrated O 
that O 
DMBT B-ABBREVIATION 
effectively O 
suppressed O 
the O 
expression O 
of O 
VEGF O 
, O 
p-VEGFR-2 O 
, O 
p-EGFR O 
, O 
and O 
p-Akt O 
. O 
These O 
results O 
suggested O 
that O 
DMBT B-ABBREVIATION 
could O 
inhibit O 
invasion O 
and O 
angiogenesis O 
by O 
downregulation O 
of O 
VEGFand O 
MMP-9 O 
, O 
resulting O 
from O 
the O 
inhibition O 
of O 
Akt O 
pathway O 
. O 
DMBT B-ABBREVIATION 
might O 
be O 
a O 
promising O 
lead O 
molecule O 
for O 
the O 
anti-metastasis O 
and O 
serve O 
as O 
a O 
therapeutic O 
agent O 
to O 
inhibit O 
breast O 
cancer O 
cell O 
invasion O 
and O 
metastasis O 
. O 

driven O 
ultraviolet O 
random O 
lasing O 
from O 
an O 
n- O 
MgZnO B-FORMULA 
/ O 
i- O 
ZnO B-FORMULA 
/ O 
SiO2 B-FORMULA 
/ O 
p- O 
Si B-FORMULA 
asymmetric O 
double O 
heterojunction O 
. O 

pumped O 
lasing O 
action O 
has O 
been O 
realized O 
in O 
ZnO B-FORMULA 
from O 
an O 
n- O 
MgZnO B-FORMULA 
/ O 
i- O 
ZnO B-FORMULA 
/ O 
SiO2 B-FORMULA 
/ O 
p- O 
Si B-FORMULA 
asymmetric O 
double O 
heterostructure O 
, O 
an O 
ultralow O 
threshold O 
of O 
3.9 O 
mA O 
was O 
obtained O 
. O 
The O 
mechanism O 
of O 
the O 
laser O 
is O 
associated O 
with O 
the O 
in O 
- O 
plane O 
random O 
resonator O 
cavities O 
formed O 
in O 
the O 
ZnO B-FORMULA 
films O 
and O 
the O 
elaborate O 
hollow O 
- O 
shaped O 
SiO2 B-FORMULA 
cladding O 
pattern O 
, O 
which O 
prevent O 
the O 
lateral O 
diffusion O 
of O 
injection O 
current O 
and O 
ultimately O 
lower O 
the O 
threshold O 
current O 
of O 
the O 
laser O 
diode O 
. O 
In O 
addition O 
, O 
a O 
waveguide O 
mechanism O 
due O 
to O 
different O 
refractive O 
indices O 
of O 
three O 
epilayers O 
enhances O 
the O 
guided O 
optical O 
field O 
on O 
the O 
ZnO B-FORMULA 
side O 
, O 
resulting O 
in O 
an O 
improved O 
light O 
extraction O 
efficiency O 
. O 

- O 
based O 
design O 
, O 
synthesis O 
, O 
and O 
biological O 
evaluation O 
of O 
N- B-FAMILY 
substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide I-FAMILY 
derivatives O 
as O 
novel O 
Mcl-1 O 
inhibitors O 
. O 

have O 
previously O 
reported O 
a O 
nanomolar O 
inhibitor O 
of O 
antiapoptotic O 
Mcl-1 O 
protein O 
, O 
3-thiomorpholin-8-oxo-8H-acenaphtho B-SYSTEMATIC 
[ I-SYSTEMATIC 
1,2-b I-SYSTEMATIC 
] I-SYSTEMATIC 
pyrrole-9-carbonitrile I-SYSTEMATIC 
( O 
S1 O 
) O 
. O 
S1 O 
plays O 
its O 
function O 
by O 
binding O 
to O 
the O 
BH3 O 
groove O 
of O 
Mcl-1 O 
. O 
Basing O 
on O 
this O 
spacial O 
structural O 
characteristic O 
, O 
we O 
developed O 
a O 
novel O 
class O 
of O 
Mcl-1 O 
inhibitor O 
using O 
fragment O 
- O 
based O 
drug O 
discovery O 
approach O 
. O 
By O 
dissecting O 
S1 O 
, O 
we O 
identified O 
the O 
compound O 
4 O 
with O 
a O 
2-hydroxypyridine B-SYSTEMATIC 
core O 
as O 
the O 
starting O 
fragment O 
. O 
In O 
the O 
following O 
molecular O 
growth O 
, O 
we O 
used O 
the O 
ligand O 
efficiency O 
evaluation O 
and O 
fit O 
quality O 
score O 
to O 
assess O 
the O 
fragments O 
. O 
A O 
novel O 
potent O 
compound O 
, O 
N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl B-SYSTEMATIC 
nicotinamide I-SYSTEMATIC 
( O 
12c O 
) O 
, O 
which O 
binds O 
Mcl-1 O 
with O 
an O 
IC(50) O 
value O 
of O 
54 O 
nM O 
was O 
obtained O 
. O 
Compound O 
12c O 
demonstrated O 
a O 
better O 
aqueous O 
solubility O 
than O 
S1 O 
. O 

- O 
dimensional O 
nanostructures O 
offer O 
a O 
host O 
of O 
intriguing O 
properties O 
which O 
are O 
distinct O 
from O 
those O 
of O 
the O 
bulk O 
material O 
, O 
owing O 
to O 
size O 
- O 
confinement O 
effects O 
and O 
amplified O 
surface O 
areas O 
. O 
Here O 
, O 
we O 
report O 
on O 
the O 
scalable O 
, O 
bottom O 
- O 
up O 
synthesis O 
of O 
ultrathin O 
coordination O 
polymer O 
nanosheets O 
via O 
surfactant O 
- O 
mediated O 
synthesis O 
and O 
subsequent O 
exfoliation O 
. O 
Layers O 
of O 
a O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
zinc B-SYSTEMATIC 
coordination O 
polymer O 
are O 
self O 
- O 
assembled O 
in O 
the O 
interlamellar O 
space O 
of O 
a O 
reverse O 
microemulsion O 
mesophase O 
into O 
stacks O 
of O 
nanosheets O 
interleaved O 
with O 
cethyltrimethylammonium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
CTAB B-ABBREVIATION 
) O 
at O 
regular O 
intervals O 
, O 
thus O 
giving O 
rise O 
to O 
a O 
lamellar O 
hybrid O 
mesostructure O 
with O 
a O 
lattice O 
period O 
of O 
∼8 O 
nm O 
and O 
an O 
underlying O 
highly O 
crystalline O 
substructure O 
. O 
The O 
basic O 
structural O 
motif O 
is O 
composed O 
of O 
2D O 
acetato B-SYSTEMATIC 
- I-SYSTEMATIC 
benzimidazolato I-SYSTEMATIC 
- I-SYSTEMATIC 
zinc I-SYSTEMATIC 
layers O 
of O 
tetrahedrally O 
coordinated O 
zinc B-SYSTEMATIC 
joined O 
together O 
by O 
anionic O 
acetate B-SYSTEMATIC 
and O 
benzimidazolate B-SYSTEMATIC 
ligands O 
. O 
The O 
hierarchical O 
structure O 
was O 
studied O 
by O 
PXRD O 
, O 
TEM O 
, O 
EDX O 
, O 
EELS O 
, O 
AFM O 
, O 
and O 
solid O 
- O 
state O 
NMR O 
spectroscopy O 
, O 
revealing O 
a O 
high O 
level O 
of O 
order O 
on O 
both O 
the O 
atomic O 
and O 
mesoscale O 
, O 
suggesting O 
fairly O 
strong O 
interactions O 
along O 
the O 
organic O 
- O 
inorganic O 
hybrid O 
interface O 
. O 
Exfoliation O 
of O 
the O 
hybrid O 
material O 
in O 
organic O 
solvents O 
such O 
as O 
THF B-ABBREVIATION 
and O 
chloroform B-TRIVIAL 
yields O 
sheet- O 
and O 
belt O 
- O 
like O 
nanostructures O 
with O 
lateral O 
sizes O 
between O 
10's O 
and O 
100's O 
of O 
nanometers O 
and O 
a O 
height O 
of O 
about O 
10 O 
nm O 
measured O 
by O 
AFM O 
, O 
which O 
precisely O 
maps O 
the O 
basal O 
spacing O 
of O 
the O 
lamellar O 
mesostructure O 
; O 
further O 
exfoliation O 
results O 
in O 
nanobelts O 
with O 
minimum O 
sizes O 
around O 
4 O 
nm O 
. O 
Finally O 
, O 
the O 
sheetlike O 
nanostructures O 
behave O 
as O 
morphological O 
chameleons O 
, O 
transforming O 
into O 
highly O 
regular O 
multiwalled O 
coordination O 
polymer O 
nanotubes O 
upon O 
treatment O 
with O 
organic O 
solvents O 
. O 

- O 
drug O 
interactions O 
between O 
rosuvastatin B-TRIVIAL 
and O 
oral O 
antidiabetic O 
drugs O 
occurring O 
at O 
the O 
level O 
of O 
OATP1B1 O 
. O 

anion O 
- O 
transporting O 
polypeptide O 
1B1 O 
( O 
OATP1B1 O 
) O 
is O 
an O 
important O 
hepatic O 
uptake O 
transporter O 
, O 
of O 
which O 
the O 
polymorphic O 
variant O 
OATP1B1*15 O 
( O 
Asn130Asp O 
and O 
Val174Ala O 
) O 
has O 
been O 
associated O 
with O 
decreased O 
transport O 
activity O 
. O 
Rosuvastatin B-TRIVIAL 
is O 
an O 
OATP1B1 O 
substrate O 
and O 
often O 
concomitantly O 
prescribed O 
with O 
oral O 
antidiabetics O 
in O 
the O 
clinic O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
possible O 
drug O 
- O 
drug O 
interactions O 
between O 
these O 
drugs O 
at O 
the O 
level O 
of O 
OATP1B1 O 
and O 
OATP1B1*15 O 
. O 
We O 
generated O 
human O 
embryonic O 
kidney O 
(HEK)293 O 
cells O 
stably O 
overexpressing O 
OATP1B1 O 
or O 
OATP1B1*15 O 
that O 
showed O 
similar O 
protein O 
expression O 
levels O 
of O 
OATP1B1 O 
and O 
OATP1B1*15 O 
at O 
the O 
cell O 
membrane O 
as O 
measured O 
by O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 
In O 
HEK-OATP1B1*15 O 
cells O 
, O 
the O 
V(max) O 
for O 
OATP1B1 O 
- O 
mediated O 
transport O 
of O 
E(2)17β-G O 
( O 
estradiol B-SYSTEMATIC 
17β-d-glucuronide I-SYSTEMATIC 
) O 
was O 
decreased O 
> O 
60% O 
, O 
whereas O 
K(m) O 
values O 
( O 
Michaelis O 
constant O 
) O 
were O 
comparable O 
. O 
Uptake O 
of O 
rosuvastatin B-TRIVIAL 
in O 
HEK-OATP1B1 O 
cells O 
( O 
K(m) O 
13.1 O 
± O 
0.43 O 
μM O 
) O 
was O 
nearly O 
absent O 
in O 
HEK-OATP1B1*15 O 
cells O 
. O 
Interestingly O 
, O 
several O 
oral O 
antidiabetics O 
( O 
glyburide B-TRIVIAL 
, O 
glimepiride B-TRIVIAL 
, O 
troglitazone B-TRIVIAL 
, O 
pioglitazone B-TRIVIAL 
, O 
glipizide B-TRIVIAL 
, O 
gliclazide B-TRIVIAL 
, O 
and O 
tolbutamide B-TRIVIAL 
) O 
, O 
but O 
not O 
metformin B-TRIVIAL 
, O 
were O 
identified O 
as O 
significant O 
inhibitors O 
of O 
the O 
OATP1B1 O 
- O 
mediated O 
transport O 
of O 
rosuvastatin B-TRIVIAL 
. O 
The O 
IC(50) O 
values O 
for O 
inhibition O 
of O 
E(2)17β-G B-SYSTEMATIC 
uptake O 
were O 
similar O 
between O 
OATP1B1 O 
and O 
OATP1B1*15 O 
. O 
In O 
conclusion O 
, O 
these O 
studies O 
indicate O 
that O 
several O 
oral O 
antidiabetic O 
drugs O 
affect O 
the O 
OATP1B1 O 
- O 
mediated O 
uptake O 
of O 
rosuvastatin B-TRIVIAL 
in O 
vitro O 
. O 
The O 
next O 
step O 
will O 
be O 
to O 
translate O 
these O 
data O 
to O 
the O 
clinical O 
situation O 
, O 
as O 
it O 
remains O 
to O 
be O 
established O 
whether O 
the O 
studied O 
oral O 
antidiabetics O 
indeed O 
affect O 
the O 
clinical O 
pharmacokinetic O 
profile O 
of O 
rosuvastatin B-TRIVIAL 
in O 
patients O 
. O 

- O 
assembly O 
of O 
morphology O 
- O 
tunable O 
architectures O 
from O 
tetraarylmethane B-FAMILY 
derivatives O 
for O 
targeted O 
drug O 
delivery O 
. O 

compounds O 
consisting O 
of O 
two O 
pyrogallol B-TRIVIAL 
and O 
two O 
aniline B-SYSTEMATIC 
units O 
, O 
namely O 
, O 
Ar2CAr'2 B-FORMULA 
{ O 
Ar O 
= O 
3,4,5-C6H2(OH)3 B-SYSTEMATIC 
and O 
Ar O 
' O 
= O 
3,5-R2-4-C6H2NH2 B-SYSTEMATIC 
[ O 
R O 
= O 
Me O 
( O 
1 O 
) O 
, O 
iPr B-FORMULA 
( O 
2 O 
) O 
] O 
} O 
exhibit O 
excellent O 
self O 
- O 
assembly O 
behavior O 
. O 
Compound O 
1 O 
yields O 
size O 
- O 
tunable O 
hollow O 
nanospheres O 
( O 
HNSs O 
) O 
with O 
a O 
narrow O 
size O 
distribution O 
, O 
and O 
2 O 
yields O 
various O 
morphologies O 
ranging O 
from O 
microtubules O 
to O 
microrods O 
via O 
self O 
- O 
assembly O 
induced O 
by O 
hydrogen B-SYSTEMATIC 
bonding O 
and O 
π-π O 
stacking O 
interactions O 
. O 
On O 
the O 
basis O 
of O 
the O 
experimental O 
results O 
, O 
a O 
plausible O 
mechanism O 
for O 
morphology O 
tunability O 
was O 
proposed O 
. O 
As O 
a O 
means O 
of O 
utilizing O 
the O 
self O 
- O 
assembled O 
HNSs O 
for O 
targeting O 
controlled O 
drug O 
delivery O 
, O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
and O 
rhodamine B-TRIVIAL 
6G I-TRIVIAL 
( O 
Rh6G B-ABBREVIATION 
) O 
were O 
grafted O 
onto O 
compound O 
1 O 
to O 
yield O 
the O 
FA-Rh6G-1 B-ABBREVIATION 
complex O 
. O 
The O 
HNSs O 
fabricated O 
with O 
FA-Rh6G-1 B-ABBREVIATION 
showed O 
low O 
cytotoxicity O 
against O 
human O 
embryonic O 
kidney O 
293T O 
cells O 
and O 
CT26 O 
colon O 
carcinoma O 
cells O 
and O 
good O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
loading O 
capacity O 
( O 
9.6 O 
wt O 
% O 
) O 
. O 
The O 
FA O 
receptor O 
- O 
mediated O 
endocytosis O 
of O 
FA-Rh6G-1 B-ABBREVIATION 
HNSs O 
examined O 
by O 
using O 
a O 
confocal O 
laser O 
scanning O 
microscope O 
and O 
a O 
flow O 
cytometer O 
revealed O 
that O 
the O 
uptake O 
of O 
FA-Rh6G-1 B-ABBREVIATION 
HNSs O 
into O 
CT26 O 
cells O 
was O 
induced O 
by O 
FA O 
receptor O 
- O 
mediated O 
endocytosis O 
. O 
In O 
vitro O 
drug O 
delivery O 
tests O 
showed O 
that O 
the O 
DOX B-ABBREVIATION 
molecules O 
were O 
released O 
from O 
the O 
resulting O 
HNSs O 
in O 
a O 
sustainable O 
and O 
pH-dependent O 
manner O 
, O 
demonstrating O 
a O 
potential O 
application O 
for O 
HNSs O 
in O 
targeted O 
drug O 
delivery O 
for O 
cancer O 
therapy O 
. O 

of O 
a O 
key O 
aminoglycoside B-FAMILY 
phosphotransferase O 
in O 
gentamicin B-FAMILY 
biosynthesis O 
. O 

is O 
an O 
aminoglycoside B-FAMILY 
antibiotic O 
obtained O 
from O 
cultures O 
of O 
Micromonospora O 
as O 
the O 
important O 
anti-infective O 
agents O 
. O 
Gentamicin B-FAMILY 
which O 
lacks O 
3'-hydroxyl B-SYSTEMATIC 
group O 
can O 
avoid O 
the O 
attack O 
from O 
the O 
modification O 
enzymes O 
of O 
antibiotic O 
- O 
resistant O 
bacteria O 
in O 
clinic O 
. O 
Consequently O 
, O 
C-3 O 
' O 
dehydroxylation O 
is O 
the O 
key O 
step O 
in O 
gentamicins B-FAMILY 
biosynthesis O 
. O 
We O 
suppose O 
that O 
there O 
are O 
some O 
enzymes O 
responsible O 
for O 
converting O 
intermediate O 
JI-20A B-IDENTIFIER 
to O 
3',4'-bisdehydroxylated O 
final O 
product O 
gentamicin B-TRIVIAL 
C I-TRIVIAL 
( O 
1a O 
) O 
, O 
while O 
phosphorylation O 
of O 
3'-OH B-SYSTEMATIC 
is O 
possibly O 
the O 
first O 
step O 
for O 
C-3 O 
' O 
dehydroxylation O 
. O 
The O 
gentamicin B-FAMILY 
biosynthetic O 
gene O 
gntI O 
, O 
encoding O 
an O 
aminoglycoside B-FAMILY 
phosphotransferase O 
, O 
was O 
cloned O 
from O 
Micromonospora O 
echinospora O 
ATCC15835 O 
and O 
overexpressed O 
in O 
Escherichia O 
coli O 
. O 
The O 
resulting O 
phosphotransferase O 
was O 
purified O 
, O 
and O 
the O 
kinetic O 
parameters O 
for O 
Kanamycin B-TRIVIAL 
A I-TRIVIAL 
, O 
Kanamycin B-TRIVIAL 
B I-TRIVIAL 
, O 
Neomycin B-TRIVIAL 
B I-TRIVIAL 
and O 
Amikacin B-TRIVIAL 
were O 
determined O 
. O 
Elucidation O 
of O 
NMR O 
data O 
of O 
phosphorylated B-TRIVIAL 
kanamycin I-TRIVIAL 
B I-TRIVIAL 
has O 
unambiguously O 
demonstrated O 
a O 
regiospecific O 
phosphorylation O 
of O 
3'-hydroxyl B-SYSTEMATIC 
of O 
the O 
6-aminohexose B-SYSTEMATIC 
ring O 
. O 
The O 
results O 
described O 
here O 
partly O 
confirm O 
that O 
the O 
3'-dehydroxylation O 
step O 
is O 
preceded O 
by O 
a O 
3 O 
' O 
phosphorylation O 
step O 
. O 
It O 
is O 
predicted O 
that O 
GntI O 
belongs O 
to O 
a O 
new O 
aminoglycoside B-FAMILY 
phosphotransferase O 
group O 
involved O 
with O 
aminoglycoside B-FAMILY 
antibiotics O 
biosynthesis O 
pathway O 
. O 

of O 
Pt B-FORMULA 
nanowires O 
by O 
atomic O 
layer O 
deposition O 
on O 
highly O 
ordered O 
pyrolytic O 
graphite B-TRIVIAL 
. O 

formation O 
of O 
Pt B-FORMULA 
nanowires O 
( O 
NWs O 
) O 
by O 
atomic O 
layer O 
deposition O 
on O 
highly O 
ordered O 
pyrolytic O 
graphite B-TRIVIAL 
( O 
HOPG O 
) O 
is O 
investigated O 
. O 
Pt B-FORMULA 
is O 
deposited O 
only O 
at O 
the O 
step O 
edges O 
of O 
HOPG O 
and O 
not O 
on O 
the O 
basal O 
planes O 
, O 
leading O 
to O 
the O 
formation O 
of O 
laterally O 
aligned O 
Pt B-FORMULA 
NWs O 
. O 
A O 
growth O 
model O 
involving O 
a O 
morphological O 
transition O 
from O 
0-D O 
to O 
1-D O 
structures O 
via O 
coalescence O 
is O 
presented O 
. O 
The O 
width O 
of O 
the O 
NWs O 
grows O 
at O 
a O 
rate O 
greater O 
than O 
twice O 
the O 
vertical O 
growth O 
rate O 
. O 
This O 
asymmetry O 
is O 
ascribed O 
to O 
the O 
wetting O 
properties O 
of O 
Pt B-FORMULA 
on O 
HOPG O 
as O 
influenced O 
by O 
the O 
formation O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 
A O 
difference O 
in O 
Pt B-FORMULA 
growth O 
kinetics O 
based O 
on O 
crystallographic O 
orientation O 
may O 
also O 
contribute O 
. O 

lateralization O 
, O 
critical O 
to O 
mediation O 
of O 
cognitive O 
functions O 
and O 
to O 
" O 
multitasking O 
, O 
" O 
is O 
disrupted O 
in O 
conditions O 
such O 
as O 
attention O 
deficit O 
disorder O 
and O 
schizophrenia O 
. O 
Both O 
low O 
- O 
level O 
lead O 
( O 
Pb B-FORMULA 
) O 
exposure O 
and O 
prenatal O 
stress O 
( O 
PS O 
) O 
have O 
been O 
associated O 
with O 
mesocorticolimbic O 
system O 
- O 
mediated O 
executive O 
- O 
function O 
cognitive O 
and O 
attention O 
deficits O 
. O 
Mesocorticolimbic O 
systems O 
demonstrate O 
significant O 
laterality O 
. O 
Thus O 
, O 
altered O 
brain O 
lateralization O 
could O 
play O 
a O 
role O 
in O 
this O 
behavioral O 
toxicity O 
. O 
This O 
study O 
examined O 
laterality O 
of O 
mesocorticolimbic O 
monoamines B-FAMILY 
( O 
frontal O 
cortex O 
, O 
nucleus O 
accumbens O 
, O 
striatum O 
, O 
midbrain O 
) O 
and O 
amino B-FAMILY 
acids I-FAMILY 
( O 
frontal O 
cortex O 
) O 
in O 
male O 
and O 
female O 
rats O 
subjected O 
to O 
lifetime O 
Pb B-FORMULA 
exposure O 
( O 
0 O 
or O 
50 O 
ppm O 
in O 
drinking O 
water O 
) O 
, O 
PS O 
( O 
restraint O 
stress O 
on O 
gestational O 
days O 
16-17 O 
) O 
, O 
or O 
the O 
combination O 
with O 
and O 
without O 
repeated O 
learning O 
behavioral O 
experience O 
. O 
Control O 
males O 
exhibited O 
prominent O 
laterality O 
, O 
particularly O 
in O 
midbrain O 
and O 
also O 
in O 
frontal O 
cortex O 
and O 
striatum O 
; O 
females O 
exhibited O 
less O 
laterality O 
, O 
and O 
this O 
was O 
primarily O 
striatal O 
. O 
Lateralized O 
Pb B-FORMULA 
± O 
PS O 
induced O 
neurotransmitter O 
changes O 
were O 
assessed O 
only O 
in O 
males O 
because O 
of O 
limited O 
sample O 
sizes O 
of O 
Pb B-FORMULA 
+ O 
PS O 
females O 
. O 
In O 
males O 
, O 
Pb B-FORMULA 
± O 
PS O 
changes O 
occurred O 
in O 
left O 
hemisphere O 
of O 
frontal O 
cortex O 
and O 
right O 
hemisphere O 
of O 
midbrain O 
. O 
Behavioral O 
experience O 
modified O 
the O 
laterality O 
of O 
Pb B-FORMULA 
± O 
PS-induced O 
neurotransmitter O 
changes O 
in O 
a O 
region O 
- O 
dependent O 
manner O 
. O 
Notably O 
, O 
behavioral O 
experience O 
eliminated O 
Pb B-FORMULA 
± O 
PS O 
neurotransmitter O 
changes O 
in O 
males O 
. O 
These O 
findings O 
underscore O 
the O 
critical O 
need O 
to O 
evaluate O 
both O 
sexes O 
and O 
brain O 
hemispheres O 
for O 
the O 
mechanistic O 
understanding O 
of O 
sex O 
- O 
dependent O 
differences O 
in O 
neuro- O 
and O 
behavioral O 
toxicity O 
. O 
Furthermore O 
, O 
assessment O 
of O 
central O 
nervous O 
system O 
mechanisms O 
in O 
the O 
absence O 
of O 
behavioral O 
experience O 
, O 
shown O 
here O 
for O 
males O 
, O 
may O 
constitute O 
less O 
relevant O 
models O 
of O 
human O 
health O 
effects O 
. O 

kills O 
proliferating O 
and O 
nonproliferating O 
malignant O 
glioma O 
cells O 
through O 
caspase O 
- O 
independent O 
necroptosis O 
mediated O 
by O 
apoptosis O 
- O 
inducing O 
factor O 
. O 

( O 
UCD38B B-IDENTIFIER 
) O 
and O 
glycinyl-amiloride B-TRIVIAL 
( O 
UCD74A B-IDENTIFIER 
) O 
are O 
cell O 
- O 
permeant O 
and O 
cell O 
- O 
impermeant O 
derivatives O 
of O 
amiloride B-TRIVIAL 
, O 
respectively O 
, O 
and O 
used O 
here O 
to O 
identify O 
the O 
cellular O 
mechanisms O 
of O 
action O 
underlying O 
their O 
antiglioma O 
effects O 
. O 
UCD38B B-IDENTIFIER 
comparably O 
kills O 
proliferating O 
and O 
nonproliferating O 
gliomas O 
cells O 
when O 
cell O 
cycle O 
progression O 
is O 
arrested O 
either O 
by O 
cyclin O 
D1 O 
siRNA O 
or O 
by O 
acidification O 
. O 
Cell O 
impermeant O 
UCD74A B-IDENTIFIER 
inhibits O 
plasmalemmal O 
urokinase O 
plasminogen O 
activator O 
( O 
uPA O 
) O 
and O 
the O 
type O 
1 O 
sodium B-SYSTEMATIC 
-proton O 
exchanger O 
with O 
potencies O 
analogous O 
to O 
UCD38B B-IDENTIFIER 
, O 
but O 
is O 
cytostatic O 
. O 
In O 
contrast O 
, O 
UCD38B B-IDENTIFIER 
targets O 
intracellular O 
uPA O 
causing O 
mistrafficking O 
of O 
uPA O 
into O 
perinuclear O 
mitochondria O 
, O 
reducing O 
the O 
mitochondrial O 
membrane O 
potential O 
, O 
and O 
followed O 
by O 
the O 
release O 
of O 
apoptotic O 
inducible O 
factor O 
( O 
AIF O 
) O 
. O 
AIF O 
nuclear O 
translocation O 
is O 
followed O 
by O 
a O 
caspase O 
- O 
independent O 
necroptotic O 
cell O 
death O 
. O 
Reduction O 
in O 
AIF O 
expression O 
by O 
siRNA O 
reduces O 
the O 
antiglioma O 
cytotoxic O 
effects O 
of O 
UCD38B B-IDENTIFIER 
, O 
while O 
not O 
activating O 
the O 
caspase O 
pathway O 
. O 
Ultrastructural O 
changes O 
shortly O 
following O 
treatment O 
with O 
UCD38B B-IDENTIFIER 
demonstrate O 
dilation O 
of O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
and O 
mitochondrial O 
swelling O 
followed O 
by O 
nuclear O 
condensation O 
within O 
hours O 
consistent O 
with O 
a O 
necroptotic O 
cell O 
death O 
differing O 
from O 
apoptosis O 
and O 
from O 
autophagy O 
. O 
These O 
drug O 
mechanism O 
of O 
action O 
studies O 
demonstrate O 
that O 
UCD38B B-IDENTIFIER 
induces O 
a O 
cell O 
cycle O 
- O 
independent O 
, O 
caspase O 
- O 
independent O 
necroptotic O 
glioma O 
cell O 
death O 
that O 
is O 
mediated O 
by O 
AIF O 
and O 
independent O 
of O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
and O 
H2AX O 
activation O 
. O 

protein O 
Rad9 O 
plays O 
an O 
important O 
role O 
in O 
nucleotide B-FAMILY 
excision O 
repair O 
. O 

, O 
an O 
evolutionarily O 
conserved O 
checkpoint O 
gene O 
with O 
multiple O 
functions O 
for O 
preserving O 
genomic O 
integrity O 
, O 
has O 
been O 
shown O 
to O 
play O 
important O 
roles O 
in O 
homologous O 
recombination O 
repair O 
, O 
base O 
excision O 
repair O 
and O 
mismatch O 
repair O 
. O 
However O 
, O 
whether O 
Rad9 O 
has O 
an O 
impact O 
on O 
nucleotide B-FAMILY 
excision O 
repair O 
remains O 
unknown O 
. O 
Here O 
we O 
demonstrated O 
that O 
Rad9 O 
was O 
involved O 
in O 
nucleotide B-FAMILY 
excision O 
repair O 
and O 
loss O 
of O 
Rad9 O 
led O 
to O 
defective O 
removal O 
of O 
the O 
UV O 
- O 
derived O 
photoproduct O 
6-4PP B-SYSTEMATIC 
( O 
6,4 B-SYSTEMATIC 
pyrimidine I-SYSTEMATIC 
- I-SYSTEMATIC 
pyrimidone I-SYSTEMATIC 
) O 
and O 
the O 
BPDE B-ABBREVIATION 
( O 
anti- O 
benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide B-SYSTEMATIC 
)-DNA O 
adducts O 
in O 
mammalian O 
cells O 
. O 
We O 
also O 
demonstrated O 
that O 
Rad9 O 
could O 
co O 
- O 
localize O 
with O 
XPC O 
in O 
response O 
to O 
local O 
UV O 
irradiation O 
. O 
However O 
, O 
our O 
data O 
showed O 
that O 
Rad9 O 
was O 
not O 
required O 
for O 
the O 
photoproducts O 
recognition O 
step O 
of O 
nucleotide B-FAMILY 
excision O 
repair O 
. O 
Further O 
investigation O 
revealed O 
that O 
reduction O 
of O 
Rad9 O 
reduced O 
the O 
UV-induced O 
transcription O 
of O 
the O 
genes O 
of O 
the O 
nucleotide B-FAMILY 
excision O 
repair O 
factors O 
DDB2 O 
, O 
XPC O 
, O 
DDB1 O 
and O 
XPB O 
and O 
DDB2 O 
protein O 
levels O 
in O 
human O 
cells O 
. O 
Interestingly O 
, O 
knockdown O 
of O 
one O 
subunit O 
of O 
DNA O 
damage O 
recognition O 
complex O 
, O 
hHR23B O 
impaired O 
Rad9-loading O 
onto O 
UV-damaged O 
chromatin O 
. O 
Based O 
on O 
these O 
results O 
, O 
we O 
suggest O 
that O 
Rad9 O 
plays O 
an O 
important O 
role O 
in O 
nucleotide B-FAMILY 
excision O 
repair O 
through O 
mechanisms O 
including O 
maintaining O 
DDB2 O 
protein O 
level O 
in O 
human O 
cells O 
. O 

and O 
antibacterial O 
evaluation O 
of O 
a O 
novel O 
series O 
of O 
10-hydroxyl B-FAMILY 
ketolide I-FAMILY 
derivatives O 
. O 

novel O 
series O 
of O 
10-hydroxyl B-FAMILY 
ketolide I-FAMILY 
derivatives O 
were O 
synthesized O 
, O 
during O 
which O 
a O 
distinctive O 
intermediate O 
, O 
3-O-descladinosyl-3-oxo-11-deoxy-10,11-epoxy-6-O-methylerythromycin B-SYSTEMATIC 
A I-SYSTEMATIC 
, O 
was O 
obtained O 
from O 
6-O-methylerythromycin B-SYSTEMATIC 
A I-SYSTEMATIC 
. O 
The O 
structure O 
and O 
stereochemistry O 
of O 
this O 
novel O 
structure O 
were O 
confirmed O 
via O 
NMR O 
and O 
X-ray O 
crystallography O 
. O 
Moreover O 
, O 
antibacterial O 
evaluations O 
were O 
established O 
in O 
order O 
to O 
assess O 
our O 
modifications O 
and O 
acquire O 
a O 
deep O 
understanding O 
of O 
the O 
ketolides B-FAMILY 
' O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
. O 

in O 
diabetes O 
after O 
Roux-en-Y O 
gastric O 
bypass O 
( O 
RYGB O 
) O 
often O 
occur O 
days O 
after O 
surgery O 
. O 
Surgically O 
induced O 
hormonal O 
changes O 
and O 
the O 
restrictive O 
postoperative O 
diet O 
are O 
proposed O 
mechanisms O 
. O 
We O 
evaluated O 
the O 
contribution O 
of O 
caloric O 
restriction O 
versus O 
surgically O 
induced O 
changes O 
to O 
glucose B-TRIVIAL 
homeostasis O 
in O 
the O 
immediate O 
postoperative O 
period.RESEARCH O 
DESIGN O 
AND O 
METHODSPatients O 
with O 
type O 
2 O 
diabetes O 
planning O 
to O 
undergo O 
RYGB O 
participated O 
in O 
a O 
prospective O 
two O 
- O 
period O 
study O 
( O 
each O 
period O 
involved O 
a O 
10-day O 
inpatient O 
stay O 
and O 
periods O 
were O 
separated O 
by O 
a O 
minimum O 
of O 
6 O 
weeks O 
of O 
wash O 
- O 
out O 
) O 
in O 
which O 
patients O 
served O 
as O 
their O 
own O 
controls O 
. O 
The O 
presurgery O 
period O 
consisted O 
of O 
diet O 
alone O 
. O 
The O 
postsurgery O 
period O 
was O 
matched O 
in O 
all O 
aspects O 
( O 
daily O 
matched O 
diet O 
) O 
and O 
included O 
RYGB O 
surgery O 
. O 
Glucose B-TRIVIAL 
measurements O 
were O 
performed O 
every O 
4 O 
h O 
throughout O 
the O 
study O 
. O 
A O 
mixed O 
meal O 
challenge O 
test O 
was O 
performed O 
before O 
and O 
after O 
each O 
period.RESULTSTen O 
patients O 
completed O 
the O 
study O 
and O 
had O 
the O 
following O 
characteristics O 
: O 
age O 
, O 
53.2 O 
years O 
( O 
95% O 
CI O 
, O 
48.0-58.4 O 
) O 
; O 
BMI O 
, O 
51.2 O 
kg O 
/ O 
m(2) O 
( O 
46.1-56.4 O 
) O 
; O 
diabetes O 
duration O 
, O 
7.4 O 
years O 
( O 
4.8-10.0 O 
) O 
; O 
and O 
HbA1c O 
, O 
8.52% O 
( O 
7.08-9.96 O 
) O 
. O 
Patients O 
lost O 
7.3 O 
kg O 
( O 
8.1-6.5 O 
) O 
during O 
the O 
presurgery O 
period O 
versus O 
4 O 
kg O 
( O 
6.2-1.7 O 
) O 
during O 
the O 
postsurgery O 
period O 
( O 
P O 
= O 
0.01 O 
between O 
periods O 
) O 
. O 
Daily O 
glycemia O 
in O 
the O 
presurgery O 
period O 
was O 
significantly O 
lower O 
( O 
1293.58 O 
mg O 
/ O 
dL*day O 
[1,096.83-1,490.33) O 
vs O 
. O 
1478.8 O 
mg O 
/ O 
dL*day O 
[ O 
1,277.47-1,680.13 O 
] O 
) O 
compared O 
with O 
the O 
postsurgery O 
period O 
( O 
P O 
= O 
0.02 O 
between O 
periods O 
) O 
. O 
The O 
improvements O 
in O 
the O 
fasting O 
and O 
maximum O 
poststimulation O 
glucose B-TRIVIAL 
and O 
6-h O 
glucose B-TRIVIAL 
area O 
under O 
the O 
curve O 
( O 
primary O 
outcome O 
) O 
were O 
similar O 
during O 
both O 
periods.CONCLUSIONS O 
Glucose B-TRIVIAL 
homeostasis O 
improved O 
in O 
response O 
to O 
a O 
reduced O 
caloric O 
diet O 
, O 
with O 
a O 
greater O 
effect O 
observed O 
in O 
the O 
absence O 
of O 
surgery O 
as O 
compared O 
with O 
after O 
RYGB O 
. O 
These O 
findings O 
suggest O 
that O 
reduced O 
calorie O 
ingestion O 
can O 
explain O 
the O 
marked O 
improvement O 
in O 
diabetes O 
control O 
observed O 
after O 
RYGB O 
. O 

of O 
Xanthurenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
putative O 
endogenous O 
Group O 
II O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
agonist O 
, O 
on O 
sensory O 
transmission O 
in O 
the O 
thalamus O 
. O 

acid I-TRIVIAL 
( O 
XA O 
) O 
, O 
a O 
molecule O 
arising O 
from O 
tryptophan B-TRIVIAL 
metabolism O 
by O 
transamination O 
of O 
3-hydroxykynurenine B-SYSTEMATIC 
, O 
has O 
recently O 
been O 
identified O 
as O 
an O 
endogenous O 
Group O 
II O 
( O 
mGlu2 O 
and O 
mGlu3 O 
) O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptor O 
ligand O 
in O 
vitro O 
. O 
Impairments O 
in O 
Group O 
II O 
mGlu O 
receptor O 
expression O 
and O 
function O 
have O 
been O 
implicated O 
in O 
the O 
pathophysiology O 
of O 
schizophrenia O 
, O 
as O 
have O 
multiple O 
steps O 
in O 
the O 
kynurenine B-TRIVIAL 
metabolism O 
pathway O 
. O 
Therefore O 
, O 
we O 
examined O 
XA O 
in O 
vivo O 
to O 
further O 
investigate O 
its O 
potential O 
as O 
a O 
Group O 
II O 
mGlu O 
receptor O 
ligand O 
using O 
a O 
preparation O 
that O 
has O 
been O 
previously O 
demonstrated O 
to O 
efficiently O 
reveal O 
the O 
action O 
of O 
other O 
Group O 
II O 
mGlu O 
receptor O 
ligands O 
in O 
vivo O 
. O 
Extracellular O 
single O 
- O 
neurone O 
recordings O 
were O 
made O 
in O 
the O 
rat O 
ventrobasal O 
thalamus O 
( O 
VB O 
) O 
in O 
conjunction O 
with O 
iontophoresis O 
of O 
agonists O 
, O 
an O 
antagonist O 
and O 
a O 
positive O 
allosteric O 
modulator O 
and O 
/ O 
or O 
intravenous O 
( O 
i.v O 
. O 
) O 
injection O 
of O 
XA O 
. O 
We O 
found O 
the O 
XA O 
effect O 
on O 
sensory O 
inhibition O 
, O 
when O 
applied O 
iontophoretically O 
and O 
i.v O 
. O 
, O 
was O 
similar O 
to O 
that O 
of O 
other O 
Group O 
II O 
mGlu O 
receptor O 
agonists O 
in O 
reducing O 
inhibition O 
evoked O 
in O 
the O 
VB O 
from O 
the O 
thalamic O 
reticular O 
nucleus O 
upon O 
physiological O 
sensory O 
stimulation O 
. O 
Furthermore O 
, O 
we O 
postulate O 
that O 
XA O 
may O 
be O 
the O 
first O 
potential O 
endogenous O 
allosteric O 
agonist O 
( O 
termed O 
' O 
endocoid O 
' O 
) O 
for O 
the O 
mGlu O 
receptors O 
. O 
As O 
the O 
Group O 
II O 
receptors O 
and O 
kynurenine B-TRIVIAL 
metabolism O 
pathway O 
have O 
both O 
been O 
heavily O 
implicated O 
in O 
the O 
pathophysiology O 
of O 
schizophrenia O 
, O 
XA O 
could O 
play O 
a O 
pivotal O 
role O 
in O 
antipsychotic O 
research O 
as O 
this O 
potential O 
endocoid O 
represents O 
both O 
a O 
convergence O 
within O 
these O 
two O 
biological O 
parameters O 
and O 
a O 
novel O 
class O 
of O 
Group O 
II O 
mGlu O 
receptor O 
ligand O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

and O 
evaluation O 
of O 
Janus B-FAMILY 
type I-FAMILY 
nucleosides I-FAMILY 
as O 
potential O 
HCV O 
NS5B O 
polymerase O 
inhibitors O 
. O 

synthesis O 
of O 
new O 
ribo B-MULTIPLE 
and I-MULTIPLE 
2'-β-C-methyl I-MULTIPLE 
ribo I-MULTIPLE 
Janus I-MULTIPLE 
type I-MULTIPLE 
nucleosides I-MULTIPLE 
J-AA O 
, O 
J-AG O 
and O 
J-AU O 
is O 
reported O 
along O 
with O 
their O 
ability O 
to O 
block O 
HCV O 
and O 
HIV O 
replication O 
. O 
Their O 
toxicity O 
was O 
also O 
assessed O 
in O 
Huh7 O 
, O 
human O 
lymphocytes O 
, O 
CEM O 
and O 
Vero O 
cells O 
. O 

Q-S I-MULTIPLE 
from O 
the O 
plant O 
endophytic O 
fungus O 
Pestalotiopsis O 
fici O 
. O 

new O 
isoprenylated B-TRIVIAL 
chromone I-TRIVIAL 
derivatives O 
, O 
pestaloficiols B-MULTIPLE 
Q I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
R I-MULTIPLE 
( O 
2 O 
) O 
, O 
and O 
one O 
new O 
benzofuran B-SYSTEMATIC 
derivative O 
, O 
pestaloficiol B-TRIVIAL 
S I-TRIVIAL 
( O 
3 O 
) O 
, O 
along O 
with O 
three O 
known O 
metabolites O 
, O 
anofinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
4 O 
) O 
, O 
siccayne B-TRIVIAL 
( O 
5 O 
) O 
, O 
and O 
pyrenophorol B-TRIVIAL 
( O 
6 O 
) O 
were O 
isolated O 
from O 
solid O 
cultures O 
of O 
the O 
plant O 
endophytic O 
fungus O 
Pestalotiopsis O 
fici O 
. O 
Their O 
structures O 
were O 
elucidated O 
primarily O 
by O 
NMR O 
spectroscopy O 
, O 
and O 
the O 
absolute O 
of O 
the O 
C-6 O 
secondary B-FAMILY 
alcohol I-FAMILY 
in O 
1 O 
was O 
deduced O 
on O 
the O 
basis O 
of O 
circular O 
dichroism O 
( O 
CD O 
) O 
data O 
. O 
Compound O 
5 O 
showed O 
cytotoxic O 
activity O 
against O 
the O 
human O 
cancer O 
cell O 
lines O 
, O 
HeLa O 
and O 
HT29 O 
, O 
with O 
IC50 O 
values O 
of O 
48.2 O 
and O 
33.9μM O 
, O 
respectively O 
. O 

pharmacokinetics O 
analysis O 
of O 
cyclophosphamide B-TRIVIAL 
with O 
genetic O 
effects O 
in O 
patients O 
undergoing O 
hematopoietic O 
stem O 
cell O 
transplantation O 
. O 

: O 
To O 
build O 
a O 
population O 
pharmacokinetic O 
( O 
PK O 
) O 
model O 
of O 
cyclophosphamide B-TRIVIAL 
( O 
CY O 
) O 
and O 
its O 
metabolite O 
, O 
4-hydroxycyclophosphamide B-SYSTEMATIC 
( O 
HCY B-ABBREVIATION 
) O 
, O 
in O 
patients O 
undergoing O 
allogeneic O 
haematopoietic O 
stem O 
cell O 
transplantation O 
( O 
HSCT O 
) O 
and O 
to O 
identify O 
covariates O 
, O 
including O 
genetic O 
polymorphisms O 
, O 
which O 
affect O 
CY O 
and O 
HCY B-ABBREVIATION 
PK O 
parameters O 
. O 
METHOD O 
: O 
The O 
study O 
cohort O 
comprised O 
21 O 
patients O 
undergoing O 
HSCT O 
who O 
received O 
CY O 
intravenously O 
between O 
2009 O 
and O 
2011 O 
. O 
Clinical O 
characteristics O 
and O 
CY O 
and O 
HCY B-ABBREVIATION 
concentration O 
data O 
were O 
collected O 
for O 
all O 
patients O 
, O 
and O 
ABCB1 O 
, O 
ABCC2 O 
, O 
GSTA1 O 
, O 
GSTM1 O 
, O 
GSTP1 O 
, O 
GSTT1 O 
, O 
CYP2B6 O 
, O 
CYP2C19 O 
, O 
and O 
CYP3A5 O 
genotyping O 
was O 
performed O 
. O 
A O 
hypothetical O 
enzyme O 
compartment O 
was O 
conducted O 
using O 
the O 
NONMEM O 
program O 
. O 
RESULTS O 
: O 
A O 
population O 
PK O 
analysis O 
showed O 
that O 
the O 
ABCC2 O 
1249 O 
genotype O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
levels O 
significantly O 
affected O 
non-induced O 
clearance O 
( O 
CL O 
UI O 
) O 
and O 
induced O 
clearance O 
( O 
CL O 
I O 
) O 
of O 
CY O 
, O 
respectively O 
. O 
The O 
final O 
estimate O 
of O 
the O 
mean O 
CL O 
UI O 
and O 
CL O 
I O 
of O 
CY O 
was O 
15.5 O 
and O 
0.683 O 
L O 
/ O 
h O 
, O 
respectively O 
, O 
and O 
the O 
mean O 
volume O 
of O 
distribution O 
( O 
V O 
1 O 
) O 
of O 
CY O 
was O 
88 O 
L O 
. O 
The O 
inter O 
- O 
individual O 
variability O 
for O 
CL O 
UI O 
, O 
CL O 
I O 
, O 
and O 
V O 
1 O 
of O 
CY O 
was O 
52.8 O 
, O 
200 O 
, O 
and O 
18 O 
% O 
, O 
respectively O 
. O 
Additionally O 
, O 
the O 
CL O 
UI O 
of O 
CY O 
was O 
significantly O 
decreased O 
to O 
approximately O 
51 O 
% O 
in O 
patients O 
with O 
the O 
1249 O 
GA O 
heterozygous O 
genotype O 
compared O 
to O 
those O 
with O 
the O 
1249 O 
GG O 
wild O 
- O 
type O 
genotype O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
There O 
were O 
only O 
three O 
heterozygous O 
GA O 
variants O 
of O 
ABCC2 O 
1249 O 
in O 
the O 
study O 
patients O 
. O 
CONCLUSIONS O 
: O 
The O 
population O 
PK O 
model O 
developed O 
in O 
this O 
study O 
implies O 
an O 
influence O 
of O 
genetic O 
factors O 
on O 
the O 
clearance O 
of O 
CY O 
. O 
Clearance O 
was O 
moderately O 
reduced O 
in O 
patients O 
with O 
the O 
ABCC2 O 
1249GA O 
heterozygous O 
genotype O 
. O 

adhesion O 
kinase O 
( O 
FAK O 
) O 
is O 
emerging O 
as O 
a O 
promising O 
cancer O 
target O 
because O 
it O 
is O 
highly O 
expressed O 
at O 
both O 
the O 
transcriptional O 
and O 
translational O 
level O 
in O 
cancer O 
and O 
is O 
involved O 
in O 
many O 
aspects O 
of O 
tumor O 
growth O 
, O 
invasion O 
, O 
and O 
metastasis O 
. O 
Existing O 
FAK O 
- O 
based O 
therapeutics O 
focus O 
on O 
inhibiting O 
the O 
kinase's O 
catalytic O 
function O 
and O 
not O 
the O 
large O 
scaffold O 
it O 
creates O 
that O 
includes O 
many O 
oncogenic O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
and O 
tumor O 
suppressor O 
proteins O 
. O 
Targeting O 
the O 
FAK O 
scaffold O 
is O 
a O 
feasible O 
and O 
promising O 
approach O 
for O 
developing O 
highly O 
specific O 
therapeutics O 
that O 
disrupt O 
FAK O 
signaling O 
pathways O 
in O 
cancer O 
. O 

mechanisms O 
leading O 
to O 
the O 
deposition O 
of O 
colloidal O 
particles O 
in O 
a O 
copper B-SYSTEMATIC 
-gold O 
galvanic O 
microreactor O 
are O 
investigated O 
. O 
Using O 
in O 
situ O 
current O 
density O 
measurements O 
and O 
particle O 
velocimetry O 
, O 
we O 
establish O 
correlations O 
between O 
the O 
spatial O 
arrangement O 
and O 
the O 
geometry O 
of O 
the O 
electrodes O 
, O 
current O 
density O 
distribution O 
, O 
and O 
particle O 
aggregation O 
behavior O 
. O 
Ionic O 
transport O 
phenomena O 
are O 
responsible O 
for O 
the O 
occurrence O 
of O 
strongly O 
localized O 
high O 
current O 
density O 
at O 
the O 
edges O 
and O 
corners O 
of O 
the O 
copper B-SYSTEMATIC 
electrodes O 
at O 
large O 
electrode O 
separation O 
, O 
leading O 
to O 
a O 
preferential O 
aggregation O 
of O 
colloidal O 
particles O 
at O 
the O 
electrode O 
edges O 
. O 
Preferential O 
aggregation O 
appears O 
to O 
be O 
the O 
result O 
of O 
a O 
combination O 
of O 
electrophoretic O 
effects O 
and O 
changes O 
in O 
bulk O 
electrolyte O 
flow O 
patterns O 
. O 
We O 
demonstrate O 
that O 
electrolyte O 
flow O 
is O 
most O 
likely O 
driven O 
by O 
electrochemical O 
potential O 
gradients O 
of O 
reaction O 
products O 
formed O 
during O 
the O 
inhomogeneous O 
copper B-SYSTEMATIC 
dissolution O 
. O 

4- B-FAMILY 
substituted-2(1H)-phthalazinone I-FAMILY 
derivatives O 
: O 
synthesis O 
, O 
molecular O 
modeling O 
study O 
and O 
their O 
effects O 
on O 
α-receptors O 
. O 

4-(4-bromophenyl)phthalazine B-SYSTEMATIC 
derivatives O 
connected O 
via O 
an O 
alkyl B-FAMILY 
spacer O 
to O 
amine B-SYSTEMATIC 
or O 
N- B-FAMILY 
substituted I-FAMILY 
piperazine I-FAMILY 
were O 
designed O 
and O 
synthesized O 
as O 
promising O 
α-adrenoceptor O 
antagonists O 
. O 
The O 
structures O 
of O 
the O 
phthalazine B-TRIVIAL 
derivatives O 
were O 
established O 
using O 
elemental O 
and O 
spectral O 
analyses O 
. O 
Twelve O 
of O 
the O 
tested O 
compounds O 
displayed O 
significant O 
α-blocking O 
activity O 
. O 
Molecular O 
modeling O 
studies O 
were O 
performed O 
to O 
rationalize O 
the O 
biological O 
results O 
. O 
Among O 
the O 
tested O 
compounds O 
, O 
7j O 
displayed O 
the O 
best O 
- O 
fitting O 
score O 
and O 
the O 
highest O 
in O 
vitro O 
activity O 
. O 

single O 
gold O 
microshell O 
, O 
which O 
was O 
elaborately O 
fabricated O 
to O 
carry O 
numerous O 
hot O 
spots O 
on O 
its O 
own O 
surface O 
, O 
enabled O 
the O 
acquisition O 
of O 
the O 
SERS O 
spectra O 
from O 
the O 
molecules O 
on O 
non-SERS O 
active O 
substrates O 
such O 
as O 
Si B-FORMULA 
/ O 
SiO2 B-FORMULA 
, O 
ITO B-ABBREVIATION 
, O 
and O 
glass O 
. O 
A O 
self O 
- O 
assembled O 
monolayer O 
of O 
11-mercaptoundecanols B-FAMILY 
on O 
the O 
gold O 
microshell O 
offered O 
an O 
easy O 
and O 
reliable O 
way O 
to O 
electrically O 
insulate O 
from O 
the O 
underlying O 
flat O 
Pt B-FORMULA 
electrode O 
and O 
accomplish O 
in O 
situ O 
monitoring O 
the O 
electrochemical O 
reaction O 
with O 
minimal O 
interference O 
. O 

leaf O 
tea O 
( O 
GLT O 
) O 
contains O 
guava O 
leaf O 
polyphenol B-FAMILY 
( O 
Gvpp O 
) O 
, O 
which O 
regulates O 
the O 
absorption O 
of O 
dietary O 
carbohydrate B-FAMILY 
from O 
the O 
intestines O 
. O 
Borderline O 
diabetics O 
, O 
who O 
are O 
at O 
high O 
risk O 
of O 
development O 
of O 
diabetes O 
, O 
take O 
GLT O 
to O 
suppress O 
a O 
rapid O 
increase O 
of O 
blood O 
sugar B-FAMILY 
level O 
after O 
meals O 
. O 
However O 
, O 
patients O 
with O 
diabetes O 
in O 
whom O 
diabetic O 
drugs O 
or O 
warfarin B-TRIVIAL 
as O 
a O 
blood O 
thinner O 
are O 
prescribed O 
also O 
take O 
GLT O 
with O 
the O 
expectation O 
of O 
glycemic O 
control O 
. O 
Therefore O 
, O 
we O 
studied O 
whether O 
GLT O 
had O 
potential O 
for O 
inhibition O 
or O 
induction O 
of O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
and O 
an O 
influence O 
on O 
the O 
action O 
of O 
warfarin B-TRIVIAL 
. O 
Extract O 
of O 
guava O 
leaf O 
( O 
GvEx O 
) O 
consists O 
of O 
carbohydrate B-FAMILY 
and O 
polyphenols B-FAMILY 
, O 
which O 
are O 
Gvpp O 
, O 
quercetin B-TRIVIAL 
, O 
and O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
. O 
These O 
polyphenols B-FAMILY 
, O 
but O 
not O 
GvEx O 
, O 
showed O 
a O 
certain O 
level O 
of O 
inhibition O 
of O 
human-cDNA-expressed O 
CYPs O 
. O 
In O 
a O 
comparison O 
of O 
GLT O 
and O 
grapefruit O 
juice O 
, O 
GLT O 
showed O 
weaker O 
inhibition O 
of O 
CYP O 
activities O 
and O 
of O 
midazolam B-TRIVIAL 
1'-hydroxylation O 
than O 
grapefruit O 
juice O 
. O 
Furthermore O 
, O 
neither O 
liver O 
weight O 
nor O 
CYP3A O 
expression O 
in O 
the O 
liver O 
was O 
changed O 
in O 
rats O 
that O 
received O 
GvEx O 
for O 
90 O 
days O 
compared O 
with O 
the O 
control O 
group O 
. O 
When O 
rats O 
were O 
concomitantly O 
treated O 
with O 
GLT O 
and O 
warfarin B-TRIVIAL 
, O 
the O 
prolongation O 
of O 
clotting O 
time O 
of O 
blood O 
by O 
warfarin B-TRIVIAL 
was O 
not O 
influenced O 
. O 
These O 
data O 
suggest O 
that O 
GLT O 
is O 
unlikely O 
to O 
interact O 
with O 
drugs O 
. O 

profiling O 
discovers O 
the O 
dieldrin B-TRIVIAL 
organochlorinated O 
pesticide O 
affects O 
leucine B-TRIVIAL 
availability O 
in O 
yeast O 
. O 

to O 
organochlorinated O 
pesticides O 
such O 
as O 
dieldrin B-TRIVIAL 
has O 
been O 
linked O 
to O 
Parkinson's O 
and O 
Alzheimer's O 
diseases O 
, O 
endocrine O 
disruption O 
, O 
and O 
cancer O 
, O 
but O 
the O 
cellular O 
and O 
molecular O 
mechanisms O 
of O 
toxicity O 
behind O 
these O 
effects O 
remain O 
largely O 
unknown O 
. O 
Here O 
we O 
demonstrate O 
, O 
using O 
a O 
functional O 
genomics O 
approach O 
in O 
the O 
model O 
eukaryote O 
Saccharomyces O 
cerevisiae O 
, O 
that O 
dieldrin B-TRIVIAL 
alters O 
leucine B-TRIVIAL 
availability O 
. O 
This O 
model O 
is O 
supported O 
by O 
multiple O 
lines O 
of O 
congruent O 
evidence O 
: O 
( O 
1 O 
) O 
mutants O 
defective O 
in O 
amino B-FAMILY 
acid I-FAMILY 
signaling O 
or O 
transport O 
are O 
sensitive O 
to O 
dieldrin B-TRIVIAL 
, O 
which O 
is O 
reversed O 
by O 
the O 
addition O 
of O 
exogenous O 
leucine B-TRIVIAL 
; O 
( O 
2 O 
) O 
dieldrin B-TRIVIAL 
sensitivity O 
of O 
wild O 
- O 
type O 
or O 
mutant O 
strains O 
is O 
dependent O 
upon O 
leucine B-TRIVIAL 
concentration O 
in O 
the O 
media O 
; O 
( O 
3 O 
) O 
overexpression O 
of O 
proteins O 
that O 
increase O 
intracellular O 
leucine B-TRIVIAL 
confer O 
resistance O 
to O 
dieldrin B-TRIVIAL 
; O 
( O 
4 O 
) O 
leucine B-TRIVIAL 
uptake O 
is O 
inhibited O 
in O 
the O 
presence O 
of O 
dieldrin B-TRIVIAL 
; O 
and O 
( O 
5 O 
) O 
dieldrin B-TRIVIAL 
induces O 
the O 
amino B-FAMILY 
acid I-FAMILY 
starvation O 
response O 
. O 
Additionally O 
, O 
we O 
demonstrate O 
that O 
appropriate O 
negative O 
regulation O 
of O 
the O 
Ras O 
/ O 
protein O 
kinase O 
A O 
pathway O 
, O 
along O 
with O 
an O 
intact O 
pyruvate B-TRIVIAL 
dehydrogenase O 
complex O 
, O 
is O 
required O 
for O 
dieldrin B-TRIVIAL 
tolerance O 
. O 
Many O 
yeast O 
genes O 
described O 
in O 
this O 
study O 
have O 
human O 
orthologs O 
that O 
may O 
modulate O 
dieldrin B-TRIVIAL 
toxicity O 
in O 
humans O 
. O 

arginine B-TRIVIAL 
- O 
leucine B-TRIVIAL 
block O 
copolypeptide O 
( O 
R60 O 
L20 O 
) O 
is O 
synthesized O 
, O 
which O 
is O 
capable O 
of O 
forming O 
vesicles O 
with O 
controllable O 
sizes O 
, O 
able O 
to O 
transport O 
hydrophilic O 
cargo O 
across O 
the O 
cell O 
membrane O 
, O 
and O 
exhibit O 
relatively O 
low O 
cytotoxicity O 
. O 
The O 
R60 O 
L20 O 
vesicles O 
also O 
possess O 
the O 
ability O 
to O 
deliver O 
DNA O 
into O 
mammalian O 
cells O 
for O 
transfection O 
. O 
Although O 
the O 
transfection O 
efficiency O 
is O 
lower O 
than O 
that O 
of O 
the O 
commercially O 
available O 
transfection O 
agent O 
Lipofectamine B-TRIVIAL 
2000 I-TRIVIAL 
, O 
the O 
R60 O 
L20 O 
vesicles O 
are O 
able O 
to O 
achieve O 
transfection O 
with O 
significantly O 
lower O 
cytotoxicity O 
and O 
immunogenicity O 
. O 
This O 
behavior O 
is O 
potentially O 
due O 
to O 
its O 
stronger O 
interaction O 
with O 
DNA O 
which O 
subsequently O 
provides O 
better O 
protection O 
against O 
anionic O 
heparin O 
. O 

and O 
anti-allergic O 
activity O 
of O 
2-((bis(trimethylsilyl)methylthio B-MULTIPLE 
/ I-MULTIPLE 
methylsulfonyl)methyl)-5-aryl-1,3,4-oxadiazoles I-MULTIPLE 
. O 

new O 
class O 
of O 
sila B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
1,3,4-oxadiazoles I-FAMILY 
was O 
synthesized O 
by O 
a O 
convenient O 
synthetic O 
method O 
. O 
Both O 
silathio B-MULTIPLE 
/ I-MULTIPLE 
silasulfonyl I-MULTIPLE 
acetic I-MULTIPLE 
acids I-MULTIPLE 
were O 
efficiently O 
condensed O 
with O 
benzohydrazides B-FAMILY 
in O 
the O 
presence O 
of O 
phosphorus B-SYSTEMATIC 
oxychloride I-SYSTEMATIC 
to O 
give O 
sila B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
1,3,4-oxadiazoles I-FAMILY 
in O 
high O 
yields O 
. O 
The O 
compounds O 
displayed O 
variable O 
extent O 
of O 
anti-allergic O 
activity O 
on O 
IgE O 
/ O 
Ag-stimulated O 
RBL-2H3 O 
cells O 
at O 
50 O 
and O 
100 O 
μM O 
concentrations O 
. O 
Compounds O 
having O 
sulfonyl B-SYSTEMATIC 
moiety O 
with O 
bis(trimethylsilyl)-1,3,4-oxadiazoles B-FAMILY 
( O 
5a-c O 
) O 
, O 
exhibited O 
better O 
anti-allergic O 
activities O 
than O 
those O 
of O 
compounds O 
having O 
sulphur B-SYSTEMATIC 
moiety O 
with O 
bis(trimethylsilyl)-1,3,4-oxadiazoles B-FAMILY 
( O 
4a-c O 
) O 
. O 

withdrawal O 
elicits O 
oxidative O 
/ O 
nitrosative O 
damage O 
in O 
the O 
rat O 
cerebral O 
cortex O 
. O 

are O 
inhibitors O 
of O 
the O 
enzyme O 
3-hydroxy-3-methylglutaryl B-SYSTEMATIC 
coenzyme I-SYSTEMATIC 
A I-SYSTEMATIC 
reductase O 
, O 
the O 
rate O 
- O 
limiting O 
step O 
in O 
cholesterol B-TRIVIAL 
biosynthesis O 
. O 
Statins O 
effectively O 
prevent O 
and O 
reduce O 
the O 
risk O 
of O 
coronary O 
artery O 
disease O 
through O 
lowering O 
serum O 
cholesterol B-TRIVIAL 
, O 
and O 
also O 
exert O 
anti-thrombotic O 
, O 
anti-inflammatory O 
and O 
antioxidant O 
effects O 
independently O 
of O 
changes O 
in O 
cholesterol B-TRIVIAL 
levels O 
. O 
On O 
the O 
other O 
hand O 
, O 
clinical O 
and O 
experimental O 
evidence O 
suggests O 
that O 
abrupt O 
cessation O 
of O 
statin O 
treatment O 
( O 
i.e O 
. O 
statin O 
withdrawal O 
) O 
is O 
associated O 
with O 
a O 
deleterious O 
rebound O 
phenomenon O 
. O 
In O 
fact O 
, O 
statin O 
withdrawal O 
increases O 
the O 
risk O 
of O 
thrombotic O 
vascular O 
events O 
, O 
causes O 
impairment O 
of O 
endothelium O 
- O 
dependent O 
relaxation O 
and O 
facilitates O 
experimental O 
seizures O 
. O 
However O 
, O 
evidence O 
for O 
statin O 
withdrawal O 
- O 
induced O 
detrimental O 
effects O 
to O 
the O 
brain O 
parenchyma O 
is O 
still O 
lacking O 
. O 
In O 
the O 
present O 
study O 
adult O 
male O 
Wistar O 
rats O 
were O 
treated O 
with O 
atorvastatin B-TRIVIAL 
for O 
seven O 
days O 
( O 
10mg O 
/ O 
kg O 
/ O 
day O 
) O 
and O 
neurochemical O 
assays O 
were O 
performed O 
in O 
the O 
cerebral O 
cortex O 
30min O 
( O 
atorvastatin B-TRIVIAL 
treatment O 
) O 
or O 
24h O 
( O 
atorvastatin B-TRIVIAL 
withdrawal O 
) O 
after O 
the O 
last O 
atorvastatin B-TRIVIAL 
administration O 
. O 
We O 
found O 
that O 
atorvastatin B-TRIVIAL 
withdrawal O 
decreased O 
levels O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
mitochondrial O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
, O 
whereas O 
increased O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
and O 
immunoreactivity O 
for O 
the O 
protein O 
nitration O 
marker O 
3-nitrotyrosine B-SYSTEMATIC 
in O 
the O 
cerebral O 
cortex O 
. O 
Catalase O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
and O 
xanthine B-TRIVIAL 
oxidase O 
activities O 
were O 
not O 
altered O 
by O 
atorvastatin B-TRIVIAL 
treatment O 
or O 
withdrawal O 
, O 
as O 
well O 
as O 
protein O 
carbonyl B-FAMILY 
and O 
4-hydroxy-2-nonenal B-SYSTEMATIC 
immunoreactivity O 
. O 
Immunoprecipitation O 
of O 
mitochondrial O 
SOD O 
followed O 
by O 
analysis O 
of O 
3-nitrotyrosine B-SYSTEMATIC 
revealed O 
increased O 
levels O 
of O 
nitrated O 
mitochondrial O 
SOD O 
, O 
suggesting O 
the O 
mechanism O 
underlying O 
the O 
atorvastatin B-TRIVIAL 
withdrawal O 
- O 
induced O 
decrease O 
in O 
enzyme O 
activity O 
. O 
Altogether O 
, O 
our O 
results O 
indicate O 
the O 
atorvastatin B-TRIVIAL 
withdrawal O 
elicits O 
oxidative O 
/ O 
nitrosative O 
damage O 
in O 
the O 
rat O 
cerebral O 
cortex O 
, O 
and O 
that O 
changes O 
in O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
and O 
mitochondrial O 
superoxide B-TRIVIAL 
dismutase O 
activities O 
may O 
underlie O 
such O 
harmful O 
effects O 
. O 

contaminant O 
mixtures O 
induced O 
morphological O 
and O 
functional O 
changes O 
in O 
human O 
coronary O 
artery O 
endothelial O 
cells O 
under O 
culture O 
conditions O 
typifying O 
high O 
fat/ O 
sugar B-FAMILY 
diet O 
and O 
ethanol B-SYSTEMATIC 
exposure O 
. O 

has O 
been O 
reported O 
that O 
Northern O 
populations O 
are O 
exposed O 
to O 
mixtures O 
of O 
various O 
environmental O 
contaminants O 
unique O 
to O 
the O 
Arctic O 
( O 
Northern O 
contaminant O 
mixtures O 
- O 
NCM O 
) O 
at O 
a O 
large O 
range O 
of O 
concentrations O 
, O 
depending O 
on O 
their O 
geological O 
location O 
, O 
age O 
, O 
lifestyle O 
and O 
dietary O 
habits O 
. O 
To O 
determine O 
if O 
these O 
contaminants O 
may O 
contribute O 
to O 
a O 
cardiovascular O 
health O 
risk O 
, O 
especially O 
when O 
combined O 
with O 
a O 
high O 
fat O 
and O 
sugar B-FAMILY 
diet O 
and O 
ethanol B-SYSTEMATIC 
exposure O 
, O 
we O 
treated O 
human O 
coronary O 
artery O 
endothelial O 
cells O 
( O 
HCAEC O 
) O 
with O 
two O 
mixtures O 
of O 
4 O 
organic O 
( O 
NCM1 O 
) O 
or O 
22 O 
organic O 
and O 
inorganic O 
( O 
NCM2 O 
) O 
chemicals O 
detected O 
in O 
Northerners' O 
blood O 
during O 
2004-2005 O 
in O 
the O 
presence O 
or O 
absence O 
of O 
low O 
- O 
density O 
lipoprotein O 
( O 
1.5mg O 
/ O 
ml O 
) O 
, O 
very O 
- O 
low O 
- O 
density O 
lipoprotein O 
( O 
1.0mg O 
/ O 
ml O 
) O 
and O 
glucose B-TRIVIAL 
( O 
10mmol O 
/ O 
L O 
) O 
( O 
LVG O 
) O 
, O 
and O 
in O 
the O 
absence O 
or O 
presence O 
of O 
0.1% O 
ethanol B-SYSTEMATIC 
. O 
After O 
24h O 
of O 
exposure O 
, O 
cell O 
morphology O 
and O 
markers O 
of O 
cytotoxicity O 
and O 
endothelial O 
function O 
were O 
examined O 
. O 
NCM1 O 
treatment O 
did O 
not O 
affect O 
cell O 
viability O 
, O 
but O 
increased O 
cell O 
size O 
, O 
disrupted O 
cell O 
membrane O 
integrity O 
, O 
and O 
decreased O 
cell O 
density O 
, O 
uptake O 
of O 
small O 
peptides O 
, O 
release O 
of O 
endothelin-1 O 
( O 
ET-1 O 
) O 
and O 
plasminogen O 
activator O 
inhibitor O 
( O 
PAI O 
) O 
, O 
while O 
causing O 
no O 
changes O 
in O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
eNOS O 
) O 
protein O 
expression O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
release O 
. O 
In O 
contrast O 
, O 
NCM2 O 
decreased O 
cell O 
viability O 
, O 
total O 
protein O 
yield O 
, O 
uptake O 
of O 
small O 
peptides O 
, O 
eNOS O 
protein O 
expression O 
, O 
and O 
NO B-FORMULA 
release O 
and O 
caused O 
membrane O 
damage O 
, O 
but O 
caused O 
no O 
changes O 
in O 
the O 
secretion O 
of O 
ET-1 O 
, O 
prostacyclin B-TRIVIAL 
and O 
PAI O 
. O 
The O 
presence O 
of O 
LVG O 
and O 
/ O 
or O 
alcohol B-FAMILY 
did O 
or O 
did O 
not O 
influence O 
the O 
effects O 
of O 
NCM1 O 
or O 
NCM2 O 
depending O 
on O 
the O 
endpoint O 
and O 
the O 
mixture O 
examined O 
. O 
These O 
results O 
suggested O 
that O 
the O 
effects O 
of O 
one O 
or O 
one O 
group O 
of O 
contaminants O 
may O 
be O 
altered O 
by O 
the O 
presence O 
of O 
other O 
contaminants O 
, O 
and O 
that O 
with O 
or O 
without O 
the O 
interaction O 
of O 
high O 
fat O 
and O 
sugar B-FAMILY 
diet O 
and O 
/ O 
or O 
ethanol B-SYSTEMATIC 
exposure O 
, O 
NCMs O 
at O 
the O 
concentrations O 
used O 
caused O 
endothelial O 
dysfunction O 
in O 
vitro O 
. O 
It O 
remains O 
to O 
be O 
investigated O 
if O 
these O 
effects O 
of O 
NCMs O 
also O 
occur O 
in O 
vivo O 
. O 

sulfide I-SYSTEMATIC 
increases O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
with O 
calcium B-SYSTEMATIC 
-dependent O 
activation O 
of O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
in O 
endothelial O 
cells O 
. O 

sulfide I-SYSTEMATIC 
( O 
H(2)S B-FORMULA 
) O 
was O 
recently O 
discovered O 
to O 
be O 
synthesized O 
in O 
mammalian O 
tissues O 
by O 
several O 
different O 
enzymes O 
. O 
Numerous O 
studies O 
have O 
shown O 
that O 
H(2)S B-FORMULA 
has O 
vasodilator O 
and O 
antihypertensive O 
effects O 
in O 
the O 
cardiovascular O 
system O 
. O 
However O 
, O 
intracellular O 
mechanisms O 
of O 
the O 
H(2)S B-FORMULA 
-induced O 
vasodilation O 
and O 
its O 
interactions O 
with O 
other O 
endothelium O 
- O 
derived O 
relaxing O 
factors O 
, O 
such O 
as O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
remain O 
unclear O 
. O 
We O 
investigated O 
whether O 
H(2)S B-FORMULA 
directly O 
regulates O 
endothelial O 
NO B-FORMULA 
synthase O 
( O 
eNOS O 
) O 
activity O 
and O 
NO B-FORMULA 
production O 
in O 
endothelial O 
cells O 
. O 
NaHS B-FORMULA 
, O 
a O 
H(2)S B-FORMULA 
donor O 
, O 
dose O 
- O 
dependently O 
increased O 
NO B-FORMULA 
production O 
in O 
cultured O 
endothelial O 
cells O 
. O 
This O 
effect O 
was O 
abolished O 
by O 
a O 
calcium B-SYSTEMATIC 
chelator O 
( O 
BAPTA-AM B-ABBREVIATION 
) O 
, O 
but O 
not O 
by O 
the O 
absence O 
of O 
extracellular O 
calcium B-SYSTEMATIC 
. O 
The O 
NaHS B-FORMULA 
-induced O 
NO B-FORMULA 
production O 
was O 
partially O 
blocked O 
by O 
inhibitors O 
of O 
ryanodine B-TRIVIAL 
receptor O 
( O 
dantrolene B-TRIVIAL 
) O 
or O 
inositol B-SYSTEMATIC 
1,4,5-triphosphate I-SYSTEMATIC 
receptor O 
( O 
xestospongin B-TRIVIAL 
C I-TRIVIAL 
) O 
. O 
NaHS B-FORMULA 
significantly O 
increased O 
intracellular O 
calcium B-SYSTEMATIC 
concentrations O 
, O 
and O 
this O 
effect O 
was O 
attenuated O 
by O 
dantrolene B-TRIVIAL 
or O 
xestospongin B-TRIVIAL 
C I-TRIVIAL 
. O 
NaHS B-FORMULA 
induced O 
phosphorylation O 
of O 
eNOS O 
at O 
the O 
activating O 
phosphoserine B-SYSTEMATIC 
residue O 
1179 O 
. O 
The O 
NaHS B-FORMULA 
-induced O 
eNOS O 
phosphorylation O 
and O 
NO B-FORMULA 
production O 
were O 
not O 
affected O 
by O 
a O 
PI3K O 
/ O 
Akt O 
inhibitor O 
( O 
wortmannin B-TRIVIAL 
) O 
. O 
The O 
data O 
of O 
this O 
study O 
suggest O 
that O 
H(2)S B-FORMULA 
directly O 
acts O 
on O 
endothelial O 
cells O 
to O 
induce O 
eNOS O 
activation O 
and O 
NO B-FORMULA 
production O 
by O 
releasing O 
calcium B-SYSTEMATIC 
from O 
the O 
intracellular O 
store O 
in O 
endoplasmic O 
reticulum O 
, O 
which O 
may O 
explain O 
one O 
of O 
mechanisms O 
of O 
its O 
vasodilator O 
function O 
. O 

pesticide O 
levels O 
and O 
risk O 
of O 
Alzheimer's O 
disease O 
in O 
north O 
Indian O 
population O 
. O 

disease O 
( O 
AD O 
) O 
could O 
result O 
from O 
a O 
multifactorial O 
process O 
involving O 
both O 
genetic O 
predisposition O 
and O 
exposure O 
to O 
environmental O 
factors O 
like O 
pesticides O 
. O 
A O 
case O 
control O 
study O 
of O 
70 O 
patients O 
of O 
AD O 
and O 
75 O 
controls O 
was O 
done O 
to O 
examine O 
the O 
association O 
between O 
organochlorine B-FAMILY 
pesticides O 
( O 
OCPs O 
) O 
and O 
risk O 
of O 
AD O 
. O 
OCPs O 
( O 
hexachlorocyclohexane B-SYSTEMATIC 
( O 
HCH B-ABBREVIATION 
) O 
, O 
aldrin B-TRIVIAL 
, O 
dieldrin B-TRIVIAL 
, O 
endosulfan B-TRIVIAL 
, O 
pp'-dichlorodiphenyldichloroethylene B-SYSTEMATIC 
( O 
pp'-DDE B-ABBREVIATION 
) O 
, O 
op'-DDE B-ABBREVIATION 
, O 
pp'-dichlorodiphenyltrichloroethane B-SYSTEMATIC 
( O 
pp'-DDT B-ABBREVIATION 
) O 
, O 
op'-DDT B-ABBREVIATION 
, O 
pp'-dichlorodiphenyldichloroethane B-SYSTEMATIC 
( O 
pp'-DDD B-ABBREVIATION 
) O 
and O 
op'-DDD B-ABBREVIATION 
) O 
were O 
extracted O 
from O 
blood O 
and O 
quantitatively O 
estimated O 
using O 
gas O 
chromatography O 
. O 
A O 
Mann-Whitney O 
U O 
test O 
revealed O 
significant O 
difference O 
in O 
β-HCH B-ABBREVIATION 
levels O 
( O 
U O 
= O 
1237 O 
, O 
W O 
= O 
4087 O 
, O 
z O 
= O 
-6.296 O 
, O 
p O 
= O 
0 O 
, O 
r O 
= O 
-0.71 O 
) O 
, O 
dieldrin B-TRIVIAL 
levels O 
( O 
U O 
= O 
1449 O 
, O 
W O 
= O 
4299 O 
, O 
z O 
= O 
-5.809 O 
, O 
p O 
= O 
0 O 
, O 
r O 
= O 
-0.68 O 
) O 
and O 
pp'-DDE B-ABBREVIATION 
levels O 
( O 
U O 
= O 
2062 O 
, O 
W O 
= O 
4912 O 
, O 
z O 
= O 
-2.698 O 
, O 
p O 
= O 
0.007 O 
, O 
r O 
= O 
-0.59 O 
) O 
between O 
AD O 
patients O 
and O 
controls O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
supports O 
epidemiological O 
studies O 
that O 
associate O 
exposure O 
to O 
pesticides O 
with O 
increased O 
risk O 
of O 
AD O 
, O 
and O 
we O 
identified O 
the O 
specific O 
pesticides O 
β-HCH B-ABBREVIATION 
, O 
dieldrin B-TRIVIAL 
and O 
pp'-DDE B-ABBREVIATION 
that O 
are O 
associated O 
with O 
the O 
risk O 
of O 
AD O 
in O 
the O 
north O 
Indian O 
population O 
. O 
However O 
, O 
further O 
research O 
is O 
needed O 
to O 
establish O 
the O 
potential O 
role O 
of O 
these O 
OCPs O 
as O 
an O 
etiologic O 
agent O 
for O 
AD O 
case O 
. O 

and O 
metabolism O 
of O 
[(14)C]anagliptin B-SYSTEMATIC 
, O 
a O 
novel O 
dipeptidyl O 
peptidase-4 O 
inhibitor O 
, O 
in O 
humans O 
. O 

. O 
The O 
disposition O 
of O 
anagliptin B-TRIVIAL 
, O 
an O 
orally O 
active O 
, O 
highly O 
selective O 
dipeptidyl O 
peptidase-4 O 
inhibitor O 
, O 
was O 
investigated O 
after O 
a O 
single O 
oral O 
dose O 
of O 
100 O 
mg O 
/ O 
1.92 O 
MBq O 
[(14)C]anagliptin B-SYSTEMATIC 
to O 
six O 
healthy O 
men O 
. O 
Almost O 
all O 
the O 
dose O 
( O 
98.2% O 
) O 
was O 
recovered O 
within O 
168 O 
h O 
: O 
73.2% O 
in O 
urine O 
and O 
25.0% O 
in O 
faeces O 
. O 
2 O 
. O 
Anagliptin B-TRIVIAL 
was O 
rapidly O 
absorbed O 
, O 
with O 
peak O 
plasma O 
concentrations O 
of O 
unchanged O 
drug O 
attained O 
at O 
a O 
mean O 
time O 
of O 
1.8-h O 
postdose O 
. O 
Mean O 
fraction O 
of O 
the O 
dose O 
absorbed O 
was O 
> O 
73% O 
. O 
Unchanged O 
drug O 
and O 
a O 
carboxylate B-SYSTEMATIC 
metabolite O 
( O 
M1 O 
) O 
were O 
the O 
major O 
components O 
in O 
plasma O 
, O 
accounting O 
for O 
66 O 
and O 
23.4% O 
of O 
total O 
plasma O 
radioactivity O 
area O 
under O 
the O 
curve O 
, O 
respectively O 
. O 
3 O 
. O 
Anagliptin B-TRIVIAL 
was O 
incompletely O 
metabolized O 
, O 
with O 
about O 
50% O 
dose O 
eliminated O 
as O 
unchanged O 
drug O 
( O 
46.6% O 
in O 
urine O 
and O 
4.1% O 
in O 
faeces O 
) O 
. O 
Metabolism O 
to O 
M1 O 
accounted O 
for O 
29.2% O 
of O 
the O 
dose O 
. O 
No O 
other O 
metabolite O 
accounted O 
for O 
> O 
1% O 
dose O 
in O 
excreta O 
or O 
yielded O 
measurable O 
systemic O 
exposure O 
. O 
Terminal O 
half O 
- O 
life O 
of O 
anagliptin B-TRIVIAL 
and O 
M1 O 
was O 
4.37 O 
and O 
9.88 O 
h O 
, O 
respectively O 
. O 
Renal O 
clearance O 
of O 
unbound O 
anagliptin B-TRIVIAL 
and O 
unbound O 
M1 O 
far O 
exceeded O 
glomerular O 
filtration O 
rate O 
, O 
indicating O 
active O 
renal O 
elimination O 
: O 
that O 
might O 
reflect O 
the O 
fact O 
that O 
anagliptin B-TRIVIAL 
may O 
be O 
a O 
substrate O 
of O 
OAT1 O 
, O 
OAT3 O 
, O 
MDR1 O 
and O 
MRP2 O 
, O 
and O 
M1 O 
a O 
substrate O 
of O 
OAT3 O 
, O 
BCRP O 
, O 
MRP2 O 
and O 
MRP4 O 
. O 

-Based O 
Amphiphilic O 
Block O 
Copolymers O 
: O 
Synthesis O 
, O 
Micellization O 
, O 
and O 
Bioapplication O 
. O 

- O 
responsive O 
amphiphilic O 
diblock O 
copolymers O 
, O 
poly(6-O-methacryloyl-d-galactopyranose-co-2-(N,N-dimethylaminoethyl) B-FAMILY 
methacrylate)-b-poly(pyridyl I-FAMILY 
disulfide I-FAMILY 
ethyl I-FAMILY 
methylacrylate I-FAMILY 
) I-FAMILY 
( O 
P(MAGP-co-DMAEMA)-b-PPDSMA B-ABBREVIATION 
) O 
were O 
obtained O 
by O 
deprotection O 
of O 
poly((6-O-methacryloyl-1,2:3,4-di-O-isopropylidene-d-galactopyranose)-co-DMAEMA)-b-PPDSMA B-FAMILY 
[ O 
P(MAlpGP-co-DMAEMA)-b-PPDSMA B-ABBREVIATION 
] O 
, O 
which O 
were O 
prepared O 
via O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
( O 
RAFT O 
) O 
polymerization O 
of O 
PDSMA B-ABBREVIATION 
using O 
P(MAlpGP-co-DMAEMA) B-ABBREVIATION 
as O 
macro-RAFT O 
agent O 
. O 
Dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
studies O 
showed O 
that O 
diblock O 
copolymers O 
P(MAGP-co-DMAEMA)-b-PPDSMA B-ABBREVIATION 
can O 
self O 
- O 
assemble O 
into O 
micelles O 
. O 
Doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
could O 
be O 
encapsulated O 
by O 
P(MAGP-co-DMAEMA)-b-PPDSMA B-ABBREVIATION 
upon O 
micellization O 
and O 
released O 
upon O 
adding O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
into O 
the O 
micelle O 
solution O 
. O 
The O 
galactose B-TRIVIAL 
functional O 
groups O 
in O 
the O 
PMAGP B-ABBREVIATION 
block O 
had O 
specific O 
interaction O 
with O 
HepG2 O 
cells O 
, O 
and O 
P(MAGP-co-DMAEMA)-b-PPDSMA B-ABBREVIATION 
can O 
act O 
as O 
gene O 
delivery O 
vehicle O 
. O 
So O 
, O 
this O 
kind O 
of O 
polymer O 
has O 
potential O 
applications O 
in O 
hepatoma O 
- O 
targeting O 
drug O 
and O 
gene O 
delivery O 
and O 
biodetection O 
. O 

of O 
PLGA B-ABBREVIATION 
nanoparticles O 
formulation O 
containing O 
L-DOPA B-ABBREVIATION 
by O 
applying O 
the O 
central O 
composite O 
design O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
prepare O 
L-DOPA B-ABBREVIATION 
loaded O 
poly(D,L-lactide-co-glycolide) B-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
nanoparticles O 
by O 
a O 
modified O 
water O 
- O 
in O 
- O 
oil O 
- O 
in O 
- O 
water O 
( O 
W(1) O 
/ O 
O O 
/ O 
W(2) O 
) O 
emulsification O 
solvent O 
evaporation O 
method O 
. O 
A O 
central O 
composite O 
design O 
was O 
applied O 
for O 
optimization O 
of O 
the O 
formulation O 
parameters O 
and O 
for O 
studying O 
the O 
effects O 
of O 
three O 
independent O 
variables O 
: O 
PLGA B-ABBREVIATION 
concentration O 
, O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
concentration O 
and O 
organic O 
solvent O 
removal O 
rate O 
on O 
the O 
particle O 
size O 
and O 
the O 
entrapment O 
efficiency O 
( O 
response O 
variables O 
) O 
. O 
Second O 
- O 
order O 
models O 
were O 
obtained O 
to O 
adequately O 
describe O 
the O 
influence O 
of O 
the O 
independent O 
variables O 
on O 
the O 
selected O 
responses O 
. O 
The O 
analysis O 
of O 
variance O 
showed O 
that O 
the O 
three O 
independent O 
variables O 
had O 
significant O 
effects O 
( O 
p O 
< O 
0.05 O 
) O 
on O 
the O 
responses O 
. O 
The O 
experimental O 
results O 
were O 
in O 
perfect O 
accordance O 
with O 
the O 
predictions O 
estimated O 
by O 
the O 
models O 
. O 
Using O 
the O 
desirability O 
approach O 
and O 
overlay O 
contour O 
plots O 
, O 
the O 
optimal O 
preparation O 
area O 
can O 
be O 
highlighted O 
. O 
It O 
was O 
found O 
that O 
the O 
optimum O 
values O 
of O 
the O 
responses O 
could O 
be O 
obtained O 
at O 
higher O 
concentration O 
of O 
PLGA B-ABBREVIATION 
( O 
5% O 
, O 
w O 
/ O 
v O 
) O 
and O 
PVA B-ABBREVIATION 
( O 
6% O 
, O 
w O 
/ O 
v O 
) O 
; O 
and O 
faster O 
organic O 
solvent O 
removal O 
rate O 
( O 
700 O 
rpm O 
) O 
. O 
The O 
corresponding O 
particle O 
size O 
was O 
256.2 O 
nm O 
and O 
the O 
entrapment O 
efficiency O 
was O 
62.19% O 
. O 
FTIR O 
investigation O 
confirmed O 
that O 
the O 
L-DOPA B-ABBREVIATION 
and O 
PLGA B-ABBREVIATION 
polymer O 
maintained O 
its O 
backbone O 
structure O 
in O 
the O 
fabrication O 
of O 
nanoparticles O 
. O 
The O 
scanning O 
electron O 
microscopic O 
images O 
of O 
nanoparticles O 
showed O 
that O 
all O 
particles O 
had O 
spherical O 
shape O 
with O 
porous O 
outer O 
skin O 
. O 
The O 
results O 
suggested O 
that O 
PLGA B-ABBREVIATION 
nanoparticles O 
might O 
represent O 
a O 
promising O 
formulation O 
for O 
brain O 
delivery O 
of O 
L-DOPA B-ABBREVIATION 
. O 
The O 
preparation O 
of O 
L-DOPA B-ABBREVIATION 
loaded O 
PLGA B-ABBREVIATION 
nanoparticles O 
can O 
be O 
optimized O 
by O 
the O 
central O 
composite O 
design O 
. O 

of O 
a O 
small O 
- O 
molecule O 
inhibitor O 
of O 
HIV-1 O 
assembly O 
that O 
targets O 
the O 
phosphatidylinositol B-SYSTEMATIC 
(4,5)-bisphosphate I-SYSTEMATIC 
binding O 
site O 
of O 
the O 
HIV-1 O 
matrix O 
protein O 
. O 

development O 
of O 
drug O 
resistance O 
remains O 
a O 
critical O 
problem O 
for O 
current O 
HIV-1 O 
antiviral O 
therapies O 
, O 
creating O 
a O 
need O 
for O 
new O 
inhibitors O 
of O 
HIV-1 O 
replication O 
. O 
We O 
previously O 
reported O 
on O 
a O 
novel O 
anti-HIV-1 O 
compound O 
, O 
N(2)-(phenoxyacetyl)-N-[4-(1-piperidinylcarbonyl)benzyl]glycinamide B-SYSTEMATIC 
( O 
14 O 
) O 
, O 
that O 
binds O 
to O 
the O 
highly O 
conserved O 
phosphatidylinositol B-SYSTEMATIC 
(4,5)-bisphosphate I-SYSTEMATIC 
( O 
PI(4,5)P(2) B-SYSTEMATIC 
) O 
binding O 
pocket O 
of O 
the O 
HIV-1 O 
matrix O 
( O 
MA O 
) O 
protein O 
. O 
In O 
this O 
study O 
, O 
we O 
re O 
- O 
evaluate O 
the O 
hits O 
from O 
the O 
virtual O 
screen O 
used O 
to O 
identify O 
compound O 
14 O 
and O 
test O 
them O 
directly O 
in O 
an O 
HIV-1 O 
replication O 
assay O 
using O 
primary O 
human O 
peripheral O 
blood O 
mononuclear O 
cells O 
. O 
This O 
study O 
resulted O 
in O 
the O 
identification O 
of O 
three O 
new O 
compounds O 
with O 
antiviral O 
activity O 
; O 
2-(4-{[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl})-1-piperazinyl)-N-(4-methylphenyl)acetamide B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
3-(2-ethoxyphenyl)-5-[[4-(4-nitrophenyl)piperazin-1-yl]methyl]-1,2,4-oxadiazole B-SYSTEMATIC 
( O 
17 O 
) O 
, O 
and O 
N-[4-ethoxy-3-(1-piperidinylsulfonyl)phenyl]-2-(imidazo[2,1-b][1,3]thiazol-6-yl)acetamide B-SYSTEMATIC 
( O 
18 O 
) O 
, O 
with O 
compound O 
7 O 
being O 
the O 
most O 
potent O 
of O 
these O 
hits O 
. O 
Mechanistic O 
studies O 
on O 
7 O 
demonstrated O 
that O 
it O 
directly O 
interacts O 
with O 
and O 
functions O 
through O 
HIV-1 O 
MA O 
. O 
In O 
accordance O 
with O 
our O 
drug O 
target O 
, O 
compound O 
7 O 
competes O 
with O 
PI(4,5)P(2) B-SYSTEMATIC 
for O 
MA O 
binding O 
and O 
, O 
as O 
a O 
result O 
, O 
diminishes O 
the O 
production O 
of O 
new O 
virus O 
. O 
Mutation O 
of O 
residues O 
within O 
the O 
PI(4,5)P(2) B-SYSTEMATIC 
binding O 
site O 
of O 
MA O 
decreased O 
the O 
antiviral O 
effect O 
of O 
compound O 
7 O 
. O 
Additionally O 
, O 
compound O 
7 O 
displays O 
a O 
broadly O 
neutralizing O 
anti-HIV O 
activity O 
, O 
with O 
IC(50) O 
values O 
of O 
7.5-15.6 O 
μM O 
for O 
the O 
group O 
M O 
isolates O 
tested O 
. O 
Taken O 
together O 
, O 
these O 
results O 
point O 
towards O 
a O 
novel O 
chemical O 
probe O 
that O 
can O 
be O 
used O 
to O 
more O 
closely O 
study O 
the O 
biological O 
role O 
of O 
MA O 
and O 
could O 
, O 
through O 
further O 
optimization O 
, O 
lead O 
to O 
a O 
new O 
class O 
of O 
anti-HIV-1 O 
therapeutics O 
. O 

effect O 
of O 
daily O 
fisetin B-TRIVIAL 
supplementation O 
in O 
high O 
fat O 
fed O 
Sprague-Dawley O 
rats O 
. O 

aimed O 
to O 
test O 
whether O 
fisetin B-TRIVIAL 
could O 
modulate O 
cholesterol B-TRIVIAL 
homeostasis O 
in O 
rats O 
with O 
diet O 
- O 
induced O 
hypercholesterolemia O 
, O 
and O 
further O 
investigated O 
the O 
underlying O 
mechanisms O 
by O 
which O 
fisetin B-TRIVIAL 
exerts O 
its O 
cholesterol B-TRIVIAL 
lowering O 
effect O 
. O 
Blood O 
lipid O 
profile O 
, O 
hepatic O 
cholesterol B-TRIVIAL 
content O 
, O 
as O 
well O 
as O 
gene O 
expressions O 
in O 
cholesterol B-TRIVIAL 
metabolism O 
were O 
examined O 
. O 
Elevated O 
levels O 
of O 
total O 
cholesterol B-TRIVIAL 
and O 
LDL- O 
cholesterol B-TRIVIAL 
, O 
along O 
with O 
hepatic O 
cholesterol B-TRIVIAL 
content O 
in O 
a O 
high O 
fat O 
group O 
were O 
found O 
to O 
be O 
significantly O 
reduced O 
by O 
fisetin B-TRIVIAL 
. O 
The O 
high O 
fat O 
diet O 
significantly O 
decreased O 
hepatic O 
mRNA O 
levels O 
of O 
LDLR O 
, O 
SREBP2 O 
, O 
HMGCR O 
and O 
PCSK9 O 
in O 
comparison O 
to O 
the O 
control O 
diet O 
, O 
however O 
, O 
fisetin B-TRIVIAL 
did O 
not O 
further O 
elicit O 
any O 
changes O 
in O 
mRNA O 
levels O 
of O 
the O 
same O 
genes O 
. O 
The O 
high O 
fat O 
diet O 
dramatically O 
increased O 
the O 
transcript O 
levels O 
of O 
CYP7A1 O 
, O 
which O 
was O 
subsequently O 
reversed O 
by O 
the O 
fisetin B-TRIVIAL 
. O 
In O 
HepG2 O 
cells O 
, O 
fisetin B-TRIVIAL 
was O 
found O 
to O 
increase O 
the O 
levels O 
of O 
a O 
nuclear O 
form O 
of O 
SREBP2 O 
and O 
LDLR O 
. O 
In O 
conclusion O 
, O 
fisetin B-TRIVIAL 
supplementation O 
displayed O 
hypocholesterolemic O 
effects O 
by O 
modulating O 
the O 
expression O 
of O 
genes O 
associated O 
with O 
cholesterol B-TRIVIAL 
and O 
bile B-FAMILY 
acid I-FAMILY 
metabolism O 
. O 

bisphenol B-TRIVIAL 
a I-TRIVIAL 
exposure O 
alters O 
sex O 
- O 
specific O 
estrogen B-FAMILY 
receptor O 
expression O 
in O 
the O 
neonatal O 
rat O 
hypothalamus O 
and O 
amygdala O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
exposure O 
is O 
ubiquitous O 
, O 
and O 
in O 
laboratory O 
animals O 
, O 
early O 
- O 
life O 
BPA B-ABBREVIATION 
exposure O 
has O 
been O 
shown O 
to O 
alter O 
sex O 
- O 
specific O 
neural O 
organization O 
, O 
neuroendocrine O 
physiology O 
, O 
and O 
behavior O 
. O 
The O 
specific O 
mechanisms O 
underlying O 
these O 
brain O 
- O 
related O 
outcomes O 
, O 
however O 
, O 
remain O 
largely O 
unknown O 
, O 
constraining O 
the O 
capacity O 
to O 
ascertain O 
the O 
potential O 
human O 
relevance O 
of O 
neural O 
effects O 
observed O 
in O 
animal O 
models O 
. O 
In O 
the O 
perinatal O 
rat O 
brain O 
, O 
estrogen B-FAMILY 
is O 
masculinizing O 
, O 
suggesting O 
that O 
BPA B-ABBREVIATION 
-induced O 
perturbation O 
of O 
estrogen B-FAMILY 
receptor O 
( O 
ESR O 
) O 
expression O 
may O 
underpin O 
later O 
in O 
- O 
life O 
neuroendocrine O 
effects O 
. O 
We O 
hypothesized O 
that O 
prenatal O 
BPA B-ABBREVIATION 
exposure O 
alters O 
sex O 
- O 
specific O 
ESR1 O 
( O 
ERα O 
) O 
and O 
ESR2 O 
( O 
ERβ O 
) O 
expression O 
in O 
postnatal O 
limbic O 
nuclei O 
. O 
Sprague O 
Dawley O 
rats O 
were O 
mated O 
and O 
gavaged O 
on O 
gestational O 
days O 
( O 
GDs O 
) O 
6-21 O 
with O 
vehicle O 
, O 
2.5 O 
or O 
25 O 
μg O 
/ O 
kg O 
bw O 
/ O 
day O 
BPA B-ABBREVIATION 
, O 
or O 
5 O 
or O 
10 O 
μg O 
/ O 
kg O 
bw O 
/ O 
day O 
ethinyl B-TRIVIAL 
estradiol I-TRIVIAL 
. O 
An O 
additional O 
group O 
was O 
restrained O 
but O 
not O 
gavaged O 
( O 
naïve O 
control O 
) O 
. O 
Offspring O 
were O 
sacrificed O 
the O 
day O 
after O 
birth O 
to O 
quantify O 
ESR O 
gene O 
expression O 
throughout O 
the O 
hypothalamus O 
and O 
amygdala O 
by O 
in O 
situ O 
hybridization O 
. O 
Relative O 
to O 
the O 
vehicle O 
group O 
, O 
significant O 
effects O 
of O 
BPA B-ABBREVIATION 
were O 
observed O 
on O 
ESR1 O 
and O 
ESR2 O 
expression O 
throughout O 
the O 
mediobasal O 
hypothalamus O 
and O 
amygdala O 
in O 
both O 
sexes O 
. O 
Significant O 
differences O 
in O 
ESR O 
expression O 
were O 
also O 
observed O 
in O 
the O 
mediobasal O 
hypothalamus O 
and O 
amygdala O 
of O 
the O 
naïve O 
control O 
group O 
compared O 
with O 
the O 
vehicle O 
group O 
, O 
highlighting O 
the O 
potential O 
for O 
gavage O 
to O 
influence O 
gene O 
expression O 
in O 
the O 
developing O 
brain O 
. O 
These O 
results O 
indicate O 
that O 
ESR O 
expression O 
in O 
the O 
neonatal O 
brain O 
of O 
both O 
sexes O 
can O 
be O 
altered O 
by O 
low O 
- O 
dose O 
prenatal O 
BPA B-ABBREVIATION 
exposure O 
. O 

Glycol I-FAMILY 
and O 
Polyethylenimine B-FAMILY 
Dual-Functionalized O 
Nano- O 
Graphene B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
for O 
Photothermally O 
Enhanced O 
Gene O 
Delivery O 
. O 

oxide I-SYSTEMATIC 
( O 
GO O 
) O 
has O 
been O 
extensively O 
explored O 
in O 
nanomedicine O 
for O 
its O 
excellent O 
physiochemical O 
, O 
electrical O 
, O 
and O 
optical O 
properties O 
. O 
Here O 
, O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
and O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
are O 
covalently O 
conjugated O 
to O 
GO O 
via O 
amide B-FAMILY 
bonds O 
, O 
obtaining O 
a O 
physiologically O 
stable O 
dual O 
- O 
polymer O 
- O 
functionalized O 
nano-GO O 
conjugate O 
( O 
NGO- O 
PEG B-ABBREVIATION 
- O 
PEI B-ABBREVIATION 
) O 
with O 
ultra O 
- O 
small O 
size O 
. O 
Compared O 
with O 
free O 
PEI B-ABBREVIATION 
and O 
the O 
GO- O 
PEI B-ABBREVIATION 
conjugate O 
without O 
PEGylation O 
, O 
NGO- O 
PEG B-ABBREVIATION 
- O 
PEI B-ABBREVIATION 
shows O 
superior O 
gene O 
transfection O 
efficiency O 
without O 
serum O 
interference O 
, O 
as O 
well O 
as O 
reduced O 
cytotoxicity O 
. O 
Utilizing O 
the O 
NIR O 
optical O 
absorbance O 
of O 
NGO O 
, O 
the O 
cellular O 
uptake O 
of O 
NGO- O 
PEG B-ABBREVIATION 
- O 
PEI B-ABBREVIATION 
is O 
shown O 
to O 
be O 
enhanced O 
under O 
a O 
low O 
power O 
NIR O 
laser O 
irradiation O 
, O 
owing O 
to O 
the O 
mild O 
photothermal O 
heating O 
that O 
increases O 
the O 
cell O 
membrane O 
permeability O 
without O 
significantly O 
damaging O 
cells O 
. O 
As O 
the O 
results O 
, O 
remarkably O 
enhanced O 
plasmid O 
DNA O 
transfection O 
efficiencies O 
induced O 
by O 
the O 
NIR O 
laser O 
are O 
achieved O 
using O 
NGO- O 
PEG B-ABBREVIATION 
- O 
PEI B-ABBREVIATION 
as O 
the O 
light O 
- O 
responsive O 
gene O 
carrier O 
. O 
More O 
importantly O 
, O 
it O 
is O 
shown O 
that O 
our O 
NGO- O 
PEG B-ABBREVIATION 
- O 
PEI B-ABBREVIATION 
is O 
able O 
to O 
deliver O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
into O 
cells O 
under O 
the O 
control O 
of O 
NIR O 
light O 
, O 
resulting O 
in O 
obvious O 
down O 
- O 
regulation O 
of O 
the O 
target O 
gene O 
, O 
Polo O 
- O 
like O 
kinase O 
1 O 
( O 
Plk1 O 
) O 
, O 
in O 
the O 
presence O 
of O 
laser O 
irradiation O 
. O 
This O 
study O 
is O 
the O 
first O 
to O 
use O 
photothermally O 
enhanced O 
intracellular O 
trafficking O 
of O 
nanocarriers O 
for O 
light O 
- O 
controllable O 
gene O 
delivery O 
. O 
This O 
work O 
also O 
encourages O 
further O 
explorations O 
of O 
functionalized O 
nano-GO O 
as O 
a O 
photocontrollable O 
nanovector O 
for O 
combined O 
photothermal O 
and O 
gene O 
therapies O 
. O 

association O 
between O 
daily O 
calcium B-SYSTEMATIC 
intake O 
and O 
sarcopenia O 
in O 
older O 
, O 
non-obese O 
Korean O 
adults O 
: O 
the O 
fourth O 
Korea O 
national O 
health O 
and O 
nutrition O 
examination O 
survey O 
( O 
KNHANES O 
IV O 
) O 
2009 O 
. O 

data O 
suggest O 
that O 
variations O 
in O 
calcium B-SYSTEMATIC 
intake O 
may O 
influence O 
body O 
weight O 
and O 
composition O 
; O 
however O 
, O 
the O 
relationship O 
between O 
daily O 
calcium B-SYSTEMATIC 
intake O 
and O 
muscle O 
mass O 
has O 
not O 
been O 
well O 
established O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
assess O 
the O 
relationship O 
between O 
daily O 
calcium B-SYSTEMATIC 
intake O 
and O 
sarcopenia O 
. O 
We O 
analyzed O 
data O 
for O 
older O 
adults O 
( O 
over O 
60 O 
years O 
) O 
from O 
the O 
fourth O 
Korea O 
National O 
Health O 
and O 
Nutrition O 
Examination O 
Survey O 
( O 
KNHANES O 
) O 
conducted O 
in O 
2009 O 
. O 
A O 
total O 
of O 
1339 O 
Non-Obese O 
( O 
BMI O 
between O 
18.5 O 
and O 
25 O 
kg O 
/ O 
m(2) O 
) O 
, O 
older O 
adults O 
( O 
592 O 
men O 
and O 
707 O 
women O 
) O 
were O 
enrolled O 
. O 
Dietary O 
variables O 
were O 
assessed O 
using O 
a O 
nutrition O 
survey O 
that O 
used O 
a O 
24-hour O 
recall O 
method O 
. O 
Daily O 
calcium B-SYSTEMATIC 
intake O 
based O 
on O 
the O 
consumption O 
of O 
each O 
food O 
item O 
was O 
calculated O 
. O 
Sarcopenia O 
was O 
defined O 
as O 
an O 
appendicular O 
skeletal O 
muscle O 
mass O 
divided O 
by O 
body O 
weight O 
less O 
than O 
2 O 
SD O 
below O 
the O 
sex O 
- O 
specific O 
mean O 
for O 
young O 
adults O 
. O 
We O 
found O 
that O 
daily O 
calcium B-SYSTEMATIC 
intake O 
was O 
negatively O 
correlated O 
with O 
total O 
body O 
fat O 
percentage O 
and O 
positively O 
correlated O 
with O 
appendicular O 
skeletal O 
mass O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Participants O 
with O 
sarcopenia O 
appear O 
to O 
have O 
significantly O 
lower O 
daily O 
calcium B-SYSTEMATIC 
intakes O 
than O 
participants O 
without O 
sarcopenia O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
The O 
unadjusted O 
prevalence O 
of O 
sarcopenia O 
according O 
to O 
daily O 
calcium B-SYSTEMATIC 
intake O 
tertiles O 
were O 
6.3% O 
, O 
4.3% O 
, O 
and O 
2.7% O 
in O 
tertiles O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
, O 
respectively O 
. O 
After O 
adjustment O 
for O 
age O 
, O 
sex O 
, O 
BMI O 
, O 
total O 
energy O 
intake O 
, O 
and O 
lifestyle O 
factors O 
, O 
compared O 
with O 
those O 
in O 
the O 
lowest O 
tertile O 
of O 
daily O 
calcium B-SYSTEMATIC 
intake O 
, O 
participants O 
in O 
the O 
highest O 
tertile O 
had O 
an O 
odds O 
ratio O 
for O 
sarcopenia O 
of O 
0.295 O 
( O 
95% O 
confidence O 
interval O 
, O 
0.087-0.768 O 
; O 
p O 
for O 
trend O 
= O 
0.014 O 
) O 
. O 
We O 
found O 
that O 
daily O 
calcium B-SYSTEMATIC 
intake O 
, O 
corrected O 
for O 
total O 
energy O 
intake O 
and O 
serum O 
25(OH)D B-SYSTEMATIC 
status O 
, O 
was O 
significantly O 
lower O 
in O 
subjects O 
with O 
sarcopenia O 
than O 
in O 
those O 
without O 
. O 
Our O 
results O 
suggest O 
a O 
strong O 
inverse O 
association O 
between O 
daily O 
calcium B-SYSTEMATIC 
intake O 
and O 
sarcopenia O 
in O 
non-obese O 
, O 
older O 
Korean O 
adults O 
. O 

Common O 
Bean O 
Genotypes O 
with O 
Contrasting O 
Response O 
to O 
Phosphorus B-SYSTEMATIC 
Deficiency O 
Show O 
Variations O 
in O 
the O 
microRNA O 
399- O 
Mediated O 
PvPHO2 O 
Regulation O 
within O 
the O 
PvPHR1 O 
Signaling O 
Pathway O 
. O 

production O 
of O 
the O 
important O 
legume O 
, O 
the O 
common O 
bean O 
( O 
Phaseolus O 
vulgaris O 
) O 
, O 
is O 
often O 
limited O 
by O 
low O 
phosphorus B-SYSTEMATIC 
( O 
P B-FORMULA 
) O 
in O 
the O 
soil O 
. O 
The O 
genotypes O 
, O 
BAT477 O 
and O 
DOR364 O 
, O 
of O 
the O 
common O 
bean O 
have O 
contrasting O 
responses O 
to O 
P B-FORMULA 
starvation O 
. O 
Plants O 
from O 
the O 
BAT477 O 
P B-FORMULA 
deficiency O 
tolerant O 
genotype O 
showed O 
higher O 
phosphate B-SYSTEMATIC 
content O 
and O 
root O 
biomass O 
as O 
compared O 
to O 
the O 
DOR364 O 
plants O 
under O 
P B-FORMULA 
starvation O 
. O 
The O 
PvPHR1 O 
transcription O 
factor O 
- O 
signaling O 
pathway O 
plays O 
an O 
essential O 
role O 
in O 
the O 
response O 
to O 
P B-FORMULA 
starvation O 
. O 
PvPHO2 O 
, O 
a O 
negative O 
regulator O 
of O 
this O 
pathway O 
, O 
encodes O 
an O 
ubiquitin O 
E2 O 
conjugase O 
that O 
promotes O 
degradation O 
of O 
P B-FORMULA 
-responsive O 
proteins O 
and O 
is O 
the O 
target O 
gene O 
of O 
PvmiR399 O 
. O 
PvPHO2 O 
is O 
downregulated O 
in O 
BAT477 O 
plants O 
under O 
P B-FORMULA 
deficiency O 
, O 
while O 
such O 
a O 
response O 
is O 
not O 
observed O 
in O 
P B-FORMULA 
-starved O 
DOR364 O 
plants O 
. O 
Five O 
putative O 
PvmiR399 O 
binding O 
sites O 
were O 
identified O 
in O 
the O 
5 O 
' O 
UTR O 
region O 
in O 
both O 
genotypes O 
. O 
While O 
four O 
sites O 
showed O 
an O 
identical O 
DNA O 
sequence O 
, O 
the O 
fifth O 
( O 
binding O 
site O 
of O 
PvPHO2 O 
one O 
) O 
showed O 
three O 
base O 
changes O 
and O 
higher O 
complementarity O 
scores O 
in O 
DOR364 O 
as O 
compared O 
to O 
BAT477 O 
. O 
Modified O 
5'RACE O 
experiments O 
indicated O 
that O 
PvmiR399 O 
binding O 
and O 
/ O 
or O 
processing O 
was O 
affected O 
in O 
DOR364 O 
P B-FORMULA 
-starved O 
plants O 
. O 
We O 
propose O 
that O 
a O 
less O 
efficient O 
cleavage O 
of O 
the O 
PvPHO2 O 
mRNA O 
directed O 
by O 
PvmiR399 O 
would O 
result O 
in O 
a O 
higher O 
PvPHO2 O 
- O 
mediated O 
degradation O 
of O 
P B-FORMULA 
-responsive O 
proteins O 
in O 
the O 
DOR364 O 
genotype O 
with O 
decreased O 
P O 
deficiency O 
tolerance O 
. O 

assisted O 
assignment O 
of O 
kahalalide B-TRIVIAL 
Y I-TRIVIAL 
configuration O 
using O 
an O 
NMR-constrained O 
conformational O 
search O 
. O 

of O 
the O 
absolute O 
configuration O 
of O 
cyclic O 
peptides O 
frequently O 
yields O 
challenges O 
, O 
leaving O 
one O 
or O 
more O 
stereogenic O 
centers O 
unassigned O 
due O 
to O 
small O 
quantities O 
of O 
sample O 
and O 
the O 
limited O 
utility O 
of O 
Marfey's O 
or O 
other O 
methods O 
for O 
assigning O 
amino B-MULTIPLE 
or I-MULTIPLE 
hydroxy I-MULTIPLE 
acids I-MULTIPLE 
. O 
Here O 
, O 
we O 
report O 
isolation O 
of O 
kahalalide B-TRIVIAL 
Y I-TRIVIAL 
( O 
1 O 
) O 
from O 
Bryopsis O 
pennata O 
for O 
the O 
first O 
time O 
; O 
in O 
addition O 
, O 
the O 
application O 
of O 
a O 
combination O 
of O 
molecular O 
modeling O 
and O 
NOE O 
distance O 
constraint O 
calculations O 
was O 
utilized O 
to O 
determine O 
the O 
conformation O 
of O 
1 O 
and O 
the O 
absolute O 
configuration O 
of O 
the O 
final O 
stereogenic O 
center O 
of O 
1 O 
. O 
Using O 
the O 
Schrödinger O 
suite O 
, O 
the O 
structure O 
of O 
1 O 
was O 
sketched O 
in O 
Maestro O 
and O 
minimized O 
using O 
the O 
OPLS2005 O 
force O 
field O 
in O 
Macromodel O 
. O 
A O 
conformational O 
search O 
was O 
performed O 
separately O 
for O 
structures O 
having O 
an O 
R O 
or O 
S O 
configuration O 
at O 
C-3 O 
of O 
the O 
beta-hydroxy B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
subunit O 
that O 
completes O 
the O 
cyclic O 
scaffold O 
of O 
1 O 
, O 
after O 
which O 
multiple O 
minimizations O 
for O 
all O 
generated O 
conformers O 
were O 
carried O 
out O 
. O 
The O 
lowest O 
energy O 
conformers O 
of O 
R O 
and O 
S O 
stereoisomers O 
were O 
then O 
subjected O 
to O 
B3LYP O 
geometry O 
optimizations O 
including O 
solvent O 
effects O 
. O 
The O 
S O 
stereoisomer O 
was O 
shown O 
to O 
be O 
in O 
excellent O 
agreement O 
with O 
the O 
NOE O 
- O 
derived O 
distance O 
constraints O 
and O 
hydrogen B-SYSTEMATIC 
-bonding O 
stability O 
studies O 
. O 

with O 
chronic O 
airway O 
diseases O 
may O 
be O 
more O 
susceptible O 
to O 
adverse O 
effects O 
of O 
air O 
pollutants O 
including O 
diesel O 
exhaust O 
particles O 
( O 
DEP O 
) O 
. O 
We O 
investigated O 
effects O 
of O 
foetal O 
calf O 
serum O 
( O 
FCS O 
) O 
on O 
DEP-induced O 
changes O 
in O 
airway O 
epithelial O 
cell O 
apoptosis O 
and O 
inflammation O 
. O 
DEP O 
( O 
50-200 O 
μg O 
/ O 
ml O 
) O 
increased O 
A549 O 
cell O 
viability O 
in O 
the O 
absence O 
of O 
FCS O 
. O 
In O 
the O 
presence O 
of O 
3.3%FCS O 
, O 
DEP O 
( O 
50-400 O 
μg O 
/ O 
ml O 
) O 
decreased O 
A549 O 
cell O 
viability O 
. O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
, O 
33 O 
mM O 
) O 
and O 
the O 
c-jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
inhibitor O 
( O 
SP600125 B-IDENTIFIER 
, O 
33 O 
μM O 
) O 
further O 
decreased O 
the O 
viability O 
in O 
the O 
presence O 
of O 
DEP O 
( O 
200 O 
μg O 
/ O 
ml O 
) O 
and O 
3.3% O 
FCS O 
. O 
Under O 
serum O 
- O 
free O 
( O 
SF O 
) O 
condition O 
, O 
DEP O 
( O 
50 O 
μg O 
/ O 
ml O 
) O 
reduced O 
apoptotic O 
cells O 
; O 
however O 
, O 
when O 
3.3% O 
FCS O 
added O 
to O 
the O 
culture O 
medium O 
, O 
this O 
effect O 
was O 
abolished O 
. O 
DEP O 
( O 
200 O 
μg O 
/ O 
ml O 
) O 
induced O 
mRNA O 
expression O 
of O 
p21(CIP1 O 
/ O 
WAF1 O 
) O 
both O 
in O 
absence O 
or O 
presence O 
of O 
3.3% O 
FCS O 
and O 
enhanced O 
JNK2 O 
mRNA O 
expression O 
only O 
in O 
the O 
presence O 
of O 
3.3% O 
FCS O 
. O 
Under O 
SF O 
condition O 
, O 
DEP O 
( O 
50 O 
μg O 
/ O 
ml O 
) O 
induced O 
mRNA O 
expression O 
for O 
p27 O 
and O 
p53 O 
, O 
whereas O 
cyclin O 
E O 
mRNA O 
expression O 
was O 
inhibited O 
by O 
DEP O 
( O 
50 O 
and O 
200 O 
μg O 
/ O 
ml O 
) O 
. O 
Furthermore O 
, O 
DEP O 
( O 
200 O 
μg O 
/ O 
ml O 
) O 
decreased O 
the O 
release O 
of O 
interleukin O 
(IL)-8 O 
in O 
the O 
absence O 
of O 
FCS O 
. O 
In O 
conclusion O 
, O 
FCS O 
modulates O 
effects O 
of O 
DEP O 
on O 
cell O 
death O 
, O 
cell O 
cycle O 
and O 
apoptosis O 
regulating O 
proteins O 
, O 
and O 
IL-8 O 
release O 
by O 
activating O 
oxidant O 
stress O 
pathways O 
, O 
JNK O 
and O 
NF-κB O 
. O 
Extravasation O 
of O 
serum O 
, O 
as O 
occurs O 
in O 
the O 
inflamed O 
airways O 
of O 
patients O 
with O 
chronic O 
airway O 
diseases O 
such O 
as O 
asthma O 
and O 
COPD O 
, O 
may O 
render O 
airway O 
epithelial O 
cells O 
more O 
susceptible O 
to O 
the O 
deleterious O 
effects O 
of O 
DEP O 
. O 

and O 
Flavonoids B-FAMILY 
from O 
Viscum O 
album O 
Inhibit O 
LPS-Stimulated O 
Production O 
of O 
Pro O 
- O 
inflammatory O 
Cytokines O 
in O 
Bone O 
Marrow O 
- O 
Derived O 
Dendritic O 
Cells O 
. O 

new O 
diarylheptanoids B-FAMILY 
, O 
(3S,5R)-3-hydroxy-5-methoxy-1,7-bis(4-hydroxyphenyl)-6E-heptene B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(3S,5S)-3-hydroxy-5-methoxy-1,7-bis(4-hydroxyphenyl)-6E-heptene B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
(3S)-3-hydroxy-1,7-bis(4-hydroxyphenyl)-6E-hepten-5-one B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
four O 
new O 
flavonoid B-FAMILY 
glycosides I-FAMILY 
, O 
3,7,3'-tri-O-methylquercetin-4'-O-β-d-apiofuranosyl-(1→2)-O-β-d-glucopyranoside B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
7,3'-di-O-methylquercetin-4'-O-β-d-glucopyranosyl-3-O-[6‴-(3-hydroxy-3-methylglutaroyl)]-α-d-glucopyranoside B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
7,3'-di-O-methylquercetin-4'-O-β-d-glucopyranosyl-3-O-[(6'''''→5'''')-O-1'''''-(sinap-4-yl)-β-d-glucopyranosyl-6‴-(3-hydroxy-3-methylglutaroyl)]-α-d-glucopyranoside B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
and O 
(2S)-5-hydroxy-7,3'-dimethoxyflavanone-4'-O-β-d-apiofuranosyl-(1→5)-O-β-d-apiofuranosyl-(1→2)-O-β-d-glucopyranoside B-SYSTEMATIC 
( O 
9 O 
) O 
, O 
and O 
17 O 
known O 
compounds O 
were O 
isolated O 
from O 
the O 
leaves O 
and O 
twigs O 
of O 
Viscum O 
album O 
. O 
Compounds O 
1 O 
, O 
4 O 
, O 
and O 
19 O 
significantly O 
inhibited O 
LPS-stimulated O 
production O 
of O 
TNF-α O 
, O 
IL-6 O 
, O 
and O 
IL-12p40 O 
with O 
IC50 O 
values O 
ranging O 
from O 
0.09 O 
± O 
0.01 O 
to O 
8.96 O 
± O 
0.45 O 
μM O 
. O 
(+)-Medioresinol B-TRIVIAL 
( O 
13 O 
) O 
showed O 
inhibitory O 
effects O 
on O 
LPS-stimulated O 
production O 
of O 
IL-12p40 O 
with O 
an O 
IC50 O 
value O 
of O 
2 O 
± O 
0.15 O 
μM O 
. O 

-induced O 
neuronal O 
damage O 
and O 
altered O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptor O 
function O 
in O 
rat O 
primary O 
forebrain O 
culture O 
. O 

, O 
a O 
noncompetitive O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptor O 
antagonist O 
, O 
is O 
frequently O 
used O 
in O 
pediatric O 
general O 
anesthesia O 
. O 
Accumulating O 
evidence O 
from O 
animal O 
experiments O 
has O 
demonstrated O 
that O 
ketamine B-TRIVIAL 
causes O 
neuronal O 
cell O 
death O 
during O 
the O 
brain O 
growth O 
spurt O 
. O 
To O 
elucidate O 
the O 
underlying O 
mechanisms O 
associated O 
with O 
ketamine B-TRIVIAL 
-induced O 
neuronal O 
toxicity O 
and O 
search O 
for O 
approaches O 
or O 
agents O 
to O 
prevent O 
ketamine B-TRIVIAL 
' O 
s O 
adverse O 
effects O 
on O 
the O 
developing O 
brain O 
, O 
a O 
primary O 
nerve O 
cell O 
culture O 
system O 
was O 
utilized O 
. O 
Neurons O 
harvested O 
from O 
the O 
forebrain O 
of O 
newborn O 
rats O 
were O 
maintained O 
under O 
normal O 
control O 
conditions O 
or O 
exposed O 
to O 
either O 
ketamine B-TRIVIAL 
( O 
10 O 
µM O 
) O 
or O 
ketamine B-TRIVIAL 
plus O 
L-carnitine B-TRIVIAL 
( O 
an O 
antioxidant O 
; O 
1-100 O 
µM O 
) O 
for O 
24h O 
, O 
followed O 
by O 
a O 
24-h O 
withdrawal O 
period O 
. O 
Ketamine B-TRIVIAL 
exposure O 
resulted O 
in O 
elevated O 
NMDA B-ABBREVIATION 
receptor O 
( O 
NR1 O 
) O 
expression O 
, O 
increased O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
as O 
indicated O 
by O 
higher O 
levels O 
of O 
8-oxoguanine B-SYSTEMATIC 
production O 
, O 
and O 
enhanced O 
neuronal O 
damage O 
. O 
Coadministration O 
of O 
L-carnitine B-TRIVIAL 
significantly O 
diminished O 
ROS O 
generation O 
and O 
provided O 
near O 
complete O 
protection O 
of O 
neurons O 
from O 
ketamine B-TRIVIAL 
-induced O 
cell O 
death O 
. O 
NMDA B-ABBREVIATION 
receptors O 
regulate O 
channels O 
that O 
are O 
highly O 
permeable O 
to O 
calcium B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
imaging O 
data O 
demonstrated O 
that O 
neurons O 
exposed O 
to O 
ketamine B-TRIVIAL 
had O 
a O 
significantly O 
elevated O 
amplitude O 
of O 
calcium B-SYSTEMATIC 
influx O 
and O 
higher O 
intracellular O 
free O 
calcium B-SYSTEMATIC 
concentrations O 
( O 
[ O 
Ca(2+) B-FORMULA 
]i O 
) O 
evoked O 
by O 
NMDA B-ABBREVIATION 
( O 
50 O 
µM O 
) O 
, O 
compared O 
with O 
control O 
neurons O 
. O 
These O 
findings O 
suggest O 
that O 
prolonged O 
ketamine B-TRIVIAL 
exposure O 
produces O 
an O 
increase O 
in O 
NMDA B-ABBREVIATION 
receptor O 
expression O 
( O 
compensatory O 
upregulation O 
) O 
, O 
which O 
allows O 
for O 
a O 
higher O 
/ O 
toxic O 
influx O 
of O 
calcium B-SYSTEMATIC 
into O 
neurons O 
once O 
ketamine B-TRIVIAL 
is O 
removed O 
from O 
the O 
system O 
, O 
leading O 
to O 
elevated O 
ROS O 
generation O 
and O 
neuronal O 
cell O 
death O 
. O 
L-Carnitine B-TRIVIAL 
appears O 
to O 
be O 
a O 
promising O 
agent O 
in O 
preventing O 
or O 
reversing O 
ketamine B-TRIVIAL 
' O 
s O 
toxic O 
effects O 
on O 
neurons O 
at O 
an O 
early O 
developmental O 
stage O 
. O 

objective O 
of O 
the O 
present O 
work O 
was O 
to O 
evaluate O 
the O 
broadest O 
toxic O 
effect O 
of O 
some O 
synthetic O 
additives O 
of O 
colorants O 
and O 
/ O 
or O 
flavors O 
on O 
different O 
body O 
organs O 
and O 
metabolic O 
aspects O 
in O 
rats O 
. O 
A O 
number O 
of O 
chemical O 
food O 
color O 
and O 
flavor O 
additives O 
are O 
routinely O 
added O 
during O 
processing O 
to O 
improve O 
the O 
aesthetic O 
appearance O 
of O 
the O 
dietary O 
items O 
. O 
However O 
, O 
many O 
of O 
them O 
are O 
toxic O 
after O 
prolonged O 
use O 
. O 
In O 
this O 
experiment O 
, O 
a O 
total O 
of O 
100 O 
male O 
albino O 
rats O 
of O 
Spargue O 
Dawley O 
strain O 
were O 
divided O 
into O 
10 O 
groups O 
: O 
G(1) O 
was O 
fed O 
basal O 
diet O 
and O 
served O 
as O 
control O 
, O 
G(2) O 
: O 
basal O 
diet O 
+ O 
Brilliant B-TRIVIAL 
blue I-TRIVIAL 
( O 
blue O 
dye O 
, O 
No O 
. O 
2 O 
, O 
124 O 
mg O 
/ O 
kg O 
diet O 
) O 
, O 
G(3) O 
: O 
basal O 
diet O 
+ O 
carmoisine B-TRIVIAL 
( O 
red O 
dye O 
, O 
No O 
. O 
3 O 
, O 
70 O 
mg O 
/ O 
kg O 
diet O 
) O 
, O 
G(4) O 
: O 
basal O 
diet O 
+ O 
tartrazine B-TRIVIAL 
( O 
yellow O 
dye O 
, O 
FD O 
& O 
C O 
yellow O 
No O 
. O 
5 O 
, O 
75 O 
mg O 
/ O 
kg O 
diet O 
) O 
, O 
G(5) O 
: O 
basal O 
diet O 
+ O 
trans-anethole B-TRIVIAL 
( O 
4.5 O 
g O 
/ O 
kg O 
diet O 
) O 
G(6) O 
: O 
basal O 
diet O 
+ O 
propylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
0.25 O 
g O 
/ O 
kg O 
diet O 
) O 
, O 
G(7) O 
: O 
basal O 
diet O 
+ O 
vanillin B-TRIVIAL 
( O 
1.25 O 
g O 
/ O 
kg O 
diet O 
) O 
, O 
G(8) O 
: O 
basal O 
diet O 
+ O 
Brilliant B-TRIVIAL 
blue I-TRIVIAL 
+ O 
propylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
, O 
G(9) O 
: O 
basal O 
diet O 
+ O 
carmoisine B-TRIVIAL 
+ O 
trans-anethole B-TRIVIAL 
, O 
G(10) O 
: O 
basal O 
diet O 
+ O 
tartrazine B-TRIVIAL 
+ O 
vanillin B-TRIVIAL 
for O 
42 O 
successive O 
days O 
. O 
All O 
food O 
colorants O 
mixed O 
with O 
or O 
without O 
flavor O 
additives O 
induced O 
a O 
significant O 
decrease O 
in O 
body O 
weight O 
, O 
hemoglobin O 
concentration O 
and O 
red O 
blood O 
cell O 
count O 
. O 
Also O 
there O 
was O 
a O 
significant O 
decrease O 
in O 
reduced O 
glutathione B-TRIVIAL 
content O 
; O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
and O 
superoxide B-TRIVIAL 
dismutase O 
activities O 
in O 
both O 
blood O 
and O 
liver O 
compared O 
to O 
control O 
group O 
. O 
On O 
the O 
other O 
hand O 
, O 
a O 
significant O 
increase O 
in O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
alkaline O 
phosphatase O 
activities O 
, O 
bilirubin B-TRIVIAL 
, O 
urea B-TRIVIAL 
, O 
creatinine B-TRIVIAL 
, O 
total O 
protein O 
and O 
albumin O 
were O 
observed O 
in O 
all O 
test O 
groups O 
when O 
compared O 
to O 
control O 
group O 
. O 
Finally O 
, O 
it O 
is O 
advisable O 
to O 
limit O 
the O 
uses O 
of O 
these O 
food O 
colorants O 
and O 
/ O 
or O 
food O 
flavor O 
additives O 
especially O 
those O 
used O 
by O 
children O 
. O 

of O 
hydrogen B-SYSTEMATIC 
with O 
fluorine B-SYSTEMATIC 
within O 
three O 
pairs O 
of O 
structurally O 
similar O 
small O 
molecule O 
inhibitors O 
of O 
heat O 
shock O 
protein O 
90 O 
( O 
HSP90 O 
) O 
resulted O 
in O 
differences O 
in O 
inhibition O 
constants O 
( O 
Ki O 
) O 
in O 
vitro O 
as O 
well O 
as O 
marked O 
differences O 
in O 
rat O 
intravenous O 
pharmacokinetic O 
profiles O 
. O 
The O 
difference O 
in O 
pharmacokinetic O 
profiles O 
between O 
lower O 
and O 
higher O 
affinity O 
inhibitors O 
( O 
LAIs O 
and O 
HAIs O 
, O 
respectively O 
) O 
was O 
characterized O 
by O 
remarkably O 
different O 
estimates O 
for O 
steady O 
- O 
state O 
volumes O 
of O 
distribution O 
( O 
Vss O 
: O 
1.8 O 
to O 
2 O 
versus O 
10 O 
to O 
13 O 
L O 
/ O 
kg O 
) O 
with O 
comparable O 
clearance O 
estimates O 
( O 
3.2 O 
to O 
3.5 O 
L O 
/ O 
h O 
/ O 
kg O 
) O 
. O 
When O 
the O 
observed O 
Vss O 
estimates O 
were O 
compared O 
to O 
the O 
values O 
predicted O 
with O 
the O 
tissue O 
- O 
composition O 
- O 
based O 
model O 
, O 
the O 
observed O 
Vss O 
estimates O 
for O 
HAIs O 
were O 
4 O 
to O 
8-fold O 
larger O 
than O 
the O 
predicted O 
values O 
whereas O 
the O 
Vss O 
values O 
for O 
LAIs O 
were O 
comparable O 
each O 
other O 
. O 
Accordingly O 
, O 
a O 
negative O 
relationship O 
between O 
in O 
vitro O 
HSP90 O 
Ki O 
versus O 
in O 
vivo O 
Vss O 
estimates O 
was O 
observed O 
among O 
these O 
inhibitors O 
. O 
We O 
therefore O 
hypothesized O 
that O 
pharmacokinetic O 
profiles O 
of O 
these O 
inhibitors O 
could O 
be O 
characterized O 
by O 
target O 
- O 
mediated O 
drug O 
disposition O 
( O 
TMDD O 
) O 
model O 
. O 
In O 
vivo O 
equilibrium O 
dissociation O 
constant O 
( O 
KD O 
) O 
estimates O 
for O 
HAIs O 
due O 
to O 
target O 
binding O 
by O 
TMDD O 
model O 
with O 
rapid O 
binding O 
approximation O 
were O 
1 O 
to O 
6 O 
nM O 
( O 
equivalent O 
to O 
0.3 O 
to O 
2 O 
nM O 
free O 
drug O 
) O 
, O 
which O 
appeared O 
comparable O 
to O 
the O 
in O 
vitro O 
Ki O 
estimates O 
( O 
2 O 
to O 
3 O 
nM O 
) O 
. O 
In O 
vivo O 
KD O 
values O 
of O 
LAIs O 
were O 
not O 
accurately O 
determined O 
by O 
the O 
TMDD O 
model O 
, O 
likely O 
due O 
to O 
non-specific O 
binding O 
dependent-tissue O 
distribution O 
obscuring O 
TMDD O 
profiles O 
. O 
Overall O 
, O 
these O 
results O 
suggest O 
that O 
the O 
observed O 
large O 
Vss O 
estimates O 
for O 
potent O 
HSP90 O 
inhibitors O 
are O 
likely O 
due O 
to O 
pharmacological O 
target O 
binding O 
. O 

acid I-TRIVIAL 
derivatives O 
as O 
inhibitors O 
for O 
chorismatases O 
and O 
isochorismatases O 
. O 

and O 
isochorismatases O 
catalyse O 
the O 
hydrolysis O 
of O 
chorismate B-TRIVIAL 
or O 
isochorismate B-TRIVIAL 
leading O 
to O 
unsaturated B-SYSTEMATIC 
cyclohexenoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
. O 
Based O 
on O 
simplification O 
of O 
the O 
physiological O 
substrates O 
, O 
two O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
-derived O 
compounds O 
, O 
differing O 
in O 
the O 
saturation O 
of O 
the O 
side O 
chain O 
, O 
were O 
developed O 
. O 
In O 
contrast O 
to O 
earlier O 
inhibitor O 
studies O 
, O 
the O 
compounds O 
described O 
here O 
do O 
not O 
have O 
an O 
ether O 
bond O 
and O 
therefore O 
can O 
be O 
synthesised O 
very O 
easily O 
in O 
one O 
or O 
two O 
steps O 
without O 
the O 
need O 
for O 
protective O 
groups O 
. O 
Both O 
substances O 
demonstrate O 
inhibition O 
of O 
the O 
isochorismatase O 
EntB O 
from O 
Escherichia O 
coli O 
and O 
the O 
chorismatases O 
FkbO O 
and O 
Hyg5 O 
from O 
Streptomyces O 
. O 
For O 
chorismatases O 
, O 
the O 
unsaturated O 
compound O 
shows O 
IC(50) O 
values O 
in O 
the O 
millimolar O 
range O 
, O 
while O 
the O 
saturated O 
compound O 
is O 
the O 
better O 
inhibitor O 
with O 
IC(50) O 
values O 
in O 
the O 
micromolar O 
/ O 
low O 
millimolar O 
range O 
; O 
for O 
the O 
isochorismatase O 
tested O 
both O 
compounds O 
inhibit O 
in O 
the O 
micromolar O 
range O 
. O 
Further O 
, O 
an O 
analysis O 
of O 
the O 
apparent O 
K(m) O 
values O 
for O 
FkbO O 
and O 
EntB O 
was O 
performed O 
, O 
showing O 
that O 
both O 
inhibitors O 
act O 
in O 
a O 
competitive O 
manner O 
. O 
Due O 
to O 
the O 
ease O 
of O 
modifying O 
these O 
new O 
inhibitors O 
they O 
are O 
a O 
suitable O 
starting O 
point O 
for O 
exploring O 
further O 
functionalised O 
derivatives O 
. O 

hydrolysis O 
in O 
high O 
temperature O 
water O 
. O 

investigated O 
the O 
hydrolysis O 
of O 
anisole B-TRIVIAL 
to O 
phenol B-SYSTEMATIC 
in O 
high O 
- O 
temperature O 
water O 
with O 
and O 
without O 
water O 
- O 
tolerant O 
Lewis B-FAMILY 
acid I-FAMILY 
catalysis O 
. O 
With O 
no O 
catalyst O 
present O 
, O 
anisole B-TRIVIAL 
hydrolyzes O 
to O 
phenol B-SYSTEMATIC 
in O 
97% O 
yield O 
after O 
24 O 
hours O 
at O 
365 O 
°C O 
, O 
our O 
experimentally O 
determined O 
optimal O 
temperature O 
and O 
time O 
. O 
Experiments O 
with O 
varied O 
water O 
density O 
and O 
analysis O 
of O 
comparable O 
literature O 
data O 
suggest O 
that O 
anisole B-TRIVIAL 
hydrolysis O 
is O 
almost O 
third O 
order O 
in O 
water O 
, O 
when O 
the O 
S(N)2 O 
mechanism O 
dominates O 
. O 
Of O 
the O 
water O 
- O 
tolerant O 
Lewis B-FAMILY 
acid I-FAMILY 
catalysts O 
studied O 
, O 
In(OTf)(3) B-FORMULA 
offered O 
the O 
best O 
phenol B-SYSTEMATIC 
yield O 
. O 
Anisole B-TRIVIAL 
hydrolysis O 
was O 
first O 
order O 
in O 
catalyst O 
and O 
first O 
order O 
in O 
substrate O 
. O 
Introducing O 
In(OTf)(3) B-FORMULA 
catalysis O 
lowered O 
the O 
activation O 
energy O 
for O 
anisole B-TRIVIAL 
hydrolysis O 
to O 
31 O 
± O 
1 O 
kcal O 
mol(-1) O 
. O 
Anisole B-TRIVIAL 
hydrolysis O 
in O 
high O 
- O 
temperature O 
water O 
with O 
In(OTf)(3) B-FORMULA 
catalysis O 
is O 
competitive O 
with O 
other O 
techniques O 
in O 
the O 
literature O 
based O 
on O 
rate O 
and O 
yield O 
. O 
In O 
the O 
presence O 
of O 
5 O 
mol% O 
In(OTf)(3) B-FORMULA 
catalyst O 
, O 
anisole B-TRIVIAL 
hydrolyzes O 
to O 
phenol B-SYSTEMATIC 
in O 
97% O 
yield O 
after O 
90 O 
minutes O 
at O 
300 O 
°C O 
. O 

from O 
Erica O 
multiflora O 
leaf O 
extract O 
stimulates O 
melanogenesis O 
in O 
B16 O 
murine O 
melanoma O 
cells O 
through O 
the O 
inhibition O 
of O 
ERK1 O 
/ O 
2 O 
activation O 
. O 

diseases O 
are O 
usually O 
managed O 
using O 
UVB O 
light O 
which O 
increases O 
the O 
patients O 
' O 
risk O 
for O 
skin O 
cancer O 
. O 
Here O 
, O 
we O 
evaluated O 
the O 
melanogenesis O 
stimulatory O 
effects O 
of O 
leaf O 
extracts O 
of O 
Erica O 
multiflora O 
, O 
a O 
medicinal O 
plant O 
from O 
the O 
Mediterranean O 
region O 
, O 
and O 
its O 
active O 
component O 
, O 
lup-20(29)-en-3-one B-SYSTEMATIC 
, O 
as O 
possible O 
therapeutic O 
agents O 
to O 
address O 
hypopigmentation O 
disorders O 
. O 
B16 O 
murine O 
melanoma O 
cells O 
were O 
treated O 
with O 
E O 
. O 
multiflora O 
extracts O 
or O 
its O 
active O 
component O 
lupenone B-TRIVIAL 
to O 
evaluate O 
their O 
effects O 
on O 
melanin O 
biosynthesis O 
. O 
The O 
mechanism O 
underlying O 
the O 
observed O 
effects O 
was O 
also O 
determined O 
. O 
Bioactivity O 
- O 
guided O 
fractionation O 
of O 
fifteen O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fractions O 
identified O 
fraction O 
2 O 
to O 
have O 
melanogenesis O 
stimulatory O 
effects O 
due O 
to O 
its O 
ability O 
to O 
decrease O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
phosphorylated O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
1 O 
and O 
2 O 
activation O 
. O 
Preparative O 
TLC O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
2 O 
revealed O 
the O 
presence O 
of O 
lup-20(29)-en-3-one B-SYSTEMATIC 
as O 
the O 
major O 
bioactive O 
component O 
. O 
B16 O 
cells O 
treated O 
with O 
lup-20(29)-en-3-one B-SYSTEMATIC 
increased O 
melanin O 
content O 
without O 
cytotoxicity O 
. O 
To O 
determine O 
the O 
mechanism O 
for O 
the O 
observed O 
effects O 
of O 
lup-20(29)-en-3-one B-SYSTEMATIC 
, O 
the O 
tyrosinase O 
enzyme O 
activity O 
, O 
the O 
tyrosinase O 
protein O 
expression O 
, O 
and O 
the O 
activation O 
of O 
phosphorylated O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
1 O 
and O 
2 O 
were O 
determined O 
. O 
In O 
addition O 
, O 
the O 
expression O 
of O 
the O 
tyrosinase O 
mRNA O 
was O 
quantified O 
using O 
real O 
- O 
time O 
PCR O 
. O 
Results O 
showed O 
that O 
lup-20(29)-en-3-one B-SYSTEMATIC 
has O 
no O 
effect O 
on O 
the O 
tyrosinase O 
enzyme O 
activity O 
but O 
can O 
increase O 
tyrosinase O 
expression O 
at O 
both O 
the O 
transcriptional O 
and O 
translational O 
levels O 
. O 
The O 
increase O 
in O 
the O 
tyrosinase O 
mRNA O 
expression O 
was O 
most O 
likely O 
due O 
to O 
the O 
inhibited O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
phosphorylated O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
1 O 
and O 
2 O 
activation O 
. O 
We O 
report O 
for O 
the O 
first O 
time O 
that O 
E O 
. O 
multiflora O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
and O 
its O 
active O 
compound O 
lup-20(29)-en-3-one B-SYSTEMATIC 
stimulate O 
melanogenesis O 
by O 
increasing O 
the O 
tyrosinase O 
enzyme O 
expression O 
via O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
phosphorylated O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
1 O 
and O 
2 O 
phosphorylation O 
inhibition O 
, O 
making O 
it O 
a O 
possible O 
treatment O 
for O 
hypopigmentation O 
diseases O 
. O 

of O 
thiazolidine-2,4-dione B-SYSTEMATIC 
/ O 
biphenylcarbonitrile B-SYSTEMATIC 
hybrid O 
as O 
dual O 
PPAR O 
α O 
/ O 
γ O 
modulator O 
with O 
antidiabetic O 
effect O 
: O 
in O 
vitro O 
, O 
in O 
silico O 
and O 
in O 
vivo O 
approaches O 
. O 

small O 
series O 
of O 
thiazolidine-2,4-dione B-SYSTEMATIC 
and O 
barbituric B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
1-4 O 
was O 
prepared O 
using O 
a O 
short O 
synthetic O 
route O 
, O 
and O 
all O 
compounds O 
were O 
characterized O 
by O 
elemental O 
analysis O 
, O 
mass O 
spectrometry O 
, O 
and O 
NMR O 
( O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
) O 
spectroscopy O 
. O 
Their O 
in O 
vitro O 
relative O 
expression O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
and O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
γ O 
was O 
evaluated O 
. O 
Compound O 
1 O 
showed O 
an O 
increase O 
in O 
the O 
mRNA O 
expression O 
of O 
both O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
isoforms O 
, O 
as O 
well O 
as O 
the O 
GLUT-4 O 
levels O 
. O 
The O 
antidiabetic O 
activity O 
of O 
compound O 
1 O 
was O 
determined O 
at O 
50 O 
mg O 
/ O 
kg O 
single O 
dose O 
using O 
a O 
non-insulin O 
- O 
dependent O 
diabetes O 
mellitus O 
rat O 
model O 
. O 
The O 
results O 
indicated O 
a O 
significant O 
decrease O 
in O 
plasma O 
glucose B-TRIVIAL 
levels O 
. O 
Additionally O 
, O 
we O 
performed O 
a O 
molecular O 
docking O 
of O 
compound O 
1 O 
into O 
the O 
ligand O 
binding O 
pocket O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
and O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
γ O 
. O 
In O 
these O 
binding O 
models O 
, O 
compound O 
1 O 
may O 
bind O 
into O 
the O 
active O 
site O 
of O 
both O 
isoforms O 
showing O 
important O 
short O 
contacts O 
with O 
the O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
γ O 
residues O 
: O 
Tyr B-FORMULA 
473 O 
, O 
His B-FORMULA 
449 O 
, O 
Ser B-FORMULA 
289 O 
, O 
His B-FORMULA 
323 O 
; O 
and O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
residues O 
: O 
Tyr B-FORMULA 
464 O 
, O 
His B-FORMULA 
440 O 
, O 
Ser B-FORMULA 
280 O 
and O 
Tyr B-FORMULA 
314 O 
. O 

amino B-FAMILY 
acids I-FAMILY 
and O 
monofluoroacetate B-SYSTEMATIC 
from O 
Dichapetalum O 
michelsonii O 
( O 
Umutambasha O 
) O 
, O 
a O 
toxic O 
plant O 
from O 
Rwanda O 
. O 

the O 
course O 
of O 
our O 
investigations O 
on O 
Umutambasha O 
in O 
order O 
to O 
identify O 
its O 
convulsant O 
principles O 
, O 
small O 
quantities O 
of O 
monofluoroacetate B-SYSTEMATIC 
were O 
observed O 
in O 
stem O 
bark O 
, O 
leaves O 
, O 
and O 
fruits O 
of O 
this O 
plant O 
newly O 
identified O 
as O 
Dichapetalum O 
michelsonii O 
Hauman O 
. O 
Conclusive O 
evidence O 
for O 
a O 
monofluoroacetate B-SYSTEMATIC 
presence O 
came O 
from O 
its O 
isolation O 
from O 
the O 
freeze O 
- O 
dried O 
extract O 
of O 
stem O 
bark O 
. O 
Three O 
free O 
unusual O 
amino B-FAMILY 
acids I-FAMILY 
, O 
named O 
N-methyl-α-alanine B-SYSTEMATIC 
, O 
N-methyl-β-alanine B-SYSTEMATIC 
, O 
and O 
2,7-diaminooctan-1,8-dioic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
described O 
for O 
the O 
first O 
time O 
in O 
a O 
plant O 
, O 
and O 
known O 
trigonelline B-TRIVIAL 
were O 
also O 
isolated O 
from O 
the O 
stem O 
bark O 
of O 
D O 
. O 
michelsonii O 
. O 
Structure O 
elucidations O 
were O 
mainly O 
achieved O 
by O 
spectroscopic O 
methods O 
( O 
1H B-FORMULA 
-NMR O 
, O 
2D-NMR O 
, O 
MS O 
) O 
and O 
by O 
comparison O 
with O 
authentic O 
references O 
. O 
These O 
unusual O 
amino B-FAMILY 
acids I-FAMILY 
were O 
detected O 
by O 
a O 
fast O 
, O 
reliable O 
TLC O 
analysis O 
in O 
all O 
our O 
batches O 
of O 
Umutambasha O 
, O 
suggesting O 
that O 
they O 
could O 
be O 
used O 
for O 
identification O 
purposes O 
in O 
case O 
of O 
human O 
or O 
livestock O 
intoxications O 
. O 
Finally O 
, O 
EEG O 
recordings O 
and O 
behavioural O 
observations O 
performed O 
in O 
mice O 
suggested O 
that O 
the O 
convulsive O 
patterns O 
produced O 
by O 
Umutambasha O 
are O 
the O 
consequence O 
of O 
monofluoroacetate B-SYSTEMATIC 
presence O 
in O 
D O 
. O 
michelsonii O 
. O 

generation O 
and O 
liver O 
X O 
receptor O 
- O 
dependent O 
reverse O 
cholesterol B-TRIVIAL 
transport O 
: O 
not O 
all O 
roads O 
lead O 
to O 
Rome O 
. O 

cholesterol B-TRIVIAL 
metabolism O 
is O 
a O 
tightly O 
regulated O 
process O 
, O 
dependent O 
in O 
part O 
on O 
activation O 
of O 
nuclear O 
liver O 
X O 
receptors O 
( O 
LXRs O 
) O 
to O 
increase O 
expression O 
of O 
genes O 
mediating O 
removal O 
of O 
excess O 
cholesterol B-TRIVIAL 
from O 
cells O 
in O 
the O 
reverse O 
cholesterol B-TRIVIAL 
transport O 
pathway O 
. O 
LXRs O 
are O 
thought O 
to O 
be O 
activated O 
predominantly O 
by O 
oxysterols B-FAMILY 
generated O 
enzymatically O 
from O 
cholesterol B-TRIVIAL 
in O 
different O 
cell O 
organelles O 
. O 
Defects O 
resulting O 
in O 
slowed O 
release O 
of O 
cholesterol B-TRIVIAL 
from O 
late O 
endosomes O 
and O 
lysosomes O 
or O 
reduction O 
in O 
sterol B-FAMILY 
-27-hydroxylase O 
activity O 
lead O 
to O 
specific O 
blocks O 
in O 
oxysterol B-FAMILY 
production O 
and O 
impaired O 
LXR-dependent O 
gene O 
activation O 
. O 
This O 
block O 
does O 
not O 
appear O 
to O 
be O 
compensated O 
by O 
oxysterol B-FAMILY 
production O 
in O 
other O 
cell O 
compartments O 
. O 
The O 
purpose O 
of O 
this O 
review O 
is O 
to O 
summarize O 
current O 
knowledge O 
about O 
oxysterol B-FAMILY 
-dependent O 
activation O 
by O 
LXR O 
of O 
genes O 
involved O 
in O 
reverse O 
cholesterol B-TRIVIAL 
transport O 
, O 
and O 
what O 
these O 
defects O 
of O 
cell O 
cholesterol B-TRIVIAL 
homeostasis O 
can O 
teach O 
us O 
about O 
the O 
critical O 
pathways O 
of O 
oxysterol B-FAMILY 
generation O 
for O 
expression O 
of O 
LXR-dependent O 
genes O 
. O 

formation O 
of O 
the O 
atherosclerotic O 
lesion O 
is O 
a O 
complex O 
process O 
influenced O 
by O 
an O 
array O 
of O 
inflammatory O 
and O 
lipid O 
metabolism O 
pathways O 
. O 
We O 
previously O 
demonstrated O 
that O 
NR4A O 
nuclear O 
receptors O 
are O 
highly O 
induced O 
in O 
macrophages O 
in O 
response O 
to O 
inflammatory O 
stimuli O 
and O 
modulate O 
the O 
expression O 
of O 
genes O 
linked O 
to O 
inflammation O 
in O 
vitro O 
. O 
Here O 
we O 
used O 
mouse O 
genetic O 
models O 
to O 
assess O 
the O 
impact O 
of O 
NR4A O 
expression O 
on O 
atherosclerosis O 
development O 
and O 
macrophage O 
polarization O 
. O 
Transplantation O 
of O 
wild O 
- O 
type O 
, O 
Nur77⁻ O 
/ O 
⁻ O 
, O 
or O 
Nor1⁻ O 
/ O 
⁻ O 
nan O 
hematopoetic O 
precursors O 
into O 
LDL O 
receptor O 
(LDLR)⁻ O 
/ O 
⁻ O 
recipient O 
mice O 
led O 
to O 
comparable O 
development O 
of O 
atherosclerotic O 
lesions O 
after O 
high- O 
cholesterol B-TRIVIAL 
diet O 
. O 
We O 
also O 
observed O 
comparable O 
induction O 
of O 
genes O 
linked O 
to O 
M1 O 
and O 
M2 O 
responses O 
in O 
wild O 
- O 
type O 
and O 
Nur77-null O 
macrophages O 
in O 
response O 
to O 
lipopolysaccharides O 
and O 
interleukin O 
(IL)-4 O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
activation O 
of O 
the O 
nuclear O 
receptor O 
liver O 
X O 
receptor O 
( O 
LXR O 
) O 
strongly O 
suppressed O 
M1 O 
responses O 
, O 
and O 
ablation O 
of O 
signal O 
transductor O 
and O 
activator O 
of O 
transcription O 
6 O 
( O 
STAT6 O 
) O 
strongly O 
suppressed O 
M2 O 
responses O 
. O 
Recent O 
studies O 
have O 
suggested O 
that O 
alterations O 
in O 
levels O 
of O 
Ly6C(lo) O 
monocytes O 
may O 
be O 
a O 
contributor O 
to O 
inflammation O 
and O 
atherosclerosis O 
. O 
In O 
our O 
study O 
, O 
loss O 
of O 
Nur77 O 
, O 
but O 
not O 
Nor1 O 
, O 
was O 
associated O 
with O 
decreased O 
abundance O 
of O 
Ly6C(lo) O 
monocytes O 
, O 
but O 
this O 
change O 
was O 
not O 
correlated O 
with O 
atherosclerotic O 
lesion O 
development O 
. O 
Collectively O 
, O 
our O 
results O 
suggest O 
that O 
alterations O 
in O 
the O 
Ly6C(lo) O 
monocyte O 
population O 
and O 
bone O 
marrow O 
NR4A O 
expression O 
do O 
not O 
play O 
dominant O 
roles O 
in O 
macrophage O 
polarization O 
or O 
the O 
development O 
of O 
atherosclerosis O 
in O 
mice O 
. O 

inducing O 
activity O 
of O 
benzophenanthridine B-FAMILY 
- I-FAMILY 
type I-FAMILY 
alkaloids I-FAMILY 
and O 
2-arylbenzofuran B-FAMILY 
neolignans I-FAMILY 
in O 
HCT116 O 
colon O 
carcinoma O 
cells O 
. O 

compounds O 
belonging O 
to O 
different O 
classes O 
of O 
alkaloids O 
( O 
1-9 O 
) O 
and O 
lignans B-FAMILY 
( O 
10-13 O 
) O 
, O 
isolated O 
from O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
roots O 
of O 
the O 
African O 
medicinal O 
plant O 
Zanthoxylum O 
capense O 
, O 
were O 
assayed O 
for O 
their O 
ability O 
as O 
apoptosis O 
inducers O 
in O 
HCT116 O 
colon O 
carcinoma O 
cells O 
. O 
The O 
cytotoxicity O 
of O 
these O 
compounds O 
was O 
evaluated O 
in O 
HCT116 O 
colon O 
carcinoma O 
cells O 
by O 
the O 
MTS B-ABBREVIATION 
assay O 
. O 
Out O 
of O 
the O 
tested O 
compounds O 
, O 
three O 
benzophenanthridine B-FAMILY 
alkaloids I-FAMILY 
( O 
1 O 
, O 
4 O 
, O 
and O 
7 O 
) O 
, O 
a O 
dibenzyl B-SYSTEMATIC 
butyrolactone I-SYSTEMATIC 
lignan I-SYSTEMATIC 
( O 
10 O 
) O 
, O 
and O 
two O 
2-arylbenzofuran B-FAMILY 
neolignans I-FAMILY 
( O 
12 O 
and O 
13 O 
) O 
displayed O 
significant O 
cytotoxicity O 
to O 
HCT116 O 
cells O 
, O 
confirmed O 
by O 
the O 
Guava O 
ViaCount O 
viability O 
assay O 
. O 
The O 
selected O 
compounds O 
( O 
1 O 
, O 
4 O 
, O 
7 O 
, O 
10 O 
, O 
12 O 
, O 
and O 
13 O 
) O 
were O 
further O 
tested O 
for O 
apoptosis O 
induction O 
activity O 
in O 
HCT116 O 
cells O 
, O 
by O 
evaluation O 
of O 
nuclear O 
morphology O 
following O 
Hoechst O 
staining O 
, O 
and O 
by O 
caspase-3 O 
like O 
activity O 
assays O 
. O 
Morphologic O 
evaluation O 
of O 
HCT116 O 
nuclei O 
following O 
Hoechst O 
staining O 
and O 
fluorescence O 
microscopy O 
revealed O 
that O 
compounds O 
1 O 
, O 
4 O 
, O 
7 O 
, O 
10 O 
, O 
12 O 
, O 
and O 
13 O 
induced O 
apoptosis O 
in O 
HCT116 O 
colon O 
carcinoma O 
cells O 
, O 
producing O 
similar O 
, O 
or O 
higher O 
, O 
apoptosis O 
levels O 
when O 
compared O 
with O 
5-fluorouracil B-SYSTEMATIC 
( O 
5-FU B-SYSTEMATIC 
) O 
, O 
the O 
cornerstone O 
cytotoxic O 
used O 
in O 
colon O 
cancer O 
treatment O 
for O 
several O 
decades O 
. O 
In O 
fact O 
, O 
HCT116 O 
cells O 
developed O 
morphological O 
changes O 
characteristic O 
of O 
apoptosis O 
, O 
including O 
chromatin O 
condensation O 
, O 
nuclear O 
fragmentation O 
and O 
formation O 
of O 
apoptotic O 
bodies O 
. O 
Importantly O 
, O 
compounds O 
4 O 
and O 
13 O 
at O 
20μM O 
were O 
the O 
most O 
promising O 
in O 
this O 
study O 
, O 
inducing O 
respectively O 
~11- O 
and O 
7-fold O 
increases O 
in O 
apoptotic O 
cells O 
as O 
compared O 
to O 
vehicle O 
control O 
, O 
whereas O 
5-FU B-SYSTEMATIC 
increased O 
apoptosis O 
by O 
~2-fold O 
. O 
Apoptosis O 
induction O 
for O 
compounds O 
4 O 
and O 
13 O 
was O 
further O 
confirmed O 
by O 
caspase-3 O 
- O 
like O 
activity O 
assays O 
, O 
which O 
showed O 
respectively O 
~2- O 
and O 
1.5-fold O 
increases O 
in O 
caspase-3 O 
- O 
like O 
activity O 
compared O 
to O 
vehicle O 
control O 
. O 
These O 
results O 
suggested O 
that O 
specific O 
benzophenanthridine B-FAMILY 
alkaloids I-FAMILY 
and O 
2-arylbenzofuran B-FAMILY 
neolignans I-FAMILY 
isolated O 
from O 
Zanthoxylum O 
capense O 
show O 
strong O 
anticancer O 
activity O 
in O 
HCT116 O 
colon O 
carcinoma O 
cells O 
. O 

acids I-FAMILY 
as O 
CRTh2 O 
antagonists O 
. O 

throughput O 
screening O 
identified O 
the O 
pyrazole-4-acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
substructure O 
as O 
CRTh2 O 
receptor O 
antagonists O 
. O 
Optimisation O 
of O 
the O 
compounds O 
uncovered O 
a O 
tight O 
SAR O 
but O 
also O 
identified O 
some O 
low O 
nanomolar O 
inhibitors O 
. O 

Silicon B-SYSTEMATIC 
Nanowires O 
by O 
Metal O 
- O 
Assisted O 
Etching O 
of O 
Metallurgical O 
Silicon B-SYSTEMATIC 
: O 
A O 
New O 
Route O 
to O 
Nanostructured O 
Solar-Grade O 
Silicon B-SYSTEMATIC 
. O 

metal O 
assisted O 
chemical O 
etching O 
( O 
MaCE O 
) O 
, O 
superior O 
purification O 
of O 
dirty O 
Si B-FORMULA 
was O 
observed O 
, O 
from O 
99.74 O 
to O 
99.9884% O 
for O 
metallurgical O 
Si B-FORMULA 
and O 
from O 
99.999772 O 
to O 
99.999899% O 
for O 
upgraded O 
metallurgical O 
Si B-FORMULA 
. O 
Meanwhile O 
, O 
large O 
area O 
of O 
silicon B-SYSTEMATIC 
nanowires O 
( O 
SiNW O 
) O 
was O 
fabricated O 
. O 
The O 
purification O 
effect O 
induced O 
∼35% O 
increase O 
in O 
photocurrent O 
for O 
SiNW O 
based O 
photoelectrochemical O 
cell O 
. O 

cerevisiae O 
and O 
S O 
. O 
uvarum O 
are O 
two O 
domesticated O 
species O 
of O 
the O 
Saccharomyces O 
sensu O 
stricto O 
clade O 
that O 
diverged O 
around O 
100 O 
Ma O 
after O 
whole O 
- O 
genome O 
duplication O 
. O 
Both O 
have O 
retained O 
many O 
duplicated O 
genes O 
associated O 
with O 
glucose B-TRIVIAL 
fermentation O 
and O 
are O 
characterized O 
by O 
the O 
ability O 
to O 
achieve O 
grape O 
must O 
fermentation O 
. O 
Nevertheless O 
, O 
these O 
two O 
species O 
differ O 
for O 
many O 
other O 
traits O 
, O 
indicating O 
that O 
they O 
underwent O 
different O 
evolutionary O 
histories O 
. O 
To O 
determine O 
how O 
the O 
evolutionary O 
histories O 
of O 
S O 
. O 
cerevisiae O 
and O 
S O 
. O 
uvarum O 
are O 
mirrored O 
on O 
the O 
proteome O 
, O 
we O 
analyzed O 
the O 
genetic O 
variability O 
of O 
the O 
proteomes O 
of O 
domesticated O 
strains O 
of O 
these O 
two O 
species O 
by O 
quantitative O 
mass O 
spectrometry O 
. O 
Overall O 
, O 
445 O 
proteins O 
were O 
quantified O 
. O 
Massive O 
variations O 
of O 
protein O 
abundances O 
were O 
found O 
, O 
that O 
clearly O 
differentiated O 
the O 
two O 
species O 
. O 
Abundance O 
variations O 
in O 
specific O 
metabolic O 
pathways O 
could O 
be O 
related O 
to O 
phenotypic O 
traits O 
known O 
to O 
discriminate O 
the O 
two O 
species O 
. O 
In O 
addition O 
, O 
proteins O 
encoded O 
by O 
duplicated O 
genes O 
were O 
shown O 
to O 
be O 
differently O 
recruited O 
in O 
each O 
species O 
. O 
Comparing O 
the O 
strain O 
differentiation O 
based O 
on O 
the O 
proteome O 
variability O 
to O 
those O 
based O 
on O 
the O 
phenotypic O 
and O 
genetic O 
variations O 
further O 
revealed O 
that O 
the O 
strains O 
of O 
S O 
. O 
uvarum O 
and O 
some O 
strains O 
of O 
S O 
. O 
cerevisiae O 
displayed O 
similar O 
fermentative O 
performances O 
despite O 
strong O 
proteomic O 
and O 
genomic O 
differences O 
. O 
Altogether O 
, O 
these O 
results O 
indicate O 
that O 
the O 
ability O 
of O 
S O 
. O 
cerevisae O 
and O 
S O 
. O 
uvarum O 
to O 
complete O 
grape O 
must O 
fermentation O 
arose O 
through O 
different O 
evolutionary O 
roads O 
, O 
involving O 
different O 
metabolic O 
pathways O 
and O 
duplicated O 
genes O 
. O 

olitorius O 
L O 
. O 
is O 
grown O 
in O 
Taiwan O 
during O 
summer O 
. O 
Tender O 
leaves O 
are O 
crushed O 
and O 
washed O 
by O 
running O 
water O 
before O 
eating O 
. O 
Five O 
fractions O 
including O 
crude O 
phenolic O 
extracts O 
( O 
using O 
80 O 
per O 
cent O 
aqueous O 
acetone B-SYSTEMATIC 
) O 
of O 
whole O 
plant O 
, O 
leaf O 
, O 
stem O 
, O 
washed O 
leaf O 
( O 
WL O 
) O 
and O 
dried O 
water O 
washing O 
material O 
( O 
WW O 
) O 
were O 
used O 
in O 
this O 
study O 
. O 
Linoleic B-TRIVIAL 
acid I-TRIVIAL 
autoxidation O 
inhibitions O 
on O 
all O 
fractions O 
were O 
higher O 
than O 
that O 
on O 
α-tocopherol B-TRIVIAL 
. O 
Except O 
for O 
WL O 
and O 
WW O 
, O 
other O 
fractions O 
also O 
showed O 
DPPH B-ABBREVIATION 
radical O 
scavenging O 
efficiency O 
. O 
The O 
effect O 
of O 
all O 
fractions O 
on O 
the O 
regulation O 
of O 
inflammatory O 
responses O 
in O 
lipopolysaccharide O 
(LPS)-stimulated O 
J774A.1 O 
macrophage O 
cells O 
was O 
investigated O 
. O 
All O 
fractions O 
diminished O 
LPS-induced O 
protein O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
cyclooxygenase O 
2 O 
( O 
COX-2 O 
) O 
. O 
Nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
, O 
downstream O 
products O 
, O 
were O 
also O 
suppressed O 
in O 
dose O 
- O 
dependent O 
manners O 
, O 
except O 
for O 
WL O 
and O 
WW O 
. O 
Oxidative O 
modification O 
and O 
loss O 
of O 
leaf O 
phenolics B-FAMILY 
after O 
kneading O 
and O 
washing O 
greatly O 
affected O 
DPPH B-ABBREVIATION 
radical O 
scavenging O 
and O 
inflammatory O 
responses O 
. O 

of O 
chain O 
length O 
and O 
double O 
bond O 
on O 
the O 
aqueous O 
behavior O 
of O 
choline B-FAMILY 
carboxylate I-FAMILY 
soaps O 
. O 

preceding O 
studies O 
, O 
we O 
demonstrated O 
that O 
choline B-FAMILY 
carboxylates I-FAMILY 
ChC(m) B-FAMILY 
with O 
alkyl B-FAMILY 
chain O 
lengths O 
of O 
m O 
= O 
12 O 
- O 
18 O 
are O 
highly O 
water O 
- O 
soluble O 
( O 
for O 
m O 
= O 
12 O 
, O 
soluble O 
up O 
to O 
93 O 
wt O 
% O 
soap O 
and O 
0 O 
°C O 
) O 
. O 
In O 
addition O 
, O 
choline B-FAMILY 
soaps O 
are O 
featured O 
by O 
an O 
extraordinary O 
lyotropic O 
phase O 
behavior O 
. O 
With O 
decreasing O 
water O 
concentration O 
, O 
the O 
following O 
phases O 
were O 
found O 
: O 
micellar O 
phase O 
(L(1)) O 
, O 
discontinuous O 
cubic O 
phase O 
( O 
I(1) O 
' O 
and O 
I(1) O 
" O 
) O 
, O 
hexagonal O 
phase O 
(H(1)) O 
, O 
bicontinuous O 
cubic O 
phase O 
(V(1)) O 
, O 
and O 
lamellar O 
phase O 
(L(α)) O 
. O 
The O 
present O 
work O 
is O 
also O 
focused O 
on O 
the O 
lyotropic O 
phase O 
behavior O 
of O 
choline B-FAMILY 
soaps O 
but O 
with O 
shorter O 
alkyl B-FAMILY 
chains O 
or O 
different O 
alkyl B-FAMILY 
chain O 
properties O 
. O 
We O 
have O 
investigated O 
the O 
aqueous O 
phase O 
behavior O 
of O 
choline B-FAMILY 
soaps O 
with O 
C(8) B-FORMULA 
and O 
C(10) B-FORMULA 
chain O 
- O 
lengths O 
( O 
choline B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
and O 
choline B-SYSTEMATIC 
decanoate I-SYSTEMATIC 
) O 
and O 
with O 
a O 
C(18) B-FORMULA 
chain O 
- O 
length O 
with O 
a O 
cis-double O 
bond O 
( O 
choline B-TRIVIAL 
oleate I-TRIVIAL 
) O 
. O 
We O 
found O 
that O 
choline B-SYSTEMATIC 
decanoate I-SYSTEMATIC 
follows O 
the O 
lyotropic O 
phase O 
behavior O 
of O 
the O 
longer O 
- O 
chain O 
homologues O 
mentioned O 
above O 
. O 
Choline B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
in O 
water O 
shows O 
no O 
discontinuous O 
cubic O 
phases O 
, O 
but O 
an O 
extended O 
, O 
isotropic O 
micellar O 
solution O 
phase O 
. O 
In O 
addition O 
, O 
choline B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
is O 
at O 
the O 
limit O 
between O 
a O 
surfactant O 
and O 
a O 
hydrotrope O 
. O 
The O 
double O 
bond O 
in O 
choline B-TRIVIAL 
oleate I-TRIVIAL 
leads O 
also O 
to O 
a O 
better O 
solubility O 
in O 
water O 
and O 
a O 
decrease O 
of O 
the O 
solubilization O 
temperature O 
. O 
It O 
also O 
influences O 
the O 
Gaussian O 
curvature O 
of O 
the O 
aggregates O 
which O 
results O 
in O 
a O 
loss O 
of O 
discontinuous O 
cubic O 
phases O 
in O 
the O 
binary O 
phase O 
diagram O 
. O 
The O 
different O 
lyotropic O 
mesophases O 
were O 
identified O 
by O 
the O 
penetration O 
scan O 
technique O 
with O 
polarizing O 
light O 
microscope O 
and O 
visual O 
observations O 
. O 
To O 
clarify O 
the O 
structural O 
behavior O 
small O 
( O 
SAXS O 
) O 
and O 
wide O 
( O 
WAXS O 
) O 
angle O 
X-ray O 
scattering O 
were O 
performed O 
. O 
To O 
further O 
characterize O 
the O 
extended O 
, O 
isotropic O 
micellar O 
solution O 
phase O 
in O 
the O 
binary O 
phase O 
diagram O 
of O 
choline B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
viscosity O 
and O 
conductivity O 
measurements O 
were O 
also O 
carried O 
out O 
. O 

determine O 
the O 
prevalence O 
of O 
people O 
with O 
diabetes O 
who O 
meet O 
hemoglobin O 
A(1c) O 
( O 
A1C O 
) O 
, O 
blood O 
pressure O 
( O 
BP O 
) O 
, O 
and O 
LDL O 
cholesterol B-TRIVIAL 
( O 
ABC O 
) O 
recommendations O 
, O 
and O 
their O 
current O 
statin O 
use O 
, O 
factors O 
associated O 
with O 
goal O 
achievement O 
, O 
and O 
changes O 
in O 
the O 
proportion O 
achieving O 
goals O 
between O 
1988 O 
and O 
2010.RESEARCH O 
AND O 
DESIGN O 
METHODSData O 
were O 
cross O 
- O 
sectional O 
from O 
the O 
National O 
Health O 
and O 
Nutrition O 
Examination O 
Surveys O 
( O 
NHANES O 
) O 
from O 
1988-1994 O 
, O 
1999-2002 O 
, O 
2003-2006 O 
, O 
and O 
2007-2010 O 
. O 
Participants O 
were O 
4926 O 
adults O 
aged O 
≥ O 
20 O 
years O 
who O 
self O 
- O 
reported O 
a O 
previous O 
diagnosis O 
of O 
diabetes O 
and O 
completed O 
the O 
household O 
interview O 
and O 
physical O 
examination O 
( O 
n O 
= O 
1558 O 
for O 
valid O 
LDL O 
levels O 
) O 
. O 
Main O 
outcome O 
measures O 
were O 
A1C O 
, O 
BP O 
, O 
and O 
LDL O 
cholesterol B-TRIVIAL 
, O 
in O 
accordance O 
with O 
the O 
American O 
Diabetes O 
Association O 
recommendations O 
, O 
and O 
current O 
use O 
of O 
statins.RESULTSIn O 
2007-2010 O 
, O 
52.5% O 
of O 
people O 
with O 
diabetes O 
achieved O 
A1C O 
< O 
7.0% O 
( O 
< O 
53 O 
mmol O 
/ O 
mol O 
) O 
, O 
51.1% O 
achieved O 
BP O 
< O 
130 O 
/ O 
80 O 
mmHg O 
, O 
56.2% O 
achieved O 
LDL O 
< O 
100 O 
mg O 
/ O 
dL O 
, O 
and O 
18.8% O 
achieved O 
all O 
three O 
ABCs O 
. O 
These O 
levels O 
of O 
control O 
were O 
significant O 
improvements O 
from O 
1988 O 
to O 
1994 O 
( O 
all O 
P O 
< O 
0.05 O 
) O 
. O 
Statin O 
use O 
significantly O 
increased O 
between O 
1988-1994 O 
( O 
4.2% O 
) O 
and O 
2007-2010 O 
( O 
51.4% O 
, O 
P O 
< O 
0.01 O 
) O 
. O 
Compared O 
with O 
non-Hispanic O 
whites O 
, O 
Mexican O 
Americans O 
were O 
less O 
likely O 
to O 
meet O 
A1C O 
and O 
LDL O 
goals O 
( O 
P O 
< O 
0.03 O 
) O 
, O 
and O 
non-Hispanic O 
blacks O 
were O 
less O 
likely O 
to O 
meet O 
BP O 
and O 
LDL O 
goals O 
( O 
P O 
< O 
0.02 O 
) O 
. O 
Compared O 
with O 
non-Hispanic O 
blacks O 
, O 
Mexican O 
Americans O 
were O 
less O 
likely O 
to O 
meet O 
A1C O 
goals O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Younger O 
individuals O 
were O 
less O 
likely O 
to O 
meet O 
A1C O 
and O 
LDL O 
goals.CONCLUSIONSDespite O 
significant O 
improvement O 
during O 
the O 
past O 
decade O 
, O 
achieving O 
the O 
ABC O 
goals O 
remains O 
suboptimal O 
among O 
adults O 
with O 
diabetes O 
, O 
particularly O 
in O 
some O 
minority O 
groups O 
. O 
Substantial O 
opportunity O 
exists O 
to O 
further O 
improve O 
diabetes O 
control O 
and O 
, O 
thus O 
, O 
to O 
reduce O 
diabetes O 
- O 
related O 
morbidity O 
and O 
mortality O 
. O 

mining O 
activities O 
have O 
been O 
implicated O 
as O 
sources O 
that O 
increase O 
stream O 
specific O 
conductance O 
in O 
Central O 
Appalachia O 
. O 
The O 
present O 
study O 
characterized O 
potential O 
sources O 
of O 
elevated O 
ionic O 
strength O 
for O 
small O 
subwatersheds O 
within O 
the O 
Coal B-TRIVIAL 
, O 
Upper O 
Kanawha O 
, O 
Gauley O 
, O 
and O 
New O 
Rivers O 
in O 
West O 
Virginia O 
. O 
From O 
a O 
large O 
monitoring O 
data O 
set O 
developed O 
by O 
the O 
West O 
Virginia O 
Department O 
of O 
Environmental O 
Protection O 
, O 
162 O 
< O 
20-km(2)-watersheds O 
were O 
identified O 
that O 
had O 
detailed O 
land O 
cover O 
information O 
in O 
southwestern O 
West O 
Virginia O 
with O 
at O 
least O 
one O 
water O 
chemistry O 
sample O 
. O 
Scatter O 
plots O 
of O 
specific O 
conductance O 
were O 
generated O 
for O 
nine O 
land O 
cover O 
classifications O 
: O 
open O 
water O 
, O 
agriculture O 
, O 
forest O 
, O 
residential O 
, O 
barren O 
, O 
total O 
mining O 
, O 
valley O 
fill O 
, O 
abandoned O 
mine O 
lands O 
, O 
and O 
mining O 
excluding O 
valley O 
fill O 
and O 
abandoned O 
mine O 
lands O 
. O 
Conductivity O 
was O 
negatively O 
correlated O 
with O 
the O 
percentage O 
of O 
forest O 
area O 
and O 
positively O 
associated O 
with O 
other O 
land O 
uses O 
. O 
In O 
a O 
multiple O 
regression O 
, O 
the O 
percentage O 
of O 
area O 
in O 
valley O 
fill O 
was O 
the O 
strongest O 
contributor O 
to O 
increased O 
ionic O 
strength O 
, O 
followed O 
by O 
percentage O 
of O 
area O 
in O 
urban O 
( O 
residential O 
/ O 
buildings O 
) O 
land O 
use O 
and O 
other O 
mining O 
land O 
use O 
. O 
Based O 
on O 
the O 
10th O 
quantile O 
regression O 
, O 
300 O 
µS O 
/ O 
cm O 
was O 
exceeded O 
at O 
3.3% O 
of O 
area O 
in O 
valley O 
fill O 
. O 
In O 
most O 
catchments O 
, O 
HCO B-FORMULA 
3(-) I-FORMULA 
and O 
SO B-FORMULA 
4(2-) I-FORMULA 
concentrations O 
were O 
greater O 
than O 
Cl(-) B-FORMULA 
concentration O 
. O 
These O 
findings O 
confirm O 
coal O 
mining O 
activities O 
as O 
the O 
primary O 
source O 
of O 
high O 
conductivity O 
waters O 
. O 
Such O 
activities O 
might O 
be O 
redressed O 
with O 
the O 
goal O 
of O 
protecting O 
sources O 
of O 
dilute O 
freshwater O 
in O 
the O 
region O 
. O 

of O 
cellular O 
topoisomerase O 
IIα O 
inhibition O 
to O 
cytotoxicity O 
and O 
published O 
genotoxicity O 
of O 
fluoroquinolone B-SYSTEMATIC 
antibiotics O 
in O 
V79 O 
cells O 
. O 

( O 
FQ O 
) O 
antibiotics O 
are O 
bacteriocidal O 
through O 
inhibition O 
of O 
the O 
bacterial O 
gyrase O 
and O 
at O 
sufficient O 
concentrations O 
in O 
vitro O 
, O 
they O 
can O 
inhibit O 
the O 
homologous O 
eukaryotic O 
topoisomerase O 
( O 
TOPO O 
) O 
II O 
enzyme O 
. O 
FQ O 
exert O 
a O 
variety O 
of O 
genotoxic O 
effects O 
in O 
mammalian O 
systems O 
through O 
mechanisms O 
not O 
yet O 
established O 
, O 
but O 
which O 
are O 
postulated O 
to O 
involve O 
inhibition O 
of O 
TOPO O 
II O 
enzymes O 
. O 
To O 
assess O 
the O 
relationship O 
of O 
inhibition O 
of O 
cell O 
nuclear O 
TOPO O 
II O 
to O 
cytotoxicity O 
and O 
reported O 
genotoxicity O 
, O 
two O 
FQ O 
, O 
clinafloxacin B-TRIVIAL 
( O 
CLFX B-ABBREVIATION 
) O 
and O 
lomefloxacin B-TRIVIAL 
( O 
LOFX B-ABBREVIATION 
) O 
, O 
having O 
available O 
genotoxicity O 
data O 
showing O 
substantial O 
differences O 
with O 
CLFX B-ABBREVIATION 
being O 
more O 
potent O 
than O 
LOFX B-ABBREVIATION 
, O 
were O 
selected O 
for O 
study O 
. O 
The O 
relative O 
inhibitory O 
activities O 
of O 
these O 
FQ O 
on O 
nuclear O 
TOPO O 
IIα O 
in O 
cultured O 
Chinese O 
hamster O 
lung O 
fibroblasts O 
( O 
V79 O 
cells O 
) O 
over O 
dose O 
ranges O 
and O 
at O 
equimolar O 
concentrations O 
were O 
assessed O 
by O 
measuring O 
nuclear O 
stabilized O 
cleavage O 
complexes O 
of O 
TOPO O 
IIα-DNA O 
. O 
Cytotoxicity O 
was O 
measured O 
by O 
relative O 
cell O 
counts O 
. O 
Both O 
FQ O 
inhibited O 
V79 O 
cell O 
nuclear O 
TOPO O 
IIα O 
. O 
The O 
lowest O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
levels O 
for O 
TOPO O 
IIα O 
inhibition O 
were O 
55μM O 
for O 
CLFX B-ABBREVIATION 
, O 
and O 
516μM O 
for O 
LOFX B-ABBREVIATION 
. O 
The O 
no O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
- O 
levels O 
were O 
41μM O 
for O 
CLFX B-ABBREVIATION 
, O 
and O 
258μM O 
for O 
LOFX B-ABBREVIATION 
. O 
At O 
equimolar O 
concentrations O 
( O 
175μM O 
) O 
, O 
CLFX B-ABBREVIATION 
was O 
more O 
potent O 
than O 
LOFX B-ABBREVIATION 
. O 
Likewise O 
, O 
CLFX B-ABBREVIATION 
was O 
more O 
cytotoxic O 
than O 
LOFX B-ABBREVIATION 
. O 
Thus O 
, O 
the O 
two O 
FQ O 
, O 
inhibited O 
TOPO O 
IIα O 
in O 
intact O 
V79 O 
cells O 
, O 
differed O 
in O 
their O 
potencies O 
and O 
exhibited O 
no O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
levels O 
. O 
These O 
findings O 
are O 
in O 
concordance O 
with O 
published O 
genotoxicity O 
data O 
and O 
observed O 
cytotoxicity O 
. O 

inhibitors O 
are O 
the O 
mainstay O 
of O 
anti-influenza O 
treatment O 
. O 
Oseltamivir B-TRIVIAL 
is O 
the O 
most O 
widely O 
used O 
drug O 
but O 
is O 
currently O 
available O 
only O 
as O 
an O 
oral O 
formulation O 
. O 
Resistance O 
spreads O 
rapidly O 
in O 
seasonal O 
H1N1 O 
influenza O 
A O 
viruses O 
, O 
which O 
were O 
universally O 
resistant O 
in O 
2008 O 
, O 
because O 
of O 
the O 
H275Y O 
mutation O 
in O 
the O 
neuraminidase O 
( O 
nan O 
) O 
gene O 
. O 
Oseltamivir B-TRIVIAL 
is O 
a O 
prodrug O 
for O 
the O 
active O 
carboxylate B-SYSTEMATIC 
metabolite O 
. O 
Ex O 
vivo O 
conversion O 
in O 
blood O 
samples O 
may O 
have O 
confounded O 
early O 
pharmacokinetic O 
studies O 
. O 
Oseltamivir B-TRIVIAL 
shows O 
dose O 
linear O 
kinetics O 
, O 
and O 
oseltamivir B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
has O 
an O 
elimination O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
β O 
) O 
after O 
oral O 
administration O 
in O 
healthy O 
individuals O 
of O 
approximately O 
7.7 O 
hours O 
. O 
Oseltamivir B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
is O 
eliminated O 
primarily O 
by O 
tubular O 
secretion O 
, O 
and O 
both O 
clearance O 
and O 
tissue O 
distribution O 
are O 
reduced O 
by O 
probenecid B-TRIVIAL 
. O 
The O 
H275Y O 
mutation O 
in O 
nan O 
confers O 
high O 
- O 
level O 
oseltamivir B-TRIVIAL 
resistance O 
and O 
intermediate O 
peramivir B-TRIVIAL 
resistance O 
but O 
does O 
not O 
alter O 
zanamivir B-TRIVIAL 
susceptibility O 
. O 
Zanamivir B-TRIVIAL 
is O 
available O 
as O 
a O 
powder O 
for O 
inhalation O 
, O 
and O 
a O 
parenteral O 
form O 
is O 
under O 
development O 
. O 
Zanamivir B-TRIVIAL 
distributes O 
in O 
an O 
apparent O 
volume O 
of O 
distribution O 
approximating O 
that O 
of O 
extracellular O 
water O 
and O 
is O 
rapidly O 
eliminated O 
( O 
t(1 O 
/ O 
2 O 
) O 
β O 
of O 
approximately O 
3 O 
hours O 
) O 
. O 
Peramivir B-TRIVIAL 
is O 
slowly O 
eliminated O 
( O 
t(1 O 
/ O 
2 O 
) O 
β O 
of O 
7.7-20.8 O 
hours O 
) O 
and O 
is O 
prescribed O 
as O 
either O 
a O 
once O 
- O 
daily O 
injection O 
or O 
as O 
a O 
single O 
infusion O 
. O 
Laninamivir B-TRIVIAL 
is O 
a O 
recently O 
developed O 
slowly O 
eliminated O 
compound O 
for O 
administration O 
by O 
inhalation O 
. O 

thioglycolic B-TRIVIAL 
Acid I-TRIVIAL 
as O 
a O 
versatile O 
antimicrobial O 
agent O 
. O 

functionalized O 
chitosans O 
hold O 
great O 
potential O 
for O 
the O 
development O 
of O 
effective O 
and O 
broad O 
- O 
spectrum O 
antibiotics O 
, O 
representative O 
chitosan O 
derivatives O 
were O 
tested O 
for O 
antimicrobial O 
activity O 
in O 
neutral O 
media O 
: O 
trimethyl B-SYSTEMATIC 
chitosan O 
( O 
TMC O 
) O 
, O 
carboxy-methyl B-SYSTEMATIC 
chitosan O 
( O 
CMC O 
) O 
, O 
and O 
chitosan- O 
thioglycolic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
TGA B-ABBREVIATION 
; O 
medium O 
molecular O 
weight O 
: O 
MMW- O 
TGA B-ABBREVIATION 
; O 
low O 
molecular O 
weight O 
: O 
LMW- O 
TGA B-ABBREVIATION 
) O 
. O 
Colony O 
forming O 
assays O 
indicated O 
that O 
LMW- O 
TGA B-ABBREVIATION 
displayed O 
superior O 
antimicrobial O 
activity O 
over O 
the O 
other O 
derivatives O 
tested O 
: O 
a O 
30 O 
min O 
incubation O 
killed O 
100% O 
Streptococcus O 
sobrinus O 
( O 
Gram O 
- O 
positive O 
bacteria O 
) O 
and O 
reduced O 
colony O 
counts O 
by O 
99.99% O 
in O 
Neisseria O 
subflava O 
( O 
Gram O 
- O 
negative O 
bacteria O 
) O 
and O 
99.97% O 
in O 
Candida O 
albicans O 
( O 
fungi O 
) O 
. O 
To O 
elucidate O 
LMW- O 
TGA B-ABBREVIATION 
effects O 
at O 
the O 
cellular O 
level O 
, O 
microscopic O 
studies O 
were O 
performed O 
. O 
Use O 
of O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
( O 
FITC B-ABBREVIATION 
)-labeled O 
chitosan O 
derivates O 
in O 
confocal O 
microscopy O 
showed O 
that O 
LMW- O 
TGA B-ABBREVIATION 
attaches O 
to O 
microbial O 
cell O 
walls O 
, O 
while O 
transmission O 
electron O 
microscopy O 
indicated O 
that O 
this O 
derivative O 
severely O 
affects O 
cell O 
wall O 
integrity O 
and O 
intracellular O 
ultrastructure O 
in O 
all O 
species O 
tested O 
. O 
We O 
therefore O 
propose O 
LMW- O 
TGA B-ABBREVIATION 
as O 
a O 
promising O 
and O 
effective O 
broad O 
- O 
band O 
antimicrobial O 
compound O 
. O 

discovery O 
of O 
potent O 
and O 
selective O 
4-aminothienopyridines B-FAMILY 
as O 
B-Raf O 
kinase O 
inhibitors O 
. O 

series O 
of O 
novel O 
, O 
potent O 
4-aminothienopyridine B-SYSTEMATIC 
B-Raf O 
kinase O 
inhibitors O 
was O 
designed O 
and O 
synthesized O 
using O 
knowledge O 
- O 
based O 
design O 
. O 
Compounds O 
5f O 
, O 
and O 
6k O 
exhibited O 
not O 
only O 
excellent O 
potency O 
in O 
both O 
enzyme O 
assay O 
( O 
IC(50)=5.1 O 
, O 
16.6 O 
nM O 
) O 
and O 
cellular O 
assay O 
( O 
IC(50)=0.2 O 
, O 
0.2 O 
μM O 
) O 
, O 
but O 
also O 
had O 
an O 
outstanding O 
selectivity O 
profile O 
against O 
other O 
kinases O 
. O 

baking O 
applications O 
involving O 
starch O 
gelatinisation O 
, O 
surfactants O 
such O 
as O 
sodium B-SYSTEMATIC 
stearoyl I-SYSTEMATIC 
lactylate I-SYSTEMATIC 
( O 
SSL B-ABBREVIATION 
) O 
and O 
monoacylglycerols B-FAMILY 
( O 
MAG B-ABBREVIATION 
) O 
and O 
Bacillus O 
stearothermophilus O 
maltogenic O 
alpha-amylase O 
( O 
BStA O 
) O 
can O 
be O 
used O 
jointly O 
. O 
We O 
here O 
showed O 
that O 
SSL B-ABBREVIATION 
but O 
not O 
MAG B-ABBREVIATION 
delays O 
wheat O 
starch O 
hydrolysis O 
by O 
BStA O 
. O 
The O 
effects O 
were O 
explained O 
in O 
terms O 
of O 
different O 
degrees O 
of O 
adsorption O 
of O 
the O 
surfactants O 
on O 
the O 
starch O 
granule O 
surface O 
, O 
retarded O 
and O 
/ O 
or O 
decreased O 
water O 
uptake O 
and O 
delayed O 
availability O 
of O 
gelatinised O 
starch O 
for O 
hydrolysis O 
by O 
BStA O 
. O 
Additional O 
experiments O 
with O 
waxy O 
maize O 
starch O 
led O 
to O 
the O 
conclusion O 
that O 
SSL B-ABBREVIATION 
impacts O 
swelling O 
power O 
and O 
carbohydrate B-FAMILY 
leaching O 
more O 
by O 
covering O 
the O 
starch O 
granule O 
surface O 
than O 
by O 
forming O 
amylose O 
- O 
lipid O 
complexes O 
. O 
SSL B-ABBREVIATION 
postponed O 
starch O 
hydrolysis O 
by O 
BStA O 
, O 
but O 
this O 
did O 
not O 
influence O 
subsequent O 
starch O 
gelation O 
. O 
Finally O 
, O 
when O 
adding O 
SSL B-ABBREVIATION 
or O 
MAG B-ABBREVIATION 
on O 
top O 
of O 
BStA O 
to O 
starch O 
suspensions O 
, O 
the O 
effect O 
of O 
the O 
surfactants O 
on O 
gel O 
strength O 
predominated O 
over O 
that O 
of O 
BStA O 
. O 

progress O 
has O 
been O 
made O 
recently O 
in O 
the O 
development O 
of O 
Organic O 
Ionic O 
Plastic O 
Crystals O 
( O 
OIPCs O 
) O 
, O 
a O 
unique O 
family O 
of O 
solid O 
state O 
electrolytes O 
with O 
applications O 
in O 
electrochemical O 
devices O 
such O 
as O 
lithium B-SYSTEMATIC 
batteries O 
and O 
dye O 
- O 
sensitised O 
solar O 
cells O 
. O 
The O 
negligible O 
volatility O 
of O 
OIPCs O 
renders O 
them O 
more O 
suitable O 
than O 
molecular O 
species O 
for O 
long O 
- O 
term O 
device O 
use O 
, O 
while O 
the O 
high O 
thermal O 
and O 
electrochemical O 
stability O 
of O 
many O 
OIPCs O 
fulfils O 
an O 
essential O 
requirement O 
for O 
solid O 
state O 
electrolytes O 
for O 
many O 
device O 
applications O 
. O 
However O 
, O 
the O 
complex O 
mechanisms O 
of O 
conduction O 
through O 
these O 
materials O 
, O 
both O 
in O 
their O 
pure O 
state O 
and O 
in O 
the O 
presence O 
of O 
a O 
small O 
amount O 
of O 
a O 
second O 
component O 
( O 
such O 
as O 
lithium B-SYSTEMATIC 
salts O 
to O 
enable O 
their O 
use O 
in O 
lithium B-SYSTEMATIC 
batteries O 
) O 
are O 
still O 
not O 
fully O 
understood O 
. O 
At O 
the O 
same O 
time O 
, O 
the O 
range O 
of O 
anions O 
and O 
cations O 
utilised O 
in O 
the O 
synthesis O 
of O 
plastic O 
crystal O 
phases O 
continues O 
to O 
increase O 
. O 
This O 
perspective O 
concentrates O 
on O 
recent O 
research O 
into O 
both O 
fundamental O 
and O 
device O 
- O 
oriented O 
aspects O 
of O 
these O 
materials O 
. O 
Important O 
fundamental O 
understanding O 
of O 
the O 
physical O 
properties O 
and O 
transport O 
mechanisms O 
of O 
different O 
OIPCs O 
has O 
been O 
achieved O 
through O 
use O 
of O 
techniques O 
including O 
variable O 
temperature O 
solid O 
- O 
state O 
NMR O 
and O 
crystallographic O 
analysis O 
, O 
as O 
well O 
as O 
detailed O 
molecular O 
dynamics O 
simulations O 
. O 
In O 
parallel O 
, O 
the O 
applicability O 
of O 
these O 
materials O 
as O 
electrolytes O 
for O 
dye O 
- O 
sensitised O 
solar O 
cells O 
and O 
lithium B-SYSTEMATIC 
batteries O 
is O 
being O 
more O 
widely O 
demonstrated O 
. O 
The O 
possibility O 
of O 
using O 
OIPCs O 
as O 
solid O 
state O 
electrolytes O 
for O 
fuel O 
cells O 
is O 
also O 
discussed O 
. O 

enhancement O 
: O 
Designed O 
to O 
target O 
HIV-1 O 
protease O 
, O 
a O 
novel O 
γ-hydroxyphosphonate B-SYSTEMATIC 
has O 
been O 
found O 
to O 
significantly O 
enhance O 
viral O 
replication O 
in O 
a O 
panel O 
of O 
clinically O 
relevant O 
R5 O 
HIV-1 O 
isolates O 
. O 
This O 
unexpected O 
result O 
constitutes O 
the O 
first O 
instance O 
of O 
a O 
small O 
molecule O 
capable O 
of O 
doing O 
this O 
, O 
and O 
it O 
has O 
implications O 
for O 
the O 
preparation O 
and O 
use O 
of O 
R5 O 
isolates O 
in O 
vaccine O 
and O 
drug O 
development O 
. O 

construction O 
and O 
biological O 
evaluation O 
of O 
enmein B-TRIVIAL 
-type O 
diterpenoid B-FAMILY 
analogues O 
as O 
potential O 
anticancer O 
agents O 
. O 

library O 
of O 
promising O 
enmein B-TRIVIAL 
-type O 
14-O-diterpenoid B-FAMILY 
derivatives O 
was O 
constructed O 
from O 
a O 
commercially O 
available O 
kaurene B-TRIVIAL 
-type O 
oridonin B-TRIVIAL 
by O 
practical O 
and O 
efficient O 
synthetic O 
methods O 
. O 
These O 
synthetic O 
derivatives O 
were O 
evaluated O 
for O 
their O 
antiproliferative O 
activities O 
against O 
a O 
set O 
of O 
four O 
human O 
cancer O 
cell O 
lines O 
. O 
The O 
IC50 O 
values O 
are O 
similar O 
to O 
or O 
improved O 
over O 
those O 
of O 
the O 
parent O 
molecule O 
and O 
paclitaxel B-TRIVIAL 
, O 
the O 
latter O 
of O 
which O 
was O 
used O 
as O 
a O 
positive O 
control O 
. O 
Compound O 
29 O 
was O 
further O 
investigated O 
for O 
its O 
apoptotic O 
properties O 
against O 
human O 
hepatocarcinoma O 
Bel-7402 O 
cells O 
to O 
better O 
understand O 
its O 
mode O 
of O 
action O 
. O 
Moreover O 
, O 
compound O 
29 O 
was O 
shown O 
to O 
have O 
potent O 
antitumor O 
activity O 
in O 
vivo O 
in O 
studies O 
with O 
a O 
murine O 
model O 
of O 
gastric O 
cancer O 
( O 
MGC-803 O 
mice O 
) O 
. O 
These O 
results O 
warrant O 
further O 
preclinical O 
investigations O 
of O 
these O 
diterpenoid B-FAMILY 
-based O 
analogues O 
as O 
potential O 
novel O 
anticancer O 
chemotherapeutics O 
. O 

induces O 
apoptosis O 
through O 
suppression O 
of O 
JNK O 
signaling O 
pathway O 
in O 
HL-60 O 
cells O 
. O 

( O 
TSN B-ABBREVIATION 
) O 
, O 
a O 
triterpenoid B-FAMILY 
isolated O 
from O 
Melia O 
toosendan O 
Sieb O 
. O 
et O 
Zucc O 
. O 
, O 
has O 
been O 
found O 
to O 
suppress O 
proliferation O 
and O 
induce O 
apoptosis O 
in O 
a O 
variety O 
of O 
human O 
cancer O 
cells O 
. O 
However O 
, O 
the O 
mechanism O 
how O 
TSN B-ABBREVIATION 
induces O 
apoptosis O 
remains O 
poorly O 
understood O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
effects O 
of O 
TSN B-ABBREVIATION 
on O 
the O 
growth O 
, O 
cell O 
cycle O 
arrest O 
, O 
induction O 
of O 
apoptosis O 
and O 
the O 
involved O 
signaling O 
pathway O 
in O 
human O 
promyelocytic O 
leukemia O 
HL-60 O 
cells O 
. O 
Proliferation O 
of O 
HL-60 O 
cells O 
was O 
inhibited O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
with O 
the O 
IC(50 O 
( O 
48 O 
h O 
) O 
) O 
of O 
28 O 
ng O 
/ O 
mL O 
. O 
The O 
growth O 
inhibition O 
was O 
due O 
primarily O 
to O 
the O 
S O 
phase O 
arrest O 
and O 
cell O 
apoptosis O 
. O 
Cell O 
apoptosis O 
induced O 
by O 
TSN B-ABBREVIATION 
was O 
confirmed O 
by O 
Annexin O 
V- O 
FITC B-ABBREVIATION 
/ O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
staining O 
. O 
The O 
increase O 
of O 
the O 
pro O 
- O 
apoptotic O 
protein O 
Bax O 
, O 
cleaved O 
PARP O 
and O 
caspase-3 O 
, O 
and O 
the O 
decrease O 
of O 
anti-apoptotic O 
protein O 
Bcl-2 O 
were O 
observed O 
. O 
Western O 
blot O 
analysis O 
indicated O 
that O 
TSN B-ABBREVIATION 
inhibits O 
the O 
CDC42 O 
/ O 
MEKK1 O 
/ O 
JNK O 
pathway O 
. O 
Taken O 
together O 
, O 
our O 
study O 
suggested O 
, O 
for O 
the O 
first O 
time O 
, O 
that O 
the O 
pro O 
- O 
apoptotic O 
effects O 
of O 
TSN B-ABBREVIATION 
on O 
HL-60 O 
cells O 
were O 
mediated O 
through O 
JNK O 
signaling O 
pathway O 
. O 

Gene O 
Expression O 
in O 
the O 
Liver O 
of O 
Streptozotocin B-TRIVIAL 
-induced O 
and O 
Spontaneous O 
Type O 
1 O 
Diabetic O 
Rats O 
. O 

investigations O 
have O 
shown O 
a O 
relation O 
between O 
diabetes O 
and O 
alterations O 
of O 
the O 
liver O 
circadian O 
clock O 
. O 
We O 
investigated O 
the O 
diurnal O 
expression O 
of O 
clock O 
genes O 
and O 
clock O 
- O 
controlled O 
genes O 
( O 
CCGs O 
) O 
in O 
3-hour O 
intervals O 
for O 
a O 
24-h O 
period O 
in O 
the O 
livers O 
of O 
male O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
) O 
- O 
treated O 
rats O 
, O 
male O 
spontaneous O 
type O 
1 O 
diabetic O 
LEW.1AR1-iddm O 
( O 
Iddm O 
) O 
rats O 
, O 
and O 
Iddm O 
rats O 
treated O 
for O 
10 O 
days O 
with O 
insulin O 
. O 
Hepatic O 
mRNA O 
was O 
extracted O 
, O 
and O 
the O 
relative O 
expression O 
of O 
clock O 
genes O 
( O 
Per1 O 
, O 
Per2 O 
, O 
Bmal1 O 
, O 
Clock O 
, O 
Cry1 O 
) O 
, O 
as O 
well O 
as O 
CCGs O 
( O 
Dbp O 
, O 
E4bp4 O 
, O 
RevErbα O 
, O 
Rorα O 
, O 
Pparγ O 
) O 
, O 
was O 
analyzed O 
by O 
reverse O 
transcription O 
followed O 
by O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
. O 
Diabetic O 
STZ B-ABBREVIATION 
and O 
Iddm O 
rats O 
, O 
as O 
well O 
as O 
insulin O 
- O 
substituted O 
Iddm O 
rats O 
, O 
exhibited O 
a O 
significant O 
diurnal O 
expression O 
pattern O 
of O 
clock O 
genes O 
as O 
determined O 
by O 
Cosinor O 
analysis O 
; O 
however O 
, O 
the O 
MESOR O 
( O 
midline O 
estimating O 
statistic O 
of O 
rhythm O 
) O 
of O 
Bmal1 O 
, O 
Per2 O 
, O 
and O 
Clock O 
transcript O 
expression O 
was O 
altered O 
in O 
Iddm O 
and O 
insulin O 
- O 
substituted O 
Iddm O 
rats O 
. O 
The O 
hepatic O 
expression O 
of O 
the O 
CCGs O 
Dbp O 
and O 
RevErbα O 
revealed O 
a O 
diurnal O 
rhythm O 
in O 
all O 
investigated O 
groups O 
. O 
Insulin O 
administration O 
to O 
Iddm O 
rats O 
normalized O 
the O 
enhanced O 
MESOR O 
in O 
the O 
expression O 
of O 
Dbp O 
, O 
RevErbα O 
, O 
and O 
E4bp4 O 
to O 
the O 
levels O 
of O 
normoglycemic O 
controls O 
. O 
Cosinor O 
analysis O 
indicated O 
no O 
diurnal O 
rhythm O 
of O 
Pparγ O 
expression O 
in O 
the O 
livers O 
of O 
diabetic O 
STZ B-ABBREVIATION 
or O 
Iddm O 
rats O 
or O 
in O 
those O 
of O 
insulin O 
- O 
substituted O 
Iddm O 
rats O 
. O 
Also O 
, O 
insulin O 
substitution O 
could O 
not O 
reverse O 
the O 
decreased O 
MESOR O 
of O 
Pparγ O 
expression O 
in O 
Iddm O 
rats O 
. O 
In O 
consequence O 
of O 
the O 
diabetic O 
disease O 
, O 
changes O 
in O 
the O 
expression O 
of O 
clock O 
genes O 
and O 
CCGs O 
suggest O 
alterations O 
in O 
the O 
hepatic O 
peripheral O 
clock O 
mechanism O 
. O 

A I-TRIVIAL 
reverses O 
P-glycoprotein O 
- O 
mediated O 
multidrug O 
resistance O 
of O 
MCF7 O 
/ O 
ADR O 
cells O 
by O 
G2 O 
/ O 
M O 
arrest O 
. O 

A I-TRIVIAL 
is O 
a O 
naturally O 
occurring O 
monoflavonoid B-FAMILY 
isolated O 
from O 
the O 
root O 
of O 
Scutellaria O 
baicalensis O 
Georgi O 
, O 
which O 
has O 
been O 
used O 
in O 
traditional O 
Chinese O 
medicine O 
for O 
its O 
anti-tumor O 
, O 
anti-inflammatory O 
and O 
anti-bacterial O 
properties O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
reversal O 
effect O 
and O 
the O 
fundamental O 
mechanisms O 
of O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
in O 
MCF7 O 
/ O 
ADR O 
cells O 
. O 
Data O 
indicated O 
that O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
showed O 
strong O 
reversal O 
potency O 
in O 
MCF7 O 
/ O 
ADR O 
cells O 
and O 
the O 
reversal O 
fold O 
( O 
RF O 
) O 
reached O 
4.68 O 
. O 
After O 
treatment O 
with O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
, O 
MCF7 O 
/ O 
ADR O 
cells O 
displayed O 
reduced O 
functional O 
activity O 
and O 
expression O 
of O 
MDR1 O 
at O 
both O 
the O 
protein O 
and O 
mRNA O 
levels O 
. O 
Meanwhile O 
, O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
induced O 
cells O 
G2 O 
/ O 
M O 
arrest O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
by O 
increasing O 
the O 
expression O 
of O 
p-Chk2 O 
( O 
Thr68 O 
) O 
. O 
Moreover O 
, O 
western O 
blot O 
and O 
EMSA O 
assays O 
were O 
used O 
to O 
reveal O 
the O 
inhibition O 
of O 
NF-κB O 
in O 
nucleus O 
and O 
the O 
suppression O 
of O 
NF-κB O 
binding O 
activity O 
by O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
. O 
NSC B-IDENTIFIER 
109555 I-IDENTIFIER 
ditosylate I-IDENTIFIER 
-Chk2 O 
inhibitor O 
partly O 
dismissed O 
G2 O 
/ O 
M O 
arrest O 
induced O 
by O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
, O 
reversed O 
the O 
increased O 
trend O 
of O 
p-Chk2 O 
and O 
p-P53 O 
( O 
Ser20 O 
) O 
, O 
inhibited O 
the O 
decreasing O 
effect O 
of O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
on O 
the O 
expression O 
of O 
P-gp O 
and O 
decreased O 
the O 
reversal O 
fold O 
of O 
90μM O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
from O 
4.68 O 
fold O 
to O 
1.73 O 
fold O 
. O 
In O 
conclusion O 
, O 
we O 
suggested O 
that O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
reversed O 
MDR O 
by O 
G2 O 
/ O 
M O 
arrest O 
and O 
the O 
underlying O 
mechanism O 
attributed O 
to O 
the O 
suppression O 
of O 
P-gp O 
expression O 
via O 
Chk2 O 
/ O 
P53 O 
/ O 
NF-κB O 
signaling O 
pathway O 
. O 

acid I-TRIVIAL 
biosynthesis O 
catalyzed O 
by O 
retinal B-TRIVIAL 
dehydrogenases O 
relies O 
on O 
a O 
rate O 
- O 
limiting O 
conformational O 
transition O 
associated O 
with O 
substrate O 
recognition O 
. O 

acid I-TRIVIAL 
( O 
RA O 
) O 
, O 
a O 
metabolite O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
, O 
exerts O 
pleiotropic O 
effects O 
throughout O 
life O 
in O 
vertebrate O 
organisms O 
. O 
Thus O 
, O 
RA O 
action O 
must O 
be O 
tightly O 
regulated O 
through O 
the O 
coordinated O 
action O 
of O 
biosynthetic O 
and O 
degrading O 
enzymes O 
. O 
The O 
last O 
step O 
of O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
biosynthesis O 
is O 
irreversibly O 
catalyzed O 
by O 
the O 
NAD B-ABBREVIATION 
-dependent O 
retinal B-TRIVIAL 
dehydrogenases O 
( O 
RALDH O 
) O 
, O 
which O 
are O 
members O 
of O 
the O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
) O 
superfamily O 
. O 
Low O 
intracellular O 
retinal B-TRIVIAL 
concentrations O 
imply O 
efficient O 
substrate O 
molecular O 
recognition O 
to O 
ensure O 
high O 
affinity O 
and O 
specificity O 
of O 
RALDHs O 
for O 
retinal B-TRIVIAL 
. O 
This O 
study O 
addresses O 
the O 
molecular O 
basis O 
of O 
retinal B-TRIVIAL 
recognition O 
in O 
human O 
ALDH1A1 O 
( O 
or O 
RALDH1 O 
) O 
and O 
rat O 
ALDH1A2 O 
( O 
or O 
RALDH2 O 
) O 
, O 
through O 
the O 
comparison O 
of O 
the O 
catalytic O 
behavior O 
of O 
retinal B-TRIVIAL 
analogs O 
and O 
use O 
of O 
the O 
fluorescence O 
properties O 
of O 
retinol B-TRIVIAL 
. O 
We O 
show O 
that O 
, O 
in O 
contrast O 
to O 
long O 
chain O 
unsaturated O 
substrates O 
, O 
the O 
rate O 
- O 
limiting O 
step O 
of O 
retinal B-TRIVIAL 
oxidation O 
by O 
RALDHs O 
is O 
associated O 
with O 
acylation O 
. O 
Use O 
of O 
the O 
fluorescence O 
resonance O 
energy O 
transfer O 
upon O 
retinol B-TRIVIAL 
interaction O 
with O 
RALDHs O 
provides O 
evidence O 
that O 
retinal B-TRIVIAL 
recognition O 
occurs O 
in O 
two O 
steps O 
: O 
binding O 
into O 
the O 
substrate O 
access O 
channel O 
, O 
and O 
a O 
slower O 
structural O 
reorganization O 
with O 
a O 
rate O 
constant O 
of O 
the O 
same O 
magnitude O 
as O 
the O 
kcat O 
for O 
retinal B-TRIVIAL 
oxidation O 
: O 
0.18 O 
vs O 
. O 
0.07 O 
and O 
0.25 O 
vs O 
. O 
0.1 O 
s(-1) O 
for O 
ALDH1A1 O 
and O 
ALDH1A2 O 
, O 
respectively O 
. O 
This O 
suggests O 
that O 
the O 
conformational O 
transition O 
of O 
the O 
RALDH- O 
retinal B-TRIVIAL 
complex O 
significantly O 
contributes O 
to O 
the O 
rate O 
- O 
limiting O 
step O 
that O 
controls O 
the O 
kinetics O 
of O 
retinal B-TRIVIAL 
oxidation O 
, O 
as O 
a O 
prerequisite O 
for O 
the O 
formation O 
of O 
a O 
catalytically O 
competent O 
Michaelis O 
complex O 
. O 
This O 
conclusion O 
is O 
consistent O 
with O 
the O 
general O 
notion O 
that O 
structural O 
flexibility O 
within O 
the O 
active O 
site O 
of O 
ALDH O 
enzymes O 
has O 
been O 
shown O 
to O 
be O 
an O 
integral O 
component O 
of O 
catalysis O 
. O 

Modified O 
oligodeoxyribonucleotides O 
for O 
the O 
study O 
of O 
2-deoxyribose B-SYSTEMATIC 
damage O 
in O 
DNA O 
. O 

- O 
defined O 
substrates O 
for O 
the O 
study O 
of O 
oxidative O 
processes O 
are O 
important O 
for O 
the O 
elucidation O 
of O 
the O 
role O 
of O 
DNA O 
damage O 
in O 
the O 
etiology O 
of O 
diseases O 
such O 
as O 
cancer O 
. O 
We O 
have O 
synthesized O 
3'- O 
modified O 
oligodeoxyribonucleotides O 
( O 
ODNs O 
) O 
using O 
5'→3 O 
' O 
' O 
reverse O 
' O 
DNA O 
synthesis O 
for O 
the O 
study O 
of O 
2-deoxyribose B-SYSTEMATIC 
oxidative O 
damage O 
to O 
DNA O 
. O 
The O 
modified O 
monomers O 
designed O 
for O 
these O 
studies O 
all O 
share O 
a O 
common O 
feature O 
, O 
they O 
lack O 
the O 
naturally O 
occurring O 
3'-hydroxyl B-SYSTEMATIC 
group O 
found O 
in O 
2-deoxyribonucleosides B-FAMILY 
. O 
Modified O 
H-phosphonates B-FAMILY 
containing O 
3'-phenyl B-FAMILY 
selenides I-FAMILY 
as O 
well O 
as O 
saturated B-MULTIPLE 
and I-MULTIPLE 
unsaturated I-MULTIPLE 
sugars I-MULTIPLE 
were O 
obtained O 
and O 
incorporated O 
in O 
ODNs B-FAMILY 
. O 
These O 
ODNs B-FAMILY 
were O 
used O 
to O 
investigate O 
the O 
fate O 
of O 
C3'-dideoxyribonucleotide B-FAMILY 
radicals O 
in O 
DNA O 
. O 

and O 
biological O 
evaluation O 
of O 
prodrugs O 
of O 
2-fluoro-2-deoxyribose-1-phosphate B-SYSTEMATIC 
and O 
2,2-difluoro-2-deoxyribose-1-phosphate B-SYSTEMATIC 
. O 

report O 
in O 
this O 
Letter O 
the O 
synthesis O 
of O 
prodrugs O 
of O 
2-fluoro-2-deoxyarabinose-1-phosphate B-SYSTEMATIC 
and O 
2,2-difluoro-2-deoxyribose-1-phosphate B-SYSTEMATIC 
. O 
We O 
demonstrate O 
the O 
difficulty O 
of O 
realising O 
a O 
phosphorylation O 
step O 
on O 
the O 
anomeric O 
position O 
of O 
2-deoxyribose B-SYSTEMATIC 
, O 
and O 
we O 
discover O 
that O 
introduction O 
of O 
fluorine B-SYSTEMATIC 
atoms O 
on O 
the O 
2 O 
position O 
of O 
2-deoxyribose B-SYSTEMATIC 
enables O 
the O 
phosphorylation O 
step O 
: O 
in O 
fact O 
, O 
the O 
stability O 
of O 
the O 
prodrugs O 
increases O 
with O 
the O 
degree O 
of O 
2-fluorination O 
. O 
Stability O 
studies O 
of O 
produgs O 
of O 
2-fluoro-2-deoxyribose-1-phosphate B-SYSTEMATIC 
and O 
2,2-difluoro-2-deoxyribose-1-phosphate B-SYSTEMATIC 
in O 
acidic O 
and O 
neutral O 
conditions O 
were O 
conducted O 
to O 
confirm O 
our O 
observation O 
. O 
Biological O 
evaluation O 
of O 
prodrugs O 
of O 
2,2-difluoro-2-deoxyribose-1-phosphate B-SYSTEMATIC 
for O 
antiviral O 
and O 
cytotoxic O 
activity O 
is O 
reported O 
. O 

effects O 
of O 
amphetamine B-TRIVIAL 
mixtures O 
in O 
primary O 
hepatocytes O 
are O 
severely O 
aggravated O 
under O 
hyperthermic O 
conditions O 
. O 

consumers O 
are O 
often O 
, O 
deliberately O 
or O 
not O 
, O 
polydrug O 
abusers O 
. O 
Predicting O 
combination O 
effects O 
based O 
on O 
concentration O 
- O 
response O 
analysis O 
of O 
individual O 
components O 
is O 
a O 
valid O 
strategy O 
for O 
accurate O 
toxicological O 
assessment O 
of O 
mixtures O 
. O 
We O 
previously O 
reported O 
that O 
joint O 
effects O 
of O 
3,4-methylenedioxymethamphetamine B-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
, O 
ecstasy B-TRIVIAL 
) O 
and O 
three O 
other O 
often O 
co O 
- O 
ingested O 
amphetamines B-FAMILY 
( O 
methamphetamine B-TRIVIAL 
, O 
4-methylthyoamphetamine B-SYSTEMATIC 
and O 
D-amphetamine B-TRIVIAL 
) O 
could O 
be O 
predicted O 
by O 
the O 
concentration O 
addition O 
( O 
CA O 
) O 
model O 
in O 
HepG2 O 
cells O 
. O 
We O 
sought O 
to O 
further O 
evaluate O 
the O 
relevance O 
of O 
these O 
findings O 
by O 
extending O 
these O 
studies O 
to O 
a O 
cell O 
model O 
that O 
more O 
closely O 
mimics O 
the O 
in O 
vivo O 
situation O 
. O 
Detailed O 
cytotoxic O 
information O 
of O 
the O 
four O 
individual O 
amphetamines B-FAMILY 
on O 
primary O 
rat O 
hepatocytes O 
was O 
recorded O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
, O 
at O 
37°C O 
and O 
40.5°C O 
, O 
simulating O 
the O 
rise O 
in O 
body O 
temperature O 
that O 
could O 
be O 
induced O 
following O 
amphetamine B-TRIVIAL 
intake O 
. O 
Mixture O 
expectations O 
were O 
calculated O 
using O 
CA O 
and O 
independent O 
action O 
( O 
IA O 
) O 
models O 
. O 
At O 
37°C O 
, O 
concentration O 
- O 
dependent O 
cytotoxicity O 
occurred O 
for O 
the O 
drugs O 
individually O 
and O 
combined O 
. O 
Mixture O 
effects O 
were O 
accurately O 
predicted O 
by O 
the O 
CA O 
model O 
, O 
while O 
the O 
IA O 
model O 
underestimated O 
cytotoxicity O 
. O 
At O 
40.5°C O 
these O 
cytotoxic O 
effects O 
were O 
aggravated O 
. O 
Our O 
findings O 
provide O 
evidence O 
of O 
the O 
increased O 
risks O 
associated O 
with O 
the O 
abuse O 
of O 
amphetamine B-TRIVIAL 
mixtures O 
, O 
especially O 
during O 
hyperthermia O 
, O 
emphasising O 
the O 
need O 
to O 
increase O 
awareness O 
of O 
misinformed O 
users O 
who O 
believe O 
these O 
drugs O 
are O 
safe O 
. O 

role O 
of O 
diallyl B-FAMILY 
sulfides I-FAMILY 
and O 
dipropyl B-FAMILY 
sulfides I-FAMILY 
in O 
the O 
in O 
vitro O 
antimicrobial O 
activity O 
of O 
the O 
essential O 
oil O 
of O 
garlic O 
, O 
Allium O 
sativum O 
L O 
. O 
, O 
and O 
Leek O 
, O 
Allium O 
porrum O 
L O 
. O 

in O 
vitro O 
antibacterial O 
activity O 
of O 
essential O 
oils O 
( O 
EOs O 
) O 
obtained O 
from O 
fresh O 
bulbs O 
of O 
garlic O 
, O 
Allium O 
sativum O 
L O 
. O 
, O 
and O 
leek O 
, O 
Allium O 
porrum O 
L O 
. O 
( O 
Alliaceae O 
) O 
, O 
was O 
studied O 
. O 
A O 
. O 
sativum O 
( O 
garlic O 
) O 
EO O 
showed O 
a O 
good O 
antimicrobial O 
activity O 
against O 
Staphylococcus O 
aureus O 
( O 
inhibition O 
zone O 
14.8 O 
mm O 
) O 
, O 
Pseudomonas O 
aeruginosa O 
( O 
inhibition O 
zone O 
21.1 O 
mm O 
) O 
, O 
and O 
Escherichia O 
coli O 
( O 
inhibition O 
zone O 
11 O 
mm O 
) O 
, O 
whereas O 
the O 
EO O 
of O 
A O 
. O 
porrum O 
( O 
leek O 
) O 
had O 
no O 
antimicrobial O 
activity O 
. O 
The O 
main O 
constituents O 
of O 
the O 
garlic O 
EO O 
were O 
diallyl B-SYSTEMATIC 
monosulfide I-SYSTEMATIC 
, O 
diallyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
DADS B-ABBREVIATION 
) O 
, O 
diallyl B-SYSTEMATIC 
trisulfide I-SYSTEMATIC 
, O 
and O 
diallyl B-SYSTEMATIC 
tetrasulfide I-SYSTEMATIC 
. O 
The O 
EO O 
of O 
A O 
. O 
porrum O 
was O 
characterized O 
by O 
the O 
presence O 
of O 
dipropyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
DPDS B-ABBREVIATION 
) O 
, O 
dipropyl B-SYSTEMATIC 
trisulfide I-SYSTEMATIC 
, O 
and O 
dipropyl B-SYSTEMATIC 
tetrasulfide I-SYSTEMATIC 
. O 
The O 
antimicrobial O 
activities O 
of O 
the O 
DADS B-ABBREVIATION 
and O 
DPDS B-ABBREVIATION 
were O 
also O 
studied O 
. O 
The O 
results O 
obtained O 
suggest O 
that O 
the O 
presence O 
of O 
the O 
allyl B-SYSTEMATIC 
group O 
is O 
fundamental O 
for O 
the O 
antimicrobial O 
activity O 
of O 
these O 
sulfide B-SYSTEMATIC 
derivatives O 
when O 
they O 
are O 
present O 
in O 
Allium O 
or O 
in O 
other O 
species O 
( O 
DADS B-ABBREVIATION 
inhibition O 
zone O 
on O 
S O 
. O 
aureus O 
15.9 O 
mm O 
, O 
P O 
. O 
aeruginosa O 
21.9 O 
mm O 
, O 
E O 
. O 
coli O 
11.4 O 
mm O 
) O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
benzofurano[3,2-d]pyrimidin-2-ones B-FAMILY 
, O 
a O 
new O 
series O 
of O 
HIV-1 O 
nucleotide B-FAMILY 
-competing O 
reverse O 
transcriptase O 
inhibitors O 
. O 

of O 
our O 
sample O 
collection O 
led O 
to O 
the O 
identification O 
of O 
a O 
set O 
of O 
benzofurano[3,2-d]pyrimidine-2-one B-SYSTEMATIC 
hits O 
acting O 
as O 
nucleotide B-FAMILY 
-competing O 
HIV-1 O 
reverse O 
transcriptase O 
inhibitiors O 
( O 
NcRTI O 
) O 
. O 
Significant O 
improvement O 
in O 
antiviral O 
potency O 
was O 
achieved O 
when O 
substituents O 
were O 
introduced O 
at O 
positions O 
N1 O 
, O 
C4 O 
, O 
C7 O 
and O 
C8 O 
on O 
the O 
benzofuranopyrimidone B-SYSTEMATIC 
scaffold O 
. O 
The O 
series O 
was O 
optimized O 
from O 
low O 
micromolar O 
enzymatic O 
activity O 
against O 
HIV-1 O 
RT O 
and O 
no O 
antiviral O 
activity O 
to O 
low O 
nanomolar O 
antiviral O 
potency O 
. O 
Further O 
profiling O 
of O 
inhibitor O 
30 O 
showed O 
promising O 
overall O 
in O 
vitro O 
properties O 
and O 
also O 
demonstrated O 
that O 
its O 
potency O 
was O 
maintained O 
against O 
viruses O 
resistant O 
to O 
the O 
other O 
major O 
classes O 
of O 
HIV-1 O 
RT O 
inhibitors O 
. O 

extracted O 
from O 
the O 
skin O 
of O 
unicorn O 
leatherjacket O 
at O 
different O 
temperatures O 
( O 
45 O 
, O 
55 O 
, O 
65 O 
and O 
75°C O 
) O 
in O 
the O 
presence O 
and O 
the O 
absence O 
of O 
soybean O 
trypsin B-TRIVIAL 
inhibitor O 
( O 
SBTI O 
; O 
100 O 
units O 
/ O 
g O 
pretreated O 
skin O 
) O 
for O 
12h O 
were O 
characterised O 
. O 
In O 
general O 
, O 
the O 
addition O 
of O 
SBTI O 
resulted O 
in O 
the O 
lower O 
yield O 
, O 
regardless O 
of O 
extraction O 
temperature O 
. O 
Higher O 
yield O 
was O 
obtained O 
when O 
higher O 
extraction O 
temperature O 
was O 
used O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Gelatin O 
from O 
skin O 
extracted O 
at O 
75°C O 
in O 
the O 
absence O 
of O 
SBTI O 
showed O 
the O 
highest O 
yield O 
( O 
10.66 O 
± O 
0.41% O 
) O 
( O 
based O 
on O 
dry O 
weight O 
) O 
. O 
The O 
highest O 
α-amino B-SYSTEMATIC 
group O 
content O 
was O 
observed O 
in O 
gelatin O 
extracted O 
at O 
55°C O 
without O 
SBTI O 
incorporated O 
. O 
The O 
band O 
intensity O 
of O 
β-chain O 
and O 
α- O 
chains O 
increased O 
as O 
the O 
extraction O 
temperature O 
increased O 
, O 
particularly O 
above O 
55°C O 
. O 
Gelatin O 
extracted O 
at O 
65°C O 
with O 
and O 
without O 
SBTI O 
incorporation O 
exhibited O 
the O 
highest O 
gel O 
strength O 
( O 
178 O 
± O 
7.5 O 
g O 
and O 
170.47 O 
± O 
1.3 O 
g O 
, O 
respectively O 
) O 
. O 
FTIR O 
spectra O 
indicated O 
that O 
a O 
greater O 
loss O 
of O 
molecular O 
order O 
of O 
triple O 
helix O 
with O 
a O 
higher O 
degradation O 
was O 
found O 
in O 
gelatin O 
extracted O 
at O 
55°C O 
in O 
the O 
absence O 
SBTI O 
. O 
Gelatin O 
extracted O 
at O 
65°C O 
, O 
either O 
with O 
or O 
without O 
SBTI O 
, O 
had O 
the O 
highest O 
EAI O 
and O 
ESI O 
with O 
high O 
foam O 
expansion O 
and O 
stability O 
. O 
Thus O 
, O 
the O 
extraction O 
of O 
gelatin O 
from O 
the O 
skin O 
of O 
unicorn O 
leatherjacket O 
at O 
temperature O 
sufficiently O 
high O 
could O 
render O 
the O 
gelatin O 
with O 
less O 
degradation O 
. O 

- O 
release O 
prednisone B-TRIVIAL 
decreases O 
complaints O 
and O 
fatigue O 
compared O 
to O 
standard O 
prednisolone B-TRIVIAL 
in O 
patients O 
with O 
adrenal O 
insufficiency O 
. O 

with O 
adrenal O 
insufficiency O 
( O 
AI O 
) O 
receive O 
first O 
glucocorticoid O 
replacement O 
dose O 
after O 
waking O 
, O 
resulting O 
in O 
a O 
3-5 O 
h O 
delay O 
compared O 
to O 
physiological O 
secretion O 
. O 
Impaired O 
quality O 
of O 
life O 
( O 
QoL O 
) O 
and O 
fatigue O 
might O 
be O 
due O 
to O 
this O 
delayed O 
dose O 
scheme O 
. O 
Modified O 
- O 
release O 
glucocorticoid O 
preparations O 
might O 
have O 
therapeutic O 
advantages O 
. O 
Exploratory O 
pilot O 
study O 
including O 
14 O 
patients O 
with O 
AI O 
was O 
conducted O 
in O 
a O 
single O 
university O 
center O 
. O 
Patients O 
on O 
morning O 
dose O 
prednisolone B-TRIVIAL 
( O 
5 O 
mg O 
) O 
were O 
included O 
, O 
switched O 
to O 
modified O 
- O 
release O 
prednisone B-TRIVIAL 
( O 
5 O 
mg O 
) O 
at O 
10 O 
PM O 
for O 
3 O 
months O 
, O 
and O 
then O 
switched O 
back O 
on O 
standard O 
prednisolone B-TRIVIAL 
. O 
3 O 
standardized O 
questionnaires O 
( O 
GBB-24 O 
, O 
MFI O 
, O 
and O 
AddiQoL O 
) O 
investigating O 
complaints O 
and O 
fatigue O 
were O 
completed O 
at O 
baseline O 
, O 
after O 
3 O 
, O 
and O 
6 O 
months O 
. O 
Data O 
regarding O 
clinical O 
and O 
hormonal O 
parameters O 
were O 
assessed O 
. O 
Modified O 
- O 
release O 
prednisone B-TRIVIAL 
showed O 
significant O 
improvement O 
in O 
one O 
of O 
4 O 
scales O 
of O 
GBB-24 O 
and O 
positive O 
trends O 
to O 
better O 
scores O 
in O 
3 O 
of O 
4 O 
scales O 
. O 
The O 
global O 
score O 
of O 
discomfort O 
improved O 
significantly O 
. O 
The O 
MFI O 
showed O 
also O 
significant O 
improvement O 
in O 
3 O 
of O 
5 O 
scales O 
and O 
positive O 
trend O 
to O 
better O 
scores O 
in O 
2 O 
scales O 
. O 
Significant O 
changes O 
to O 
better O 
scores O 
were O 
seen O 
in O 
4 O 
out O 
of O 
30 O 
items O 
of O 
the O 
AddiQoL O 
. O 
Modified O 
- O 
release O 
prednisone B-TRIVIAL 
showed O 
decreased O 
complaints O 
and O 
fatigue O 
compared O 
to O 
standard O 
prednisolone B-TRIVIAL 
indicating O 
importance O 
of O 
glucocorticoid O 
increase O 
in O 
early O 
morning O 
hours O 
before O 
waking O 
. O 

the O 
Lattice O 
Strain O 
Dependence O 
of O 
Monolayer O 
Pt B-FORMULA 
Shell O 
Activity O 
toward O 
Oxygen B-SYSTEMATIC 
Reduction O 
. O 

strain O 
of O 
Pt B-FORMULA 
-based O 
catalysts O 
reflecting O 
d-band O 
status O 
is O 
the O 
decisive O 
factor O 
of O 
their O 
catalytic O 
activity O 
toward O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
. O 
For O 
the O 
newly O 
arisen O 
monolayer O 
Pt B-FORMULA 
system O 
, O 
however O 
, O 
no O 
general O 
strategy O 
to O 
isolate O 
the O 
lattice O 
strain O 
has O 
been O 
achieved O 
due O 
to O 
the O 
short O 
- O 
range O 
ordering O 
structure O 
of O 
monolayer O 
Pt B-FORMULA 
shells O 
on O 
different O 
facets O 
of O 
core O 
nanoparticles O 
. O 
Herein O 
, O 
based O 
on O 
the O 
extended O 
X-ray O 
absorption O 
fine O 
structure O 
of O 
monolayer O 
Pt B-FORMULA 
atoms O 
on O 
various O 
single O 
crystal O 
facets O 
, O 
we O 
propose O 
an O 
effective O 
methodology O 
for O 
evaluating O 
the O 
lattice O 
strain O 
of O 
monolayer O 
Pt B-FORMULA 
shells O 
on O 
core O 
nanoparticles O 
. O 
The O 
quantitative O 
lattice O 
strain O 
establishes O 
a O 
direct O 
correlation O 
to O 
monolayer O 
Pt B-FORMULA 
shell O 
ORR O 
activity O 
. O 

profiling O 
of O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
in O 
rat O 
urine O 
and O 
faeces O 
after O 
oral O 
administration O 
. O 

oral O 
administration O 
of O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
, O 
the O 
compound O 
and O 
its O 
metabolites O 
were O 
identified O 
and O 
quantified O 
in O 
rat O 
urine O 
and O 
faeces O 
by O 
liquid O 
chromatography O 
coupled O 
with O 
triple O 
quadrupole O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
. O 
Ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
( O 
200 O 
mg O 
/ O 
kg O 
) O 
was O 
orally O 
administered O 
to O 
rats O 
by O 
gastric O 
intubation O 
, O 
and O 
urine O 
and O 
faeces O 
samples O 
were O 
then O 
collected O 
during O 
the O 
next O 
24 O 
h O 
using O 
metabolic O 
cages O 
. O 
Samples O 
were O 
prepared O 
by O 
solid O 
phase O 
extraction O 
and O 
analysed O 
by O 
LC-MS O 
/ O 
MS O 
. O 
The O 
precursor O 
- O 
product O 
ion O 
pairs O 
used O 
for O 
LC-MS O 
/ O 
MS O 
analysis O 
were O 
: O 
m O 
/ O 
z O 
945→475 O 
for O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
, O 
799→637 O 
for O 
ginsenoside B-TRIVIAL 
Rg1 I-TRIVIAL 
, O 
783→475 O 
for O 
ginsenoside B-TRIVIAL 
Rg2 I-TRIVIAL 
, O 
637→475 O 
for O 
ginsenosides B-MULTIPLE 
Rh1 I-MULTIPLE 
and I-MULTIPLE 
F1 I-MULTIPLE 
, O 
475→391 O 
for O 
protopanaxatriol B-TRIVIAL 
, O 
and O 
779→641 O 
for O 
digoxin B-TRIVIAL 
( O 
internal O 
standard O 
) O 
. O 
The O 
major O 
ginsenosides B-FAMILY 
excreted O 
in O 
urine O 
were O 
ginsenosides B-MULTIPLE 
Re I-MULTIPLE 
and I-MULTIPLE 
Rg1 I-MULTIPLE 
, O 
and O 
only O 
minimal O 
amounts O 
of O 
ginsenosides B-MULTIPLE 
Rg2 I-MULTIPLE 
and I-MULTIPLE 
Rh1 I-MULTIPLE 
were O 
found O 
. O 
Greater O 
amounts O 
of O 
ginsenoside B-FAMILY 
metabolites O 
were O 
detected O 
in O 
the O 
faeces O 
samples O 
; O 
biotransformation O 
to O 
ginsenoside B-TRIVIAL 
Rg1 I-TRIVIAL 
was O 
predominant O 
but O 
further O 
deglycosylated O 
metabolites O 
including O 
ginsenoside B-TRIVIAL 
F1 I-TRIVIAL 
and O 
protopanaxatriol B-TRIVIAL 
were O 
additionally O 
detected O 
. O 
The O 
total O 
recovery O 
of O 
ginsenosides B-FAMILY 
over O 
24 O 
h O 
was O 
approximately O 
46% O 
. O 

embeurekols I-FAMILY 
from O 
Embellisia O 
eureka O 
, O 
an O 
endophyte O 
of O 
Cladanthus O 
arabicus O 
. O 

new O 
polyketides O 
( O 
(-)-1 O 
, O 
(+)-1 O 
, O 
and O 
2 O 
) O 
were O 
isolated O 
from O 
the O 
EtOAc B-FORMULA 
extract O 
of O 
the O 
fungus O 
Embellisia O 
eureka O 
, O 
an O 
endophyte O 
of O 
the O 
Moroccan O 
plant O 
Cladanthus O 
arabicus O 
( O 
Asteraceae O 
) O 
. O 
The O 
structures O 
of O 
these O 
new O 
compounds O 
were O 
determined O 
on O 
the O 
basis O 
of O 
one- O 
and O 
two O 
- O 
dimensional O 
NMR O 
spectroscopy O 
as O 
well O 
as O 
by O 
high O 
- O 
resolution O 
mass O 
spectrometry O 
. O 
The O 
absolute O 
configurations O 
of O 
(-)-1 O 
, O 
(+)-1 O 
, O 
and O 
2 O 
were O 
determined O 
by O 
TDDFT O 
ECD O 
calculations O 
of O 
solution O 
conformers O 
, O 
online O 
HPLC-ECD O 
analysis O 
, O 
and O 
the O 
modified O 
Mosher O 
method O 
. O 

hydrochloride I-SYSTEMATIC 
selectively O 
inhibits O 
human O 
ovarian O 
cancer O 
cell O 
proliferation O 
and O 
tumor O 
neovascularization O 
with O 
very O 
low O 
toxicity O 
. O 

tumor O 
cell O 
proliferation O 
and O 
robust O 
neovascularization O 
are O 
prominent O 
features O 
of O 
aggressive O 
ovarian O 
cancers O 
. O 
Although O 
great O 
efforts O 
in O 
anti-ovarian O 
cancer O 
therapy O 
have O 
been O 
made O 
in O 
the O 
past O 
4 O 
decades O 
, O 
the O 
5-year O 
survival O 
rates O 
for O 
ovarian O 
cancer O 
patients O 
are O 
still O 
poor O 
, O 
and O 
effective O 
drugs O 
to O 
cure O 
ovarian O 
cancer O 
patients O 
are O 
absent O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
anti-cancer O 
effects O 
of O 
lycorine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
LH O 
) O 
, O 
a O 
novel O 
anti-ovarian O 
cancer O 
agent O 
, O 
using O 
the O 
highly O 
- O 
invasive O 
ovarian O 
cancer O 
cell O 
line O 
, O 
Hey1B O 
, O 
as O 
a O 
model O 
. O 
Our O 
data O 
showed O 
that O 
LH O 
effectively O 
inhibited O 
mitotic O 
proliferation O 
of O 
Hey1B O 
cells O 
( O 
half O 
maximal O 
inhibitory O 
concentration=1.2μM O 
) O 
with O 
very O 
low O 
toxicity O 
, O 
resulting O 
in O 
cell O 
cycle O 
arrest O 
at O 
the O 
G2 O 
/ O 
M O 
transition O 
through O 
enhanced O 
expression O 
of O 
the O 
cell O 
cycle O 
inhibitor O 
p21 O 
and O 
marked O 
down O 
- O 
regulation O 
of O 
cyclin O 
D3 O 
expression O 
. O 
Moreover O 
, O 
LH O 
suppressed O 
both O 
the O 
formation O 
of O 
capillary O 
- O 
like O 
tubes O 
by O 
Hey1B O 
cells O 
cultured O 
in O 
vitro O 
and O 
the O 
ovarian O 
cancer O 
cell O 
- O 
dominant O 
neovascularization O 
in O 
vivo O 
when O 
administered O 
to O 
Hey1B-xenotransplanted O 
mice O 
. O 
LH O 
also O 
suppressed O 
the O 
expression O 
of O 
several O 
key O 
angiogenic O 
genes O 
, O 
including O 
VE-cadherin O 
, O 
vascular O 
endothelial O 
growth O 
factor O 
, O 
and O 
Sema4D O 
, O 
and O 
reduced O 
Akt O 
phosphorylation O 
in O 
Hey1B O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
LH O 
selectively O 
inhibits O 
ovarian O 
cancer O 
cell O 
proliferation O 
and O 
neovascularization O 
and O 
is O 
a O 
potential O 
drug O 
candidate O 
for O 
anti-ovarian O 
cancer O 
therapy O 
. O 

receptors O 
are O 
targets O 
for O 
a O 
wide O 
range O 
of O 
ligands O 
, O 
both O 
natural O 
and O 
synthetic O 
, O 
that O 
regulate O 
their O 
activity O 
and O 
provide O 
a O 
means O 
to O 
pharmacologically O 
modulate O 
the O 
receptor O 
. O 
Recent O 
emphasis O 
in O 
the O 
nuclear O 
receptor O 
field O 
has O 
focused O 
on O 
selective O 
nuclear O 
receptor O 
modulators O 
, O 
which O 
can O 
display O 
graded O 
transcriptional O 
responses O 
and O 
tissue O 
selective O 
pharmacological O 
responses O 
that O 
deviate O 
from O 
the O 
prototypical O 
agonist O 
or O 
antagonist O 
. O 
Understanding O 
the O 
molecular O 
mechanism O 
of O 
action O 
of O 
these O 
selective O 
modulators O 
will O 
provide O 
significant O 
insight O 
toward O 
the O 
development O 
of O 
the O 
next O 
generation O 
of O 
modulators O 
. O 
Although O 
most O 
nuclear O 
receptor O 
structural O 
studies O 
have O 
primarily O 
focused O 
on O 
obtaining O 
ligand O 
- O 
receptor O 
cocrystal O 
structures O 
, O 
recent O 
studies O 
implicate O 
an O 
important O 
role O 
for O 
protein O 
dynamics O 
in O 
the O 
mechanism O 
of O 
action O 
of O 
nuclear O 
receptor O 
ligands O 
. O 
Here O 
we O 
review O 
nuclear O 
receptor O 
studies O 
reporting O 
how O 
ligands O 
modulate O 
the O 
conformational O 
dynamics O 
of O 
the O 
nuclear O 
receptor O 
ligand O 
- O 
binding O 
domain O 
( O 
LBD O 
) O 
. O 
A O 
particular O 
emphasis O 
is O 
placed O 
on O 
protein O 
NMR O 
and O 
hydrogen B-SYSTEMATIC 
/ O 
deuterium B-SYSTEMATIC 
exchange O 
( O 
HDX O 
) O 
techniques O 
and O 
how O 
they O 
provide O 
complementary O 
information O 
that O 
, O 
when O 
combined O 
with O 
crystallography O 
, O 
provide O 
detailed O 
insight O 
into O 
the O 
function O 
of O 
nuclear O 
receptors O 
. O 

, O 
a O 
novel O 
nonaromatic O 
B-ring O 
flavonoid B-FAMILY 
, O 
induces O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
and O 
apoptosis O 
in O 
human O 
hepatoma O 
cells O 
. O 

was O 
a O 
novel O 
nonaromatic O 
B-ring O 
flavonoid B-FAMILY 
obtained O 
from O 
Macrothelypteris O 
torresiana O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
investigated O 
the O 
antitumor O 
activity O 
and O 
the O 
antineoplastic O 
mechanism O 
of O 
DICO B-ABBREVIATION 
. O 
Our O 
study O 
showed O 
that O 
DICO B-ABBREVIATION 
inhibited O 
the O 
growth O 
of O 
HepG2 O 
cells O 
in O 
dose O 
and O 
time O 
- O 
dependent O 
manners O 
. O 
As O 
well O 
as O 
DICO B-ABBREVIATION 
induced O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
and O 
apoptosis O 
via O 
a O 
ROS O 
- O 
mediated O 
mitochondrial O 
pathway O 
. O 
Western O 
blot O 
assay O 
demonstrated O 
that O 
DICO B-ABBREVIATION 
decreased O 
Bcl-2 O 
level O 
and O 
induced O 
Bax O 
translocation O 
to O 
cause O 
cytochrome O 
c O 
release O 
. O 
Subsequently O 
, O 
caspase-9 O 
and O 
caspase-3 O 
were O 
activated O 
. O 
Meanwhile O 
, O 
the O 
alterations O 
of O 
cyclin O 
A O 
and O 
B1 O 
, O 
p-CDK1 O 
and O 
p-cdc25c O 
levels O 
were O 
also O 
observed O 
in O 
response O 
to O 
DICO B-ABBREVIATION 
treatment O 
. O 
Taken O 
together O 
, O 
DICO B-ABBREVIATION 
displayed O 
a O 
significant O 
antitumor O 
effect O 
through O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
and O 
apoptosis O 
induction O 
, O 
which O 
suggested O 
DICO B-ABBREVIATION 
might O 
have O 
therapeutic O 
potential O 
against O 
tumors O 
. O 

determination O 
of O 
methanol B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
, O 
acetone B-SYSTEMATIC 
, O 
and O 
ethanol B-SYSTEMATIC 
in O 
human O 
blood O 
by O 
gas O 
chromatography O 
with O 
flame O 
ionization O 
detection O 
. O 

: O 
Methanol B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
, O 
acetone B-SYSTEMATIC 
, O 
and O 
ethanol B-SYSTEMATIC 
, O 
which O 
are O 
commonly O 
used O 
as O 
biomarkers O 
of O 
several O 
diseases O 
, O 
in O 
acute O 
intoxications O 
, O 
and O 
forensic O 
settings O 
, O 
can O 
be O 
detected O 
and O 
quantified O 
in O 
biological O 
fluids O 
. O 
Gas O 
chromatography O 
(GC)-mass O 
spectrometry O 
techniques O 
are O 
complex O 
, O 
require O 
highly O 
trained O 
personnel O 
and O 
expensive O 
materials O 
. O 
Gas O 
chromatographic O 
determinations O 
of O 
ethanol B-SYSTEMATIC 
, O 
methanol B-SYSTEMATIC 
, O 
and O 
acetone B-SYSTEMATIC 
have O 
been O 
reported O 
in O 
one O 
study O 
with O 
suboptimal O 
accuracy O 
. O 
Our O 
objective O 
was O 
to O 
improve O 
the O 
assessment O 
of O 
these O 
compounds O 
in O 
human O 
blood O 
using O 
GC O 
with O 
flame O 
ionization O 
detection.Methods O 
: O 
An O 
amount O 
of O 
50 O 
µl O 
of O 
blood O 
was O 
diluted O 
with O 
300 O 
µl O 
of O 
sterile O 
water O 
, O 
40 O 
µl O 
of O 
10% O 
sodium B-SYSTEMATIC 
tungstate I-SYSTEMATIC 
, O 
and O 
20 O 
µl O 
of O 
1% O 
sulphuric B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
After O 
centrifugation O 
, O 
1 O 
µl O 
of O 
the O 
supernatant O 
was O 
inje O 
- O 
cted O 
into O 
the O 
gas O 
chromatograph O 
. O 
We O 
used O 
a O 
dimethylpolysiloxane B-FAMILY 
capillary O 
column O 
of O 
30 O 
m O 
0.25 O 
mm O 
0.25 O 
µm.Results O 
: O 
We O 
observed O 
linear O 
correlations O 
from O 
7.5 O 
to O 
240 O 
mg O 
/ O 
l O 
for O 
methanol B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
, O 
and O 
acetone B-SYSTEMATIC 
and O 
from O 
75 O 
to O 
2400 O 
mg O 
/ O 
l O 
for O 
ethanol B-SYSTEMATIC 
. O 
Precision O 
at O 
concentrations O 
15 O 
, O 
60 O 
, O 
and O 
120 O 
mg O 
/ O 
l O 
for O 
methanol B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
, O 
and O 
acetone B-SYSTEMATIC 
and O 
150 O 
, O 
600 O 
, O 
and O 
1200 O 
mg O 
/ O 
ml O 
for O 
ethanol B-SYSTEMATIC 
were O 
0.8-6.9% O 
. O 
Ranges O 
of O 
accuracy O 
were O 
94.7-98.9% O 
for O 
methanol B-SYSTEMATIC 
, O 
91.2-97.4% O 
for O 
acetaldehyde B-SYSTEMATIC 
, O 
96.1-98.7% O 
for O 
acetone B-SYSTEMATIC 
, O 
and O 
105.5-111.6% O 
for O 
ethanol B-SYSTEMATIC 
. O 
Limits O 
of O 
detection O 
were O 
0.8 O 
mg O 
/ O 
l O 
for O 
methanol B-SYSTEMATIC 
, O 
0.61 O 
mg O 
/ O 
l O 
for O 
acetaldehyde B-SYSTEMATIC 
, O 
0.58 O 
mg O 
/ O 
l O 
for O 
acetone B-SYSTEMATIC 
, O 
and O 
0.53 O 
mg O 
/ O 
l O 
for O 
ethanol B-SYSTEMATIC 
.Conclusion O 
: O 
This O 
method O 
is O 
suitable O 
for O 
routine O 
clinical O 
and O 
forensic O 
practices O 
. O 

charging O 
of O 
aqueous O 
microjets O 
was O 
characterized O 
by O 
measuring O 
streaming O 
currents O 
as O 
a O 
function O 
of O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
salt O 
concentration O 
. O 
Measured O 
streaming O 
currents O 
at O 
high O 
salt O 
concentrations O 
( O 
up O 
to O 
0.5 O 
M O 
) O 
varied O 
nonmonotonically O 
with O 
the O 
jet O 
velocity O 
and O 
can O 
be O 
explained O 
by O 
a O 
multipolar O 
charge O 
distribution O 
at O 
the O 
nozzle O 
- O 
water O 
interface O 
. O 
In O 
the O 
case O 
of O 
potassium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
no O 
multipolar O 
charge O 
distribution O 
is O 
observed O 
. O 
Electrokinetic O 
potentials O 
were O 
estimated O 
from O 
the O 
streaming O 
currents O 
, O 
under O 
the O 
assumption O 
that O 
all O 
excess O 
charges O 
are O 
confined O 
within O 
the O 
liquid O 
jet O 
. O 
Measured O 
photoelectron O 
spectra O 
indicate O 
much O 
smaller O 
streaming O 
potentials O 
. O 
To O 
resolve O 
the O 
apparent O 
discrepancy O 
, O 
we O 
propose O 
that O 
a O 
significant O 
fraction O 
of O 
excess O 
charges O 
evaporates O 
in O 
the O 
form O 
of O 
ion O 
- O 
water O 
clusters O 
. O 

and O 
non-edible O 
olive O 
oils O 
discrimination O 
by O 
the O 
application O 
of O 
a O 
sensory O 
olfactory O 
system O 
based O 
on O 
tin B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
sensors O 
. O 

array O 
of O 
semiconductor O 
sensors O 
has O 
been O 
developed O 
to O 
discriminate O 
virgin O 
olive O 
oil O 
samples O 
based O 
on O 
their O 
organoleptic O 
characteristics O 
. O 
The O 
multisensor O 
, O 
developed O 
at O 
laboratory O 
, O 
is O 
composed O 
by O 
14 O 
sensing O 
elements O 
of O 
tin B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
thin O 
layers O 
( O 
doped O 
with O 
Cr B-FORMULA 
and O 
In B-FORMULA 
, O 
and O 
undoped O 
) O 
deposited O 
by O 
the O 
reactive O 
sputtering O 
technique O 
. O 
The O 
sensors O 
are O 
stable O 
and O 
show O 
good O 
repeatability O 
. O 
Off O 
- O 
flavors O 
and O 
extra O 
- O 
virgin O 
olive O 
oil O 
samples O 
, O 
taken O 
at O 
the O 
outlet O 
of O 
the O 
vertical O 
centrifuge O 
of O 
a O 
small O 
experimental O 
olive O 
oil O 
mill O 
and O 
sensory O 
evaluated O 
, O 
have O 
been O 
used O 
. O 
A O 
good O 
discrimination O 
of O 
edible O 
( O 
extra O 
- O 
virgin O 
and O 
virgin O 
) O 
from O 
non-edible O 
( O 
lampante O 
) O 
olive O 
oils O 
has O 
been O 
obtained O 
through O 
the O 
statistical O 
method O 
of O 
principal O 
component O 
analysis O 
( O 
PCA O 
) O 
. O 

dose O 
response O 
study O 
to O 
assess O 
effects O 
after O 
dietary O 
administration O 
of O 
diisononyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DINP B-ABBREVIATION 
) O 
in O 
gestation O 
and O 
lactation O 
on O 
male O 
rat O 
sexual O 
development O 
. O 

rat O 
sexual O 
development O 
was O 
evaluated O 
after O 
dietary O 
administration O 
of O 
0 O 
, O 
760 O 
, O 
3800 O 
, O 
11400 O 
ppm O 
diisononyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DiNP B-ABBREVIATION 
) O 
and O 
7600 O 
ppm O 
dibutyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DBP B-ABBREVIATION 
) O 
from O 
gestation O 
day O 
( O 
GD O 
) O 
12 O 
to O 
postnatal O 
day O 
( O 
PND O 
) O 
14 O 
. O 
Maternal O 
weight O 
was O 
reduced O 
on O 
GD O 
20 O 
, O 
PND O 
2 O 
and O 
14 O 
at O 
11400 O 
ppm O 
DiNP B-ABBREVIATION 
. O 
Pup O 
weight O 
was O 
reduced O 
on O 
PND O 
2 O 
and O 
14 O 
at O 
11400 O 
and O 
3800 O 
ppm O 
DiNP B-ABBREVIATION 
. O 
DBP B-ABBREVIATION 
induced O 
multinucleated O 
germ O 
cells O 
( O 
MNGs O 
) O 
and O 
Leydig O 
cell O 
aggregates O 
( O 
LCAs O 
) O 
in O 
PND O 
2 O 
testes O 
. O 
7600 O 
ppm O 
DBP B-ABBREVIATION 
reduced O 
anogenital O 
distance O 
( O 
AGD O 
) O 
on O 
PND O 
2 O 
and O 
14 O 
, O 
and O 
increased O 
nipple O 
retention O 
and O 
reproductive O 
tract O 
malformations O 
on O 
PND O 
49 O 
. O 
DiNP B-ABBREVIATION 
induced O 
MNGs O 
( O 
3800 O 
ppm O 
) O 
and O 
LCAs O 
( O 
11400 O 
ppm O 
) O 
on O 
PND O 
2 O 
, O 
and O 
reduced O 
AGD O 
( O 
11400 O 
ppm O 
) O 
on O 
PND O 
14 O 
. O 
DiNP B-ABBREVIATION 
did O 
not O 
alter O 
AGD O 
, O 
nipple O 
retention O 
or O 
reproductive O 
tract O 
malformations O 
on O 
PND O 
49 O 
. O 
Global O 
endpoint O 
analysis O 
showed O 
no O 
evidence O 
of O 
a O 
rat O 
" O 
phthalate B-FAMILY 
syndrome O 
" O 
on O 
PND O 
49 O 
with O 
DiNP B-ABBREVIATION 
administration O 
. O 

and O 
antitumor O 
activity O 
of O 
N-sulfonyl-3,7-dioxo-5β-cholan-24-amides B-FAMILY 
, O 
ursodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
. O 

series O 
of O 
N-sulfonyl-3,7-dioxo-5β-cholan-24-amides B-FAMILY 
, O 
ursodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
, O 
have O 
been O 
designed O 
and O 
synthesized O 
in O 
nine O 
steps O 
starting O 
from O 
ursodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
in O 
vitro O 
antitumor O 
activity O 
of O 
the O 
target O 
compounds O 
has O 
been O 
evaluated O 
against O 
HCT-116 O 
, O 
MCF-7 O 
, O 
K562 O 
, O 
and O 
SGC-7901 O 
cell O 
lines O 
. O 
The O 
pharmacological O 
results O 
showed O 
that O 
most O 
of O 
the O 
prepared O 
compounds O 
display O 
excellent O 
selective O 
cytotoxicity O 
toward O 
HCT-116 O 
, O 
MCF-7 O 
, O 
and O 
K562 O 
cell O 
lines O 
. O 
Particularly O 
, O 
compounds O 
10c O 
, O 
10f O 
and O 
10g O 
show O 
high O 
inhibitory O 
activity O 
on O 
these O 
human O 
cancer O 
cell O 
lines O 
( O 
IC50 O 
: O 
2.39-9.34 O 
μM O 
) O 
. O 
Conversely O 
, O 
all O 
compounds O 
are O 
generally O 
inactive O 
against O 
SGC-7901 O 
, O 
with O 
only O 
10b O 
having O 
IC₅₀ O 
below O 
50 O 
μM O 
. O 

calorie O 
and O 
carbohydrate B-FAMILY 
diet O 
: O 
to O 
improve O 
the O 
cardiovascular O 
risk O 
indicators O 
in O 
overweight O 
or O 
obese O 
adults O 
with O 
prediabetes O 
. O 

objective O 
was O 
to O 
evaluate O 
the O 
effects O 
of O 
a O 
moderate O 
calorie O 
and O 
carbohydrate B-FAMILY 
-restricted O 
diet O 
on O 
cardiovascular O 
risk O 
indicators O 
in O 
overweight O 
or O 
obese O 
patients O 
with O 
prediabetes O 
. O 
A O 
clinical O 
trial O 
was O 
conducted O 
in O 
which O 
86 O 
subjects O 
presenting O 
with O 
overweight O 
or O 
obesity O 
and O 
prediabetes O 
received O 
a O 
personalized O 
diet O 
of O 
1200 O 
to O 
1700 O 
calories O 
with O 
a O 
distribution O 
of O 
50 O 
% O 
carbohydrates B-FAMILY 
, O 
20 O 
% O 
proteins O 
, O 
and O 
30 O 
% O 
fat O 
. O 
Body O 
weight O 
, O 
fat O 
mass O 
, O 
and O 
lean O 
mass O 
were O 
measured O 
through O 
bioimpedance O 
. O 
Glucose B-TRIVIAL 
, O 
total O 
cholesterol B-TRIVIAL 
, O 
high O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
and O 
low O 
density O 
cholesterol B-TRIVIAL 
, O 
and O 
triglycerides B-FAMILY 
were O 
measured O 
. O 
The O 
measurements O 
were O 
taken O 
at O 
the O 
beginning O 
of O 
, O 
and O 
at O 
, O 
6 O 
and O 
12 O 
months O 
during O 
the O 
intervention O 
, O 
and O 
the O 
differences O 
were O 
compared O 
by O 
paired O 
Student's O 
t O 
and O 
χ(2) O 
tests O 
. O 
At O 
12 O 
months O 
, O 
a O 
significant O 
reduction O 
was O 
noticed O 
in O 
body O 
weight O 
in O 
patients O 
with O 
overweight O 
and O 
obesity O 
( O 
72.4 O 
± O 
7.8-69.6 O 
± O 
7.5 O 
kg O 
) O 
( O 
85.7 O 
± O 
14.8-80.2 O 
± O 
12.7 O 
kg O 
) O 
with O 
body O 
mass O 
index O 
( O 
28.2 O 
± O 
0.8-27.2 O 
± O 
2.1 O 
kg O 
/ O 
m(2) O 
) O 
( O 
34.3 O 
± O 
3.5-32.1 O 
± O 
3.2 O 
kg O 
/ O 
m(2) O 
) O 
, O 
systolic O 
( O 
120.9 O 
± O 
14.2-112.4 O 
± O 
11.5 O 
mmHg O 
) O 
( O 
124.1 O 
± O 
11.9-115.7 O 
± O 
14 O 
mmHg O 
) O 
, O 
diastolic O 
blood O 
pressures O 
( O 
79 O 
± O 
9.3-71.8 O 
± O 
8.3 O 
mmHg O 
) O 
( O 
80.4 O 
± O 
9.0-73.7 O 
± O 
13.1 O 
mmHg O 
) O 
, O 
glucose B-TRIVIAL 
( O 
106 O 
± O 
8.9-95.9 O 
± O 
7.5 O 
mg O 
/ O 
dL O 
) O 
( O 
107.3 O 
± O 
7.0-97.0 O 
± O 
8.2 O 
mg O 
/ O 
dL O 
) O 
, O 
and O 
significant O 
improvement O 
on O 
lipid O 
profile O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
restrictions O 
in O 
the O 
calorie O 
and O 
carbohydrate B-FAMILY 
diet O 
decrease O 
the O 
cardiovascular O 
risk O 
indicators O 
in O 
overweight O 
or O 
obese O 
adults O 
with O 
prediabetes O 
. O 

2-aminooctahydrocyclopentalene-3a-carboxamides B-FAMILY 
as O 
potent O 
CCR2 O 
antagonists O 
. O 

CCR2 O 
antagonists O 
with O 
a O 
novel O 
2-aminooctahydrocyclopentalene-3a-carboxamide B-SYSTEMATIC 
scaffold O 
were O 
designed O 
. O 
SAR O 
studies O 
led O 
to O 
a O 
series O 
of O 
potent O 
compounds O 
. O 
For O 
example O 
, O 
compound O 
51 O 
had O 
a O 
good O 
PK O 
profile O 
in O 
both O 
dog O 
and O 
monkey O 
, O 
and O 
exhibited O 
excellent O 
efficacy O 
when O 
dosed O 
orally O 
in O 
an O 
inflammation O 
model O 
in O 
hCCR2 O 
KI O 
mice O 
. O 
In O 
addition O 
, O 
an O 
asymmetric O 
synthesis O 
to O 
the O 
core O 
structures O 
was O 
developed O 
. O 

by O 
steroids B-FAMILY 
after O 
neurotrauma O 
in O 
organotypic O 
spinal O 
cord O 
cultures O 
: O 
A O 
key O 
role O 
for O 
progesterone B-TRIVIAL 
receptors O 
and O 
steroidal O 
modulators O 
of O 
GABAA O 
receptors O 
. O 

is O 
neuroprotective O 
after O 
spinal O 
cord O 
injury O 
, O 
however O 
its O 
mechanism O 
of O 
action O 
remains O 
unexplored O 
. O 
Here O 
we O 
used O 
organotypic O 
spinal O 
cord O 
slice O 
cultures O 
from O 
3 O 
weeks O 
- O 
old O 
mice O 
to O 
evaluate O 
the O 
mechanisms O 
of O 
neuroprotection O 
by O 
progesterone B-TRIVIAL 
and O 
its O 
5α-reduced O 
metabolites O 
. O 
In O 
vitro O 
spinal O 
cord O 
injury O 
, O 
using O 
a O 
weight O 
drop O 
model O 
, O 
induced O 
a O 
decrease O 
in O 
the O 
number O 
of O 
motoneurons O 
. O 
This O 
was O 
correlated O 
with O 
an O 
increase O 
in O 
the O 
number O 
of O 
dying O 
cells O 
( O 
PI(+) O 
cells O 
) O 
and O 
in O 
LDH O 
release O 
. O 
Addition O 
of O 
10 O 
μM O 
of O 
progesterone B-TRIVIAL 
, O 
5α-dihydroprogesterone B-SYSTEMATIC 
( O 
5α-DHP B-SYSTEMATIC 
) O 
or O 
allopregnanolone B-TRIVIAL 
( O 
3α B-SYSTEMATIC 
, I-SYSTEMATIC 
5α-tetrahydroprogesterone I-SYSTEMATIC 
) O 
to O 
the O 
medium O 
at O 
the O 
time O 
of O 
injury O 
rescued O 
the O 
spinal O 
cord O 
slices O 
from O 
the O 
effects O 
of O 
damage O 
. O 
Progesterone B-TRIVIAL 
prevented O 
membrane O 
cell O 
damage O 
, O 
motoneuron O 
loss O 
and O 
cell O 
death O 
. O 
These O 
effects O 
were O 
not O 
due O 
to O 
its O 
bioconversion O 
to O 
5α-DHP B-SYSTEMATIC 
nor O 
to O 
allopregnanolone B-TRIVIAL 
, O 
as O 
supported O 
by O 
the O 
finasteride B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
5α-reductase O 
enzymes O 
, O 
and O 
by O 
the O 
absence O 
of O 
5α-reduced O 
progesterone B-TRIVIAL 
metabolites O 
in O 
the O 
slices O 
analyzed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 
The O 
neuroprotective O 
effects O 
of O 
progesterone B-TRIVIAL 
required O 
PR O 
as O 
they O 
could O 
not O 
be O 
observed O 
in O 
slices O 
from O 
homozygous O 
knockout O 
PR(- O 
/ O 
- O 
) O 
mice O 
. O 
Allopregnanolone B-TRIVIAL 
treatment O 
was O 
also O 
neuroprotective O 
. O 
Its O 
effects O 
were O 
not O 
due O 
to O 
its O 
bioconversion O 
back O 
to O 
5α-DHP B-SYSTEMATIC 
, O 
which O 
can O 
activate O 
gene O 
transcription O 
via O 
PR O 
, O 
because O 
they O 
were O 
still O 
observed O 
in O 
slices O 
from O 
knockout O 
PR(- O 
/ O 
- O 
) O 
mice O 
. O 
Allopregnanolone B-TRIVIAL 
effects O 
involved O 
GABAA O 
receptors O 
, O 
as O 
they O 
were O 
inhibited O 
by O 
the O 
selective O 
GABAA O 
receptor O 
antagonist O 
Gabazine B-TRIVIAL 
, O 
in O 
both O 
PR(+ O 
/ O 
+ O 
) O 
and O 
PR(- O 
/ O 
- O 
) O 
mice O 
. O 
Altogether O 
, O 
these O 
findings O 
identify O 
both O 
PR O 
and O 
GABAA O 
receptors O 
as O 
important O 
targets O 
for O 
neuroprotection O 
by O 
progestagens B-FAMILY 
after O 
spinal O 
cord O 
injury O 
. O 

its O 
characterisation O 
in O 
2001 O 
, O 
the O 
mGlu8-selective O 
agonist O 
DCPG B-ABBREVIATION 
has O 
been O 
widely O 
used O 
to O 
explore O 
the O 
potential O 
functional O 
role O 
of O 
this O 
group O 
III O 
mGlu O 
receptor O 
within O 
the O 
central O 
nervous O 
system O 
. O 
This O 
research O 
has O 
implicated O 
mGlu8 O 
receptors O 
in O 
a O 
number O 
of O 
disease O 
states O 
and O 
conditions O 
such O 
as O 
epilepsy O 
and O 
anxiety O 
, O 
suggesting O 
that O 
mGlu8-selective O 
ligands O 
may O 
hold O 
important O 
therapeutic O 
potential O 
. O 
However O 
, O 
there O 
is O 
evidence O 
that O 
DCPG B-ABBREVIATION 
exerts O 
off O 
- O 
target O 
effects O 
at O 
higher O 
concentrations O 
, O 
limiting O 
its O 
use O 
as O 
an O 
mGlu8-selective O 
agonist O 
. O 
Here O 
, O 
we O 
have O 
used O 
field O 
recordings O 
in O 
rat O 
hippocampal O 
slices O 
to O 
investigate O 
the O 
effects O 
of O 
DCPG B-ABBREVIATION 
in O 
the O 
lateral O 
perforant O 
path O 
( O 
LPP O 
) O 
, O 
a O 
pathway O 
known O 
to O 
express O 
high O 
levels O 
of O 
mGlu8 O 
. O 
We O 
show O 
that O 
DCPG B-ABBREVIATION 
does O 
inhibit O 
excitatory O 
transmission O 
in O 
this O 
pathway O 
, O 
but O 
produces O 
a O 
biphasic O 
concentration O 
- O 
response O 
curve O 
suggesting O 
activation O 
of O 
two O 
distinct O 
receptor O 
types O 
. O 
The O 
putative O 
mGlu8-selective O 
antagonist O 
MDCPG B-ABBREVIATION 
antagonises O 
the O 
high O 
, O 
but O 
not O 
the O 
low O 
, O 
potency O 
component O 
of O 
this O 
concentration O 
- O 
response O 
curve O 
. O 
In O 
addition O 
, O 
higher O 
concentrations O 
of O 
DCPG B-ABBREVIATION 
also O 
depress O 
excitatory O 
transmission O 
in O 
the O 
medial O 
perforant O 
path O 
( O 
MPP O 
) O 
, O 
a O 
pathway O 
expressing O 
very O 
low O 
levels O 
of O 
mGlu8 O 
receptors O 
. O 
Experiments O 
in O 
slices O 
from O 
mice O 
lacking O 
mGlu8 O 
receptors O 
indicate O 
that O 
concentrations O 
of O 
DCPG B-ABBREVIATION 
> O 
1 O 
μM O 
produce O 
large O 
non-selective O 
effects O 
in O 
both O 
the O 
LPP O 
and O 
MPP O 
. O 
Further O 
experiments O 
in O 
slices O 
from O 
mGlu2 O 
, O 
4 O 
and O 
7 O 
knock O 
- O 
out O 
mice O 
, O 
as O 
well O 
as O 
in O 
an O 
mGlu2-deficient O 
substrain O 
of O 
Wistar O 
rat O 
, O 
reveal O 
that O 
these O 
non-selective O 
effects O 
are O 
mediated O 
primarily O 
by O 
mGlu2 O 
receptors O 
. O 
Taken O 
together O 
, O 
our O 
results O 
confirm O 
the O 
mGlu8 O 
- O 
selectivity O 
of O 
DCPG B-ABBREVIATION 
at O 
submicromolar O 
concentrations O 
, O 
but O 
suggest O 
that O 
care O 
must O 
be O 
taken O 
when O 
employing O 
higher O 
concentrations O 
of O 
the O 
agonist O 
, O 
which O 
may O 
additionally O 
activate O 
mGlu2 O 
receptors O 
, O 
especially O 
at O 
synapses O 
where O 
their O 
expression O 
is O 
high O 
. O 
MDCPG B-ABBREVIATION 
may O 
be O 
a O 
useful O 
tool O 
in O 
determining O 
whether O 
observable O 
DCPG B-ABBREVIATION 
effects O 
are O 
attributable O 
to O 
mGlu8 O 
, O 
versus O 
mGlu2 O 
, O 
receptor O 
activation O 
. O 

- O 
responsive O 
polymeric O 
materials O 
is O 
one O 
of O 
the O 
fastest O 
growing O 
fields O 
of O 
the O 
21st O 
century O 
, O 
with O 
the O 
annual O 
number O 
of O 
papers O 
published O 
more O 
than O 
quadrupling O 
in O 
the O 
last O 
ten O 
years O 
. O 
The O 
responsiveness O 
of O 
polymer O 
solution O 
assemblies O 
and O 
surfaces O 
to O 
biological O 
stimuli O 
( O 
e.g O 
. O 
pH O 
, O 
reduction O 
- O 
oxidation O 
, O 
enzymes O 
, O 
glucose B-TRIVIAL 
) O 
and O 
externally O 
applied O 
triggers O 
( O 
e.g O 
. O 
temperature O 
, O 
light O 
, O 
solvent O 
quality O 
) O 
shows O 
particular O 
promise O 
for O 
various O 
biomedical O 
applications O 
including O 
drug O 
delivery O 
, O 
tissue O 
engineering O 
, O 
medical O 
diagnostics O 
, O 
and O 
bioseparations O 
. O 
Furthermore O 
, O 
the O 
integration O 
of O 
copolymer O 
architectures O 
into O 
stimuli O 
- O 
responsive O 
materials O 
design O 
enables O 
exquisite O 
control O 
over O 
the O 
locations O 
of O 
responsive O 
sites O 
within O 
self O 
- O 
assembled O 
nanostructures O 
. O 
The O 
combination O 
of O 
new O 
synthesis O 
techniques O 
and O 
well O 
- O 
defined O 
copolymer O 
self O 
- O 
assembly O 
has O 
facilitated O 
substantial O 
developments O 
in O 
stimuli O 
- O 
responsive O 
materials O 
in O 
recent O 
years O 
. O 
In O 
this O 
tutorial O 
review O 
, O 
we O 
discuss O 
several O 
methods O 
that O 
have O 
been O 
employed O 
to O 
synthesize O 
self O 
- O 
assembling O 
and O 
stimuli O 
- O 
responsive O 
copolymers O 
for O 
biomedical O 
applications O 
, O 
and O 
we O 
identify O 
common O 
themes O 
in O 
the O 
response O 
mechanisms O 
among O 
the O 
targeted O 
stimuli O 
. O 
Additionally O 
, O 
we O 
highlight O 
parallels O 
between O 
the O 
chemistries O 
used O 
for O 
generating O 
solution O 
assemblies O 
and O 
those O 
employed O 
for O 
creating O 
copolymer O 
surfaces O 
. O 

: O 
improved O 
synthesis O 
and O 
interaction O 
with O 
soluble O 
Aβ1-42 O 
oligomers O 
. O 

- O 
binding O 
assays O 
that O 
are O 
used O 
to O 
evaluate O 
anti-aggregation O 
ability O 
of O 
small O 
molecule O 
inhibitors O 
towards O 
amyloids O 
are O 
known O 
to O 
be O 
prone O 
to O 
false O 
- O 
positive O 
effects O 
due O 
to O 
spectral O 
overlaps O 
between O 
the O 
dye O 
and O 
the O 
inhibitor O 
. O 
Aza-BODIPY B-SYSTEMATIC 
dye O 
, O 
which O 
has O 
both O 
excitation O 
and O 
emission O 
maxima O 
above O 
600nm O 
, O 
exhibits O 
a O 
significant O 
increase O 
in O 
its O 
fluorescence O 
intensity O 
in O 
the O 
presence O 
of O 
soluble O 
oligomers O 
of O 
Aβ1-42 O 
. O 
These O 
results O 
indicate O 
that O 
aza-BODIPY B-SYSTEMATIC 
could O 
serve O 
as O 
a O 
near-IR O 
probe O 
for O 
detecting O 
conformational O 
changes O 
of O 
Aβ1-42 O 
soluble O 
oligomers O 
in O 
vitro O 
, O 
and O 
it O 
should O 
eliminate O 
false O 
- O 
positive O 
effects O 
that O 
are O 
associated O 
with O 
currently O 
utilized O 
thioflavin B-TRIVIAL 
T I-TRIVIAL 
-based O 
dyes O 
. O 
In O 
addition O 
, O 
a O 
facile O 
synthesis O 
of O 
aza-BODIPY B-SYSTEMATIC 
has O 
been O 
developed O 
, O 
which O 
might O 
further O 
expand O 
the O 
applications O 
of O 
this O 
dye O 
. O 

are O 
long O 
- O 
lived O 
and O 
far O 
more O 
numerous O 
than O 
the O 
short O 
- O 
lived O 
osteoblasts O 
and O 
osteoclasts O 
. O 
Immured O 
within O 
the O 
lacunar O 
- O 
canalicular O 
system O 
and O 
mineralized O 
matrix O 
, O 
osteocytes O 
are O 
ideally O 
located O 
throughout O 
the O 
bone O 
to O 
detect O 
the O 
need O 
for O 
, O 
and O 
accordingly O 
choreograph O 
, O 
the O 
bone O 
regeneration O 
process O 
by O 
independently O 
controlling O 
rate O 
limiting O 
steps O 
of O 
bone O 
resorption O 
and O 
formation O 
. O 
Consistent O 
with O 
this O 
role O 
, O 
emerging O 
evidence O 
indicates O 
that O 
signals O 
arising O 
from O 
apoptotic O 
and O 
old O 
/ O 
or O 
dysfunctional O 
osteocytes O 
are O 
seminal O 
culprits O 
in O 
the O 
pathogenesis O 
of O 
involutional O 
, O 
post O 
- O 
menopausal O 
, O 
steroid B-FAMILY 
- O 
, O 
and O 
immobilization O 
- O 
induced O 
osteoporosis O 
. O 
Osteocyte O 
- O 
originated O 
signals O 
may O 
also O 
contribute O 
to O 
the O 
increased O 
bone O 
fragility O 
associated O 
with O 
bone O 
matrix O 
disorders O 
like O 
osteogenesis O 
imperfecta O 
, O 
and O 
perhaps O 
the O 
rapid O 
reversal O 
of O 
bone O 
turnover O 
above O 
baseline O 
following O 
discontinuation O 
of O 
anti-resorptive O 
treatments O 
, O 
like O 
denosumab O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
" O 
The O 
Osteocyte O 
" O 
. O 

anion O 
transporting O 
polypeptides O 
( O 
OATP O 
) O 
have O 
been O 
extensively O 
recognized O 
as O 
key O 
determinants O 
of O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
, O 
and O 
excretion O 
of O 
various O 
drugs O 
because O 
of O 
their O 
broad O 
substrate O 
specificity O 
, O 
wide O 
tissue O 
distribution O 
, O 
and O 
the O 
involvement O 
of O 
drug O 
- O 
drug O 
interaction O 
. O 
As O 
the O 
first O 
cloned O 
human O 
OATP O 
, O 
OATP1A2 O 
has O 
been O 
found O 
to O 
transport O 
a O 
wide O 
spectrum O 
of O 
endogenous O 
and O 
exogenous O 
compounds O 
. O 
Bovine O 
Oapt1a2 O 
shared O 
high O 
homology O 
with O 
the O 
human O 
transporter O 
and O 
is O 
considered O 
as O 
its O 
functional O 
ortholog O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
expressed O 
bovine O 
Oatp1a2 O 
in O 
human O 
embryonic O 
kidney O 
293 O 
cells O 
and O 
found O 
that O 
, O 
unlike O 
human O 
OATP1A2 O 
, O 
the O 
transport O 
of O 
estrone-3-sulfate B-SYSTEMATIC 
( O 
E-3-S B-SYSTEMATIC 
) O 
exhibited O 
biphasic O 
saturation O 
kinetics O 
. O 
The O 
K(m) O 
values O 
are O 
0.25 O 
± O 
0.08 O 
and O 
46.6 O 
± O 
18.5 O 
µM O 
, O 
and O 
V(max) O 
values O 
were O 
24.5 O 
±4.4 O 
and O 
375 O 
± O 
142 O 
pmol O 
/ O 
mg O 
protein O 
/ O 
min O 
for O 
high- O 
and O 
low O 
- O 
affinity O 
sites O 
, O 
respectively O 
, O 
suggesting O 
the O 
presence O 
of O 
multiple O 
binding O 
sites O 
. O 
Further O 
study O 
on O 
other O 
Oatp1a2 O 
substrates O 
showed O 
that O 
the O 
high O 
affinity O 
component O 
for O 
E-3-S B-SYSTEMATIC 
is O 
responsible O 
for O 
the O 
interaction O 
with O 
taurocholate B-TRIVIAL 
, O 
bromsulphthalein B-TRIVIAL 
, O 
and O 
rifampicin B-TRIVIAL 
and O 
is O 
sensitive O 
to O 
proton O 
concentration O 
change O 
, O 
whereas O 
the O 
low O 
affinity O 
binding O 
site O 
is O 
only O 
involved O 
in O 
the O 
binding O 
of O 
the O 
antitumor O 
drug O 
methotrexate B-TRIVIAL 
and O 
had O 
no O 
response O 
to O 
change O 
of O 
pH O 
. O 

hepatocarcinogens O 
induce O 
cytomegaly O 
, O 
which O 
reflects O 
aberrant O 
cell O 
cycling O 
and O 
increased O 
ploidy O 
, O 
from O 
the O 
early O 
stages O 
of O 
administration O 
to O 
animals O 
. O 
To O 
clarify O 
the O 
regulatory O 
molecular O 
mechanisms O 
behind O 
cell O 
cycle O 
aberrations O 
related O 
to O 
the O 
early O 
stages O 
of O 
hepatocarcinogenesis O 
, O 
we O 
performed O 
gene O 
expression O 
analysis O 
using O 
microarrays O 
and O 
real O 
- O 
time O 
reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
followed O 
by O 
immunohistochemical O 
analysis O 
in O 
the O 
livers O 
of O 
rats O 
treated O 
with O 
the O 
cytomegaly O 
inducing O 
hepatocarcinogens O 
thioacetamide B-SYSTEMATIC 
( O 
TAA B-ABBREVIATION 
) O 
, O 
fenbendazole B-TRIVIAL 
, O 
and O 
methyleugenol B-SYSTEMATIC 
, O 
the O 
cytomegaly O 
non-inducing O 
hepatocarcinogen O 
piperonyl B-SYSTEMATIC 
butoxide I-SYSTEMATIC 
( O 
PBO B-ABBREVIATION 
) O 
, O 
or O 
the O 
non-carcinogenic O 
hepatotoxicants O 
acetaminophen B-TRIVIAL 
and O 
α-naphthyl B-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
, O 
for O 
28 O 
days O 
. O 
Gene O 
expression O 
profiling O 
showed O 
that O 
cell O 
cycle O 
- O 
related O 
genes O 
, O 
especially O 
those O 
of O 
G(2) O 
/ O 
M O 
phase O 
, O 
were O 
mostly O 
upregulated O 
after O 
TAA B-ABBREVIATION 
treatment O 
. O 
Immunohistochemical O 
analysis O 
was O 
performed O 
on O 
cell O 
cycle O 
proteins O 
that O 
were O 
upregulated O 
by O 
TAA B-ABBREVIATION 
treatment O 
and O 
on O 
related O 
proteins O 
. O 
All O 
hepatocarcinogens O 
, O 
irrespective O 
of O 
their O 
cytomegaly O 
inducing O 
potential O 
, O 
increased O 
liver O 
cells O 
immunoreactive O 
for O 
p21(Cip1) O 
, O 
which O 
acts O 
on O 
cells O 
arrested O 
in O 
G(1) O 
phase O 
, O 
and O 
for O 
Aurora O 
B O 
or O 
Incenp O 
, O 
which O 
is O 
suggestive O 
of O 
an O 
increase O 
in O 
a O 
cell O 
population O 
with O 
chromosomal O 
instability O 
caused O 
by O 
overexpression O 
. O 
PBO B-ABBREVIATION 
did O 
not O 
induce O 
cell O 
proliferation O 
after O 
28-day O 
treatment O 
. O 
Hepatocarcinogens O 
that O 
induced O 
cell O 
proliferation O 
after O 
28-day O 
treatment O 
also O 
caused O 
an O 
increase O 
in O 
p53(+) O 
cells O 
in O 
parallel O 
with O 
increased O 
apoptotic O 
cells O 
, O 
as O 
well O 
as O 
increased O 
population O 
of O 
cells O 
expressing O 
M O 
phase O 
- O 
related O 
proteins O 
nuclear O 
Cdc2 O 
, O 
phospho-Histone O 
H3 O 
, O 
and O 
HP1α O 
. O 
These O 
results O 
suggest O 
that O 
hepatocarcinogens O 
may O 
increase O 
cellular O 
populations O 
arrested O 
in O 
G(1) O 
phase O 
or O 
showing O 
chromosomal O 
instability O 
after O 
28-day O 
treatment O 
. O 
Hepatocarcinogens O 
that O 
induce O 
cell O 
cycle O 
facilitation O 
may O 
cause O 
M O 
phase O 
arrest O 
accompanied O 
by O 
apoptosis O 
. O 

of O 
salinomycin B-TRIVIAL 
on O 
human O 
bone O 
marrow O 
- O 
derived O 
mesenchymal O 
stem O 
cells O 
in O 
vitro O 
. O 

hypotheses O 
on O 
the O 
origin O 
of O 
cancer O 
stem O 
cells O 
( O 
CSCs O 
) O 
exist O 
, O 
including O 
that O 
CSCs O 
develop O 
from O 
transformed O 
human O 
bone O 
marrow O 
mesenchymal O 
stem O 
cells O 
( O 
hBMSC O 
) O 
. O 
Since O 
the O 
polyether O 
antibiotic O 
salinomycin B-TRIVIAL 
selectively O 
kills O 
CSCs O 
, O 
the O 
present O 
study O 
aims O 
to O 
elucidate O 
the O 
effects O 
of O 
salinomycin B-TRIVIAL 
on O 
normal O 
hBMSC O 
. O 
The O 
immunophenotype O 
of O 
hBMSC O 
after O 
salinomycin B-TRIVIAL 
exposure O 
was O 
observed O 
by O 
flow O 
cytometry O 
. O 
The O 
multi O 
- O 
differentiation O 
capacity O 
of O 
hBMSC O 
was O 
evaluated O 
by O 
Oil B-TRIVIAL 
Red I-TRIVIAL 
O I-TRIVIAL 
and O 
van O 
Kossa O 
staining O 
. O 
Cytotoxic O 
effects O 
of O 
salinomycin B-TRIVIAL 
were O 
monitored O 
by O 
the O 
[ O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl B-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
] O 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
. O 
Furthermore O 
, O 
spheroid O 
formation O 
and O 
migration O 
capacity O 
were O 
assessed O 
. O 
There O 
were O 
no O 
differences O 
in O 
the O 
immunophenotype O 
and O 
multi O 
- O 
differentiation O 
capacity O 
of O 
hBMSC O 
induced O 
by O 
salinomycin B-TRIVIAL 
treatment O 
. O 
Cytotoxic O 
effects O 
were O 
observed O 
at O 
concentrations O 
of O 
30 O 
μM O 
and O 
above O 
. O 
Neither O 
the O 
migration O 
capability O 
nor O 
the O 
ability O 
to O 
form O 
spheroids O 
was O 
affected O 
. O 
Essential O 
functional O 
properties O 
of O 
hBMSC O 
were O 
unaffected O 
by O 
salinomycin B-TRIVIAL 
. O 
However O 
, O 
dose O 
- O 
dependent O 
cytotoxicity O 
effects O 
could O 
be O 
observed O 
. O 
Overall O 
, O 
low O 
dose O 
salinomycin B-TRIVIAL 
showed O 
no O 
negative O 
effects O 
on O 
hBMSC O 
. O 
Since O 
mesenchymal O 
stem O 
cells O 
from O 
various O 
sources O 
respond O 
differently O 
, O 
further O 
in O 
vitro O 
studies O 
are O 
needed O 
to O 
clarify O 
the O 
effect O 
of O 
salinomycin B-TRIVIAL 
on O 
tissue O 
- O 
specific O 
stem O 
cells O 
. O 

in O 
urocanic B-TRIVIAL 
acid I-TRIVIAL 
, O 
histamine B-TRIVIAL 
, O 
putrescine B-TRIVIAL 
and O 
cadaverine B-TRIVIAL 
levels O 
in O 
Indian O 
mackerel O 
( O 
Rastrelliger O 
kanagurta O 
) O 
during O 
storage O 
at O 
different O 
temperatures O 
. O 

, O 
putrescine B-TRIVIAL 
cadaverine B-TRIVIAL 
and O 
cis-urocanic B-TRIVIAL 
acid I-TRIVIAL 
( O 
UCA B-ABBREVIATION 
) O 
have O 
all O 
been O 
implicated O 
or O 
suggested O 
in O 
scombroid O 
fish O 
poisoning O 
. O 
However O 
, O 
there O 
is O 
little O 
information O 
on O 
UCA B-ABBREVIATION 
especially O 
during O 
storage O 
. O 
Changes O 
in O 
their O 
contents O 
during O 
storage O 
of O 
whole O 
Indian O 
mackerel O 
at O 
0 O 
, O 
3±1 O 
, O 
10±1 O 
for O 
up O 
to O 
15days O 
and O 
23±2°C O 
for O 
up O 
to O 
2days O 
were O 
monitored O 
. O 
Fresh O 
muscles O 
contained O 
14.83mg O 
/ O 
kg O 
trans-UCA B-ABBREVIATION 
, O 
2.23mg O 
/ O 
kg O 
cis-UCA B-ABBREVIATION 
and O 
1.86mg O 
/ O 
kg O 
cadaverine B-TRIVIAL 
. O 
Histamine B-TRIVIAL 
and O 
putrescine B-TRIVIAL 
were O 
not O 
detected O 
. O 
After O 
15days O 
at O 
0 O 
and O 
3°C O 
, O 
trans-UCA B-ABBREVIATION 
content O 
increased O 
to O 
52.83 O 
and O 
189.51mg O 
/ O 
kg O 
, O 
respectively O 
, O 
and O 
decreased O 
to O 
< O 
2mg O 
/ O 
kg O 
at O 
the O 
other O 
two O 
temperatures O 
. O 
Storage O 
at O 
10°C O 
also O 
resulted O 
in O 
an O 
increase O 
in O 
trans-UCA B-ABBREVIATION 
after O 
3days O 
, O 
only O 
to O 
decrease O 
after O 
6days O 
. O 
The O 
concentration O 
of O 
cis-UCA B-ABBREVIATION 
increased O 
nearly O 
13-fold O 
after O 
15days O 
at O 
0 O 
and O 
3°C O 
, O 
decreased O 
at O 
10°C O 
and O 
remained O 
unchanged O 
at O 
23°C O 
. O 
Histamine B-TRIVIAL 
, O 
putrescine B-TRIVIAL 
and O 
cadaverine B-TRIVIAL 
levels O 
increased O 
significantly O 
( O 
P O 
value O 
< O 
0.05 O 
) O 
at O 
all O 
temperatures O 
especially O 
at O 
23°C O 
. O 

of O 
the O 
free O 
energy O 
of O 
ATP B-ABBREVIATION 
binding O 
to O 
wild O 
- O 
type O 
and O 
mutant O 
Kir6.2 O 
potassium B-SYSTEMATIC 
channels O 
. O 

-sensitive O 
K(+) B-FORMULA 
( O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
) O 
channels O 
, O 
comprised O 
of O 
pore O 
- O 
forming O 
Kir6.x O 
and O 
regulatory O 
SURx O 
subunits O 
, O 
play O 
important O 
roles O 
in O 
many O 
cellular O 
functions O 
; O 
because O 
of O 
their O 
sensitivity O 
to O 
inhibition O 
by O 
intracellular O 
ATP B-ABBREVIATION 
, O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
provide O 
a O 
link O 
between O 
cell O 
metabolism O 
and O 
membrane O 
electrical O 
activity O 
. O 
We O 
constructed O 
structural O 
homology O 
models O 
of O 
Kir6.2 O 
and O 
a O 
series O 
of O 
Kir6.2 O 
channels O 
carrying O 
mutations O 
within O 
the O 
putative O 
ATP B-ABBREVIATION 
-binding O 
site O 
. O 
Computational O 
docking O 
was O 
carried O 
out O 
to O 
determine O 
the O 
conformation O 
of O 
ATP B-ABBREVIATION 
in O 
its O 
binding O 
site O 
. O 
The O 
Linear O 
Interaction O 
Energy O 
( O 
LIE O 
) O 
method O 
was O 
used O 
to O 
estimate O 
the O 
free O 
- O 
energy O 
of O 
ATP B-ABBREVIATION 
binding O 
to O 
wild O 
- O 
type O 
and O 
mutant O 
Kir6.2 O 
channels O 
. O 
Comparisons O 
of O 
the O 
theoretical O 
binding O 
free O 
energies O 
for O 
ATP B-ABBREVIATION 
with O 
those O 
determined O 
from O 
mutational O 
experiments O 
enabled O 
the O 
identification O 
of O 
the O 
most O 
probable O 
conformation O 
of O 
ATP B-ABBREVIATION 
bound O 
to O 
the O 
Kir6.2 O 
channel O 
. O 
A O 
set O 
of O 
LIE O 
parameters O 
was O 
defined O 
that O 
may O 
enable O 
prediction O 
of O 
the O 
effects O 
of O 
additional O 
Kir6.2 O 
mutations O 
within O 
the O 
ATP B-ABBREVIATION 
binding O 
site O 
on O 
the O 
affinity O 
for O 
ATP B-ABBREVIATION 
. O 

the O 
discovery O 
of O 
electroluminescence O 
in O 
the O 
phenyl B-SYSTEMATIC 
-based O 
conjugated O 
polymers O 
in O 
1990 O 
, O 
the O 
field O 
of O 
polymer O 
optoelectronics O 
has O 
matured O 
to O 
the O 
extent O 
that O 
presently O 
a O 
wide O 
class O 
of O 
devices O 
have O 
been O 
commercialized O 
. O 
These O 
range O 
from O 
both O 
miniature O 
and O 
wide-area O 
light O 
emitting O 
devices O 
to O 
hybrid O 
photovoltaic O 
devices O 
. O 
Similarly O 
, O 
our O 
understanding O 
of O 
the O 
fundamental O 
processes O 
that O 
determine O 
these O 
optoelectronic O 
properties O 
has O 
also O 
progressed O 
. O 
In O 
particular O 
, O 
owing O 
to O 
insights O 
from O 
both O 
experimental O 
and O 
theoretical O 
investigations O 
, O 
the O 
role O 
of O 
the O 
primary O 
excited O 
states O 
, O 
i.e O 
. O 
, O 
excitons O 
, O 
is O 
now O 
considerably O 
clearer O 
. O 
This O 
review O 
discusses O 
these O 
primary O 
excited O 
states O 
and O 
explains O 
how O 
the O 
three O 
key O 
roles O 
of O 
electron O 
- O 
electron O 
interactions O 
, O 
electron O 
- O 
nuclear O 
coupling O 
, O 
and O 
disorder O 
determine O 
their O 
properties O 
. O 
We O 
show O 
that O 
the O 
properties O 
of O 
an O 
exciton O 
are O 
more O 
readily O 
understood O 
by O 
decomposing O 
it O 
into O 
two O 
effective O 
particles O 
. O 
First O 
, O 
a O 
relative O 
particle O 
that O 
describes O 
the O 
size O 
and O 
binding O 
energy O 
of O 
the O 
electron O 
- O 
hole O 
pair O 
. O 
Second O 
, O 
a O 
center O 
- O 
of O 
- O 
mass O 
particle O 
that O 
describes O 
the O 
extent O 
of O 
the O 
delocalization O 
of O 
the O 
electron O 
- O 
hole O 
pair O 
. O 
Disorder O 
and O 
coupling O 
to O 
the O 
normal O 
modes O 
localizes O 
the O 
center O 
- O 
of O 
- O 
mass O 
particle O 
and O 
provides O 
a O 
quantitative O 
definition O 
of O 
chromophores O 
in O 
conjugated O 
polymers O 
, O 
paving O 
the O 
way O 
for O 
a O 
first O 
- O 
principles O 
theory O 
of O 
exciton O 
diffusion O 
in O 
these O 
systems O 
. O 

mediates O 
testosterone B-TRIVIAL 
-induced O 
vasodilation O 
of O 
microvascular O 
resistance O 
vessels O 
. O 

knowledge O 
of O 
how O 
androgens B-FAMILY 
influence O 
the O 
cardiovascular O 
system O 
is O 
far O 
from O 
complete O 
, O 
and O 
this O 
lack O 
of O 
understanding O 
is O 
especially O 
true O 
of O 
how O 
androgens B-FAMILY 
affect O 
resistance O 
vessels O 
. O 
Our O 
aim O 
was O 
to O 
identify O 
the O 
signaling O 
mechanisms O 
stimulated O 
by O 
testosterone B-TRIVIAL 
( O 
TES B-ABBREVIATION 
) O 
in O 
microvascular O 
arteries O 
and O 
to O 
understand O 
how O 
these O 
mechanisms O 
mediate O 
TES B-ABBREVIATION 
-induced O 
vasodilation O 
. O 
Mesenteric O 
microvessels O 
were O 
isolated O 
from O 
male O 
Sprague-Dawley O 
rats O 
. O 
Tension O 
studies O 
demonstrated O 
a O 
rapid O 
, O 
concentration O 
- O 
dependent O 
, O 
vasodilatory O 
response O 
to O 
TES B-ABBREVIATION 
that O 
did O 
not O 
involve O 
protein O 
synthesis O 
or O 
aromatization O 
to O 
17β-estradiol B-SYSTEMATIC 
. O 
Dichlorofluorescein B-SYSTEMATIC 
fluorescence O 
and O 
nitrotyrosine B-SYSTEMATIC 
immunoblot O 
experiments O 
indicated O 
that O 
TES B-ABBREVIATION 
stimulated O 
peroxynitrite B-SYSTEMATIC 
formation O 
in O 
microvessels O 
, O 
and O 
functional O 
studies O 
demonstrated O 
that O 
TES B-ABBREVIATION 
-induced O 
vasodilation O 
was O 
inhibited O 
by O 
scavenging O 
peroxynitrite B-SYSTEMATIC 
. O 
As O 
predicted O 
, O 
TES B-ABBREVIATION 
enhanced O 
the O 
production O 
of O 
both O 
peroxynitrite B-SYSTEMATIC 
precursors O 
( O 
i.e O 
. O 
, O 
superoxide B-TRIVIAL 
and O 
nitic B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) O 
, O 
and O 
xanthine B-TRIVIAL 
oxidase O 
was O 
identified O 
as O 
the O 
likely O 
source O 
of O 
TES B-ABBREVIATION 
-stimulated O 
superoxide B-TRIVIAL 
production O 
. O 
Functional O 
and O 
biochemical O 
studies O 
indicated O 
that O 
TES B-ABBREVIATION 
signaling O 
involved O 
activity O 
of O 
the O 
phosphoinositide B-FAMILY 
3 O 
( O 
PI3 O 
) O 
kinase O 
- O 
protein O 
kinase O 
B O 
( O 
Akt O 
) O 
cascade O 
initiated O 
by O 
activation O 
of O 
the O 
androgen B-FAMILY 
receptor O 
and O 
culminated O 
in O 
enhanced O 
production O 
of O 
cGMP B-ABBREVIATION 
and O 
microvascular O 
vasodilation O 
. O 
These O 
findings O 
, O 
derived O 
from O 
a O 
variety O 
of O 
analytical O 
and O 
functional O 
approaches O 
, O 
provide O 
evidence O 
for O 
a O 
novel O 
nongenomic O 
signaling O 
mechanism O 
for O 
androgen B-FAMILY 
action O 
in O 
the O 
microvasculature O 
: O 
TES B-ABBREVIATION 
-stimulated O 
vasodilation O 
mediated O 
primarily O 
by O 
peroxynitrite B-SYSTEMATIC 
formed O 
from O 
xanthine B-TRIVIAL 
oxidase O 
- O 
generated O 
superoxide B-TRIVIAL 
and O 
NO B-FORMULA 
. O 
This O 
response O 
was O 
associated O 
with O 
activation O 
of O 
the O 
PI3 O 
kinase-Akt O 
signaling O 
cascade O 
initiated O 
by O 
activation O 
of O 
the O 
androgen B-FAMILY 
receptor O 
. O 
We O 
propose O 
this O 
mechanism O 
could O 
account O 
for O 
TES B-ABBREVIATION 
-stimulated O 
cGMP B-ABBREVIATION 
production O 
in O 
microvessels O 
and O 
, O 
ultimately O 
, O 
vasodilation O 
. O 

Y-family O 
of O 
DNA O 
polymerases O 
support O 
of O 
translesion O 
DNA O 
synthesis O 
( O 
TLS O 
) O 
associated O 
with O 
stalled O 
DNA O 
replication O 
by O 
DNA O 
damage O 
. O 
Recently O 
, O 
a O 
number O 
of O 
studies O 
suggest O 
that O 
some O 
specialized O 
TLS O 
polymerases O 
also O 
support O 
other O 
aspects O 
of O 
DNA O 
metabolism O 
beyond O 
TLS O 
in O 
vivo O 
. O 
Here O 
we O 
show O 
that O 
mouse O 
polymerase O 
kappa O 
( O 
Polκ O 
) O 
could O 
accumulate O 
at O 
laser O 
- O 
induced O 
sites O 
of O 
damage O 
in O 
vivo O 
resembling O 
polymerases O 
eta O 
and O 
iota O 
. O 
The O 
recruitment O 
was O 
mediated O 
through O 
Polκ O 
C B-FORMULA 
-terminus O 
which O 
contains O 
the O 
PCNA-interacting O 
peptide O 
, O 
ubiquitin O 
zinc B-SYSTEMATIC 
finger O 
motif O 
2 O 
and O 
nuclear O 
localization O 
signal O 
. O 
Interestingly O 
, O 
this O 
recruitment O 
was O 
significantly O 
reduced O 
in O 
MSH2-deficient O 
LoVo O 
cells O 
and O 
Rad18-depleted O 
cells O 
. O 
We O 
further O 
observed O 
that O 
Polκ-deficient O 
mouse O 
embryo O 
fibroblasts O 
were O 
abnormally O 
sensitive O 
to O 
H2O2 B-FORMULA 
treatment O 
and O 
displayed O 
defects O 
in O 
both O 
single O 
- O 
strand O 
break O 
repair O 
and O 
double O 
- O 
strand O 
break O 
repair O 
. O 
We O 
speculate O 
that O 
Polκ O 
may O 
have O 
an O 
important O 
role O 
in O 
strand O 
break O 
repair O 
following O 
oxidative O 
stress O 
in O 
vivo O 
. O 

area O 
resist O 
- O 
free O 
soft O 
lithographic O 
patterning O 
of O 
graphene B-TRIVIAL 
. O 

area O 
low O 
- O 
cost O 
patterning O 
is O 
a O 
challenging O 
problem O 
in O 
graphene B-TRIVIAL 
research O 
. O 
A O 
resist O 
- O 
free O 
, O 
single O 
- O 
step O 
, O 
large O 
area O 
and O 
cost O 
effective O 
soft O 
lithographic O 
patterning O 
strategy O 
is O 
presented O 
for O 
graphene B-TRIVIAL 
. O 
The O 
technique O 
is O 
applicable O 
on O 
any O 
arbitrary O 
substrate O 
that O 
needs O 
to O 
be O 
covered O 
with O 
a O 
graphene B-TRIVIAL 
film O 
and O 
provides O 
a O 
viable O 
route O 
to O 
large O 
- O 
area O 
patterning O 
of O 
graphene B-TRIVIAL 
for O 
device O 
applications O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
pesticide O 
residues O 
in O 
market O 
vegetables O 
in O 
Shaanxi O 
Province O 
of O 
China O 
. O 
The O 
concentrations O 
of O 
33 O 
pesticides O 
were O 
determined O 
by O 
gas O 
chromatography O 
( O 
GC O 
) O 
in O 
285 O 
samples O 
. O 
Ten O 
organophosphorus B-FAMILY 
pesticides O 
( O 
OPs O 
) O 
were O 
found O 
in O 
concentrations O 
ranging O 
from O 
0.004 O 
to O 
0.257 O 
mg O 
/ O 
kg O 
. O 
The O 
mean O 
levels O 
of O 
omethoate B-TRIVIAL 
, O 
phorate B-TRIVIAL 
, O 
chlorpyrifos B-TRIVIAL 
, O 
methidathion B-TRIVIAL 
, O 
ethoprophos B-TRIVIAL 
in O 
vegetables O 
exceeded O 
the O 
maximum O 
residue O 
limits O 
( O 
MRLs O 
) O 
allowed O 
by O 
the O 
Ministry O 
of O 
Health O 
, O 
of O 
China O 
. O 
Other O 
detectable O 
OP O 
pesticide O 
residues O 
levels O 
were O 
below O 
their O 
MRLs O 
. O 
Dicofol B-TRIVIAL 
were O 
detectable O 
in O 
green O 
pepper O 
and O 
chives O 
samples O 
. O 
Five O 
pyrethroid B-FAMILY 
pesticides O 
( O 
PYRs O 
) O 
were O 
detectable O 
in O 
vegetable O 
samples O 
respectively O 
. O 
The O 
results O 
provide O 
useful O 
information O 
on O 
the O 
current O 
contamination O 
status O 
of O 
a O 
key O 
agricultural O 
area O 
in O 
China O 
, O 
and O 
point O 
to O 
the O 
need O 
for O 
urgent O 
action O 
to O 
control O 
the O 
excessive O 
use O 
of O 
some O 
chemicals O 
. O 

present O 
study O 
evaluates O 
the O 
influence O 
of O 
drying O 
and O 
cooking O 
processes O 
on O 
the O 
health O 
properties O 
of O 
two O 
bell O 
Capsicum O 
annuum O 
L O 
. O 
cultivars O 
Roggiano O 
and O 
Senise O 
compared O 
with O 
fresh O 
peppers O 
. O 
The O 
content O 
of O 
phytochemicals O 
decreased O 
in O 
the O 
order O 
fresh O 
> O 
dried O 
> O 
dried O 
frying O 
processes O 
. O 
HPLC O 
analysis O 
was O 
applied O 
to O 
quantify O 
five O 
flavonoids B-FAMILY 
from O 
peppers O 
. O 
Apigenin B-TRIVIAL 
was O 
identified O 
as O 
main O 
constituent O 
. O 
Its O 
content O 
was O 
affected O 
by O 
drying O 
and O 
dried O 
frying O 
processes O 
. O 
The O 
antioxidant O 
activity O 
was O 
evaluated O 
by O 
DPPH B-ABBREVIATION 
, O 
ABTS B-ABBREVIATION 
, O 
β-carotene B-TRIVIAL 
bleaching O 
test O 
and O 
Fe B-FORMULA 
-chelating O 
activity O 
assay O 
. O 
A O 
comparable O 
radical O 
scavenging O 
activity O 
was O 
observed O 
for O 
both O 
cultivars O 
. O 
Interestingly O 
, O 
frying O 
process O 
did O 
not O 
influenced O 
this O 
property O 
. O 
Roggiano O 
peppers O 
exhibited O 
the O 
highest O 
antioxidant O 
activity O 
using O 
β-carotene B-TRIVIAL 
bleaching O 
test O 
with O 
IC(50) O 
values O 
of O 
38.1 O 
and O 
24.9 O 
μg O 
/ O 
mL O 
for O 
total O 
extract O 
and O 
n-hexane B-SYSTEMATIC 
fraction O 
, O 
respectively O 
. O 
GC-MS O 
analysis O 
of O 
lipophilic O 
fraction O 
revealed O 
the O 
presence O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
vitamin B-FAMILY 
E I-FAMILY 
as O 
major O 
components O 
. O 
In O 
the O 
inhibition O 
of O 
the O 
carbohydrate B-FAMILY 
-hydrolyzing O 
enzymes O 
fresh O 
Senise O 
peppers O 
exerted O 
the O 
strongest O 
activity O 
against O 
α-amylase O 
with O 
an O 
IC(50) O 
value O 
of O 
55.3 O 
μg O 
/ O 
mL O 
. O 
Our O 
results O 
indicate O 
that O 
C O 
. O 
annuum O 
cultivars O 
Roggiano O 
and O 
Senise O 
have O 
an O 
interestingly O 
potential O 
health O 
benefits O 
not O 
influenced O 
by O 
processes O 
that O 
are O 
used O 
before O 
consumption O 
. O 

mycotoxin B-TRIVIAL 
T-2 I-TRIVIAL 
inhibits O 
hepatic O 
cytochrome O 
P4503A O 
activity O 
in O 
pigs O 
. O 

are O 
toxic O 
metabolites O 
produced O 
by O 
fungi O 
that O 
readily O 
colonize O 
crops O 
. O 
After O 
ingestion O 
, O 
these O 
mycotoxins O 
can O 
compromise O 
intestinal O 
health O 
, O 
and O 
once O 
entering O 
the O 
blood O 
stream O 
, O 
even O 
affect O 
the O 
liver O 
and O 
its O 
metabolizing O 
enzymes O 
. O 
It O 
was O 
therefore O 
the O 
aim O 
of O 
the O 
present O 
study O 
to O 
investigate O 
the O 
effect O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
, O 
an O 
emerging O 
and O 
potent O 
Fusarium O 
mycotoxin O 
, O 
on O 
the O 
enzymatic O 
activity O 
of O 
cytochrome O 
P4503A O 
( O 
CYP3A O 
) O 
metabolizing O 
enzymes O 
in O 
the O 
liver O 
of O 
pigs O 
. O 
In O 
addition O 
, O 
a O 
yeast O 
- O 
derived O 
feed O 
additive O 
that O 
claims O 
to O 
bind O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
was O 
included O 
in O 
the O 
study O 
to O 
evaluate O 
its O 
efficacy O 
. O 
Our O 
results O 
demonstrated O 
that O 
a O 
14-days O 
intake O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
contaminated O 
feed O 
at O 
a O 
dose O 
of O 
903μg O 
/ O 
kg O 
feed O 
, O 
whether O 
or O 
not O 
combined O 
with O 
the O 
mycotoxin O 
binder O 
, O 
results O 
in O 
a O 
substantial O 
inhibition O 
of O 
the O 
CYP3A O 
activity O 
in O 
the O 
liver O 
of O 
pigs O 
. O 
This O 
result O 
may O 
be O 
of O 
importance O 
for O 
animal O 
health O 
, O 
the O 
pharmacokinetics O 
and O 
the O 
withdrawal O 
time O 
of O 
drugs O 
that O 
are O 
substrate O 
of O 
CYP3A O 
enzymes O 
, O 
and O 
consequently O 
can O 
be O 
a O 
threat O 
for O 
public O 
health O 
with O 
respect O 
to O 
tissue O 
residues O 
of O 
these O 
drugs O 
. O 

diacetate I-SYSTEMATIC 
( O 
DCFH-DA B-ABBREVIATION 
) O 
assay O 
: O 
a O 
quantitative O 
method O 
for O 
oxidative O 
stress O 
assessment O 
of O 
nanoparticle O 
- O 
treated O 
cells O 
. O 

consensus O 
exists O 
on O 
how O 
to O 
address O 
possible O 
toxicity O 
of O 
nanomaterials O 
as O 
they O 
interfere O 
with O 
most O 
in O 
vitro O 
screening O 
tests O 
based O 
on O 
colorimetric O 
and O 
fluorimetric O 
probes O 
such O 
as O 
the O 
dichloro-dihydro-fluorescein B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
( O 
DCFH-DA B-ABBREVIATION 
) O 
assay O 
for O 
detection O 
of O 
oxidative O 
species O 
. O 
In O 
the O 
present O 
research O 
, O 
nanomaterial O 
interaction O 
with O 
DCFH-DA B-ABBREVIATION 
was O 
studied O 
in O 
relation O 
to O 
its O 
nature O 
and O 
/ O 
or O 
assay O 
conditions O 
( O 
cell O 
- O 
based O 
and O 
time O 
exposure O 
) O 
by O 
incubating O 
Rhodamine B-FAMILY 
( O 
Rhd B-ABBREVIATION 
)-labeled O 
25nm O 
and O 
50nm O 
silica B-TRIVIAL 
( O 
SiO2 B-FORMULA 
) O 
, O 
naked O 
and O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
coated I-TRIVIAL 
magnetite I-TRIVIAL 
, O 
( O 
Fe3O4 B-FORMULA 
) O 
and O 
maghemite B-TRIVIAL 
( O 
Fe2O3 B-FORMULA 
) O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
) O 
and O 
poly(ethylene B-FAMILY 
oxide)-poly(lactide I-FAMILY 
/ I-FAMILY 
glycolide I-FAMILY 
) I-FAMILY 
acid I-FAMILY 
( O 
PLGA-PEO B-ABBREVIATION 
) O 
nanoparticles O 
( O 
NPs O 
) O 
with O 
metabolically O 
active O 
rat O 
hepatocytes O 
for O 
4 O 
and O 
24-h O 
periods O 
. O 
Data O 
indicated O 
that O 
nanoparticle O 
uptake O 
correlated O 
with O 
quenching O 
of O 
dye O 
fluorescence O 
emission O 
. O 
In O 
spite O 
of O 
their O 
masking O 
effect O 
, O 
the O 
oxidative O 
potential O 
of O 
NPs O 
could O 
be O 
detected O 
at O 
a O 
limited O 
threshold O 
concentration O 
when O 
exposed O 
for O 
periods O 
of O 
time O 
longer O 
than O 
those O 
frequently O 
used O 
for O 
this O 
test O 
. O 
However O 
, O 
changes O 
in O 
the O 
experimental O 
conditions O 
did O 
not O 
systematically O 
result O 
in O 
free O 
radical O 
formation O 
for O 
all O 
nanomaterials O 
tested O 
. O 
Overall O 
data O 
indicate O 
that O 
despite O 
the O 
quenching O 
effect O 
of O 
nanoparticles O 
on O 
DCFH-DA B-ABBREVIATION 
assay O 
, O 
it O 
can O 
be O 
considered O 
as O 
a O 
useful O 
tool O 
for O 
quantitative O 
measurement O 
of O 
NPs-induced O 
oxidative O 
stress O 
by O 
minor O 
modifications O 
of O 
standardized O 
protocols O 
. O 

statistical O 
approach O 
for O 
analyzing O 
the O 
development O 
of O 
(1)H B-FORMULA 
multiple O 
- O 
quantum O 
coherence O 
in O 
solids O 
. O 

novel O 
statistical O 
approach O 
for O 
analyzing O 
(1)H B-FORMULA 
multiple O 
- O 
quantum O 
( O 
MQ O 
) O 
spin O 
dynamics O 
in O 
so O 
- O 
called O 
spin O 
- O 
counting O 
solid O 
- O 
state O 
NMR O 
experiments O 
is O 
presented O 
. O 
The O 
statistical O 
approach O 
is O 
based O 
on O 
the O 
percolation O 
theory O 
with O 
Monte O 
Carlo O 
methods O 
and O 
is O 
examined O 
by O 
applying O 
it O 
to O 
the O 
experimental O 
results O 
of O 
three O 
solid O 
samples O 
having O 
unique O 
hydrogen B-SYSTEMATIC 
arrangement O 
for O 
1-3 O 
dimensions O 
: O 
the O 
n-alkane B-FAMILY 
/ O 
d-urea B-TRIVIAL 
inclusion O 
complex O 
as O 
a O 
one O 
- O 
dimensional O 
( O 
1D O 
) O 
system O 
, O 
whose O 
(1)H B-FORMULA 
nuclei O 
align O 
approximately O 
in O 
1D O 
, O 
and O 
magnesium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
and O 
adamantane B-TRIVIAL 
as O 
a O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
and O 
a O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
system O 
, O 
respectively O 
. O 
Four O 
lattice O 
models O 
, O 
linear O 
, O 
honeycomb O 
, O 
square O 
and O 
cubic O 
, O 
are O 
used O 
to O 
represent O 
the O 
(1)H B-FORMULA 
arrangement O 
of O 
the O 
three O 
samples O 
. O 
It O 
is O 
shown O 
that O 
the O 
MQ O 
dynamics O 
in O 
adamantane B-TRIVIAL 
is O 
consistent O 
with O 
that O 
calculated O 
using O 
the O 
cubic O 
lattice O 
and O 
that O 
in O 
Mg(OH)2 B-FORMULA 
with O 
that O 
calculated O 
using O 
the O 
honeycomb O 
and O 
the O 
square O 
lattices O 
. O 
For O 
n-C20H42 B-FORMULA 
/ O 
d-urea B-TRIVIAL 
, O 
these O 
4 O 
lattice O 
models O 
fail O 
to O 
express O 
its O 
result O 
. O 
It O 
is O 
shown O 
that O 
a O 
more O 
realistic O 
model O 
representing O 
the O 
(1)H B-FORMULA 
arrangement O 
of O 
n-C20H42 B-FORMULA 
/ O 
d-urea B-TRIVIAL 
can O 
describe O 
the O 
result O 
. O 
The O 
present O 
approach O 
can O 
thus O 
be O 
used O 
to O 
determine O 
(1)H B-FORMULA 
arrangement O 
in O 
solids O 
. O 

, O 
Asians O 
have O 
lower O 
areal O 
bone O 
mineral O 
density O 
, O 
but O 
their O 
rates O 
of O 
hip O 
and O 
wrist O 
fractures O 
are O 
lower O 
than O 
Caucasians O 
. O 
Therefore O 
, O 
we O 
used O 
high O 
- O 
resolution O 
pQCT O 
( O 
HR-pQCT O 
) O 
to O 
determine O 
whether O 
differences O 
in O 
bone O 
macro- O 
and O 
microstructure O 
, O 
BMD O 
and O 
bone O 
strength O 
at O 
the O 
distal O 
radius O 
are O 
apparent O 
in O 
Asian O 
( O 
n O 
= O 
91 O 
, O 
53 O 
males O 
, O 
38 O 
females O 
, O 
17.3 O 
± O 
1.5 O 
yrs O 
) O 
and O 
Caucasian O 
( O 
n O 
= O 
89 O 
, O 
46 O 
males O 
, O 
43 O 
females O 
, O 
18.1 O 
± O 
1.8 O 
yrs O 
) O 
adolescents O 
and O 
young O 
adults O 
. O 
HR-pQCT O 
outcomes O 
included O 
total O 
BMD O 
( O 
Tt.BMD O 
) O 
, O 
trabecular O 
bone O 
volume O 
fraction O 
( O 
BV O 
/ O 
TV O 
) O 
, O 
trabecular O 
number O 
( O 
Tb.N O 
) O 
, O 
thickness O 
( O 
Tb.Th O 
) O 
and O 
separation O 
( O 
Tb.Sp O 
) O 
. O 
We O 
used O 
an O 
automated O 
segmentation O 
algorithm O 
to O 
determine O 
total O 
bone O 
area O 
( O 
Tt.Ar O 
) O 
, O 
cortical O 
BMD O 
( O 
Ct.BMD O 
) O 
, O 
porosity O 
( O 
Ct.Po O 
) O 
and O 
thickness O 
( O 
Ct.Th O 
) O 
, O 
and O 
we O 
applied O 
finite O 
element O 
analysis O 
to O 
HR-pQCT O 
scans O 
to O 
estimate O 
bone O 
strength O 
. O 
We O 
fit O 
sex O 
- O 
specific O 
multivariable O 
regression O 
models O 
to O 
compare O 
bone O 
outcomes O 
between O 
Asians O 
and O 
Caucasians O 
, O 
adjusting O 
for O 
age O 
, O 
age O 
at O 
menarche O 
( O 
girls O 
) O 
, O 
lean O 
mass O 
, O 
ulnar O 
length O 
, O 
dietary O 
calcium B-SYSTEMATIC 
intake O 
and O 
physical O 
activity O 
. O 
In O 
males O 
, O 
after O 
adjusting O 
for O 
covariates O 
, O 
Asians O 
had O 
11% O 
greater O 
Tt.BMD O 
, O 
8% O 
greater O 
Ct.BMD O 
and O 
25% O 
lower O 
Ct.Po O 
than O 
Caucasians O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Also O 
, O 
Asians O 
had O 
9% O 
smaller O 
Tt.Ar O 
and O 
27% O 
greater O 
Ct.Th O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
In O 
females O 
, O 
Asians O 
had O 
smaller O 
Tt.Ar O 
than O 
Caucasians O 
( O 
16% O 
, O 
p O 
< O 
0.001 O 
) O 
, O 
but O 
this O 
difference O 
was O 
not O 
significant O 
after O 
adjusting O 
for O 
covariates O 
. O 
Asian O 
females O 
had O 
5% O 
greater O 
Ct.BMD O 
, O 
12% O 
greater O 
Ct.Th O 
and O 
11% O 
lower O 
Tb.Sp O 
than O 
Caucasians O 
after O 
adjusting O 
for O 
covariates O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Estimated O 
bone O 
strength O 
did O 
not O 
differ O 
between O 
Asian O 
and O 
Caucasian O 
males O 
or O 
females O 
. O 
Our O 
study O 
supports O 
the O 
notion O 
of O 
compensatory O 
elements O 
of O 
bone O 
structure O 
that O 
sustain O 
bone O 
strength O 
; O 
smaller O 
bones O 
as O 
observed O 
between O 
those O 
of O 
Asian O 
compared O 
with O 
Caucasian O 
origin O 
, O 
have O 
, O 
on O 
average O 
, O 
more O 
dense O 
, O 
less O 
porous O 
and O 
thicker O 
cortices O 
. O 
Longitudinal O 
studies O 
are O 
needed O 
to O 
determine O 
whether O 
ethnic O 
differences O 
in O 
bone O 
structure O 
exist O 
in O 
childhood O 
, O 
persist O 
into O 
old O 
age O 
and O 
whether O 
they O 
influence O 
fracture O 
risk O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

-binding O 
proteins O 
: O 
Functions O 
in O 
cell O 
regulation O 
beyond O 
lipid O 
metabolism O 
. O 

-binding O 
( O 
OSBP O 
) O 
- O 
related O 
proteins O 
( O 
ORPs O 
) O 
constitute O 
a O 
family O 
of O 
sterol B-FAMILY 
and O 
phosphoinositide B-FAMILY 
binding O 
/ O 
transfer O 
proteins O 
in O 
eukaryotes O 
from O 
yeast O 
to O 
man O 
. O 
While O 
their O 
functions O 
have O 
mainly O 
been O 
addressed O 
in O 
cellular O 
lipid O 
metabolism O 
or O 
sterol B-FAMILY 
transport O 
, O 
increasing O 
evidence O 
points O 
to O 
more O 
versatile O 
regulatory O 
roles O 
in O 
a O 
spectrum O 
of O 
cellular O 
regimes O 
. O 
In O 
fact O 
ORPs O 
do O 
not O 
appear O 
to O 
be O 
robust O 
controllers O 
of O 
lipid O 
homeostasis O 
. O 
Several O 
ORPs O 
localize O 
at O 
membrane O 
contacts O 
sites O 
( O 
MCS O 
) O 
, O 
where O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
is O 
apposed O 
with O 
other O 
organelle O 
limiting O 
membranes O 
. O 
Apparently O 
, O 
ORPs O 
have O 
the O 
capacity O 
to O 
control O 
the O 
formation O 
of O 
MCS O 
or O 
activity O 
of O 
enzymatic O 
machineries O 
at O 
these O 
sites O 
. O 
Thereby O 
, O 
ORPs O 
most O 
likely O 
affect O 
organelle O 
membrane O 
lipid O 
compositions O 
, O 
with O 
impacts O 
on O 
signaling O 
and O 
vesicle O 
transport O 
, O 
but O 
also O 
cellular O 
lipid O 
metabolism O 
. O 
Moreover O 
, O 
an O 
increasing O 
number O 
of O 
protein O 
interaction O 
partners O 
of O 
ORPs O 
have O 
been O 
identified O 
, O 
connecting O 
these O 
proteins O 
with O 
various O 
aspects O 
of O 
cell O 
regulation O 
. O 
Small O 
molecular O 
anti-proliferative O 
compounds O 
, O 
ORPphilins O 
, O 
were O 
recently O 
found O 
to O 
target O 
two O 
members O 
of O 
the O 
ORP O 
family O 
, O 
OSBP O 
and O 
ORP4 O 
, O 
revealing O 
an O 
essential O 
function O 
of O 
ORPs O 
in O 
cancer O 
cell O 
proliferation O 
and O 
survival O 
. O 
Further O 
functions O 
assigned O 
for O 
ORPs O 
include O 
regulation O 
of O 
extracellular O 
signal O 
regulated O 
kinase O 
( O 
ERK O 
) O 
activity O 
( O 
OSBP O 
) O 
, O 
control O 
of O 
ER-late O 
endosome O 
MCS O 
and O 
late O 
endosome O 
motility O 
( O 
ORP1L O 
) O 
, O 
regulation O 
of O 
β1-integrin O 
activity O 
( O 
ORP3 O 
) O 
, O 
modulation O 
of O 
hepatocyte O 
insulin O 
signaling O 
and O 
macrophage O 
migration O 
( O 
ORP8 O 
) O 
, O 
as O 
well O 
as O 
post-Golgi O 
vesicle O 
transport O 
, O 
phosphatidylinositol-4-phosphate B-SYSTEMATIC 
and O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
signaling O 
and O 
nitrogen B-SYSTEMATIC 
sensing O 
( O 
Saccharomyces O 
cerevisiae O 
Osh4p O 
) O 
. O 
These O 
and O 
other O 
recent O 
observations O 
shed O 
light O 
on O 
the O 
ORPs O 
as O 
integrators O 
of O 
lipid O 
signals O 
with O 
an O 
unforeseen O 
variety O 
of O 
vital O 
cellular O 
processes O 
. O 

we O 
describe O 
the O 
development O 
and O 
implementation O 
of O 
a O 
nanoporous O 
cell O 
- O 
therapy O 
device O 
with O 
controllable O 
biodegradation O 
. O 
Dopamine B-TRIVIAL 
-secreting O 
PC12 O 
cells O 
were O 
housed O 
within O 
newly O 
formulated O 
alginate- O 
glutamine B-TRIVIAL 
degradable O 
polylysine B-FAMILY 
( O 
A-GD- O 
PLL B-ABBREVIATION 
) O 
microcapsules O 
. O 
The O 
A-GD- O 
PLL B-ABBREVIATION 
microcapsules O 
provided O 
a O 
3-D O 
microenvironment O 
for O 
good O 
spatial O 
cell O 
growth O 
, O 
viability O 
and O 
proliferation O 
. O 
The O 
microcapsules O 
were O 
subsequently O 
placed O 
within O 
a O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
- O 
coated O 
poly(ε-caprolactone) B-FAMILY 
( O 
PCL B-ABBREVIATION 
) O 
chamber O 
covered O 
with O 
a O 
PEG-grafted B-ABBREVIATION 
PCL I-ABBREVIATION 
nanoporous O 
membrane O 
formed O 
by O 
phase O 
inversion O 
. O 
To O 
enhance O 
PC12 O 
cell O 
growth O 
and O 
to O 
assist O 
in O 
controlled O 
degradation O 
of O 
both O 
the O 
PC12 O 
cells O 
and O 
the O 
device O 
construct O 
, O 
small O 
PCL B-ABBREVIATION 
capsules O 
containing O 
neural O 
growth O 
factor O 
( O 
PCL B-ABBREVIATION 
-NGF O 
) O 
and O 
a O 
poly(lactic B-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
pellet O 
containing O 
glutamine B-TRIVIAL 
( O 
PLGA B-ABBREVIATION 
- O 
GLN B-FORMULA 
) O 
were O 
also O 
placed O 
within O 
the O 
PCL B-ABBREVIATION 
chamber O 
. O 
Release O 
of O 
NGF O 
from O 
the O 
PCL B-ABBREVIATION 
-NGF O 
capsules O 
facilitated O 
cell O 
proliferation O 
and O 
viability O 
, O 
while O 
the O 
controlled O 
release O 
of O 
GLN B-FORMULA 
from O 
the O 
PLGA B-ABBREVIATION 
- O 
GLN B-FORMULA 
pellet O 
resulted O 
in O 
A-GD- O 
PLL B-ABBREVIATION 
microcapsule O 
degradation O 
and O 
eventual O 
PC12 O 
cell O 
death O 
following O 
a O 
pre O 
- O 
specified O 
period O 
of O 
time O 
( O 
4 O 
weeks O 
in O 
this O 
study O 
) O 
. O 
In O 
vivo O 
, O 
our O 
device O 
was O 
found O 
to O 
be O 
well O 
tolerated O 
and O 
we O 
successfully O 
demonstrated O 
the O 
controlled O 
release O 
of O 
dopamine B-TRIVIAL 
over O 
a O 
period O 
of O 
four O 
weeks O 
. O 
This O 
integrated O 
biodegradable O 
device O 
holds O 
great O 
promise O 
for O 
the O 
future O 
treatment O 
of O 
a O 
variety O 
of O 
diseases O 
. O 

, O 
a O 
novel O 
acetylcholinesterase O 
inhibitor O 
, O 
protects O 
against O 
glutamate B-TRIVIAL 
-induced O 
neuronal O 
excitotoxicity O 
via O 
activating O 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor/ O 
phosphoinositide B-FAMILY 
3-kinase O 
/ O 
Akt O 
cascade O 
. O 

( O 
B12H B-ABBREVIATION 
) O 
, O 
derived O 
from O 
the O 
Chinese O 
medicinal O 
component O 
huperzine B-TRIVIAL 
A I-TRIVIAL 
, O 
was O 
originally O 
designed O 
as O 
a O 
novel O 
acetylcholinesterase O 
( O 
AChE O 
) O 
inhibitor O 
. O 
In O 
this O 
paper O 
, O 
we O 
report O 
that O 
B12H B-ABBREVIATION 
( O 
24-h O 
pretreatment O 
) O 
effectively O 
blocked O 
glutamate B-TRIVIAL 
-induced O 
neuronal O 
excitotoxicity O 
in O 
cerebellar O 
granule O 
neurons O 
( O 
CGNs O 
) O 
. O 
However O 
, O 
the O 
huge O 
discrepancy O 
between O 
the O 
EC50 O 
value O 
and O 
IC50 O 
value O 
of O 
B12H B-ABBREVIATION 
, O 
to O 
protect O 
against O 
neuronal O 
toxicity O 
( O 
0.09μM O 
) O 
and O 
to O 
block O 
the O 
NMDA B-ABBREVIATION 
receptor O 
( O 
21.8μM O 
) O 
respectively O 
, O 
suggests O 
that O 
the O 
neuroprotection O 
of O 
B12H B-ABBREVIATION 
might O 
be O 
not O 
primarily O 
due O 
to O 
the O 
blockade O 
of O 
the O 
NMDA B-ABBREVIATION 
receptor O 
. O 
Pretreatment O 
by O 
specific O 
antagonists O 
of O 
alpha7-nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
α7nAChR O 
) O 
, O 
but O 
not O 
muscarinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
mAChR O 
) O 
or O 
α4β2nAChR O 
, O 
decreased O 
the O 
neuroprotection O 
of O 
B12H B-ABBREVIATION 
. O 
The O 
neuroprotection O 
of O 
B12H B-ABBREVIATION 
could O 
also O 
be O 
abolished O 
by O 
the O 
pretreatment O 
of O 
specific O 
PI3-K O 
inhibitors O 
. O 
Furthermore O 
, O 
B12H B-ABBREVIATION 
restored O 
the O 
suppressed O 
activation O 
of O 
the O 
Akt O 
pathway O 
caused O 
by O 
glutamate B-TRIVIAL 
as O 
evidenced O 
by O 
the O 
decreased O 
expressions O 
of O 
pSer B-FORMULA 
473-Akt O 
and O 
pSer B-FORMULA 
9-GSK3β O 
. O 
All O 
these O 
results O 
suggest O 
that O 
B12H B-ABBREVIATION 
substantially O 
protected O 
CGNs O 
against O 
glutamate B-TRIVIAL 
-induced O 
neuronal O 
excitotoxicity O 
via O 
activating O 
α7nAChR O 
/ O 
PI3-K O 
/ O 
Akt O 
cascade O 
. O 

effect O 
of O 
C B-FORMULA 
-vacancy O 
on O 
hydrogen B-SYSTEMATIC 
storage O 
and O 
characterization O 
of O 
H2 B-FORMULA 
modes O 
on O 
Ti B-FORMULA 
functionalized O 
C60 B-TRIVIAL 
fullerene I-TRIVIAL 
a O 
first O 
principles O 
study O 
. O 

functional O 
theory O 
calculations O 
were O 
performed O 
to O 
examine O 
the O 
effect O 
of O 
a O 
C B-FORMULA 
vacancy O 
on O 
the O 
physisorption O 
of O 
H(2) B-FORMULA 
onto O 
Ti B-FORMULA 
-functionalized O 
C(60) B-TRIVIAL 
fullerene I-TRIVIAL 
when O 
H(2) B-FORMULA 
is O 
oriented O 
along O 
the O 
x- O 
, O 
y- O 
, O 
and O 
z-axes O 
of O 
the O 
fullerene B-TRIVIAL 
. O 
The O 
effect O 
of O 
the O 
C B-FORMULA 
vacancy O 
on O 
the O 
physisorption O 
modes O 
of O 
H(2) B-FORMULA 
was O 
investigated O 
as O 
a O 
function O 
of O 
H(2) B-FORMULA 
binding O 
energy O 
within O 
the O 
energy O 
window O 
( O 
-0.2 O 
to O 
-0.6 O 
eV O 
) O 
targeted O 
by O 
the O 
Department O 
of O 
Energy O 
( O 
DOE O 
) O 
, O 
and O 
as O 
functions O 
of O 
a O 
variety O 
of O 
other O 
physicochemical O 
properties O 
. O 
The O 
results O 
indicate O 
that O 
the O 
preferential O 
orientations O 
of O 
H(2) B-FORMULA 
in O 
the O 
defect O 
- O 
free O 
( O 
i.e O 
. O 
, O 
no O 
C B-FORMULA 
vacancy O 
) O 
C(60)TiH(2) B-FORMULA 
complex O 
are O 
along O 
the O 
x- O 
and O 
y-axes O 
of O 
C(60) B-TRIVIAL 
( O 
with O 
adsorption O 
energies O 
of O 
-0.23 O 
and O 
-0.21 O 
eV O 
, O 
respectively O 
) O 
, O 
making O 
these O 
orientations O 
the O 
most O 
suitable O 
ones O 
for O 
hydrogen B-SYSTEMATIC 
storage O 
, O 
in O 
contrast O 
to O 
the O 
results O 
obtained O 
for O 
defect O 
- O 
containing O 
fullerenes O 
. O 
The O 
defect O 
- O 
containing O 
( O 
i.e O 
. O 
, O 
containing O 
a O 
C B-FORMULA 
vacancy O 
) O 
C(59)TiH(2) B-FORMULA 
complex O 
do O 
not O 
exhibit O 
adsorption O 
energies O 
within O 
the O 
targeted O 
energy O 
range O 
. O 
Charge O 
transfer O 
occurs O 
from O 
Ti B-FORMULA 
3d O 
to O 
C B-FORMULA 
2p O 
of O 
the O 
fullerene B-TRIVIAL 
. O 
The O 
binding O 
of O 
H(2) B-FORMULA 
is O 
dominated O 
by O 
the O 
pairwise O 
support O 
- O 
metal O 
interaction O 
energy O 
E(i)(Cn O 
. O 
. O 
. O 
Ti B-FORMULA 
) O 
, O 
and O 
the O 
role O 
of O 
the O 
fullerene B-TRIVIAL 
is O 
not O 
restricted O 
to O 
supporting O 
the O 
metal O 
. O 
The O 
C B-FORMULA 
vacancy O 
enhances O 
the O 
adsorption O 
energy O 
of O 
Ti B-FORMULA 
, O 
in O 
contrast O 
to O 
that O 
of O 
H(2) B-FORMULA 
. O 
A O 
significant O 
reduction O 
in O 
the O 
energy O 
gap O 
of O 
the O 
pristine O 
C(60) B-TRIVIAL 
fullerene I-TRIVIAL 
is O 
observed O 
when O 
TiH(2) B-FORMULA 
is O 
adsorbed O 
by O 
it O 
. O 
While O 
the O 
C( B-FAMILY 
n I-FAMILY 
) I-FAMILY 
fullerene I-FAMILY 
readily O 
participates O 
in O 
nucleophilic O 
processes O 
, O 
the O 
adjacent O 
TiH(2) B-FORMULA 
fragment O 
is O 
available O 
for O 
electrophilic O 
processes O 
. O 

: O 
a O 
candidate O 
antipsychotic O 
compound O 
with O 
procognitive O 
efficacy O 
in O 
rodents O 
. O 

antipsychotics O 
, O 
e.g O 
. O 
haloperidol B-TRIVIAL 
, O 
chlorpromazine B-TRIVIAL 
, O 
are O 
potent O 
at O 
controlling O 
the O 
positive O 
symptoms O 
of O 
schizophrenia O 
but O 
frequently O 
elicit O 
extrapyramidal O 
motor O 
side-effects O 
. O 
The O 
introduction O 
of O 
atypical O 
antipsychotics O 
such O 
as O 
risperidone B-TRIVIAL 
, O 
olanzapine B-TRIVIAL 
and O 
clozapine B-TRIVIAL 
has O 
obviated O 
this O 
problem O 
, O 
but O 
none O 
of O 
the O 
current O 
drugs O 
seem O 
to O 
improve O 
the O 
cognitive O 
deficits O 
accompanying O 
schizophrenia O 
. O 
Thus O 
there O 
is O 
an O 
unmet O 
need O 
for O 
agents O 
that O 
not O 
only O 
suppress O 
the O 
psychotic O 
symptoms O 
but O 
also O 
ameliorate O 
the O 
impairment O 
of O 
cognition O 
. O 
Here O 
, O 
we O 
report O 
the O 
preclinical O 
properties O 
of O 
a O 
candidate O 
antipsychotic O 
, O 
Egis-11150 B-NO_CLASS 
, O 
that O 
shows O 
marked O 
pro O 
- O 
cognitive O 
efficacy O 
. O 
Egis-11150 B-NO_CLASS 
displayed O 
high O 
affinity O 
for O 
adrenergic O 
α(1) O 
, O 
α(2c) O 
, O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
5-HT₇ O 
, O 
moderate O 
affinity O 
for O 
adrenergic O 
α(2a) O 
and O 
D₂ O 
receptors O 
. O 
It O 
was O 
a O 
functional O 
antagonist O 
on O 
all O 
of O 
the O 
above O 
receptors O 
, O 
with O 
the O 
exception O 
of O 
5-HT₇ O 
receptors O 
, O 
where O 
it O 
was O 
an O 
inverse O 
agonist O 
. O 
Phencyclidine B-TRIVIAL 
-induced O 
hypermotility O 
in O 
mice O 
and O 
inhibition O 
of O 
conditioned O 
avoidance O 
response O 
in O 
rats O 
were O 
assessed O 
to O 
estimate O 
efficacy O 
against O 
the O 
positive O 
and O 
social O 
withdrawal O 
test O 
in O 
rats O 
was O 
used O 
to O 
predict O 
efficacy O 
against O 
the O 
negative O 
symptoms O 
of O 
schizophrenia O 
. O 
Passive O 
- O 
avoidance O 
learning O 
, O 
novel O 
object O 
recognition O 
and O 
radial O 
maze O 
tests O 
in O 
rats O 
were O 
used O 
to O 
assess O 
pro O 
- O 
cognitive O 
activity O 
, O 
while O 
phencyclidine B-TRIVIAL 
-induced O 
disruption O 
of O 
prepulse O 
inhibition O 
in O 
mice O 
was O 
examined O 
to O 
test O 
for O 
effects O 
on O 
attention O 
. O 
Egis-11150 B-NO_CLASS 
( O 
0.01-0.3 O 
mg O 
/ O 
kg O 
, O 
ip O 
. O 
) O 
was O 
effective O 
in O 
all O 
of O 
the O 
preclinical O 
models O 
of O 
schizophrenia O 
examined O 
. O 
Moreover O 
, O 
a O 
robust O 
pro O 
- O 
cognitive O 
profile O 
was O 
apparent O 
. O 
In O 
summary O 
, O 
work O 
in O 
preclinical O 
models O 
indicates O 
that O 
Egis-11150 B-NO_CLASS 
is O 
a O 
potential O 
treatment O 
for O 
controlling O 
the O 
psychosis O 
as O 
well O 
as O 
the O 
cognitive O 
dysfunction O 
in O 
schizophrenia O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

- O 
proteins O 
are O 
glycoproteins O 
that O 
occur O 
in O 
higher O 
plants O 
and O 
are O 
involved O 
in O 
important O 
processes O 
like O 
cell O 
differentiation O 
and O 
plant O 
growth O 
. O 
In O 
the O 
medicinal O 
plant O 
Echinacea O 
purpurea O 
L O 
. O 
, O 
they O 
belong O 
to O 
the O 
putative O 
immunomodulating O 
compounds O 
and O 
are O 
structurally O 
well O 
characterized O 
. O 
For O 
microscopic O 
localization O 
of O 
arabinogalactan O 
- O 
proteins O 
, O 
synthetic O 
(β-D-Glc)3 B-SYSTEMATIC 
Yariv I-SYSTEMATIC 
phenylglycoside I-SYSTEMATIC 
that O 
specifically O 
binds O 
to O 
most O 
plant O 
arabinogalactan O 
- O 
proteins O 
was O 
used O 
to O 
label O 
arabinogalactan O 
- O 
proteins O 
in O 
fresh O 
cut O 
sections O 
of O 
stems O 
and O 
petioles O 
of O 
Echinacea O 
purpurea O 
. O 
Polyclonal O 
antibodies O 
against O 
(β-D-Glc)3 B-SYSTEMATIC 
Yariv I-SYSTEMATIC 
phenylglycoside I-SYSTEMATIC 
were O 
used O 
to O 
detect O 
the O 
arabinogalactan O 
- O 
protein- O 
(β-D-Glc)3 B-SYSTEMATIC 
Yariv I-SYSTEMATIC 
phenylglycoside I-SYSTEMATIC 
complex O 
. O 
After O 
addition O 
of O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
-conjugated O 
secondary O 
antibodies O 
, O 
the O 
sections O 
were O 
analyzed O 
by O 
confocal O 
laser O 
scanning O 
microscopy O 
. O 
Arabinogalactan O 
- O 
proteins O 
are O 
localized O 
mainly O 
in O 
the O 
central O 
cylinder O 
in O 
the O 
collateral O 
vascular O 
bundles O 
, O 
especially O 
in O 
the O 
area O 
of O 
the O 
xylem O 
. O 
In O 
cell O 
walls O 
of O 
fully O 
differentiated O 
vessels O 
and O 
tracheids O 
, O 
arabinogalactan O 
- O 
proteins O 
have O 
been O 
detected O 
mainly O 
at O 
the O 
inner O 
area O 
of O 
the O 
wall O 
close O 
to O 
the O 
cell O 
lumina O 
. O 
Intense O 
labeling O 
occurs O 
around O 
pit O 
canals O 
connecting O 
adjacent O 
vessels O 
. O 
Furthermore O 
, O 
arabinogalactan O 
- O 
proteins O 
are O 
present O 
in O 
the O 
lumina O 
of O 
cells O 
of O 
the O 
sclerenchyma O 
caps O 
and O 
in O 
companion O 
cells O 
of O 
the O 
phloem O 
. O 

observed O 
spontaneous O 
activation O 
of O 
ethephon B-TRIVIAL 
as O 
a O 
butyrylcholinesterase O 
inhibitor O 
. O 

plant O 
growth O 
regulator O 
ethephon B-TRIVIAL 
( O 
2-chloroethylphosphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
inhibits O 
human O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
by O 
making O 
a O 
covalent O 
adduct O 
on O 
the O 
active O 
site O 
serine B-TRIVIAL 
198 O 
. O 
Our O 
goal O 
was O 
to O 
extend O 
earlier O 
studies O 
on O 
ethephon B-TRIVIAL 
inhibition O 
. O 
Addition O 
of O 
freshly O 
prepared O 
ethephon B-TRIVIAL 
to O 
BChE O 
in O 
buffered O 
medium O 
, O 
at O 
pH O 
7 O 
and O 
22 O 
°C O 
, O 
resulted O 
in O 
no O 
inhibition O 
initially O 
. O 
However O 
, O 
inhibition O 
developed O 
progressively O 
over O 
60 O 
min O 
of O 
incubation O 
. O 
Preincubation O 
of O 
ethephon B-TRIVIAL 
in O 
pH O 
7-9 O 
buffers O 
increased O 
its O 
initial O 
inhibitory O 
potency O 
. O 
These O 
observations O 
indicated O 
that O 
ethephon B-TRIVIAL 
itself O 
was O 
not O 
the O 
inhibitor O 
. O 
About O 
3% O 
of O 
the O 
initial O 
ethephon B-TRIVIAL 
could O 
be O 
trapped O 
as O 
a O 
BChE O 
adduct O 
. O 
Mass O 
spectral O 
analysis O 
of O 
the O 
active O 
site O 
peptide O 
from O 
inhibited O 
BChE O 
showed O 
that O 
the O 
inhibitor O 
added O 
a O 
mass O 
of O 
108 O 
Da O 
to O 
the O 
active O 
site O 
serine B-TRIVIAL 
on O 
peptide O 
FGES198AGAAS O 
. O 
This O 
result O 
rules O 
out O 
a O 
previous O 
hypothesis O 
that O 
ethephon B-TRIVIAL 
adds O 
HPO3 B-FORMULA 
to O 
BChE O 
( O 
added O 
mass O 
of O 
80 O 
Da O 
) O 
. O 
To O 
accommodate O 
these O 
observations O 
, O 
we O 
propose O 
that O 
in O 
aqueous O 
media O 
at O 
neutral O 
to O 
slightly O 
alkaline O 
pH O 
about O 
3% O 
of O 
the O 
ethephon B-TRIVIAL 
is O 
converted O 
( O 
t1 O 
/ O 
2 O 
= O 
9.9 O 
h O 
at O 
pH O 
7 O 
) O 
into O 
a O 
cyclic B-SYSTEMATIC 
oxaphosphetane I-SYSTEMATIC 
which O 
is O 
the O 
actual O 
BChE O 
inhibitor O 
forming O 
the O 
2-hydroxyethylphosphonate B-SYSTEMATIC 
adduct O 
on O 
BChE O 
at O 
Ser B-FORMULA 
198 O 
while O 
about O 
97% O 
of O 
the O 
ethephon B-TRIVIAL 
breaks O 
down O 
to O 
ethylene B-SYSTEMATIC 
( O 
t1 O 
/ O 
2 O 
= O 
11-48 O 
h O 
at O 
pH O 
7 O 
) O 
which O 
is O 
responsible O 
for O 
plant O 
growth O 
regulation O 
. O 

energy O 
collection O 
in O 
a O 
porphyrin-imide-corrole B-FAMILY 
ensemble O 
. O 

assembly O 
consisting O 
of O 
three O 
units O 
, O 
that O 
is O 
, O 
a O 
meso- B-FAMILY 
substituted I-FAMILY 
corrole I-FAMILY 
() O 
, O 
1,8 B-SYSTEMATIC 
naphthaleneimide I-SYSTEMATIC 
() O 
, O 
and O 
a O 
Zn B-FORMULA 
porphyrin B-FAMILY 
() O 
, O 
has O 
been O 
synthesized O 
. O 
NIE B-ABBREVIATION 
is O 
connected O 
to O 
C3 O 
through O 
a O 
1,3-phenylene B-SYSTEMATIC 
bridge O 
and O 
to O 
the O 
ZnP B-FORMULA 
unit O 
through O 
a O 
direct O 
CC B-FORMULA 
bond O 
. O 
The O 
convergent O 
synthetic O 
strategy O 
includes O 
the O 
preparation O 
of O 
a O 
trans-A2 B-FAMILY 
B-corrole I-FAMILY 
possessing O 
the O 
imide B-SYSTEMATIC 
unit O 
, O 
followed O 
by O 
Sonogashira O 
coupling O 
with O 
a O 
meso- B-FAMILY 
substituted I-FAMILY 
A3 I-FAMILY 
B-porphyrin I-FAMILY 
. O 
The O 
photophysical O 
processes O 
in O 
the O 
resulting O 
triad O 
are O 
examined O 
and O 
compared O 
with O 
those O 
of O 
the O 
corresponding O 
dyad O 
and O 
the O 
constituent O 
reference O 
models O 
, O 
, O 
and O 
. O 
Excitation O 
of O 
the O 
NIE B-ABBREVIATION 
unit O 
in O 
leads O 
to O 
a O 
fast O 
energy O 
transfer O 
of O 
98 O 
% O 
efficiency O 
to O 
C3 O 
with O 
a O 
rate O 
ken O 
= O 
7.5×10(10) O 
s(-1) O 
, O 
whereas O 
excitation O 
of O 
the O 
corrole B-FAMILY 
unit O 
leads O 
to O 
a O 
reactivity O 
of O 
the O 
excited O 
state O 
identical O 
to O 
that O 
of O 
the O 
model O 
, O 
with O 
a O 
deactivation O 
rate O 
to O 
the O 
ground O 
state O 
k=2.5×10(8) O 
s(-1) O 
. O 
Energy O 
transfer O 
to O 
C3 O 
and O 
to O 
ZnP B-FORMULA 
moieties O 
follows O 
excitation O 
of O 
NIE B-ABBREVIATION 
in O 
the O 
triad O 
. O 
The O 
rates O 
are O 
ken O 
= O 
7.5×10(10) O 
s(-1) O 
and O 
ken O 
= O 
2.5×10(10) O 
s(-1) O 
for O 
the O 
sensitization O 
of O 
the O 
C3 O 
and O 
ZnP B-FORMULA 
unit O 
, O 
respectively O 
. O 
The O 
light O 
energy O 
transferred O 
from O 
NIE B-ABBREVIATION 
to O 
Zn B-FORMULA 
porphyrin B-FAMILY 
unit O 
is O 
ultimately O 
funneled O 
to O 
the O 
corrole B-FAMILY 
component O 
, O 
which O 
is O 
the O 
final O 
recipient O 
of O 
the O 
excitation O 
energy O 
absorbed O 
by O 
the O 
different O 
components O 
of O 
the O 
array O 
. O 
The O 
latter O 
process O 
occurs O 
with O 
a O 
rate O 
ken O 
= O 
3.4×10(9) O 
s(-1) O 
and O 
89 O 
% O 
efficiency O 
. O 
Energy O 
transfer O 
processes O 
take O 
place O 
in O 
all O 
cases O 
by O 
a O 
Förster O 
( O 
dipole O 
- O 
dipole O 
) O 
mechanism O 
. O 
The O 
theory O 
predicts O 
quite O 
satisfactorily O 
the O 
rate O 
for O 
the O 
ZnP B-FORMULA 
/ O 
C3 O 
couple O 
, O 
where O 
components O 
are O 
separated O 
by O 
about O 
23 O 
Å O 
, O 
but O 
results O 
in O 
calculated O 
rates O 
that O 
are O 
one O 
to O 
two O 
orders O 
of O 
magnitude O 
higher O 
for O 
the O 
couples O 
NIE B-ABBREVIATION 
/ O 
ZnP B-FORMULA 
( O 
D O 
/ O 
A O 
) O 
and O 
NIE B-ABBREVIATION 
/ O 
C3 O 
, O 
which O 
are O 
separated O 
by O 
distances O 
of O 
about O 
14 O 
and O 
10 O 
Å O 
, O 
respectively O 
. O 

and O 
Thermal O 
Denitrogenation O 
of O 
Bulky O 
Triazoline B-FAMILY 
Crystals O 
: O 
Insights O 
into O 
Solid-to-Solid O 
Transformation O 
. O 

photoinduced O 
and O 
thermal O 
denitrogenation O 
of O 
crystalline O 
triazolines B-FAMILY 
with O 
bulky O 
substituents O 
leads O 
to O 
the O 
quantitative O 
formation O 
of O 
aziridines B-FAMILY 
in O 
clean O 
solid O 
- O 
to O 
- O 
solid O 
reactions O 
despite O 
very O 
large O 
structural O 
changes O 
in O 
the O 
transition O 
from O 
reactant O 
to O 
product O 
. O 
Analysis O 
of O 
the O 
reaction O 
progress O 
by O 
powder O 
X-ray O 
diffraction O 
, O 
solid O 
- O 
state O 
(13)C B-FORMULA 
CPMAS O 
NMR O 
, O 
solid O 
- O 
state O 
FTIR O 
spectroscopy O 
, O 
and O 
thermal O 
analysis O 
has O 
revealed O 
that O 
solid O 
- O 
to O 
- O 
solid O 
reactions O 
proceed O 
either O 
through O 
metastable O 
phases O 
susceptible O 
to O 
amorphization O 
or O 
by O 
mechanisms O 
that O 
involve O 
a O 
reconstructive O 
phase O 
transition O 
that O 
culminates O 
in O 
the O 
formation O 
of O 
the O 
stable O 
phase O 
of O 
the O 
product O 
. O 
While O 
the O 
key O 
for O 
a O 
solid O 
- O 
to O 
- O 
solid O 
transformation O 
is O 
that O 
the O 
reaction O 
occurs O 
below O 
the O 
eutectic O 
temperature O 
of O 
the O 
reactant O 
and O 
product O 
two O 
- O 
component O 
system O 
, O 
experimental O 
evidence O 
suggests O 
that O 
those O 
reactions O 
will O 
undergo O 
a O 
reconstructive O 
phase O 
transition O 
when O 
they O 
take O 
place O 
above O 
the O 
glass O 
transition O 
temperature O 
. O 

and O 
saponins B-FAMILY 
from O 
Zizyphus O 
incurva O 
. O 

new O 
flavonol B-FAMILY 
triglycoside I-FAMILY 
, O 
myricetin-3-O-[β-xylopyranosyl-(1-2)-α-rhamnopyranoside]-4'-O-α B-SYSTEMATIC 
-rhamnopyranoside I-SYSTEMATIC 
, O 
named O 
as O 
bayarin B-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Zizyphus O 
incurva O 
Roxb O 
. O 
( O 
Rhamnaceae O 
) O 
along O 
with O 
eight O 
known O 
compounds O 
: O 
six O 
flavonoids B-FAMILY 
and O 
two O 
saponins B-FAMILY 
. O 
All O 
of O 
these O 
compounds O 
were O 
isolated O 
for O 
the O 
first O 
time O 
from O 
this O 
plant O 
. O 
Structures O 
of O 
these O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
. O 

-related O 
antibiotics O 
from O 
marine O 
Streptomyces O 
antibioticus O 
PTZ0016 O 
. O 

indanomycin B-TRIVIAL 
-related O 
antibiotics O 
2-5 O 
were O 
isolated O 
from O 
the O 
cultured O 
broth O 
of O 
marine O 
Streptomyces O 
antibioticus O 
strain O 
PTZ0016 O 
. O 
Their O 
structures O 
were O 
characterised O 
as O 
16-deethylindanomycin B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
iso-16-deethylindanomycin B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
16-deethylindanomycin B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
4 O 
) O 
and O 
iso-16-deethylindanomycin B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
5 O 
) O 
on O 
the O 
basis O 
of O 
NMR O 
, O 
HR-ESI-MS O 
and O 
CD O 
evidences O 
. O 
Compounds O 
3-5 O 
are O 
new O 
additions O 
to O 
the O 
class O 
of O 
indanomycin B-TRIVIAL 
antibiotics O 
. O 
All O 
isolated O 
compounds O 
showed O 
in O 
vitro O 
activity O 
against O 
Staphylococcus O 
aureus O 
with O 
minimal O 
inhibitory O 
concentration O 
at O 
4.0-8.0 O 
μg O 
/ O 
ml O 
. O 

anion O 
transporter-1 O 
( O 
OAT1 O 
) O 
mediates O 
the O 
body O 
disposition O 
of O 
a O 
diverse O 
array O 
of O 
clinically O 
important O 
drugs O 
, O 
including O 
anti-HIV O 
therapeutics O 
, O 
anti-tumor O 
drugs O 
, O 
antibiotics O 
, O 
anti-hypertensives O 
, O 
and O 
anti-inflammatories O 
. O 
Therefore O 
, O 
understanding O 
the O 
regulation O 
of O 
OAT1 O 
has O 
profound O 
clinical O 
significance O 
. O 
We O 
previously O 
established O 
that O 
OAT1 O 
constitutively O 
internalizes O 
from O 
and O 
recycles O 
back O 
to O 
cell O 
surface O 
, O 
and O 
that O 
activation O 
of O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
inhibits O 
OAT1 O 
activity O 
by O 
promoting O 
ubiquitination O 
of O 
the O 
transporter O 
, O 
which O 
then O 
leads O 
to O 
an O 
accelerated O 
internalization O 
of O 
the O 
transporter O 
from O 
cell O 
surface O 
to O 
intracellular O 
compartments O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
demonstrated O 
that O 
PKC O 
isoform O 
PKC-alpha O 
was O 
responsible O 
for O 
OAT1 O 
ubiquitination O 
. O 
To O 
directly O 
address O 
the O 
role O 
of O 
OAT1 O 
ubiquitination O 
, O 
we O 
then O 
generated O 
two O 
OAT1 O 
mutants O 
, O 
each O 
having O 
multiple O 
lysines B-FAMILY 
( O 
K O 
) O 
simultaneously O 
mutated O 
to O 
arginine B-TRIVIAL 
( O 
R O 
) O 
. O 
One O 
mutant O 
K163 O 
/ O 
297 O 
/ O 
303 O 
/ O 
315 O 
/ O 
321R O 
lost O 
sensitivities O 
to O 
PKC-induced O 
inhibition O 
of O 
transport O 
activity O 
, O 
to O 
PKC-induced O 
ubiquitination O 
, O 
and O 
to O 
PKC-induced O 
acceleration O 
of O 
transporter O 
internalization O 
. O 
Further O 
dissecting O 
each O 
lysine B-TRIVIAL 
within O 
this O 
mutant O 
, O 
we O 
identified O 
Lys B-FORMULA 
297 O 
, O 
Lys B-FORMULA 
303 O 
and O 
Lys B-FORMULA 
315 O 
being O 
the O 
ubiquitin O 
- O 
conjugation O 
sites O 
. O 
Interestingly O 
, O 
mutating O 
any O 
one O 
of O 
the O 
three O 
lysines B-FAMILY 
prevented O 
the O 
ubiquitin O 
- O 
conjugation O 
to O 
the O 
other O 
two O 
lysines B-FAMILY 
, O 
suggesting O 
that O 
Lys B-FORMULA 
297 O 
, O 
Lys B-FORMULA 
303 O 
and O 
Lys B-FORMULA 
315 O 
may O 
form O 
an O 
optimal O 
structure O 
to O 
interact O 
with O 
ubiquitination O 
machineries O 
. O 
This O 
is O 
the O 
first O 
demonstration O 
that O 
Lys B-FORMULA 
297 O 
, O 
Lys B-FORMULA 
303 O 
and O 
Lys B-FORMULA 
315 O 
play O 
synergistic O 
role O 
in O 
PKC-regulated O 
OAT1 O 
ubiquitination O 
, O 
trafficking O 
and O 
transport O 
activity O 
. O 

acid I-TRIVIAL 
, O 
rutin B-TRIVIAL 
and O 
hyperoside B-TRIVIAL 
content O 
in O 
Fragaria O 
vesca O 
, O 
F O 
. O 
viridis O 
and O 
F O 
. O 
moschata O 
in O 
Lithuania O 
. O 

Lithuania O 
, O 
two O 
species O 
of O 
the O 
genus O 
Fragaria O 
L O 
. O 
( O 
Rosaceae O 
) O 
, O 
F O 
. O 
vesca O 
L O 
. O 
and O 
F O 
. O 
viridis O 
Weston O 
, O 
occur O 
naturally O 
in O 
the O 
wild O 
and O 
two O 
others O 
, O 
F O 
. O 
moschata O 
Weston O 
and O 
F O 
. O 
× O 
ananassa O 
Duchesne O 
ex O 
Rozier O 
are O 
found O 
escaped O 
from O 
cultivation O 
. O 
The O 
main O 
objective O 
of O 
this O 
study O 
was O 
to O 
establish O 
the O 
variation O 
pattern O 
in O 
the O 
content O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
rutin B-TRIVIAL 
and O 
hyperoside B-TRIVIAL 
in O 
leaves O 
and O 
fruits O 
of O 
the O 
native O 
Lithuanian O 
species O 
. O 
In O 
this O 
work O 
, O 
the O 
chemical O 
polymorphisms O 
of O 
different O 
Fragaria O 
species O 
were O 
studied O 
by O 
growing O 
plants O 
side O 
by O 
side O 
under O 
the O 
same O 
cultivated O 
field O 
conditions O 
. O 
F O 
. O 
vesca O 
fruits O 
had O 
the O 
highest O 
rutin B-TRIVIAL 
( O 
1.38 O 
± O 
0.19 O 
mg O 
g(-1) O 
DM O 
) O 
, O 
hyperoside B-TRIVIAL 
( O 
0.69 O 
± O 
0.1 O 
mg O 
g(-1) O 
DM O 
) O 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
( O 
2.25 O 
± O 
0.34 O 
mg O 
g(-1) O 
DM O 
) O 
content O 
, O 
followed O 
by O 
F O 
. O 
viridis O 
and O 
F O 
. O 
moschata O 
. O 
Our O 
results O 
showed O 
that O 
the O 
leaves O 
should O 
be O 
taken O 
into O 
account O 
as O 
important O 
rutin B-TRIVIAL 
and O 
hyperoside B-TRIVIAL 
contributors O 
for O 
strawberries O 
. O 

pestis O 
, O 
the O 
causative O 
agent O 
of O 
plague O 
, O 
utilizes O 
a O 
type O 
III O 
secretion O 
system O 
( O 
T3SS O 
) O 
to O 
intoxicate O 
host O 
cells O 
. O 
The O 
injection O 
of O 
T3SS O 
substrates O 
must O 
be O 
carefully O 
controlled O 
, O 
and O 
dysregulation O 
leads O 
to O 
altered O 
infection O 
kinetics O 
and O 
early O 
clearance O 
of O 
Y. O 
pestis O 
. O 
While O 
the O 
sequence O 
of O 
events O 
leading O 
up O 
to O 
cell O 
contact O 
and O 
initiation O 
of O 
translocation O 
has O 
received O 
much O 
attention O 
, O 
the O 
regulatory O 
events O 
that O 
take O 
place O 
after O 
effector O 
translocation O 
is O 
less O 
understood O 
. O 
Here O 
we O 
show O 
that O 
the O 
regulator O 
YopK O 
is O 
required O 
to O 
maintain O 
fidelity O 
of O 
substrate O 
specificity O 
, O 
in O 
addition O 
to O 
controlling O 
translocation O 
rate O 
. O 
YopK O 
was O 
found O 
to O 
interact O 
with O 
YopD O 
within O 
targeted O 
cells O 
during O 
Y. O 
pestis O 
infection O 
, O 
suggesting O 
that O 
YopK's O 
regulatory O 
mechanism O 
involves O 
a O 
direct O 
interaction O 
with O 
the O 
translocation O 
pore O 
. O 
In O 
addition O 
, O 
we O 
identified O 
a O 
single O 
amino B-FAMILY 
acid I-FAMILY 
in O 
YopK O 
that O 
is O 
essential O 
for O 
translocation O 
rate O 
regulation O 
but O 
is O 
dispensable O 
for O 
maintaining O 
fidelity O 
of O 
translocation O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
expression O 
of O 
YopK O 
within O 
host O 
cells O 
was O 
sufficient O 
to O 
downregulate O 
translocation O 
rate O 
, O 
but O 
it O 
did O 
not O 
affect O 
translocation O 
fidelity O 
. O 
Together O 
, O 
our O 
data O 
support O 
a O 
model O 
in O 
which O 
YopK O 
is O 
a O 
bifunctional O 
protein O 
whose O 
activities O 
are O 
genetically O 
and O 
spatially O 
distinct O 
such O 
that O 
fidelity O 
control O 
occurs O 
within O 
bacteria O 
and O 
rate O 
control O 
occurs O 
within O 
host O 
cells O 
. O 

- O 
wide O 
Analysis O 
Reveals O 
TET- O 
and O 
TDG-Dependent O 
5-Methylcytosine B-SYSTEMATIC 
Oxidation O 
Dynamics O 
. O 

dioxygenases O 
successively O 
oxidize O 
5-methylcytosine B-SYSTEMATIC 
( O 
5mC B-SYSTEMATIC 
) O 
in O 
mammalian O 
genomes O 
to O 
5-hydroxymethylcytosine B-SYSTEMATIC 
( O 
5hmC B-SYSTEMATIC 
) O 
, O 
5- B-SYSTEMATIC 
formylcytosine I-SYSTEMATIC 
( O 
5fC B-SYSTEMATIC 
) O 
, O 
and O 
5-carboxylcytosine B-SYSTEMATIC 
( O 
5caC B-SYSTEMATIC 
) O 
. O 
5fC B-SYSTEMATIC 
/ O 
5caC B-SYSTEMATIC 
can O 
be O 
excised O 
and O 
repaired O 
to O 
regenerate O 
unmodified O 
cytosines B-FAMILY 
by O 
thymine B-TRIVIAL 
-DNA O 
glycosylase O 
( O 
TDG O 
) O 
and O 
base O 
excision O 
repair O 
( O 
BER O 
) O 
pathway O 
, O 
but O 
it O 
is O 
unclear O 
to O 
what O 
extent O 
and O 
at O 
which O 
part O 
of O 
the O 
genome O 
this O 
active O 
demethylation O 
process O 
takes O 
place O 
. O 
Here O 
, O 
we O 
have O 
generated O 
genome O 
- O 
wide O 
distribution O 
maps O 
of O 
5hmC B-SYSTEMATIC 
/ O 
5fC B-SYSTEMATIC 
/ O 
5caC B-SYSTEMATIC 
using O 
modification O 
- O 
specific O 
antibodies O 
in O 
wild O 
- O 
type O 
and O 
Tdg O 
- O 
deficient O 
mouse O 
embryonic O 
stem O 
cells O 
( O 
ESCs O 
) O 
. O 
In O 
wild O 
- O 
type O 
mouse O 
ESCs O 
, O 
5fC B-SYSTEMATIC 
/ O 
5caC B-SYSTEMATIC 
accumulates O 
to O 
detectable O 
levels O 
at O 
major O 
satellite O 
repeats O 
but O 
not O 
at O 
nonrepetitive O 
loci O 
. O 
In O 
contrast O 
, O 
Tdg O 
depletion O 
in O 
mouse O 
ESCs O 
causes O 
marked O 
accumulation O 
of O 
5fC B-SYSTEMATIC 
and O 
5caC B-SYSTEMATIC 
at O 
a O 
large O 
number O 
of O 
proximal O 
and O 
distal O 
gene O 
regulatory O 
elements O 
. O 
Thus O 
, O 
these O 
results O 
reveal O 
the O 
genome O 
- O 
wide O 
view O 
of O 
iterative O 
5mC B-SYSTEMATIC 
oxidation O 
dynamics O 
and O 
indicate O 
that O 
TET O 
/ O 
TDG-dependent O 
active O 
DNA O 
demethylation O 
process O 
occurs O 
extensively O 
in O 
the O 
mammalian O 
genome O 
. O 

effects O 
of O 
selenium B-SYSTEMATIC 
on O 
oxidative O 
damage O 
and O 
oxidative O 
stress O 
related O 
gene O 
expression O 
in O 
rat O 
liver O 
under O 
chronic O 
poisoning O 
of O 
arsenic B-SYSTEMATIC 
. O 

( O 
As B-FORMULA 
) O 
is O 
a O 
toxic O 
metalloid O 
existing O 
widely O 
in O 
the O 
environment O 
, O 
and O 
chronic O 
exposure O 
to O 
it O 
through O 
contaminated O 
drinking O 
water O 
has O 
become O 
a O 
global O 
problem O 
of O 
public O 
health O 
. O 
The O 
present O 
study O 
focused O 
on O 
the O 
protective O 
effects O 
of O 
selenium B-SYSTEMATIC 
on O 
oxidative O 
damage O 
of O 
chronic O 
arsenic B-SYSTEMATIC 
poisoning O 
in O 
rat O 
liver O 
. O 
Rats O 
were O 
divided O 
into O 
four O 
groups O 
at O 
random O 
and O 
given O 
designed O 
treatments O 
for O 
20weeks O 
. O 
The O 
oxidative O 
damage O 
of O 
liver O 
tissue O 
was O 
evaluated O 
by O 
lipid O 
peroxidation O 
and O 
antioxidant O 
enzymes O 
. O 
Oxidative O 
stress O 
related O 
genes O 
were O 
detected O 
to O 
reflect O 
the O 
liver O 
stress O 
state O 
at O 
the O 
molecular O 
level O 
. O 
Compared O 
to O 
the O 
control O 
and O 
Na2SeO3 B-FORMULA 
groups O 
, O 
the O 
MDA B-ABBREVIATION 
content O 
in O 
liver O 
tissue O 
was O 
decreased O 
and O 
the O 
activities O 
of O 
antioxidant O 
enzymes O 
were O 
increased O 
in O 
the O 
Na2SeO3 B-FORMULA 
intervention O 
group O 
. O 
The O 
mRNA O 
levels O 
of O 
SOD1 O 
, O 
CAT O 
, O 
GPx O 
and O 
Txnrd1 O 
were O 
increased O 
significantly O 
( O 
P O 
< O 
0.05 O 
) O 
in O 
the O 
combined O 
Na2SeO3 B-FORMULA 
+ O 
NaAsO2 B-FORMULA 
treatment O 
group O 
. O 
The O 
expressions O 
of O 
HSP70 O 
and O 
HO-1 O 
were O 
significantly O 
( O 
P O 
< O 
0.05 O 
) O 
increased O 
in O 
the O 
NaAsO2 B-FORMULA 
group O 
and O 
reduced O 
in O 
the O 
combined O 
treatment O 
group O 
. O 
The O 
results O 
indicate O 
that O 
long O 
- O 
term O 
intake O 
of O 
NaAsO2 B-FORMULA 
causes O 
oxidative O 
damage O 
in O 
the O 
rat O 
liver O 
, O 
and O 
Na2SeO3 B-FORMULA 
protects O 
liver O 
cells O 
by O 
adjusting O 
the O 
expression O 
of O 
oxidative O 
stress O 
related O 
genes O 
to O 
improve O 
the O 
activities O 
of O 
antioxidant O 
enzymes O 
. O 

mix O 
- O 
rapid O 
freeze O 
is O 
a O 
powerful O 
method O 
to O 
study O 
the O 
mechanisms O 
of O 
enzyme O 
- O 
substrate O 
reactions O 
in O 
solution O 
. O 
Here O 
we O 
report O 
a O 
protocol O 
that O 
combines O 
this O 
method O 
with O 
normal O 
( O 
non-resonance O 
) O 
Raman O 
microscopy O 
to O 
enable O 
us O 
to O 
define O 
molecular O 
details O 
of O 
intermediates O 
at O 
early O 
time O 
points O 
. O 
With O 
this O 
combined O 
method O 
, O 
SHV-1 O 
, O 
a O 
class O 
A O 
β-lactamase O 
, O 
and O 
tazobactam B-TRIVIAL 
, O 
a O 
commercially O 
available O 
β-lactamase O 
inhibitor O 
, O 
were O 
rapidly O 
mixed O 
on O 
the O 
millisecond O 
time O 
scale O 
and O 
then O 
were O 
flash O 
- O 
frozen O 
by O 
injection O 
into O 
an O 
isopentane B-SYSTEMATIC 
solution O 
surrounded O 
by O 
liquid O 
nitrogen B-SYSTEMATIC 
. O 
The O 
" O 
ice O 
" O 
was O 
finally O 
freeze O 
- O 
dried O 
and O 
characterized O 
by O 
Raman O 
microscopy O 
. O 
We O 
found O 
that O 
the O 
reaction O 
is O 
almost O 
complete O 
in O 
solution O 
at O 
25 O 
ms O 
, O 
giving O 
rise O 
to O 
a O 
major O 
population O 
composed O 
of O 
the O 
trans-enamine B-SYSTEMATIC 
intermediate O 
. O 
Between O 
25 O 
and O 
500 O 
ms O 
, O 
minor O 
populations O 
of O 
protonated O 
imine B-SYSTEMATIC 
are O 
detected O 
that O 
have O 
previously O 
been O 
postulated O 
to O 
precede O 
enamine B-SYSTEMATIC 
intermediates O 
. O 
However O 
, O 
within O 
1 O 
s O 
, O 
the O 
imines B-FAMILY 
are O 
converted O 
entirely O 
to O 
enamines B-FAMILY 
. O 
Interestingly O 
, O 
with O 
this O 
method O 
, O 
we O 
can O 
measure O 
directly O 
the O 
turnover O 
number O 
of O 
SHV-1 O 
and O 
tazobactam B-TRIVIAL 
. O 
The O 
enzyme O 
is O 
completely O 
inhibited O 
at O 
1 O 
: O 
4 O 
ratio O 
( O 
enzyme O 
: O 
inhibitor O 
) O 
or O 
greater O 
, O 
a O 
number O 
that O 
agrees O 
with O 
the O 
turnover O 
number O 
derived O 
from O 
steady O 
- O 
state O 
kinetic O 
methods O 
. O 
This O 
application O 
, O 
employing O 
non-intensity O 
- O 
enhanced O 
Raman O 
spectroscopy O 
, O 
provides O 
a O 
general O 
and O 
effective O 
route O 
to O 
study O 
the O 
early O 
events O 
in O 
enzyme O 
- O 
substrate O 
reactions O 
. O 

administration O 
of O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
rapidly O 
enhances O 
novel O 
object O 
recognition O 
among O 
mice O 
. O 

IV I-TRIVIAL 
( O 
Val(1)-Tyr(2)-Ile(3)-His(4)-Pro(5)-Phe(6) B-FORMULA 
) O 
has O 
demonstrated O 
potential O 
cognitive O 
- O 
enhancing O 
effects O 
. O 
The O 
present O 
investigation O 
assessed O 
and O 
characterized O 
: O 
( O 
1 O 
) O 
dose O 
- O 
dependency O 
of O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
' O 
s O 
cognitive O 
enhancement O 
in O 
a O 
C57BL O 
/ O 
6J O 
mouse O 
model O 
of O 
novel O 
object O 
recognition O 
, O 
( O 
2 O 
) O 
the O 
time O 
- O 
course O 
for O 
these O 
effects O 
, O 
( O 
3 O 
) O 
the O 
identity O 
of O 
residues O 
in O 
the O 
hexapeptide B-FAMILY 
important O 
to O 
these O 
effects O 
and O 
( O 
4 O 
) O 
the O 
necessity O 
of O 
actions O 
at O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
receptors O 
for O 
procognitive O 
activity O 
. O 
Assessment O 
of O 
C57BL O 
/ O 
6J O 
mice O 
in O 
a O 
novel O 
object O 
recognition O 
task O 
demonstrated O 
that O 
prior O 
administration O 
of O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
( O 
0.1 O 
, O 
1 O 
, O 
or O 
10 O 
, O 
but O 
not O 
0.01 O 
nmol O 
, O 
i.c.v O 
. O 
) O 
significantly O 
enhanced O 
novel O 
object O 
recognition O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
These O 
effects O 
were O 
time O 
dependent O 
, O 
with O 
improved O 
novel O 
object O 
recognition O 
observed O 
when O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
( O 
0.1 O 
nmol O 
, O 
i.c.v O 
. O 
) O 
was O 
administered O 
10 O 
or O 
20 O 
, O 
but O 
not O 
30 O 
min O 
prior O 
to O 
the O 
onset O 
of O 
the O 
novel O 
object O 
recognition O 
testing O 
. O 
An O 
alanine B-TRIVIAL 
scan O 
of O 
the O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
peptide O 
revealed O 
that O 
replacement O 
of O 
the O 
Val B-ABBREVIATION 
( O 
1 O 
) O 
, O 
Ile B-FORMULA 
( O 
3 O 
) O 
, O 
His B-FORMULA 
( O 
4 O 
) O 
, O 
or O 
Phe B-FORMULA 
( O 
6 O 
) O 
residues O 
with O 
Ala B-FORMULA 
attenuated O 
peptide-induced O 
improvements O 
in O 
novel O 
object O 
recognition O 
, O 
whereas O 
Tyr B-FORMULA 
( O 
2 O 
) O 
or O 
Pro B-FORMULA 
( O 
5 O 
) O 
replacement O 
did O 
not O 
significantly O 
affect O 
performance O 
. O 
Administration O 
of O 
the O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
receptor O 
antagonist O 
, O 
divalinal-Ang B-TRIVIAL 
IV I-TRIVIAL 
( O 
20 O 
nmol O 
, O 
i.c.v O 
. O 
) O 
, O 
reduced O 
( O 
but O 
did O 
not O 
abolish O 
) O 
novel O 
object O 
recognition O 
; O 
however O 
, O 
this O 
antagonist O 
completely O 
blocked O 
the O 
procognitive O 
effects O 
of O 
angiotensin B-TRIVIAL 
I I-TRIVIAL 
V O 
( O 
0.1 O 
nmol O 
, O 
i.c.v O 
. O 
) O 
in O 
this O 
task O 
. O 
Rotorod O 
testing O 
demonstrated O 
no O 
locomotor O 
effects O 
with O 
any O 
angiotensin B-TRIVIAL 
I I-TRIVIAL 
V O 
or O 
divalinal-Ang B-TRIVIAL 
I I-TRIVIAL 
V O 
dose O 
tested O 
. O 
These O 
data O 
demonstrate O 
that O 
angiotensin B-TRIVIAL 
I I-TRIVIAL 
V O 
produces O 
a O 
rapid O 
enhancement O 
of O 
associative O 
learning O 
and O 
memory O 
performance O 
in O 
a O 
mouse O 
model O 
that O 
was O 
dependent O 
on O 
the O 
angiotensin B-TRIVIAL 
I I-TRIVIAL 
V O 
receptor O 
. O 

of O 
the O 
inhibitory O 
activity O 
of O 
Abeliophyllum O 
distichum O 
leaf O 
constituents O 
against O 
aldose B-FAMILY 
reductase O 
by O 
using O 
high O 
- O 
speed O 
counter O 
current O 
chromatography O 
. O 

isolated O 
five O 
phenolic B-FAMILY 
glycosides I-FAMILY 
( O 
acteoside B-TRIVIAL 
, O 
eutigoside B-TRIVIAL 
B I-TRIVIAL 
, O 
isoacteoside B-TRIVIAL 
, O 
rutin B-TRIVIAL 
and O 
cornoside B-TRIVIAL 
) O 
from O 
Abeliophyllum O 
distichum O 
leaves O 
by O 
high O 
- O 
speed O 
counter O 
current O 
chromatography O 
( O 
HSCCC O 
) O 
using O 
a O 
solvent O 
system O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
: O 
n-butanol B-SYSTEMATIC 
: O 
water O 
( O 
8 O 
: O 
0.7 O 
: O 
5 O 
) O 
. O 
We O 
determined O 
the O 
purity O 
of O 
the O 
5 O 
compounds O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
, O 
and O 
confirmed O 
their O 
chemical O 
structures O 
by O 
using O 
nuclear O 
magnetic O 
resonance O 
data O 
. O 
We O 
examined O 
the O 
inhibitory O 
effect O 
of O 
these O 
compounds O 
on O 
rat O 
lens O 
aldose B-FAMILY 
reductase O 
. O 
Among O 
these O 
compounds O 
, O 
acteoside B-TRIVIAL 
( O 
1 O 
) O 
showed O 
the O 
most O 
potent O 
inhibitory O 
effect O 
, O 
with O 
an O 
IC50 O 
value O 
of O 
1.39 O 
μM O 
. O 
The O 
inhibitory O 
effect O 
of O 
1 O 
was O 
5 O 
times O 
greater O 
than O 
that O 
of O 
quercetin B-TRIVIAL 
( O 
7.05 O 
μM O 
) O 
, O 
which O 
was O 
used O 
as O 
a O 
positive O 
control O 
. O 
These O 
results O 
suggest O 
that O 
acteoside B-TRIVIAL 
may O 
be O 
a O 
promising O 
agent O 
for O 
the O 
prevention O 
or O 
treatment O 
of O 
diabetic O 
complications O 
. O 
Moreover O 
, O 
HSCCC O 
is O 
a O 
promising O 
method O 
for O 
the O 
isolation O 
and O 
purification O 
of O 
biologically O 
active O 
compounds O 
from O 
natural O 
products O 
. O 

nuclear O 
thioredoxin-1 O 
potentiates O 
cadmium B-SYSTEMATIC 
-induced O 
cytotoxicity O 
. O 

( O 
Cd B-FORMULA 
) O 
is O 
a O 
widely O 
dispersed O 
environmental O 
agent O 
that O 
causes O 
oxidative O 
toxicity O 
through O 
mechanisms O 
that O 
are O 
sensitive O 
to O 
thioredoxin-1 O 
( O 
Trx1 O 
) O 
. O 
Trx1 O 
is O 
a O 
cytoplasmic O 
protein O 
that O 
translocates O 
to O 
nuclei O 
during O 
oxidative O 
stress O 
. O 
Recent O 
research O 
shows O 
that O 
interaction O 
of O 
Trx1 O 
with O 
actin O 
plays O 
a O 
critical O 
role O 
in O 
cell O 
survival O 
and O 
that O 
increased O 
nuclear O 
Trx-1 O 
potentiates O 
proinflammatory O 
signaling O 
and O 
death O 
in O 
cell O 
and O 
mouse O 
models O 
. O 
These O 
observations O 
indicate O 
that O 
oxidative O 
toxicity O 
caused O 
by O 
low O 
- O 
dose O 
Cd B-FORMULA 
could O 
involve O 
disruption O 
of O 
actin-Trx1 O 
interaction O 
, O 
nuclear O 
Trx1 O 
translocation O 
, O 
and O 
potentiation O 
of O 
proinflammatory O 
cell O 
death O 
mechanisms O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
role O 
of O 
nuclei O 
- O 
localized O 
Trx1 O 
in O 
Cd B-FORMULA 
-induced O 
inflammation O 
and O 
cytotoxicity O 
using O 
in O 
vitro O 
and O 
in O 
vivo O 
models O 
. O 
The O 
results O 
show O 
that O 
Cd B-FORMULA 
stimulated O 
nuclear O 
translocation O 
of O 
Trx1 O 
and O 
p65 O 
of O 
NF-κB O 
. O 
Elevation O 
of O 
Trx1 O 
in O 
nuclei O 
in O 
in O 
vitro O 
cells O 
and O 
kidney O 
of O 
transgenic O 
mice O 
potentiated O 
Cd B-FORMULA 
-stimulated O 
NF-κB O 
activation O 
and O 
cell O 
death O 
. O 
Cd B-FORMULA 
-stimulated O 
Trx1 O 
nuclear O 
translocation O 
and O 
NF-κB O 
activation O 
were O 
inhibited O 
by O 
cytochalasin B-TRIVIAL 
D I-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
actin O 
polymerization O 
, O 
suggesting O 
that O 
actin O 
regulates O 
Trx1 O 
nuclear O 
translocation O 
and O 
NF-κB O 
activation O 
by O 
Cd B-FORMULA 
. O 
A O 
nuclear O 
- O 
targeted O 
dominant O 
negative O 
form O 
of O 
Trx1 O 
blocked O 
Cd B-FORMULA 
-stimulated O 
NF-κB O 
activation O 
and O 
decreased O 
cell O 
death O 
. O 
Addition O 
of O 
zinc B-SYSTEMATIC 
, O 
known O 
to O 
antagonize O 
Cd B-FORMULA 
toxicity O 
by O 
increasing O 
metallothionein O 
, O 
had O 
no O 
effect O 
on O 
Cd B-FORMULA 
-stimulated O 
nuclear O 
translocation O 
of O 
Trx1 O 
and O 
NF-κB O 
activation O 
. O 
Taken O 
together O 
, O 
the O 
results O 
show O 
that O 
nuclear O 
translocation O 
and O 
accumulation O 
of O 
redox O 
- O 
active O 
Trx1 O 
in O 
nuclei O 
play O 
an O 
important O 
role O 
in O 
Cd B-FORMULA 
-induced O 
inflammation O 
and O 
cell O 
death O 
. O 

evidence O 
suggests O 
a O 
possible O 
role O 
for O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
in O 
the O 
neuropathophysiology O 
of O 
autism O 
spectrum O 
disorders O 
( O 
ASD O 
) O 
, O 
but O 
the O 
extent O 
of O 
this O 
impairment O 
is O 
unclear O 
. O 
A O 
non-invasive O 
, O 
in O 
vivo O 
measure O 
of O 
GABA B-ABBREVIATION 
involves O 
transcranial O 
magnetic O 
stimulation O 
( O 
TMS O 
) O 
of O 
the O 
primary O 
motor O 
cortex O 
to O 
probe O 
cortical O 
inhibition O 
. O 
Individuals O 
diagnosed O 
with O 
ASD O 
( O 
high O 
- O 
functioning O 
autism O 
or O 
Asperger's O 
disorder O 
) O 
( O 
n O 
= O 
36 O 
[ O 
28 O 
male O 
] O 
; O 
mean O 
age O 
: O 
26 O 
years O 
) O 
and O 
a O 
group O 
of O 
healthy O 
individuals O 
( O 
n O 
= O 
34 O 
[ O 
23 O 
male O 
] O 
; O 
mean O 
age O 
: O 
26.21 O 
years O 
) O 
( O 
matched O 
for O 
age O 
, O 
gender O 
, O 
and O 
cognitive O 
function O 
) O 
were O 
administered O 
motor O 
cortical O 
TMS O 
paradigms O 
putatively O 
measuring O 
activity O 
at O 
GABAA O 
and O 
GABAB O 
receptors O 
( O 
i.e O 
. O 
, O 
short O 
and O 
long O 
interval O 
paired O 
pulse O 
TMS O 
, O 
cortical O 
silent O 
period O 
) O 
. O 
All O 
cortical O 
inhibition O 
paradigms O 
yielded O 
no O 
difference O 
between O 
ASD O 
and O 
control O 
groups O 
. O 
There O 
was O 
, O 
however O 
, O 
evidence O 
for O 
short O 
interval O 
cortical O 
inhibition O 
( O 
SICI O 
) O 
deficits O 
among O 
those O 
ASD O 
participants O 
who O 
had O 
experienced O 
early O 
language O 
delay O 
, O 
suggesting O 
that O 
GABA B-ABBREVIATION 
may O 
be O 
implicated O 
in O 
an O 
ASD O 
subtype O 
. O 
The O 
current O 
findings O 
do O 
not O 
support O 
a O 
broad O 
role O 
for O 
GABA B-ABBREVIATION 
in O 
the O 
neuropathophysiology O 
of O 
ASD O 
, O 
but O 
provide O 
further O 
indication O 
that O 
GABAA O 
could O 
be O 
involved O 
in O 
ASD O 
where O 
there O 
is O 
a O 
delay O 
in O 
language O 
acquisition O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

Alkaloids I-FAMILY 
from O 
a O 
Marine O 
- O 
Derived O 
Fungus O 
, O 
Stagonosporopsis O 
cucurbitacearum O 
, O 
and O 
Their O 
Activities O 
against O 
Azole B-FAMILY 
-Resistant O 
Candida O 
albicans O 
. O 

new O 
4-hydroxy-2-pyridone B-FAMILY 
alkaloids I-FAMILY 
, O 
didymellamides B-MULTIPLE 
A-D I-MULTIPLE 
( O 
1-4 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
marine O 
- O 
derived O 
fungus O 
Stagonosporopsis O 
cucurbitacearum O 
. O 
The O 
structures O 
of O 
1-4 O 
were O 
elucidated O 
from O 
spectroscopic O 
data O 
( O 
NMR O 
, O 
MS O 
, O 
and O 
IR O 
) O 
, O 
and O 
the O 
absolute O 
configuration O 
of O 
1 O 
was O 
determined O 
by O 
X-ray O 
diffraction O 
analysis O 
. O 
Didymellamide B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
exhibited O 
antifungal O 
activity O 
against O 
azole B-FAMILY 
-resistant O 
Candida O 
albicans O 
. O 

activation O 
of O 
AMP O 
activated O 
kinase O 
( O 
AMPK O 
) O 
by O 
metformin B-TRIVIAL 
has O 
proven O 
to O 
be O 
a O 
beneficial O 
therapeutic O 
approach O 
for O 
the O 
treatment O 
of O 
type O 
II O 
diabetes O 
. O 
Despite O 
improved O 
glucose B-TRIVIAL 
regulation O 
achieved O 
by O 
administration O 
of O 
small O 
molecule O 
activators O 
of O 
AMPK O 
, O 
the O 
potential O 
negative O 
impact O 
of O 
enhanced O 
AMPK O 
activity O 
on O 
insulin O 
secretion O 
by O 
the O 
pancreatic O 
beta O 
cell O 
is O 
an O 
important O 
consideration O 
. O 
In O 
this O 
review O 
, O 
we O 
discuss O 
our O 
current O 
understanding O 
of O 
the O 
role O 
of O 
AMPK O 
in O 
central O 
functions O 
of O 
the O 
pancreatic O 
beta O 
cell O 
, O 
including O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
( O 
GSIS O 
) O 
, O 
proliferation O 
, O 
and O 
survival O 
. O 
In O 
addition O 
we O 
discuss O 
the O 
controversy O 
surrounding O 
the O 
role O 
of O 
AMPK O 
in O 
insulin O 
secretion O 
, O 
underscoring O 
the O 
merits O 
and O 
caveats O 
of O 
methods O 
used O 
to O 
date O 
. O 

-type O 
saponins B-FAMILY 
from O 
heat O 
- O 
processed O 
Gynostemma O 
pentaphyllum O 
show O 
fortified O 
activity O 
against O 
A549 O 
cells O 
. O 

ethanol B-SYSTEMATIC 
extract O 
from O 
heat O 
- O 
processed O 
Gynostemma O 
pentaphyllum O 
showed O 
more O 
potent O 
cytotoxic O 
activity O 
against O 
human O 
lung O 
adenocarcinoma O 
A549 O 
cells O 
than O 
that O 
of O 
raw O 
G O 
. O 
pentaphyllum O 
. O 
Four O 
constituents O 
were O 
isolated O 
from O 
heat O 
- O 
processed O 
G O 
. O 
pentaphyllum O 
using O 
resin O 
HP-20 O 
, O 
silica B-TRIVIAL 
gel I-TRIVIAL 
and O 
reversed O 
ODS O 
column O 
chromatography O 
. O 
They O 
were O 
identified O 
by O 
mass O 
and O 
NMR O 
spectra O 
as O 
damulin B-TRIVIAL 
A I-TRIVIAL 
and O 
damulin B-TRIVIAL 
B I-TRIVIAL 
, O 
gypenoside B-TRIVIAL 
L I-TRIVIAL 
and O 
gypenoside B-TRIVIAL 
LI I-TRIVIAL 
, O 
respectively O 
. O 
To O 
evaluate O 
the O 
efficacy O 
of O 
these O 
four O 
constituents O 
, O 
the O 
MTT B-ABBREVIATION 
cytotoxicity O 
assay O 
was O 
performed O 
using O 
A549 O 
cells O 
. O 
Based O 
on O 
the O 
structure O 
of O 
these O 
four O 
constituents O 
, O 
the O 
results O 
indicate O 
that O 
the O 
hydroxyl B-SYSTEMATIC 
group O 
in O 
C-2 O 
and O 
double O 
bond O 
in O 
C20(21) O 
and O 
C20(22) O 
positions O 
are O 
of O 
importance O 
in O 
inhibition O 
of O 
A549 O 
cell O 
proliferation O 
. O 

β-cell O 
dysfunction O 
, O 
a O 
hallmark O 
of O 
type O 
2 O 
diabetes O 
, O 
can O 
be O 
programmed O 
by O 
adverse O 
fetal O 
environment O 
. O 
We O 
have O 
shown O 
that O 
fetal O 
glucocorticoids O 
( O 
GCs O 
) O 
participate O 
in O 
this O 
programming O 
through O 
inhibition O 
of O 
β-cell O 
development O 
. O 
Here O 
we O 
have O 
investigated O 
the O 
molecular O 
mechanisms O 
underlying O 
this O 
regulation O 
. O 
We O 
showed O 
that O 
GCs O 
stimulate O 
the O 
expression O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor-γ O 
coactivator-1α O 
( O 
PGC-1α O 
) O 
, O 
a O 
coregulator O 
of O 
the O 
GCs O 
receptor O 
( O 
GR O 
) O 
, O 
and O 
that O 
the O 
overexpression O 
of O 
PGC-1α O 
represses O 
genes O 
important O 
for O 
β-cell O 
development O 
and O 
function O 
. O 
More O 
precisely O 
, O 
PGC-1α O 
inhibited O 
the O 
expression O 
of O 
the O 
key O 
β-cell O 
transcription O 
factor O 
pancreatic O 
duodenal O 
homeobox O 
1 O 
( O 
Pdx1 O 
) O 
. O 
This O 
repression O 
required O 
the O 
GR O 
and O 
was O 
mediated O 
through O 
binding O 
of O 
a O 
GR O 
/ O 
PGC-1α O 
complex O 
to O 
the O 
Pdx1 O 
promoter O 
. O 
To O 
explore O 
PGC-1α O 
function O 
, O 
we O 
generated O 
mice O 
with O 
inducible O 
β-cell O 
PGC-1α O 
overexpression O 
. O 
Mice O 
overexpressing O 
PGC-1α O 
exhibited O 
at O 
adult O 
age O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
associated O 
with O 
reduced O 
insulin O 
secretion O 
, O 
decreased O 
β-cell O 
mass O 
, O 
and O 
β-cell O 
hypotrophy O 
. O 
Interestingly O 
, O 
PGC-1α O 
expression O 
in O 
fetal O 
life O 
only O 
was O 
sufficient O 
to O 
impair O 
adult O 
β-cell O 
function O 
whereas O 
β-cell O 
PGC-1α O 
overexpression O 
from O 
adult O 
age O 
had O 
no O 
consequence O 
on O 
β-cell O 
function O 
. O 
Altogether O 
, O 
our O 
results O 
demonstrate O 
that O 
the O 
GR O 
and O 
PGC-1α O 
participate O 
in O 
the O 
fetal O 
programming O 
of O 
adult O 
β-cell O 
function O 
through O 
inhibition O 
of O 
Pdx1 O 
expression O 
. O 

inhibits O 
myofibroblast O 
differentiation O 
in O 
nasal O 
polyp O 
- O 
derived O 
fibroblasts O 
via O 
the O 
p38 O 
pathway O 
. O 

purposes O 
of O 
this O 
study O 
were O 
to O 
determine O 
whether O 
berberine B-TRIVIAL 
has O 
any O 
effect O 
on O 
phenotype O 
changes O 
and O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
production O 
in O 
nasal O 
polyp O 
- O 
derived O 
fibroblasts O 
( O 
NPDFs O 
) O 
and O 
to O 
investigate O 
the O 
underlying O 
molecular O 
mechanism O 
. O 
NPDFs O 
were O 
pre O 
- O 
treated O 
with O 
berberine B-TRIVIAL 
prior O 
to O 
induction O 
by O 
transforming O 
growth O 
factor O 
(TGF)-β1 O 
. O 
The O 
expression O 
of O 
α-smooth O 
muscle O 
actin O 
( O 
SMA O 
) O 
and O 
collagen O 
type O 
I O 
mRNA O 
was O 
determined O 
by O 
a O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
, O 
and O 
the O 
expression O 
of O 
α-SMA O 
protein O 
and O 
collagen O 
type O 
I O 
was O 
determined O 
by O 
western O 
blotting O 
and O 
/ O 
or O 
immunofluorescent O 
staining O 
. O 
The O 
total O 
soluble O 
collagen O 
production O 
was O 
analysed O 
by O 
the O 
SirCol O 
collagen O 
assay O 
. O 
The O 
expression O 
of O 
several O 
signaling O 
molecules O 
of O 
the O 
TGF-β1 O 
pathway O 
was O 
evaluated O 
by O 
western O 
blot O 
analysis O 
. O 
In O 
TGF-β1-induced O 
NPDFs O 
, O 
berberine B-TRIVIAL 
significantly O 
inhibited O 
the O 
expression O 
of O 
α-SMA O 
and O 
collagen O 
type O 
I O 
mRNA O 
and O 
reduced O 
α-SMA O 
and O 
collagen O 
protein O 
levels O 
. O 
Berberine B-TRIVIAL 
only O 
suppressed O 
the O 
expression O 
of O 
pp38 O 
among O 
the O 
evaluated O 
signaling O 
molecules O 
. O 
SB203580 B-IDENTIFIER 
( O 
a O 
specific O 
inhibitor O 
of O 
p38 O 
kinase O 
) O 
markedly O 
suppressed O 
the O 
increased O 
expression O 
of O 
collagen O 
type O 
I O 
and O 
α-SMA O 
in O 
TGF-β1-induced O 
NPDFs O 
. O 
Berberine B-TRIVIAL 
exerts O 
suppressive O 
effects O 
on O 
phenotype O 
changes O 
and O 
ECM O 
production O 
in O 
NPDFs O 
via O 
p38 O 
signaling O 
pathway O 
interference O 
. O 
The O 
findings O 
provide O 
new O 
therapeutic O 
options O 
for O 
ECM O 
production O 
in O 
nasal O 
polyps O 
. O 

CB₁ O 
receptor O 
in O 
the O 
modulation O 
of O 
stress O 
coping O 
behavior O 
in O 
mice O 
: O 
the O 
role O 
of O 
serotonin B-TRIVIAL 
and O 
different O 
forebrain O 
neuronal O 
subpopulations O 
. O 

endocannabinoid O 
system O 
( O 
ECS O 
) O 
may O 
either O 
enhance O 
or O 
inhibit O 
responses O 
to O 
aversive O 
stimuli O 
, O 
possibly O 
caused O 
by O 
its O 
modulatory O 
activity O 
on O 
diverse O 
neurotransmitters O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
investigate O 
the O 
involvement O 
of O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
and O 
catecholamines B-FAMILY 
, O 
as O 
well O 
as O 
the O 
role O 
of O 
glutamatergic O 
and O 
GABAergic O 
cannabinoid O 
type O 
1 O 
(CB(1)) O 
receptor O 
, O 
in O 
responses O 
to O 
the O 
antidepressant O 
- O 
like O 
doses O 
of O 
the O 
CB(1) O 
receptor O 
agonist O 
Δ(9)-tetrahydrocannabinol B-SYSTEMATIC 
( O 
THC B-ABBREVIATION 
) O 
and O 
the O 
antagonist O 
rimonabant B-TRIVIAL 
in O 
the O 
forced O 
swim O 
test O 
( O 
FST O 
) O 
. O 
Mice O 
received O 
acute O 
injections O 
of O 
low O 
doses O 
of O 
THC B-ABBREVIATION 
( O 
0.1 O 
or O 
0.5 O 
mg O 
/ O 
kg O 
) O 
or O 
high O 
dose O 
of O 
rimonabant B-TRIVIAL 
( O 
3 O 
or O 
10 O 
mg O 
/ O 
kg O 
) O 
after O 
treatment O 
with O 
the O 
5-HT B-SYSTEMATIC 
synthesis O 
inhibitor O 
pCPA B-ABBREVIATION 
( O 
100 O 
mg O 
/ O 
kg O 
, O 
4 O 
days O 
) O 
, O 
the O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
receptor O 
antagonist O 
WAY100635 B-IDENTIFIER 
( O 
1 O 
mg O 
/ O 
kg O 
, O 
acute O 
) O 
or O 
the O 
non-selective O 
blocker O 
of O 
catecholamine B-TRIVIAL 
synthesis O 
, O 
AMPT B-ABBREVIATION 
( O 
20 O 
mg O 
/ O 
kg O 
, O 
acute O 
) O 
. O 
THC B-ABBREVIATION 
and O 
rimonabant B-TRIVIAL 
were O 
also O 
tested O 
in O 
mutant O 
mice O 
lacking O 
CB(1) O 
receptor O 
in O 
specific O 
forebrain O 
neuronal O 
subpopulations O 
. O 
Both O 
THC B-ABBREVIATION 
and O 
rimonabant B-TRIVIAL 
induced O 
antidepressant O 
- O 
like O 
effects O 
, O 
quantified O 
as O 
immobility O 
in O 
the O 
FST O 
. O 
However O 
, O 
only O 
THC B-ABBREVIATION 
effects O 
were O 
reversed O 
by O 
pCPA B-ABBREVIATION 
or O 
WAY100635 B-IDENTIFIER 
. O 
In O 
contrast O 
, O 
only O 
AMPT B-ABBREVIATION 
could O 
attenuate O 
the O 
rimonabant B-TRIVIAL 
effect O 
. O 
We O 
also O 
found O 
decreased O 
immobility O 
in O 
mice O 
lacking O 
the O 
CB(1) O 
receptor O 
in O 
glutamatergic O 
cortical O 
neurons O 
, O 
but O 
not O 
in O 
forebrain O 
GABAergic O 
neurons O 
, O 
as O 
compared O 
with O 
wild O 
- O 
type O 
controls O 
. O 
The O 
effect O 
of O 
THC B-ABBREVIATION 
persisted O 
in O 
mutant O 
mice O 
with O 
CB(1) O 
receptor O 
inactivation O 
in O 
GABAergic O 
neurons O 
, O 
whereas O 
rimonabant B-TRIVIAL 
effects O 
were O 
alleviated O 
in O 
these O 
mutants O 
. O 
Thus O 
, O 
employing O 
both O 
pharmacological O 
and O 
genetic O 
tools O 
, O 
we O 
could O 
show O 
that O 
the O 
ECS O 
regulates O 
stress O 
responses O 
by O 
influencing O 
GABAergic O 
, O 
glutamatergic O 
and O 
monoaminergic O 
transmission O 
. O 
The O 
antidepressant O 
- O 
like O 
action O 
of O 
THC B-ABBREVIATION 
depends O 
on O 
serotonergic O 
neurotransmission O 
, O 
whereas O 
rimonabant B-TRIVIAL 
effects O 
are O 
mediated O 
by O 
CB(1) O 
receptor O 
on O 
GABAergic O 
neurons O 
and O 
by O 
catecholamine B-TRIVIAL 
signaling O 
. O 

pressure O 
and O 
levels O 
of O 
Fe B-FORMULA 
, O 
Ca B-FORMULA 
, O 
Mg B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Na B-FORMULA 
and O 
K B-FORMULA 
in O 
the O 
hair O 
of O 
young O 
Bantu O 
men O 
from O 
Tanzania O 
. O 

imbalance O 
in O 
the O 
body O 
may O 
significantly O 
contribute O 
to O 
the O 
development O 
and O 
course O 
of O 
hypertension O 
. O 
In O 
this O 
paper O 
, O 
blood O 
pressure O 
figures O 
have O 
been O 
linked O 
to O 
the O 
levels O 
of O 
Fe B-FORMULA 
, O 
Ca B-FORMULA 
, O 
Mg B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Na B-FORMULA 
and O 
K B-FORMULA 
in O 
hair O 
. O 
The O 
research O 
sample O 
was O 
composed O 
of O 
young O 
men O 
( O 
n O 
= O 
91 O 
) O 
aged O 
13-21 O 
, O 
from O 
the O 
town O 
of O 
Mafinga O 
, O 
Iringa O 
District O 
, O 
Tanzania O 
. O 
The O 
data O 
collected O 
included O 
their O 
age O 
, O 
tribal O 
background O 
and O 
weekly O 
diet O 
. O 
Based O 
on O 
body O 
mass O 
index O 
, O 
the O 
participants O 
were O 
categorised O 
into O 
pre O 
- O 
defined O 
subgroups O 
. O 
To O 
examine O 
how O 
the O 
minerals O 
in O 
question O 
affect O 
blood O 
pressure O 
, O 
correlation O 
analysis O 
and O 
multiple O 
ridge O 
regression O 
analysis O 
were O 
performed O 
. O 
Analysis O 
of O 
ridge O 
regression O 
findings O 
for O 
the O 
researched O 
group O 
( O 
n O 
= O 
91 O 
) O 
shows O 
that O 
the O 
minerals O 
under O 
scrutiny O 
account O 
for O 
systolic O 
blood O 
pressure O 
variation O 
in O 
13 O 
% O 
and O 
in O 
15 O 
% O 
for O 
diastolic O 
blood O 
pressure O 
variation O 
. O 
After O 
including O 
two O 
additional O 
variables O 
- O 
calendar O 
age O 
and O 
body O 
mass O 
index O 
- O 
in O 
regression O 
analysis O 
, O 
the O 
ultimate O 
coefficient O 
of O 
determination O 
( O 
R O 
( O 
2 O 
) O 
) O 
changes O 
for O 
systolic O 
blood O 
pressure O 
and O 
remains O 
the O 
same O 
for O 
diastolic O 
blood O 
pressure O 
( O 
R O 
( O 
2 O 
) O 
= O 
0.194 O 
and O 
R O 
( O 
2 O 
) O 
= O 
0.156 O 
, O 
respectively O 
) O 
. O 
Nutritional O 
analysis O 
shows O 
that O 
the O 
students O 
included O 
in O 
the O 
study O 
received O 
insufficient O 
calories O 
per O 
day O 
( O 
1,500-2,200 O 
kcal O 
) O 
. O 
The O 
group O 
of O 
students O 
with O 
abnormal O 
blood O 
pressure O 
were O 
not O 
aware O 
of O 
their O 
poor O 
health O 
. O 
Research O 
findings O 
may O 
result O 
from O 
progressive O 
environmental O 
changes O 
and O 
poor O 
nutrition O 
in O 
terms O 
of O 
food O 
quantity O 
and O 
quality O 
, O 
which O 
had O 
an O 
impact O 
on O 
the O 
subjects O 
' O 
blood O 
pressure O 
. O 
Hair O 
analysis O 
used O 
to O 
determine O 
mineral O 
content O 
in O 
the O 
body O 
may O 
be O 
an O 
auxiliary O 
tool O 
in O 
identifying O 
the O 
links O 
between O 
factors O 
leading O 
to O 
the O 
development O 
of O 
hypertension O 
. O 

or O 
nondynamic O 
? O 
Helical O 
trajectory O 
in O 
hexabenzocoronene B-SYSTEMATIC 
nanotubes O 
biased O 
by O 
a O 
detachable O 
chiral O 
auxiliary O 
. O 

ether B-SYSTEMATIC 
vapor O 
was O 
allowed O 
to O 
diffuse O 
into O 
a O 
CH(2)Cl(2) B-FORMULA 
solution O 
of O 
an O 
enantiomer O 
of O 
a O 
hexa B-SYSTEMATIC 
- I-SYSTEMATIC 
peri I-SYSTEMATIC 
- I-SYSTEMATIC 
hexabenzocoronene I-SYSTEMATIC 
( O 
HBC B-ABBREVIATION 
) O 
derivative O 
carrying O 
a O 
chiral O 
(BINAP)Pt B-FORMULA 
(II) I-FORMULA 
-appended O 
coordination O 
metallacycle O 
( O 
HBC(Py)([(R)-Pt] B-FORMULA 
) O 
or O 
HBC(Py)([(S)-Pt]) B-FORMULA 
) O 
, O 
screw O 
- O 
sense O 
- O 
selective O 
assembly O 
took O 
place O 
to O 
give O 
optically O 
active O 
nanotubes O 
( O 
NT( O 
Py B-FORMULA 
)( O 
[ B-FORMULA 
(R)-Pt I-FORMULA 
] I-FORMULA 
) O 
or O 
NT( O 
Py B-FORMULA 
)( O 
[ B-FORMULA 
(S)-Pt I-FORMULA 
] I-FORMULA 
) O 
) O 
with O 
helical O 
chirality O 
, O 
which O 
were O 
enriched O 
in O 
either O 
left O 
- O 
handed O 
( O 
M)-NT( O 
Py B-FORMULA 
)( O 
[ B-FORMULA 
(R)-Pt I-FORMULA 
] I-FORMULA 
) O 
or O 
right O 
- O 
handed O 
( O 
P)-NT( O 
Py B-FORMULA 
)( O 
[ B-FORMULA 
(S)-Pt I-FORMULA 
] I-FORMULA 
) O 
, O 
depending O 
on O 
the O 
absolute O 
configuration O 
of O 
the O 
(BINAP)Pt B-FORMULA 
(II) I-FORMULA 
pendant O 
. O 
When O 
MeOH B-FORMULA 
was O 
used O 
instead O 
of O 
ether O 
for O 
the O 
vapor O 
- O 
diffusion O 
- O 
induced O 
assembly O 
, O 
nanocoils O 
formed O 
along O 
with O 
the O 
nanotubes O 
. O 
As O 
determined O 
by O 
scanning O 
electron O 
microscopy O 
, O 
the O 
diastereomeric O 
excess O 
of O 
the O 
nanocoils O 
was O 
60% O 
( O 
80 O 
: O 
20 O 
diastereomeric O 
ratio O 
) O 
. O 
Removal O 
of O 
the O 
(BINAP)Pt B-FORMULA 
(II) I-FORMULA 
pendants O 
from O 
NT( O 
Py B-FORMULA 
)( O 
[ B-FORMULA 
(R)-Pt I-FORMULA 
] I-FORMULA 
) O 
or O 
NT( O 
Py B-FORMULA 
)( O 
[ B-FORMULA 
(S)-Pt I-FORMULA 
] I-FORMULA 
) O 
with O 
ethylenediamine B-SYSTEMATIC 
yielded O 
metal O 
- O 
free O 
nanotubes O 
( O 
NT( O 
Py B-FORMULA 
) O 
) O 
that O 
remained O 
optically O 
active O 
even O 
upon O 
heating O 
without O 
any O 
change O 
in O 
the O 
circular O 
dichroism O 
spectral O 
profile O 
. O 
No O 
helical O 
inversion O 
took O 
place O 
when O 
NT( O 
Py B-FORMULA 
) O 
derived O 
from O 
HBC(Py)([(R)-Pt]) B-FORMULA 
or O 
HBC(Py)([(S)-Pt]) B-FORMULA 
was O 
allowed O 
to O 
complex O 
with O 
(BINAP)Pt B-FORMULA 
(II) I-FORMULA 
with O 
an O 
absolute O 
configuration O 
opposite O 
to O 
the O 
original O 
one O 
. O 

of O 
repeated O 
dosing O 
on O 
rifampin B-TRIVIAL 
exposure O 
in O 
BALB O 
/ O 
c O 
mice O 
. O 

discovery O 
of O 
novel O 
therapeutics O 
for O 
the O 
treatment O 
of O 
tuberculosis O 
involves O 
routine O 
testing O 
in O 
a O 
mouse O 
model O 
over O 
four O 
weeks O 
of O 
daily O 
dosing O 
with O 
test O 
compounds O 
. O 
In O 
this O 
model O 
, O 
daily O 
oral O 
administration O 
of O 
rifampin B-TRIVIAL 
( O 
10mg O 
/ O 
kg O 
) O 
showed O 
significantly O 
lower O 
plasma O 
exposure O 
on O 
day O 
5 O 
compared O 
to O 
day O 
1 O 
. O 
The O 
absence O 
of O 
PXR O 
- O 
mediated O 
induction O 
of O 
mouse O 
Cyp3a O 
isoforms O 
was O 
confirmed O 
in O 
the O 
present O 
study O 
by O 
incubating O 
liver O 
microsomes O 
prepared O 
from O 
control O 
and O 
rifampin B-TRIVIAL 
treated O 
mice O 
with O 
probe O 
substrates O 
of O 
CYP3A O 
. O 
To O 
test O 
whether O 
the O 
reduction O 
in O 
exposure O 
was O 
due O 
to O 
Pgp O 
- O 
mediated O 
efflux O 
, O 
verapamil B-TRIVIAL 
, O 
a O 
known O 
Pgp O 
inhibitor O 
, O 
was O 
dosed O 
to O 
the O 
rifampin B-TRIVIAL 
pre O 
- O 
treated O 
mice O 
which O 
led O 
to O 
an O 
increase O 
in O 
exposure O 
to O 
that O 
obtained O 
after O 
a O 
single O 
dose O 
of O 
rifampin B-TRIVIAL 
, O 
suggesting O 
the O 
role O 
of O 
Pgp O 
induction O 
in O 
reducing O 
exposure O 
to O 
rifampin B-TRIVIAL 
. O 
To O 
further O 
confirm O 
Pgp O 
induction O 
in O 
rifampin B-TRIVIAL 
treated O 
mice O 
, O 
digoxin B-TRIVIAL 
, O 
a O 
known O 
substrate O 
of O 
Pgp O 
, O 
was O 
administered O 
to O 
the O 
rifampin B-TRIVIAL 
pre O 
- O 
treated O 
mice O 
, O 
and O 
a O 
significant O 
drop O 
in O 
the O 
digoxin B-TRIVIAL 
exposure O 
was O 
observed O 
compared O 
to O 
the O 
control O 
group O 
. O 
Collectively O 
, O 
our O 
results O 
show O 
that O 
repeated O 
administration O 
of O 
rifampin B-TRIVIAL 
in O 
mice O 
leads O 
to O 
a O 
reduction O 
in O 
oral O 
exposure O 
due O 
to O 
induction O 
of O 
Pgp O 
- O 
mediated O 
efflux O 
of O 
rifampin B-TRIVIAL 
, O 
and O 
not O 
via O 
induction O 
of O 
CYP3A O 
isoforms O 
. O 

and O 
electrical O 
detection O 
of O 
single O 
- O 
molecule O 
translocation O 
through O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

current O 
through O 
a O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
SWCNT O 
) O 
was O 
monitored O 
at O 
the O 
same O 
time O 
as O 
fluorescence O 
was O 
recorded O 
from O 
charged O 
dye O 
molecules O 
translocating O 
through O 
the O 
SWCNT O 
. O 
Fluorescence O 
bursts O 
generally O 
follow O 
ion O 
current O 
peaks O 
with O 
a O 
delay O 
time O 
consistent O 
with O 
diffusion O 
from O 
the O 
end O 
of O 
the O 
SWCNT O 
to O 
the O 
fluorescence O 
collection O 
point O 
. O 
The O 
fluorescence O 
amplitude O 
distribution O 
of O 
the O 
bursts O 
is O 
consistent O 
with O 
single O 
- O 
molecule O 
signals O 
. O 
Thus O 
each O 
peak O 
in O 
the O 
ion O 
current O 
flowing O 
through O 
the O 
SWCNT O 
is O 
associated O 
with O 
the O 
translocation O 
of O 
a O 
single O 
molecule O 
. O 
Ion O 
current O 
peaks O 
( O 
as O 
opposed O 
to O 
blockades O 
) O 
were O 
produced O 
by O 
both O 
positively O 
( O 
Rhodamine B-TRIVIAL 
6G I-TRIVIAL 
) O 
and O 
negatively O 
( O 
Alexa B-TRIVIAL 
546 I-TRIVIAL 
) O 
charged O 
molecules O 
, O 
showing O 
that O 
the O 
charge O 
filtering O 
responsible O 
for O 
the O 
current O 
bursts O 
is O 
caused O 
by O 
the O 
molecules O 
themselves O 
. O 

new O 
cyclic O 
peptide O 
containing O 
the O 
isoDGR O 
motif O 
that O 
, O 
after O 
coupling O 
to O 
albumin O 
, O 
selectively O 
binds O 
αvβ3 O 
, O 
an O 
integrin O 
overexpressed O 
in O 
the O 
tumor O 
vasculature O 
. O 
IsoDGR-tagged O 
albumin O 
binds O 
tumor O 
vessels O 
and O 
can O 
be O 
exploited O 
as O 
a O 
carrier O 
for O 
the O 
preparation O 
of O 
tumor O 
vasculature O 
- O 
selective O 
nanomedicines O 
, O 
such O 
as O 
gold O 
nanoparticles O 
( O 
Au B-FORMULA 
) O 
carrying O 
tumor O 
necrosis O 
factor O 
α O 
( O 
TNF O 
) O 
, O 
a O 
potent O 
vascular O 
damaging O 
agent O 
. O 

protects O 
endothelial O 
function O 
in O 
hyperglycemia O 
- O 
induced O 
oxidative O 
stress O 
through O 
an O 
antioxidant O 
mechanism O 
. O 

oxidative O 
stress O 
is O 
involved O 
in O 
the O 
pathogenesis O 
and O 
progression O 
of O 
diabetes O 
. O 
Antioxidants O 
are O 
therapeutically O 
beneficial O 
for O 
oxidative O 
stress O 
- O 
associated O 
diseases O 
. O 
Boldine B-TRIVIAL 
( O 
[s]-2,9-dihydroxy-1,10-dimethoxyaporphine B-SYSTEMATIC 
) O 
is O 
a O 
major O 
alkaloid O 
present O 
in O 
the O 
leaves O 
and O 
bark O 
of O 
the O 
boldo O 
tree O 
( O 
Peumus O 
boldus O 
Molina O 
) O 
, O 
with O 
known O 
an O 
antioxidant O 
activity O 
. O 
This O 
study O 
examined O 
the O 
protective O 
effects O 
of O 
boldine B-TRIVIAL 
against O 
high O 
glucose B-TRIVIAL 
-induced O 
oxidative O 
stress O 
in O 
rat O 
aortic O 
endothelial O 
cells O 
( O 
RAEC O 
) O 
and O 
its O 
mechanisms O 
of O 
vasoprotection O 
related O 
to O 
diabetic O 
endothelial O 
dysfunction O 
. O 
In O 
RAEC O 
exposed O 
to O 
high O 
glucose B-TRIVIAL 
( O 
30 O 
mM O 
) O 
for O 
48 O 
h O 
, O 
pre O 
- O 
treatment O 
with O 
boldine B-TRIVIAL 
reduced O 
the O 
elevated O 
ROS O 
and O 
nitrotyrosine B-SYSTEMATIC 
formation O 
, O 
and O 
preserved O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
production O 
. O 
Pre O 
- O 
incubation O 
with O 
β-NAPDH B-ABBREVIATION 
reduced O 
the O 
acetylcholine B-SYSTEMATIC 
-induced O 
endothelium O 
- O 
dependent O 
relaxation O 
; O 
this O 
attenuation O 
was O 
reversed O 
by O 
boldine B-TRIVIAL 
. O 
Compared O 
with O 
control O 
, O 
endothelium O 
- O 
dependent O 
relaxation O 
in O 
the O 
aortas O 
of O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
) O 
- O 
treated O 
diabetic O 
rats O 
was O 
significantly O 
improved O 
by O 
both O 
acute O 
( O 
1 O 
μM O 
, O 
30 O 
min O 
) O 
and O 
chronic O 
( O 
20mg O 
/ O 
kg O 
/ O 
daily O 
, O 
i.p O 
. O 
, O 
7 O 
days O 
) O 
treatment O 
with O 
boldine B-TRIVIAL 
. O 
Intracellular O 
superoxide B-TRIVIAL 
and O 
peroxynitrite B-SYSTEMATIC 
formation O 
measured O 
by O 
DHE B-ABBREVIATION 
fluorescence O 
or O 
chemiluminescence O 
assay O 
were O 
higher O 
in O 
sections O 
of O 
aortic O 
rings O 
from O 
diabetic O 
rats O 
compared O 
with O 
control O 
. O 
Chronic O 
boldine B-TRIVIAL 
treatment O 
normalized O 
ROS O 
over O 
- O 
production O 
in O 
the O 
diabetic O 
group O 
and O 
this O 
correlated O 
with O 
reduction O 
of O 
NAD(P)H B-ABBREVIATION 
oxidase O 
subunits O 
, O 
NOX2 O 
and O 
p47(phox) O 
. O 
The O 
present O 
study O 
shows O 
that O 
boldine B-TRIVIAL 
reversed O 
the O 
increased O 
ROS O 
formation O 
in O 
high O 
glucose B-TRIVIAL 
-treated O 
endothelial O 
cells O 
and O 
restored O 
endothelial O 
function O 
in O 
STZ B-ABBREVIATION 
-induced O 
diabetes O 
by O 
inhibiting O 
oxidative O 
stress O 
and O 
thus O 
increasing O 
NO B-FORMULA 
bioavailability O 
. O 

toxicogenomics O 
approach O 
was O 
applied O 
to O 
assess O 
the O 
usefulness O 
of O 
the O 
mouse O 
cytotoxic O 
T O 
cell O 
line O 
CTLL-2 O 
for O 
in O 
vitro O 
immunotoxicity O 
testing O 
. O 
CTLL-2 O 
cells O 
were O 
exposed O 
for O 
6 O 
h O 
to O 
two O 
model O 
immunotoxic O 
compounds O 
: O 
( O 
1 O 
) O 
the O 
mycotoxin O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
, O 
1 O 
and O 
2 O 
μM O 
) O 
, O 
a O 
ribotoxic O 
stress O 
inducer O 
, O 
and O 
( O 
2 O 
) O 
the O 
organotin B-FAMILY 
compound O 
tributyltin B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
TBTO B-ABBREVIATION 
, O 
100 O 
and O 
200 O 
nM O 
) O 
, O 
an O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
inducer O 
. O 
Effects O 
on O 
whole O 
- O 
genome O 
mRNA O 
expression O 
were O 
assessed O 
by O 
microarray O 
analysis O 
. O 
The O 
biological O 
interpretation O 
of O 
the O 
microarray O 
data O 
indicated O 
that O 
TBTO B-ABBREVIATION 
( O 
200 O 
nM O 
) O 
induced O 
genes O 
involved O 
in O 
T O 
cell O 
activation O 
, O 
ER O 
stress O 
, O 
NFκB O 
activation O 
and O 
apoptosis O 
, O 
which O 
agreed O 
very O 
well O 
with O 
results O 
obtained O 
before O 
on O 
TBTO B-ABBREVIATION 
exposed O 
Jurkat O 
cells O 
and O 
mouse O 
primary O 
thymocytes O 
. O 
Remarkably O 
, O 
DON B-ABBREVIATION 
( O 
2 O 
μM O 
) O 
downregulated O 
genes O 
involved O 
in O 
T O 
cell O 
activation O 
, O 
ER O 
stress O 
and O 
apoptosis O 
, O 
which O 
is O 
opposite O 
to O 
results O 
obtained O 
before O 
for O 
DON B-ABBREVIATION 
-exposed O 
Jurkat O 
cells O 
and O 
mouse O 
primary O 
thymocytes O 
. O 
Furthermore O 
, O 
the O 
results O 
for O 
DON B-ABBREVIATION 
in O 
CTLL-2 O 
cells O 
are O 
also O 
opposite O 
to O 
the O 
results O 
obtained O 
for O 
TBTO B-ABBREVIATION 
in O 
CTLL-2 O 
cells O 
. O 
In O 
agreement O 
with O 
the O 
lack O 
of O 
induction O 
of O 
ER O 
stress O 
and O 
apoptosis O 
, O 
viability O 
assays O 
showed O 
that O 
CTLL-2 O 
cells O 
are O 
much O 
more O 
resistant O 
to O 
the O 
toxicity O 
of O 
DON B-ABBREVIATION 
than O 
Jurkat O 
cells O 
and O 
primary O 
thymocytes O 
. O 
We O 
propose O 
that O 
CTLL-2 O 
cells O 
lack O 
the O 
signal O 
transduction O 
that O 
induces O 
ER O 
stress O 
and O 
apoptosis O 
in O 
response O 
to O 
ribotoxic O 
stress O 
. O 
Based O 
on O 
the O 
results O 
for O 
TBTO B-ABBREVIATION 
and O 
DON B-ABBREVIATION 
, O 
the O 
CTLL-2 O 
cell O 
line O 
does O 
not O 
yield O 
an O 
added O 
value O 
for O 
immunotoxicity O 
compared O 
to O 
the O 
human O 
Jurkat O 
T O 
cell O 
line O 
. O 

-Conjugated O 
PEG B-ABBREVIATION 
on O 
Single O 
Walled O 
Carbon B-SYSTEMATIC 
Nanotubes O 
for O 
Targeting O 
Delivery O 
of O 
Doxorubicin B-TRIVIAL 
to O 
Cancer O 
Cells O 
. O 

highly O 
effective O 
drug O 
carrier O 
is O 
constructed O 
by O 
coating O 
folic B-TRIVIAL 
acid I-TRIVIAL 
-terminated O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
-FA O 
) O 
on O 
single O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
in O 
a O 
facile O 
non-covalent O 
method O 
. O 
The O 
anti-cancer O 
drug O 
, O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
, O 
is O 
further O 
loaded O 
on O 
the O 
surface O 
of O 
SWNTs O 
at O 
a O 
very O 
high O 
loading O 
efficiency O 
, O 
149.3 O 
± O 
4.1% O 
. O 
The O 
drug O 
system O 
( O 
DOX B-ABBREVIATION 
/ O 
PEG B-ABBREVIATION 
-FA O 
/ O 
SWNTs O 
) O 
exhibits O 
excellent O 
stability O 
under O 
neutral O 
pH O 
conditions O 
such O 
as O 
serum O 
, O 
but O 
dramatically O 
releases O 
DOX B-ABBREVIATION 
at O 
reduced O 
pH O 
typical O 
of O 
the O 
tumour O 
environment O 
and O 
intracellular O 
lysosomes O 
and O 
endosomes O 
. O 
With O 
the O 
help O 
of O 
FA O 
, O 
DOX B-ABBREVIATION 
/ O 
PEG B-ABBREVIATION 
-FA O 
/ O 
SWNTs O 
tend O 
to O 
selectively O 
attach O 
onto O 
cancer O 
cells O 
and O 
enter O 
the O 
lysosomes O 
or O 
endosomes O 
by O 
clathrin O 
- O 
mediated O 
endocytosis O 
. O 
This O 
can O 
greatly O 
improve O 
the O 
pharmaceutical O 
efficiency O 
and O 
reduce O 
potential O 
side O 
effects O 
. O 

importance O 
of O 
direct O 
and O 
trophic O 
uranium B-SYSTEMATIC 
exposures O 
in O 
the O 
crayfish O 
Orconectes O 
limosus O 
: O 
Implication O 
for O 
predicting O 
uranium B-SYSTEMATIC 
bioaccumulation O 
and O 
its O 
associated O 
toxicity O 
. O 

that O 
occur O 
at O 
sublethal O 
concentrations O 
in O 
the O 
environment O 
may O 
lead O 
to O 
chronic O 
exposure O 
in O 
aquatic O 
organisms O 
. O 
If O 
these O 
pollutants O 
bioaccumulate O 
, O 
then O 
organisms O 
higher O 
in O 
the O 
food O 
chain O 
may O 
also O 
be O 
at O 
risk O 
. O 
Increased O 
attention O 
has O 
thus O 
been O 
focused O 
on O 
the O 
relative O 
importance O 
of O 
dietary O 
uptake O 
, O 
but O 
additional O 
knowledge O 
of O 
the O 
cellular O 
distribution O 
of O 
metals O 
after O 
dietary O 
exposure O 
is O 
required O 
to O 
assess O 
the O 
potential O 
toxicity O 
. O 
The O 
authors O 
address O 
concerns O 
relating O 
to O 
increasing O 
uranium B-SYSTEMATIC 
( O 
U B-FORMULA 
) O 
concentrations O 
( O 
from O 
12 O 
µg O 
/ O 
L O 
to O 
2 O 
mg O 
/ O 
L O 
) O 
in O 
the O 
freshwater O 
ecosystem O 
caused O 
by O 
anthropogenic O 
activities O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
is O 
to O 
compare O 
uranium B-SYSTEMATIC 
bioaccumulation O 
levels O 
in O 
tissues O 
and O 
in O 
the O 
subcellular O 
environment O 
. O 
The O 
authors O 
focused O 
on O 
the O 
cytosol O 
fraction O 
and O 
its O 
microlocalization O 
( O 
TEM-EDX O 
) O 
in O 
the O 
gills O 
and O 
the O 
hepatopancreas O 
( O 
HP O 
) O 
of O 
the O 
crayfish O 
Orconectes O 
limosus O 
after O 
10 O 
d O 
of O 
direct O 
exposure O 
( O 
at O 
concentrations O 
of O 
20 O 
, O 
100 O 
, O 
and O 
500 O 
µg O 
/ O 
L O 
) O 
and O 
five O 
trophic O 
exposure O 
treatments O 
( O 
at O 
concentrations O 
from O 
1 O 
to O 
20 O 
µg O 
/ O 
g O 
) O 
. O 
Results O 
indicated O 
that O 
adsorption O 
of O 
uranium B-SYSTEMATIC 
on O 
the O 
cuticle O 
represents O 
the O 
main O 
contribution O 
of O 
total O 
uranium B-SYSTEMATIC 
accumulation O 
to O 
the O 
animal O 
. O 
Accumulation O 
in O 
the O 
gills O 
should O 
be O 
considered O 
only O 
as O 
a O 
marker O 
of O 
waterborne O 
uranium B-SYSTEMATIC 
exposure O 
. O 
Accumulation O 
in O 
the O 
HP O 
after O 
trophic O 
environmental O 
exposure O 
conditions O 
was O 
higher O 
( O 
18.9 O 
± O 
3.8 O 
µg O 
/ O 
g O 
) O 
than O 
after O 
direct O 
exposure O 
. O 
Moreover O 
, O 
no O 
significant O 
difference O 
in O 
the O 
subcellular O 
distribution O 
of O 
uranium B-SYSTEMATIC 
( O 
50% O 
) O 
in O 
HP O 
was O 
observed O 
between O 
animals O 
that O 
had O 
been O 
exposed O 
to O 
both O 
types O 
of O 
treatment O 
. O 
A O 
potential O 
toxic O 
effect O 
after O 
uranium B-SYSTEMATIC 
accumulation O 
could O 
therefore O 
exist O 
after O 
trophic O 
exposure O 
. O 
This O 
confirms O 
the O 
need O 
to O 
focus O 
further O 
studies O 
on O 
the O 
metal O 
( O 
uranium B-SYSTEMATIC 
) O 
risk O 
assessment O 
. O 

is O 
increasing O 
evidence O 
that O 
exposure O 
to O 
stressors O 
in O 
adolescence O 
has O 
long O 
- O 
lasting O 
effects O 
on O 
emotional O 
and O 
cognitive O 
behavior O 
, O 
but O 
little O 
is O 
known O 
as O 
to O 
whether O 
reproductive O 
functions O 
are O 
affected O 
. O 
We O 
investigated O 
appetitive O 
and O 
consummatory O 
aspects O 
of O 
sexual O 
behavior O 
in O 
male O 
rats O 
that O 
were O 
exposed O 
to O 
chronic O 
social O 
instability O 
stress O 
( O 
SS O 
, O 
n=24 O 
) O 
for O 
16 O 
days O 
in O 
mid O 
- O 
adolescence O 
compared O 
to O 
control O 
rats O 
( O 
CTL O 
, O 
n=24 O 
) O 
. O 
Over O 
five O 
sexual O 
behavior O 
test O 
sessions O 
with O 
a O 
receptive O 
female O 
, O 
SS O 
rats O 
made O 
fewer O 
ejaculations O 
( O 
p=0.02 O 
) O 
and O 
had O 
longer O 
latencies O 
to O 
ejaculation O 
( O 
p=0.03 O 
) O 
. O 
When O 
only O 
data O 
from O 
rats O 
that O 
ejaculated O 
in O 
the O 
fifth O 
session O 
were O 
analyzed O 
, O 
SS O 
rats O 
( O 
n=18 O 
) O 
had O 
reduced O 
copulatory O 
efficiency O 
( O 
more O 
mounts O 
and O 
intromissions O 
before O 
ejaculation O 
) O 
compared O 
to O 
CTL O 
rats O 
( O 
n=19 O 
) O 
( O 
p=0.004 O 
) O 
, O 
and O 
CTL O 
rats O 
were O 
twice O 
as O 
likely O 
as O 
SS O 
rats O 
to O 
make O 
more O 
than O 
one O 
ejaculation O 
in O 
the O 
fifth O 
session O 
( O 
p=0.05 O 
) O 
. O 
Further O 
, O 
more O 
CTL O 
( O 
14 O 
/ O 
24 O 
) O 
than O 
SS O 
( O 
5 O 
/ O 
25 O 
) O 
rats O 
ejaculated O 
in O 
four O 
or O 
more O 
sessions O 
( O 
p=0.05 O 
) O 
. O 
SS O 
rats O 
had O 
lower O 
plasma O 
testosterone B-TRIVIAL 
concentrations O 
than O 
CTL O 
rats O 
( O 
p=0.05 O 
) O 
, O 
but O 
did O 
not O 
differ O 
in O 
androgen B-FAMILY 
receptor O 
, O 
estrogen B-FAMILY 
receptor O 
alpha O 
, O 
or O 
Fos O 
immunoreactive O 
cell O 
counts O 
in O 
the O 
medial O 
preoptic O 
area O 
. O 
The O 
groups O 
did O 
not O 
differ O 
in O 
a O 
partner O 
preference O 
test O 
administered O 
between O 
the O 
fourth O 
and O 
fifth O 
sexual O 
behavior O 
session O 
. O 
The O 
results O 
suggest O 
that O 
developmental O 
history O 
contributes O 
to O 
individual O 
differences O 
in O 
reproductive O 
behavior O 
, O 
and O 
that O 
stress O 
exposures O 
in O 
adolescence O 
may O 
be O 
a O 
factor O 
in O 
sexual O 
sluggishness O 
. O 

structure O 
analysis O 
of O 
a O 
solid O 
solution O 
of O 
milbemycins B-MULTIPLE 
A3 I-MULTIPLE 
and I-MULTIPLE 
A4 I-MULTIPLE 
. O 

A3 I-MULTIPLE 
and I-MULTIPLE 
A4 I-MULTIPLE 
are O 
pharmaceutically O 
and O 
agriculturally O 
useful O 
macrolides O 
isolated O 
from O 
Streptomyces O 
species O 
. O 
The O 
molecular O 
structures O 
of O 
the O 
title O 
compounds O 
were O 
unambiguously O 
established O 
by O 
a O 
single O 
crystal O 
X-ray O 
analysis O 
of O 
the O 
solid O 
solution O 
of O 
both O 
compounds O 
. O 
The O 
crystals O 
present O 
trigonal O 
system O 
, O 
space O 
group O 
P32 O 
with O 
Z O 
= O 
3 O 
, O 
unit O 
cell O 
dimensions O 
: O 
a O 
= O 
12.2211(4) O 
, O 
c O 
= O 
17.5372(7) O 
Å O 
; O 
V O 
= O 
2268.4(1) O 
Å(3) O 
, O 
μ O 
= O 
0.082 O 
mm(- O 
1) O 
; O 
d O 
= O 
1.183 O 
g O 
cm(- O 
3) O 
. O 
An O 
interesting O 
system O 
of O 
intramolecular O 
hydrogen B-SYSTEMATIC 
bonds O 
and O 
weak O 
intermolecular O 
CH B-FORMULA 
… O 
O B-FORMULA 
type O 
hydrogen B-SYSTEMATIC 
bond O 
was O 
observed O 
in O 
the O 
solid O 
state O 
. O 

Energies O 
of O 
the O 
Hydrocarboxyl B-SYSTEMATIC 
Radical O 
from O 
a O 
RCCSD(T) O 
Study O 
. O 

RCCSD(T) O 
/ O 
cc-pVQZ O 
potential O 
energy O 
surface O 
is O 
constructed O 
for O 
the O 
HOCO B-FORMULA 
radical O 
in O 
the O 
ground O 
electronic O 
state O 
and O 
used O 
to O 
compute O 
rotation O 
- O 
vibration O 
levels O 
of O 
HOCO B-FORMULA 
and O 
DOCO B-FORMULA 
. O 
Two O 
numerical O 
strategies O 
are O 
employed O 
to O 
study O 
in O 
detail O 
the O 
wave O 
function O 
properties O 
. O 
The O 
importance O 
of O 
stretch O 
- O 
bend O 
coupling O 
, O 
such O 
as O 
ν4 O 
/ O 
ν5 O 
and O 
ν3 O 
/ O 
ν4 O 
, O 
for O 
the O 
internal O 
dynamics O 
is O 
demonstrated O 
. O 
The O 
rotational O 
constants O 
computed O 
for O 
the O 
vibrational O 
ground O 
state O 
of O 
trans O 
and O 
cis O 
conformers O 
are O 
in O 
good O 
agreement O 
with O 
experimental O 
values O 
. O 

models O 
of O 
co O 
- O 
evolution O 
between O 
brood O 
parasites O 
and O 
their O 
hosts O 
primarily O 
focus O 
upon O 
the O 
cost O 
to O 
hosts O 
in O 
the O 
current O 
reproductive O 
bout O 
, O 
the O 
impact O 
of O 
brood O 
parasitism O 
may O 
carry O 
over O 
to O 
future O 
reproductive O 
attempts O 
by O 
altering O 
resource O 
allocation O 
. O 
Glucocorticoid O 
stress O 
hormones O 
help O 
mediate O 
resource O 
allocation O 
to O 
reproduction O 
, O 
yet O 
they O 
have O 
rarely O 
been O 
examined O 
in O 
brood O 
parasitic O 
systems O 
. O 
Here O 
we O 
determined O 
if O 
shifts O 
in O 
parental O 
care O 
and O 
corticosterone B-TRIVIAL 
had O 
carry O 
- O 
over O 
effects O 
on O 
future O 
reproductive O 
effort O 
in O 
the O 
rufous O 
- O 
and O 
- O 
white O 
wren O 
( O 
Thryophilus O 
rufalbus O 
) O 
, O 
a O 
host O 
of O 
the O 
Central O 
American O 
striped O 
cuckoo O 
( O 
Tapera O 
naevia O 
) O 
. O 
We O 
found O 
that O 
parasitized O 
parents O 
had O 
significantly O 
higher O 
stress O 
- O 
induced O 
, O 
but O 
not O 
baseline O 
, O 
corticosterone B-TRIVIAL 
than O 
natural O 
parents O 
during O 
the O 
fledgling O 
stage O 
, O 
which O 
was O 
associated O 
with O 
changes O 
in O 
parental O 
care O 
. O 
The O 
high O 
investment O 
in O 
current O 
reproduction O 
while O 
parasitized O 
may O 
be O 
due O 
to O 
the O 
value O 
of O 
fledged O 
chicks O 
in O 
tropical O 
systems O 
. O 
This O 
maladaptive O 
response O 
by O 
parasitized O 
parents O 
was O 
associated O 
with O 
delayed O 
re O 
- O 
nesting O 
and O 
a O 
reduced O 
likelihood O 
of O 
nesting O 
in O 
the O 
subsequent O 
breeding O 
season O 
. O 
Although O 
a O 
reduction O 
in O 
future O 
reproductive O 
effort O 
can O 
result O 
from O 
a O 
combination O 
of O 
factors O 
, O 
this O 
work O 
suggests O 
that O 
fitness O 
costs O 
of O 
brood O 
parasitism O 
are O 
mediated O 
by O 
changes O 
in O 
corticosterone B-TRIVIAL 
and O 
parental O 
care O 
behavior O 
that O 
carry O 
over O 
into O 
subsequent O 
breeding O 
seasons O 
. O 

repressed O 
DNA O 
mismatch O 
repair O 
in O 
human O 
breast O 
cancer O 
cells O 
. O 

mismatch O 
repair O 
( O 
MMR O 
) O 
has O 
been O 
recently O 
implicated O 
to O 
play O 
a O 
significant O 
role O 
in O 
breast O 
cancer O 
progression O 
, O 
however O 
, O 
few O 
studies O 
have O 
examined O 
how O 
various O 
carcinogens O 
affect O 
MMR O 
system O 
in O 
breast O 
cancer O 
cells O 
. O 
The O 
present O 
study O 
employs O 
an O 
in O 
vivo O 
MMR O 
assay O 
developed O 
in O 
our O 
laboratory O 
to O 
assess O 
how O 
prevalent O 
environmental O 
carcinogens O 
such O 
as O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
affect O 
MMR O 
activity O 
in O 
human O 
breast O 
carcinoma O 
cells O 
. O 
Specifically O 
, O 
we O 
quantitatively O 
measured O 
MMR O 
activity O 
in O 
ZR75-1 O 
cells O 
after O 
they O 
were O 
exposed O 
to O 
benzo[α]pyrene B-SYSTEMATIC 
( O 
BaP B-ABBREVIATION 
) O 
, O 
a O 
prototypical O 
PAH B-ABBREVIATION 
, O 
at O 
various O 
concentrations O 
. O 
Our O 
findings O 
revealed O 
that O 
BaP B-ABBREVIATION 
exposure O 
at O 
high O 
concentrations O 
of O 
1 O 
and O 
5 O 
μM O 
induced O 
significant O 
inhibition O 
of O 
MMR O 
activity O 
in O 
ZR75-1 O 
cells O 
. O 
Further O 
, O 
we O 
also O 
identified O 
that O 
MMR O 
repression O 
induced O 
by O 
5 O 
μM O 
BaP B-ABBREVIATION 
was O 
mediated O 
through O 
one O 
of O 
the O 
MMR O 
key O 
proteins O 
MSH6 O 
as O 
significant O 
reduction O 
in O 
protein O 
level O 
was O 
detected O 
by O 
western O 
blot O 
. O 
More O 
importantly O 
, O 
ectopic O 
expression O 
of O 
hMSH6 O 
restored O 
MMR O 
activity O 
in O 
the O 
BaP B-ABBREVIATION 
treated O 
cells O 
to O 
the O 
same O 
level O 
as O 
in O 
the O 
control O 
cells O 
. O 
Impaired O 
MMR O 
plays O 
an O 
important O 
role O 
in O 
carcinogenesis O 
. O 
Our O 
findings O 
suggest O 
that O 
BaP B-ABBREVIATION 
induced O 
repression O 
of O 
MMR O 
activity O 
may O 
also O 
contribute O 
to O 
the O 
progression O 
of O 
mutagenesis O 
event O 
. O 
Meanwhile O 
, O 
the O 
present O 
study O 
also O 
for O 
the O 
first O 
demonstrated O 
that O 
our O 
in O 
vivo O 
DNA O 
MMR O 
assay O 
can O 
be O 
applied O 
in O 
the O 
field O 
of O 
environmental O 
toxicology O 
. O 

DEACETYLASE O 
INHIBITION O 
AFFECTS O 
SODIUM B-SYSTEMATIC 
IODIDE I-SYSTEMATIC 
SYMPORTER O 
( O 
NIS O 
) O 
EXPRESSION O 
AND O 
INDUCES O 
¹³¹I B-FORMULA 
CYTOTOXICITY O 
IN O 
ANAPLASTIC O 
THYROID O 
CANCER O 
CELLS O 
. O 

: O 
Anaplastic O 
thyroid O 
cancers O 
( O 
ATC O 
) O 
represent O 
only O 
1-2% O 
of O 
all O 
thyroid O 
tumors O 
, O 
but O 
they O 
account O 
for O 
up O 
to O 
50% O 
of O 
the O 
mortality O 
. O 
Treatment O 
of O 
differentiated O 
thyroid O 
carcinomas O 
is O 
well O 
standardized O 
and O 
the O 
use O 
of O 
radioiodine B-SYSTEMATIC 
represents O 
an O 
essential O 
step O 
; O 
in O 
contrast O 
, O 
there O 
is O 
no O 
standardized O 
therapeutic O 
approach O 
for O 
anaplastic O 
tumors O 
and O 
their O 
prognosis O 
is O 
poor O 
. O 
The O 
resistance O 
of O 
anaplastic O 
thyroid O 
cancer O 
to O 
radioiodine B-SYSTEMATIC 
treatment O 
is O 
principally O 
due O 
to O 
the O 
absence O 
of O 
expression O 
of O 
the O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
( O 
NIS O 
) O 
, O 
mainly O 
due O 
to O 
epigenetic O 
silencing O 
. O 
The O 
acetylation O 
status O 
of O 
histones O 
is O 
involved O 
in O 
the O 
epigenetic O 
control O 
of O 
gene O 
expression O 
and O 
is O 
usually O 
disrupted O 
in O 
advanced O 
thyroid O 
cancer O 
. O 
Histone O 
deacetylase O 
inhibitors O 
have O 
been O 
demonstrated O 
as O 
potent O 
anticancer O 
drugs O 
with O 
several O 
different O 
effects O 
on O 
cell O 
viability O 
and O 
differentiation O 
. O 
Methods O 
: O 
Stabilized O 
anaplastic O 
thyroid O 
cancer O 
cell O 
lines O 
( O 
BHT-101 O 
and O 
CAL-62 O 
) O 
and O 
primary O 
cultures O 
from O 
patients O 
who O 
underwent O 
thyroidectomy O 
for O 
anaplastic O 
thyroid O 
cancer O 
were O 
treated O 
with O 
the O 
histone O 
deacetylase O 
inhibitor O 
LBH589 B-IDENTIFIER 
. O 
After O 
treatment O 
, O 
we O 
evaluated O 
the O 
expression O 
and O 
function O 
of O 
NIS O 
. O 
Gene O 
expression O 
was O 
evaluated O 
by O 
real O 
- O 
time O 
PCR O 
( O 
RT-PCR O 
) O 
; O 
NIS O 
promoter O 
activity O 
was O 
determined O 
with O 
a O 
luciferase O 
reporter O 
assay O 
; O 
and O 
protein O 
expression O 
was O 
assessed O 
through O 
immunofluorescence O 
. O 
We O 
tested O 
the O 
protein O 
function O 
by O 
125I B-FORMULA 
uptake O 
and O 
efflux O 
experiments O 
; O 
finally O 
the O 
cytotoxic O 
effect O 
of O 
131I B-FORMULA 
was O 
determined O 
with O 
a O 
clonogenic O 
assay O 
. O 
Results O 
: O 
Our O 
results O 
demonstrate O 
that O 
treatment O 
with O 
LBH589 B-IDENTIFIER 
leads O 
to O 
NIS O 
RNA O 
expression O 
as O 
shown O 
by O 
RT-PCR O 
and O 
luciferase O 
assay O 
, O 
and O 
to O 
protein O 
expression O 
as O 
determined O 
by O 
immunofluorescence O 
in O 
vitro O 
and O 
by O 
immunohistochemistry O 
in O 
xenograft O 
tumors O 
. O 
Moreover O 
, O 
125I B-FORMULA 
uptake O 
and O 
efflux O 
experiments O 
show O 
the O 
correct O 
protein O 
function O 
and O 
iodine B-SYSTEMATIC 
retention O 
, O 
that O 
translate O 
into O 
cytotoxicity O 
effects O 
, O 
as O 
demonstrated O 
by O 
a O 
clonogenic O 
assay O 
with O 
131I B-FORMULA 
. O 
Conclusions O 
: O 
This O 
study O 
supplies O 
a O 
new O 
potential O 
strategy O 
for O 
the O 
treatment O 
of O 
ATC O 
by O 
modifying O 
gene O 
expression O 
with O 
the O 
aim O 
of O 
inducing O 
responsiveness O 
towards O 
radioiodine B-SYSTEMATIC 
therapy O 
. O 

and O 
stability O 
assessment O 
of O 
blue O 
ferric B-FAMILY 
anthocyanin I-FAMILY 
chelates O 
in O 
liquid O 
pectin O 
- O 
stabilised O 
model O 
systems O 
. O 

formation O 
of O 
blue O 
coloured O 
ferric B-FAMILY 
anthocyanin I-FAMILY 
chelates O 
and O 
their O 
colour O 
stability O 
during O 
storage O 
and O 
thermal O 
treatment O 
were O 
monitored O 
in O 
a O 
pH O 
range O 
relevant O 
to O 
food O 
( O 
3.6-5.0 O 
) O 
. O 
Liquid O 
model O 
systems O 
were O 
composed O 
of O 
different O 
types O 
of O 
Citrus O 
pectins O 
, O 
juices O 
( O 
J O 
) O 
and O 
the O 
respective O 
phenolic O 
extracts O 
( O 
E O 
) O 
from O 
elderberry O 
( O 
EB O 
) O 
, O 
black O 
currant O 
( O 
BC O 
) O 
, O 
red O 
cabbage O 
( O 
RC O 
) O 
and O 
purple O 
carrot O 
( O 
PC O 
) O 
in O 
the O 
presence O 
of O 
ferric B-SYSTEMATIC 
ions O 
. O 
For O 
EB O 
, O 
BC O 
and O 
PC O 
, O 
pure O 
blue O 
colours O 
devoid O 
of O 
a O 
violet O 
tint O 
were O 
exclusively O 
observed O 
for O 
the O 
phenolic O 
extracts O 
and O 
at O 
pH O 
values O 
≥ O 
4.5 O 
in O 
model O 
systems O 
containing O 
high O 
methoxylated O 
and O 
amidated O 
pectins O 
, O 
respectively O 
. O 
Colour O 
and O 
its O 
stability O 
strongly O 
depended O 
on O 
the O 
amount O 
of O 
ferric B-SYSTEMATIC 
ions O 
and O 
the O 
plant O 
source O 
; O 
however O 
, O 
colour O 
decay O 
could O 
generally O 
be O 
described O 
as O 
a O 
pseudo O 
- O 
first O 
- O 
order O 
kinetics O 
. O 
Despite O 
optimal O 
colour O 
hues O 
for O 
RC-E O 
and O 
RC-J O 
, O 
storage O 
and O 
heat O 
stabilities O 
were O 
poor O 
. O 
Highest O 
colour O 
intensities O 
and O 
best O 
stabilities O 
were O 
observed O 
for O 
model O 
systems O 
containing O 
PC-E O 
at O 
a O 
molar O 
anthocyanin B-FAMILY 
: O 
ferric B-SYSTEMATIC 
ion O 
ratio O 
of O 
1 O 
: O 
2 O 
. O 
Ascorbic B-MULTIPLE 
and I-MULTIPLE 
lactic I-MULTIPLE 
acids I-MULTIPLE 
interfered O 
with O 
ferric B-SYSTEMATIC 
ions O 
, O 
thus O 
significantly O 
affecting O 
blue O 
colour O 
evolution O 
and O 
stability O 
. O 
Colour O 
loss O 
strongly O 
depended O 
on O 
heat O 
exposure O 
with O 
activation O 
energies O 
ranging O 
between O 
60.5 O 
and O 
78.4 O 
kJ O 
/ O 
mol O 
. O 
The O 
comprehensive O 
evaluation O 
of O 
the O 
interrelationship O 
of O 
pigment O 
source O 
, O 
pH O 
conditions O 
and O 
pectin O 
type O 
on O 
chelate O 
formation O 
and O 
stability O 
demonstrated O 
that O 
ferric B-FAMILY 
anthocyanin I-FAMILY 
chelates O 
are O 
promising O 
natural O 
blue O 
food O 
colourants O 
. O 

, O 
molecular O 
modeling O 
and O 
evaluation O 
of O 
novel O 
N'-2-(4-benzylpiperidin- B-FAMILY 
/ I-FAMILY 
piperazin-1-yl)acylhydrazone I-FAMILY 
derivatives O 
as O 
dual O 
inhibitors O 
for O 
cholinesterases O 
and O 
Aβ O 
aggregation O 
. O 

develop O 
new O 
drugs O 
for O 
treatment O 
of O 
Alzheimer's O 
disease O 
, O 
a O 
group O 
of O 
N'-2-(4-Benzylpiperidin- B-FAMILY 
/ I-FAMILY 
piperazin-1-yl)acylhydrazones I-FAMILY 
was O 
designed O 
, O 
synthesized O 
and O 
tested O 
for O 
their O 
ability O 
to O 
inhibit O 
acetylcholinesterase O 
, O 
butyrylcholinesterase O 
and O 
aggregation O 
of O 
amyloid O 
beta O 
peptides O 
( O 
1-40 O 
, O 
1-42 O 
and O 
1-40_1-42 O 
) O 
. O 
The O 
enzyme O 
inhibition O 
assay O 
results O 
indicated O 
that O 
compounds O 
moderately O 
inhibit O 
both O 
acetylcholinesterase O 
and O 
butyrylcholinesterase O 
. O 
β-Amyloid O 
aggregation O 
results O 
showed O 
that O 
all O 
compounds O 
exhibited O 
remarkable O 
Aβ O 
fibril O 
aggregation O 
inhibition O 
activity O 
with O 
a O 
nearly O 
similar O 
potential O 
as O 
the O 
reference O 
compound O 
rifampicin B-TRIVIAL 
, O 
which O 
makes O 
them O 
promising O 
anti-Alzheimer O 
drug O 
candidates O 
. O 
Docking O 
experiments O 
were O 
carried O 
out O 
with O 
the O 
aim O 
to O 
understand O 
the O 
interactions O 
of O 
the O 
most O 
active O 
compounds O 
with O 
the O 
active O 
site O 
of O 
the O 
cholinesterase O 
enzymes O 
. O 

deficiency O 
induced O 
in O 
Swiss O 
3T3 O 
cells O 
by O 
a O 
low- O 
zinc B-SYSTEMATIC 
medium O 
impairs O 
calcium B-SYSTEMATIC 
entry O 
and O 
two O 
mechanisms O 
of O 
entry O 
are O 
involved O 
. O 

deficiency O 
in O 
3T3 O 
cells O 
induced O 
by O 
the O 
use O 
of O 
diethylenetriaminepentaacetate B-SYSTEMATIC 
( O 
DTPA B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
impair O 
calcium B-SYSTEMATIC 
entry O 
associated O 
with O 
failure O 
of O 
proliferation O 
when O 
the O 
cells O 
are O 
stimulated O 
with O 
polypeptide O 
growth O 
factors O 
( O 
GF O 
) O 
. O 
These O 
functions O 
of O 
zinc B-SYSTEMATIC 
have O 
been O 
evaluated O 
here O 
in O 
the O 
same O 
clone O 
of O 
cells O 
by O 
simple O 
depletion O 
using O 
a O 
low- O 
zinc B-SYSTEMATIC 
medium O 
( O 
0.05 O 
μmol O 
/ O 
L O 
zinc B-SYSTEMATIC 
) O 
without O 
chelator O 
. O 
Confluent O 
cells O 
were O 
maintained O 
for O 
1 O 
day O 
in O 
the O 
low- O 
zinc B-SYSTEMATIC 
medium O 
without O 
GF O 
, O 
then O 
loaded O 
with O 
Fluo-4 B-ABBREVIATION 
, O 
and O 
stimulated O 
with O 
GF O 
. O 
Calcium B-SYSTEMATIC 
entry O 
was O 
measured O 
by O 
the O 
increase O 
in O 
sustained O 
fluorescence O 
. O 
It O 
was O 
preceded O 
by O 
the O 
release O 
of O 
stored O 
calcium B-SYSTEMATIC 
as O 
observed O 
in O 
the O 
previous O 
study O 
using O 
DTPA B-ABBREVIATION 
. O 
Zinc B-SYSTEMATIC 
deprivation O 
decreased O 
calcium B-SYSTEMATIC 
entry O 
when O 
calcium B-SYSTEMATIC 
was O 
added O 
at O 
0 O 
or O 
0.05 O 
mmol O 
/ O 
L O 
but O 
not O 
when O 
0.1 O 
mmol O 
/ O 
L O 
or O 
higher O 
. O 
Cell O 
proliferation O 
reflected O 
similar O 
effects O 
of O 
zinc B-SYSTEMATIC 
and O 
calcium B-SYSTEMATIC 
concentrations O 
. O 
In O 
a O 
newly O 
acquired O 
clone O 
of O 
3T3 O 
cells O 
, O 
GF O 
did O 
not O 
induce O 
internal O 
calcium B-SYSTEMATIC 
release O 
but O 
thapsigargin B-TRIVIAL 
( O 
TG O 
) O 
did O 
. O 
When O 
added O 
in O 
a O 
low- O 
calcium B-SYSTEMATIC 
medium O 
, O 
both O 
agonists O 
stimulated O 
calcium B-SYSTEMATIC 
entry O 
when O 
external O 
calcium B-SYSTEMATIC 
was O 
added O 
, O 
suggesting O 
that O 
two O 
different O 
mechanisms O 
of O 
entry O 
were O 
impaired O 
by O 
zinc B-SYSTEMATIC 
deficiency O 
. O 
Zinc B-SYSTEMATIC 
deficiency O 
produced O 
by O 
DTPA B-ABBREVIATION 
in O 
the O 
newer O 
clones O 
gave O 
similar O 
results O 
, O 
decreasing O 
calcium B-SYSTEMATIC 
entry O 
induced O 
by O 
both O 
agonists O 
. O 
The O 
effects O 
of O 
GF O 
and O 
TG O 
were O 
not O 
additive O 
. O 
The O 
results O 
confirm O 
the O 
earlier O 
observation O 
that O 
zinc B-SYSTEMATIC 
deficiency O 
impairs O 
calcium B-SYSTEMATIC 
entry O 
into O 
3T3 O 
cells O 
when O 
stimulated O 
by O 
GF O 
and O 
show O 
that O 
the O 
cells O 
can O 
take O 
up O 
calcium B-SYSTEMATIC 
by O 
either O 
store O 
- O 
operated O 
or O 
receptor O 
- O 
operated O 
mechanisms O 
. O 

effects O 
on O 
cognition O 
and O 
emotion O 
in O 
schizophrenia O 
and O 
its O 
neurochemical O 
modulation O 
in O 
the O 
brain O 
. O 

is O 
a O 
central O 
nervous O 
system O 
wake O 
promoting O 
agent O 
used O 
for O 
the O 
treatment O 
of O 
excessive O 
daytime O 
sleeping O 
. O 
Its O 
vigilance O 
promoting O 
properties O 
and O 
low O 
abuse O 
potential O 
has O 
intrigued O 
the O 
scientific O 
community O 
and O 
has O 
led O 
to O 
use O 
it O 
as O 
a O 
cognitive O 
enhancer O 
, O 
before O 
its O 
neural O 
functions O 
were O 
understood O 
. O 
Here O 
, O 
we O 
review O 
the O 
effects O 
of O 
modafinil B-TRIVIAL 
in O 
human O 
cognition O 
and O 
emotion O 
and O 
its O 
specific O 
actions O 
on O 
symptoms O 
in O 
patients O 
with O 
schizophrenia O 
and O 
whether O 
these O 
are O 
consistently O 
effective O 
throughout O 
the O 
literature O 
. O 
We O 
also O 
performed O 
a O 
systematic O 
review O 
on O 
the O 
effects O 
of O 
modafinil B-TRIVIAL 
on O 
neurotransmitter O 
signalling O 
in O 
different O 
areas O 
of O 
the O 
brain O 
in O 
order O 
to O 
better O 
understand O 
the O 
neuromechanisms O 
of O 
its O 
cognitive O 
and O 
emotional O 
enhancing O 
properties O 
. O 
A O 
review O 
of O 
its O 
effects O 
in O 
schizophrenia O 
suggests O 
that O 
modafinil B-TRIVIAL 
facilitates O 
cognitive O 
functions O 
, O 
with O 
pro O 
- O 
mnemonic O 
effects O 
and O 
problem O 
solving O 
improvements O 
. O 
Emotional O 
processing O 
also O 
appears O 
to O 
be O 
enhanced O 
by O 
the O 
drug O 
, O 
although O 
to O 
date O 
there O 
are O 
only O 
a O 
limited O 
number O 
of O 
studies O 
. O 
The O 
systematic O 
review O 
on O 
the O 
neurochemical O 
modulation O 
of O 
the O 
modafinil B-TRIVIAL 
suggests O 
that O 
its O 
mnemonic O 
enhancing O 
properties O 
might O 
be O 
the O 
result O 
of O 
glutamatergic O 
and O 
dopaminergic O 
increased O 
neuronal O 
activation O 
in O 
the O 
hippocampus O 
and O 
in O 
the O 
prefrontal O 
cortex O 
respectively O 
. O 
Other O 
neurotransmitters O 
were O 
also O 
activated O 
by O 
modafinil B-TRIVIAL 
in O 
various O 
limbic O 
brain O 
areas O 
, O 
suggesting O 
that O 
the O 
drug O 
acts O 
on O 
these O 
brain O 
regions O 
to O 
influence O 
emotional O 
responses O 
. O 
These O 
reviews O 
seek O 
to O 
delineate O 
the O 
neuronal O 
mechanisms O 
by O 
which O 
modafinil B-TRIVIAL 
affects O 
cognitive O 
and O 
emotional O 
function O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

for O 
metal O 
- O 
surface O 
interactions O 
and O 
their O 
role O 
in O 
stabilizing O 
well O 
- O 
defined O 
immobilized O 
Ru-NHC B-FAMILY 
alkene I-FAMILY 
metathesis O 
catalysts O 
. O 

interactions O 
are O 
demonstrated O 
to O 
direct O 
the O 
stability O 
of O 
well O 
- O 
defined O 
Ru-NHC B-FORMULA 
-based O 
heterogeneous O 
alkene B-FAMILY 
metathesis O 
catalysts O 
. O 
By O 
providing O 
key O 
stabilization O 
of O 
the O 
active O 
sites O 
, O 
higher O 
catalytic O 
performance O 
is O 
achieved O 
. O 
Specifically O 
, O 
they O 
can O 
be O 
described O 
as O 
interactions O 
between O 
the O 
metal O 
center O 
( O 
active O 
site O 
) O 
and O 
the O 
surface O 
functionality O 
of O 
the O 
support O 
, O 
and O 
they O 
have O 
been O 
detected O 
by O 
surface O 
- O 
enhanced O 
(1)H B-FORMULA 
- O 
(29)Si B-FORMULA 
NMR O 
spectroscopy O 
of O 
the O 
ligand O 
and O 
(31)P B-FORMULA 
solid O 
- O 
state O 
NMR O 
of O 
the O 
catalyst O 
precursor O 
. O 
They O 
are O 
present O 
only O 
when O 
the O 
metal O 
center O 
is O 
attached O 
to O 
the O 
surface O 
via O 
a O 
flexible O 
linker O 
( O 
a O 
propyl B-SYSTEMATIC 
group O 
) O 
, O 
which O 
allows O 
the O 
active O 
site O 
to O 
either O 
react O 
with O 
the O 
substrate O 
or O 
relax O 
, O 
reversibly O 
, O 
to O 
the O 
surface O 
, O 
thus O 
providing O 
stability O 
. O 
In O 
contrast O 
, O 
the O 
use O 
of O 
a O 
rigid O 
linker O 
( O 
here O 
mesitylphenyl B-SYSTEMATIC 
) O 
leads O 
to O 
a O 
well O 
- O 
defined O 
active O 
site O 
far O 
away O 
from O 
the O 
surface O 
, O 
stabilized O 
only O 
by O 
a O 
phosphine B-SYSTEMATIC 
ligand O 
which O 
under O 
reaction O 
conditions O 
leaves O 
probably O 
irreversibly O 
, O 
leading O 
to O 
faster O 
decomposition O 
and O 
deactivation O 
of O 
the O 
catalysts O 
. O 

of O 
reabsorptive O 
barriers O 
require O 
both O 
a O 
means O 
to O 
provide O 
realistic O 
physiologic O 
cues O 
to O 
and O 
quantify O 
transport O 
across O 
a O 
layer O 
of O 
cells O 
forming O 
the O 
barrier O 
. O 
Here O 
we O 
have O 
topographically O 
- O 
patterned O 
porous O 
membranes O 
with O 
several O 
user O 
- O 
defined O 
pattern O 
types O 
. O 
To O 
demonstrate O 
the O 
utility O 
of O 
the O 
patterned O 
membranes O 
, O 
we O 
selected O 
one O 
type O 
of O 
pattern O 
and O 
applied O 
it O 
to O 
a O 
membrane O 
to O 
serve O 
as O 
a O 
cell O 
culture O 
support O 
in O 
a O 
microfluidic O 
model O 
of O 
a O 
renal O 
reabsorptive O 
barrier O 
. O 
The O 
topographic O 
cues O 
in O 
the O 
model O 
resemble O 
physiological O 
cues O 
found O 
in O 
vivo O 
while O 
the O 
porous O 
structure O 
allows O 
quantification O 
of O 
transport O 
across O 
the O 
cell O 
layer O 
. O 
Sub O 
- O 
micron O 
surface O 
topography O 
generated O 
via O 
hot O 
- O 
embossing O 
onto O 
a O 
track O 
- O 
etched O 
polycarbonate B-FAMILY 
membrane O 
, O 
fully O 
replicated O 
topographical O 
features O 
and O 
preserved O 
porous O 
architecture O 
. O 
Pore O 
size O 
and O 
shape O 
were O 
analyzed O 
with O 
SEM O 
and O 
image O 
analysis O 
to O 
determine O 
the O 
effect O 
of O 
hot O 
embossing O 
on O 
pore O 
morphology O 
. O 
The O 
membrane O 
was O 
assembled O 
into O 
a O 
bilayer O 
microfluidic O 
device O 
and O 
a O 
human O 
kidney O 
proximal O 
tubule O 
epithelial O 
cell O 
line O 
( O 
HK-2 O 
) O 
and O 
primary O 
renal O 
proximal O 
tubule O 
epithelial O 
cells O 
( O 
RPTEC O 
) O 
were O 
cultured O 
to O 
confluency O 
on O 
the O 
membrane O 
. O 
Immunofluorescent O 
staining O 
of O 
both O 
cell O 
types O 
revealed O 
protein O 
expression O 
indicative O 
of O 
the O 
formation O 
of O 
a O 
reabsorptive O 
barrier O 
responsive O 
to O 
mechanical O 
stimulation O 
: O 
ZO-1 O 
( O 
tight O 
junction O 
) O 
, O 
paxillin O 
( O 
focal O 
adhesions O 
) O 
and O 
acetylated O 
α-tubulin O 
( O 
primary O 
cilia O 
) O 
. O 
HK-2 O 
and O 
RPTEC O 
aligned O 
in O 
the O 
direction O 
of O 
ridge O 
/ O 
groove O 
topography O 
of O 
the O 
membrane O 
in O 
the O 
device O 
, O 
evidence O 
that O 
the O 
device O 
has O 
mechanical O 
control O 
over O 
cell O 
response O 
. O 
This O 
topographically O 
- O 
patterned O 
porous O 
membrane O 
provides O 
an O 
in O 
vitro O 
platform O 
on O 
which O 
to O 
model O 
reabsorptive O 
barriers O 
with O 
meaningful O 
applications O 
for O 
understanding O 
biological O 
transport O 
phenomenon O 
, O 
underlying O 
disease O 
mechanisms O 
, O 
and O 
drug O 
toxicity O 
. O 

nucleoside I-FAMILY 
phosphonates I-FAMILY 
containing O 
a O 
second O 
phosphonate B-SYSTEMATIC 
group O 
are O 
potent O 
inhibitors O 
of O 
6-oxopurine B-SYSTEMATIC 
phosphoribosyltransferases O 
and O 
have O 
antimalarial O 
activity O 
. O 

nucleoside I-FAMILY 
phosphonates I-FAMILY 
( O 
ANPs B-FAMILY 
) O 
that O 
contain O 
a O 
6-oxopurine B-SYSTEMATIC 
base O 
are O 
good O 
inhibitors O 
of O 
the O 
Plasmodium O 
falciparum O 
( O 
Pf O 
) O 
and O 
Plasmodium O 
vivax O 
( O 
Pv O 
) O 
6-oxopurine B-SYSTEMATIC 
phosphoribosyltransferases O 
( O 
PRTs O 
) O 
. O 
Chemical O 
modifications O 
based O 
on O 
the O 
crystal O 
structure O 
of O 
2-(phosphonoethoxy)ethylguanine B-SYSTEMATIC 
( O 
PEEG B-ABBREVIATION 
) O 
in O 
complex O 
with O 
human O 
HGPRT O 
have O 
led O 
to O 
the O 
design O 
of O 
new O 
ANPs B-FAMILY 
. O 
These O 
novel O 
compounds O 
contain O 
a O 
second O 
phosphonate B-SYSTEMATIC 
group O 
attached O 
to O 
the O 
ANP B-ABBREVIATION 
scaffold O 
. O 
{[(2-[(Guanine-9H-yl)methyl]propane-1,3-diyl)bis(oxy)]bis(methylene)}diphosphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
compound O 
17 O 
) O 
exhibited O 
a O 
Ki O 
value O 
of O 
30 O 
nM O 
for O 
human O 
HGPRT O 
and O 
70 O 
nM O 
for O 
Pf O 
HGXPRT O 
. O 
The O 
crystal O 
structure O 
of O 
this O 
compound O 
in O 
complex O 
with O 
human O 
HGPRT O 
shows O 
that O 
it O 
fills O 
or O 
partially O 
fills O 
three O 
critical O 
locations O 
in O 
the O 
active O 
site O 
: O 
the O 
binding O 
sites O 
of O 
the O 
purine B-TRIVIAL 
base O 
, O 
the O 
5'-phosphate B-SYSTEMATIC 
group O 
, O 
and O 
pyrophosphate B-SYSTEMATIC 
. O 
This O 
is O 
the O 
first O 
HG(X)PRT O 
inhibitor O 
that O 
has O 
been O 
able O 
to O 
achieve O 
this O 
result O 
. O 
Prodrugs O 
have O 
been O 
synthesized O 
resulting O 
in O 
IC50 O 
values O 
as O 
low O 
as O 
3.8 O 
μM O 
for O 
Pf O 
grown O 
in O 
cell O 
culture O 
, O 
up O 
to O 
25-fold O 
lower O 
compared O 
to O 
the O 
parent O 
compounds O 
. O 

of O 
3,4-DHPEA-EDA B-SYSTEMATIC 
oxidation O 
products O 
in O 
virgin O 
olive O 
oil O 
by O 
high O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
mass O 
spectrometry O 
. O 

derivatives O 
are O 
the O 
most O 
important O 
antioxidants O 
of O 
virgin O 
olive O 
oil O 
( O 
VOO O 
) O 
, O 
and O 
their O 
oxidation O 
products O 
could O 
be O 
used O 
as O 
molecular O 
markers O 
of O 
VOO O 
freshness O 
to O 
define O 
the O 
VOO O 
autoxidation O 
state O 
. O 
The O 
aim O 
of O 
this O 
research O 
was O 
to O 
characterise O 
the O 
dialdehydic B-SYSTEMATIC 
form O 
of O 
decarboxymethyl B-SYSTEMATIC 
elenolic I-SYSTEMATIC 
acid I-SYSTEMATIC 
linked O 
to O 
hydroxytyrosol B-SYSTEMATIC 
( O 
3,4-DHPEA-EDA B-SYSTEMATIC 
) O 
oxidation O 
products O 
to O 
find O 
analytical O 
indicators O 
that O 
could O 
be O 
used O 
as O 
early O 
evaluation O 
index O 
of O 
the O 
VOO O 
autoxidation O 
state O 
. O 
3,4-DHPEA-EDA B-SYSTEMATIC 
was O 
oxidised O 
by O 
enzymatic O 
and O 
Fenton O 
reactions O 
. O 
Terpenic O 
structure O 
oxidation O 
products O 
accumulated O 
in O 
VOO O 
during O 
the O 
autoxidation O 
process O 
, O 
thus O 
they O 
may O 
be O 
used O 
as O 
early O 
evaluation O 
index O 
of O 
the O 
VOO O 
autoxidation O 
state O 
before O 
fatty B-FAMILY 
acids I-FAMILY 
oxidation O 
. O 

- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
is O 
an O 
important O 
regulator O 
of O 
synaptic O 
transmission O 
and O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
in O 
the O 
hippocampus O 
and O 
in O 
other O 
brain O 
regions O 
, O 
playing O 
a O 
role O 
in O 
the O 
formation O 
of O 
certain O 
forms O 
of O 
memory O 
. O 
The O 
effects O 
of O 
BDNF O 
in O 
LTP O 
are O 
mediated O 
by O 
TrkB O 
( O 
tropomyosin O 
- O 
related O 
kinase O 
B O 
) O 
receptors O 
, O 
which O 
are O 
known O 
to O 
be O 
coupled O 
to O 
the O 
activation O 
of O 
the O 
Ras O 
/ O 
ERK O 
, O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
/ O 
Akt O 
and O 
phospholipase O 
C-γ O 
( O 
PLC-γ O 
) O 
pathways O 
. O 
The O 
role O 
of O 
BDNF O 
in O 
LTP O 
is O 
best O 
studied O 
in O 
the O 
hippocampus O 
, O 
where O 
the O 
neurotrophin O 
is O 
thought O 
to O 
act O 
at O 
pre- O 
and O 
post O 
- O 
synaptic O 
levels O 
. O 
Recent O 
studies O 
have O 
shown O 
that O 
BDNF O 
regulates O 
the O 
transport O 
of O 
mRNAs O 
along O 
dendrites O 
and O 
their O 
translation O 
at O 
the O 
synapse O 
, O 
by O 
modulating O 
the O 
initiation O 
and O 
elongation O 
phases O 
of O 
protein O 
synthesis O 
, O 
and O 
by O 
acting O 
on O 
specific O 
miRNAs O 
. O 
Furthermore O 
, O 
the O 
effect O 
of O 
BDNF O 
on O 
transcription O 
regulation O 
may O 
further O 
contribute O 
to O 
long O 
- O 
term O 
changes O 
in O 
the O 
synaptic O 
proteome O 
. O 
In O 
this O 
review O 
we O 
discuss O 
the O 
recent O 
progress O 
in O 
understanding O 
the O 
mechanisms O 
contributing O 
to O 
the O 
short- O 
and O 
long O 
- O 
term O 
regulation O 
of O 
the O 
synaptic O 
proteome O 
by O 
BDNF O 
, O 
and O 
the O 
role O 
in O 
synaptic O 
plasticity O 
, O 
which O 
is O 
likely O 
to O 
influence O 
learning O 
and O 
memory O 
formation O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
BDNF O 
' O 
. O 

and O 
spermatogenic O 
activity O 
of O 
alkylamide B-FAMILY 
-rich O 
ethanol B-SYSTEMATIC 
solution O 
extract O 
of O 
Anacyclus O 
pyrethrum O 
DC O 
. O 

pyrethrum O 
( O 
A O 
. O 
pyrethrum O 
) O 
has O 
been O 
used O 
as O 
Vajikaran O 
Rasayana O 
( O 
aphrodisiac O 
) O 
in O 
traditional O 
Indian O 
ayurvedic O 
medicine O 
to O 
treat O 
male O 
sexual O 
dysfunction O 
, O 
including O 
infertility O 
. O 
Aphrodisiac O 
activity O 
may O 
be O 
due O 
to O 
an O 
increase O 
in O 
the O 
production O 
or O 
effect O 
of O 
androgens B-FAMILY 
, O 
so O 
this O 
study O 
sought O 
to O 
evaluate O 
the O 
androgenic O 
and O 
spermatogenic O 
potential O 
of O 
the O 
alkylamide B-FAMILY 
-rich O 
ethanol B-SYSTEMATIC 
solution O 
extract O 
. O 
Male O 
Wistar O 
strain O 
rats O 
weighing O 
between O 
150 O 
and O 
180 O 
g O 
were O 
completely O 
randomized O 
divided O 
into O 
five O 
groups O 
. O 
The O 
ethanol B-SYSTEMATIC 
solution O 
extract O 
of O 
A O 
. O 
pyrethrum O 
was O 
administered O 
to O 
groups O 
of O 
rats O 
in O 
50 O 
, O 
100 O 
, O 
and O 
150 O 
mg O 
/ O 
kg O 
doses O 
for O 
a O 
period O 
of O 
28 O 
days O 
, O 
and O 
the O 
action O 
was O 
compared O 
with O 
control O 
and O 
testosterone B-TRIVIAL 
-treated O 
rats O 
. O 
Thirteen O 
N-alkylamides B-FAMILY 
were O 
detected O 
in O 
the O 
extract O 
by O 
using O 
HPLC O 
/ O 
UV O 
/ O 
electrospray O 
ionization O 
mass O 
spectrometry O 
method O 
. O 
Extract O 
administration O 
at O 
all O 
the O 
doses O 
produced O 
significant O 
increase O 
in O 
body O 
weight O 
, O 
sperm O 
count O 
, O 
motility O 
, O 
and O 
viability O 
along O 
with O 
serum O 
testosterone B-TRIVIAL 
, O 
luteinizing O 
hormone O 
, O 
and O 
follicle O 
- O 
stimulating O 
hormone O 
concentrations O 
. O 
Histoarchitecture O 
of O 
testis O 
revealed O 
increased O 
spermatogenic O 
activities O 
. O 
Seminal O 
fructose B-TRIVIAL 
content O 
was O 
also O 
significantly O 
increased O 
after O 
28 O 
days O 
of O 
treatment O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
ethanol B-SYSTEMATIC 
solution O 
extract O 
of O 
the O 
roots O 
of O 
A O 
. O 
pyrethrum O 
has O 
androgenic O 
potential O 
and O 
may O 
improve O 
male O 
fertility O 
by O 
enhancing O 
spermatogenesis O 
. O 

twigs O 
of O 
Cudrania O 
tricuspidata O 
were O 
found O 
to O 
show O 
strong O 
tyrosinase O 
inhibitory O 
activity O 
, O 
and O 
further O 
detailed O 
component O 
analysis O 
resulted O 
in O 
the O 
isolation O 
of O 
a O 
new O 
flavanol B-FAMILY 
glucoside I-FAMILY 
, O 
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside B-FAMILY 
( O 
1 O 
) O 
, O 
plus O 
twenty O 
- O 
seven O 
known O 
compounds O 
( O 
2-28 O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
ESI-MS O 
and O 
NMR O 
spectral O 
data O 
. O 
Among O 
the O 
isolated O 
compounds O 
, O 
trans-dihydromorin B-TRIVIAL 
( O 
8 O 
) O 
, O 
oxyresveratrol B-TRIVIAL 
( O 
9 O 
) O 
, O 
and O 
steppogenin B-TRIVIAL 
( O 
12 O 
) O 
were O 
found O 
to O 
exhibit O 
significant O 
tyrosinase O 
inhibition O 
activities O 
. O 
Moreover O 
, O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
these O 
isolated O 
compounds O 
was O 
also O 
discussed O 
. O 

of O 
aqueous O 
doash O 
extract O 
on O 
urinary O 
mutagenicity O 
in O 
rats O 
exposed O 
to O 
heterocyclic B-FAMILY 
amines I-FAMILY 
. O 

( O 
Origanum O 
majorana O 
) O 
is O 
an O 
herbaceous O 
plant O 
found O 
commonly O 
in O 
Saudi O 
Arabia O 
. O 
It O 
is O 
used O 
as O 
a O 
food O 
flavor O 
and O 
a O 
folk O 
remedy O 
to O 
treat O 
a O 
number O 
of O 
diseases O 
. O 
The O 
2-amino-3-methylimidazo[4,5-f] B-SYSTEMATIC 
quinoline I-SYSTEMATIC 
( O 
IQ O 
) O 
and O 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
are O 
the O 
most O 
abundant O 
of O 
the O 
heterocyclic B-FAMILY 
amine I-FAMILY 
carcinogens O 
present O 
in O 
cooked O 
food O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
potential O 
of O 
doash O 
tea O 
to O 
influence O 
carcinogen O 
metabolism O 
was O 
investigated O 
indirectly O 
using O 
heterocyclic B-FAMILY 
amines I-FAMILY 
as O 
model O 
mutagens O 
, O 
IQ O 
and O 
PhIP B-ABBREVIATION 
. O 
Results O 
obtained O 
showed O 
that O 
doash O 
tea O 
had O 
no O 
influence O 
on O 
body O 
weight O 
in O 
both O 
the O 
studies O 
. O 
Rats O 
were O 
treated O 
with O 
different O 
doses O 
of O 
IQ O 
( O 
1 O 
, O 
3 O 
, O 
5 O 
and O 
10 O 
mg O 
/ O 
kg O 
) O 
or O 
PhIP B-ABBREVIATION 
( O 
1 O 
, O 
5 O 
, O 
10 O 
and O 
20 O 
mg O 
/ O 
kg O 
) O 
. O 
The O 
selected O 
dosage O 
was O 
5 O 
mg O 
/ O 
kg O 
for O 
both O 
heterocyclic B-FAMILY 
amines I-FAMILY 
. O 
Results O 
obtained O 
revealed O 
that O 
rats O 
treated O 
with O 
doash O 
tea O 
and O 
given O 
a O 
single O 
dose O 
of O 
the O 
heterocyclic B-FAMILY 
amines I-FAMILY 
, O 
whether O 
for O 
1 O 
day O 
( O 
short O 
- O 
term O 
) O 
or O 
for O 
1 O 
month O 
( O 
long O 
term O 
) O 
, O 
showed O 
a O 
statistically O 
significant O 
decrease O 
in O 
their O 
excretion O 
of O 
indirect O 
mutagens O 
( O 
IQ O 
or O 
PhIP B-ABBREVIATION 
) O 
. O 
Following O 
treatment O 
of O 
the O 
rats O 
with O 
a O 
single O 
oral O 
dose O 
of O 
IQ O 
or O 
PhIP B-ABBREVIATION 
, O 
the O 
highest O 
mutagenic O 
activity O 
determined O 
in O 
the O 
presence O 
of O 
an O 
activation O 
system O 
was O 
excreted O 
in O 
the O 
urine O 
after O 
24 O 
h O 
, O 
with O 
much O 
lower O 
levels O 
of O 
mutagencity O 
being O 
excreted O 
during O 
subsequent O 
elimination O 
from O 
the O 
body O 
. O 
No O 
mutagenicity O 
was O 
observed O 
in O 
the O 
absence O 
of O 
an O 
activation O 
system O 
that O 
is O 
direct O 
- O 
acting O 
mutagenicity O 
using O 
( O 
IQ O 
and O 
PhIP B-ABBREVIATION 
) O 
. O 
Statistical O 
analysis O 
revealed O 
that O 
, O 
in O 
comparison O 
with O 
the O 
control O 
group O 
, O 
the O 
aqueous O 
doash O 
extract O 
significantly O 
reduced O 
the O 
mutagenic O 
response O 
after O 
24 O 
h O 
. O 
It O 
was O 
concluded O 
that O 
doash O 
extract O 
significantly O 
decreased O 
the O 
excretion O 
of O 
mutagens O 
in O 
comparison O 
with O 
the O 
control O 
group O 
( O 
water O 
only O 
) O 
. O 

X O 
Receptors O 
and O 
female O 
reproduction O 
: O 
when O 
cholesterol B-TRIVIAL 
meets O 
fertility O 
! O 

role O 
of O 
cholesterol B-TRIVIAL 
in O 
female O 
reproductive O 
physiology O 
has O 
been O 
suspected O 
for O 
a O 
long O 
time O 
, O 
while O 
the O 
molecular O 
bases O 
were O 
unknown O 
. O 
Cholesterol B-TRIVIAL 
is O 
the O 
precursor O 
of O 
ovarian O 
steroid B-FAMILY 
biosynthesis O 
and O 
is O 
also O 
essential O 
for O 
fertility O 
. O 
In O 
the O 
uterus O 
, O 
cholesterol B-TRIVIAL 
is O 
essential O 
to O 
achieve O 
correct O 
contractions O 
at O 
term O 
, O 
but O 
an O 
excessive O 
uterine O 
cholesterol B-TRIVIAL 
concentration O 
has O 
been O 
associated O 
with O 
contractility O 
defects O 
. O 
Liver O 
X O 
Receptor O 
( O 
LXR O 
) O 
α O 
and O 
LXR O 
β O 
are O 
nuclear O 
receptors O 
activated O 
by O 
oxysterols B-FAMILY 
, O 
oxidized O 
derivatives O 
of O 
cholesterol B-TRIVIAL 
. O 
Since O 
their O 
discovery O 
, O 
the O 
role O 
of O 
LXR O 
in O 
the O 
control O 
of O 
cholesterol B-TRIVIAL 
homeostasis O 
has O 
been O 
widely O 
described O 
. O 
Beyond O 
their O 
cholesterol B-TRIVIAL 
-lowering O 
role O 
, O 
more O 
recent O 
data O 
have O 
linked O 
these O 
nuclear O 
receptors O 
to O 
various O 
physiological O 
processes O 
. O 
In O 
particular O 
, O 
they O 
control O 
ovarian O 
endocrine O 
and O 
exocrine O 
functions O 
, O 
as O 
well O 
as O 
uterine O 
contractility O 
. O 
Their O 
contribution O 
to O 
female O 
reproductive O 
cancers O 
will O 
also O 
be O 
discussed O 
. O 
This O 
review O 
will O 
try O 
to O 
enlighten O 
on O 
the O 
LXR O 
as O 
a O 
molecular O 
link O 
between O 
dietary O 
cholesterol B-TRIVIAL 
and O 
reproductive O 
diseases O 
in O 
women O 
. O 
In O 
the O 
future O 
, O 
a O 
better O 
comprehension O 
of O 
the O 
various O 
physiological O 
processes O 
regulated O 
by O 
the O 
LXR O 
will O 
help O 
to O 
develop O 
new O 
ligands O 
to O 
prevent O 
or O 
to O 
cure O 
these O 
pathologies O 
in O 
women O 
. O 

intensity O 
ultrasonic O 
( O 
HUS O 
, O 
20 O 
kHz O 
, O 
400 O 
W O 
) O 
pre O 
- O 
treatments O 
of O 
soybean O 
protein O 
isolate O 
( O 
SPI O 
) O 
improved O 
the O 
water O 
holding O 
capacity O 
( O 
WHC O 
) O 
, O 
gel O 
strength O 
and O 
gel O 
firmness O 
( O 
final O 
elastic O 
moduli O 
) O 
of O 
glucono-δ-lactone B-TRIVIAL 
induced O 
SPI O 
gels O 
( O 
GISG O 
) O 
. O 
Sonication O 
time O 
( O 
0 O 
, O 
5 O 
, O 
20 O 
, O 
and O 
40 O 
min O 
) O 
had O 
a O 
significant O 
effect O 
on O 
the O 
above O 
three O 
properties O 
. O 
20 O 
min O 
HUS-GISG O 
had O 
the O 
highest O 
WHC O 
( O 
95.53 O 
± O 
0.25% O 
) O 
, O 
gel O 
strength O 
( O 
60.9 O 
± O 
2.87 O 
g O 
) O 
and O 
gel O 
firmness O 
( O 
96340Pa O 
) O 
, O 
compared O 
with O 
other O 
samples O 
. O 
Moreover O 
, O 
SH B-FORMULA 
groups O 
and O 
non-covalent O 
interactions O 
of O 
GISG O 
also O 
changed O 
after O 
HUS O 
pre O 
- O 
treatments O 
. O 
The O 
HUS O 
GISG O 
had O 
denser O 
and O 
more O 
uniform O 
microstructures O 
than O 
the O 
untreated O 
GISG O 
. O 
Rheological O 
investments O 
showed O 
that O 
the O 
cooling O 
step O 
( O 
reduce O 
the O 
temperature O 
from O 
95 O 
to O 
25 O 
°C O 
at O 
a O 
speed O 
of O 
2 O 
°C O 
/ O 
min O 
) O 
was O 
more O 
important O 
for O 
the O 
HUS O 
GISG O 
network O 
formation O 
while O 
the O 
heat O 
preservation O 
step O 
( O 
keep O 
temperature O 
at O 
95 O 
for O 
20 O 
min O 
) O 
was O 
more O 
important O 
for O 
the O 
untreated O 
GISG O 
. O 
HUS O 
reduced O 
the O 
particle O 
size O 
of O 
SPI O 
and O 
Pearson O 
correlation O 
test O 
showed O 
that O 
the O 
particle O 
size O 
of O 
SPI O 
dispersions O 
was O 
negatively O 
correlated O 
with O 
WHC O 
, O 
gel O 
strength O 
and O 
gel O 
firmness O 
. O 

naturel O 
! O 
(+)-Usnic B-TRIVIAL 
acid I-TRIVIAL 
( O 
green O 
) O 
is O 
a O 
weak O 
antimalarial O 
agent O 
, O 
however O 
, O 
in O 
conjugation O 
with O 
known O 
antimalarial O 
scaffolds O 
and O 
drugs O 
, O 
such O 
as O 
dihydroartemisinin B-SYSTEMATIC 
( O 
blue O 
) O 
, O 
potent O 
activity O 
against O 
the O 
blood O 
- O 
stage O 
parasite O 
can O 
be O 
seen O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
compound O 
shown O 
exhibits O 
an O 
IC(50) O 
value O 
of O 
1.4 O 
nM O 
against O 
Plasmodium O 
falciparum O 
in O 
vitro O 
and O 
proved O 
nearly O 
as O 
efficacious O 
as O 
artesunate B-TRIVIAL 
in O 
a O 
mouse O 
model O 
of O 
infection O 
. O 

- O 
gel O 
nanoglues O 
for O 
an O 
organic O 
binder O 
- O 
free O 
TiO2 B-FORMULA 
nanofiber O 
anode O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 

TiO2 B-FORMULA 
nanofiber O 
anode O 
is O 
glued O 
using O 
a O 
sol O 
- O 
gel O 
reaction O 
to O 
improve O 
cycle O 
performance O 
and O 
Coulombic O 
efficiencies O 
. O 
The O 
hydrolysis O 
- O 
condensation O 
process O 
produces O 
TiO2 B-FORMULA 
nanoglues O 
consisting O 
of O 
TiO2 B-FORMULA 
nanoparticles O 
, O 
providing O 
strong O 
adhesion O 
between O 
nanofibers O 
and O 
the O 
current O 
collector O 
as O 
well O 
as O 
between O 
nanofibers O 
, O 
rendering O 
favourable O 
transporting O 
properties O 
of O 
electrons O 
and O 
Li B-FORMULA 
ions O 
in O 
the O 
TiO2 B-FORMULA 
nanofiber O 
electrode O 
, O 
and O 
eventually O 
leading O 
to O 
the O 
excellent O 
performance O 
of O 
Li B-FORMULA 
ion O 
batteries O 
exhibiting O 
an O 
excellent O 
initial O 
Coulombic O 
efficiency O 
( O 
~85% O 
) O 
, O 
cycle O 
performance O 
up O 
to O 
100 O 
cycles O 
, O 
and O 
high O 
rate O 
capability O 
( O 
60% O 
at O 
5 O 
C O 
) O 
. O 

composite O 
microspheres O 
based O 
on O 
magnetic O 
mesoporous O 
silica B-TRIVIAL 
nanoparticle O 
for O 
drug O 
delivery O 
. O 

composite O 
microspheres O 
, O 
consisting O 
of O 
a O 
core O 
of O 
Fe3O4 B-FORMULA 
nanoparticle O 
, O 
a O 
sandwiched O 
layer O 
of O 
mesoporous O 
silica B-TRIVIAL 
and O 
a O 
shell O 
of O 
crosslinked O 
poly B-FAMILY 
( I-FAMILY 
methacrylic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PMAA B-ABBREVIATION 
) O 
, O 
were O 
successfully O 
synthesized O 
via O 
distillation O 
precipitation O 
polymerization O 
. O 
The O 
pKa O 
of O 
the O 
composite O 
microsphere O 
increased O 
with O 
the O 
increase O 
in O 
the O 
crosslinking O 
density O 
. O 
Doxorubicin B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
DOX B-ABBREVIATION 
) O 
was O 
applied O 
as O 
a O 
model O 
drug O 
, O 
and O 
the O 
behavior O 
of O 
drug O 
storage O 
/ O 
release O 
was O 
investigated O 
. O 
The O 
cumulative O 
release O 
of O 
DOX B-ABBREVIATION 
-loaded O 
composite O 
microsphere O 
in O 
vitro O 
showed O 
that O 
the O 
drug O 
release O 
rate O 
was O 
much O 
faster O 
below O 
its O 
pKa O 
than O 
that O 
of O 
above O 
its O 
pKa O 
. O 
Because O 
pH O 
of O 
most O 
tumor O 
tissues O 
was O 
lower O 
than O 
that O 
of O 
normal O 
tissues O 
, O 
the O 
pH-responsive O 
composite O 
microspheres O 
are O 
promising O 
drug O 
delivery O 
system O 
especially O 
for O 
cancer O 
therapy O 
. O 

is O 
a O 
bimodal O 
modulator O 
of O 
TRPA1 O 
channels O 
. O 

is O 
a O 
non-narcotic O 
derivative O 
of O 
morphine B-TRIVIAL 
, O 
which O 
acts O 
as O 
a O 
dopamine B-TRIVIAL 
agonist O 
and O 
is O 
clinically O 
used O 
to O 
treat O 
" O 
off O 
- O 
states O 
" O 
in O 
patients O 
suffering O 
from O 
Parkinson's O 
disease O 
. O 
Adverse O 
effects O 
of O 
apomorphine B-TRIVIAL 
treatment O 
include O 
severe O 
emesis O 
and O 
nausea O 
, O 
and O 
ulceration O 
and O 
pain O 
at O 
the O 
injection O 
site O 
. O 
We O 
wanted O 
to O 
test O 
whether O 
sensory O 
transient O 
receptor O 
potential O 
( O 
TRP O 
) O 
channels O 
are O 
a O 
molecular O 
target O 
for O 
apomorphine B-TRIVIAL 
. O 
Here O 
, O 
we O 
show O 
that O 
rTRPV1 O 
, O 
rTRPV2 O 
, O 
rTRPV3 O 
, O 
and O 
mTRPV4 O 
, O 
as O 
well O 
as O 
hTRPM8 O 
, O 
and O 
rTRPM3 O 
, O 
which O 
are O 
expressed O 
in O 
dorsal O 
root O 
ganglion O 
neurons O 
, O 
are O 
insensitive O 
toward O 
apomorphine B-TRIVIAL 
treatment O 
. O 
This O 
also O 
applied O 
to O 
the O 
cellular O 
redox O 
sensor O 
hTRPM2 O 
. O 
On O 
the O 
contrary O 
, O 
human O 
TRPA1 O 
could O 
be O 
concentration O 
- O 
dependently O 
modulated O 
by O 
apomorphine B-TRIVIAL 
. O 
Whereas O 
the O 
addition O 
of O 
apomorphine B-TRIVIAL 
in O 
the O 
low O 
micromolar O 
range O 
produced O 
an O 
irreversible O 
activation O 
of O 
the O 
channel O 
, O 
application O 
of O 
higher O 
concentrations O 
caused O 
a O 
reversible O 
voltage O 
- O 
dependent O 
inhibition O 
of O 
heterologously O 
expressed O 
TRPA1 O 
channels O 
, O 
resulting O 
from O 
a O 
reduction O 
of O 
single O 
- O 
channel O 
open O 
times O 
. O 
In O 
addition O 
, O 
we O 
provide O 
evidence O 
that O 
apomorphine B-TRIVIAL 
also O 
acts O 
on O 
endogenous O 
TRPA1 O 
in O 
cultured O 
dorsal O 
root O 
ganglion O 
neurons O 
from O 
rats O 
and O 
in O 
the O 
enterochromaffin O 
model O 
cell O 
line O 
QGP-1 O 
, O 
from O 
which O 
serotonin B-TRIVIAL 
is O 
released O 
upon O 
activation O 
of O 
TRPA1 O 
. O 
Our O 
study O 
shows O 
that O 
human O 
TRPA1 O 
is O 
a O 
target O 
for O 
apomorphine B-TRIVIAL 
, O 
suggesting O 
that O 
an O 
activation O 
of O 
TRPA1 O 
might O 
contribute O 
to O 
adverse O 
side O 
effects O 
such O 
as O 
nausea O 
and O 
painful O 
injections O 
, O 
which O 
can O 
occur O 
during O 
treatment O 
with O 
apomorphine B-TRIVIAL 
. O 

show O 
that O 
bismuth B-SYSTEMATIC 
nanostructures O 
form O 
three O 
- O 
dimensional O 
patterns O 
governed O 
by O 
two O 
- O 
dimensional O 
electronic O 
effects O 
. O 
Scanning O 
tunneling O 
microscopy O 
reveals O 
that O 
both O 
the O 
vertical O 
and O 
the O 
lateral O 
dimensions O 
of O 
the O 
structures O 
strongly O 
favor O 
certain O 
values O 
and O 
that O 
the O 
preferred O 
widths O 
are O 
substantially O 
different O 
for O 
each O 
preferred O 
height O 
. O 
First O 
- O 
principles O 
calculations O 
demonstrate O 
that O 
this O 
vertical O 
- O 
lateral O 
correlation O 
is O 
governed O 
by O 
the O 
Fermi O 
surface O 
topology O 
and O 
that O 
this O 
is O 
itself O 
sensitively O 
dependent O 
on O 
the O 
dimensions O 
of O 
the O 
structure O 
. O 

receptor O 
- O 
dependent O 
function O 
and O 
plasticity O 
in O 
inhibitory O 
circuits O 
. O 

receptors O 
have O 
been O 
known O 
to O 
play O 
a O 
central O 
role O 
in O 
long O 
- O 
term O 
potentiation O 
at O 
glutamatergic O 
synapses O 
in O 
principal O 
cells O 
for O 
thirty O 
years O 
. O 
In O 
contrast O 
, O 
their O 
roles O 
in O 
the O 
development O 
and O 
activity O 
- O 
dependent O 
plasticity O 
of O 
synapses O 
in O 
inhibitory O 
circuits O 
have O 
only O 
recently O 
begun O 
to O 
be O 
understood O 
. O 
Progress O 
has O 
, O 
to O 
a O 
great O 
extent O 
, O 
been O 
hampered O 
by O 
the O 
extensive O 
diversity O 
of O 
GABAergic O 
cell O 
types O 
in O 
the O 
CNS O 
. O 
However O 
, O 
anatomical O 
, O 
immunohistochemical O 
and O 
electrophysiological O 
methods O 
have O 
allowed O 
distinct O 
types O 
to O 
be O 
identified O 
, O 
with O 
the O 
result O 
that O 
consistent O 
patterns O 
of O 
synaptic O 
plasticity O 
have O 
begun O 
to O 
emerge O 
. O 
This O 
review O 
summarizes O 
recent O 
evidence O 
on O 
the O 
role O 
of O 
NMDA B-ABBREVIATION 
receptors O 
in O 
the O 
development O 
and O 
plasticity O 
of O 
GABAergic O 
synapses O 
on O 
principal O 
cells O 
and O 
of O 
glutamatergic O 
synapses O 
on O 
identified O 
interneurons O 
. O 
A O 
major O 
challenge O 
is O 
to O 
understand O 
how O 
NMDA B-ABBREVIATION 
receptors O 
affect O 
the O 
routing O 
of O 
information O 
in O 
healthy O 
inhibitory O 
circuits O 
, O 
and O 
how O 
changes O 
in O 
NMDA B-ABBREVIATION 
receptor O 
function O 
may O 
contribute O 
to O 
altered O 
circuit O 
function O 
in O 
disorders O 
such O 
as O 
schizophrenia O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
" O 
Glutamate B-TRIVIAL 
receptor O 
- O 
dependent O 
synaptic O 
plasticity O 
" O 
. O 

activity O 
of O 
viscera O 
extract O 
from O 
hybrid O 
catfish O 
( O 
Clarias O 
macrocephalus O 
× O 
Clarias O 
gariepinus O 
) O 
was O 
studied O 
. O 
The O 
optimal O 
pH O 
and O 
temperature O 
were O 
9 O 
and O 
50°C O 
, O 
respectively O 
, O 
when O 
toothed O 
ponyfish O 
( O 
Gazza O 
minuta O 
) O 
muscle O 
was O 
used O 
as O 
a O 
substrate O 
. O 
When O 
viscera O 
extract O 
from O 
hybrid O 
catfish O 
was O 
used O 
for O 
the O 
production O 
of O 
protein O 
hydrolysate O 
from O 
toothed O 
ponyfish O 
muscle O 
, O 
extract O 
concentration O 
, O 
reaction O 
time O 
, O 
and O 
fish O 
muscle O 
/ O 
buffer O 
ratio O 
affected O 
the O 
hydrolysis O 
and O 
nitrogen B-SYSTEMATIC 
recovery O 
( O 
NR O 
) O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Optimum O 
conditions O 
for O 
toothed O 
ponyfish O 
muscle O 
hydrolysis O 
were O 
3.5% O 
hybrid O 
catfish O 
viscera O 
extract O 
, O 
15 O 
min O 
reaction O 
time O 
and O 
fish O 
muscle O 
/ O 
buffer O 
ratio O 
of O 
1 O 
: O 
3 O 
( O 
w O 
/ O 
v O 
) O 
. O 
High O 
correlation O 
between O 
the O 
degree O 
of O 
hydrolysis O 
( O 
DH O 
) O 
and O 
NR O 
( O 
R(2)=0.974 O 
) O 
was O 
observed O 
. O 
Freeze O 
- O 
dried O 
hydrolysate O 
had O 
a O 
high O 
protein O 
content O 
( O 
89.02% O 
, O 
dry O 
weight O 
basis O 
) O 
and O 
it O 
was O 
brownish O 
yellow O 
in O 
colour O 
( O 
L(∗)=63.67 O 
, O 
a(∗)=6.33 O 
, O 
b(∗)=22.41 O 
) O 
. O 
The O 
protein O 
hydrolysate O 
contained O 
a O 
high O 
amount O 
of O 
essential O 
amino B-FAMILY 
acids I-FAMILY 
( O 
48.22% O 
) O 
and O 
had O 
arginine B-TRIVIAL 
and O 
lysine B-TRIVIAL 
as O 
the O 
dominant O 
amino B-FAMILY 
acids I-FAMILY 
. O 

based O 
clays O 
have O 
a O 
wide O 
range O 
of O 
applications O 
that O 
are O 
going O 
to O 
contribute O 
to O 
increase O 
human O 
exposure O 
to O 
these O 
materials O 
. O 
One O 
of O 
the O 
most O 
promising O 
uses O 
of O 
clays O 
is O 
the O 
development O 
of O 
reinforced O 
food O 
contact O 
materials O 
that O 
results O 
in O 
nanocomposites O 
with O 
improved O 
barrier O 
properties O 
. O 
Different O 
organoclays O 
have O 
been O 
developed O 
introducing O 
modifiers O 
in O 
the O 
natural O 
clay O 
which O 
is O 
commercially O 
available O 
. O 
However O 
, O 
the O 
toxicological O 
aspects O 
of O 
these O 
materials O 
have O 
been O 
scarcely O 
studied O 
so O 
far O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
cytotoxic O 
effects O 
of O 
a O 
non O 
- O 
modified O 
clay O 
( O 
Cloisite B-FAMILY 
® O 
Na+ B-FORMULA 
) O 
and O 
an O 
organoclay O 
( O 
Cloisite B-FAMILY 
® O 
30B O 
) O 
have O 
been O 
investigated O 
in O 
the O 
hepatic O 
cell O 
line O 
HepG2 O 
. O 
Only O 
Cloisite B-FAMILY 
® O 
30B O 
showed O 
cytotoxicity O 
. O 
In O 
order O 
to O 
elucidate O 
the O 
toxic O 
mechanisms O 
underlying O 
these O 
effects O 
, O 
apoptosis O 
, O 
inflammation O 
, O 
oxidative O 
stress O 
and O 
genotoxicity O 
biomarkers O 
were O 
assayed O 
. O 
Moreover O 
, O 
a O 
morphology O 
study O 
with O 
light O 
and O 
electron O 
microscopy O 
was O 
performed O 
. O 
Results O 
showed O 
genotoxic O 
effects O 
and O 
glutathione B-TRIVIAL 
decrease O 
. O 
The O 
most O 
relevant O 
ultraestructural O 
alterations O 
observed O 
were O 
mitochondrial O 
degeneration O 
, O 
dilated O 
endomembrane O 
systems O 
, O 
heterophagosomes O 
formation O 
, O 
fat O 
droplets O 
appearance O 
and O 
presence O 
of O 
nuclear O 
lipid O 
inclusions O 
. O 
Cloisite B-FAMILY 
® O 
30B O 
, O 
therefore O 
, O 
induces O 
toxic O 
effects O 
in O 
HepG2 O 
cells O 
. O 
Further O 
research O 
is O 
needed O 
to O 
assess O 
the O 
risk O 
of O 
this O 
clay O 
on O 
the O 
human O 
health O 
. O 

/ O 
Kdm2b O 
recruits O 
polycomb O 
repressive O 
complex O 
1 O 
to O 
CpG B-ABBREVIATION 
islands O 
and O 
regulates O 
H2A O 
ubiquitylation O 
. O 

repressive O 
complex O 
1 O 
( O 
PRC1 O 
) O 
catalyzes O 
lysine B-TRIVIAL 
119 O 
monoubiquitylation O 
on O 
H2A O 
( O 
H2AK119ub1 O 
) O 
and O 
regulates O 
pluripotency O 
in O 
embryonic O 
stem O 
cells O 
( O 
ESCs O 
) O 
. O 
However O 
, O 
the O 
mechanisms O 
controlling O 
the O 
binding O 
of O 
PRC1 O 
to O 
genomic O 
sites O 
and O 
its O 
catalytic O 
activity O 
are O 
poorly O 
understood O 
. O 
Here O 
, O 
we O 
show O 
that O 
Fbxl10 O 
interacts O 
with O 
Ring1B O 
and O 
Nspc1 O 
, O 
forming O 
a O 
noncanonical O 
PRC1 O 
that O 
is O 
required O 
for O 
H2AK119ub1 O 
in O 
mouse O 
ESCs O 
. O 
Genome O 
- O 
wide O 
analyses O 
reveal O 
that O 
Fbxl10 O 
preferentially O 
binds O 
to O 
CpG B-ABBREVIATION 
islands O 
and O 
colocalizes O 
with O 
Ring1B O 
on O 
Polycomb O 
target O 
genes O 
. O 
Notably O 
, O 
Fbxl10 O 
depletion O 
causes O 
a O 
decrease O 
in O 
Ring1B O 
binding O 
to O 
target O 
genes O 
and O 
a O 
major O 
loss O 
of O 
H2AK119ub1 O 
. O 
Furthermore O 
, O 
genetic O 
analyses O 
demonstrate O 
that O 
Fbxl10 O 
DNA O 
binding O 
capability O 
and O 
integration O 
into O 
PRC1 O 
are O 
required O 
for O 
H2AK119 O 
ubiquitylation O 
. O 
ESCs O 
lacking O 
Fbxl10 O 
, O 
like O 
previously O 
characterized O 
Polycomb O 
mutants O 
, O 
cannot O 
differentiate O 
properly O 
. O 
These O 
results O 
demonstrate O 
that O 
Fbxl10 O 
has O 
a O 
key O 
role O 
in O 
regulating O 
Ring1B O 
recruitment O 
to O 
its O 
target O 
genes O 
and O 
H2AK119 O 
ubiquitylation O 
in O 
ESCs O 
. O 

multivitamin O 
intakes O 
during O 
pregnancy O 
and O 
postweaning O 
obesogenic O 
diets O 
interact O 
to O 
affect O 
the O 
relationship O 
between O 
expression O 
of O 
PPAR O 
genes O 
and O 
glucose B-TRIVIAL 
regulation O 
in O 
the O 
offspring O 
. O 

multivitamin O 
intake O 
( O 
HV O 
) O 
during O 
pregnancy O 
increases O 
body O 
fat O 
and O 
weight O 
and O 
alters O 
glucose B-TRIVIAL 
and O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
in O 
Wistar O 
rat O 
offspring O 
. O 
This O 
study O 
investigated O 
the O 
expression O 
of O 
peroxisome O 
- O 
proliferator O 
activated O 
receptors O 
( O 
PPARs O 
) O 
genes O 
involved O 
in O 
regulation O 
of O 
glucose B-TRIVIAL 
and O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
in O 
their O 
tissues O 
. O 
Dams O 
received O 
the O 
AIN-93G O 
diet O 
with O 
either O 
the O 
regular O 
( O 
RV O 
) O 
or O 
10-fold O 
multivitamins O 
( O 
HV O 
) O 
during O 
pregnancy O 
. O 
Male O 
offspring O 
were O 
weaned O 
to O 
either O 
the O 
RV O 
diet O 
( O 
RV-RV O 
and O 
HV-RV O 
) O 
or O 
an O 
obesogenic O 
diet O 
( O 
RV-Ob O 
and O 
HV-Ob O 
) O 
. O 
Gene O 
expression O 
of O 
PPARs O 
in O 
tissues O 
was O 
analyzed O 
by O 
real O 
- O 
time O 
reverse O 
transcriptase O 
polymerase O 
chain O 
reaction O 
. O 
Gestational O 
diet O 
( O 
GD O 
) O 
did O 
not O 
affect O 
PPARs O 
gene O 
expression O 
in O 
offspring O 
at O 
either O 
birth O 
or O 
weaning O 
. O 
In O 
liver O 
, O 
at O 
14 O 
weeks O 
postweaning O 
, O 
PPAR-γ O 
was O 
30% O 
lower O 
in O 
the O 
HV-RV O 
and O 
30% O 
higher O 
in O 
HV-Ob O 
than O 
in O 
the O 
RV-RV O 
group O 
[ O 
GD O 
P=.76 O 
, O 
postweaning O 
diet O 
( O 
PD O 
) O 
P=.19 O 
, O 
interaction O 
P=.02 O 
, O 
by O 
two O 
- O 
way O 
analysis O 
of O 
variance O 
] O 
. O 
In O 
muscle O 
, O 
PPAR-α O 
expression O 
was O 
affected O 
by O 
GD O 
and O 
PD O 
( O 
GD O 
P=.05 O 
, O 
PD O 
P O 
< O 
0.01 O 
, O 
interaction O 
P=.07 O 
) O 
. O 
In O 
adipose O 
tissue O 
, O 
PPAR-α O 
expression O 
was O 
higher O 
in O 
all O 
groups O 
compared O 
to O 
RV-RV O 
( O 
GD O 
P=.25 O 
, O 
PD O 
P=.85 O 
, O 
interaction O 
P=.03 O 
) O 
. O 
PPAR-γ O 
mRNA O 
levels O 
correlated O 
with O 
abdominal O 
fat O 
( O 
r=0.45 O 
, O 
P O 
< O 
0.05 O 
) O 
and O 
insulin O 
resistance O 
index O 
( O 
r=0.39 O 
, O 
P O 
< O 
0.05 O 
) O 
. O 
In O 
liver O 
, O 
PPAR-γ O 
expression O 
correlated O 
with O 
insulin O 
resistance O 
index O 
in O 
offspring O 
from O 
RV O 
( O 
r=-0.62 O 
, O 
P O 
< O 
0.05 O 
) O 
, O 
but O 
not O 
in O 
those O 
from O 
HV O 
dams O 
( O 
r=0.13 O 
, O 
P O 
> O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
the O 
HV O 
diet O 
during O 
pregnancy O 
interacts O 
with O 
postweaning O 
diets O 
in O 
determining O 
the O 
expression O 
of O 
PPARs O 
genes O 
in O 
a O 
tissue- O 
and O 
age O 
- O 
dependent O 
manner O 
and O 
uncouples O 
the O 
relationship O 
between O 
these O 
genes O 
and O 
glucose B-TRIVIAL 
regulation O 
and O 
fat O 
mass O 
in O 
the O 
rat O 
offspring O 
. O 

new O 
triterpenoids B-FAMILY 
from O 
the O 
fungus O 
Perenniporia O 
maackiae O 
. O 

new O 
triterpenoids B-FAMILY 
, O 
3β-(2-methoxy-oxalyloxy)-24-methylene-lanost-8-en-21-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
3β-(2-methoxy-oxalyloxy)-15α-hydroxy-24-methylene-lanost-8-en-21-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
cultures O 
of O 
the O 
fungus O 
Perenniporia O 
maackiae O 
, O 
together O 
with O 
two O 
previously O 
known O 
triterpenoids B-FAMILY 
( O 
3 O 
and O 
4 O 
) O 
. O 
Their O 
structures O 
were O 
determined O 
by O 
spectroscopic O 
methods O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
, O 
and O 
MS O 
analyses O 
. O 
All O 
compounds O 
were O 
evaluated O 
for O 
their O 
cytotoxic O 
activities O 
on O 
five O 
tumor O 
cell O 
lines O 
. O 

between O 
carbapenem B-FAMILY 
consumption O 
and O 
antimicrobial O 
resistance O 
rates O 
of O 
Acinetobacter O 
baumannii O 
in O 
a O 
university O 
- O 
affiliated O 
hospital O 
in O 
China O 
. O 

investigate O 
the O 
correlation O 
between O 
carbapenem B-FAMILY 
consumption O 
and O 
rates O 
of O 
antimicrobial O 
resistance O 
in O 
Acinetobacter O 
baumannii O 
, O 
carbapenem B-FAMILY 
consumption O 
was O 
expressed O 
as O 
defined O 
daily O 
dose O 
based O 
on O 
the O 
World O 
Health O 
Organization O 
( O 
WHO O 
) O 
anatomical O 
therapeutic O 
chemical O 
classification O 
index O 
. O 
Clinical O 
isolates O 
from O 
2001-2009 O 
were O 
collected O 
and O 
analyzed O 
using O 
WHONET O 
5.4 O 
software O 
. O 
Results O 
show O 
that O 
the O 
consumption O 
of O 
imipenem B-TRIVIAL 
/ O 
cilastatin B-TRIVIAL 
, O 
meropenem B-TRIVIAL 
, O 
and O 
total O 
carbapenem B-FAMILY 
is O 
significantly O 
correlated O 
with O 
imipenem B-TRIVIAL 
resistance O 
in O 
A O 
baumannii O 
( O 
r O 
= O 
0.818 O 
, O 
P O 
= O 
0.007 O 
; O 
r O 
= O 
0.817 O 
, O 
P O 
= O 
0.007 O 
; O 
r O 
= O 
0.827 O 
, O 
P O 
= O 
0.006 O 
) O 
. O 
Furthermore O 
, O 
total O 
carbapenem B-FAMILY 
consumption O 
is O 
significantly O 
correlated O 
with O 
meropenem B-TRIVIAL 
resistance O 
in O 
A O 
baumannii O 
( O 
r O 
= O 
0.9 O 
, O 
P O 
= O 
0.037 O 
) O 
. O 
In O 
addition O 
, O 
consumption O 
of O 
imipenem B-TRIVIAL 
/ O 
cilastatin B-TRIVIAL 
, O 
meropenem B-TRIVIAL 
, O 
and O 
total O 
carbapenem B-FAMILY 
is O 
associated O 
with O 
A O 
baumannii O 
resistance O 
to O 
piperacillin B-TRIVIAL 
- O 
tazobactam B-TRIVIAL 
, O 
ceftazidime B-TRIVIAL 
, O 
cefepime B-TRIVIAL 
, O 
amikacin B-TRIVIAL 
, O 
and O 
levofloxacin B-TRIVIAL 
. O 
These O 
drugs O 
are O 
mainly O 
β-lactams B-FAMILY 
, O 
aminoglycosides B-FAMILY 
, O 
and O 
fluoroquinolones B-FAMILY 
. O 
The O 
imipenem B-TRIVIAL 
and O 
meropenem B-TRIVIAL 
resistance O 
rates O 
are O 
significantly O 
correlated O 
with O 
resistance O 
rates O 
to O 
numerous O 
antimicrobial O 
drugs O 
( O 
eg O 
, O 
β-lactams B-FAMILY 
, O 
aminoglycosides B-FAMILY 
, O 
and O 
fluoroquinolones B-FAMILY 
) O 
in O 
A O 
baumannii O 
. O 
Therefore O 
, O 
increased O 
consumption O 
of O 
carbapenem B-FAMILY 
may O 
contribute O 
to O 
the O 
development O 
of O 
resistance O 
in O 
A O 
baumannii O 
to O 
imipenem B-TRIVIAL 
, O 
meropenem B-TRIVIAL 
, O 
and O 
other O 
antimicrobial O 
drugs O 
. O 
Cross O 
- O 
resistance O 
possibly O 
occurs O 
among O 
imipenem B-TRIVIAL 
/ O 
cilastatin B-TRIVIAL 
and O 
meropenem B-TRIVIAL 
, O 
as O 
well O 
as O 
with O 
β-lactams B-FAMILY 
, O 
aminoglycosides B-FAMILY 
, O 
and O 
fluoroquinolones B-FAMILY 
. O 

-induced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
promotes O 
vesicular O 
transport O 
in O 
blood O 
- O 
brain O 
barrier O 
endothelial O 
cells O 
. O 

' O 
s O 
( O 
METH B-ABBREVIATION 
) O 
neurotoxicity O 
is O 
thought O 
to O 
be O 
in O 
part O 
due O 
to O 
its O 
ability O 
to O 
induce O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
dysfunction O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
METH B-ABBREVIATION 
on O 
barrier O 
properties O 
of O 
cultured O 
rat O 
primary O 
brain O 
microvascular O 
endothelial O 
cells O 
( O 
BMVECs O 
) O 
. O 
Transendothelial O 
flux O 
doubled O 
in O 
response O 
to O 
METH B-ABBREVIATION 
, O 
irrespective O 
of O 
the O 
size O 
of O 
tracer O 
used O 
. O 
At O 
the O 
same O 
time O 
, O 
transendothelial O 
electrical O 
resistance O 
was O 
unchanged O 
as O 
was O 
the O 
ultrastructural O 
appearance O 
of O 
inter O 
- O 
endothelial O 
junctions O 
and O 
the O 
distribution O 
of O 
key O 
junction O 
proteins O 
, O 
suggesting O 
that O 
METH B-ABBREVIATION 
promoted O 
vesicular O 
but O 
not O 
junctional O 
transport O 
. O 
Indeed O 
, O 
METH B-ABBREVIATION 
significantly O 
increased O 
uptake O 
of O 
horseradish O 
peroxidase O 
into O 
vesicular O 
structures O 
. O 
METH B-ABBREVIATION 
also O 
enhanced O 
transendothelial O 
migration O 
of O 
lymphocytes O 
indicating O 
that O 
the O 
endothelial O 
barrier O 
against O 
both O 
molecules O 
and O 
cells O 
was O 
compromised O 
. O 
Barrier O 
breakdown O 
was O 
only O 
observed O 
in O 
response O 
to O 
METH B-ABBREVIATION 
at O 
low O 
micromolar O 
concentrations O 
, O 
with O 
enhanced O 
vesicular O 
uptake O 
peaking O 
at O 
1 O 
μM O 
METH B-ABBREVIATION 
. O 
The O 
BMVEC O 
response O 
to O 
METH B-ABBREVIATION 
also O 
involved O 
rapid O 
activation O 
of O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
and O 
its O 
inhibition O 
abrogated O 
METH B-ABBREVIATION 
-induced O 
permeability O 
and O 
lymphocyte O 
migration O 
, O 
indicating O 
that O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
was O 
a O 
key O 
mediator O 
of O 
BBB O 
disruption O 
in O 
response O 
to O 
METH B-ABBREVIATION 
. O 
This O 
study O 
underlines O 
the O 
key O 
role O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
in O 
BBB O 
function O 
and O 
describes O 
a O 
novel O 
mechanism O 
of O 
drug O 
- O 
induced O 
fluid O 
- O 
phase O 
transcytosis O 
at O 
the O 
BBB O 
. O 

vitro O 
characterization O 
of O 
organophosphorus B-FAMILY 
compound O 
hydrolysis O 
by O 
native O 
and O 
recombinant O 
human O 
prolidase O 
. O 

prolidase O 
is O 
a O 
binuclear O 
metalloenzyme O 
, O 
which O 
can O 
potentially O 
function O 
as O 
a O 
catalytic O 
bioscavenger O 
for O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
nerve O 
agents O 
. O 
Although O 
the O 
biochemical O 
properties O 
of O 
native O 
prolidase O 
purified O 
from O 
human O 
erythrocytes O 
, O 
liver O 
, O 
kidney O 
, O 
and O 
fibroblast O 
cells O 
are O 
well O 
known O 
, O 
it O 
is O 
very O 
poorly O 
characterized O 
with O 
regard O 
to O 
its O 
OP O 
hydrolyzing O 
activity O 
. O 
Also O 
, O 
the O 
high O 
cost O 
of O 
purification O 
of O 
large O 
quantities O 
of O 
native O 
enzyme O 
limits O 
its O 
use O 
as O 
a O 
bioscavenger O 
. O 
Thus O 
, O 
recombinant O 
human O 
prolidase O 
with O 
similar O 
biochemical O 
properties O 
to O 
those O 
of O 
native O 
enzyme O 
would O 
be O 
more O 
suitable O 
as O 
a O 
catalytic O 
bioscavenger O 
. O 
In O 
this O 
study O 
, O 
we O 
established O 
an O 
Escherichia O 
coli O 
expression O 
system O 
, O 
which O 
produced O 
a O 
large O 
amount O 
of O 
tagged O 
human O 
liver O 
prolidase O 
that O 
was O 
purified O 
to O 
over O 
95% O 
purity O 
from O 
the O 
soluble O 
fraction O 
of O 
cell O 
lysate O 
by O 
affinity O 
chromatography O 
on O 
Streptavidin O 
- O 
agarose O 
resin O 
. O 
The O 
catalytic O 
properties O 
of O 
the O 
recombinant O 
enzyme O 
were O 
compared O 
in O 
vitro O 
with O 
those O 
of O 
highly O 
purified O 
prolidase O 
I O 
isolated O 
from O 
human O 
erythrocytes O 
. O 
The O 
catalytic O 
properties O 
of O 
recombinant O 
prolidase O 
overlap O 
with O 
those O 
of O 
the O 
erythrocyte O 
- O 
derived O 
native O 
enzyme O 
. O 
Both O 
enzymes O 
efficiently O 
hydrolyzed O 
diisopropylfluorophosphate B-SYSTEMATIC 
, O 
sarin B-TRIVIAL 
, O 
soman B-TRIVIAL 
, O 
tabun B-TRIVIAL 
and O 
cyclosarin B-TRIVIAL 
, O 
but O 
were O 
much O 
less O 
efficient O 
at O 
hydrolyzing O 
paraoxon B-TRIVIAL 
and O 
methyl B-SYSTEMATIC 
paraoxon I-SYSTEMATIC 
. O 
These O 
results O 
suggest O 
that O 
human O 
prolidase O 
expressed O 
in O 
E O 
. O 
coli O 
is O 
suitable O 
for O 
further O 
development O 
as O 
a O 
catalytic O 
bioscavenger O 
for O 
OP O 
nerve O 
agents O 
. O 

ethylenediaminetetraacetic B-SYSTEMATIC 
Acid I-SYSTEMATIC 
conjugates O 
protect O 
Mammalian O 
cells O 
from O 
bacterial O 
cells O 
. O 

ethylenediaminetetraacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EDTA B-ABBREVIATION 
) O 
conjugates O 
were O 
synthesized O 
by O 
the O 
esterification O 
of O 
cellulose O 
with O 
ethylenediaminetetraacetic B-SYSTEMATIC 
dianhydride I-SYSTEMATIC 
( O 
EDTAD B-ABBREVIATION 
) O 
. O 
The O 
new O 
materials O 
provided O 
potent O 
antimicrobial O 
activities O 
against O 
Staphylococcus O 
aureus O 
( O 
S O 
. O 
aureus O 
, O 
Gram O 
- O 
positive O 
bacteria O 
) O 
and O 
Pseudomonas O 
aeruginosa O 
( O 
P O 
. O 
aeruginosa O 
, O 
Gram O 
- O 
negative O 
bacteria O 
) O 
, O 
and O 
inhibited O 
the O 
formation O 
of O 
bacterial O 
biofilms O 
. O 
The O 
biocompatibility O 
of O 
the O 
new O 
cellulose- O 
EDTA B-ABBREVIATION 
conjugates O 
was O 
evaluated O 
with O 
mouse O 
skin O 
fibroblasts O 
for O 
up O 
to O 
14 O 
days O 
. O 
SEM O 
observation O 
and O 
DNA O 
content O 
analysis O 
suggested O 
that O 
the O 
new O 
materials O 
sustained O 
the O 
viability O 
of O 
fibroblast O 
cells O 
. O 
Moreover O 
, O 
in O 
mouse O 
skin O 
fibroblast O 
- O 
bacteria O 
co O 
- O 
culture O 
systems O 
, O 
the O 
new O 
cellulose- O 
EDTA B-ABBREVIATION 
conjugates O 
prevented O 
bacterial O 
biofilm O 
formation O 
and O 
protected O 
the O 
mammalian O 
cells O 
from O 
the O 
bacterial O 
cells O 
for O 
at O 
least O 
one O 
day O 
. O 

of O 
2,2',3,3',6,6'-hexachlorobiphenyl B-SYSTEMATIC 
( O 
PCB B-ABBREVIATION 
136 I-ABBREVIATION 
) O 
atropisomers O 
in O 
tissue O 
slices O 
from O 
phenobarbital B-TRIVIAL 
or O 
dexamethasone B-TRIVIAL 
-induced O 
rats O 
is O 
sex O 
- O 
dependent O 
. O 

1 O 
. O 
Chiral O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
such O 
as O 
PCB B-ABBREVIATION 
136 I-ABBREVIATION 
enantioselectively O 
sensitize O 
the O 
ryanodine B-TRIVIAL 
receptor O 
( O 
RyR O 
) O 
. O 
In O 
light O 
of O 
recent O 
evidence O 
that O 
PCBs B-ABBREVIATION 
cause O 
developmental O 
neurotoxicity O 
via O 
RyR-dependent O 
mechanisms O 
, O 
this O 
suggests O 
that O 
enantioselective O 
PCB B-ABBREVIATION 
metabolism O 
may O 
influence O 
the O 
developmental O 
neurotoxicity O 
of O 
chiral O 
PCBs B-ABBREVIATION 
. O 
However O 
, O 
enantioselective O 
disposition O 
of O 
PCBs B-ABBREVIATION 
has O 
not O 
been O 
fully O 
characterized O 
. O 
2 O 
. O 
The O 
effect O 
of O 
sex O 
and O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
enzyme O 
induction O 
on O 
the O 
enantioselective O 
metabolism O 
of O 
PCB B-ABBREVIATION 
136 I-ABBREVIATION 
was O 
studied O 
using O 
liver O 
tissue O 
slices O 
prepared O 
from O 
naïve O 
control O 
( O 
CTL O 
) O 
, O 
phenobarbital B-TRIVIAL 
( O 
PB O 
; O 
CYP2B O 
inducer O 
) O 
or O 
dexamethasone B-TRIVIAL 
( O 
DEX B-ABBREVIATION 
; O 
CYP3A O 
inducer O 
) O 
pretreated O 
adult O 
Sprague-Dawley O 
rats O 
. O 
PCB B-ABBREVIATION 
136 I-ABBREVIATION 
metabolism O 
was O 
also O 
examined O 
in O 
hippocampal O 
slices O 
derived O 
from O 
untreated O 
rat O 
pups O 
. O 
3 O 
. O 
In O 
liver O 
tissue O 
slices O 
, O 
hydroxylated B-ABBREVIATION 
PCB I-ABBREVIATION 
( O 
OH-PCB B-FORMULA 
) O 
profiles O 
depended O 
on O 
sex O 
and O 
inducer O 
pretreatment O 
, O 
and O 
OH-PCB B-FORMULA 
levels O 
followed O 
the O 
rank O 
orders O 
male O 
> O 
female O 
and O 
PB O 
> O 
DEX B-ABBREVIATION 
> O 
CTL O 
. O 
In O 
contrast O 
, O 
the O 
enantiomeric O 
enrichment O 
of O 
PCB B-ABBREVIATION 
136 I-ABBREVIATION 
and O 
its O 
metabolites O 
was O 
independent O 
of O 
sex O 
and O 
inducer O 
pretreatment O 
. O 
Only O 
small O 
amounts O 
of O 
PCB B-ABBREVIATION 
136 I-ABBREVIATION 
partitioned O 
into O 
hippocampal O 
tissue O 
slices O 
and O 
no O 
OH-PCB B-FORMULA 
metabolites O 
were O 
detected O 
. O 
4 O 
. O 
Our O 
results O 
suggest O 
that O 
enantioselective O 
metabolism O 
, O 
sex O 
and O 
induction O 
status O 
of O 
P450 O 
enzymes O 
in O 
the O 
liver O 
may O 
modulate O 
the O 
neurotoxic O 
outcomes O 
of O 
developmental O 
exposure O 
to O 
chiral O 
PCBs B-ABBREVIATION 
. O 

of O 
sediment-associated O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
with O 
granular O 
activated O 
carbon B-SYSTEMATIC 
. O 

of O 
activated O 
carbon B-SYSTEMATIC 
( O 
AC O 
) O 
to O 
sediments O 
has O 
been O 
proposed O 
as O 
a O 
method O 
to O 
reduce O 
ecotoxicological O 
risks O 
of O 
sediment O 
- O 
bound O 
contaminants O 
. O 
The O 
present O 
study O 
explores O 
the O 
effectiveness O 
of O 
granular O 
AC O 
( O 
GAC O 
) O 
in O 
extracting O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbon I-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
from O 
highly O 
contaminated O 
sediments O 
. O 
Four O 
candidate O 
GAC O 
materials O 
were O 
screened O 
in O 
terms O 
of O 
PAH B-ABBREVIATION 
extraction O 
efficiency O 
using O 
single O 
- O 
step O 
24-h O 
GAC O 
extractions O 
, O 
with O 
traditional O 
24-h O 
Tenax O 
extraction O 
as O 
a O 
reference O 
. O 
Subsequently O 
, O 
sorption O 
of O 
native O 
PAHs B-ABBREVIATION 
to O 
the O 
best O 
performing O 
GAC O 
1240W O 
( O 
0.45-1.70 O 
mm O 
) O 
was O 
studied O 
for O 
sediment O 
only O 
and O 
for O 
GAC-sediment O 
mixtures O 
at O 
different O 
GAC-sediment O 
weight O 
ratios O 
, O 
using O 
76-µm O 
polyoxymethylene B-FAMILY 
( O 
POM B-ABBREVIATION 
) O 
passive O 
samplers O 
. O 
Granular O 
AC O 
sorption O 
parameters O 
for O 
PAHs B-ABBREVIATION 
were O 
determined O 
by O 
subtracting O 
the O 
contribution O 
of O 
PAH B-ABBREVIATION 
sorption O 
to O 
sediment O 
from O 
PAH B-ABBREVIATION 
sorption O 
to O 
the O 
GAC-sediment O 
mixture O 
. O 
It O 
appears O 
that O 
the O 
binding O 
of O 
PAHs B-ABBREVIATION 
and O 
the O 
effectiveness O 
of O 
GAC O 
to O 
reduce O 
sediment O 
porewater O 
concentrations O 
were O 
highly O 
dependent O 
on O 
the O 
GAC-sediment O 
mixing O 
ratio O 
and O 
hydrophobicity O 
of O 
the O 
PAH B-ABBREVIATION 
. O 
Despite O 
the O 
considerable O 
fouling O 
of O 
GAC O 
by O 
organic O 
matter O 
and O 
oil O 
, O 
50 O 
to O 
90% O 
of O 
the O 
most O 
available O 
PAH B-ABBREVIATION 
was O 
extracted O 
by O 
the O 
GAC O 
during O 
a O 
28-d O 
contact O 
time O 
, O 
at O 
a O 
dose O 
as O 
low O 
as O 
4% O 
, O 
which O 
also O 
is O 
a O 
feasible O 
dose O 
in O 
field O 
- O 
scale O 
applications O 
aimed O 
at O 
cleaning O 
the O 
sediment O 
by O 
GAC O 
addition O 
and O 
removal O 
. O 

vivo O 
biocompatibility O 
, O 
sustained O 
- O 
release O 
and O 
stability O 
of O 
triptorelin B-TRIVIAL 
formulations O 
based O 
on O 
a O 
liquid O 
, O 
degradable O 
polymer O 
. O 

poly(lactic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
hexPLA B-ABBREVIATION 
) O 
is O 
a O 
viscous O 
polymer O 
, O 
which O 
degrades O 
in O 
the O 
presence O 
of O 
water O 
similar O 
to O 
the O 
structure O 
related O 
poly(lactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
. O 
With O 
hydrophilic O 
active O 
compounds O 
, O 
like O 
Triptorelin B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
the O 
lipophilic O 
polymer O 
was O 
formulated O 
in O 
form O 
of O 
parenterally O 
injectable O 
suspensions O 
. O 
This O 
first O 
in O 
vivo O 
study O 
toward O 
the O 
biocompatibility O 
of O 
hexPLA B-ABBREVIATION 
implants O 
in O 
rats O 
over O 
3 O 
months O 
in O 
comparison O 
to O 
in O 
situ O 
forming O 
poly(lactic B-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
formulations O 
is O 
presented O 
here O 
. O 
The O 
hexPLA B-ABBREVIATION 
implants O 
showed O 
only O 
a O 
mild O 
acute O 
inflammation O 
at O 
the O 
injection O 
site O 
after O 
application O 
, O 
which O 
continuously O 
regressed O 
. O 
In O 
contrast O 
to O 
the O 
PLGA B-ABBREVIATION 
formulations O 
, O 
hexPLA B-ABBREVIATION 
did O 
not O 
provoke O 
an O 
encapsulation O 
of O 
the O 
implant O 
with O 
extracellular O 
matrix O 
. O 
Prior O 
to O 
the O 
formulation O 
application O 
, O 
the O 
stability O 
of O 
Triptorelin B-TRIVIAL 
inside O 
the O 
hexPLA B-ABBREVIATION 
matrix O 
was O 
assessed O 
under O 
different O 
storage O 
conditions O 
and O 
in O 
the O 
presence O 
of O 
buffer O 
to O 
simulate O 
a O 
peptide O 
degrading O 
environment O 
. O 
At O 
5°C O 
Triptorelin B-TRIVIAL 
showed O 
a O 
stability O 
of O 
98% O 
inside O 
the O 
polymer O 
for O 
at O 
least O 
6 O 
months O 
. O 
The O 
stability O 
was O 
still O 
78% O 
at O 
an O 
elevated O 
temperature O 
of O 
40°C O 
. O 
HexPLA B-ABBREVIATION 
protected O 
the O 
incorporated O 
peptide O 
from O 
the O 
surrounding O 
aqueous O 
environment O 
, O 
which O 
resulted O 
in O 
20% O 
less O 
degradation O 
inside O 
the O 
polymer O 
compared O 
to O 
the O 
solution O 
. O 
This O 
protection O 
effect O 
supports O 
the O 
use O 
of O 
Triptorelin B-TRIVIAL 
- O 
hexPLA B-ABBREVIATION 
formulations O 
for O 
parenteral O 
sustained O 
- O 
release O 
formulations O 
. O 
In O 
a O 
second O 
in O 
vivo O 
evaluation O 
in O 
Wistar O 
Hannover O 
rats O 
, O 
formulations O 
containing O 
5% O 
and O 
10% O 
Triptorelin B-TRIVIAL 
in O 
the O 
polymeric O 
matrix O 
released O 
the O 
active O 
compound O 
continuously O 
for O 
6 O 
months O 
. O 
The O 
formulations O 
showed O 
a O 
higher O 
release O 
during O 
the O 
initial O 
7 O 
days O 
, O 
which O 
is O 
necessary O 
for O 
the O 
clinical O 
use O 
to O 
down O 
- O 
regulate O 
all O 
GnRH-receptors O 
. O 
Afterwards O 
, O 
a O 
zero O 
order O 
drug O 
release O 
was O 
observed O 
over O 
the O 
first O 
3 O 
months O 
. O 
After O 
3 O 
months O 
, O 
the O 
plasma O 
levels O 
decreased O 
slowly O 
but O 
remained O 
at O 
effective O 
concentrations O 
for O 
the O 
total O 
of O 
6 O 
months O 
. O 
Furthermore O 
, O 
a O 
qualitative O 
in O 
vitro O 
- O 
in O 
vivo O 
correlation O 
was O 
observed O 
, O 
possibly O 
facilitating O 
future O 
optimization O 
of O 
the O 
Triptorelin B-TRIVIAL 
- O 
hexPLA B-ABBREVIATION 
sustained O 
- O 
release O 
formulations O 
. O 

investigated O 
whether O 
glycation O 
gap O 
( O 
G-Gap O 
) O 
, O 
an O 
index O 
of O 
intracellular O 
glycation O 
of O 
proteins O 
, O 
was O 
associated O 
with O 
diabetes O 
complications.RESEARCH O 
DESIGN O 
AND O 
METHODSWe O 
measured O 
concomitantly O 
HbA(1c) O 
and O 
fructosamine B-SYSTEMATIC 
in O 
925 O 
patients O 
with O 
type O 
2 O 
diabetes O 
to O 
calculate O 
the O 
G-Gap O 
, O 
defined O 
as O 
the O 
difference O 
between O 
measured O 
HbA(1c) O 
, O 
and O 
fructosamine B-SYSTEMATIC 
-based O 
predicted O 
HbA(1c) O 
. O 
Patients O 
were O 
explored O 
for O 
retinopathy O 
, O 
nephropathy O 
, O 
peripheral O 
neuropathy O 
, O 
cardiac O 
autonomic O 
neuropathy O 
( O 
n O 
= O 
512 O 
) O 
, O 
and O 
silent O 
myocardial O 
ischemia O 
( O 
n O 
= O 
506).RESULTSMacroproteinuria O 
was O 
the O 
only O 
complication O 
that O 
was O 
associated O 
with O 
G-Gap O 
( O 
prevalence O 
in O 
the O 
first O 
, O 
second O 
, O 
and O 
third O 
tertile O 
of O 
G-Gap O 
: O 
2.9 O 
, O 
6.2 O 
, O 
and O 
11.0% O 
, O 
respectively O 
; O 
P O 
< O 
0.001 O 
) O 
. O 
The O 
G-Gap O 
was O 
higher O 
in O 
patients O 
with O 
macroproteinuria O 
than O 
in O 
those O 
without O 
( O 
1.06 O 
± O 
1.62 O 
vs O 
. O 
0.03 O 
± O 
1.30% O 
; O 
P O 
< O 
0.0001 O 
) O 
. O 
Because O 
HbA(1c) O 
was O 
associated O 
with O 
both O 
G-Gap O 
( O 
HbA(1c) O 
7 O 
± O 
1.4 O 
, O 
7.9 O 
± O 
1.4 O 
, O 
and O 
10.1 O 
± O 
1.8% O 
in O 
the O 
first O 
, O 
second O 
, O 
and O 
third O 
G-Gap O 
tertile O 
, O 
respectively O 
; O 
P O 
< O 
0.0001 O 
) O 
and O 
macroproteinuria O 
( O 
HbA(1c) O 
8.8 O 
± O 
2.2% O 
if O 
macroproteinuria O 
, O 
8.3 O 
± O 
2.0% O 
if O 
none O 
; O 
P O 
< O 
0.05 O 
) O 
, O 
and O 
because O 
it O 
could O 
have O 
been O 
a O 
confounder O 
, O 
we O 
matched O 
54 O 
patients O 
with O 
macroproteinuria O 
and O 
200 O 
patients O 
without O 
for O 
HbA(1c) O 
. O 
Because O 
macroproteinuria O 
was O 
associated O 
with O 
lower O 
serum O 
albumin O 
and O 
fructosamine B-SYSTEMATIC 
levels O 
, O 
which O 
might O 
account O 
for O 
higher O 
G-Gap O 
, O 
we O 
calculated O 
in O 
this O 
subpopulation O 
albumin O 
- O 
indexed O 
fructosamine B-SYSTEMATIC 
and O 
G-Gap O 
; O 
macroproteinuria O 
was O 
independently O 
associated O 
with O 
male O 
gender O 
( O 
odds O 
ratio O 
[ O 
OR O 
] O 
, O 
3.2 O 
; O 
95% O 
CI O 
, O 
1.5-6.7 O 
; O 
P O 
< O 
0.01 O 
) O 
, O 
hypertension O 
( O 
2.9 O 
; O 
[ O 
1.1-7.5 O 
] O 
; O 
P O 
< O 
0.05 O 
) O 
, O 
and O 
the O 
third O 
tertile O 
of O 
albumin O 
- O 
indexed O 
G-Gap O 
( O 
2.3 O 
; O 
[ O 
1.1-4.4 O 
] O 
; O 
P O 
< O 
0.05 O 
) O 
in O 
multivariate O 
analysis.CONCLUSIONIn O 
type O 
2 O 
diabetic O 
patients O 
, O 
G-Gap O 
was O 
associated O 
with O 
macroproteinuria O 
, O 
independently O 
of O 
HbA(1c) O 
, O 
albumin O 
levels O 
, O 
and O 
confounding O 
factors O 
, O 
suggesting O 
a O 
specific O 
role O 
of O 
intracellular O 
glycation O 
susceptibility O 
on O 
kidney O 
glomerular O 
changes O 
. O 

smoke O 
( O 
CS O 
) O 
exposure O 
may O 
cause O 
oxidative O 
stress O 
in O 
the O 
lung O 
, O 
leading O 
to O 
cell O 
death O 
and O 
long O 
- O 
term O 
injury O 
. O 
Monascus O 
adlay O 
( O 
MA O 
) O 
with O 
antioxidant O 
components O 
produced O 
by O 
inoculating O 
adlay O 
( O 
Cois O 
lachrymal O 
- O 
jobi O 
L O 
. O 
var O 
. O 
ma O 
- O 
yuen O 
Stapf O 
) O 
with O 
Monascus O 
purpureus O 
may O 
protect O 
lung O 
against O 
CS-induced O 
lung O 
injuries O 
in O 
rats O 
. O 
MA O 
and O 
lovastatin B-TRIVIAL 
had O 
higher O 
antioxidant O 
activities O 
than O 
either O 
M O 
. O 
purpureus O 
or O 
adlay O 
. O 
CS O 
exposure O 
caused O 
significant O 
lung O 
damage O 
, O 
as O 
evidenced O 
by O 
higher O 
levels O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
neutrophil O 
infiltration O 
, O 
dityrosine B-TRIVIAL 
and O 
4-HNE B-SYSTEMATIC 
, O 
as O 
well O 
as O 
lower O 
levels O 
of O 
Mn B-FORMULA 
- O 
superoxide B-TRIVIAL 
dismutase O 
and O 
catalase O 
expression O 
. O 
Lung O 
tissues O 
with O 
CS O 
exposure O 
had O 
higher O 
levels O 
of O 
ER O 
stress O 
, O 
apoptosis O 
, O 
autophagy O 
and O 
emphysema O 
- O 
related O 
placenta O 
growth O 
factor O 
( O 
PlGF O 
) O 
expressions O 
. O 
All O 
CS-induced O 
injuries O 
were O 
significantly O 
suppressed O 
by O 
MA O 
supplements O 
. O 
MA O 
would O 
be O 
a O 
beneficial O 
nutritional O 
therapy O 
to O 
ameliorate O 
CS-induced O 
lung O 
injury O 
via O 
preserving O 
antioxidant O 
defense O 
mechanisms O 
, O 
decreasing O 
oxidative O 
stress O 
and O 
inhibiting O 
ER O 
stress O 
, O 
autophagy O 
, O 
apoptosis O 
and O 
emphysema O 
- O 
related O 
risk O 
factor O 
. O 

(III) I-SYSTEMATIC 
regulates O 
the O 
nitrogen B-SYSTEMATIC 
assimilation O 
in O 
soybean O 
seedlings O 
under O 
ultraviolet-B O 
radiation O 
. O 

( O 
UV-B O 
, O 
280-320 O 
nm O 
) O 
radiation O 
has O 
seriously O 
affected O 
the O 
growth O 
of O 
plants O 
. O 
Finding O 
the O 
technology O 
/ O 
method O 
to O 
alleviate O 
the O 
damage O 
of O 
UV-B O 
radiation O 
has O 
become O 
a O 
frontal O 
topic O 
in O 
the O 
field O 
of O 
environmental O 
science O 
. O 
The O 
pretreatment O 
with O 
rare O 
earth O 
elements O 
( O 
REEs O 
) O 
is O 
an O 
effective O 
method O 
, O 
but O 
the O 
regulation O 
mechanism O 
of O 
REEs O 
is O 
unknown O 
. O 
Here O 
, O 
the O 
regulation O 
effects O 
of O 
lanthanum B-SYSTEMATIC 
( O 
La B-FORMULA 
(III) I-FORMULA 
) O 
on O 
nitrogen B-SYSTEMATIC 
assimilation O 
in O 
soybean O 
seedlings O 
( O 
Glycine O 
max O 
L O 
. O 
) O 
under O 
ultraviolet-B O 
radiation O 
were O 
investigated O 
to O 
elucidate O 
the O 
regulation O 
mechanism O 
of O 
REEs O 
on O 
plants O 
under O 
UV-B O 
radiation O 
. O 
UV-B O 
radiation O 
led O 
to O 
the O 
inhibition O 
in O 
the O 
activities O 
of O 
the O 
key O 
enzymes O 
( O 
nitrate B-SYSTEMATIC 
reductase O 
, O 
glutamine B-TRIVIAL 
synthetase O 
, O 
glutamate B-TRIVIAL 
synthase O 
) O 
in O 
the O 
nitrogen B-SYSTEMATIC 
assimilation O 
, O 
the O 
decrease O 
in O 
the O 
contents O 
of O 
nitrate B-SYSTEMATIC 
and O 
soluble O 
proteins O 
, O 
as O 
well O 
as O 
the O 
increase O 
in O 
the O 
content O 
of O 
amino B-FAMILY 
acid I-FAMILY 
in O 
soybean O 
seedlings O 
. O 
The O 
change O 
degree O 
of O 
UV-B O 
radiation O 
at O 
the O 
high O 
level O 
(0.45 O 
W O 
m(-2)) O 
was O 
higher O 
than O 
that O 
of O 
UV-B O 
radiation O 
at O 
the O 
low O 
level O 
(0.15 O 
W O 
m(-2)) O 
. O 
The O 
pretreatment O 
with O 
20 O 
mg O 
L(-1) O 
La B-FORMULA 
(III) I-FORMULA 
could O 
alleviate O 
the O 
effects O 
of O 
UV-B O 
radiation O 
on O 
the O 
activities O 
of O 
nitrate B-SYSTEMATIC 
reductase O 
, O 
glutamine B-TRIVIAL 
synthetase O 
, O 
glutamate B-TRIVIAL 
synthase O 
, O 
and O 
glutamate B-TRIVIAL 
dehydrogenase O 
, O 
promoting O 
amino B-FAMILY 
acid I-FAMILY 
conversion O 
and O 
protein O 
synthesis O 
in O 
soybean O 
seedlings O 
. O 
The O 
regulation O 
effect O 
of O 
La B-FORMULA 
(III) I-FORMULA 
under O 
UV-B O 
radiation O 
at O 
the O 
low O 
level O 
was O 
better O 
than O 
that O 
of O 
UV-B O 
radiation O 
at O 
the O 
high O 
level O 
. O 
The O 
results O 
indicated O 
that O 
the O 
pretreatment O 
with O 
20 O 
mg O 
L(-1) O 
La B-FORMULA 
(III) I-FORMULA 
could O 
alleviate O 
the O 
inhibition O 
of O 
UV-B O 
radiation O 
on O 
nitrogen B-SYSTEMATIC 
assimilation O 
in O 
soybean O 
seedlings O 
. O 

structures O 
and O 
thermochemistry O 
of O 
neutral O 
histidine B-TRIVIAL 
and O 
its O 
conjugated O 
acid O 
and O 
base O 
. O 

exploration O 
of O 
the O 
conformational O 
space O 
of O 
neutral O 
, O 
protonated O 
and O 
deprotonated O 
histidine B-TRIVIAL 
has O 
been O 
conducted O 
at O 
the O 
G4MP2 O 
level O 
. O 
Theoretical O 
protonation O 
and O 
deprotonation O 
thermochemistry O 
as O 
well O 
as O 
heats O 
of O 
formation O 
of O 
gaseous O 
histidine B-TRIVIAL 
and O 
its O 
ionized O 
forms O 
have O 
been O 
calculated O 
at O 
the O 
G4 O 
level O 
considering O 
either O 
the O 
most O 
stable O 
conformers O 
or O 
an O 
equilibrium O 
population O 
of O 
conformers O 
at O 
298 O 
K O 
. O 
These O 
theoretical O 
results O 
were O 
compared O 
to O 
evaluated O 
experimental O 
determinations O 
. O 
Recommended O 
proton O 
affinity O 
and O 
protonation O 
entropy O 
deduced O 
from O 
these O 
comparisons O 
are O 
PA( O 
His B-FORMULA 
) O 
= O 
980 O 
kJ O 
mol(-1) O 
and O 
ΔpS( O 
His B-FORMULA 
) O 
∼ O 
0 O 
J O 
mol(-1) O 
K(-1) O 
, O 
thus O 
leading O 
to O 
a O 
gas-phase O 
basicity O 
value O 
of O 
GB( O 
His B-FORMULA 
) O 
= O 
947.5 O 
kJ O 
mol(-1) O 
. O 
Similarly O 
, O 
gas O 
phase O 
acidity O 
parameters O 
are O 
ΔacidH(o)( O 
His B-FORMULA 
) O 
= O 
1373 O 
kJ O 
mol(-1) O 
, O 
ΔacidS( O 
His B-FORMULA 
) O 
∼ O 
10 O 
J O 
mol(-1) O 
K(-1) O 
and O 
ΔacidG(o)( O 
His B-FORMULA 
) O 
= O 
1343 O 
kJ O 
mol(-1) O 
. O 
Computed O 
G4 O 
heats O 
of O 
formation O 
values O 
are O 
equal O 
to O 
-290 O 
, O 
265 O 
and O 
-451 O 
kJ O 
mol(-1) O 
for O 
gaseous O 
neutral O 
histidine B-TRIVIAL 
and O 
its O 
protonated O 
and O 
deprotonated O 
forms O 
, O 
respectively O 
. O 
The O 
present O 
computational O 
data O 
correct O 
, O 
and O 
complete O 
, O 
previous O 
thermochemical O 
parameter O 
estimates O 
proposed O 
for O 
gas-phase O 
histidine O 
and O 
its O 
acido O 
- O 
basic O 
properties O 
. O 

addiction O 
and O 
obesity O 
appear O 
to O 
share O 
several O 
properties O 
. O 
Both O 
can O 
be O 
defined O 
as O 
disorders O 
in O 
which O 
the O 
saliency O 
of O 
a O 
specific O 
type O 
of O 
reward O 
( O 
food O 
or O 
drug O 
) O 
becomes O 
exaggerated O 
relative O 
to O 
, O 
and O 
at O 
the O 
expense O 
of O 
others O 
rewards O 
. O 
Both O 
drugs O 
and O 
food O 
have O 
powerful O 
reinforcing O 
effects O 
, O 
which O 
are O 
in O 
part O 
mediated O 
by O 
abrupt O 
dopamine B-TRIVIAL 
increases O 
in O 
the O 
brain O 
reward O 
centres O 
. O 
The O 
abrupt O 
dopamine B-TRIVIAL 
increases O 
, O 
in O 
vulnerable O 
individuals O 
, O 
can O 
override O 
the O 
brain's O 
homeostatic O 
control O 
mechanisms O 
. O 
These O 
parallels O 
have O 
generated O 
interest O 
in O 
understanding O 
the O 
shared O 
vulnerabilities O 
between O 
addiction O 
and O 
obesity O 
. O 
Predictably O 
, O 
they O 
also O 
engendered O 
a O 
heated O 
debate O 
. O 
Specifically O 
, O 
brain O 
imaging O 
studies O 
are O 
beginning O 
to O 
uncover O 
common O 
features O 
between O 
these O 
two O 
conditions O 
and O 
delineate O 
some O 
of O 
the O 
overlapping O 
brain O 
circuits O 
whose O 
dysfunctions O 
may O 
underlie O 
the O 
observed O 
deficits O 
. O 
The O 
combined O 
results O 
suggest O 
that O 
both O 
obese O 
and O 
drug O 
- O 
addicted O 
individuals O 
suffer O 
from O 
impairments O 
in O 
dopaminergic O 
pathways O 
that O 
regulate O 
neuronal O 
systems O 
associated O 
not O 
only O 
with O 
reward O 
sensitivity O 
and O 
incentive O 
motivation O 
, O 
but O 
also O 
with O 
conditioning O 
, O 
self O 
- O 
control O 
, O 
stress O 
reactivity O 
and O 
interoceptive O 
awareness O 
. O 
In O 
parallel O 
, O 
studies O 
are O 
also O 
delineating O 
differences O 
between O 
them O 
that O 
centre O 
on O 
the O 
key O 
role O 
that O 
peripheral O 
signals O 
involved O 
with O 
homeostatic O 
control O 
exert O 
on O 
food O 
intake O 
. O 
Here O 
, O 
we O 
focus O 
on O 
the O 
shared O 
neurobiological O 
substrates O 
of O 
obesity O 
and O 
addiction O 
. O 

ligand O 
screening O 
is O 
an O 
integral O 
part O 
of O 
the O 
modern O 
drug O 
discovery O 
process O 
. O 
Traditional O 
ligand O 
- O 
based O 
, O 
virtual O 
screening O 
approaches O 
are O 
fast O 
but O 
require O 
a O 
set O 
of O 
structurally O 
diverse O 
ligands O 
known O 
to O 
bind O 
to O 
the O 
target O 
. O 
Traditional O 
structure O 
- O 
based O 
approaches O 
require O 
high O 
- O 
resolution O 
target O 
protein O 
structures O 
and O 
are O 
computationally O 
demanding O 
. O 
In O 
contrast O 
, O 
the O 
recently O 
developed O 
threading O 
/ O 
structure O 
- O 
based O 
FINDSITE O 
- O 
based O 
approaches O 
have O 
the O 
advantage O 
that O 
they O 
are O 
as O 
fast O 
as O 
traditional O 
ligand O 
- O 
based O 
approaches O 
and O 
yet O 
overcome O 
the O 
limitations O 
of O 
traditional O 
ligand- O 
or O 
structure O 
- O 
based O 
approaches O 
. O 
These O 
new O 
methods O 
can O 
use O 
predicted O 
low O 
- O 
resolution O 
structures O 
and O 
infer O 
the O 
likelihood O 
of O 
a O 
ligand O 
binding O 
to O 
a O 
target O 
by O 
utilizing O 
ligand O 
information O 
excised O 
from O 
the O 
target's O 
remote O 
or O 
close O 
homologous O 
proteins O 
and O 
/ O 
or O 
libraries O 
of O 
ligand O 
binding O 
databases O 
. O 
Here O 
, O 
we O 
develop O 
an O 
improved O 
version O 
of O 
FINDSITE O 
, O 
FINDSITE(filt) O 
, O 
that O 
filters O 
out O 
false O 
positive O 
ligands O 
in O 
threading O 
identified O 
templates O 
by O 
a O 
better O 
binding O 
site O 
detection O 
procedure O 
that O 
includes O 
information O 
about O 
the O 
binding O 
site O 
amino B-FAMILY 
acid I-FAMILY 
similarity O 
. O 
We O 
then O 
combine O 
FINDSITE(filt) O 
with O 
FINDSITE O 
(X) O 
that O 
uses O 
publicly O 
available O 
binding O 
databases O 
ChEMBL O 
and O 
DrugBank O 
for O 
virtual O 
ligand O 
screening O 
. O 
The O 
combined O 
approach O 
, O 
FINDSITE(comb) O 
, O 
is O 
compared O 
to O 
two O 
traditional O 
docking O 
methods O 
, O 
AUTODOCK O 
Vina O 
and O 
DOCK O 
6 O 
, O 
on O 
the O 
DUD O 
benchmark O 
set O 
. O 
It O 
is O 
shown O 
to O 
be O 
significantly O 
better O 
in O 
terms O 
of O 
enrichment O 
factor O 
, O 
dependence O 
on O 
target O 
structure O 
quality O 
, O 
and O 
speed O 
. O 
FINDSITE(comb) O 
is O 
then O 
tested O 
for O 
virtual O 
ligand O 
screening O 
on O 
a O 
large O 
set O 
of O 
3576 O 
generic O 
targets O 
from O 
the O 
DrugBank O 
database O 
as O 
well O 
as O 
a O 
set O 
of O 
168 O 
Human O 
GPCRs O 
. O 
Excluding O 
close O 
homologues O 
, O 
FINDSITE(comb) O 
gives O 
an O 
average O 
enrichment O 
factor O 
of O 
52.1 O 
for O 
generic O 
targets O 
and O 
22.3 O 
for O 
GPCRs O 
within O 
the O 
top O 
1% O 
of O 
the O 
screened O 
compound O 
library O 
. O 
Around O 
65% O 
of O 
the O 
targets O 
have O 
better O 
than O 
random O 
enrichment O 
factors O 
. O 
The O 
performance O 
is O 
insensitive O 
to O 
target O 
structure O 
quality O 
, O 
as O 
long O 
as O 
it O 
has O 
a O 
TM-score O 
≥ O 
0.4 O 
to O 
native O 
. O 
Thus O 
, O 
FINDSITE(comb) O 
makes O 
the O 
screening O 
of O 
millions O 
of O 
compounds O 
across O 
entire O 
proteomes O 
feasible O 
. O 
The O 
FINDSITE(comb) O 
web O 
service O 
is O 
freely O 
available O 
for O 
academic O 
users O 
at O 
http O 
: O 
/ O 
/ O 
cssb.biology.gatech.edu O 
/ O 
skolnick O 
/ O 
webservice O 
/ O 
FINDSITE-COMB O 
/ O 
index.html O 
. O 

of O 
Azocompost O 
and O 
urea B-TRIVIAL 
on O 
the O 
herbage O 
yield O 
and O 
contents O 
and O 
compositions O 
of O 
essential O 
oils O 
from O 
two O 
genotypes O 
of O 
dragonhead O 
( O 
Dracocephalum O 
moldavica O 
L O 
. O 
) O 
in O 
two O 
regions O 
of O 
Iran O 
. O 

is O 
an O 
annual O 
, O 
herbaceous O 
, O 
balm O 
- O 
scented O 
and O 
spicy O 
aromatic O 
member O 
of O 
the O 
family O 
Lamiaceae O 
. O 
We O 
examined O 
effects O 
of O 
different O 
sources O 
of O 
nitrogen B-SYSTEMATIC 
on O 
the O 
content O 
and O 
composition O 
of O 
essential O 
oils O 
in O 
two O 
genotypes O 
of O 
dragonhead O 
in O 
two O 
regions O 
of O 
Iran O 
. O 
The O 
sources O 
of O 
nitrogen B-SYSTEMATIC 
used O 
were O 
100% O 
urea B-TRIVIAL 
( O 
70 O 
kg O 
N O 
ha(-1) O 
) O 
, O 
75% O 
urea B-TRIVIAL 
( O 
52.5 O 
kg O 
N O 
ha(-1))+25% O 
Azocompost O 
( O 
3.85 O 
tonha(-1) O 
) O 
, O 
50% O 
urea B-TRIVIAL 
( O 
35 O 
kg O 
N O 
ha(-1))+50% O 
Azocompost O 
( O 
7.77 O 
tonha(-1) O 
) O 
, O 
25% O 
urea B-TRIVIAL 
( O 
17.5 O 
kg O 
N O 
ha(-1))+75% O 
Azocompost O 
( O 
11.55 O 
tonha(-1) O 
) O 
, O 
and O 
100% O 
Azocompost O 
( O 
15.55 O 
tonha(-1) O 
) O 
. O 
Optimal O 
yield O 
and O 
content O 
of O 
essential O 
oil O 
at O 
both O 
locations O 
for O 
both O 
genotypes O 
were O 
obtained O 
by O 
applying O 
50% O 
urea B-TRIVIAL 
+ O 
50% O 
Azocompost O 
. O 
Geraniol B-TRIVIAL 
, O 
geranial B-TRIVIAL 
, O 
and O 
geranyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
were O 
the O 
most O 
abundant O 
compounds O 
. O 
For O 
both O 
genotypes O 
and O 
both O 
locations O 
, O 
application O 
of O 
50% O 
urea B-TRIVIAL 
+ O 
50% O 
Azocompost O 
increased O 
levels O 
of O 
geraniol B-TRIVIAL 
and O 
geranial B-TRIVIAL 
, O 
and O 
application O 
of O 
Azocompost O 
alone O 
increased O 
levels O 
of O 
geranyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
Overall O 
, O 
we O 
conclude O 
that O 
the O 
application O 
of O 
50% O 
urea B-TRIVIAL 
with O 
50% O 
Azocompost O 
is O 
recommended O 
for O 
optimising O 
the O 
content O 
and O 
composition O 
of O 
essential O 
oils O 
in O 
dragonhead O 
. O 

NuA4 O 
is O 
an O 
essential O 
yeast O 
histone O 
acetyltransferase O 
( O 
HAT O 
) O 
complex O 
that O 
targets O 
histones O 
H4 O 
and O 
H2A O 
in O 
nucleosome O 
substrates O 
. O 
While O 
Piccolo O 
NuA4's O 
catalytic O 
subunit O 
Esa1 O 
alone O 
is O 
unable O 
to O 
acetylate O 
nucleosomal O 
histones O 
, O 
its O 
accessory O 
subunits O 
, O 
Yng2 O 
and O 
Epl1 O 
, O 
enable O 
Esa1 O 
to O 
bind O 
to O 
and O 
to O 
act O 
on O 
nucleosomes O 
. O 
We O 
previously O 
determined O 
that O 
the O 
Tudor O 
domain O 
of O 
Esa1 O 
and O 
the O 
EPcA O 
homology O 
domain O 
of O 
Epl1 O 
play O 
critical O 
roles O 
in O 
Piccolo O 
NuA4's O 
ability O 
to O 
act O 
on O 
the O 
nucleosome O 
. O 
In O 
this O 
work O 
, O 
we O 
pinpoint O 
a O 
loop O 
within O 
the O 
Esa1 O 
Tudor O 
domain O 
and O 
a O 
short O 
basic O 
region O 
at O 
the O 
N B-FORMULA 
terminus O 
of O 
the O 
Epl1 O 
EPcA O 
domain O 
as O 
necessary O 
for O 
this O 
nucleosomal O 
HAT O 
activity O 
. O 
We O 
also O 
show O 
that O 
this O 
Esa1 O 
Tudor O 
domain O 
loop O 
region O 
is O 
positioned O 
close O 
to O 
nucleosomal O 
DNA O 
and O 
that O 
the O 
Epl1 O 
EPcA O 
basic O 
region O 
is O 
in O 
proximity O 
to O 
the O 
N B-FORMULA 
-terminal O 
histone O 
H2A O 
tail O 
, O 
the O 
globular O 
region O 
of O 
histone O 
H4 O 
, O 
and O 
also O 
to O 
nucleosomal O 
DNA O 
when O 
Piccolo O 
NuA4 O 
interacts O 
with O 
the O 
nucleosome O 
. O 
Since O 
neither O 
region O 
identified O 
is O 
required O 
for O 
Piccolo O 
NuA4 O 
to O 
bind O 
to O 
nucleosomes O 
and O 
yet O 
both O 
are O 
needed O 
to O 
acetylate O 
nucleosomes O 
, O 
these O 
regions O 
may O 
function O 
after O 
the O 
enzyme O 
binds O 
nucleosomes O 
to O 
disengage O 
substrate O 
histone O 
tails O 
from O 
nucleosomal O 
DNA O 
. O 

sinensis O 
and O 
its O 
major O 
bioactive O 
compound O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
inhibit O 
LPS-induced O 
inflammation O 
in O 
nuclear O 
factor-κB O 
transgenic O 
mice O 
as O 
evaluated O 
by O 
in O 
vivo O 
bioluminescence O 
imaging O 
. O 

the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
anti-inflammatory O 
effects O 
of O 
a O 
nutritious O 
vegetable O 
Toona O 
sinensis O 
( O 
leaf O 
extracts O 
, O 
TS O 
) O 
and O 
its O 
major O 
bioactive O 
compound O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
by O 
analysing O 
LPS-induced O 
NF-κB O 
activation O 
in O 
transgenic O 
mice O 
, O 
using O 
bioluminescence O 
imaging O 
. O 
Mice O 
were O 
challenged O 
intraperitoneally O 
with O 
LPS O 
( O 
1mg O 
/ O 
kg O 
) O 
and O 
treated O 
orally O 
with O 
TS O 
or O 
GA O 
( O 
100 O 
or O 
5mg O 
/ O 
kg O 
, O 
respectively O 
) O 
. O 
In O 
vivo O 
and O 
ex O 
vivo O 
imaging O 
showed O 
that O 
LPS O 
increased O 
NF-κB O 
luminescence O 
in O 
the O 
abdominal O 
region O 
, O 
which O 
was O 
significantly O 
inhibited O 
by O 
TS O 
or O 
GA O 
. O 
Immunohistochemical O 
and O 
ELISA O 
analyses O 
confirmed O 
that O 
TS O 
and O 
GA O 
inhibited O 
LPS-induced O 
NF-κB O 
, O 
interleukin-1β O 
, O 
and O 
tumour O 
necrosis O 
factor-α O 
expression O 
. O 
Microarray O 
analysis O 
revealed O 
that O 
biological O 
pathways O 
associated O 
with O 
metabolism O 
and O 
the O 
immune O 
responses O 
were O 
affected O 
by O 
TS O 
or O 
GA O 
. O 
Particularly O 
, O 
LPS-induced O 
thioredoxin O 
- O 
like O 
4B O 
( O 
TXNL4B O 
) O 
2 O 
expression O 
in O 
the O 
small O 
intestine O 
, O 
and O 
TXNL4B O 
, O 
iNOS O 
, O 
and O 
COX-2 O 
expression O 
in O 
RAW O 
264.7 O 
cells O 
were O 
significantly O 
inhibited O 
by O 
TS O 
or O 
GA O 
. O 
Thus O 
, O 
the O 
anti-inflammatory O 
potential O 
of O 
TS O 
was O 
mediated O 
by O 
the O 
downregulation O 
of O 
NF-κB O 
pathway O 
. O 

in O 
vitro O 
and O 
in O 
vivo O 
toxicity O 
of O 
siRNA-lipoplexes O 
with O 
addition O 
of O 
polyglutamate B-FAMILY 
. O 

previously O 
designed O 
a O 
new O 
siRNA O 
vector O 
that O 
efficiently O 
silences O 
genes O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
vector O 
originality O 
is O 
based O 
on O 
the O 
fact O 
that O 
, O 
in O 
addition O 
to O 
the O 
siRNA O 
molecule O 
, O 
it O 
contains O 
two O 
components O 
: O 
1 O 
) O 
a O 
cationic O 
liposome O 
that O 
auto O 
- O 
associates O 
with O 
the O 
siRNA O 
to O 
form O 
particles O 
called O 
" O 
lipoplexes O 
" O 
and O 
, O 
2 O 
) O 
an O 
anionic O 
polymer O 
which O 
enhances O 
the O 
lipoplex's O 
efficiency O 
. O 
This O 
anionic O 
polymer O 
can O 
be O 
a O 
nucleic O 
acid O 
, O 
a O 
polypeptide O 
or O 
a O 
polysaccharide O 
. O 
We O 
show O 
here O 
how O 
the O 
nature O 
of O 
the O 
added O 
anionic O 
polymer O 
into O 
our O 
siRNA O 
delivery O 
system O 
impacts O 
the O 
toxic O 
effects O 
induced O 
by O 
siRNA O 
lipoplexes O 
. O 
We O 
first O 
observed O 
that O 
: O 
(i) O 
siRNA O 
lipoplexes O 
- O 
induced O 
toxicity O 
was O 
cell O 
line O 
dependent O 
, O 
tumoral O 
cell O 
lines O 
being O 
the O 
more O 
sensitive O 
; O 
and O 
(ii) O 
plasmid O 
DNA O 
- O 
containing O 
siRNA O 
lipoplexes O 
were O 
more O 
toxic O 
than O 
polyglutamate B-FAMILY 
-containing O 
ones O 
or O 
cationic O 
liposomes O 
. O 
We O 
next O 
determined O 
that O 
the O 
toxicity O 
induced O 
by O 
plasmid O 
- O 
containing O 
lipoplexes O 
is O 
a O 
long O 
- O 
lasting O 
effect O 
that O 
decreased O 
cell O 
survival O 
capacity O 
for O 
several O 
generations O 
. O 
We O 
also O 
found O 
that O 
treated O 
cells O 
underwent O 
death O 
following O 
apoptosis O 
pathway O 
. O 
Systemic O 
injection O 
to O 
mice O 
of O 
siRNA O 
lipoplexes O 
, O 
rather O 
than O 
of O 
cationic O 
liposome O 
, O 
triggered O 
a O 
production O 
of O 
several O 
cytokines O 
in O 
mice O 
and O 
replacement O 
of O 
plasmid O 
by O 
polyglutamate B-FAMILY 
reduced O 
the O 
elevation O 
of O 
all O 
assayed O 
cytokines O 
. O 
In O 
order O 
to O 
enhance O 
siRNA O 
lipoplexes O 
efficiency O 
, O 
the O 
addition O 
of O 
polyglutamate B-FAMILY 
as O 
anionic O 
polymer O 
should O 
be O 
preferred O 
to O 
plasmid O 
DNA O 
as O 
far O 
as O 
in O 
vitro O 
as O 
well O 
as O 
in O 
vivo O 
toxicity O 
is O 
concerned O 
. O 

loaded O 
solid O 
lipid O 
nanoparticles O 
: O 
An O 
efficient O 
formulation O 
approach O 
for O 
cerebral O 
ischemic O 
reperfusion O 
injury O 
in O 
rats O 
. O 

: O 
To O 
evaluate O 
curcumin B-TRIVIAL 
loaded O 
solid O 
lipid O 
nanoparticles O 
( O 
C-SLNs O 
) O 
in O 
the O 
experimental O 
paradigm O 
of O 
cerebral O 
ischemia O 
( O 
BCCAO O 
model O 
) O 
in O 
rats O 
. O 
METHODS O 
AND O 
RESULTS O 
: O 
Oral O 
administration O 
of O 
free O 
curcumin B-TRIVIAL 
and O 
C-SLNs O 
( O 
25 O 
and O 
50mg O 
/ O 
kg O 
) O 
was O 
started O 
5days O 
prior O 
and O 
continued O 
for O 
3days O 
after O 
BCCAO O 
. O 
Alleviation O 
in O 
behavioral O 
, O 
oxidative O 
and O 
nitrosative O 
stress O 
, O 
acetylcholinesterase O 
, O 
mitochondrial O 
enzyme O 
complexes O 
, O 
and O 
physiological O 
parameters O 
were O 
assessed O 
. O 
Confirmation O 
of O 
effective O 
brain O 
delivery O 
of O 
C-SLNs O 
( O 
p.o O 
) O 
was O 
done O 
using O 
biodistribution O 
studies O 
in O 
mice O 
and O 
confocal O 
microscopy O 
of O 
rat O 
brain O 
section O 
. O 
There O 
was O 
an O 
improvement O 
of O 
90% O 
in O 
cognition O 
and O 
52% O 
inhibition O 
of O 
acetylcholinesterase O 
versus O 
cerebral O 
ischemic O 
group O 
( O 
I O 
/ O 
R O 
) O 
. O 
Neurological O 
scoring O 
improved O 
by O 
79% O 
. O 
Levels O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
glutathione B-TRIVIAL 
, O 
and O 
mitochondrial O 
complex O 
enzyme O 
activities O 
were O 
significantly O 
increased O 
, O 
while O 
lipid O 
peroxidation O 
, O 
nitrite B-SYSTEMATIC 
, O 
and O 
acetylcholinesterase O 
levels O 
decreased O 
( O 
p O 
< O 
0.05 O 
) O 
after O 
C-SLNs O 
administration O 
. O 
It O 
is O 
noteworthy O 
to O 
report O 
the O 
restoration O 
of O 
SOD O 
, O 
GSH B-ABBREVIATION 
, O 
catalase O 
, O 
and O 
mitochondrial O 
complex O 
enzyme O 
levels O 
equivalent O 
to O 
sham O 
control O 
values O 
. O 
Gamma-scintigraphic O 
studies O 
show O 
16.4 O 
and O 
30 O 
times O 
improvement O 
in O 
brain O 
bioavailability O 
( O 
AUC O 
) O 
upon O 
oral O 
and O 
i.v O 
administration O 
of O 
C-SLNs O 
versus O 
solubilized O 
curcumin B-TRIVIAL 
( O 
C-S O 
) O 
. O 
CONCLUSIONS O 
: O 
Study O 
indicates O 
protective O 
role O 
of O 
curcumin B-TRIVIAL 
against O 
cerebral O 
ischemic O 
insult O 
; O 
provided O 
it O 
is O 
packaged O 
suitably O 
for O 
improved O 
brain O 
delivery O 
. O 

remains O 
a O 
major O 
challenge O 
in O 
drug O 
development O 
. O 
Although O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
remains O 
the O 
gold O 
standard O 
biomarker O 
of O 
liver O 
injury O 
, O 
alternative O 
biomarker O 
strategies O 
to O 
better O 
predict O 
the O 
potential O 
for O 
severe O 
drug O 
- O 
induced O 
liver O 
injury O 
( O 
DILI O 
) O 
are O 
essential O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
utility O 
of O 
glutamate B-TRIVIAL 
dehydrogenase O 
( O 
GLDH O 
) O 
, O 
purine B-TRIVIAL 
nucleoside I-TRIVIAL 
phosphorylase O 
( O 
PNP O 
) O 
, O 
malate B-TRIVIAL 
dehydrogenase O 
( O 
MDH O 
) O 
, O 
and O 
paraxonase O 
1 O 
( O 
PON1 O 
) O 
as O 
indicators O 
of O 
liver O 
injury O 
in O 
cohorts O 
of O 
human O 
subjects O 
, O 
including O 
healthy O 
subjects O 
across O 
age O 
and O 
gender O 
, O 
subjects O 
with O 
a O 
variety O 
of O 
liver O 
impairments O 
, O 
and O 
several O 
cases O 
of O 
acetaminophen B-TRIVIAL 
poisoning O 
. O 
In O 
the O 
healthy O 
subjects O 
, O 
levels O 
of O 
GLDH O 
and O 
MDH O 
were O 
not O 
affected O 
by O 
age O 
or O 
gender O 
. O 
Reference O 
ranges O 
for O 
GLDH O 
and O 
MDH O 
in O 
healthy O 
subjects O 
were O 
1-10 O 
and O 
79-176U O 
/ O 
L O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
the O 
levels O 
of O 
PON1 O 
and O 
PNP O 
were O 
not O 
consistent O 
across O 
cohorts O 
of O 
healthy O 
subjects O 
. O 
Furthermore O 
, O 
GLDH O 
and O 
MDH O 
had O 
a O 
strong O 
correlation O 
with O 
elevated O 
ALT O 
levels O 
and O 
possessed O 
a O 
high O 
predictive O 
power O 
for O 
liver O 
injury O 
, O 
as O 
determined O 
by O 
ROC O 
analysis O 
. O 
In O 
contrast O 
, O 
PON1 O 
and O 
PNP O 
did O 
not O 
detect O 
liver O 
injury O 
in O 
our O 
study O 
. O 
Finally O 
, O 
evaluation O 
of O 
patients O 
with O 
acetaminophen B-TRIVIAL 
-induced O 
liver O 
injury O 
provided O 
evidence O 
that O 
both O 
GLDH O 
and O 
MDH O 
might O 
have O 
utility O 
as O 
biomarkers O 
of O 
DILI O 
in O 
humans O 
. O 
This O 
study O 
is O 
the O 
first O 
to O 
evaluate O 
GLDH O 
, O 
MDH O 
, O 
PON1 O 
, O 
and O 
PNP O 
in O 
a O 
large O 
number O 
of O 
human O 
subjects O 
and O 
, O 
and O 
it O 
provides O 
an O 
impetus O 
for O 
prospective O 
clinical O 
studies O 
to O 
fully O 
evaluate O 
the O 
diagnostic O 
value O 
of O 
GLDH O 
and O 
MDH O 
for O 
detection O 
of O 
liver O 
injury O 
. O 

of O 
a O 
novel O 
benzimidazole B-SYSTEMATIC 
derivative O 
as O 
a O 
highly O 
potent O 
NPY O 
Y5 O 
receptor O 
antagonist O 
with O 
an O 
anti-obesity O 
profile O 
. O 

of O 
HTS O 
hit O 
1 O 
for O 
NPY O 
Y5 O 
receptor O 
binding O 
affinity O 
, O 
CYP450 O 
inhibition O 
, O 
solubility O 
and O 
metabolic O 
stability O 
led O 
to O 
the O 
identification O 
of O 
some O 
orally O 
available O 
oxygen B-SYSTEMATIC 
-linker O 
derivatives O 
for O 
in O 
vivo O 
study O 
. O 
Among O 
them O 
, O 
derivative O 
4i O 
inhibited O 
food O 
intake O 
induced O 
by O 
the O 
NPY O 
Y5 O 
selective O 
agonist O 
, O 
and O 
chronic O 
oral O 
administration O 
of O 
4i O 
in O 
DIO O 
mice O 
caused O 
a O 
dose O 
- O 
dependent O 
reduction O 
of O 
body O 
weight O 
gain O 
. O 

- O 
based O 
discovery O 
of O 
new O 
highly O 
substituted O 
1H-pyrrolo[2,3-b]- B-FAMILY 
and I-FAMILY 
3H-imidazolo[4,5-b]-pyridines I-FAMILY 
as O 
focal O 
adhesion O 
kinase O 
inhibitors O 
. O 

adhesion O 
kinase O 
( O 
FAK O 
) O 
is O 
considered O 
as O 
an O 
attractive O 
target O 
for O 
oncology O 
, O 
and O 
small O 
- O 
molecule O 
inhibitors O 
are O 
reported O 
to O 
be O 
in O 
clinical O 
testing O 
. O 
In O 
a O 
surface O 
plasmon O 
resonance O 
( O 
SPR O 
) O 
- O 
mediated O 
fragment O 
screening O 
campaign O 
, O 
we O 
discovered O 
bicyclic O 
scaffolds O 
like O 
1H-pyrazolo[3,4-d]pyrimidines B-FAMILY 
binding O 
to O 
the O 
hinge O 
region O 
of O 
FAK O 
. O 
By O 
an O 
accelerated O 
knowledge O 
- O 
based O 
fragment O 
growing O 
approach O 
, O 
essential O 
pharmacophores O 
were O 
added O 
. O 
The O 
establishment O 
of O 
highly O 
substituted O 
unprecedented O 
1H-pyrrolo[2,3-b]pyridine B-SYSTEMATIC 
derivatizations O 
provided O 
compounds O 
with O 
submicromolar O 
cellular O 
FAK O 
inhibition O 
potential O 
. O 
The O 
combination O 
of O 
substituents O 
on O 
the O 
bicyclic O 
templates O 
and O 
the O 
nature O 
of O 
the O 
core O 
structure O 
itself O 
have O 
a O 
significant O 
impact O 
on O 
the O 
compounds O 
FAK O 
selectivity O 
. O 
Structural O 
analysis O 
revealed O 
that O 
the O 
appropriately O 
substituted O 
pyrrolo[2,3-b]pyridine B-SYSTEMATIC 
induced O 
a O 
rare O 
helical O 
DFG-loop O 
conformation O 
. O 
The O 
discovered O 
synthetic O 
route O 
to O 
introduce O 
three O 
different O 
substituents O 
independently O 
paves O 
the O 
way O 
for O 
versatile O 
applications O 
of O 
the O 
7-azaindole B-SYSTEMATIC 
core O 
. O 

disrupts O 
endosteal O 
bone O 
formation O 
during O 
distraction O 
osteogenesis O 
by O 
local O 
adipocytic O 
infiltration O 
. O 

( O 
Rosi B-ABBREVIATION 
) O 
is O 
a O 
drug O 
in O 
the O 
thiazolidinedione B-FAMILY 
class O 
for O 
treatment O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
, O 
which O 
binds O 
and O 
activates O 
PPARγ O 
nuclear O 
receptor O 
in O 
fat O 
cells O 
, O 
sensitizing O 
them O 
to O 
insulin O 
. O 
Despite O 
proven O 
antidiabetic O 
efficacy O 
, O 
Rosi B-ABBREVIATION 
therapy O 
may O 
be O 
associated O 
with O 
trabecular O 
bone O 
loss O 
and O 
an O 
increased O 
risk O 
of O 
fractures O 
. O 
To O 
examine O 
the O 
potential O 
side O 
effects O 
of O 
Rosi B-ABBREVIATION 
treatment O 
on O 
bone O 
formation O 
, O 
we O 
delivered O 
Rosi B-ABBREVIATION 
to O 
mice O 
using O 
a O 
combined O 
model O 
of O 
distraction O 
osteogenesis O 
( O 
DO O 
) O 
and O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
. O 
DO O 
provides O 
a O 
unique O 
method O 
to O 
isolate O 
the O 
sequence O 
of O 
intramembranous O 
bone O 
formation O 
, O 
an O 
important O 
component O 
of O 
both O 
fracture O 
healing O 
and O 
bone O 
homeostasis O 
. O 
Four O 
groups O 
of O 
n=6 O 
mice O 
were O 
used O 
to O 
compare O 
the O 
effects O 
of O 
Rosi B-ABBREVIATION 
on O 
bone O 
formation O 
and O 
cellular O 
composition O 
in O 
both O 
diabetic O 
( O 
Avy O 
/ O 
a O 
strain O 
) O 
and O 
non-diabetic O 
mice O 
( O 
a O 
/ O 
a O 
strain O 
) O 
. O 
New O 
bone O 
formation O 
was O 
examined O 
by O 
high O 
resolution O 
radiographs O 
, O 
micro O 
- O 
computed O 
tomography O 
, O 
and O 
histology O 
. O 
Precursor O 
cells O 
in O 
the O 
distraction O 
gap O 
were O 
quantitated O 
using O 
immunohistochemical O 
stains O 
for O 
proliferating O 
cell O 
nuclear O 
antigen O 
. O 
Committed O 
osteoblasts O 
and O 
adipocytes O 
in O 
the O 
gap O 
were O 
identified O 
and O 
quantitated O 
by O 
immunostaining O 
for O 
osteocalcin O 
and O 
FABP4 O 
/ O 
aP2 O 
, O 
respectively O 
. O 
The O 
diabetic O 
model O 
developed O 
obesity O 
, O 
hyperglycemia O 
, O 
hyperinsulinemia O 
and O 
insulin O 
resistance O 
, O 
while O 
the O 
control O 
littermates O 
remained O 
lean O 
, O 
normoglycemic O 
and O 
insulin O 
sensitive O 
. O 
Rosi B-ABBREVIATION 
treatment O 
decreased O 
levels O 
of O 
non-fasted O 
glucose B-TRIVIAL 
and O 
insulin O 
and O 
improved O 
insulin O 
sensitivity O 
in O 
the O 
A(vy) O 
/ O 
a O 
mice O 
, O 
but O 
had O 
no O 
effect O 
in O 
a O 
/ O 
a O 
mice O 
, O 
indicating O 
antidiabetic O 
efficacy O 
of O 
Rosi B-ABBREVIATION 
at O 
the O 
tested O 
dose O 
. O 
Despite O 
the O 
diabetic O 
, O 
obese O 
mice O 
having O 
twice O 
the O 
number O 
of O 
fat O 
cells O 
in O 
their O 
marrow O 
than O 
the O 
non-diabetic O 
mice O 
, O 
bone O 
formation O 
using O 
DO O 
was O 
not O 
adversely O 
affected O 
by O 
the O 
diabetes O 
itself O 
. O 
However O 
, O 
Rosi B-ABBREVIATION 
treatment O 
significantly O 
diminished O 
intramembranous O 
endosteal O 
bone O 
formation O 
, O 
while O 
increasing O 
adipogenesis O 
in O 
and O 
adjacent O 
to O 
the O 
distraction O 
gap O 
up O 
to O 
3.5- O 
to O 
3.8-fold O 
in O 
both O 
diabetic O 
and O 
non-diabetic O 
models O 
. O 
This O 
effect O 
was O 
independent O 
of O 
the O 
anti-diabetic O 
therapeutic O 
response O 
. O 
These O 
results O 
raise O 
the O 
question O 
of O 
whether O 
osteoblast O 
precursors O 
are O 
inhibited O 
in O 
their O 
development O 
or O 
actually O 
converted O 
to O 
adipocytic O 
phenotypes O 
, O 
possibly O 
via O 
marrow O 
fat O 
PPARγ O 
nuclear O 
receptor O 
. O 

and O 
subsidies O 
are O 
increasingly O 
being O 
considered O 
as O 
potential O 
policy O 
instruments O 
to O 
incentivize O 
consumers O 
to O 
improve O 
their O 
food O 
and O 
beverage O 
consumption O 
patterns O 
and O 
related O 
health O 
outcomes O 
. O 
This O 
study O 
provided O 
a O 
systematic O 
review O 
of O 
recent O 
U.S O 
. O 
studies O 
on O 
the O 
price O 
elasticity O 
of O 
demand O 
for O 
sugar B-FAMILY 
-sweetened O 
beverages O 
( O 
SSBs O 
) O 
, O 
fast O 
food O 
, O 
and O 
fruits O 
and O 
vegetables O 
, O 
as O 
well O 
as O 
the O 
direct O 
associations O 
of O 
prices O 
/ O 
taxes O 
with O 
body O 
weight O 
outcomes O 
. O 
Based O 
on O 
the O 
recent O 
literature O 
, O 
the O 
price O 
elasticity O 
of O 
demand O 
for O 
SSBs O 
, O 
fast O 
food O 
, O 
fruits O 
and O 
vegetables O 
was O 
estimated O 
to O 
be O 
-1.21 O 
, O 
-0.52 O 
, O 
-0.49 O 
and O 
-0.48 O 
, O 
respectively O 
. O 
The O 
studies O 
that O 
linked O 
soda O 
taxes O 
to O 
weight O 
outcomes O 
showed O 
minimal O 
impacts O 
on O 
weight O 
; O 
however O 
, O 
they O 
were O 
based O 
on O 
existing O 
state O 
- O 
level O 
sales O 
taxes O 
that O 
were O 
relatively O 
low O 
. O 
Higher O 
fast O 
- O 
food O 
prices O 
were O 
associated O 
with O 
lower O 
weight O 
outcomes O 
particularly O 
among O 
adolescents O 
, O 
suggesting O 
that O 
raising O 
prices O 
would O 
potentially O 
impact O 
weight O 
outcomes O 
. O 
Lower O 
fruit O 
and O 
vegetable O 
prices O 
were O 
generally O 
found O 
to O 
be O 
associated O 
with O 
lower O 
body O 
weight O 
outcomes O 
among O 
both O 
low O 
- O 
income O 
children O 
and O 
adults O 
, O 
suggesting O 
that O 
subsidies O 
that O 
would O 
reduce O 
the O 
cost O 
of O 
fruits O 
and O 
vegetables O 
for O 
lower O 
- O 
socioeconomic O 
populations O 
may O 
be O 
effective O 
in O 
reducing O 
obesity O 
. O 
Pricing O 
instruments O 
should O 
continue O 
to O 
be O 
considered O 
and O 
evaluated O 
as O 
potential O 
policy O 
instruments O 
to O 
address O 
public O 
health O 
risks O 
. O 

Synthetase O 
1 O 
Is O 
Induced O 
by O 
Gram O 
- O 
negative O 
Bacteria O 
and O 
Lipopolysaccharide O 
and O 
Is O 
Required O 
for O 
Phospholipid O 
Turnover O 
in O 
Stimulated O 
Macrophages O 
. O 

enzyme O 
acyl-CoA B-ABBREVIATION 
synthetase O 
1 O 
( O 
ACSL1 O 
) O 
is O 
induced O 
by O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
( O 
PPARα O 
) O 
and O 
PPARγ O 
in O 
insulin O 
target O 
tissues O 
, O 
such O 
as O 
skeletal O 
muscle O 
and O 
adipose O 
tissue O 
, O 
and O 
plays O 
an O 
important O 
role O 
in O 
β-oxidation O 
in O 
these O 
tissues O 
. O 
In O 
macrophages O 
, O 
however O 
, O 
ACSL1 O 
mediates O 
inflammatory O 
effects O 
without O 
significant O 
effects O 
on O 
β-oxidation O 
. O 
Thus O 
, O 
the O 
function O 
of O 
ACSL1 O 
varies O 
in O 
different O 
tissues O 
. O 
We O 
therefore O 
investigated O 
the O 
signals O 
and O 
signal O 
transduction O 
pathways O 
resulting O 
in O 
ACSL1 O 
induction O 
in O 
macrophages O 
as O 
well O 
as O 
the O 
consequences O 
of O 
ACSL1 O 
deficiency O 
for O 
phospholipid O 
turnover O 
in O 
LPS-activated O 
macrophages O 
. O 
LPS O 
, O 
Gram O 
- O 
negative O 
bacteria O 
, O 
IFN-γ O 
, O 
and O 
TNFα O 
all O 
induce O 
ACSL1 O 
expression O 
in O 
macrophages O 
, O 
whereas O 
PPAR O 
agonists O 
do O 
not O 
. O 
LPS-induced O 
ACSL1 O 
expression O 
is O 
dependent O 
on O 
Toll O 
- O 
like O 
receptor O 
4 O 
( O 
TLR4 O 
) O 
and O 
its O 
adaptor O 
protein O 
TRIF O 
( O 
Toll O 
- O 
like O 
receptor O 
adaptor O 
molecule O 
1 O 
) O 
but O 
does O 
not O 
require O 
the O 
MyD88 O 
( O 
myeloid O 
differentiation O 
primary O 
response O 
gene O 
88 O 
) O 
arm O 
of O 
TLR4 O 
signaling O 
; O 
nor O 
does O 
it O 
require O 
STAT1 O 
( O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
1 O 
) O 
for O 
maximal O 
induction O 
. O 
Furthermore O 
, O 
ACSL1 O 
deletion O 
attenuates O 
phospholipid O 
turnover O 
in O 
LPS-stimulated O 
macrophages O 
. O 
Thus O 
, O 
the O 
regulation O 
and O 
biological O 
function O 
of O 
ACSL1 O 
in O 
macrophages O 
differ O 
markedly O 
from O 
that O 
in O 
insulin O 
target O 
tissues O 
. O 
These O 
results O 
suggest O 
that O 
ACSL1 O 
may O 
have O 
an O 
important O 
role O 
in O 
the O 
innate O 
immune O 
response O 
. O 
Further O 
, O 
these O 
findings O 
illustrate O 
an O 
interesting O 
paradigm O 
in O 
which O 
the O 
same O 
enzyme O 
, O 
ACSL1 O 
, O 
confers O 
distinct O 
biological O 
effects O 
in O 
different O 
cell O 
types O 
, O 
and O 
these O 
disparate O 
functions O 
are O 
paralleled O 
by O 
differences O 
in O 
the O 
pathways O 
that O 
regulate O 
its O 
expression O 
. O 

tolerance O 
to O 
copper B-SYSTEMATIC 
, O 
but O 
no O 
evidence O 
of O 
population O 
- O 
level O 
genetic O 
differences O 
in O 
a O 
widely O 
- O 
dispersing O 
native O 
barnacle O 
. O 

many O 
estuaries O 
having O 
high O 
levels O 
of O 
metal O 
pollution O 
, O 
species O 
are O 
found O 
to O 
persist O 
in O 
these O 
stressful O 
environments O 
. O 
Populations O 
of O 
estuarine O 
invertebrates O 
exposed O 
to O 
toxic O 
concentrations O 
of O 
such O 
metals O 
may O 
be O 
under O 
selection O 
. O 
However O 
, O 
in O 
species O 
with O 
a O 
wide-dispersal O 
potential O 
, O 
any O 
short O 
- O 
term O 
results O 
of O 
localized O 
selection O 
may O 
be O 
counteracted O 
by O 
external O 
recruitment O 
from O 
populations O 
not O 
under O 
selection O 
. O 
The O 
barnacle O 
Amphibalanus O 
variegatus O 
is O 
found O 
in O 
nearshore O 
coastal O 
environments O 
as O 
well O 
as O 
sheltered O 
embayments O 
and O 
estuaries O 
, O 
including O 
metal O 
- O 
impacted O 
estuaries O 
, O 
from O 
New O 
South O 
Wales O 
, O 
Australia O 
to O 
Western O 
Australia O 
. O 
The O 
fertilised O 
eggs O 
of O 
A O 
. O 
variegatus O 
are O 
brooded O 
internally O 
and O 
released O 
as O 
larvae O 
( O 
nauplii O 
) O 
, O 
which O 
remain O 
in O 
the O 
water O 
- O 
column O 
for O 
~14 O 
days O 
before O 
settling O 
. O 
Hence O 
the O 
species O 
has O 
a O 
considerable O 
dispersal O 
capacity O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
examine O 
whether O 
populations O 
of O 
A O 
. O 
variegatus O 
from O 
metal O 
- O 
impacted O 
sites O 
, O 
displayed O 
a O 
greater O 
tolerance O 
to O 
a O 
toxicant O 
( O 
copper B-SYSTEMATIC 
) O 
than O 
reference O 
populations O 
. O 
Adult O 
barnacles O 
where O 
collected O 
from O 
twenty O 
sites O 
within O 
two O 
metal O 
- O 
impacted O 
and O 
fourteen O 
sites O 
within O 
two O 
reference O 
estuaries O 
. O 
Within O 
24 O 
h O 
, O 
adults O 
were O 
induced O 
to O 
spawn O 
and O 
the O 
offspring O 
were O 
exposed O 
to O 
copper B-SYSTEMATIC 
in O 
a O 
laboratory O 
assay O 
. O 
Larvae O 
collected O 
from O 
the O 
metal O 
- O 
impacted O 
estuaries O 
demonstrated O 
a O 
greater O 
tolerance O 
to O 
copper B-SYSTEMATIC 
compared O 
to O 
those O 
from O 
reference O 
sites O 
. O 
To O 
determine O 
if O 
selection O 
/ O 
localised O 
in O 
the O 
metal O 
impacted O 
sites O 
was O 
occurring O 
, O 
the O 
genetic O 
structure O 
of O 
populations O 
at O 
three O 
sites O 
was O 
examined O 
using O 
an O 
AFLP O 
methodology O 
. O 
No O 
evidence O 
of O 
unique O 
population O 
identity O 
and O 
or O 
selection O 
( O 
outlier O 
loci O 
) O 
was O 
detected O 
suggesting O 
that O 
: O 
( O 
1 O 
) O 
the O 
tolerance O 
displayed O 
in O 
the O 
assay O 
was O 
derived O 
from O 
acclimation O 
during O 
development O 
; O 
and O 
/ O 
or O 
( O 
2 O 
) O 
that O 
the O 
populations O 
are O 
open O 
preventing O 
the O 
fixation O 
of O 
any O 
unique O 
alleles O 
. O 

novel O 
permeation O 
enhancer O 
: O 
N-succinyl B-TRIVIAL 
chitosan O 
on O 
the O 
intranasal O 
absorption O 
of O 
isosorbide B-SYSTEMATIC 
dinitrate I-SYSTEMATIC 
in O 
rats O 
. O 

purpose O 
of O 
this O 
paper O 
is O 
to O 
study O 
the O 
potential O 
of O 
N-succinyl B-TRIVIAL 
chitosan O 
as O 
a O 
novel O 
permeation O 
enhancer O 
for O 
the O 
intranasal O 
absorption O 
of O 
isosorbide B-SYSTEMATIC 
dinitrate I-SYSTEMATIC 
( O 
ISDN B-ABBREVIATION 
) O 
. O 
A O 
series O 
of O 
N-succinyl B-TRIVIAL 
chitosan O 
( O 
NSCS O 
) O 
with O 
different O 
degree O 
of O 
succinylation O 
( O 
DS O 
) O 
and O 
molecular O 
weight O 
were O 
synthesized O 
. O 
An O 
in O 
situ O 
nasal O 
perfusion O 
technique O 
in O 
rats O 
was O 
utilized O 
to O 
investigate O 
the O 
effect O 
of O 
NSCS O 
substitution O 
degree O 
, O 
NSCS O 
molecular O 
weight O 
and O 
concentration O 
on O 
the O 
intranasal O 
absorption O 
of O 
ISDN B-ABBREVIATION 
. O 
The O 
absorption O 
enhancing O 
effect O 
of O 
NSCS O 
was O 
compared O 
with O 
that O 
of O 
chitosan O 
. O 
It O 
was O 
found O 
that O 
all O 
the O 
NSCS O 
investigated O 
improved O 
the O 
intranasal O 
absorption O 
of O 
ISDN B-ABBREVIATION 
remarkably O 
. O 
Better O 
promoting O 
effect O 
was O 
observed O 
for O 
0.1% O 
NSCS O 
50 O 
( O 
63 O 
) O 
compared O 
with O 
0.5% O 
chitosan O 
50 O 
. O 
In O 
nasal O 
ciliotoxicity O 
test O 
, O 
both O 
NSCS O 
and O 
chitosan O 
investigated O 
showed O 
good O 
safety O 
profiles O 
. O 
Thereafter O 
, O 
in O 
vivo O 
studies O 
of O 
the O 
selected O 
formulations O 
were O 
carried O 
out O 
in O 
rats O 
and O 
the O 
pharmacokinetic O 
parameters O 
were O 
calculated O 
and O 
compared O 
with O 
that O 
of O 
intravenous O 
injection O 
. O 
Both O 
in O 
situ O 
and O 
in O 
vivo O 
studies O 
demonstrated O 
that O 
NSCS O 
is O 
more O 
effective O 
than O 
chitosan O 
in O 
promoting O 
intranasal O 
absorption O 
of O 
ISDN B-ABBREVIATION 
. O 
Taking O 
both O 
absorption O 
enhancing O 
and O 
safety O 
reason O 
into O 
account O 
, O 
we O 
suggest O 
NSCS O 
is O 
a O 
promising O 
intranasal O 
absorption O 
enhancer O 
. O 

stacking O 
on O 
protein O 
amide B-FAMILY 
fragments O 
. O 

less O 
polar O 
π-surface O 
of O 
protein O 
amide B-FAMILY 
groups O 
is O 
exposed O 
in O 
many O 
receptor O 
binding O 
sites O 
, O 
either O 
as O 
part O 
of O 
the O 
backbone O 
or O 
in O 
Gln B-FORMULA 
/ O 
Asn B-FORMULA 
side O 
chains O 
. O 
Using O 
quantum O 
chemical O 
calculations O 
and O 
Protein O 
Data O 
Bank O 
( O 
PDB O 
) O 
searches O 
on O 
model O 
systems O 
, O 
we O 
investigate O 
the O 
energetics O 
and O 
geometric O 
preferences O 
for O 
the O 
stacking O 
on O 
amide B-FAMILY 
groups O 
of O 
a O 
large O 
number O 
of O 
heteroarenes B-FAMILY 
that O 
are O 
relevant O 
to O 
medicinal O 
chemistry O 
. O 
From O 
this O 
study O 
, O 
we O 
discern O 
that O 
the O 
stacking O 
energy O 
of O 
an O 
aromatic O 
ligand O 
substituent O 
can O 
be O 
improved O 
by O 
: O 
1 O 
) O 
orienting O 
the O 
fragment O 
dipole O 
vector O 
such O 
that O 
it O 
is O 
aligned O 
in O 
an O 
antiparallel O 
fashion O 
with O 
the O 
dipole O 
of O 
the O 
interacting O 
protein O 
amide B-FAMILY 
group O 
, O 
2 O 
) O 
increasing O 
its O 
dipole O 
moment O 
, O 
and O 
3 O 
) O 
decreasing O 
its O 
π-electron O 
density O 
. O 
These O 
guidelines O 
should O 
be O 
helpful O 
to O 
more O 
rationally O 
exploit O 
this O 
interaction O 
type O 
in O 
future O 
structure O 
- O 
based O 
drug O 
design O 
. O 

crown B-FAMILY 
- I-FAMILY 
ether I-FAMILY 
loop O 
- O 
derivatized O 
oligothiophene B-FAMILY 
doubly O 
attached O 
on O 
gold O 
surface O 
as O 
cation O 
- O 
binding O 
switchable O 
molecular O 
junction O 
. O 

crown B-FAMILY 
- I-FAMILY 
ether I-FAMILY 
dithiol I-FAMILY 
quaterthiophene I-FAMILY 
is O 
synthesized O 
and O 
immobilized O 
on O 
gold O 
surface O 
by O 
double O 
covalent O 
fixation O 
. O 
UV-vis O 
spectroscopy O 
and O 
cyclic O 
voltammetry O 
show O 
that O 
the O 
corresponding O 
dithioester B-SYSTEMATIC 
precursor O 
can O 
complex O 
Pb(2+) B-FORMULA 
in O 
solution O 
and O 
that O 
this O 
property O 
is O 
maintained O 
for O 
monolayers O 
of O 
the O 
dithiol B-SYSTEMATIC 
on O 
gold O 
. O 
Current-voltage O 
measurements O 
by O 
eutectic O 
GaIn B-FORMULA 
drop O 
contact O 
on O 
the O 
monolayer O 
show O 
a O 
significant O 
increase O 
( O 
up O 
to O 
1.6 O 
× O 
10(3) O 
times O 
) O 
of O 
the O 
current O 
at O 
low O 
bias O 
after O 
Pb(2+) B-FORMULA 
complexation O 
. O 

genome O 
of O 
influenza O 
A O 
viruses O 
( O 
IAV O 
) O 
is O 
split O 
into O 
eight O 
viral O 
RNAs O 
( O 
vRNAs O 
) O 
that O 
are O 
encapsidated O 
as O 
viral O 
ribonucleoproteins O 
. O 
The O 
existence O 
of O 
a O 
segment-specific O 
packaging O 
mechanism O 
is O 
well O 
established O 
, O 
but O 
the O 
molecular O 
basis O 
of O 
this O 
mechanism O 
remains O 
to O 
be O 
deciphered O 
. O 
Selective O 
packaging O 
could O 
be O 
mediated O 
by O 
direct O 
interaction O 
between O 
the O 
vRNA O 
packaging O 
regions O 
, O 
but O 
such O 
interactions O 
have O 
never O 
been O 
demonstrated O 
in O 
virions O 
. O 
Recently O 
, O 
we O 
showed O 
that O 
the O 
eight O 
vRNAs O 
of O 
a O 
human O 
H3N2 O 
IAV O 
form O 
a O 
single O 
interaction O 
network O 
in O 
vitro O 
that O 
involves O 
regions O 
of O 
the O 
vRNAs O 
known O 
to O 
contain O 
packaging O 
signals O 
in O 
the O 
case O 
of O 
H1N1 O 
IAV O 
strains O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
eight O 
vRNAs O 
of O 
an O 
avian O 
H5N2 O 
IAV O 
also O 
form O 
a O 
single O 
network O 
of O 
interactions O 
in O 
vitro O 
, O 
but O 
, O 
interestingly O 
, O 
the O 
interactions O 
and O 
the O 
regions O 
of O 
the O 
vRNAs O 
they O 
involve O 
differ O 
from O 
those O 
described O 
for O 
the O 
human O 
H3N2 O 
virus O 
. O 
We O 
identified O 
the O 
vRNA O 
sequences O 
involved O 
in O 
five O 
of O 
these O 
interactions O 
at O 
the O 
nucleotide B-FAMILY 
level O 
, O 
and O 
in O 
two O 
cases O 
, O 
we O 
validated O 
the O 
existence O 
of O 
the O 
interaction O 
using O 
compensatory O 
mutations O 
in O 
the O 
interacting O 
sequences O 
. O 
Electron O 
tomography O 
also O 
revealed O 
significant O 
differences O 
in O 
the O 
interactions O 
taking O 
place O 
between O 
viral O 
ribonucleoproteins O 
in O 
H5N2 O 
and O 
H3N2 O 
virions O 
, O 
despite O 
their O 
canonical O 
' O 
7 O 
+ O 
1 O 
' O 
arrangement O 
. O 

of O 
aldehydes B-FAMILY 
by O 
histidine B-TRIVIAL 
-containing O 
dipeptides O 
: O 
from O 
chemistry O 
to O 
clinical O 
implications O 
. O 

are O 
generated O 
by O 
oxidized O 
lipids O 
and O 
carbohydrates B-FAMILY 
at O 
increased O 
levels O 
under O 
conditions O 
of O 
metabolic O 
imbalance O 
and O 
oxidative O 
stress O 
during O 
atherosclerosis O 
, O 
myocardial O 
and O 
cerebral O 
ischemia O 
, O 
diabetes O 
, O 
neurodegenerative O 
diseases O 
and O 
trauma O 
. O 
In O 
most O 
tissues O 
, O 
aldehydes B-FAMILY 
are O 
detoxified O 
by O 
oxidoreductases O 
that O 
catalyze O 
the O 
oxidation O 
or O 
the O 
reduction O 
of O 
aldehydes B-FAMILY 
or O 
enzymatic O 
and O 
nonenzymatic O 
conjugation O 
with O 
low O 
molecular O 
weight O 
thiols B-FAMILY 
and O 
amines B-FAMILY 
, O 
such O 
as O 
glutathione B-TRIVIAL 
and O 
histidine B-TRIVIAL 
dipeptides O 
. O 
Histidine B-TRIVIAL 
dipeptides O 
are O 
present O 
in O 
micromolar O 
to O 
millimolar O 
range O 
in O 
the O 
tissues O 
of O 
vertebrates O 
, O 
where O 
they O 
are O 
involved O 
in O 
a O 
variety O 
of O 
physiological O 
functions O 
such O 
as O 
pH O 
buffering O 
, O 
metal O 
chelation O 
, O 
oxidant O 
and O 
aldehyde B-SYSTEMATIC 
scavenging O 
. O 
Histidine B-TRIVIAL 
dipeptides O 
such O 
as O 
carnosine B-TRIVIAL 
form O 
Michael O 
adducts O 
with O 
lipid O 
- O 
derived O 
unsaturated B-FAMILY 
aldehydes I-FAMILY 
, O 
and O 
react O 
with O 
carbohydrate B-FAMILY 
-derived O 
oxo- B-MULTIPLE 
and I-MULTIPLE 
hydroxy-aldehydes I-MULTIPLE 
forming O 
products O 
of O 
unknown O 
structure O 
. O 
Although O 
these O 
peptides O 
react O 
with O 
electrophilic O 
molecules O 
at O 
lower O 
rate O 
than O 
glutathione B-TRIVIAL 
, O 
they O 
can O 
protect O 
glutathione B-TRIVIAL 
from O 
modification O 
by O 
oxidant O 
and O 
they O 
may O 
be O 
important O 
for O 
aldehyde B-SYSTEMATIC 
quenching O 
in O 
glutathione B-TRIVIAL 
-depleted O 
cells O 
or O 
extracellular O 
space O 
where O 
glutathione B-TRIVIAL 
is O 
scarce O 
. O 
Consistent O 
with O 
in O 
vitro O 
findings O 
, O 
treatment O 
with O 
carnosine B-TRIVIAL 
has O 
been O 
shown O 
to O 
diminish O 
ischemic O 
injury O 
, O 
improve O 
glucose B-TRIVIAL 
control O 
, O 
ameliorate O 
the O 
development O 
of O 
complications O 
in O 
animal O 
models O 
of O 
diabetes O 
and O 
obesity O 
, O 
promote O 
wound O 
healing O 
and O 
decrease O 
atherosclerosis O 
. O 
The O 
protective O 
effects O 
of O 
carnosine B-TRIVIAL 
have O 
been O 
linked O 
to O 
its O 
anti-oxidant O 
properties O 
, O 
its O 
ability O 
to O 
promote O 
glycolysis O 
, O 
detoxify O 
reactive O 
aldehydes B-FAMILY 
and O 
enhance O 
histamine B-TRIVIAL 
levels O 
. O 
Thus O 
, O 
treatment O 
with O 
carnosine B-TRIVIAL 
and O 
related O 
histidine B-TRIVIAL 
dipeptides O 
may O 
be O 
a O 
promising O 
strategy O 
for O 
the O 
prevention O 
and O 
treatment O 
of O 
diseases O 
associated O 
with O 
high O 
carbonyl B-FAMILY 
load O 
. O 

Approaches O 
to O 
RBC O 
Mimicry O 
and O 
Oxygen B-SYSTEMATIC 
Carrier O 
Systems O 
. O 

blood O 
or O 
red O 
blood O 
cell O 
( O 
RBC O 
) O 
transfusions O 
are O 
highly O 
significant O 
, O 
clinically O 
, O 
for O 
blood O 
replacement O 
therapies O 
in O 
traumatic O 
injuries O 
, O 
presurgical O 
conditions O 
, O 
and O 
anemias O 
. O 
However O 
, O 
natural O 
RBC O 
- O 
based O 
products O 
suffer O 
from O 
limited O 
shelf O 
life O 
due O 
to O 
pathological O 
contamination O 
and O 
also O 
present O 
risks O 
of O 
refractoriness O 
, O 
graft O 
- O 
versus O 
- O 
host O 
disease O 
, O 
immunosuppression O 
, O 
and O 
acute O 
lung O 
injury O 
. O 
These O 
issues O 
can O 
be O 
only O 
partially O 
resolved O 
by O 
pathogen O 
reduction O 
technologies O 
, O 
serological O 
blood O 
testing O 
, O 
leukoreduction O 
, O 
and O 
specialized O 
storage O 
; O 
hence O 
, O 
they O 
severely O 
affect O 
the O 
efficacy O 
and O 
safety O 
of O 
the O 
blood O 
products O 
. O 
Consequently O 
, O 
there O 
is O 
a O 
significant O 
interest O 
in O 
synthetic O 
RBC O 
analogues O 
that O 
can O 
mimic O 
its O 
oxygen B-SYSTEMATIC 
-transport O 
properties O 
while O 
allowing O 
convenient O 
manufacture O 
, O 
reproducibility O 
, O 
long O 
shelf O 
life O 
, O 
and O 
reduced O 
biological O 
risks O 
. O 
To O 
this O 
end O 
, O 
the O 
current O 
Review O 
provides O 
a O 
comprehensive O 
description O 
and O 
discussion O 
of O 
the O 
various O 
research O 
approaches O 
and O 
current O 
state O 
- O 
of O 
- O 
the O 
- O 
art O 
in O 
synthetically O 
mimicking O 
RBC's O 
oxygen B-SYSTEMATIC 
-carrying O 
biochemical O 
properties O 
, O 
as O 
well O 
as O 
the O 
biophysical O 
parameters O 
( O 
shape O 
, O 
size O 
and O 
mechanical O 
modulus O 
) O 
that O 
influence O 
RBCs O 
' O 
hemodynamic O 
transport O 
properties O 
in O 
blood O 
flow O 
. O 

: O 
The O 
neurotransmitter O 
dopamine B-TRIVIAL 
plays O 
a O 
key O 
role O 
in O 
cognitive O 
functions O 
that O 
are O 
associated O 
with O 
fronto O 
- O 
striatal O 
circuitry O 
and O 
has O 
been O 
implicated O 
in O 
many O 
neuropsychiatric O 
disorders O 
. O 
However O 
, O 
there O 
is O 
a O 
large O 
variability O 
in O 
the O 
direction O 
and O 
extent O 
of O 
dopaminergic O 
drug O 
effects O 
across O 
individuals O 
. O 
OBJECTIVES O 
: O 
We O 
investigated O 
whether O 
individual O 
differences O 
in O 
dopaminergic O 
drug O 
effects O 
on O 
human O 
fronto O 
- O 
striatal O 
functioning O 
are O 
associated O 
with O 
individual O 
differences O 
in O 
white O 
matter O 
tracts O 
. O 
METHODS O 
: O 
The O 
effects O 
of O 
the O 
dopamine B-TRIVIAL 
receptor O 
agonist O 
bromocriptine B-TRIVIAL 
were O 
assessed O 
using O 
functional O 
magnetic O 
resonance O 
imaging O 
in O 
22 O 
healthy O 
volunteers O 
in O 
a O 
placebo O 
- O 
controlled O 
, O 
double O 
- O 
blind O 
, O 
within O 
- O 
subject O 
design O 
. O 
Human O 
psychopharmacology O 
and O 
functional O 
neuroimaging O 
were O 
combined O 
with O 
functional O 
connectivity O 
analyses O 
and O 
structural O 
connectivity O 
analyses O 
to O 
establish O 
a O 
link O 
between O 
dopaminergic O 
drug O 
effects O 
on O 
fronto O 
- O 
striatal O 
function O 
and O 
fronto O 
- O 
striatal O 
anatomy O 
. O 
RESULTS O 
: O 
We O 
demonstrate O 
that O 
bromocriptine B-TRIVIAL 
alters O 
functional O 
signals O 
associated O 
with O 
attention O 
switching O 
in O 
the O 
basal O 
ganglia O 
. O 
Crucially O 
, O 
individual O 
differences O 
in O 
the O 
drug's O 
effect O 
on O 
these O 
signals O 
could O 
be O 
predicted O 
from O 
individual O 
differences O 
in O 
fronto O 
- O 
striato O 
- O 
thalamic O 
white O 
matter O 
tracts O 
, O 
as O 
indexed O 
by O 
diffusion O 
tensor O 
imaging O 
. O 
Anatomical O 
fronto O 
- O 
striatal O 
connectivity O 
also O 
predicted O 
drug O 
effects O 
on O 
switch O 
- O 
related O 
functional O 
connectivity O 
between O 
the O 
basal O 
ganglia O 
and O 
the O 
prefrontal O 
cortex O 
. O 
CONCLUSIONS O 
: O 
These O 
data O 
reinforce O 
the O 
link O 
between O 
dopamine B-TRIVIAL 
, O 
cognition O 
and O 
the O 
basal O 
ganglia O 
and O 
have O 
implications O 
for O 
the O 
individual O 
tailoring O 
of O 
dopaminergic O 
drug O 
therapy O 
based O 
on O 
anatomical O 
fronto O 
- O 
striatal O 
connection O 
strength O 
. O 

interactions O 
of O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
and O 
oxytetracycline B-SYSTEMATIC 
against O 
various O 
drug O 
resistant O 
Staphylococcus O 
aureus O 
strains O 
in O 
vitro O 
. O 

gallate I-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
, O 
the O 
major O 
catechin B-TRIVIAL 
contained O 
in O 
tea O 
leaves O 
, O 
is O 
known O 
to O 
possess O 
the O 
synergistic O 
anti-staphylococcal O 
activity O 
in O 
combination O 
with O 
various O 
β-lactam B-TRIVIAL 
antibiotics O 
and O 
tetracycline B-FAMILY 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
explored O 
the O 
in O 
vitro O 
combinatory O 
effect O 
of O 
EGCG B-ABBREVIATION 
in O 
combination O 
with O 
oxytetracycline B-SYSTEMATIC 
against O 
eight O 
standard O 
strains O 
and O 
clinical O 
isolates O 
of O 
Staphylococcus O 
aureus O 
, O 
including O 
erythromycin B-TRIVIAL 
, O 
methicillin B-TRIVIAL 
and O 
tetracycline B-FAMILY 
resistant O 
strains O 
. O 
The O 
minimum O 
inhibitory O 
concentrations O 
were O 
determined O 
by O 
the O 
broth O 
microdilution O 
assay O 
and O 
the O 
data O 
were O 
evaluated O 
according O 
to O 
the O 
sum O 
of O 
fractional O 
inhibitory O 
concentrations O 
( O 
∑FIC O 
) O 
. O 
Our O 
results O 
showed O 
synergistic O 
and O 
additive O 
interactions O 
against O 
all O 
S O 
. O 
aureus O 
strains O 
tested O 
( O 
∑FIC O 
0.288-0.631 O 
) O 
, O 
two O 
of O 
which O 
were O 
multidrug O 
resistant O 
. O 
According O 
to O 
our O 
best O 
knowledge O 
, O 
it O 
is O 
the O 
first O 
report O 
on O 
the O 
EGCG B-ABBREVIATION 
synergy O 
with O 
oxytetracycline B-SYSTEMATIC 
. O 
Considering O 
its O 
significant O 
synergistic O 
antimicrobial O 
effect O 
and O 
low O 
toxicity O 
, O 
we O 
suggest O 
EGCG B-ABBREVIATION 
as O 
a O 
promising O 
compound O 
for O 
the O 
development O 
of O 
new O 
anti-staphylococcal O 
formulations O 
. O 

cancer O 
is O 
associated O 
with O 
enhanced O 
cell O 
proliferation O 
due O 
to O 
high O 
concentrations O 
of O 
estrogens B-FAMILY 
, O 
and O 
decreased O 
cell O 
differentiation O 
due O 
to O 
low O 
levels O 
of O 
progesterone B-TRIVIAL 
and O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
. O 
It O 
is O 
also O 
associated O 
with O 
aberrant O 
inflammatory O 
responses O 
and O 
concomitant O 
increased O 
production O 
of O 
prostaglandins B-FAMILY 
. O 
The O 
human O 
members O 
of O 
the O 
aldo O 
- O 
keto O 
reductase O 
1B O 
( O 
AKR1B O 
) O 
subfamily O 
, O 
AKR1B1 O 
and O 
AKR1B10 O 
, O 
have O 
roles O 
in O 
these O 
processes O 
and O 
can O 
thus O 
be O 
implicated O 
in O 
endometrial O 
cancer O 
. O 
To O 
date O 
, O 
there O 
have O 
been O 
no O 
reports O 
on O 
the O 
expression O 
of O 
AKR1B1 O 
in O 
endometrial O 
cancer O 
, O 
while O 
AKR1B10 O 
has O 
only O 
been O 
studied O 
at O 
the O 
cellular O 
level O 
. O 
To O 
evaluate O 
the O 
roles O 
of O 
these O 
AKR1B O 
enzymes O 
, O 
we O 
investigated O 
expression O 
of O 
AKR1B1 O 
and O 
AKR1B10 O 
in O 
47 O 
paired O 
samples O 
of O 
cancerous O 
and O 
adjacent O 
control O 
endometrium O 
at O 
the O 
mRNA O 
and O 
protein O 
levels O 
, O 
by O 
quantitative O 
PCR O 
, O 
Western O 
blotting O 
and O 
immunohistochemistry O 
staining O 
. O 
There O 
were O 
significantly O 
lower O 
mRNA O 
and O 
protein O 
levels O 
of O 
AKR1B1 O 
in O 
cancerous O 
tissues O 
compared O 
to O 
adjacent O 
endometrium O 
. O 
The O 
gene O 
expression O 
of O 
AKR1B10 O 
at O 
the O 
mRNA O 
level O 
was O 
significantly O 
increased O 
, O 
while O 
there O 
were O 
significantly O 
decreased O 
protein O 
levels O 
. O 
Immunohistochemistry O 
revealed O 
that O 
both O 
of O 
these O 
enzymes O 
were O 
present O 
in O 
all O 
of O 
the O 
samples O 
, O 
and O 
are O 
located O 
in O 
epithelial O 
cells O 
of O 
cancerous O 
and O 
control O 
endometrial O 
glands O 
. O 
Elevated O 
levels O 
in O 
adjacent O 
non-cancerous O 
tissues O 
imply O 
that O 
these O 
enzymes O 
are O 
more O 
important O 
in O 
the O 
initiation O 
of O 
endometrial O 
cancer O 
than O 
in O 
its O 
progression O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
on O 
the O 
expression O 
of O 
AKR1B1 O 
and O 
AKR1B10 O 
in O 
endometrial O 
cancer O 
. O 
Further O 
studies O 
are O 
needed O 
to O 
define O 
the O 
precise O 
roles O 
of O 
these O 
enzymes O 
in O 
the O 
pathogenesis O 
of O 
endometrial O 
cancer O 
. O 

- O 
review O 
: O 
Foldosome O 
regulation O 
of O 
androgen B-FAMILY 
receptor O 
action O 
in O 
prostate O 
cancer O 
. O 

hormone I-FAMILY 
receptors O 
play O 
diverse O 
roles O 
in O 
many O 
aspects O 
of O 
human O 
physiology O 
including O 
cell O 
division O 
, O 
apoptosis O 
and O 
homeostasis O 
, O 
tissue O 
differentiation O 
, O 
sexual O 
development O 
and O 
response O 
to O 
stress O 
. O 
These O 
ligand O 
- O 
activated O 
transcription O 
factors O 
require O 
the O 
functional O 
activity O 
of O 
numerous O 
chaperone O 
and O 
chaperone O 
- O 
associated O 
proteins O 
, O 
collectively O 
termed O 
the O 
foldosome O 
, O 
at O 
the O 
crucial O 
step O 
of O 
ligand O 
recognition O 
and O 
binding O 
. O 
Since O 
the O 
initial O 
isolation O 
of O 
foldosome O 
components O 
and O 
pioneering O 
research O 
by O 
Pratt O 
, O 
Toft O 
and O 
colleagues O 
we O 
understand O 
much O 
regarding O 
cytosolic O 
receptor O 
function O 
. O 
The O 
classical O 
view O 
, O 
that O 
the O 
role O 
of O 
foldosome O 
components O 
is O 
restricted O 
to O 
the O 
cytosol O 
, O 
has O 
been O 
modified O 
over O 
recent O 
years O 
by O 
research O 
highlighting O 
additional O 
roles O 
of O 
chaperone O 
proteins O 
in O 
nuclear O 
translocation O 
and O 
target O 
gene O 
expression O 
. O 
Further O 
, O 
dysregulation O 
of O 
chaperone O 
activity O 
and O 
expression O 
has O 
been O 
implicated O 
in O 
various O 
cancers O 
, O 
including O 
breast O 
and O 
prostate O 
cancer O 
. O 
Consequently O 
, O 
the O 
foldosome O 
provides O 
an O 
attractive O 
therapeutic O 
target O 
in O 
steroid B-FAMILY 
hormone I-FAMILY 
receptor O 
- O 
driven O 
malignancies O 
. O 
This O 
review O 
summarises O 
current O 
knowledge O 
of O 
how O 
the O 
foldosome O 
impacts O 
upon O 
androgen B-FAMILY 
receptor O 
signalling O 
, O 
which O 
is O 
the O 
key O 
therapeutic O 
target O 
on O 
prostate O 
cancer O 
, O 
and O 
how O 
foldosome O 
components O 
may O 
be O 
used O 
as O 
biomarkers O 
or O 
therapeutic O 
targets O 
in O 
this O 
disease O 
. O 

organic O 
thin O 
- O 
film O 
transistors O 
( O 
VOTFTs O 
) O 
are O 
promising O 
devices O 
to O 
overcome O 
the O 
transconductance O 
and O 
cut O 
- O 
off O 
frequency O 
restrictions O 
of O 
horizontal O 
organic O 
thin O 
- O 
film O 
transistors O 
. O 
The O 
basic O 
physical O 
mechanisms O 
of O 
VOTFT O 
operation O 
, O 
however O 
, O 
are O 
not O 
well O 
understood O 
and O 
VOTFTs O 
often O 
require O 
complex O 
patterning O 
techniques O 
using O 
self O 
- O 
assembly O 
processes O 
which O 
impedes O 
a O 
future O 
large O 
- O 
area O 
production O 
. O 
In O 
this O 
contribution O 
, O 
high O 
- O 
performance O 
vertical O 
organic O 
transistors O 
comprising O 
pentacene B-SYSTEMATIC 
for O 
p- O 
type O 
operation O 
and O 
C60 B-TRIVIAL 
for O 
n O 
- O 
type O 
operation O 
are O 
presented O 
. O 
The O 
static O 
current-voltage O 
behavior O 
as O 
well O 
as O 
the O 
fundamental O 
scaling O 
laws O 
of O 
such O 
transistors O 
are O 
studied O 
, O 
disclosing O 
a O 
remarkable O 
transistor O 
operation O 
with O 
a O 
behavior O 
limited O 
by O 
injection O 
of O 
charge O 
carriers O 
. O 
The O 
transistors O 
are O 
manufactured O 
by O 
photolithography O 
, O 
in O 
contrast O 
to O 
other O 
VOTFT O 
concepts O 
using O 
self O 
- O 
assembled O 
source O 
electrodes O 
. O 
Fluorinated O 
photoresist O 
and O 
solvent O 
compounds O 
allow O 
for O 
photolithographical O 
patterning O 
directly O 
and O 
strongly O 
onto O 
the O 
organic O 
materials O 
, O 
simplifying O 
the O 
fabrication O 
protocol O 
and O 
making O 
VOTFTs O 
a O 
prospective O 
candidate O 
for O 
future O 
high O 
- O 
performance O 
applications O 
of O 
organic O 
transistors O 
. O 

-catalyzed O 
diastereoselective O 
arylation O 
of O 
tryptophan B-TRIVIAL 
derivatives O 
: O 
total O 
synthesis O 
of O 
(+)-naseseazines B-MULTIPLE 
a I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
. O 

copper B-SYSTEMATIC 
-catalyzed O 
arylation O 
of O 
tryptophan B-TRIVIAL 
derivatives O 
is O 
reported O 
. O 
The O 
reaction O 
proceeds O 
with O 
high O 
site- O 
and O 
diastereoselectivity O 
to O 
provide O 
aryl B-FAMILY 
pyrroloindoline I-FAMILY 
products O 
in O 
one O 
step O 
from O 
simple O 
starting O 
materials O 
. O 
The O 
utility O 
of O 
this O 
transformation O 
is O 
highlighted O 
in O 
the O 
five O 
- O 
step O 
syntheses O 
of O 
the O 
natural O 
products O 
(+)-naseseazine B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
. O 

and O 
extracerebral O 
cholesterol B-TRIVIAL 
metabolism O 
and O 
CSF O 
markers O 
of O 
Alzheimer's O 
disease O 
. O 

disturbances O 
of O 
the O 
cholesterol B-TRIVIAL 
synthesis O 
and O 
metabolism O 
described O 
in O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
may O 
be O 
both O 
a O 
consequence O 
of O 
the O 
neurodegenerative O 
process O 
and O 
a O 
contributor O 
to O 
the O 
pathogenesis O 
. O 
These O 
putative O 
relationships O 
and O 
their O 
underlying O 
mechanisms O 
are O 
not O 
well O 
understood O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
relationship O 
between O 
the O 
cerebral O 
and O 
extracerebral O 
cholesterol B-TRIVIAL 
synthesis O 
and O 
metabolism O 
, O 
and O 
the O 
AD O 
pathology O 
as O 
reflected O 
by O 
CSF O 
markers O 
in O 
humans O 
. O 
We O 
evaluated O 
the O 
relationships O 
between O 
the O 
plasma O 
and O 
the O 
cerebrospinal O 
fluid O 
( O 
CSF O 
) O 
concentrations O 
of O 
cholesterol B-TRIVIAL 
, O 
the O 
cholesterol B-TRIVIAL 
precursors O 
lanosterol B-TRIVIAL 
, O 
lathosterol B-TRIVIAL 
and O 
desmosterol B-TRIVIAL 
, O 
and O 
the O 
cholesterol B-TRIVIAL 
elimination O 
products O 
24S-hydroxycholesterol B-SYSTEMATIC 
and O 
27-hydroxycholesterol B-SYSTEMATIC 
, O 
and O 
the O 
CSF O 
markers O 
for O 
AD O 
pathology O 
Aβ1-42 O 
and O 
p-tau181 O 
in O 
86 O 
subjects O 
with O 
normal O 
cognition O 
and O 
in O 
107 O 
AD O 
patients O 
. O 
CSF O 
desmosterol B-TRIVIAL 
, O 
cholesterol B-TRIVIAL 
and O 
24S-hydroxycholesterol B-SYSTEMATIC 
in O 
the O 
AD O 
group O 
, O 
and O 
CSF O 
24S-hydroxycholesterol B-SYSTEMATIC 
in O 
the O 
control O 
group O 
correlated O 
with O 
the O 
p-tau181 O 
levels O 
. O 
Neither O 
CSF O 
nor O 
plasma O 
concentrations O 
of O 
the O 
included O 
compounds O 
correlated O 
with O 
the O 
CSF O 
Aβ1-42 O 
levels O 
. O 
In O 
multivariate O 
regression O 
tests O 
including O 
age O 
, O 
gender O 
, O 
albumin O 
ratio O 
, O 
number O 
of O 
the O 
APOEɛ4 O 
alleles O 
, O 
and O 
diagnosis O 
, O 
p-tau181 O 
levels O 
independently O 
predicted O 
the O 
CSF O 
desmosterol B-TRIVIAL 
, O 
cholesterol B-TRIVIAL 
and O 
24S-hydroxycholesterol B-SYSTEMATIC 
concentrations O 
. O 
The O 
associations O 
remained O 
significant O 
for O 
CSF O 
cholesterol B-TRIVIAL 
and O 
24S-hydroxycholesterol B-SYSTEMATIC 
when O 
analyses O 
were O 
separately O 
performed O 
in O 
the O 
AD O 
group O 
. O 
The O 
results O 
suggest O 
that O 
alterations O 
of O 
CNS O 
cholesterol B-TRIVIAL 
de O 
novo O 
genesis O 
and O 
metabolism O 
are O 
related O 
to O 
neurodegeneration O 
and O 
in O 
particular O 
to O 
the O 
cerebral O 
accumulation O 
of O 
phosphorylated O 
tau O 
. O 

, O 
antioxidant O 
and O 
characterisation O 
of O 
phenolic B-FAMILY 
compounds O 
in O 
soybeans O 
, O 
flaxseed O 
and O 
olives O 
. O 

distribution O 
of O 
free O 
and O 
bound O 
phenolic B-FAMILY 
compounds O 
present O 
in O 
soybean O 
, O 
flaxseed O 
and O 
olive O 
were O 
investigated O 
. O 
The O 
phenolic B-FAMILY 
compounds O 
were O 
fractionated O 
on O 
the O 
basis O 
on O 
their O 
solubility O 
characteristics O 
in O 
water O 
, O 
alcohol B-FAMILY 
, O 
dilute O 
base O 
and O 
dilute O 
acid O 
. O 
Reversed O 
phase O 
high O 
pressure O 
liquid O 
chromatography O 
( O 
RP-HPLC O 
) O 
and O 
mass O 
spectrometry O 
( O 
MS O 
) O 
were O 
used O 
for O 
identification O 
of O 
individual O 
components O 
of O 
phenolic B-FAMILY 
compounds O 
. O 
Antioxidant O 
activity O 
( O 
AA% O 
) O 
of O 
free O 
and O 
bound O 
phenolic B-FAMILY 
compounds O 
was O 
measured O 
using O 
the O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
/ O 
β-carotene B-TRIVIAL 
assay O 
. O 
The O 
water O 
- O 
soluble O 
phenolic B-FAMILY 
compound O 
fractions O 
represented O 
68-81% O 
, O 
50-72% O 
and O 
46-56% O 
of O 
the O 
total O 
phenolic B-FAMILY 
compounds O 
measured O 
in O 
full O 
- O 
fat O 
soybean O 
, O 
olive O 
and O 
flaxseed O 
, O 
respectively O 
. O 
Methanolic O 
extraction O 
of O 
free O 
phenolic B-FAMILY 
compounds O 
without O 
heat O 
, O 
solubilised O 
21-56% O 
, O 
42-62% O 
and O 
34-51% O 
of O 
the O 
total O 
phenolic B-FAMILY 
compounds O 
measured O 
in O 
soybean O 
, O 
olive O 
and O 
flaxseed O 
, O 
respectively O 
; O 
methanol B-SYSTEMATIC 
extraction O 
of O 
free O 
phenolic B-FAMILY 
compounds O 
with O 
heat O 
solubilised O 
a O 
further O 
24-34% O 
, O 
31-37% O 
and O 
36-37% O 
of O 
phenolic B-FAMILY 
compounds O 
from O 
soybean O 
, O 
olive O 
and O 
flaxseed O 
, O 
respectively O 
. O 
Further O 
dilute O 
alkali O 
and O 
dilute O 
acid O 
solubilised O 
the O 
remaining O 
10-40% O 
, O 
1-21% O 
and O 
12-29% O 
of O 
the O 
total O 
phenolic B-FAMILY 
compounds O 
from O 
soybean O 
, O 
olive O 
and O 
flaxseed O 
, O 
respectively O 
. O 
Results O 
indicated O 
that O 
the O 
full O 
- O 
fat O 
meals O 
of O 
soybean O 
, O 
flaxseed O 
and O 
olive O 
showed O 
higher O 
antioxidant O 
activity O 
compared O 
to O 
defatted O 
meals O 
. O 
RP-HPLC O 
and O 
LC-MS O 
/ O 
MS O 
profil1 O 
for O 
soybean O 
, O 
flaxseed O 
and O 
olive O 
indicate O 
two O 
classes O 
of O 
phenolic B-FAMILY 
compounds O 
designated O 
as O 
free O 
and O 
bound O 
phenolic B-FAMILY 
compounds O 
. O 

chromosomal O 
passenger O 
complex O 
( O 
CPC O 
) O 
acts O 
as O 
a O 
key O 
regulator O 
of O 
mitosis O 
, O 
preventing O 
asymmetric O 
segregation O 
of O 
chromosomal O 
material O 
into O 
daughter O 
cells O 
. O 
The O 
CPC O 
is O 
composed O 
of O 
three O 
non-enzymatic O 
components O 
termed O 
Survivin O 
, O 
the O 
inner O 
centromere O 
protein O 
( O 
INCENP O 
) O 
and O 
Borealin O 
, O 
and O 
an O 
enzymatic O 
component O 
, O 
Aurora O 
B O 
kinase O 
. O 
Survivin O 
is O 
necessary O 
for O 
the O 
appropriate O 
separation O 
of O 
sister O 
chromatids O 
during O 
mitosis O 
and O 
is O 
involved O 
in O 
liver O 
regeneration O 
, O 
but O 
its O 
role O 
in O 
regenerative O 
processes O 
is O 
incompletely O 
elucidated O 
. O 
Whether O 
Survivin O 
, O 
which O 
is O 
classified O 
as O 
an O 
inhibitor O 
of O 
apoptosis O 
protein O 
( O 
IAP O 
) O 
based O 
on O 
domain O 
composition O 
, O 
also O 
has O 
a O 
role O 
in O 
apoptosis O 
is O 
controversial O 
. O 
The O 
present O 
study O 
examined O 
the O 
in O 
vivo O 
effects O 
of O 
Survivin O 
ablation O 
in O 
the O 
liver O 
and O 
during O 
liver O 
regeneration O 
after O 
70% O 
hepatectomy O 
in O 
a O 
hepatocyte O 
- O 
specific O 
knockout O 
mouse O 
model O 
. O 
The O 
absence O 
of O 
Survivin O 
caused O 
a O 
reduction O 
in O 
the O 
number O 
of O 
hepatocytes O 
in O 
the O 
liver O 
, O 
together O 
with O 
an O 
increase O 
in O 
cell O 
volume O 
, O 
macronucleation O 
and O 
polyploidy O 
, O 
but O 
no O 
changes O 
in O 
apoptosis O 
. O 
During O 
liver O 
regeneration O 
, O 
mitosis O 
of O 
hepatocytes O 
was O 
associated O 
with O 
mislocalization O 
of O 
the O 
members O 
of O 
the O 
CPC O 
, O 
which O 
were O 
no O 
longer O 
detectable O 
at O 
the O 
centromere O 
despite O 
an O 
unchanged O 
protein O 
amount O 
. O 
Furthermore O 
, O 
the O 
loss O 
of O 
survivin O 
in O 
regenerating O 
hepatocytes O 
was O 
associated O 
with O 
reduced O 
levels O 
of O 
phosphorylated O 
Histone O 
H3 O 
at O 
serine B-TRIVIAL 
28 O 
and O 
abolished O 
phosphorylation O 
of O 
CENP-A O 
and O 
Hec1 O 
at O 
serine B-TRIVIAL 
55 O 
, O 
which O 
is O 
a O 
consequence O 
of O 
decreased O 
Aurora O 
B O 
kinase O 
activity O 
. O 
These O 
data O 
indicate O 
that O 
Survivin O 
expression O 
determines O 
hepatocyte O 
number O 
during O 
liver O 
development O 
and O 
liver O 
regeneration O 
. O 
Lack O 
of O 
Survivin O 
causes O 
mislocalization O 
of O 
the O 
CPC O 
members O 
in O 
combination O 
with O 
reduced O 
Aurora O 
B O 
activity O 
, O 
leading O 
to O 
impaired O 
phosphorylation O 
of O 
its O 
centromeric O 
target O 
proteins O 
and O 
inappropriate O 
cytokinesis O 
. O 

atomic O 
force O 
microscope O 
( O 
AFM O 
) O 
is O 
a O 
powerful O 
instrument O 
for O 
nanolithography O 
, O 
which O 
is O 
well O 
characterized O 
in O 
air O 
where O 
the O 
deposition O 
process O 
is O 
steered O 
by O 
capillary O 
action O 
. O 
In O 
contrast O 
, O 
AFM O 
patterning O 
has O 
been O 
seldom O 
achieved O 
in O 
liquid O 
, O 
mostly O 
via O 
electrochemical O 
deposition O 
. O 
This O 
study O 
investigates O 
the O 
pressure O 
- O 
controlled O 
local O 
deposition O 
of O 
nanoparticles O 
in O 
a O 
liquid O 
environment O 
using O 
a O 
FluidFM O 
. O 
Fluorescent O 
25 O 
nm O 
polystyrene B-SYSTEMATIC 
nanospheres O 
were O 
chosen O 
as O 
nanoobjects O 
to O 
be O 
dispensed O 
because O 
they O 
enable O 
both O 
the O 
in O 
situ O 
monitoring O 
of O 
the O 
process O 
by O 
optical O 
microscopy O 
and O 
the O 
ex O 
situ O 
high O 
- O 
resolution O 
characterization O 
of O 
the O 
pattern O 
by O 
e.g O 
. O 
scanning O 
electron O 
microscopy O 
. O 
The O 
FluidFM O 
microchannel O 
was O 
filled O 
with O 
an O 
aqueous O 
solution O 
of O 
negatively O 
charged O 
nanoparticles O 
to O 
be O 
delivered O 
onto O 
a O 
glass O 
surface O 
coated O 
with O 
a O 
polycation O 
. O 
An O 
overpressure O 
in O 
the O 
internal O 
fluidic O 
circuit O 
leads O 
to O 
the O 
deposition O 
of O 
nanoparticle O 
dots O 
and O 
lines O 
under O 
the O 
tip O 
, O 
while O 
the O 
force O 
control O 
regulates O 
the O 
contact O 
between O 
the O 
probe O 
and O 
the O 
surface O 
. O 
The O 
nanoparticle O 
adsorption O 
process O 
depends O 
both O 
on O 
applied O 
pressure O 
and O 
contact O 
time O 
( O 
respectively O 
tip O 
velocity O 
) O 
and O 
can O 
be O 
described O 
using O 
the O 
Langmuir O 
approximation O 
for O 
the O 
random O 
sequential O 
adsorption O 
model O 
. O 
Moreover O 
, O 
we O 
observed O 
that O 
the O 
force O 
setpoint O 
, O 
which O 
does O 
not O 
influence O 
the O 
capillary O 
- O 
driven O 
mechanism O 
in O 
air O 
, O 
indeed O 
affects O 
the O 
hydrodynamic O 
resistance O 
at O 
the O 
tip O 
aperture O 
and O 
therefore O 
the O 
volumetric O 
flow O 
. O 
The O 
described O 
method O 
demonstrates O 
the O 
potential O 
of O 
FluidFM O 
in O 
depositing O 
nano O 
- O 
sized O 
objects O 
in O 
liquid O 
with O 
nanometre O 
precision O 
. O 

effects O 
of O 
erythropoietin O 
on O 
astrocytic O 
swelling O 
after O 
oxygen B-SYSTEMATIC 
- O 
glucose B-TRIVIAL 
deprivation O 
and O 
reoxygenation O 
: O 
mediation O 
through O 
AQP4 O 
expression O 
and O 
MAPK O 
pathway O 
. O 

in O 
vivo O 
studies O 
have O 
shown O 
that O 
erythropoietin O 
( O 
EPO O 
) O 
offers O 
strong O 
protection O 
against O 
brain O 
edema O 
. O 
However O 
, O 
the O 
intracellular O 
and O 
molecular O 
mechanisms O 
behind O 
this O 
beneficial O 
effect O 
have O 
not O 
been O 
specified O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
human O 
erythropoietin O 
( O 
rhEPO O 
) O 
reduces O 
the O 
astrocytic O 
swelling O 
created O 
by O 
oxygen B-SYSTEMATIC 
- O 
glucose B-TRIVIAL 
deprivation O 
followed O 
by O 
reoxygenation O 
( O 
OGD O 
/ O 
Reox O 
) O 
in O 
vitro O 
and O 
whether O 
this O 
effect O 
can O 
be O 
mediated O 
through O 
the O 
modulation O 
of O 
aquaporin4 O 
( O 
AQP4 O 
) O 
expression O 
in O 
the O 
plasma O 
membrane O 
( O 
PM O 
) O 
and O 
phosphorylation O 
of O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
pathway O 
( O 
MAPK O 
) O 
pathway O 
. O 
Our O 
results O 
showed O 
that O 
OGD O 
/ O 
Reox O 
produced O 
increase O 
in O 
cell O 
volume O 
, O 
morphological O 
swelling O 
, O 
and O 
mitochondrial O 
swelling O 
. O 
These O 
changes O 
were O 
associated O 
with O 
the O 
up O 
- O 
regulation O 
of O 
AQP4 O 
in O 
PM O 
and O 
the O 
over O 
- O 
activation O 
of O 
MAPK O 
. O 
Silencing O 
AQP4 O 
expression O 
using O 
small O 
interfering O 
ribonucleic O 
acid O 
for O 
AQP4 O 
was O 
found O 
to O 
block O 
astrocytic O 
swelling O 
. O 
Inhibition O 
of O 
the O 
over O 
- O 
activation O 
of O 
MAPK O 
mitigated O 
the O 
PM O 
AQP4 O 
overabundance O 
and O 
cellular O 
swelling O 
. O 
As O 
expected O 
, O 
treatment O 
with O 
rhEPO O 
significantly O 
reduced O 
the O 
OGD O 
/ O 
Reox O 
- O 
induced O 
increase O 
in O 
cell O 
volume O 
, O 
morphological O 
swelling O 
, O 
and O 
mitochondrial O 
swelling O 
as O 
well O 
as O 
the O 
up O 
- O 
regulation O 
of O 
AQP4 O 
in O 
PM O 
. O 
In O 
addition O 
, O 
cultures O 
treated O 
with O 
the O 
neutralizing O 
anti-EPO O 
antibody O 
worsened O 
the O 
PM O 
AQP4 O 
abundance O 
and O 
cellular O 
swelling O 
, O 
abolishing O 
the O 
protective O 
effects O 
mediated O 
by O 
rhEPO O 
treatment O 
. O 
Furthermore O 
, O 
the O 
over O 
- O 
activation O 
of O 
these O 
MAPK O 
after O 
OGD O 
/ O 
Reox O 
was O 
attenuated O 
by O 
rhEPO O 
treatment O 
significantly O 
. O 
In O 
conclusion O 
, O 
our O 
data O 
strongly O 
suggest O 
that O 
rhEPO O 
can O 
protect O 
astrocytes O 
from O 
swelling O 
caused O 
by O 
ischemia O 
and O 
reperfusion O 
- O 
like O 
injury O 
. O 
This O 
neuroprotective O 
capacity O 
is O 
partially O 
mediated O 
by O 
diminishing O 
the O 
MAPK-activity O 
- O 
dependent O 
overabundance O 
of O 
AQP4 O 
in O 
PM O 
. O 

potential O 
of O 
solvent-minimized O 
extraction O 
methods O 
in O 
the O 
determination O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
in O 
fish O 
oils O 
. O 

oil O 
has O 
been O 
identified O 
as O 
one O 
of O 
the O 
most O 
important O 
contributors O 
to O 
the O 
level O 
of O 
Persistent O 
Organic O 
Pollutants O 
( O 
POPs O 
) O 
in O 
feed O 
products O 
. O 
The O 
determination O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
in O 
fish O 
oils O 
is O 
complicated O 
due O 
to O 
the O 
fat O 
matrix O 
, O 
which O 
affects O 
both O 
extraction O 
efficiency O 
and O 
analytical O 
quality O 
. O 
This O 
article O 
reviews O 
and O 
addresses O 
two O 
of O 
the O 
most O 
relevant O 
analytical O 
methods O 
for O 
determining O 
11 O 
mutagenic O 
and O 
carcinogenic O 
PAHs B-ABBREVIATION 
, O 
as O 
well O 
as O 
two O 
EPA O 
indicator O 
PAHs B-ABBREVIATION 
in O 
fish O 
oils O 
. O 
We O 
discuss O 
and O 
critically O 
evaluate O 
two O 
different O 
extraction O 
procedures O 
, O 
such O 
as O 
ultrasound O 
- O 
assisted O 
solvent O 
extraction O 
( O 
USAE O 
) O 
and O 
ultrasound O 
- O 
assisted O 
emulsification O 
- O 
microextraction O 
( O 
USAEME O 
) O 
. O 
Clean O 
- O 
up O 
of O 
extracts O 
was O 
performed O 
by O 
solid O 
- O 
phase O 
extraction O 
using O 
C18 O 
and O 
glass O 
columns O 
containing O 
silica B-TRIVIAL 
gel I-TRIVIAL 
and O 
florisil B-TRIVIAL 
for O 
USAE O 
or O 
only O 
C18 O 
for O 
USAEME O 
. O 
Detection O 
of O 
the O 
selected O 
PAHs B-ABBREVIATION 
was O 
carried O 
out O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
fluorescence O 
detection O 
for O 
determination O 
. O 
Optimization O 
of O 
the O 
variables O 
affecting O 
extraction O 
by O 
the O 
selected O 
extraction O 
techniques O 
was O 
conducted O 
and O 
recoveries O 
ranged O 
from O 
70% O 
to O 
100% O 
by O 
USAE O 
and O 
from O 
70% O 
to O 
108% O 
by O 
USAEME O 
with O 
estimated O 
quantification O 
limits O 
between O 
0.02 O 
and O 
2.6μg O 
/ O 
kg O 
were O 
achieved O 
. O 
Moreover O 
, O 
the O 
applicability O 
of O 
the O 
selected O 
methods O 
was O 
evaluated O 
by O 
the O 
analysis O 
of O 
real O 
samples O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
time O 
that O 
USAEME O 
has O 
been O 
applied O 
to O 
the O 
determination O 
of O 
PAHs B-ABBREVIATION 
in O 
food O 
matrices O 
, O 
such O 
as O 
oil O 
fish O 
samples O 
. O 
The O 
methods O 
proposed O 
were O 
applied O 
to O 
the O 
determination O 
of O 
the O 
target O 
PAHs B-ABBREVIATION 
in O 
fish O 
samples O 
from O 
different O 
countries O 
, O 
and O 
it O 
was O 
found O 
that O 
the O 
low O 
PAH B-ABBREVIATION 
contamination O 
of O 
the O 
selected O 
fish O 
oils O 
could O 
mainly O 
occur O 
by O 
atmospheric O 
sources O 
. O 

and O 
biological O 
evaluation O 
of O 
analogues O 
of O 
the O 
kinase O 
inhibitor O 
nilotinib B-TRIVIAL 
as O 
Abl O 
and O 
Kit O 
inhibitors O 
. O 

importance O 
of O 
the O 
trifluoromethyl B-SYSTEMATIC 
group O 
in O 
the O 
polypharmacological O 
profile O 
of O 
nilotinib B-TRIVIAL 
was O 
investigated O 
. O 
Molecular O 
editing O 
of O 
nilotinib B-TRIVIAL 
led O 
to O 
the O 
design O 
, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
analogues O 
where O 
the O 
trifluoromethyl B-SYSTEMATIC 
group O 
was O 
replaced O 
by O 
a O 
proton O 
, O 
fluorine B-SYSTEMATIC 
and O 
a O 
methyl B-SYSTEMATIC 
group O 
. O 
While O 
these O 
analogues O 
were O 
less O 
active O 
than O 
nilotinib B-TRIVIAL 
toward O 
Abl O 
, O 
their O 
activity O 
toward O 
Kit O 
was O 
comparable O 
, O 
with O 
the O 
monofluorinated O 
analogue O 
being O 
the O 
most O 
active O 
. O 
Docking O 
of O 
nilotinib B-TRIVIAL 
and O 
of O 
analogues O 
2a-c O 
to O 
the O 
binding O 
pocket O 
of O 
Abl O 
and O 
of O 
Kit O 
showed O 
that O 
the O 
lack O 
of O 
shape O 
complementarity O 
in O 
Kit O 
is O 
compensated O 
by O 
the O 
stabilizing O 
effect O 
from O 
its O 
juxtamembrane O 
region O 
. O 

exposure O 
to O 
paclobutrazol B-TRIVIAL 
causes O 
hepatic O 
steatosis O 
in O 
male O 
rockfish O 
Sebastiscus O 
marmoratus O 
and O 
the O 
mechanism O 
involved O 
. O 

( O 
PBZ B-ABBREVIATION 
) O 
is O 
a O 
triazole B-FAMILY 
-containing O 
fungicide O 
which O 
is O 
widely O 
used O 
in O 
agriculture O 
. O 
Acute O 
toxicity O 
can O 
follow O 
its O 
extensive O 
use O 
but O 
it O 
is O 
generally O 
weaker O 
than O 
traditional O 
pesticides O 
such O 
as O 
organochlorine B-FAMILY 
and O 
organophosphorus B-FAMILY 
. O 
However O 
, O 
its O 
adverse O 
effects O 
on O 
aquatic O 
organisms O 
need O 
to O 
be O 
investigated O 
. O 
This O 
study O 
was O 
conducted O 
to O 
investigate O 
the O 
effect O 
of O 
PBZ B-ABBREVIATION 
exposure O 
on O 
the O 
hepatic O 
lipid O 
metabolism O 
of O 
Sebastiscus O 
marmoratus O 
. O 
After O 
PBZ B-ABBREVIATION 
exposure O 
for O 
50 O 
days O 
, O 
hepatic O 
lipid O 
droplets O 
were O 
enlarged O 
and O 
the O 
hepatic O 
total O 
lipid O 
, O 
triglyceride B-FAMILY 
, O 
total O 
cholesterol B-TRIVIAL 
and O 
free B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
content O 
had O 
increased O 
in O 
a O 
dose O 
dependent O 
manner O 
compared O 
to O 
the O 
control O 
. O 
The O 
mRNA O 
expression O 
of O 
lipid O 
metabolism O 
associated O 
genes O 
such O 
as O 
peroxisome O 
proliferator O 
- O 
activated O 
receptors O 
( O 
PPARs O 
) O 
, O 
androgen B-FAMILY 
receptor O 
, O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
1 O 
, O 
fatty B-FAMILY 
acid I-FAMILY 
synthesis O 
, O 
fatty B-FAMILY 
acid I-FAMILY 
bing O 
protein O 
4 O 
, O 
liver O 
X O 
receptor O 
α O 
( O 
LXRα O 
) O 
and O 
stearoyl-CoA B-TRIVIAL 
desaturase O 
were O 
up O 
- O 
regulated O 
by O 
PBZ B-ABBREVIATION 
exposure O 
. O 
These O 
results O 
indicated O 
that O 
triazole B-FAMILY 
-containing O 
fungicides O 
might O 
affect O 
the O 
metabolism O 
and O 
health O 
of O 
fish O 
via O 
the O 
multi O 
- O 
signal O 
pathways O 
of O 
nuclear O 
receptors O 
such O 
as O 
PPARs O 
and O 
LXR O 
. O 

demonstrate O 
an O 
innovative O 
technique O 
for O 
the O 
direct O 
measurement O 
on O 
the O 
shear O 
modulus O 
of O 
an O 
individual O 
nanorod O 
. O 
This O 
measurement O 
is O 
based O 
on O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
and O 
microfabrication O 
techniques O 
. O 
A O 
nanorod O 
is O 
first O 
aligned O 
along O 
the O 
edge O 
of O 
a O 
small O 
trench O 
in O 
a O 
silicon B-SYSTEMATIC 
substrate O 
, O 
and O 
then O 
one O 
end O 
of O 
the O 
nanorod O 
is O 
fixed O 
on O 
the O 
substrate O 
. O 
When O 
an O 
AFM O 
tip O 
scans O 
over O 
the O 
nanorod O 
in O 
contact O 
mode O 
, O 
the O 
nanorod O 
will O 
be O 
twisted O 
by O 
the O 
comprehensive O 
action O 
from O 
the O 
force O 
of O 
the O 
AFM O 
tip O 
, O 
confinement O 
from O 
the O 
trench O 
edge O 
and O 
the O 
fixing O 
end O 
. O 
The O 
shear O 
deformation O 
and O 
the O 
corresponding O 
force O 
that O 
caused O 
the O 
deformation O 
can O 
be O 
retrieved O 
from O 
topography O 
and O 
lateral O 
force O 
image O 
, O 
respectively O 
. O 
By O 
small O 
- O 
angle O 
approximation O 
, O 
the O 
shear O 
modulus O 
of O 
the O 
ZnO B-FORMULA 
NR O 
, O 
which O 
has O 
a O 
radius O 
of O 
166 O 
nm O 
and O 
a O 
length O 
of O 
4 O 
μm O 
, O 
is O 
measured O 
to O 
be O 
8.1 O 
± O 
1.9 O 
GPa O 
. O 
This O 
method O 
can O 
be O 
applied O 
directly O 
to O 
characterize O 
the O 
shear O 
modulus O 
of O 
any O 
nanowire O 
/ O 
nanorod O 
that O 
possesses O 
a O 
polygon O 
cross O 
section O 
. O 

of O 
airway O 
obstruction O 
in O 
response O 
to O 
β2-agonists O 
is O 
highly O 
variable O 
among O 
asthmatics O 
, O 
which O 
is O 
partially O 
attributed O 
to O 
genetic O 
factors O 
. O 
In O 
a O 
genome O 
- O 
wide O 
association O 
study O 
of O 
acute O 
bronchodilator O 
response O 
( O 
BDR O 
) O 
to O 
inhaled O 
albuterol B-TRIVIAL 
, O 
534 O 
290 O 
single- O 
nucleotide B-FAMILY 
polymorphisms O 
( O 
SNPs O 
) O 
were O 
tested O 
in O 
403 O 
white O 
trios O 
from O 
the O 
Childhood O 
Asthma O 
Management O 
Program O 
using O 
five O 
statistical O 
models O 
to O 
determine O 
the O 
most O 
robust O 
genetic O 
associations O 
. O 
The O 
primary O 
replication O 
phase O 
included O 
1397 O 
polymorphisms O 
in O 
three O 
asthma O 
trials O 
( O 
pooled O 
n=764 O 
) O 
. O 
The O 
second O 
replication O 
phase O 
tested O 
13 O 
SNPs O 
in O 
three O 
additional O 
asthma O 
populations O 
( O 
n=241 O 
, O 
n=215 O 
and O 
n=592 O 
) O 
. O 
An O 
intergenic O 
SNP O 
on O 
chromosome O 
10 O 
, O 
rs11252394 O 
, O 
proximal O 
to O 
several O 
excellent O 
biological O 
candidates O 
, O 
significantly O 
replicated O 
( O 
P=1.98 O 
× O 
10(-7) O 
) O 
in O 
the O 
primary O 
replication O 
trials O 
. O 
An O 
intronic O 
SNP O 
( O 
rs6988229 O 
) O 
in O 
the O 
collagen O 
( O 
COL22A1 O 
) O 
locus O 
also O 
provided O 
strong O 
replication O 
signals O 
( O 
P=8.51 O 
× O 
10(-6) O 
) O 
. O 
This O 
study O 
applied O 
a O 
robust O 
approach O 
for O 
testing O 
the O 
genetic O 
basis O 
of O 
BDR O 
and O 
identified O 
novel O 
loci O 
associated O 
with O 
this O 
drug O 
response O 
in O 
asthmatics.The O 
Pharmacogenomics O 
Journal O 
advance O 
online O 
publication O 
, O 
19 O 
March O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
tpj.2013.5 O 
. O 

interactions O 
have O 
been O 
systematically O 
studied O 
using O 
tetraoxacalix[2]arene[2]triazine B-SYSTEMATIC 
1 O 
, O 
an O 
electron O 
- O 
deficient O 
and O 
cavity O 
self O 
- O 
tunable O 
macrocyclic O 
host O 
, O 
as O 
an O 
electron O 
- O 
neutral O 
molecular O 
probe O 
. O 
As O 
revealed O 
by O 
electrospray O 
ionization O 
mass O 
spectrometry O 
( O 
ESI-MS O 
) O 
, O 
fluorescence O 
titration O 
and O 
X-ray O 
crystallography O 
, O 
tetraoxacalix[2]arene[2]triazine B-SYSTEMATIC 
has O 
been O 
found O 
to O 
form O 
1 O 
: O 
1 O 
complexes O 
with O 
four O 
typical O 
polyatomic O 
anions O 
of O 
different O 
geometries O 
and O 
shapes O 
in O 
the O 
gaseous O 
phase O 
, O 
in O 
solution O 
, O 
and O 
in O 
the O 
solid O 
state O 
. O 
The O 
association O 
constants O 
for O 
the O 
formation O 
of O 
anion-π O 
complexes O 
in O 
acetonitrile B-SYSTEMATIC 
are O 
in O 
the O 
range O 
of O 
239 O 
to O 
16950 O 
M(-1) O 
, O 
following O 
the O 
order O 
of O 
1· O 
NO(3)(-) B-FORMULA 
> O 
1· O 
BF(4)(-) B-FORMULA 
> O 
1· O 
PF(6)(-) B-FORMULA 
> O 
1· O 
SCN(-) B-FORMULA 
. O 
X-ray O 
molecular O 
structures O 
of O 
the O 
complexes O 
showed O 
that O 
two O 
opposing O 
triazine B-FAMILY 
rings O 
of O 
tetraoxacalix[2]arene[2]triazine B-SYSTEMATIC 
act O 
as O 
a O 
pair O 
of O 
tweezers O 
to O 
interact O 
with O 
the O 
included O 
anions O 
through O 
cooperative O 
anion-π O 
and O 
lone O 
- O 
pair O 
electron-π O 
interactions O 
. O 
The O 
generality O 
of O 
anion-π O 
interactions O 
and O 
diverse O 
anion-π O 
interaction O 
motifs O 
can O 
provide O 
a O 
new O 
dimension O 
in O 
the O 
study O 
of O 
molecular O 
recognition O 
and O 
self O 
- O 
assembly O 
. O 
Moreover O 
, O 
this O 
study O 
potentiates O 
the O 
effect O 
of O 
anion-π O 
interactions O 
in O 
chemical O 
and O 
biological O 
systems O 
, O 
especially O 
those O 
involving O 
anion O 
and O 
electron O 
- O 
deficient O 
aromatic O 
species O 
. O 

perovskite B-TRIVIAL 
nanoparticles O 
for O 
high O 
efficiency O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

synthesis O 
of O 
highly O 
crystalline O 
perovskite B-TRIVIAL 
BaSnO3 B-FORMULA 
nanoparticles O 
for O 
use O 
as O 
photoanode O 
materials O 
in O 
dye O 
- O 
sensitized O 
solar O 
cells O 
( O 
DSSCs O 
) O 
is O 
reported O 
, O 
and O 
the O 
photovoltaic O 
properties O 
of O 
DSSCs O 
based O 
on O 
BaSnO3 B-FORMULA 
nanoparticles O 
( O 
BaSnO3 B-FORMULA 
cells O 
) O 
are O 
demonstrated O 
. O 
The O 
resulting O 
DSSCs O 
exhibit O 
remarkably O 
rapid O 
charge O 
collection O 
and O 
a O 
DSSC O 
fabricated O 
with O 
a O 
BaSnO3 B-FORMULA 
film O 
thickness O 
of O 
43 O 
µm O 
leads O 
to O 
a O 
high O 
energy O 
conversion O 
efficiency O 
of O 
5.2 O 
% O 
, O 
which O 
is O 
one O 
of O 
the O 
highest O 
reported O 
for O 
ternary B-SYSTEMATIC 
oxide I-SYSTEMATIC 
-based O 
DSSCs O 
. O 
More O 
importantly O 
, O 
the O 
BaSnO3 B-FORMULA 
cells O 
show O 
superior O 
charge O 
collection O 
in O 
nanoparticle O 
films O 
compared O 
to O 
TiO2 B-FORMULA 
cells O 
and O 
could O 
offer O 
a O 
breakthrough O 
in O 
the O 
efficiencies O 
of O 
DSSCs O 
. O 

social O 
behavior O 
in O 
chicks O 
exposed O 
to O 
sodium B-SYSTEMATIC 
valproate I-SYSTEMATIC 
during O 
the O 
last O 
week O 
of O 
embryogenesis O 
. O 

AND O 
OBJECTIVES O 
: O 
To O 
evaluate O 
direct O 
exposure O 
to O 
sodium B-SYSTEMATIC 
valproate I-SYSTEMATIC 
( O 
VPA B-ABBREVIATION 
) O 
during O 
embryogenesis O 
, O 
we O 
administered O 
VPA B-ABBREVIATION 
to O 
chick O 
embryos O 
and O 
examined O 
their O 
social O 
behaviors O 
after O 
hatching O 
. O 
METHODS O 
AND O 
RESULTS O 
: O 
Embryos O 
treated O 
with O 
VPA B-ABBREVIATION 
( O 
35 O 
μmol O 
/ O 
egg O 
) O 
on O 
day O 
14 O 
were O 
similar O 
to O 
controls O 
for O 
hatching O 
date O 
( O 
day O 
21 O 
) O 
and O 
hatchlings O 
' O 
abilities O 
, O 
such O 
as O 
motor O 
, O 
imprinting O 
, O 
and O 
surface O 
righting O 
. O 
However O 
, O 
these O 
VPA B-ABBREVIATION 
chicks O 
on O 
posthatching O 
day O 
3 O 
scored O 
significantly O 
low O 
in O 
the O 
chick's O 
social O 
separation O 
stress O 
( O 
SSS O 
) O 
test O 
as O 
follows O 
. O 
Aggregation O 
test O 
evaluated O 
the O 
speed O 
of O 
four O 
chicks O 
, O 
individually O 
isolated O 
by O 
a O 
cardboard O 
in O 
a O 
box O 
, O 
to O 
aggregate O 
upon O 
removal O 
of O 
the O 
cardboards O 
. O 
Belongingness O 
test O 
evaluated O 
the O 
speed O 
of O 
a O 
chick O 
isolated O 
at O 
a O 
corner O 
to O 
join O 
the O 
group O 
of O 
three O 
chicks O 
placed O 
at O 
the O 
opposite O 
corner O 
. O 
Vocalization O 
test O 
for O 
each O 
chick O 
was O 
performed O 
in O 
an O 
isolated O 
corner O 
by O 
using O 
a O 
sound O 
level O 
meter O 
. O 
The O 
results O 
demonstrated O 
that O 
compared O 
with O 
controls O 
, O 
VPA B-ABBREVIATION 
chicks O 
were O 
significantly O 
slow O 
in O 
aggregation O 
( O 
12.7 O 
± O 
2.5 O 
s O 
vs O 
. O 
2.9 O 
± O 
0.9 O 
s O 
, O 
p O 
= O 
0.006 O 
) O 
and O 
belongingness O 
( O 
3.6 O 
± O 
0.28 O 
s O 
/ O 
40 O 
cm O 
vs O 
. O 
2.6 O 
± O 
0.14 O 
s O 
/ O 
40 O 
cm O 
, O 
P O 
= O 
0.003 O 
) O 
and O 
weak O 
in O 
vocalization O 
( O 
13.4 O 
± O 
2.8 O 
dB O 
/ O 
30 O 
s O 
vs O 
. O 
26.7 O 
± O 
1.3 O 
dB O 
/ O 
30 O 
s O 
, O 
P O 
= O 
0.001 O 
) O 
, O 
respectively O 
. O 
Weight O 
of O 
cerebellum O 
of O 
VAP B-ABBREVIATION 
chick O 
was O 
15 O 
% O 
lighter O 
than O 
controls O 
( O 
P O 
= O 
0.004 O 
) O 
. O 
CONCLUSIONS O 
: O 
Chick O 
embryos O 
exposed O 
to O 
VPA B-ABBREVIATION 
during O 
the O 
last O 
week O 
of O 
embryogenesis O 
had O 
impaired O 
social O 
behaviors O 
in O 
spite O 
of O 
normal O 
mortar O 
and O 
imprinting O 
ability O 
. O 
The O 
present O 
method O 
will O 
be O 
a O 
useful O 
animal O 
model O 
for O 
assessing O 
the O 
effects O 
of O 
environment O 
during O 
embryogenesis O 
on O 
social O 
behaviors O 
in O 
later O 
life O 
. O 

activation O 
of O 
the O 
tyrosine B-TRIVIAL 
kinases O 
Lck O 
and O 
ZAP-70 O 
initiates O 
signaling O 
downstream O 
of O 
the O 
T-cell O 
receptor O 
. O 
We O 
had O 
previously O 
reported O 
the O 
structure O 
of O 
an O 
autoinhibited O 
ZAP-70 O 
variant O 
in O 
which O 
two O 
regulatory O 
tyrosine B-TRIVIAL 
residues O 
( O 
315 O 
and O 
319 O 
) O 
in O 
the O 
SH2-kinase O 
linker O 
were O 
replaced O 
by O 
phenylalanine B-TRIVIAL 
. O 
We O 
now O 
present O 
the O 
crystal O 
structure O 
of O 
ZAP-70 O 
in O 
which O 
Tyr B-FORMULA 
315 O 
and O 
Tyr B-FORMULA 
319 O 
are O 
not O 
mutated O 
, O 
leading O 
to O 
the O 
recognition O 
of O 
a O 
five O 
- O 
residue O 
sequence O 
register O 
error O 
in O 
the O 
SH2-kinase O 
linker O 
of O 
the O 
original O 
crystallographic O 
model O 
. O 
The O 
revised O 
model O 
identifies O 
distinct O 
roles O 
for O 
these O 
two O 
tyrosines B-FAMILY 
. O 
As O 
seen O 
in O 
a O 
recently O 
reported O 
structure O 
of O 
the O 
related O 
tyrosine B-TRIVIAL 
kinase O 
Syk O 
, O 
Tyr B-FORMULA 
315 O 
of O 
ZAP-70 O 
is O 
part O 
of O 
a O 
hydrophobic O 
interface O 
between O 
the O 
regulatory O 
apparatus O 
and O 
the O 
kinase O 
domain O 
, O 
and O 
the O 
integrity O 
of O 
this O 
interface O 
would O 
be O 
lost O 
upon O 
engagement O 
of O 
doubly O 
- O 
phosphorylated O 
peptides O 
by O 
the O 
SH2 O 
domains O 
. O 
Tyr B-FORMULA 
319 O 
is O 
not O 
necessarily O 
dislodged O 
by O 
SH2 O 
engagement O 
, O 
which O 
activates O 
ZAP-70 O 
by O 
only O 
∼5-fold O 
in O 
vitro O 
. O 
In O 
contrast O 
, O 
phosphorylation O 
by O 
Lck O 
activates O 
ZAP-70 O 
by O 
∼100-fold O 
. O 
This O 
difference O 
is O 
due O 
to O 
the O 
ability O 
of O 
Tyr B-FORMULA 
319 O 
to O 
suppress O 
ZAP-70 O 
activity O 
even O 
when O 
the O 
SH2 O 
domains O 
are O 
dislodged O 
from O 
the O 
kinase O 
domain O 
, O 
providing O 
stringent O 
control O 
of O 
ZAP-70 O 
activity O 
downstream O 
of O 
Lck O 
. O 

Investigation O 
of O 
Generator-Collector O 
Microwell O 
Arrays O 
for O 
Improving O 
Electroanalytical O 
Selectivity O 
: O 
Application O 
to O 
Selective O 
Dopamine B-TRIVIAL 
Detection O 
in O 
the O 
Presence O 
of O 
Ascorbic B-TRIVIAL 
Acid I-TRIVIAL 
. O 

generator O 
- O 
collector O 
assemblies O 
consisting O 
of O 
an O 
array O 
of O 
recessed O 
disks O 
( O 
generator O 
electrodes O 
) O 
with O 
a O 
gold O 
layer O 
( O 
collector O 
electrode O 
) O 
deposited O 
over O 
the O 
top O 
- O 
plane O 
insulator O 
reportedly O 
allow O 
increased O 
selectivity O 
and O 
sensitivity O 
during O 
electrochemical O 
detection O 
of O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
in O 
the O 
presence O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
, O 
a O 
situation O 
which O 
is O 
frequently O 
encountered O 
. O 
In O 
sensor O 
design O 
, O 
the O 
potential O 
of O 
the O 
disk O 
electrodes O 
is O 
set O 
to O 
the O 
wave O 
plateau O 
of O 
DA O 
, O 
whereas O 
the O 
plane O 
electrode O 
is O 
biased O 
at O 
the O 
irreversible O 
wave O 
plateau O 
of O 
AA O 
before O 
the O 
onset O 
of O 
the O 
DA O 
oxidation O 
wave O 
. O 
Thus O 
, O 
AA O 
is O 
scavenged O 
but O 
DA O 
is O 
allowed O 
to O 
enter O 
the O 
nanocavities O 
to O 
be O 
oxidized O 
at O 
the O 
disk O 
electrodes O 
, O 
and O 
its O 
signal O 
is O 
further O 
amplified O 
by O 
redox O 
cycling O 
between O 
disk O 
and O 
plane O 
electrodes O 
. O 
Several O 
different O 
theoretical O 
approaches O 
are O 
elaborated O 
herein O 
to O 
analyze O 
the O 
behavior O 
of O 
the O 
system O 
, O 
and O 
their O 
conclusions O 
are O 
successfully O 
tested O 
by O 
experiments O 
. O 
This O 
reveals O 
the O 
crucial O 
role O 
of O 
the O 
plane O 
- O 
electrode O 
area O 
which O 
screens O 
access O 
to O 
the O 
recessed O 
disks O 
( O 
i.e O 
. O 
acts O 
as O 
a O 
diffusional O 
Faraday O 
cage O 
) O 
and O 
simultaneously O 
contributes O 
to O 
amplification O 
of O 
the O 
analyte O 
signal O 
through O 
positive O 
feedback O 
, O 
as O 
occurs O 
in O 
interdigitated O 
arrays O 
and O 
scanning O 
electrochemical O 
microscopy O 
. O 
Simulations O 
also O 
allow O 
for O 
the O 
evaluation O 
of O 
the O 
benefits O 
of O 
different O 
geometries O 
inspired O 
by O 
the O 
above O 
design O 
and O 
different O 
operating O 
modes O 
for O 
increasing O 
the O 
sensor O 
performance O 
. O 

analyte O 
signal O 
standard O 
addition O 
method O 
for O 
simultaneous O 
determination O 
of O 
sulphadiazine B-TRIVIAL 
and O 
trimethoprim B-TRIVIAL 
in O 
bovine O 
milk O 
and O 
veterinary O 
medicines O 
. O 

analyte O 
signal O 
standard O 
addition O 
method O 
has O 
been O 
used O 
for O 
the O 
simultaneous O 
determination O 
of O 
sulphadiazine B-TRIVIAL 
and O 
trimethoprim B-TRIVIAL 
by O 
spectrophotometry O 
in O 
some O 
bovine O 
milk O 
and O 
veterinary O 
medicines O 
. O 
The O 
method O 
combines O 
the O 
advantages O 
of O 
standard O 
addition O 
method O 
with O 
the O 
net O 
analyte O 
signal O 
concept O 
which O 
enables O 
the O 
extraction O 
of O 
information O 
concerning O 
a O 
certain O 
analyte O 
from O 
spectra O 
of O 
multi O 
- O 
component O 
mixtures O 
. O 
This O 
method O 
has O 
some O 
advantages O 
such O 
as O 
the O 
use O 
of O 
a O 
full O 
spectrum O 
realisation O 
, O 
therefore O 
it O 
does O 
not O 
require O 
calibration O 
and O 
prediction O 
step O 
and O 
only O 
a O 
few O 
measurements O 
require O 
for O 
the O 
determination O 
. O 
Cloud O 
point O 
extraction O 
based O 
on O 
the O 
phenomenon O 
of O 
solubilisation O 
used O 
for O 
extraction O 
of O 
sulphadiazine B-TRIVIAL 
and O 
trimethoprim B-TRIVIAL 
in O 
bovine O 
milk O 
. O 
It O 
is O 
based O 
on O 
the O 
induction O 
of O 
micellar O 
organised O 
media O 
by O 
using O 
Triton B-TRIVIAL 
X-100 I-TRIVIAL 
as O 
an O 
extraction O 
solvent O 
. O 
At O 
the O 
optimum O 
conditions O 
, O 
the O 
norm O 
of O 
NAS O 
vectors O 
increased O 
linearly O 
with O 
concentrations O 
in O 
the O 
range O 
of O 
1.0-150.0 O 
μmolL(-1) O 
for O 
both O 
sulphadiazine B-TRIVIAL 
and O 
trimethoprim B-TRIVIAL 
. O 
The O 
limits O 
of O 
detection O 
( O 
LOD O 
) O 
for O 
sulphadiazine B-TRIVIAL 
and O 
trimethoprim B-TRIVIAL 
were O 
0.86 O 
and O 
0.92 O 
μmolL(-1) O 
, O 
respectively O 
. O 

manufacturing O 
processes O 
in O 
chip O 
industries O 
are O 
complex O 
, O 
and O 
many O 
kinds O 
of O 
raw O 
materials O 
and O 
solvents O 
of O 
different O 
nature O 
are O 
used O 
, O 
most O 
of O 
which O 
are O 
highly O 
toxic O 
and O 
dangerous O 
. O 
During O 
the O 
machine O 
preventive O 
maintenance O 
period O 
, O 
these O 
toxic O 
and O 
harmful O 
substances O 
will O 
escape O 
from O 
the O 
sealed O 
reaction O 
chamber O 
to O 
the O 
clean O 
workshop O 
environment O 
and O 
endanger O 
the O 
health O 
of O 
the O 
workers O 
on O 
- O 
site O 
, O 
resulting O 
in O 
occupational O 
diseases O 
. O 
From O 
the O 
perspective O 
of O 
prevention O 
, O 
the O 
spread O 
and O 
prediction O 
of O 
hydrochloric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HCl B-FORMULA 
) O 
that O 
escaped O 
from O 
the O 
metal O 
- O 
etching O 
chamber O 
during O 
maintenance O 
were O 
studied O 
in O 
this O 
article O 
. O 
The O 
computational O 
fluid O 
dynamics O 
technology O 
was O 
used O 
for O 
a O 
three O 
- O 
dimensional O 
numerical O 
simulation O 
of O 
the O 
indoor O 
air O 
velocity O 
field O 
and O 
the O 
HCl B-FORMULA 
concentration O 
field O 
, O 
and O 
the O 
simulation O 
results O 
were O 
then O 
compared O 
with O 
the O 
on O 
- O 
site O 
monitoring O 
data O 
to O 
verify O 
the O 
correctness O 
and O 
feasibility O 
. O 
The O 
occupational O 
hazards O 
and O 
control O 
measures O 
were O 
analyzed O 
based O 
on O 
the O 
numerical O 
simulation O 
, O 
and O 
the O 
optimal O 
control O 
measure O 
was O 
obtained O 
. O 
In O 
this O 
article O 
, O 
using O 
the O 
method O 
of O 
ambient O 
air O 
to O 
analyze O 
the O 
occupational O 
exposure O 
can O 
provide O 
a O 
new O 
idea O 
to O 
the O 
field O 
of O 
occupational O 
health O 
research O 
in O 
the O 
integrated O 
circuit O 
industry O 
and O 
had O 
theoretical O 
and O 
practical O 
significance O 
. O 

is O 
a O 
delicious O 
subtropical O 
fruit O 
with O 
great O 
health O 
- O 
beneficial O 
effects O 
. O 
It O 
has O 
been O 
utilised O 
for O 
disease O 
prevention O 
and O 
health O 
care O 
since O 
ancient O 
age O 
. O 
To O 
explore O 
the O 
chemicals O 
responsible O 
for O 
the O 
health O 
benefits O 
, O 
water O 
- O 
soluble O 
polysaccharides O 
were O 
extracted O 
from O 
longan O 
flesh O 
in O 
this O 
work O 
. O 
A O 
pure O 
polysaccharide O 
( O 
LPS1 O 
) O 
was O 
obtained O 
through O 
column O 
purification O 
. O 
Analysis O 
by O 
gas O 
chromatography O 
showed O 
LPS1 O 
was O 
a O 
homopolysaccharide O 
of O 
glucose B-TRIVIAL 
with O 
glycosidic O 
linkage O 
of O 
→6)-D-Glc-(1→ O 
. O 
Nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
spectra O 
indicated O 
that O 
the O 
conﬁguration O 
of O 
anomeric O 
carbon B-SYSTEMATIC 
in O 
glucose B-TRIVIAL 
residual O 
was O 
α- O 
form O 
. O 
The O 
polysaccharide O 
structure O 
was O 
further O 
confirmed O 
to O 
be O 
(1→6)-α-D-glucan O 
by O 
chemcial O 
shift O 
of O 
C6 O 
. O 
The O 
molecular O 
weight O 
of O 
LPS1 O 
was O 
calculated O 
to O 
be O 
108 O 
kDa O 
, O 
which O 
had O 
661 O 
glucose B-TRIVIAL 
residuals O 
. O 
Anticancer O 
assay O 
showed O 
that O 
LPS1 O 
had O 
anticancer O 
activity O 
against O 
the O 
growth O 
of O 
HepG2 O 
cells O 
to O 
a O 
certain O 
extent O 
. O 
However O 
, O 
it O 
did O 
not O 
show O 
any O 
cytotoxicity O 
against O 
MCF-7 O 
breast O 
cancer O 
cells O 
. O 

by O 
vancomycin B-TRIVIAL 
-conjugated O 
acryl B-TRIVIAL 
nanoparticles O 
and O 
morphological O 
component O 
analysis O 
. O 

Nanoparticles O 
are O 
currently O 
attracting O 
considerable O 
attention O 
because O 
of O 
their O 
ability O 
to O 
conjugate O 
to O 
various O 
substances O 
. O 
As O 
such O 
, O 
these O 
nanoparticles O 
can O 
assist O 
the O 
transfer O 
of O 
the O 
conjugated O 
substance O 
to O 
target O 
tissues O 
where O 
they O 
are O 
gradually O 
released O 
. O 
In O 
this O 
study O 
, O 
vancomycin B-TRIVIAL 
-conjugated O 
nanoparticles O 
( O 
VCM B-ABBREVIATION 
NPs O 
) O 
were O 
prepared O 
. O 
The O 
antibacterial O 
activity O 
of O 
VCM B-ABBREVIATION 
NPs O 
was O 
compared O 
with O 
that O 
of O 
VCM B-ABBREVIATION 
alone O 
by O 
exposure O 
to O 
vancomycin B-TRIVIAL 
-resistant O 
enterococci O 
( O 
VRE O 
) O 
. O 
The O 
morphology O 
of O 
the O 
cells O 
was O 
then O 
analyzed O 
by O 
electron O 
microscopy O 
. O 
VCM B-ABBREVIATION 
NPs O 
were O 
found O 
to O 
have O 
more O 
potent O 
antibacterial O 
activity O 
against O 
VRE O 
compared O 
to O 
VCM B-ABBREVIATION 
alone O 
, O 
but O 
the O 
activity O 
against O 
vancomycin B-TRIVIAL 
-sensitive O 
enterococci O 
( O 
VSE O 
) O 
remained O 
the O 
same O 
. O 
The O 
antibacterial O 
activity O 
of O 
nanoparticles O 
alone O 
was O 
the O 
same O 
against O 
VSE O 
and O 
VRE O 
. O 
The O 
nanoparticles O 
were O 
found O 
to O 
induce O 
characteristic O 
morphological O 
changes O 
in O 
the O 
bacteria O 
based O 
on O 
scanning O 
and O 
transmission O 
electron O 
microscopy O 
. O 
The O 
results O 
suggest O 
that O 
the O 
strong O 
antibacterial O 
activity O 
of O 
VCM B-ABBREVIATION 
NPs O 
against O 
VRE O 
may O 
be O 
attributable O 
not O 
only O 
to O 
the O 
well O 
- O 
known O 
control O 
release O 
carrier O 
property O 
of O 
the O 
nanoparticles O 
but O 
to O 
an O 
additional O 
mechanism O 
that O 
involves O 
VCM B-ABBREVIATION 
NPs O 
avoiding O 
the O 
drug O 
resistant O 
mechanism O 
of O 
VRE O 
. O 

new O 
triterpenoid B-FAMILY 
from O 
the O 
rhizomes O 
of O 
Nelumbo O 
nucifera O 
. O 

new O 
triterpenoid B-FAMILY 
, O 
2α,24-diacetoxy-3β-hydroxyolean-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
was O 
characterised O 
from O 
the O 
rhizomes O 
of O 
Nelumbo O 
nucifera O 
Gaertn O 
by O 
spectroscopic O 
and O 
chemical O 
methods O 
along O 
with O 
four O 
known O 
compounds O 
, O 
hyptatic B-TRIVIAL 
acid-A I-TRIVIAL 
( O 
2α,3β,24-trihydroxyolean-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
( O 
2 O 
) O 
, O 
maslinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
2α,3β-dihydroxyoleane-12-ene-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
, O 
betulin B-TRIVIAL 
and O 
lupeol B-TRIVIAL 
. O 

A I-TRIVIAL 
: O 
A O 
new O 
cytotoxic O 
compound O 
isolated O 
from O 
the O 
epiphytic O 
dinoflagellate O 
Ostreopsis O 
cf O 
. O 
ovata O 
from O 
the O 
coastal O 
waters O 
of O 
Jeju O 
Island O 
, O 
Korea O 
. O 

A I-TRIVIAL 
was O 
isolated O 
from O 
cultures O 
of O 
the O 
epiphytic O 
dinoflagellate O 
Ostreopsis O 
cf O 
. O 
ovata O 
from O 
the O 
coastal O 
waters O 
of O 
Jeju O 
Island O 
, O 
Korea O 
. O 
The O 
compound O 
, O 
a O 
non-palytoxin O 
derivative O 
, O 
has O 
a O 
polyhydroxy B-FAMILY 
chain O 
ending O 
with O 
the O 
primary B-FAMILY 
amino I-FAMILY 
group O 
and O 
contains O 
an O 
amide B-FAMILY 
bond O 
, O 
along O 
with O 
two O 
tetrahydropyran B-SYSTEMATIC 
rings O 
in O 
the O 
chain O 
. O 
Its O 
chemical O 
structure O 
was O 
elucidated O 
by O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
spectroscopy O 
methods O 
and O 
confirmed O 
by O 
mass O 
analysis O 
. O 
The O 
compound O 
exhibited O 
significant O 
cytotoxicity O 
in O 
the O 
brine O 
shrimp O 
lethality O 
test O 
at O 
a O 
concentration O 
of O 
0.9μg O 
/ O 
mL O 
. O 

concise O 
synthesis O 
of O 
pyrazole B-SYSTEMATIC 
analogues O 
of O 
combretastatin B-TRIVIAL 
A1 I-TRIVIAL 
as O 
potent O 
anti-tubulin O 
agents O 
. O 

A1 I-TRIVIAL 
( O 
CA1 B-ABBREVIATION 
) O 
binds O 
to O 
the O 
β-subunit O 
at O 
the O 
colchicine B-TRIVIAL 
binding O 
site O 
of O 
tubulin O 
and O 
inhibits O 
polymerization O 
. O 
As O 
such O 
, O 
it O 
is O 
both O 
an O 
antitumor O 
agent O 
and O 
a O 
vascular O 
disrupting O 
agent O 
. O 
It O 
has O 
been O 
shown O 
to O 
be O 
at O 
least O 
tenfold O 
more O 
potent O 
than O 
combretastatin B-TRIVIAL 
A4 I-TRIVIAL 
( O 
CA4 B-ABBREVIATION 
) O 
in O 
terms O 
of O 
vascular O 
shutdown O 
, O 
which O 
correlates O 
with O 
its O 
metabolism O 
to O 
reactive O 
ortho-quinone B-TRIVIAL 
species O 
that O 
are O 
assumed O 
to O 
be O 
directly O 
cytotoxic O 
in O 
tumor O 
cells O 
. O 
A O 
series O 
of O 
3,4-diarylpyrazoles B-FAMILY 
were O 
concisely O 
synthesized O 
, O 
one O 
of O 
which O 
, O 
3-methoxy-6-[4-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-yl]benzene-1,2-diol B-SYSTEMATIC 
( O 
27 O 
) O 
, O 
proved O 
to O 
be O 
a O 
cytotoxic O 
anti-tubulin O 
agent O 
with O 
low O 
nanomolar O 
potency O 
. O 
We O 
also O 
report O 
that O 
combretastatins B-FAMILY 
, O 
including O 
CA1 B-ABBREVIATION 
, O 
CA4 B-ABBREVIATION 
, O 
and O 
27 O 
, O 
are O 
effective O 
against O 
mesothelioma O 
cell O 
lines O 
and O 
therefore O 
have O 
significant O 
clinical O 
promise O 
. O 
Metabolism O 
experiments O 
demonstrate O 
that O 
27 O 
retains O 
the O 
ability O 
to O 
form O 
ortho-quinone B-TRIVIAL 
species O 
, O 
while O 
the O 
pyrazole B-SYSTEMATIC 
ring O 
shows O 
high O 
metabolic O 
stability O 
, O 
suggesting O 
that O 
this O 
compound O 
might O 
result O 
in O 
better O 
pharmacokinetic O 
profiles O 
than O 
CA1 B-ABBREVIATION 
, O 
with O 
similar O 
pharmacodynamic O 
properties O 
and O 
clinical O 
potential O 
. O 

new O 
isoflavone B-FAMILY 
glycosides I-FAMILY 
, O 
ammopiptanosides B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
, O 
have O 
been O 
isolated O 
from O 
the O 
95% O 
EtOH B-FORMULA 
extract O 
of O 
the O 
twigs O 
of O 
Ammopiptanthus O 
nanus O 
( O 
M.Pop O 
. O 
) O 
Cheng O 
f O 
. O 
, O 
together O 
with O 
six O 
known O 
compounds O 
, O 
and O 
their O 
structures O 
were O 
characterized O 
by O 
spectroscopic O 
methods O 
and O 
compared O 
with O 
the O 
data O 
in O 
the O 
literature O 
. O 

bioavailability O 
of O 
copper B-SYSTEMATIC 
in O 
soil O 
estimated O 
by O 
uptake O 
and O 
elimination O 
kinetics O 
in O 
the O 
springtail O 
Folsomia O 
candida O 
. O 

study O 
aimed O 
to O 
assess O 
the O 
bioavailability O 
of O 
copper B-SYSTEMATIC 
in O 
soil O 
, O 
by O 
measuring O 
its O 
uptake O 
kinetics O 
into O 
a O 
representative O 
soil O 
invertebrate O 
, O 
the O 
collembolan O 
Folsomia O 
candida O 
. O 
The O 
animals O 
were O 
exposed O 
to O 
25 O 
or O 
100 O 
μg O 
Cu B-FORMULA 
g(-1) O 
dry O 
LUFA O 
2.2 O 
soil O 
at O 
nominal O 
pH( O 
CaCl2 B-FORMULA 
) O 
4.5 O 
, O 
5.5 O 
, O 
or O 
6.5 O 
during O 
14 O 
days O 
after O 
which O 
they O 
were O 
transferred O 
to O 
clean O 
soil O 
for O 
14 O 
days O 
elimination O 
. O 
Uptake O 
and O 
elimination O 
rate O 
constants O 
were O 
calculated O 
based O 
on O 
total O 
and O 
extractable O 
soil O 
concentrations O 
and O 
porewater O 
concentrations O 
using O 
one O 
- O 
compartment O 
first O 
- O 
order O 
kinetics O 
modelling O 
. O 
Copper B-SYSTEMATIC 
was O 
present O 
in O 
the O 
animals O 
at O 
a O 
basal O 
physiological O 
level O 
of O 
40-90 O 
μg O 
g(-1)dry O 
weight O 
, O 
on O 
top O 
of O 
this O 
uptake O 
and O 
elimination O 
kinetics O 
were O 
observed O 
. O 
Uptake O 
rates O 
constants O 
varied O 
between O 
0.02 O 
and O 
0.17 O 
g(soil) O 
g(animal)(-1) O 
day(-1) O 
, O 
being O 
higher O 
at O 
lower O 
exposure O 
level O 
, O 
but O 
did O 
not O 
differ O 
significantly O 
between O 
different O 
soil O 
pH O 
levels O 
. O 
Elimination O 
rate O 
constants O 
ranged O 
between O 
0.04 O 
and O 
0.2 O 
day(-1) O 
and O 
were O 
negligible O 
( O 
k(2) O 
< O 
0.001 O 
day(-1) O 
) O 
at O 
pH O 
4.5 O 
and O 
6.5 O 
. O 
Multiple O 
linear O 
regressions O 
showed O 
that O 
the O 
pH O 
effect O 
on O 
copper B-SYSTEMATIC 
uptake O 
was O 
only O 
significant O 
when O 
taking O 
into O 
account O 
cation O 
exchange O 
capacity O 
, O 
or O 
calcium B-SYSTEMATIC 
and O 
dissolved O 
organic O 
carbon B-SYSTEMATIC 
levels O 
in O 
the O 
pore O 
water O 
. O 
Copper B-SYSTEMATIC 
concentrations O 
in O 
the O 
animals O 
however O 
, O 
never O 
were O 
higher O 
than O 
185 O 
μg O 
g(-1) O 
dry O 
weight O 
, O 
independent O 
of O 
exposure O 
level O 
and O 
pH O 
, O 
suggesting O 
homeostatic O 
regulation O 
. O 
These O 
results O 
show O 
that O 
the O 
chemical O 
composition O 
of O 
the O 
pore O 
water O 
does O 
affect O 
bioavailability O 
of O 
copper B-SYSTEMATIC 
in O 
soil O 
, O 
but O 
that O 
copper B-SYSTEMATIC 
uptake O 
in O 
collembolans O 
is O 
dominated O 
by O 
homeostatic O 
regulation O 
rather O 
than O 
by O 
soil O 
properties O 
like O 
pH O 
. O 

to O 
the O 
brain O 
is O 
a O 
feared O 
complication O 
of O 
systemic O 
cancer O 
, O 
associated O 
with O 
significant O 
morbidity O 
and O 
poor O 
prognosis O 
. O 
A O 
better O 
understanding O 
of O 
the O 
tumor O 
metabolism O 
might O 
help O 
us O 
meet O 
the O 
challenges O 
in O 
controlling O 
brain O 
metastases O 
. O 
The O 
study O 
aims O 
to O 
characterize O 
the O 
metabolic O 
profile O 
of O 
brain O 
metastases O 
of O 
different O 
origin O 
using O 
high O 
resolution O 
magic O 
angle O 
spinning O 
( O 
HR-MAS O 
) O 
magnetic O 
resonance O 
spectroscopy O 
( O 
MRS O 
) O 
to O 
correlate O 
the O 
metabolic O 
profiles O 
to O 
clinical O 
and O 
pathological O 
information O 
. O 
Biopsy O 
samples O 
of O 
human O 
brain O 
metastases O 
( O 
n O 
= O 
49 O 
) O 
were O 
investigated O 
. O 
A O 
significant O 
correlation O 
between O 
lipid O 
signals O 
and O 
necrosis O 
in O 
brain O 
metastases O 
was O 
observed O 
( O 
p O 
< O 
0.01 O 
) O 
, O 
irrespective O 
of O 
their O 
primary O 
origin O 
. O 
The O 
principal O 
component O 
analysis O 
( O 
PCA O 
) O 
showed O 
that O 
brain O 
metastases O 
from O 
malignant O 
melanomas O 
cluster O 
together O 
, O 
while O 
lung O 
carcinomas O 
were O 
metabolically O 
heterogeneous O 
and O 
overlap O 
with O 
other O 
subtypes O 
. O 
Metastatic O 
melanomas O 
have O 
higher O 
amounts O 
of O 
glycerophosphocholine B-TRIVIAL 
than O 
other O 
brain O 
metastases O 
. O 
A O 
significant O 
correlation O 
between O 
microscopically O 
visible O 
lipid O 
droplets O 
estimated O 
by O 
Nile B-TRIVIAL 
Red I-TRIVIAL 
staining O 
and O 
MR O 
visible O 
lipid O 
signals O 
was O 
observed O 
in O 
metastatic O 
lung O 
carcinomas O 
( O 
p O 
= O 
0.01 O 
) O 
, O 
indicating O 
that O 
the O 
proton O 
MR O 
visible O 
lipid O 
signals O 
arise O 
from O 
cytoplasmic O 
lipid O 
droplets O 
. O 
MRS O 
- O 
based O 
metabolomic O 
profiling O 
is O 
a O 
useful O 
tool O 
for O 
exploring O 
the O 
metabolic O 
profiles O 
of O 
metastatic O 
brain O 
tumors O 
. O 

in O 
therapeutic O 
kinase O 
inhibitors O 
continues O 
to O 
grow O 
beyond O 
success O 
in O 
oncology O 
. O 
To O 
date O 
, O 
ATP B-ABBREVIATION 
-mimetic O 
kinase O 
inhibitors O 
have O 
focused O 
primarily O 
on O 
monocyclic O 
and O 
bicyclic O 
heterocyclic O 
cores O 
. O 
We O 
sought O 
to O 
expand O 
on O 
the O 
repertoire O 
of O 
potential O 
cores O 
for O 
kinase O 
inhibition O 
by O 
exploring O 
tricyclic O 
variants O 
of O 
classical O 
bicyclic O 
hinge O 
binding O 
motifs O 
such O 
as O 
pyrrolopyridine B-SYSTEMATIC 
and O 
pyrrolopyrazine B-SYSTEMATIC 
. O 
Herein O 
we O 
describe O 
the O 
syntheses O 
of O 
eight O 
alternative O 
tricyclic O 
cores O 
as O 
well O 
as O 
in O 
vitro O 
screening O 
results O 
for O 
representative O 
kinases O 
of O 
potential O 
therapeutic O 
interest O 
. O 

of O 
intravenous O 
nicotine B-TRIVIAL 
on O 
prepulse O 
inhibition O 
in O 
smokers O 
and O 
non-smokers O 
: O 
relationship O 
with O 
familial O 
smoking O 
. O 

: O 
The O 
reinforcing O 
properties O 
of O 
nicotine B-TRIVIAL 
may O 
be O 
, O 
in O 
part O 
, O 
derived O 
from O 
its O 
ability O 
to O 
enhance O 
certain O 
forms O 
of O 
cognitive O 
processing O 
. O 
Several O 
animal O 
and O 
human O 
studies O 
have O 
shown O 
that O 
nicotine B-TRIVIAL 
increases O 
prepulse O 
inhibition O 
( O 
PPI O 
) O 
of O 
the O 
startle O 
reflex O 
. O 
However O 
, O 
it O 
remains O 
unclear O 
whether O 
these O 
effects O 
are O 
related O 
to O 
smoking O 
susceptibility O 
. O 
OBJECTIVES O 
: O 
The O 
current O 
study O 
examined O 
the O 
effects O 
of O 
intravenously O 
delivered O 
nicotine B-TRIVIAL 
on O 
PPI O 
in O 
smokers O 
and O 
non-smokers O 
, O 
as O 
well O 
as O 
its O 
association O 
with O 
a O 
quantitative O 
index O 
of O 
familial O 
smoking O 
. O 
METHODS O 
: O 
The O 
sample O 
consisted O 
of O 
30 O 
non-smokers O 
and O 
16 O 
smokers O 
, O 
who O 
completed O 
an O 
initial O 
assessment O 
, O 
followed O 
on O 
a O 
separate O 
day O 
by O 
a O 
laboratory O 
assessment O 
of O 
PPI O 
prior O 
to O 
and O 
following O 
each O 
of O 
two O 
intravenous O 
nicotine B-TRIVIAL 
infusions O 
. O 
Separate O 
doses O 
were O 
used O 
in O 
smoker O 
and O 
non-smoker O 
samples O 
. O 
RESULTS O 
: O 
Analyses O 
indicated O 
that O 
both O 
nicotine B-TRIVIAL 
infusions O 
acutely O 
enhanced O 
PPI O 
among O 
non-smokers O 
, O 
and O 
this O 
enhancement O 
was O 
positively O 
related O 
to O 
the O 
degree O 
of O 
smoking O 
among O 
first O 
and O 
second O 
- O 
degree O 
relatives O 
. O 
Smokers O 
also O 
displayed O 
PPI O 
enhancement O 
after O 
receiving O 
the O 
first O 
infusion O 
, O 
but O 
this O 
effect O 
was O 
unrelated O 
to O 
familial O 
smoking O 
. O 
CONCLUSIONS O 
: O 
These O 
data O 
suggest O 
that O 
the O 
PPI O 
paradigm O 
may O 
have O 
utility O 
as O 
an O 
endophenotype O 
for O 
cognitive O 
processes O 
which O 
contribute O 
to O 
smoking O 
risk O 
. O 

- O 
driven O 
magnesium B-SYSTEMATIC 
based O 
Janus O 
micromotors O 
for O 
environmental O 
remediation O 
. O 

describe O 
the O 
use O 
of O 
seawater O 
as O 
fuel O 
to O 
propel O 
Janus O 
micromotors O 
. O 
The O 
new O 
micromotors O 
consist O 
of O 
biodegradable O 
and O 
environmentally O 
friendly O 
magnesium B-SYSTEMATIC 
microparticles O 
and O 
a O 
nickel B-SYSTEMATIC 
-gold O 
bilayer O 
patch O 
for O 
magnetic O 
guidance O 
and O 
surface O 
modification O 
. O 
Such O 
seawater O 
- O 
driven O 
micromotors O 
, O 
which O 
utilize O 
macrogalvanic O 
corrosion O 
and O 
chloride B-SYSTEMATIC 
pitting O 
corrosion O 
processes O 
, O 
eliminate O 
the O 
need O 
for O 
external O 
fuels O 
to O 
offer O 
efficient O 
and O 
prolonged O 
propulsion O 
towards O 
diverse O 
applications O 
in O 
aquatic O 
environments O 
. O 

role O 
of O 
ATP B-ABBREVIATION 
-sensitive O 
potassium B-SYSTEMATIC 
channels O 
in O 
cerebral O 
ischemia O 
. O 

-sensitive O 
potassium B-SYSTEMATIC 
( O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
) O 
channels O 
are O 
weak O 
, O 
inward O 
rectifiers O 
that O 
couple O 
metabolic O 
status O 
to O 
cell O 
membrane O 
electrical O 
activity O 
, O 
thus O 
modulating O 
many O 
cellular O 
functions O 
. O 
An O 
increase O 
in O 
the O 
ADP B-ABBREVIATION 
/ O 
ATP B-ABBREVIATION 
ratio O 
opens O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
, O 
leading O 
to O 
membrane O 
hyperpolarization O 
. O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
are O 
ubiquitously O 
expressed O 
in O 
neurons O 
located O 
in O 
different O 
regions O 
of O 
the O 
brain O 
, O 
including O 
the O 
hippocampus O 
and O 
cortex O 
. O 
Brief O 
hypoxia O 
triggers O 
membrane O 
hyperpolarization O 
in O 
these O 
central O 
neurons O 
. O 
In O 
vivo O 
animal O 
studies O 
confirmed O 
that O 
knocking O 
out O 
the O 
Kir6.2 O 
subunit O 
of O 
the O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
increases O 
ischemic O 
infarction O 
, O 
and O 
overexpression O 
of O 
the O 
Kir6.2 O 
subunit O 
reduces O 
neuronal O 
injury O 
from O 
ischemic O 
insults O 
. O 
These O 
findings O 
provide O 
the O 
basis O 
for O 
a O 
practical O 
strategy O 
whereby O 
activation O 
of O 
endogenous O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
reduces O 
cellular O 
damage O 
resulting O 
from O 
cerebral O 
ischemic O 
stroke O 
. O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channel O 
modulators O 
may O 
prove O 
to O 
be O 
clinically O 
useful O 
as O 
part O 
of O 
a O 
combination O 
therapy O 
for O 
stroke O 
management O 
in O 
the O 
future O 
. O 

from O 
Alnus O 
glutinosa O 
Bark O 
and O 
Their O 
Chemoprotective O 
Effect O 
on O 
Human O 
Lymphocytes O 
DNA O 
. O 

study O 
of O 
secondary O 
metabolites O 
from O 
the O 
bark O 
of O 
Alnus O 
glutinosa O 
led O 
to O 
the O 
isolation O 
of O 
fourteen O 
diarylheptanoids B-FAMILY 
: O 
oregonin B-TRIVIAL 
( O 
1 O 
) O 
, O 
platyphylloside B-TRIVIAL 
( O 
2 O 
) O 
, O 
rubranoside B-TRIVIAL 
A I-TRIVIAL 
( O 
3 O 
) O 
, O 
rubranoside B-TRIVIAL 
B I-TRIVIAL 
( O 
4 O 
) O 
, O 
hirsutanonol B-TRIVIAL 
( O 
5 O 
) O 
, O 
hirsutenone B-TRIVIAL 
( O 
6 O 
) O 
, O 
hirsutanonol-5-O-β-D-glucopyranoside B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
platyphyllonol-5-O-β-D-xylopyranoside B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
aceroside B-TRIVIAL 
VII I-TRIVIAL 
( O 
9 O 
) O 
, O 
alnuside B-TRIVIAL 
A I-TRIVIAL 
( O 
10 O 
) O 
, O 
alnuside B-TRIVIAL 
B I-TRIVIAL 
( O 
11 O 
) O 
, O 
1,7-bis-(3,4-dihydoxyphenyl)-5-hydroxy-heptane-3-O-β-D-xylopyranoside B-SYSTEMATIC 
( O 
12 O 
) O 
, O 
(5S)-1-(4-hydroxyphenyl)-7-(3,4-dihydroxyphenyl)-5-O-β-D-glucopyranosyl-heptan-3-one B-SYSTEMATIC 
( O 
13 O 
) O 
, O 
and O 
(5S)-1,7-bis-(3,4-dihydroxyphenyl)-5-O-β-D-[6-(3,4-dimethoxycinnamoylglucopyranosyl)]-heptan-3-one B-SYSTEMATIC 
( O 
14 O 
) O 
. O 
All O 
of O 
the O 
diarylheptanoids B-FAMILY 
, O 
except O 
1 O 
and O 
5 O 
, O 
were O 
found O 
in O 
A. O 
glutinosa O 
for O 
the O 
first O 
time O 
, O 
while O 
13 O 
and O 
14 O 
were O 
new O 
compounds O 
. O 
The O 
structures O 
were O 
determined O 
by O 
spectroscopic O 
techniques O 
: O 
1D O 
and O 
2D O 
NMR O 
, O 
HR-ESI-MS O 
, O 
FTIR O 
, O 
UV O 
, O 
and O 
CD O 
. O 
All O 
isolated O 
compounds O 
were O 
analyzed O 
for O 
an O 
in O 
vitro O 
protective O 
effect O 
on O 
chromosome O 
aberrations O 
in O 
peripheral O 
human O 
lymphocytes O 
using O 
the O 
cytokinesis O 
- O 
block O 
micronucleus O 
assay O 
. O 
The O 
majority O 
of O 
them O 
, O 
including O 
the O 
new O 
compounds O 
13 O 
and O 
14 O 
, O 
exerted O 
a O 
pronounced O 
effect O 
in O 
decreasing O 
DNA O 
damage O 
in O 
human O 
lymphocytes O 
. O 
Diarylheptanoids B-FAMILY 
1 O 
, O 
2 O 
, O 
5 O 
, O 
13 O 
, O 
and O 
14 O 
at O 
a O 
concentration O 
of O 
1 O 
µg O 
/ O 
mL O 
decreased O 
the O 
frequency O 
of O 
micronuclei O 
by O 
52.8 O 
% O 
, O 
43.8 O 
% O 
, O 
63.6 O 
% O 
, O 
44.4 O 
% O 
, O 
and O 
56 O 
% O 
, O 
respectively O 
, O 
exerting O 
a O 
much O 
stronger O 
effect O 
than O 
the O 
synthetic O 
protector O 
amifostine B-TRIVIAL 
( O 
17.2 O 
% O 
, O 
c O 
= O 
1 O 
µg O 
/ O 
mL O 
) O 
. O 

of O 
serotonin B-TRIVIAL 
mechanism O 
in O 
methamphetamine B-TRIVIAL 
-induced O 
chronic O 
pulmonary O 
toxicity O 
in O 
rats O 
. O 

widest O 
distribution O 
and O 
the O 
highest O 
uptake O 
of O 
methamphetamine B-TRIVIAL 
( O 
MA O 
) O 
in O 
the O 
human O 
body O 
occurred O 
in O 
the O 
lungs O 
, O 
so O 
that O 
more O 
and O 
more O 
attention O 
should O 
be O 
paid O 
to O 
MA-induced O 
pulmonary O 
toxicity O 
. O 
MA O 
induces O 
the O 
release O 
of O 
serotonin B-TRIVIAL 
, O 
which O 
is O 
an O 
important O 
mediator O 
in O 
pulmonary O 
disease O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
chronic O 
response O 
of O 
the O 
lung O 
to O 
MA O 
and O 
its O 
potential O 
mechanism O 
in O 
rats O 
. O 
Models O 
of O 
the O 
chronic O 
toxicity O 
of O 
MA O 
were O 
established O 
with O 
MA O 
of O 
5 O 
mg O 
/ O 
kg O 
and O 
10 O 
mg O 
/ O 
kg O 
( O 
intraperitoneally O 
, O 
twice O 
per O 
day O 
) O 
for O 
5 O 
weeks O 
. O 
It O 
was O 
found O 
that O 
the O 
high O 
dose O 
of O 
MA O 
induced O 
rat O 
pulmonary O 
toxicity O 
: O 
crowded O 
lung O 
parenchyma O 
, O 
thickened O 
septum O 
, O 
reduced O 
number O 
of O 
alveolar O 
sacs O 
, O 
inflammatory O 
cell O 
infiltration O 
, O 
and O 
pulmonary O 
arteriolar O 
remodeling O 
. O 
In O 
addition O 
, O 
MA O 
resulted O 
in O 
a O 
significant O 
increase O 
in O 
the O 
lung O 
serotonin B-TRIVIAL 
concentration O 
and O 
the O 
marked O 
upregulation O 
of O 
tryptophan B-TRIVIAL 
hydroxylase O 
1 O 
, O 
vesicular O 
monoamine O 
transporter O 
2 O 
, O 
serotonin B-TRIVIAL 
transporter O 
, O 
and O 
downregulation O 
of O 
monoamine B-FAMILY 
oxidase-A O 
. O 
These O 
findings O 
suggest O 
that O 
MA O 
induced O 
chronic O 
pulmonary O 
toxicity O 
, O 
which O 
is O 
concerned O 
with O 
the O 
elevated O 
serotonin B-TRIVIAL 
concentration O 
in O 
rat O 
lungs O 
by O 
increased O 
synthesis O 
, O 
reduced O 
metabolism O 
, O 
augmented O 
accumulation O 
, O 
and O 
promoted O 
release O 
of O 
serotonin B-TRIVIAL 
. O 

receptors O 
in O 
bile B-FAMILY 
acid I-FAMILY 
metabolism O 
. O 

acids I-FAMILY 
are O 
signaling O 
molecules O 
that O 
activate O 
nuclear O 
receptors O 
, O 
such O 
as O 
farnesoid O 
X O 
receptor O 
, O 
pregnane B-TRIVIAL 
X O 
receptor O 
, O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
, O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
, O 
and O 
play O 
a O 
critical O 
role O 
in O 
the O 
regulation O 
of O 
lipid O 
, O 
glucose B-TRIVIAL 
, O 
energy O 
, O 
and O 
drug O 
metabolism O 
. O 
These O 
xenobiotic O 
/ O 
endobiotic O 
- O 
sensing O 
nuclear O 
receptors O 
regulate O 
phase O 
I O 
oxidation O 
, O 
phase O 
II O 
conjugation O 
, O 
and O 
phase O 
III O 
transport O 
in O 
bile B-FAMILY 
acid I-FAMILY 
and O 
drug O 
metabolism O 
in O 
the O 
digestive O 
system O 
. O 
Integration O 
of O 
bile B-FAMILY 
acid I-FAMILY 
metabolism O 
with O 
drug O 
metabolism O 
controls O 
absorption O 
, O 
transport O 
, O 
and O 
metabolism O 
of O 
nutrients O 
and O 
drugs O 
to O 
maintain O 
metabolic O 
homeostasis O 
and O 
also O 
protects O 
against O 
liver O 
injury O 
, O 
inflammation O 
, O 
and O 
related O 
metabolic O 
diseases O 
, O 
such O 
as O 
nonalcoholic O 
fatty O 
liver O 
disease O 
, O 
diabetes O 
, O 
and O 
obesity O 
. O 
Bile B-FAMILY 
- I-FAMILY 
acid I-FAMILY 
-based O 
drugs O 
targeting O 
nuclear O 
receptors O 
are O 
in O 
clinical O 
trials O 
for O 
treating O 
cholestatic O 
liver O 
diseases O 
and O 
fatty O 
liver O 
disease O 
. O 

p450 O 
- O 
mediated O 
changes O 
in O 
oxycodone B-TRIVIAL 
pharmacokinetics O 
/ O 
pharmacodynamics O 
and O 
their O 
clinical O 
implications O 
. O 

recent O 
years O 
the O 
use O 
of O 
the O 
opioid O 
oxycodone B-TRIVIAL 
has O 
increased O 
markedly O 
and O 
replacing O 
morphine B-TRIVIAL 
as O 
the O 
first O 
- O 
line O 
choice O 
of O 
opioid O 
in O 
several O 
countries O 
. O 
There O 
are O 
formulations O 
for O 
oral O 
immediate O 
, O 
oral O 
extended O 
release O 
and O 
intravenous O 
use O 
. O 
The O 
bioavailability O 
is O 
higher O 
than O 
for O 
morphine B-TRIVIAL 
and O 
less O 
variable O 
. O 
Oxycodone B-TRIVIAL 
is O 
primarily O 
metabolized O 
in O 
the O 
liver O 
by O 
the O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
enzymes O 
with O 
CYP3A O 
as O 
the O 
major O 
metabolic O 
pathway O 
and O 
CYP2D6 O 
as O 
the O 
minor O 
metabolic O 
pathway O 
to O 
noroxycodone B-TRIVIAL 
, O 
oxymorphone B-TRIVIAL 
and O 
noroxymorphone B-TRIVIAL 
. O 
Oxycodone B-TRIVIAL 
exerts O 
its O 
analgesic O 
effect O 
via O 
the O 
µ-opioid O 
receptor O 
. O 
The O 
metabolism O 
of O 
CYP2D6 O 
substrates O 
varies O 
to O 
a O 
large O 
degree O 
between O 
individuals O 
as O 
a O 
result O 
of O 
allele O 
functionality O 
. O 
Poor O 
metabolizers O 
( O 
PM O 
) O 
have O 
two O 
non-functional O 
alleles O 
, O 
extensive O 
metabolizers O 
( O 
EM O 
) O 
are O 
homozygous O 
with O 
two O 
functional O 
alleles O 
or O 
heterozygous O 
with O 
one O 
functional O 
allele O 
and O 
ultrarapid O 
metabolizers O 
( O 
UM O 
) O 
have O 
more O 
than O 
two O 
functional O 
alleles O 
. O 
There O 
are O 
pronounced O 
interethnic O 
differences O 
in O 
the O 
allele O 
distribution O 
. O 
On O 
the O 
basis O 
of O 
studies O 
performed O 
thus O 
far O 
, O 
oxycodone B-TRIVIAL 
concentrations O 
in O 
comparison O 
with O 
EM O 
are O 
similar O 
in O 
PM O 
and O 
reduced O 
in O 
UM O 
. O 
The O 
pharmacokinetics O 
in O 
UM O 
are O 
insufficiently O 
investigated O 
. O 
Simultaneous O 
inhibition O 
of O 
both O 
CYP3A O 
and O 
CYP2D6 O 
results O 
in O 
increased O 
oxycodone B-TRIVIAL 
concentrations O 
and O 
such O 
a O 
combination O 
should O 
be O 
avoided O 
. O 
A O 
similar O 
effect O 
is O 
to O 
be O 
expected O 
with O 
use O 
of O 
a O 
CYP3A O 
inhibitor O 
in O 
CYP2D6 O 
PM O 
. O 
Concomitant O 
use O 
of O 
enzyme O 
inducers O 
such O 
as O 
rifampicin B-TRIVIAL 
, O 
St O 
John's O 
wort O 
and O 
carbamazepine B-TRIVIAL 
should O 
be O 
avoided O 
because O 
of O 
the O 
risk O 
of O 
subtherapeutic O 
concentrations O 
of O 
oxycodone B-TRIVIAL 
. O 
When O 
the O 
dosage O 
of O 
morphine B-TRIVIAL 
may O 
result O 
in O 
unpredictable O 
bioavailability O 
, O 
like O 
in O 
patients O 
with O 
severe O 
hepatic O 
cirrhosis O 
, O 
oxycodone B-TRIVIAL 
might O 
be O 
beneficial O 
because O 
it O 
has O 
higher O 
and O 
less O 
variability O 
in O 
bioavailability O 
between O 
patients O 
than O 
morphine B-TRIVIAL 
. O 

new O 
triterpenoid B-FAMILY 
saponin I-FAMILY 
from O 
Glinus O 
oppositifolius O 
with O 
α-glucosidase O 
inhibitory O 
activity O 
. O 

of O 
α-glucosidase O 
inhibitory O 
activity O 
led O 
to O 
the O 
isolation O 
of O 
six O 
triterpene B-FAMILY 
saponins I-FAMILY 
from O 
the O 
aerial O 
parts O 
of O 
Glinus O 
oppositifolius O 
including O 
one O 
new O 
and O 
five O 
known O 
constituents O 
. O 
The O 
structure O 
of O 
the O 
new O 
saponin B-FAMILY 
, O 
glinoside B-TRIVIAL 
C I-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
established O 
as O 
16-O-(β-D-glucopyranosyl)-3β,12β,16β,21α,22-pentahydroxy B-SYSTEMATIC 
hopane I-SYSTEMATIC 
by O 
extensive O 
use O 
of O 
1-D O 
, O 
2-D O 
NMR O 
and O 
mass O 
spectral O 
techniques O 
. O 
The O 
other O 
constituents O 
identified O 
were O 
3-O-(β-D-xylopyranosyl)-spergulagenin B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
spergulacin B-TRIVIAL 
( O 
3 O 
) O 
, O 
spergulin B-TRIVIAL 
A I-TRIVIAL 
( O 
4 O 
) O 
, O 
spergulacin B-TRIVIAL 
A I-TRIVIAL 
( O 
5 O 
) O 
and O 
spergulin B-TRIVIAL 
B I-TRIVIAL 
( O 
6 O 
) O 
. O 
Compound O 
1 O 
exhibited O 
the O 
greatest O 
inhibition O 
of O 
the O 
enzyme O 
with O 
IC50 O 
of O 
127 O 
± O 
30 O 
µM O 
. O 
Kinetics O 
study O 
for O 
the O 
compound O 
1 O 
demonstrated O 
mixed O 
type O 
of O 
inhibition O 
( O 
Ki O 
= O 
157.9 O 
µM O 
) O 
. O 

acid I-FAMILY 
amides I-FAMILY 
, O 
chalcone B-TRIVIAL 
- I-TRIVIAL 
aroylacrylic I-TRIVIAL 
acid I-TRIVIAL 
chimeras O 
: O 
Design O 
, O 
antiproliferative O 
activity O 
and O 
inhibition O 
of O 
tubulin O 
polymerization O 
. O 

activity O 
of O 
twenty O 
- O 
nine O 
(E)-4-aryl-4-oxo-2-butenoic B-FAMILY 
acid I-FAMILY 
amides I-FAMILY 
against O 
three O 
human O 
tumor O 
cell O 
lines O 
( O 
HeLa O 
, O 
FemX O 
, O 
and O 
K562 O 
) O 
is O 
reported O 
. O 
Compounds O 
showed O 
antiproliferative O 
activity O 
in O 
one O 
- O 
digit O 
micromolar O 
to O 
submicromolar O 
concentrations O 
. O 
The O 
most O 
active O 
derivatives O 
toward O 
all O 
the O 
cell O 
lines O 
tested O 
bear O 
alkyl B-FAMILY 
substituents O 
on O 
the O 
aroyl O 
moiety O 
of O 
the O 
molecules O 
. O 
Fourteen O 
compounds O 
showed O 
tubulin O 
assembly O 
inhibition O 
at O 
concentrations O 
< O 
20 O 
μM O 
. O 
The O 
most O 
potent O 
inhibitor O 
of O 
tubulin O 
assembly O 
was O 
unsubstituted O 
compound O 
1 O 
, O 
with O 
IC50 O 
= O 
2.9 O 
μM O 
. O 
Compound O 
23 O 
had O 
an O 
oral O 
LD50in O 
vivo O 
of O 
45 O 
mg O 
/ O 
kg O 
in O 
mice O 
. O 
Cell O 
cycle O 
analysis O 
on O 
K562 O 
cells O 
showed O 
that O 
compounds O 
1 O 
, O 
2 O 
and O 
23 O 
caused O 
accumulation O 
of O 
cells O 
in O 
the O 
G2 O 
/ O 
M O 
phase O 
, O 
but O 
inhibition O 
of O 
microtubule O 
polymerization O 
is O 
not O 
the O 
principal O 
mode O 
of O 
action O 
of O 
the O 
compounds O 
. O 
Nevertheless O 
, O 
they O 
may O 
be O 
useful O 
leads O 
for O 
the O 
design O 
of O 
a O 
new O 
class O 
of O 
antitubulin O 
agents O 
. O 

the O 
enteroenteric O 
recirculation O 
of O 
apixaban B-TRIVIAL 
, O 
a O 
factor O 
Xa O 
inhibitor O 
: O 
administration O 
of O 
activated O 
charcoal O 
to O 
bile O 
duct O 
- O 
cannulated O 
rats O 
and O 
dogs O 
receiving O 
an O 
intravenous O 
dose O 
and O 
use O 
of O 
drug O 
transporter O 
knockout O 
rats O 
. O 

study O 
described O 
here O 
investigated O 
the O 
impact O 
of O 
intestinal O 
excretion O 
( O 
IE O 
; O 
excretion O 
of O 
drug O 
directly O 
from O 
circulation O 
to O 
intestinal O 
lumen O 
) O 
, O 
enteroenteric O 
recirculation O 
( O 
EER O 
) O 
, O 
and O 
renal O 
tubule O 
recirculation O 
( O 
RTR O 
) O 
on O 
apixaban B-TRIVIAL 
pharmacokinetics O 
and O 
disposition O 
. O 
The O 
experimental O 
approaches O 
involve O 
integrating O 
apixaban B-TRIVIAL 
elimination O 
pathways O 
with O 
pharmacokinetic O 
profiles O 
obtained O 
from O 
bile O 
duct O 
- O 
cannulated O 
( O 
BDC O 
) O 
rats O 
and O 
dogs O 
receiving O 
i.v O 
. O 
doses O 
together O 
with O 
oral O 
administration O 
of O 
activated O 
charcoal B-TRIVIAL 
( O 
AC O 
) O 
. O 
Additionally O 
, O 
the O 
role O 
of O 
P-gp O 
( O 
P-glycoprotein O 
; O 
abcb1 O 
) O 
and O 
BCRP O 
( O 
breast O 
cancer O 
resistance O 
protein O 
; O 
abcg2 O 
) O 
in O 
apixaban B-TRIVIAL 
disposition O 
was O 
evaluated O 
in O 
experiments O 
using O 
transporter O 
inhibitors O 
and O 
transporter O 
knockout O 
( O 
KO O 
) O 
rats O 
. O 
Approximately O 
20-50% O 
of O 
an O 
apixaban B-TRIVIAL 
i.v O 
. O 
dose O 
was O 
found O 
in O 
feces O 
of O 
BDC O 
rats O 
and O 
dogs O 
, O 
suggesting O 
IE O 
leading O 
to O 
fecal O 
elimination O 
and O 
intestinal O 
clearance O 
( O 
IC O 
) O 
. O 
The O 
fecal O 
elimination O 
, O 
IC O 
, O 
and O 
systemic O 
clearance O 
of O 
apixaban B-TRIVIAL 
were O 
increased O 
upon O 
AC O 
administration O 
in O 
both O 
BDC O 
rats O 
and O 
dogs O 
and O 
were O 
decreased O 
in O 
BDC O 
rats O 
dosed O 
with O 
GF-120918 B-IDENTIFIER 
, O 
a O 
dual O 
BCRP O 
and O 
P-gp O 
inhibitor O 
) O 
. O 
BCRP O 
appeared O 
to O 
play O 
a O 
more O 
important O 
role O 
for O 
absorption O 
and O 
intestinal O 
and O 
renal O 
elimination O 
of O 
apixaban B-TRIVIAL 
than O 
P-gp O 
in O 
transporter-KO O 
rats O 
after O 
oral O 
and O 
i.v O 
. O 
dosing O 
, O 
which O 
led O 
to O 
a O 
higher O 
level O 
of O 
active O 
renal O 
excretion O 
in O 
rat O 
than O 
other O 
species O 
. O 
These O 
data O 
demonstrate O 
that O 
apixaban B-TRIVIAL 
undergoes O 
IE O 
, O 
EER O 
, O 
and O 
RTR O 
that O 
are O 
facilitated O 
by O 
efflux O 
transporters O 
. O 
Intestinal O 
reabsorption O 
of O 
apixaban B-TRIVIAL 
could O 
be O 
interrupted O 
by O 
AC O 
even O 
at O 
3 O 
hours O 
post O 
- O 
drug O 
dose O 
in O 
dogs O 
( O 
late O 
charcoal B-TRIVIAL 
effect O 
) O 
. O 
This O 
study O 
demonstrates O 
that O 
the O 
intestine O 
is O 
an O 
organ O 
for O 
direct O 
clearance O 
and O 
redistribution O 
of O 
apixaban B-TRIVIAL 
. O 
The O 
IE O 
, O 
EER O 
, O 
and O 
RTR O 
contribute O 
to O 
overall O 
pharmacokinetic O 
profiles O 
of O 
apixaban B-TRIVIAL 
. O 
IE O 
as O 
a O 
clearance O 
pathway O 
, O 
balanced O 
with O 
metabolism O 
and O 
renal O 
excretion O 
, O 
helps O 
decrease O 
the O 
impacts O 
of O 
intrinsic O 
( O 
renal O 
or O 
hepatic O 
impairment O 
) O 
and O 
extrinsic O 
( O 
drug O 
- O 
drug O 
interactions O 
) O 
factors O 
on O 
apixaban B-TRIVIAL 
disposition O 
. O 

ingestion O 
toxicity O 
of O 
three O 
Lamiaceae O 
essential O 
oils O 
( O 
EOs O 
) O 
- O 
Hyptis O 
suaveolens O 
, O 
Rosmarinus O 
officinalis O 
and O 
Lavandula O 
angustifolia O 
- O 
incorporated O 
in O 
protein O 
baits O 
was O 
evaluated O 
against O 
Bactrocera O 
oleae O 
, O 
a O 
worldwide O 
pest O 
of O 
olive O 
fruits O 
. O 
In O 
laboratory O 
conditions O 
, O 
all O 
the O 
tested O 
EOs O 
showed O 
dose O 
- O 
dependent O 
toxicity O 
on O 
B O 
. O 
oleae O 
, O 
with O 
mortality O 
rates O 
ranging O 
from O 
12% O 
( O 
EO O 
concentration O 
: O 
0.01% O 
w O 
: O 
v O 
) O 
to O 
100% O 
( O 
EO O 
concentration O 
: O 
1.75% O 
w O 
: O 
v O 
) O 
. O 
Semi-field O 
results O 
highlighted O 
the O 
toxicity O 
of O 
L O 
. O 
angustifolia O 
and O 
H O 
. O 
suaveolens O 
EOs O 
, O 
which O 
exerted O 
more O 
than O 
60% O 
of O 
flies O 
mortality O 
at O 
a O 
concentration O 
of O 
1.75% O 
( O 
w O 
: O 
v O 
) O 
. O 
Gas O 
Chromatography-Electron O 
Impact O 
Mass O 
Spectrometry O 
analyses O 
of O 
the O 
three O 
EOs O 
showed O 
that O 
H O 
. O 
suaveolens O 
EO O 
was O 
dominated O 
by O 
monoterpene B-FAMILY 
and O 
sesquiterpene B-FAMILY 
hydrocarbons I-FAMILY 
. O 
Oxygenated B-FAMILY 
monoterpenes I-FAMILY 
were O 
the O 
main O 
chemical O 
class O 
in O 
R O 
. O 
officinalis O 
and O 
L O 
. O 
angustifolia O 
EOs O 
. O 
Further O 
research O 
is O 
needed O 
to O 
evaluate O 
the O 
efficacy O 
of O 
these O 
EOs O 
plus O 
food O 
bait O 
against O 
the O 
olive O 
fruit O 
fly O 
in O 
the O 
open O 
field O 
. O 

and O 
antimycobacterial O 
evaluation O 
of O 
pyrazinamide B-SYSTEMATIC 
derivatives O 
with O 
benzylamino B-SYSTEMATIC 
substitution O 
. O 

series O 
of O 
19 O 
new O 
compounds O 
related O 
to O 
pyrazinamide B-SYSTEMATIC 
were O 
synthesized O 
, O 
characterized O 
with O 
analytical O 
data O 
and O 
screened O 
for O 
in O 
vitro O 
whole O 
cell O 
antimycobacterial O 
activity O 
against O 
Mycobacterium O 
tuberculosis O 
H37Rv O 
, O 
Mycobacterium O 
kansasii O 
and O 
two O 
types O 
of O 
Mycobacterium O 
avium O 
. O 
The O 
series O 
consisted O 
of O 
3-(benzylamino)-5-cyanopyrazine-2-carboxamides B-FAMILY 
and O 
3-(benzylamino)pyrazine-2,5-dicarbonitriles B-FAMILY 
with O 
various O 
substituents O 
on O 
the O 
phenyl B-SYSTEMATIC 
ring O 
. O 
RP-HPLC O 
method O 
was O 
used O 
to O 
determine O 
the O 
lipophilicity O 
of O 
the O 
prepared O 
compounds O 
. O 
Nine O 
compounds O 
exerted O 
similar O 
or O 
better O 
activity O 
against O 
Mycobacterium O 
tuberculosis O 
compared O 
to O 
pyrazinamide B-SYSTEMATIC 
( O 
MIC=6.25-12.5 O 
μg O 
/ O 
mL O 
) O 
. O 
3-(Benzylamino)pyrazine-2,5-dicarbonitrile B-SYSTEMATIC 
inhibited O 
all O 
of O 
the O 
tested O 
mycobacterial O 
strains O 
with O 
MIC O 
within O 
the O 
range O 
12.5-25 O 
μg O 
/ O 
mL O 
. O 
Although O 
not O 
the O 
most O 
active O 
, O 
4-NH(2) B-SYSTEMATIC 
substituted O 
compounds O 
possessed O 
the O 
lowest O 
in O 
vitro O 
cytotoxicity O 
( O 
hepatotoxicity O 
) O 
, O 
leading O 
to O 
selectivity O 
index O 
SI=5.5 O 
and O 
SI O 
> O 
21 O 
. O 

and O 
other O 
elements O 
in O 
selected O 
herbal O 
tea O 
plant O 
species O 
and O 
their O 
infusions O 
. O 

determination O 
of O 
Al B-FORMULA 
, O 
B B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Ni B-FORMULA 
, O 
P B-FORMULA 
, O 
Zn B-FORMULA 
and O 
Ca B-FORMULA 
, O 
K B-FORMULA 
, O 
Mg B-FORMULA 
by O 
inductively O 
coupled O 
plasma O 
optical O 
emission O 
spectrometry O 
( O 
ICP-OES O 
) O 
and O 
flame O 
atomic O 
absorption O 
spectroscopy O 
( O 
FAAS O 
) O 
, O 
respectively O 
, O 
in O 
digests O 
and O 
infusions O 
of O 
Hibiscus O 
sabdariffa O 
( O 
petals O 
) O 
, O 
Rosa O 
canina O 
( O 
receptacles O 
) O 
, O 
Ginkgo O 
biloba O 
( O 
leaves O 
) O 
, O 
Cymbopogon O 
citratus O 
( O 
leaves O 
) O 
, O 
Aloe O 
vera O 
( O 
leaves O 
) O 
and O 
Panax O 
ginseng O 
( O 
roots O 
) O 
was O 
carried O 
out O 
in O 
this O 
study O 
. O 
Particular O 
attention O 
has O 
been O 
given O 
to O 
Al B-FORMULA 
and O 
heavy O 
metals O 
for O 
the O 
identification O 
of O 
possible O 
raw O 
material O 
contaminants O 
, O 
their O 
transformation O 
into O 
the O 
infusion O 
and O 
for O 
predicting O 
their O 
eventual O 
role O 
in O 
the O 
human O 
diet O 
during O 
daily O 
consumption O 
. O 
Additionally O 
, O 
Ion O 
Chromatography O 
( O 
IC O 
) O 
speciation O 
of O 
Al B-FORMULA 
in O 
the O 
leachates O 
was O 
carried O 
out O 
. O 
In O 
dry O 
herbs O 
, O 
hibiscus O 
and O 
ginkgo O 
appeared O 
to O 
contain O 
the O 
greatest O 
contents O 
of O 
Al B-FORMULA 
, O 
Fe B-FORMULA 
, O 
K B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Zn B-FORMULA 
and O 
B B-FORMULA 
, O 
Mg B-FORMULA 
, O 
P B-FORMULA 
, O 
respectively O 
. O 
A O 
. O 
vera O 
contained O 
the O 
highest O 
amount O 
of O 
Ca B-FORMULA 
and O 
highest O 
values O 
of O 
Cu B-FORMULA 
and O 
P B-FORMULA 
were O 
observed O 
in O 
ginseng O 
. O 
In O 
infusions O 
, O 
the O 
topmost O 
concentrations O 
of O 
Al B-FORMULA 
, O 
B B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Fe B-FORMULA 
, O 
P B-FORMULA 
, O 
K B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Zn B-FORMULA 
were O 
detected O 
in O 
those O 
prepared O 
from O 
hibiscus O 
petals O 
, O 
Ca B-FORMULA 
from O 
aloe O 
leaves O 
and O 
Mg B-FORMULA 
from O 
leaves O 
of O 
ginkgo O 
. O 
According O 
to O 
a O 
possible O 
daily O 
consumption O 
exceeding O 
1L O 
, O 
hibiscus O 
decoction O 
was O 
identified O 
as O 
potentially O 
dietetically O 
significant O 
in O 
the O 
content O 
of O 
certain O 
elements O 
. O 
It O 
seems O 
to O 
be O 
possibly O 
one O 
of O 
the O 
top O 
contributors O 
of O 
B B-FORMULA 
from O 
food O 
( O 
up O 
to O 
5.5±0.2mg O 
/ O 
L O 
) O 
. O 
The O 
Mg B-FORMULA 
contained O 
in O 
the O 
infusion O 
( O 
up O 
to O 
106±5mg O 
/ O 
L O 
) O 
may O 
be O 
a O 
contributor O 
in O 
the O 
attenuation O 
of O 
blood O 
pressure O 
. O 
A O 
high O 
amount O 
of O 
accessible O 
Mn B-FORMULA 
( O 
up O 
to O 
17.4±1.1mg O 
/ O 
L O 
) O 
can O 
probably O 
have O 
an O 
adverse O 
effect O 
in O 
humans O 
. O 
The O 
total O 
Al B-FORMULA 
allowance O 
( O 
up O 
to O 
1.2±0.1mg O 
/ O 
L O 
) O 
suggests O 
that O 
no O 
more O 
than O 
1L O 
of O 
the O 
hibiscus O 
infusion O 
should O 
be O 
consumed O 
per O 
day O 
by O 
sensitive O 
individuals O 
including O 
pregnant O 
women O 
and O 
should O 
be O 
completely O 
excluded O 
from O 
the O 
diet O 
of O 
children O 
under O 
6months O 
of O 
age O 
and O 
children O 
with O 
chronic O 
renal O 
failure O 
. O 

G O 
protein O 
coupled O 
receptor O 
55 O 
( O 
GPR55 O 
) O 
is O 
a O 
lysophosphatidylinositol B-FAMILY 
( O 
LPI B-ABBREVIATION 
) O 
receptor O 
that O 
is O 
also O 
responsive O 
to O 
certain O 
cannabinoids O 
. O 
Although O 
GPR55 O 
has O 
been O 
implicated O 
in O 
several O 
(patho)physiological O 
functions O 
, O 
its O 
role O 
is O 
still O 
enigmatic O 
mainly O 
owing O 
to O 
the O 
lack O 
of O 
selective O 
GPR55 O 
antagonists O 
. O 
Here O 
we O 
show O 
that O 
the O 
compound O 
CID16020046 B-IDENTIFIER 
( O 
( B-SYSTEMATIC 
4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo I-SYSTEMATIC 
[ I-SYSTEMATIC 
3,4-c I-SYSTEMATIC 
] I-SYSTEMATIC 
pyrazol-5-yl I-SYSTEMATIC 
] I-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
is O 
a O 
selective O 
GPR55 O 
antagonist O 
. O 
In O 
yeast O 
cells O 
expressing O 
human O 
GPR55 O 
, O 
CID16020046 B-IDENTIFIER 
antagonized O 
agonist O 
- O 
induced O 
receptor O 
activation O 
. O 
In O 
HEK293 O 
cells O 
stably O 
expressing O 
human O 
GPR55 O 
( O 
HEK-GPR55 O 
) O 
, O 
the O 
compound O 
behaved O 
as O 
an O 
antagonist O 
on O 
LPI B-ABBREVIATION 
-mediated O 
Ca2+ B-FORMULA 
release O 
and O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
( O 
ERK1 O 
/ O 
2 O 
) O 
activation O 
, O 
but O 
not O 
in O 
HEK293 O 
cells O 
expressing O 
cannabinoid O 
receptor O 
1 O 
or O 
2 O 
( O 
CB1 O 
or O 
CB2 O 
) O 
. O 
CID16020046 B-IDENTIFIER 
concentration O 
- O 
dependently O 
inhibited O 
LPI B-ABBREVIATION 
-induced O 
activation O 
of O 
nuclear O 
factor O 
of O 
activated O 
T-cells O 
( O 
NFAT O 
) O 
, O 
nuclear O 
factor O 
kappa O 
of O 
activated O 
B O 
cells O 
( O 
NF-κB O 
) O 
and O 
serum O 
response O 
element O 
( O 
SRE O 
) O 
, O 
translocation O 
of O 
NFAT O 
and O 
NF-κB O 
, O 
and O 
GPR55 O 
internalization O 
. O 
It O 
reduced O 
LPI B-ABBREVIATION 
-induced O 
wound O 
healing O 
in O 
primary O 
human O 
lung O 
microvascular O 
endothelial O 
cells O 
( O 
HMVEC-L O 
) O 
and O 
reversed O 
LPI B-ABBREVIATION 
-inhibited O 
platelet O 
aggregation O 
, O 
suggesting O 
a O 
novel O 
role O 
for O 
GPR55 O 
in O 
platelet O 
and O 
endothelial O 
cell O 
function O 
. O 
CID16020046 B-IDENTIFIER 
is O 
therefore O 
a O 
valuable O 
tool O 
to O 
study O 
GPR55 O 
- O 
mediated O 
mechanisms O 
in O 
primary O 
cells O 
and O 
tissues O 
. O 

mesoporous O 
boron B-FAMILY 
- I-FAMILY 
doped I-FAMILY 
carbons I-FAMILY 
as O 
metal O 
- O 
free O 
electrocatalysts O 
for O 
the O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
in O 
alkaline O 
solution O 
. O 

mesoporous O 
boron B-FAMILY 
- I-FAMILY 
doped I-FAMILY 
carbons I-FAMILY 
( O 
BOMCs O 
) O 
were O 
prepared O 
by O 
co O 
- O 
impregnation O 
and O 
carbonization O 
of O 
sucrose B-TRIVIAL 
and O 
4-hydroxyphenylboronic B-SYSTEMATIC 
acid I-SYSTEMATIC 
into O 
SBA B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
silica B-TRIVIAL 
template O 
. O 
Nitrogen B-SYSTEMATIC 
sorption O 
, O 
small O 
angle O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
reveals O 
that O 
BOMCs O 
possess O 
highly O 
ordered O 
mesoporous O 
structure O 
, O 
uniform O 
pore O 
size O 
distribution O 
, O 
and O 
high O 
surface O 
area O 
. O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
analysis O 
demonstrates O 
that O 
B B-FORMULA 
atoms O 
can O 
be O 
successfully O 
doped O 
into O 
the O 
framework O 
of O 
OMCs O 
. O 
Due O 
to O 
the O 
desirable O 
characteristics O 
of O 
BOMCs O 
, O 
BOMCs O 
are O 
highly O 
active O 
, O 
cheap O 
, O 
and O 
selective O 
metal O 
- O 
free O 
electrocatalysts O 
for O 
the O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
in O 
alkaline O 
solution O 
. O 
Although O 
B B-FORMULA 
content O 
is O 
a O 
key O 
factor O 
in O 
determining O 
ORR O 
activity O 
, O 
the O 
ORR O 
activity O 
of O 
BOMCs O 
is O 
also O 
dependent O 
on O 
the O 
surface O 
area O 
. O 
The O 
high O 
surface O 
area O 
of O 
BOMCs O 
facilitates O 
the O 
exposure O 
of O 
the O 
active O 
sites O 
for O 
ORR O 
. O 
BOMCs O 
may O 
be O 
further O 
exploited O 
as O 
potentially O 
efficient O 
and O 
inexpensive O 
metal O 
- O 
free O 
ORR O 
catalysts O 
with O 
good O 
long O 
- O 
term O 
stability O 
in O 
alkaline O 
solution O 
. O 

- O 
assembled O 
pH-sensitive O 
cholesteryl B-TRIVIAL 
pullulan O 
nanogel O 
as O 
a O 
protein O 
delivery O 
vehicle O 
. O 

self O 
- O 
assembled O 
nanogel O 
, O 
derived O 
from O 
an O 
acid O 
- O 
labile O 
cholesteryl B-TRIVIAL 
-modified O 
pullulan O 
( O 
acL-CHP O 
) O 
, O 
was O 
prepared O 
by O 
grafting O 
vinyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
- O 
cholesterol B-TRIVIAL 
substituents O 
onto O 
a O 
100 O 
kD O 
pullulan O 
main O 
chain O 
polymer O 
backbone O 
. O 
Stable O 
nanogels O 
are O 
formed O 
by O 
acL-CHP O 
self O 
- O 
assemblies O 
at O 
neutral O 
pH O 
. O 
The O 
hydrodynamic O 
radius O 
of O 
the O 
nanogels O 
, O 
observed O 
to O 
be O 
26.5 O 
± O 
5.1 O 
nm O 
at O 
pH O 
7 O 
, O 
increased O 
by O 
~135% O 
upon O 
acidification O 
of O 
the O 
solution O 
to O 
pH O 
4 O 
. O 
SEC O 
analysis O 
of O 
the O 
acL-CHP O 
nanogel O 
at O 
pH O 
4 O 
showed O 
that O 
the O 
grafts O 
were O 
nearly O 
80% O 
degraded O 
after O 
24 O 
h O 
, O 
whereas O 
little O 
or O 
no O 
degradation O 
was O 
observed O 
over O 
the O 
same O 
time O 
period O 
for O 
a O 
pH O 
stable O 
analog O 
( O 
acS-CHP O 
) O 
at O 
pH O 
4 O 
or O 
the O 
acL-CHP O 
at O 
pH O 
7 O 
. O 
Complexation O 
of O 
BSA O 
with O 
the O 
acL-CHP O 
nanogel O 
was O 
observed O 
at O 
pH O 
7 O 
with O 
subsequent O 
release O 
of O 
the O 
protein O 
upon O 
acidification O 
. O 
These O 
findings O 
suggest O 
that O 
stimuli O 
- O 
responsive O 
, O 
self O 
- O 
assembled O 
nanogels O 
can O 
release O 
protein O 
cargo O 
in O 
a O 
manner O 
that O 
is O 
controlled O 
by O 
the O 
degradation O 
rate O 
of O 
the O 
cholesterol B-TRIVIAL 
-pullulan O 
grafting O 
moiety O 
. O 

Highly O 
Crystalline O 
Manganese-Doped B-SYSTEMATIC 
Iron I-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Nanocontainer O 
with O 
Predesigned O 
Void O 
Volume O 
and O 
Shape O 
for O 
Theranostic O 
Applications O 
. O 

Mn-doped B-SYSTEMATIC 
iron I-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanocontainers O 
, O 
formed O 
by O 
a O 
novel O 
one O 
- O 
pot O 
synthetic O 
process O 
, O 
fulfill O 
the O 
dual O 
requirements O 
of O 
delivering O 
an O 
effective O 
dose O 
of O 
an O 
anticancer O 
drug O 
to O 
tumor O 
tissue O 
and O 
enabling O 
image O 
- O 
contrast O 
monitoring O 
of O 
the O 
nanocontainer O 
fate O 
through O 
T2 O 
-weighted O 
magnetic O 
resonance O 
imaging O 
, O 
thereby O 
determining O 
the O 
optimal O 
balance O 
between O 
diagnostic O 
and O 
therapeutic O 
moieties O 
in O 
an O 
all O 
- O 
in O 
- O 
one O 
theranostic O 
nanoplatform O 
. O 

vivo O 
HIF O 
- O 
mediated O 
reductive O 
carboxylation O 
is O 
regulated O 
by O 
citrate B-FAMILY 
levels O 
and O 
sensitizes O 
VHL-deficient O 
cells O 
to O 
glutamine B-TRIVIAL 
deprivation O 
. O 

and O 
VHL-deficient O 
cells O 
use O 
glutamine B-TRIVIAL 
to O 
generate O 
citrate B-FAMILY 
and O 
lipids O 
through O 
reductive O 
carboxylation O 
( O 
RC O 
) O 
of O 
α-ketoglutarate B-TRIVIAL 
. O 
To O 
gain O 
insights O 
into O 
the O 
role O 
of O 
HIF O 
and O 
the O 
molecular O 
mechanisms O 
underlying O 
RC O 
, O 
we O 
took O 
advantage O 
of O 
a O 
panel O 
of O 
disease O 
- O 
associated O 
VHL O 
mutants O 
and O 
showed O 
that O 
HIF O 
expression O 
is O 
necessary O 
and O 
sufficient O 
for O 
the O 
induction O 
of O 
RC O 
in O 
human O 
renal O 
cell O 
carcinoma O 
( O 
RCC O 
) O 
cells O 
. O 
HIF O 
expression O 
drastically O 
reduced O 
intracellular O 
citrate B-FAMILY 
levels O 
. O 
Feeding O 
VHL-deficient O 
RCC O 
cells O 
with O 
acetate B-SYSTEMATIC 
or O 
citrate B-FAMILY 
or O 
knocking O 
down O 
PDK-1 O 
and O 
ACLY O 
restored O 
citrate B-FAMILY 
levels O 
and O 
suppressed O 
RC O 
. O 
These O 
data O 
suggest O 
that O 
HIF-induced O 
low O 
intracellular O 
citrate B-FAMILY 
levels O 
promote O 
the O 
reductive O 
flux O 
by O 
mass O 
action O 
to O 
maintain O 
lipogenesis O 
. O 
Using O 
[(1-13)C]glutamine B-SYSTEMATIC 
, O 
we O 
demonstrated O 
in O 
vivo O 
RC O 
activity O 
in O 
VHL-deficient O 
tumors O 
growing O 
as O 
xenografts O 
in O 
mice O 
. O 
Lastly O 
, O 
HIF O 
rendered O 
VHL-deficient O 
cells O 
sensitive O 
to O 
glutamine B-TRIVIAL 
deprivation O 
in O 
vitro O 
, O 
and O 
systemic O 
administration O 
of O 
glutaminase O 
inhibitors O 
suppressed O 
the O 
growth O 
of O 
RCC O 
cells O 
as O 
mice O 
xenografts O 
. O 

type O 
7 O 
receptor O 
neuroprotection O 
against O 
NMDA B-ABBREVIATION 
-induced O 
excitotoxicity O 
is O 
PDGFβ O 
receptor O 
dependent O 
. O 

serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
type O 
7 O 
receptor O 
is O 
expressed O 
throughout O 
the O 
CNS O 
including O 
the O 
hippocampus O 
. O 
Long O 
- O 
term O 
( O 
2-24 O 
h O 
) O 
activation O 
of O 
5-HT7 O 
receptors O 
regulates O 
growth O 
factor O 
receptor O 
expression O 
, O 
including O 
the O 
expression O 
of O 
platelet O 
- O 
derived O 
growth O 
factor O 
( O 
PDGF O 
) O 
β O 
receptors O 
. O 
Direct O 
activation O 
of O 
PDGFβ O 
receptors O 
in O 
primary O 
hippocampal O 
and O 
cortical O 
neurons O 
inhibits O 
NMDA B-ABBREVIATION 
receptor O 
activity O 
and O 
attenuates O 
NMDA B-ABBREVIATION 
receptor O 
- O 
induced O 
neurotoxicity O 
. O 
Our O 
objective O 
was O 
to O 
investigate O 
whether O 
the O 
5-HT7 O 
receptor O 
- O 
induced O 
increase O 
in O 
PDGFβ O 
receptor O 
expression O 
would O 
be O 
similarly O 
neuroprotective O 
. O 
We O 
demonstrate O 
that O 
5-HT7 O 
receptor O 
agonist O 
treatment O 
in O 
primary O 
hippocampal O 
neurons O 
also O 
increases O 
the O 
expression O 
of O 
phospholipase O 
C O 
( O 
PLC O 
) O 
γ O 
, O 
a O 
downstream O 
effector O 
of O 
PDGFβ O 
receptors O 
associated O 
with O 
the O 
inhibition O 
of O 
NMDA B-ABBREVIATION 
receptor O 
activity O 
. O 
To O 
determine O 
if O 
the O 
up O 
- O 
regulation O 
of O 
PDGFβ O 
receptors O 
is O 
neuroprotective O 
, O 
primary O 
hippocampal O 
neurons O 
were O 
incubated O 
with O 
the O 
5-HT7 O 
receptor O 
agonist O 
, O 
LP B-IDENTIFIER 
12 I-IDENTIFIER 
, O 
for O 
24 O 
h O 
. O 
Indeed O 
, O 
LP B-IDENTIFIER 
12 I-IDENTIFIER 
treatment O 
prevented O 
NMDA B-ABBREVIATION 
-induced O 
neurotoxicity O 
and O 
this O 
effect O 
was O 
dependent O 
on O 
PDGFβ O 
receptor O 
kinase O 
activity O 
. O 
Treatment O 
of O 
primary O 
neurons O 
with O 
LP B-IDENTIFIER 
12 I-IDENTIFIER 
also O 
differentially O 
altered O 
NMDA B-ABBREVIATION 
receptor O 
subunit O 
expression O 
, O 
reducing O 
the O 
expression O 
of O 
NR1 O 
and O 
NR2B O 
, O 
but O 
not O 
NR2A O 
. O 
These O 
findings O 
demonstrate O 
the O 
potential O 
for O 
providing O 
growth O 
factor O 
receptor O 
- O 
dependent O 
neuroprotective O 
effects O 
using O 
small O 
- O 
molecule O 
ligands O 
of O 
G O 
protein O 
- O 
coupled O 
receptors O 
. O 

and O 
Cytostatic O 
and O 
Antiviral O 
Activities O 
of O 
2'-Deoxy-2',2'-difluororibo- B-MULTIPLE 
and I-MULTIPLE 
2'-Deoxy-2'-fluororibonucleosides I-MULTIPLE 
Derived O 
from O 
7-(Het)aryl-7-deazaadenines B-FAMILY 
. O 

series O 
of O 
sugar B-FAMILY 
-modified O 
derivatives O 
of O 
cytostatic O 
7-heteroaryl-7-deazaadenosines B-FAMILY 
( O 
2'-deoxy-2'-fluororibo- B-MULTIPLE 
and I-MULTIPLE 
2'-deoxy-2',2'-difluororibonucleosides I-MULTIPLE 
) O 
bearing O 
an O 
aryl B-FAMILY 
or O 
heteroaryl B-FAMILY 
group O 
at O 
position O 
7 O 
was O 
prepared O 
and O 
screened O 
for O 
biological O 
activity O 
. O 
The O 
difluororibonucleosides B-FAMILY 
were O 
prepared O 
by O 
non- O 
stereoselective O 
glycosidation O 
of O 
6-chloro-7-deazapurine B-SYSTEMATIC 
with O 
benzoyl B-SYSTEMATIC 
- I-SYSTEMATIC 
protected I-SYSTEMATIC 
2-deoxy-2,2-difluoro-D-erythro-pentofuranosyl-1-mesylate I-SYSTEMATIC 
, O 
followed O 
by O 
amination O 
and O 
aqueous O 
Suzuki O 
cross O 
- O 
couplings O 
with O 
(het)arylboronic B-FAMILY 
acids I-FAMILY 
. O 
The O 
fluororibo B-SYSTEMATIC 
derivatives O 
were O 
prepared O 
by O 
aqueous O 
palladium B-SYSTEMATIC 
-catalyzed O 
cross O 
- O 
coupling O 
reactions O 
of O 
the O 
corresponding O 
7-iodo-7-deazaadenine B-SYSTEMATIC 
2'-deoxy-2'-fluororibonucleoside I-SYSTEMATIC 
20 O 
with O 
(het)arylboronic B-FAMILY 
acids I-FAMILY 
. O 
The O 
key O 
intermediate O 
20 O 
was O 
prepared O 
by O 
a O 
six O 
- O 
step O 
sequence O 
from O 
the O 
corresponding O 
arabinonucleoside B-FAMILY 
by O 
selective O 
protection O 
of O 
3'- B-MULTIPLE 
and I-MULTIPLE 
5'-hydroxy I-MULTIPLE 
groups O 
with O 
acid O 
- O 
labile O 
groups O 
, O 
followed O 
by O 
stereoselective O 
SN O 
2 O 
fluorination O 
and O 
deprotection O 
. O 
Some O 
of O 
the O 
title O 
nucleosides B-FAMILY 
and O 
7-iodo-7-deazaadenine B-SYSTEMATIC 
intermediates O 
showed O 
micromolar O 
cytostatic O 
or O 
anti-HCV O 
activity O 
. O 
The O 
most O 
active O 
were O 
7-iodo B-SYSTEMATIC 
and O 
7-ethynyl B-SYSTEMATIC 
derivatives O 
. O 
The O 
corresponding O 
2'-deoxy-2',2'-difluororibonucleoside B-FAMILY 
5'-O-triphosphates I-FAMILY 
were O 
found O 
to O 
be O 
good O 
substrates O 
for O 
bacterial O 
DNA O 
polymerases O 
, O 
but O 
are O 
inhibitors O 
of O 
human O 
polymerase O 
α O 
. O 

and O 
sex O 
steroids B-FAMILY 
levels O 
in O 
congenital O 
lifetime O 
isolated O 
GH O 
deficiency O 
. O 

hormone O 
( O 
GH O 
) O 
and O 
prolactin O 
share O 
similarities O 
in O 
structure O 
and O 
function O 
. O 
We O 
have O 
previously O 
shown O 
that O 
women O 
with O 
congenital O 
isolated O 
GH O 
deficiency O 
( O 
IGHD O 
) O 
caused O 
by O 
a O 
homozygous O 
mutation O 
in O 
the O 
GHRH O 
receptor O 
gene O 
( O 
GHRHR O 
) O 
( O 
MUT O 
/ O 
MUT O 
) O 
have O 
a O 
short O 
reproductive O 
life O 
, O 
with O 
anticipated O 
climacteric O 
. O 
At O 
climacteric O 
, O 
they O 
have O 
lower O 
prolactin O 
levels O 
than O 
normal O 
controls O 
( O 
N O 
/ O 
N O 
) O 
. O 
Because O 
they O 
are O 
able O 
to O 
breast O 
feed O 
, O 
we O 
hypothesized O 
that O 
this O 
prolactin O 
reduction O 
is O 
limited O 
to O 
climacteric O 
, O 
as O 
result O 
of O 
lower O 
estradiol B-TRIVIAL 
exposure O 
of O 
the O 
lactotrophs O 
. O 
The O 
purposes O 
of O 
this O 
work O 
were O 
to O 
assess O 
prolactin O 
levels O 
in O 
broader O 
age O 
adults O 
homozygous O 
and O 
heterozygous O 
( O 
MUT O 
/ O 
N O 
) O 
for O 
the O 
mutation O 
and O 
in O 
normal O 
controls O 
( O 
N O 
/ O 
N O 
) O 
, O 
and O 
to O 
correlate O 
them O 
to O 
sex O 
steroids B-FAMILY 
levels O 
. O 
We O 
enrolled O 
24 O 
GH-naïve O 
MUT O 
/ O 
MUT O 
( O 
12 O 
female O 
) O 
, O 
25 O 
MUT O 
/ O 
N O 
( O 
14 O 
female O 
) O 
, O 
and O 
25 O 
N O 
/ O 
N O 
( O 
11 O 
female O 
) O 
subjects O 
, O 
aged O 
25-65 O 
years O 
. O 
Anthropometric O 
data O 
and O 
serum O 
prolactin O 
, O 
estradiol B-TRIVIAL 
, O 
total O 
testosterone B-TRIVIAL 
, O 
and O 
sex O 
hormone O 
binding O 
globulin O 
( O 
SHBG O 
) O 
were O 
measured O 
. O 
Free O 
testosterone B-TRIVIAL 
was O 
calculated O 
. O 
Prolactin O 
levels O 
were O 
similar O 
in O 
the O 
three O 
groups O 
. O 
In O 
males O 
, O 
testosterone B-TRIVIAL 
and O 
SHBG O 
levels O 
were O 
higher O 
in O 
MUT O 
/ O 
MUT O 
in O 
comparison O 
to O 
N O 
/ O 
N O 
. O 
There O 
was O 
no O 
difference O 
in O 
free O 
testosterone B-TRIVIAL 
among O 
groups O 
. O 
In O 
all O 
74 O 
individuals O 
, O 
prolactin O 
correlated O 
inversely O 
with O 
age O 
( O 
p O 
< O 
0.0001 O 
) O 
and O 
directly O 
with O 
serum O 
estradiol B-TRIVIAL 
( O 
p O 
= O 
0.018 O 
) O 
. O 
Prolactin O 
levels O 
in O 
subjects O 
with O 
IGHD O 
due O 
to O 
a O 
homozygous O 
GHRHR O 
mutation O 
are O 
similar O 
to O 
heterozygous O 
and O 
normal O 
homozygous O 
, O 
but O 
total O 
testosterone B-TRIVIAL 
and O 
SHBG O 
are O 
higher O 
in O 
male O 
MUT O 
/ O 
MUT O 
, O 
with O 
no O 
difference O 
in O 
free O 
testosterone B-TRIVIAL 
. O 
The O 
reduced O 
prolactin O 
level O 
is O 
limited O 
to O 
climacteric O 
period O 
, O 
possibly O 
due O 
to O 
reduced O 
estrogen B-FAMILY 
exposure O 
. O 

of O 
NO2 B-FORMULA 
with O 
Zr B-FORMULA 
-based O 
MOF O 
: O 
effects O 
of O 
the O 
size O 
of O 
organic O 
linkers O 
on O 
NO2 B-FORMULA 
adsorption O 
at O 
ambient O 
conditions O 
. O 

-based O 
metal O 
organic O 
framework O 
( O 
Zr B-FORMULA 
-MOF O 
) O 
, O 
UiO-66 B-IDENTIFIER 
and O 
UiO-67 B-IDENTIFIER 
, O 
were O 
synthesized O 
and O 
used O 
as O 
adsorbents O 
of O 
NO(2) B-FORMULA 
at O 
ambient O 
temperatures O 
in O 
either O 
dry O 
or O 
moist O 
conditions O 
. O 
The O 
samples O 
were O 
characterized O 
before O 
and O 
after O 
exposure O 
to O 
NO(2) B-FORMULA 
by O 
X-ray O 
diffraction O 
, O 
scanning O 
electron O 
microscopy O 
, O 
N(2) B-FORMULA 
-adsorption O 
at O 
77 O 
K O 
, O 
thermal O 
analysis O 
, O 
and O 
infrared O 
spectroscopy O 
. O 
The O 
results O 
indicate O 
the O 
important O 
effect O 
of O 
a O 
ligand O 
size O 
on O 
the O 
adsorption O 
of O 
NO(2) B-FORMULA 
on O 
Zr B-FORMULA 
-MOF O 
materials O 
. O 
While O 
the O 
large O 
size O 
of O 
the O 
4,4-benzenebiphenyldicarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
BDPC B-ABBREVIATION 
) O 
ligand O 
has O 
a O 
positive O 
impact O 
on O 
the O 
adsorption O 
of O 
NO(2) B-FORMULA 
on O 
UiO-67 B-IDENTIFIER 
in O 
moist O 
conditions O 
, O 
the O 
opposite O 
effect O 
is O 
found O 
in O 
dry O 
conditions O 
. O 
The O 
large O 
pore O 
volume O 
of O 
UiO-67 B-IDENTIFIER 
enhances O 
the O 
adsorption O 
of O 
moisture O 
and O 
formation O 
of O 
nitric B-MULTIPLE 
and I-MULTIPLE 
nitrous I-MULTIPLE 
acids I-MULTIPLE 
. O 
The O 
small O 
pore O 
sizes O 
of O 
UiO-66 B-IDENTIFIER 
favor O 
the O 
NO(2) B-FORMULA 
removal O 
in O 
dry O 
conditions O 
via O 
dispersive O 
forces O 
. O 
Upon O 
interaction O 
of O 
NO(2) B-FORMULA 
molecules O 
with O 
the O 
Zr B-FORMULA 
-MOF O 
in O 
dry O 
conditions O 
, O 
the O 
bond O 
between O 
the O 
organic O 
linker O 
and O 
metallic O 
oxide B-SYSTEMATIC 
center O 
is O 
broken O 
, O 
leading O 
to O 
the O 
formation O 
of O 
nitrate B-SYSTEMATIC 
and O 
nitrite B-SYSTEMATIC 
species O 
. O 
Moreover O 
, O 
organic O 
ligands O 
also O 
contribute O 
to O 
the O 
NO(2) B-FORMULA 
reactive O 
adsorption O 
via O 
nitration O 
reaction O 
. O 

describe O 
a O 
genetic O 
AND O 
gate O 
for O 
cell O 
- O 
targeted O 
metabolic O 
labeling O 
and O 
proteomic O 
analysis O 
in O 
complex O 
cellular O 
systems O 
. O 
The O 
centerpiece O 
of O 
the O 
AND O 
gate O 
is O 
a O 
bisected O 
methionyl B-TRIVIAL 
-tRNA O 
synthetase O 
( O 
MetRS O 
) O 
that O 
charges O 
the O 
Met B-FORMULA 
surrogate O 
azidonorleucine B-SYSTEMATIC 
( O 
Anl B-ABBREVIATION 
) O 
to O 
tRNA( O 
Met B-FORMULA 
) O 
. O 
Cellular O 
protein O 
labeling O 
occurs O 
only O 
upon O 
activation O 
of O 
two O 
different O 
promoters O 
that O 
drive O 
expression O 
of O 
the O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
fragments O 
of O 
the O 
bisected O 
MetRS O 
. O 
Anl B-ABBREVIATION 
-labeled O 
proteins O 
can O 
be O 
tagged O 
with O 
fluorescent O 
dyes O 
or O 
affinity O 
reagents O 
via O 
either O 
copper B-SYSTEMATIC 
-catalyzed O 
or O 
strain O 
- O 
promoted O 
azide-alkyne O 
cycloaddition O 
. O 
Protein O 
labeling O 
is O 
apparent O 
within O 
5 O 
min O 
after O 
addition O 
of O 
Anl B-ABBREVIATION 
to O 
bacterial O 
cells O 
in O 
which O 
the O 
AND O 
gate O 
has O 
been O 
activated O 
. O 
This O 
method O 
allows O 
spatial O 
and O 
temporal O 
control O 
of O 
proteomic O 
labeling O 
and O 
identification O 
of O 
proteins O 
made O 
in O 
specific O 
cellular O 
subpopulations O 
. O 
The O 
approach O 
is O 
demonstrated O 
by O 
selective O 
labeling O 
of O 
proteins O 
in O 
bacterial O 
cells O 
immobilized O 
in O 
the O 
center O 
of O 
a O 
laminar O 
- O 
flow O 
microfluidic O 
channel O 
, O 
where O 
they O 
are O 
exposed O 
to O 
overlapping O 
, O 
opposed O 
gradients O 
of O 
inducers O 
of O 
the O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
MetRS O 
fragments O 
. O 
The O 
observed O 
labeling O 
profile O 
is O 
predicted O 
accurately O 
from O 
the O 
strengths O 
of O 
the O 
individual O 
input O 
signals O 
. O 

homeodomain O 
( O 
PHD O 
) O 
- O 
type O 
zinc B-SYSTEMATIC 
fingers O 
play O 
an O 
important O 
role O 
in O 
recognizing O 
chromatin O 
modifications O 
and O 
recruiting O 
regulatory O 
proteins O 
to O 
specific O 
genes O 
. O 
A O 
specific O 
module O 
containing O 
a O 
conventional O 
PHD O 
finger O 
followed O 
by O 
an O 
extended O 
PHD O 
finger O 
exists O 
in O 
the O 
mammalian O 
AF10 O 
protein O 
, O 
among O 
a O 
few O 
others O 
. O 
AF10 O 
has O 
mostly O 
been O 
studied O 
in O 
the O 
context O 
of O 
the O 
leukemic O 
MLL-AF10 O 
fusion O 
protein O 
, O 
which O 
lacks O 
the O 
N B-FORMULA 
-terminal O 
PHD O 
fingers O 
of O 
AF10 O 
. O 
Although O 
this O 
domain O 
of O 
AF10 O 
is O 
the O 
most O 
conserved O 
region O 
of O 
the O 
protein O 
, O 
its O 
biological O 
significance O 
has O 
not O 
been O 
elucidated O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
genetic O 
and O 
biochemical O 
approaches O 
to O 
examine O 
the O 
PHD1-PHD2 O 
region O 
of O 
the O 
Caenorhabditis O 
elegans O 
ortholog O 
of O 
AF10 O 
, O 
zinc B-SYSTEMATIC 
finger O 
protein O 
1 O 
( O 
ZFP-1 O 
) O 
. O 
We O 
demonstrate O 
that O 
the O 
PHD1-PHD2 O 
region O 
is O 
essential O 
for O 
viability O 
and O 
that O 
the O 
first O 
PHD O 
finger O 
contributes O 
to O 
the O 
preferred O 
binding O 
of O 
PHD1-PHD2 O 
to O 
lysine B-TRIVIAL 
4-methylated O 
histone O 
H3 O 
tails O 
. O 
Moreover O 
, O 
we O 
show O 
that O 
ZFP-1 O 
localization O 
peaks O 
overlap O 
with O 
H3K4 O 
methylation O 
- O 
enriched O 
promoters O 
of O 
actively O 
expressed O 
genes O 
genomewide O 
and O 
that O 
H3K4 O 
methylation O 
is O 
important O 
for O 
ZFP-1 O 
localization O 
to O 
promoters O 
in O 
the O 
embryo O 
. O 
We O 
predict O 
that O 
the O 
essential O 
biological O 
role O 
of O 
the O 
PHD1-PHD2 O 
module O 
of O 
ZFP-1 O 
/ O 
AF10 O 
is O 
connected O 
to O 
the O 
regulation O 
of O 
actively O 
expressed O 
genes O 
during O 
early O 
development O 
. O 

D I-SYSTEMATIC 
in O 
Obese O 
Youth O 
Across O 
the O 
Spectrum O 
of O 
Glucose B-TRIVIAL 
Tolerance O 
From O 
Normal O 
to O 
Prediabetes O 
to O 
Type O 
2 O 
Diabetes O 
. O 

1 O 
) O 
determine O 
if O 
plasma O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
25[OH]D B-SYSTEMATIC 
) O 
concentrations O 
differ O 
among O 
obese O 
youth O 
with O 
normal O 
glucose B-TRIVIAL 
tolerance O 
( O 
NGT O 
) O 
versus O 
prediabetes O 
versus O 
type O 
2 O 
diabetes O 
, O 
and O 
2 O 
) O 
assess O 
the O 
relationships O 
between O 
25(OH)D B-SYSTEMATIC 
and O 
in O 
vivo O 
insulin O 
sensitivity O 
and O 
β-cell O 
function O 
in O 
this O 
cohort.RESEARCH O 
DESIGN O 
AND O 
METHODSPlasma O 
25(OH)D B-SYSTEMATIC 
concentrations O 
were O 
examined O 
in O 
banked O 
specimens O 
in O 
9- O 
to O 
20-year- O 
old O 
obese O 
youth O 
( O 
n O 
= O 
175 O 
; O 
male O 
42.3% O 
, O 
black O 
46.3% O 
) O 
( O 
NGT O 
, O 
n O 
= O 
105 O 
; O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
[ O 
IGT O 
] O 
, O 
n O 
= O 
43 O 
; O 
type O 
2 O 
diabetes O 
, O 
n O 
= O 
27 O 
) O 
who O 
had O 
in O 
vivo O 
insulin O 
sensitivity O 
and O 
secretion O 
measured O 
by O 
hyperinsulinemic O 
- O 
euglycemic O 
and O 
hyperglycemic O 
clamp O 
techniques O 
and O 
had O 
an O 
assessment O 
of O 
total O 
body O 
composition O 
and O 
abdominal O 
adiposity.RESULTSThe O 
mean O 
age O 
and O 
BMI O 
of O 
the O 
subjects O 
were O 
14.3 O 
± O 
2.1 O 
years O 
and O 
35.7 O 
± O 
5.6 O 
kg O 
/ O 
m(2) O 
, O 
respectively O 
. O 
BMI O 
, O 
plasma O 
25(OH)D B-SYSTEMATIC 
, O 
and O 
the O 
proportion O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
-deficient O 
and O 
-insufficient O 
children O 
did O 
not O 
differ O 
across O 
the O 
three O 
groups O 
. O 
Furthermore O 
, O 
there O 
was O 
no O 
association O 
between O 
25(OH)D B-SYSTEMATIC 
and O 
in O 
vivo O 
insulin O 
sensitivity O 
or O 
β-cell O 
function O 
relative O 
to O 
insulin O 
sensitivity O 
( O 
disposition O 
index O 
) O 
in O 
all O 
groups O 
combined O 
or O 
in O 
each O 
group O 
separately.CONCLUSIONSOur O 
data O 
in O 
obese O 
youth O 
show O 
1 O 
) O 
no O 
differences O 
in O 
plasma O 
25(OH)D B-SYSTEMATIC 
concentrations O 
across O 
the O 
glucose B-TRIVIAL 
tolerance O 
groups O 
, O 
and O 
2 O 
) O 
no O 
relationship O 
between O 
25(OH)D B-SYSTEMATIC 
and O 
in O 
vivo O 
insulin O 
sensitivity O 
and O 
β-cell O 
function O 
relative O 
to O 
insulin O 
sensitivity O 
in O 
any O 
of O 
the O 
groups O 
. O 
It O 
remains O 
uncertain O 
if O 
enhancement O 
of O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
status O 
could O 
improve O 
pathophysiological O 
mechanisms O 
of O 
prediabetes O 
and O 
type O 
2 O 
diabetes O 
in O 
obese O 
youth O 
. O 

effect O 
of O 
manganese B-SYSTEMATIC 
on O 
dopamine B-TRIVIAL 
toxicity O 
and O 
dopamine B-TRIVIAL 
transporter O 
( O 
DAT O 
) O 
in O 
control O 
and O 
DAT O 
transfected O 
HEK O 
cells O 
. O 

exposure O 
to O 
Mn B-FORMULA 
results O 
in O 
the O 
development O 
of O 
a O 
neurological O 
disorder O 
known O 
as O 
manganism O 
characterized O 
by O 
neurological O 
deficits O 
resembling O 
that O 
seen O 
in O 
Parkinsonism O 
. O 
Although O 
dopaminergic O 
neurons O 
within O 
the O 
nigrostriatal O 
pathway O 
appear O 
intact O 
, O 
Mn B-FORMULA 
-induced O 
irregularities O 
in O 
DA O 
transmission O 
have O 
been O 
observed O 
including O 
decreased O 
amphetamine B-TRIVIAL 
-induced O 
DA O 
release O 
and O 
loss O 
of O 
the O 
dopamine B-TRIVIAL 
transporter O 
( O 
DAT O 
) O 
. O 
Results O 
of O 
studies O 
to O 
evaluate O 
the O 
effect O 
of O 
Mn B-FORMULA 
and O 
DA O 
on O 
cell O 
viability O 
in O 
control O 
and O 
DAT-transfected O 
HEK O 
cells O 
reveal O 
that O 
Mn B-FORMULA 
is O 
equally O 
toxic O 
to O 
both O 
cell O 
lines O 
whereas O 
DA O 
was O 
only O 
toxic O 
to O 
cells O 
containing O 
DAT O 
. O 
DA O 
toxicity O 
was O 
saturable O 
suggesting O 
that O 
transport O 
may O 
be O 
rate O 
limiting O 
. O 
When O 
Mn B-FORMULA 
and O 
DA O 
were O 
added O 
simultaneously O 
to O 
the O 
media O 
, O 
cell O 
toxicity O 
was O 
similar O 
to O 
that O 
produced O 
by O 
Mn B-FORMULA 
alone O 
suggesting O 
that O 
Mn B-FORMULA 
may O 
suppress O 
DA O 
uptake O 
in O 
the O 
DAT O 
containing O 
cells O 
. O 
Preincubation O 
of O 
DA O 
prior O 
to O 
the O 
addition O 
of O 
Mn B-FORMULA 
resulted O 
in O 
cell O 
death O 
which O 
was O 
essentially O 
additive O 
with O 
that O 
produced O 
independently O 
by O 
the O 
two O 
agents O 
. O 
Mn B-FORMULA 
was O 
also O 
shown O 
to O 
decrease O 
DA O 
uptake O 
and O 
amphetamine B-TRIVIAL 
-induced O 
DA O 
efflux O 
in O 
DAT O 
containing O 
cells O 
. O 
Time O 
- O 
lapsed O 
confocal O 
microscopy O 
indicates O 
that O 
Mn B-FORMULA 
can O 
promote O 
trafficking O 
of O 
cell O 
surface O 
DAT O 
into O 
intracellular O 
compartments O 
which O 
may O 
account O 
for O 
the O 
decrease O 
in O 
DA O 
uptake O 
and O 
DA O 
efflux O 
in O 
these O 
cells O 
. O 
Mn B-FORMULA 
-induced O 
internalization O 
of O 
DAT O 
may O 
provide O 
an O 
explanation O 
for O 
disruption O 
in O 
DA O 
transmission O 
previously O 
reported O 
in O 
the O 
striatum O 
. O 

new O 
phenolic B-FAMILY 
glycosides I-FAMILY 
from O 
Inula O 
cappa O 
DC O 
. O 

new O 
phenolic B-FAMILY 
glycosides I-FAMILY 
were O 
isolated O 
from O 
the O 
ethanol B-SYSTEMATIC 
extract O 
of O 
the O 
roots O 
of O 
Inula O 
cappa O 
DC O 
. O 
Their O 
structures O 
were O 
defined O 
as O 
4-[(6-O-(E)-caffeoyl)-β-D-glucopyranosyl]vanillic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
3-O-[β-D-apiofurarnosyl-(1-6)-β-D-glucopyranoxy]-6-hydroxy-p-cymene B-SYSTEMATIC 
( O 
2 O 
) O 
on O 
the O 
basis O 
of O 
spectral O 
analysis O 
. O 

of O 
Apis O 
mellifera O 
bee O 
venom O 
activities O 
by O 
suramin B-TRIVIAL 
. O 

this O 
work O 
we O 
evaluated O 
the O 
ability O 
of O 
suramin B-TRIVIAL 
, O 
a O 
polysulfonated B-FAMILY 
naphthylurea I-FAMILY 
derivative O 
, O 
to O 
antagonize O 
the O 
cytotoxic O 
and O 
enzymatic O 
effects O 
of O 
the O 
crude O 
venom O 
of O 
Apis O 
mellifera O 
. O 
Suramin B-TRIVIAL 
was O 
efficient O 
to O 
decrease O 
the O 
lethality O 
in O 
a O 
dose O 
- O 
dependent O 
way O 
. O 
The O 
hemoconcentration O 
caused O 
by O 
lethal O 
dose O 
injection O 
of O 
bee O 
venom O 
was O 
abolished O 
by O 
suramin B-TRIVIAL 
( O 
30 O 
μg O 
/ O 
g O 
) O 
. O 
The O 
edematogenic O 
activity O 
of O 
the O 
venom O 
( O 
0.3 O 
μg O 
/ O 
g O 
) O 
was O 
antagonized O 
by O 
suramin B-TRIVIAL 
( O 
10 O 
μg O 
/ O 
g O 
) O 
in O 
all O 
treatment O 
protocols O 
. O 
The O 
changes O 
in O 
the O 
vascular O 
permeability O 
caused O 
by O 
A O 
. O 
mellifera O 
( O 
1 O 
μg O 
/ O 
g O 
) O 
venom O 
were O 
inhibited O 
by O 
suramin B-TRIVIAL 
( O 
30 O 
μg O 
/ O 
g O 
) O 
in O 
the O 
pre- O 
and O 
posttreatment O 
as O 
well O 
as O 
when O 
the O 
venom O 
was O 
preincubated O 
with O 
suramin B-TRIVIAL 
. O 
In O 
addition O 
, O 
suramin B-TRIVIAL 
also O 
inhibited O 
cultured O 
endothelial O 
cell O 
lesion O 
, O 
as O 
well O 
as O 
in O 
vitro O 
myotoxicity O 
, O 
evaluated O 
in O 
mouse O 
extensor O 
digitorumlongus O 
muscle O 
, O 
which O 
was O 
inhibited O 
by O 
suramin B-TRIVIAL 
( O 
10 O 
and O 
25 O 
μM O 
) O 
, O 
decreasing O 
the O 
rate O 
of O 
CK O 
release O 
, O 
showing O 
that O 
suramin B-TRIVIAL 
protected O 
the O 
sarcolemma O 
against O 
damage O 
induced O 
by O 
components O 
of O 
bee O 
venom O 
( O 
2.5 O 
μg O 
/ O 
mL O 
) O 
. O 
Moreover O 
, O 
suramin B-TRIVIAL 
inhibited O 
the O 
in O 
vivo O 
myotoxicity O 
induced O 
by O 
i.m O 
. O 
injection O 
of O 
A O 
. O 
mellifera O 
venom O 
in O 
mice O 
( O 
0.5 O 
μg O 
/ O 
g O 
) O 
. O 
The O 
analysis O 
of O 
the O 
area O 
under O 
the O 
plasma O 
CK O 
vs O 
. O 
time O 
curve O 
showed O 
that O 
preincubation O 
, O 
pre- O 
and O 
posttreatment O 
with O 
suramin B-TRIVIAL 
( O 
30 O 
μg O 
/ O 
g O 
) O 
inhibited O 
bee O 
venom O 
myotoxic O 
activity O 
in O 
mice O 
by O 
about O 
89% O 
, O 
45% O 
and O 
40% O 
, O 
respectively O 
. O 
Suramin B-TRIVIAL 
markedly O 
inhibited O 
the O 
PLA2 O 
activity O 
in O 
a O 
concentration O 
- O 
dependent O 
way O 
( O 
1-30 O 
μM O 
) O 
. O 
Being O 
suramin B-TRIVIAL 
a O 
polyanion O 
molecule O 
, O 
the O 
effects O 
observed O 
may O 
be O 
due O 
to O 
the O 
interaction O 
of O 
its O 
charges O 
with O 
the O 
polycation O 
components O 
present O 
in O 
A O 
. O 
mellifera O 
bee O 
venom O 
. O 

: O 
Bioterrorism O 
is O 
a O 
terrorist O 
action O 
involving O 
the O 
intentional O 
release O 
or O 
dissemination O 
of O 
a O 
biological O 
warfare O 
agent O 
( O 
BWA O 
) O 
, O 
which O 
includes O 
some O 
bacteria O 
, O 
viruses O 
, O 
rickettsiae O 
, O 
fungi O 
or O 
biological O 
toxins O 
. O 
BWA O 
is O 
a O 
naturally O 
occurring O 
or O 
human O 
- O 
modified O 
form O 
that O 
may O 
kill O 
or O 
incapacitate O 
humans O 
, O 
animals O 
or O 
plants O 
as O 
an O 
act O 
of O 
war O 
or O 
terrorism O 
. O 
BWA O 
is O 
a O 
weapon O 
of O 
choice O 
for O 
mass O 
destruction O 
and O 
terrorism O 
, O 
because O 
of O 
the O 
incubation O 
period O 
, O 
less O 
effective O 
amount O 
than O 
chemical O 
warfare O 
agents O 
, O 
easily O 
distribution O 
, O 
odorless O 
, O 
colorless O 
, O 
difficult O 
to O 
detect O 
, O 
no O 
need O 
of O 
specialized O 
equipment O 
for O 
production O 
and O 
naturally O 
distribution O 
which O 
can O 
easily O 
be O 
obtained O 
. O 
BWA O 
may O 
be O 
disseminating O 
as O 
an O 
aerosol O 
, O 
spray O 
, O 
explosive O 
device O 
, O 
and O 
by O 
food O 
or O 
water O 
. O 
CLASSIFICATION O 
: O 
Based O 
on O 
the O 
risk O 
for O 
human O 
health O 
, O 
BWAs O 
have O 
been O 
prioritized O 
into O 
three O 
categories O 
of O 
A O 
, O 
B O 
and O 
C O 
. O 
Category O 
A O 
includes O 
microorganisms O 
or O 
toxins O 
that O 
easily O 
spread O 
, O 
leading O 
to O 
intoxication O 
with O 
high O 
death O 
rates O 
such O 
as O 
Anthrax O 
, O 
Botulism O 
, O 
Plague O 
, O 
Smallpox O 
, O 
Tularemia O 
and O 
Viral O 
hemorrhagic O 
fevers O 
. O 
Category O 
B O 
has O 
lower O 
toxicity O 
with O 
wider O 
range O 
, O 
including O 
Staphylococcal O 
Entrotoxin O 
type O 
B O 
( O 
SEB O 
) O 
, O 
Epsilon O 
toxin O 
of O 
Clostridium O 
perfringens O 
, O 
Ricin O 
, O 
Saxotoxins B-FAMILY 
, O 
Abrin O 
and O 
Trichothecene B-FAMILY 
mycotoxins O 
. O 
The O 
C O 
category O 
includes O 
emerging O 
pathogens O 
that O 
could O 
also O 
be O 
engineered O 
for O 
mass O 
spread O 
such O 
as O 
Hanta O 
viruses O 
, O 
multidrug O 
- O 
resistant O 
tuberculosis O 
, O 
Nipah O 
virus O 
, O 
the O 
tick O 
- O 
borne O 
encephalitis O 
viruses O 
, O 
hemorrhagic O 
fever O 
viruses O 
and O 
yellow O 
fever O 
. O 
CLINICAL O 
MANIFESTATIONS O 
OF O 
BIOTOXINS O 
IN O 
HUMAN O 
: O 
Clinical O 
features O 
and O 
severity O 
of O 
intoxication O 
depend O 
on O 
the O 
agent O 
and O 
exposed O 
dose O 
, O 
route O 
of O 
entry O 
, O 
individual O 
variation O 
and O 
environmental O 
factors O 
. O 
Onset O 
of O 
symptoms O 
varies O 
from O 
2-24 O 
h O 
in O 
Ricin O 
to O 
24-96 O 
h O 
in O 
Botulism O 
. O 
Clinical O 
manifestations O 
also O 
vary O 
from O 
irritation O 
of O 
the O 
eyes O 
, O 
skin O 
and O 
mucus O 
membranes O 
in O 
T(2) B-TRIVIAL 
toxin I-TRIVIAL 
to O 
an O 
acute O 
flaccid O 
paralysis O 
of O 
bilateral O 
cranial O 
nerve O 
impairment O 
of O 
descending O 
manner O 
in O 
botulism O 
. O 
Most O 
of O 
the O 
pyrogenic O 
toxins O 
such O 
as O 
SEB O 
produce O 
the O 
same O 
signs O 
and O 
symptoms O 
as O 
toxic O 
shock O 
syndrome O 
including O 
a O 
rapid O 
drop O 
in O 
blood O 
pressure O 
, O 
elevated O 
temperature O 
, O 
and O 
multiple O 
organ O 
failure O 
. O 
MANAGEMENT O 
: O 
There O 
is O 
no O 
specific O 
antidote O 
or O 
effective O 
treatment O 
for O 
most O 
of O 
the O 
biotoxins O 
. O 
The O 
clinical O 
management O 
is O 
thus O 
more O 
supportive O 
and O 
symptomatic O 
. O 
Fortunately O 
vaccines O 
are O 
now O 
available O 
for O 
most O 
of O 
BWA O 
. O 
Therefore O 
, O 
immunization O 
of O 
personnel O 
at O 
risk O 
of O 
exposure O 
is O 
recommended O 
. O 
CONCLUSION O 
: O 
Biotoxins O 
are O 
very O 
wide O 
and O 
bioterrorism O 
is O 
a O 
heath O 
and O 
security O 
threat O 
that O 
may O 
induce O 
national O 
and O 
international O 
problems O 
. O 
Therefore O 
, O 
the O 
security O 
authorities O 
, O 
health O 
professional O 
and O 
even O 
public O 
should O 
be O 
aware O 
of O 
bioterrorism O 
. O 

cell O 
transport O 
in O 
microfluidic O 
devices O 
is O 
a O 
topic O 
of O 
interest O 
as O 
their O 
utility O 
is O 
becoming O 
appreciated O 
by O 
cell O 
and O 
molecular O 
biologist O 
. O 
Cell O 
transport O 
should O 
minimize O 
mechanical O 
stress O 
due O 
to O 
friction O 
or O 
pressure O 
gradients O 
. O 
Optical O 
forces O 
have O 
the O 
advantage O 
of O 
applying O 
their O 
forces O 
across O 
the O 
cell O 
volume O 
and O 
not O 
only O 
at O 
the O 
cell O 
membrane O 
and O 
are O 
thus O 
preferable O 
. O 
Optical O 
pushing O 
by O 
scattering O 
force O 
is O 
a O 
suitable O 
candidate O 
so O 
highly O 
dependent O 
on O 
the O 
photon O 
irradiance O 
field O 
inside O 
the O 
propagation O 
capillary O 
which O 
in O 
turn O 
is O 
determined O 
by O 
the O 
waveguide O 
properties O 
delivering O 
the O 
radiation O 
pressure O 
. O 
Here O 
we O 
present O 
a O 
numerical O 
approach O 
to O 
predict O 
the O 
optical O 
scattering O 
force O 
, O 
speed O 
and O 
trajectory O 
of O 
cells O 
as O 
a O 
function O 
of O 
waveguide O 
and O 
propagation O 
capillary O 
geometry O 
. O 
Experimental O 
verification O 
of O 
the O 
simulation O 
approach O 
is O 
demonstrated O 
using O 
polystyrene B-SYSTEMATIC 
microspheres O 
and O 
leukemia O 
cells O 
. O 
Effects O 
of O 
optical O 
fibre O 
to O 
waveguide O 
alignment O 
, O 
capillary O 
wall O 
angle O 
and O 
temperature O 
on O 
the O 
dynamic O 
viscosity O 
on O 
speed O 
and O 
position O 
of O 
the O 
microspheres O 
and O 
cells O 
inside O 
the O 
propagation O 
capillary O 
are O 
demonstrated O 
. O 

of O 
solvent O 
and O 
alkaline B-FAMILY 
earth I-FAMILY 
metals I-FAMILY 
on O 
the O 
heat O 
- O 
induced O 
precipitation O 
process O 
of O 
sodium B-SYSTEMATIC 
caseinate O 
. O 

precipitation O 
temperatures O 
of O 
sodium B-SYSTEMATIC 
caseinate O 
in O 
H(2)O B-FORMULA 
and O 
D(2)O B-FORMULA 
in O 
the O 
presence O 
of O 
Mg(2+) B-FORMULA 
, O 
Ca(2+) B-FORMULA 
, O 
Sr(2+) B-FORMULA 
and O 
Ba(2+) B-FORMULA 
were O 
investigated O 
through O 
fluorescence O 
, O 
turbidity O 
and O 
conductivity O 
experiments O 
. O 
As O 
for O 
the O 
ability O 
of O 
the O 
divalent O 
cations O 
( O 
1-17.5mM O 
) O 
to O 
induce O 
the O 
precipitation O 
process O 
in O 
H(2)O B-FORMULA 
, O 
the O 
sequence O 
Ba(2+) B-FORMULA 
≥ O 
Ca(2+) B-FORMULA 
> O 
Mg(2+) B-FORMULA 
> O 
Sr(2+) B-FORMULA 
was O 
found O 
. O 
Remarkably O 
, O 
while O 
at O 
low O 
salt O 
concentrations O 
( O 
< O 
10mM O 
) O 
precipitation O 
temperatures O 
(T(Ps)) O 
were O 
found O 
to O 
change O 
significantly O 
depending O 
on O 
the O 
specific O 
cation O 
, O 
at O 
higher O 
concentrations O 
( O 
> O 
10mM O 
) O 
the O 
differences O 
among O 
the O 
different O 
cations O 
were O 
greatly O 
reduced O 
. O 
By O 
fitting O 
these O 
results O 
with O 
a O 
modified O 
Jones-Dole O 
equation O 
, O 
we O 
confirmed O 
that O 
the O 
less O 
hydrated O 
ions O 
possess O 
a O 
greater O 
capacity O 
to O 
induce O 
precipitation O 
. O 
In O 
D(2)O B-FORMULA 
, O 
the O 
order O 
of O 
ion O 
ability O 
to O 
induce O 
caseinate O 
precipitation O 
was O 
Ba(2+) B-FORMULA 
> O 
Ca(2+) B-FORMULA 
> O 
Sr(2+) B-FORMULA 
> O 
Mg(2+) B-FORMULA 
. O 
The O 
different O 
hydrophobicity O 
between O 
D(2)O B-FORMULA 
and O 
H(2)O B-FORMULA 
was O 
shown O 
to O 
affect O 
significantly O 
the O 
T(Ps) O 
of O 
caseinate O 
in O 
the O 
presence O 
of O 
calcium B-SYSTEMATIC 
, O 
strontium B-SYSTEMATIC 
and O 
barium B-SYSTEMATIC 
. O 

of O 
(TiO2)x(Cu2O)y B-FAMILY 
alloys O 
for O 
efficient O 
photoelectrochemical O 
water O 
splitting O 
. O 

formation O 
of O 
(TiO(2))(x)(Cu(2)O)(y) B-FAMILY 
solid O 
- O 
solutions O 
is O 
investigated O 
using O 
a O 
global O 
optimization O 
evolutionary O 
algorithm O 
. O 
First O 
- O 
principles O 
calculations O 
based O 
on O 
density O 
functional O 
theory O 
are O 
then O 
used O 
to O 
gain O 
insight O 
into O 
the O 
electronic O 
properties O 
of O 
these O 
alloys O 
. O 
We O 
find O 
that O 
: O 
(i) O 
Ti B-FORMULA 
and O 
Cu B-FORMULA 
in O 
(TiO(2))(x)(Cu(2)O)(y) B-FAMILY 
alloys O 
have O 
similar O 
local O 
environments O 
as O 
in O 
bulk O 
TiO(2) B-FORMULA 
and O 
Cu(2)O B-FORMULA 
except O 
for O 
( O 
TiO(2) B-FORMULA 
)( O 
Cu(2)O B-FORMULA 
) O 
which O 
has O 
some O 
trigonal O 
- O 
planar O 
Cu B-FORMULA 
ions O 
. O 
(ii) O 
The O 
predicted O 
optical O 
band O 
gaps O 
are O 
around O 
2.1 O 
eV O 
( O 
590 O 
nm O 
) O 
, O 
thus O 
having O 
much O 
better O 
performance O 
in O 
the O 
absorption O 
of O 
visible O 
light O 
compared O 
with O 
both O 
binary O 
oxides B-FAMILY 
. O 
(iii) O 
(TiO(2))(2)(Cu(2)O) B-FORMULA 
has O 
the O 
lowest O 
formation O 
energy O 
amongst O 
all O 
studied O 
alloys O 
and O 
the O 
positions O 
of O 
its O 
band O 
edges O 
are O 
found O 
to O 
be O 
suitable O 
for O 
solar O 
- O 
driven O 
water O 
splitting O 
applications O 
. O 

of O 
EGF O 
/ O 
EGFR O 
activation O 
with O 
naphtho[1,2-b]furan-4,5-dione B-SYSTEMATIC 
blocks O 
migration O 
and O 
invasion O 
of O 
MDA-MB-231 O 
cells O 
. O 

( O 
NFD B-ABBREVIATION 
) O 
, O 
a O 
bioactive O 
component O 
of O 
Avicennia O 
marina O 
, O 
has O 
been O 
demonstrated O 
to O 
display O 
anti-cancer O 
activity O 
. O 
Activation O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
(EGFR)-induced O 
signaling O 
pathway O 
has O 
been O 
correlated O 
with O 
cancer O 
metastasis O 
in O 
various O 
tumors O 
, O 
including O 
breast O 
carcinoma O 
. O 
We O 
use O 
EGF O 
as O 
a O 
metastatic O 
inducer O 
of O 
MDA-MB-231 O 
cells O 
to O 
investigate O 
the O 
effect O 
of O 
NFD B-ABBREVIATION 
on O 
cell O 
migration O 
and O 
invasion O 
. O 
NFD B-ABBREVIATION 
suppressed O 
EGF O 
- O 
mediated O 
protein O 
levels O 
of O 
c-Jun O 
and O 
c-Fos O 
, O 
and O 
reduced O 
MMP-9 O 
expression O 
and O 
activity O 
, O 
concomitantly O 
with O 
a O 
marked O 
inhibition O 
on O 
cell O 
migration O 
and O 
invasion O 
without O 
obvious O 
cellular O 
cytotoxicity O 
. O 
NFD B-ABBREVIATION 
abrogated O 
EGF-induced O 
phosphorylation O 
of O 
EGF O 
receptor O 
( O 
EGFR O 
) O 
and O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
( O 
PI3K O 
) O 
/ O 
Akt O 
. O 
The O 
specific O 
PI3K O 
inhibitor O 
, O 
wortmannin B-TRIVIAL 
, O 
blocked O 
significantly O 
EGF-induced O 
cell O 
migration O 
and O 
invasion O 
. O 
Furthermore O 
, O 
the O 
EGFR O 
inhibitor O 
AG1478 B-IDENTIFIER 
inhibited O 
EGF-induced O 
MMP-9 O 
expression O 
, O 
cell O 
migration O 
and O 
invasion O 
, O 
as O 
well O 
as O 
the O 
activation O 
of O 
PI3K O 
/ O 
Akt O 
, O 
suggesting O 
that O 
PI3K O 
/ O 
Akt O 
activation O 
occur O 
downstream O 
of O 
EGFR O 
activation O 
. O 
These O 
findings O 
suggest O 
that O 
NFD B-ABBREVIATION 
inhibited O 
the O 
EGF-induced O 
invasion O 
and O 
migration O 
of O 
MDA-MB-231 O 
cells O 
via O 
EGFR-dependent O 
PI3K O 
/ O 
Akt O 
signaling O 
, O 
leading O 
to O 
the O 
down O 
- O 
regulation O 
of O 
MMP-9 O 
expression O 
. O 
These O 
results O 
provide O 
a O 
novel O 
mechanism O 
to O 
explain O 
the O 
role O 
of O 
NFD B-ABBREVIATION 
as O 
a O 
potent O 
anti-metastatic O 
agent O 
in O 
MDA-MB-231 O 
cells O 
. O 

characterization O 
of O 
1-nitrosocyclohexyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
a O 
long O 
- O 
acting O 
nitroxyl B-SYSTEMATIC 
donor O 
that O 
shows O 
vasorelaxant O 
and O 
antiaggregatory O 
effects O 
. O 

( O 
HNO B-FORMULA 
) O 
donors O 
have O 
potential O 
benefit O 
in O 
the O 
treatment O 
of O 
heart O 
failure O 
and O 
other O 
cardiovascular O 
diseases O 
. O 
1-Nitrosocyclohexyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
NCA B-ABBREVIATION 
) O 
, O 
a O 
new O 
HNO B-FORMULA 
donor O 
, O 
in O 
contrast O 
to O 
the O 
classic O 
HNO B-FORMULA 
donors O 
Angeli's B-TRIVIAL 
salt I-TRIVIAL 
and O 
isopropylamine B-SYSTEMATIC 
NONOate I-SYSTEMATIC 
, O 
predominantly O 
releases O 
HNO B-FORMULA 
and O 
has O 
a O 
longer O 
half O 
- O 
life O 
. O 
This O 
study O 
investigated O 
the O 
vasodilatative O 
properties O 
of O 
NCA B-ABBREVIATION 
in O 
isolated O 
aortic O 
rings O 
and O 
human O 
platelets O 
and O 
its O 
mechanism O 
of O 
action O 
. O 
NCA B-ABBREVIATION 
was O 
applied O 
on O 
aortic O 
rings O 
isolated O 
from O 
wild O 
- O 
type O 
mice O 
and O 
apolipoprotein O 
E-deficient O 
mice O 
and O 
in O 
endothelial O 
- O 
denuded O 
aortae O 
. O 
The O 
mechanism O 
of O 
action O 
of O 
HNO B-FORMULA 
was O 
examined O 
by O 
applying O 
NCA B-ABBREVIATION 
in O 
the O 
absence O 
and O 
presence O 
of O 
the O 
HNO B-FORMULA 
scavenger O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
inhibitors O 
of O 
soluble O 
guanylyl B-TRIVIAL 
cyclase O 
( O 
sGC O 
) O 
, O 
adenylyl B-TRIVIAL 
cyclase O 
( O 
AC O 
) O 
, O 
calcitonin O 
gene O 
- O 
related O 
peptide O 
receptor O 
( O 
CGRP O 
) O 
, O 
and O 
K(+) B-FORMULA 
channels O 
. O 
NCA B-ABBREVIATION 
induced O 
a O 
concentration O 
- O 
dependent O 
relaxation O 
( O 
EC(50) O 
, O 
4.4 O 
µM O 
) O 
. O 
This O 
response O 
did O 
not O 
differ O 
between O 
all O 
groups O 
, O 
indicating O 
an O 
endothelium O 
- O 
independent O 
relaxation O 
effect O 
. O 
The O 
concentration O 
- O 
response O 
was O 
markedly O 
decreased O 
in O 
the O 
presence O 
of O 
excess O 
GSH B-ABBREVIATION 
; O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
scavenger O 
2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide B-SYSTEMATIC 
had O 
no O 
effect O 
. O 
Inhibitors O 
of O 
sGC O 
, O 
CGRP O 
, O 
and O 
voltage O 
- O 
dependent O 
K(+) B-FORMULA 
channels O 
each O 
significantly O 
impaired O 
the O 
vasodilator O 
response O 
to O 
NCA B-ABBREVIATION 
. O 
In O 
contrast O 
, O 
inhibitors O 
of O 
AC O 
, O 
ATP B-ABBREVIATION 
-sensitive O 
K(+) B-FORMULA 
channels O 
, O 
or O 
high O 
- O 
conductance O 
Ca(2+) B-FORMULA 
-activated O 
K(+) B-FORMULA 
channels O 
did O 
not O 
change O 
the O 
effects O 
of O 
NCA B-ABBREVIATION 
. O 
NCA B-ABBREVIATION 
significantly O 
reduced O 
contractile O 
response O 
and O 
platelet O 
aggregation O 
mediated O 
by O 
the O 
thromboxane B-TRIVIAL 
A(2) I-TRIVIAL 
mimetic O 
9,11-dideoxy-11α,9α-epoxymethanoprostaglandin B-SYSTEMATIC 
F(2)(α) I-SYSTEMATIC 
in O 
a O 
cGMP B-ABBREVIATION 
-dependent O 
manner O 
. O 
In O 
summary O 
, O 
NCA B-ABBREVIATION 
shows O 
vasoprotective O 
effects O 
and O 
may O 
have O 
a O 
promising O 
profile O 
as O 
a O 
therapeutic O 
agent O 
in O 
vascular O 
dysfunction O 
, O 
warranting O 
further O 
evaluation O 
. O 

effects O 
of O 
the O 
cyanobacterial O 
neurotoxin O 
anatoxin-a B-TRIVIAL 
: O 
Morphological O 
, O 
physiological O 
and O 
biochemical O 
responses O 
in O 
aquatic O 
macrophyte O 
, O 
Ceratophyllum O 
demersum O 
. O 

is O 
one O 
of O 
the O 
common O 
and O 
major O 
cyanobacterial O 
neurotoxins O 
acting O 
as O 
a O 
powerful O 
agonist O 
at O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChR O 
) O 
. O 
In O 
recent O 
years O 
, O 
the O 
toxin O 
has O 
become O 
the O 
focus O 
of O 
public O 
attention O 
, O 
due O 
to O 
the O 
mass O 
development O 
of O 
cyanobacteria O 
( O 
cyanobacterial O 
blooms O 
) O 
in O 
freshwater O 
bodies O 
triggered O 
by O 
eutrophication O 
and O 
climate O 
change O 
. O 
Anatoxin-a B-TRIVIAL 
is O 
suspected O 
to O 
have O 
a O 
distinct O 
toxic O 
mechanism O 
depending O 
on O 
physiological O 
and O 
nervous O 
systems O 
in O 
exposed O 
organisms O 
. O 
The O 
numerous O 
researches O 
have O 
been O 
actively O 
conducted O 
with O 
respect O 
to O 
the O 
toxic O 
effects O 
of O 
anatoxin-a B-TRIVIAL 
on O 
mammals O 
; O 
however O 
, O 
little O 
research O 
has O 
aimed O 
at O 
its O 
possible O 
effects O 
on O 
aquatic O 
plants O 
, O 
wherein O 
well O 
- O 
structured O 
nervous O 
system O 
is O 
absent O 
with O 
the O 
lack O 
of O 
various O 
components O 
of O 
the O 
acetylcholine B-SYSTEMATIC 
mechanism O 
. O 
In O 
this O 
study O 
, O 
submerged O 
macrophyte O 
Ceratophyllum O 
demersum O 
( O 
C O 
. O 
demersum O 
) O 
was O 
adopted O 
to O 
examine O 
the O 
effects O 
of O 
anatoxin-a B-TRIVIAL 
on O 
morphological O 
( O 
growth O 
) O 
, O 
physiological O 
( O 
photosynthetic O 
pigment O 
contents O 
) O 
and O 
biochemical O 
( O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
level O 
, O 
biotransformation O 
and O 
antioxidative O 
enzymes O 
) O 
responses O 
in O 
the O 
aquatic O 
plant O 
at O 
environmentally O 
relevant O 
concentrations O 
( O 
0.005 O 
, O 
0.05 O 
, O 
0.5 O 
, O 
5 O 
and O 
50 O 
μg O 
/ O 
L O 
) O 
. O 
The O 
significant O 
elevation O 
of O 
antioxidative O 
enzymes O 
in O 
parallel O 
with O 
increased O 
formation O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
appeared O 
from O 
0.5 O 
μg O 
/ O 
L O 
of O 
anatoxin-a B-TRIVIAL 
. O 
In O 
the O 
measurement O 
of O 
photosynthetic O 
pigments O 
, O 
the O 
decrease O 
in O 
chlorophyll B-TRIVIAL 
a I-TRIVIAL 
content O 
was O 
detected O 
at O 
5 O 
and O 
50 O 
μg O 
/ O 
L O 
, O 
whereas O 
the O 
increase O 
in O 
carotenoids O 
/ O 
total O 
chlorophyll B-FAMILY 
was O 
observed O 
from O 
0.05 O 
μg O 
/ O 
L O 
. O 
Accordingly O 
, O 
the O 
alteration O 
in O 
growth O 
was O 
manifested O 
in O 
the O 
presence O 
of O 
5 O 
and O 
50 O 
μg O 
/ O 
L O 
of O 
anatoxin-a B-TRIVIAL 
. O 
The O 
results O 
clearly O 
indicate O 
that O 
anatoxin-a B-TRIVIAL 
can O 
disrupt O 
homeostasis O 
of O 
C O 
. O 
demersum O 
through O 
induction O 
of O 
oxidative O 
stress O 
; O 
furthermore O 
this O 
aquatic O 
plant O 
possesses O 
effective O 
defense O 
mechanisms O 
to O 
cope O 
with O 
low O 
concentrations O 
of O 
anatoxin-a B-TRIVIAL 
. O 

increases O 
Pi O 
- O 
mediated O 
vascular O 
calcification O 
and O 
induces O 
premature O 
senescence O 
in O 
vascular O 
smooth O 
muscle O 
cells O 
. O 

mechanisms O 
have O 
been O 
proposed O 
to O 
explain O 
the O 
vascular O 
toxicity O 
of O 
arsenic B-SYSTEMATIC 
. O 
Some O 
of O 
them O 
are O 
described O 
in O 
this O 
work O 
, O 
such O 
as O 
stress O 
- O 
induced O 
premature O 
senescence O 
( O 
SIPS O 
) O 
, O 
dedifferentiation O 
, O 
and O 
medial O 
vascular O 
calcification O 
, O 
and O 
they O 
all O 
affect O 
vascular O 
smooth O 
muscle O 
cells O 
( O 
VSMC O 
) O 
. O 
Rat O 
aortic O 
VSMC O 
were O 
treated O 
with O 
1-100 O 
µM O 
of O 
either O 
sodium B-SYSTEMATIC 
arsenate I-SYSTEMATIC 
( O 
As B-FORMULA 
(V) I-FORMULA 
) O 
, O 
sodium B-SYSTEMATIC 
arsenite I-SYSTEMATIC 
( O 
As B-FORMULA 
(III) I-FORMULA 
) O 
, O 
monomethylarsonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
or O 
dimethylarsinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
None O 
of O 
the O 
treatments O 
induced O 
VSMC O 
calcification O 
in O 
the O 
presence O 
of O 
1mM O 
inorganic O 
phosphate B-SYSTEMATIC 
( O 
Pi O 
) O 
, O 
but O 
1 O 
µM O 
As B-FORMULA 
(III) I-FORMULA 
did O 
increase O 
calcification O 
when O 
induced O 
with O 
2.5mM O 
Pi O 
. O 
A O 
lactate B-FAMILY 
dehydrogenase O 
assay O 
revealed O 
that O 
this O 
increase O 
was O 
explained O 
by O 
a O 
rise O 
in O 
cytotoxicity O 
due O 
to O 
simultaneous O 
incubation O 
with O 
1 O 
µM O 
As B-FORMULA 
(III) I-FORMULA 
and O 
2.5mM O 
Pi O 
. O 
This O 
calcification O 
increase O 
was O 
also O 
observed O 
in O 
the O 
aortas O 
of O 
a O 
vascular O 
calcification O 
model O 
: O 
5 O 
/ O 
6 O 
nephrectomized O 
rats O 
fed O 
with O 
a O 
high O 
Pi O 
diet O 
and O 
treated O 
with O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
. O 
Several O 
known O 
mechanisms O 
that O 
might O 
explain O 
arsenic B-SYSTEMATIC 
toxicity O 
in O 
our O 
experimental O 
model O 
were O 
discarded O 
: O 
apoptosis O 
, O 
oxidative O 
stress O 
, O 
and O 
inflammasome O 
activation O 
. O 
Nevertheless O 
, O 
both O 
senescence O 
- O 
associated O 
β-galactosidase O 
activity O 
and O 
p21 O 
expression O 
were O 
increased O 
by O 
As B-FORMULA 
(III) I-FORMULA 
, O 
which O 
reveals O 
the O 
induction O 
of O 
SIPS O 
. O 
As B-FORMULA 
(III) I-FORMULA 
also O 
caused O 
dedifferentiation O 
of O 
VSMC O 
, O 
as O 
shown O 
by O 
the O 
reduced O 
expression O 
of O 
the O 
VSMC O 
markers O 
SM22α O 
and O 
calponin O 
. O 
Senescence O 
and O 
gene O 
expression O 
were O 
also O 
observed O 
in O 
the O 
aortas O 
of O 
healthy O 
rats O 
treated O 
with O 
50 O 
ppm O 
As B-FORMULA 
(V) I-FORMULA 
in O 
drinking O 
water O 
for O 
1 O 
month O 
. O 
In O 
conclusion O 
, O 
both O 
premature O 
senescence O 
in O 
aortic O 
VSMC O 
with O 
phenotypic O 
dedifferentiation O 
and O 
the O 
increase O 
of O 
Pi-induced O 
calcification O 
are O 
novel O 
mechanisms O 
of O 
arsenic B-SYSTEMATIC 
vasculotoxicity O 
. O 

- O 
standing O 
films O 
have O 
increasing O 
applications O 
in O 
the O 
biomedical O 
field O 
as O 
drug O 
delivery O 
systems O 
for O 
wound O 
healing O 
and O 
tissue O 
engineering O 
. O 
Here O 
, O 
we O 
prepared O 
free O 
- O 
standing O 
membranes O 
by O 
the O 
layer O 
- O 
by O 
- O 
layer O 
assembly O 
of O 
chitosan O 
and O 
alginate O 
, O 
two O 
widely O 
used O 
biomaterials O 
. O 
Our O 
aim O 
was O 
to O 
produce O 
a O 
thick O 
membrane O 
and O 
to O 
study O 
the O 
permeation O 
of O 
model O 
drugs O 
and O 
the O 
adhesion O 
of O 
muscle O 
cells O 
. O 
We O 
first O 
defined O 
the O 
optimal O 
growth O 
conditions O 
in O 
terms O 
of O 
pH O 
and O 
alginate O 
concentration O 
. O 
The O 
membranes O 
could O 
be O 
easily O 
detached O 
from O 
polystyrene B-SYSTEMATIC 
or O 
polypropylene B-SYSTEMATIC 
substrate O 
without O 
any O 
postprocessing O 
step O 
. O 
The O 
dry O 
thickness O 
was O 
varied O 
over O 
a O 
large O 
range O 
from O 
4 O 
to O 
35 O 
μm O 
. O 
A O 
2-fold O 
swelling O 
was O 
observed O 
by O 
confocal O 
microscopy O 
when O 
they O 
were O 
immersed O 
in O 
PBS O 
. O 
In O 
addition O 
, O 
we O 
quantified O 
the O 
permeation O 
of O 
model O 
drugs O 
( O 
fluorescent O 
dextrans O 
) O 
through O 
the O 
free O 
- O 
standing O 
membrane O 
, O 
which O 
depended O 
on O 
the O 
dextran O 
molecular O 
weight O 
. O 
Finally O 
, O 
we O 
showed O 
that O 
myoblast O 
cells O 
exhibited O 
a O 
preferential O 
adhesion O 
on O 
the O 
alginate O 
- O 
ending O 
membrane O 
as O 
compared O 
to O 
the O 
chitosan O 
- O 
ending O 
membrane O 
or O 
to O 
the O 
substrate O 
side O 
. O 

Change O 
and O 
Mobility O 
Enhancement O 
in O 
PEDOT B-ABBREVIATION 
: O 
PSS B-ABBREVIATION 
by O 
Adding O 
Co-solvents O 
. O 

ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
EG O 
) O 
to O 
poly(3,4-ethylenedioxythiophene) B-SYSTEMATIC 
: O 
poly(styrenesulfonate) B-FAMILY 
( O 
PEDOT B-ABBREVIATION 
: O 
PSS B-ABBREVIATION 
) O 
solution O 
improves O 
the O 
crystallinity O 
of O 
the O 
PEDOT B-ABBREVIATION 
and O 
the O 
ordering O 
of O 
the O 
PEDOT B-ABBREVIATION 
nanocrystals O 
in O 
solid O 
films O 
. O 
The O 
carrier O 
- O 
mobility O 
enhancement O 
is O 
confirmed O 
by O 
using O 
ion O 
- O 
gel O 
transistors O 
combined O 
with O 
in O 
situ O 
UV-vis-NIR O 
spectroscopy O 
. O 

anaesthetics O 
exert O 
protective O 
effects O 
on O 
the O 
heart O 
against O 
perioperative O 
ischaemic O 
injury O 
. O 
However O 
, O 
there O 
is O 
growing O 
evidence O 
that O 
these O 
cardioprotective O 
properties O 
are O 
reduced O 
in O 
case O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
A O 
strong O 
predictor O 
of O 
postoperative O 
cardiac O 
function O 
is O 
myocardial O 
substrate O 
metabolism O 
. O 
In O 
the O 
type O 
2 O 
diabetic O 
heart O 
, O 
substrate O 
metabolism O 
is O 
shifted O 
from O 
glucose B-TRIVIAL 
utilisation O 
to O 
fatty B-FAMILY 
acid I-FAMILY 
oxidation O 
, O 
resulting O 
in O 
metabolic O 
inflexibility O 
and O 
cardiac O 
dysfunction O 
. O 
The O 
ischaemic O 
heart O 
also O 
loses O 
its O 
metabolic O 
flexibility O 
and O 
can O 
switch O 
to O 
glucose B-TRIVIAL 
or O 
fatty B-FAMILY 
acid I-FAMILY 
oxidation O 
as O 
its O 
preferential O 
state O 
, O 
which O 
may O 
deteriorate O 
cardiac O 
function O 
even O 
further O 
in O 
case O 
of O 
type O 
2 O 
diabetes O 
mellitus.Recent O 
experimental O 
studies O 
suggest O 
that O 
the O 
cardioprotective O 
properties O 
of O 
volatile O 
anaesthetics O 
partly O 
rely O 
on O 
changing O 
myocardial O 
substrate O 
metabolism O 
. O 
Interventions O 
that O 
target O 
at O 
restoration O 
of O 
metabolic O 
derangements O 
, O 
like O 
lifestyle O 
and O 
pharmacological O 
interventions O 
, O 
may O 
therefore O 
be O 
an O 
interesting O 
candidate O 
to O 
reduce O 
perioperative O 
complications O 
. O 
This O 
review O 
will O 
focus O 
on O 
the O 
current O 
knowledge O 
regarding O 
myocardial O 
substrate O 
metabolism O 
during O 
volatile O 
anaesthesia O 
in O 
the O 
obese O 
and O 
type O 
2 O 
diabetic O 
heart O 
during O 
perioperative O 
ischaemia O 
. O 

work O 
reports O 
the O 
chemical O 
composition O 
of O 
the O 
essential O 
oil O 
of O 
Lippia O 
sidoides O 
( O 
EOLS O 
) O 
and O 
evaluation O 
of O 
the O 
topical O 
effect O 
of O 
EOLS O 
and O 
thymol B-TRIVIAL 
against O 
different O 
irritant O 
agents O 
in O 
vivo O 
. O 
The O 
essential O 
oil O 
was O 
obtained O 
by O 
hydrodistillation O 
, O 
and O 
gas O 
chromatography O 
/ O 
mass O 
spectrometry O 
analysis O 
identified O 
the O 
main O 
constituents O 
: O 
thymol B-TRIVIAL 
( O 
84.9% O 
) O 
and O 
p-cymene B-TRIVIAL 
( O 
5.33% O 
) O 
. O 
The O 
antiinflammatory O 
activity O 
was O 
evaluated O 
using O 
the O 
mouse O 
models O 
of O 
acute O 
ear O 
inflammation O 
induced O 
by O 
croton O 
oil O 
, O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
, O 
phenol B-SYSTEMATIC 
or O 
histamine B-TRIVIAL 
, O 
and O 
chronic O 
inflammation O 
induced O 
by O 
croton O 
oil O 
. O 
The O 
topical O 
application O 
of O 
EOLS O 
or O 
thymol B-TRIVIAL 
at O 
a O 
dose O 
of O 
2 O 
mg O 
/ O 
ear O 
significantly O 
reduced O 
( O 
p O 
< O 
0.001 O 
) O 
ear O 
edema O 
induced O 
with O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
by O 
45.1% O 
and O 
47.4% O 
and O 
reduced O 
ear O 
edema O 
induced O 
with O 
phenol B-SYSTEMATIC 
by O 
33.2% O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
54.7% O 
( O 
p O 
< O 
0.01 O 
) O 
in O 
acute O 
ear O 
edema O 
. O 
However O 
, O 
a O 
proinflammatory O 
effect O 
of O 
EOLS O 
and O 
thymol B-TRIVIAL 
was O 
evidenced O 
when O 
it O 
was O 
applied O 
for O 
more O 
than O 
1 O 
day O 
. O 
There O 
were O 
no O 
statistical O 
differences O 
in O 
antiedematogenic O 
activity O 
between O 
EOLS O 
and O 
thymol B-TRIVIAL 
. O 
In O 
conclusion O 
, O 
the O 
results O 
indicate O 
that O 
thymol B-TRIVIAL 
is O 
the O 
constituent O 
responsible O 
for O 
the O 
topical O 
antiinflammatory O 
activity O 
of O 
EOLS O 
. O 
Thus O 
, O 
these O 
findings O 
could O 
justify O 
the O 
popular O 
use O 
of O 
L. O 
sidoides O 
by O 
alternative O 
medicine O 
, O 
but O 
chronic O 
use O 
has O 
an O 
inflammatory O 
effect O 
. O 

Modification O 
of O 
Lysozyme O 
, O 
Glucose B-SYSTEMATIC 
6-Phosphate I-SYSTEMATIC 
Dehydrogenase O 
, O 
and O 
Bovine O 
Eye O 
Lens O 
Proteins O 
Induced O 
by O 
Peroxyl B-SYSTEMATIC 
Radicals O 
: O 
Role O 
of O 
Oxidizable O 
Amino B-FAMILY 
Acid I-FAMILY 
Residues O 
. O 

and O 
structural O 
alterations O 
to O 
lysozyme O 
( O 
LYSO O 
) O 
, O 
glucose B-SYSTEMATIC 
6-phosphate I-SYSTEMATIC 
dehydrogenase O 
( O 
G6PD O 
) O 
, O 
and O 
bovine O 
eye O 
lens O 
proteins O 
( O 
BLP O 
) O 
promoted O 
by O 
peroxyl B-SYSTEMATIC 
radicals O 
generated O 
by O 
the O 
thermal O 
decomposition O 
of O 
2,2'-azobis(2-amidinopropane) B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
AAPH B-ABBREVIATION 
) O 
under O 
aerobic O 
conditions O 
were O 
investigated O 
. O 
SDS B-ABBREVIATION 
-PAGE O 
analysis O 
of O 
the O 
AAPH B-ABBREVIATION 
-treated O 
proteins O 
revealed O 
the O 
occurrence O 
of O 
protein O 
aggregation O 
, O 
cross O 
- O 
linking O 
, O 
and O 
fragmentation O 
; O 
BLP O 
, O 
which O 
are O 
naturally O 
organized O 
in O 
globular O 
assemblies O 
, O 
were O 
the O 
most O 
affected O 
proteins O 
. O 
Transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
analysis O 
of O 
BLP O 
shows O 
the O 
formation O 
of O 
complex O 
protein O 
aggregates O 
after O 
treatment O 
with O 
AAPH B-ABBREVIATION 
. O 
These O 
structural O 
modifications O 
were O 
accompanied O 
by O 
the O 
formation O 
of O 
protein O 
carbonyl B-FAMILY 
groups O 
and O 
protein O 
hydroperoxides B-FAMILY 
. O 
The O 
yield O 
of O 
carbonyls B-FAMILY 
was O 
lower O 
than O 
that O 
for O 
protein O 
hydroperoxide B-FAMILY 
generation O 
and O 
was O 
unrelated O 
to O 
protein O 
fragmentation O 
. O 
The O 
oxidized O 
proteins O 
were O 
also O 
characterized O 
by O 
significant O 
oxidation O 
of O 
Met B-FORMULA 
, O 
Trp B-FORMULA 
, O 
and O 
Tyr B-FORMULA 
( O 
but O 
not O 
other O 
) O 
residues O 
, O 
and O 
low O 
levels O 
of O 
dityrosine B-TRIVIAL 
. O 
As O 
the O 
dityrosine B-TRIVIAL 
yield O 
is O 
too O 
low O 
to O 
account O 
for O 
the O 
observed O 
cross O 
- O 
linking O 
, O 
we O 
propose O 
that O 
aggregation O 
is O 
associated O 
with O 
tryptophan B-TRIVIAL 
oxidation O 
and O 
Trp B-FORMULA 
-derived O 
cross O 
- O 
links O 
. O 
It O 
is O 
also O 
proposed O 
that O 
Trp B-FORMULA 
oxidation O 
products O 
play O 
a O 
fundamental O 
role O 
in O 
nonrandom O 
fragmentation O 
and O 
carbonyl B-FAMILY 
group O 
formation O 
particularly O 
for O 
LYSO O 
and O 
G6PD O 
. O 
These O 
data O 
point O 
to O 
a O 
complex O 
mechanism O 
of O 
peroxyl B-SYSTEMATIC 
-radical O 
mediated O 
modification O 
of O 
proteins O 
with O 
monomeric O 
( O 
LYSO O 
) O 
, O 
dimeric O 
( O 
G6PD O 
) O 
, O 
and O 
multimeric O 
( O 
BLP O 
) O 
structural O 
organization O 
, O 
which O 
not O 
only O 
results O 
in O 
oxidation O 
of O 
protein O 
side O 
chains O 
but O 
also O 
gives O 
rise O 
to O 
radical O 
- O 
mediated O 
protein O 
cross O 
- O 
links O 
and O 
fragmentation O 
, O 
with O 
Trp B-FORMULA 
species O 
being O 
critical O 
intermediates O 
. O 

Do O 
Not O 
Consume O 
/ O 
do O 
Not O 
Use O 
concentrations O 
for O 
potassium B-SYSTEMATIC 
permanganate I-SYSTEMATIC 
in O 
drinking O 
water O 
. O 

the O 
past O 
decade O 
, O 
regulatory O 
authorities O 
and O 
water O 
purveyors O 
have O 
become O 
increasingly O 
concerned O 
with O 
accidental O 
or O 
intentional O 
adulteration O 
of O 
municipal O 
drinking O 
water O 
. O 
Emergency O 
response O 
guidelines O 
, O 
such O 
as O 
the O 
' O 
Do O 
Not O 
Consume O 
' O 
or O 
use O 
concentration O 
limits O 
derived O 
herein O 
, O 
can O 
be O 
used O 
to O 
notify O 
the O 
public O 
in O 
such O 
cases O 
. O 
Potassium B-SYSTEMATIC 
permanganate I-SYSTEMATIC 
( O 
KMnO(4) B-FORMULA 
) O 
is O 
used O 
to O 
control O 
iron O 
concentrations O 
and O 
to O 
reduce O 
the O 
levels O 
of O 
nuisance O 
materials O 
that O 
affect O 
odor O 
or O 
taste O 
of O 
finished O 
drinking O 
water O 
. O 
Manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
is O 
recognized O 
an O 
essential O 
nutrient O 
, O 
permanganate B-SYSTEMATIC 
( O 
MnO4 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
) O 
and O 
manganous B-SYSTEMATIC 
( O 
Mn(+2) B-FORMULA 
) O 
ions O 
are O 
caustic O 
, O 
and O 
the O 
acute O 
toxicity O 
of O 
KMnO(4) B-FORMULA 
is O 
defined O 
by O 
its O 
oxidant O 
/ O 
irritant O 
properties O 
and O 
by O 
the O 
toxicity O 
of O 
Mn B-FORMULA 
. O 
Ingestion O 
of O 
small O 
amounts O 
( O 
4-20 O 
mg O 
/ O 
kg O 
) O 
of O 
aqueous O 
KMnO(4) B-FORMULA 
solutions O 
that O 
are O 
above O 
200 O 
mg O 
/ O 
L O 
causes O 
gastrointestinal O 
distress O 
, O 
while O 
bolus O 
ingestion O 
has O 
caused O 
respiratory O 
arrest O 
following O 
coagulative O 
necrosis O 
and O 
hemorrhage O 
in O 
the O 
esophagus O 
, O 
stomach O 
, O 
or O 
liver O 
. O 
Dilute O 
KMnO(4) B-FORMULA 
solutions O 
( O 
1-100 O 
mg O 
/ O 
L O 
) O 
are O 
used O 
as O 
a O 
topical O 
antiseptics O 
and O 
astringents O 
, O 
but O 
> O 
1 O 
: O 
5000 O 
( O 
200 O 
mg O 
/ O 
L O 
) O 
dilutions O 
can O 
irritate O 
or O 
discolor O 
sensitive O 
mucous O 
membranes O 
and O 
direct O 
skin O 
or O 
ocular O 
contact O 
with O 
concentrated O 
KMnO(4) B-FORMULA 
can O 
perforate O 
tissues O 
. O 
Based O 
on O 
clinical O 
experience O 
with O 
200 O 
mg O 
/ O 
L O 
KMnO(4) B-FORMULA 
, O 
a O 
Do O 
Not O 
Consume O 
concentration O 
of O 
7 O 
mg O 
/ O 
L O 
KMnO(4) B-FORMULA 
( O 
equivalent O 
to O 
2 O 
mg O 
Mn B-FORMULA 
/L O 
) O 
is O 
recommended O 
. O 
Recognizing O 
limited O 
empirical O 
data O 
from O 
which O 
to O 
calculate O 
an O 
ocular O 
reference O 
value O 
, O 
a O 
skin O 
contact O 
' O 
Do O 
Not O 
Use O 
' O 
concentration O 
of O 
30 O 
mg O 
Mn B-FORMULA 
/L O 
is O 
recommended O 
based O 
on O 
the O 
skin O 
irritation O 
in O 
some O 
patients O 
after O 
a O 
10-min O 
contact O 
with O 
100 O 
mg O 
KMnO4 B-FORMULA 
/L O 
. O 

bowel O 
disease O 
is O 
an O 
urgent O 
public O 
health O 
problem O 
with O 
a O 
high O 
incidence O 
in O 
developed O 
countries O 
. O 
Alterations O 
of O 
lifestyle O 
or O 
dietary O 
interventions O 
may O 
attenuate O 
the O 
disease O 
progression O 
and O 
increase O 
the O 
efficacy O 
of O 
current O 
therapies O 
. O 
Here O 
we O 
tested O 
the O 
effect O 
of O 
chronic O 
supplementation O 
with O 
a O 
mineral O 
extract O 
from O 
red O 
marine O 
algae O 
- O 
rich O 
in O 
calcium B-SYSTEMATIC 
( O 
34% O 
) O 
, O 
magnesium B-SYSTEMATIC 
, O 
phosphorus B-SYSTEMATIC 
, O 
selenium B-SYSTEMATIC 
and O 
other O 
trace O 
minerals O 
- O 
in O 
a O 
clinically O 
relevant O 
model O 
of O 
spontaneous O 
enterocolitis O 
, O 
interleukin O 
( O 
IL)-10(- O 
/ O 
- O 
) O 
mice O 
. O 
The O 
mineral O 
extract O 
was O 
administered O 
in O 
the O 
drinking O 
water O 
of O 
Il10(- O 
/ O 
- O 
) O 
mice O 
on O 
C57BL O 
/ O 
6 O 
J O 
and O 
BALB O 
/ O 
c O 
strain O 
backgrounds O 
for O 
25 O 
weeks O 
commencing O 
from O 
3 O 
to O 
4 O 
weeks O 
of O 
age O 
. O 
The O 
mineral O 
extract O 
ameliorated O 
the O 
spontaneous O 
development O 
of O 
colitis O 
and O 
severity O 
of O 
disease O 
in O 
Il10(- O 
/ O 
- O 
) O 
mice O 
on O 
a O 
C57BL O 
/ O 
6 O 
J O 
background O 
. O 
Mineral O 
extract O 
- O 
treated O 
Il10(- O 
/ O 
- O 
) O 
C57BL O 
/ O 
6 O 
J O 
strain O 
mice O 
had O 
significantly O 
reduced O 
mortality O 
, O 
circulating O 
levels O 
of O 
serum O 
Amyloid O 
A O 
and O 
reduced O 
colonic O 
tissue O 
damage O 
. O 
In O 
contrast O 
, O 
comparable O 
treatment O 
of O 
Il10(- O 
/ O 
- O 
) O 
mice O 
on O 
a O 
BALB O 
/ O 
c O 
background O 
with O 
the O 
mineral O 
extract O 
did O 
not O 
alter O 
the O 
course O 
of O 
colitis O 
. O 
These O 
data O 
demonstrate O 
that O 
chronic O 
supplementation O 
with O 
a O 
natural O 
mineral O 
extract O 
selectively O 
ameliorates O 
spontaneous O 
mild O 
- O 
moderate O 
colitis O 
in O 
Il10(- O 
/ O 
- O 
) O 
mice O 
on O 
a O 
C57BL O 
/ O 
6 O 
J O 
, O 
but O 
does O 
not O 
attenuate O 
more O 
moderate O 
- O 
severe O 
colitis O 
in O 
BALB O 
/ O 
c O 
strain O 
animals O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

variant O 
in O 
the O 
carboxyl B-SYSTEMATIC 
-terminus O 
of O 
connexin O 
40 O 
alters O 
GAP O 
junctions O 
and O 
increases O 
risk O 
for O 
tetralogy O 
of O 
Fallot O 
. O 

gene O 
( O 
MIM O 
no O 
. O 
121013 O 
) O 
, O 
localized O 
at O 
1q21.1 O 
, O 
encodes O 
for O 
the O 
cardiac O 
gap O 
junction O 
protein O 
connexin O 
40 O 
. O 
In O 
humans O 
, O 
copy O 
number O 
variants O 
of O 
chromosome O 
1q21.1 O 
have O 
been O 
associated O 
with O 
variable O 
phenotypes O 
comprising O 
congenital O 
heart O 
disease O 
( O 
CHD O 
) O 
, O 
including O 
isolated O 
TOF O 
. O 
In O 
mice O 
, O 
the O 
deletion O 
of O 
Gja5 O 
can O 
cause O 
a O 
variety O 
of O 
complex O 
CHDs O 
, O 
in O 
particular O 
of O 
the O 
cardiac O 
outflow O 
tract O 
, O 
corresponding O 
to O 
TOF O 
in O 
many O 
cases O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
screened O 
for O 
mutations O 
in O 
the O 
GJA5 O 
gene O 
178 O 
unrelated O 
probands O 
with O 
isolated O 
TOF O 
. O 
A O 
heterozygous O 
nucleotide B-FAMILY 
change O 
( O 
c.793C O 
> O 
T O 
) O 
in O 
exon O 
2 O 
of O 
the O 
gene O 
leading O 
to O 
the O 
p.Pro265Ser O 
variant O 
at O 
the O 
carboxyl B-SYSTEMATIC 
-terminus O 
of O 
the O 
protein O 
was O 
found O 
in O 
two O 
unrelated O 
sporadic O 
patients O 
, O 
one O 
with O 
classic O 
anatomy O 
and O 
one O 
with O 
pulmonary O 
atresia O 
. O 
This O 
GJA5 O 
missense O 
substitution O 
was O 
not O 
observed O 
in O 
1568 O 
ethnically O 
- O 
matched O 
control O 
chromosomes O 
. O 
Immunofluorescent O 
staining O 
and O 
confocal O 
microscopy O 
revealed O 
that O 
cells O 
expressing O 
the O 
mutant O 
protein O 
form O 
sparse O 
or O 
no O 
visible O 
gap O 
- O 
junction O 
plaques O 
in O 
the O 
region O 
of O 
cell O 
- O 
cell O 
contact O 
. O 
Moreover O 
, O 
analysis O 
of O 
the O 
transfer O 
of O 
the O 
gap O 
junction O 
permanent O 
tracer O 
lucifer O 
yellow O 
showed O 
that O 
cells O 
expressing O 
the O 
mutant O 
protein O 
have O 
a O 
reduced O 
rate O 
of O 
dye O 
transfer O 
compared O 
with O 
wild O 
- O 
type O 
cells O 
. O 
Finally O 
, O 
use O 
of O 
a O 
zebrafish O 
model O 
revealed O 
that O 
microinjection O 
of O 
the O 
GJA5-p.Pro265Ser O 
mutant O 
disrupts O 
overall O 
morphology O 
of O 
the O 
heart O 
tube O 
in O 
the O 
37% O 
( O 
22 O 
/ O 
60 O 
) O 
of O 
embryos O 
, O 
compared O 
with O 
the O 
6% O 
( O 
4 O 
/ O 
66 O 
) O 
of O 
the O 
GJA5 O 
wild O 
- O 
type O 
- O 
injected O 
embryos O 
. O 
These O 
findings O 
implicate O 
GJA5 O 
gene O 
as O 
a O 
novel O 
susceptibility O 
gene O 
for O 
TOF O 
. O 

metabolites O 
often O 
retain O 
the O 
pharmacological O 
activity O 
of O 
parent O 
compound O 
, O 
and O 
the O 
position O 
of O 
hydroxylation O 
determines O 
the O 
formation O 
of O 
chemically O 
reactive O 
intermediates O 
such O 
as O 
quinones B-FAMILY 
and O 
analogues O 
from O 
para- O 
and O 
/ O 
or O 
ortho-hydroxylation O 
of O 
phenols B-FAMILY 
or O 
arylamines B-FAMILY 
. O 
Therefore O 
, O 
the O 
identification O 
of O 
exact O 
position O 
of O 
hydroxylation O 
is O 
often O 
required O 
at O 
the O 
early O 
development O 
stage O 
of O 
new O 
drug O 
candidates O 
. O 
In O 
many O 
cases O 
, O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
provides O 
identical O 
MS O 
/ O 
MS O 
spectra O 
among O 
isomeric O 
hydroxylated O 
metabolites O 
, O 
and O 
therefore O 
, O 
it O 
alone O 
cannot O 
unequivocally O 
identify O 
the O 
exact O 
position(s) O 
of O 
hydroxylation O 
. O 
Ion O 
mobility O 
spectrometry O 
( O 
IMS O 
) O 
, O 
integrated O 
with O 
LC-MS O 
/ O 
MS O 
, O 
recently O 
demonstrates O 
the O 
capability O 
of O 
separating O 
isomeric O 
species O 
based O 
on O 
differences O 
in O 
their O 
drift O 
times O 
from O 
IMS O 
, O 
which O 
are O 
linearly O 
proportional O 
to O 
the O 
collision O 
cross O 
- O 
section O 
( O 
CCS O 
) O 
reflecting O 
physical O 
size O 
and O 
shape O 
. O 
In O 
the O 
present O 
study O 
, O 
a O 
chemical O 
derivatization O 
of O 
isomeric O 
hydroxylated O 
metabolites O 
with O 
2-fluoro-N-methyl B-SYSTEMATIC 
pyridinium I-SYSTEMATIC 
p-toluenesulfonate I-SYSTEMATIC 
was O 
found O 
to O 
confer O 
distinct O 
theoretical O 
CCS O 
value O 
on O 
each O 
isomer O 
by O 
forming O 
corresponding O 
N-methyl B-SYSTEMATIC 
pyridine I-SYSTEMATIC 
( O 
NMP B-ABBREVIATION 
) O 
derivative O 
. O 
The O 
regression O 
lines O 
established O 
by O 
the O 
comparison O 
between O 
theoretical O 
CCS O 
values O 
and O 
observed O 
drift O 
times O 
from O 
IMS O 
for O 
each O 
set O 
of O 
parent O 
compound O 
( O 
labetalol B-TRIVIAL 
, O 
ezetimibe B-TRIVIAL 
, O 
atorvastatin B-TRIVIAL 
and O 
warfarin B-TRIVIAL 
) O 
and O 
its O 
MS O 
/ O 
MS O 
product O 
ions O 
accurately O 
and O 
selectively O 
projected O 
the O 
actual O 
drift O 
times O 
of O 
NMP B-ABBREVIATION 
derivatives O 
of O 
corresponding O 
aromatic O 
or O 
isomeric O 
hydroxylated O 
metabolites O 
. O 
The O 
established O 
method O 
was O 
used O 
for O 
the O 
accurate O 
assignment O 
of O 
predominant O 
formation O 
of O 
2-hydroxylated O 
metabolite O 
from O 
imipramine B-TRIVIAL 
in O 
NADPH B-ABBREVIATION 
- O 
fortified O 
human O 
liver O 
microsomes O 
. O 
The O 
present O 
application O 
expands O 
the O 
versatility O 
of O 
LC-IMS-MS O 
technique O 
to O 
the O 
structure O 
identification O 
of O 
isomeric O 
hydroxylated O 
metabolites O 
at O 
the O 
early O 
stage O 
for O 
drug O 
development O 
. O 

part O 
of O 
our O 
ongoing O 
research O 
on O 
the O 
antibacterial O 
activity O 
of O 
Achyrocline O 
satureioides O 
, O 
this O 
study O 
seeks O 
to O 
better O 
understand O 
the O 
interactions O 
between O 
the O 
metabolites O 
isolated O 
from O 
this O 
plant O 
. O 
For O 
this O 
purpose O 
, O 
the O 
combined O 
effect O 
of O 
23-methyl-6-O-desmethylauricepyrone B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
quercetin B-TRIVIAL 
( O 
2 O 
) O 
and O 
3-O-methylquercetin B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
obtained O 
through O 
bioguided O 
fractionation O 
from O 
A O 
. O 
satureioides O 
ethanol B-SYSTEMATIC 
extract O 
, O 
was O 
evaluated O 
against O 
Staphylococcus O 
aureus O 
and O 
Escherichia O 
coli O 
. O 
In O 
first O 
place O 
, O 
the O 
antibacterial O 
effect O 
of O 
the O 
combination O 
of O 
flavonols B-FAMILY 
2 O 
and O 
3 O 
was O 
assessed O 
, O 
as O 
these O 
showed O 
individual O 
effectiveness O 
lower O 
than O 
or O 
equal O 
to O 
that O 
of O 
the O 
fraction O 
from O 
which O 
they O 
were O 
obtained O 
. O 
When O 
the O 
flavonols B-FAMILY 
were O 
applied O 
together O 
at O 
concentrations O 
below O 
their O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
values O 
, O 
a O 
synergistic O 
effect O 
( O 
FICI O 
< O 
0.3 O 
) O 
against O 
S O 
. O 
aureus O 
was O 
observed O 
. O 
In O 
addition O 
, O 
compounds O 
2 O 
and O 
3 O 
in O 
combination O 
reduced O 
1000 O 
times O 
the O 
MIC O 
of O 
compound O 
1 O 
, O 
showing O 
a O 
clear O 
synergistic O 
interaction O 
( O 
FICI O 
< O 
0.15 O 
) O 
in O 
treatments O 
against O 
the O 
Gram O 
( O 
+ O 
) O 
bacterium O 
. O 
The O 
most O 
active O 
combination O 
against O 
E O 
. O 
coli O 
showed O 
an O 
additive O 
interaction O 
( O 
FICI O 
< O 
0.62 O 
) O 
between O 
the O 
three O 
assayed O 
compounds O 
1-3 O 
. O 
These O 
results O 
indicated O 
the O 
existence O 
of O 
concerted O 
action O 
between O 
these O 
metabolites O 
, O 
evidence O 
of O 
the O 
importance O 
of O 
the O 
synergistic O 
interactions O 
between O 
the O 
components O 
of O 
plant O 
- O 
derived O 
extracts O 
for O 
the O 
control O 
of O 
pathogenic O 
bacteria O 
. O 

the O 
human O 
cell O 
cycle O 
, O 
the O 
Myt1 O 
kinase O 
is O 
a O 
crucial O 
regulator O 
of O 
the O 
G2 O 
/ O 
M O 
transition O 
. O 
Because O 
this O 
membrane O 
- O 
associated O 
kinase O 
is O 
hard O 
to O 
obtain O 
and O 
assay O 
, O 
there O 
is O 
a O 
distinct O 
lack O 
of O 
data O 
so O 
far O 
. O 
Here O 
we O 
report O 
the O 
derivatization O 
of O 
a O 
glycoglycerolipid O 
which O 
was O 
shown O 
previously O 
to O 
be O 
active O 
in O 
a O 
Myt1 O 
activity O 
assay O 
. O 
These O 
compounds O 
were O 
tested O 
in O 
a O 
binding O 
assay O 
together O 
with O 
a O 
set O 
of O 
common O 
kinase O 
inhibitors O 
against O 
a O 
full O 
- O 
length O 
Myt1 O 
expressed O 
in O 
a O 
human O 
cell O 
line O 
. O 
Dasatinib B-TRIVIAL 
exhibited O 
nanomolar O 
affinity O 
whereas O 
broad O 
coverage O 
inhibitors O 
such O 
as O 
sunitinib B-TRIVIAL 
and O 
staurosporine B-TRIVIAL 
derivatives O 
did O 
not O 
show O 
any O 
effect O 
. O 
We O 
also O 
carried O 
out O 
docking O 
studies O 
for O 
the O 
most O 
potent O 
compounds O 
allowing O 
further O 
insights O 
into O 
the O 
inhibitor O 
interaction O 
of O 
this O 
kinase O 
. O 
The O 
glycoglycerolipids O 
showed O 
no O 
significant O 
effects O 
in O 
the O 
binding O 
assay O 
, O 
endorsing O 
the O 
idea O 
of O 
a O 
mechanism O 
of O 
action O 
distant O 
from O 
the O 
active O 
site O 
. O 

causes O 
an O 
enormous O 
health O 
and O 
economic O 
impact O 
in O 
Japan O 
. O 
We O 
investigated O 
the O 
relation O 
between O 
lifestyle O 
and O 
bone O 
fracture O 
in O 
middle O 
- O 
aged O 
and O 
elderly O 
women O 
. O 
This O 
was O 
a O 
population O 
- O 
based O 
, O 
multicenter O 
, O 
cross O 
- O 
sectional O 
survey O 
for O 
postmenopausal O 
osteoporosis O 
in O 
Chiba O 
City O 
, O 
Japan O 
( O 
Chiba O 
bone O 
survey O 
) O 
. O 
This O 
survey O 
included O 
64809 O 
Japanese O 
women O 
aged O 
> O 
40 O 
years O 
. O 
All O 
participants O 
underwent O 
anthropometric O 
measurements O 
including O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
and O 
completed O 
a O 
structured O 
, O 
nurse O 
- O 
assisted O 
, O 
self O 
- O 
administered O 
questionnaire O 
also O 
including O 
patient O 
lifestyle O 
. O 
Bone O 
fracture O 
during O 
the O 
recent O 
5 O 
years O 
was O 
observed O 
in O 
5.3% O 
, O 
and O 
the O 
fracture O 
group O 
had O 
significantly O 
higher O 
age O 
, O 
BMI O 
, O 
and O 
number O 
of O 
births O 
, O 
family O 
histories O 
of O 
kyphosis O 
and O 
hip O 
fracture O 
, O 
diabetes O 
mellitus O 
( O 
DM O 
) O 
, O 
dyslipidemia O 
, O 
kidney O 
disease O 
, O 
exercise O 
, O 
fall O 
, O 
and O 
osteoporosis O 
, O 
and O 
had O 
significantly O 
lower O 
BMD O 
and O 
proportion O 
of O 
menstruating O 
participants O 
. O 
Logistic O 
regression O 
analysis O 
revealed O 
that O 
bone O 
fracture O 
was O 
closely O 
associated O 
with O 
not O 
only O 
low O 
bone O 
mass O 
but O 
also O 
age O 
, O 
fall O 
, O 
family O 
histories O 
of O 
kyphosis O 
and O 
hip O 
fracture O 
, O 
DM O 
, O 
kidney O 
disease O 
, O 
menopause O 
, O 
and O 
lifestyle O 
factors O 
of O 
dieting O 
, O 
exercise O 
, O 
and O 
alcohol B-FAMILY 
. O 
Women's O 
health O 
care O 
focusing O 
on O 
lifestyle O 
- O 
related O 
fracture O 
risks O 
such O 
as O 
dieting O 
, O 
exercise O 
, O 
and O 
alcohol B-FAMILY 
appears O 
necessary O 
to O 
prevent O 
bone O 
fracture O 
in O 
postmenopausal O 
osteoporosis O 
. O 

observe O 
changes O 
in O 
the O 
molecular O 
conductivity O 
of O 
individual O 
oligophenylene B-FAMILY 
- I-FAMILY 
vinylene I-FAMILY 
( O 
OPV B-ABBREVIATION 
) O 
molecules O 
due O 
to O 
interactions O 
with O 
small O 
aromatic O 
molecules O 
. O 
Fluorescence O 
experiments O 
were O 
correlated O 
with O 
scanning O 
tunneling O 
microscopy O 
measurements O 
in O 
order O 
to O 
determine O 
the O 
origin O 
of O 
the O 
observed O 
effect O 
. O 
Both O 
nitrobenzene B-SYSTEMATIC 
and O 
1,4-dinitrobenzene B-SYSTEMATIC 
decreased O 
fluorescence O 
intensity O 
and O 
molecular O 
conductivity O 
, O 
while O 
toluene B-TRIVIAL 
had O 
no O 
effect O 
. O 
The O 
observed O 
changes O 
in O 
the O 
fluorescence O 
and O 
conduction O 
of O 
OPV B-ABBREVIATION 
correlate O 
well O 
with O 
the O 
electron O 
withdrawing O 
ability O 
of O 
the O 
interacting O 
aromatic O 
molecules O 
. O 
These O 
results O 
demonstrate O 
the O 
potential O 
usefulness O 
of O 
OPV B-ABBREVIATION 
as O 
a O 
sensor O 
for O 
aromatic O 
compounds O 
containing O 
electron O 
withdrawing O 
groups O 
. O 

induces O 
phase O 
II O 
enzymes O 
via O 
Nrf2 O 
in O 
human O 
hepatocytes O 
in O 
vitro O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
xanthohumol B-TRIVIAL 
may O 
exert O 
chemoprotective O 
activity O 
through O 
the O 
modulation O 
of O 
the O 
nuclear O 
factor O 
erythroid-2 O 
- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
pathway O 
in O 
immortalized O 
normal O 
THLE-2 O 
hepatocytes O 
and O 
a O 
hepatocellular O 
carcinoma O 
HepG2 O 
cell O 
line O 
. O 
Cells O 
were O 
incubated O 
in O 
the O 
presence O 
of O 
xanthohumol B-TRIVIAL 
and O 
the O 
activation O 
of O 
Nrf2 O 
and O 
expression O 
of O 
genes O 
controlled O 
by O 
this O 
transcription O 
factor O 
were O 
evaluated O 
. O 
Additionally O 
, O 
p53 O 
level O 
was O 
assessed O 
. O 
Xanthohumol B-TRIVIAL 
increased O 
the O 
expression O 
and O 
led O 
to O 
the O 
activation O 
of O 
Nrf2 O 
in O 
both O 
cell O 
lines O 
. O 
However O 
, O 
in O 
contrast O 
to O 
normal O 
cells O 
the O 
expression O 
of O 
genes O 
controlled O 
by O 
this O 
transcription O 
factor O 
was O 
not O 
affected O 
in O 
HepG2 O 
cells O 
, O 
except O 
for O 
GSTA O 
and O 
GSTP O 
. O 
Xanthohumol B-TRIVIAL 
, O 
beside O 
the O 
induction O 
of O 
GSTs O 
and O 
HO-1 O 
, O 
significantly O 
elevated O 
NQO1 O 
expression O 
in O 
concert O 
with O 
p53 O 
level O 
in O 
normal O 
hepatocytes O 
. O 
The O 
activation O 
of O 
Nrf2 O 
pathway O 
and O 
subsequently O 
phase O 
II O 
enzymes O 
in O 
concert O 
with O 
p53 O 
induction O 
in O 
normal O 
hepatocytes O 
may O 
account O 
for O 
the O 
molecular O 
mechanism O 
of O 
the O 
chemopreventive O 
activity O 
of O 
xanthohumol B-TRIVIAL 
. O 
On O 
the O 
other O 
hand O 
its O 
cytotoxicity O 
towards O 
HCC O 
cells O 
shown O 
in O 
this O 
study O 
indicates O 
that O 
it O 
may O 
also O 
be O 
considered O 
as O 
potentially O 
chemotherapeutic O 
. O 

potential O 
of O 
targeting O 
lipid O 
aldehydes B-FAMILY 
and O 
lipoxidation O 
end O 
- O 
products O 
in O 
the O 
treatment O 
of O 
ocular O 
disease O 
. O 

reactions O 
and O 
the O 
subsequent O 
accumulation O 
of O 
advanced O 
lipoxidation O 
end O 
products O 
( O 
ALEs O 
) O 
have O 
been O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
many O 
of O 
the O 
leading O 
causes O 
of O 
visual O 
impairment O 
. O 
Here O 
, O 
we O 
begin O 
by O 
outlining O 
some O 
of O 
the O 
major O 
lipid O 
aldehydes B-FAMILY 
produced O 
through O 
lipoxidation O 
reactions O 
, O 
the O 
ALEs O 
formed O 
upon O 
their O 
reaction O 
with O 
proteins O 
, O 
and O 
the O 
endogenous O 
aldehyde B-SYSTEMATIC 
metabolizing O 
enzymes O 
involved O 
in O 
protecting O 
cells O 
against O 
lipoxidation O 
mediated O 
damage O 
. O 
Discussions O 
are O 
subsequently O 
focused O 
on O 
the O 
clinical O 
and O 
experimental O 
evidence O 
supporting O 
the O 
contribution O 
of O 
lipid O 
aldehydes B-FAMILY 
and O 
ALEs O 
in O 
the O 
development O 
of O 
ocular O 
diseases O 
. O 
From O 
these O 
discussions O 
, O 
it O 
is O 
clear O 
that O 
inhibition O 
of O 
lipoxidation O 
reactions O 
and O 
ALE O 
formation O 
could O 
represent O 
a O 
new O 
therapeutic O 
avenue O 
for O 
the O 
treatment O 
of O 
a O 
broad O 
range O 
of O 
ocular O 
disorders O 
. O 
Current O 
and O 
emerging O 
pharmacological O 
strategies O 
to O 
prevent O 
or O 
neutralize O 
the O 
effects O 
of O 
lipid O 
aldehydes B-FAMILY 
and O 
ALEs O 
are O 
therefore O 
considered O 
, O 
with O 
particular O 
emphasis O 
on O 
the O 
potential O 
of O 
these O 
drugs O 
for O 
treatment O 
of O 
diseases O 
of O 
the O 
eye O 
. O 

-dependent O 
protein O 
kinase11 O 
and O 
24 O 
modulate O 
the O 
activity O 
of O 
the O 
inward O 
rectifying O 
K+ B-FORMULA 
channels O 
in O 
Arabidopsis O 
pollen O 
tubes O 
. O 

( O 
K(+) B-FORMULA 
) O 
influx O 
into O 
pollen O 
tubes O 
via O 
K(+) B-FORMULA 
transporters O 
is O 
essential O 
for O 
pollen O 
tube O 
growth O 
; O 
however O 
, O 
the O 
mechanism O 
by O 
which O 
K(+) B-FORMULA 
transporters O 
are O 
regulated O 
in O 
pollen O 
tubes O 
remains O 
unknown O 
. O 
Here O 
, O 
we O 
report O 
that O 
Arabidopsis O 
thaliana O 
Ca(2+) B-FORMULA 
-dependent O 
protein O 
kinase11 O 
( O 
CPK11 O 
) O 
and O 
CPK24 O 
are O 
involved O 
in O 
Ca(2+) B-FORMULA 
-dependent O 
regulation O 
of O 
the O 
inward O 
K(+) B-FORMULA 
( O 
K(+) B-FORMULA 
in O 
) O 
channels O 
in O 
pollen O 
tubes O 
. O 
Using O 
patch O 
- O 
clamp O 
analysis O 
, O 
we O 
demonstrated O 
that O 
K(+) B-FORMULA 
in O 
currents O 
of O 
pollen O 
tube O 
protoplasts O 
were O 
inhibited O 
by O 
elevated O 
[ O 
Ca(2+) B-FORMULA 
]cyt O 
. O 
However O 
, O 
disruption O 
of O 
CPK11 O 
or O 
CPK24 O 
completely O 
impaired O 
the O 
Ca(2+) B-FORMULA 
-dependent O 
inhibition O 
of O 
K(+) B-FORMULA 
in O 
currents O 
and O 
enhanced O 
pollen O 
tube O 
growth O 
. O 
Moreover O 
, O 
the O 
cpk11 O 
cpk24 O 
double O 
mutant O 
exhibited O 
similar O 
phenotypes O 
as O 
the O 
corresponding O 
single O 
mutants O 
, O 
suggesting O 
that O 
these O 
two O 
CDPKs O 
function O 
in O 
the O 
same O 
signaling O 
pathway O 
. O 
Bimolecular O 
fluorescence O 
complementation O 
and O 
coimmunoprecipitation O 
experiments O 
showed O 
that O 
CPK11 O 
could O 
interact O 
with O 
CPK24 O 
in O 
vivo O 
. O 
Furthermore O 
, O 
CPK11 O 
phosphorylated O 
the O 
N B-FORMULA 
terminus O 
of O 
CPK24 O 
in O 
vitro O 
, O 
suggesting O 
that O 
these O 
two O 
CDPKs O 
work O 
together O 
as O 
part O 
of O 
a O 
kinase O 
cascade O 
. O 
Electrophysiological O 
assays O 
demonstrated O 
that O 
the O 
Shaker O 
pollen O 
K(+) B-FORMULA 
in O 
channel O 
is O 
the O 
main O 
contributor O 
to O 
pollen O 
tube O 
K(+) B-FORMULA 
in O 
currents O 
and O 
acts O 
as O 
the O 
downstream O 
target O 
of O 
the O 
CPK11-CPK24 O 
pathway O 
. O 
We O 
conclude O 
that O 
CPK11 O 
and O 
CPK24 O 
together O 
mediate O 
the O 
Ca(2+) B-FORMULA 
-dependent O 
inhibition O 
of O 
K(+) B-FORMULA 
in O 
channels O 
and O 
participate O 
in O 
the O 
regulation O 
of O 
pollen O 
tube O 
growth O 
in O 
Arabidopsis O 
. O 

( O 
Se B-FORMULA 
) O 
seed O 
priming O 
induced O 
growth O 
and O 
biochemical O 
changes O 
in O 
wheat O 
under O 
water O 
deficit O 
conditions O 
. O 

stand O 
establishment O 
at O 
early O 
growth O 
stages O 
in O 
wheat O 
( O 
Triticum O 
aestivum O 
L O 
. O 
) O 
due O 
to O 
drought O 
stress O 
is O 
a O 
major O 
problem O 
that O 
limits O 
overall O 
efficiency O 
and O 
yield O 
of O 
crop O 
. O 
Priming O 
of O 
seed O 
is O 
an O 
effective O 
method O 
for O 
raising O 
seed O 
performance O 
and O 
improving O 
tolerance O 
of O 
crops O 
to O 
abiotic O 
stresses O 
especially O 
drought O 
. O 
The O 
seeds O 
of O 
two O 
local O 
wheat O 
cultivars O 
( O 
Kohistan-97 O 
and O 
Pasban-90 O 
) O 
were O 
soaked O 
in O 
distilled O 
water O 
or O 
sodium B-SYSTEMATIC 
selenate I-SYSTEMATIC 
solutions O 
of O 
25 O 
, O 
50 O 
, O 
75 O 
, O 
and O 
100 O 
μM O 
for O 
1 O 
/ O 
2 O 
or O 
1 O 
h O 
at O 
25 O 
°C O 
and O 
later O 
re O 
- O 
dried O 
to O 
their O 
original O 
moisture O 
levels O 
before O 
sowing O 
. O 
One O 
- O 
hour O 
priming O 
significantly O 
increased O 
root O 
length O 
stress O 
tolerance O 
index O 
, O 
dry O 
matter O 
stress O 
tolerance O 
index O 
, O 
and O 
total O 
biomass O 
of O 
seedlings O 
; O 
however O 
, O 
no O 
significant O 
effect O 
of O 
changing O 
duration O 
of O 
Se B-FORMULA 
seed O 
priming O 
was O 
observed O 
on O 
plant O 
height O 
stress O 
tolerance O 
index O 
and O 
shoot O 
/ O 
root O 
ratio O 
. O 
Among O 
cultivars O 
, O 
Kohistan-97 O 
was O 
found O 
to O 
be O 
more O 
responsive O 
to O 
Se B-FORMULA 
seed O 
treatment O 
as O 
1 O 
h O 
priming O 
at O 
100 O 
μM O 
significantly O 
increased O 
its O 
total O 
biomass O 
by O 
43 O 
% O 
as O 
compared O 
to O 
control O 
treatment O 
. O 
Although O 
biomass O 
of O 
seedlings O 
was O 
not O 
affected O 
with O 
Se B-FORMULA 
seed O 
priming O 
under O 
normal O 
conditions O 
, O 
but O 
it O 
increased O 
significantly O 
with O 
increase O 
in O 
rates O 
of O 
Se B-FORMULA 
under O 
drought O 
stress O 
conditions O 
. O 
One O 
- O 
hour O 
priming O 
at O 
75 O 
μM O 
increased O 
the O 
total O 
sugar B-FAMILY 
content O 
and O 
total O 
free O 
amino B-FAMILY 
acids I-FAMILY 
in O 
both O 
wheat O 
cultivars O 
. O 
A O 
more O 
significant O 
decrease O 
in O 
soluble O 
proteins O 
of O 
seedlings O 
was O 
observed O 
by O 
1 O 
h O 
priming O 
than O 
1 O 
/ O 
2 O 
h O 
priming O 
under O 
drought O 
stress O 
conditions O 
. O 

glucose B-TRIVIAL 
, O 
insulin O 
and O 
free B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
concentrations O 
synergistically O 
enhance O 
perilipin O 
3 O 
expression O 
and O 
lipid O 
accumulation O 
in O 
macrophages O 
. O 

: O 
Perilipin O 
( O 
PLIN O 
) O 
3 O 
, O 
an O 
intracellular O 
lipid O 
droplet O 
(LD)-associated O 
protein O 
, O 
is O 
implicated O 
in O 
foam O 
cell O 
formation O 
. O 
Since O 
metabolic O 
derangements O 
found O 
in O 
metabolic O 
syndrome O 
, O 
such O 
as O 
high O 
serum O 
levels O 
of O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
FFAs B-FAMILY 
) O 
, O 
are O 
major O 
risk O 
factors O 
promoting O 
atherosclerosis O 
, O 
we O 
investigated O 
whether O 
PLIN3 O 
expression O 
is O 
affected O 
by O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
OA O 
) O 
using O 
RAW264.7 O 
cells O 
. O 
METHODS O 
: O 
Real O 
- O 
time O 
PCR O 
and O 
Western O 
blotting O 
were O 
performed O 
to O 
detect O 
PLIN3 O 
or O 
PLIN2 O 
expression O 
. O 
Oil B-TRIVIAL 
- I-TRIVIAL 
red I-TRIVIAL 
O I-TRIVIAL 
staining O 
and O 
Lipid O 
Analysis O 
were O 
employed O 
to O 
measure O 
cellular O 
content O 
of O 
triacylglycerides B-FAMILY 
( O 
TAG B-ABBREVIATION 
) O 
and O 
cholesterol B-TRIVIAL 
. O 
RESULTS O 
: O 
PLIN3 O 
mRNA O 
was O 
stimulated O 
by O 
high O 
glucose B-TRIVIAL 
or O 
insulin O 
concentrations O 
individually O 
, O 
but O 
not O 
by O 
OA O 
. O 
A O 
combination O 
of O 
any O 
two O 
factors O 
did O 
not O 
enhance O 
PLIN3 O 
expression O 
any O 
more O 
than O 
that O 
evoked O 
by O 
glucose B-TRIVIAL 
alone O 
at O 
24h O 
. O 
Interestingly O 
, O 
however O 
, O 
simultaneous O 
addition O 
of O 
all O 
three O 
factors O 
synergistically O 
enhanced O 
the O 
PLIN3 O 
expression O 
. O 
This O 
synergistic O 
effect O 
was O 
not O 
apparent O 
for O 
PLIN2 O 
mRNA O 
expression O 
. O 
Inhibitors O 
of O 
Src O 
family O 
tyrosine B-TRIVIAL 
kinase O 
and O 
/ O 
or O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
, O 
both O 
of O 
which O 
are O 
activated O 
by O 
insulin O 
and O 
FFA B-ABBREVIATION 
signaling O 
, O 
partially O 
suppressed O 
PLIN3 O 
expression O 
induced O 
by O 
the O 
combination O 
of O 
the O 
three O 
factors O 
. O 
While O 
simultaneous O 
addition O 
of O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
OA O 
remarkably O 
increased O 
the O 
cellular O 
content O 
of O 
TAG B-ABBREVIATION 
and O 
cholesterol B-TRIVIAL 
, O 
knocking O 
- O 
down O 
of O 
PLIN3 O 
predominantly O 
reduced O 
TAG B-ABBREVIATION 
content O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
indicate O 
that O 
PLIN3 O 
expression O 
is O 
synergistically O 
stimulated O 
by O 
high O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
FFA B-ABBREVIATION 
concentrations O 
, O 
in O 
parallel O 
with O 
TAG B-ABBREVIATION 
accumulation O 
in O 
macrophages O 
. O 
This O 
finding O 
raises O 
new O 
evidence O 
of O 
PLIN3 O 
involvement O 
in O 
conversion O 
of O 
macrophages O 
into O 
foam O 
cells O 
. O 

acids I-FAMILY 
( O 
EETs B-ABBREVIATION 
) O 
play O 
a O 
protective O 
role O 
against O 
damaging O 
processes O 
in O 
the O 
kidney O 
. O 
We O 
have O 
assessed O 
the O 
effect O 
of O 
polymorphisms O 
in O 
EETs B-ABBREVIATION 
-producing O 
enzymes O 
( O 
CYP2C8 O 
and O 
CYP2J2 O 
) O 
and O 
other O 
proteins O 
involved O 
in O 
calcineurin O 
inhibitors O 
( O 
CNIs O 
) O 
disposition O 
( O 
CYP3A4 O 
, O 
CYP3A5 O 
, O 
and O 
ABCB1 O 
) O 
on O 
graft O 
function O 
and O 
clinical O 
outcome O 
in O 
166 O 
renal O 
transplant O 
recipients O 
treated O 
with O 
CNIs O 
. O 
Both O 
CYP2C8*3 O 
and O 
donor O 
age O 
greater O 
than O 
48 O 
years O 
were O 
associated O 
to O 
a O 
higher O 
incidence O 
of O 
delayed O 
graft O 
function O 
( O 
DGF O 
) O 
[ O 
OR O 
= O 
2.01 O 
( O 
1.1-4.1 O 
) O 
, O 
P O 
= O 
0.04 O 
and O 
5.14 O 
( O 
2.4-10.9 O 
) O 
, O 
P O 
< O 
0.0001 O 
; O 
respectively O 
] O 
and O 
worse O 
creatinine B-TRIVIAL 
clearance O 
1 O 
year O 
after O 
grafting O 
( O 
P O 
< O 
0.05 O 
and O 
P O 
< O 
0.001 O 
, O 
respectively O 
) O 
. O 
In O 
addition O 
, O 
carrying O 
4-6 O 
variants O 
in O 
the O 
3 O 
ABCB1 O 
loci O 
and O 
older O 
donor O 
age O 
were O 
individually O 
associated O 
to O 
higher O 
incidence O 
of O 
calcineurin O 
- O 
inhibitor O 
- O 
induced O 
nephrotoxicity O 
[ O 
OR O 
= O 
2.38 O 
( O 
1.1-5.4 O 
) O 
, O 
P O 
= O 
0.03 O 
and O 
OR O 
= O 
1.03 O 
( O 
1.01-1.06 O 
) O 
, O 
P O 
= O 
0.038 O 
] O 
. O 
Regression O 
analyses O 
confirmed O 
the O 
relevant O 
effect O 
of O 
both O 
CYP2C8*3 O 
and O 
donor O 
age O 
on O 
graft O 
dysfunction O 
. O 
Carrying O 
the O 
2C8*3 O 
allele O 
and O 
having O 
a O 
donor O 
older O 
than O 
48 O 
years O 
was O 
defined O 
as O 
a O 
high O 
- O 
risk O 
status O 
and O 
observed O 
to O 
be O 
highly O 
related O 
to O 
DGF O 
[ O 
OR O 
= O 
3.91 O 
( O 
1.46-10.48 O 
) O 
, O 
P O 
< O 
0.01 O 
] O 
and O 
worse O 
creatinine B-TRIVIAL 
clearance O 
( O 
P O 
= O 
0.033 O 
) O 
. O 
Our O 
results O 
show O 
that O 
genetic O 
and O 
clinical O 
parameters O 
can O 
be O 
combined O 
to O 
identify O 
risk O 
factors O 
for O 
allograft O 
dysfunction O 
in O 
renal O 
transplant O 
recipients O 
. O 

review O 
of O 
population O 
pharmacokinetic O 
analyses O 
of O 
imatinib B-TRIVIAL 
and O 
relationships O 
with O 
treatment O 
outcomes O 
. O 

population O 
pharmacokinetic O 
( O 
PPK O 
) O 
analyses O 
of O 
the O 
anticancer O 
drug O 
imatinib B-TRIVIAL 
have O 
been O 
performed O 
to O 
investigate O 
different O 
patient O 
populations O 
and O 
covariate O 
effects O 
. O 
The O 
present O 
analysis O 
offers O 
a O 
systematic O 
qualitative O 
and O 
quantitative O 
summary O 
and O 
comparison O 
of O 
those O 
. O 
Its O 
primary O 
objective O 
was O 
to O 
provide O 
useful O 
information O 
for O 
evaluating O 
the O 
expectedness O 
of O 
imatinib B-TRIVIAL 
plasma O 
concentration O 
measurements O 
in O 
the O 
frame O 
of O 
therapeutic O 
drug O 
monitoring O 
. O 
The O 
secondary O 
objective O 
was O 
to O 
review O 
clinically O 
important O 
concentration O 
- O 
effect O 
relationships O 
to O 
provide O 
help O 
in O 
evaluating O 
the O 
potential O 
suitability O 
of O 
plasma O 
concentration O 
values O 
. O 
Nine O 
PPK O 
models O 
describing O 
total O 
imatinib B-TRIVIAL 
plasma O 
concentration O 
were O 
identified O 
. O 
Parameter O 
estimates O 
were O 
standardized O 
to O 
common O 
covariate O 
values O 
whenever O 
possible O 
. O 
Predicted O 
median O 
exposure O 
( O 
C O 
min O 
) O 
was O 
derived O 
by O 
simulations O 
and O 
ranged O 
between O 
models O 
from O 
555 O 
to O 
1388 O 
ng O 
/ O 
mL O 
( O 
grand O 
median O 
: O 
870 O 
ng O 
/ O 
mL O 
and O 
interquartile O 
" O 
reference O 
" O 
range O 
: O 
520-1390 O 
ng O 
/ O 
mL O 
) O 
. O 
Covariates O 
of O 
potential O 
clinical O 
importance O 
( O 
up O 
to O 
30% O 
change O 
in O 
pharmacokinetic O 
predicted O 
by O 
at O 
least O 
1 O 
model O 
) O 
included O 
body O 
weight O 
, O 
albumin O 
, O 
α1 O 
acid O 
glycoprotein O 
, O 
and O 
white O 
blood O 
cell O 
count O 
. O 
Various O 
other O 
covariates O 
were O 
included O 
but O 
were O 
statistically O 
not O 
significant O 
or O 
seemed O 
clinically O 
less O 
important O 
or O 
physiologically O 
controversial O 
. O 
Concentration O 
- O 
response O 
relationships O 
had O 
more O 
importance O 
below O 
the O 
average O 
reference O 
range O 
and O 
concentration O 
- O 
toxicity O 
relationships O 
above O 
. O 
Therapeutic O 
drug O 
monitoring O 
- O 
guided O 
dosage O 
adjustment O 
seems O 
justified O 
for O 
imatinib B-TRIVIAL 
, O 
but O 
a O 
formal O 
predictive O 
therapeutic O 
range O 
remains O 
difficult O 
to O 
propose O 
in O 
the O 
absence O 
of O 
prospective O 
target O 
concentration O 
intervention O 
trials O 
. O 
To O 
evaluate O 
the O 
expectedness O 
of O 
a O 
drug O 
concentration O 
measurement O 
in O 
practice O 
, O 
this O 
review O 
allows O 
comparison O 
of O 
the O 
measurement O 
either O 
to O 
the O 
average O 
reference O 
range O 
or O 
to O 
a O 
specific O 
range O 
accounting O 
for O 
individual O 
patient O 
characteristics O 
. O 
For O 
future O 
research O 
, O 
external O 
PPK O 
model O 
validation O 
or O 
meta-model O 
development O 
should O 
be O 
considered O 
. O 

lines O 
of O 
evidence O 
, O 
including O 
the O 
recent O 
discovery O 
of O 
novel O 
susceptibility O 
genes O 
, O 
point O 
out O 
an O 
important O 
role O 
for O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
signaling O 
pathway O 
in O 
the O 
development O 
of O 
pheochromocytoma O 
. O 
Analyzing O 
a O 
set O 
of O 
pheochromocytomas O 
from O 
patients O 
with O 
different O 
genetic O 
backgrounds O 
, O 
we O 
observed O 
and O 
confirmed O 
a O 
significant O 
overexpression O 
of O 
key O 
mTOR O 
complex O 
( O 
mTORC O 
) O 
signaling O 
mediators O 
. O 
Using O 
selective O 
ATP B-ABBREVIATION 
-competitive O 
inhibitors O 
targeting O 
both O 
mTORC1 O 
and O 
mTORC2 O 
, O 
we O 
significantly O 
arrested O 
the O 
in O 
vitro O 
cell O 
proliferation O 
and O 
blocked O 
migration O 
of O 
pheochromocytoma O 
cells O 
as O 
a O 
result O 
of O 
the O 
pharmacological O 
suppression O 
of O 
the O 
Akt O 
/ O 
mTOR O 
signaling O 
pathway O 
. O 
Moreover O 
, O 
AZD8055 B-IDENTIFIER 
, O 
a O 
selective O 
ATP B-ABBREVIATION 
-competitive O 
dual O 
mTORC1 O 
/ O 
2 O 
small O 
molecular O 
inhibitor O 
, O 
significantly O 
reduced O 
the O 
tumor O 
burden O 
in O 
a O 
model O 
of O 
metastatic O 
pheochromocytoma O 
using O 
female O 
athymic O 
nude O 
mice O 
. O 
This O 
study O 
suggests O 
that O 
targeting O 
both O 
mTORC1 O 
and O 
mTORC2 O 
is O 
a O 
potentially O 
rewarding O 
strategy O 
and O 
supports O 
the O 
application O 
of O 
selective O 
inhibitors O 
in O 
combinatorial O 
drug O 
regimens O 
for O 
metastatic O 
pheochromocytoma O 
. O 

advent O 
of O 
neurochemical O 
brain O 
imaging O 
methods O 
has O 
provided O 
an O 
opportunity O 
to O 
study O 
the O 
neurochemistry O 
of O 
the O 
human O 
brain O 
in O 
normal O 
and O 
abnormal O 
development O 
. O 
The O 
aim O 
of O 
this O 
article O 
is O 
to O 
provide O 
an O 
update O 
on O 
recent O 
major O 
developments O 
in O 
neurochemical O 
imaging O 
in O 
schizophrenia O 
research O 
. O 
In O 
this O 
concise O 
review O 
, O 
we O 
discuss O 
the O 
major O 
findings O 
on O 
three O 
neurotransmitters O 
, O 
namely O 
dopamine B-TRIVIAL 
, O 
serotonin B-TRIVIAL 
and O 
glutamate B-TRIVIAL 
. O 
The O 
most O 
promising O 
radioligand O 
for O 
D(2) O 
/ O 
D(3) O 
neuroreceptor O 
imaging O 
is O 
the O 
agonist O 
[(11)C]PHNO B-SYSTEMATIC 
, O 
with O 
higher O 
in O 
vivo O 
affinity O 
for O 
D(3) O 
than O 
D(2) O 
receptors O 
, O 
which O 
can O 
be O 
used O 
to O 
measure O 
amphetamine B-TRIVIAL 
-induced O 
release O 
of O 
dopamine B-TRIVIAL 
, O 
and O 
therefore O 
a O 
potential O 
model O 
of O 
dopaminergic O 
alterations O 
in O 
schizophrenia O 
. O 
Recent O 
development O 
of O 
selective O 
radiotracers O 
allow O 
imaging O 
of O 
the O 
serotonin B-TRIVIAL 
transporter O 
( O 
SERT O 
) O 
using O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
with O 
selective O 
tracers O 
such O 
as O 
[(11)C]DASB B-SYSTEMATIC 
. O 
Additionally O 
, O 
the O 
glutamatergic O 
hypothesis O 
has O 
evolved O 
from O 
theory O 
to O 
phase O 
III O 
clinical O 
trials O 
of O 
newer O 
agents O 
with O 
novel O 
mechanisms O 
. O 
With O 
the O 
development O 
of O 
newer O 
radioligands O 
and O 
the O 
in O 
vivo O 
application O 
of O 
magnetic O 
resonance O 
spectroscopy O 
( O 
MRS O 
) O 
at O 
relatively O 
high O 
magnetic O 
field O 
strengths O 
, O 
there O 
is O 
ample O 
scope O 
for O 
further O 
neuroimaging O 
advances O 
. O 

pathway O 
to O 
22,23-dioxocholestanic B-SYSTEMATIC 
chain O 
derivatives O 
and O 
their O 
usefulness O 
for O 
obtaining O 
brassinosteroid B-FAMILY 
analogues O 
. O 

the O 
functionality O 
of O 
the O 
pentacyclic B-FAMILY 
steroidal I-FAMILY 
derivative O 
7a O 
as O 
important O 
synthon O 
to O 
obtain O 
new O 
brassinosteroid B-FAMILY 
analogs O 
, O 
we O 
have O 
accomplished O 
the O 
derivatization O 
of O 
hecogenin B-TRIVIAL 
, O 
a O 
sapogenin O 
from O 
the O 
25R O 
serie O 
containing O 
a O 
carbonyl B-FAMILY 
group O 
at O 
C-12 O 
, O 
to O 
a O 
22,23-dioxocholestanic B-SYSTEMATIC 
chain O 
derivative O 
. O 
Starting O 
from O 
hecogenin B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
5a O 
) O 
or O 
hecogenin B-SYSTEMATIC 
tosylate I-SYSTEMATIC 
( O 
5b O 
) O 
, O 
we O 
obtained O 
two O 
pentacyclic O 
derivatives O 
( O 
7a O 
and O 
7b O 
) O 
which O 
were O 
subjected O 
to O 
an O 
oxidation O 
reaction O 
on O 
the O 
double O 
bond O 
at O 
C-12(23) O 
to O 
obtain O 
a O 
22,23-dioxocholestanic B-SYSTEMATIC 
chain O 
, O 
with O 
the O 
regeneration O 
of O 
the O 
carbonyl B-FAMILY 
group O 
at O 
C-12 O 
. O 
Reduction O 
of O 
the O 
carbonyl B-FAMILY 
groups O 
lead O 
to O 
the O 
20-epi-12,23-dihydroxy-22-oxo B-SYSTEMATIC 
system O 
11a-b O 
. O 
The O 
absolute O 
configuration O 
of O 
compound O 
11a O 
was O 
established O 
by O 
X-ray O 
diffraction O 
analysis O 
. O 

pulposus O 
from O 
the O 
porcine O 
intervertebral O 
disc O 
was O 
separated O 
chromatographically O 
to O 
discover O 
substrates O 
of O 
microbial O 
transglutaminase O 
. O 
Highly O 
purified O 
proteins O 
were O 
prepared O 
, O 
among O 
them O 
type O 
II O 
collagen O 
, O 
the O 
major O 
protein O 
of O 
the O 
nucleus O 
pulposus O 
. O 
Determination O 
of O 
substrates O 
was O 
performed O 
by O 
transglutaminase O 
- O 
mediated O 
incorporation O 
of O 
biotinylated O 
probes O 
displaying O 
several O 
glutamine B-TRIVIAL 
and O 
lysine B-TRIVIAL 
donor O 
proteins O 
. O 
Type O 
II O 
collagen O 
was O 
only O 
labeled O 
if O 
smaller O 
nucleus O 
pulposus O 
proteins O 
were O 
present O 
. O 
One O 
of O 
the O 
modulating O 
proteins O 
was O 
serotransferrin O 
, O 
a O 
lysine B-TRIVIAL 
donor O 
substrate O 
of O 
bacterial O 
transglutaminase O 
. O 
An O 
additional O 
substrate O 
was O 
the O 
carboxy B-SYSTEMATIC 
-terminal O 
propeptide O 
of O 
type O 
II O 
collagen O 
, O 
chondrocalcin O 
. O 
Chondrocalcin O 
, O 
a O 
regulator O 
of O 
type O 
II O 
collagen O 
fibrillogenesis O 
, O 
occurs O 
abundantly O 
in O 
juvenile O 
cartilage O 
and O 
nucleus O 
pulposus O 
. O 
Accordingly O 
, O 
the O 
protein O 
may O 
be O 
regarded O 
as O 
an O 
excellent O 
additive O 
for O 
the O 
preparation O 
of O 
injectable O 
stem O 
cells O 
in O 
nucleus O 
pulposus O 
- O 
like O 
matrices O 
cross O 
- O 
linked O 
by O 
microbial O 
transglutaminase O 
. O 

and O 
cytotoxicity O 
of O 
3-aryl B-FAMILY 
acrylic I-FAMILY 
amide I-FAMILY 
derivatives O 
of O 
the O 
simplified O 
saframycin B-TRIVIAL 
- O 
ecteinascidin B-TRIVIAL 
skeleton O 
prepared O 
from O 
l-dopa B-ABBREVIATION 
. O 

four O 
compounds O 
with O 
diversified O 
3-aryl B-FAMILY 
acrylic I-FAMILY 
amide I-FAMILY 
side O 
chains O 
of O 
the O 
simplified O 
saframycin B-TRIVIAL 
- O 
ecteinascidin B-TRIVIAL 
pentacyclic O 
skeleton O 
were O 
synthesized O 
via O 
a O 
14-step O 
stereospecific O 
route O 
starting O 
from O 
l-dopa B-ABBREVIATION 
. O 
The O 
cytotoxicities O 
of O 
these O 
compounds O 
were O 
tested O 
against O 
eight O 
human O 
tumor O 
cell O 
lines O 
including O 
HCT-8 O 
, O 
BEL-7402 O 
, O 
BGC-803 O 
, O 
A549 O 
, O 
A2780 O 
, O 
MCF-7 O 
, O 
MX-1 O 
, O 
and O 
MDA-MB-231 O 
. O 
Most O 
of O 
these O 
compounds O 
exhibited O 
potent O 
antitumor O 
activity O 
, O 
and O 
a O 
preliminary O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
was O 
discussed O 
. O 
Compound O 
28 O 
with O 
3-thiophenyl B-SYSTEMATIC 
acrylic I-SYSTEMATIC 
amide I-SYSTEMATIC 
side O 
chain O 
exhibited O 
selective O 
cytotoxicity O 
against O 
MDA-MB-231 O 
cell O 
line O 
with O 
the O 
IC50 O 
value O 
of O 
50 O 
nM O 
. O 

dynamics O 
in O 
colloidal O 
Au₂Cd B-FORMULA 
alloy- O 
CdSe B-FORMULA 
core O 
/ O 
shell O 
nanocrystals O 
. O 

- O 
semiconductor O 
nanocrystal O 
heterostructures O 
are O 
model O 
systems O 
for O 
understanding O 
the O 
interplay O 
between O 
the O 
localized O 
surface O 
plasmon O 
resonances O 
in O 
the O 
metal O 
domain O 
and O 
the O 
relaxation O 
of O 
the O 
excited O 
carriers O 
in O 
the O 
semiconductor O 
domain O 
. O 
Here O 
we O 
report O 
the O 
synthesis O 
of O 
colloidal O 
Au₂Cd B-FORMULA 
(core)/ O 
CdSe B-FORMULA 
( O 
shell O 
) O 
nanocrystal O 
heterostructures O 
, O 
which O 
were O 
characterized O 
extensively O 
with O 
several O 
structural O 
and O 
optical O 
techniques O 
, O 
including O 
time O 
- O 
resolved O 
fluorescence O 
and O 
broad O 
- O 
band O 
transient O 
absorption O 
spectroscopy O 
( O 
both O 
below O 
and O 
above O 
the O 
CdSe B-FORMULA 
band O 
gap O 
) O 
. O 
The O 
dynamics O 
of O 
the O 
transient O 
plasmon O 
peak O 
was O 
dominated O 
by O 
the O 
relaxation O 
of O 
hot O 
carriers O 
in O 
the O 
metal O 
core O 
, O 
its O 
spectral O 
shape O 
was O 
independent O 
of O 
the O 
pump O 
wavelength O 
, O 
and O 
the O 
bleaching O 
lifetime O 
was O 
about O 
half O 
a O 
picosecond O 
, O 
comparable O 
with O 
the O 
value O 
found O 
in O 
the O 
AuCd B-FORMULA 
seeds O 
used O 
for O 
the O 
synthesis O 
. O 

capacity O 
, O 
polyphenolic B-FAMILY 
content O 
and O 
tandem O 
HPLC-DAD-ESI O 
/ O 
MS O 
profiling O 
of O 
phenolic B-FAMILY 
compounds O 
from O 
the O 
South O 
American O 
berries O 
Luma O 
apiculata O 
and O 
L O 
. O 
chequén O 
. O 

Myrtaceae O 
fruits O 
were O 
gathered O 
by O 
South O 
American O 
Amerindians O 
as O 
a O 
food O 
source O 
. O 
At O 
present O 
, O 
there O 
is O 
still O 
some O 
regional O 
consume O 
of O 
the O 
small O 
berries O 
from O 
trees O 
belonging O 
to O 
genus O 
Luma O 
that O 
occurs O 
in O 
southern O 
Chile O 
and O 
Argentina O 
. O 
The O 
aerial O 
parts O 
and O 
berries O 
from O 
Luma O 
apiculata O 
and O 
Luma O 
chequen O 
were O 
investigated O 
for O 
phenolic B-FAMILY 
constituents O 
and O 
antioxidant O 
capacity O 
. O 
A O 
high O 
performance O 
electrospray O 
ionisation O 
mass O 
spectrometry O 
method O 
was O 
developed O 
for O 
the O 
rapid O 
identification O 
of O 
phenolics B-FAMILY 
in O 
polar O 
extracts O 
from O 
both O 
species O 
. O 
Thirty O 
- O 
one O 
phenolic B-FAMILY 
compounds O 
were O 
detected O 
and O 
27 O 
were O 
identified O 
or O 
tentatively O 
characterised O 
based O 
on O 
photodiode O 
array O 
UV-vis O 
spectra O 
( O 
DAD O 
) O 
, O 
ESI-MS-MS O 
spectrometric O 
data O 
and O 
spiking O 
experiments O 
with O 
authentic O 
standards O 
. O 
Twelve O 
phenolic B-FAMILY 
compounds O 
were O 
detected O 
in O 
L O 
. O 
apiculata O 
fruits O 
and O 
12 O 
in O 
the O 
aerial O 
parts O 
while O 
L O 
. O 
chequen O 
yielded O 
10 O 
compounds O 
in O 
fruits O 
and O 
16 O 
in O 
aerial O 
parts O 
, O 
respectively O 
. O 
From O 
the O 
compounds O 
occurring O 
in O 
both O 
Luma O 
species O 
, O 
seven O 
were O 
identified O 
as O 
tannins B-FAMILY 
or O 
their O 
monomers O 
, O 
15 O 
were O 
flavonol B-TRIVIAL 
derivatives O 
and O 
five O 
were O 
anthocyanins B-FAMILY 
. O 
The O 
whole O 
berry O 
and O 
aerial O 
parts O 
extracts O 
presented O 
high O 
antioxidant O 
capacity O 
in O 
the O 
DPPH B-ABBREVIATION 
assay O 
( O 
IC50 O 
of O 
10.41±0.02 O 
and O 
2.44±0.03μg O 
/ O 
mL O 
for O 
L O 
. O 
apiculata O 
, O 
12.89±0.05 O 
and O 
3.22±0.05 O 
for O 
L O 
. O 
chequen O 
, O 
respectively O 
) O 
, O 
which O 
can O 
be O 
related O 
to O 
the O 
diverse O 
range O 
of O 
phenolics B-FAMILY 
detected O 
. O 
The O 
antioxidant O 
capacity O 
together O 
with O 
the O 
high O 
polyphenolic B-FAMILY 
contents O 
and O 
compounds O 
identified O 
can O 
support O 
at O 
least O 
in O 
part O 
, O 
their O 
use O 
as O 
botanical O 
drugs O 
. O 
From O 
the O 
compounds O 
identified O 
in O 
both O 
species O 
, O 
3-O-(6″-O-galloyl)-hexose B-SYSTEMATIC 
derivatives O 
of O 
myricetin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
laricitrin B-TRIVIAL 
and O 
isorhamnetin B-TRIVIAL 
are O 
reported O 
for O 
the O 
first O 
time O 
for O 
the O 
genus O 
Luma O 
. O 

from O 
Paeonia O 
suffruticosa O 
Protects O 
Hepatic O 
Cells O 
via O 
Up-regulation O 
of O 
Heme B-FAMILY 
Oxygenase-1 O 
. O 

suffruticosa O 
has O 
been O 
traditionally O 
employed O 
for O 
vitalizing O 
blood O 
circulation O 
and O 
alleviating O 
liver O 
and O 
inflammatory O 
diseases O 
. O 
The O 
pathways O 
by O 
which O 
palbinone B-TRIVIAL 
( O 
PB O 
) O 
isolated O 
from O 
P O 
. O 
suffruticosa O 
mediates O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
induction O 
were O 
investigated O 
using O 
the O 
specific O 
inhibitors O 
for O 
PI3K O 
and O 
mitogen O 
activated O 
protein O 
kinases O 
pathways O 
. O 
The O 
effect O 
of O 
PB O 
- O 
treatment O 
on O 
Nrf2 O 
translocalization O 
and O 
HO-1-antioxidant O 
response O 
element O 
( O 
ARE O 
) O 
regulation O 
was O 
examined O 
employing O 
Western O 
blot O 
and O 
luciferase O 
assays O 
. O 
PB O 
induced O 
HO-1 O 
expression O 
via O 
the O 
activation O 
of O 
Nrf2 O 
in O 
the O 
hepatic O 
cells O 
, O 
and O 
ARE-dependent O 
genes O 
were O 
stimulated O 
via O 
the O 
PB O 
- O 
mediated O 
Nrf2 O 
activation O 
. O 
PB O 
- O 
mediated O 
HO-1 O 
expression O 
could O 
be O 
involved O 
with O 
PI3K O 
/ O 
Akt O 
and O 
ERK1 O 
/ O 
2 O 
pathways O 
. O 
Our O 
study O 
suggests O 
the O 
mechanism O 
by O 
which O 
PB O 
induces O 
HO-1 O 
expression O 
in O 
the O 
hepatic O 
cells O 
. O 
This O 
might O 
substantiate O 
the O 
traditional O 
applications O 
of O 
P O 
. O 
suffruticosa O 
for O 
the O 
treatment O 
of O 
oxidative O 
stress O 
- O 
related O 
diseases O 
including O 
oxidant O 
and O 
inflammatory O 
- O 
mediated O 
vascular O 
and O 
liver O 
diseases O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
surface O 
control O 
of O 
complement O 
recognition O 
and O 
activation O 
. O 

nanotubes O 
( O 
CNTs O 
) O 
are O 
receiving O 
considerable O 
attention O 
in O 
site O 
- O 
specific O 
drug O 
and O 
nucleic O 
acid O 
delivery O 
, O 
photodynamic O 
therapy O 
, O 
and O 
photoacoustic O 
molecular O 
imaging O 
. O 
Despite O 
these O 
advances O 
, O 
nanotubes O 
may O 
activate O 
the O 
complement O 
system O 
( O 
an O 
integral O 
part O 
of O 
innate O 
immunity O 
) O 
, O 
which O 
can O 
induce O 
clinically O 
significant O 
anaphylaxis O 
. O 
We O 
demonstrate O 
that O 
single O 
- O 
walled O 
CNTs O 
coated O 
with O 
human O 
serum O 
albumin O 
activate O 
the O 
complement O 
system O 
through O 
C1q O 
- O 
mediated O 
classical O 
and O 
the O 
alternative O 
pathways O 
. O 
Surface O 
coating O 
with O 
methoxypoly(ethylene B-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
-based O 
amphiphiles O 
, O 
which O 
confers O 
solubility O 
and O 
prolongs O 
circulation O 
profiles O 
of O 
CNTs O 
, O 
activates O 
the O 
complement O 
system O 
differently O 
, O 
depending O 
on O 
the O 
amphiphile O 
structure O 
. O 
CNTs O 
with O 
linear O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
amphiphiles O 
trigger O 
the O 
lectin O 
pathway O 
of O 
the O 
complement O 
through O 
both O 
L-ficolin O 
and O 
mannan O 
- O 
binding O 
lectin O 
recognition O 
. O 
The O 
lectin O 
pathway O 
activation O 
, O 
however O 
, O 
did O 
not O 
trigger O 
the O 
amplification O 
loop O 
of O 
the O 
alternative O 
pathway O 
. O 
An O 
amphiphile O 
with O 
branched O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
architecture O 
also O 
activated O 
the O 
lectin O 
pathway O 
but O 
only O 
through O 
L-ficolin O 
recognition O 
. O 
Importantly O 
, O 
this O 
mode O 
of O 
activation O 
neither O 
generated O 
anaphylatoxins O 
nor O 
induced O 
triggering O 
of O 
the O 
effector O 
arm O 
of O 
the O 
complement O 
system O 
. O 
These O 
observations O 
provide O 
a O 
major O 
step O 
toward O 
nanomaterial O 
surface O 
modification O 
with O 
polymers O 
that O 
have O 
the O 
properties O 
to O 
significantly O 
improve O 
innate O 
immunocompatibility O 
by O 
limiting O 
the O 
formation O 
of O 
complement O 
C3 O 
and O 
C5 O 
convertases O 
. O 

mechanisms O 
of O 
action O 
involved O 
in O 
the O 
neurotoxicity O 
of O 
solvents O 
are O 
poorly O 
understood O 
. O 
In O 
vitro O 
studies O 
have O 
suggested O 
that O 
the O 
effects O 
of O 
some O 
solvents O 
might O 
be O 
due O 
to O 
the O 
formation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
This O 
study O 
assesses O 
hydroxyl B-SYSTEMATIC 
radical O 
( O 
OH B-FORMULA 
) O 
generation O 
and O 
measures O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
in O 
the O 
cerebral O 
tissue O 
of O 
rats O 
exposed O 
to O 
six O 
solvents O 
( O 
n-hexane B-SYSTEMATIC 
, O 
n-octane B-SYSTEMATIC 
, O 
toluene B-TRIVIAL 
, O 
n-butylbenzene B-SYSTEMATIC 
, O 
cyclohexane B-SYSTEMATIC 
and O 
1,2,4-trimethylcyclohexane B-SYSTEMATIC 
) O 
. O 
Three O 
of O 
these O 
solvents O 
have O 
been O 
shown O 
to O 
generate O 
ROS O 
in O 
studies O 
carried O 
out O 
in O 
vitro O 
on O 
granular O 
cell O 
cultures O 
from O 
rat O 
cerebellum O 
. O 
We O 
assessed O 
OH B-FORMULA 
production O 
by O 
quantifying O 
the O 
rate O 
of O 
formation O 
of O 
3,4-dihydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
using O 
a O 
trapping O 
agent O 
, O 
4-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
infused O 
via O 
the O 
microdialysis O 
probe O 
, O 
into O 
the O 
prefrontal O 
cortex O 
of O 
rats O 
exposed O 
intraperitoneally O 
to O 
the O 
solvents O 
. O 
Extracellular O 
MDA B-ABBREVIATION 
was O 
quantified O 
in O 
microdialysates O 
collected O 
from O 
the O 
prefrontal O 
cortex O 
of O 
rats O 
exposed O 
, O 
6h O 
/ O 
day O 
for O 
ten O 
days O 
, O 
to O 
1000ppm O 
of O 
the O 
solvents O 
( O 
except O 
for O 
n-butylbenzene B-SYSTEMATIC 
, O 
generated O 
at O 
830ppm O 
) O 
in O 
inhalation O 
chambers O 
. O 
Tissue O 
levels O 
of O 
free O 
and O 
total O 
MDA B-ABBREVIATION 
were O 
measured O 
in O 
different O 
brain O 
structures O 
for O 
rats O 
acutely O 
( O 
intraperitoneal O 
route O 
) O 
and O 
sub O 
- O 
acutely O 
( O 
inhalation O 
) O 
exposed O 
to O 
solvents O 
. O 
None O 
of O 
the O 
six O 
solvents O 
studied O 
increased O 
the O 
production O 
of O 
hydroxyl B-SYSTEMATIC 
radicals O 
in O 
the O 
prefrontal O 
cortex O 
after O 
acute O 
administration O 
. O 
Nor O 
did O 
they O 
increase O 
extracellular O 
or O 
tissue O 
levels O 
of O 
MDA B-ABBREVIATION 
after O 
10 O 
days O 
' O 
inhalation O 
exposure O 
. O 
On O 
the O 
other O 
hand O 
, O 
a O 
decrease O 
in O 
the O 
concentrations O 
of O 
free O 
MDA B-ABBREVIATION 
in O 
brain O 
structures O 
was O 
observed O 
after O 
acute O 
administration O 
of O 
n-hexane B-SYSTEMATIC 
, O 
1,2,4-trimethylcyclohexane B-SYSTEMATIC 
, O 
toluene B-TRIVIAL 
and O 
n-butylbenzene B-SYSTEMATIC 
. O 
Therefore O 
, O 
data O 
of O 
this O 
study O 
carried O 
out O 
in O 
vivo O 
did O 
not O 
confirm O 
observations O 
made O 
in O 
vitro O 
on O 
cell O 
cultures O 
. O 

of O 
biologically O 
important O 
cations O 
such O 
as O 
na(+) B-FORMULA 
, O 
k(+) B-FORMULA 
, O 
ca(2+) B-FORMULA 
, O 
cu(2+) B-FORMULA 
, O 
and O 
fe(3+) B-FORMULA 
using O 
magnetic O 
nanoemulsions O 
. O 

report O 
a O 
simple O 
approach O 
to O 
the O 
ultrasensitive O 
detection O 
of O 
biologically O 
important O 
metal O 
ions O 
using O 
a O 
magnetic O 
nanoemulsion O 
. O 
The O 
nanoemulsion O 
used O 
in O 
our O 
study O 
was O 
an O 
oil O 
- O 
in O 
- O 
water O 
emulsion O 
droplet O 
of O 
average O 
size O 
∼190 O 
nm O 
containing O 
ferrimagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
of O 
average O 
size O 
∼10 O 
nm O 
. O 
In O 
a O 
static O 
magnetic O 
field O 
, O 
the O 
emulsion O 
droplets O 
self O 
- O 
assemble O 
into O 
a O 
nanoarray O 
with O 
distinct O 
interdroplet O 
spacing O 
. O 
In O 
the O 
presence O 
of O 
cations O 
in O 
the O 
solution O 
, O 
the O 
nanofluid O 
array O 
shows O 
a O 
large O 
blue O 
shift O 
in O 
the O 
diffracted O 
Bragg O 
peak O 
and O 
a O 
visually O 
perceivable O 
color O 
change O 
due O 
to O 
changes O 
in O 
the O 
electrical O 
double O 
layer O 
upon O 
the O 
diffusion O 
of O 
cations O 
. O 
The O 
colloidal O 
force O 
- O 
distance O 
measurements O 
in O 
the O 
presence O 
of O 
cations O 
show O 
large O 
variations O 
at O 
the O 
onset O 
of O 
repulsion O 
in O 
the O 
presence O 
of O 
cations O 
. O 
The O 
sensor O 
shows O 
good O 
selectivity O 
to O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
, O 
Ca(2+) B-FORMULA 
, O 
Cu(2+) B-FORMULA 
, O 
and O 
Fe(3+) B-FORMULA 
ions O 
and O 
offers O 
a O 
rapid O 
response O 
compared O 
to O 
conventional O 
techniques O 
. O 
This O 
approach O 
can O 
be O 
useful O 
for O 
the O 
recognition O 
of O 
biologically O 
important O 
cations O 
. O 

extract O 
of O 
Adiantum O 
capillus O 
- O 
veneris O 
L O 
. O 
suppresses O 
the O 
production O 
of O 
inflammatory O 
mediators O 
by O 
inhibiting O 
NF-κB O 
activation O 
. O 

RELEVANCE O 
: O 
Adiantum O 
capillus O 
- O 
veneris O 
L O 
. O 
is O 
a O 
wildly O 
distributed O 
plant O 
species O 
and O 
has O 
been O 
extensively O 
used O 
in O 
south O 
of O 
China O 
as O 
traditional O 
folk O 
medicine O 
for O 
the O 
treatment O 
of O 
inflammatory O 
diseases O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
investigate O 
the O 
anti-inflammatory O 
effect O 
of O 
ethanolic O 
extracts O 
of O 
Adiantum O 
capillus O 
- O 
veneris O 
L O 
. O 
and O 
the O 
involvement O 
of O 
NF-κB O 
signaling O 
in O 
the O 
regulation O 
of O 
inflammation O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
plant O 
ethanolic O 
extracts O 
were O 
initially O 
tested O 
against O 
lipopolysaccharide O 
(LPS)-induced O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
production O 
in O 
RAW264.7 O 
mouse O 
macrophages O 
, O 
and O 
interleukin O 
6 O 
( O 
IL-6 O 
) O 
and O 
tumor O 
necrosis O 
factor O 
( O 
TNF O 
) O 
production O 
in O 
human O 
U937 O 
monocytes O 
. O 
The O 
effect O 
of O 
the O 
plant O 
extracts O 
on O 
the O 
transcription O 
factor O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
pathway O 
was O 
evaluated O 
in O 
TNF-α O 
stimulated O 
HepG2 O 
cells O 
by O 
luciferase O 
gene O 
reporter O 
assay O 
and O 
Western O 
blotting O 
at O 
the O 
transcriptional O 
and O 
translational O 
levels O 
. O 
Subsequently O 
, O 
the O 
inhibition O 
of O 
NF-κB O 
downstream O 
gene O 
expression O 
( O 
IL-8 O 
and O 
ICAM-1 O 
) O 
by O 
the O 
plant O 
extracts O 
was O 
assessed O 
via O 
quantitative O 
real O 
time O 
polymerase O 
chain O 
reaction O 
( O 
qPCR O 
) O 
. O 
Lastly O 
, O 
the O 
anti-inflammatory O 
activities O 
of O 
the O 
plant O 
extracts O 
in O 
vivo O 
were O 
evaluated O 
by O 
testing O 
spleen O 
index O 
and O 
NF-κB O 
related O 
protein O 
expression O 
in O 
LPS-stimulated O 
CD1 O 
mice O 
. O 
RESULTS O 
: O 
The O 
plant O 
ethanolic O 
extracts O 
effectively O 
suppressed O 
PGE2 B-ABBREVIATION 
, O 
IL-6 O 
and O 
TNF O 
release O 
with O 
an O 
IC50 O 
less O 
than O 
50μg O 
/ O 
ml O 
. O 
Moreover O 
, O 
luciferase O 
expression O 
could O 
be O 
specifically O 
blocked O 
in O 
HepG2 O 
cells O 
, O 
not O 
in O 
HEK293 O 
cells O 
, O 
showing O 
that O 
the O 
plant O 
extracts O 
displayed O 
a O 
cell O 
- O 
specific O 
pattern O 
on O 
NF-κB O 
gene O 
transcription O 
. O 
The O 
assayed O 
biological O 
activity O 
also O 
depended O 
on O 
the O 
order O 
of O 
adding O 
TNF-α O 
and O 
the O 
plant O 
extracts O 
because O 
the O 
plant O 
extracts O 
could O 
only O 
block O 
the O 
NF-κB O 
activation O 
if O 
added O 
earlier O 
but O 
were O 
unable O 
to O 
stop O 
the O 
signal O 
when O 
added O 
after O 
TNF-α O 
. O 
However O 
, O 
the O 
plant O 
extracts O 
did O 
not O 
exert O 
any O 
effect O 
on O 
ubiquitination O 
which O 
regulates O 
several O 
steps O 
in O 
the O 
NF-κB O 
pathway O 
. O 
Additionally O 
, O 
the O 
plant O 
extracts O 
down O 
- O 
regulated O 
phosphorylation O 
of O 
IKKα O 
/ O 
β O 
at O 
S176 O 
/ O 
180 O 
, O 
p38 O 
at O 
T180 O 
/ O 
Y182 O 
and O 
p65 O 
at O 
S536 O 
, O 
but O 
not O 
p65 O 
at O 
S276 O 
. O 
This O 
was O 
confirmed O 
by O 
their O 
ability O 
to O 
selectively O 
abrogate O 
the O 
induction O 
of O 
IL-8 O 
transcription O 
, O 
whereas O 
the O 
ICAM-1 O 
gene O 
, O 
which O 
is O 
not O 
transcribed O 
selectively O 
by O 
an O 
NF-κB O 
complex O 
containing O 
a O 
form O 
of O 
p65 O 
phosphorylated O 
on O 
Ser B-FORMULA 
536 O 
, O 
did O 
not O 
change O 
. O 
Finally O 
, O 
the O 
plant O 
extracts O 
at O 
200μg O 
/ O 
mg O 
could O 
normalize O 
the O 
LPS-induced O 
elevation O 
of O 
spleen O 
index O 
as O 
well O 
as O 
NF-κB O 
and O 
p38 O 
activations O 
in O 
CD1 O 
mice O 
. O 
CONCLUSION O 
: O 
The O 
present O 
studies O 
presents O 
the O 
potential O 
utilization O 
of O 
this O 
plant O 
extracts O 
, O 
as O 
a O 
natural O 
resources O 
for O 
the O 
development O 
of O 
an O 
anti-inflammatory O 
medicine O 
. O 

monoxide I-SYSTEMATIC 
protects O 
against O 
ovariectomy O 
- O 
induced O 
bone O 
loss O 
by O 
inhibiting O 
osteoclastogenesis O 
. O 

monoxide I-SYSTEMATIC 
( O 
CO B-FORMULA 
) O 
has O 
been O 
shown O 
to O 
have O 
remarkable O 
therapeutic O 
value O 
at O 
low O 
dosage O 
by O 
suppressing O 
inflammation O 
via O 
inhibitory O 
effects O 
on O 
macrophages O 
, O 
which O 
are O 
also O 
precursors O 
of O 
osteoclasts O 
( O 
OC O 
) O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
whether O 
CO B-FORMULA 
limits O 
bone O 
loss O 
through O 
its O 
effects O 
on O 
osteoclastogenesis O 
. O 
Intraperitoneal O 
injection O 
of O 
CO B-FORMULA 
-releasing O 
molecule O 
2 O 
( O 
CORM2 O 
) O 
into O 
mice O 
with O 
reduced O 
bone O 
mass O 
due O 
to O 
ovariectomy O 
( O 
OVX O 
) O 
resulted O 
in O 
significantly O 
elevated O 
bone O 
mass O 
. O 
Increased O 
serum O 
levels O 
of O 
collagen O 
- O 
type O 
I O 
fragments O 
, O 
tartrate B-TRIVIAL 
-resistant O 
acid O 
phosphatase O 
5b O 
, O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
due O 
to O 
OVX O 
were O 
also O 
decreased O 
when O 
treated O 
with O 
CORM2 O 
. O 
In O 
vitro O 
, O 
CORM2 O 
inhibited O 
receptor O 
activator O 
of O 
nuclear O 
factor-κB O 
ligand O 
(RANKL)-induced O 
OC O 
formation O 
without O 
affecting O 
bone O 
resorption O 
. O 
CORM2 O 
reduced O 
long O 
- O 
lasting O 
ROS O 
levels O 
and O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
activation O 
in O 
response O 
to O 
RANKL O 
. O 
Inhibition O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
partially O 
reduced O 
the O 
inhibitory O 
effect O 
of O 
CO B-FORMULA 
. O 
CO B-FORMULA 
induced O 
increase O 
of O 
peroxiredoxin O 
1 O 
( O 
PRX1 O 
) O 
in O 
BMM O 
. O 
Down O 
- O 
regulation O 
of O 
PRX1 O 
reduced O 
the O 
inhibitory O 
effect O 
of O 
CO B-FORMULA 
on O 
OC O 
formation O 
and O 
sustained O 
the O 
ROS O 
levels O 
induced O 
by O 
RANKL O 
, O 
suggesting O 
that O 
CO B-FORMULA 
reduces O 
generation O 
of O 
ROS O 
and O 
scavenges O 
ROS O 
to O 
inhibit O 
osteoclastogenesis O 
. O 
These O 
data O 
suggest O 
that O 
the O 
inhibitory O 
effect O 
of O 
CO B-FORMULA 
on O 
osteoclastogenesis O 
is O 
caused O 
by O 
impaired O 
RANKL O 
signaling O 
through O 
defective O 
NF-κB O 
activation O 
and O 
reduced O 
levels O 
of O 
long O 
- O 
lasting O 
ROS O 
. O 
These O 
changes O 
result O 
in O 
decreased O 
bone O 
loss O 
. O 
Our O 
data O 
highlight O 
the O 
potential O 
utility O 
of O 
CO B-FORMULA 
for O 
ameliorating O 
bone O 
loss O 
induced O 
by O 
loss O 
of O 
ovarian O 
function O 
. O 

effects O 
of O 
diosmetin B-TRIVIAL 
with O 
erythromycin B-TRIVIAL 
against O 
ABC O 
transporter O 
over O 
- O 
expressed O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
RN4220 O 
/ O 
pUL5054 O 
and O 
inhibition O 
of O 
MRSA O 
pyruvate B-TRIVIAL 
kinase O 
. O 

prevalence O 
of O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
worldwide O 
with O 
limited O 
therapeutic O 
options O 
is O 
a O 
growing O 
public O 
health O 
concern O 
. O 
Natural O 
products O 
have O 
been O 
shown O 
to O 
possess O 
antibacterial O 
actions O 
against O 
MRSA O 
. O 
Flavonoids B-FAMILY 
from O 
natural O 
products O 
have O 
been O 
shown O 
to O 
possess O 
antibacterial O 
actions O 
against O 
MRSA O 
by O 
antagonizing O 
its O 
resistance O 
mechanisms O 
. O 
Diosmin B-TRIVIAL 
and O 
diosmetin B-TRIVIAL 
are O 
natural O 
flavonoids B-FAMILY 
found O 
in O 
a O 
variety O 
of O 
citrus O 
fruits O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
diosmin B-TRIVIAL 
and O 
diosmetin B-TRIVIAL 
could O 
inhibit O 
the O 
growth O 
of O 
MRSA O 
and O 
the O 
in O 
vitro O 
enzymatic O 
activity O 
of O 
a O 
newly O 
discovered O 
MRSA O 
drug O 
target O 
, O 
pyruvate B-TRIVIAL 
kinase O 
( O 
PK O 
) O 
. O 
By O 
using O 
a O 
panel O 
of O 
MRSA O 
strains O 
with O 
known O 
resistant O 
mechanisms O 
, O 
neither O 
diosmin B-TRIVIAL 
nor O 
diosmetin B-TRIVIAL 
was O 
shown O 
to O 
possess O 
direct O 
antibacterial O 
activities O 
against O 
all O 
tested O 
MRSA O 
strains O 
. O 
However O 
, O 
in O 
checkerboard O 
assay O 
, O 
we O 
found O 
that O 
diosmetin B-TRIVIAL 
together O 
with O 
erythromycin B-TRIVIAL 
, O 
could O 
synergistically O 
inhibit O 
the O 
growth O 
of O 
ABC-pump O 
overexpressed O 
MRSA-RN4220 O 
/ O 
pUL5054 O 
, O 
and O 
time O 
kill O 
assay O 
also O 
showed O 
that O 
the O 
antibacterial O 
activities O 
of O 
diosmetin B-TRIVIAL 
with O 
erythromycin B-TRIVIAL 
were O 
bactericidal O 
. O 
Diosmetin B-TRIVIAL 
was O 
further O 
shown O 
to O 
significantly O 
suppress O 
the O 
MRSA O 
PK O 
activities O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
In O 
conclusion O 
, O 
the O 
inhibition O 
of O 
MRSA O 
PK O 
by O 
diosmetin B-TRIVIAL 
could O 
lead O 
to O 
a O 
deficiency O 
of O 
ATP B-ABBREVIATION 
and O 
affect O 
the O 
bacterial O 
efflux O 
pump O 
which O 
might O 
contribute O 
to O 
the O 
antibacterial O 
actions O 
of O 
diosmetin B-TRIVIAL 
against O 
MRSA O 
. O 

effect O 
of O 
7-methoxyflavone B-SYSTEMATIC 
isolated O 
from O 
Zornia O 
brasiliensis O 
. O 

this O 
study O 
, O 
we O 
investigated O 
the O 
antinociceptive O 
effect O 
of O 
7-methoxyflavone B-SYSTEMATIC 
( O 
7MF B-SYSTEMATIC 
) O 
in O 
mice O 
using O 
the O 
following O 
tests O 
: O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
writhing O 
, O 
glutamate B-TRIVIAL 
- O 
and O 
formalin B-TRIVIAL 
-induced O 
nociception O 
and O 
hotplate O 
. O 
7MF B-SYSTEMATIC 
( O 
30 O 
, O 
50 O 
, O 
100 O 
and O 
300 O 
μmol O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
reduced O 
the O 
number O 
of O 
writhes O 
, O 
with O 
ID(50) O 
= O 
82.5 O 
± O 
11.7 O 
μmol O 
/ O 
kg O 
and O 
E O 
(max) O 
= O 
58.4% O 
. O 
7MF B-SYSTEMATIC 
treatment O 
( O 
100 O 
μmol O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
inhibited O 
paw O 
- O 
licking O 
time O 
in O 
the O 
neurogenic O 
phase O 
of O 
the O 
formalin B-TRIVIAL 
pain O 
response O 
( O 
65.6% O 
) O 
and O 
did O 
not O 
decrease O 
the O 
nociceptive O 
response O 
in O 
the O 
inflammatory O 
phase O 
. O 
In O 
addition O 
, O 
in O 
glutamate B-TRIVIAL 
-induced O 
nociception O 
, O 
7MF B-SYSTEMATIC 
inhibited O 
26% O 
of O 
the O 
nociceptive O 
answer O 
. O 
On O 
the O 
other O 
hand O 
, O 
7MF B-SYSTEMATIC 
did O 
not O 
increase O 
the O 
latency O 
time O 
of O 
the O 
animals O 
in O 
the O 
hotplate O 
test O 
. O 
These O 
results O 
suggest O 
that O 
7MF B-SYSTEMATIC 
has O 
peripheral O 
antinociceptive O 
activity O 
. O 

demonstrated O 
previously O 
that O 
monocytes O 
and O 
macrophages O 
are O 
target O 
cells O 
for O 
the O 
Rho-modifying O 
Clostridium O 
botulinum O 
C3 O 
ADP B-ABBREVIATION 
-ribosyltransferase O 
. O 
Here O 
, O 
we O 
report O 
the O 
construction O 
, O 
expression O 
and O 
characterization O 
of O 
a O 
recombinant O 
streptavidin-C3 O 
fusion O 
protein O 
which O 
allows O 
for O 
delivery O 
of O 
biotin B-TRIVIAL 
-labelled O 
molecules O 
into O 
the O 
cytosol O 
of O 
macrophages O 
via O 
enzymatically O 
inactive O 
C3bot1E174Q O 
. O 
The O 
enzyme O 
domain O 
of O 
diphtheria O 
toxin O 
was O 
used O 
as O 
cargo O 
to O 
demonstrate O 
proof O 
of O 
principle O 
. O 
This O 
transport O 
system O 
could O 
represent O 
an O 
attractive O 
tool O 
for O 
experimental O 
monocyte O 
/ O 
macrophage O 
pharmacology O 
. O 

derivatized O 
analogues O 
of O 
3-(acetylhydroxyamino)propyl B-SYSTEMATIC 
phosphonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
FR900098 B-IDENTIFIER 
) O 
as O 
antimalarials O 
. O 

explore O 
the O 
hitherto O 
successful O 
derivatization O 
of O 
the O 
α-carbon B-SYSTEMATIC 
of O 
fosmidomycin B-TRIVIAL 
, O 
a O 
series O 
of O 
new O 
α- O 
substituted O 
analogues O 
was O 
prepared O 
. O 
This O 
was O 
done O 
by O 
introduction O 
of O 
a O 
heteroatom O 
( O 
N B-FORMULA 
or O 
O B-FORMULA 
) O 
in O 
α- O 
position O 
to O 
the O 
phosphonate B-SYSTEMATIC 
and O 
using O 
the O 
resultant O 
OH B-FORMULA 
and O 
NH₂ B-FORMULA 
groups O 
as O 
a O 
handle O 
for O 
appending O 
a O 
variety O 
of O 
substituents O 
by O 
means O 
of O 
several O 
functional O 
groups O 
such O 
as O 
ether B-SYSTEMATIC 
, O 
amide B-FAMILY 
, O 
urea B-TRIVIAL 
, O 
and O 
1,4-triazole B-SYSTEMATIC 
. O 
The O 
synthesized O 
molecules O 
, O 
as O 
a O 
racemic O 
mixture O 
, O 
were O 
assayed O 
for O 
their O 
EcDXR O 
inhibitory O 
potency O 
. O 
Both O 
the O 
α-azido B-SYSTEMATIC 
-analogue O 
and O 
the O 
α-hydroxylated O 
analogue O 
proved O 
most O 
promising O 
, O 
and O 
docking O 
experiments O 
were O 
performed O 
. O 
Although O 
several O 
compounds O 
showed O 
high O 
potency O 
when O 
assayed O 
against O 
Plasmodium O 
falciparum O 
K1 O 
in O 
human O 
erythrocytes O 
, O 
a O 
clear O 
correlation O 
between O 
the O 
enzyme O 
inhibition O 
constants O 
and O 
P O 
. O 
falciparum O 
inhibition O 
concentrations O 
could O 
not O 
be O 
found O 
. O 

Scaffold O 
Repurposing O 
for O 
Neglected O 
Disease O 
Drug O 
Discovery O 
: O 
Discovery O 
of O 
an O 
Efficacious O 
, O 
Lapatanib B-TRIVIAL 
-Derived O 
Lead O 
Compound O 
for O 
Trypanosomiasis O 
. O 

African O 
trypanosomiasis O 
( O 
HAT O 
) O 
is O 
a O 
neglected O 
tropical O 
disease O 
caused O 
by O 
the O 
protozoan O 
parasite O 
Trypanosoma O 
brucei O 
. O 
Because O 
drugs O 
in O 
use O 
against O 
HAT O 
are O 
toxic O 
and O 
require O 
intravenous O 
dosing O 
, O 
new O 
drugs O 
are O 
needed O 
. O 
Initiating O 
lead O 
discovery O 
campaigns O 
by O 
using O 
chemical O 
scaffolds O 
from O 
drugs O 
approved O 
for O 
other O 
indications O 
can O 
speed O 
up O 
drug O 
discovery O 
for O 
neglected O 
diseases O 
. O 
We O 
demonstrated O 
recently O 
that O 
the O 
4-anilinoquinazolines B-FAMILY 
lapatinib B-TRIVIAL 
( O 
GW572016 B-IDENTIFIER 
, O 
1 O 
) O 
and O 
canertinib B-TRIVIAL 
( O 
CI-1033 B-IDENTIFIER 
) O 
kill O 
T O 
. O 
brucei O 
with O 
low O 
micromolar O 
EC50 O 
values O 
. O 
We O 
now O 
report O 
promising O 
activity O 
of O 
analogues O 
of O 
1 O 
, O 
which O 
provided O 
an O 
excellent O 
starting O 
point O 
for O 
optimization O 
of O 
the O 
chemotype O 
. O 
Our O 
compound O 
optimization O 
that O 
has O 
led O 
to O 
synthesis O 
of O 
several O 
potent O 
4-anilinoquinazolines B-FAMILY 
, O 
including O 
NEU617 B-IDENTIFIER 
, O 
23a O 
, O 
a O 
highly O 
potent O 
, O 
orally O 
bioavailable O 
inhibitor O 
of O 
trypanosome O 
replication O 
. O 
At O 
the O 
cellular O 
level O 
, O 
23a O 
blocks O 
duplication O 
of O 
the O 
kinetoplast O 
and O 
arrests O 
cytokinesis O 
, O 
making O 
it O 
a O 
new O 
chemical O 
tool O 
for O 
studying O 
regulation O 
of O 
the O 
trypanosome O 
cell O 
cycle O 
. O 

sesquiterpene B-FAMILY 
derivatives O 
from O 
the O 
leaves O 
of O 
Tripterygium O 
wilfordii O 
. O 

new O 
dihydroagarofuran B-FAMILY 
sesquiterpene I-FAMILY 
polyol I-FAMILY 
esters I-FAMILY 
, O 
triptersinines B-MULTIPLE 
A-L I-MULTIPLE 
( O 
1-12 O 
) O 
, O 
and O 
eight O 
known O 
sesquiterpene B-FAMILY 
pyridine B-FAMILY 
alkaloids I-FAMILY 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Tripterygium O 
wilfordii O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
analyses O 
, O 
including O 
UV O 
, O 
IR O 
, O 
and O 
NMR O 
experiments O 
( O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
COSY O 
, O 
NOESY O 
, O 
HSQC O 
, O 
and O 
HMBC O 
) O 
. O 
Furthermore O 
, O 
in O 
an O 
in O 
vitro O 
bioassay O 
, O 
compounds O 
1 O 
, O 
9 O 
, O 
11 O 
, O 
13 O 
, O 
14 O 
, O 
and O 
18 O 
showed O 
moderate O 
inhibitory O 
effects O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
in O 
LPS-induced O 
macrophages O 
at O 
5 O 
μM O 
; O 
all O 
compounds O 
were O 
inactive O 
when O 
tested O 
against O 
five O 
human O 
cancer O 
cell O 
lines O 
( O 
IC(50) O 
values O 
> O 
1 O 
μM O 
) O 
. O 

and O 
synthesis O 
of O 
a O 
tetrahydroisoquinoline B-SYSTEMATIC 
-based O 
hydroxamate B-SYSTEMATIC 
derivative O 
( O 
ZYJ-34v B-IDENTIFIER 
) O 
, O 
an O 
oral O 
active O 
histone O 
deacetylase O 
inhibitor O 
with O 
potent O 
antitumor O 
activity O 
. O 

our O 
previous O 
study O 
we O 
developed O 
a O 
novel O 
series O 
of O 
tetrahydroisoquinoline B-SYSTEMATIC 
-based O 
hydroxamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
as O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitors O 
( O 
Bioorg O 
. O 
Med O 
. O 
Chem O 
. O 
, O 
2010 O 
, O 
18 O 
, O 
1761-1772 O 
. O 
, O 
J O 
. O 
Med O 
. O 
Chem O 
. O 
, O 
2011 O 
, O 
54 O 
, O 
2823-2838 O 
. O 
) O 
, O 
among O 
which O 
compound O 
ZYJ-34 B-IDENTIFIER 
c O 
( O 
1 O 
) O 
was O 
identified O 
and O 
validated O 
as O 
the O 
most O 
potent O 
one O 
with O 
marked O 
in O 
vitro O 
and O 
in O 
vivo O 
antitumor O 
potency O 
( O 
J O 
. O 
Med O 
. O 
Chem O 
. O 
, O 
2011 O 
, O 
54 O 
, O 
5532-5539 O 
. O 
) O 
. O 
Herein O 
further O 
modification O 
of O 
1 O 
afforded O 
another O 
oral O 
active O 
analogue O 
ZYJ-34 B-IDENTIFIER 
v O 
( O 
2 O 
) O 
with O 
simplified O 
structure O 
and O 
lower O 
molecular O 
weight O 
. O 
Biological O 
evaluation O 
of O 
compound O 
2 O 
showed O 
efficacious O 
inhibition O 
against O 
HDAC1 O 
, O 
2 O 
, O 
3 O 
and O 
6 O 
, O 
which O 
was O 
confirmed O 
by O 
western O 
blot O 
analysis O 
results O 
. O 
Most O 
importantly O 
, O 
compound O 
2 O 
exhibited O 
similar O 
even O 
more O 
potent O 
in O 
vitro O 
and O 
in O 
vivo O 
antitumor O 
activities O 
relative O 
to O 
the O 
approved O 
HDAC O 
inhibitor O 
SAH B-ABBREVIATION 
A O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

signaling O 
cascades O 
elicited O 
by O 
different O 
formyl B-SYSTEMATIC 
Peptide O 
receptor O 
2 O 
( O 
FPR2 O 
) O 
agonists O 
. O 

formyl B-SYSTEMATIC 
peptide O 
receptor O 
2 O 
( O 
FPR2 O 
) O 
is O 
a O 
remarkably O 
versatile O 
transmembrane O 
protein O 
belonging O 
to O 
the O 
G O 
- O 
protein O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
family O 
. O 
FPR2 O 
is O 
activated O 
by O 
an O 
array O 
of O 
ligands O 
, O 
which O 
include O 
structurally O 
unrelated O 
lipids O 
and O 
peptide O 
/ O 
proteins O 
agonists O 
, O 
resulting O 
in O 
different O 
intracellular O 
responses O 
in O 
a O 
ligand O 
- O 
specific O 
fashion O 
. O 
In O 
addition O 
to O 
the O 
anti-inflammatory O 
lipid O 
, O 
lipoxin B-TRIVIAL 
A4 I-TRIVIAL 
, O 
several O 
other O 
endogenous O 
agonists O 
also O 
bind O 
FPR2 O 
, O 
including O 
serum O 
amyloid O 
A O 
, O 
glucocorticoid O 
- O 
induced O 
annexin O 
1 O 
, O 
urokinase O 
and O 
its O 
receptor O 
, O 
suggesting O 
that O 
the O 
activation O 
of O 
FPR2 O 
may O 
result O 
in O 
potent O 
pro- O 
or O 
anti-inflammatory O 
responses O 
. O 
Other O 
endogenous O 
ligands O 
, O 
also O 
present O 
in O 
biological O 
samples O 
, O 
include O 
resolvins B-FAMILY 
, O 
amyloidogenic O 
proteins O 
, O 
such O 
as O 
beta O 
amyloid O 
(Aβ)-42 O 
and O 
prion O 
protein O 
(Prp)106-126 O 
, O 
the O 
neuroprotective O 
peptide O 
, O 
humanin O 
, O 
antibacterial O 
peptides O 
, O 
annexin O 
1- O 
derived O 
peptides O 
, O 
chemokine O 
variants O 
, O 
the O 
neuropeptides O 
, O 
vasoactive O 
intestinal O 
peptide O 
( O 
VIP O 
) O 
and O 
pituitary O 
adenylate B-TRIVIAL 
cyclase O 
activating O 
polypeptide O 
(PACAP)-27 O 
, O 
and O 
mitochondrial O 
peptides O 
. O 
Upon O 
activation O 
, O 
intracellular O 
domains O 
of O 
FPR2 O 
mediate O 
signaling O 
to O 
G O 
- O 
proteins O 
, O 
which O 
trigger O 
several O 
agonist O 
- O 
dependent O 
signal O 
transduction O 
pathways O 
, O 
including O 
activation O 
of O 
phospholipase O 
C O 
( O 
PLC O 
) O 
, O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
isoforms O 
, O 
the O 
phosphoinositide B-FAMILY 
3-kinase O 
( O 
PI3K O 
) O 
/ O 
protein O 
kinase O 
B O 
( O 
Akt O 
) O 
pathway O 
, O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
pathway O 
, O 
p38MAPK O 
, O 
as O 
well O 
as O 
the O 
phosphorylation O 
of O 
cytosolic O 
tyrosine B-TRIVIAL 
kinases O 
, O 
tyrosine B-TRIVIAL 
kinase O 
receptor O 
transactivation O 
, O 
phosphorylation O 
and O 
nuclear O 
translocation O 
of O 
regulatory O 
transcriptional O 
factors O 
, O 
release O 
of O 
calcium B-SYSTEMATIC 
and O 
production O 
of O 
oxidants O 
. O 
FPR2 O 
is O 
an O 
attractive O 
therapeutic O 
target O 
, O 
because O 
of O 
its O 
involvement O 
in O 
a O 
range O 
of O 
normal O 
physiological O 
processes O 
and O 
pathological O 
diseases O 
. O 
Here O 
, O 
we O 
review O 
and O 
discuss O 
the O 
most O 
significant O 
findings O 
on O 
the O 
intracellular O 
pathways O 
and O 
on O 
the O 
cross O 
- O 
communication O 
between O 
FPR2 O 
and O 
tyrosine B-TRIVIAL 
kinase O 
receptors O 
triggered O 
by O 
different O 
FPR2 O 
agonists O 
. O 

and O 
Rearrangement O 
of O 
a O 
Lung O 
Surfactant O 
Lipid O 
at O 
the O 
Air-Water O 
Interface O 
during O 
Exposure O 
to O 
the O 
Pollutant O 
Gas O 
Ozone B-TRIVIAL 
. O 

presence O 
of O 
unsaturated O 
lipids O 
in O 
lung O 
surfactant O 
is O 
important O 
for O 
proper O 
respiratory O 
function O 
. O 
In O 
this O 
work O 
, O 
we O 
have O 
used O 
neutron O 
reflection O 
and O 
surface O 
pressure O 
measurements O 
to O 
study O 
the O 
reaction O 
of O 
the O 
ubiquitous O 
pollutant O 
gas-phase O 
ozone B-TRIVIAL 
, O 
O3 B-FORMULA 
, O 
with O 
pure O 
and O 
mixed O 
phospholipid O 
monolayers O 
at O 
the O 
air O 
- O 
water O 
interface O 
. O 
The O 
results O 
reveal O 
that O 
the O 
reaction O 
of O 
the O 
unsaturated O 
lipid O 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
, O 
POPC B-ABBREVIATION 
, O 
with O 
ozone B-TRIVIAL 
leads O 
to O 
the O 
rapid O 
loss O 
of O 
the O 
terminal O 
C9 O 
portion O 
of O 
the O 
oleoyl B-TRIVIAL 
strand O 
of O 
POPC B-ABBREVIATION 
from O 
the O 
air O 
- O 
water O 
interface O 
. O 
The O 
loss O 
of O 
the O 
C9 O 
portion O 
from O 
the O 
interface O 
is O 
accompanied O 
by O 
an O 
increase O 
in O 
the O 
surface O 
pressure O 
( O 
decrease O 
in O 
surface O 
tension O 
) O 
of O 
the O 
film O 
at O 
the O 
air O 
- O 
water O 
interface O 
. O 
The O 
results O 
suggest O 
that O 
the O 
portion O 
of O 
the O 
oxidized O 
oleoyl B-TRIVIAL 
strand O 
that O 
is O 
still O 
attached O 
to O 
the O 
lipid O 
headgroup O 
rapidly O 
reverses O 
its O 
orientation O 
and O 
penetrates O 
the O 
air O 
- O 
water O 
interface O 
alongside O 
the O 
original O 
headgroup O 
, O 
thus O 
increasing O 
the O 
surface O 
pressure O 
. O 
The O 
reaction O 
of O 
POPC B-ABBREVIATION 
with O 
ozone B-TRIVIAL 
also O 
leads O 
to O 
a O 
loss O 
of O 
material O 
from O 
the O 
palmitoyl B-TRIVIAL 
strand O 
, O 
but O 
the O 
loss O 
of O 
palmitoyl B-TRIVIAL 
material O 
occurs O 
after O 
the O 
loss O 
of O 
the O 
terminal O 
C9 O 
portion O 
from O 
the O 
oleoyl B-TRIVIAL 
strand O 
of O 
the O 
molecule O 
, O 
suggesting O 
that O 
the O 
palmitoyl B-TRIVIAL 
material O 
is O 
lost O 
in O 
a O 
secondary O 
reaction O 
step O 
. O 
Further O 
experiments O 
studying O 
the O 
reaction O 
of O 
mixed O 
monolayers O 
composed O 
of O 
unsaturated O 
lipid O 
POPC B-ABBREVIATION 
and O 
saturated O 
lipid O 
dipalmitoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
, O 
DPPC B-ABBREVIATION 
, O 
revealed O 
that O 
no O 
loss O 
of O 
DPPC B-ABBREVIATION 
from O 
the O 
air O 
- O 
water O 
interface O 
occurs O 
, O 
eliminating O 
the O 
possibility O 
that O 
a O 
reactive O 
species O 
such O 
as O 
an O 
OH B-FORMULA 
radical O 
is O 
formed O 
and O 
is O 
able O 
to O 
attack O 
nearby O 
lipid O 
chains O 
. O 
The O 
reaction O 
of O 
ozone B-TRIVIAL 
with O 
the O 
mixed O 
films O 
does O 
cause O 
a O 
significant O 
change O 
in O 
the O 
surface O 
pressure O 
of O 
the O 
air O 
- O 
water O 
interface O 
. O 
Thus O 
, O 
the O 
reaction O 
of O 
unsaturated O 
lipids O 
in O 
lung O 
surfactant O 
changes O 
and O 
impairs O 
the O 
physical O 
properties O 
of O 
the O 
film O 
at O 
the O 
air O 
- O 
water O 
interface O 
. O 

approaches O 
directed O 
toward O 
Alzheimer O 
disease O 
are O 
diversifying O 
in O 
parallel O 
with O 
a O 
growing O 
number O 
of O 
promising O 
targets O 
. O 
Investigations O 
on O 
the O 
microtubule O 
- O 
associated O 
protein O 
tau O 
yielded O 
innovative O 
targets O 
backed O 
by O 
recent O 
findings O 
about O 
the O 
central O 
role O 
of O 
tau O 
in O 
numerous O 
neurodegenerative O 
diseases O 
. O 
In O 
this O 
review O 
, O 
we O 
summarize O 
the O 
recent O 
evolution O 
in O 
the O 
development O 
of O 
nonpeptidic O 
small O 
molecules O 
tau O 
aggregation O 
inhibitors O 
( O 
TAGIs O 
) O 
and O 
their O 
advancement O 
toward O 
clinical O 
trials O 
. O 
The O 
compounds O 
are O 
classified O 
according O 
to O 
their O 
chemical O 
structures O 
, O 
providing O 
correlative O 
insights O 
into O 
their O 
pharmacology O 
. O 
Overall O 
, O 
shared O 
structure O 
- O 
activity O 
traits O 
are O 
emerging O 
, O 
as O 
well O 
as O 
specific O 
binding O 
modes O 
related O 
to O 
their O 
ability O 
to O 
engage O 
in O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 
Medicinal O 
chemistry O 
efforts O 
on O 
TAGIs O 
together O 
with O 
encouraging O 
in O 
vivo O 
data O 
argue O 
for O 
successful O 
translation O 
to O 
the O 
clinic O 
. O 

nanoparticles O 
( O 
UCNPs O 
) O 
have O 
recently O 
shown O 
great O 
potential O 
as O 
contrast O 
agents O 
in O 
biological O 
applications O 
. O 
In O 
developing O 
different O 
UCNPs O 
, O 
the O 
characterization O 
of O 
their O 
quantum O 
yield O 
( O 
QY O 
) O 
is O 
a O 
crucial O 
issue O 
, O 
as O 
the O 
typically O 
drastic O 
decrease O 
in O 
QY O 
for O 
low O 
excitation O 
power O 
densities O 
can O 
either O 
impose O 
a O 
severe O 
limitation O 
or O 
provide O 
an O 
opportunity O 
in O 
many O 
applications O 
. O 
The O 
power O 
density O 
dependence O 
of O 
the O 
QY O 
is O 
governed O 
by O 
the O 
competition O 
between O 
the O 
energy O 
transfer O 
upconversion O 
( O 
ETU O 
) O 
rate O 
and O 
the O 
linear O 
decay O 
rate O 
in O 
the O 
depopulation O 
of O 
the O 
intermediate O 
state O 
of O 
the O 
involved O 
activator O 
in O 
the O 
upconversion O 
process O 
. O 
Here O 
we O 
show O 
that O 
the O 
QYs O 
of O 
Yb(3+) B-FORMULA 
sensitized O 
two O 
- O 
photon O 
upconversion O 
emissions O 
can O 
be O 
well O 
characterized O 
by O 
the O 
balancing O 
power O 
density O 
, O 
at O 
which O 
the O 
ETU O 
rate O 
and O 
the O 
linear O 
decay O 
rate O 
have O 
equal O 
contributions O 
, O 
and O 
its O 
corresponding O 
QY O 
. O 
The O 
results O 
in O 
this O 
paper O 
provide O 
a O 
method O 
to O 
fully O 
describe O 
the O 
QY O 
of O 
upconverting O 
nanoparticles O 
for O 
arbitrary O 
excitation O 
power O 
densities O 
, O 
and O 
is O 
a O 
fast O 
and O 
simple O 
approach O 
for O 
assessing O 
the O 
applicability O 
of O 
UCNPs O 
from O 
the O 
perspective O 
of O 
energy O 
conversion O 
. O 

rhythm O 
of O 
salivary O 
cortisol B-TRIVIAL 
in O 
infants O 
with O 
congenital O 
heart O 
disease O 
. O 

with O 
congenital O 
heart O 
disease O 
( O 
CHD O 
) O 
have O 
associated O 
extracardiac O 
co O 
- O 
morbidities O 
at O 
the O 
time O 
of O 
surgery O 
and O 
during O 
ongoing O 
growth O 
and O 
development O 
. O 
Perioperative O 
events O 
include O 
disrupted O 
glucose B-TRIVIAL 
homeostasis O 
, O 
capillary O 
leak O 
, O 
and O 
fluid O 
retention O 
. O 
The O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
( O 
HPA O 
) O 
axis O 
has O 
an O 
important O 
role O 
in O 
homeostasis O 
in O 
that O 
the O 
secretion O 
of O 
cortisol B-TRIVIAL 
contributes O 
to O 
the O 
response O 
to O 
stress O 
, O 
glucose B-TRIVIAL 
regulation O 
, O 
blood O 
volume O 
control O 
, O 
and O 
immune O 
regulation O 
. O 
We O 
investigated O 
the O 
diurnal O 
rhythm O 
of O 
the O 
HPA O 
axis O 
in O 
infants O 
with O 
CHD O 
by O 
measuring O 
salivary O 
cortisol B-TRIVIAL 
in O 
the O 
morning O 
( O 
0600-0900 O 
h-circadian O 
peak O 
) O 
and O 
evening O 
( O 
2100-2400 O 
h-circadian O 
nadir O 
) O 
. O 
Twenty O 
- O 
nine O 
infants O 
aged O 
12 O 
weeks O 
to O 
1 O 
year O 
were O 
included O 
: O 
16 O 
with O 
acyanotic O 
disease O 
( O 
SpO(2) O 
≥ O 
90 O 
% O 
) O 
and O 
13 O 
with O 
cyanotic O 
disease O 
( O 
SpO2 O 
< O 
90 O 
% O 
) O 
. O 
Morning O 
salivary O 
cortisol B-TRIVIAL 
was O 
similar O 
between O 
the O 
two O 
groups O 
[ O 
acyanotic O 
7 O 
nmol O 
/ O 
L O 
( O 
1.8-23.1 O 
) O 
; O 
cyanotic O 
9.7 O 
nmol O 
/ O 
L O 
( O 
0.9-15.6 O 
) O 
; O 
p O 
= O 
0.68 O 
] O 
. O 
Evening O 
salivary O 
cortisol B-TRIVIAL 
was O 
similar O 
between O 
the O 
two O 
groups O 
[ O 
acyanotic O 
0.9 O 
nmol O 
/ O 
L O 
( O 
0.2-8.5 O 
) O 
; O 
cyanotic O 
1.4 O 
nmol O 
/ O 
L O 
( O 
0.5-14.9 O 
) O 
; O 
p O 
= O 
0.32 O 
] O 
. O 
Both O 
cyanotic O 
and O 
acyanotic O 
groups O 
demonstrated O 
an O 
intact O 
diurnal O 
rhythm O 
. O 
In O 
conclusion O 
, O 
chronic O 
hypoxia O 
secondary O 
to O 
cyanotic O 
CHD O 
does O 
not O 
affect O 
the O 
circadian O 
rhythm O 
of O 
the O 
HPA O 
axis O 
. O 
By O 
12 O 
weeks O 
of O 
age O 
, O 
infants O 
with O 
hypoxia O 
secondary O 
to O 
cyanotic O 
CHD O 
have O 
a O 
normal O 
cortisol B-TRIVIAL 
diurnal O 
rhythm O 
. O 

of O 
functionally O 
relevant O 
lysine B-TRIVIAL 
residues O 
that O 
modulate O 
human O 
farnesoid O 
x O 
receptor O 
activation O 
. O 

amino B-FAMILY 
acid I-FAMILY 
lysine B-TRIVIAL 
residues O 
play O 
an O 
important O 
role O 
in O 
regulation O 
of O 
nuclear O 
receptors O 
[ O 
e.g O 
. O 
, O 
farnesyl B-TRIVIAL 
X O 
receptor O 
( O 
FXR O 
) O 
] O 
, O 
leading O 
to O 
enhanced O 
or O 
suppressed O 
biologic O 
activity O 
. O 
To O 
understand O 
the O 
molecular O 
mechanisms O 
and O 
the O 
subsequent O 
effects O 
in O 
modulating O 
FXR O 
functions O 
in O 
diverse O 
biologic O 
processes O 
, O 
we O 
individually O 
replaced O 
eight O 
highly O 
conserved O 
lysine B-TRIVIAL 
residues O 
of O 
human O 
FXR O 
( O 
hFXR O 
) O 
with O 
arginine B-TRIVIAL 
. O 
The O 
effects O 
of O 
each O 
mutated O 
FXR O 
on O 
target O 
gene O 
activation O 
, O 
subcellular O 
localization O 
, O 
protein O 
- O 
protein O 
association O 
, O 
and O 
protein-DNA O 
interaction O 
were O 
investigated O 
. O 
Results O 
demonstrated O 
that O 
K122R O 
, O 
K210R O 
, O 
K339R O 
, O 
and O 
K460R O 
mutants O 
of O 
hFXR O 
significantly O 
impaired O 
target O 
gene O 
[ O 
organic O 
solute O 
transporter O 
α O 
/ O 
β O 
and O 
bile B-FAMILY 
salt I-FAMILY 
export O 
pump O 
( O 
BSEP O 
) O 
] O 
promoter O 
reporter O 
activity O 
in O 
a O 
ligand O 
- O 
dependent O 
fashion O 
. O 
None O 
of O 
the O 
four O 
mutants O 
affected O 
the O 
nuclear O 
localization O 
of O 
FXR O 
. O 
Protein O 
interaction O 
studies O 
show O 
that O 
K210R O 
slightly O 
but O 
significantly O 
decreased O 
FXR/ O 
retinoid B-FAMILY 
X O 
receptor O 
( O 
RXR O 
) O 
binding O 
affinity O 
but O 
enhanced O 
the O 
interaction O 
of O 
FXR O 
with O 
lysine B-TRIVIAL 
methyltransferase O 
Set7 O 
/ O 
9 O 
by O 
∼21% O 
. O 
K460R O 
decreased O 
the O 
FXR O 
interaction O 
with O 
Set7 O 
/ O 
9 O 
by O 
∼45% O 
but O 
had O 
no O 
significant O 
effects O 
on O 
interaction O 
with O 
RXR O 
. O 
Electrophoretic O 
mobility O 
shift O 
assays O 
demonstrated O 
that O 
hFXR-K210R O 
and O 
-K339R O 
reduced O 
the O 
protein-DNA O 
( O 
IR1 O 
element O 
at O 
hBSEP O 
promoter O 
) O 
binding O 
affinity O 
by O 
∼80 O 
and O 
∼90% O 
, O 
respectively O 
. O 
Computational O 
- O 
based O 
protein O 
modeling O 
studies O 
were O 
consistent O 
with O 
these O 
results O 
and O 
provided O 
further O 
insights O 
into O 
the O 
potential O 
underlying O 
mechanisms O 
responsible O 
for O 
these O 
results O 
. O 
In O 
conclusion O 
, O 
four O 
highly O 
conserved O 
lysine B-TRIVIAL 
residues O 
of O 
hFXR O 
, O 
K122 O 
, O 
K210 O 
, O 
K339 O 
, O 
and O 
K460 O 
, O 
have O 
been O 
identified O 
that O 
play O 
a O 
critical O 
role O 
in O 
FXR O 
target O 
gene O 
regulation O 
and O 
molecular O 
interaction O 
( O 
protein O 
- O 
protein O 
and O 
protein-DNA O 
) O 
. O 

and O 
thermal O 
stability O 
of O 
purple O 
- O 
fleshed O 
sweet O 
potato O 
anthocyanins B-FAMILY 
in O 
aqueous O 
solutions O 
with O 
various O 
pH O 
values O 
and O 
fruit O 
juices O 
. O 

anthocyanins B-FAMILY 
were O 
identified O 
in O 
the O 
purple O 
- O 
fleshed O 
sweet O 
potato O 
cultivar O 
Jihei O 
No O 
. O 
1 O 
. O 
The O 
main O 
anthocyanins B-FAMILY 
were O 
3-sophoroside-5-glucoside B-SYSTEMATIC 
derivatives O 
from O 
cyanidin B-TRIVIAL 
and O 
peonidin B-TRIVIAL 
, O 
acylated O 
with O 
p-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
, O 
or O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
. O 
A O 
unique O 
anthocyanin B-FAMILY 
, O 
delphinidin-3,5-diglucoside B-SYSTEMATIC 
was O 
also O 
found O 
. O 
The O 
thermal O 
stability O 
of O 
purple O 
- O 
fleshed O 
sweet O 
potato O 
anthocyanins B-FAMILY 
( O 
PSPAs O 
) O 
followed O 
a O 
first O 
- O 
order O 
kinetics O 
model O 
. O 
Aqueous O 
solutions O 
with O 
various O 
pH O 
( O 
2 O 
, O 
3 O 
, O 
4 O 
, O 
5 O 
, O 
and O 
6 O 
) O 
and O 
fruit O 
juices O 
( O 
apple O 
, O 
pear O 
, O 
grapefruit O 
, O 
orange O 
, O 
tangerine O 
, O 
kiwifruit O 
, O 
and O 
lemon O 
) O 
were O 
coloured O 
with O 
PSPAs O 
. O 
The O 
enrichment O 
and O 
degradation O 
kinetics O 
of O 
anthocyanins B-FAMILY 
in O 
these O 
matrices O 
were O 
investigated O 
at O 
80 O 
, O 
90 O 
, O 
and O 
100°C O 
. O 
A O 
higher O 
stability O 
of O 
anthocyanins B-FAMILY 
was O 
obtained O 
in O 
aqueous O 
solutions O 
with O 
pH O 
3 O 
and O 
4 O 
and O 
in O 
apple O 
and O 
pear O 
juices O 
. O 
Moreover O 
, O 
the O 
activation O 
energies O 
for O 
PSPA O 
degradation O 
in O 
aqueous O 
solutions O 
with O 
various O 
pH O 
and O 
fruit O 
juices O 
ranged O 
from O 
66.56 O 
kJ O 
/ O 
mol O 
to O 
111.57 O 
kJ O 
/ O 
mol O 
and O 
46.76 O 
kJ O 
/ O 
mol O 
to O 
75.68 O 
kJ O 
/ O 
mol O 
, O 
respectively O 
. O 

of O 
novel O 
tricyclic O 
CRTh2 O 
receptor O 
antagonists O 
from O 
a O 
(E)-2-cyano-3-(1H-indol-3-yl)acrylamide B-SYSTEMATIC 
scaffold O 
. O 

acid I-SYSTEMATIC 
( O 
1 O 
) O 
was O 
discovered O 
in O 
a O 
HTS O 
campaign O 
for O 
CRTh2 O 
receptor O 
antagonists O 
. O 
An O 
SAR O 
around O 
this O 
hit O 
could O 
be O 
established O 
and O 
representatives O 
with O 
interesting O 
activity O 
profiles O 
were O 
obtained O 
. O 
Ring O 
closing O 
tactics O 
to O 
convert O 
this O 
hit O 
series O 
into O 
a O 
novel O 
2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole B-SYSTEMATIC 
based O 
CRTh2 O 
receptor O 
antagonist O 
series O 
is O 
presented O 
. O 

of O 
implantable O 
glucose B-TRIVIAL 
biosensors O 
for O 
" O 
real O 
- O 
time O 
" O 
monitoring O 
is O 
reliant O 
on O 
controlling O 
the O 
negative O 
tissue O 
reaction O 
at O 
the O 
sensor O 
tissue O 
interphase O 
. O 
A O 
novel O 
polymer O 
coating O 
consisting O 
of O 
poly(lactic-co-glycolic) B-FAMILY 
acid I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
microsphere O 
dispersed O 
in O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
hydrogels O 
was O 
evaluated O 
in O 
combination O 
with O 
dummy O 
sensors O 
as O 
a O 
" O 
smart O 
" O 
drug O 
eluting O 
biocompatible O 
coating O 
for O 
implantable O 
biosensors O 
to O 
prevent O 
the O 
foreign O 
body O 
response O 
, O 
and O 
thus O 
enhance O 
sensor O 
performance O 
in O 
vivo O 
. O 
The O 
polymeric O 
microspheres O 
slowly O 
release O 
tissue O 
- O 
modifying O 
drugs O 
at O 
the O 
implantation O 
sites O 
to O 
control O 
the O 
inflammation O 
and O 
fibrous O 
encapsulation O 
, O 
while O 
the O 
hydrogel O 
allows O 
rapid O 
analyte O 
diffusion O 
to O 
the O 
sensing O 
elements O 
. O 
Dummy O 
sensors O 
with O 
identical O 
dimensions O 
to O 
that O 
of O 
the O 
functional O 
glucose B-TRIVIAL 
sensors O 
( O 
0.5×0.5×5mm O 
) O 
were O 
coated O 
with O 
the O 
PLGA B-ABBREVIATION 
/ O 
PVA B-ABBREVIATION 
composites O 
using O 
a O 
mold O 
fabrication O 
process O 
. O 
Both O 
normal O 
and O 
diabetic O 
rats O 
were O 
used O 
in O 
the O 
current O 
study O 
to O 
investigate O 
the O 
effect O 
of O 
the O 
diabetic O 
state O 
on O 
tissue O 
sensor O 
interactions O 
. O 
It O 
was O 
evident O 
that O 
the O 
PLGA B-ABBREVIATION 
/ O 
PVA B-ABBREVIATION 
hydrogel O 
composite O 
was O 
able O 
to O 
form O 
a O 
uniform O 
coating O 
around O 
the O 
dummy O 
sensor O 
and O 
stayed O 
intact O 
throughout O 
the O 
course O 
of O 
the O 
study O 
( O 
one O 
month O 
) O 
. O 
Tissue O 
samples O 
containing O 
dummy O 
sensors O 
that O 
were O 
coated O 
with O 
dexamethasone B-TRIVIAL 
free O 
composites O 
exhibited O 
acute O 
and O 
chronic O 
inflammation O 
as O 
well O 
as O 
fibrous O 
encapsulation O 
in O 
both O 
normal O 
and O 
diabetic O 
rats O 
. O 
However O 
, O 
the O 
diabetic O 
rats O 
exhibited O 
decreased O 
intensity O 
and O 
delayed O 
onset O 
of O 
the O 
foreign O 
body O 
response O 
following O 
implantation O 
of O 
drug O 
free O 
dummy O 
sensors O 
in O 
comparison O 
to O 
those O 
of O 
normal O 
rats O 
. O 
On O 
the O 
other O 
hand O 
, O 
tissues O 
containing O 
dummy O 
sensors O 
that O 
were O 
coated O 
with O 
dexamethasone B-TRIVIAL 
containing O 
composites O 
remained O 
normal O 
( O 
i.e O 
. O 
similar O 
to O 
untreated O 
tissues O 
) O 
, O 
with O 
no O 
inflammatory O 
reaction O 
or O 
fibrous O 
encapsulation O 
occurring O 
over O 
the O 
one O 
- O 
month O 
period O 
in O 
both O 
the O 
normal O 
and O 
diabetic O 
rats O 
. O 
The O 
feasibility O 
of O 
utilizing O 
PLGA B-ABBREVIATION 
microsphere/ O 
PVA B-ABBREVIATION 
hydrogel O 
composites O 
as O 
coatings O 
for O 
implantable O 
biosensors O 
was O 
demonstrated O 
. O 
This O 
polymeric O 
composite O 
is O 
an O 
innovative O 
approach O 
to O 
control O 
the O 
foreign O 
body O 
reaction O 
at O 
the O 
tissue O 
- O 
device O 
interface O 
to O 
prolong O 
biosensor O 
lifetime O 
. O 

cl B-FORMULA 
⋅⋅⋅ O 
h B-FORMULA 
and O 
o B-FORMULA 
⋅⋅⋅ O 
h B-FORMULA 
interactions O 
in O 
self O 
- O 
assembled O 
1,5-dichloroanthraquinone B-SYSTEMATIC 
layers O 
on O 
au(111) B-FORMULA 
. O 

role O 
of O 
halogen B-FAMILY 
bonds O 
in O 
self O 
- O 
assembled O 
networks O 
for O 
systems O 
with O 
Br B-FORMULA 
and O 
I B-FORMULA 
ligands O 
has O 
recently O 
been O 
studied O 
with O 
scanning O 
tunneling O 
microscopy O 
( O 
STM O 
) O 
, O 
which O 
provides O 
physical O 
insight O 
at O 
the O 
atomic O 
scale O 
. O 
Here O 
, O 
we O 
study O 
the O 
supramolecular O 
interactions O 
of O 
1,5-dichloroanthraquinone B-SYSTEMATIC 
molecules O 
on O 
Au(111) B-FORMULA 
, O 
including O 
Cl B-FORMULA 
ligands O 
, O 
by O 
using O 
STM O 
. O 
Two O 
different O 
molecular O 
structures O 
of O 
chevron O 
and O 
square O 
networks O 
are O 
observed O 
, O 
and O 
their O 
molecular O 
models O 
are O 
proposed O 
. O 
Both O 
molecular O 
structures O 
are O 
stabilized O 
by O 
intermolecular O 
Cl B-FORMULA 
⋅⋅⋅ O 
H B-FORMULA 
and O 
O B-FORMULA 
⋅⋅⋅ O 
H B-FORMULA 
hydrogen B-SYSTEMATIC 
bonds O 
with O 
marginal O 
contributions O 
from O 
Cl B-FORMULA 
-related O 
halogen B-FAMILY 
bonds O 
, O 
as O 
revealed O 
by O 
density O 
functional O 
theory O 
calculations O 
. O 
Our O 
study O 
shows O 
that O 
, O 
in O 
contrast O 
to O 
Br B-FORMULA 
- O 
and O 
I B-FORMULA 
-related O 
halogen B-FAMILY 
bonds O 
, O 
Cl B-FORMULA 
-related O 
halogen B-FAMILY 
bonds O 
weakly O 
contribute O 
to O 
the O 
molecular O 
structure O 
due O 
to O 
a O 
modest O 
positive O 
potential O 
( O 
σ O 
hole O 
) O 
of O 
the O 
Cl B-FORMULA 
ligands O 
. O 

of O 
direct B-TRIVIAL 
blue I-TRIVIAL 
15 I-TRIVIAL 
by O 
Fenton O 
/ O 
ultrasonic O 
process O 
using O 
a O 
zero B-SYSTEMATIC 
- I-SYSTEMATIC 
valent I-SYSTEMATIC 
iron I-SYSTEMATIC 
aggregate O 
catalyst O 
. O 

of O 
direct O 
azo B-SYSTEMATIC 
dye O 
, O 
direct B-TRIVIAL 
blue I-TRIVIAL 
15 I-TRIVIAL 
( O 
DB15 B-ABBREVIATION 
) O 
, O 
by O 
an O 
advanced O 
Fenton O 
process O 
coupled O 
with O 
ultrasonic O 
irradiation O 
( O 
Fenton O 
/ O 
US O 
) O 
was O 
investigated O 
. O 
Zero B-SYSTEMATIC 
- I-SYSTEMATIC 
valent I-SYSTEMATIC 
iron I-SYSTEMATIC 
( O 
ZVI B-ABBREVIATION 
) O 
aggregates O 
were O 
used O 
as O 
the O 
catalyst O 
. O 
A O 
positive O 
synergistic O 
effect O 
occurred O 
when O 
Fenton's B-FAMILY 
reagent I-FAMILY 
was O 
combined O 
with O 
ultrasonic O 
irradiation O 
. O 
Experimental O 
results O 
showed O 
that O 
the O 
optimum O 
conditions O 
for O 
decolourization O 
were O 
pH O 
3 O 
, O 
Fe(0) B-FORMULA 
1g O 
/ O 
L O 
, O 
H(2)O(2) B-FORMULA 
5.15×10(-3)mol O 
/ O 
L O 
with O 
ultrasound O 
density O 
of O 
120W O 
/ O 
L O 
at O 
60kHz O 
. O 
These O 
conditions O 
yielded O 
99% O 
decolouration O 
of O 
4.7×10(-5) O 
M O 
DB15 O 
( O 
4130 O 
ADMI O 
) O 
solution O 
within O 
10min O 
. O 
DB15 B-ABBREVIATION 
decolouration O 
follows O 
the O 
first O 
- O 
order O 
decolouration O 
kinetics O 
. O 
Although O 
the O 
solutions O 
containing O 
H(2)CO(3) B-FORMULA 
, O 
Cl(-) B-FORMULA 
, O 
ClO(4)(-) B-FORMULA 
, O 
NO(3)(-) B-FORMULA 
and O 
SO(4)(2-) B-FORMULA 
ions O 
did O 
not O 
have O 
a O 
significant O 
effect O 
on O 
the O 
decolouration O 
, O 
the O 
H(2)PO(4)(-) B-FORMULA 
ion O 
did O 
decrease O 
the O 
decolouration O 
rate O 
. O 
High O 
ultrasonic O 
input O 
power O 
accelerated O 
the O 
reaction O 
and O 
increased O 
decolourization O 
efficiency O 
. O 
The O 
cost O 
effectiveness O 
of O 
this O 
process O 
at O 
high O 
ultrasound O 
density O 
could O 
be O 
controlled O 
despite O 
the O 
high O 
electricity O 
costs O 
incurred O 
by O 
the O 
process O 
. O 
ZVI B-ABBREVIATION 
aggregates O 
were O 
reusable O 
; O 
however O 
, O 
an O 
increase O 
in O 
the O 
number O 
of O 
times O 
ZVI B-ABBREVIATION 
was O 
recycled O 
decreased O 
the O 
decolourization O 
rate O 
. O 
This O 
study O 
demonstrates O 
that O 
a O 
Fenton O 
/ O 
US O 
process O 
can O 
effectively O 
decolour O 
the O 
direct O 
azo B-SYSTEMATIC 
dye O 
DB15 B-ABBREVIATION 
in O 
wastewater O 
. O 

and O 
antitubercular O 
activity O 
of O 
2-(substituted B-FAMILY 
phenyl I-FAMILY 
/ I-FAMILY 
benzyl-amino)-6-(4-chlorophenyl)-5-(methoxycarbonyl)-4-methyl-3,6-dihydropyrimidin-1-ium I-FAMILY 
chlorides I-FAMILY 
. O 

series O 
of O 
2-(substituted B-FAMILY 
phenyl I-FAMILY 
/ I-FAMILY 
benzyl-amino)-6-(4-chlorophenyl)-5-(methoxycarbonyl)-4-methyl-3,6-dihydropyrimidin-1-ium I-FAMILY 
chlorides I-FAMILY 
7-13 O 
and O 
15 O 
was O 
synthesized O 
in O 
their O 
hydrochloride B-FAMILY 
salt O 
form O 
. O 
The O 
title O 
compounds O 
were O 
characterized O 
by O 
FT-IR O 
, O 
NMR O 
( O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
) O 
and O 
elemental O 
analysis O 
. O 
They O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
antitubercular O 
activity O 
against O 
Mycobacterium O 
tuberculosis O 
H37Rv O 
, O 
multidrug O 
resistance O 
tuberculosis O 
and O 
extensively O 
drug O 
resistance O 
tuberculosis O 
by O 
agar O 
diffusion O 
method O 
and O 
tested O 
for O 
the O 
cytotoxic O 
action O 
on O 
peripheral O 
blood O 
mononuclear O 
cells O 
by O 
MTT B-ABBREVIATION 
assay O 
. O 
Among O 
all O 
the O 
tested O 
compounds O 
in O 
the O 
series O 
, O 
compounds O 
7 O 
and O 
11 O 
emerged O 
as O 
promising O 
antitubercular O 
agents O 
at O 
16 O 
μg O 
/ O 
mL O 
against O 
multidrug O 
resistance O 
tuberculosis O 
and O 
over O 
64 O 
μg O 
/ O 
mL O 
against O 
extensively O 
drug O 
resistance O 
tuberculosis O 
. O 
The O 
conformational O 
features O 
and O 
supramolecular O 
assembly O 
of O 
the O 
promising O 
compounds O 
7 O 
and O 
11 O 
were O 
determined O 
by O 
single O 
crystal O 
X-ray O 
study O 
. O 

the O 
late O 
19th O 
century O 
, O 
it O 
was O 
already O 
known O 
that O 
severe O 
infections O 
could O 
be O 
associated O 
with O 
cardiovascular O 
collapse O 
, O 
a O 
fact O 
essentially O 
attributed O 
to O 
cardiac O 
failure O 
. O 
A O 
major O 
experimental O 
work O 
in O 
the O 
rabbit O 
, O 
published O 
by O 
Romberg O 
and O 
Pässler O 
in O 
1899 O 
, O 
shifted O 
attention O 
to O 
disturbed O 
peripheral O 
vascular O 
tone O 
as O 
the O 
mechanism O 
of O 
hypotension O 
in O 
these O 
conditions O 
. O 
In O 
the O 
first O 
half O 
of O 
the O 
20th O 
century O 
, O 
great O 
progresses O 
were O 
made O 
in O 
the O 
pathophysiologic O 
understanding O 
of O 
hemorrhagic O 
and O 
traumatic O 
shocks O 
, O 
while O 
researchers O 
devoted O 
relatively O 
little O 
attention O 
to O 
septic O 
shock O 
. O 
Progress O 
in O 
the O 
hemodynamic O 
understanding O 
of O 
septic O 
shock O 
resumed O 
with O 
the O 
advent O 
of O 
critical O 
care O 
units O 
. O 
The O 
hyperdynamic O 
state O 
was O 
recognized O 
in O 
the O 
late O 
fifties O 
and O 
early O 
sixties O 
. O 
The O 
present O 
short O 
review O 
ends O 
with O 
landmark O 
studies O 
by O 
Max O 
Harry O 
Weil O 
, O 
demonstrating O 
the O 
importance O 
of O 
venous O 
pooling O 
, O 
and O 
John O 
H O 
. O 
Siegel O 
, O 
which O 
introduced O 
the O 
concept O 
of O 
deficient O 
peripheral O 
utilization O 
of O 
oxygen B-SYSTEMATIC 
, O 
inspiring O 
later O 
work O 
on O 
the O 
microvascular O 
disturbances O 
of O 
septic O 
shock O 
. O 

acid I-FAMILY 
sequence O 
of O 
the O 
ligand O 
- O 
binding O 
domain O 
of O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
1 O 
predicts O 
sensitivity O 
of O 
wild O 
birds O 
to O 
effects O 
of O 
dioxin B-FAMILY 
-like O 
compounds O 
. O 

sensitivity O 
of O 
avian O 
species O 
to O 
the O 
toxic O 
effects O 
of O 
dioxin B-FAMILY 
-like O 
compounds O 
( O 
DLCs O 
) O 
varies O 
up O 
to O 
1000-fold O 
among O 
species O 
, O 
and O 
this O 
variability O 
has O 
been O 
associated O 
with O 
interspecies O 
differences O 
in O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
1 O 
ligand O 
- O 
binding O 
domain O 
( O 
AHR1 O 
LBD O 
) O 
sequence O 
. O 
We O 
previously O 
showed O 
that O 
LD(50) O 
values O 
, O 
based O 
on O 
in O 
ovo O 
exposures O 
to O 
DLCs O 
, O 
were O 
significantly O 
correlated O 
with O 
in O 
vitro O 
EC(50) O 
values O 
obtained O 
with O 
a O 
luciferase O 
reporter O 
gene O 
( O 
LRG O 
) O 
assay O 
that O 
measures O 
AHR1 O 
- O 
mediated O 
induction O 
of O 
cytochrome O 
P4501A O 
in O 
COS-7 O 
cells O 
transfected O 
with O 
avian O 
AHR1 O 
constructs O 
. O 
Those O 
findings O 
suggest O 
that O 
the O 
AHR1 O 
LBD O 
sequence O 
and O 
the O 
LRG O 
assay O 
can O 
be O 
used O 
to O 
predict O 
avian O 
species O 
sensitivity O 
to O 
DLCs O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
AHR1 O 
LBD O 
sequences O 
of O 
86 O 
avian O 
species O 
were O 
studied O 
, O 
and O 
differences O 
at O 
amino B-FAMILY 
acid I-FAMILY 
sites O 
256 O 
, O 
257 O 
, O 
297 O 
, O 
324 O 
, O 
337 O 
, O 
and O 
380 O 
were O 
identified O 
. O 
Site O 
- O 
directed O 
mutagenesis O 
, O 
the O 
LRG O 
assay O 
, O 
and O 
homology O 
modeling O 
highlighted O 
the O 
importance O 
of O 
each O 
amino B-FAMILY 
acid I-FAMILY 
site O 
in O 
AHR1 O 
sensitivity O 
to O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
and O 
other O 
DLCs O 
. O 
The O 
results O 
of O 
the O 
study O 
revealed O 
that O 
( O 
1 O 
) O 
only O 
amino B-FAMILY 
acids I-FAMILY 
at O 
sites O 
324 O 
and O 
380 O 
affect O 
the O 
sensitivity O 
of O 
AHR1 O 
expression O 
constructs O 
of O 
the O 
86 O 
avian O 
species O 
to O 
DLCs O 
and O 
( O 
2 O 
) O 
in O 
vitro O 
luciferase O 
activity O 
of O 
AHR1 O 
constructs O 
containing O 
only O 
the O 
LBD O 
of O 
the O 
species O 
of O 
interest O 
is O 
significantly O 
correlated O 
( O 
r O 
( O 
2 O 
) O 
= O 
0.93 O 
, O 
p O 
< O 
0.0001 O 
) O 
with O 
in O 
ovo O 
toxicity O 
data O 
for O 
those O 
species O 
. O 
These O 
results O 
indicate O 
promise O 
for O 
the O 
use O 
of O 
AHR1 O 
LBD O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
independently O 
, O 
or O 
combined O 
with O 
the O 
LRG O 
assay O 
, O 
to O 
predict O 
avian O 
species O 
sensitivity O 
to O 
DLCs O 
. O 

exposure O 
to O 
calcineurin O 
inhibitors O 
and O 
corticosteroids O 
poses O 
renal O 
transplant O 
recipients O 
( O 
RTR O 
) O 
at O 
high O 
risk O 
for O 
development O 
of O 
new O 
- O 
onset O 
diabetes O 
after O 
transplantation O 
( O 
NODAT O 
) O 
. O 
Pancreatic O 
β-cell O 
dysfunction O 
may O 
be O 
crucial O 
to O 
the O 
pathophysiology O 
of O 
NODAT O 
and O 
specific O 
markers O 
for O 
β-cell O 
dysfunction O 
may O 
have O 
additive O 
value O 
for O 
predicting O 
NODAT O 
in O 
this O 
population O 
. O 
Therefore O 
, O 
we O 
prospectively O 
investigated O 
whether O 
proinsulin O 
, O 
as O 
a O 
marker O 
of O 
pancreatic O 
β-cell O 
dysfunction O 
, O 
is O 
associated O 
with O 
future O 
development O 
of O 
NODAT O 
and O 
improves O 
prediction O 
of O 
it.RESEARCH O 
DESIGN O 
AND O 
METHODSAll O 
RTR O 
between O 
2001 O 
and O 
2003 O 
with O 
a O 
functioning O 
graft O 
for O 
≥ O 
1 O 
year O 
were O 
considered O 
eligible O 
for O 
inclusion O 
, O 
except O 
for O 
subjects O 
with O 
diabetes O 
at O 
baseline O 
who O 
were O 
excluded O 
. O 
We O 
recorded O 
incidence O 
of O 
NODAT O 
until O 
April O 
2012.RESULTSA O 
total O 
of O 
487 O 
RTR O 
( O 
age O 
50 O 
± O 
12 O 
years O 
, O 
55% O 
men O 
) O 
participated O 
at O 
a O 
median O 
time O 
of O 
6 O 
( O 
interquartile O 
range O 
[ O 
IQR O 
] O 
, O 
2.6-11.5 O 
) O 
years O 
after O 
transplantation O 
. O 
Median O 
fasting O 
proinsulin O 
levels O 
were O 
16.6 O 
( O 
IQR O 
, O 
11.0-24.2 O 
) O 
pmol O 
/ O 
L O 
. O 
During O 
median O 
follow O 
- O 
up O 
for O 
10.1 O 
( O 
IQR O 
, O 
9.1-10.4 O 
) O 
years O 
, O 
42 O 
( O 
35% O 
) O 
RTR O 
had O 
development O 
of O 
NODAT O 
in O 
the O 
highest O 
quartile O 
of O 
the O 
distribution O 
of O 
proinsulin O 
versus O 
34 O 
( O 
9% O 
) O 
in O 
the O 
lowest O 
three O 
quartiles O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
In O 
Cox O 
regression O 
analyses O 
, O 
proinsulin O 
( O 
hazard O 
ratio O 
, O 
2.29 O 
; O 
95% O 
confidence O 
interval O 
, O 
1.85-2.83 O 
; O 
P O 
< O 
0.001 O 
) O 
was O 
strongly O 
associated O 
with O 
NODAT O 
development O 
. O 
This O 
was O 
independent O 
of O 
age O 
, O 
sex O 
, O 
calcineurine O 
inhibitors O 
, O 
prednisolone B-TRIVIAL 
use O 
, O 
components O 
of O 
the O 
metabolic O 
syndrome O 
, O 
or O 
homeostasis O 
model O 
assessment.CONCLUSIONSIn O 
conclusion O 
, O 
fasting O 
proinsulin O 
is O 
strongly O 
associated O 
with O 
NODAT O 
development O 
in O 
RTR O 
. O 
Our O 
results O 
highlight O 
the O 
role O 
of O 
β-cell O 
dysfunction O 
in O 
the O 
pathophysiology O 
of O 
NODAT O 
and O 
indicate O 
the O 
potential O 
value O 
of O 
proinsulin O 
for O 
identification O 
of O 
RTR O 
at O 
increased O 
risk O 
for O 
NODAT O 
. O 

study O 
presents O 
the O 
application O 
of O 
a O 
headspace O 
solid O 
- O 
phase O 
microextraction O 
( O 
HS-SPME O 
) O 
method O 
on O 
the O 
analysis O 
of O 
Muscat O 
- O 
based O 
wines O 
volatiles O 
by O 
comprehensive O 
two O 
- O 
dimensional O 
gas O 
chromatography O 
( O 
GC×GC O 
) O 
and O 
Time-Of-Flight O 
mass O 
spectrometry O 
( O 
TOF-MS O 
) O 
. O 
The O 
aroma O 
patterns O 
were O 
established O 
for O 
different O 
samples O 
of O 
Asti O 
Spumante O 
and O 
Moscato O 
d'Asti O 
wines O 
, O 
stored O 
in O 
bottles O 
for O 
6months O 
at O 
different O 
temperatures O 
. O 
Wines O 
stored O 
at O 
5°C O 
for O 
6months O 
did O 
not O 
show O 
significant O 
changes O 
in O 
flavor O 
; O 
otherwise O 
, O 
the O 
samples O 
stored O 
at O 
15 O 
and O 
25°C O 
, O 
showed O 
a O 
significant O 
decrease O 
in O 
linalool B-TRIVIAL 
, O 
β-damascenone B-TRIVIAL 
, O 
ethyl B-SYSTEMATIC 
hexanoate I-SYSTEMATIC 
, O 
and O 
ethyl B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
levels O 
. O 
In O 
these O 
last O 
samples O 
, O 
α-terpineol B-TRIVIAL 
, O 
hotrienol B-TRIVIAL 
, O 
nerol B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
furanic B-MULTIPLE 
linalool I-MULTIPLE 
oxides I-MULTIPLE 
A I-MULTIPLE 
/ I-MULTIPLE 
B I-MULTIPLE 
and O 
rose B-TRIVIAL 
oxide I-TRIVIAL 
concentrations O 
significantly O 
increased O 
. O 
A O 
mathematical O 
approach O 
was O 
developed O 
and O 
applied O 
to O 
raw O 
data O 
exported O 
after O 
the O 
chromatographic O 
course O 
, O 
in O 
order O 
(i) O 
to O 
normalise O 
different O 
2D O 
chromatograms O 
, O 
permitting O 
their O 
direct O 
comparison O 
and O 
(ii) O 
to O 
automatically O 
identify O 
and O 
calculate O 
from O 
pixel O 
- O 
to O 
- O 
pixel O 
re O 
- O 
designed O 
2D O 
chromatograms O 
any O 
differences O 
among O 
key O 
volatile O 
compounds O 
. O 

lechleri O 
Müll O 
. O 
Arg O 
. O 
( O 
Euphorbiaceae O 
) O 
stem O 
bark O 
essential O 
oil O 
as O 
possible O 
mutagen O 
- O 
protective O 
food O 
ingredient O 
against O 
heterocyclic B-FAMILY 
amines I-FAMILY 
from O 
cooked O 
food O 
. O 

Amazonian O 
Croton O 
lechleri O 
stem O 
bark O 
essential O 
oil O 
was O 
tested O 
for O 
its O 
anti-mutagenic O 
potential O 
by O 
performing O 
the O 
Ames O 
test O 
against O 
heterocyclic B-FAMILY 
amines I-FAMILY 
( O 
HCAs B-ABBREVIATION 
) O 
, O 
in O 
continuing O 
research O 
on O 
applicative O 
functional O 
profile O 
of O 
this O 
phytocomplex O 
as O 
food O 
ingredient O 
( O 
Rossi O 
et O 
al O 
. O 
, O 
2011 O 
) O 
. O 
Salmonella O 
typhimurium O 
strain O 
TA98 O 
was O 
used O 
with O 
and O 
without O 
metabolic O 
activation O 
( O 
S9 O 
mix O 
) O 
. O 
The O 
anti-mutagenic O 
properties O 
was O 
assayed O 
with O 
the O 
following O 
HCAs B-ABBREVIATION 
: O 
2-amino-3-methylimidazo-[4,5-f]quinoline B-SYSTEMATIC 
( O 
IQ O 
) O 
, O 
2-amino-3,4-dimethylimidazo-[4,5-f]quinoline B-SYSTEMATIC 
( O 
MeIQ B-ABBREVIATION 
) O 
, O 
2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline B-SYSTEMATIC 
( O 
MeIQx B-ABBREVIATION 
) O 
, O 
the O 
imidazoles B-FAMILY 
2-amino-6-methyldipyrido-[1,2-a:3',2'-d]imidazole B-SYSTEMATIC 
( O 
Glu-P-1 B-TRIVIAL 
) O 
and O 
2-aminodipirydo-[1,2-a:3',2'-d]imidazole B-SYSTEMATIC 
( O 
Glu-P-2 B-TRIVIAL 
) O 
. O 
All O 
HCAs B-ABBREVIATION 
with O 
S9 O 
induced O 
mutagenicity O 
at O 
10(-10)mol O 
/ O 
plate O 
. O 
Without O 
S9 O 
, O 
IQ O 
and O 
MeIQ B-ABBREVIATION 
showed O 
mutagenicity O 
at O 
10(-8)mol O 
/ O 
plate O 
, O 
MeIQx B-ABBREVIATION 
and O 
Glu-P-1 B-TRIVIAL 
at O 
10(-5)mol O 
/ O 
plate O 
, O 
while O 
Glu-P-2 B-TRIVIAL 
was O 
inactive O 
. O 
In O 
presence O 
of O 
HACs B-FAMILY 
( O 
10(-9)mol O 
/ O 
plate O 
) O 
, O 
C O 
. O 
lechleri O 
essential O 
oil O 
was O 
tested O 
for O 
mutagen O 
- O 
protective O 
properties O 
( O 
concentration O 
range O 
: O 
0.01-0.10mg O 
/ O 
plate O 
) O 
taking O 
the O 
Highest O 
Uneffective O 
Dose O 
( O 
HUD O 
) O 
as O 
threshold O 
reference O 
. O 
With O 
S9 O 
mix O 
, O 
C O 
. O 
lechleri O 
essential O 
oil O 
displayed O 
a O 
significant O 
reduction O 
of O 
revertants O 
at O 
0.05mg O 
/ O 
plate O 
, O 
from O 
21% O 
to O 
34% O 
. O 
The O 
essential O 
oil O 
showed O 
mutagen O 
- O 
protective O 
efficacy O 
against O 
IQ O 
and O 
MeIQ B-ABBREVIATION 
tested O 
as O 
direct O 
mutagens O 
( O 
10(-7)mol O 
/ O 
plate O 
) O 
, O 
with O 
a O 
revertants O 
percentage O 
reduction O 
of O 
39% O 
and O 
40% O 
, O 
respectively O 
. O 
No O 
anti-mutagen O 
capacity O 
was O 
noted O 
for O 
MeIQx B-ABBREVIATION 
and O 
Glu-P-1 B-TRIVIAL 
( O 
10(-5)mol O 
/ O 
plate O 
) O 
. O 
Since O 
HACs B-FAMILY 
are O 
known O 
as O 
possible O 
colon O 
and O 
liver O 
cancer O 
inducers O 
, O 
C O 
. O 
lechleri O 
essential O 
oil O 
was O 
tested O 
for O 
its O 
cytotoxicity O 
and O 
anti-proliferative O 
capacity O 
against O 
LoVo O 
and O 
HepG2 O 
cancer O 
cell O 
lines O 
showing O 
IC50 O 
of O 
74.95±0.05μg O 
/ O 
ml O 
( O 
LoVo O 
) O 
and O 
82.28±0.03μg O 
/ O 
ml O 
( O 
HepG2 O 
) O 
, O 
displaying O 
a O 
promising O 
role O 
of O 
this O 
essential O 
oil O 
as O 
a O 
functional O 
food O 
ingredient O 
with O 
interesting O 
mutagen O 
preventing O 
properties O 
. O 

Receptor O 
mRNA O 
Measured O 
by O 
Quantitative O 
Real O 
Time O 
PCR O 
is O 
Decreased O 
in O 
the O 
Urethral O 
Mucosa O 
of O 
Patients O 
with O 
Middle O 
Idiopathic O 
Hypospadias O 
. O 

action O 
is O 
exerted O 
through O 
the O 
androgen B-FAMILY 
receptor O 
. O 
The O 
normal O 
46,XY O 
genital O 
virilization O 
depends O 
on O 
androgen B-FAMILY 
receptor O 
gene O 
expression O 
, O 
which O 
is O 
tissue O 
specific O 
, O 
and O 
requires O 
normal O 
androgen B-FAMILY 
receptor O 
mRNA O 
levels O 
in O 
androgen B-FAMILY 
sensitive O 
tissues O 
. O 
Hypospadias O 
is O 
a O 
frequent O 
male O 
genital O 
abnormality O 
, O 
potentially O 
related O 
to O 
reduced O 
androgen B-FAMILY 
sensitivity O 
in O 
genital O 
tissues O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
compare O 
, O 
by O 
quantitative O 
real O 
time O 
PCR O 
, O 
the O 
amount O 
of O 
androgen B-FAMILY 
receptor O 
mRNA O 
in O 
cells O 
obtained O 
from O 
the O 
urethral O 
mucosa O 
of O 
patients O 
with O 
middle O 
idiopathic O 
hypospadias O 
with O 
the O 
androgen B-FAMILY 
receptor O 
mRNA O 
levels O 
observed O 
in O 
control O 
phimosis O 
subjects O 
with O 
eutopic O 
urethral O 
opening O 
. O 
Prepubertal O 
individuals O 
were O 
studied O 
, O 
including O 
41 O 
controls O 
and O 
17 O 
hypospadias O 
patients O 
with O 
mean O 
( O 
SD O 
) O 
ages O 
of O 
4.7 O 
( O 
2.1 O 
) O 
years O 
and O 
4 O 
( O 
3 O 
) O 
years O 
, O 
respectively O 
. O 
We O 
observed O 
significantly O 
less O 
androgen B-FAMILY 
receptor O 
mRNA O 
in O 
the O 
urethral O 
mucosa O 
of O 
patients O 
with O 
hypospadias O 
than O 
in O 
the O 
controls O 
( O 
p=0.002 O 
) O 
. O 
The O 
correlation O 
between O 
the O 
level O 
of O 
androgen B-FAMILY 
receptor O 
mRNA O 
expression O 
and O 
the O 
penile O 
size O 
was O 
almost O 
statistically O 
significant O 
only O 
in O 
hypospadias O 
patients O 
( O 
r=0.47 O 
; O 
p=0.053 O 
) O 
. O 
We O 
also O 
established O 
the O 
number O 
of O 
CAG O 
repeats O 
in O 
exon O 
1 O 
of O 
the O 
androgen B-FAMILY 
receptor O 
gene O 
by O 
GeneScan O 
analysis O 
. O 
No O 
significant O 
difference O 
was O 
observed O 
in O 
the O 
number O 
of O 
CAG O 
repeats O 
when O 
patients O 
and O 
controls O 
were O 
compared O 
. O 
A O 
negative O 
correlation O 
between O 
the O 
CAG O 
repeats O 
and O 
penile O 
size O 
was O 
detected O 
in O 
patients O 
with O 
hypospadias O 
, O 
but O 
not O 
in O 
controls O 
. O 
Our O 
data O 
suggest O 
that O 
a O 
critical O 
lower O 
level O 
of O 
androgen B-FAMILY 
receptor O 
mRNA O 
expression O 
could O 
be O 
a O 
determining O 
factor O 
in O 
the O 
development O 
of O 
middle O 
hypospadias O 
. O 

Induces O 
Cell O 
Survival O 
, O 
Migration O 
and O 
Anti-Adhesiveness O 
of O 
Endothelial O 
Cells O 
via O 
Nitric B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Production O 
. O 

is O 
a O 
phenolic B-FAMILY 
compound O 
mainly O 
found O 
in O 
the O 
Pinus O 
species O 
. O 
To O 
determine O 
the O 
vascular O 
functions O 
of O 
pinosylvin B-TRIVIAL 
, O 
we O 
first O 
examined O 
both O 
proliferation O 
and O 
apoptosis O 
of O 
bovine O 
aortic O 
endothelial O 
cells O 
( O 
BAECs O 
) O 
in O 
the O 
presence O 
of O 
pinosylvin B-TRIVIAL 
. O 
When O 
BAECs O 
were O 
treated O 
with O 
pinosylvin B-TRIVIAL 
, O 
etoposide B-TRIVIAL 
- O 
or O 
starvation O 
- O 
induced O 
apoptosis O 
was O 
shown O 
to O 
be O 
significantly O 
reduced O 
. O 
The O 
anti-apoptotic O 
effect O 
of O 
pinosylvin B-TRIVIAL 
was O 
mediated O 
by O 
inhibition O 
of O 
caspase-3 O 
. O 
Moreover O 
, O 
pinosylvin B-TRIVIAL 
was O 
shown O 
to O 
activate O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthetase O 
( O 
eNOS O 
) O 
. O 
At O 
1 O 
pM O 
, O 
pinosylvin B-TRIVIAL 
appeared O 
to O 
have O 
a O 
cell O 
- O 
proliferative O 
effect O 
in O 
the O 
endothelial O 
cell O 
. O 
The O 
pinosylvin B-TRIVIAL 
-induced O 
cell O 
proliferation O 
was O 
declined O 
by O 
treatment O 
with O 
L-NAME B-ABBREVIATION 
, O 
an O 
eNOS O 
inhibitor O 
. O 
Then O 
, O 
we O 
found O 
that O 
pinosylvin B-TRIVIAL 
had O 
a O 
stimulatory O 
effect O 
on O 
cell O 
migration O 
and O 
tube O 
formation O 
. O 
These O 
stimulatory O 
effects O 
suggest O 
that O 
pinosylvin B-TRIVIAL 
is O 
likely O 
to O 
act O 
as O 
a O 
pro O 
- O 
angiogenic O 
factor O 
. O 
Yet O 
another O 
effect O 
of O 
pinosylvin B-TRIVIAL 
was O 
inhibition O 
of O 
lipopolysaccharide-induced O 
THP-1 O 
cell O 
adhesion O 
to O 
endothelial O 
cells O 
. O 
Altogether O 
, O 
we O 
propose O 
that O 
pinosylvin B-TRIVIAL 
may O 
be O 
utilized O 
as O 
a O 
phytotherapic O 
agent O 
for O 
the O 
prevention O 
of O 
cardiovascular O 
inflammatory O 
diseases O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

fungi O 
from O 
Miquelia O 
dentata O 
Bedd O 
. O 
, O 
produce O 
the O 
anti-cancer O 
alkaloid O 
, O 
camptothecine B-TRIVIAL 
. O 

( O 
Campothecin B-TRIVIAL 
, O 
CPT B-ABBREVIATION 
) O 
, O 
a O 
quinoline B-FAMILY 
alkaloid I-FAMILY 
, O 
is O 
a O 
potent O 
inhibitor O 
of O 
eukaryotic O 
topoisomerase O 
I O 
. O 
Several O 
semi-synthetic O 
derivatives O 
of O 
CPT B-ABBREVIATION 
are O 
in O 
clinical O 
use O 
against O 
ovarian O 
, O 
small O 
lung O 
and O 
refractory O 
ovarian O 
cancers O 
. O 
While O 
CPT B-ABBREVIATION 
is O 
produced O 
by O 
several O 
plant O 
species O 
belonging O 
to O 
the O 
Asterid O 
clade O 
, O 
in O 
recent O 
years O 
, O 
efforts O 
have O 
been O 
made O 
to O 
isolate O 
endophytic O 
fungi O 
from O 
some O 
of O 
these O 
plants O 
as O 
possible O 
alternative O 
sources O 
of O 
CPT B-ABBREVIATION 
. O 
In O 
this O 
study O 
we O 
report O 
the O 
isolation O 
of O 
three O 
endophytic O 
fungi O 
from O 
fruit O 
and O 
seed O 
regions O 
of O 
Miquelia O 
dentata O 
( O 
Icacinaceae O 
) O 
, O 
that O 
produce O 
CPT B-ABBREVIATION 
, O 
9-methoxy B-SYSTEMATIC 
CPT I-SYSTEMATIC 
( O 
9-MeO-CPT B-SYSTEMATIC 
) O 
and O 
10-hydroxy B-SYSTEMATIC 
CPT I-SYSTEMATIC 
( O 
10-OH-CPT B-SYSTEMATIC 
) O 
. O 
All O 
the O 
three O 
fungi O 
identified O 
as O 
, O 
Fomitopsis O 
sp O 
. O 
P O 
. O 
Karst O 
( O 
MTCC O 
10177 O 
) O 
, O 
Alternaria O 
alternata O 
( O 
Fr O 
. O 
) O 
Keissl O 
( O 
MTCC O 
5477 O 
) O 
and O 
Phomposis O 
sp O 
. O 
( O 
Sacc O 
. O 
) O 
produced O 
CPT B-ABBREVIATION 
, O 
9-MeO-CPT B-SYSTEMATIC 
and O 
10-OH-CPT B-SYSTEMATIC 
in O 
mycelial O 
mats O 
in O 
shake O 
flasks O 
containing O 
potato O 
dextrose O 
broth O 
. O 
Methanolic O 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extracts O 
of O 
these O 
fungal O 
species O 
were O 
cytotoxic O 
to O 
colon O 
and O 
breast O 
cancer O 
cell O 
lines O 
. O 
We O 
discuss O 
these O 
results O 
in O 
the O 
context O 
of O 
the O 
recent O 
interest O 
in O 
endophytic O 
fungi O 
as O 
possible O 
alternative O 
sources O 
of O 
plant O 
secondary O 
metabolites O 
. O 

and O 
SAR O 
of O 
aminothiazole B-SYSTEMATIC 
fused O 
benzazepines B-FAMILY 
as O 
selective O 
dopamine B-TRIVIAL 
D2 O 
partial O 
agonists O 
. O 

(D(2)) O 
partial O 
agonists O 
( O 
D2PAs O 
) O 
have O 
been O 
regarded O 
as O 
a O 
potential O 
treatment O 
for O 
schizophrenia O 
patients O 
with O 
expected O 
better O 
side O 
effect O 
profiles O 
than O 
currently O 
marketed O 
antipsychotics O 
. O 
Herein O 
we O 
report O 
the O 
synthesis O 
and O 
SAR O 
of O 
a O 
series O 
of O 
aminothiazole B-SYSTEMATIC 
fused O 
benzazepines B-FAMILY 
as O 
selective O 
D(2) O 
partial O 
agonists O 
. O 
These O 
compounds O 
have O 
good O 
selectivity O 
, O 
CNS O 
drug O 
- O 
like O 
properties O 
and O 
tunable O 
D(2) O 
partial O 
agonism O 
. O 
One O 
of O 
the O 
key O 
compounds O 
, O 
8h O 
, O 
has O 
good O 
in O 
vitro O 
/ O 
in O 
vivo O 
ADME O 
characteristics O 
, O 
and O 
is O 
active O 
in O 
a O 
rat O 
amphetamine B-TRIVIAL 
-induced O 
locomotor O 
activity O 
model O 
. O 

of O 
" O 
Intestinal O 
luminal O 
nitrogen B-SYSTEMATIC 
metabolism O 
: O 
role O 
of O 
the O 
gut O 
microbiota O 
and O 
consequences O 
for O 
the O 
host O 
" O 
. O 

and O 
endogenous O 
proteins O 
are O 
mixed O 
in O 
the O 
small O 
intestinal O 
lumen O 
with O 
the O 
microbiota O 
. O 
Although O 
experimental O 
evidences O 
suggest O 
that O 
the O 
intestinal O 
microbiota O 
is O 
able O 
to O 
incorporate O 
and O 
degrade O 
some O 
of O 
the O 
available O 
amino B-FAMILY 
acids I-FAMILY 
, O 
it O 
appears O 
that O 
the O 
microbiota O 
is O 
also O 
able O 
to O 
synthesize O 
amino B-FAMILY 
acids I-FAMILY 
raising O 
the O 
view O 
that O 
amino B-FAMILY 
acid I-FAMILY 
exchange O 
between O 
the O 
microbiota O 
and O 
host O 
can O 
proceed O 
in O 
both O 
directions O 
. O 
Although O 
the O 
net O 
result O 
of O 
such O 
exchanges O 
remains O 
to O 
be O 
determined O 
, O 
it O 
is O 
likely O 
that O 
a O 
significant O 
part O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
recovered O 
from O 
the O 
alimentary O 
proteins O 
are O 
used O 
by O 
the O 
microbiota O 
. O 
In O 
the O 
large O 
intestine O 
, O 
where O 
the O 
density O 
of O 
bacteria O 
is O 
much O 
higher O 
than O 
in O 
the O 
small O 
intestine O 
and O 
the O 
transit O 
time O 
much O 
longer O 
, O 
the O 
residual O 
undigested O 
luminal O 
proteins O 
and O 
peptides O 
can O 
be O 
degraded O 
in O 
amino B-FAMILY 
acids I-FAMILY 
by O 
the O 
microbiota O 
. O 
These O 
amino B-FAMILY 
acids I-FAMILY 
cannot O 
be O 
absorbed O 
to O 
a O 
significant O 
extent O 
by O 
the O 
colonic O 
epithelium O 
, O 
but O 
are O 
precursors O 
for O 
the O 
synthesis O 
of O 
numerous O 
metabolic O 
end O 
products O 
in O 
reactions O 
made O 
by O 
the O 
microbiota O 
. O 
Among O 
these O 
products O 
, O 
some O 
like O 
short O 
- O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
organic O 
acids O 
are O 
energy O 
substrates O 
for O 
the O 
colonic O 
mucosa O 
and O 
several O 
peripheral O 
tissues O 
while O 
others O 
like O 
sulfide B-SYSTEMATIC 
and O 
ammonia B-SYSTEMATIC 
can O 
affect O 
the O 
energy O 
metabolism O 
of O 
colonic O 
epithelial O 
cells O 
. O 
More O 
work O 
is O 
needed O 
to O 
clarify O 
the O 
overall O 
effects O 
of O 
the O 
intestinal O 
microbiota O 
on O 
nitrogenous O 
compound O 
metabolism O 
and O 
consequences O 
on O 
gut O 
and O 
more O 
generally O 
host O 
health O 
. O 

photoirradiation O 
of O 
benzo[a]pyrene B-SYSTEMATIC 
metabolites O 
: O 
induction O 
of O 
cytotoxicity O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
and O 
lipid O 
peroxidation O 
. O 

( O 
BaP B-ABBREVIATION 
) O 
is O 
a O 
prototype O 
for O 
studying O 
carcinogenesis O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
. O 
We O 
have O 
long O 
been O 
interested O 
in O 
studying O 
the O 
phototoxicity O 
of O 
PAHs B-ABBREVIATION 
. O 
In O 
this O 
study O 
, O 
we O 
determined O 
that O 
metabolism O 
of O 
BaP B-ABBREVIATION 
by O 
human O 
skin O 
HaCaT O 
keratinocytes O 
resulted O 
in O 
six O 
identified O 
phase O 
I O 
metabolites O 
, O 
for O 
example O 
, O 
BaP B-SYSTEMATIC 
trans-7,8-dihydrodiol I-SYSTEMATIC 
( O 
BaP B-SYSTEMATIC 
t-7,8-diol I-SYSTEMATIC 
) O 
, O 
BaP B-SYSTEMATIC 
t-4,5-diol I-SYSTEMATIC 
, O 
BaP B-SYSTEMATIC 
t-9,10-diol I-SYSTEMATIC 
, O 
3-hydroxybenzo[a]pyrene B-SYSTEMATIC 
( O 
3-OH-BaP B-SYSTEMATIC 
) O 
, O 
BaP B-SYSTEMATIC 
( I-SYSTEMATIC 
7,10 I-SYSTEMATIC 
/ I-SYSTEMATIC 
8,9)tetrol I-SYSTEMATIC 
, O 
and O 
BaP B-SYSTEMATIC 
( I-SYSTEMATIC 
7 I-SYSTEMATIC 
/ I-SYSTEMATIC 
8,9,10)tetrol I-SYSTEMATIC 
. O 
The O 
photocytotoxicity O 
of O 
BaP B-ABBREVIATION 
, O 
3-OH-BaP B-SYSTEMATIC 
, O 
BaP B-SYSTEMATIC 
t-7,8-diol I-SYSTEMATIC 
, O 
BaP B-SYSTEMATIC 
trans-7,8-diol-anti-9,10-epoxide I-SYSTEMATIC 
( O 
BPDE B-ABBREVIATION 
) O 
, O 
and O 
BaP B-SYSTEMATIC 
( I-SYSTEMATIC 
7,10 I-SYSTEMATIC 
/ I-SYSTEMATIC 
8,9)tetrol I-SYSTEMATIC 
in O 
the O 
HaCaT O 
keratinocytes O 
was O 
examined O 
. O 
When O 
irradiated O 
with O 
1 O 
J O 
/ O 
cm(2) O 
UVA O 
light O 
, O 
these O 
compounds O 
when O 
tested O 
at O 
doses O 
of O 
0.1 O 
, O 
0.2 O 
, O 
and O 
0.5 O 
μM O 
, O 
all O 
induced O 
photocytotoxicity O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
When O 
photoirradiation O 
was O 
conducted O 
in O 
the O 
presence O 
of O 
a O 
lipid O 
( O 
methyl B-SYSTEMATIC 
linoleate I-SYSTEMATIC 
) O 
, O 
BaP B-ABBREVIATION 
metabolites O 
, O 
BPDE B-ABBREVIATION 
, O 
and O 
three O 
related O 
PAHs B-ABBREVIATION 
, O 
pyrene B-SYSTEMATIC 
, O 
7,8,9,10-tetrahydro-BaP B-SYSTEMATIC 
trans-7,8-diol I-SYSTEMATIC 
, O 
and O 
7,8,9,10-tetrahydro-BaP B-SYSTEMATIC 
trans-9,10-diol I-SYSTEMATIC 
, O 
all O 
induced O 
lipid O 
peroxidation O 
. O 
The O 
formation O 
of O 
lipid O 
peroxides O 
by O 
BaP B-SYSTEMATIC 
t-7,8-diol I-SYSTEMATIC 
was O 
inhibited O 
by O 
NaN3 B-FORMULA 
and O 
enhanced O 
by O 
deuterated B-SYSTEMATIC 
methanol I-SYSTEMATIC 
, O 
which O 
suggests O 
that O 
singlet O 
oxygen B-SYSTEMATIC 
may O 
be O 
involved O 
in O 
the O 
generation O 
of O 
lipid O 
peroxides O 
. O 
The O 
formation O 
of O 
lipid O 
hydroperoxides B-FAMILY 
was O 
partially O 
inhibited O 
by O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
. O 
Electron O 
spin O 
resonance O 
spin O 
trapping O 
experiments O 
indicated O 
that O 
both O 
singlet O 
oxygen B-SYSTEMATIC 
and O 
superoxide B-TRIVIAL 
radical O 
anion O 
were O 
generated O 
from O 
UVA O 
photoirradiation O 
of O 
BPDE B-ABBREVIATION 
in O 
a O 
light O 
dose O 
responding O 
manner O 
. O 

transporters O 
, O 
including O 
two O 
members O 
: O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
( O 
ABC O 
) O 
transporters O 
and O 
solute O 
carrier O 
( O 
SLC O 
) O 
transporters O 
are O 
proteins O 
that O 
play O 
important O 
roles O 
to O 
facilitate O 
molecules O 
into O 
and O 
out O 
of O 
cells O 
. O 
Consequently O 
, O 
these O 
transporters O 
can O 
be O 
major O 
determinants O 
of O 
the O 
therapeutic O 
efficacy O 
, O 
toxicity O 
and O 
pharmacokinetics O 
of O 
a O 
variety O 
of O 
drugs O 
. O 
Considering O 
the O 
time O 
and O 
expense O 
of O 
bio O 
- O 
experiments O 
taking O 
, O 
research O 
should O 
be O 
driven O 
by O 
evaluation O 
of O 
efficacy O 
and O 
safety O 
. O 
Computational O 
methods O 
arise O 
to O 
be O 
a O 
complementary O 
choice O 
. O 
In O 
this O 
article O 
, O 
we O 
provide O 
an O 
overview O 
of O 
the O 
contribution O 
that O 
computational O 
methods O 
made O 
in O 
transporters O 
field O 
in O 
the O 
past O 
decades O 
. O 
At O 
the O 
beginning O 
, O 
we O 
present O 
a O 
brief O 
introduction O 
about O 
the O 
structure O 
and O 
function O 
of O 
major O 
members O 
of O 
two O 
families O 
in O 
transporters O 
. O 
In O 
the O 
second O 
part O 
, O 
we O 
focus O 
on O 
widely O 
used O 
computational O 
methods O 
in O 
different O 
aspects O 
of O 
transporters O 
research O 
. O 
In O 
the O 
absence O 
of O 
a O 
high O 
- O 
resolution O 
structure O 
of O 
most O 
of O 
transporters O 
, O 
homology O 
modeling O 
is O 
a O 
useful O 
tool O 
to O 
interpret O 
experimental O 
data O 
and O 
potentially O 
guide O 
experimental O 
studies O 
. O 
We O 
summarize O 
reported O 
homology O 
modeling O 
in O 
this O 
review O 
. O 
Researches O 
in O 
computational O 
methods O 
cover O 
major O 
members O 
of O 
transporters O 
and O 
a O 
variety O 
of O 
topics O 
including O 
the O 
classification O 
of O 
substrates O 
and O 
/ O 
or O 
inhibitors O 
, O 
prediction O 
of O 
protein O 
- O 
ligand O 
interactions O 
, O 
constitution O 
of O 
binding O 
pocket O 
, O 
phenotype O 
of O 
non-synonymous O 
single O 
- O 
nucleotide O 
polymorphisms O 
, O 
and O 
the O 
conformation O 
analysis O 
that O 
try O 
to O 
explain O 
the O 
mechanism O 
of O 
action O 
. O 
As O 
an O 
example O 
, O 
one O 
of O 
the O 
most O 
important O 
transporters O 
P-gp O 
is O 
elaborated O 
to O 
explain O 
the O 
differences O 
and O 
advantages O 
of O 
various O 
computational O 
models O 
. O 
In O 
the O 
third O 
part O 
, O 
the O 
challenges O 
of O 
developing O 
computational O 
methods O 
to O 
get O 
reliable O 
prediction O 
, O 
as O 
well O 
as O 
the O 
potential O 
future O 
directions O 
in O 
transporter O 
related O 
modeling O 
are O 
discussed O 
. O 

stearoyl-CoA B-TRIVIAL 
desaturase O 
1 O 
( O 
SCD-1 O 
) O 
gene O 
expression O 
is O 
negatively O 
regulated O 
by O 
thyroid B-FAMILY 
hormone I-FAMILY 
without O 
direct O 
binding O 
of O 
thyroid B-FAMILY 
hormone I-FAMILY 
receptor O 
to O 
the O 
gene O 
promoter O 
. O 

desaturase-1 O 
( O 
SCD-1 O 
) O 
plays O 
a O 
pivotal O 
role O 
in O 
an O 
increase O 
of O 
triglyceride B-FAMILY 
by O 
an O 
excess O 
of O 
dietary O 
carbohydrate B-FAMILY 
intake O 
. O 
Dietary O 
carbohydrates B-FAMILY 
increase O 
SCD-1 O 
gene O 
expression O 
in O 
liver O 
by O 
sterol B-FAMILY 
response O 
element O 
binding O 
protein O 
(SREBP)-1c-dependent O 
and O 
SREBP-1c O 
-independent O 
pathways O 
. O 
Previous O 
report O 
demonstrated O 
that O 
thyroid B-FAMILY 
hormone I-FAMILY 
( O 
TH O 
) O 
negatively O 
regulates O 
mouse O 
SCD-1 O 
gene O 
promoter O 
before O 
SREBP-1c O 
was O 
revealed O 
. O 
We O 
reported O 
that O 
TH O 
negatively O 
regulates O 
SREBP-1c O 
recently O 
. O 
Therefore O 
, O 
in O 
the O 
current O 
study O 
, O 
we O 
examined O 
whether O 
and O 
how O 
TH O 
regulates O 
human O 
SCD-1 O 
gene O 
expression O 
and O 
evaluated O 
SREBP-1c O 
effect O 
on O 
the O 
negative O 
regulation O 
. O 
Luciferase O 
assays O 
revealed O 
that O 
TH O 
suppresses O 
both O 
mouse O 
and O 
human O 
SCD-1 O 
gene O 
promoter O 
activity O 
. O 
In O 
SREBP-1 O 
knockdown O 
HepG2 O 
cells O 
, O 
TH O 
still O 
suppresses O 
SCD-1 O 
gene O 
promoter O 
activity O 
, O 
and O 
it O 
also O 
exerted O 
the O 
negative O 
regulation O 
under O 
cotransfection O 
of O 
a O 
small O 
amount O 
of O 
SREBP-1c O 
. O 
These O 
data O 
indicated O 
that O 
SREBP-1c O 
does O 
not O 
play O 
the O 
decisive O 
role O 
for O 
the O 
negative O 
regulation O 
by O 
TH O 
. O 
The O 
responsible O 
region O 
for O 
the O 
negative O 
regulation O 
in O 
human O 
SCD-1 O 
gene O 
promoter O 
turned O 
out O 
to O 
be O 
between O 
-124 O 
and O 
-92 O 
bp O 
, O 
referred O 
to O 
as O 
site O 
A O 
. O 
Chromatin O 
immunoprecipitation O 
assays O 
demonstrated O 
that O 
TH O 
receptor-β O 
is O 
recruited O 
to O 
the O 
region O 
upon O 
T(3) O 
administration O 
, O 
although O 
TR-β O 
does O 
not O 
bind O 
directly O 
to O 
site O 
A O 
. O 
In O 
conclusion O 
, O 
TH O 
negatively O 
regulates O 
human O 
SCD-1 O 
gene O 
expression O 
in O 
without O 
direct O 
binding O 
of O 
the O 
TH O 
receptor O 
to O 
the O 
SCD-1 O 
gene O 
promoter O 
. O 

titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
induces O 
genotoxicity O 
and O 
apoptosis O 
in O 
human O 
lung O 
cancer O 
cell O 
line O 
, O 
A549 O 
. O 

increased O 
inhaled O 
application O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
( O 
TiO(2) B-FORMULA 
NPs O 
) O 
increases O 
the O 
potential O 
pulmonary O 
health O 
risks O 
. O 
The O 
present O 
investigations O 
were O 
carried O 
out O 
to O 
study O 
the O 
TiO(2) B-FORMULA 
NPs-induced O 
apoptosis O 
, O 
oxidative O 
stress O 
and O 
genotoxicity O 
in O 
the O 
human O 
lung O 
cancer O 
cell O 
line O 
, O 
A549 O 
, O 
a O 
widely O 
used O 
cell O 
system O 
for O 
pulmonary O 
toxicity O 
studies O 
. O 
Tetrazolium B-FAMILY 
bromide I-FAMILY 
salt I-FAMILY 
and O 
lactate B-FAMILY 
dehydrogenase O 
release O 
assays O 
were O 
used O 
to O 
study O 
the O 
cytotoxicity O 
. O 
The O 
genotoxicity O 
studies O 
were O 
carried O 
out O 
using O 
cytokinesis O 
block O 
micronucleus O 
assay O 
. O 
Apoptosis O 
was O 
confirmed O 
by O 
the O 
formation O 
of O 
apoptotic O 
bodies O 
and O 
altered O 
expression O 
( O 
messenger O 
RNA O 
( O 
mRNA O 
) O 
and O 
protein O 
) O 
of O 
markers O 
such O 
as O 
P(53) O 
, O 
P(21) O 
, O 
Bax O 
, O 
Bcl(2) O 
and O 
cleaved O 
caspase-3 O 
. O 
Cells O 
exposed O 
to O 
TiO(2) B-FORMULA 
NPs O 
( O 
10 O 
and O 
50 O 
μg O 
/ O 
ml O 
) O 
for O 
6-24 O 
h O 
shows O 
significant O 
induction O 
in O 
oxidative O 
stress O 
, O 
that O 
is O 
, O 
the O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
malondialdehyde B-TRIVIAL 
and O 
decrease O 
in O 
the O 
activity O 
of O 
catalase O 
and O 
glutathione B-TRIVIAL 
. O 
TiO(2) B-FORMULA 
NPs O 
exposure O 
also O 
induces O 
the O 
formation O 
of O 
apoptotic O 
bodies O 
and O 
micronucleus O 
as O 
marker O 
of O 
genotoxicity O 
. O 
A O 
significant O 
up O 
- O 
regulation O 
in O 
the O 
expression O 
of O 
apoptosis O 
markers O 
such O 
as O 
P(53) O 
, O 
P(21) O 
and O 
cleaved O 
caspase-3 O 
was O 
observed O 
, O 
while O 
the O 
levels O 
were O 
down O 
- O 
regulated O 
for O 
Bcl(2) O 
at O 
both O 
mRNA O 
and O 
protein O 
levels O 
. O 
TiO(2) B-FORMULA 
NPs O 
exposure O 
could O 
not O 
pose O 
significant O 
effects O 
on O 
Bax O 
expression O 
. O 
Data O 
indicate O 
that O 
nano- O 
TiO(2) B-FORMULA 
induces O 
oxidative O 
stress O 
, O 
genotoxicity O 
and O 
apoptosis O 
in O 
human O 
lung O 
cancer O 
cell O 
line O 
, O 
A549 O 
. O 
Our O 
result O 
also O 
identifies O 
the O 
mechanisms O 
involved O 
in O 
TiO(2) B-FORMULA 
NP-induced O 
changes O 
in O 
A549 O 
cells O 
. O 
Perhaps O 
, O 
reporting O 
for O 
the O 
first O 
time O 
, O 
the O 
association O 
of O 
TiO(2) B-FORMULA 
NPs-induced O 
genotoxicity O 
and O 
apoptosis O 
at O 
transcriptional O 
and O 
translational O 
level O 
in O 
the O 
human O 
lung O 
cancer O 
cell O 
line O 
, O 
A549 O 
cells O 
. O 

and O 
validation O 
of O 
a O 
simple O 
LC O 
method O 
for O 
the O 
determination O 
of O 
phenacetin B-TRIVIAL 
, O 
coumarin B-TRIVIAL 
, O 
tolbutamide B-TRIVIAL 
, O 
chlorzoxazone B-SYSTEMATIC 
, O 
testosterone B-TRIVIAL 
and O 
their O 
metabolites O 
as O 
markers O 
of O 
cytochromes O 
1A2 O 
, O 
2A6 O 
, O 
2C11 O 
, O 
20 O 
and O 
3A2 O 
in O 
rat O 
microsomal O 
medium O 
. O 

P450 O 
enzymes O 
are O 
responsible O 
for O 
the O 
oxidative O 
metabolism O 
of O 
most O 
pharmaceutical O 
compounds O 
. O 
A O 
" O 
cocktail O 
" O 
approach O 
which O 
employs O 
simultaneous O 
administration O 
of O 
a O 
mixture O 
of O 
substrates O 
of O 
CYP O 
enzymes O 
was O 
often O 
used O 
to O 
assess O 
the O 
metabolic O 
activity O 
of O 
multiple O 
P450 O 
forms O 
in O 
one O 
experiment O 
. O 
Phenacetin B-TRIVIAL 
, O 
coumarin B-TRIVIAL 
, O 
tolbutamide B-TRIVIAL 
, O 
chlorzoxazone B-SYSTEMATIC 
and O 
testosterone B-TRIVIAL 
are O 
commonly O 
used O 
as O 
probe O 
substrates O 
to O 
evaluate O 
cytochrome O 
P450 O 
function O 
. O 
An O 
analytical O 
strategy O 
to O 
simultaneously O 
extract O 
and O 
analyze O 
the O 
five O 
probe O 
substrates O 
and O 
their O 
major O 
metabolites O 
by O 
HPLC-DAD O 
was O 
developed O 
. O 
The O 
incubation O 
was O 
done O 
with O 
all O 
the O 
substrates O 
in O 
one O 
step O 
. O 
The O 
ten O 
analytes O 
were O 
extracted O 
simultaneously O 
by O 
solid O 
- O 
phase O 
extraction O 
( O 
SPE O 
) O 
from O 
rat O 
liver O 
microsomes O 
. O 
A O 
C18 O 
analytical O 
column O 
and O 
mobile O 
phase O 
composed O 
of O 
acetonitrile B-SYSTEMATIC 
and O 
0.02% O 
aqueous O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
were O 
used O 
for O 
the O 
chromatographic O 
separation O 
with O 
DAD O 
detection O 
. O 
Limits O 
of O 
quantification O 
varied O 
between O 
0.02378 O 
and O 
0.2361 O 
microg O 
/ O 
mL O 
which O 
contributed O 
to O 
quantify O 
all O 
these O 
drugs O 
and O 
metabolites O 
with O 
UV O 
detection O 
. O 
The O 
method O 
is O 
applicable O 
for O 
the O 
modeling O 
and O 
description O 
of O 
pharmacological O 
interactions O 
on O 
rat O 
cytochromes O 
P450 O 
or O 
can O 
be O 
used O 
for O 
in O 
vitro O 
evaluation O 
of O 
cytochromes O 
1A2 O 
, O 
2A6 O 
, O 
2C11 O 
, O 
20 O 
and O 
3A2 O 
. O 

glycosides I-FAMILY 
with O 
lipid O 
accumulation O 
inhibitory O 
activity O 
and O 
simultaneous O 
quantitative O 
analysis O 
of O 
15 O 
polyphenols B-FAMILY 
and O 
caffeine B-TRIVIAL 
in O 
the O 
flower O 
buds O 
of O 
Camellia O 
sinensis O 
from O 
different O 
regions O 
by O 
LCMS O 
. O 

simultaneous O 
quantitative O 
analytical O 
method O 
for O 
15 O 
major O 
polyphenols B-FAMILY 
, O 
e.g O 
. O 
five O 
catechins B-FAMILY 
( O 
1-5 O 
) O 
and O 
10 O 
flavonols B-FAMILY 
( O 
6- O 
15 O 
) O 
, O 
as O 
functional O 
constituents O 
in O 
the O 
extracts O 
of O 
" O 
tea O 
flowers O 
" O 
, O 
the O 
flower O 
buds O 
of O 
Camellia O 
sinensis O 
( O 
Theaceae O 
) O 
, O 
has O 
been O 
developed O 
. O 
The O 
content O 
of O 
caffeine B-TRIVIAL 
( O 
16 O 
) O 
, O 
which O 
showed O 
similar O 
chromatographic O 
behaviour O 
under O 
the O 
analytical O 
conditions O 
, O 
was O 
also O 
determined O 
. O 
To O 
approve O 
the O 
validity O 
of O 
the O 
newly O 
developed O 
protocol O 
, O 
thirteen O 
extracts O 
of O 
the O 
plant's O 
flower O 
buds O 
collected O 
from O 
different O 
regions O 
, O 
i.e O 
. O 
China O 
, O 
Taiwan O 
, O 
Japan O 
and O 
India O 
, O 
were O 
evaluated O 
. O 
The O 
results O 
indicated O 
that O 
the O 
assay O 
was O 
reproducible O 
and O 
precise O 
, O 
and O 
could O 
be O 
readily O 
underutilised O 
for O 
the O 
quality O 
evaluation O 
of O 
tea O 
flowers O 
on O 
the O 
basis O 
of O 
polyphenols B-FAMILY 
' O 
contents O 
. O 
It O 
was O 
noteworthy O 
that O 
the O 
contents O 
of O 
two O 
major O 
constituents O 
, O 
kaempferol B-SYSTEMATIC 
3-O-β-d-glucopyranosyl-(1→3)-α-l-rhamnopyranosyl-(1→6)-β-d-glucopyranoside I-SYSTEMATIC 
( O 
10 O 
) O 
and O 
kaempferol B-SYSTEMATIC 
3-O-β-d-glucopyranosyl-(1→3)-α-l-rhamnopyranosyl-(1→6)-β-d-galactopyranoside I-SYSTEMATIC 
( O 
11 O 
) O 
, O 
varied O 
by O 
region O 
where O 
the O 
flower O 
buds O 
were O 
produced O 
. O 
A O 
new O 
flavonol B-FAMILY 
glycoside I-FAMILY 
, O 
chakaflavonoside B-TRIVIAL 
B I-TRIVIAL 
( O 
17 O 
) O 
, O 
which O 
was O 
isolated O 
in O 
the O 
course O 
of O 
this O 
analytical O 
study O 
, O 
was O 
found O 
to O 
show O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
-albumin O 
- O 
induced O 
lipid O 
accumulation O 
inhibitory O 
activity O 
. O 

and O 
biological O 
evaluation O 
of O 
novel O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
inhibitors O 
: O 
Solubilized O 
4- B-FAMILY 
substituted I-FAMILY 
benzimidazole I-FAMILY 
analogs O 
of O 
2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole B-SYSTEMATIC 
( O 
ZSTK474 B-IDENTIFIER 
) O 
. O 

range O 
of O 
4- O 
substituted O 
derivatives O 
of O 
the O 
pan O 
class O 
I O 
PI O 
3-kinase O 
inhibitor O 
2-(difluoromethyl)-1-[4,6-di-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole B-SYSTEMATIC 
( O 
ZSTK474 B-IDENTIFIER 
) O 
were O 
prepared O 
in O 
a O 
search O 
for O 
more O 
soluble O 
analogs O 
. O 
4-Aminoalkoxy B-FAMILY 
substituents O 
provided O 
the O 
most O 
potent O 
derivatives O 
, O 
with O 
the O 
4-O(CH2)3NMe2 B-SYSTEMATIC 
analog O 
(compound O 
14 O 
) O 
being O 
identified O 
as O 
displaying O 
the O 
best O 
overall O 
activity O 
in O 
combination O 
with O 
good O 
aqueous O 
solubility O 
( O 
25 O 
mg O 
/ O 
mL O 
for O 
the O 
hydrochloride B-FAMILY 
salt O 
) O 
. O 
This O 
compound O 
was O 
tested O 
in O 
a O 
U87MG O 
xenograft O 
model O 
, O 
but O 
displayed O 
less O 
potency O 
than O 
ZSTK474 B-IDENTIFIER 
as O 
a O 
result O 
of O 
an O 
unfavorable O 
pharmacokinetic O 
profile O 
. O 

vitro O 
evaluation O 
of O 
the O 
protective O 
effects O 
of O 
4-thujanol B-SYSTEMATIC 
against O 
mitomycin-C B-TRIVIAL 
and O 
cyclophosphamide B-TRIVIAL 
-induced O 
genotoxic O 
damage O 
in O 
human O 
peripheral O 
lymphocytes O 
. O 

( O 
sabinene B-SYSTEMATIC 
hydrate I-SYSTEMATIC 
) O 
, O 
a O 
bicyclic B-FAMILY 
monoterpene I-FAMILY 
alcohol I-FAMILY 
, O 
is O 
found O 
in O 
the O 
essential O 
oils O 
of O 
many O 
aromatic O 
and O 
medicinal O 
plants O 
and O 
is O 
widely O 
used O 
as O 
a O 
fragrance O 
and O 
flavouring O 
agent O 
in O 
many O 
different O 
products O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
protective O 
effects O 
of O 
4-thujanol B-SYSTEMATIC 
against O 
the O 
genotoxic O 
effects O 
induced O 
by O 
mitomycin B-TRIVIAL 
C I-TRIVIAL 
( O 
MMC B-ABBREVIATION 
) O 
and O 
cyclophosphamide B-TRIVIAL 
( O 
CP O 
) O 
in O 
human O 
lymphocytes O 
, O 
using O 
the O 
chromosome O 
aberrations O 
, O 
sister O 
chromatid O 
exchanges O 
, O 
and O 
micronucleus O 
tests O 
, O 
in O 
the O 
absence O 
and O 
in O 
the O 
presence O 
of O 
S9 O 
mix O 
, O 
respectively O 
. O 
The O 
cells O 
were O 
treated O 
with O 
0.25 O 
µg O 
/ O 
mL O 
MMC B-ABBREVIATION 
and O 
28 O 
µg O 
/ O 
mL O 
CP O 
as O 
alone O 
and O 
cotreated O 
with O 
13 O 
+ O 
0.25 O 
, O 
26 O 
+ O 
0.25 O 
, O 
and O 
52 O 
+ O 
0.25 O 
µg O 
/ O 
mL O 
4-thujanol B-SYSTEMATIC 
+ O 
MMC B-ABBREVIATION 
and O 
with O 
13 O 
+ O 
28 O 
, O 
26 O 
+ O 
28 O 
, O 
and O 
52 O 
+ O 
28 O 
µg O 
/ O 
mL O 
4-thujanol B-SYSTEMATIC 
+ O 
CP O 
as O 
a O 
mixture O 
. O 
The O 
present O 
study O 
showed O 
that O 
4-thujanol B-SYSTEMATIC 
was O 
unable O 
to O 
reduce O 
the O 
genetic O 
damage O 
induced O 
by O 
MMC B-ABBREVIATION 
, O 
in O 
the O 
absence O 
of O 
S9 O 
mix O 
. O 
On O 
the O 
other O 
hand O 
, O 
probably O 
the O 
metabolites O 
of O 
4-thujanol B-SYSTEMATIC 
act O 
as O 
an O 
antagonist O 
and O 
markedly O 
antagonize O 
CP-induced O 
genotoxicity O 
, O 
in O 
the O 
presence O 
of O 
S9 O 
mix O 
. O 
In O 
general O 
, O 
4-thujanol B-SYSTEMATIC 
+ O 
MMC B-ABBREVIATION 
and O 
4-thujanol B-SYSTEMATIC 
+ O 
CP O 
decreased O 
the O 
mitotic O 
index O 
, O 
proliferation O 
index O 
and O 
nuclear O 
division O 
index O 
to O 
the O 
same O 
extent O 
or O 
more O 
than O 
those O 
of O 
individual O 
exposure O 
of O 
MMC B-ABBREVIATION 
or O 
CP O 
. O 
In O 
conclusion O 
, O 
4-thujanol B-SYSTEMATIC 
significantly O 
reduced O 
( O 
p O 
< O 
0.001 O 
) O 
the O 
genotoxic O 
damage O 
induced O 
by O 
CP O 
but O 
not O 
MMC B-ABBREVIATION 
when O 
compared O 
with O 
the O 
respective O 
positive O 
control O 
alone O 
. O 
We O 
can O 
suggest O 
that O 
4-thujanol B-SYSTEMATIC 
may O 
improve O 
the O 
chemopreventive O 
effects O 
and O 
may O 
also O 
reduce O 
the O 
harmful O 
side O 
effects O 
of O 
CP O 
, O 
which O 
is O 
widely O 
used O 
in O 
chemotherapy O 
against O 
cancer O 
, O 
without O 
reducing O 
its O 
antiproliferative O 
activities O 
. O 

and O 
Characterization O 
of O 
Molecular O 
Nonwoven O 
Fabrics O 
Consisting O 
of O 
Cross O 
- O 
Linked O 
Poly(γ-methyl-l-glutamate) B-FAMILY 
. O 

nonwoven O 
fabrics O 
in O 
the O 
form O 
of O 
ultrathin O 
layer O 
- O 
by O 
- O 
layer O 
( O 
LbL O 
) O 
helical O 
polymer O 
films O 
with O 
covalent O 
cross O 
- O 
linking O 
were O 
assembled O 
on O 
substrates O 
by O 
an O 
alternate O 
ester B-FAMILY 
- O 
amide B-FAMILY 
exchange O 
reaction O 
between O 
poly(γ-methyl B-FAMILY 
l-glutamate I-FAMILY 
) I-FAMILY 
( O 
PMLG B-ABBREVIATION 
) O 
and O 
cross O 
- O 
linking O 
agent O 
ethylene B-SYSTEMATIC 
diamine I-SYSTEMATIC 
or O 
4,4'-diamino B-SYSTEMATIC 
azobenzene I-SYSTEMATIC 
. O 
The O 
regular O 
growth O 
of O 
helical O 
monolayers O 
without O 
excessive O 
adsorption O 
and O 
the O 
formation O 
of O 
amide B-FAMILY 
bonds O 
were O 
confirmed O 
by O 
ultraviolet O 
- O 
visible O 
( O 
UV-vis O 
) O 
spectrophotometry O 
, O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
( O 
QCM O 
) O 
, O 
ellipsometry O 
, O 
and O 
infrared O 
reflection O 
- O 
absorption O 
spectroscopy O 
( O 
IR-RAS O 
) O 
measurements O 
. O 
Nanostructures O 
with O 
high O 
uniformity O 
and O 
ultrathin O 
films O 
with O 
few O 
defects O 
formed O 
by O 
helical O 
rod O 
segments O 
of O 
PMLG B-ABBREVIATION 
were O 
characterized O 
by O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
and O 
Kelvin O 
probe O 
force O 
microscopy O 
( O 
KFM O 
) O 
. O 

berry O 
( O 
Aristotelia O 
chilensis O 
) O 
and O 
the O 
constituent O 
delphinidin B-FAMILY 
glycoside I-FAMILY 
inhibit O 
photoreceptor O 
cell O 
death O 
induced O 
by O 
visible O 
light O 
. O 

protective O 
effects O 
of O 
maqui O 
berry O 
( O 
Aristotelia O 
chilensis O 
) O 
extract O 
( O 
MBE O 
) O 
and O 
its O 
major O 
anthocyanins B-FAMILY 
[ O 
delphinidin B-SYSTEMATIC 
3,5-O-diglucoside I-SYSTEMATIC 
( O 
D3G5G B-SYSTEMATIC 
) O 
and O 
delphinidin B-SYSTEMATIC 
3-O-sambubioside-5-O-glucoside I-SYSTEMATIC 
( O 
D3S5G B-SYSTEMATIC 
) O 
] O 
against O 
light O 
- O 
induced O 
murine O 
photoreceptor O 
cells O 
( O 
661W O 
) O 
death O 
were O 
evaluated O 
. O 
Viability O 
of O 
661W O 
after O 
light O 
treatment O 
for O 
24h O 
, O 
assessed O 
by O 
the O 
tetrazolium B-SYSTEMATIC 
salt O 
( O 
WST-8 O 
) O 
assay O 
and O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
nuclear O 
staining O 
, O 
was O 
improved O 
by O 
addition O 
of O 
MBE O 
, O 
D3G5G B-SYSTEMATIC 
, O 
and O 
D3S5G B-SYSTEMATIC 
. O 
Intracellular O 
radical O 
activation O 
in O 
661W O 
, O 
evaluated O 
using O 
the O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
(ROS)-sensitive O 
probe O 
5-(and-6)-chloromethyl-2,7-dichlorodihydro B-MULTIPLE 
fluorescein I-MULTIPLE 
diacetate I-MULTIPLE 
acetyl I-MULTIPLE 
ester I-MULTIPLE 
( O 
CM-H2DCFDA B-ABBREVIATION 
) O 
, O 
was O 
reduced O 
by O 
MBE O 
and O 
its O 
anthocyanins B-FAMILY 
. O 
The O 
anti-apoptosis O 
mechanism O 
of O 
MBE O 
was O 
evaluated O 
by O 
light O 
- O 
induced O 
phosphorylation O 
of O 
p38 O 
. O 
MBE O 
significantly O 
suppressed O 
the O 
light O 
- O 
induced O 
phosphorylation O 
of O 
p38 O 
. O 
These O 
findings O 
indicate O 
that O 
MBE O 
and O 
its O 
anthocyanidins B-FAMILY 
suppress O 
the O 
light O 
- O 
induced O 
photoreceptor O 
cell O 
death O 
by O 
inhibiting O 
ROS O 
production O 
, O 
suggesting O 
that O 
the O 
inhibition O 
of O 
phosphorylated-p38 O 
may O 
be O 
involved O 
in O 
the O 
underlying O 
mechanism O 
. O 

delivery O 
of O 
an O 
aerosolized O 
recombinant O 
human O 
butyrylcholinesterase O 
pretreatment O 
protects O 
against O 
aerosolized O 
paraoxon B-TRIVIAL 
in O 
macaques O 
. O 

( O 
BChE O 
) O 
is O 
the O 
leading O 
pretreatment O 
candidate O 
against O 
exposure O 
to O 
organophosphates B-FAMILY 
( O 
OPs O 
) O 
, O 
which O 
pose O 
an O 
ever O 
increasing O 
public O 
and O 
military O 
health O 
. O 
Since O 
respiratory O 
failure O 
is O 
the O 
primary O 
cause O 
of O 
death O 
following O 
acute O 
OP O 
poisoning O 
, O 
an O 
inhaled O 
BChE O 
therapeutic O 
could O 
prove O 
highly O 
efficacious O 
in O 
preventing O 
acute O 
toxicity O 
as O 
well O 
as O 
the O 
associated O 
delayed O 
neuropathy O 
. O 
To O 
address O 
this O 
, O 
studies O 
have O 
been O 
performed O 
in O 
mice O 
and O 
macaques O 
using O 
Chinese O 
Hamster O 
Ovary O 
cells O 
( O 
CHO O 
) O 
- O 
derived O 
recombinant O 
( O 
r O 
) O 
BChE O 
delivered O 
by O 
the O 
pulmonary O 
route O 
, O 
to O 
examine O 
whether O 
the O 
deposition O 
of O 
both O 
macaque O 
( O 
Ma O 
) O 
and O 
human O 
( O 
Hu O 
) O 
rBChE O 
administered O 
as O 
aerosols O 
( O 
aer O 
) O 
favored O 
the O 
creation O 
and O 
retention O 
of O 
an O 
efficient O 
protective O 
" O 
pulmonary O 
bioshield O 
" O 
that O 
could O 
scavenge O 
incoming O 
( O 
inhaled O 
) O 
OPs O 
in O 
situ O 
thereby O 
preventing O 
entry O 
into O 
the O 
circulation O 
and O 
inhibition O 
of O 
plasma O 
BChE O 
and O 
AChE O 
on O 
red O 
blood O 
cells O 
( O 
RBC-AChE O 
) O 
and O 
in O 
cholinergic O 
synapses O 
. O 
In O 
contrast O 
to O 
parenteral O 
delivery O 
of O 
rBChE O 
, O 
which O 
currently O 
requires O 
posttranslational O 
modification O 
for O 
good O 
plasma O 
stability O 
, O 
an O 
unmodified O 
aer-rBChE O 
pretreatment O 
given O 
1-40h O 
prior O 
to O 
> O 
1 O 
LD50 O 
of O 
aer- O 
paraoxon B-TRIVIAL 
( O 
Px O 
) O 
was O 
able O 
to O 
prevent O 
inhibition O 
of O 
circulating O 
cholinesterase O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
These O 
studies O 
are O 
the O 
first O 
to O 
show O 
protection O 
by O 
rBChE O 
against O 
a O 
pesticide O 
such O 
as O 
paraoxon B-TRIVIAL 
when O 
delivered O 
directly O 
into O 
the O 
lung O 
and O 
bode O 
well O 
for O 
the O 
use O 
of O 
a O 
non-invasive O 
and O 
consumer O 
friendly O 
method O 
of O 
rHuBChE O 
delivery O 
as O 
a O 
human O 
treatment O 
to O 
counteract O 
OP O 
toxicity O 
. O 

acetonide I-TRIVIAL 
intravitreal O 
implant O 
( O 
Iluvien B-TRIVIAL 
® O 
) O 
: O 
in O 
diabetic O 
macular O 
oedema O 
. O 

acetonide I-TRIVIAL 
intravitreal O 
implant O 
( O 
Iluvien B-TRIVIAL 
® O 
) O 
is O 
an O 
injectable O 
, O 
non-erodible O 
, O 
corticosteroid B-TRIVIAL 
implant O 
that O 
is O 
approved O 
in O 
several O 
European O 
countries O 
for O 
the O 
treatment O 
of O 
chronic O 
diabetic O 
macular O 
oedema O 
( O 
DMO O 
) O 
. O 
In O 
analyses O 
of O 
two O 
multinational O 
trials O 
in O 
patients O 
with O 
DMO O 
previously O 
treated O 
with O 
macular O 
laser O 
photocoagulation O 
, O 
fluocinolone B-TRIVIAL 
acetonide I-TRIVIAL 
intravitreal O 
implant O 
0.2 O 
μg O 
/ O 
day O 
was O 
significantly O 
more O 
efficacious O 
than O 
sham O 
injection O 
in O 
improving O 
visual O 
acuity O 
. O 
At O 
24 O 
months O 
post O 
injection O 
, O 
29 O 
% O 
of O 
fluocinolone B-TRIVIAL 
acetonide I-TRIVIAL 
intravitreal O 
implant O 
0.2 O 
μg O 
/ O 
day O 
recipients O 
had O 
an O 
improvement O 
in O 
the O 
best O 
- O 
corrected O 
visual O 
acuity O 
( O 
BCVA O 
) O 
letter O 
score O 
of O 
≥ O 
15 O 
compared O 
with O 
16 O 
% O 
in O 
the O 
sham O 
injection O 
group O 
( O 
p O 
= O 
0.002 O 
) O 
[ O 
primary O 
endpoint O 
] O 
. O 
Treatment O 
benefit O 
was O 
most O 
evident O 
in O 
the O 
subgroup O 
of O 
patients O 
whose O 
duration O 
of O 
DMO O 
was O 
≥ O 
3 O 
years O 
. O 
In O 
this O 
subgroup O 
at O 
36 O 
months O 
, O 
34 O 
% O 
of O 
fluocinolone B-TRIVIAL 
acetonide I-TRIVIAL 
intravitreal O 
implant O 
0.2 O 
μg O 
/ O 
day O 
recipients O 
had O 
an O 
increase O 
in O 
the O 
BCVA O 
score O 
of O 
≥ O 
15 O 
, O 
compared O 
with O 
13 O 
% O 
of O 
sham O 
injection O 
recipients O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Fluocinolone B-TRIVIAL 
acetonide I-TRIVIAL 
intravitreal O 
implant O 
recipients O 
also O 
had O 
generally O 
greater O 
benefits O 
than O 
sham O 
injection O 
recipients O 
on O 
secondary O 
endpoints O 
. O 
In O 
patients O 
who O 
were O 
phakic O 
in O 
the O 
study O 
eye O 
at O 
baseline O 
, O 
cataracts O 
occurred O 
in O 
82 O 
% O 
of O 
fluocinolone B-TRIVIAL 
acetonide I-TRIVIAL 
intravitreal O 
implant O 
0.2 O 
μg O 
/ O 
day O 
recipients O 
and O 
51 O 
% O 
of O 
sham O 
injection O 
recipients O 
. O 
Overall O 
, O 
37 O 
% O 
and O 
12 O 
% O 
of O 
patients O 
in O 
the O 
fluocinolone B-TRIVIAL 
acetonide I-TRIVIAL 
intravitreal O 
implant O 
and O 
sham O 
injection O 
groups O 
developed O 
raised O 
intraocular O 
pressure O 
( O 
IOP O 
) O 
, O 
which O 
was O 
generally O 
controlled O 
with O 
IOP-lowering O 
drugs O 
. O 

anemones O 
possess O 
a O 
number O 
of O 
peptide O 
toxins O 
that O 
target O 
ion O 
channels O 
which O 
provide O 
powerful O 
tools O 
to O 
study O 
the O 
molecular O 
basis O 
of O 
diverse O 
signaling O 
pathways O 
. O 
It O 
is O 
also O 
acknowledged O 
that O 
currents O 
through O 
Erg1 O 
K(+) B-FORMULA 
channels O 
in O 
cardiac O 
myocytes O 
are O 
important O 
for O 
electrical O 
stability O 
of O 
the O 
heart O 
and O 
alterations O 
in O 
its O 
activity O 
has O 
been O 
linked O 
to O 
the O 
onset O 
of O 
a O 
potentially O 
life O 
- O 
threatening O 
heart O 
condition O 
named O 
long O 
QT O 
syndrome O 
type O 
2 O 
. O 
Here O 
, O 
we O 
report O 
that O 
a O 
crude O 
extract O 
from O 
sea O 
anemone O 
Condylactis O 
gigantea O 
significantly O 
increases O 
the O 
QT O 
interval O 
and O 
has O 
arrhythmogenic O 
effects O 
in O 
the O 
rat O 
heart O 
. O 
Furthermore O 
, O 
a O 
bioassay O 
- O 
guided O 
purification O 
procedure O 
allowed O 
the O 
isolation O 
of O 
a O 
chromatographic O 
fraction O 
containing O 
a O 
major O 
component O 
with O 
a O 
molecular O 
mass O 
of O 
4478 O 
Da O 
from O 
the O 
crude O 
extract O 
, O 
which O 
causes O 
a O 
significant O 
inhibition O 
of O 
whole O 
- O 
cell O 
patch O 
- O 
clamp O 
currents O 
through O 
recombinant O 
Erg1 O 
channels O 
, O 
responsible O 
of O 
the O 
rapid O 
delayed O 
rectifying O 
current O 
crucial O 
for O 
electrical O 
activity O 
in O 
the O 
heart O 
. O 
Further O 
studies O 
could O 
provide O 
relevant O 
information O 
on O 
the O 
molecular O 
mechanism O 
of O 
C O 
. O 
gigantea O 
peptide O 
toxins O 
which O 
represent O 
promising O 
tools O 
in O 
studying O 
the O 
physiology O 
of O 
diverse O 
ion O 
channels O 
. O 

fluoride I-SYSTEMATIC 
induces O 
apoptosis O 
in O 
odontoblasts O 
via O 
a O 
JNK-dependent O 
mechanism O 
. O 

fluoride I-SYSTEMATIC 
( O 
NaF B-FORMULA 
) O 
is O 
widely O 
used O 
for O 
the O 
treatment O 
of O 
dental O 
caries O 
and O 
dentin O 
hypersensitivity O 
. O 
However O 
, O 
its O 
pro O 
- O 
apoptotic O 
effect O 
on O 
odontoblasts O 
may O 
lead O 
to O 
harmful O 
side-effects O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
pro O 
- O 
apoptotic O 
effects O 
of O 
NaF B-FORMULA 
in O 
odontoblasts O 
and O 
elucidate O 
the O 
possible O 
underlying O 
molecular O 
mechanisms O 
. O 
NaF B-FORMULA 
generated O 
cytotoxic O 
effects O 
in O 
odontoblast O 
- O 
lineage O 
cell O 
( O 
OLC O 
) O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
Exposure O 
of O 
cells O 
to O 
4mM O 
NaF B-FORMULA 
for O 
24h O 
induced O 
caspase-3 O 
activation O 
, O 
ultrastructural O 
alterations O 
, O 
and O 
resulted O 
in O 
the O 
translocation O 
of O 
Bax O 
to O 
the O 
mitochondria O 
and O 
the O 
release O 
of O 
cytochrome O 
c O 
from O 
the O 
mitochondrial O 
inter O 
- O 
membrane O 
space O 
into O 
the O 
cytosol O 
, O 
indicating O 
that O 
fluoride B-SYSTEMATIC 
-mediated O 
apoptosis O 
is O 
mitochondria O 
- O 
dependent O 
. O 
Fluoride B-SYSTEMATIC 
treatment O 
also O 
increased O 
phosphorylation O 
of O 
JNK O 
and O 
ERK O 
, O 
but O 
not O 
p38 O 
, O 
and O 
apoptosis O 
induced O 
by O 
fluoride B-SYSTEMATIC 
was O 
notably O 
or O 
partly O 
suppressed O 
by O 
treatment O 
with O 
JNK O 
or O 
ERK O 
inhibitors O 
, O 
respectively O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
suggest O 
that O 
NaF B-FORMULA 
induces O 
apoptosis O 
in O 
OLC O 
odontoblasts O 
through O 
a O 
JNK-dependent O 
mitochondrial O 
pathway O 
. O 

- O 
based O 
grapefruit O 
juice O 
(GFJ)-drug O 
interactions O 
are O 
mainly O 
due O 
to O 
mechanism O 
- O 
based O 
irreversible O 
inhibition O 
of O 
metabolizing O 
enzyme O 
CYP3A4 O 
by O 
GFJ O 
components O 
, O 
but O 
the O 
transporter O 
organic O 
anion O 
transporting O 
polypeptide O 
(OATP)2B1 O 
is O 
also O 
a O 
putative O 
site O 
of O 
interaction O 
between O 
drugs O 
and O 
fruit O 
juices O 
( O 
FJ O 
) O 
in O 
the O 
absorption O 
process O 
. O 
Here O 
we O 
aimed O 
to O 
investigate O 
the O 
effect O 
of O 
preincubation O 
with O 
FJ O 
on O 
OATP2B1 O 
- O 
mediated O 
transport O 
of O 
drugs O 
in O 
vitro O 
. O 
When O 
OATP2B1-expressing O 
Xenopus O 
oocytes O 
were O 
preincubated O 
with O 
GFJ O 
, O 
orange O 
juice O 
( O 
OJ O 
) O 
, O 
or O 
apple O 
juice O 
( O 
AJ O 
) O 
, O 
AJ O 
induced O 
a O 
remarkable O 
decrease O 
in O 
OATP2B1 O 
- O 
mediated O 
estrone-3-sulfate B-SYSTEMATIC 
uptake O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
( O 
IC(50) O 
= O 
1.5% O 
) O 
. O 
A O 
similar O 
but O 
less O 
potent O 
effect O 
was O 
observed O 
with O 
OJ O 
( O 
IC(50) O 
= O 
21% O 
) O 
, O 
whereas O 
GFJ O 
had O 
no O 
effect O 
. O 
Similar O 
results O 
were O 
obtained O 
in O 
preincubation O 
studies O 
using O 
fexofenadine B-TRIVIAL 
. O 
Preincubation O 
with O 
OJ O 
and O 
AJ O 
resulted O 
in O 
time O 
- O 
dependent O 
inhibition O 
of O 
OATP2B1 O 
. O 
Again O 
, O 
AJ O 
had O 
the O 
more O 
potent O 
effect O 
; O 
its O 
action O 
lasted O 
for O 
at O 
least O 
240 O 
minutes O 
, O 
suggesting O 
that O 
AJ O 
irreversibly O 
inhibits O 
OATP2B1 O 
- O 
mediated O 
drug O 
uptake O 
. O 
Kinetic O 
analysis O 
revealed O 
that O 
coincubation O 
and O 
preincubation O 
with O 
AJ O 
reduced O 
OATP2B1 O 
- O 
mediated O 
estrone-3-sulfate B-SYSTEMATIC 
uptake O 
via O 
competitive O 
and O 
noncompetitive O 
mechanisms O 
, O 
respectively O 
. O 
Thus O 
, O 
OATP2B1 O 
is O 
functionally O 
impaired O 
through O 
both O 
competitive O 
and O 
long O 
- O 
lasting O 
inhibition O 
mechanisms O 
by O 
AJ O 
and O 
OJ O 
, O 
but O 
not O 
GFJ O 
. O 
Interestingly O 
, O 
although O 
GFJ O 
but O 
not O 
AJ O 
is O 
able O 
to O 
irreversibly O 
inhibit O 
CYP3A4 O 
, O 
in O 
the O 
case O 
of O 
OATP2B1 O 
, O 
AJ O 
but O 
not O 
GFJ O 
has O 
a O 
long O 
- O 
lasting O 
inhibitory O 
effect O 
. O 
Accordingly O 
, O 
complex O 
FJ-drug O 
interactions O 
may O 
occur O 
in O 
vivo O 
, O 
and O 
their O 
clinical O 
significance O 
should O 
be O 
examined O 
. O 

( O 
CT-1 O 
) O 
, O 
a O 
member O 
of O 
the O 
interleukin O 
(IL)-6 O 
family O 
, O 
is O 
reported O 
to O 
exhibit O 
a O 
plethora O 
of O 
pleiotropic O 
effects O 
in O 
the O 
heart O 
such O 
as O 
cytoprotective O 
, O 
pro O 
- O 
proliferative O 
and O 
pro O 
- O 
fibrotic O 
ones O 
. O 
An O 
extensive O 
research O 
has O 
been O 
devoted O 
on O 
proliferative O 
and O 
profibrotic O 
effects O 
of O 
CT-1 O 
on O 
the O 
heart O 
. O 
Thus O 
the O 
present O 
review O 
has O 
been O 
aimed O 
to O 
critically O 
define O 
the O 
cytoprotective O 
effects O 
of O 
CT-1 O 
and O 
the O 
cellular O 
and O 
molecular O 
mechanisms O 
involved O 
in O 
them O 
. O 
Although O 
many O 
effects O 
of O 
CT-1 O 
have O 
been O 
described O 
on O 
the O 
heart O 
, O 
CT-1 O 
has O 
now O 
also O 
been O 
reported O 
to O 
exhibit O 
important O 
protective O 
effects O 
in O 
other O 
organs O 
such O 
as O 
liver O 
, O 
kidney O 
or O 
nervous O 
system O 
. O 
CT-1 O 
produces O 
its O 
effects O 
through O 
a O 
unique O 
receptor O 
system O 
comprising O 
LIF O 
receptor O 
( O 
LIFRβ O 
) O 
and O 
a O 
common O 
signal O 
transducer O 
, O 
the O 
glycoprotein O 
130 O 
( O 
gp130 O 
) O 
. O 
The O 
signaling O 
pathway O 
downstream O 
from O 
gp130 O 
is O 
based O 
on O 
at O 
least O 
, O 
three O 
distinct O 
pathways O 
: O 
1 O 
) O 
the O 
janus O 
kinase O 
/ O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
( O 
JAK O 
/ O 
STAT O 
) O 
pathway O 
, O 
2 O 
) O 
the O 
p42 O 
/ O 
44 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
p42 O 
/ O 
44 O 
MAPK O 
) O 
pathway O 
, O 
also O 
known O 
as O 
the O 
extracellular O 
receptor O 
kinase-1 O 
/ O 
2 O 
( O 
ERK1 O 
/ O 
2 O 
) O 
pathway O 
, O 
and O 
3 O 
) O 
the O 
phosphatidylinositol B-FAMILY 
3-OH I-FAMILY 
kinase O 
( O 
PI3K O 
) O 
/ O 
Akt O 
pathway O 
. O 
Since O 
CT-1 O 
easily O 
achieves O 
its O 
cytoprotective O 
effects O 
via O 
a O 
combination O 
of O 
the O 
above O 
three O 
signaling O 
pathways O 
, O 
it O 
becomes O 
quite O 
necessary O 
to O 
determine O 
which O 
pathway(s) O 
is O 
involved O 
in O 
each O 
particular O 
effect O 
of O 
CT-1 O 
. O 
In O 
each O 
of O 
its O 
target O 
organs O 
, O 
CT-1 O 
may O 
also O 
display O 
differential O 
mechanisms O 
of O 
cytoprotection O 
, O 
and O 
thus O 
it O 
is O 
relevant O 
to O 
understand O 
how O 
these O 
mechanisms O 
are O 
locally O 
regulated O 
. O 

acid I-SYSTEMATIC 
( O 
12-HSA B-SYSTEMATIC 
) O 
xerogels O 
derived O 
from O 
12-HSA B-SYSTEMATIC 
- O 
acetronitrile B-SYSTEMATIC 
organogels O 
are O 
highly O 
effective O 
sorbent O 
materials O 
capable O 
of O 
adsorbing O 
apolar O 
, O 
spilled O 
materials O 
in O 
aqueous O 
environments O 
. O 
12-HSA B-SYSTEMATIC 
xerogels O 
made O 
from O 
12-HSA B-SYSTEMATIC 
- O 
acetronitrile B-SYSTEMATIC 
organogels O 
are O 
more O 
effective O 
than O 
12-HSA B-SYSTEMATIC 
xerogels O 
made O 
from O 
12-HSA B-SYSTEMATIC 
- O 
pentane B-SYSTEMATIC 
organogels O 
because O 
of O 
the O 
highly O 
branched O 
fibrillar O 
networks O 
established O 
in O 
acetonitrile B-SYSTEMATIC 
molecular O 
gels O 
. O 
This O 
difference O 
arises O 
because O 
of O 
dissimilarities O 
in O 
the O 
network O 
structure O 
between O 
12-HSA B-SYSTEMATIC 
in O 
various O 
solvents O 
. O 
These O 
xerogels O 
, O 
being O 
thermoreversible O 
, O 
allow O 
for O 
both O 
the O 
spilled O 
oil O 
to O 
be O 
reclaimed O 
but O 
also O 
the O 
gelator O 
may O 
be O 
reused O 
to O 
engineer O 
new O 
xerogels O 
for O 
oil O 
spill O 
containment O 
and O 
cleanup O 
. O 

Mus O 
musculus O 
myosin-18A O 
gene O 
is O 
expressed O 
as O 
two O 
alternatively O 
spliced O 
isoforms O 
, O 
α O 
and O 
β O 
, O 
with O 
reported O 
roles O 
in O 
Golgi O 
localization O 
, O 
in O 
maintenance O 
of O 
cytoskeleton O 
, O 
and O 
as O 
receptors O 
for O 
immunological O 
surfactant O 
proteins O 
. O 
Both O 
myosin-18A O 
isoforms O 
feature O 
a O 
myosin O 
motor O 
domain O 
, O 
a O 
single O 
predicted O 
IQ O 
motif O 
, O 
and O 
a O 
long O 
coiled O 
- O 
coil O 
reminiscent O 
of O 
myosin-2 O 
. O 
The O 
myosin-18Aα O 
isoform O 
, O 
additionally O 
, O 
has O 
an O 
N B-FORMULA 
-terminal O 
PDZ O 
domain O 
. O 
Recombinant O 
heavy O 
meromyosin- O 
and O 
subfragment-1 O 
( O 
S1 O 
) O 
- O 
like O 
constructs O 
for O 
both O 
myosin-18Aα O 
and O 
-18β O 
species O 
were O 
purified O 
from O 
the O 
baculovirus O 
/ O 
Sf9 O 
cell O 
expression O 
system O 
. O 
These O 
constructs O 
bound O 
both O 
essential O 
and O 
regulatory O 
light O 
chains O 
, O 
indicating O 
an O 
additional O 
noncanonical O 
light O 
chain O 
binding O 
site O 
in O 
the O 
neck O 
. O 
Myosin-18Aα-S1 O 
and O 
-18Aβ-S1 O 
molecules O 
bound O 
actin O 
weakly O 
with O 
Kd O 
values O 
of O 
4.9 O 
and O 
54 O 
μm O 
, O 
respectively O 
. O 
The O 
actin O 
binding O 
data O 
could O 
be O 
modeled O 
by O 
assuming O 
an O 
equilibrium O 
between O 
two O 
myosin O 
conformations O 
, O 
a O 
competent O 
and O 
an O 
incompetent O 
form O 
to O 
bind O 
actin O 
. O 
Actin O 
binding O 
was O 
unchanged O 
by O 
presence O 
of O 
nucleotide B-FAMILY 
. O 
Both O 
myosin-18A O 
isoforms O 
bound O 
N-methylanthraniloyl-nucleotides B-FAMILY 
, O 
but O 
the O 
rate O 
of O 
ATP B-ABBREVIATION 
hydrolysis O 
was O 
very O 
slow O 
( O 
< O 
0.002 O 
s(-1) O 
) O 
and O 
not O 
significantly O 
enhanced O 
by O 
actin O 
. O 
Phosphorylation O 
of O 
the O 
regulatory O 
light O 
chain O 
had O 
no O 
effect O 
on O 
ATP B-ABBREVIATION 
hydrolysis O 
, O 
and O 
neither O 
did O 
the O 
addition O 
of O 
tropomyosin O 
or O 
of O 
GOLPH3 O 
, O 
a O 
myosin-18A O 
binding O 
partner O 
. O 
Electron O 
microscopy O 
of O 
myosin-18A-S1 O 
showed O 
that O 
the O 
lever O 
is O 
strongly O 
angled O 
with O 
respect O 
to O 
the O 
long O 
axis O 
of O 
the O 
motor O 
domain O 
, O 
suggesting O 
a O 
pre O 
- O 
power O 
stroke O 
conformation O 
regardless O 
of O 
the O 
presence O 
of O 
ATP B-ABBREVIATION 
. O 
These O 
data O 
lead O 
us O 
to O 
conclude O 
that O 
myosin-18A O 
does O 
not O 
operate O 
as O 
a O 
traditional O 
molecular O 
motor O 
in O 
cells O 
. O 

parameters O 
in O 
exfoliating O 
graphite B-TRIVIAL 
into O 
graphene B-TRIVIAL 
. O 

graphite B-TRIVIAL 
into O 
few O 
- O 
layers O 
graphene B-TRIVIAL 
sheets O 
( O 
GS O 
) O 
in O 
water O 
is O 
very O 
appealing O 
as O 
an O 
environmental O 
- O 
friendly O 
, O 
low O 
- O 
cost O 
, O 
low O 
- O 
energy O 
method O 
of O 
obtaining O 
graphene B-TRIVIAL 
. O 
Very O 
high O 
GS O 
concentrations O 
in O 
water O 
( O 
0.7 O 
mg O 
mL(-1) O 
) O 
were O 
obtained O 
by O 
optimizing O 
the O 
nature O 
of O 
dispersant O 
and O 
the O 
type O 
of O 
ultra O 
- O 
sonic O 
generator O 
. O 
We O 
find O 
that O 
a O 
multi O 
- O 
step O 
sonication O 
procedure O 
involving O 
both O 
tip O 
and O 
bath O 
sources O 
considerably O 
enhances O 
the O 
yield O 
of O 
exfoliated O 
GS O 
. O 
Raman O 
and O 
transmission O 
electron O 
microscopy O 
indicate O 
few O 
- O 
layers O 
graphene B-TRIVIAL 
patches O 
with O 
typical O 
size O 
of O 
∼0.65 O 
μm O 
in O 
one O 
dimension O 
and O 
∼0.35 O 
μm O 
in O 
the O 
other O 
. O 
These O 
were O 
further O 
employed O 
in O 
combination O 
with O 
water O 
- O 
dispersed O 
CNTs O 
to O 
fabricate O 
conductive O 
transparent O 
electrodes O 
for O 
a O 
molecularly O 
- O 
controlled O 
solar O 
- O 
cell O 
with O 
an O 
open O 
- O 
circuit O 
voltage O 
of O 
0.53 O 
V O 
. O 

Can O 
We O 
Learn O 
about O 
Dispersion O 
from O 
the O 
Conformer O 
Surface O 
of O 
n-Pentane B-SYSTEMATIC 
? O 

earlier O 
work O 
[ O 
Gruzman O 
, O 
D O 
. O 
; O 
Karton O 
, O 
A O 
. O 
; O 
Martin O 
, O 
J O 
. O 
M O 
. O 
L O 
. O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
A O 
2009 O 
, O 
113 O 
, O 
11974 O 
] O 
, O 
we O 
showed O 
that O 
conformer O 
energies O 
in O 
alkanes B-FAMILY 
( O 
and O 
other O 
systems O 
) O 
are O 
highly O 
dispersion O 
- O 
driven O 
and O 
that O 
uncorrected O 
DFT O 
functionals O 
fail O 
badly O 
at O 
reproducing O 
them O 
, O 
while O 
simple O 
empirical O 
dispersion O 
corrections O 
tend O 
to O 
overcorrect O 
. O 
To O 
gain O 
greater O 
insight O 
into O 
the O 
nature O 
of O 
the O 
phenomenon O 
, O 
we O 
have O 
mapped O 
the O 
torsional O 
surface O 
of O 
n-pentane B-SYSTEMATIC 
to O 
10-degree O 
resolution O 
at O 
the O 
CCSD(T)-F12 O 
level O 
near O 
the O 
basis O 
set O 
limit O 
. O 
The O 
data O 
obtained O 
have O 
been O 
decomposed O 
by O 
order O 
of O 
perturbation O 
theory O 
, O 
excitation O 
level O 
, O 
and O 
same O 
- O 
spin O 
vs O 
opposite O 
- O 
spin O 
character O 
. O 
A O 
large O 
number O 
of O 
approximate O 
electronic O 
structure O 
methods O 
have O 
been O 
considered O 
, O 
as O 
well O 
as O 
several O 
empirical O 
dispersion O 
corrections O 
. O 
Our O 
chief O 
conclusions O 
are O 
as O 
follows O 
: O 
( O 
a O 
) O 
the O 
effect O 
of O 
dispersion O 
is O 
dominated O 
by O 
same O 
- O 
spin O 
correlation O 
( O 
or O 
triplet O 
- O 
pair O 
correlation O 
, O 
from O 
a O 
different O 
perspective O 
) O 
; O 
( O 
b O 
) O 
singlet O 
- O 
pair O 
correlation O 
is O 
important O 
for O 
the O 
surface O 
, O 
but O 
qualitatively O 
very O 
dissimilar O 
to O 
the O 
dispersion O 
component O 
; O 
( O 
c O 
) O 
single O 
and O 
double O 
excitations O 
beyond O 
third O 
order O 
are O 
essentially O 
unimportant O 
for O 
this O 
surface O 
; O 
( O 
d O 
) O 
connected O 
triple O 
excitations O 
do O 
play O 
a O 
role O 
but O 
are O 
statistically O 
very O 
similar O 
to O 
the O 
MP2 O 
singlet O 
- O 
pair O 
correlation O 
; O 
( O 
e O 
) O 
the O 
form O 
of O 
the O 
damping O 
function O 
is O 
crucial O 
for O 
good O 
performance O 
of O 
empirical O 
dispersion O 
corrections O 
; O 
( O 
f O 
) O 
at O 
least O 
in O 
the O 
lower O 
- O 
energy O 
regions O 
, O 
SCS-MP2 O 
and O 
especially O 
MP2.5 O 
perform O 
very O 
well O 
; O 
( O 
g O 
) O 
novel O 
spin O 
- O 
component O 
scaled O 
double O 
hybrid O 
functionals O 
such O 
as O 
DSD-PBEP86-D2 O 
acquit O 
themselves O 
very O 
well O 
for O 
this O 
problem O 
. O 

- O 
dose O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
and O 
estrogen B-FAMILY 
increase O 
ventricular O 
arrhythmias O 
following O 
ischemia O 
- O 
reperfusion O 
in O 
female O 
rat O 
hearts O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
an O 
environmental O 
estrogenic O 
endocrine O 
disruptor O 
that O 
may O 
have O 
adverse O 
health O 
impacts O 
on O 
a O 
range O 
of O 
tissue O 
/ O 
systems O 
. O 
In O 
previous O 
studies O 
, O 
we O 
reported O 
that O 
BPA B-ABBREVIATION 
rapidly O 
promoted O 
arrhythmias O 
in O 
female O 
rodent O 
hearts O 
through O 
alteration O 
of O 
myocyte O 
calcium B-SYSTEMATIC 
handling O 
. O 
In O 
the O 
present O 
study O 
we O 
investigated O 
the O 
acute O 
effects O 
of O 
BPA B-ABBREVIATION 
on O 
ventricular O 
arrhythmias O 
and O 
infarction O 
following O 
ischemia O 
- O 
reperfusion O 
in O 
rat O 
hearts O 
. O 
Rat O 
hearts O 
were O 
subjected O 
to O 
20min O 
of O 
global O 
ischemia O 
followed O 
by O 
reperfusion O 
. O 
In O 
female O 
, O 
but O 
not O 
male O 
hearts O 
, O 
acute O 
exposure O 
to O 
1nM O 
BPA B-ABBREVIATION 
, O 
either O 
alone O 
or O 
combined O 
with O 
1nM O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
, O 
during O 
reperfusion O 
resulted O 
in O 
a O 
marked O 
increase O 
in O 
the O 
duration O 
of O 
sustained O 
ventricular O 
arrhythmias O 
. O 
BPA B-ABBREVIATION 
plus O 
E2 O 
increased O 
the O 
duration O 
ventricular O 
fibrillation O 
, O 
and O 
the O 
duration O 
of O 
VF O 
as O 
a O 
fraction O 
of O 
total O 
duration O 
of O 
sustained O 
ventricular O 
arrhythmia O 
. O 
The O 
pro O 
- O 
arrhythmic O 
effects O 
of O 
estrogens B-FAMILY 
were O 
abolished O 
by O 
MPP B-ABBREVIATION 
combined O 
with O 
PHTPP B-ABBREVIATION 
, O 
suggesting O 
the O 
involvements O 
of O 
both O 
ERα O 
and O 
ERβ O 
signaling O 
. O 
In O 
contrast O 
to O 
their O 
pro O 
- O 
arrhythmic O 
effects O 
, O 
BPA B-ABBREVIATION 
and O 
E2 O 
reduced O 
infarction O 
size O 
, O 
agreeing O 
with O 
previously O 
described O 
protective O 
effect O 
of O 
estrogen B-FAMILY 
against O 
cardiac O 
infarction O 
. O 
In O 
conclusion O 
, O 
rapid O 
exposure O 
to O 
low O 
dose O 
BPA B-ABBREVIATION 
, O 
particularly O 
when O 
combined O 
with O 
E2 O 
, O 
exacerbates O 
ventricular O 
arrhythmia O 
following O 
IR O 
injury O 
in O 
female O 
rat O 
hearts O 
. O 

Graphene B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
and O 
Gold O 
Nanoclusters O 
: O 
A O 
Synergistic O 
Catalyst O 
with O 
Surprisingly O 
High O 
Peroxidase O 
- O 
Like O 
Activity O 
Over O 
a O 
Broad O 
pH O 
Range O 
and O 
its O 
Application O 
for O 
Cancer O 
Cell O 
Detection O 
. O 

synergistic O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
-gold O 
nanocluster O 
( O 
GO-AuNC O 
) O 
hybrid O 
has O 
been O 
constructed O 
as O 
an O 
enzyme O 
mimic O 
that O 
is O 
able O 
to O 
show O 
high O 
catalytic O 
activity O 
over O 
a O 
broad O 
pH O 
range O 
, O 
especially O 
at O 
neutral O 
pH O 
. O 
Importantly O 
, O 
the O 
target O 
- O 
functionalized O 
hybrid O 
has O 
been O 
applied O 
as O 
a O 
robust O 
nanoprobe O 
for O 
selective O 
, O 
quantitative O 
, O 
and O 
fast O 
colorimetric O 
detection O 
of O 
cancer O 
cells O 
. O 

of O 
plant O 
stanol B-FAMILY 
derivatives O 
in O 
the O 
modulation O 
of O 
cholesterol B-TRIVIAL 
metabolism O 
and O 
liver O 
gene O 
expression O 
in O 
mice O 
. O 

present O 
study O 
was O 
to O 
evaluate O 
the O 
cholesterol B-TRIVIAL 
-lowering O 
effect O 
of O 
two O 
novel O 
plant O 
stanol B-FAMILY 
derivatives O 
and O 
its O 
potential O 
molecular O 
mechanism O 
in O 
hyper- O 
cholesterol B-TRIVIAL 
mice O 
induced O 
by O 
a O 
high- O 
cholesterol B-TRIVIAL 
diet O 
. O 
Results O 
showed O 
that O 
oral O 
administration O 
of O 
plant O 
stanyl B-FAMILY 
hemisuccinate I-FAMILY 
( O 
2× O 
, O 
5× O 
) O 
and O 
plant O 
stanyl B-FAMILY 
sorbitol I-FAMILY 
succinate I-FAMILY 
( O 
2× O 
, O 
5× O 
) O 
effectively O 
attenuated O 
the O 
serum O 
total O 
cholesterol B-TRIVIAL 
and O 
low O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
levels O 
, O 
while O 
had O 
no O 
effect O 
on O 
the O 
serum O 
triacylglycerol B-FAMILY 
and O 
high O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
. O 
And O 
plant O 
stanol B-FAMILY 
derivatives O 
decreased O 
liver O 
cholesterol B-TRIVIAL 
concentration O 
and O 
increased O 
faecal O 
cholesterol B-TRIVIAL 
output O 
. O 
Meanwhile O 
, O 
both O 
plant O 
stanyl B-FAMILY 
hemisuccinate I-FAMILY 
and O 
plant O 
stanyl B-FAMILY 
sorbitol I-FAMILY 
succinate I-FAMILY 
could O 
remarkably O 
promote O 
liver O 
X O 
receptor O 
alpha O 
( O 
LXRα O 
) O 
expression O 
, O 
and O 
increased O 
cholesterol B-TRIVIAL 
7α-hydroxylase O 
( O 
CYP7A1 O 
) O 
expression O 
and O 
faecal O 
total O 
bile B-FAMILY 
acid I-FAMILY 
output O 
to O 
varying O 
degrees O 
. O 
These O 
results O 
suggested O 
two O 
novel O 
plant O 
stanol B-FAMILY 
derivatives O 
possessed O 
hypocholesterolemic O 
effect O 
, O 
and O 
the O 
cholesterol B-TRIVIAL 
-lowering O 
action O 
of O 
plant O 
stanol B-FAMILY 
derivatives O 
may O 
be O 
through O 
activating O 
the O 
potential O 
LXRα-CYP7A1- O 
bile B-FAMILY 
acid I-FAMILY 
excretion O 
pathway O 
. O 

Levels O 
of O 
Inosine B-TRIVIAL 
in O 
a O 
Mouse O 
Model O 
of O 
Inflammation O 
. O 

possible O 
mechanism O 
linking O 
inflammation O 
with O 
cancer O 
involves O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
, O 
nitrogen B-SYSTEMATIC 
, O 
and O 
halogen B-FAMILY 
species O 
by O 
activated O 
macrophages O 
and O 
neutrophils O 
infiltrating O 
sites O 
of O 
infection O 
or O 
tissue O 
damage O 
, O 
with O 
these O 
chemical O 
mediators O 
causing O 
damage O 
that O 
ultimately O 
leads O 
to O 
cell O 
death O 
and O 
mutation O 
. O 
To O 
determine O 
the O 
most O 
biologically O 
deleterious O 
chemistries O 
of O 
inflammation O 
, O 
we O 
previously O 
assessed O 
products O 
across O 
the O 
spectrum O 
of O 
DNA O 
damage O 
arising O 
in O 
inflamed O 
tissues O 
in O 
the O 
SJL O 
mouse O 
model O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
overproduction O 
( O 
Pang O 
et O 
al O 
. O 
( O 
2007 O 
) O 
Carcinogenesis O 
28 O 
, O 
1807 O 
- O 
1813 O 
) O 
. O 
Among O 
the O 
anticipated O 
DNA O 
damage O 
chemistries O 
, O 
we O 
observed O 
significant O 
changes O 
only O 
in O 
lipid O 
peroxidation O 
- O 
derived O 
etheno B-SYSTEMATIC 
adducts O 
. O 
We O 
have O 
now O 
developed O 
an O 
isotope O 
- O 
dilution O 
, O 
liquid O 
chromatography O 
- O 
coupled O 
, O 
tandem O 
quadrupole O 
mass O 
spectrometric O 
method O 
to O 
quantify O 
representative O 
species O 
across O 
the O 
spectrum O 
of O 
RNA O 
damage O 
products O 
predicted O 
to O 
arise O 
at O 
sites O 
of O 
inflammation O 
, O 
including O 
nucleobase B-FAMILY 
deamination O 
( O 
xanthosine B-TRIVIAL 
and O 
inosine B-TRIVIAL 
) O 
, O 
oxidation O 
( O 
8-oxoguanosine B-SYSTEMATIC 
) O 
, O 
and O 
alkylation O 
( O 
1,N(6)-ethenoadenosine B-SYSTEMATIC 
) O 
. O 
Application O 
of O 
the O 
method O 
to O 
the O 
liver O 
, O 
spleen O 
, O 
and O 
kidney O 
from O 
the O 
SJL O 
mouse O 
model O 
revealed O 
generally O 
higher O 
levels O 
of O 
oxidative O 
background O 
RNA O 
damage O 
than O 
was O 
observed O 
in O 
DNA O 
in O 
control O 
mice O 
. O 
However O 
, O 
compared O 
to O 
control O 
mice O 
, O 
RcsX O 
treatment O 
to O 
induce O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
overproduction O 
resulted O 
in O 
significant O 
increases O 
only O 
in O 
inosine B-TRIVIAL 
and O 
only O 
in O 
the O 
spleen O 
. O 
Further O 
, O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibitor O 
, O 
N-methylarginine B-SYSTEMATIC 
, O 
did O 
not O 
significantly O 
affect O 
the O 
levels O 
of O 
inosine B-TRIVIAL 
in O 
control O 
and O 
RcsX O 
- O 
treated O 
mice O 
. O 
The O 
differences O 
between O 
DNA O 
and O 
RNA O 
damage O 
in O 
the O 
same O 
animal O 
model O 
of O 
inflammation O 
point O 
to O 
possible O 
influences O 
from O 
DNA O 
repair O 
, O 
RcsX-induced O 
alterations O 
in O 
adenosine B-TRIVIAL 
deaminase O 
activity O 
, O 
and O 
differential O 
accessibility O 
of O 
DNA O 
and O 
RNA O 
to O 
reactive O 
oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
as O 
determinants O 
of O 
nucleic O 
acid O 
damage O 
during O 
inflammation O 
. O 

characterization O 
of O 
three O 
mouse O 
formyl B-SYSTEMATIC 
peptide O 
receptors O 
. O 

evolutionary O 
relationship O 
and O 
functional O 
correlation O 
between O 
human O 
formyl B-SYSTEMATIC 
peptide O 
receptors O 
( O 
FPRs O 
) O 
and O 
their O 
mouse O 
counterparts O 
remain O 
incompletely O 
understood O 
. O 
We O 
examined O 
three O 
members O 
of O 
the O 
mouse O 
formyl B-SYSTEMATIC 
peptide O 
receptor O 
subfamily O 
( O 
mFprs O 
) O 
and O 
found O 
that O 
they O 
differ O 
in O 
agonist O 
preference O 
and O 
cellular O 
distributions O 
. O 
When O 
stably O 
expressed O 
in O 
transfected O 
rat O 
basophilic O 
leukemia O 
( O 
RBL-2H3 O 
) O 
cells O 
, O 
mFpr1 O 
was O 
readily O 
activated O 
by O 
N B-FORMULA 
-formylated O 
peptides O 
derived O 
from O 
Listeria O 
monocytogenes O 
( O 
fMIVTLF O 
) O 
, O 
Staphylococcus O 
aureus O 
( O 
fMIFL O 
) O 
, O 
and O 
mitochondria O 
( O 
fMMYALF O 
) O 
. O 
In O 
contrast O 
, O 
the O 
Escherichia O 
coli O 
- O 
derived O 
fMLF O 
was O 
1000-fold O 
less O 
potent O 
. O 
The O 
aforementioned O 
peptides O 
were O 
much O 
less O 
efficacious O 
at O 
mFpr2 O 
, O 
which O 
responded O 
better O 
to O 
the O 
synthetic O 
hexapeptide B-FAMILY 
WKYMVm O 
, O 
the O 
synthetic O 
agonists O 
Quin-C1 B-TRIVIAL 
( O 
a O 
substituted O 
quinazolinone B-SYSTEMATIC 
) O 
, O 
and O 
compound O 
43 O 
( O 
a O 
nitrosylated B-FAMILY 
pyrazolone I-FAMILY 
derivative O 
) O 
. O 
Saturation O 
binding O 
assays O 
showed O 
that O 
mFpr1 O 
and O 
mFpr2 O 
were O 
expressed O 
at O 
similar O 
levels O 
on O 
the O 
cell O 
surface O 
, O 
although O 
their O 
affinity O 
for O 
N- B-SYSTEMATIC 
formyl-Met-Leu-Phe-Ile-Ile-Lys- I-SYSTEMATIC 
fluorescein I-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
varied O 
by O 
more O 
than O 
1000-fold O 
[ O 
dissociation O 
constant O 
(K(d)) O 
values O 
of O 
2.8 O 
nM O 
for O 
mFpr1 O 
and O 
4.8 O 
μM O 
for O 
mFpr2 O 
] O 
) O 
. O 
Contrary O 
to O 
these O 
receptors O 
, O 
mFpr-rs1 O 
responded O 
poorly O 
to O 
all O 
the O 
previously O 
mentioned O 
peptides O 
that O 
were O 
tested O 
. O 
Fluorescent O 
microscopy O 
revealed O 
an O 
intracellular O 
distribution O 
pattern O 
of O 
mFpr-rs1 O 
. O 
On O 
the O 
basis O 
of O 
these O 
results O 
, O 
we O 
conclude O 
that O 
mFpr1 O 
is O 
an O 
ortholog O 
of O 
human O 
FPR1 O 
with O 
certain O 
pharmacologic O 
properties O 
of O 
human O 
FPR2 O 
/ O 
ALX O 
, O 
whereas O 
mFpr2 O 
has O 
much O 
lower O 
affinity O 
for O 
formyl B-SYSTEMATIC 
peptides O 
. O 
The O 
intracellular O 
distribution O 
of O 
mFpr-rs1 O 
suggests O 
an O 
evolutionary O 
correlation O 
with O 
human O 
FPR3 O 
. O 

zinc B-SYSTEMATIC 
-catalyzed O 
hydrosilylation O 
of O 
ketones B-FAMILY 
and O 
the O 
effect O 
of O 
carboxylate B-SYSTEMATIC 
on O 
the O 
enantioselectivity O 
. O 

chiral O 
ligands O 
containing O 
(R,R)-diaminocyclohexane B-SYSTEMATIC 
moieties O 
and O 
pyrrole B-SYSTEMATIC 
, O 
furan B-SYSTEMATIC 
, O 
or O 
benzene B-SYSTEMATIC 
have O 
been O 
synthesized O 
. O 
These O 
ligands O 
were O 
tested O 
in O 
enantioselective O 
zinc B-SYSTEMATIC 
-catalyzed O 
hydrosilylation O 
reactions O 
; O 
excellent O 
enantioselectivities O 
were O 
obtained O 
when O 
the O 
ligands O 
containing O 
(R,R)-diaminocyclohexane B-SYSTEMATIC 
moieties O 
and O 
furan B-SYSTEMATIC 
rings O 
were O 
used O 
. O 
For O 
comparison O 
, O 
zinc B-SYSTEMATIC 
chloride I-SYSTEMATIC 
combined O 
with O 
different O 
potassium B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
salts O 
and O 
ligands O 
were O 
also O 
tested O 
for O 
catalytic O 
hydrosilylation O 
reactions O 
. O 
Chirality O 
25 O 
: O 
275-280 O 
, O 
2013 O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

treatment O 
options O 
for O 
epilepsy O 
: O 
focus O 
on O 
perampanel B-TRIVIAL 
. O 

is O 
a O 
new O 
chemical O 
entity O 
recently O 
approved O 
in O 
the O 
United O 
States O 
( O 
US O 
) O 
and O 
European O 
Union O 
( O 
EU O 
) O 
as O 
adjunctive O 
treatment O 
of O 
partial O 
- O 
onset O 
seizures O 
with O 
and O 
without O 
secondary O 
generalization O 
in O 
patients O 
with O 
epilepsy O 
aged O 
12 O 
years O 
and O 
older O 
. O 
Pharmacological O 
studies O 
suggest O 
that O 
perampanel B-TRIVIAL 
acts O 
with O 
a O 
new O 
mechanism O 
of O 
action O 
via O 
non-competitive O 
antagonism O 
of O 
the O 
ionotropic O 
α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AMPA B-ABBREVIATION 
) O 
receptor O 
of O 
glutamate B-TRIVIAL 
, O 
the O 
main O 
mediator O 
of O 
excitatory O 
neurotransmission O 
in O 
the O 
central O 
nervous O 
system O 
. O 
Perampanel B-TRIVIAL 
is O 
completely O 
absorbed O 
after O 
oral O 
administration O 
. O 
The O 
drug O 
is O 
95% O 
bound O 
to O 
plasma O 
proteins O 
and O 
is O 
extensively O 
metabolized O 
by O 
oxidation O 
followed O 
by O 
glucuronidation O 
. O 
Perampanel B-TRIVIAL 
has O 
an O 
elimination O 
half O 
- O 
life O 
of O 
approximately O 
52-129h O 
, O 
allowing O 
once O 
daily O 
dosing O 
, O 
with O 
peak O 
plasma O 
levels O 
observed O 
0.25-2h O 
post O 
- O 
dose O 
. O 
Randomized O 
placebo O 
- O 
controlled O 
trials O 
of O 
adjunctive O 
treatment O 
have O 
demonstrated O 
that O 
once O 
- O 
daily O 
perampanel B-TRIVIAL 
doses O 
of O 
4-12mg O 
/ O 
day O 
significantly O 
reduced O 
partial O 
- O 
onset O 
seizure O 
frequency O 
in O 
patients O 
with O 
pharmacoresistant O 
epilepsy O 
along O 
with O 
a O 
favorable O 
tolerability O 
profile O 
. O 
In O 
perampanel B-TRIVIAL 
pivotal O 
trials O 
, O 
the O 
most O 
frequently O 
reported O 
treatment O 
emergent O 
adverse O 
events O 
( O 
> O 
10% O 
) O 
included O 
dizziness O 
, O 
somnolence O 
, O 
fatigue O 
and O 
headache O 
. O 
Perampanel B-TRIVIAL 
therapeutic O 
response O 
was O 
maintained O 
in O 
patients O 
included O 
in O 
the O 
long O 
term O 
open O 
- O 
label O 
extension O 
studies O 
for O 
up O 
to O 
4 O 
years O 
. O 
Based O 
on O 
these O 
data O 
, O 
perampanel B-TRIVIAL 
offers O 
a O 
valuable O 
option O 
in O 
the O 
add O 
- O 
on O 
treatment O 
of O 
partial O 
- O 
onset O 
and O 
secondarily O 
generalized O 
seizures O 
. O 

, O 
characterization O 
and O 
heterologous O 
expression O 
of O 
the O 
indolocarbazole B-SYSTEMATIC 
biosynthetic O 
gene O 
cluster O 
from O 
marine O 
- O 
derived O 
Streptomyces O 
sanyensis O 
FMA O 
. O 

indolocarbazole B-SYSTEMATIC 
( O 
ICZ B-ABBREVIATION 
) O 
alkaloids O 
have O 
attracted O 
much O 
attention O 
due O 
to O 
their O 
unique O 
structures O 
and O 
potential O 
therapeutic O 
applications O 
. O 
A O 
series O 
of O 
ICZs B-FAMILY 
were O 
recently O 
isolated O 
and O 
identified O 
from O 
a O 
marine O 
- O 
derived O 
actinomycete O 
strain O 
, O 
Streptomyces O 
sanyensis O 
FMA O 
. O 
To O 
elucidate O 
the O 
biosynthetic O 
machinery O 
associated O 
with O 
ICZs B-FAMILY 
production O 
in O 
S O 
. O 
sanyensis O 
FMA O 
, O 
PCR O 
using O 
degenerate O 
primers O 
was O 
carried O 
out O 
to O 
clone O 
the O 
FAD B-ABBREVIATION 
-dependent O 
monooxygenase O 
gene O 
fragment O 
for O 
ICZ B-ABBREVIATION 
ring O 
formation O 
, O 
which O 
was O 
used O 
as O 
a O 
probe O 
to O 
isolate O 
the O 
34.6-kb O 
DNA O 
region O 
containing O 
the O 
spc O 
gene O 
cluster O 
. O 
Sequence O 
analysis O 
revealed O 
genes O 
for O 
ICZ B-ABBREVIATION 
ring O 
formation O 
( O 
spcO O 
, O 
D O 
, O 
P O 
, O 
C O 
) O 
, O 
sugar B-FAMILY 
unit O 
formation O 
( O 
spcA O 
, O 
B O 
, O 
E O 
, O 
K O 
, O 
J O 
, O 
I O 
) O 
, O 
glycosylation O 
( O 
spcN O 
, O 
G O 
) O 
, O 
methylation O 
( O 
spcMA O 
, O 
MB O 
) O 
, O 
as O 
well O 
as O 
regulation O 
( O 
spcR O 
) O 
. O 
Their O 
involvement O 
in O 
ICZ B-ABBREVIATION 
biosynthesis O 
was O 
confirmed O 
by O 
gene O 
inactivation O 
and O 
heterologous O 
expression O 
in O 
Streptomyces O 
coelicolor O 
M1152 O 
. O 
This O 
work O 
represents O 
the O 
first O 
cloning O 
and O 
characterization O 
of O 
an O 
ICZ B-ABBREVIATION 
gene O 
cluster O 
isolated O 
from O 
a O 
marine O 
- O 
derived O 
actinomycete O 
strain O 
and O 
would O 
be O 
helpful O 
for O 
thoroughly O 
understanding O 
the O 
biosynthetic O 
mechanism O 
of O 
ICZ B-FAMILY 
glycosides I-FAMILY 
. O 

of O 
silver B-SYSTEMATIC 
nanoparticles O 
on O 
the O 
liver O 
and O 
hepatocytes O 
in O 
vitro O 
. O 

the O 
increasing O 
use O 
and O 
incorporation O 
of O 
nanoparticles O 
( O 
NPs O 
) O 
into O 
consumer O 
products O 
, O 
screening O 
for O 
potential O 
toxicity O 
is O 
necessary O 
to O 
ensure O 
customer O 
safety O 
. O 
NPs O 
have O 
been O 
shown O 
to O 
translocate O 
to O 
the O 
bloodstream O 
following O 
inhalation O 
and O 
ingestion O 
, O 
and O 
such O 
studies O 
demonstrate O 
that O 
the O 
liver O 
is O 
an O 
important O 
organ O 
for O 
accumulation O 
. O 
Silver B-SYSTEMATIC 
( O 
Ag B-FORMULA 
) O 
NPs O 
are O 
highly O 
relevant O 
for O 
human O 
exposure O 
due O 
to O 
their O 
use O 
in O 
food O 
contact O 
materials O 
, O 
dietary O 
supplements O 
, O 
and O 
antibacterial O 
wound O 
treatments O 
. O 
Due O 
to O 
the O 
large O 
number O 
of O 
different O 
NPs O 
already O 
used O 
in O 
various O 
products O 
and O 
being O 
developed O 
for O 
new O 
applications O 
, O 
it O 
is O 
essential O 
that O 
relevant O 
, O 
quick O 
, O 
and O 
cheap O 
methods O 
of O 
in O 
vitro O 
risk O 
assessment O 
suitable O 
for O 
these O 
new O 
materials O 
are O 
established O 
. O 
Therefore O 
, O 
this O 
study O 
used O 
a O 
simple O 
hepatocytes O 
model O 
combined O 
with O 
an O 
in O 
vivo O 
injection O 
model O 
to O 
simulate O 
the O 
passage O 
of O 
a O 
small O 
amount O 
of O 
NPs O 
into O 
the O 
bloodstream O 
following O 
exposure O 
, O 
e.g O 
. O 
, O 
via O 
ingestion O 
or O 
inhalation O 
, O 
and O 
examined O 
the O 
potential O 
of O 
Ag B-FORMULA 
NPs O 
of O 
20 O 
nm O 
diameter O 
to O 
cause O 
toxicity O 
, O 
inflammation O 
, O 
and O 
oxidative O 
stress O 
in O 
the O 
liver O 
following O 
in O 
vivo O 
exposures O 
of O 
female O 
Wistar O 
rats O 
via O 
iv O 
injection O 
to O 
50 O 
μg O 
of O 
NPs O 
and O 
in O 
vitro O 
exposures O 
using O 
the O 
human O 
hepatocyte O 
cell O 
line O 
C3A O 
. O 
We O 
found O 
that O 
Ag B-FORMULA 
NPs O 
were O 
highly O 
cytotoxic O 
to O 
hepatocytes O 
( O 
LC(50) O 
lactate B-FAMILY 
dehydrogenase O 
: O 
2.5 O 
μg O 
/ O 
cm(2) O 
) O 
and O 
affected O 
hepatocyte O 
homeostasis O 
by O 
reducing O 
albumin O 
release O 
. O 
At O 
sublethal O 
concentrations O 
with O 
normal O 
cell O 
or O 
tissue O 
morphology O 
, O 
Ag B-FORMULA 
NPs O 
were O 
detected O 
in O 
cytoplasm O 
and O 
nuclei O 
of O 
hepatocytes O 
. O 
We O 
observed O 
similar O 
effects O 
of O 
Ag B-FORMULA 
NPs O 
on O 
inflammatory O 
mediator O 
expression O 
in O 
vitro O 
and O 
in O 
vivo O 
with O 
increase O 
of O 
interleukin-8 O 
( O 
IL-8 O 
) O 
/ O 
macrophage O 
inflammatory O 
protein O 
2 O 
, O 
IL-1RI O 
, O 
and O 
tumor O 
necrosis O 
factor-α O 
expression O 
in O 
both O 
models O 
and O 
increased O 
IL-8 O 
protein O 
release O 
in O 
vitro O 
. O 
This O 
article O 
presents O 
evidence O 
of O 
the O 
potential O 
toxicity O 
and O 
inflammogenic O 
potential O 
of O 
Ag B-FORMULA 
NPs O 
in O 
the O 
liver O 
following O 
ingestion O 
. O 
In O 
addition O 
, O 
the O 
similarities O 
between O 
in O 
vitro O 
and O 
in O 
vivo O 
responses O 
are O 
striking O 
and O 
encouraging O 
for O 
future O 
reduction O 
, O 
refinement O 
, O 
and O 
replacement O 
of O 
animal O 
studies O 
by O 
the O 
use O 
of O 
hepatocyte O 
cell O 
lines O 
in O 
particle O 
risk O 
assessment O 
. O 

effect O 
of O 
casein O 
glycomacropeptide O 
( O 
GMP O 
) O 
as O 
a O 
specific O 
regulating O 
mediator O 
in O 
obese O 
rats O 
induced O 
by O 
high O 
- O 
fat O 
( O 
HF O 
) O 
diet O 
was O 
investigated O 
. O 
Male O 
obese O 
Sprague-Dawley O 
( O 
SD O 
) O 
rats O 
induced O 
by O 
high O 
- O 
fat O 
diet O 
for O 
8weeks O 
period O 
were O 
fed O 
high O 
- O 
fat O 
, O 
high O 
- O 
fat O 
with O 
GMP O 
of O 
100mg O 
/ O 
kg O 
BW O 
( O 
HFLG O 
) O 
, O 
200mg O 
/ O 
kg O 
BW O 
( O 
HFMG O 
) O 
and O 
400mg O 
/ O 
kg O 
BW O 
( O 
HFHG O 
) O 
for O 
6weeks O 
. O 
Compared O 
with O 
the O 
high O 
- O 
fat O 
control O 
( O 
HFC O 
) O 
group O 
GMP O 
supplementation O 
significantly O 
decreased O 
adipose O 
tissue O 
weight O 
, O 
activity O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
( O 
FAS O 
) O 
and O 
glycerol-3-phosphate B-SYSTEMATIC 
dehydrogenase O 
( O 
GPDH O 
) O 
. O 
Hepatic O 
lipid O 
droplet O 
size O 
, O 
plasma O 
and O 
hepatic O 
lipid O 
levels O 
markedly O 
reduced O 
. O 
Moreover O 
, O 
GMP O 
reduces O 
plasma O 
total O 
cholesterol B-TRIVIAL 
and O 
low O 
- O 
density O 
lipoprotein O 
( O 
LDL O 
) O 
cholesterol B-TRIVIAL 
as O 
well O 
as O 
hepatic- O 
cholesterol B-TRIVIAL 
and O 
triglycerides B-FAMILY 
. O 
The O 
liver O 
steatosis O 
observed O 
in O 
obese O 
rats O 
was O 
also O 
prevented O 
by O 
GMP O 
supplement O 
. O 
In O 
addition O 
, O 
GMP O 
significantly O 
diminished O 
mitochondrial O 
and O 
liver O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
production O 
, O 
and O 
obviously O 
elevated O 
the O 
activities O 
of O 
mitochondrial O 
and O 
hepatic O 
superoxidase O 
dismutase O 
( O 
SOD O 
) O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
. O 
Leptin O 
production O 
and O 
proinflammatory O 
cytokines O 
such O 
as O 
TNF-α O 
and O 
IL-6 O 
secretion O 
decreased O 
. O 
Taken O 
together O 
, O 
GMP O 
can O 
reduce O 
lipid O 
accumulation O 
and O 
enhance O 
antioxidant O 
capability O 
of O 
obese O 
rats O 
. O 
It O 
suggests O 
that O 
GMP O 
can O 
counteract O 
high O 
- O 
fat O 
diet O 
- O 
induced O 
obesity O 
, O 
which O 
might O 
make O 
it O 
a O 
potential O 
ingredient O 
with O 
anti-obesity O 
activity O 
. O 

between O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporters O 
and O 
oxysterols B-FAMILY 
. O 

-binding O 
cassette O 
( O 
ABC O 
) O 
transporters O 
constitute O 
a O 
ubiquitous O 
superfamily O 
of O 
membrane O 
proteins O 
responsible O 
for O 
the O 
translocation O 
of O 
several O 
substances O 
across O 
membranes O 
using O 
the O 
chemical O 
energy O 
provided O 
by O 
ATP B-ABBREVIATION 
hydrolysis O 
. O 
ABC O 
transporters O 
participate O 
in O 
many O 
physiological O 
and O 
pathophysiological O 
processes O 
, O 
including O 
cholesterol B-TRIVIAL 
and O 
lipid O 
transportation O 
and O 
multidrug O 
resistance O 
. O 
Oxysterols B-FAMILY 
are O 
the O 
products O 
of O 
cholesterol B-TRIVIAL 
oxidation O 
, O 
formed O 
by O 
both O 
enzymatic O 
and O 
non-enzymatic O 
mechanisms O 
. O 
The O 
role O 
of O 
oxysterols B-FAMILY 
in O 
cholesterol B-TRIVIAL 
metabolism O 
and O 
several O 
diseases O 
has O 
been O 
widely O 
investigated O 
, O 
but O 
many O 
questions O 
remain O 
to O 
be O 
answered O 
. O 
Several O 
lines O 
of O 
evidence O 
link O 
ABC O 
transporter O 
functions O 
with O 
cholesterol B-TRIVIAL 
and O 
oxysterol B-FAMILY 
metabolism O 
. O 
This O 
review O 
discusses O 
ABC O 
transporters O 
, O 
oxysterols B-FAMILY 
, O 
and O 
how O 
they O 
interact O 
with O 
each O 
other O 
. O 

of O 
asiatic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
pentacyclic B-FAMILY 
triterpene I-FAMILY 
on O 
attenuating O 
the O 
key O 
enzymes O 
activities O 
of O 
carbohydrate B-FAMILY 
metabolism O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
. O 

acid I-TRIVIAL 
( O 
AA O 
) O 
, O 
a O 
triterpenoid B-FAMILY 
derivative O 
of O 
Centella O 
asiatica O 
, O 
has O 
shown O 
significant O 
biological O 
effects O 
of O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
. O 
Aim O 
of O 
this O 
investigation O 
was O 
to O 
evaluate O 
the O 
antihyperglycemic O 
effect O 
of O 
AA O 
on O 
the O 
activities O 
of O 
hepatic O 
enzymes O 
of O 
carbohydrate B-FAMILY 
metabolism O 
in O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
)-induced O 
diabetic O 
rats O 
. O 
To O 
induce O 
diabetes O 
mellitus O 
, O 
rats O 
were O 
injected O 
with O 
streptozotocin B-TRIVIAL 
intraperitoneally O 
at O 
a O 
single O 
dose O 
of O 
40 O 
mg O 
/ O 
kg O 
b.w O 
. O 
Diabetic O 
rats O 
showed O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
increased O 
in O 
plasma O 
glucose B-TRIVIAL 
, O 
glycosylated O 
hemoglobin O 
and O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
decreased O 
in O 
circulating O 
insulin O 
and O 
hemoglobin O 
. O 
The O 
altered O 
activities O 
of O 
key O 
enzymes O 
such O 
as O 
glucose B-TRIVIAL 
-6-phosphatase O 
and O 
fructose B-TRIVIAL 
-1,6-bisphosphatase O 
of O 
carbohydrate B-FAMILY 
metabolism O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
increased O 
whereas O 
hexokinase O 
, O 
pyruvate B-TRIVIAL 
kinase O 
, O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
and O 
glycogen O 
content O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
decreased O 
in O 
the O 
liver O 
of O 
diabetic O 
rats O 
and O 
also O 
increased O 
activities O 
of O 
aspartate B-TRIVIAL 
transaminase O 
( O 
AST O 
) O 
, O 
alanine B-TRIVIAL 
transaminase O 
( O 
ALT O 
) O 
and O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
. O 
Oral O 
administration O 
of O 
AA O 
( O 
5 O 
, O 
10 O 
and O 
20 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
and O 
glibenclamide B-TRIVIAL 
( O 
600 O 
μg O 
/ O 
kg O 
b.w O 
. O 
) O 
to O 
diabetic O 
rats O 
for O 
45 O 
days O 
prevented O 
the O 
above O 
alteration O 
and O 
reverted O 
to O 
near O 
normalcy O 
. O 
Protection O 
of O 
body O 
weight O 
loss O 
of O 
diabetic O 
rats O 
by O 
AA O 
was O 
also O 
observed O 
. O 
No O 
significant O 
effect O 
was O 
observed O 
in O 
normal O 
rats O 
treated O 
with O 
AA O 
( O 
20 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
. O 
In O 
this O 
search O 
, O 
AA O 
found O 
to O 
be O 
potential O 
bioactive O 
compound O 
to O 
regulate O 
the O 
carbohydrate B-FAMILY 
metabolism O 
by O 
modulating O 
the O 
key O 
regulatory O 
enzymes O 
in O 
diabetic O 
rats O 
. O 
These O 
findings O 
merit O 
further O 
research O 
in O 
this O 
field O 
. O 

radical O 
reactions O 
in O 
two O 
dimensions O 
: O 
a O 
case O 
study O 
on O 
photochlorination O 
of O 
graphene B-TRIVIAL 
. O 

, O 
a O 
two O 
- O 
dimensional O 
giant O 
- O 
molecule O 
of O 
sp(2) O 
-bonded O 
carbon B-SYSTEMATIC 
atoms O 
, O 
provides O 
a O 
perfect O 
platform O 
for O 
studying O 
free O 
radical O 
reaction O 
chemistry O 
in O 
two O 
- O 
dimensions O 
, O 
which O 
holds O 
promise O 
to O 
control O 
the O 
chemical O 
functionality O 
of O 
graphene B-TRIVIAL 
. O 
Free O 
- O 
radical O 
photochlorination O 
of O 
graphene B-TRIVIAL 
is O 
used O 
as O 
an O 
example O 
to O 
investigate O 
the O 
thickness O 
, O 
stacking O 
order O 
, O 
and O 
single- O 
and O 
double O 
- O 
side O 
dependent O 
reactivity O 
in O 
graphene B-TRIVIAL 
. O 
Anomalously O 
low O 
reactivity O 
is O 
observed O 
in O 
the O 
photochlorination O 
of O 
AB-stacked O 
bilayer O 
graphene B-TRIVIAL 
in O 
comparison O 
with O 
that O 
of O 
few O 
- O 
layer O 
graphene B-TRIVIAL 
. O 
Double O 
- O 
sided O 
chlorination O 
of O 
graphene B-TRIVIAL 
shows O 
higher O 
reactivity O 
and O 
chlorine B-SYSTEMATIC 
coverage O 
than O 
single O 
- O 
sided O 
reaction O 
. O 
It O 
is O 
also O 
experimentally O 
and O 
theoretically O 
demonstrated O 
that O 
chlorine B-SYSTEMATIC 
free O 
radicals O 
at O 
low O 
coverage O 
prefer O 
to O 
form O 
a O 
stable O 
charge O 
- O 
transfer O 
complex O 
with O 
graphene B-TRIVIAL 
, O 
which O 
highly O 
enhances O 
graphene B-TRIVIAL 
' O 
s O 
conductivity O 
and O 
simultaneously O 
generates O 
a O 
pseudo O 
- O 
bandgap O 
through O 
noninvasive O 
doping O 
. O 
Moreover O 
, O 
the O 
initial O 
accumulation O 
of O 
chlorine B-SYSTEMATIC 
radicals O 
is O 
considered O 
as O 
the O 
rate O 
- O 
determining O 
step O 
of O 
photochlorination O 
of O 
graphene B-TRIVIAL 
. O 

tyrosine B-TRIVIAL 
phosphatase O 
1B O 
inhibitory O 
effect O 
by O 
dammarane B-TRIVIAL 
-type O 
triterpenes B-FAMILY 
from O 
hydrolyzate O 
of O 
total O 
Gynostemma O 
pentaphyllum O 
saponins B-FAMILY 
. O 

tyrosine B-TRIVIAL 
phosphatase O 
1B O 
( O 
PTP1B O 
) O 
is O 
an O 
important O 
factor O 
in O 
non-insulin O 
- O 
dependent O 
diabetes O 
mellitus O 
( O 
type-2 O 
diabetes O 
) O 
, O 
and O 
a O 
promising O 
target O 
for O 
treatment O 
of O 
diabetes O 
and O 
obesity O 
. O 
Therefore O 
, O 
the O 
aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
inhibitory O 
activities O 
of O 
constituents O 
( O 
three O 
new O 
together O 
with O 
twelve O 
known O 
triterpenes B-FAMILY 
compounds O 
) O 
isolated O 
from O 
the O 
hydrolyzate O 
of O 
total O 
saponins B-FAMILY 
from O 
Gynostemma O 
pentaphyllum O 
. O 
Their O 
structures O 
were O 
accomplished O 
mainly O 
base O 
on O 
the O 
spectroscopic O 
methods O 
, O 
and O 
then O 
were O 
further O 
confirmed O 
by O 
X-ray O 
crystal O 
diffraction O 
. O 
All O 
the O 
compounds O 
were O 
evaluated O 
for O 
inhibitory O 
activity O 
against O 
PTP1B O 
. O 
Current O 
data O 
suggested O 
that O 
the O 
compounds O 
1 O 
, O 
3 O 
, O 
12 O 
, O 
13 O 
and O 
14 O 
were O 
considered O 
to O 
be O 
potential O 
as O 
antidiabetic O 
agents O 
, O 
in O 
which O 
they O 
could O 
significantly O 
inhibit O 
the O 
PTP1B O 
enzyme O 
activity O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 

, O 
mercury B-SYSTEMATIC 
, O 
and O 
cadmium B-SYSTEMATIC 
in O 
blood O 
and O 
their O 
relation O 
to O 
diet O 
among O 
Swedish O 
adults O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
the O 
body O 
burden O 
of O 
lead O 
( O 
Pb B-FORMULA 
) O 
, O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
, O 
and O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
in O 
blood O 
among O 
Swedish O 
adults O 
and O 
the O 
association O 
between O 
blood O 
levels O 
, O 
diet O 
and O 
other O 
lifestyle O 
factors O 
. O 
The O 
study O 
was O 
based O 
on O 
a O 
subgroup O 
( O 
n=273 O 
) O 
of O 
the O 
national O 
survey O 
Riksmaten O 
2010-2011 O 
( O 
4-day O 
food O 
records O 
and O 
questionnaire O 
) O 
. O 
Lead O 
, O 
Hg B-FORMULA 
, O 
and O 
Cd B-FORMULA 
were O 
measured O 
in O 
whole O 
blood O 
, O 
and O 
Cd B-FORMULA 
additionally O 
in O 
urine O 
, O 
by O 
mass O 
or O 
fluorescence O 
spectrometry O 
methods O 
. O 
The O 
median O 
values O 
( O 
5-95th O 
percentiles O 
) O 
of O 
the O 
metals O 
in O 
blood O 
were O 
as O 
follows O 
; O 
Pb B-FORMULA 
: O 
13.4 O 
( O 
5.8-28.6 O 
) O 
μg O 
/ O 
L O 
, O 
Hg B-FORMULA 
: O 
1.13 O 
( O 
0.31-3.45 O 
) O 
μg O 
/ O 
L O 
, O 
and O 
Cd B-FORMULA 
: O 
0.19 O 
( O 
0.09-1.08 O 
) O 
μg O 
/ O 
L O 
. O 
All O 
three O 
metals O 
increased O 
with O 
increasing O 
age O 
. O 
Lead O 
levels O 
in O 
blood O 
were O 
positively O 
associated O 
with O 
intakes O 
of O 
game O 
and O 
alcohol B-FAMILY 
, O 
Hg B-FORMULA 
was O 
related O 
to O 
fish O 
intake O 
, O 
and O 
blood O 
Cd B-FORMULA 
related O 
to O 
smoking O 
and O 
low O 
iron B-SYSTEMATIC 
stores O 
and O 
to O 
a O 
low O 
meat O 
intake O 
. O 
Body O 
burdens O 
of O 
the O 
studied O 
metals O 
were O 
generally O 
below O 
health O 
based O 
reference O 
values O 
, O 
but O 
several O 
individuals O 
had O 
blood O 
Pb B-FORMULA 
levels O 
above O 
the O 
reference O 
point O 
for O 
possible O 
nephrotoxic O 
and O 
developmental O 
neurotoxic O 
effects O 
. O 
As O 
health O 
effects O 
cannot O 
be O 
excluded O 
, O 
individuals O 
with O 
high O 
Pb B-FORMULA 
exposure O 
should O 
aim O 
at O 
decreasing O 
their O 
body O 
burden O 
, O 
both O 
from O 
food O 
and O 
from O 
other O 
exposure O 
routes O 
. O 

self O 
- O 
complianced O 
and O 
self O 
- O 
rectifying O 
resistive O 
switching O 
in O 
Ag B-FORMULA 
-electroded O 
single O 
Na B-FORMULA 
-doped O 
ZnO B-FORMULA 
nanowires O 
. O 

demonstrate O 
current O 
self O 
- O 
complianced O 
and O 
self O 
- O 
rectifying O 
bipolar O 
resistive O 
switching O 
in O 
an O 
Ag B-FORMULA 
-electroded O 
Na B-FORMULA 
-doped O 
ZnO B-FORMULA 
nanowire O 
device O 
. O 
The O 
resistive O 
switching O 
is O 
controlled O 
by O 
the O 
formation O 
and O 
rupture O 
of O 
an O 
Ag B-FORMULA 
nanoisland O 
chain O 
on O 
the O 
surface O 
along O 
the O 
Na B-FORMULA 
-doped O 
ZnO B-FORMULA 
nanowire O 
. O 
Na B-FORMULA 
-doping O 
plays O 
important O 
roles O 
in O 
both O 
the O 
self O 
- O 
compliance O 
and O 
self O 
- O 
rectifying O 
properties O 
. O 

Ni(OH)2 B-FORMULA 
Nanoboxes O 
: O 
Fast O 
Fabrication O 
and O 
Enhanced O 
Sensing O 
for O 
Glucose B-TRIVIAL 
. O 

by O 
Pearson's O 
hard O 
and O 
soft O 
acid O 
- O 
base O 
( O 
HSAB O 
) O 
principle O 
, O 
uniform O 
amorphous O 
Ni(OH)2 B-FORMULA 
nanoboxes O 
with O 
intact O 
shell O 
structures O 
and O 
various O 
sizes O 
are O 
quickly O 
fabricated O 
by O 
deliberately O 
selecting O 
S2 B-FORMULA 
O3 I-FORMULA 
( I-FORMULA 
2- I-FORMULA 
) I-FORMULA 
as O 
the O 
coordinating O 
etchant O 
toward O 
Cu2 B-FORMULA 
O I-FORMULA 
templates O 
and O 
optimizing O 
the O 
reaction O 
conditions O 
. O 
It O 
is O 
found O 
that O 
not O 
only O 
the O 
solvent O 
system O 
but O 
also O 
the O 
employing O 
of O 
a O 
surfactant O 
is O 
vital O 
for O 
the O 
fabrication O 
of O 
the O 
nanoboxes O 
. O 
Ni(OH)2 B-FORMULA 
nanoboxes O 
, O 
as O 
an O 
example O 
, O 
demonstrate O 
an O 
improved O 
electrochemical O 
sensing O 
ability O 
for O 
glucose B-TRIVIAL 
, O 
which O 
might O 
be O 
due O 
to O 
their O 
amorphous O 
and O 
hollow O 
structural O 
features O 
. O 

PEG B-ABBREVIATION 
Hydrogels O 
: O 
3D O 
Scaffolds O 
for O 
Guided O 
Cell O 
Growth O 
. O 

prospective O 
study O 
of O 
selenium B-SYSTEMATIC 
concentration O 
and O 
risk O 
of O 
preeclampsia O 
in O 
pregnant O 
Iranian O 
women O 
: O 
a O 
nested O 
case O 
- O 
control O 
study O 
. O 

remains O 
a O 
leading O 
cause O 
of O 
maternal O 
and O 
perinatal O 
mortality O 
and O 
morbidity O 
worldwide O 
; O 
however O 
, O 
its O 
specific O 
etiology O 
still O 
remains O 
obscure O 
. O 
Some O 
studies O 
implicate O 
poor O 
maternal O 
selenium B-SYSTEMATIC 
status O 
predisposing O 
the O 
mother O 
to O 
preeclampsia O 
. O 
This O 
study O 
was O 
designed O 
to O 
determine O 
changes O 
in O 
plasma O 
selenium B-SYSTEMATIC 
levels O 
in O 
women O 
having O 
preeclampsia O 
as O 
compared O 
with O 
those O 
with O 
normal O 
pregnancy O 
. O 
In O 
a O 
nested O 
case O 
- O 
control O 
study O 
, O 
650 O 
normal O 
primigravida O 
in O 
their O 
first O 
24-28 O 
weeks O 
participated O 
in O 
the O 
study O 
. O 
After O 
3 O 
months O 
of O 
follow O 
- O 
up O 
of O 
all O 
subjects O 
, O 
blood O 
selenium B-SYSTEMATIC 
levels O 
were O 
measured O 
in O 
38 O 
women O 
presenting O 
consecutively O 
with O 
preeclampsia O 
and O 
in O 
38 O 
women O 
having O 
a O 
normal O 
pregnancy O 
by O 
atomic O 
absorption O 
spectrophotometry O 
. O 
Birth O 
outcomes O 
were O 
recorded O 
, O 
such O 
as O 
gestational O 
age O 
at O 
delivery O 
, O 
height O 
, O 
weight O 
, O 
birth O 
head O 
circumflex O 
and O 
1-min O 
Apgar O 
score O 
. O 
Preeclampsia O 
affects O 
about O 
5.84 O 
% O 
of O 
pregnancies O 
, O 
and O 
in O 
our O 
study O 
, O 
there O 
were O 
no O 
significant O 
differences O 
in O 
age O 
, O 
anthropometric O 
indices O 
, O 
and O 
family O 
history O 
of O 
preeclampsia O 
between O 
the O 
preeclamptic O 
and O 
control O 
groups O 
. O 
The O 
selenium B-SYSTEMATIC 
concentrations O 
in O 
plasma O 
in O 
women O 
with O 
preeclampsia O 
were O 
significantly O 
lower O 
as O 
compared O 
with O 
those O 
in O 
women O 
with O 
normal O 
pregnancy O 
( O 
70.63 O 
± O 
21.41 O 
versus O 
82.03 O 
± O 
15.54 O 
μg O 
/ O 
L O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
Being O 
in O 
the O 
bottom O 
tertile O 
of O 
selenium B-SYSTEMATIC 
concentration O 
( O 
less O 
than O 
62.2 O 
μg O 
/ O 
L O 
) O 
was O 
associated O 
with O 
greater O 
risk O 
of O 
preeclampsia O 
in O 
pregnant O 
women O 
. O 
The O 
reduced O 
selenium B-SYSTEMATIC 
in O 
the O 
maternal O 
circulations O 
observed O 
in O 
the O 
preeclamptic O 
mothers O 
support O 
the O 
hypothesis O 
that O 
insufficient O 
selenium B-SYSTEMATIC 
concentration O 
may O 
be O 
a O 
contributing O 
factor O 
to O 
the O 
pathophysiological O 
mechanisms O 
associated O 
with O 
preeclampsia O 
, O 
and O 
optimizing O 
the O 
dietary O 
selenium B-SYSTEMATIC 
intake O 
through O 
supplementation O 
could O 
produce O 
demonstrable O 
clinical O 
benefits O 
. O 

of O 
amino-pyrimidine B-SYSTEMATIC 
inhibitors O 
of O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
: O 
kinase O 
profiling O 
guided O 
optimization O 
of O 
a O 
1,2,3-benzotriazole B-SYSTEMATIC 
lead O 
. O 

series O 
of O 
amino-pyrimidines B-FAMILY 
was O 
developed O 
based O 
upon O 
an O 
initial O 
kinase O 
cross O 
- O 
screening O 
hit O 
from O 
a O 
CDK2 O 
program O 
. O 
Kinase O 
profiling O 
and O 
structure O 
- O 
based O 
drug O 
design O 
guided O 
the O 
optimization O 
from O 
the O 
initial O 
1,2,3-benzotriazole B-SYSTEMATIC 
hit O 
to O 
a O 
potent O 
and O 
selective O 
JNK O 
inhibitor O 
, O 
compound O 
24f O 
( O 
JNK1 O 
and O 
2 O 
IC(50)=16 O 
and O 
66 O 
nM O 
, O 
respectively O 
) O 
, O 
with O 
bioavailability O 
in O 
rats O 
and O 
suitable O 
for O 
further O 
in O 
vivo O 
pharmacological O 
evaluation O 
. O 

nicotine B-TRIVIAL 
vaccine O 
immunogenicity O 
with O 
liposomes O 
. O 

major O 
liability O 
of O 
existing O 
nicotine B-TRIVIAL 
vaccine O 
candidates O 
is O 
the O 
wide O 
variation O 
in O 
anti- O 
nicotine B-TRIVIAL 
immune O 
responses O 
among O 
clinical O 
trial O 
participants O 
. O 
In O 
order O 
to O 
address O 
this O 
liability O 
, O 
significant O 
emphasis O 
has O 
been O 
directed O 
at O 
evaluating O 
adjuvants O 
and O 
delivery O 
systems O 
that O 
confer O 
more O 
robust O 
potentiation O 
of O 
the O 
anti- O 
nicotine B-TRIVIAL 
immune O 
response O 
. O 
Toward O 
that O 
end O 
, O 
we O 
have O 
initiated O 
work O 
that O 
seeks O 
to O 
exploit O 
the O 
adjuvant O 
effect O 
of O 
liposomes O 
, O 
with O 
or O 
without O 
Toll O 
- O 
like O 
receptor O 
agonist(s) O 
. O 
The O 
results O 
of O 
the O 
murine O 
immunization O 
study O 
described O 
herein O 
support O 
the O 
hypothesis O 
that O 
a O 
liposomal O 
nicotine B-TRIVIAL 
vaccine O 
formulation O 
may O 
provide O 
a O 
means O 
for O 
addressing O 
the O 
immunogenicity O 
challenge O 
. O 

and O 
synthesis O 
of O 
novel O 
2-methyl-4,5- B-FAMILY 
substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one I-FAMILY 
derivatives O 
as O 
telomerase O 
inhibitors O 
. O 

novel O 
4,5-tetrahydropyrazolo[1,5-d][1,4]oxazepine B-SYSTEMATIC 
derivatives O 
have O 
been O 
synthesized O 
and O 
purified O 
to O 
be O 
screened O 
for O 
anticancer O 
activity O 
. O 
By O 
a O 
modified O 
TRAP O 
assay O 
, O 
some O 
titled O 
compounds O 
were O 
tested O 
against O 
telomerase O 
, O 
and O 
compound O 
4a O 
showed O 
the O 
most O 
potent O 
inhibitory O 
activity O 
with O 
IC(50) O 
value O 
at O 
0.78 O 
± O 
0.22 O 
μM O 
. O 
Western O 
blot O 
assays O 
showed O 
that O 
compounds O 
4a O 
and O 
4b O 
could O 
inhibit O 
expression O 
of O 
Cyclin O 
D1 O 
, O 
TERT O 
, O 
phospho-AKT O 
and O 
PI3K O 
/ O 
AKT O 
pathway O 
. O 

is O 
a O 
devastating O 
worldwide O 
widespread O 
tropical O 
disease O 
that O 
currently O 
affects O 
more O 
than O 
230 O 
million O 
people O 
, O 
making O 
it O 
an O 
issue O 
of O 
great O 
socioeconomic O 
and O 
public O 
health O 
importance O 
. O 
Unfortunatelly O 
there O 
is O 
a O 
single O 
drug O 
for O 
the O 
treatment O 
of O 
all O 
forms O 
of O 
schistosomiasis O 
, O 
praziquantel B-TRIVIAL 
, O 
which O 
was O 
introduced O 
in O 
therapy O 
in O 
1980 O 
. O 
The O 
article O 
goes O 
by O 
antimony O 
compounds O 
, O 
emetine B-TRIVIAL 
, O 
hydantoin B-TRIVIAL 
, O 
nitrofurans B-FAMILY 
, O 
lucanthone B-TRIVIAL 
, O 
hycanthone B-TRIVIAL 
, O 
oxamniquine B-TRIVIAL 
derivatives O 
and O 
organophosphates B-FAMILY 
until O 
it O 
finally O 
gets O 
to O 
praziquantel B-TRIVIAL 
derivatives O 
. O 
The O 
intent O 
of O 
this O 
review O 
is O 
to O 
provide O 
a O 
panorama O 
of O 
drugs O 
that O 
were O 
and O 
are O 
being O 
used O 
in O 
human O 
chemotherapy O 
looking O 
to O 
the O 
past O 
to O 
improve O 
rational O 
design O 
drugs O 
in O 
the O 
future O 
. O 
Not O 
only O 
clinical O 
used O 
compounds O 
will O 
be O 
shown O 
but O 
also O 
synthesized O 
and O 
tested O 
compounds O 
in O 
vitro O 
and O 
in O 
vivo O 
in O 
animal O 
models O 
which O 
haven't O 
yet O 
to O 
be O 
used O 
in O 
humans O 
. O 
Prospects O 
for O 
drug O 
discovery O 
and O 
vaccines O 
to O 
be O 
used O 
in O 
the O 
treatment O 
and O 
prevention O 
of O 
schistosomiasis O 
, O 
clinical O 
trials O 
, O 
concerns O 
about O 
the O 
resistance O 
/ O 
decreased O 
effectiveness O 
of O 
the O 
treatment O 
, O 
and O 
patent O 
database O 
will O 
also O 
be O 
discussed O 
. O 
At O 
the O 
end O 
of O 
the O 
review O 
the O 
reader O 
will O 
notice O 
that O 
much O 
has O 
been O 
done O 
but O 
much O 
still O 
needs O 
to O 
be O 
done O 
yet O 
. O 

and O 
synthesis O 
of O 
melodamide B-TRIVIAL 
A I-TRIVIAL 
, O 
a O 
new O 
anti-inflammatory O 
phenolic B-FAMILY 
amide I-FAMILY 
from O 
the O 
leaves O 
of O 
Melodorum O 
fruticosum O 
. O 

with O 
twelve O 
known O 
compounds O 
( O 
2-13 O 
) O 
, O 
melodamide B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
a O 
new O 
phenolic B-FAMILY 
amide I-FAMILY 
possessing O 
p-quinol B-TRIVIAL 
moiety O 
, O 
was O 
purified O 
and O 
characterized O 
from O 
the O 
methanolic O 
extracts O 
of O 
the O 
leaves O 
of O 
Melodorum O 
fruticosum O 
. O 
The O 
structure O 
of O 
melodamide B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
was O 
established O 
with O 
a O 
combination O 
of O 
2D O 
NMR O 
experiments O 
, O 
HR-ESI-MS O 
and O 
X-ray O 
analyses O 
. O 
The O 
other O 
known O 
compounds O 
were O 
identified O 
by O 
comparison O 
of O 
their O 
spectroscopic O 
and O 
physical O 
data O 
with O 
those O 
reported O 
in O 
the O 
literature O 
. O 
Moreover O 
, O 
some O 
isolated O 
compounds O 
were O 
examined O 
for O 
their O 
inhibitory O 
activity O 
towards O 
superoxide B-TRIVIAL 
anion O 
generation O 
and O 
elastase O 
release O 
in O 
human O 
neutrophils O 
. O 
Among O 
the O 
tested O 
compounds O 
, O 
1 O 
, O 
3 O 
, O 
and O 
5 O 
exhibited O 
strong O 
inhibition O 
of O 
superoxide B-TRIVIAL 
anion O 
generation O 
with O 
IC50 O 
values O 
ranging O 
from O 
5.25 O 
to O 
8.65 O 
µM O 
. O 
Furthermore O 
, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
melodamide B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
and O 
its O 
analogs O 
( O 
14a-p O 
) O 
were O 
described O 
. O 

: O 
Autism O 
and O 
related O 
pervasive O 
developmental O 
disorders O 
( O 
PDD O 
) O 
are O 
characterized O 
by O 
impairments O 
in O 
social O 
interaction O 
and O 
communication O 
, O 
restricted O 
interests O 
, O 
and O 
repetitive O 
and O 
stereotyped O 
patterns O 
of O 
behavior O 
. O 
Individuals O 
with O 
PDD O 
frequently O 
display O 
irritability O 
and O 
disruptive O 
behaviors O 
including O 
tantrums O 
, O 
self O 
- O 
injurious O 
behavior O 
, O 
and O 
aggression O 
. O 
Atypical O 
antipsychotics O 
are O 
currently O 
the O 
most O 
efficacious O 
pharmacological O 
interventions O 
available O 
for O 
treatment O 
of O 
irritability O 
associated O 
with O 
PDD O 
. O 
OBJECTIVES O 
: O 
This O 
article O 
aims O 
to O 
review O 
the O 
body O 
of O 
literature O 
pertaining O 
to O 
the O 
use O 
of O 
atypical O 
antipsychotics O 
in O 
the O 
treatment O 
of O 
patients O 
with O 
PDD O 
. O 
METHODS O 
: O 
A O 
PubMed O 
literature O 
search O 
was O 
conducted O 
using O 
the O 
following O 
key O 
words O 
: O 
autism O 
, O 
pervasive O 
developmental O 
disorders O 
, O 
atypical O 
antipsychotics O 
, O 
risperidone B-TRIVIAL 
, O 
aripiprazole B-TRIVIAL 
, O 
quetiapine B-TRIVIAL 
, O 
ziprasidone B-TRIVIAL 
, O 
olanzapine B-TRIVIAL 
, O 
clozapine B-TRIVIAL 
, O 
paliperidone B-TRIVIAL 
, O 
iloperidone B-TRIVIAL 
, O 
asenapine B-TRIVIAL 
, O 
and O 
lurasidone B-TRIVIAL 
. O 
Search O 
terms O 
were O 
limited O 
to O 
English O 
language O 
, O 
human O 
subjects O 
, O 
and O 
publication O 
from O 
1999 O 
to O 
present O 
. O 
Relevant O 
references O 
from O 
identified O 
articles O 
were O 
also O 
reviewed O 
. O 
RESULTS O 
: O 
The O 
efficacy O 
and O 
tolerability O 
of O 
risperidone B-TRIVIAL 
and O 
aripiprazole B-TRIVIAL 
for O 
the O 
treatment O 
of O 
irritability O 
in O 
autism O 
have O 
been O 
established O 
with O 
multi O 
- O 
site O 
, O 
randomized O 
, O 
controlled O 
trials O 
. O 
Studies O 
supporting O 
the O 
use O 
of O 
other O 
atypical O 
antipsychotics O 
are O 
either O 
limited O 
in O 
scope O 
or O 
less O 
robust O 
in O 
their O 
findings O 
, O 
though O 
newer O 
agents O 
such O 
as O 
ziprasidone B-TRIVIAL 
and O 
paliperidone B-TRIVIAL 
show O 
promise O 
. O 
CONCLUSIONS O 
: O 
Atypical O 
antipsychotics O 
are O 
currently O 
first O 
- O 
line O 
pharmacological O 
agents O 
for O 
the O 
treatment O 
of O 
irritability O 
and O 
associated O 
behaviors O 
in O 
children O 
with O 
PDD O 
. O 
Further O 
placebo O 
- O 
controlled O 
studies O 
are O 
warranted O 
to O 
characterize O 
the O 
efficacy O 
and O 
tolerability O 
of O 
the O 
majority O 
of O 
these O 
medications O 
. O 
There O 
is O 
also O 
a O 
need O 
for O 
the O 
development O 
of O 
novel O 
, O 
targeted O 
drugs O 
with O 
more O 
favorable O 
long O 
- O 
term O 
side O 
effect O 
profiles O 
. O 

accumulation O 
inhibitory O 
effects O 
of O 
phenylpropanoid B-FAMILY 
glycosides I-FAMILY 
from O 
Boschniakia O 
rossica O 
Fedtsch O 
et O 
Flerov O 
. O 

- O 
guided O 
fractionation O 
led O 
to O 
isolation O 
of O 
five O 
new O 
phenylpropanol B-FAMILY 
glycosides I-FAMILY 
, O 
rossicasides B-FAMILY 
G O 
( O 
1 O 
) O 
, O 
H O 
( O 
2 O 
) O 
, O 
I O 
( O 
3 O 
) O 
, O 
J O 
( O 
4 O 
) O 
, O 
and O 
K O 
( O 
5 O 
) O 
, O 
together O 
with O 
seven O 
known O 
compounds O 
( O 
6-12 O 
) O 
from O 
Boschniakia O 
rossica O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
chemical O 
and O 
spectroscopic O 
methods O 
( O 
UV O 
, O 
IR O 
, O 
HRESI-TOF-MS O 
, O 
1D O 
and O 
2D O 
NMR O 
) O 
. O 
Activity O 
screening O 
results O 
showed O 
that O 
some O 
isolates O 
had O 
TG O 
accumulation O 
inhibitory O 
effects O 
in O 
HepG2 O 
cells O 
. O 
Furthermore O 
, O 
the O 
structure O 
- O 
activity O 
relationship O 
was O 
partly O 
clarified O 
. O 

developed O 
a O 
photo O 
- O 
activatable O 
firefly O 
luciferase O 
( O 
fLuc O 
) O 
whose O 
activation O 
can O 
be O 
controlled O 
by O 
light O 
. O 
A O 
photocaged O 
lysine B-TRIVIAL 
analogue O 
was O 
site O 
- O 
specifically O 
incorporated O 
into O 
fLuc O 
to O 
replace O 
its O 
key O 
catalytic O 
lysine B-TRIVIAL 
residue- O 
Lys B-FORMULA 
529 O 
, O 
rendering O 
fLuc O 
inactive O 
until O 
light O 
- O 
triggered O 
removal O 
of O 
the O 
caging O 
group O 
. O 
This O 
photo O 
- O 
induced O 
gain O 
- O 
of O 
- O 
luminescence O 
provides O 
a O 
facile O 
approach O 
for O 
assessing O 
the O 
photolysis O 
efficiency O 
of O 
this O 
valuable O 
photosensitive O 
lysine B-TRIVIAL 
analogue O 
within O 
the O 
context O 
of O 
its O 
carrier O 
protein O 
in O 
vitro O 
and O 
in O 
living O 
cells O 
. O 
We O 
further O 
took O 
advantage O 
of O 
the O 
spatial O 
and O 
temporal O 
activation O 
feature O 
of O 
pfLuc O 
for O 
intracellular O 
measurement O 
of O 
labile O 
ATP B-ABBREVIATION 
levels O 
without O 
impairment O 
of O 
a O 
cell's O 
physiology O 
. O 

Copper B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Nanotube O 
Arrays O 
Driven O 
by O 
the O 
Nanoscale O 
Kirkendall O 
effect O 
. O 

annealing O 
conditions O 
( O 
environment O 
, O 
temperature O 
, O 
and O 
duration O 
) O 
are O 
applied O 
to O 
study O 
the O 
nanoscale O 
Kirkendall O 
effect O 
of O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
nanowire O 
( O 
NW O 
) O 
arrays O 
on O 
a O 
Si B-FORMULA 
substrate O 
. O 
The O 
results O 
show O 
that O 
an O 
appropriate O 
amount O 
of O 
oxygen B-SYSTEMATIC 
supply O 
is O 
crucial O 
for O 
uniform O 
transformation O 
from O 
Cu B-FORMULA 
NWs O 
( O 
average O 
diameter O 
∼50 O 
nm O 
) O 
into O 
Cu B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanotube O 
arrays O 
. O 
An O 
annealing O 
duration O 
of O 
30 O 
min O 
at O 
200 O 
°C O 
in O 
a O 
low O 
vacuum O 
environment O 
reveals O 
that O 
the O 
voids O 
are O 
not O 
uniformly O 
distributed O 
at O 
the O 
Cu B-FORMULA 
/ O 
Cu B-SYSTEMATIC 
oxide I-SYSTEMATIC 
interface O 
. O 
This O 
suggests O 
that O 
void O 
growth O 
is O 
due O 
to O 
surface O 
diffusion O 
of O 
Cu B-FORMULA 
along O 
void O 
surfaces O 
. O 
Annealing O 
above O 
200 O 
°C O 
for O 
60 O 
min O 
resulted O 
in O 
complete O 
transformation O 
from O 
Cu B-FORMULA 
NWs O 
into O 
Cu B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanotubes O 
. O 
X-ray O 
photoelectron O 
spectroscopy O 
characterization O 
indicates O 
that O 
the O 
Cu B-FAMILY 
oxides I-FAMILY 
formed O 
at O 
200 O 
°C O 
and O 
300 O 
°C O 
are O 
Cu(2) B-FORMULA 
O I-FORMULA 
and O 
CuO B-FORMULA 
, O 
respectively O 
. O 
It O 
is O 
demonstrated O 
that O 
the O 
transformation O 
from O 
Cu B-FORMULA 
NW O 
arrays O 
into O 
Cu B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanotube O 
arrays O 
can O 
be O 
combined O 
with O 
the O 
joining O 
of O 
stacked O 
Si B-FORMULA 
chips O 
in O 
a O 
single O 
- O 
process O 
step O 
with O 
reasonable O 
joint O 
shear O 
strength O 
. O 
Transmission O 
electron O 
microscopy O 
- O 
electron O 
energy O 
loss O 
spectroscopy O 
elemental O 
mapping O 
analysis O 
reveals O 
that O 
the O 
joint O 
interface O 
is O 
Cu B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 
The O 
outward O 
diffusion O 
of O 
Cu B-FORMULA 
driven O 
by O 
the O 
nanoscale O 
Kirkendall O 
effect O 
is O 
believed O 
to O 
enhance O 
the O 
joining O 
process O 
. O 
By O 
controlling O 
the O 
environment O 
, O 
temperature O 
, O 
and O 
duration O 
, O 
joined O 
Cu(2) B-FORMULA 
O I-FORMULA 
or O 
CuO B-FORMULA 
nanotube O 
stacked O 
chips O 
can O 
be O 
achieved O 
, O 
which O 
serve O 
as O 
a O 
platform O 
for O 
the O 
further O 
development O 
of O 
nanostructured O 
, O 
stacked O 
devices O 
. O 

transitions O 
of O 
protonated O 
and O 
deprotonated O 
amino B-FAMILY 
acids I-FAMILY 
in O 
aqueous O 
solution O 
in O 
the O 
region O 
145-300 O 
nm O 
studied O 
by O 
attenuated O 
total O 
reflection O 
far O 
- O 
ultraviolet O 
spectroscopy O 
. O 

electronic O 
transitions O 
of O 
20 O 
naturally O 
occurring O 
amino B-FAMILY 
acids I-FAMILY 
in O 
aqueous O 
solution O 
were O 
studied O 
with O 
attenuated O 
total O 
reflection O 
far O 
- O 
ultraviolet O 
( O 
ATR-FUV O 
) O 
spectroscopy O 
in O 
the O 
region O 
from O 
145 O 
to O 
300 O 
nm O 
. O 
From O 
the O 
measured O 
ATR O 
spectra O 
of O 
sample O 
solutions O 
, O 
the O 
FUV O 
absorption O 
spectra O 
attributed O 
to O 
the O 
amino B-FAMILY 
acids I-FAMILY 
were O 
separated O 
from O 
the O 
intense O 
solvent O 
absorption O 
by O 
using O 
a O 
modified O 
Kramers-Kronig O 
transformation O 
method O 
. O 
The O 
FUV O 
absorption O 
spectra O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
reflect O 
the O 
protonation O 
states O 
of O 
the O 
backbone O 
and O 
side-chain O 
structures O 
. O 
The O 
contributions O 
of O 
the O 
side O 
chains O 
to O 
the O 
spectra O 
were O 
also O 
examined O 
from O 
the O 
difference O 
spectra O 
subtracting O 
the O 
corresponding O 
Gly B-FORMULA 
spectrum O 
from O 
each O 
spectrum O 
. O 
The O 
observed O 
spectra O 
were O 
compared O 
mostly O 
with O 
the O 
electronic O 
transition O 
studies O 
of O 
the O 
molecular O 
fragments O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
in O 
gas O 
phase O 
. O 
The O 
FUV O 
spectra O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
exhibited O 
the O 
intra- O 
and O 
intermolecular O 
electronic O 
interactions O 
of O 
the O 
solute O 
- O 
solute O 
as O 
well O 
as O 
the O 
solute O 
- O 
solvent O 
, O 
and O 
those O 
are O 
essential O 
factors O 
to O 
elucidate O 
UV O 
photochemical O 
processes O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
in O 
aqueous O 
solution O 
. O 

injury O 
and O 
infection O 
are O 
often O 
followed O 
by O 
accelerated O 
protein O 
catabolism O 
and O 
acute O 
insulin O 
resistance O 
. O 
This O 
results O 
in O 
several O 
effects O 
that O 
complicate O 
and O 
prolong O 
recovery O 
, O 
including O 
weakness O 
, O 
immobility O 
, O 
impaired O 
wound O 
healing O 
, O 
and O 
organ O 
dysfunction O 
. O 
Recent O 
studies O 
have O 
demonstrated O 
the O 
development O 
of O 
GH O 
resistance O 
during O 
severe O 
inflammation O 
, O 
providing O 
a O 
potential O 
mechanism O 
for O 
the O 
protein O 
loss O 
that O 
follows O 
injury O 
and O 
infection O 
. O 
To O 
understand O 
this O 
GH O 
resistance O 
, O 
we O 
recently O 
developed O 
a O 
murine O 
model O 
of O 
acute O 
injury O 
. O 
Mice O 
were O 
subjected O 
to O 
soft O 
- O 
tissue O 
injury O 
, O 
alone O 
or O 
combined O 
with O 
hemorrhage O 
, O 
and O 
injected O 
iv O 
with O 
GH O 
30 O 
, O 
60 O 
, O 
or O 
90 O 
minutes O 
later O 
. O 
Hepatic O 
GH O 
signaling O 
was O 
measured O 
via O 
Western O 
analysis O 
. O 
GH-induced O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
5 O 
phosphorylation O 
was O 
decreased O 
immediately O 
after O 
completion O 
of O 
the O 
trauma O 
procedure O 
, O 
and O 
at O 
30 O 
and O 
60 O 
minutes O 
, O 
but O 
further O 
decreased O 
by O 
90 O 
minutes O 
after O 
trauma O 
. O 
Combined O 
trauma O 
and O 
hemorrhage O 
resulted O 
in O 
severely O 
decreased O 
GH-induced O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
5 O 
phosphorylation O 
compared O 
with O 
trauma O 
alone O 
, O 
and O 
this O 
was O 
true O 
at O 
all O 
time O 
points O 
studied O 
. O 
Western O 
analysis O 
revealed O 
an O 
apparent O 
decrease O 
in O 
the O 
molecular O 
weight O 
of O 
the O 
hepatic O 
GH O 
receptor O 
( O 
GHR O 
) O 
after O 
trauma O 
and O 
hemorrhage O 
, O 
but O 
not O 
trauma O 
alone O 
. O 
Additional O 
studies O 
determined O 
that O 
the O 
hemorrhage O 
- O 
induced O 
decrease O 
in O 
receptor O 
size O 
was O 
not O 
due O 
to O 
changes O 
in O 
GHR O 
N B-FORMULA 
-linked O 
glycosylation O 
. O 
These O 
results O 
suggest O 
that O 
GH O 
sensitivity O 
is O 
rapidly O 
impaired O 
after O 
acute O 
injury O 
and O 
that O 
trauma O 
combined O 
with O 
hemorrhage O 
results O 
in O 
a O 
more O 
severe O 
form O 
of O 
GH O 
resistance O 
resulting O 
from O 
alteration O 
or O 
inactivation O 
of O 
hepatic O 
GHR O 
. O 

- O 
based O 
design O 
and O 
synthesis O 
of O 
novel O 
pseudosaccharine B-TRIVIAL 
derivatives O 
as O 
antiproliferative O 
agents O 
and O 
kinase O 
inhibitors O 
. O 

study O 
is O 
concerned O 
with O 
the O 
implementation O 
of O 
structure O 
- O 
based O 
techniques O 
for O 
the O 
design O 
of O 
new O 
heterocyclic O 
compounds O 
based O 
on O 
pseudosaccharine B-TRIVIAL 
scaffold O 
with O 
protein O 
kinase O 
inhibition O 
activity O 
. O 
This O 
nucleus O 
was O 
exploited O 
based O 
on O 
the O 
well O 
- O 
known O 
quinazoline B-SYSTEMATIC 
core O 
and O 
its O 
interactions O 
with O 
several O 
protein O 
kinases O 
. O 
Two O 
series O 
of O 
compounds O 
employing O 
this O 
new O 
scaffold O 
were O 
synthesized O 
and O 
evaluated O 
at O 
enzymatic O 
and O 
cellular O 
levels O 
. O 
Compound O 
9b O 
displayed O 
broad O 
spectrum O 
antiproliferative O 
activity O 
on O 
NCI O 
60-cell O 
lines O 
panel O 
with O 
mean O 
GI50 O 
of O 
5.4 O 
μM O 
. O 
Investigation O 
of O 
the O 
molecular O 
mechanism O 
showed O 
probable O 
inhibitory O 
activity O 
against O 
Src O 
kinase O 
. O 

formation O 
of O 
lipid O 
bilayers O 
under O 
mechanical O 
stress O 
is O 
critical O 
to O 
biological O 
processes O 
. O 
A O 
series O 
of O 
coarse O 
grained O 
molecular O 
dynamics O 
simulations O 
of O 
lipid O 
bilayers O 
with O 
carbon B-SYSTEMATIC 
nanoparticles O 
different O 
in O 
size O 
have O 
been O 
performed O 
. O 
Surface O 
tension O 
was O 
applied O 
to O 
study O 
the O 
disruption O 
of O 
lipid O 
bilayers O 
by O 
nanoparticles O 
and O 
the O 
formation O 
of O 
pores O 
inside O 
the O 
bilayers O 
. O 
The O 
presence O 
of O 
small O 
nanoparticles O 
enhances O 
the O 
probability O 
of O 
water O 
penetration O 
thus O 
decreasing O 
the O 
membrane O 
rupture O 
tension O 
, O 
while O 
big O 
nanoparticles O 
have O 
the O 
opposite O 
effect O 
. O 
Nanoparticle O 
volume O 
affects O 
bilayer O 
strength O 
indirectly O 
, O 
and O 
particle O 
surface O 
density O 
can O 
complicate O 
the O 
interaction O 
. O 
The O 
structural O 
, O 
dynamic O 
, O 
elastic O 
properties O 
and O 
lateral O 
densities O 
of O 
lipid O 
bilayers O 
with O 
nanoparticles O 
under O 
mechanical O 
stress O 
were O 
analyzed O 
. O 
The O 
results O 
demonstrate O 
the O 
ability O 
of O 
nanoparticles O 
to O 
adjust O 
the O 
structural O 
and O 
dynamic O 
properties O 
of O 
a O 
lipid O 
membrane O 
, O 
and O 
to O 
efficiently O 
regulate O 
the O 
pore O 
formation O 
behavior O 
and O 
hydrophobicity O 
of O 
membranes O 
. O 

Obliteration O 
Using O 
Three-Dimensional O 
Composite O 
Scaffolds O 
Consisting O 
of O 
Polycaprolactone B-FAMILY 
/ O 
β-Tricalcium B-SYSTEMATIC 
Phosphate I-SYSTEMATIC 
/ O 
Collagen O 
Nanofibers O 
: O 
An O 
In O 
Vitro O 
and O 
In O 
Vivo O 
Study O 
. O 

different O 
composite O 
scaffolds O 
, O 
solid O 
- O 
freeform O 
- O 
fabricated O 
PCL B-ABBREVIATION 
/ O 
β-TCP B-ABBREVIATION 
supplemented O 
with O 
and O 
without O 
collagen O 
nanofibers O 
are O 
fabricated O 
. O 
These O 
scaffolds O 
are O 
evaluated O 
whether O 
a O 
combination O 
of O 
collagen O 
nanofibers O 
with O 
PCL B-ABBREVIATION 
/ O 
β-TCP B-ABBREVIATION 
can O 
promote O 
osteogenesis O 
in O 
a O 
mastoid O 
obliteration O 
. O 
To O 
assess O 
the O 
effects O 
of O 
the O 
cellular O 
activities O 
of O 
osteoblast O 
- O 
like O 
- O 
cells O 
( O 
MG63 O 
) O 
, O 
SEM O 
images O 
and O 
MTT B-ABBREVIATION 
assays O 
are O 
conducted O 
. O 
Experimental O 
mastoid O 
obliteration O 
is O 
performed O 
using O 
guinea O 
pigs O 
that O 
are O 
divided O 
group O 
A O 
( O 
PCL B-ABBREVIATION 
/ O 
β-TCP B-ABBREVIATION 
/ O 
collagen O 
- O 
nanofiber O 
scaffold O 
) O 
and O 
group O 
B O 
( O 
PCL B-ABBREVIATION 
/ O 
β-TCP B-ABBREVIATION 
scaffold O 
) O 
. O 
The O 
results O 
reveal O 
that O 
PCL B-ABBREVIATION 
/ O 
β-TCP B-ABBREVIATION 
/ O 
collagen O 
scaffold O 
provide O 
much O 
broader O 
cell O 
attachment O 
sites O 
than O 
PCL B-ABBREVIATION 
/ O 
β-TCP B-ABBREVIATION 
scaffold O 
. O 
The O 
µ-CT O 
and O 
fluorescent O 
microscopy O 
results O 
reveal O 
that O 
the O 
acceleration O 
of O 
early O 
new O 
bone O 
formation O 
within O 
the O 
pores O 
and O 
scaffold O 
itself O 
at O 
week O 
4 O 
post O 
- O 
operation O 
is O 
more O 
effective O 
in O 
group O 
A O 
. O 
In O 
addition O 
, O 
based O 
on O 
the O 
results O 
of O 
the O 
histological O 
and O 
µ-CT O 
at O 
12 O 
weeks O 
post O 
- O 
surgery O 
, O 
the O 
effective O 
regeneration O 
of O 
bone O 
in O 
the O 
PCL B-ABBREVIATION 
/ O 
β-TCP B-ABBREVIATION 
/ O 
collagen O 
scaffold O 
is O 
appeared O 
. O 

advances O 
in O 
polymerization O 
techniques O 
as O 
well O 
as O 
selective O 
chemical O 
modification O 
of O 
carbohydrates B-FAMILY 
, O 
glycopolymers O 
and O 
glyco O 
- O 
nanoparticles O 
are O 
emerging O 
as O 
an O 
important O 
class O 
of O 
materials O 
with O 
tailored O 
properties O 
or O 
novel O 
nanotechnology O 
- O 
based O 
platforms O 
for O 
a O 
number O 
of O 
applications O 
. O 
The O 
field O 
of O 
the O 
so O 
- O 
called O 
glyco O 
- O 
nanotechnology O 
is O 
starting O 
to O 
show O 
some O 
promises O 
for O 
future O 
clinical O 
applications O 
. O 
Glyco O 
- O 
nanoparticles O 
, O 
due O 
to O 
their O 
versatile O 
nature O 
, O 
could O 
offer O 
a O 
platform O 
for O 
the O 
design O 
of O 
carbohydrate B-FAMILY 
-based O 
vaccines O 
and O 
possibly O 
allow O 
the O 
development O 
of O 
new O 
single O 
- O 
dose O 
vaccines O 
in O 
disease O 
areas O 
of O 
unmet O 
need O 
. O 
This O 
paper O 
surveys O 
the O 
emerging O 
roles O 
of O 
carbohydrate B-FAMILY 
-based O 
polymeric O 
and O 
nanomaterials O 
for O 
biomolecular O 
recognition O 
processes O 
and O 
vaccine O 
development O 
. O 

treatment O 
induces O 
proteasomal O 
degradation O 
of O 
over O 
- O 
expressed O 
acetylcholinesterase O 
( O 
AChE-S O 
) O 
and O 
inhibit O 
GSK3β O 
. O 

is O 
one O 
of O 
the O 
most O 
widely O 
used O 
mood O 
- O 
stabilizing O 
agents O 
for O 
the O 
treatment O 
of O 
bipolar O 
disorder O 
. O 
Lithium B-SYSTEMATIC 
is O 
also O 
a O 
potent O 
inhibitor O 
of O 
glycogen O 
synthase O 
kinase-3β O 
( O 
GSK3β O 
) O 
activity O 
, O 
which O 
is O 
linked O 
to O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
In O 
experiments O 
with O 
cultured O 
HEK293T O 
cells O 
, O 
we O 
show O 
here O 
that O 
GSK3β O 
stabilizes O 
synaptic O 
acetylcholinesterase O 
( O 
AChE-S O 
) O 
, O 
a O 
critical O 
component O 
of O 
AD O 
development O 
. O 
Cells O 
treated O 
with O 
lithium B-SYSTEMATIC 
exhibited O 
rapid O 
proteasomal O 
degradation O 
of O 
AChE-S O 
. O 
Furthermore O 
treatment O 
of O 
the O 
cells O 
with O 
MG132 B-IDENTIFIER 
, O 
an O 
inhibitor O 
of O 
the O 
26S O 
proteasome O 
, O 
prevented O 
the O 
destabilizing O 
effect O 
of O 
lithium B-SYSTEMATIC 
on O 
AChE-S O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
suggest O 
that O 
regulation O 
of O 
AChE-S O 
protein O 
stability O 
may O 
be O 
an O 
important O 
biological O 
target O 
of O 
lithium B-SYSTEMATIC 
therapy O 
. O 

microfluidic O 
platform O 
is O 
reported O 
for O 
various O 
experimentation O 
schemes O 
on O 
cell O 
membrane O 
models O 
and O 
membrane O 
proteins O 
using O 
a O 
combination O 
of O 
electrical O 
and O 
optical O 
measurements O 
, O 
including O 
confocal O 
microscopy O 
. O 
Bilayer O 
lipid O 
membranes O 
( O 
BLMs O 
) O 
are O 
prepared O 
in O 
the O 
device O 
upon O 
spontaneous O 
and O 
instantaneous O 
thinning O 
of O 
the O 
lipid O 
solution O 
in O 
a O 
100-μm O 
dry O 
- O 
etched O 
aperture O 
in O 
a O 
12.5-μm O 
thick O 
Teflon B-TRIVIAL 
foil O 
. O 
Using O 
this O 
quasi O 
- O 
automated O 
approach O 
, O 
a O 
remarkable O 
100% O 
membrane O 
formation O 
yield O 
is O 
reached O 
( O 
including O 
reflushing O 
in O 
4% O 
of O 
the O 
cases O 
) O 
, O 
and O 
BLMs O 
are O 
stable O 
for O 
up O 
to O 
36 O 
h O 
. O 
Furthermore O 
, O 
the O 
potential O 
of O 
this O 
platform O 
is O 
demonstrated O 
for O 
(i) O 
the O 
in O 
- O 
depth O 
characterization O 
of O 
BLMs O 
comprising O 
both O 
synthetic O 
and O 
natural O 
lipids O 
( O 
1,2-diphytanoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DPhPC B-ABBREVIATION 
) O 
and O 
L-α-phosphatidylcholine B-FAMILY 
( O 
L-α-PC B-ABBREVIATION 
)/ O 
cholesterol B-TRIVIAL 
, O 
respectively O 
) O 
in O 
terms O 
of O 
seal O 
resistance O 
, O 
capacitance O 
, O 
surface O 
area O 
, O 
specific O 
capacitance O 
, O 
and O 
membrane O 
hydrophobic O 
thickness O 
; O 
(ii) O 
confocal O 
microscopy O 
imaging O 
of O 
phase O 
separation O 
in O 
sphingomyelin B-FAMILY 
/ O 
L-α-PC B-ABBREVIATION 
/ O 
cholesterol B-TRIVIAL 
ternary O 
membranes O 
; O 
(iii) O 
electrical O 
measurements O 
of O 
individual O 
nanopores O 
( O 
α-hemolysin O 
, O 
gramicidin B-FAMILY 
) O 
; O 
and O 
(iv) O 
indirect O 
assessment O 
of O 
the O 
alteration O 
of O 
membrane O 
properties O 
upon O 
exposure O 
to O 
chemical O 
stimuli O 
using O 
the O 
natural O 
nanopore O 
gramicidin B-FAMILY 
as O 
a O 
sensor O 
. O 

fluorescent O 
sensing O 
of O 
DNA O 
using O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
a O 
conjugated O 
cationic O 
polymer O 
. O 

explore O 
the O 
interactions O 
between O 
a O 
fluorescein B-TRIVIAL 
( O 
FAM B-ABBREVIATION 
)-labeled O 
single O 
- O 
stranded O 
DNA O 
( O 
P O 
) O 
, O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
, O 
and O 
a O 
cationic O 
conjugated O 
polymer O 
, O 
poly B-FAMILY 
[ I-FAMILY 
(9,9-bis(6'-N,N,N-trimethylammonium)hexyl)-fluorenylene I-FAMILY 
phenylene I-FAMILY 
dibromide I-FAMILY 
] I-FAMILY 
( O 
PFP B-ABBREVIATION 
) O 
. O 
It O 
is O 
found O 
that O 
the O 
fluorescence O 
change O 
of O 
P-GO- O 
PFP B-ABBREVIATION 
system O 
is O 
dependent O 
on O 
the O 
addition O 
order O 
of O 
P O 
and O 
PFP B-ABBREVIATION 
. O 
When O 
adding O 
PFP B-ABBREVIATION 
into O 
P O 
/ O 
GO O 
complex O 
, O 
the O 
fluorescence O 
resonance O 
energy O 
transfer O 
( O 
FRET O 
) O 
from O 
PFP B-ABBREVIATION 
to O 
P O 
is O 
inefficient O 
. O 
If O 
P O 
is O 
added O 
to O 
PFP B-ABBREVIATION 
/ O 
GO O 
complex O 
, O 
efficient O 
FRET O 
is O 
obtained O 
. O 
This O 
may O 
be O 
attributed O 
to O 
the O 
equal O 
binding O 
ability O 
for O 
P O 
and O 
PFP B-ABBREVIATION 
to O 
GO O 
. O 
The O 
results O 
of O 
time O 
- O 
resolved O 
fluorescence O 
and O 
fluorescence O 
anisotropy O 
support O 
the O 
different O 
fluorescent O 
response O 
under O 
different O 
addition O 
order O 
of O 
P O 
and O 
PFP B-ABBREVIATION 
to O 
GO O 
. O 
Based O 
on O 
the O 
above O 
phenomenon O 
, O 
we O 
demonstrate O 
a O 
method O 
to O 
reduce O 
the O 
high O 
background O 
signal O 
of O 
a O 
traditional O 
PFP B-ABBREVIATION 
-based O 
DNA O 
sensor O 
by O 
introducing O 
GO O 
. O 
In O 
comparison O 
to O 
the O 
use O 
of O 
single O 
PFP B-ABBREVIATION 
, O 
the O 
combination O 
of O 
PFP B-ABBREVIATION 
with O 
GO O 
- O 
based O 
method O 
shows O 
enhanced O 
sensitivity O 
with O 
a O 
detection O 
limit O 
as O 
low O 
as O 
40 O 
pM O 
for O 
target O 
DNA O 
detection O 
. O 

of O 
early O 
- O 
life O 
stress O 
, O 
on O 
group O 
III O 
mGlu O 
receptor O 
levels O 
in O 
the O 
rat O 
hippocampus O 
: O 
effects O 
of O 
ketamine B-TRIVIAL 
, O 
electroconvulsive O 
shock O 
therapy O 
and O 
fluoxetine B-TRIVIAL 
treatment O 
. O 

glutamatergic O 
system O 
is O 
increasingly O 
being O 
viewed O 
as O 
a O 
promising O 
target O 
for O 
the O 
development O 
of O 
novel O 
treatments O 
for O 
depression O 
. O 
The O 
group O 
III O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
( O 
mGlu(4 O 
, O 
7 O 
) O 
and O 
( O 
8 O 
) O 
receptors O 
) O 
in O 
particular O 
are O 
beginning O 
to O 
show O 
promise O 
in O 
this O 
respect O 
. O 
It O 
remains O 
unclear O 
how O 
antidepressant O 
medications O 
modulate O 
mGlu O 
receptors O 
. O 
In O 
this O 
study O 
we O 
investigated O 
the O 
effects O 
of O 
three O 
antidepressant O 
treatments O 
( O 
fluoxetine B-TRIVIAL 
, O 
ketamine B-TRIVIAL 
and O 
electroconvulsive O 
shock O 
therapy O 
( O 
ECT O 
) O 
) O 
. O 
Ketamine B-TRIVIAL 
is O 
an O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
which O 
possess O 
a O 
rapid O 
antidepressant O 
therapeutic O 
profile O 
and O 
moreover O 
is O 
effective O 
in O 
cases O 
of O 
treatment-resistant O 
depression O 
. O 
Furthermore O 
, O 
ECT O 
is O 
also O 
a O 
therapeutic O 
strategy O 
possessing O 
increased O 
efficacy O 
compared O 
to O 
conventional O 
monoamine B-FAMILY 
based O 
therapies O 
. O 
The O 
effect O 
these O 
two O 
highly O 
efficacious O 
treatments O 
have O 
on O 
hippocampal O 
group O 
III O 
mGlu O 
receptors O 
remains O 
completely O 
unexplored O 
. O 
To O 
redress O 
this O 
deficit O 
we O 
investigated O 
the O 
effects O 
these O 
treatments O 
and O 
the O 
prototypical O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitor O 
( O 
SSRI O 
) O 
fluoxetine B-TRIVIAL 
would O 
have O 
on O 
hippocampal O 
group O 
III O 
mGlu O 
receptor O 
mRNA O 
levels O 
in O 
naïve O 
Sprague-Dawley O 
rats O 
and O 
rats O 
which O 
had O 
undergone O 
early O 
- O 
life O 
stress O 
in O 
the O 
form O 
of O 
the O 
maternal O 
separation O 
( O 
MS O 
) O 
procedure O 
. O 
We O 
found O 
MS O 
significantly O 
reduced O 
mGlu(4) O 
receptor O 
expression O 
and O 
fluoxetine B-TRIVIAL 
reversed O 
this O 
MS O 
induced O 
change O 
. O 
ECT O 
and O 
ketamine B-TRIVIAL 
treatment O 
significantly O 
reduced O 
mGlu(4) O 
receptor O 
expression O 
in O 
non-separated O 
( O 
NS O 
) O 
animals O 
while O 
having O 
no O 
effect O 
in O 
MS O 
animals O 
. O 
Fluoxetine B-TRIVIAL 
and O 
ECT O 
significantly O 
increased O 
mGlu(7) O 
receptor O 
expression O 
in O 
NS O 
animals O 
. O 
This O 
work O 
demonstrates O 
changes O 
to O 
mGlu(4) O 
receptor O 
expression O 
may O 
be O 
a O 
lasting O 
molecular O 
change O 
which O 
occurs O 
due O 
to O 
early O 
- O 
life O 
stress O 
. O 
Taken O 
together O 
our O 
data O 
shows O 
there O 
are O 
selective O 
changes O 
to O 
group O 
III O 
mGlu O 
receptors O 
under O 
basal O 
and O 
early O 
- O 
life O 
stress O 
conditions O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

of O 
biological O 
evaluation O 
of O 
pyrazole B-MULTIPLE 
/ I-MULTIPLE 
imidazole I-MULTIPLE 
amides I-MULTIPLE 
as O 
mGlu5 O 
receptor O 
negative O 
allosteric O 
modulators O 
. O 

of O 
SAR O 
in O 
a O 
5-aryl-3-acylpyridinyl-pyrazoles B-FAMILY 
and O 
1-aryl-4-acylpyridinyl B-FAMILY 
imidazoles I-FAMILY 
series O 
of O 
mGlu5 O 
receptor O 
negative O 
allosteric O 
modulators O 
( O 
mGluR5 O 
NAMs O 
) O 
using O 
a O 
functional O 
cell O 
- O 
based O 
assay O 
is O 
described O 
in O 
this O 
Letter O 
. O 
Analysis O 
of O 
the O 
Ligand O 
- O 
lipophilic O 
efficiency O 
( O 
LipE O 
) O 
of O 
compounds O 
provided O 
new O 
insight O 
for O 
the O 
design O 
of O 
potent O 
mGluR5 O 
negative O 
allosteric O 
modulators O 
with O 
anti-depressant O 
activities O 
. O 

initial O 
excitement O 
and O 
countless O 
efforts O 
to O 
find O 
a O 
pharmacological O 
agent O 
that O 
disrupts O 
the O 
excitotoxic O 
pathway O 
of O 
ischemic O 
neuronal O 
death O 
have O 
only O 
led O 
to O 
disappointing O 
clinical O 
trials O 
. O 
Currently O 
, O 
a O 
thrombolytic O 
agent O 
called O 
recombinant O 
tissue O 
plasminogen O 
activator O 
( O 
rt-PA O 
) O 
is O 
the O 
only O 
pharmacological O 
treatment O 
available O 
for O 
patients O 
with O 
acute O 
ischemic O 
stroke O 
in O 
most O 
countries O 
. O 
Even O 
though O 
its O 
efficacy O 
has O 
been O 
confirmed O 
repeatedly O 
, O 
rt-PA O 
is O 
considerably O 
underused O 
due O 
to O 
reasons O 
including O 
a O 
short O 
therapeutic O 
window O 
and O 
repeated O 
complications O 
associated O 
with O 
its O 
use O 
. O 
A O 
search O 
for O 
alternative O 
mechanisms O 
that O 
may O 
operate O 
dependently O 
or O 
independently O 
with O 
the O 
well O 
- O 
established O 
excitotoxic O 
mechanism O 
has O 
led O 
researchers O 
to O 
the O 
discovery O 
of O 
newly O 
described O 
non- O 
glutamate B-TRIVIAL 
mechanisms O 
. O 
Among O 
the O 
latter O 
, O 
transient O 
receptor O 
potential O 
melastatin O 
7 O 
( O 
TRPM7 O 
) O 
is O 
one O 
of O 
the O 
important O 
nonglutamate O 
mechanisms O 
in O 
stroke O 
, O 
which O 
has O 
been O 
evaluated O 
in O 
both O 
in O 
- O 
vitro O 
and O 
in O 
- O 
vivo O 
. O 
In O 
this O 
review O 
, O 
we O 
will O 
discuss O 
the O 
current O 
state O 
of O 
pharmacological O 
treatments O 
of O 
ischemic O 
stroke O 
and O 
provide O 
evidence O 
that O 
TRPM7 O 
is O 
a O 
promising O 
therapeutic O 
target O 
of O 
stroke O 
. O 

vitro O 
synergistic O 
interaction O 
between O 
amide B-FAMILY 
piplartine B-TRIVIAL 
and O 
antimicrobial O 
peptide O 
dermaseptin O 
against O 
Schistosoma O 
mansoni O 
schistosomula O 
and O 
adult O 
worms O 
. O 

is O 
one O 
of O 
the O 
world's O 
major O 
public O 
health O 
problems O 
, O 
and O 
praziquantel B-TRIVIAL 
is O 
the O 
only O 
available O 
drug O 
to O 
treat O 
this O 
notable O 
neglected O 
disease O 
. O 
Drug O 
combinations O 
have O 
been O 
considered O 
an O 
important O 
strategy O 
for O 
treatment O 
of O 
infectious O 
diseases O 
, O 
which O 
might O 
enhance O 
therapeutic O 
efficacy O 
and O 
delaying O 
resistance O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
examined O 
the O 
in O 
vitro O 
activities O 
of O 
the O 
amide B-FAMILY 
piplartine B-TRIVIAL 
and O 
the O 
antimicrobial O 
peptide O 
dermaseptin O 
1 O 
administered O 
singly O 
or O 
in O 
combination O 
against O 
Schistosoma O 
mansoni O 
of O 
different O 
ages O 
including O 
3-hour- O 
old O 
and O 
7-day- O 
old O 
schistosomula O 
and O 
49-day- O 
old O 
adult O 
schistosomes O 
as O 
well O 
as O 
on O 
egg O 
output O 
by O 
adult O 
worms O 
. O 
We O 
calculated O 
the O 
median O 
lethal O 
concentrations O 
(LC(50)) O 
of O 
7.87 O 
and O 
17.99 O 
μM O 
on O 
49-day- O 
old O 
adults O 
, O 
11.02 O 
and O 
71.58 O 
μM O 
on O 
7-day- O 
old O 
schistosomula O 
, O 
and O 
70.87 O 
and O 
98.42 O 
μM O 
on O 
3-hour- O 
old O 
schistosomula O 
for O 
piplartine B-TRIVIAL 
and O 
dermaseptin O 
, O 
respectively O 
. O 
Most O 
Piplartine B-TRIVIAL 
/ O 
dermaseptin O 
combinations O 
showed O 
synergistic O 
effect O 
, O 
with O 
combination O 
index O 
( O 
CI O 
) O 
values O 
less O 
than O 
0.9 O 
when O 
S O 
. O 
mansoni O 
adults O 
or O 
schistosomula O 
were O 
simultaneously O 
incubated O 
with O 
both O 
drugs O 
in O 
vitro O 
; O 
synergy O 
between O 
these O 
two O 
compounds O 
was O 
also O 
indicated O 
using O 
isobolograms O 
. O 
Additionally O 
, O 
we O 
observed O 
alterations O 
on O 
the O 
tegumental O 
surface O 
of O 
schistosomula O 
and O 
adult O 
schistosomes O 
by O 
means O 
of O 
laser O 
scanning O 
confocal O 
microscopy O 
. O 
Furthermore O 
, O 
egg O 
laying O 
of O 
surviving O 
worms O 
was O 
considerably O 
more O 
reduced O 
when O 
exposed O 
to O 
the O 
piplartine B-TRIVIAL 
/ O 
dermaseptin O 
combinations O 
than O 
each O 
drug O 
alone O 
, O 
and O 
this O 
inhibition O 
was O 
irreversible O 
. O 
This O 
is O 
the O 
first O 
report O 
on O 
the O 
synergistic O 
effect O 
between O 
piplartine B-TRIVIAL 
and O 
dermaseptin O 
against O 
S O 
. O 
mansoni O 
and O 
opens O 
the O 
route O 
to O 
further O 
studies O 
( O 
e.g O 
. O 
in O 
vivo O 
) O 
to O 
characterize O 
this O 
combination O 
in O 
greater O 
detail O 
. O 

Objective O 
: O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
influence O 
of O 
process O 
parameters O 
, O 
binder O 
content O 
and O 
binder O 
addition O 
method O 
on O 
characteristics O 
of O 
the O 
granules O 
obtained O 
by O 
melt O 
granulation O 
( O 
MG O 
) O 
in O 
fluidized O 
bed O 
. O 
Methods O 
: O 
Spray O 
- O 
on O 
experiments O 
were O 
performed O 
according O 
to O 
2(3) O 
full O 
factorial O 
design O 
. O 
The O 
effect O 
of O 
binder O 
content O 
, O 
molten O 
binder O 
feed O 
rate O 
, O 
and O 
spray O 
air O 
pressure O 
on O 
granule O 
size O 
and O 
size O 
distribution O 
, O 
granule O 
shape O 
, O 
ﬂowability O 
and O 
drug O 
release O 
rate O 
was O 
investigated O 
. O 
In O 
the O 
in O 
situ O 
experiments O 
, O 
the O 
influence O 
of O 
binder O 
particle O 
size O 
and O 
binder O 
content O 
was O 
evaluated O 
. O 
Solid O 
- O 
state O 
characterization O 
was O 
performed O 
by O 
means O 
of O 
differential O 
scanning O 
calorimetry O 
, O 
X-ray O 
powder O 
diffraction O 
and O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
. O 
Results O 
: O 
Size O 
of O 
the O 
granules O 
obtained O 
by O 
spray O 
- O 
on O 
procedure O 
was O 
significantly O 
influenced O 
by O 
binder O 
content O 
and O 
spray O 
air O 
pressure O 
, O 
while O 
the O 
width O 
of O 
particle O 
size O 
distribution O 
was O 
mainly O 
affected O 
by O 
binder O 
feed O 
rate O 
. O 
Spray O 
air O 
pressure O 
showed O 
the O 
most O 
significant O 
influence O 
on O 
granule O 
shape O 
. O 
It O 
was O 
shown O 
that O 
smooth O 
and O 
spherical O 
particles O 
with O 
good O 
flow O 
properties O 
may O 
be O 
obtained O 
by O 
both O 
procedures O 
, O 
spray O 
- O 
on O 
and O 
in O 
situ O 
MG O 
. O 
The O 
results O 
obtained O 
indicated O 
the O 
influence O 
of O 
agglomeration O 
mechanism O 
on O 
granule O 
sphericity O 
, O 
with O 
higher O 
degree O 
of O 
granule O 
sphericity O 
observed O 
when O 
immersion O 
and O 
layering O 
was O 
the O 
dominant O 
mechanism O 
. O 
Paracetamol B-TRIVIAL 
release O 
from O 
granulates O 
was O 
very O 
rapid O 
, O 
but O 
after O 
compression O 
of O 
the O 
granules O 
into O 
tablets O 
, O 
drug O 
release O 
was O 
considerably O 
slower O 
. O 
Solid O 
- O 
state O 
analysis O 
confirmed O 
that O 
the O 
physical O 
form O 
of O 
the O 
granulate O 
components O 
remained O 
unaffected O 
after O 
the O 
MG O 
process O 
. O 
Conclusion O 
: O 
The O 
results O 
presented O 
indicate O 
that O 
MG O 
in O 
fluidized O 
bed O 
could O 
be O 
a O 
good O 
alternative O 
to O 
conventional O 
granulation O 
techniques O 
. O 

of O 
the O 
anti-cancer O 
agent O 
upamostat B-TRIVIAL 
by O 
the O 
mARC O 
enzyme O 
system O 
. O 

1 O 
. O 
Upamostat B-TRIVIAL 
( O 
Mesupron B-TRIVIAL 
® O 
) O 
is O 
a O 
new O 
small O 
molecule O 
serine B-TRIVIAL 
protease O 
inhibitor O 
. O 
The O 
drug O 
candidate O 
was O 
developed O 
to O 
inhibit O 
the O 
urokinase O 
- O 
type O 
plasminogen O 
activator O 
( O 
uPA O 
) O 
system O 
, O 
which O 
plays O 
a O 
major O 
role O 
in O 
tumor O 
invasion O 
and O 
metastasis O 
. O 
Upamostat B-TRIVIAL 
is O 
currently O 
in O 
clinical O 
development O 
as O 
an O 
anti-metastatic O 
and O 
non-cytotoxic O 
agent O 
against O 
pancreatic O 
and O 
breast O 
cancer O 
. O 
2 O 
. O 
Upamostat B-TRIVIAL 
is O 
the O 
orally O 
available O 
amidoxime B-SYSTEMATIC 
- O 
( O 
i.e O 
. O 
hydroxyamidine B-SYSTEMATIC 
- O 
) O 
prodrug O 
of O 
the O 
pharmacologically O 
active O 
form O 
, O 
WX-UK1 B-IDENTIFIER 
. O 
In O 
this O 
study O 
, O 
the O 
reductive O 
enzymatic O 
activation O 
of O 
upamostat B-TRIVIAL 
to O 
its O 
corresponding O 
amidine O 
WX-UK1 B-IDENTIFIER 
was O 
analyzed O 
. O 
3 O 
. O 
The O 
recently O 
discovered O 
molybdenum B-SYSTEMATIC 
enzyme O 
" O 
mitochondrial O 
Amidoxime B-SYSTEMATIC 
Reducing O 
Component O 
" O 
( O 
mARC O 
) O 
catalyses O 
together O 
with O 
its O 
electron O 
transport O 
proteins O 
cytochrome O 
b(5) O 
and O 
NADH B-ABBREVIATION 
cytochrome O 
b(5) O 
reductase O 
the O 
reduction O 
of O 
N B-FORMULA 
-hydroxylated O 
prodrugs O 
. O 
In O 
vitro O 
biotransformation O 
assays O 
with O 
porcine O 
subcellular O 
fractions O 
and O 
the O 
reconstituted O 
human O 
enzymes O 
demonstrate O 
an O 
mARC-dependent O 
N B-FORMULA 
-reduction O 
of O 
upamostat B-TRIVIAL 
. O 

transcription O 
by O 
cellular O 
RNA O 
polymerase O 
requires O 
the O 
efficient O 
removal O 
of O 
noncognate O 
nucleotide B-FAMILY 
residues O 
that O 
are O 
occasionally O 
incorporated O 
. O 
Mis O 
- O 
incorporation O 
causes O 
the O 
transcription O 
elongation O 
complex O 
to O 
backtrack O 
, O 
releasing O 
a O 
single O 
strand O 
3'-RNA O 
segment O 
bearing O 
a O 
noncognate O 
residue O 
, O 
which O 
is O 
hydrolyzed O 
by O 
the O 
active O 
center O 
that O 
carries O 
two O 
Mg(2+) B-FORMULA 
ions O 
. O 
However O 
, O 
in O 
most O 
x-ray O 
structures O 
only O 
one O 
Mg(2+) B-FORMULA 
is O 
present O 
. O 
This O 
Mg(2+) B-FORMULA 
is O 
tightly O 
bound O 
to O 
the O 
active O 
center O 
aspartates B-FAMILY 
, O 
creating O 
an O 
inactive O 
stable O 
state O 
. O 
The O 
first O 
residue O 
of O 
the O 
single O 
strand O 
RNA O 
segment O 
in O 
the O 
backtracked O 
transcription O 
elongation O 
complex O 
strongly O 
promotes O 
transcript O 
hydrolytic O 
cleavage O 
by O 
establishing O 
a O 
network O 
of O 
interactions O 
that O 
force O 
a O 
shift O 
of O 
stably O 
bound O 
Mg(2+) B-FORMULA 
to O 
release O 
some O 
of O 
its O 
aspartate B-TRIVIAL 
coordination O 
valences O 
for O 
binding O 
to O 
the O 
second O 
Mg(2+) B-FORMULA 
thus O 
enabling O 
catalysis O 
. O 
Such O 
a O 
rearrangement O 
that O 
we O 
call O 
active O 
center O 
tuning O 
( O 
ACT O 
) O 
occurs O 
when O 
all O 
recognition O 
contacts O 
of O 
the O 
active O 
center O 
- O 
bound O 
RNA O 
segment O 
are O 
established O 
and O 
verified O 
by O 
tolerance O 
to O 
stress O 
. O 
Transcription O 
factor O 
Gre O 
builds O 
on O 
the O 
ACT O 
mechanism O 
in O 
the O 
same O 
reaction O 
by O 
increasing O 
the O 
retention O 
of O 
the O 
second O 
Mg(2+) B-FORMULA 
and O 
by O 
activating O 
the O 
attacking O 
water O 
, O 
causing O 
3000-4000-fold O 
reaction O 
acceleration O 
and O 
strongly O 
reinforcing O 
proofreading O 
. O 
The O 
unified O 
mechanism O 
for O 
RNA O 
synthesis O 
and O 
degradation O 
by O 
RNA O 
polymerase O 
predicts O 
that O 
ACT O 
also O 
executes O 
NTP O 
selection O 
thereby O 
contributing O 
to O 
high O 
transcription O 
fidelity O 
. O 

waterborne O 
copper B-SYSTEMATIC 
toxicity O 
to O 
the O 
euryhaline O 
copepod O 
Acartia O 
tonsa O 
at O 
different O 
salinities O 
: O 
Influence O 
of O 
natural O 
freshwater O 
and O 
marine O 
dissolved O 
organic O 
matter O 
. O 

influence O 
of O 
natural O 
dissolved O 
organic O 
matter O 
( O 
DOM O 
) O 
on O 
acute O 
waterborne O 
Cu B-FORMULA 
toxicity O 
was O 
evaluated O 
in O 
the O 
euryhaline O 
copepod O 
Acartia O 
tonsa O 
at O 
3 O 
different O 
water O 
salinities O 
. O 
Three O 
sources O 
of O 
freshwater O 
DOM O 
( O 
extracted O 
by O 
reverse O 
osmosis O 
) O 
and O 
2 O 
sources O 
of O 
marine O 
DOM O 
( O 
extracted O 
using O 
a O 
solid O 
- O 
phase O 
technique O 
) O 
were O 
used O 
. O 
Artificial O 
salt O 
water O 
was O 
used O 
to O 
prepare O 
the O 
experimental O 
media O 
. O 
Different O 
combinations O 
of O 
Cu B-FORMULA 
concentrations O 
and O 
DOM O 
sources O 
and O 
concentrations O 
were O 
tested O 
at O 
salinities O 
of O 
5 O 
, O 
15 O 
, O 
and O 
30 O 
ppt O 
. O 
Toxicity O 
data O 
( O 
48-h O 
median O 
lethal O 
concentration O 
[ O 
LC50 O 
] O 
values O 
) O 
were O 
calculated O 
based O 
on O 
dissolved O 
Cu B-FORMULA 
concentrations O 
. O 
In O 
a O 
broad O 
view O 
, O 
data O 
showed O 
that O 
increasing O 
salinity O 
was O 
protective O 
against O 
the O 
acute O 
waterborne O 
Cu B-FORMULA 
toxicity O 
. O 
In O 
general O 
, O 
Cu B-FORMULA 
toxicity O 
was O 
also O 
lower O 
in O 
the O 
presence O 
than O 
in O 
the O 
absence O 
of O 
DOM O 
. O 
Toxicity O 
( O 
48-h O 
LC50 O 
) O 
values O 
from O 
all O 
treatments O 
at O 
the O 
same O 
salinity O 
showed O 
a O 
positive O 
linear O 
relationship O 
with O 
the O 
dissolved O 
organic O 
carbon B-SYSTEMATIC 
( O 
DOC O 
) O 
. O 
Thus O 
, O 
the O 
protective O 
effect O 
of O 
DOM O 
against O 
the O 
acute O 
Cu B-FORMULA 
toxicity O 
seems O 
to O 
be O 
dependent O 
mainly O 
on O 
the O 
DOM O 
concentration O 
. O 
However O 
, O 
it O 
seems O 
also O 
to O 
be O 
dependent O 
to O 
some O 
extent O 
on O 
the O 
source O 
of O 
DOM O 
used O 
. O 
In O 
summary O 
, O 
findings O 
reported O 
in O 
the O 
present O 
study O 
clearly O 
indicate O 
that O 
both O 
salinity O 
and O 
DOM O 
( O 
source O 
and O 
concentration O 
) O 
should O 
be O 
taken O 
into O 
account O 
in O 
the O 
development O 
of O 
an O 
estuarine O 
version O 
of O 
the O 
biotic O 
ligand O 
model O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1412-1419 O 
. O 
© O 
2013 O 
SETAC O 
. O 

of O 
the O 
combined O 
artesunate B-TRIVIAL 
and O 
mefloquine B-TRIVIAL 
antimalarial O 
drugs O 
on O 
rat O 
embryos O 
. O 

combination O 
therapy O 
( O 
ACT O 
) O 
is O 
the O 
first O 
choice O 
therapy O 
for O 
falciparum O 
malaria O 
. O 
Data O 
on O 
the O 
safety O 
of O 
ACTs O 
in O 
pregnancy O 
are O 
limited O 
and O 
controversial O 
and O 
the O 
use O 
is O 
not O 
recommended O 
on O 
the O 
first O 
trimester O 
. O 
To O 
evaluate O 
the O 
effects O 
of O 
isolated O 
and O 
combined O 
artesunate B-TRIVIAL 
(AS)/ O 
mefloquine B-TRIVIAL 
( O 
MQ O 
) O 
on O 
embryo O 
rats O 
, O 
pregnant O 
rats O 
were O 
treated O 
orally O 
with O 
AS O 
( O 
15 O 
and O 
40 O 
mg O 
/ O 
kg O 
body O 
weight O 
( O 
bwt O 
) O 
/ O 
day O 
) O 
, O 
MQ O 
( O 
30 O 
and O 
80 O 
mg O 
/ O 
kg O 
bwt O 
/ O 
day O 
) O 
and O 
AS O 
/ O 
MQ O 
( O 
15 O 
/ O 
30 O 
and O 
40 O 
/ O 
80 O 
mg O 
/ O 
kg O 
bwt O 
/ O 
day O 
) O 
on O 
days O 
9-11 O 
post O 
coitum O 
( O 
pc O 
) O 
. O 
The O 
dams O 
were O 
euthanized O 
on O 
day O 
12 O 
pc O 
and O 
gestational O 
and O 
embryos O 
histological O 
parameters O 
were O 
evaluated O 
. O 
Embryolethality O 
and O 
histopathological O 
anomalies O 
were O 
significant O 
when O 
AS O 
was O 
given O 
alone O 
or O 
combined O 
with O 
MQ O 
. O 
Combination O 
of O 
AS O 
and O 
MQ O 
did O 
not O 
enhance O 
their O 
toxicity O 
compared O 
to O 
their O 
separate O 
administrations O 
; O 
on O 
the O 
other O 
side O 
, O 
there O 
was O 
a O 
reduction O 
in O 
the O 
toxic O 
effects O 
of O 
the O 
AS O 
when O 
combined O 
with O 
MQ O 
. O 
Isolated O 
MQ O 
did O 
not O 
induce O 
developmental O 
toxicity O 
. O 

effects O 
of O 
inorganic O 
arsenic B-SYSTEMATIC 
on O 
gilthead O 
seabream O 
( O 
Sparus O 
aurata O 
L O 
. O 
) O 
. O 

( O 
As B-FORMULA 
) O 
has O 
been O 
associated O 
with O 
multitude O 
of O 
animal O 
and O 
human O 
health O 
problems O 
; O 
however O 
, O 
its O 
impact O 
on O 
host O 
immune O 
system O 
has O 
not O 
been O 
extensively O 
investigated O 
. O 
In O 
fish O 
, O 
there O 
are O 
very O 
few O 
works O 
on O 
the O 
potential O 
risks O 
or O 
problems O 
associated O 
to O 
the O 
presence O 
of O 
arsenic B-SYSTEMATIC 
. O 
In O 
the O 
present O 
study O 
we O 
have O 
evaluated O 
the O 
effects O 
of O 
exposure O 
( O 
30 O 
days O 
) O 
to O 
sub O 
- O 
lethal O 
concentrations O 
of O 
arsenic B-SYSTEMATIC 
( O 
5μM O 
As2O3 B-FORMULA 
) O 
in O 
the O 
teleost O 
fish O 
gilthead O 
seabream O 
( O 
Sparus O 
aurata O 
) O 
, O 
with O 
special O 
emphasis O 
in O 
the O 
innate O 
immune O 
response O 
. O 
The O 
arsenic B-SYSTEMATIC 
concentration O 
was O 
determined O 
using O 
atomic O 
fluorescence O 
spectrometry O 
( O 
AFS O 
) O 
in O 
liver O 
and O 
muscle O 
of O 
exposed O 
fish O 
showing O 
As B-FORMULA 
accumulation O 
in O 
the O 
liver O 
after O 
30 O 
days O 
of O 
exposure O 
. O 
The O 
hepatosomatic O 
index O 
was O 
increased O 
at O 
significant O 
extent O 
after O 
10 O 
days O 
but O 
returned O 
to O 
control O 
values O 
after O 
30 O 
days O 
of O 
exposure O 
. O 
Histological O 
alterations O 
in O 
the O 
liver O 
were O 
observed O 
including O 
hypertrophy O 
, O 
vacuolization O 
and O 
cell O 
- O 
death O 
processes O 
. O 
Focusing O 
on O 
the O 
immunological O 
response O 
, O 
the O 
humoral O 
immune O 
parameters O 
( O 
seric O 
IgM O 
, O 
complement O 
and O 
peroxidase O 
activities O 
) O 
were O 
no O 
affected O 
to O 
a O 
statistically O 
significant O 
extent O 
. O 
Regarding O 
the O 
cellular O 
innate O 
parameters O 
, O 
head O 
- O 
kidney O 
leucocyte O 
peroxidase O 
, O 
respiratory O 
burst O 
and O 
phagocytic O 
activities O 
were O 
significantly O 
increased O 
after O 
10 O 
days O 
of O 
exposition O 
compared O 
to O 
the O 
control O 
fish O 
. O 
Overall O 
, O 
As B-FORMULA 
-exposure O 
in O 
the O 
seabream O 
affects O 
the O 
immune O 
system O 
. O 
How O 
this O 
might O 
interfere O 
with O 
fish O 
biology O 
, O 
aquaculture O 
management O 
or O 
human O 
consumers O 
warrants O 
further O 
investigations O 
. O 
This O 
paper O 
describes O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
immunotoxicological O 
effects O 
of O 
arsenic B-SYSTEMATIC 
exposure O 
in O 
the O 
gilthead O 
seabream O 
, O 
which O 
is O 
a O 
species O 
with O 
the O 
largest O 
production O 
in O 
Mediterranean O 
aquaculture O 
. O 

acuminata O 
Royle O 
Ex O 
Lindl O 
. O 
blunts O 
production O 
of O 
pro O 
- O 
inflammatory O 
mediators O 
eicosanoids B-FAMILY 
. O 
, O 
leukotrienes B-FAMILY 
, O 
cytokines O 
in O 
vitro O 
and O 
in O 
vivo O 
models O 
of O 
acute O 
inflammatory O 
responses O 
. O 

RELEVANCE O 
: O 
Atropa O 
acuminata O 
Royle O 
Ex O 
Lindl O 
. O 
has O 
been O 
widely O 
used O 
in O 
folk O 
medicine O 
for O 
several O 
inflammatory O 
disorders O 
such O 
as O 
arthritis O 
, O 
asthma O 
, O 
conjunctivitis O 
, O 
encephalitis O 
, O 
pancreatitis O 
, O 
peritonitis O 
, O 
acute O 
infections O 
and O 
neuroinflammatory O 
disorders O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
Our O 
aim O 
was O 
to O 
evaluate O 
Atropa O 
acuminata O 
for O 
its O 
anti-inflammatory O 
properties O 
and O 
to O 
delineate O 
its O 
possible O 
mechanism O 
of O 
action O 
on O 
the O 
modulation O 
of O 
the O 
inflammatory O 
mediators O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
We O 
investigated O 
the O 
inhibitory O 
action O 
of O 
ethanolic O 
extract O 
of O 
Atropa O 
acuminata O 
( O 
AAEE O 
) O 
on O 
production O 
of O 
NO B-FORMULA 
, O 
TNF-α O 
and O 
IL-1β O 
in O 
lipopolysaccharide O 
(LPS)-stimulated O 
RAW264.7 O 
cells O 
and O 
also O 
assayed O 
it O 
for O 
COX O 
1 O 
/ O 
2 O 
and O 
5-LOX O 
inhibitory O 
activities O 
. O 
Next O 
AAEE O 
was O 
tested O 
in O 
acute O 
inflammatory O 
animal O 
models O 
. O 
, O 
carragenean O 
induced O 
rat O 
paw O 
edema O 
, O 
carragenean O 
induce O 
pleurisy O 
in O 
rats O 
and O 
vascular O 
permeability O 
in O 
mice O 
and O 
the O 
effects O 
on O 
NO B-FORMULA 
, O 
PGE2 B-ABBREVIATION 
and O 
LTB4 O 
production O 
in O 
the O 
pleural O 
fluid O 
and O 
paw O 
exudates O 
were O 
evaluated O 
. O 
In O 
addition O 
the O 
effects O 
on O 
leukocyte O 
migration O 
and O 
exudation O 
and O 
vascular O 
permeability O 
were O 
also O 
observed O 
. O 
RESULTS O 
: O 
Our O 
findings O 
summarized O 
novel O 
anti-inflammatory O 
mechanisms O 
for O 
Atropa O 
acuminata O 
based O 
on O 
dual O 
in O 
vitro O 
cyclooxygenase O 
1 O 
/ O 
2/ O 
and O 
5-Lipoxygenase O 
inhibitory O 
activities O 
and O 
also O 
significant O 
downregulation O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
pro O 
- O 
inflammatory O 
cytokin O 
( O 
TNF-α O 
and O 
Il-1 O 
β O 
) O 
release O 
in O 
LPS-stimulated O 
RAW O 
246.7 O 
macrophage O 
cell O 
line O 
. O 
In O 
acute O 
inflammatory O 
models O 
in O 
vivo O 
( O 
carragenean O 
induced O 
edema O 
, O 
carragenean O 
induced O 
pleurisy O 
in O 
rats O 
and O 
vascular O 
permeability O 
in O 
mice O 
) O 
, O 
AAEE O 
exhibited O 
an O 
extensive O 
diverse O 
mechanism O 
for O 
anti-inflammatory O 
properties O 
. O 
This O 
was O 
indicated O 
on O 
the O 
basis O 
of O 
dose O 
dependent O 
suppression O 
of O 
multi O 
targeted O 
inflammatory O 
mediators O 
. O 
, O 
NO B-FORMULA 
, O 
TNF-α O 
and O 
IL-1β O 
, O 
eicosanoids B-FAMILY 
. O 
, O 
PGE2 B-ABBREVIATION 
and O 
leukotrienes B-FAMILY 
. O 
, O 
LTB4 O 
along O 
with O 
significantly O 
decreased O 
leucocyte O 
migration O 
, O 
exudation O 
and O 
decreased O 
vascular O 
permeability O 
. O 
These O 
effects O 
were O 
more O 
potent O 
and O 
prolonged O 
than O 
traditional O 
NSAIDS O 
, O 
thereby O 
indicating O 
fewer O 
side O 
effects O 
. O 
AAEE O 
was O 
found O 
to O 
be O 
safe O 
for O 
long O 
term O 
administration O 
, O 
as O 
confirmed O 
by O 
the O 
results O 
of O 
acute O 
toxicity O 
studies O 
and O 
MTT B-ABBREVIATION 
assay O 
. O 
The O 
complex O 
mode O 
of O 
action O 
of O 
the O 
herbs O 
was O 
attributed O 
possibly O 
due O 
to O 
the O 
high O 
polyphenolic B-FAMILY 
, O 
flavanol B-FAMILY 
and O 
flavonoid B-FAMILY 
content O 
present O 
in O 
the O 
extracts O 
as O 
observed O 
by O 
means O 
of O 
quantitative O 
screening O 
for O 
phytochemicals O 
. O 
CONCLUSION O 
: O 
Our O 
study O 
provides O 
scientific O 
evidence O 
to O 
support O 
the O 
traditional O 
anti-inflammatory O 
uses O 
of O 
Atropa O 
acuminata O 
and O 
is O 
probably O 
due O 
to O 
inhibitory O 
effects O 
on O 
multiple O 
inflammatory O 
mediators O 
which O 
indicates O 
a O 
promising O 
potential O 
for O 
the O 
development O 
of O 
a O 
strong O 
anti-inflammatory O 
agent O 
from O 
this O 
plant O 
. O 

a O 
structure O 
based O 
design O 
approach O 
we O 
have O 
identified O 
a O 
series O 
of O 
indazole B-SYSTEMATIC 
substituted O 
pyrrolopyrazines B-FAMILY 
, O 
which O 
are O 
potent O 
inhibitors O 
of O 
JAK3 O 
. O 
Intramolecular O 
electronic O 
repulsion O 
was O 
used O 
as O 
a O 
strategy O 
to O 
induce O 
a O 
strong O 
conformational O 
bias O 
within O 
the O 
ligand O 
. O 
Compounds O 
bearing O 
this O 
conformation O 
participated O 
in O 
a O 
favorable O 
hydrophobic O 
interaction O 
with O 
a O 
cysteine B-TRIVIAL 
residue O 
in O 
the O 
JAK3 O 
binding O 
pocket O 
, O 
which O 
imparted O 
high O 
selectivity O 
versus O 
the O 
kinome O 
and O 
improved O 
selectivity O 
within O 
the O 
JAK O 
family O 
. O 

-Catalyzed O 
Tandem O 
Enyne B-SYSTEMATIC 
Cyclization/ O 
1,2 B-FAMILY 
Ester I-FAMILY 
Migration O 
Reaction O 
Controlled O 
by O 
Substituent O 
Effects O 
of O 
All-Carbon B-FAMILY 
1,6-Enynyl I-FAMILY 
Esters I-FAMILY 
. O 

the O 
move O 
: O 
A O 
novel O 
PtCl2 B-FORMULA 
-catalyzed O 
tandem O 
1,6-enyne B-SYSTEMATIC 
cyclization/ O 
1,2-acyloxy B-SYSTEMATIC 
migration O 
reaction O 
was O 
developed O 
, O 
which O 
was O 
shown O 
to O 
be O 
controlled O 
by O 
substitution O 
effects O 
. O 
Using O 
this O 
method O 
, O 
a O 
series O 
of O 
substituted O 
enol B-FAMILY 
esters I-FAMILY 
containing O 
the O 
cyclopentenyl B-SYSTEMATIC 
motif O 
were O 
prepared O 
in O 
moderate O 
to O 
high O 
yields O 
. O 

of O 
a O 
bioassay O 
- O 
derived O 
ivermectin B-TRIVIAL 
lowest O 
observed O 
effect O 
concentration O 
on O 
life O 
- O 
cycle O 
traits O 
of O 
the O 
nematode O 
Caenorhabditis O 
elegans O 
. O 

pharmaceutical O 
ivermectin B-TRIVIAL 
is O 
used O 
to O 
treat O 
parasitic O 
infections O 
, O 
such O 
as O 
those O 
caused O 
by O 
nematodes O 
. O 
While O 
several O 
studies O 
have O 
demonstrated O 
the O 
severe O 
effects O 
of O 
ivermectin B-TRIVIAL 
on O 
non-target O 
organisms O 
, O 
little O 
is O 
known O 
about O 
the O 
drug's O 
impact O 
on O 
free O 
- O 
living O 
nematodes O 
. O 
In O 
the O 
present O 
work O 
, O 
a O 
full O 
life O 
- O 
cycle O 
experiment O 
was O 
conducted O 
to O 
estimate O 
how O 
an O 
ivermectin B-TRIVIAL 
lowest O 
observed O 
effect O 
concentration O 
derived O 
from O 
a O 
Caenorhabditis O 
elegans O 
bioassay O 
( O 
endpoint O 
reproduction O 
) O 
might O 
translate O 
into O 
effects O 
at O 
the O 
population O 
level O 
of O 
this O 
free O 
- O 
living O 
nematode O 
. O 
The O 
results O 
showed O 
that O 
fecundity O 
decreased O 
to O 
levels O 
similar O 
to O 
those O 
determined O 
in O 
the O 
bioassay O 
after O 
a O 
time O 
of O 
corresponding O 
duration O 
( O 
18.6 O 
% O 
inhibition O 
compared O 
to O 
the O 
control O 
) O 
, O 
but O 
the O 
impact O 
then O 
rather O 
weakened O 
until O 
the O 
end O 
of O 
the O 
experiment O 
, O 
at O 
which O 
point O 
the O 
net O 
reproductive O 
rate O 
(R(0)) O 
was O 
still O 
, O 
but O 
not O 
significantly O 
, O 
reduced O 
by O 
12.4 O 
% O 
. O 
Moreover O 
, O 
the O 
average O 
lifespan O 
, O 
length O 
of O 
the O 
reproductive O 
period O 
, O 
maximum O 
daily O 
reproduction O 
rate O 
, O 
and O 
intrinsic O 
rate O 
of O 
increase O 
(r(m)) O 
were O 
significantly O 
reduced O 
by O 
30 O 
, O 
25.9 O 
, O 
11.2 O 
, O 
and O 
3.5 O 
% O 
, O 
respectively O 
. O 
The O 
experiment O 
revealed O 
that O 
a O 
4-day O 
bioassay O 
is O 
protective O 
enough O 
for O 
C O 
. O 
elegans O 
with O 
respect O 
to O 
ivermectin B-TRIVIAL 
' O 
s O 
effects O 
on O 
fecundity O 
. O 
However O 
, O 
the O 
pronounced O 
effects O 
of O 
a O 
low O 
drug O 
concentration O 
on O 
survival O 
, O 
a O 
highly O 
elastic O 
trait O 
, O 
may O 
better O 
account O 
for O 
the O 
observed O 
population O 
- O 
level O 
response O 
, O 
i.e O 
. O 
, O 
a O 
decrease O 
of O 
r(m) O 
, O 
than O 
the O 
effects O 
on O 
fecundity O 
. O 
These O 
results O 
emphasize O 
that O 
full O 
life O 
- O 
cycle O 
experiments O 
are O 
valuable O 
for O 
assessment O 
of O 
pollutants O 
, O 
because O 
the O 
effects O 
on O 
several O 
life O 
- O 
cycle O 
traits O 
can O 
be O 
simultaneously O 
measured O 
and O 
integrated O 
into O 
an O 
ecologically O 
relevant O 
parameter O 
, O 
the O 
population O 
growth O 
rate O 
, O 
that O 
reflects O 
a O 
population's O 
response O 
to O 
a O 
specific O 
pollutant O 
. O 

isothiocyanate I-SYSTEMATIC 
reverses O 
platinum B-SYSTEMATIC 
resistance O 
by O 
a O 
GSH B-ABBREVIATION 
-dependent O 
mechanism O 
in O 
cancer O 
cells O 
with O 
epithelial O 
- O 
mesenchymal O 
transition O 
phenotype O 
. O 

( O 
Pt B-FORMULA 
) O 
- O 
based O 
chemotherapy O 
is O 
an O 
important O 
regimen O 
in O 
the O 
clinical O 
treatment O 
of O 
cancer O 
, O 
but O 
development O 
of O 
drug O 
resistance O 
presents O 
a O 
major O 
challenge O 
. O 
One O 
key O 
mechanism O 
involved O 
in O 
resistance O 
to O 
Pt B-FORMULA 
drugs O 
is O 
the O 
decrease O 
of O 
intracellular O 
Pt B-FORMULA 
due O 
to O 
the O 
drug O 
efflux O 
through O 
the O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
- O 
mediated O 
export O 
, O 
and O 
this O 
is O 
particularly O 
significant O 
in O 
cancer O 
cells O 
with O 
stem O 
- O 
cell O 
like O 
properties O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
showed O 
that O 
two O 
Pt B-FORMULA 
-resistant O 
human O 
cancer O 
cell O 
lines O 
exhibited O 
stem O 
- O 
cell O 
like O 
EMT O 
properties O 
, O 
had O 
high O 
cellular O 
GSH B-ABBREVIATION 
and O 
accumulated O 
significantly O 
less O 
cellular O 
Pt B-FORMULA 
compared O 
to O 
their O 
parental O 
cells O 
, O 
and O 
failed O 
to O 
undergo O 
apoptosis O 
when O 
exposed O 
to O 
Pt B-FORMULA 
at O 
the O 
drug O 
concentrations O 
toxic O 
to O 
the O 
parental O 
cells O 
. O 
Importantly O 
, O 
we O 
found O 
that O 
the O 
natural O 
compound O 
β-phenylethyl B-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
( O 
PEITC B-ABBREVIATION 
) O 
was O 
able O 
to O 
effectively O 
abolish O 
this O 
drug O 
resistant O 
mechanism O 
by O 
effective O 
depletion O 
of O 
cellular O 
GSH B-ABBREVIATION 
, O 
leading O 
to O 
a O 
significant O 
increase O 
in O 
cellular O 
Pt B-FORMULA 
as O 
well O 
as O 
DNA O 
- O 
bound O 
Pt B-FORMULA 
. O 
A O 
combination O 
of O 
PEITC B-ABBREVIATION 
and O 
Pt B-FORMULA 
showed O 
a O 
striking O 
synergistic O 
anticancer O 
activity O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
, O 
as O 
evidenced O 
by O 
an O 
increase O 
in O 
drug O 
- O 
induced O 
apoptosis O 
, O 
a O 
loss O 
of O 
colony O 
formation O 
capacity O 
, O 
and O 
significant O 
suppression O 
of O 
tumor O 
growth O 
in O 
mice O 
. O 
Taken O 
together O 
, O 
our O 
study O 
shows O 
a O 
promising O 
therapeutic O 
strategy O 
to O 
overcome O 
drug O 
resistance O 
to O 
platinum B-SYSTEMATIC 
-based O 
chemotherapy O 
and O 
may O 
potentially O 
have O 
broad O 
implications O 
in O 
clinical O 
treatment O 
of O 
cancer O 
. O 

roles O 
of O 
aldo O 
- O 
keto O 
reductases O 
( O 
AKR1C1 O 
and O 
AKR1C3 O 
) O 
in O 
development O 
of O 
cisplatin B-TRIVIAL 
resistance O 
in O 
human O 
colon O 
cancers O 
. O 

( O 
cis-diamminedichloroplatinum B-SYSTEMATIC 
, O 
CDDP B-ABBREVIATION 
) O 
is O 
widely O 
used O 
for O 
treatment O 
of O 
patients O 
with O 
solid O 
tumors O 
formed O 
in O 
various O 
organs O 
including O 
the O 
lung O 
, O 
prostate O 
and O 
cervix O 
, O 
but O 
is O 
much O 
less O 
sensitive O 
in O 
colon O 
and O 
breast O 
cancers O 
. O 
One O 
major O 
factor O 
implicated O 
in O 
the O 
ineffectiveness O 
has O 
been O 
suggested O 
to O 
be O 
acquisition O 
of O 
the O 
CDDP B-ABBREVIATION 
resistance O 
. O 
Here O 
, O 
we O 
established O 
the O 
CDDP B-ABBREVIATION 
-resistant O 
phenotypes O 
of O 
human O 
colon O 
HCT15 O 
cells O 
by O 
continuously O 
exposing O 
them O 
to O 
incremental O 
concentrations O 
of O 
the O 
drug O 
, O 
and O 
monitored O 
expressions O 
of O 
aldo O 
- O 
keto O 
reductases O 
( O 
AKRs O 
) O 
1A1 O 
, O 
1B1 O 
, O 
1B10 O 
, O 
1C1 O 
, O 
1C2 O 
and O 
1C3 O 
. O 
Among O 
the O 
six O 
AKRs O 
, O 
AKR1C1 O 
and O 
AKR1C3 O 
are O 
highly O 
induced O 
with O 
the O 
CDDP B-ABBREVIATION 
resistance O 
. O 
The O 
resistance O 
lowered O 
the O 
sensitivity O 
toward O 
cellular O 
damages O 
evoked O 
by O 
oxidative O 
stress O 
- O 
derived O 
aldehydes B-FAMILY 
, O 
4-hydroxy-2-nonenal B-SYSTEMATIC 
and O 
4-oxo-2-nonenal B-SYSTEMATIC 
that O 
are O 
detoxified O 
by O 
AKR1C1 O 
and O 
AKR1C3 O 
. O 
Overexpression O 
of O 
AKR1C1 O 
or O 
AKR1C3 O 
in O 
the O 
parental O 
HCT15 O 
cells O 
mitigated O 
the O 
cytotoxicity O 
of O 
the O 
aldehydes B-FAMILY 
and O 
CDDP B-ABBREVIATION 
. O 
Knockdown O 
of O 
both O 
AKR1C1 O 
and O 
AKR1C3 O 
in O 
the O 
resistant O 
cells O 
or O 
treatment O 
of O 
the O 
cells O 
with O 
specific O 
inhibitors O 
of O 
the O 
AKRs O 
increased O 
the O 
sensitivity O 
to O 
CDDP B-ABBREVIATION 
toxicity O 
. O 
Thus O 
, O 
the O 
two O 
AKRs O 
participate O 
in O 
the O 
mechanism O 
underlying O 
the O 
CDDP B-ABBREVIATION 
resistance O 
probably O 
via O 
detoxification O 
of O 
the O 
aldehydes B-FAMILY 
resulting O 
from O 
enhanced O 
oxidative O 
stress O 
. O 
The O 
resistant O 
cells O 
also O 
showed O 
an O 
enhancement O 
in O 
proteolytic O 
activity O 
of O 
proteasome O 
accompanied O 
by O 
overexpression O 
of O 
its O 
catalytic O 
subunits O 
( O 
PSMβ9 O 
and O 
PSMβ10 O 
) O 
. O 
Pretreatment O 
of O 
the O 
resistant O 
cells O 
with O 
a O 
potent O 
proteasome O 
inhibitor O 
Z-Leu-Leu-Leu- B-FORMULA 
al I-FORMULA 
augmented O 
the O 
CDDP B-ABBREVIATION 
sensitization O 
elicited O 
by O 
the O 
AKR O 
inhibitors O 
. O 
Additionally O 
, O 
the O 
treatment O 
of O 
the O 
cells O 
with O 
Z-Leu-Leu-Leu- B-FORMULA 
al I-FORMULA 
and O 
the O 
AKR O 
inhibitors O 
induced O 
the O 
expressions O 
of O 
the O 
two O 
AKRs O 
and O 
proteasome O 
subunits O 
. O 
Collectively O 
, O 
these O 
results O 
suggest O 
the O 
involvement O 
of O 
up O 
- O 
regulated O 
AKR1C1 O 
, O 
AKR1C3 O 
and O 
proteasome O 
in O 
CDDP B-ABBREVIATION 
resistance O 
of O 
colon O 
cancers O 
and O 
support O 
a O 
chemotherapeutic O 
role O 
for O 
their O 
inhibitors O 
. O 

and O 
activation O 
of O 
Akt1 O 
is O 
a O 
crucial O 
signaling O 
event O 
that O 
promotes O 
adipogenesis O 
. O 
However O 
, O 
neither O 
the O 
complex O 
multistep O 
process O 
that O 
leads O 
to O 
activation O 
of O 
Akt1 O 
through O 
phosphorylation O 
at O 
Thr B-FORMULA 
³⁰⁸ O 
and O 
Ser B-FORMULA 
⁴⁷³ O 
nor O 
the O 
mechanism O 
by O 
which O 
Akt1 O 
stimulates O 
adipogenesis O 
is O 
fully O 
understood O 
. O 
We O 
found O 
that O 
the O 
BSD O 
domain O 
- O 
containing O 
signal O 
transducer O 
and O 
Akt O 
interactor O 
( O 
BSTA O 
) O 
promoted O 
phosphorylation O 
of O 
Akt1 O 
at O 
Ser B-FORMULA 
⁴⁷³ O 
in O 
various O 
human O 
and O 
murine O 
cells O 
, O 
and O 
we O 
uncovered O 
a O 
function O 
for O 
the O 
BSD O 
domain O 
in O 
BSTA-Akt1 O 
complex O 
formation O 
. O 
The O 
mammalian O 
target O 
of O 
rapamycin O 
complex O 
2 O 
( O 
mTORC2 O 
) O 
facilitated O 
the O 
phosphorylation O 
of O 
BSTA O 
and O 
its O 
association O 
with O 
Akt1 O 
, O 
and O 
the O 
BSTA-Akt1 O 
interaction O 
promoted O 
the O 
association O 
of O 
mTORC2 O 
with O 
Akt1 O 
and O 
phosphorylation O 
of O 
Akt1 O 
at O 
Ser B-FORMULA 
⁴⁷³ O 
in O 
response O 
to O 
growth O 
factor O 
stimulation O 
. O 
Furthermore O 
, O 
analyses O 
of O 
bsta O 
gene O 
- O 
trap O 
murine O 
embryonic O 
stem O 
cells O 
revealed O 
an O 
essential O 
function O 
for O 
BSTA O 
and O 
phosphorylation O 
of O 
Akt1 O 
at O 
Ser B-FORMULA 
⁴⁷³ O 
in O 
promoting O 
adipocyte O 
differentiation O 
, O 
which O 
required O 
suppression O 
of O 
the O 
expression O 
of O 
the O 
gene O 
encoding O 
the O 
transcription O 
factor O 
FoxC2 O 
. O 
These O 
findings O 
indicate O 
that O 
BSTA O 
is O 
a O 
molecular O 
switch O 
that O 
promotes O 
phosphorylation O 
of O 
Akt1 O 
at O 
Ser B-FORMULA 
⁴⁷³ O 
and O 
reveal O 
an O 
mTORC2-BSTA-Akt1-FoxC2 O 
- O 
mediated O 
signaling O 
mechanism O 
that O 
is O 
critical O 
for O 
adipocyte O 
differentiation O 
. O 

tris(o-phenylenedioxy)cyclotriphosphazene B-SYSTEMATIC 
( O 
TPP B-ABBREVIATION 
) O 
is O 
used O 
as O 
ahost O 
for O 
organizing O 
dipolar O 
molecular O 
rotor O 
guests O 
into O 
regular O 
trigonal O 
arrays O 
. O 
Inclusion O 
of O 
molecular O 
rotors O 
with O 
transversely O 
dipolar O 
rotators O 
into O 
TPP B-ABBREVIATION 
channels O 
is O 
followed O 
by O 
solid O 
- O 
state O 
nuclear O 
magnetic O 
resonance O 
, O 
diifferential O 
scanning O 
calorimetry O 
, O 
X-ray O 
diffraction O 
, O 
and O 
dielectric O 
spectroscopy O 
. O 
The O 
more O 
polar O 
of O 
the O 
two O 
rotors O 
does O 
not O 
form O 
an O 
inclusion O 
. O 
The O 
second O 
rotor O 
forms O 
two O 
different O 
inclusions O 
differing O 
in O 
crystallite O 
size O 
and O 
the O 
rotational O 
barriers O 
. O 

nanoantennas O 
facilitate O 
the O 
manipulation O 
of O 
light O 
fields O 
on O 
deeply O 
sub O 
- O 
diffraction O 
- O 
limited O 
length O 
scales O 
, O 
but O 
high O 
dissipative O 
losses O 
in O 
metals O 
make O 
new O 
approaches O 
for O 
an O 
efficient O 
energy O 
transfer O 
in O 
extended O 
on O 
- O 
chip O 
integrated O 
plasmonic O 
circuits O 
mandatory O 
. O 
We O 
demonstrate O 
in O 
this O 
article O 
efficient O 
photon O 
transfer O 
in O 
discrete O 
optoplasmonic O 
molecules O 
comprising O 
gold O 
nanoparticle O 
( O 
NP O 
) O 
dimer O 
antennas O 
located O 
in O 
the O 
evanescent O 
field O 
of O 
a O 
2 O 
μm O 
diameter O 
polystyrene B-SYSTEMATIC 
bead O 
, O 
which O 
served O 
as O 
an O 
optical O 
microcavity O 
( O 
OM O 
) O 
. O 
The O 
optoplasmonic O 
molecules O 
were O 
generated O 
through O 
a O 
guided O 
self O 
- O 
assembly O 
strategy O 
in O 
which O 
the O 
OMs O 
were O 
immobilized O 
in O 
binding O 
sites O 
generated O 
by O 
quartz B-TRIVIAL 
( O 
SiO2 B-FORMULA 
) O 
or O 
silicon B-SYSTEMATIC 
posts O 
that O 
contained O 
plasmonic O 
nanoantennas O 
on O 
their O 
tips O 
. O 
Control O 
of O 
the O 
post O 
height O 
facilitated O 
an O 
accurate O 
positioning O 
of O 
the O 
plasmonic O 
antennas O 
into O 
the O 
evanescent O 
field O 
of O 
the O 
whispering O 
gallery O 
modes O 
located O 
in O 
the O 
equatorial O 
plane O 
of O 
the O 
OM O 
. O 
Cy3 B-FAMILY 
and O 
Cy5.5 B-FAMILY 
dyes O 
were O 
tethered O 
to O 
the O 
plasmonic O 
antennas O 
through O 
oligonucleotide O 
spacers O 
to O 
act O 
as O 
on O 
- O 
chip O 
light O 
sources O 
. O 
The O 
intensity O 
of O 
Cy3 B-FAMILY 
was O 
found O 
to O 
be O 
increased O 
relative O 
to O 
that O 
of O 
Cy5.5 B-FAMILY 
in O 
the O 
vicinity O 
of O 
the O 
plasmonic O 
antennas O 
where O 
strongly O 
enhanced O 
electric O 
field O 
intensity O 
and O 
optical O 
density O 
of O 
states O 
selectively O 
increase O 
the O 
excitation O 
and O 
emission O 
rates O 
of O 
Cy3 B-FAMILY 
due O 
to O 
spectral O 
overlap O 
with O 
the O 
plasmon O 
. O 
The O 
fluorescent O 
dyes O 
preferentially O 
emitted O 
into O 
the O 
OM O 
, O 
which O 
efficiently O 
trapped O 
and O 
recirculated O 
the O 
photons O 
. O 
We O 
experimentally O 
determined O 
a O 
relative O 
photon O 
transfer O 
efficiency O 
of O 
44% O 
in O 
non-optimized O 
self O 
- O 
assembled O 
optoplasmonic O 
molecules O 
in O 
this O 
proof O 
- O 
of O 
- O 
principle O 
study O 
. O 

response O 
to O 
centrally O 
- O 
acting O 
drugs O 
is O 
highly O 
variable O 
between O 
individuals O 
and O 
does O 
not O 
always O 
correlate O 
with O 
plasma O 
drug O 
levels O 
. O 
Drug O 
- O 
metabolizing O 
CYP O 
enzymes O 
in O 
the O 
brain O 
may O 
contribute O 
to O 
this O 
variability O 
by O 
affecting O 
local O 
drug O 
and O 
metabolite O 
concentrations O 
. O 
CYP2D O 
metabolizes O 
codeine B-TRIVIAL 
to O 
the O 
active O 
morphine B-TRIVIAL 
metabolite O 
. O 
We O 
investigate O 
the O 
effect O 
of O 
inhibiting O 
brain O 
, O 
and O 
not O 
liver O 
, O 
CYP2D O 
activity O 
on O 
codeine B-TRIVIAL 
-induced O 
analgesia O 
. O 
Rats O 
received O 
intracerebroventricular O 
injections O 
of O 
CYP2D O 
inhibitors O 
( O 
20μg O 
propranolol B-TRIVIAL 
or O 
40μg O 
propafenone B-TRIVIAL 
) O 
or O 
vehicle O 
controls O 
. O 
Compared O 
to O 
vehicle O 
- O 
pretreated O 
rats O 
, O 
inhibitor O 
- O 
pretreated O 
rats O 
had O 
: O 
a O 
) O 
lower O 
analgesia O 
in O 
the O 
tail O 
- O 
flick O 
test O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
lower O 
areas O 
under O 
the O 
analgesia O 
- O 
time O 
curve O 
( O 
p O 
< O 
0.02 O 
) O 
within O 
the O 
first O 
hour O 
after O 
30mg O 
/ O 
kg O 
subcutaneous O 
codeine B-TRIVIAL 
, O 
b O 
) O 
lower O 
morphine B-TRIVIAL 
concentrations O 
and O 
morphine B-TRIVIAL 
to O 
codeine B-TRIVIAL 
ratios O 
in O 
the O 
brain O 
( O 
p O 
< O 
0.02 O 
and O 
p O 
< O 
0.05 O 
, O 
respectively O 
) O 
, O 
but O 
not O 
in O 
plasma O 
( O 
p O 
> O 
0.6 O 
and O 
p O 
> O 
0.7 O 
, O 
respectively O 
) O 
, O 
tested O 
at O 
30min O 
after O 
30mg O 
/ O 
kg O 
subcutaneous O 
codeine B-TRIVIAL 
, O 
and O 
c O 
) O 
lower O 
morphine B-TRIVIAL 
formation O 
from O 
codeine B-TRIVIAL 
ex O 
vivo O 
by O 
brain O 
membranes O 
( O 
p O 
< O 
0.04 O 
) O 
, O 
but O 
not O 
by O 
liver O 
microsomes O 
( O 
p O 
> O 
0.9 O 
) O 
. O 
Analgesia O 
trended O 
toward O 
a O 
correlation O 
with O 
brain O 
morphine B-TRIVIAL 
concentrations O 
( O 
p=0.07 O 
) O 
and O 
correlated O 
with O 
brain O 
morphine B-TRIVIAL 
to O 
codeine B-TRIVIAL 
ratios O 
( O 
p O 
< O 
0.005 O 
) O 
, O 
but O 
not O 
with O 
plasma O 
morphine B-TRIVIAL 
concentrations O 
( O 
p O 
> O 
0.8 O 
) O 
or O 
plasma O 
morphine B-TRIVIAL 
to O 
codeine O 
ratios O 
( O 
p O 
> O 
0.8 O 
) O 
. O 
Our O 
findings O 
suggest O 
that O 
brain O 
CYP2D O 
affects O 
brain O 
morphine B-TRIVIAL 
levels O 
after O 
peripheral O 
codeine B-TRIVIAL 
administration O 
, O 
and O 
may O 
thereby O 
alter O 
codeine B-TRIVIAL 
' O 
s O 
therapeutic O 
efficacy O 
, O 
side-effect O 
profile O 
and O 
abuse O 
liability O 
. O 
Brain O 
CYPs O 
are O 
highly O 
variable O 
due O 
to O 
genetics O 
, O 
environmental O 
factors O 
and O 
age O 
, O 
and O 
may O 
therefore O 
contribute O 
to O 
interindividual O 
variation O 
in O 
the O 
response O 
to O 
centrally O 
- O 
acting O 
drugs O 
. O 

sequence O 
of O 
the O 
enterococcal O 
cytolysin O 
imparts O 
unusual O 
lanthionine B-TRIVIAL 
stereochemistry O 
. O 

enterococcal O 
cytolysin O 
is O 
a O 
two O 
- O 
component O 
lantibiotic O 
of O 
unknown O 
structure O 
with O 
hemolytic O 
activity O 
that O 
is O 
important O 
for O 
virulence O 
. O 
We O 
prepared O 
cytolysin O 
by O 
coexpression O 
of O 
each O 
precursor O 
peptide O 
with O 
the O 
synthetase O 
CylM O 
in O 
Escherichia O 
coli O 
and O 
characterized O 
its O 
structure O 
. O 
Unexpectedly O 
, O 
cytolysin O 
is O 
to O 
our O 
knowledge O 
the O 
first O 
example O 
of O 
a O 
lantibiotic O 
containing O 
lanthionine B-TRIVIAL 
and O 
methyllanthionine B-SYSTEMATIC 
structures O 
with O 
different O 
stereochemistries O 
in O 
the O 
same O 
peptide O 
. O 
The O 
stereochemistry O 
is O 
determined O 
by O 
the O 
sequence O 
of O 
the O 
substrate O 
peptide O 
. O 

silencing O 
and O 
LIM-homeodomain O 
protein O 
- O 
induced O 
activation O 
are O 
mediated O 
by O 
a O 
bi O 
- O 
functional O 
response O 
element O 
in O 
the O 
rat O 
GnRH B-ABBREVIATION 
receptor O 
gene O 
. O 

transcription O 
factor O 
and O 
LIM O 
homeodomain O 
proteins O 
Islet1 O 
( O 
ISL1 O 
) O 
and O 
LIM O 
homeobox O 
3 O 
( O 
LHX3 O 
) O 
are O 
suspected O 
to O 
be O 
involved O 
in O 
gonadotrope O 
cell O 
fate O 
and O 
maintenance O 
. O 
The O 
GnRH B-ABBREVIATION 
receptor O 
gene O 
( O 
Gnrhr O 
) O 
, O 
crucial O 
for O 
gonadotrope O 
function O 
, O 
is O 
expressed O 
in O 
the O 
pituitary O 
gland O 
from O 
embryonic O 
day O 
13.5 O 
onward O 
, O 
well O 
before O 
LH O 
and O 
FSH O 
β-subunits O 
. O 
This O 
expression O 
pattern O 
together O 
with O 
the O 
presence O 
of O 
WGATAR O 
and O 
TAAT O 
motifs O 
in O 
Gnrhr O 
promoter O 
sequences O 
suggests O 
the O 
involvement O 
of O 
early O 
transcription O 
factors O 
in O 
promoter O 
activation O 
. O 
In O 
this O 
study O 
, O 
using O 
a O 
well O 
- O 
characterized O 
transgenic O 
mouse O 
model O 
, O 
GATA2 O 
was O 
found O 
colocalized O 
with O 
Gnrhr O 
promoter O 
activity O 
in O 
the O 
pituitary O 
. O 
Transient O 
transfection O 
of O 
Gnrhr O 
promoter O 
luciferase O 
fusion O 
constructs O 
together O 
with O 
either O 
GATA2 O 
expression O 
vectors O 
or O 
small O 
interfering O 
RNA O 
in O 
gonadotrope O 
cell O 
lines O 
indicated O 
that O 
GATA2 O 
, O 
which O 
typically O 
acts O 
as O 
a O 
trans-activator O 
, O 
unexpectedly O 
repressed O 
Gnrhr O 
promoter O 
activity O 
. O 
Using O 
DNA O 
chromatography O 
affinity O 
and O 
EMSA O 
, O 
we O 
demonstrated O 
that O 
GATA2 O 
operates O 
via O 
a O 
response O 
element O 
containing O 
a O 
peculiar O 
palindromic O 
GATA O 
motif O 
that O 
overlaps O 
a O 
critical O 
TAAT O 
motif O 
involved O 
in O 
LHX3 O 
/ O 
ISL1 O 
trans-activation O 
. O 
Indeed O 
, O 
despite O 
the O 
inhibitory O 
action O 
of O 
GATA2 O 
, O 
this O 
element O 
displayed O 
a O 
clear O 
- O 
cut O 
enhancer O 
activity O 
in O 
gonadotrope O 
cells O 
. O 
Chromatin O 
immunoprecipitation O 
assays O 
indicated O 
that O 
GATA2 O 
, O 
LHX3 O 
, O 
and O 
ISL1 O 
interact O 
with O 
a O 
Gnrhr O 
promoter O 
fragment O 
encompassing O 
this O 
element O 
. O 
The O 
trans-repressive O 
action O 
of O 
GATA2 O 
on O 
Gnrhr O 
promoter O 
activity O 
is O 
likely O 
balanced O 
or O 
even O 
hindered O 
by O 
trans-activating O 
effects O 
of O 
LIM O 
homeodomain O 
proteins O 
via O 
this O 
novel O 
bifunctional O 
LIM O 
/ O 
GATA O 
response O 
element O 
. O 
Such O 
a O 
hierarchical O 
interplay O 
may O 
contribute O 
to O 
finely O 
adjust O 
Gnrhr O 
gene O 
expression O 
in O 
gonadotrope O 
cell O 
lineage O 
during O 
pituitary O 
development O 
as O 
well O 
as O 
in O 
the O 
adult O 
animal O 
. O 

this O 
paper O 
, O 
the O 
controlled O 
release O 
of O 
aroma O 
compounds O 
from O 
cyclodextrins O 
( O 
CDs O 
) O 
and O 
CD O 
polymers O 
was O 
studied O 
by O 
multiple O 
headspace O 
extraction O 
( O 
MHE O 
) O 
experiments O 
. O 
Mentha O 
piperita O 
essential O 
oil O 
was O 
obtained O 
by O 
Soxhlet O 
extraction O 
and O 
identification O 
of O 
the O 
major O 
compounds O 
was O 
performed O 
by O 
GC-MS O 
analysis O 
. O 
Menthol B-TRIVIAL 
, O 
menthone B-TRIVIAL 
, O 
pulegone B-TRIVIAL 
and O 
eucalyptol B-TRIVIAL 
were O 
identified O 
as O 
the O 
major O 
components O 
. O 
Retention O 
of O 
standard O 
compounds O 
in O 
the O 
presence O 
of O 
different O 
CDs O 
and O 
CD O 
polymers O 
has O 
been O 
realised O 
by O 
static O 
headspace O 
gas O 
chromatography O 
( O 
SH-GC O 
) O 
at O 
25 O 
°C O 
in O 
the O 
aqueous O 
or O 
gaseous O 
phase O 
. O 
Stability O 
constants O 
for O 
standard O 
compounds O 
and O 
for O 
compounds O 
in O 
essential O 
oil O 
have O 
been O 
also O 
determined O 
with O 
monomeric O 
CD O 
derivatives O 
. O 
The O 
obtained O 
results O 
indicated O 
the O 
formation O 
of O 
a O 
1 O 
: O 
1 O 
inclusion O 
complex O 
for O 
all O 
the O 
studied O 
compounds O 
. O 
Molecular O 
modelling O 
was O 
used O 
to O 
investigate O 
the O 
complementarities O 
between O 
host O 
and O 
guest O 
. O 
This O 
study O 
showed O 
that O 
β-CDs B-FAMILY 
were O 
the O 
most O 
versatile O 
CDs O 
and O 
that O 
β-CD B-ABBREVIATION 
polymers O 
could O 
perform O 
the O 
controlled O 
release O 
of O 
aroma O 
compounds O 
. O 

involvement O 
in O 
exposure O 
to O 
low O 
dose O 
of O 
benzene B-SYSTEMATIC 
. O 

: O 
To O 
establish O 
if O 
serum O 
levels O 
of O 
interleukin-10 O 
( O 
IL-10 O 
) O 
in O 
subjects O 
exposed O 
to O 
benzene B-SYSTEMATIC 
are O 
connected O 
with O 
age O 
, O 
working O 
years O 
, O 
and O 
employment O 
age O 
. O 
METHODS O 
: O 
We O 
evaluated O 
serum O 
levels O 
of O 
IL-10 O 
in O 
51 O 
employees O 
working O 
in O 
oil O 
refinery O 
( O 
group O 
A O 
) O 
and O 
in O 
16 O 
office O 
workers O 
who O 
resided O 
in O 
the O 
same O 
area O 
( O 
group O 
B O 
) O 
. O 
RESULTS O 
: O 
There O 
was O 
no O 
statistically O 
significant O 
difference O 
between O 
serum O 
concentrations O 
of O 
IL-10 O 
in O 
groups O 
A O 
and O 
B O 
. O 
There O 
was O 
a O 
statistically O 
significant O 
dependent O 
relationship O 
in O 
group O 
A O 
between O 
age O 
, O 
working O 
years O 
, O 
and O 
serum O 
concentration O 
of O 
IL-10 O 
. O 
There O 
was O 
a O 
statistically O 
significant O 
and O 
positive O 
dependent O 
relationship O 
in O 
group O 
A O 
between O 
serum O 
concentration O 
of O 
IL-10 O 
and O 
employment O 
age O 
. O 
CONCLUSIONS O 
: O 
The O 
role O 
played O 
by O 
IL-10 O 
in O 
benzene B-SYSTEMATIC 
immune O 
suppression O 
may O 
be O 
relevant O 
and O 
attention O 
should O 
be O 
directed O 
toward O 
assessment O 
of O 
age O 
, O 
working O 
years O 
, O 
and O 
employment O 
age O 
in O 
benzene B-SYSTEMATIC 
-exposed O 
populations O 
. O 

multidrug O 
transporter O 
, O 
breast O 
cancer O 
resistance O 
protein O 
, O 
ABCG2 O 
, O 
is O 
up O 
- O 
regulated O 
in O 
certain O 
chemoresistant O 
cancer O 
cells O 
and O 
in O 
the O 
mammary O 
gland O 
during O 
lactation O 
. O 
We O 
investigated O 
the O 
role O 
of O 
the O 
lactogenic O 
hormone O 
prolactin O 
( O 
PRL O 
) O 
in O 
the O 
regulation O 
of O 
ABCG2 O 
. O 
PRL O 
dose O 
- O 
dependently O 
induced O 
ABCG2 O 
expression O 
in O 
T-47D O 
human O 
breast O 
cancer O 
cells O 
. O 
This O 
induction O 
was O 
significantly O 
reduced O 
by O 
short O 
- O 
interfering O 
RNA O 
- O 
mediated O 
knockdown O 
of O 
Janus O 
kinase O 
2 O 
( O 
JAK2 O 
) O 
. O 
Knockdown O 
or O 
pharmacologic O 
inhibition O 
of O 
the O 
down O 
- O 
stream O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription-5 O 
( O 
STAT5 O 
) O 
also O 
blunted O 
the O 
induction O 
of O 
ABCG2 O 
by O 
PRL O 
, O 
suggesting O 
a O 
role O 
for O 
the O 
JAK2 O 
/ O 
STAT5 O 
pathway O 
in O 
PRL-induced O 
ABCG2 O 
expression O 
. O 
Corroborating O 
these O 
findings O 
, O 
we O 
observed O 
PRL-stimulated O 
STAT5 O 
recruitment O 
to O 
a O 
region O 
containing O 
a O 
putative O 
γ-interferon O 
activation O 
sequence O 
( O 
GAS O 
) O 
element O 
at O 
-434 O 
base O 
pairs O 
upstream O 
of O 
the O 
ABCG2 O 
transcription O 
start O 
site O 
. O 
Introduction O 
of O 
a O 
single O 
mutation O 
to O 
the O 
-434 O 
GAS O 
element O 
significantly O 
attenuated O 
PRL-stimulated O 
activity O 
of O 
a O 
luciferase O 
reporter O 
driven O 
by O 
the O 
ABCG2 O 
gene O 
promoter O 
and O 
5'-flanking O 
region O 
containing O 
the O 
-434 O 
GAS O 
motif O 
. O 
In O 
addition O 
, O 
this O 
GAS O 
element O 
showed O 
strong O 
copy O 
number O 
dependency O 
in O 
its O 
response O 
to O 
PRL O 
treatment O 
. O 
Interestingly O 
, O 
inhibitors O 
against O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
and O 
phosphoinositide B-FAMILY 
-3-kinase O 
signaling O 
pathways O 
significantly O 
decreased O 
the O 
induction O 
of O 
ABCG2 O 
by O 
PRL O 
without O 
altering O 
STAT5 O 
recruitment O 
to O 
the O 
GAS O 
element O 
. O 
We O 
conclude O 
that O 
the O 
JAK2 O 
/ O 
STAT5 O 
pathway O 
is O 
required O 
but O 
not O 
sufficient O 
for O 
the O 
induction O 
of O 
ABCG2 O 
by O 
PRL O 
. O 

as O 
Atypical O 
Opioid O 
Receptor O 
Ligands O 
. O 

neoclerodane B-FAMILY 
diterpene I-FAMILY 
salvinorin B-TRIVIAL 
A I-TRIVIAL 
is O 
the O 
major O 
active O 
component O 
of O 
the O 
hallucinogenic O 
mint O 
plant O 
Salvia O 
divinorum O 
Epling O 
and O 
Játiva O 
( O 
Lamiaceae O 
) O 
. O 
Since O 
the O 
finding O 
that O 
salvinorin B-TRIVIAL 
A I-TRIVIAL 
exerts O 
its O 
potent O 
psychotropic O 
actions O 
through O 
the O 
activation O 
of O 
opioid O 
receptors O 
, O 
the O 
site O 
of O 
action O 
of O 
morphine B-TRIVIAL 
and O 
related O 
analogues O 
, O 
there O 
has O 
been O 
much O 
interest O 
in O 
elucidating O 
the O 
underlying O 
mechanisms O 
behind O 
its O 
effects O 
. O 
These O 
effects O 
are O 
particularly O 
remarkable O 
because O 
( O 
1 O 
) O 
salvinorin B-TRIVIAL 
A I-TRIVIAL 
is O 
the O 
first O 
reported O 
non-nitrogenous O 
opioid O 
receptor O 
agonist O 
and O 
( O 
2 O 
) O 
its O 
effects O 
are O 
not O 
mediated O 
through O 
the O 
previously O 
investigated O 
targets O 
of O 
psychotomimetics O 
. O 
This O 
Perspective O 
outlines O 
our O 
research O 
program O 
, O 
illustrating O 
a O 
new O 
direction O 
to O 
the O 
development O 
of O 
tools O 
to O 
further O 
elucidate O 
the O 
biological O 
mechanisms O 
of O 
drug O 
tolerance O 
and O 
dependence O 
. O 
The O 
information O 
gained O 
from O 
these O 
efforts O 
is O 
expected O 
to O 
facilitate O 
the O 
design O 
of O 
novel O 
agents O 
to O 
treat O 
pain O 
, O 
drug O 
abuse O 
, O 
and O 
other O 
central O 
nervous O 
system O 
disorders O 
. O 

substituted I-FAMILY 
2'-benzoylpyridine I-FAMILY 
thiosemicarbazone I-FAMILY 
chelators O 
with O 
potent O 
and O 
selective O 
anti-neoplastic O 
activity O 
: O 
novel O 
ligands O 
that O 
limit O 
methemoglobin O 
formation O 
. O 

chelators O 
, O 
including O 
the O 
2'-benzoylpyridine B-FAMILY 
thiosemicarbazones I-FAMILY 
( O 
BpT B-ABBREVIATION 
) O 
class O 
, O 
show O 
marked O 
potential O 
as O 
anticancer O 
agents O 
. O 
Importantly O 
, O 
3-aminopyridine-2-carboxaldehyde B-SYSTEMATIC 
thiosemicarbazone I-SYSTEMATIC 
( O 
3-AP B-SYSTEMATIC 
) O 
has O 
been O 
investigated O 
in O 
> O 
20 O 
phase O 
I O 
and O 
II O 
clinical O 
trials O 
. O 
However O 
, O 
side O 
effects O 
associated O 
with O 
3-AP B-SYSTEMATIC 
administration O 
include O 
methemoglobinemia O 
. O 
Considering O 
this O 
problem O 
, O 
novel O 
BpT B-ABBREVIATION 
analogues O 
were O 
designed O 
bearing O 
hydrophobic O 
, O 
electron O 
- O 
donating O 
substituents O 
at O 
the O 
para O 
position O 
of O 
the O 
phenyl B-SYSTEMATIC 
group O 
( O 
RBpT B-FAMILY 
) O 
. O 
Their O 
Fe(III B-FORMULA 
/ I-FORMULA 
II I-FORMULA 
) I-FORMULA 
redox O 
potentials O 
were O 
all O 
within O 
the O 
range O 
accessible O 
to O 
cellular O 
oxidants O 
and O 
reductants O 
, O 
suggesting O 
they O 
can O 
redox O 
cycle O 
. O 
These O 
RBpT B-FAMILY 
ligands O 
exhibited O 
potent O 
and O 
selective O 
antiproliferative O 
activity O 
, O 
which O 
was O 
comparable O 
or O 
exceeded O 
their O 
BpT B-ABBREVIATION 
counterparts O 
. O 
Major O 
findings O 
include O 
that O 
methemoglobin O 
formation O 
mediated O 
by O 
the O 
lipophilic O 
t-BuBpT B-ABBREVIATION 
series O 
was O 
significantly O 
( O 
p O 
< O 
0.05-0.001 O 
) O 
decreased O 
in O 
comparison O 
to O 
3-AP B-SYSTEMATIC 
in O 
intact O 
red O 
blood O 
cells O 
and O 
were O 
generally O 
comparable O 
to O 
the O 
control O 
. O 
These O 
data O 
indicate O 
the O 
t-BuBpT B-ABBREVIATION 
ligands O 
may O 
minimize O 
methemoglobinemia O 
, O 
which O 
is O 
a O 
marked O 
advantage O 
over O 
3-AP B-SYSTEMATIC 
and O 
other O 
potent O 
thiosemicarbazones B-FAMILY 
. O 

study O 
assessed O 
the O 
ability O 
of O 
multisite O 
quantitative O 
ultrasound O 
( O 
mQUS O 
) O 
to O 
predict O 
fracture O 
over O 
a O 
five O 
- O 
year O 
follow O 
- O 
up O 
. O 
Participants O 
were O 
a O 
subset O 
of O 
the O 
Canadian O 
Multicentre O 
Osteoporosis O 
Study O 
. O 
mQUS-assessed O 
speed O 
of O 
sound O 
( O 
SOS O 
in O 
m O 
/ O 
s O 
) O 
at O 
three O 
sites O 
( O 
distal O 
radius O 
, O 
tibia O 
and O 
phalanx O 
) O 
and O 
extensive O 
questionnaires O 
were O 
completed O 
, O 
after O 
which O 
participants O 
were O 
followed O 
for O 
five O 
years O 
and O 
incident O 
fractures O 
recorded O 
. O 
Two O 
survival O 
analyses O 
were O 
completed O 
for O 
each O 
site O 
- O 
a O 
univariate O 
analysis O 
and O 
an O 
adjusted O 
multivariate O 
analysis O 
controlling O 
for O 
age O 
, O 
anti-resorptive O 
use O 
, O 
femoral O 
neck O 
bone O 
mineral O 
density O 
, O 
number O 
of O 
diseases O 
, O 
previous O 
fractures O 
, O 
BMI O 
, O 
parental O 
history O 
of O 
hip O 
fracture O 
, O 
current O 
smoking O 
, O 
current O 
alcoholic B-FAMILY 
drinks O 
> O 
3 O 
per O 
day O 
, O 
current O 
using O 
glucocorticoids O 
, O 
and O 
rheumatoid O 
arthritis O 
diagnosis O 
( O 
variables O 
from O 
the O 
FRAX O 
10-year O 
fracture O 
risk O 
assessment O 
tool O 
) O 
. O 
The O 
unit O 
of O 
change O 
for O 
regression O 
analyses O 
was O 
one O 
standard O 
deviation O 
for O 
all O 
measurement O 
sites O 
, O 
specific O 
to O 
site O 
and O 
sex O 
. O 
Separate O 
analyses O 
were O 
completed O 
for O 
all O 
clinical O 
fractures O 
, O 
non-vertebral O 
fractures O 
and O 
hip O 
fractures O 
by O 
sex O 
. O 
There O 
were O 
2633 O 
women O 
and O 
1108 O 
men O 
included O 
and O 
they O 
experienced O 
204 O 
incident O 
fractures O 
over O 
five O 
years O 
( O 
5.5% O 
fractured O 
) O 
. O 
Univariate O 
models O 
revealed O 
statistically O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
predictive O 
ability O 
of O 
mQUS O 
for O 
all O 
three O 
measurement O 
sites O 
for O 
women O 
alone O 
for O 
all O 
three O 
fracture O 
types O 
( O 
one O 
standard O 
deviation O 
decrease O 
in O 
SOS O 
was O 
associated O 
with O 
a O 
52-130% O 
increase O 
in O 
the O 
risk O 
of O 
fracture O 
) O 
, O 
but O 
not O 
for O 
the O 
men's O 
group O 
. O 
The O 
adjusted O 
model O 
found O 
that O 
measures O 
at O 
the O 
distal O 
radius O 
and O 
tibia O 
in O 
the O 
women's O 
group O 
could O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
predict O 
all O 
clinical O 
fractures O 
and O 
non-vertebral O 
fractures O 
within O 
the O 
next O 
five O 
years O 
( O 
one O 
standard O 
deviation O 
decrease O 
in O 
SOS O 
was O 
associated O 
with O 
a O 
25-31% O 
increase O 
in O 
the O 
risk O 
of O 
fracture O 
) O 
. O 
mQUS O 
provided O 
significant O 
five O 
- O 
year O 
clinical O 
fracture O 
prediction O 
in O 
women O 
, O 
independent O 
of O 
bone O 
mineral O 
density O 
and O 
other O 
significant O 
risk O 
factors O 
for O 
fracture O 
, O 
when O 
measured O 
at O 
the O 
distal O 
radius O 
and O 
tibia O 
sites O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

of O 
melanogenesis O 
and O 
antioxidant O 
defense O 
system O 
in O 
melanocytes O 
by O 
amikacin B-TRIVIAL 
. O 

is O 
principally O 
used O 
to O 
treat O 
infections O 
caused O 
by O 
microorganisms O 
resistant O 
to O 
other O 
aminoglycosides B-FAMILY 
. O 
Ototoxicity O 
is O 
one O 
of O 
the O 
side O 
effects O 
of O 
amikacin B-TRIVIAL 
, O 
but O 
the O 
causative O 
mechanism O 
of O 
damage O 
to O 
the O 
ear O 
has O 
not O 
been O 
fully O 
established O 
. O 
Thus O 
, O 
the O 
aim O 
of O 
this O 
work O 
was O 
to O 
examine O 
the O 
impact O 
of O 
amikacin B-TRIVIAL 
on O 
the O 
melanogenesis O 
and O 
antioxidant O 
defense O 
system O 
in O 
cultured O 
human O 
normal O 
melanocytes O 
( O 
HEMa-LP O 
) O 
. O 
Amikacin B-TRIVIAL 
induced O 
the O 
concentration O 
- O 
dependent O 
loss O 
in O 
melanocytes O 
viability O 
. O 
The O 
value O 
of O 
EC50 O 
was O 
determined O 
to O 
be O 
~7.5 O 
mM O 
. O 
The O 
analyzed O 
antibiotic O 
inhibited O 
melanin O 
biosynthesis O 
in O 
concentration O 
- O 
dependent O 
manner O 
. O 
Increasing O 
the O 
amikacin B-TRIVIAL 
concentration O 
also O 
resulted O 
in O 
a O 
decrease O 
in O 
cellular O 
tyrosinase O 
activity O 
. O 
To O 
study O 
the O 
antioxidant O 
defense O 
system O 
in O 
melanocytes O 
, O 
the O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
in O 
cells O 
exposed O 
to O 
amikacin B-TRIVIAL 
were O 
determined O 
. O 
Significant O 
changes O 
in O 
cellular O 
antioxidant O 
enzymes O 
activities O 
were O 
observed O 
. O 
Modulation O 
of O 
melanogenesis O 
and O 
the O 
antioxidant O 
status O 
of O 
melanocytes O 
resulting O 
from O 
the O 
use O 
of O 
amikacin B-TRIVIAL 
in O 
vitro O 
may O 
explain O 
a O 
potential O 
role O 
of O 
melanin O 
and O 
melanocytes O 
in O 
the O 
mechanisms O 
of O 
aminoglycosides B-FAMILY 
ototoxic O 
effects O 
in O 
vivo O 
. O 

compare O 
the O 
distribution O 
of O 
carotenoids O 
across O 
the O 
grain O 
, O 
non-corn O 
and O 
corn O 
cereals O 
were O 
hand O 
dissected O 
into O 
endosperm O 
, O 
germ O 
and O 
aleurone O 
fractions O 
. O 
Total O 
carotenoid O 
content O 
( O 
TCC O 
) O 
and O 
carotenoid O 
composition O 
were O 
analysed O 
using O 
spectrophotometry O 
and O 
HPLC O 
. O 
Cereal O 
carotenoid O 
composition O 
was O 
similar O 
; O 
however O 
, O 
concentrations O 
varied O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Endosperm O 
fractions O 
had O 
TCC O 
ranging O 
from O 
0.88 O 
to O 
2.27 O 
and O 
14.17 O 
to O 
31.35mg O 
/ O 
kg O 
in O 
non-corn O 
cereals O 
and O 
corn O 
, O 
respectively O 
. O 
TCC O 
, O 
lutein B-TRIVIAL 
and O 
zeaxanthin B-TRIVIAL 
in O 
germ O 
fractions O 
were O 
higher O 
in O 
non-corn O 
cereals O 
than O 
in O 
corn O 
. O 
Lutein B-TRIVIAL 
and O 
zeaxanthin B-TRIVIAL 
contents O 
were O 
lower O 
in O 
non-corn O 
cereal O 
endosperms O 
. O 
The O 
aleurone O 
layer O 
had O 
zeaxanthin B-TRIVIAL 
levels O 
2- O 
to O 
5-fold O 
higher O 
than O 
lutein B-TRIVIAL 
among O 
the O 
cereals O 
. O 
Positive O 
significant O 
correlations O 
( O 
p O 
< O 
0.05 O 
) O 
were O 
found O 
between O 
TCC O 
, O 
carotenoids O 
analysed O 
by O 
HPLC O 
and O 
DPPH B-ABBREVIATION 
results O 
. O 
This O 
study O 
is O 
the O 
first O 
to O 
report O 
on O 
carotenoid O 
composition O 
of O 
the O 
aleurone O 
layer O 
. O 
Our O 
findings O 
suggest O 
that O 
the O 
aleurone O 
of O 
wheat O 
, O 
oat O 
, O 
corn O 
and O 
germ O 
of O 
barley O 
have O 
significantly O 
enhanced O 
carotenoid O 
levels O 
. O 

- O 
dependent O 
dysregulation O 
of O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
in O 
male O 
mice O 
is O 
associated O 
with O 
choline B-FAMILY 
- O 
and O 
folate B-TRIVIAL 
-deficient O 
diet O 
- O 
induced O 
liver O 
injury O 
. O 

of O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
- O 
related O 
metabolic O 
processes O 
is O 
a O 
major O 
contributor O 
to O 
the O 
pathogenesis O 
of O 
nonalcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
. O 
It O 
is O 
well O 
established O 
that O 
genetic O 
and O 
gender O 
- O 
specific O 
variations O 
in O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
contribute O 
to O 
the O 
vulnerability O 
to O 
NAFLD O 
in O 
humans O 
. O 
To O 
examine O 
the O 
role O 
of O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
dysregulation O 
in O 
the O 
pathogenesis O 
and O 
individual O 
susceptibility O 
to O 
NAFLD O 
, O 
we O 
used O 
a O 
" O 
population O 
- O 
based O 
" O 
mouse O 
model O 
where O 
male O 
mice O 
from O 
7 O 
inbred O 
were O 
fed O 
a O 
choline B-FAMILY 
- O 
and O 
folate B-TRIVIAL 
-deficient O 
( O 
CFD O 
) O 
diet O 
for O 
12 O 
wk O 
. O 
Strain O 
- O 
dependent O 
down O 
- O 
regulation O 
of O 
several O 
key O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
genes O 
, O 
including O 
methionine B-TRIVIAL 
adenosyltransferase O 
1α O 
( O 
Mat1a O 
) O 
, O 
cystathionine B-TRIVIAL 
-β-synthase O 
( O 
Cbs O 
) O 
, O 
methylenetetrahydrofolate B-SYSTEMATIC 
reductase O 
( O 
Mthfr O 
) O 
, O 
adenosyl B-TRIVIAL 
-homocysteinase O 
( O 
Ahcy O 
) O 
, O 
and O 
methylenetetrahydrofolate B-SYSTEMATIC 
dehydrogenase O 
1 O 
( O 
Mthfd1 O 
) O 
, O 
was O 
observed O 
. O 
These O 
changes O 
were O 
strongly O 
associated O 
with O 
interstrain O 
variability O 
in O 
liver O 
injury O 
( O 
steatosis O 
, O 
necrosis O 
, O 
inflammation O 
, O 
and O 
activation O 
of O 
fibrogenesis O 
) O 
and O 
hyperhomocysteinemia O 
. O 
Mechanistically O 
, O 
the O 
decreased O 
expression O 
of O 
Mat1a O 
, O 
Ahcy O 
, O 
and O 
Mthfd1 O 
was O 
linked O 
to O 
a O 
reduced O 
level O 
and O 
promoter O 
binding O 
of O 
transcription O 
factor O 
CCAAT O 
/ O 
enhancer O 
binding O 
protein O 
β O 
( O 
CEBPβ O 
) O 
, O 
which O 
directly O 
regulates O 
their O 
transcription O 
. O 
The O 
strain O 
specificity O 
of O 
diet O 
- O 
induced O 
dysregulation O 
of O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
suggests O 
that O 
interstrain O 
variation O 
in O 
the O 
regulation O 
of O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
may O 
contribute O 
to O 
the O 
differential O 
vulnerability O 
to O 
NFLD O 
and O 
that O 
correcting O 
the O 
imbalance O 
may O 
be O 
considered O 
as O 
preventive O 
and O 
treatment O 
strategies O 
for O 
NAFLD.-Pogribny O 
, O 
I O 
. O 
P O 
. O 
, O 
Kutanzi O 
, O 
K O 
. O 
, O 
Melnyk O 
, O 
S O 
. O 
, O 
de O 
Conti O 
, O 
A O 
. O 
, O 
Tryndyak O 
, O 
V O 
. O 
, O 
Montgomery O 
, O 
B O 
. O 
, O 
Pogribna O 
, O 
M O 
. O 
, O 
Muskhelishvili O 
, O 
L O 
. O 
, O 
Latendresse O 
, O 
J O 
. O 
R O 
. O 
, O 
James O 
, O 
S O 
. O 
J O 
. O 
, O 
Beland O 
, O 
F O 
. O 
A O 
. O 
, O 
Rusyn O 
, O 
I O 
. O 
Strain O 
- O 
dependent O 
dysregulation O 
of O 
one- O 
carbon B-SYSTEMATIC 
metabolism O 
in O 
male O 
mice O 
is O 
associated O 
with O 
choline B-FAMILY 
- O 
and O 
folate B-TRIVIAL 
-deficient O 
diet O 
- O 
induced O 
liver O 
injury O 
. O 

display O 
a O 
compensatory O 
survival O 
response O 
against O 
cadmium B-SYSTEMATIC 
toxicity O 
by O 
a O 
mechanism O 
mediated O 
by O 
EGFR O 
and O 
Src O 
. O 

the O 
liver O 
is O 
a O 
cadmium B-SYSTEMATIC 
-target O 
organ O 
, O 
hepatocyte O 
response O 
involved O 
in O 
its O 
toxicity O 
is O 
not O 
yet O 
elucidated O 
. O 
A O 
link O 
between O 
this O 
heavy O 
metal O 
treatment O 
and O 
Stat3 O 
signaling O 
pathways O 
was O 
examined O 
in O 
primary O 
mouse O 
hepatocytes O 
. O 
We O 
provided O 
evidence O 
of O 
a O 
novel O 
link O 
among O 
NADPH B-ABBREVIATION 
oxidase O 
and O 
Stat3 O 
signaling O 
, O 
mediated O 
by O 
Src O 
, O 
EGFR O 
, O 
and O 
Erk1 O 
/ O 
2 O 
. O 
Cadmium B-SYSTEMATIC 
activates O 
NADPH B-ABBREVIATION 
oxidase O 
. O 
ROS O 
produced O 
by O 
this O 
oxidase O 
activates O 
Src O 
, O 
enable O 
that O 
in O 
turn O 
, O 
transactivates O 
EGFR O 
that O 
activates O 
Stat3 O 
in O 
tyrosine B-TRIVIAL 
, O 
allowing O 
its O 
dimerization O 
. O 
Also O 
, O 
ROS O 
from O 
NADPH B-ABBREVIATION 
oxidase O 
favors O 
ERK1 O 
/ O 
2 O 
activation O 
that O 
phosphorylates O 
Stat3 O 
in O 
serine B-TRIVIAL 
, O 
resulting O 
in O 
a O 
compensatory O 
or O 
adaptive O 
survival O 
response O 
such O 
as O 
production O 
of O 
metallothionein-II O 
in O 
short O 
Cd B-FORMULA 
exposure O 
times O 
. O 
However O 
, O 
after O 
12h O 
CdCl2 B-FORMULA 
treatment O 
, O 
cell O 
viability O 
diminished O 
in O 
50% O 
, O 
accompanied O 
by O 
a O 
drastic O 
decrease O 
of O 
metallothionein-II O 
production O 
, O 
and O 
an O 
increase O 
in O 
p53 O 
activation O 
and O 
the O 
pro O 
- O 
apoptotic O 
protein O 
Bax O 
. O 

-induced O 
apoptosis O 
is O 
dependent O 
on O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
independent O 
of O 
induction O 
of O 
endoplasmic O 
reticulum O 
stress O 
in O 
renal O 
cell O 
carcinoma O 
. O 

, O 
a O 
sesquiterpene B-FAMILY 
lactone I-FAMILY 
, O 
exhibits O 
anti-inflammatory O 
and O 
anti-tumor O 
activities O 
. O 
Here O 
, O 
we O 
investigated O 
whether O 
helenalin B-TRIVIAL 
could O 
induce O 
apoptosis O 
in O 
human O 
renal O 
carcinoma O 
Caki O 
cells O 
. O 
Helenalin B-TRIVIAL 
increased O 
apoptosis O 
in O 
dose O 
dependent O 
manner O 
in O 
Caki O 
cells O 
, O 
and O 
also O 
induced O 
apoptosis O 
in O 
other O 
carcinoma O 
cells O 
, O 
such O 
as O 
human O 
renal O 
carcinoma O 
ACHN O 
cells O 
, O 
human O 
colon O 
carcinoma O 
HT29 O 
and O 
HCT116 O 
cells O 
. O 
We O 
found O 
that O 
helenalin B-TRIVIAL 
markedly O 
induced O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
- O 
related O 
genes O 
, O 
such O 
as O 
regulated O 
in O 
development O 
and O 
DNA O 
damage O 
responses O 
( O 
REDD O 
) O 
1 O 
, O 
activating O 
transcription O 
factor-4 O 
( O 
ATF4 O 
) O 
and O 
/ O 
or O 
the O 
CCAAT O 
enhancer O 
- O 
binding O 
protein O 
- O 
homologous O 
protein O 
( O 
CHOP O 
) O 
. O 
However O 
, O 
down O 
- O 
regulation O 
of O 
ATF4 O 
and O 
/ O 
or O 
CHOP O 
expression O 
by O 
siRNA O 
had O 
no O 
effect O 
on O 
helenalin B-TRIVIAL 
-induced O 
apoptosis O 
in O 
Caki O 
and O 
HCT116 O 
cells O 
. O 
Helenalin B-TRIVIAL 
increased O 
production O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
Furthermore O 
, O 
ROS O 
scavengers O 
, O 
N-acetylcystine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
and O 
glutathione B-SYSTEMATIC 
ethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
GEE B-ABBREVIATION 
) O 
, O 
reduced O 
helenalin B-TRIVIAL 
-induced O 
apoptosis O 
. O 
Taken O 
together O 
, O 
helenalin B-TRIVIAL 
induced O 
apoptosis O 
via O 
ROS O 
generation O 
in O 
human O 
renal O 
carcinoma O 
Caki O 
cells O 
. O 

yellow I-TRIVIAL 
a I-TRIVIAL 
inhibits O 
lipopolysaccharide-induced O 
inflammatory O 
signal O 
transduction O 
in O 
human O 
alveolar O 
epithelial O 
A549 O 
cells O 
. O 

yellow I-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
HSYA B-ABBREVIATION 
) O 
is O 
an O 
active O 
ingredient O 
obtained O 
from O 
the O 
flower O 
of O 
Carthamus O 
tinctorius O 
L O 
. O 
The O 
present O 
study O 
investigated O 
the O 
effects O 
of O 
HSYA B-ABBREVIATION 
on O 
lipopolysaccharide O 
(LPS)-induced O 
inflammatory O 
signal O 
transduction O 
in O 
human O 
alveolar O 
epithelial O 
A549 O 
cells O 
. O 
A549 O 
cells O 
stimulated O 
with O 
LPS O 
were O 
incubated O 
with O 
three O 
doses O 
of O 
HSYA B-ABBREVIATION 
( O 
1 O 
, O 
4 O 
and O 
16μmol O 
/ O 
L O 
) O 
. O 
HSYA B-ABBREVIATION 
suppressed O 
the O 
expression O 
of O 
TLR-4 O 
, O 
Myd88 O 
, O 
ICAM-1 O 
, O 
TNFα O 
, O 
IL-1β O 
and O 
IL-6 O 
at O 
the O 
mRNA O 
and O 
protein O 
level O 
, O 
and O 
inhibited O 
the O 
adhesion O 
of O 
leukocytes O 
to O 
A549 O 
cells O 
. O 
HSYA B-ABBREVIATION 
treatment O 
also O 
decreased O 
NF-κB O 
p65 O 
nuclear O 
translocation O 
and O 
inhibited O 
the O 
phosphorylation O 
of O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
p38 O 
MAPK O 
) O 
. O 
These O 
findings O 
suggest O 
that O 
HSYA B-ABBREVIATION 
effectively O 
inhibits O 
LPS-induced O 
inflammatory O 
signal O 
transduction O 
in O 
A549 O 
cells O 
. O 

restores O 
cognitive O 
deficits O 
and O 
improves O 
amyloid O 
and O 
Tau O 
pathologies O 
in O 
a O 
senescence O 
- O 
accelerated O 
mouse O 
model O 
. O 

is O 
associated O 
with O 
a O 
deterioration O 
of O 
cognitive O 
performance O 
and O 
with O 
increased O 
risk O 
of O 
neurodegenerative O 
disorders O 
. O 
Hypertension O 
is O 
the O 
most O 
- O 
prevalent O 
modifiable O 
risk O 
factor O 
for O 
cardiovascular O 
morbidity O 
and O 
mortality O 
worldwide O 
, O 
and O 
clinical O 
data O 
suggest O 
that O 
hypertension O 
is O 
a O 
risk O 
factor O 
for O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
In O 
the O 
present O 
study O 
we O 
tested O 
whether O 
propranolol B-TRIVIAL 
, O 
a O 
β-receptor O 
antagonist O 
commonly O 
used O 
as O 
antihypertensive O 
drug O 
, O 
could O 
ameliorate O 
the O 
cognitive O 
impairments O 
and O 
increases O 
in O 
AD O 
- O 
related O 
markers O 
shown O 
by O 
the O 
senescence O 
- O 
accelerated O 
mouse O 
prone-8 O 
( O 
SAMP8 O 
) O 
. O 
Propranolol B-TRIVIAL 
administration O 
( O 
5 O 
mg O 
/ O 
kg O 
for O 
3 O 
weeks O 
) O 
to O 
6-month- O 
old O 
SAMP8 O 
mice O 
attenuated O 
cognitive O 
memory O 
impairments O 
shown O 
by O 
these O 
mice O 
in O 
the O 
novel O 
object O 
recognition O 
test O 
. O 
In O 
the O 
hippocampus O 
of O 
SAMP8 O 
mice O 
it O 
has O 
been O 
found O 
increases O 
in O 
Aβ(42) O 
levels O 
, O 
the O 
principal O 
constituent O 
of O 
amyloid O 
plaques O 
observed O 
in O 
AD O 
, O 
accompanied O 
by O 
both O 
an O 
increased O 
expression O 
of O 
the O 
cleaving O 
enzyme O 
BACE1 O 
and O 
a O 
decreased O 
expression O 
of O 
the O 
degrading O 
enzyme O 
IDE O 
. O 
All O 
these O 
effects O 
were O 
reversed O 
by O 
propranolol B-TRIVIAL 
treatment O 
. O 
Tau O 
hyperphosphorylation O 
( O 
PHF-1 O 
epitope O 
) O 
shown O 
by O 
SAMP8 O 
mice O 
at O 
this O 
age O 
was O 
also O 
decreased O 
in O 
the O 
hippocampus O 
of O 
propranolol B-TRIVIAL 
-treated O 
mice O 
, O 
an O 
effect O 
probably O 
related O 
to O 
a O 
decrease O 
in O 
JNK1 O 
expression O 
. O 
Interestingly O 
, O 
propranolol B-TRIVIAL 
also O 
phosphorylated O 
Akt O 
in O 
SAMP8 O 
mice O 
, O 
which O 
was O 
associated O 
with O 
an O 
increase O 
of O 
glycogen O 
synthase O 
kinase-3β O 
phosphorylation O 
, O 
contributing O 
therefore O 
to O 
the O 
reductions O 
in O 
Tau O 
hyperphosphorylation O 
. O 
Synaptic O 
pathology O 
in O 
SAMP8 O 
mice O 
, O 
as O 
shown O 
by O 
decreases O 
in O 
synaptophysin O 
and O 
BDNF O 
, O 
was O 
also O 
counteracted O 
by O 
propranolol B-TRIVIAL 
treatment O 
. O 
Overall O 
, O 
propranolol B-TRIVIAL 
might O 
be O 
beneficial O 
in O 
age O 
- O 
related O 
brain O 
dysfunction O 
and O 
could O 
be O 
an O 
emerging O 
candidate O 
for O 
the O 
treatment O 
of O 
other O 
neurodegenerative O 
diseases O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

tools O 
in O 
diagnosis O 
and O 
biomonitoring O 
of O 
intoxications O 
with O 
organophosphorothioates B-FAMILY 
: O 
Case O 
studies O 
with O 
chlorpyrifos B-TRIVIAL 
and O 
diazinon B-TRIVIAL 
. O 

( O 
OP O 
) O 
pesticides O 
are O 
neurotoxic O 
compounds O 
that O 
are O 
widely O 
used O 
in O 
agriculture O 
. O 
Classical O 
methods O 
for O 
monitoring O 
OP O 
exposure O 
comprise O 
the O 
measurement O 
of O 
intact O 
OP O 
, O 
its O 
metabolites O 
or O 
cholinesterase O 
activity O 
. O 
Newly O 
developed O 
methods O 
focus O 
on O 
the O 
analysis O 
of O 
the O 
OP O 
adduct O 
bound O 
to O 
proteins O 
such O 
as O 
butyrylcholinesterase O 
( O 
BuChE O 
) O 
and O 
albumin O 
. O 
These O 
adducts O 
can O 
be O 
analyzed O 
by O 
means O 
of O 
fluoride B-SYSTEMATIC 
reactivation O 
or O 
by O 
analysis O 
with O 
LC-MS O 
/ O 
MS O 
of O 
the O 
pepsin O 
or O 
pronase O 
digest O 
of O 
butyrylcholinesterase O 
and O 
albumin O 
, O 
respectively O 
. O 
The O 
utility O 
of O 
these O 
methods O 
is O 
illustrated O 
through O 
the O 
analysis O 
of O 
plasma O 
samples O 
obtained O 
from O 
patients O 
taken O 
1-49days O 
after O 
ingestion O 
of O 
the O 
organophosphate B-FAMILY 
pesticides O 
chlorpyrifos B-TRIVIAL 
and O 
/ O 
or O 
diazinon B-TRIVIAL 
. O 
Thus O 
, O 
in O 
this O 
particular O 
case O 
several O 
independent O 
methodologies O 
were O 
applied O 
to O 
the O 
biomedical O 
samples O 
, O 
all O 
pointing O 
to O 
the O 
same O 
exposure O 
. O 

Studies O 
of O 
Burkholderia O 
cenocepaciad- O 
Glycero-β-d-manno B-SYSTEMATIC 
- I-SYSTEMATIC 
heptose I-SYSTEMATIC 
7-Phosphate I-SYSTEMATIC 
Kinase O 
( O 
HldA O 
) O 
and O 
Characterization O 
of O 
Inhibitors O 
with O 
Antibiotic O 
Adjuvant O 
and O 
Antivirulence O 
Properties O 
. O 

an O 
essential O 
constituent O 
of O 
the O 
outer O 
membrane O 
of O 
Gram O 
- O 
negative O 
bacteria O 
, O 
lipopolysaccharide O 
contributes O 
significantly O 
to O 
virulence O 
and O 
antibiotic O 
resistance O 
. O 
The O 
lipopolysaccharide O 
biosynthetic O 
pathway O 
therefore O 
serves O 
as O 
a O 
promising O 
therapeutic O 
target O 
for O 
antivirulence O 
drugs O 
and O 
antibiotic O 
adjuvants O 
. O 
Here O 
we O 
report O 
the O 
structural O 
- O 
functional O 
studies O 
of O 
d-glycero-β-d-manno B-SYSTEMATIC 
- I-SYSTEMATIC 
heptose I-SYSTEMATIC 
7-phosphate I-SYSTEMATIC 
kinase O 
( O 
HldA O 
) O 
, O 
an O 
absolutely O 
conserved O 
enzyme O 
in O 
this O 
pathway O 
, O 
from O 
Burkholderia O 
cenocepacia O 
. O 
HldA O 
is O 
structurally O 
similar O 
to O 
members O 
of O 
the O 
PfkB O 
carbohydrate B-FAMILY 
kinase O 
family O 
and O 
appears O 
to O 
catalyze O 
heptose B-FAMILY 
phosphorylation O 
via O 
an O 
in O 
- O 
line O 
mechanism O 
mediated O 
mainly O 
by O 
a O 
conserved O 
aspartate B-TRIVIAL 
, O 
Asp B-FORMULA 
270 O 
. O 
Moreover O 
, O 
we O 
report O 
the O 
structures O 
of O 
HldA O 
in O 
complex O 
with O 
two O 
potent O 
inhibitors O 
in O 
which O 
both O 
inhibitors O 
adopt O 
a O 
folded O 
conformation O 
and O 
occupy O 
the O 
nucleotide B-FAMILY 
-binding O 
sites O 
. O 
Together O 
, O 
these O 
results O 
provide O 
important O 
insight O 
into O 
the O 
mechanism O 
of O 
HldA O 
- O 
catalyzed O 
heptose B-FAMILY 
phosphorylation O 
and O 
necessary O 
information O 
for O 
further O 
development O 
of O 
HldA O 
inhibitors O 
. O 

actions O 
of O 
rottlerin B-TRIVIAL 
from O 
Mallotus O 
philippinensis O 
in O 
experimental O 
mast O 
cell O 
- O 
mediated O 
anaphylactic O 
models O 
. O 

is O 
an O 
acquired O 
hypersensitivity O 
reaction O 
of O 
the O 
immune O 
system O 
mediated O 
by O 
cross O 
- O 
linking O 
of O 
the O 
allergen O 
- O 
specific O 
IgE O 
- O 
bound O 
high O 
- O 
affinity O 
IgE O 
receptors O 
, O 
leading O 
to O 
immediate O 
mast O 
cell O 
degranulation O 
. O 
Rottlerin B-TRIVIAL 
is O 
an O 
active O 
molecule O 
isolated O 
from O 
Mallotus O 
philippinensis O 
, O 
a O 
medicinal O 
plant O 
used O 
in O 
Ayurvedic O 
Medicine O 
System O 
for O 
anti-allergic O 
and O 
anti-helminthic O 
treatments O 
. O 
The O 
present O 
study O 
investigated O 
potential O 
anti-allergic O 
effects O 
of O 
rottlerin B-TRIVIAL 
in O 
animal O 
models O 
of O 
IgE-dependent O 
anaphylaxis O 
and O 
the O 
anti-allergic O 
mechanisms O 
of O 
action O 
of O 
rottlerin B-TRIVIAL 
in O 
mast O 
cells O 
. O 
Anti-allergic O 
actions O 
of O 
rottlerin B-TRIVIAL 
were O 
evaluated O 
in O 
passive O 
cutaneous O 
anaphylaxis O 
and O 
passive O 
systemic O 
anaphylaxis O 
mouse O 
models O 
, O 
and O 
in O 
anaphylactic O 
contraction O 
of O 
bronchial O 
rings O 
isolated O 
from O 
sensitized O 
guinea O 
pigs O 
. O 
Direct O 
mast O 
cell O 
- O 
stabilizing O 
effect O 
of O 
rottlerin B-TRIVIAL 
was O 
examined O 
in O 
RBL-2H3 O 
mast O 
cell O 
line O 
. O 
Anti-allergic O 
signaling O 
mechanisms O 
of O 
action O 
of O 
rottlerin B-TRIVIAL 
in O 
mast O 
cells O 
were O 
also O 
examined O 
. O 
Rottlerin B-TRIVIAL 
prevented O 
IgE O 
- O 
mediated O 
cutaneous O 
vascular O 
extravasation O 
, O 
hypothermia O 
, O 
elevation O 
in O 
plasma O 
histamine B-TRIVIAL 
level O 
and O 
tracheal O 
tissue O 
mast O 
cell O 
degranulation O 
in O 
mice O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
addition O 
, O 
rottlerin B-TRIVIAL 
suppressed O 
ovalbumin O 
- O 
induced O 
guinea O 
pig O 
bronchial O 
smooth O 
muscle O 
contraction O 
. O 
Furthermore O 
, O 
rottlerin B-TRIVIAL 
concentration O 
- O 
dependently O 
blocked O 
IgE O 
- O 
mediated O 
immediate O 
release O 
of O 
β-hexosaminidase O 
from O 
RBL-2H3 O 
mast O 
cells O 
. O 
Rottlerin B-TRIVIAL 
was O 
found O 
to O 
inhibit O 
IgE-induced O 
PLCγ1 O 
and O 
Akt O 
phosphorylation O 
, O 
production O 
of O 
IP3 O 
and O 
rise O 
in O 
cytosolic O 
Ca(2+) B-FORMULA 
level O 
in O 
mast O 
cells O 
. O 
We O 
report O 
here O 
for O 
the O 
first O 
time O 
that O 
rottlerin B-TRIVIAL 
possesses O 
anti-allergic O 
activity O 
by O 
blocking O 
IgE-induced O 
mast O 
cell O 
degranulation O 
, O 
providing O 
a O 
foundation O 
for O 
developing O 
rottlerin B-TRIVIAL 
for O 
the O 
treatment O 
of O 
allergic O 
asthma O 
and O 
other O 
mast O 
cell O 
- O 
mediated O 
allergic O 
disorders O 
. O 

hyperthermia O 
has O 
been O 
known O 
as O 
a O 
cause O 
of O 
male O 
infertility O 
but O 
the O 
exact O 
mechanism O 
leading O 
to O 
impaired O 
spermatogenesis O 
is O 
unknown O 
. O 
This O 
work O 
was O 
aimed O 
to O 
investigate O 
the O 
role O 
of O 
scrotal O 
hyperthermia O 
on O 
cell O 
proliferation O 
and O 
apoptosis O 
in O 
testes O 
. O 
The O 
rats O 
were O 
randomly O 
allotted O 
into O 
one O 
of O 
the O 
four O 
experimental O 
groups O 
: O 
A O 
( O 
control O 
) O 
, O 
B O 
( O 
1 O 
day O 
after O 
scrotal O 
hyperthermia O 
) O 
, O 
C O 
( O 
14 O 
days O 
after O 
scrotal O 
hyperthermia O 
) O 
, O 
and O 
D O 
( O 
35 O 
days O 
after O 
scrotal O 
hyperthermia O 
) O 
; O 
each O 
group O 
comprised O 
7 O 
animals O 
. O 
Scrotal O 
hyperthermia O 
was O 
carried O 
out O 
in O 
a O 
thermostatically O 
controlled O 
water O 
bath O 
at O 
43°C O 
for O 
30 O 
min O 
once O 
daily O 
for O 
6 O 
consecutive O 
days O 
. O 
Control O 
rats O 
were O 
treated O 
in O 
the O 
same O 
way O 
, O 
except O 
the O 
testes O 
were O 
immersed O 
in O 
a O 
water O 
bath O 
maintained O 
at O 
22°C O 
. O 
Hyperthermia O 
- O 
exposed O 
rats O 
were O 
killed O 
under O 
50 O 
mg O 
/ O 
kg O 
ketamine B-TRIVIAL 
anaesthesia O 
and O 
tissue O 
samples O 
were O 
obtained O 
for O 
biochemical O 
and O 
histopathological O 
investigations O 
. O 
Hyperthermia O 
treatment O 
significantly O 
decreased O 
the O 
testicular O 
antioxidant O 
system O 
, O 
including O 
decreases O 
in O 
the O 
glutathione B-TRIVIAL 
level O 
, O 
superoxide B-TRIVIAL 
dismutase O 
, O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
activities O 
. O 
Moreover O 
, O 
exposure O 
to O 
hyperthermia O 
resulted O 
in O 
lipid O 
peroxidation O 
increase O 
in O 
testes O 
. O 
Our O 
data O 
indicate O 
a O 
significant O 
reduction O 
in O 
the O 
expression O 
of O 
proliferating O 
cell O 
nuclear O 
antigen O 
and O 
an O 
enhancement O 
in O 
the O 
activity O 
of O 
terminal O 
deoxynucleotidyl O 
transferase O 
dUTP B-ABBREVIATION 
nick O 
end O 
labelling O 
after O 
scrotal O 
hyperthermia O 
. O 
In O 
scrotal O 
hyperthermia O 
, O 
the O 
mitochondrial O 
degeneration O 
, O 
dilatation O 
of O 
smooth O 
endoplasmic O 
reticulum O 
, O 
and O 
enlarged O 
intercellular O 
spaces O 
were O 
observed O 
in O 
both O 
Sertoli O 
and O 
spermatid O 
cells O 
. O 
Scrotal O 
hyperthermia O 
is O 
one O 
of O 
the O 
major O 
factors O 
that O 
impair O 
spermatogenesis O 
in O 
testis O 
. O 
This O 
heat O 
stress O 
is O 
shown O 
to O 
be O 
closely O 
associated O 
with O 
oxidative O 
stress O 
, O 
followed O 
by O 
apoptosis O 
of O 
germ O 
cells O 
. O 

Remodeling O 
by O 
Rosuvastatin B-TRIVIAL 
Normalizes O 
TSC2- O 
/ O 
meth O 
Cell O 
Phenotype O 
through O 
the O 
Expression O 
of O 
Tuberin O 
. O 

sclerosis O 
complex O 
( O 
TSC O 
) O 
is O 
a O 
multi O 
- O 
systemic O 
syndrome O 
caused O 
by O 
mutations O 
in O 
TSC1 O 
or O 
TSC2 O 
gene O 
. O 
In O 
TSC2-null O 
cells O 
, O 
Rheb O 
, O 
a O 
member O 
of O 
the O 
Ras O 
family O 
of O 
GTPases O 
, O 
is O 
constitutively O 
activated O 
. O 
Statins O 
inhibit O 
3-hydroxy-3-methylglutaryl B-SYSTEMATIC 
coenzyme I-SYSTEMATIC 
A I-SYSTEMATIC 
reductase O 
and O 
block O 
the O 
synthesis O 
of O 
isoprenoid B-FAMILY 
lipids O 
with O 
inhibition O 
of O 
Rheb O 
farnesylation O 
and O 
RhoA O 
geranylgeranylation O 
. O 
The O 
effects O 
of O 
rosuvastatin B-TRIVIAL 
on O 
the O 
function O 
of O 
human O 
TSC2(- O 
/ O 
- O 
) O 
and O 
TSC2(- O 
/ O 
meth O 
) O 
α-actin O 
smooth O 
muscle O 
( O 
ASM O 
) O 
cells O 
have O 
been O 
investigated O 
. O 
The O 
TSC2(- O 
/ O 
- O 
) O 
and O 
TSC2(- O 
/ O 
meth O 
) O 
ASM O 
cells O 
, O 
previously O 
isolated O 
in O 
our O 
laboratory O 
from O 
the O 
renal O 
angiomyolipoma O 
of O 
two O 
TSC O 
patients O 
, O 
do O 
not O 
express O 
tuberin O 
and O 
bear O 
loss O 
of O 
heterozigosity O 
caused O 
by O 
a O 
double O 
hit O 
on O 
TSC2 O 
and O 
methylation O 
of O 
TSC2 O 
promoter O 
, O 
respectively O 
. O 
Exposure O 
to O 
rosuvastatin B-TRIVIAL 
affected O 
TSC2(- O 
/ O 
meth O 
) O 
ASM O 
cell O 
growth O 
and O 
promoted O 
tuberin O 
expression O 
by O 
acting O 
as O 
a O 
demethylating O 
agent O 
. O 
This O 
occurred O 
without O 
changes O 
in O 
interleukin O 
release O 
. O 
Rosuvastatin B-TRIVIAL 
also O 
reduced O 
RhoA O 
activation O 
in O 
TSC2(- O 
/ O 
meth O 
) O 
ASM O 
cells O 
, O 
and O 
it O 
required O 
coadministration O 
with O 
the O 
specific O 
mTOR O 
( O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
) O 
inhibitor O 
rapamycin B-TRIVIAL 
to O 
be O 
effective O 
in O 
TSC2(- O 
/ O 
- O 
) O 
ASM O 
cells O 
. O 
Rapamycin B-TRIVIAL 
enhanced O 
rosuvastatin B-TRIVIAL 
effect O 
in O 
inhibiting O 
cell O 
proliferation O 
in O 
TSC2(- O 
/ O 
- O 
) O 
and O 
TSC2(- O 
/ O 
meth O 
) O 
ASM O 
cells O 
. O 
Rosuvastatin B-TRIVIAL 
alone O 
did O 
not O 
alter O 
phosphorylation O 
of O 
S6 O 
and O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
, O 
and O 
at O 
the O 
higher O 
concentration O 
, O 
rosuvastatin B-TRIVIAL 
and O 
rapamycin B-TRIVIAL 
slightly O 
decreased O 
ERK O 
phosphorylation O 
. O 
These O 
results O 
suggest O 
that O 
rosuvastatin B-TRIVIAL 
may O 
potentially O 
represent O 
a O 
treatment O 
adjunct O 
to O 
the O 
therapy O 
with O 
mTOR O 
inhibitors O 
now O 
in O 
clinical O 
development O 
for O 
TSC O 
. O 
In O 
particular O 
, O 
rosuvastatin B-TRIVIAL 
appears O 
useful O 
when O 
the O 
disease O 
is O 
originated O 
by O 
epigenetic O 
defects O 
. O 

hydroxy-carboxylic B-FAMILY 
acid I-FAMILY 
receptor O 
( O 
HCA1 O 
) O 
is O 
a O 
G O 
protein O 
- O 
coupled O 
receptor O 
that O 
is O 
highly O 
expressed O 
on O 
adipocytes O 
and O 
considered O 
a O 
potential O 
target O 
for O 
the O 
treatment O 
of O 
dyslipidemia O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
investigated O 
the O 
pharmacological O 
properties O 
of O 
naturally O 
occurring O 
variants O 
in O 
this O 
receptor O 
( O 
H43Q O 
, O 
A110V O 
, O 
S172L O 
, O 
and O 
D253H O 
) O 
. O 
After O 
transient O 
expression O 
of O 
these O 
receptors O 
into O 
human O 
embryonic O 
kidney O 
293 O 
cells O 
, O 
basal O 
and O 
ligand O 
- O 
induced O 
signaling O 
were O 
assessed O 
using O 
luciferase O 
reporter O 
gene O 
assays O 
. O 
The O 
A110V O 
, O 
S172L O 
, O 
and O 
D253 O 
variants O 
showed O 
reduced O 
basal O 
activity O 
; O 
the O 
S172L O 
mutant O 
displayed O 
a O 
decrease O 
in O 
potency O 
to O 
the O 
endogenous O 
ligand O 
L-lactate B-TRIVIAL 
. O 
Both O 
the O 
S172L O 
and O 
D253H O 
variants O 
also O 
showed O 
impaired O 
cell O 
surface O 
expression O 
, O 
which O 
may O 
in O 
part O 
explain O 
the O 
reduced O 
activity O 
of O 
these O 
receptors O 
. O 
The O 
impact O 
of O 
a O 
loss O 
in O 
HCA1 O 
function O 
on O 
lipid O 
accumulation O 
was O 
investigated O 
in O 
the O 
adipocyte O 
cell O 
line O 
, O 
OP9 O 
. O 
In O 
these O 
cells O 
, O 
endogenous O 
HCA1 O 
transcript O 
levels O 
rapidly O 
increased O 
and O 
reached O 
maximal O 
levels O 
3 O 
days O 
after O 
the O 
addition O 
of O 
differentiation O 
media O 
. O 
Knockdown O 
of O 
HCA1 O 
using O 
siRNA O 
resulted O 
in O 
an O 
increase O 
in O 
lipid O 
accumulation O 
as O 
assessed O 
by O 
quantification O 
of O 
Nile B-TRIVIAL 
Red I-TRIVIAL 
staining O 
and O 
TLC O 
analysis O 
. O 
Our O 
data O 
suggest O 
that O 
lipid O 
homeostasis O 
may O 
be O 
altered O 
in O 
carriers O 
of O 
selected O 
HCA1 O 
missense O 
variants O 
. O 

release O 
is O 
regulated O 
by O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
sensitive O 
to O 
mGluR2 O 
/ O 
3 O 
ligands O 
and O 
activated O 
by O 
N-acetylaspartylglutamate B-SYSTEMATIC 
( O 
NAAG B-ABBREVIATION 
) O 
. O 

presence O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGluRs O 
) O 
of O 
group O 
II O 
modulating O 
glycine B-TRIVIAL 
exocytosis O 
from O 
glycinergic O 
nerve O 
endings O 
of O 
mouse O 
spinal O 
cord O 
was O 
investigated O 
. O 
Purified O 
synaptosomes O 
were O 
selectively O 
prelabeled O 
with O 
[(3)H]glycine B-SYSTEMATIC 
through O 
the O 
neuronal O 
transporter O 
GlyT2 O 
and O 
subsequently O 
depolarized O 
by O 
superfusion O 
with O 
12 O 
mM O 
KCl B-FORMULA 
. O 
The O 
selective O 
mGluR2 O 
/ O 
3 O 
agonist O 
LY379268 B-IDENTIFIER 
inhibited O 
the O 
K(+) B-FORMULA 
-evoked O 
overflow O 
of O 
[(3)H]glycine B-SYSTEMATIC 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
( O 
EC(50) O 
about O 
0.2 O 
nM O 
) O 
. O 
The O 
effect O 
of O 
LY379268 B-IDENTIFIER 
was O 
prevented O 
by O 
the O 
selective O 
mGluR2 O 
/ O 
3 O 
antagonist O 
LY341495 B-IDENTIFIER 
( O 
IC(50) O 
about O 
1 O 
nM O 
) O 
. O 
N-acetylaspartylglutamate B-SYSTEMATIC 
( O 
NAAG B-ABBREVIATION 
) O 
inhibited O 
[(3)H]glycine B-SYSTEMATIC 
overflow O 
with O 
extraordinary O 
potency O 
( O 
EC(50) O 
about O 
50 O 
fmol O 
) O 
. O 
In O 
contrast O 
, O 
glutamate B-TRIVIAL 
was O 
ineffective O 
up O 
to O 
0.1 O 
nM O 
, O 
excluding O 
that O 
glutamate B-TRIVIAL 
contamination O 
of O 
commercial O 
NAAG B-ABBREVIATION 
samples O 
is O 
responsible O 
for O 
the O 
reported O 
activity O 
of O 
NAAG B-ABBREVIATION 
at O 
mGluR3 O 
. O 
LY341495 B-IDENTIFIER 
antagonized O 
the O 
NAAG B-ABBREVIATION 
inhibition O 
of O 
[(3)H]glycine B-SYSTEMATIC 
release O 
. O 
The O 
effect O 
of O 
a O 
combination O 
of O 
maximally O 
effective O 
concentrations O 
of O 
LY379268 B-IDENTIFIER 
and O 
NAAG B-ABBREVIATION 
exhibited O 
no O 
additivity O 
. O 
The O 
non-hydrolysable O 
NAAG B-ABBREVIATION 
analogue O 
N-acetylaspartyl-β- B-SYSTEMATIC 
linked I-SYSTEMATIC 
glutamate I-SYSTEMATIC 
( O 
β-NAAG B-ABBREVIATION 
) O 
antagonized O 
NAAG B-ABBREVIATION 
and O 
LY379268 B-IDENTIFIER 
. O 
In O 
conclusion O 
, O 
our O 
results O 
show O 
that O 
glycinergic O 
nerve O 
endings O 
in O 
spinal O 
cord O 
are O 
endowed O 
with O 
group O 
II O 
mGluRs O 
mediating O 
inhibition O 
of O 
glycine B-TRIVIAL 
exocytosis O 
. O 
NAAG B-ABBREVIATION 
can O 
activate O 
these O 
presynaptic O 
receptors O 
with O 
extremely O 
high O 
affinity O 
and O 
with O 
characteristics O 
compatible O 
with O 
the O 
reported O 
mGluR3 O 
pharmacology O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

supercoiling O 
is O 
an O 
inherent O 
consequence O 
of O 
twisting O 
DNA O 
and O 
is O 
critical O 
for O 
regulating O 
gene O 
expression O 
and O 
DNA O 
replication O 
. O 
However O 
, O 
DNA O 
supercoiling O 
at O 
a O 
genomic O 
scale O 
in O 
human O 
cells O 
is O 
uncharacterized O 
. O 
To O 
map O 
supercoiling O 
, O 
we O 
used O 
biotinylated B-SYSTEMATIC 
trimethylpsoralen I-SYSTEMATIC 
as O 
a O 
DNA O 
structure O 
probe O 
to O 
show O 
that O 
the O 
human O 
genome O 
is O 
organized O 
into O 
supercoiling O 
domains O 
. O 
Domains O 
are O 
formed O 
and O 
remodeled O 
by O 
RNA O 
polymerase O 
and O 
topoisomerase O 
activities O 
and O 
are O 
flanked O 
by O 
GC-AT O 
boundaries O 
and O 
CTCF O 
insulator O 
protein O 
- O 
binding O 
sites O 
. O 
Underwound O 
domains O 
are O 
transcriptionally O 
active O 
and O 
enriched O 
in O 
topoisomerase O 
I O 
, O 
' O 
open O 
' O 
chromatin O 
fibers O 
and O 
DNase O 
I O 
sites O 
, O 
but O 
they O 
are O 
depleted O 
of O 
topoisomerase O 
II O 
. O 
Furthermore O 
, O 
DNA O 
supercoiling O 
affects O 
additional O 
levels O 
of O 
chromatin O 
compaction O 
as O 
underwound O 
domains O 
are O 
cytologically O 
decondensed O 
, O 
topologically O 
constrained O 
and O 
decompacted O 
by O 
transcription O 
of O 
short O 
RNAs O 
. O 
We O 
suggest O 
that O 
supercoiling O 
domains O 
create O 
a O 
topological O 
environment O 
that O 
facilitates O 
gene O 
activation O 
, O 
providing O 
an O 
evolutionary O 
purpose O 
for O 
clustering O 
genes O 
along O 
chromosomes O 
. O 

alkaloids I-FAMILY 
from O 
Aconitum O 
kirinense O 
. O 

new O 
C(18)-diterpenoid B-FAMILY 
alkaloid I-FAMILY 
, O 
kirinenine B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
root O 
of O 
Aconitum O 
kirinense O 
, O 
along O 
with O 
eight O 
known O 
diterpenoid B-FAMILY 
alkaloids I-FAMILY 
. O 
The O 
structures O 
of O 
all O 
compounds O 
were O 
characterized O 
on O 
the O 
basis O 
of O 
extensive O 
NMR O 
and O 
MS O 
analyses O 
and O 
by O 
comparison O 
with O 
literature O 
values O 
, O 
and O 
the O 
new O 
one O 
was O 
further O 
confirmed O 
by O 
X-ray O 
crystallographic O 
diffraction O 
. O 
All O 
the O 
compounds O 
were O 
isolated O 
from O 
the O 
title O 
plant O 
for O 
the O 
first O 
time O 
. O 

sugar B-FAMILY 
tunes O 
your O 
clock O 
. O 

cellular O 
circadian O 
clocks O 
are O 
set O 
by O 
the O 
light O 
/ O 
dark O 
cycle O 
, O 
these O 
clocks O 
can O 
be O 
reset O 
by O 
what O 
we O 
eat O 
. O 
Two O 
papers O 
in O 
this O 
issue O 
of O 
Cell O 
Metabolism O 
reveal O 
that O 
O B-FORMULA 
-GlcNAcylation O 
of O 
clock O 
proteins O 
, O 
which O 
is O 
dependent O 
on O 
nutrients O 
, O 
adjusts O 
our O 
circadian O 
clock O 
( O 
Kaasik O 
et O 
al O 
. O 
, O 
2013 O 
; O 
Li O 
et O 
al O 
. O 
, O 
2013 O 
) O 
. O 

report O 
the O 
seeded O 
synthesis O 
of O 
gold O 
nanoparticles O 
( O 
GNPs O 
) O 
via O 
the O 
reduction O 
of O 
HAuCl4 B-FORMULA 
by O 
( O 
L31 O 
and O 
F68 O 
) O 
triblock O 
copolymer O 
( O 
TBP O 
) O 
mixtures O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
focused O 
on O 
[ O 
TBP O 
] O 
/ O 
[ O 
Au B-FORMULA 
(III) I-FORMULA 
] O 
ratios O 
of O 
1-5 O 
( O 
≈1 O 
mM O 
HAuCl4 B-FORMULA 
) O 
and O 
seed O 
sizes O 
~20 O 
nm O 
. O 
Under O 
these O 
conditions O 
, O 
the O 
GNP O 
growth O 
rate O 
is O 
dominated O 
by O 
both O 
the O 
TBP O 
and O 
seed O 
concentrations O 
. O 
With O 
seeding O 
, O 
the O 
final O 
GNP O 
size O 
distributions O 
are O 
bimodal O 
. O 
Increasing O 
the O 
seed O 
concentration O 
( O 
up O 
to O 
~0.1 O 
nM O 
) O 
decreases O 
the O 
mean O 
particle O 
sizes O 
10-fold O 
, O 
from O 
~1000 O 
to O 
100 O 
nm O 
. O 
The O 
particles O 
in O 
the O 
bimodal O 
distribution O 
are O 
formed O 
by O 
the O 
competitive O 
direct O 
growth O 
in O 
solution O 
and O 
the O 
aggregative O 
growth O 
on O 
the O 
seeds O 
. O 
By O 
monitoring O 
kinetics O 
of O 
GNP O 
growth O 
, O 
we O 
propose O 
that O 
( O 
1 O 
) O 
the O 
surface O 
of O 
the O 
GNP O 
seeds O 
embedded O 
in O 
the O 
TBP O 
cavities O 
form O 
catalytic O 
centers O 
for O 
GNP O 
growth O 
and O 
( O 
2 O 
) O 
large O 
GNPs O 
are O 
formed O 
by O 
the O 
aggregation O 
of O 
GNP O 
seeds O 
in O 
an O 
autocatalytic O 
growth O 
process O 
. O 

GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
- O 
mediated O 
signalling O 
in O 
temporal O 
lobe O 
epilepsy O 
. O 

tonic O 
activation O 
of O 
extrasynaptic O 
GABAA O 
receptors O 
by O 
extracellular O 
GABA B-ABBREVIATION 
provides O 
a O 
powerful O 
means O 
of O 
regulating O 
neuronal O 
excitability O 
. O 
A O 
consistent O 
finding O 
from O 
studies O 
that O 
have O 
used O 
various O 
models O 
of O 
temporal O 
lobe O 
epilepsy O 
is O 
that O 
tonic O 
GABAA O 
receptor O 
- O 
mediated O 
conductances O 
are O 
largely O 
preserved O 
in O 
epileptic O 
brain O 
( O 
in O 
contrast O 
to O 
synaptic O 
inhibition O 
which O 
is O 
often O 
reduced O 
) O 
. O 
Tonic O 
inhibition O 
is O 
therefore O 
an O 
attractive O 
target O 
for O 
antiepileptic O 
drugs O 
. O 
However O 
, O 
the O 
network O 
consequences O 
of O 
a O 
commonly O 
used O 
approach O 
to O 
augment O 
tonic O 
GABAA O 
receptor O 
- O 
mediated O 
conductances O 
by O 
global O 
manipulation O 
of O 
extracellular O 
GABA B-ABBREVIATION 
are O 
difficult O 
to O 
predict O 
without O 
understanding O 
how O 
epileptogenesis O 
alters O 
the O 
pharmacology O 
and O 
GABA B-ABBREVIATION 
sensitivity O 
of O 
tonic O 
inhibition O 
, O 
and O 
how O 
manipulation O 
of O 
tonic O 
conductances O 
modulates O 
the O 
output O 
of O 
individual O 
neurons O 
. O 
Here O 
we O 
review O 
the O 
current O 
literature O 
on O 
epilepsy O 
- O 
associated O 
changes O 
in O 
tonic O 
GABAA O 
receptor O 
- O 
mediated O 
signalling O 
, O 
and O 
speculate O 
about O 
possible O 
effects O 
they O 
have O 
at O 
the O 
network O 
level O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
New O 
Targets O 
and O 
Approaches O 
to O 
the O 
Treatment O 
of O 
Epilepsy O 
' O 
. O 

models O 
are O 
valuable O 
instruments O 
in O 
defining O 
the O 
pathogenesis O 
of O 
diabetic O 
nephropathy O 
( O 
DN O 
) O 
, O 
but O 
they O 
only O 
partially O 
recapitulate O 
disease O 
manifestations O 
of O 
human O 
DN O 
, O 
limiting O 
their O 
utility O 
. O 
To O 
define O 
the O 
molecular O 
similarities O 
and O 
differences O 
between O 
human O 
and O 
murine O 
DN O 
, O 
we O 
performed O 
a O 
cross O 
- O 
species O 
comparison O 
of O 
glomerular O 
transcriptional O 
networks O 
. O 
Glomerular O 
gene O 
expression O 
was O 
profiled O 
in O 
patients O 
with O 
early O 
type O 
2 O 
DN O 
and O 
in O 
three O 
mouse O 
models O 
( O 
streptozotocin B-TRIVIAL 
DBA O 
/ O 
2 O 
, O 
C57BLKS O 
db O 
/ O 
db O 
, O 
and O 
eNOS-deficient O 
C57BLKS O 
db O 
/ O 
db O 
mice O 
) O 
. O 
Species O 
- O 
specific O 
transcriptional O 
networks O 
were O 
generated O 
and O 
compared O 
with O 
a O 
novel O 
network O 
- O 
matching O 
algorithm O 
. O 
Three O 
shared O 
human O 
- O 
mouse O 
cross O 
- O 
species O 
glomerular O 
transcriptional O 
networks O 
containing O 
143 O 
( O 
Human-DBA O 
STZ B-ABBREVIATION 
) O 
, O 
97 O 
( O 
Human-BKS O 
db O 
/ O 
db O 
) O 
, O 
and O 
162 O 
( O 
Human-BKS O 
eNOS(- O 
/ O 
- O 
) O 
db O 
/ O 
db O 
) O 
gene O 
nodes O 
were O 
generated O 
. O 
Shared O 
nodes O 
across O 
all O 
networks O 
reflected O 
established O 
pathogenic O 
mechanisms O 
of O 
diabetes O 
complications O 
, O 
such O 
as O 
elements O 
of O 
Janus O 
kinase O 
( O 
JAK O 
) O 
/ O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
( O 
STAT O 
) O 
and O 
vascular O 
endothelial O 
growth O 
factor O 
receptor O 
( O 
VEGFR O 
) O 
signaling O 
pathways O 
. O 
In O 
addition O 
, O 
novel O 
pathways O 
not O 
previously O 
associated O 
with O 
DN O 
and O 
cross O 
- O 
species O 
gene O 
nodes O 
and O 
pathways O 
unique O 
to O 
each O 
of O 
the O 
human O 
- O 
mouse O 
networks O 
were O 
discovered O 
. O 
The O 
human O 
- O 
mouse O 
shared O 
glomerular O 
transcriptional O 
networks O 
will O 
assist O 
DN O 
researchers O 
in O 
selecting O 
mouse O 
models O 
most O 
relevant O 
to O 
the O 
human O 
disease O 
process O 
of O 
interest O 
. O 
Moreover O 
, O 
they O 
will O 
allow O 
identification O 
of O 
new O 
pathways O 
shared O 
between O 
mice O 
and O 
humans O 
. O 

content O 
and O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
of O 
legume O 
fractions O 
. O 

faba O 
bean O 
( O 
Vicia O 
faba O 
L O 
. O 
) O 
subspecies O 
major O 
and O 
minor O 
and O 
lentil O 
seeds O 
grown O 
in O 
Algeria O 
were O 
separated O 
into O 
cotyledons O 
and O 
hulls O 
. O 
These O 
fractions O 
, O 
together O 
with O 
their O 
corresponding O 
whole O 
seeds O 
, O 
were O 
extracted O 
with O 
two O 
solvents O 
, O 
aqueous O 
( O 
70% O 
) O 
acetone B-SYSTEMATIC 
and O 
( O 
80% O 
) O 
ethanol B-SYSTEMATIC 
, O 
and O 
evaluated O 
for O 
antioxidant O 
activity O 
in O 
relation O 
to O 
their O 
phenolic B-FAMILY 
contents O 
. O 
Acetone B-SYSTEMATIC 
selectively O 
extracted O 
tannins B-FAMILY 
from O 
faba O 
beans O 
. O 
The O 
hulls O 
always O 
exhibited O 
high O 
antioxidant O 
activity O 
, O 
measured O 
using O 
the O 
reducing O 
power O 
( O 
RP O 
) O 
, O 
antiradical O 
activity O 
( O 
DPPH B-ABBREVIATION 
) O 
or O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
( O 
ORAC O 
) O 
assays O 
. O 
Aqueous O 
ethanol B-SYSTEMATIC 
( O 
80% O 
) O 
extract O 
of O 
lentil O 
hulls O 
exhibited O 
high O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
preferentially O 
inhibiting O 
15-LOX O 
( O 
IC(50) O 
, O 
55 O 
μg O 
/ O 
ml O 
) O 
, O 
with O 
moderate O 
COX-1 O 
( O 
IC(50) O 
, O 
66 O 
μg O 
/ O 
ml O 
) O 
and O 
COX-2 O 
( O 
IC(50) O 
, O 
119 O 
μg O 
/ O 
ml O 
) O 
inhibitory O 
effects O 
on O 
the O 
COX O 
pathway O 
, O 
whereas O 
faba O 
bean O 
hull O 
extracts O 
exerted O 
relatively O 
mild O 
LOX O 
inhibitory O 
activity O 
. O 

of O 
pyrrolizidine B-FAMILY 
alkaloids I-FAMILY 
in O 
commercial O 
honey O 
using O 
liquid O 
chromatography O 
- O 
ion O 
trap O 
mass O 
spectrometry O 
. O 

alkaloids I-FAMILY 
( O 
PAs O 
) O 
are O 
known O 
secondary O 
plant O 
metabolites O 
which O 
can O 
cause O 
hepatotoxicity O 
in O 
both O 
humans O 
and O 
livestock O 
. O 
PAs O 
can O 
be O 
consumed O 
through O 
the O 
use O 
of O 
plants O 
for O 
food O 
, O 
medicinal O 
purposes O 
and O 
as O 
contaminants O 
of O 
agricultural O 
crops O 
and O 
food O 
. O 
PA O 
contaminated O 
grain O 
has O 
posed O 
the O 
largest O 
health O 
risk O 
, O 
although O 
any O 
PA O 
contamination O 
in O 
our O 
food O 
chain O 
should O 
be O 
recognised O 
as O 
a O 
potential O 
health O 
threat O 
. O 
For O 
this O 
purpose O 
, O 
retail O 
honeys O 
were O 
tested O 
by O 
LC-MS O 
/ O 
MS O 
. O 
The O 
method O 
allows O 
for O 
specific O 
identification O 
of O 
toxic O 
retronecine B-TRIVIAL 
and O 
otonecine B-TRIVIAL 
-type O 
PAs O 
by O 
comparison O 
to O 
reference O 
compounds O 
via O 
a O 
spectral O 
library O 
. O 
In O 
total O 
, O 
50 O 
honey O 
samples O 
were O 
matched O 
to O 
the O 
reference O 
spectra O 
within O 
a O 
set O 
of O 
tolerance O 
parameters O 
. O 
Accurate O 
data O 
analysis O 
and O 
quick O 
detection O 
of O 
positive O 
samples O 
was O 
possible O 
. O 
Positive O 
samples O 
contained O 
an O 
average O 
PA O 
concentration O 
of O 
1260 O 
μg O 
kg(-1) O 
of O 
honey O 
. O 
Good O 
linear O 
calibrations O 
were O 
obtained O 
( O 
R(2) O 
> O 
0.991 O 
) O 
. O 
LOD O 
and O 
LOQ O 
ranged O 
from O 
0.0134 O 
to O 
0.0305 O 
and O 
0.0446 O 
to O 
0.1018 O 
μg O 
mL(-1) O 
, O 
respectively O 
. O 

nanoparticle O 
directed O 
assembly O 
of O 
functionalized O 
graphene B-TRIVIAL 
nanosheets O 
into O 
hierarchical O 
structures O 
with O 
hybrid O 
compositions O 
for O 
flexible O 
supercapacitors O 
. O 

structures O 
of O 
hybrid O 
materials O 
with O 
the O 
controlled O 
compositions O 
have O 
been O 
shown O 
to O 
offer O 
a O 
breakthrough O 
for O 
energy O 
storage O 
and O 
conversion O 
. O 
Here O 
, O 
we O 
report O 
the O 
integrative O 
assembly O 
of O 
chemically O 
modified O 
graphene B-TRIVIAL 
( O 
CMG O 
) O 
building O 
blocks O 
into O 
hierarchical O 
complex O 
structures O 
with O 
the O 
hybrid O 
composition O 
for O 
high O 
performance O 
flexible O 
pseudocapacitors O 
. O 
The O 
formation O 
mechanism O 
of O 
hierarchical O 
CMG/ O 
Nafion B-TRIVIAL 
/ O 
RuO2 B-FORMULA 
( O 
CMGNR O 
) O 
microspheres O 
, O 
which O 
is O 
triggered O 
by O 
the O 
cooperative O 
interplay O 
during O 
the O 
in O 
situ O 
synthesis O 
of O 
RuO2 B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
, O 
was O 
extensively O 
investigated O 
. O 
In O 
particular O 
, O 
the O 
hierarchical O 
CMGNR O 
microspheres O 
consisting O 
of O 
the O 
aggregates O 
of O 
CMG/ O 
Nafion B-TRIVIAL 
( O 
CMGN O 
) O 
nanosheets O 
and O 
RuO2 B-FORMULA 
NPs O 
provided O 
large O 
surface O 
area O 
and O 
facile O 
ion O 
accessibility O 
to O 
storage O 
sites O 
, O 
while O 
the O 
interconnected O 
nanosheets O 
offered O 
continuous O 
electron O 
pathways O 
and O 
mechanical O 
integrity O 
. O 
The O 
synergistic O 
effect O 
of O 
CMGNR O 
hybrids O 
on O 
the O 
supercapacitor O 
( O 
SC O 
) O 
performance O 
was O 
derived O 
from O 
the O 
hybrid O 
composition O 
of O 
pseudocapacitive O 
RuO2 B-FORMULA 
NPs O 
with O 
the O 
conductive O 
CMGNs O 
as O 
well O 
as O 
from O 
structural O 
features O 
. O 
Consequently O 
, O 
the O 
CMGNR-SCs O 
showed O 
a O 
specific O 
capacitance O 
as O 
high O 
as O 
160 O 
F O 
g(-1) O 
, O 
three O 
- O 
fold O 
higher O 
than O 
that O 
of O 
conventional O 
graphene B-TRIVIAL 
SCs O 
, O 
and O 
a O 
capacitance O 
retention O 
of O 
> O 
95% O 
of O 
the O 
maximum O 
value O 
even O 
after O 
severe O 
bending O 
and O 
1000 O 
charge O 
- O 
discharge O 
tests O 
due O 
to O 
the O 
structural O 
and O 
compositional O 
features O 
. O 

and O 
biological O 
evaluation O 
of O 
nucleoside B-FAMILY 
analogues O 
than O 
contain O 
silatrane B-TRIVIAL 
on O 
the O 
basis O 
of O 
the O 
structure O 
of O 
acyclovir B-TRIVIAL 
( O 
ACV B-ABBREVIATION 
) O 
as O 
novel O 
inhibitors O 
of O 
hepatitis O 
B O 
virus O 
( O 
HBV O 
) O 
. O 

B O 
virus O 
( O 
HBV O 
) O 
infection O 
causes O 
major O 
public O 
health O 
problems O 
worldwide O 
. O 
Acyclovir B-TRIVIAL 
( O 
ACV B-ABBREVIATION 
) O 
is O 
mainly O 
used O 
to O 
inhibit O 
herpes O 
simplex O 
virus O 
( O 
HSV O 
) O 
rather O 
than O 
HBV O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
the O 
combination O 
principle O 
to O 
design O 
and O 
synthesize O 
nucleoside B-FAMILY 
analogues O 
that O 
contain O 
silatrane B-TRIVIAL 
on O 
the O 
basis O 
of O 
the O 
structure O 
of O 
ACV B-ABBREVIATION 
. O 
We O 
found O 
that O 
the O 
compounds O 
were O 
effective O 
inhibitors O 
of O 
HBV O 
, O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
All O 
of O 
the O 
compounds O 
showed O 
suppressive O 
activity O 
on O 
the O 
expression O 
of O 
HBV O 
surface O 
antigen O 
( O 
HBsAg O 
) O 
and O 
HBV O 
e O 
antigen O 
( O 
HBeAg O 
) O 
in O 
the O 
HepG2.2.15 O 
cell O 
line O 
with O 
low O 
cytotoxicity O 
. O 
One O 
of O 
compounds O 
was O 
studied O 
in O 
HBV O 
transgenic O 
mice O 
model O 
, O 
and O 
the O 
test O 
results O 
showed O 
its O 
ability O 
to O 
reduce O 
the O 
levels O 
of O 
HBsAg O 
, O 
HBeAg O 
and O 
HBV O 
DNA O 
by O 
ELASE O 
and O 
qPCR O 
. O 
Furthermore O 
, O 
significant O 
improvement O 
of O 
T O 
lymphocyte O 
was O 
observed O 
after O 
treatment O 
, O 
as O 
evaluated O 
by O 
flow O 
cytometry O 
( O 
FCM O 
) O 
. O 

recombination O 
( O 
HR O 
) O 
is O 
an O 
essential O 
process O 
in O 
cells O 
that O 
provides O 
repair O 
of O 
DNA O 
double O 
- O 
strand O 
breaks O 
and O 
lesions O 
that O 
block O 
DNA O 
replication O 
. O 
RAD51 O 
is O 
an O 
evolutionarily O 
conserved O 
protein O 
that O 
is O 
central O 
to O 
HR O 
. O 
Overexpression O 
of O 
RAD51 O 
protein O 
is O 
common O 
in O 
cancer O 
cells O 
and O 
represents O 
a O 
potential O 
therapeutic O 
target O 
in O 
oncology O 
. O 
We O 
previously O 
described O 
a O 
chemical O 
inhibitor O 
of O 
RAD51 O 
, O 
called O 
RI-1 B-IDENTIFIER 
( O 
referred O 
to O 
as O 
compound O 
1 O 
in O 
this O 
report O 
) O 
. O 
The O 
chloromaleimide B-SYSTEMATIC 
group O 
of O 
this O 
compound O 
is O 
thought O 
to O 
act O 
as O 
a O 
Michael O 
acceptor O 
and O 
react O 
with O 
the O 
thiol B-FAMILY 
group O 
on O 
C319 O 
of O 
RAD51 O 
, O 
using O 
a O 
conjugate O 
addition O 
- O 
elimination O 
mechanism O 
. O 
In O 
order O 
to O 
reduce O 
the O 
likelihood O 
of O 
off O 
- O 
target O 
effects O 
and O 
to O 
improve O 
compound O 
stability O 
in O 
biological O 
systems O 
, O 
we O 
developed O 
an O 
analogue O 
of O 
compound O 
1 O 
that O 
lacks O 
maleimide B-SYSTEMATIC 
-based O 
reactivity O 
but O 
retains O 
RAD51 O 
inhibitory O 
activity O 
. O 
This O 
compound O 
, O 
1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-morpholino-1H-pyrrole-2,5-dione B-SYSTEMATIC 
, O 
named O 
RI-2 B-IDENTIFIER 
( O 
referred O 
to O 
as O 
compound O 
7a O 
in O 
this O 
report O 
) O 
, O 
appears O 
to O 
bind O 
reversibly O 
to O 
the O 
same O 
site O 
on O 
the O 
RAD51 O 
protein O 
as O 
does O 
compound O 
1 O 
. O 
Like O 
compound O 
1 O 
, O 
compound O 
7a O 
specifically O 
inhibits O 
HR O 
repair O 
in O 
human O 
cells O 
. O 

( O 
EPO O 
) O 
is O 
the O 
main O 
regulator O 
of O 
red O 
blood O 
cell O 
production O 
but O 
there O 
exists O 
also O 
a O 
variety O 
of O 
nonhematopoietic O 
properties O 
. O 
More O 
recent O 
data O 
show O 
that O 
EPO O 
is O 
also O 
associated O 
with O 
the O 
protection O 
of O 
tissues O 
suffering O 
from O 
ischemia O 
and O 
reperfusion O 
injury O 
as O 
well O 
as O 
with O 
improved O 
regeneration O 
in O 
various O 
organ O 
systems O 
, O 
in O 
particular O 
the O 
skin O 
. O 
This O 
review O 
highlights O 
the O 
mechanisms O 
of O 
EPO O 
in O 
the O 
different O 
stages O 
of O 
wound O 
healing O 
and O 
the O 
reparative O 
processes O 
in O 
the O 
skin O 
emphasizing O 
pathophysiological O 
mechanisms O 
and O 
potential O 
clinical O 
applications O 
. O 
There O 
is O 
clear O 
evidence O 
that O 
EPO O 
effectively O 
influences O 
all O 
wound O 
- O 
healing O 
phases O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
This O 
includes O 
inflammation O 
, O 
tissue O 
, O 
and O 
blood O 
vessel O 
formation O 
as O 
well O 
as O 
the O 
remodeling O 
of O 
the O 
wound O 
. O 
The O 
molecular O 
mechanism O 
is O 
predominantly O 
based O 
on O 
an O 
increased O 
expression O 
of O 
the O 
endothelial O 
and O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
synthase O 
with O 
a O 
consecutive O 
rapid O 
supply O 
of O 
NO B-FORMULA 
as O 
well O 
as O 
an O 
increased O 
content O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
in O 
the O 
wound O 
. O 
The O 
improved O 
understanding O 
of O 
the O 
functions O 
and O 
regulatory O 
mechanisms O 
of O 
EPO O 
in O 
the O 
context O 
of O 
wound O 
- O 
healing O 
problems O 
and O 
ischemia O 
/ O 
reperfusion O 
injury O 
, O 
especially O 
during O 
flap O 
surgery O 
, O 
may O 
lead O 
to O 
new O 
considerations O 
of O 
this O 
growth O 
hormone O 
for O 
its O 
regular O 
clinical O 
application O 
in O 
patients O 
. O 

Polyaniline I-FAMILY 
-Based O 
Organic O 
Electrodes O 
for O 
Controlled O 
Electrical O 
Stimulation O 
of O 
Human O 
Osteosarcoma O 
Cells O 
. O 

conducting O 
polymers O 
( O 
CPs O 
) O 
were O 
found O 
to O 
stimulate O 
various O 
cell O 
types O 
such O 
as O 
neurons O 
, O 
osteoblasts O 
, O 
and O 
fibroblasts O 
in O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
studies O 
. O 
However O 
, O 
to O 
our O 
knowledge O 
, O 
no O 
studies O 
have O 
been O 
reported O 
on O 
the O 
utility O 
of O 
CPs O 
in O 
stimulation O 
of O 
cancer O 
or O 
tumor O 
cells O 
in O 
the O 
literature O 
. O 
Here O 
we O 
report O 
a O 
facile O 
fabrication O 
method O 
of O 
self O 
- O 
doped O 
sulfonated B-FAMILY 
polyaniline I-FAMILY 
( O 
SPAN B-ABBREVIATION 
) O 
- O 
based O 
interdigitated O 
electrodes O 
( O 
IDEs O 
) O 
for O 
controlled O 
electrical O 
stimulation O 
of O 
human O 
osteosarcoma O 
( O 
HOS O 
) O 
cells O 
. O 
Increased O 
degree O 
of O 
sulfonation O 
was O 
found O 
to O 
increase O 
the O 
SPAN B-ABBREVIATION 
conductivity O 
, O 
which O 
in O 
turn O 
improved O 
the O 
cell O 
attachment O 
and O 
cell O 
growth O 
without O 
electrical O 
stimulation O 
. O 
However O 
, O 
an O 
enhanced O 
cell O 
growth O 
was O 
observed O 
under O 
controlled O 
electrical O 
( O 
AC O 
) O 
stimulation O 
at O 
low O 
applied O 
voltage O 
and O 
frequency O 
( O 
≤ O 
800 O 
mV O 
and O 
≤ O 
1 O 
kHz O 
) O 
. O 
The O 
cell O 
growth O 
reached O 
a O 
maximum O 
threshold O 
at O 
an O 
applied O 
voltage O 
or O 
frequency O 
and O 
beyond O 
which O 
pronounced O 
cell O 
death O 
was O 
observed O 
. O 
We O 
believe O 
that O 
these O 
organic O 
electrodes O 
may O 
find O 
utility O 
in O 
electrical O 
stimulation O 
of O 
cancer O 
or O 
tumor O 
cells O 
for O 
therapy O 
and O 
research O 
and O 
may O 
also O 
provide O 
an O 
alternative O 
to O 
the O 
conventional O 
metal O 
- O 
based O 
electrodes O 
. O 

insensitivity O 
syndrome O 
. O 

insensitivity O 
syndrome O 
( O 
AIS O 
) O 
is O 
a O 
disorder O 
caused O 
by O 
a O 
mutation O 
of O 
the O 
gene O 
encoding O 
the O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
; O 
Xq11-q12 O 
) O 
. O 
The O 
prevalence O 
of O 
AIS O 
has O 
been O 
estimated O 
to O 
be O 
one O 
case O 
in O 
every O 
20000 O 
to O 
64000 O 
newborn O 
males O 
for O 
the O 
complete O 
syndrome O 
( O 
CAIS O 
) O 
, O 
and O 
the O 
prevalence O 
is O 
unknown O 
for O 
the O 
partial O 
syndrome O 
( O 
PAIS O 
) O 
. O 
The O 
symptoms O 
range O 
from O 
phenotypically O 
normal O 
males O 
with O 
impaired O 
spermatogenesis O 
to O 
phenotypically O 
normal O 
women O 
with O 
primary O 
amenorrhea O 
. O 
Various O 
forms O 
of O 
ambiguous O 
genitalia O 
have O 
been O 
observed O 
at O 
birth O 
. O 
The O 
diagnosis O 
is O 
confirmed O 
by O 
determining O 
the O 
exact O 
mutation O 
in O 
the O 
AR O 
gene O 
. O 
PAIS O 
individuals O 
require O 
precise O 
diagnosis O 
as O 
early O 
as O 
possible O 
so O 
that O 
the O 
sex O 
can O 
be O 
assigned O 
, O 
treatment O 
can O 
be O 
recommended O 
, O 
and O 
they O 
can O 
receive O 
proper O 
genetic O 
counseling O 
. O 
After O 
birth O 
, O 
differential O 
diagnosis O 
should O 
be O 
performed O 
using O 
other O 
forms O 
of O 
abnormal O 
sexual O 
differentiation O 
of O 
primary O 
amenorrhea O 
. O 
The O 
treatment O 
of O 
AIS O 
is O 
based O 
on O 
reinforcement O 
sexual O 
identity O 
, O 
gonadectomy O 
planning O 
, O 
and O 
hormone O 
replacement O 
therapy O 
. O 
The O 
prognosis O 
for O 
CAIS O 
is O 
good O 
if O 
the O 
testicular O 
tissue O 
is O 
removed O 
at O 
the O 
appropriate O 
time O 
. O 
For O 
PAIS O 
, O 
the O 
prognosis O 
depends O 
on O 
the O 
ambiguity O 
of O 
the O 
genitalia O 
and O 
physical O 
and O 
psychosocial O 
adjustment O 
to O 
the O 
assigned O 
sex O 
. O 

of O 
refraction O 
, O 
density O 
, O 
and O 
solubility O 
of O 
ammonium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
solutions O 
at O 
high O 
pressure O 
. O 

asymmetric O 
moissanite B-TRIVIAL 
anvil O 
cell O 
is O 
used O 
to O 
study O 
aqueous O 
solutions O 
of O 
ammonium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
at O 
pressures O 
up O 
to O 
10 O 
kbar O 
. O 
The O 
index O 
of O 
refraction O 
is O 
measured O 
using O 
the O 
rotating O 
Fabry-Perot O 
technique O 
, O 
with O 
an O 
accuracy O 
of O 
approximately O 
1% O 
. O 
The O 
mass O 
density O 
and O 
molar O 
volume O 
of O 
the O 
solutions O 
are O 
estimated O 
using O 
the O 
measured O 
index O 
values O 
, O 
and O 
the O 
molar O 
volume O 
is O 
used O 
to O 
predict O 
the O 
pressure O 
dependence O 
of O 
the O 
solubility O 
. O 
The O 
solubility O 
derived O 
from O 
the O 
index O 
of O 
refraction O 
measurements O 
is O 
shown O 
to O 
agree O 
with O 
that O 
which O 
is O 
determined O 
by O 
direct O 
observation O 
of O 
the O 
onset O 
of O 
crystallization O 
. O 

of O 
TiO2 B-FORMULA 
photocatalytic O 
activity O 
in O 
a O 
HDPE O 
- O 
based O 
food O 
packaging O 
on O 
the O 
structural O 
and O 
microbiological O 
stability O 
of O 
a O 
short O 
- O 
ripened O 
cheese O 
. O 

high O 
density O 
polyethylene B-SYSTEMATIC 
(HDPE)/ O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
( O 
CaCO(3) B-FORMULA 
) O 
film O 
containing O 
TiO(2) B-FORMULA 
was O 
prepared O 
via O 
blown O 
film O 
extrusion O 
process O 
. O 
The O 
photocatalytic O 
properties O 
of O 
this O 
film O 
were O 
evaluated O 
by O 
voltammetric O 
, O 
UV-Vis O 
spectrophotometric O 
and O 
gas O 
chromatographic O 
measurements O 
following O 
the O 
decomposition O 
rate O 
of O 
suitably O 
selected O 
molecular O 
probes O 
, O 
such O 
as O 
4-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
. O 
The O 
film O 
containing O 
1% O 
w O 
/ O 
w O 
of O 
TiO(2) B-FORMULA 
displayed O 
a O 
profitable O 
and O 
reproducible O 
photoinduced O 
degradation O 
activity O 
towards O 
target O 
organic O 
compounds O 
. O 
The O 
effect O 
of O 
packaging O 
photocatalytic O 
activity O 
on O 
the O 
structural O 
and O 
microbiological O 
stability O 
of O 
a O 
short O 
- O 
ripened O 
cheese O 
was O 
studied O 
. O 
Cheese O 
structure O 
was O 
assessed O 
by O 
dynamic O 
, O 
small O 
deformation O 
rheological O 
tests O 
. O 
A O 
container O 
consisting O 
of O 
a O 
multilayer O 
material O 
, O 
where O 
the O 
layer O 
brought O 
in O 
contact O 
with O 
the O 
food O 
, O 
made O 
from O 
the O 
HDPE+ O 
CaCO(3) B-FORMULA 
+ O 
TiO(2) B-FORMULA 
composite O 
matrix O 
, O 
was O 
able O 
to O 
provide O 
a O 
greater O 
maintenance O 
of O 
the O 
original O 
cheese O 
structure O 
than O 
a O 
rigid O 
container O 
currently O 
used O 
, O 
mainly O 
due O 
to O 
the O 
inhibition O 
of O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
bacteria O 
and O 
coliforms O 
. O 

of O 
a O 
potent O 
and O 
selective O 
free B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
receptor O 
1 O 
agonist O 
with O 
low O 
lipophilicity O 
and O 
high O 
oral O 
bioavailability O 
. O 

free B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
receptor O 
1 O 
( O 
FFA1 O 
, O 
also O 
known O 
as O 
GPR40 O 
) O 
mediates O 
enhancement O 
of O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
and O 
is O 
emerging O 
as O 
a O 
new O 
target O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
. O 
Several O 
FFA1 O 
agonists O 
are O 
known O 
, O 
but O 
the O 
majority O 
of O 
these O 
suffer O 
from O 
high O 
lipophilicity O 
. O 
We O 
have O 
previously O 
reported O 
the O 
FFA1 O 
agonist O 
3 O 
( O 
TUG-424 B-IDENTIFIER 
) O 
. O 
We O 
here O 
describe O 
the O 
continued O 
structure O 
- O 
activity O 
exploration O 
and O 
optimization O 
of O 
this O 
compound O 
series O 
, O 
leading O 
to O 
the O 
discovery O 
of O 
the O 
more O 
potent O 
agonist O 
40 O 
, O 
a O 
compound O 
with O 
low O 
lipophilicity O 
, O 
excellent O 
in O 
vitro O 
metabolic O 
stability O 
and O 
permeability O 
, O 
complete O 
oral O 
bioavailability O 
, O 
and O 
appreciable O 
efficacy O 
on O 
glucose B-TRIVIAL 
tolerance O 
in O 
mice O 
. O 

sub O 
- O 
monolayer O 
distribution O 
of O 
isolated O 
molecular O 
Fe14 B-FORMULA 
(bta)6 I-FORMULA 
nanomagnets O 
is O 
deposited O 
intact O 
on O 
a O 
Au(111) B-FORMULA 
surface O 
and O 
investigated O 
by O 
X-ray O 
magnetic O 
circular O 
dichroism O 
spectroscopy O 
. O 
The O 
entropy O 
variation O 
with O 
respect O 
to O 
the O 
applied O 
magnetic O 
field O 
is O 
extracted O 
from O 
the O 
magnetization O 
curves O 
and O 
evidences O 
high O 
magnetocaloric O 
values O 
at O 
the O 
single O 
molecule O 
level O 
. O 

the O 
film O 
formation O 
of O 
latex O 
, O 
particle O 
deformation O 
can O 
occur O 
by O 
processes O 
of O 
wet O 
sintering O 
, O 
dry O 
sintering O 
, O 
or O 
capillary O 
action O 
. O 
When O 
latex O 
films O 
dry O 
nonuniformly O 
and O 
when O 
particles O 
deform O 
and O 
coalesce O 
while O 
the O 
film O 
is O 
still O 
wet O 
, O 
a O 
detrimental O 
skin O 
layer O 
will O 
develop O 
at O 
the O 
film O 
surface O 
. O 
In O 
their O 
process O 
model O 
, O 
Routh O 
and O 
Russel O 
proposed O 
that O 
the O 
operative O 
particle O 
deformation O 
mechanism O 
can O 
be O 
determined O 
by O 
the O 
values O 
of O 
control O 
parameters O 
on O 
a O 
deformation O 
map O 
. O 
Here O 
, O 
the O 
film O 
formation O 
processes O 
of O 
three O 
methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
/ O 
butyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
copolymer O 
latexes O 
with O 
high O 
glass O 
transition O 
temperatures O 
(T(g)) O 
, O 
ranging O 
from O 
45 O 
to O 
64 O 
°C O 
, O 
have O 
been O 
studied O 
when O 
heated O 
by O 
infrared O 
radiation O 
. O 
Adjusting O 
the O 
infrared O 
( O 
IR O 
) O 
power O 
density O 
enables O 
the O 
film O 
temperature O 
, O 
polymer O 
viscosity O 
, O 
and O 
evaporation O 
rate O 
during O 
latex O 
film O 
formation O 
to O 
be O 
controlled O 
precisely O 
. O 
Different O 
polymer O 
particle O 
deformation O 
mechanisms O 
have O 
been O 
demonstrated O 
for O 
the O 
same O 
latex O 
under O 
a O 
variety O 
of O 
film O 
formation O 
process O 
conditions O 
. O 
When O 
the O 
temperature O 
is O 
too O 
high O 
, O 
a O 
skin O 
layer O 
develops O 
. O 
On O 
the O 
other O 
hand O 
, O 
when O 
the O 
temperature O 
is O 
too O 
low O 
, O 
particles O 
deform O 
by O 
dry O 
sintering O 
, O 
and O 
the O 
process O 
requires O 
extended O 
time O 
periods O 
. O 
The O 
deduced O 
mechanisms O 
can O 
be O 
interpreted O 
and O 
explained O 
by O 
the O 
Routh-Russel O 
deformation O 
maps O 
. O 
Film O 
formation O 
of O 
hard O 
( O 
high O 
T(g) O 
) O 
coatings O 
is O 
achieved O 
without O 
using O 
coalescing O 
aids O 
that O 
emit O 
volatile O 
organic O 
compounds O 
( O 
VOCs O 
) O 
, O 
which O 
is O 
a O 
significant O 
technical O 
achievement O 
. O 

monovalent O 
cation O 
- O 
binding O 
sites O 
in O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
. O 

ions O 
are O 
non-essential O 
activators O 
of O 
several O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
( O 
ALDHs O 
) O 
, O 
whereas O 
a O 
few O 
others O 
require O 
the O 
cation O 
for O 
activity O 
. O 
Two O 
kinds O 
of O 
cation O 
- O 
binding O 
sites O 
, O 
which O 
we O 
named O 
intra O 
- O 
subunit O 
and O 
inter O 
- O 
subunit O 
, O 
have O 
been O 
observed O 
in O 
crystal O 
structures O 
of O 
ALDHs O 
, O 
and O 
based O 
on O 
reported O 
crystallographic O 
data O 
, O 
we O 
here O 
propose O 
the O 
existence O 
of O 
a O 
third O 
kind O 
located O 
in O 
the O 
central O 
cavity O 
of O 
some O 
tetrameric O 
ALDHs O 
. O 
Given O 
the O 
high O 
structural O 
similarity O 
between O 
these O 
enzymes O 
, O 
cation O 
- O 
binding O 
sites O 
may O 
be O 
present O 
in O 
many O 
other O 
members O 
of O 
this O 
superfamily O 
. O 
To O 
explore O 
the O 
prevalence O 
of O 
these O 
sites O 
, O 
we O 
compared O 
37 O 
known O 
crystal O 
structures O 
from O 
13 O 
different O 
ALDH O 
families O 
and O 
evaluated O 
the O 
possible O 
existence O 
of O 
a O 
cation O 
on O 
the O 
basis O 
of O 
the O 
number O 
, O 
distance O 
and O 
geometry O 
of O 
its O 
potential O 
interactions O 
, O 
as O 
well O 
as O 
of O 
B-factor O 
values O 
of O 
modeled O 
cations O 
obtained O 
in O 
new O 
refinements O 
of O 
some O 
reported O 
crystal O 
structures O 
. O 
Also O 
, O 
by O 
performing O 
multiple O 
alignments O 
of O 
855 O 
non-redundant O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
, O 
we O 
assessed O 
the O 
degree O 
of O 
conservation O 
in O 
their O 
respective O 
families O 
of O 
the O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
putatively O 
relevant O 
for O 
cation O 
binding O 
. O 
Among O 
the O 
ALDH O 
enzymes O 
studied O 
, O 
and O 
according O 
to O 
our O 
analyses O 
, O 
potential O 
intra O 
- O 
subunit O 
cation O 
- O 
binding O 
sites O 
seem O 
to O 
be O 
present O 
in O 
most O 
members O 
of O 
ALDH2 O 
, O 
ALDH1L O 
, O 
ALDH4 O 
, O 
ALDH5 O 
, O 
ALDH7 O 
, O 
ALDH10 O 
, O 
and O 
ALDH25 O 
families O 
, O 
as O 
well O 
as O 
in O 
the O 
bacterial O 
and O 
fungal O 
members O 
of O 
the O 
ALDH9 O 
family O 
and O 
in O 
a O 
few O 
ALDH1 O 
, O 
ALDH6 O 
, O 
ALDH11 O 
and O 
ALDH26 O 
enzymes O 
; O 
potential O 
inter O 
- O 
subunit O 
sites O 
in O 
members O 
of O 
ALDH1L O 
, O 
ALDH3 O 
, O 
ALDH4 O 
from O 
bacillales O 
, O 
ALDH5 O 
, O 
ALDH7 O 
, O 
ALDH9 O 
, O 
ALDH10 O 
, O 
ALDH11 O 
and O 
ALDH25 O 
families O 
; O 
and O 
potential O 
central O 
- O 
cavity O 
sites O 
only O 
in O 
some O 
bacterial O 
and O 
animal O 
ALDH9s O 
and O 
in O 
most O 
members O 
of O 
the O 
ALDH1L O 
family O 
. O 
Because O 
potassium B-SYSTEMATIC 
is O 
the O 
most O 
abundant O 
intracellular O 
cation O 
, O 
we O 
propose O 
that O 
these O 
are O 
potassium B-SYSTEMATIC 
-binding O 
sites O 
, O 
but O 
the O 
specific O 
structural O 
and O 
/ O 
or O 
functional O 
roles O 
of O 
the O 
cation O 
bound O 
to O 
these O 
different O 
sites O 
remain O 
to O 
be O 
investigated O 
. O 

nut O 
procyanidins B-FAMILY 
ameliorate O 
streptozocin B-TRIVIAL 
-induced O 
hyperglycemia O 
by O 
regulating O 
gluconeogenesis O 
. O 

gluconeogenesis O 
is O 
a O 
major O 
contributor O 
to O 
blood O 
glucose B-TRIVIAL 
in O 
diabetes O 
mellitus O 
. O 
Our O 
previous O 
study O 
indicated O 
that O 
areca O 
nut O 
extract O 
enriched O 
with O 
catechin B-TRIVIAL 
-based O 
procyanidins B-FAMILY 
from O 
oligomers O 
to O 
polymers O 
gave O 
rise O 
to O 
anti-inflammatory O 
effects O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Here O 
we O 
have O 
surveyed O 
the O 
molecular O 
features O 
of O 
areca O 
nut O 
procyanidins B-FAMILY 
( O 
ANPs O 
) O 
using O 
quadrupole O 
time O 
- O 
of O 
- O 
flight O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
( O 
Q-TOF O 
LC O 
/ O 
MS O 
) O 
and O 
the O 
resulting O 
mass O 
spectrum O 
accurately O 
described O 
ANP O 
from O 
monomer O 
to O 
hexadecamer O 
. O 
Furthermore O 
, O 
the O 
potential O 
of O 
ANP O 
in O 
terms O 
of O 
blood O 
glucose B-TRIVIAL 
homeostasis O 
was O 
explored O 
using O 
cyclic B-SYSTEMATIC 
adenosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
( O 
cAMP B-ABBREVIATION 
)/ O 
dexamethasone B-TRIVIAL 
stimulated O 
primary O 
mouse O 
hepatocytes O 
and O 
multiple O 
low O 
dose O 
streptozocin B-TRIVIAL 
( O 
MLD- O 
STZ B-ABBREVIATION 
) O 
treated O 
mice O 
. O 
With O 
the O 
primary O 
hepatocytes O 
, O 
ANP O 
dose O 
- O 
dependently O 
inhibited O 
gluconeogenesis O 
and O 
reduced O 
the O 
mRNA O 
expression O 
of O 
two O 
gluconeogenic O 
key O 
enzymes O 
, O 
phosphoenol B-SYSTEMATIC 
- I-SYSTEMATIC 
pyruvate I-SYSTEMATIC 
carboxykinase O 
( O 
PEPCK O 
) O 
and O 
glucose B-TRIVIAL 
-6-phosphatase O 
( O 
G6Pase O 
) O 
. O 
Intragastrically O 
feeding O 
of O 
10mg O 
/ O 
kg O 
ANP O 
for O 
4weeks O 
reduced O 
the O 
levels O 
of O 
fasting O 
blood O 
glucose B-TRIVIAL 
, O 
PEPCK O 
and O 
G6Pase O 
in O 
MLD- O 
STZ B-ABBREVIATION 
mice O 
. O 
In O 
additional O 
, O 
the O 
level O 
of O 
5'-AMP B-SYSTEMATIC 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
expression O 
showed O 
a O 
trend O 
towards O 
being O 
restored O 
in O 
the O 
ANP O 
treated O 
MLD- O 
STZ B-ABBREVIATION 
-mice O 
. O 
This O 
study O 
indicated O 
that O 
ANP O 
has O 
the O 
potential O 
to O 
improve O 
hyperglycemia O 
by O 
regulating O 
gluconeogenic O 
related O 
kinases O 
in O 
MLD- O 
STZ B-ABBREVIATION 
-mice O 
. O 

of O 
thermally O 
stable O 
cellulose O 
nanocrystals O 
by O 
phosphoric B-SYSTEMATIC 
Acid I-SYSTEMATIC 
hydrolysis O 
. O 

account O 
of O 
their O 
intriguing O 
mechanical O 
properties O 
, O 
low O 
cost O 
, O 
and O 
renewable O 
nature O 
, O 
high O 
- O 
aspect O 
- O 
ratio O 
cellulose O 
nanocrystals O 
( O 
CNCs O 
) O 
are O 
an O 
attractive O 
component O 
for O 
many O 
nanomaterials O 
. O 
Due O 
to O 
hydrogen B-SYSTEMATIC 
bonding O 
between O 
their O 
surface O 
hydroxyl B-SYSTEMATIC 
groups O 
, O 
unmodified O 
CNCs O 
( O 
H-CNCs O 
) O 
aggregate O 
easily O 
and O 
are O 
often O 
difficult O 
to O 
disperse O 
. O 
It O 
is O 
shown O 
here O 
that O 
on O 
account O 
of O 
ionic O 
repulsion O 
between O 
charged O 
surface O 
groups O 
, O 
slightly O 
phosphorylated O 
CNCs O 
( O 
P-CNCs O 
, O 
average O 
dimensions O 
31 O 
± O 
14 O 
× O 
316 O 
± O 
127 O 
nm O 
, O 
surface O 
charge O 
density O 
= O 
10.8 O 
± O 
2.7 O 
mmol O 
/ O 
kg O 
cellulose O 
) O 
, O 
prepared O 
by O 
controlled O 
hydrolysis O 
of O 
cotton O 
with O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
are O 
readily O 
dispersible O 
and O 
form O 
stable O 
dispersions O 
in O 
polar O 
solvents O 
such O 
as O 
water O 
, O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
, O 
and O 
dimethylformamide B-SYSTEMATIC 
. O 
Thermogravimetric O 
analyses O 
reveal O 
that O 
these O 
P-CNCs O 
exhibit O 
a O 
much O 
higher O 
thermal O 
stability O 
than O 
partially O 
sulfated O 
CNCs O 
( O 
S-CNCs O 
) O 
, O 
which O 
are O 
frequently O 
employed O 
, O 
but O 
suffer O 
from O 
limited O 
thermal O 
stability O 
. O 
Nanocomposites O 
of O 
an O 
ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
- O 
epichlorohydrin B-TRIVIAL 
copolymer O 
and O 
H-CNCs O 
, O 
S-CNCs O 
, O 
and O 
P-CNCs O 
were O 
prepared O 
, O 
and O 
their O 
mechanical O 
properties O 
were O 
studied O 
by O 
dynamic O 
mechanical O 
thermal O 
analysis O 
. O 
The O 
results O 
show O 
that O 
P-CNCs O 
offer O 
a O 
reinforcing O 
capability O 
that O 
is O 
comparable O 
to O 
that O 
of O 
H-CNCs O 
or O 
S-CNCs O 
. O 

- O 
mediated O 
NF-κB O 
survival O 
signaling O 
impairment O 
by O 
cisplatin B-TRIVIAL 
enhances O 
JNK O 
activation O 
allowing O 
synergistic O 
apoptosis O 
of O 
renal O 
proximal O 
tubular O 
cells O 
. O 

-induced O 
nephrotoxicity O 
is O 
an O 
important O 
limiting O 
factor O 
for O 
cisplatin B-TRIVIAL 
use O 
. O 
Tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
is O 
known O 
to O 
contribute O 
to O 
cisplatin B-TRIVIAL 
-induced O 
nephrotoxicity O 
by O 
inducing O 
an O 
inflammatory O 
process O 
aggravating O 
the O 
primary O 
injury O 
, O 
thereby O 
resulting O 
in O 
acute O 
kidney O 
injury O 
( O 
AKI O 
) O 
. O 
The O 
present O 
study O 
investigates O 
the O 
pathways O 
synergistically O 
activated O 
by O 
cisplatin B-TRIVIAL 
and O 
TNF-α O 
responsible O 
for O 
TNF-α-enhanced O 
cisplatin B-TRIVIAL 
-induced O 
renal O 
cell O 
injury O 
. O 
To O 
do O 
so O 
, O 
immortalized O 
renal O 
proximal O 
tubular O 
epithelial O 
cells O 
( O 
IM-PTECs O 
) O 
were O 
co O 
- O 
treated O 
with O 
TNF-α O 
and O 
cisplatin B-TRIVIAL 
. O 
Under O 
these O 
conditions O 
, O 
cisplatin B-TRIVIAL 
induced O 
dose O 
- O 
dependent O 
apoptosis O 
in O 
IM-PTECs O 
, O 
which O 
was O 
significantly O 
enhanced O 
by O 
TNF-α O 
. O 
Transcriptomic O 
analysis O 
revealed O 
that O 
cisplatin B-TRIVIAL 
inhibited O 
the O 
typical O 
TNF-α O 
response O 
and O 
cisplatin B-TRIVIAL 
/ O 
TNF-α O 
treatment O 
up O 
- O 
regulated O 
cell O 
death O 
pathways O 
while O 
it O 
down O 
- O 
regulated O 
survival O 
pathways O 
compared O 
to O 
cisplatin B-TRIVIAL 
alone O 
. O 
In O 
concordance O 
, O 
the O 
gene O 
expression O 
levels O 
of O 
kidney O 
injury O 
markers O 
combined O 
with O 
activation O 
of O 
specific O 
inflammatory O 
mediators O 
were O 
enhanced O 
by O 
cisplatin B-TRIVIAL 
/ O 
TNF-α O 
treatment O 
, O 
resembling O 
the O 
in O 
vivo O 
cisplatin B-TRIVIAL 
-induced O 
nephrotoxicity O 
response O 
. O 
Furthermore O 
, O 
combined O 
cisplatin B-TRIVIAL 
/ O 
TNF-α O 
treatment O 
inhibited O 
NF-κB O 
nuclear O 
translocation O 
and O 
NF-κB O 
- O 
mediated O 
gene O 
transcription O 
leading O 
to O 
enhanced O 
and O 
prolonged O 
JNK O 
and O 
c-Jun O 
phosphorylation O 
. O 
JNK O 
sustained O 
activation O 
further O 
inhibited O 
NF-κB O 
signaling O 
via O 
a O 
feedback O 
loop O 
mechanism O 
. O 
This O 
led O 
to O 
an O 
alteration O 
in O 
the O 
transcription O 
of O 
the O 
NF-κB-induced O 
anti-apoptotic O 
genes O 
c-IAP2 O 
, O 
Bcl-XL O 
, O 
Bruce O 
and O 
Bcl2 O 
and O 
pro O 
- O 
apoptotic O 
genes O 
Bfk O 
and O 
Xaf1 O 
and O 
consequently O 
to O 
sensitization O 
of O 
the O 
IM-PTECs O 
toward O 
cisplatin B-TRIVIAL 
/ O 
TNF-α-induced O 
toxicity O 
. O 
In O 
conclusion O 
, O 
our O 
findings O 
support O 
a O 
model O 
whereby O 
renal O 
cells O 
exposed O 
to O 
both O 
cisplatin B-TRIVIAL 
and O 
TNF-α O 
switch O 
into O 
a O 
more O 
pro O 
- O 
apoptotic O 
and O 
inflammatory O 
program O 
by O 
altering O 
their O 
NF-κB O 
/ O 
JNK O 
/ O 
c-Jun O 
balance O 
. O 

are O 
an O 
ideal O 
tool O 
to O 
screen O 
for O 
differences O 
in O 
gene O 
expression O 
of O 
thousands O 
of O 
genes O 
simultaneously O 
. O 
However O 
, O 
often O 
commercial O 
arrays O 
are O 
not O 
available O 
. O 
In O 
this O 
study O 
, O 
we O 
performed O 
microarray O 
analyses O 
to O 
evaluate O 
patterns O 
of O 
gene O 
transcription O 
following O 
exposure O 
to O 
two O 
natural O 
and O 
one O 
anthropogenic O 
stressor O 
. O 
cDNA O 
microarrays O 
compiled O 
of O 
three O 
life O 
stage O 
specific O 
and O 
three O 
stressor O 
- O 
specific O 
EST O 
libraries O 
, O 
yielding O 
1734 O 
different O 
EST O 
sequences O 
, O 
were O 
used O 
. O 
We O 
exposed O 
juveniles O 
of O 
the O 
water O 
flea O 
Daphnia O 
magna O 
for O 
48 O 
, O 
96 O 
and O 
144 O 
h O 
to O 
three O 
stressors O 
known O 
to O 
exert O 
strong O 
selection O 
in O 
natural O 
populations O 
of O 
this O 
species O 
i.e O 
. O 
a O 
sublethal O 
concentration O 
of O 
the O 
pesticide O 
carbaryl B-TRIVIAL 
, O 
infective O 
spores O 
of O 
the O 
endoparasite O 
Pasteuria O 
ramosa O 
, O 
and O 
fish O 
predation O 
risk O 
mimicked O 
by O 
exposure O 
to O 
fish O 
kairomones O 
. O 
A O 
total O 
of O 
148 O 
gene O 
fragments O 
were O 
differentially O 
expressed O 
compared O 
to O 
the O 
control O 
. O 
Based O 
on O 
a O 
PCA O 
, O 
the O 
exposure O 
treatments O 
were O 
separated O 
into O 
two O 
main O 
groups O 
based O 
on O 
the O 
extent O 
of O 
the O 
transcriptional O 
response O 
: O 
a O 
low O 
and O 
a O 
high O 
( O 
144 O 
h O 
of O 
fish O 
or O 
carbaryl B-TRIVIAL 
exposure O 
and O 
96 O 
h O 
of O 
parasite O 
exposure O 
) O 
stress O 
group O 
. O 
Firstly O 
, O 
we O 
observed O 
a O 
general O 
stress O 
- O 
related O 
transcriptional O 
expression O 
profile O 
independent O 
of O 
the O 
treatment O 
characterized O 
by O 
repression O 
of O 
transcripts O 
involved O 
in O 
transcription O 
, O 
translation O 
, O 
signal O 
transduction O 
and O 
energy O 
metabolism O 
. O 
Secondly O 
, O 
we O 
observed O 
treatment-specific O 
responses O 
including O 
signs O 
of O 
migration O 
to O 
deeper O 
water O 
layers O 
in O 
response O 
to O 
fish O 
predation O 
, O 
structural O 
challenge O 
of O 
the O 
cuticle O 
in O 
response O 
to O 
carbaryl B-TRIVIAL 
exposure O 
, O 
and O 
disturbance O 
of O 
the O 
ATP B-ABBREVIATION 
production O 
in O 
parasite O 
exposure O 
. O 
A O 
third O 
important O 
conclusion O 
is O 
that O 
transcription O 
expression O 
patterns O 
exhibit O 
stress O 
- O 
specific O 
changes O 
over O 
time O 
. O 
Parasite O 
exposure O 
shows O 
the O 
most O 
differentially O 
expressed O 
gene O 
fragments O 
after O 
96 O 
h O 
. O 
The O 
peak O 
of O 
differentially O 
expressed O 
transcripts O 
came O 
only O 
after O 
144 O 
h O 
of O 
fish O 
exposure O 
, O 
while O 
carbaryl B-TRIVIAL 
exposure O 
induced O 
a O 
more O 
stable O 
number O 
of O 
differently O 
expressed O 
gene O 
fragments O 
over O 
time O 
. O 

of O 
silver B-SYSTEMATIC 
nanoparticle O 
formation O 
and O 
agglomeration O 
inside O 
the O 
cavitation O 
bubble O 
after O 
pulsed O 
laser O 
ablation O 
in O 
liquid O 
. O 

of O 
PCDD B-MULTIPLE 
/ I-MULTIPLE 
Fs I-MULTIPLE 
, O 
dioxin B-FAMILY 
- I-FAMILY 
like I-FAMILY 
PCBs I-FAMILY 
, O 
PBDEs B-ABBREVIATION 
, O 
and O 
hexachlorobenzene B-SYSTEMATIC 
in O 
fat O 
samples O 
from O 
cattle O 
of O 
different O 
ages O 
and O 
gender O 
in O 
Korea O 
. O 

dibenzo-p-dioxins I-MULTIPLE 
and I-MULTIPLE 
dibenzofurans I-MULTIPLE 
( O 
PCDD B-MULTIPLE 
/ I-MULTIPLE 
Fs I-MULTIPLE 
) O 
, O 
dioxin B-FAMILY 
- I-FAMILY 
like I-FAMILY 
polychlorinated I-FAMILY 
biphenyls I-FAMILY 
( O 
DL-PCBs B-FAMILY 
) O 
, O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
, O 
and O 
hexachlorobenzene B-SYSTEMATIC 
( O 
HCB B-ABBREVIATION 
) O 
concentrations O 
were O 
determined O 
in O 
abdominal O 
fat O 
samples O 
from O 
30 O 
cattle O 
. O 
The O 
relationships O 
between O 
chemicals O 
, O 
age O 
, O 
and O 
gender O 
were O 
investigated O 
. O 
The O 
concentration O 
of O 
PCDD B-MULTIPLE 
/ I-MULTIPLE 
Fs I-MULTIPLE 
ranged O 
from O 
0.01 O 
to O 
1.36 O 
pg O 
TEQ O 
g(-1) O 
fat O 
, O 
DL-PCBs B-FAMILY 
ranged O 
from O 
0.17 O 
to O 
1.64 O 
pg O 
TEQ O 
g(-1) O 
fat O 
, O 
PBDEs B-ABBREVIATION 
ranged O 
from O 
135 O 
to O 
725 O 
pgg(-1) O 
fat O 
, O 
and O 
HCB B-ABBREVIATION 
ranged O 
from O 
25.5 O 
to O 
2061 O 
pgg(-1) O 
fat O 
. O 
A O 
comparison O 
between O 
cattle's O 
age O 
and O 
gender O 
vs O 
. O 
the O 
concentration O 
of O 
contaminants O 
revealed O 
higher O 
concentrations O 
of O 
PCDD B-MULTIPLE 
/ I-MULTIPLE 
Fs I-MULTIPLE 
and O 
DL-PCBs B-FAMILY 
in O 
cattle O 
aged O 
more O 
than O 
3 O 
years O 
; O 
no O 
difference O 
between O 
genders O 
was O 
apparent O 
. O 
Moreover O 
, O 
the O 
concentrations O 
of O 
PBDEs B-ABBREVIATION 
in O 
cattle O 
fat O 
did O 
not O 
correspond O 
with O 
the O 
age O 
of O 
cattle O 
. O 
Relative O 
to O 
cattle O 
1.5-2.5 O 
years O 
of O 
age O 
, O 
cattle O 
aged O 
3 O 
and O 
4 O 
years O 
had O 
higher O 
concentration O 
of O 
HCB B-ABBREVIATION 
but O 
the O 
concentration O 
difference O 
was O 
not O 
clear O 
at O 
age O 
5 O 
. O 
Human O 
exposures O 
to O 
these O 
compounds O 
from O 
beef O 
sources O 
were O 
calculated O 
based O 
on O 
beef O 
consumption O 
. O 

beneficial O 
effects O 
of O 
physical O 
exercise O 
on O 
stable O 
coronary O 
artery O 
disease O 
( O 
CAD O 
) O 
have O 
been O 
shown O 
by O 
an O 
increasing O 
number O 
of O 
studies O 
. O 
Exercise O 
training O 
leads O 
to O 
an O 
improved O 
bioavailability O 
of O 
the O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
partially O 
attenuates O 
endothelial O 
dysfunction O 
. O 
Further O 
effects O 
are O 
an O 
economization O 
of O 
ventricular O 
function O 
and O 
a O 
reduction O 
of O 
cardiovascular O 
risk O 
factors O 
. O 
In O 
clinical O 
studies O 
exercise O 
training O 
was O 
associated O 
with O 
a O 
decreased O 
total O 
and O 
cardiovascular O 
mortality O 
and O 
a O 
reduced O 
angina O 
pectoris O 
threshold O 
. O 
Thus O 
exercise O 
training O 
has O 
developed O 
to O 
an O 
evidence O 
- O 
based O 
therapeutic O 
option O 
of O 
stable O 
CAD O 
with O 
a O 
Class O 
Ia O 
recommendation O 
in O 
the O 
guidelines O 
. O 

acid I-FAMILY 
grafted O 
chitosan O 
for O 
high O 
performance O 
gene O 
delivery O 
: O 
comparison O 
of O 
amino B-FAMILY 
acid I-FAMILY 
hydrophobicity O 
on O 
vector O 
and O 
polyplex O 
characteristics O 
. O 

develop O 
a O 
safe O 
, O 
effective O 
, O 
and O 
biocompatible O 
gene O 
delivery O 
vector O 
, O 
a O 
series O 
of O 
hydrophobic O 
amino B-FAMILY 
acid I-FAMILY 
grafted O 
chitosan O 
( O 
AGC O 
) O 
derivatives O 
were O 
synthesized O 
by O 
carbodiimide B-SYSTEMATIC 
mediated O 
coupling O 
reaction O 
. O 
Chemical O 
characterization O 
of O 
AGC O 
polymers O 
was O 
performed O 
by O 
NMR O 
and O 
elemental O 
analysis O 
. O 
AGC O 
polymers O 
demonstrated O 
excellent O 
blood O 
compatibility O 
and O 
cell O 
viability O 
, O 
as O 
evaluated O 
by O 
hemolysis O 
and O 
MTT B-ABBREVIATION 
assay O 
, O 
respectively O 
. O 
AGC O 
polymers O 
could O 
effectively O 
bind O 
and O 
condense O 
plasmid O 
DNA O 
( O 
pDNA O 
) O 
to O 
form O 
polyplexes O 
in O 
the O 
size O 
range O 
of O 
161-263 O 
nm O 
and O 
possessed O 
net O 
cationic O 
charge O 
. O 
The O 
resultant O 
polyplex O 
showed O 
3.4-5.4-fold O 
greater O 
cellular O 
uptake O 
and O 
13-30-fold O 
higher O 
transfection O 
efficiency O 
in O 
HEK O 
293 O 
cells O 
as O 
compared O 
to O 
unmodified O 
chitosan O 
. O 
Moreover O 
, O 
both O 
cellular O 
uptake O 
and O 
transfection O 
efficiency O 
improved O 
with O 
the O 
increasing O 
amino B-FAMILY 
acid I-FAMILY 
hydrophobicity O 
. O 
Hydrophobic O 
amino B-FAMILY 
acid I-FAMILY 
substitution O 
contributed O 
to O 
the O 
enhance O 
pDNA O 
release O 
at O 
cytosolic O 
pH O 
. O 
These O 
data O 
demonstrate O 
AGC O 
polymers O 
as O 
a O 
promising O 
novel O 
nonviral O 
gene O 
delivery O 
vector O 
. O 

combination O 
of O 
[ B-MULTIPLE 
+ I-MULTIPLE 
] I-MULTIPLE 
and I-MULTIPLE 
[-]-Huperzine I-MULTIPLE 
A I-MULTIPLE 
improves O 
protection O 
against O 
soman O 
toxicity O 
compared O 
to O 
[+]-Huperzine B-TRIVIAL 
A I-TRIVIAL 
in O 
guinea O 
pigs O 
. O 

neuropathologic O 
mechanisms O 
after O 
exposure O 
to O 
lethal O 
doses O 
of O 
nerve O 
agent O 
are O 
complex O 
and O 
involve O 
multiple O 
biochemical O 
pathways O 
. O 
Effective O 
treatment O 
requires O 
drugs O 
that O 
can O 
simultaneously O 
protect O 
by O 
reversible O 
binding O 
to O 
the O 
acetylcholinesterase O 
( O 
AChE O 
) O 
and O 
blocking O 
cascades O 
of O 
seizure O 
related O 
brain O 
damage O 
, O 
inflammation O 
, O 
neuronal O 
degeneration O 
as O 
well O 
as O 
promoting O 
induction O 
of O 
neuroregeneration O 
. O 
[-]-Huperzine B-TRIVIAL 
A I-TRIVIAL 
( O 
[-]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
) O 
, O 
is O 
a O 
naturally O 
occurring O 
potent O 
reversible O 
AChE O 
inhibitor O 
that O 
penetrates O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
It O 
also O 
has O 
several O 
neuroprotective O 
effects O 
including O 
modification O 
of O 
beta-amyloid O 
peptide O 
, O 
reduction O 
of O 
oxidative O 
stress O 
, O 
anti-inflammatory O 
, O 
anti-apoptotic O 
and O 
induction O 
and O 
regulation O 
of O 
nerve O 
growth O 
factor O 
. O 
Toxicities O 
at O 
higher O 
doses O 
restrict O 
the O 
neuroporotective O 
ability O 
of O 
[-]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
for O 
treatment O 
. O 
The O 
synthetic O 
stereoisomer O 
, O 
[+]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
, O 
is O 
less O 
toxic O 
due O 
to O 
poor O 
AChE O 
inhibition O 
and O 
is O 
suitable O 
for O 
both O 
pre- O 
/ O 
post O 
- O 
exposure O 
treatments O 
of O 
nerve O 
agent O 
toxicity O 
. O 
[+]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
block O 
the O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
)-induced O 
seizure O 
in O 
rats O 
, O 
reduce O 
excitatory O 
amino B-FAMILY 
acid I-FAMILY 
induced O 
neurotoxicity O 
and O 
also O 
prevent O 
soman O 
induced O 
toxicity O 
with O 
minimum O 
performance O 
decrement O 
. O 
Unique O 
combinations O 
of O 
two O 
stereo O 
- O 
isomers O 
of O 
Hup B-ABBREVIATION 
A I-ABBREVIATION 
may O 
provide O 
an O 
excellent O 
pre O 
/ O 
post O 
- O 
treatment O 
drug O 
for O 
the O 
nerve O 
agent O 
induced O 
seizure O 
/ O 
status O 
epilepticus O 
. O 
We O 
investigated O 
a O 
combination O 
of O 
[+]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
with O 
a O 
small O 
dose O 
of O 
[-]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
( O 
[ B-MULTIPLE 
+ I-MULTIPLE 
] I-MULTIPLE 
and I-MULTIPLE 
[-]-Hup I-MULTIPLE 
A I-MULTIPLE 
) O 
against O 
soman B-TRIVIAL 
toxicity O 
. O 
Our O 
data O 
showed O 
that O 
pretreatment O 
with O 
a O 
combination O 
[ B-MULTIPLE 
+ I-MULTIPLE 
] I-MULTIPLE 
and I-MULTIPLE 
[-]-Hup I-MULTIPLE 
A I-MULTIPLE 
significantly O 
increased O 
the O 
survival O 
rate O 
and O 
reduced O 
behavioral O 
abnormalities O 
after O 
exposure O 
to O 
1.2×LD50 O 
soman O 
compared O 
to O 
[+]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
in O 
guinea O 
pigs O 
. O 
In O 
addition O 
, O 
[ B-MULTIPLE 
+ I-MULTIPLE 
] I-MULTIPLE 
and I-MULTIPLE 
[-]-Hup I-MULTIPLE 
A I-MULTIPLE 
pretreatment O 
inhibited O 
the O 
development O 
of O 
high O 
power O 
of O 
EEG O 
better O 
than O 
[+]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
pretreatment O 
alone O 
. O 
These O 
data O 
suggest O 
that O 
a O 
combination O 
of O 
[ B-MULTIPLE 
+ I-MULTIPLE 
] I-MULTIPLE 
and I-MULTIPLE 
[-]-Hup I-MULTIPLE 
A I-MULTIPLE 
offers O 
better O 
protection O 
than O 
[+]-Hup B-ABBREVIATION 
A I-ABBREVIATION 
and O 
serves O 
as O 
a O 
potent O 
medical O 
countermeasure O 
against O 
lethal O 
dose O 
nerve O 
agent O 
toxicity O 
in O 
guinea O 
pigs O 
. O 

to O 
3D O 
transition O 
in O 
the O 
B6H(y) B-FAMILY 
anions O 
. O 

energy O 
surfaces O 
of O 
anionic O 
B(6)H(y) B-FAMILY 
clusters O 
were O 
sampled O 
using O 
the O 
coalescence O 
kick O 
method O 
. O 
We O 
found O 
that O 
the O 
planar O 
to O 
three O 
- O 
dimensional O 
transition O 
occurs O 
in O 
this O 
system O 
when O 
y O 
= O 
4 O 
. O 
This O 
is O 
an O 
important O 
discovery O 
because O 
this O 
transition O 
suggests O 
a O 
major O 
structural O 
change O 
as O 
a O 
function O 
of O 
dehydrogenation O 
for O 
the O 
stoichiometric O 
B(n)H(n)(-) B-FAMILY 
polyhedral B-FAMILY 
boranes I-FAMILY 
. O 
We O 
also O 
found O 
that O 
the O 
B(6)H(3)(-) B-FORMULA 
global O 
minimum O 
structure O 
has O 
an O 
optical O 
isomer O 
. O 
The O 
chemical O 
bonding O 
patterns O 
revealed O 
by O 
the O 
adaptive O 
natural O 
density O 
partitioning O 
( O 
AdNDP O 
) O 
analysis O 
explain O 
the O 
geometric O 
structure O 
of O 
all O 
clusters O 
presented O 
here O 
. O 
From O 
our O 
chemical O 
bonding O 
analysis O 
, O 
we O 
concluded O 
that O 
the O 
2D-3D O 
transition O 
occurs O 
at O 
B(6)H(4)(-) B-FORMULA 
because O 
the O 
addition O 
of O 
one O 
extra O 
hydrogen B-SYSTEMATIC 
atom O 
further O 
destroys O 
the O 
network O 
of O 
the O 
peripheral O 
2c-2e O 
B-B B-FORMULA 
σ- O 
bonding O 
, O 
making O 
planar O 
structures O 
less O 
stable O 
, O 
and O 
because O 
the O 
distorted O 
octahedral O 
structure O 
provides O 
some O 
occupation O 
of O 
all O 
s- O 
and O 
p-AOs O 
of O 
boron B-SYSTEMATIC 
, O 
avoiding O 
the O 
presence O 
of O 
any O 
empty O 
atomic O 
orbitals O 
. O 
Theoretical O 
vertical O 
electron O 
detachment O 
energies O 
( O 
VDEs O 
) O 
were O 
calculated O 
for O 
comparison O 
with O 
future O 
experimental O 
work O 
. O 

estradiol B-TRIVIAL 
regulates O 
glucose B-TRIVIAL 
metabolism O 
via O 
the O 
sympathetic O 
nervous O 
system O 
in O 
female O 
rats O 
. O 

- O 
term O 
reduced O 
hypothalamic O 
estrogen B-FAMILY 
signaling O 
leads O 
to O 
increased O 
food O 
intake O 
and O 
decreased O 
locomotor O 
activity O 
and O 
energy O 
expenditure O 
, O 
and O 
ultimately O 
results O 
in O 
obesity O 
and O 
insulin O 
resistance O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
aimed O 
to O 
determine O 
the O 
acute O 
obesity O 
- O 
independent O 
effects O 
of O 
hypothalamic O 
estrogen B-FAMILY 
signaling O 
on O 
glucose B-TRIVIAL 
metabolism O 
. O 
We O 
studied O 
endogenous O 
glucose B-TRIVIAL 
production O 
( O 
EGP O 
) O 
and O 
insulin O 
sensitivity O 
during O 
selective O 
modulation O 
of O 
systemic O 
or O 
intrahypothalamic O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
signaling O 
in O 
rats O 
1 O 
week O 
after O 
ovariectomy O 
( O 
OVX O 
) O 
. O 
OVX O 
caused O 
a O 
17% O 
decrease O 
in O 
plasma O 
glucose B-TRIVIAL 
, O 
which O 
was O 
completely O 
restored O 
by O 
systemic O 
E2 O 
. O 
Likewise O 
, O 
the O 
administration O 
of O 
E2 O 
by O 
microdialysis O 
, O 
either O 
in O 
the O 
hypothalamic O 
paraventricular O 
nucleus O 
( O 
PVN O 
) O 
or O 
in O 
the O 
ventromedial O 
nucleus O 
( O 
VMH O 
) O 
, O 
restored O 
plasma O 
glucose B-TRIVIAL 
. O 
The O 
infusion O 
of O 
an O 
E2 O 
antagonist O 
via O 
reverse O 
microdialysis O 
into O 
the O 
PVN O 
or O 
VMH O 
attenuated O 
the O 
effect O 
of O 
systemic O 
E2 O 
on O 
plasma O 
glucose B-TRIVIAL 
. O 
Furthermore O 
, O 
E2 O 
administration O 
in O 
the O 
VMH O 
, O 
but O 
not O 
in O 
the O 
PVN O 
, O 
increased O 
EGP O 
and O 
induced O 
hepatic O 
insulin O 
resistance O 
. O 
E2 O 
administration O 
in O 
both O 
the O 
PVN O 
and O 
the O 
VMH O 
resulted O 
in O 
peripheral O 
insulin O 
resistance O 
. O 
Finally O 
, O 
sympathetic O 
, O 
but O 
not O 
parasympathetic O 
, O 
hepatic O 
denervation O 
blunted O 
the O 
effect O 
of O 
E2 O 
in O 
the O 
VMH O 
on O 
both O 
EGP O 
and O 
hepatic O 
insulin O 
sensitivity O 
. O 
In O 
conclusion O 
, O 
intrahypothalamic O 
estrogen B-FAMILY 
regulates O 
peripheral O 
and O 
hepatic O 
insulin O 
sensitivity O 
via O 
sympathetic O 
signaling O 
to O 
the O 
liver O 
. O 

paper O 
investigates O 
polyphenol B-FAMILY 
oxidase O 
( O 
PPO O 
) O 
activity O 
, O 
reduced O 
weight O 
percentage O 
after O 
sun O 
drying O 
, O 
and O 
the O 
changes O 
in O 
colour O 
and O 
appearance O 
of O 
green O 
pepper O 
( O 
Piper O 
nigrum O 
Linnaeus O 
) O 
berries O 
after O 
blanching O 
and O 
sun O 
drying O 
. O 
The O 
results O 
show O 
that O 
the O 
degree O 
of O 
reduced O 
weight O 
percentage O 
and O 
browning O 
in O 
green O 
pepper O 
berries O 
after O 
blanching O 
for O 
10 O 
min O 
is O 
greater O 
at O 
100°C O 
than O 
at O 
90 O 
and O 
80°C O 
. O 
Moreover O 
, O 
the O 
samples O 
blanched O 
at O 
100°C O 
for O 
10 O 
min O 
had O 
the O 
fastest O 
water O 
loss O 
, O 
but O 
the O 
lowest O 
PPO O 
activity O 
. O 
Thus O 
, O 
the O 
PPO O 
enzymatic O 
oxidation O 
of O 
polyphenols B-FAMILY 
might O 
not O 
be O 
the O 
only O 
reason O 
for O 
the O 
browning O 
of O 
green O 
pepper O 
berries O 
. O 
This O 
result O 
is O 
significantly O 
different O 
from O 
that O 
of O 
Variyar O 
, O 
Pendharkar O 
, O 
Banerjeea O 
, O 
and O 
Bandyopadhyay O 
( O 
1988 O 
) O 
and O 
therefore O 
deserves O 
further O 
study O 
. O 

the O 
male O 
brain O 
, O 
the O 
medial O 
preoptic O 
nucleus O 
( O 
POM O 
) O 
is O 
known O 
to O 
be O 
a O 
critical O 
relay O 
for O 
the O 
activation O 
of O 
sexual O 
behaviour O 
, O 
with O 
the O 
aromatisation O 
of O 
testosterone B-TRIVIAL 
into O 
17β-oestradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
playing O 
a O 
key O 
role O 
. O 
Acute O 
stress O 
has O 
been O 
shown O 
to O 
differentially O 
modulate O 
the O 
aromatase O 
enzyme O 
in O 
this O 
and O 
other O 
brain O 
nuclei O 
in O 
a O 
sex O 
- O 
specific O 
manner O 
. O 
In O 
POM O 
specifically O 
, O 
stress O 
induces O 
increases O 
in O 
aromatase O 
activity O 
( O 
AA O 
) O 
that O 
are O 
both O 
rapid O 
and O 
reversible O 
. O 
How O 
the O 
physiological O 
processes O 
initiated O 
during O 
an O 
acute O 
stress O 
response O 
mediate O 
sex- O 
and O 
nuclei- O 
specific O 
changes O 
in O 
AA O 
and O 
which O 
stress O 
response O 
hormones O 
are O 
involved O 
remains O 
to O 
be O 
determined O 
. O 
By O 
examining O 
the O 
relative O 
effects O 
of O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
, O 
arginine B-TRIVIAL 
vasotocin I-TRIVIAL 
( O 
AVT B-ABBREVIATION 
, O 
the O 
avian O 
homologue O 
to O 
arginine B-TRIVIAL 
vasopressin I-TRIVIAL 
) O 
and O 
corticotrophin O 
- O 
releasing O 
factor O 
( O 
CRF O 
) O 
, O 
the O 
present O 
study O 
aimed O 
to O 
define O 
the O 
hormone O 
profile O 
regulating O 
stress O 
- O 
induced O 
increases O 
in O 
AA O 
in O 
the O 
POM O 
. O 
We O 
found O 
that O 
CORT B-ABBREVIATION 
, O 
AVT B-ABBREVIATION 
and O 
CRF O 
all O 
appear O 
to O 
play O 
some O 
role O 
in O 
these O 
changes O 
in O 
the O 
male O 
brain O 
. O 
In O 
addition O 
, O 
these O 
effects O 
occur O 
in O 
a O 
targeted O 
manner O 
, O 
such O 
that O 
modulation O 
of O 
the O 
enzyme O 
by O 
these O 
hormones O 
only O 
occurs O 
in O 
the O 
POM O 
rather O 
than O 
in O 
all O 
aromatase O 
- O 
expressing O 
nuclei O 
. O 
Similarly O 
, O 
in O 
the O 
female O 
brain O 
, O 
the O 
experimental O 
effects O 
were O 
restricted O 
to O 
the O 
POM O 
but O 
only O 
CRF O 
was O 
capable O 
of O 
inducing O 
the O 
stress O 
- O 
like O 
increases O 
in O 
AA O 
. O 
These O 
data O 
further O 
demonstrate O 
the O 
high O 
degree O 
of O 
specificity O 
( O 
nuclei- O 
, O 
sex- O 
and O 
hormone O 
- O 
specific O 
effects O 
) O 
in O 
this O 
system O 
, O 
highlighting O 
the O 
complexity O 
of O 
the O 
stress O 
- O 
aromatase O 
link O 
and O 
suggesting O 
modes O 
through O 
which O 
the O 
nongenomic O 
modulation O 
of O 
this O 
enzyme O 
can O 
result O 
in O 
targeted O 
, O 
rapid O 
changes O 
in O 
local O 
oestrogen B-FAMILY 
concentrations O 
. O 

tautomerization O 
of O 
a O 
UV O 
sunscreen O 
( O 
4-tert-butyl-4'-methoxydibenzoylmethane B-SYSTEMATIC 
) O 
in O 
acetonitrile B-SYSTEMATIC 
studied O 
by O 
steady O 
- O 
state O 
and O 
laser O 
flash O 
photolysis O 
. O 

photothermal O 
tautomerization O 
processes O 
between O 
enol B-SYSTEMATIC 
and O 
keto B-SYSTEMATIC 
forms O 
of O 
4-tert-butyl-4'-methoxydibenzoylmethane B-SYSTEMATIC 
( O 
trade O 
name O 
, O 
Avobenzone B-TRIVIAL 
) O 
in O 
acetonitrile B-SYSTEMATIC 
have O 
been O 
studied O 
by O 
steady O 
- O 
state O 
and O 
laser O 
flash O 
photolysis O 
. O 
The O 
keto B-SYSTEMATIC 
form O 
is O 
produced O 
upon O 
photolysis O 
of O 
the O 
enol B-SYSTEMATIC 
in O 
only O 
acetonitrile B-SYSTEMATIC 
with O 
a O 
quantum O 
yield O 
of O 
0.014 O 
. O 
The O 
molar O 
absorptivity O 
of O 
the O 
keto B-SYSTEMATIC 
form O 
was O 
determined O 
. O 
Phototautomerization O 
from O 
the O 
keto B-SYSTEMATIC 
to O 
the O 
enol B-SYSTEMATIC 
form O 
was O 
not O 
seen O 
. O 
Laser O 
flash O 
photolysis O 
of O 
the O 
keto B-SYSTEMATIC 
form O 
recognized O 
the O 
formation O 
of O 
the O 
triplet O 
state O 
. O 
In O 
the O 
dark O 
, O 
the O 
keto B-SYSTEMATIC 
form O 
underwent O 
thermal O 
tautomerization O 
to O 
the O 
enol B-SYSTEMATIC 
with O 
a O 
lifetime O 
of O 
5.1 O 
h O 
at O 
295 O 
K O 
. O 
The O 
enolization O 
rate O 
in O 
acetonitrile B-SYSTEMATIC 
was O 
not O 
accelerated O 
by O 
the O 
presence O 
of O 
alcohols B-FAMILY 
and O 
/ O 
or O 
water O 
but O 
increased O 
with O 
increasing O 
temperature O 
and O 
followed O 
the O 
Arrhenius O 
expression O 
. O 
The O 
activation O 
energy O 
and O 
the O 
frequency O 
factor O 
were O 
determined O 
for O 
the O 
enolization O 
process O 
from O 
the O 
keto B-SYSTEMATIC 
to O 
the O 
enol B-SYSTEMATIC 
form O 
. O 
On O 
the O 
basis O 
of O 
the O 
energy O 
states O 
of O 
the O 
tautomers O 
and O 
isomers O 
as O 
estimated O 
by O 
DFT O 
calculations O 
, O 
a O 
schematic O 
energy O 
diagram O 
was O 
determined O 
for O 
the O 
photothermal O 
tautomerization O 
processes O 
in O 
acetonitrile B-SYSTEMATIC 
. O 

: O 
The O 
metabolic O 
syndrome O 
( O 
MetS O 
) O 
is O 
an O 
increasing O 
epidemiologic O 
challenge O 
and O 
cardiovascular O 
risk O 
factor O 
. O 
Interleukin-6 O 
( O 
IL-6 O 
) O 
is O 
a O 
cytokine O 
that O 
exerts O 
its O 
biological O 
function O 
via O 
a O 
complex O 
orchestration O 
of O 
soluble O 
and O 
membrane O 
bound O 
receptors O 
. O 
We O 
have O 
investigated O 
associations O 
between O 
IL-6 O 
and O 
its O 
soluble O 
receptors O 
, O 
soluble O 
IL-6 O 
receptor O 
( O 
sIL-6r O 
) O 
and O 
soluble O 
glycoprotein O 
130 O 
( O 
sGP130 O 
) O 
and O 
the O 
metabolic O 
syndrome O 
. O 
Furthermore O 
, O 
we O 
have O 
investigated O 
possible O 
associations O 
with O 
endothelial O 
dysfunction O 
and O 
arterial O 
stiffness O 
. O 
METHODS O 
: O 
A O 
total O 
of O 
563 O 
subjects O 
were O 
included O 
in O 
this O 
study O 
. O 
The O 
Adult O 
Treatment O 
Panel O 
III O 
criteria O 
of O 
the O 
National O 
Cholesterol B-TRIVIAL 
Education O 
Program O 
were O 
used O 
for O 
the O 
definition O 
of O 
MetS O 
. O 
We O 
used O 
commercially O 
available O 
ELISA O 
to O 
analyse O 
circulating O 
levels O 
of O 
the O 
markers O 
. O 
Pulse O 
wave O 
propagation O 
time O 
( O 
PWP O 
) O 
was O 
determined O 
to O 
assess O 
arterial O 
stiffness O 
. O 
RESULTS O 
: O 
The O 
criteria O 
for O 
having O 
MetS O 
were O 
filled O 
by O 
221 O 
subjects O 
. O 
sGP130 O 
, O 
sIL-6r O 
and O 
IL-6 O 
levels O 
were O 
elevated O 
in O 
subjects O 
with O 
MetS O 
( O 
p O 
< O 
0.05 O 
for O 
all O 
markers O 
) O 
, O 
and O 
are O 
associated O 
with O 
increasing O 
components O 
of O 
MetS O 
. O 
Particularly O 
hypertriglyceridaemia O 
, O 
hypertension O 
and O 
fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
seem O 
to O 
carry O 
this O 
association O 
. O 
sGP130 O 
( O 
p O 
< O 
0.01 O 
) O 
, O 
IL-6 O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
partially O 
sIL-6r O 
( O 
p O 
< O 
0.05 O 
) O 
correlated O 
with O 
markers O 
of O 
endothelial O 
function O 
( O 
E-selectin O 
, O 
I-CAM-1 O 
, O 
V-CAM-1 O 
) O 
and O 
inversely O 
with O 
PWP O 
after O 
adjustment O 
for O 
relevant O 
covariates O 
. O 
CONCLUSION O 
: O 
sGP130 O 
, O 
sIL-6r O 
and O 
IL-6 O 
were O 
significantly O 
elevated O 
in O 
subjects O 
with O 
MetS O 
. O 
In O 
addition O 
, O 
sGP130 O 
, O 
IL-6 O 
and O 
partially O 
sIL-6r O 
were O 
associated O 
with O 
markers O 
of O 
endothelial O 
function O 
and O 
arterial O 
stiffness O 
. O 
This O 
finding O 
sheds O 
new O 
light O 
on O 
the O 
role O 
of O 
these O 
inflammatory O 
cytokines O 
in O 
subjects O 
with O 
MetS O 
and O 
the O 
development O 
and O 
progression O 
of O 
clinically O 
silent O 
atherosclerosis O 
. O 

extraction O 
and O 
analysis O 
of O 
cylindrospermopsin B-TRIVIAL 
from O 
human O 
serum O 
and O 
urine O 
. O 

naturally O 
derived O 
cyanotoxin O 
, O 
cylindrospermopsin B-TRIVIAL 
( O 
CYN B-ABBREVIATION 
) O 
, O 
has O 
been O 
detected O 
in O 
freshwater O 
systems O 
worldwide O 
and O 
poses O 
a O 
threat O 
to O 
human O 
health O 
. O 
The O 
methods O 
for O 
the O 
extraction O 
and O 
detection O 
of O 
this O 
toxin O 
in O 
source O 
water O 
are O 
well O 
documented O 
, O 
but O 
methods O 
for O 
CYN B-ABBREVIATION 
determination O 
in O 
exposed O 
individuals O 
have O 
not O 
been O 
investigated O 
. O 
In O 
this O 
study O 
, O 
the O 
extraction O 
and O 
detection O 
of O 
CYN B-ABBREVIATION 
from O 
two O 
different O 
matrices O 
, O 
serum O 
and O 
urine O 
, O 
was O 
explored O 
. O 
Both O 
serum O 
and O 
urine O 
matrices O 
inherently O 
produce O 
interference O 
with O 
analytical O 
analyses O 
and O 
require O 
extensive O 
clean O 
- O 
up O 
. O 
Methods O 
for O 
extraction O 
of O 
CYN B-ABBREVIATION 
from O 
both O 
matrices O 
were O 
developed O 
and O 
validated O 
using O 
fortified O 
samples O 
. O 
Serum O 
extraction O 
included O 
homogenization O 
followed O 
by O 
protein O 
precipitation O 
and O 
solid O 
phase O 
extraction O 
( O 
SPE O 
) O 
. O 
Urine O 
samples O 
were O 
processed O 
using O 
filtration O 
, O 
pH O 
manipulation O 
, O 
and O 
SPE O 
. O 
Analyses O 
using O 
a O 
commercially O 
available O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
ELISA O 
) O 
and O 
liquid O 
chromatography O 
coupled O 
with O 
mass O 
spectrometry O 
( O 
LC O 
/ O 
MS O 
/ O 
MS O 
) O 
were O 
assessed O 
. O 
Matrix O 
effects O 
inhibited O 
ELISA's O 
use O 
as O 
a O 
quantitative O 
tool O 
for O 
both O 
matrices O 
. O 
LC O 
/ O 
MS O 
/ O 
MS O 
was O 
determined O 
to O 
be O 
the O 
most O 
effective O 
and O 
reproducible O 
means O 
to O 
detect O 
and O 
quantify O 
CYN B-ABBREVIATION 
. O 
The O 
method O 
detection O 
limits O 
determined O 
in O 
this O 
study O 
using O 
LC O 
/ O 
MS O 
/ O 
MS O 
were O 
0.25 O 
and O 
0.5 O 
ng O 
mL(-1) O 
for O 
serum O 
and O 
urine O 
, O 
respectively O 
. O 
This O 
method O 
can O 
be O 
used O 
to O 
test O 
individuals O 
exposed O 
to O 
blooms O 
of O 
cyanobacteria O 
producing O 
CYN B-ABBREVIATION 
. O 

dependence O 
of O 
transport O 
properties O 
of O 
spiro-MeOTAD B-SYSTEMATIC 
as O 
a O 
hole O 
transport O 
material O 
in O 
solid O 
- O 
state O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

internal O 
transport O 
and O 
recombination O 
parameters O 
of O 
solid O 
- O 
state O 
dye O 
- O 
sensitized O 
solar O 
cells O 
( O 
ssDSCs O 
) O 
using O 
the O 
amorphous O 
organic O 
semiconductor O 
2,2',7,7'-tetrakis(N,N-di-p-methoxyphenylamine)-9,9'-spirobifluorene B-SYSTEMATIC 
( O 
spiro-MeOTAD B-SYSTEMATIC 
) O 
as O 
a O 
hole O 
transport O 
material O 
( O 
HTM O 
) O 
are O 
investigated O 
using O 
electrical O 
impedance O 
spectroscopy O 
. O 
Devices O 
were O 
fabricated O 
using O 
flat O 
and O 
nanostructured O 
TiO2 B-FORMULA 
and O 
compared O 
to O 
systems O 
using O 
nanostructured O 
ZrO2 B-FORMULA 
to O 
differentiate O 
between O 
the O 
transport O 
processes O 
within O 
the O 
different O 
components O 
of O 
the O 
ssDSC O 
. O 
The O 
effect O 
of O 
chemically O 
p-doping O 
the O 
HTM O 
on O 
its O 
transport O 
was O 
investigated O 
, O 
and O 
its O 
temperature O 
dependence O 
was O 
examined O 
and O 
analyzed O 
using O 
the O 
Arrhenius O 
equation O 
. O 
Using O 
this O 
approach O 
the O 
activation O 
energy O 
of O 
the O 
hole O 
hopping O 
transport O 
within O 
the O 
undoped O 
spiro-MeOTAD B-SYSTEMATIC 
film O 
was O 
determined O 
to O 
be O 
0.34 O 
± O 
0.02 O 
and O 
0.4 O 
± O 
0.02 O 
eV O 
for O 
the O 
mesoporous O 
TiO2 B-FORMULA 
and O 
ZrO2 B-FORMULA 
systems O 
, O 
respectively O 
. O 

effects O 
on O 
CYP3A4 O 
activity O 
studied O 
by O 
its O 
simultaneous O 
and O 
time O 
- O 
separated O 
administration O 
with O 
simvastatin B-TRIVIAL 
and O 
atorvastatin B-TRIVIAL 
. O 

: O 
To O 
characterise O 
further O 
the O 
previously O 
observed O 
cytochrome O 
P450 O 
3A4 O 
( O 
CYP3A4 O 
) O 
interaction O 
of O 
the O 
dual O 
orexin O 
receptor O 
antagonist O 
almorexant B-TRIVIAL 
. O 
METHODS O 
: O 
Pharmacokinetic O 
interactions O 
were O 
investigated O 
( O 
n O 
= O 
14 O 
healthy O 
male O 
subjects O 
in O 
two O 
treatment O 
groups O 
) O 
between O 
almorexant B-TRIVIAL 
at O 
steady O 
- O 
state O 
when O 
administered O 
either O 
concomitantly O 
or O 
2 O 
h O 
after O 
administration O 
of O 
single O 
doses O 
of O 
simvastatin B-TRIVIAL 
( O 
40 O 
mg O 
) O 
or O 
atorvastatin B-TRIVIAL 
( O 
40 O 
mg O 
) O 
. O 
RESULTS O 
: O 
Almorexant B-TRIVIAL 
dose O 
- O 
dependently O 
increased O 
simvastatin B-TRIVIAL 
exposure O 
(AUC(0-∞)) O 
when O 
administered O 
concomitantly O 
[ O 
geometric O 
mean O 
ratios O 
( O 
90 O 
% O 
CI O 
) O 
: O 
2.5 O 
( O 
2.1 O 
, O 
2.9 O 
) O 
( O 
100 O 
mg O 
) O 
, O 
3.9 O 
( O 
3.3 O 
, O 
4.6 O 
) O 
( O 
200 O 
mg O 
) O 
] O 
, O 
but O 
not O 
C(max) O 
[ O 
3.7 O 
( O 
3 O 
, O 
4.5 O 
) O 
for O 
both O 
doses O 
] O 
. O 
Time O 
- O 
separated O 
administration O 
resulted O 
in O 
relevant O 
reductions O 
of O 
the O 
interaction O 
[ O 
AUC(0-∞) O 
: O 
1.4 O 
( O 
1.2 O 
, O 
1.7 O 
) O 
( O 
100 O 
mg O 
) O 
, O 
1.7 O 
( O 
1.5 O 
, O 
2 O 
) O 
( O 
200 O 
mg O 
) O 
; O 
C(max) O 
: O 
1.5 O 
( O 
1.3 O 
, O 
1.9 O 
) O 
( O 
100 O 
mg O 
) O 
, O 
1.9 O 
( O 
1.6 O 
, O 
2.4 O 
) O 
( O 
200 O 
mg O 
) O 
] O 
. O 
Similar O 
results O 
were O 
obtained O 
for O 
hydroxyacid B-SYSTEMATIC 
simvastatin I-SYSTEMATIC 
. O 
Independent O 
of O 
almorexant B-TRIVIAL 
dose O 
and O 
relative O 
time O 
of O 
administration O 
, O 
AUC(0-∞) O 
and O 
C(max) O 
of O 
atorvastatin B-TRIVIAL 
increased O 
( O 
ratios O 
ranged O 
from O 
1.1 O 
to O 
1.5 O 
) O 
. O 
AUC(0-∞) O 
and O 
C(max) O 
of O 
o-hydroxy B-SYSTEMATIC 
atorvastatin I-SYSTEMATIC 
decreased O 
dose O 
- O 
independently O 
[ O 
AUC(0-∞) O 
: O 
0.8 O 
( O 
0.8 O 
, O 
0.9 O 
) O 
( O 
100 O 
mg O 
) O 
, O 
0.6 O 
( O 
0.5 O 
, O 
0.6 O 
) O 
( O 
200 O 
mg O 
) O 
; O 
C(max) O 
: O 
0.3 O 
( O 
0.3 O 
, O 
0.4 O 
) O 
( O 
100 O 
mg O 
) O 
, O 
0.2 O 
( O 
0.2 O 
, O 
0.3 O 
) O 
( O 
200 O 
mg O 
) O 
] O 
when O 
atorvastatin B-TRIVIAL 
was O 
concomitantly O 
administered O 
. O 
C(max) O 
of O 
o-hydroxy B-SYSTEMATIC 
atorvastatin I-SYSTEMATIC 
slightly O 
decreased O 
( O 
0.8 O 
for O 
both O 
doses O 
) O 
following O 
time O 
- O 
separated O 
administration O 
; O 
AUC(0-∞) O 
was O 
unchanged O 
. O 
CONCLUSIONS O 
: O 
Whereas O 
almorexant B-TRIVIAL 
increased O 
simvastatin B-TRIVIAL 
exposure O 
dose- O 
and O 
relative O 
time O 
of O 
administration O 
- O 
dependently O 
, O 
atorvastatin B-TRIVIAL 
exposure O 
increased O 
to O 
a O 
smaller O 
extent O 
and O 
irrespective O 
of O 
dose O 
and O 
time O 
. O 
This O 
suggests O 
that O 
the O 
observed O 
interaction O 
of O 
almorexant B-TRIVIAL 
with O 
simvastatin B-TRIVIAL 
is O 
mainly O 
caused O 
by O 
intestinal O 
CYP3A4 O 
inhibition O 
, O 
whereas O 
the O 
interaction O 
with O 
atorvastatin B-TRIVIAL 
is O 
more O 
due O 
to O 
hepatic O 
CYP3A4 O 
inhibition O 
. O 

release O 
of O 
5-fluorouracil B-SYSTEMATIC 
from O 
pH-sensitive O 
and O 
colon O 
targeted O 
pellets O 
: O 
an O 
industrially O 
feasible O 
approach O 
. O 

, O 
reliant O 
on O 
pH-sensitivity O 
and O 
time O 
- O 
dependency O 
for O 
drug O 
delivery O 
, O 
provide O 
one O 
of O 
the O 
most O 
versatile O 
opportunities O 
for O 
targeting O 
colon O 
. O 
5-Fluorouracil B-SYSTEMATIC 
( O 
5-FU B-SYSTEMATIC 
) O 
loaded O 
pellets O 
were O 
prepared O 
by O 
extrusion O 
- O 
spheronization O 
using O 
Avicel(®) O 
PH101 O 
as O 
a O 
spheronization O 
aid O 
and O 
hydroxypropylmethylcellulose O 
K4M O 
( O 
HPMC O 
K4M O 
) O 
solution O 
as O 
a O 
binder O 
. O 
A O 
3(2) O 
full O 
factorial O 
design O 
was O 
employed O 
to O 
optimize O 
spheronization O 
speed O 
and O 
time O 
. O 
Obtained O 
pellets O 
were O 
evaluated O 
for O 
flow O 
properties O 
, O 
pellet O 
size O 
, O 
roundness O 
and O 
aspect O 
ratio O 
. O 
Optimized O 
batch O 
was O 
coated O 
in O 
a O 
bottom O 
- O 
spray O 
fluidized O 
bed O 
processor O 
( O 
FBP O 
) O 
with O 
an O 
inner O 
coat O 
of O 
sustained O 
release O 
polymer O 
Eudragit B-FAMILY 
NE30D I-FAMILY 
and O 
an O 
outer O 
coat O 
of O 
pH-sensitive O 
polymer O 
Eudragit B-FAMILY 
FS30D I-FAMILY 
. O 
The O 
coating O 
levels O 
were O 
statistically O 
optimized O 
and O 
in O 
vitro O 
drug O 
release O 
was O 
monitored O 
by O 
changing O 
pH O 
media O 
method O 
. O 
Optimized O 
system O 
with O 
15% O 
inner O 
and O 
outer O 
coating O 
levels O 
revealed O 
t(50%) O 
( O 
time O 
required O 
for O 
50% O 
drug O 
release O 
) O 
to O 
be O 
about O 
9 O 
h O 
while O 
almost O 
complete O 
drug O 
was O 
released O 
in O 
24 O 
h O 
( O 
98.71 O 
± O 
1.33% O 
) O 
with O 
highest O 
dissolution O 
efficiency O 
(DE(24h)) O 
of O 
58.71% O 
. O 
The O 
optimization O 
model O 
was O 
validated O 
; O 
the O 
predicted O 
and O 
experimental O 
/ O 
actual O 
values O 
for O 
validation O 
batch O 
( O 
M1 O 
) O 
were O 
in O 
close O 
tolerance O 
and O 
the O 
standard O 
error O 
( O 
SE O 
) O 
was O 
also O 
small O 
. O 
Drug O 
release O 
was O 
also O 
studied O 
at O 
pH O 
7.4 O 
. O 
Scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
demonstrated O 
average O 
coating O 
thickness O 
to O 
be O 
32.5 O 
± O 
3 O 
µm O 
. O 
Hence O 
, O 
the O 
present O 
study O 
provides O 
constructive O 
results O 
for O 
colon O 
targeting O 
of O 
5-FU B-SYSTEMATIC 
pellets O 
with O 
industrially O 
feasible O 
processes O 
. O 

role O 
of O 
voltage O 
- O 
gated O 
potassium B-SYSTEMATIC 
channels O 
Kv2.1 O 
and O 
Kv2.2 O 
in O 
the O 
regulation O 
of O 
insulin O 
and O 
somatostatin O 
release O 
from O 
pancreatic O 
islets O 
. O 

voltage O 
- O 
gated O 
potassium B-SYSTEMATIC 
channels O 
Kv2.1 O 
and O 
Kv2.2 O 
are O 
highly O 
expressed O 
in O 
pancreatic O 
islets O 
, O 
yet O 
their O 
contribution O 
to O 
islet O 
hormone O 
secretion O 
is O 
not O 
fully O 
understood O 
. O 
Here O 
we O 
investigate O 
the O 
role O 
of O 
Kv2 O 
channels O 
in O 
pancreatic O 
islets O 
using O 
a O 
combination O 
of O 
genetic O 
and O 
pharmacologic O 
approaches O 
. O 
Pancreatic O 
β-cells O 
from O 
Kv2.1(- O 
/ O 
- O 
) O 
mice O 
possess O 
reduced O 
Kv O 
current O 
and O 
display O 
greater O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
( O 
GSIS O 
) O 
relative O 
to O 
WT O 
β-cells O 
. O 
Inhibition O 
of O 
Kv2.x O 
channels O 
with O 
selective O 
peptidyl O 
[ O 
guangxitoxin-1E O 
( O 
GxTX-1E O 
) O 
] O 
or O 
small O 
molecule O 
( O 
RY796 B-IDENTIFIER 
) O 
inhibitors O 
enhances O 
GSIS O 
in O 
isolated O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mouse O 
and O 
human O 
islets O 
, O 
but O 
not O 
in O 
islets O 
from O 
Kv2.1(- O 
/ O 
- O 
) O 
mice O 
. O 
However O 
, O 
in O 
WT O 
mice O 
neither O 
inhibitor O 
improved O 
glucose B-TRIVIAL 
tolerance O 
in O 
vivo O 
. O 
GxTX-1E O 
and O 
RY796 B-IDENTIFIER 
enhanced O 
somatostatin B-TRIVIAL 
release O 
in O 
isolated O 
human O 
and O 
mouse O 
islets O 
and O 
in O 
situ O 
perfused O 
pancreata O 
from O 
WT O 
and O 
Kv2.1(- O 
/ O 
- O 
) O 
mice O 
. O 
Kv2.2 O 
silencing O 
in O 
mouse O 
islets O 
by O 
adenovirus O 
- O 
small O 
hairpin O 
RNA O 
( O 
shRNA O 
) O 
specifically O 
enhanced O 
islet O 
somatostatin B-TRIVIAL 
, O 
but O 
not O 
insulin O 
, O 
secretion O 
. O 
In O 
mice O 
lacking O 
somatostatin B-TRIVIAL 
receptor O 
5 O 
, O 
GxTX-1E O 
stimulated O 
insulin O 
secretion O 
and O 
improved O 
glucose B-TRIVIAL 
tolerance O 
. O 
Collectively O 
, O 
these O 
data O 
show O 
that O 
Kv2.1 O 
regulates O 
insulin O 
secretion O 
in O 
β-cells O 
and O 
Kv2.2 O 
modulates O 
somatostatin B-TRIVIAL 
release O 
in O 
δ-cells O 
. O 
Development O 
of O 
selective O 
Kv2.1 O 
inhibitors O 
without O 
cross O 
inhibition O 
of O 
Kv2.2 O 
may O 
provide O 
new O 
avenues O 
to O 
promote O 
GSIS O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
. O 

profiling O 
of O 
native O 
group O 
II O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
in O 
primary O 
cortical O 
neuronal O 
cultures O 
using O 
a O 
FLIPR O 
. O 

group O 
II O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
comprised O 
of O 
the O 
mGlu2 O 
and O 
mGlu3 O 
receptor O 
subtypes O 
have O 
gained O 
recognition O 
in O 
recent O 
years O 
as O 
potential O 
targets O 
for O 
psychiatric O 
disorders O 
, O 
including O 
anxiety O 
and O 
schizophrenia O 
. O 
In O 
addition O 
to O 
studies O 
already O 
indicating O 
which O 
subtype O 
mediates O 
the O 
anxiolytic O 
and O 
anti-psychotic O 
effects O 
observed O 
in O 
disease O 
models O 
, O 
studies O 
to O 
help O 
further O 
define O 
the O 
preferred O 
properties O 
of O 
selective O 
group O 
II O 
mGlu O 
receptor O 
ligands O 
will O 
be O 
essential O 
. O 
Comparison O 
of O 
the O 
in O 
vitro O 
properties O 
of O 
these O 
ligands O 
to O 
their O 
in O 
vivo O 
efficacy O 
and O 
tolerance O 
profiles O 
may O 
help O 
provide O 
these O 
additional O 
insights O 
. O 
We O 
have O 
developed O 
a O 
relatively O 
high O 
- O 
throughput O 
native O 
group O 
II O 
mGlu O 
receptor O 
functional O 
assay O 
to O 
aid O 
this O 
characterisation O 
. O 
We O 
have O 
utilised O 
dissociated O 
primary O 
cortical O 
neuronal O 
cultures O 
, O 
which O 
after O 
7 O 
days O 
in O 
vitro O 
have O 
formed O 
functional O 
synaptic O 
connections O 
and O 
display O 
periodic O 
and O 
spontaneous O 
synchronised O 
calcium B-SYSTEMATIC 
( O 
Ca(2+) B-FORMULA 
) O 
oscillations O 
in O 
response O 
to O 
intrinsic O 
action O 
potential O 
bursts O 
. O 
We O 
herein O 
demonstrate O 
that O 
in O 
addition O 
to O 
non-selective O 
group O 
II O 
mGlu O 
receptor O 
agonists O 
, O 
(2R,4R)-APDC B-SYSTEMATIC 
, O 
LY379268 B-IDENTIFIER 
and O 
DCG-IV B-IDENTIFIER 
, O 
a O 
selective O 
mGlu2 O 
agonist O 
, O 
LY541850 B-IDENTIFIER 
, O 
and O 
mGlu2 O 
positive O 
allosteric O 
modulators O 
, O 
BINA O 
and O 
CBiPES O 
, O 
inhibit O 
the O 
frequency O 
of O 
synchronised O 
Ca(2+) B-FORMULA 
oscillations O 
in O 
primary O 
cultures O 
of O 
rat O 
and O 
mouse O 
cortical O 
neurons O 
. O 
Use O 
of O 
cultures O 
from O 
wild O 
- O 
type O 
, O 
mGlu2(- O 
/ O 
- O 
) O 
, O 
mGlu3(- O 
/ O 
- O 
) O 
and O 
mGlu2 O 
/ O 
3(- O 
/ O 
- O 
) O 
mice O 
allowed O 
us O 
to O 
further O 
probe O 
the O 
contribution O 
of O 
mGlu2 O 
and O 
mGlu3 O 
, O 
and O 
revealed O 
LY541850 B-IDENTIFIER 
to O 
be O 
a O 
partial O 
mGlu2 O 
agonist O 
and O 
a O 
full O 
mGlu3 O 
antagonist O 
. O 
Overnight O 
pre O 
- O 
treatment O 
of O 
cultures O 
with O 
these O 
ligands O 
revealed O 
a O 
preferred O 
desensitisation O 
profile O 
after O 
treatment O 
with O 
a O 
positive O 
allosteric O 
modulator O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

conformational O 
assignments O 
and O 
conformational O 
evolution O 
of O 
tyrosine B-TRIVIAL 
by O 
laser O 
desorption O 
supersonic O 
jet O 
laser O 
spectroscopy O 
. O 

number O 
of O 
conformers O 
and O 
their O 
structures O 
of O 
tyrosine B-TRIVIAL 
are O 
reassigned O 
on O 
the O 
basis O 
of O 
resonance O 
enhanced O 
multiphoton O 
ionization O 
( O 
REMPI O 
) O 
, O 
ultraviolet O 
- O 
ultraviolet O 
hole O 
burning O 
( O 
UV-UV O 
HB O 
) O 
, O 
infrared O 
( O 
IR O 
) O 
dip O 
spectra O 
, O 
and O 
quantum O 
chemical O 
calculations O 
. O 
From O 
comparison O 
between O 
REMPI O 
and O 
UV-UV O 
HB O 
spectra O 
, O 
it O 
was O 
found O 
that O 
12 O 
conformers O 
coexist O 
in O 
the O 
supersonic O 
jet O 
. O 
The O 
structures O 
of O 
these O 
conformers O 
are O 
determined O 
by O 
the O 
IR O 
spectra O 
and O 
theoretical O 
calculations O 
. O 
The O 
number O 
of O 
conformers O 
is O 
more O 
than O 
that O 
reported O 
in O 
the O 
previous O 
reports O 
( O 
8 O 
conformers O 
) O 
, O 
and O 
is O 
rationalized O 
by O 
the O 
systematic O 
formation O 
of O 
conformers O 
from O 
simpler O 
molecules O 
without O 
substituents O 
, O 
just O 
like O 
evolution O 
. O 
The O 
importance O 
of O 
dipole O 
- O 
dipole O 
interaction O 
between O 
an O 
amino-acid B-FAMILY 
chain O 
and O 
hydroxyl B-SYSTEMATIC 
group O 
at O 
the O 
benzene B-SYSTEMATIC 
ring O 
was O 
also O 
discussed O 
. O 

Emerging O 
' O 
mycotoxins O 
in O 
cereals O 
processing O 
chains O 
: O 
changes O 
of O 
enniatins B-FAMILY 
during O 
beer O 
and O 
bread O 
making O 
. O 

represent O 
an O 
emerging O 
food O 
safety O 
issue O 
because O 
of O 
their O 
extensive O 
incidence O 
, O 
documented O 
in O 
recent O 
decades O 
, O 
in O 
various O 
small O 
grain O 
cereals O 
. O 
This O 
study O 
was O 
concerned O 
with O 
the O 
fate O 
of O 
these O 
Fusarium O 
mycotoxins O 
within O 
malting O 
, O 
brewing O 
, O 
milling O 
and O 
baking O 
, O 
when O 
employed O 
for O 
the O 
processing O 
of O 
contaminated O 
barley O 
and O 
wheat O 
. O 
Besides O 
enniatins B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
A1 I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
and I-MULTIPLE 
B1 I-MULTIPLE 
, O 
also O 
deoxynivalenol B-TRIVIAL 
and O 
its O 
conjugated O 
form O 
( O 
deoxynivalenol-3-glucoside B-SYSTEMATIC 
) O 
were O 
determined O 
in O 
almost O 
all O 
tested O 
cereal O 
- O 
based O 
samples O 
. O 
Significant O 
decline O 
of O 
enniatins B-FAMILY 
occurred O 
within O 
all O 
technologies O 
, O 
with O 
the O 
largest O 
drop O 
in O 
their O 
concentrations O 
observed O 
in O 
the O 
brewing O 
process O 
. O 
While O 
enniatins B-FAMILY 
were O 
not O 
detectable O 
in O 
final O 
beers O 
, O 
they O 
were O 
almost O 
quantitatively O 
transferred O 
to O 
spent O 
grains O 
, O 
probably O 
because O 
of O 
their O 
limited O 
water O 
solubility O 
. O 
Regarding O 
bread O 
baking O 
, O 
levels O 
of O 
enniatins B-FAMILY 
decreased O 
down O 
to O 
30% O 
of O 
their O 
concentration O 
in O 
the O 
initial O 
flour O 
used O 
for O 
baking O 
. O 
In O 
this O 
case O 
, O 
degradation O 
at O 
higher O 
temperatures O 
might O 
be O 
assumed O 
. O 

Mechanisms O 
of O 
the O 
antitumor O 
activity O 
of O 
SB225002 B-IDENTIFIER 
: O 
A O 
novel O 
microtubule O 
inhibitor O 
. O 

( O 
SB O 
) O 
is O 
an O 
IL-8 O 
receptor O 
B O 
( O 
IL-8RB O 
) O 
antagonist O 
that O 
has O 
previously O 
been O 
shown O 
to O 
inhibit O 
IL-8 O 
- O 
based O 
cancer O 
cell O 
invasion O 
, O 
and O 
to O 
possess O 
in O 
vivo O 
anti-inflammatory O 
and O 
anti-nociceptive O 
effects O 
. O 
The O 
present O 
study O 
presented O 
an O 
evidence O 
for O 
the O 
cell O 
cycle O 
- O 
targeting O 
activity O 
of O 
SB O 
in O 
a O 
panel O 
of O 
p53-mutant O 
human O 
cancer O 
cell O 
lines O 
of O 
different O 
origin O 
, O 
and O 
investigated O 
the O 
underlying O 
molecular O 
mechanisms O 
. O 
A O 
combination O 
of O 
cell O 
cycle O 
analysis O 
, O 
immunocytometry O 
, O 
immunoblotting O 
, O 
and O 
RNA O 
interference O 
revealed O 
that O 
SB O 
induced O 
a O 
BubR1-dependent O 
mitotic O 
arrest O 
. O 
Mechanistically O 
, O 
SB O 
was O 
shown O 
to O 
possess O 
a O 
microtubule O 
destabilizing O 
activity O 
evidenced O 
by O 
hyperphosphorylation O 
of O 
Bcl2 O 
and O 
BclxL O 
, O 
suppression O 
of O 
microtubule O 
polymerization O 
and O 
induction O 
of O 
a O 
prometaphase O 
arrest O 
. O 
Molecular O 
docking O 
studies O 
suggested O 
that O 
SB O 
has O 
a O 
good O 
affinity O 
towards O 
vinblastine B-TRIVIAL 
-binding O 
site O 
on O 
β-tubulin O 
subunit O 
. O 
Of O 
note O 
, O 
SB265610 B-IDENTIFIER 
which O 
is O 
a O 
close O 
structural O 
analogue O 
of O 
SB225002 B-IDENTIFIER 
with O 
a O 
potent O 
IL-8RB O 
antagonistic O 
activity O 
did O 
not O 
exhibit O 
a O 
similar O 
antimitotic O 
activity O 
. O 
Importantly O 
, O 
in O 
P-glycoprotein O 
overexpressing O 
NCI O 
/ O 
Adr-Res O 
cells O 
the O 
antitumor O 
activity O 
of O 
SB O 
was O 
unaffected O 
by O 
multidrug O 
resistance O 
. O 
Interestingly O 
, O 
the O 
mechanisms O 
of O 
SB-induced O 
cell O 
death O 
were O 
cell O 
- O 
line O 
dependent O 
, O 
where O 
in O 
invasive O 
hepatocellular O 
carcinoma O 
HLE O 
cells O 
the O 
significant O 
contribution O 
of O 
BAK-dependent O 
mitochondrial O 
apoptosis O 
was O 
demonstrated O 
. O 
Conversely O 
, O 
SB O 
activated O 
p38 O 
MAPK O 
signaling O 
in O 
colorectal O 
adenocarcinoma O 
cells O 
SW480 O 
, O 
and O 
pharmacologic O 
inhibition O 
of O 
p38 O 
MAPK O 
activity O 
revealed O 
its O 
key O 
role O 
in O 
mediating O 
SB-induced O 
caspase O 
- O 
independent O 
cell O 
death O 
. O 
In O 
summary O 
, O 
the O 
present O 
study O 
introduced O 
SB O 
as O 
a O 
promising O 
antitumor O 
agent O 
which O 
has O 
the O 
potential O 
to O 
exert O 
its O 
activity O 
through O 
dual O 
mechanisms O 
involving O 
microtubules O 
targeting O 
and O 
interference O 
with O 
IL-8-drivin O 
cancer O 
progression O 
. O 

this O 
study O 
seven O 
published O 
methods O 
of O 
extraction O 
of O 
skin O 
free O 
and O 
bound O 
volatile O 
compounds O 
have O 
been O 
compared O 
. O 
The O 
free O 
and O 
bound O 
volatiles O 
were O 
separated O 
by O 
solid O 
phase O 
extraction O 
( O 
SPE O 
) O 
and O 
then O 
analysed O 
by O 
gas O 
chromatography O 
coupled O 
with O 
mass O 
spectrometry O 
( O 
GC-MS O 
) O 
. O 
The O 
results O 
showed O 
that O 
the O 
extraction O 
of O 
volatile O 
compounds O 
from O 
grapes O 
is O 
highly O 
affected O 
by O 
extraction O 
solution O 
features O 
. O 
The O 
solution O 
at O 
pH O 
3.2 O 
and O 
0% O 
ethanol B-SYSTEMATIC 
resulted O 
the O 
most O 
effective O 
as O 
it O 
led O 
to O 
the O 
extraction O 
of O 
a O 
higher O 
number O 
and O 
amount O 
of O 
free O 
and O 
glycosilated O 
volatile O 
compounds O 
. O 
The O 
selected O 
extraction O 
method O 
of O 
grape O 
skin O 
and O 
the O 
process O 
of O 
pulp O 
juice O 
were O 
validated O 
for O 
quantitative O 
determination O 
of O 
a O 
wide O 
range O 
of O 
grape O 
aroma O 
compounds O 
. O 
A O 
total O 
of O 
37 O 
free O 
and O 
bound O 
grape O 
aroma O 
compounds O 
were O 
quantified O 
by O 
GC-MS O 
in O 
selective O 
ion O 
monitoring O 
modality O 
( O 
SIM O 
) O 
. O 
Among O 
them O 
, O 
26 O 
volatile O 
compounds O 
resulted O 
validated O 
in O 
grape O 
skin O 
and O 
pulp O 
juice O 
. O 

in O 
vitro O 
and O 
in O 
vivo O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
bone O 
, O 
bone O 
cells O 
and O 
fracture O 
repair O 
. O 

: O 
Cigarette O 
smoke O 
has O 
negative O 
effects O 
on O 
bone O 
metabolism O 
and O 
fracture O 
repair O 
. O 
However O 
, O 
no O 
study O 
has O 
reviewed O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
bone O 
and O 
fracture O 
repair O 
independent O 
of O 
other O 
constituents O 
of O 
cigarette O 
smoke O 
. O 
The O 
authors O 
review O 
the O 
existing O 
evidence O 
of O 
the O 
effect O 
of O 
nicotine B-TRIVIAL 
on O 
' O 
bone O 
' O 
and O 
' O 
bone O 
cells O 
' O 
and O 
fracture O 
repair O 
, O 
drawing O 
conclusions O 
relevant O 
to O 
clinical O 
practice O 
and O 
future O 
research O 
. O 
AREAS O 
COVERED O 
: O 
A O 
literature O 
review O 
was O 
conducted O 
using O 
PRISMA O 
guidelines O 
and O 
PubMed O 
, O 
Cochrane O 
, O 
MEDLINE O 
/ O 
OVID O 
, O 
EMBASE O 
, O 
NHS O 
Evidence O 
and O 
Google O 
scholar O 
databases O 
. O 
Articles O 
were O 
included O 
if O 
they O 
specifically O 
investigated O 
the O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
' O 
bone O 
' O 
or O 
fracture O 
repair O 
in O 
animal O 
or O 
human O 
models O 
or O 
in O 
vitro O 
effects O 
on O 
' O 
bone O 
cells O 
' O 
. O 
A O 
total O 
of O 
64 O 
papers O 
were O 
included O 
in O 
this O 
review O 
, O 
of O 
which O 
15 O 
were O 
human O 
in O 
vitro O 
studies O 
and O 
49 O 
animal O 
studies O 
wherein O 
9 O 
were O 
in O 
vitro O 
and O 
40 O 
in O 
vivo O 
. O 
In O 
vivo O 
studies O 
of O 
the O 
effects O 
of O 
nicotine B-TRIVIAL 
in O 
animals O 
demonstrated O 
widespread O 
effects O 
on O 
bone O 
including O 
osteoneogenesis O 
, O 
osseointegration O 
, O 
steady O 
- O 
state O 
skeletal O 
bone O 
and O 
genes O 
and O 
cytokines O 
relevant O 
to O 
bone O 
cell O 
physiology O 
and O 
bone O 
homeostasis O 
. O 
In O 
these O 
studies O 
, O 
nicotine B-TRIVIAL 
' O 
s O 
effects O 
are O 
predominately O 
negative O 
, O 
inhibiting O 
bone O 
cell O 
metabolism O 
and O 
fracture O 
repair O 
, O 
whereas O 
most O 
in O 
vitro O 
studies O 
reported O 
biphasic O 
responses O 
in O 
all O 
bone O 
cells O 
except O 
osteoclastic O 
cells O 
. O 
EXPERT O 
OPINION O 
: O 
The O 
review O 
suggests O 
that O 
nicotine B-TRIVIAL 
has O 
effects O 
on O 
osteoneogenesis O 
, O 
osseointegration O 
and O 
steady O 
- O 
state O 
skeletal O 
bone O 
in O 
animal O 
in O 
vivo O 
models O 
, O 
as O 
well O 
as O 
effects O 
on O 
all O 
' O 
bone O 
cells O 
' O 
, O 
via O 
several O 
mechanisms O 
in O 
both O 
animal O 
and O 
human O 
cell O 
in O 
vitro O 
studies O 
. O 
The O 
effect O 
of O 
nicotine B-TRIVIAL 
is O 
dose O 
- O 
dependent O 
, O 
with O 
higher O 
concentrations O 
having O 
predominantly O 
negative O 
effects O 
, O 
whereas O 
at O 
low O 
concentrations O 
a O 
stimulatory O 
effect O 
is O 
seen O 
. O 
Stimulatory O 
effects O 
on O 
certain O 
cells O 
may O 
indicate O 
a O 
possible O 
, O 
limited O 
therapeutic O 
role O 
; O 
advice O 
regarding O 
smoking O 
cessation O 
perioperatively O 
should O 
remain O 
due O 
to O 
the O 
other O 
harmful O 
components O 
of O 
cigarette O 
smoke O 
, O 
but O 
there O 
may O 
be O 
scope O 
for O 
allowing O 
the O 
use O 
of O 
nicotine B-TRIVIAL 
patches O 
instead O 
of O 
complete O 
abstention O 
. O 
Further O 
research O 
into O 
clinical O 
outcomes O 
is O 
required O 
before O 
the O 
exact O 
response O 
of O 
bone O 
and O 
fracture O 
repair O 
in O 
humans O 
to O 
nicotine B-TRIVIAL 
is O 
known O 
. O 

Bacoside B-TRIVIAL 
B I-TRIVIAL 
' O 
- O 
the O 
need O 
remains O 
for O 
establishing O 
identity O 
. O 

monnieri O 
is O 
fast O 
gaining O 
popularity O 
for O 
its O 
beneficial O 
effects O 
on O 
cognition O 
and O 
memory O 
. O 
The O 
active O 
constituents O 
of O 
the O 
plant O 
were O 
putatively O 
identified O 
as O 
' O 
bacosides B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
' O 
in O 
older O 
publications O 
. O 
Subsequently O 
' O 
bacoside B-TRIVIAL 
A I-TRIVIAL 
' O 
was O 
identified O 
as O 
a O 
mixture O 
of O 
four O 
saponins B-FAMILY 
[ O 
bacoside B-TRIVIAL 
A3 I-TRIVIAL 
( O 
1 O 
) O 
, O 
bacopaside B-TRIVIAL 
II I-TRIVIAL 
( O 
2 O 
) O 
, O 
bacopasaponin B-TRIVIAL 
C I-TRIVIAL 
( O 
3 O 
) O 
and O 
the O 
jujobogenin B-TRIVIAL 
isomer O 
of O 
the O 
latter O 
( O 
4 O 
) O 
] O 
and O 
was O 
considered O 
as O 
part O 
of O 
major O 
constituents O 
of O 
the O 
herb O 
along O 
with O 
bacopaside B-TRIVIAL 
I I-TRIVIAL 
( O 
5 O 
) O 
. O 
These O 
major O 
saponins B-FAMILY 
now O 
form O 
part O 
of O 
analytical O 
monographs O 
in O 
many O 
Pharmacopoeia O 
. O 
However O 
identity O 
of O 
' O 
bacoside B-TRIVIAL 
B I-TRIVIAL 
' O 
still O 
appears O 
controversial O 
with O 
seemingly O 
contradictory O 
information O 
available O 
in O 
the O 
scientific O 
literature O 
. O 
At O 
the O 
same O 
time O 
quality O 
of O 
many O 
extracts O 
and O 
herbal O 
products O 
derived O 
from O 
the O 
plant O 
is O 
still O 
being O 
determined O 
based O 
on O 
the O 
content O 
of O 
' O 
bacosides B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
' O 
. O 
We O 
have O 
elaborated O 
these O 
issues O 
in O 
this O 
article O 
along O 
with O 
our O 
recommendations O 
to O 
move O 
forward O 
towards O 
achieving O 
scientific O 
clarity O 
on O 
the O 
subject O 
. O 

present O 
a O 
thermodynamically O 
robust O 
coarse O 
- O 
grained O 
model O 
to O 
simulate O 
folding O 
of O 
RNA O 
in O 
monovalent O 
salt O 
solutions O 
. O 
The O 
model O 
includes O 
stacking O 
, O 
hydrogen B-SYSTEMATIC 
bond O 
, O 
and O 
electrostatic O 
interactions O 
as O 
fundamental O 
components O 
in O 
describing O 
the O 
stability O 
of O 
RNA O 
structures O 
. O 
The O 
stacking O 
interactions O 
are O 
parametrized O 
using O 
a O 
set O 
of O 
nucleotide B-FAMILY 
-specific O 
parameters O 
, O 
which O 
were O 
calibrated O 
against O 
the O 
thermodynamic O 
measurements O 
for O 
single O 
- O 
base O 
stacks O 
and O 
base O 
- O 
pair O 
stacks O 
. O 
All O 
hydrogen B-SYSTEMATIC 
bonds O 
are O 
assumed O 
to O 
have O 
the O 
same O 
strength O 
, O 
regardless O 
of O 
their O 
context O 
in O 
the O 
RNA O 
structure O 
. O 
The O 
ionic O 
buffer O 
is O 
modeled O 
implicitly O 
, O 
using O 
the O 
concept O 
of O 
counterion O 
condensation O 
and O 
the O 
Debye-Hückel O 
theory O 
. O 
The O 
three O 
adjustable O 
parameters O 
in O 
the O 
model O 
were O 
determined O 
by O 
fitting O 
the O 
experimental O 
data O 
for O 
two O 
RNA O 
hairpins O 
and O 
a O 
pseudoknot O 
. O 
A O 
single O 
set O 
of O 
parameters O 
provides O 
good O 
agreement O 
with O 
thermodynamic O 
data O 
for O 
the O 
three O 
RNA O 
molecules O 
over O 
a O 
wide O 
range O 
of O 
temperatures O 
and O 
salt O 
concentrations O 
. O 
In O 
the O 
process O 
of O 
calibrating O 
the O 
model O 
, O 
we O 
establish O 
the O 
extent O 
of O 
counterion O 
condensation O 
onto O 
the O 
single O 
- O 
stranded O 
RNA O 
backbone O 
. O 
The O 
reduced O 
backbone O 
charge O 
is O 
independent O 
of O 
the O 
ionic O 
strength O 
and O 
is O 
60% O 
of O 
the O 
RNA O 
bare O 
charge O 
at O 
37 O 
°C O 
. O 
Our O 
model O 
can O 
be O 
used O 
to O 
predict O 
the O 
folding O 
thermodynamics O 
for O 
any O 
RNA O 
molecule O 
in O 
the O 
presence O 
of O 
monovalent O 
ions O 
. O 

of O 
gabapentin B-TRIVIAL 
by O 
LAT1 O 
( O 
SLC7A5 O 
) O 
. O 

is O 
used O 
in O 
the O 
treatment O 
of O 
epilepsy O 
and O 
neuropathic O 
pain O 
. O 
Gabapentin B-TRIVIAL 
has O 
high O 
and O 
saturable O 
permeability O 
across O 
the O 
BBB O 
, O 
but O 
no O 
mechanistic O 
studies O 
underpinning O 
this O 
process O 
have O 
been O 
reported O 
. O 
The O 
aim O 
of O 
the O 
current O 
study O 
was O 
to O 
investigate O 
the O 
transport O 
of O 
gabapentin B-TRIVIAL 
in O 
a O 
model O 
of O 
the O 
BBB O 
, O 
identify O 
the O 
important O 
drug O 
transporter(s) O 
and O 
to O 
use O 
mathematical O 
modelling O 
to O 
quantify O 
the O 
processes O 
involved O 
. O 
A O 
human O 
brain O 
endothelial O 
cell O 
line O 
( O 
hCMEC O 
/ O 
D3 O 
) O 
was O 
utilised O 
as O 
an O 
in O 
- O 
vitro O 
model O 
of O 
the O 
BBB O 
. O 
Uptake O 
of O 
radiolabeled B-TRIVIAL 
gabapentin I-TRIVIAL 
into O 
cells O 
in O 
the O 
presence O 
of O 
chemical O 
inhibitors O 
, O 
siRNA O 
or O 
overexpressed O 
drug O 
transporters O 
of O 
interest O 
was O 
investigated O 
. O 
Gabapentin B-TRIVIAL 
was O 
demonstrated O 
to O 
be O 
a O 
LAT1 O 
substrate O 
in O 
brain O 
endothelial O 
cells O 
( O 
LAT1-process O 
; O 
Km=530μM O 
and O 
Vmax=7039pmoles O 
/ O 
million O 
cells O 
/ O 
min O 
versus O 
other O 
- O 
processes O 
; O 
Km=923μM O 
and O 
Vmax=3656pmoles O 
/ O 
million O 
cells O 
/ O 
min O 
) O 
and O 
in O 
transfected O 
HEK O 
293 O 
LAT1 O 
cells O 
( O 
LAT1-process O 
; O 
Km=217μM O 
and O 
Vmax=5192pmoles O 
/ O 
million O 
cells O 
/ O 
min O 
versus O 
otherprocesses O 
; O 
Km=1546μM O 
and O 
Vmax=3375pmoles O 
/ O 
million O 
cells O 
/ O 
min O 
) O 
. O 
At O 
physiological O 
concentrations O 
of O 
gabapentin B-TRIVIAL 
, O 
LAT1 O 
mediated O 
transport O 
was O 
3 O 
or O 
~10-fold O 
higher O 
than O 
the O 
other O 
transport O 
processes O 
in O 
the O 
two O 
systems O 
, O 
respectively O 
, O 
demonstrating O 
clear O 
selectivity O 
for O 
gabapentin B-TRIVIAL 
. O 
In-silico O 
structural O 
homology O 
modelling O 
confirmed O 
that O 
LAT1 O 
could O 
have O 
the O 
LeuT O 
conserved O 
fold O 
and O 
functions O 
by O 
the O 
alternative O 
access O 
mechanism O 
. O 
Mathematical O 
modelling O 
of O 
this O 
mechanism O 
revealed O 
revised O 
significance O 
of O 
Vmax O 
and O 
Km O 
so O 
that O 
a O 
low O 
Km O 
may O 
not O 
necessarily O 
imply O 
a O 
high O 
affinity O 
transport O 
process O 
. O 
Gabapentin B-TRIVIAL 
was O 
negative O 
for O 
OCT O 
like O 
transport O 
and O 
LAT2 O 
activity O 
in O 
the O 
hCMEC O 
/ O 
D3 O 
and O 
OCT1 O 
transfected O 
cells O 
. O 
Our O 
data O 
shows O 
that O 
gabapentin B-TRIVIAL 
is O 
a O 
substrate O 
for O 
the O 
influx O 
transporter O 
LAT1 O 
at O 
therapeutic O 
concentrations O 
. O 

role O 
of O 
mitochondria O 
and O 
biotransformation O 
in O 
abamectin B-TRIVIAL 
-induced O 
cytotoxicity O 
in O 
isolated O 
rat O 
hepatocytes O 
. O 

( O 
ABA B-ABBREVIATION 
) O 
, O 
which O 
belongs O 
to O 
the O 
family O 
of O 
avermectins B-FAMILY 
, O 
is O 
used O 
as O 
a O 
parasiticide O 
; O 
however O 
, O 
ABA B-ABBREVIATION 
poisoning O 
can O 
impair O 
liver O 
function O 
. O 
In O 
a O 
previous O 
study O 
using O 
isolated O 
rat O 
liver O 
mitochondria O 
, O 
we O 
observed O 
that O 
ABA B-ABBREVIATION 
inhibited O 
the O 
activity O 
of O 
adenine B-TRIVIAL 
nucleotide I-TRIVIAL 
translocator O 
and O 
FoF1-ATPase O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
characterize O 
the O 
mechanism O 
of O 
ABA B-ABBREVIATION 
toxicity O 
in O 
isolated O 
rat O 
hepatocytes O 
and O 
to O 
evaluate O 
whether O 
this O 
effect O 
is O 
dependent O 
on O 
its O 
metabolism O 
. O 
The O 
toxicity O 
of O 
ABA B-ABBREVIATION 
was O 
assessed O 
by O 
monitoring O 
oxygen B-SYSTEMATIC 
consumption O 
and O 
mitochondrial O 
membrane O 
potential O 
, O 
intracellular O 
ATP B-ABBREVIATION 
concentration O 
, O 
cell O 
viability O 
, O 
intracellular O 
Ca(2+) B-FORMULA 
homeostasis O 
, O 
release O 
of O 
cytochrome O 
c O 
, O 
caspase O 
3 O 
activity O 
and O 
necrotic O 
cell O 
death O 
. O 
ABA B-ABBREVIATION 
reduces O 
cellular O 
respiration O 
in O 
cells O 
energized O 
with O 
glutamate B-TRIVIAL 
and O 
malate B-TRIVIAL 
or O 
succinate B-TRIVIAL 
. O 
The O 
hepatocytes O 
that O 
were O 
previously O 
incubated O 
with O 
proadifen B-TRIVIAL 
, O 
a O 
cytochrome O 
P450 O 
inhibitor O 
, O 
are O 
more O 
sensitive O 
to O 
the O 
compound O 
as O 
observed O 
by O 
a O 
rapid O 
decrease O 
in O 
the O 
mitochondrial O 
membrane O 
potential O 
accompanied O 
by O 
reductions O 
in O 
ATP B-ABBREVIATION 
concentration O 
and O 
cell O 
viability O 
and O 
a O 
disruption O 
of O 
intracellular O 
Ca(2+) B-FORMULA 
homeostasis O 
followed O 
by O 
necrosis O 
. O 
Our O 
results O 
indicate O 
that O 
ABA B-ABBREVIATION 
biotransformation O 
reduces O 
its O 
toxicity O 
, O 
and O 
its O 
toxic O 
action O 
is O 
related O 
to O 
the O 
inhibition O 
of O 
mitochondrial O 
activity O 
, O 
which O 
leads O 
to O 
decreased O 
synthesis O 
of O 
ATP B-ABBREVIATION 
followed O 
by O 
cell O 
death O 
. O 

atomic O 
- O 
level O 
observation O 
and O 
chemical O 
analysis O 
of O 
ZnSe B-FORMULA 
synthesized O 
by O 
in O 
situ O 
high O 
- O 
throughput O 
reactive O 
fiber O 
drawing O 
. O 

demonstrate O 
a O 
high O 
- O 
throughput O 
method O 
for O 
synthesizing O 
zinc B-SYSTEMATIC 
selenide I-SYSTEMATIC 
( O 
ZnSe B-FORMULA 
) O 
in O 
situ O 
during O 
fiber O 
drawing O 
. O 
Central O 
to O 
this O 
method O 
is O 
a O 
thermally O 
activated O 
chemical O 
reaction O 
occurring O 
across O 
multiple O 
interfaces O 
between O 
alternately O 
layered O 
elemental O 
zinc B-SYSTEMATIC 
- O 
( O 
Zn B-FORMULA 
- O 
) O 
and O 
selenium B-SYSTEMATIC 
- O 
( O 
Se B-FORMULA 
- O 
) O 
rich O 
films O 
embedded O 
in O 
a O 
preform O 
and O 
drawn O 
into O 
meters O 
of O 
fiber O 
at O 
a O 
temperature O 
well O 
below O 
the O 
melting O 
temperature O 
of O 
either O 
Zn B-FORMULA 
or O 
ZnSe B-FORMULA 
. O 
By O 
depositing O 
50 O 
nm O 
thick O 
layers O 
of O 
Zn B-FORMULA 
interleaved O 
between O 
1 O 
μm O 
thick O 
Se B-FORMULA 
layers O 
, O 
a O 
controlled O 
breakup O 
of O 
the O 
Zn B-FORMULA 
sheet O 
is O 
achieved O 
, O 
thereby O 
enabling O 
a O 
complete O 
and O 
controlled O 
chemical O 
reaction O 
. O 
The O 
thermodynamics O 
and O 
kinetics O 
of O 
this O 
synthesis O 
process O 
are O 
studied O 
using O 
thermogravimetric O 
analysis O 
and O 
differential O 
scanning O 
calorimetry O 
, O 
and O 
the O 
in O 
- O 
fiber O 
compound O 
is O 
analyzed O 
by O 
a O 
multiplicity O 
of O 
materials O 
characterization O 
tools O 
, O 
including O 
transmission O 
electron O 
microscopy O 
, O 
Raman O 
microscopy O 
, O 
energy O 
- O 
dispersive O 
X-ray O 
spectroscopy O 
, O 
and O 
X-ray O 
diffraction O 
, O 
all O 
resulting O 
in O 
unambiguous O 
identification O 
of O 
ZnSe B-FORMULA 
as O 
the O 
compound O 
produced O 
from O 
the O 
reactive O 
fiber O 
draw O 
. O 
Furthermore O 
, O 
we O 
characterize O 
the O 
in O 
- O 
fiber O 
ZnSe B-FORMULA 
/ O 
Se97S3 O 
heterojunction O 
to O 
demonstrate O 
the O 
prospect O 
of O 
ZnSe B-FORMULA 
-based O 
fiber O 
optoelectronic O 
devices O 
. O 
The O 
ability O 
to O 
synthesize O 
new O 
compounds O 
during O 
fiber O 
drawing O 
at O 
nanometer O 
scale O 
precision O 
and O 
to O 
characterize O 
them O 
at O 
the O 
atomic O 
- O 
level O 
extends O 
the O 
architecture O 
and O 
materials O 
selection O 
compatible O 
with O 
multimaterial O 
fiber O 
drawing O 
, O 
thus O 
paving O 
the O 
way O 
toward O 
more O 
complex O 
and O 
sophisticated O 
functionality O 
. O 

chloride I-SYSTEMATIC 
speciation O 
, O 
mechanisms O 
of O 
cytotoxicity O 
on O 
human O 
pulmonary O 
cells O 
, O 
and O 
synergistic O 
toxicity O 
with O 
zinc B-SYSTEMATIC 
. O 

is O 
used O 
in O 
numerous O 
industrial O 
sectors O 
, O 
leading O 
to O 
occupational O 
diseases O 
, O 
particularly O 
by O 
inhalation O 
. O 
Cobalt B-SYSTEMATIC 
-associated O 
mechanisms O 
of O 
toxicity O 
are O 
far O 
from O 
being O 
understood O 
and O 
information O 
that O 
could O 
improve O 
knowledge O 
in O 
this O 
area O 
is O 
required O 
. O 
We O 
investigated O 
the O 
impact O 
of O 
a O 
soluble O 
cobalt B-SYSTEMATIC 
compound O 
, O 
CoCl(2)·6H(2)O B-FORMULA 
, O 
on O 
the O 
BEAS-2B O 
lung O 
epithelial O 
cell O 
line O 
, O 
as O 
well O 
as O 
its O 
impact O 
on O 
metal O 
homeostasis O 
. O 
Cobalt B-SYSTEMATIC 
speciation O 
in O 
different O 
culture O 
media O 
, O 
in O 
particular O 
soluble O 
and O 
precipitated O 
cobalt B-SYSTEMATIC 
species O 
, O 
was O 
investigated O 
via O 
theoretical O 
and O 
analytical O 
approaches O 
. O 
The O 
cytotoxic O 
effects O 
of O 
cobalt B-SYSTEMATIC 
on O 
the O 
cells O 
were O 
assessed O 
. O 
Upon O 
exposure O 
of O 
BEAS-2B O 
cells O 
to O 
cobalt B-SYSTEMATIC 
, O 
intracellular O 
accumulation O 
of O 
cobalt B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
was O 
demonstrated O 
using O 
direct O 
in O 
situ O 
microchemical O 
analysis O 
based O 
on O 
ion O 
micro O 
- O 
beam O 
techniques O 
and O 
analysis O 
after O 
cell O 
lysis O 
by O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometry O 
( O 
ICP-MS O 
) O 
. O 
Microchemical O 
imaging O 
revealed O 
that O 
cobalt B-SYSTEMATIC 
was O 
rather O 
homogeneously O 
distributed O 
in O 
the O 
nucleus O 
and O 
in O 
the O 
cytoplasm O 
whereas O 
zinc B-SYSTEMATIC 
was O 
more O 
abundant O 
in O 
the O 
nucleus O 
. O 
The O 
modulation O 
of O 
zinc B-SYSTEMATIC 
homeostasis O 
led O 
to O 
the O 
evaluation O 
of O 
the O 
effect O 
of O 
combined O 
cobalt B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
exposure O 
. O 
In O 
this O 
case O 
, O 
a O 
clear O 
synergistic O 
increase O 
in O 
toxicity O 
was O 
observed O 
as O 
well O 
as O 
a O 
substantial O 
increase O 
in O 
zinc B-SYSTEMATIC 
content O 
within O 
cells O 
. O 
Western O 
blots O 
performed O 
under O 
the O 
same O 
coexposure O 
conditions O 
revealed O 
a O 
decrease O 
in O 
ZnT1 O 
expression O 
, O 
suggesting O 
that O 
cobalt B-SYSTEMATIC 
could O 
inhibit O 
zinc B-SYSTEMATIC 
release O 
through O 
the O 
modulation O 
of O 
ZnT1 O 
. O 
Overall O 
, O 
this O 
study O 
highlights O 
the O 
potential O 
hazard O 
to O 
lung O 
function O 
, O 
of O 
combined O 
exposure O 
to O 
cobalt B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
. O 

the O 
activity O 
- O 
dependent O 
mechanisms O 
guiding O 
functional O 
maturation O 
of O 
synaptic O 
transmission O 
postsynaptically O 
are O 
well O 
characterized O 
, O 
less O 
is O 
known O 
about O 
the O 
corresponding O 
presynaptic O 
mechanisms O 
. O 
Here O 
we O 
show O 
that O 
during O 
the O 
first O 
postnatal O 
week O 
, O 
a O 
subset O 
of O 
CA3-CA1 O 
synapses O 
express O 
postsynaptically O 
induced O 
LTP O 
that O 
is O 
tightly O 
associated O 
with O 
a O 
robust O 
decrease O 
in O 
synaptic O 
facilitation O 
, O 
consistent O 
with O 
an O 
increase O 
in O 
release O 
probability O 
(P(r)) O 
. O 
The O 
loss O 
of O 
facilitation O 
is O 
readily O 
induced O 
by O 
physiologically O 
relevant O 
pairing O 
protocols O 
at O 
immature O 
synapses O 
and O 
is O 
dependent O 
on O 
activation O 
of O 
NMDA B-ABBREVIATION 
-receptors O 
but O 
not O 
L- O 
type O 
calcium B-SYSTEMATIC 
channels O 
. O 
The O 
putative O 
pre- O 
and O 
postsynaptic O 
components O 
of O 
neonatal O 
LTP O 
were O 
distinguished O 
in O 
their O 
downstream O 
signaling O 
requirements O 
, O 
PKC O 
activity O 
being O 
selectively O 
needed O 
for O 
the O 
decrease O 
in O 
facilitation O 
but O 
not O 
for O 
synaptic O 
potentiation O 
per O 
se O 
. O 
These O 
data O 
suggest O 
that O 
maturation O 
of O 
glutamatergic O 
synapses O 
involves O 
a O 
critical O 
period O 
during O 
which O 
presynaptic O 
function O 
is O 
highly O 
susceptible O 
to O 
activity O 
- O 
dependent O 
regulation O 
via O 
a O 
PKC-dependent O 
mechanism O 
. O 

simulation O 
of O 
chemical O 
reactions O 
inside O 
an O 
isolated O 
spherical O 
bubble O 
of O 
oxygen B-SYSTEMATIC 
has O 
been O 
performed O 
for O 
various O 
ambient O 
bubble O 
radii O 
at O 
different O 
frequencies O 
and O 
acoustic O 
amplitudes O 
to O 
study O 
the O 
effects O 
of O 
these O 
two O 
parameters O 
on O 
the O 
range O 
of O 
ambient O 
radius O 
for O 
an O 
active O 
bubble O 
in O 
sonochemical O 
reactions O 
. O 
The O 
employed O 
model O 
combines O 
the O 
dynamic O 
of O 
bubble O 
collapse O 
with O 
the O 
chemical O 
kinetics O 
of O 
single O 
cavitation O 
bubble O 
. O 
Results O 
from O 
this O 
model O 
were O 
compared O 
with O 
some O 
experimental O 
results O 
presented O 
in O 
the O 
literature O 
and O 
good O 
apparent O 
trends O 
between O 
them O 
were O 
observed O 
. O 
The O 
numerical O 
calculations O 
of O 
this O 
study O 
showed O 
that O 
there O 
always O 
exists O 
an O 
optimal O 
ambient O 
bubble O 
radius O 
at O 
which O 
the O 
production O 
of O 
oxidizing O 
species O 
at O 
the O 
end O 
of O 
the O 
bubble O 
collapse O 
attained O 
their O 
upper O 
limit O 
. O 
It O 
was O 
shown O 
that O 
the O 
range O 
of O 
ambient O 
radius O 
for O 
an O 
active O 
bubble O 
increased O 
with O 
increasing O 
acoustic O 
amplitude O 
and O 
decreased O 
with O 
increasing O 
ultrasound O 
frequency O 
. O 
The O 
optimal O 
ambient O 
radius O 
decreased O 
with O 
increasing O 
frequency O 
. O 
Analysis O 
of O 
curves O 
showing O 
optimal O 
ambient O 
radius O 
versus O 
acoustic O 
amplitude O 
for O 
different O 
ultrasonic O 
frequencies O 
indicated O 
that O 
for O 
200 O 
and O 
300kHz O 
, O 
the O 
optimal O 
ambient O 
radius O 
increased O 
linearly O 
with O 
increasing O 
acoustic O 
amplitude O 
up O 
to O 
3atm O 
. O 
However O 
, O 
slight O 
minima O 
of O 
optimal O 
radius O 
were O 
observed O 
for O 
the O 
curves O 
obtained O 
at O 
500 O 
and O 
1000kHz O 
. O 

consumption O 
of O 
n-3 B-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
differentially O 
modulates O 
gene O 
expression O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
and O 
gamma O 
and O 
hypoxia O 
- O 
inducible O 
factor O 
1 O 
alpha O 
in O 
subcutaneous O 
adipose O 
tissue O 
of O 
obese O 
adolescents O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effect O 
of O 
long O 
- O 
chain O 
omega-3 B-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
( O 
n-3 B-ABBREVIATION 
PUFA I-ABBREVIATION 
) O 
supplementation O 
on O 
metabolic O 
state O 
and O 
gene O 
expression O 
in O 
subcutaneous O 
adipose O 
tissues O 
of O 
obese O 
adolescents O 
. O 
Obese O 
adolescents O 
( O 
n O 
= O 
26 O 
, O 
10 O 
girls O 
and O 
16 O 
boys O 
) O 
aged O 
12.4 O 
± O 
2.1 O 
years O 
were O 
assigned O 
to O 
a O 
12-week O 
regimen O 
of O 
n-3 B-ABBREVIATION 
PUFA I-ABBREVIATION 
intake O 
. O 
Five O 
times O 
per O 
day O 
, O 
subjects O 
received O 
a O 
food O 
supplement O 
consisting O 
of O 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
and O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
( O 
3 O 
g O 
per O 
day O 
, O 
944 O 
mg O 
EPA B-ABBREVIATION 
, O 
and O 
2088 O 
mg O 
DHA B-ABBREVIATION 
) O 
. O 
Blood O 
parameters O 
were O 
measured O 
, O 
and O 
subcutaneous O 
adipose O 
tissue O 
biopsies O 
were O 
analyzed O 
to O 
determine O 
gene O 
expression O 
at O 
baseline O 
and O 
after O 
12 O 
weeks O 
. O 
Student's O 
t O 
test O 
and O 
the O 
Wilcoxon O 
signed O 
- O 
rank O 
test O 
were O 
used O 
to O 
estimate O 
differences O 
in O 
arithmetic O 
means O 
of O 
pre- O 
and O 
post O 
- O 
dietary O 
supplementation O 
for O 
various O 
anthropometric O 
, O 
biochemical O 
, O 
clinical O 
, O 
and O 
gene O 
expression O 
parameters O 
. O 
After O 
12 O 
weeks O 
, O 
n-3 B-ABBREVIATION 
PUFA I-ABBREVIATION 
consumption O 
was O 
associated O 
with O 
decreased O 
body O 
mass O 
index O 
( O 
29.7 O 
± O 
4.6 O 
vs O 
. O 
27.8 O 
± O 
4.4 O 
kg O 
/ O 
m(2) O 
; O 
P O 
< O 
0.001 O 
) O 
, O 
waist O 
circumference O 
( O 
93.2 O 
± O 
9.9 O 
vs O 
. O 
90.5 O 
± O 
10 O 
cm O 
; O 
P O 
< O 
0.003 O 
) O 
, O 
hip O 
circumference O 
( O 
102.9 O 
± O 
10.9 O 
vs O 
. O 
101.1 O 
± O 
10.9 O 
cm O 
; O 
P O 
< O 
0.014 O 
) O 
, O 
and O 
blood O 
triglyceride B-FAMILY 
levels O 
( O 
220.8 O 
± O 
27.4 O 
vs O 
. O 
99.7 O 
± O 
32.7 O 
mg O 
/ O 
dL O 
; O 
P O 
< O 
0.001 O 
) O 
. O 
Fatty B-FAMILY 
acid I-FAMILY 
supplementation/ O 
n3 B-ABBREVIATION 
PUFA I-ABBREVIATION 
supplementation O 
was O 
associated O 
with O 
a O 
downregulated O 
expression O 
of O 
the O 
genes O 
encoding O 
PPARγ O 
and O 
PGC-1α O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
and O 
an O 
upregulated O 
expression O 
of O 
the O 
genes O 
encoding O 
PPARα O 
( O 
P O 
< O 
0.007 O 
) O 
and O 
SREBP1 O 
( O 
P O 
< O 
0.021 O 
) O 
. O 
The O 
expressions O 
of O 
SOD2 O 
( O 
P O 
< O 
0.04 O 
) O 
, O 
CAT O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
GPX3 O 
( O 
P O 
< O 
0.032 O 
) O 
and O 
HIF-1α O 
protein O 
also O 
decreased O 
. O 
Our O 
study O 
demonstrated O 
that O 
n-3 B-ABBREVIATION 
PUFA I-ABBREVIATION 
consumption O 
and O 
dietary O 
restriction O 
improved O 
the O 
anthropometric O 
parameters O 
and O 
decreased O 
the O 
triglycerides B-FAMILY 
levels O 
of O 
the O 
adolescents O 
, O 
suggesting O 
a O 
reduction O 
in O 
hypoxia O 
in O 
subcutaneous O 
adipose O 
tissue O 
. O 

trisulfur B-SYSTEMATIC 
radical O 
anion O 
: O 
fundamentals O 
and O 
applications O 
in O 
materials O 
science O 
, O 
electrochemistry O 
, O 
analytical O 
chemistry O 
and O 
geochemistry O 
. O 

trisulfur B-SYSTEMATIC 
radical O 
anion O 
[S3]˙(-) B-FORMULA 
is O 
well O 
- O 
known O 
from O 
inorganic O 
chemistry O 
textbooks O 
as O 
the O 
blue O 
chromophore O 
in O 
ultramarine O 
blues O 
in O 
which O 
this O 
highly O 
reactive O 
species O 
is O 
trapped O 
in O 
a O 
zeolitic O 
framework O 
. O 
Recent O 
findings O 
have O 
revealed O 
that O 
[S3]˙(-) B-FORMULA 
has O 
a O 
multi O 
- O 
faceted O 
role O 
in O 
a O 
variety O 
of O 
media O 
, O 
including O 
alkali O 
metal- O 
sulfur B-SYSTEMATIC 
batteries O 
, O 
aqueous O 
solutions O 
at O 
high O 
temperatures O 
and O 
pressures O 
, O 
and O 
ionic O 
liquids O 
; O 
it O 
has O 
also O 
been O 
used O 
to O 
detect O 
trace O 
amounts O 
of O 
water O 
in O 
organic O 
solvents O 
. O 
This O 
tutorial O 
review O 
illustrates O 
how O 
various O 
physical O 
techniques O 
are O 
used O 
to O 
identify O 
a O 
reactive O 
species O 
in O 
solution O 
and O 
shows O 
how O 
elucidation O 
of O 
electronic O 
structures O 
can O 
be O 
used O 
to O 
explain O 
spectroscopic O 
and O 
structural O 
properties O 
. O 
Examples O 
of O 
the O 
function O 
of O 
[S3]˙(-) B-FORMULA 
in O 
materials O 
science O 
, O 
electrochemistry O 
, O 
analytical O 
chemistry O 
and O 
geochemistry O 
are O 
used O 
to O 
illustrate O 
the O 
widespread O 
influence O 
of O 
this O 
fundamentally O 
important O 
triatomic B-SYSTEMATIC 
sulfur I-SYSTEMATIC 
species O 
. O 

and O 
inflammatory O 
effects O 
of O 
organic O 
extracts O 
from O 
traffic O 
- O 
related O 
particulate O 
matter O 
in O 
human O 
lung O 
epithelial O 
A549 O 
cells O 
: O 
the O 
role O 
of O 
quinones B-FAMILY 
. O 

- O 
related O 
particulate O 
matter O 
( O 
PM O 
) O 
is O 
associated O 
with O 
adverse O 
health O 
effects O 
. O 
Quinones B-FAMILY 
present O 
in O 
the O 
traffic O 
- O 
related O 
PM O 
are O 
hypothesized O 
to O 
contribute O 
to O 
these O 
harmful O 
effects O 
through O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
. O 
However O 
, O 
the O 
impacts O 
of O 
the O 
traffic O 
- O 
related O 
PM O 
and O 
quinones B-FAMILY 
on O 
inflammatory O 
processes O 
and O 
genotoxic O 
damages O 
are O 
less O 
well O 
known O 
. O 
In O 
present O 
study O 
we O 
aimed O 
to O 
examine O 
the O 
genotoxic O 
and O 
inflammatory O 
impacts O 
of O 
organic O 
extracts O 
from O 
traffic O 
- O 
related O 
PM O 
( O 
oTRP O 
) O 
in O 
human O 
lung O 
epithelial O 
A549 O 
cells O 
, O 
and O 
reveal O 
the O 
contributions O 
from O 
quinones B-FAMILY 
. O 
Significant O 
cytotoxicity O 
and O 
DNA O 
damage O 
were O 
caused O 
by O 
oTRP O 
. O 
The O 
pro O 
- O 
inflammatory O 
genes O 
, O 
interleukin-6 O 
( O 
Il-6 O 
) O 
, O 
interleukin-8 O 
( O 
Il-8 O 
) O 
and O 
tumor O 
necrosis O 
factor O 
( O 
Tnf O 
) O 
, O 
and O 
two O 
aromatic B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
- O 
regulated O 
genes O 
, O 
Cyp1a1 O 
and O 
1b1 O 
, O 
were O 
significantly O 
up O 
- O 
regulated O 
by O 
oTRP O 
. O 
A O 
concomitant O 
increase O 
in O 
ROS O 
was O 
observed O 
, O 
suggesting O 
that O 
oTRP O 
may O 
mediate O 
genotoxic O 
and O 
inflammatory O 
effects O 
through O 
oxidative O 
stress O 
pathway O 
. O 
Second O 
, O 
the O 
effects O 
from O 
two O 
typical O 
airborne O 
quinones B-FAMILY 
, O 
9,10-anthraquinone B-SYSTEMATIC 
( O 
AQ O 
) O 
and O 
1,4-naphthroquinone B-SYSTEMATIC 
( O 
NQ O 
) O 
were O 
compared O 
. O 
NQ O 
, O 
but O 
not O 
AQ O 
, O 
induced O 
significant O 
DNA O 
damage O 
in O 
A549 O 
cells O 
. O 
NQ O 
up O 
- O 
regulated O 
Il-8 O 
, O 
Tnf O 
, O 
and O 
Mcp-1 O 
genes O 
, O 
while O 
AQ O 
induced O 
the O 
expression O 
of O 
Rantes O 
gene O 
. O 
These O 
results O 
suggest O 
that O 
the O 
NQ O 
and O 
AQ O 
may O 
participate O 
in O 
the O 
pro O 
- O 
inflammatory O 
responses O 
through O 
releasing O 
different O 
types O 
of O 
cytokines O 
/ O 
chemokines O 
. O 

effect O 
of O 
the O 
non-psychotropic O 
plant O 
cannabinoid O 
cannabigerol B-TRIVIAL 
on O 
experimental O 
inflammatory O 
bowel O 
disease O 
. O 

bowel O 
disease O 
( O 
IBD O 
) O 
is O 
an O 
incurable O 
disease O 
which O 
affects O 
millions O 
of O 
people O 
in O 
industrialized O 
countries O 
. O 
Anecdotal O 
and O 
scientific O 
evidence O 
suggests O 
that O 
Cannabis O 
use O 
may O 
have O 
a O 
positive O 
impact O 
in O 
IBD O 
patients O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
cannabigerol B-TRIVIAL 
( O 
CBG B-ABBREVIATION 
) O 
, O 
a O 
non-psychotropic O 
Cannabis O 
- O 
derived O 
cannabinoid O 
, O 
in O 
a O 
murine O 
model O 
of O 
colitis O 
. O 
Colitis O 
was O 
induced O 
in O 
mice O 
by O 
intracolonic O 
administration O 
of O 
dinitrobenzene B-SYSTEMATIC 
sulphonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DNBS B-ABBREVIATION 
) O 
. O 
Inflammation O 
was O 
assessed O 
by O 
evaluating O 
inflammatory O 
markers O 
/ O 
parameters O 
( O 
colon O 
weight O 
/ O 
colon O 
length O 
ratio O 
and O 
myeloperoxidase O 
activity O 
) O 
, O 
by O 
histological O 
analysis O 
and O 
immunohistochemistry O 
; O 
interleukin-1β O 
, O 
interleukin-10 O 
and O 
interferon-γ O 
levels O 
by O 
ELISA O 
, O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
by O 
western O 
blot O 
and O 
RT-PCR O 
; O 
CuZn B-FORMULA 
- O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
by O 
a O 
colorimetric O 
assay O 
. O 
Murine O 
macrophages O 
and O 
intestinal O 
epithelial O 
cells O 
were O 
used O 
to O 
evaluate O 
the O 
effect O 
of O 
CBG O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
and O 
oxidative O 
stress O 
, O 
respectively O 
. O 
CBG B-ABBREVIATION 
reduced O 
colon O 
weight O 
/ O 
colon O 
length O 
ratio O 
, O 
myeloperoxidase O 
activity O 
, O 
and O 
iNOS O 
expression O 
, O 
increased O 
SOD O 
activity O 
and O 
normalized O 
interleukin-1β O 
, O 
interleukin-10 O 
and O 
interferon-γ O 
changes O 
associated O 
to O 
DNBS B-ABBREVIATION 
administration O 
. O 
In O 
macrophages O 
, O 
CBG B-ABBREVIATION 
reduced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
and O 
iNOS O 
protein O 
( O 
but O 
not O 
mRNA O 
) O 
expression O 
. O 
Rimonabant B-TRIVIAL 
( O 
a O 
CB1 O 
receptor O 
antagonist O 
) O 
did O 
not O 
change O 
the O 
effect O 
of O 
CBG B-ABBREVIATION 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
, O 
while O 
SR144528 B-IDENTIFIER 
( O 
a O 
CB2 O 
receptor O 
antagonist O 
) O 
further O 
increased O 
the O 
inhibitory O 
effect O 
of O 
CBG B-ABBREVIATION 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
. O 
In O 
conclusion O 
, O 
CBG B-ABBREVIATION 
attenuated O 
murine O 
colitis O 
, O 
reduced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
in O 
macrophages O 
( O 
effect O 
being O 
modulated O 
by O 
the O 
CB2 O 
receptor O 
) O 
and O 
reduced O 
ROS O 
formation O 
in O 
intestinal O 
epithelial O 
cells O 
. O 
CBG B-ABBREVIATION 
could O 
be O 
considered O 
for O 
clinical O 
experimentation O 
in O 
IBD O 
patients O 
. O 

ordered O 
cubic O 
mesostructured O 
polymer/ O 
silica B-TRIVIAL 
composite O 
films O 
grown O 
at O 
the O 
air O 
/ O 
water O 
interface O 
. O 

silica B-TRIVIAL 
composite O 
films O 
, O 
stable O 
to O 
calcination O 
, O 
were O 
produced O 
using O 
catanionic O 
surfactant O 
mixtures O 
( O 
hexadecyltrimethylammonium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
CTAB B-ABBREVIATION 
) O 
and O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
) O 
and O 
polymers O 
( O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
or O 
polyacrylamide B-SYSTEMATIC 
( O 
PAAm B-ABBREVIATION 
) O 
) O 
at O 
the O 
air O 
/ O 
water O 
interface O 
. O 
Film O 
formation O 
processes O 
were O 
probed O 
by O 
time O 
- O 
resolved O 
neutron O 
reflectivity O 
measurements O 
. O 
Grazing O 
incidence O 
X-ray O 
diffraction O 
( O 
GID O 
) O 
measurements O 
indicate O 
that O 
the O 
mesophase O 
geometry O 
of O 
the O 
interfacial O 
films O 
could O 
be O 
controlled O 
to O 
give O 
lamellar O 
, O 
2D O 
hexagonal O 
, O 
and O 
several O 
cubic O 
phases O 
( O 
Pn3¯m O 
, O 
Fm3¯m O 
, O 
and O 
Im3¯m O 
) O 
by O 
varying O 
the O 
polyelectrolyte O 
molecular O 
weight O 
, O 
polyelectrolyte O 
chemical O 
nature O 
, O 
or O 
the O 
cationic O 
: O 
anionic O 
surfactant O 
molar O 
ratio O 
. O 
On O 
the O 
basis O 
of O 
GID O 
results O 
, O 
a O 
phase O 
diagram O 
for O 
the O 
catanionic O 
surfactant O 
/ O 
polyelectrolyte/ O 
TMOS B-ABBREVIATION 
film O 
system O 
was O 
drawn O 
. O 
These O 
films O 
can O 
be O 
easily O 
removed O 
from O 
the O 
interface O 
and O 
mesoporous O 
silica B-TRIVIAL 
films O 
which O 
retain O 
the O 
film O 
geometry O 
can O 
be O 
obtained O 
after O 
calcination O 
; O 
moreover O 
, O 
this O 
film O 
preparation O 
method O 
provides O 
a O 
simple O 
way O 
to O 
impart O 
polymer O 
functionality O 
into O 
the O 
mesostructured O 
silica B-TRIVIAL 
wall O 
, O 
which O 
means O 
these O 
films O 
have O 
potential O 
applications O 
in O 
a O 
variety O 
of O 
fields O 
such O 
as O 
catalysis O 
, O 
molecular O 
separation O 
, O 
and O 
drug O 
delivery O 
. O 

are O 
important O 
industrial O 
materials O 
. O 
However O 
, O 
many O 
nanoparticles O 
show O 
biological O 
effects O 
, O 
including O 
toxic O 
activity O 
. O 
Metal O 
ion O 
release O 
is O 
the O 
most O 
important O 
factor O 
affecting O 
the O 
biological O 
effects O 
of O 
nanoparticles O 
. O 
In O 
addition O 
, O 
nanoparticles O 
have O 
large O 
adsorption O 
ability O 
. O 
The O 
adsorption O 
ability O 
, O 
in O 
particular O 
protein O 
adsorption O 
to O 
nanoparticles O 
, O 
has O 
an O 
effect O 
on O 
cellular O 
uptake O 
and O 
cellular O 
metabolisms O 
. O 
Moreover O 
, O 
the O 
adsorption O 
ability O 
of O 
nanoparticles O 
causes O 
artificial O 
effects O 
in O 
in O 
vitro O 
systems O 
. O 
Consequently O 
, O 
accurate O 
determination O 
of O 
released O 
or O 
secreted O 
proteins O 
such O 
as O 
lactate B-FAMILY 
dehydrogenase O 
and O 
cytokines O 
adsorbed O 
to O 
nanoparticles O 
is O 
affected O 
. O 
In O 
addition O 
, O 
artificial O 
effects O 
cause O 
overestimation O 
or O 
underestimation O 
of O 
the O 
cytotoxicity O 
of O 
nanoparticles O 
. O 
Therefore O 
, O 
measurement O 
of O 
the O 
protein O 
adsorption O 
of O 
nanoparticles O 
is O 
important O 
. O 
Some O 
methods O 
for O 
the O 
determination O 
of O 
the O 
adsorption O 
to O 
nanoparticles O 
have O 
been O 
suggested O 
. O 
The O 
flow O 
field O 
- O 
flow O 
fractionation O 
method O 
is O 
one O 
of O 
the O 
efficient O 
techniques O 
for O 
determining O 
proteins O 
on O 
the O 
surface O 
of O 
nanoparticles O 
. O 
The O 
cellular O 
effects O 
caused O 
by O 
nanoparticles O 
should O 
be O 
carefully O 
considered O 
. O 

of O 
four O 
organophosphonate B-FAMILY 
derivatives O 
on O 
N-(3,5-dinitrobenzoyl)-L-leucine-n-propylamide B-SYSTEMATIC 
stationary O 
phase O 
by O 
molecular O 
modeling O 
. O 

groups O 
of O 
organophosphonate B-FAMILY 
derivatives O 
enantiomers O 
were O 
separated O 
on O 
N-(3,5-dinitrobenzoyl)-S-leucine B-SYSTEMATIC 
chiral O 
stationary O 
phase O 
. O 
The O 
three O 
- O 
dimensional O 
structures O 
of O 
the O 
complexes O 
between O 
the O 
single O 
enantiotopic O 
chiral O 
compounds O 
and O 
chiral O 
stationary O 
phase O 
have O 
been O 
studied O 
using O 
molecular O 
model O 
and O 
molecular O 
dynamics O 
simulation O 
. O 
Detailed O 
results O 
regarding O 
the O 
conformation O 
, O 
auto O 
- O 
docking O 
, O 
and O 
thermodynamic O 
estimation O 
are O 
presented O 
. O 
The O 
elution O 
order O 
of O 
the O 
enantiomer O 
could O 
be O 
determined O 
from O 
the O 
energy O 
. O 
The O 
predicted O 
chiral O 
discrimination O 
was O 
obtained O 
by O 
computational O 
results O 
. O 

A-E I-MULTIPLE 
, O 
cytotoxic O 
oplopane B-FAMILY 
sesquiterpenes I-FAMILY 
from O 
Ligularia O 
songarica O 
. O 

new O 
highly O 
oxygenated B-FAMILY 
oplopane I-FAMILY 
sesquiterpenes I-FAMILY 
, O 
songaricalarins B-MULTIPLE 
A-E I-MULTIPLE 
( O 
1-5 O 
) O 
, O 
and O 
two O 
known O 
analogues O 
( O 
6 O 
and O 
7 O 
) O 
were O 
isolated O 
from O 
the O 
roots O 
and O 
rhizomes O 
of O 
Ligularia O 
songarica O 
. O 
Their O 
structures O 
and O 
configurations O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
, O 
including O 
2D-NMR O 
techniques O 
, O 
and O 
the O 
structure O 
of O 
1 O 
was O 
confirmed O 
by O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
. O 
All O 
compounds O 
were O 
evaluated O 
for O 
in O 
vitro O 
cytotoxic O 
activity O 
against O 
cultured O 
A-549 O 
, O 
MCF-7 O 
, O 
KB O 
, O 
and O 
KBVIN O 
cells O 
, O 
and O 
4 O 
exhibited O 
cytotoxicity O 
with O 
EC50 O 
values O 
of O 
4.9 O 
, O 
0.8 O 
, O 
3.4 O 
, O 
and O 
3.2 O 
μg O 
/ O 
mL O 
, O 
respectively O 
. O 

( O 
IL-1 O 
) O 
inhibitors O 
potentially O 
have O 
a O 
role O 
as O 
antiinflammatory O 
agents O 
in O 
refractory O 
gout O 
or O 
for O 
patients O 
who O 
are O 
unable O 
to O 
tolerate O 
conventional O 
therapy O 
, O 
such O 
as O 
nonsteroidal O 
antiinflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
, O 
colchicine B-TRIVIAL 
, O 
or O 
glucocorticoids O 
, O 
for O 
acute O 
attacks O 
. O 
Additionally O 
, O 
IL-1 O 
inhibitors O 
may O 
also O 
help O 
patients O 
with O 
polyarticular O 
and O 
tophaceous O 
gout O 
by O 
making O 
them O 
less O 
vulnerable O 
to O 
breakthrough O 
attacks O 
during O 
initiation O 
of O 
chronic O 
urate O 
- O 
lowering O 
treatment O 
, O 
the O 
mainstay O 
of O 
gout O 
therapy O 
. O 
Because O 
evidence O 
highlights O 
the O 
role O 
of O 
proinflammatory O 
cytokine O 
IL-1 O 
in O 
the O 
inflammation O 
process O 
during O 
an O 
acute O 
gouty O 
attack O 
, O 
IL-1 O 
inhibitors O 
are O 
used O 
to O 
modulate O 
the O 
pathogenesis O 
of O 
a O 
variety O 
of O 
autoinflammatory O 
diseases O 
, O 
providing O 
support O 
for O 
its O 
potential O 
role O 
in O 
the O 
inflammatory O 
process O 
of O 
gout O 
. O 
After O 
NSAIDs O 
, O 
colchicine B-TRIVIAL 
, O 
and O 
steroids B-FAMILY 
, O 
IL-1 O 
inhibitors O 
are O 
beneficial O 
as O 
fourth O 
- O 
line O 
therapy O 
for O 
acute O 
gout O 
attacks O 
due O 
to O 
their O 
high O 
cost O 
and O 
limited O 
clinical O 
experience O 
. O 
The O 
IL-1 O 
inhibitors O 
used O 
in O 
gout O 
are O 
anakinra O 
, O 
canakinumab O 
, O 
and O 
rilonacept O 
. O 
Based O 
on O 
published O 
evidence O 
, O 
anakinra O 
has O 
limited O 
support O 
in O 
the O 
form O 
of O 
anecdotal O 
case O 
reports O 
to O 
justify O 
its O 
use O 
for O 
treating O 
gout O 
. O 
Canakinumab's O 
toxic O 
profile O 
in O 
clinical O 
trials O 
precludes O 
its O 
use O 
in O 
treating O 
patients O 
for O 
gout O 
, O 
and O 
rilonacept O 
shows O 
promise O 
with O 
a O 
few O 
well O 
- O 
designed O 
studies O 
to O 
support O 
its O 
use O 
in O 
gout O 
patients O 
initiating O 
urate O 
- O 
lowering O 
treatment O 
. O 
When O 
combined O 
with O 
current O 
traditional O 
therapies O 
, O 
these O 
newer O 
agents O 
present O 
clinicians O 
and O 
patients O 
with O 
more O 
potential O 
treatment O 
options O 
in O 
the O 
difficult O 
- O 
to O 
- O 
treat O 
gout O 
population O 
. O 

prolyl O 
4-hydroxylases O 
( O 
C-P4H O 
) O 
are O 
required O 
for O 
formation O 
of O 
extracellular O 
matrices O 
in O 
higher O 
eukaryotes O 
. O 
These O 
enzymes O 
convert O 
proline B-TRIVIAL 
residues O 
within O 
the O 
repeat O 
regions O 
of O 
collagen O 
polypeptides O 
to O 
4-hydroxyproline B-SYSTEMATIC 
, O 
a O 
modification O 
essential O 
for O 
the O 
stability O 
of O 
the O 
final O 
triple O 
helix O 
. O 
C-P4H O 
are O 
most O 
often O 
oligomeric O 
complexes O 
, O 
with O 
enzymatic O 
activity O 
contributed O 
by O 
the O 
α O 
subunits O 
, O 
and O 
the O 
β O 
subunits O 
formed O 
by O 
protein O 
disulfide B-SYSTEMATIC 
isomerase O 
( O 
PDI O 
) O 
. O 
Here O 
, O 
we O 
characterize O 
this O 
enzyme O 
class O 
in O 
the O 
important O 
human O 
parasitic O 
nematode O 
Brugia O 
malayi O 
. O 
All O 
potential O 
C-P4H O 
subunits O 
were O 
identified O 
by O 
detailed O 
bioinformatic O 
analysis O 
of O 
sequence O 
databases O 
, O 
function O 
was O 
investigated O 
both O 
by O 
RNAi O 
in O 
the O 
parasite O 
and O 
heterologous O 
expression O 
in O 
Caenorhabditis O 
elegans O 
, O 
whereas O 
biochemical O 
activity O 
and O 
complex O 
formation O 
were O 
examined O 
via O 
co O 
- O 
expression O 
in O 
insect O 
cells O 
. O 
Simultaneous O 
RNAi O 
of O 
two O 
B O 
. O 
malayi O 
C-P4H O 
α O 
subunit O 
- O 
like O 
genes O 
resulted O 
in O 
a O 
striking O 
, O 
highly O 
penetrant O 
body O 
morphology O 
phenotype O 
in O 
parasite O 
larvae O 
. O 
This O 
was O 
replicated O 
by O 
single O 
RNAi O 
of O 
a O 
B O 
. O 
malayi O 
C-P4H O 
β O 
subunit O 
- O 
like O 
PDI O 
. O 
Surprisingly O 
, O 
however O 
, O 
the O 
B O 
. O 
malayi O 
proteins O 
were O 
not O 
capable O 
of O 
rescuing O 
a O 
C O 
. O 
elegans O 
α O 
subunit O 
mutant O 
, O 
whereas O 
the O 
human O 
enzymes O 
could O 
. O 
In O 
contrast O 
, O 
the O 
B O 
. O 
malayi O 
PDI O 
did O 
functionally O 
complement O 
the O 
lethal O 
phenotype O 
of O 
a O 
C O 
. O 
elegans O 
β O 
subunit O 
mutant O 
. O 
Comparison O 
of O 
recombinant O 
and O 
parasite O 
derived O 
material O 
indicates O 
that O 
enzymatic O 
activity O 
may O 
be O 
dependent O 
on O 
a O 
non-reducible O 
covalent O 
link O 
, O 
present O 
only O 
in O 
the O 
parasite O 
. O 
We O 
therefore O 
demonstrate O 
that O 
C-P4H O 
activity O 
is O 
essential O 
for O 
development O 
of O 
B O 
. O 
malayi O 
and O 
uncover O 
a O 
novel O 
parasite O 
- O 
specific O 
feature O 
of O 
these O 
collagen O 
biosynthetic O 
enzymes O 
that O 
may O 
be O 
exploited O 
in O 
future O 
parasite O 
control O 
. O 

microscopically O 
reversible O 
approach O 
toward O 
computing O 
reaction O 
probabilities O 
via O 
classical O 
trajectory O 
simulation O 
has O 
been O 
developed O 
that O 
bins O 
trajectories O 
symmetrically O 
on O 
the O 
basis O 
of O 
their O 
initial O 
and O 
final O 
classical O 
actions O 
. O 
The O 
symmetrical O 
quasi O 
- O 
classical O 
( O 
SQC O 
) O 
approach O 
involves O 
defining O 
a O 
classical O 
action O 
window O 
function O 
centered O 
at O 
integer O 
quantum O 
values O 
of O 
the O 
action O 
, O 
choosing O 
a O 
width O 
parameter O 
that O 
is O 
less O 
than O 
unit O 
quantum O 
width O 
, O 
and O 
applying O 
the O 
window O 
function O 
to O 
both O 
initial O 
reactant O 
and O 
final O 
product O 
vibrational O 
states O 
. O 
Calculations O 
were O 
performed O 
using O 
flat O 
histogram O 
windows O 
and O 
Gaussian O 
windows O 
over O 
a O 
range O 
of O 
width O 
parameters O 
. O 
Use O 
of O 
the O 
Wigner O 
distribution O 
function O 
was O 
also O 
investigated O 
as O 
a O 
possible O 
choice O 
. O 
It O 
was O 
demonstrated O 
for O 
collinear O 
H B-FORMULA 
+ O 
H2 B-FORMULA 
reactive O 
scattering O 
on O 
the O 
BKMP2 O 
potential O 
energy O 
surface O 
that O 
reaction O 
probabilities O 
computed O 
via O 
the O 
SQC O 
methodology O 
using O 
a O 
Gaussian O 
window O 
function O 
of O 
1 O 
/ O 
2 O 
unit O 
width O 
produces O 
good O 
agreement O 
with O 
quantum O 
mechanical O 
results O 
over O 
the O 
0.4-0.6 O 
eV O 
energy O 
range O 
relevant O 
to O 
the O 
ground O 
vibrational O 
state O 
to O 
the O 
ground O 
vibrational O 
state O 
reactive O 
transition O 
. O 

have O 
developed O 
a O 
3-dimensional O 
human O 
hemi O 
- O 
cornea O 
which O 
comprises O 
an O 
immortalized O 
epithelial O 
cell O 
line O 
and O 
keratocytes O 
embedded O 
in O 
a O 
collagen O 
stroma O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
have O 
used O 
MTT B-ABBREVIATION 
reduction O 
of O 
the O 
whole O 
tissue O 
to O 
clarify O 
whether O 
the O 
production O 
of O 
this O 
complex O 
3-D-model O 
is O 
transferable O 
into O 
other O 
laboratories O 
and O 
whether O 
these O 
tissues O 
can O 
be O 
constructed O 
reproducibly O 
. O 
Our O 
results O 
demonstrate O 
the O 
reproducible O 
production O 
of O 
the O 
hemi O 
- O 
cornea O 
model O 
according O 
to O 
standard O 
operation O 
procedures O 
using O 
15 O 
independent O 
batches O 
of O 
reconstructed O 
hemi O 
- O 
cornea O 
models O 
in O 
two O 
independent O 
laboratories O 
each O 
. O 
Furthermore O 
, O 
the O 
hemi O 
- O 
cornea O 
tissues O 
have O 
been O 
treated O 
with O 
20 O 
chemicals O 
of O 
different O 
eye O 
- O 
irritating O 
potential O 
under O 
blind O 
conditions O 
to O 
assess O 
the O 
performance O 
and O 
limitations O 
of O 
our O 
test O 
system O 
comparing O 
three O 
different O 
prediction O 
models O 
. O 
The O 
most O 
suitable O 
prediction O 
model O 
revealed O 
an O 
overall O 
in O 
vitro O 
- O 
in O 
vivo O 
concordance O 
of O 
80% O 
and O 
70% O 
in O 
the O 
participating O 
laboratories O 
, O 
respectively O 
, O 
and O 
an O 
inter O 
- O 
laboratory O 
concordance O 
of O 
80% O 
. O 
Sensitivity O 
of O 
the O 
test O 
was O 
77% O 
and O 
specificity O 
was O 
between O 
57% O 
and O 
86% O 
to O 
discriminate O 
classified O 
from O 
non-classified O 
chemicals O 
. O 
We O 
conclude O 
that O 
additional O 
physiologically O 
relevant O 
endpoints O 
in O 
both O 
epithelium O 
and O 
stroma O 
have O 
to O 
be O 
developed O 
for O 
the O 
reliable O 
prediction O 
of O 
all O 
GHS O 
classes O 
of O 
eye O 
irritation O 
in O 
one O 
stand O 
alone O 
test O 
system O 
. O 

of O 
nosokophic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
predicted O 
intermediate O 
of O 
moenomycins B-FAMILY 
, O 
from O 
nosokomycin B-TRIVIAL 
-producing O 
Streptomyces O 
sp O 
. O 
K04-0144 O 
. O 

new O 
actinomycete O 
metabolite O 
designated O 
nosokophic B-TRIVIAL 
acid I-TRIVIAL 
was O 
isolated O 
from O 
the O 
culture O 
broth O 
of O 
nosokomycin B-TRIVIAL 
-producing O 
Streptomyces O 
sp O 
. O 
K04-0144 O 
, O 
and O 
the O 
structure O 
was O 
elucidated O 
by O 
various O 
NMR O 
experiments O 
. O 
Nosokophic B-TRIVIAL 
acid I-TRIVIAL 
was O 
found O 
to O 
be O 
3-phosphoglycosyl-2-sesquiterpenyl B-SYSTEMATIC 
dihydroxypropionic I-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
a O 
predicted O 
biosynthetic O 
intermediate O 
of O 
nosokomycin B-TRIVIAL 
-related O 
moenomycins B-FAMILY 
. O 
The O 
compound O 
showed O 
no O 
activity O 
against O 
MRSA O 
, O 
but O 
potentiated O 
imipenem O 
activity O 
against O 
MRSA O 
by O 
512-fold O 
. O 

signaling O 
pathways O 
are O 
believed O 
to O 
be O 
involved O 
in O 
the O 
epileptogenic O 
process O 
that O 
triggers O 
the O 
subsequent O 
changes O 
in O 
the O 
brain O 
causing O 
epilepsy O 
. O 
The O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
is O 
a O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
that O 
in O 
the O 
brain O 
, O 
regulates O 
several O 
important O 
physiological O 
functions O 
such O 
as O 
neuronal O 
development O 
and O 
synaptic O 
plasticity O 
, O 
and O 
also O 
seems O 
to O 
be O 
involved O 
in O 
many O 
pathologies O 
, O 
including O 
epilepsy O 
and O 
psychiatric O 
disorders O 
. O 
Previous O 
work O 
in O 
animal O 
models O 
of O 
both O 
genetic O 
and O 
acquired O 
generalized O 
convulsive O 
epilepsies O 
, O 
has O 
suggested O 
that O 
modulators O 
of O 
the O 
mTOR O 
signaling O 
pathway O 
may O 
have O 
beneficial O 
neuroprotective O 
and O 
antiepileptogenic O 
effects O 
. O 
Here O 
, O 
we O 
investigated O 
for O 
the O 
first O 
time O 
, O 
the O 
effect O 
of O 
some O 
treatment O 
schedules O 
( O 
i.e O 
. O 
early O 
chronic O 
, O 
sub O 
- O 
chronic O 
and O 
acute O 
) O 
with O 
the O 
specific O 
mTOR O 
inhibitor O 
rapamycin B-TRIVIAL 
, O 
on O 
the O 
development O 
of O 
absence O 
seizures O 
and O 
seizure O 
parameters O 
as O 
well O 
as O 
depressive O 
- O 
like O 
behavior O 
in O 
WAG O 
/ O 
Rij O 
rats O 
, O 
a O 
genetic O 
model O 
of O 
absence O 
epilepsy O 
, O 
epileptogenesis O 
and O 
mild O 
- O 
depression O 
comorbidity O 
. O 
In O 
addition O 
, O 
we O 
studied O 
the O 
possible O 
interaction O 
between O 
rapamycin B-TRIVIAL 
treatment O 
and O 
the O 
effects O 
of O 
bacterial O 
lipopolysaccharide O 
( O 
LPS O 
) O 
endotoxin O 
administration O 
, O 
which O 
is O 
known O 
to O 
aggravate O 
absence O 
seizures O 
through O 
generation O 
of O 
increased O 
neuroinflammatory O 
responses O 
. O 
We O 
found O 
that O 
rapamycin B-TRIVIAL 
( O 
early O 
chronic O 
treatment O 
for O 
17 O 
weeks O 
, O 
starting O 
at O 
P45 O 
) O 
exhibited O 
clear O 
antiepileptogenic O 
properties O 
also O 
in O 
this O 
animal O 
epilepsy O 
model O 
; O 
however O 
, O 
this O 
effect O 
was O 
accompanied O 
by O 
unexpected O 
prodepressant O 
effects O 
. O 
Both O 
acute O 
and O 
sub O 
- O 
chronic O 
( O 
7 O 
day O 
) O 
treatments O 
also O 
had O 
anti-absence O 
properties O 
, O 
but O 
the O 
sub O 
- O 
chronic O 
treatment O 
produced O 
contrasting O 
antidepressant O 
properties O 
in O 
the O 
WAG O 
/ O 
Rij O 
rats O 
that O 
were O 
not O 
seen O 
in O 
control O 
Wistar O 
rats O 
. O 
The O 
rapamycin B-TRIVIAL 
/ O 
LPS O 
co O 
- O 
administration O 
studies O 
showed O 
that O 
rapamycin B-TRIVIAL 
blocked O 
or O 
prevented O 
the O 
LPS-dependent O 
increase O 
in O 
absence O 
seizures O 
, O 
suggesting O 
an O 
anti-inflammatory- O 
like O 
protective O 
action O 
. O 
In O 
conclusion O 
, O 
we O 
have O 
demonstrated O 
a O 
novel O 
antiepileptogenic O 
effect O 
of O 
rapamycin B-TRIVIAL 
in O 
a O 
well O 
- O 
established O 
animal O 
model O 
of O 
absence O 
epilepsy O 
, O 
and O 
we O 
suggest O 
that O 
this O 
effect O 
may O 
be O 
mediated O 
by O 
the O 
inhibition O 
of O 
inflammatory O 
processes O 
that O 
are O 
developed O 
in O 
the O 
brain O 
of O 
these O 
specific O 
animals O 
during O 
epileptogenesis O 
and O 
during O 
seizures O 
. O 
Our O 
experiments O 
here O 
suggest O 
new O 
insights O 
into O 
this O 
intriguing O 
field O 
, O 
which O 
deserves O 
to O 
be O 
further O 
explored O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
New O 
Targets O 
and O 
Approaches O 
to O 
the O 
Treatment O 
of O 
Epilepsy O 
' O 
. O 

new O 
glycosides O 
, O 
2-methyl B-SYSTEMATIC 
pyromeconic I-SYSTEMATIC 
acid I-SYSTEMATIC 
3-O-β-d-glucopyranoside-6'-(O-4″-hydroxybenzoate) I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
6'-O-p-hydroxybenzoyl-gardoside B-SYSTEMATIC 
( O 
2 O 
) O 
and O 
four O 
known O 
iridoid B-FAMILY 
glycosides I-FAMILY 
( O 
3-6 O 
) O 
were O 
isolated O 
from O 
the O 
whole O 
plant O 
of O 
Vitex O 
negundo O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
including O 
HR-ESI-MS O 
, O 
1D O 
and O 
2D O 
NMR O 
. O 

vitro O 
and O 
in O 
vivo O 
evaluation O 
of O 
an O 
in O 
situ O 
gel O 
forming O 
system O 
for O 
the O 
delivery O 
of O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
develop O 
a O 
controlled O 
delivery O 
system O 
for O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
using O 
a O 
Poloxamer B-TRIVIAL 
based O 
in O 
situ O 
gel O 
forming O 
polymer O 
. O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
kept O 
its O 
full O 
biological O 
activity O 
and O 
higher O 
serum O 
half O 
- O 
life O 
compared O 
to O 
the O 
original O 
octreotide B-TRIVIAL 
. O 
The O 
designed O 
drug O 
delivery O 
system O 
contained O 
low O 
concentration O 
of O 
Poloxamer B-TRIVIAL 
407 I-TRIVIAL 
( O 
P407 B-IDENTIFIER 
) O 
( O 
< O 
0.16% O 
) O 
with O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
as O 
a O 
polymeric O 
additive O 
. O 
Rheological O 
measurements O 
of O 
gel O 
vehicle O 
formulations O 
indicated O 
that O 
the O 
in O 
situ O 
gel O 
forming O 
system O 
with O 
optimum O 
sol O 
- O 
gel O 
transition O 
temperature O 
of O 
28.7°C O 
could O 
be O 
formed O 
using O 
a O 
combination O 
of O 
P407 B-IDENTIFIER 
and O 
PVA B-ABBREVIATION 
at O 
ratio O 
of O 
15-10% O 
( O 
w O 
/ O 
v O 
) O 
. O 
The O 
effect O 
of O 
formulation O 
additives O 
such O 
as O 
buffering O 
agents O 
on O 
rheological O 
behavior O 
demonstrated O 
that O 
sodium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
and O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
have O 
opposite O 
effect O 
on O 
sol O 
- O 
gel O 
transition O 
temperature O 
of O 
the O 
system O 
. O 
Using O 
buffering O 
agents O 
, O 
it O 
was O 
possible O 
to O 
shift O 
the O 
sol O 
- O 
gel O 
transition O 
to O 
lower O 
or O 
higher O 
temperatures O 
. O 
The O 
in O 
vitro O 
release O 
profiles O 
of O 
octreotide B-TRIVIAL 
and O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
from O 
the O 
selected O 
P407 B-IDENTIFIER 
/ O 
PVA B-ABBREVIATION 
formulations O 
were O 
measured O 
using O 
a O 
membrane O 
- O 
less O 
device O 
. O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
showed O 
slower O 
release O 
rate O 
from O 
the O 
gel O 
system O 
with O 
different O 
release O 
kinetic O 
compared O 
to O 
octreotide B-TRIVIAL 
. O 
In O 
animal O 
studies O 
, O 
a O 
sustained O 
release O 
rate O 
was O 
achieved O 
with O 
both O 
PEGylated B-MULTIPLE 
and I-MULTIPLE 
non-PEGylated I-MULTIPLE 
octreotide I-MULTIPLE 
, O 
but O 
longer O 
delivery O 
was O 
observed O 
for O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
. O 
Tissue O 
histopathological O 
studies O 
confirmed O 
the O 
biocompatibility O 
of O 
the O 
delivery O 
system O 
for O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
, O 
supporting O 
the O 
suitability O 
of O 
P407 B-IDENTIFIER 
/ O 
PVA B-ABBREVIATION 
mixture O 
as O 
an O 
injectable O 
drug O 
delivery O 
system O 
. O 
The O 
total O 
effects O 
of O 
increasing O 
PEGylated O 
peptide O 
half O 
- O 
life O 
and O 
prolonged O 
release O 
from O 
thermoresponsive O 
gel O 
system O 
offer O 
the O 
potential O 
for O 
sustained O 
delivery O 
of O 
PEGylated B-TRIVIAL 
octreotide I-TRIVIAL 
. O 

activity O 
of O 
the O 
liposome O 
- O 
encapsulated O 
cyclic B-FAMILY 
dipeptides I-FAMILY 
, O 
cyclo(His-Gly) B-FORMULA 
and O 
cyclo(His-Ala) B-FORMULA 
. O 

dipeptides I-FAMILY 
have O 
been O 
well O 
characterized O 
for O 
their O 
biological O 
activity O 
, O 
including O 
antimicrobial O 
and O 
anticancer O 
activities O 
. O 
Cyclo(His-Gly) B-FORMULA 
and O 
cyclo(His-Ala) B-FORMULA 
have O 
also O 
recently O 
demonstrated O 
significant O 
anticancer O 
activity O 
against O 
a O 
range O 
of O 
cell O 
lines O 
, O 
however O 
, O 
as O 
a O 
result O 
of O 
their O 
physicochemistry O 
, O 
namely O 
high O 
solubility O 
and O 
low O 
lipophilicity O 
, O 
it O 
can O 
be O 
predicted O 
that O 
cellular O 
permeability O 
would O 
be O 
low O 
, O 
making O 
them O 
ideal O 
candidates O 
for O 
liposome O 
drug O 
delivery O 
. O 
Liposomes O 
were O 
composed O 
of O 
phosphatidylcholine B-FAMILY 
, O 
hydrogenated O 
soy O 
phosphatidylcholine B-FAMILY 
( O 
HSPC O 
) O 
, O 
stearylamine B-SYSTEMATIC 
, O 
alpha-tocopherol B-TRIVIAL 
and O 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene B-SYSTEMATIC 
glycol)-2000 I-SYSTEMATIC 
] I-SYSTEMATIC 
( O 
PEG-DSPE B-ABBREVIATION 
) O 
or O 
folate B-FAMILY 
- I-FAMILY 
polyethylene I-FAMILY 
glycol I-FAMILY 
- I-FAMILY 
cholesteryl I-FAMILY 
hemisuccinate I-FAMILY 
( O 
F-PEG-CHEMS B-ABBREVIATION 
) O 
using O 
the O 
thin O 
- O 
film O 
hydration O 
method O 
and O 
characterized O 
for O 
size O 
and O 
encapsulation O 
. O 
The O 
cytotoxic O 
activity O 
of O 
the O 
encapsulated O 
cyclic B-FAMILY 
dipeptides I-FAMILY 
was O 
tested O 
against O 
HeLa O 
, O 
low O 
folate B-TRIVIAL 
HeLa O 
and O 
MCF-7 O 
cells O 
and O 
found O 
to O 
have O 
limited O 
improvement O 
in O 
activity O 
. O 
However O 
, O 
modification O 
of O 
the O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
with O 
folic B-TRIVIAL 
acid I-TRIVIAL 
to O 
target O 
folate O 
receptors O 
significantly O 
decreased O 
the O 
IC50 O 
values O 
recorded O 
in O 
all O 
cells O 
lines O 
tested O 
, O 
particularly O 
HeLa O 
cells O 
cultured O 
in O 
media O 
containing O 
physiological O 
concentrations O 
of O 
folic B-TRIVIAL 
acid I-TRIVIAL 
with O 
the O 
lowest O 
IC50 O 
being O 
recorded O 
as O 
0.0962 O 
mM O 
for O 
folate B-TRIVIAL 
-targeted O 
cyclo(His-Ala) B-FORMULA 
. O 
Therefore O 
, O 
hydrophilic O 
cyclic B-FAMILY 
dipeptides I-FAMILY 
are O 
ideal O 
candidates O 
for O 
inclusion O 
into O 
targeted O 
drug O 
delivery O 
systems O 
such O 
as O 
liposomes O 
. O 

expression O 
of O 
Cyr61 O 
, O 
an O 
extracellular O 
cysteine B-TRIVIAL 
-rich O 
heparin O 
- O 
binding O 
protein O 
, O 
has O 
been O 
associated O 
with O 
a O 
malignant O 
cell O 
phenotype O 
and O 
poor O 
outcome O 
in O 
prostate O 
cancers O 
. O 
Although O 
Cyr61 O 
was O 
found O 
by O 
us O 
to O 
be O 
overproduced O 
in O 
androgen B-FAMILY 
-independent O 
PC-3 O 
cells O 
treated O 
with O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
its O 
significance O 
is O 
still O 
unclear O 
. O 
We O 
therefore O 
aimed O 
to O 
determine O 
how O 
and O 
why O 
Cyr61 O 
protein O 
is O 
overexpressed O 
in O 
NAC B-ABBREVIATION 
-treated O 
cells O 
. O 
Here O 
, O 
we O 
found O 
that O 
Cyr61 O 
protein O 
level O 
markedly O 
increased O 
in O 
cells O 
treated O 
with O 
NAC B-ABBREVIATION 
at O 
high O 
cell O 
seeding O 
density O 
. O 
Silencing O 
of O 
Cyr61 O 
by O 
siRNA O 
induced O 
enhanced O 
activity O 
of O 
caspase-3 O 
/ O 
7 O 
, O 
upregulation O 
of O 
the O 
proapototic O 
Bok O 
, O 
BimL O 
and O 
BimS O 
, O 
cleavage O 
of O 
apoptosis O 
hallmarkers O 
such O 
as O 
Bax O 
, O 
PARP O 
and O 
caspase-3 O 
, O 
and O 
downregulation O 
of O 
antiapoptotic O 
Bcl2 O 
, O 
Bcl-xL O 
and O 
Mcl-1 O 
proteins O 
. O 
NAC B-ABBREVIATION 
treatment O 
caused O 
a O 
reduction O 
of O 
extracellular O 
medium O 
pH O 
to O 
acidic O 
and O 
an O 
increase O 
in O 
Akt O 
phosphorylation O 
, O 
after O 
which O 
the O 
replacement O 
with O 
NAC B-ABBREVIATION 
-free O 
medium O 
returned O 
them O 
to O 
control O 
levels O 
within O 
24h O 
. O 
Acid O 
stimulation O 
increased O 
the O 
levels O 
of O 
Cyr61 O 
and O 
p-Akt O 
proteins O 
, O 
whereas O 
it O 
suppressed O 
the O 
induction O 
of O 
proapoptotic O 
and O 
antiapoptotic O 
proteins O 
. O 
Overall O 
, O 
our O 
data O 
indicate O 
that O 
PC-3 O 
cells O 
overproduce O 
Cyr61 O 
protein O 
via O 
activation O 
of O 
the O 
PI3K O 
/ O 
Akt O 
signaling O 
as O 
a O 
part O 
of O 
the O 
survival O 
mechanisms O 
under O 
the O 
conditions O 
causing O 
extracellular O 
acidity O 
and O 
further O 
cytotoxicity O 
. O 

( O 
Pb B-FORMULA 
) O 
is O 
considered O 
to O 
be O 
a O 
multi O 
- O 
target O 
toxicant O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
to O 
evaluate O 
the O 
protective O 
effect O 
of O 
aqueous O 
extract O 
of O 
Corchorus O 
olitorius O 
leaves O 
against O 
Pb-acetate B-SYSTEMATIC 
induced O 
toxic O 
manifestation O 
in O 
blood O 
, O 
liver O 
, O 
kidney O 
, O 
brain O 
and O 
heart O 
of O 
Wistar O 
rats O 
. O 
The O 
Pb-acetate B-SYSTEMATIC 
( O 
5mg O 
/ O 
kg O 
body O 
weight O 
) O 
treated O 
rats O 
exhibited O 
a O 
significant O 
inhibition O 
of O 
co B-FAMILY 
- I-FAMILY 
enzymes I-FAMILY 
Q I-FAMILY 
, O 
antioxidant O 
enzymes O 
and O 
reduced O 
glutathione B-TRIVIAL 
levels O 
in O 
the O 
tissues O 
. O 
In O 
addition O 
, O 
the O 
extent O 
of O 
lipid O 
peroxidation O 
, O 
DNA O 
fragmentation O 
and O 
haematological O 
parameters O 
were O 
significantly O 
altered O 
in O 
the O 
Pb-acetate B-SYSTEMATIC 
treated O 
rats O 
as O 
compared O 
to O 
control O 
. O 
Simultaneous O 
administration O 
of O 
test O 
extract O 
( O 
25 O 
, O 
50 O 
and O 
100mg O 
/ O 
kg O 
body O 
weight O 
) O 
, O 
could O 
significantly O 
restore O 
the O 
biochemical O 
and O 
haematological O 
parameters O 
near O 
to O 
the O 
normal O 
status O 
through O 
antioxidant O 
activity O 
and O 
/ O 
or O 
by O 
preventing O 
bioaccumulation O 
of O 
Pb B-FORMULA 
within O 
the O 
tissues O 
of O 
experimental O 
rats O 
. O 
Presence O 
of O 
substantial O 
quantity O 
of O 
phenolics B-FAMILY 
and O 
flavonoids B-FAMILY 
in O 
the O 
extract O 
may O 
be O 
responsible O 
for O 
the O 
observed O 
protective O 
role O 
against O 
Pb B-FORMULA 
-intoxication O 
. O 

organometallic O 
chemistry O 
of O 
cycloheptatrienyl B-SYSTEMATIC 
zirconium I-SYSTEMATIC 
complexes O 
. O 

tutorial O 
review O 
summarizes O 
the O 
organometallic O 
chemistry O 
derived O 
from O 
the O 
half O 
- O 
sandwich O 
complex O 
[ O 
(η(7)-C(7)H(7))ZrCl(tmeda) B-FORMULA 
] O 
, O 
which O 
was O 
used O 
as O 
an O 
efficient O 
and O 
versatile O 
starting O 
material O 
for O 
the O 
incorporation O 
of O 
monoanionic O 
ligands O 
into O 
the O 
cycloheptatrienyl B-SYSTEMATIC 
zirconium I-SYSTEMATIC 
coordination O 
sphere O 
by O 
conventional O 
salt O 
metathesis O 
reactions O 
. O 
A O 
broad O 
variety O 
of O 
ligands O 
was O 
employed O 
, O 
affording O 
novel O 
and O 
previously O 
inaccessible O 
cycloheptatrienyl B-SYSTEMATIC 
( O 
sandwich O 
) O 
complexes O 
of O 
the O 
type O 
[ O 
(η(7)-C(7)H(7))Zr(Y) B-FORMULA 
] O 
; O 
Y O 
comprises O 
pentadienyl B-SYSTEMATIC 
, O 
cyclopentadienyl B-SYSTEMATIC 
, O 
allyl B-SYSTEMATIC 
, O 
phospholyl B-SYSTEMATIC 
, O 
boratabenzene B-SYSTEMATIC 
, O 
imidazolin-2-iminato B-SYSTEMATIC 
and O 
amido B-SYSTEMATIC 
systems O 
. O 
The O 
cycloheptatrienyl B-SYSTEMATIC 
ring O 
in O 
these O 
systems O 
usually O 
acts O 
as O 
an O 
" O 
innocent O 
spectator O 
ligand O 
" O 
, O 
but O 
reactivity O 
can O 
arise O 
from O 
the O 
second O 
ligand O 
Y O 
or O 
the O 
Lewis O 
acidity O 
of O 
the O 
, O 
formally O 
, O 
Zr(+iv) B-FORMULA 
center O 
, O 
which O 
was O 
probed O 
in O 
selected O 
examples O 
and O 
put O 
in O 
perspective O 
to O 
related O 
studies O 
. O 
The O 
corresponding O 
results O 
emphasize O 
why O 
the O 
use O 
of O 
[ O 
(η(7)-C(7)H(7))ZrCl(tmeda) B-FORMULA 
] O 
is O 
clearly O 
an O 
advancement O 
in O 
the O 
chemistry O 
of O 
the O 
still O 
fairly O 
unexplored O 
area O 
of O 
cycloheptatrienyl B-FAMILY 
transition I-FAMILY 
metal I-FAMILY 
complexes I-FAMILY 
. O 

/ I-MULTIPLE 
pyridodithiazine I-MULTIPLE 
1,1-Dioxides I-MULTIPLE 
Structurally O 
Related O 
to O 
the O 
ATP B-ABBREVIATION 
-Sensitive O 
Potassium B-SYSTEMATIC 
Channel O 
Openers O 
1,2,4-Benzo B-FAMILY 
/ I-FAMILY 
pyridothiadiazine I-FAMILY 
1,1-Dioxides I-FAMILY 
Exert O 
a O 
Myorelaxant O 
Activity O 
Linked O 
to O 
a O 
Distinct O 
Mechanism O 
of O 
Action O 
. O 

synthesis O 
of O 
diversely O 
substituted O 
3-alkyl B-MULTIPLE 
/ I-MULTIPLE 
aralkyl I-MULTIPLE 
/ I-MULTIPLE 
arylamino-1,4,2-benzodithiazine I-MULTIPLE 
1,1-dioxides I-MULTIPLE 
and O 
3-alkylaminopyrido[4,3-e]-1,4,2-dithiazine B-FAMILY 
1,1-dioxides I-FAMILY 
is O 
described O 
. O 
Their O 
biological O 
activities O 
on O 
pancreatic O 
β-cells O 
and O 
on O 
smooth O 
muscle O 
cells O 
were O 
compared O 
to O 
those O 
of O 
the O 
reference O 
ATP B-ABBREVIATION 
-sensitive O 
potassium B-SYSTEMATIC 
channel O 
( O 
KATP O 
channel O 
) O 
openers O 
diazoxide B-SYSTEMATIC 
and O 
7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine B-SYSTEMATIC 
1,1-dioxide I-SYSTEMATIC 
. O 
The O 
aim O 
was O 
to O 
assess O 
the O 
impact O 
on O 
biological O 
activities O 
of O 
the O 
replacement O 
of O 
the O 
1,2,4-thiadiazine B-SYSTEMATIC 
ring O 
by O 
an O 
isosteric O 
1,4,2-dithiazine B-SYSTEMATIC 
ring O 
. O 
Most O 
of O 
the O 
dithiazine B-FAMILY 
analogues O 
were O 
found O 
to O 
be O 
inactive O 
on O 
the O 
pancreatic O 
tissue O 
, O 
although O 
some O 
compounds O 
bearing O 
a O 
1-phenylethylamino B-SYSTEMATIC 
side O 
chain O 
at O 
the O 
3- O 
position O 
exerted O 
a O 
marked O 
myorelaxant O 
activity O 
. O 
Such O 
an O 
effect O 
did O 
not O 
appear O 
to O 
be O 
related O 
to O 
the O 
opening O 
of O 
KATP O 
channels O 
but O 
rather O 
reflected O 
a O 
mechanism O 
of O 
action O 
similar O 
to O 
that O 
of O 
calcium B-SYSTEMATIC 
channel O 
blockers O 
. O 
Tightly O 
related O 
3-(1-phenylethyl)sulfanyl-4H-1,2,4-benzothiadiazine B-FAMILY 
1,1-dioxides I-FAMILY 
were O 
also O 
found O 
to O 
exert O 
a O 
pronounced O 
myorelaxant O 
activity O 
, O 
resulting O 
from O 
both O 
a O 
KATP O 
channel O 
activation O 
and O 
a O 
calcium B-SYSTEMATIC 
channel O 
blocker O 
mechanism O 
. O 
The O 
present O 
work O 
highlights O 
the O 
critical O 
importance O 
of O 
an O 
intracyclic O 
NH B-FORMULA 
group O 
at O 
the O 
4- O 
position O 
, O 
as O 
well O 
as O 
an O 
exocyclic O 
NH B-FORMULA 
group O 
linked O 
to O 
the O 
3- O 
position O 
of O 
the O 
benzo- B-MULTIPLE 
and I-MULTIPLE 
pyridothiadiazine I-MULTIPLE 
dioxides I-MULTIPLE 
, O 
for O 
activity O 
on O 
KATP O 
channels O 
. O 

type O 
II O 
fatty B-FAMILY 
acid I-FAMILY 
biosynthesis O 
( O 
FAS O 
II O 
) O 
inhibitors O 
as O 
multistage O 
antimalarial O 
agents O 
. O 

is O 
a O 
potentially O 
fatal O 
disease O 
caused O 
by O 
Plasmodium O 
parasites O 
and O 
poses O 
a O 
major O 
medical O 
risk O 
in O 
large O 
parts O 
of O 
the O 
world O 
. O 
The O 
development O 
of O 
new O 
, O 
affordable O 
antimalarial O 
drugs O 
is O 
of O 
vital O 
importance O 
as O 
there O 
are O 
increasing O 
reports O 
of O 
resistance O 
to O 
the O 
currently O 
available O 
therapeutics O 
. O 
In O 
addition O 
, O 
most O 
of O 
the O 
current O 
drugs O 
used O 
for O 
chemoprophylaxis O 
merely O 
act O 
on O 
parasites O 
already O 
replicating O 
in O 
the O 
blood O 
. O 
At O 
this O 
point O 
, O 
a O 
patient O 
might O 
already O 
be O 
suffering O 
from O 
the O 
symptoms O 
associated O 
with O 
the O 
disease O 
and O 
could O 
additionally O 
be O 
infectious O 
to O 
an O 
Anopheles O 
mosquito O 
. O 
These O 
insects O 
act O 
as O 
a O 
vector O 
, O 
subsequently O 
spreading O 
the O 
disease O 
to O 
other O 
humans O 
. O 
In O 
order O 
to O 
cure O 
not O 
only O 
malaria O 
but O 
prevent O 
transmission O 
as O 
well O 
, O 
a O 
drug O 
must O 
target O 
both O 
the O 
blood- O 
and O 
pre O 
- O 
erythrocytic O 
liver O 
stages O 
of O 
the O 
parasite O 
. O 
P O 
. O 
falciparum O 
( O 
Pf O 
) O 
enoyl B-FAMILY 
acyl I-FAMILY 
carrier O 
protein O 
( O 
ACP O 
) O 
reductase O 
( O 
ENR O 
) O 
is O 
a O 
key O 
enzyme O 
of O 
plasmodial O 
type O 
II O 
fatty B-FAMILY 
acid I-FAMILY 
biosynthesis O 
( O 
FAS O 
II O 
) O 
. O 
It O 
has O 
been O 
shown O 
to O 
be O 
essential O 
for O 
liver O 
- O 
stage O 
development O 
of O 
Plasmodium O 
berghei O 
and O 
is O 
therefore O 
qualified O 
as O 
a O 
target O 
for O 
true O 
causal O 
chemoprophylaxis O 
. O 
Using O 
virtual O 
screening O 
based O 
on O 
two O 
crystal O 
structures O 
of O 
PfENR O 
, O 
we O 
identified O 
a O 
structurally O 
novel O 
class O 
of O 
FAS O 
inhibitors O 
. O 
Subsequent O 
chemical O 
optimization O 
yielded O 
two O 
compounds O 
that O 
are O 
effective O 
against O 
multiple O 
stages O 
of O 
the O 
malaria O 
parasite O 
. O 
These O 
two O 
most O 
promising O 
derivatives O 
were O 
found O 
to O 
inhibit O 
blood O 
- O 
stage O 
parasite O 
growth O 
with O 
IC(50) O 
values O 
of O 
1.7 O 
and O 
3 O 
μM O 
and O 
lead O 
to O 
a O 
more O 
prominent O 
developmental O 
attenuation O 
of O 
liver O 
- O 
stage O 
parasites O 
than O 
the O 
gold O 
- O 
standard O 
drug O 
, O 
primaquine B-TRIVIAL 
. O 

naphthoquinone O 
diospyrin B-TRIVIAL 
is O 
an O 
inhibitor O 
of O 
DNA O 
gyrase O 
with O 
a O 
novel O 
mechanism O 
of O 
action O 
. O 

and O 
other O 
bacterial O 
diseases O 
represent O 
a O 
significant O 
threat O 
to O 
human O 
health O 
. O 
The O 
DNA O 
topoisomerases O 
are O 
excellent O 
targets O 
for O 
chemotherapy O 
, O 
and O 
DNA O 
gyrase O 
in O 
particular O 
is O 
a O 
well O 
- O 
validated O 
target O 
for O 
antibacterial O 
agents O 
. O 
Naphthoquinones B-FAMILY 
( O 
e.g O 
. O 
diospyrin B-TRIVIAL 
and O 
7-methyljuglone B-SYSTEMATIC 
) O 
have O 
been O 
shown O 
to O 
have O 
therapeutic O 
potential O 
, O 
particularly O 
against O 
Mycobacterium O 
tuberculosis O 
. O 
We O 
have O 
found O 
that O 
these O 
compounds O 
are O 
inhibitors O 
of O 
the O 
supercoiling O 
reaction O 
catalyzed O 
by O 
M O 
. O 
tuberculosis O 
gyrase O 
and O 
other O 
gyrases O 
. O 
Our O 
evidence O 
strongly O 
suggests O 
that O 
the O 
compounds O 
bind O 
to O 
the O 
N B-FORMULA 
-terminal O 
domain O 
of O 
GyrB O 
, O 
which O 
contains O 
the O 
ATPase O 
active O 
site O 
, O 
but O 
are O 
not O 
competitive O 
inhibitors O 
of O 
the O 
ATPase O 
reaction O 
. O 
We O 
propose O 
that O 
naphthoquinones B-FAMILY 
bind O 
to O 
GyrB O 
at O 
a O 
novel O 
site O 
close O 
to O 
the O 
ATPase O 
site O 
. O 
This O 
novel O 
mode O 
of O 
action O 
could O 
be O 
exploited O 
to O 
develop O 
new O 
antibacterial O 
agents O 
. O 

- O 
kynurenine B-TRIVIAL 
hypothesis O 
of O 
depression O 
: O 
historical O 
overview O 
and O 
recent O 
developments O 
. O 

mini O 
- O 
review O 
focuses O 
on O 
the O 
studies O 
of O 
late O 
Prof O 
. O 
IP O 
Lapin O 
( O 
1903 O 
- O 
2012 O 
) O 
and O 
his O 
research O 
team O 
on O 
the O 
role O 
of O 
methoxyindole B-SYSTEMATIC 
and O 
kynurenine B-TRIVIAL 
( O 
KYN B-ABBREVIATION 
) O 
pathways O 
of O 
tryptophan B-TRIVIAL 
( O 
TRP B-ABBREVIATION 
) O 
metabolism O 
in O 
the O 
pathogenesis O 
of O 
depression O 
and O 
action O 
mechanisms O 
of O 
antidepressant O 
effect O 
. O 
In O 
the O 
late O 
60s O 
of O 
the O 
last O 
century O 
Prof O 
. O 
IP O 
Lapin O 
suggested O 
that O 
" O 
intensification O 
of O 
central O 
serotoninergic O 
processes O 
is O 
a O 
determinant O 
of O 
the O 
thymoleptic O 
( O 
mood O 
elevating O 
) O 
component O 
" O 
while O 
" O 
activation O 
of O 
noradrenergic O 
processes O 
is O 
responsible O 
for O 
psychoenergetic O 
and O 
motor O 
- O 
stimulating O 
component O 
of O 
the O 
clinical O 
antidepressant O 
effect O 
" O 
. O 
The O 
cause O 
of O 
serotonin B-TRIVIAL 
deficiency O 
in O 
depression O 
was O 
attributed O 
to O 
the O 
shunt O 
of O 
TRP B-ABBREVIATION 
" O 
metabolism O 
away O 
from O 
serotonin B-TRIVIAL 
production O 
towards O 
KYN B-ABBREVIATION 
production O 
" O 
due O 
to O 
cortisol B-TRIVIAL 
-induced O 
activation O 
of O 
liver O 
enzyme O 
, O 
tryptophan B-TRIVIAL 
2,3- O 
dioxygenase O 
, O 
the O 
rate O 
- O 
limiting O 
enzyme O 
of O 
TRP B-ABBREVIATION 
- O 
KYN B-ABBREVIATION 
pathway O 
. O 
Prof O 
. O 
Lapin O 
suggested O 
and O 
discovered O 
that O 
KYN B-ABBREVIATION 
and O 
its O 
metabolites O 
affect O 
brain O 
functions O 
, O 
and O 
proposed O 
the O 
role O 
of O 
neurokynurenines O 
in O 
pathogenesis O 
of O 
depression O 
and O 
action O 
mechanisms O 
of O 
antidepressant O 
effect O 
( O 
kynurenine B-TRIVIAL 
hypothesis O 
) O 
. O 
Further O 
research O 
suggested O 
the O 
antidepressant O 
and O 
cognition- O 
enhancing O 
effects O 
of O 
post- O 
serotonin B-TRIVIAL 
metabolite O 
, O 
N-acetylserotonin B-SYSTEMATIC 
( O 
NAS B-ABBREVIATION 
) O 
, O 
an O 
agonist O 
to O 
tyrosine B-TRIVIAL 
kinase O 
B O 
( O 
TrkB O 
) O 
receptor O 
; O 
and O 
link O 
between O 
depression O 
and O 
chronic O 
inflammation O 
- O 
associated O 
disorders O 
( O 
e.g O 
. O 
, O 
insulin O 
resistance O 
, O 
hepatitis O 
C O 
virus O 
) O 
via O 
inflammation O 
- O 
induced O 
activation O 
of O 
indoleamine B-SYSTEMATIC 
2,3- O 
dioxygenase O 
, O 
brain O 
located O 
rate O 
- O 
limiting O 
enzyme O 
of O 
TRY B-ABBREVIATION 
- O 
KYN B-ABBREVIATION 
metabolism O 
. O 
NAS B-ABBREVIATION 
and O 
kynurenines B-FAMILY 
might O 
be O 
the O 
targets O 
for O 
prevention O 
and O 
treatment O 
of O 
depression O 
and O 
associated O 
conditions O 
. O 

of O 
intracellular O 
delivery O 
of O 
doxorubicin B-TRIVIAL 
from O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
nanoparticles O 
by O 
means O 
of O 
fluorescence O 
lifetime O 
imaging O 
and O 
confocal O 
Raman O 
microscopy O 
. O 

intracellular O 
delivery O 
of O 
Doxorubicin B-TRIVIAL 
( O 
Dox B-ABBREVIATION 
) O 
from O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
( O 
PLGA B-ABBREVIATION 
) O 
nanoparticles O 
stabilised O 
with O 
bovine O 
serum O 
albumin O 
, O 
in O 
HepG2 O 
cells O 
, O 
is O 
studied O 
via O 
flow O 
cytometry O 
, O 
fluorescence O 
lifetime O 
imaging O 
microscopy O 
( O 
FLIM O 
) O 
, O 
confocal O 
Raman O 
microscopy O 
( O 
CRM O 
) O 
and O 
cell O 
viability O 
studies O 
. O 
Flow O 
cytometry O 
shows O 
that O 
the O 
initial O 
uptake O 
of O 
PLGA B-ABBREVIATION 
and O 
Dox B-ABBREVIATION 
follow O 
the O 
same O 
kinetics O 
. O 
However O 
, O 
following O 
8 O 
h O 
of O 
incubation O 
, O 
the O 
fluorescence O 
intensity O 
and O 
cellular O 
uptake O 
of O 
Dox B-ABBREVIATION 
decreases O 
, O 
while O 
in O 
the O 
case O 
of O 
PLGA B-ABBREVIATION 
both O 
parameters O 
remain O 
constant O 
. O 
FLIM O 
shows O 
the O 
presence O 
of O 
a O 
single O 
- O 
lifetime O 
species O 
, O 
with O 
a O 
lifetime O 
of O 
1.15 O 
ns O 
when O 
measured O 
inside O 
the O 
cells O 
. O 
Cell O 
viability O 
decreases O 
by O 
approximately O 
20% O 
when O 
incubated O 
for O 
24 O 
h O 
with O 
PLGA B-ABBREVIATION 
loaded O 
with O 
Dox B-ABBREVIATION 
, O 
with O 
a O 
particle O 
concentration O 
of O 
100 O 
µg O 
· O 
mL(-1) O 
. O 
At O 
the O 
single O 
- O 
cell O 
level O 
, O 
CRM O 
shows O 
changes O 
in O 
the O 
bands O 
from O 
DNA O 
and O 
proteins O 
in O 
the O 
cell O 
nucleus O 
when O 
incubated O 
with O 
PLGA B-ABBREVIATION 
loaded O 
with O 
Dox B-ABBREVIATION 
. O 

polymerase O 
II O 
( O 
Pol O 
II O 
) O 
is O 
a O 
well O 
- O 
characterized O 
DNA-dependent O 
RNA O 
polymerase O 
, O 
which O 
has O 
also O 
been O 
reported O 
to O 
have O 
RNA-dependent O 
RNA O 
polymerase O 
( O 
RdRP O 
) O 
activity O 
. O 
Natural O 
cellular O 
RNA O 
substrates O 
of O 
mammalian O 
Pol O 
II O 
, O 
however O 
, O 
have O 
not O 
been O 
identified O 
and O 
the O 
cellular O 
function O 
of O 
the O 
Pol O 
II O 
RdRP O 
activity O 
is O 
unknown O 
. O 
We O 
found O 
that O 
Pol O 
II O 
can O 
use O 
a O 
non-coding O 
RNA O 
, O 
B2 O 
RNA O 
, O 
as O 
both O 
a O 
substrate O 
and O 
a O 
template O 
for O 
its O 
RdRP O 
activity O 
. O 
Pol O 
II O 
extends O 
B2 O 
RNA O 
by O 
18 O 
nt O 
on O 
its O 
3'-end O 
in O 
an O 
internally O 
templated O 
reaction O 
. O 
The O 
RNA O 
product O 
resulting O 
from O 
extension O 
of O 
B2 O 
RNA O 
by O 
the O 
Pol O 
II O 
RdRP O 
can O 
be O 
removed O 
from O 
Pol O 
II O 
by O 
a O 
factor O 
present O 
in O 
nuclear O 
extracts O 
. O 
Treatment O 
of O 
cells O 
with O 
α-amanitin B-TRIVIAL 
or O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
revealed O 
that O 
extension O 
of O 
B2 O 
RNA O 
by O 
Pol O 
II O 
destabilizes O 
the O 
RNA O 
. O 
Our O 
studies O 
provide O 
compelling O 
evidence O 
that O 
mammalian O 
Pol O 
II O 
acts O 
as O 
an O 
RdRP O 
to O 
control O 
the O 
stability O 
of O 
a O 
cellular O 
RNA O 
by O 
extending O 
its O 
3'-end O 
. O 

- O 
one O 
samples O 
of O 
traditionally O 
- O 
prepared O 
( O 
home O 
- O 
made O 
) O 
and O 
ready O 
- O 
made O 
( O 
commercial O 
) O 
St O 
. O 
John's O 
Wort O 
olive O 
oil O 
macerates O 
were O 
profiled O 
for O 
their O 
in O 
vitro O 
antimicrobial O 
and O 
antiprotozoal O 
activity O 
. O 
Their O 
cytotoxic O 
potential O 
was O 
evaluated O 
on O 
MRC-5 O 
fibroblasts O 
. O 
In O 
the O 
antiprotozoal O 
assays O 
, O 
ten O 
of O 
the O 
oils O 
inhibited O 
Trypanosoma O 
brucei O 
rhodesiense O 
( O 
IC(50) O 
15.9-64.5 O 
μg O 
/ O 
mL O 
) O 
, O 
while O 
only O 
one O 
oil O 
exerted O 
antimicrobial O 
activity O 
towards O 
Staphylococcus O 
aureus O 
( O 
IC(50)=88.7 O 
μg O 
/ O 
mL O 
) O 
. O 
LC-DAD-MS O 
data O 
revealed O 
the O 
presence O 
of O 
pseudohypericin B-TRIVIAL 
( O 
0.135-3.280 O 
μg O 
/ O 
g O 
) O 
and O 
hypericin B-TRIVIAL 
( O 
0.277-6.634 O 
μg O 
/ O 
g O 
) O 
in O 
all O 
the O 
oils O 
, O 
whereas O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1.063 O 
μg O 
/ O 
g O 
) O 
was O 
detected O 
only O 
in O 
one O 
oil O 
sample O 
. O 
Hyperforin B-TRIVIAL 
was O 
detected O 
in O 
four O 
( O 
0.977-2.399 O 
μg O 
/ O 
g O 
) O 
and O 
adhyperforin B-TRIVIAL 
in O 
six O 
samples O 
( O 
0.005-3.165 O 
μg O 
/ O 
g O 
) O 
. O 
Hypericin B-TRIVIAL 
and O 
pseudohypericin B-TRIVIAL 
were O 
common O 
in O 
the O 
active O 
oils O 
, O 
whereas O 
hyperforin B-TRIVIAL 
, O 
adhyperforin B-TRIVIAL 
, O 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
were O 
absent O 
in O 
these O 
samples O 
. O 
Our O 
results O 
indicated O 
that O 
if O 
the O 
correct O 
plant O 
material O 
is O 
used O 
, O 
the O 
infused O 
oils O 
from O 
Hypericum O 
perforatum O 
may O 
contain O 
active O 
components O 
. O 

Co3O4 B-FORMULA 
particles O 
threaded O 
by O 
carbon B-SYSTEMATIC 
nanotube O 
arrays O 
as O 
integrated O 
structure O 
anodes O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 

Co3O4 B-FORMULA 
particles O 
threaded O 
by O 
ultra O 
- O 
long O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
MWCNT O 
) O 
arrays O 
were O 
prepared O 
by O 
a O 
hydrothermal O 
process O 
and O 
subsequent O 
calcination O 
. O 
The O 
Co3O4 B-FORMULA 
octahedron O 
with O 
the O 
( O 
111 O 
) O 
facets O 
attaches O 
to O 
MWCNTs O 
uniformly O 
and O 
closely O 
. O 
The O 
composite O 
can O 
be O 
used O 
as O 
an O 
integrated O 
anode O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
( O 
LIBs O 
) O 
without O 
any O 
other O 
additives O 
( O 
such O 
as O 
conductive O 
additives O 
and O 
polymer O 
binder O 
) O 
, O 
which O 
exhibits O 
a O 
high O 
reversible O 
capacity O 
of O 
725 O 
mA O 
h O 
g(-1) O 
at O 
a O 
current O 
density O 
of O 
100 O 
mA O 
g(-1) O 
, O 
and O 
excellent O 
cyclic O 
stability O 
without O 
capacity O 
degradation O 
over O 
100 O 
cycles O 
at O 
a O 
current O 
density O 
of O 
500 O 
mA O 
g(-1) O 
. O 
The O 
high O 
performance O 
can O 
be O 
attributed O 
to O 
the O 
unique O 
structure O 
: O 
(i) O 
the O 
ultra O 
- O 
long O 
MWCNT O 
array O 
facilitates O 
fast O 
electron O 
transfer O 
; O 
(ii) O 
the O 
tight O 
adhesion O 
between O 
Co3O4 B-FORMULA 
and O 
MWCNTs O 
prevents O 
particle O 
drifting O 
and O 
agglomeration O 
; O 
(iii) O 
the O 
free O 
space O 
between O 
MWCNTs O 
promotes O 
fast O 
ion O 
transport O 
and O 
alleviates O 
the O 
large O 
volume O 
variation O 
during O 
discharge O 
- O 
charge O 
process O 
. O 
This O 
work O 
demonstrates O 
the O 
great O 
potential O 
of O 
MWCNT O 
arrays O 
as O 
substrate O 
and O 
provides O 
insights O 
for O 
the O 
design O 
and O 
direct O 
use O 
of O 
MWCNT O 
array O 
- O 
based O 
materials O 
in O 
LIBs O 
, O 
which O 
will O 
be O 
helpful O 
for O 
future O 
development O 
of O 
high O 
- O 
performance O 
electrode O 
materials O 
. O 

effects O 
of O 
gender O 
difference O 
on O 
monocrotaline B-TRIVIAL 
-induced O 
pulmonary O 
hypertension O 
in O 
rats O 
. O 

present O 
study O 
aimed O 
to O 
compare O 
the O 
effect O 
of O 
gender O 
difference O 
on O 
hemodynamic O 
consequences O 
in O 
the O 
development O 
of O 
monocrotaline B-TRIVIAL 
( O 
MCT B-ABBREVIATION 
)-induced O 
pulmonary O 
hypertension O 
in O 
rat O 
. O 
The O 
effect O 
of O 
antioxidant O 
enzyme O 
systems O 
on O 
the O 
development O 
of O 
pulmonary O 
hypertension O 
mediated O 
by O 
the O 
phytotoxin O 
MCT B-ABBREVIATION 
and O 
the O 
effect O 
of O 
gender O 
on O 
these O 
antioxidant O 
systems O 
were O 
also O 
investigated O 
. O 
For O 
this O 
purpose O 
, O 
the O 
right O 
ventricular O 
pressures O 
( O 
RVPs O 
) O 
and O 
right O 
ventricular O 
/ O 
heart O 
weight O 
( O 
HW O 
) O 
ratios O 
were O 
compared O 
between O 
groups O 
and O 
the O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
level O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
activities O 
were O 
determined O 
in O 
lung O 
and O 
liver O 
tissue O 
samples O 
of O 
rats O 
. O 
RVP O 
and O 
right O 
ventricular O 
/ O 
HW O 
ratios O 
significantly O 
increased O 
in O 
the O 
MCT B-ABBREVIATION 
group O 
compared O 
to O 
the O 
control O 
group O 
. O 
In O 
the O 
MCT B-ABBREVIATION 
group O 
, O 
RVP O 
was O 
significantly O 
higher O 
in O 
males O 
than O 
females O 
. O 
MCT B-ABBREVIATION 
-induced O 
pulmonary O 
hypertension O 
resulted O 
in O 
decreased O 
GSH B-ABBREVIATION 
level O 
, O 
decreased O 
GST O 
and O 
SOD O 
activities O 
and O 
increased O 
CAT O 
activity O 
in O 
lung O 
and O 
liver O 
tissues O 
of O 
both O 
male O 
and O 
female O 
rats O 
. O 
In O 
addition O 
, O 
the O 
lung O 
and O 
liver O 
GSH B-ABBREVIATION 
level O 
and O 
GST O 
and O 
SOD O 
levels O 
were O 
higher O 
in O 
female O 
control O 
rats O 
compared O 
to O 
male O 
control O 
rats O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
, O 
that O 
antioxidant O 
enzyme O 
activities O 
were O 
different O 
between O 
the O 
groups O 
, O 
highlight O 
the O 
possible O 
role O 
of O 
oxidative O 
stress O 
in O 
the O 
pathogenesis O 
of O 
MCT B-ABBREVIATION 
-induced O 
pulmonary O 
hypertension O 
in O 
rats O 
. O 
Moreover O 
, O 
the O 
lower O 
antioxidant O 
defense O 
capacity O 
of O 
male O 
rats O 
than O 
female O 
rats O 
may O 
be O 
considered O 
as O 
a O 
cause O 
of O 
more O 
aggressive O 
course O 
of O 
MCT B-ABBREVIATION 
-induced O 
pulmonary O 
hypertension O 
in O 
males O 
compared O 
to O 
females O 
. O 

new O 
sesquiterpenoids B-FAMILY 
, O 
aristoyunnolins B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
an O 
artifact O 
of O 
isolation O 
[ O 
7-O-ethyl B-SYSTEMATIC 
madolin I-SYSTEMATIC 
W I-SYSTEMATIC 
( O 
7 O 
) O 
] O 
, O 
and O 
12 O 
known O 
analogues O 
were O 
isolated O 
from O 
stems O 
of O 
Aristolochia O 
yunnanensis O 
. O 
The O 
structures O 
were O 
determined O 
by O 
combined O 
chemical O 
and O 
spectral O 
methods O 
, O 
and O 
the O 
absolute O 
configurations O 
of O 
compounds O 
2 O 
, O 
3 O 
, O 
5-7 O 
, O 
9 O 
, O 
14 O 
, O 
and O 
17 O 
were O 
determined O 
by O 
the O 
modified O 
Mosher's O 
method O 
and O 
CD O 
analysis O 
. O 
Compounds O 
1-19 O 
were O 
screened O 
using O 
a O 
bioassay O 
system O 
designed O 
to O 
evaluate O 
the O 
effect O 
on O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
signaling O 
pathways O 
. O 
Among O 
three O 
MAPKs O 
( O 
ERK1 O 
/ O 
2 O 
, O 
JNK O 
, O 
and O 
p38 O 
) O 
, O 
compounds O 
1 O 
, O 
4 O 
, O 
10-13 O 
, O 
16 O 
, O 
18 O 
, O 
and O 
19 O 
exhibited O 
selective O 
inhibition O 
of O 
the O 
phosphorylation O 
of O 
ERK1 O 
/ O 
2 O 
. O 
Compounds O 
16 O 
and O 
19 O 
were O 
more O 
active O 
than O 
the O 
positive O 
control O 
PD98059 B-IDENTIFIER 
, O 
a O 
known O 
inhibitor O 
of O 
the O 
ERK1 O 
/ O 
2 O 
signaling O 
pathway O 
. O 

self O 
- O 
healing O 
encapsulation O 
of O 
vaccine O 
antigens O 
in O 
PLGA B-ABBREVIATION 
microspheres O 
. O 

, O 
we O 
describe O 
the O 
detailed O 
development O 
of O 
a O 
simple O 
and O 
effective O 
method O 
to O 
microencapsulate O 
vaccine O 
antigens O 
in O 
poly(lactic B-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
by O 
simple O 
mixing O 
of O 
preformed O 
active O 
self O 
- O 
microencapsulating O 
( O 
SM O 
) O 
PLGA B-ABBREVIATION 
microspheres O 
in O 
a O 
low O 
concentration O 
aqueous O 
antigen O 
solution O 
at O 
modest O 
temperature O 
( O 
10-38 O 
°C O 
) O 
. O 
Co-encapsulating O 
protein O 
- O 
sorbing O 
vaccine O 
adjuvants O 
and O 
polymer O 
plasticizers O 
were O 
used O 
to O 
" O 
actively O 
" O 
load O 
the O 
protein O 
in O 
the O 
polymer O 
pores O 
and O 
facilitate O 
polymer O 
self O 
- O 
healing O 
at O 
a O 
temperature O 
> O 
the O 
hydrated O 
polymer O 
glass O 
transition O 
temperature O 
, O 
respectively O 
. O 
The O 
microsphere O 
formulation O 
parameters O 
and O 
loading O 
conditions O 
to O 
provide O 
optimal O 
active O 
self O 
- O 
healing O 
microencapsulation O 
of O 
vaccine O 
antigens O 
in O 
PLGA B-ABBREVIATION 
was O 
investigated O 
. O 
Active O 
self O 
- O 
healing O 
encapsulation O 
of O 
two O 
antigens O 
, O 
ovalbumin O 
and O 
tetanus O 
toxoid O 
( O 
TT O 
) O 
, O 
in O 
PLGA B-ABBREVIATION 
microspheres O 
was O 
adjusted O 
by O 
preparing O 
blank O 
microspheres O 
containing O 
different O 
vaccine O 
adjuvants O 
( O 
aluminum B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
( O 
Al(OH)₃ B-FORMULA 
) O 
or O 
calcium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
) O 
. O 
Active O 
loading O 
of O 
vaccine O 
antigen O 
in O 
Al(OH)₃ B-FORMULA 
- O 
PLGA B-ABBREVIATION 
microspheres O 
was O 
found O 
to O 
: O 
a O 
) O 
increase O 
with O 
an O 
increasing O 
loading O 
of O 
Al(OH)₃ B-FORMULA 
( O 
0.88-3 O 
wt.% O 
) O 
and O 
addition O 
of O 
porosigen O 
, O 
b O 
) O 
decrease O 
when O 
the O 
inner O 
Al(OH)₃ B-FORMULA 
/ O 
trehalose B-TRIVIAL 
phase O 
to O 
1 O 
mL O 
outer O 
oil O 
phase O 
and O 
size O 
of O 
microspheres O 
was O 
respectively O 
> O 
0.2 O 
mL O 
and O 
63 O 
μm O 
, O 
and O 
c O 
) O 
change O 
negligibly O 
by O 
PLGA B-ABBREVIATION 
concentration O 
and O 
initial O 
incubation O 
( O 
loading O 
) O 
temperature O 
. O 
Encapsulation O 
of O 
protein O 
sorbing O 
Al(OH)₃ B-FORMULA 
in O 
PLGA B-ABBREVIATION 
microspheres O 
resulted O 
in O 
suppression O 
of O 
self O 
- O 
healing O 
of O 
PLGA B-ABBREVIATION 
pores O 
, O 
which O 
was O 
then O 
overcome O 
by O 
improving O 
polymer O 
chain O 
mobility O 
, O 
which O 
in O 
turn O 
was O 
accomplished O 
by O 
coincorporating O 
hydrophobic O 
plasticizers O 
in O 
PLGA B-ABBREVIATION 
. O 
Active O 
self O 
- O 
healing O 
microencapsulation O 
of O 
manufacturing O 
process O 
- O 
labile O 
TT O 
in O 
PLGA B-ABBREVIATION 
was O 
found O 
to O 
: O 
a O 
) O 
obviate O 
micronization- O 
and O 
organic O 
solvent-induced O 
TT O 
degradation O 
, O 
b O 
) O 
improve O 
antigen O 
loading O 
( O 
1.4-1.8 O 
wt.% O 
TT O 
) O 
and O 
encapsulation O 
efficiency O 
( O 
~97% O 
) O 
, O 
c O 
) O 
provide O 
nearly O 
homogeneous O 
distribution O 
and O 
stabilization O 
of O 
antigen O 
in O 
polymer O 
, O 
and O 
d O 
) O 
provide O 
improved O 
in O 
vitro O 
controlled O 
release O 
of O 
antigenic O 
TT O 
. O 

and O 
disposition O 
of O 
[14C]n-butyl-p-hydroxybenzoate B-SYSTEMATIC 
in O 
male O 
and O 
female O 
Harlan O 
Sprague O 
Dawley O 
rats O 
following O 
oral O 
administration O 
and O 
dermal O 
application O 
. O 

( O 
n-butylparaben B-SYSTEMATIC 
, O 
BPB B-ABBREVIATION 
) O 
is O 
an O 
antioxidant O 
used O 
in O 
foods O 
, O 
pharmaceuticals O 
and O 
cosmetics O 
. O 
This O 
study O 
investigated O 
the O 
disposition O 
of O 
ring O 
- O 
labelled O 
[(14)C]BPB B-SYSTEMATIC 
in O 
Harlan O 
Sprague O 
Dawley O 
rats O 
, O 
and O 
in O 
rat O 
and O 
human O 
hepatocytes O 
. O 
BPB B-ABBREVIATION 
was O 
rapidly O 
cleared O 
in O 
hepatocytes O 
from O 
rat O 
( O 
t(1 O 
/ O 
2 O 
) O 
= O 
3-4 O 
min O 
) O 
and O 
human O 
( O 
t(1 O 
/ O 
2 O 
) O 
= O 
20-30 O 
min O 
) O 
. O 
The O 
major O 
metabolites O 
detected O 
in O 
rat O 
hepatocytes O 
were O 
hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
in O 
human O 
hepatocytes O 
were O 
hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
hydroxyhippuric B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
[(14)C]BPB B-SYSTEMATIC 
was O 
administered O 
to O 
male O 
rats O 
orally O 
at O 
10 O 
, O 
100 O 
or O 
1000 O 
mg O 
/ O 
kg O 
, O 
intravenously O 
at O 
10 O 
mg O 
/ O 
kg O 
and O 
dermally O 
at O 
10 O 
and O 
100 O 
mg O 
/ O 
kg O 
; O 
female O 
rats O 
were O 
administered O 
oral O 
doses O 
at O 
10 O 
mg O 
/ O 
kg O 
. O 
Oral O 
doses O 
of O 
BPB B-ABBREVIATION 
were O 
well O 
- O 
absorbed O 
( O 
> O 
83% O 
) O 
and O 
eliminated O 
chiefly O 
in O 
urine O 
( O 
83-84% O 
) O 
; O 
≤ O 
1% O 
of O 
the O 
radioactivity O 
remained O 
in O 
tissues O 
at O 
24 O 
h O 
or O 
72 O 
h O 
after O 
dosing O 
. O 
About O 
4% O 
and O 
8% O 
, O 
respectively O 
, O 
of O 
100 O 
mg O 
/ O 
kg O 
dermal O 
doses O 
were O 
absorbed O 
in O 
24 O 
h O 
and O 
72 O 
h O 
, O 
and O 
about O 
50% O 
of O 
a O 
10 O 
mg O 
/ O 
kg O 
dose O 
was O 
absorbed O 
in O 
72 O 
h O 
. O 
Metabolites O 
detected O 
in O 
urine O 
included O 
those O 
previously O 
reported O 
, O 
BPB-glucuronide B-TRIVIAL 
, O 
BPB-sulfate B-SYSTEMATIC 
, O 
hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
hydroxyhippuric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
but O 
also O 
novel O 
metabolites O 
arising O 
from O 
ring O 
hydroxylation O 
followed O 
by O 
glucuronidation O 
and O 
sulfation O 
. O 

aqueous O 
self O 
- O 
assembled O 
micellar O 
system O 
( O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
SDS B-ABBREVIATION 
, O 
decorated O 
with O 
various O 
adhesive O 
sites O 
, O 
cryptand B-FAMILY 
Kryptofix B-TRIVIAL 
222 I-TRIVIAL 
and O 
crown B-FAMILY 
ether I-FAMILY 
18-Crown-6 B-SYSTEMATIC 
molecules O 
) O 
has O 
been O 
investigated O 
by O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
and O 
small O 
angle O 
x-ray O 
scattering O 
( O 
SAXS O 
) O 
to O 
have O 
insights O 
into O 
the O 
micellar O 
structure O 
, O 
the O 
micellar O 
interactions O 
, O 
and O 
the O 
aggregation O 
properties O 
of O 
the O 
system O 
. O 
DLS O 
demonstrates O 
the O 
existence O 
of O 
populations O 
of O 
aggregates O 
in O 
the O 
submicrometer O 
/ O 
micrometer O 
range O 
, O 
while O 
the O 
Guinier O 
analysis O 
of O 
the O 
SAXS O 
curves O 
helps O 
in O 
detailing O 
objects O 
smaller O 
than O 
30 O 
nm O 
. O 
The O 
aggregates O 
of O 
micelles O 
are O 
here O 
named O 
cluster O 
phases O 
of O 
micelles O 
( O 
CPMs O 
) O 
. O 
Considering O 
that O 
SDS B-ABBREVIATION 
micelles O 
in O 
water O 
do O 
not O 
aggregate O 
at O 
low O 
concentration O 
, O 
it O 
is O 
shown O 
that O 
macrocyclic O 
ligands O 
induce O 
the O 
SDS B-ABBREVIATION 
micelle O 
aggregation O 
as O 
a O 
function O 
of O 
the O 
concentration O 
( O 
i.e O 
. O 
, O 
investigated O 
ligand/ O 
SDS B-ABBREVIATION 
molar O 
ratios O 
are O 
5 O 
, O 
1.5 O 
, O 
1 O 
, O 
and O 
0.5 O 
) O 
and O 
hydrophobicity O 
of O 
the O 
adhesive O 
sites O 
. O 
The O 
sizes O 
and O 
the O 
percentages O 
of O 
the O 
micelles O 
and O 
the O 
CPMs O 
have O 
been O 
monitored O 
to O 
test O 
the O 
stability O 
and O 
reversibility O 
of O 
the O 
system O 
. O 
DLS O 
results O 
clearly O 
show O 
that O 
the O 
aggregation O 
processes O 
of O 
the O 
decorated O 
micelles O 
are O 
reproducible O 
at O 
time O 
intervals O 
of O 
the O 
order O 
of O 
1 O 
month O 
, O 
while O 
the O 
stability O 
may O 
not O 
be O 
entirely O 
maintained O 
after O 
a O 
year O 
. O 
As O 
an O 
issue O 
of O 
particular O 
relevance O 
, O 
the O 
higher O 
the O 
ligand O 
/ O 
surfactant O 
molar O 
ratio O 
, O 
the O 
larger O 
are O 
the O 
CPMs O 
induced O 
. O 
The O 
K222 B-ABBREVIATION 
ligand O 
results O 
in O 
being O 
more O 
effective O 
in O 
promoting O 
the O 
micellar O 
aggregation O 
than O 
18C6 B-SYSTEMATIC 
as O 
a O 
consequence O 
of O 
the O 
different O 
hydrophobicity O 
. O 

to O 
lambda-cyhalothrin B-TRIVIAL 
, O 
a O 
synthetic O 
pyrethroid B-FAMILY 
, O 
increases O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
and O 
induces O 
genotoxicity O 
in O 
rat O 
peripheral O 
blood O 
. O 

( O 
LTC B-ABBREVIATION 
) O 
is O 
a O 
synthetic O 
pyrethroid B-FAMILY 
with O 
a O 
broad O 
spectrum O 
of O 
insecticidal O 
and O 
acaricidal O 
activities O 
used O 
to O 
control O 
a O 
wide O 
range O 
of O 
insect O 
pests O 
in O 
a O 
variety O 
of O 
applications O 
. O 
However O 
, O 
there O 
is O 
little O 
known O 
about O 
its O 
adverse O 
effects O 
, O 
in O 
particular O 
those O 
related O 
to O 
its O 
genotoxicity O 
in O 
humans O 
. O 
To O 
elucidate O 
the O 
genotoxicity O 
mechanisms O 
of O 
LTC B-ABBREVIATION 
, O 
the O 
micronuclei O 
( O 
MN O 
) O 
frequencies O 
, O 
the O 
levels O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
erythrocyte O 
osmotic O 
fragility O 
, O 
nitrite B-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
formation O 
, O 
protein O 
carbonyl B-FAMILY 
( O 
PCO O 
) O 
levels O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
production O 
were O 
evaluated O 
for O 
a O 
period O 
of O 
7 O 
, O 
14 O 
and O 
21 O 
days O 
. O 
Our O 
results O 
show O 
that O 
exposure O 
rat O 
to O 
LTC B-ABBREVIATION 
( O 
1 O 
/ O 
10DL50 O 
= O 
6.23 O 
mg O 
/ O 
kg O 
) O 
for O 
a O 
period O 
of O 
7 O 
, O 
14 O 
and O 
21 O 
days O 
induced O 
a O 
noticeable O 
genotoxic O 
effect O 
in O 
rat O 
peripheral O 
blood O 
evidenced O 
by O 
a O 
significant O 
increase O 
in O 
the O 
frequency O 
of O 
MN O 
only O 
at O 
day O 
21 O 
of O 
treatment O 
. O 
Significant O 
differences O 
between O 
the O 
two O 
groups O 
were O 
observed O 
in O 
erythrocyte O 
osmotic O 
fragility O 
. O 
Further O 
, O 
a O 
significant O 
( O 
p O 
< O 
0.01 O 
) O 
increase O 
in O 
ROS O 
contents O 
, O 
NO B-FORMULA 
formation O 
, O 
PCO O 
levels O 
and O 
lipid O 
peroxidation O 
in O 
erythrocytes O 
were O 
observed O 
at O 
different O 
times O 
of O 
treatments O 
, O 
suggesting O 
the O 
implication O 
of O 
oxidative O 
stress O 
in O 
its O 
toxicity O 
. O 
These O 
results O 
confirm O 
the O 
genotoxic O 
and O 
the O 
pro O 
- O 
oxidant O 
effects O 
of O 
LTC B-ABBREVIATION 
in O 
rat O 
peripheral O 
blood O 
. O 

UDP B-ABBREVIATION 
-glucuronyltransferase O 
2B15 O 
polymorphism O 
and O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
concentrations O 
in O 
blood O 
: O 
results O 
from O 
physiologically O 
based O 
kinetic O 
modelling O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
a O 
chemical O 
in O 
widespread O 
use O 
that O 
is O 
under O 
scientific O 
discussion O 
due O 
to O 
its O 
endocrine O 
activity O 
. O 
Controversies O 
exist O 
about O 
how O 
to O 
interpret O 
reportedly O 
high O 
blood O 
concentrations O 
measured O 
in O 
uncontrolled O 
situations O 
. O 
Physiologically O 
based O 
pharmaco- O 
/ O 
toxicokinetic O 
modelling O 
resulted O 
in O 
10-100-fold O 
lower O 
blood O 
concentrations O 
than O 
those O 
reported O 
. O 
Moreover O 
, O 
in O 
controlled O 
situations O 
, O 
BPA B-ABBREVIATION 
did O 
not O 
exceed O 
the O 
level O 
of O 
detection O 
( O 
< O 
0.3 O 
ng O 
/ O 
ml O 
) O 
in O 
human O 
blood O 
or O 
urine O 
. O 
Using O 
a O 
validated O 
human O 
PBK O 
model O 
, O 
this O 
study O 
investigated O 
the O 
influence O 
of O 
functionally O 
relevant O 
polymorphic O 
UGT2B15 O 
, O 
the O 
enzyme O 
mediating O 
BPA B-ABBREVIATION 
metabolism O 
, O 
on O 
the O 
BPA B-ABBREVIATION 
concentration O 
- O 
time O 
profile O 
in O 
human O 
blood O 
. O 
Maximum O 
concentrations O 
( O 
C O 
( O 
max O 
) O 
) O 
and O 
areas O 
under O 
the O 
curves O 
( O 
AUCs O 
) O 
in O 
blood O 
from O 
high O 
and O 
low O 
metabolisers O 
differed O 
by O 
a O 
factor O 
of O 
4.7 O 
and O 
4.6 O 
, O 
respectively O 
( O 
doses O 
: O 
1 O 
and O 
0.05 O 
μg O 
/ O 
kg O 
/ O 
day O 
) O 
. O 
Low O 
metabolisers O 
excreted O 
a O 
greater O 
proportion O 
of O 
BPA B-ABBREVIATION 
via O 
the O 
sulphate B-SYSTEMATIC 
pathway O 
compared O 
to O 
high O 
metabolisers O 
. O 
This O 
finding O 
explains O 
why O 
C O 
( O 
max O 
) O 
and O 
AUC O 
increased O 
to O 
a O 
smaller O 
extent O 
, O 
as O 
predicted O 
from O 
in O 
vitro O 
data O 
obtained O 
with O 
transfected O 
cells O 
possessing O 
only O 
the O 
UGT2B15 O 
variants O 
. O 
The O 
highest O 
C O 
( O 
max O 
) O 
value O 
calculated O 
in O 
the O 
subject O 
with O 
the O 
lowest O 
metabolic O 
clearance O 
was O 
roughly O 
40 O 
pg O 
/ O 
ml O 
, O 
which O 
is O 
far O 
lower O 
than O 
reported O 
high O 
blood O 
concentrations O 
, O 
which O 
in O 
turn O 
cannot O 
be O 
explained O 
by O 
genetically O 
impaired O 
UGT2B15 O 
activity O 
. O 
From O 
the O 
risk O 
assessment O 
perspective O 
, O 
our O 
results O 
indicate O 
that O 
the O 
traditional O 
uncertainty O 
factor O 
is O 
sufficient O 
to O 
account O 
for O 
the O 
variability O 
in O 
the O 
polymorphic O 
glucuronidation O 
of O 
BPA B-ABBREVIATION 
. O 

: O 
By O 
consensus O 
, O 
a O 
thyrotropin O 
( O 
TSH O 
) O 
level O 
persistently O 
> O 
10 O 
mIU O 
/ O 
L O 
is O 
an O 
indication O 
for O 
the O 
treatment O 
of O 
subclinical O 
hypothyroidism O 
( O 
SCH O 
) O 
. O 
Controversy O 
exists O 
regarding O 
patients O 
whose O 
TSH O 
level O 
is O 
elevated O 
but O 
< O 
10 O 
mIU O 
/ O 
L O 
. O 
Recently O 
, O 
the O 
American O 
Thyroid O 
Association O 
( O 
ATA O 
) O 
and O 
the O 
American O 
Association O 
of O 
Clinical O 
Endocrinologists O 
( O 
AACE O 
) O 
published O 
their O 
position O 
about O 
factors O 
that O 
should O 
be O 
considered O 
in O 
the O 
decision O 
on O 
treating O 
SCH O 
. O 
This O 
study O 
evaluated O 
the O 
frequency O 
of O 
these O 
factors O 
among O 
adult O 
( O 
non-pregnant O 
) O 
women O 
with O 
SCH O 
whose O 
TSH O 
levels O 
are O 
≤ O 
10 O 
mIU O 
/ O 
L O 
. O 
Methods O 
: O 
The O 
presence O 
of O 
the O 
conditions O 
that O 
should O 
be O 
considered O 
for O 
the O 
treatment O 
of O 
SCH O 
according O 
to O 
ATA O 
and O 
AACE O 
was O 
evaluated O 
in O 
252 O 
women O 
who O 
were O 
diagnosed O 
with O 
SCH O 
and O 
had O 
TSH O 
levels O 
≤ O 
10 O 
mIU O 
/ O 
L O 
. O 
Pregnant O 
women O 
were O 
excluded O 
. O 
Results O 
: O 
Antithyroperoxidase O 
antibodies O 
( O 
TPOAbs O 
) O 
were O 
detected O 
in O 
137 O 
( O 
54.3% O 
) O 
women O 
. O 
A O 
high O 
cardiovascular O 
risk O 
was O 
observed O 
in O 
43 O 
( O 
17% O 
) O 
women O 
. O 
Eighty O 
( O 
31.7% O 
) O 
women O 
who O 
were O 
not O 
at O 
high O 
cardiovascular O 
risk O 
presented O 
at O 
least O 
one O 
classical O 
risk O 
factor O 
( O 
arterial O 
hypertension O 
, O 
elevated O 
level O 
of O 
low O 
- O 
density O 
lipoprotein- O 
cholesterol B-TRIVIAL 
or O 
low O 
level O 
of O 
high O 
- O 
density O 
lipoprotein- O 
cholesterol B-TRIVIAL 
, O 
smoking O 
, O 
or O 
first O 
- O 
degree O 
family O 
history O 
of O 
premature O 
coronary O 
artery O 
disease O 
) O 
. O 
At O 
least O 
one O 
symptom O 
or O 
sign O 
of O 
hypothyroidism O 
that O 
could O 
not O 
be O 
explained O 
by O 
another O 
condition O 
was O 
observed O 
in O 
180 O 
( O 
71.4% O 
) O 
women O 
. O 
Two O 
hundred O 
thirty O 
- O 
two O 
( O 
92% O 
) O 
women O 
had O 
positive O 
TPOAbs O 
, O 
or O 
at O 
least O 
one O 
classical O 
cardiovascular O 
risk O 
factor O 
, O 
or O 
at O 
least O 
one O 
symptom O 
or O 
sign O 
of O 
hypothyroidism O 
. O 
Conclusions O 
: O 
According O 
to O 
the O 
new O 
ATA O 
and O 
AACE O 
guidelines O 
, O 
L-T4 B-ABBREVIATION 
therapy O 
would O 
be O 
considered O 
for O 
92% O 
of O 
women O 
with O 
SCH O 
and O 
TSH O 
≤ O 
10 O 
mIU O 
/ O 
L O 
. O 

sintering O 
: O 
a O 
novel O 
technique O 
used O 
in O 
the O 
design O 
, O 
optimization O 
and O 
biopharmaceutical O 
evaluation O 
of O 
propranolol B-FORMULA 
HCl I-FORMULA 
gastric O 
floating O 
tablets O 
. O 

The O 
objective O 
of O 
the O 
present O 
investigation O 
was O 
to O 
study O 
the O 
applicability O 
of O 
thermal O 
sintering O 
technique O 
for O 
the O 
development O 
of O 
gastric O 
floating O 
tablets O 
of O 
propranolol B-FORMULA 
HCl I-FORMULA 
. O 
Formulations O 
were O 
prepared O 
using O 
four O 
independent O 
variables O 
, O 
namely O 
(i) O 
polymer O 
quantity O 
, O 
(ii) O 
sodium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
concentration O 
, O 
(iii) O 
sintering O 
temperature O 
and O 
(iv) O 
sintering O 
time O 
. O 
Floating O 
lag O 
time O 
and O 
t(95) O 
were O 
taken O 
as O 
dependent O 
variables O 
. O 
Tablets O 
were O 
prepared O 
by O 
the O 
direct O 
compression O 
method O 
and O 
were O 
evaluated O 
for O 
physicochemical O 
properties O 
, O 
in O 
vitro O 
buoyancy O 
and O 
dissolution O 
studies O 
. O 
From O 
the O 
drug O 
release O 
studies O 
, O 
it O 
was O 
observed O 
that O 
drug O 
retarding O 
property O 
mainly O 
depends O 
upon O 
the O 
sintering O 
temperature O 
and O 
time O 
of O 
exposure O 
. O 
The O 
statistically O 
optimized O 
formulation O 
( O 
PTSso O 
) O 
was O 
characterized O 
by O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
and O 
differential O 
scanning O 
calorimetry O 
studies O 
, O 
and O 
no O 
significant O 
chemical O 
interaction O 
between O 
drug O 
and O 
polymer O 
was O 
observed O 
. O 
Optimized O 
formulation O 
was O 
stable O 
at O 
accelerated O 
conditions O 
for O 
a O 
period O 
of O 
six O 
months O 
. O 
PTSso O 
was O 
evaluated O 
for O 
in O 
vivo O 
buoyancy O 
studies O 
in O 
humans O 
for O 
both O 
fed O 
and O 
fasted O 
states O 
and O 
found O 
that O 
gastric O 
residence O 
time O 
of O 
the O 
floating O 
tablets O 
were O 
enhanced O 
by O 
fed O 
stage O 
but O 
not O 
in O 
fasted O 
state O 
. O 
Optimized O 
formulation O 
PTSso O 
and O 
commercial O 
formulation O 
Ciplar B-TRIVIAL 
LA I-TRIVIAL 
80 I-TRIVIAL 
were O 
subjected O 
to O 
bioavailability O 
studies O 
in O 
healthy O 
human O 
volunteers O 
by O 
estimating O 
pharmacokinetic O 
parameters O 
such O 
as O 
C(max) O 
, O 
T(max) O 
, O 
area O 
under O 
curve O 
(AUC)(,) O 
elimination O 
rate O 
constant O 
(K(el)) O 
, O 
biological O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
) O 
and O 
mean O 
residence O 
time O 
( O 
MRT O 
) O 
. O 
There O 
was O 
a O 
significant O 
increase O 
in O 
the O 
bioavailability O 
of O 
the O 
propranolol B-FORMULA 
HCl I-FORMULA 
from O 
PTSso O 
formulation O 
, O 
which O 
was O 
evident O 
from O 
increased O 
AUC O 
levels O 
and O 
larger O 
MRT O 
values O 
than O 
Ciplar B-TRIVIAL 
LA I-TRIVIAL 
80 I-TRIVIAL 
. O 

accuracy O 
of O 
DNA O 
synthesis O 
depends O 
on O 
the O 
accuracy O 
of O 
the O 
polymerase O 
as O 
well O 
as O 
the O 
quality O 
and O 
concentration(s) O 
of O 
the O 
available O 
5'-deoxynucleoside-triphosphate B-SYSTEMATIC 
DNA O 
precursors O 
( O 
dNTPs B-ABBREVIATION 
) O 
. O 
The O 
relationships O 
between O 
dNTPs B-ABBREVIATION 
and O 
error O 
rates O 
have O 
been O 
studied O 
in O 
vitro O 
, O 
but O 
only O 
limited O 
insights O 
exist O 
into O 
these O 
correlations O 
during O 
in O 
vivo O 
replication O 
. O 
We O 
have O 
investigated O 
this O 
issue O 
in O 
the O 
bacterium O 
Escherichia O 
coli O 
by O 
analyzing O 
the O 
mutational O 
properties O 
of O 
dcd O 
and O 
ndk O 
strains O 
. O 
These O 
strains O 
, O 
defective O 
in O 
dCTP B-ABBREVIATION 
deaminase O 
and O 
nucleoside B-FAMILY 
diphosphate I-FAMILY 
kinase O 
, O 
respectively O 
, O 
are O 
characterized O 
by O 
both O 
disturbances O 
of O 
dNTP B-ABBREVIATION 
pools O 
and O 
a O 
mutator O 
phenotype O 
. O 
ndk O 
strains O 
have O 
been O 
studied O 
before O 
, O 
but O 
were O 
included O 
in O 
this O 
study O 
, O 
as O 
controversies O 
exist O 
regarding O 
the O 
source O 
of O 
its O 
mutator O 
phenotype O 
. O 
We O 
show O 
that O 
dcd O 
strains O 
suffer O 
from O 
increased O 
intracellular O 
levels O 
of O 
dCTP B-ABBREVIATION 
( O 
4-fold O 
) O 
and O 
reduced O 
levels O 
of O 
dGTP B-ABBREVIATION 
( O 
2-fold O 
) O 
, O 
while O 
displaying O 
, O 
as O 
measured O 
using O 
a O 
set O 
of O 
lacZ O 
reversion O 
markers O 
in O 
a O 
mismatch O 
- O 
repair O 
defective O 
( O 
mutL O 
) O 
background O 
, O 
a O 
strong O 
mutator O 
effect O 
for O 
G·C→T·A O 
and O 
A·T→T·A O 
transversions O 
( O 
27- O 
and O 
42-fold O 
enhancement O 
, O 
respectively O 
) O 
. O 
In O 
contrast O 
, O 
ndk O 
strains O 
possess O 
a O 
lowered O 
dATP B-ABBREVIATION 
level O 
( O 
4-fold O 
) O 
and O 
modestly O 
enhanced O 
dCTP B-ABBREVIATION 
level O 
( O 
2-fold O 
) O 
, O 
while O 
its O 
mutator O 
effect O 
is O 
specific O 
for O 
just O 
the O 
A·T→T·A O 
transversions O 
. O 
The O 
two O 
strains O 
also O 
display O 
differential O 
mutability O 
for O 
rifampicin B-TRIVIAL 
-resistant O 
mutants O 
. O 
Overall O 
, O 
our O 
analysis O 
reveals O 
for O 
both O 
strains O 
a O 
satisfactory O 
correlation O 
between O 
dNTP B-ABBREVIATION 
pool O 
alterations O 
and O 
the O 
replication O 
error O 
rates O 
, O 
and O 
also O 
suggests O 
that O 
a O 
minimal O 
explanation O 
for O 
the O 
ndk O 
mutator O 
does O 
not O 
require O 
assumptions O 
beyond O 
the O 
predicted O 
effect O 
of O 
the O 
dNTP B-ABBREVIATION 
pools O 
. O 

concentrations O 
in O 
shrimp O 
( O 
Penaeus O 
semisulcatus O 
and O 
Penaeus O 
monodon O 
) O 
caught O 
from O 
the O 
coastal O 
areas O 
in O 
Southern O 
Iran O 
. O 

study O 
was O 
undertaken O 
to O 
determine O 
the O 
concentration O 
of O 
cadmium B-SYSTEMATIC 
in O 
two O 
shrimp O 
species O 
, O 
namely O 
, O 
Penaeus O 
semisulcatus O 
and O 
Penaeus O 
monodon O 
caught O 
from O 
the O 
coastal O 
areas O 
in O 
southern O 
Iran O 
. O 
Cadmium B-SYSTEMATIC 
concentration O 
was O 
determined O 
by O 
graphite B-TRIVIAL 
furnace O 
atomic O 
absorption O 
spectrophotometry O 
in O 
91 O 
shrimp O 
samples O 
after O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
/ O 
perchloric B-SYSTEMATIC 
acid I-SYSTEMATIC 
digestion O 
. O 
Accuracy O 
of O 
the O 
analysis O 
was O 
checked O 
by O 
various O 
methods O 
including O 
the O 
use O 
of O 
reference O 
material O 
. O 
The O 
mean O 
± O 
SD O 
of O 
cadmium B-SYSTEMATIC 
concentrations O 
in O 
shrimp O 
samples O 
were O 
0.128 O 
± O 
0.144 O 
( O 
μg O 
/ O 
g O 
) O 
. O 
The O 
cadmium B-SYSTEMATIC 
concentrations O 
ranged O 
from O 
0.01 O 
to O 
0.96 O 
μg O 
/ O 
g O 
of O 
the O 
muscle O 
tissues O 
of O 
shrimp O 
. O 
Higher O 
cadmium B-SYSTEMATIC 
concentration O 
in O 
shrimp O 
samples O 
was O 
found O 
in O 
summer O 
( O 
significant O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
results O 
show O 
that O 
the O 
mean O 
concentration O 
of O 
cadmium B-SYSTEMATIC 
in O 
shrimp O 
is O 
lower O 
than O 
the O 
maximum O 
allowed O 
levels O 
according O 
to O 
International O 
standards O 
, O 
although O 
the O 
concentration O 
of O 
cadmium B-SYSTEMATIC 
in O 
only O 
one O 
sample O 
was O 
more O 
than O 
the O 
amount O 
recommended O 
by O 
Food O 
and O 
Agriculture O 
Organization O 
. O 
Therefore O 
, O 
no O 
risk O 
to O 
the O 
consumer O 
arises O 
from O 
the O 
cadmium B-SYSTEMATIC 
contents O 
of O 
the O 
shrimp O 
caught O 
in O 
these O 
areas O 
. O 

stem O 
/ O 
progenitor O 
cells O 
( O 
NSPCs O 
) O 
are O 
multipotent O 
cells O 
within O 
the O 
embryonic O 
and O 
adult O 
brain O 
that O 
give O 
rise O 
to O 
both O 
neuronal O 
and O 
glial O 
cell O 
lineages O 
. O 
Maintenance O 
of O 
NSPC O 
multipotency O 
is O 
promoted O 
by O 
low O 
oxygen B-SYSTEMATIC 
tension O 
, O 
although O 
the O 
metabolic O 
underpinnings O 
of O 
this O 
trait O 
have O 
not O 
been O 
described O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
metabolic O 
state O 
of O 
undifferentiated O 
NSPCs O 
in O 
culture O 
, O 
and O 
tested O 
their O 
relative O 
reliance O 
on O 
oxidative O 
versus O 
glycolytic O 
metabolism O 
for O 
survival O 
, O 
as O 
well O 
as O 
their O 
dependence O 
on O 
hypoxia O 
inducible O 
factor-1alpha O 
( O 
HIF-1α O 
) O 
expression O 
for O 
maintenance O 
of O 
metabolic O 
phenotype O 
. O 
Unlike O 
primary O 
neurons O 
, O 
NSPCs O 
from O 
embryonic O 
and O 
adult O 
mice O 
survived O 
prolonged O 
hypoxia O 
in O 
culture O 
. O 
In O 
addition O 
, O 
NSPCs O 
displayed O 
greater O 
susceptibility O 
to O 
glycolytic O 
inhibition O 
compared O 
with O 
primary O 
neurons O 
, O 
even O 
in O 
the O 
presence O 
of O 
alternative O 
mitochondrial O 
TCA B-ABBREVIATION 
substrates O 
. O 
NSPCs O 
were O 
also O 
more O 
resistant O 
than O 
neurons O 
to O 
mitochondrial O 
cyanide B-SYSTEMATIC 
toxicity O 
, O 
less O 
capable O 
of O 
utilizing O 
galactose B-TRIVIAL 
as O 
an O 
alternative O 
substrate O 
to O 
glucose B-TRIVIAL 
, O 
and O 
more O 
susceptible O 
to O 
pharmacological O 
inhibition O 
of O 
the O 
pentose B-FAMILY 
phosphate I-FAMILY 
pathway O 
by O 
6-aminonicotinamide B-SYSTEMATIC 
. O 
Inducible O 
deletion O 
of O 
exon O 
1 O 
of O 
the O 
Hif1a O 
gene O 
improved O 
the O 
ability O 
of O 
NSPCs O 
to O 
utilize O 
pyruvate B-TRIVIAL 
during O 
glycolytic O 
inhibition O 
, O 
but O 
did O 
not O 
alter O 
other O 
parameters O 
of O 
metabolism O 
, O 
including O 
their O 
ability O 
to O 
withstand O 
prolonged O 
hypoxia O 
. O 
Taken O 
together O 
, O 
these O 
data O 
indicate O 
that O 
NSPCs O 
have O 
a O 
relatively O 
low O 
requirement O 
for O 
oxidative O 
metabolism O 
for O 
their O 
survival O 
and O 
that O 
hypoxic O 
resistance O 
is O 
not O 
dependent O 
upon O 
HIF-1α O 
signaling O 
. O 

membrane O 
disruptions O 
occur O 
in O 
mechanically O 
active O 
tissues O 
such O 
as O 
the O 
epidermis O 
and O 
can O 
lead O 
to O 
cell O 
death O 
if O 
the O 
damage O 
remains O 
unrepaired O 
. O 
Repair O 
occurs O 
through O 
fusion O 
of O 
vesicle O 
patches O 
to O 
the O 
damaged O 
membrane O 
region O 
. O 
The O 
enzyme O 
phospholipase O 
D O 
( O 
PLD O 
) O 
is O 
involved O 
in O 
membrane O 
traffickiing O 
; O 
therefore O 
, O 
the O 
role O 
of O 
PLD O 
in O 
membrane O 
repair O 
was O 
investigated O 
. O 
Generation O 
of O 
membrane O 
disruptions O 
by O 
lifting O 
epidermal O 
keratinocytes O 
from O 
the O 
substratum O 
induced O 
PLD O 
activation O 
, O 
whereas O 
removal O 
of O 
cells O 
from O 
the O 
substratum O 
via O 
trypsinization O 
had O 
no O 
effect O 
. O 
Pretreatment O 
with O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D₃ I-SYSTEMATIC 
, O 
previously O 
shown O 
to O 
increase O 
PLD1 O 
expression O 
and O 
activity O 
, O 
had O 
no O 
effect O 
on O 
, O 
and O 
a O 
PLD2-selective O 
( O 
but O 
not O 
a O 
PLD1-selective O 
) O 
inhibitor O 
decreased O 
, O 
cell O 
lifting O 
- O 
induced O 
PLD O 
activation O 
, O 
suggesting O 
PLD2 O 
as O 
the O 
isoform O 
activated O 
. O 
PLD2 O 
interacts O 
functionally O 
with O 
the O 
glycerol B-TRIVIAL 
channel O 
aquaporin-3 O 
( O 
AQP3 O 
) O 
to O 
produce O 
phosphatidylglycerol B-FAMILY 
( O 
PG O 
) O 
; O 
however O 
, O 
wounding O 
resulted O 
in O 
decreased O 
PG O 
production O 
, O 
suggesting O 
a O 
potential O 
PG O 
deficiency O 
in O 
wounded O 
cells O 
. O 
Cell O 
lifting O 
- O 
induced O 
PLD O 
activation O 
was O 
transient O 
, O 
consistent O 
with O 
a O 
possible O 
role O 
in O 
membrane O 
repair O 
, O 
and O 
PLD O 
inhibitors O 
inhibited O 
membrane O 
resealing O 
upon O 
laser O 
injury O 
. O 
In O 
an O 
in O 
vivo O 
full O 
- O 
thickness O 
mouse O 
skin O 
wound O 
model O 
, O 
PG O 
accelerated O 
wound O 
healing O 
. O 
These O 
results O 
suggest O 
that O 
PLD O 
and O 
the O 
PLD2 O 
/ O 
AQP3 O 
signaling O 
module O 
may O 
be O 
involved O 
in O 
membrane O 
repair O 
and O 
wound O 
healing O 
. O 

are O 
a O 
diverse O 
group O 
of O 
compounds O 
whose O 
inevitable O 
release O 
into O 
the O 
environment O 
warrants O 
study O 
of O 
the O 
fundamental O 
processes O 
that O 
govern O 
the O 
ingestion O 
, O 
uptake O 
and O 
accumulation O 
in O 
aquatic O 
organisms O 
. O 
Nanomaterials O 
have O 
the O 
ability O 
to O 
transfer O 
to O 
higher O 
trophic O 
levels O 
in O 
aquatic O 
ecosystems O 
, O 
and O 
recent O 
evidence O 
suggests O 
that O 
the O 
surface O 
chemistry O 
of O 
both O 
the O 
nanoparticle O 
and O 
biological O 
membrane O 
can O 
influence O 
uptake O 
kinetics O 
. O 
Therefore O 
, O 
our O 
study O 
investigates O 
the O 
effect O 
of O 
surface O 
functionalization O 
on O 
uptake O 
, O 
internalization O 
and O 
depuration O 
in O 
Daphnia O 
spp O 
. O 
Uncharged O 
( O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
; O 
PEG B-ABBREVIATION 
) O 
, O 
positively O 
charged O 
( O 
amino B-FAMILY 
-terminated O 
: O 
NH2 B-FORMULA 
) O 
and O 
negatively O 
charged O 
( O 
carboxyl B-SYSTEMATIC 
-modified O 
; O 
COOH B-FORMULA 
) O 
cadmium B-SYSTEMATIC 
selenide I-SYSTEMATIC 
/ O 
zinc B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
quantum O 
dots O 
were O 
used O 
to O 
monitor O 
ingestion O 
, O 
uptake O 
and O 
depuration O 
of O 
nanometals O 
in O 
Daphnia O 
magna O 
and O 
Ceriodaphnia O 
dubia O 
over O 
24h O 
of O 
exposure O 
. O 
These O 
studies O 
demonstrated O 
that O 
particles O 
with O 
higher O 
negative O 
charge O 
( O 
COOH B-FORMULA 
quantum O 
dots O 
) O 
were O 
taken O 
up O 
to O 
a O 
greater O 
extent O 
by O 
Daphnia O 
( O 
259.17±17.70 O 
RFU O 
/ O 
20 O 
Daphnia O 
) O 
than O 
either O 
the O 
NH2 B-FORMULA 
( O 
150.01±18.91 O 
) O 
or O 
PEG B-ABBREVIATION 
quantum O 
dots O 
( O 
95.17±9.78 O 
) O 
, O 
however O 
this O 
is O 
likely O 
related O 
to O 
the O 
functional O 
groups O 
attached O 
to O 
the O 
nanoparticles O 
as O 
there O 
were O 
no O 
real O 
differences O 
in O 
zeta O 
potential O 
. O 
Whole O 
body O 
fluorescence O 
associates O 
well O 
with O 
fluorescent O 
microscopic O 
images O 
obtained O 
at O 
the O 
24h O 
timepoint O 
. O 
Confocal O 
and O 
electron O 
microscopic O 
analysis O 
clearly O 
demonstrated O 
that O 
all O 
three O 
types O 
of O 
quantum O 
dots O 
could O 
cross O 
the O 
intestinal O 
epithelial O 
barrier O 
and O 
be O 
translocated O 
to O 
other O 
cells O 
. O 
Upon O 
cessation O 
of O 
exposure O 
, O 
elimination O 
of O 
all O 
three O 
materials O 
was O 
biphasic O 
with O 
rapid O 
initial O 
clearance O 
that O 
likely O 
represents O 
elimination O 
of O 
material O 
remaining O 
in O 
the O 
GI O 
tract O 
followed O 
by O 
a O 
much O 
slower O 
elimination O 
phase O 
that O 
likely O 
represents O 
elimination O 
of O 
internalized O 
material O 
. O 
These O 
studies O 
demonstrate O 
that O 
daphnids O 
can O 
take O 
up O 
intact O 
nanomaterial O 
from O 
the O 
water O 
column O 
and O 
that O 
this O 
uptake O 
is O 
strongly O 
influenced O 
by O 
particle O 
surface O 
functionalization O 
. O 
In O 
addition O 
, O 
the O 
usefulness O 
of O 
using O 
quantum O 
dots O 
as O 
a O 
proxy O 
for O 
other O 
nanometals O 
( O 
no O 
acute O 
toxicity O 
, O 
clear O 
visualization O 
in O 
electron O 
microscopy O 
) O 
, O 
in O 
conjunction O 
with O 
several O 
different O 
imaging O 
techniques O 
in O 
assessing O 
uptake O 
and O 
accumulation O 
of O 
nanoparticles O 
in O 
daphnids O 
was O 
demonstrated O 
. O 

molecular O 
orientation O 
and O 
dynamics O 
of O 
di-t-butylnitroxide B-SYSTEMATIC 
( O 
DTBN B-ABBREVIATION 
) O 
and O 
4-oxo-2,2,6,6-tetramethyl-1-piperidinyl-1-oxyl B-SYSTEMATIC 
( O 
TEMPONE B-ABBREVIATION 
) O 
radicals O 
in O 
the O 
organic O 
1D O 
nanochannels O 
of O 
tris(o-phenylenedioxy)cyclotriphosphazene B-SYSTEMATIC 
( O 
TPP B-ABBREVIATION 
) O 
were O 
investigated O 
by O 
examining O 
inclusion O 
compounds O 
( O 
ICs O 
) O 
diluted O 
by O 
the O 
co O 
- O 
inclusion O 
of O 
nonradicals O 
using O 
electron O 
spin O 
resonance O 
( O 
ESR O 
) O 
. O 
Spectral O 
simulation O 
showed O 
that O 
the O 
axial O 
rotation O 
of O 
DTBN B-ABBREVIATION 
or O 
TEMPONE B-ABBREVIATION 
molecules O 
is O 
excited O 
in O 
TPP B-ABBREVIATION 
nanochannels O 
with O 
activation O 
energies O 
of O 
3 O 
and O 
10 O 
kJ O 
mol(-1) O 
, O 
respectively O 
. O 
The O 
rotation O 
axes O 
for O 
both O 
DTBN B-ABBREVIATION 
and O 
TEMPONE B-ABBREVIATION 
were O 
determined O 
to O 
be O 
almost O 
parallel O 
to O 
the O 
principal O 
y-axis O 
of O 
the O 
g O 
tensor O 
, O 
which O 
agrees O 
with O 
the O 
result O 
reported O 
for O 
2,2,6,6-tetramethyl-1-piperidinyl-1-oxyl B-SYSTEMATIC 
( O 
TEMPO B-ABBREVIATION 
) O 
in O 
TPP B-ABBREVIATION 
nanochannels O 
, O 
which O 
has O 
the O 
activation O 
energy O 
of O 
5 O 
kJ O 
mol(-1) O 
. O 
These O 
results O 
indicate O 
that O 
the O 
molecular O 
orientations O 
of O 
guest O 
nitroxide B-SYSTEMATIC 
radicals O 
are O 
almost O 
independent O 
of O 
the O 
molecular O 
sizes O 
of O 
the O 
guest O 
radicals O 
in O 
TPP B-ABBREVIATION 
nanochannels O 
, O 
although O 
the O 
molecular O 
dynamics O 
are O 
dependent O 
on O 
the O 
molecular O 
sizes O 
. O 

of O 
hepatic O 
4-hydroxylation O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D3 I-SYSTEMATIC 
through O 
CYP3A4 O 
induction O 
in O 
vitro O 
and O 
in O 
vivo O 
: O 
Implications O 
for O 
drug O 
- O 
induced O 
osteomalacia O 
. O 

- O 
term O 
therapy O 
with O 
certain O 
drugs O 
, O 
especially O 
cytochrome O 
P450 O 
( O 
P450 O 
; O 
CYP)-inducing O 
agents O 
, O 
confers O 
an O 
increased O 
risk O 
of O 
osteomalacia O 
that O 
is O 
attributed O 
to O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
. O 
Human O 
CYP24A1 O 
, O 
CYP3A4 O 
, O 
and O 
CYP27B1 O 
catalyze O 
the O 
inactivation O 
and O 
activation O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
and O 
have O 
been O 
implicated O 
in O 
the O 
adverse O 
drug O 
response O 
. O 
In O 
this O 
study O 
, O 
the O 
inducibility O 
of O 
these O 
enzymes O 
and O 
monohydroxylation O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D3 I-SYSTEMATIC 
( O 
25OHD3 B-SYSTEMATIC 
) O 
were O 
evaluated O 
after O 
exposure O 
to O 
P450-inducing O 
drugs O 
. O 
With O 
human O 
hepatocytes O 
, O 
treatment O 
with O 
phenobarbital B-TRIVIAL 
, O 
hyperforin B-TRIVIAL 
, O 
carbamazepine B-TRIVIAL 
, O 
and O 
rifampin B-TRIVIAL 
significantly O 
increased O 
the O 
levels O 
of O 
CYP3A4 O 
, O 
but O 
not O 
CYP24A1 O 
or O 
CYP27B1 O 
mRNA O 
. O 
In O 
addition O 
, O 
rifampin B-TRIVIAL 
pretreatment O 
resulted O 
in O 
an O 
8-fold O 
increase O 
in O 
formation O 
of O 
the O 
major O 
metabolite O 
of O 
25OHD3 B-SYSTEMATIC 
, O 
4β,25(OH)2 B-SYSTEMATIC 
D3 I-SYSTEMATIC 
. O 
This O 
inductive O 
effect O 
was O 
blocked O 
by O 
the O 
addition O 
of O 
6',7'-dihydroxybergamottin B-SYSTEMATIC 
, O 
a O 
selective O 
CYP3A4 O 
inhibitor O 
. O 
With O 
human O 
renal O 
proximal O 
tubular O 
HK-2 O 
cells O 
, O 
treatment O 
with O 
the O 
same O 
inducers O 
did O 
not O 
alter O 
CYP3A4 O 
, O 
CYP24A1 O 
, O 
or O 
CYP27B1 O 
expression O 
. O 
24R,25(OH)2 B-SYSTEMATIC 
D3 I-SYSTEMATIC 
was O 
the O 
predominant O 
monohydroxy B-SYSTEMATIC 
metabolite O 
produced O 
from O 
25OHD3 B-SYSTEMATIC 
, O 
but O 
its O 
formation O 
was O 
unaffected O 
by O 
the O 
inducers O 
. O 
With O 
healthy O 
volunteers O 
, O 
the O 
mean O 
plasma O 
concentration O 
of O 
4β,25(OH)2 B-SYSTEMATIC 
D3 I-SYSTEMATIC 
was O 
increased O 
60% O 
( O 
p O 
< O 
0.01 O 
) O 
after O 
short O 
- O 
term O 
rifampin B-TRIVIAL 
administration O 
. O 
This O 
was O 
accompanied O 
by O 
a O 
statistically O 
significant O 
reduction O 
in O 
plasma O 
1α,25(OH)2 B-SYSTEMATIC 
D3 I-SYSTEMATIC 
( O 
-10% O 
; O 
p O 
= O 
0.03 O 
) O 
, O 
and O 
a O 
nonsignificant O 
change O 
in O 
24R,25(OH)2 B-SYSTEMATIC 
D3 I-SYSTEMATIC 
( O 
-8% O 
; O 
p O 
= O 
0.09 O 
) O 
levels O 
. O 
Further O 
analysis O 
revealed O 
a O 
negative O 
correlation O 
between O 
the O 
increase O 
in O 
4β,25(OH)2 B-SYSTEMATIC 
D3 I-SYSTEMATIC 
and O 
decrease O 
in O 
1α,25(OH)2 B-SYSTEMATIC 
D3 I-SYSTEMATIC 
levels O 
. O 
Examination O 
of O 
the O 
plasma O 
monohydroxy B-SYSTEMATIC 
metabolite/ O 
25OHD3 B-SYSTEMATIC 
ratios O 
indicated O 
selective O 
induction O 
of O 
the O 
CYP3A4-dependent O 
4β-hydroxylation O 
pathway O 
of O 
25OHD3 B-SYSTEMATIC 
elimination O 
. O 
These O 
results O 
suggest O 
that O 
induction O 
of O 
hepatic O 
CYP3A4 O 
may O 
be O 
important O 
in O 
the O 
etiology O 
of O 
drug O 
- O 
induced O 
osteomalacia O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

their O 
discovery O 
almost O 
40 O 
years O 
ago O 
, O 
isoforms O 
of O 
the O 
lipid O 
- O 
activated O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
family O 
were O 
initially O 
regarded O 
only O 
as O 
downstream O 
effectors O 
of O 
the O 
second O 
messengers O 
calcium B-SYSTEMATIC 
and O 
diacylglycerol B-FAMILY 
, O 
undergoing O 
activation O 
upon O 
phospholipid O 
hydrolysis O 
in O 
response O 
to O 
acute O 
stimuli O 
. O 
Subsequently O 
, O 
several O 
isoforms O 
were O 
found O 
to O 
be O 
associated O 
with O 
the O 
inhibitory O 
effects O 
of O 
lipid O 
over O 
- O 
supply O 
on O 
glucose B-TRIVIAL 
homeostasis O 
, O 
especially O 
the O 
negative O 
cross O 
- O 
talk O 
with O 
insulin O 
signal O 
transduction O 
, O 
observed O 
upon O 
accumulation O 
of O 
diacylglycerol B-FAMILY 
in O 
insulin O 
target O 
tissues O 
. O 
The O 
PKC O 
family O 
has O 
therefore O 
attracted O 
much O 
attention O 
in O 
diabetes O 
and O 
obesity O 
research O 
, O 
because O 
intracellular O 
lipid O 
accumulation O 
is O 
strongly O 
correlated O 
with O 
defective O 
insulin O 
action O 
and O 
the O 
development O 
of O 
type O 
2 O 
diabetes O 
. O 
Causal O 
roles O 
for O 
various O 
isoforms O 
in O 
the O 
generation O 
of O 
insulin O 
resistance O 
have O 
more O 
recently O 
been O 
confirmed O 
using O 
PKC-deficient O 
mice O 
. O 
However O 
, O 
during O 
characterization O 
of O 
these O 
animals O 
, O 
it O 
became O 
increasingly O 
evident O 
that O 
the O 
enzymes O 
play O 
key O 
roles O 
in O 
the O 
modulation O 
of O 
lipid O 
metabolism O 
itself O 
, O 
and O 
may O 
control O 
the O 
supply O 
of O 
lipids O 
between O 
tissues O 
such O 
as O 
adipose O 
and O 
liver O 
. O 
Molecular O 
studies O 
have O 
also O 
demonstrated O 
roles O 
for O 
PKC O 
isoforms O 
in O 
several O 
aspects O 
of O 
lipid O 
metabolism O 
, O 
such O 
as O 
adipocyte O 
differentiation O 
and O 
hepatic O 
lipogenesis O 
. O 
While O 
the O 
precise O 
mechanisms O 
involved O 
, O 
especially O 
the O 
identities O 
of O 
protein O 
substrates O 
, O 
are O 
still O 
unclear O 
, O 
the O 
emerging O 
picture O 
suggests O 
that O 
the O 
currently O 
held O 
view O 
of O 
the O 
contribution O 
of O 
PKC O 
isoforms O 
to O 
metabolism O 
is O 
an O 
over O 
- O 
simplification O 
. O 
Although O 
PKCs O 
may O 
inhibit O 
insulin O 
signal O 
transduction O 
, O 
these O 
enzymes O 
are O 
not O 
merely O 
downstream O 
effectors O 
of O 
lipid O 
accumulation O 
, O 
but O 
in O 
fact O 
control O 
the O 
fate O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
thus O 
the O 
tail O 
wags O 
the O 
dog O 
. O 

therapeutics O 
have O 
traditionally O 
faced O 
many O 
challenges O 
including O 
low O 
bioavailability O 
, O 
poor O 
proteolytic O 
stability O 
and O 
difficult O 
cellular O 
uptake O 
. O 
Conformationally O 
constraining O 
the O 
backbone O 
of O 
a O 
peptide O 
into O 
a O 
macrocyclic O 
ring O 
often O 
ameliorates O 
these O 
problems O 
and O 
allows O 
for O 
the O 
development O 
of O 
a O 
variety O 
of O 
new O 
drugs O 
. O 
Such O 
peptide O 
- O 
based O 
pharmaceuticals O 
can O 
enhance O 
the O 
multi O 
- O 
faceted O 
functionality O 
of O 
peptide O 
side O 
chains O 
, O 
permitting O 
the O 
peptides O 
to O 
bind O 
cellular O 
targets O 
and O 
receptors O 
necessary O 
to O 
impart O 
their O 
role O 
, O 
while O 
protecting O 
them O 
from O 
degrading O 
cellular O 
influences O 
. O 
In O 
the O 
work O 
described O 
here O 
, O 
we O 
developed O 
three O 
cyclic O 
peptides O 
, O 
VP O 
mimic1 O 
, O 
VP O 
mimic2 O 
and O 
OT O 
mimic1 O 
, O 
which O 
mimic O 
endocrine O 
hormones O 
vasopressin B-FAMILY 
and O 
oxytocin B-TRIVIAL 
. O 
Making O 
notable O 
changes O 
to O 
the O 
overall O 
structure O 
and O 
composition O 
of O 
the O 
parent O 
hormones O 
, O 
we O 
synthesized O 
the O 
mimics O 
and O 
tested O 
their O 
durability O 
against O 
treatment O 
with O 
three O 
proteases O 
chosen O 
for O 
their O 
specificity O 
: O 
pepsin O 
, O 
alpha-chymotrypsin O 
, O 
and O 
pronase O 
. O 
Vasopressin B-FAMILY 
and O 
oxytocin B-TRIVIAL 
contain O 
a O 
disulfide B-SYSTEMATIC 
linkage O 
leaving O 
them O 
particularly O 
vulnerable O 
to O 
deactivation O 
from O 
the O 
reducing O 
environment O 
inside O 
the O 
cell O 
. O 
Thus O 
, O 
we O 
increased O 
the O 
complexity O 
of O 
our O 
assays O 
by O 
adding O 
reducing O 
agent O 
glutathione B-TRIVIAL 
to O 
each O 
mixture O 
. O 
Subsequently O 
, O 
we O 
discovered O 
each O 
of O 
our O 
mimics O 
withstood O 
protease O 
treatment O 
with O 
less O 
degradation O 
and O 
/ O 
or O 
a O 
slower O 
rate O 
of O 
degradation O 
as O 
compared O 
to O 
both O 
parent O 
hormones O 
and O 
a O 
linear O 
control O 
peptide O 
. O 

deficits O 
in O 
schizophrenia O 
are O 
critically O 
important O 
predictors O 
of O 
long O 
- O 
term O 
psychosocial O 
outcome O 
and O 
are O 
not O 
significantly O 
ameliorated O 
by O 
currently O 
available O 
medications O 
. O 
Cognitive O 
remediation O 
training O 
has O 
shown O 
promise O 
for O 
alleviating O 
cognitive O 
symptoms O 
of O 
schizophrenia O 
, O 
but O 
the O 
clinical O 
significance O 
has O 
often O 
been O 
limited O 
by O 
small O 
effect O 
sizes O 
. O 
Approaches O 
that O 
achieve O 
larger O 
improvement O 
involve O 
time O 
requirements O 
that O 
can O 
be O 
cost O 
- O 
prohibitive O 
within O 
the O 
current O 
clinical O 
care O 
system O 
. O 
This O 
mini O 
- O 
review O 
evaluates O 
the O 
theoretical O 
potential O 
of O 
a O 
pharmacological O 
enhancement O 
strategy O 
of O 
cognitive O 
remediation O 
training O 
with O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
agonists O 
. O 
nAChR O 
agonists O 
can O 
facilitate O 
sensory O 
processing O 
, O 
alertness O 
, O 
attention O 
, O 
learning O 
and O 
memory O 
. O 
While O 
these O 
effects O 
may O 
be O 
too O 
subtle O 
and O 
short O 
- O 
lasting O 
to O 
be O 
of O 
clinical O 
relevance O 
as O 
a O 
primary O 
treatment O 
of O 
cognitive O 
deficits O 
, O 
they O 
constitute O 
an O 
ideal O 
effects O 
profile O 
for O 
enhancing O 
training O 
benefits O 
. O 
Several O 
mechanisms O 
are O 
described O 
through O 
which O 
repeated O 
coupling O 
of O 
cognitive O 
training O 
challenges O 
with O 
nAChR O 
stimulation O 
may O 
enhance O 
and O 
accelerate O 
cognitive O 
remediation O 
training O 
effects O 
, O 
advancing O 
such O 
interventions O 
into O 
more O 
effective O 
and O 
practicable O 
treatments O 
of O 
some O 
of O 
the O 
most O 
debilitating O 
symptoms O 
of O 
schizophrenia O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

films O 
of O 
ethylene B-SYSTEMATIC 
- I-SYSTEMATIC 
vinyl I-SYSTEMATIC 
alcohol I-SYSTEMATIC 
copolymer O 
( O 
EVOH B-FORMULA 
) O 
containing O 
flavonoid B-FAMILY 
-rich O 
cocoa O 
were O 
developed O 
. O 
To O 
understand O 
their O 
potential O 
application O 
as O 
active O 
packaging O 
material O 
, O 
antioxidant O 
and O 
antimicrobial O 
properties O 
of O 
the O 
films O 
were O 
determined O 
as O 
well O 
as O 
the O 
antioxidant O 
activity O 
of O 
the O 
release O 
compounds O 
in O 
Caco-2 O 
human O 
epithelial O 
colorectal O 
adenocarcinoma O 
cells O 
. O 
Exposure O 
of O 
the O 
films O 
to O 
aqueous O 
food O 
simulant O 
showed O 
antioxidant O 
capacity O 
. O 
The O 
release O 
of O 
cocoa O 
extract O 
components O 
was O 
dependent O 
on O 
the O 
antioxidant O 
concentration O 
incorporated O 
in O 
the O 
film O 
and O 
on O 
temperature O 
. O 
Cocoa O 
extract O 
and O 
the O 
fraction O 
obtained O 
after O 
in O 
vitro O 
gastrointestinal O 
digestion O 
presented O 
antioxidant O 
activity O 
against O 
oxidative O 
stress O 
induced O 
by O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
in O 
Caco-2 O 
cells O 
. O 
Films O 
with O 
10% O 
, O 
15% O 
, O 
and O 
20% O 
cocoa O 
extract O 
produced O 
bactericidal O 
effect O 
against O 
Staphylococcus O 
aureus O 
, O 
Listeria O 
monocytogenes O 
, O 
Escherichia O 
coli O 
and O 
Salmonella O 
enterica O 
. O 
The O 
application O 
of O 
films O 
to O 
an O 
infant O 
milk O 
formula O 
, O 
previously O 
inoculated O 
with O 
L O 
. O 
monocytogenes O 
, O 
inhibited O 
the O 
growth O 
of O 
bacteria O 
1.5log O 
units O 
the O 
first O 
day O 
and O 
showed O 
sustained O 
release O 
, O 
inhibiting O 
0.52 O 
and O 
0.76log O 
units O 
, O 
respectively O 
, O 
by O 
the O 
sixth O 
day O 
, O 
while O 
cocoa O 
powder O 
added O 
directly O 
did O 
not O 
produce O 
any O 
effect O 
. O 

phenolic O 
profiles O 
and O 
antioxidant O 
activity O 
of O 
litchi O 
pulp O 
of O 
13 O 
varieties O 
were O 
investigated O 
. O 
The O 
free O 
, O 
bound O 
and O 
total O 
phenolic O 
contents O 
were O 
66.17-226.03 O 
, O 
11.18-40.54 O 
, O 
and O 
101.51-259.18 O 
mg O 
of O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
equivalents O 
/ O 
100 O 
g O 
, O 
respectively O 
. O 
The O 
free O 
, O 
bound O 
and O 
total O 
flavonoid B-FAMILY 
contents O 
were O 
16.68-110.33 O 
, O 
10.48-22.75 O 
, O 
and O 
39.43-129.86 O 
mg O 
of O 
catechin B-TRIVIAL 
equivalents O 
/ O 
100 O 
g O 
, O 
respectively O 
. O 
Free O 
phenolics B-FAMILY 
and O 
flavonoids B-FAMILY 
contributed O 
averagely O 
80.1% O 
and O 
75% O 
to O 
their O 
total O 
contents O 
, O 
respectively O 
. O 
Six O 
individual O 
phenolics B-FAMILY 
( O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
(+)-catechin B-TRIVIAL 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
, O 
(-)-epicatechin B-SYSTEMATIC 
, O 
and O 
rutin B-TRIVIAL 
) O 
were O 
detected O 
in O 
litchi O 
pulp O 
by O 
HPLC O 
. O 
The O 
contents O 
of O 
each O 
compound O 
in O 
free O 
and O 
bound O 
fractions O 
were O 
determined O 
. O 
Significant O 
varietal O 
discrepancy O 
in O 
antioxidant O 
activity O 
was O 
also O 
found O 
by O 
FRAP O 
and O 
DPPH B-ABBREVIATION 
scavenging O 
capacity O 
methods O 
. O 
Antioxidant O 
activity O 
was O 
significantly O 
correlated O 
with O 
phenolic O 
and O 
flavonoid B-FAMILY 
contents O 
. O 
Thus O 
, O 
phenolics B-FAMILY 
and O 
flavonoids B-FAMILY 
exist O 
mainly O 
in O 
the O 
free O 
form O 
in O 
litchi O 
pulp O 
. O 
There O 
were O 
significant O 
varietal O 
differences O 
in O 
phytochemical O 
contents O 
and O 
antioxidant O 
activity O 
of O 
litchi O 
pulp O 
. O 

, O 
the O 
true O 
structure O 
of O 
PM181104 B-IDENTIFIER 
, O 
an O 
anti- O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
thiazolyl B-SYSTEMATIC 
peptide O 
from O 
the O 
marine O 
- O 
derived O 
bacterium O 
Kocuria O 
palustris O 
. O 

new O 
thiazolyl B-SYSTEMATIC 
peptide O 
, O 
kocurin B-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
culture O 
broths O 
of O 
a O 
marine O 
- O 
derived O 
Kocuria O 
palustris O 
. O 
Its O 
structural O 
elucidation O 
was O 
accomplished O 
using O 
a O 
combination O 
of O 
spectroscopic O 
and O 
chemical O 
methods O 
, O 
including O 
HRMS O 
, O 
extensive O 
1D O 
and O 
2D O 
NMR O 
analysis O 
, O 
MS O 
/ O 
MS O 
fragmentation O 
, O 
and O 
chemical O 
degradation O 
and O 
Marfey's O 
analysis O 
of O 
the O 
resulting O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
. O 
The O 
structure O 
herein O 
reported O 
corrects O 
that O 
previously O 
assigned O 
to O 
PM181104 B-IDENTIFIER 
( O 
3 O 
) O 
. O 
Kocurin B-TRIVIAL 
displayed O 
activity O 
against O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
, O 
with O 
MIC O 
values O 
in O 
the O 
submicromolar O 
range O 
. O 

profiles O 
of O 
hippocampal O 
regenerative O 
sprouting O 
- O 
related O 
genes O 
and O 
their O 
regulation O 
by O 
E-64d B-TRIVIAL 
in O 
a O 
developmental O 
rat O 
model O 
of O 
penicillin B-FAMILY 
-induced O 
recurrent O 
epilepticus O 
. O 

( O 
a O 
calpain O 
and O 
autophagy O 
inhibitor O 
) O 
has O 
previously O 
been O 
shown O 
safe O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
in O 
humans O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
potential O 
protective O 
mechanism O 
of O 
E-64d B-TRIVIAL 
on O 
hippocampal O 
aberrant O 
mossy O 
fiber O 
sprouting O 
was O 
examined O 
in O 
a O 
developmental O 
rat O 
model O 
of O 
penicillin B-FAMILY 
-induced O 
recurrent O 
epilepticus O 
. O 
A O 
seizure O 
was O 
induced O 
by O 
penicillin B-FAMILY 
every O 
other O 
day O 
in O 
Sprague-Dawley O 
rats O 
from O 
postnatal O 
day O 
21 O 
( O 
P21 O 
) O 
. O 
The O 
rats O 
were O 
randomly O 
assigned O 
into O 
the O 
control O 
group O 
( O 
CONT1 O 
) O 
, O 
the O 
control O 
plus O 
E-64d B-TRIVIAL 
( O 
CONT2 O 
) O 
, O 
the O 
seizure O 
group O 
( O 
EXP1 O 
) O 
and O 
the O 
seizure O 
plus O 
E-64d B-TRIVIAL 
( O 
EXP2 O 
) O 
. O 
On O 
P51 O 
, O 
mossy O 
fiber O 
sprouting O 
and O 
related O 
gene O 
expression O 
in O 
hippocampus O 
were O 
assessed O 
by O 
Timm O 
staining O 
and O 
real O 
- O 
time O 
RT-PCR O 
methods O 
, O 
respectively O 
. O 
To O 
validate O 
the O 
RT-PCR O 
results O 
, O 
western O 
blot O 
analysis O 
was O 
performed O 
on O 
selected O 
genes O 
. O 
E-64d B-TRIVIAL 
obviously O 
suppressed O 
the O 
aberrant O 
mossy O 
fiber O 
sprouting O 
in O 
the O 
supragranular O 
region O 
of O 
dentate O 
gyrus O 
and O 
CA3 O 
subfield O 
of O 
hippocampus O 
. O 
Among O 
the O 
total O 
twelve O 
genes O 
, O 
six O 
genes O 
were O 
strongly O 
up- O 
( O 
MT-3 O 
, O 
ACAT1 O 
, O 
clusterin O 
and O 
ApoE O 
) O 
or O 
down- O 
( O 
ZnT-1 O 
and O 
PRG-3 O 
) O 
regulated O 
by O 
developmental O 
seizures O 
( O 
EXP1 O 
) O 
compared O 
with O 
that O 
in O 
the O 
CONT1 O 
. O 
Up-regulation O 
of O 
ApoE O 
and O 
Clusterin O 
was O 
blocked O 
by O 
pretreatment O 
with O 
E-64d B-TRIVIAL 
both O 
in O 
mRNA O 
and O 
protein O 
levels O 
. O 
Further O 
, O 
E-64d B-TRIVIAL 
-pretreated O 
seizure O 
rats O 
( O 
EXP2 O 
) O 
showed O 
a O 
significant O 
downregulation O 
of O 
mRNA O 
expression O 
of O 
PRG-1 O 
, O 
PRG-3 O 
and O 
PRG-5 O 
, O 
cathepsin O 
B O 
and O 
ApoE O 
, O 
as O 
well O 
as O 
up O 
- O 
regulated O 
nSMase O 
and O 
ANX7 O 
in O 
hippocampus O 
when O 
compared O 
with O 
EXP1 O 
rats O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
suggest O 
that O 
E-64d B-TRIVIAL 
, O 
an O 
elective O 
inhibitor O 
of O 
calpain O 
and O 
autophagy O 
, O 
is O 
potentially O 
useful O 
in O 
the O 
treatment O 
of O 
developmental O 
seizure O 
- O 
induced O 
brain O 
damage O 
both O 
by O 
regulating O 
abnormal O 
zinc B-SYSTEMATIC 
signal O 
transduction O 
and O 
through O 
the O 
modulation O 
of O 
altered O 
lipid O 
metabolism O 
via O 
ApoE O 
/ O 
clusterin O 
pathway O 
in O 
hippocampus O 
. O 

effects O 
of O 
dietary O 
exposure O 
to O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
on O 
intestinal O 
and O 
hepatic O 
biotransformation O 
enzymes O 
and O 
drug O 
transporter O 
systems O 
in O 
broiler O 
chickens O 
. O 

effects O 
of O 
the O 
mycotoxin B-TRIVIAL 
T-2 I-TRIVIAL 
on O 
hepatic O 
and O 
intestinal O 
drug O 
- O 
metabolizing O 
enzymes O 
( O 
cytochrome O 
P450 O 
) O 
and O 
drug O 
transporter O 
systems O 
( O 
MDR1 O 
and O 
MRP2 O 
) O 
in O 
poultry O 
were O 
investigated O 
during O 
this O 
study O 
. O 
Broiler O 
chickens O 
received O 
either O 
uncontaminated O 
feed O 
, O 
feed O 
contaminated O 
with O 
68μg O 
/ O 
kg O 
or O 
752μg O 
/ O 
kg O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
. O 
After O 
3weeks O 
, O 
the O 
animals O 
were O 
euthanized O 
and O 
MDR1 O 
, O 
MRP2 O 
, O 
CYP1A4 O 
, O 
CYP1A5 O 
and O 
CYP3A37 O 
mRNA O 
expression O 
were O 
analyzed O 
using O 
qRT-PCR O 
. O 
Along O 
the O 
entire O 
length O 
of O 
the O 
small O 
intestine O 
no O 
significant O 
differences O 
were O 
observed O 
. O 
In O 
the O 
liver O 
, O 
genes O 
coding O 
for O 
CYP1A4 O 
, O 
CYP1A5 O 
and O 
CYP3A37 O 
were O 
significantly O 
down O 
- O 
regulated O 
in O 
the O 
group O 
exposed O 
to O 
752μg O 
/ O 
kg O 
T-2 O 
. O 
For O 
CYP1A4 O 
, O 
even O 
a O 
contamination O 
level O 
of O 
68μg O 
/ O 
kg O 
T-2 O 
caused O 
a O 
significant O 
decrease O 
in O 
mRNA O 
expression O 
. O 
Expression O 
of O 
MDR1 O 
was O 
not O 
significantly O 
decreased O 
in O 
the O 
liver O 
. O 
In O 
contrast O 
, O 
hepatic O 
MRP2 O 
expression O 
was O 
significantly O 
down O 
- O 
regulated O 
after O 
exposure O 
to O 
752μg O 
/ O 
kg O 
T-2 O 
. O 
Hepatic O 
and O 
intestinal O 
microsomes O 
were O 
prepared O 
to O 
test O 
the O 
enzymatic O 
activity O 
of O 
CYP3A O 
. O 
In O 
the O 
ileum O 
and O 
liver O 
CYP3A O 
activity O 
was O 
significantly O 
increased O 
in O 
the O 
group O 
receiving O 
752μg O 
/ O 
kg O 
T-2 O 
compared O 
to O 
the O 
control O 
group O 
. O 
The O 
results O 
of O 
this O 
study O 
show O 
that O 
drug O 
metabolizing O 
enzymes O 
and O 
drug O 
transporter O 
mechanisms O 
can O 
be O 
influenced O 
due O 
to O 
prolonged O 
exposure O 
to O 
relevant O 
doses O 
of O 
T-2 O 
. O 

. O 
Precision O 
- O 
cut O 
liver O 
slices O 
are O 
a O 
valuable O 
in O 
vitro O 
model O 
system O 
to O 
study O 
the O 
metabolism O 
and O 
toxicity O 
of O 
xenobiotics O 
. O 
Liver O 
slices O 
retain O 
tissue O 
architecture O 
so O 
that O 
all O 
cell O 
types O 
are O 
present O 
and O 
intercellular O 
communication O 
between O 
the O 
various O 
cell O 
types O 
is O 
retained O 
. O 
2 O 
. O 
Precision O 
- O 
cut O 
liver O 
slices O 
from O 
humans O 
and O 
other O 
species O 
have O 
been O 
used O 
to O 
study O 
pathways O 
of O 
phase O 
I O 
( O 
e.g O 
. O 
cytochrome O 
P450-dependent O 
biotransformations O 
) O 
and O 
II O 
( O 
e.g O 
. O 
conjugation O 
with O 
D-glucuronic B-TRIVIAL 
acid I-TRIVIAL 
, O 
sulphate B-SYSTEMATIC 
and O 
glutathione B-TRIVIAL 
) O 
metabolism O 
of O 
a O 
wide O 
range O 
of O 
xenobiotics O 
. O 
3 O 
. O 
Liver O 
slices O 
can O 
also O 
be O 
employed O 
to O 
investigate O 
the O 
induction O 
and O 
inhibition O 
of O 
xenobiotic O 
metabolizing O 
enzymes O 
and O 
to O 
obtain O 
kinetic O 
data O 
on O 
the O 
rates O 
of O 
metabolism O 
of O 
xenobiotics O 
. O 
4 O 
. O 
Precision O 
- O 
cut O 
liver O 
slices O 
from O 
humans O 
and O 
other O 
species O 
have O 
been O 
used O 
to O 
study O 
the O 
toxicity O 
of O 
a O 
wide O 
variety O 
of O 
xenobiotics O 
. O 
Toxicity O 
can O 
be O 
assessed O 
by O 
various O 
techniques O 
including O 
gene O 
expression O 
, O 
morphological O 
examination O 
and O 
a O 
wide O 
range O 
of O 
biochemical O 
endpoints O 
. O 
5 O 
. O 
Precision O 
- O 
cut O 
liver O 
slices O 
can O 
be O 
utilized O 
to O 
examine O 
species O 
differences O 
in O 
hepatic O 
xenobiotic O 
metabolism O 
and O 
xenobiotic O 
- O 
induced O 
toxicity O 
, O 
thus O 
permitting O 
comparisons O 
between O 
animal O 
species O 
and O 
humans O 
. O 

Changes O 
in O 
Cytochrome O 
c O 
Oxidase O 
Induced O 
by O 
Binding O 
of O 
Sodium B-SYSTEMATIC 
and O 
Calcium B-SYSTEMATIC 
Ions O 
: O 
An O 
ATR-FTIR O 
Study O 
. O 

total O 
reflection O 
Fourier O 
transform O 
infrared O 
( O 
ATR-FTIR O 
) O 
spectroscopy O 
was O 
used O 
to O 
investigate O 
the O 
binding O 
of O 
Na(+) B-FORMULA 
and O 
Ca(2+) B-FORMULA 
cations O 
to O 
bovine O 
cytochrome O 
c O 
oxidase O 
in O 
its O 
fully O 
oxidized O 
and O 
partially O 
reduced O 
, O 
cyanide B-SYSTEMATIC 
-ligated O 
( O 
a(2+)a3(3+)- O 
CN B-FORMULA 
) O 
( O 
mixed O 
valence O 
) O 
forms O 
. O 
These O 
ions O 
induced O 
distinctly O 
different O 
IR O 
binding O 
spectra O 
, O 
indicating O 
that O 
the O 
induced O 
structural O 
changes O 
are O 
different O 
. O 
Despite O 
this O 
, O 
their O 
binding O 
spectra O 
were O 
mutually O 
exclusive O 
, O 
confirming O 
their O 
known O 
competitive O 
binding O 
behavior O 
. O 
Dissociation O 
constants O 
for O 
Na(+) B-FORMULA 
and O 
Ca(2+) B-FORMULA 
with O 
the O 
oxidized O 
enzyme O 
were O 
1.2 O 
mM O 
and O 
11 O 
μM O 
, O 
respectively O 
and O 
Na(+) B-FORMULA 
binding O 
appeared O 
to O 
involve O 
cooperative O 
binding O 
of O 
two O 
Na(+) B-FORMULA 
. O 
Ca(2+) B-FORMULA 
binding O 
induced O 
a O 
large O 
IR O 
spectrum O 
, O 
with O 
prominent O 
amide B-FAMILY 
I O 
/ O 
II O 
polypeptide O 
changes O 
, O 
bandshifts O 
assigned O 
to O 
carboxylate B-SYSTEMATIC 
and O 
an O 
arginine B-TRIVIAL 
, O 
and O 
a O 
number O 
of O 
bandshifts O 
of O 
heme B-TRIVIAL 
a I-TRIVIAL 
. O 
The O 
Na(+) B-FORMULA 
-induced O 
binding O 
spectrum O 
showed O 
much O 
weaker O 
amide B-FAMILY 
I O 
/ O 
II O 
and O 
heme B-TRIVIAL 
a I-TRIVIAL 
changes O 
but O 
had O 
similar O 
shifts O 
assignable O 
to O 
carboxylate B-SYSTEMATIC 
and O 
arginine B-TRIVIAL 
residues O 
. O 
Yeast O 
CcO O 
also O 
displayed O 
a O 
calcium B-SYSTEMATIC 
-induced O 
IR O 
and O 
UV O 
/ O 
visible O 
binding O 
spectra O 
, O 
though O 
of O 
lower O 
intensities O 
. O 
This O 
was O 
attributed O 
to O 
the O 
difficulty O 
in O 
fully O 
depleting O 
Ca(2+) B-FORMULA 
from O 
its O 
binding O 
site O 
, O 
as O 
has O 
been O 
found O 
with O 
bacterial O 
CcOs O 
. O 
The O 
implications O 
of O 
Ca(2+) B-FORMULA 
/ O 
Na(+) B-FORMULA 
ion O 
binding O 
are O 
discussed O 
in O 
terms O 
of O 
structure O 
and O 
possible O 
modulation O 
of O 
core O 
catalytic O 
function O 
. O 

editing O 
is O 
one O 
of O 
the O 
post O 
- O 
transcriptional O 
processes O 
that O 
commonly O 
occur O 
in O 
plant O 
plastids O 
and O 
mitochondria O 
. O 
In O 
Arabidopsis O 
, O 
34 O 
C-to-U O 
RNA O 
editing O 
events O 
, O 
affecting O 
transcripts O 
of O 
18 O 
plastid O 
genes O 
, O 
have O 
been O 
identified O 
. O 
Here O 
, O 
we O 
examined O 
the O 
editing O 
and O 
expression O 
of O 
these O 
transcripts O 
in O 
different O 
organs O 
, O 
and O 
in O 
green O 
and O 
non-green O 
seedlings O 
( O 
etiolated O 
, O 
cia5-2 O 
, O 
ispF O 
and O 
ispG O 
albino O 
mutants O 
, O 
lincomycin B-TRIVIAL 
- O 
, O 
and O 
norflurazon B-TRIVIAL 
-treated O 
) O 
. O 
The O 
editing O 
efficiency O 
of O 
Arabidopsis O 
plastid O 
transcripts O 
varies O 
from O 
site O 
to O 
site O 
, O 
and O 
may O 
be O 
specifically O 
regulated O 
in O 
different O 
tissues O 
. O 
Steady O 
state O 
levels O 
of O 
plastid O 
transcripts O 
are O 
low O 
or O 
undetectable O 
in O 
etiolated O 
seedlings O 
, O 
but O 
most O 
editing O 
sites O 
are O 
edited O 
with O 
efficiencies O 
similar O 
to O 
those O 
observed O 
in O 
green O 
seedlings O 
. O 
By O 
contrast O 
, O 
the O 
editing O 
of O 
some O 
sites O 
is O 
completely O 
lost O 
or O 
significantly O 
reduced O 
in O 
other O 
non-green O 
tissues O 
; O 
for O 
instance O 
, O 
the O 
editing O 
of O 
ndhB-149 O 
, O 
ndhB-1255 O 
, O 
and O 
ndhD-2 O 
is O 
completely O 
lost O 
in O 
roots O 
and O 
in O 
lincomycin B-TRIVIAL 
-treated O 
seedlings O 
. O 
The O 
editing O 
of O 
ndhD-2 O 
is O 
also O 
completely O 
lost O 
in O 
albino O 
mutants O 
and O 
norflurazon B-TRIVIAL 
-treated O 
seedlings O 
. O 
However O 
, O 
matK-640 O 
is O 
completely O 
edited O 
, O 
and O 
accD-794 O 
, O 
atpF-92 O 
, O 
psbE-214 O 
, O 
psbF-77 O 
, O 
psbZ-50 O 
, O 
and O 
rps14-50 O 
are O 
completely O 
or O 
highly O 
edited O 
in O 
both O 
green O 
and O 
non-green O 
tissues O 
. O 
In O 
addition O 
, O 
the O 
expression O 
of O 
nucleus O 
- O 
encoded O 
RNA O 
polymerase O 
dependent O 
transcripts O 
is O 
specifically O 
induced O 
by O 
lincomycin B-TRIVIAL 
, O 
and O 
the O 
splicing O 
of O 
ndhB O 
transcripts O 
is O 
significantly O 
reduced O 
in O 
the O 
albino O 
mutants O 
and O 
inhibitor O 
- O 
treated O 
seedlings O 
. O 
Our O 
results O 
indicate O 
that O 
plastid O 
gene O 
expression O 
, O 
and O 
the O 
splicing O 
and O 
editing O 
of O 
plastid O 
transcripts O 
are O 
specifically O 
and O 
differentially O 
regulated O 
in O 
various O 
types O 
of O 
non-green O 
tissues O 
. O 

behaviour O 
response O 
and O 
esterase O 
inhibition O 
in O 
the O 
earthworm O 
, O 
Lumbricus O 
terrestris O 
, O 
after O 
exposure O 
to O 
chlorpyrifos B-TRIVIAL 
. O 

avoidance O 
response O 
of O 
earthworms O 
to O 
polluted O 
soils O 
has O 
been O 
standardised O 
using O 
a O 
simple O 
and O 
low O 
- O 
cost O 
test O 
, O 
which O 
facilitates O 
soil O 
toxicity O 
screening O 
. O 
In O 
this O 
study O 
, O 
the O 
avoidance O 
response O 
of O 
Lumbricus O 
terrestris O 
was O 
quantified O 
in O 
chlorpyrifos B-TRIVIAL 
-spiked O 
soils O 
, O 
depending O 
on O 
the O 
pesticide O 
concentration O 
and O 
exposure O 
duration O 
. O 
The O 
inhibition O 
of O 
acetylcholinesterase O 
( O 
AChE O 
) O 
and O 
carboxylesterase O 
( O 
CbE O 
) O 
activities O 
was O 
also O 
determined O 
as O 
indirect O 
measures O 
of O 
pesticide O 
bioavailability O 
. O 
The O 
effects O 
of O 
different O 
chlorpyrifos B-TRIVIAL 
concentrations O 
were O 
examined O 
in O 
a O 
standardised O 
test O 
( O 
two O 
- O 
chamber O 
system O 
) O 
with O 
0.6 O 
, O 
3 O 
and O 
15 O 
mg O 
/ O 
kg O 
chlorpyrifos B-TRIVIAL 
. O 
A O 
modification O 
of O 
the O 
test O 
involved O 
a O 
pre O 
- O 
exposure O 
step O 
( O 
24 O 
, O 
48 O 
or O 
72 O 
h O 
) O 
in O 
soils O 
spiked O 
with O 
15 O 
mg O 
/ O 
kg O 
. O 
In O 
both O 
protocols O 
, O 
earthworms O 
were O 
unable O 
to O 
avoid O 
the O 
contaminated O 
soils O 
. O 
However O 
, O 
the O 
esterase O 
activities O 
showed O 
that O 
all O 
earthworms O 
were O 
exposed O 
to O 
chlorpyrifos B-TRIVIAL 
. O 
Acetylcholinesterase O 
activity O 
did O 
not O 
change O 
in O 
earthworms O 
in O 
the O 
standardised O 
behavioural O 
test O 
( O 
0.58 O 
± O 
0.2 O 
U O 
/ O 
mg O 
protein O 
, O 
mean O 
± O 
SD O 
; O 
n O 
= O 
72 O 
) O 
, O 
whereas O 
the O 
CbE O 
activity O 
was O 
significantly O 
inhibited O 
( O 
62-87 O 
% O 
inhibition O 
) O 
in O 
earthworms O 
exposed O 
to O 
3 O 
and O 
15 O 
mg O 
/ O 
kg O 
. O 
In O 
the O 
modified O 
test O 
, O 
earthworms O 
had O 
greatly O 
inhibited O 
AChE O 
activity O 
( O 
0.088 O 
± O 
0.034 O 
U O 
/ O 
mg O 
protein O 
, O 
n O 
= O 
72 O 
) O 
, O 
which O 
was O 
supported O 
by O 
reactivation O 
of O 
the O 
inhibited O 
enzyme O 
activity O 
in O 
the O 
presence O 
of O 
pralidoxime B-TRIVIAL 
( O 
2-PAM B-SYSTEMATIC 
) O 
. O 
Similarly O 
, O 
the O 
CbE O 
activity O 
was O 
significantly O 
inhibited O 
in O 
earthworms O 
with O 
all O 
treatments O 
. O 
This O 
study O 
suggests O 
that O 
the O 
avoidance O 
behaviour O 
test O 
for O 
organophosphorus B-FAMILY 
-contaminated O 
soils O 
could O 
be O 
supported O 
by O 
specific O 
biomarkers O 
to O 
facilitate O 
a O 
better O 
understanding O 
of O 
pesticide O 
exposure O 
and O 
toxicity O 
during O 
this O 
test O 
. O 

Pharmacokinetics O 
and O 
Pharmacodynamics O 
of O 
Zaleplon B-TRIVIAL 
Delivered O 
as O 
a O 
Thermally O 
Generated O 
Aerosol O 
in O 
a O 
Single O 
Breath O 
to O 
Volunteers O 
. O 

, O 
pharmacodynamics O 
, O 
safety O 
, O 
and O 
tolerability O 
of O 
inhaled O 
zaleplon B-TRIVIAL 
were O 
assessed O 
in O 
healthy O 
volunteers O 
. O 
Forty O 
participants O 
received O 
0.5 O 
, O 
1 O 
, O 
2 O 
, O 
or O 
4 O 
mg O 
zaleplon B-TRIVIAL 
or O 
placebo O 
as O 
a O 
thermally O 
generated O 
aerosol O 
in O 
a O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
parallel O 
- O 
group O 
, O 
dose O 
escalation O 
study O 
. O 
Blood O 
was O 
collected O 
up O 
to O 
24 O 
hours O 
after O 
dosing O 
, O 
and O 
sedation O 
was O 
assessed O 
up O 
to O 
8 O 
hours O 
. O 
Following O 
inhalation O 
, O 
the O 
observed O 
median O 
time O 
to O 
maximum O 
plasma O 
concentrations O 
( O 
25% O 
, O 
75% O 
) O 
was O 
1.89 O 
( O 
1.45 O 
, O 
3.08 O 
) O 
minutes O 
and O 
the O 
mean O 
( O 
SD O 
) O 
elimination O 
half O 
- O 
life O 
was O 
1.24 O 
( O 
0.24 O 
) O 
hours O 
. O 
The O 
equilibration O 
half O 
- O 
life O 
for O 
sedation O 
( O 
t1 O 
/ O 
2 O 
ke0 O 
) O 
was O 
1.16 O 
( O 
0.62 O 
, O 
2.17 O 
) O 
minutes O 
. O 
The O 
zaleplon B-TRIVIAL 
AUC O 
was O 
dose O 
proportional O 
across O 
doses O 
, O 
with O 
a O 
slope O 
( O 
90% O 
confidence O 
interval O 
) O 
of O 
log-AUC O 
versus O 
log O 
- O 
dose O 
of O 
0.92 O 
( O 
0.82 O 
, O 
1.02 O 
) O 
. O 
No O 
clinically O 
significant O 
changes O 
were O 
noted O 
in O 
laboratory O 
values O 
, O 
vital O 
signs O 
, O 
or O 
spirometry O 
. O 
The O 
most O 
common O 
adverse O 
events O 
were O 
dizziness O 
, O 
somnolence O 
, O 
euphoria O 
, O 
headache O 
, O 
and O 
visual O 
disturbance O 
. O 
Zaleplon B-TRIVIAL 
inhalation O 
represents O 
a O 
safe O 
, O 
well O 
- O 
tolerated O 
means O 
of O 
rapidly O 
achieving O 
effective O 
plasma O 
concentrations O 
. O 

Azoles B-FAMILY 
: O 
Structural O 
Insights O 
into O 
Undesired O 
Tight O 
Binding O 
to O 
Cholesterol B-TRIVIAL 
-Metabolizing O 
CYP46A1 O 
. O 

there O 
are O 
currently O 
three O 
generations O 
of O 
antifungal O 
azoles B-FAMILY 
on O 
the O 
market O 
, O 
even O 
the O 
third O 
generation O 
agents O 
show O 
undesired O 
interactions O 
with O 
human O 
cytochrome O 
P450 O 
enzymes O 
. O 
CYP46A1 O 
is O 
a O 
cholesterol B-TRIVIAL 
-metabolizing O 
P450 O 
in O 
the O 
brain O 
tightly O 
binding O 
a O 
number O 
of O 
structurally O 
distinct O 
azoles B-FAMILY 
. O 
Previously O 
, O 
we O 
determined O 
the O 
crystal O 
structures O 
of O 
CYP46A1 O 
in O 
complex O 
with O 
voriconazole B-TRIVIAL 
and O 
clotrimazole B-TRIVIAL 
, O 
and O 
in O 
the O 
present O 
work O 
we O 
co O 
- O 
crystallized O 
the O 
P450 O 
with O 
posaconazole B-TRIVIAL 
at O 
2.5 O 
Å O 
resolution O 
. O 
This O 
long O 
antifungal O 
drug O 
coordinates O 
the O 
P450 O 
heme B-FAMILY 
iron B-SYSTEMATIC 
with O 
the O 
nitrogen B-SYSTEMATIC 
atom O 
of O 
its O 
terminal O 
azole B-FAMILY 
ring O 
and O 
adopts O 
a O 
linear O 
configuration O 
occupying O 
the O 
whole O 
length O 
of O 
the O 
substrate O 
access O 
channel O 
and O 
extending O 
beyond O 
the O 
protein O 
surface O 
. O 
Numerous O 
drug O 
- O 
protein O 
interactions O 
determine O 
the O 
submicromolar O 
Kd O 
of O 
posaconazole B-TRIVIAL 
for O 
CYP46A1 O 
. O 
We O 
compared O 
the O 
crystal O 
structure O 
of O 
posaconazole B-TRIVIAL 
-bound O 
CYP46A1 O 
with O 
those O 
of O 
the O 
P450 O 
in O 
complex O 
with O 
other O 
drugs O 
including O 
the O 
antifungal O 
voriconazole B-TRIVIAL 
and O 
clotrimazole B-TRIVIAL 
. O 
We O 
also O 
analyzed O 
the O 
accommodation O 
of O 
posaconazole B-TRIVIAL 
in O 
the O 
active O 
site O 
of O 
the O 
target O 
enzymes O 
, O 
CYPs O 
51 O 
, O 
from O 
several O 
pathogenic O 
species O 
. O 
These O 
and O 
the O 
solution O 
studies O 
with O 
different O 
marketed O 
azoles B-FAMILY 
, O 
collectively O 
, O 
allowed O 
us O 
to O 
identify O 
the O 
determinants O 
of O 
tight O 
azole B-FAMILY 
binding O 
to O 
CYP46A1 O 
and O 
generate O 
an O 
overall O 
picture O 
of O 
azole B-FAMILY 
binding O 
to O 
this O 
important O 
P450 O 
. O 
The O 
data O 
obtained O 
suggest O 
that O 
development O 
of O 
CYP51-specific O 
antifungal O 
agents O 
will O 
continue O 
to O 
be O 
a O 
challenge O 
. O 
Therefore O 
, O 
structural O 
understanding O 
of O 
the O 
azole B-FAMILY 
binding O 
not O 
only O 
to O 
CYPs O 
51 O 
from O 
the O 
pathogenic O 
species O 
but O 
also O 
to O 
different O 
human O 
P450s O 
is O 
required O 
to O 
deal O 
efficiently O 
with O 
this O 
challenge O 
. O 

of O 
hydroxychavicol B-SYSTEMATIC 
and O 
its O 
dimers O 
, O 
the O 
lipase O 
inhibitors O 
contained O 
in O 
the O 
Indonesian O 
spice O 
, O 
Eugenia O 
polyantha O 
. O 

of O 
pancreatic O 
lipase O 
is O 
effective O 
for O 
a O 
prevention O 
of O 
obesity O 
. O 
Eugenia O 
polyantha O 
is O 
a O 
tropical O 
tree O 
whose O 
leaves O 
are O 
known O 
as O 
a O 
spice O 
and O 
also O 
as O 
an O 
ingredient O 
for O 
Jamu O 
, O 
the O 
traditional O 
medicine O 
of O 
Indonesia O 
. O 
We O 
found O 
inhibitory O 
activity O 
against O 
pancreatic O 
lipase O 
in O 
the O 
extract O 
of O 
E O 
. O 
polyantha O 
leaves O 
. O 
Purification O 
of O 
the O 
active O 
principals O 
resulted O 
in O 
isolation O 
of O 
hydroxychavicol B-SYSTEMATIC 
, O 
and O 
two O 
structurally O 
new O 
dimers O 
. O 
All O 
of O 
the O 
isolated O 
compounds O 
showed O 
inhibitory O 
activity O 
against O 
the O 
porcine O 
pancreatic O 
lipase O 
and O 
high O 
content O 
of O 
hydroxychavicol B-SYSTEMATIC 
( O 
1.83 O 
wt.% O 
) O 
indicated O 
this O 
compound O 
to O 
be O 
responsible O 
for O 
the O 
majority O 
of O 
inhibitory O 
activity O 
of O 
E O 
. O 
polyantha O 
extract O 
. O 
Furthermore O 
, O 
hydroxychavicol B-SYSTEMATIC 
is O 
reported O 
to O 
possess O 
anti-carcinogenic O 
, O 
anti-oxidant O 
, O 
anti-microbial O 
and O 
anti-inflammatory O 
activity O 
which O 
is O 
related O 
to O 
traditional O 
usage O 
of O 
this O 
plant O 
. O 
These O 
results O 
offer O 
this O 
plant O 
as O 
an O 
attractive O 
material O 
for O 
treating O 
various O 
health O 
problems O 
including O 
obesity O 
. O 

- O 
induced O 
ER O 
calcium B-SYSTEMATIC 
release O 
and O 
inhibitory O 
effects O 
of O 
methionine B-TRIVIAL 
choline I-TRIVIAL 
in O 
cultured O 
rat O 
hippocampal O 
neurons O 
. O 

, O 
a O 
ubiquitous O 
neurotoxicant O 
, O 
can O 
result O 
in O 
learning O 
and O 
memory O 
dysfunction O 
. O 
Long O 
term O 
potentiation O 
in O 
the O 
hippocampus O 
, O 
a O 
potential O 
neural O 
substrate O 
for O 
learning O 
and O 
memory O 
, O 
is O 
thought O 
to O 
be O 
linked O 
to O 
calcium B-SYSTEMATIC 
-triggered O 
intracellular O 
events O 
. O 
In O 
this O 
study O 
, O 
laser O 
scanning O 
confocal O 
microscopy O 
was O 
used O 
to O 
examine O 
the O 
effects O 
of O 
Pb(2+) B-FORMULA 
on O 
intracellular O 
and O 
endoplasmic O 
reticulum O 
free O 
calcium B-SYSTEMATIC 
concentration O 
( O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
and O 
[ O 
Ca(2+) B-FORMULA 
](ER O 
) O 
) O 
in O 
cultured O 
neonatal O 
rat O 
hippocampal O 
neurons O 
and O 
their O 
possible O 
antagonism O 
by O 
methionine B-TRIVIAL 
choline I-TRIVIAL 
; O 
understanding O 
these O 
effects O 
would O 
help O 
explain O 
the O 
lead O 
- O 
induced O 
cognitive O 
and O 
learning O 
dysfunction O 
and O 
explore O 
efficient O 
safety O 
and O 
relief O 
strategies O 
. O 
The O 
results O 
showed O 
that O 
Pb(2+) B-FORMULA 
increased O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
and O 
decreased O 
[ O 
Ca(2+) B-FORMULA 
](ER O 
) O 
linearly O 
in O 
a O 
time- O 
and O 
concentration O 
- O 
dependant O 
manner O 
, O 
and O 
Pb(2+) B-FORMULA 
addition O 
after O 
the O 
applying O 
of O 
a O 
ryanodine B-TRIVIAL 
receptor O 
( O 
RyR O 
) O 
antagonist O 
and O 
an O 
inositol-1,4,5-triphosphate B-SYSTEMATIC 
receptor O 
( O 
IP(3)R O 
) O 
antagonist O 
did O 
not O 
increase O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
. O 
The O 
addition O 
of O 
10 O 
, O 
20 O 
, O 
or O 
40 O 
mmol O 
/ O 
L O 
methionine B-TRIVIAL 
choline I-TRIVIAL 
simultaneously O 
with O 
addition O 
of O 
10 O 
μmol O 
/ O 
L O 
Pb(2+) B-FORMULA 
decreased O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
in O 
Ca(2+) B-FORMULA 
-free O 
culture O 
medium O 
by O 
39.0% O 
, O 
66.0% O 
, O 
and O 
61.6% O 
, O 
respectively O 
, O 
in O 
a O 
concentration O 
- O 
dependant O 
manner O 
in O 
a O 
certain O 
dose O 
range O 
. O 
Our O 
results O 
suggest O 
that O 
Pb(2+) B-FORMULA 
induces O 
ER O 
calcium B-SYSTEMATIC 
release O 
to O 
increase O 
the O 
resting O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
; O 
and O 
methionine B-TRIVIAL 
choline I-TRIVIAL 
inhibit O 
this O 
increase O 
in O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
. O 

and O 
other O 
camptothecin B-TRIVIAL 
derivatives O 
poison O 
Leishmania O 
DNA-topoisomerase O 
IB O 
leading O 
to O 
a O 
strong O 
leishmanicidal O 
effect O 
. O 

aim O 
of O 
this O 
work O 
is O 
the O 
in O 
vitro O 
and O 
ex O 
vivo O 
assessment O 
of O 
the O 
leishmanicidal O 
activity O 
of O 
camptothecin B-TRIVIAL 
and O 
three O 
analogues O 
used O 
in O 
cancer O 
therapy O 
: O 
topotecan B-TRIVIAL 
( O 
Hycantim B-TRIVIAL 
( O 
® O 
) O 
) O 
, O 
gimatecan B-TRIVIAL 
( O 
ST1481 B-IDENTIFIER 
) O 
and O 
the O 
pro O 
- O 
drug O 
irinotecan B-TRIVIAL 
( O 
Camptosar B-TRIVIAL 
( O 
® O 
) O 
) O 
as O 
well O 
as O 
its O 
active O 
metabolite O 
SN-38 B-IDENTIFIER 
against O 
Leishmania O 
infantum O 
. O 
The O 
activity O 
of O 
camptothecin B-TRIVIAL 
and O 
its O 
derivatives O 
was O 
studied O 
on O 
extracellular O 
L O 
. O 
infantum O 
infrared O 
- O 
emitting O 
promastigotes O 
and O 
on O 
an O 
ex O 
vivo O 
murine O 
model O 
of O 
infected O 
splenocytes O 
with O 
L O 
. O 
infantum O 
fluorescent O 
amastigotes O 
. O 
In O 
situ O 
formation O 
of O 
SDS O 
/ O 
KCl O 
precipitable O 
DNA O 
- O 
protein O 
complexes O 
in O 
Leishmania O 
promastigotes O 
indicated O 
that O 
these O 
drugs O 
are O 
DNA O 
topoisomerase O 
IB O 
poisons O 
. O 
The O 
inhibitory O 
potency O 
of O 
camptothecin B-TRIVIAL 
derivatives O 
on O 
recombinant O 
L O 
. O 
infantum O 
topoisomerase O 
IB O 
was O 
assessed O 
in O 
vitro O 
showing O 
that O 
gimatecan B-TRIVIAL 
is O 
the O 
most O 
active O 
compound O 
preventing O 
the O 
relaxation O 
of O 
supercoiled O 
DNA O 
at O 
submicromolar O 
concentrations O 
. O 
Cleavage O 
equilibrium O 
assays O 
in O 
Leishmania O 
topoisomerase O 
IB O 
show O 
that O 
gimatecan B-TRIVIAL 
changes O 
the O 
equilibrium O 
towards O 
cleavage O 
at O 
much O 
lower O 
concentrations O 
than O 
the O 
other O 
camptothecin B-TRIVIAL 
derivatives O 
and O 
that O 
this O 
effect O 
persists O 
over O 
time O 
. O 
Gimatecan B-TRIVIAL 
and O 
camptothecin B-TRIVIAL 
were O 
the O 
most O 
powerful O 
compounds O 
preventing O 
cell O 
growth O 
of O 
free O 
- O 
living O 
L O 
. O 
infantum O 
promastigotes O 
within O 
the O 
same O 
concentration O 
range O 
. O 
All O 
these O 
compounds O 
killed O 
L O 
. O 
infantum O 
splenocyte O 
- O 
infecting O 
amastigotes O 
within O 
the O 
nanomolar O 
range O 
. O 
The O 
amastigote O 
form O 
showed O 
higher O 
sensitivity O 
to O 
topoisomerase O 
IB O 
poisons O 
( O 
with O 
high O 
therapeutic O 
selectivity O 
indexes O 
) O 
than O 
free O 
- O 
living O 
promastigotes O 
. O 
All O 
the O 
compounds O 
assayed O 
poisoned O 
L O 
. O 
infantum O 
DNA O 
topoisomerase O 
IB O 
leading O 
to O 
a O 
strong O 
leishmanicidal O 
effect O 
. O 
Camptothecin B-TRIVIAL 
derivatives O 
are O 
suitable O 
for O 
reducing O 
the O 
parasitic O 
burden O 
of O 
ex O 
vivo O 
infected O 
splenocytes O 
. O 
The O 
selectivity O 
index O 
of O 
gimatecan B-TRIVIAL 
makes O 
it O 
a O 
promising O 
drug O 
against O 
this O 
neglected O 
disease O 
. O 

-induced O 
hypertension O 
: O 
The O 
beneficial O 
effects O 
of O 
melatonin B-TRIVIAL 
. O 

: O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
effects O 
of O 
melatonin B-TRIVIAL 
on O 
biochemical O 
and O 
cardiovascular O 
changes O 
resulting O 
from O 
exposure O 
to O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
, O 
a O 
polychlorinated B-FAMILY 
dibenzo-para-dioxin I-FAMILY 
.Methods O 
: O 
A O 
total O 
of O 
24 O 
Sprague-Dawley O 
rats O 
were O 
divided O 
equally O 
into O 
the O 
following O 
four O 
groups O 
: O 
( O 
1 O 
) O 
control O 
group O 
was O 
administered O 
with O 
0.5 O 
mL O 
corn O 
oil O 
by O 
gavage O 
and O 
0.5 O 
cc O 
vehicle O 
of O 
melatonin B-TRIVIAL 
( O 
proportionally O 
nine O 
parts O 
physiological O 
serum O 
+ O 
one O 
part O 
ethyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) O 
intraperitoneally O 
for O 
4 O 
weeks O 
, O 
( O 
2 O 
) O 
the O 
melatonin B-TRIVIAL 
group O 
was O 
given O 
5 O 
mg O 
/ O 
kg O 
/ O 
day O 
melatonin B-TRIVIAL 
intraperitoneally O 
for O 
4 O 
weeks O 
, O 
( O 
3 O 
) O 
the O 
TCDD B-ABBREVIATION 
group O 
was O 
given O 
500 O 
ng O 
/ O 
kg O 
/ O 
day O 
TCDD B-ABBREVIATION 
by O 
gavage O 
for O 
4 O 
weeks O 
and O 
( O 
4 O 
) O 
the O 
TCDD B-ABBREVIATION 
+ O 
melatonin B-TRIVIAL 
group O 
was O 
given O 
TCDD B-ABBREVIATION 
( O 
500 O 
ng O 
/ O 
kg O 
/ O 
day O 
) O 
by O 
gavage O 
and O 
melatonin B-TRIVIAL 
( O 
5 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
intraperitoneally O 
simultaneously O 
for O 
4 O 
weeks O 
. O 
Systolic O 
blood O 
pressure O 
was O 
evaluated O 
by O 
the O 
tail O 
- O 
cuff O 
method O 
. O 
Vascular O 
responses O 
to O 
phenylephrine B-TRIVIAL 
and O 
acetylcholine B-SYSTEMATIC 
were O 
evaluated O 
in O 
the O 
isolated O 
thoracic O 
aortas.Results O 
: O 
TCDD B-ABBREVIATION 
not O 
only O 
augmented O 
the O 
systolic O 
blood O 
pressure O 
but O 
also O 
increased O 
the O 
contractile O 
responses O 
to O 
phenylephrine B-TRIVIAL 
in O 
aorta O 
. O 
Melatonin B-TRIVIAL 
reversed O 
the O 
blood O 
pressure O 
augmented O 
by O 
TCDD B-ABBREVIATION 
and O 
decreased O 
the O 
contractile O 
responses O 
to O 
phenylephrine B-TRIVIAL 
in O 
aorta O 
. O 
TCDD B-ABBREVIATION 
induced O 
an O 
increase O 
in O 
the O 
malondialdehyde B-TRIVIAL 
levels O 
in O 
kidney O 
tissue O 
and O 
melatonin B-TRIVIAL 
did O 
not O 
change O 
it O 
. O 
Therefore O 
, O 
TCDD B-ABBREVIATION 
caused O 
a O 
decrease O 
in O 
glutathione B-TRIVIAL 
levels O 
in O 
kidney O 
tissues O 
and O 
melatonin B-TRIVIAL 
reversed O 
it.Conclusion O 
: O 
Present O 
data O 
demonstrated O 
that O 
TCDD B-ABBREVIATION 
may O 
lead O 
to O 
an O 
increase O 
in O 
blood O 
pressure O 
via O 
increased O 
renal O 
oxidative O 
stress O 
and O 
vascular O 
reactivity O 
. O 
However O 
, O 
melatonin B-TRIVIAL 
might O 
ameliorate O 
the O 
blood O 
pressure O 
disturbed O 
by O 
TCDD B-ABBREVIATION 
in O 
part O 
by O 
decreasing O 
the O 
oxidant O 
activity O 
induced O 
by O 
TCDD B-ABBREVIATION 
. O 

nonsteroidal O 
anti-inflammatory O 
drugs O 
often O 
cause O 
ulcers O 
in O 
the O 
duodenum O 
in O 
humans O 
, O 
the O 
role O 
of O 
cyclooxygenase O 
( O 
COX O 
) O 
isoforms O 
in O 
the O 
pathogenesis O 
of O 
duodenal O 
ulcers O 
has O 
not O 
been O 
fully O 
elucidated O 
. O 
We O 
examined O 
in O 
cats O 
the O 
1 O 
) O 
ulcerogenic O 
effects O 
of O 
selective O 
COX-1 O 
( O 
SC-560 B-IDENTIFIER 
, O 
ketorolac B-TRIVIAL 
) O 
and O 
COX-2 O 
( O 
celecoxib B-TRIVIAL 
, O 
meloxicam B-TRIVIAL 
) O 
inhibitors O 
on O 
the O 
gastrointestinal O 
mucosa O 
, O 
2 O 
) O 
effect O 
of O 
feeding O 
and O 
cimetidine B-TRIVIAL 
on O 
the O 
expression O 
of O 
COX O 
isoforms O 
and O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
level O 
in O 
the O 
duodenum O 
, O 
and O 
3 O 
) O 
localization O 
of O 
COX O 
isoforms O 
in O 
the O 
duodenum O 
. O 
COX O 
inhibitors O 
were O 
administered O 
after O 
the O 
morning O 
meal O 
in O 
cats O 
once O 
daily O 
for O 
3 O 
days O 
. O 
Gastrointestinal O 
lesions O 
were O 
examined O 
on O 
day O 
4 O 
. O 
Localization O 
and O 
expression O 
of O 
COX O 
isoforms O 
( O 
by O 
immunohistochemistry O 
, O 
Western O 
blot O 
) O 
and O 
PGE(2) B-ABBREVIATION 
level O 
( O 
by O 
enzyme O 
immunoassay O 
) O 
were O 
examined O 
. O 
Results O 
were O 
as O 
follows O 
. O 
First O 
, O 
selective O 
COX-1 O 
or O 
COX-2 O 
inhibitors O 
alone O 
produced O 
marked O 
ulcers O 
in O 
the O 
duodenum O 
but O 
did O 
not O 
cause O 
obvious O 
lesions O 
in O 
the O 
small O 
intestine O 
. O 
Coadministration O 
of O 
SC-560 B-IDENTIFIER 
and O 
celecoxib B-TRIVIAL 
produced O 
marked O 
lesions O 
in O 
the O 
small O 
intestine O 
. O 
Second O 
, O 
feeding O 
increased O 
both O 
the O 
expression O 
of O 
COX O 
isoforms O 
and O 
PGE(2) B-ABBREVIATION 
level O 
in O 
the O 
duodenum O 
, O 
and O 
the O 
effects O 
were O 
markedly O 
inhibited O 
by O 
pretreatment O 
with O 
cimetidine B-TRIVIAL 
. O 
Third O 
, O 
COX-1 O 
was O 
localized O 
in O 
goblet O 
and O 
Brunner's O 
gland O 
cells O 
, O 
Meissner's O 
and O 
Auerbach's O 
plexus O 
, O 
smooth O 
muscle O 
cells O 
, O 
and O 
arterioles O 
; O 
and O 
COX-2 O 
was O 
observed O 
in O 
capillaries O 
, O 
venules O 
, O 
and O 
basal O 
granulated O 
cells O 
. O 
The O 
expression O 
of O 
COX O 
isoforms O 
in O 
the O 
duodenum O 
is O 
up O 
- O 
regulated O 
by O 
feeding O 
, O 
and O 
inhibition O 
of O 
either O 
COX-1 O 
or O 
COX-2 O 
causes O 
ulcers O 
in O 
the O 
duodenum O 
, O 
suggesting O 
that O 
both O 
isoforms O 
play O 
an O 
important O 
role O 
in O 
the O 
protection O 
of O 
the O 
duodenal O 
mucosa O 
. O 

mediated O 
controlled O 
release O 
from O 
a O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
based O 
hydrogel O 
. O 

synthetic O 
amino B-FAMILY 
acid I-FAMILY 
bearing O 
a O 
furan B-SYSTEMATIC 
functionality O 
was O 
developed O 
and O 
incorporated O 
into O 
peptide O 
sequences O 
using O 
solid O 
phase O 
synthesis O 
. O 
Peptides O 
expressing O 
the O 
furan B-SYSTEMATIC 
moiety O 
were O 
attached O 
to O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
hydrogels O 
through O 
a O 
thermally O 
reversible O 
covalent O 
bond O 
formed O 
by O 
a O 
Diels-Alder O 
reaction O 
. O 
Reactions O 
of O 
thiol B-FAMILY 
and O 
maleimide B-TRIVIAL 
PEG I-TRIVIAL 
macromers O 
in O 
an O 
off O 
- O 
stoichiometric O 
Michael O 
addition O 
were O 
performed O 
, O 
such O 
that O 
the O 
maleimide B-SYSTEMATIC 
moiety O 
was O 
in O 
excess O 
, O 
to O 
create O 
hydrogel O 
networks O 
with O 
pendant O 
Diels-Alder O 
compatible O 
tethering O 
sites O 
, O 
that O 
is O 
, O 
the O 
maleimide B-SYSTEMATIC 
. O 
By O 
making O 
use O 
of O 
the O 
Diels-Alder O 
reaction O 
, O 
it O 
was O 
possible O 
to O 
control O 
the O 
release O 
rate O 
of O 
reversibly O 
bound O 
moieties O 
from O 
the O 
hydrogel O 
by O 
changing O 
the O 
temperature O 
; O 
higher O 
temperatures O 
favor O 
a O 
faster O 
retro-Diels-Alder O 
reaction O 
and O 
, O 
therefore O 
, O 
a O 
faster O 
release O 
from O 
the O 
polymer O 
network O 
. O 
This O 
concept O 
was O 
demonstrated O 
by O 
incorporating O 
a O 
fluorescently O 
labeled O 
furan B-SYSTEMATIC 
-RGDS O 
sequence O 
into O 
a O 
hydrogel O 
possessing O 
excess O 
maleimide B-SYSTEMATIC 
functionalities O 
and O 
monitoring O 
the O 
subsequent O 
liberation O 
of O 
RGDS O 
at O 
various O 
temperatures O 
, O 
illustrating O 
a O 
Diels-Alder O 
mediated O 
release O 
mechanism O 
. O 
The O 
release O 
profile O 
was O 
quantified O 
at O 
temperatures O 
ranging O 
from O 
physiological O 
( O 
37 O 
°C O 
) O 
to O 
80 O 
°C O 
. O 
By O 
changing O 
the O 
temperature O 
, O 
varying O 
extents O 
of O 
release O 
were O 
attained O 
over O 
the O 
time O 
course O 
of O 
several O 
days O 
, O 
ranging O 
from O 
40% O 
release O 
for O 
lower O 
temperatures O 
to O 
complete O 
release O 
for O 
the O 
highest O 
temperature O 
considered O 
. O 
Further O 
confirmation O 
of O 
a O 
reaction O 
- O 
diffusion O 
controlled O 
release O 
mechanism O 
was O 
obtained O 
through O 
comparison O 
of O 
experimental O 
release O 
data O 
to O 
a O 
reaction O 
- O 
diffusion O 
model O 
of O 
the O 
release O 
. O 
In O 
addition O 
to O 
thermal O 
modulation O 
, O 
tuning O 
of O 
the O 
release O 
rate O 
was O 
accomplished O 
by O 
altering O 
the O 
number O 
of O 
possible O 
Diels-Alder O 
tethering O 
sites O 
present O 
in O 
the O 
hydrogel O 
. O 
Increasing O 
the O 
amount O 
of O 
free O 
maleimide B-SYSTEMATIC 
and O 
, O 
therefore O 
, O 
the O 
number O 
of O 
potential O 
Diels-Alder O 
reaction O 
sites O 
, O 
effectively O 
slowed O 
the O 
release O 
of O 
peptide O 
from O 
the O 
polymer O 
. O 
For O 
instance O 
, O 
doubling O 
the O 
amount O 
of O 
maleimide B-SYSTEMATIC 
sites O 
present O 
in O 
the O 
hydrogel O 
system O 
decreased O 
the O 
amount O 
of O 
peptide O 
released O 
from O 
approximately O 
60% O 
to O 
about O 
40% O 
in O 
the O 
same O 
span O 
of O 
time O 
. O 

occurs O 
in O 
15-20 O 
% O 
of O 
women O 
with O 
menstrual O 
disturbances O 
and O 
30-40 O 
% O 
of O 
infertile O 
women O 
and O 
it O 
can O 
adversely O 
affect O 
the O 
fertility O 
. O 
High O 
molecular O 
weight O 
prolactin O 
( O 
macroprolactin O 
) O 
has O 
long O 
been O 
known O 
in O 
hyperprolactinemic O 
fertile O 
women O 
. O 
However O 
, O 
the O 
prevalence O 
of O 
macroprolactinemia O 
in O 
hyperprolactinemic O 
infertile O 
women O 
is O 
not O 
known O 
. O 
This O 
cross O 
- O 
sectional O 
study O 
was O 
carried O 
out O 
during O 
the O 
period O 
of O 
June O 
2010 O 
and O 
June O 
2011 O 
at O 
a O 
single O 
tertiary O 
care O 
centre O 
. O 
All O 
women O 
who O 
attended O 
the O 
infertility O 
clinic O 
during O 
this O 
period O 
were O 
screened O 
for O 
hyperprolactinemia O 
and O 
only O 
women O 
with O 
hyperprolactinemia O 
and O 
infertility O 
were O 
further O 
studied O 
for O 
the O 
presence O 
of O 
macroprolactin O 
by O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
precipitation O 
assay O 
. O 
We O 
compared O 
the O 
clinical O 
, O 
hormonal O 
profile O 
and O 
fertility O 
outcome O 
of O 
infertile O 
women O 
with O 
true O 
hyperprolactinemia O 
and O 
macroprolacinemia O 
using O 
appropriate O 
statistical O 
tests O 
. O 
Of O 
1163 O 
infertile O 
women O 
, O 
183 O 
( O 
15.7 O 
% O 
) O 
had O 
hyperprolactinemia O 
[ O 
134 O 
( O 
73 O 
% O 
) O 
had O 
primary O 
infertility O 
and O 
49 O 
( O 
27 O 
% O 
) O 
had O 
secondary O 
infertility O 
] O 
. O 
Out O 
of O 
these O 
183 O 
women O 
with O 
hyperprolactinemia O 
, O 
one O 
had O 
microadenoma O 
, O 
161 O 
had O 
true O 
idiopathic O 
hyperprolactinemia O 
and O 
21 O 
( O 
11.5 O 
% O 
) O 
women O 
had O 
macroprolactinemia O 
. O 
The O 
prevalence O 
of O 
oligomenorrhea O 
and O 
galactorrhea O 
were O 
significantly O 
higher O 
in O 
patients O 
with O 
true O 
hyperprolactinemia O 
than O 
macroprolactinemia O 
( O 
46 O 
vs O 
. O 
14 O 
% O 
, O 
p O 
< O 
0.008 O 
and O 
30 O 
vs O 
. O 
5 O 
% O 
, O 
p O 
= O 
0.01 O 
respectively O 
) O 
. O 
Twenty O 
- O 
two O 
patients O 
( O 
13.5 O 
% O 
) O 
of O 
true O 
hyperprolactinemia O 
and O 
two O 
( O 
9 O 
% O 
) O 
in O 
macroprolactinemia O 
became O 
pregnant O 
during O 
the O 
study O 
period O 
. O 
Prolactin O 
measurement O 
should O 
be O 
a O 
part O 
of O 
routine O 
evaluation O 
of O 
couples O 
referred O 
to O 
infertility O 
clinics O 
. O 
Macroprolactin O 
screening O 
is O 
mandatory O 
when O 
clinical O 
features O 
and O 
serum O 
PRL O 
assay O 
results O 
are O 
conflicting O 
. O 
Patients O 
with O 
macroprolactinemia O 
should O 
be O 
investigated O 
for O 
causes O 
of O 
infertility O 
other O 
than O 
hyperprolactinemia O 
. O 

activity O 
and O 
mechanism O 
of O 
action O 
of O 
ceftazidime B-TRIVIAL 
and O 
apigenin B-TRIVIAL 
combination O 
against O 
ceftazidime B-TRIVIAL 
-resistant O 
Enterobacter O 
cloacae O 
. O 

purpose O 
of O 
this O 
investigation O 
was O 
to O 
examine O 
the O 
antibacterial O 
and O 
synergistic O 
effect O 
of O 
naturally O 
occurring O 
flavonoids B-FAMILY 
, O 
apigenin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
naringenin B-TRIVIAL 
and O 
ceftazidime B-TRIVIAL 
when O 
use O 
singly O 
and O 
in O 
combination O 
against O 
ceftazidime B-TRIVIAL 
-resistant O 
Enterobacter O 
cloacae O 
strains O 
by O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
, O 
checkerboard O 
and O 
viable O 
count O 
methods O 
. O 
The O 
mode O 
of O 
actions O 
were O 
also O 
studied O 
by O 
electronmicoscopy O 
, O 
enzyme O 
assay O 
, O 
outer O 
and O 
inner O 
membrane O 
permeabilisation O 
. O 
The O 
results O 
showed O 
that O 
these O 
strains O 
were O 
positive O 
in O 
the O 
ESBL-ampC O 
genes O 
combination O 
by O 
multiplex O 
PCR O 
. O 
These O 
findings O 
were O 
confirmed O 
by O 
MICs O 
that O 
these O 
strains O 
were O 
resistant O 
to O 
ceftazidime B-TRIVIAL 
, O 
cefepime B-TRIVIAL 
and O 
flomoxef B-TRIVIAL 
at O 
> O 
1024 O 
, O 
16-24 O 
, O 
> O 
256 O 
μg O 
/ O 
ml O 
respectively O 
, O 
while O 
susceptible O 
to O 
imipenem B-TRIVIAL 
at O 
1-2 O 
μg O 
/ O 
ml O 
. O 
The O 
synergistic O 
activity O 
was O 
observed O 
at O 
ceftazidime B-TRIVIAL 
plus O 
either O 
apigenin B-TRIVIAL 
or O 
naringenin B-TRIVIAL 
combinations O 
with O 
FIC O 
indixes O 
between O 
< O 
0.01 O 
and O 
< O 
0.27 O 
against O 
these O 
strains O 
, O 
whereas O 
ceftazidime B-TRIVIAL 
plus O 
clavulanic B-TRIVIAL 
acid I-TRIVIAL 
or O 
quercetin B-TRIVIAL 
did O 
not O 
exhibit O 
synergy O 
. O 
The O 
modulation O 
of O 
ceftazidime B-TRIVIAL 
-resistance O 
by O 
apigenin B-TRIVIAL 
or O 
narigenin B-TRIVIAL 
significantly O 
enhanced O 
the O 
activities O 
of O 
ceftazidime B-TRIVIAL 
. O 
The O 
5,7-OH B-SYSTEMATIC 
group O 
of O 
A O 
ring O 
and O 
one O 
4'-OH B-SYSTEMATIC 
group O 
of O 
the O 
B O 
ring O 
in O 
apigenin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
are O 
important O 
for O 
synergistic O 
activity O 
. O 
Viable O 
counts O 
showed O 
that O 
the O 
killing O 
of O 
ceftazidime B-TRIVIAL 
-resistant O 
E O 
. O 
cloacae O 
DMST O 
21394 O 
( O 
CREC O 
) O 
cells O 
by O 
3 O 
μg O 
/ O 
ml O 
ceftazidime B-TRIVIAL 
was O 
potentiated O 
by O 
3 O 
μg O 
/ O 
ml O 
apigenin B-TRIVIAL 
to O 
low O 
levels O 
( O 
10(3) O 
cfu O 
/ O 
ml O 
) O 
over O 
6h O 
. O 
Electronmicroscopy O 
clearly O 
showed O 
that O 
ceftazidime B-TRIVIAL 
3 O 
μg O 
/ O 
ml O 
in O 
combination O 
with O 
3 O 
μg O 
/ O 
ml O 
of O 
apigenin B-TRIVIAL 
also O 
caused O 
marked O 
morphological O 
damage O 
of O 
cell O 
wall O 
, O 
cell O 
shape O 
and O 
plasma O 
membrane O 
of O 
this O 
strain O 
. O 
Enzymes O 
assays O 
indicated O 
that O 
apigenin B-TRIVIAL 
showed O 
marked O 
inhibitory O 
activity O 
against O 
penicillinase O 
type O 
IV O 
from O 
E O 
. O 
cloacae O 
. O 
The O 
results O 
for O 
outer O 
membrane O 
( O 
OM O 
) O 
permeabilization O 
in O 
both O 
nitrocefin B-TRIVIAL 
( O 
NCF B-ABBREVIATION 
) O 
assay O 
and O 
crystal B-TRIVIAL 
violet I-TRIVIAL 
uptake O 
showed O 
that O 
the O 
combination O 
of O 
ceftazidime B-TRIVIAL 
plus O 
apigenin B-TRIVIAL 
significantly O 
altered O 
OM O 
permeabilisation O 
of O 
CREC O 
compared O 
to O 
control O 
or O 
single O 
treatment O 
of O 
these O 
agents O 
. O 
Both O 
o-nitrophenyl-β-D-galactoside B-SYSTEMATIC 
( O 
ONPG B-ABBREVIATION 
) O 
uptake O 
and O 
release O 
of O 
UV-absorbing O 
material O 
concentrations O 
results O 
exhibited O 
that O 
ceftazidime B-TRIVIAL 
and O 
apigenin B-TRIVIAL 
combination O 
damaged O 
CREC O 
cytoplasmic O 
membrane O 
( O 
CM O 
) O 
and O 
caused O 
subsequent O 
leakage O 
of O 
intracellular O 
constituents O 
. O 
From O 
the O 
results O 
, O 
it O 
can O 
be O 
concluded O 
that O 
apigenin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
have O 
the O 
synergistic O 
effect O 
with O 
ceftazidime B-TRIVIAL 
to O 
reverse O 
bacterial O 
resistance O 
to O 
this O 
cephalosporin B-FAMILY 
against O 
CREC O 
. O 
This O 
activity O 
may O 
be O 
involved O 
three O 
mechanisms O 
of O 
action O 
by O 
apigenin B-TRIVIAL 
. O 
The O 
first O 
is O 
on O 
the O 
peptidoglycan O 
synthesis O 
inhibition O 
. O 
The O 
second O 
mechanism O 
is O 
inhibition O 
the O 
activity O 
of O 
certain O 
β-lactamase O 
enzymes O 
. O 
The O 
third O 
mode O 
of O 
action O 
is O 
alteration O 
of O 
OM O 
and O 
CM O 
permeabilization O 
. O 
Apigenin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
have O 
a O 
sufficient O 
margin O 
of O 
safety O 
for O 
therapeutic O 
use O 
. O 
For O 
this O 
reason O 
, O 
apigenin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
offer O 
for O 
the O 
development O 
of O 
a O 
valuable O 
adjunct O 
to O 
ceftazidime B-TRIVIAL 
against O 
CREC O 
, O 
which O 
currently O 
almost O 
cephalosporins B-FAMILY 
resistance O 
. O 

transformation O 
of O 
asiatic B-TRIVIAL 
acid I-TRIVIAL 
. O 

acid I-TRIVIAL 
( O 
1 O 
) O 
, O 
a O 
major O 
pentacyclic B-FAMILY 
triterpene I-FAMILY 
of O 
Centella O 
asiatica O 
, O 
was O 
subjected O 
to O 
transformation O 
by O 
Penicillium O 
lilacinum O 
ACCC O 
31890 O 
, O 
Fusarium O 
equiseti O 
CGMCC O 
3.3658 O 
, O 
and O 
Streptomyces O 
griseus O 
CGMCC O 
4.18 O 
strains O 
. O 
Incubation O 
of O 
asiatic B-TRIVIAL 
acid I-TRIVIAL 
with O 
P O 
. O 
lilacinum O 
ACCC O 
31890 O 
and O 
F O 
. O 
equiseti O 
CGMCC O 
3.3658 O 
gave O 
an O 
identical O 
product O 
: O 
2α,3β,15α,23-tetrahydroxyurs-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
. O 
Biotransformation O 
of O 
asiatic B-TRIVIAL 
acid I-TRIVIAL 
by O 
S O 
. O 
griseus O 
CGMCC O 
4.18 O 
resulted O 
in O 
three O 
derivatives O 
: O 
2α,3β,21β,23-tetrahydroxyurs-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
2α,3β,23-trihydroxyurs-12-en-28 B-SYSTEMATIC 
, I-SYSTEMATIC 
30-dioic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
and O 
2α,3β,23,30-tetrahydroxyurs-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
5 O 
) O 
. O 
The O 
structures O 
of O 
those O 
derivatives O 
were O 
deduced O 
from O 
their O 
spectral O 
data O 
. O 
Products O 
( O 
2 O 
) O 
, O 
( O 
3 O 
) O 
, O 
and O 
( O 
4 O 
) O 
were O 
new O 
compounds O 
. O 
In O 
addition O 
, O 
the O 
in O 
vitro O 
cytotoxicities O 
of O 
those O 
derivatives O 
along O 
with O 
1 O 
were O 
evaluated O 
with O 
several O 
human O 
cancer O 
cell O 
lines O 
. O 

and O 
relaxometric O 
characterization O 
of O 
a O 
MRI O 
Gd B-FORMULA 
-based O 
probe O 
responsive O 
to O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
decarboxylase O 
enzymatic O 
activity O 
. O 

contrast O 
agent O 
based O 
systems O 
, O 
which O 
selectively O 
visualize O 
specific O 
cells O 
, O 
e.g O 
. O 
, O 
neurons O 
in O 
the O 
brain O 
, O 
would O 
be O 
of O 
substantial O 
importance O 
for O 
the O 
fast O 
developing O 
field O 
of O 
molecular O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
. O 
We O 
report O 
here O 
the O 
synthesis O 
and O 
in O 
vitro O 
validation O 
of O 
a O 
Gd B-FORMULA 
(III) I-FORMULA 
-based O 
contrast O 
agent O 
designed O 
to O 
act O 
as O 
an O 
MRI O 
responsive O 
probe O 
for O 
imaging O 
the O 
activity O 
of O 
the O 
enzyme O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
decarboxylase O 
( O 
GAD O 
) O 
present O 
in O 
neurons O 
. O 
Upon O 
the O 
action O 
of O 
the O 
enzyme O 
, O 
the O 
Gd B-FORMULA 
(III) I-FORMULA 
complex O 
increases O 
its O 
hydration O 
sphere O 
and O 
takes O 
on O 
a O 
residual O 
positive O 
charge O 
that O 
promotes O 
its O 
binding O 
to O 
endogenous O 
macromolecules O 
. O 
Both O 
effects O 
contribute O 
in O 
a O 
synergic O 
way O 
to O 
generate O 
a O 
marked O 
relaxation O 
enhancement O 
, O 
which O 
directly O 
reports O 
enzyme O 
activity O 
and O 
will O 
allow O 
activity O 
detection O 
of O 
GAD O 
positive O 
cells O 
in O 
vitro O 
and O 
in O 
vivo O 
selectively O 
. O 

and O 
antiproliferative O 
evaluation O 
of O 
piperazine-1-carbothiohydrazide B-SYSTEMATIC 
derivatives O 
of O 
indolin-2-one B-SYSTEMATIC 
. O 

varying O 
the O 
substituents O 
(R(1)) O 
at O 
the O 
indolin-2-one B-SYSTEMATIC 
scaffold O 
, O 
a O 
series O 
of O 
indolin-2-one B-SYSTEMATIC 
derivatives O 
bearing O 
4-phenylpiperazine-1-carbothiohydrazide B-SYSTEMATIC 
moiety O 
at O 
the O 
C3- O 
position O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
antiproliferative O 
activity O 
against O 
three O 
human O 
cancer O 
cell O 
lines O 
. O 
We O 
further O 
selected O 
the O 
5-chloroindolin-2-one B-SYSTEMATIC 
moiety O 
for O 
the O 
extension O 
to O 
another O 
series O 
of O 
compounds O 
by O 
varying O 
the O 
substituents O 
(R(2)) O 
at O 
the O 
phenyl B-SYSTEMATIC 
group O 
connected O 
with O 
the O 
piperazine B-SYSTEMATIC 
ring O 
. O 
Among O 
all O 
the O 
compounds O 
synthesized O 
, O 
6d O 
and O 
6l O 
were O 
most O 
potent O 
with O 
IC50 O 
values O 
of O 
3.59 O 
and O 
5.58μM O 
, O 
respectively O 
against O 
A549 O 
lung O 
cancer O 
cells O 
, O 
while O 
5f O 
and O 
6l O 
possessed O 
IC50 O 
values O 
of O 
3.49 O 
and O 
4.57μM O 
, O 
respectively O 
against O 
HCT-116 O 
colon O 
cancer O 
cells O 
which O 
were O 
comparable O 
to O 
that O 
of O 
Sunitinib B-TRIVIAL 
, O 
an O 
indolin-2-one B-SYSTEMATIC 
derivative O 
in O 
cancer O 
therapy O 
. O 

Hyperglycemia O 
may O 
increase O 
mortality O 
in O 
patients O 
who O 
receive O 
total O 
parenteral O 
nutrition O 
( O 
TPN O 
) O 
. O 
However O 
, O 
this O 
has O 
not O 
been O 
well O 
studied O 
in O 
noncritically O 
ill O 
patients O 
( O 
i.e O 
. O 
, O 
patients O 
in O 
the O 
nonintensive O 
care O 
unit O 
setting O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
mean O 
blood O 
glucose B-TRIVIAL 
level O 
during O 
TPN O 
infusion O 
is O 
associated O 
with O 
increased O 
mortality O 
in O 
noncritically O 
ill O 
hospitalized O 
patients O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
This O 
prospective O 
multicenter O 
study O 
involved O 
19 O 
Spanish O 
hospitals O 
. O 
Noncritically O 
ill O 
patients O 
who O 
were O 
prescribed O 
TPN O 
were O 
included O 
prospectively O 
, O 
and O 
data O 
were O 
collected O 
on O 
demographic O 
, O 
clinical O 
, O 
and O 
laboratory O 
variables O 
as O 
well O 
as O 
on O 
in O 
- O 
hospital O 
mortality O 
. O 
RESULTS O 
The O 
study O 
included O 
605 O 
patients O 
( O 
mean O 
age O 
63.2 O 
± O 
15.7 O 
years O 
) O 
. O 
The O 
daily O 
mean O 
TPN O 
values O 
were O 
1.63 O 
± O 
323 O 
kcal O 
, O 
3.2 O 
± O 
0.7 O 
g O 
carbohydrates B-FAMILY 
/ O 
kg O 
, O 
1.26 O 
± O 
0.3 O 
g O 
amino B-FAMILY 
acids I-FAMILY 
/ O 
kg O 
, O 
and O 
0.9 O 
± O 
0.2 O 
g O 
lipids O 
/ O 
kg O 
. O 
Multiple O 
logistic O 
regression O 
analysis O 
showed O 
that O 
the O 
patients O 
who O 
had O 
mean O 
blood O 
glucose B-TRIVIAL 
levels O 
> O 
180 O 
mg O 
/ O 
dL O 
during O 
the O 
TPN O 
infusion O 
had O 
a O 
risk O 
of O 
mortality O 
that O 
was O 
5.6 O 
times O 
greater O 
than O 
those O 
with O 
mean O 
blood O 
glucose B-TRIVIAL 
levels O 
< O 
140 O 
mg O 
/ O 
dL O 
( O 
95% O 
CI O 
1.47-21.4 O 
mg O 
/ O 
dL O 
) O 
after O 
adjusting O 
for O 
age O 
, O 
sex O 
, O 
nutritional O 
state O 
, O 
presence O 
of O 
diabetes O 
or O 
hyperglycemia O 
before O 
starting O 
TPN O 
, O 
diagnosis O 
, O 
prior O 
comorbidity O 
, O 
carbohydrates B-FAMILY 
infused O 
, O 
use O 
of O 
steroid B-FAMILY 
therapy O 
, O 
SD O 
of O 
blood O 
glucose B-TRIVIAL 
level O 
, O 
insulin O 
units O 
supplied O 
, O 
infectious O 
complications O 
, O 
albumin O 
, O 
C-reactive O 
protein O 
, O 
and O 
HbA1c O 
levels O 
. O 
CONCLUSIONS O 
Hyperglycemia O 
( O 
mean O 
blood O 
glucose B-TRIVIAL 
level O 
> O 
180 O 
mg O 
/ O 
dL O 
) O 
in O 
noncritically O 
ill O 
patients O 
who O 
receive O 
TPN O 
is O 
associated O 
with O 
a O 
higher O 
risk O 
of O 
in O 
- O 
hospital O 
mortality O 
. O 

of O 
Charge-Dependent O 
Transport O 
and O 
Toxicity O 
of O 
Peptide-Functionalized O 
Silver B-SYSTEMATIC 
Nanoparticles O 
Using O 
Zebrafish O 
Embryos O 
and O 
Single O 
Nanoparticle O 
Plasmonic O 
Spectroscopy O 
. O 

possess O 
unusually O 
high O 
surface O 
area O 
- O 
to O 
- O 
volume O 
ratios O 
, O 
and O 
surface O 
- O 
determined O 
physicochemical O 
properties O 
. O 
It O 
is O 
essential O 
to O 
understand O 
their O 
surface O 
- O 
dependent O 
toxicity O 
in O 
order O 
to O 
rationally O 
design O 
biocompatible O 
nanomaterials O 
for O 
a O 
wide O 
variety O 
of O 
applications O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
functionalized O 
the O 
surfaces O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
Ag B-FORMULA 
NPs O 
, O 
11.7 O 
± O 
2.7 O 
nm O 
in O 
diameters O 
) O 
with O 
three O 
biocompatible O 
peptides O 
( O 
CALNNK O 
, O 
CALNNS O 
, O 
CALNNE O 
) O 
to O 
prepare O 
positively O 
( O 
Ag B-FORMULA 
-CALNNK O 
NPs O 
+ O 
ζ O 
) O 
, O 
negatively O 
( O 
Ag B-FORMULA 
-CALNNS O 
NPs-2ζ O 
) O 
, O 
and O 
more O 
negatively O 
charged O 
NPs O 
( O 
Ag B-FORMULA 
-CALNNE O 
NPs-4ζ O 
) O 
, O 
respectively O 
. O 
Each O 
peptide O 
differs O 
in O 
a O 
single O 
amino B-FAMILY 
acid I-FAMILY 
at O 
its O 
C B-FORMULA 
-terminus O 
, O 
which O 
minimizes O 
the O 
effects O 
of O 
peptide O 
sequences O 
and O 
serves O 
as O 
a O 
model O 
molecule O 
to O 
create O 
positive O 
, O 
neutral O 
and O 
negative O 
charges O 
on O 
the O 
surface O 
of O 
the O 
NPs O 
at O 
pH O 
4-10 O 
. O 
We O 
have O 
studied O 
their O 
charge O 
- O 
dependent O 
transport O 
into O 
early O 
- O 
developing O 
( O 
cleavage O 
- O 
stage O 
) O 
zebrafish O 
embryos O 
and O 
their O 
effects O 
on O 
embryonic O 
development O 
using O 
dark O 
- O 
field O 
optical O 
microscopy O 
and O 
spectroscopy O 
( O 
DFOMS O 
) O 
. O 
We O 
found O 
that O 
all O 
three O 
Ag B-FORMULA 
-peptide O 
NPs O 
passively O 
diffused O 
into O 
the O 
embryos O 
via O 
their O 
chorionic O 
pore O 
canals O 
, O 
and O 
stayed O 
inside O 
the O 
embryos O 
throughout O 
their O 
entire O 
development O 
( O 
120 O 
h O 
) O 
, O 
showing O 
charge O 
- O 
independent O 
diffusion O 
modes O 
and O 
charge O 
- O 
dependent O 
diffusion O 
coefficients O 
. O 
Notably O 
, O 
the O 
NPs O 
create O 
charge O 
- O 
dependent O 
toxic O 
effects O 
on O 
embryonic O 
development O 
, O 
showing O 
that O 
the O 
Ag B-FORMULA 
-CALNNK O 
NPs O 
+ O 
ζ O 
( O 
positively O 
charged O 
) O 
are O 
the O 
most O 
biocompatible O 
while O 
the O 
Ag B-FORMULA 
-CALNNE O 
NPs-4ζ O 
( O 
more O 
negatively O 
charged O 
) O 
are O 
the O 
most O 
toxic O 
. O 
By O 
comparing O 
with O 
our O 
previous O 
studies O 
of O 
the O 
same O 
sized O 
citrated O 
Ag B-FORMULA 
and O 
Au B-FORMULA 
NPs O 
, O 
the O 
Ag B-FORMULA 
-peptide O 
NPs O 
are O 
much O 
more O 
biocompatible O 
than O 
the O 
citrated O 
Ag B-FORMULA 
NPs O 
, O 
and O 
nearly O 
as O 
biocompatible O 
as O 
the O 
Au B-FORMULA 
NPs O 
, O 
showing O 
the O 
dependence O 
of O 
nanotoxicity O 
upon O 
the O 
surface O 
charges O 
, O 
surface O 
functional O 
groups O 
and O 
chemical O 
compositions O 
of O 
the O 
NPs O 
. O 
This O 
study O 
also O 
demonstrates O 
powerful O 
applications O 
of O 
single O 
NP O 
plasmonic O 
spectroscopy O 
for O 
quantitative O 
analysis O 
of O 
single O 
NPs O 
in O 
vivo O 
and O 
in O 
tissues O 
, O 
and O 
reveals O 
the O 
possibility O 
of O 
rational O 
design O 
of O 
biocompatible O 
NPs O 
. O 

optimised O 
method O 
for O 
the O 
accurate O 
determination O 
of O 
zeranol B-TRIVIAL 
and O 
diethylstilbestrol B-SYSTEMATIC 
in O 
animal O 
tissues O 
using O 
isotope O 
dilution O 
- O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
. O 

dilution O 
- O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
( O 
ID-LC O 
/ O 
MS O 
) O 
has O 
been O 
established O 
as O 
a O 
candidate O 
reference O 
method O 
for O 
the O 
accurate O 
determination O 
of O 
growth O 
promoters O 
( O 
zeranol B-TRIVIAL 
, O 
taleranol B-TRIVIAL 
, O 
and O 
diethylstilbesterol B-SYSTEMATIC 
) O 
in O 
raw O 
meat O 
samples O 
. O 
Sample O 
preparation O 
processes O 
including O 
an O 
enzymatic O 
hydrolysis O 
, O 
extraction O 
, O 
and O 
SPE O 
clean O 
- O 
up O 
were O 
optimised O 
. O 
The O 
sensitivity O 
difference O 
of O 
trans- B-MULTIPLE 
and I-MULTIPLE 
cis-diethylstilbestrol I-MULTIPLE 
( O 
isomerizing O 
in O 
sample O 
preparation O 
processes O 
) O 
by O 
the O 
LC O 
/ O 
MS O 
was O 
measured O 
by O 
running O 
a O 
trans O 
/ O 
cis O 
mixture O 
( O 
ratio O 
measured O 
by O 
a O 
quantitative O 
NMR O 
) O 
with O 
and O 
without O 
sample O 
matrices O 
, O 
and O 
applied O 
for O 
the O 
determination O 
of O 
total O 
diethylstilbestrol B-SYSTEMATIC 
. O 
Validity O 
, O 
repeatability O 
, O 
and O 
reproducibility O 
of O 
the O 
analytical O 
method O 
were O 
tested O 
by O 
measuring O 
gravimetrically O 
fortified O 
samples O 
( O 
chicken O 
breast O 
, O 
bovine O 
muscles O 
, O 
and O 
porcine O 
muscle O 
) O 
in O 
a O 
number O 
of O 
different O 
time O 
periods O 
. O 
Measurement O 
results O 
agreed O 
with O 
the O 
fortified O 
values O 
within O 
their O 
uncertainties O 
. O 
The O 
method O 
provided O 
accurate O 
results O 
of O 
the O 
target O 
analytes O 
in O 
the O 
range O 
of O 
0.05-15μg O 
/ O 
kg O 
with O 
the O 
relative O 
expanded O 
uncertainty O 
of O 
2-15% O 
. O 

- O 
sized O 
, O 
2D O 
single O 
crystals O 
of O 
perylene B-SYSTEMATIC 
are O 
grown O 
by O 
both O 
solution O 
- O 
cast O 
and O 
physical O 
vapor O 
transport O 
methods O 
. O 
The O 
crystals O 
have O 
a O 
atomically O 
flat O 
parallelogram O 
morphology O 
and O 
the O 
aspect O 
ratios O 
of O 
the O 
lateral O 
extension O 
compared O 
to O 
the O 
thickness O 
are O 
up O 
to O 
10(3) O 
. O 
The O 
atomically O 
flat O 
feature O 
leads O 
to O 
good O 
interface O 
contact O 
, O 
making O 
a O 
single O 
- O 
crystal O 
field O 
- O 
effect O 
transistor O 
with O 
higher O 
mobility O 
. O 
The O 
mobility O 
of O 
atomically O 
flat O 
crystals O 
can O 
be O 
10(3) O 
-10(4) O 
times O 
higher O 
than O 
rough O 
crystals O 
. O 

of O 
complexity O 
of O 
the O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
to O 
a O 
non-covalent O 
structure O 
with O 
minimal O 
chemically O 
defined O 
components O 
represents O 
an O 
attractive O 
avenue O 
for O 
understanding O 
the O 
biology O 
of O 
the O 
ECM O 
. O 
The O 
resulting O 
system O 
could O 
lead O 
to O 
the O 
design O 
of O 
tailor O 
- O 
made O 
biomaterials O 
that O 
incorporate O 
varying O 
functionalities O 
. O 
Negatively O 
charged O 
glycosaminoglycans O 
are O 
the O 
major O 
components O 
of O 
the O 
ECM O 
. O 
Their O 
interaction O 
with O 
positively O 
charged O 
proteins O 
is O 
important O 
for O 
dynamic O 
three O 
- O 
dimensional O 
scaffold O 
formation O 
and O 
function O 
. O 
We O 
designed O 
and O 
screened O 
minimal O 
peptide O 
motifs O 
whose O 
conjugates O 
with O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
interact O 
with O 
heparin O 
to O 
form O 
non-covalent O 
hydrogels O 
. O 
Here O 
we O 
show O 
the O 
structure O 
/ O 
function O 
relationship O 
of O 
the O 
(RA)(n) O 
and O 
(KA)(n) O 
motifs O 
and O 
determined O 
that O 
both O 
basic O 
residues O 
and O 
the O 
heparin O 
- O 
induced O 
α-helix O 
formation O 
are O 
important O 
for O 
the O 
assembly O 
process O 
. O 
Simple O 
rules O 
allowed O 
us O 
to O 
tune O 
various O 
aspects O 
of O 
the O 
matrix O 
system O 
such O 
as O 
the O 
gelation O 
rates O 
, O 
biodegradability O 
, O 
rheological O 
properties O 
, O 
and O 
biofunctionality O 
. O 
The O 
hydrogels O 
can O 
encapsulate O 
cells O 
and O 
support O 
cell O 
survival O 
. O 

methods O 
for O 
pharmacokinetic O 
/ O 
pharmacodynamic O 
modeling O 
of O 
pazopanib B-TRIVIAL 
-induced O 
increases O 
in O 
blood O 
pressure O 
and O 
transaminases O 
. O 

between O 
plasma O 
pazopanib B-TRIVIAL 
concentrations O 
and O 
the O 
probability O 
of O 
elevations O 
in O 
blood O 
pressure O 
, O 
a O 
marker O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
receptor O 
inhibition O 
, O 
and O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
were O 
investigated O 
with O 
logistic O 
regression O 
models O 
. O 
Data O 
from O 
a O 
Phase O 
I O 
dose O 
- O 
escalation O 
study O 
in O 
cancer O 
patients O 
( O 
n O 
= O 
57 O 
) O 
were O 
examined O 
to O 
determine O 
the O 
relationship O 
between O 
steady O 
- O 
state O 
trough O 
plasma O 
pazopanib B-TRIVIAL 
concentrations O 
( O 
Cτ O 
) O 
and O 
a O 
clinically O 
significant O 
blood O 
pressure O 
increase O 
, O 
using O 
a O 
Bayesian O 
logistic O 
regression O 
model O 
. O 
Data O 
from O 
5 O 
monotherapy O 
studies O 
in O 
cancer O 
patients O 
( O 
n O 
= O 
344 O 
) O 
were O 
pooled O 
to O 
investigate O 
the O 
relationship O 
between O 
Cτ O 
and O 
maximum O 
ALT O 
≥ O 
3× O 
the O 
upper O 
limit O 
of O 
normal O 
( O 
ULN O 
) O 
, O 
using O 
a O 
Bayesian O 
logistic O 
regression O 
model O 
incorporating O 
an O 
asymptote O 
. O 
Both O 
models O 
were O 
fit O 
using O 
WinBUGS O 
. O 
The O 
median O 
( O 
95% O 
credible O 
interval O 
, O 
CrI O 
) O 
Cτ O 
at O 
which O 
the O 
probability O 
of O 
a O 
clinically O 
significant O 
increase O 
in O 
blood O 
pressure O 
was O 
50% O 
( O 
EC50 O 
) O 
was O 
12.3 O 
μg O 
/ O 
mL O 
( O 
6.12 O 
, O 
18.4 O 
) O 
. O 
The O 
median O 
( O 
95% O 
CrI O 
) O 
EC50 O 
for O 
the O 
maximum O 
probability O 
of O 
ALT O 
≥ O 
3 O 
× O 
ULN O 
was O 
15.4 O 
μg O 
/ O 
mL O 
( O 
3.8 O 
, O 
41.2 O 
) O 
and O 
the O 
median O 
( O 
95% O 
CrI O 
) O 
maximum O 
probability O 
of O 
ALT O 
≥ O 
3 O 
× O 
ULN O 
was O 
21% O 
( O 
14.5 O 
, O 
43.1 O 
) O 
. O 
Results O 
suggest O 
that O 
dose O 
adjustments O 
could O 
be O 
useful O 
in O 
managing O 
the O 
potential O 
for O 
hepatotoxicity O 
. O 

novel O 
mechanism O 
by O 
which O 
SDF-1β O 
protects O 
cardiac O 
cells O 
from O 
palmitate B-TRIVIAL 
-induced O 
ER O 
stress O 
and O 
apoptosis O 
via O 
CXCR7 O 
and O 
AMPK O 
/ O 
p38 O 
MAPK O 
- O 
mediated O 
IL-6 O 
generation O 
. O 

studied O 
the O 
protective O 
effect O 
of O 
stromal O 
cell O 
- O 
derived O 
factor-1beta O 
( O 
SDF-1β O 
) O 
on O 
cardiac O 
cells O 
from O 
lipotoxicity O 
in O 
vitro O 
and O 
diabetes O 
in O 
vivo O 
. O 
Exposure O 
of O 
cardiac O 
cells O 
to O 
palmitate B-TRIVIAL 
increased O 
apoptosis O 
by O 
activating O 
NADPH B-ABBREVIATION 
oxidase O 
- O 
associated O 
nitrosative O 
stress O 
and O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
, O 
which O 
abolished O 
by O 
pretreatment O 
with O 
SDF-1β O 
via O 
up O 
- O 
regulation O 
of O 
AMPK O 
- O 
mediated O 
p38 O 
MAPK O 
phosphorylation O 
and O 
IL-6 O 
production O 
. O 
The O 
SDF-1β O 
cardiac O 
protection O 
could O 
be O 
abolished O 
by O 
inhibition O 
of O 
AMPK O 
, O 
p38 O 
MAPK O 
or O 
IL-6 O 
. O 
Activation O 
of O 
AMPK O 
or O 
addition O 
of O 
recombinant O 
IL-6 O 
recaptured O 
a O 
similar O 
cardiac O 
protection O 
. O 
SDF-1β O 
receptor O 
CXCR4 O 
antagonist O 
AMD3100 B-IDENTIFIER 
or O 
CXCR4 O 
siRNA O 
could O 
not O 
, O 
but O 
CXCR7 O 
siRNA O 
completely O 
abolish O 
SDF-1β's O 
protection O 
from O 
palmitate B-TRIVIAL 
-induced O 
apoptosis O 
and O 
activation O 
of O 
AMPK O 
and O 
p38 O 
MAPK O 
. O 
Administration O 
of O 
SDF-1β O 
to O 
diabetic O 
rats O 
, O 
induced O 
by O 
high O 
- O 
fat O 
- O 
diet O 
feeding O 
with O 
a O 
small O 
dose O 
of O 
streptozotocin B-TRIVIAL 
, O 
could O 
significantly O 
reduce O 
cardiac O 
apoptosis O 
and O 
increase O 
in O 
AMPK O 
phosphorylation O 
along O 
with O 
a O 
prevention O 
of O 
diabetes O 
- O 
induced O 
cardiac O 
oxidative O 
damage O 
, O 
inflammation O 
, O 
hypertrophy O 
and O 
remodeling O 
. O 
These O 
results O 
showed O 
that O 
SDF-1β O 
protects O 
palmitate B-TRIVIAL 
-induced O 
cardiac O 
apoptosis O 
, O 
which O 
is O 
mediated O 
by O 
NADPH B-ABBREVIATION 
oxidase O 
- O 
activated O 
nitrosative O 
damage O 
and O 
ER O 
stress O 
, O 
via O 
CXCR7 O 
to O 
activate O 
AMPK O 
/ O 
p38 O 
MAPK O 
- O 
mediated O 
IL-6 O 
generation O 
. O 
The O 
cardiac O 
protection O 
by O 
SDF-1β O 
from O 
diabetes O 
- O 
induced O 
oxidative O 
damage O 
, O 
cell O 
death O 
and O 
remodeling O 
was O 
also O 
associated O 
with O 
AMPK O 
activation O 
. O 

circadian O 
rhythm O 
of O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
secretion O 
from O 
the O 
adrenal O 
cortex O 
is O 
regulated O 
by O 
the O 
suprachiasmatic O 
nucleus O 
( O 
SCN O 
) O 
, O 
which O 
is O 
entrained O 
to O 
the O 
light O 
- O 
dark O 
cycle O 
. O 
Since O 
the O 
circadian O 
CORT B-ABBREVIATION 
rhythm O 
is O 
associated O 
with O 
circadian O 
expression O 
of O 
the O 
steroidogenic O 
acute O 
regulatory O 
( O 
StAR O 
) O 
protein O 
, O 
we O 
investigated O 
the O 
24h O 
pattern O 
of O 
hormonal O 
secretion O 
( O 
ACTH O 
and O 
CORT B-ABBREVIATION 
) O 
, O 
steroidogenic O 
gene O 
expression O 
( O 
StAR O 
, O 
SF-1 O 
, O 
DAX1 O 
and O 
Nurr77 O 
) O 
and O 
the O 
expression O 
of O 
genes O 
involved O 
in O 
ACTH O 
signalling O 
( O 
MC2R O 
and O 
MRAP O 
) O 
in O 
rats O 
entrained O 
to O 
a O 
normal O 
light O 
- O 
dark O 
cycle O 
. O 
We O 
found O 
that O 
circadian O 
changes O 
in O 
ACTH O 
and O 
CORT B-ABBREVIATION 
were O 
associated O 
with O 
the O 
circadian O 
expression O 
of O 
all O 
gene O 
targets O 
; O 
with O 
SF-1 O 
, O 
Nurr77 O 
and O 
MRAP O 
peaking O 
in O 
the O 
evening O 
, O 
and O 
DAX1 O 
and O 
MC2R O 
peaking O 
in O 
the O 
morning O 
. O 
Since O 
disruption O 
of O 
normal O 
SCN O 
activity O 
by O 
exposure O 
to O 
constant O 
light O 
abolishes O 
the O 
circadian O 
rhythm O 
of O 
CORT B-ABBREVIATION 
in O 
the O 
rat O 
, O 
we O 
also O 
investigated O 
whether O 
the O 
AM-PM O 
variation O 
of O 
our O 
target O 
genes O 
was O 
also O 
disrupted O 
in O 
rats O 
exposed O 
to O 
constant O 
light O 
conditions O 
for O 
5weeks O 
. O 
We O 
found O 
that O 
the O 
disruption O 
of O 
the O 
AM-PM O 
variation O 
of O 
ACTH O 
and O 
CORT B-ABBREVIATION 
secretion O 
in O 
rats O 
exposed O 
to O 
constant O 
light O 
was O 
accompanied O 
by O 
a O 
loss O 
of O 
AM-PM O 
variation O 
in O 
StAR O 
, O 
SF-1 O 
and O 
DAX1 O 
, O 
and O 
a O 
reversed O 
AM-PM O 
variation O 
in O 
Nurr77 O 
, O 
MC2R O 
and O 
MRAP O 
. O 
Our O 
data O 
suggest O 
that O 
circadian O 
expression O 
of O 
StAR O 
is O 
regulated O 
by O 
the O 
circadian O 
expression O 
of O 
nuclear O 
receptors O 
and O 
proteins O 
involved O 
in O 
both O 
ACTH O 
signalling O 
and O 
StAR O 
transcription O 
. O 
We O 
propose O 
that O 
ACTH O 
regulates O 
the O 
secretion O 
of O 
CORT B-ABBREVIATION 
via O 
the O 
circadian O 
control O 
of O 
steroidogenic O 
gene O 
pathways O 
that O 
become O 
dysregulated O 
under O 
the O 
influence O 
of O 
constant O 
light O 
. O 

-functionalized O 
few O 
- O 
layer O 
graphene B-TRIVIAL 
sheets O 
as O 
active O 
catalysts O 
for O 
oxidative O 
dehydrogenation O 
reactions O 
. O 

for O 
this O 
month's O 
cover O 
is O 
the O 
group O 
from O 
the O 
Center O 
for O 
Nanophase O 
Materials O 
Sciences O 
( O 
CNMS O 
) O 
at O 
the O 
Oak O 
Ridge O 
National O 
Laboratory O 
. O 
The O 
illustration O 
is O 
of O 
the O 
catalytic O 
activity O 
of O 
the O 
reported O 
oxygen B-SYSTEMATIC 
-functionalized O 
few O 
- O 
layer O 
graphenes B-FAMILY 
, O 
whereas O 
the O 
micrograph O 
background O 
image O 
is O 
of O 
the O 
same O 
graphenes B-FAMILY 
recorded O 
by O 
the O 
authors O 
using O 
a O 
new O 
helium B-SYSTEMATIC 
-ion O 
microscope O 
at O 
the O 
CNMS O 
. O 
Read O 
the O 
full O 
text O 
of O 
the O 
article O 
at O 
10.1002 O 
/ O 
cssc.201200756 O 
. O 

maternal O 
" O 
junk O 
- O 
food O 
" O 
diet O 
reduces O 
sensitivity O 
to O 
the O 
opioid O 
antagonist O 
naloxone B-TRIVIAL 
in O 
offspring O 
postweaning O 
. O 

exposure O 
to O 
a O 
maternal O 
" O 
junk O 
- O 
food O 
" O 
diet O 
has O 
been O 
demonstrated O 
to O 
increase O 
the O 
preference O 
for O 
palatable O 
diets O 
in O 
adult O 
offspring O 
. O 
We O 
aimed O 
to O 
determine O 
whether O 
this O 
increased O 
preference O 
could O 
be O 
attributed O 
to O 
changes O 
in O 
μ-opioid O 
receptor O 
expression O 
within O 
the O 
mesolimbic O 
reward O 
pathway O 
. O 
We O 
report O 
here O 
that O 
mRNA O 
expression O 
of O 
the O 
μ-opioid O 
receptor O 
in O 
the O 
ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
at O 
weaning O 
was O 
1.4-fold O 
( O 
males O 
) O 
and O 
1.9-fold O 
( O 
females O 
) O 
lower O 
in O 
offspring O 
of O 
junk O 
- O 
food O 
(JF)-fed O 
rat O 
dams O 
than O 
in O 
offspring O 
of O 
dams O 
fed O 
a O 
standard O 
rodent O 
diet O 
( O 
control O 
) O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Administration O 
of O 
the O 
opioid O 
antagonist O 
naloxone B-TRIVIAL 
to O 
offspring O 
given O 
a O 
palatable O 
diet O 
postweaning O 
significantly O 
reduced O 
fat O 
intake O 
in O 
control O 
offspring O 
( O 
males O 
: O 
7.7 O 
± O 
0.7 O 
vs O 
. O 
5.4 O 
± O 
0.6 O 
g O 
/ O 
kg O 
/ O 
d O 
; O 
females O 
: O 
6.9 O 
± O 
0.3 O 
vs O 
. O 
3.9 O 
± O 
0.5 O 
g O 
/ O 
kg O 
/ O 
d O 
; O 
P O 
< O 
0.05 O 
) O 
, O 
but O 
not O 
in O 
male O 
JF O 
offspring O 
( O 
8.6 O 
± O 
0.6 O 
vs O 
. O 
7.1 O 
± O 
0.5 O 
g O 
/ O 
kg O 
/ O 
d O 
) O 
and O 
was O 
less O 
effective O 
at O 
reducing O 
fat O 
intake O 
in O 
JF O 
females O 
( O 
42.2 O 
± O 
6 O 
vs O 
. O 
23.1 O 
± O 
4.1% O 
reduction O 
, O 
P O 
< O 
0.05 O 
) O 
. O 
Similar O 
findings O 
were O 
observed O 
for O 
total O 
energy O 
intake O 
. O 
Naloxone B-TRIVIAL 
treatment O 
did O 
not O 
affect O 
intake O 
of O 
standard O 
rodent O 
feed O 
in O 
control O 
or O 
JF O 
offspring O 
. O 
These O 
findings O 
suggest O 
that O 
exposure O 
to O 
a O 
maternal O 
junk O 
- O 
food O 
diet O 
results O 
in O 
early O 
desensitization O 
of O 
the O 
opioid O 
system O 
which O 
may O 
explain O 
the O 
increased O 
preference O 
for O 
junk O 
food O 
in O 
these O 
offspring O 
. O 

effects O 
of O 
gypenosides B-FAMILY 
on O 
seven O 
human O 
cytochrome O 
P450 O 
enzymes O 
in O 
vitro O 
. O 

the O 
various O 
possible O 
causes O 
for O 
drug O 
interactions O 
, O 
pharmacokinetic O 
factors O 
such O 
as O 
inhibition O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
, O 
especially O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
enzymes O 
, O 
are O 
regarded O 
as O 
the O 
most O 
frequent O 
and O 
clinically O 
important O 
. O 
Gypenosides B-FAMILY 
is O 
widely O 
used O 
as O 
functional O 
food O 
and O 
over O 
- O 
the O 
- O 
counter O 
drug O 
in O 
East O 
Asia O 
. O 
In O 
this O 
study O 
, O 
the O 
in O 
vitro O 
inhibitory O 
effects O 
of O 
gypenosides B-FAMILY 
on O 
the O 
major O 
human O 
CYP O 
enzymes O 
( O 
CYP1A2 O 
, O 
CYP2B6 O 
, O 
CYP2C8 O 
, O 
CYP2C9 O 
, O 
CYP2C19 O 
, O 
CYP2D6 O 
, O 
and O 
CYP3A4 O 
) O 
activities O 
in O 
human O 
liver O 
microsomes O 
were O 
examined O 
using O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 
Gypenosides B-FAMILY 
showed O 
the O 
strongest O 
inhibition O 
of O 
CYP2D6 O 
, O 
followed O 
by O 
CYP2C8 O 
, O 
CYP3A4 O 
and O 
CYP2C9 O 
. O 
The O 
IC50 O 
values O 
were O 
1.61μg O 
/ O 
mL O 
, O 
20.06μg O 
/ O 
mL O 
, O 
34.76μg O 
/ O 
mL O 
( O 
CYP3A4/ O 
midazolam B-TRIVIAL 
) O 
, O 
46.73μg O 
/ O 
mL O 
( O 
CYP3A4/ O 
testosterone B-TRIVIAL 
) O 
, O 
and O 
54.52μg O 
/ O 
mL O 
, O 
respectively O 
. O 
Gypenosides B-FAMILY 
exhibited O 
competitive O 
inhibition O 
of O 
CYP2D6 O 
( O 
Ki=1.18 O 
) O 
. O 
In O 
conclusion O 
, O 
Gypenosides B-FAMILY 
might O 
cause O 
herb O 
- O 
drug O 
interactions O 
via O 
inhibition O 
of O 
CYP2D6 O 
. O 
An O 
in O 
vivo O 
study O 
is O 
needed O 
to O 
examine O 
this O 
further O 
. O 

β-lactams I-FAMILY 
as O 
antibacterial O 
agents O 
: O 
facing O 
antioxidant O 
activity O 
of O 
N-methylthio- B-FAMILY 
azetidinones I-FAMILY 
. O 

series O 
of O 
N-methylthio-β-lactams B-FAMILY 
with O 
antibacterial O 
activity O 
were O 
thoroughly O 
evaluated O 
as O 
antioxidants O 
. O 
We O 
found O 
that O 
only O 
the O 
presence O 
of O 
a O 
polyphenolic B-FAMILY 
moiety O 
anchored O 
to O 
the O 
β-lactam B-TRIVIAL 
ring O 
ensured O 
an O 
adequate O 
antioxidant O 
potency O 
. O 
New O 
compounds O 
, O 
efficiently O 
combining O 
in O 
one O 
structure O 
antioxidant O 
and O 
antibacterial O 
activity O 
, O 
may O 
provide O 
a O 
promising O 
basis O 
for O 
the O 
development O 
of O 
new O 
leads O 
useful O 
in O 
adverse O 
clinical O 
conditions O 
such O 
as O 
in O 
cystic O 
fibrosis O 
patients O 
, O 
in O 
whom O 
colonization O 
by O 
MRSA O 
and O 
epithelial O 
damage O 
by O 
chronic O 
pulmonary O 
oxidative O 
stress O 
take O 
place O 
. O 

diarylheptanoid B-FAMILY 
phytoestrogen O 
from O 
Curcuma O 
comosa O 
, O 
1,7-diphenyl-4,6-heptadien-3-ol B-SYSTEMATIC 
, O 
accelerates O 
human O 
osteoblast O 
proliferation O 
and O 
differentiation O 
. O 

comosa O 
Roxb O 
. O 
is O 
ginger O 
- O 
family O 
plant O 
used O 
to O 
relieve O 
menopausal O 
symptoms O 
. O 
Previous O 
work O 
showed O 
that O 
C O 
. O 
comosa O 
extracts O 
protect O 
mice O 
from O 
ovariectomy O 
- O 
induced O 
osteopenia O 
with O 
minimal O 
effects O 
on O 
reproductive O 
organs O 
, O 
and O 
identified O 
the O 
diarylheptanoid B-FAMILY 
(3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol B-SYSTEMATIC 
( O 
DPHD B-ABBREVIATION 
) O 
as O 
the O 
major O 
active O 
component O 
of O 
C O 
. O 
comosa O 
rhizomes O 
. O 
At O 
1-10μM O 
, O 
DPHD B-ABBREVIATION 
increased O 
differentiation O 
in O 
transformed O 
mouse O 
osteoblasts O 
, O 
but O 
the O 
effect O 
of O 
DPHD B-ABBREVIATION 
on O 
normal O 
bone O 
cells O 
was O 
unknown O 
. O 
We O 
examined O 
the O 
concentration O 
dependency O 
and O 
mechanism O 
of O 
action O 
of O 
DPHD B-ABBREVIATION 
relative O 
to O 
17β-estradiol B-SYSTEMATIC 
in O 
nontransformed O 
human O 
osteoblasts O 
( O 
h-OB O 
) O 
. O 
The O 
h-OB O 
were O 
10-100 O 
fold O 
more O 
sensitive O 
to O 
DPHD B-ABBREVIATION 
than O 
transformed O 
osteoblasts O 
: O 
DPHD B-ABBREVIATION 
increased O 
h-OB O 
proliferation O 
at O 
10nM O 
and O 
, O 
at O 
100nM O 
, O 
activated O 
MAP O 
kinase O 
signaling O 
within O 
30min O 
. O 
In O 
long O 
- O 
term O 
differentiation O 
assays O 
, O 
responses O 
of O 
h-OB O 
to O 
DPHD B-ABBREVIATION 
were O 
significant O 
at O 
10nM O 
, O 
and O 
optimal O 
response O 
in O 
most O 
cases O 
was O 
at O 
100nM O 
. O 
At O 
7-21 O 
days O 
, O 
DPHD B-ABBREVIATION 
accelerated O 
osteoblast O 
differentiation O 
, O 
indicated O 
by O 
alkaline O 
phosphatase O 
activity O 
and O 
osteoblast O 
- O 
specific O 
mRNA O 
production O 
. O 
Effects O 
of O 
DPHD B-ABBREVIATION 
were O 
eliminated O 
by O 
the O 
estrogen B-FAMILY 
receptor O 
antagonist O 
ICI182780 B-IDENTIFIER 
. O 
During O 
differentiation O 
, O 
DPHD B-ABBREVIATION 
promoted O 
early O 
expression O 
of O 
osteoblast O 
transcription O 
factors O 
, O 
RUNX2 O 
and O 
osterix O 
. O 
Subsequently O 
, O 
DPHD B-ABBREVIATION 
accelerated O 
production O 
of O 
bone O 
structural O 
genes O 
, O 
including O 
COL1A1 O 
and O 
osteocalcin O 
comparably O 
to O 
17β-estradiol B-SYSTEMATIC 
. O 
In O 
h-OB O 
, O 
DPHD B-ABBREVIATION 
increased O 
the O 
osteoprotegerin O 
to O 
RANKL O 
ratio O 
and O 
supported O 
mineralization O 
more O 
efficiently O 
than O 
10nM O 
17β-estradiol B-SYSTEMATIC 
. O 
We O 
conclude O 
that O 
DPHD B-ABBREVIATION 
promotes O 
human O 
osteoblast O 
function O 
in O 
vitro O 
effectively O 
at O 
nanomolar O 
concentrations O 
, O 
making O 
it O 
a O 
promising O 
compound O 
to O 
protect O 
bone O 
in O 
menopausal O 
women O 
. O 

genotoxicity O 
of O 
PEI B-ABBREVIATION 
-based O 
nanoparticles O 
is O 
reduced O 
by O 
acetylation O 
of O 
polyethylenimine B-FAMILY 
amines I-FAMILY 
in O 
human O 
primary O 
cells O 
. O 

ultrasmall O 
size O 
and O 
unique O 
properties O 
of O 
polymeric O 
nanoparticles O 
( O 
NPs O 
) O 
have O 
led O 
to O 
raising O 
concerns O 
about O 
their O 
potential O 
cyto- O 
and O 
genotoxicity O 
on O 
biological O 
systems O 
. O 
Polyethylenimine B-FAMILY 
( O 
PEI B-ABBREVIATION 
) O 
is O 
a O 
highly O 
positive O 
charged O 
polymer O 
and O 
is O 
known O 
to O 
have O 
varying O 
degree O 
of O 
toxic O 
effect O 
to O 
cells O 
based O 
on O 
its O 
chemical O 
structure O 
( O 
i.e O 
. O 
, O 
amount O 
of O 
primary B-MULTIPLE 
and I-MULTIPLE 
secondary I-MULTIPLE 
amine I-MULTIPLE 
) O 
. O 
Herein O 
, O 
drug O 
delivery O 
carriers O 
such O 
as O 
PEI B-ABBREVIATION 
- O 
PLGA B-ABBREVIATION 
nanoparticles O 
( O 
PEI B-ABBREVIATION 
-NPs O 
) O 
and O 
acetylated B-ABBREVIATION 
PEI I-ABBREVIATION 
- O 
PLGA B-ABBREVIATION 
nanoparticles O 
( O 
AcPEI B-ABBREVIATION 
-NPs O 
) O 
were O 
utilized O 
to O 
examine O 
the O 
effect O 
of O 
acetylation O 
on O 
NPs O 
biocompatibility O 
and O 
genotoxicity O 
, O 
using O 
human O 
primary O 
cells O 
as O 
in O 
vitro O 
model O 
. O 
Cell O 
uptake O 
of O 
NPs O 
was O 
characterized O 
along O 
with O 
their O 
effects O 
on O 
cellular O 
viability O 
. O 
The O 
results O 
indicate O 
that O 
both O 
NPs O 
showed O 
an O 
equivalent O 
behavior O 
in O 
terms O 
of O 
uptake O 
and O 
biocompatibility O 
. O 
In O 
depth O 
analysis O 
of O 
NP O 
uptake O 
on O 
cell O 
biology O 
evidenced O 
that O 
these O 
nanoparticles O 
induced O 
dose O 
dependant O 
genotoxic O 
effects O 
. O 
This O 
phenomenon O 
was O 
significantly O 
reduced O 
by O 
PEI B-ABBREVIATION 
acetylation O 
. O 
Endocytosed O 
PEI B-ABBREVIATION 
-NPs O 
trigger O 
an O 
oxidative O 
stress O 
on O 
cells O 
by O 
inducing O 
the O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
which O 
cause O 
DNA O 
damage O 
without O 
apparently O 
affecting O 
cell O 
viability O 
. O 
Thus O 
, O 
the O 
genotoxicity O 
of O 
nanoparticles O 
, O 
that O 
could O 
be O 
used O 
as O 
non-viral O 
drug O 
carriers O 
, O 
should O 
be O 
evaluated O 
based O 
on O 
the O 
intracellular O 
level O 
of O 
ROS O 
generation O 
and O 
DNA O 
damage O 
even O 
in O 
absence O 
of O 
a O 
significant O 
cell O 
death O 
. O 

are O 
an O 
important O 
cause O 
of O 
chemical O 
- O 
induced O 
occupational O 
asthma O 
. O 
This O 
type O 
of O 
immunologically O 
mediated O 
asthma O 
is O 
often O 
characterized O 
by O 
a O 
predominant O 
granulocytic O 
inflammation O 
in O 
the O 
airways O 
, O 
rather O 
than O 
an O 
infiltration O 
by O 
lymphocytes O 
. O 
We O 
sought O 
to O 
determine O 
the O 
contribution O 
of O 
granulocytes O 
in O 
the O 
outcome O 
of O 
chemical O 
- O 
induced O 
asthma O 
using O 
general O 
and O 
specific O 
leukocyte O 
depletion O 
strategies O 
in O 
an O 
established O 
mouse O 
model O 
of O 
isocyanate B-SYSTEMATIC 
asthma O 
. O 
On O 
days O 
1 O 
and O 
8 O 
, O 
BALB O 
/ O 
c O 
mice O 
received O 
dermal O 
applications O 
with O 
toluene-2,4-diisocyanate B-SYSTEMATIC 
( O 
TDI B-ABBREVIATION 
) O 
or O 
vehicle O 
( O 
acetone B-SYSTEMATIC 
olive O 
oil O 
) O 
, O 
followed O 
by O 
two O 
ip O 
injections O 
of O 
cyclophosphamide B-TRIVIAL 
( O 
CP O 
, O 
days O 
11 O 
and O 
13 O 
) O 
, O 
or O 
one O 
iv O 
injection O 
of O 
antigranulocyte O 
receptor O 
1 O 
( O 
aGR1 O 
, O 
day O 
13 O 
) O 
monoclonal O 
antibody O 
( O 
mAb O 
) O 
, O 
or O 
two O 
ip O 
injections O 
of O 
Ly6G-specific O 
mAb O 
( O 
1A8 O 
, O 
days O 
13 O 
and O 
14 O 
) O 
. O 
On O 
day O 
15 O 
, O 
the O 
mice O 
were O 
challenged O 
( O 
oropharyngeal O 
administration O 
) O 
with O 
TDI B-ABBREVIATION 
or O 
vehicle O 
. O 
The O 
next O 
day O 
, O 
we O 
assessed O 
methacholine B-TRIVIAL 
airway O 
hyperreactivity O 
( O 
AHR O 
) O 
; O 
bronchoalveolar O 
lavage O 
differential O 
cell O 
count O 
; O 
histopathology O 
and O 
total O 
serum O 
IgE O 
; O 
and O 
auricular O 
lymphocyte O 
subpopulations O 
and O 
release O 
of O 
interleukin O 
(IL)-2 O 
, O 
IL-4 O 
, O 
IL-10 O 
, O 
IL-13 O 
, O 
and O 
gamma O 
interferon O 
by O 
these O 
lymphocytes O 
. O 
CP O 
depleted O 
all O 
leukocyte O 
types O 
and O 
completely O 
prevented O 
AHR O 
and O 
airway O 
inflammation O 
. O 
aGR1 O 
depleted O 
granulocytes O 
and O 
CD8(+) O 
lymphocytes O 
, O 
which O 
resulted O 
in O 
a O 
partial O 
prevention O 
in O 
AHR O 
but O 
no O 
decrease O 
in O 
airway O 
inflammation O 
. O 
Depletion O 
of O 
Ly6G-positive O 
granulocytes O 
, O 
i.e O 
. O 
, O 
both O 
neutrophils O 
and O 
eosinophils O 
, O 
prevented O 
AHR O 
and O 
lung O 
epithelial O 
damage O 
and O 
significantly O 
reduced O 
airway O 
inflammation O 
. O 
Injection O 
of O 
aGR1 O 
or O 
1A8 O 
led O 
to O 
significantly O 
changed O 
cytokine O 
release O 
patterns O 
in O 
TDI B-ABBREVIATION 
-treated O 
mice O 
. O 
Granulocytes O 
, O 
both O 
neutrophils O 
and O 
eosinophils O 
, O 
are O 
key O 
cellular O 
players O 
in O 
this O 
model O 
of O 
chemical O 
- O 
induced O 
asthma O 
. O 

REVERSE O 
TRANSCRIPTASE O 
INHIBITORS O 
INDUCE O 
A O 
MITOPHAGY-ASSOCIATED O 
ENDOTHELIAL O 
DYSFUNCTION O 
THAT O 
IS O 
REVERSED O 
BY O 
COENZYME B-TRIVIAL 
Q10 I-TRIVIAL 
CO O 
- O 
TREATMENT O 
. O 

complications O 
have O 
been O 
documented O 
in O 
HIV-1 O 
infected O 
populations O 
, O 
and O 
antiretroviral O 
therapy O 
may O 
play O 
a O 
role O 
. O 
Nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitors O 
( O 
NRTI O 
) O 
are O 
antiretrovirals O 
known O 
to O 
induce O 
mitochondrial O 
damage O 
in O 
endothelial O 
cells O 
, O 
culminating O 
in O 
endothelial O 
dysfunction O 
, O 
an O 
initiating O 
event O 
in O 
atherogenesis O 
. O 
Though O 
the O 
mechanism O 
for O 
NRTI-induced O 
endothelial O 
toxicity O 
is O 
not O 
yet O 
clear O 
, O 
our O 
prior O 
work O 
suggested O 
that O 
a O 
mitochondrial O 
oxidative O 
stress O 
may O 
be O 
involved O 
. O 
To O 
further O 
delineate O 
the O 
mechanism O 
of O 
toxicity O 
, O 
endothelial O 
cells O 
were O 
treated O 
with O 
NRTI O 
of O 
varying O 
subclasses O 
, O 
and O 
the O 
level O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
mitochondrial O 
function O 
were O 
assessed O 
. O 
To O 
test O 
whether O 
rescue O 
of O 
mitochondrial O 
electron O 
transport O 
attenuated O 
NRTI-induced O 
endothelial O 
dysfunction O 
, O 
in O 
some O 
cases O 
, O 
cells O 
were O 
co O 
- O 
treated O 
with O 
the O 
electron O 
transport O 
cofactor O 
coenzyme B-TRIVIAL 
Q10 I-TRIVIAL 
( O 
Q10 B-ABBREVIATION 
) O 
. O 
At O 
4-6h O 
, O 
NRTI O 
increased O 
levels O 
of O 
ROS O 
but O 
decreased O 
the O 
activities O 
of O 
electron O 
transport O 
chain O 
complexes O 
I-IV O 
, O 
levels O 
of O 
ATP B-ABBREVIATION 
and O 
the O 
NAD B-ABBREVIATION 
/ O 
NADH B-ABBREVIATION 
ratio O 
. O 
Moreover O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
levels O 
were O 
decreased O 
, O 
while O 
endothelin-1 O 
release O 
was O 
increased O 
. O 
Q10 B-ABBREVIATION 
abolished O 
NRTI-induced O 
mitochondria O 
injury O 
and O 
effects O 
on O 
endothelial O 
agonist O 
production O 
. O 
Interestingly O 
, O 
in O 
cells O 
treated O 
with O 
NRTI O 
only O 
, O 
markers O 
for O 
mitochondrial O 
toxicity O 
returned O 
to O 
baseline O 
levels O 
by O 
18-24h O 
, O 
suggesting O 
a O 
compensatory O 
mechanism O 
for O 
clearing O 
damaged O 
mitochondria O 
. O 
Using O 
confocal O 
microscopy O 
, O 
with O 
confirmation O 
utilizing O 
the O 
autophagy O 
and O 
mitophagy O 
markers O 
LC-3 O 
and O 
NIX O 
, O 
respectively O 
, O 
we O 
observed O 
autophagy O 
of O 
mitochondria O 
at O 
8-10 O 
h O 
after O 
treatment O 
. O 
Q10 B-ABBREVIATION 
prevented O 
NRTI O 
- O 
mediated O 
increase O 
in O 
LC-3 O 
. O 
These O 
findings O 
suggest O 
that O 
NRTI-induced O 
mitophagy O 
may O 
be O 
involved O 
in O 
NRTI-induced O 
endothelial O 
dysfunction O 
and O 
that O 
this O 
damage O 
likely O 
results O 
from O 
oxidant O 
injury O 
. O 
Further O 
, O 
Q10 B-ABBREVIATION 
supplementation O 
could O 
potentially O 
prevent O 
NRTI-induced O 
endothelial O 
dysfunction O 
. O 

intake O 
of O 
macronutrients O 
( O 
carbohydrate B-FAMILY 
, O 
protein O 
, O 
and O 
fat O 
) O 
has O 
been O 
associated O 
with O 
risk O 
of O 
chronic O 
conditions O 
such O 
as O 
obesity O 
and O 
diabetes O 
. O 
Family O 
studies O 
have O 
reported O 
a O 
moderate O 
contribution O 
of O 
genetics O 
to O 
variation O 
in O 
macronutrient O 
intake O 
. O 
In O 
a O 
genome O 
- O 
wide O 
meta-analysis O 
of O 
a O 
population O 
- O 
based O 
discovery O 
cohort O 
( O 
n O 
= O 
33 O 
533 O 
) O 
, O 
rs838133 O 
in O 
FGF21 O 
( O 
19q13.33 O 
) O 
, O 
rs197273 O 
near O 
TRAF O 
family O 
member O 
- O 
associated O 
NF-kappa-B O 
activator O 
( O 
TANK O 
) O 
( O 
2p24.2 O 
) O 
, O 
and O 
rs10163409 O 
in O 
FTO O 
( O 
16q12.2 O 
) O 
were O 
among O 
the O 
top O 
associations O 
( O 
P O 
< O 
10(-5) O 
) O 
for O 
percentage O 
of O 
total O 
caloric O 
intake O 
from O 
protein O 
and O 
carbohydrate B-FAMILY 
. O 
rs838133 O 
was O 
replicated O 
in O 
silico O 
in O 
an O 
independent O 
sample O 
from O 
the O 
Cohorts O 
for O 
Heart O 
and O 
Aging O 
Research O 
in O 
Genomic O 
Epidemiology O 
Consortium O 
( O 
CHARGE O 
) O 
Nutrition O 
Working O 
Group O 
( O 
n O 
= O 
38 O 
360 O 
) O 
and O 
attained O 
genome O 
- O 
wide O 
significance O 
in O 
combined O 
analysis O 
( O 
Pjoint O 
= O 
7.9 O 
× O 
10(-9) O 
) O 
. O 
A O 
cytokine O 
involved O 
in O 
cellular O 
metabolism O 
, O 
FGF21 O 
is O 
a O 
potential O 
susceptibility O 
gene O 
for O 
obesity O 
and O 
type O 
2 O 
diabetes O 
. O 
Our O 
results O 
highlight O 
the O 
potential O 
of O 
genetic O 
variation O 
for O 
determining O 
dietary O 
macronutrient O 
intake O 
. O 

fear O 
recognition O 
in O 
regular O 
cocaine B-TRIVIAL 
users O 
is O 
not O 
attributable O 
to O 
elevated O 
impulsivity O 
or O 
conduct O 
disorder O 
prior O 
to O 
cocaine B-TRIVIAL 
use O 
. O 

previously O 
reported O 
that O 
regular O 
recreational O 
intranasal O 
cocaine B-TRIVIAL 
users O 
exhibit O 
impaired O 
recognition O 
of O 
facial O 
expressions O 
of O 
fear O 
compared O 
to O 
occasional O 
cocaine B-TRIVIAL 
users O 
and O 
cocaine B-TRIVIAL 
-naïve O 
controls O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
re O 
- O 
investigate O 
this O 
phenomenon O 
after O 
controlling O 
for O 
impulsivity O 
, O 
conduct O 
disorder O 
( O 
CD O 
) O 
and O 
anti-social O 
personality O 
disorder O 
( O 
ASPD O 
) O 
. O 
We O 
employed O 
a O 
cross O 
- O 
sectional O 
design O 
to O 
compare O 
31 O 
cocaine B-TRIVIAL 
-naïve O 
participants O 
, O 
35 O 
occasional O 
cocaine B-TRIVIAL 
users O 
and O 
20 O 
regular O 
recreational O 
cocaine B-TRIVIAL 
users O 
. O 
An O 
emotional O 
facial O 
expression O 
( O 
EFE O 
) O 
task O 
which O 
comprised O 
a O 
male O 
and O 
a O 
female O 
face O 
expressing O 
six O 
basic O 
emotions O 
morphed O 
to O 
differing O 
degrees O 
of O 
emotional O 
intensity O 
was O 
administered O 
together O 
with O 
questionnaires O 
to O 
assess O 
: O 
CD O 
, O 
ASPD O 
and O 
impulsiveness O 
. O 
ASPD O 
was O 
not O 
a O 
significant O 
covariate O 
for O 
EFE O 
performance O 
but O 
impulsiveness O 
and O 
CD O 
were O 
significant O 
covariates O 
. O 
After O 
treating O 
impulsiveness O 
and O 
CD O 
as O 
covariates O 
we O 
again O 
observed O 
a O 
group O 
difference O 
in O 
fear O 
recognition O 
ability O 
attributable O 
to O 
the O 
particularly O 
impaired O 
performance O 
of O 
regular O 
cocaine B-TRIVIAL 
users O 
. O 
This O 
suggests O 
that O 
, O 
although O 
elevated O 
impulsiveness O 
and O 
CD O 
before O 
the O 
age O 
of O 
15 O 
years O 
, O 
may O 
predispose O 
a O 
relative O 
inability O 
to O 
recognize O 
facial O 
expressions O 
of O 
fear O 
in O 
adulthood O 
, O 
subsequent O 
regular O 
recreational O 
use O 
of O 
cocaine B-TRIVIAL 
represents O 
an O 
additional O 
factor O 
that O 
is O 
specifically O 
associated O 
with O 
a O 
selective O 
deficit O 
in O 
fear O 
recognition O 
. O 

hinged O 
directly O 
on O 
benzimidazoles B-FAMILY 
and O 
their O 
ribofuranosides B-FAMILY 
to O 
inhibit O 
hepatitis O 
C O 
virus O 
. O 

new O 
compound O 
library O 
that O 
contained O 
20 O 
hinged O 
benzimidazole B-SYSTEMATIC 
- O 
coumarin B-TRIVIAL 
hybrids O 
and O 
their O 
β-d-ribofuranosides B-FAMILY 
was O 
established O 
. O 
The O 
anti-hepatitis O 
C O 
virus O 
( O 
HCV O 
) O 
activity O 
of O 
all O 
novel O 
coumarin B-TRIVIAL 
derivatives O 
, O 
which O 
were O 
obtained O 
by O 
use O 
of O 
organic O 
synthetic O 
methods O 
, O 
was O 
tested O 
. O 
Two O 
of O 
these O 
hybrids O 
exhibited O 
appealing O 
EC50 O 
values O 
of O 
as O 
low O 
as O 
3 O 
and O 
5.5 O 
μM O 
. O 
The O 
best O 
selectivity O 
index O 
was O 
14 O 
. O 
The O 
incorporation O 
of O 
a O 
d-ribofuranose B-TRIVIAL 
into O 
the O 
hinged O 
hybrids O 
provided O 
the O 
corresponding O 
nucleosides B-FAMILY 
with O 
the O 
β O 
configuration O 
, O 
one O 
of O 
which O 
inhibited O 
HCV O 
replication O 
with O 
an O 
EC50 O 
value O 
of O 
20 O 
μM O 
. O 
Additionally O 
, O 
the O 
structure O 
- O 
activity O 
relationship O 
is O 
elucidated O 
on O 
the O 
basis O 
of O 
the O 
functional O 
groups O 
that O 
were O 
attached O 
to O 
the O 
nuclei O 
of O 
benzimidazole B-SYSTEMATIC 
, O 
coumarin B-TRIVIAL 
, O 
and O 
ribofuranose B-TRIVIAL 
of O 
the O 
hybrids O 
. O 

Supramolecular O 
Engineering O 
of O 
Hydrogen B-SYSTEMATIC 
-Bonded O 
Nanostructures O 
at O 
Surfaces O 
: O 
Predicting O 
Self-Assembly O 
in O 
2D O 
. O 

report O 
a O 
joint O 
computational O 
and O 
experimental O 
study O 
on O 
the O 
concentration O 
- O 
dependent O 
self O 
- O 
assembly O 
of O 
a O 
flat O 
C3-symmetric O 
molecule O 
at O 
surfaces O 
. O 
As O 
a O 
model O 
system O 
we O 
have O 
chosen O 
a O 
rigid O 
molecular O 
module O 
, O 
1,3,5-tris(pyridine-4-ylethynyl)benzene B-SYSTEMATIC 
, O 
which O 
can O 
undergo O 
self O 
- O 
association O 
via O 
hydrogen B-SYSTEMATIC 
bonding O 
( O 
H B-FORMULA 
-bonding O 
) O 
to O 
form O 
ordered O 
2D O 
nanostructures O 
. O 
In O 
particular O 
, O 
the O 
lattice O 
Monte O 
Carlo O 
method O 
, O 
combined O 
with O 
density O 
functional O 
calculations O 
, O 
was O 
employed O 
to O 
explore O 
the O 
spontaneous O 
supramolecular O 
organization O 
of O 
this O 
tripod O 
- O 
shaped O 
molecule O 
under O 
surface O 
confinement O 
. O 
We O 
analyzed O 
the O 
stability O 
of O 
different O 
weak O 
H B-FORMULA 
-bonded O 
patterns O 
and O 
the O 
influence O 
of O 
the O 
concentration O 
of O 
the O 
starting O 
molecule O 
on O 
the O 
2D O 
supramolecular O 
packing O 
. O 
We O 
found O 
that O 
ordered O 
, O 
densely O 
packed O 
monolayers O 
and O 
2D O 
porous O 
networks O 
are O 
obtained O 
at O 
high O 
and O 
low O 
concentrations O 
, O 
respectively O 
. O 
A O 
concentration O 
- O 
dependent O 
scanning O 
tunneling O 
microscopy O 
investigation O 
of O 
the O 
molecular O 
self O 
- O 
assembly O 
at O 
a O 
graphite B-TRIVIAL 
-solution O 
interface O 
revealed O 
supramolecular O 
motifs O 
, O 
which O 
are O 
in O 
perfect O 
agreement O 
with O 
those O 
obtained O 
by O 
simulations O 
. O 
Therefore O 
, O 
our O 
computational O 
approach O 
represents O 
a O 
step O 
forward O 
toward O 
the O 
deterministic O 
prediction O 
of O 
molecular O 
self O 
- O 
assembly O 
at O 
surfaces O 
and O 
interfaces O 
. O 

and O 
evaluation O 
of O 
stable O 
substrate O 
analogs O 
as O 
potential O 
modulators O 
of O 
cyclodiphosphate B-SYSTEMATIC 
synthase O 
IspF O 
. O 

IspF O 
substrate O 
analogs O 
were O 
synthesized O 
. O 
In O 
the O 
presence O 
of O 
substrate O 
analogs O 
, O 
the O 
E O 
. O 
coli O 
IspF- O 
MEP B-ABBREVIATION 
complex O 
shows O 
activities O 
distinct O 
from O 
IspF O 
, O 
and O 
bisphosphonates B-FAMILY 
( O 
BP O 
) O 
behave O 
differently O 
than O 
their O 
diphosphate B-SYSTEMATIC 
( O 
DP O 
) O 
counterparts O 
. O 
Bisphosphonate B-SYSTEMATIC 
analogs O 
activate O 
and O 
/ O 
or O 
stabilize O 
IspF O 
, O 
and O 
only O 
the O 
closest O 
structural O 
substrate O 
analog O 
weakly O 
inhibits O 
the O 
IspF- O 
MEP B-ABBREVIATION 
complex O 
. O 

dose O 
for O 
estimation O 
of O 
cadmium B-SYSTEMATIC 
reference O 
level O 
for O 
osteoporosis O 
in O 
a O 
Chinese O 
female O 
population O 
. O 

this O 
study O 
, O 
the O 
reference O 
level O 
of O 
cadmium B-SYSTEMATIC 
in O 
urine O 
and O 
blood O 
related O 
with O 
bone O 
damage O 
was O 
assessed O 
using O 
benchmark O 
dose O 
in O 
a O 
Chinese O 
female O 
population O 
. O 
Total O 
of O 
338 O 
women O 
was O 
recruited O 
, O 
and O 
urine O 
and O 
blood O 
samples O 
were O 
collected O 
from O 
each O 
individual O 
for O 
determination O 
of O 
cadmium B-SYSTEMATIC 
in O 
urine O 
( O 
UCd O 
) O 
and O 
blood O 
( O 
BCd O 
) O 
. O 
Bone O 
mineral O 
density O 
was O 
measured O 
by O 
dual O 
energy O 
X-ray O 
absorptiometry O 
. O 
BMD O 
and O 
BMDL O 
were O 
calculated O 
corresponding O 
to O 
additional O 
risk O 
of O 
5% O 
and O 
10% O 
. O 
With O 
benchmark O 
response O 
( O 
BMR O 
) O 
of O 
5% O 
/ O 
10% O 
, O 
the O 
BMD O 
of O 
BCd O 
, O 
UCd O 
related O 
with O 
osteoporosis O 
was O 
1.88μg O 
/ O 
L O 
/ O 
3.23μg O 
/ O 
L O 
and O 
5.30μg O 
/ O 
g O 
crea O 
/ O 
9.06μg O 
/ O 
g O 
crea O 
, O 
and O 
the O 
BMDL-05 O 
was O 
1.39μg O 
/ O 
L O 
/ O 
2.38μg O 
/ O 
L O 
and O 
3.78μg O 
/ O 
g O 
crea O 
/ O 
6.36μg O 
/ O 
g O 
crea O 
; O 
the O 
BMD O 
of O 
BCd O 
, O 
UCd O 
related O 
with O 
low O 
bone O 
mass O 
was O 
0.95μg O 
/ O 
L O 
/ O 
3.12μg O 
/ O 
L O 
and O 
3.12μg O 
/ O 
g O 
crea O 
/ O 
5.87μg O 
/ O 
g O 
crea O 
, O 
and O 
the O 
BMDL-05 O 
was O 
0.72μg O 
/ O 
L O 
/ O 
1.35μg O 
/ O 
L O 
and O 
2.14μg O 
/ O 
g O 
crea O 
/ O 
3.99μg O 
/ O 
g O 
crea O 
. O 
The O 
BMD O 
of O 
UCd O 
in O 
people O 
over O 
60years O 
old O 
was O 
much O 
lower O 
than O 
that O 
of O 
people O 
less O 
than O 
60years O 
old O 
. O 
BMD O 
value O 
was O 
related O 
with O 
ages O 
and O 
effects O 
biomarkers O 
. O 
Our O 
data O 
showed O 
that O 
BMD O 
of O 
UCd O 
associated O 
with O 
osteoporosis O 
was O 
lower O 
than O 
that O 
previously O 
estimated O 
. O 

conclusions O 
from O 
the O 
functional O 
dissection O 
of O 
oxygenases O 
for O 
biosynthesis O 
of O 
actinorhodin B-TRIVIAL 
and O 
related O 
streptomyces O 
antibiotics O 
. O 

( O 
ACT B-ABBREVIATION 
) O 
produced O 
by O 
Streptomyces O 
coelicolor O 
A3(2) O 
belongs O 
to O 
the O 
benzoisochromanequinone B-SYSTEMATIC 
( O 
BIQ B-ABBREVIATION 
) O 
class O 
of O 
antibiotics O 
. O 
ActVA-ORF5 O 
, O 
a O 
flavin B-FAMILY 
-dependent O 
monooxygenase O 
( O 
FMO O 
) O 
essential O 
for O 
ACT B-ABBREVIATION 
biosynthesis O 
, O 
forms O 
a O 
two O 
- O 
component O 
enzyme O 
system O 
in O 
combination O 
with O 
a O 
flavin B-FAMILY 
: O 
NADH B-ABBREVIATION 
oxidoreductase O 
, O 
ActVB O 
. O 
The O 
genes O 
for O 
homologous O 
two O 
- O 
component O 
FMOs O 
are O 
found O 
in O 
the O 
biosynthetic O 
gene O 
clusters O 
for O 
two O 
other O 
BIQs B-FAMILY 
, O 
granaticin B-TRIVIAL 
( O 
GRA B-ABBREVIATION 
) O 
and O 
medermycin B-TRIVIAL 
( O 
MED B-ABBREVIATION 
) O 
, O 
and O 
a O 
closely O 
related O 
antibiotic O 
, O 
alnumycin B-TRIVIAL 
( O 
ALN B-ABBREVIATION 
) O 
. O 
Our O 
functional O 
analysis O 
of O 
these O 
FMOs O 
( O 
ActVA-ORF5 O 
, O 
Gra B-ABBREVIATION 
-ORF21 O 
, O 
Med B-ABBREVIATION 
-ORF7 O 
, O 
and O 
AlnT O 
) O 
in O 
S. O 
coelicolor O 
unambiguously O 
demonstrated O 
that O 
ActVA-ORF5 O 
and O 
Gra B-ABBREVIATION 
-ORF21 O 
are O 
bifunctional O 
and O 
capable O 
of O 
both O 
p-quinone B-SYSTEMATIC 
formation O 
at O 
C-6 O 
in O 
the O 
central O 
ring O 
and O 
C-8 O 
hydroxylation O 
in O 
the O 
lateral O 
ring O 
, O 
whereas O 
Med B-ABBREVIATION 
-ORF7 O 
catalyzes O 
only O 
p-quinone B-SYSTEMATIC 
formation O 
. O 
No O 
p-quinone B-SYSTEMATIC 
formation O 
on O 
a O 
BIQ B-ABBREVIATION 
substrate O 
was O 
observed O 
for O 
AlnT O 
, O 
which O 
is O 
involved O 
in O 
lateral O 
p-quinone B-SYSTEMATIC 
formation O 
in O 
ALN B-ABBREVIATION 
. O 

differentiation O 
factor O 
15 O 
stimulates O 
rapamycin B-TRIVIAL 
-sensitive O 
ovarian O 
cancer O 
cell O 
growth O 
and O 
invasion O 
. O 

of O 
novel O 
molecular O 
markers O 
and O 
therapeutic O 
targets O 
may O 
improve O 
survival O 
rates O 
for O 
patients O 
with O 
ovarian O 
cancer O 
. O 
In O 
the O 
current O 
study O 
, O 
immunohistochemical O 
( O 
IHC O 
) O 
analysis O 
of O 
two O 
human O 
ovarian O 
tumor O 
tissue O 
arrays O 
showed O 
high O 
staining O 
for O 
GDF15 O 
in O 
a O 
majority O 
of O 
tissues O 
. O 
Exogenous O 
stimulation O 
of O 
ovarian O 
cancer O 
cell O 
lines O 
with O 
recombinant O 
human O 
GDF15 O 
( O 
rhGDF15 O 
) O 
or O 
stable O 
over O 
- O 
expression O 
of O 
a O 
GDF15 O 
expression O 
plasmid O 
promoted O 
anchorage O 
- O 
independent O 
growth O 
, O 
increased O 
invasion O 
, O 
and O 
up O 
- O 
regulation O 
of O 
matrix O 
metalloproteinases O 
( O 
MMPs O 
) O 
and O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
. O 
MMP O 
inhibition O 
suppressed O 
GDF15 O 
- O 
mediated O 
invasion O 
. O 
In O 
addition O 
, O 
IHC O 
analysis O 
of O 
human O 
ovarian O 
tumor O 
tissue O 
arrays O 
indicated O 
that O 
GDF15 O 
expression O 
correlated O 
significantly O 
with O 
high O 
MMP2 O 
and O 
MMP9 O 
expression O 
. O 
Exogenous O 
and O 
endogenous O 
GDF15 O 
over O 
- O 
expression O 
stimulated O 
phosphorylation O 
of O 
p38 O 
, O 
Erk1 O 
/ O 
2 O 
, O 
and O 
Akt O 
. O 
Pharmacologic O 
inhibition O 
of O 
p38 O 
, O 
MEK O 
, O 
or O 
PI3K O 
suppressed O 
GDF15-stimulated O 
growth O 
. O 
Further O 
, O 
proliferation O 
, O 
growth O 
, O 
and O 
invasion O 
of O 
GDF15 O 
stable O 
clones O 
were O 
blocked O 
by O 
rapamycin B-TRIVIAL 
. O 
IHC O 
analysis O 
demonstrated O 
significant O 
correlation O 
between O 
GDF15 O 
expression O 
and O 
phosphorylation O 
of O 
mTOR O 
. O 
Finally O 
, O 
knockdown O 
of O 
endogenous O 
GDF15 O 
or O 
neutralization O 
of O 
secreted O 
GDF15 O 
suppressed O 
invasion O 
and O 
growth O 
of O 
a O 
GDF15-over O 
- O 
expressing O 
ovarian O 
cancer O 
cell O 
line O 
. O 
These O 
data O 
indicate O 
that O 
GDF15 O 
over O 
- O 
expression O 
, O 
which O 
occurred O 
in O 
a O 
majority O 
of O 
human O 
ovarian O 
cancers O 
, O 
promoted O 
rapamycin B-TRIVIAL 
-sensitive O 
invasion O 
and O 
growth O 
of O 
ovarian O 
cancer O 
cells O 
. O 
Inhibition O 
of O 
mTOR O 
may O 
be O 
an O 
effective O 
therapeutic O 
strategy O 
for O 
ovarian O 
cancers O 
that O 
over O 
- O 
express O 
GDF15 O 
. O 
Future O 
studies O 
should O 
examine O 
GDF15 O 
as O 
a O 
novel O 
molecular O 
target O 
for O 
blocking O 
ovarian O 
cancer O 
progression O 
. O 

and O 
decoction O 
of O 
wild O 
German O 
chamomile O 
: O 
bioactivity O 
and O 
characterization O 
of O 
organic O 
acids O 
and O 
phenolic B-FAMILY 
compounds O 
. O 

products O 
represent O 
a O 
rich O 
source O 
of O 
biologically O 
active O 
compounds O 
and O 
are O 
an O 
example O 
of O 
molecular O 
diversity O 
, O 
with O 
recognised O 
potential O 
in O 
drug O 
discovery O 
. O 
Herein O 
, O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
Matricaria O 
recutita O 
L O 
. O 
( O 
German O 
chamomile O 
) O 
and O 
its O 
decoction O 
and O 
infusion O 
( O 
the O 
most O 
consumed O 
preparations O 
of O 
this O 
herb O 
) O 
were O 
submitted O 
to O 
an O 
analysis O 
of O 
phytochemicals O 
and O 
bioactivity O 
evaluation O 
. O 
The O 
antioxidant O 
activity O 
was O 
determined O 
by O 
free O 
radicals O 
scavenging O 
activity O 
, O 
reducing O 
power O 
and O 
inhibition O 
of O 
lipid O 
peroxidation O 
; O 
the O 
antitumour O 
potential O 
was O 
tested O 
in O 
human O 
tumour O 
cell O 
lines O 
( O 
breast O 
, O 
lung O 
, O 
colon O 
, O 
cervical O 
and O 
hepatocellular O 
carcinomas O 
) O 
, O 
and O 
the O 
hepatotoxicity O 
was O 
evaluated O 
using O 
a O 
porcine O 
liver O 
primary O 
cell O 
culture O 
( O 
non-tumour O 
cells O 
) O 
. O 
All O 
the O 
samples O 
revealed O 
antioxidant O 
properties O 
. O 
The O 
decoction O 
exhibited O 
no O 
antitumour O 
activity O 
( O 
GI(50) O 
> O 
400 O 
μg O 
/ O 
mL O 
) O 
which O 
could O 
indicate O 
that O 
this O 
bioactivity O 
might O 
be O 
related O 
to O 
compounds O 
( O 
including O 
phenolic B-FAMILY 
compounds O 
) O 
that O 
were O 
not O 
extracted O 
or O 
that O 
were O 
affected O 
by O 
the O 
decoction O 
procedure O 
. O 
Both O 
plant O 
methanol B-SYSTEMATIC 
extract O 
and O 
infusion O 
showed O 
inhibitory O 
activity O 
to O 
the O 
growth O 
of O 
HCT O 
- O 
15 O 
( O 
GI(50) O 
250.24 O 
and O 
298.23 O 
μg O 
/ O 
mL O 
, O 
respectively O 
) O 
and O 
HeLa O 
( O 
GI(50) O 
259.36 O 
and O 
277.67 O 
μg O 
/ O 
mL O 
, O 
respectively O 
) O 
cell O 
lines O 
, O 
without O 
hepatotoxicity O 
( O 
GI(50) O 
> O 
400 O 
μg O 
/ O 
mL O 
) O 
. O 
Infusion O 
and O 
decoction O 
gave O 
higher O 
contents O 
of O 
organic O 
acids O 
( O 
24.42 O 
and O 
23.35 O 
g O 
/ O 
100g O 
dw O 
) O 
. O 
Otherwise O 
, O 
the O 
plant O 
methanol B-SYSTEMATIC 
extract O 
contained O 
the O 
highest O 
amounts O 
of O 
both O 
phenolic B-FAMILY 
acids I-FAMILY 
( O 
3.99 O 
g O 
/ O 
100g O 
dw O 
) O 
and O 
flavonoids B-FAMILY 
( O 
2.59 O 
g O 
/ O 
100g O 
dw O 
) O 
. O 
The O 
major O 
compound O 
found O 
in O 
all O 
the O 
preparations O 
was O 
luteolin B-FAMILY 
O-acylhexoside I-FAMILY 
. O 
Overall O 
, O 
German O 
chamomile O 
contains O 
important O 
phytochemicals O 
with O 
bioactive O 
properties O 
( O 
mainly O 
antitumour O 
potential O 
selective O 
to O 
colon O 
and O 
cervical O 
carcinoma O 
cell O 
lines O 
) O 
to O 
be O 
explored O 
in O 
the O 
pharmaceutical O 
, O 
food O 
and O 
cosmetics O 
industries O 
. O 

of O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
1 O 
in O 
the O 
basolateral O 
amygdala O 
- O 
driven O 
prefrontal O 
cortical O 
deactivation O 
in O 
inflammatory O 
pain O 
in O 
the O 
rat O 
. O 

changes O 
in O 
the O 
amygdala O 
and O 
limbic O 
cortex O 
networks O 
have O 
been O 
widely O 
shown O 
in O 
chronic O 
pain O 
. O 
We O 
have O 
here O 
investigated O 
the O 
role O 
of O 
group O 
I O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGluRs O 
) O 
in O 
the O 
basolateral O 
amygdala O 
( O 
BLA O 
) O 
pre O 
- O 
infra O 
- O 
limbic O 
( O 
PL-IL O 
) O 
divisions O 
of O 
the O 
medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
neuron O 
connections O 
after O 
carrageenan O 
- O 
induced O 
inflammatory O 
pain O 
in O 
the O 
rat O 
. O 
Intra O 
- O 
plantar O 
injection O 
of O 
carrageenan O 
decreased O 
either O 
spontaneous O 
or O 
mechanically O 
/ O 
electrically O 
evoked O 
activity O 
of O 
PL O 
cortex O 
pyramidal O 
neurons O 
which O 
responded O 
with O 
excitation O 
in O 
a O 
way O 
prevented O 
by O 
CPCOOEt B-FORMULA 
, O 
a O 
selective O 
mGluR1 O 
antagonist O 
, O 
though O 
not O 
by O 
MPEP B-ABBREVIATION 
, O 
a O 
selective O 
mGluR5 O 
antagonist O 
. O 
Accordingly O 
, O 
intra-BLA O 
microinjection O 
of O 
DHPG B-ABBREVIATION 
, O 
a O 
group O 
I O 
mGluR O 
agonist O 
, O 
caused O 
PL O 
cortex O 
neuron O 
activity O 
depression O 
, O 
antagonized O 
by O 
CPCCOEt B-FORMULA 
. O 
CPCOOEt B-FORMULA 
, O 
but O 
not O 
MPEP B-ABBREVIATION 
, O 
reduced O 
also O 
carrageenan O 
- O 
induced O 
mechanical O 
allodynia O 
. O 
The O 
PL O 
cortex O 
cell O 
deactivation O 
in O 
inflammatory O 
pain O 
condition O 
was O 
associated O 
with O 
increased O 
GABA B-ABBREVIATION 
( O 
conversely O 
glutamate B-TRIVIAL 
was O 
decreased O 
) O 
in O 
the O 
PL O 
/ O 
IL O 
cortex O 
. O 
The O 
local O 
application O 
of O 
bicuculline B-TRIVIAL 
, O 
a O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
selective O 
antagonist O 
, O 
reduced O 
mechanical O 
allodynia O 
. O 
An O 
over O 
- O 
expression O 
of O 
mGluR1 O 
, O 
but O 
not O 
mGluR5 O 
, O 
have O 
been O 
observed O 
in O 
the O 
PL-IL O 
cortex O 
after O 
inflammatory O 
pain O 
suggesting O 
an O 
increased O 
mGluR1-dependent O 
cross O 
- O 
talk O 
among O 
BLA O 
and O 
IL-PL O 
cortex O 
neurons O 
in O 
inflammatory O 
pain O 
conditions O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
have O 
been O 
long O 
regarded O 
as O 
by O 
- O 
products O 
of O 
a O 
cascade O 
of O 
reactions O 
stemming O 
from O 
cellular O 
oxygen B-SYSTEMATIC 
metabolism O 
, O 
which O 
, O 
if O 
they O 
accumulate O 
to O 
toxic O 
levels O 
, O 
can O 
have O 
detrimental O 
effects O 
on O 
cellular O 
biomolecules O 
. O 
However O 
, O 
more O 
recently O 
, O 
the O 
recognition O 
of O 
ROS O 
as O 
mediators O 
of O 
cellular O 
communications O 
has O 
led O 
to O 
their O 
classification O 
as O 
signalling O 
mediators O 
in O 
their O 
own O 
right O 
. O 
The O 
prototypic O 
redox O 
- O 
regulated O 
targets O 
downstream O 
of O 
ROS O 
are O 
the O 
protein O 
tyrosine B-TRIVIAL 
phosphatases O 
, O 
and O 
the O 
wealth O 
of O 
research O 
that O 
has O 
focused O 
on O 
this O 
area O 
has O 
come O 
to O 
shape O 
our O 
understanding O 
of O 
how O 
redox O 
- O 
signalling O 
contributes O 
to O 
and O 
facilitates O 
protein O 
tyrosine B-TRIVIAL 
phosphorylation O 
signalling O 
cascades O 
. O 
However O 
, O 
it O 
is O 
becoming O 
increasingly O 
apparent O 
that O 
there O 
is O 
more O 
to O 
this O 
system O 
than O 
simply O 
the O 
negative O 
regulation O 
of O 
protein O 
tyrosine B-TRIVIAL 
phosphatases O 
. O 
Identification O 
of O 
redox O 
- O 
sensitive O 
kinases O 
such O 
as O 
Src O 
led O 
to O 
the O 
slow O 
emergence O 
of O 
a O 
role O 
for O 
redox O 
regulation O 
of O 
tyrosine B-TRIVIAL 
kinases O 
. O 
A O 
flow O 
of O 
evidence O 
, O 
which O 
has O 
increased O 
exponentially O 
in O 
recent O 
times O 
as O 
a O 
result O 
of O 
the O 
development O 
of O 
new O 
methods O 
for O 
the O 
detection O 
of O 
oxidative O 
modifications O 
, O 
demonstrates O 
that O 
, O 
by O 
concurrent O 
oxidative O 
activation O 
of O 
tyrosine B-TRIVIAL 
kinases O 
, O 
ROS O 
fine O 
tune O 
the O 
duration O 
and O 
amplification O 
of O 
the O 
phosphorylation O 
signal O 
. O 
A O 
more O 
thorough O 
understanding O 
of O 
the O 
complex O 
regulatory O 
mechanism O 
of O 
redox O 
- O 
modification O 
will O 
allow O 
targeting O 
of O 
both O 
the O 
production O 
of O 
ROS O 
and O 
their O 
downstream O 
effectors O 
for O 
therapeutic O 
purposes O 
. O 
The O 
present O 
review O 
assesses O 
the O 
most O 
relevant O 
recent O 
literature O 
that O 
demonstrates O 
a O 
role O 
for O 
kinase O 
regulation O 
by O 
oxidation O 
, O 
highlights O 
the O 
most O 
significant O 
findings O 
and O 
proposes O 
future O 
directions O 
for O 
this O 
crucial O 
area O 
of O 
redox O 
biology O 
. O 

this O 
paper O 
we O 
present O 
detailed O 
dynamic O 
electrochemical O 
measurements O 
in O 
a O 
flame O 
plasma O 
electrolyte O 
in O 
the O 
presence O 
of O 
tungsten B-FAMILY 
oxide I-FAMILY 
salts I-FAMILY 
. O 
Defined O 
reproducible O 
redox O 
processes O 
are O 
measured O 
using O 
conventional O 
cyclic O 
voltammetry O 
in O 
an O 
operational O 
potential O 
window O 
between O 
1 O 
and O 
-9 O 
V O 
. O 
This O 
wide O 
potential O 
window O 
is O 
possible O 
due O 
to O 
the O 
absence O 
of O 
solvent O 
and O 
its O 
associated O 
limits O 
due O 
to O 
solvent O 
electrolysis O 
at O 
high O 
over O 
potentials O 
. O 
The O 
measurements O 
were O 
enabled O 
through O 
the O 
development O 
of O 
a O 
new O 
reference O 
electrode O 
, O 
composed O 
of O 
yttria B-TRIVIAL 
stabilised O 
zirconia B-TRIVIAL 
( O 
YSZ O 
) O 
which O 
maintains O 
a O 
stable O 
potential O 
at O 
1100 O 
K O 
. O 
In O 
this O 
paper O 
we O 
focus O 
on O 
developing O 
a O 
phenomenological O 
understanding O 
of O 
electron O 
transfer O 
at O 
the O 
solid O 
- O 
gas O 
interface O 
, O 
using O 
cyclic O 
voltammetry O 
. O 
The O 
effect O 
of O 
working O 
electrode O 
surface O 
area O 
and O 
material O 
, O 
as O 
well O 
as O 
potential O 
scan O 
rate O 
on O 
the O 
voltammetric O 
redox O 
features O 
is O 
presented O 
. O 
We O 
discuss O 
the O 
physical O 
origin O 
of O 
the O 
observed O 
Faradaic O 
current O 
peaks O 
measured O 
in O 
a O 
flame O 
plasma O 
electrolyte O 
, O 
and O 
propose O 
a O 
simple O 
model O 
to O 
describe O 
the O 
redox O 
processes O 
occurring O 
. O 
We O 
conclude O 
that O 
redox O 
processes O 
at O 
the O 
solid O 
- O 
gas O 
interface O 
are O 
actually O 
similar O 
to O 
the O 
analogous O 
processes O 
at O 
the O 
solid O 
- O 
liquid O 
interface O 
described O 
by O 
conventional O 
electrochemical O 
theory O 
; O 
the O 
departures O 
are O 
mainly O 
due O 
to O 
the O 
mass O 
transport O 
processes O 
that O 
dominate O 
in O 
the O 
gas O 
phase O 
. O 
We O 
associate O 
migration O 
effects O 
with O 
the O 
total O 
absence O 
of O 
any O 
oxidation O 
processes O 
. O 

and O 
tellurite B-TRIVIAL 
form O 
mixed O 
seleno- B-MULTIPLE 
and I-MULTIPLE 
tellurotrisulfides I-MULTIPLE 
with O 
CstR O 
from O 
Staphylococcus O 
aureus O 
. O 

aureus O 
CstR O 
( O 
CsoR O 
- O 
like O 
sulfur B-SYSTEMATIC 
transferase O 
repressor O 
) O 
is O 
a O 
member O 
of O 
the O 
CsoR O 
family O 
of O 
transition B-FAMILY 
metal I-FAMILY 
sensing O 
metalloregulatory O 
proteins O 
. O 
Unlike O 
CsoR O 
, O 
CstR O 
does O 
not O 
form O 
a O 
stable O 
complex O 
with O 
transition B-FAMILY 
metals I-FAMILY 
but O 
instead O 
reacts O 
with O 
sulfite B-SYSTEMATIC 
to O 
form O 
a O 
mixture O 
of O 
di- B-MULTIPLE 
and I-MULTIPLE 
trisulfide I-MULTIPLE 
species O 
, O 
CstR2( O 
RS-SR B-FAMILY 
' I-FAMILY 
) O 
and O 
CstR2( O 
RS-S-SR B-FAMILY 
' I-FAMILY 
)n)n=1 O 
or O 
2 O 
, O 
respectively O 
. O 
Here O 
, O 
we O 
investigate O 
if O 
CstR O 
performs O 
similar O 
chemistry O 
with O 
related O 
chalcogen B-FAMILY 
oxyanions I-FAMILY 
selenite B-TRIVIAL 
and O 
tellurite B-TRIVIAL 
. O 
In O 
this O 
work O 
we O 
show O 
by O 
high O 
resolution O 
tandem O 
mass O 
spectrometry O 
that O 
CstR O 
is O 
readily O 
modified O 
by O 
selenite B-TRIVIAL 
( O 
SeO3(2-) B-FORMULA 
) O 
or O 
tellurite B-TRIVIAL 
( O 
TeO3(2-) B-FORMULA 
) O 
to O 
form O 
a O 
mixture O 
of O 
intersubunit O 
disulfides B-FAMILY 
and O 
selenotrisulfides B-FAMILY 
or O 
tellurotrisulfides B-FAMILY 
, O 
respectively O 
, O 
between O 
Cys B-FORMULA 
31 O 
and O 
Cys B-FORMULA 
60 O 
' O 
. O 
Analogous O 
studies O 
with O 
S O 
. O 
aureus O 
CsoR O 
reveals O 
no O 
reaction O 
with O 
selenite B-TRIVIAL 
and O 
minimal O 
reaction O 
with O 
tellurite B-TRIVIAL 
. O 
All O 
cross O 
- O 
linked O 
forms O 
of O 
CstR O 
exhibit O 
reduced O 
DNA O 
binding O 
affinity O 
. O 
We O 
show O 
that O 
Cys B-FORMULA 
31 O 
initiates O 
the O 
reaction O 
with O 
sulfite B-SYSTEMATIC 
through O 
the O 
formation O 
of O 
S-sulfocysteine B-SYSTEMATIC 
( O 
RS-SO3(2-) B-FAMILY 
) O 
and O 
Cys B-FORMULA 
60 O 
is O 
required O 
to O 
fully O 
derivatize O 
CstR O 
to O 
CstR2( O 
RS-SR B-FAMILY 
' I-FAMILY 
) O 
and O 
CstR2( O 
RS-S-SR B-FAMILY 
' I-FAMILY 
) O 
. O 
The O 
modification O 
of O 
Cys B-FORMULA 
31 O 
also O 
drives O 
an O 
allosteric O 
switch O 
that O 
negatively O 
regulates O 
DNA O 
binding O 
while O 
derivatization O 
of O 
Cys B-FORMULA 
60 O 
alone O 
has O 
no O 
effect O 
on O 
DNA O 
binding O 
. O 
These O 
results O 
highlight O 
the O 
differences O 
between O 
CstRs O 
and O 
CsoRs O 
in O 
chemical O 
reactivity O 
and O 
metal O 
ion O 
selectivity O 
and O 
establish O 
Cys B-FORMULA 
31 O 
as O 
the O 
functionally O 
important O 
cysteine B-TRIVIAL 
residue O 
in O 
CstRs O 
. O 

the O 
discovery O 
of O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
, O 
thousands O 
of O 
papers O 
have O 
been O 
published O 
on O 
this O 
phenomenon O 
. O 
With O 
this O 
massive O 
amount O 
of O 
information O 
, O 
it O 
is O 
often O 
difficult O 
, O 
especially O 
for O 
someone O 
not O 
directly O 
involved O 
in O 
the O 
field O 
, O 
not O 
to O 
be O 
overwhelmed O 
. O 
The O 
goal O 
of O 
this O 
review O 
is O 
to O 
peel O 
away O 
as O 
many O 
layers O 
as O 
possible O 
, O 
and O 
probe O 
the O 
core O 
properties O 
of O 
LTP O 
. O 
We O 
would O 
argue O 
that O 
the O 
many O 
dozens O 
of O 
proteins O 
that O 
have O 
been O 
implicated O 
in O 
the O 
phenomenon O 
are O 
not O 
essential O 
, O 
but O 
rather O 
modulate O 
, O 
often O 
in O 
indirect O 
ways O 
, O 
the O 
threshold O 
and O 
/ O 
or O 
magnitude O 
of O 
LTP O 
. O 
What O 
is O 
required O 
is O 
NMDA B-ABBREVIATION 
receptor O 
activation O 
followed O 
by O 
CaMKII O 
activation O 
. O 
The O 
consequence O 
of O 
CaMKII O 
activation O 
is O 
the O 
rapid O 
recruitment O 
of O 
AMPA B-ABBREVIATION 
receptors O 
to O 
the O 
synapse O 
. O 
This O 
recruitment O 
is O 
independent O 
of O 
AMPA B-ABBREVIATION 
receptor O 
subunit O 
type O 
, O 
but O 
absolutely O 
requires O 
an O 
adequate O 
pool O 
of O 
surface O 
receptors O 
. O 
An O 
important O 
unresolved O 
issue O 
is O 
how O 
exactly O 
CaMKII O 
activation O 
leads O 
to O 
modifications O 
in O 
the O 
PSD O 
to O 
allow O 
rapid O 
enrichment O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
GluR-dep O 
synaptic O 
plasticity O 
' O 
. O 

of O 
electrical O 
and O 
thermomechanical O 
properties O 
of O 
silver B-SYSTEMATIC 
nanowire O 
composites O 
by O 
the O 
introduction O 
of O 
nonconductive O 
nanoparticles O 
: O 
experiment O 
and O 
simulation O 
. O 

conductive O 
polymer O 
nanocomposites O 
have O 
been O 
applied O 
extensively O 
in O 
many O 
fields O 
to O 
develop O 
the O 
next O 
generation O 
of O 
devices O 
. O 
Large O 
amounts O 
of O 
conductive O 
nanofillers O 
in O 
polymer O 
matrices O 
are O 
, O 
however O 
, O 
often O 
required O 
for O 
a O 
sufficiently O 
high O 
electrical O 
conductivity O 
, O 
which O 
in O 
turn O 
deteriorates O 
the O 
desired O 
thermomechanical O 
properties O 
. O 
We O 
illustrate O 
a O 
novel O 
but O 
facile O 
strategy O 
to O 
improve O 
the O 
electrical O 
conductivity O 
and O 
the O 
thermomechanical O 
property O 
of O 
silver B-SYSTEMATIC 
nanowire O 
/ O 
polymer O 
nanocomposites O 
. O 
We O 
find O 
that O 
one O 
may O 
increase O 
the O 
electrical O 
conductivity O 
of O 
silver B-SYSTEMATIC 
nanowire O 
/ O 
polymer O 
nanocomposites O 
by O 
up O 
to O 
about O 
8 O 
orders O 
of O 
magnitude O 
by O 
introducing O 
silica B-TRIVIAL 
nanoparticles O 
with O 
nanocomposites O 
. O 
The O 
electrical O 
percolation O 
threshold O 
volume O 
fraction O 
of O 
silver B-SYSTEMATIC 
nanowires O 
decreases O 
from O 
0.12 O 
to O 
0.02 O 
. O 
Thermomechanical O 
properties O 
also O 
improve O 
as O 
silica B-TRIVIAL 
nanoparticles O 
are O 
introduced O 
. O 
We O 
carry O 
out O 
extensive O 
Monte O 
Carlo O 
simulations O 
to O 
elucidate O 
the O 
effects O 
of O 
silica B-TRIVIAL 
nanoparticles O 
at O 
a O 
molecular O 
level O 
and O 
find O 
that O 
van O 
der O 
Waals O 
attractive O 
interaction O 
between O 
silica B-TRIVIAL 
nanoparticles O 
and O 
silver B-SYSTEMATIC 
nanowires O 
dominates O 
over O 
the O 
depletion O 
- O 
induced O 
interaction O 
between O 
silver B-SYSTEMATIC 
nanowires O 
, O 
thus O 
improving O 
the O 
dispersion O 
of O 
silver B-SYSTEMATIC 
nanowires O 
. O 
Without O 
silica B-TRIVIAL 
nanoparticles O 
, O 
silver B-SYSTEMATIC 
nanowires O 
tend O 
to O 
aggregate O 
, O 
which O 
is O 
why O 
additional O 
silver B-SYSTEMATIC 
nanowires O 
are O 
required O 
for O 
a O 
desired O 
electrical O 
conductivity O 
. O 
On O 
the O 
other O 
hand O 
, O 
with O 
silica B-TRIVIAL 
nanoparticles O 
mixed O 
, O 
the O 
electrical O 
percolating O 
network O 
is O 
likely O 
to O 
form O 
at O 
a O 
smaller O 
volume O 
fraction O 
of O 
silver B-SYSTEMATIC 
nanowires O 
. O 

current O 
study O 
was O 
aimed O 
to O 
scrutinize O 
acetylcholinesterase O 
( O 
AchE O 
) O 
inhibitory O 
profile O 
of O 
two O 
antidepressants O 
, O 
diazepam B-TRIVIAL 
and O 
phenobarbitone B-TRIVIAL 
. O 
The O 
experimental O 
designed O 
was O 
based O 
on O 
Michaelis-Menten O 
parameters O 
( O 
apparent O 
Michaelis O 
constant O 
( O 
aKm O 
) O 
and O 
apparent O 
maximum O 
velocity O 
( O 
aVm O 
) O 
) O 
that O 
estimate O 
inhibition O 
( O 
% O 
) O 
as O 
well O 
as O 
the O 
type O 
of O 
inhibition O 
( O 
mechanism O 
) O 
. O 
The O 
results O 
showed O 
marked O 
inhibition O 
of O 
AchE O 
by O 
diazepam B-TRIVIAL 
and O 
the O 
values O 
of O 
aKm O 
and O 
aVm O 
were O 
65.5% O 
and O 
52.63% O 
, O 
respectively O 
. O 
These O 
values O 
suggested O 
a O 
competitive O 
type O 
of O 
antagonism O 
for O 
diazepam B-TRIVIAL 
. O 
Similar O 
trend O 
of O 
antagonism O 
was O 
shown O 
by O 
phenobarbitone B-TRIVIAL 
when O 
it O 
was O 
subjected O 
to O 
the O 
challenge O 
of O 
AchE O 
with O 
aKm O 
and O 
aVm O 
values O 
of O 
51.99% O 
and O 
71.80% O 
, O 
respectively O 
. O 
It O 
is O 
concluded O 
that O 
diazepam B-TRIVIAL 
and O 
phenobarbitone B-TRIVIAL 
exhibited O 
prominent O 
AchE O 
attenuation O 
apart O 
from O 
their O 
well O 
- O 
established O 
antidepressant O 
activity O 
, O 
which O 
could O 
be O 
more O 
useful O 
in O 
related O 
diseased O 
conditions O 
. O 

ethyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
exhibits O 
stronger O 
intestinal O 
anticarcinogenic O 
potency O 
and O 
effects O 
on O 
transcript O 
profiles O 
compared O 
to O 
hydroxytyrosol B-SYSTEMATIC 
. O 

anticarcinogenic O 
activity O 
of O 
hydroxytyrosyl B-SYSTEMATIC 
ethyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
HTy-Et B-FORMULA 
) O 
compared O 
to O 
its O 
precursor O 
hydroxytyrosol B-SYSTEMATIC 
( O 
HTy B-ABBREVIATION 
) O 
has O 
been O 
studied O 
in O 
human O 
Caco-2 O 
colon O 
adenocarcinoma O 
cells O 
. O 
451 O 
and O 
977 O 
genes O 
were O 
differentially O 
expressed O 
in O 
Caco-2 O 
cells O 
exposed O 
to O 
HTy B-ABBREVIATION 
or O 
HTy-Et B-FORMULA 
for O 
24h O 
, O 
respectively O 
, O 
compared O 
with O 
untreated O 
cells O 
( O 
P O 
< O 
0.005 O 
; O 
FDR=0 O 
) O 
, O 
using O 
Affymetrix O 
microarrays O 
. O 
Results O 
showed O 
that O 
both O 
HTy B-ABBREVIATION 
and O 
HTy-Et B-FORMULA 
inhibited O 
cell O 
proliferation O 
and O 
arrested O 
the O 
cell O 
cycle O 
by O 
up O 
- O 
regulating O 
p21 O 
and O 
CCNG2 O 
and O 
down O 
- O 
regulating O 
CCNB1 O 
protein O 
expression O 
. O 
HTy B-ABBREVIATION 
and O 
HTy-Et B-FORMULA 
also O 
altered O 
the O 
transcription O 
of O 
specific O 
genes O 
involved O 
in O 
apoptosis O 
, O 
as O 
suggested O 
by O 
the O 
up O 
- O 
regulation O 
of O 
BNIP3 O 
, O 
BNIP3L O 
, O 
PDCD4 O 
and O 
ATF3 O 
and O 
the O 
activation O 
of O 
caspase-3 O 
. O 
Moreover O 
, O 
these O 
polyphenols B-FAMILY 
up O 
- O 
regulated O 
xenobiotic O 
metabolizing O 
enzymes O 
UGT1A10 O 
and O 
CYP1A1 O 
, O 
enhancing O 
carcinogen O 
detoxification O 
. O 
In O 
conclusion O 
, O 
these O 
results O 
highlight O 
that O 
HTy B-ABBREVIATION 
and O 
its O 
derivative O 
HTy-Et B-FORMULA 
modulate O 
molecular O 
mechanisms O 
involved O 
in O 
colon O 
cancer O 
, O 
with O 
HTy-Et B-FORMULA 
being O 
more O 
effective O 
than O 
HTy B-ABBREVIATION 
. O 

roles O 
of O 
methamphetamine B-TRIVIAL 
in O 
modulating O 
spatial O 
memory O 
consolidation O 
, O 
retrieval O 
, O 
reconsolidation O 
and O 
the O 
accompanying O 
changes O 
of O 
ERK O 
and O 
CREB O 
activation O 
in O 
hippocampus O 
and O 
prefrontal O 
cortex O 
. O 

of O 
abuse O 
modulated O 
learning O 
and O 
memory O 
in O 
humans O 
yet O 
the O 
underlying O 
mechanism O 
remained O 
unclear O 
. O 
The O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
and O 
the O 
transcription O 
factor O 
cAMP B-ABBREVIATION 
response O 
element O 
- O 
binding O 
protein O 
( O 
CREB O 
) O 
were O 
involved O 
in O 
neuroplastic O 
changes O 
associated O 
with O 
learning O 
and O 
memory O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
used O 
a O 
Morris O 
water O 
maze O 
to O 
examine O 
the O 
effect O 
of O 
methamphetamine B-TRIVIAL 
( O 
METH B-ABBREVIATION 
) O 
on O 
different O 
processes O 
of O 
spatial O 
memory O 
in O 
mice O 
. O 
We O 
then O 
investigated O 
the O 
status O 
of O 
ERK O 
and O 
CREB O 
in O 
the O 
hippocampus O 
and O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
. O 
We O 
found O 
that O 
1 O 
mg O 
/ O 
kg O 
dose O 
of O 
METH B-ABBREVIATION 
facilitated O 
spatial O 
memory O 
consolidation O 
when O 
it O 
was O 
injected O 
immediately O 
after O 
the O 
last O 
learning O 
trial O 
. O 
In O 
contrast O 
, O 
the O 
same O 
dose O 
of O 
METH B-ABBREVIATION 
had O 
no O 
effect O 
on O 
spatial O 
memory O 
retrieval O 
when O 
it O 
was O 
injected O 
30 O 
min O 
before O 
the O 
test O 
. O 
Furthermore O 
, O 
1 O 
mg O 
/ O 
kg O 
dose O 
of O 
METH B-ABBREVIATION 
injected O 
immediately O 
after O 
retrieval O 
had O 
no O 
effect O 
on O 
spatial O 
memory O 
reconsolidation O 
. O 
Activation O 
of O 
both O 
ERK O 
and O 
CREB O 
in O 
the O 
hippocampus O 
was O 
found O 
following O 
memory O 
consolidation O 
but O 
not O 
after O 
retrieval O 
or O 
reconsolidation O 
in O 
METH B-ABBREVIATION 
-treated O 
mouse O 
groups O 
. O 
In O 
contrast O 
, O 
activation O 
of O 
both O 
ERK O 
and O 
CREB O 
in O 
the O 
PFC O 
was O 
found O 
following O 
memory O 
retrieval O 
but O 
not O 
other O 
processes O 
in O 
METH B-ABBREVIATION 
-treated O 
mouse O 
groups O 
. O 
These O 
results O 
suggested O 
that O 
METH B-ABBREVIATION 
facilitated O 
spatial O 
memory O 
consolidation O 
but O 
not O 
retrieval O 
or O 
reconsolidation O 
. O 
Moreover O 
, O 
activation O 
of O 
the O 
ERK O 
and O 
CREB O 
signaling O 
pathway O 
in O 
the O 
hippocampus O 
might O 
be O 
involved O 
in O 
METH B-ABBREVIATION 
-induced O 
spatial O 
memory O 
changes O 
. O 

and O 
cadmium B-SYSTEMATIC 
concentrations O 
in O 
goat O 
, O 
cow O 
, O 
sheep O 
, O 
and O 
buffalo O 
milks O 
from O 
different O 
regions O 
of O 
Iran O 
. O 

total O 
, O 
137 O 
goat O 
, O 
cow O 
, O 
sheep O 
, O 
and O 
buffalo O 
milk O 
samples O 
were O 
collected O 
in O 
different O 
regions O 
of O 
Iran O 
and O 
analysed O 
to O 
determine O 
concentrations O 
of O 
lead O 
and O 
cadmium B-SYSTEMATIC 
by O 
a O 
graphite B-TRIVIAL 
furnace O 
atomic O 
absorption O 
spectrometric O 
method O 
. O 
The O 
mean O 
recovery O 
of O 
the O 
analytical O 
method O 
was O 
96.3% O 
and O 
104% O 
for O 
cadmium B-SYSTEMATIC 
and O 
lead O 
, O 
respectively O 
. O 
The O 
mean O 
lead O 
and O 
cadmium B-SYSTEMATIC 
contents O 
obtained O 
from O 
137 O 
samples O 
were O 
1.93 O 
± O 
1.48 O 
( O 
range O 
: O 
0.18-6.11 O 
ng O 
/ O 
ml O 
) O 
and O 
9.51 O 
± O 
4.93 O 
ng O 
/ O 
ml O 
( O 
range O 
: O 
1.84 O 
ng O 
/ O 
ml-30.50 O 
ng O 
/ O 
ml O 
) O 
, O 
respectively O 
. O 
Lead O 
concentration O 
in O 
8.1% O 
of O 
sheep O 
and O 
1.9% O 
of O 
cow O 
milk O 
samples O 
was O 
higher O 
than O 
the O 
newly O 
established O 
Codex O 
standard O 
. O 
The O 
mean O 
concentrations O 
of O 
cadmium B-SYSTEMATIC 
and O 
lead O 
in O 
animals O 
aged O 
≤ O 
3 O 
years O 
( O 
n=80 O 
; O 
1.4 O 
± O 
1.05 O 
ng O 
/ O 
ml O 
and O 
7.91 O 
± O 
3.6 O 
ng O 
/ O 
ml O 
, O 
respectively O 
) O 
were O 
lower O 
than O 
in O 
animals O 
aged O 
> O 
3 O 
years O 
( O 
n=58 O 
; O 
2.69 O 
± O 
1.67 O 
ng O 
/ O 
ml O 
and O 
11.8 O 
± O 
5.71 O 
ng O 
/ O 
ml O 
, O 
respectively O 
) O 
. O 

and O 
Near O 
Perfect O 
Macroscopic O 
Alignment O 
of O 
Fluorescent O 
Triangulenium B-TRIVIAL 
Salt O 
in O 
Spin O 
Cast O 
Thin O 
Films O 
on O 
PTFE B-ABBREVIATION 
. O 

fluorescent O 
, O 
discotic O 
trioxatriangulenium B-SYSTEMATIC 
dyes O 
were O 
aligned O 
by O 
simple O 
spin O 
casting O 
on O 
substrates O 
with O 
friction O 
transferred O 
PTFE B-ABBREVIATION 
layers O 
. O 
The O 
fluorescent O 
crystalline O 
thin O 
films O 
show O 
near O 
perfect O 
macroscopic O 
alignment O 
on O 
centimeter O 
large O 
areas O 
directly O 
from O 
spin O 
casting O 
. O 
Gracing O 
Incidence O 
X-ray O 
Diffraction O 
( O 
GIXD O 
) O 
unambiguously O 
allowed O 
to O 
determine O 
a O 
long O 
range O 
order O 
unit O 
cell O 
as O 
well O 
as O 
its O 
orientation O 
with O 
respect O 
to O 
the O 
PTFE B-ABBREVIATION 
fibers O 
. O 
Further O 
analysis O 
of O 
the O 
X-ray O 
data O 
, O 
in O 
conjunction O 
with O 
polarized O 
absorption O 
spectroscopy O 
, O 
suggest O 
a O 
lamellar O 
packing O 
model O 
with O 
alternating O 
layers O 
of O 
alkyl B-FAMILY 
chains O 
and O 
ionic O 
dyes O 
oriented O 
parallel O 
to O 
the O 
substrate O 
. O 
This O 
structure O 
results O 
in O 
a O 
highly O 
anisotropic O 
electrostatic O 
potential O 
around O 
the O 
cationic O 
chromophore O 
, O 
causing O 
significant O 
shifts O 
in O 
energy O 
and O 
orientation O 
of O 
the O 
optical O 
transitions O 
. O 
Thus O 
, O 
the O 
optical O 
properties O 
of O 
the O 
material O 
are O 
, O 
to O 
a O 
large O 
extent O 
, O 
controlled O 
by O 
the O 
position O 
of O 
the O 
otherwise O 
inert O 
PF6- O 
counter O 
ions O 
. O 
The O 
bright O 
fluorescence O 
from O 
the O 
films O 
is O 
also O 
polarized O 
parallel O 
to O 
the O 
PTFE B-ABBREVIATION 
alignment O 
layer O 
. O 
Doping O 
of O 
the O 
thin O 
films O 
with O 
fluorescent O 
energy O 
acceptor O 
traps O 
shows O 
that O 
efficient O 
exciton O 
migration O 
takes O 
place O 
in O 
the O 
thin O 
films O 
. O 
The O 
excellent O 
exciton O 
transfer O 
capabilities O 
, O 
in O 
conjunction O 
with O 
the O 
perfect O 
alignment O 
, O 
might O 
be O 
of O 
interest O 
in O 
future O 
applications O 
in O 
solar O 
energy O 
harvesting O 
or O 
as O 
thin O 
film O 
sensors O 
. O 

work O 
uses O 
ATR-FTIR O 
spectroscopic O 
imaging O 
to O 
study O 
the O 
dissolution O 
of O 
delayed O 
release O 
and O 
pH O 
resistant O 
compressed O 
coating O 
pharmaceutical O 
tablets O 
. O 
Tablets O 
with O 
an O 
inner O 
core O 
and O 
outer O 
shell O 
were O 
constructed O 
using O 
a O 
custom O 
designed O 
compaction O 
cell O 
. O 
The O 
core O 
of O 
the O 
delayed O 
release O 
tablets O 
consisted O 
of O 
hydroxypropyl B-SYSTEMATIC 
methylcellulose O 
( O 
HPMC O 
) O 
and O 
caffeine B-TRIVIAL 
. O 
The O 
shell O 
consisted O 
of O 
microcrystalline O 
cellulose O 
( O 
MCC O 
) O 
and O 
glucose B-TRIVIAL 
. O 
The O 
core O 
of O 
the O 
pH O 
resistant O 
formulations O 
was O 
an O 
ibuprofen B-TRIVIAL 
and O 
PEG B-ABBREVIATION 
melt O 
and O 
the O 
shell O 
was O 
constructed O 
from O 
HPMC O 
and O 
a O 
basic O 
buffer O 
. O 
UV O 
/ O 
vis O 
spectroscopy O 
was O 
used O 
to O 
monitor O 
the O 
lag O 
- O 
time O 
of O 
drug O 
release O 
and O 
visible O 
optical O 
video O 
imaging O 
was O 
used O 
as O 
a O 
complementary O 
imaging O 
technique O 
with O 
a O 
larger O 
field O 
of O 
view O 
. O 
Two O 
delayed O 
release O 
mechanisms O 
were O 
established O 
. O 
For O 
tablets O 
with O 
soluble O 
shell O 
sections O 
, O 
lag O 
- O 
time O 
was O 
dependent O 
upon O 
rapid O 
shell O 
dissolution O 
. O 
For O 
tablets O 
with O 
less O 
soluble O 
shells O 
, O 
the O 
lag O 
- O 
time O 
was O 
controlled O 
by O 
the O 
rate O 
of O 
dissolution O 
medium O 
ingress O 
through O 
the O 
shell O 
and O 
the O 
subsequent O 
expansion O 
of O 
the O 
wet O 
HPMC O 
core O 
. O 
The O 
pH O 
resistant O 
formulations O 
prevented O 
crystallization O 
of O 
the O 
ibuprofen B-TRIVIAL 
in O 
the O 
core O 
during O 
dissolution O 
despite O 
an O 
acidic O 
dissolution O 
medium O 
. O 
FTIR O 
imaging O 
produced O 
important O 
information O 
about O 
the O 
physical O 
and O 
chemical O 
processes O 
occurring O 
at O 
the O 
interface O 
between O 
tablet O 
sections O 
during O 
dissolution O 
. O 

and O 
dissipation O 
of O 
kresoxim B-TRIVIAL 
methyl I-TRIVIAL 
in O 
apple O 
under O 
field O 
condition O 
. O 

dissipation O 
and O 
residual O 
levels O 
of O 
kresoxim B-TRIVIAL 
methyl I-TRIVIAL 
in O 
apple O 
under O 
field O 
condition O 
were O 
determined O 
by O 
using O 
HPLC-DAD O 
with O 
QuEChERS O 
method O 
. O 
At O 
fortification O 
levels O 
of O 
0.05 O 
, O 
0.1 O 
, O 
0.5 O 
and O 
1.0mgkg(-1) O 
in O 
apple O 
, O 
it O 
was O 
shown O 
that O 
recoveries O 
were O 
ranged O 
from O 
91.1% O 
to O 
96.9% O 
with O 
coefficient O 
variation O 
of O 
the O 
method O 
( O 
CV% O 
) O 
for O 
repeatability O 
ranged O 
from O 
1.27% O 
to O 
4.77% O 
. O 
The O 
limit O 
of O 
quantification O 
( O 
LOQ O 
) O 
of O 
the O 
method O 
was O 
0.05mgkg(-1) O 
. O 
The O 
dissipation O 
rates O 
of O 
kresoxim B-TRIVIAL 
methyl I-TRIVIAL 
were O 
described O 
by O 
using O 
first O 
- O 
order O 
kinetics O 
and O 
its O 
half O 
- O 
life O 
, O 
as O 
they O 
are O 
ranged O 
from O 
4.58 O 
to O 
4.77days O 
in O 
apple O 
. O 
The O 
terminal O 
residues O 
of O 
kresoxim B-TRIVIAL 
methyl I-TRIVIAL 
were O 
below O 
the O 
FAO O 
/ O 
WHO O 
maximum O 
residue O 
limit O 
( O 
MRL O 
, O 
0.2mgkg(-1) O 
) O 
in O 
apple O 
when O 
measured O 
14days O 
after O 
the O 
final O 
application O 
, O 
which O 
suggested O 
that O 
the O 
use O 
of O 
this O 
fungicide O 
was O 
safe O 
for O 
humans O 
. O 
This O 
study O 
would O 
help O 
in O 
providing O 
the O 
basic O 
information O 
for O 
developing O 
regulation O 
to O 
guard O 
a O 
safe O 
use O 
of O 
kresoxim B-TRIVIAL 
methyl I-TRIVIAL 
in O 
apple O 
orchard O 
and O 
to O 
prevent O 
health O 
problem O 
from O 
consumers O 
. O 

-Based O 
Quantum O 
Dot O 
Induced O 
Autophagy O 
Formation O 
for O 
Cell O 
Survival O 
via O 
Oxidative O 
Stress O 
. O 

dots O 
( O 
QDs O 
) O 
are O 
one O 
of O 
most O 
utilized O 
nanomaterials O 
in O 
nanocrystalline O 
semiconductors O 
. O 
QDs O 
emit O 
near O 
- O 
infrared O 
fluorescence O 
and O 
can O 
be O 
applied O 
as O 
probes O 
for O 
detecting O 
vasculature O 
and O 
imaging O 
in O 
biological O 
systems O 
. O 
Since O 
QDs O 
have O 
potential O 
in O 
clinical O 
application O 
, O 
the O 
toxicity O 
of O 
QDs O 
needs O 
to O 
be O 
carefully O 
evaluated O 
. O 
In O 
our O 
present O 
study O 
, O 
we O 
elucidate O 
the O 
cytotoxic O 
mechanisms O 
of O 
QDs O 
using O 
a O 
mouse O 
renal O 
adenocarcinoma O 
( O 
RAG O 
) O 
cell O 
line O 
. O 
QDs O 
in O 
RAG O 
cells O 
increased O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
levels O 
and O 
induced O 
autophagy O 
at O 
6 O 
h O 
, O 
leading O 
to O 
subsequent O 
apoptosis O 
at O 
24 O 
h O 
. O 
QDs O 
entered O 
the O 
cells O 
and O 
were O 
located O 
within O 
the O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
, O 
endosome O 
, O 
and O 
lysosome O 
at O 
6 O 
h O 
and O 
endosome O 
, O 
lysosome O 
, O 
and O 
mitochondria O 
at O 
24 O 
h O 
. O 
However O 
, O 
QDs O 
only O 
affected O 
mitochondrial O 
function O 
and O 
did O 
not O 
induce O 
ER O 
stress O 
. O 
N-Acetylcysteine B-SYSTEMATIC 
, O 
an O 
antioxidant O 
agent O 
, O 
reduced O 
intracellular O 
ROS O 
levels O 
and O 
decreased O 
QD-induced O 
autophagy O 
but O 
enhanced O 
QD-induced O 
cell O 
death O 
. O 
Moreover O 
, O 
3-methylamphetamine B-SYSTEMATIC 
( O 
an O 
autophagy O 
inhibitor O 
) O 
also O 
reduced O 
the O 
cell O 
viability O 
in O 
QD O 
- O 
treated O 
cells O 
. O 
These O 
findings O 
suggest O 
that O 
ROS O 
plays O 
an O 
essential O 
role O 
in O 
the O 
regulation O 
of O 
QD-induced O 
autophagy O 
, O 
which O 
subsequently O 
enhances O 
cell O 
survival O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
oxidative O 
stress O 
- O 
induced O 
autophagy O 
is O 
a O 
defense O 
/ O 
survival O 
mechanism O 
against O 
the O 
cytotoxicity O 
of O 
QD O 
. O 

of O 
iodide B-SYSTEMATIC 
deficiency O 
in O 
the O 
lactating O 
rat O 
and O 
pup O 
using O 
a O 
biologically O 
based O 
dose O 
- O 
response O 
model O 
. O 

biologically O 
based O 
dose O 
- O 
response O 
( O 
BBDR O 
) O 
model O 
for O 
the O 
hypothalamic O 
- O 
pituitary O 
thyroid O 
( O 
HPT O 
) O 
axis O 
in O 
the O 
lactating O 
rat O 
and O 
nursing O 
pup O 
was O 
developed O 
to O 
describe O 
the O 
perturbations O 
caused O 
by O 
iodide B-SYSTEMATIC 
deficiency O 
on O 
the O 
HPT O 
axis O 
. O 
Model O 
calibrations O 
, O 
carried O 
out O 
by O 
adjusting O 
key O 
model O 
parameters O 
, O 
were O 
used O 
as O 
a O 
technique O 
to O 
evaluate O 
HPT O 
axis O 
adaptations O 
to O 
dietary O 
iodide B-SYSTEMATIC 
intake O 
in O 
euthyroid O 
( O 
4.1-39 O 
µg O 
iodide B-SYSTEMATIC 
/ O 
day O 
) O 
and O 
iodide B-SYSTEMATIC 
-deficient O 
( O 
0.31 O 
and O 
1.2 O 
µg O 
iodide B-SYSTEMATIC 
/ O 
day O 
) O 
conditions O 
. O 
Iodide B-SYSTEMATIC 
-deficient O 
conditions O 
in O 
both O 
the O 
dam O 
and O 
the O 
pup O 
were O 
described O 
with O 
increased O 
blood O 
flow O 
to O 
the O 
thyroid O 
gland O 
, O 
TSH O 
- O 
mediated O 
increase O 
in O 
thyroidal O 
uptake O 
of O 
iodide B-SYSTEMATIC 
and O 
binding O 
of O 
iodide B-SYSTEMATIC 
in O 
the O 
thyroid O 
gland O 
( O 
organification O 
) O 
, O 
and O 
, O 
in O 
general O 
, O 
reduced O 
thyroid B-FAMILY 
hormone I-FAMILY 
production O 
and O 
metabolism O 
. O 
Alterations O 
in O 
thyroxine B-TRIVIAL 
( O 
T4 O 
) O 
homeostasis O 
were O 
more O 
apparent O 
than O 
for O 
triiodothyronine B-TRIVIAL 
( O 
T3 O 
) O 
. O 
Model O 
- O 
predicted O 
average O 
daily O 
area O 
- O 
under O 
- O 
the O 
- O 
serum O 
- O 
concentration O 
- O 
curve O 
( O 
nM-day O 
) O 
values O 
for O 
T4 O 
at O 
steady O 
state O 
in O 
the O 
dam O 
and O 
pup O 
decreased O 
by O 
14-15% O 
for O 
the O 
1.2 O 
µg O 
iodide B-SYSTEMATIC 
/ O 
day O 
iodide B-SYSTEMATIC 
-deficient O 
diet O 
and O 
42-52% O 
for O 
the O 
0.31 O 
µg O 
iodide B-SYSTEMATIC 
/ O 
day O 
iodide B-SYSTEMATIC 
-deficient O 
diet O 
. O 
In O 
rat O 
pups O 
that O 
were O 
iodide B-SYSTEMATIC 
deficient O 
during O 
gestation O 
and O 
lactation O 
, O 
these O 
decreases O 
in O 
serum O 
T4 O 
levels O 
were O 
associated O 
with O 
declines O 
in O 
thyroid B-FAMILY 
hormone I-FAMILY 
in O 
the O 
fetal O 
brain O 
and O 
a O 
suppression O 
of O 
synaptic O 
responses O 
in O 
the O 
hippocampal O 
region O 
of O 
the O 
brain O 
of O 
the O 
adult O 
offspring O 
( O 
Gilbert O 
et O 
al O 
. O 
, O 
2013 O 
) O 
. O 

of O 
randomly O 
and O 
vertically O 
embedded O 
graphene B-TRIVIAL 
nanosheets O 
in O 
activated O 
carbon B-SYSTEMATIC 
film O 
as O 
a O 
counter O 
electrode O 
for O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

new O 
approach O 
has O 
been O 
developed O 
to O 
randomly O 
and O 
vertically O 
embed O 
the O 
graphene B-TRIVIAL 
nanosheets O 
( O 
GNs O 
) O 
in O 
the O 
activated O 
carbon B-SYSTEMATIC 
( O 
AC O 
) O 
film O 
in O 
an O 
applied O 
electric O 
field O 
. O 
The O 
activated O 
carbon B-SYSTEMATIC 
( O 
AC O 
) O 
nanoparticles O 
in O 
suspension O 
during O 
electrophoresis O 
play O 
an O 
important O 
role O 
in O 
supporting O 
the O 
GNs O 
perpendicular O 
to O 
the O 
FTO B-ABBREVIATION 
( O 
fluorine B-SYSTEMATIC 
- I-SYSTEMATIC 
doped I-SYSTEMATIC 
tin I-SYSTEMATIC 
oxide I-SYSTEMATIC 
) O 
glass O 
. O 
Insufficient O 
amount O 
of O 
AC O 
nanoparticles O 
might O 
result O 
in O 
a O 
deposition O 
of O 
GNs O 
parallel O 
to O 
the O 
FTO B-ABBREVIATION 
glass O 
, O 
leading O 
to O 
incomplete O 
utilization O 
of O 
the O 
surface O 
area O 
accessible O 
to O 
electrolyte O 
ions O 
. O 
An O 
AC O 
cathode O 
with O 
randomly O 
and O 
vertically O 
embedded O 
GNs O 
facilitated O 
electrolyte O 
penetration O 
and O 
electron O 
conduction O 
. O 
The O 
photoelectron O 
conversion O 
efficiency O 
of O 
the O 
cell O 
was O 
increased O 
to O 
7.50% O 
by O 
employing O 
the O 
AC O 
cathode O 
with O 
randomly O 
and O 
vertically O 
embedded O 
GNs O 
. O 

have O 
coronary O 
heart O 
disease O 
( O 
CHD O 
) O 
later O 
than O 
men O 
. O 
This O 
review O 
describes O 
studies O 
of O 
CHD O 
risk O 
factors O 
or O 
outcomes O 
based O 
on O 
studies O 
of O 
premenopausal O 
women O 
followed O 
through O 
the O 
menopause O 
transition O 
, O 
and O 
prospective O 
cohort O 
studies O 
of O 
younger O 
or O 
older O 
women O 
with O 
CHD O 
risk O 
markers O 
or O 
disease O 
outcomes O 
in O 
the O 
context O 
of O 
their O 
menopause O 
history O 
. O 
Major O 
early O 
reports O 
from O 
both O 
types O 
of O 
studies O 
are O 
included O 
in O 
order O 
to O 
put O 
more O 
recent O 
work O 
in O 
context O 
. O 
Most O 
attention O 
has O 
been O 
paid O 
to O 
the O 
Healthy O 
Women O 
Study O 
( O 
HWS O 
) O 
, O 
Study O 
of O 
Women's O 
Health O 
across O 
the O 
Nation O 
( O 
SWAN O 
) O 
, O 
the O 
Nurses' O 
Health O 
Study O 
( O 
NHS O 
) O 
, O 
and O 
the O 
Rancho O 
Bernardo O 
Study O 
( O 
RBS O 
) O 
because O 
they O 
continue O 
to O 
produce O 
recent O 
publications O 
designed O 
to O 
distinguish O 
the O 
effect O 
of O 
age O 
from O 
the O 
effect O 
of O 
menopause O 
. O 
Understanding O 
these O 
differences O 
has O 
important O 
implications O 
for O 
women's O 
cardiovascular O 
health O 
, O 
but O 
remains O 
incomplete O 
. O 
Transition O 
studies O 
have O 
relatively O 
short O 
( O 
< O 
10 O 
years O 
) O 
follow O 
- O 
up O 
and O 
exclude O 
women O 
with O 
surgical O 
menopause O 
. O 
Cohort O 
studies O 
suggest O 
that O 
women O 
with O 
oophorectomy O 
are O 
at O 
greater O 
risk O 
for O 
CHD O 
than O 
intact O 
women O 
, O 
pointing O 
to O 
a O 
greater O 
risk O 
from O 
testosterone B-TRIVIAL 
deficiency O 
than O 
from O 
estradiol B-TRIVIAL 
levels O 
. O 

effect O 
of O 
oxygen B-SYSTEMATIC 
heteroatoms O 
on O 
the O 
single O 
molecule O 
conductance O 
of O 
saturated O 
chains O 
. O 

molecule O 
conductance O 
measurements O 
on O 
alkanedithiols B-FAMILY 
and O 
alkoxydithiols B-FAMILY 
( O 
dithiolated B-FAMILY 
oligoethers I-FAMILY 
) O 
were O 
performed O 
using O 
the O 
STM-controlled O 
break O 
junction O 
method O 
in O 
order O 
to O 
ascertain O 
how O 
the O 
oxygen B-SYSTEMATIC 
heteroatoms O 
in O 
saturated O 
linear O 
chains O 
impact O 
the O 
molecular O 
conductance O 
. O 
The O 
experimental O 
results O 
show O 
that O 
the O 
difference O 
in O 
conductance O 
increases O 
with O 
chain O 
length O 
, O 
over O 
the O 
range O 
studied O 
. O 
Comparisons O 
with O 
electronic O 
structure O 
calculations O 
and O 
previous O 
work O 
on O 
alkanes B-FAMILY 
indicate O 
that O 
the O 
conductance O 
of O 
the O 
oligoethers B-FAMILY 
is O 
lower O 
than O 
that O 
of O 
alkane B-FAMILY 
chains O 
with O 
the O 
same O 
length O 
. O 
Electronic O 
structure O 
calculations O 
allow O 
the O 
difference O 
in O 
the O 
conductance O 
of O 
these O 
two O 
families O 
of O 
molecules O 
to O 
be O 
traced O 
to O 
differences O 
in O 
the O 
spatial O 
distribution O 
of O 
the O 
molecular O 
orbitals O 
that O 
contribute O 
most O 
to O 
the O 
conductance O 
. O 
A O 
pathway O 
analysis O 
of O 
the O 
electronic O 
coupling O 
through O 
the O 
chain O 
is O 
used O 
to O 
explain O 
how O 
the O 
difference O 
in O 
conductance O 
between O 
the O 
alkane B-FAMILY 
and O 
oligoether O 
molecules O 
depends O 
on O 
the O 
chain O 
length O 
. O 

nanodisks O 
as O 
an O 
efficient O 
platform O 
for O 
Doxorubicin B-TRIVIAL 
delivery O 
to O 
cancer O 
cells O 
. O 

report O 
a O 
facile O 
approach O 
to O 
using O 
laponite B-TRIVIAL 
( O 
LAP B-ABBREVIATION 
) O 
nanodisks O 
as O 
a O 
platform O 
for O 
efficient O 
delivery O 
of O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
to O 
cancer O 
cells O 
. O 
In O 
this O 
study O 
, O 
DOX B-ABBREVIATION 
was O 
encapsulated O 
into O 
the O 
interlayer O 
space O 
of O 
LAP B-ABBREVIATION 
through O 
an O 
ionic O 
exchange O 
process O 
with O 
an O 
exceptionally O 
high O 
loading O 
efficiency O 
of O 
98.3 O 
± O 
0.77% O 
. O 
The O 
successful O 
DOX B-ABBREVIATION 
loading O 
was O 
extensively O 
characterized O 
via O 
different O 
methods O 
. O 
In O 
vitro O 
drug O 
release O 
study O 
shows O 
that O 
the O 
release O 
of O 
DOX B-ABBREVIATION 
from O 
LAP B-ABBREVIATION 
/ O 
DOX B-ABBREVIATION 
nanodisks O 
is O 
pH-dependent O 
, O 
and O 
DOX B-ABBREVIATION 
is O 
released O 
at O 
a O 
quicker O 
rate O 
at O 
acidic O 
pH O 
condition O 
( O 
pH O 
= O 
5.4 O 
) O 
than O 
at O 
physiological O 
pH O 
condition O 
. O 
Importantly O 
, O 
cell O 
viability O 
assay O 
results O 
reveal O 
that O 
LAP B-ABBREVIATION 
/ O 
DOX B-ABBREVIATION 
nanodisks O 
display O 
a O 
much O 
higher O 
therapeutic O 
efficacy O 
in O 
inhibiting O 
the O 
growth O 
of O 
a O 
model O 
cancer O 
cell O 
line O 
( O 
human O 
epithelial O 
carcinoma O 
cells O 
, O 
KB O 
cells O 
) O 
than O 
free O 
DOX B-ABBREVIATION 
drug O 
at O 
the O 
same O 
DOX B-ABBREVIATION 
concentration O 
. O 
The O 
enhanced O 
antitumor O 
efficacy O 
is O 
primarily O 
due O 
to O 
the O 
much O 
more O 
cellular O 
uptake O 
of O 
the O 
LAP B-ABBREVIATION 
/ O 
DOX B-ABBREVIATION 
nanodisks O 
than O 
that O 
of O 
free O 
DOX B-ABBREVIATION 
, O 
which O 
has O 
been O 
confirmed O 
by O 
confocal O 
laser O 
scanning O 
microscope O 
and O 
flow O 
cytometry O 
analysis O 
. O 
The O 
high O 
DOX B-ABBREVIATION 
payload O 
and O 
enhanced O 
antitumor O 
efficacy O 
render O 
LAP B-ABBREVIATION 
nanodisks O 
as O 
a O 
robust O 
carrier O 
system O 
for O 
different O 
biomedical O 
applications O 
. O 

in O 
triglyceride B-FAMILY 
levels O 
are O 
associated O 
with O 
clinical O 
response O 
to O 
clozapine B-TRIVIAL 
treatment O 
. O 

in O 
serum O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
levels O 
are O 
associated O 
with O 
clinical O 
response O 
to O 
clozapine B-TRIVIAL 
treatment O 
. O 
Clozapine B-TRIVIAL 
is O 
the O 
most O 
efficacious O 
therapy O 
for O 
treatment O 
of O 
refractory O 
schizophrenia O 
, O 
although O 
its O 
use O 
is O 
well O 
recognised O 
to O 
be O 
associated O 
with O 
substantial O 
metabolic O 
dysfunction O 
. O 
Interestingly O 
, O 
there O 
is O 
some O 
evidence O 
that O 
the O 
therapeutic O 
benefit O 
of O 
clozapine B-TRIVIAL 
is O 
associated O 
with O 
treatment-emergent O 
weight O 
gain O 
and O 
dyslipidaemia O 
, O 
specifically O 
hypertriglyceridaemia O 
. O 
In O 
this O 
prospective O 
observational O 
study O 
, O 
we O 
examine O 
associations O 
between O 
therapeutic O 
response O 
to O 
clozapine B-TRIVIAL 
in O 
49 O 
patients O 
with O 
treatment-resistant O 
schizophrenia O 
and O 
lipid O 
dysregulation O 
. O 
An O 
increase O 
in O 
TG O 
levels O 
was O 
strongly O 
predictive O 
of O 
clinical O 
improvement O 
( O 
B=9.33 O 
, O 
t O 
= O 
3.56 O 
, O 
df=4 O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
of O 
improvement O 
in O 
positive O 
PANSS O 
scores O 
( O 
B=2.85 O 
, O 
t=3.61 O 
, O 
df=4 O 
, O 
p=0.001 O 
) O 
as O 
well O 
as O 
negative O 
PANSS O 
scores O 
( O 
B=1.93 O 
, O 
t=2.36 O 
, O 
df=4 O 
, O 
p=0.02 O 
) O 
, O 
when O 
controlling O 
for O 
potential O 
confounds O 
of O 
weight O 
gain O 
, O 
change O 
in O 
waist O 
circumference O 
, O 
baseline O 
antipsychotic O 
polypharmacy O 
and O 
serum O 
clozapine B-TRIVIAL 
levels O 
. O 
This O 
finding O 
suggests O 
that O 
clozapine B-TRIVIAL 
' O 
s O 
therapeutic O 
efficacy O 
is O 
linked O 
to O 
serum O 
lipid O 
changes O 
. O 
Hypertriglyceridaemia O 
as O 
a O 
predictor O 
of O 
clinical O 
response O 
in O 
patients O 
treated O 
with O 
clozapine B-TRIVIAL 
merits O 
further O 
investigation O 
in O 
order O 
to O 
better O 
elucidate O 
its O 
effect O 
on O 
the O 
pharmacological O 
activity O 
of O 
clozapine B-TRIVIAL 
. O 

charge O 
- O 
density O 
waves O 
in O 
a O 
cuprate B-SYSTEMATIC 
superconductor O 
. O 

materials O 
hosting O 
high O 
- O 
temperature O 
superconductivity O 
( O 
HTS O 
) O 
also O 
exhibit O 
various O 
forms O 
of O 
charge O 
and O 
spin O 
ordering O 
whose O 
significance O 
is O 
not O 
fully O 
understood O 
. O 
So O 
far O 
, O 
static O 
charge O 
- O 
density O 
waves O 
( O 
CDWs O 
) O 
have O 
been O 
detected O 
by O 
diffraction O 
probes O 
only O 
at O 
particular O 
doping O 
levels O 
or O 
in O 
an O 
applied O 
external O 
field O 
. O 
However O 
, O 
dynamic O 
CDWs O 
may O 
also O 
be O 
present O 
more O 
broadly O 
and O 
their O 
detection O 
, O 
characterization O 
and O 
relationship O 
with O 
HTS O 
remain O 
open O 
problems O 
. O 
Here O 
we O 
present O 
a O 
method O 
based O 
on O 
ultrafast O 
spectroscopy O 
to O 
detect O 
the O 
presence O 
and O 
measure O 
the O 
lifetimes O 
of O 
CDW O 
fluctuations O 
in O 
cuprates B-FAMILY 
. O 
In O 
an O 
underdoped O 
La1.9Sr0.1CuO4 B-FORMULA 
film O 
( O 
Tc O 
= O 
26 O 
K O 
) O 
, O 
we O 
observe O 
collective O 
excitations O 
of O 
CDW O 
that O 
persist O 
up O 
to O 
100 O 
K O 
. O 
This O 
dynamic O 
CDW O 
fluctuates O 
with O 
a O 
characteristic O 
lifetime O 
of O 
2 O 
ps O 
at O 
T O 
= O 
5 O 
K O 
that O 
decreases O 
to O 
0.5 O 
ps O 
at O 
T O 
= O 
100 O 
K O 
. O 
In O 
contrast O 
, O 
in O 
an O 
optimally O 
doped O 
La1.84Sr0.16CuO4 B-FORMULA 
film O 
( O 
Tc O 
= O 
38.5 O 
K O 
) O 
, O 
we O 
detect O 
no O 
signatures O 
of O 
fluctuating O 
CDWs O 
at O 
any O 
temperature O 
, O 
favouring O 
the O 
competition O 
scenario O 
. O 
This O 
work O 
forges O 
a O 
path O 
for O 
studying O 
fluctuating O 
order O 
parameters O 
in O 
various O 
superconductors O 
and O 
other O 
materials O 
. O 

acid I-TRIVIAL 
modulates O 
fluoride B-SYSTEMATIC 
-induced O 
oxidative O 
hepatotoxicity O 
in O 
male O 
Wistar O 
rats O 
. O 

present O 
study O 
is O 
aimed O 
to O 
evaluate O 
the O 
protective O 
effect O 
of O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
on O 
fluoride B-SYSTEMATIC 
-induced O 
oxidative O 
hepatotoxicity O 
in O 
male O 
Wistar O 
rats O 
. O 
Fluoride B-SYSTEMATIC 
( O 
25 O 
mg O 
/ O 
L O 
) O 
was O 
given O 
orally O 
to O 
induce O 
hepatotoxicity O 
for O 
12 O 
weeks O 
. O 
Hepatic O 
damage O 
were O 
assessed O 
using O 
status O 
of O 
pathophysiological O 
markers O 
like O 
serum O 
marker O 
enzymes O 
like O 
aspartate B-TRIVIAL 
transaminase O 
, O 
alanine B-TRIVIAL 
transaminase O 
, O 
alkaline O 
phosphatase O 
, O 
acid O 
phosphatase O 
, O 
gamma B-SYSTEMATIC 
glutamyl I-SYSTEMATIC 
transferase O 
, O 
lactate B-FAMILY 
dehydrogenase O 
, O 
bilirubin B-TRIVIAL 
, O 
lipid O 
profile O 
, O 
total O 
protein O 
content O 
levels O 
, O 
and O 
histopathological O 
studies O 
. O 
Treatment O 
with O 
FA O 
significantly O 
reduced O 
the O 
degree O 
of O 
histological O 
aberrations O 
and O 
rescued O 
lipid O 
peroxidation O 
, O 
as O 
observed O 
from O 
reduced O 
levels O 
of O 
lipid O 
hydroperoxides B-FAMILY 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
restored O 
levels O 
of O 
enzymic O 
and O 
non-enzymic O 
antioxidants O 
, O 
and O 
total O 
protein O 
content O 
, O 
with O 
a O 
concomitant O 
decline O 
in O 
the O 
levels O 
of O 
marker O 
enzymes O 
and O 
lipid O 
profile O 
in O 
fluoride B-SYSTEMATIC 
-induced O 
rats O 
. O 
These O 
results O 
suggest O 
that O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
has O 
the O 
ability O 
to O 
protect O 
fluoride B-SYSTEMATIC 
-induced O 
hepatic O 
damage O 
. O 

electric O 
fields O 
in O 
films O 
of O 
CF3Cl B-FORMULA 
, O 
CF2Cl2 B-FORMULA 
and O 
CFCl3 B-FORMULA 
. O 

are O 
presented O 
showing O 
the O 
spontaneous O 
formation O 
of O 
electric O 
fields O 
within O 
solid O 
films O 
of O 
the O 
chlorofluorocarbons B-FAMILY 
( O 
CFCs B-FAMILY 
) O 
CF(3)Cl B-FORMULA 
, O 
CF(2)Cl(2) B-FORMULA 
and O 
CFCl(3) B-FORMULA 
as O 
a O 
function O 
of O 
film O 
deposition O 
temperature O 
from O 
40 O 
K O 
and O 
above O 
. O 
Electric O 
fields O 
, O 
which O 
arise O 
through O 
dipole O 
alignment O 
and O 
lie O 
in O 
the O 
range O 
of O 
a O 
few O 
times O 
10(7) O 
V O 
m(-1) O 
to O 
a O 
few O 
times O 
10(6) O 
V O 
m(-1) O 
, O 
decrease O 
as O 
the O 
degree O 
of O 
chlorination O 
increases O 
. O 
Maximum O 
deposition O 
temperatures O 
for O 
display O 
of O 
an O 
electric O 
field O 
lie O 
at O 
~50 O 
K O 
, O 
~65 O 
K O 
and O 
~52 O 
K O 
for O 
CF(3)Cl B-FORMULA 
, O 
CF(2)Cl(2) B-FORMULA 
and O 
CFCl(3) B-FORMULA 
respectively O 
. O 
CFCl(3) B-FORMULA 
films O 
possess O 
electric O 
fields O 
which O 
show O 
an O 
onset O 
of O 
temporal O 
metastability O 
between O 
deposition O 
temperatures O 
of O 
46 O 
K O 
and O 
50 O 
K O 
. O 
CF(3)Cl B-FORMULA 
and O 
CF(2)Cl(2) B-FORMULA 
demonstrate O 
temperatures O 
of O 
~65 O 
K O 
and O 
~80 O 
K O 
at O 
which O 
the O 
electric O 
field O 
in O 
the O 
film O 
is O 
removed O 
by O 
heating O 
, O 
so O 
- O 
called O 
Curie O 
points O 
, O 
with O 
decay O 
of O 
the O 
field O 
spread O 
over O 
more O 
than O 
10 O 
K O 
. O 
CFCl(3) B-FORMULA 
displays O 
a O 
comparatively O 
sharp O 
Curie O 
point O 
at O 
55 O 
K O 
. O 
This O 
variety O 
of O 
behaviour O 
arises O 
despite O 
the O 
resemblance O 
of O 
these O 
three O 
species O 
in O 
terms O 
of O 
electronic O 
structure O 
and O 
gas O 
phase O 
dipole O 
moment O 
, O 
emphasising O 
the O 
requirement O 
for O 
detailed O 
chemical O 
models O 
of O 
this O 
phenomenon O 
. O 

and O 
demelanizing O 
activity O 
of O 
Ganoderma O 
lucidum O 
extract O 
, O 
p-hydroxybenzoic B-MULTIPLE 
and I-MULTIPLE 
cinnamic I-MULTIPLE 
acids I-MULTIPLE 
and O 
their O 
synthetic O 
acetylated B-FAMILY 
glucuronide I-FAMILY 
methyl I-FAMILY 
esters I-FAMILY 
. O 

extracts O 
or O 
isolated O 
compounds O 
may O 
be O 
useful O 
in O 
the O 
search O 
of O 
new O 
potent O 
antimicrobial O 
agents O 
. O 
Herein O 
, O 
it O 
is O 
described O 
the O 
synthesis O 
of O 
protected O 
( O 
acetylated O 
) O 
glucuronide O 
derivatives O 
of O 
p-hydroxybenzoic B-MULTIPLE 
and I-MULTIPLE 
cinnamic I-MULTIPLE 
acids I-MULTIPLE 
, O 
two O 
compounds O 
identified O 
in O 
the O 
medicinal O 
mushroom O 
Ganoderma O 
lucidum O 
. O 
Their O 
antimicrobial O 
and O 
demelanizing O 
activities O 
were O 
evaluated O 
and O 
compared O 
to O 
the O 
parent O 
acids O 
and O 
G O 
. O 
lucidum O 
extract O 
. O 
p-Hydroxybenzoic B-MULTIPLE 
and I-MULTIPLE 
cinnamic I-MULTIPLE 
acids I-MULTIPLE 
, O 
as O 
also O 
their O 
protected O 
glucuronide O 
derivatives O 
revealed O 
high O 
antimicrobial O 
( O 
antibacterial O 
and O 
antifungal O 
) O 
activity O 
, O 
even O 
better O 
than O 
the O 
one O 
showed O 
by O 
commercial O 
standards O 
. O 
Despite O 
the O 
variation O 
in O 
the O 
order O 
of O 
parent O 
acids O 
and O 
the O 
protected O 
glucuronide O 
derivatives O 
, O 
their O 
antimicrobial O 
activity O 
was O 
always O 
higher O 
than O 
the O 
one O 
revealed O 
by O 
the O 
extract O 
. O 
Nevertheless O 
, O 
the O 
extract O 
was O 
the O 
only O 
one O 
with O 
demelanizing O 
activity O 
against O 
Aspergillus O 
niger O 
. O 
The O 
acetylated O 
glucuronide O 
derivatives O 
could O 
be O 
deprotected O 
to O 
obtain O 
glucuronide O 
metabolites O 
, O 
which O 
circulate O 
in O 
the O 
human O 
organism O 
as O 
products O 
of O 
the O 
metabolism O 
of O 
the O 
parent O 
compounds O 
. O 

amplified O 
polymorphic-DNA O 
analysis O 
for O 
detecting O 
genotoxic O 
effects O 
of O 
Boron B-SYSTEMATIC 
on O 
maize O 
( O 
Zea O 
mays O 
L O 
. O 
) O 
. O 

study O 
was O 
carried O 
out O 
to O 
investigate O 
the O 
genotoxic O 
effect O 
of O 
boron B-SYSTEMATIC 
( O 
B B-FORMULA 
) O 
on O 
maize O 
using O 
randomly O 
amplified O 
polymorphic O 
DNA O 
( O 
RAPD O 
) O 
method O 
. O 
Experimental O 
design O 
was O 
conducted O 
under O 
0 O 
, O 
5 O 
, O 
10 O 
, O 
25 O 
, O 
50 O 
, O 
100 O 
, O 
125 O 
, O 
and O 
150 O 
ppm O 
B B-FORMULA 
exposures O 
, O 
and O 
physiological O 
changes O 
have O 
revealed O 
a O 
sharp O 
decrease O 
in O 
root O 
growth O 
rates O 
from O 
28% O 
to O 
85% O 
, O 
starting O 
from O 
25 O 
ppm O 
to O 
150 O 
ppm O 
, O 
respectively O 
. O 
RAPD-polymerase O 
chain O 
reaction O 
( O 
PCR O 
) O 
analysis O 
shows O 
that O 
DNA O 
alterations O 
are O 
clearly O 
observed O 
from O 
beginning O 
to O 
100 O 
ppm O 
. O 
B B-FORMULA 
-induced O 
inhibition O 
in O 
root O 
growth O 
had O 
a O 
positive O 
correlation O 
with O 
DNA O 
alterations O 
. O 
Total O 
soluble O 
protein O 
, O 
root O 
and O 
stem O 
lengths O 
, O 
and O 
B B-FORMULA 
content O 
analysis O 
in O 
root O 
and O 
leaves O 
encourage O 
these O 
results O 
as O 
a O 
consequence O 
. O 
These O 
preliminary O 
findings O 
reveal O 
that O 
B B-FORMULA 
causes O 
chromosomal O 
aberration O 
and O 
genotoxic O 
effects O 
on O 
maize O 
. O 
Meanwhile O 
, O 
usage O 
of O 
RAPD-PCR O 
technique O 
is O 
a O 
suitable O 
biomarker O 
to O 
detect O 
genotoxic O 
effect O 
of O 
B B-FORMULA 
on O 
maize O 
and O 
other O 
crops O 
for O 
the O 
future O 
. O 

receptors O 
are O 
faced O 
with O 
a O 
multitude O 
of O 
stressors O 
that O 
include O 
abiotic O 
and O 
biotic O 
factors O 
creating O 
a O 
challenge O 
for O 
assessing O 
risk O 
of O 
chemical O 
exposure O 
. O 
Of O 
particular O 
interest O 
and O 
importance O 
are O 
the O 
effects O 
of O 
contaminants O 
on O 
inter O 
- O 
species O 
interactions O 
such O 
as O 
competition O 
and O 
predator O 
- O 
prey O 
relationships O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
environmentally O 
relevant O 
concentrations O 
of O 
the O 
commonly O 
used O 
insecticide O 
, O 
malathion B-TRIVIAL 
, O 
would O 
alter O 
predator O 
avoidance O 
behavior O 
in O 
a O 
freshwater O 
gastropod O 
that O 
could O 
translate O 
to O 
increased O 
predation O 
risk O 
. O 
We O 
exposed O 
adult O 
Physa O 
pomilia O 
snails O 
to O 
0 O 
, O 
0.25 O 
, O 
or O 
1 O 
mg O 
/ O 
L O 
malathion B-TRIVIAL 
for O 
2 O 
, O 
24 O 
, O 
or O 
48 O 
h O 
and O 
evaluated O 
predator O 
avoidance O 
using O 
a O 
behavioral O 
assay O 
in O 
which O 
snails O 
were O 
exposed O 
to O 
cues O 
from O 
predatory O 
crayfish O 
. O 
We O 
found O 
a O 
significant O 
reduction O 
in O 
predator O 
avoidance O 
in O 
snails O 
exposed O 
to O 
both O 
concentrations O 
of O 
malathion B-TRIVIAL 
after O 
48 O 
h O 
of O 
exposure O 
. O 
To O 
evaluate O 
whether O 
observed O 
effects O 
of O 
malathion B-TRIVIAL 
on O 
predator O 
avoidance O 
actually O 
increased O 
susceptibility O 
of O 
snails O 
to O 
predators O 
, O 
we O 
conducted O 
a O 
predator O 
challenge O 
experiment O 
. O 
Snails O 
exposed O 
to O 
0.25 O 
mg O 
/ O 
L O 
malathion B-TRIVIAL 
for O 
48 O 
h O 
were O 
significantly O 
more O 
susceptible O 
to O 
predation O 
. O 
That O 
increased O 
predation O 
risk O 
was O 
evident O 
48 O 
h O 
after O 
initial O 
malathion B-TRIVIAL 
exposures O 
is O 
a O 
unique O 
result O 
because O 
most O 
studies O 
have O 
evaluated O 
behavioral O 
responses O 
soon O 
after O 
( O 
< O 
12 O 
h O 
) O 
initiation O 
of O 
pesticide O 
exposure O 
. O 
The O 
extent O 
to O 
which O 
the O 
observed O 
interactions O 
affect O 
natural O 
populations O 
, O 
and O 
the O 
mechanisms O 
through O 
which O 
they O 
are O 
mediated O 
are O 
largely O 
unexplored O 
. O 
However O 
, O 
our O 
study O 
is O 
the O 
first O 
to O 
show O 
that O 
a O 
commonly O 
used O 
insecticide O 
decreases O 
predator O 
avoidance O 
and O 
may O 
actually O 
increase O 
predation O 
susceptibility O 
in O 
gastropods O 
at O 
concentrations O 
several O 
orders O 
of O 
magnitude O 
below O 
acute O 
toxicity O 
levels O 
. O 

protects O 
against O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
-induced O 
nephrotoxicity O 
by O 
facilitating O 
arsenic B-SYSTEMATIC 
metabolism O 
and O 
decreasing O 
oxidative O 
stress O 
. O 

trioxide I-SYSTEMATIC 
( O 
As2O3 B-FORMULA 
) O 
is O 
an O 
environmental O 
toxicant O 
and O 
a O 
potent O 
antineoplastic O 
agent O 
. O 
Exposure O 
to O 
arsenic B-SYSTEMATIC 
causes O 
renal O 
cancer O 
. O 
Resveratrol B-TRIVIAL 
is O 
a O 
well O 
- O 
known O 
polyphenolic B-FAMILY 
compound O 
that O 
is O 
reported O 
to O 
reduce O 
As2O3 B-FORMULA 
-induced O 
cardiotoxicity O 
. O 
The O 
present O 
study O 
aimed O 
to O 
investigate O 
the O 
effect O 
of O 
resveratrol B-TRIVIAL 
on O 
As2O3 B-FORMULA 
-induced O 
nephrotoxicity O 
and O 
arsenic B-SYSTEMATIC 
metabolism O 
. O 
Chinese O 
Dragon-Li O 
cats O 
were O 
injected O 
with O 
1 O 
mg O 
/ O 
kg O 
As2O3 B-FORMULA 
on O 
alternate O 
days O 
; O 
resveratrol B-TRIVIAL 
( O 
3 O 
mg O 
/ O 
kg O 
) O 
was O 
administered O 
via O 
the O 
forearm O 
vein O 
1 O 
h O 
before O 
the O 
As2O3 B-FORMULA 
treatment O 
. O 
On O 
the O 
sixth O 
day O 
, O 
the O 
cats O 
were O 
killed O 
to O 
determine O 
the O 
histological O 
renal O 
damage O 
, O 
renal O 
function O 
, O 
the O 
accumulation O 
of O 
arsenic B-SYSTEMATIC 
, O 
and O 
antioxidant O 
activities O 
in O 
the O 
kidney O 
. O 
Urine O 
samples O 
were O 
taken O 
for O 
arsenic B-SYSTEMATIC 
speciation O 
. O 
In O 
the O 
resveratrol B-TRIVIAL 
+ O 
As2O3 B-FORMULA 
-treated O 
group O 
, O 
activities O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
catalase O 
, O 
and O 
superoxide B-TRIVIAL 
dismutase O 
, O 
the O 
ratio O 
of O 
reduced O 
glutathione B-TRIVIAL 
to O 
oxidized B-TRIVIAL 
glutathione I-TRIVIAL 
, O 
the O 
total O 
arsenic B-SYSTEMATIC 
concentrations O 
, O 
and O 
the O 
percentage O 
of O 
methylated B-SYSTEMATIC 
arsenic I-SYSTEMATIC 
in O 
urine O 
were O 
significantly O 
increased O 
. O 
The O 
concentrations O 
of O 
renal O 
malondialdehyde B-TRIVIAL 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
8-hydroxydeoxyguanosine B-SYSTEMATIC 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
, O 
and O 
renal O 
arsenic B-SYSTEMATIC 
accumulation O 
were O 
significantly O 
decreased O 
and O 
reduced O 
renal O 
morphologic O 
injury O 
was O 
observed O 
compared O 
with O 
the O 
As2O3 B-FORMULA 
-treated O 
group O 
. O 
These O 
results O 
demonstrate O 
that O 
resveratrol B-TRIVIAL 
could O 
significantly O 
scavenge O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
inhibit O 
As2O3 B-FORMULA 
-induced O 
oxidative O 
damage O 
, O 
and O 
significantly O 
attenuate O 
the O 
accumulation O 
of O 
arsenic B-SYSTEMATIC 
in O 
renal O 
tissues O 
by O 
facilitating O 
As2O3 B-FORMULA 
metabolism O 
. O 
These O 
data O 
suggest O 
that O 
use O 
of O 
resveratrol B-TRIVIAL 
as O 
postremission O 
therapy O 
for O 
acute O 
promyelocytic O 
leukemia O 
as O 
well O 
as O 
adjunctive O 
therapy O 
in O 
patients O 
with O 
exposure O 
to O 
arsenic B-SYSTEMATIC 
may O 
decrease O 
arsenic B-SYSTEMATIC 
nephrotoxicity O 
. O 

vitro O 
characterisation O 
of O 
the O 
novel O 
positive O 
allosteric O 
modulators O 
of O 
the O 
mGlu₅ O 
receptor O 
, O 
LSN2463359 B-IDENTIFIER 
and O 
LSN2814617 B-IDENTIFIER 
, O 
and O 
their O 
effects O 
on O 
sleep O 
architecture O 
and O 
operant O 
responding O 
in O 
the O 
rat O 
. O 

demonstrated O 
functional O 
interaction O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
5 O 
( O 
mGlu₅ O 
) O 
receptors O 
with O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptors O 
has O 
prompted O 
speculation O 
that O 
their O 
activation O 
may O 
offer O 
a O 
potential O 
treatment O 
for O 
aspects O 
of O 
schizophrenia O 
. O 
Development O 
of O 
selective O 
mGlu₅ O 
agonists O 
has O 
been O 
difficult O 
, O 
but O 
several O 
different O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
molecules O 
have O 
now O 
been O 
identified O 
. O 
This O 
study O 
describes O 
two O 
novel O 
mGlu₅ O 
PAMs O 
, O 
LSN2463359 B-IDENTIFIER 
( O 
N-(1-methylethyl)-5-(pyridin-4-ylethynyl)pyridine-2-carboxamide B-SYSTEMATIC 
) O 
and O 
LSN2814617 B-IDENTIFIER 
[ O 
(7S)-3-tert-butyl-7-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine B-SYSTEMATIC 
] O 
, O 
which O 
are O 
useful O 
tools O 
for O 
this O 
field O 
of O 
research O 
. O 
Both O 
compounds O 
are O 
potent O 
and O 
selective O 
potentiators O 
of O 
human O 
and O 
rat O 
mGlu₅ O 
receptors O 
in O 
vitro O 
, O 
displaying O 
curve O 
shift O 
ratios O 
of O 
two O 
to O 
three O 
fold O 
in O 
the O 
concentration O 
- O 
response O 
relationship O 
to O 
glutamate B-TRIVIAL 
or O 
the O 
glutamate B-TRIVIAL 
receptor O 
agonist O 
, O 
DHPG B-ABBREVIATION 
, O 
with O 
no O 
detectable O 
intrinsic O 
agonist O 
properties O 
. O 
Both O 
compounds O 
displaced O 
the O 
mGlu₅ O 
receptor O 
antagonist O 
radioligand O 
, O 
[³H]MPEP B-SYSTEMATIC 
in O 
vitro O 
and O 
, O 
following O 
oral O 
administration O 
reached O 
brain O 
concentrations O 
sufficient O 
to O 
occupy O 
hippocampal O 
mGlu₅ O 
receptors O 
as O 
measured O 
in O 
vivo O 
by O 
dose O 
- O 
dependent O 
displacement O 
from O 
the O 
hippocampus O 
of O 
intravenously O 
administered O 
MPEPy B-ABBREVIATION 
. O 
In O 
vivo O 
EEG O 
studies O 
demonstrated O 
that O 
these O 
mGlu₅ O 
PAMs O 
have O 
marked O 
wake O 
- O 
promoting O 
properties O 
but O 
little O 
in O 
the O 
way O 
of O 
rebound O 
hypersomnolence O 
. O 
In O 
contrast O 
, O 
the O 
previously O 
described O 
mGlu₅ O 
PAMs O 
CDPPB B-ABBREVIATION 
and O 
ADX47273 B-IDENTIFIER 
showed O 
relatively O 
poor O 
evidence O 
of O 
in O 
vivo O 
target O 
engagement O 
in O 
either O 
receptor O 
occupancy O 
assays O 
or O 
EEG O 
disturbance O 
. O 
Wake O 
- O 
promoting O 
doses O 
of O 
LSN2463359 B-IDENTIFIER 
and O 
LSN2814617 B-IDENTIFIER 
attenuated O 
deficits O 
in O 
performance O 
induced O 
by O 
the O 
competitive O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
in O 
two O 
tests O 
of O 
operant O 
behaviour O 
: O 
the O 
variable O 
interval O 
30 O 
s O 
task O 
and O 
the O 
DMTP O 
task O 
. O 
These O 
effects O 
were O 
lost O 
if O 
the O 
dose O 
of O 
either O 
compound O 
extended O 
into O 
the O 
range O 
which O 
disrupted O 
performance O 
in O 
the O 
baseline O 
DMTP O 
task O 
. O 
However O 
, O 
the O 
improvements O 
in O 
response O 
accuracy O 
induced O 
by O 
the O 
mGlu₅ O 
potentiators O 
in O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
-treated O 
rats O 
were O 
not O 
delay O 
- O 
dependent O 
and O 
, O 
therefore O 
, O 
perhaps O 
more O 
likely O 
reflected O 
optimization O 
of O 
general O 
arousal O 
than O 
specific O 
beneficial O 
effects O 
on O 
discrete O 
cognitive O 
processes O 
. O 
The O 
systematic O 
profiling O 
of O 
LSN2463359 B-IDENTIFIER 
and O 
LSN2814617 B-IDENTIFIER 
alongside O 
other O 
previously O 
described O 
molecules O 
will O 
help O 
determine O 
more O 
precisely O 
how O 
mGlu₅ O 
potentiator O 
pharmacology O 
might O 
provide O 
therapeutic O 
benefit O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

protective O 
role O 
of O 
l-carnitine B-TRIVIAL 
against O 
cylindrospermopsin B-TRIVIAL 
-induced O 
oxidative O 
stress O 
in O 
tilapia O 
( O 
Oreochromis O 
niloticus O 
) O 
. O 

( O 
CYN B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
most O 
important O 
cyanotoxins O 
in O 
terms O 
of O 
both O 
human O 
health O 
and O 
environmental O 
quality O 
and O 
is O 
produced O 
by O 
several O 
different O 
species O 
of O 
cyanobacteria O 
, O 
including O 
Aphanizomenon O 
ovalisporum O 
. O 
The O 
principal O 
mechanisms O 
of O 
action O 
of O 
CYN B-ABBREVIATION 
involve O 
inhibition O 
of O 
protein O 
and O 
glutathione B-TRIVIAL 
synthesis O 
. O 
In O 
addition O 
, O 
CYN B-ABBREVIATION 
-mediated O 
genotoxicity O 
results O 
from O 
DNA O 
fragmentation O 
. O 
The O 
results O 
of O 
both O 
in O 
vivo O 
and O 
in O 
vitro O 
studies O 
suggest O 
that O 
oxidative O 
stress O 
also O 
plays O 
a O 
significant O 
role O 
in O 
CYN B-ABBREVIATION 
pathogenesis O 
in O 
fish O 
. O 
We O 
investigated O 
the O 
protective O 
effects O 
of O 
l-carnitine B-TRIVIAL 
( O 
LC O 
) O 
pre O 
- O 
treatment O 
on O 
A O 
. O 
ovalisporum O 
- O 
induced O 
oxidative O 
stress O 
in O 
cells O 
containing O 
CYN B-ABBREVIATION 
and O 
deoxy-CYN B-SYSTEMATIC 
, O 
or O 
pure O 
standard O 
CYN B-ABBREVIATION 
, O 
in O 
tilapia O 
( O 
Oreochromis O 
niloticus O 
) O 
that O 
had O 
been O 
acutely O 
exposed O 
via O 
oral O 
administration O 
. O 
Various O 
oxidative O 
stress O 
markers O 
, O 
including O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
, O 
protein O 
oxidation O 
, O 
DNA O 
oxidation O 
, O 
and O 
the O 
ratio O 
of O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
to O 
oxidised B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
) O 
, O 
and O 
the O 
activities O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
and O 
gamma-glutamyl-cysteine B-TRIVIAL 
synthetase O 
( O 
γ-GCS O 
) O 
, O 
were O 
evaluated O 
in O 
the O 
livers O 
and O 
kidneys O 
of O 
fish O 
in O 
the O 
absence O 
and O 
presence O 
of O 
400 O 
or O 
880mgLC O 
/ O 
kgfish O 
/ O 
day O 
during O 
a O 
21 O 
day O 
period O 
prior O 
to O 
CYN B-ABBREVIATION 
-intoxication O 
. O 
The O 
results O 
of O 
our O 
study O 
demonstrated O 
for O 
the O 
first O 
time O 
the O 
beneficial O 
antioxidant O 
effects O 
of O 
LC O 
dietary O 
supplementation O 
on O 
oxidative O 
stress O 
status O 
in O 
fish O 
. O 
No O 
pro O 
- O 
oxidant O 
effects O 
were O 
detected O 
at O 
any O 
of O 
the O 
LC O 
doses O 
assayed O 
, O 
suggesting O 
that O 
LC O 
is O 
a O 
chemoprotectant O 
that O 
reduces O 
hepatic O 
and O 
renal O 
oxidative O 
stress O 
and O 
may O 
be O 
effective O 
when O 
used O 
for O 
the O 
prophylaxis O 
and O 
treatment O 
of O 
CYN B-ABBREVIATION 
-related O 
intoxication O 
in O 
fish O 
. O 

gecko O 
- O 
foot O 
- O 
mimetic O 
dry O 
adhesives O 
based O 
on O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

can O 
run O 
freely O 
on O 
vertical O 
walls O 
and O 
even O 
ceilings O 
. O 
Recent O 
studies O 
have O 
discovered O 
that O 
gecko's O 
extraordinary O 
climbing O 
ability O 
comes O 
from O 
a O 
remarkable O 
design O 
of O 
nature O 
with O 
nanoscale O 
beta-keratin O 
elastic O 
hairs O 
on O 
their O 
feet O 
and O 
toes O 
, O 
which O 
collectively O 
generate O 
sufficiently O 
strong O 
van O 
der O 
Waals O 
force O 
to O 
hold O 
the O 
animal O 
onto O 
an O 
opposing O 
surface O 
while O 
at O 
the O 
same O 
time O 
disengaging O 
at O 
will O 
. O 
Vertically O 
aligned O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
VA-CNT O 
) O 
arrays O 
, O 
resembling O 
gecko's O 
adhesive O 
foot O 
hairs O 
with O 
additional O 
superior O 
mechanical O 
, O 
chemical O 
and O 
electrical O 
properties O 
, O 
have O 
been O 
demonstrated O 
to O 
be O 
a O 
promising O 
candidate O 
for O 
advanced O 
fibrillar O 
dry O 
adhesives O 
. O 
The O 
VA-CNT O 
arrays O 
with O 
tailor O 
- O 
made O 
hierarchical O 
structures O 
can O 
be O 
patterned O 
and O 
/ O 
or O 
transferred O 
onto O 
various O 
flexible O 
substrates O 
, O 
including O 
responsive O 
polymers O 
. O 
This O 
, O 
together O 
with O 
recent O 
advances O 
in O 
nanofabrication O 
techniques O 
, O 
could O 
offer O 
' O 
smart O 
' O 
dry O 
adhesives O 
for O 
various O 
potential O 
applications O 
, O 
even O 
where O 
traditional O 
adhesives O 
cannot O 
be O 
used O 
. O 
A O 
detailed O 
understanding O 
of O 
the O 
underlying O 
mechanisms O 
governing O 
the O 
material O 
properties O 
and O 
adhesion O 
performances O 
is O 
critical O 
to O 
the O 
design O 
and O 
fabrication O 
of O 
gecko O 
inspired O 
CNT O 
dry O 
adhesives O 
of O 
practical O 
significance O 
. O 
In O 
this O 
feature O 
article O 
, O 
we O 
present O 
an O 
overview O 
of O 
recent O 
progress O 
in O 
both O 
fundamental O 
and O 
applied O 
frontiers O 
for O 
the O 
development O 
of O 
CNT O 
- O 
based O 
adhesives O 
by O 
summarizing O 
important O 
studies O 
in O 
this O 
exciting O 
field O 
, O 
including O 
our O 
own O 
work O 
. O 

biosensor O 
based O 
on O 
conducting O 
poly(5-formylindole) B-FAMILY 
for O 
sensitive O 
detection O 
of O 
Ramos O 
cells O 
. O 

signal O 
- O 
on O 
electrochemiluminescence O 
( O 
ECL O 
) O 
biosensor O 
devoted O 
to O 
the O 
detection O 
of O 
Ramos O 
cells O 
was O 
fabricated O 
based O 
on O 
a O 
novel O 
conducting O 
polymer O 
, O 
poly(5-formylindole) B-FAMILY 
( O 
P5FIn B-ABBREVIATION 
) O 
, O 
which O 
was O 
synthesized O 
electrochemically O 
by O 
direct O 
anodic O 
oxidation O 
of O 
5- B-SYSTEMATIC 
formylindole I-SYSTEMATIC 
( O 
5FIn B-SYSTEMATIC 
) O 
. O 
This O 
ECL O 
platform O 
was O 
presented O 
by O 
covalently O 
coupling O 
the O 
18-mer O 
amino O 
- O 
substituted O 
oligonucleotide O 
( O 
ODN O 
) O 
probes O 
with O 
aldehyde B-SYSTEMATIC 
groups O 
that O 
are O 
strongly O 
reactive O 
toward O 
a O 
variety O 
of O 
nucleophiles O 
on O 
the O 
surface O 
of O 
solid O 
substrates O 
. O 
The O 
specific O 
identification O 
and O 
high O 
- O 
affinity O 
between O 
aptamers O 
and O 
target O 
cells O 
, O 
gold O 
nanoparticles O 
( O 
AuNPs O 
) O 
enhanced O 
ECL O 
nanoprobes O 
, O 
along O 
with O 
P5FIn B-ABBREVIATION 
induced O 
ECL O 
quenching O 
contributed O 
greatly O 
to O 
the O 
sensitivity O 
and O 
selectivity O 
. O 
The O 
ECL O 
signals O 
were O 
logarithmically O 
linear O 
with O 
the O 
concentration O 
of O 
Ramos O 
cells O 
in O 
a O 
wide O 
determination O 
range O 
from O 
500 O 
to O 
1 O 
× O 
10(5) O 
cells O 
mL(-1) O 
, O 
and O 
the O 
corresponding O 
detection O 
limit O 
was O 
300 O 
cells O 
mL(-1) O 
. O 

study O 
determined O 
the O 
nutritional O 
potential O 
of O 
Thai O 
indigenous O 
fruits O 
in O 
terms O 
of O 
nutrients O 
, O 
bioactive O 
compounds O 
, O 
and O 
antioxidant O 
activities O 
. O 
Three O 
indigenous O 
fruits O 
were O 
collected O 
at O 
two O 
conservation O 
areas O 
in O 
Kanchanaburi O 
province O 
, O 
Thailand O 
. O 
The O 
results O 
showed O 
that O 
Phyllanthus O 
emblica O 
L O 
. O 
exhibited O 
the O 
highest O 
levels O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
( O 
575±452mg O 
/ O 
100g O 
) O 
, O 
total O 
phenolics B-FAMILY 
( O 
TP O 
) O 
( O 
3703±1244mGAE O 
/ O 
100g O 
) O 
, O 
and O 
antioxidant O 
activities O 
, O 
as O 
measured O 
by O 
DPPH B-ABBREVIATION 
, O 
FRAP O 
and O 
ORAC O 
assays O 
. O 
Compared O 
to O 
the O 
other O 
two O 
fruits O 
, O 
Antidesma O 
velutinosum O 
Blume O 
contained O 
higher O 
levels O 
of O 
most O 
nutrients O 
and O 
dietary O 
fibre O 
( O 
15.6±5.9g O 
/ O 
100g O 
) O 
, O 
as O 
well O 
as O 
carotenoids O 
( O 
335±98μg O 
/ O 
100g O 
) O 
and O 
phytosterols B-FAMILY 
( O 
22.1±3.9mg O 
/ O 
100g O 
) O 
. O 
Spondias O 
pinnata O 
( O 
L.f O 
. O 
) O 
Kurz O 
was O 
high O 
in O 
total O 
phenolics B-FAMILY 
( O 
3178±887mGAE O 
/ O 
100g O 
) O 
and O 
antioxidant O 
activity O 
. O 
Moreover O 
, O 
high O 
correlations O 
were O 
found O 
between O 
TP O 
and O 
antioxidant O 
activities O 
( O 
r O 
> O 
0.9 O 
) O 
. O 
These O 
Thai O 
indigenous O 
fruits O 
are O 
potentially O 
good O 
sources O 
of O 
nutrients O 
, O 
bioactive O 
compounds O 
, O 
and O 
antioxidant O 
activities O 
. O 
Conservation O 
and O 
utilisation O 
should O 
be O 
promoted O 
for O 
food O 
security O 
and O 
consumption O 
as O 
part O 
of O 
a O 
healthy O 
diet O 
. O 

oxide I-SYSTEMATIC 
for O 
effective O 
radionuclide O 
removal O 
. O 

we O 
show O 
the O 
efficacy O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
for O 
rapid O 
removal O 
of O 
some O 
of O 
the O 
most O 
toxic O 
and O 
radioactive O 
long O 
- O 
lived O 
human O 
- O 
made O 
radionuclides O 
from O 
contaminated O 
water O 
, O 
even O 
from O 
acidic O 
solutions O 
( O 
pH O 
< O 
2 O 
) O 
. O 
The O 
interaction O 
of O 
GO O 
with O 
actinides B-FAMILY 
including O 
Am B-FORMULA 
(III) I-FORMULA 
, O 
Th B-FORMULA 
(IV) I-FORMULA 
, O 
Pu B-FORMULA 
(IV) I-FORMULA 
, O 
Np B-FORMULA 
(V) I-FORMULA 
, O 
U B-FORMULA 
(VI) I-FORMULA 
and O 
typical O 
fission O 
products O 
Sr B-FORMULA 
(II) I-FORMULA 
, O 
Eu B-FORMULA 
(III) I-FORMULA 
and O 
Tc B-FORMULA 
(VII) I-FORMULA 
were O 
studied O 
, O 
along O 
with O 
their O 
sorption O 
kinetics O 
. O 
Cation O 
/ O 
GO O 
coagulation O 
occurs O 
with O 
the O 
formation O 
of O 
nanoparticle O 
aggregates O 
of O 
GO O 
sheets O 
, O 
facilitating O 
their O 
removal O 
. O 
GO O 
is O 
far O 
more O 
effective O 
in O 
removal O 
of O 
transuranium B-FAMILY 
elements O 
from O 
simulated O 
nuclear O 
waste O 
solutions O 
than O 
other O 
routinely O 
used O 
sorbents O 
such O 
as O 
bentonite B-FAMILY 
clays O 
and O 
activated O 
carbon B-SYSTEMATIC 
. O 
These O 
results O 
point O 
toward O 
a O 
simple O 
methodology O 
to O 
mollify O 
the O 
severity O 
of O 
nuclear O 
waste O 
contamination O 
, O 
thereby O 
leading O 
to O 
effective O 
measures O 
for O 
environmental O 
remediation O 
. O 

enable O 
glucocorticoid O 
receptor O 
recruitment O 
to O 
fine O 
- O 
tune O 
estrogen B-FAMILY 
receptor O 
transcriptional O 
responses O 
. O 

receptors O 
( O 
NRs O 
) O 
are O 
central O 
regulators O 
of O 
pathophysiological O 
processes O 
; O 
however O 
, O 
how O 
their O 
responses O 
intertwine O 
is O 
still O 
not O 
fully O 
understood O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
and O 
how O 
steroid B-FAMILY 
NRs O 
can O 
influence O 
each O 
other's O 
activity O 
under O 
co O 
- O 
agonist O 
treatment O 
. O 
We O 
used O 
a O 
unique O 
system O 
consisting O 
of O 
a O 
multicopy O 
integration O 
of O 
an O 
estrogen B-FAMILY 
receptor O 
responsive O 
unit O 
that O 
allows O 
direct O 
visualization O 
and O 
quantification O 
of O 
estrogen B-FAMILY 
receptor O 
alpha O 
( O 
ERα O 
) O 
DNA O 
binding O 
, O 
co O 
- O 
regulator O 
recruitment O 
and O 
transcriptional O 
readout O 
. O 
We O 
find O 
that O 
ERα O 
DNA O 
loading O 
is O 
required O 
for O 
other O 
type O 
I O 
nuclear O 
receptors O 
to O 
be O 
co O 
- O 
recruited O 
after O 
dual O 
agonist O 
treatment O 
. O 
We O 
focused O 
on O 
ERα O 
/ O 
glucocorticoid O 
receptor O 
interplay O 
and O 
demonstrated O 
that O 
it O 
requires O 
steroid B-FAMILY 
receptor O 
coactivators O 
( O 
SRC-2 O 
, O 
SRC-3 O 
) O 
and O 
the O 
mediator O 
component O 
MED14 O 
. O 
We O 
then O 
validated O 
this O 
cooperative O 
interplay O 
on O 
endogenous O 
target O 
genes O 
in O 
breast O 
cancer O 
cells O 
. O 
Taken O 
together O 
, O 
this O 
work O 
highlights O 
another O 
layer O 
of O 
mechanistic O 
complexity O 
through O 
which O 
NRs O 
cross O 
- O 
talk O 
with O 
each O 
other O 
on O 
chromatin O 
under O 
multiple O 
hormonal O 
stimuli O 
. O 

pituitary O 
- O 
adrenal O 
activity O 
during O 
schedule O 
- O 
induced O 
polydipsia O 
of O 
water O 
and O 
ethanol B-SYSTEMATIC 
in O 
cynomolgus O 
monkeys O 
( O 
Macaca O 
fascicularis O 
) O 
. O 

: O 
Intermittent O 
delivery O 
of O 
an O 
important O 
commodity O 
( O 
e.g O 
. O 
, O 
food O 
pellets O 
) O 
generates O 
excessive O 
behaviors O 
as O 
an O 
adjunct O 
to O 
the O 
schedule O 
of O 
reinforcement O 
( O 
adjunctive O 
behaviors O 
) O 
that O 
are O 
hypothesized O 
to O 
be O 
due O 
to O 
conflict O 
between O 
engaging O 
and O 
escaping O 
a O 
situation O 
where O 
reinforcement O 
is O 
delivered O 
, O 
but O 
at O 
suboptimal O 
rates O 
. O 
OBJECTIVES O 
: O 
This O 
study O 
characterized O 
the O 
endocrine O 
correlates O 
during O 
schedule O 
- O 
induced O 
polydipsia O 
of O 
water O 
and O 
ethanol B-SYSTEMATIC 
using O 
a O 
longitudinal O 
approach O 
in O 
non-human O 
primates O 
. O 
METHODS O 
: O 
Plasma O 
adrenocorticotropic O 
hormone O 
( O 
ACTH O 
) O 
and O 
cortisol B-TRIVIAL 
were O 
measured O 
in O 
samples O 
from O 
awake O 
cynomolgus O 
monkeys O 
( O 
Macaca O 
fascicularis O 
, O 
11 O 
adult O 
males O 
) O 
obtained O 
at O 
the O 
onset O 
, O 
mid O 
- O 
day O 
, O 
and O 
offset O 
of O 
their O 
12-h O 
light O 
cycle O 
. O 
The O 
monkeys O 
were O 
induced O 
to O 
drink O 
water O 
and O 
ethanol B-SYSTEMATIC 
( O 
4 O 
% O 
w O 
/ O 
v O 
, O 
in O 
water O 
) O 
using O 
a O 
fixed O 
time O 
( O 
FT O 
) O 
300-s O 
interval O 
schedule O 
of O 
pellet O 
delivery O 
. O 
The O 
induction O 
fluid O 
changed O 
every O 
30 O 
sessions O 
in O 
the O 
following O 
order O 
: O 
water O 
, O 
0.5 O 
g O 
/ O 
kg O 
ethanol B-SYSTEMATIC 
, O 
1 O 
g O 
/ O 
kg O 
ethanol B-SYSTEMATIC 
, O 
and O 
1.5 O 
g O 
/ O 
kg O 
ethanol B-SYSTEMATIC 
. O 
Following O 
induction O 
, O 
ethanol B-SYSTEMATIC 
and O 
water O 
were O 
concurrently O 
available O 
for O 
22 O 
h O 
/ O 
day O 
. O 
RESULTS O 
: O 
The O 
FT O 
300-s O 
schedule O 
gradually O 
increased O 
ACTH O 
, O 
but O 
not O 
cortisol B-TRIVIAL 
, O 
during O 
water O 
induction O 
to O 
a O 
plateau O 
sustained O 
throughout O 
ethanol B-SYSTEMATIC 
induction O 
in O 
every O 
monkey O 
. O 
Upon O 
termination O 
of O 
the O 
schedule O 
, O 
ACTH O 
decreased O 
to O 
baseline O 
and O 
cortisol B-TRIVIAL 
below O 
baseline O 
. O 
Diurnal O 
ACTH O 
and O 
cortisol B-TRIVIAL 
were O 
unrelated O 
to O 
the O 
dose O 
of O 
ethanol B-SYSTEMATIC 
, O 
but O 
ACTH O 
rhythm O 
flattened O 
at O 
0.5 O 
g O 
/ O 
kg O 
/ O 
day O 
and O 
remained O 
flattened O 
. O 
CONCLUSIONS O 
: O 
The O 
coincidence O 
of O 
elevated O 
ACTH O 
with O 
the O 
initial O 
experience O 
of O 
drinking O 
to O 
intoxication O 
may O 
have O 
altered O 
the O 
mechanisms O 
involved O 
in O 
the O 
transition O 
to O 
heavy O 
drinking O 
. O 

Global O 
Sensitivity O 
Analysis O 
of O 
n-Butanol B-SYSTEMATIC 
Combustion O 
. O 

model O 
for O 
the O 
combustion O 
of O 
butanol B-SYSTEMATIC 
is O 
studied O 
using O 
a O 
recently O 
developed O 
theoretical O 
method O 
for O 
the O 
systematic O 
improvement O 
of O 
the O 
kinetic O 
mechanism O 
. O 
The O 
butanol B-SYSTEMATIC 
mechanism O 
includes O 
1446 O 
reactions O 
, O 
and O 
we O 
demonstrate O 
that O 
it O 
is O 
straightforward O 
and O 
computationally O 
feasible O 
to O 
implement O 
a O 
full O 
global O 
sensitivity O 
analysis O 
incorporating O 
all O 
the O 
reactions O 
. O 
In O 
addition O 
, O 
we O 
extend O 
our O 
previous O 
analysis O 
of O 
ignition O 
- O 
delay O 
targets O 
to O 
include O 
species O 
targets O 
. O 
The O 
combination O 
of O 
species O 
and O 
ignition O 
targets O 
leads O 
to O 
multitarget O 
global O 
sensitivity O 
analysis O 
, O 
which O 
allows O 
for O 
a O 
more O 
complete O 
mechanism O 
validation O 
procedure O 
than O 
we O 
previously O 
implemented O 
. O 
The O 
inclusion O 
of O 
species O 
sensitivity O 
analysis O 
allows O 
for O 
a O 
direct O 
comparison O 
between O 
reaction O 
pathway O 
analysis O 
and O 
global O 
sensitivity O 
analysis O 
. O 

determination O 
of O 
exogenous O 
formaldehyde B-SYSTEMATIC 
in O 
blood O 
of O 
rats O 
during O 
and O 
after O 
inhalation O 
exposure O 
. O 

( O 
FA O 
) O 
is O 
suspected O 
of O 
being O 
associated O 
with O 
the O 
development O 
of O 
leukemia O 
. O 
An O 
inhalation O 
experiment O 
with O 
FA O 
was O 
performed O 
in O 
rats O 
to O 
study O 
whether O 
FA O 
can O 
enter O 
the O 
blood O 
and O 
could O 
thus O 
cause O 
systemic O 
toxicity O 
in O 
remote O 
tissues O 
such O 
as O 
the O 
bone O 
marrow O 
. O 
Therefore O 
, O 
a O 
sophisticated O 
analytical O 
method O 
was O 
developed O 
to O 
detect O 
blood O 
concentrations O 
of O 
FA O 
during O 
and O 
after O 
single O 
6-h O 
exposure O 
by O 
inhalation O 
. O 
In O 
order O 
to O 
differentiate O 
between O 
exogenous O 
and O 
endogenous O 
FA O 
the O 
rats O 
were O 
exposed O 
to O 
stable O 
isotope O 
( O 
(13)C B-FORMULA 
) O 
labeled O 
FA O 
by O 
inhalation O 
. O 
During O 
and O 
after O 
exposure O 
of O 
the O 
rats O 
to O 
(13)C-FA B-SYSTEMATIC 
their O 
blood O 
was O 
analyzed O 
to O 
determine O 
the O 
ratio O 
between O 
labeled O 
and O 
natural O 
FA O 
in O 
blood O 
and O 
the O 
total O 
blood O 
concentration O 
of O 
FA O 
. O 
With O 
respect O 
to O 
sensitivity O 
, O 
with O 
the O 
applied O 
method O 
exogenous O 
(13)C-FA B-SYSTEMATIC 
could O 
have O 
been O 
detected O 
in O 
blood O 
at O 
a O 
concentration O 
approximately O 
1.5% O 
of O 
the O 
endogenous O 
FA O 
blood O 
concentration O 
. O 
Exogenous O 
(13)C-FA B-SYSTEMATIC 
was O 
not O 
detectable O 
in O 
the O 
blood O 
of O 
rats O 
either O 
during O 
or O 
up O 
to O 
30 O 
min O 
after O 
the O 
exposure O 
. O 
It O 
was O 
concluded O 
that O 
the O 
inhalation O 
of O 
(13)C-FA B-SYSTEMATIC 
at O 
10 O 
ppm O 
for O 
6h O 
did O 
not O 
result O 
in O 
an O 
increase O 
of O 
the O 
total O 
FA O 
concentration O 
in O 
blood O 
. O 

effect O 
of O 
bark O 
and O 
empty O 
pod O 
extracts O 
from O 
Acacia O 
auriculiformis O 
against O 
paracetamol B-TRIVIAL 
intoxicated O 
liver O 
injury O 
and O 
alloxan B-TRIVIAL 
induced O 
type O 
II O 
diabetes O 
. O 

present O 
study O 
is O 
designed O 
to O 
decipher O 
a O 
clinical O 
evidence O 
and O 
biochemical O 
support O 
for O 
hepatoprotective O 
and O 
antidiabetic O 
efficacy O 
of O 
Acacia O 
auriculiformis O 
by O 
its O 
bark O 
and O 
empty O 
pods O 
. O 
Animal O 
models O 
with O 
paracetamol B-TRIVIAL 
intoxicated O 
liver O 
injury O 
and O 
alloxan B-TRIVIAL 
induced O 
diabetes O 
were O 
used O 
in O 
a O 
7 O 
and O 
14days O 
trial O 
respectively O 
. O 
The O 
interventions O 
were O 
tested O 
at O 
200 O 
and O 
400mg O 
/ O 
kg O 
b.w O 
. O 
for O 
bark O 
extract O 
; O 
100 O 
and O 
200mg O 
/ O 
kg O 
b.w O 
. O 
for O 
empty O 
pod O 
extract O 
. O 
Both O 
interventions O 
restored O 
the O 
liver O 
function O 
markers O 
( O 
alanine B-TRIVIAL 
transaminase O 
: O 
ALT O 
, O 
aspartate B-TRIVIAL 
transaminase O 
: O 
AST O 
, O 
alkaline O 
phosphatase O 
: O 
ALP O 
, O 
total O 
bilirubin B-TRIVIAL 
and O 
total O 
protein O 
) O 
and O 
hepatic O 
antioxidants O 
( O 
superoxide B-TRIVIAL 
dismutase O 
: O 
SOD O 
, O 
catalase O 
: O 
CAT O 
, O 
reduced O 
glutathione B-TRIVIAL 
: O 
GSH B-ABBREVIATION 
and O 
glutathione B-TRIVIAL 
peroxidase O 
: O 
GPx O 
) O 
to O 
the O 
normal O 
levels O 
than O 
elevated O 
levels O 
noticed O 
on O 
paracetamol B-TRIVIAL 
control O 
at O 
P O 
< O 
0.001 O 
. O 
Reversal O 
of O 
hepatoarchitecture O 
has O 
also O 
been O 
registered O 
and O 
the O 
hepatoprotection O 
is O 
comparable O 
to O 
the O 
reference O 
drug O 
silymarin B-FAMILY 
. O 
Similarly O 
, O 
substantial O 
elevations O 
of O 
blood O 
glucose B-TRIVIAL 
, O 
distorted O 
lipid O 
profile O 
( O 
total O 
cholesterol B-TRIVIAL 
: O 
TC O 
, O 
triglycerides B-FAMILY 
: O 
TGs O 
, O 
high O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
: O 
HDL-C O 
and O 
low O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
: O 
LDL-C O 
) O 
and O 
kidney O 
function O 
signs O 
( O 
creatinine B-TRIVIAL 
and O 
urea B-TRIVIAL 
) O 
have O 
been O 
refurbished O 
to O 
the O 
desirable O 
levels O 
on O 
par O 
with O 
the O 
standard O 
antidiabetic O 
glibenclamide B-TRIVIAL 
. O 
The O 
results O 
signify O 
the O 
importance O 
of O 
bark O 
and O 
empty O 
pod O 
extracts O 
of O 
A O 
. O 
auriculiformis O 
as O 
good O 
therapeutic O 
candidates O 
for O 
liver O 
injury O 
and O 
diabetes O 
. O 

glycation O 
of O 
natural O 
actomyosin O 
( O 
NAM O 
) O 
with O 
glucosamine B-TRIVIAL 
in O 
a O 
liquid O 
system O 
at O 
moderate O 
temperatures O 
. O 

protein O 
functionality O 
plays O 
an O 
important O 
role O 
in O 
routine O 
applications O 
in O 
the O 
food O 
industry O 
. O 
Glycation O 
by O 
the O 
Maillard O 
reaction O 
is O 
a O 
naturally O 
occurring O 
process O 
, O 
which O 
can O 
be O 
used O 
to O 
develop O 
new O 
ingredients O 
with O 
improved O 
functionality O 
using O 
a O 
food O 
grade O 
approach O 
. O 
Actomyosin O 
was O 
conjugated O 
with O 
glucose B-TRIVIAL 
or O 
glucosamine B-TRIVIAL 
in O 
a O 
liquid O 
system O 
at O 
moderate O 
temperatures O 
( O 
40°C O 
) O 
. O 
Sugar B-FAMILY 
to O 
protein O 
conjugation O 
was O 
evident O 
by O 
UV-Vis O 
spectral O 
changes O 
, O 
with O 
the O 
glycation O 
level O 
determined O 
by O 
matrix O 
assisted O 
laser O 
desorption O 
/ O 
ionisation O 
mass O 
spectrometry O 
. O 
Parameters O 
for O 
glycation O 
of O 
muscle O 
protein O 
were O 
optimised O 
using O 
the O 
bidimensional O 
hierarchical O 
clustering O 
analyses O 
. O 
The O 
best O 
glycation O 
conditions O 
were O 
40°C O 
for O 
8h O 
at O 
1 O 
: O 
3 O 
protein O 
: O 
sugar B-FAMILY 
ratio O 
. O 
Solubility O 
and O 
emulsifying O 
properties O 
of O 
glycoconjugates O 
were O 
significantly O 
improved O 
as O 
compared O 
to O 
non-glycated O 
proteins O 
. O 
At O 
pH O 
7 O 
glycated O 
actomyosin O 
was O 
on O 
average O 
31% O 
more O 
soluble O 
compared O 
to O 
non O 
- O 
treated O 
protein O 
. O 
Glucosamine B-TRIVIAL 
was O 
found O 
to O 
be O 
more O 
effective O 
for O 
glycation O 
and O 
provided O 
higher O 
protein O 
functionality O 
as O 
compared O 
to O 
glucose B-TRIVIAL 
. O 

novel O 
surface O 
plasmon O 
resonance O 
( O 
SPR O 
) O 
biosensor O 
using O 
lectin O 
as O 
bioreceptor O 
was O 
developed O 
for O 
the O 
rapid O 
detection O 
of O 
Escherichia O 
coli O 
( O 
E O 
. O 
coli O 
) O 
O157 O 
: O 
H7 O 
. O 
The O 
selective O 
interaction O 
of O 
lectins O 
with O 
carbohydrate B-FAMILY 
components O 
from O 
bacterial O 
cells O 
surface O 
was O 
used O 
as O 
the O 
recognition O 
principle O 
for O 
the O 
detection O 
. O 
Five O 
types O 
of O 
lectins O 
from O 
Triticum O 
vulgaris O 
, O 
Canavailia O 
ensiformis O 
, O 
Ulex O 
europaeus O 
, O 
Arachis O 
hypogaea O 
, O 
and O 
Maackia O 
amurensis O 
, O 
were O 
employed O 
to O 
evaluate O 
the O 
selectivity O 
of O 
the O 
approach O 
for O 
binding O 
E O 
. O 
coli O 
O157 O 
: O 
H7 O 
effectively O 
. O 
A O 
detection O 
limit O 
of O 
3×10(3) O 
cfu O 
mL(-1) O 
was O 
obtained O 
for O 
determination O 
of O 
E O 
. O 
coli O 
O157 O 
: O 
H7 O 
when O 
used O 
the O 
lectin O 
from O 
T O 
. O 
vulgaris O 
as O 
the O 
binding O 
molecule O 
. O 
Furthermore O 
, O 
the O 
proposed O 
biosensor O 
was O 
used O 
to O 
detect O 
E O 
. O 
coli O 
O157 O 
: O 
H7 O 
in O 
real O 
food O 
samples O 
. O 
Results O 
showed O 
that O 
the O 
lectin O 
based O 
SPR O 
biosensor O 
was O 
sensitive O 
, O 
reliable O 
and O 
effective O 
for O 
detection O 
of O 
E O 
. O 
coli O 
O157 O 
: O 
H7 O 
, O 
which O 
hold O 
a O 
great O 
promise O 
in O 
food O 
safety O 
analysis O 
. O 

- O 
degradable O 
cationic O 
poly(ketal B-FAMILY 
amidoamine I-FAMILY 
) I-FAMILY 
for O 
enhanced O 
RNA O 
interference O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

delivery O 
of O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
is O 
one O 
of O 
major O 
challenges O 
in O 
the O 
successful O 
applications O 
of O 
siRNA O 
in O 
clinic O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
report O 
a O 
new O 
acid O 
- O 
degradable O 
poly(ketal B-FAMILY 
amidoamine I-FAMILY 
) I-FAMILY 
( O 
PKAA B-ABBREVIATION 
) O 
as O 
a O 
siRNA O 
carrier O 
, O 
which O 
has O 
high O 
delivery O 
efficiency O 
and O 
low O 
cytotoxicity O 
. O 
PKAA B-ABBREVIATION 
was O 
designed O 
to O 
have O 
acid O 
- O 
cleavable O 
ketal O 
linkages O 
in O 
the O 
backbone O 
of O 
cationic O 
biodegradable O 
poly(amidoamine) B-SYSTEMATIC 
. O 
PKAA B-ABBREVIATION 
efficiently O 
self O 
- O 
assembled O 
with O 
siRNA O 
to O 
form O 
nanocomplexes O 
with O 
a O 
diameter O 
of O 
~200 O 
nm O 
and O 
slightly O 
positive O 
charges O 
, O 
which O 
are O 
stable O 
under O 
physiological O 
conditions O 
, O 
but O 
rapidly O 
release O 
siRNA O 
at O 
acidic O 
pH O 
. O 
PKAA B-ABBREVIATION 
exhibited O 
sufficient O 
buffering O 
capability O 
and O 
endosomolytic O 
activity O 
due O 
mainly O 
to O 
the O 
presence O 
of O 
secondary B-FAMILY 
amine I-FAMILY 
groups O 
in O 
its O 
backbone O 
and O 
rapid O 
degradation O 
in O 
acidic O 
endosomes O 
, O 
leading O 
to O 
the O 
enhanced O 
release O 
of O 
siRNA O 
to O 
cytoplasm O 
. O 
Cell O 
culture O 
studies O 
demonstrated O 
that O 
PKAA B-ABBREVIATION 
is O 
capable O 
of O 
delivering O 
anti-TNF O 
( O 
tumor O 
necrosis O 
factor)-α O 
siRNA O 
to O 
lipopolysaccharide O 
(LPS)-stimulated O 
macrophages O 
and O 
significantly O 
inhibits O 
the O 
expression O 
of O 
TNF-α O 
. O 
A O 
mouse O 
model O 
of O 
acetaminophen B-TRIVIAL 
( O 
APAP B-ABBREVIATION 
)-induced O 
acute O 
liver O 
failure O 
was O 
used O 
to O 
evaluate O 
in O 
vivo O 
siRNA O 
delivery O 
efficacy O 
of O 
PKAA B-ABBREVIATION 
. O 
PKAA B-ABBREVIATION 
/ O 
anti-TNF-α O 
siRNA O 
nanocomplexes O 
significantly O 
reduced O 
the O 
ALT O 
( O 
alanine B-TRIVIAL 
transaminase O 
) O 
and O 
the O 
hepatic O 
cellular O 
damages O 
in O 
APAP B-ABBREVIATION 
-intoxicated O 
mice O 
. O 
We O 
anticipate O 
that O 
acid O 
- O 
degradable O 
PKAA B-ABBREVIATION 
has O 
great O 
potential O 
as O 
siRNA O 
carriers O 
based O 
on O 
its O 
excellent O 
biocompatibility O 
, O 
pH O 
sensitivity O 
, O 
potential O 
endosomolytic O 
activity O 
, O 
and O 
high O 
delivery O 
efficiency O 
. O 

virus O 
( O 
EBV O 
) O 
infects O 
more O 
than O 
90% O 
of O 
the O 
world O 
population O 
. O 
Following O 
primary O 
infection O 
, O 
Epstein-Barr O 
virus O 
persists O 
in O 
an O 
asymptomatic O 
latent O 
state O 
. O 
Occasionally O 
, O 
it O 
may O 
switch O 
to O 
lytic O 
infection O 
. O 
Latent O 
EBV O 
infection O 
has O 
been O 
associated O 
with O 
several O 
diseases O 
, O 
such O 
as O 
Burkitt O 
lymphoma O 
( O 
BL O 
) O 
. O 
To O 
date O 
, O 
there O 
are O 
no O 
available O 
drugs O 
to O 
target O 
latent O 
EBV O 
, O 
and O 
the O 
existing O 
broad O 
- O 
spectrum O 
antiviral O 
drugs O 
are O 
mainly O 
active O 
against O 
lytic O 
viral O 
infection O 
. O 
Thus O 
, O 
using O 
computational O 
molecular O 
docking O 
, O 
a O 
virtual O 
screen O 
of O 
a O 
library O 
of O 
small O 
molecules O 
, O 
including O 
xanthones B-FAMILY 
and O 
flavonoids B-FAMILY 
( O 
described O 
with O 
potential O 
for O 
antiviral O 
activity O 
against O 
EBV O 
) O 
, O 
was O 
carried O 
out O 
targeting O 
EBV O 
proteins O 
. O 
The O 
more O 
interesting O 
molecules O 
were O 
selected O 
for O 
further O 
computational O 
analysis O 
, O 
and O 
sub O 
- O 
sequently O 
, O 
the O 
compounds O 
were O 
tested O 
in O 
the O 
Raji O 
( O 
BL O 
) O 
cell O 
line O 
, O 
to O 
evaluate O 
their O 
activity O 
against O 
latent O 
EBV O 
. O 
This O 
work O 
identified O 
three O 
novel O 
sulfated O 
small O 
molecules O 
capable O 
of O 
decreasing O 
EBV O 
levels O 
in O 
a O 
BL O 
. O 
Therefore O 
, O 
the O 
in O 
silico O 
screening O 
presents O 
a O 
good O 
approach O 
for O 
the O 
development O 
of O 
new O 
anti-EBV O 
agents O 
. O 

of O 
organic O 
anion O 
- O 
transporting O 
polypeptides O 
in O 
the O 
hepatic O 
uptake O 
of O 
dioscin B-TRIVIAL 
in O 
rats O 
and O 
humans O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
clarify O 
the O 
mechanism O 
underlying O 
hepatic O 
uptake O 
of O 
dioscin B-TRIVIAL 
( O 
diosgenyl B-SYSTEMATIC 
2,4-di-O-a-L-rhamnopyranosyl-p-D-glucopyranoside I-SYSTEMATIC 
) O 
, O 
an O 
herbal O 
ingredient O 
with O 
antihepatitis O 
activity O 
, O 
in O 
rats O 
and O 
humans O 
. O 
The O 
liver O 
uptake O 
index O 
( O 
LUI O 
) O 
in O 
vivo O 
, O 
perfused O 
rat O 
liver O 
in O 
situ O 
, O 
rat O 
liver O 
slices O 
, O 
isolated O 
rat O 
hepatocytes O 
, O 
and O 
human O 
organic O 
anion O 
- O 
transporting O 
polypeptide O 
(OATP)-transfected O 
cells O 
in O 
vitro O 
were O 
used O 
to O 
evaluate O 
hepatic O 
uptake O 
of O 
dioscin B-TRIVIAL 
. O 
Values O 
of O 
11.9% O 
± O 
1.6% O 
and O 
15.0% O 
± O 
0.9% O 
of O 
dose O 
for O 
uptake O 
of O 
dioscin B-TRIVIAL 
were O 
observed O 
by O 
LUI O 
in O 
vivo O 
and O 
perfused O 
rat O 
livers O 
in O 
situ O 
, O 
respectively O 
. O 
The O 
time O 
course O 
of O 
dioscin B-TRIVIAL 
uptake O 
by O 
rat O 
liver O 
slices O 
was O 
temperature O 
- O 
dependent O 
. O 
Uptake O 
of O 
dioscin B-TRIVIAL 
by O 
rat O 
liver O 
slices O 
and O 
isolated O 
rat O 
hepatocytes O 
was O 
inhibited O 
significantly O 
by O 
Oatp O 
modulators O 
, O 
such O 
as O 
ibuprofen B-TRIVIAL 
( O 
Oatp1a1 O 
inhibitor O 
) O 
, O 
digoxin B-TRIVIAL 
( O 
Oatp1a4 O 
substrate O 
) O 
, O 
and O 
glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
( O 
Oatp1b2 O 
inhibitor O 
) O 
, O 
but O 
not O 
by O 
TEA B-ABBREVIATION 
or O 
p-aminohippurate B-TRIVIAL 
. O 
Uptake O 
of O 
dioscin B-TRIVIAL 
in O 
rat O 
hepatocytes O 
and O 
OATP1B3-human O 
embryonic O 
kidney O 
( O 
HEK O 
) O 
293 O 
cells O 
indicated O 
a O 
saturable O 
process O 
with O 
a O 
Km O 
of O 
3.75 O 
± O 
0.51 O 
μM O 
and O 
2.08 O 
± O 
0.27 O 
μM O 
, O 
respectively O 
. O 
(-)-Epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
, O 
cyclosporin B-TRIVIAL 
A I-TRIVIAL 
, O 
rifampicin B-TRIVIAL 
, O 
and O 
telmisartan B-TRIVIAL 
inhibited O 
transport O 
of O 
dioscin B-TRIVIAL 
in O 
OATP1B3-HEK293 O 
cells O 
. O 
However O 
, O 
transcellular O 
transport O 
of O 
dioscin B-TRIVIAL 
in O 
OATP1B1- O 
or O 
OATP1B1 O 
/ O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2-Madin-Darby O 
canine O 
kidney O 
strain O 
II O 
cells O 
was O 
not O 
observed O 
. O 
These O 
results O 
indicate O 
that O 
hepatic O 
uptake O 
of O 
dioscin B-TRIVIAL 
is O 
involved O 
in O 
OATP1B3 O 
in O 
humans O 
, O 
and O 
multiple O 
Oatps O 
might O 
participate O 
in O 
this O 
process O 
in O 
rats O 
. O 

chimeric O 
spider O 
silk- O 
uranium B-SYSTEMATIC 
binding O 
proteins O 
. O 

metals O 
constitute O 
a O 
source O 
of O 
environmental O 
pollution O 
. O 
Here O 
, O 
novel O 
functional O 
hybrid O 
biomaterials O 
for O 
specific O 
interactions O 
with O 
heavy O 
metals O 
are O 
designed O 
by O 
bioengineering O 
consensus O 
sequence O 
repeats O 
from O 
spider O 
silk O 
of O 
Nephila O 
clavipes O 
with O 
repeats O 
of O 
a O 
uranium B-SYSTEMATIC 
peptide O 
recognition O 
motif O 
from O 
a O 
mutated O 
33-residue O 
of O 
calmodulin O 
protein O 
from O 
Paramecium O 
tetraurelia O 
. O 
The O 
self O 
- O 
assembly O 
features O 
of O 
the O 
silk O 
to O 
control O 
nanoscale O 
organic O 
/ O 
inorganic O 
material O 
interfaces O 
provides O 
new O 
biomaterials O 
for O 
uranium B-SYSTEMATIC 
recovery O 
. O 
With O 
subsequent O 
enzymatic O 
digestion O 
of O 
the O 
silk O 
to O 
concentrate O 
the O 
sequestered O 
metals O 
, O 
options O 
can O 
be O 
envisaged O 
to O 
use O 
these O 
new O 
chimeric O 
protein O 
systems O 
in O 
environmental O 
engineering O 
, O 
including O 
to O 
remediate O 
environments O 
contaminated O 
by O 
uranium B-SYSTEMATIC 
. O 

informatics O 
uncovers O 
a O 
new O 
role O 
for O 
moexipril B-TRIVIAL 
as O 
a O 
novel O 
inhibitor O 
of O 
cAMP B-ABBREVIATION 
phosphodiesterase-4 O 
( O 
PDE4 O 
) O 
. O 

is O 
one O 
of O 
eleven O 
known O 
cyclic B-FAMILY 
nucleotide I-FAMILY 
phosphodiesterase O 
families O 
and O 
plays O 
a O 
pivotal O 
role O 
in O 
mediating O 
hydrolytic O 
degradation O 
of O 
the O 
important O 
cyclic B-FAMILY 
nucleotide I-FAMILY 
second O 
messenger O 
, O 
cyclic B-SYSTEMATIC 
3'5 I-SYSTEMATIC 
' I-SYSTEMATIC 
adenosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
( O 
cAMP B-ABBREVIATION 
) O 
. O 
PDE4 O 
inhibitors O 
are O 
known O 
to O 
have O 
anti-inflammatory O 
properties O 
, O 
but O 
their O 
use O 
in O 
the O 
clinic O 
has O 
been O 
hampered O 
by O 
mechanism O 
- O 
associated O 
side O 
effects O 
that O 
limit O 
maximally O 
tolerated O 
doses O 
. O 
In O 
an O 
attempt O 
to O 
initiate O 
the O 
development O 
of O 
better O 
- O 
tolerated O 
PDE4 O 
inhibitors O 
we O 
have O 
surveyed O 
existing O 
approved O 
drugs O 
for O 
PDE4-inhibitory O 
activity O 
. O 
With O 
this O 
objective O 
, O 
we O 
utilised O 
a O 
high O 
- O 
throughput O 
computational O 
approach O 
that O 
identified O 
moexipril B-TRIVIAL 
, O 
a O 
well O 
tolerated O 
and O 
safe O 
angiotensin B-FAMILY 
-converting O 
enzyme O 
( O 
ACE O 
) O 
inhibitor O 
, O 
as O 
a O 
PDE4 O 
inhibitor O 
. O 
Experimentally O 
we O 
showed O 
that O 
moexipril B-TRIVIAL 
and O 
two O 
structurally O 
related O 
analogues O 
acted O 
in O 
the O 
micro O 
molar O 
range O 
to O 
inhibit O 
PDE4 O 
activity O 
. O 
Employing O 
a O 
FRET O 
- O 
based O 
biosensor O 
constructed O 
from O 
the O 
nucleotide B-FAMILY 
binding O 
domain O 
of O 
the O 
type O 
1 O 
exchange O 
protein O 
activated O 
by O 
cAMP B-ABBREVIATION 
, O 
EPAC1 O 
, O 
we O 
demonstrated O 
that O 
moexipril B-TRIVIAL 
markedly O 
potentiated O 
the O 
ability O 
of O 
forskolin B-TRIVIAL 
to O 
increase O 
intracellular O 
cAMP B-ABBREVIATION 
levels O 
. O 
Finally O 
, O 
we O 
demonstrated O 
that O 
the O 
PDE4 O 
inhibitory O 
effect O 
of O 
moexipril B-TRIVIAL 
is O 
functionally O 
able O 
to O 
induce O 
phosphorylation O 
of O 
the O 
small O 
heat O 
shock O 
protein O 
, O 
Hsp20 O 
, O 
by O 
cAMP B-ABBREVIATION 
dependent O 
protein O 
kinase O 
A O 
. O 
Our O 
data O 
suggest O 
that O 
moexipril B-TRIVIAL 
is O 
a O 
bona O 
fide O 
PDE4 O 
inhibitor O 
that O 
may O 
provide O 
the O 
starting O 
point O 
for O 
development O 
of O 
novel O 
PDE4 O 
inhibitors O 
with O 
an O 
improved O 
therapeutic O 
window O 
. O 

activities O 
of O 
6-iodouridine B-SYSTEMATIC 
and O 
its O 
prodrugs O 
and O 
potential O 
for O 
combination O 
therapy O 
. O 

by O 
Plasmodium O 
falciparum O 
to O 
almost O 
all O 
clinically O 
used O 
antimalarial O 
drugs O 
requires O 
the O 
development O 
of O 
new O 
classes O 
of O 
antimalarials O 
. O 
6-Iodouridine B-SYSTEMATIC 
( O 
15 O 
) O 
, O 
a O 
novel O 
and O 
potent O 
inhibitor O 
of O 
orotidine B-SYSTEMATIC 
5'-monophosphate I-SYSTEMATIC 
decarboxylase O 
( O 
ODCase O 
) O 
, O 
exhibited O 
efficacy O 
in O 
a O 
mouse O 
model O 
infected O 
by O 
P O 
. O 
chabaudi O 
chabaudi O 
. O 
Compound O 
15 O 
exhibited O 
promising O 
antimalarial O 
activity O 
against O 
P O 
. O 
falciparum O 
, O 
including O 
drug O 
- O 
resistant O 
isolates O 
, O 
and O 
no O 
rapid O 
drug O 
- O 
resistant O 
populations O 
of O 
the O 
parasite O 
were O 
observed O 
when O 
challenged O 
with O 
15 O 
. O 
Uridine B-TRIVIAL 
provided O 
options O 
to O 
overcome O 
any O 
toxicity O 
in O 
the O 
host O 
but O 
still O 
suppressing O 
the O 
parasite O 
load O 
when O 
treated O 
with O 
15 O 
. O 
In O 
drug O 
combination O 
studies O 
, O 
compound O 
15 O 
showed O 
good O 
efficacy O 
in O 
vivo O 
with O 
artemisinin B-TRIVIAL 
and O 
azithromycin B-TRIVIAL 
. O 
The O 
propionyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
of O 
15 O 
exhibited O 
superior O 
antimalarial O 
efficacy O 
. O 
Antimalarial O 
activities O 
of O 
15 O 
and O 
its O 
prodrugs O 
and O 
potential O 
for O 
combination O 
therapy O 
are O 
discussed O 
in O 
the O 
context O 
of O 
novel O 
strategies O 
. O 

responses O 
in O 
ammonia B-SYSTEMATIC 
excretion O 
, O 
sodium B-SYSTEMATIC 
fluxes O 
and O 
gill O 
permeability O 
explain O 
different O 
sensitivities O 
to O 
acute O 
high O 
environmental O 
ammonia B-SYSTEMATIC 
in O 
three O 
freshwater O 
teleosts O 
. O 

examined O 
the O 
acute O 
physiological O 
responses O 
to O 
high O 
environmental O 
ammonia B-SYSTEMATIC 
( O 
HEA O 
) O 
, O 
particularly O 
the O 
linkages O 
between O 
branchial O 
ammonia B-SYSTEMATIC 
fluxes O 
and O 
unidirectional O 
Na(+) B-FORMULA 
fluxes O 
, O 
as O 
well O 
as O 
urea B-TRIVIAL 
excretion O 
, O 
cortisol B-TRIVIAL 
, O 
and O 
indicators O 
of O 
gill O 
permeability O 
in O 
three O 
freshwater O 
teleosts O 
differing O 
in O 
their O 
sensitivities O 
to O 
ammonia B-SYSTEMATIC 
; O 
the O 
highly O 
sensitive O 
salmonid O 
Oncorhynchus O 
mykiss O 
( O 
rainbow O 
trout O 
) O 
, O 
the O 
less O 
sensitive O 
cyprinid O 
Cyprinus O 
carpio O 
( O 
common O 
carp O 
) O 
and O 
the O 
highly O 
resistant O 
cyprinid O 
Carassius O 
auratus O 
( O 
goldfish O 
) O 
. O 
Fish O 
were O 
acutely O 
exposed O 
to O 
two O 
sub O 
- O 
lethal O 
ammonia B-SYSTEMATIC 
concentrations O 
( O 
as O 
NH(4)HCO(3) B-FORMULA 
) O 
at O 
pH O 
7.9 O 
: O 
1 O 
mM O 
for O 
a O 
period O 
of O 
12 O 
h O 
, O 
identical O 
for O 
all O 
species O 
, O 
and O 
5 O 
mM O 
for O 
the O 
cyprinids O 
and O 
1.4 O 
mM O 
for O 
the O 
trout O 
for O 
3 O 
h O 
. O 
Elevation O 
of O 
plasma O 
cortisol B-TRIVIAL 
at O 
both O 
levels O 
of O 
HEA O 
was O 
apparent O 
in O 
all O 
species O 
. O 
At O 
1 O 
mM O 
, O 
ammonia B-SYSTEMATIC 
excretion O 
( O 
J( O 
amm B-ABBREVIATION 
) O 
) O 
was O 
inhibited O 
to O 
a O 
greater O 
extent O 
in O 
trout O 
than O 
cyprinids O 
and O 
concurrently O 
a O 
significantly O 
higher O 
plasma O 
ammonia B-SYSTEMATIC 
level O 
was O 
evident O 
in O 
trout O 
. O 
However O 
J( O 
amm B-ABBREVIATION 
) O 
was O 
reversed O 
in O 
all O 
species O 
at O 
5 O 
or O 
1.4 O 
mM O 
. O 
Goldfish O 
showed O 
a O 
significant O 
increase O 
in O 
urea B-TRIVIAL 
excretion O 
rate O 
( O 
J( O 
urea B-TRIVIAL 
) O 
) O 
during O 
HEA O 
exposure O 
. O 
In O 
carp O 
and O 
trout O 
, O 
neither O 
level O 
of O 
HEA O 
elevated O 
J( O 
urea B-TRIVIAL 
) O 
but O 
urea B-TRIVIAL 
production O 
was O 
increased O 
as O 
evidenced O 
by O 
a O 
considerable O 
elevation O 
of O 
plasma O 
urea B-TRIVIAL 
. O 
At O 
1mM O 
HEA O 
, O 
Na(+) B-FORMULA 
imbalance O 
became O 
progressively O 
more O 
severe O 
in O 
trout O 
and O 
carp O 
due O 
to O 
a O 
stimulation O 
of O 
unidirectional O 
Na(+) B-FORMULA 
efflux O 
( O 
J(out)( O 
Na B-FORMULA 
) O 
) O 
without O 
a O 
concomitant O 
increase O 
in O 
unidirectional O 
Na(+) B-FORMULA 
influx O 
( O 
J(in)( O 
Na B-FORMULA 
) O 
) O 
. O 
Additionally O 
, O 
a O 
transient O 
reduction O 
of O 
J(in)( O 
Na B-FORMULA 
) O 
was O 
evident O 
in O 
trout O 
. O 
Goldfish O 
showed O 
an O 
opposite O 
trend O 
for O 
J(out)( O 
Na B-FORMULA 
) O 
with O 
reduced O 
efflux O 
rates O 
and O 
a O 
positive O 
Na(+) B-FORMULA 
balance O 
during O 
the O 
first O 
few O 
hours O 
of O 
HEA O 
. O 
However O 
, O 
after O 
12 O 
h O 
of O 
exposure O 
, O 
both O 
J(in)( O 
Na B-FORMULA 
) O 
and O 
J(out)( O 
Na B-FORMULA 
) O 
were O 
also O 
increased O 
in O 
both O 
carp O 
and O 
goldfish O 
, O 
whereas O 
only O 
J(out)( O 
Na B-FORMULA 
) O 
was O 
increased O 
in O 
trout O 
, O 
leading O 
to O 
a O 
net O 
Na(+) B-FORMULA 
loss O 
. O 
Na(+) B-FORMULA 
homeostasis O 
was O 
entirely O 
disrupted O 
in O 
all O 
three O 
species O 
when O 
subjected O 
to O 
the O 
5 O 
or O 
1.4 O 
mM O 
ammonia B-SYSTEMATIC 
for O 
3 O 
h O 
: O 
J(in)( O 
Na B-FORMULA 
) O 
was O 
significantly O 
inhibited O 
while O 
considerable O 
activation O 
of O 
J(out)( O 
Na B-FORMULA 
) O 
was O 
observed O 
. O 
Diffusive O 
water O 
efflux O 
rates O 
and O 
net O 
K(+) B-FORMULA 
loss O 
rates O 
across O 
the O 
gills O 
were O 
enhanced O 
during O 
HEA O 
only O 
in O 
trout O 
, O 
indicating O 
an O 
increment O 
in O 
gill O 
transcellular O 
permeability O 
. O 
Transepithelial O 
potential O 
was O 
increased O 
in O 
all O 
the O 
species O 
during O 
ammonia B-SYSTEMATIC 
exposure O 
, O 
but O 
to O 
the O 
least O 
extent O 
in O 
goldfish O 
. O 
Overall O 
, O 
for O 
several O 
different O 
physiological O 
systems O 
, O 
trout O 
were O 
most O 
disturbed O 
, O 
and O 
goldfish O 
were O 
least O 
disturbed O 
by O 
HEA O 
, O 
helping O 
to O 
explain O 
the O 
differential O 
ammonia B-SYSTEMATIC 
tolerance O 
of O 
the O 
three O 
species O 
. O 

levels O 
of O 
prenatal O 
zinc B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
had O 
different O 
effects O 
on O 
neonatal O 
neurobehavioral O 
development O 
. O 

deficient O 
or O 
excessive O 
of O 
essential O 
nutrients O 
had O 
adverse O 
effects O 
. O 
Effects O 
of O 
different O 
levels O 
of O 
prenatal O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
and O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
on O 
fetal O 
neurobehavioral O 
development O 
remain O 
unclear O 
. O 
To O 
determine O 
the O 
effects O 
of O 
different O 
cord O 
serum O 
levels O 
of O 
Zn B-FORMULA 
and O 
Se B-FORMULA 
on O 
neurobehavioral O 
development O 
in O 
neonates O 
and O 
to O 
explore O 
possible O 
threshold O 
level O 
of O 
Zn B-FORMULA 
and O 
Se B-FORMULA 
based O 
on O 
fetal O 
neurodevelopment O 
, O 
we O 
conducted O 
this O 
epidemiological O 
research O 
. O 
In O 
the O 
multi O 
- O 
center O 
study O 
, O 
we O 
investigated O 
these O 
questions O 
in O 
927 O 
mother O 
- O 
newborn O 
pairs O 
in O 
Shanghai O 
, O 
China O 
, O 
from O 
2008 O 
through O 
2009 O 
. O 
Umbilical O 
cord O 
serum O 
concentrations O 
of O 
Zn B-FORMULA 
and O 
Se B-FORMULA 
were O 
measured O 
and O 
Neonatal O 
Behavioral O 
Neurological O 
Assessment O 
( O 
NBNA O 
) O 
tests O 
were O 
conducted O 
. O 
The O 
median O 
cord O 
serum O 
Zn B-FORMULA 
and O 
Se B-FORMULA 
concentrations O 
were O 
794.3μg O 
/ O 
L O 
and O 
63.1μg O 
/ O 
L O 
, O 
respectively O 
. O 
A O 
nonlinear O 
relationship O 
was O 
observed O 
between O 
cord O 
serum O 
Zn B-FORMULA 
and O 
NBNA O 
after O 
adjusting O 
for O 
potential O 
confounders O 
. O 
NBNA O 
score O 
decreased O 
with O 
increasing O 
Zn B-FORMULA 
levels O 
after O 
794.3μg O 
/ O 
L O 
( O 
adjusted O 
β=-3.0 O 
, O 
95% O 
CI O 
: O 
-3.6 O 
to O 
-2.4 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Additionally O 
, O 
an O 
invert O 
U-shape O 
with O 
a O 
threshold O 
Se B-FORMULA 
of O 
100μg O 
/ O 
L O 
was O 
observed O 
between O 
cord O 
serum O 
Se B-FORMULA 
and O 
NBNA O 
. O 
The O 
adjusted O 
regression O 
coefficient O 
was O 
4.4 O 
( O 
95% O 
CI O 
: O 
3.6-5.2 O 
, O 
p O 
< O 
0.001 O 
) O 
for O 
Se B-FORMULA 
< O 
100μg O 
/ O 
L O 
while O 
-3.6 O 
( O 
95% O 
CI O 
: O 
-6.1 O 
to O 
-1.1 O 
, O 
p O 
< O 
0.01 O 
) O 
for O 
Se B-FORMULA 
≥ O 
100μg O 
/ O 
L O 
. O 
Of O 
the O 
927 O 
infants O 
, O 
50% O 
had O 
a O 
high O 
level O 
Zn B-FORMULA 
( O 
≥ O 
794.3μg O 
/ O 
L O 
) O 
and O 
8.6% O 
had O 
a O 
high O 
level O 
Se B-FORMULA 
( O 
≥ O 
100μg O 
/ O 
L O 
) O 
. O 
High O 
levels O 
of O 
both O 
Zn B-FORMULA 
and O 
Se B-FORMULA 
mainly O 
had O 
adverse O 
effects O 
on O 
behavior O 
and O 
passive O 
tone O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Taken O 
together O 
, O 
our O 
study O 
suggested O 
that O 
a O 
threshold O 
of O 
cord O 
blood O 
Zn B-FORMULA 
and O 
Se B-FORMULA 
was O 
existed O 
for O 
fetal O 
neurodevelopment O 
and O 
the O 
prevalence O 
of O 
excessive O 
Zn B-FORMULA 
was O 
high O 
. O 
Thus O 
, O 
the O 
supplementation O 
of O 
Zn B-FORMULA 
during O 
pregnancy O 
should O 
be O 
considered O 
with O 
caution O 
in O 
Shanghai O 
, O 
China O 
. O 

hundred O 
eighty O 
- O 
seven O 
honey O 
samples O 
from O 
an O 
Atlantic O 
European O 
area O 
were O 
studied O 
to O 
determine O 
their O 
nutritional O 
compositions O 
and O 
antioxidant O 
capacities O 
, O 
as O 
well O 
as O 
the O 
relationships O 
between O 
them O 
. O 
The O 
results O 
showed O 
that O 
heather O 
, O 
polyfloral O 
, O 
blackberry O 
, O 
and O 
eucalyptus O 
honeys O 
had O 
the O 
highest O 
carbohydrate B-FAMILY 
contents O 
, O 
whereas O 
honeydew O 
and O 
chestnut O 
honeys O 
had O 
the O 
lowest O 
. O 
There O 
were O 
some O 
important O 
differences O 
among O 
the O 
honey O 
types O 
, O 
which O 
were O 
related O 
to O 
the O 
presence O 
of O 
minor O 
components O 
. O 
The O 
protein O 
contents O 
were O 
significantly O 
higher O 
in O 
honeydew O 
and O 
chestnut O 
honeys O 
, O 
and O 
the O 
same O 
results O 
were O 
obtained O 
for O 
mineral O 
contents O 
. O 
Related O 
to O 
the O 
presence O 
of O 
several O 
antioxidant O 
compounds O 
, O 
heather O 
honey O 
had O 
the O 
highest O 
phenolic O 
content O 
, O 
whereas O 
honeydew O 
and O 
chestnut O 
honeys O 
had O 
the O 
highest O 
flavonoid B-FAMILY 
contents O 
. O 
Multivariate O 
analysis O 
showed O 
that O 
some O 
variables O 
, O 
such O 
as O 
the O 
amounts O 
of O 
flavonoids B-FAMILY 
, O 
minerals O 
, O 
proteins O 
, O 
and O 
phenols B-FAMILY 
, O 
were O 
significantly O 
correlated O 
with O 
antioxidant O 
activity O 
. O 
The O 
regression O 
analysis O 
produced O 
a O 
significant O 
model O 
( O 
R(2)=0.716 O 
; O 
F=154.680 O 
; O 
P O 
< O 
0.001 O 
) O 
that O 
related O 
the O 
antioxidant O 
activity O 
and O 
the O 
flavonoids B-FAMILY 
, O 
K B-FORMULA 
, O 
and O 
P B-FORMULA 
contents O 
. O 

regulates O 
obesity O 
by O 
targeting O 
mTORC1 O 
signaling O 
. O 

, O 
a O 
flavonol B-TRIVIAL 
present O 
in O 
vegetables O 
and O 
fruits O 
, O 
possesses O 
antioxidative O 
and O 
anti-inflammatory O 
properties O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
demonstrated O 
that O 
fisetin B-TRIVIAL 
prevents O 
diet O 
- O 
induced O 
obesity O 
through O 
regulation O 
of O 
the O 
signaling O 
of O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
( O 
mTORC1 O 
) O 
, O 
a O 
central O 
mediator O 
of O 
cellular O 
growth O 
, O 
cellular O 
proliferation O 
and O 
lipid O 
biosynthesis O 
. O 
To O 
evaluate O 
whether O 
fisetin B-TRIVIAL 
regulates O 
mTORC1 O 
signaling O 
, O 
we O 
investigated O 
the O 
phosphorylation O 
and O 
kinase O 
activity O 
of O 
the O 
70-kDa O 
ribosomal O 
protein O 
S6 O 
kinase O 
1 O 
( O 
S6K1 O 
) O 
and O 
mTORC1 O 
in O 
3T3-L1 O 
preadipocytes O 
. O 
Fisetin B-TRIVIAL 
treatment O 
of O 
preadipocytes O 
reduced O 
the O 
phosphorylation O 
of O 
S6K1 O 
and O 
mTORC1 O 
in O 
a O 
time- O 
and O 
concentration O 
- O 
dependent O 
manner O 
. O 
To O 
further O 
our O 
understanding O 
of O 
how O 
fisetin B-TRIVIAL 
negatively O 
regulates O 
mTORC1 O 
signaling O 
, O 
we O 
analyzed O 
the O 
phosphorylation O 
of O 
S6K1 O 
, O 
mTOR O 
and O 
Akt O 
in O 
fisetin B-TRIVIAL 
-treated O 
TSC2-knockdown O 
cells O 
. O 
The O 
results O 
suggested O 
that O 
fisetin B-TRIVIAL 
treatment O 
inhibits O 
mTORC1 O 
activity O 
in O 
an O 
Akt O 
- O 
dependent O 
manner O 
. O 
Recent O 
studies O 
have O 
shown O 
that O 
adipocyte O 
differentiation O 
is O 
dependent O 
on O 
mTORC1 O 
activity O 
. O 
Fisetin B-TRIVIAL 
treatment O 
inhibited O 
adipocyte O 
differentiation O 
, O 
consistent O 
with O 
the O 
negative O 
effect O 
of O 
fisetin B-TRIVIAL 
on O 
mTOR O 
. O 
The O 
inhibitory O 
effect O 
of O 
fisetin B-TRIVIAL 
on O 
adipogenesis O 
is O 
dependent O 
of O 
mTOR O 
activity O 
, O 
suggesting O 
that O 
fisetin B-TRIVIAL 
inhibits O 
adipogenesis O 
and O 
the O 
accumulation O 
of O 
intracellular O 
triglycerides B-FAMILY 
during O 
adipocyte O 
differentiation O 
by O 
targeting O 
mTORC1 O 
signaling O 
. O 
Fisetin B-TRIVIAL 
supplementation O 
in O 
mice O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
significantly O 
attenuated O 
HFD-induced O 
increases O 
in O 
body O 
weight O 
and O 
white O 
adipose O 
tissue O 
. O 
We O 
also O 
observed O 
that O 
fisetin B-TRIVIAL 
efficiently O 
suppressed O 
the O 
phosphorylation O 
of O 
Akt O 
, O 
S6K1 O 
and O 
mTORC1 O 
in O 
adipose O 
tissue O 
. O 
Collectively O 
, O 
these O 
results O 
suggest O 
that O 
inhibition O 
of O 
mTORC1 O 
signaling O 
by O 
fisetin B-TRIVIAL 
prevents O 
adipocyte O 
differentiation O 
of O 
3T3-L1 O 
preadipocytes O 
and O 
obesity O 
in O 
HFD-fed O 
mice O 
. O 
Therefore O 
, O 
fisetin B-TRIVIAL 
may O 
be O 
a O 
useful O 
phytochemical O 
agent O 
for O 
attenuating O 
diet O 
- O 
induced O 
obesity O 
. O 

potential O 
health O 
risks O 
is O 
a O 
significant O 
challenge O 
due O 
to O 
large O 
numbers O 
of O 
diverse O 
chemicals O 
with O 
poorly O 
characterized O 
exposures O 
and O 
mechanisms O 
of O 
toxicities O 
. O 
The O 
present O 
study O 
analyzes O 
976 O 
chemicals O 
( O 
including O 
failed O 
pharmaceuticals O 
, O 
alternative O 
plasticizers O 
, O 
food O 
additives O 
, O 
and O 
pesticides O 
) O 
in O 
Phase O 
I O 
and O 
II O 
of O 
the O 
U.S O 
. O 
EPA's O 
ToxCast O 
™ O 
project O 
across O 
331 O 
cell O 
- O 
free O 
enzymatic O 
and O 
ligand O 
- O 
binding O 
high O 
- O 
throughput O 
screening O 
( O 
HTS O 
) O 
assays O 
. O 
Half O 
- O 
maximal O 
activity O 
concentrations O 
( O 
AC50 O 
) O 
were O 
identified O 
for O 
729 O 
chemicals O 
in O 
256 O 
assays O 
( O 
7135 O 
chemical O 
- O 
assay O 
pairs O 
) O 
. O 
Some O 
of O 
the O 
most O 
commonly O 
affected O 
assays O 
were O 
CYPs O 
( O 
CYP2C9 O 
, O 
CYP2C19 O 
) O 
, O 
transporters O 
( O 
mitochondrial O 
TSPO O 
, O 
norepinephrine B-TRIVIAL 
, O 
dopaminergic O 
) O 
, O 
and O 
GPCRs O 
( O 
aminergic O 
) O 
. O 
Heavy O 
metals O 
, O 
surfactants O 
, O 
and O 
dithiocarbamate B-SYSTEMATIC 
fungicides O 
showed O 
promiscuous O 
, O 
but O 
distinctly O 
different O 
patterns O 
of O 
activity O 
whereas O 
many O 
of O 
the O 
pharma O 
compounds O 
showed O 
promiscuous O 
activity O 
across O 
GPCRs O 
. O 
Literature O 
analysis O 
confirmed O 
> O 
50% O 
of O 
the O 
activities O 
for O 
the O 
most O 
potent O 
chemical O 
- O 
assay O 
pairs O 
( O 
56 O 
) O 
, O 
but O 
also O 
revealed O 
10 O 
missed O 
interactions O 
. O 
Twenty O 
- O 
two O 
chemicals O 
with O 
known O 
estrogenic O 
activity O 
were O 
correctly O 
identified O 
for O 
the O 
majority O 
( O 
77% O 
) O 
, O 
missing O 
only O 
the O 
weaker O 
interactions O 
. O 
In O 
many O 
cases O 
, O 
novel O 
findings O 
for O 
previously O 
unreported O 
chemical O 
- O 
target O 
combinations O 
clustered O 
with O 
known O 
chemical O 
- O 
target O 
interactions O 
. O 
Results O 
from O 
this O 
large O 
inventory O 
of O 
chemical O 
- O 
biological O 
interactions O 
can O 
inform O 
read O 
- O 
across O 
methods O 
as O 
well O 
as O 
to O 
link O 
potential O 
targets O 
to O 
molecular O 
initiating O 
events O 
in O 
adverse O 
outcome O 
pathways O 
for O 
diverse O 
toxicities O 
. O 
This O 
abstract O 
does O 
not O 
necessarily O 
reflect O 
U.S O 
. O 
EPA O 
policy O 
. O 

- O 
site O 
conformational O 
equilibrium O 
in O 
nerve O 
- O 
agent O 
adducts O 
of O 
acetylcholinesterase O 
: O 
Possible O 
implications O 
for O 
the O 
HI-6 B-IDENTIFIER 
antidote O 
substrate O 
specificity O 
. O 

agents O 
such O 
as O 
tabun B-TRIVIAL 
, O 
cyclosarin B-TRIVIAL 
and O 
Russian B-TRIVIAL 
VX I-TRIVIAL 
inhibit O 
the O 
essential O 
enzyme O 
acetylcholinesterase O 
( O 
AChE O 
) O 
by O 
organophosphorylating O 
the O 
catalytic O 
serine B-TRIVIAL 
residue O 
. O 
Nucleophiles O 
, O 
such O 
as O 
oximes B-FAMILY 
, O 
are O 
used O 
as O 
antidotes O 
as O 
they O 
can O 
reactivate O 
and O 
restore O 
the O 
function O 
of O 
the O 
inhibited O 
enzyme O 
. O 
The O 
oxime B-SYSTEMATIC 
HI-6 B-IDENTIFIER 
shows O 
a O 
notably O 
low O 
activity O 
on O 
tabun B-TRIVIAL 
adducts O 
but O 
can O 
effectively O 
reactivate O 
adducts O 
of O 
cyclosarin B-TRIVIAL 
and O 
Russian B-TRIVIAL 
VX I-TRIVIAL 
. O 
To O 
examine O 
the O 
structural O 
basis O 
for O 
the O 
pronounced O 
substrate O 
specificity O 
of O 
HI-6 B-IDENTIFIER 
, O 
we O 
determined O 
the O 
binary O 
crystal O 
structures O 
of O 
Mus O 
musculus O 
AChE O 
( O 
mAChE O 
) O 
conjugated O 
by O 
cyclosarin B-TRIVIAL 
and O 
Russian B-TRIVIAL 
VX I-TRIVIAL 
and O 
found O 
a O 
conformational O 
mobility O 
of O 
the O 
side O 
chains O 
of O 
Phe B-FORMULA 
338 O 
and O 
His B-FORMULA 
447 O 
. O 
The O 
interaction O 
between O 
HI-6 B-IDENTIFIER 
and O 
tabun B-TRIVIAL 
-adducts O 
of O 
AChE O 
were O 
subsequently O 
investigated O 
using O 
a O 
combination O 
of O 
time O 
resolved O 
fluorescence O 
spectroscopy O 
and O 
X-ray O 
crystallography O 
. O 
Our O 
findings O 
show O 
that O 
HI-6 B-IDENTIFIER 
binds O 
to O 
tabun B-TRIVIAL 
inhibited O 
Homo O 
sapiens O 
AChE O 
( O 
hAChE O 
) O 
with O 
an O 
IC50 O 
value O 
of O 
300μM O 
and O 
suggest O 
that O 
the O 
reactive O 
nucleophilic O 
moiety O 
of O 
HI-6 B-IDENTIFIER 
is O 
excluded O 
from O 
the O 
phosphorus B-SYSTEMATIC 
atom O 
of O 
tabun B-TRIVIAL 
. O 
We O 
propose O 
that O 
a O 
conformational O 
mobility O 
of O 
the O 
side O 
- O 
chains O 
of O 
Phe B-FORMULA 
338 O 
and O 
His B-FORMULA 
447 O 
is O 
a O 
common O 
feature O 
in O 
nerve O 
- O 
agent O 
adducts O 
of O 
AChE O 
. O 
We O 
also O 
suggest O 
that O 
the O 
conformational O 
mobility O 
allow O 
HI-6 B-IDENTIFIER 
to O 
reactivate O 
conjugates O 
of O 
cyclosarin B-TRIVIAL 
and O 
Russian B-TRIVIAL 
VX I-TRIVIAL 
while O 
a O 
reduced O 
mobility O 
in O 
tabun B-TRIVIAL 
conjugated O 
AChE O 
results O 
in O 
steric O 
hindrance O 
that O 
prevents O 
efficient O 
reactivation O 
. O 

as O 
an O 
antitumor O 
agent O 
: O 
a O 
retrospective O 
review O 
. O 

review O 
summarizes O 
the O 
progress O 
that O 
has O 
been O 
made O 
recently O 
in O 
the O 
medicinal O 
chemistry O 
of O 
cantharidin B-TRIVIAL 
, O 
a O 
potent O 
antitumor O 
agent O 
from O 
traditional O 
Chinese O 
medicine O 
. O 
Thousands O 
of O 
analogs O 
have O 
been O 
synthesized O 
on O 
the O 
basis O 
of O 
cantharidin B-TRIVIAL 
, O 
a O 
part O 
of O 
which O 
shows O 
excellent O 
properties O 
, O 
in O 
particular O 
, O 
norcantharidin B-TRIVIAL 
and O 
norcantharimide B-TRIVIAL 
. O 
Despite O 
the O 
enormous O 
efforts O 
made O 
, O 
the O 
intriguing O 
bioactivities O 
, O 
mechanism O 
, O 
indications O 
, O 
and O 
their O 
interplay O 
are O 
still O 
ill O 
- O 
defined O 
. O 
This O 
review O 
provides O 
our O 
up O 
- O 
to O 
- O 
date O 
understanding O 
in O 
connection O 
with O 
the O 
therapeutic O 
use O 
, O 
mechanism O 
, O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
and O 
interesting O 
properties O 
of O 
cantharidin B-TRIVIAL 
analogs O 
. O 
Considerable O 
development O 
in O 
the O 
design O 
of O 
cantharidin B-TRIVIAL 
analogs O 
, O 
in O 
combination O 
with O 
mechanistic O 
studies O 
, O 
has O 
laid O 
a O 
foundation O 
for O 
transforming O 
novel O 
antitumor O 
drugs O 
into O 
the O 
clinic O 
. O 

situ O 
forming O 
reduction O 
- O 
sensitive O 
degradable O 
nanogels O 
were O 
designed O 
and O 
developed O 
based O 
on O 
poly(ethylene B-FAMILY 
glycol)-b-poly(2-(hydroxyethyl I-FAMILY 
) I-FAMILY 
methacrylate I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
acryloyl I-FAMILY 
carbonate I-FAMILY 
) I-FAMILY 
( O 
PEG-P(HEMA-co-AC) B-ABBREVIATION 
) O 
block O 
copolymers O 
for O 
efficient O 
loading O 
as O 
well O 
as O 
triggered O 
intracellular O 
release O 
of O 
proteins O 
. O 
PEG-P(HEMA-co-AC) B-ABBREVIATION 
copolymers O 
were O 
prepared O 
with O 
controlled O 
Mn O 
of O 
9.1 O 
, O 
9.5 O 
, O 
and O 
9.9 O 
kg O 
/ O 
mol O 
and O 
varying O 
numbers O 
of O 
AC O 
units O 
per O 
molecule O 
of O 
7 O 
, O 
9 O 
and O 
11 O 
, O 
respectively O 
( O 
denoted O 
as O 
copolymer O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
) O 
by O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
copolymerization O 
. O 
These O 
copolymers O 
were O 
freely O 
soluble O 
in O 
phosphate B-SYSTEMATIC 
buffer O 
but O 
formed O 
disulfide B-SYSTEMATIC 
-cross O 
- O 
linked O 
nanogels O 
with O 
defined O 
sizes O 
ranging O 
from O 
72.5 O 
to O 
124.1 O 
nm O 
in O 
the O 
presence O 
of O 
cystamine B-TRIVIAL 
via O 
ring O 
- O 
opening O 
reaction O 
with O 
cyclic B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
groups O 
. O 
The O 
sizes O 
of O 
nanogels O 
decreased O 
with O 
increasing O 
AC O 
units O 
as O 
a O 
result O 
of O 
increased O 
cross O 
- O 
linking O 
density O 
. O 
Dynamic O 
light O 
scattering O 
studies O 
showed O 
that O 
these O 
nanogels O 
though O 
stable O 
at O 
physiological O 
conditions O 
were O 
rapidly O 
dissociated O 
in O 
response O 
to O 
10 O 
mM O 
dithiothreitol B-SYSTEMATIC 
( O 
DTT B-ABBREVIATION 
) O 
. O 
Interestingly O 
, O 
FITC B-ABBREVIATION 
-labeled O 
cytochrome O 
C O 
( O 
FITC B-ABBREVIATION 
-CC O 
) O 
could O 
be O 
readily O 
loaded O 
into O 
nanogels O 
with O 
remarkable O 
loading O 
efficiencies O 
( O 
up O 
to O 
98.2% O 
) O 
and O 
loading O 
contents O 
( O 
up O 
to O 
48.2 O 
wt.% O 
) O 
. O 
The O 
in O 
vitro O 
release O 
studies O 
showed O 
that O 
release O 
of O 
FITC B-ABBREVIATION 
-CC O 
was O 
minimal O 
under O 
physiological O 
conditions O 
but O 
significantly O 
enhanced O 
under O 
reductive O 
conditions O 
in O 
the O 
presence O 
of O 
10 O 
mM O 
DTT B-ABBREVIATION 
with O 
about O 
96.8% O 
of O 
FITC B-ABBREVIATION 
-CC O 
released O 
in O 
22 O 
h O 
from O 
nanogel O 
1 O 
. O 
In O 
contrast O 
, O 
protein O 
release O 
from O 
1,4-butanediamine B-SYSTEMATIC 
cross O 
- O 
linked O 
nanogels O 
( O 
reduction O 
- O 
insensitive O 
control O 
) O 
remained O 
low O 
under O 
otherwise O 
the O 
same O 
conditions O 
. O 
MTT B-ABBREVIATION 
assays O 
showed O 
that O 
these O 
nanogels O 
were O 
nontoxic O 
to O 
HeLa O 
cells O 
up O 
to O 
a O 
tested O 
concentration O 
of O 
2 O 
mg O 
/ O 
mL O 
. O 
Confocal O 
microscopy O 
results O 
showed O 
that O 
nanogel O 
1 O 
delivered O 
and O 
released O 
FITC B-ABBREVIATION 
-CC O 
into O 
the O 
perinuclei O 
region O 
of O 
HeLa O 
cells O 
following O 
8 O 
h O 
incubation O 
. O 
CC-loaded O 
reductively O 
degradable O 
nanogels O 
demonstrated O 
apparently O 
better O 
apoptotic O 
activity O 
than O 
free O 
CC O 
as O 
well O 
as O 
reduction O 
- O 
insensitive O 
controls O 
. O 
These O 
in O 
situ O 
forming O 
, O 
surfactant O 
and O 
oil O 
- O 
free O 
, O 
and O 
reduction O 
- O 
sensitive O 
degradable O 
nanogels O 
are O 
highly O 
promising O 
for O 
targeted O 
protein O 
therapy O 
. O 

assembly O 
of O 
gold O 
nanoparticle O 
through O 
the O 
recognition O 
of O 
unmodified O 
antibody O 
was O 
developed O 
. O 
The O 
use O 
of O 
peptide O 
( O 
Cys-Ala-Leu-Asn-Asn B-FORMULA 
) O 
as O 
ligands O 
to O 
stabilize O 
and O 
functionalize O 
gold O 
nanoparticles O 
provides O 
technical O 
and O 
operational O 
convenience O 
. O 
These O 
peptide-capped O 
particles O 
in O 
different O 
sizes O 
are O 
recognized O 
by O 
antibody O 
and O 
assembly O 
to O 
form O 
dimers O 
and O 
expanded O 
hybrid O 
material O 
by O 
controlling O 
the O 
conditions O 
. O 
The O 
interparticle O 
spacing O 
of O 
these O 
assemblies O 
was O 
well O 
studied O 
with O 
small O 
- O 
angle O 
X-ray O 
scattering O 
measurements O 
, O 
and O 
it O 
was O 
found O 
that O 
the O 
interparticle O 
spacing O 
is O 
inversely O 
dependent O 
on O 
the O 
particle O 
size O 
. O 
This O 
relationship O 
of O 
interparticle O 
spacing O 
and O 
particle O 
size O 
is O 
closely O 
related O 
to O 
the O 
structure O 
of O 
antibody O 
linker O 
. O 
Therefore O 
, O 
analyzing O 
the O 
interparticle O 
spacing O 
of O 
assemblies O 
can O 
reveal O 
the O 
equilibrium O 
configuration O 
of O 
IgG O 
. O 
Based O 
on O 
the O 
investigation O 
, O 
the O 
Fab-Fab O 
angle O 
of O 
IgG O 
is O 
obtained O 
to O 
be O 
≈102° O 
and O 
the O 
Fab O 
arms O 
are O 
≈7.8 O 
nm O 
. O 
These O 
results O 
provide O 
new O 
experimental O 
data O 
on O 
the O 
structure O 
of O 
flexible O 
IgG O 
. O 

improves O 
performance O 
in O 
an O 
attentional O 
set O 
shifting O 
task O 
in O 
rats O 
. O 

large O 
number O 
of O 
studies O 
in O 
both O 
humans O 
and O 
experimental O 
animals O 
have O 
demonstrated O 
nicotine B-TRIVIAL 
-induced O 
improvements O 
in O 
various O 
aspects O 
of O 
cognitive O 
function O 
, O 
including O 
attention O 
and O 
memory O 
. O 
The O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
is O 
thought O 
to O 
be O 
critically O 
involved O 
in O 
the O 
modulation O 
of O 
executive O 
function O 
and O 
these O 
attentional O 
processes O 
are O 
enhanced O 
by O 
nicotine B-TRIVIAL 
acting O 
at O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
. O 
The O 
involvement O 
of O 
nicotinic O 
processes O 
on O 
cognitive O 
flexibility O 
in O 
particular O 
has O 
not O 
been O 
specifically O 
investigated O 
. O 
The O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
attentional O 
flexibility O 
were O 
therefore O 
evaluated O 
using O 
the O 
rodent O 
attentional O 
set O 
shifting O 
task O 
in O 
rats O 
. O 
Nicotine B-TRIVIAL 
injected O 
both O 
acutely O 
and O 
following O 
repeated O 
pre O 
- O 
exposure O 
significantly O 
improved O 
both O 
intradimensional O 
and O 
extradimensional O 
set O 
shifting O 
performance O 
in O 
the O 
task O 
. O 
Further O 
investigation O 
of O 
the O 
acute O 
effects O 
of O 
nicotine B-TRIVIAL 
demonstrated O 
this O 
improvement O 
in O 
attentional O 
flexibility O 
to O 
be O 
dose O 
- O 
dependent O 
. O 
These O 
results O 
implicate O 
the O 
nicotinic O 
receptor O 
system O 
in O 
the O 
mediation O 
of O 
processes O 
underlying O 
cognitive O 
flexibility O 
and O 
suggest O 
that O 
nicotine B-TRIVIAL 
improves O 
attentional O 
flexibility O 
in O 
rats O 
, O 
both O 
within O 
and O 
between O 
perceptual O 
dimensions O 
of O 
a O 
compound O 
stimulus O 
. O 
Nicotine B-TRIVIAL 
-induced O 
alterations O 
in O 
prefrontal O 
circuitry O 
may O 
underlie O 
these O 
effects O 
on O 
cognitive O 
flexibility O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

damage O 
and O 
genetic O 
rearrangements O 
are O 
hallmarks O 
of O 
cancer O 
. O 
However O 
, O 
gene O 
fusions O 
as O 
driver O 
mutations O 
in O 
cancer O 
have O 
classically O 
been O 
a O 
distinction O 
in O 
leukemia O 
and O 
other O 
rare O 
instances O 
until O 
recently O 
with O 
the O 
discovery O 
of O 
gene O 
fusion O 
events O 
occurring O 
in O 
50 O 
to O 
75% O 
of O 
prostate O 
cancer O 
patients O 
. O 
The O 
discovery O 
of O 
the O 
TMPRSS2-ERG O 
fusion O 
sparked O 
an O 
onslaught O 
of O 
discovery O 
and O 
innovation O 
resulting O 
in O 
a O 
delineation O 
of O 
prostate O 
cancer O 
via O 
a O 
molecular O 
signature O 
of O 
gene O 
fusion O 
events O 
. O 
The O 
increased O 
commonality O 
of O 
high O 
- O 
throughput O 
sequencing O 
data O 
coupled O 
with O 
improved O 
bioinformatics O 
approaches O 
not O 
only O 
elucidated O 
the O 
molecular O 
underpinnings O 
of O 
prostate O 
cancer O 
progression O 
, O 
but O 
the O 
mechanisms O 
of O 
gene O 
fusion O 
biogenesis O 
. O 
Interestingly O 
, O 
the O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
, O 
already O 
known O 
to O 
play O 
a O 
significant O 
role O 
in O 
prostate O 
cancer O 
tumorigenesis O 
, O 
has O 
recently O 
been O 
implicated O 
in O 
the O 
processes O 
resulting O 
in O 
gene O 
fusions O 
by O 
inducing O 
the O 
spatial O 
proximity O 
of O 
genes O 
involved O 
in O 
rearrangements O 
, O 
promoting O 
the O 
formation O 
of O 
double O 
- O 
strand O 
DNA O 
breaks O 
( O 
DSB O 
) O 
, O 
and O 
facilitating O 
the O 
recruitment O 
of O 
proteins O 
for O 
non-homologous O 
end O 
- O 
joining O 
( O 
NHEJ O 
) O 
. O 
Our O 
increased O 
understanding O 
of O 
the O 
mechanisms O 
inducing O 
genomic O 
instability O 
may O 
lead O 
to O 
improved O 
diagnostic O 
and O 
therapeutic O 
strategies O 
. O 
To O 
date O 
, O 
the O 
majority O 
of O 
prostate O 
cancer O 
patients O 
can O 
be O 
molecularly O 
stratified O 
based O 
on O 
their O 
gene O 
fusion O 
status O 
thereby O 
increasing O 
the O 
potential O 
for O 
tailoring O 
more O 
specific O 
and O 
effective O 
therapies O 
. O 

conversion O 
efficiencies O 
in O 
excess O 
of O 
7% O 
have O 
been O 
achieved O 
with O 
bulk O 
heterojunction O 
( O 
BHJ O 
) O 
- O 
type O 
organic O 
solar O 
cells O 
using O 
two O 
components O 
: O 
p- O 
and O 
n-doped O 
materials O 
. O 
The O 
energy O 
level O 
and O 
absorption O 
profile O 
of O 
the O 
active O 
layer O 
can O 
be O 
tuned O 
by O 
introduction O 
of O 
an O 
additional O 
component O 
. O 
Careful O 
design O 
of O 
the O 
additional O 
component O 
is O 
required O 
to O 
achieve O 
optimal O 
panchromatic O 
absorption O 
, O 
suitable O 
energy O 
- O 
level O 
offset O 
, O 
balanced O 
electron O 
and O 
hole O 
mobility O 
, O 
and O 
good O 
light O 
- O 
harvesting O 
efficiency O 
. O 
This O 
article O 
reviews O 
the O 
recent O 
progress O 
on O 
ternary O 
organic O 
photovoltaic O 
systems O 
, O 
including O 
polymer O 
/ O 
small O 
molecule O 
/ O 
functional O 
fullerene B-TRIVIAL 
, O 
polymer O 
/ O 
polymer O 
/ O 
functional O 
fullerene B-TRIVIAL 
, O 
small O 
molecule O 
/ O 
small O 
molecule O 
/ O 
functional O 
fullerene B-TRIVIAL 
, O 
polymer O 
/ O 
functional O 
fullerene B-TRIVIAL 
I O 
/ O 
functional O 
fullerene B-TRIVIAL 
II O 
, O 
and O 
polymer O 
/ O 
quantum O 
dot O 
or O 
metal O 
/ O 
functional O 
fullerene B-TRIVIAL 
systems O 
. O 

pieces O 
of O 
evidence O 
indicate O 
that O 
the O 
rostral O 
ventrolateral O 
medulla O 
( O 
RVLM O 
) O 
is O 
probably O 
one O 
of O 
the O 
key O 
neural O 
structures O 
mediating O 
the O 
pressor O 
effects O 
of O 
orexins O 
in O 
the O 
brain O 
. O 
Nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase/ O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NOS/ O 
NO B-FORMULA 
) O 
system O 
in O 
the O 
RVLM O 
modulates O 
cardiovascular O 
activities O 
. O 
Our O 
experiments O 
were O 
designed O 
to O 
test O 
the O 
hypothesis O 
that O 
orexin-A O 
( O 
OXA O 
) O 
is O 
involved O 
in O 
the O 
mechanism O 
of O 
stress O 
- O 
induced O 
hypertension O 
( O 
SIH O 
) O 
by O 
adjusting O 
NOS/ O 
NO B-FORMULA 
system O 
in O 
the O 
RVLM O 
. O 
The O 
stress O 
- O 
induced O 
hypertensive O 
rats O 
( O 
SIHR O 
) O 
model O 
was O 
established O 
by O 
electric O 
foot O 
- O 
shocks O 
and O 
noises O 
. O 
Here O 
we O 
examined O 
the O 
expression O 
of O 
OXA O 
immunoreactive O 
( O 
OXA-IR O 
) O 
cells O 
in O 
the O 
lateral O 
hypothalamus O 
( O 
LH O 
) O 
and O 
the O 
protein O 
level O 
of O 
orexin O 
1 O 
receptor O 
( O 
OX1R O 
) O 
in O 
the O 
RVLM O 
of O 
SIHR O 
, O 
and O 
we O 
found O 
that O 
the O 
expressions O 
of O 
OXA-IR O 
and O 
OX1R O 
were O 
higher O 
than O 
those O 
of O 
the O 
control O 
group O 
. O 
The O 
double O 
- O 
staining O 
immunohistochemical O 
evidence O 
showed O 
that O 
OX1R O 
immunoreactive O 
( O 
OX1R-IR O 
) O 
cells O 
and O 
neuronal O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
nNOS O 
) O 
or O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
immunoreactive O 
( O 
IR O 
) O 
cells O 
were O 
co O 
- O 
localizated O 
in O 
the O 
RVLM O 
. O 
Microinjection O 
of O 
OXA O 
( O 
10 O 
, O 
50 O 
, O 
100 O 
pmol O 
/ O 
100 O 
nl O 
) O 
into O 
the O 
unilateral O 
( O 
right O 
) O 
RVLM O 
of O 
control O 
rats O 
or O 
SIHR O 
produced O 
pressor O 
and O 
tachycardiac O 
effects O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
SB-408124 B-IDENTIFIER 
( O 
100 O 
pmol O 
/ O 
100 O 
nl O 
, O 
an O 
antagonist O 
of O 
OX1R O 
) O 
or O 
TCS B-IDENTIFIER 
OX2 I-IDENTIFIER 
29 I-IDENTIFIER 
( O 
100 O 
pmol O 
/ O 
100 O 
nl O 
, O 
an O 
antagonist O 
of O 
OX2R O 
) O 
partly O 
abolished O 
the O 
cardiovascular O 
effects O 
of O 
exogenously O 
- O 
administrated O 
OXA O 
into O 
the O 
RVLM O 
of O 
control O 
rats O 
and O 
SIHR O 
, O 
and O 
lowered O 
the O 
increased O 
systolic O 
blood O 
pressure O 
( O 
SBP O 
) O 
and O 
heart O 
rate O 
( O 
HR O 
) O 
of O 
SIHR O 
, O 
with O 
no O 
difference O 
in O 
statistical O 
significance O 
between O 
the O 
two O 
antagonists O 
' O 
effects O 
. O 
Microinjection O 
into O 
the O 
RVLM O 
of O 
both O 
control O 
and O 
SIHR O 
groups O 
of O 
7-Ni O 
( O 
0.05 O 
pmol O 
/ O 
100 O 
nl O 
, O 
nNOS O 
inhibitor O 
) O 
or O 
Methylene B-TRIVIAL 
Blue I-TRIVIAL 
[ O 
100 O 
pmol O 
/ O 
100 O 
nl O 
, O 
an O 
inhibitor O 
of O 
soluble O 
guanylate B-TRIVIAL 
cyclase O 
( O 
sGC O 
) O 
] O 
suppressed O 
the O 
OXA-induced O 
increase O 
of O 
SBP O 
and O 
HR O 
, O 
whereas O 
microinjection O 
of O 
AG O 
( O 
1 O 
, O 
10 O 
, O 
100 O 
pmol O 
/ O 
100 O 
nl O 
) O 
had O 
no O 
obvious O 
effects O 
on O 
the O 
OXA-induced O 
increase O 
of O 
SBP O 
and O 
HR O 
. O 
Our O 
results O 
indicate O 
that O 
OXA O 
in O 
the O 
RVLM O 
may O 
participate O 
in O 
the O 
central O 
regulation O 
of O 
cardiovascular O 
activities O 
in O 
SIHR O 
, O 
and O 
OX1R O 
and O 
OX2R O 
both O 
have O 
important O 
roles O 
in O 
it O 
. O 
The O 
cardiovascular O 
effects O 
of O 
OXA O 
in O 
the O 
RVLM O 
may O 
be O 
induced O 
by O 
nNOS O 
- O 
derived O 
NO B-FORMULA 
, O 
which O 
activated O 
sGC-associated O 
signaling O 
pathway O 
. O 

knockout O 
mice O 
exhibit O 
impaired O 
adipocyte O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
polypeptide O 
receptor O 
( O 
GIPR O 
) O 
expression O 
. O 

-dependent O 
insulinotropic O 
polypeptide O 
( O 
GIP O 
) O 
is O 
an O 
incretin O 
hormone O 
that O 
also O 
plays O 
a O 
regulatory O 
role O 
in O 
fat O 
metabolism O 
. O 
In O 
3T3-L1 O 
cells O 
, O 
resistin O 
was O 
demonstrated O 
to O 
be O 
a O 
key O 
mediator O 
of O 
GIP O 
stimulation O 
of O 
lipoprotein O 
lipase O 
( O 
LPL O 
) O 
activity O 
, O 
involving O 
activation O 
of O 
protein O 
kinase O 
B O 
( O 
PKB O 
) O 
and O 
reduced O 
phosphorylation O 
of O 
liver O 
kinase O 
B1 O 
( O 
LKB1 O 
) O 
and O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
. O 
The O 
current O 
study O 
was O 
initiated O 
to O 
determine O 
whether O 
resistin O 
has O 
additional O 
roles O 
in O 
GIP-regulated O 
adipocyte O 
functions O 
. O 
Analysis O 
of O 
primary O 
adipocytes O 
isolated O 
from O 
Retn(- O 
/ O 
- O 
) O 
, O 
Retn(+ O 
/ O 
- O 
) O 
, O 
and O 
Retn(+ O 
/ O 
+ O 
) O 
mice O 
found O 
that O 
GIP O 
stimulated O 
the O 
PKB O 
/ O 
LKB1 O 
/ O 
AMPK O 
/ O 
LPL O 
pathway O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
uptake O 
only O 
in O 
Retn(+ O 
/ O 
+ O 
) O 
adipocytes O 
, O 
suggesting O 
that O 
GIP O 
signaling O 
and O 
/ O 
or O 
GIP O 
responsiveness O 
were O 
compromised O 
in O 
Retn(+ O 
/ O 
- O 
) O 
and O 
Retn(- O 
/ O 
- O 
) O 
adipocytes O 
. O 
GIP O 
receptor O 
( O 
GIPR O 
) O 
protein O 
and O 
mRNA O 
were O 
decreased O 
in O 
Retn(+ O 
/ O 
- O 
) O 
and O 
Retn(- O 
/ O 
- O 
) O 
adipocytes O 
, O 
but O 
resistin O 
treatment O 
rescued O 
LPL O 
responsiveness O 
to O 
GIP O 
. O 
In O 
addition O 
, O 
genes O 
encoding O 
tumor O 
necrosis O 
factor O 
( O 
TNF O 
) O 
, O 
TNF O 
receptor O 
2 O 
( O 
TNFR2 O 
) O 
, O 
and O 
the O 
signaling O 
proteins O 
stress O 
- O 
activated O 
protein O 
kinase O 
( O 
SAPK O 
) O 
/ O 
Jun O 
NH(2) B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
, O 
were O 
downregulated O 
, O 
and O 
phosphorylated O 
levels O 
of O 
SAPK O 
/ O 
JNK O 
/ O 
c-Jun O 
were O 
decreased O 
in O 
Retn(- O 
/ O 
- O 
) O 
mice O 
. O 
Chromatin O 
immunoprecipitation O 
assays O 
were O 
used O 
to O 
identify O 
a O 
12-O-tetradecanoylphorbol-13-acetate B-SYSTEMATIC 
( O 
TPA B-ABBREVIATION 
)-response O 
element O 
( O 
TRE-III O 
) O 
responsible O 
for O 
c-Jun O 
- O 
mediated O 
transcriptional O 
activation O 
of O 
Gipr O 
. O 
Blunted O 
GIP O 
responsiveness O 
in O 
Retn(+ O 
/ O 
- O 
) O 
and O 
Retn(- O 
/ O 
- O 
) O 
adipocytes O 
was O 
therefore O 
largely O 
due O 
to O 
the O 
greatly O 
reduced O 
GIPR O 
expression O 
associated O 
with O 
decreased O 
c-Jun O 
- O 
mediated O 
transcriptional O 
activation O 
of O 
Gipr O 
. O 

and O 
magnetic O 
structures O 
and O 
physical O 
properties O 
of O 
a O 
new O 
pyroxene B-FAMILY 
NaMnGe2O6 B-FORMULA 
synthesized O 
under O 
high O 
pressure O 
. O 

new O 
pyroxene B-FAMILY 
compound O 
, O 
NaMnGe(2)O(6) B-FORMULA 
, O 
has O 
been O 
synthesized O 
at O 
3 O 
GPa O 
and O 
800 O 
°C O 
and O 
fully O 
characterized O 
by O 
X-ray O 
single O 
- O 
crystal O 
diffraction O 
, O 
neutron O 
powder O 
diffraction O 
, O 
and O 
measurements O 
of O 
magnetization O 
and O 
specific O 
heat O 
. O 
NaMnGe(2)O(6) B-FORMULA 
crystallizes O 
into O 
a O 
monoclinic O 
C2 O 
/ O 
c O 
structure O 
with O 
unit O 
- O 
cell O 
parameters O 
a O 
= O 
9.859(2) O 
Å O 
, O 
b O 
= O 
8.7507(18) O 
Å O 
, O 
c O 
= O 
5.5724(11) O 
Å O 
, O 
and O 
β O 
= O 
105.64(3)° O 
at O 
153 O 
K O 
. O 
A O 
cooperative O 
Jahn-Teller O 
distortion O 
is O 
formed O 
by O 
an O 
ordering O 
of O 
the O 
longest O 
Mn-O B-FORMULA 
bonds O 
between O 
two O 
neighboring O 
octahedra O 
along O 
the O 
chain O 
direction O 
. O 
This O 
feature O 
distinguishes O 
NaMnGe(2)O(6) B-FORMULA 
from O 
other O 
pyroxene B-FAMILY 
compounds O 
without O 
Jahn-Teller O 
active O 
cations O 
and O 
suggests O 
that O 
the O 
Jahn-Teller O 
distortion O 
competes O 
with O 
the O 
intrinsic O 
local O 
distortion O 
in O 
the O 
pyroxene B-FAMILY 
structure O 
. O 
No O 
orbital O 
order O 
- O 
disorder O 
transition O 
has O 
been O 
found O 
up O 
to O 
750 O 
K O 
. O 
Like O 
other O 
alkali O 
- O 
metal O 
pyroxenes B-FAMILY 
with O 
S O 
> O 
( O 
1 O 
) O 
/ O 
( O 
2 O 
) O 
, O 
NaMnGe(2)O(6) B-FORMULA 
( O 
S O 
= O 
2 O 
) O 
was O 
found O 
to O 
undergo O 
a O 
long O 
- O 
range O 
antiferromagnetic O 
( O 
AF O 
) O 
ordering O 
at O 
T(N) O 
= O 
7 O 
K O 
due O 
to O 
intrachain O 
and O 
interchain O 
exchange O 
interactions O 
. O 
Due O 
to O 
the O 
peculiar O 
structural O 
features O 
and O 
the O 
corresponding O 
magnetic O 
coupling O 
, O 
the O 
weak O 
AF O 
spin O 
ordering O 
gives O 
way O 
to O 
a O 
ferromagnetic O 
- O 
like O 
state O 
at O 
a O 
sufficiently O 
high O 
magnetic O 
field O 
. O 
Specific O 
- O 
heat O 
measurements O 
demonstrated O 
that O 
a O 
large O 
portion O 
of O 
the O 
magnetic O 
entropy O 
, O 
> O 
60% O 
, O 
has O 
been O 
removed O 
above O 
T(N) O 
as O 
a O 
result O 
of O 
strong O 
spin O 
correlations O 
within O 
the O 
quasi O 
- O 
one O 
- O 
dimensional O 
Mn(3+) B-FORMULA 
-spin O 
chains O 
. O 
The O 
Reitveld O 
refinement O 
of O 
neutron O 
powder O 
diffraction O 
data O 
gives O 
a O 
commensurate O 
magnetic O 
structure O 
defined O 
by O 
k O 
= O 
[ O 
0 O 
0 O 
0.5 O 
] O 
with O 
Mn B-FORMULA 
moments O 
aligned O 
mainly O 
along O 
the O 
c-axis O 
with O 
a O 
small O 
component O 
along O 
both O 
a- O 
and O 
b-axes O 
. O 

two O 
- O 
dimensional O 
model O 
of O 
a O 
solid O 
- O 
supported O 
enzyme O 
catalyst O 
bead O 
is O 
fabricated O 
on O 
a O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
with O 
dissipation O 
monitoring O 
( O 
QCM-D O 
) O 
sensor O 
to O 
measure O 
in O 
situ O 
interfacial O 
stability O 
and O 
mechanical O 
properties O 
of O 
Candida O 
antarctica O 
Lipase O 
B O 
( O 
CAL O 
B O 
) O 
under O 
varied O 
conditions O 
relating O 
to O 
ring O 
- O 
opening O 
polymerization O 
. O 
The O 
model O 
was O 
fabricated O 
using O 
a O 
dual O 
photochemical O 
approach O 
, O 
where O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PMMA B-ABBREVIATION 
) O 
thin O 
films O 
were O 
cross O 
- O 
linked O 
by O 
a O 
photoactive O 
benzophenone B-SYSTEMATIC 
monolayer O 
and O 
blended O 
cross O 
- O 
linking O 
agent O 
. O 
This O 
process O 
produces O 
two O 
- O 
dimensional O 
, O 
homogeneous O 
, O 
rigid O 
PMMA B-ABBREVIATION 
layers O 
, O 
which O 
mimic O 
commercial O 
acrylic B-SYSTEMATIC 
resins O 
in O 
a O 
QCM-D O 
experiment O 
. O 
Adsorption O 
of O 
CAL O 
B O 
to O 
PMMA B-ABBREVIATION 
in O 
QCM-D O 
under O 
varied O 
buffer O 
ionic O 
strengths O 
produces O 
a O 
viscoelastic O 
enzyme O 
surface O 
that O 
becomes O 
more O 
rigid O 
as O 
ionic O 
strength O 
increases O 
. O 
The O 
rigid O 
CAL O 
B/ O 
PMMA B-ABBREVIATION 
interface O 
demonstrates O 
up O 
to O 
20% O 
desorption O 
of O 
enzyme O 
with O 
increasing O 
trace O 
water O 
content O 
. O 
Increased O 
polycaprolactone B-SYSTEMATIC 
( O 
PCL B-ABBREVIATION 
) O 
binding O 
at O 
the O 
enzyme O 
surface O 
was O 
also O 
observed O 
, O 
indicating O 
greater O 
PCL B-ABBREVIATION 
affinity O 
for O 
a O 
more O 
hydrated O 
enzyme O 
surface O 
. O 
The O 
enzyme O 
layer O 
destabilized O 
with O 
increasing O 
temperature O 
, O 
yielding O 
near O 
complete O 
reversible O 
catalyst O 
desorption O 
in O 
the O 
model O 
. O 

vitamin B-FAMILY 
E I-FAMILY 
: O 
sidechain O 
substitution O 
is O 
key O 
to O 
the O 
reactivity O 
of O 
naphthyridinol B-SYSTEMATIC 
antioxidants O 
in O 
lipid O 
bilayers O 
. O 

series O 
of O 
naphthyridinol B-SYSTEMATIC 
analogs O 
of O 
α-tocopherol B-TRIVIAL 
( O 
α-TOH B-ABBREVIATION 
, O 
right O 
) O 
with O 
varying O 
sidechain O 
substitution O 
was O 
synthesized O 
to O 
determine O 
how O 
systematic O 
changes O 
in O 
the O 
lipophilicity O 
of O 
these O 
potent O 
antioxidants O 
impact O 
their O 
radical O 
- O 
trapping O 
activities O 
in O 
lipid O 
bilayers O 
, O 
regenerability O 
by O 
water O 
- O 
soluble O 
reductants O 
, O 
and O 
binding O 
to O 
human O 
tocopherol B-FAMILY 
transport O 
protein O 
( O 
TTP O 
) O 
. O 
The O 
activities O 
of O 
the O 
naphthyridinols B-FAMILY 
were O 
assayed O 
in O 
phosphatidylcholine B-FAMILY 
unilamellar O 
liposomes O 
using O 
a O 
recently O 
developed O 
high O 
- O 
throughput O 
assay O 
that O 
employs O 
a O 
boron B-SYSTEMATIC 
dipyrromethene I-SYSTEMATIC 
conjugate O 
of O 
α-TOH B-ABBREVIATION 
( O 
H(2)B-PMHC O 
) O 
that O 
undergoes O 
fluorescence O 
enhancement O 
upon O 
oxidation O 
. O 
The O 
naphthyridinols B-FAMILY 
afforded O 
a O 
dose O 
- O 
dependent O 
protection O 
of O 
H(2)B-PMHC O 
consistent O 
with O 
unprecedented O 
peroxyl B-SYSTEMATIC 
radical O 
- O 
trapping O 
activity O 
in O 
lipid O 
bilayers O 
. O 
While O 
sidechain O 
length O 
and O 
/ O 
or O 
branching O 
had O 
no O 
effect O 
on O 
their O 
apparent O 
reactivity O 
, O 
it O 
dramatically O 
impacted O 
reaction O 
stoichiometry O 
, O 
with O 
more O 
lipophilic O 
compounds O 
trapping O 
two O 
peroxyl B-SYSTEMATIC 
radicals O 
and O 
more O 
hydrophilic O 
compounds O 
trapping O 
significantly O 
less O 
than O 
one O 
. O 
It O 
is O 
suggested O 
that O 
the O 
less O 
lipophilic O 
compounds O 
autoxidize O 
rapidly O 
in O 
the O 
aqueous O 
phase O 
and O 
that O 
preferential O 
partitioning O 
of O 
the O 
more O 
lipophilic O 
compounds O 
to O 
the O 
bilayer O 
protects O 
them O 
from O 
autoxidation O 
. O 
The O 
cooperativity O 
of O 
a O 
lipophilic O 
naphthyridinol B-SYSTEMATIC 
with O 
water O 
- O 
soluble O 
reducing O 
agents O 
was O 
also O 
studied O 
in O 
liposomes O 
using O 
H(2)B-PMHC O 
and O 
revealed O 
superior O 
regenerability O 
by O 
each O 
of O 
ascorbate B-TRIVIAL 
, O 
N-acetylcysteine B-SYSTEMATIC 
, O 
and O 
urate B-SYSTEMATIC 
when O 
compared O 
to O 
α-TOH B-ABBREVIATION 
. O 
Binding O 
assays O 
with O 
human O 
TTP O 
, O 
a O 
key O 
determinant O 
of O 
the O 
bioavailability O 
of O 
the O 
tocopherols B-FAMILY 
, O 
reveal O 
that O 
the O 
naphthyiridinols B-FAMILY 
can O 
be O 
very O 
good O 
ligands O 
for O 
the O 
protein O 
. O 
In O 
fact O 
, O 
naphthyridinols B-FAMILY 
with O 
sidechains O 
of O 
eight O 
or O 
more O 
carbons B-FAMILY 
had O 
affinities O 
for O 
TTP O 
which O 
were O 
similar O 
to O 
, O 
and O 
in O 
one O 
case O 
10-fold O 
better O 
than O 
, O 
α-TOH B-ABBREVIATION 
. O 

study O 
of O 
four O 
flavones B-FAMILY 
of O 
Glycyrrhiza O 
in O 
rat O 
plasma O 
using O 
HPLC-MS O 
. O 

OF O 
THE O 
STUDY O 
: O 
This O 
study O 
aimed O 
to O 
develop O 
a O 
specific O 
HPLC-MS O 
method O 
for O 
simultaneous O 
quantification O 
of O 
four O 
flavones B-FAMILY 
of O 
Glycyrrhiza O 
in O 
rat O 
plasma O 
after O 
oral O 
administration O 
and O 
to O 
describe O 
the O 
pharmacokinetics O 
of O 
four O 
flavones B-FAMILY 
in O 
rat O 
plasma O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
A O 
simple O 
, O 
sensitive O 
and O 
selective O 
method O 
for O 
simultaneous O 
determination O 
of O 
four O 
flavones B-FAMILY 
of O 
Glycyrrhiza O 
in O 
rat O 
plasma O 
, O 
i.e O 
. O 
, O 
liquiritin B-TRIVIAL 
, O 
isoliquiritin B-TRIVIAL 
, O 
liquiritigenin B-TRIVIAL 
, O 
isoliquiritigenin B-TRIVIAL 
, O 
by O 
high O 
performance O 
liquid O 
chromato O 
- O 
graphy O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
) O 
with O 
negative O 
electrospray O 
ionization O 
mode O 
, O 
was O 
developed O 
and O 
validated O 
. O 
The O 
method O 
was O 
applied O 
to O 
investigate O 
the O 
pharmacokinetics O 
of O 
four O 
flavones B-FAMILY 
in O 
rat O 
plasma O 
after O 
oral O 
administration O 
of O 
Glycyrrhiza O 
flavones B-FAMILY 
. O 
Chromatographic O 
separation O 
was O 
accomplished O 
on O 
an O 
Agilent O 
TC-C18 O 
column O 
( O 
4.6mm×250mm O 
, O 
5μm O 
) O 
, O 
with O 
gradient O 
elution O 
by O 
using O 
a O 
mixture O 
of O 
methanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
A O 
) O 
and O 
acetonitrile B-SYSTEMATIC 
( O 
B O 
) O 
as O 
the O 
mobile O 
phase O 
at O 
a O 
flow O 
rate O 
of O 
0.8mL O 
/ O 
min O 
. O 
RESULTS O 
: O 
The O 
calibration O 
curves O 
for O 
four O 
flavones B-FAMILY 
had O 
good O 
linearity O 
in O 
the O 
measured O 
range O 
with O 
higher O 
than O 
0.997 O 
. O 
Relative O 
standard O 
deviations O 
( O 
RSDs O 
) O 
of O 
the O 
intra- O 
and O 
inter O 
- O 
day O 
precision O 
at O 
different O 
levels O 
were O 
all O 
less O 
than O 
4.8% O 
. O 
The O 
pharmacokinetic O 
profile O 
of O 
four O 
flavones B-FAMILY 
in O 
rat O 
plasma O 
was O 
fitted O 
with O 
a O 
two O 
- O 
compartment O 
model O 
detected O 
by O 
a O 
simple O 
, O 
rapid O 
and O 
accurate O 
HPLC-MS O 
method O 
. O 
Time O 
( O 
h O 
) O 
to O 
reach O 
peak O 
concentration O 
( O 
μg O 
/ O 
mL O 
) O 
of O 
liquiritin B-TRIVIAL 
( O 
2.69±0.04 O 
) O 
, O 
isoliquiritin B-TRIVIAL 
( O 
10.16±0.02 O 
) O 
, O 
liquiritigenin B-TRIVIAL 
( O 
2.83±0.02 O 
) O 
, O 
isoliquiritigenin B-TRIVIAL 
( O 
0.28±0.01 O 
) O 
were O 
2.02±0.23 O 
, O 
1.97±0.20 O 
, O 
0.48±0.02 O 
, O 
1.93±0.36 O 
, O 
respectively O 
. O 
The O 
distribution O 
and O 
elimination O 
half O 
- O 
life O 
( O 
h O 
) O 
and O 
area O 
under O 
the O 
concentration O 
- O 
time O 
curve O 
( O 
μg O 
/ O 
mL⁎h O 
) O 
from O 
t=0 O 
to O 
last O 
time O 
of O 
liquiritin B-TRIVIAL 
, O 
isoliquiritin B-TRIVIAL 
, O 
liquiritigenin B-TRIVIAL 
, O 
isoliquiritigenin B-TRIVIAL 
were O 
1.02±0.48 O 
/ O 
2.27±0.53 O 
/ O 
16.97±0.43 O 
, O 
2.04±1.01 O 
/ O 
2.38±0.80 O 
/ O 
69.20±5.24 O 
, O 
0.35±0.10 O 
/ O 
4.26±0.16 O 
/ O 
14.83±0.11 O 
, O 
1.18±0.32 O 
/ O 
3.04 O 
, O 
±0.22 O 
/ O 
2.10±0.09 O 
, O 
respectively O 
. O 
Isoliquiritin B-TRIVIAL 
presented O 
the O 
phenomenon O 
of O 
double O 
peaks O 
and O 
the O 
others O 
appeared O 
together O 
in O 
a O 
single O 
and O 
plateau O 
absorption O 
phase O 
. O 
Isoliquiritigenin B-TRIVIAL 
had O 
the O 
lowest O 
oral O 
bioavailability O 
because O 
of O 
Cmax O 
and O 
AUC0-∞ O 
. O 
Liquiritigenin B-TRIVIAL 
had O 
the O 
fastest O 
absorption O 
and O 
distribution O 
rate O 
and O 
the O 
lowest O 
elimination O 
rate O 
according O 
to O 
Tmax O 
, O 
t1 O 
/ O 
2α O 
, O 
t1 O 
/ O 
2β O 
. O 
CONCLUSIONS O 
: O 
This O 
paper O 
first O 
reported O 
on O 
identification O 
and O 
determination O 
of O 
four O 
flavones B-FAMILY 
of O 
Glycyrrhiza O 
in O 
rat O 
plasma O 
and O 
their O 
respective O 
pharmacokinetic O 
characteristics O 
. O 
The O 
results O 
provided O 
a O 
meaningful O 
basis O 
for O 
better O 
understanding O 
the O 
absorption O 
mechanism O 
of O 
Glycyrrhiza O 
and O 
evaluating O 
the O 
clinical O 
application O 
of O 
this O 
medicine O 
. O 

C I-TRIVIAL 
Produced O 
by O 
Bacillus O 
subtilis O 
EA-CB0015 O 
. O 

subtilis O 
EA-CB0015 O 
was O 
isolated O 
from O 
the O 
phyllosphere O 
of O 
a O 
banana O 
plant O 
and O 
tested O 
for O 
its O 
potential O 
to O 
produce O 
bioactive O 
compounds O 
against O 
Mycosphaerella O 
fijiensis O 
. O 
Using O 
a O 
dual O 
plate O 
culture O 
technique O 
the O 
cell O 
- O 
free O 
supernatant O 
of O 
B O 
. O 
subtilis O 
EA-CB0015 O 
produced O 
inhibition O 
values O 
of O 
89 O 
± O 
1% O 
. O 
The O 
active O 
compounds O 
were O 
purified O 
by O 
solid O 
- O 
phase O 
extraction O 
and O 
HPLC O 
, O 
and O 
their O 
primary O 
structures O 
determined O 
using O 
mass O 
spectrometry O 
and O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
. O 
A O 
new O 
fengycin B-FAMILY 
isoform O 
, O 
fengycin B-TRIVIAL 
C I-TRIVIAL 
, O 
with O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
Glu-Orn-Tyr-Thr-Glu-Val-Pro-Gln-Thr-Ile B-FORMULA 
was O 
isolated O 
. O 
The O 
peptidic O 
moiety O 
differs O 
from O 
fengycin B-TRIVIAL 
B I-TRIVIAL 
at O 
position O 
9 O 
and O 
from O 
fengycin B-TRIVIAL 
A I-TRIVIAL 
at O 
positions O 
6 O 
and O 
9 O 
. O 
The O 
β-hydroxy B-FAMILY 
fatty I-FAMILY 
acyl I-FAMILY 
chain O 
is O 
connected O 
to O 
the O 
N B-FORMULA 
-terminal O 
of O 
the O 
decapeptide B-FAMILY 
and O 
can O 
be O 
saturated O 
or O 
unsaturated O 
, O 
ranging O 
from O 
14 O 
to O 
18 O 
carbons B-FAMILY 
. O 
The O 
C B-FORMULA 
-terminal O 
residue O 
of O 
the O 
peptidic O 
moiety O 
is O 
linked O 
to O 
the O 
tyrosine B-TRIVIAL 
residue O 
at O 
position O 
3 O 
, O 
forming O 
the O 
branching O 
point O 
of O 
the O 
acyl B-FAMILY 
peptide O 
and O 
the O 
eight O 
- O 
membered O 
cyclic B-FAMILY 
lactone I-FAMILY 
. O 

function O 
of O 
prejunctional O 
adenosine B-TRIVIAL 
A1 O 
receptors O 
expressed O 
by O 
perivascular O 
sympathetic O 
nerves O 
in O 
DOCA B-ABBREVIATION 
-salt O 
hypertensive O 
rats O 
. O 

sympathetic O 
nervous O 
system O 
activity O 
contributes O 
to O 
deoxycorticosterone B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
DOCA B-ABBREVIATION 
)-salt O 
hypertension O 
in O 
rats O 
. O 
ATP B-ABBREVIATION 
and O 
norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
are O 
coreleased O 
from O 
perivascular O 
sympathetic O 
nerves O 
. O 
NE O 
acts O 
at O 
prejunctional O 
α2-adrenergic O 
receptors O 
( O 
α2ARs O 
) O 
to O 
inhibit O 
NE O 
release O 
, O 
and O 
α2AR O 
function O 
is O 
impaired O 
in O 
DOCA B-ABBREVIATION 
-salt O 
rats O 
. O 
Adenosine B-TRIVIAL 
, O 
an O 
enzymatic O 
ATP B-ABBREVIATION 
degradation O 
product O 
, O 
acts O 
at O 
prejunctional O 
A1 O 
adenosine B-TRIVIAL 
receptors O 
( O 
A1Rs O 
) O 
to O 
inhibit O 
NE O 
release O 
. O 
We O 
tested O 
the O 
hypothesis O 
that O 
prejunctional O 
A1R O 
function O 
is O 
impaired O 
in O 
sympathetic O 
nerves O 
supplying O 
mesenteric O 
arteries O 
( O 
MAs O 
) O 
and O 
veins O 
( O 
MVs O 
) O 
of O 
DOCA B-ABBREVIATION 
-salt O 
rats O 
. O 
Electrically O 
evoked O 
NE O 
release O 
and O 
constrictions O 
of O 
blood O 
vessels O 
were O 
studied O 
in O 
vitro O 
with O 
use O 
of O 
amperometry O 
to O 
measure O 
NE O 
oxidation O 
currents O 
and O 
video O 
microscopy O 
, O 
respectively O 
. O 
Immunohistochemical O 
methods O 
were O 
used O 
to O 
localize O 
tyrosine B-TRIVIAL 
hydroxylase O 
( O 
TH O 
) O 
and O 
A1Rs O 
in O 
perivascular O 
sympathetic O 
nerves O 
. O 
TH O 
and O 
A1Rs O 
colocalized O 
to O 
perivascular O 
sympathetic O 
nerves O 
. O 
Adenosine B-TRIVIAL 
and O 
N(6)-cyclopentyl-adenosine B-SYSTEMATIC 
( O 
CPA B-ABBREVIATION 
, O 
A1R O 
agonist O 
) O 
constricted O 
MVs O 
but O 
not O 
MAs O 
. O 
Adenosine B-TRIVIAL 
and O 
CPA B-ABBREVIATION 
( O 
0.001-10 O 
µM O 
) O 
inhibited O 
neurogenic O 
constrictions O 
and O 
NE O 
release O 
in O 
MAs O 
and O 
MVs O 
. O 
DOCA B-ABBREVIATION 
-salt O 
arteries O 
were O 
resistant O 
to O 
adenosine B-TRIVIAL 
and O 
CPA B-ABBREVIATION 
-mediated O 
inhibition O 
of O 
NE O 
release O 
and O 
constriction O 
. O 
The O 
A2A O 
adenosine B-TRIVIAL 
receptor O 
agonist O 
CGS21680 B-IDENTIFIER 
( O 
C23H29N7O6.HCl.xH2O B-FORMULA 
) O 
( O 
0.001-0.1 O 
μM O 
) O 
did O 
not O 
alter O 
NE O 
oxidation O 
currents O 
. O 
We O 
conclude O 
that O 
there O 
are O 
prejunctional O 
A1Rs O 
in O 
arteries O 
and O 
both O 
pre- O 
and O 
postjunctional O 
A1Rs O 
in O 
veins O 
; O 
thus O 
, O 
adenosine B-TRIVIAL 
selectively O 
constricts O 
the O 
veins O 
. O 
Prejunctional O 
A1R O 
function O 
is O 
impaired O 
in O 
arteries O 
, O 
but O 
not O 
veins O 
, O 
from O 
DOCA B-ABBREVIATION 
-salt O 
rats O 
. O 
Sympathetic O 
autoreceptor O 
dysfunction O 
is O 
not O 
specific O 
to O 
α2ARs O 
, O 
but O 
there O 
is O 
a O 
more O 
general O 
disruption O 
of O 
prejunctional O 
mechanisms O 
controlling O 
sympathetic O 
neurotransmitter O 
release O 
in O 
DOCA B-ABBREVIATION 
-salt O 
hypertension O 
. O 

effect O 
of O 
apricots O 
on O 
the O 
experimental O 
cataract O 
model O 
formed O 
by O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
. O 

study O 
was O 
designed O 
in O 
order O 
to O 
investigate O 
whether O 
sun O 
dried O 
apricots O 
have O 
a O 
preventive O 
effect O 
on O 
the O 
experimental O 
cataract O 
model O 
formed O 
by O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
in O 
rats O 
. O 
Fifty O 
- O 
nine O 
Spraque-Dawley O 
rat O 
pups O 
were O 
divided O 
into O 
three O 
groups O 
. O 
Group O 
1 O 
( O 
control O 
group O 
) O 
consisted O 
of O 
twenty O 
rat O 
pups O 
, O 
born O 
from O 
the O 
rats O 
nourished O 
ad O 
libitum O 
. O 
Group O 
2 O 
consisted O 
of O 
18 O 
newborn O 
rats O 
, O 
born O 
from O 
the O 
rats O 
nourished O 
ad O 
libitum O 
with O 
10% O 
sun O 
dried O 
natural O 
apricots O 
. O 
Group O 
3 O 
consisted O 
of O 
21 O 
newborn O 
rats O 
, O 
born O 
from O 
the O 
rats O 
nourished O 
ad O 
libitum O 
. O 
Subcutaneous O 
( O 
30nmol O 
/ O 
gr O 
) O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
injection O 
was O 
applied O 
to O 
all O 
the O 
newborn O 
rats O 
except O 
the O 
control O 
group O 
( O 
Group O 
1 O 
) O 
on O 
postpartum O 
day O 
10 O 
. O 
Cataract O 
development O 
was O 
graded O 
by O 
slit O 
- O 
lamp O 
examination O 
and O 
photography O 
. O 
Encapsulated O 
lenses O 
were O 
analyzed O 
for O 
reduced O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
a O 
marker O 
of O 
lipid O 
per O 
oxidation O 
. O 
Lenses O 
were O 
also O 
analyzed O 
for O 
total O 
nitrite B-SYSTEMATIC 
( O 
TN O 
) O 
. O 
The O 
presence O 
of O 
oxidative O 
stress O 
in O 
selenite B-TRIVIAL 
cataract O 
development O 
and O 
its O 
prevention O 
by O 
sun O 
dried O 
apricots O 
. O 

of O 
silymarin O 
flavonolignans B-FAMILY 
with O 
organic O 
anion O 
- O 
transporting O 
polypeptides O 
. O 

anion O 
- O 
transporting O 
polypeptides O 
( O 
OATPs O 
) O 
are O 
multispecific O 
transporters O 
mediating O 
the O 
uptake O 
of O 
endogenous O 
compounds O 
and O 
xenobiotics O 
in O 
tissues O 
that O 
are O 
important O 
for O 
drug O 
absorption O 
and O 
elimination O 
, O 
including O 
the O 
intestine O 
and O 
liver O 
. O 
Silymarin O 
is O 
a O 
popular O 
herbal O 
supplement O 
often O 
used O 
by O 
patients O 
with O 
chronic O 
liver O 
disease O 
; O 
higher O 
oral O 
doses O 
than O 
those O 
customarily O 
used O 
( O 
140 O 
mg O 
three O 
times O 
/ O 
day O 
) O 
are O 
being O 
evaluated O 
clinically O 
. O 
The O 
present O 
study O 
examined O 
the O 
effect O 
of O 
silymarin O 
flavonolignans B-FAMILY 
on O 
OATP1B1- O 
, O 
OATP1B3- O 
, O 
and O 
OATP2B1 O 
- O 
mediated O 
transport O 
in O 
cell O 
lines O 
stably O 
expressing O 
these O 
transporters O 
and O 
in O 
human O 
hepatocytes O 
. O 
In O 
overexpressing O 
cell O 
lines O 
, O 
OATP1B1- O 
and O 
OATP1B3 O 
- O 
mediated O 
estradiol-17β-glucuronide B-SYSTEMATIC 
uptake O 
and O 
OATP2B1 O 
- O 
mediated O 
estrone-3-sulfate B-SYSTEMATIC 
uptake O 
were O 
inhibited O 
by O 
most O 
of O 
the O 
silymarin O 
flavonolignans B-FAMILY 
investigated O 
. O 
OATP1B1- O 
, O 
OATP1B3- O 
, O 
and O 
OATP2B1 O 
- O 
mediated O 
substrate O 
transport O 
was O 
inhibited O 
efficiently O 
by O 
silymarin O 
( O 
IC50 O 
values O 
of O 
1.3 O 
, O 
2.2 O 
and O 
0.3 O 
µM O 
, O 
respectively O 
) O 
, O 
silybin B-TRIVIAL 
A I-TRIVIAL 
( O 
IC50 O 
values O 
of O 
9.7 O 
, O 
2.7 O 
and O 
4.5 O 
µM O 
, O 
respectively O 
) O 
, O 
silybin B-TRIVIAL 
B I-TRIVIAL 
( O 
IC50 O 
values O 
of O 
8.5 O 
, O 
5 O 
and O 
0.8 O 
µM O 
, O 
respectively O 
) O 
, O 
and O 
silychristin B-TRIVIAL 
( O 
IC50 O 
values O 
of O 
9 O 
, O 
36.4 O 
, O 
and O 
3.6 O 
µM O 
, O 
respectively O 
) O 
. O 
Furthermore O 
, O 
silymarin O 
, O 
silybin B-TRIVIAL 
A I-TRIVIAL 
, O 
and O 
silybin B-TRIVIAL 
B I-TRIVIAL 
( O 
100 O 
µM O 
) O 
significantly O 
inhibited O 
OATP O 
- O 
mediated O 
estradiol-17β-glucuronide B-SYSTEMATIC 
and O 
rosuvastatin B-TRIVIAL 
uptake O 
into O 
human O 
hepatocytes O 
. O 
Calculation O 
of O 
the O 
maximal O 
unbound O 
portal O 
vein O 
concentrations O 
/ O 
IC50 O 
values O 
indicated O 
a O 
low O 
risk O 
for O 
silymarin O 
- O 
drug O 
interactions O 
in O 
hepatic O 
uptake O 
with O 
a O 
customary O 
silymarin O 
dose O 
. O 
The O 
extent O 
of O 
silymarin O 
- O 
drug O 
interactions O 
depends O 
on O 
OATP O 
isoform O 
specificity O 
and O 
concentrations O 
of O 
flavonolignans B-FAMILY 
at O 
the O 
site O 
of O 
drug O 
transport O 
. O 
Higher O 
than O 
customary O 
doses O 
of O 
silymarin O 
, O 
or O 
formulations O 
with O 
improved O 
bioavailability O 
, O 
may O 
increase O 
the O 
risk O 
of O 
flavonolignan B-FAMILY 
interactions O 
with O 
OATP O 
substrates O 
in O 
patients O 
. O 

order O 
to O 
develop O 
in O 
vitro O 
risk O 
assessment O 
systems O 
for O 
skin O 
sensitization O 
, O 
it O 
is O 
important O 
to O 
predict O 
a O 
threshold O 
from O 
the O 
murine O 
local O 
lymph O 
node O 
assay O 
( O 
LLNA O 
) O 
. O 
We O 
first O 
confirmed O 
that O 
the O 
combination O 
of O 
the O 
human O 
Cell O 
Line O 
Activation O 
Test O 
( O 
h-CLAT O 
) O 
and O 
the O 
SH O 
test O 
improved O 
the O 
accuracy O 
and O 
sensitivity O 
of O 
prediction O 
of O 
LLNA O 
data O 
compared O 
with O 
each O 
individual O 
test O 
. O 
Next O 
, O 
we O 
assessed O 
the O 
mutual O 
correlations O 
among O 
maximum O 
amount O 
of O 
change O 
of O 
cell O 
- O 
surface O 
thiols B-FAMILY 
( O 
MAC O 
value O 
) O 
in O 
the O 
SH O 
test O 
, O 
CV75 O 
value O 
( O 
concentration O 
giving O 
75% O 
cell O 
viability O 
) O 
in O 
a O 
cytotoxicity O 
assay O 
, O 
EC150 O 
and O 
EC200 O 
values O 
( O 
thresholds O 
concentrations O 
of O 
CD86 O 
and O 
CD54 O 
expression O 
, O 
respectively O 
) O 
in O 
h-CLAT O 
and O 
published O 
LLNA O 
thresholds O 
of O 
64 O 
chemicals O 
. O 
Based O 
on O 
the O 
results O 
, O 
we O 
selected O 
MAC O 
value O 
and O 
the O 
minimum O 
of O 
CV75 O 
, O 
EC150 O 
( O 
CD86 O 
) O 
and O 
EC200 O 
( O 
CD54 O 
) O 
as O 
descriptors O 
for O 
the O 
input O 
layer O 
of O 
an O 
artificial O 
neural O 
network O 
( O 
ANN O 
) O 
system O 
. O 
The O 
ANN-predicted O 
values O 
were O 
well O 
correlated O 
with O 
reported O 
LLNA O 
thresholds O 
. O 
We O 
also O 
found O 
a O 
correlation O 
between O 
the O 
SH O 
test O 
and O 
the O 
peptide O 
- O 
binding O 
assay O 
used O 
to O 
evaluate O 
hapten O 
- O 
protein O 
complex O 
formation O 
. O 
Thus O 
, O 
this O 
model O 
, O 
which O 
we O 
designate O 
as O 
the O 
" O 
iSENS O 
ver O 
. O 
1 O 
" O 
, O 
may O 
be O 
useful O 
for O 
risk O 
assessment O 
of O 
skin O 
sensitization O 
potential O 
of O 
chemicals O 
from O 
in O 
vitro O 
test O 
data O 
. O 

Symmetry O 
Quantum O 
Hall O 
States O 
in O 
Dual-Gated O 
ABA O 
Trilayer O 
Graphene B-TRIVIAL 
. O 

trilayer O 
graphene B-TRIVIAL 
is O 
a O 
unique O 
2D O 
electron O 
system O 
with O 
mirror O 
reflection O 
symmetry O 
and O 
unconventional O 
quantum O 
Hall O 
effect O 
. O 
We O 
present O 
low O 
- O 
temperature O 
transport O 
measurements O 
on O 
dual O 
- O 
gated O 
suspended O 
trilayer O 
graphene B-TRIVIAL 
in O 
the O 
quantum O 
Hall O 
( O 
QH O 
) O 
regime O 
. O 
We O 
observe O 
QH O 
plateaus O 
at O 
filling O 
factors O 
ν O 
= O 
-8 O 
, O 
-2 O 
, O 
2 O 
, O 
6 O 
, O 
and O 
10 O 
, O 
which O 
is O 
in O 
agreement O 
with O 
the O 
full O 
- O 
parameter O 
tight O 
binding O 
calculations O 
. O 
In O 
high O 
magnetic O 
fields O 
, O 
odd O 
- O 
integer O 
plateaus O 
are O 
also O 
resolved O 
, O 
indicating O 
almost O 
complete O 
lifting O 
of O 
the O 
12-fold O 
degeneracy O 
of O 
the O 
lowest O 
Landau O 
level O 
( O 
LL O 
) O 
. O 
Under O 
an O 
out O 
- O 
of O 
- O 
plane O 
electric O 
field O 
E⊥ O 
, O 
we O 
observe O 
degeneracy O 
breaking O 
and O 
transitions O 
between O 
QH O 
plateaus O 
. O 
Interestingly O 
, O 
depending O 
on O 
its O 
direction O 
, O 
E⊥ O 
selectively O 
breaks O 
the O 
LL O 
degeneracies O 
in O 
the O 
electron O 
- O 
doped O 
or O 
hole O 
- O 
doped O 
regimes O 
. O 
Our O 
results O 
underscore O 
the O 
rich O 
interaction O 
- O 
induced O 
phenomena O 
in O 
trilayer O 
graphene B-TRIVIAL 
. O 

of O 
microRNA O 
and O 
gene O 
expression O 
profiling O 
in O 
triazole B-FAMILY 
fungicide O 
- O 
treated O 
HepG2 O 
cell O 
line O 
. O 

( O 
miRNA O 
) O 
plays O 
an O 
important O 
role O 
in O 
various O 
diseases O 
and O 
in O 
cellular O 
and O 
molecular O 
responses O 
to O 
toxicants O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
differential O 
expression O 
of O 
miRNAs O 
in O 
response O 
to O 
three O 
triazole B-FAMILY 
fungicides O 
( O 
myclobutanil B-TRIVIAL 
, O 
propiconazole B-TRIVIAL 
, O 
and O 
triadimefon B-TRIVIAL 
) O 
. O 
The O 
human O 
hepatoma O 
cell O 
line O 
( O 
HepG2 O 
) O 
was O 
treated O 
with O 
the O 
above O 
triazoles B-FAMILY 
for O 
3 O 
h O 
or O 
48 O 
h O 
. O 
miRNA O 
- O 
based O 
microarray O 
experiments O 
were O 
carried O 
out O 
using O 
the O 
Agilent O 
human O 
miRNA O 
v13 O 
array O 
. O 
At O 
early O 
exposure O 
( O 
3h O 
) O 
, O 
six O 
miRNAs O 
were O 
differentially O 
expressed O 
and O 
at O 
late O 
exposure O 
( O 
48 O 
h O 
) O 
, O 
three O 
miRNAs O 
were O 
significantly O 
expressed O 
. O 
Overall O 
, O 
this O 
study O 
provides O 
an O 
array O 
of O 
potential O 
biomarkers O 
for O 
the O 
above O 
triazole B-FAMILY 
fungicides O 
. O 
Furthermore O 
, O 
these O 
miRNAs O 
induced O 
by O 
triazoles B-FAMILY 
could O 
be O 
the O 
foundation O 
for O 
the O 
development O 
of O 
a O 
miRNA O 
- O 
based O 
toxic O 
biomarker O 
library O 
that O 
can O 
predict O 
environmental O 
toxicity O 
. O 

study O 
of O 
the O 
decomposition O 
of O 
ethyl B-MULTIPLE 
and I-MULTIPLE 
ethyl I-MULTIPLE 
3-phenyl I-MULTIPLE 
glycidate I-MULTIPLE 
. O 

mechanism O 
of O 
the O 
decomposition O 
of O 
ethyl B-MULTIPLE 
and I-MULTIPLE 
ethyl I-MULTIPLE 
3-phenyl I-MULTIPLE 
glycidate I-MULTIPLE 
in O 
gas O 
phase O 
was O 
studied O 
by O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
and O 
MP2 O 
methods O 
. O 
A O 
proposed O 
mechanism O 
for O 
the O 
reaction O 
indicates O 
that O 
the O 
ethyl B-SYSTEMATIC 
side O 
of O 
the O 
ester O 
is O 
eliminated O 
as O 
ethylene B-SYSTEMATIC 
through O 
a O 
concerted O 
six O 
- O 
membered O 
cyclic O 
transition O 
state O 
, O 
and O 
the O 
unstable O 
intermediate O 
glycidic B-TRIVIAL 
acid I-TRIVIAL 
decarboxylates O 
rapidly O 
to O 
give O 
the O 
corresponding O 
aldehyde B-SYSTEMATIC 
. O 
Two O 
possible O 
pathways O 
for O 
glycidic B-TRIVIAL 
acid I-TRIVIAL 
decarboxylation O 
were O 
studied O 
: O 
one O 
via O 
a O 
five O 
- O 
membered O 
cyclic O 
transition O 
state O 
, O 
and O 
the O 
other O 
via O 
a O 
four O 
- O 
membered O 
cyclic O 
transition O 
state O 
. O 
The O 
results O 
of O 
the O 
calculations O 
indicate O 
that O 
the O 
decarboxylation O 
reaction O 
occurs O 
via O 
a O 
mechanism O 
with O 
five O 
- O 
membered O 
cyclic O 
transition O 
state O 
. O 

of O 
arsenite B-SYSTEMATIC 
in O 
astrocytes O 
on O 
neuronal O 
signaling O 
transduction O 
. O 

main O 
purpose O 
of O 
this O 
study O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
arsenite B-SYSTEMATIC 
induces O 
neurotoxicity O 
via O 
effects O 
on O 
astrocytes O 
. O 
Astrocytes O 
were O 
exposed O 
to O 
0 O 
, O 
5 O 
or O 
10 O 
μM O 
arsenite B-SYSTEMATIC 
in O 
medium O 
for O 
24 O 
h O 
, O 
and O 
then O 
astrocyte O 
- O 
conditioned O 
medium O 
( O 
ACM O 
) O 
was O 
collected O 
after O 
incubation O 
with O 
fresh O 
medium O 
for O 
6 O 
h O 
. O 
Primary O 
neuron O 
cultures O 
were O 
divided O 
into O 
four O 
groups O 
due O 
to O 
ACM O 
, O 
which O 
were O 
neurons O 
without O 
ACM O 
exposure O 
( O 
group O 
I O 
) O 
and O 
neurons O 
exposed O 
to O 
ACM O 
from O 
0 O 
, O 
5 O 
or O 
10 O 
μM O 
arsenite B-SYSTEMATIC 
treated O 
astrocytes O 
( O 
group O 
II-IV O 
) O 
. O 
Protein O 
expression O 
of O 
N-methyl-d-aspartate B-SYSTEMATIC 
receptors O 
( O 
NR1 O 
, O 
NR2A O 
, O 
NR2B O 
) O 
, O 
calmodulin O 
- O 
dependent O 
protein O 
kinase O 
II O 
( O 
CaMKII O 
) O 
and O 
adenylate B-TRIVIAL 
cyclase O 
( O 
AC O 
) O 
in O 
neurons O 
were O 
measured O 
after O 
incubation O 
with O 
ACM O 
for O 
4 O 
, O 
8 O 
or O 
12 O 
h O 
. O 
Morphological O 
changes O 
and O 
synaptic O 
formation O 
were O 
observed O 
after O 
a O 
72 O 
h-incubation O 
with O 
ACM O 
. O 
Compared O 
to O 
group O 
II O 
, O 
synaptic O 
formation O 
and O 
protein O 
expression O 
of O 
NR2A O 
, O 
NR2B O 
, O 
CaMKII O 
and O 
AC O 
in O 
group O 
III O 
and O 
IV O 
were O 
significantly O 
suppressed O 
. O 
Moreover O 
, O 
synaptic O 
formation O 
and O 
protein O 
expression O 
of O 
CaMKII O 
and O 
AC O 
in O 
group O 
II O 
were O 
significantly O 
enhanced O 
when O 
compared O 
with O 
group O 
I O 
. O 
Taken O 
together O 
, O 
findings O 
from O 
this O 
study O 
suggested O 
that O 
arsenic B-SYSTEMATIC 
in O 
astrocytes O 
might O 
impair O 
synaptic O 
formation O 
through O 
disturbing O 
astrocytic O 
effects O 
on O 
neuronal O 
signal O 
transduction O 
. O 

transitions O 
in O 
mixed O 
ternary O 
noble B-FAMILY 
gas O 
clusters O 
. O 

properties O 
of O 
noble B-FAMILY 
gas O 
systems O 
can O 
be O 
greatly O 
extended O 
by O 
heterogeneous O 
mixtures O 
of O 
elements O 
. O 
The O 
geometrical O 
structures O 
and O 
energies O 
of O 
mixed O 
Ar B-FORMULA 
- O 
Kr B-FORMULA 
- O 
Xe B-FORMULA 
clusters O 
were O 
investigated O 
using O 
ternary O 
Lennard-Jones O 
( O 
TLJ O 
) O 
potential O 
. O 
For O 
the O 
Ar19Kr B-FAMILY 
n I-FAMILY 
Xe19 I-FAMILY 
, O 
Ar19Kr19Xe B-FAMILY 
n I-FAMILY 
, O 
and O 
Ar B-FAMILY 
n I-FAMILY 
Kr19Xe19 I-FAMILY 
( O 
n O 
= O 
0-17 O 
) O 
clusters O 
investigated O 
, O 
the O 
results O 
show O 
that O 
only O 
two O 
minimum O 
energy O 
configurations O 
exist O 
, O 
i.e O 
. O 
, O 
polytetrahedron O 
and O 
six O 
- O 
fold O 
pancake O 
. O 
The O 
inner O 
core O 
of O 
all O 
these O 
clusters O 
is O 
composed O 
mainly O 
of O 
Ar B-FORMULA 
atoms O 
, O 
and O 
Kr B-FORMULA 
and O 
Xe B-FORMULA 
atoms O 
are O 
distributed O 
on O 
the O 
surface O 
with O 
well O 
mixed O 
pattern O 
for O 
polytetrahedral O 
and O 
segregate O 
pattern O 
for O 
six O 
- O 
fold O 
pancake O 
configurations O 
. O 
The O 
relative O 
stability O 
property O 
of O 
Ar B-FORMULA 
- O 
Kr B-FORMULA 
- O 
Xe B-FORMULA 
clusters O 
with O 
a O 
certain O 
composition O 
is O 
discussed O 
. O 
Moreover O 
, O 
the O 
role O 
of O 
heterogeneity O 
on O 
the O 
strain O 
was O 
investigated O 
, O 
and O 
reduced O 
strain O 
energies O 
in O 
Ar B-FORMULA 
- O 
Kr B-FORMULA 
- O 
Xe B-FORMULA 
clusters O 
were O 
studied O 
to O 
find O 
possible O 
ways O 
of O 
reducing O 
strain O 
. O 
The O 
results O 
showed O 
that O 
the O 
strain O 
energies O 
were O 
affected O 
mainly O 
by O 
Ar B-FORMULA 
- O 
Ar B-FORMULA 
, O 
Ar B-FORMULA 
- O 
Kr B-FORMULA 
, O 
and O 
Xe B-FORMULA 
- O 
Xe B-FORMULA 
bonds O 
. O 

study O 
on O 
transcriptional O 
activity O 
of O 
17 O 
parabens B-FAMILY 
mediated O 
by O 
estrogen B-FAMILY 
receptor O 
α O 
and O 
β O 
and O 
androgen B-FAMILY 
receptor O 
. O 

structure O 
- O 
activity O 
relationships O 
of O 
parabens B-FAMILY 
which O 
are O 
widely O 
used O 
as O 
preservatives O 
for O 
transcriptional O 
activities O 
mediated O 
by O 
human O 
estrogen B-FAMILY 
receptor O 
α O 
( O 
hERα O 
) O 
, O 
hERβ O 
and O 
androgen B-FAMILY 
receptor O 
( O 
hAR O 
) O 
were O 
investigated O 
. O 
Fourteen O 
of O 
17 O 
parabens B-FAMILY 
exhibited O 
hERα O 
and O 
/ O 
or O 
hERβ O 
agonistic O 
activity O 
at O 
concentrations O 
of O 
⩽1×10(-5)M O 
, O 
whereas O 
none O 
of O 
the O 
17 O 
parabens B-FAMILY 
showed O 
AR O 
agonistic O 
or O 
antagonistic O 
activity O 
. O 
Among O 
12 O 
parabens B-FAMILY 
with O 
linear O 
alkyl B-FAMILY 
chains O 
ranging O 
in O 
length O 
from O 
C1 O 
to O 
C12 O 
, O 
heptylparaben B-SYSTEMATIC 
( O 
C7 O 
) O 
and O 
pentylparaben B-SYSTEMATIC 
( O 
C5 O 
) O 
showed O 
the O 
most O 
potent O 
ERα O 
and O 
ERβ O 
agonistic O 
activity O 
in O 
the O 
order O 
of O 
10(-7)M O 
and O 
10(-8)M O 
, O 
respectively O 
, O 
and O 
the O 
activities O 
decreased O 
in O 
a O 
stepwise O 
manner O 
as O 
the O 
alkyl O 
chain O 
was O 
shortened O 
to O 
C1 O 
or O 
lengthened O 
to O 
C12 O 
. O 
Most O 
parabens B-FAMILY 
showing O 
estrogenic O 
activity O 
exhibited O 
ERβ-agonistic O 
activity O 
at O 
lower O 
concentrations O 
than O 
those O 
inducing O 
ERα-agonistic O 
activity O 
. O 
The O 
estrogenic O 
activity O 
of O 
butylparaben B-SYSTEMATIC 
was O 
markedly O 
decreased O 
by O 
incubation O 
with O 
rat O 
liver O 
microsomes O 
, O 
and O 
the O 
decrease O 
of O 
activity O 
was O 
blocked O 
by O 
a O 
carboxylesterase O 
inhibitor O 
. O 
These O 
results O 
indicate O 
that O 
parabens B-FAMILY 
are O 
selective O 
agonists O 
for O 
ERβ O 
over O 
ERα O 
; O 
their O 
interactions O 
with O 
ERα O 
/ O 
β O 
are O 
dependent O 
on O 
the O 
size O 
and O 
bulkiness O 
of O 
the O 
alkyl B-FAMILY 
groups O 
; O 
and O 
they O 
are O 
metabolized O 
by O 
carboxylesterases O 
, O 
leading O 
to O 
attenuation O 
of O 
their O 
estrogenic O 
activity O 
. O 

and O 
anti-metastatic O 
actions O 
of O 
wogonin B-TRIVIAL 
isolated O 
from O 
Scutellaria O 
baicalensis O 
roots O 
through O 
anti-lymphangiogenesis O 
. O 

growth O 
and O 
metastasis O 
are O 
associated O 
with O 
angiogenesis O 
and O 
lymphangiogenesis O 
through O 
the O 
production O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
or O 
VEGF-C O 
in O 
tumors O 
, O 
and O 
the O 
phosphorylation O 
of O 
VEGF O 
receptor O 
(VEGFR)-2 O 
or O 
VEGFR-3 O 
in O 
vascular O 
endothelial O 
cells O 
or O 
lymphatic O 
endothelial O 
cells O 
( O 
LECs O 
) O 
. O 
Tumor O 
- O 
associated O 
macrophages O 
( O 
TAMs O 
) O 
play O 
an O 
important O 
role O 
in O 
tumor O 
lymphangiogenesis O 
, O 
and O 
consequently O 
stimulate O 
metastasis O 
through O 
the O 
lymphatic O 
system O 
to O 
lymph O 
nodes O 
. O 
We O 
examined O 
the O 
effects O 
of O 
wogonin B-TRIVIAL 
isolated O 
from O 
Scutellaria O 
baicalensis O 
roots O 
on O 
tumor O 
growth O 
and O 
metastasis O 
using O 
a O 
highly O 
metastatic O 
model O 
in O 
osteosarcoma O 
LM8-bearing O 
mice O 
. O 
Wogonin B-TRIVIAL 
( O 
25 O 
and O 
50 O 
mg O 
/ O 
kg O 
, O 
twice O 
daily O 
) O 
reduced O 
tumor O 
growth O 
and O 
metastasis O 
to O 
the O 
lung O 
, O 
liver O 
and O 
kidney O 
, O 
angiogenesis O 
( O 
CD31-positive O 
cells O 
) O 
, O 
lymphangiogenesis O 
( O 
LYVE-1-positive O 
cells O 
) O 
, O 
and O 
TAM O 
( O 
F4 O 
/ O 
80-positive O 
cell O 
) O 
numbers O 
in O 
the O 
tumors O 
of O 
LM8-bearing O 
mice O 
. O 
Wogonin B-TRIVIAL 
( O 
10-100 O 
μM O 
) O 
also O 
inhibited O 
increases O 
in O 
IL-1β O 
production O 
and O 
cyclooxygenase O 
(COX)-2 O 
expression O 
induced O 
by O 
lipopolysaccharide O 
in O 
THP-1 O 
macrophages O 
. O 
Wogonin B-TRIVIAL 
had O 
no O 
effect O 
on O 
VEGF-C O 
production O 
in O 
LM8 O 
cells O 
, O 
or O 
VEGFR-3 O 
expression O 
in O 
human O 
lymphatic O 
endothelial O 
cells O 
( O 
HLECs O 
) O 
, O 
however O 
, O 
it O 
inhibited O 
VEGF-C-induced O 
VEGFR-3 O 
phosphorylation O 
in O 
HLECs O 
. O 
The O 
anti-tumor O 
and O 
anti-metastatic O 
actions O 
of O 
wogonin B-TRIVIAL 
may O 
be O 
associated O 
with O 
the O 
inhibition O 
of O 
VEGF-C-induced O 
lymphangiogenesis O 
through O 
a O 
reduction O 
in O 
VEGF-C-induced O 
VEGFR-3 O 
phosphorylation O 
by O 
the O 
inhibition O 
of O 
COX-2 O 
expression O 
and O 
IL-1β O 
production O 
in O 
TAMs O 
. O 

drug O 
release O 
from O 
curcumin B-TRIVIAL 
-loaded O 
PLGA B-ABBREVIATION 
nanoparticles O 
induces O 
G2 O 
/ O 
M O 
block O 
in O 
breast O 
cancer O 
cells O 
. O 

nanoparticles O 
are O 
among O 
the O 
most O 
studied O 
polymer O 
nanoformulations O 
for O 
several O 
drugs O 
against O 
different O 
kinds O 
of O 
malignant O 
diseases O 
, O 
thanks O 
to O 
their O 
in O 
vivo O 
stability O 
and O 
tumor O 
localization O 
exploiting O 
the O 
well O 
- O 
documented O 
" O 
enhanced O 
permeation O 
and O 
retention O 
" O 
( O 
EPR O 
) O 
effect O 
. O 
In O 
this O 
paper O 
, O 
we O 
have O 
developed O 
uniform O 
curcumin B-TRIVIAL 
-bearing O 
PLGA B-ABBREVIATION 
nanoparticles O 
by O 
a O 
single O 
- O 
emulsion O 
process O 
, O 
which O 
exhibited O 
a O 
curcumin B-TRIVIAL 
release O 
following O 
a O 
Fickian O 
- O 
law O 
diffusion O 
over O 
10 O 
days O 
in O 
vitro O 
. O 
PLGA B-ABBREVIATION 
nanoparticles O 
were O 
about O 
120 O 
nm O 
in O 
size O 
, O 
as O 
determined O 
by O 
dynamic O 
light O 
scattering O 
, O 
with O 
a O 
surface O 
negative O 
charge O 
of O 
-30 O 
mV O 
. O 
The O 
loading O 
ratio O 
of O 
encapsulated O 
drug O 
in O 
our O 
PLGA B-ABBREVIATION 
nanoformulation O 
was O 
8 O 
wt% O 
. O 
PLGA B-ABBREVIATION 
encapsulation O 
provided O 
efficient O 
protection O 
of O 
curcumin B-TRIVIAL 
from O 
environment O 
, O 
as O 
determined O 
by O 
fluorescence O 
emission O 
experiments O 
. O 
Next O 
, O 
we O 
have O 
investigated O 
the O 
possibility O 
to O 
study O 
the O 
intracellular O 
degradation O 
of O 
nanoparticles O 
associated O 
with O 
a O 
specific O 
G2 O 
/ O 
M O 
blocking O 
effect O 
on O 
MCF7 O 
breast O 
cancer O 
cells O 
caused O 
by O 
curcumin B-TRIVIAL 
release O 
in O 
the O 
cytoplasm O 
, O 
which O 
provided O 
direct O 
evidence O 
on O 
the O 
mechanism O 
of O 
action O 
of O 
our O 
nanocomplex O 
. O 
This O 
study O 
was O 
carried O 
out O 
using O 
Annexin O 
V O 
- O 
based O 
cell O 
death O 
analysis O 
, O 
MTT B-ABBREVIATION 
assessment O 
of O 
proliferation O 
, O 
flow O 
cytometry O 
, O 
and O 
confocal O 
laser O 
scanning O 
microscopy O 
. O 
PLGA B-ABBREVIATION 
nanoparticles O 
proved O 
to O 
be O 
completely O 
safe O 
, O 
suggesting O 
a O 
potential O 
utilization O 
of O 
this O 
nanocomplex O 
to O 
improve O 
the O 
intrinsically O 
poor O 
bioavailability O 
of O 
curcumin B-TRIVIAL 
for O 
the O 
treatment O 
of O 
severe O 
malignant O 
breast O 
cancer O 
. O 

exposure O 
and O 
recovery O 
modify O 
the O 
interrenal O 
and O 
thyroidal O 
activities O 
and O 
the O 
mitochondria O 
- O 
rich O 
cell O 
function O 
in O 
the O 
climbing O 
perch O 
Anabas O 
testudineus O 
Bloch O 
. O 

examined O 
the O 
effects O 
of O 
carbaryl B-TRIVIAL 
( O 
1-naphthyl B-SYSTEMATIC 
methylcarbamate I-SYSTEMATIC 
; O 
sevin B-TRIVIAL 
) O 
, O 
a O 
carbamate B-FAMILY 
pesticide O 
, O 
on O 
interrenal O 
and O 
thyroid O 
activities O 
and O 
mitochondrial O 
rich O 
( O 
MR O 
) O 
cell O 
function O 
in O 
climbing O 
perch O 
to O 
understand O 
the O 
physiological O 
basis O 
of O 
toxicity O 
acclimation O 
in O 
this O 
fish O 
to O 
the O 
chemical O 
stressor O 
. O 
Carbaryl B-TRIVIAL 
exposure O 
( O 
5-20 O 
mg O 
L(-1) O 
) O 
for O 
48 O 
h O 
increased O 
cortisol B-TRIVIAL 
and O 
glucose B-TRIVIAL 
, O 
but O 
decreased O 
the O 
T(3) O 
level O 
without O 
affecting O 
T(4) O 
concentration O 
in O 
the O 
plasma O 
. O 
These O 
responses O 
of O 
the O 
carbaryl B-TRIVIAL 
-exposed O 
fish O 
were O 
nullified O 
and O 
a O 
rise O 
in O 
plasma O 
T(4) O 
occurred O 
in O 
these O 
fish O 
when O 
they O 
were O 
kept O 
for O 
96 O 
h O 
recovery O 
in O 
clean O 
water O 
. O 
A O 
tight O 
plasma O 
mineral O 
control O 
was O 
indicated O 
in O 
the O 
carbaryl B-TRIVIAL 
-exposed O 
fish O 
as O 
reflected O 
by O 
the O 
unchanged O 
plasma O 
Na B-FORMULA 
, O 
K B-FORMULA 
, O 
Ca B-FORMULA 
and O 
inorganic O 
phosphate B-SYSTEMATIC 
levels O 
. O 
The O 
ouabain B-TRIVIAL 
-sensitive O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
-ATPase O 
activity O 
showed O 
an O 
increase O 
in O 
the O 
gills O 
but O 
the O 
intestinal O 
and O 
renal O 
tissues O 
showed O 
little O 
response O 
to O 
carbaryl B-TRIVIAL 
treatment O 
. O 
However O 
, O 
substantial O 
increases O 
in O 
the O 
intestinal O 
and O 
renal O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
-ATPase O 
activities O 
occurred O 
in O 
the O 
recovery O 
fish O 
. O 
The O 
MR O 
cells O 
in O 
the O 
branchial O 
epithelia O 
showed O 
a O 
strong O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
-ATPase O 
immunoreactivity O 
to O 
carbaryl B-TRIVIAL 
treatment O 
indicating O 
an O 
activated O 
MR O 
cell O 
function O 
. O 
The O 
numerical O 
MR O 
cell O 
density O 
remained O 
unchanged O 
, O 
but O 
stretching O 
of O 
secondary O 
gill O 
lamellae O 
as O 
part O 
of O 
gill O 
remodeling O 
occurred O 
during O 
carbaryl B-TRIVIAL 
exposure O 
. O 
The O 
increased O 
surface O 
of O 
these O 
lamellae O 
with O 
abundant O 
MR O 
cells O 
as O 
a O 
result O 
of O 
its O 
migration O 
into O 
the O 
lamellar O 
surface O 
points O 
to O 
marked O 
structural O 
and O 
functional O 
modifications O 
of O 
these O 
cells O 
in O 
the O 
carbaryl B-TRIVIAL 
-treated O 
fish O 
which O 
is O 
likely O 
to O 
a O 
target O 
for O 
carbaryl B-TRIVIAL 
action O 
. O 
The O 
rise O 
in O 
plasma O 
T(4) O 
and O 
the O 
restoration O 
of O 
normal O 
branchial O 
epithelia O 
in O 
the O 
recovery O 
fish O 
indicate O 
a O 
thyroidal O 
involvement O 
in O 
the O 
recovery O 
response O 
and O 
survival O 
. O 
Our O 
data O 
thus O 
provide O 
evidence O 
that O 
carbaryl B-TRIVIAL 
exposure O 
and O 
its O 
recovery O 
evoke O 
interrenal O 
and O 
thyroid O 
disruption O 
in O 
this O 
fish O 
leading O 
to O 
a O 
modified O 
osmotic O 
response O 
including O 
an O 
altered O 
MR O 
cell O 
function O 
. O 

- O 
based O 
screening O 
identifies O 
paroxetine B-TRIVIAL 
as O 
an O 
inhibitor O 
of O 
diabetic O 
endothelial O 
dysfunction O 
. O 

have O 
conducted O 
a O 
phenotypic O 
screening O 
in O 
endothelial O 
cells O 
exposed O 
to O 
elevated O 
extracellular O 
glucose B-TRIVIAL 
( O 
an O 
in O 
vitro O 
model O 
of O 
hyperglycemia O 
) O 
to O 
identify O 
compounds O 
that O 
prevent O 
hyperglycemia O 
- O 
induced O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
formation O 
without O 
adversely O 
affecting O 
cell O 
viability O 
. O 
From O 
a O 
focused O 
library O 
of O 
> O 
6000 O 
clinically O 
used O 
drug O 
- O 
like O 
and O 
pharmacologically O 
active O 
compounds O 
, O 
several O 
classes O 
of O 
active O 
compounds O 
emerged O 
, O 
with O 
a O 
confirmed O 
hit O 
rate O 
of O 
< O 
0.5% O 
. O 
Follow O 
- O 
up O 
studies O 
focused O 
on O 
paroxetine B-TRIVIAL 
, O 
a O 
clinically O 
used O 
antidepressant O 
compound O 
that O 
has O 
not O 
been O 
previously O 
implicated O 
in O 
the O 
context O 
of O 
hyperglycemia O 
or O 
diabetes O 
. O 
Paroxetine B-TRIVIAL 
reduced O 
hyperglycemia O 
- O 
induced O 
mitochondrial O 
ROS O 
formation O 
, O 
mitochondrial O 
protein O 
oxidation O 
, O 
and O 
mitochondrial O 
and O 
nuclear O 
DNA O 
damage O 
, O 
without O 
interfering O 
with O 
mitochondrial O 
electron O 
transport O 
or O 
cellular O 
bioenergetics O 
. O 
The O 
ability O 
of O 
paroxetine B-TRIVIAL 
to O 
improve O 
hyperglycemic O 
endothelial O 
cell O 
injury O 
was O 
unique O 
among O 
serotonin B-TRIVIAL 
reuptake O 
blockers O 
and O 
can O 
be O 
attributed O 
to O 
its O 
antioxidant O 
effect O 
, O 
which O 
primarily O 
resides O 
within O 
its O 
sesamol B-TRIVIAL 
moiety O 
. O 
Paroxetine B-TRIVIAL 
maintained O 
the O 
ability O 
of O 
vascular O 
rings O 
to O 
respond O 
to O 
the O 
endothelium O 
- O 
dependent O 
relaxant O 
acetylcholine B-SYSTEMATIC 
, O 
both O 
during O 
in O 
vitro O 
hyperglycemia O 
and O 
ex O 
vivo O 
, O 
in O 
a O 
rat O 
model O 
of O 
streptozotocin B-TRIVIAL 
-induced O 
diabetes O 
. O 
Thus O 
, O 
the O 
current O 
work O 
identifies O 
a O 
novel O 
pharmacological O 
action O 
of O 
paroxetine B-TRIVIAL 
as O 
a O 
protector O 
of O 
endothelial O 
cells O 
against O 
hyperglycemic O 
injury O 
and O 
raises O 
the O 
potential O 
of O 
repurposing O 
of O 
this O 
drug O 
for O 
the O 
experimental O 
therapy O 
of O 
diabetic O 
cardiovascular O 
complications O 
. O 

of O 
antiproliferative O 
effects O 
of O 
metformine B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
on O 
estrogen B-FAMILY 
-induced O 
endometrial O 
hyperplasia O 
in O 
rats O 
. O 

has O 
been O 
shown O 
to O 
inhibit O 
the O 
growth O 
of O 
endometriotic O 
implants O 
, O 
and O 
reverse O 
endometrial O 
hyperplasia O 
when O 
combined O 
with O 
oral O 
contraceptive O 
in O 
a O 
case O 
report O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
compare O 
the O 
antiproliferative O 
effects O 
of O 
medroxyprogesterone B-TRIVIAL 
acetate I-TRIVIAL 
( O 
MPA B-ABBREVIATION 
) O 
, O 
and O 
metformin B-TRIVIAL 
in O 
oopherectomized O 
rat O 
endometrium O 
. O 
Forty O 
oopherectomized O 
Wistar-Albino O 
rats O 
were O 
used O 
, O 
and O 
assigned O 
to O 
receive O 
saline O 
, O 
17 B-SYSTEMATIC 
β I-SYSTEMATIC 
Estradiol I-SYSTEMATIC 
hemihydrate I-SYSTEMATIC 
( O 
4 O 
mg O 
/ O 
kg O 
) O 
, O 
17 B-SYSTEMATIC 
β I-SYSTEMATIC 
Estradiol I-SYSTEMATIC 
hemihydrate I-SYSTEMATIC 
( O 
4 O 
mg O 
/ O 
kg O 
) O 
and O 
metformin B-TRIVIAL 
( O 
50 O 
mg O 
/ O 
kg O 
) O 
, O 
17 B-SYSTEMATIC 
β I-SYSTEMATIC 
Estradiol I-SYSTEMATIC 
hemihydrate I-SYSTEMATIC 
( O 
4 O 
mg O 
/ O 
kg O 
) O 
and O 
MPA B-ABBREVIATION 
( O 
1 O 
mg O 
/ O 
day O 
) O 
for O 
14 O 
days O 
. O 
Histological O 
markers O 
of O 
uterotrophy O 
, O 
including O 
endometrial O 
height O 
, O 
luminal O 
ephitelial O 
cell O 
height O 
and O 
density O 
of O 
endometrial O 
glands O 
on O 
hysterectomy O 
speciments O 
were O 
quantified O 
for O 
each O 
specimen O 
. O 
Rats O 
treated O 
with O 
estradiol B-TRIVIAL 
had O 
significantly O 
increased O 
in O 
endometrial O 
height O 
, O 
endomerial O 
luminal O 
epithelial O 
height O 
and O 
endometrial O 
gland O 
densitiy O 
than O 
the O 
other O 
groups O 
. O 
Metformin B-TRIVIAL 
and O 
MPA B-SYSTEMATIC 
acetate I-SYSTEMATIC 
significantly O 
reduced O 
all O 
parameters O 
indicating O 
endometrial O 
hyperplasia O 
, O 
and O 
uterotrophy O 
with O 
respect O 
to O 
the O 
control O 
group O 
. O 
Antiproliferative O 
effects O 
of O 
metformin B-TRIVIAL 
, O 
and O 
MPA B-ABBREVIATION 
was O 
found O 
to O 
be O 
comparable O 
for O 
all O 
three O 
parameters O 
. O 
In O 
conclusion O 
, O 
metformin B-TRIVIAL 
attenuates O 
estrogen B-FAMILY 
-induced O 
endometrial O 
hyperplasia O 
in O 
ooferectomized O 
rats O 
to O 
the O 
same O 
degree O 
as O 
progesterone B-TRIVIAL 
. O 

acid I-SYSTEMATIC 
induced O 
neuronal O 
cells O 
death O 
through O 
oxidative O 
stress O 
- O 
mediated O 
p38-MAPK O 
activation O 
pathway O 
regulated O 
mitochondria O 
- O 
dependent O 
apoptotic O 
signals O 
. O 

acid I-SYSTEMATIC 
( O 
CA O 
) O 
, O 
a O 
toxic O 
chlorinated O 
analog O 
of O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
is O 
widely O 
used O 
in O 
chemical O 
industries O 
as O 
an O 
herbicide O 
, O 
detergent O 
, O 
and O 
disinfectant O 
, O 
and O 
chemical O 
intermediates O 
that O 
are O 
formed O 
during O 
the O 
synthesis O 
of O 
various O 
products O 
. O 
In O 
addition O 
, O 
CA O 
has O 
been O 
found O 
as O 
a O 
by O 
- O 
product O 
of O 
chlorination O 
disinfection O 
of O 
drinking O 
water O 
. O 
However O 
, O 
there O 
is O 
little O 
known O 
about O 
neurotoxic O 
injuries O 
of O 
CA O 
on O 
the O 
mammalian O 
, O 
the O 
toxic O 
effects O 
and O 
molecular O 
mechanisms O 
of O 
CA-induced O 
neuronal O 
cell O 
injury O 
are O 
mostly O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
cytotoxicity O 
of O 
CA O 
on O 
cultured O 
Neuro-2a O 
cells O 
and O 
investigated O 
the O 
possible O 
mechanisms O 
of O 
CA-induced O 
neurotoxicity O 
. O 
Treatment O 
of O 
Neuro-2a O 
cells O 
with O 
CA O 
significantly O 
reduced O 
the O 
number O 
of O 
viable O 
cells O 
( O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
with O 
a O 
range O 
from O 
0.1 O 
to O 
3mM O 
) O 
, O 
increased O 
the O 
generation O 
of O 
ROS O 
, O 
and O 
reduced O 
the O 
intracellular O 
levels O 
of O 
glutathione B-TRIVIAL 
depletion O 
. O 
CA O 
also O 
increased O 
the O 
number O 
of O 
sub-G1 O 
hypodiploid O 
cells O 
; O 
increased O 
mitochondrial O 
dysfunction O 
( O 
loss O 
of O 
MMP O 
, O 
cytochrome O 
c O 
release O 
, O 
and O 
accompanied O 
by O 
Bcl-2 O 
and O 
Mcl-1 O 
down O 
- O 
regulation O 
and O 
Bax O 
up O 
- O 
regulation O 
) O 
, O 
and O 
activated O 
the O 
caspase O 
cascades O 
activations O 
, O 
which O 
displayed O 
features O 
of O 
mitochondria O 
- O 
dependent O 
apoptosis O 
pathway O 
. O 
These O 
CA-induced O 
apoptosis O 
- O 
related O 
signals O 
were O 
markedly O 
prevented O 
by O 
the O 
antioxidant O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
. O 
Moreover O 
, O 
CA O 
activated O 
the O 
JNK O 
and O 
p38-MAPK O 
pathways O 
, O 
but O 
did O 
not O 
that O 
ERK1 O 
/ O 
2 O 
pathway O 
, O 
in O 
treated O 
Neuro-2a O 
cells O 
. O 
Pretreatment O 
with O 
NAC B-ABBREVIATION 
and O 
specific O 
p38-MAPK O 
inhibitor O 
( O 
SB203580 B-IDENTIFIER 
) O 
, O 
but O 
not O 
JNK O 
inhibitor O 
( O 
SP600125 B-IDENTIFIER 
) O 
effectively O 
abrogated O 
the O 
phosphorylation O 
of O 
p38-MAPK O 
and O 
attenuated O 
the O 
apoptotic O 
signals O 
( O 
including O 
: O 
decrease O 
in O 
cytotoxicity O 
, O 
caspase-3 O 
/ O 
-7 O 
activation O 
, O 
the O 
cytosolic O 
cytochrome O 
c O 
release O 
, O 
and O 
the O 
reversed O 
alteration O 
of O 
Bcl-2 O 
and O 
Bax O 
mRNA O 
) O 
in O 
CA O 
- O 
treated O 
Neuro-2a O 
cells O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
oxidative O 
stress O 
- O 
induced O 
p38-MAPK O 
activated O 
pathway O 
- O 
regulated O 
mitochondria O 
- O 
dependent O 
apoptosis O 
plays O 
an O 
important O 
role O 
in O 
CA-caused O 
neuronal O 
cell O 
death O 
. O 

by O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
of O 
sterols B-FAMILY 
and O 
oxysterols B-FAMILY 
in O 
brain O 
of O 
the O 
newborn O 
Dhcr7(Δ3-5 O 
/ O 
T93M O 
) O 
mouse O 
: O 
A O 
model O 
of O 
Smith-Lemli-Opitz O 
syndrome O 
. O 

this O 
study O 
the O 
sterol B-FAMILY 
and O 
oxysterol B-FAMILY 
profile O 
of O 
newborn O 
brain O 
from O 
the O 
Dhcr7(Δ3-5 O 
/ O 
T93M O 
) O 
mouse O 
model O 
of O 
Smith-Lemli-Opitz O 
syndrome O 
( O 
SLOS O 
) O 
has O 
been O 
investigated O 
. O 
This O 
is O 
a O 
viable O 
mouse O 
model O 
which O 
is O 
compound O 
heterozygous O 
containing O 
one O 
nan O 
allele O 
and O 
one O 
T93M O 
mutation O 
on O 
Dhcr7 O 
. O 
We O 
find O 
the O 
SLOS O 
mouse O 
has O 
reduced O 
levels O 
of O 
cholesterol B-TRIVIAL 
and O 
desmosterol B-TRIVIAL 
and O 
increased O 
levels O 
of O 
7- B-MULTIPLE 
and I-MULTIPLE 
8-dehydrocholesterol I-MULTIPLE 
and O 
of O 
7- B-MULTIPLE 
and I-MULTIPLE 
8-dehydrodesmosterol I-MULTIPLE 
in O 
brain O 
compared O 
to O 
the O 
wild O 
type O 
. O 
The O 
profile O 
of O 
enzymatically O 
formed O 
oxysterols B-FAMILY 
in O 
the O 
SLOS O 
mouse O 
resembles O 
that O 
in O 
the O 
wild O 
type O 
but O 
the O 
level O 
of O 
24S-hydroxycholesterol B-SYSTEMATIC 
, O 
the O 
dominating O 
cholesterol B-TRIVIAL 
metabolite O 
, O 
is O 
reduced O 
in O 
a O 
similar O 
proportion O 
to O 
that O 
of O 
cholesterol B-TRIVIAL 
. O 
A O 
number O 
of O 
oxysterols B-FAMILY 
abundant O 
in O 
the O 
SLOS O 
mouse O 
are O 
probably O 
derived O 
from O 
7-dehydrocholesterol B-SYSTEMATIC 
, O 
however O 
, O 
the O 
mechanism O 
of O 
their O 
formation O 
is O 
unclear O 
. O 

of O 
Primary O 
Substituted O 
Hydrocarbons B-FAMILY 
onto O 
Solid O 
Gallium B-SYSTEMATIC 
Substrates O 
. O 

of O 
a O 
series O 
of O 
primary O 
substituted O 
hydrocarbons B-FAMILY 
( O 
RX O 
; O 
C18H37PO(OH)2 B-FORMULA 
( O 
ODPA B-ABBREVIATION 
) O 
, O 
C17H35COOH B-FORMULA 
, O 
C18H37OH B-FORMULA 
, O 
C18H37NH2 B-FORMULA 
, O 
and O 
C18H37SH B-FORMULA 
) O 
onto O 
solid O 
gallium B-SYSTEMATIC 
substrates O 
with O 
and O 
without O 
UV/ O 
ozone B-TRIVIAL 
treatment O 
was O 
studied O 
using O 
contact O 
angle O 
goniometry O 
, O 
spectroscopic O 
ellipsometry O 
, O 
and O 
cyclic O 
voltammetry O 
( O 
CV O 
) O 
. O 
UV/ O 
ozone B-TRIVIAL 
treatment O 
offered O 
a O 
hydrophilic O 
surface O 
( O 
water O 
contact O 
angle O 
(θ(water)) O 
less O 
than O 
10° O 
) O 
, O 
reflecting O 
the O 
formation O 
of O 
a O 
surface O 
oxide B-SYSTEMATIC 
layer O 
with O 
the O 
maximum O 
thickness O 
of O 
ca O 
. O 
1 O 
nm O 
and O 
possibly O 
the O 
removal O 
of O 
surface O 
contaminants O 
. O 
Upon O 
immersion O 
in O 
a O 
toluene B-TRIVIAL 
solution O 
of O 
a O 
RX O 
, O 
θ(water) O 
increased O 
due O 
to O 
adsorption O 
of O 
the O 
RX O 
onto O 
gallium B-SYSTEMATIC 
substrates O 
. O 
In O 
particular O 
, O 
UV/ O 
ozone B-TRIVIAL 
-treated O 
gallium B-SYSTEMATIC 
substrates O 
( O 
UV- O 
Ga B-FORMULA 
) O 
immersed O 
in O 
an O 
ODPA B-ABBREVIATION 
solution O 
exhibited O 
θ(water) O 
close O 
to O 
105° O 
. O 
The O 
ellipsometric O 
thickness O 
of O 
the O 
adsorbed O 
ODPA B-ABBREVIATION 
layer O 
was O 
ca O 
. O 
2.4 O 
nm O 
, O 
and O 
CV O 
data O 
measured O 
in O 
an O 
acetonitrile B-SYSTEMATIC 
solution O 
showed O 
significant O 
inhibition O 
of O 
redox O 
reaction O 
on O 
the O 
substrate O 
surface O 
. O 
These O 
results O 
indicate O 
the O 
formation O 
of O 
a O 
densely O 
packed O 
ODPA B-ABBREVIATION 
monolayer O 
on O 
UV- O 
Ga B-FORMULA 
. O 
The O 
coverage O 
of O 
a O 
C17H35COOH B-FORMULA 
layer O 
adsorbed O 
onto O 
UV- O 
Ga B-FORMULA 
was O 
lower O 
, O 
as O 
shown O 
by O 
smaller O 
θ(water) O 
( O 
ca O 
. O 
99° O 
) O 
, O 
smaller O 
ellipsometric O 
thickness O 
( O 
ca O 
. O 
1.3 O 
nm O 
) O 
, O 
and O 
smaller O 
electrode O 
reaction O 
inhibition O 
. O 
Adsorption O 
of O 
the O 
other O 
RX O 
onto O 
UV- O 
Ga B-FORMULA 
was O 
weaker O 
, O 
as O 
indicated O 
by O 
smaller O 
θ(water) O 
( O 
82°-92° O 
) O 
. O 
ODPA B-ABBREVIATION 
did O 
not O 
strongly O 
adsorb O 
onto O 
UV O 
- O 
untreated O 
gallium B-SYSTEMATIC 
substrates O 
, O 
suggesting O 
that O 
the O 
ODPA B-ABBREVIATION 
adsorption O 
mainly O 
originates O 
from O 
hydrogen B-SYSTEMATIC 
bond O 
interaction O 
of O 
a O 
phosphonate B-SYSTEMATIC 
group O 
with O 
surface O 
oxide B-SYSTEMATIC 
. O 
These O 
results O 
will O 
provide O 
a O 
means O 
for O 
controlling O 
the O 
surface O 
properties O 
of O 
oxide B-SYSTEMATIC 
-coated O 
gallium B-SYSTEMATIC 
that O 
play O 
an O 
essential O 
role O 
in O 
monolayer O 
conductivity O 
measurements O 
and O 
electroanalytical O 
applications O 
. O 

assessment O 
of O 
pure O 
, O 
hybrid O 
, O 
meta O 
, O 
and O 
hybrid O 
- O 
meta O 
GGA O 
density O 
functional O 
theory O 
methods O 
for O 
open O 
- O 
shell O 
systems O 
: O 
the O 
case O 
of O 
the O 
nonheme O 
iron B-SYSTEMATIC 
enzyme O 
8R-LOX O 
. O 

of O 
metastability O 
in O 
amorphous O 
ices O 
: O 
2H B-FORMULA 
-NMR O 
relaxation O 
. O 

high O 
- O 
frequency O 
reorientation O 
dynamics O 
of O 
O-(2)H B-FORMULA 
bonds O 
is O 
investigated O 
in O 
various O 
amorphous O 
ices O 
including O 
eHDA O 
( O 
expanded O 
high O 
density O 
amorphous O 
ice O 
) O 
, O 
LDA-II O 
( O 
low O 
density O 
amorphous O 
ice O 
II O 
) O 
and O 
HGW O 
( O 
hyperquenched O 
glassy O 
water O 
) O 
using O 
(2)H B-FORMULA 
-NMR O 
spin O 
- O 
lattice O 
relaxation O 
as O 
a O 
local O 
probe O 
. O 
Both O 
low O 
density O 
forms O 
, O 
HGW O 
and O 
LDA-II O 
, O 
show O 
similar O 
spin O 
- O 
lattice O 
relaxation O 
but O 
differ O 
in O 
the O 
thermal O 
stability O 
with O 
respect O 
to O 
the O 
transition O 
into O 
crystalline O 
cubic O 
ice O 
I(c) O 
. O 
HGW O 
already O 
transforms O 
slightly O 
above O 
135 O 
K O 
whereas O 
LDA-II O 
crystallizes O 
at O 
150 O 
K O 
. O 
eHDA O 
is O 
distinguishable O 
from O 
other O 
high O 
density O 
amorphous O 
ices O 
in O 
its O 
thermal O 
stability O 
and O 
spin O 
- O 
lattice O 
relaxation O 
. O 
Its O 
relaxation O 
times O 
are O 
much O 
larger O 
compared O 
to O 
those O 
of O 
VHDA O 
( O 
very O 
high O 
density O 
amorphous O 
ice O 
) O 
and O 
uHDA O 
( O 
unrelaxed O 
high O 
density O 
amorphous O 
ice O 
) O 
. O 
eHDA O 
does O 
not O 
show O 
annealing O 
effects O 
, O 
transforms O 
sharply O 
into O 
LDA-II O 
above O 
123 O 
K O 
and O 
provides O 
higher O 
thermal O 
stability O 
as O 
compared O 
to O 
other O 
high O 
density O 
forms O 
. O 

Expression O 
in O 
the O 
Subfornical O 
Organ O 
Enhances O 
the O 
Sensitivity O 
of O 
Nax O 
, O 
the O 
Brain O 
Sodium B-SYSTEMATIC 
-Level O 
Sensor O 
, O 
to O 
Suppress O 
Salt O 
Intake O 
. O 

homeostasis O 
is O 
essential O 
to O 
survival O 
, O 
but O 
brain O 
mechanisms O 
for O 
salt O 
- O 
intake O 
control O 
have O 
not O 
been O 
fully O 
elucidated O 
. O 
Here O 
, O 
we O 
found O 
that O 
the O 
sensitivity O 
of O 
Nax O 
channels O 
to O 
[ O 
Na(+) B-FORMULA 
]o O 
is O 
dose O 
- O 
dependently O 
enhanced O 
by O 
endothelin-3 O 
( O 
ET-3 O 
) O 
. O 
Nax O 
channels O 
began O 
to O 
open O 
when O 
[ O 
Na(+) B-FORMULA 
]o O 
exceeded O 
∼150 O 
mM O 
without O 
ET-3 O 
, O 
but O 
opened O 
fully O 
at O 
a O 
physiological O 
[ O 
Na(+) B-FORMULA 
]o O 
( O 
135-145 O 
mM O 
) O 
with O 
1 O 
nM O 
ET-3 O 
. O 
Importantly O 
, O 
ET-3 O 
was O 
expressed O 
in O 
the O 
subfornical O 
organ O 
( O 
SFO O 
) O 
along O 
with O 
Nax O 
, O 
and O 
the O 
level O 
was O 
robustly O 
increased O 
by O 
dehydration O 
. O 
Pharmacological O 
experiments O 
revealed O 
that O 
endothelin O 
receptor O 
B O 
( O 
ETBR O 
) O 
signaling O 
is O 
involved O 
in O 
this O 
modulation O 
of O 
Nax O 
gating O 
through O 
protein O 
kinase O 
C O 
and O 
ERK1 O 
/ O 
2 O 
activation O 
. O 
ETBR O 
agonists O 
increased O 
the O 
firing O 
rate O 
of O 
GABAergic O 
neurons O 
via O 
lactate B-FAMILY 
in O 
the O 
SFO O 
, O 
and O 
an O 
ETBR O 
antagonist O 
attenuated O 
salt O 
aversion O 
during O 
dehydration O 
. O 
These O 
results O 
indicate O 
that O 
ET-3 O 
expression O 
in O 
the O 
SFO O 
is O 
tightly O 
coupled O 
with O 
body O 
- O 
fluid O 
homeostasis O 
through O 
modulation O 
of O 
the O 
[ O 
Na(+) B-FORMULA 
]o O 
sensitivity O 
of O 
Nax O 
. O 

( O 
ECT O 
) O 
is O 
a O 
physical O 
technique O 
that O 
allows O 
cytotoxic O 
molecules O 
to O 
be O 
efficiently O 
released O 
in O 
tumor O 
cells O 
by O 
inducing O 
transient O 
cell O 
plasma O 
membrane O 
permeabilization O 
. O 
The O 
main O 
antitumoral O 
drugs O 
used O 
in O 
ECT O 
are O 
nonpermeant O 
bleomycin B-FAMILY 
and O 
low O 
permeant O 
cisplatin B-TRIVIAL 
. O 
The O 
method O 
is O 
nowadays O 
applied O 
in O 
clinics O 
as O 
a O 
palliative O 
treatment O 
. O 
In O 
order O 
to O 
improve O 
it O 
, O 
we O 
took O 
advantage O 
of O 
a O 
human O 
3D O 
multicellular O 
tumor O 
spheroid O 
as O 
a O 
model O 
of O 
tumor O 
to O 
visually O 
and O 
molecularly O 
assess O 
the O 
effect O 
of O 
ECT O 
. O 
We O 
used O 
bleomycin B-FAMILY 
and O 
cisplatin B-TRIVIAL 
to O 
confirm O 
its O 
relevance O 
and O 
doxorubicin B-TRIVIAL 
to O 
show O 
its O 
potential O 
to O 
screen O 
new O 
antitumor O 
drug O 
candidates O 
for O 
ECT O 
. O 
Confocal O 
microscopy O 
was O 
used O 
to O 
visualize O 
the O 
topological O 
distribution O 
of O 
permeabilized O 
cells O 
in O 
3D O 
spheroids O 
subjected O 
to O 
electric O 
pulses O 
. O 
Our O 
results O 
revealed O 
that O 
all O 
cells O 
were O 
efficiently O 
permeabilized O 
, O 
whatever O 
their O 
localization O 
in O 
the O 
spheroid O 
, O 
even O 
those O 
in O 
the O 
core O 
. O 
The O 
combination O 
of O 
antitumor O 
drugs O 
and O 
electric O 
pulses O 
( O 
ECT O 
) O 
led O 
to O 
changes O 
in O 
spheroid O 
macroscopic O 
morphology O 
and O 
cell O 
cohesion O 
, O 
to O 
tumor O 
spheroid O 
growth O 
arrest O 
and O 
finally O 
to O 
its O 
complete O 
apoptosis O 
- O 
mediated O 
dislocation O 
, O 
mimicking O 
previously O 
observed O 
in O 
vivo O 
situations O 
. O 
Taken O 
together O 
, O 
these O 
results O 
indicate O 
that O 
the O 
spheroid O 
model O 
is O 
relevant O 
for O 
the O 
study O 
and O 
optimization O 
of O 
electromediated O 
drug O 
delivery O 
protocols O 
. O 

constitutive O 
active/ O 
androstane B-TRIVIAL 
receptor O 
( O 
CAR O 
) O 
regulates O 
hepatic O 
drug O 
metabolism O 
by O 
activating O 
genes O 
such O 
as O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
and O 
certain O 
transferases O 
. O 
p38 O 
mitogen O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
is O 
highly O 
activated O 
in O 
human O 
primary O 
hepatocytes O 
but O 
barely O 
in O 
human O 
hepatoma O 
cell O 
- O 
lines O 
including O 
HepG2 O 
cells O 
. O 
Liganded-CAR O 
induced O 
CYP2B6 O 
mRNA O 
in O 
human O 
primary O 
hepatocytes O 
far O 
more O 
effectively O 
than O 
in O 
HepG2 O 
cells O 
ectopically O 
expressing O 
CAR O 
. O 
Here O 
, O 
we O 
have O 
now O 
found O 
that O 
activation O 
of O 
p38 O 
MAPK O 
by O 
anisomycin B-TRIVIAL 
potentiated O 
induction O 
of O 
CYP2B6 O 
mRNA O 
by O 
CAR O 
ligand O 
in O 
HepG2 O 
cells O 
to O 
levels O 
observed O 
in O 
ligand O 
- O 
treated O 
human O 
primary O 
hepatocytes O 
. O 
siRNA O 
knockdown O 
of O 
p38 O 
MAPK O 
abrogated O 
the O 
ability O 
of O 
anisomycin B-TRIVIAL 
to O 
synergistically O 
induce O 
CYP2B6 O 
mRNA O 
. O 
In O 
addition O 
to O 
CYP2B6 O 
, O 
anisomycin B-TRIVIAL 
co O 
- O 
treatment O 
potentiated O 
an O 
increase O 
in O 
CYP2A7 O 
and O 
CYP2C9 O 
mRNAs O 
but O 
not O 
CYP3A4 O 
or O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
1A1 O 
mRNAs O 
. O 
Thus O 
, O 
activated O 
p38 O 
MAPK O 
is O 
required O 
for O 
liganded-CAR O 
to O 
selectively O 
activate O 
a O 
set O 
of O 
genes O 
that O 
encode O 
drug O 
metabolizing O 
enzymes O 
. O 
Our O 
present O 
results O 
suggest O 
that O 
CAR O 
- O 
mediated O 
induction O 
of O 
these O 
enzymes O 
can O 
not O 
be O 
understood O 
by O 
ligand O 
binding O 
alone O 
because O 
the O 
specificity O 
and O 
magnitude O 
of O 
induction O 
are O 
co O 
- O 
determined O 
by O 
a O 
given O 
cell O 
signaling O 
such O 
as O 
p38 O 
MAPK O 
; O 
both O 
physiological O 
and O 
pathophysiological O 
states O 
of O 
cell O 
signaling O 
may O 
have O 
a O 
strong O 
impact O 
in O 
hepatic O 
drug O 
metabolizing O 
capability O 
during O 
therapeutic O 
treatments O 
. O 

and O 
renal O 
regional O 
hemodynamic O 
effects O 
of O 
urotensin B-TRIVIAL 
II I-TRIVIAL 
in O 
neonatal O 
pigs O 
. O 

expression O 
of O 
the O 
peptide O 
hormone O 
urotensin B-TRIVIAL 
II I-TRIVIAL 
( O 
UII B-ABBREVIATION 
) O 
and O 
its O 
receptor O 
( O 
UTR O 
) O 
are O 
dependent O 
on O 
kidney O 
maturation O 
and O 
anatomical O 
regions O 
. O 
However O 
, O 
renal O 
regional O 
hemodynamic O 
effects O 
of O 
UII B-ABBREVIATION 
in O 
neonates O 
are O 
unclear O 
. O 
Here O 
, O 
we O 
investigated O 
regional O 
hemodynamic O 
responses O 
to O 
acute O 
intrarenal O 
arterial O 
administration O 
of O 
UII B-ABBREVIATION 
in O 
newborn O 
pigs O 
. O 
Western O 
immunoblotting O 
and O 
immunofluorescence O 
confirmed O 
UTR O 
expression O 
and O 
membrane O 
localization O 
in O 
newborn O 
pig O 
renal O 
afferent O 
arterioles O 
and O 
afferent O 
arteriolar O 
smooth O 
muscle O 
cells O 
respectively O 
. O 
Intrarenal O 
arterial O 
bolus O 
injections O 
of O 
human O 
UII O 
( O 
hUII O 
; O 
1-100 O 
ng O 
/ O 
kg O 
) O 
resulted O 
in O 
a O 
dose O 
- O 
dependent O 
decrease O 
in O 
total O 
renal O 
blood O 
flow O 
( O 
RBF O 
) O 
and O 
an O 
increase O 
in O 
mean O 
arterial O 
pressure O 
( O 
MAP O 
) O 
and O 
renal O 
vascular O 
resistance O 
( O 
RVR O 
) O 
in O 
newborn O 
pigs O 
. O 
Moreover O 
, O 
hUII O 
dose O 
dependently O 
reduced O 
cortical O 
blood O 
flow O 
( O 
CBF O 
) O 
but O 
increased O 
medullary O 
blood O 
flow O 
( O 
MBF O 
) O 
in O 
the O 
piglets O 
. O 
hUII-induced O 
MAP O 
elevation O 
and O 
hemodynamic O 
changes O 
were O 
inhibited O 
by O 
urantide B-TRIVIAL 
, O 
a O 
UTR O 
antagonist O 
, O 
but O 
not O 
losartan B-TRIVIAL 
, O 
a O 
type O 
1 O 
angiotensin O 
II O 
receptor O 
antagonist O 
. O 
U-73122 B-IDENTIFIER 
, O 
a O 
phospholipase O 
C O 
( O 
PLC O 
) O 
inhibitor O 
, O 
and O 
2-aminoethoxydiphenyl B-SYSTEMATIC 
borate I-SYSTEMATIC 
, O 
an O 
inositol B-SYSTEMATIC 
1,4,5 I-SYSTEMATIC 
trisphosphate I-SYSTEMATIC 
( O 
IP3 O 
) O 
receptor O 
antagonist O 
, O 
attenuated O 
hUII-induced O 
MAP O 
and O 
RVR O 
elevations O 
, O 
RBF O 
and O 
CBF O 
reductions O 
, O 
but O 
not O 
MBF O 
increase O 
. O 
These O 
findings O 
indicate O 
that O 
intrarenal O 
arterial O 
administration O 
of O 
hUII O 
elevates O 
blood O 
pressure O 
and O 
induces O 
region O 
- O 
selective O 
renal O 
hemodynamic O 
changes O 
in O 
newborn O 
pigs O 
. O 
Our O 
data O 
also O 
suggest O 
that O 
the O 
PLC O 
/ O 
IP3 O 
signaling O 
pathway O 
contributes O 
to O 
hUII-induced O 
alterations O 
in O 
MAP O 
, O 
RBF O 
, O 
RVR O 
, O 
and O 
CBF O 
but O 
not O 
MBF O 
in O 
newborn O 
pigs O 
. O 

model O 
parametrization O 
of O 
hydrogen B-SYSTEMATIC 
bonds O 
and O 
stacking O 
interactions O 
of O 
RNA O 
from O 
melting O 
temperatures O 
. O 

about O 
molecular O 
interactions O 
in O 
DNA O 
can O 
be O 
obtained O 
from O 
experimental O 
melting O 
temperature O 
data O 
by O 
using O 
mesoscopic O 
statistical O 
physics O 
models O 
. O 
Here O 
, O 
we O 
extend O 
the O 
technique O 
to O 
RNA O 
and O 
show O 
that O 
the O 
new O 
parameters O 
correctly O 
reproduce O 
known O 
properties O 
such O 
as O 
the O 
stronger O 
hydrogen B-SYSTEMATIC 
bonds O 
of O 
AU O 
base O 
pairs O 
. O 
We O 
also O 
were O 
able O 
to O 
calculate O 
a O 
complete O 
set O 
of O 
elastic O 
constants O 
for O 
all O 
10 O 
irreducible O 
combinations O 
of O 
nearest O 
neighbours O 
( O 
NNs O 
) O 
. O 
We O 
believe O 
that O 
this O 
is O 
particularly O 
useful O 
as O 
experimentally O 
derived O 
information O 
about O 
RNA O 
elasticity O 
is O 
relatively O 
scarce O 
. O 
The O 
melting O 
temperature O 
prediction O 
using O 
the O 
present O 
model O 
improves O 
over O 
those O 
from O 
traditional O 
NN O 
model O 
, O 
providing O 
thus O 
an O 
alternative O 
way O 
to O 
calculate O 
these O 
temperatures O 
for O 
RNA O 
. O 
Additionally O 
, O 
we O 
calculated O 
the O 
site O 
- O 
dependent O 
base O 
pair O 
oscillation O 
to O 
explain O 
why O 
RNA O 
shows O 
larger O 
oscillation O 
amplitudes O 
despite O 
having O 
stronger O 
AU O 
hydrogen B-SYSTEMATIC 
bonds O 
. O 

conducted O 
a O 
90-day O 
feeding O 
study O 
to O 
investigate O 
subchronic O 
toxicity O 
of O 
rice O 
hull O 
fiber O 
. O 
Sprague O 
Dawley O 
rats O 
were O 
randomly O 
divided O 
into O 
four O 
groups O 
; O 
each O 
received O 
a O 
diet O 
containing O 
0% O 
, O 
2.5% O 
, O 
3.75% O 
and O 
5.0% O 
( O 
w O 
/ O 
w O 
) O 
rice O 
hull O 
fiber O 
for O 
90days O 
. O 
Clinical O 
observations O 
were O 
carried O 
out O 
daily O 
, O 
with O 
weekly O 
measurements O 
of O 
body O 
weight O 
and O 
food O 
consumption O 
. O 
We O 
performed O 
ophthalmic O 
and O 
histological O 
examinations O 
at O 
termination O 
. O 
Blood O 
and O 
urine O 
samples O 
were O 
collected O 
to O 
measure O 
hematology O 
and O 
clinical O 
chemistry O 
parameters O 
. O 
No O 
mortality O 
, O 
ophthalmic O 
abnormalities O 
, O 
or O 
adverse O 
treatment O 
- O 
related O 
effects O 
were O 
seen O 
during O 
clinical O 
observations O 
, O 
hematological O 
tests O 
, O 
or O 
analyses O 
of O 
urine O 
. O 
Macroscopic O 
or O 
microscopic O 
examinations O 
of O 
organs O 
revealed O 
no O 
treatment O 
related O 
abnormalities O 
. O 
The O 
only O 
treatment O 
related O 
significant O 
changes O 
were O 
reduced O 
concentrations O 
of O 
fasting O 
blood O 
glucose B-TRIVIAL 
( O 
up O 
to O 
17.6% O 
) O 
and O 
cholesterol B-TRIVIAL 
( O 
up O 
to O 
22.0% O 
) O 
, O 
typical O 
benefits O 
of O 
dietary O 
fiber O 
, O 
in O 
males O 
treated O 
with O 
3.75 O 
and O 
5% O 
rice O 
hull O 
fiber O 
. O 
The O 
no O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
- O 
level O 
( O 
NOAEL O 
) O 
for O 
rice O 
hull O 
fiber O 
was O 
5.0% O 
for O 
both O 
genders O 
( O 
females O 
, O 
3.80g O 
/ O 
kg O 
body O 
weight O 
/ O 
day O 
; O 
males O 
, O 
4.11g O 
/ O 
kg O 
body O 
weight O 
/ O 
day O 
) O 
. O 

cliff O 
avoidance O 
reaction O 
in O 
dopamine B-TRIVIAL 
transporter O 
knockout O 
mice O 
. O 

: O 
Impulsivity O 
is O 
a O 
key O 
feature O 
of O 
disorders O 
that O 
include O 
attention O 
- O 
deficit O 
/ O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
. O 
The O 
cliff O 
avoidance O 
reaction O 
( O 
CAR O 
) O 
assesses O 
maladaptive O 
impulsive O 
rodent O 
behavior O 
. O 
Dopamine B-TRIVIAL 
transporter O 
knockout O 
( O 
DAT-KO O 
) O 
mice O 
display O 
features O 
of O 
ADHD O 
and O 
are O 
candidates O 
in O 
which O 
to O 
test O 
other O 
impulsive O 
phenotypes O 
. O 
OBJECTIVES O 
: O 
Impulsivity O 
of O 
DAT-KO O 
mice O 
was O 
assessed O 
in O 
the O 
CAR O 
paradigm O 
. O 
For O 
comparison O 
, O 
attentional O 
deficits O 
were O 
also O 
assessed O 
in O 
prepulse O 
inhibition O 
( O 
PPI O 
) O 
in O 
which O 
DAT-KO O 
mice O 
have O 
been O 
shown O 
to O 
exhibit O 
impaired O 
sensorimotor O 
gating O 
. O 
RESULTS O 
: O 
DAT-KO O 
mice O 
exhibited O 
a O 
profound O 
CAR O 
impairment O 
compared O 
to O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mice O 
. O 
As O 
expected O 
, O 
DAT-KO O 
mice O 
showed O 
PPI O 
deficits O 
compared O 
to O 
WT O 
mice O 
. O 
Furthermore O 
, O 
the O 
DAT-KO O 
mice O 
with O 
the O 
most O 
impaired O 
CAR O 
exhibited O 
the O 
most O 
severe O 
PPI O 
deficits O 
. O 
Treatment O 
with O 
methylphenidate B-SYSTEMATIC 
or O 
nisoxetine B-TRIVIAL 
ameliorated O 
CAR O 
impairments O 
in O 
DAT-KO O 
mice O 
. O 
CONCLUSION O 
: O 
These O 
results O 
suggest O 
that O 
DAT-KO O 
mice O 
exhibit O 
impulsive O 
CAR O 
behavior O 
that O 
correlates O 
with O 
their O 
PPI O 
deficits O 
. O 
Blockade O 
of O 
monoamine B-FAMILY 
transporters O 
, O 
especially O 
the O 
norepinephrine B-TRIVIAL 
transporter O 
( O 
NET O 
) O 
in O 
the O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
, O 
may O 
contribute O 
to O 
pharmacological O 
improvement O 
of O 
impulsivity O 
in O 
these O 
mice O 
. O 

, O 
pharmacodynamics O 
and O 
clinical O 
use O 
of O 
valganciclovir B-TRIVIAL 
in O 
newborns O 
with O 
symptomatic O 
congenital O 
cytomegalovirus O 
infection O 
. O 

cytomegalovirus O 
infection O 
is O 
the O 
most O 
common O 
cause O 
of O 
nonhereditary O 
sensorineural O 
hearing O 
loss O 
and O 
an O 
important O 
cause O 
of O 
psychomotor O 
retardation O 
. O 
Newborns O 
suffering O 
from O 
symptomatic O 
congenital O 
cytomegalovirus O 
infection O 
have O 
been O 
typically O 
treated O 
with O 
i.v O 
. O 
ganciclovir B-TRIVIAL 
( O 
GCV B-ABBREVIATION 
) O 
. O 
Nowadays O 
valganciclovir B-TRIVIAL 
( O 
V-GCV B-ABBREVIATION 
) O 
, O 
a O 
mono-valyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
pro O 
- O 
drug O 
of O 
GCV B-ABBREVIATION 
, O 
is O 
available O 
as O 
an O 
oral O 
syrup O 
. O 
The O 
existing O 
literature O 
demonstrated O 
that O 
V-GCV B-ABBREVIATION 
is O 
well O 
absorbed O 
from O 
the O 
gastrointestinal O 
tract O 
and O 
is O 
rapidly O 
converted O 
into O 
GCV B-ABBREVIATION 
in O 
the O 
intestinal O 
wall O 
and O 
liver O 
. O 
The O 
mechanism O 
of O 
antiviral O 
action O 
is O 
the O 
same O 
that O 
has O 
been O 
described O 
for O 
GCV B-ABBREVIATION 
. O 
All O 
these O 
characteristics O 
make O 
this O 
formulation O 
particularly O 
suitable O 
for O 
the O 
symptomatic O 
congenitally O 
infected O 
newborns O 
. O 
In O 
neonates O 
, O 
V-GCV B-ABBREVIATION 
oral O 
formulation O 
proved O 
stable O 
and O 
constant O 
GVC O 
plasma O 
concentrations O 
, O 
in O 
the O 
suggested O 
therapeutic O 
range O 
. O 
The O 
syrup O 
demonstrated O 
to O 
be O 
clinically O 
effective O 
and O 
well O 
tolerated O 
and O 
to O 
be O 
appropriate O 
for O 
a O 
prolonged O 
post O 
- O 
discharge O 
therapy O 
avoiding O 
the O 
discomfort O 
of O 
hospitalization O 
, O 
reducing O 
the O 
risk O 
for O 
nosocomial O 
infections O 
and O 
decreasing O 
the O 
cost O 
for O 
the O 
National O 
Health O 
Service O 
. O 
This O 
article O 
reviews O 
all O 
the O 
available O 
literature O 
about O 
V-GCV B-ABBREVIATION 
syrup O 
in O 
the O 
treatment O 
of O 
newborns O 
and O 
infants O 
with O 
congenital O 
CMV O 
infection O 
with O 
the O 
regard O 
to O 
pharmacokinetics O 
, O 
pharmacodynamic O 
properties O 
and O 
clinical O 
use O 
, O 
focussing O 
on O 
new O 
data O 
and O 
on O 
our O 
experience O 
. O 

conducted O 
a O 
large O 
scale O 
investigation O 
of O 
the O 
bioaccessibility O 
of O 
12 O 
trace O 
elements O 
from O 
11 O 
marine O 
mollusc O 
species O 
( O 
scallop O 
, O 
oyster O 
, O 
clam O 
, O 
abalone O 
, O 
snail O 
, O 
and O 
mussel O 
) O 
collected O 
from O 
five O 
locations O 
in O 
Chinese O 
coastal O 
waters O 
. O 
The O 
bioaccessibility O 
of O 
all O 
the O 
12 O 
trace O 
elements O 
was O 
generally O 
high O 
, O 
with O 
the O 
average O 
values O 
ranging O 
from O 
42.5% O 
to O 
90.7% O 
. O 
The O 
highest O 
bioaccessibility O 
was O 
observed O 
for O 
As B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Ni B-FORMULA 
and O 
Se B-FORMULA 
, O 
and O 
the O 
lowest O 
for O 
Fe B-FORMULA 
, O 
Co B-FORMULA 
and O 
Pb B-FORMULA 
. O 
Steaming O 
decreased O 
the O 
bioaccessibility O 
of O 
all O 
12 O 
trace O 
elements O 
and O 
thus O 
diminished O 
their O 
risks O 
. O 
No O 
correlation O 
was O 
observed O 
between O 
the O 
bioaccessibility O 
and O 
the O 
total O 
concentration O 
of O 
the O 
12 O 
elements O 
. O 
However O 
, O 
there O 
was O 
a O 
significant O 
correlation O 
between O 
the O 
bioaccessibility O 
of O 
the O 
12 O 
elements O 
and O 
their O 
subcellular O 
distribution O 
. O 
For O 
most O 
trace O 
elements O 
, O 
a O 
significantly O 
negative O 
relationship O 
was O 
demonstrated O 
between O 
the O 
bioaccessibility O 
and O 
the O 
elemental O 
partitioning O 
in O 
the O 
metal O 
- O 
rich O 
granule O 
fraction O 
or O 
in O 
the O 
cellular O 
debris O 
fraction O 
, O 
and O 
a O 
significantly O 
positive O 
correlation O 
was O 
observed O 
between O 
the O 
bioaccessibility O 
and O 
the O 
elemental O 
partitioning O 
in O 
the O 
heat O 
- O 
stable O 
protein O 
fraction O 
and O 
in O 
the O 
trophically O 
available O 
fraction O 
. O 
Hence O 
, O 
the O 
elemental O 
subcellular O 
distribution O 
, O 
especially O 
the O 
elemental O 
partitioning O 
in O 
the O 
trophically O 
available O 
fraction O 
, O 
might O 
be O 
a O 
good O 
predictor O 
of O 
the O 
bioaccessibility O 
and O 
risks O 
of O 
trace O 
elements O 
in O 
molluscs O 
. O 

and O 
antioxidant O 
activities O 
of O 
thymoquinone B-TRIVIAL 
and O 
limonene B-TRIVIAL 
in O 
atherogenic O 
suspension O 
fed O 
rats O 
. O 

hypolipidemic O 
and O 
antioxidant O 
actions O 
of O 
thymoquinone B-TRIVIAL 
( O 
TQ O 
) O 
and O 
limonene B-TRIVIAL 
( O 
LMN B-ABBREVIATION 
) O 
were O 
investigated O 
by O 
giving O 
1 O 
ml O 
of O 
10mg O 
TQ O 
or O 
200mg O 
LMN B-ABBREVIATION 
suspension O 
, O 
by O 
gavage O 
in O 
two O 
equal O 
doses O 
( O 
morning O 
and O 
evening O 
) O 
of O 
0.5 O 
ml O 
each O 
for O 
30 O 
days O 
, O 
in O 
rats O 
, O 
fed O 
an O 
atherogenic O 
suspension O 
. O 
These O 
compounds O 
effectively O 
ameliorated O 
all O 
the O 
altered O 
cardiovascular O 
risk O 
parameters O 
via O 
a O 
reduction O 
in O 
HMG-CoA B-ABBREVIATION 
reductase O 
activity O 
, O 
along O 
with O 
an O 
increase O 
in O 
arylesterase O 
activity O 
. O 
The O 
compounds O 
significantly O 
blocked O 
the O 
shift O 
in O 
buoyancy O 
from O 
less O 
atherogenic O 
lb-LDL O 
to O 
highly O 
atherogenic O 
sd-LDL O 
, O 
restoring O 
the O 
percent O 
distribution O 
of O 
LDL-C O 
and O 
apoB O 
into O 
sd-LDL O 
and O 
lb-LDL O 
to O 
near O 
normal O 
levels O 
. O 
These O 
compounds O 
also O 
blocked O 
basal O 
and O 
maximal O 
formation O 
of O 
CD O 
and O 
malondialdehyde B-TRIVIAL 
, O 
and O 
lengthened O 
the O 
lag O 
times O 
of O 
LDL O 
, O 
sd-LDL O 
and O 
lb-LDL O 
in O 
the O 
order O 
TQ> O 
LMN B-ABBREVIATION 
. O 
Our O 
results O 
strongly O 
suggest O 
an O 
important O 
therapeutic O 
use O 
of O 
test O 
compounds O 
, O 
especially O 
TQ O 
, O 
in O 
the O 
prevention O 
of O 
cardiovascular O 
disease O 
risks O 
parameters O 
. O 

- O 
of O 
- O 
flight O 
secondary O 
ion O 
mass O 
spectrometry O 
( O 
TOF-SIMS O 
) O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
are O 
employed O 
to O 
characterize O 
a O 
wedge O 
- O 
shaped O 
crater O 
eroded O 
by O 
a O 
40 O 
keV O 
C(60) B-TRIVIAL 
( I-TRIVIAL 
+ I-TRIVIAL 
) I-TRIVIAL 
cluster O 
ion O 
beam O 
on O 
an O 
organic O 
thin O 
film O 
of O 
402 O 
nm O 
of O 
barium B-SYSTEMATIC 
arachidate I-SYSTEMATIC 
( O 
AA O 
) O 
multilayers O 
prepared O 
by O 
the O 
Langmuir-Blodgett O 
( O 
LB O 
) O 
technique O 
. O 
Sample O 
cooling O 
to O 
90 O 
K O 
was O 
used O 
to O 
help O 
reduce O 
chemical O 
damage O 
, O 
improve O 
depth O 
resolution O 
and O 
maintain O 
constant O 
erosion O 
rate O 
during O 
depth O 
profiling O 
. O 
The O 
film O 
was O 
characterized O 
at O 
90 O 
K O 
, O 
135 O 
K O 
, O 
165 O 
K O 
, O 
205 O 
K O 
, O 
265 O 
K O 
and O 
300 O 
K O 
. O 
It O 
is O 
shown O 
that O 
sample O 
cooling O 
to O 
205 O 
K O 
or O 
lower O 
helps O 
to O 
inhibit O 
erosion O 
rate O 
decay O 
, O 
whereas O 
at O 
300 O 
K O 
and O 
265 O 
K O 
the O 
erosion O 
rate O 
continues O 
to O 
drop O 
after O 
250 O 
nm O 
of O 
erosion O 
, O 
reaching O 
about O 
half O 
of O 
the O 
initial O 
value O 
after O 
removal O 
of O 
the O 
entire O 
film O 
. O 
Depth O 
profiles O 
are O 
acquired O 
from O 
the O 
SIMS O 
images O 
of O 
the O 
eroded O 
wedge O 
crater O 
. O 
The O 
results O 
suggest O 
that O 
sample O 
cooling O 
only O 
slightly O 
improves O 
the O 
altered O 
layer O 
thickness O 
, O 
but O 
eliminates O 
the O 
decrease O 
in O 
erosion O 
rate O 
observed O 
above O 
265 O 
K O 
. O 

RELEVANCE O 
: O 
Traditional O 
medicines O 
in O 
the O 
form O 
of O 
plants O 
, O 
animals O 
and O 
/ O 
or O 
minerals O 
are O 
used O 
by O 
millions O 
of O 
South O 
Africans O 
. O 
There O 
is O 
currently O 
no O 
data O 
regarding O 
the O 
commonly O 
used O 
mineral O 
elements O 
thus O 
the O 
potential O 
benefits O 
or O 
hazards O 
of O 
such O 
products O 
remain O 
unclear O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Metal O 
and O 
crystalline O 
salts O 
were O 
purchased O 
from O 
a O 
rural O 
market O 
( O 
Nongoma O 
, O 
Zululand O 
, O 
South O 
Africa O 
) O 
. O 
Information O 
regarding O 
the O 
colloquial O 
name O 
, O 
price O 
and O 
weight O 
was O 
recorded O 
. O 
Energy O 
dispersive O 
X-ray O 
spectroscopy O 
( O 
EDX O 
) O 
was O 
used O 
to O 
quantatively O 
determine O 
the O 
unknown O 
salts O 
. O 
RESULTS O 
: O 
Six O 
widely O 
available O 
salts O 
were O 
analyzed O 
. O 
Ndonya O 
, O 
as O 
it O 
is O 
colloquially O 
known O 
, O 
refers O 
to O 
two O 
products O 
which O 
look O 
identical O 
to O 
the O 
untrained O 
eye O 
- O 
one O 
is O 
dyed O 
table O 
salt B-TRIVIAL 
and O 
the O 
other O 
is O 
hexavalent B-SYSTEMATIC 
chromium I-SYSTEMATIC 
. O 
A O 
further O 
product O 
used O 
medicinally O 
, O 
although O 
not O 
widely O 
available O 
, O 
was O 
identified O 
as O 
iron B-SYSTEMATIC 
chromite I-SYSTEMATIC 
ore O 
. O 
CONCLUSIONS O 
: O 
The O 
array O 
of O 
substances O 
documented O 
, O 
ranging O 
from O 
benign O 
to O 
carcinogenic O 
, O 
stresses O 
the O 
importance O 
of O 
documenting O 
components O 
used O 
in O 
traditional O 
medicine O 
and O 
confirms O 
the O 
necessity O 
to O 
regulate O 
South O 
Africa O 
traditional O 
medicine O 
. O 
Healthcare O 
workers O 
should O 
be O 
aware O 
of O 
the O 
complexities O 
of O 
using O 
such O 
metal O 
salt O 
. O 

of O 
modified O 
high O 
- O 
amylose O 
maize O 
starch- O 
α-naphthol B-SYSTEMATIC 
complexes O 
and O 
their O 
influence O 
on O 
rheological O 
properties O 
of O 
wheat O 
starch O 
. O 

can O 
form O 
inclusion O 
complexes O 
with O 
diverse O 
small O 
molecules O 
. O 
Modified O 
starch O 
has O 
different O 
and O 
unique O 
properties O 
compared O 
with O 
its O 
native O 
counterpart O 
. O 
In O 
this O 
study O 
, O 
chemically O 
/ O 
enzymatically O 
modified O 
high O 
- O 
amylose O 
maize O 
starches O 
were O 
used O 
to O 
make O 
inclusion O 
complexes O 
with O 
α-naphthol B-SYSTEMATIC 
, O 
and O 
the O 
physical O 
properties O 
of O 
complexes O 
and O 
their O 
influences O 
on O 
the O 
rheology O 
of O 
wheat O 
starch O 
were O 
characterized O 
. O 
The O 
results O 
showed O 
that O 
modification O 
of O 
starch O 
had O 
little O 
influence O 
on O 
the O 
wide O 
angle O 
X-ray O 
diffraction O 
pattern O 
of O 
complex O 
( O 
eightfold O 
single O 
helix O 
) O 
, O 
but O 
did O 
so O 
on O 
the O 
complexation O 
index O 
and O 
precipitation O 
yield O 
. O 
Inclusion O 
complexes O 
with O 
chemically O 
modified O 
starch O 
showed O 
a O 
lower O 
range O 
of O 
thermostability O 
and O 
recrystallization O 
temperatures O 
. O 
Addition O 
of O 
complex O 
considerably O 
influenced O 
the O 
rheological O 
properties O 
of O 
wheat O 
starch O 
, O 
and O 
the O 
effect O 
was O 
dependent O 
on O 
the O 
type O 
of O 
modified O 
starch O 
used O 
. O 
It O 
may O 
be O 
concluded O 
that O 
starch O 
inclusion O 
complexes O 
, O 
with O 
a O 
range O 
of O 
properties O 
and O 
potential O 
food O 
applications O 
, O 
may O 
be O 
feasibly O 
prepared O 
by O 
using O 
diverse O 
modified O 
high O 
- O 
amylose O 
maize O 
starches O 
. O 

glycosides I-FAMILY 
from O 
the O 
stems O 
of O 
Callicarpa O 
peii O 
( O 
hemostatic O 
drug O 
) O 
. O 

new O 
trisaccharide B-FAMILY 
intermediates O 
of O 
phenylethanoid B-FAMILY 
glycosides I-FAMILY 
, O 
peiioside B-TRIVIAL 
A(1) I-TRIVIAL 
/ I-TRIVIAL 
A(2) I-TRIVIAL 
( O 
1a O 
/ O 
1b O 
) O 
and O 
peiioside B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
n-BuOH B-FORMULA 
fraction O 
of O 
MeOH B-FORMULA 
extract O 
of O 
the O 
stems O 
of O 
Callicarpa O 
peii O 
H.T O 
. O 
Chang O 
, O 
together O 
with O 
five O 
biogenetic O 
relevant O 
known O 
compounds O 
3-7 O 
. O 
The O 
structures O 
of O 
compounds O 
1 O 
and O 
2 O 
were O 
elucidated O 
by O 
extensive O 
spectroscopic O 
methods O 
( O 
especially O 
2D-NMR O 
techniques O 
) O 
and O 
acid O 
- O 
catalyzed O 
hydrolysis O 
as O 
O-α-l-rhamnopyranosyl-(1″→3')-O-[β-d-apiofuranosyl-(1‴→6')] B-SYSTEMATIC 
-4'-O-[(E)-caffeoyl]-d-glucopyranoside I-SYSTEMATIC 
] I-SYSTEMATIC 
( O 
1a O 
/ O 
1b O 
) O 
, O 
3,4-dihydroxy-β-phenylethoxy-O-[β-d-apiofuranosyl-(1‴→6')-α-l-rhamnopyranosyl-(1″→3')-O-β-d-glucopyranoside] B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
respectively O 
. O 
On O 
the O 
basis O 
of O 
the O 
isolated O 
compounds O 
, O 
a O 
presumable O 
biogenetic O 
pathway O 
of O 
the O 
biologically O 
interesting O 
phenylethanoid B-FAMILY 
glycosides I-FAMILY 
about O 
forsythoside B-TRIVIAL 
B I-TRIVIAL 
( O 
3 O 
) O 
and O 
acteoside B-TRIVIAL 
( O 
4 O 
) O 
isolated O 
from O 
this O 
species O 
was O 
proposed O 
. O 
Isolation O 
of O 
five O 
related O 
intermediates O 
( O 
1-2 O 
, O 
5-7 O 
) O 
provided O 
further O 
support O 
for O 
the O 
biogenetic O 
path O 
. O 
This O 
is O 
the O 
first O 
report O 
about O 
phytochemical O 
research O 
on O 
C O 
. O 
peii O 
and O 
the O 
biogenetic O 
hypothesis O 
of O 
forsythoside B-TRIVIAL 
B I-TRIVIAL 
and O 
acteoside B-TRIVIAL 
. O 

targets O 
of O 
dietary O 
polyphenols B-FAMILY 
in O 
disease O 
: O 
a O 
case O 
for O 
the O 
chemokine O 
network O 
and O 
energy O 
metabolism O 
. O 

, O 
non-acute O 
inflammation O 
is O 
behind O 
conditions O 
that O 
represent O 
most O 
of O 
the O 
disease O 
burden O 
in O 
humans O 
and O 
is O 
clearly O 
linked O 
to O 
immune O 
and O 
metabolic O 
mechanisms O 
. O 
The O 
convergence O 
of O 
pathways O 
involving O 
the O 
immune O 
response O 
, O 
oxidative O 
stress O 
, O 
increased O 
circulating O 
lipids O 
and O 
aberrant O 
insulin O 
signaling O 
results O 
in O 
CCL2-associated O 
macrophage O 
recruitment O 
and O 
altered O 
energy O 
metabolism O 
. O 
The O 
CCL2 O 
/ O 
CCR2 O 
pathway O 
and O 
the O 
energy O 
sensor O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
are O 
attractive O 
therapeutic O 
targets O 
as O 
a O 
part O 
of O 
preventive O 
management O 
of O 
disease O 
. O 
Several O 
effects O 
of O 
polyphenols B-FAMILY 
are O 
useful O 
in O 
this O 
scenario O 
, O 
including O 
a O 
reduction O 
in O 
the O 
activities O 
of O 
cytokines O 
and O 
modulation O 
of O 
cellular O 
metabolism O 
through O 
histone O 
deacetylase O 
inhibitors O 
, O 
AMPK O 
activators O 
, O 
calorie O 
- O 
restriction O 
mimetics O 
or O 
epigenetic O 
regulators O 
. O 
Research O 
is O 
currently O 
underway O 
to O 
develop O 
orally O 
active O 
drugs O 
with O 
these O 
effects O 
, O 
but O 
it O 
is O 
convenient O 
to O 
examine O 
more O 
closely O 
what O 
we O 
are O 
eating O 
. O 
If O 
a O 
lack O 
of O 
relevance O 
in O 
terms O 
of O 
toxicity O 
and O 
substantial O 
effectiveness O 
are O 
confirmed O 
, O 
plant O 
- O 
derived O 
components O 
may O 
provide O 
useful O 
druggable O 
components O 
and O 
dietary O 
supplements O 
. O 
We O 
consider O 
therapeutic O 
actions O 
as O 
a O 
combination O 
of O 
synergistic O 
and O 
/ O 
or O 
antagonistic O 
interactions O 
in O 
a O 
multi O 
- O 
target O 
strategy O 
. O 
Hence O 
, O 
improvement O 
in O 
food O 
through O 
enrichment O 
with O 
polyphenols B-FAMILY 
with O 
demonstrated O 
activity O 
may O 
represent O 
a O 
major O 
advance O 
in O 
the O 
design O 
of O 
diets O 
with O 
both O 
industrial O 
and O 
sanitary O 
value O 
. O 

novel O 
phosphodiesterase O 
10A O 
inhibitor O 
THPP-1 B-IDENTIFIER 
has O 
antipsychotic O 
- O 
like O 
effects O 
in O 
rat O 
and O 
improves O 
cognition O 
in O 
rat O 
and O 
rhesus O 
monkey O 
. O 

10A O 
( O 
PDE10A O 
) O 
is O 
a O 
novel O 
target O 
for O 
the O 
treatment O 
of O 
schizophrenia O 
that O 
may O 
address O 
multiple O 
symptomatic O 
domains O 
associated O 
with O 
this O 
disorder O 
. O 
PDE10A O 
is O 
highly O 
expressed O 
in O 
the O 
brain O 
and O 
functions O 
to O 
metabolically O 
inactivate O 
the O 
important O 
second O 
messengers O 
cAMP B-ABBREVIATION 
and O 
cGMP B-ABBREVIATION 
. O 
Here O 
we O 
describe O 
effects O 
of O 
a O 
potent O 
and O 
orally O 
bioavailable O 
PDE10A O 
inhibitor O 
[ O 
2-(6-chloropyridin-3-yl)-4-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl](imidazo[1,5-a]pyridin-1-yl)methanone B-SYSTEMATIC 
] O 
( O 
THPP-1 B-IDENTIFIER 
) O 
on O 
striatal O 
signaling O 
pathways O 
, O 
in O 
behavioral O 
tests O 
that O 
predict O 
antipsychotic O 
potential O 
, O 
and O 
assays O 
that O 
measure O 
episodic O 
- O 
like O 
memory O 
in O 
rat O 
and O 
executive O 
function O 
in O 
rhesus O 
monkey O 
. O 
THPP-1 B-IDENTIFIER 
exhibits O 
nanomolar O 
potency O 
on O 
the O 
PDE10A O 
enzyme O 
, O 
demonstrates O 
excellent O 
pharmacokinetic O 
properties O 
in O 
multiple O 
preclinical O 
animal O 
species O 
, O 
and O 
is O 
selective O 
for O 
PDE10A O 
over O 
other O 
PDE O 
families O 
of O 
enzymes O 
. O 
THPP-1 B-IDENTIFIER 
significantly O 
increased O 
phosphorylation O 
of O 
proteins O 
in O 
the O 
striatum O 
involved O 
in O 
synaptic O 
plasticity O 
, O 
including O 
the O 
a-amino-3-hydroxy-5-methylisoxazole-4-proprionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
receptor O 
( O 
AMPA B-ABBREVIATION 
) O 
GluR1 O 
subunit O 
, O 
extracellular O 
receptor O 
kinase O 
( O 
ERK O 
) O 
, O 
and O 
cAMP B-ABBREVIATION 
-response O 
element O 
binding O 
protein O 
( O 
CREB O 
) O 
. O 
THPP-1 B-IDENTIFIER 
produced O 
dose O 
- O 
dependent O 
effects O 
in O 
preclinical O 
assays O 
predictive O 
of O 
antipsychotic O 
activity O 
including O 
attenuation O 
of O 
MK-801 B-IDENTIFIER 
-induced O 
psychomotor O 
activation O 
and O 
condition O 
avoidance O 
responding O 
in O 
rats O 
. O 
At O 
similar O 
plasma O 
exposures O 
, O 
THPP-1 B-IDENTIFIER 
significantly O 
increased O 
object O 
recognition O 
memory O 
in O 
rat O 
and O 
attenuated O 
a O 
ketamine B-TRIVIAL 
-induced O 
deficit O 
in O 
the O 
object O 
retrieval O 
detour O 
task O 
in O 
rhesus O 
monkey O 
. O 
These O 
findings O 
suggest O 
that O 
PDE10A O 
inhibitors O 
have O 
the O 
potential O 
to O 
impact O 
multiple O 
symptomatic O 
domains O 
of O 
schizophrenia O 
including O 
positive O 
symptoms O 
and O 
cognitive O 
impairment O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

cucurbitacins B-MULTIPLE 
E I-MULTIPLE 
, I-MULTIPLE 
D I-MULTIPLE 
and I-MULTIPLE 
I I-MULTIPLE 
: O 
investigation O 
of O 
their O 
cytotoxicity O 
toward O 
human O 
chondrosarcoma O 
SW O 
1353 O 
cell O 
line O 
and O 
their O 
biotransformation O 
in O 
man O 
liver O 
. O 

are O 
a O 
class O 
of O 
natural O 
compounds O 
known O 
for O 
their O 
numerous O 
potential O 
pharmacological O 
effects O 
. O 
The O 
purpose O 
of O 
this O 
work O 
was O 
to O 
compare O 
the O 
cytotoxicity O 
of O 
three O 
cucurbitacins B-MULTIPLE 
I I-MULTIPLE 
, I-MULTIPLE 
D I-MULTIPLE 
, I-MULTIPLE 
E I-MULTIPLE 
on O 
the O 
chondrosarcoma O 
SW O 
1353 O 
cancer O 
cell O 
line O 
and O 
to O 
investigate O 
their O 
biotransformation O 
in O 
man O 
. O 
Cucurbitacins B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
D I-MULTIPLE 
showed O 
a O 
very O 
strong O 
cytotoxicity O 
, O 
which O 
was O 
higher O 
than O 
that O 
of O 
cytochalasin B-TRIVIAL 
D I-TRIVIAL 
, O 
used O 
as O 
a O 
drug O 
reference O 
. O 
Almost O 
100% O 
of O 
the O 
cells O 
were O 
apoptotic O 
as O 
observed O 
by O 
DNA O 
fragmentation O 
( O 
TUNEL O 
assay O 
) O 
after O 
12 O 
h O 
with O 
cucurbitacins B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
D I-MULTIPLE 
( O 
1 O 
μM O 
) O 
and O 
cucurbitacin B-TRIVIAL 
E I-TRIVIAL 
( O 
10 O 
μM O 
) O 
. O 
In O 
terms O 
of O 
IC(50) O 
values O 
, O 
cucurbitacins B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
E I-MULTIPLE 
presented O 
a O 
higher O 
toxicity O 
compared O 
to O 
that O 
of O 
cucurbitacin B-TRIVIAL 
D I-TRIVIAL 
( O 
MTT B-ABBREVIATION 
assay O 
) O 
. O 
Cucurbitacin B-TRIVIAL 
E I-TRIVIAL 
was O 
readily O 
hydrolyzed O 
by O 
human O 
hepatic O 
microsomes O 
, O 
leading O 
to O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
( O 
K(m) O 
22 O 
μM O 
, O 
V(max) O 
571 O 
nmol O 
/ O 
mg O 
proteins O 
/ O 
min O 
) O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
three O 
cucurbitacins B-FAMILY 
were O 
hydroxylated O 
at O 
a O 
very O 
low O 
extent O 
, O 
but O 
they O 
were O 
sulfated O 
and O 
glucuronidated O 
. O 
In O 
terms O 
of O 
V(max) O 
/ O 
K(m) O 
, O 
the O 
cucurbitacin B-TRIVIAL 
E I-TRIVIAL 
was O 
the O 
best O 
substrate O 
of O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
. O 
This O 
study O 
shows O 
that O 
cucurbitacins B-MULTIPLE 
I I-MULTIPLE 
, I-MULTIPLE 
D I-MULTIPLE 
and I-MULTIPLE 
E I-MULTIPLE 
present O 
a O 
potent O 
cytotoxic O 
activity O 
toward O 
the O 
chondrosarcoma O 
SW O 
1353 O 
cell O 
line O 
and O 
are O 
metabolized O 
as O 
sulfate B-SYSTEMATIC 
and O 
glucuronide B-TRIVIAL 
conjugates O 
. O 

: O 
Several O 
conventional O 
pharmaceuticals O 
like O 
non-steroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAIDS O 
) O 
or O 
selective O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
inhibitors O 
have O 
been O 
demonstrated O 
to O 
exert O 
anti-proliferative O 
effects O 
and O 
to O 
induce O 
apoptosis O 
in O 
a O 
variety O 
of O 
cell O 
lines O 
, O 
e.g O 
. O 
colon O 
, O 
stomach O 
, O 
or O 
prostate O 
cancer O 
cells O 
. O 
STW O 
5 O 
(Iberogast(®)) O 
, O 
a O 
combination O 
of O 
nine O 
plant O 
extracts O 
, O 
is O 
widely O 
used O 
in O 
the O 
treatment O 
of O 
gastrointestinal O 
disorders O 
, O 
including O 
functional O 
dyspepsia O 
and O 
irritable O 
bowel O 
syndrome O 
for O 
which O 
the O 
involvement O 
of O 
an O 
inflammatory O 
etiology O 
is O 
discussed O 
. O 
To O 
investigate O 
the O 
possible O 
anti-proliferative O 
effects O 
, O 
STW O 
5 O 
and O 
its O 
components O 
have O 
been O 
tested O 
by O 
using O 
the O 
colon O 
- O 
carcinoma O 
cell O 
line O 
HT-29 O 
. O 
The O 
analyses O 
have O 
been O 
performed O 
in O 
comparison O 
to O 
acetylsalicylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
ASA B-ABBREVIATION 
) O 
and O 
diclofenac B-TRIVIAL 
( O 
Diclo B-ABBREVIATION 
) O 
, O 
which O 
are O 
well O 
- O 
known O 
to O 
reduce O 
colon O 
carcinoma O 
risk O 
. O 
RESULTS O 
: O 
STW O 
5 O 
showed O 
significant O 
anti-proliferative O 
and O 
pro O 
- O 
apoptotic O 
effects O 
on O 
HT-29 O 
cancer O 
cells O 
, O 
similar O 
to O 
NSAIDs O 
under O 
test O 
. O 
However O 
, O 
using O 
the O 
LDH O 
assay O 
, O 
STW O 
5 O 
revealed O 
significantly O 
lower O 
cytotoxicity O 
than O 
Diclo B-ABBREVIATION 
at O 
same O 
concentrations O 
. O 
In O 
contrast O 
to O 
NSAIDs O 
, O 
STW O 
5 O 
induced O 
COX-1 O 
/ O 
COX-2 O 
, O 
caspase-3 O 
and O 
Bax O 
mRNA O 
expressions O 
in O 
HT-29 O 
and O 
blocked O 
LPS O 
mediated O 
translocation O 
of O 
the O 
NF-κB O 
p65 O 
from O 
the O 
cytoplasm O 
into O 
the O 
nucleus O 
in O 
PMA B-ABBREVIATION 
-differentiated O 
THP-1 O 
macrophages O 
. O 
These O 
effects O 
might O 
be O 
relevant O 
, O 
e.g O 
. O 
for O 
prevention O 
of O 
undesirable O 
side O 
effects O 
like O 
gastric O 
erosions O 
. O 
CONCLUSION O 
: O 
Our O 
data O 
suggest O 
that O 
the O 
pro O 
- O 
apoptotic O 
effect O 
of O 
STW O 
5 O 
on O 
HT-29 O 
cells O 
is O 
involving O 
multiple O 
targets O 
and O 
is O 
possibly O 
due O 
to O 
an O 
activation O 
of O 
the O 
caspase O 
cascade O 
via O 
mitochondrial O 
destabilization O 
. O 
Active O 
concentrations O 
of O 
STW O 
5 O 
are O 
, O 
in O 
relation O 
to O 
therapeutic O 
doses O 
, O 
comparable O 
to O 
those O 
of O 
ASA B-ABBREVIATION 
and O 
Diclo B-ABBREVIATION 
, O 
suggesting O 
a O 
similar O 
favorable O 
effect O 
on O 
colon O 
carcinoma O 
risk O 
. O 

activates O 
glucose B-TRIVIAL 
uptake O 
via O 
GLUT4 O 
translocation O 
and O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
in O 
MCF-7 O 
cells O 
. O 

relationship O 
between O 
estrogen B-FAMILY 
and O 
some O 
types O 
of O 
breast O 
cancer O 
has O 
been O 
clearly O 
established O 
. O 
However O 
, O 
although O 
several O 
studies O 
have O 
demonstrated O 
the O 
relationship O 
between O 
estrogen B-FAMILY 
and O 
glucose B-TRIVIAL 
uptake O 
via O 
PI3K O 
/ O 
Akt O 
in O 
other O 
tissues O 
, O 
not O 
too O 
much O 
is O 
known O 
about O 
the O 
possible O 
cross O 
talk O 
between O 
them O 
for O 
development O 
and O 
maintenance O 
of O 
breast O 
cancer O 
. O 
This O 
study O 
was O 
designed O 
to O 
test O 
the O 
rapid O 
effects O 
of O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
or O 
its O 
membrane O 
- O 
impermeable O 
form O 
conjugated O 
with O 
bovine O 
serum O 
albumin O 
( O 
E2BSA O 
) O 
on O 
glucose B-TRIVIAL 
uptake O 
in O 
a O 
positive O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
breast O 
cancer O 
cell O 
line O 
, O 
through O 
the O 
possible O 
relationship O 
between O 
key O 
components O 
of O 
the O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
and O 
acute O 
steroid B-FAMILY 
treatment O 
. O 
MCF-7 O 
human O 
breast O 
cancer O 
cells O 
were O 
cultured O 
in O 
standard O 
conditions O 
. O 
Then O 
10nM O 
of O 
17β-estradiol B-SYSTEMATIC 
or O 
estradiol B-TRIVIAL 
BSA O 
conjugated O 
were O 
administrated O 
before O 
obtaining O 
the O 
cell O 
lysates O 
. O 
To O 
study O 
the O 
glucose B-TRIVIAL 
uptake O 
, O 
the O 
glucose B-TRIVIAL 
fluorescent O 
analogue O 
2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-d-glucose B-SYSTEMATIC 
was O 
used O 
. O 
We O 
report O 
an O 
ER-dependent O 
activation O 
of O 
some O 
of O 
the O 
key O 
steps O 
of O 
the O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
cascade O 
that O 
leads O 
cells O 
to O 
improve O 
some O 
mechanisms O 
that O 
finally O 
increase O 
glucose B-TRIVIAL 
uptake O 
capacity O 
. O 
Our O 
data O 
suggest O 
that O 
both O 
E2 O 
and O 
E2BSA O 
enhance O 
the O 
entrance O 
of O 
the O 
fluorescent O 
glucose B-TRIVIAL 
analogue O 
2-NBDG B-SYSTEMATIC 
, O 
and O 
also O 
activates O 
s O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
, O 
leading O 
to O 
translocation O 
of O 
GLUT4 O 
to O 
the O 
plasma O 
membrane O 
in O 
an O 
ERα O 
dependent O 
manner O 
. O 
E2 O 
enhances O 
ER-dependent O 
rapid O 
signaling O 
triggered O 
, O 
partially O 
in O 
the O 
plasma O 
membrane O 
, O 
allowing O 
ERα-positive O 
MCF-7 O 
breast O 
cancer O 
cells O 
to O 
increase O 
glucose B-TRIVIAL 
uptake O 
, O 
which O 
could O 
be O 
essential O 
to O 
meet O 
the O 
energy O 
demands O 
of O 
the O 
high O 
rate O 
of O 
proliferation O 
. O 

arthritis O 
( O 
RA O 
) O 
is O 
a O 
chronic O 
autoimmune O 
disease O 
in O 
which O 
imbalances O 
in O 
pro- O 
and O 
anti-inflammatory O 
cytokines O 
promote O 
the O 
induction O 
of O 
autoimmunity O 
, O 
inflammation O 
and O 
joint O 
destruction O 
. O 
Methotrexate B-TRIVIAL 
, O 
the O 
standard O 
disease O 
- O 
modifying O 
anti-rheumatic O 
drug O 
( O 
DMARD O 
) O 
, O 
has O 
shown O 
a O 
gradual O 
loss O 
of O 
efficacy O 
in O 
a O 
significant O 
proportion O 
of O 
patients O 
, O 
probably O 
due O 
to O 
the O 
onset O 
of O 
drug O 
resistance O 
, O 
and O 
thus O 
it O 
was O 
hoped O 
that O 
the O 
development O 
of O 
biologics O 
would O 
revolutionise O 
RA O 
management O 
. O 
Even O 
though O 
biologics O 
have O 
improved O 
the O 
therapy O 
of O 
patients O 
refractive O 
to O 
DMARDs O 
, O 
they O 
require O 
parenteral O 
administration O 
and O 
may O 
leave O 
patients O 
open O 
to O 
serious O 
infection O 
and O 
cancer O 
. O 
Therefore O 
, O 
attention O 
has O 
also O 
been O 
focused O 
on O 
inhibitors O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
, O 
signalling O 
enzymes O 
that O 
play O 
key O 
roles O 
in O 
pathogenic O 
cytokine O 
production O 
, O 
and O 
their O 
downstream O 
effector O 
pathways O 
, O 
in O 
order O 
to O 
create O 
safe O 
and O 
effective O 
oral O 
drugs O 
. O 
This O 
article O 
therefore O 
provides O 
an O 
overview O 
of O 
the O 
structure O 
and O 
function O 
of O 
MAPKs O 
and O 
their O 
role O 
in O 
the O 
pathogenesis O 
of O 
RA O 
as O 
context O 
to O 
describing O 
the O 
advances O 
in O 
the O 
development O 
of O 
specific O 
, O 
druggable O 
MAPK O 
inhibitors O 
. O 
Their O 
potential O 
as O 
therapies O 
in O 
the O 
management O 
of O 
RA O 
is O 
also O 
discussed O 
. O 

withdrawal O 
produces O 
ERK-dependent O 
and O 
ERK O 
- O 
independent O 
epigenetic O 
marks O 
in O 
neurons O 
of O 
the O 
nucleus O 
accumbens O 
and O 
lateral O 
septum O 
. O 

changes O 
such O 
as O 
covalent O 
modifications O 
of O 
histone O 
proteins O 
represent O 
complex O 
molecular O 
signatures O 
that O 
provide O 
a O 
cellular O 
memory O 
of O 
previously O 
experienced O 
stimuli O 
without O 
irreversible O 
changes O 
of O 
the O 
genetic O 
code O 
. O 
In O 
this O 
study O 
we O 
show O 
that O 
new O 
gene O 
expression O 
induced O 
in O 
vivo O 
by O 
morphine B-TRIVIAL 
withdrawal O 
occurs O 
with O 
concomitant O 
epigenetic O 
modifications O 
in O 
brain O 
regions O 
critically O 
involved O 
in O 
drug O 
- O 
dependent O 
behaviors O 
. O 
We O 
found O 
that O 
naloxone B-TRIVIAL 
-precipitated O 
withdrawal O 
, O 
but O 
not O 
chronic O 
morphine B-TRIVIAL 
administration O 
, O 
caused O 
a O 
strong O 
induction O 
of O 
phospho B-SYSTEMATIC 
-histone O 
H3 O 
immunoreactivity O 
in O 
the O 
nucleus O 
accumbens O 
( O 
NAc O 
) O 
shell O 
/ O 
core O 
and O 
in O 
the O 
lateral O 
septum O 
( O 
LS O 
) O 
, O 
a O 
change O 
that O 
was O 
accompanied O 
by O 
augmented O 
H3 O 
acetylation O 
( O 
lys B-FORMULA 
14 O 
) O 
in O 
neurons O 
of O 
the O 
NAc O 
shell O 
. O 
Morphine B-TRIVIAL 
withdrawal O 
induced O 
the O 
phosphorylation O 
of O 
the O 
epigenetic O 
factor O 
methyl B-SYSTEMATIC 
- O 
CpG B-ABBREVIATION 
-binding O 
protein O 
2 O 
( O 
MeCP2 O 
) O 
in O 
Ser B-FORMULA 
421 O 
both O 
in O 
the O 
LS O 
and O 
the O 
NAc O 
shell O 
. O 
These O 
epigenetic O 
changes O 
were O 
accompanied O 
by O 
the O 
activation O 
of O 
members O 
of O 
the O 
ERK O 
pathway O 
as O 
well O 
as O 
increased O 
expression O 
of O 
the O 
immediate O 
early O 
genes O 
( O 
IEG O 
) O 
c-fos O 
and O 
activity O 
- O 
regulated O 
cytoskeleton O 
- O 
associated O 
protein O 
( O 
Arc O 
/ O 
Arg3.1 O 
) O 
. O 
Using O 
a O 
pharmacological O 
approach O 
, O 
we O 
found O 
that O 
H3 O 
phosphorylation O 
and O 
IEG O 
expression O 
were O 
partially O 
dependent O 
on O 
ERK O 
activation O 
, O 
while O 
MeCP2 O 
phosphorylation O 
was O 
fully O 
ERK O 
- O 
independent O 
. O 
These O 
findings O 
provide O 
new O 
important O 
information O 
on O 
the O 
role O 
of O 
the O 
ERK O 
pathway O 
in O 
the O 
regulation O 
of O 
epigenetic O 
marks O 
and O 
gene O 
expression O 
that O 
may O 
concur O 
to O 
regulate O 
in O 
vivo O 
the O 
cellular O 
changes O 
underlying O 
the O 
onset O 
of O 
the O 
opioid O 
withdrawal O 
syndrome O 
. O 

structural O 
data O 
revealed O 
that O 
the O 
CP29 O 
protein O 
of O 
higher O 
plant O 
Photosystem O 
II O 
( O 
PSII O 
) O 
contains O 
13 O 
chlorophylls B-FAMILY 
( O 
Chls B-FAMILY 
) O 
per O 
complex O 
[ O 
Pan O 
et O 
al O 
. O 
, O 
Nat O 
. O 
Struct O 
. O 
Mol O 
. O 
Biol O 
. O 
2011 O 
, O 
18 O 
, O 
309 O 
] O 
, O 
i.e O 
. O 
, O 
five O 
Chls O 
more O 
than O 
in O 
the O 
predicted O 
CP29 O 
homology O 
- O 
based O 
structure O 
model O 
[ O 
Bassi O 
et O 
al O 
. O 
, O 
Proc O 
. O 
Natl O 
. O 
Acad O 
. O 
Sci O 
. O 
USA O 
1999 O 
, O 
96 O 
, O 
10056 O 
] O 
. O 
This O 
lack O 
of O 
consensus O 
presents O 
a O 
constraint O 
on O 
the O 
interpretation O 
of O 
CP29 O 
optical O 
spectra O 
and O 
their O 
underlying O 
electronic O 
structure O 
. O 
To O 
address O 
this O 
problem O 
, O 
we O 
present O 
new O 
low O 
- O 
temperature O 
( O 
5 O 
K O 
) O 
absorption O 
, O 
fluorescence O 
, O 
and O 
hole O 
- O 
burned O 
( O 
HB O 
) O 
spectra O 
for O 
CP29 O 
proteins O 
from O 
spinach O 
, O 
which O 
are O 
compared O 
with O 
the O 
previously O 
reported O 
data O 
. O 
We O 
focus O 
on O 
excitation O 
energy O 
transfer O 
( O 
EET O 
) O 
and O 
the O 
nature O 
of O 
the O 
lowest O 
- O 
energy O 
state(s) O 
. O 
We O 
argue O 
that O 
CP29 O 
proteins O 
previously O 
studied O 
by O 
HB O 
spectroscopy O 
lacked O 
at O 
least O 
one O 
Chl B-ABBREVIATION 
a I-ABBREVIATION 
molecule O 
( O 
i.e O 
. O 
, O 
a615 O 
or O 
a611 O 
) O 
, O 
which O 
along O 
with O 
Chl O 
a612 O 
contribute O 
to O 
the O 
lowest O 
energy O 
state O 
in O 
more O 
intact O 
CP29 O 
, O 
and O 
one O 
Chl B-ABBREVIATION 
b I-ABBREVIATION 
( O 
most O 
likely O 
b607 O 
) O 
. O 
This O 
is O 
why O 
the O 
low O 
- O 
energy O 
state O 
and O 
fluorescence O 
maxima O 
reported O 
by O 
Pieper O 
et O 
al O 
. O 
[ O 
Photochem O 
. O 
Photobiol O 
. O 
2000 O 
, O 
71 O 
, O 
574 O 
] O 
were O 
blueshifted O 
by O 
~ O 
1 O 
nm O 
, O 
the O 
low O 
- O 
energy O 
state O 
appeared O 
to O 
be O 
highly O 
localized O 
on O 
a O 
single O 
Chl B-ABBREVIATION 
a I-ABBREVIATION 
molecule O 
, O 
and O 
the O 
position O 
of O 
the O 
low O 
- O 
energy O 
state O 
was O 
independent O 
of O 
burning O 
fluence O 
. O 
In O 
contrast O 
, O 
the O 
position O 
of O 
the O 
nonresonant O 
HB O 
spectrum O 
shifts O 
blue O 
with O 
increasing O 
fluence O 
in O 
intact O 
CP29 O 
, O 
as O 
this O 
state O 
is O 
strongly O 
contributed O 
to O 
by O 
several O 
pigments O 
( O 
i.e O 
. O 
, O 
a611 O 
, O 
a612 O 
, O 
a615 O 
and O 
a610 O 
) O 
. O 
Zero O 
- O 
phonon O 
hole O 
widths O 
obtained O 
for O 
the O 
Chl B-ABBREVIATION 
b I-ABBREVIATION 
band O 
at O 
638.5 O 
nm O 
( O 
5 O 
K O 
) O 
revealed O 
two O 
independent O 
Chl B-ABBREVIATION 
b I-ABBREVIATION 
→ O 
Chl B-ABBREVIATION 
a I-ABBREVIATION 
EET O 
times O 
, O 
i.e O 
. O 
, O 
4 O 
± O 
0.5 O 
ps O 
and O 
0.4 O 
± O 
0.1 O 
ps O 
. O 
The O 
latter O 
value O 
is O 
a O 
factor O 
of O 
two O 
faster O 
than O 
previously O 
observed O 
by O 
HB O 
spectroscopy O 
and O 
very O 
similar O 
to O 
the O 
one O 
observed O 
by O 
Gradinaru O 
et O 
al O 
. O 
[ O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
B O 
2000 O 
, O 
104 O 
, O 
9330 O 
] O 
in O 
pump O 
- O 
probe O 
experiments O 
. O 
EET O 
time O 
from O 
650 O 
nm O 
Chl B-ABBREVIATION 
b I-ABBREVIATION 
→ O 
Chl B-ABBREVIATION 
a I-ABBREVIATION 
and O 
downward O 
EET O 
from O 
Chl(s) O 
a O 
state(s) O 
at O 
665 O 
nm O 
occurs O 
in O 
4.9 O 
± O 
0.7 O 
ps O 
. O 
These O 
findings O 
provide O 
important O 
constraints O 
for O 
excitonic O 
calculations O 
that O 
are O 
discussed O 
in O 
the O 
accompanying O 
paper O 
( O 
Part O 
II O 
) O 
. O 

characterisation O 
of O 
flavonoids B-FAMILY 
from O 
Sophora O 
alopecuroides O 
L O 
. O 
by O 
HPLC O 
/ O 
DAD O 
/ O 
ESI-MSn O 
. O 

HPLC O 
/ O 
DAD O 
/ O 
ESI-MSn O 
method O 
was O 
established O 
to O 
characterise O 
flavonoids B-FAMILY 
in O 
the O 
seeds O 
of O 
Sophora O 
alopecuroides O 
L O 
. O 
All O 
the O 
flavonoids B-FAMILY 
exhibited O 
abundant O 
[ O 
M- O 
H B-FORMULA 
]- O 
ions O 
, O 
which O 
triggered O 
data O 
- O 
dependent O 
multistage O 
mass O 
spectrometry O 
fragmentations O 
. O 
Characteristic O 
UV O 
spectra O 
were O 
used O 
to O 
confirm O 
flavonoid B-FAMILY 
subtypes O 
. O 
In O 
total O 
, O 
22 O 
flavonoids B-FAMILY 
and O 
two O 
phenolic B-FAMILY 
compounds O 
were O 
detected O 
and O 
identified O 
. O 
Five O 
of O 
them O 
were O 
identified O 
by O 
comparing O 
with O 
reference O 
standards O 
, O 
and O 
the O 
others O 
were O 
characterised O 
based O 
on O 
the O 
retention O 
behaviour O 
, O 
multistage O 
fragmentation O 
feature O 
and O 
UV O 
absorption O 
. O 
A O 
total O 
of O 
19 O 
compounds O 
were O 
reported O 
from O 
S O 
. O 
alopecuroides O 
for O 
the O 
first O 
time O 
. O 
This O 
method O 
accomplished O 
rapid O 
profiling O 
of O 
flavonoid B-FAMILY 
constituents O 
in O 
S O 
. O 
alopecuroides O 
L O 
. O 

- O 
induced O 
glycosylation O 
of O 
whey O 
protein O 
improves O 
solubility O 
and O 
thermal O 
stability O 
over O 
a O 
wide O 
pH O 
range O 
. O 
However O 
, O 
the O 
relationship O 
between O 
structural O 
changes O 
and O 
functional O 
enhancement O 
upon O 
glycosylation O 
is O 
not O 
well O 
- O 
characterized O 
. O 
Therefore O 
, O 
our O 
objective O 
was O 
to O 
characterise O 
these O 
structural O 
changes O 
and O 
determine O 
the O 
protein O 
conformation O 
at O 
various O 
pH O 
and O 
thermal O 
treatments O 
, O 
using O 
surface O 
- O 
enhanced O 
Raman O 
- O 
spectroscopy O 
. O 
The O 
spectra O 
of O 
glycosylated O 
protein O 
revealed O 
a O 
new O 
peak O 
at O 
983cm(-1) O 
that O 
can O 
be O 
used O 
as O 
a O 
Raman O 
marker O 
for O 
the O 
early O 
stage O 
glycosylation O 
. O 
Upon O 
glycosylation O 
, O 
structural O 
variations O 
were O 
significant O 
at O 
the O 
disulfide B-SYSTEMATIC 
, O 
hydrophobic O 
, O 
amide B-FAMILY 
III O 
, O 
amide B-FAMILY 
II O 
, O 
and O 
amide B-FAMILY 
I O 
regions O 
. O 
Ionisation O 
of O 
carboxyl B-SYSTEMATIC 
groups O 
at O 
all O 
tested O 
pH O 
values O 
, O 
and O 
increased O 
β-sheet O 
configuration O 
were O 
also O 
observed O 
. O 
The O 
noted O 
structural O 
modifications O 
imparted O 
molecular O 
rigidity O 
and O 
a O 
consequent O 
resistance O 
to O 
denaturation O 
upon O 
thermal O 
treatment O 
over O 
a O 
wide O 
pH O 
range O 
. O 
These O 
findings O 
can O 
be O 
used O 
to O 
explain O 
various O 
functional O 
enhancements O 
of O 
whey O 
protein O 
upon O 
glycosylation O 
. O 

glomerular O 
kidney O 
diseases O 
are O 
often O 
accompanied O 
with O 
a O 
massive O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
that O 
affect O 
the O 
function O 
of O 
the O 
glomerular O 
filtration O 
barrier O 
and O 
contribute O 
to O 
mesangiolysis O 
via O 
the O 
induction O 
of O 
cell O 
death O 
in O 
mesangial O 
cells O 
. O 
Intriguingly O 
, O 
ROS O 
also O 
trigger O 
fine O 
- O 
tuned O 
signalling O 
processes O 
that O 
affect O 
gene O 
expression O 
and O 
cell O 
proliferation O 
or O 
migration O 
. O 
To O 
define O 
such O 
redox O 
- O 
driven O 
signalling O 
devices O 
, O 
a O 
proteomics O 
approach O 
was O 
performed O 
to O 
identify O 
the O 
formation O 
of O 
protein O 
complexes O 
induced O 
by O 
ROS O 
. O 
To O 
this O 
end O 
, O 
protein O 
lysates O 
of O 
human O 
podocytes O 
were O 
treated O 
with O 
or O 
without O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
250 O 
μM O 
) O 
. O 
Thereafter O 
cell O 
lysates O 
were O 
subjected O 
to O 
diagonal O 
2D O 
gel O 
electrophoresis O 
and O 
putative O 
redox O 
- O 
affected O 
proteins O 
were O 
analysed O 
by O 
MS O 
/ O 
MS O 
analysis O 
. O 
Among O 
others O 
, O 
the O 
regulatory O 
subunit O 
of O 
protein O 
kinase O 
A O 
( O 
PKA O 
) O 
could O 
be O 
identified O 
that O 
forms O 
homodimers O 
under O 
oxidative O 
conditions O 
. O 
To O 
evaluate O 
whether O 
ROS O 
dependent O 
dimerization O 
of O 
PKA O 
also O 
occurs O 
in O 
a O 
more O 
physiological O 
setting O 
, O 
rat O 
mesangial O 
cells O 
were O 
treated O 
with O 
platelet O 
- O 
derived O 
growth O 
factor-BB O 
( O 
PDGF-BB O 
) O 
to O 
induce O 
ROS O 
formation O 
. O 
This O 
regimen O 
resulted O 
in O 
a O 
redox O 
dependent O 
dimerization O 
of O 
the O 
R-subunits O 
of O 
PKA O 
. O 
To O 
demonstrate O 
whether O 
PDGF-BB O 
induced O 
ROS O 
formation O 
affects O 
PKA O 
dependent O 
pathways O 
, O 
the O 
effects O 
of O 
PDGF-BB O 
on O 
phosphorylation O 
of O 
serine B-TRIVIAL 
157 O 
of O 
vasodilator O 
stimulated O 
protein O 
( O 
VASP O 
) O 
a O 
classical O 
target O 
of O 
PKA O 
were O 
analysed O 
. O 
Interestingly O 
PDGF-BB O 
induced O 
VASP O 
phosphorylation O 
in O 
a O 
ROS O 
dependent O 
manner O 
but O 
independent O 
of O 
changes O 
in O 
cAMP B-ABBREVIATION 
levels O 
. O 
Taken O 
together O 
, O 
we O 
demonstrate O 
a O 
redox O 
- O 
mediated O 
activation O 
of O 
PKA O 
by O 
PDGF-BB O 
thus O 
highlighting O 
a O 
physiological O 
role O 
of O 
ROS O 
as O 
regulator O 
of O 
PKA O 
activity O 
in O 
rat O 
mesangial O 
cells O 
. O 

Dynamics O 
of O 
Excitons O 
and O 
Hole-Polarons O 
in O 
Composite O 
P3HT B-ABBREVIATION 
/ O 
PCBM B-ABBREVIATION 
Nanoparticles O 
. O 

dynamics O 
of O 
charge O 
separation O 
in O 
aqueous O 
suspensions O 
of O 
regioregular O 
P3HT B-ABBREVIATION 
nanoparticles O 
containing O 
PCBM B-ABBREVIATION 
were O 
investigated O 
for O 
the O 
first O 
time O 
using O 
femtosecond O 
transient O 
absorption O 
spectroscopy O 
. O 
This O 
investigation O 
is O 
supported O 
by O 
the O 
recently O 
reported O 
use O 
of O 
regioregular O 
P3HT B-ABBREVIATION 
/ O 
PCBM B-ABBREVIATION 
nanoparticles O 
as O 
charge O 
trapping O 
and O 
storage O 
devices O 
. O 
In O 
this O 
study O 
, O 
the O 
presence O 
of O 
excited O 
- O 
state O 
and O 
charge O 
- O 
separated O 
species O 
, O 
including O 
singlet O 
excitons O 
, O 
polymer O 
polarons O 
and O 
free O 
charges O 
, O 
generated O 
in O 
rr- O 
P3HT B-ABBREVIATION 
/ O 
PCBM B-ABBREVIATION 
nanoparticles O 
was O 
identified O 
through O 
visible O 
pump O 
and O 
visible O 
/ O 
near O 
- O 
infrared O 
probe O 
femtosecond O 
transient O 
absorption O 
spectroscopy O 
at O 
a O 
range O 
of O 
electron O 
acceptor O 
concentrations O 
. O 
The O 
decrease O 
of O 
the O 
singlet O 
exciton O 
lifetime O 
by O 
charge O 
transfer O 
to O 
PCBM B-ABBREVIATION 
is O 
well O 
described O 
by O 
a O 
one O 
- O 
dimensional O 
diffusion O 
model O 
with O 
a O 
P3HT B-ABBREVIATION 
domain O 
size O 
of O 
approximately O 
5 O 
nm O 
for O 
5-50 O 
wt O 
% O 
PCBM B-ABBREVIATION 
. O 
This O 
model O 
also O 
indicates O 
that O 
bimolecular O 
recombination O 
is O 
the O 
dominant O 
charge O 
recombination O 
mechanism O 
at O 
20 O 
wt O 
% O 
PCBM B-ABBREVIATION 
and O 
above O 
. O 

of O 
hydrogen B-SYSTEMATIC 
bonding O 
on O 
internal O 
conversion O 
of O 
GFP O 
- O 
like O 
chromophores O 
. O 
II O 
. O 
The O 
meta-amino B-SYSTEMATIC 
systems O 
. O 

rationalize O 
the O 
efficient O 
quenching O 
of O 
the O 
fluorescence O 
and O 
the O 
Z O 
→ O 
E O 
photoisomerization O 
of O 
m-ABDI B-ABBREVIATION 
, O 
the O 
meta-amino B-SYSTEMATIC 
analogue O 
of O 
the O 
green O 
fluorescent O 
protein O 
( O 
GFP O 
) O 
chromophore O 
, O 
in O 
protic O 
solvents O 
, O 
the O 
femtosecond O 
time O 
- O 
resolved O 
fluorescence O 
and O 
transient O 
infrared O 
( O 
TRIR O 
) O 
spectra O 
of O 
m-ABDI B-ABBREVIATION 
in O 
CD3CN B-FORMULA 
, O 
CH3OH B-FORMULA 
, O 
and O 
CD3OD B-FORMULA 
are O 
determined O 
. O 
For O 
solutions O 
in O 
CD3CN B-FORMULA 
, O 
the O 
fluorescence O 
decay O 
lifetime O 
is O 
∼7.9 O 
ns O 
and O 
IR O 
absorption O 
lines O 
near O 
1513 O 
, O 
1531 O 
, O 
1557 O 
, O 
and O 
1613 O 
cm(-1) O 
of O 
m-ABDI B-ABBREVIATION 
in O 
its O 
electronically O 
excited O 
state O 
were O 
observed O 
with O 
a O 
decay O 
time O 
> O 
5 O 
ns O 
. O 
For O 
solutions O 
in O 
CH3OH B-FORMULA 
, O 
the O 
fluorescence O 
decay O 
is O 
double O 
exponential O 
with O 
time O 
constants O 
of O 
∼16 O 
and O 
62 O 
ps O 
. O 
In O 
addition O 
to O 
IR O 
absorption O 
lines O 
of O 
m-ABDI B-ABBREVIATION 
in O 
its O 
electronically O 
excited O 
state O 
with O 
a O 
decay O 
time O 
of O 
∼16 O 
ps O 
, O 
new O 
features O 
near O 
1513 O 
, O 
1532 O 
, O 
1554 O 
, O 
and O 
1592 O 
cm(-1) O 
were O 
observed O 
to O 
have O 
a O 
rise O 
time O 
of O 
∼19 O 
ps O 
and O 
a O 
decay O 
constant O 
of O 
∼58 O 
ps O 
, O 
indicating O 
formation O 
of O 
an O 
intermediate O 
. O 
The O 
assignments O 
for O 
the O 
IR O 
spectra O 
of O 
the O 
ground O 
and O 
excited O 
states O 
were O 
assisted O 
with O 
DFT O 
and O 
TDDFT O 
calculations O 
, O 
respectively O 
. O 
We O 
conclude O 
that O 
the O 
torsion O 
of O 
the O 
exocyclic O 
C═C B-FORMULA 
bond O 
( O 
the O 
τ O 
torsion O 
) O 
is O 
responsible O 
for O 
the O 
nonradiative O 
decay O 
of O 
electronically O 
excited O 
m-ABDI B-ABBREVIATION 
in O 
CD3CN B-FORMULA 
. O 
However O 
, O 
in O 
CH3OH B-FORMULA 
and O 
CD3OD B-FORMULA 
, O 
the O 
solute O 
- O 
solvent O 
hydrogen B-SYSTEMATIC 
bonding O 
( O 
SSHB O 
) O 
interactions O 
diminish O 
significantly O 
the O 
barrier O 
of O 
the O 
τ O 
torsion O 
and O 
induce O 
a O 
new O 
pathway O 
that O 
competes O 
successfully O 
with O 
the O 
τ O 
torsion O 
, O 
consistent O 
with O 
the O 
efficient O 
fluorescence O 
quenching O 
and O 
the O 
diminished O 
yield O 
for O 
Z O 
→ O 
E O 
photoisomerization O 
. O 
The O 
new O 
pathway O 
is O 
likely O 
associated O 
with O 
excited O 
- O 
state O 
proton O 
transfer O 
( O 
ESPT O 
) O 
from O 
the O 
solvent O 
to O 
m-ABDI B-ABBREVIATION 
, O 
particularly O 
the O 
carbonyl B-FAMILY 
group O 
, O 
and O 
generates O 
an O 
intermediate O 
( O 
ESPT* O 
) O 
that O 
is O 
weakly O 
fluorescent O 
. O 

Identification O 
and O 
Characterization O 
of O 
an O 
Essential O 
Pyruvate B-TRIVIAL 
Transporter O 
from O 
Trypanosoma O 
brucei O 
. O 

export O 
is O 
an O 
essential O 
physiological O 
process O 
for O 
the O 
bloodstream O 
form O 
of O 
T O 
. O 
brucei O 
as O 
the O 
parasite O 
would O 
otherwise O 
accumulate O 
this O 
end O 
product O 
of O 
glucose B-TRIVIAL 
metabolism O 
to O 
toxic O 
levels O 
. O 
In O 
the O 
studies O 
reported O 
here O 
genetic O 
complementation O 
in O 
Saccharomyces O 
cerevisiae O 
has O 
been O 
employed O 
to O 
identify O 
a O 
gene O 
( O 
TbPT0 O 
) O 
that O 
encodes O 
this O 
vital O 
pyruvate B-TRIVIAL 
transporter O 
from O 
T O 
. O 
brucei O 
. O 
Expression O 
of O 
TbPT0 O 
in O 
S O 
. O 
cerevisiae O 
reveals O 
that O 
TbPT0 O 
is O 
a O 
high O 
affinity O 
pyruvate B-TRIVIAL 
transporter O 
. O 
TbPT0 O 
belongs O 
to O 
a O 
clustered O 
multigene O 
family O 
consisting O 
of O 
five O 
members O 
, O 
whose O 
expression O 
is O 
up O 
- O 
regulated O 
in O 
the O 
bloodstream O 
form O 
. O 
Interestingly O 
, O 
TbPT O 
family O 
permeases O 
are O 
related O 
to O 
polytopic O 
proteins O 
from O 
plants O 
but O 
not O 
to O 
characterized O 
monocarboxylate B-SYSTEMATIC 
transporters O 
from O 
mammals O 
. O 
Remarkably O 
, O 
inhibition O 
of O 
the O 
TbPT O 
gene O 
family O 
expression O 
in O 
bloodstream O 
parasites O 
by O 
RNAi O 
is O 
lethal O 
, O 
confirming O 
the O 
physiological O 
relevance O 
of O 
these O 
transporters O 
. O 
The O 
discovery O 
of O 
TbPT0 O 
reveals O 
for O 
the O 
first O 
time O 
the O 
identity O 
of O 
the O 
essential O 
pyruvate B-TRIVIAL 
transporter O 
and O 
provides O 
a O 
potential O 
drug O 
target O 
against O 
the O 
mammalian O 
life O 
cycle O 
stage O 
of O 
T O 
. O 
brucei O 
. O 

of O 
bisphenol-A B-TRIVIAL 
on O 
insulin O 
signal O 
transduction O 
and O 
glucose B-TRIVIAL 
oxidation O 
in O 
skeletal O 
muscle O 
of O 
adult O 
male O 
albino O 
rat O 
. O 

estrogenic O 
monomer O 
bisphenol-A B-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
an O 
endocrine O 
- O 
disrupting O 
chemical O 
used O 
in O 
the O 
production O 
of O 
epoxy B-SYSTEMATIC 
resins O 
, O 
plastic O 
food O 
and O 
beverage O 
containers O 
, O 
leading O 
to O 
ubiquitous O 
human O 
exposure O 
. O 
Environmentally O 
relevant O 
doses O 
of O 
BPA B-ABBREVIATION 
have O 
profound O 
effects O 
on O 
mice O 
endocrine O 
pancreas O 
. O 
It O 
increases O 
pancreatic O 
insulin O 
content O 
and O 
favors O 
postprandial O 
hyperinsulinemia O 
and O 
insulin O 
resistance O 
in O 
male O 
mice O 
. O 
Skeletal O 
muscle O 
plays O 
a O 
crucial O 
role O 
in O 
maintaining O 
systemic O 
glucose B-TRIVIAL 
metabolism O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
possible O 
effects O 
of O 
BPA B-ABBREVIATION 
on O 
insulin O 
- O 
signaling O 
molecules O 
and O 
glucose B-TRIVIAL 
oxidation O 
in O 
skeletal O 
muscle O 
of O 
male O 
rat O 
. O 
Adult O 
male O 
Wistar O 
albino O 
rats O 
were O 
divided O 
into O 
three O 
groups O 
. O 
Group O 
I O 
: O 
control O 
( O 
vehicle O 
treated O 
) O 
and O 
groups O 
II O 
and O 
III O 
were O 
administered O 
with O 
BPA B-ABBREVIATION 
orally O 
( O 
20 O 
and O 
200 O 
mg O 
/ O 
kg O 
bw O 
/ O 
day O 
, O 
respectively O 
) O 
. O 
Although O 
there O 
was O 
no O 
change O 
in O 
the O 
levels O 
of O 
insulin O 
receptor O 
( O 
IR O 
) O 
, O 
Akt O 
( O 
protein O 
kinase O 
B O 
) O 
and O 
glucose B-TRIVIAL 
transporter-4 O 
( O 
GLUT4 O 
) O 
messenger O 
RNA O 
, O 
BPA B-ABBREVIATION 
significantly O 
decreased O 
the O 
IR O 
, O 
Akt O 
and O 
GLUT4 O 
protein O 
levels O 
( O 
both O 
plasma O 
membrane O 
and O 
cytosolic O 
fraction O 
) O 
of O 
the O 
gastrocnemius O 
muscle O 
. O 
There O 
was O 
an O 
increase O 
in O 
serum O 
insulin O 
and O 
decrease O 
in O 
serum O 
testosterone B-TRIVIAL 
levels O 
but O 
fasting O 
blood O 
glucose B-TRIVIAL 
level O 
remained O 
unaltered O 
. O 
In O 
conclusion O 
, O 
BPA B-ABBREVIATION 
has O 
adverse O 
effects O 
on O 
phosphorylation O 
of O 
Akt O 
, O 
GLUT4 O 
translocation O 
and O 
(14)C-glucose B-SYSTEMATIC 
oxidation O 
. O 

- O 
dependent O 
changes O 
in O 
hepatic O 
and O 
intestinal O 
induction O 
of O 
cytochrome O 
P450 O 
3A O 
after O 
administration O 
of O 
dexamethasone B-TRIVIAL 
to O 
rats O 
. O 

1 O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
the O 
dose O 
of O 
and O 
the O 
number O 
of O 
times O 
an O 
inducer O 
was O 
administered O 
and O 
the O 
duration O 
of O 
induction O 
of O 
hepatic O 
and O 
intestinal O 
cytochrome O 
P450 O 
3A O 
( O 
CYP3A O 
) O 
in O 
rats O 
using O 
dexamethasone B-SYSTEMATIC 
21-phosphate I-SYSTEMATIC 
( O 
DEX-P B-ABBREVIATION 
) O 
and O 
midazolam B-TRIVIAL 
( O 
MDZ B-ABBREVIATION 
) O 
as O 
an O 
inducer O 
and O 
a O 
substrate O 
to O 
CYP3A O 
, O 
respectively O 
. O 
2 O 
. O 
The O 
number O 
of O 
times O 
DEX-P B-ABBREVIATION 
was O 
administered O 
was O 
not O 
a O 
significant O 
factor O 
in O 
the O 
induction O 
of O 
either O 
hepatic O 
or O 
intestinal O 
CYP3A O 
; O 
however O 
, O 
administration O 
of O 
DEX-P B-ABBREVIATION 
multiple O 
times O 
markedly O 
decreased O 
the O 
bioavailability O 
of O 
DEX-P B-ABBREVIATION 
by O 
self O 
- O 
induction O 
of O 
CYP3A O 
. O 
3 O 
. O 
CYP3A O 
induction O 
in O 
the O 
liver O 
increased O 
depending O 
on O 
the O 
dose O 
of O 
DEX-P B-ABBREVIATION 
, O 
whereas O 
that O 
in O 
intestine O 
showed O 
a O 
mild O 
increase O 
, O 
but O 
the O 
induction O 
level O 
was O 
almost O 
constant O 
regardless O 
of O 
the O 
dose O 
of O 
DEX-P B-ABBREVIATION 
. O 
4 O 
. O 
Administration O 
of O 
a O 
single O 
dose O 
of O 
DEX-P B-ABBREVIATION 
showed O 
a O 
temporal O 
increase O 
in O 
CYP3A O 
activity O 
in O 
both O 
tissues O 
and O 
the O 
induction O 
ratios O 
reached O 
maximum O 
values O 
at O 
12 O 
h O 
after O 
DEX-P B-ABBREVIATION 
administration O 
. O 
On O 
the O 
other O 
hand O 
, O 
a O 
mild O 
increase O 
of O 
CYP3A O 
activity O 
, O 
which O 
lasted O 
for O 
at O 
least O 
48 O 
h O 
, O 
was O 
observed O 
in O 
both O 
tissues O 
after O 
administration O 
of O 
multiple O 
doses O 
. O 
5 O 
. O 
Some O 
physiological O 
compounds O 
such O 
as O 
cytokines O 
might O 
be O 
involved O 
in O 
decreasing O 
the O 
CYP3A O 
activity O 
to O 
maintain O 
homeostasis O 
of O 
the O 
body O 
. O 

is O 
a O 
common O 
mode O 
of O 
cell O 
death O 
that O 
contributes O 
to O 
neuronal O 
loss O 
associated O 
with O 
neurodegeneration O 
. O 
Single- O 
nucleotide B-FAMILY 
polymorphisms O 
( O 
SNPs O 
) O 
in O 
chromosomal O 
DNA O 
are O 
contributing O 
factors O 
dictating O 
natural O 
susceptibility O 
of O 
humans O 
to O 
disease O 
. O 
Here O 
, O 
the O 
most O 
common O 
SNPs O 
affecting O 
neuronal O 
vulnerability O 
to O 
apoptosis O 
are O 
reviewed O 
in O 
the O 
context O 
of O 
neurological O 
disorders O 
. O 
Polymorphic O 
variants O 
in O 
genes O 
encoding O 
apoptotic O 
proteins O 
, O 
either O 
from O 
the O 
extrinsic O 
( O 
FAS O 
, O 
TNF-α O 
, O 
CASP8 O 
) O 
or O 
the O 
intrinsic O 
( O 
BAX O 
, O 
BCL2 O 
, O 
CASP3 O 
, O 
CASP9 O 
) O 
pathways O 
could O 
be O 
highly O 
valuable O 
in O 
the O 
diagnosis O 
of O 
neurodegenerative O 
diseases O 
and O 
stroke O 
. O 
Interestingly O 
, O 
the O 
Arg72Pro O 
SNP O 
in O 
TP53 O 
, O 
the O 
gene O 
encoding O 
tumor O 
suppressor O 
p53 O 
, O 
was O 
recently O 
revealed O 
a O 
biomarker O 
of O 
poor O 
prognosis O 
in O 
stroke O 
due O 
to O 
its O 
ability O 
to O 
modulate O 
neuronal O 
apoptotic O 
death O 
. O 
Search O 
for O 
new O 
SNPs O 
responsible O 
for O 
genetic O 
variability O 
to O 
apoptosis O 
will O 
ensure O 
the O 
implementation O 
of O 
novel O 
diagnostic O 
and O 
prognostic O 
tools O 
, O 
as O 
well O 
as O 
therapeutic O 
strategies O 
against O 
neurological O 
diseases O 
. O 

of O 
pretibial O 
myxedema O 
with O 
dexamethazone B-TRIVIAL 
injected O 
subcutaneously O 
by O 
mesotherapy O 
needles O 
. O 

myxedema O 
( O 
PTM O 
) O 
is O 
a O 
rare O 
extrathyroidal O 
manifestation O 
of O 
Graves' O 
disease O 
that O 
requires O 
treatment O 
when O 
the O 
clinical O 
picture O 
is O 
markedly O 
evident O 
. O 
In O 
addition O 
to O 
topical O 
treatment O 
with O 
steroid B-FAMILY 
ointments O 
, O 
there O 
have O 
been O 
previous O 
reports O 
of O 
subcutaneous O 
injections O 
of O 
steroids B-FAMILY 
. O 
This O 
procedure O 
may O 
cause O 
nodular O 
degeneration O 
of O 
the O 
skin O 
due O 
to O 
fat O 
atrophy O 
when O 
standard O 
needles O 
are O 
used O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
have O 
tried O 
a O 
novel O 
modality O 
of O 
treatment O 
of O 
PTM O 
by O 
injecting O 
a O 
solution O 
of O 
dexamethasone B-TRIVIAL 
in O 
the O 
subcutaneous O 
tissue O 
using O 
needles O 
employed O 
for O 
mesotherapy O 
. O 
These O 
needles O 
are O 
≤ O 
4 O 
mm O 
long O 
and O 
deliver O 
the O 
medication O 
within O 
the O 
dermis O 
or O 
the O 
first O 
layer O 
of O 
the O 
subcutaneous O 
fat O 
. O 
We O 
have O 
treated O 
five O 
patients O 
, O 
four O 
with O 
diffuse O 
and O 
one O 
with O 
elephanthiasic O 
PTM O 
. O 
We O 
utilized O 
multiple O 
injections O 
of O 
a O 
solution O 
of O 
dexamethasone B-TRIVIAL 
, O 
lidocaine B-TRIVIAL 
, O 
and O 
saline O 
in O 
the O 
PTM O 
plaque O 
and O 
in O 
the O 
pretibial O 
area O 
, O 
both O 
in O 
the O 
PTM O 
plaque O 
and O 
in O 
the O 
area O 
surrounding O 
the O 
lesions O 
, O 
once O 
a O 
week O 
for O 
three O 
consecutive O 
weeks O 
. O 
Two O 
patients O 
with O 
a O 
more O 
severe O 
form O 
of O 
PTM O 
underwent O 
another O 
two O 
cycles O 
four O 
to O 
six O 
weeks O 
after O 
initial O 
treatment O 
. O 
Patients O 
were O 
studied O 
before O 
and O 
after O 
treatment O 
by O 
clinical O 
assessment O 
and O 
ultrasound O 
of O 
the O 
pretibial O 
skin O 
. O 
The O 
treatment O 
was O 
well O 
- O 
tolerated O 
, O 
with O 
only O 
moderate O 
pain O 
upon O 
injection O 
of O 
the O 
solution O 
. O 
One O 
month O 
after O 
treatment O 
, O 
all O 
patients O 
showed O 
improvement O 
of O 
PTM O 
at O 
clinical O 
assessment O 
and O 
a O 
reduction O 
of O 
the O 
thickness O 
of O 
the O 
lesions O 
at O 
ultrasound O 
of O 
∼15% O 
, O 
involving O 
mostly O 
the O 
dermis O 
. O 
Moreover O 
, O 
all O 
patients O 
reported O 
amelioration O 
of O 
the O 
leg O 
appearance O 
. O 
The O 
present O 
study O 
, O 
although O 
preliminary O 
, O 
shows O 
that O 
intralesion O 
steroid B-FAMILY 
injection O 
with O 
mesotherapy O 
needles O 
in O 
PTM O 
is O 
effective O 
and O 
well O 
tolerated O 
, O 
and O 
does O 
not O 
cause O 
undesired O 
long O 
- O 
term O 
modifications O 
of O 
the O 
skin O 
. O 
More O 
studies O 
are O 
warranted O 
to O 
standardize O 
such O 
treatment O 
in O 
larger O 
groups O 
of O 
patients O 
. O 

ligands O 
for O 
adenosine B-TRIVIAL 
receptors O 
. O 

is O 
increasing O 
in O 
developing O 
fluorescent O 
ligands O 
for O 
characterization O 
of O 
adenosine B-TRIVIAL 
receptors O 
( O 
ARs O 
) O 
, O 
which O 
hold O 
a O 
promise O 
of O 
usefulness O 
in O 
the O 
drug O 
discovery O 
process O 
. O 
The O 
size O 
of O 
a O 
strategically O 
labeled O 
AR O 
ligand O 
can O 
be O 
greatly O 
increased O 
after O 
the O 
attachment O 
of O 
a O 
fluorophore O 
. O 
The O 
choice O 
of O 
dye O 
moiety O 
( O 
e.g O 
. O 
Alexa B-TRIVIAL 
Fluor I-TRIVIAL 
488 I-TRIVIAL 
) O 
, O 
attachment O 
point O 
and O 
linker O 
length O 
can O 
alter O 
the O 
selectivity O 
and O 
potency O 
of O 
the O 
parent O 
molecule O 
. O 
Fluorescent O 
derivatives O 
of O 
adenosine B-TRIVIAL 
agonists O 
and O 
antagonists O 
( O 
e.g O 
. O 
XAC B-ABBREVIATION 
and O 
other O 
heterocyclic O 
antagonist O 
scaffolds O 
) O 
have O 
been O 
synthesized O 
and O 
characterized O 
pharmacologically O 
. O 
Some O 
are O 
useful O 
AR O 
probes O 
for O 
flow O 
cytometry O 
, O 
fluorescence O 
correlation O 
spectroscopy O 
, O 
fluorescence O 
microscopy O 
, O 
fluorescence O 
polarization O 
, O 
fluorescence O 
resonance O 
energy O 
transfer O 
, O 
and O 
scanning O 
confocal O 
microscopy O 
. O 
Thus O 
, O 
the O 
approach O 
of O 
fluorescent O 
labeled O 
GPCR O 
ligands O 
, O 
including O 
those O 
for O 
ARs O 
, O 
is O 
a O 
growing O 
dynamic O 
research O 
field O 
. O 

carbon B-SYSTEMATIC 
nanoplates O 
from O 
regenerated O 
silk O 
proteins O 
for O 
supercapacitors O 
. O 

carbon B-SYSTEMATIC 
-based O 
microporous O 
nanoplates O 
containing O 
numerous O 
heteroatoms O 
( O 
H-CMNs O 
) O 
are O 
fabricated O 
from O 
regenerated O 
silk O 
fibroin O 
by O 
the O 
carbonization O 
and O 
activation O 
of O 
KOH B-FORMULA 
. O 
The O 
H-CMNs O 
exhibit O 
superior O 
electrochemical O 
performance O 
, O 
displaying O 
a O 
specific O 
capacitance O 
of O 
264 O 
F O 
/ O 
g O 
in O 
aqueous O 
electrolytes O 
, O 
a O 
specific O 
energy O 
of O 
133 O 
Wh O 
/ O 
kg O 
, O 
a O 
specific O 
power O 
of O 
217 O 
kW O 
/ O 
kg O 
, O 
and O 
a O 
stable O 
cycle O 
life O 
over O 
10000 O 
cycles O 
. O 

high O 
throughput O 
screen O 
identified O 
adamantane B-TRIVIAL 
dipeptide O 
1 O 
as O 
an O 
inhibitor O 
of O 
Ebola O 
virus O 
( O 
EboV O 
) O 
infection O 
. O 
Hit O 
- O 
to O 
- O 
lead O 
optimization O 
to O 
determine O 
the O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
identified O 
the O 
more O 
potent O 
EboV O 
inhibitor O 
2 O 
and O 
a O 
photoaffinity O 
labeling O 
agent O 
3 O 
. O 
These O 
anti-viral O 
compounds O 
were O 
employed O 
to O 
identify O 
the O 
target O 
as O 
Niemann-Pick O 
C1 O 
( O 
NPC1 O 
) O 
, O 
a O 
host O 
protein O 
that O 
binds O 
the O 
EboV O 
glycoprotein O 
and O 
is O 
essential O 
for O 
infection O 
. O 
These O 
studies O 
establish O 
NPC1 O 
as O 
a O 
promising O 
target O 
for O 
anti-viral O 
therapy O 
. O 

and O 
phenolic B-FAMILY 
constituents O 
from O 
the O 
fruiting O 
bodies O 
of O 
the O 
basidiomycete O 
Sarcodon O 
joedes O 
. O 

secondary O 
metabolites O 
, O 
including O 
four O 
steroids B-FAMILY 
, O 
four O 
phenolics B-FAMILY 
and O 
one O 
cerebroside B-FAMILY 
, O 
were O 
isolated O 
from O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
the O 
fruiting O 
bodies O 
of O 
the O 
basidiomycete O 
Sarcodon O 
joedes O 
. O 
The O 
isolated O 
compounds O 
were O 
identified O 
by O 
spectroscopic O 
analyses O 
as O 
(22E,24R)-6β-methoxyergosta-7,22-diene-3β,5α-diol B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
2',3'-diacetoxy-3,4,5',6',4″-pentahydroxy-p-terphenyl B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
cerebroside B-TRIVIAL 
B I-TRIVIAL 
( O 
3 O 
) O 
, O 
ergosta-7,22-dien-3β-ol B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
ergosterol B-TRIVIAL 
peroxide I-TRIVIAL 
( O 
5 O 
) O 
, O 
(22E,24R)-3β-hydroxy-ergosta-5,22-dien-7-one B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
7 O 
) O 
, O 
methyl B-SYSTEMATIC 
p-hydroxybenzoate I-SYSTEMATIC 
( O 
8 O 
) O 
and O 
3,4-dihydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
9 O 
) O 
. O 
The O 
cytotoxic O 
activities O 
of O 
these O 
compounds O 
were O 
evaluated O 
. O 
All O 
these O 
compounds O 
were O 
isolated O 
from O 
this O 
fungus O 
for O 
the O 
first O 
time O 
. O 

and O 
characterization O 
of O 
an O 
MRI O 
Gd B-FORMULA 
-based O 
probe O 
designed O 
to O 
target O 
the O 
translocator O 
protein O 
. O 

is O 
the O 
lead O 
compound O 
of O 
a O 
recently O 
reported O 
pyrazolo[1,5-a]pyrimidineacetamide B-SYSTEMATIC 
series O 
, O 
targeting O 
the O 
translocator O 
protein O 
( O 
TSPO O 
18 O 
kDa O 
) O 
, O 
and O 
as O 
such O 
, O 
this O 
structure O 
, O 
as O 
well O 
as O 
closely O 
related O 
derivatives O 
, O 
have O 
been O 
already O 
successfully O 
used O 
as O 
positron O 
emission O 
tomography O 
radioligands O 
. O 
On O 
the O 
basis O 
of O 
the O 
pharmacological O 
core O 
of O 
this O 
ligands O 
series O 
, O 
a O 
new O 
magnetic O 
resonance O 
imaging O 
probe O 
, O 
coded O 
DPA-C(6)-(Gd)DOTAMA B-FORMULA 
was O 
designed O 
and O 
successfully O 
synthesized O 
in O 
six O 
steps O 
and O 
13% O 
overall O 
yield O 
from O 
DPA-713 B-IDENTIFIER 
. O 
The O 
Gd-DOTA B-SYSTEMATIC 
monoamide I-SYSTEMATIC 
cage O 
( O 
DOTA B-ABBREVIATION 
= O 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
represents O 
the O 
magnetic O 
resonance O 
imaging O 
reporter O 
, O 
which O 
is O 
spaced O 
from O 
the O 
phenylpyrazolo[1,5-a]pyrimidineacetamide B-SYSTEMATIC 
moiety O 
( O 
DPA-713 B-IDENTIFIER 
motif O 
) O 
by O 
a O 
six O 
carbon B-SYSTEMATIC 
-atom O 
chain O 
. O 
DPA-C(6)-(Gd)DOTAMA B-FORMULA 
relaxometric O 
characterization O 
showed O 
the O 
typical O 
behavior O 
of O 
a O 
small O 
- O 
sized O 
molecule O 
( O 
relaxivity O 
value O 
: O 
6.02 O 
mM(-1) O 
s(-1) O 
at O 
20 O 
MHz O 
) O 
. O 
The O 
good O 
hydrophilicity O 
of O 
the O 
metal O 
chelate O 
makes O 
DPA-C(6)-(Gd)DOTAMA B-FORMULA 
soluble O 
in O 
water O 
, O 
affecting O 
thus O 
its O 
biodistribution O 
with O 
respect O 
to O 
the O 
parent O 
lipophilic O 
DPA-713 B-IDENTIFIER 
molecule O 
. O 
For O 
this O 
reason O 
, O 
it O 
was O 
deemed O 
of O 
interest O 
to O 
load O 
the O 
probe O 
to O 
a O 
large O 
carrier O 
in O 
order O 
to O 
increase O 
its O 
residence O 
lifetime O 
in O 
blood O 
. O 
Whereas O 
DPA-C(6)-(Gd)DOTAMA B-FORMULA 
binds O 
to O 
serum O 
albumin O 
with O 
a O 
low O 
affinity O 
constant O 
, O 
it O 
can O 
be O 
entrapped O 
into O 
liposomes O 
( O 
both O 
in O 
the O 
membrane O 
and O 
in O 
the O 
inner O 
aqueous O 
cavity O 
) O 
. O 
The O 
stability O 
of O 
the O 
supramolecular O 
adduct O 
formed O 
by O 
the O 
Gd B-FORMULA 
-complex O 
and O 
liposomes O 
was O 
assessed O 
by O 
a O 
competition O 
test O 
with O 
albumin O 
. O 

and O 
composition O 
of O 
model O 
cheeses O 
influence O 
sodium B-SYSTEMATIC 
NMR O 
mobility O 
, O 
kinetics O 
of O 
sodium B-SYSTEMATIC 
release O 
and O 
sodium B-SYSTEMATIC 
partition O 
coefficients O 
. O 

mobility O 
and O 
release O 
of O 
sodium B-SYSTEMATIC 
ions O 
were O 
assessed O 
in O 
model O 
cheeses O 
with O 
three O 
different O 
lipid O 
/ O 
protein O 
ratios O 
, O 
with O 
or O 
without O 
added O 
NaCl B-FORMULA 
. O 
The O 
rheological O 
properties O 
of O 
the O 
cheeses O 
were O 
analysed O 
using O 
uniaxial O 
compression O 
tests O 
. O 
Microstructure O 
was O 
characterised O 
by O 
confocal O 
laser O 
scanning O 
microscopy O 
. O 
(23)Na B-FORMULA 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
spectroscopy O 
was O 
used O 
to O 
study O 
the O 
molecular O 
mobility O 
of O 
sodium B-SYSTEMATIC 
ions O 
in O 
model O 
cheeses O 
through O 
measurements O 
of O 
the O 
relaxation O 
and O 
creation O 
times O 
. O 
Greater O 
mobility O 
was O 
observed O 
in O 
cheeses O 
containing O 
a O 
lower O 
protein O 
content O 
and O 
with O 
added O 
NaCl B-FORMULA 
. O 
The O 
kinetics O 
of O 
sodium B-SYSTEMATIC 
release O 
from O 
the O 
cheese O 
to O 
an O 
aqueous O 
phase O 
was O 
correlated O 
with O 
the O 
mobility O 
of O 
sodium B-SYSTEMATIC 
ions O 
. O 
The O 
highest O 
rates O 
of O 
sodium B-SYSTEMATIC 
release O 
were O 
observed O 
with O 
a O 
lower O 
protein O 
content O 
and O 
with O 
added O 
NaCl B-FORMULA 
. O 
The O 
water O 
/ O 
cheese O 
partition O 
coefficients O 
of O 
sodium B-SYSTEMATIC 
increased O 
when O 
NaCl B-FORMULA 
was O 
added O 
or O 
the O 
protein O 
content O 
was O 
higher O 
. O 
The O 
study O 
highlighted O 
the O 
effect O 
of O 
model O 
cheese O 
characteristics O 
on O 
molecular O 
and O 
macroscopic O 
behaviours O 
of O 
sodium B-SYSTEMATIC 
. O 

pharmacology O 
of O 
L-DOPA B-ABBREVIATION 
-induced O 
dyskinesia O 
in O 
Parkinson's O 
disease O 
. O 

( O 
L-DOPA B-ABBREVIATION 
) O 
remains O 
the O 
most O 
effective O 
symptomatic O 
treatment O 
of O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
However O 
, O 
long O 
- O 
term O 
administration O 
of O 
L-DOPA B-ABBREVIATION 
is O 
marred O 
by O 
the O 
emergence O 
of O 
abnormal O 
involuntary O 
movements O 
, O 
i.e O 
. O 
, O 
L-DOPA B-ABBREVIATION 
-induced O 
dyskinesia O 
( O 
LID O 
) O 
. O 
Years O 
of O 
intensive O 
research O 
have O 
yielded O 
significant O 
progress O 
in O 
the O 
quest O 
to O 
elucidate O 
the O 
mechanisms O 
leading O 
to O 
the O 
development O 
and O 
expression O 
of O 
dyskinesia O 
and O 
maintenance O 
of O 
the O 
dyskinetic O 
state O 
, O 
but O 
the O 
search O 
for O 
a O 
complete O 
understanding O 
is O 
still O 
ongoing O 
. O 
Herein O 
, O 
we O 
summarize O 
the O 
current O 
knowledge O 
of O 
the O 
pharmacology O 
of O 
LID O 
in O 
PD O 
. O 
Specifically O 
, O 
we O 
review O 
evidence O 
gathered O 
from O 
postmortem O 
and O 
pharmacological O 
studies O 
, O 
both O 
preclinical O 
and O 
clinical O 
, O 
and O 
discuss O 
the O 
involvement O 
of O 
dopaminergic O 
and O 
nondopaminergic O 
systems O 
, O 
including O 
glutamatergic O 
, O 
opioid O 
, O 
serotonergic O 
, O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
)-ergic O 
, O 
adenosine B-TRIVIAL 
, O 
cannabinoid O 
, O 
adrenergic O 
, O 
histaminergic O 
, O 
and O 
cholinergic O 
systems O 
. O 
Moreover O 
, O 
we O 
discuss O 
changes O 
occurring O 
in O 
transcription O 
factors O 
, O 
intracellular O 
signaling O 
, O 
and O 
gene O 
expression O 
in O 
the O 
dyskinetic O 
phenotype O 
. O 
Inasmuch O 
as O 
a O 
multitude O 
of O 
neurotransmitters O 
and O 
receptors O 
play O 
a O 
role O 
in O 
the O 
etiology O 
of O 
dyskinesia O 
, O 
we O 
propose O 
that O 
to O 
optimally O 
alleviate O 
this O 
motor O 
complication O 
, O 
it O 
may O 
be O 
necessary O 
to O 
develop O 
combined O 
treatment O 
approaches O 
that O 
will O 
target O 
simultaneously O 
more O 
than O 
one O 
neurotransmitter O 
system O 
. O 
This O 
could O 
be O 
achieved O 
via O 
three O 
ways O 
as O 
follows O 
: O 
1 O 
) O 
by O 
developing O 
compounds O 
that O 
will O 
interact O 
simultaneously O 
to O 
a O 
multitude O 
of O 
receptors O 
with O 
the O 
required O 
agonist O 
/ O 
antagonist O 
effect O 
at O 
each O 
target O 
, O 
2 O 
) O 
by O 
targeting O 
intracellular O 
signaling O 
cascades O 
where O 
the O 
signals O 
mediated O 
by O 
multiple O 
receptors O 
converge O 
, O 
and O 
/ O 
or O 
3 O 
) O 
to O 
regulate O 
gene O 
expression O 
in O 
a O 
manner O 
that O 
has O 
effects O 
on O 
signaling O 
by O 
multiple O 
pathways O 
. O 

- O 
based O 
optimization O 
of O 
oxadiazole B-FAMILY 
-based O 
GSK-3 O 
inhibitors O 
. O 

of O 
glycogen O 
synthase O 
kinase-3 O 
( O 
GSK-3 O 
) O 
induces O 
neuroprotective O 
effects O 
, O 
e.g O 
. O 
decreases O 
β-amyloid O 
production O 
and O 
reduces O 
tau O 
hyperphosphorylation O 
, O 
which O 
are O 
both O 
associated O 
with O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
The O 
two O 
isoforms O 
of O 
GSK-3 O 
in O 
mammalians O 
are O 
GSK-3α O 
and O 
β O 
, O 
which O 
share O 
98% O 
homology O 
in O 
their O 
catalytic O 
domains O 
. O 
We O 
investigated O 
GSK-3 O 
inhibitors O 
based O 
on O 
2 O 
different O 
scaffolds O 
in O 
order O 
to O 
elucidate O 
the O 
demands O 
of O 
the O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
[ O 
1 O 
] O 
. O 
Particularly O 
, O 
the O 
oxadiazole B-FAMILY 
scaffold O 
provided O 
potent O 
and O 
selective O 
GSK-3 O 
inhibitors O 
. O 
For O 
example O 
, O 
the O 
most O 
potent O 
inhibitor O 
of O 
the O 
present O 
series O 
, O 
the O 
acetamide B-SYSTEMATIC 
26d O 
, O 
is O 
characterized O 
by O 
an O 
IC50 O 
of O 
2 O 
nM O 
for O 
GSK-3α O 
and O 
17 O 
nM O 
for O 
GSK-3β O 
. O 
In O 
addition O 
, O 
the O 
benzodioxane B-SYSTEMATIC 
8g O 
showed O 
up O 
to O 
27-fold O 
selectivity O 
for O 
GSK-3α O 
over O 
GSK-3β O 
, O 
with O 
an O 
IC50 O 
of O 
35 O 
nM O 
for O 
GSK-3α O 
. O 
Two O 
GSK-3 O 
inhibitors O 
were O 
further O 
profiled O 
for O 
efficacy O 
and O 
toxicity O 
in O 
the O 
wild O 
- O 
type O 
( O 
wt O 
) O 
zebrafish O 
embryo O 
assay O 
to O 
evaluate O 
simultaneously O 
permeability O 
and O 
safety O 
. O 

assisted O 
drug O 
design O 
: O 
identification O 
of O 
a O 
potent O 
quinazoline B-SYSTEMATIC 
-based O 
Aurora O 
kinase O 
inhibitor O 
. O 

describe O 
the O 
3D-QSAR- O 
assisted O 
design O 
of O 
an O 
Aurora O 
kinase O 
A O 
inhibitor O 
with O 
improved O 
physicochemical O 
properties O 
, O 
in O 
vitro O 
activity O 
, O 
and O 
in O 
vivo O 
pharmacokinetic O 
profiles O 
over O 
those O 
of O 
the O 
initial O 
lead O 
. O 
Three O 
different O 
3D-QSAR O 
models O 
were O 
built O 
and O 
validated O 
by O 
using O 
a O 
set O 
of O 
66 O 
pyrazole B-SYSTEMATIC 
( O 
Model O 
I O 
) O 
and O 
furanopyrimidine B-SYSTEMATIC 
( O 
Model O 
II O 
) O 
compounds O 
with O 
IC(50) O 
values O 
toward O 
Aurora O 
kinase O 
A O 
ranging O 
from O 
33 O 
nM O 
to O 
10.5 O 
μM O 
. O 
The O 
best O 
3D-QSAR O 
model O 
, O 
Model O 
III O 
, O 
constructed O 
with O 
24 O 
training O 
set O 
compounds O 
from O 
both O 
series O 
, O 
showed O 
robustness O 
( O 
r(2) O 
( O 
CV O 
) O 
= O 
0.54 O 
and O 
0.52 O 
for O 
CoMFA O 
and O 
CoMSIA O 
, O 
respectively O 
) O 
and O 
superior O 
predictive O 
capacity O 
for O 
42 O 
test O 
set O 
compounds O 
( O 
R(2) O 
( O 
pred O 
) O 
= O 
0.52 O 
and O 
0.67 O 
, O 
CoMFA O 
and O 
CoMSIA O 
) O 
. O 
Superimposition O 
of O 
CoMFA O 
and O 
CoMSIA O 
Model O 
III O 
over O 
the O 
crystal O 
structure O 
of O 
Aurora O 
kinase O 
A O 
suggests O 
the O 
potential O 
to O 
improve O 
the O 
activity O 
of O 
the O 
ligands O 
by O 
decreasing O 
the O 
steric O 
clash O 
with O 
Val147 O 
and O 
Leu139 O 
and O 
by O 
increasing O 
hydrophobic O 
contact O 
with O 
Leu139 O 
and O 
Gly216 O 
residues O 
in O 
the O 
solvent-exposed O 
region O 
of O 
the O 
enzyme O 
. O 
Based O 
on O 
these O 
suggestions O 
, O 
the O 
rational O 
redesign O 
of O 
furanopyrimidine B-SYSTEMATIC 
24 O 
( O 
clog O 
P=7.41 O 
; O 
Aurora O 
A O 
IC(50) O 
= O 
43 O 
nM O 
; O 
HCT-116 O 
IC(50) O 
= O 
400 O 
nM O 
) O 
led O 
to O 
the O 
identification O 
of O 
quinazoline B-SYSTEMATIC 
67 O 
( O 
clog O 
P=5.28 O 
; O 
Aurora O 
A O 
IC(50) O 
= O 
25 O 
nM O 
; O 
HCT-116 O 
IC(50) O 
= O 
23 O 
nM O 
) O 
. O 
Rat O 
in O 
vivo O 
pharmacokinetic O 
studies O 
showed O 
that O 
67 O 
has O 
better O 
systemic O 
exposure O 
after O 
i.v O 
. O 
administration O 
than O 
24 O 
, O 
and O 
holds O 
potential O 
for O 
further O 
development O 
. O 

study O 
was O 
carried O 
out O 
to O 
investigate O 
comparatively O 
some O 
serum O 
mineral O 
levels O 
of O 
cigarette O 
smokers O 
. O 
A O 
total O 
of O 
25 O 
nonsmokers O 
( O 
control O 
group O 
) O 
and O 
50 O 
long O 
- O 
term O 
cigarette O 
smokers O 
( O 
smoking O 
for O 
at O 
least O 
15 O 
years O 
; O 
smoker O 
group O 
) O 
were O 
participated O 
in O 
the O 
study O 
. O 
Subjects O 
were O 
between O 
25 O 
and O 
40 O 
years O 
old O 
. O 
Control O 
and O 
smoker O 
groups O 
were O 
matched O 
for O 
age O 
, O 
sex O 
and O 
body O 
mass O 
index O 
status O 
. O 
The O 
blood O 
samples O 
were O 
taken O 
from O 
smokers O 
and O 
nonsmokers O 
after O 
12 O 
h O 
of O 
fasting O 
period O 
. O 
The O 
levels O 
of O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
, O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
, O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
, O 
magnesium B-SYSTEMATIC 
( O 
Mg B-FORMULA 
) O 
, O 
calcium B-SYSTEMATIC 
( O 
Ca B-FORMULA 
) O 
, O 
potassium B-SYSTEMATIC 
( O 
K B-FORMULA 
) O 
, O 
chlorine B-SYSTEMATIC 
( O 
Cl B-FORMULA 
) O 
, O 
sodium B-SYSTEMATIC 
( O 
Na B-FORMULA 
) O 
and O 
phosphorus B-SYSTEMATIC 
( O 
P B-FORMULA 
) O 
were O 
measured O 
by O 
autoanalyzer O 
using O 
commercial O 
kits O 
. O 
Student's O 
t O 
test O 
was O 
used O 
to O 
compare O 
the O 
control O 
and O 
smoker O 
groups O 
, O 
and O 
p O 
< O 
0.05 O 
indicated O 
a O 
significant O 
difference O 
. O 
Pearson's O 
correlation O 
coefficient O 
was O 
used O 
to O 
demonstrate O 
the O 
relationship O 
among O 
parameters O 
in O 
smoker O 
and O 
control O 
groups O 
. O 
Although O 
there O 
was O 
no O 
statistical O 
difference O 
( O 
p O 
> O 
0.05 O 
) O 
between O 
the O 
groups O 
regarding O 
the O 
levels O 
of O 
K B-FORMULA 
, O 
P B-FORMULA 
, O 
Mg B-FORMULA 
, O 
Na B-FORMULA 
, O 
Cl B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Ca B-FORMULA 
and O 
Cu B-FORMULA 
, O 
some O 
positive O 
correlations O 
were O 
observed O 
in O 
controls O 
but O 
not O 
in O 
smokers O 
. O 
Therefore O 
, O 
it O 
was O 
concluded O 
that O 
smoking O 
does O 
not O 
affect O 
the O 
serum O 
mineral O 
levels O 
. O 
However O 
, O 
it O 
may O 
negatively O 
affect O 
some O 
important O 
positive O 
correlations O 
among O 
minerals O 
observed O 
in O 
healthy O 
individuals O 
. O 

Assembled O 
Graphene B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Aerogels O 
with O 
Outstanding O 
Mechanical O 
Performance O 
and O 
Superhigh O 
Chemical O 
Activity O 
. O 

, O 
an O 
extremely O 
important O 
aggregation O 
state O 
of O 
various O 
self O 
- O 
assembled O 
nanoscale O 
building O 
blocks O 
, O 
have O 
great O 
potential O 
in O 
fields O 
ranging O 
from O 
energy O 
storage O 
to O 
thermal O 
insulation O 
. O 
However O 
, O 
the O 
porosity O 
of O 
aerogels O 
makes O 
them O 
mechanically O 
weak O 
in O 
most O 
cases O 
, O 
and O 
the O 
chemical O 
activity O 
of O 
the O 
resulting O 
aerogel O 
needs O 
consideration O 
. O 
Herein O 
, O 
chemically O 
crosslinked O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
3D O 
aerogels O 
with O 
large O 
specific O 
surface O 
areas O 
( O 
up O 
to O 
850 O 
m(2) O 
g(-1) O 
) O 
, O 
outstanding O 
mechanical O 
performance O 
( O 
up O 
to O 
20 O 
MPa O 
Young's O 
modulus O 
, O 
1 O 
MPa O 
yield O 
strength O 
and O 
45 O 
J O 
g(-1) O 
specific O 
energy O 
adsorption O 
) O 
, O 
and O 
superhigh O 
chemical O 
activity O 
( O 
toward O 
some O 
reducing O 
gases O 
such O 
as O 
H2 B-FORMULA 
S I-FORMULA 
, O 
HI B-FORMULA 
, O 
and O 
SO2 B-FORMULA 
) O 
, O 
are O 
fabricated O 
by O 
assembling O 
2D O 
GO O 
sheets O 
edge O 
- O 
to O 
- O 
edge O 
into O 
uniform O 
, O 
3D O 
hydrogel O 
networks O 
with O 
subsequent O 
supercritical O 
fluid O 
drying O 
. O 
These O 
aerogels O 
are O 
superior O 
to O 
other O 
3D O 
frameworks O 
( O 
e.g O 
. O 
graphene B-TRIVIAL 
aerogels O 
) O 
assembled O 
via O 
partial O 
overlapping O 
of O 
the O 
basal O 
planes O 
of O 
the O 
2D O 
building O 
blocks O 
. O 

Receptor O 
for O 
Advanced O 
Glycation O 
End-Product O 
(sRAGE)/ O 
Pentosidine B-TRIVIAL 
Ratio O 
: O 
A O 
Potential O 
Risk O 
Factor O 
Determinant O 
for O 
Type O 
2 O 
Diabetic O 
Retinopathy O 
. O 

study O 
aims O 
to O 
investigate O 
potential O 
diabetic O 
retinopathy O 
( O 
DR O 
) O 
risk O 
factors O 
by O 
evaluating O 
the O 
circulating O 
levels O 
of O 
pentosidine B-TRIVIAL 
, O 
soluble O 
receptor O 
for O 
advanced O 
glycation O 
end O 
- O 
product O 
( O 
sRAGE O 
) O 
, O 
advanced O 
oxidation O 
protein O 
product O 
( O 
AOPP O 
) O 
as O 
well O 
as O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activities O 
in O 
DR O 
patients O 
. O 
A O 
total O 
of O 
235 O 
healthy O 
controls O 
, O 
171 O 
type O 
2 O 
diabetic O 
without O 
retinopathy O 
( O 
DNR O 
) O 
and O 
200 O 
diabetic O 
retinopathy O 
( O 
DR O 
) O 
patients O 
were O 
recruited O 
. O 
Plasma O 
was O 
extracted O 
for O 
the O 
estimation O 
of O 
pentosidine B-TRIVIAL 
, O 
sRAGE O 
, O 
AOPP O 
levels O 
and O 
GPx O 
activity O 
whereas O 
peripheral O 
blood O 
mononuclear O 
cells O 
were O 
disrupted O 
for O 
SOD O 
activity O 
measurement O 
. O 
DNR O 
and O 
DR O 
patients O 
showed O 
significantly O 
higher O 
levels O 
of O 
plasma O 
pentosidine B-TRIVIAL 
, O 
sRAGE O 
and O 
AOPP O 
but O 
lower O 
GPx O 
and O 
SOD O 
activities O 
when O 
compared O 
to O 
healthy O 
controls O 
. O 
The O 
sRAGE/ O 
pentosidine B-TRIVIAL 
ratio O 
in O 
DR O 
patients O 
was O 
significantly O 
lower O 
than O 
the O 
ratio O 
detected O 
in O 
DNR O 
patients O 
. O 
Proliferative O 
DR O 
patients O 
had O 
significantly O 
higher O 
levels O 
of O 
plasma O 
pentosidine B-TRIVIAL 
, O 
sRAGE O 
, O 
AOPP O 
and O 
sRAGE/ O 
pentosidine B-TRIVIAL 
ratio O 
than O 
non-proliferative O 
DR O 
patients O 
. O 
High O 
HbA1c O 
level O 
, O 
long O 
duration O 
of O 
diabetes O 
and O 
low O 
sRAGE/ O 
pentosidine B-TRIVIAL 
ratio O 
were O 
determined O 
as O 
the O 
risk O 
factors O 
for O 
DR O 
. O 
This O 
study O 
suggests O 
that O 
sRAGE/ O 
pentosidine B-TRIVIAL 
ratio O 
could O 
serve O 
as O 
a O 
risk O 
factor O 
determinant O 
for O 
type O 
2 O 
DR O 
as O 
it O 
has O 
a O 
positive O 
correlation O 
with O 
the O 
severity O 
of O 
DR O 
. O 

, O 
little O 
is O 
known O 
about O 
a O 
number O 
issues O 
concerning O 
kava O 
( O 
Piper O 
methysticum O 
) O 
, O 
including O 
(i) O 
whether O 
kava O 
has O 
any O 
withdrawal O 
or O 
addictive O 
effects O 
; O 
(ii) O 
if O 
genetic O 
polymorphisms O 
of O 
the O 
cytochrome O 
( O 
CYP O 
) O 
P450 O 
2D6 O 
liver O 
enzyme O 
moderates O 
any O 
potential O 
adverse O 
effects O 
; O 
and O 
(iii) O 
if O 
medicinal O 
application O 
of O 
kava O 
has O 
any O 
negative O 
or O 
beneficial O 
effect O 
on O 
sexual O 
function O 
and O 
experience O 
. O 
The O 
study O 
design O 
was O 
a O 
6-week O 
, O 
double O 
- O 
blind O 
, O 
randomized O 
controlled O 
trial O 
( O 
n O 
= O 
75 O 
) O 
involving O 
chronic O 
administration O 
of O 
kava O 
( O 
one O 
tablet O 
of O 
kava O 
twice O 
per O 
day O 
; O 
120 O 
mg O 
of O 
kavalactones B-FAMILY 
per O 
day O 
, O 
titrated O 
in O 
non-response O 
to O 
two O 
tablets O 
of O 
kava O 
twice O 
per O 
day O 
; O 
240 O 
mg O 
of O 
kavalactones B-FAMILY 
) O 
or O 
placebo O 
for O 
participants O 
with O 
generalized O 
anxiety O 
disorder O 
. O 
Results O 
showed O 
no O 
significant O 
differences O 
across O 
groups O 
for O 
liver O 
function O 
tests O 
, O 
nor O 
were O 
there O 
any O 
significant O 
adverse O 
reactions O 
that O 
could O 
be O 
attributed O 
to O 
kava O 
. O 
No O 
differences O 
in O 
withdrawal O 
or O 
addiction O 
were O 
found O 
between O 
groups O 
. O 
Interesting O 
, O 
kava O 
significantly O 
increased O 
female's O 
sexual O 
drive O 
compared O 
to O 
placebo O 
( O 
p O 
= O 
0.04 O 
) O 
on O 
a O 
sub O 
- O 
domain O 
of O 
the O 
Arizona O 
Sexual O 
Experience O 
Scale O 
( O 
ASEX O 
) O 
, O 
with O 
no O 
negative O 
effects O 
seen O 
in O 
males O 
. O 
Further O 
, O 
it O 
was O 
found O 
that O 
there O 
was O 
a O 
highly O 
significant O 
correlation O 
between O 
ASEX O 
reduction O 
( O 
improved O 
sexual O 
function O 
and O 
performance O 
) O 
and O 
anxiety O 
reduction O 
in O 
the O 
whole O 
sample O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Three-Dimensional O 
Nanoporous O 
Alumina B-TRIVIAL 
as O 
a O 
Template O 
for O 
Hierarchical O 
TiO2 B-FORMULA 
Nanotube O 
Arrays O 
. O 

micro- O 
/ O 
nano O 
- O 
structures O 
made O 
easy O 
. O 
By O 
using O 
extremely O 
rough O 
, O 
chemically O 
etched O 
microstructured O 
aluminium B-SYSTEMATIC 
foils O 
, O 
anodization O 
in O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
under O 
very O 
harsh O 
conditions O 
, O 
e.g O 
. O 
, O 
10 O 
wt% O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
room O 
temperature O 
, O 
can O 
be O 
repeatedly O 
accomplished O 
without O 
suffering O 
from O 
breakdown O 
. O 
As O 
a O 
result O 
, O 
an O 
alumina B-TRIVIAL 
membrane O 
with O 
a O 
three O 
- O 
dimensionally O 
distributed O 
nanopore O 
structure O 
is O 
formed O 
, O 
which O 
can O 
be O 
used O 
as O 
a O 
general O 
template O 
to O 
fabricate O 
hierarchical O 
micro- O 
/ O 
nano O 
- O 
structures O 
. O 

dimerization O 
- O 
based O 
plasmonic O 
nanoswitch O 
for O 
biodetection O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
. O 

oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
( O 
ROS O 
and O 
RNS O 
) O 
are O 
continuously O 
produced O 
in O 
the O 
cellular O 
systems O 
and O 
are O 
controlled O 
by O 
several O 
antioxidant O 
mechanisms O 
. O 
Here O 
, O 
we O 
developed O 
a O 
straightforward O 
, O 
sensitive O 
, O 
and O 
quantitative O 
assay O 
for O 
the O 
colorimetric O 
and O 
spectroscopic O 
detection O 
of O 
various O 
ROS O 
and O 
RNS O 
such O 
as O 
H2O2 B-FORMULA 
, O 
·OH B-FORMULA 
, O 
(-)OCl B-FORMULA 
, O 
NO· B-FORMULA 
, O 
and O 
O2(-) B-FORMULA 
using O 
glutathione B-TRIVIAL 
-modified O 
gold O 
nanoparticles O 
( O 
GSH B-ABBREVIATION 
-AuNPs O 
) O 
. O 
A O 
basic O 
principle O 
here O 
is O 
that O 
the O 
GSHs B-FAMILY 
on O 
the O 
AuNP O 
surface O 
can O 
be O 
readily O 
detached O 
via O 
the O 
formation O 
of O 
glutathione B-FAMILY 
disulfides I-FAMILY 
upon O 
the O 
addition O 
of O 
ROS O 
and O 
RNS O 
, O 
and O 
destabilized O 
particles O 
can O 
aggregate O 
to O 
generate O 
the O 
plasmonic O 
couplings O 
between O 
plasmonic O 
AuNPs O 
that O 
trigger O 
the O 
red O 
shift O 
in O 
UV-vis O 
spectrum O 
and O 
solution O 
color O 
change O 
. O 
For O 
nonradical O 
species O 
such O 
as O 
H2O2 B-FORMULA 
, O 
this O 
process O 
can O 
be O 
more O 
efficiently O 
achieved O 
by O 
converting O 
them O 
into O 
radical O 
species O 
via O 
the O 
Fenton O 
reaction O 
. O 
Using O 
this O 
strategy O 
, O 
we O 
were O 
able O 
to O 
rapidly O 
and O 
quantitatively O 
distinguish O 
among O 
cancerous O 
and O 
normal O 
cells O 
based O 
on O 
ROS O 
and O 
RNS O 
production O 
. O 

of O 
adamantane B-TRIVIAL 
based O 
highly O 
potent O 
HDAC O 
inhibitors O 
. O 

, O 
we O 
report O 
the O 
development O 
of O 
highly O 
potent O 
HDAC O 
inhibitors O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 
A O 
series O 
of O 
adamantane B-TRIVIAL 
and O 
nor- O 
adamantane B-TRIVIAL 
based O 
HDAC O 
inhibitors O 
were O 
designed O 
, O 
synthesized O 
and O 
screened O 
for O 
the O 
inhibitory O 
activity O 
of O 
HDAC O 
. O 
A O 
number O 
of O 
compounds O 
exhibited O 
GI50 O 
of O 
10-100 O 
nM O 
in O 
human O 
HCT116 O 
, O 
NCI-H460 O 
and O 
U251 O 
cancer O 
cells O 
, O 
in O 
vitro O 
. O 
Compound O 
32 O 
displays O 
efficacy O 
in O 
human O 
tumour O 
animal O 
xenograft O 
model O 
. O 

- O 
wide O 
integrated O 
analyses O 
of O 
androgen B-FAMILY 
receptor O 
signaling O 
in O 
prostate O 
cancer O 
based O 
on O 
high O 
- O 
throughput O 
technology O 
. O 

androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
is O 
a O 
steroid B-FAMILY 
hormone O 
receptor O 
that O 
functions O 
as O 
a O 
ligand O 
- O 
dependent O 
transcriptional O 
factor O 
, O 
which O 
plays O 
a O 
key O 
role O 
in O 
the O 
development O 
and O 
progression O 
of O 
prostate O 
cancer O 
. O 
Recent O 
advancement O 
in O 
high O 
throughput O 
technologies O 
including O 
microarrays O 
and O 
deep O 
- O 
sequencing O 
provides O 
unbiased O 
genome O 
- O 
wide O 
knowledge O 
on O 
the O 
AR O 
signaling O 
including O 
datasets O 
for O 
androgen B-FAMILY 
-regulated O 
gene O 
expression O 
and O 
genomic O 
binding O 
sites O 
for O 
AR O 
. O 
In O 
the O 
present O 
review O 
, O 
we O 
will O 
briefly O 
summarize O 
the O 
main O 
features O 
of O 
the O 
AR O 
signaling O 
as O 
well O 
as O 
the O 
individual O 
AR O 
target O 
genes O 
identified O 
by O 
the O 
integration O 
of O 
multiple O 
datasets O 
in O 
prostate O 
cancer O 
. O 
Cap O 
analysis O 
gene O 
expression O 
( O 
CAGE O 
) O 
is O 
also O 
featured O 
as O 
a O 
unique O 
transcriptome O 
method O 
, O 
which O 
particularly O 
determines O 
the O 
androgen B-FAMILY 
-dependent O 
transcription O 
start O 
points O 
in O 
prostate O 
cancer O 
. O 

role O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
in O 
endocrine O 
control O 
of O 
metabolism O 
in O 
the O 
liver O 
. O 

review O 
summarizes O 
the O 
emerging O 
role O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
in O 
mediating O 
endocrine O 
regulation O 
of O 
metabolic O 
fluxes O 
in O 
the O 
liver O 
. O 
There O 
are O 
a O 
number O 
of O 
hormones O 
which O 
, O 
when O 
acting O 
on O 
the O 
liver O 
, O 
alter O 
AMPK O 
activation O 
. O 
Here O 
we O 
describe O 
those O 
hormones O 
associated O 
with O 
activation O 
and O 
de-activation O 
of O 
AMPK O 
and O 
the O 
potential O 
mechanisms O 
for O 
changes O 
in O 
AMPK O 
activation O 
state O 
. O 
The O 
actions O 
of O 
these O 
hormones O 
, O 
in O 
many O 
cases O 
, O 
are O 
consistent O 
with O 
downstream O 
effects O 
of O 
AMPK O 
signaling O 
thus O 
strengthening O 
the O 
circumstantial O 
case O 
for O 
AMPK O 
- O 
mediated O 
hormone O 
action O 
. O 
In O 
recent O 
years O 
, O 
genetic O 
mouse O 
models O 
have O 
also O 
been O 
used O 
in O 
an O 
attempt O 
to O 
establish O 
the O 
role O 
of O 
AMPK O 
in O 
hormone O 
- O 
stimulated O 
metabolism O 
in O 
the O 
liver O 
. O 
Few O 
experiments O 
have O 
, O 
however O 
, O 
firmly O 
established O 
a O 
causal O 
relationship O 
between O 
hormone O 
action O 
at O 
the O 
liver O 
and O 
AMPK O 
signaling O 
. O 

disease O 
( O 
AD O 
) O 
is O 
a O 
complex O 
neurodegenerative O 
disorder O 
, O 
typified O 
by O 
the O 
pathological O 
accumulation O 
of O 
ß-amyloid O 
peptides O 
( O 
Aß O 
) O 
and O 
neurofibrillary O 
tangles O 
within O 
the O 
brain O 
, O 
culminating O 
to O 
cognitive O 
impairment O 
. O 
Epidemiological O 
and O 
biochemical O 
data O 
have O 
suggested O 
a O 
link O 
between O 
cholesterol B-TRIVIAL 
content O 
, O 
APP O 
( O 
amyloid O 
precursor O 
protein O 
) O 
processing O 
, O 
Aß O 
, O 
inflammation O 
and O 
AD O 
. O 
The O 
intricacy O 
of O 
the O 
disease O 
presents O 
considerable O 
challenges O 
for O 
the O 
development O 
of O 
newer O 
therapeutic O 
agents O 
. O 
Liver O 
X O 
receptors O 
( O 
LXRa O 
and O 
LXRß O 
) O 
are O 
oxysterol B-FAMILY 
activated O 
nuclear O 
receptors O 
that O 
play O 
essential O 
role O 
in O 
lipid O 
and O 
glucose B-TRIVIAL 
homeostasis O 
, O 
steroidogenesis O 
and O 
inflammatory O 
responses O 
. O 
LXR O 
signalling O 
impacts O 
the O 
development O 
of O 
AD O 
pathology O 
through O 
multiple O 
pathways O 
. O 
Reports O 
indicate O 
that O 
genetic O 
loss O 
of O 
either O 
lxra O 
or O 
lxrß O 
in O 
APP O 
/ O 
PS1 O 
transgenic O 
mice O 
results O 
in O 
increased O 
amyloid O 
plaque O 
load O 
. O 
Studies O 
also O 
suggest O 
that O 
ligand O 
activation O 
of O 
LXRs O 
in O 
Tg2576 O 
mice O 
enhanced O 
, O 
the O 
expression O 
of O 
genes O 
linked O 
with O 
cholesterol B-TRIVIAL 
efflux O 
e.g O 
. O 
apoe O 
, O 
abca-1 O 
, O 
down O 
regulated O 
APP O 
processing O 
and O 
Aß O 
production O 
with O 
significant O 
improvement O 
in O 
memory O 
functions O 
. O 
LXR O 
agonists O 
have O 
also O 
depicted O 
to O 
inhibit O 
neuroinflammation O 
through O 
modulation O 
of O 
microglial O 
phagocytosis O 
and O 
by O 
repressing O 
the O 
expression O 
of O 
cox2 O 
, O 
mcp1 O 
and O 
iNos O 
in O 
glial O 
cells O 
. O 
This O 
review O 
summarizes O 
in O 
brief O 
the O 
biology O 
of O 
LXRs O 
, O 
with O 
an O 
emphasis O 
on O 
their O 
probable O 
pathophysiological O 
mechanisms O 
that O 
may O 
elicit O 
the O 
defending O 
role O 
of O 
these O 
receptors O 
in O 
brains O 
of O 
AD O 
patients O 
. O 

fuel O 
spills O 
have O 
occurred O 
on O 
subantarctic O 
Macquarie O 
Island O 
( O 
54°30 O 
' O 
S O 
158°57 O 
' O 
E O 
) O 
associated O 
with O 
storing O 
fuel O 
and O 
generating O 
power O 
for O 
the O 
island's O 
research O 
station O 
. O 
The O 
Australian O 
Antarctic O 
Division O 
began O 
full O 
- O 
scale O 
, O 
on O 
- O 
site O 
remediation O 
of O 
these O 
sites O 
in O 
2009 O 
. O 
To O 
develop O 
appropriate O 
target O 
concentrations O 
for O 
remediation O 
, O 
acute O 
and O 
chronic O 
tests O 
were O 
developed O 
with O 
the O 
endemic O 
earthworm O 
, O 
Microscolex O 
macquariensis O 
, O 
using O 
avoidance O 
, O 
survival O 
, O 
and O 
reproduction O 
as O 
endpoints O 
. O 
Uncontaminated O 
low O 
( O 
3% O 
) O 
, O 
medium O 
( O 
11% O 
) O 
, O 
and O 
high O 
( O 
38-48% O 
) O 
carbon B-SYSTEMATIC 
content O 
soils O 
from O 
Macquarie O 
Island O 
were O 
used O 
to O 
examine O 
the O 
influence O 
of O 
soil O 
carbon B-SYSTEMATIC 
on O 
toxicity O 
. O 
Soils O 
were O 
spiked O 
with O 
Special O 
Antarctic O 
Blend O 
( O 
SAB O 
) O 
diesel O 
and O 
used O 
either O 
immediately O 
to O 
simulate O 
a O 
fresh O 
spill O 
or O 
after O 
four O 
weeks O 
to O 
simulate O 
an O 
aged O 
spill O 
. O 
Earthworms O 
were O 
sensitive O 
to O 
fresh O 
SAB O 
, O 
with O 
significant O 
avoidance O 
at O 
181 O 
mg O 
/ O 
kg O 
; O 
acute O 
14-d O 
survival O 
median O 
lethal O 
concentration O 
( O 
LC50 O 
) O 
of O 
103 O 
mg O 
/ O 
kg O 
for O 
low O 
carbon B-SYSTEMATIC 
soil O 
; O 
and O 
juvenile O 
production O 
median O 
effective O 
concentration O 
( O 
EC50 O 
) O 
of O 
317 O 
mg O 
/ O 
kg O 
for O 
high O 
carbon B-SYSTEMATIC 
soil O 
. O 
Earthworms O 
were O 
less O 
sensitive O 
to O 
aged O 
SAB O 
than O 
to O 
fresh O 
SAB O 
in O 
high O 
carbon B-SYSTEMATIC 
soil O 
for O 
juvenile O 
production O 
( O 
EC50 O 
of O 
1753 O 
and O 
317 O 
mg O 
/ O 
kg O 
, O 
respectively O 
) O 
, O 
but O 
were O 
more O 
sensitive O 
for O 
adult O 
survival O 
( O 
LC50 O 
of O 
2322 O 
and O 
1364 O 
mg O 
/ O 
kg O 
, O 
respectively O 
) O 
. O 
Using O 
M O 
. O 
macquariensis O 
as O 
a O 
surrogate O 
for O 
soil O 
quality O 
, O 
approximately O 
50 O 
to O 
200 O 
mg O 
SAB O 
/ O 
kg O 
soil O 
would O 
be O 
a O 
sufficiently O 
protective O 
remediation O 
target O 
. O 

delivery O 
with O 
hyperbranched O 
polylysine B-FAMILY 
: O 
A O 
comparative O 
study O 
with O 
linear O 
and O 
dendritic O 
polylysine B-FAMILY 
. O 

and O 
polylysine B-FAMILY 
are O 
among O 
the O 
most O 
investigated O 
synthetic O 
polymeric O 
carriers O 
for O 
DNA O 
delivery O 
. O 
Apart O 
from O 
their O 
practical O 
use O 
, O 
these O 
2 O 
classes O 
of O 
polymers O 
are O 
also O 
of O 
interest O 
from O 
a O 
fundamental O 
point O 
of O 
view O 
as O 
they O 
both O 
can O 
be O 
prepared O 
in O 
different O 
architectures O 
( O 
linear O 
and O 
branched O 
/ O 
dendritic O 
) O 
and O 
in O 
a O 
wide O 
range O 
of O 
molecular O 
weights O 
, O 
which O 
is O 
attractive O 
to O 
establish O 
basic O 
structure O 
- O 
activity O 
relationships O 
. O 
This O 
manuscript O 
reports O 
the O 
results O 
of O 
an O 
extensive O 
study O 
on O 
the O 
influence O 
of O 
molecular O 
weight O 
and O 
architecture O 
of O 
a O 
library O 
of O 
polylysine B-FAMILY 
variants O 
that O 
includes O 
linear O 
, O 
dendritic O 
and O 
hyperbranched O 
polylysine B-FAMILY 
. O 
Hyperbranched O 
polylysine B-FAMILY 
is O 
a O 
new O 
polylysine B-FAMILY 
-based O 
carrier O 
that O 
is O 
structurally O 
related O 
to O 
dendritic O 
polylysine B-FAMILY 
but O 
possesses O 
a O 
randomly O 
branched O 
structure O 
. O 
Hyperbranched O 
polylysine B-FAMILY 
is O 
attractive O 
as O 
it O 
can O 
be O 
prepared O 
in O 
a O 
one O 
- O 
step O 
process O 
on O 
a O 
large O 
scale O 
. O 
The O 
performance O 
of O 
these O 
3 O 
classes O 
of O 
polylysine B-FAMILY 
analogs O 
was O 
evaluated O 
by O 
assessing O 
eGFP O 
and O 
IgG O 
production O 
in O 
transient O 
gene O 
expression O 
experiments O 
with O 
CHO O 
DG44 O 
cells O 
, O 
which O 
revealed O 
that O 
protein O 
production O 
generally O 
increased O 
with O 
increasing O 
molecular O 
weight O 
and O 
that O 
at O 
comparable O 
molecular O 
weight O 
, O 
the O 
hyperbranched O 
analogs O 
were O 
superior O 
as O 
compared O 
to O 
the O 
dendritic O 
and O 
linear O 
polylysines B-FAMILY 
. O 
To O 
understand O 
the O 
differences O 
between O 
the O 
gene O 
delivery O 
properties O 
of O 
the O 
hyperbranched O 
polylysine B-FAMILY 
analogs O 
on O 
the O 
one O 
hand O 
and O 
the O 
dendritic O 
and O 
linear O 
polylysines B-FAMILY 
on O 
the O 
other O 
hand O 
, O 
the O 
uptake O 
and O 
trafficking O 
of O 
the O 
corresponding O 
polyplexes O 
were O 
investigated O 
. O 
These O 
experiments O 
allowed O 
us O 
to O 
identify O 
(i) O 
polyplex O 
- O 
external O 
cell O 
membrane O 
binding O 
, O 
(ii) O 
free O 
, O 
unbound O 
polylysine B-FAMILY 
coexisting O 
with O 
polyplexes O 
as O 
well O 
as O 
(iii) O 
polymer O 
buffer O 
capacity O 
as O 
three O 
possible O 
factors O 
that O 
may O 
contribute O 
to O 
the O 
superior O 
transfection O 
properties O 
of O 
the O 
hyperbranched O 
polylysines B-FAMILY 
as O 
compared O 
to O 
their O 
linear O 
and O 
dendritic O 
analogs O 
. O 
Altogether O 
, O 
the O 
results O 
of O 
this O 
study O 
indicate O 
that O 
hyperbranched O 
polylysine B-FAMILY 
is O 
an O 
interesting O 
, O 
alternative O 
synthetic O 
gene O 
carrier O 
. O 
Hyperbranched O 
polylysine B-FAMILY 
can O 
be O 
produced O 
at O 
low O 
costs O 
and O 
in O 
large O 
quantities O 
, O 
is O 
partially O 
biodegradable O 
, O 
which O 
may O 
help O 
to O 
prevent O 
cumulative O 
cytotoxicity O 
, O 
and O 
possesses O 
transfection O 
properties O 
that O 
can O 
approach O 
those O 
of O 
PEI B-ABBREVIATION 
. O 

compelling O 
challenge O 
in O 
the O 
therapy O 
of O 
epilepsy O 
is O 
to O 
develop O 
anti-epileptogenic O 
drugs O 
with O 
an O 
impact O 
on O 
the O 
disease O 
progression O 
. O 
The O 
search O 
for O 
novel O 
targets O 
has O 
focused O 
recently O 
on O 
brain O 
inflammation O 
since O 
this O 
phenomenon O 
appears O 
to O 
be O 
an O 
integral O 
part O 
of O 
the O 
diseased O 
hyperexcitable O 
brain O 
tissue O 
from O 
which O 
spontaneous O 
and O 
recurrent O 
seizures O 
originate O 
. O 
Although O 
the O 
contribution O 
of O 
specific O 
proinflammatory O 
pathways O 
to O 
the O 
mechanism O 
of O 
ictogenesis O 
in O 
epileptic O 
tissue O 
has O 
been O 
demonstrated O 
in O 
experimental O 
models O 
, O 
the O 
role O 
of O 
these O 
pathways O 
in O 
epileptogenesis O 
is O 
still O 
under O 
evaluation O 
. O 
We O 
review O 
the O 
evidence O 
conceptually O 
supporting O 
the O 
involvement O 
of O 
brain O 
inflammation O 
and O 
the O 
associated O 
blood O 
- O 
brain O 
barrier O 
damage O 
in O 
epileptogenesis O 
, O 
and O 
describe O 
the O 
available O 
pharmacological O 
evidence O 
where O 
post O 
- O 
injury O 
intervention O 
with O 
anti-inflammatory O 
drugs O 
has O 
been O 
attempted O 
. O 
Our O 
review O 
will O 
focus O 
on O 
three O 
main O 
inflammatory O 
pathways O 
, O 
namely O 
the O 
IL-1 O 
receptor O 
/ O 
Toll O 
- O 
like O 
receptor O 
signaling O 
, O 
COX-2 O 
and O 
the O 
TGF-β O 
signaling O 
. O 
The O 
mechanisms O 
underlying O 
neuronal O 
- O 
glia O 
network O 
dysfunctions O 
induced O 
by O 
brain O 
inflammation O 
are O 
also O 
discussed O 
, O 
highlighting O 
novel O 
neuromodulatory O 
effects O 
of O 
classical O 
inflammatory O 
mediators O 
such O 
as O 
cytokines O 
and O 
prostaglandins B-FAMILY 
. O 
The O 
increase O 
in O 
knowledge O 
about O 
a O 
role O 
of O 
inflammation O 
in O 
disease O 
progression O 
, O 
may O 
prompt O 
the O 
use O 
of O 
specific O 
anti-inflammatory O 
drugs O 
for O 
developing O 
disease O 
- O 
modifying O 
treatments O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
New O 
Targets O 
and O 
Approaches O 
to O 
the O 
Treatment O 
of O 
Epilepsy O 
' O 
. O 

acid I-TRIVIAL 
inhibits O 
angiogenesis O 
through O 
inhibiting O 
PHD2-VHL-HIF-1α O 
pathway O 
. O 

previous O 
studies O 
revealed O 
that O 
gambogic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
, O 
the O 
major O 
active O 
ingredient O 
of O 
gamboge O 
, O 
possessed O 
antiangiogenic O 
activities O 
. O 
In O 
this O 
study O 
, O 
we O 
further O 
explored O 
the O 
mechanism O 
of O 
inhibition O 
effects O 
of O 
GA O 
in O 
tumor O 
angiogenesis O 
. O 
The O 
results O 
of O 
luciferase O 
, O 
RT-PCR O 
, O 
and O 
ELISA O 
assays O 
indicated O 
that O 
GA O 
significantly O 
decreased O 
transcription O 
activation O 
, O 
mRNA O 
expression O 
, O 
and O 
secretion O 
of O 
VEGF O 
in O 
hypoxia O 
. O 
We O 
detected O 
that O 
GA O 
had O 
no O 
effect O 
on O 
mRNA O 
level O 
of O 
HIF-1α O 
which O 
targets O 
VEGF O 
gene O 
, O 
but O 
the O 
increase O 
of O 
HIF-1α O 
protein O 
expression O 
in O 
hypoxia O 
was O 
repressed O 
by O 
GA O 
, O 
which O 
can O 
be O 
reversed O 
by O 
proteasomal O 
inhibitor O 
MG132 O 
and O 
siRNA O 
of O 
VHL O 
. O 
But O 
GA O 
exhibited O 
no O 
effect O 
on O 
expression O 
of O 
VHL O 
both O 
in O 
normoxia O 
and O 
hypoxia O 
. O 
HIF O 
prolyl B-TRIVIAL 
hydroxylases O 
( O 
PHD O 
enzymes O 
) O 
act O 
as O 
oxygen B-SYSTEMATIC 
sensors O 
regulating O 
HIF O 
, O 
and O 
hence O 
angiogenesis O 
. O 
Our O 
results O 
showed O 
that O 
GA O 
potentially O 
enhanced O 
level O 
of O 
PHD2 O 
, O 
the O 
most O 
important O 
HIF O 
hydroxylase O 
, O 
and O 
showed O 
no O 
effect O 
on O 
PHD1 O 
and O 
PHD3 O 
. O 
Transient O 
transfection O 
of O 
siRNA O 
of O 
PHD2 O 
could O 
eliminate O 
GA-induced O 
VEGF O 
secretion O 
increase O 
. O 
Growth O 
of O 
HepG2 O 
xenografts O 
in O 
BALB O 
/ O 
cA O 
nude O 
mice O 
was O 
inhibited O 
by O 
GA O 
and O 
angiogenesis O 
was O 
repressed O 
significantly O 
in O 
tumor O 
xenografts O 
by O 
immunohistochemical O 
staining O 
of O 
CD-31 O 
, O 
a O 
vascular O 
endothelial O 
marker O 
, O 
accompanied O 
with O 
decrease O 
of O 
HIF-1α O 
and O 
increase O 
of O 
PHD2 O 
expression O 
in O 
tissue O 
extracts O 
. O 
This O 
work O 
provides O 
the O 
demonstration O 
that O 
GA O 
shows O 
anti-angiogenic O 
effects O 
via O 
inhibiting O 
PHD2-VHL-HIF-1α O 
pathway O 
. O 

Effect O 
in O 
Solution-Grown O 
p- O 
Type O 
ZnO B-FORMULA 
Nanowires O 
and O 
Films O 
. O 

the O 
piezotronic O 
effect O 
in O 
p- O 
type O 
piezoelectric O 
semiconductor O 
is O 
critical O 
for O 
developing O 
a O 
complete O 
piezotronic O 
theory O 
and O 
designing O 
/ O 
fabricating O 
novel O 
piezotronic O 
applications O 
with O 
more O 
complex O 
functionality O 
. O 
Using O 
a O 
low O 
temperature O 
solution O 
method O 
, O 
we O 
were O 
able O 
to O 
produce O 
ultralong O 
( O 
up O 
to O 
60 O 
μm O 
in O 
length O 
) O 
Sb B-FORMULA 
doped O 
p- O 
type O 
ZnO B-FORMULA 
nanowires O 
on O 
both O 
rigid O 
and O 
flexible O 
substrates O 
. O 
For O 
the O 
p- O 
type O 
nanowire O 
field O 
effect O 
transistor O 
, O 
the O 
on O 
/ O 
off O 
ratio O 
, O 
threshold O 
voltage O 
, O 
mobility O 
, O 
and O 
carrier O 
concentration O 
of O 
0.2% O 
Sb B-FORMULA 
-doped O 
sample O 
are O 
found O 
to O 
be O 
10(5) O 
, O 
2.1 O 
V O 
, O 
0.82 O 
cm(2)·V(-1)·s(-1) O 
, O 
and O 
2.6 O 
× O 
10(17) O 
cm(-3) O 
, O 
respectively O 
, O 
and O 
the O 
corresponding O 
values O 
for O 
1% O 
Sb B-FORMULA 
doped O 
samples O 
are O 
10(4) O 
, O 
2 O 
V O 
, O 
1.24 O 
cm(2)·V(-1)·s(-1) O 
, O 
and O 
3.8 O 
× O 
10(17) O 
cm(-3) O 
. O 
We O 
further O 
investigated O 
the O 
universality O 
of O 
piezotronic O 
effect O 
in O 
the O 
as-synthesized O 
Sb B-FORMULA 
-doped O 
p- O 
type O 
ZnO B-FORMULA 
NWs O 
and O 
reported O 
for O 
the O 
first O 
time O 
strain O 
- O 
gated O 
piezotronic O 
transistors O 
as O 
well O 
as O 
piezopotential O 
- O 
driven O 
mechanical O 
energy O 
harvesting O 
based O 
on O 
solution O 
- O 
grown O 
p- O 
type O 
ZnO B-FORMULA 
NWs O 
. O 
The O 
results O 
presented O 
here O 
broaden O 
the O 
scope O 
of O 
piezotronics O 
and O 
extend O 
the O 
framework O 
for O 
its O 
potential O 
applications O 
in O 
electronics O 
, O 
optoelectronics O 
, O 
smart O 
MEMS O 
/ O 
NEMS O 
, O 
and O 
human O 
- O 
machine O 
interfacing O 
. O 

are O 
associated O 
with O 
obesity O 
. O 
However O 
, O 
the O 
relationships O 
between O 
adipokines O 
, O 
specifically O 
vaspin O 
, O 
obesity O 
, O 
and O 
obesity O 
- O 
related O 
variables O 
remain O 
controversial O 
, O 
and O 
only O 
a O 
few O 
studies O 
have O 
been O 
conducted O 
which O 
examines O 
them O 
in O 
children O 
. O 
We O 
investigated O 
the O 
relationships O 
between O 
obesity O 
in O 
prepubertal O 
Korean O 
children O 
and O 
three O 
types O 
of O 
adipokines O 
: O 
vaspin O 
, O 
leptin O 
, O 
and O 
visfatin O 
. O 
In O 
this O 
cross O 
- O 
sectional O 
study O 
, O 
168 O 
nine O 
- O 
year O 
- O 
old O 
boys O 
and O 
176 O 
nine O 
- O 
year O 
- O 
old O 
girls O 
participated O 
in O 
a O 
school O 
- O 
based O 
health O 
examination O 
program O 
. O 
Children O 
were O 
classified O 
as O 
overweight O 
using O 
the O 
Korean O 
Pediatric O 
Society O 
2007 O 
guidelines O 
. O 
Overweight O 
boys O 
and O 
girls O 
had O 
higher O 
leptin O 
and O 
vaspin O 
levels O 
than O 
both O 
boys O 
and O 
girls O 
of O 
normal O 
weight O 
, O 
whereas O 
only O 
overweight O 
boys O 
had O 
higher O 
visfatin O 
levels O 
than O 
normal O 
weight O 
boys O 
. O 
Leptin O 
, O 
visfatin O 
and O 
vaspin O 
concentrations O 
were O 
correlated O 
with O 
obesity O 
- O 
related O 
variables O 
. O 
A O 
multiple O 
logistic O 
regression O 
analysis O 
showed O 
that O 
systolic O 
blood O 
pressure O 
( O 
SBP O 
) O 
, O 
total O 
cholesterol B-TRIVIAL 
( O 
TC O 
) O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
, O 
homeostasis O 
model O 
assessment O 
of O 
insulin O 
resistance O 
( O 
HOMA-IR O 
) O 
, O 
leptin O 
, O 
and O 
vaspin O 
were O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
being O 
overweight O 
, O 
whereas O 
high O 
- O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
cholesterol B-TRIVIAL 
was O 
associated O 
with O 
a O 
decreased O 
risk O 
of O 
being O 
overweight O 
. O 
Elevated O 
vaspin O 
and O 
leptin O 
levels O 
are O 
associated O 
with O 
obesity O 
in O 
prepubertal O 
Korean O 
children O 
. O 

of O 
blood O 
- O 
retinal O 
barrier O 
development O 
on O 
formation O 
of O 
selenite B-TRIVIAL 
nuclear O 
cataract O 
in O 
rat O 
. O 

cataract O 
, O 
as O 
an O 
experimental O 
animal O 
model O 
of O 
nuclear O 
cataract O 
to O 
mimic O 
human O 
senile O 
cataract O 
, O 
is O 
produced O 
only O 
when O 
overdose O 
selenite B-TRIVIAL 
is O 
injected O 
to O 
neonatal O 
rats O 
before O 
eyelid O 
opening O 
. O 
To O 
clarify O 
the O 
cause O 
of O 
age O 
differences O 
on O 
selenite B-TRIVIAL 
cataract O 
formation O 
in O 
rats O 
, O 
mRNA O 
expression O 
of O 
GPx1 O 
, O 
MsrA O 
and O 
MsrB1 O 
, O 
as O 
well O 
as O 
GPx O 
activity O 
in O 
Wistar O 
rat O 
lens O 
at O 
different O 
ages O 
were O 
assayed O 
, O 
level O 
of O 
lipid O 
peroxidation O 
, O 
extent O 
of O 
lens O 
damage O 
induced O 
by O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
and O 
barricade O 
function O 
of O 
blood O 
- O 
retinal O 
barrier O 
( O 
BRB O 
) O 
were O 
investigated O 
. O 
The O 
results O 
showed O 
that O 
mRNA O 
expressions O 
and O 
activity O 
of O 
antioxidant O 
enzymes O 
in O 
neonatal O 
rat O 
lens O 
before O 
eyelid O 
opening O 
were O 
the O 
highest O 
and O 
then O 
decreased O 
with O 
age O 
, O 
and O 
revealed O 
by O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
using O 
lanthanum B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
as O 
tracer O 
that O 
higher O 
selenite B-TRIVIAL 
content O 
entering O 
eyes O 
injured O 
lens O 
and O 
resulted O 
in O 
cataract O 
formation O 
for O 
immature O 
BRB O 
before O 
eyelid O 
opening O 
, O 
moreover O 
, O 
a O 
little O 
selenite B-TRIVIAL 
content O 
entering O 
eyes O 
was O 
not O 
enough O 
to O 
induce O 
cataract O 
formation O 
after O 
eyelid O 
opening O 
because O 
of O 
mature O 
BRB O 
. O 

suppresses O 
LPS-induced O 
endotoxemia O 
and O 
adjuvant O 
- O 
induced O 
arthritis O 
primarily O 
through O 
blockade O 
of O 
ROS O 
formation O 
, O 
NFkB O 
and O 
MAPK O 
activation O 
. O 

release O 
inflammatory O 
mediators O 
to O 
defense O 
harmful O 
stimuli O 
upon O 
bacterial O 
invasion O 
, O 
however O 
, O 
excessive O 
inflammatory O 
reaction O 
leads O 
to O 
tissue O 
damage O 
and O 
manifestation O 
of O 
pathological O 
states O 
. O 
Therefore O 
, O 
targeting O 
on O 
uncontrolled O 
inflammation O 
seems O 
feasible O 
to O 
control O 
numerous O 
inflammation O 
- O 
associated O 
diseases O 
. O 
Under O 
the O 
drug O 
screening O 
process O 
of O 
synthetic O 
diphenylpyrazole B-SYSTEMATIC 
derivatives O 
, O 
we O 
discovered O 
compound O 
yuwen02f1 B-TRIVIAL 
possesses O 
anti-inflammatory O 
effects O 
in O 
decreasing O 
the O 
release O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
including O 
TNFα O 
and O 
IL-6 O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
as O 
well O 
as O 
inhibiting O 
migration O 
of O 
LPS-stimulated O 
phagocytes O 
. O 
In O 
addition O 
, O 
we O 
observed O 
that O 
the O 
molecular O 
mechanism O 
of O 
yuwen02f1 B-TRIVIAL 
-mediated O 
anti-inflammation O 
is O 
associated O 
with O 
decreasing O 
phosphorylation O 
of O 
MAPK O 
molecules O 
including O 
ERK1 O 
/ O 
2 O 
, O 
JNK O 
and O 
p38 O 
, O 
and O 
attenuating O 
translocation O 
of O 
p47(phox) O 
and O 
p67(phox) O 
to O 
the O 
cell O 
membrane O 
. O 
Yuwen02f1 B-TRIVIAL 
also O 
reverses O 
IκBα O 
degradation O 
and O 
attenuates O 
the O 
expression O 
of O 
NFκB O 
- O 
related O 
downstream O 
inducible O 
enzymes O 
like O 
iNOS O 
and O 
COX-2 O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
yuwen02f1 B-TRIVIAL 
attenuates O 
some O 
pathological O 
syndromes O 
of O 
LPS-induced O 
sepsis O 
and O 
adjuvant O 
- O 
induced O 
arthritis O 
in O 
mice O 
, O 
as O 
evidenced O 
by O 
decreasing O 
the O 
cytokine O 
production O 
, O 
reversing O 
thrombocytopenic O 
syndrome O 
, O 
protecting O 
the O 
mice O 
from O 
tissue O 
injury O 
in O 
septic O 
mice O 
, O 
and O 
attenuating O 
paw O 
edema O 
in O 
arthritic O 
mice O 
as O 
well O 
. O 
These O 
results O 
suggest O 
that O 
yuwen02f1 B-TRIVIAL 
is O 
a O 
potential O 
anti-inflammatory O 
agent O 
for O 
alleviating O 
syndromes O 
of O 
acute O 
and O 
chronic O 
inflammatory O 
diseases O 
as O 
evidenced O 
by O 
attenuating O 
the O 
generation O 
of O 
cytokines O 
and O 
down O 
- O 
regulating O 
the O 
expression O 
of O 
iNOS O 
and O 
COX-2 O 
through O 
the O 
blockade O 
of O 
ROS O 
generation O 
and O 
NADPH B-ABBREVIATION 
oxidase O 
, O 
NFκB O 
and O 
MAPK O 
activation O 
pathways O 
in O 
LPS-stimulated O 
phagocytes O 
. O 

aimed O 
to O 
find O 
the O 
relationship O 
between O 
serum O 
transforming O 
growth O 
factor O 
beta O 
1(TGF-β1) O 
and O 
urinary O 
monocyte O 
chemoattractant O 
protein-1 O 
( O 
MCP-1 O 
) O 
throughout O 
the O 
course O 
of O 
diabetic O 
nephropathy O 
( O 
DN O 
) O 
and O 
to O 
assess O 
the O 
relationship O 
between O 
both O 
levels O 
and O 
other O 
parameters O 
of O 
renal O 
injury O 
such O 
as O 
albumin/ O 
creatinine B-TRIVIAL 
ratio O 
and O 
estimated O 
glomerular O 
filtration O 
rate O 
( O 
eGFR O 
) O 
. O 
Serum O 
TGF-β1 O 
, O 
urinary O 
MCP-1 O 
, O 
eGFR O 
, O 
and O 
glycosylated O 
hemoglobin O 
( O 
HbA1c O 
) O 
were O 
measured O 
in O 
60 O 
patients O 
with O 
type O 
II O 
diabetes O 
mellitus O 
with O 
different O 
degrees O 
of O 
nephropathy O 
( O 
20 O 
patients O 
with O 
normoalbuminuria O 
, O 
20 O 
patients O 
with O 
microalbuminuria O 
, O 
and O 
20 O 
patients O 
with O 
macroalbuminuria O 
) O 
and O 
compared O 
with O 
20 O 
matched O 
healthy O 
control O 
subjects O 
. O 
Both O 
the O 
levels O 
of O 
serum O 
TGF-β1 O 
and O 
urinary O 
MCP-1 O 
were O 
significantly O 
higher O 
in O 
patients O 
with O 
micro- O 
and O 
macroalbuminuria O 
( O 
137.8 O 
± O 
69.5 O 
and O 
329.25 O 
± O 
41.46 O 
ng O 
/ O 
dl O 
, O 
respectively O 
, O 
for O 
TGF-β1 O 
and O 
167.41 O 
± O 
50.23 O 
and O 
630.87 O 
± O 
318.1 O 
ng O 
/ O 
g O 
creatinine B-TRIVIAL 
, O 
respectively O 
, O 
for O 
MCP-1 O 
) O 
compared O 
with O 
normoalbuminuric O 
patients O 
and O 
healthy O 
controls O 
( O 
33.25 O 
± O 
17.5 O 
and O 
29.64 O 
± O 
10.57 O 
ng O 
/ O 
dl O 
, O 
respectively O 
, O 
for O 
TGF-β1 O 
and O 
63.85 O 
± O 
21.15 O 
and O 
61.5 O 
± O 
24.81 O 
ng O 
/ O 
g O 
creatinine B-TRIVIAL 
, O 
respectively O 
, O 
for O 
MCP-1 O 
; O 
p O 
< O 
0.001 O 
) O 
. O 
There O 
was O 
a O 
positive O 
significant O 
correlation O 
between O 
the O 
levels O 
of O 
serum O 
TGF-β1 O 
and O 
those O 
of O 
urinary O 
MCP-1 O 
( O 
r O 
= O 
0.73 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Also O 
, O 
serum O 
TGF-β1 O 
and O 
urinary O 
MCP-1 O 
correlated O 
positively O 
with O 
HbA1c O 
( O 
r O 
= O 
0.49 O 
and O 
0.55 O 
, O 
respectively O 
, O 
p O 
< O 
0.05 O 
for O 
both O 
) O 
and O 
inversely O 
with O 
eGFR O 
( O 
r O 
= O 
-0.69 O 
and O 
-0.6 O 
, O 
respectively O 
, O 
p O 
< O 
0.001 O 
for O 
both O 
) O 
. O 
We O 
can O 
conclude O 
that O 
serum O 
TGF-β1 O 
and O 
urinary O 
MCP-1 O 
can O 
be O 
used O 
as O 
the O 
markers O 
for O 
detection O 
of O 
progression O 
of O 
DN O 
. O 
Antagonizing O 
TGF-β1 O 
and O 
MCP-1 O 
might O 
be O 
helpful O 
in O 
attenuating O 
the O 
progression O 
of O 
nephropathy O 
in O 
diabetic O 
patients O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
develop O 
and O 
evaluate O 
a O 
novel O 
drug O 
solubilization O 
platform O 
( O 
so O 
- O 
called O 
solid O 
nanodispersion O 
) O 
prepared O 
by O 
a O 
simple O 
co O 
- O 
grinding O 
and O 
solvent-free O 
process O 
. O 
Using O 
structurally O 
diverse O 
model O 
compounds O 
from O 
the O 
Pfizer O 
drug O 
library O 
, O 
including O 
ingliforib B-TRIVIAL 
, O 
furosemide B-TRIVIAL 
and O 
celecoxib B-TRIVIAL 
, O 
we O 
successfully O 
prepared O 
stable O 
solid O 
nanodispersions O 
( O 
SNDs O 
) O 
without O 
the O 
use O 
of O 
solvent O 
or O 
heat O 
. O 
Stable O 
colloidal O 
particles O 
( O 
< O 
350nm O 
) O 
containing O 
drug O 
, O 
polyvinylpyrrolidone B-SYSTEMATIC 
( B-TRIVIAL 
PVP I-TRIVIAL 
) I-TRIVIAL 
K12 I-TRIVIAL 
and O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
in O 
1 O 
: O 
2.75 O 
: O 
0.25 O 
ratio O 
were O 
produced O 
after O 
2h O 
of O 
co O 
- O 
grinding O 
. O 
The O 
composition O 
and O 
particle O 
size O 
of O 
SNDs O 
were O 
optimized O 
by O 
varying O 
the O 
grinding O 
media O 
size O 
, O 
powder O 
- O 
to O 
- O 
grinding O 
media O 
ratio O 
, O 
milling O 
speed O 
and O 
milling O 
time O 
. O 
The O 
resulting O 
formulations O 
contained O 
crystalline O 
drug O 
and O 
were O 
stable O 
at O 
room O 
temperature O 
for O 
over O 
one O 
month O 
. O 
Greater O 
than O 
80% O 
of O 
the O 
drug O 
was O 
released O 
from O 
the O 
SND O 
in O 
less O 
than O 
30min O 
, O 
with O 
sustained O 
supersaturation O 
over O 
4h O 
. O 
Using O 
furosemide B-TRIVIAL 
( O 
BCS O 
class O 
IV O 
compound O 
) O 
as O 
a O 
model O 
compound O 
, O 
we O 
conducted O 
transport O 
studies O 
with O 
Madin-Darby O 
canine O 
kidney O 
cells O 
transfected O 
with O 
human O 
MDR1 O 
gene O 
( O 
MDCK O 
/ O 
MDR1 O 
) O 
, O 
followed O 
by O 
pharmacokinetics O 
studies O 
in O 
rats O 
. O 
Results O 
showed O 
that O 
the O 
SND O 
formulation O 
enhanced O 
the O 
absorptive O 
flux O 
of O 
furosemide B-TRIVIAL 
by O 
more O 
than O 
3-fold O 
. O 
In O 
the O 
pharmacokinetics O 
studies O 
, O 
the O 
SND O 
formulation O 
increased O 
Cmax O 
and O 
AUC O 
of O 
furosemide B-TRIVIAL 
by O 
36.6 O 
and O 
43.2 O 
fold O 
respectively O 
, O 
relative O 
to O 
Methocel O 
formulation O 
. O 
Interestingly O 
, O 
physical O 
mixture O 
containing O 
furosemide B-TRIVIAL 
, O 
PVP B-TRIVIAL 
K12 I-TRIVIAL 
and O 
SDS B-ABBREVIATION 
produced O 
a O 
similar O 
level O 
of O 
oral O 
exposure O 
as O 
the O 
SNDs O 
, O 
albeit O 
with O 
a O 
longer O 
Tmax O 
than O 
the O 
SND O 
formulation O 
. O 
The O 
results O 
suggest O 
that O 
PVP B-TRIVIAL 
K12 I-TRIVIAL 
and O 
SDS B-ABBREVIATION 
were O 
able O 
to O 
increase O 
the O 
furosemide B-TRIVIAL 
free O 
fraction O 
available O 
for O 
oral O 
absorption O 
. O 
Low O 
solubility O 
, O 
poor O 
permeability O 
, O 
and O 
high O 
first O 
- O 
pass O 
effect O 
of O 
furosemide B-TRIVIAL 
may O 
also O 
have O 
produced O 
the O 
effect O 
that O 
small O 
improvements O 
in O 
solubilization O 
resulted O 
in O 
significant O 
potentiation O 
of O 
the O 
oral O 
exposure O 
of O 
the O 
physical O 
mixture O 
. O 
However O 
the O 
use O 
of O 
a O 
physical O 
mixture O 
of O 
drug O 
, O 
polymer O 
and O 
surfactant O 
, O 
to O 
increase O 
drug O 
bioavailability O 
cannot O 
be O 
generalized O 
to O 
all O 
drugs O 
. O 
There O 
are O 
only O 
a O 
few O 
reported O 
cases O 
of O 
such O 
phenomenon O 
. O 
While O 
SNDs O 
may O 
not O 
be O 
the O 
only O 
option O 
to O 
solubilize O 
compounds O 
in O 
every O 
case O 
, O 
SNDs O 
are O 
expected O 
to O 
be O 
applicable O 
to O 
a O 
broader O 
chemical O 
space O 
of O 
pharmaceutical O 
compounds O 
compared O 
to O 
a O 
physical O 
mixture O 
. O 
Ultimately O 
, O 
formulation O 
scientists O 
have O 
to O 
exercise O 
judgment O 
in O 
choosing O 
the O 
appropriate O 
formulation O 
strategy O 
for O 
the O 
compound O 
of O 
interest O 
. O 
SNDs O 
represent O 
a O 
significant O 
improvement O 
over O 
current O 
enabling O 
technologies O 
such O 
as O 
nanocrystal O 
and O 
spray O 
- O 
dried O 
dispersion O 
technologies O 
, O 
in O 
that O 
SNDs O 
are O 
simple O 
, O 
do O 
not O 
require O 
solvent O 
or O 
heat O 
, O 
are O 
applicable O 
to O 
a O 
structurally O 
diverse O 
chemical O 
space O 
, O 
and O 
are O 
amenable O 
to O 
the O 
development O 
of O 
solid O 
dosage O 
forms O 
. O 

plants O 
are O 
one O 
of O 
the O 
most O 
important O 
sources O 
of O 
drugs O 
used O 
in O 
the O 
pharmaceutical O 
industry O 
. O 
Among O 
traditional O 
medicinal O 
plants O 
, O 
Lippia O 
gracilis O 
Schauer O 
( O 
Verbenaceae O 
) O 
had O 
been O 
used O 
for O 
several O 
medicinal O 
purposes O 
in O 
Brazilian O 
northeastern O 
. O 
In O 
this O 
study O 
, O 
leaf O 
essential O 
oil O 
( O 
EO O 
) O 
of O 
L O 
. O 
gracilis O 
was O 
prepared O 
using O 
hydrodistillation O 
. O 
Followed O 
by O 
GC-MS O 
analysis O 
, O 
its O 
composition O 
was O 
characterized O 
by O 
the O 
presence O 
of O 
thymol B-TRIVIAL 
( O 
55.50% O 
) O 
, O 
as O 
major O 
constituent O 
. O 
The O 
effects O 
of O 
EO O 
on O 
cell O 
proliferation O 
and O 
apoptosis O 
induction O 
were O 
investigated O 
in O 
HepG2 O 
cells O 
. O 
Furthermore O 
, O 
mice O 
bearing O 
Sarcoma O 
180 O 
tumor O 
cells O 
were O 
used O 
to O 
confirm O 
its O 
in O 
vivo O 
effectiveness O 
. O 
EO O 
and O 
its O 
constituents O 
( O 
thymol B-TRIVIAL 
, O 
p-cymene B-TRIVIAL 
, O 
γ-terpinene B-TRIVIAL 
and O 
myrcene B-TRIVIAL 
) O 
displayed O 
cytotoxicity O 
to O 
different O 
tumor O 
cell O 
lines O 
. O 
EO O 
treatment O 
caused O 
G1 O 
arrest O 
in O 
HepG2 O 
cells O 
accompanied O 
by O 
the O 
induction O 
of O 
DNA O 
fragmentation O 
without O 
affecting O 
cell O 
membrane O 
integrity O 
. O 
Cell O 
morphology O 
consistent O 
with O 
apoptosis O 
and O 
a O 
remarkable O 
activation O 
of O 
caspase-3 O 
were O 
also O 
observed O 
, O 
suggesting O 
induction O 
of O 
caspase O 
- O 
dependent O 
apoptotic O 
cell O 
death O 
. O 
In O 
vivo O 
antitumor O 
study O 
showed O 
tumor O 
growth O 
inhibition O 
rates O 
of O 
38.5-41.9% O 
. O 
In O 
conclusion O 
, O 
the O 
tested O 
essential O 
oil O 
of O 
L O 
. O 
gracilis O 
leaves O 
, O 
which O 
has O 
thymol B-TRIVIAL 
as O 
its O 
major O 
constituent O 
, O 
possesses O 
significant O 
in O 
vitro O 
and O 
in O 
vivo O 
antitumor O 
activity O 
. O 
These O 
data O 
suggest O 
that O 
leaf O 
essential O 
oil O 
of O 
L O 
. O 
gracilis O 
is O 
a O 
potential O 
medicinal O 
resource O 
. O 

of O 
the O 
first O 
K(+) B-FORMULA 
channel O 
blockers O 
from O 
the O 
venom O 
of O 
the O 
Moroccan O 
scorpion O 
Buthus O 
occitanus O 
Paris O 
. O 

availability O 
of O 
a O 
large O 
variety O 
of O 
specific O 
blockers O 
, O 
which O 
inhibit O 
different O 
K(+) B-FORMULA 
currents O 
, O 
would O 
help O 
to O 
elucidate O 
their O 
differences O 
in O 
physiological O 
function O 
. O 
Short O 
peptide O 
toxins O 
isolated O 
from O 
scorpion O 
venoms O 
are O 
able O 
to O 
block O 
voltage O 
- O 
dependent O 
or O 
Ca(2+) B-FORMULA 
-activated O 
K(+) B-FORMULA 
channels O 
. O 
Here O 
, O 
we O 
have O 
studied O 
the O 
venom O 
of O 
the O 
Moroccan O 
scorpion O 
Buthus O 
occitanus O 
Paris O 
( O 
BoP O 
) O 
in O 
order O 
to O 
find O 
new O 
peptides O 
, O 
which O 
could O 
enlarge O 
our O 
structure O 
- O 
function O 
relationship O 
knowledge O 
on O 
the O 
Kv1.3 O 
blocker O 
Kaliotoxin O 
( O 
KTX O 
) O 
that O 
belongs O 
to O 
the O 
α-KTx3.1 O 
family O 
. O 
Indeed O 
and O 
since O 
more O 
a O 
decade O 
, O 
KTX O 
is O 
widely O 
used O 
by O 
international O 
investigators O 
because O 
it O 
exhibits O 
a O 
quite O 
sharp O 
specificity O 
and O 
a O 
high O 
- O 
affinity O 
for O 
the O 
Kv1.3 O 
channel O 
, O 
which O 
is O 
not O 
only O 
a O 
neuronal O 
channel O 
but O 
also O 
a O 
therapeutic O 
target O 
for O 
diverse O 
autoimmune O 
diseases O 
such O 
as O 
multiple O 
sclerosis O 
, O 
type O 
1 O 
diabetes O 
, O 
and O 
rheumatoid O 
arthritis O 
. O 
The O 
BoP O 
venom O 
was O 
first O 
investigated O 
using O 
HPLC O 
and O 
MALDI-TOF O 
/ O 
MS O 
. O 
Further O 
, O 
the O 
HPLC O 
fractions O 
were O 
screened O 
by O 
ELISA O 
with O 
antibodies O 
raised O 
against O 
KTX O 
. O 
These O 
antibodies O 
recognized O 
at O 
least O 
three O 
components O 
toxic O 
in O 
mice O 
by O 
intracerebroventricular O 
injection O 
. O 
They O 
were O 
further O 
pharmacologically O 
characterized O 
by O 
competition O 
using O 
(125)I B-FORMULA 
-KTX O 
bound O 
to O 
its O 
specific O 
binding O 
sites O 
on O 
rat O 
brain O 
synaptosomes O 
. O 
A O 
single O 
component O 
( O 
4161 O 
Da O 
) O 
inhibited O 
totally O 
the O 
(125)I B-FORMULA 
-KTX O 
binding O 
and O 
with O 
high O 
- O 
affinity O 
( O 
IC50 O 
= O 
0.1 O 
nM O 
) O 
, O 
while O 
the O 
two O 
other O 
components O 
poorly O 
competed O 
with O 
( O 
IC50 O 
> O 
100 O 
nM O 
) O 
. O 
These O 
toxins O 
were O 
sequenced O 
in O 
full O 
by O 
Edman's O 
degradation O 
. O 
The O 
high O 
- O 
affinity O 
ligand O 
( O 
BoPKTX O 
) O 
shares O 
86% O 
sequence O 
identity O 
with O 
KTX O 
and O 
was O 
classified O 
as O 
toxin O 
α-KTx3.17 O 
. O 
The O 
two O 
others O 
peptides O 
( O 
BoP1 O 
and O 
BoP2 O 
, O 
4093 O 
Da O 
and O 
4121 O 
Da O 
, O 
respectively O 
) O 
only O 
differ O 
by O 
a O 
Lys B-FORMULA 
/ O 
Arg B-FORMULA 
mutation O 
. O 
Their O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
were O 
related O 
to O 
Martentoxin O 
, O 
which O 
has O 
been O 
characterized O 
from O 
the O 
Chinese O 
scorpion O 
Buthus O 
martenzi O 
Karch O 
and O 
described O 
as O 
both O 
a O 
BKCa O 
and O 
Kv1.3 O 
blocker O 
. O 
Accordingly O 
, O 
they O 
belong O 
to O 
the O 
α-KTx16 O 
family O 
. O 

of O 
Morphine B-TRIVIAL 
Analgesic O 
Tolerance O 
by O 
Ethanol B-SYSTEMATIC 
in O 
the O 
Mouse O 
. O 

chronic O 
use O 
of O 
opioids O 
in O 
humans O 
, O 
accompanied O 
by O 
the O 
development O 
of O 
tolerance O 
, O 
is O 
a O 
dangerous O 
phenomenon O 
in O 
its O 
own O 
right O 
. O 
However O 
chronic O 
opioid O 
use O 
is O 
often O 
made O 
more O 
dangerous O 
by O 
the O 
co O 
- O 
consumption O 
of O 
other O 
substances O 
. O 
It O 
has O 
been O 
observed O 
that O 
the O 
blood O 
level O 
of O 
opioids O 
in O 
postmortem O 
analyses O 
of O 
addicts O 
, O 
who O 
consumed O 
ethanol B-SYSTEMATIC 
along O 
with O 
the O 
opioid O 
, O 
was O 
much O 
less O 
than O 
that O 
observed O 
in O 
individuals O 
that O 
died O 
from O 
opioids O 
alone O 
. O 
This O 
relationship O 
between O 
ethanol B-SYSTEMATIC 
and O 
opioids O 
led O 
us O 
to O 
investigate O 
the O 
hypothesis O 
that O 
ethanol B-SYSTEMATIC 
alters O 
tolerance O 
to O 
opioids O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
report O 
that O 
ethanol B-SYSTEMATIC 
significantly O 
and O 
dose O 
- O 
dependently O 
reduced O 
the O 
antinociceptive O 
tolerance O 
produced O 
by O 
morphine B-TRIVIAL 
and O 
the O 
cross O 
tolerance O 
between O 
DAMGO B-ABBREVIATION 
and O 
morphine B-TRIVIAL 
in O 
the O 
mouse O 
tail O 
- O 
flick O 
test O 
. O 
The O 
reversal O 
of O 
morphine B-TRIVIAL 
tolerance O 
was O 
partially O 
blocked O 
by O 
both O 
the O 
GABAA O 
receptor O 
blocker O 
bicuculline B-TRIVIAL 
and O 
by O 
the O 
GABAB O 
receptor O 
blocker O 
phaclofen B-TRIVIAL 
and O 
the O 
administration O 
of O 
both O 
inhibitors O 
completely O 
reversed O 
the O 
effects O 
of O 
ethanol B-SYSTEMATIC 
on O 
morphine B-TRIVIAL 
tolerance O 
. O 
Diazepam B-TRIVIAL 
, O 
like O 
ethanol B-SYSTEMATIC 
, O 
decreased O 
morphine B-TRIVIAL 
tolerance O 
. O 
However O 
, O 
this O 
inhibition O 
was O 
reversed O 
by O 
the O 
GABAA O 
antagonist O 
bicuculline B-TRIVIAL 
but O 
not O 
by O 
the O 
GABAB O 
antagonist O 
phaclofen B-TRIVIAL 
. O 
These O 
findings O 
have O 
important O 
implications O 
for O 
individuals O 
who O 
abuse O 
opioids O 
and O 
ethanol B-SYSTEMATIC 
as O 
well O 
as O 
suggest O 
a O 
mechanism O 
to O 
reduce O 
the O 
amount O 
of O 
opioid O 
needed O 
in O 
chronic O 
pain O 
treatment O 
. O 

nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
genotypes O 
and O 
haplotypes O 
modify O 
the O 
responses O 
to O 
sildenafil B-TRIVIAL 
in O 
patients O 
with O 
erectile O 
dysfunction O 
. O 

dysfunction O 
( O 
ED O 
) O 
is O 
usually O 
treated O 
with O 
sildenafil B-TRIVIAL 
. O 
Although O 
genetic O 
polymorphisms O 
in O 
the O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
eNOS O 
) O 
gene O 
may O 
impair O 
endogenous O 
NO B-FORMULA 
formation O 
, O 
there O 
is O 
little O 
information O 
about O 
how O 
eNOS O 
polymorphisms O 
and O 
haplotypes O 
affect O 
the O 
responses O 
to O 
sildenafil B-TRIVIAL 
. O 
We O 
studied O 
118 O 
patients O 
; O 
63 O 
patients O 
had O 
ED O 
secondary O 
to O 
radical O 
prostatectomy O 
( O 
PED O 
) O 
and O 
55 O 
had O 
organic O 
, O 
clinical O 
ED O 
. O 
eNOS O 
genotypes O 
for O 
three O 
eNOS O 
polymorphisms O 
( O 
T(-786)C O 
, O 
rs2070744 O 
; O 
a O 
variable O 
number O 
of O 
tandem O 
repeats O 
( O 
VNTR O 
) O 
in O 
intron O 
4 O 
; O 
and O 
Glu298Asp O 
, O 
rs1799983 O 
) O 
were O 
determined O 
, O 
and O 
eNOS O 
haplotypes O 
were O 
estimated O 
using O 
PHASE O 
2.1 O 
. O 
The O 
clinical O 
responses O 
to O 
sildenafil B-TRIVIAL 
were O 
evaluated O 
and O 
the O 
patients O 
were O 
classified O 
as O 
good O 
responders O 
( O 
GR O 
) O 
or O 
poor O 
responders O 
( O 
PR O 
) O 
when O 
their O 
changes O 
in O 
five O 
- O 
item O 
version O 
of O 
International O 
Index O 
for O 
Erectile O 
Function O 
questionnaire O 
were O 
above O 
or O 
below O 
the O 
median O 
value O 
. O 
The O 
TC O 
/ O 
CC O 
genotypes O 
and O 
the O 
C O 
allele O 
for O 
the O 
T(-786)C O 
polymorphism O 
were O 
more O 
common O 
in O 
GR O 
, O 
compared O 
with O 
PR O 
patients O 
with O 
PED O 
. O 
However O 
, O 
the O 
4b4a O 
/ O 
4a4a O 
genotypes O 
and O 
the O 
4a O 
allele O 
for O 
the O 
VNTR O 
polymorphism O 
in O 
intron O 
4 O 
were O 
more O 
common O 
in O 
GR O 
, O 
compared O 
with O 
PR O 
patients O 
with O 
clinical O 
ED O 
. O 
The O 
C-4a-Glu O 
haplotype O 
was O 
more O 
common O 
in O 
GR O 
than O 
in O 
PR O 
patients O 
with O 
PED O 
. O 
Conversely O 
, O 
the O 
T-4b-Asp O 
haplotype O 
was O 
less O 
common O 
in O 
GR O 
than O 
in O 
PR O 
patients O 
with O 
PED O 
. O 
No O 
other O 
significant O 
differences O 
were O 
found O 
. O 
Our O 
findings O 
show O 
evidence O 
that O 
eNOS O 
polymorphisms O 
affect O 
the O 
responses O 
of O 
PED O 
and O 
clinical O 
ED O 
patients O 
to O 
sildenafil B-TRIVIAL 
. O 

of O 
tacrolimus B-TRIVIAL 
and O 
major O 
metabolites O 
in O 
kidney O 
transplant O 
recipients O 
as O 
a O 
function O 
of O 
diabetes O 
mellitus O 
and O 
cytochrome O 
P450 O 
3A O 
gene O 
polymorphism O 
. O 

1 O 
. O 
Disposition O 
of O 
tacrolimus B-TRIVIAL 
and O 
its O 
major O 
metabolites O 
, O 
13-O-desmethyl B-SYSTEMATIC 
tacrolimus I-SYSTEMATIC 
and O 
15-O-desmethyl B-SYSTEMATIC 
tacrolimus I-SYSTEMATIC 
, O 
was O 
evaluated O 
in O 
stable O 
kidney O 
transplant O 
recipients O 
in O 
relation O 
to O 
diabetes O 
mellitus O 
and O 
genetic O 
polymorphism O 
of O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
3A O 
. O 
2 O 
. O 
Steady O 
- O 
state O 
concentration O 
- O 
time O 
profiles O 
were O 
obtained O 
for O 
12-hour O 
or O 
2-hour O 
post O 
- O 
dose O 
, O 
in O 
20 O 
( O 
11 O 
with O 
diabetes O 
) O 
and O 
32 O 
( O 
24 O 
with O 
diabetes O 
) O 
patients O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
single O 
nucleotide B-FAMILY 
polymorphisms O 
of O 
the O 
following O 
genes O 
: O 
CYP3A4 O 
( O 
CYP3A4 O 
: O 
CYP3A4*1B O 
, O 
-392A O 
> O 
G O 
) O 
, O 
3A5 O 
( O 
CYP3A5 O 
: O 
CYP3A5*3 O 
, O 
6986A O 
> O 
G O 
) O 
and O 
P-glycoprotein O 
( O 
ABCB1 O 
: O 
3435C O 
> O 
T O 
) O 
were O 
characterized O 
. O 
3 O 
. O 
Dose O 
- O 
normalized O 
concentrations O 
of O 
tacrolimus B-TRIVIAL 
or O 
metabolites O 
were O 
higher O 
in O 
diabetic O 
patients O 
. O 
CYP3A4*1B O 
carriers O 
and O 
CYP3A5 O 
expressers O 
, O 
independently O 
or O 
when O 
assessed O 
as O 
a O 
combined O 
CYP3A4-3A5 O 
genotype O 
, O 
had O 
significantly O 
lower O 
dose O 
- O 
normalized O 
pre O 
- O 
dose O 
( O 
C(0) O 
/ O 
dose O 
) O 
and O 
2-hour O 
post O 
- O 
dose O 
( O 
C(2) O 
/ O 
dose O 
) O 
concentrations O 
of O 
tacrolimus B-TRIVIAL 
and O 
metabolites O 
. O 
Non-diabetic O 
patients O 
with O 
at O 
least O 
one O 
CYP3A4*1B O 
and O 
CYP3A5*1 O 
allele O 
had O 
lower O 
C(0) O 
/ O 
dose O 
as O 
compared O 
to O 
the O 
rest O 
of O 
the O 
population O 
. O 
4 O 
. O 
Genetic O 
polymorphism O 
of O 
CYP3A5 O 
or O 
CYP3A4 O 
influence O 
tacrolimus B-TRIVIAL 
or O 
metabolites O 
dose O 
- O 
normalized O 
concentrations O 
but O 
not O 
metabolite O 
to O 
parent O 
concentration O 
ratios O 
. O 
The O 
effect O 
of O 
diabetes O 
on O 
tacrolimus B-TRIVIAL 
metabolism O 
is O 
subject O 
to O 
debate O 
and O 
requires O 
a O 
larger O 
sample O 
size O 
of O 
genetically O 
stratified O 
subjects O 
. O 

effect O 
of O 
intranasal O 
oxytocin B-TRIVIAL 
treatment O 
on O 
conditioned O 
fear O 
extinction O 
and O 
recall O 
in O 
a O 
healthy O 
human O 
sample O 
. O 

: O 
To O 
improve O 
outcomes O 
for O 
patients O 
undergoing O 
extinction O 
- O 
based O 
therapies O 
( O 
e.g O 
. O 
, O 
exposure O 
therapy O 
) O 
for O 
anxiety O 
disorders O 
such O 
as O 
post O 
- O 
traumatic O 
stress O 
disorder O 
( O 
PTSD O 
) O 
, O 
there O 
has O 
been O 
interest O 
in O 
identifying O 
pharmaceutical O 
compounds O 
that O 
might O 
facilitate O 
fear O 
extinction O 
learning O 
and O 
recall O 
. O 
Oxytocin B-TRIVIAL 
( O 
OT O 
) O 
is O 
a O 
mammalian O 
neuropeptide O 
that O 
modulates O 
activation O 
of O 
fear O 
extinction O 
- O 
based O 
neural O 
circuits O 
and O 
fear O 
responses O 
. O 
Little O 
is O 
known O 
, O 
however O 
, O 
about O 
the O 
effects O 
of O 
OT O 
treatment O 
on O 
conditioned O 
fear O 
responding O 
and O 
extinction O 
in O 
humans O 
. O 
OBJECTIVES O 
: O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
assess O 
the O 
effects O 
of O 
OT O 
in O 
a O 
fear O 
- O 
potentiated O 
startle O 
task O 
of O 
fear O 
conditioning O 
and O 
extinction O 
. O 
METHODS O 
: O 
A O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
study O 
of O 
44 O 
healthy O 
human O 
participants O 
was O 
conducted O 
. O 
Participants O 
underwent O 
a O 
conditioned O 
fear O 
acquisition O 
procedure O 
, O 
after O 
which O 
they O 
were O 
randomized O 
to O 
treatment O 
group O 
and O 
delivered O 
OT O 
( O 
24 O 
IU O 
) O 
or O 
placebo O 
via O 
intranasal O 
( O 
IN O 
) O 
spray O 
. O 
Forty O 
- O 
five O 
minutes O 
after O 
treatment O 
, O 
participants O 
underwent O 
extinction O 
training O 
. O 
Twenty O 
- O 
four O 
hours O 
later O 
, O 
subjects O 
were O 
tested O 
for O 
extinction O 
recall O 
. O 
RESULTS O 
: O 
Relative O 
to O 
placebo O 
, O 
the O 
OT O 
group O 
showed O 
increased O 
fear O 
- O 
potentiated O 
startle O 
responding O 
during O 
the O 
earliest O 
stage O 
of O 
extinction O 
training O 
relative O 
to O 
placebo O 
; O 
however O 
, O 
all O 
treatment O 
groups O 
showed O 
the O 
same O 
level O 
of O 
reduced O 
responding O 
by O 
the O 
end O 
of O 
extinction O 
training O 
. O 
Twenty O 
- O 
four O 
hours O 
later O 
, O 
the O 
OT O 
group O 
showed O 
significantly O 
higher O 
recall O 
of O 
extinction O 
relative O 
to O 
placebo O 
. O 
CONCLUSIONS O 
: O 
The O 
current O 
study O 
provides O 
preliminary O 
evidence O 
that O 
OT O 
may O 
facilitate O 
fear O 
extinction O 
recall O 
in O 
humans O 
. O 
These O 
results O 
support O 
further O 
study O 
of O 
OT O 
as O 
a O 
potential O 
adjunctive O 
treatment O 
for O 
extinction O 
- O 
based O 
therapies O 
in O 
fear O 
- O 
related O 
disorders O 
. O 

Pharmacology O 
of O 
the O 
Dopamine B-TRIVIAL 
Transporter O 
: O 
Atypical O 
Inhibitors O 
, O 
Allosteric O 
Modulators O 
and O 
Partial O 
Substrates O 
. O 

dopamine B-TRIVIAL 
transporter O 
( O 
DAT O 
) O 
is O 
a O 
sodium B-SYSTEMATIC 
-coupled O 
symporter O 
protein O 
responsible O 
for O 
modulating O 
the O 
concentration O 
of O 
extraneuronal O 
dopamine B-TRIVIAL 
in O 
the O 
brain O 
. O 
The O 
DAT O 
is O 
a O 
principle O 
target O 
of O 
various O 
psychostimulant O 
, O 
nootropic O 
and O 
antidepressant O 
drugs O 
, O 
as O 
well O 
as O 
certain O 
drugs O 
used O 
recreationally O 
, O 
including O 
the O 
notoriously O 
addictive O 
stimulant O 
cocaine B-TRIVIAL 
. O 
DAT O 
ligands O 
have O 
traditionally O 
been O 
divided O 
into O 
two O 
categories O 
: O 
cocaine B-TRIVIAL 
-like O 
inhibitors O 
and O 
amphetamine B-TRIVIAL 
-like O 
substrates O 
. O 
Whereas O 
inhibitors O 
block O 
monoamine B-FAMILY 
uptake O 
by O 
the O 
DAT O 
, O 
but O 
are O 
not O 
translocated O 
across O 
the O 
membrane O 
, O 
substrates O 
are O 
actively O 
translocated O 
and O 
trigger O 
DAT O 
- O 
mediated O 
release O 
of O 
dopamine B-TRIVIAL 
by O 
reversal O 
of O 
the O 
translocation O 
cycle O 
. O 
As O 
both O 
inhibitors O 
and O 
substrates O 
increase O 
extraneuronal O 
dopamine B-TRIVIAL 
levels O 
, O 
it O 
is O 
often O 
assumed O 
that O 
all O 
DAT O 
ligands O 
posses O 
an O 
addictive O 
liability O 
equivalent O 
to O 
cocaine B-TRIVIAL 
. O 
However O 
, O 
the O 
recent O 
development O 
of O 
novel O 
' O 
atypical O 
' O 
inhibitors O 
and O 
' O 
partial O 
substrate O 
' O 
ligands O 
with O 
reduced O 
or O 
even O 
a O 
complete O 
lack O 
of O 
cocaine B-TRIVIAL 
-like O 
rewarding O 
effects O 
suggests O 
that O 
addictiveness O 
is O 
not O 
a O 
constant O 
property O 
of O 
DAT-affecting O 
compounds O 
. O 
These O 
atypical O 
ligands O 
do O 
not O 
conform O 
to O 
the O 
classical O 
preconception O 
that O 
all O 
DAT O 
inhibitors O 
( O 
or O 
substrates O 
) O 
are O 
functionally O 
and O 
mechanistically O 
alike O 
. O 
Instead O 
, O 
they O 
suggest O 
the O 
possibility O 
that O 
the O 
DAT O 
exhibits O 
some O 
of O 
the O 
ligand O 
- O 
specific O 
' O 
pleiotropic O 
' O 
functional O 
qualities O 
inherent O 
to O 
G O 
- O 
protein O 
- O 
coupled O 
receptors O 
. O 
That O 
is O 
, O 
ligands O 
with O 
different O 
chemical O 
structures O 
induce O 
specific O 
conformational O 
changes O 
in O 
the O 
transporter O 
protein O 
, O 
which O 
can O 
be O 
differentially O 
transduced O 
by O 
the O 
cell O 
, O 
ultimately O 
eliciting O 
unique O 
behavioral O 
and O 
psychical O 
effects O 
. O 
The O 
present O 
overview O 
discusses O 
compounds O 
with O 
conformation O 
- O 
specific O 
activity O 
, O 
useful O 
not O 
only O 
as O 
tools O 
for O 
studying O 
the O 
mechanics O 
of O 
dopamine B-TRIVIAL 
transport O 
, O 
but O 
also O 
as O 
leads O 
for O 
medication O 
development O 
in O 
addictive O 
disorders O 
. O 

dehydrogenase O 
type O 
1 O 
contributes O 
to O 
the O 
balance O 
between O 
7-keto- B-MULTIPLE 
and I-MULTIPLE 
7-hydroxy-oxysterols I-MULTIPLE 
in O 
vivo O 
. O 

dehydrogenase O 
1 O 
( O 
11βHSD1 O 
; O 
EC O 
1.1.1.146 O 
) O 
generates O 
active O 
glucocorticoids O 
from O 
inert O 
11-keto B-SYSTEMATIC 
metabolites O 
. O 
However O 
, O 
it O 
can O 
also O 
metabolize O 
alternative O 
substrates O 
, O 
including O 
7β-hydroxy- B-MULTIPLE 
and I-MULTIPLE 
7-keto-cholesterol I-MULTIPLE 
( O 
7βOHC B-SYSTEMATIC 
, O 
7KC B-SYSTEMATIC 
) O 
. O 
This O 
has O 
been O 
demonstrated O 
in O 
vitro O 
but O 
its O 
consequences O 
in O 
vivo O 
are O 
uncertain O 
. O 
We O 
used O 
genetically O 
modified O 
mice O 
to O 
investigate O 
the O 
contribution O 
of O 
11βHSD1 O 
to O 
the O 
balance O 
of O 
circulating O 
levels O 
of O 
7KC B-SYSTEMATIC 
and O 
7βOHC B-SYSTEMATIC 
in O 
vivo O 
, O 
and O 
dissected O 
in O 
vitro O 
the O 
kinetics O 
of O 
the O 
interactions O 
between O 
oxysterols B-FAMILY 
and O 
glucocorticoids O 
for O 
metabolism O 
by O 
the O 
mouse O 
enzyme O 
. O 
Circulating O 
levels O 
of O 
7KC B-SYSTEMATIC 
and O 
7βOHC B-SYSTEMATIC 
in O 
mice O 
were O 
91.3±22.3 O 
and O 
22.6±5.7nM O 
respectively O 
, O 
increasing O 
to O 
1240±220 O 
and O 
406±39nM O 
in O 
ApoE(- O 
/ O 
- O 
) O 
mice O 
receiving O 
atherogenic O 
western O 
diet O 
. O 
Disruption O 
of O 
11βHSD1 O 
in O 
mice O 
increased O 
( O 
p O 
< O 
0.05 O 
) O 
the O 
7KC B-SYSTEMATIC 
/ O 
7βOHC B-SYSTEMATIC 
ratio O 
in O 
plasma O 
( O 
by O 
20% O 
) O 
and O 
also O 
in O 
isolated O 
microsomes O 
( O 
2 O 
fold O 
) O 
. O 
The O 
7KC B-SYSTEMATIC 
/ O 
7βOHC B-SYSTEMATIC 
ratio O 
was O 
similarly O 
increased O 
when O 
NADPH B-ABBREVIATION 
generation O 
was O 
restricted O 
by O 
disruption O 
of O 
hexose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
. O 
Reduction O 
and O 
oxidation O 
of O 
7-oxysterols B-FAMILY 
by O 
murine O 
11βHSD1 O 
proceeded O 
more O 
slowly O 
and O 
substrate O 
affinity O 
was O 
lower O 
than O 
for O 
glucocorticoids O 
. O 
in O 
vitro O 
7βOHC B-SYSTEMATIC 
was O 
a O 
competitive O 
inhibitor O 
of O 
oxidation O 
of O 
corticosterone B-TRIVIAL 
( O 
Ki=0.9μM O 
) O 
, O 
whereas O 
7KC B-SYSTEMATIC 
only O 
weakly O 
inhibited O 
reduction O 
of O 
11-dehydrocorticosterone B-SYSTEMATIC 
. O 
However O 
, O 
supplementation O 
of O 
7-oxysterols B-FAMILY 
in O 
cultured O 
cells O 
, O 
secondary O 
to O 
cholesterol B-TRIVIAL 
loading O 
, O 
preferentially O 
slowed O 
reduction O 
of O 
glucocorticoids O 
, O 
rather O 
than O 
oxidation O 
. O 
Thus O 
, O 
in O 
mouse O 
, O 
11βHSD1 O 
influenced O 
the O 
abundance O 
and O 
balance O 
of O 
circulating O 
and O 
tissue O 
levels O 
of O 
7βOHC B-SYSTEMATIC 
and O 
7KC B-SYSTEMATIC 
, O 
promoting O 
reduction O 
of O 
7KC B-SYSTEMATIC 
. O 
In O 
health O 
, O 
7-oxysterols B-FAMILY 
are O 
unlikely O 
to O 
regulate O 
glucocorticoid O 
metabolism O 
. O 
However O 
, O 
in O 
hyperlipidaemia O 
, O 
7-oxysterols B-FAMILY 
may O 
inhibit O 
glucocorticoid O 
metabolism O 
and O 
modulate O 
signaling O 
through O 
corticosteroid B-TRIVIAL 
receptors O 
. O 

effect O 
of O 
liquid O 
( O 
LSF O 
) O 
and O 
solid O 
state O 
fermentation O 
( O 
SSF O 
) O 
of O 
lentils O 
for O 
production O 
of O 
water O 
- O 
soluble O 
fractions O 
with O 
antioxidant O 
and O 
antihypertensive O 
properties O 
was O 
studied O 
. O 
LSF O 
was O 
performed O 
either O 
spontaneously O 
( O 
NF O 
) O 
or O 
by O 
Lactobacillus O 
plantarum O 
( O 
LP O 
) O 
while O 
SSF O 
was O 
performed O 
by O 
Bacillus O 
subtilis O 
( O 
BS O 
) O 
. O 
Native O 
lactic O 
flora O 
in O 
NF O 
adapted O 
better O 
than O 
L O 
. O 
plantarum O 
to O 
fermentative O 
broth O 
and O 
BS O 
counts O 
increased O 
4 O 
logCFU O 
/ O 
g O 
up O 
to O 
48 O 
h O 
of O 
SSF O 
. O 
LSF O 
water O 
- O 
soluble O 
fractions O 
had O 
higher O 
( O 
P O 
≤ O 
0.05 O 
) O 
free O 
amino B-FAMILY 
groups O 
, O 
GABA B-ABBREVIATION 
content O 
, O 
antioxidant O 
and O 
angiotensin O 
I-converting O 
enzyme O 
inhibitory O 
( O 
ACEI O 
) O 
activities O 
than O 
SSF O 
. O 
In O 
addition O 
, O 
GABA B-ABBREVIATION 
and O 
ACEI O 
activity O 
of O 
LSF O 
increased O 
in O 
a O 
time O 
- O 
dependent O 
manner O 
. O 
Proteolysis O 
by O 
BS O 
was O 
limited O 
, O 
with O 
slight O 
changes O 
in O 
free O 
amino B-FAMILY 
groups O 
, O 
while O 
GABA B-ABBREVIATION 
, O 
total O 
phenolic B-FAMILY 
compounds O 
and O 
antioxidant O 
capacity O 
increased O 
throughout O 
fermentation O 
. O 
Higher O 
antihypertensive O 
potential O 
was O 
observed O 
in O 
NF O 
( O 
96 O 
h O 
) O 
characterised O 
by O 
the O 
highest O 
GABA B-ABBREVIATION 
content O 
( O 
10.42 O 
mg O 
/ O 
g O 
extract O 
) O 
, O 
ACE-inhibitory O 
potency O 
( O 
expressed O 
as O 
IC(50) O 
) O 
of O 
0.18 O 
mg O 
protein O 
/ O 
ml O 
and O 
antioxidant O 
capacity O 
of O 
0.26 O 
mmol O 
Trolox B-TRIVIAL 
equivalents O 
/ O 
g O 
extract O 
. O 
Therefore O 
, O 
water O 
- O 
soluble O 
fermented O 
lentil O 
extracts O 
obtained O 
by O 
LSF O 
are O 
particularly O 
promising O 
as O 
functional O 
ingredients O 
in O 
preventing O 
hypertension O 
. O 

and O 
clean O 
release O 
of O 
vertical O 
Si B-FORMULA 
nanowires O 
by O 
wet O 
chemical O 
etching O 
based O 
on O 
alkali B-FAMILY 
hydroxides I-FAMILY 
. O 

simple O 
method O 
to O 
release O 
Si B-FORMULA 
nanowires O 
( O 
SiNWs O 
) O 
from O 
a O 
substrate O 
, O 
with O 
their O 
original O 
length O 
almost O 
intact O 
, O 
is O 
demonstrated O 
. O 
By O 
exploiting O 
the O 
unique O 
chemistry O 
involved O 
for O 
the O 
fabrication O 
of O 
vertical O 
arrays O 
of O 
SiNWs O 
in O 
metal O 
- O 
assisted O 
chemical O 
etching O 
( O 
MaCE O 
) O 
based O 
either O 
on O 
HF B-FORMULA 
/ O 
AgNO3 B-FORMULA 
or O 
HF B-FORMULA 
/ O 
H2O2 B-FORMULA 
chemistries O 
, O 
wet O 
etching O 
with O 
alkali B-FAMILY 
hydroxides I-FAMILY 
such O 
as O 
NaOH B-FORMULA 
or O 
KOH B-FORMULA 
preferentially O 
attacks O 
the O 
bottom O 
part O 
of O 
the O 
vertical O 
SiNWs O 
. O 
A O 
protective O 
layer O 
of O 
Si B-FORMULA 
oxide B-SYSTEMATIC 
is O 
found O 
to O 
exist O 
on O 
the O 
outer O 
wall O 
of O 
the O 
SiNWs O 
and O 
to O 
play O 
the O 
key O 
role O 
of O 
etch O 
mask O 
during O 
the O 
release O 
- O 
etching O 
by O 
alkali B-FAMILY 
hydroxides I-FAMILY 
. O 
The O 
clean O 
release O 
of O 
SiNWs O 
also O 
enables O 
the O 
repeated O 
use O 
of O 
the O 
Si B-FORMULA 
substrate O 
for O 
the O 
fabrication O 
of O 
vertical O 
SiNW O 
arrays O 
by O 
MaCE O 
. O 
The O 
released O 
SiNWs O 
are O 
further O 
used O 
for O 
the O 
fabrication O 
of O 
field O 
- O 
effect O 
transistors O 
on O 
a O 
flexible O 
plastic O 
substrate O 
. O 
The O 
method O 
developed O 
here O 
, O 
when O 
combined O 
with O 
a O 
suitable O 
assembling O 
technique O 
, O 
can O 
be O 
very O 
useful O 
in O 
implementing O 
flexible O 
electronics O 
, O 
or O 
in O 
the O 
fabrication O 
of O 
SiNW O 
composites O 
with O 
other O 
functional O 
materials O 
. O 

first O 
dehydration O 
and O 
the O 
competing O 
reaction O 
pathways O 
of O 
glucose B-TRIVIAL 
homogeneously O 
and O 
heterogeneously O 
catalyzed O 
by O 
acids O 
. O 

dehydration O 
mechanisms O 
for O 
glucose B-TRIVIAL 
in O 
β-pyranose B-FAMILY 
( O 
BP O 
) O 
and O 
in O 
open O 
- O 
chain O 
( O 
OC O 
) O 
forms O 
, O 
catalyzed O 
by O 
acids O 
homogeneously O 
and O 
heterogeneously O 
, O 
were O 
investigated O 
using O 
density O 
functional O 
and O 
two O 
- O 
layer O 
ONIOM O 
calculations O 
. O 
The O 
first O 
dehydration O 
reaction O 
and O 
competing O 
reaction O 
pathways O 
are O 
the O 
main O 
focus O 
of O 
the O 
present O 
study O 
. O 
The O 
energetics O 
of O 
five O 
dehydration O 
and O 
two O 
isomerization O 
pathways O 
were O 
examined O 
for O 
the O 
protonated O 
form O 
of O 
BP O 
in O 
acidic O 
aqueous O 
solutions O 
and O 
the O 
most O 
favorable O 
pathway O 
of O 
these O 
was O 
found O 
to O 
be O 
the O 
dehydration O 
at O 
the O 
anomeric O 
site O 
. O 
No O 
dehydration O 
pathway O 
of O 
OC O 
glucose B-TRIVIAL 
is O 
favored O 
over O 
its O 
isomerization O 
to O 
BP O 
or O 
to O 
fructose B-TRIVIAL 
. O 
The O 
relative O 
ease O 
of O 
dehydration O 
over O 
isomerization O 
depends O 
on O 
the O 
selection O 
of O 
the O 
reaction O 
media O 
for O 
the O 
protonated O 
form O 
of O 
BP O 
. O 
These O 
two O 
reaction O 
pathways O 
catalyzed O 
by O 
a O 
surface O 
Brönsted O 
acid O 
site O 
were O 
then O 
examined O 
and O 
the O 
isomerization O 
pathway O 
was O 
found O 
to O 
be O 
more O 
favorable O 
than O 
dehydration O 
at O 
the O 
anomeric O 
site O 
on O 
a O 
surface O 
acid O 
site O 
. O 
These O 
mechanistic O 
insights O 
provide O 
an O 
important O 
guide O 
for O 
the O 
catalyst O 
design O 
/ O 
selection O 
of O 
the O 
reaction O 
media O 
for O 
glucose B-TRIVIAL 
dehydration O 
. O 

acidic O 
varieties O 
of O 
muskmelon O 
( O 
Cucumis O 
melo O 
L O 
. O 
) O 
are O 
emerging O 
onto O 
the O 
UK O 
market O 
. O 
These O 
melons O 
contain O 
almost O 
twice O 
the O 
amount O 
of O 
citric B-TRIVIAL 
acid I-TRIVIAL 
compared O 
to O 
standard O 
melons O 
and O 
are O 
described O 
as O 
' O 
zesty O 
and O 
fresh O 
' O 
. O 
This O 
study O 
compared O 
the O 
flavour O 
components O 
of O 
three O 
acidic O 
varieties O 
with O 
a O 
standard O 
Galia O 
- O 
type O 
melon O 
. O 
The O 
volatile O 
and O 
semivolatile O 
compounds O 
were O 
extracted O 
, O 
using O 
dynamic O 
headspace O 
extraction O 
( O 
DHE O 
) O 
or O 
solid O 
- O 
phase O 
microextraction O 
( O 
SPME O 
) O 
and O 
solid O 
phase O 
extraction O 
( O 
SPE O 
) O 
, O 
respectively O 
, O 
followed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC-MS O 
) O 
and O 
gas O 
chromatography O 
- O 
olfactometry O 
( O 
GC-O O 
) O 
. O 
More O 
than O 
50 O 
volatile O 
and O 
50 O 
semivolatile O 
compounds O 
were O 
identified O 
in O 
the O 
headspace O 
and O 
the O 
SPE O 
extracts O 
, O 
respectively O 
. O 
GC-O O 
revealed O 
15 O 
odour O 
- O 
active O 
components O 
in O 
the O 
headspace O 
, O 
with O 
esters B-FAMILY 
being O 
consistently O 
higher O 
in O 
the O 
acidic O 
variety O 
. O 
This O 
study O 
showed O 
quantitative O 
and O 
qualitative O 
differences O 
among O 
all O 
four O 
varieties O 
and O 
key O 
differences O 
between O 
acidic O 
varieties O 
and O 
standard O 
melons O 
. O 

: O 
Levothyroxine B-TRIVIAL 
has O 
been O 
shown O 
to O 
enhance O 
pregnancy O 
outcomes O 
in O 
women O 
with O 
hypothyroidism O 
requiring O 
In O 
Vitro O 
Fertilization O 
( O 
IVF O 
) O 
. O 
However O 
, O 
the O 
precise O 
magnitude O 
of O 
these O 
benefits O 
remains O 
to O 
be O 
determined O 
. O 
In O 
particular O 
, O 
it O 
has O 
yet O 
to O 
be O 
clarified O 
whether O 
levothyroxine B-TRIVIAL 
may O 
fully O 
overcome O 
the O 
detrimental O 
effects O 
of O 
hypothyroidism O 
or O 
, O 
conversely O 
, O 
whether O 
affected O 
women O 
remain O 
at O 
reduced O 
prognosis O 
for O 
pregnancy O 
outcomes O 
. O 
Methods O 
: O 
Patients O 
who O 
underwent O 
IVF-ICSI O 
( O 
IVF-intracytoplasmic O 
sperm O 
injection O 
) O 
over O 
a O 
three O 
- O 
year O 
period O 
were O 
reviewed O 
. O 
Cases O 
were O 
deemed O 
eligible O 
if O 
they O 
were O 
diagnosed O 
with O 
clinical O 
or O 
subclinical O 
hypothyroidism O 
and O 
were O 
receiving O 
levothyroxine B-TRIVIAL 
. O 
Controls O 
were O 
two O 
subsequently O 
age O 
- O 
matched O 
euthyroid O 
women O 
for O 
every O 
case O 
. O 
Both O 
cases O 
and O 
controls O 
were O 
selected O 
only O 
if O 
serum O 
TSH O 
was O 
≤ O 
2.5 O 
mIU O 
/ O 
L O 
. O 
Results O 
: O 
One O 
hundred O 
thirty O 
- O 
seven O 
women O 
with O 
treated O 
hypothyroidism O 
and O 
274 O 
controls O 
were O 
included O 
. O 
Baseline O 
characteristics O 
of O 
the O 
two O 
study O 
groups O 
were O 
similar O 
with O 
the O 
exception O 
of O 
BMI O 
, O 
which O 
was O 
slightly O 
higher O 
among O 
the O 
cases O 
( O 
22.9 O 
± O 
3.9 O 
versus O 
21.9 O 
± O 
3.3 O 
Kg O 
/ O 
m2 O 
, O 
p=0.013 O 
) O 
. O 
Most O 
IVF-ICSI O 
cycle O 
outcome O 
variables O 
were O 
also O 
similar O 
with O 
the O 
exception O 
of O 
a O 
higher O 
rate O 
of O 
cancellation O 
for O 
poor O 
response O 
( O 
3.6% O 
versus O 
0.7% O 
, O 
p=0.04 O 
) O 
, O 
a O 
longer O 
duration O 
of O 
stimulation O 
( O 
10.9 O 
± O 
2.2 O 
versus O 
10.1 O 
± O 
2 O 
days O 
, O 
p=0.001 O 
) O 
, O 
a O 
higher O 
proportion O 
of O 
women O 
failing O 
to O 
obtain O 
viable O 
embryos O 
( O 
17% O 
versus O 
7% O 
, O 
p=0.006 O 
) O 
, O 
and O 
a O 
lower O 
fertilization O 
rate O 
( O 
75% O 
versus O 
86% O 
, O 
p=0.017 O 
) O 
among O 
cases O 
. O 
Conversely O 
, O 
the O 
clinical O 
pregnancy O 
rate O 
per O 
started O 
cycle O 
, O 
the O 
implantation O 
rate O 
and O 
the O 
live O 
birth O 
rate O 
per O 
started O 
cycle O 
did O 
not O 
differ O 
; O 
they O 
were O 
36% O 
and O 
34% O 
( O 
p=0.93 O 
) O 
, O 
28% O 
and O 
22% O 
( O 
p=0.11 O 
) O 
and O 
30% O 
and O 
27% O 
( O 
p=0.50 O 
) O 
in O 
cases O 
and O 
controls O 
, O 
respectively O 
. O 
Subgroup O 
analyses O 
comparing O 
women O 
with O 
( O 
n=79 O 
) O 
and O 
without O 
( O 
n=58 O 
) O 
thyroid O 
autoimmunity O 
and O 
comparing O 
women O 
who O 
were O 
diagnosed O 
with O 
overt O 
hypothyroidism O 
( O 
n=70 O 
) O 
or O 
subclinical O 
hypothyroidism O 
( O 
n=67 O 
) O 
failed O 
to O 
identify O 
relevant O 
differences O 
. O 
Conclusions O 
: O 
In O 
our O 
population O 
, O 
IVF-ICSI O 
outcome O 
was O 
not O 
significantly O 
hampered O 
in O 
women O 
with O 
adequately O 
treated O 
hypothyroidism O 
. O 
The O 
magnitude O 
of O 
the O 
detected O 
differences O 
in O 
cycle O 
outcome O 
was O 
mild O 
and O 
we O 
failed O 
to O 
document O 
any O 
differences O 
for O 
the O 
most O 
relevant O 
outcomes O 
, O 
i.e O 
. O 
pregnancy O 
rate O 
, O 
implantation O 
rate O 
and O 
delivery O 
rate O 
. O 
In O 
conclusion O 
, O 
adequate O 
levothyroxine B-TRIVIAL 
treatment O 
maintaining O 
TSH O 
serum O 
levels O 
below O 
2.5 O 
mIU O 
/ O 
L O 
may O 
overcome O 
the O 
detrimental O 
effects O 
of O 
hypothyroidism O 
. O 

Cherry O 
Seed O 
Kernel O 
Extract O 
Increases O 
Heme B-FAMILY 
Oxygenase-1 O 
Expression O 
and O 
Decreases O 
Representation O 
of O 
CD3+ O 
TNF-α O 
+ O 
and O 
CD3 O 
+ O 
IL-8+ O 
Subpopulations O 
in O 
Peripheral O 
Blood O 
Leukocyte O 
Cultures O 
from O 
Type O 
2 O 
Diabetes O 
Patients O 
. O 

present O 
study O 
evaluates O 
a O 
hypothesis O 
that O 
sour O 
cherry O 
( O 
Prunus O 
cerasus O 
) O 
seed O 
extracts O 
( O 
SCE O 
) O 
modulate O 
CD3+ O 
T O 
lymphocyte O 
activity O 
in O 
ways O 
predictive O 
of O 
potential O 
for O 
uses O 
of O 
SCE O 
in O 
management O 
of O 
inflammatory O 
diseases O 
. O 
Peripheral O 
blood O 
mononuclear O 
cells O 
( O 
PBMC O 
) O 
from O 
12 O 
type O 
2 O 
diabetes O 
( O 
T2DM O 
) O 
patients O 
and O 
eight O 
healthy O 
control O 
subjects O 
were O 
cultured O 
24 O 
h O 
with O 
100 O 
ng O 
/ O 
ml O 
lipopolysaccharide O 
( O 
LPS O 
) O 
to O 
increase O 
inflammatory O 
signaling O 
and O 
co O 
- O 
incubated O 
with O 
0.5-100 O 
µg O 
/ O 
ml O 
SCE O 
. O 
Cultures O 
were O 
evaluated O 
by O 
two O 
- O 
color O 
flow O 
cytometry O 
for O 
percent O 
representation O 
of O 
CD3+ O 
IL8+ O 
and O 
CD3 O 
+ O 
TNF-α O 
+ O 
cells O 
which O 
express O 
interleukin-8 O 
( O 
IL-8 O 
) O 
, O 
and O 
tumor O 
necrosis O 
factor-α O 
, O 
( O 
TNF-α+ O 
) O 
respectively O 
, O 
and O 
by O 
enzyme O 
- O 
linked O 
immunoassay O 
for O 
lymphocyte O 
- O 
associated O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
, O 
known O 
to O 
be O 
induced O 
by O 
SCE O 
) O 
. O 
SCE O 
dosage O 
ranges O 
of O 
0.5-100 O 
µg O 
/ O 
ml O 
in O 
cell O 
cultures O 
significantly O 
suppressed O 
LPS-increased O 
CD3 O 
+ O 
TNF-α O 
+ O 
and O 
CD3 O 
+ O 
IL8+ O 
representation O 
from O 
all O 
participants O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
with O 
greater O 
pharmacological O 
effect O 
noted O 
in O 
suppression O 
of O 
CD3 O 
+ O 
TNF-α O 
+ O 
noted O 
in O 
cells O 
from O 
T2DM O 
patients O 
versus O 
healthy O 
control O 
subjects O 
. O 
These O 
effects O 
correlated O 
with O 
increased O 
HO-1 O 
expression O 
in O 
SCE O 
- O 
treated O 
PBMC O 
from O 
all O 
subjects O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Since O 
TNF-α O 
and O 
IL-8 O 
are O 
diagnostic O 
/ O 
prognostic O 
biomarkers O 
for O 
many O 
inflammatory O 
syndromes O 
, O 
the O 
capacity O 
of O 
SCE O 
to O 
down O 
- O 
regulate O 
representation O 
of O 
cells O 
that O 
express O 
them O 
suggests O 
potential O 
for O 
therapeutic O 
use O 
of O 
SCE O 
in O 
T2DM O 
and O 
other O 
diseases O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

cell O 
resistance O 
to O 
chemotherapy O 
is O 
still O 
a O 
heavy O 
burden O 
that O 
impairs O 
treatment O 
of O 
cancer O 
patients O 
. O 
Both O 
intrinsic O 
and O 
acquired O 
resistance O 
results O 
from O 
the O 
numerous O 
genetic O 
and O 
epigenetic O 
changes O 
occurring O 
in O 
cancer O 
cells O 
. O 
Most O 
of O 
the O 
hallmarks O 
of O 
cancer O 
cells O 
provide O 
general O 
mechanisms O 
to O 
sustain O 
stresses O 
such O 
as O 
the O 
ones O 
induced O 
by O 
chemotherapeutic O 
drugs O 
. O 
Moreover O 
, O 
specific O 
changes O 
in O 
the O 
target O 
bring O 
resistance O 
to O 
specific O 
drugs O 
like O 
modification O 
in O 
nucleotide B-FAMILY 
synthesis O 
enzymes O 
upon O 
anti-metabolite O 
exposure O 
, O 
in O 
microtubule O 
composition O 
upon O 
spindle O 
poison O 
treatment O 
, O 
in O 
topoisomerase O 
activity O 
upon O 
topoisomerase O 
inhibitor O 
incubation O 
or O 
in O 
intracellular O 
signaling O 
pathways O 
when O 
targeting O 
tyrosine B-TRIVIAL 
kinase O 
receptors O 
. O 
Finally O 
, O 
the O 
stemness O 
properties O 
of O 
a O 
few O 
cancer O 
cells O 
as O 
well O 
as O 
components O 
of O 
the O 
tumor O 
stroma O 
, O 
like O 
fibroblasts O 
and O 
tumor O 
- O 
associated O 
macrophages O 
but O 
also O 
hypoxia O 
, O 
also O 
help O 
tumor O 
to O 
resist O 
to O 
anticancer O 
agents O 
. O 
These O 
processes O 
provide O 
an O 
additional O 
level O 
of O 
complexity O 
to O 
the O 
understanding O 
of O 
the O 
tumor O 
resistance O 
phenomenon O 
. O 
This O 
review O 
aims O 
to O 
describe O 
the O 
different O 
general O 
mechanisms O 
as O 
well O 
as O 
some O 
examples O 
of O 
specific O 
on O 
target O 
modifications O 
inducing O 
cancer O 
cell O 
resistance O 
to O 
chemotherapy O 
at O 
the O 
molecular O 
level O 
. O 
Perspectives O 
to O 
develop O 
more O 
efficient O 
treatment O 
, O 
using O 
genomic O 
signature O 
or O 
more O 
specific O 
biomarkers O 
to O 
characterize O 
putative O 
resistance O 
mechanisms O 
in O 
patients O 
before O 
choosing O 
the O 
more O 
appropriate O 
treatment O 
, O 
will O 
also O 
be O 
discussed O 
. O 

of O 
abdominal O 
fat O 
accumulation O 
in O 
rats O 
by O 
8-week O 
ingestion O 
of O 
a O 
newly O 
developed O 
sweetener O 
made O 
from O 
high O 
fructose B-TRIVIAL 
corn O 
syrup O 
. O 

studies O 
have O 
shown O 
that O 
ingestion O 
of O 
high- O 
fructose B-TRIVIAL 
corn O 
syrup O 
( O 
HFCS O 
) O 
may O 
cause O 
an O 
increase O 
in O 
body O 
weight O 
and O 
abdominal O 
fat O 
. O 
We O 
recently O 
developed O 
a O 
new O 
sweetener O 
containing O 
rare O 
sugars B-FAMILY 
( O 
rare O 
sugar B-FAMILY 
syrup O 
; O 
RSS O 
) O 
by O 
slight O 
isomerization O 
of O 
HFCS O 
. O 
Here O 
, O 
the O 
functional O 
effects O 
of O 
RSS O 
on O 
body O 
weight O 
and O 
abdominal O 
fat O 
, O 
and O 
biochemical O 
parameters O 
in O 
Wistar O 
rats O 
were O 
examined O 
. O 
Rats O 
( O 
n=30 O 
) O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
and O 
maintained O 
for O 
8-weeks O 
on O 
starch O 
, O 
starch O 
+ O 
HFCS O 
( O 
50 O 
: O 
50 O 
) O 
, O 
and O 
starch O 
+ O 
RSS O 
( O 
50 O 
: O 
50 O 
) O 
diets O 
. O 
Rats O 
in O 
the O 
Starch O 
and O 
HFCS O 
groups O 
gained O 
significantly O 
more O 
body O 
weight O 
and O 
abdominal O 
fat O 
than O 
the O 
RSS O 
group O 
. O 
Fasting O 
serum O 
insulin O 
in O 
the O 
RSS O 
group O 
was O 
significantly O 
lower O 
than O 
in O 
the O 
Starch O 
and O 
HFCS O 
groups O 
, O 
although O 
serum O 
glucose B-TRIVIAL 
in O 
the O 
HFCS O 
and O 
RSS O 
groups O 
was O 
significantly O 
lower O 
than O 
that O 
in O 
the O 
Starch O 
group O 
. O 
Thus O 
, O 
the O 
substitution O 
of O 
HFCS O 
with O 
RSS O 
prevents O 
obesity O 
induced O 
by O 
the O 
consumption O 
of O 
HFCS O 
. O 

optimum O 
nanoprecipitation O 
technique O 
for O 
gelatin O 
nanoparticles O 
is O 
established O 
, O 
based O 
on O 
aqueous O 
gelatin O 
solution O 
and O 
ethanolic O 
solution O 
containing O 
stabilizer O 
. O 
Crosslinking O 
with O 
glutaraldehyde B-TRIVIAL 
results O 
in O 
stable O 
gelatine O 
nanoparticles O 
. O 
Several O 
factors O 
such O 
as O 
the O 
surfactant O 
concentration O 
, O 
type O 
of O 
surfactant O 
, O 
type O 
of O 
nonsolvent O 
and O 
gelatin O 
concentration O 
are O 
evaluated O 
. O 
Gelatin O 
nanoparticles O 
with O 
200-300 O 
nm O 
can O 
be O 
produced O 
using O 
20-30 O 
mg O 
mL(-1) O 
of O 
gelatin O 
and O 
a O 
minimum O 
of O 
7% O 
w O 
/ O 
v O 
stabilizer O 
( O 
Poloxamer O 
407 O 
or O 
188 O 
) O 
. O 
Furthermore O 
, O 
methanol B-SYSTEMATIC 
and O 
ethanol B-SYSTEMATIC 
are O 
good O 
nonsolvents O 
, O 
whereas O 
other O 
nonsolvents O 
such O 
as O 
acetone B-SYSTEMATIC 
, O 
isopropyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
, O 
and O 
acetonitrile B-SYSTEMATIC 
, O 
result O 
in O 
phase O 
separation O 
and O 
visible O 
precipitates O 
. O 
The O 
entrapment O 
efficiency O 
of O 
fluorescein B-SYSTEMATIC 
- I-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
( O 
FITC B-ABBREVIATION 
)-dextran O 
as O 
model O 
drug O 
was O 
determined O 
to O 
50% O 
with O 
no O 
substantial O 
effect O 
on O 
particle O 
size O 
. O 
80% O 
of O 
the O 
drug O 
is O 
only O 
released O 
after O 
enzymatic O 
digestion O 
. O 

in O 
vivo O 
system O 
for O 
monitoring O 
small O 
- O 
molecule O 
- O 
mediated O 
neuronal O 
branching O 
has O 
been O 
developed O 
by O 
using O 
C O 
. O 
elegans O 
. O 
Growth O 
- O 
promoting O 
compounds O 
can O 
be O 
detected O 
by O 
visual O 
inspection O 
of O 
GFPlabeled O 
cholinergic O 
neurons O 
, O 
as O 
axonal O 
branching O 
occurs O 
following O 
treatment O 
with O 
neurotrophic O 
agents O 
. O 
Investigation O 
of O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
the O 
neurotrophic O 
natural O 
product O 
clovanemagnolol B-TRIVIAL 
( O 
1 O 
) O 
led O 
us O 
to O 
a O 
comparable O 
chemically O 
edited O 
derivative O 
. O 

and O 
anti-tumor O 
evaluation O 
of O 
novel O 
25-hydroxyprotopanaxadiol B-SYSTEMATIC 
analogs O 
incorporating O 
natural O 
amino B-FAMILY 
acids I-FAMILY 
. O 

the O 
current O 
study O 
, O 
derivatives O 
of O 
25-hydroxyprotopanaxadiol B-SYSTEMATIC 
( O 
25-OH-PPD B-SYSTEMATIC 
) O 
were O 
prepared O 
and O 
their O 
in O 
vitro O 
anti-tumor O 
activities O 
were O 
tested O 
on O 
six O 
different O 
human O 
tumor O 
cell O 
lines O 
by O 
standard O 
MTT B-ABBREVIATION 
assay O 
. O 
The O 
results O 
showed O 
that O 
combining O 
an O 
ester B-FAMILY 
group O 
combined O 
with O 
the O 
presence O 
of O 
an O 
amino B-FAMILY 
acid I-FAMILY 
moiety O 
led O 
to O 
a O 
10-fold O 
improved O 
anti-tumor O 
activity O 
. O 
Compound O 
1c O 
exhibited O 
the O 
best O 
anti-tumor O 
activity O 
in O 
the O 
in O 
vitro O 
assays O 
. O 
Compounds O 
2c O 
, O 
3c O 
, O 
4c O 
, O 
5c O 
, O 
6c O 
and O 
8b O 
showed O 
better O 
anti-tumor O 
activities O 
compared O 
to O 
the O 
parent O 
compound O 
25-OH-PPD B-SYSTEMATIC 
. O 
The O 
current O 
results O 
may O 
provide O 
useful O 
data O 
for O 
researching O 
and O 
developing O 
new O 
anti-cancer O 
agents O 
. O 

of O 
dopamine B-TRIVIAL 
transporter O 
serine B-TRIVIAL 
7 O 
modulates O 
cocaine B-TRIVIAL 
analog O 
binding O 
. O 

an O 
approach O 
to O 
elucidating O 
dopamine B-TRIVIAL 
transporter O 
( O 
DAT O 
) O 
phosphorylation O 
characteristics O 
, O 
we O 
examined O 
in O 
vitro O 
phosphorylation O 
of O 
a O 
recombinant O 
rat O 
DAT O 
N B-FORMULA 
-terminal O 
peptide O 
( O 
NDAT O 
) O 
using O 
purified O 
protein O 
kinases O 
. O 
We O 
found O 
that O 
NDAT O 
becomes O 
phosphorylated O 
at O 
single O 
distinct O 
sites O 
by O 
protein O 
kinase O 
A O 
( O 
Ser B-FORMULA 
-7 O 
) O 
and O 
calcium B-SYSTEMATIC 
-calmodulin O 
- O 
dependent O 
protein O 
kinase O 
II O 
( O 
Ser B-FORMULA 
-13 O 
) O 
and O 
at O 
multiple O 
sites O 
( O 
Ser B-FORMULA 
-4 O 
, O 
Ser B-FORMULA 
-7 O 
, O 
and O 
Ser B-FORMULA 
-13 O 
) O 
by O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
, O 
implicating O 
these O 
residues O 
as O 
potential O 
sites O 
of O 
DAT O 
phosphorylation O 
by O 
these O 
kinases O 
. O 
Mapping O 
of O 
rat O 
striatal O 
DAT O 
phosphopeptides O 
by O 
two O 
- O 
dimensional O 
thin O 
layer O 
chromatography O 
revealed O 
basal O 
and O 
PKC-stimulated O 
phosphorylation O 
of O 
the O 
same O 
peptide O 
fragments O 
and O 
comigration O 
of O 
PKC-stimulated O 
phosphopeptide O 
fragments O 
with O 
NDAT O 
Ser B-FORMULA 
-7 O 
phosphopeptide O 
markers O 
. O 
We O 
further O 
confirmed O 
by O 
site O 
- O 
directed O 
mutagenesis O 
and O 
mass O 
spectrometry O 
that O 
Ser B-FORMULA 
-7 O 
is O 
a O 
site O 
for O 
PKC-stimulated O 
phosphorylation O 
in O 
heterologously O 
expressed O 
rat O 
and O 
human O 
DATs O 
. O 
Mutation O 
of O 
Ser B-FORMULA 
-7 O 
and O 
nearby O 
residues O 
strongly O 
reduced O 
the O 
affinity O 
of O 
rat O 
DAT O 
for O 
the O 
cocaine B-TRIVIAL 
analog O 
(-)-2β-carbomethoxy-3β-(4-fluorophenyl) B-SYSTEMATIC 
tropane I-SYSTEMATIC 
( O 
CFT B-ABBREVIATION 
) O 
, O 
whereas O 
in O 
rat O 
striatal O 
tissue O 
, O 
conditions O 
that O 
promote O 
DAT O 
phosphorylation O 
caused O 
increased O 
CFT B-ABBREVIATION 
affinity O 
. O 
Ser B-FORMULA 
-7 O 
mutation O 
also O 
affected O 
zinc B-SYSTEMATIC 
modulation O 
of O 
CFT B-ABBREVIATION 
binding O 
, O 
with O 
Ala B-FORMULA 
and O 
Asp B-FORMULA 
substitutions O 
inducing O 
opposing O 
effects O 
. O 
These O 
results O 
identify O 
Ser B-FORMULA 
-7 O 
as O 
a O 
major O 
site O 
for O 
basal O 
and O 
PKC-stimulated O 
phosphorylation O 
of O 
native O 
and O 
expressed O 
DAT O 
and O 
suggest O 
that O 
Ser B-FORMULA 
-7 O 
phosphorylation O 
modulates O 
transporter O 
conformational O 
equilibria O 
, O 
shifting O 
the O 
transporter O 
between O 
high O 
and O 
low O 
affinity O 
cocaine B-TRIVIAL 
binding O 
states O 
. O 

have O 
recently O 
shown O 
that O 
thermolysine O 
, O 
a O 
protease O 
enzyme O 
obtained O 
from O 
Bacillus O 
thermoproteolyticus O 
rokko O 
, O 
can O 
be O 
used O 
to O 
trigger O 
the O 
gelation O 
of O 
FEFK O 
( O 
F O 
, O 
phenylalanine B-TRIVIAL 
; O 
E O 
, O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
; O 
K O 
, O 
lysine B-TRIVIAL 
) O 
tetrapeptides O 
through O 
reverse O 
hydrolysis O 
and O 
formation O 
of O 
longer O 
peptide O 
sequences O 
, O 
mainly O 
octapeptides O 
, O 
that O 
self O 
- O 
assemble O 
readily O 
. O 
In O 
this O 
article O 
we O 
investigate O 
the O 
effect O 
of O 
enzyme O 
concentration O 
on O 
the O 
morphology O 
and O 
properties O 
of O 
enzymatically O 
triggered O 
peptide O 
hydrogels O 
using O 
HPLC O 
, O 
FTIR O 
, O 
real O 
- O 
time O 
SAXS O 
, O 
TEM O 
, O 
and O 
shear O 
rheology O 
. O 
We O 
have O 
shown O 
that O 
the O 
enzyme O 
concentration O 
, O 
Cenz O 
, O 
does O 
not O 
affect O 
the O 
final O 
composition O 
of O 
the O 
samples O 
. O 
Instead O 
, O 
this O 
is O 
dictated O 
by O 
the O 
initial O 
tetrapeptide O 
concentration O 
, O 
C0 O 
, O 
suggesting O 
the O 
existence O 
of O 
a O 
chemical O 
equilibrium O 
. O 
We O 
went O 
on O 
to O 
show O 
that O 
Cenz O 
does O 
not O 
affect O 
the O 
self O 
- O 
assembly O 
of O 
these O 
peptides O 
at O 
a O 
molecular O 
level O 
either O 
nor O 
the O 
structure O 
of O 
the O 
fibrillar O 
network O 
formed O 
at O 
the O 
nanometer O 
scale O 
. O 
Interestingly O 
, O 
the O 
mechanical O 
properties O 
were O 
found O 
to O 
be O 
affected O 
by O 
Cenz O 
, O 
where O 
the O 
shear O 
moduli O 
of O 
the O 
hydrogels O 
were O 
found O 
to O 
increase O 
with O 
increasing O 
Cenz O 
. O 
These O 
results O 
suggest O 
that O 
morphological O 
differences O 
between O 
the O 
hydrogels O 
at O 
the O 
microscale O 
are O 
at O 
the O 
origin O 
of O 
their O 
difference O 
in O 
mechanical O 
properties O 
. O 
In O 
this O 
paper O 
, O 
we O 
propose O 
a O 
morphological O 
model O 
in O 
which O 
denser O 
network O 
regions O 
are O 
found O 
around O 
the O 
enzymes O 
, O 
resulting O 
in O 
the O 
creation O 
of O 
heterogeneous O 
networks O 
. O 
These O 
were O 
confirmed O 
by O 
TEM O 
measurements O 
. O 
The O 
existence O 
of O 
these O 
denser O 
network O 
regions O 
will O 
result O 
in O 
the O 
reinforcement O 
of O 
the O 
hydrogels O 
, O 
thus O 
, O 
explaining O 
the O 
high O 
shear O 
moduli O 
obtained O 
increasing O 
Cenz O 
. O 

- O 
mediated O 
transcriptional O 
silencing O 
prevents O 
deleterious O 
effects O 
of O 
transposon O 
activity O 
and O 
controls O 
the O 
expression O 
of O 
protein O 
- O 
coding O 
genes O 
. O 
It O 
involves O 
long O 
noncoding O 
RNAs O 
( O 
lncRNAs O 
) O 
. O 
In O 
Arabidopsis O 
thaliana O 
, O 
some O 
of O 
those O 
lncRNAs O 
are O 
produced O 
by O 
a O 
specialized O 
RNA O 
Polymerase O 
V O 
( O 
Pol O 
V O 
) O 
. O 
The O 
mechanism O 
by O 
which O 
lncRNAs O 
affect O 
chromatin O 
structure O 
and O 
mRNA O 
production O 
remains O 
mostly O 
unknown O 
. O 
Here O 
we O 
identify O 
the O 
SWI O 
/ O 
SNF O 
ATP B-ABBREVIATION 
-dependent O 
nucleosome O 
- O 
remodeling O 
complex O 
as O 
a O 
component O 
of O 
the O 
RNA O 
- O 
mediated O 
transcriptional O 
silencing O 
pathway O 
. O 
We O 
found O 
that O 
SWI3B O 
, O 
an O 
essential O 
subunit O 
of O 
the O 
SWI O 
/ O 
SNF O 
complex O 
, O 
physically O 
interacts O 
with O 
a O 
lncRNA O 
- O 
binding O 
protein O 
, O 
IDN2 O 
. O 
SWI O 
/ O 
SNF O 
subunits O 
contribute O 
to O 
lncRNA O 
- O 
mediated O 
transcriptional O 
silencing O 
. O 
Moreover O 
, O 
Pol O 
V O 
mediates O 
stabilization O 
of O 
nucleosomes O 
on O 
silenced O 
regions O 
. O 
We O 
propose O 
that O 
Pol O 
V-produced O 
lncRNAs O 
mediate O 
transcriptional O 
silencing O 
by O 
guiding O 
the O 
SWI O 
/ O 
SNF O 
complex O 
and O 
establishing O 
positioned O 
nucleosomes O 
on O 
specific O 
genomic O 
loci O 
. O 
We O 
further O 
propose O 
that O 
guiding O 
ATP B-ABBREVIATION 
-dependent O 
chromatin O 
- O 
remodeling O 
complexes O 
may O 
be O 
a O 
more O 
general O 
function O 
of O 
lncRNAs O 
. O 

of O 
MoS2 B-FORMULA 
and O 
MoSe2 B-FORMULA 
films O 
with O 
vertically O 
aligned O 
layers O 
. O 

materials O 
consist O 
of O 
molecular O 
layers O 
stacked O 
together O 
by O 
weak O 
interlayer O 
interactions O 
. O 
They O 
often O 
crystallize O 
to O 
form O 
atomically O 
smooth O 
thin O 
films O 
, O 
nanotubes O 
, O 
and O 
platelet O 
or O 
fullerene B-TRIVIAL 
-like O 
nanoparticles O 
due O 
to O 
the O 
anisotropic O 
bonding O 
. O 
Structures O 
that O 
predominately O 
expose O 
edges O 
of O 
the O 
layers O 
exhibit O 
high O 
surface O 
energy O 
and O 
are O 
often O 
considered O 
unstable O 
. O 
In O 
this O 
communication O 
, O 
we O 
present O 
a O 
synthesis O 
process O 
to O 
grow O 
MoS2 B-FORMULA 
and O 
MoSe2 B-FORMULA 
thin O 
films O 
with O 
vertically O 
aligned O 
layers O 
, O 
thereby O 
maximally O 
exposing O 
the O 
edges O 
on O 
the O 
film O 
surface O 
. O 
Such O 
edge O 
- O 
terminated O 
films O 
are O 
metastable O 
structures O 
of O 
MoS2 B-FORMULA 
and O 
MoSe2 B-FORMULA 
, O 
which O 
may O 
find O 
applications O 
in O 
diverse O 
catalytic O 
reactions O 
. O 
We O 
have O 
confirmed O 
their O 
catalytic O 
activity O 
in O 
a O 
hydrogen B-SYSTEMATIC 
evolution O 
reaction O 
( O 
HER O 
) O 
, O 
in O 
which O 
the O 
exchange O 
current O 
density O 
correlates O 
directly O 
with O 
the O 
density O 
of O 
the O 
exposed O 
edge O 
sites O 
. O 

enzyme O 
γ-glutamyltransferase O 
( O 
GGT O 
) O 
catalyzes O 
the O 
hydrolysis O 
of O 
the O 
γ-glutamyl B-TRIVIAL 
isopeptide O 
bond O 
of O 
glutathione B-TRIVIAL 
conjugates O 
( O 
donor O 
substrates O 
) O 
, O 
releasing O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
, O 
or O 
the O 
transfer O 
of O 
the O 
donor's O 
γ-glutamyl B-TRIVIAL 
group O 
to O 
an O 
acceptor O 
substrate O 
, O 
such O 
as O 
a O 
dipeptide B-FAMILY 
. O 
The O 
specificity O 
of O 
GGT O 
for O 
xenobiotic O 
donor O 
substrates O 
has O 
not O 
been O 
fully O 
characterized O 
. O 
The O 
transpeptidation O 
activity O 
of O 
bovine O 
kidney O 
GGT O 
was O 
measured O 
with O 
glycylglycine B-TRIVIAL 
as O 
the O 
acceptor O 
substrate O 
and O 
several O 
glutathione B-TRIVIAL 
conjugate O 
donor O 
substrates O 
, O 
representative O 
of O 
detoxication O 
products O 
of O 
polycyclic O 
aromatic O 
xenobiotics O 
. O 
HPLC O 
separation O 
with O 
UV O 
detection O 
was O 
used O 
for O 
quantitation O 
. O 
The O 
commonly O 
- O 
used O 
chromogenic O 
substrate O 
γ-glutamyl-p-nitroanilide B-SYSTEMATIC 
was O 
also O 
tested O 
. O 
Michaelis O 
constants O 
( O 
Km O 
) O 
were O 
obtained O 
for O 
4-nitrobenzylglutathione B-SYSTEMATIC 
( O 
0.075mM O 
) O 
, O 
2,4-dinitrophenylglutathione B-SYSTEMATIC 
( O 
0.30mM O 
) O 
, O 
4-methylbiphenylylglutathione B-SYSTEMATIC 
( O 
0.12mM O 
) O 
, O 
1-menaphthylglutathione B-SYSTEMATIC 
( O 
0.23mM O 
) O 
, O 
and O 
9-methylanthracenylglutathione B-SYSTEMATIC 
( O 
0.22mM O 
) O 
, O 
indicating O 
a O 
trend O 
towards O 
higher O 
values O 
for O 
bulkier O 
substrates O 
. O 
These O 
results O 
provide O 
insight O 
into O 
the O 
capacity O 
of O 
GGT O 
to O 
act O 
in O 
the O 
biotransformation O 
of O 
aromatic O 
compounds O 
, O 
many O 
of O 
which O 
are O 
of O 
toxicological O 
importance O 
. O 

and O 
electrochemical O 
investigations O 
of O 
the O 
fluorescent O 
probe O 
, O 
4,4'-bis(2-benzoxazolyl)stilbene B-SYSTEMATIC 
. O 

solution O 
, O 
4,4'-bis(2-benzoxazolyl)stilbene B-SYSTEMATIC 
( O 
BBS B-ABBREVIATION 
) O 
was O 
found O 
to O 
exhibit O 
consistently O 
high O 
absolute O 
fluorescence O 
quantum O 
yields O 
( O 
Φ(fl) O 
≥ O 
0.88 O 
) O 
and O 
a O 
monoexponential O 
lifetime O 
, O 
both O 
independent O 
of O 
BBS B-ABBREVIATION 
concentration O 
. O 
The O 
BBS B-ABBREVIATION 
steady O 
- O 
state O 
and O 
time O 
- O 
resolved O 
photophysics O 
were O 
investigated O 
by O 
different O 
techniques O 
to O 
understand O 
the O 
various O 
deactivation O 
pathways O 
. O 
Nonradiative O 
deactivation O 
of O 
BBS B-ABBREVIATION 
singlet O 
excited O 
state O 
by O 
intersystem O 
crossing O 
was O 
found O 
to O 
be O 
negligible O 
. O 
Other O 
than O 
fluorescence O 
, O 
the O 
excited O 
state O 
of O 
BBS B-ABBREVIATION 
was O 
found O 
to O 
be O 
deactivated O 
by O 
trans-cis O 
photoisomerization O 
. O 
At O 
low O 
concentrations O 
( O 
≈5 O 
μg O 
/ O 
mL O 
) O 
, O 
UV O 
spectroscopy O 
and O 
laser O 
flash O 
photolysis O 
showed O 
concordant O 
results O 
that O 
the O 
photoinduced O 
cis O 
isomer O 
gradually O 
replaced O 
the O 
original O 
absorption O 
spectrum O 
of O 
the O 
pure O 
trans O 
isomer O 
. O 
However O 
, O 
at O 
high O 
concentrations O 
( O 
≈0.2 O 
mg O 
/ O 
mL O 
) O 
, O 
(1)H B-FORMULA 
NMR O 
and O 
DOSY O 
measurements O 
confirmed O 
that O 
irradiating O 
BBS B-ABBREVIATION 
at O 
350 O 
nm O 
induced O 
a O 
conversion O 
from O 
the O 
trans-BBS B-ABBREVIATION 
into O 
its O 
cis O 
isomer O 
by O 
photoisomerization O 
. O 
It O 
was O 
further O 
found O 
that O 
the O 
stilbene B-TRIVIAL 
moiety O 
of O 
both O 
isomers O 
was O 
photocleaved O 
. O 
The O 
resulting O 
photoproduct O 
was O 
an O 
aldehyde B-SYSTEMATIC 
that O 
was O 
oxidized O 
under O 
ambient O 
conditions O 
to O 
its O 
corresponding O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
i.e O 
. O 
, O 
4-(1,3-benzoxazol-2-yl)benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
The O 
structure O 
of O 
the O 
photoproduct O 
was O 
unequivocally O 
confirmed O 
by O 
X-ray O 
diffraction O 
. O 
Spectroscopic O 
investigation O 
of O 
BBS B-ABBREVIATION 
showed O 
a O 
limited O 
photoisomerization O 
after O 
irradiation O 
at O 
350 O 
nm O 
of O 
a O 
trans O 
solution O 
. O 
The O 
BBS B-ABBREVIATION 
electrochemistry O 
showed O 
irreversible O 
oxidation O 
, O 
resulting O 
in O 
an O 
unstable O 
and O 
highly O 
reactive O 
radical O 
cation O 
. O 
Similarly O 
, O 
the O 
cathodic O 
process O 
was O 
also O 
found O 
to O 
be O 
irreversible O 
, O 
giving O 
rise O 
to O 
a O 
radical O 
anion O 
and O 
showing O 
its O 
n-doping O 
character O 
. O 

DNA O 
origami O 
method O 
produces O 
programmable O 
nanoscale O 
objects O 
that O 
form O 
when O 
one O 
long O 
scaffold O 
strand O 
hybridizes O 
to O 
numerous O 
oligonucleotide O 
staple O 
strands O 
. O 
One O 
scaffold O 
strand O 
is O 
dominating O 
the O 
field O 
: O 
M13mp18 O 
, O 
a O 
bacteriophage O 
- O 
derived O 
vector O 
7249 O 
nucleotides B-FAMILY 
in O 
length O 
. O 
The O 
full O 
- O 
length O 
M13 O 
is O 
typically O 
folded O 
by O 
using O 
over O 
200 O 
staple O 
oligonucleotides O 
. O 
Here O 
we O 
report O 
the O 
convenient O 
preparation O 
of O 
a O 
704 O 
nt O 
fragment O 
dubbed O 
" O 
M1.3 O 
" O 
as O 
a O 
linear O 
or O 
cyclic O 
scaffold O 
and O 
the O 
assembly O 
of O 
small O 
origami O 
structures O 
with O 
just O 
15-24 O 
staple O 
strands O 
. O 
A O 
typical O 
M1.3 O 
origami O 
is O 
large O 
enough O 
to O 
be O 
visualized O 
by O 
TEM O 
, O 
but O 
small O 
enough O 
to O 
show O 
a O 
cooperativity O 
in O 
its O 
assembly O 
and O 
thermal O 
denaturation O 
that O 
is O 
reminiscent O 
of O 
oligonucleotide O 
duplexes O 
. O 
Due O 
to O 
its O 
medium O 
size O 
, O 
M1.3 O 
origami O 
with O 
globally O 
modified O 
staples O 
is O 
affordable O 
. O 
As O 
a O 
proof O 
of O 
principle O 
, O 
two O 
origami O 
structures O 
with O 
globally O 
5'-capped O 
staples O 
were O 
prepared O 
and O 
were O 
shown O 
to O 
give O 
higher O 
UV-melting O 
points O 
than O 
the O 
corresponding O 
assembly O 
with O 
unmodified O 
DNA O 
. O 
M1.3 O 
has O 
the O 
size O 
of O 
a O 
gene O 
, O 
not O 
a O 
genome O 
, O 
and O 
may O 
function O 
as O 
a O 
model O 
for O 
gene O 
- O 
based O 
nanostructures O 
. O 
Small O 
origami O 
with O 
M1.3 O 
as O 
a O 
scaffold O 
may O 
serve O 
as O 
a O 
workbench O 
for O 
chemical O 
, O 
physical O 
, O 
and O 
biological O 
experiments O 
. O 

GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
subunits O 
to O 
alcohol B-FAMILY 
-induced O 
conditioned O 
taste O 
aversion O 
and O 
recovery O 
from O 
acute O 
alcohol B-FAMILY 
intoxication O 
. O 

type O 
A O 
receptors O 
( O 
GABA B-ABBREVIATION 
(A)-R O 
) O 
are O 
important O 
for O 
ethanol B-SYSTEMATIC 
actions O 
and O 
it O 
is O 
of O 
interest O 
to O 
link O 
individual O 
subunits O 
with O 
specific O 
ethanol B-SYSTEMATIC 
behaviors O 
. O 
We O 
studied O 
nan O 
mutant O 
mice O 
for O 
six O 
different O 
GABA B-ABBREVIATION 
(A)-R O 
subunits O 
( O 
α1 O 
, O 
α2 O 
, O 
α3 O 
, O 
α4 O 
, O 
α5 O 
and O 
δ O 
) O 
. O 
Only O 
mice O 
lacking O 
the O 
α2 O 
subunit O 
showed O 
reduction O 
of O 
conditioned O 
taste O 
aversion O 
( O 
CTA O 
) O 
to O 
ethanol B-SYSTEMATIC 
. O 
These O 
results O 
are O 
in O 
agreement O 
with O 
data O 
from O 
knock O 
- O 
in O 
mice O 
with O 
mutation O 
of O 
the O 
ethanol B-SYSTEMATIC 
-sensitive O 
site O 
in O 
the O 
α2-subunit O 
( O 
Blednov O 
et O 
al O 
. O 
, O 
2011 O 
) O 
. O 
All O 
together O 
, O 
they O 
indicate O 
that O 
aversive O 
property O 
of O 
ethanol B-SYSTEMATIC 
is O 
dependent O 
on O 
ethanol B-SYSTEMATIC 
action O 
on O 
α2 O 
- O 
containing O 
GABA B-ABBREVIATION 
(A)-R O 
. O 
Deletion O 
of O 
the O 
α2-subunit O 
led O 
to O 
faster O 
recovery O 
whereas O 
absence O 
of O 
the O 
α3-subunit O 
slowed O 
recovery O 
from O 
ethanol B-SYSTEMATIC 
-induced O 
incoordination O 
( O 
rotarod O 
) O 
. O 
Deletion O 
of O 
the O 
other O 
four O 
subunits O 
did O 
not O 
affect O 
this O 
behavior O 
. O 
Similar O 
changes O 
in O 
this O 
behavior O 
for O 
the O 
α2 O 
and O 
α3 O 
nan O 
mutants O 
were O 
found O 
for O 
flurazepam B-TRIVIAL 
motor O 
incoordination O 
. O 
However O 
, O 
no O 
differences O 
in O 
recovery O 
were O 
found O 
in O 
motor O 
- O 
incoordinating O 
effects O 
of O 
an O 
α1-selective O 
modulator O 
( O 
zolpidem B-TRIVIAL 
) O 
or O 
an O 
α4-selective O 
agonist O 
( O 
gaboxadol B-TRIVIAL 
) O 
. O 
Therefore O 
, O 
recovery O 
of O 
rotarod O 
incoordination O 
is O 
under O 
control O 
of O 
two O 
GABA B-ABBREVIATION 
(A)-R O 
subunits O 
: O 
α2 O 
and O 
α3 O 
. O 
For O 
motor O 
activity O 
, O 
α3 O 
nan O 
mice O 
demonstrated O 
higher O 
activation O 
by O 
ethanol B-SYSTEMATIC 
( O 
1 O 
g O 
/ O 
kg O 
) O 
whereas O 
both O 
α2 O 
( O 
- O 
/ O 
- O 
) O 
and O 
α3 O 
( O 
- O 
/ O 
Y O 
) O 
knockout O 
mice O 
were O 
less O 
sensitive O 
to O 
ethanol B-SYSTEMATIC 
-induced O 
reduction O 
of O 
motor O 
activity O 
( O 
1.5 O 
g O 
/ O 
kg O 
) O 
. O 
These O 
studies O 
demonstrate O 
that O 
the O 
effects O 
of O 
ethanol B-SYSTEMATIC 
at O 
GABAergic O 
synapses O 
containing O 
α2 O 
subunit O 
are O 
important O 
for O 
specific O 
behavioral O 
effects O 
of O 
ethanol B-SYSTEMATIC 
which O 
may O 
be O 
relevant O 
to O 
the O 
genetic O 
linkage O 
of O 
the O 
α2 O 
subunit O 
with O 
human O 
alcoholism O 
. O 

of O 
volume O 
ratio O 
of O 
ultrafiltrate O 
to O 
sample O 
solution O 
on O 
the O 
analysis O 
of O 
free O 
drug O 
and O 
measurement O 
of O 
free O 
carbamazepine B-TRIVIAL 
in O 
clinical O 
drug O 
monitoring O 
. O 

ultrafiltration O 
( O 
UF O 
) O 
usually O 
has O 
a O 
large O 
volume O 
ratio O 
of O 
ultrafiltrate O 
to O 
sample O 
solution O 
, O 
and O 
this O 
ratio O 
cannot O 
be O 
well O 
controlled O 
. O 
It O 
can O 
break O 
the O 
balance O 
of O 
protein O 
- O 
binding O 
equilibrium O 
and O 
exert O 
an O 
influence O 
on O 
the O 
analysis O 
of O 
free O 
drug O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
influence O 
of O 
volume O 
ratio O 
of O 
ultrafiltrate O 
to O 
sample O 
solution O 
on O 
the O 
analysis O 
of O 
free O 
drug O 
in O 
human O 
plasma O 
. O 
We O 
used O 
carbamazepine B-TRIVIAL 
as O 
a O 
model O 
drug O 
and O 
studied O 
the O 
effect O 
of O 
different O 
centrifugation O 
times O 
on O 
ultrafitrate O 
volume O 
and O 
the O 
related O 
effects O 
on O 
unbound O 
carbamazepine B-TRIVIAL 
measurement O 
. O 
Moreover O 
, O 
we O 
compared O 
the O 
hollow O 
fiber O 
centrifugal O 
ultrafiltration O 
( O 
HFCF-UF O 
) O 
with O 
traditional O 
UF O 
. O 
Our O 
results O 
showed O 
that O 
the O 
ultrafiltrate O 
volume O 
was O 
changed O 
from O 
40 O 
to O 
400 O 
μL O 
with O 
the O 
increase O 
of O 
centrifugation O 
time O 
for O 
the O 
traditional O 
UF O 
, O 
and O 
the O 
related O 
changes O 
in O 
unbound O 
concentration O 
were O 
significant O 
. O 
The O 
rate O 
of O 
protein O 
binding O 
( O 
BP O 
) O 
was O 
changed O 
from O 
40% O 
to O 
70% O 
. O 
In O 
contrast O 
, O 
a O 
tiny O 
and O 
invariant O 
ultrafiltrate O 
yield O 
( O 
40 O 
μL O 
) O 
was O 
obtained O 
using O 
the O 
HFCF-UF O 
method O 
, O 
and O 
the O 
BP O 
rate O 
was O 
around O 
72% O 
. O 
In O 
addition O 
, O 
with O 
the O 
HFCF-UF O 
method O 
, O 
the O 
volume O 
ratio O 
of O 
ultrafiltrate O 
to O 
sample O 
solution O 
could O 
be O 
also O 
well O 
controlled O 
by O 
the O 
inner O 
diameters O 
of O 
both O 
the O 
glass O 
tube O 
and O 
hollow O 
fiber O 
. O 
The O 
HFCF-UF O 
method O 
was O 
a O 
more O 
accurate O 
plasma O 
pretreatment O 
procedure O 
, O 
by O 
which O 
the O 
in O 
vivo O 
balance O 
of O 
protein O 
- O 
binding O 
equilibrium O 
was O 
hardly O 
broken O 
. O 
Therefore O 
, O 
this O 
method O 
was O 
successfully O 
employed O 
to O 
quantify O 
the O 
free O 
fraction O 
of O 
carbamazepine B-TRIVIAL 
in O 
clinical O 
samples O 
. O 

, O 
voltage O 
- O 
dependent O 
NMDA B-ABBREVIATION 
receptor O 
antagonism O 
by O 
hydrophobic O 
anions O 
. O 

receptor O 
( O 
NMDAR O 
) O 
antagonists O 
are O 
dissociative O 
anesthetics O 
, O 
drugs O 
of O 
abuse O 
, O 
and O 
are O 
of O 
therapeutic O 
interest O 
in O 
neurodegeneration O 
and O 
neuropsychiatric O 
disease O 
. O 
Many O 
well O 
- O 
known O 
NMDAR O 
antagonists O 
are O 
positively O 
charged O 
, O 
voltage O 
- O 
dependent O 
channel O 
blockers O 
. O 
We O 
recently O 
showed O 
that O 
the O 
hydrophobic O 
anion O 
dipicrylamine B-TRIVIAL 
( O 
DPA B-ABBREVIATION 
) O 
negatively O 
regulates O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
function O 
by O 
a O 
mechanism O 
indistinguishable O 
from O 
that O 
of O 
sulfated B-FAMILY 
neurosteroids I-FAMILY 
. O 
Because O 
sulfated O 
neurosteroids B-FAMILY 
also O 
modulate O 
NMDARs O 
, O 
here O 
we O 
examined O 
the O 
effects O 
of O 
DPA B-ABBREVIATION 
on O 
NMDAR O 
function O 
. O 
In O 
rat O 
hippocampal O 
neurons O 
DPA B-ABBREVIATION 
inhibited O 
currents O 
gated O 
by O 
300 O 
µM O 
NMDA B-ABBREVIATION 
with O 
an O 
IC(50) O 
of O 
2.3 O 
µM O 
. O 
Neither O 
onset O 
nor O 
offset O 
of O 
antagonism O 
exhibited O 
dependence O 
on O 
channel O 
activation O 
but O 
exhibited O 
a O 
noncompetitive O 
profile O 
. O 
DPA B-ABBREVIATION 
antagonism O 
was O 
independent O 
of O 
NMDAR O 
subunit O 
composition O 
and O 
was O 
similar O 
at O 
extrasynaptic O 
and O 
total O 
receptor O 
populations O 
. O 
Surprisingly O 
, O 
similar O 
to O 
cationic O 
channel O 
blockers O 
but O 
unlike O 
sulfated B-FAMILY 
neurosteroids I-FAMILY 
, O 
DPA B-ABBREVIATION 
antagonism O 
was O 
voltage O 
dependent O 
. O 
Onset O 
and O 
offset O 
of O 
DPA B-ABBREVIATION 
antagonism O 
were O 
nearly O 
10-fold O 
faster O 
than O 
DPA B-ABBREVIATION 
-induced O 
increases O 
in O 
membrane O 
capacitance O 
, O 
suggesting O 
that O 
membrane O 
interactions O 
do O 
not O 
directly O 
explain O 
antagonism O 
. O 
Furthermore O 
, O 
voltage O 
dependence O 
did O 
not O 
derive O 
from O 
association O 
of O 
DPA B-ABBREVIATION 
with O 
a O 
site O 
on O 
NMDARs O 
directly O 
accessible O 
to O 
the O 
outer O 
membrane O 
leaflet O 
, O 
assessed O 
by O 
DPA B-ABBREVIATION 
translocation O 
experiments O 
. O 
Consistent O 
with O 
the O 
expected O 
lack O 
of O 
channel O 
block O 
, O 
DPA B-ABBREVIATION 
antagonism O 
did O 
not O 
interact O 
with O 
permeant O 
ions O 
. O 
Therefore O 
, O 
we O 
speculate O 
that O 
voltage O 
dependence O 
may O 
arise O 
from O 
interactions O 
of O 
DPA B-ABBREVIATION 
with O 
the O 
inherent O 
voltage O 
dependence O 
of O 
channel O 
gating O 
. O 
Overall O 
, O 
we O 
conclude O 
that O 
DPA B-ABBREVIATION 
noncompetitively O 
inhibits O 
NMDA B-ABBREVIATION 
-induced O 
current O 
by O 
a O 
novel O 
voltage O 
- O 
dependent O 
mechanism O 
and O 
represents O 
a O 
new O 
class O 
of O 
anionic O 
NMDAR O 
antagonists O 
. O 

- O 
based O 
optimization O 
of O 
angiostatic O 
agent O 
6DBF7 B-SYSTEMATIC 
, O 
an O 
allosteric O 
antagonist O 
of O 
galectin-1 O 
. O 

( O 
gal-1 O 
) O 
, O 
which O 
binds O 
β-galactoside O 
groups O 
on O 
various O 
cell O 
surface O 
receptors O 
, O 
is O 
crucial O 
to O 
cell O 
adhesion O 
and O 
migration O 
, O 
and O 
is O 
found O 
to O 
be O 
elevated O 
in O 
several O 
cancers O 
. O 
Previously O 
, O 
we O 
reported O 
on O 
6DBF7 B-SYSTEMATIC 
, O 
a O 
dibenzofuran B-SYSTEMATIC 
( O 
DBF B-ABBREVIATION 
) O 
- O 
based O 
peptidomimetic O 
of O 
the O 
gal-1 O 
antagonist O 
anginex O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
used O 
a O 
structure O 
- O 
based O 
approach O 
to O 
optimize O 
6DBF7 B-SYSTEMATIC 
. O 
Initial O 
NMR O 
studies O 
showed O 
that O 
6DBF7 B-SYSTEMATIC 
binds O 
to O 
gal-1 O 
on O 
one O 
side O 
of O 
the O 
β-sandwich O 
away O 
from O 
the O 
lectin's O 
carbohydrate B-FAMILY 
binding O 
site O 
. O 
Although O 
an O 
alanine B-TRIVIAL 
scan O 
of O 
6DBF7 B-SYSTEMATIC 
showed O 
that O 
the O 
two O 
cationic O 
groups O 
( O 
lysines B-FAMILY 
) O 
in O 
the O 
partial O 
peptide O 
are O 
crucial O 
to O 
its O 
angiostatic O 
activity O 
, O 
it O 
is O 
the O 
hydrophobic O 
face O 
of O 
the O 
amphipath O 
that O 
appears O 
to O 
interact O 
directly O 
with O 
the O 
surface O 
of O 
gal-1 O 
. O 
Based O 
on O 
this O 
structural O 
information O 
, O 
we O 
designed O 
and O 
tested O 
additional O 
DBF B-ABBREVIATION 
analogs O 
. O 
In O 
particular O 
, O 
substitution O 
of O 
the O 
C B-FORMULA 
-terminal O 
Asp B-FORMULA 
for O 
alanine B-TRIVIAL 
and O 
branched O 
alkyl B-FAMILY 
side O 
chains O 
( O 
Val B-ABBREVIATION 
, O 
Leu B-FORMULA 
, O 
Ile B-FORMULA 
) O 
for O 
linear O 
ones O 
( O 
Nle B-FORMULA 
, O 
Nva B-ABBREVIATION 
) O 
rendered O 
the O 
greatest O 
improvements O 
in O 
activity O 
. O 
Flow O 
cytometry O 
with O 
gal-1(- O 
/ O 
- O 
) O 
splenocytes O 
showed O 
that O 
6DBF7 B-SYSTEMATIC 
and O 
two O 
of O 
its O 
more O 
potent O 
analogs O 
( O 
DB16 B-NO_CLASS 
and O 
DB21 B-NO_CLASS 
) O 
can O 
fully O 
inhibit O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
-gal-1 O 
binding O 
. O 
Moreover O 
, O 
heteronuclear O 
single O 
- O 
quantum O 
coherence O 
NMR O 
titrations O 
showed O 
that O 
the O 
presence O 
of O 
DB16 B-NO_CLASS 
decreases O 
gal-1 O 
affinity O 
for O 
lactose B-TRIVIAL 
, O 
indicating O 
that O 
the O 
peptidomimetic O 
targets O 
gal-1 O 
as O 
a O 
noncompetitive O 
, O 
allosteric O 
inhibitor O 
of O 
glycan O 
binding O 
. O 
Using O 
tumor O 
mouse O 
models O 
( O 
B16F10 O 
melanoma O 
, O 
LS174 O 
lung O 
, O 
and O 
MA148 O 
ovarian O 
) O 
, O 
we O 
found O 
that O 
DB21 B-NO_CLASS 
inhibits O 
tumor O 
angiogenesis O 
and O 
tumor O 
growth O 
significantly O 
better O 
than O 
6DBF7 B-SYSTEMATIC 
, O 
DB16 B-NO_CLASS 
, O 
or O 
anginex O 
. O 
DB21 B-NO_CLASS 
is O 
currently O 
being O 
developed O 
further O 
and O 
holds O 
promise O 
for O 
the O 
management O 
of O 
human O 
cancer O 
in O 
the O 
clinic O 
. O 

attenuates O 
tumour O 
cell O 
- O 
mediated O 
breaching O 
of O 
the O 
lymphendothelial O 
barrier O 
and O 
prevents O 
intravasation O 
and O 
metastasis O 
. O 

beneficial O 
effects O 
of O 
xanthohumol B-TRIVIAL 
have O 
been O 
reported O 
, O 
and O 
basic O 
research O 
provided O 
evidence O 
for O 
anti-cancer O 
effects O 
. O 
Furthermore O 
, O 
xanthohumol B-TRIVIAL 
was O 
shown O 
to O 
inhibit O 
the O 
migration O 
of O 
endothelial O 
cells O 
. O 
Therefore O 
, O 
this O 
study O 
investigated O 
the O 
anti-metastatic O 
potential O 
of O 
xanthohumol B-TRIVIAL 
. O 
MCF-7 O 
breast O 
cancer O 
spheroids O 
which O 
are O 
placed O 
on O 
lymphendothelial O 
cells O 
( O 
LECs O 
) O 
induce O 
" O 
circular O 
chemorepellent-induced O 
defects O 
" O 
( O 
CCIDs O 
) O 
in O 
the O 
LEC O 
monolayer O 
resembling O 
gates O 
for O 
intravasating O 
tumour O 
bulks O 
at O 
an O 
early O 
step O 
of O 
lymph O 
node O 
colonisation O 
. O 
NF-κB O 
reporter- O 
, O 
EROD- O 
, O 
SELE- O 
, O 
12(S)-HETE B-SYSTEMATIC 
- O 
and O 
adhesion O 
assays O 
were O 
performed O 
to O 
investigate O 
the O 
anti-metastatic O 
properties O 
of O 
xanthohumol B-TRIVIAL 
. O 
Western O 
blot O 
analyses O 
were O 
used O 
to O 
elucidate O 
the O 
mechanisms O 
inhibiting O 
CCID O 
formation O 
. O 
Xanthohumol B-TRIVIAL 
inhibited O 
the O 
activity O 
of O 
CYP O 
, O 
SELE O 
and O 
NF-kB O 
and O 
consequently O 
, O 
the O 
formation O 
of O 
CCIDs O 
at O 
low O 
micromolar O 
concentrations O 
. O 
More O 
specifically O 
, O 
xanthohumol B-TRIVIAL 
affected O 
ICAM-1 O 
expression O 
and O 
adherence O 
of O 
MCF-7 O 
cells O 
to O 
LECs O 
, O 
which O 
is O 
a O 
prerequisite O 
for O 
CCID O 
formation O 
. O 
Furthermore O 
, O 
markers O 
of O 
epithelial O 
- O 
to O 
- O 
mesenchymal O 
transition O 
( O 
EMT O 
) O 
and O 
of O 
cell O 
mobility O 
such O 
as O 
paxillin O 
, O 
MCL2 O 
and O 
S100A4 O 
were O 
suppressed O 
by O 
xanthohumol B-TRIVIAL 
. O 
Xanthohumol B-TRIVIAL 
attenuated O 
tumour O 
cell O 
- O 
mediated O 
defects O 
at O 
the O 
lymphendothelial O 
barrier O 
and O 
inhibited O 
EMT O 
- O 
like O 
effects O 
thereby O 
providing O 
a O 
mechanistic O 
explanation O 
for O 
the O 
anti-intravasative O 
/ O 
anti-metastatic O 
properties O 
of O 
xanthohumol B-TRIVIAL 
. O 

- O 
dependent O 
vapor O 
pressures O 
of O 
solid O 
explosives O 
and O 
their O 
byproducts O 
are O 
calculated O 
to O 
an O 
accuracy O 
of O 
0.32 O 
log O 
units O 
using O 
a O 
modified O 
form O 
of O 
the O 
conductor O 
- O 
like O 
screening O 
model O 
for O 
real O 
solvents O 
( O 
COSMO-RS O 
) O 
. O 
Accurate O 
predictions O 
for O 
solids O 
within O 
COSMO-RS O 
require O 
correction O 
for O 
the O 
free O 
energy O 
of O 
fusion O 
as O 
well O 
as O 
other O 
effects O 
such O 
as O 
van O 
der O 
Waals O 
interactions O 
. O 
Limited O 
experimental O 
data O 
on O 
explosives O 
is O 
available O 
to O 
determine O 
these O 
corrections O 
, O 
and O 
thus O 
we O 
have O 
extended O 
the O 
COSMO-RS O 
model O 
by O 
introducing O 
a O 
quantitative O 
structure O 
- O 
property O 
relationship O 
to O 
estimate O 
a O 
lumped O 
correction O 
factor O 
using O 
only O 
information O 
from O 
standard O 
quantum O 
chemistry O 
calculations O 
. O 
This O 
modification O 
improves O 
the O 
COSMO-RS O 
estimate O 
of O 
ambient O 
vapor O 
pressure O 
by O 
more O 
than O 
1 O 
order O 
of O 
magnitude O 
for O 
a O 
range O 
of O 
nitrogen B-SYSTEMATIC 
-rich O 
explosives O 
and O 
their O 
derivatives O 
, O 
bringing O 
the O 
theoretical O 
predictions O 
to O 
within O 
typical O 
experimental O 
error O 
bars O 
for O 
vapor O 
pressure O 
measurements O 
. O 
The O 
estimated O 
temperature O 
dependence O 
of O 
these O 
vapor O 
pressures O 
also O 
agrees O 
well O 
with O 
available O 
experimental O 
data O 
, O 
which O 
is O 
particularly O 
important O 
for O 
estimating O 
environmental O 
transport O 
and O 
gas O 
evolution O 
for O 
buried O 
explosives O 
or O 
environmentally O 
contaminated O 
locations O 
. O 
This O 
technique O 
is O 
then O 
used O 
to O 
predict O 
vapor O 
pressures O 
for O 
a O 
number O 
of O 
explosives O 
and O 
degradation O 
products O 
for O 
which O 
experimental O 
data O 
is O 
not O 
readily O 
available O 
. O 

( O 
PEI B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
most O 
broadly O 
used O 
polycations O 
for O 
gene O 
delivery O 
due O 
to O 
its O 
high O 
transfection O 
efficiency O 
and O 
commercial O 
availability O 
but O 
materials O 
are O 
cytotoxic O 
and O 
often O 
polydisperse O 
. O 
The O 
goal O 
of O 
current O 
work O 
is O 
to O 
develop O 
an O 
alternative O 
family O 
of O 
polycations O 
based O 
on O 
controlled O 
living O 
radical O 
polymerization O 
( O 
CLRP O 
) O 
and O 
to O 
optimize O 
the O 
polymer O 
structure O 
for O 
efficient O 
gene O 
delivery O 
. O 
In O 
this O 
study O 
, O 
well O 
- O 
defined O 
poly(glycidyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
P(GMA) B-ABBREVIATION 
) O 
homopolymers O 
were O 
synthesized O 
using O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
( O 
RAFT O 
) O 
polymerization O 
followed O 
by O 
decoration O 
using O 
three O 
different O 
types O 
of O 
oligoamines B-FAMILY 
, O 
i.e O 
. O 
, O 
tetraethylenepentamine B-SYSTEMATIC 
( O 
TEPA B-ABBREVIATION 
) O 
, O 
pentaethylenehexamine B-SYSTEMATIC 
( O 
PEHA B-ABBREVIATION 
) O 
, O 
and O 
tris(2-aminoethyl)amine B-SYSTEMATIC 
( O 
TREN B-ABBREVIATION 
) O 
, O 
respectively O 
, O 
to O 
generate O 
various O 
P(GMA-oligoamine) B-FAMILY 
homopolycations O 
. O 
The O 
effect O 
of O 
P(GMA) B-ABBREVIATION 
backbone O 
length O 
and O 
structure O 
of O 
oligoamine B-FAMILY 
on O 
gene O 
transfer O 
efficiency O 
was O 
then O 
determined O 
. O 
The O 
optimal O 
polymer O 
, O 
P(GMA-TEPA)(50) B-ABBREVIATION 
, O 
provided O 
comparable O 
transfection O 
efficiency O 
but O 
lower O 
cytotoxicity O 
than O 
PEI B-ABBREVIATION 
. O 
P(GMA-TEPA)(50) B-ABBREVIATION 
was O 
then O 
used O 
as O 
the O 
cationic O 
block O 
in O 
diblock O 
copolymers O 
containing O 
hydrophilic O 
N-(2-hydroxypropyl) B-SYSTEMATIC 
methacrylamide I-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
and O 
oligo(ethylene B-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
monomethyl I-FAMILY 
ether I-FAMILY 
methacrylate I-FAMILY 
( O 
OEGMA B-ABBREVIATION 
) O 
. O 
Polyplexes O 
of O 
block O 
copolymers O 
were O 
stable O 
against O 
aggregation O 
in O 
physiological O 
salt O 
condition O 
and O 
in O 
Opti-MEM O 
due O 
to O 
the O 
shielding O 
effect O 
of O 
P(HPMA) B-ABBREVIATION 
and O 
P(OEGMA) B-ABBREVIATION 
. O 
However O 
, O 
the O 
presence O 
of O 
the O 
HPMA B-ABBREVIATION 
/ O 
OEGMA B-ABBREVIATION 
block O 
significantly O 
decreased O 
the O 
transfection O 
efficacy O 
of O 
P(GMA-TEPA)(50) B-ABBREVIATION 
homopolycation O 
. O 
To O 
compensate O 
for O 
reduced O 
cell O 
uptake O 
caused O 
by O 
the O 
hydrophilic O 
shell O 
of O 
polyplex O 
, O 
the O 
integrin O 
- O 
binding O 
peptide O 
, O 
RGD O 
, O 
was O 
conjugated O 
to O 
the O 
hydrophilic O 
chain O 
end O 
of O 
P(OEGMA)(15)-b-P(GMA-TEPA)(50) B-ABBREVIATION 
copolymer O 
by O 
Michael O 
- O 
type O 
addition O 
reaction O 
. O 
At O 
low O 
polymer O 
to O 
DNA O 
ratios O 
, O 
the O 
RGD-functionalized O 
polymer O 
showed O 
increased O 
gene O 
delivery O 
efficiency O 
to O 
HeLa O 
cells O 
compared O 
to O 
analogous O 
polymers O 
lacking O 
RGD O 
. O 

of O 
saccharide B-FAMILY 
protection O 
against O 
epigallocatechin-3-gallate B-SYSTEMATIC 
deterioration O 
in O 
aqueous O 
solutions O 
. O 

investigated O 
the O 
mechanisms O 
of O 
the O 
protection O 
conferred O 
by O 
sugars B-FAMILY 
to O 
epigallocatechin-3-gallate B-SYSTEMATIC 
( O 
EGCG B-ABBREVIATION 
) O 
against O 
deterioration O 
. O 
Additionally O 
, O 
we O 
present O 
a O 
rapid O 
method O 
for O 
evaluating O 
the O 
deterioration O 
rate O 
of O 
EGCG B-ABBREVIATION 
using O 
absorbance O 
spectroscopy O 
. O 
We O 
found O 
that O 
various O 
sugars B-FAMILY 
provided O 
different O 
levels O 
of O 
protection O 
at O 
identical O 
weight O 
percentage O 
, O 
and O 
the O 
combination O 
of O 
sugars B-FAMILY 
and O 
β-lactoglobulin O 
nanocomplexes O 
provided O 
greater O 
protection O 
for O 
EGCG B-ABBREVIATION 
than O 
each O 
protective O 
component O 
alone O 
. O 
We O 
suggest O 
that O 
the O 
concentration O 
- O 
dependent O 
protection O 
by O 
sugars B-FAMILY 
resulted O 
from O 
a O 
combination O 
of O 
mechanisms O 
, O 
including O 
: O 
( O 
1 O 
) O 
reduced O 
aqueous O 
O2 B-FORMULA 
solubility O 
, O 
( O 
2 O 
) O 
scavenging O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
and O 
( O 
3 O 
) O 
chelation O 
of O 
traces O 
of O 
transition B-FAMILY 
metal I-FAMILY 
ions O 
, O 
which O 
is O 
suggested O 
to O 
be O 
the O 
main O 
reason O 
for O 
the O 
differences O 
among O 
the O 
sugars B-FAMILY 
. O 
The O 
observed O 
protective O 
effect O 
of O 
sugars B-FAMILY 
can O 
be O 
easily O 
applied O 
by O 
the O 
industry O 
in O 
proper O 
selection O 
of O 
sugars B-FAMILY 
for O 
enrichment O 
of O 
syrups O 
or O 
concentrates O 
with O 
EGCG B-ABBREVIATION 
and O 
for O 
the O 
preparation O 
of O 
enriched O 
beverages O 
and O 
foods O 
for O 
health O 
promotion O 
. O 

objective O 
of O 
the O 
present O 
study O 
was O 
to O 
characterize O 
the O 
effect O 
of O 
insulin O 
plus O 
hCG O 
on O 
the O 
expression O 
of O 
steroidogenic O 
enzymes O 
( O 
P450scc O 
and O 
CYP17 O 
) O 
in O 
polycystic O 
ovaries O 
of O 
rats O 
. O 
Changes O 
in O 
estrous O 
cycle O 
, O 
ovarian O 
morphology O 
, O 
hormonal O 
levels O 
, O 
and O 
protein O 
levels O 
by O 
immunohistochemistry O 
and O 
western O 
- O 
blot O 
were O 
determined O 
. O 
Rats O 
treated O 
with O 
insulin O 
plus O 
hCG O 
displayed O 
abnormal O 
estrous O 
cycles O 
with O 
increasing O 
androgen B-FAMILY 
biosynthesis O 
. O 
Meanwhile O 
, O 
insulin O 
plus O 
hCG O 
resulted O 
in O 
multiple O 
large O 
cysts O 
with O 
diminished O 
granulosa O 
layers O 
and O 
increased O 
thecal O 
layers O 
and O 
stromal O 
- O 
interstitial O 
tissue O 
. O 
Moreover O 
, O 
there O 
was O 
an O 
increase O 
in O 
the O 
expression O 
of O 
P450scc O 
and O 
CYP17 O 
in O 
thecal O 
and O 
stromal O 
cells O 
in O 
our O 
PCOS O 
rat O 
model O 
compared O 
with O 
control O 
rats O 
. O 
These O 
results O 
indicate O 
that O 
administration O 
of O 
insulin O 
with O 
hCG O 
can O 
synergistically O 
result O 
in O 
endogenous O 
hyperandrogenism O 
which O 
may O 
partially O 
upregulate O 
the O 
expression O 
of O 
steroidogenic O 
enzymes O 
in O 
ovarian O 
tissue O 
. O 

COX-2 O 
inhibitors O 
( O 
COXib O 
) O 
belonging O 
to O 
the O 
class O 
of O 
diaryl B-FAMILY 
heterocycles I-FAMILY 
( O 
e.g O 
. O 
, O 
celecoxib B-TRIVIAL 
, O 
rofecoxib B-TRIVIAL 
, O 
etc O 
. O 
) O 
, O 
are O 
devoid O 
of O 
the O 
undesirable O 
effects O 
due O 
to O 
their O 
capacity O 
to O 
inhibit O 
selectively O 
inducible O 
( O 
COX-2 O 
) O 
, O 
responsible O 
for O 
inflammatory O 
effects O 
but O 
not O 
constitutive O 
cyclooxygenase-1 O 
(COX-1)(COX) O 
; O 
responsible O 
for O 
cytoprotective O 
effects O 
on O 
gastric O 
mucosa O 
. O 
In O 
addition O 
, O 
several O 
reports O 
have O 
identified O 
an O 
increased O 
risk O 
of O 
cardiovascular O 
events O 
associated O 
with O 
the O 
use O 
of O 
COXib O 
. O 
We O 
have O 
developed O 
a O 
new O 
series O 
of O 
anti-inflammatory O 
agents O 
( B-MULTIPLE 
1,5-diarylpyrrole-3-alkoxyethyl I-MULTIPLE 
esters I-MULTIPLE 
and I-MULTIPLE 
ether I-MULTIPLE 
s O 
) O 
. O 
To O 
evaluate O 
the O 
effect O 
of O 
two O 
1,5-diarylpyrrole-3-alkoxyethyl B-FAMILY 
ether I-FAMILY 
s O 
, O 
VA44 B-IDENTIFIER 
1 O 
and O 
VA42 B-IDENTIFIER 
8 O 
( O 
up O 
to O 
100μM O 
) O 
, O 
respectively O 
, O 
in O 
comparison O 
with O 
two O 
well O 
known O 
COXib O 
, O 
celecoxi B-TRIVIAL 
b O 
and O 
rofecoxi B-TRIVIAL 
b O 
, O 
on O 
HaCaT O 
cell O 
( O 
keratinocytes O 
) O 
proliferation O 
and O 
toxicity O 
. O 
Crucial O 
molecules O 
in O 
cell O 
cycle O 
progression O 
, O 
i.e O 
. O 
NFκB O 
and O 
ERK O 
as O 
targets O 
/ O 
mediators O 
and O 
cyclin O 
D1 O 
and O 
p21 O 
Cip1 O 
/ O 
Kip O 
as O 
final O 
effectors O 
were O 
evaluated O 
by O 
Western O 
blot O 
, O 
immunohystochemistry O 
and O 
q-PCR O 
analysis O 
. O 
Both O 
compounds O 
, O 
VA44 B-IDENTIFIER 
1 O 
and O 
VA42 B-IDENTIFIER 
8 O 
, O 
showed O 
a O 
strong O 
inhibition O 
of O 
cell O 
proliferation O 
, O 
and O 
did O 
not O 
exhibit O 
cytotoxicity O 
. O 
The O 
anti-proliferative O 
effect O 
was O 
accompanied O 
by O 
a O 
strong O 
activation O 
of O 
ERK O 
and O 
induction O 
of O 
the O 
cell O 
cycle O 
inhibitor O 
p21 O 
. O 
In O 
addition O 
, O 
there O 
was O 
a O 
clear O 
inhibition O 
of O 
the O 
transcription O 
factor O 
NF-κB O 
and O 
downregulation O 
of O 
cyclin O 
D1 O 
, O 
with O 
enforced O 
inhibition O 
of O 
the O 
HaCaT O 
cell O 
cycle O 
progression O 
. O 
These O 
data O 
suggest O 
that O 
compounds O 
VA44 B-IDENTIFIER 
1 O 
and O 
VA42 B-IDENTIFIER 
8 O 
, O 
along O 
with O 
their O 
role O 
in O 
inhibiting O 
COX-2 O 
and O 
inflammation O 
, O 
could O 
have O 
a O 
possible O 
therapeutic O 
( O 
topical O 
and O 
systemic O 
) O 
use O 
against O 
skin O 
proliferative O 
disorders O 
, O 
such O 
as O 
psoriasis O 
. O 

- O 
specific O 
regulation O 
of O 
5-HT1B O 
receptors O 
in O 
the O 
rat O 
brain O 
by O 
chronic O 
venlafaxine B-TRIVIAL 
treatment O 
. O 

: O 
Venlafaxine B-TRIVIAL 
is O 
a O 
non-selective O 
serotonin B-TRIVIAL 
and O 
noradrenaline B-TRIVIAL 
reuptake O 
inhibitor O 
antidepressant O 
drug O 
for O 
which O 
clinical O 
studies O 
have O 
suggested O 
a O 
high O 
level O 
efficacy O 
and O 
a O 
possible O 
early O 
action O 
onset O 
compared O 
to O 
the O 
classical O 
antidepressants O 
. O 
Its O 
therapeutic O 
effects O 
might O 
be O 
due O 
, O 
at O 
least O 
in O 
part O 
, O 
to O 
adaptive O 
changes O 
in O 
serotonergic O 
neurotransmission O 
, O 
through O 
the O 
activation O 
of O 
the O 
different O 
5-HT B-SYSTEMATIC 
receptor O 
subtypes O 
. O 
5-HT1B O 
receptors O 
are O 
located O 
in O 
the O 
axon O 
terminals O 
of O 
both O 
serotonergic O 
and O 
non-serotonergic O 
neurons O 
, O 
where O 
they O 
act O 
as O 
inhibitory O 
autoreceptors O 
or O 
heteroreceptors O 
, O 
respectively O 
. O 
However O 
, O 
the O 
information O 
about O 
the O 
involvement O 
of O 
this O 
subtype O 
in O 
the O 
mechanism O 
of O 
action O 
of O 
antidepressants O 
is O 
limited O 
and O 
quite O 
controversial O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effect O 
of O 
venlafaxine B-TRIVIAL 
( O 
10 O 
mg O 
kg(-1) O 
day(-1) O 
, O 
p.o O 
. O 
) O 
after O 
21 O 
days O 
of O 
treatment O 
on O 
the O 
density O 
of O 
5-HT1B O 
receptors O 
and O 
their O 
functionality O 
in O 
rat O 
brain O 
. O 
METHODS O 
: O 
Effects O 
of O 
chronic O 
venlafaxine B-TRIVIAL 
were O 
evaluated O 
at O 
different O 
levels O 
of O 
5-HT1B O 
receptor O 
by O 
using O 
receptor O 
autoradiography O 
, O 
[(35)S]GTPγS B-SYSTEMATIC 
binding O 
, O 
and O 
the O 
regulation O 
of O 
body O 
temperature O 
induced O 
by O 
selective O 
5-HT1B O 
agonist O 
. O 
RESULTS O 
: O 
Our O 
results O 
show O 
that O 
venlafaxine B-TRIVIAL 
induced O 
an O 
increase O 
in O 
sensitivity O 
of O 
5-HT1B O 
receptors O 
in O 
hypothalamus O 
both O 
at O 
G O 
- O 
protein O 
level O 
and O 
the O 
control O 
of O 
core O 
temperature O 
without O 
affecting O 
the O 
receptor O 
density O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
demonstrate O 
that O 
adaptive O 
changes O 
on O 
5-HT1B O 
receptors O 
induced O 
by O 
chronic O 
administration O 
of O 
venlafaxine B-TRIVIAL 
exhibit O 
regional O 
differences O 
suggesting O 
that O 
the O 
hypothalamus O 
might O 
be O 
an O 
important O 
site O 
of O 
drug O 
action O 
. O 

hollow O 
nanospheres O 
( O 
AuHSs O 
) O 
and O 
gold O 
hollow O 
nanocubes O 
( O 
AuHCs O 
) O 
were O 
synthesized O 
by O 
the O 
galvanic O 
replacement O 
technique O 
using O 
silver B-SYSTEMATIC 
nano O 
templates O 
. O 
Colloidal O 
AuHSs O 
are O 
found O 
to O 
have O 
a O 
higher O 
sensitivity O 
factor O 
than O 
that O 
of O 
AuHCs O 
. O 
This O 
value O 
decreases O 
for O 
both O 
shapes O 
when O 
the O 
nanoparticles O 
are O 
assembled O 
on O 
a O 
quartz B-TRIVIAL 
substrate O 
by O 
using O 
the O 
Langmuir-Blodgett O 
technique O 
. O 
AuHSs O 
are O 
observed O 
to O 
have O 
the O 
larger O 
effect O 
. O 
It O 
is O 
observed O 
that O 
as O 
the O 
separation O 
gap O 
between O 
AuHCs O 
nanoparticles O 
decreases O 
, O 
their O 
localized O 
surface O 
plasmon O 
resonance O 
band O 
red O 
shifts O 
more O 
than O 
AuHSs O 
. O 
This O 
is O 
accounted O 
for O 
by O 
the O 
discrete O 
dipole O 
approximation O 
( O 
DDA O 
) O 
calculations O 
. O 
The O 
coupling O 
between O 
the O 
plasmon O 
fields O 
of O 
the O 
AuHCs O 
pair O 
is O 
stronger O 
than O 
that O 
between O 
AuHSs O 
pair O 
. O 
Using O 
the O 
DDA O 
calculation O 
, O 
this O 
is O 
found O 
to O 
be O 
due O 
to O 
geometric O 
factors O 
, O 
as O 
well O 
as O 
to O 
the O 
difference O 
in O 
the O 
plasmonic O 
field O 
intensity O 
. O 
The O 
calculation O 
also O 
showed O 
that O 
the O 
plasmon O 
field O 
distributions O 
of O 
both O 
AuHCs O 
and O 
AuHSs O 
were O 
distorted O 
by O 
the O 
quartz B-TRIVIAL 
substrate O 
in O 
a O 
different O 
manner O 
. O 
It O 
is O 
also O 
observed O 
that O 
the O 
surface O 
- O 
enhanced O 
Raman O 
spectrum O 
of O 
thiophenol B-SYSTEMATIC 
is O 
stronger O 
when O 
measured O 
on O 
AuHCs O 
than O 
on O 
AuHSs O 
. O 
This O 
is O 
due O 
to O 
the O 
difference O 
in O 
the O 
plasmon O 
field O 
distribution O 
as O 
well O 
as O 
the O 
fact O 
that O 
the O 
AuHCs O 
have O 
a O 
higher O 
scattering O 
/ O 
absorption O 
yield O 
ratio O 
. O 

bizarre O 
pharmacology O 
of O 
the O 
ATP B-ABBREVIATION 
release O 
channel O 
pannexin1 O 
. O 

were O 
originally O 
thought O 
to O 
represent O 
a O 
second O 
and O 
redundant O 
family O 
of O 
gap O 
junction O 
proteins O 
in O 
addition O 
to O 
the O 
well O 
characterized O 
connexins O 
. O 
However O 
, O 
it O 
is O 
now O 
evident O 
that O 
pannexins O 
function O 
as O 
unapposed O 
membrane O 
channels O 
and O 
the O 
major O 
role O 
of O 
Panx1 O 
is O 
that O 
of O 
an O 
ATP B-ABBREVIATION 
release O 
channel O 
. O 
Despite O 
the O 
contrasting O 
functional O 
roles O 
, O 
connexins O 
, O 
innexins O 
and O 
pannexins O 
share O 
pharmacological O 
properties O 
. O 
Most O 
gap O 
junction O 
blockers O 
also O 
attenuate O 
the O 
function O 
of O 
Panx1 O 
, O 
including O 
carbenoxolone B-TRIVIAL 
, O 
mefloquine B-TRIVIAL 
and O 
flufenamic B-TRIVIAL 
acid I-TRIVIAL 
. O 
However O 
, O 
in O 
contrast O 
to O 
connexin O 
based O 
gap O 
junction O 
channels O 
, O 
Panx1 O 
channel O 
activity O 
can O 
be O 
attenuated O 
by O 
several O 
groups O 
of O 
drugs O 
hitherto O 
considered O 
very O 
specific O 
for O 
other O 
proteins O 
. O 
The O 
drugs O 
affecting O 
Panx1 O 
channels O 
include O 
several O 
transport O 
inhibitors O 
, O 
chloride B-SYSTEMATIC 
channel O 
blockers O 
, O 
mitochondrial O 
inhibitors O 
, O 
P2X7 O 
receptor O 
ligands O 
, O 
inflammasome O 
inhibitors O 
and O 
malaria O 
drugs O 
. O 
These O 
observations O 
indicate O 
that O 
Panx1 O 
may O 
play O 
an O 
extended O 
role O 
in O 
a O 
wider O 
spectrum O 
of O 
physiological O 
functions O 
. O 
Alternatively O 
, O 
Panx1 O 
may O 
share O 
structural O 
domains O 
with O 
other O 
proteins O 
, O 
not O 
readily O 
revealed O 
by O 
sequence O 
alignments O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Connexin O 
based O 
channels O 
' O 

force O 
of O 
the O 
spontaneously O 
contracting O 
zebrafish O 
heart O 
, O 
in O 
the O 
assessment O 
of O 
cardiovascular O 
toxicity O 
: O 
Application O 
on O 
adriamycin B-TRIVIAL 
. O 

heart O 
of O 
the O 
zebrafish O 
has O 
been O 
used O 
extensively O 
to O 
assess O 
the O 
cardiotoxic O 
effect O 
of O 
compounds O 
, O 
using O 
the O 
frequency O 
of O 
heart O 
contractions O 
as O 
the O 
main O 
index O 
of O 
cardiac O 
response O 
to O 
drugs O 
. O 
In O 
this O 
study O 
, O 
the O 
force O 
and O 
the O 
frequency O 
generated O 
by O 
the O 
spontaneously O 
contracting O 
zebrafish O 
heart O 
, O 
isolated O 
in O 
saline O 
, O 
were O 
found O 
to O 
be O 
0.87±0.05mN O 
and O 
1.54±0.03Hz O 
( O 
n=6 O 
) O 
respectively O 
within O 
the O 
first O 
hour O 
of O 
recording O 
. O 
Both O 
values O 
of O 
force O 
and O 
frequency O 
remained O 
constant O 
for O 
over O 
8h O 
. O 
The O 
advantage O 
of O 
prolonged O 
vitality O 
in O 
the O 
assessment O 
of O 
cardiovascular O 
toxicity O 
was O 
shown O 
using O 
the O 
well O 
- O 
known O 
anticancer O 
drug O 
adriamycin B-TRIVIAL 
, O 
which O 
has O 
severe O 
cardiotoxic O 
side O 
effects O 
. O 
At O 
10.0μM O 
there O 
was O 
a O 
21.05±4.42% O 
( O 
p=0.02 O 
, O 
n=4 O 
) O 
decrease O 
in O 
the O 
force O 
of O 
contraction O 
, O 
while O 
the O 
frequency O 
was O 
not O 
affected O 
after O 
3h O 
treatment O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
At O 
50 O 
and O 
100.0μM O 
there O 
was O 
a O 
33.24±3.0 O 
and O 
46.6±4.80% O 
irreversible O 
decrease O 
in O 
force O 
( O 
p O 
< O 
0.05 O 
, O 
n=4 O 
) O 
, O 
while O 
a O 
18.02±4.07% O 
and O 
16.16±4.07% O 
reversible O 
increase O 
was O 
observed O 
in O 
the O 
frequency O 
( O 
p=0.02 O 
, O 
n=4 O 
) O 
. O 
These O 
contradictory O 
positive O 
chronotropic O 
and O 
negative O 
inotropic O 
responses O 
indicate O 
the O 
strong O 
inhibitory O 
effect O 
of O 
adriamycin B-TRIVIAL 
on O 
ventricular O 
cardiomyocytes O 
and O 
its O 
excitatory O 
effects O 
on O 
auto O 
- O 
rhythmical O 
pacemaker O 
cells O 
. O 
If O 
heart O 
frequency O 
was O 
the O 
only O 
parameter O 
used O 
to O 
assess O 
the O 
cardiotoxic O 
effect O 
of O 
adriamycin B-TRIVIAL 
, O 
at O 
the O 
above O 
range O 
of O 
concentrations O 
, O 
this O 
compound O 
would O 
have O 
been O 
classified O 
as O 
non-cardiotoxic O 
. O 

and O 
urinary O 
excretion O 
of O 
A B-FAMILY 
- I-FAMILY 
type I-FAMILY 
procyanidin I-FAMILY 
oligomers O 
from O 
Litchi O 
chinensis O 
pericarp O 
in O 
rats O 
by O 
selected O 
ion O 
monitoring O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 

studies O 
with O 
A O 
- O 
type O 
oligomeric O 
procyanidins B-FAMILY 
from O 
litchi O 
( O 
Litchi O 
chinensis O 
) O 
pericarp O 
( O 
LPOPC O 
) O 
suggested O 
its O 
protective O 
effect O 
against O 
cardiovascular O 
diseases O 
. O 
However O 
, O 
there O 
is O 
no O 
consensus O 
on O 
the O 
absorption O 
and O 
metabolism O 
of O 
LPOPC O 
. O 
It O 
was O 
demonstrated O 
that O 
the O 
main O 
components O 
in O 
LPOPC O 
were O 
(-)-epicatechin B-SYSTEMATIC 
, O 
A B-FAMILY 
- I-FAMILY 
type I-FAMILY 
procyanidin I-FAMILY 
dimers O 
, O 
trimers O 
and O 
tetramers O 
. O 
Rats O 
were O 
orally O 
administered O 
different O 
levels O 
of O 
LPOPC O 
( O 
150 O 
and O 
300 O 
mg O 
/ O 
kgbw O 
) O 
, O 
the O 
procyanidins B-FAMILY 
and O 
their O 
microbial O 
metabolites O 
in O 
urine O 
were O 
identified O 
by O 
HPLC-MS O 
/ O 
MS O 
analysis O 
18 O 
h O 
post O 
- O 
administration O 
. O 
Data O 
indicated O 
that O 
seven O 
aromatic O 
acid O 
metabolites O 
excreted O 
were O 
significantly O 
increased O 
by O 
300 O 
mg O 
/ O 
kgbw O 
of O 
LPOPC O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
However O 
, O 
only O 
(-)-epicatechin B-SYSTEMATIC 
and O 
its O 
methylated O 
derivatives O 
were O 
detected O 
in O 
rat O 
plasma O 
1h O 
after O 
300 O 
mg O 
/ O 
kgbw O 
of O 
LPOPC O 
administration O 
. O 
The O 
total O 
EC O 
content O 
absorbed O 
in O 
plasma O 
was O 
only O 
2.54 O 
± O 
0.53 O 
μmol O 
/ O 
L O 
, O 
indicating O 
that O 
the O 
biological O 
properties O 
of O 
LPOPC O 
should O 
be O 
probably O 
explained O 
by O 
its O 
microbial O 
degraded O 
phenolic B-FAMILY 
acids I-FAMILY 
. O 

2A O 
receptor O 
modulates O 
inflammation O 
and O 
phenotype O 
in O 
experimental O 
abdominal O 
aortic O 
aneurysms O 
. O 

of O 
the O 
adenosine B-TRIVIAL 
2A O 
receptor O 
( O 
A(2A)R O 
) O 
reduces O 
inflammation O 
in O 
models O 
of O 
acute O 
injury O 
but O 
contribution O 
in O 
development O 
of O 
chronic O 
abdominal O 
aortic O 
aneurysms O 
( O 
AAAs O 
) O 
is O 
unknown O 
. O 
Elastase O 
perfusion O 
to O 
induce O 
AAA O 
formation O 
in O 
A(2A)R-knockout O 
( O 
A(2A)RKO O 
) O 
and O 
C57BL6 O 
/ O 
J O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mice O 
resulted O 
in O 
nearly O 
100% O 
larger O 
aneurysms O 
in O 
A(2A)RKO O 
compared O 
to O 
WT O 
at O 
d O 
14 O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
with O 
evidence O 
of O 
greater O 
elastin O 
fragmentation O 
, O 
more O 
immune O 
cell O 
infiltration O 
, O 
and O 
increased O 
matrix O 
metallatoproteinase O 
( O 
MMP O 
) O 
9 O 
expression O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Separately O 
, O 
exogenous O 
A(2A)R O 
antagonism O 
in O 
elastase O 
- O 
perfused O 
WT O 
mice O 
also O 
resulted O 
in O 
larger O 
aneurysms O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
while O 
A(2A)R O 
agonism O 
limited O 
aortic O 
dilatation O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Activated O 
Thy-1.2(+) O 
T O 
lymphocytes O 
from O 
WT O 
mice O 
treated O 
in O 
vitro O 
with O 
A(2A)R O 
antagonist O 
increased O 
cytokine O 
production O 
, O 
and O 
treatment O 
with O 
A(2A)R O 
agonist O 
decreased O 
cytokine O 
production O 
( O 
P O 
< O 
0.05 O 
for O 
all O 
) O 
. O 
Primary O 
activated O 
CD4(+) O 
T O 
lymphocytes O 
from O 
A(2A)RKO O 
mice O 
exhibited O 
greater O 
chemotaxis O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
A(2A)R O 
antagonist O 
increased O 
chemotaxis O 
of O 
activated O 
CD4(+) O 
cells O 
from O 
WT O 
mice O 
in O 
vitro O 
, O 
and O 
A(2A)R O 
agonist O 
reduced O 
this O 
effect O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
A(2A)R O 
activation O 
attenuates O 
AAA O 
formation O 
partly O 
by O 
inhibiting O 
immune O 
cell O 
recruitment O 
and O 
reducing O 
elastin O 
fragmentation O 
. O 
These O 
findings O 
support O 
augmenting O 
A(2A)R O 
signaling O 
as O 
a O 
putative O 
target O 
for O 
limiting O 
aneurysm O 
formation.-Bhamidipati O 
, O 
C O 
. O 
M O 
. O 
, O 
Mehta O 
, O 
G O 
. O 
S O 
. O 
, O 
Moehle O 
, O 
C O 
. O 
W O 
. O 
, O 
Meher O 
, O 
A O 
. O 
K O 
. O 
, O 
Su O 
, O 
G O 
. O 
, O 
Vigneshwar O 
, O 
N O 
. O 
G O 
. O 
, O 
Barbery O 
, O 
C O 
. O 
, O 
Sharma O 
, O 
A O 
. O 
K O 
. O 
, O 
Kron O 
, O 
I O 
. O 
L O 
. O 
, O 
Laubach O 
, O 
V O 
. O 
E O 
. O 
, O 
Owens O 
, O 
G O 
. O 
K O 
. O 
, O 
Upchurch O 
Jr O 
. O 
, O 
G O 
. O 
R O 
. O 
, O 
Ailawadi O 
, O 
G O 
. O 
Adenosine B-TRIVIAL 
2A O 
receptor O 
modulates O 
inflammation O 
and O 
phenotype O 
in O 
experimental O 
abdominal O 
aortic O 
aneurysms O 
. O 

light O 
delivered O 
by O 
artificial O 
illumination O 
systems O 
, O 
and O 
in O 
particular O 
by O 
halogen B-FAMILY 
quartz B-TRIVIAL 
bulbs O 
, O 
contains O 
UVA O 
, O 
UVB O 
, O 
and O 
UVC O 
radiation O 
, O 
is O 
genotoxic O 
to O 
both O 
bacterial O 
and O 
human O 
cells O 
and O 
is O 
potently O 
carcinogenic O 
to O 
hairless O 
mice O 
. O 
Since O 
IARC O 
has O 
classified O 
UV O 
radiation O 
in O 
Group O 
1 O 
, O 
any O 
source O 
of O 
UV O 
light O 
poses O 
a O 
carcinogenic O 
hazard O 
to O 
humans O 
. O 
Suitable O 
regulations O 
would O 
be O 
needed O 
in O 
order O 
to O 
control O 
the O 
safety O 
of O 
the O 
light O 
emitted O 
by O 
artificial O 
light O 
sources O 
. O 

Carriers O 
of O 
drugs O 
in O 
cancer O 
therapy O 
are O 
required O 
to O 
reduce O 
side-effects O 
of O 
the O 
drugs O 
to O 
normal O 
cells O 
. O 
Here O 
we O 
constructed O 
killed O 
recombinant O 
Bacillus O 
subtilis O 
spores O 
( O 
SA1 O 
) O 
that O 
expressed O 
streptavidin O 
as O 
a O 
chimeric O 
fusion O 
to O 
the O 
spore O 
coat O 
protein O 
CotB O 
and O 
used O 
the O 
spores O 
as O 
bioparticle O 
carrier O 
. O 
When O 
bound O 
with O 
biotinylated O 
cetuximab O 
these O 
spores O 
could O 
specifically O 
target O 
to O 
the O 
epidermal O 
growth O 
factor O 
receptor O 
on O 
HT O 
29 O 
colon O 
cancer O 
cells O 
, O 
thereby O 
delivered O 
paclitaxel B-TRIVIAL 
to O 
the O 
cells O 
with O 
4-fold O 
higher O 
efficiency O 
, O 
as O 
indicated O 
by O 
fluorescent O 
intensity O 
of O 
paclitaxel B-TRIVIAL 
Oregon B-TRIVIAL 
Green I-TRIVIAL 
488 I-TRIVIAL 
bound O 
to O 
HT29 O 
cells O 
. O 
Based O 
on O 
real O 
- O 
time O 
monitoring O 
of O 
cell O 
index O 
, O 
the O 
IC50 O 
of O 
growth O 
of O 
HT29 O 
cells O 
by O 
paclitaxel B-TRIVIAL 
-SA1-cetuximab O 
was O 
estimated O 
to O 
be O 
2.9 O 
nM O 
approximately O 
5-fold O 
lower O 
than O 
water O 
- O 
soluble O 
paclitaxel B-TRIVIAL 
( O 
14.5 O 
nM O 
) O 
. O 
Instability O 
of O 
DNA O 
content O 
was O 
observed O 
when O 
cells O 
were O 
treated O 
with O 
16 O 
nM O 
paclitaxel B-TRIVIAL 
-SA1-cetuximab O 
, O 
resulting O 
in O 
a O 
2-fold O 
enhancement O 
in O 
polyploidy O 
cells O 
. O 
Thus O 
, O 
by O 
targeting O 
the O 
release O 
of O 
paclitaxel B-TRIVIAL 
to O 
HT29 O 
cells O 
, O 
spore O 
- O 
associated O 
cetuximab O 
augmented O 
the O 
inhibitory O 
effect O 
of O 
paclitaxel B-TRIVIAL 
on O 
cell O 
division O 
and O 
proliferation O 
. O 
The O 
SA1 O 
could O 
be O 
used O 
as O 
a O 
" O 
universal O 
" O 
drug O 
carrier O 
to O 
target O 
specific O 
biomarkers O 
on O 
cancer O 
cells O 
by O 
conjugating O 
with O 
suitable O 
biotinylated O 
antibodies O 
. O 

S O 
enhances O 
memory O 
and O 
mitigates O 
memory O 
impairment O 
induced O 
by O 
MK801 B-IDENTIFIER 
, O 
scopolamine B-TRIVIAL 
or O 
Aβ1-42 O 
in O 
mice O 
novel O 
object O 
and O 
object O 
location O 
recognition O 
tasks O 
. O 

S O 
( O 
NPS O 
) O 
, O 
the O 
endogenous O 
ligand O 
of O 
NPSR O 
, O 
has O 
been O 
shown O 
to O 
promote O 
arousal O 
and O 
anxiolytic O 
- O 
like O 
effects O 
. O 
According O 
to O 
the O 
predominant O 
distribution O 
of O 
NPSR O 
in O 
brain O 
tissues O 
associated O 
with O 
learning O 
and O 
memory O 
, O 
NPS O 
has O 
been O 
reported O 
to O 
modulate O 
cognitive O 
function O 
in O 
rodents O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
role O 
of O 
NPS O 
in O 
memory O 
formation O 
, O 
and O 
determined O 
whether O 
NPS O 
could O 
mitigate O 
memory O 
impairment O 
induced O 
by O 
selective O 
N-methyl-d-aspartate B-SYSTEMATIC 
receptor O 
antagonist O 
MK801 B-IDENTIFIER 
, O 
muscarinic O 
cholinergic O 
receptor O 
antagonist O 
scopolamine B-TRIVIAL 
or O 
Aβ1-42 O 
in O 
mice O 
, O 
using O 
novel O 
object O 
and O 
object O 
location O 
recognition O 
tasks O 
. O 
Intracerebroventricular O 
( O 
i.c.v O 
. O 
) O 
injection O 
of O 
1 O 
nmol O 
NPS O 
5 O 
min O 
after O 
training O 
not O 
only O 
facilitated O 
object O 
recognition O 
memory O 
formation O 
, O 
but O 
also O 
prolonged O 
memory O 
retention O 
in O 
both O 
tasks O 
. O 
The O 
improvement O 
of O 
object O 
recognition O 
memory O 
induced O 
by O 
NPS O 
could O 
be O 
blocked O 
by O 
the O 
selective O 
NPSR O 
antagonist O 
SHA B-IDENTIFIER 
68 I-IDENTIFIER 
, O 
indicating O 
pharmacological O 
specificity O 
. O 
Then O 
, O 
we O 
found O 
that O 
i.c.v O 
. O 
injection O 
of O 
NPS O 
reversed O 
memory O 
disruption O 
induced O 
by O 
MK801 B-IDENTIFIER 
, O 
scopolamine B-TRIVIAL 
or O 
Aβ1-42 O 
in O 
both O 
tasks O 
. O 
In O 
summary O 
, O 
our O 
results O 
indicate O 
that O 
NPS O 
facilitates O 
memory O 
formation O 
and O 
prolongs O 
the O 
retention O 
of O 
memory O 
through O 
activation O 
of O 
the O 
NPSR O 
, O 
and O 
mitigates O 
amnesia O 
induced O 
by O 
blockage O 
of O 
glutamatergic O 
or O 
cholinergic O 
system O 
or O 
by O 
Aβ1-42 O 
, O 
suggesting O 
that O 
NPS O 
/ O 
NPSR O 
system O 
may O 
be O 
a O 
new O 
target O 
for O 
enhancing O 
memory O 
and O 
treating O 
amnesia O 
. O 

, O 
spectral O 
and O 
antimicrobial O 
evaluation O 
of O 
some O 
novel O 
1-methyl-3-alkyl-2,6-diphenylpiperidin-4-one B-FAMILY 
oxime I-FAMILY 
carbonates I-FAMILY 
. O 

of O 
some O 
novel O 
biologically O 
active O 
piperidin-4-one B-FAMILY 
oxime I-FAMILY 
carbonates I-FAMILY 
from O 
1-methyl-3alkyl-2,6-diphenylpiperidin-4-one B-FAMILY 
oximes I-FAMILY 
and O 
substituted O 
chloroformates B-FAMILY 
was O 
carried O 
out O 
in O 
the O 
presence O 
of O 
potassium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
as O 
base O 
and O 
tetrabutylammonium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
TBAB B-ABBREVIATION 
) O 
as O 
catalyst O 
. O 
The O 
newly O 
synthesized O 
compounds O 
were O 
characterized O 
by O 
IR O 
, O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
NMR O 
and O 
LC-mass O 
spectra O 
. O 
Based O 
on O 
the O 
(1)H B-FORMULA 
NMR O 
analysis O 
, O 
all O 
the O 
compounds O 
were O 
found O 
to O 
adopt O 
normal O 
chair O 
conformation O 
with O 
equatorial O 
orientation O 
of O 
all O 
the O 
substituents O 
. O 
For O 
all O 
the O 
synthesized O 
compounds O 
( O 
5a-5l O 
) O 
antimicrobial O 
activity O 
has O 
been O 
tested O 
against O 
bacterial O 
and O 
fungal O 
strains O 
using O 
Streptomycin B-TRIVIAL 
and O 
Amphotericin B-TRIVIAL 
B I-TRIVIAL 
as O 
standards O 
. O 

- O 
positive O 
bacteria O 
build O 
pili O 
on O 
their O 
cell O 
surface O 
via O 
a O 
class O 
C O 
sortase O 
- O 
catalyzed O 
transpeptidation O 
mechanism O 
from O 
pilin O 
protein O 
substrates O 
. O 
Despite O 
the O 
availability O 
of O 
several O 
crystal O 
structures O 
, O 
pilus O 
- O 
related O 
C O 
sortases O 
remain O 
poorly O 
characterized O 
to O 
date O 
, O 
and O 
their O 
mechanisms O 
of O 
transpeptidation O 
and O 
regulation O 
need O 
to O 
be O 
further O 
investigated O 
. O 
The O 
available O 
3-dimensional O 
structures O 
of O 
these O 
enzymes O 
reveal O 
a O 
typical O 
sortase O 
fold O 
, O 
except O 
for O 
the O 
presence O 
of O 
a O 
unique O 
feature O 
represented O 
by O 
an O 
N B-FORMULA 
-terminal O 
highly O 
flexible O 
loop O 
known O 
as O 
the O 
" O 
lid O 
. O 
" O 
This O 
region O 
interacts O 
with O 
the O 
residues O 
composing O 
the O 
catalytic O 
triad O 
and O 
covers O 
the O 
active O 
site O 
, O 
thus O 
maintaining O 
the O 
enzyme O 
in O 
an O 
autoinhibited O 
state O 
and O 
preventing O 
the O 
accessibility O 
to O 
the O 
substrate O 
. O 
It O 
is O 
believed O 
that O 
enzyme O 
activation O 
may O 
occur O 
only O 
after O 
lid O 
displacement O 
from O 
the O 
catalytic O 
domain O 
. O 
In O 
this O 
work O 
, O 
we O 
provide O 
the O 
first O 
direct O 
evidence O 
of O 
the O 
regulatory O 
role O 
of O 
the O 
lid O 
, O 
demonstrating O 
that O 
it O 
is O 
possible O 
to O 
obtain O 
in O 
vitro O 
an O 
efficient O 
polymerization O 
of O 
pilin O 
subunits O 
using O 
an O 
active O 
C O 
sortase O 
lid O 
mutant O 
carrying O 
a O 
single O 
residue O 
mutation O 
in O 
the O 
lid O 
region O 
. O 
Moreover O 
, O 
biochemical O 
analyses O 
of O 
this O 
recombinant O 
mutant O 
reveal O 
that O 
the O 
lid O 
confers O 
thermodynamic O 
and O 
proteolytic O 
stability O 
to O 
the O 
enzyme.-Cozzi O 
, O 
R O 
. O 
, O 
Zerbini O 
, O 
F O 
. O 
, O 
Assfalg O 
, O 
M O 
. O 
, O 
D'Onofrio O 
, O 
M O 
. O 
, O 
Biagini O 
, O 
M O 
. O 
, O 
Martinelli O 
, O 
M O 
. O 
, O 
Nuccitelli O 
, O 
A O 
. O 
, O 
Norais O 
, O 
N O 
. O 
, O 
Telford O 
, O 
J O 
. O 
L O 
. O 
, O 
Maione O 
, O 
D O 
. O 
, O 
Rinaudo O 
, O 
C O 
. O 
D O 
. O 
Group O 
B O 
Streptococcus O 
pilus O 
sortase O 
regulation O 
: O 
a O 
single O 
mutation O 
in O 
the O 
lid O 
region O 
induces O 
pilin O 
protein O 
polymerization O 
in O 
vitro O 
. O 

II O 
receptor O 
blockers O 
( O 
ARBs O 
) O 
are O 
used O 
to O 
treat O 
hypertension O 
. O 
Most O 
ARBs O 
are O 
metabolized O 
by O 
CYP2C9 O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
evaluate O 
the O 
possible O 
association O 
between O 
sex O 
, O 
polymorphisms O 
in O 
the O 
CYP2C8 O 
and O 
CYP2C9 O 
genes O 
, O 
and O 
the O 
pharmacokinetics O 
of O 
losartan B-TRIVIAL 
, O 
valsartan B-TRIVIAL 
, O 
candesartan B-TRIVIAL 
, O 
and O 
telmisartan B-TRIVIAL 
. O 
The O 
study O 
population O 
comprised O 
246 O 
healthy O 
volunteers O 
from O 
seven O 
single O 
- O 
dose O 
clinical O 
trials O 
: O 
64 O 
from O 
two O 
candesartan B-TRIVIAL 
studies O 
, O 
43 O 
from O 
a O 
telmisartan B-TRIVIAL 
study O 
, O 
36 O 
from O 
a O 
losartan B-TRIVIAL 
study O 
, O 
and O 
103 O 
from O 
three O 
valsartan B-TRIVIAL 
studies O 
. O 
DNA O 
was O 
extracted O 
from O 
blood O 
samples O 
and O 
single O 
- O 
nucleotide O 
polymorphisms O 
in O 
the O 
CYP2C8 O 
( O 
CYP2C8*2 O 
, O 
CYP2C8*3 O 
, O 
CYP2C8*4 O 
, O 
CYP2C8*5 O 
) O 
and O 
CYP2C9 O 
( O 
CYP2C9*2 O 
, O 
CYP2C9*3 O 
) O 
genes O 
were O 
evaluated O 
using O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
. O 
Sex O 
only O 
affected O 
telmisartan B-TRIVIAL 
pharmacokinetics O 
, O 
since O 
women O 
showed O 
a O 
higher O 
telmisartan B-TRIVIAL 
C(max) O 
than O 
men O 
( O 
590.5 O 
± O 
75.8 O 
ng O 
/ O 
ml O 
versus O 
282.1 O 
± O 
30.8 O 
ng O 
/ O 
ml O 
; O 
P O 
≤ O 
0.01 O 
) O 
. O 
CYP2C9 O 
variants O 
were O 
associated O 
only O 
with O 
losartan B-TRIVIAL 
pharmacokinetics O 
: O 
the O 
half O 
- O 
life O 
of O 
losartan B-TRIVIAL 
was O 
higher O 
in O 
CYP2C9*3 O 
allele O 
carriers O 
( O 
3.1 O 
± O 
0.4 O 
hours O 
) O 
than O 
in O 
volunteers O 
with O 
the O 
wild O 
- O 
type O 
genotype O 
( O 
2.3 O 
± O 
0.1 O 
hours O 
) O 
( O 
P O 
≤ O 
0.05 O 
) O 
. O 
CYP2C8 O 
polymorphisms O 
were O 
associated O 
only O 
with O 
valsartan B-TRIVIAL 
pharmacokinetics O 
, O 
since O 
*2 O 
allele O 
carriers O 
showed O 
faster O 
clearance O 
( O 
1.07 O 
± O 
0.57 O 
l O 
/ O 
h·kg O 
) O 
than O 
those O 
with O 
the O 
wild O 
- O 
type O 
genotype O 
( O 
0.48 O 
± O 
0.72 O 
l O 
/ O 
h·kg O 
; O 
P O 
≤ O 
0.01 O 
) O 
and O 
carriers O 
of O 
the O 
*3 O 
allele O 
( O 
0.35 O 
± O 
0.49 O 
l O 
/ O 
h·kg O 
; O 
P O 
≤ O 
0.001 O 
) O 
. O 
These O 
results O 
suggest O 
that O 
genotypes O 
for O 
CYP2C9 O 
and O 
CYP2C8 O 
are O 
relevant O 
to O 
the O 
pharmacokinetics O 
of O 
losartan B-TRIVIAL 
and O 
valsartan B-TRIVIAL 
, O 
respectively O 
, O 
but O 
not O 
the O 
pharmacokinetics O 
of O 
candesartan B-TRIVIAL 
or O 
telmisartan B-TRIVIAL 
. O 

dual O 
role O 
of O 
Se B-FORMULA 
on O 
Cd B-FORMULA 
toxicity O 
: O 
evidences O 
from O 
the O 
uptake O 
of O 
Cd B-FORMULA 
and O 
some O 
essential O 
elements O 
and O 
the O 
growth O 
responses O 
in O 
paddy O 
rice O 
. O 

study O 
was O 
carried O 
out O 
to O 
investigate O 
the O 
effects O 
of O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
on O 
the O 
uptake O 
and O 
translocation O 
of O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
and O 
essential O 
elements O 
in O 
paddy O 
rice O 
( O 
Oryza O 
sativa O 
L O 
. O 
, O 
Shuangyou O 
998 O 
) O 
. O 
Selenium B-SYSTEMATIC 
could O 
alleviate O 
/ O 
aggravate O 
Cd B-FORMULA 
toxicity O 
in O 
paddy O 
rice O 
, O 
which O 
depended O 
on O 
the O 
dosages O 
of O 
Se B-FORMULA 
and O 
/ O 
or O 
Cd B-FORMULA 
. O 
When O 
Cd B-FORMULA 
treatment O 
level O 
was O 
as O 
low O 
as O 
35.6 O 
μM O 
, O 
≤ O 
12.7 O 
μM O 
Se B-FORMULA 
could O 
inhibit O 
the O 
uptake O 
of O 
Cd B-FORMULA 
in O 
paddy O 
rice O 
and O 
increase O 
the O 
biomass O 
of O 
paddy O 
rice O 
; O 
however O 
, O 
with O 
Cd B-FORMULA 
levels O 
reaching O 
89-178 O 
μM O 
, O 
the O 
addition O 
of O 
Se B-FORMULA 
resulted O 
in O 
increases O 
in O 
Cd B-FORMULA 
uptake O 
and O 
exacerbated O 
the O 
growth O 
of O 
paddy O 
rice O 
. O 
Cd B-FORMULA 
always O 
inhibited O 
the O 
uptake O 
of O 
Se B-FORMULA 
. O 
Cd B-FORMULA 
alone O 
suppressed O 
the O 
uptake O 
of O 
Ca B-FORMULA 
, O 
Mg B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Cu B-FORMULA 
, O 
and O 
Zn B-FORMULA 
; O 
however O 
, O 
Se B-FORMULA 
reversed O 
the O 
decreases O 
in O 
the O 
concentrations O 
of O 
the O 
said O 
elements O 
, O 
suggesting O 
an O 
element O 
regulation O 
mechanism O 
to O 
relieve O 
Cd B-FORMULA 
toxicity O 
. O 
Without O 
Cd B-FORMULA 
in O 
the O 
solution O 
, O 
low O 
doses O 
of O 
Se B-FORMULA 
increased O 
the O 
biomasses O 
of O 
shoots O 
and O 
roots O 
at O 
the O 
expense O 
of O 
the O 
more O 
or O 
less O 
decreases O 
in O 
the O 
concentrations O 
of O 
Ca B-FORMULA 
, O 
Mg B-FORMULA 
, O 
K B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Cu B-FORMULA 
, O 
and O 
shoot O 
Zn B-FORMULA 
, O 
indicating O 
an O 
antagonistic O 
effect O 
of O 
Se B-FORMULA 
on O 
these O 
cations O 
. O 
The O 
presence O 
of O 
Cd B-FORMULA 
could O 
also O 
reverse O 
these O 
decreases O 
especially O 
at O 
the O 
highest O 
treatment O 
levels O 
for O 
both O 
Se B-FORMULA 
and O 
Cd B-FORMULA 
, O 
also O 
suggesting O 
an O 
element O 
regulation O 
mechanism O 
responsible O 
for O 
the O 
detoxification O 
of O 
high O 
dosages O 
of O 
Se B-FORMULA 
. O 
Consequently O 
, O 
when O 
Se B-FORMULA 
is O 
used O 
to O 
alleviate O 
Cd B-FORMULA 
toxicity O 
, O 
attention O 
must O 
be O 
paid O 
to O 
the O 
Cd B-FORMULA 
pollution O 
extent O 
and O 
doses O 
of O 
Se B-FORMULA 
supplement O 
. O 

attractive O 
method O 
to O 
response O 
the O 
current O 
energy O 
crisis O 
and O 
produce O 
sustainable O 
nonpolluting O 
power O 
source O 
is O 
harvesting O 
energy O 
from O 
our O 
living O 
environment O 
. O 
However O 
, O 
the O 
energy O 
in O 
our O 
living O 
environment O 
always O 
exists O 
in O 
low O 
- O 
frequency O 
form O 
, O 
which O 
is O 
very O 
difficult O 
to O 
be O 
utilized O 
directly O 
. O 
Here O 
, O 
we O 
demonstrated O 
a O 
novel O 
sandwich O 
- O 
shape O 
triboelectric O 
nanogenerator O 
to O 
convert O 
low O 
- O 
frequency O 
mechanical O 
energy O 
to O 
electric O 
energy O 
with O 
double O 
frequency O 
. O 
An O 
aluminum B-SYSTEMATIC 
film O 
was O 
placed O 
between O 
two O 
polydimethylsiloxane B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
membranes O 
to O 
realize O 
frequency O 
multiplication O 
by O 
twice O 
contact O 
electrifications O 
within O 
one O 
cycle O 
of O 
external O 
force O 
. O 
The O 
working O 
mechanism O 
was O 
studied O 
by O 
finite O 
element O 
simulation O 
. O 
Additionally O 
, O 
the O 
well O 
- O 
designed O 
micro O 
/ O 
nano O 
dual O 
- O 
scale O 
structures O 
( O 
i.e O 
. O 
, O 
pyramids O 
and O 
V-shape O 
grooves O 
) O 
fabricated O 
atop O 
PDMS B-ABBREVIATION 
surface O 
was O 
employed O 
to O 
enhance O 
the O 
device O 
performance O 
. O 
The O 
output O 
peak O 
voltage O 
, O 
current O 
density O 
, O 
and O 
energy O 
volume O 
density O 
achieved O 
465 O 
V O 
, O 
13.4 O 
μA O 
/ O 
cm(2) O 
, O 
and O 
53.4 O 
mW O 
/ O 
cm(3) O 
, O 
respectively O 
. O 
This O 
novel O 
nanogenerator O 
was O 
systematically O 
investigated O 
and O 
also O 
demonstrated O 
as O 
a O 
reliable O 
power O 
source O 
, O 
which O 
can O 
be O 
directly O 
used O 
to O 
not O 
only O 
lighten O 
five O 
commercial O 
light O 
- O 
emitting O 
diodes O 
( O 
LEDs O 
) O 
but O 
also O 
drive O 
an O 
implantable O 
3-D O 
microelectrode O 
array O 
for O 
neural O 
prosthesis O 
without O 
any O 
energy O 
storage O 
unit O 
or O 
rectification O 
circuit O 
. O 
This O 
is O 
the O 
first O 
demonstration O 
of O 
the O 
nanogenerator O 
for O 
directly O 
driving O 
biomedical O 
microsystems O 
, O 
which O 
extends O 
the O 
application O 
fields O 
of O 
the O 
nanogenerator O 
and O 
drives O 
it O 
closer O 
to O 
practical O 
applications O 
. O 

, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
novel O 
hybrid O 
compounds O 
of O 
imidazole B-SYSTEMATIC 
scaffold O 
- O 
based O 
2-benzylbenzofuran B-SYSTEMATIC 
as O 
potent O 
anticancer O 
agents O 
. O 

series O 
of O 
novel O 
hybrid O 
compounds O 
between O 
2-benzylbenzofuran B-SYSTEMATIC 
and O 
imidazole B-SYSTEMATIC 
has O 
been O 
prepared O 
and O 
evaluated O 
in O 
vitro O 
against O 
a O 
panel O 
of O 
human O 
tumor O 
cell O 
lines O 
. O 
The O 
results O 
suggest O 
that O 
the O 
existence O 
of O 
benzimidazole B-SYSTEMATIC 
ring O 
and O 
substitution O 
of O 
the O 
imidazolyl B-SYSTEMATIC 
-3 O 
- O 
position O 
with O 
a O 
naphthylacyl B-FAMILY 
or O 
4-methoxyphenacyl B-FAMILY 
group O 
were O 
vital O 
for O 
modulating O 
cytotoxic O 
activity O 
. O 
In O 
particular O 
, O 
hybrid O 
compounds O 
46 O 
and O 
47 O 
were O 
found O 
to O 
be O 
the O 
most O 
potent O 
derivatives O 
against O 
5 O 
strains O 
human O 
tumor O 
cell O 
lines O 
and O 
more O 
active O 
than O 
cisplatin B-TRIVIAL 
( O 
DDP B-ABBREVIATION 
) O 
, O 
and O 
exhibited O 
cytotoxic O 
activities O 
selectively O 
against O 
breast O 
carcinoma O 
( O 
MCF-7 O 
) O 
and O 
myeloid O 
liver O 
carcinoma O 
( O 
SMMC-7721 O 
) O 
, O 
respectively O 
. O 

part O 
of O 
the O 
National O 
Institute O 
for O 
Health O 
and O 
Clinical O 
Excellence O 
( O 
NICE O 
) O 
single O 
technology O 
appraisal O 
( O 
STA O 
) O 
process O 
, O 
the O 
manufacturer O 
of O 
golimumab O 
( O 
Simponi(®) O 
; O 
Merck O 
Sharp O 
& O 
Dohme O 
, O 
USA O 
) O 
was O 
invited O 
to O 
submit O 
evidence O 
for O 
its O 
clinical O 
and O 
cost O 
effectiveness O 
for O 
the O 
treatment O 
of O 
rheumatoid O 
arthritis O 
( O 
RA O 
) O 
after O 
the O 
failure O 
of O 
previous O 
disease O 
- O 
modifying O 
antirheumatic O 
drugs O 
( O 
DMARDs O 
) O 
. O 
The O 
School O 
of O 
Health O 
and O 
Related O 
Research O 
Technology O 
Appraisal O 
Group O 
( O 
ScHARR-TAG O 
) O 
at O 
The O 
University O 
of O 
Sheffield O 
was O 
commissioned O 
to O 
act O 
as O 
the O 
independent O 
Evidence O 
Review O 
Group O 
( O 
ERG O 
) O 
. O 
This O 
article O 
provides O 
details O 
of O 
the O 
manufacturer's O 
initial O 
submission O 
, O 
the O 
ERG's O 
clarification O 
questions O 
and O 
the O 
ERG O 
report O 
submitted O 
to O 
NICE O 
. O 
The O 
decision O 
made O 
by O 
NICE O 
is O 
provided O 
alongside O 
a O 
brief O 
comment O 
on O 
additional O 
results O 
produced O 
from O 
an O 
additional O 
analysis O 
requested O 
by O 
NICE O 
on O 
behalf O 
of O 
the O 
Committee O 
. O 
The O 
ERG O 
produced O 
a O 
critical O 
review O 
of O 
the O 
evidence O 
for O 
the O 
clinical O 
and O 
cost O 
effectiveness O 
of O 
the O 
technology O 
based O 
on O 
upon O 
the O 
manufacturer's O 
submission O 
to O 
NICE O 
. O 
The O 
clinical O 
evidence O 
was O 
derived O 
from O 
three O 
randomized O 
controlled O 
trials O 
of O 
golimumab O 
in O 
the O 
treatment O 
of O 
moderate O 
to O 
severe O 
RA O 
: O 
GO-FORWARD O 
and O 
Kay O 
et O 
al O 
. O 
( O 
DMARD-experienced O 
population O 
) O 
and O 
GO-AFTER O 
( O 
tumour O 
necrosis O 
factor O 
[TNF]-α O 
inhibitor O 
- O 
experienced O 
population O 
) O 
. O 
The O 
ERG O 
considered O 
that O 
the O 
trials O 
were O 
of O 
reasonable O 
methodological O 
quality O 
and O 
measured O 
a O 
clinically O 
relevant O 
range O 
of O 
outcomes O 
. O 
The O 
trials O 
for O 
golimumab O 
, O 
as O 
well O 
as O 
comparator O 
treatments O 
, O 
were O 
synthesized O 
using O 
mixed O 
- O 
treatment O 
comparison O 
methods O 
for O 
the O 
DMARD-experienced O 
population O 
and O 
an O 
indirect O 
comparison O 
using O 
the O 
Bucher O 
method O 
for O 
the O 
TNF-α O 
inhibitor O 
- O 
experienced O 
population O 
. O 
The O 
trials O 
used O 
were O 
appropriate O 
, O 
although O 
no O 
definitive O 
judgement O 
regarding O 
the O 
comparative O 
efficacy O 
of O 
golimumab O 
with O 
other O 
biologics O 
was O 
possible O 
. O 
The O 
manufacturer O 
provided O 
a O 
DMARD-experienced O 
population O 
model O 
and O 
a O 
TNF-α O 
inhibitor O 
- O 
experienced O 
population O 
model O 
. O 
The O 
models O 
allowed O 
sequences O 
of O 
treatments O 
to O 
be O 
evaluated O 
for O 
each O 
population O 
, O 
although O 
a O 
fully O 
incremental O 
analysis O 
between O 
the O 
use O 
of O 
golimumab O 
following O 
DMARD O 
failure O 
and O 
the O 
use O 
of O 
golimumab O 
following O 
TNF-α O 
inhibitor O 
failure O 
was O 
not O 
possible O 
. O 
Several O 
limitations O 
with O 
the O 
model O 
were O 
identified O 
, O 
and O 
after O 
a O 
request O 
from O 
NICE O 
and O 
suspension O 
of O 
the O 
appraisal O 
, O 
the O 
manufacturer O 
submitted O 
sensitivity O 
analyses O 
with O 
an O 
additional O 
American O 
College O 
of O 
Rheumatology O 
70 O 
% O 
improvement O 
criteria O 
( O 
ACR70 O 
) O 
health O 
state O 
included O 
, O 
using O 
SF-36 O 
data O 
directly O 
from O 
the O 
GO-FORWARD O 
study O 
. O 
The O 
annual O 
rate O 
of O 
the O 
Health O 
Assessment O 
Questionnaire O 
( O 
HAQ O 
) O 
score O 
increase O 
for O 
patients O 
receiving O 
palliative O 
treatment O 
was O 
also O 
changed O 
from O 
0.09 O 
to O 
0.06 O 
. O 
The O 
further O 
analyses O 
provided O 
highlighted O 
the O 
particular O 
sensitivity O 
of O 
the O 
results O 
to O 
HAQ O 
progression O 
rates O 
and O 
the O 
re O 
- O 
administration O 
frequency O 
for O 
rituximab O 
in O 
the O 
TNF-α O 
inhibitor O 
- O 
experienced O 
population O 
. O 
The O 
Appraisal O 
Committee O 
concluded O 
that O 
golimumab O 
should O 
be O 
recommended O 
in O 
combination O 
with O 
methotrexate B-TRIVIAL 
as O 
an O 
option O 
for O 
patients O 
with O 
severe O 
active O 
RA O 
who O 
have O 
failed O 
on O 
conventional O 
DMARDs O 
, O 
or O 
who O 
have O 
failed O 
on O 
a O 
TNF-α O 
inhibitor O 
and O 
are O 
contraindicated O 
to O 
or O 
withdrawn O 
from O 
rituximab O 
. O 

this O 
paper O 
a O 
combination O 
of O 
NIR O 
spectroscopy O 
and O 
FTIR O 
and O 
Raman O 
microspectroscopy O 
was O 
used O 
to O 
elucidate O 
the O 
effects O 
of O 
different O 
salts O 
( O 
NaCl B-FORMULA 
, O 
KCl B-FORMULA 
and O 
MgSO(4) B-FORMULA 
) O 
on O 
structural O 
proteins O 
and O 
their O 
hydration O 
in O 
muscle O 
tissue O 
. O 
Multivariate O 
multi O 
- O 
block O 
technique O 
Consensus O 
Principal O 
Component O 
Analysis O 
enabled O 
integration O 
of O 
different O 
vibrational O 
spectroscopic O 
techniques O 
: O 
macroscopic O 
information O 
obtained O 
by O 
NIR O 
spectroscopy O 
is O 
directly O 
related O 
to O 
microscopic O 
information O 
obtained O 
by O 
FTIR O 
and O 
Raman O 
microspectroscopy O 
. O 
Changes O 
in O 
protein O 
secondary O 
structure O 
observed O 
at O 
different O 
concentrations O 
of O 
salts O 
were O 
linked O 
to O 
changes O 
in O 
protein O 
hydration O 
affinity O 
. O 
The O 
evidence O 
for O 
this O 
was O 
given O 
by O 
connecting O 
the O 
underlying O 
FTIR O 
bands O 
of O 
the O 
amide B-FAMILY 
I O 
region O 
( O 
1700-1600 O 
cm(-1) O 
) O 
and O 
the O 
water O 
region O 
( O 
3500-3000 O 
cm(-1) O 
) O 
with O 
water O 
vibrations O 
obtained O 
by O 
NIR O 
spectroscopy O 
. O 
In O 
addition O 
, O 
Raman O 
microspectroscopy O 
demonstrated O 
that O 
different O 
cations O 
affected O 
structures O 
of O 
aromatic B-FAMILY 
amino I-FAMILY 
acid I-FAMILY 
residues O 
differently O 
, O 
which O 
indicates O 
that O 
cation-π O 
interactions O 
play O 
an O 
important O 
role O 
in O 
determination O 
of O 
the O 
final O 
structure O 
of O 
protein O 
molecules O 
. O 

have O 
developed O 
an O 
approach O 
termed O 
PUB-NChIP O 
( O 
proximity O 
utilizing O 
biotinylation O 
with O 
native O 
ChIP O 
) O 
to O 
purify O 
and O 
study O 
the O 
protein O 
composition O 
of O 
chromatin O 
in O 
proximity O 
to O 
a O 
nuclear O 
protein O 
of O 
interest O 
. O 
It O 
is O 
based O 
on O 
coexpression O 
of O 
( O 
1 O 
) O 
a O 
protein O 
of O 
interest O 
, O 
fused O 
with O 
the O 
bacterial O 
biotin B-TRIVIAL 
ligase O 
BirA O 
, O 
together O 
with O 
( O 
2 O 
) O 
a O 
histone O 
fused O 
to O 
a O 
biotin B-TRIVIAL 
acceptor O 
peptide O 
( O 
BAP O 
) O 
, O 
which O 
is O 
specifically O 
biotinylated O 
by O 
BirA-fusion O 
in O 
the O 
proximity O 
of O 
the O 
protein O 
of O 
interest O 
. O 
Using O 
the O 
RAD18 O 
protein O 
as O 
a O 
model O 
, O 
we O 
demonstrate O 
that O 
the O 
RAD18-proximal O 
chromatin O 
is O 
enriched O 
in O 
some O 
H4 O 
acetylated O 
species O 
. O 
Moreover O 
, O 
the O 
RAD18-proximal O 
chromatin O 
containing O 
a O 
replacement O 
histone O 
H2AZ O 
has O 
a O 
different O 
pattern O 
of O 
H4 O 
acetylation O 
. O 
Finally O 
, O 
biotin B-TRIVIAL 
pulse O 
- O 
chase O 
experiments O 
show O 
that O 
the O 
H4 O 
acetylation O 
pattern O 
starts O 
to O 
resemble O 
the O 
acetylation O 
pattern O 
of O 
total O 
H4 O 
after O 
the O 
proximity O 
of O 
chromatin O 
to O 
RAD18 O 
has O 
been O 
lost O 
. O 

a O 
recent O 
disclosure O 
, O 
we O 
described O 
the O 
discovery O 
of O 
dimeric O 
, O 
prolinamide B-TRIVIAL 
-based O 
NS5A O 
replication O 
complex O 
inhibitors O 
exhibiting O 
excellent O 
potency O 
towards O 
an O 
HCV O 
genotype O 
1b O 
replicon O 
. O 
That O 
disclosure O 
dealt O 
with O 
the O 
SAR O 
exploration O 
of O 
the O 
peripheral O 
region O 
of O 
our O 
lead O 
chemotype O 
, O 
and O 
herein O 
is O 
described O 
the O 
SAR O 
uncovered O 
from O 
a O 
complementary O 
effort O 
that O 
focused O 
on O 
the O 
central O 
core O 
region O 
. O 
From O 
this O 
effort O 
, O 
the O 
contribution O 
of O 
the O 
core O 
region O 
to O 
the O 
overall O 
topology O 
of O 
the O 
pharmacophore O 
, O 
primarily O 
vector O 
orientation O 
and O 
planarity O 
, O 
was O 
determined O 
, O 
with O 
a O 
set O 
of O 
analogs O 
exhibiting O 
< O 
10 O 
nM O 
EC(50) O 
in O 
a O 
genotype O 
1b O 
replicon O 
assay O 
. O 

silico O 
identification O 
of O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerase-1 O 
inhibitors O 
and O 
their O 
chemosensitizing O 
effects O 
against O 
cisplatin B-TRIVIAL 
-resistant O 
human O 
gastric O 
cancer O 
cells O 
. O 

polymerase-1 O 
( O 
PARP-1 O 
) O 
enzyme O 
is O 
involved O 
in O 
the O 
repair O 
of O 
DNA O 
damages O 
made O 
by O 
certain O 
anticancer O 
agents O 
. O 
It O 
is O 
suggested O 
that O 
PARP-1 O 
inhibitors O 
potentiate O 
the O 
cytotoxic O 
effects O 
and O 
circumvent O 
the O 
resistance O 
of O 
DNA-modifying O 
anticancer O 
agents O 
such O 
as O 
cisplatin B-TRIVIAL 
. O 
In O 
this O 
study O 
, O 
we O 
conducted O 
virtual O 
screening O 
of O 
Korea O 
Chemical O 
Bank O 
database O 
targeting O 
PARP-1 O 
and O 
identified O 
several O 
potent O 
PARP-1 O 
inhibitors O 
with O 
submicromolar O 
IC50 O 
values O 
( O 
77-79nM O 
) O 
. O 
We O 
then O 
examined O 
the O 
chemosensitization O 
of O 
cisplatin B-TRIVIAL 
by O 
pre O 
- O 
treatment O 
of O 
PARP-1 O 
inhibitors O 
in O 
cisplatin B-TRIVIAL 
-resistant O 
human O 
gastric O 
cancer O 
cells O 
. O 
Our O 
results O 
show O 
that O 
PARP-1 O 
inhibitors O 
suppress O 
the O 
formation O 
of O 
poly(ADP-ribose) B-SYSTEMATIC 
and O 
enhance O 
the O 
cytotoxicity O 
of O 
cisplatin B-TRIVIAL 
. O 

toxicity O 
and O 
estrogenic O 
potency O 
of O 
zearalenone B-TRIVIAL 
in O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
. O 

( O 
ZEA B-ABBREVIATION 
, O 
F2 O 
) O 
is O 
one O 
of O 
the O 
most O 
common O 
mycotoxins O 
and O 
the O 
only O 
known O 
mycoestrogen B-FAMILY 
. O 
It O 
enters O 
the O 
food O 
and O 
feed O 
chain O 
from O 
contaminated O 
cereals O 
and O 
infiltrates O 
into O 
sewage O 
or O 
natural O 
waters O 
posing O 
potential O 
threat O 
to O 
exposed O 
livestock O 
, O 
wildlife O 
and O 
humans O 
. O 
Therefore O 
evaluation O 
of O 
its O 
biological O 
effects O 
is O 
of O 
international O 
importance O 
. O 
We O 
performed O 
toxicological O 
tests O 
on O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
larvae O 
and O 
adults O 
. O 
Developmental O 
toxicity O 
was O 
assessed O 
by O 
an O 
extended O 
( O 
5 O 
days O 
) O 
fish O 
embryo O 
toxicity O 
test O 
( O 
FET O 
) O 
. O 
Effects O 
of O 
early O 
ZEA B-ABBREVIATION 
exposure O 
were O 
concentration O 
- O 
dependent O 
with O 
LC50 O 
and O 
LC10 O 
values O 
of O 
893 O 
and O 
335μg O 
/ O 
L O 
. O 
In O 
larvae O 
exposed O 
to O 
500μg O 
/ O 
L O 
and O 
above O 
, O 
ZEA B-ABBREVIATION 
induced O 
similar O 
phenotype O 
to O 
has O 
( O 
heart O 
- O 
and O 
soul O 
) O 
showing O 
defects O 
in O 
heart O 
and O 
eye O 
development O 
and O 
upward O 
curvature O 
of O 
the O 
body O 
axis O 
. O 
From O 
250μg O 
/ O 
L O 
at O 
72hpf O 
the O 
gap O 
in O 
the O 
melanophore O 
streak O 
at O 
the O 
base O 
of O 
the O 
tail O 
fin O 
was O 
missing O 
and O 
the O 
fin O 
fold O 
was O 
abnormal O 
, O 
suggesting O 
disturbance O 
in O 
the O 
development O 
of O 
the O 
adult O 
tail O 
fin O 
primordium O 
. O 
Estrogenic O 
potency O 
was O 
measured O 
on O 
the O 
basis O 
of O 
Vitellogenin O 
( O 
Vtg O 
) O 
protein O 
( O 
adults O 
) O 
levels O 
and O 
relative O 
abundance O 
of O 
vitellogenin-1 O 
mRNA O 
( O 
vtg-1 O 
) O 
( O 
larvae O 
and O 
adults O 
) O 
. O 
qRT-PCR O 
in O 
larvae O 
proved O 
to O 
be O 
sufficient O 
substitute O 
to O 
adult O 
tests O 
and O 
sensitive O 
enough O 
to O 
detect O 
ZEA B-ABBREVIATION 
in O 
0.1μg O 
/ O 
L O 
concentrations O 
, O 
that O 
is O 
close O 
to O 
levels O 
observed O 
in O 
wastewaters O 
. O 
Developmental O 
defects O 
reveal O 
that O 
besides O 
direct O 
estrogenic O 
effects O 
, O 
zearalenone B-TRIVIAL 
might O 
interact O 
with O 
other O 
ontogenic O 
pathways O 
. O 

activity O 
contributes O 
to O 
the O 
monoaminergic O 
damage O 
caused O 
by O 
serial O 
exposure O 
to O 
stress O 
and O 
methamphetamine B-TRIVIAL 
. O 

( O 
Meth B-ABBREVIATION 
) O 
is O 
a O 
widely O 
abused O 
psychostimulant O 
that O 
causes O 
long O 
- O 
term O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
and O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
depletions O 
. O 
Stress O 
and O 
Meth B-ABBREVIATION 
abuse O 
are O 
comorbid O 
events O 
in O 
society O 
and O 
stress O 
exacerbates O 
Meth B-ABBREVIATION 
-induced O 
monoaminergic O 
terminal O 
damage O 
. O 
Stress O 
is O 
also O 
known O 
to O 
produce O 
neuroinflammation O 
. O 
This O 
study O 
examined O 
the O 
role O 
of O 
the O 
neuroinflammatory O 
mediator O 
, O 
cyclooxygenase O 
( O 
COX O 
) O 
, O 
in O 
the O 
depletions O 
of O 
monoamines B-FAMILY 
caused O 
by O 
serial O 
exposure O 
to O 
chronic O 
unpredictable O 
stress O 
( O 
CUS O 
) O 
and O 
Meth B-ABBREVIATION 
. O 
CUS O 
produced O 
an O 
increase O 
in O 
COX-2 O 
protein O 
expression O 
and O 
enhanced O 
Meth B-ABBREVIATION 
-induced O 
monoaminergic O 
depletions O 
in O 
the O 
striatum O 
and O 
hippocampus O 
. O 
The O 
enhanced O 
DA O 
and O 
5-HT B-SYSTEMATIC 
depletions O 
in O 
the O 
striatum O 
, O 
but O 
not O 
the O 
hippocampus O 
, O 
were O 
prevented O 
by O 
pretreatment O 
with O 
COX O 
inhibitor O 
, O 
ketoprofen B-TRIVIAL 
, O 
during O 
stress O 
or O 
during O 
Meth B-ABBREVIATION 
; O 
however O 
, O 
ketoprofen B-TRIVIAL 
did O 
not O 
attenuate O 
the O 
monoaminergic O 
damage O 
caused O 
by O 
Meth B-ABBREVIATION 
alone O 
. O 
The O 
COX-dependent O 
enhancement O 
by O 
stress O 
of O 
Meth B-ABBREVIATION 
-induced O 
monoaminergic O 
depletions O 
was O 
independent O 
of O 
hyperthermia O 
, O 
as O 
ketoprofen B-TRIVIAL 
did O 
not O 
attenuate O 
Meth B-ABBREVIATION 
-induced O 
hyperthermia O 
. O 
In O 
addition O 
, O 
the O 
EP1 O 
receptor O 
antagonist O 
, O 
SC-51089 B-IDENTIFIER 
, O 
did O 
not O 
attenuate O 
DA O 
or O 
5-HT B-SYSTEMATIC 
depletions O 
caused O 
by O 
stress O 
and O 
Meth B-ABBREVIATION 
. O 
These O 
findings O 
illustrate O 
that O 
COX O 
activity O 
, O 
but O 
not O 
activation O 
of O 
the O 
EP1 O 
receptor O 
, O 
is O 
responsible O 
for O 
the O 
potentiation O 
of O 
Meth B-ABBREVIATION 
-induced O 
damage O 
to O 
striatal O 
monoamine B-FAMILY 
terminals O 
by O 
stress O 
and O 
suggests O 
the O 
use O 
of O 
anti-inflammatory O 
drugs O 
for O 
mitigating O 
the O 
neurotoxic O 
effects O 
associated O 
with O 
the O 
combination O 
of O 
stress O 
and O 
Meth B-ABBREVIATION 
. O 

properties O 
of O 
lard O 
- O 
based O 
diacylglycerols B-FAMILY 
in O 
blends O 
with O 
lard O 
. O 

objective O 
of O 
the O 
study O 
was O 
to O 
investigate O 
how O 
blending O 
of O 
triacylglycerols B-FAMILY 
and O 
diacylglycerols B-FAMILY 
affected O 
the O 
melting O 
and O 
crystallisation O 
properties O 
in O 
a O 
solid O 
fat O 
system O 
. O 
Lard O 
- O 
based O 
diacylglycerols B-FAMILY 
( O 
DAGs B-ABBREVIATION 
) O 
were O 
blended O 
with O 
lard O 
in O 
various O 
concentrations O 
( O 
0% O 
, O 
1% O 
, O 
5% O 
, O 
10% O 
, O 
20% O 
, O 
50% O 
, O 
60% O 
, O 
70% O 
, O 
80% O 
, O 
90% O 
, O 
and O 
100% O 
) O 
. O 
The O 
melting O 
and O 
crystallisation O 
properties O 
were O 
investigated O 
by O 
the O 
determination O 
of O 
dropping O 
point O 
( O 
DP O 
) O 
, O 
solid O 
fat O 
content O 
( O 
SFC O 
) O 
, O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
and O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
. O 
In O 
general O 
, O 
the O 
effects O 
of O 
DAGs B-ABBREVIATION 
were O 
found O 
to O 
be O 
dependent O 
on O 
concentration O 
. O 
The O 
DP O 
was O 
significantly O 
( O 
P O 
< O 
0.0001 O 
) O 
decreased O 
when O 
DAGs B-ABBREVIATION 
were O 
added O 
to O 
the O 
lard O 
from O 
5-50% O 
, O 
whereas O 
the O 
DP O 
was O 
increased O 
( O 
P O 
< O 
0.0001 O 
) O 
when O 
the O 
blends O 
contained O 
more O 
than O 
60% O 
DAGs B-ABBREVIATION 
. O 
The O 
DSC O 
thermograms O 
showed O 
that O 
DAGs B-ABBREVIATION 
changed O 
the O 
melting O 
and O 
crystallisation O 
profiles O 
of O 
lard O 
. O 
The O 
crystallisation O 
onset O 
point O 
increased O 
( O 
P O 
< O 
0.05 O 
) O 
with O 
increasing O 
the O 
DAG B-ABBREVIATION 
concentrations O 
( O 
10-100% O 
) O 
. O 
The O 
melting O 
peaks O 
and O 
off O 
- O 
set O 
points O 
generally O 
shifted O 
slightly O 
towards O 
higher O 
temperatures O 
as O 
the O 
content O 
of O 
DAGs B-ABBREVIATION 
increased O 
above O 
50% O 
. O 
DAG B-ABBREVIATION 
content O 
of O 
5% O 
and O 
10% O 
resulted O 
in O 
lowering O 
of O 
the O 
off O 
- O 
set O 
point O 
. O 
The O 
lard O 
contained O 
both O 
β O 
and O 
β O 
' O 
crystals O 
. O 
The O 
β O 
form O 
was O 
more O 
pronounced O 
in O 
the O 
blends O 
with O 
high O 
concentrations O 
of O 
DAGs B-ABBREVIATION 
. O 
Blending O 
of O 
TAGs B-ABBREVIATION 
and O 
DAGs B-ABBREVIATION 
may O 
serve O 
as O 
a O 
solution O 
to O 
achieve O 
specific O 
functional O 
properties O 
in O 
products O 
containing O 
solid O 
fats O 
. O 

of O 
aflatoxins B-FAMILY 
, O 
deoxynivalenol B-TRIVIAL 
, O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
and O 
zearalenone B-TRIVIAL 
in O 
wheat O 
and O 
oat O 
based O 
bran O 
supplements O 
sold O 
in O 
the O 
Spanish O 
market O 
. O 

aflatoxins B-FAMILY 
( O 
AFs O 
) O 
, O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
, O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
( O 
OTA B-ABBREVIATION 
) O 
and O 
zearalenone B-TRIVIAL 
( O 
ZEA B-ABBREVIATION 
) O 
are O 
mycotoxins O 
produced O 
by O 
fungal O 
species O 
which O 
can O 
contaminate O 
, O 
alone O 
or O 
simultaneously O 
, O 
cereal O 
- O 
based O 
raw O 
materials O 
. O 
Usually O 
, O 
the O 
higher O 
mycotoxins O 
concentrations O 
in O 
cereals O 
are O 
found O 
in O 
the O 
external O 
layers O 
of O 
the O 
grain O 
( O 
bran O 
) O 
. O 
Nowadays O 
bran O 
is O 
increasingly O 
consumed O 
for O 
its O 
high O 
fibre O 
concentration O 
. O 
The O 
objectives O 
of O 
this O 
study O 
were O 
determining O 
the O 
concentration O 
of O 
these O 
mycotoxins O 
in O 
bran O 
samples O 
intended O 
for O 
direct O 
human O 
consumption O 
and O 
to O 
study O 
the O 
influence O 
of O 
some O 
characteristics O 
of O 
the O 
samples O 
that O 
may O 
affect O 
the O 
mycotoxins O 
content O 
, O 
there O 
are O 
not O 
studies O 
about O 
fibre O 
for O 
direct O 
human O 
consumption O 
. O 
67 O 
bran O 
samples O 
from O 
shops O 
and O 
supermarkets O 
from O 
two O 
different O 
Spanish O 
cities O 
were O 
analyzed O 
, O 
being O 
37 O 
samples O 
of O 
wheat O 
bran O 
and O 
the O 
remaining O 
of O 
oat O 
bran O 
. O 
The O 
results O 
showed O 
a O 
major O 
presence O 
of O 
DON B-ABBREVIATION 
in O 
the O 
analyzed O 
samples O 
, O 
with O 
levels O 
above O 
the O 
EU O 
legislation O 
in O 
some O 
samples O 
. O 
Presence O 
of O 
DON B-ABBREVIATION 
was O 
more O 
frequent O 
in O 
wheat O 
samples O 
, O 
compared O 
to O 
oats O 
ones O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Extruded O 
or O 
toasted O 
samples O 
, O 
subjected O 
to O 
a O 
heat O 
treatment O 
during O 
processing O 
, O 
presented O 
a O 
significantly O 
lower O 
concentration O 
of O 
OTA B-ABBREVIATION 
, O 
and O 
differences O 
between O 
the O 
organically O 
and O 
conventionally O 
produced O 
samples O 
were O 
also O 
detected O 
in O 
OTA B-ABBREVIATION 
, O 
which O 
showed O 
higher O 
levels O 
in O 
the O 
organic O 
samples O 
. O 
Co-occurrence O 
was O 
frequently O 
found O 
between O 
the O 
Fusarium O 
mycotoxins O 
( O 
ZEA B-ABBREVIATION 
and O 
DON B-ABBREVIATION 
) O 
. O 
Due O 
to O 
the O 
high O 
levels O 
of O 
DON B-ABBREVIATION 
in O 
the O 
analyzed O 
samples O 
, O 
a O 
calculation O 
of O 
DON B-ABBREVIATION 
intake O 
has O 
been O 
made O 
and O 
it O 
has O 
been O 
demonstrated O 
that O 
bran O 
can O 
account O 
for O 
an O 
important O 
percentage O 
of O 
DON B-ABBREVIATION 
exposure O 
in O 
the O 
total O 
diet O 
. O 

of O 
fruit O 
juices O 
with O 
pine O 
bark O 
extract O 
( O 
PBE O 
) O 
could O 
be O 
a O 
strategy O 
to O 
compensate O 
for O 
phenolic B-FAMILY 
losses O 
during O 
the O 
gastrointestinal O 
digestion O 
. O 
A O 
coculture O 
system O 
with O 
Caco-2 O 
cells O 
and O 
RAW O 
264.7 O 
macrophages O 
was O 
established O 
as O 
an O 
in O 
vitro O 
model O 
of O 
inflamed O 
human O 
intestinal O 
epithelium O 
for O 
evaluating O 
the O 
anti-inflammatory O 
capacity O 
of O 
fruit O 
juices O 
enriched O 
with O 
PBE O 
( O 
0.5 O 
g O 
L(-1) O 
) O 
before O 
and O 
after O 
in O 
vitro O 
digestion O 
. O 
The O 
digestion O 
of O 
both O 
PBE O 
- O 
enriched O 
pineapple O 
and O 
red O 
fruit O 
juice O 
led O 
to O 
significant O 
changes O 
in O 
most O 
of O 
the O 
analysed O 
phenolic B-FAMILY 
compounds O 
. O 
The O 
in O 
vitro O 
inflammatory O 
state O 
showed O 
cell O 
barrier O 
dysfunction O 
and O 
overproduction O 
of O 
IL-8 O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
In O 
the O 
inflamed O 
cells O 
, O 
incubation O 
with O 
nondigested O 
samples O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
the O 
production O 
of O 
IL-8 O 
and O 
NO B-FORMULA 
compared O 
with O 
digested O 
samples O 
. O 
ROS O 
production O 
increased O 
in O 
the O 
inflamed O 
cells O 
exposed O 
to O 
digested O 
commercial O 
red O 
fruit O 
juice O 
( O 
86.8±1.3% O 
) O 
compared O 
with O 
fresh O 
juice O 
( O 
77.4±0.8% O 
) O 
and O 
increased O 
in O 
the O 
inflamed O 
cells O 
exposed O 
to O 
digested O 
enriched O 
red O 
fruit O 
juice O 
( O 
82.6±1.6% O 
) O 
compared O 
with O 
the O 
fresh O 
enriched O 
juice O 
( O 
55.8±6% O 
) O 
. O 
The O 
anti-inflammatory O 
properties O 
of O 
PBE O 
- O 
enriched O 
fruit O 
juices O 
decreased O 
after O 
digestion O 
; O 
further O 
research O 
on O 
the O 
bioavailability O 
of O 
the O 
assayed O 
compounds O 
is O 
needed O 
to O 
properly O 
assess O 
their O 
usefulness O 
for O 
the O 
treatment O 
of O 
gut O 
inflammation O 
. O 

of O 
D-penicillamine B-TRIVIAL 
, O 
a O 
sequestering O 
acetaldehyde B-SYSTEMATIC 
agent O 
, O 
in O 
the O 
prevention O 
of O 
alcohol B-FAMILY 
relapse O 
- O 
like O 
drinking O 
in O 
rats O 
. O 

: O 
Nowadays O 
, O 
very O 
few O 
approved O 
anti-relapse O 
treatments O 
for O 
alcoholism O 
exist O 
, O 
and O 
their O 
overall O 
efficacy O 
can O 
be O 
considered O 
moderate O 
. O 
An O 
exciting O 
rationale O 
drug O 
development O 
opportunity O 
for O 
the O 
treatment O 
of O 
chronic O 
alcoholism O 
is O 
the O 
use O 
of O 
acetaldehyde B-SYSTEMATIC 
sequestering O 
agents O 
. O 
Although O 
these O 
compounds O 
are O 
able O 
to O 
attenuate O 
or O 
prevent O 
most O 
of O 
the O 
behavioral O 
and O 
neurochemical O 
effects O 
of O 
ethanol B-SYSTEMATIC 
, O 
the O 
efficacy O 
of O 
acetaldehyde B-SYSTEMATIC 
sequestration O 
, O 
by O 
using O 
agents O 
such O 
as O 
D-penicillamine B-TRIVIAL 
( O 
DP O 
) O 
, O 
in O 
relapse O 
prevention O 
has O 
not O 
been O 
studied O 
yet O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
analyze O 
the O 
effects O 
of O 
DP O 
treatment O 
on O 
the O 
alcohol B-FAMILY 
deprivation O 
effect O 
( O 
ADE O 
) O 
in O 
long O 
- O 
term O 
ethanol B-SYSTEMATIC 
-experienced O 
rats O 
as O 
a O 
model O 
of O 
relapse O 
behavior O 
and O 
measure O 
drug O 
plasma O 
and O 
brain O 
levels O 
during O 
treatment O 
. O 
METHODS O 
: O 
Rats O 
were O 
subcutaneously O 
implanted O 
with O 
mini O 
- O 
osmotic O 
pumps O 
delivering O 
0 O 
, O 
0.25 O 
, O 
or O 
1 O 
mg O 
/ O 
h O 
of O 
DP O 
during O 
1 O 
week O 
. O 
The O 
efficacy O 
to O 
prevent O 
ADE O 
was O 
determined O 
. O 
DP O 
plasma O 
and O 
brain O 
levels O 
achieved O 
during O 
its O 
subcutaneous O 
administration O 
were O 
measured O 
. O 
In O 
a O 
second O 
experiment O 
, O 
animals O 
received O 
bilateral O 
infusions O 
of O 
0 O 
or O 
1.5 O 
μg O 
/ O 
h O 
of O 
DP O 
directly O 
into O 
pVTA O 
, O 
and O 
the O 
appearance O 
of O 
ADE O 
was O 
evaluated O 
. O 
RESULTS O 
: O 
One O 
milligram O 
per O 
hour O 
, O 
but O 
not O 
0.25 O 
mg O 
/ O 
h O 
, O 
DP O 
infusion O 
prevented O 
ADE O 
and O 
reduced O 
the O 
total O 
ethanol B-SYSTEMATIC 
preference O 
in O 
animals O 
. O 
DP O 
plasma O 
concentrations O 
associated O 
with O 
ADE O 
suppression O 
were O 
around O 
3-4 O 
μg O 
/ O 
ml O 
, O 
and O 
brain O 
DP O 
levels O 
in O 
these O 
conditions O 
were O 
about O 
2-3 O 
% O 
of O 
those O 
found O 
in O 
plasma O 
. O 
Intra-pVTA O 
DP O 
administration O 
also O 
suppressed O 
ADE O 
. O 
CONCLUSION O 
: O 
DP O 
is O 
able O 
to O 
prevent O 
alcohol B-FAMILY 
-relapse O 
- O 
like O 
drinking O 
in O 
rats O 
suggesting O 
that O 
this O 
drug O 
may O 
be O 
a O 
useful O 
new O 
tool O 
in O 
the O 
management O 
of O 
relapse O 
in O 
alcohol B-FAMILY 
-dependent O 
patients O 
. O 

Background O 
: O 
Organic O 
porous O 
material O 
is O 
a O 
promising O 
carrier O 
for O 
enhancing O 
the O 
dissolution O 
of O 
poorly O 
water O 
soluble O 
drug O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
enhance O 
dissolution O 
and O 
oral O 
bioavailability O 
of O 
lovastatin B-TRIVIAL 
( O 
LV O 
) O 
by O 
preparing O 
a O 
porous O 
starch O 
microsphere O 
foam O 
( O 
PSM O 
) O 
using O 
a O 
novel O 
method O 
, O 
meanwhile O 
, O 
looking O 
into O 
the O 
mechanism O 
of O 
improving O 
dissolution O 
of O 
LV O 
. O 
Methods O 
: O 
PSM O 
was O 
prepared O 
by O 
the O 
W O 
/ O 
O O 
emulsion O 
- O 
freeze O 
thawing O 
method O 
. O 
The O 
porous O 
structure O 
of O 
PSM O 
was O 
characterized O 
by O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
and O 
nitrogen B-SYSTEMATIC 
adsorption O 
/ O 
desorption O 
analysis O 
. O 
The O 
adsorption O 
role O 
of O 
nanopores O 
on O 
the O 
drug O 
dissolution O 
and O 
physical O 
state O 
of O 
LV O 
was O 
systematically O 
studied O 
by O 
instrumental O 
analysis O 
, O 
and O 
in O 
vitro O 
and O 
in O 
vivo O 
drug O 
dissolution O 
studies O 
. O 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
was O 
used O 
to O 
evaluate O 
carrier O 
cytotoxicity O 
. O 
Results O 
: O 
The O 
SEM O 
images O 
of O 
PSM O 
showed O 
nanometer O 
- O 
sized O 
pores O 
. O 
Physical O 
state O 
characterization O 
indicated O 
that O 
porous O 
structure O 
effectively O 
limited O 
the O 
degree O 
of O 
crystallinity O 
of O 
LV O 
. O 
The O 
results O 
of O 
in O 
vitro O 
and O 
in O 
vivo O 
tests O 
testified O 
that O 
PSM O 
accelerated O 
the O 
release O 
of O 
LV O 
and O 
enhanced O 
its O 
oral O 
bioavailability O 
in O 
comparison O 
with O 
crude O 
LV O 
and O 
commercial O 
capsules O 
. O 
The O 
loaded O 
PSM O 
powder O 
indicated O 
a O 
good O 
physical O 
stability O 
under O 
storage O 
for O 
12 O 
months O 
. O 
MTT B-ABBREVIATION 
assay O 
shows O 
PSM O 
has O 
no O 
toxicity O 
for O 
Caco-2 O 
cell O 
. O 
Conclusion O 
: O 
The O 
preparation O 
was O 
a O 
promising O 
method O 
to O 
produce O 
small O 
and O 
uniform O 
PSM O 
with O 
markedly O 
enhanced O 
dissolution O 
rate O 
and O 
oral O 
bioavailability O 
due O 
to O 
the O 
spatial O 
confinement O 
effect O 
of O 
porous O 
structure O 
. O 
The O 
present O 
work O 
demonstrates O 
the O 
significant O 
potential O 
for O 
the O 
use O 
of O 
PSM O 
as O 
a O 
novel O 
delivery O 
system O 
for O 
poorly O 
water O 
soluble O 
drugs O 
. O 

address O 
the O 
growing O 
interest O 
of O 
consumers O 
for O 
information O 
on O 
the O 
provenance O 
of O 
foodstuffs O 
, O 
the O 
production O 
chain O 
of O 
world O 
renowned O 
Moscato O 
d'Asti O 
white O 
wine O 
has O 
been O 
studied O 
using O 
the O 
distribution O 
of O 
lanthanides B-FAMILY 
as O 
chemical O 
markers O 
. O 
From O 
soil O 
to O 
must O 
, O 
upon O 
every O 
stage O 
of O 
the O 
chain O 
, O 
samples O 
have O 
been O 
taken O 
and O 
analysed O 
with O 
ICP-MS O 
in O 
order O 
to O 
verify O 
whether O 
the O 
original O 
fingerprint O 
of O 
soil O 
is O 
maintained O 
or O 
not O 
along O 
the O 
chain O 
. O 
Results O 
of O 
this O 
traceability O 
study O 
show O 
clearly O 
that O 
lanthanides B-FAMILY 
fingerprint O 
is O 
kept O 
unaltered O 
in O 
the O 
passage O 
soil O 
- O 
grapes O 
- O 
must O 
, O 
while O 
fractionation O 
occurs O 
upon O 
wine O 
clarifying O 
with O 
bentonites B-FAMILY 
. O 
The O 
second O 
part O 
of O 
the O 
work O 
involves O 
a O 
study O 
on O 
102 O 
samples O 
of O 
Moscato O 
d'Asti O 
musts O 
in O 
order O 
to O 
verify O 
how O 
they O 
reflect O 
the O 
features O 
of O 
the O 
different O 
geographical O 
zones O 
where O 
they O 
come O 
from O 
, O 
and O 
to O 
build O 
a O 
basis O 
to O 
be O 
able O 
to O 
identify O 
possible O 
adulterations O 
performed O 
by O 
addition O 
of O 
foreign O 
musts O 
. O 

the O 
UGT1A O 
haplotype O 
associated O 
with O 
irinotecan B-TRIVIAL 
-induced O 
hematological O 
toxicity O 
in O 
metastatic O 
colorectal O 
cancer O 
patients O 
treated O 
with O 
5-fluorouracil B-SYSTEMATIC 
/ O 
irinotecan B-TRIVIAL 
-based O 
regimens O 
. O 

the O 
importance O 
of O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
1A1*28 O 
in O 
irinotecan B-TRIVIAL 
pharmacogenetics O 
, O 
our O 
capability O 
to O 
predict O 
drug O 
- O 
induced O 
severe O 
toxicity O 
remains O 
limited O 
. O 
We O 
aimed O 
at O 
identifying O 
novel O 
genetic O 
markers O 
that O 
would O 
improve O 
prediction O 
of O 
irinotecan B-TRIVIAL 
toxicity O 
and O 
response O 
in O 
advanced O 
colorectal O 
cancer O 
patients O 
treated O 
with O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
leucovorin B-TRIVIAL 
) O 
, O 
fluorouracil B-SYSTEMATIC 
( O 
5-FU B-SYSTEMATIC 
) O 
, O 
and O 
irinotecan B-TRIVIAL 
( O 
camptosar B-TRIVIAL 
) O 
- O 
based O 
regimens O 
. O 
The O 
relationships O 
between O 
UGT1A O 
candidate O 
markers O 
across O 
the O 
gene O 
( O 
n O 
= O 
21 O 
) O 
and O 
toxicity O 
were O 
prospectively O 
evaluated O 
in O 
167 O 
patients O 
. O 
We O 
included O 
variants O 
in O 
the O 
3'untranscribed O 
region O 
( O 
3'UTR O 
) O 
of O 
the O 
UGT1A O 
locus O 
, O 
not O 
studied O 
in O 
this O 
context O 
yet O 
. O 
These O 
genetic O 
markers O 
were O 
further O 
investigated O 
in O 
250 O 
Italian O 
FOLFIRI B-TRIVIAL 
-treated O 
patients O 
. O 
Several O 
functional O 
UGT1A O 
variants O 
, O 
including O 
UGT1A1*28 O 
, O 
significantly O 
influenced O 
risk O 
of O 
severe O 
hematologic O 
toxicity O 
. O 
As O 
previously O 
reported O 
in O 
the O 
Italian O 
cohort O 
, O 
a O 
5-marker O 
risk O 
haplotype O 
[ O 
haplotype O 
II O 
( O 
HII O 
) O 
; O 
UGTs O 
1A9 O 
/ O 
1A7 O 
/ O 
1A1 O 
] O 
was O 
associated O 
with O 
severe O 
neutropenia O 
in O 
our O 
cohort O 
[ O 
odds O 
ratio O 
( O 
OR O 
) O 
= O 
2.43 O 
; O 
P O 
= O 
0.004 O 
] O 
. O 
The O 
inclusion O 
of O 
a O 
3'UTR O 
single O 
- O 
nucleotide O 
polymorphism O 
( O 
SNP O 
) O 
permitted O 
refinement O 
of O 
the O 
previously O 
defined O 
HI O 
, O 
in O 
which O 
HIa O 
was O 
associated O 
with O 
the O 
absence O 
of O 
severe O 
neutropenia O 
in O 
combined O 
cohorts O 
( O 
OR O 
= O 
0.55 O 
; O 
P O 
= O 
0.038 O 
) O 
. O 
Among O 
all O 
tested O 
UGT1A O 
variations O 
and O 
upon O 
multivariate O 
analyses O 
, O 
no O 
UGT1A1 O 
SNPs O 
remained O 
significant O 
, O 
whereas O 
three O 
SNPs O 
located O 
in O 
the O 
central O 
region O 
of O 
UGT1A O 
were O 
linked O 
to O 
neutropenia O 
grade O 
3-4 O 
. O 
Haplotype O 
analyses O 
of O 
these O 
markers O 
with O 
the O 
3'UTR O 
SNP O 
allowed O 
the O 
identification O 
of O 
a O 
protective O 
HI O 
( O 
OR O 
= O 
0.5 O 
; O 
P O 
= O 
0.048 O 
) O 
and O 
two O 
risk O 
haplotypes O 
, O 
HII O 
and O 
HIII O 
, O 
characterized O 
by O 
2 O 
and O 
3 O 
unfavorable O 
alleles O 
, O 
respectively O 
, O 
revealing O 
a O 
dosage O 
effect O 
( O 
ORs O 
of O 
2.15 O 
and O 
5.28 O 
; O 
P O 
≤ O 
0.03 O 
) O 
. O 
Our O 
results O 
suggest O 
that O 
specific O 
SNPs O 
in O 
UGT1A O 
, O 
other O 
than O 
UGT1A1*28 O 
, O 
may O 
influence O 
irinotecan B-TRIVIAL 
toxicity O 
and O 
should O 
be O 
considered O 
to O 
refine O 
pharmacogenetic O 
testing O 
. O 

lipid O 
nanoparticles O 
are O 
promising O 
drug O 
delivery O 
vehicles O 
, O 
passive O 
release O 
of O 
encapsulated O 
contents O 
at O 
the O 
target O 
site O 
is O 
often O 
slow O 
. O 
Herein O 
, O 
we O 
report O 
contents O 
release O 
from O 
targeted O 
, O 
polymer O 
- O 
coated O 
, O 
echogenic O 
lipid O 
nanoparticles O 
in O 
the O 
cell O 
cytoplasm O 
by O 
redox O 
trigger O 
and O 
simultaneously O 
enhanced O 
by O 
diagnostic O 
frequency O 
ultrasound O 
. O 
The O 
lipid O 
nanoparticles O 
were O 
polymerized O 
on O 
the O 
external O 
leaflet O 
using O 
a O 
disulfide B-SYSTEMATIC 
cross O 
- O 
linker O 
. O 
In O 
the O 
presence O 
of O 
cytosolic O 
concentrations O 
of O 
glutathione B-TRIVIAL 
, O 
the O 
lipid O 
nanoparticles O 
released O 
76% O 
of O 
encapsulated O 
contents O 
. O 
Plasma O 
concentrations O 
of O 
glutathione B-TRIVIAL 
failed O 
to O 
release O 
the O 
encapsulated O 
contents O 
. O 
Application O 
of O 
3 O 
MHz O 
ultrasound O 
for O 
2 O 
min O 
simultaneously O 
with O 
the O 
reducing O 
agent O 
enhanced O 
the O 
release O 
to O 
96% O 
. O 
Folic B-TRIVIAL 
acid I-TRIVIAL 
conjugated O 
, O 
doxorubicin B-TRIVIAL 
-loaded O 
nanoparticles O 
showed O 
enhanced O 
uptake O 
and O 
higher O 
cytotoxicity O 
in O 
cancer O 
cells O 
overexpressing O 
the O 
folate B-TRIVIAL 
receptor O 
( O 
compared O 
to O 
the O 
control O 
) O 
. O 
With O 
further O 
developments O 
, O 
these O 
lipid O 
nanoparticles O 
have O 
the O 
potential O 
to O 
be O 
used O 
as O 
multimodal O 
nanocarriers O 
for O 
simultaneous O 
targeted O 
drug O 
delivery O 
and O 
ultrasound O 
imaging O 
. O 

Sec7 O 
Guanine B-TRIVIAL 
Nucleotide B-FAMILY 
Exchange O 
Factor O 
GBF1 O 
Regulates O 
Membrane O 
Recruitment O 
of O 
BIG1 O 
and O 
BIG2 O 
Guanine B-TRIVIAL 
Nucleotide B-FAMILY 
Exchange O 
Factors O 
to O 
the O 
Trans-Golgi O 
Network O 
( O 
TGN O 
) O 
. O 

Sec7 O 
guanine B-TRIVIAL 
nucleotide B-FAMILY 
exchange O 
factors O 
( O 
GEFs O 
) O 
activate O 
ADP B-ABBREVIATION 
-ribosylation O 
factors O 
( O 
ARFs O 
) O 
to O 
facilitate O 
coating O 
of O 
transport O 
vesicles O 
within O 
the O 
secretory O 
and O 
endosomal O 
pathways O 
. O 
GBF1 O 
recruits O 
COPI O 
to O 
pre-Golgi O 
and O 
Golgi O 
compartments O 
, O 
whereas O 
BIG1 O 
and O 
BIG2 O 
recruit O 
AP1 O 
and O 
GGA O 
clathrin O 
adaptors O 
to O 
the O 
trans-Golgi O 
network O 
( O 
TGN O 
) O 
and O 
endosomes O 
. O 
Here O 
, O 
we O 
report O 
a O 
functional O 
cascade O 
between O 
these O 
GEFs O 
by O 
showing O 
that O 
GBF1-activated O 
ARFs O 
( O 
ARF4 O 
and O 
ARF5 O 
, O 
but O 
not O 
ARF3 O 
) O 
facilitate O 
BIG1 O 
and O 
BIG2 O 
recruitment O 
to O 
the O 
TGN O 
. O 
We O 
localize O 
GBF1 O 
ultrastructurally O 
to O 
the O 
pre-Golgi O 
, O 
the O 
Golgi O 
, O 
and O 
also O 
the O 
TGN O 
. O 
Our O 
findings O 
suggest O 
a O 
model O 
in O 
which O 
GBF1 O 
localized O 
within O 
pre-Golgi O 
and O 
Golgi O 
compartments O 
mediates O 
ARF O 
activation O 
to O 
facilitate O 
recruitment O 
of O 
COPI O 
to O 
membranes O 
, O 
whereas O 
GBF1 O 
localized O 
at O 
the O 
TGN O 
mediates O 
ARF O 
activation O 
that O 
leads O 
to O 
the O 
recruitment O 
of O 
BIG1 O 
and O 
BIG2 O 
to O 
the O 
TGN O 
. O 
Membrane O 
- O 
associated O 
BIG1 O 
/ O 
2 O 
then O 
activates O 
ARFs O 
that O 
recruit O 
clathrin O 
adaptors O 
. O 
In O 
this O 
cascade O 
, O 
an O 
early O 
acting O 
GEF O 
( O 
GBF1 O 
) O 
activates O 
ARFs O 
that O 
mediate O 
recruitment O 
of O 
late O 
acting O 
GEFs O 
( O 
BIG1 O 
/ O 
2 O 
) O 
to O 
coordinate O 
coating O 
events O 
within O 
the O 
pre-Golgi O 
/ O 
Golgi O 
/ O 
TGN O 
continuum O 
. O 
Such O 
coordination O 
may O 
optimize O 
the O 
efficiency O 
and O 
/ O 
or O 
selectivity O 
of O 
cargo O 
trafficking O 
through O 
the O 
compartments O 
of O 
the O 
secretory O 
pathway O 
. O 

the O 
photocatalytic O 
activity O 
of O 
anatase O 
TiO2 B-FORMULA 
by O 
improving O 
the O 
specific O 
facet O 
- O 
induced O 
spontaneous O 
separation O 
of O 
photogenerated O 
electrons O 
and O 
holes O 
. O 

, O 
it O 
has O 
been O 
proven O 
that O 
directional O 
flow O 
of O 
photogenerated O 
charge O 
carriers O 
occurs O 
on O 
specific O 
facets O 
of O 
TiO(2) B-FORMULA 
nanocrystals O 
. O 
Herein O 
, O 
we O 
demonstrate O 
that O 
the O 
photocatalytic O 
activity O 
of O 
anatase O 
TiO(2) B-FORMULA 
nanocrystals O 
in O 
both O 
photoreduction O 
and O 
photooxidation O 
processes O 
can O 
be O 
enhanced O 
by O 
selectively O 
depositing O 
Pt B-FORMULA 
nanoparticles O 
on O 
the O 
{ O 
101 O 
} O 
facets O 
, O 
which O 
strengthens O 
spontaneously O 
surface O 
- O 
induced O 
separation O 
between O 
photogenerated O 
electrons O 
and O 
holes O 
in O 
the O 
photocatalysis O 
process O 
. O 
An O 
optimal O 
ratio O 
of O 
the O 
oxidative O 
{ O 
1 O 
} O 
facets O 
to O 
the O 
reductive O 
{ O 
101 O 
} O 
facets O 
exists O 
with O 
regard O 
to O 
the O 
photocatalysis O 
of O 
the O 
faceted O 
TiO(2) B-FORMULA 
nanocrystals O 
, O 
and O 
this O 
is O 
crucial O 
for O 
balancing O 
the O 
recombination O 
and O 
redox O 
reaction O 
rates O 
of O 
photogenerated O 
electrons O 
and O 
holes O 
. O 
The O 
present O 
work O 
might O 
help O 
us O 
gain O 
deeper O 
insight O 
into O 
the O 
relation O 
between O 
the O 
specific O 
surface O 
of O 
semiconductor O 
photocatalysts O 
and O 
their O 
photocatalytic O 
activities O 
and O 
provides O 
us O 
with O 
a O 
new O 
route O 
to O 
design O 
photocatalysts O 
with O 
high O 
photocatalytic O 
activity O 
. O 

of O 
leishmaniasis O 
part O 
X O 
: O 
synthesis O 
and O 
bioevaluation O 
of O 
novel O 
terpenyl B-FAMILY 
heterocycles I-FAMILY 
. O 

novel O 
α B-MULTIPLE 
and I-MULTIPLE 
β I-MULTIPLE 
ionone I-MULTIPLE 
based O 
chalcones B-FAMILY 
and O 
their O 
dihydropyrazolidines B-FAMILY 
/ O 
pyrazolidines B-FAMILY 
have O 
been O 
synthesized O 
and O 
evaluated O 
for O 
their O 
in O 
vitro O 
and O 
in O 
vivo O 
antileishmanial O 
activities O 
against O 
Leishmania O 
donovani O 
. O 
Amongest O 
all O 
, O 
one O 
compound O 
( O 
4d O 
) O 
exhibited O 
significant O 
in O 
vitro O 
activity O 
against O 
intracellular O 
amastigotes O 
of O 
Leishmania O 
donovani O 
with O 
IC(50) O 
values O 
of O 
7.49 O 
μM O 
and O 
was O 
found O 
promising O 
as O 
compared O 
to O 
reference O 
drug O 
, O 
miltefosine B-TRIVIAL 
. O 
On O 
the O 
basis O 
of O 
good O 
Selectivity O 
Index O 
( O 
S.I O 
. O 
) O 
, O 
the O 
compound O 
was O 
further O 
tested O 
for O 
its O 
in O 
vivo O 
response O 
against O 
Leishmania O 
donovani O 
/ O 
hamster O 
model O 
and O 
has O 
shown O 
significant O 
inhibition O 
of O 
parasite O 
multiplication O 
( O 
81% O 
) O 
. O 
The O 
present O 
study O 
has O 
helped O 
us O 
in O 
identifying O 
a O 
new O 
lead O 
that O 
could O 
be O 
exploited O 
as O 
a O 
potential O 
antileishmanial O 
agent O 
. O 

guanide B-SYSTEMATIC 
compounds O 
which O 
bind O 
the O 
CXCR4 O 
co O 
- O 
receptor O 
and O 
inhibit O 
HIV-1 O 
infection O 
. O 

G O 
- O 
protein O 
coupled O 
receptor O 
CXCR4 O 
is O 
a O 
co O 
- O 
receptor O 
for O 
HIV-1 O 
infection O 
and O 
is O 
involved O 
in O 
signaling O 
cell O 
migration O 
and O 
proliferation O 
. O 
In O 
a O 
previous O 
study O 
of O 
non O 
- O 
peptide O 
, O 
guanide B-SYSTEMATIC 
-based O 
CXCR4 O 
- O 
binding O 
compounds O 
, O 
spermine B-MULTIPLE 
and I-MULTIPLE 
spermidine I-MULTIPLE 
phenylguanides I-MULTIPLE 
inhibited O 
HIV-1 O 
entry O 
at O 
low O 
micromolar O 
concentrations O 
. O 
Subsequently O 
, O 
crystal O 
structures O 
of O 
CXCR4 O 
were O 
used O 
to O 
dock O 
a O 
series O 
of O 
naphthylguanide B-SYSTEMATIC 
derivatives O 
of O 
the O 
polyamines B-FAMILY 
spermidine B-TRIVIAL 
and O 
spermine B-TRIVIAL 
. O 
Synthesis O 
and O 
evaluation O 
of O 
the O 
naphthylguanide B-SYSTEMATIC 
compounds O 
identified O 
our O 
best O 
compound O 
, O 
spermine B-SYSTEMATIC 
tris-1-naphthylguanide I-SYSTEMATIC 
, O 
which O 
bound O 
CXCR4 O 
with O 
an O 
IC(50) O 
of O 
40 O 
nM O 
and O 
inhibited O 
the O 
infection O 
of O 
TZM-bl O 
cells O 
with O 
X4 O 
, O 
but O 
not O 
R5 O 
, O 
strains O 
of O 
HIV-1 O 
with O 
an O 
IC(50) O 
of O 
50-100 O 
nM O 
. O 

: O 
A O 
Negative O 
Regulator O 
of O 
Basal O 
Glucose B-TRIVIAL 
-Stimulated O 
Insulin O 
Secretion O 
. O 

fasting O 
blood O 
glucose B-TRIVIAL 
( O 
FBG O 
) O 
is O 
associated O 
with O 
increased O 
risk O 
for O 
the O 
development O 
of O 
type O 
2 O 
diabetes O 
and O 
cardiovascular O 
- O 
associated O 
mortality O 
. O 
Genome O 
- O 
wide O 
association O 
studies O 
( O 
GWAS O 
) O 
have O 
linked O 
polymorphisms O 
in O 
G6PC2 O 
with O 
variations O 
in O 
FBG O 
and O 
body O 
fat O 
, O 
although O 
not O 
insulin O 
sensitivity O 
or O 
glucose B-TRIVIAL 
tolerance O 
. O 
G6PC2 O 
encodes O 
an O 
islet O 
- O 
specific O 
, O 
endoplasmic O 
reticulum O 
- O 
resident O 
glucose B-TRIVIAL 
-6-phosphatase O 
catalytic O 
subunit O 
. O 
A O 
combination O 
of O 
in O 
situ O 
perfused O 
pancreas O 
, O 
in O 
vitro O 
isolated O 
islet O 
, O 
and O 
in O 
vivo O 
analyses O 
were O 
used O 
to O 
explore O 
the O 
function O 
of O 
G6pc2 O 
in O 
mice O 
. O 
G6pc2 O 
deletion O 
had O 
little O 
effect O 
on O 
insulin O 
sensitivity O 
and O 
glucose B-TRIVIAL 
tolerance O 
, O 
whereas O 
body O 
fat O 
was O 
reduced O 
in O 
female O 
G6pc2 O 
knockout O 
( O 
KO O 
) O 
mice O 
on O 
both O 
a O 
chow O 
and O 
high O 
- O 
fat O 
diet O 
, O 
observations O 
that O 
are O 
all O 
consistent O 
with O 
human O 
GWAS O 
data O 
. O 
G6pc2 O 
deletion O 
resulted O 
in O 
a O 
leftward O 
shift O 
in O 
the O 
dose O 
- O 
response O 
curve O 
for O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
( O 
GSIS O 
) O 
. O 
As O 
a O 
consequence O 
, O 
under O 
fasting O 
conditions O 
in O 
which O 
plasma O 
insulin O 
levels O 
were O 
identical O 
, O 
blood O 
glucose B-TRIVIAL 
levels O 
were O 
reduced O 
in O 
G6pc2 O 
KO O 
mice O 
, O 
again O 
consistent O 
with O 
human O 
GWAS O 
data O 
. O 
Glucose B-TRIVIAL 
-6-phosphatase O 
activity O 
was O 
reduced O 
, O 
whereas O 
basal O 
cytoplasmic O 
calcium B-SYSTEMATIC 
levels O 
were O 
elevated O 
in O 
islets O 
isolated O 
from O 
G6pc2 O 
KO O 
mice O 
. O 
These O 
data O 
suggest O 
that O 
G6pc2 O 
represents O 
a O 
novel O 
, O 
negative O 
regulator O 
of O 
basal O 
GSIS O 
that O 
acts O 
by O 
hydrolyzing O 
glucose-6-phosphate B-SYSTEMATIC 
, O 
thereby O 
reducing O 
glycolytic O 
flux O 
. O 

is O 
a O 
metabolic O 
sensor O 
that O 
helps O 
maintain O 
cellular O 
energy O 
homeostasis O 
. O 
Despite O 
evidence O 
linking O 
AMPK O 
with O 
tumor O 
suppressor O 
functions O 
, O 
the O 
role O 
of O 
AMPK O 
in O 
tumorigenesis O 
and O 
tumor O 
metabolism O 
is O 
unknown O 
. O 
Here O 
we O 
show O 
that O 
AMPK O 
negatively O 
regulates O 
aerobic O 
glycolysis O 
( O 
the O 
Warburg O 
effect O 
) O 
in O 
cancer O 
cells O 
and O 
suppresses O 
tumor O 
growth O 
in O 
vivo O 
. O 
Genetic O 
ablation O 
of O 
the O 
α1 O 
catalytic O 
subunit O 
of O 
AMPK O 
accelerates O 
Myc O 
- O 
induced O 
lymphomagenesis O 
. O 
Inactivation O 
of O 
AMPKα O 
in O 
both O 
transformed O 
and O 
nontransformed O 
cells O 
promotes O 
a O 
metabolic O 
shift O 
to O 
aerobic O 
glycolysis O 
, O 
increased O 
allocation O 
of O 
glucose B-TRIVIAL 
carbon B-SYSTEMATIC 
into O 
lipids O 
, O 
and O 
biomass O 
accumulation O 
. O 
These O 
metabolic O 
effects O 
require O 
normoxic O 
stabilization O 
of O 
the O 
hypoxia O 
- O 
inducible O 
factor-1α O 
( O 
HIF-1α O 
) O 
, O 
as O 
silencing O 
HIF-1α O 
reverses O 
the O 
shift O 
to O 
aerobic O 
glycolysis O 
and O 
the O 
biosynthetic O 
and O 
proliferative O 
advantages O 
conferred O 
by O 
reduced O 
AMPKα O 
signaling O 
. O 
Together O 
our O 
findings O 
suggest O 
that O 
AMPK O 
activity O 
opposes O 
tumor O 
development O 
and O 
that O 
its O 
loss O 
fosters O 
tumor O 
progression O 
in O 
part O 
by O 
regulating O 
cellular O 
metabolic O 
pathways O 
that O 
support O 
cell O 
growth O 
and O 
proliferation O 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
cause O 
neurobehavioral O 
toxicity O 
, O 
but O 
their O 
effects O 
on O 
visual O 
behavior O 
remain O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
impact O 
of O 
PBDEs B-ABBREVIATION 
on O 
visual O 
behavior O 
was O 
examined O 
using O 
optokinetic O 
responses O 
and O 
phototaxis O 
in O 
zebrafish O 
larvae O 
. O 
Zebrafish O 
embryos O 
were O 
exposed O 
to O 
pentabrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
mixture O 
( O 
DE-71 O 
) O 
at O 
concentrations O 
of O 
0 O 
, O 
0.32 O 
, O 
3.58 O 
, O 
and O 
31 O 
µg O 
/ O 
L O 
until O 
15 O 
d O 
postfertilization O 
. O 
The O 
authors O 
then O 
assessed O 
photoreceptor O 
opsin O 
expression O 
, O 
retinal O 
histology O 
, O 
and O 
visual O 
behavior O 
of O 
the O 
larvae O 
. O 
The O 
results O 
showed O 
that O 
the O 
transcriptions O 
of O 
the O 
opsin O 
genes O 
, O 
zfrho O 
and O 
zfgr1 O 
, O 
were O 
significantly O 
upregulated O 
. O 
Western O 
blotting O 
further O 
demonstrated O 
a O 
significant O 
increase O 
in O 
rhodopsin O 
protein O 
expression O 
after O 
exposure O 
of O 
the O 
larvae O 
to O 
DE-71 O 
. O 
Histological O 
examination O 
revealed O 
the O 
following O 
morphological O 
alterations O 
in O 
the O 
retina O 
: O 
increased O 
area O 
of O 
inner O 
nuclear O 
layer O 
, O 
decreased O 
area O 
of O 
inner O 
plexiform O 
layer O 
, O 
and O 
decreased O 
density O 
of O 
ganglion O 
cells O 
. O 
Tests O 
of O 
optokinetic O 
and O 
phototactic O 
behavior O 
showed O 
hyperactive O 
responses O 
on O 
exposure O 
to O 
DE-71 O 
, O 
including O 
increased O 
saccadic O 
eye O 
movements O 
and O 
phototactic O 
response O 
. O 
The O 
present O 
study O 
is O 
the O 
first O 
to O 
demonstrate O 
that O 
the O 
acute O 
exposure O 
of O 
zebrafish O 
larvae O 
to O 
DE-71 O 
causes O 
biochemical O 
and O 
structural O 
changes O 
in O 
the O 
eye O 
that O 
lead O 
to O 
behavioral O 
alterations O 
. O 
Analysis O 
of O 
these O 
visual O 
behavioral O 
paradigms O 
may O 
be O 
useful O 
in O 
predicting O 
the O 
adverse O 
effects O 
of O 
toxicants O 
on O 
visual O 
function O 
in O 
fish O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1370-1375 O 
. O 
© O 
2013 O 
SETAC O 
. O 

: O 
Coronary O 
flow O 
reserve O 
( O 
CFR O 
) O 
provides O 
independent O 
prognostic O 
information O 
in O 
diabetic O 
patients O 
with O 
known O 
or O 
suspected O 
coronary O 
artery O 
disease O 
. O 
However O 
, O 
there O 
have O 
been O 
no O 
substantial O 
data O 
to O 
evaluate O 
CFR O 
in O 
prediabetics O 
. O 
Accordingly O 
, O 
we O 
aimed O 
to O 
evaluate O 
CFR O 
in O 
subjects O 
with O 
prediabetes O 
using O 
second O 
harmonic O 
transthoracic O 
Doppler O 
echocardiography O 
. O 
METHODS O 
AND O 
RESULTS O 
: O 
We O 
measured O 
CFR O 
of O 
65 O 
subjects O 
with O 
prediabetes O 
, O 
45 O 
patients O 
with O 
overt O 
type O 
2 O 
diabetes O 
, O 
and O 
43 O 
sex O 
and O 
age O 
matched O 
normoglycemic O 
healthy O 
subjects O 
with O 
normal O 
glucose B-TRIVIAL 
tolerance O 
. O 
Ages O 
, O 
gender O 
, O 
existence O 
of O 
hypertension O 
or O 
hypercholesterolemia O 
, O 
smoking O 
status O 
were O 
similar O 
among O 
the O 
groups O 
. O 
CFR O 
was O 
significantly O 
lower O 
in O 
diabetics O 
( O 
2.15±0.39 O 
) O 
than O 
in O 
prediabetics O 
( O 
2.39±0.45 O 
) O 
and O 
controls O 
( O 
2.75±0.35 O 
) O 
; O 
in O 
addition O 
, O 
it O 
was O 
significantly O 
lower O 
in O 
prediabetics O 
than O 
controls O 
. O 
Only O 
2 O 
( O 
5% O 
) O 
of O 
control O 
subjects O 
had O 
abnormal O 
CFR O 
( O 
< O 
2 O 
) O 
but O 
11 O 
( O 
17% O 
) O 
prediabetic O 
subjects O 
and O 
19 O 
( O 
42% O 
) O 
diabetic O 
patients O 
had O 
abnormal O 
CFR O 
. O 
We O 
found O 
that O 
only O 
age O 
( O 
β=-0.31 O 
, O 
P O 
< O 
0.01 O 
) O 
and O 
presence O 
of O 
the O 
diabetes O 
( O 
β=-0.57 O 
, O 
P O 
< O 
0.01 O 
) O 
were O 
significant O 
predictors O 
of O 
lower O 
CFR O 
in O 
a O 
multivariable O 
model O 
that O 
adjusted O 
for O 
other O 
variables O 
. O 
CFR O 
was O 
significantly O 
and O 
inversely O 
correlated O 
with O 
age O 
( O 
r=-0.15 O 
, O 
P=0.04 O 
) O 
, O 
fasting O 
glucose B-TRIVIAL 
level O 
( O 
r=-0.27 O 
, O 
P=0.001 O 
) O 
, O 
postprandial O 
glucose B-TRIVIAL 
level O 
( O 
r=0.43 O 
, O 
P O 
< O 
0.001 O 
) O 
, O 
hemoglobin O 
A1C O 
level O 
( O 
r=-0.34 O 
, O 
P O 
< O 
0.001 O 
) O 
, O 
LDL O 
cholesterol B-TRIVIAL 
level O 
( O 
r=0.22 O 
, O 
P=0.009 O 
) O 
, O 
mitral O 
A O 
velocity O 
( O 
r=-0.27 O 
, O 
P=0.001 O 
) O 
and O 
Tei O 
index O 
( O 
r=-0.19 O 
, O 
P=0.02 O 
) O 
, O 
whereas O 
mitral O 
E O 
/ O 
A O 
ratio O 
, O 
mitral O 
Em O 
( O 
r=0.18 O 
, O 
P=0.02 O 
) O 
, O 
mitral O 
Em O 
/ O 
Am O 
ratio O 
( O 
r=0.23 O 
, O 
P=0.004 O 
) O 
were O 
significantly O 
and O 
positively O 
correlated O 
with O 
CFR O 
. O 
CONCLUSION O 
: O 
CFR O 
is O 
impaired O 
in O 
subjects O 
with O 
prediabetics O 
, O 
but O 
this O 
impairment O 
is O 
not O 
as O 
severe O 
as O 
that O 
in O 
diabetics O 
. O 

the O 
benefit O 
of O 
magnetic O 
magnesium B-SYSTEMATIC 
nanocarrier O 
in O 
cardiovascular O 
toxicity O 
of O 
aluminum B-SYSTEMATIC 
phosphide I-SYSTEMATIC 
. O 

present O 
study O 
was O 
designed O 
to O 
determine O 
the O 
effect O 
of O 
a O 
new O 
(25)Mg(2+) B-FORMULA 
-carrying O 
nanoparticle O 
( O 
(25)MgPMC16 B-FORMULA 
) O 
on O 
energy O 
depletion O 
, O 
oxidative O 
stress O 
, O 
and O 
electrocardiographic O 
( O 
ECG O 
) O 
parameters O 
on O 
heart O 
tissue O 
of O 
the O 
rats O 
poisoned O 
by O 
aluminum B-SYSTEMATIC 
phosphide I-SYSTEMATIC 
( O 
AlP B-FORMULA 
) O 
. O 
(25)MgPMC16 B-FORMULA 
at O 
doses O 
of O 
0.025 O 
, O 
0.05 O 
, O 
and O 
0.1 O 
median O 
lethal O 
dose O 
( O 
LD50 O 
= O 
896 O 
mg O 
/ O 
kg O 
) O 
was O 
administered O 
intravenously O 
(iv) O 
30 O 
min O 
after O 
a O 
single O 
intragastric O 
administration O 
of O 
AlP B-FORMULA 
( O 
0.25 O 
LD50 O 
) O 
. O 
Sodium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
( O 
Bicarb B-ABBREVIATION 
; O 
2 O 
mEq O 
/ O 
kg O 
, O 
iv O 
) O 
was O 
used O 
as O 
the O 
standard O 
therapy O 
. O 
After O 
anesthesia O 
, O 
the O 
animals O 
were O 
rapidly O 
connected O 
to O 
an O 
electronic O 
cardiovascular O 
monitoring O 
device O 
for O 
monitoring O 
of O 
ECG O 
, O 
blood O 
pressure O 
( O 
BP O 
) O 
, O 
and O 
heart O 
rate O 
( O 
HR O 
) O 
. O 
Later O 
lipid O 
peroxidation O 
, O 
antioxidant O 
power O 
, O 
ATP B-ABBREVIATION 
/ O 
ADP B-ABBREVIATION 
ratio O 
, O 
and O 
Mg B-FORMULA 
concentration O 
in O 
the O 
heart O 
were O 
evaluated O 
. O 
Results O 
indicated O 
that O 
after O 
AlP B-FORMULA 
administration O 
, O 
BP O 
and O 
HR O 
decreased O 
while O 
R-R O 
duration O 
increased O 
. O 
(25)MgPMC16 B-FORMULA 
significantly O 
increased O 
the O 
BP O 
and O 
HR O 
at O 
all O 
doses O 
used O 
. O 
We O 
found O 
a O 
considerable O 
increase O 
in O 
antioxidant O 
power O 
, O 
Mg B-FORMULA 
level O 
in O 
the O 
plasma O 
and O 
the O 
heart O 
and O 
a O 
reduction O 
in O 
lipid O 
peroxidation O 
and O 
ADP B-ABBREVIATION 
/ O 
ATP B-ABBREVIATION 
ratio O 
at O 
various O 
doses O 
of O 
(25)MgPMC16 B-FORMULA 
, O 
but O 
(25)MgPMC16 B-FORMULA 
-0.025 O 
+ O 
Bicarb B-ABBREVIATION 
was O 
the O 
most O 
effective O 
combination O 
therapy O 
. O 
The O 
results O 
of O 
this O 
study O 
support O 
that O 
(25)MgPMC16 B-FORMULA 
can O 
increase O 
heart O 
energy O 
by O 
active O 
transport O 
of O 
Mg B-FORMULA 
inside O 
the O 
cardiac O 
cells O 
. O 
(25)MgPMC16 O 
seems O 
ameliorating O 
Al B-FORMULA 
P-induced O 
toxicity O 
and O 
cardiac O 
failure O 
necessitating O 
further O 
studies O 
. O 

are O 
not O 
major O 
components O 
responsible O 
for O 
the O 
beneficial O 
effect O 
of O 
Camellia O 
sinensis O 
on O 
the O 
ovarian O 
δ-ALA B-SYSTEMATIC 
-D O 
activity O 
inhibited O 
by O 
cadmium B-SYSTEMATIC 
. O 

has O 
been O 
associated O 
with O 
a O 
wide O 
spectrum O 
of O 
deleterious O 
effects O 
on O 
the O 
reproductive O 
tissues O 
, O 
including O 
ovary O 
. O 
This O 
investigation O 
evaluated O 
the O 
protective O 
role O 
of O 
Camellia O 
sinensis O 
( O 
green O 
, O 
white O 
and O 
red O 
teas O 
) O 
in O 
the O 
cadmium B-SYSTEMATIC 
-induced O 
inhibition O 
of O 
ovarian O 
δ-aminolevulinate B-SYSTEMATIC 
dehydratase O 
( O 
δ-ALA B-SYSTEMATIC 
-D O 
) O 
activity O 
in O 
vitro O 
and O 
ex O 
vivo O 
. O 
This O 
study O 
demonstrated O 
that O 
green O 
and O 
white O 
teas O 
restored O 
the O 
cow O 
ovary O 
δ-ALA B-SYSTEMATIC 
-D O 
activity O 
inhibited O 
by O 
cadmium B-SYSTEMATIC 
whereas O 
red O 
tea O 
had O 
no O 
effect O 
in O 
vitro O 
. O 
In O 
addition O 
, O 
green O 
tea O 
was O 
able O 
to O 
restore O 
enzyme O 
activity O 
inhibited O 
after O 
acute O 
cadmium B-SYSTEMATIC 
exposure O 
in O 
mice O 
ovary O 
. O 
Teas O 
infusions O 
composition O 
was O 
assessed O 
by O 
HPLC O 
in O 
a O 
quantitative O 
assay O 
for O 
catechins B-FAMILY 
, O 
purine B-FAMILY 
alkaloids I-FAMILY 
and O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
as O 
well O 
as O 
total O 
polyphenol B-FAMILY 
content O 
. O 
The O 
greatest O 
effect O 
of O 
green O 
tea O 
observed O 
in O 
vitro O 
as O 
well O 
as O 
the O 
protective O 
role O 
presented O 
in O 
the O 
ex O 
vivo O 
study O 
could O 
be O 
attributed O 
to O 
the O 
major O 
content O 
of O 
phenols B-FAMILY 
, O 
but O 
not O 
catechins B-FAMILY 
. O 
In O 
fact O 
, O 
catechins B-FAMILY 
were O 
not O 
able O 
to O 
restore O 
enzyme O 
activity O 
inhibited O 
by O 
cadmium B-SYSTEMATIC 
, O 
demonstrating O 
that O 
these O 
compounds O 
are O 
not O 
major O 
components O 
responsible O 
for O 
the O 
beneficial O 
effect O 
of O 
green O 
tea O 
observed O 
in O 
this O 
study O 
. O 
This O 
study O 
demonstrated O 
the O 
helpful O 
effect O 
of O 
green O 
tea O 
infusion O 
in O 
ameliorating O 
a O 
marker O 
protein O 
of O 
cadmium B-SYSTEMATIC 
intoxication O 
in O 
ovarian O 
tissue O 
. O 

considerations O 
for O 
PAMAM B-ABBREVIATION 
dendrimer O 
therapeutics O 
. O 

have O 
previously O 
shown O 
that O 
methotrexate B-TRIVIAL 
( O 
MTX B-ABBREVIATION 
) O 
conjugated O 
to O 
a O 
cancer O 
- O 
specific O 
poly B-FAMILY 
amido I-FAMILY 
amine I-FAMILY 
( O 
PAMAM B-ABBREVIATION 
) O 
dendrimer O 
has O 
a O 
higher O 
therapeutic O 
index O 
than O 
MTX B-ABBREVIATION 
alone O 
. O 
Unfortunately O 
, O 
these O 
therapeutics O 
have O 
been O 
difficult O 
to O 
advance O 
because O 
of O 
the O 
complicated O 
syntheses O 
and O 
an O 
incomplete O 
understanding O 
of O 
the O 
dendrimer O 
properties O 
. O 
We O 
wished O 
to O 
address O 
these O 
obstacles O 
by O 
using O 
copper B-SYSTEMATIC 
-free O 
click O 
chemistry O 
to O 
functionalize O 
the O 
dendrimer O 
scaffolds O 
and O 
to O 
exploring O 
the O 
effects O 
of O 
two O 
dendrimer O 
properties O 
( O 
the O 
targeting O 
ligand O 
and O 
drug O 
linkage O 
) O 
on O 
cytotoxicity O 
. O 
We O 
conjugated O 
either O 
ester B-FAMILY 
or O 
amide B-FAMILY 
-linker O 
modified O 
MTX B-ABBREVIATION 
to O 
dendrimer O 
scaffolds O 
with O 
or O 
without O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
. O 
Because O 
of O 
multivalency O 
, O 
the O 
FA O 
and O 
MTX B-ABBREVIATION 
functionalized O 
dendrimers O 
had O 
similar O 
capacities O 
to O 
target O 
the O 
folate B-TRIVIAL 
receptor O 
on O 
cancer O 
cells O 
. O 
Additionally O 
, O 
we O 
found O 
that O 
the O 
ester B-FAMILY 
- O 
and O 
amide B-FAMILY 
-linker O 
modified O 
MTX B-ABBREVIATION 
compounds O 
had O 
similar O 
cytotoxicity O 
but O 
the O 
dendrimer- O 
ester B-FAMILY 
MTX B-ABBREVIATION 
conjugates O 
were O 
much O 
more O 
cytotoxic O 
than O 
the O 
dendrimer- O 
amide B-FAMILY 
MTX B-ABBREVIATION 
conjugates O 
. O 
These O 
results O 
clarify O 
the O 
impact O 
of O 
these O 
properties O 
on O 
therapeutic O 
efficacy O 
and O 
will O 
allow O 
us O 
to O 
design O 
more O 
effective O 
polymer O 
therapeutics O 
. O 

goal O 
of O 
this O 
study O 
was O 
to O 
monitor O 
the O 
anti-proliferative O 
activity O 
of O 
Rosmarinus O 
officinalis O 
and O 
Salvia O 
officinalis O 
extracts O 
against O 
cancer O 
cells O 
and O 
to O 
correlate O 
this O 
activity O 
with O 
their O 
phytochemical O 
profiles O 
using O 
liquid O 
chromatography O 
/ O 
diode O 
array O 
detection O 
/ O 
electrospray O 
ion O 
trap O 
tandem O 
mass O 
spectrometry O 
( O 
LC O 
/ O 
DAD O 
/ O 
ESI-MS(n) O 
) O 
. O 
For O 
the O 
quantitative O 
estimation O 
of O 
triterpenic B-FAMILY 
acids I-FAMILY 
in O 
the O 
crude O 
extracts O 
an O 
NMR O 
based O 
methodology O 
was O 
used O 
and O 
compared O 
with O 
the O 
HPLC O 
measurements O 
, O 
both O 
applied O 
for O 
the O 
first O 
time O 
, O 
for O 
the O 
case O 
of O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Both O 
extracts O 
exerted O 
cytotoxic O 
activity O 
through O 
dose O 
- O 
dependent O 
impairment O 
of O 
viability O 
and O 
mitochondrial O 
activity O 
of O 
rat O 
insulinoma O 
m5F O 
( O 
RINm5F O 
) O 
cells O 
. O 
Decrease O 
of O 
RINm5F O 
viability O 
was O 
mediated O 
by O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
)-induced O 
apoptosis O 
. O 
Importantly O 
, O 
these O 
extracts O 
potentiated O 
NO B-FORMULA 
and O 
TNF-α O 
release O 
from O 
macrophages O 
therefore O 
enhancing O 
their O 
cytocidal O 
action O 
. O 
The O 
rosemary O 
extract O 
developed O 
more O 
pronounced O 
antioxidant O 
, O 
cytotoxic O 
and O 
immunomodifying O 
activities O 
, O 
probably O 
due O 
to O 
the O 
presence O 
of O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
a O 
higher O 
concentration O 
of O 
carnosic B-TRIVIAL 
acid I-TRIVIAL 
in O 
its O 
phytochemical O 
profile O 
. O 

damage O 
and O 
oxidative O 
stress O 
in O 
human O 
B O 
lymphoblastoid O 
cells O 
after O 
combined O 
exposure O 
to O 
hexavalent B-SYSTEMATIC 
chromium I-SYSTEMATIC 
and O 
nickel B-SYSTEMATIC 
compounds O 
. O 

the O 
present O 
study O 
, O 
human O 
B O 
lymphoblastoid O 
cells O 
were O 
exposed O 
to O 
potassium B-SYSTEMATIC 
dichromate I-SYSTEMATIC 
and O 
/ O 
or O 
nickel B-SYSTEMATIC 
chloride I-SYSTEMATIC 
for O 
24h O 
or O 
48h O 
. O 
The O 
cell O 
viability O 
and O 
DNA O 
damage O 
induced O 
by O 
these O 
compounds O 
was O 
measured O 
with O 
the O 
CCK-8 O 
assay O 
and O 
Comet O 
assay O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
the O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
were O 
measured O 
using O 
commercially O 
available O 
kits O 
. O 
Our O 
results O 
indicated O 
that O 
potassium B-SYSTEMATIC 
dichromate I-SYSTEMATIC 
could O 
decrease O 
cell O 
viability O 
and O 
induce O 
DNA O 
damage O 
in O 
human O 
B O 
lymphoblastoid O 
cells O 
in O 
a O 
time O 
- O 
and O 
concentration O 
- O 
dependent O 
manner O 
, O 
but O 
the O 
toxicity O 
of O 
nickel B-SYSTEMATIC 
chloride I-SYSTEMATIC 
was O 
not O 
so O 
obvious O 
at O 
concentrations O 
used O 
in O 
our O 
study O 
. O 
The O 
results O 
of O 
ROS O 
showed O 
that O 
both O 
two O 
compounds O 
could O 
only O 
induce O 
weak O 
elevation O 
of O 
ROS O 
level O 
, O 
but O 
MDA B-ABBREVIATION 
levels O 
were O 
significantly O 
enhanced O 
. O 
Antagonistic O 
effects O 
of O 
cytotoxicity O 
were O 
mainly O 
found O 
between O 
Cr B-FORMULA 
(VI) I-FORMULA 
and O 
Ni B-FORMULA 
(II) I-FORMULA 
, O 
and O 
synergistic O 
effects O 
of O 
DNA O 
damage O 
and O 
oxidative O 
stress O 
were O 
partially O 
found O 
between O 
these O 
two O 
compounds O 
. O 
Moreover O 
, O 
there O 
were O 
good O 
correlations O 
between O 
the O 
results O 
of O 
comet O 
assay O 
and O 
the O 
results O 
of O 
oxidative O 
stress O 
assays O 
. O 
It O 
is O 
suggested O 
that O 
synergistic O 
DNA O 
damage O 
induced O 
by O 
simultaneously O 
exposure O 
of O 
hexavalent B-SYSTEMATIC 
chromium I-SYSTEMATIC 
and O 
nickel B-SYSTEMATIC 
compounds O 
is O 
possibly O 
related O 
to O 
oxidative O 
stress O 
. O 

Rh2(S-IBAZ)4 B-FORMULA 
-catalyzed O 
cyclopropanation O 
of O 
alkenes B-FAMILY 
, O 
alkynes B-FAMILY 
, O 
and O 
allenes B-FAMILY 
: O 
asymmetric O 
synthesis O 
of O 
diacceptor O 
cyclopropylphosphonates B-FAMILY 
and O 
alkylidenecyclopropanes B-FAMILY 
. O 

mild O 
and O 
highly O 
stereoselective O 
rhodium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
-catalyzed O 
cyclopropanation O 
of O 
alkenes B-FAMILY 
, O 
alkynes B-FAMILY 
, O 
and O 
allenes B-FAMILY 
with O 
diacceptor O 
diazo B-SYSTEMATIC 
compounds O 
is O 
reported O 
. O 
Using O 
the O 
phosphonate B-SYSTEMATIC 
moiety O 
as O 
an O 
efficient O 
trans-directing O 
group O 
, O 
the O 
first O 
catalytic O 
asymmetric O 
route O 
to O 
diacceptor O 
cycloprop(en)ylphosphonates B-FAMILY 
was O 
developed O 
by O 
employing O 
an O 
α-cyano B-SYSTEMATIC 
diazophosphonate I-SYSTEMATIC 
and O 
Rh(2)(S-IBAZ)(4) B-FORMULA 
as O 
chiral O 
catalyst O 
. O 
The O 
isosteric O 
character O 
of O 
phosphonic B-MULTIPLE 
and I-MULTIPLE 
carboxylic I-MULTIPLE 
acid I-MULTIPLE 
derivatives O 
allowed O 
the O 
alternative O 
use O 
of O 
an O 
α-cyano B-SYSTEMATIC 
diazo I-SYSTEMATIC 
ester I-SYSTEMATIC 
in O 
the O 
process O 
, O 
leading O 
to O 
α-cyano B-FAMILY 
cycloprop(en)ylcarboxylates I-FAMILY 
in O 
high O 
yields O 
and O 
stereoselectivities O 
. O 
Taking O 
advantage O 
of O 
the O 
particular O 
reactivity O 
of O 
the O 
cyanocarbene B-SYSTEMATIC 
intermediates O 
involved O 
in O 
this O 
system O 
, O 
the O 
scope O 
of O 
compatible O 
substrates O 
could O 
be O 
extended O 
to O 
substituted O 
allenes B-FAMILY 
, O 
leading O 
to O 
the O 
development O 
of O 
the O 
first O 
catalytic O 
enantioselective O 
method O 
for O 
the O 
synthesis O 
of O 
diacceptor O 
alkylidenecyclopropanes B-FAMILY 
. O 

of O 
isotope O 
dilution O 
mass O 
spectrometric O 
( O 
ID-MS O 
) O 
method O 
to O 
determine O 
niacin B-TRIVIAL 
in O 
infant O 
formula O 
, O 
breakfast O 
cereals O 
and O 
multivitamins O 
. O 

isotope O 
dilution O 
LC O 
/ O 
mass O 
spectrometric O 
( O 
ID-LC O 
/ O 
MS O 
) O 
method O 
was O 
developed O 
as O 
a O 
candidate O 
reference O 
method O 
for O 
the O 
accurate O 
determination O 
of O 
niacin B-TRIVIAL 
in O 
infant O 
formula O 
, O 
breakfast O 
cereals O 
and O 
multivitamin O 
. O 
After O 
spiking O 
nicotinamide-d(4) B-SYSTEMATIC 
as O 
an O 
internal O 
standard O 
, O 
infant O 
formula O 
and O 
breakfast O 
cereal O 
samples O 
were O 
hydrolysed O 
under O 
alkaline O 
condition O 
. O 
Samples O 
were O 
then O 
analysed O 
in O 
SRM O 
mode O 
to O 
detect O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
nicotinic B-SYSTEMATIC 
acid-d(4) I-SYSTEMATIC 
at O 
m O 
/ O 
z O 
124→80 O 
and O 
127→84 O 
, O 
respectively O 
. O 
In O 
the O 
case O 
of O 
multivitamin O 
sample O 
that O 
contains O 
mainly O 
free O 
nicotinamide B-TRIVIAL 
, O 
LC O 
/ O 
MS O 
monitored O 
nicotinamide B-TRIVIAL 
and O 
nicotinamide-d(4) B-SYSTEMATIC 
at O 
their O 
SRM O 
channels O 
of O 
m O 
/ O 
z O 
123→80 O 
and O 
m O 
/ O 
z O 
127→84 O 
, O 
respectively O 
, O 
after O 
simple O 
extraction O 
. O 
The O 
repeatability O 
and O 
reproducibility O 
were O 
tested O 
for O 
the O 
validation O 
of O 
the O 
developed O 
ID O 
/ O 
LC-MS O 
method O 
. O 
Additionally O 
, O 
the O 
developed O 
analytical O 
method O 
was O 
applied O 
to O 
determine O 
total O 
niacin B-TRIVIAL 
contents O 
in O 
homogenised O 
infant O 
formula O 
, O 
homogenised O 
multivitamin O 
, O 
and O 
commercially O 
available O 
products O 
including O 
different O 
types O 
of O 
infant O 
formula O 
, O 
breakfast O 
cereals O 
, O 
and O 
multivitamin O 
tablets O 
. O 

growth O 
factor O 
23 O 
inhibits O 
extrarenal O 
synthesis O 
of O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
in O 
human O 
monocytes O 
. O 

D I-FAMILY 
is O 
a O 
potent O 
stimulator O 
of O 
monocyte O 
innate O 
immunity O 
, O 
and O 
this O 
effect O 
is O 
mediated O 
via O 
intracrine O 
conversion O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
25OHD B-SYSTEMATIC 
) O 
to O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
1,25(OH)(2) B-SYSTEMATIC 
D I-SYSTEMATIC 
) O 
. O 
In O 
the O 
kidney O 
, O 
synthesis O 
of O 
1,25(OH)(2) B-SYSTEMATIC 
D I-SYSTEMATIC 
is O 
suppressed O 
by O 
fibroblast O 
growth O 
factor O 
23 O 
( O 
FGF23 O 
) O 
, O 
via O 
transcriptional O 
suppression O 
of O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
-activating O 
enzyme O 
1α-hydroxylase O 
( O 
CYP27B1 O 
) O 
. O 
We O 
hypothesized O 
that O 
FGF23 O 
also O 
suppresses O 
CYP27B1 O 
in O 
monocytes O 
, O 
with O 
concomitant O 
effects O 
on O 
intracrine O 
responses O 
to O 
1,25(OH)(2) B-SYSTEMATIC 
D I-SYSTEMATIC 
. O 
Healthy O 
donor O 
peripheral O 
blood O 
mononuclear O 
cell O 
monocytes O 
( O 
PBMCm O 
) O 
and O 
peritoneal O 
dialysate O 
monocyte O 
( O 
PDm O 
) O 
effluent O 
from O 
kidney O 
disease O 
patients O 
were O 
assessed O 
at O 
baseline O 
to O 
confirm O 
the O 
presence O 
of O 
mRNA O 
for O 
FGF23 O 
receptors O 
( O 
FGFRs O 
) O 
, O 
with O 
Klotho O 
and O 
FGFR1 O 
being O 
more O 
strongly O 
expressed O 
than O 
FGFR2 O 
/ O 
3 O 
/ O 
4 O 
in O 
both O 
cell O 
types O 
. O 
Immunohistochemistry O 
showed O 
coexpression O 
of O 
Klotho O 
and O 
FGFR1 O 
in O 
PBMCm O 
and O 
PDm O 
, O 
with O 
this O 
effect O 
being O 
enhanced O 
following O 
treatment O 
with O 
FGF23 O 
in O 
PBMCm O 
but O 
not O 
PDm O 
. O 
Treatment O 
with O 
FGF23 O 
activated O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
and O 
protein O 
kinase O 
B O 
( O 
Akt O 
) O 
pathways O 
in O 
PBMCm O 
, O 
demonstrating O 
functional O 
FGFR O 
signaling O 
in O 
these O 
cells O 
. O 
FGF23 O 
treatment O 
of O 
PBMCm O 
and O 
PDm O 
decreased O 
expression O 
of O 
mRNA O 
for O 
CYP27B1 O 
. O 
In O 
PBMCm O 
this O 
was O 
associated O 
with O 
downregulation O 
of O 
25OHD B-SYSTEMATIC 
to O 
1,25(OH)(2) B-SYSTEMATIC 
D I-SYSTEMATIC 
metabolism O 
, O 
and O 
concomitant O 
suppression O 
of O 
intracrine O 
induced O 
24-hydroxylase O 
( O 
CYP24A1 O 
) O 
and O 
antibacterial O 
cathelicidin O 
( O 
LL37 O 
) O 
. O 
FGF23 O 
suppression O 
of O 
CYP27B1 O 
was O 
particularly O 
pronounced O 
in O 
PBMCm O 
treated O 
with O 
interleukin O 
- O 
15 O 
to O 
stimulate O 
synthesis O 
of O 
1,25(OH)(2) B-SYSTEMATIC 
D I-SYSTEMATIC 
. O 
These O 
data O 
indicate O 
that O 
FGF23 O 
can O 
inhibit O 
extra O 
- O 
renal O 
expression O 
of O 
CYP27B1 O 
and O 
subsequent O 
intracrine O 
responses O 
to O 
1,25(OH)(2) B-SYSTEMATIC 
D I-SYSTEMATIC 
in O 
two O 
different O 
human O 
monocyte O 
models O 
. O 
Elevated O 
expression O 
of O 
FGF23 O 
may O 
therefore O 
play O 
a O 
crucial O 
role O 
in O 
defining O 
immune O 
responses O 
to O 
vitamin B-FAMILY 
D I-FAMILY 
and O 
this O 
, O 
in O 
turn O 
, O 
may O 
be O 
a O 
key O 
determinant O 
of O 
infection O 
in O 
patients O 
with O 
chronic O 
kidney O 
disease O 
( O 
CKD O 
) O 
. O 

Chitosan- O 
Polyglutamic B-FAMILY 
Acid I-FAMILY 
Hybrid O 
Nanoparticles O 
for O 
Biomedical O 
Applications O 
. O 

spite O 
of O 
their O 
attractive O 
features O 
, O 
widespread O 
biomedical O 
applications O 
of O 
CS O 
nanoparticles O 
are O 
yet O 
to O 
be O 
realized O 
due O 
to O 
their O 
poor O 
stability O 
in O 
physiological O 
conditions O 
, O 
such O 
as O 
in O 
buffer O 
system O 
at O 
pH O 
7.4 O 
. O 
Buffer O 
- O 
stable O 
chitosan O 
- O 
based O 
hybrid O 
NPs O 
( O 
HNPs O 
) O 
are O 
reported O 
and O 
characterized O 
. O 
Buffer O 
stability O 
is O 
achieved O 
by O 
introducing O 
polyglutamic B-FAMILY 
acid I-FAMILY 
to O 
chitosan O 
. O 
The O 
effect O 
of O 
PGA B-ABBREVIATION 
to O 
CS O 
molar O 
ratio O 
and O 
crosslinking O 
on O 
HNP O 
integrity O 
, O 
buffer O 
stability O 
, O 
and O 
biodegradability O 
are O 
studied O 
. O 
Preliminary O 
in O 
vitro O 
studies O 
are O 
carried O 
out O 
to O 
evaluate O 
targeted O 
uptake O 
efficiency O 
of O 
folate B-TRIVIAL 
conjugated O 
HNPs O 
. O 
Successful O 
demonstration O 
of O 
buffer O 
stability O 
and O 
cancer O 
cell O 
targeting O 
by O 
HNPs O 
achieves O 
important O 
milestones O 
for O 
chitosan O 
- O 
based O 
nanoparticle O 
technology O 
. O 

of O 
GluN2 O 
subunit O 
identity O 
on O 
NMDA B-ABBREVIATION 
receptor O 
function O 
. O 

receptors O 
( O 
NMDARs O 
) O 
are O 
ligand O 
- O 
gated O 
ion O 
channels O 
( O 
' O 
ionotropic O 
' O 
receptors O 
) O 
activated O 
by O 
the O 
major O 
excitatory O 
neurotransmitter O 
, O 
l-glutamate B-TRIVIAL 
. O 
While O 
the O 
term O 
' O 
the O 
NMDAR O 
' O 
is O 
often O 
used O 
it O 
obscures O 
the O 
fact O 
that O 
this O 
class O 
of O 
receptor O 
contains O 
within O 
it O 
members O 
whose O 
properties O 
are O 
as O 
different O 
as O 
they O 
are O 
similar O 
. O 
This O 
heterogeneity O 
was O 
evident O 
from O 
early O 
electrophysiological O 
, O 
pharmacological O 
and O 
biochemical O 
assessments O 
of O 
the O 
functional O 
properties O 
of O 
NMDARs O 
and O 
while O 
the O 
molecular O 
basis O 
of O 
this O 
heterogeneity O 
has O 
taken O 
many O 
years O 
to O 
elucidate O 
, O 
it O 
indicated O 
from O 
the O 
outset O 
that O 
the O 
diversity O 
of O 
NMDAR O 
phenotypes O 
could O 
allow O 
this O 
receptor O 
family O 
to O 
subserve O 
a O 
variety O 
of O 
functions O 
in O 
the O 
mammalian O 
central O 
nervous O 
system O 
. O 
In O 
this O 
review O 
we O 
highlight O 
some O 
recent O 
studies O 
that O 
have O 
identified O 
structural O 
elements O 
within O 
GluN2 O 
subunits O 
that O 
contribute O 
to O 
the O 
heterogeneous O 
biophysical O 
properties O 
of O 
NMDARs O 
, O 
consider O 
why O 
some O 
recently O 
described O 
novel O 
pharmacological O 
tools O 
may O 
permit O 
better O 
identification O 
of O 
native O 
NMDAR O 
subtypes O 
, O 
examine O 
the O 
evidence O 
that O 
NMDAR O 
subtypes O 
differentially O 
contribute O 
to O 
the O 
induction O 
of O 
long O 
- O 
term O 
potentiation O 
and O 
long O 
- O 
term O 
depression O 
and O 
discuss O 
how O 
through O 
the O 
use O 
of O 
chimeric O 
proteins O 
additional O 
insights O 
have O 
been O 
obtained O 
that O 
account O 
for O 
NMDAR O 
subtype O 
- O 
dependency O 
of O 
physiological O 
and O 
pathophysiological O 
signalling O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
GluR-dep O 
synaptic O 
plasticity O 
' O 
. O 

and O 
Structure O 
Elucidation O 
of O 
Three O 
New O 
Dolastanes B-FAMILY 
from O 
the O 
Brown O 
Alga O 
Dilophus O 
spiralis O 
. O 

new O 
dolastane B-FAMILY 
diterpenes I-FAMILY 
( O 
1-3 O 
) O 
and O 
five O 
previously O 
reported O 
perhydroazulenes B-FAMILY 
were O 
isolated O 
from O 
the O 
organic O 
extracts O 
of O 
the O 
brown O 
alga O 
Dilophus O 
spiralis O 
. O 
The O 
structure O 
elucidation O 
and O 
the O 
assignment O 
of O 
the O 
relative O 
configurations O 
of O 
the O 
isolated O 
natural O 
products O 
were O 
based O 
on O 
extensive O 
analyses O 
of O 
their O 
spectroscopic O 
data O 
, O 
whereas O 
the O 
absolute O 
configuration O 
of O 
metabolite O 
2 O 
was O 
determined O 
through O 
its O 
chemical O 
conversion O 
to O 
a O 
previously O 
isolated O 
compound O 
of O 
known O 
configuration O 
. O 

glycogen O 
synthase O 
kinase-3β O 
/ O 
nuclear O 
factor O 
- O 
kappa O 
B O 
pathway O 
is O 
involved O 
in O 
cinobufagin B-TRIVIAL 
-induced O 
apoptosis O 
in O 
cultured O 
osteosarcoma O 
cells O 
. O 

, O 
a O 
major O 
component O 
of O 
cinobufacini O 
( O 
huachansu O 
) O 
, O 
is O 
an O 
important O 
cardenolidal B-FAMILY 
steroid I-FAMILY 
. O 
Several O 
studies O 
have O 
suggested O 
that O 
cinobufagin B-TRIVIAL 
has O 
potent O 
anti-cancer O 
effects O 
. O 
The O 
present O 
study O 
examines O 
the O 
apoptosis O 
- O 
inducing O 
activity O 
and O 
the O 
underlying O 
mechanism O 
of O 
action O 
of O 
cinobufagin B-TRIVIAL 
in O 
osteosarcoma O 
( O 
OS O 
) O 
cells O 
. O 
Our O 
results O 
showed O 
that O 
cinobufagin B-TRIVIAL 
potently O 
inhibited O 
the O 
proliferation O 
of O 
U2OS O 
, O 
MG63 O 
and O 
SaOS-2 O 
cells O 
. O 
Significant O 
increases O 
in O 
G2 O 
/ O 
M O 
cell O 
- O 
cycle O 
arrest O 
and O 
apoptosis O 
in O 
OS O 
cells O 
were O 
also O 
observed O 
. O 
The O 
expression O 
levels O 
of O 
several O 
apoptotic O 
proteins O 
were O 
assessed O 
after O 
cinobufagin B-TRIVIAL 
treatment O 
in O 
U2OS O 
cells O 
. O 
Among O 
them O 
, O 
xIAP O 
, O 
cIAP-1 O 
, O 
survivin O 
and O 
Bcl-2 O 
levels O 
decreased O 
remarkably O 
, O 
while O 
the O 
levels O 
of O 
Bax O 
and O 
cleaved-PARP O 
increased O 
. O 
Furthermore O 
, O 
we O 
validated O 
the O 
inhibition O 
of O 
GSK-3β O 
/ O 
NF-κB O 
signaling O 
following O 
cinobufagin B-TRIVIAL 
treatment O 
. O 
Western O 
blots O 
showed O 
a O 
decrease O 
in O 
nuclear O 
p65 O 
protein O 
expression O 
after O 
exposure O 
to O 
different O 
concentrations O 
of O 
cinobufagin B-TRIVIAL 
, O 
while O 
the O 
phosphorylation O 
of O 
GSK-3β O 
was O 
simultaneously O 
increased O 
. O 
Transduction O 
with O 
constitutively O 
active O 
forms O 
of O 
GSK-3β O 
could O 
protect O 
against O 
the O 
downregulation O 
of O 
p65 O 
and O 
upregulation O 
of O 
cleaved-PARP O 
that O 
are O 
induced O 
by O 
cinobufagin B-TRIVIAL 
treatment O 
. O 
However O 
, O 
combined O 
treatment O 
with O 
cinobufagin B-TRIVIAL 
and O 
SB216367 B-IDENTIFIER 
resulted O 
in O 
a O 
significant O 
reduction O 
in O 
p65 O 
and O 
an O 
increase O 
in O 
cleaved-PARP O 
in O 
U2OS O 
cells O 
. O 
Altogether O 
, O 
these O 
results O 
show O 
that O 
cinobufagin B-TRIVIAL 
is O 
a O 
promising O 
agent O 
for O 
the O 
treatment O 
of O 
OS O 
. O 
These O 
studies O 
are O 
the O 
first O 
to O 
reveal O 
the O 
involvement O 
of O 
the O 
GSK-3β O 
/ O 
NF-κB O 
pathway O 
in O 
cinobufagin B-TRIVIAL 
-induced O 
apoptosis O 
. O 

acid I-FAMILY 
derived O 
quinazolines B-FAMILY 
as O 
Rock O 
/ O 
PKA O 
inhibitors O 
. O 

and O 
lead O 
optimization O 
studies O 
for O 
Rock O 
inhibitors O 
based O 
on O 
amino B-FAMILY 
acid I-FAMILY 
-derived O 
quinazolines B-FAMILY 
are O 
described O 
. O 
Studies O 
demonstrated O 
that O 
these O 
amino B-FAMILY 
acid I-FAMILY 
derived O 
quinazolinones B-FAMILY 
were O 
mainly O 
pan-Rock O 
( O 
I O 
& O 
II O 
) O 
inhibitors O 
. O 
While O 
selectivity O 
against O 
other O 
kinases O 
could O 
be O 
achieved O 
, O 
selectivity O 
for O 
most O 
of O 
these O 
compounds O 
against O 
PKA O 
was O 
not O 
achieved O 
. O 
This O 
is O 
distinct O 
from O 
Rock O 
inhibitors O 
based O 
on O 
non- O 
amino B-FAMILY 
acid I-FAMILY 
derived O 
quinazolinones B-FAMILY 
, O 
where O 
high O 
selectivity O 
against O 
PKA O 
could O 
be O 
obtained O 
. O 
( O 
22 O 
) O 
The O 
inhibitors O 
presented O 
here O 
in O 
some O 
cases O 
possessed O 
sub O 
- O 
nanomolar O 
inhibition O 
of O 
Rock O 
, O 
nanomolar O 
potency O 
in O 
ppMLC O 
cell O 
based O 
assays O 
, O 
low O 
to O 
fair O 
cytochrome O 
P-450 O 
inhibition O 
, O 
and O 
good O 
human O 
microsomal O 
stability O 
. O 

Glycosylated O 
with O 
Both O 
d- B-MULTIPLE 
and I-MULTIPLE 
l-Arabinoses I-MULTIPLE 
from O 
the O 
South O 
China O 
Sea O 
Gorgonian O 
Dichotella O 
gemmacea O 
. O 

new O 
19-hydroxy B-FAMILY 
steroidal I-FAMILY 
glycosides I-FAMILY 
, O 
namely O 
, O 
junceellosides B-MULTIPLE 
E-G I-MULTIPLE 
( O 
2-4 O 
) O 
, O 
were O 
isolated O 
together O 
with O 
the O 
known O 
analogue O 
junceelloside B-TRIVIAL 
C I-TRIVIAL 
( O 
1 O 
) O 
from O 
the O 
South O 
China O 
Sea O 
gorgonian O 
Dichotella O 
gemmacea O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
elucidated O 
by O 
a O 
combination O 
of O 
detailed O 
spectroscopic O 
analyses O 
, O 
chemical O 
methods O 
, O 
and O 
comparison O 
with O 
reported O 
data O 
. O 
These O 
glycosides O 
are O 
found O 
to O 
have O 
sugar B-FAMILY 
moieties O 
of O 
both O 
β-l- B-MULTIPLE 
and I-MULTIPLE 
β-d-arabinopyranoses I-MULTIPLE 
by O 
HPLC O 
analysis O 
of O 
their O 
thiocarbamoyl-thiazolidine B-SYSTEMATIC 
derivatives O 
and O 
those O 
of O 
authentic O 
d- B-MULTIPLE 
and I-MULTIPLE 
l-arabinoses I-MULTIPLE 
, O 
leading O 
to O 
the O 
structure O 
revision O 
of O 
junceelloside B-TRIVIAL 
C I-TRIVIAL 
( O 
1 O 
) O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
steroidal O 
glycosides O 
from O 
the O 
gorgonian O 
D O 
. O 
gemmacea O 
and O 
the O 
first O 
report O 
of O 
glycosides O 
with O 
β-l-arabinopyranose B-TRIVIAL 
from O 
marine O 
sources O 
. O 

whole O 
mount O 
in O 
situ O 
hybridization O 
to O 
examine O 
thyroid B-FAMILY 
hormone I-FAMILY 
deiodinase O 
expression O 
in O 
embryonic O 
and O 
larval O 
zebrafish O 
: O 
A O 
tool O 
for O 
examining O 
OH-BDE B-FORMULA 
toxicity O 
to O 
early O 
life O 
stages O 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
and O 
their O 
oxidative O 
metabolites O 
( O 
hydroxylated B-FAMILY 
PBDEs I-FAMILY 
; O 
OH-BDEs B-FAMILY 
) O 
are O 
known O 
endocrine O 
disrupting O 
contaminants O 
that O 
have O 
been O 
shown O 
to O 
disrupt O 
thyroid B-FAMILY 
hormone I-FAMILY 
regulation O 
both O 
in O 
mammals O 
and O 
in O 
fish O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
precise O 
organ O 
and O 
tissue O 
locations O 
that O 
express O 
genes O 
critical O 
to O 
thyroid B-FAMILY 
hormone I-FAMILY 
regulation O 
in O 
developing O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
, O 
and O 
to O 
determine O 
the O 
effects O 
of O 
an O 
OH-BDE B-FORMULA 
on O 
their O 
expression O 
. O 
While O 
RT-PCR O 
can O 
provide O 
quantitative O 
data O 
on O 
gene O 
expression O 
, O 
it O 
lacks O 
spatial O 
sensitivity O 
to O 
examine O 
localized O 
gene O 
expression O 
; O 
and O 
, O 
isolation O 
of O 
organs O 
from O 
zebrafish O 
embryos O 
is O 
technically O 
difficult O 
, O 
if O 
not O 
impossible O 
. O 
For O 
this O 
reason O 
, O 
the O 
present O 
study O 
used O 
whole O 
mount O 
in O 
situ O 
hybridization O 
to O 
simultaneously O 
localize O 
and O 
quantify O 
gene O 
expression O 
in O 
vivo O 
. O 
While O 
PBDEs B-ABBREVIATION 
and O 
OH-BDEs B-FAMILY 
have O 
been O 
shown O 
to O 
inhibit O 
the O 
activity O 
and O 
expression O 
of O 
deiodionases O 
, O 
a O 
family O 
of O 
enzymes O 
that O 
regulate O 
thyroid B-FAMILY 
hormone I-FAMILY 
concentrations O 
intracellularly O 
, O 
it O 
is O 
unclear O 
whether O 
or O 
not O 
they O 
can O 
affect O 
regional O 
expression O 
of O 
the O 
different O 
isoforms O 
during O 
early O 
development O 
. O 
In O 
this O 
study O 
we O 
investigated O 
deiodinase O 
1 O 
( O 
Dio1 O 
) O 
, O 
deiodinase O 
2 O 
( O 
Dio2 O 
) O 
, O 
and O 
deiodinase O 
3 O 
( O 
Dio3 O 
) O 
mRNA O 
expression O 
at O 
the O 
following O 
life O 
stages O 
( O 
2 O 
, O 
8 O 
, O 
and O 
1k-cells O 
; O 
50%-epiboly O 
, O 
6 O 
and O 
18-somites O 
, O 
22 O 
, O 
24 O 
, O 
48 O 
, O 
72 O 
hpf O 
and O 
/ O 
or O 
10 O 
dpf O 
) O 
in O 
zebrafish O 
and O 
found O 
life O 
stage O 
specific O 
expression O 
of O 
these O 
genes O 
that O 
were O 
highly O 
localized O 
. O 
To O 
demonstrate O 
the O 
use O 
of O 
this O 
technique O 
for O 
investigating O 
potential O 
endocrine O 
disrupting O 
effects O 
, O 
zebrafish O 
embryos O 
were O 
exposed O 
to O 
1 O 
, O 
10 O 
and O 
100nM O 
6-OH-BDE-47 B-SYSTEMATIC 
. O 
Significant O 
increases O 
in O 
mean O 
intensity O 
of O 
Dio1 O 
and O 
Dio3 O 
expression O 
in O 
the O 
periventricular O 
zone O 
of O 
brain O 
and O 
pronephric O 
duct O 
, O 
respectively O 
( O 
quantified O 
by O 
measuring O 
intensity O 
of O 
coloration O 
using O 
ImageJ O 
analysis O 
software O 
) O 
were O 
observed O 
, O 
suggesting O 
localized O 
response O 
at O 
the O 
HPT O 
axis O 
with O 
the O 
possibility O 
of O 
impacting O 
neurodevelopment O 
. O 
Our O 
results O 
demonstrate O 
effects O 
of O 
OH-BDEs B-FAMILY 
on O 
thyroid O 
regulating O 
gene O 
expression O 
and O 
provide O 
more O 
insight O 
into O 
potential O 
sites O 
of O 
injury O 
during O 
early O 
life O 
stages O 
. O 

acting O 
oximes B-FAMILY 
in O 
reactivation O 
of O 
tabun B-TRIVIAL 
-phosphoramidated O 
AChE O 
. O 

( O 
OP O 
) O 
inhibit O 
acetylcholinesterase O 
( O 
AChE O 
, O 
EC O 
3.1.1.7 O 
) O 
, O 
both O 
in O 
peripheral O 
tissues O 
and O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
, O 
causing O 
adverse O 
and O 
sometimes O 
fatal O 
effects O 
due O 
to O 
the O 
accumulation O 
of O 
neurotransmitter O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
. O 
The O 
currently O 
used O 
therapy O 
, O 
focusing O 
on O 
the O 
reactivation O 
of O 
inhibited O 
AChE O 
, O 
is O 
limited O 
to O 
peripheral O 
tissues O 
because O 
commonly O 
used O 
quaternary B-FAMILY 
pyridinium I-FAMILY 
oxime I-FAMILY 
reactivators O 
do O 
not O 
cross O 
the O 
blood O 
brain O 
barrier O 
( O 
BBB O 
) O 
at O 
therapeutically O 
relevant O 
levels O 
. O 
A O 
directed O 
library O 
of O 
thirty O 
uncharged O 
oximes B-FAMILY 
that O 
contain O 
tertiary B-SYSTEMATIC 
amine I-SYSTEMATIC 
or O 
imidazole B-SYSTEMATIC 
protonable O 
functional O 
groups O 
that O 
should O 
cross O 
the O 
BBB O 
as O 
unionized O 
species O 
was O 
tested O 
as O 
tabun B-TRIVIAL 
-hAChE O 
conjugate O 
reactivators O 
along O 
with O 
three O 
reference O 
oximes B-FAMILY 
: O 
DAM B-ABBREVIATION 
( O 
diacetylmonoxime B-SYSTEMATIC 
) O 
, O 
MINA B-ABBREVIATION 
( O 
monoisonitrosoacetone B-SYSTEMATIC 
) O 
, O 
and O 
2-PAM B-SYSTEMATIC 
. O 
The O 
oxime B-SYSTEMATIC 
RS150D B-IDENTIFIER 
[ O 
N-((1-(3-(2-((hydroxyimino)methyl)-1H-imidazol-1-yl)propyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide B-SYSTEMATIC 
] O 
was O 
highlighted O 
as O 
the O 
most O 
promising O 
reactivator O 
of O 
the O 
tabun B-TRIVIAL 
-hAChE O 
conjugate O 
. O 
We O 
also O 
observed O 
that O 
oximes B-FAMILY 
RS194B B-NO_CLASS 
[ O 
N-(2-(azepan-1-yl)ethyl)-2-(hydroxyimino)acetamide B-SYSTEMATIC 
] O 
and O 
RS41A B-NO_CLASS 
[ O 
2-(hydroxyimino)-N-(2-(pyrrolidin-1-yl)ethyl)acetamide B-SYSTEMATIC 
] O 
, O 
which O 
emerged O 
as O 
lead O 
uncharged O 
reactivators O 
of O 
phosphylated O 
hAChE O 
with O 
other O 
OPs O 
( O 
sarin B-TRIVIAL 
, O 
cyclosarin B-TRIVIAL 
and O 
VX O 
) O 
, O 
exhibited O 
only O 
moderate O 
reactivation O 
potency O 
for O 
tabun B-TRIVIAL 
inhibited O 
hAChE O 
. O 
This O 
implies O 
that O 
geometry O 
of O 
oxime B-SYSTEMATIC 
access O 
to O 
the O 
phosphorus B-SYSTEMATIC 
atom O 
conjugated O 
to O 
the O 
active O 
serine B-TRIVIAL 
is O 
an O 
important O 
criterion O 
for O 
efficient O 
reactivation O 
, O 
along O 
with O 
the O 
chemical O 
nature O 
of O 
the O 
conjugated O 
moiety O 
: O 
phosphorate B-SYSTEMATIC 
, O 
phosphonate B-SYSTEMATIC 
, O 
or O 
phosphoramidate B-SYSTEMATIC 
. O 
Moreover O 
, O 
modification O 
of O 
the O 
active O 
center O 
through O 
mutagenesis O 
enhances O 
the O 
rates O 
of O 
reactivation O 
. O 
The O 
phosphoramidated-hAChE O 
choline B-FAMILY 
-binding O 
site O 
mutant O 
Y337A O 
showed O 
three O 
- O 
times O 
enhanced O 
reactivation O 
capacity O 
with O 
non- O 
triazole B-FAMILY 
imidazole B-SYSTEMATIC 
containing O 
aldoximes B-FAMILY 
( O 
RS113B B-IDENTIFIER 
, O 
RS113A B-IDENTIFIER 
and O 
RS115A B-IDENTIFIER 
) O 
and O 
acetamide B-SYSTEMATIC 
derivative O 
( O 
RS194B B-NO_CLASS 
) O 
than O 
with O 
2PAM B-ABBREVIATION 
. O 

selective O 
SYK O 
inhibitor O 
P505 B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
( O 
PRT062607 B-IDENTIFIER 
) O 
inhibits O 
B O 
cell O 
signaling O 
and O 
function O 
in O 
vitro O 
and O 
in O 
vivo O 
and O 
augments O 
the O 
activity O 
of O 
fludarabine B-TRIVIAL 
in O 
chronic O 
lymphocytic O 
leukemia O 
. O 

receptor O 
( O 
BCR O 
) O 
associated O 
kinases O 
including O 
spleen O 
tyrosine B-TRIVIAL 
kinase O 
( O 
SYK O 
) O 
contribute O 
to O 
the O 
pathogenesis O 
of O 
B-cell O 
malignancies O 
. O 
SYK O 
is O 
persistently O 
phosphorylated O 
in O 
a O 
subset O 
of O 
non-Hodgkin O 
lymphoma O 
( O 
NHL O 
) O 
and O 
chronic O 
lymphocytic O 
leukemia O 
( O 
CLL O 
) O 
, O 
and O 
SYK O 
inhibition O 
results O 
in O 
abrogation O 
of O 
downstream O 
kinase O 
activity O 
and O 
apoptosis O 
. O 
P505 B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
( O 
also O 
known O 
as O 
PRT062607 B-IDENTIFIER 
) O 
is O 
a O 
novel O 
, O 
highly O 
selective O 
, O 
and O 
orally O 
bioavailable O 
small O 
molecule O 
SYK O 
inhibitor O 
( O 
SYK O 
IC(50) O 
= O 
1 O 
nM O 
) O 
with O 
anti-SYK O 
activity O 
that O 
is O 
at O 
least O 
80-fold O 
greater O 
than O 
its O 
affinity O 
for O 
other O 
kinases O 
. O 
We O 
evaluated O 
the O 
preclinical O 
characteristics O 
of O 
P505 B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
in O 
models O 
of O 
NHL O 
and O 
CLL O 
. O 
P505 B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
successfully O 
inhibited O 
SYK O 
- O 
mediated O 
B-cell O 
receptor O 
signaling O 
and O 
decreased O 
cell O 
viability O 
in O 
NHL O 
and O 
CLL O 
. O 
Oral O 
dosing O 
in O 
mice O 
prevented O 
BCR O 
- O 
mediated O 
splenomegaly O 
and O 
significantly O 
inhibited O 
NHL O 
tumor O 
growth O 
in O 
a O 
xenograft O 
model O 
. O 
In O 
addition O 
, O 
combination O 
treatment O 
of O 
primary O 
CLL O 
cells O 
with O 
P505 B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
plus O 
fludarabine B-TRIVIAL 
produced O 
synergistic O 
enhancement O 
of O 
activity O 
at O 
nanomolar O 
concentrations O 
. O 
Our O 
findings O 
support O 
the O 
ongoing O 
development O 
of O 
P505 B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
as O 
a O 
therapeutic O 
agent O 
for O 
B-cell O 
malignancies O 
. O 
A O 
dose O 
finding O 
study O 
in O 
healthy O 
volunteers O 
has O 
been O 
completed O 
. O 

- O 
area O 
fabrication O 
of O 
periodic O 
sub O 
- O 
15 O 
nm O 
- O 
width O 
single O 
- O 
layer O 
graphene B-TRIVIAL 
nanorings O 
. O 

periodically O 
aligned O 
array O 
of O 
graphene B-TRIVIAL 
nanorings O 
( O 
GRNRs O 
) O 
with O 
a O 
sub O 
- O 
15 O 
nm O 
linewidth O 
at O 
a O 
pitch O 
of O 
450 O 
nm O 
is O 
fabricated O 
with O 
a O 
large O 
area O 
, O 
9 O 
cm(2) O 
, O 
through O 
conventional O 
nanoimprint O 
lithography O 
coupled O 
with O 
sophisticated O 
metal O 
deposition O 
and O 
plasma O 
- O 
etching O 
processes O 
. O 
The O 
existence O 
of O 
the O 
single O 
- O 
layer O 
GRNRs O 
is O 
verified O 
by O 
various O 
techniques O 
. O 

: O 
an O 
old O 
drug O 
with O 
new O 
potential O 
. O 

is O 
an O 
amino B-SYSTEMATIC 
thiol I-SYSTEMATIC 
with O 
the O 
chemical O 
formula O 
HSCH2CH2NH2 B-FORMULA 
. O 
Endogenously O 
, O 
cysteamine B-TRIVIAL 
is O 
derived O 
from O 
coenzyme B-TRIVIAL 
A I-TRIVIAL 
degradation O 
, O 
although O 
its O 
plasma O 
concentrations O 
are O 
low O 
. O 
Most O 
experience O 
with O 
cysteamine B-TRIVIAL 
as O 
a O 
drug O 
originates O 
from O 
the O 
field O 
of O 
the O 
orphan O 
disease O 
cystinosis O 
, O 
in O 
which O 
cysteamine B-TRIVIAL 
is O 
prescribed O 
to O 
decrease O 
intralysosomal O 
cystine B-TRIVIAL 
accumulation O 
. O 
However O 
, O 
over O 
the O 
years O 
, O 
the O 
drug O 
has O 
been O 
used O 
for O 
several O 
other O 
applications O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
In O 
this O 
article O 
, O 
we O 
review O 
the O 
different O 
applications O 
of O 
cysteamine B-TRIVIAL 
, O 
ending O 
with O 
an O 
overview O 
of O 
ongoing O 
clinical O 
trials O 
for O 
new O 
indications O 
, O 
such O 
as O 
neurodegenerative O 
disorders O 
and O 
nonalcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
. O 
The O 
recent O 
development O 
of O 
an O 
enteric O 
- O 
coated O 
cysteamine B-TRIVIAL 
formulation O 
makes O 
cysteamine B-TRIVIAL 
more O 
patient O 
friendly O 
and O 
will O 
extend O 
its O 
applicability O 
for O 
both O 
old O 
and O 
new O 
indications O 
. O 

levels O 
of O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
and O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
- O 
alpha O 
in O 
breast O 
cancer O 
tissues O 
are O 
associated O 
with O 
promoting O 
cancer O 
cell O 
proliferation O 
. O 

acids I-FAMILY 
are O 
endogenous O 
ligands O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
- O 
alpha O 
( O 
PPARα O 
) O 
, O 
which O 
is O 
linked O 
to O 
the O 
regulation O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
uptake O 
, O 
lipid O 
metabolism O 
and O 
breast O 
cancer O 
cell O 
growth O 
. O 
This O 
study O 
was O 
designed O 
to O 
screen O 
candidate O 
fatty B-FAMILY 
acids I-FAMILY 
from O 
breast O 
cancer O 
tissue O 
and O 
to O 
investigate O 
the O 
effects O 
of O 
these O 
candidate O 
fatty B-FAMILY 
acids I-FAMILY 
on O 
PPARα O 
expression O 
, O 
cell O 
growth O 
and O 
cell O 
cycle O 
progression O 
in O 
breast O 
cancer O 
cell O 
lines O 
. O 
One O 
breast O 
cancer O 
tissue O 
and O 
one O 
reference O 
tissue O 
were O 
each O 
taken O 
from O 
30 O 
individual O 
breasts O 
to O 
examine O 
for O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
and O 
PPARα O 
expression O 
. O 
The O 
cancer O 
cell O 
lines O 
MDA-MB-231 O 
( O 
ER- O 
) O 
, O 
MCF-7 O 
( O 
ER O 
+ O 
+ O 
++ O 
) O 
and O 
BT-474 O 
( O 
ER O 
+ O 
+ O 
) O 
were O 
used O 
to O 
explore O 
the O 
mechanisms O 
regulating O 
cell O 
proliferation O 
. O 
We O 
found O 
that O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
and O 
PPARα O 
were O 
highly O 
expressed O 
in O 
the O 
breast O 
cancer O 
tissues O 
. O 
AA O 
stimulated O 
the O 
growth O 
of O 
all O 
three O 
breast O 
cancer O 
cells O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
growth O 
stimulatory O 
effect O 
of O 
AA O 
was O 
associated O 
with O 
PPARα O 
activation O 
, O 
and O 
the O 
most O 
potent O 
effect O 
was O 
found O 
in O 
MCF-7 O 
cells O 
. O 
The O 
stimulation O 
of O 
cell O 
proliferation O 
by O 
AA O 
was O 
accompanied O 
by O 
the O 
increased O 
expression O 
of O 
cyclin O 
E O 
, O 
a O 
reduced O 
population O 
of O 
G1 O 
phase O 
cells O 
, O 
and O 
a O 
faster O 
G1 O 
/ O 
S O 
phase O 
transition O 
. O 
In O 
contrast O 
, O 
AA O 
had O 
no O 
effects O 
on O 
the O 
levels O 
of O 
CDK2 O 
, O 
CDK4 O 
, O 
cyclin O 
D1 O 
, O 
p27 O 
, O 
Bcl-2 O 
and O 
Bax O 
. O 
Our O 
results O 
demonstrate O 
that O 
high O 
levels O 
of O 
AA O 
and O 
PPARα O 
expression O 
in O 
human O 
breast O 
cancer O 
tissues O 
are O 
associated O 
with O 
ER-overexpressed O 
breast O 
cancer O 
cell O 
proliferation O 
, O 
which O 
is O 
involved O 
in O 
activating O 
PPARα O 
, O 
stimulating O 
cyclin O 
E O 
expression O 
, O 
and O 
promoting O 
faster O 
G1 O 
/ O 
S O 
transition O 
. O 

cyclometallated B-FAMILY 
iridium I-FAMILY 
(III) I-FAMILY 
complex O 
as O 
a O 
c-myc O 
G-quadruplex O 
stabilizer O 
and O 
down O 
- O 
regulator O 
of O 
c-myc O 
oncogene O 
expression O 
. O 

new O 
cyclometallated B-FAMILY 
iridium I-FAMILY 
(III) I-FAMILY 
complex O 
with O 
the O 
2,2'-biquinoline B-SYSTEMATIC 
N B-FORMULA 
-donor O 
ligand O 
has O 
been O 
synthesized O 
and O 
characterized O 
. O 
The O 
interaction O 
and O 
affinity O 
of O 
the O 
complex O 
towards O 
c-myc O 
G-quadruplex O 
and O 
duplex O 
DNA O 
have O 
been O 
investigated O 
using O 
UV O 
/ O 
Vis O 
spectroscopy O 
and O 
gel O 
mobility O 
shift O 
assay O 
. O 
These O 
studies O 
revealed O 
that O 
complex O 
1 O 
binds O 
to O 
c-myc O 
G-quadruplexes O 
( O 
Pu22 O 
and O 
Pu27 O 
) O 
with O 
high O 
affinity O 
but O 
does O 
not O 
interact O 
with O 
duplex O 
DNA O 
either O 
by O 
intercalation O 
or O 
groove O 
binding O 
. O 
The O 
ability O 
of O 
1 O 
to O 
stabilize O 
c-myc O 
G-quadruplex O 
DNA O 
in O 
vitro O 
has O 
also O 
been O 
examined O 
through O 
a O 
PCR O 
stop O 
assay O 
and O 
a O 
cell O 
- O 
based O 
luciferase O 
reporter O 
assay O 
. O 
Complex O 
1 O 
displays O 
promising O 
cytotoxic O 
activity O 
against O 
the O 
HeLa O 
cell O 
line O 
with O 
sub O 
- O 
micromolar O 
potency O 
. O 

high O 
- O 
performance O 
liquid O 
chromatographic O 
determination O 
of O 
a O 
rhein B-TRIVIAL 
- O 
diclofenac B-TRIVIAL 
prodrug O 
and O 
its O 
active O 
compounds O 
. O 

order O 
to O 
study O 
the O 
hydrolytic O 
characterization O 
of O 
an O 
anti-inflammatory O 
prodrug O 
( O 
RD-1 O 
) O 
in O 
vitro O 
, O 
a O 
simple O 
, O 
specific O 
, O 
precise O 
and O 
accurate O 
method O 
for O 
the O 
simultaneous O 
determination O 
of O 
prodrug O 
and O 
its O 
two O 
hydrolytic O 
active O 
compounds O 
was O 
development O 
using O 
reverse O 
phase O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
RP-HPLC O 
) O 
. O 
The O 
chromatographic O 
separation O 
was O 
performed O 
on O 
an O 
ODS-2 O 
C18 O 
column O 
( O 
250 O 
mm O 
x O 
4.6 O 
mm O 
, O 
5 O 
microm O 
particle O 
size O 
) O 
with O 
a O 
simple O 
elution O 
programme O 
. O 
The O 
mobile O 
phase O 
was O 
methanol B-SYSTEMATIC 
-0.1% O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
solution O 
( O 
adjusted O 
pH O 
to O 
2.3 O 
) O 
( O 
80 O 
: O 
20 O 
, O 
v O 
/ O 
v O 
) O 
; O 
wavelength O 
of O 
257nm O 
and O 
mobile O 
phase O 
flow O 
rate O 
of O 
1 O 
mL O 
/ O 
min O 
was O 
utilized O 
for O 
the O 
quantitative O 
analysis O 
. O 
Excellent O 
linear O 
behaviors O 
over O 
the O 
investigated O 
concentration O 
ranges O 
were O 
observed O 
with O 
the O 
values O 
of O 
R2 O 
higher O 
than O 
0.999 O 
for O 
all O 
the O 
analytes O 
. O 
The O 
validated O 
method O 
was O 
successfully O 
applied O 
to O 
the O 
simultaneous O 
determination O 
of O 
prodrug O 
and O 
its O 
active O 
components O 
. O 

and O 
infrared O 
absorption O 
of O 
protonated B-FAMILY 
naphthalenes I-FAMILY 
( O 
1-C10H9+ B-SYSTEMATIC 
and O 
2-C10H9+ B-SYSTEMATIC 
) O 
and O 
their O 
neutral O 
counterparts O 
in O 
solid O 
para-hydrogen B-SYSTEMATIC 
. O 

naphthalene I-SYSTEMATIC 
( O 
C(10)H(9)(+) B-FORMULA 
) O 
and O 
its O 
neutral O 
counterparts O 
( O 
hydronaphthyl B-SYSTEMATIC 
radicals O 
, O 
C(10)H(9) B-FORMULA 
) O 
are O 
important O 
intermediates O 
in O 
the O 
reactions O 
of O 
aromatic O 
compounds O 
and O 
in O 
understanding O 
the O 
unidentified O 
infrared O 
( O 
IR O 
) O 
emissions O 
from O 
interstellar O 
media O 
. O 
We O 
report O 
the O 
IR O 
spectra O 
of O 
1-C(10)H(9)(+) B-SYSTEMATIC 
, O 
2-C(10)H(9)(+) B-SYSTEMATIC 
, O 
1-C(10)H(9) B-SYSTEMATIC 
, O 
and O 
2-C(10)H(9) B-SYSTEMATIC 
trapped O 
in O 
solid O 
para-hydrogen B-SYSTEMATIC 
( O 
p-H(2) B-SYSTEMATIC 
) O 
; O 
the O 
latter O 
three O 
are O 
new O 
. O 
These O 
species O 
were O 
produced O 
upon O 
electron O 
bombardment O 
of O 
a O 
mixture O 
of O 
naphthalene B-SYSTEMATIC 
( O 
C(10)H(8) B-FORMULA 
) O 
and O 
p-H(2) B-SYSTEMATIC 
during O 
matrix O 
deposition O 
. O 
The O 
intensities O 
of O 
IR O 
features O 
of O 
1-C(10)H(9)(+) B-SYSTEMATIC 
decreased O 
after O 
the O 
matrix O 
was O 
maintained O 
in O 
darkness O 
for O 
19 O 
h O 
, O 
whereas O 
those O 
of O 
1-C(10)H(9) B-SYSTEMATIC 
and O 
2-C(10)H(9) B-SYSTEMATIC 
increased O 
. O 
Irradiation O 
of O 
this O 
matrix O 
sample O 
with O 
light O 
at O 
365 O 
nm O 
diminished O 
lines O 
of O 
1-C(10)H(9)(+) B-SYSTEMATIC 
and O 
2-C(10)H(9) B-SYSTEMATIC 
and O 
enhanced O 
lines O 
of O 
1-C(10)H(9) B-SYSTEMATIC 
and O 
2-C(10)H(9)(+) B-SYSTEMATIC 
; O 
the O 
latter O 
species O 
was O 
unstable O 
and O 
converted O 
to O 
1-C(10)H(9)(+) B-SYSTEMATIC 
in O 
less O 
than O 
30 O 
min O 
and O 
2-C(10)H(9) B-SYSTEMATIC 
was O 
converted O 
to O 
1-C(10)H(9) B-SYSTEMATIC 
at O 
365 O 
nm O 
. O 
Observed O 
wavenumbers O 
and O 
relative O 
intensities O 
of O 
these O 
species O 
agree O 
satisfactorily O 
with O 
the O 
anharmonic O 
vibrational O 
wavenumbers O 
and O 
IR O 
intensities O 
predicted O 
with O 
the O 
B3PW91 O 
/ O 
6-311 O 
+ O 
+ O 
G(2d,2p) O 
method O 
. O 
Compared O 
with O 
spectra O 
recorded O 
previously O 
with O 
IR O 
photodissociation O 
of O 
Ar B-FORMULA 
-tagged O 
C(10)H(9)(+) B-FORMULA 
or O 
IR O 
multiphoton O 
dissociation O 
of O 
C(10)H(9)(+) B-FORMULA 
, O 
our O 
method O 
has O 
the O 
advantages O 
of O 
producing O 
high O 
- O 
resolution O 
IR O 
spectra O 
with O 
a O 
wide O 
spectral O 
coverage O 
, O 
true O 
IR O 
intensity O 
and O 
excellent O 
ratio O 
of O 
signal O 
to O 
noise O 
; O 
both O 
protonated O 
species O 
and O 
their O 
neutral O 
counterparts O 
are O 
produced O 
with O 
little O 
interference O 
from O 
other O 
fragments O 
. O 
With O 
these O 
advantages O 
, O 
the O 
IR O 
spectra O 
of O 
1-C(10)H(9)(+) B-SYSTEMATIC 
, O 
2-C(10)H(9)(+) B-SYSTEMATIC 
, O 
1-C(10)H(9) B-SYSTEMATIC 
, O 
and O 
2-C(10)H(9) B-SYSTEMATIC 
are O 
here O 
clearly O 
characterized O 
. O 

reverse O 
transcriptase O 
( O 
RT O 
) O 
undergoes O 
a O 
series O 
of O 
conformational O 
changes O 
during O 
viral O 
replication O 
and O 
is O 
a O 
central O 
target O 
for O 
antiretroviral O 
therapy O 
. O 
The O 
intrinsic O 
flexibility O 
of O 
RT O 
can O 
provide O 
novel O 
allosteric O 
sites O 
for O 
inhibition O 
. O 
Crystals O 
of O 
RT O 
that O 
diffract O 
X-rays O 
to O 
better O 
than O 
2 O 
Å O 
resolution O 
facilitated O 
the O 
probing O 
of O 
RT O 
for O 
new O 
druggable O 
sites O 
using O 
fragment O 
screening O 
by O 
X-ray O 
crystallography O 
. O 
A O 
total O 
of O 
775 O 
fragments O 
were O 
grouped O 
into O 
143 O 
cocktails O 
, O 
which O 
were O 
soaked O 
into O 
crystals O 
of O 
RT O 
in O 
complex O 
with O 
the O 
non- O 
nucleoside B-FAMILY 
drug O 
rilpivirine B-TRIVIAL 
( O 
TMC278 B-IDENTIFIER 
) O 
. O 
Seven O 
new O 
sites O 
were O 
discovered O 
, O 
including O 
the O 
Incoming O 
Nucleotide B-FAMILY 
Binding O 
, O 
Knuckles O 
, O 
NNRTI O 
Adjacent O 
, O 
and O 
399 O 
sites O 
, O 
located O 
in O 
the O 
polymerase O 
region O 
of O 
RT O 
, O 
and O 
the O 
428 O 
, O 
RNase O 
H O 
Primer O 
Grip O 
Adjacent O 
, O 
and O 
507 O 
sites O 
, O 
located O 
in O 
the O 
RNase O 
H O 
region O 
. O 
Three O 
of O 
these O 
sites O 
( O 
Knuckles O 
, O 
NNRTI O 
Adjacent O 
, O 
and O 
Incoming O 
Nucleotide B-FAMILY 
Binding O 
) O 
are O 
inhibitory O 
and O 
provide O 
opportunities O 
for O 
discovery O 
of O 
new O 
anti-AIDS O 
drugs O 
. O 

Article O 
describes O 
the O 
generation O 
of O 
a O 
patterned O 
surface O 
that O 
can O 
be O 
postpolymerization O 
modified O 
to O 
incorporate O 
fragile O 
macromolecules O 
or O 
delicate O 
biomolecules O 
without O 
the O 
need O 
for O 
special O 
equipment O 
. O 
Two O 
monomers O 
that O 
undergo O 
different O 
click O 
reactions O 
, O 
pentafluorophenyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
( O 
PFPA B-ABBREVIATION 
) O 
and O 
4-(trimethylsilyl) B-SYSTEMATIC 
ethynylstyrene I-SYSTEMATIC 
( O 
TMSES B-ABBREVIATION 
) O 
, O 
were O 
sequentially O 
polymerized O 
from O 
a O 
silicon B-SYSTEMATIC 
surface O 
in O 
the O 
presence O 
of O 
a O 
shadowmask O 
with O 
UV O 
light O 
, O 
generating O 
12.5 O 
and O 
62 O 
μm O 
pitch O 
patterns O 
. O 
Two O 
different O 
dyes O 
, O 
1-aminomethylpyrene B-SYSTEMATIC 
( O 
AMP B-ABBREVIATION 
) O 
and O 
5-azidofluorescein B-SYSTEMATIC 
( O 
AF O 
) O 
, O 
were O 
covalently O 
attached O 
to O 
the O 
polymer O 
brushes O 
through O 
aminolysis O 
and O 
dual O 
desilylation/ O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
-catalyzed O 
alkyne B-FAMILY 
/ O 
azide B-SYSTEMATIC 
cycloaddition O 
( O 
CuAAC O 
) O 
in O 
one O 
pot O 
. O 
Unlike O 
most O 
CuAAC O 
reactions O 
, O 
the O 
terminal O 
alkyne O 
of O 
TMSES B-ABBREVIATION 
was O 
not O 
deprotected O 
prior O 
to O 
functionalization O 
. O 
Although O 
a O 
2 O 
nm O 
thickness O 
increase O 
was O 
observed O 
for O 
poly(PFPA) B-FAMILY 
brushes O 
after O 
polymerization O 
of O 
TMSES B-ABBREVIATION 
, O 
cross O 
- O 
contamination O 
was O 
not O 
visible O 
through O 
fluorescence O 
microscopy O 
after O 
functionalization O 
. O 

properties O 
, O 
metabolism O 
, O 
and O 
disposition O 
of O 
linaclotide B-TRIVIAL 
, O 
a O 
novel O 
therapeutic O 
peptide O 
approved O 
for O 
the O 
treatment O 
of O 
irritable O 
bowel O 
syndrome O 
with O 
constipation O 
and O 
chronic O 
idiopathic O 
constipation O 
. O 

, O 
a O 
potent O 
guanylate B-TRIVIAL 
cyclase O 
C O 
agonist O 
, O 
is O 
a O 
therapeutic O 
peptide O 
approved O 
in O 
the O 
United O 
States O 
for O 
the O 
treatment O 
of O 
irritable O 
bowel O 
syndrome O 
with O 
constipation O 
and O 
chronic O 
idiopathic O 
constipation O 
. O 
We O 
present O 
for O 
the O 
first O 
time O 
the O 
metabolism O 
, O 
degradation O 
, O 
and O 
disposition O 
of O 
linaclotide B-TRIVIAL 
in O 
animals O 
and O 
humans O 
. O 
We O 
examined O 
the O 
metabolic O 
stability O 
of O 
linaclotide B-TRIVIAL 
in O 
conditions O 
that O 
mimic O 
the O 
gastrointestinal O 
tract O 
and O 
characterized O 
the O 
metabolite O 
MM-419447 B-IDENTIFIER 
( O 
CCEYCCNPACTGC O 
) O 
, O 
which O 
contributes O 
to O 
the O 
pharmacologic O 
effects O 
of O 
linaclotide B-TRIVIAL 
. O 
Systemic O 
exposure O 
to O 
these O 
active O 
peptides O 
is O 
low O 
in O 
rats O 
and O 
humans O 
, O 
and O 
the O 
low O 
systemic O 
and O 
portal O 
vein O 
concentrations O 
of O 
linaclotide B-TRIVIAL 
and O 
MM-419447 B-IDENTIFIER 
observed O 
in O 
the O 
rat O 
confirmed O 
both O 
peptides O 
are O 
minimally O 
absorbed O 
after O 
oral O 
administration O 
. O 
Linaclotide B-TRIVIAL 
is O 
stable O 
in O 
the O 
acidic O 
environment O 
of O 
the O 
stomach O 
and O 
is O 
converted O 
to O 
MM-419447 B-IDENTIFIER 
in O 
the O 
small O 
intestine O 
. O 
The O 
disulfide B-SYSTEMATIC 
bonds O 
of O 
both O 
peptides O 
are O 
reduced O 
in O 
the O 
small O 
intestine O 
, O 
where O 
they O 
are O 
subsequently O 
proteolyzed O 
and O 
degraded O 
. O 
After O 
oral O 
administration O 
of O 
linaclotide B-TRIVIAL 
, O 
< O 
1% O 
of O 
the O 
dose O 
was O 
excreted O 
as O 
active O 
peptide O 
in O 
rat O 
feces O 
and O 
a O 
mean O 
of O 
3-5% O 
in O 
human O 
feces O 
; O 
in O 
both O 
cases O 
MM-419447 B-IDENTIFIER 
was O 
the O 
predominant O 
peptide O 
recovered O 
. O 
MM-419447 B-IDENTIFIER 
exhibits O 
high O 
- O 
affinity O 
binding O 
in O 
vitro O 
to O 
T84 O 
cells O 
, O 
resulting O 
in O 
a O 
significant O 
, O 
concentration O 
- O 
dependent O 
accumulation O 
of O 
intracellular O 
cyclic B-SYSTEMATIC 
guanosine-3',5'-monophosphate I-SYSTEMATIC 
( O 
cGMP B-ABBREVIATION 
) O 
. O 
In O 
rat O 
models O 
of O 
gastrointestinal O 
function O 
, O 
orally O 
dosed O 
MM-419447 B-IDENTIFIER 
significantly O 
increased O 
fluid O 
secretion O 
into O 
small O 
intestinal O 
loops O 
, O 
increased O 
intraluminal O 
cGMP B-ABBREVIATION 
, O 
and O 
caused O 
a O 
dose O 
- O 
dependent O 
acceleration O 
in O 
gastrointestinal O 
transit O 
. O 
These O 
results O 
demonstrate O 
the O 
importance O 
of O 
the O 
active O 
metabolite O 
in O 
contributing O 
to O 
linaclotide B-TRIVIAL 
' O 
s O 
pharmacology O 
. O 

new O 
tirucallane B-FAMILY 
triterpenoids I-FAMILY 
from O 
the O 
leaves O 
of O 
Aquilaria O 
sinensis O 
. O 

new O 
tirucallane B-FAMILY 
triterpenoids I-FAMILY 
, O 
aquilacallanes B-MULTIPLE 
A-B I-MULTIPLE 
( O 
1-2 O 
) O 
, O 
together O 
with O 
15 O 
known O 
compounds O 
( O 
3-17 O 
) O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Aquilaria O 
sinensis O 
. O 
The O 
structures O 
of O 
these O 
new O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analyses O 
. O 
All O 
compounds O 
were O 
evaluated O 
for O 
their O 
cytotoxic O 
activity O 
against O 
five O 
human O 
cancer O 
cell O 
lines O 
. O 
The O 
known O 
compounds O 
, O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
7 O 
) O 
and O 
5,7,4'-trimethoxyflavone B-SYSTEMATIC 
( O 
14 O 
) O 
, O 
exhibited O 
weak O 
cytotoxic O 
activity O 
against O 
some O 
cells O 
. O 

- I-TRIVIAL 
trans I-TRIVIAL 
retinoic I-TRIVIAL 
acid I-TRIVIAL 
protects O 
hepatocellular O 
carcinoma O 
cells O 
against O 
serum O 
- O 
starvation O 
- O 
induced O 
cell O 
death O 
by O 
upregulating O 
collagen O 
8A2 O 
. O 

a O 
therapeutic O 
or O 
chemopreventative O 
agent O 
for O 
various O 
cancers O 
, O 
all B-TRIVIAL 
- I-TRIVIAL 
trans I-TRIVIAL 
retinoic I-TRIVIAL 
acid I-TRIVIAL 
( O 
atRA B-ABBREVIATION 
) O 
has O 
been O 
reported O 
to O 
inhibit O 
growth O 
, O 
induce O 
apoptosis O 
or O 
cause O 
differentiation O 
. O 
It O 
was O 
found O 
that O 
atRA B-ABBREVIATION 
could O 
protect O 
hepatocellular O 
carcinoma O 
( O 
HCC O 
) O 
cells O 
against O 
cell O 
death O 
induced O 
by O 
serum O 
starvation O 
. O 
Furthermore O 
, O 
it O 
was O 
found O 
that O 
atRA B-ABBREVIATION 
could O 
enhance O 
cell O 
adhesion O 
, O 
but O 
had O 
no O 
effect O 
on O 
the O 
cell O 
cycle O 
and O 
apoptosis O 
. O 
Using O 
an O 
Illumina O 
Human O 
HT-12 O 
v4 O 
expression O 
microarray O 
, O 
207 O 
upregulated O 
and O 
173 O 
downregulated O 
genes O 
were O 
identified O 
in O 
HepG2 O 
cells O 
treated O 
with O 
atRA B-ABBREVIATION 
. O 
The O 
most O 
upregulated O 
genes O 
are O 
cytochrome O 
P450 O 
family O 
26 O 
subfamily O 
A O 
polypeptide O 
1 O 
( O 
CYP26A1 O 
) O 
, O 
histidine B-TRIVIAL 
triad O 
nucleotide O 
binding O 
protein O 
3 O 
( O 
HINT3 O 
) O 
, O 
miR-1282 O 
and O 
cytochrome O 
P450 O 
family O 
26 O 
subfamily O 
B O 
polypeptide O 
1 O 
( O 
CYP26B1 O 
) O 
, O 
which O 
showed O 
more O 
than O 
fivefold O 
greater O 
expression O 
. O 
Using O 
Gene O 
Ontology O 
analysis O 
, O 
the O 
greatest O 
significance O 
was O 
found O 
in O 
extracellular O 
- O 
matrix O 
- O 
related O 
molecular O 
functions O 
and O 
the O 
cellular O 
component O 
in O 
upregulated O 
genes O 
. O 
The O 
upregulation O 
of O 
collagen O 
8A2 O 
( O 
COL8A2 O 
) O 
was O 
further O 
confirmed O 
using O 
quantitative O 
RT-PCR O 
and O 
western O 
blotting O 
. O 
Knockdown O 
of O 
COL8A2 O 
blocked O 
enhancement O 
in O 
the O 
early O 
stage O 
of O 
cell O 
adhesion O 
by O 
atRA B-ABBREVIATION 
treatment O 
. O 
Re-expression O 
of O 
COL8A2 O 
in O 
COL8A2-knocked O 
- O 
down O 
HCC O 
cells O 
reversed O 
the O 
effect O 
of O 
small O 
interfering O 
RNA-COL8A2 O 
. O 
In O 
addition O 
, O 
COL8A2 O 
could O 
increase O 
HCC O 
cell O 
migration O 
and O 
invasion O 
. O 
Thus O 
, O 
COL8A2 O 
was O 
identified O 
as O 
the O 
key O 
protein O 
involved O 
in O 
the O 
enhancement O 
of O 
cell O 
adhesion O 
of O 
atRA B-ABBREVIATION 
under O 
serum O 
- O 
free O 
conditions O 
. O 
In O 
conclusion O 
, O 
atRA B-ABBREVIATION 
protects O 
HCC O 
cells O 
against O 
serum O 
- O 
starvation O 
- O 
induced O 
cell O 
death O 
by O 
enhancing O 
cell O 
adhesion O 
, O 
and O 
COL8A2 O 
plays O 
an O 
important O 
role O 
in O 
HCC O 
cell O 
migration O 
and O 
invasion O 
. O 

and O 
Antibacterial O 
Cembranoids B-FAMILY 
from O 
a O 
South O 
China O 
Sea O 
Soft O 
Coral O 
, O 
Lobophytum O 
sp O 
. O 

examination O 
of O 
a O 
South O 
China O 
Sea O 
soft O 
coral O 
Lobophytum O 
sp O 
. O 
led O 
to O 
the O 
isolation O 
of O 
three O 
new O 
α-methylene-γ-lactone B-SYSTEMATIC 
-containing O 
cembranoids B-FAMILY 
, O 
( B-SYSTEMATIC 
1R*,3R* I-SYSTEMATIC 
, I-SYSTEMATIC 
4R*,14R*,7E,11E)-3,4-epoxycembra-7,11,15(17)-trien-16,14-olide I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
( B-SYSTEMATIC 
1R*,7S*,14S*,3E I-SYSTEMATIC 
, I-SYSTEMATIC 
11E)-7-hydroperoxycembra-3,8(19),11,15(17)-tetraen-16,14-olide I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
( B-SYSTEMATIC 
1R*,7S*,14S* I-SYSTEMATIC 
, I-SYSTEMATIC 
3E,11E)-18-acetoxy-7-hydroperoxycembra-3,8(19),11,15(17)-tetraen-16,14-olide I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
along O 
with O 
eleven O 
known O 
analogues O 
4-14 O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
through O 
extensive O 
spectroscopic O 
analysis O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
data O 
. O 
Compounds O 
1-3 O 
exhibited O 
moderate O 
cytotoxic O 
activity O 
against O 
the O 
selected O 
tumor O 
cell O 
lines O 
. O 
Moreover O 
, O 
2 O 
and O 
3 O 
were O 
found O 
to O 
be O 
moderate O 
inhibitors O 
against O 
the O 
bacteria O 
S O 
. O 
aureus O 
and O 
S O 
. O 
pneumoniae O 
. O 

prospects O 
for O 
vinblastine B-TRIVIAL 
analogues O 
as O 
anticancer O 
agents O 
. O 

et O 
al O 
. O 
synthesized O 
a O 
series O 
of O 
C20 O 
' O 
urea B-TRIVIAL 
derivatives O 
of O 
vinblastine B-TRIVIAL 
that O 
matched O 
or O 
exceeded O 
the O 
potency O 
of O 
vinblastine B-TRIVIAL 
in O 
cell O 
growth O 
inhibition O 
assays O 
. O 
The O 
studies O 
demonstrated O 
the O 
importance O 
of O 
the O 
H B-FORMULA 
-bond O 
donor O 
on O 
the O 
C20 O 
' O 
position O 
and O 
revealed O 
the O 
presence O 
of O 
a O 
space O 
surrounding O 
the O 
C20 O 
' O 
substituent O 
that O 
tolerates O 
a O 
wide O 
variety O 
of O 
substituents O 
, O 
remarkably O 
enhancing O 
potency O 
of O 
vinblastine B-TRIVIAL 
analogues O 
. O 

separation O 
of O 
patchouli B-TRIVIAL 
alcohol I-TRIVIAL 
from O 
the O 
essential O 
oil O 
of O 
Cablin O 
potchouli O 
by O 
inclusion O 
crystalline O 
method O 
. O 

this O 
article O 
, O 
we O 
have O 
focused O 
on O 
the O 
application O 
of O 
non-traditional O 
separation O 
approach O 
, O 
the O 
host O 
- O 
guest O 
inclusion O 
method O 
, O 
into O 
the O 
separation O 
of O 
the O 
active O 
component O 
patchouli B-TRIVIAL 
alcohol I-TRIVIAL 
from O 
the O 
essential O 
oil O 
of O 
Cablin O 
potchouli O 
Herb O 
. O 
The O 
host O 
molecule O 
1,1,6,6-tetraphenylhexa-2,4-diyne-1,6-diol B-SYSTEMATIC 
( O 
A O 
) O 
was O 
used O 
to O 
selectively O 
recognise O 
the O 
guest O 
molecule O 
patchouli B-TRIVIAL 
alcohol I-TRIVIAL 
( O 
B O 
) O 
in O 
the O 
essential O 
oil O 
of O 
Pogostemon O 
cablin O 
( O 
Blanco O 
) O 
Benth O 
through O 
two O 
strong O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 
The O 
inclusion O 
compound O 
was O 
structurally O 
determined O 
by O 
the O 
single O 
crystal O 
X-ray O 
diffraction O 
. O 
The O 
separation O 
effect O 
was O 
examined O 
by O 
gas O 
chromatography O 
for O 
the O 
whole O 
essential O 
oil O 
and O 
the O 
inclusion O 
compound O 
, O 
showing O 
that O 
the O 
inclusion O 
crystalline O 
method O 
is O 
simple O 
, O 
rapid O 
and O 
effective O 
for O 
the O 
separation O 
of O 
patchouli B-TRIVIAL 
alcohol I-TRIVIAL 
from O 
the O 
essential O 
oil O 
of O 
C O 
. O 
potchouli O 
Herb O 
. O 

anthocyanins B-FAMILY 
from O 
phytoresources O 
and O 
their O 
chemical O 
researches O 
. O 

are O 
a O 
class O 
of O 
naturally O 
occurring O 
polyphenols B-FAMILY 
which O 
have O 
been O 
most O 
widely O 
studied O 
in O 
recent O 
decades O 
for O 
the O 
rapid O 
development O 
of O 
relative O 
techniques O 
. O 
This O 
article O 
first O 
reviews O 
the O 
various O 
anthocyanin B-FAMILY 
resources O 
including O 
fruits O 
, O 
flowers O 
, O 
vegetables O 
and O 
beverages O 
. O 
Besides O 
the O 
direct O 
extraction O 
from O 
natural O 
resources O 
, O 
anthocyanins B-FAMILY 
can O 
also O 
be O 
obtained O 
by O 
semi- O 
or O 
total O 
synthesis O 
. O 
After O 
the O 
introduction O 
of O 
new O 
representative O 
anthocyanins B-FAMILY 
found O 
in O 
the O 
past O 
few O 
years O 
and O 
the O 
major O 
relationships O 
between O 
structures O 
and O 
stability O 
, O 
modern O 
separation O 
and O 
analysis O 
technologies O 
in O 
related O 
studies O 
were O 
summarised O 
, O 
which O 
play O 
an O 
important O 
role O 
in O 
chemical O 
researches O 
of O 
anthocyanins B-FAMILY 
. O 

sheets O 
: O 
gram O 
- O 
scale O 
synthesis O 
of O 
graphene B-TRIVIAL 
sheets O 
by O 
a O 
catalytic O 
arc O 
- O 
discharge O 
method O 
( O 
small O 
8 O 
/ O 
2013 O 
) O 
. O 

- O 
scale O 
amounts O 
of O 
high O 
- O 
quality O 
graphene B-TRIVIAL 
sheets O 
are O 
synthesized O 
on O 
page O 
1330 O 
through O 
an O 
arc O 
- O 
discharge O 
method O 
. O 
An O 
arc O 
, O 
which O 
is O 
generated O 
between O 
two O 
graphite B-TRIVIAL 
rods O 
when O 
a O 
high O 
voltage O 
is O 
applied O 
by O 
Y O 
. O 
Liu O 
and O 
co O 
- O 
workers O 
, O 
can O 
cause O 
the O 
graphite B-TRIVIAL 
layers O 
to O 
separate O 
into O 
graphene B-TRIVIAL 
sheets O 
via O 
a O 
high O 
- O 
temperature O 
exfoliation O 
, O 
or O 
even O 
broken O 
into O 
small O 
clusters O 
/ O 
atoms O 
, O 
which O 
then O 
form O 
graphene B-TRIVIAL 
sheets O 
by O 
catalytic O 
growth O 
, O 
demonstrating O 
that O 
two O 
mechanisms O 
exist O 
in O 
an O 
arc O 
discharge O 
process O 
simultaneously O 
. O 

: O 
a O 
new O 
microbial O 
diketopiperazine B-FAMILY 
from O 
a O 
terrestrial O 
Bacillus O 
subtilis O 
strain O 
B38 O 
. O 

continuation O 
of O 
our O 
search O 
for O 
bioactive O 
secondary O 
metabolites O 
from O 
terrestrial O 
Bacillus O 
spp O 
. O 
, O 
a O 
new O 
microbial O 
diketopiperazine B-FAMILY 
, O 
cis-cyclo-(His,Leu) B-FORMULA 
( O 
1 O 
) O 
was O 
isolated O 
from O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
a O 
strain O 
B O 
. O 
subtilis O 
B38 O 
, O 
together O 
with O 
cis-cyclo-(Phe,Phe) B-FORMULA 
( O 
2 O 
) O 
, O 
tryptophane B-TRIVIAL 
( O 
3 O 
) O 
, O 
cis-cyclo-(Leu,Tyr) B-FORMULA 
( O 
4 O 
) O 
, O 
cis-cyclo-(Trp,Tyr) B-FORMULA 
( O 
5 O 
) O 
and O 
macrolactin B-TRIVIAL 
A I-TRIVIAL 
( O 
6 O 
) O 
. O 
The O 
chemical O 
structures O 
of O 
the O 
isolated O 
compounds O 
were O 
identified O 
by O 
comparison O 
of O 
their O 
1D O 
, O 
2D O 
NMR O 
and O 
HRESIMS O 
data O 
with O 
authentic O 
spectra O 
and O 
literatures O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
time O 
that O 
cyclo-(His,Leu) B-FORMULA 
has O 
been O 
isolated O 
from O 
natural O 
products O 
. O 

dispersion O 
, O 
membrane O 
curvature O 
, O 
and O 
penetration O 
induced O 
by O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
wrapped O 
with O 
lipids O 
and O 
PEGylated O 
lipids O 
. O 

- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
wrapped O 
with O 
different O 
types O 
of O 
lipids O 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
)-grafted O 
lipids O 
were O 
simulated O 
with O 
lipid O 
bilayers O 
. O 
Simulations O 
were O 
carried O 
out O 
with O 
the O 
previously O 
parametrized O 
coarse O 
- O 
grained O 
( O 
CG O 
) O 
SWNT O 
and O 
PEG B-ABBREVIATION 
force O 
fields O 
that O 
had O 
captured O 
the O 
experimentally O 
observed O 
conformations O 
of O 
self O 
- O 
assembled O 
SWNT-lipid O 
complexes O 
and O 
phase O 
behavior O 
of O 
PEG B-ABBREVIATION 
-grafted O 
lipids O 
. O 
Simulations O 
of O 
multiple O 
copies O 
of O 
the O 
SWNT O 
in O 
water O 
show O 
that O 
all O 
pure O 
SWNTs O 
aggregate O 
, O 
lipid O 
- O 
wrapped O 
SWNTs O 
partially O 
aggregate O 
, O 
but O 
those O 
wrapped O 
with O 
lipids O 
grafted O 
to O 
PEG B-ABBREVIATION 
( O 
M(w) O 
= O 
550 O 
) O 
completely O 
disperse O 
, O 
indicating O 
the O 
effect O 
of O 
short O 
PEG B-ABBREVIATION 
chains O 
on O 
interparticle O 
aggregation O 
, O 
in O 
agreement O 
with O 
experiment O 
. O 
Starting O 
with O 
initial O 
SWNT O 
orientation O 
parallel O 
to O 
the O 
bilayer O 
surface O 
, O 
SWNTs O 
wrapped O 
with O 
lysophospholipids O 
and O 
PEG B-ABBREVIATION 
( O 
M(w) O 
= O 
550)-grafted O 
lipids O 
insert O 
into O 
the O 
hydrophobic O 
region O 
of O 
the O 
bilayer O 
, O 
while O 
SWNTs O 
wrapped O 
with O 
phospholipids O 
and O 
longer O 
PEG B-ABBREVIATION 
( O 
M(w) O 
= O 
2000)-grafted O 
lipids O 
do O 
not O 
. O 
These O 
indicate O 
that O 
SWNTs O 
insert O 
because O 
of O 
the O 
hydrophobic O 
interaction O 
with O 
the O 
bilayer O 
tails O 
, O 
but O 
the O 
tight O 
wrapping O 
of O 
charged O 
lipid O 
headgroups O 
and O 
long O 
hydrophilic O 
PEG B-ABBREVIATION 
chains O 
can O 
weaken O 
the O 
hydrophobic O 
interaction O 
and O 
inhibit O 
SWNT O 
insertion O 
. O 
The O 
inserted O 
SWNTs O 
contact O 
the O 
entire O 
tails O 
of O 
neighboring O 
lipids O 
in O 
one O 
leaflet O 
of O 
the O 
bilayer O 
, O 
which O 
disorders O 
the O 
lipid O 
bilayer O 
and O 
induces O 
positive O 
curvature O 
. O 
Our O 
findings O 
indicate O 
that O 
interparticle O 
aggregation O 
, O 
SWNT O 
penetration O 
, O 
and O 
membrane O 
curvature O 
can O 
be O 
modulated O 
by O 
the O 
SWNT-lipid O 
structure O 
and O 
the O 
PEG B-ABBREVIATION 
length O 
. O 

A I-TRIVIAL 
interferes O 
with O 
thyroid O 
specific O 
gene O 
expression O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
an O 
endocrine O 
- O 
disrupting O 
chemical O 
that O 
leads O 
to O 
low O 
- O 
dose O 
human O 
exposure O 
due O 
to O 
its O 
ability O 
to O 
leach O 
from O 
chemically O 
derived O 
products O 
, O 
as O 
polycarbonate B-FAMILY 
plastics O 
and O 
epoxy B-SYSTEMATIC 
resin O 
. O 
In O 
addition O 
to O 
its O 
known O 
xeno O 
- O 
endocrine O 
action O 
, O 
BPA B-ABBREVIATION 
exerts O 
a O 
wide O 
range O 
of O 
metabolic O 
effects O 
. O 
Despite O 
the O 
documented O 
BPA B-ABBREVIATION 
exposure O 
outcomes O 
on O 
synthesis O 
of O 
thyroid B-FAMILY 
hormones I-FAMILY 
, O 
there O 
are O 
not O 
any O 
data O 
available O 
on O 
its O 
actions O 
on O 
the O 
thyroid O 
follicular O 
cells O 
, O 
site O 
of O 
synthesis O 
of O 
the O 
thyroid B-FAMILY 
hormones I-FAMILY 
. O 
Recently O 
, O 
it O 
has O 
been O 
shown O 
that O 
several O 
environmental O 
pollutants O 
, O 
as O 
BPA B-ABBREVIATION 
, O 
can O 
exert O 
a O 
thyroid O 
disrupting O 
activity O 
. O 
In O 
this O 
study O 
, O 
we O 
employed O 
in O 
vitro O 
and O 
in O 
vivo O 
( O 
zebrafish O 
) O 
models O 
to O 
examine O 
the O 
effects O 
of O 
BPA B-ABBREVIATION 
in O 
regulating O 
the O 
expression O 
of O 
genes O 
involved O 
in O 
the O 
thyroid B-FAMILY 
hormone I-FAMILY 
synthesis O 
and O 
of O 
their O 
transcriptional O 
regulators O 
at O 
BPA B-ABBREVIATION 
doses O 
as O 
low O 
as O 
10(-9)M O 
, O 
a O 
dose O 
that O 
is O 
environmentally O 
pertinent O 
and O 
far O 
below O 
the O 
one O 
detected O 
in O 
infants O 
plasma O 
. O 
In O 
both O 
systems O 
we O 
could O 
detect O 
an O 
altered O 
expression O 
of O 
the O 
genes O 
involved O 
in O 
thyroid B-FAMILY 
hormones I-FAMILY 
synthesis O 
and O 
of O 
thyroid O 
specific O 
transcriptional O 
factors O 
in O 
BPA B-ABBREVIATION 
dose O 
and O 
time O 
dependent O 
manner O 
. O 
Our O 
results O 
suggest O 
that O 
BPA B-ABBREVIATION 
exerts O 
a O 
direct O 
effect O 
on O 
thyroid O 
follicular O 
cell O 
. O 
We O 
show O 
that O 
these O 
cells O 
can O 
" O 
sense O 
" O 
very O 
low O 
amount O 
of O 
BPA B-ABBREVIATION 
. O 
Thus O 
they O 
, O 
potentially O 
, O 
represent O 
an O 
ideal O 
in O 
vitro O 
system O 
to O 
develop O 
assays O 
to O 
detect O 
BPA B-ABBREVIATION 
and O 
other O 
pollutants O 
with O 
thyroid O 
disrupting O 
activity O 
at O 
level O 
far O 
below O 
the O 
ones O 
considered O 
to O 
be O 
environmental O 
relevant O 
. O 
Moreover O 
, O 
this O 
report O 
may O 
provide O 
new O 
insight O 
into O 
the O 
mode O 
of O 
BPA B-ABBREVIATION 
-induced O 
deregulation O 
of O 
physiological O 
processes O 
as O 
well O 
as O 
on O 
the O 
extensively O 
debated O 
molecular O 
pathways O 
underlying O 
its O 
biological O 
activities O 
. O 

of O 
robust O 
enzyme O 
nanocapsules O 
for O 
effective O 
organophosphate B-FAMILY 
decontamination O 
, O 
detoxification O 
, O 
and O 
protection O 
. O 

of O 
organophosphorous B-FAMILY 
hydrolase O 
with O 
enhanced O 
enzyme O 
activity O 
and O 
stability O 
are O 
prepared O 
via O 
in O 
situ O 
polymerization O 
, O 
providing O 
a O 
novel O 
class O 
of O 
nanoparticles O 
for O 
the O 
decontamination O 
and O 
detoxification O 
of O 
organophosphates B-FAMILY 
such O 
as O 
chemical O 
warfare O 
agents O 
and O 
pesticides O 
. O 
Using O 
the O 
nanocapsules O 
as O 
building O 
blocks O 
, O 
bioactive O 
nanocomposites O 
are O 
also O 
fabricated O 
, O 
enabling O 
their O 
use O 
for O 
organophosphate B-FAMILY 
protection O 
. O 

protection O 
against O 
aluminium B-SYSTEMATIC 
induced O 
altered O 
lipid O 
profile O 
and O 
membrane O 
integrity O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
Zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
supplementation O 
on O 
lipid O 
profile O 
and O 
fluidity O 
of O 
cerebrum O 
and O 
cerebellum O 
membranes O 
of O 
rats O 
treated O 
with O 
aluminium B-SYSTEMATIC 
( O 
Al B-FORMULA 
) O 
. O 
Sprague O 
dawley O 
male O 
rats O 
were O 
divided O 
into O 
four O 
different O 
treatment O 
groups O 
viz O 
: O 
Control O 
, O 
aluminium B-SYSTEMATIC 
treated O 
, O 
zinc B-SYSTEMATIC 
treated O 
and O 
aluminium B-SYSTEMATIC 
+ O 
zinc B-SYSTEMATIC 
treated O 
. O 
Aluminium B-SYSTEMATIC 
( O 
AlCl3 B-FORMULA 
) O 
was O 
administered O 
orally O 
at O 
a O 
dose O 
of O 
100mg O 
/ O 
kgb.wt O 
. O 
/ O 
day O 
( O 
dissolved O 
in O 
drinking O 
water O 
) O 
. O 
Zinc B-SYSTEMATIC 
as O 
zinc B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
was O 
supplemented O 
to O 
rats O 
at O 
a O 
dose O 
of O 
227mg O 
/ O 
l O 
in O 
drinking O 
water O 
. O 
A O 
significant O 
decrease O 
in O 
the O 
levels O 
of O 
total O 
lipids O 
, O 
glycolipids O 
, O 
phospholipids O 
, O 
cholesterol B-TRIVIAL 
and O 
gangliosides B-FAMILY 
contents O 
were O 
observed O 
in O 
both O 
the O 
cerebrum O 
and O 
cerebellum O 
following O 
Al B-FORMULA 
exposure O 
, O 
which O 
were O 
found O 
to O 
be O 
significantly O 
increased O 
following O 
Zn B-FORMULA 
supplementation O 
. O 
On O 
the O 
contrary O 
, O 
Al B-FORMULA 
treatment O 
caused O 
a O 
significant O 
increase O 
in O 
the O 
formation O 
of O 
conjugated O 
dienes B-FAMILY 
, O 
which O 
were O 
observed O 
to O 
be O 
reduced O 
on O 
Zn B-FORMULA 
co O 
- O 
treatment O 
. O 
Further O 
, O 
Al B-FORMULA 
treatment O 
significantly O 
elevated O 
the O 
fluorescence O 
polarization O 
, O 
anisotropy O 
and O 
order O 
parameter O 
, O 
which O 
however O 
were O 
normalized O 
upon O 
Zn B-FORMULA 
co O 
- O 
administration O 
. O 
Hence O 
, O 
the O 
present O 
study O 
depicts O 
the O 
potential O 
of O 
Zn B-FORMULA 
in O 
moderating O 
the O 
changes O 
caused O 
by O 
Al B-FORMULA 
on O 
membrane O 
composition O 
and O 
fluidity O 
in O 
rat O 
brain O 
. O 

essential O 
oil O 
from O 
air O 
dried O 
buds O 
and O 
roots O 
of O 
Calligonum O 
polygonoides O 
Linn O 
. O 
, O 
has O 
been O 
extracted O 
from O 
dry O 
steam O 
distillation O 
and O 
analysed O 
for O 
chemical O 
composition O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 
In O 
total O 
, O 
27 O 
and O 
10 O 
compounds O 
were O 
analysed O 
qualitatively O 
and O 
quantitatively O 
, O 
accounting O 
for O 
68.42% O 
and O 
82.12% O 
total O 
contents O 
of O 
the O 
essential O 
oils O 
of O 
buds O 
and O 
roots O 
, O 
respectively O 
. O 
It O 
contains O 
a O 
complex O 
mixture O 
of O 
terpenoids B-FAMILY 
, O 
hydrocarbons B-FAMILY 
, O 
phenolic B-FAMILY 
compounds O 
, O 
acid O 
derivatives O 
and O 
ketones B-FAMILY 
. O 
The O 
main O 
component O 
of O 
essential O 
oil O 
was O 
ethyl B-SYSTEMATIC 
homovanillate I-SYSTEMATIC 
( O 
11.79% O 
) O 
in O 
buds O 
and O 
drimenol B-TRIVIAL 
( O 
29.42% O 
) O 
in O 
roots O 
. O 

collision O 
- O 
induced O 
dissociation O 
of O 
hydrated B-SYSTEMATIC 
magnesium I-SYSTEMATIC 
: O 
experimental O 
and O 
theoretical O 
investigation O 
of O 
the O 
binding O 
energies O 
for O 
Mg(2+)(H2O)x B-FAMILY 
complexes O 
( O 
x=2-10 O 
) O 
. O 

sequential O 
bond O 
energies O 
of O 
Mg(2+)(H2O)x B-FAMILY 
complexes O 
, O 
in O 
which O 
x=2-10 O 
, O 
are O 
measured O 
by O 
threshold O 
collision O 
- O 
induced O 
dissociation O 
in O 
a O 
guided O 
ion O 
beam O 
tandem O 
mass O 
spectrometer O 
. O 
From O 
an O 
electrospray O 
ionization O 
source O 
that O 
produces O 
an O 
initial O 
distribution O 
of O 
Mg(2+)(H2O)x B-FAMILY 
complexes O 
in O 
which O 
x=7-10 O 
, O 
complexes O 
down O 
to O 
x=3 O 
are O 
formed O 
by O 
using O 
an O 
in O 
- O 
source O 
fragmentation O 
technique O 
. O 
Complexes O 
smaller O 
than O 
Mg(2+)(H2O)3 B-FORMULA 
cannot O 
be O 
formed O 
in O 
this O 
source O 
because O 
charge O 
separation O 
into O 
MgOH(+)(H2O) B-FORMULA 
and O 
H3O(+) B-FORMULA 
is O 
a O 
lower O 
- O 
energy O 
pathway O 
than O 
simple O 
water O 
loss O 
from O 
Mg(2+)(H2O)3 B-FORMULA 
. O 
The O 
kinetic O 
energy O 
dependent O 
cross O 
sections O 
for O 
dissociation O 
of O 
Mg(2+)(H2O)x B-FAMILY 
complexes O 
, O 
in O 
which O 
x=3-10 O 
, O 
are O 
examined O 
over O 
a O 
wide O 
energy O 
range O 
to O 
monitor O 
all O 
dissociation O 
products O 
and O 
are O 
modeled O 
to O 
obtain O 
0 O 
and O 
298 O 
K O 
binding O 
energies O 
. O 
Analysis O 
of O 
both O 
primary O 
and O 
secondary O 
water O 
molecule O 
losses O 
from O 
each O 
sized O 
complex O 
provides O 
thermochemistry O 
for O 
the O 
sequential O 
hydration O 
energies O 
of O 
Mg(2+) B-FORMULA 
for O 
x=2-10 O 
and O 
the O 
first O 
experimental O 
values O 
for O 
x=2-4 O 
. O 
Additionally O 
, O 
the O 
thermodynamic O 
onsets O 
leading O 
to O 
the O 
charge O 
- O 
separation O 
products O 
from O 
Mg(2+)(H2O)3 B-FORMULA 
and O 
Mg(2+)(H2O)4 B-FORMULA 
are O 
determined O 
for O 
the O 
first O 
time O 
. O 
Our O 
experimental O 
results O 
for O 
x=3-7 O 
agree O 
well O 
with O 
quantum O 
chemical O 
calculations O 
performed O 
here O 
and O 
previously O 
calculated O 
binding O 
enthalpies O 
, O 
as O 
well O 
as O 
previous O 
measurements O 
for O 
x=6 O 
. O 
The O 
present O 
values O 
for O 
x=7-10 O 
are O 
slightly O 
lower O 
than O 
previous O 
experimental O 
results O 
and O 
theory O 
, O 
but O 
within O 
experimental O 
uncertainties O 
. O 

understanding O 
of O 
the O 
interaction O 
between O 
thienorphine B-TRIVIAL 
and O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
isoforms O 
. O 

has O 
been O 
demonstrated O 
to O 
be O 
a O 
potent O 
, O 
long O 
- O 
acting O 
partial O 
opioid O 
agonist O 
. O 
It O 
is O 
being O 
developed O 
as O 
a O 
good O 
candidate O 
to O 
treat O 
opioid O 
dependence O 
. O 
The O 
thienorphine B-TRIVIAL 
' O 
s O 
glucuronide O 
was O 
detected O 
after O 
thienorphine B-TRIVIAL 
was O 
incubated O 
with O 
human O 
liver O 
microsomes O 
( O 
HLMs O 
) O 
. O 
Recombinant O 
UGT O 
isoforms O 
screening O 
experiment O 
and O 
enzyme O 
kinetic O 
study O 
showed O 
that O 
UGT1A1 O 
completely O 
contributed O 
to O 
the O 
glucuronidation O 
of O 
thienorphine B-TRIVIAL 
. O 
Among O 
the O 
tested O 
UGT O 
isoforms O 
, O 
UGT1A3 O 
and O 
UGT2B7 O 
were O 
inhibited O 
by O 
thienorphine B-TRIVIAL 
, O 
with O 
other O 
UGT O 
isoforms O 
negligibly O 
influenced O 
. O 
The O 
inhibition O 
type O 
is O 
competitive O 
, O 
and O 
inhibition O 
kinetic O 
parameters O 
(K(i)) O 
were O 
1.65 O 
and O 
5.27 O 
μM O 
for O 
UGT1A3 O 
and O 
UGT2B7 O 
, O 
respectively O 
. O 
However O 
, O 
due O 
to O 
low O 
plasma O 
concentration O 
of O 
thienorphine B-TRIVIAL 
, O 
in O 
vivo O 
drug O 
- O 
drug O 
interaction O 
might O 
not O 
occur O 
. O 

to O 
the O 
lack O 
of O 
tissue O 
available O 
for O 
islet O 
transplantation O 
, O 
new O 
sources O 
of O 
β-cells O 
have O 
been O 
sought O 
for O 
the O 
treatment O 
of O 
type O 
1 O 
diabetes O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
the O 
human O 
exocrid O 
fraction O 
from O 
the O 
islet O 
isolation O 
procedure O 
could O 
be O 
reprogrammed O 
to O 
provide O 
additional O 
islet O 
tissue O 
for O 
transplantation O 
. O 
The O 
exocrine O 
enriched O 
cells O 
rapidly O 
dedifferentiated O 
in O 
culture O 
and O 
grew O 
as O 
a O 
mesenchymal O 
monolayer O 
. O 
Genetic O 
lineage O 
tracing O 
confirmed O 
that O 
these O 
mesenchymal O 
cells O 
arose O 
in O 
part O 
through O 
a O 
process O 
of O 
epithelial O 
to O 
mesenchymal O 
transitioning O 
( O 
EMT O 
) O 
. O 
A O 
protocol O 
was O 
developed O 
whereby O 
transduction O 
of O 
these O 
mesenchymal O 
cells O 
with O 
adenoviruses O 
containing O 
Pdx1 O 
, O 
Ngn3 O 
, O 
MafA O 
and O 
Pax4 O 
generated O 
a O 
population O 
of O 
cells O 
that O 
were O 
enriched O 
in O 
glucagon O 
- O 
secreting O 
α- O 
like O 
cells O 
. O 
Transdifferentiation O 
or O 
reprogramming O 
towards O 
insulin O 
secreting O 
β-cells O 
was O 
enhanced O 
, O 
however O 
, O 
when O 
using O 
unpassaged O 
cells O 
in O 
combination O 
with O 
inhibition O 
of O 
EMT O 
by O 
inclusion O 
of O 
ROCK O 
and O 
TGF-β1 O 
inhibitors O 
. O 
Resultant O 
cells O 
were O 
able O 
to O 
secrete O 
insulin O 
in O 
response O 
to O 
glucose B-TRIVIAL 
and O 
on O 
transplantation O 
, O 
to O 
normalise O 
blood O 
glucose B-TRIVIAL 
levels O 
in O 
streptozotocin B-TRIVIAL 
diabetic O 
NOD O 
/ O 
Scid O 
mice O 
. O 
In O 
conclusion O 
, O 
reprogramming O 
of O 
human O 
exocrine O 
enriched O 
tissue O 
can O 
best O 
be O 
achieved O 
using O 
fresh O 
material O 
under O 
conditions O 
whereby O 
EMT O 
is O 
inhibited O 
. O 
.rather O 
than O 
allowing O 
the O 
culture O 
to O 
expand O 
as O 
a O 
mesenchymal O 
monolayer O 
. O 

of O 
a O 
flavonoid B-FAMILY 
, O 
apigenin B-SYSTEMATIC 
7-O-glucoside I-SYSTEMATIC 
, O 
from O 
Mentha O 
longifolia O 
( O 
L O 
. O 
) O 
Hudson O 
subspecies O 
longifolia O 
and O 
its O 
genotoxic O 
potency O 
. O 

is O 
a O 
medicinal O 
and O 
aromatic O 
plant O 
belonging O 
to O 
the O 
Lamiaceae O 
family O 
, O 
which O 
is O 
widely O 
used O 
in O 
food O 
, O 
flavor O 
, O 
cosmetic O 
and O 
pharmaceutical O 
industries O 
. O 
Recently O 
, O 
it O 
has O 
been O 
found O 
that O 
the O 
use O 
of O 
Mentha O 
as O 
a O 
pharmaceutical O 
source O 
is O 
based O 
on O 
its O 
phytochemical O 
constituents O 
that O 
have O 
far O 
been O 
identified O 
as O 
tannins B-FAMILY 
, O 
saponins B-FAMILY 
, O 
phenolic B-FAMILY 
acids I-FAMILY 
and O 
flavonoids B-FAMILY 
. O 
This O 
study O 
was O 
designed O 
to O 
evaluate O 
the O 
mutagenic O 
and O 
antimutagenic O 
activities O 
of O 
apigenin B-SYSTEMATIC 
7-O-glucoside I-SYSTEMATIC 
( O 
A7G B-SYSTEMATIC 
) O 
, O 
a O 
flavonoid B-FAMILY 
isolated O 
from O 
Mentha O 
longifolia O 
( O 
L O 
. O 
) O 
Hudson O 
subspecies O 
longifolia O 
( O 
ML O 
) O 
. O 
The O 
possible O 
antimutagenic O 
potential O 
of O 
A7G B-SYSTEMATIC 
was O 
examined O 
against O 
mutagens O 
ethyl B-SYSTEMATIC 
methanesulfonate I-SYSTEMATIC 
and O 
acridine B-TRIVIAL 
in O 
an O 
eukaryotic O 
cell O 
system O 
Saccharomyces O 
cerevisiae O 
and O 
sodium B-SYSTEMATIC 
azide I-SYSTEMATIC 
in O 
Salmonella O 
typhimurium O 
TA1535 O 
and O 
9-aminoacridine B-SYSTEMATIC 
in O 
S O 
. O 
typhimurium O 
TA1537 O 
. O 
According O 
to O 
our O 
findings O 
, O 
any O 
concentrations O 
of O 
the O 
A7G B-SYSTEMATIC 
used O 
did O 
not O 
show O 
mutagenic O 
activity O 
but O 
exerted O 
strong O 
antimutagenic O 
activities O 
at O 
tested O 
concentrations O 
. O 
The O 
inhibition O 
rates O 
for O 
the O 
Ames O 
test O 
ranged O 
from O 
27.2% O 
( O 
S O 
. O 
typhimurium O 
TA1535 O 
: O 
0.4 O 
μM O 
/ O 
plate O 
) O 
to O 
91.1% O 
( O 
S O 
. O 
typhimurium O 
TA1537 O 
: O 
0.2 O 
μM O 
/ O 
plate O 
) O 
and O 
for O 
the O 
yeast O 
deletion O 
assay O 
from O 
4% O 
to O 
57.7% O 
. O 
This O 
genotoxicological O 
study O 
suggests O 
that O 
a O 
flavonoid B-FAMILY 
from O 
ML O 
owing O 
to O 
antimutagenic O 
properties O 
is O 
of O 
great O 
pharmacological O 
importance O 
and O 
might O 
be O 
beneficial O 
to O 
industries O 
producing O 
food O 
additives O 
, O 
cosmetics O 
and O 
pharmaceuticals O 
products O 
. O 

and O 
cyclical O 
transformations O 
between O 
solid O 
and O 
hollow O 
nanostructures O 
in O 
confined O 
reactions O 
of O 
manganese B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
silica B-TRIVIAL 
within O 
nanosized O 
spheres O 
. O 

of O 
MnO B-FORMULA 
@ O 
SiO(2) B-FORMULA 
nanospheres O 
in O 
a O 
reducing O 
gas O 
environment O 
resulted O 
in O 
the O 
transformation O 
of O 
the O 
core O 
- O 
shell O 
structure O 
into O 
a O 
hollow O 
structure O 
as O 
a O 
result O 
of O 
outward O 
diffusion O 
of O 
MnO B-FORMULA 
species O 
into O 
the O 
thermodynamically O 
more O 
stable O 
silicate B-FAMILY 
phase O 
. O 
When O 
the O 
hollow O 
silicate B-FAMILY 
nanospheres O 
were O 
oxidized O 
, O 
the O 
interior O 
cavities O 
were O 
refilled O 
with O 
a O 
Mn(3)O(4) B-FORMULA 
phase O 
segregated O 
from O 
the O 
silicate B-FAMILY 
phase O 
, O 
and O 
the O 
hollow O 
structure O 
reverted O 
to O 
the O 
initial O 
core O 
- O 
shell O 
structure O 
. O 
More O 
interestingly O 
, O 
when O 
catalytically O 
active O 
Pt B-FORMULA 
nanocrystals O 
were O 
introduced O 
into O 
the O 
manganese B-SYSTEMATIC 
oxide I-SYSTEMATIC 
/ O 
silica B-TRIVIAL 
system O 
, O 
the O 
Mn(3)O(4) B-FORMULA 
was O 
readily O 
reduced O 
to O 
the O 
chemically O 
reactive O 
MnO B-FORMULA 
, O 
even O 
at O 
low O 
temperature O 
, O 
which O 
enabled O 
reconversion O 
of O 
the O 
solid O 
nanospheres O 
with O 
a O 
Mn(3)O(4) B-FORMULA 
core O 
to O 
hollow O 
nanostructures O 
during O 
reductive O 
annealing O 
. O 
Therefore O 
, O 
when O 
MnO B-FORMULA 
@ O 
SiO(2) B-FORMULA 
/ O 
Pt B-FORMULA 
(II) I-FORMULA 
nanospheres O 
were O 
subjected O 
to O 
an O 
oxidation O 
/ O 
reduction O 
cycle O 
by O 
repeatedly O 
switching O 
the O 
flowing O 
gas O 
between O 
air O 
and O 
hydrogen B-SYSTEMATIC 
, O 
the O 
nanospheres O 
underwent O 
a O 
reversible O 
change O 
between O 
solid O 
and O 
hollow O 
structures O 
, O 
depending O 
on O 
the O 
gas O 
environment O 
. O 
The O 
solid O 
- O 
to O 
- O 
hollow O 
- O 
to O 
- O 
solid O 
transformation O 
was O 
successfully O 
cycled O 
many O 
times O 
simply O 
by O 
repeatedly O 
switching O 
the O 
flowing O 
gas O 
during O 
annealing O 
. O 

Tuning O 
of O 
the O 
Structure O 
of O 
Pt-Cu B-FORMULA 
Alloy O 
Nanocrystals O 
by O 
Glycine B-TRIVIAL 
-Mediated O 
Sequential O 
Reduction O 
Kinetics O 
. O 

Pt-Cu B-FORMULA 
alloy O 
nanocrystals O 
in O 
the O 
shape O 
of O 
dendrite O 
, O 
, O 
yolk O 
- O 
cage O 
, O 
and O 
box O 
structures O 
are O 
prepared O 
via O 
a O 
facile O 
wet O 
- O 
chemical O 
reduction O 
route O 
in O 
which O 
glycine B-TRIVIAL 
is O 
demonstrated O 
to O 
alter O 
the O 
reduction O 
kinetics O 
of O 
metal O 
cations O 
, O 
critical O 
to O 
the O 
morphology O 
of O 
the O 
obtained O 
product O 
. O 
These O 
alloy O 
nanocrystals O 
exhibit O 
superior O 
specific O 
activity O 
and O 
stability O 
in O 
the O 
electro O 
- O 
oxidation O 
of O 
methanol B-SYSTEMATIC 
. O 

mutations O 
in O 
PIK3CA O 
, O 
which O 
encodes O 
the O 
phosphoinositide B-FAMILY 
-3-kinase O 
( O 
PI3K O 
) O 
catalytic O 
subunit O 
p110α O 
, O 
occur O 
in O 
∼25% O 
of O 
human O 
breast O 
cancers O 
. O 
In O 
this O 
study O 
, O 
we O 
report O 
the O 
development O 
of O 
a O 
knock O 
- O 
in O 
mouse O 
model O 
for O 
breast O 
cancer O 
where O 
the O 
endogenous O 
Pik3ca O 
allele O 
was O 
modified O 
to O 
allow O 
tissue O 
- O 
specific O 
conditional O 
expression O 
of O 
a O 
frequently O 
found O 
Pik3ca(H1047R) O 
(Pik3ca(e20H1047R)) O 
mutant O 
allele O 
. O 
We O 
found O 
that O 
activation O 
of O 
the O 
latent O 
Pik3ca(H1047R) O 
allele O 
resulted O 
in O 
breast O 
tumors O 
with O 
multiple O 
histological O 
types O 
. O 
Whole O 
- O 
exome O 
analysis O 
of O 
the O 
Pik3ca(H1047R)-driven O 
mammary O 
tumors O 
identified O 
multiple O 
mutations O 
, O 
including O 
Trp B-FORMULA 
53 O 
mutations O 
that O 
appeared O 
spontaneously O 
during O 
the O 
development O 
of O 
adenocarinoma O 
and O 
spindle O 
cell O 
tumors O 
. O 
Further O 
, O 
we O 
used O 
this O 
model O 
to O 
test O 
the O 
efficacy O 
of O 
GDC-0941 B-IDENTIFIER 
, O 
a O 
PI3K O 
inhibitor O 
, O 
in O 
clinical O 
development O 
, O 
and O 
showed O 
that O 
the O 
tumors O 
respond O 
to O 
PI3K O 
inhibition O 
. O 

arsenite I-SYSTEMATIC 
induces O 
cyclooxygenase-2 O 
expression O 
in O 
human O 
uroepithelial O 
cells O 
through O 
MAPK O 
pathway O 
activation O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
induction O 
. O 

can O 
induce O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
leading O 
to O 
oxidative O 
stress O 
and O 
carcinogenesis O 
. O 
Bladder O 
is O 
one O 
of O 
the O 
major O 
target O 
organs O 
of O 
arsenic B-SYSTEMATIC 
, O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
may O 
play O 
an O 
important O 
role O 
in O 
arsenic B-SYSTEMATIC 
-induced O 
bladder O 
cancer O 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
arsenic B-SYSTEMATIC 
induces O 
COX-2 O 
in O 
bladder O 
cells O 
remains O 
unclear O 
. O 
This O 
study O 
aimed O 
at O 
investigating O 
arsenic B-SYSTEMATIC 
-mediated O 
intracellular O 
redox O 
status O 
and O 
signaling O 
cascades O 
leading O 
to O 
COX-2 O 
induction O 
in O 
human O 
uroepithelial O 
cells O 
( O 
SV-HUC-1 O 
) O 
. O 
SV-HUC-1 O 
cells O 
were O 
exposed O 
to O 
sodium B-SYSTEMATIC 
arsenite I-SYSTEMATIC 
and O 
COX-2 O 
expression O 
, O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
phosphorylation O 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
, O 
ROS O 
induction O 
and O 
Nrf2 O 
expression O 
were O 
quantified O 
. O 
Our O 
results O 
demonstrate O 
that O 
arsenite B-SYSTEMATIC 
( O 
1-10 O 
μM O 
) O 
elevates O 
COX-2 O 
expression O 
, O 
GSH B-ABBREVIATION 
levels O 
, O 
ROS O 
and O 
Nrf2 O 
expression O 
. O 
Arsenite B-SYSTEMATIC 
treatment O 
for O 
24h O 
stimulates O 
phosphorylation O 
of O 
ERK O 
and O 
p38 O 
, O 
but O 
not O 
JNK O 
in O 
SV-HUC-1 O 
cells O 
. O 
Induction O 
of O 
Cox-2 O 
mRNA O 
levels O 
by O 
arsenite B-SYSTEMATIC 
was O 
attenuated O 
by O 
inhibitors O 
of O 
ERK O 
, O 
p38 O 
and O 
JNK O 
. O 
Arsenite B-SYSTEMATIC 
-induced O 
ROS O 
generation O 
and O 
COX-2 O 
expression O 
were O 
significantly O 
attenuated O 
by O 
treatment O 
with O 
melatonin B-TRIVIAL 
( O 
a O 
ROS O 
scavenger O 
) O 
, O 
but O 
enhanced O 
by O 
DL-buthionine-(S B-SYSTEMATIC 
, I-SYSTEMATIC 
R)-sulfoximine I-SYSTEMATIC 
( O 
BSO B-ABBREVIATION 
, O 
an O 
inhibitor O 
of O 
gamma-glutamylcysteine B-SYSTEMATIC 
synthetase O 
( O 
γ-GCS O 
) O 
resulting O 
in O 
lower O 
GSH B-ABBREVIATION 
and O 
increased O 
ROS O 
levels O 
) O 
. O 
These O 
data O 
indicate O 
that O 
arsenite B-SYSTEMATIC 
promotes O 
an O 
induction O 
of O 
ROS O 
, O 
which O 
results O 
in O 
an O 
induction O 
of O 
COX-2 O 
expression O 
through O 
activation O 
of O 
the O 
MAPK O 
pathway O 
. O 

the O 
bioequivalence O 
of O 
pressurised O 
metered O 
dose O 
inhalers O 
1 O 
: O 
Design O 
and O 
characterisation O 
of O 
aerodynamically O 
equivalent O 
beclomethasone B-SYSTEMATIC 
dipropionate I-SYSTEMATIC 
inhalers O 
with O 
and O 
without O 
glycerol B-TRIVIAL 
as O 
a O 
non-volatile O 
excipient O 
. O 

series O 
of O 
semi-empirical O 
equations O 
were O 
utilised O 
to O 
design O 
two O 
solution O 
based O 
pressurised O 
metered O 
dose O 
inhaler O 
( O 
pMDI O 
) O 
formulations O 
, O 
with O 
equivalent O 
aerosol O 
performance O 
but O 
different O 
physicochemical O 
properties O 
. O 
Both O 
inhaler O 
formulations O 
contained O 
the O 
drug O 
, O 
beclomethasone B-SYSTEMATIC 
dipropionate I-SYSTEMATIC 
( O 
BDP B-ABBREVIATION 
) O 
, O 
a O 
volatile O 
mixture O 
of O 
ethanol B-SYSTEMATIC 
co O 
- O 
solvent O 
and O 
propellant O 
( O 
hydrofluoroalkane B-FAMILY 
- O 
HFA B-ABBREVIATION 
) O 
. O 
However O 
, O 
one O 
formulation O 
was O 
designed O 
such O 
that O 
the O 
emitted O 
aerosol O 
particles O 
contained O 
BDP B-ABBREVIATION 
and O 
glycerol B-TRIVIAL 
, O 
a O 
common O 
inhalation O 
particle O 
modifying O 
excipient O 
, O 
in O 
a O 
1 O 
: O 
1 O 
mass O 
ratio O 
. O 
By O 
modifying O 
the O 
formulation O 
parameters O 
, O 
including O 
actuator O 
orifice O 
, O 
HFA B-ABBREVIATION 
and O 
metering O 
volumes O 
, O 
it O 
was O 
possible O 
to O 
produce O 
two O 
formulations O 
( O 
glycerol B-TRIVIAL 
-free O 
and O 
glycerol B-TRIVIAL 
-containing O 
) O 
which O 
had O 
identical O 
mass O 
median O 
aerodynamic O 
diameters O 
( O 
2.4μm±0.1 O 
and O 
2.5μm±0.2 O 
) O 
, O 
fine O 
particle O 
dose O 
( O 
⩽5μm O 
; O 
66μg±6 O 
and O 
68μg±2 O 
) O 
and O 
fine O 
particle O 
fractions O 
( O 
28%±2% O 
and O 
30%±1% O 
) O 
, O 
respectively O 
. O 
These O 
observations O 
demonstrate O 
that O 
it O 
is O 
possible O 
to O 
engineer O 
formulations O 
that O 
generate O 
aerosol O 
particles O 
with O 
very O 
different O 
compositions O 
to O 
have O 
similar O 
emitted O 
dose O 
and O 
in O 
vitro O 
deposition O 
profiles O 
, O 
thus O 
making O 
them O 
equivalent O 
in O 
terms O 
of O 
aerosol O 
performance O 
. O 
Analysis O 
of O 
the O 
physicochemical O 
properties O 
of O 
each O 
formulation O 
identified O 
significant O 
differences O 
in O 
terms O 
of O 
morphology O 
, O 
thermal O 
properties O 
and O 
drug O 
dissolution O 
of O 
emitted O 
particles O 
. O 
The O 
particles O 
produced O 
from O 
both O 
formulations O 
were O 
amorphous O 
; O 
however O 
, O 
the O 
formulation O 
containing O 
glycerol B-TRIVIAL 
generated O 
particles O 
with O 
a O 
porous O 
structure O 
, O 
while O 
the O 
glycerol B-TRIVIAL 
-free O 
formulation O 
generated O 
particles O 
with O 
a O 
primarily O 
spherical O 
morphology O 
. O 
Furthermore O 
, O 
the O 
glycerol B-TRIVIAL 
-containing O 
particles O 
had O 
a O 
significantly O 
lower O 
dissolution O 
rate O 
( O 
7.8%±2.1% O 
, O 
over O 
180min O 
) O 
compared O 
to O 
the O 
glycerol B-TRIVIAL 
-free O 
particles O 
( O 
58.0%±2.9% O 
, O 
over O 
60min O 
) O 
when O 
measured O 
using O 
a O 
Franz O 
diffusion O 
cell O 
. O 
It O 
is O 
hypothesised O 
that O 
the O 
presence O 
of O 
glycerol B-TRIVIAL 
in O 
the O 
emitted O 
aerosol O 
particles O 
altered O 
solubility O 
and O 
drug O 
transport O 
, O 
which O 
may O 
have O 
implications O 
for O 
BDP B-ABBREVIATION 
pharmacokinetics O 
after O 
deposition O 
in O 
the O 
respiratory O 
tract O 
. O 

stress O 
, O 
oxytocin B-TRIVIAL 
receptor O 
gene O 
( O 
OXTR O 
) O 
polymorphism O 
, O 
and O 
mental O 
health O 
following O 
collective O 
stress O 
. O 

examined O 
whether O 
the O 
oxytocin B-TRIVIAL 
receptor O 
gene O 
( O 
OXTR O 
) O 
single O 
nucleotide B-FAMILY 
polymorphism O 
( O 
SNP O 
) O 
rs53576 O 
genotype O 
buffers O 
the O 
combined O 
impact O 
of O 
negative O 
social O 
environments O 
( O 
e.g O 
. O 
, O 
interpersonal O 
conflict O 
/ O 
constraint O 
) O 
and O 
economic O 
stress O 
on O 
post O 
- O 
traumatic O 
stress O 
( O 
PTS O 
) O 
symptoms O 
and O 
impaired O 
daily O 
functioning O 
following O 
collective O 
stress O 
( O 
September O 
11th O 
terrorist O 
attacks O 
) O 
. O 
Saliva O 
was O 
collected O 
by O 
mail O 
and O 
used O 
to O 
genotype O 
704 O 
respondents O 
. O 
Participants O 
completed O 
Web O 
- O 
based O 
assessments O 
of O 
pre-9 O 
/ O 
11 O 
mental O 
health O 
, O 
acute O 
stress O 
9-23days O 
after O 
9 O 
/ O 
11 O 
, O 
the O 
quality O 
of O 
social O 
environments O 
1year O 
post-9 O 
/ O 
11 O 
, O 
economic O 
stress O 
18months O 
post-9 O 
/ O 
11 O 
, O 
and O 
PTS O 
symptoms O 
and O 
impaired O 
functioning O 
2 O 
and O 
3years O 
post-9 O 
/ O 
11 O 
. O 
Interactions O 
between O 
negative O 
social O 
environments O 
and O 
economic O 
stress O 
were O 
examined O 
separately O 
based O 
on O 
OXTR O 
rs53576 O 
genotype O 
( O 
GG O 
vs O 
. O 
any O 
A O 
allele O 
) O 
. O 
For O 
individuals O 
with O 
an O 
A O 
allele O 
, O 
a O 
negative O 
social O 
environment O 
significantly O 
increased O 
PTS O 
symptoms O 
without O 
regard O 
to O 
the O 
level O 
of O 
economic O 
stress O 
experienced O 
. O 
However O 
, O 
for O 
respondents O 
with O 
a O 
GG O 
genotype O 
, O 
negative O 
social O 
environments O 
predicted O 
elevated O 
PTS O 
symptoms O 
only O 
for O 
those O 
also O 
experiencing O 
high O 
economic O 
stress O 
. O 
Gender O 
moderated O 
associations O 
between O 
negative O 
social O 
environments O 
, O 
economic O 
stress O 
, O 
and O 
impaired O 
functioning O 
. O 
The O 
functioning O 
of O 
females O 
was O 
most O 
affected O 
by O 
negative O 
social O 
environments O 
regardless O 
of O 
genotype O 
and O 
economic O 
stress O 
, O 
whereas O 
the O 
functioning O 
of O 
males O 
was O 
differentially O 
susceptible O 
to O 
economic O 
stress O 
depending O 
on O 
OXTR O 
genotype O 
and O 
negative O 
social O 
environments O 
. O 
These O 
findings O 
suggest O 
that O 
it O 
is O 
important O 
to O 
consider O 
the O 
combined O 
impact O 
of O 
gender O 
and O 
ongoing O 
stress O 
in O 
different O 
domains O 
as O 
moderators O 
of O 
genetic O 
vulnerability O 
following O 
collective O 
stress O 
. O 

about O 
etiologic O 
and O 
demographic O 
characteristics O 
of O 
acute O 
poisoning O 
in O 
adults O 
in O 
Qatar O 
are O 
lacking O 
. O 
This O 
prospective O 
observational O 
study O 
was O 
undertaken O 
to O 
analyze O 
characteristics O 
and O 
possible O 
determinants O 
of O 
acute O 
poisoning O 
in O 
adults O 
in O 
Qatar O 
. O 
During O 
2010 O 
, O 
18073 O 
patients O 
attended O 
the O 
emergency O 
department O 
of O 
Hamad O 
General O 
Hospital O 
, O 
a O 
teaching O 
hospital O 
in O 
Qatar O 
. O 
Out O 
of O 
them O 
, O 
599 O 
( O 
3.3% O 
) O 
patients O 
were O 
diagnosed O 
as O 
" O 
poisoning O 
case O 
" O 
with O 
either O 
chemical O 
or O 
pharmaceutical O 
substances O 
. O 
The O 
prevalence O 
rate O 
of O 
poisoning O 
incidence O 
was O 
35.3 O 
/ O 
100000 O 
population O 
. O 
Seven O 
patients O 
died O 
, O 
corresponding O 
with O 
a O 
case O 
- O 
fatality O 
rate O 
of O 
0.39 O 
/ O 
1000 O 
. O 
The O 
majority O 
were O 
male O 
( O 
65% O 
) O 
and O 
the O 
mean O 
age O 
was O 
34 O 
years O 
. O 
The O 
poisons O 
involved O 
were O 
mainly O 
chemicals O 
( O 
61.6% O 
) O 
and O 
pharmaceuticals O 
( O 
38.4% O 
) O 
. O 
Female O 
, O 
mainly O 
single O 
, O 
suffered O 
more O 
intentional O 
poisoning O 
compared O 
to O 
male O 
. O 
Of O 
the O 
patients O 
aged O 
60 O 
years O 
and O 
above O 
( O 
7.2% O 
) O 
, O 
the O 
majority O 
( O 
95.3% O 
) O 
suffered O 
unintentional O 
poisoning O 
with O 
pharmaceuticals O 
; O 
56% O 
with O 
warfarin B-TRIVIAL 
, O 
12% O 
with O 
digoxin B-TRIVIAL 
and O 
7% O 
with O 
insulin O 
. O 
Multivariate O 
analysis O 
shows O 
that O 
female O 
gender O 
, O 
single O 
status O 
, O 
younger O 
than O 
35 O 
years O 
of O 
age O 
, O 
being O 
poisoned O 
by O 
pharmaceutical O 
products O 
, O 
and O 
the O 
need O 
for O 
hospitalization O 
are O 
significant O 
determinants O 
for O 
acute O 
intentional O 
poisoning O 
after O 
adjusting O 
all O 
other O 
possible O 
covariates O 
. O 
The O 
findings O 
of O 
this O 
study O 
can O 
be O 
used O 
to O 
establish O 
awareness O 
and O 
prophylactic O 
campaigns O 
in O 
Qatar O 
. O 

iodine B-SYSTEMATIC 
nutrition O 
: O 
where O 
do O 
we O 
stand O 
in O 
2013 O 
? O 

: O 
Dietary O 
iodine B-SYSTEMATIC 
intake O 
is O 
required O 
for O 
the O 
production O 
of O 
thyroid B-FAMILY 
hormone I-FAMILY 
. O 
Consequences O 
of O 
iodine B-SYSTEMATIC 
deficiency O 
include O 
goiter O 
, O 
intellectual O 
impairments O 
, O 
growth O 
retardation O 
, O 
neonatal O 
hypothyroidism O 
, O 
and O 
increased O 
pregnancy O 
loss O 
and O 
infant O 
mortality O 
. O 
Summary O 
: O 
In O 
1990 O 
, O 
the O 
United O 
Nations O 
World O 
Summit O 
for O 
Children O 
established O 
the O 
goal O 
of O 
eliminating O 
iodine B-SYSTEMATIC 
deficiency O 
worldwide O 
. O 
Considerable O 
progress O 
has O 
since O 
been O 
achieved O 
, O 
largely O 
through O 
programs O 
of O 
universal O 
salt O 
iodization O 
. O 
Approximately O 
70% O 
of O 
all O 
households O 
worldwide O 
currently O 
have O 
access O 
to O 
adequately O 
iodized O 
salt O 
. O 
In O 
2013 O 
, O 
as O 
defined O 
by O 
a O 
national O 
or O 
subnational O 
median O 
urinary O 
iodine B-SYSTEMATIC 
concentration O 
of O 
100-299 O 
μg O 
/ O 
L O 
in O 
school O 
- O 
aged O 
children O 
, O 
111 O 
countries O 
have O 
sufficient O 
iodine B-SYSTEMATIC 
intake O 
. O 
Thirty O 
countries O 
remain O 
iodine B-SYSTEMATIC 
-deficient O 
; O 
9 O 
are O 
moderately O 
deficient O 
, O 
21 O 
are O 
mildly O 
deficient O 
, O 
and O 
none O 
are O 
currently O 
considered O 
severely O 
iodine B-SYSTEMATIC 
-deficient O 
. O 
Ten O 
countries O 
have O 
excessive O 
iodine B-SYSTEMATIC 
intake O 
. O 
In O 
North O 
America O 
, O 
both O 
the O 
United O 
States O 
and O 
Canada O 
are O 
generally O 
iodine B-SYSTEMATIC 
-sufficient O 
, O 
although O 
recent O 
data O 
suggest O 
pregnant O 
U.S O 
. O 
women O 
are O 
mildly O 
iodine B-SYSTEMATIC 
-deficient O 
. O 
Emerging O 
issues O 
include O 
discrepancies O 
between O 
urinary O 
iodine B-SYSTEMATIC 
status O 
in O 
pregnant O 
women O 
compared O 
to O 
school O 
- O 
aged O 
children O 
in O 
some O 
populations O 
, O 
the O 
problem O 
of O 
re O 
- O 
emerging O 
iodine B-SYSTEMATIC 
deficiency O 
in O 
parts O 
of O 
the O 
developed O 
world O 
, O 
the O 
importance O 
of O 
food O 
industry O 
use O 
of O 
iodized O 
salt O 
, O 
regions O 
of O 
iodine B-SYSTEMATIC 
excess O 
, O 
and O 
the O 
potential O 
effects O 
of O 
initiatives O 
to O 
lower O 
population O 
sodium B-SYSTEMATIC 
consumption O 
on O 
iodine B-SYSTEMATIC 
intake O 
. O 
Conclusions O 
: O 
Although O 
substantial O 
progress O 
has O 
been O 
made O 
over O 
the O 
last O 
several O 
decades O 
, O 
iodine B-SYSTEMATIC 
deficiency O 
remains O 
a O 
significant O 
health O 
problem O 
worldwide O 
and O 
affects O 
both O 
industrialized O 
and O 
developing O 
nations O 
. O 
The O 
ongoing O 
monitoring O 
of O 
population O 
iodine B-SYSTEMATIC 
status O 
remains O 
crucially O 
important O 
, O 
and O 
particular O 
attention O 
may O 
need O 
to O 
be O 
paid O 
to O 
monitoring O 
the O 
status O 
of O 
vulnerable O 
populations O 
, O 
such O 
as O 
pregnant O 
women O 
and O 
infants O 
. O 
There O 
is O 
also O 
need O 
for O 
ongoing O 
monitoring O 
of O 
iodized O 
salt O 
and O 
other O 
dietary O 
iodine B-SYSTEMATIC 
sources O 
in O 
order O 
to O 
prevent O 
excess O 
as O 
well O 
as O 
insufficient O 
iodine B-SYSTEMATIC 
nutrition O 
. O 
Finally O 
, O 
it O 
will O 
be O 
essential O 
to O 
coordinate O 
interventions O 
designed O 
to O 
reduce O 
population O 
sodium B-SYSTEMATIC 
intake O 
with O 
salt O 
iodization O 
programs O 
in O 
order O 
to O 
maintain O 
adequate O 
levels O 
of O 
iodine B-SYSTEMATIC 
nutrition O 
as O 
salt O 
intake O 
declines O 
. O 

knowledge O 
of O 
DNA O 
repair O 
in O 
a O 
target O 
species O 
is O 
of O 
first O 
importance O 
as O 
it O 
is O 
the O 
primary O 
line O 
of O 
defense O 
against O 
genotoxicants O 
, O 
and O 
a O 
better O 
knowledge O 
of O 
DNA O 
repair O 
capacity O 
in O 
fish O 
could O 
help O 
to O 
interpret O 
genotoxicity O 
data O 
and O 
/ O 
or O 
assist O 
in O 
the O 
choice O 
of O 
target O 
species O 
, O 
developmental O 
stage O 
and O 
tissues O 
to O 
focus O 
on O 
, O 
both O 
for O 
environmental O 
biomonitoring O 
studies O 
and O 
DNA O 
repair O 
testing O 
. O 
This O 
review O 
focuses O 
in O 
a O 
first O 
part O 
on O 
what O 
is O 
presently O 
known O 
on O 
a O 
mechanistic O 
basis O 
, O 
about O 
the O 
various O 
DNA O 
repair O 
systems O 
in O 
fish O 
, O 
in O 
vivo O 
and O 
in O 
established O 
cell O 
lines O 
. O 
Data O 
on O 
base O 
excision O 
repair O 
( O 
BER O 
) O 
, O 
direct O 
reversal O 
with O 
O(6)-alkylguanine B-FAMILY 
transferase O 
and O 
double O 
strand O 
breaks O 
repair O 
, O 
although O 
rather O 
scarce O 
, O 
are O 
being O 
reviewed O 
, O 
as O 
well O 
as O 
nucleotide B-FAMILY 
excision O 
repair O 
( O 
NER O 
) O 
and O 
photoreactivation O 
repair O 
( O 
PER O 
) O 
, O 
which O 
are O 
by O 
far O 
the O 
most O 
studied O 
repair O 
mechanisms O 
in O 
fish O 
. O 
Most O 
of O 
these O 
repair O 
mechanisms O 
seem O 
to O 
be O 
strongly O 
species O 
and O 
tissue O 
dependent O 
; O 
they O 
also O 
depend O 
on O 
the O 
developmental O 
stage O 
of O 
the O 
organisms O 
. O 
BER O 
is O 
efficient O 
in O 
vivo O 
, O 
although O 
no O 
data O 
has O 
been O 
found O 
on O 
in O 
vitro O 
models O 
. O 
NER O 
activity O 
is O 
quite O 
low O 
or O 
even O 
inexistent O 
depending O 
on O 
the O 
studies O 
; O 
however O 
this O 
lack O 
is O 
partly O 
compensated O 
by O 
a O 
strong O 
PER O 
activity O 
, O 
especially O 
in O 
early O 
developmental O 
stage O 
. O 
In O 
a O 
second O 
part O 
, O 
a O 
survey O 
of O 
the O 
ecotoxicological O 
studies O 
integrating O 
DNA O 
repair O 
as O 
a O 
parameter O 
responding O 
to O 
single O 
or O 
mixture O 
of O 
contaminant O 
is O 
realized O 
. O 
Three O 
main O 
approaches O 
are O 
being O 
used O 
: O 
the O 
measurement O 
of O 
DNA O 
repair O 
gene O 
expression O 
after O 
exposure O 
, O 
although O 
it O 
has O 
not O 
yet O 
been O 
clearly O 
established O 
whether O 
gene O 
expression O 
is O 
indicative O 
of O 
repair O 
capacity O 
; O 
the O 
monitoring O 
of O 
DNA O 
damage O 
removal O 
by O 
following O 
DNA O 
repair O 
kinetics O 
; O 
and O 
the O 
modulation O 
of O 
DNA O 
repair O 
activity O 
following O 
exposure O 
in O 
situ O 
, O 
in O 
order O 
to O 
assess O 
the O 
impact O 
of O 
exposure O 
history O 
on O 
DNA O 
repair O 
capacity O 
. O 
Since O 
all O 
DNA O 
repair O 
processes O 
are O 
possible O 
targets O 
for O 
environmental O 
pollutants O 
, O 
we O 
can O 
also O 
wonder O 
at O 
which O 
extent O 
such O 
a O 
modulation O 
of O 
repair O 
capacities O 
in O 
fish O 
could O 
be O 
the O 
base O 
for O 
the O 
development O 
of O 
new O 
biomarkers O 
of O 
genotoxicity O 
. O 
Knowing O 
the O 
importance O 
of O 
the O 
germ O 
cell O 
DNA O 
integrity O 
in O 
the O 
reproductive O 
success O 
of O 
aquatic O 
organisms O 
, O 
the O 
DNA O 
repair O 
capacity O 
of O 
such O 
cells O 
deserve O 
to O 
be O 
more O 
studied O 
, O 
as O 
well O 
as O 
DNA O 
repair O 
capacities O 
of O 
established O 
fish O 
cell O 
lines O 
. O 
The O 
limited O 
amount O 
of O 
available O 
data O 
, O 
which O 
shows O 
low O 
/ O 
slow O 
DNA O 
repair O 
capacities O 
of O 
fish O 
cell O 
lines O 
compared O 
with O 
mammalian O 
cell O 
lines O 
, O 
concerned O 
mainly O 
the O 
NER O 
system O 
; O 
thus O 
this O 
point O 
merits O 
to O 
be O 
explored O 
more O 
deeply O 
. O 
Additionally O 
, O 
since O 
some O 
of O 
the O 
DNA O 
repair O 
systems O 
appear O 
more O 
efficient O 
in O 
embryo O 
larval O 
stages O 
, O 
it O 
would O 
be O 
of O 
interest O 
to O 
consider O 
embryonic O 
cell O 
lineages O 
more O 
closely O 
. O 

and O 
dual O 
biological O 
effects O 
of O 
hydroxycinnamoyl B-SYSTEMATIC 
phenylalanyl I-SYSTEMATIC 
/ O 
prolyl B-SYSTEMATIC 
hydroxamic I-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
as O 
tyrosinase O 
inhibitor O 
and O 
antioxidant O 
. O 

previously O 
reported O 
that O 
caffeoyl-amino B-FAMILY 
acidyl-hydroxamic I-FAMILY 
acid I-FAMILY 
( O 
CA-Xaa-NHOH B-FAMILY 
) O 
acted O 
as O 
both O 
a O 
good O 
antioxidant O 
and O 
tyrosinase O 
inhibitor O 
, O 
in O 
particular O 
when O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
was O 
conjugated O 
with O 
proline B-TRIVIAL 
or O 
amino B-FAMILY 
acids I-FAMILY 
having O 
aromatic O 
ring O 
like O 
phenylalanine B-TRIVIAL 
. O 
Here O 
, O 
various O 
hydroxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HCA B-ABBREVIATION 
) O 
derivatives O 
were O 
further O 
conjugated O 
with O 
phenylalanyl B-SYSTEMATIC 
hydroxamic I-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
prolyl B-SYSTEMATIC 
hydroxamic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HCA-Phe-NHOH B-FORMULA 
and O 
HCA-Pro-NHOH B-FORMULA 
) O 
to O 
study O 
the O 
structure O 
and O 
activity O 
relationship O 
as O 
both O 
antioxidants O 
and O 
tyrosinase O 
inhibitors O 
. O 
When O 
their O 
biological O 
activities O 
were O 
evaluated O 
, O 
all O 
HCA-Phe-NHOH B-FORMULA 
and O 
HCA-Pro-NHOH B-FORMULA 
exhibited O 
enhanced O 
antioxidant O 
activity O 
compared O 
to O 
HCA B-ABBREVIATION 
alone O 
. O 
Moreover O 
, O 
derivatives O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
, O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
inhibited O 
lipid O 
peroxidation O 
more O 
efficiently O 
than O 
vitamin B-FAMILY 
E I-FAMILY 
analogue O 
( O 
Trolox B-TRIVIAL 
) O 
. O 
In O 
addition O 
, O 
derivatives O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
and O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
efficiently O 
inhibited O 
tyrosinase O 
activity O 
and O 
reduced O 
melanin O 
content O 
in O 
melanocytes O 
Mel-Ab O 
cell O 
. O 

influences O 
of O 
ethanol B-SYSTEMATIC 
on O 
early O 
exposure O 
to O 
racemic O 
methylphenidate B-SYSTEMATIC 
compared O 
with O 
dexmethylphenidate B-TRIVIAL 
in O 
humans O 
. O 

hydrolysis O 
of O 
oral O 
racemic B-TRIVIAL 
methylphenidate I-TRIVIAL 
( O 
dl-MPH B-ABBREVIATION 
) O 
by O 
carboxylesterase O 
1 O 
( O 
CES1 O 
) O 
limits O 
the O 
absolute O 
bioavailability O 
of O 
the O 
pharmacologically O 
active O 
d-MPH B-ABBREVIATION 
isomer O 
to O 
approximately O 
30% O 
and O 
that O 
of O 
the O 
inactive O 
l-MPH B-ABBREVIATION 
to O 
only O 
1-2% O 
. O 
Coadministration O 
of O 
dl-MPH B-ABBREVIATION 
with O 
ethanol B-SYSTEMATIC 
results O 
in O 
elevated O 
d-MPH B-ABBREVIATION 
plasma O 
concentrations O 
accompanied O 
by O 
CES1 O 
- O 
mediated O 
enantioselective O 
transesterification O 
of O 
l-MPH B-ABBREVIATION 
to O 
l-ethylphenidate B-SYSTEMATIC 
( O 
EPH B-ABBREVIATION 
) O 
. O 
The O 
present O 
study O 
tested O 
the O 
hypothesis O 
that O 
administration O 
of O 
the O 
pure O 
isomer O 
dexmethylphenidate B-TRIVIAL 
( O 
d-MPH B-ABBREVIATION 
) O 
will O 
overcome O 
the O 
influence O 
of O 
ethanol B-SYSTEMATIC 
on O 
d-MPH B-ABBREVIATION 
absorption O 
by O 
eliminating O 
competitive O 
CES1 O 
- O 
mediated O 
presystemic O 
metabolism O 
of O 
l-MPH B-ABBREVIATION 
to O 
l-EPH B-ABBREVIATION 
. O 
Twenty O 
- O 
four O 
healthy O 
volunteers O 
received O 
dl-MPH B-ABBREVIATION 
( O 
0.3 O 
mg O 
/ O 
kg O 
) O 
or O 
d-MPH B-ABBREVIATION 
( O 
0.15 O 
mg O 
/ O 
kg O 
) O 
, O 
with O 
or O 
without O 
ethanol B-SYSTEMATIC 
( O 
0.6 O 
g O 
/ O 
kg O 
) O 
. O 
During O 
the O 
absorption O 
phase O 
of O 
dl-MPH B-ABBREVIATION 
, O 
concomitant O 
ethanol B-SYSTEMATIC 
significantly O 
elevated O 
d-MPH B-ABBREVIATION 
plasma O 
concentrations O 
( O 
44-99% O 
; O 
P O 
< O 
0.005 O 
) O 
. O 
Furthermore O 
, O 
immediately O 
following O 
the O 
ethanol B-SYSTEMATIC 
drink O 
the O 
subjective O 
effects O 
of O 
" O 
high O 
, O 
" O 
" O 
good O 
, O 
" O 
" O 
like O 
, O 
" O 
" O 
stimulated O 
, O 
" O 
and O 
overall O 
" O 
effect O 
" O 
were O 
significantly O 
potentiated O 
( O 
P O 
≤ O 
0.01 O 
) O 
. O 
Plasma O 
l-EPH B-ABBREVIATION 
concentrations O 
exceeded O 
those O 
of O 
l-MPH B-ABBREVIATION 
. O 
Ethanol B-SYSTEMATIC 
combined O 
with O 
pure O 
d-MPH B-ABBREVIATION 
did O 
not O 
elevate O 
plasma O 
d-MPH B-ABBREVIATION 
concentrations O 
during O 
the O 
absorption O 
phase O 
, O 
and O 
the O 
ethanol B-SYSTEMATIC 
-induced O 
potentiation O 
of O 
subjective O 
effects O 
was O 
delayed O 
relative O 
to O 
dl-MPH B-ABBREVIATION 
- O 
ethanol B-SYSTEMATIC 
. O 
These O 
findings O 
are O 
consistent O 
with O 
l-MPH B-ABBREVIATION 
competitively O 
inhibiting O 
presystemic O 
CES1 O 
metabolism O 
of O 
d-MPH B-ABBREVIATION 
. O 
Ethanol B-SYSTEMATIC 
increased O 
the O 
d-MPH B-ABBREVIATION 
area O 
under O 
the O 
curve O 
(AUC)(0-inf) O 
by O 
21% O 
following O 
dl-MPH B-ABBREVIATION 
( O 
P O 
< O 
0.001 O 
) O 
and O 
14% O 
for O 
d-MPH B-ABBREVIATION 
( O 
P O 
= O 
0.001 O 
) O 
. O 
In O 
men O 
receiving O 
d-MPH B-ABBREVIATION 
- O 
ethanol B-SYSTEMATIC 
, O 
the O 
d-MPH B-ABBREVIATION 
absorption O 
partial O 
AUC(0.5-2 O 
hours O 
) O 
was O 
2.1 O 
times O 
greater O 
and O 
the O 
time O 
to O 
maximum O 
concentration O 
(T(max)) O 
occurred O 
1.1 O 
hours O 
earlier O 
than O 
in O 
women O 
, O 
consistent O 
with O 
an O 
increased O 
rate O 
of O 
d-MPH B-ABBREVIATION 
absorption O 
reducing O 
hepatic O 
extraction O 
. O 
More O 
rapid O 
absorption O 
of O 
d-MPH B-ABBREVIATION 
carries O 
implications O 
for O 
increased O 
abuse O 
liability O 
. O 

- O 
mediated O 
phosphorylation O 
of O 
fibroblast O 
growth O 
factor O 
receptor O 
1 O 
on O 
Ser B-FORMULA 
777 O 
inhibits O 
signaling O 
. O 

growth O 
factor O 
1 O 
( O 
FGF1 O 
) O 
controls O 
cellular O 
activities O 
through O 
the O 
activation O 
of O 
specific O 
cell O 
- O 
surface O 
FGF O 
receptors O 
( O 
FGFRs O 
) O 
. O 
Transphosphorylation O 
of O 
tyrosine B-TRIVIAL 
residues O 
in O 
the O 
kinase O 
domain O 
of O 
FGFRs O 
leads O 
to O 
activation O 
of O 
intracellular O 
signaling O 
cascades O 
, O 
including O 
those O 
mediated O 
by O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
. O 
FGFRs O 
also O 
contain O 
a O 
serine B-TRIVIAL 
-rich O 
C B-FORMULA 
-terminal O 
tail O 
. O 
We O 
identified O 
a O 
regulatory O 
mechanism O 
of O 
FGFR O 
signaling O 
involving O 
phosphorylation O 
of O 
Ser B-FORMULA 
( O 
777 O 
) O 
in O 
the O 
C B-FORMULA 
-terminal O 
region O 
of O 
FGFR1 O 
by O 
the O 
MAPKs O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
1 O 
( O 
ERK1 O 
) O 
and O 
ERK2 O 
. O 
Prevention O 
of O 
the O 
phosphorylation O 
of O 
Ser B-FORMULA 
( O 
777 O 
) O 
in O 
FGFR1 O 
or O 
mutation O 
of O 
Ser B-FORMULA 
( O 
777 O 
) O 
to O 
alanine B-TRIVIAL 
enhanced O 
FGF-stimulated O 
receptor O 
tyrosine B-TRIVIAL 
phosphorylation O 
and O 
increased O 
cell O 
proliferation O 
, O 
cell O 
migration O 
, O 
and O 
axonal O 
growth O 
. O 
A O 
form O 
of O 
FGFR1 O 
with O 
a O 
phosphomimetic O 
mutation O 
at O 
Ser B-FORMULA 
( O 
777 O 
) O 
exhibited O 
reduced O 
signaling O 
. O 
Activation O 
of O 
MAPKs O 
by O 
other O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
also O 
resulted O 
in O 
phosphorylation O 
of O 
Ser B-FORMULA 
( O 
777 O 
) O 
in O 
FGFR1 O 
, O 
thereby O 
enabling O 
crosstalk O 
regulation O 
of O 
FGFR O 
activity O 
by O 
other O 
signaling O 
pathways O 
. O 
Our O 
data O 
reveal O 
a O 
negative O 
feedback O 
mechanism O 
that O 
controls O 
FGF O 
signaling O 
and O 
thereby O 
protects O 
the O 
cell O 
from O 
excessive O 
activation O 
of O 
FGFR O 
. O 

( O 
Euterpe O 
oleracea O 
Mart O 
. O 
) O 
feeding O 
attenuates O 
dimethylhydrazine B-SYSTEMATIC 
-induced O 
rat O 
colon O 
carcinogenesis O 
. O 

study O 
investigated O 
the O 
protective O 
effect O 
of O 
spray O 
- O 
dried O 
açaí O 
powder O 
( O 
AP O 
) O 
intake O 
on O 
colon O 
carcinogenesis O 
induced O 
by O 
1,2-dimethylhydrazine B-SYSTEMATIC 
( O 
DMH B-ABBREVIATION 
) O 
in O 
male O 
Wistar O 
rats O 
. O 
After O 
4weeks O 
of O 
DMH B-ABBREVIATION 
administrations O 
, O 
the O 
groups O 
were O 
fed O 
with O 
standard O 
diet O 
, O 
a O 
diet O 
containing O 
2.5% O 
or O 
5.0% O 
AP O 
or O 
a O 
diet O 
containing O 
0.2% O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
for O 
10weeks O 
, O 
using O 
aberrant O 
crypt O 
foci O 
( O 
ACF O 
) O 
as O 
the O 
endpoint O 
. O 
Additionally O 
, O 
two O 
groups O 
were O 
fed O 
with O 
standard O 
diet O 
or O 
a O 
diet O 
containing O 
5.0% O 
AP O 
for O 
20weeks O 
, O 
using O 
colon O 
tumors O 
as O 
the O 
endpoint O 
. O 
In O 
ACF O 
assay O 
, O 
a O 
reduction O 
in O 
the O 
number O 
of O 
aberrant O 
crypts O 
( O 
ACs O 
) O 
and O 
ACF O 
( O 
1-3 O 
AC O 
) O 
were O 
observed O 
in O 
the O 
groups O 
fed O 
with O 
5.0% O 
AP O 
( O 
37% O 
AC O 
and O 
47% O 
ACF O 
inhibition O 
, O 
p=0.036 O 
) O 
and O 
0.2% O 
NAC B-ABBREVIATION 
( O 
39% O 
AC O 
and O 
41% O 
ACF O 
inhibition O 
, O 
p=0.042 O 
) O 
. O 
In O 
tumor O 
assay O 
, O 
a O 
reduction O 
in O 
the O 
number O 
of O 
invasive O 
tumors O 
( O 
p O 
< O 
0.005 O 
) O 
and O 
tumor O 
multiplicity O 
( O 
p=0.001 O 
) O 
was O 
observed O 
in O 
the O 
group O 
fed O 
with O 
5.0% O 
AP O 
. O 
Also O 
, O 
a O 
reduction O 
in O 
tumor O 
Ki-67 O 
cell O 
proliferation O 
( O 
p=0.003 O 
) O 
and O 
net O 
growth O 
index O 
( O 
p=0.001 O 
) O 
was O 
observed O 
in O 
the O 
group O 
fed O 
with O 
5.0% O 
AP O 
. O 
Therefore O 
the O 
findings O 
of O 
this O 
study O 
indicate O 
that O 
AP O 
feeding O 
may O 
reduce O 
the O 
development O 
of O 
chemically O 
- O 
induced O 
rat O 
colon O 
carcinogenesis O 
. O 

- O 
associated O 
macrophages O 
( O 
TAMs O 
) O 
are O 
correlated O 
with O 
poor O 
prognosis O 
in O 
many O 
human O 
cancers O 
; O 
however O 
, O 
the O 
mechanism O 
by O 
which O 
TAMs O 
facilitate O 
ovarian O 
cancer O 
cell O 
migration O 
and O 
invasion O 
remains O 
unknown O 
. O 
This O 
study O 
was O 
aimed O 
to O 
examine O 
the O 
function O 
of O 
adrenomedullin O 
( O 
ADM O 
) O 
in O 
macrophage O 
polarization O 
and O 
their O 
further O 
effects O 
on O 
the O 
migration O 
of O 
ovarian O 
cancer O 
cells O 
. O 
Exogenous O 
ADM O 
antagonist O 
and O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
specific O 
for O 
ADM O 
expression O 
were O 
treated O 
to O 
macrophages O 
and O 
EOC O 
cell O 
line O 
HO8910 O 
, O 
respectively O 
. O 
Then O 
macrophages O 
were O 
cocultured O 
with O 
HO8910 O 
cells O 
without O 
direct O 
contact O 
. O 
Flow O 
cytometry O 
, O 
Western O 
blot O 
and O 
real O 
- O 
time O 
PCR O 
were O 
used O 
to O 
detect O 
macrophage O 
phenotype O 
and O 
cytokine O 
production O 
. O 
The O 
migration O 
ability O 
and O 
cytoskeleton O 
rearrangement O 
of O 
ovarian O 
cancer O 
cells O 
were O 
determined O 
by O 
Transwell O 
migration O 
assay O 
and O 
phalloidin B-TRIVIAL 
staining O 
. O 
Western O 
blot O 
was O 
performed O 
to O 
evaluate O 
the O 
activity O 
status O 
of O 
signaling O 
molecules O 
in O 
the O 
process O 
of O 
ovarian O 
cancer O 
cell O 
migration O 
. O 
The O 
results O 
showed O 
that O 
ADM O 
induced O 
macrophage O 
phenotype O 
and O 
cytokine O 
production O 
similar O 
to O 
TAMs O 
. O 
Macrophages O 
polarized O 
by O 
ADM O 
promoted O 
the O 
migration O 
and O 
cytoskeleton O 
rearrangement O 
of O 
HO8910 O 
cells O 
. O 
The O 
expression O 
of O 
RhoA O 
and O 
its O 
downstream O 
effector O 
, O 
cofilin O 
, O 
were O 
upregulated O 
in O 
macrophage O 
- O 
induced O 
migration O 
of O 
HO8910 O 
cells O 
. O 
In O 
conclusion O 
, O 
ADM O 
could O 
polarize O 
macrophages O 
similar O 
to O 
TAMs O 
, O 
and O 
then O 
polarized O 
macrophages O 
promote O 
the O 
migration O 
of O 
ovarian O 
cancer O 
cells O 
via O 
activation O 
of O 
RhoA O 
signaling O 
pathway O 
in O 
vitro O 
. O 

, O 
synthesis O 
and O 
inhibitory O 
activities O 
of O 
naringenin B-TRIVIAL 
derivatives O 
on O 
human O 
colon O 
cancer O 
cells O 
. O 

on O 
the O 
previous O 
result O 
, O 
several O 
naringenin B-TRIVIAL 
derivatives O 
modified O 
at O 
position O 
7 O 
with O 
bulky O 
substituents O 
were O 
designed O 
and O 
synthesized O 
, O 
and O 
their O 
inhibitory O 
effects O 
on O 
HCT116 O 
human O 
colon O 
cancer O 
cells O 
were O 
tested O 
using O 
a O 
clonogenic O 
assay O 
. O 
The O 
half O 
maximal O 
inhibitory O 
concentrations O 
(IC(50)) O 
of O 
five O 
naringenin B-TRIVIAL 
derivatives O 
ranged O 
between O 
1.2 O 
μM O 
and O 
20.01 O 
μM O 
which O 
are O 
much O 
better O 
than O 
naringenin B-TRIVIAL 
used O 
as O 
a O 
control O 
. O 
In O 
addition O 
, O 
new O 
structural O 
modification O 
at O 
C-4 O 
of O 
flavanone B-TRIVIAL 
results O 
in O 
improving O 
both O 
the O 
anti-cancer O 
effect O 
and O 
anti-oxidative O 
effect O 
. O 
In O 
vitro O 
cyclin O 
dependent O 
kinase O 
2 O 
( O 
CDK2 O 
) O 
binding O 
assay O 
was O 
carried O 
out O 
based O 
on O 
the O 
previous O 
results O 
. O 
To O 
elucidate O 
the O 
possible O 
interaction O 
between O 
naringenin B-TRIVIAL 
derivatives O 
and O 
CDK2 O 
, O 
in O 
silico O 
docking O 
study O 
was O 
performed O 
. O 
This O 
result O 
demonstrates O 
the O 
rationale O 
for O 
the O 
different O 
inhibitory O 
activities O 
of O 
the O 
naringenin B-TRIVIAL 
derivatives O 
. O 
These O 
findings O 
could O 
be O 
used O 
for O 
designing O 
cancer O 
therapeutic O 
or O 
preventive O 
flavanone B-TRIVIAL 
-derived O 
agents O 
. O 

use O 
patterns O 
in O 
China O 
have O 
changed O 
in O 
recent O 
years O 
; O 
however O 
, O 
the O 
study O 
of O 
the O 
environmental O 
fate O 
of O 
current-use O 
pesticides O 
( O 
CUPs O 
) O 
and O 
their O 
ecotoxicological O 
significance O 
in O 
aquatic O 
ecosystems O 
is O 
limited O 
. O 
In O 
the O 
present O 
study O 
, O 
sediments O 
were O 
collected O 
from O 
an O 
urban O 
stream O 
in O 
the O 
Chinese O 
city O 
of O 
Guangzhou O 
. O 
Sediment-associated O 
legacy O 
organochlorine B-FAMILY 
pesticides O 
and O 
CUPs-including O 
organophosphates B-FAMILY 
, O 
pyrethroids B-FAMILY 
, O 
fipronil B-TRIVIAL 
, O 
and O 
abamectin B-TRIVIAL 
-were O 
analyzed O 
. O 
Additionally O 
, O 
the O 
relative O 
toxicity O 
of O 
the O 
sediments O 
was O 
evaluated O 
with O 
10-d O 
bioassays O 
using O 
Chironomus O 
dilutus O 
. O 
Fifteen O 
of O 
16 O 
sediments O 
collected O 
from O 
the O 
stream O 
were O 
acutely O 
toxic O 
to O 
C O 
. O 
dilutus O 
, O 
with O 
81% O 
of O 
the O 
samples O 
causing O 
100% O 
mortality O 
. O 
Abamectin B-TRIVIAL 
, O 
fipronil B-TRIVIAL 
, O 
and O 
pyrethroids B-FAMILY 
( O 
mainly O 
cypermethrin B-TRIVIAL 
) O 
were O 
identified O 
as O 
the O 
principal O 
contributors O 
to O 
the O 
noted O 
toxicity O 
in O 
the O 
midges O 
, O 
with O 
median O 
predicted O 
toxic O 
units O 
of O 
1.63 O 
, O 
1.63 O 
, O 
and O 
1.03 O 
, O 
respectively O 
. O 
Sediments O 
taken O 
from O 
downstream O 
sites O 
, O 
where O 
residential O 
and O 
industrial O 
regions O 
were O 
located O 
, O 
had O 
elevated O 
CUP O 
concentrations O 
and O 
sediment O 
toxicity O 
compared O 
with O 
upstream O 
sites O 
. O 
The O 
present O 
study O 
is O 
the O 
first O 
of O 
its O 
kind O 
to O 
link O 
sediment O 
CUPs O 
, O 
fipronil B-TRIVIAL 
, O 
and O 
abamectin B-TRIVIAL 
concentrations O 
with O 
toxicity O 
in O 
urban O 
streams O 
in O 
China O 
with O 
a O 
focus O 
on O 
shifting O 
pesticide O 
usage O 
patterns O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1040-1047 O 
. O 
© O 
2013 O 
SETAC O 
. O 

substituted I-FAMILY 
triazolothienopyrimidines I-FAMILY 
as O 
inhibitors O 
of O 
a O 
human O 
urea B-TRIVIAL 
transport O 
protein O 
( O 
UT-B O 
) O 
: O 
New O 
analogs O 
and O 
binding O 
model O 
. O 

kidney O 
urea B-TRIVIAL 
transport O 
protein O 
UT-B O 
is O 
an O 
attractive O 
target O 
for O 
the O 
development O 
of O 
small O 
- O 
molecule O 
inhibitors O 
with O 
a O 
novel O 
diuretic O 
( O 
' O 
urearetic O 
' O 
) O 
action O 
. O 
Previously O 
, O 
two O 
compounds O 
in O 
the O 
triazolothienopyrimidine B-SYSTEMATIC 
scaffold O 
( O 
1a O 
and O 
1c O 
) O 
were O 
reported O 
as O 
UT-B O 
inhibitors O 
. O 
Compound O 
1c O 
incorporates O 
a O 
1,1-difluoroethyl B-SYSTEMATIC 
group O 
, O 
which O 
affords O 
improved O 
microsomal O 
stability O 
when O 
compared O 
to O 
the O 
corresponding O 
ethyl B-SYSTEMATIC 
-substituted O 
compound O 
1a O 
. O 
Here O 
, O 
a O 
small O 
focused O 
library O 
( O 
4a-4f O 
) O 
was O 
developed O 
around O 
lead O 
inhibitor O 
1c O 
to O 
investigate O 
the O 
requirement O 
of O 
an O 
amidine B-SYSTEMATIC 
-linked O 
thiophene B-SYSTEMATIC 
in O 
the O 
inhibitor O 
scaffold O 
. O 
Two O 
compounds O 
( O 
4a O 
and O 
4b O 
) O 
with O 
nanomolar O 
inhibitory O 
potency O 
( O 
IC50≈40nM O 
) O 
were O 
synthesized O 
. O 
Computational O 
docking O 
of O 
lead O 
structure O 
1c O 
and O 
4a-4f O 
into O 
a O 
homology O 
model O 
of O 
the O 
UT-B O 
cytoplasmic O 
surface O 
suggested O 
binding O 
with O 
the O 
core O 
heterocycle O 
buried O 
deep O 
into O 
the O 
hydrophobic O 
pore O 
region O 
of O 
the O 
protein O 
. O 

alkylphospholipid O 
( O 
APL O 
) O 
analogues O 
alter O 
cholesterol B-TRIVIAL 
homoeostasis O 
in O 
HepG2 O 
cells O 
by O 
interfering O 
with O 
cholesterol B-TRIVIAL 
transport O 
from O 
the O 
plasma O 
membrane O 
to O 
the O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
and O 
at O 
the O 
same O 
time O 
stimulating O 
the O 
release O 
of O 
considerable O 
quantities O 
of O 
membrane O 
cholesterol B-TRIVIAL 
. O 
The O 
capacity O 
of O 
APLs O 
to O 
stimulate O 
cholesterol B-TRIVIAL 
efflux O 
is O 
suppressed O 
when O 
cells O 
are O 
incubated O 
simultaneously O 
with O 
APLs O 
and O 
serum O 
whilst O 
the O 
inhibition O 
of O 
cholesterol B-TRIVIAL 
transport O 
to O 
the O 
ER O 
( O 
measured O 
in O 
terms O 
of O 
the O 
synthesis O 
of O 
esterified B-TRIVIAL 
cholesterol I-TRIVIAL 
) O 
persists O 
, O 
indicating O 
that O 
both O 
effects O 
are O 
independent O 
of O 
each O 
other O 
. O 
Interestingly O 
, O 
our O 
results O 
suggest O 
that O 
both O 
raft O 
and O 
non-raft O 
membrane O 
domains O 
contribute O 
to O 
the O 
cholesterol B-TRIVIAL 
released O 
to O 
APLs O 
. O 
In O 
addition O 
, O 
a O 
marked O 
efflux O 
of O 
choline B-FAMILY 
-bearing O 
phospholipids O 
( O 
phosphatidylcholine B-FAMILY 
( O 
PC O 
) O 
and O 
sphingomyelins B-FAMILY 
( O 
SM O 
) O 
) O 
was O 
found O 
to O 
be O 
related O 
to O 
this O 
release O 
of O 
cholesterol B-TRIVIAL 
. O 
Finally O 
, O 
we O 
observed O 
that O 
APL O 
micelles O 
composed O 
of O 
cholesterol B-TRIVIAL 
might O 
act O 
as O 
donor O 
/ O 
acceptor O 
cholesterol B-TRIVIAL 
systems O 
. O 
Thus O 
, O 
the O 
findings O 
of O 
this O 
study O 
clearly O 
demonstrate O 
that O 
antitumoural O 
APLs O 
act O 
as O 
extracellular O 
acceptors O 
, O 
stimulating O 
cholesterol B-TRIVIAL 
and O 
phospholipid O 
efflux O 
, O 
although O 
they O 
may O 
also O 
play O 
a O 
role O 
as O 
cholesterol B-TRIVIAL 
donors O 
. O 

Pathways O 
of O 
Anisotropic O 
Disc O 
- O 
Shaped O 
Zeolite B-TRIVIAL 
L I-TRIVIAL 
Nanocrystals O 
with O 
Different O 
Surface O 
Properties O 
in O 
HeLa O 
Cancer O 
Cells O 
. O 

about O 
the O 
mechanisms O 
underlying O 
the O 
interactions O 
of O 
nanoparticles O 
with O 
living O 
cells O 
is O 
crucial O 
for O 
their O 
medical O 
application O 
and O 
also O 
provides O 
indications O 
of O 
the O 
putative O 
toxicity O 
of O 
such O 
materials O 
. O 
Here O 
the O 
uptake O 
and O 
intracellular O 
delivery O 
of O 
disc O 
- O 
shaped O 
zeolite B-TRIVIAL 
L I-TRIVIAL 
nanocrystals O 
as O 
porous O 
aminosilicates B-FAMILY 
with O 
well O 
- O 
defined O 
crystal O 
structure O 
, O 
uncoated O 
as O 
well O 
as O 
with O 
COOH- B-FORMULA 
, O 
NH(2) B-FORMULA 
- I-FORMULA 
, O 
polyethyleneglycol B-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
)- O 
and O 
polyallylamine B-FAMILY 
hydrochloride I-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
surface O 
coatings O 
are O 
reported O 
. O 
HeLa O 
cells O 
are O 
used O 
as O 
a O 
model O 
system O 
to O 
demonstrate O 
the O 
relation O 
between O 
these O 
particles O 
and O 
cancer O 
cells O 
. O 
Interactions O 
are O 
studied O 
in O 
terms O 
of O 
their O 
fates O 
under O 
diverse O 
in O 
vitro O 
cell O 
culture O 
conditions O 
. O 
Differently O 
charged O 
coatings O 
demonstrated O 
dissimilar O 
behavior O 
in O 
terms O 
of O 
agglomeration O 
in O 
media O 
, O 
serum O 
protein O 
adsorption O 
, O 
nanoparticle O 
cytotoxicity O 
and O 
cell O 
internalization O 
. O 
It O 
is O 
also O 
found O 
that O 
functionalized O 
disc O 
- O 
shaped O 
zeolite O 
L O 
particles O 
enter O 
the O 
cancer O 
cells O 
via O 
different O 
, O 
partly O 
not O 
yet O 
characterized O 
, O 
pathways O 
. O 
These O 
in O 
vitro O 
results O 
provide O 
additional O 
insight O 
about O 
low O 
- O 
aspect O 
ratio O 
anisotropic O 
nanoparticle O 
interactions O 
with O 
cancer O 
cells O 
and O 
demonstrate O 
the O 
possibility O 
to O 
manipulate O 
the O 
interactions O 
of O 
nanoparticles O 
and O 
cells O 
by O 
surface O 
coating O 
for O 
the O 
use O 
of O 
nanoparticles O 
in O 
medical O 
applications O 
. O 

phenyl B-SYSTEMATIC 
groups O 
improve O 
the O 
pharmacokinetic O 
profile O 
and O 
anti-inflammatory O 
effect O 
of O 
urea B-TRIVIAL 
-based O 
soluble O 
epoxide B-SYSTEMATIC 
hydrolase O 
inhibitors O 
in O 
murine O 
models O 
. O 

epoxide B-SYSTEMATIC 
hydrolase O 
inhibitors O 
( O 
sEHIs O 
) O 
are O 
anti-inflammatory O 
, O 
analgesic O 
, O 
anti-hypertensive O 
, O 
cardio- O 
and O 
renal O 
- O 
protective O 
in O 
multiple O 
animal O 
models O 
. O 
However O 
, O 
the O 
earlier O 
adamantyl B-SYSTEMATIC 
-containing O 
urea B-TRIVIAL 
-based O 
inhibitors O 
are O 
rapidly O 
metabolized O 
. O 
Therefore O 
, O 
new O 
potent O 
inhibitors O 
with O 
the O 
adamantyl B-SYSTEMATIC 
group O 
replaced O 
by O 
a O 
substituted O 
phenyl B-SYSTEMATIC 
group O 
were O 
synthesized O 
to O 
presumptively O 
offer O 
better O 
pharmacokinetic O 
( O 
PK O 
) O 
properties O 
. O 
Here O 
we O 
describe O 
the O 
improved O 
PK O 
profile O 
of O 
these O 
inhibitors O 
and O 
the O 
anti-inflammatory O 
effect O 
of O 
the O 
most O 
promising O 
one O 
in O 
a O 
murine O 
model O 
. O 
The O 
PK O 
profiles O 
of O 
inhibitors O 
were O 
determined O 
following O 
p.o O 
. O 
administration O 
and O 
serial O 
bleeding O 
in O 
mice O 
. O 
The O 
anti-inflammatory O 
effect O 
of O 
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea B-SYSTEMATIC 
( O 
TPPU B-ABBREVIATION 
) O 
, O 
the O 
most O 
promising O 
inhibitor O 
among O 
the O 
five O 
sEHIs O 
tested O 
, O 
was O 
investigated O 
in O 
a O 
lipopolysaccharide O 
(LPS)-challenged O 
murine O 
model O 
. O 
The O 
earlier O 
broadly O 
- O 
used O 
adamantyl B-SYSTEMATIC 
-containing O 
sEHI O 
, O 
trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
t-AUCB B-ABBREVIATION 
) O 
, O 
was O 
used O 
for O 
comparison O 
. O 
Compared O 
with O 
the O 
earlier O 
adamantyl B-SYSTEMATIC 
-containing O 
urea B-TRIVIAL 
-based O 
inhibitors O 
, O 
substituted O 
phenyl B-SYSTEMATIC 
-containing O 
urea B-TRIVIAL 
-based O 
inhibitors O 
afford O 
more O 
favorable O 
PK O 
properties O 
, O 
such O 
as O 
higher O 
Cmaxs O 
, O 
larger O 
AUCs O 
and O 
longer O 
t1 O 
/ O 
2s O 
, O 
which O 
, O 
as O 
expected O 
, O 
show O 
more O 
stable O 
metabolic O 
stability O 
. O 
Moreover O 
, O 
oral O 
administration O 
of O 
TPPU B-ABBREVIATION 
dramatically O 
reversed O 
the O 
shifts O 
caused O 
by O 
LPS-challenge O 
in O 
plasma O 
levels O 
of O 
inflammatory O 
cytokines O 
, O 
epoxides B-FAMILY 
and O 
corresponding O 
diols O 
, O 
which O 
is O 
more O 
potent O 
than O 
t-AUCB B-ABBREVIATION 
. O 
The O 
substituted O 
phenyl B-SYSTEMATIC 
-containing O 
sEHIs O 
are O 
more O 
metabolically O 
stable O 
than O 
those O 
with O 
adamantyl B-SYSTEMATIC 
group O 
, O 
resulting O 
in O 
more O 
potent O 
efficacy O 
in O 
vivo O 
. O 
This O 
indicates O 
a O 
new O 
strategy O 
for O 
development O 
of O 
sEHIs O 
for O 
further O 
study O 
toward O 
clinical O 
trials O 
. O 

concentrations O 
and O 
bioaccumulations O 
of O 
cadmium B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
in O 
coastal O 
watersheds O 
along O 
the O 
Chinese O 
Northern O 
Bohai O 
and O 
Yellow O 
Seas O 
. O 

( O 
Cd B-FORMULA 
) O 
and O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
in O 
surface O 
water O 
, O 
sediment O 
, O 
carp O 
, O 
and O 
crab O 
samples O 
collected O 
from O 
upstream O 
and O 
downstream O 
regions O 
of O 
coastal O 
watersheds O 
along O 
the O 
Chinese O 
Northern O 
Bohai O 
and O 
Yellow O 
Seas O 
were O 
analyzed O 
to O 
provide O 
a O 
comprehensive O 
understanding O 
and O 
assessment O 
of O 
their O 
environmental O 
concentrations O 
and O 
bioaccumulations O 
. O 
The O 
results O 
showed O 
that O 
downstream O 
waters O 
contaminated O 
with O 
Zn B-FORMULA 
would O 
have O 
adverse O 
effects O 
on O 
aquatic O 
organisms O 
. O 
Although O 
nearly O 
all O 
sediments O 
were O 
contaminated O 
with O 
Cd B-FORMULA 
due O 
to O 
human O 
activities O 
, O 
little O 
potential O 
existed O 
for O 
Cd B-FORMULA 
toxicity O 
in O 
sediment-dwelling O 
fauna O 
. O 
Concentrations O 
of O 
Cd B-FORMULA 
and O 
Zn B-FORMULA 
in O 
most O 
water O 
, O 
sediment O 
, O 
carp O 
, O 
and O 
crab O 
were O 
less O 
than O 
published O 
values O 
. O 
The O 
downstream O 
carp O 
and O 
crabs O 
had O 
higher O 
mean O 
bioaccumulation O 
factors O 
and O 
biota-sediment O 
accumulation O 
factors O 
for O 
Cd B-FORMULA 
but O 
lower O 
mean O 
biota-sediment O 
accumulation O 
factors O 
for O 
Zn B-FORMULA 
than O 
the O 
upstream O 
carp O 
and O 
crabs O 
. O 
Based O 
on O 
the O 
relationships O 
among O 
Cd B-FORMULA 
and O 
Zn B-FORMULA 
concentrations O 
in O 
water O 
, O 
sediment O 
, O 
and O 
biota O 
, O 
the O 
authors O 
conclude O 
that O 
Cd B-FORMULA 
and O 
Zn B-FORMULA 
in O 
crabs O 
primarily O 
derived O 
from O 
sediment O 
exposure O 
. O 
Although O 
Cd B-FORMULA 
and O 
Zn B-FORMULA 
in O 
water O 
and O 
sediment O 
originated O 
from O 
some O 
of O 
the O 
same O 
sources O 
, O 
the O 
sources O 
of O 
Cd B-FORMULA 
or O 
Zn B-FORMULA 
in O 
water O 
were O 
likely O 
different O 
from O 
those O 
in O 
sediment O 
. O 

of O 
the O 
natural O 
endocrine O 
disruptor O 
equol B-TRIVIAL 
on O 
the O 
pituitary O 
function O 
in O 
adult O 
male O 
rats O 
. O 

( O 
EQ O 
) O 
, O 
a O 
potent O 
biologically O 
active O 
metabolite O 
of O 
the O 
soy O 
isoflavone B-FAMILY 
daidzein B-TRIVIAL 
, O 
interacts O 
with O 
estrogen B-FAMILY 
receptors O 
( O 
ERs O 
) O 
, O 
however O 
, O 
as O 
suggested O 
recently O 
, O 
EQ O 
may O 
also O 
exert O 
anti-androgenic O 
actions O 
in O 
androgen B-FAMILY 
regulated O 
tissues O 
like O 
prostate O 
and O 
seminal O 
vesicles O 
in O 
adult O 
male O 
rats O 
. O 
However O 
, O 
data O 
regarding O 
a O 
putative O 
anti-androgenic O 
activity O 
of O 
EQ O 
on O 
pituitary O 
function O 
in O 
male O 
individuals O 
are O 
still O 
lacking O 
. O 
Therefore O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
EQ O 
on O 
androgen B-FAMILY 
- O 
and O 
estrogen B-FAMILY 
-regulated O 
gene O 
expressions O 
in O 
the O 
pituitary O 
and O 
circulating O 
luteinizing O 
hormone O 
( O 
LH O 
) O 
and O 
prolactin O 
( O 
PRL O 
) O 
levels O 
in O 
adult O 
male O 
rats O 
. O 
3-Month- O 
old O 
male O 
Sprague-Dawley O 
rats O 
( O 
n=12 O 
per O 
group O 
) O 
were O 
treated O 
by O 
gavage O 
for O 
5 O 
days O 
with O 
either O 
EQ O 
( O 
100 O 
and O 
250 O 
mg O 
/ O 
kg O 
BW O 
/ O 
day O 
) O 
or O 
vehicle O 
olive O 
oil O 
( O 
1 O 
ml O 
/ O 
rat O 
/ O 
day O 
) O 
. O 
As O 
reference O 
compound O 
, O 
the O 
pure O 
anti-androgenic O 
drug O 
flutamide B-TRIVIAL 
( O 
FLUT B-ABBREVIATION 
) O 
was O 
employed O 
at O 
a O 
dose O 
of O 
100 O 
mg O 
/ O 
kg O 
BW O 
/ O 
day O 
. O 
At O 
day O 
5 O 
, O 
animals O 
were O 
sacrificed O 
. O 
Levels O 
of O 
pituitary O 
hormones O 
and O 
gene O 
expression O 
were O 
measured O 
by O 
radioimmunoassays O 
and O 
quantitative O 
TaqMan(®) O 
real O 
- O 
time O 
reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
, O 
respectively O 
. O 
The O 
present O 
findings O 
revealed O 
that O 
the O 
pituitary O 
mechanisms O 
involved O 
in O 
the O 
effects O 
of O 
EQ O 
and O 
FLUT B-ABBREVIATION 
were O 
different O 
due O 
to O 
the O 
opposite O 
changes O 
in O 
the O 
mRNA O 
expression O 
levels O 
of O 
estrogen B-FAMILY 
receptor O 
subtype O 
alpha O 
(ERα)- O 
, O 
truncated O 
estrogen B-FAMILY 
receptor O 
product-1 O 
(TERP-1)- O 
and O 
-2 O 
(TERP-2)- O 
, O 
gonadotropin B-TRIVIAL 
releasing I-TRIVIAL 
hormone I-TRIVIAL 
receptor O 
( O 
GnRH B-ABBREVIATION 
receptor)- O 
, O 
beta-subunit O 
of O 
LH O 
(LHβ)- O 
, O 
and O 
gonadotropin O 
alpha O 
subunit O 
( O 
α-subunit O 
) O 
genes O 
. O 
EQ O 
displayed O 
typical O 
ER-agonistic O 
actions O 
as O 
shown O 
by O 
the O 
significant O 
increases O 
in O 
ERα- O 
, O 
TERP-1 O 
/ O 
-2 O 
mRNA O 
expressions O 
and O 
serum O 
PRL O 
levels O 
along O 
with O 
the O 
significant O 
reduction O 
in O 
serum O 
LH O 
levels O 
, O 
whereas O 
FLUT B-ABBREVIATION 
exerted O 
opposite O 
effects O 
on O 
gonadotropin O 
secretion O 
and O 
expression O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
are O 
the O 
first O 
in O 
vivo O 
data O 
that O 
upon O 
sub O 
- O 
acute O 
oral O 
exposure O 
of O 
EQ O 
show O 
an O 
estrogenic O 
effect O 
on O 
reproductive O 
endocrine O 
activity O 
of O 
the O 
pituitary O 
in O 
adult O 
male O 
rats O 
. O 
However O 
, O 
EQ O 
did O 
not O 
exert O 
anti-androgenic O 
effects O 
on O 
male O 
rat O 
pituitary O 
function O 
as O 
observed O 
at O 
the O 
levels O 
of O 
mRNA O 
expression O 
of O 
androgen B-FAMILY 
- O 
and O 
estrogen B-FAMILY 
-regulated O 
genes O 
and O 
circulating O 
pituitary O 
hormones O 
. O 

application O 
of O 
Near-Infrared O 
Reflectance O 
Spectroscopy O 
( O 
NIRS O 
) O 
to O 
detect O 
melamine B-TRIVIAL 
adulteration O 
of O 
soya O 
bean O 
meal O 
. O 

bean O 
products O 
are O 
used O 
widely O 
in O 
the O 
animal O 
feed O 
industry O 
as O 
a O 
protein O 
based O 
feed O 
ingredient O 
and O 
have O 
been O 
found O 
to O 
be O 
adulterated O 
with O 
melamine B-TRIVIAL 
. O 
This O 
was O 
highlighted O 
in O 
the O 
Chinese O 
scandal O 
of O 
2008 O 
. O 
Dehulled O 
soya O 
( O 
GM O 
and O 
non-GM O 
) O 
, O 
soya O 
hulls O 
and O 
toasted O 
soya O 
were O 
contaminated O 
with O 
melamine B-TRIVIAL 
and O 
spectra O 
were O 
generated O 
using O 
Near O 
Infrared O 
Reflectance O 
Spectroscopy O 
( O 
NIRS O 
) O 
. O 
By O 
applying O 
chemometrics O 
to O 
the O 
spectral O 
data O 
, O 
excellent O 
calibration O 
models O 
and O 
prediction O 
statistics O 
were O 
obtained O 
. O 
The O 
coefficients O 
of O 
determination O 
(R(2)) O 
were O 
found O 
to O 
be O 
0.89-0.99 O 
depending O 
on O 
the O 
mathematical O 
algorithm O 
used O 
, O 
the O 
data O 
pre O 
- O 
processing O 
applied O 
and O 
the O 
sample O 
type O 
used O 
. O 
The O 
corresponding O 
values O 
for O 
the O 
root O 
mean O 
square O 
error O 
of O 
calibration O 
and O 
prediction O 
were O 
found O 
to O 
be O 
0.081-0.276% O 
and O 
0.134-0.368% O 
, O 
respectively O 
, O 
again O 
depending O 
on O 
the O 
chemometric O 
treatment O 
applied O 
to O 
the O 
data O 
and O 
sample O 
type O 
. O 
In O 
addition O 
, O 
adopting O 
a O 
qualitative O 
approach O 
with O 
the O 
spectral O 
data O 
and O 
applying O 
PCA O 
, O 
it O 
was O 
possible O 
to O 
discriminate O 
between O 
the O 
four O 
samples O 
types O 
and O 
also O 
, O 
by O 
generation O 
of O 
Cooman's O 
plots O 
, O 
possible O 
to O 
distinguish O 
between O 
adulterated O 
and O 
non-adulterated O 
samples O 
. O 

deiodinase O 
types O 
I O 
, O 
II O 
, O 
and O 
III O 
( O 
D1 O 
, O 
D2 O 
, O 
and O 
D3 O 
, O 
respectively O 
) O 
, O 
which O 
constitute O 
a O 
family O 
of O 
selenoenzymes O 
, O 
activate O 
and O 
inactivate O 
thyroid O 
hormones O 
through O 
the O 
removal O 
of O 
specific O 
iodine B-SYSTEMATIC 
moieties O 
from O 
thyroxine B-TRIVIAL 
and O 
its O 
derivatives O 
. O 
These O 
enzymes O 
are O 
important O 
in O 
the O 
biological O 
effects O 
mediated O 
by O 
thyroid O 
hormones O 
. O 
The O 
expression O 
of O 
activating O 
and O 
inactivating O 
deiodinases O 
plays O 
a O 
critical O 
role O 
in O 
a O 
number O 
of O 
cell O 
systems O 
, O 
including O 
the O 
neuronal O 
system O 
, O 
during O 
development O 
as O 
well O 
as O 
in O 
adult O 
vertebrates O 
. O 
To O 
investigate O 
deiodinase O 
- O 
disrupting O 
chemicals O 
based O 
on O 
transcriptomic O 
responses O 
, O 
we O 
examined O 
differences O 
in O 
gene O 
expression O 
profiles O 
between O 
T3 O 
- O 
treated O 
and O 
deiodinase O 
- O 
knockdown O 
SH-SY5Y O 
cells O 
using O 
microarray O 
analysis O 
and O 
quantitative O 
real O 
- O 
time O 
RT-PCR O 
. O 
A O 
total O 
of O 
1558 O 
genes O 
, O 
consisting O 
of O 
755 O 
upregulated O 
and O 
803 O 
downregulated O 
genes O 
, O 
were O 
differentially O 
expressed O 
between O 
the O 
T3 O 
- O 
treated O 
and O 
deiodinase O 
- O 
knockdown O 
cells O 
. O 
The O 
expression O 
levels O 
of O 
10 O 
of O 
these O 
genes O 
( O 
ID2 O 
, O 
ID3 O 
, O 
CCL2 O 
, O 
TBX3 O 
, O 
TGOLN2 O 
, O 
C1orf71 O 
, O 
ZNF676 O 
, O 
GULP1 O 
, O 
KLF9 O 
, O 
and O 
ITGB5 O 
) O 
were O 
altered O 
by O 
deiodinase O 
- O 
disrupting O 
chemicals O 
( O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
, O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
, O 
propylthiouracil B-SYSTEMATIC 
, O 
iodoacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
methylmercury B-SYSTEMATIC 
, O 
β-estradiol B-TRIVIAL 
, O 
methimazole B-TRIVIAL 
, O 
3-methylcholanthrene B-SYSTEMATIC 
, O 
aminotriazole B-SYSTEMATIC 
, O 
amiodarone B-TRIVIAL 
, O 
cadmium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
, O 
dimethoate B-TRIVIAL 
, O 
fenvalerate B-TRIVIAL 
, O 
octylmethoxycinnamate B-SYSTEMATIC 
, O 
iopanoic B-TRIVIAL 
acid I-TRIVIAL 
, O 
methoxychlor B-TRIVIAL 
, O 
and O 
4-methylbenzylidene- B-SYSTEMATIC 
camphor I-SYSTEMATIC 
) O 
. O 
These O 
genes O 
are O 
potential O 
biomarkers O 
for O 
detecting O 
deiodinase O 
deficiency O 
and O 
predicting O 
their O 
effects O 
on O 
thyroid O 
hormone O 
production O 
. O 

and O 
targeting O 
the O 
basic O 
mechanism O 
of O 
neurodegeneration O 
: O 
The O 
role O 
of O 
peptides O 
from O 
the O 
C B-FORMULA 
-terminus O 
of O 
acetylcholinesterase O 
: O 
Non-hydrolytic O 
effects O 
of O 
ache O 
: O 
The O 
actions O 
of O 
peptides O 
derived O 
from O 
the O 
C B-FORMULA 
-terminal O 
and O 
their O 
relevance O 
to O 
neurodegeneration O 
. O 

( O 
AChE O 
) O 
is O 
now O 
well O 
- O 
established O 
widely O 
as O 
a O 
signalling O 
molecule O 
with O 
non-hydrolytic O 
functions O 
including O 
trophic O 
activity O 
in O 
a O 
diverse O 
variety O 
of O 
situations O 
in O 
both O 
neural O 
and O 
non-neural O 
tissues O 
. O 
We O 
have O 
focussed O 
on O 
the O 
observation O 
that O 
AChE O 
, O 
operating O 
as O 
a O 
trophic O 
agent O 
independent O 
of O 
its O 
enzymatic O 
action O 
, O 
does O 
indeed O 
trigger O 
calcium B-SYSTEMATIC 
entry O 
into O 
neurons O 
. O 
It O 
is O 
possible O 
that O 
AChE O 
has O 
a O 
dual O 
non-classical O 
action O 
that O 
ranges O 
along O 
a O 
trophic O 
- O 
toxic O 
axis O 
, O 
depending O 
on O 
amount O 
, O 
duration O 
of O 
availability O 
and O 
, O 
most O 
significantly O 
, O 
age O 
. O 
The O 
neurodegenerative O 
diseases O 
could O 
therefore O 
be O 
viewed O 
as O 
aberrant O 
activation O 
of O 
developmental O 
mechanisms O 
with O 
' O 
non-cholinergic O 
' O 
AChE O 
as O 
a O 
, O 
perhaps O 
the O 
, O 
pivotal O 
molecule O 
. O 
We O 
have O 
identified O 
two O 
peptides O 
that O 
could O 
be O 
cleaved O 
from O 
the O 
C B-FORMULA 
-terminus O 
of O 
T-AChE O 
, O 
one O 
( O 
T14 O 
) O 
, O 
within O 
the O 
other O 
( O 
T30 O 
) O 
, O 
and O 
which O 
have O 
a O 
strong O 
sequence O 
homology O 
to O 
the O 
comparable O 
region O 
of O 
beta-amyloid O 
whilst O 
the O 
inert O 
residue O 
within O 
the O 
T30 O 
sequence O 
( O 
' O 
T15 O 
' O 
) O 
acts O 
as O 
a O 
control O 
, O 
and O 
is O 
without O 
effect O 
. O 
We O 
have O 
subsequently O 
been O 
able O 
to O 
ascribe O 
the O 
trophic O 
- O 
toxic O 
actions O 
of O 
the O 
both O 
T14 O 
and O 
T30 O 
peptides O 
to O 
the O 
modulation O 
of O 
calcium B-SYSTEMATIC 
influx O 
via O 
an O 
allosteric O 
site O 
on O 
the O 
alpha-7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
α7-nAChR O 
) O 
. O 
If O 
the O 
scenario O 
described O 
here O 
is O 
indeed O 
the O 
primary O 
mechanism O 
of O 
neurodegeneration O 
, O 
then O 
interception O 
of O 
the O 
actions O 
of O 
the O 
' O 
non-cholinergic O 
' O 
AChE O 
- O 
peptides O 
T14 O 
and O 
T30 O 
at O 
the O 
α7-nAChR O 
, O 
would O 
be O 
a O 
promising O 
novel O 
therapy O 
for O 
arresting O 
and O 
stabilising O 
cell O 
loss O 
in O 
Alzheimer's O 
disease O 
, O 
whereas O 
detection O 
of O 
the O 
peptides O 
ideally O 
in O 
the O 
blood O 
, O 
could O 
provide O 
a O 
sensitive O 
surrogate O 
marker O 
. O 
If O 
the O 
marker O 
was O 
sensitive O 
enough O 
to O 
be O 
detected O 
pre O 
- O 
symptomatically O 
in O 
a O 
routine O 
blood O 
test O 
, O 
then O 
the O 
medication O 
for O 
arresting O 
further O 
cell O 
loss O 
could O 
be O 
initiated O 
at O 
that O 
time O 
, O 
and O 
the O 
symptoms O 
would O 
never O 
appear O 
. O 
This O 
dual O 
approach O 
of O 
identifying O 
the O 
marker O 
and O 
then O 
intercepting O 
its O 
further O 
action O 
, O 
could O 
thus O 
amount O 
to O 
an O 
effective O 
treatment O 
for O 
Alzheimer's O 
and O 
other O 
neurodegenerative O 
diseases O 
. O 

transport O 
in O 
organic O 
thin O 
film O 
transistors O 
takes O 
place O 
in O 
the O 
first O 
few O 
molecular O 
layers O 
in O 
contact O 
with O 
the O 
gate O 
dielectric O 
. O 
Here O 
we O 
demonstrate O 
that O 
the O 
charge O 
transport O 
pathways O 
in O 
these O 
devices O 
are O 
extremely O 
sensitive O 
to O 
the O 
orientational O 
defects O 
of O 
the O 
first O 
monolayers O 
, O 
which O 
arise O 
from O 
specific O 
growth O 
conditions O 
. O 
Although O 
these O 
defects O 
partially O 
heal O 
during O 
the O 
growth O 
, O 
they O 
cause O 
depletion O 
of O 
charge O 
carriers O 
in O 
the O 
first O 
monolayer O 
, O 
and O 
drive O 
the O 
current O 
to O 
flow O 
in O 
the O 
monolayers O 
above O 
the O 
first O 
one O 
. O 
Moreover O 
, O 
the O 
residual O 
defects O 
induce O 
lower O 
crystalline O 
order O 
and O 
charge O 
mobility O 
. O 
These O 
results O 
, O 
which O 
are O 
not O 
intuitively O 
explained O 
by O 
electrostatics O 
arguments O 
, O 
have O 
been O 
obtained O 
by O 
combining O 
in O 
situ O 
real O 
time O 
structural O 
and O 
electrical O 
characterization O 
together O 
with O 
ex O 
situ O 
AFM O 
measurements O 
, O 
on O 
thin O 
films O 
of O 
a O 
relevant O 
n O 
- O 
type O 
organic O 
semiconductor O 
, O 
N,N'-bis(n-octyl)-dicyanoperylene-3,4 B-SYSTEMATIC 
: I-SYSTEMATIC 
9,10-bis I-SYSTEMATIC 
dicarboximide I-SYSTEMATIC 
grown O 
by O 
sublimation O 
in O 
a O 
quasi O 
- O 
layer O 
- O 
by O 
- O 
layer O 
mode O 
at O 
different O 
substrate O 
temperatures O 
. O 

review O 
summarizes O 
selected O 
mechanistic O 
insight O 
garnered O 
from O 
reactions O 
that O 
form O 
bonds O 
between O 
main O 
group O 
elements O 
with O 
liberation O 
of O 
hydrogen B-SYSTEMATIC 
, O 
dehydrocoupling O 
or O 
dehydropolymerization O 
reactions O 
. O 
Focus O 
has O 
been O 
made O 
where O 
mechanistic O 
study O 
has O 
been O 
done O 
or O 
provides O 
unique O 
insight O 
as O 
compared O 
to O 
previous O 
work O 
. O 
Thus O 
, O 
a O 
limited O 
number O 
of O 
catalysts O 
and O 
substrates O 
will O 
be O 
discussed O 
, O 
but O 
a O 
broad O 
range O 
of O 
mechanistic O 
features O 
will O 
be O 
noted O 
. O 
A O 
comparative O 
approach O 
considering O 
dehydrocoupling O 
reactions O 
that O 
appear O 
to O 
proceed O 
by O 
certain O 
mechanistic O 
steps O 
is O 
taken O 
here O 
, O 
beginning O 
with O 
steps O 
that O 
are O 
well O 
established O 
and O 
general O 
then O 
moving O 
to O 
those O 
that O 
are O 
newer O 
, O 
at O 
least O 
to O 
this O 
application O 
. O 

anticancer O 
active O 
and O 
selective O 
phenylene B-FAMILY 
- I-FAMILY 
bisbenzothiazoles I-FAMILY 
: O 
Synthesis O 
, O 
antiproliferative O 
evaluation O 
and O 
DNA O 
binding O 
. O 

amidino B-FAMILY 
-derivatives O 
of O 
phenylene B-FAMILY 
- I-FAMILY 
bisbenzothiazoles I-FAMILY 
were O 
synthesized O 
and O 
tested O 
for O 
their O 
antiproliferative O 
activity O 
against O 
several O 
human O 
cancer O 
cell O 
lines O 
, O 
as O 
well O 
as O 
DNA O 
- O 
binding O 
properties O 
. O 
The O 
synthetic O 
approach O 
used O 
for O 
preparation O 
of O 
isomeric O 
amidino B-FAMILY 
substituted-phenylene-bis-benzothyazoles I-FAMILY 
3a-3f O 
was O 
achieved O 
by O 
condensation O 
reaction O 
of O 
isophthaloyl B-SYSTEMATIC 
dichloride I-SYSTEMATIC 
1a O 
and O 
terephthaloyl B-SYSTEMATIC 
dichloride I-SYSTEMATIC 
1b O 
or O 
with O 
phthalic B-TRIVIAL 
acid I-TRIVIAL 
1c O 
with O 
5-amidinium-2-aminobenzothiolate B-SYSTEMATIC 
2a O 
and O 
5-(imidazolinium-2-yl)-2-aminobenzothiolate B-SYSTEMATIC 
2b O 
in O 
good O 
yields O 
. O 
The O 
targeted O 
compounds O 
were O 
converted O 
in O 
the O 
desired O 
water O 
soluble O 
dihydrochloride B-SYSTEMATIC 
salts O 
by O 
reaction O 
of O 
appropriate O 
free O 
base O 
with O 
concd O 
HCl B-FORMULA 
in O 
ethanol B-SYSTEMATIC 
or O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
All O 
tested O 
compounds O 
( O 
3a-3f O 
) O 
showed O 
antiproliferative O 
effects O 
on O 
tumour O 
cells O 
in O 
a O 
concentration O 
- O 
dependant O 
manner O 
. O 
The O 
strongest O 
activity O 
and O 
cytotoxicity O 
was O 
observed O 
for O 
diimidazolinyl B-FAMILY 
substituted I-FAMILY 
phenylene I-FAMILY 
- I-FAMILY 
bisbenzothiazole I-FAMILY 
compound O 
3b O 
. O 
These O 
effects O 
were O 
shown O 
to O 
be O 
related O 
to O 
DNA O 
- O 
binding O 
properties O 
, O 
topoisomerase O 
I O 
and O 
II O 
poisoning O 
effects O 
and O 
apoptosis O 
induction O 
. O 
The O 
highest O 
tested O 
selectivity O 
towards O 
tumour O 
cells O 
was O 
observed O 
for O 
the O 
imidazolyl B-FAMILY 
substituted I-FAMILY 
phenylene I-FAMILY 
- I-FAMILY 
benzothiazole I-FAMILY 
3d O 
that O 
showed O 
no O 
cytotoxic O 
effects O 
on O 
normal O 
fibroblasts O 
making O 
it O 
an O 
excellent O 
candidate O 
for O 
further O 
chemical O 
optimization O 
and O 
preclinical O 
evaluation O 
. O 

and O 
Structure-Activity O 
Relationships O 
of O 
N-Methyl-5,6,7-trimethoxylindoles B-FAMILY 
as O 
Novel O 
Antimitotic O 
and O 
Vascular O 
Disrupting O 
Agents O 
. O 

new O 
series O 
of O 
5,6,7-trimethoxyindole B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
their O 
structure O 
- O 
activity O 
relationships O 
( O 
SARs O 
) O 
were O 
studied O 
. O 
Some O 
of O 
these O 
compounds O 
exhibited O 
strong O 
antiproliferative O 
activities O 
in O 
the O 
submicromolar O 
range O 
. O 
N-Methyl-5,6,7-trimethoxylindoles B-FAMILY 
21 O 
and O 
31 O 
displayed O 
the O 
highest O 
antiproliferative O 
activities O 
, O 
with O 
IC(50) O 
values O 
ranging O 
from O 
22 O 
to O 
125 O 
nM O 
in O 
four O 
human O 
cancer O 
cell O 
lines O 
and O 
activated O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
. O 
In O 
addition O 
to O 
vascular O 
disrupting O 
activity O 
verified O 
by O 
in O 
vitro O 
assays O 
, O 
compounds O 
21 O 
and O 
31 O 
displayed O 
much O 
higher O 
selectivity O 
for O 
activated O 
HUVECs O 
versus O 
quiescent O 
HUVECs O 
than O 
those O 
of O 
colchicine B-TRIVIAL 
and O 
combretastatinA-4 B-TRIVIAL 
. O 
The O 
polymerization O 
of O 
cancer O 
cell O 
tubulin O 
was O 
inhibited O 
and O 
the O 
cell O 
cycle O 
was O 
arrested O 
in O 
the O 
G2 O 
/ O 
M O 
phase O 
after O 
treatment O 
with O 
21 O 
and O 
31 O 
. O 
It O 
was O 
showed O 
that O 
21 O 
disrupted O 
tumor O 
vasculature O 
by O 
use O 
of O 
in O 
vivo O 
assay O 
. O 
Our O 
results O 
suggest O 
that O 
these O 
two O 
new O 
compounds O 
we O 
synthesized O 
may O 
become O 
the O 
promising O 
leads O 
for O 
the O 
development O 
of O 
vascular O 
disrupting O 
agents O 
. O 

5-HT1D O 
/ O 
1B O 
receptor O 
agonist O 
sumatriptan B-TRIVIAL 
enhances O 
fear O 
of O 
simulated O 
speaking O 
and O 
reduces O 
plasma O 
levels O 
of O 
prolactin O 
. O 

study O 
measured O 
the O 
effects O 
of O 
the O 
preferential O 
5-HT1D O 
/ O 
1B O 
receptor O 
agonist O 
sumatriptan B-TRIVIAL 
in O 
healthy O 
volunteers O 
who O 
performed O 
the O 
Simulated O 
Public O 
Speaking O 
Test O 
( O 
SPST O 
) O 
, O 
which O 
recruits O 
the O 
neural O 
network O 
involved O 
in O 
panic O 
disorder O 
and O 
social O 
anxiety O 
disorder O 
. O 
In O 
a O 
double O 
- O 
blind O 
, O 
randomised O 
experiment O 
, O 
36 O 
males O 
received O 
placebo O 
( O 
12 O 
) O 
, O 
50 O 
mg O 
( O 
12 O 
) O 
or O 
100 O 
mg O 
( O 
12 O 
) O 
of O 
sumatriptan B-TRIVIAL 
2 O 
h O 
before O 
the O 
SPST O 
. O 
Subjective O 
, O 
physiological O 
and O 
hormonal O 
measures O 
were O 
taken O 
before O 
, O 
during O 
and O 
after O 
the O 
test O 
. O 
The O 
dose O 
of O 
100 O 
mg O 
of O 
sumatriptan B-TRIVIAL 
increased O 
speech O 
- O 
induced O 
fear O 
more O 
than O 
either O 
a O 
50mg O 
dose O 
of O 
the O 
drug O 
or O 
placebo O 
. O 
The O 
largest O 
dose O 
of O 
sumatriptan B-TRIVIAL 
also O 
enhanced O 
vigilance O 
more O 
than O 
placebo O 
, O 
without O 
any O 
change O 
in O 
blood O 
pressure O 
, O 
heart O 
rate O 
or O 
electrical O 
skin O 
conductance O 
. O 
Sumatriptan B-TRIVIAL 
decreased O 
plasma O 
levels O 
of O 
prolactin O 
. O 
A O 
significant O 
but O 
moderate O 
increase O 
in O 
plasma O 
cortisol B-TRIVIAL 
after O 
SPST O 
occurred O 
, O 
independent O 
of O 
treatment O 
. O 
Because O 
sumatriptan B-TRIVIAL 
decreases O 
5-HT B-SYSTEMATIC 
release O 
into O 
the O 
extracellular O 
space O 
, O 
the O 
potentiation O 
of O 
SPST-induced O 
fear O 
caused O 
by O 
the O 
drug O 
supports O 
the O 
hypothesis O 
that O 
5-HT B-SYSTEMATIC 
attenuates O 
this O 
emotional O 
state O 
. O 
As O 
acute O 
administration O 
of O 
antidepressants O 
has O 
also O 
been O 
shown O 
to O 
enhance O 
speaking O 
fear O 
and O 
increase O 
plasma O 
prolactin O 
, O 
in O 
contrast O 
to O 
sumatriptan B-TRIVIAL 
, O 
the O 
5-HT B-SYSTEMATIC 
regulation O 
of O 
stress O 
- O 
hormone O 
release O 
is O 
likely O 
to O 
be O 
different O 
from O 
that O 
of O 
emotion O 
. O 

selective O 
2,4-diaminopyrimidine-5-carboxamide B-SYSTEMATIC 
inhibitors O 
of O 
Sky O 
kinase O 
. O 

report O 
the O 
SAR O 
around O 
a O 
series O 
of O 
2,4-diaminopyrimidine-5-carboxamide B-SYSTEMATIC 
inhibitors O 
of O 
Sky O 
kinase O 
. O 
2-Aminophenethyl B-SYSTEMATIC 
analogs O 
demonstrate O 
excellent O 
potency O 
but O 
moderate O 
kinase O 
selectivity O 
, O 
while O 
2-aminobenzyl B-SYSTEMATIC 
analogs O 
that O 
fill O 
the O 
Ala571 O 
subpocket O 
exhibit O 
good O 
inhibition O 
activity O 
and O 
excellent O 
kinase O 
selectivity O 
. O 

derivatives O 
as O 
HIV-1 O 
VIF-ElonginC O 
interaction O 
inhibitors O 
. O 

1 O 
( O 
VEC-5 O 
) O 
was O 
identified O 
as O 
a O 
potent O 
small O 
molecular O 
HIV-1 O 
VIF O 
inhibitor O 
that O 
targets O 
the O 
VIF-ElonginC O 
interaction O 
. O 
A O 
structure O 
- O 
activity O 
relationship O 
study O 
was O 
carried O 
out O 
to O 
develop O 
compounds O 
with O 
improved O 
efficacy O 
against O 
HIV-1 O 
and O 
49 O 
indolizine B-SYSTEMATIC 
derivatives O 
of O 
three O 
categories O 
were O 
designed O 
and O 
synthesized O 
. O 
We O 
found O 
that O 
5 O 
compounds O 
exhibited O 
promising O 
anti-HIV-1 O 
activity O 
and O 
the O 
most O 
active O 
compound O 
2g O 
had O 
an O 
IC(50) O 
value O 
of O 
11 O 
μM O 
. O 
These O 
results O 
provide O 
new O 
information O 
to O 
develop O 
highly O 
potent O 
small O 
- O 
molecule O 
HIV-1 O 
VIF O 
inhibitors O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

vitro O 
characterisation O 
of O 
the O 
anti-intravasative O 
properties O 
of O 
the O 
marine O 
product O 
heteronemin B-TRIVIAL 
. O 

destroy O 
the O 
function O 
of O 
infested O 
organs O 
and O 
are O 
the O 
main O 
reason O 
of O 
cancer O 
- O 
related O 
mortality O 
. O 
Heteronemin B-TRIVIAL 
, O 
a O 
natural O 
product O 
derived O 
from O 
a O 
marine O 
sponge O 
, O 
was O 
tested O 
in O 
vitro O 
regarding O 
its O 
properties O 
to O 
prevent O 
tumour O 
cell O 
intravasation O 
through O 
the O 
lymph O 
- O 
endothelial O 
barrier O 
. O 
In O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
cell O 
cultures O 
consisting O 
of O 
MCF-7 O 
breast O 
cancer O 
cell O 
spheroids O 
that O 
were O 
placed O 
on O 
lymph O 
- O 
endothelial O 
cell O 
( O 
LEC O 
) O 
monolayers O 
, O 
tumour O 
cell O 
spheroids O 
induce O 
" O 
circular O 
chemorepellent-induced O 
defects O 
" O 
( O 
CCIDs O 
) O 
in O 
the O 
LEC O 
monolayer O 
; O 
12(S)-Hydroxyeicosatetraenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
12(S)-HETE B-SYSTEMATIC 
) O 
and O 
NF-κB O 
activity O 
are O 
major O 
factors O 
inducing O 
CCIDs O 
, O 
which O 
are O 
entry O 
gates O 
for O 
tumour O 
emboli O 
intravasating O 
the O 
vasculature O 
. O 
This O 
3D O 
co O 
- O 
culture O 
is O 
a O 
validated O 
model O 
for O 
the O 
investigation O 
of O 
intravasation O 
mechanisms O 
and O 
of O 
drugs O 
preventing O 
CCID O 
formation O 
and O 
hence O 
lymph O 
node O 
metastasis O 
. O 
Furthermore O 
, O 
Western O 
blot O 
analyses O 
, O 
NF-κB O 
reporter O 
, O 
EROD O 
, O 
SELE O 
, O 
12(S)-HETE B-SYSTEMATIC 
, O 
and O 
adhesion O 
assays O 
were O 
performed O 
to O 
investigate O 
the O 
properties O 
of O 
heteronemin B-TRIVIAL 
. O 
Five O 
micromolar O 
heteronemin B-TRIVIAL 
inhibited O 
the O 
directional O 
movement O 
of O 
LECs O 
and O 
, O 
therefore O 
, O 
the O 
formation O 
of O 
CCIDs O 
, O 
which O 
were O 
induced O 
by O 
MCF-7 O 
spheroids O 
. O 
Furthermore O 
, O 
heteronemin B-TRIVIAL 
reduced O 
the O 
adhesion O 
of O 
MCF-7 O 
cells O 
to O 
LECs O 
and O 
suppressed O 
12(S)-HETE B-SYSTEMATIC 
-induced O 
expression O 
of O 
the O 
EMT O 
marker O 
paxillin O 
, O 
which O 
is O 
a O 
regulator O 
of O 
directional O 
cell O 
migration O 
. O 
The O 
activity O 
of O 
CYP1A1 O 
, O 
which O 
contributed O 
to O 
CCID O 
formation O 
, O 
was O 
also O 
inhibited O 
by O 
heteronemin B-TRIVIAL 
. O 
Hence O 
, O 
heteronemin B-TRIVIAL 
inhibits O 
important O 
mechanisms O 
contributing O 
to O 
tumour O 
intravasation O 
in O 
vitro O 
and O 
should O 
be O 
tested O 
in O 
vivo O 
. O 

semiconducting O 
polymer O 
dots O 
( O 
Pdots O 
) O 
have O 
attracted O 
great O 
interest O 
because O 
of O 
their O 
superior O 
characteristics O 
as O 
fluorescent O 
probes O 
, O 
such O 
as O 
high O 
fluorescence O 
brightness O 
, O 
fast O 
radiative O 
rates O 
, O 
and O 
excellent O 
photostability O 
. O 
However O 
, O 
currently O 
available O 
Pdots O 
generally O 
exhibit O 
broad O 
emission O 
spectra O 
, O 
which O 
significantly O 
limit O 
their O 
usefulness O 
in O 
many O 
biological O 
applications O 
involving O 
multiplex O 
detections O 
. O 
Here O 
, O 
we O 
describe O 
the O 
design O 
and O 
development O 
of O 
multicolor O 
narrow O 
emissive O 
Pdots O 
based O 
on O 
different O 
boron B-SYSTEMATIC 
dipyrromethene I-SYSTEMATIC 
( O 
BODIPY B-ABBREVIATION 
) O 
units O 
. O 
BODIPY B-ABBREVIATION 
-containing O 
semiconducting O 
polymers O 
emitting O 
at O 
multiple O 
wavelengths O 
were O 
synthesized O 
and O 
used O 
as O 
precursors O 
for O 
preparing O 
the O 
Pdots O 
, O 
where O 
intraparticle O 
energy O 
transfer O 
led O 
to O 
highly O 
bright O 
, O 
narrow O 
emissions O 
. O 
The O 
emission O 
full O 
width O 
at O 
half O 
- O 
maximum O 
of O 
the O 
resulting O 
Pdots O 
varies O 
from O 
40 O 
to O 
55 O 
nm O 
, O 
which O 
is O 
1.5-2 O 
times O 
narrower O 
than O 
those O 
of O 
conventional O 
semiconducting O 
polymer O 
dots O 
. O 
BODIPY B-ABBREVIATION 
520 O 
Pdots O 
were O 
about O 
an O 
order O 
of O 
magnitude O 
brighter O 
than O 
commercial O 
Qdot O 
525 O 
under O 
identical O 
laser O 
excitation O 
conditions O 
. O 
Fluorescence O 
imaging O 
and O 
flow O 
cytometry O 
experiments O 
indicate O 
that O 
the O 
narrow O 
emissions O 
from O 
these O 
bright O 
Pdots O 
are O 
promising O 
for O 
multiplexed O 
biological O 
detections O 
. O 

mediates O 
through O 
estrogen B-FAMILY 
receptors O 
to O 
activate O 
Akt O 
and O 
inhibit O 
apoptosis O 
effect O 
of O 
Leu27IGF-II-induced O 
IGF-II O 
receptor O 
signaling O 
activation O 
in O 
cardiomyoblasts O 
. O 

- O 
menopausal O 
women O 
show O 
dramatically O 
increased O 
cardiovascular O 
disease O 
morbidity O 
( O 
CVD O 
) O 
. O 
Danshen O 
is O 
used O 
widely O 
in O 
China O 
for O 
the O 
treatment O 
of O 
cardiovascular O 
disorders O 
, O 
including O 
coronary O 
heart O 
disease O 
. O 
Danshen O 
possesses O 
lipid O 
- O 
soluble O 
biologically O 
active O 
components O 
with O 
a O 
structure O 
similar O 
to O 
17β-estrodiol B-SYSTEMATIC 
( O 
E2 O 
) O 
. O 
This O 
study O 
assesses O 
whether O 
the O 
cardio O 
- O 
protection O 
exerted O 
by O 
Danshen O 
is O 
mediated O 
through O 
the O 
ERs O 
within O 
H9c2 O 
cardiomyoblast O 
cells O 
. O 
Cardiomyoblast O 
cells O 
pretreated O 
with O 
Fulvestrant B-TRIVIAL 
( O 
ICI B-IDENTIFIER 
182780 I-IDENTIFIER 
) O 
, O 
an O 
estrogen B-FAMILY 
receptor O 
antagonist O 
was O 
applied O 
to O 
investigate O 
the O 
estrogenic O 
activity O 
of O 
Danshen O 
. O 
The O 
Danshen O 
extract O 
preventive O 
effects O 
on O 
Leu27IGF-II-induced O 
IGF-IIR O 
signaling O 
activator O 
and O 
H9c2 O 
cell O 
apoptosis O 
were O 
identified O 
using O 
TUNEL O 
assay O 
, O 
JC-1 O 
staining O 
and O 
Western O 
blot O 
assay O 
. O 
We O 
found O 
that O 
Danshen O 
extract O 
treatments O 
significantly O 
enhanced O 
phosphorylated O 
Akt O 
through O 
estrogen B-FAMILY 
receptor O 
activation O 
to O 
inhibit O 
Leu27IGF-II-induced O 
calcineurin O 
activation O 
and O 
block O 
H9c2 O 
cell O 
apoptosis O 
. O 
Danshen O 
extracts O 
suppressed O 
the O 
IGF-IIR O 
signaling O 
proteins O 
, O 
pro O 
- O 
apoptotic O 
proteins O 
and O 
reversed O 
the O 
mitochondrial O 
membrane O 
instability O 
induced O 
by O 
Leu27IGF-II O 
. O 
However O 
, O 
the O 
cardioprotective O 
properties O 
of O 
Danshen O 
to O 
inhibit O 
Leu27IGF-II-induced O 
cell O 
apoptosis O 
and O 
promote O 
cell O 
survival O 
were O 
attenuated O 
by O 
applying O 
ICI O 
, O 
which O 
suggests O 
that O 
the O 
Danshen O 
cardioprotective O 
effect O 
is O 
mediated O 
through O 
estrogen B-FAMILY 
receptors O 
. O 
All O 
our O 
data O 
indicated O 
that O 
Danshen O 
exerts O 
strong O 
estrogenic O 
activity O 
which O 
can O 
be O 
considered O 
a O 
novel O 
selective O 
estrogen B-FAMILY 
receptor O 
modulator O 
( O 
SERM O 
) O 
against O 
IGF2R O 
signaling O 
that O 
blocks O 
cardiac O 
apoptosis O 
. O 

the O 
structure O 
and O 
proton O 
transfer O 
pathways O 
of O 
the O 
mutant O 
His B-FORMULA 
-107- O 
Tyr B-FORMULA 
of O 
human O 
carbonic O 
anhydrase O 
II O 
. O 

present O 
molecular O 
modeling O 
of O 
the O 
structure O 
and O 
possible O 
proton O 
transfer O 
pathways O 
from O 
the O 
surface O 
of O 
the O 
protein O 
to O 
the O 
zinc B-SYSTEMATIC 
-bound O 
water O 
molecule O 
in O 
the O 
active O 
site O 
of O 
the O 
mutant O 
His B-FORMULA 
-107- O 
Tyr B-FORMULA 
of O 
human O 
carbonic O 
anhydrase O 
II O 
( O 
HCAII O 
) O 
. O 
No O 
high O 
- O 
resolution O 
structure O 
or O 
crystal O 
structure O 
is O 
available O 
till O 
now O 
for O 
this O 
particular O 
mutant O 
due O 
to O 
its O 
lack O 
of O 
stability O 
at O 
physiological O 
temperature O 
. O 
Our O 
analysis O 
utilizes O 
as O 
starting O 
point O 
a O 
series O 
of O 
structures O 
derived O 
from O 
high O 
- O 
resolution O 
crystal O 
structure O 
of O 
the O 
wild O 
type O 
protein O 
. O 
While O 
many O 
of O 
the O 
structures O 
investigated O 
do O 
not O 
reveal O 
a O 
complete O 
path O 
between O 
the O 
zinc B-SYSTEMATIC 
bound O 
water O 
and O 
His B-FORMULA 
-64 O 
, O 
several O 
others O 
do O 
indicate O 
the O 
presence O 
of O 
a O 
transient O 
connection O 
even O 
when O 
His B-FORMULA 
-64 O 
is O 
present O 
in O 
its O 
outward O 
conformation O 
. O 
Mutation O 
at O 
the O 
residue O 
107 O 
also O 
reveals O 
the O 
formation O 
of O 
a O 
new O 
path O 
into O 
the O 
active O 
site O 
. O 
Competing O 
contributions O 
from O 
His B-FORMULA 
-64 O 
sidechain O 
rotation O 
from O 
its O 
outward O 
conformation O 
are O 
also O 
evaluated O 
in O 
terms O 
of O 
optimal O 
path O 
analysis O 
. O 
No O 
indication O 
of O 
a O 
lower O 
catalytic O 
efficiency O 
of O 
the O 
mutant O 
is O 
evident O 
from O 
our O 
results O 
under O 
the O 
condition O 
of O 
thermal O 
stability O 
of O 
the O 
mutant O 
. O 

acetylcholinesterase O 
( O 
AChE O 
) O 
is O 
primarily O 
a O 
hydrolytic O 
enzyme O 
, O 
metabolising O 
the O 
neurotransmitter O 
acetylcholine B-SYSTEMATIC 
in O 
cholinergic O 
synapses O 
, O 
it O 
also O 
has O 
some O 
non-catalytic O 
functions O 
in O 
the O 
brain O 
which O 
are O 
far O 
less O 
well O 
characterised O 
. O 
AChE O 
was O 
shown O 
to O 
be O 
secreted O 
or O 
shed O 
from O 
the O 
neuronal O 
cell O 
surface O 
like O 
several O 
other O 
membrane O 
proteins O 
, O 
such O 
as O 
the O 
amyloid O 
precursor O 
protein O 
( O 
APP O 
) O 
. O 
Since O 
AChE O 
does O 
not O 
possess O 
a O 
transmembrane O 
domain O 
, O 
its O 
anchorage O 
in O 
the O 
membrane O 
is O 
established O 
via O 
the O 
Proline B-TRIVIAL 
Rich O 
Membrane O 
Anchor O 
( O 
PRiMA O 
) O 
, O 
a O 
transmembrane O 
protein O 
. O 
Both O 
the O 
subunit O 
oligomerisation O 
and O 
membrane O 
anchor O 
of O 
AChE O 
are O 
shared O 
by O 
a O 
related O 
enzyme O 
, O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
, O 
the O 
physiological O 
function O 
of O 
which O 
in O 
the O 
brain O 
is O 
unclear O 
. O 
In O 
this O 
work O 
, O 
we O 
have O 
assayed O 
the O 
relative O 
activities O 
of O 
AChE O 
and O 
BChE O 
in O 
membrane O 
fractions O 
and O 
culture O 
medium O 
of O 
three O 
different O 
neuronal O 
cell O 
lines O 
, O 
namely O 
the O 
neuroblastoma O 
cell O 
lines O 
SH-SY5Y O 
and O 
NB7 O 
and O 
the O 
mouse O 
basal O 
forebrain O 
cell O 
line O 
SN56 O 
. O 
In O 
an O 
effort O 
to O 
understand O 
the O 
shedding O 
process O 
of O 
AChE O 
, O 
we O 
have O 
used O 
several O 
pharmacological O 
treatments O 
, O 
which O 
showed O 
that O 
it O 
is O 
likely O 
to O 
be O 
mediated O 
in O 
part O 
by O 
an O 
EDTA B-ABBREVIATION 
- O 
and O 
batimastat B-TRIVIAL 
-sensitive O 
, O 
but O 
GM6001 B-IDENTIFIER 
-insensitive O 
metalloprotease O 
, O 
with O 
the O 
possible O 
additional O 
involvement O 
of O 
a O 
thiol B-FAMILY 
isomerase O 
. O 
Cellular O 
release O 
of O 
AChE O 
by O 
SH-SY5Y O 
is O 
significantly O 
enhanced O 
by O 
the O 
muscarinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
mAChR O 
) O 
agonists O 
carbachol B-TRIVIAL 
or O 
muscarine B-TRIVIAL 
, O 
with O 
the O 
effect O 
of O 
carbachol B-TRIVIAL 
blocked O 
by O 
the O 
mAChR O 
antagonist O 
atropine B-TRIVIAL 
. O 
AChE O 
has O 
been O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
Alzheimer's O 
disease O 
and O 
it O 
has O 
been O 
shown O 
that O 
it O 
accelerates O 
formation O 
and O 
increases O 
toxicity O 
of O 
amyloid O 
fibrils O 
, O 
which O 
have O 
been O 
closely O 
linked O 
to O 
the O 
pathology O 
of O 
AD O 
. O 
In O 
light O 
of O 
this O 
, O 
greater O 
understanding O 
of O 
AChE O 
and O 
BChE O 
physiology O 
may O 
also O 
benefit O 
AD O 
research O 
. O 

safety O 
study O 
on O 
single O 
intravenous O 
dose O 
of O 
tetrachloro B-SYSTEMATIC 
- I-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
glycoluril I-SYSTEMATIC 
[ O 
iodogen B-TRIVIAL 
] O 
dissolved O 
in O 
dimethyl B-SYSTEMATIC 
sulphoxide I-SYSTEMATIC 
( O 
DMSO B-ABBREVIATION 
) O 
. O 

1 O 
. O 
Iodogen B-TRIVIAL 
( O 
tetrachloro B-SYSTEMATIC 
- I-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
glycoluril I-SYSTEMATIC 
) O 
dissolved O 
in O 
DMSO B-ABBREVIATION 
( O 
dimethyl B-SYSTEMATIC 
sulphoxide I-SYSTEMATIC 
) O 
appears O 
indispensable O 
in O 
radioiodination O 
of O 
hypericin B-TRIVIAL 
for O 
a O 
new O 
anticancer O 
strategy O 
. O 
We O 
studied O 
the O 
safety O 
of O 
intravenously O 
administered O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
in O 
mice O 
( O 
n O 
= O 
132 O 
) O 
. O 
2 O 
. O 
Median O 
lethal O 
dose O 
(LD(50)) O 
of O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
was O 
determined O 
with O 
doses O 
of O 
40 O 
, O 
50 O 
, O 
55 O 
, O 
60 O 
, O 
65 O 
and O 
70 O 
mg O 
/ O 
kg O 
. O 
Next O 
, O 
toxicity O 
of O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
at O 
30 O 
mg O 
/ O 
kg O 
was O 
evaluated O 
using O 
saline O 
and O 
DMSO B-ABBREVIATION 
as O 
controls O 
. O 
Changes O 
in O 
behaviour O 
, O 
body O 
weight O 
and O 
serum O 
biochemistry O 
were O 
evaluated O 
. O 
Histopathology O 
of O 
lungs O 
, O 
heart O 
, O 
liver O 
and O 
kidney O 
was O 
performed O 
. O 
3 O 
. O 
LD(50) O 
values O 
of O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
were O 
59.5 O 
mg O 
/ O 
kg O 
( O 
95% O 
confidence O 
limits O 
( O 
CI O 
) O 
: O 
54.1-65.4 O 
mg O 
/ O 
kg O 
) O 
and O 
61 O 
mg O 
/ O 
kg O 
( O 
95%CI O 
: O 
56.2-66.2 O 
mg O 
/ O 
kg O 
) O 
for O 
female O 
and O 
male O 
mice O 
, O 
respectively O 
. O 
Similar O 
to O 
that O 
of O 
control O 
groups O 
, O 
no O 
animal O 
deaths O 
were O 
encountered O 
after O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
administration O 
at O 
30 O 
mg O 
/ O 
kg O 
. O 
Body O 
weights O 
over O 
24 O 
h O 
were O 
not O 
altered O 
in O 
all O 
groups O 
, O 
but O 
significantly O 
higher O 
in O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
and O 
DMSO B-ABBREVIATION 
groups O 
( O 
p O 
< O 
0.05 O 
) O 
14 O 
d O 
post O 
- O 
injection O 
. O 
Blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
and O 
alkaline O 
phosphatase O 
increased O 
( O 
p O 
< O 
0.05 O 
) O 
in O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
group O 
without O 
clinical O 
symptoms O 
. O 
No O 
pathologies O 
were O 
found O 
by O 
gross O 
and O 
microscopic O 
inspection O 
. O 
4 O 
. O 
A O 
single O 
dose O 
of O 
iodogen B-TRIVIAL 
/ O 
DMSO B-ABBREVIATION 
up O 
to O 
30 O 
mg O 
/ O 
kg O 
, O 
over O 
3000 O 
times O 
the O 
dose O 
in O 
potential O 
human O 
applications O 
, O 
appears O 
safe O 
, O 
with O 
an O 
LD(50) O 
doubling O 
that O 
dose O 
in O 
mice O 
. O 

action O 
spirobicycloimidazolidine-2,4-diones B-FAMILY 
: O 
antidiabetic O 
agents O 
and O 
inhibitors O 
of O 
aldose B-FAMILY 
reductase O 
- O 
an O 
enzyme O 
involved O 
in O 
diabetic O 
complications O 
. O 

desired O 
3-(arylsulfonyl)spiroimidazolidine-2,4-diones B-FAMILY 
were O 
synthesized O 
by O 
reacting O 
spiroiminoimidazolidine-2,4-dione B-SYSTEMATIC 
with O 
arylsulfonyl B-FAMILY 
chlorides I-FAMILY 
. O 
Spiroimidazolidine-2,4-dione B-SYSTEMATIC 
was O 
in O 
turn O 
synthesized O 
from O 
norcamphor B-TRIVIAL 
. O 
Structures O 
of O 
the O 
synthesized O 
molecules O 
were O 
established O 
by O 
modern O 
spectroscopic O 
techniques O 
. O 
The O 
synthesized O 
compounds O 
were O 
screened O 
for O 
in O 
vivo O 
antidiabetic O 
activity O 
and O 
aldose B-FAMILY 
reductase O 
inhibition O 
. O 
Compounds O 
2a O 
, O 
2b O 
and O 
2g O 
exhibited O 
excellent O 
dual O 
activity O 
, O 
compound O 
2a O 
being O 
most O 
prominent O 
. O 
These O 
results O 
reveal O 
that O 
the O 
synthesized O 
compounds O 
may O 
serve O 
as O 
the O 
molecule O 
of O 
choice O 
to O 
treat O 
diabetes O 
and O 
diabetic O 
complications O 
using O 
a O 
single O 
medication O 
. O 

of O 
the O 
glutamatergic O 
system O 
have O 
been O 
implicated O 
in O 
the O 
pathophysiology O 
and O 
treatment O 
of O 
major O 
depression O 
. O 
In O 
order O 
to O 
investigate O 
the O 
expression O 
and O 
function O 
of O 
mGlu5 O 
receptors O 
in O 
an O 
animal O 
model O 
for O 
treatment-resistant O 
depression O 
we O 
used O 
rats O 
bred O 
for O 
congenital O 
learned O 
helplessness O 
( O 
cLH O 
) O 
and O 
the O 
control O 
strain O 
, O 
bred O 
for O 
resistance O 
against O 
inescapable O 
stress O 
, O 
congenitally O 
. O 
not O 
learned O 
helpless O 
rats O 
( O 
cNLH O 
) O 
. O 
Western O 
blot O 
analysis O 
showed O 
an O 
increased O 
expression O 
of O 
mGlu5 O 
( O 
but O 
not O 
mGlu1a O 
) O 
receptors O 
in O 
the O 
hippocampus O 
of O 
cLH O 
rats O 
, O 
as O 
compared O 
with O 
control O 
cNLH O 
rats O 
. O 
We O 
also O 
examined O 
mGlu1 O 
/ O 
5 O 
receptor O 
signaling O 
by O 
in O 
vivo O 
measurement O 
of O 
DHPG B-ABBREVIATION 
-stimulated O 
polyphosphoinositides B-FAMILY 
hydrolysis O 
. O 
Stimulation O 
of O 
(3)H-inositolmonophosphate B-SYSTEMATIC 
formation O 
induced O 
by O 
i.c.v O 
. O 
injection O 
of O 
DHPG B-ABBREVIATION 
was O 
enhanced O 
by O 
about O 
50% O 
in O 
the O 
hippocampus O 
of O 
cLH O 
rats O 
. O 
Correspondingly O 
, O 
DHPG B-ABBREVIATION 
-induced O 
long O 
- O 
term O 
depression O 
( O 
LTD O 
) O 
at O 
Schaffer O 
collateral O 
/ O 
CA1 O 
pyramidal O 
cell O 
synapses O 
was O 
amplified O 
in O 
hippocampal O 
slices O 
of O 
cLH O 
rats O 
, O 
whereas O 
LTD O 
induced O 
by O 
low O 
frequency O 
stimulation O 
of O 
the O 
Schaffer O 
collaterals O 
did O 
not O 
change O 
. O 
Moreover O 
, O 
these O 
effects O 
were O 
associated O 
with O 
decreased O 
basal O 
dendritic O 
spine O 
density O 
of O 
CA1 O 
pyramidal O 
cell O 
in O 
cLH O 
rats O 
. O 
These O 
data O 
raise O 
the O 
attractive O 
possibility O 
that O 
changes O 
in O 
the O 
expression O 
and O 
function O 
of O 
mGlu5 O 
receptors O 
in O 
the O 
hippocampus O 
might O 
underlie O 
the O 
changes O 
in O 
synaptic O 
plasticity O 
associated O 
with O 
the O 
depressive O 
- O 
like O 
phenotype O 
of O 
cLH O 
rats O 
. O 
However O 
, O 
chronic O 
treatment O 
of O 
cLH O 
rats O 
with O 
MPEP B-ABBREVIATION 
did O 
not O 
reverse O 
learned O 
helplessness O 
, O 
indicating O 
that O 
the O 
enhanced O 
mGlu5 O 
receptor O 
function O 
is O 
not O 
the O 
only O 
player O 
in O 
the O 
behavioral O 
phenotype O 
of O 
this O 
genetic O 
model O 
of O 
depression O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

thiazoles I-FAMILY 
are O 
a O 
new O 
class O 
of O 
angiogenesis O 
inhibitors O 
. O 

thiazoleamine I-FAMILY 
derivatives O 
that O 
were O 
identified O 
as O 
hits O 
in O 
a O 
screen O 
against O 
human O 
umbilical O 
vein O 
endothelial O 
cell O 
proliferation O 
were O 
subjected O 
to O 
a O 
structure O 
- O 
activity O 
relationship O 
study O 
. O 
Two O 
structurally O 
superimposable O 
scaffolds- O 
4H-thiochromeno[4,3-d]thiazol-2-amine B-SYSTEMATIC 
and O 
5,6-dihydro-4H-benzo[6,7]cyclohepta[1,2-d]thiazol-2-amine B-SYSTEMATIC 
derivatives O 
- O 
yielded O 
low O 
- O 
micromolar O 
inhibitors O 
, O 
and O 
two O 
among O 
them O 
37 O 
and O 
43 O 
also O 
exhibited O 
antiangiogenic O 
activity O 
in O 
an O 
endothelial O 
tube O 
formation O 
assay O 
. O 
Thus O 
, O 
37 O 
and O 
43 O 
can O 
serve O 
as O 
leads O 
to O 
develop O 
a O 
novel O 
class O 
of O 
antiangiogenic O 
agents O 
. O 

evaluated O 
the O 
particle O 
state O 
change O 
in O 
emulsion O 
admixtures O 
using O 
in O 
situ O 
flow O 
particle O 
imaging O 
analysis O 
( O 
FPIA O 
) O 
. O 
Ropion B-TRIVIAL 
® O 
intravenous O 
( O 
flurbiprofen B-TRIVIAL 
axetil I-TRIVIAL 
: O 
Ropion B-TRIVIAL 
® O 
) O 
served O 
as O 
the O 
model O 
emulsion O 
formulation O 
. O 
A O 
binary O 
mixture O 
of O 
Ropion B-TRIVIAL 
® O 
and O 
normal O 
saline O 
( O 
NS O 
) O 
, O 
and O 
a O 
ternary O 
admixture O 
of O 
Ropion B-TRIVIAL 
® O 
, O 
NS O 
, O 
and O 
Gaster B-TRIVIAL 
® O 
injection O 
( O 
famotidine B-TRIVIAL 
: O 
Gaster B-TRIVIAL 
® O 
) O 
or O 
Primperan B-TRIVIAL 
® O 
injection O 
( O 
metoclopramide B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
: O 
Primperan B-TRIVIAL 
® O 
) O 
were O 
prepared O 
and O 
the O 
change O 
in O 
emulsion O 
particle O 
state O 
was O 
analyzed O 
using O 
FPIA O 
under O 
in O 
situ O 
condition O 
. O 
The O 
effect O 
of O 
storage O 
on O 
pH O 
change O 
and O 
the O 
chemical O 
stability O 
of O 
flurbiprofen B-TRIVIAL 
axetil I-TRIVIAL 
were O 
also O 
investigated O 
. O 
In O 
Ropion B-TRIVIAL 
® O 
, O 
various O 
particle O 
images O 
( O 
mean O 
diameter O 
: O 
2.4 O 
µm O 
) O 
were O 
obtained O 
. O 
From O 
our O 
analysis O 
of O 
changes O 
in O 
scattergrams O 
and O 
particle O 
images O 
, O 
changing O 
behaviors O 
of O 
emulsion O 
particles O 
as O 
a O 
function O 
of O 
storage O 
time O 
depended O 
on O 
the O 
systems O 
of O 
admixture O 
samples O 
. O 
In O 
Ropion B-TRIVIAL 
® O 
/ O 
NS O 
and O 
Ropion B-TRIVIAL 
®/ O 
Gaster B-TRIVIAL 
® O 
/ O 
NS O 
systems O 
, O 
mean O 
particle O 
size O 
and O 
particle O 
number O 
increased O 
with O 
lengthening O 
storage O 
time O 
; O 
however O 
, O 
these O 
values O 
were O 
dramatically O 
increased O 
beyond O 
6 O 
h O 
in O 
the O 
Ropion B-TRIVIAL 
®/ O 
Primperan B-TRIVIAL 
® O 
/ O 
NS O 
system O 
, O 
corresponding O 
to O 
a O 
decrease O 
in O 
measured O 
pH O 
. O 
The O 
decomposition O 
of O 
flurbiprofen B-TRIVIAL 
axetil I-TRIVIAL 
due O 
to O 
incompatibility O 
was O 
not O 
observed O 
in O 
all O 
systems O 
. O 
Detailed O 
information O 
on O 
the O 
change O 
in O 
emulsion O 
particle O 
state O 
was O 
obtained O 
using O 
FPIA O 
, O 
indicating O 
that O 
this O 
method O 
is O 
useful O 
to O 
evaluate O 
state O 
changes O 
in O 
emulsion O 
admixtures O 
under O 
in O 
situ O 
condition O 
. O 

RELEVANCE O 
: O 
Caesalpinia O 
sappan O 
L O 
. O 
is O 
distributed O 
in O 
Southeast O 
Asia O 
and O 
also O 
used O 
as O 
herbal O 
medicine O 
for O 
the O 
treatment O 
of O 
various O 
diseases O 
such O 
as O 
burning O 
sensations O 
, O 
leprosy O 
, O 
dysentery O 
, O 
osteoarthritis O 
and O 
rheumatoid O 
arthritis O 
( O 
RA O 
) O 
. O 
The O 
overproduction O 
of O 
IL-6 O 
plays O 
an O 
important O 
role O 
in O 
the O 
prognosis O 
of O 
RA O 
, O 
but O 
the O 
active O 
compounds O 
from O 
the O 
extracts O 
of O 
Caesalpinia O 
sappan O 
L O 
. O 
suppressing O 
IL-6 O 
production O 
remain O 
unknown O 
. O 
AIMS O 
OF O 
THE O 
STUDY O 
: O 
Identifying O 
the O 
main O 
active O 
compounds O 
of O 
Caesalpinia O 
sappan O 
L O 
. O 
extracts O 
inhibiting O 
the O 
IL-6 O 
production O 
in O 
LPS-stimulated O 
RAW O 
264.7 O 
cells O 
by O 
partial O 
least O 
squares O 
( O 
PLS O 
) O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Sixty O 
- O 
four O 
samples O 
with O 
different O 
proportions O 
of O 
compounds O 
were O 
prepared O 
from O 
Caesalpinia O 
sappan O 
L O 
. O 
by O 
supercritical O 
CO2 B-FORMULA 
fluid O 
extraction O 
( O 
SCFE O 
) O 
and O 
refluxing O 
. O 
Each O 
of O 
64 O 
samples O 
was O 
applied O 
to O 
RAW O 
264.7 O 
cells O 
with O 
LPS O 
to O 
evaluate O 
whether O 
IL-6 O 
production O 
by O 
LPS O 
is O 
affected O 
by O 
addition O 
of O 
each O 
sample O 
. O 
The O 
IL-6 O 
production O 
in O 
medium O 
was O 
determined O 
by O 
ELISA O 
and O 
the O 
inhibitory O 
activity O 
of O 
each O 
sample O 
was O 
analyzed O 
. O 
In O 
addition O 
, O 
the O 
fingerprints O 
of O 
these O 
64 O 
samples O 
were O 
also O 
established O 
by O 
ultra O 
- O 
performance O 
liquid O 
chromatography O 
electrospray O 
ionization O 
tandem O 
mass O 
spectrometry O 
( O 
UPLC-MS O 
) O 
. O 
We O 
used O 
the O 
PLS O 
, O 
a O 
simplified O 
method O 
, O 
to O 
evaluate O 
the O 
results O 
from O 
IL-6 O 
production O 
and O 
fingerprints O 
. O 
RESULTS O 
: O 
Each O 
of O 
64 O 
samples O 
markedly O 
suppressed O 
LPS-induced O 
IL-6 O 
production O 
in O 
RAW O 
cells O 
. O 
The O 
fingerprints O 
by O 
UPLC-MS O 
clearly O 
revealed O 
variations O 
among O 
64 O 
samples O 
produced O 
in O 
different O 
extract O 
conditions O 
. O 
The O 
PLS O 
analysis O 
with O 
IL-6 O 
production O 
and O 
fingerprints O 
by O 
UPLC-MS O 
suggested O 
that O 
the O 
peaks O 
71 O 
, O 
93 O 
, O 
150 O 
, O 
157 O 
, O 
168 O 
have O 
more O 
influence O 
on O 
the O 
inhibitory O 
activity O 
of O 
Caesalpinia O 
sappan O 
L O 
. O 
extracts O 
. O 
The O 
peaks O 
71 O 
, O 
93 O 
, O 
150 O 
are O 
likely O 
representing O 
sappanone B-TRIVIAL 
A I-TRIVIAL 
, O 
protosappanin B-TRIVIAL 
E I-TRIVIAL 
and O 
neoprotosappanin B-TRIVIAL 
, O 
respectively O 
. O 
The O 
peaks O 
157 O 
and O 
168 O 
are O 
still O 
at O 
large O 
. O 
CONCLUSION O 
: O 
This O 
is O 
the O 
first O 
report O 
that O 
sappanone B-TRIVIAL 
A I-TRIVIAL 
, O 
protosappanin B-TRIVIAL 
E I-TRIVIAL 
, O 
neoprotosappanin B-TRIVIAL 
and O 
two O 
unidentified O 
compounds O 
can O 
be O 
considered O 
as O 
possible O 
active O 
compounds O 
that O 
might O 
inhibit O 
IL-6 O 
production O 
. O 
Further O 
studies O 
are O 
needed O 
to O 
confirm O 
the O 
effectiveness O 
of O 
these O 
five O 
compounds O 
on O 
IL-6 O 
production O 
and O 
possible O 
mechanism O 
. O 

- O 
suppressive O 
Maspin O 
Functions O 
as O 
a O 
Reactive O 
Oxygen B-SYSTEMATIC 
Species O 
Scavenger O 
: O 
IMPORTANCE O 
OF O 
CYSTEINE B-TRIVIAL 
RESIDUES O 
. O 

is O 
a O 
member O 
of O 
the O 
serine O 
protease O 
inhibitor O 
( O 
serpin O 
) O 
superfamily O 
and O 
displays O 
tumor O 
- O 
suppressing O 
activity O 
by O 
controlling O 
cell O 
migration O 
, O 
proliferation O 
, O 
apoptosis O 
, O 
and O 
adhesion O 
. O 
Here O 
, O 
we O 
provide O 
evidence O 
that O 
maspin O 
acts O 
as O 
a O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
scavenger O 
through O 
oxidation O 
of O 
three O 
structurally O 
exposed O 
cysteine B-FAMILY 
thiols I-FAMILY 
to O 
sulfenic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Ablation O 
of O 
these O 
cysteine B-TRIVIAL 
residues O 
in O 
maspin O 
resulted O 
in O 
a O 
significant O 
increase O 
in O 
total O 
ROS O 
production O 
in O 
mouse O 
mammary O 
TM40D O 
cells O 
. O 
Also O 
, O 
cells O 
containing O 
a O 
triple- O 
cysteine B-TRIVIAL 
mutant O 
of O 
maspin O 
showed O 
elevated O 
ERK1 O 
/ O 
2 O 
activity O 
, O 
a O 
downstream O 
target O 
of O 
ROS O 
, O 
and O 
enhanced O 
proliferation O 
and O 
colony O 
formation O 
. O 
These O 
findings O 
establish O 
a O 
novel O 
mechanism O 
by O 
which O 
maspin O 
utilizes O 
its O 
cysteine B-FAMILY 
thiols I-FAMILY 
to O 
inhibit O 
oxidative O 
stress O 
and O 
cell O 
growth O 
. O 

(I) I-SYSTEMATIC 
-catalyzed O 
borylative O 
exo-cyclization O 
of O 
alkenyl B-FAMILY 
halides I-FAMILY 
containing O 
unactivated O 
double O 
bond O 
. O 

borylative O 
exo-cyclization O 
of O 
alkenyl B-FAMILY 
halides I-FAMILY 
has O 
been O 
reported O 
. O 
The O 
reaction O 
includes O 
the O 
regioselective O 
addition O 
of O 
a O 
borylcopper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
intermediate O 
to O 
unactivated O 
terminal O 
alkenes B-FAMILY 
, O 
followed O 
by O 
the O 
intramolecular O 
substitution O 
of O 
the O 
resulting O 
alkylcopper B-FAMILY 
(I) I-FAMILY 
moiety O 
for O 
the O 
halide B-FAMILY 
leaving O 
groups O 
. O 
Experimental O 
and O 
theoretical O 
investigations O 
of O 
the O 
reaction O 
mechanism O 
have O 
also O 
been O 
described O 
. O 
This O 
reaction O 
provides O 
a O 
new O 
method O 
for O 
the O 
synthesis O 
of O 
alkylboronates B-FAMILY 
containing O 
strained O 
cycloalkyl O 
structures O 
from O 
simple O 
starting O 
materials O 
. O 

of O 
the O 
enhanced O 
oral O 
bioavailability O 
of O 
fenofibrate B-TRIVIAL 
lipid O 
formulations O 
in O 
fasted O 
humans O 
using O 
an O 
in O 
vitro O 
- O 
in O 
silico O 
- O 
in O 
vivo O 
approach O 
. O 

- O 
based O 
formulations O 
have O 
established O 
a O 
significant O 
role O 
in O 
the O 
formulation O 
of O 
poorly O 
soluble O 
drugs O 
for O 
oral O 
administration O 
. O 
In O 
order O 
to O 
better O 
understand O 
their O 
potential O 
advantages O 
over O 
solid O 
oral O 
dosage O 
forms O 
, O 
we O 
studied O 
the O 
solubility O 
and O 
dissolution O 
/ O 
precipitation O 
characteristics O 
of O 
three O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
( O 
SMEDDS O 
) O 
formulations O 
and O 
one O 
suspension O 
of O 
micronized O 
fenofibrate B-TRIVIAL 
in O 
lipid O 
excipients O 
, O 
for O 
which O 
pharmacokinetic O 
studies O 
had O 
already O 
been O 
reported O 
in O 
the O 
open O 
literature O 
. O 
The O 
in O 
vitro O 
dispersion O 
/ O 
dissolution O 
studies O 
were O 
carried O 
out O 
in O 
biorelevant O 
media O 
using O 
USP O 
II O 
apparatus O 
. O 
These O 
were O 
followed O 
up O 
by O 
in O 
silico O 
simulations O 
using O 
STELLA O 
® O 
software O 
, O 
in O 
which O 
not O 
only O 
dispersion O 
/ O 
dissolution O 
, O 
but O 
also O 
the O 
precipitation O 
and O 
re O 
- O 
dissolution O 
of O 
fenofibrate B-TRIVIAL 
was O 
taken O 
into O 
account O 
. O 
While O 
unformulated O 
drug O 
exhibited O 
poor O 
solubility O 
( O 
0.22μg O 
/ O 
mL O 
in O 
FaSSGF O 
and O 
4.31μg O 
/ O 
mL O 
in O 
FaSSIF- O 
V2(PO4) B-FORMULA 
) O 
and O 
dissolved O 
less O 
than O 
2% O 
in O 
dissolution O 
tests O 
, O 
the O 
solubility O 
of O 
fenofibrate B-TRIVIAL 
in O 
the O 
presence O 
of O 
the O 
lipid O 
excipients O 
increased O 
dramatically O 
( O 
e.g O 
. O 
, O 
to O 
65.44μg O 
/ O 
mL O 
in O 
the O 
presence O 
of O 
the O 
Myritol B-TRIVIAL 
318 I-TRIVIAL 
/ O 
TPGS B-ABBREVIATION 
/ O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
SMEDDS O 
) O 
and O 
there O 
was O 
an O 
attendant O 
increase O 
in O 
the O 
dissolution O 
( O 
over O 
80% O 
from O 
capsules O 
containing O 
the O 
Myritol B-TRIVIAL 
318 I-TRIVIAL 
/ O 
TPGS B-ABBREVIATION 
/ O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
SMEDDS O 
and O 
about O 
20% O 
from O 
the O 
dispersion O 
of O 
fenofibrate B-TRIVIAL 
in O 
lipid O 
excipients O 
) O 
. O 
For O 
the O 
four O 
lipid O 
- O 
based O 
fenofibrate B-TRIVIAL 
formulations O 
studied O 
, O 
combining O 
in O 
vitro O 
data O 
in O 
biorelevant O 
media O 
with O 
in O 
silico O 
simulation O 
resulted O 
in O 
accurate O 
prediction O 
of O 
the O 
in O 
vivo O 
human O 
plasma O 
profiles O 
. O 
The O 
point O 
estimates O 
of O 
Cmax O 
and O 
AUC O 
ratio O 
calculated O 
from O 
the O 
in O 
silico O 
and O 
in O 
vivo O 
plasma O 
profiles O 
fell O 
within O 
the O 
0.8-1.25 O 
range O 
for O 
the O 
SMEDDS O 
solution O 
and O 
capsule O 
formulations O 
, O 
suggesting O 
an O 
accurate O 
simulation O 
of O 
the O 
in O 
vivo O 
profiles O 
. O 
This O 
similarity O 
was O 
confirmed O 
by O 
calculation O 
of O 
the O 
respective O 
f2 O 
factors O 
. O 
Sensitivity O 
analysis O 
of O 
the O 
simulation O 
profiles O 
revealed O 
that O 
the O 
SMEDDS O 
formulations O 
had O 
virtually O 
removed O 
any O 
dependency O 
of O 
absorption O 
on O 
the O 
dissolution O 
rate O 
in O 
the O 
small O 
intestine O 
, O 
whereas O 
for O 
the O 
dispersion O 
in O 
lipid O 
excipients O 
, O 
this O 
barrier O 
remained O 
. O 
Such O 
results O 
pave O 
the O 
way O 
to O 
optimizing O 
the O 
performance O 
of O 
oral O 
lipid O 
- O 
based O 
formulations O 
via O 
an O 
in O 
vitro O 
- O 
in O 
silico O 
- O 
in O 
vivo O 
approach O 
. O 

between O 
group B-FAMILY 
IIb I-FAMILY 
divalent I-FAMILY 
transition I-FAMILY 
- I-FAMILY 
metal I-FAMILY 
cations O 
and O 
3-mercaptopropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
: O 
a O 
computational O 
and O 
topological O 
perspective O 
. O 

functional O 
theory O 
was O 
applied O 
to O 
study O 
the O 
interaction O 
of O 
group B-FAMILY 
IIb I-FAMILY 
transition I-FAMILY 
- I-FAMILY 
metal I-FAMILY 
cations O 
( O 
Zn(2+) B-FORMULA 
, O 
Cd(2+) B-FORMULA 
, O 
and O 
Hg(2+) B-FORMULA 
) O 
with O 
one O 
and O 
two O 
fully O 
or O 
partially O 
deprotonated O 
3-mercaptopropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
ligands O 
. O 
In O 
this O 
investigation O 
, O 
we O 
determined O 
the O 
geometries O 
of O 
all O 
possible O 
complexes O 
resulting O 
from O 
the O 
coordination O 
of O 
the O 
metal O 
ions O 
with O 
the O 
ligands O 
at O 
different O 
binding O 
sites O 
selected O 
on O 
each O 
ligand O 
. O 
The O 
relative O 
energies O 
of O 
the O 
complexes O 
, O 
metal O 
- O 
ion O 
affinities O 
, O 
free O 
energies O 
, O 
and O 
entropies O 
were O 
also O 
determined O 
. O 
The O 
natures O 
of O 
the O 
bonds O 
were O 
critically O 
analyzed O 
by O 
natural O 
bond O 
orbital O 
( O 
NBO O 
) O 
analysis O 
and O 
clarified O 
further O 
using O 
the O 
atoms O 
- O 
in O 
- O 
molecules O 
( O 
AIM O 
) O 
approach O 
. O 
The O 
substantial O 
influence O 
of O 
the O 
solvent O 
( O 
water O 
) O 
polarization O 
on O 
the O 
energetics O 
, O 
geometries O 
, O 
and O 
bonding O 
of O 
the O 
molecular O 
complexes O 
was O 
also O 
investigated O 
by O 
the O 
conductor O 
- O 
like O 
screening O 
solvation O 
model O 
( O 
COSMO O 
) O 
. O 
In O 
an O 
attempt O 
to O 
simulate O 
the O 
complexes O 
in O 
an O 
aqueous O 
environment O 
, O 
water O 
molecules O 
were O 
added O 
explicitly O 
to O 
complete O 
the O 
coordination O 
sphere O 
of O 
the O 
metal O 
cations O 
, O 
and O 
the O 
corresponding O 
metal O 
- O 
ion O 
affinities O 
were O 
calculated O 
to O 
study O 
the O 
effect O 
of O 
microhydration O 
. O 

ammonia I-SYSTEMATIC 
lyase O 
( O 
PAL O 
) O 
enzyme O 
activity O 
and O 
antioxidant O 
properties O 
of O 
some O 
cyanobacteria O 
isolates O 
. O 

the O 
present O 
study O 
, O 
six O 
cyanobacteria O 
isolates O 
were O 
evaluated O 
for O 
the O 
PAL O 
enzyme O 
activity O 
, O 
and O 
their O 
methanol B-SYSTEMATIC 
extracts O 
were O 
assessed O 
for O 
the O 
total O 
phenolic B-FAMILY 
amount O 
and O 
other O 
antioxidant O 
parameters O 
. O 
Synechocystis O 
sp O 
. O 
BASO444 O 
and O 
Synechocystis O 
sp O 
. O 
BASO673 O 
isolates O 
with O 
high O 
levels O 
of O 
total O 
phenols B-FAMILY 
( O 
66.0±1.2μg O 
/ O 
mg O 
, O 
78.1±1.8μg O 
/ O 
mg O 
, O 
respectively O 
) O 
also O 
showed O 
high O 
levels O 
of O 
PAL O 
activities O 
( O 
20.5±3.1U O 
/ O 
mg O 
protein O 
, O 
17.2±2.3U O 
/ O 
mg O 
protein O 
, O 
respectively O 
) O 
and O 
strong O 
antioxidant O 
activities O 
. O 
To O 
understand O 
the O 
effect O 
of O 
l-phenylalanine B-TRIVIAL 
( O 
l-phe B-FORMULA 
) O 
on O 
the O 
PAL O 
activity O 
, O 
total O 
phenolic B-FAMILY 
amount O 
, O 
and O 
phenolic B-FAMILY 
constituents O 
, O 
isolates O 
were O 
evaluated O 
with O 
100mg O 
/ O 
l O 
l-phe B-FORMULA 
. O 
While O 
PAL O 
activities O 
exhibited O 
no O 
significant O 
change O 
with O 
l-phe B-FORMULA 
addition O 
, O 
total O 
phenolic B-FAMILY 
amount O 
of O 
the O 
isolates O 
significantly O 
increased O 
. O 
HPLC O 
analysis O 
revealed O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
trans-cinnamic B-TRIVIAL 
acid I-TRIVIAL 
, O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
as O 
the O 
main O 
compounds O 
. O 
Results O 
suggested O 
that O 
the O 
two O 
isolate O 
mights O 
be O 
an O 
important O 
source O 
for O 
the O 
l-phe B-FORMULA 
inducible O 
phenolic B-FAMILY 
compounds O 
. O 

microtubule O 
and O 
actin O 
are O 
required O 
for O 
insulin O 
- O 
induced O 
glucose B-TRIVIAL 
uptake O 
. O 
However O 
, O 
the O 
roles O 
of O 
these O 
two O 
cytoskeletons O 
and O 
their O 
relationship O 
in O 
insulin O 
action O 
still O 
remain O 
unclear O 
. O 
In O 
this O 
work O 
, O 
we O 
examined O 
the O 
morphological O 
change O 
of O 
microtubule O 
/ O 
actin O 
and O 
their O 
involvement O 
in O 
insulin O 
signal O 
transduction O 
using O 
rat O 
skeletal O 
muscle O 
cells O 
. O 
Insulin O 
rapidly O 
led O 
to O 
microtubule O 
clustering O 
from O 
ventral O 
to O 
dorsal O 
surface O 
of O 
the O 
cell O 
. O 
Microtubule O 
filaments O 
were O 
rearranged O 
to O 
create O 
space O 
where O 
new O 
actin O 
structures O 
formed O 
. O 
Disruption O 
of O 
microtubule O 
prevented O 
insulin O 
- O 
induced O 
actin O 
remodeling O 
and O 
distal O 
insulin O 
signal O 
transduction O 
, O 
with O 
reduction O 
in O 
surface O 
glucose B-TRIVIAL 
transporter O 
isoform O 
4 O 
( O 
GLUT4 O 
) O 
and O 
glucose B-TRIVIAL 
uptake O 
. O 
Though O 
microtubule O 
mediated O 
actin O 
remodeling O 
through O 
PKCζ O 
, O 
reorganization O 
of O 
microtubule O 
depended O 
on O 
tyrosine B-TRIVIAL 
phosphorylation O 
of O 
insulin O 
receptor O 
, O 
the O 
mechanism O 
is O 
different O 
from O 
insulin O 
- O 
induced O 
actin O 
remodeling O 
, O 
which O 
relied O 
on O 
the O 
activity O 
of O 
PI3-kinase O 
and O 
PKCζ O 
. O 
We O 
propose O 
that O 
microtubule O 
network O 
is O 
required O 
for O 
insulin O 
- O 
induced O 
signal O 
transduction O 
and O 
actin O 
remodeling O 
in O 
skeletal O 
muscle O 
cells O 
. O 

, O 
Synthesis O 
, O 
Biological O 
Evaluation O 
, O 
and O 
Docking O 
Studies O 
of O 
(S)-Phenylalanine B-TRIVIAL 
Derivatives O 
with O 
a O 
2-Cyanopyrrolidine B-SYSTEMATIC 
Moiety O 
as O 
Potent O 
Dipeptidyl O 
Peptidase O 
4 O 
Inhibitors O 
. O 

novel O 
series O 
of O 
(S)-phenylalanine B-TRIVIAL 
derivatives O 
with O 
a O 
2-cyanopyrrolidine B-SYSTEMATIC 
moiety O 
were O 
designed O 
and O 
synthesized O 
through O 
a O 
rational O 
drug O 
design O 
strategy O 
. O 
Biological O 
evaluation O 
revealed O 
that O 
most O 
tested O 
compounds O 
were O 
potent O 
dipeptidyl O 
peptidase O 
4 O 
( O 
DPP-4 O 
) O 
inhibitors O 
, O 
among O 
them O 
, O 
the O 
cyclopropyl B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
phenylalanine I-FAMILY 
derivative O 
11h O 
displayed O 
the O 
most O 
potent O 
DPP-4 O 
inhibitory O 
activity O 
with O 
an O 
IC50 O 
value O 
of O 
0.247 O 
μM O 
. O 
In O 
addition O 
, O 
molecular O 
docking O 
analysis O 
of O 
the O 
representative O 
compounds O 
11h O 
, O 
11k O 
, O 
and O 
15a O 
were O 
performed O 
, O 
which O 
not O 
only O 
revealed O 
the O 
impact O 
of O 
binding O 
modes O 
on O 
DPP-4 O 
inhibitory O 
activity O 
, O 
but O 
also O 
provided O 
additional O 
methodological O 
values O 
for O 
design O 
and O 
optimization O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

nanoparticles O 
constructed O 
using O 
one O 
- O 
pot O 
encapsulation O 
of O 
a O 
fluorescent O 
polymer O 
and O 
magnetic O 
( O 
Fe3O4 B-FORMULA 
) O 
nanoparticles O 
in O 
a O 
silica B-TRIVIAL 
shell O 
. O 

of O 
biocompatible O 
silica B-TRIVIAL 
with O 
a O 
fluorescent O 
polymer O 
( O 
PDDF O 
) O 
and O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
Fe3 B-FORMULA 
O4 I-FORMULA 
) O 
to O 
form O 
uniform O 
core O 
- O 
shell O 
nanostructures O 
has O 
the O 
great O 
potential O 
to O 
form O 
particles O 
for O 
use O 
in O 
multimodal O 
bioimaging O 
applications O 
. O 
Core O 
- O 
shell O 
nanoparticles O 
( O 
PDDF/ O 
Fe3 B-FORMULA 
O4 I-FORMULA 
@ O 
SiO2 B-FORMULA 
) O 
exhibit O 
fluorescent O 
and O 
magnetic O 
properties O 
that O 
are O 
favorable O 
for O 
their O 
use O 
in O 
magnetic O 
separation O 
and O 
guiding O 
applications O 
, O 
as O 
well O 
as O 
optical O 
and O 
magnetic O 
resonance O 
( O 
MR O 
) O 
imaging O 
capabilities O 
. O 
With O 
the O 
biological O 
analysis O 
in O 
an O 
in O 
vitro O 
intracellular O 
permeation O 
and O 
cytotoxicity O 
test O 
, O 
chemical O 
conjugation O 
of O 
the O 
surface O 
using O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
molecules O 
can O 
provide O 
the O 
nanoparticles O 
with O 
cell O 
- O 
targeting O 
properties O 
, O 
localizing O 
the O 
nanoparticles O 
to O 
folate B-TRIVIAL 
receptors O 
( O 
FRs O 
) O 
on O 
target O 
KB O 
cells O 
that O 
over O 
- O 
express O 
the O 
FRs O 
. O 

CdS B-FORMULA 
- O 
Titanate B-FAMILY 
Composite O 
Nanomaterials O 
for O 
Enhanced O 
Visible-Light-Driven O 
Hydrogen B-SYSTEMATIC 
Evolution O 
. O 

Hierarchical O 
echinus O 
- O 
like O 
titanate B-FAMILY 
spheres O 
( O 
HETSs O 
) O 
, O 
serving O 
as O 
the O 
supporting O 
material O 
for O 
CdS B-FORMULA 
nanoparticles O 
, O 
are O 
synthesized O 
via O 
a O 
fast O 
one O 
- O 
step O 
hydrothermal O 
method O 
. O 
The O 
obtained O 
3D O 
CdS B-FORMULA 
-HETS O 
composite O 
materials O 
show O 
enhanced O 
H2 B-FORMULA 
generation O 
under O 
visible O 
light O 
irradiation O 
. O 

inhibits O 
Aβ(42) O 
aggregation O 
by O 
perturbing O 
the O 
H B-FORMULA 
-bond O 
network O 
in O 
and O 
around O 
the O 
central O 
hydrophobic O 
cluster O 
. O 

of O 
the O 
amyloid-β O 
peptide O 
( O 
Aβ O 
) O 
into O 
fibrillar O 
structures O 
is O 
a O 
hallmark O 
of O 
Alzheimer's O 
disease O 
. O 
Thus O 
, O 
preventing O 
self O 
- O 
assembly O 
of O 
the O 
Aβ O 
peptide O 
is O 
an O 
attractive O 
therapeutic O 
strategy O 
. O 
Here O 
, O 
we O 
used O 
experimental O 
techniques O 
and O 
atomistic O 
simulations O 
to O 
investigate O 
the O 
influence O 
of O 
carnosine B-TRIVIAL 
, O 
a O 
dipeptide B-FAMILY 
naturally O 
occurring O 
in O 
the O 
brain O 
, O 
on O 
Aβ O 
aggregation O 
. O 
Scanning O 
force O 
microscopy O 
, O 
circular O 
dichroism O 
and O 
thioflavin B-TRIVIAL 
T I-TRIVIAL 
fluorescence O 
experiments O 
showed O 
that O 
carnosine B-TRIVIAL 
does O 
not O 
modify O 
the O 
conformational O 
features O 
of O 
Aβ42 O 
but O 
nonetheless O 
inhibits O 
amyloid O 
growth O 
. O 
Molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
indicated O 
that O 
carnosine B-TRIVIAL 
interacts O 
transiently O 
with O 
monomeric O 
Aβ42 O 
by O 
salt O 
bridges O 
with O 
charged O 
side O 
chains O 
, O 
and O 
van O 
der O 
Waals O 
contacts O 
with O 
residues O 
in O 
and O 
around O 
the O 
central O 
hydrophobic O 
cluster O 
((17)LVFFA(21)) O 
. O 
NMR O 
experiments O 
on O 
the O 
nonaggregative O 
fragment O 
Aβ12-28 O 
did O 
not O 
evidence O 
specific O 
intermolecular O 
interactions O 
between O 
the O 
peptide O 
and O 
carnosine B-TRIVIAL 
, O 
in O 
agreement O 
with O 
MD O 
simulations O 
. O 
However O 
, O 
a O 
close O 
inspection O 
of O 
the O 
spectra O 
revealed O 
that O 
carnosine B-TRIVIAL 
interferes O 
with O 
the O 
local O 
propensity O 
of O 
the O 
peptide O 
to O 
form O 
backbone O 
hydrogen B-SYSTEMATIC 
bonds O 
close O 
to O 
the O 
central O 
hydrophobic O 
cluster O 
( O 
residues O 
E22 O 
, O 
S26 O 
and O 
N27 O 
) O 
. O 
Finally O 
, O 
MD O 
simulations O 
of O 
aggregation O 
- O 
prone O 
Aβ O 
heptapeptide B-FAMILY 
segments O 
show O 
that O 
carnosine B-TRIVIAL 
reduces O 
the O 
propensity O 
to O 
form O 
intermolecular O 
backbone O 
hydrogen B-SYSTEMATIC 
bonds O 
in O 
the O 
region O 
18-24 O 
. O 
Taken O 
together O 
, O 
the O 
experimental O 
and O 
simulation O 
results O 
( O 
cumulative O 
MD O 
sampling O 
of O 
0.2 O 
ms O 
) O 
suggest O 
that O 
, O 
despite O 
the O 
inability O 
of O 
carnosine B-TRIVIAL 
to O 
form O 
stable O 
contacts O 
with O 
Aβ O 
, O 
it O 
might O 
block O 
the O 
pathway O 
toward O 
toxic O 
aggregates O 
by O 
perturbing O 
the O 
hydrogen B-SYSTEMATIC 
bond O 
network O 
near O 
residues O 
with O 
key O 
roles O 
in O 
fibrillogenesis O 
. O 

organic O 
dyes O 
for O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

organic O 
dyes O 
with O 
donor O 
( O 
D O 
) O 
, O 
π-bridge O 
( O 
π O 
) O 
and O 
acceptor O 
( O 
A O 
) O 
moieties O 
for O 
dye O 
- O 
sensitized O 
solar O 
cells O 
( O 
DSCs O 
) O 
have O 
received O 
great O 
attention O 
in O 
the O 
last O 
decade O 
because O 
of O 
their O 
high O 
molar O 
absorption O 
coefficient O 
, O 
low O 
cost O 
and O 
structural O 
variety O 
. O 
In O 
the O 
early O 
stages O 
, O 
the O 
efficiency O 
of O 
DSCs O 
with O 
arylamine B-FAMILY 
organic O 
dyes O 
with O 
D-π-A O 
character O 
was O 
far O 
behind O 
that O 
of O 
DSCs O 
with O 
ruthenium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
partly O 
due O 
to O 
the O 
lack O 
of O 
information O 
about O 
the O 
relationship O 
between O 
the O 
chemical O 
structures O 
and O 
the O 
photovoltaic O 
performance O 
. O 
However O 
, O 
exciting O 
progress O 
has O 
been O 
recently O 
made O 
, O 
and O 
power O 
conversion O 
efficiencies O 
over O 
10% O 
were O 
obtained O 
for O 
DSCs O 
with O 
arylamine B-FAMILY 
organic O 
dyes O 
. O 
It O 
is O 
thus O 
that O 
the O 
recent O 
research O 
and O 
development O 
in O 
the O 
field O 
of O 
arylamine B-FAMILY 
organic O 
dyes O 
employing O 
an O 
iodide B-SYSTEMATIC 
/ O 
triiodide B-SYSTEMATIC 
redox O 
couple O 
or O 
polypyridyl B-FAMILY 
cobalt I-FAMILY 
redox O 
shuttles O 
as O 
the O 
electrolytes O 
for O 
either O 
DSCs O 
or O 
solid O 
- O 
state O 
DSCs O 
has O 
been O 
summarized O 
. O 
The O 
cell O 
performance O 
of O 
the O 
arylamine B-FAMILY 
organic O 
dyes O 
are O 
compared O 
, O 
providing O 
a O 
comprehensive O 
overview O 
of O 
arylamine B-FAMILY 
organic O 
dyes O 
, O 
demonstrating O 
the O 
advantages O 
/ O 
disadvantages O 
of O 
each O 
class O 
, O 
and O 
pointing O 
out O 
the O 
field O 
that O 
needs O 
to O 
reinforce O 
the O 
research O 
direction O 
in O 
the O 
further O 
application O 
of O 
DSCs O 
. O 

of O 
Schaeffer's B-TRIVIAL 
acid I-TRIVIAL 
analogues O 
as O 
lead O 
structures O 
of O 
mycobacterium O 
tuberculosis O 
type O 
II O 
dehydroquinase O 
using O 
a O 
rational O 
drug O 
design O 
approach O 
. O 

ligand O 
design O 
: O 
Schaeffer's B-TRIVIAL 
acid I-TRIVIAL 
analogues O 
were O 
identified O 
as O 
novel O 
inhibitors O 
of O 
M. O 
tuberculosis O 
type O 
II O 
dehydroquinase O 
, O 
a O 
key O 
enzyme O 
of O 
the O 
shikimate O 
pathway O 
. O 
Their O 
likely O 
binding O 
mode O 
was O 
predicted O 
using O 
a O 
combination O 
of O 
ensemble O 
docking O 
and O 
flexible O 
active O 
site O 
residues O 
. O 
Potentially O 
, O 
this O 
scaffold O 
could O 
provide O 
a O 
good O 
starting O 
point O 
for O 
the O 
design O 
of O 
antitubercular O 
agents O 
. O 

flavones I-FAMILY 
from O 
the O 
stems O 
and O 
leaves O 
of O 
Passiflora O 
edulis O 
Sims O 
. O 

stems O 
and O 
leaves O 
of O 
Passiflora O 
edulis O 
Sims O 
, O 
are O 
used O 
as O 
a O 
folk O 
medicine O 
for O 
treating O 
both O 
anxiety O 
and O 
nervousness O 
in O 
American O 
countries O 
. O 
Phytochemical O 
investigation O 
of O 
the O 
n-butanol B-SYSTEMATIC 
( O 
n-BuOH B-FORMULA 
) O 
fraction O 
of O 
this O 
plant O 
led O 
to O 
the O 
isolation O 
of O 
four O 
new O 
2,6-dideoxyhexose-C-glycosyl B-FAMILY 
flavones I-FAMILY 
, O 
including O 
luteolin-8-C-β-digitoxopyranosyl-4'-O-β-d-glucopyranoside B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
apigenin-8-C-β-digitoxopyranoside B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
apigenin-8-C-β-boivinopyranoside B-SYSTEMATIC 
( O 
3 O 
) O 
and O 
luteolin-8-C-β-boivinopyranoside B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
together O 
with O 
five O 
known O 
compounds O 
( O 
5-9 O 
) O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
elucidated O 
by O 
extensive O 
spectroscopic O 
methods O 
. O 
All O 
compounds O 
were O 
evaluated O 
for O 
their O 
neurite O 
outgrowth O 
enhancing O 
activities O 
and O 
the O 
results O 
indicated O 
that O 
luteolin B-TRIVIAL 
( O 
7 O 
) O 
enhanced O 
NGF-induced O 
neurite O 
outgrowth O 
in O 
PC12 O 
cells O 
at O 
50.0μM O 
. O 

functional O 
response O 
to O 
the O 
novel O 
peptide O 
cannabinoid O 
, O 
hemopressin B-TRIVIAL 
. O 

is O 
the O 
first O 
peptide O 
ligand O 
to O 
be O 
described O 
for O 
the O 
CB1 O 
cannabinoid O 
receptor O 
. O 
Hemopressin B-TRIVIAL 
acts O 
as O 
an O 
inverse O 
agonist O 
in O 
vivo O 
and O 
can O 
cross O 
the O 
blood O 
- O 
brain O 
barrier O 
to O 
both O 
inhibit O 
appetite O 
and O 
induce O 
antinociception O 
. O 
Despite O 
being O 
highly O 
effective O 
, O 
synthetic O 
CB1 O 
inverse O 
agonists O 
are O 
limited O 
therapeutically O 
due O 
to O 
unwanted O 
, O 
over O 
dampening O 
of O 
central O 
reward O 
pathways O 
. O 
However O 
, O 
hemopressin B-TRIVIAL 
appears O 
to O 
have O 
its O 
effect O 
on O 
appetite O 
by O 
affecting O 
satiety O 
rather O 
than O 
reward O 
, O 
suggesting O 
an O 
alternative O 
mode O 
of O 
action O 
which O 
might O 
avoid O 
adverse O 
side O 
effects O 
. O 
Here O 
, O 
to O 
resolve O 
the O 
neuronal O 
circuitry O 
mediating O 
hemopressin B-TRIVIAL 
' O 
s O 
actions O 
, O 
we O 
have O 
combined O 
blood- O 
oxygen B-SYSTEMATIC 
-level O 
- O 
dependent O 
, O 
pharmacological O 
- O 
challenge O 
magnetic O 
resonance O 
imaging O 
with O 
c-Fos O 
functional O 
activity O 
mapping O 
to O 
compare O 
brain O 
regions O 
responsive O 
to O 
systemic O 
administration O 
of O 
hemopressin B-TRIVIAL 
and O 
the O 
synthetic O 
CB1 O 
inverse O 
agonist O 
, O 
AM251 B-IDENTIFIER 
. O 
Using O 
these O 
complementary O 
methods O 
, O 
we O 
demonstrate O 
that O 
hemopressin B-TRIVIAL 
activates O 
distinct O 
neuronal O 
substrates O 
within O 
the O 
brain O 
, O 
focused O 
mainly O 
on O 
the O 
feeding O 
- O 
related O 
circuits O 
of O 
the O 
mediobasal O 
hypothalamus O 
and O 
in O 
nociceptive O 
regions O 
of O 
the O 
periaqueductal O 
grey O 
( O 
PAG O 
) O 
and O 
dorsal O 
raphe O 
( O 
DR O 
) O 
. O 
In O 
contrast O 
to O 
AM251 B-IDENTIFIER 
, O 
there O 
is O 
a O 
distinct O 
lack O 
of O 
activation O 
of O 
the O 
brain O 
reward O 
centres O 
, O 
such O 
as O 
the O 
ventral O 
tegmental O 
area O 
, O 
nucleus O 
accumbens O 
and O 
orbitofrontal O 
cortex O 
, O 
which O 
normally O 
form O 
a O 
functional O 
activity O 
signature O 
for O 
the O 
central O 
action O 
of O 
synthetic O 
CB1 O 
receptor O 
inverse O 
agonists O 
. O 
Thus O 
, O 
hemopressin B-TRIVIAL 
modulates O 
the O 
function O 
of O 
key O 
feeding O 
- O 
related O 
brain O 
nuclei O 
of O 
the O 
mediobasal O 
hypothalamus O 
, O 
and O 
descending O 
pain O 
pathways O 
of O 
the O 
PAG O 
and O 
DR O 
, O 
and O 
not O 
higher O 
limbic O 
structures O 
. O 
Thus O 
, O 
hemopressin B-TRIVIAL 
may O 
offer O 
behaviourally O 
selective O 
effects O 
on O 
nociception O 
and O 
appetite O 
, O 
without O 
engaging O 
reward O 
pathways O 
. O 

atrum O 
has O 
attracted O 
great O 
attention O 
for O 
its O 
antitumor O 
activity O 
. O 
However O 
, O 
the O 
mechanism O 
remains O 
unclear O 
. O 
A O 
G O 
. O 
atrum O 
polysaccharide O 
( O 
PSG-1 O 
) O 
showed O 
pronounced O 
antitumor O 
activity O 
in O 
this O 
study O 
. O 
PSG-1 O 
did O 
not O 
kill O 
CT26 O 
cells O 
directly O 
, O 
but O 
inhibited O 
the O 
proliferation O 
of O 
CT26 O 
cells O 
via O 
the O 
activation O 
of O 
peritoneal O 
macrophages O 
( O 
MΦ O 
) O 
. O 
In O 
vivo O 
, O 
PSG-1 O 
significantly O 
suppressed O 
the O 
tumor O 
growth O 
in O 
CT26 O 
tumor O 
- O 
bearing O 
mice O 
. O 
The O 
treatment O 
caused O 
a O 
significant O 
increase O 
in O 
the O 
immune O 
organ O 
index O 
and O 
the O 
phagocytosis O 
of O 
macrophages O 
. O 
The O 
production O 
of O 
TNF-α O 
, O 
IL-1β O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
also O 
increased O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
PSG-1 O 
acted O 
on O 
Toll O 
- O 
like O 
receptor O 
( O 
TLR O 
) O 
4 O 
, O 
signaled O 
through O 
p38 O 
MAPK O 
pathway O 
, O 
then O 
activated O 
NF-κB O 
and O 
stimulated O 
TNF-α O 
production O 
. O 
We O 
further O 
found O 
that O 
PSG-1 O 
increased O 
the O 
expression O 
of O 
TLR4 O 
and O 
NF-κB O 
, O 
the O 
degradation O 
of O 
IκBα O 
and O 
the O 
phosphorylation O 
of O 
p38 O 
MAPK O 
. O 
In O 
summary O 
, O 
we O 
have O 
demonstrated O 
that O 
PSG-1 O 
could O 
activate O 
macrophages O 
via O 
TLR4-dependent O 
signaling O 
pathways O 
, O 
improve O 
immunity O 
and O 
inhibit O 
tumor O 
growth O 
. O 

and O 
-independent O 
interaction O 
of O 
glucocorticoids O 
with O 
the O 
regulatory O 
pathways O 
involved O 
in O 
the O 
control O 
of O 
bile B-FAMILY 
acid I-FAMILY 
handling O 
by O 
the O 
liver O 
. O 

with O 
glucocorticoids O 
( O 
GCs O 
) O 
may O 
cause O 
adverse O 
effects O 
, O 
including O 
cholestasis O 
. O 
The O 
ability O 
of O 
dexamethasone B-TRIVIAL 
, O 
prednisolone B-TRIVIAL 
and O 
budesonide B-TRIVIAL 
to O 
affect O 
the O 
liver O 
handling O 
of O 
bile B-FAMILY 
acids I-FAMILY 
( O 
BAs O 
) O 
has O 
been O 
investigated O 
. O 
In O 
rats O 
treated O 
with O 
GCs O 
for O 
4 O 
days O 
, O 
altered O 
serum O 
and O 
bile O 
BA O 
levels O 
, O 
changed O 
conjugation O 
pattern O 
, O 
and O 
delayed O 
and O 
decreased O 
ability O 
to O 
conjugate O 
/ O 
secrete O 
exogenously O 
administered O 
deoxycholate B-SYSTEMATIC 
, O 
were O 
found O 
using O 
HPLC-MS O 
/ O 
MS O 
. O 
RT-QPCR O 
analyses O 
revealed O 
that O 
GC O 
treatment O 
also O 
induced O 
a O 
down O 
- O 
regulation O 
of O 
liver O 
nuclear O 
receptors O 
( O 
Fxr O 
, O 
Gr O 
and O 
Shp O 
) O 
, O 
transporters O 
( O 
Ntcp O 
, O 
Mrp4 O 
and O 
Bcrp O 
) O 
and O 
enzymes O 
( O 
Cyp7a1 O 
and O 
Baat O 
) O 
, O 
whereas O 
Bsep O 
, O 
Mrp2 O 
and O 
Cyp27a1 O 
were O 
up O 
- O 
regulated O 
. O 
Human O 
HepG2 O 
and O 
Alexander O 
cell O 
lines O 
were O 
used O 
as O 
in O 
vitro O 
models O 
of O 
liver O 
cells O 
with O 
and O 
without O 
constitutive O 
FXR O 
expression O 
, O 
respectively O 
. O 
In O 
HepG2 O 
cells O 
, O 
GCs O 
induced O 
a O 
decreased O 
expression O 
of O 
FXR O 
and O 
SHP O 
, O 
and O 
inhibited O 
the O 
regulatory O 
effect O 
of O 
GW4064 B-IDENTIFIER 
on O 
FXR-target O 
genes O 
. O 
In O 
Alexander O 
cells O 
, O 
only O 
when O 
they O 
were O 
transfected O 
with O 
FXR O 
+ O 
RXR O 
, O 
GW4064 B-IDENTIFIER 
caused O 
up O 
- O 
regulation O 
of O 
SHP O 
and O 
OSTβ O 
, O 
and O 
a O 
down O 
- O 
regulation O 
of O 
CYP27A1 O 
. O 
GCs O 
had O 
the O 
opposite O 
effect O 
on O 
these O 
genes O 
, O 
both O 
in O 
the O 
absence O 
and O 
in O 
the O 
presence O 
of O 
FXR O 
expression O 
. O 
Co-transfection O 
of O 
Alexander O 
cells O 
with O 
IR-1-Luc O 
and O 
FXR O 
+ O 
RXR O 
revealed O 
that O 
GCs O 
did O 
not O 
inhibit O 
but O 
moderately O 
enhanced O 
FXR O 
activity O 
. O 
Moreover O 
, O 
GCs O 
have O 
a O 
synergistic O 
effect O 
on O 
GW4064 B-IDENTIFIER 
-induced O 
FXR O 
activation O 
, O 
whereas O 
chenodeoxycholate B-TRIVIAL 
and O 
GW4064 B-IDENTIFIER 
have O 
an O 
additive O 
effect O 
. O 
In O 
conclusion O 
, O 
GCs O 
are O 
able O 
to O 
directly O 
or O 
indirectly O 
activate O 
FXR O 
but O 
they O 
also O 
antagonize O 
, O 
through O 
FXR O 
- O 
independent O 
mechanisms O 
, O 
the O 
expression O 
of O 
FXR O 
and O 
FXR O 
target O 
genes O 
involved O 
in O 
the O 
hepatic O 
handling O 
of O 
BAs O 
. O 

disease O 
( O 
CVD O 
) O 
, O 
the O 
leading O 
cause O 
of O 
death O 
in O 
developed O 
countries O 
and O 
dyslipidemia O 
, O 
is O 
a O 
major O 
risk O 
factor O 
for O 
CVD O 
. O 
We O 
previously O 
identified O 
a O 
cluster O 
of O 
quantitative O 
trait O 
loci O 
( O 
QTL O 
) O 
on O 
baboon O 
chromosome O 
11 O 
for O 
multiple O 
related O 
quantitative O 
traits O 
for O 
serum O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
. O 
Here O 
we O 
report O 
differentially O 
regulated O 
hepatic O 
genes O 
that O 
appear O 
to O 
encode O 
an O 
LDL-C O 
QTL O 
that O 
influences O 
LDL-C O 
levels O 
in O 
baboons O 
. O 
We O 
performed O 
hepatic O 
whole O 
genome O 
expression O 
profiling O 
for O 
LDL-C O 
discordant O 
baboons O 
fed O 
a O 
high- O 
cholesterol B-TRIVIAL 
, O 
high O 
- O 
fat O 
( O 
HCHF O 
) O 
diet O 
for O 
7 O 
weeks O 
. O 
We O 
detected O 
expression O 
of O 
117 O 
genes O 
within O 
the O 
QTL O 
2-LOD-support O 
interval O 
. O 
Three O 
genes O 
were O 
differentially O 
expressed O 
in O 
low O 
LDL-C O 
responders O 
and O 
8 O 
in O 
high O 
LDL-C O 
responders O 
in O 
response O 
to O 
a O 
HCHF O 
diet O 
. O 
Seven O 
genes O 
( O 
ACVR1B O 
, O 
CALCOCO1 O 
, O 
DGKA O 
, O 
ERBB3 O 
, O 
KRT73 O 
, O 
MYL6B O 
, O 
TENC1 O 
) O 
showed O 
discordant O 
expression O 
between O 
low O 
and O 
high O 
LDL-C O 
responders O 
. O 
To O 
prioritize O 
candidate O 
genes O 
, O 
we O 
integrated O 
miRNA O 
and O 
mRNA O 
expression O 
profiles O 
using O 
network O 
tools O 
and O 
found O 
that O 
four O 
candidates O 
( O 
ACVR1B O 
, O 
DGKA O 
, O 
ERBB3 O 
, O 
TENC1 O 
) O 
were O 
miRNA O 
targets O 
and O 
the O 
miRNAs O 
were O 
inversely O 
expressed O 
to O 
the O 
target O 
genes O 
. O 
Candidate O 
gene O 
expression O 
was O 
validated O 
using O 
QRT-PCR O 
and O 
Westerns O 
. O 
This O 
study O 
reveals O 
candidate O 
genes O 
that O 
influence O 
variation O 
in O 
LDL-C O 
in O 
baboons O 
and O 
potential O 
genetic O 
mechanisms O 
for O 
further O 
investigation O 
. O 

mediators O 
are O 
thought O 
to O 
be O 
involved O 
in O 
the O 
systemic O 
and O 
local O 
immune O 
response O 
induced O 
by O 
the O 
Tityus O 
serrulatus O 
scorpion O 
envenomation O 
. O 
New O 
functional O 
aspects O 
of O 
lipid O 
mediators O 
have O 
recently O 
been O 
described O 
. O 
Here O 
, O 
we O 
examine O 
the O 
unreported O 
role O 
of O 
lipid O 
mediators O 
in O 
cell O 
recruitment O 
to O 
the O 
peritoneal O 
cavity O 
after O 
an O 
injection O 
with O 
Ts2 O 
or O 
Ts6 O 
toxins O 
isolated O 
from O 
the O 
T O 
. O 
serrulatus O 
scorpion O 
venom O 
. O 
In O 
this O 
report O 
, O 
we O 
demonstrate O 
that O 
following O 
a O 
single O 
intraperitoneal O 
( O 
i.p O 
. O 
) O 
injection O 
of O 
Ts2 O 
or O 
Ts6 O 
( O 
250 O 
μg O 
/ O 
kg O 
) O 
in O 
mice O 
, O 
there O 
was O 
an O 
induction O 
of O 
leukocytosis O 
with O 
a O 
predominance O 
of O 
neutrophils O 
observed O 
at O 
4 O 
, O 
24 O 
, O 
48 O 
and O 
96 O 
h O 
. O 
Moreover O 
, O 
total O 
protein O 
, O 
leukotriene B-TRIVIAL 
(LT)B(4) I-TRIVIAL 
, O 
prostaglandin B-TRIVIAL 
(PG)E(2) I-TRIVIAL 
and O 
pro O 
- O 
inflammatory O 
cytokine O 
levels O 
were O 
increased O 
. O 
We O 
also O 
observed O 
an O 
increase O 
of O 
regulatory O 
cytokines O 
, O 
including O 
interleukin O 
(IL)-10 O 
, O 
after O 
the O 
Ts2 O 
injection O 
. O 
Finally O 
, O 
we O 
observed O 
that O 
Ts2 O 
or O 
Ts6 O 
injection O 
in O 
5-lipoxygenase O 
( O 
LO O 
) O 
deficient O 
mice O 
and O 
in O 
wild O 
type O 
( O 
WT O 
) O 
129sv O 
mice O 
pre O 
- O 
treated O 
with O 
LTs O 
and O 
PGs O 
inhibitors O 
( O 
MK-886 B-IDENTIFIER 
and O 
celecoxib B-TRIVIAL 
, O 
respectively O 
) O 
a O 
reduction O 
the O 
influx O 
of O 
leukocytes O 
occurs O 
in O 
comparison O 
to O 
WT O 
. O 
The O 
recruitment O 
of O 
these O 
cells O 
demonstrated O 
a O 
phenotype O 
characteristic O 
of O 
neutrophils O 
, O 
macrophages O 
, O 
CD4 O 
and O 
CD8 O 
lymphocytes O 
expressing O 
GR1+ O 
, O 
F4 O 
/ O 
80+ O 
, O 
CD3+ O 
/ O 
CD4+ O 
and O 
CD3+ O 
/ O 
CD8+ O 
, O 
respectively O 
. O 
In O 
conclusion O 
, O 
our O 
data O 
demonstrate O 
that O 
Ts2 O 
and O 
Ts6 O 
induce O 
inflammation O 
by O 
mechanisms O 
dependent O 
on O 
lipid O 
mediators O 
and O 
cytokine O 
production O 
. O 
Ts2 O 
may O 
play O 
a O 
regulatory O 
role O 
whereas O 
Ts6 O 
exhibits O 
pro O 
- O 
inflammatory O 
activity O 
exclusively O 
. O 

of O 
sodium B-SYSTEMATIC 
and O 
calcium B-SYSTEMATIC 
in O 
Daphnia O 
magna O 
exposed O 
to O 
silver B-SYSTEMATIC 
nanoparticles O 
. O 

toxicity O 
of O 
manufactured O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
has O 
been O 
widely O 
studied O 
, O 
but O 
the O 
influence O 
of O 
AgNPs O 
on O 
the O 
major O 
ions O 
( O 
such O 
as O 
sodium B-SYSTEMATIC 
[ O 
Na B-FORMULA 
] O 
and O 
calcium B-SYSTEMATIC 
[ O 
Ca B-FORMULA 
] O 
) O 
regulations O 
are O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
a O 
freshwater O 
cladoceran O 
Daphnia O 
magna O 
was O 
exposed O 
to O 
commercial O 
AgNPs O 
coated O 
with O 
polyvinylpyrrolidone B-SYSTEMATIC 
. O 
After O 
48 O 
h O 
, O 
the O 
Na B-FORMULA 
body O 
content O 
was O 
significantly O 
reduced O 
by O 
AgNO3 B-FORMULA 
exposure O 
, O 
but O 
the O 
Ca B-FORMULA 
body O 
content O 
was O 
significantly O 
increased O 
under O 
AgNO3 B-FORMULA 
and O 
AgNP O 
exposures O 
, O 
respectively O 
. O 
No O 
effect O 
was O 
observed O 
on O 
the O 
body O 
concentrations O 
of O 
Na B-FORMULA 
and O 
Ca B-FORMULA 
at O 
50 O 
to O 
500 O 
µg O 
/ O 
L O 
AgNPs O 
with O 
1-µM O 
cysteine B-TRIVIAL 
addition O 
. O 
Exposure O 
of O 
AgNO3 B-FORMULA 
and O 
AgNPs O 
inhibited O 
the O 
Na B-FORMULA 
influx O 
and O 
elevated O 
the O 
Na B-FORMULA 
efflux O 
. O 
In O 
contrast O 
, O 
their O 
exposure O 
increased O 
the O 
Ca B-FORMULA 
influx O 
, O 
but O 
did O 
not O 
affect O 
the O 
Ca B-FORMULA 
efflux O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
demonstrated O 
the O 
significant O 
influences O 
of O 
AgNO3 B-FORMULA 
and O 
AgNPs O 
( O 
without O 
cysteine B-TRIVIAL 
) O 
on O 
Na B-FORMULA 
and O 
Ca B-FORMULA 
regulations O 
. O 
Such O 
effect O 
of O 
AgNPs O 
on O 
Na B-FORMULA 
and O 
Ca B-FORMULA 
regulation O 
disappeared O 
after O 
cysteine B-TRIVIAL 
addition O 
, O 
indicating O 
that O 
the O 
soluble O 
Ag B-FORMULA 
released O 
from O 
AgNPs O 
played O 
a O 
major O 
role O 
in O 
the O 
ionoregulatory O 
dysfunction O 
. O 

by O 
OATP1B1 O 
and O 
OATP1B3 O 
enhances O 
the O 
cytotoxicity O 
of O 
epigallocatechin B-SYSTEMATIC 
3-O-gallate I-SYSTEMATIC 
and O 
several O 
quercetin B-TRIVIAL 
derivatives O 
. O 

anion O 
transporting O 
polypeptides O 
( O 
OATPs O 
) O 
1B1 O 
and O 
1B3 O 
are O 
transporters O 
that O 
are O 
expressed O 
selectively O 
in O 
human O 
hepatocytes O 
under O 
normal O 
conditions O 
. O 
OATP1B3 O 
is O 
also O 
expressed O 
in O 
certain O 
cancers O 
. O 
Flavonoids B-FAMILY 
such O 
as O 
green O 
tea O 
catechins B-FAMILY 
and O 
quercetin B-FAMILY 
glycosides I-FAMILY 
have O 
been O 
shown O 
to O 
modulate O 
the O 
function O 
of O 
some O 
OATPs O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
extent O 
to O 
which O 
six O 
substituted O 
quercetin B-TRIVIAL 
derivatives O 
( O 
1-6 O 
) O 
affected O 
the O 
function O 
of O 
OATP1B1 O 
and O 
OATP1B3 O 
was O 
investigated O 
. O 
Uptake O 
of O 
the O 
radiolabeled O 
model O 
substrates O 
estradiol B-SYSTEMATIC 
17β-glucuronide I-SYSTEMATIC 
, O 
estrone B-SYSTEMATIC 
3-sulfate I-SYSTEMATIC 
, O 
and O 
dehydroepiandrosterone B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
DHEAS B-ABBREVIATION 
) O 
was O 
determined O 
in O 
the O 
absence O 
and O 
presence O 
of O 
compounds O 
1-6 O 
using O 
Chinese O 
hamster O 
ovary O 
( O 
CHO O 
) O 
cells O 
stably O 
expressing O 
either O 
OATP1B1 O 
or O 
OATP1B3 O 
. O 
Several O 
of O 
compounds O 
1-6 O 
inhibited O 
OATP O 
- O 
mediated O 
uptake O 
of O 
all O 
three O 
model O 
substrates O 
, O 
suggesting O 
that O 
they O 
could O 
also O 
be O 
potential O 
substrates O 
. O 
Compound O 
6 O 
stimulated O 
OATP1B3 O 
- O 
mediated O 
estradiol B-SYSTEMATIC 
17β-glucuronide I-SYSTEMATIC 
uptake O 
by O 
increasing O 
the O 
apparent O 
affinity O 
of O 
OATP1B3 O 
for O 
its O 
substrate O 
. O 
Cytotoxicity O 
assays O 
demonstrated O 
that O 
epigallocatechin B-SYSTEMATIC 
3-O-gallate I-SYSTEMATIC 
( O 
EGCG B-ABBREVIATION 
) O 
and O 
most O 
of O 
compounds O 
1-6 O 
killed O 
preferentially O 
OATP-expressing O 
CHO O 
cells O 
. O 
EGCG B-ABBREVIATION 
, O 
1 O 
, O 
and O 
3 O 
were O 
the O 
most O 
potent O 
cytotoxic O 
compounds O 
, O 
with O 
EGCG B-ABBREVIATION 
and O 
3 O 
selectively O 
killing O 
OATP1B3-expressing O 
cells O 
. O 
Given O 
that O 
OATP1B3 O 
is O 
expressed O 
in O 
several O 
cancers O 
, O 
EGCG B-ABBREVIATION 
and O 
some O 
of O 
the O 
quercetin B-TRIVIAL 
derivatives O 
studied O 
might O 
be O 
promising O 
lead O 
compounds O 
for O 
the O 
development O 
of O 
novel O 
anticancer O 
drugs O 
. O 

-induced O 
autophagy O 
mitigates O 
cell O 
apoptosis O 
through O 
modulation O 
of O 
PI3K O 
/ O 
Akt O 
and O 
ERK O 
and O 
JNK O 
signaling O 
pathways O 
in O 
human O 
lung O 
cancer O 
cell O 
lines O 
. O 

previous O 
study O 
has O 
revealed O 
that O 
dioscin B-TRIVIAL 
, O 
a O 
compound O 
with O 
anti-inflammatory O 
, O 
lipid O 
- O 
lowering O 
, O 
anticancer O 
and O 
hepatoprotective O 
effects O 
, O 
may O 
induce O 
autophagy O 
in O 
hepatoma O 
cells O 
. O 
Autophagy O 
is O 
a O 
lysosomal O 
degradation O 
pathway O 
that O 
is O 
essential O 
for O 
cell O 
survival O 
and O 
tissue O 
homeostasis O 
. O 
In O 
this O 
study O 
, O 
the O 
role O 
of O 
autophagy O 
and O 
related O 
signaling O 
pathways O 
during O 
dioscin B-TRIVIAL 
-induced O 
apoptosis O 
in O 
human O 
lung O 
cancer O 
cells O 
was O 
investigated O 
. O 
Results O 
from O 
4'-6-diamidino-2-phenylindole B-SYSTEMATIC 
and O 
annexin-V O 
/ O 
PI O 
double O 
- O 
staining O 
assay O 
showed O 
that O 
caspase-3- O 
and O 
caspase-8-dependent O 
, O 
and O 
dose O 
- O 
dependent O 
apoptoses O 
were O 
detected O 
after O 
a O 
24-h O 
dioscin B-TRIVIAL 
treatment O 
. O 
Meanwhile O 
, O 
autophagy O 
was O 
detected O 
as O 
early O 
as O 
12 O 
h O 
after O 
an O 
exposure O 
to O 
low O 
- O 
dose O 
dioscin B-TRIVIAL 
, O 
as O 
indicated O 
by O 
an O 
up O 
- O 
regulated O 
expression O 
of O 
LC3-II O 
and O 
beclin-1 O 
proteins O 
. O 
Blockade O 
of O 
autophagy O 
with O 
bafilomycin B-TRIVIAL 
A1 I-TRIVIAL 
or O 
3-methyladenine B-SYSTEMATIC 
sensitized O 
the O 
A549 O 
and O 
H1299 O 
cells O 
to O 
apoptosis O 
. O 
Treatment O 
of O 
A549 O 
and O 
H1299 O 
cells O 
with O 
dioscin B-TRIVIAL 
caused O 
a O 
dose O 
- O 
dependent O 
increase O 
in O 
ERK1 O 
/ O 
2 O 
and O 
JNK1 O 
/ O 
2 O 
activity O 
, O 
accompanied O 
with O 
a O 
decreased O 
PI3K O 
expression O 
and O 
decreased O 
phosphorylation O 
of O 
Akt O 
and O 
mTOR O 
. O 
Taken O 
together O 
, O 
this O 
study O 
demonstrated O 
for O 
the O 
first O 
time O 
that O 
autophagy O 
occurred O 
earlier O 
than O 
apoptosis O 
during O 
dioscin B-TRIVIAL 
-induced O 
human O 
lung O 
cancer O 
cell O 
line O 
apoptosis O 
. O 
Dioscin B-TRIVIAL 
-induced O 
autophagy O 
via O 
ERK1 O 
/ O 
2 O 
and O 
JNK1 O 
/ O 
2 O 
pathways O 
may O 
provide O 
a O 
protective O 
mechanism O 
for O 
cell O 
survival O 
against O 
dioscin B-TRIVIAL 
-induced O 
apoptosis O 
to O 
act O 
as O 
a O 
cytoprotective O 
reaction O 
. O 

of O 
selenium B-SYSTEMATIC 
alone O 
or O 
in O 
combination O 
with O 
glucoraphanin B-TRIVIAL 
differentially O 
affects O 
intestinal O 
and O 
hepatic O 
antioxidant O 
and O 
phase O 
II O 
enzymes O 
in O 
growing O 
rats O 
. O 

anti-carcinogenic O 
effects O 
of O 
sulforaphane B-TRIVIAL 
( O 
SFN B-ABBREVIATION 
) O 
are O 
based O 
on O 
the O 
up O 
- O 
regulation O 
of O 
antioxidant O 
enzymes O 
( O 
AE O 
) O 
and O 
phase O 
II O 
enzymes O 
( O 
PIIE O 
) O 
through O 
the O 
transcription O 
factor O 
Nrf2 O 
. O 
Current O 
knowledge O 
on O 
the O 
roles O 
of O 
the O 
SFN B-ABBREVIATION 
precursor O 
glucoraphanin B-TRIVIAL 
( O 
GRA B-ABBREVIATION 
) O 
on O 
these O 
processes O 
is O 
limited O 
. O 
Anti-carcinogenic O 
effects O 
of O 
Se B-FORMULA 
depending O 
on O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
activity O 
have O 
also O 
been O 
reported O 
. O 
We O 
studied O 
effects O 
and O 
possible O 
synergisms O 
of O 
Se B-FORMULA 
and O 
GRA B-ABBREVIATION 
on O 
the O 
expression O 
and O 
activity O 
of O 
a O 
broad O 
spectrum O 
of O 
AE O 
and O 
PIIE O 
in O 
jejunum O 
, O 
colon O 
and O 
the O 
liver O 
of O 
rats O 
fed O 
diets O 
differing O 
in O 
Se B-FORMULA 
and O 
GRA B-ABBREVIATION 
concentration O 
. O 
In O 
all O 
organs O 
, O 
GPx1 O 
mRNA O 
expression O 
was O 
70 O 
% O 
to O 
90 O 
% O 
lower O 
in O 
Se B-FORMULA 
deficiency O 
than O 
in O 
Se B-FORMULA 
sufficiency O 
. O 
GPx2 O 
expression O 
increased O 
in O 
jejunum O 
and O 
liver O 
under O 
Se B-FORMULA 
deficiency O 
and O 
decreased O 
in O 
the O 
colon O 
. O 
Se B-FORMULA 
deficiency O 
increased O 
most O 
colonic O 
AE O 
and O 
PIIE O 
compared O 
to O 
Se B-FORMULA 
adequacy O 
. O 
Adequate O 
and O 
in O 
particular O 
supranutritive O 
Se B-FORMULA 
combined O 
with O 
GRA B-ABBREVIATION 
increased O 
colonic O 
AE O 
and O 
PIIE O 
expression O 
up O 
to O 
3.72-fold O 
. O 
In O 
the O 
liver O 
Se B-FORMULA 
deficiency O 
raised O 
the O 
expression O 
of O 
AE O 
and O 
PIIE O 
up O 
to O 
4.49-fold O 
. O 
GRA B-ABBREVIATION 
attenuated O 
liver O 
AE O 
and O 
PIIE O 
response O 
in O 
Se B-FORMULA 
deficiency O 
. O 
Expression- O 
and O 
correlation O 
analyses O 
revealed O 
that O 
Keap1 O 
mRNA O 
better O 
reflects O 
AE O 
and O 
PIIE O 
gene O 
expression O 
than O 
Nrf2 O 
mRNA O 
. O 
We O 
conclude O 
that O 
: O 
( O 
1 O 
) O 
GPx1 O 
sensitively O 
indicates O 
Se B-FORMULA 
deficiency O 
; O 
( O 
2 O 
) O 
the O 
influence O 
of O 
Se B-FORMULA 
and O 
Nrf2 O 
/ O 
Keap1 O 
on O 
GPx2 O 
expression O 
depends O 
on O 
the O 
organ O 
; O 
( O 
3 O 
) O 
GRA B-ABBREVIATION 
combined O 
with O 
supranutritive O 
Se B-FORMULA 
may O 
effectively O 
protect O 
against O 
inflammation O 
and O 
colon O 
cancer O 
; O 
( O 
4 O 
) O 
future O 
investigations O 
on O 
AE O 
and O 
PIIE O 
expression O 
should O 
consider O 
the O 
role O 
of O 
Keap1 O 
to O 
a O 
higher O 
extent O 
. O 

acid I-FAMILY 
-based O 
zwitterionic B-FAMILY 
poly(serine I-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
as O 
an O 
antifouling O 
material O 
. O 

serine B-TRIVIAL 
-based O 
zwitterionic B-FAMILY 
poly(serine I-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
( O 
pSerMA B-ABBREVIATION 
) O 
was O 
developed O 
in O 
this O 
work O 
to O 
be O 
used O 
as O 
a O 
potential O 
antifouling O 
material O 
. O 
A O 
surface O 
- O 
initiated O 
photoiniferter O 
- O 
mediated O 
polymerization O 
( O 
SI-PIMP O 
) O 
method O 
was O 
used O 
to O 
graft O 
polymer O 
brushes O 
on O 
gold O 
surfaces O 
. O 
The O 
pSerMA B-ABBREVIATION 
-grafted O 
samples O 
with O 
different O 
polymer O 
film O 
thicknesses O 
were O 
readily O 
prepared O 
by O 
varying O 
the O 
UV-irradiation O 
time O 
. O 
With O 
the O 
optimal O 
film O 
thickness O 
, O 
the O 
adsorptions O 
from O 
bovine O 
serum O 
albumin O 
, O 
human O 
serum O 
, O 
and O 
human O 
plasma O 
onto O 
the O 
pSerMA B-ABBREVIATION 
-grafted O 
surfaces O 
, O 
as O 
evaluated O 
by O 
a O 
surface O 
plasmon O 
resonance O 
( O 
SPR O 
) O 
biosensor O 
, O 
were O 
1.8 O 
, O 
9.2 O 
, O 
and O 
12.9 O 
ng O 
/ O 
cm(2) O 
, O 
respectively O 
, O 
comparable O 
to O 
the O 
traditional O 
antifouling O 
material O 
such O 
as O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
. O 
The O 
pSerMA B-ABBREVIATION 
-grafted O 
surfaces O 
also O 
strongly O 
resisted O 
adhesion O 
from O 
bovine O 
aortic O 
endothelial O 
cells O 
. O 
This O 
is O 
the O 
first O 
work O 
to O 
develop O 
an O 
amino B-FAMILY 
acid I-FAMILY 
-based O 
zwitterionic O 
polymer O 
as O 
an O 
antifouling O 
material O 
, O 
demonstrating O 
that O 
pSerMA B-ABBREVIATION 
is O 
a O 
promising O 
alternative O 
to O 
the O 
traditional O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
-based O 
antifouling O 
materials O 
. O 

grafted O 
β-cyclodextrin B-TRIVIAL 
is O 
used O 
as O 
targeting O 
sites O 
, O 
Pluronic O 
polymers O 
have O 
been O 
introduced O 
on O 
the O 
surface O 
of O 
cellulose O 
nanocrystals O 
by O 
means O 
of O 
inclusion O 
interaction O 
between O 
β-cyclodextrin B-TRIVIAL 
and O 
hydrophobic O 
segment O 
of O 
the O 
polymer O 
. O 
Because O 
of O 
the O 
steric O 
stabilization O 
effect O 
, O 
surface O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
chains O 
facilitate O 
the O 
dispersion O 
and O 
compatibility O 
of O 
nanocrystals O 
, O 
which O 
also O 
enhance O 
the O 
loading O 
levels O 
of O 
nanocrystals O 
in O 
the O 
hydrogel O 
system O 
. O 
Meanwhile O 
, O 
uncovered O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
segments O 
render O 
the O 
participating O 
inclusion O 
of O 
α-cyclodextrin B-TRIVIAL 
for O 
the O 
architecture O 
of O 
in O 
situ O 
hydrogels O 
. O 
Surface O 
grafting O 
and O 
inclusion O 
reactions O 
were O 
proved O 
by O 
solid O 
(13)C B-FORMULA 
NMR O 
and O 
FTIR O 
. O 
Grafting O 
efficiency O 
of O 
β-cyclodextrin B-TRIVIAL 
and O 
inclusion O 
efficiency O 
of O 
Pluronic O 
on O 
the O 
surface O 
of O 
nanocrystals O 
were O 
confirmed O 
by O 
UV O 
spectroscopy O 
and O 
elemental O 
analysis O 
. O 
A O 
significant O 
enhancement O 
of O 
the O 
structural O 
and O 
thermal O 
stability O 
of O 
in O 
situ O 
hydrogels O 
with O 
high O 
loading O 
levels O 
of O 
modified O 
nanocrystals O 
( O 
> O 
5.77 O 
wt O 
% O 
) O 
was O 
observed O 
by O 
rheological O 
analysis O 
. O 
Further O 
study O 
reveals O 
the O 
performance O 
and O 
behavior O 
of O 
hydrogels O 
under O 
a O 
different O 
pH O 
environment O 
. O 
Finally O 
, O 
in O 
situ O 
hydrogels O 
were O 
used O 
as O 
drug O 
carrier O 
for O 
in O 
vitro O 
release O 
of O 
doxorubicin B-TRIVIAL 
and O 
exhibit O 
the O 
behavior O 
of O 
prolonged O 
drug O 
release O 
with O 
special O 
release O 
kinetics O 
. O 

structures O 
of O 
PDMS B-ABBREVIATION 
incorporated O 
with O 
quaternary O 
ammonium B-SYSTEMATIC 
salts O 
designed O 
for O 
antibiofouling O 
and O 
fouling O 
release O 
applications O 
. O 

( O 
PDMS B-ABBREVIATION 
) O 
materials O 
have O 
been O 
extensively O 
shown O 
to O 
function O 
as O 
excellent O 
fouling O 
- O 
release O 
( O 
FR O 
) O 
coatings O 
in O 
the O 
marine O 
environment O 
. O 
The O 
incorporation O 
of O 
biocide O 
moieties O 
, O 
such O 
as O 
quaternary O 
ammonium B-SYSTEMATIC 
salts O 
( O 
QAS O 
) O 
, O 
can O 
impart O 
additional O 
antibiofouling O 
properties O 
to O 
PDMS B-ABBREVIATION 
-based O 
FR O 
coating O 
systems O 
. O 
In O 
this O 
study O 
, O 
the O 
molecular O 
surface O 
structures O 
of O 
two O 
different O 
types O 
of O 
QAS-incorporated O 
PDMS B-ABBREVIATION 
systems O 
were O 
investigated O 
in O 
different O 
chemical O 
environments O 
using O 
sum O 
frequency O 
generation O 
vibrational O 
spectroscopy O 
( O 
SFG O 
) O 
. O 
Specifically O 
, O 
a O 
series O 
of O 
PDMS B-ABBREVIATION 
coatings O 
containing O 
either O 
a O 
QAS O 
with O 
a O 
single O 
ammonium B-SYSTEMATIC 
salt O 
group O 
per O 
molecule O 
or O 
a O 
quaternary O 
ammonium B-SYSTEMATIC 
-functionalized O 
polyhedral B-FAMILY 
oligomeric I-FAMILY 
silsesquioxane I-FAMILY 
( O 
Q- O 
POSS B-ABBREVIATION 
) O 
were O 
measured O 
with O 
SFG O 
in O 
air O 
, O 
water O 
, O 
and O 
artificial O 
seawater O 
( O 
ASW O 
) O 
to O 
investigate O 
the O 
relationships O 
between O 
the O 
interfacial O 
surface O 
structures O 
of O 
these O 
materials O 
and O 
their O 
antifouling O 
properties O 
. O 
Although O 
previous O 
studies O 
have O 
shown O 
that O 
the O 
above O 
- O 
mentioned O 
materials O 
are O 
promising O 
contact O 
- O 
active O 
antifouling O 
coatings O 
, O 
slight O 
variations O 
of O 
the O 
QAS O 
structure O 
can O 
lead O 
to O 
substantial O 
differences O 
in O 
the O 
antifouling O 
performance O 
. O 
Indeed O 
, O 
the O 
SFG O 
results O 
presented O 
here O 
indicated O 
that O 
the O 
surface O 
structures O 
of O 
these O 
materials O 
depend O 
on O 
several O 
factors O 
, O 
such O 
as O 
the O 
extent O 
of O 
quaternization O 
, O 
the O 
molecular O 
weight O 
of O 
the O 
PDMS B-ABBREVIATION 
component O 
, O 
and O 
the O 
functional O 
groups O 
of O 
the O 
QAS O 
used O 
for O 
incorporation O 
into O 
the O 
PDMS B-ABBREVIATION 
matrix O 
. O 
It O 
was O 
concluded O 
that O 
in O 
aqueous O 
environments O 
a O 
lower O 
extent O 
of O 
Q- O 
POSS B-ABBREVIATION 
quaternization O 
and O 
the O 
use O 
of O 
ethoxy B-SYSTEMATIC 
( O 
instead O 
of O 
methoxy B-SYSTEMATIC 
) O 
functional O 
groups O 
for O 
QAS O 
incorporation O 
facilitated O 
the O 
extension O 
of O 
the O 
alkyl O 
chains O 
away O 
from O 
the O 
nitrogen B-SYSTEMATIC 
atom O 
of O 
the O 
QAS O 
on O 
the O 
surface O 
. O 
The O 
SFG O 
results O 
correlated O 
well O 
with O 
the O 
antifouling O 
activity O 
studies O 
that O 
indicated O 
that O 
the O 
coatings O 
exhibiting O 
a O 
lower O 
concentration O 
of O 
longer O 
alkyl O 
chains O 
protruding O 
out O 
of O 
the O 
surface O 
can O 
neutralize O 
microorganisms O 
more O 
effectively O 
, O 
ultimately O 
leading O 
to O 
better O 
antifouling O 
performance O 
. O 
Furthermore O 
, O 
the O 
results O 
of O 
this O 
study O 
provide O 
additional O 
evidence O 
that O 
incorporated O 
QAS O 
exert O 
their O 
antimicrobial O 
activity O 
through O 
a O 
two O 
- O 
step O 
interaction O 
. O 
The O 
first O 
step O 
is O 
the O 
adsorption O 
of O 
the O 
bacteria O 
on O 
the O 
surface O 
as O 
a O 
result O 
of O 
the O 
electrostatic O 
attraction O 
between O 
the O 
negatively O 
charged O 
microorganisms O 
and O 
the O 
positively O 
charged O 
QAS O 
nitrogen B-SYSTEMATIC 
atoms O 
on O 
the O 
surface O 
. O 
The O 
second O 
step O 
is O 
the O 
disruption O 
of O 
the O 
cell O 
membranes O 
by O 
the O 
penetration O 
of O 
the O 
QAS O 
long O 
, O 
extended O 
alkyl O 
chains O 
. O 

-induced O 
insulin O 
secretion O 
from O 
pancreatic O 
ß-cells O 
depends O 
critically O 
on O 
activity O 
of O 
ATP B-ABBREVIATION 
-sensitive O 
K+ B-FORMULA 
channels O 
( O 
KATP O 
channel O 
) O 
. O 
We O 
previously O 
generated O 
mice O 
lacking O 
Kir6.2 O 
, O 
the O 
pore O 
subunit O 
of O 
the O 
ß-cell O 
KATP O 
channel O 
( O 
Kir6.2- O 
/ O 
- O 
) O 
, O 
that O 
show O 
almost O 
no O 
insulin O 
secretion O 
in O 
response O 
to O 
glucose B-TRIVIAL 
in O 
vitro O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
compared O 
insulin O 
secretion O 
by O 
voluntary O 
feeding O 
( O 
self O 
- O 
motivated O 
, O 
oral O 
nutrient O 
ingestion O 
) O 
and O 
by O 
forced O 
feeding O 
( O 
intra O 
- O 
gastric O 
nutrient O 
injection O 
via O 
gavage O 
) O 
in O 
wild O 
- O 
type O 
( O 
Kir6.2+ O 
/ O 
+ O 
) O 
and O 
Kir6.2- O 
/ O 
- O 
mice O 
. O 
Under O 
ad O 
libitum O 
feeding O 
or O 
during O 
voluntary O 
feeding O 
of O 
standard O 
chow O 
, O 
blood O 
glucose B-TRIVIAL 
levels O 
and O 
plasma O 
insulin O 
levels O 
were O 
similar O 
in O 
Kir6.2+ O 
/ O 
+ O 
and O 
Kir6.2- O 
/ O 
- O 
mice O 
. O 
By O 
voluntary O 
feeding O 
of O 
carbohydrate B-FAMILY 
alone O 
, O 
insulin O 
secretion O 
was O 
induced O 
significantly O 
in O 
Kir6.2- O 
/ O 
- O 
mice O 
, O 
but O 
was O 
markedly O 
attenuated O 
compared O 
to O 
that O 
in O 
Kir6.2+ O 
/ O 
+ O 
mice O 
. O 
On O 
forced O 
feeding O 
of O 
standard O 
chow O 
or O 
carbohydrate B-FAMILY 
alone O 
, O 
the O 
insulin O 
secretory O 
response O 
was O 
markedly O 
impaired O 
or O 
completely O 
absent O 
in O 
Kir6.2- O 
/ O 
- O 
mice O 
. O 
Pre O 
- O 
treatment O 
of O 
a O 
muscarine O 
receptor O 
antagonist O 
, O 
atropine B-TRIVIAL 
methyl B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
, O 
which O 
does O 
not O 
cross O 
the O 
blood O 
- O 
brain O 
barrier O 
, O 
almost O 
completely O 
blocked O 
insulin O 
secretion O 
induced O 
by O 
voluntary O 
feeding O 
of O 
standard O 
chow O 
or O 
carbohydrate B-FAMILY 
in O 
Kir6.2- O 
/ O 
- O 
mice O 
. O 
Substantial O 
glucose B-TRIVIAL 
-induced O 
insulin O 
secretion O 
was O 
induced O 
in O 
pancreas O 
perfusion O 
study O 
of O 
Kir6.2- O 
/ O 
- O 
mice O 
only O 
in O 
the O 
presence O 
of O 
carbamylcholine B-SYSTEMATIC 
. O 
These O 
results O 
suggest O 
that O 
a O 
KATP O 
channel O 
- O 
independent O 
mechanism O 
mediated O 
by O 
the O 
vagal O 
nerve O 
plays O 
a O 
critical O 
role O 
in O 
insulin O 
secretion O 
in O 
response O 
to O 
nutrients O 
in O 
vivo O 
. O 

anti-inflammatory O 
effects O 
of O 
an O 
aqueous O 
extract O 
of O 
Welsh O 
onion O 
green O 
leaves O 
( O 
WOE O 
) O 
in O 
mice O 
was O 
investigated O 
. O 
Administration O 
of O 
WOE O 
, O 
in O 
the O 
range O 
of O 
0.25-1g O 
/ O 
kg O 
, O 
showed O 
a O 
concentration O 
dependent O 
inhibition O 
on O 
paw O 
edema O 
development O 
after O 
carrageenan O 
treatment O 
in O 
mice O 
. O 
The O 
anti-inflammatory O 
effects O 
of O 
WOE O 
were O 
closely O 
attributed O 
to O 
decreased O 
levels O 
of O 
tissue O 
NO B-FORMULA 
and O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
. O 
Further O 
evidence O 
for O 
WOE's O 
protection O 
is O 
shown O 
in O 
the O 
reduction O 
of O 
lipid O 
oxidation O 
and O 
the O 
increase O 
of O 
antioxidant O 
enzyme O 
activities O 
, O 
including O 
catalase O 
( O 
CAT O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPX O 
) O 
in O 
vivo O 
. O 
Further O 
, O 
WOE O 
also O 
decreased O 
the O 
number O 
of O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
writhing O 
responses O 
and O 
formalin B-TRIVIAL 
-induced O 
pain O 
in O 
the O 
late O 
phase O 
in O 
mice O 
. O 
Overall O 
, O 
the O 
results O 
showed O 
that O 
WOE O 
might O 
serve O 
as O 
a O 
natural O 
source O 
of O 
anti-inflammatory O 
compounds O 
. O 

and O 
synthesis O 
of O 
some O 
new O 
quinazolin-4-(3H)-ones B-FAMILY 
as O 
anticonvulsant O 
and O 
antidepressant O 
agents O 
. O 

series O 
of O 
3-[(4-substituted-benzylidene)-amino]-2-phenyl-3H-quinazolin-4-ones B-FAMILY 
( O 
5a-k O 
) O 
were O 
synthesized O 
by O 
reacting O 
3-amino-2-phenyl-1H-quinazolin-4-one B-SYSTEMATIC 
with O 
p-hydroxybenzaldehyde B-SYSTEMATIC 
, O 
and O 
then O 
further O 
with O 
various O 
alkyl B-MULTIPLE 
/ I-MULTIPLE 
benzyl I-MULTIPLE 
halides I-MULTIPLE 
or O 
substituted O 
phenacyl B-FAMILY 
bromides I-FAMILY 
. O 
The O 
structures O 
of O 
the O 
compounds O 
were O 
confirmed O 
on O 
the O 
basis O 
of O 
IR O 
, O 
NMR O 
, O 
MS O 
and O 
elemental O 
analysis O 
. O 
Anticonvulsant O 
activities O 
were O 
evaluated O 
using O 
the O 
MES O 
and O 
scPTZ O 
tests O 
. O 
Some O 
of O 
the O 
selected O 
compounds O 
were O 
evaluated O 
for O 
antidepressant O 
activity O 
by O 
forced O 
swim O 
pool O 
test O 
. O 
Compound O 
3-[(4-butoxy-benzylidene)-amino]-2-phenyl-3H-quinazolin-4-one B-SYSTEMATIC 
was O 
emerged O 
as O 
the O 
most O 
promising O 
anticonvulsant O 
agent O 
without O 
any O 
motor O 
impairment O 
effect O 
. O 
The O 
whole O 
brain O 
GABA B-ABBREVIATION 
estimation O 
of O 
brain O 
homogenate O 
indicated O 
that O 
the O 
anticonvulsant O 
activity O 
of O 
above O 
mentioned O 
quinazolinone B-SYSTEMATIC 
derivatives O 
might O 
be O 
due O 
to O 
an O 
increased O 
GABA B-ABBREVIATION 
concentration O 
. O 

of O 
cytochrome O 
P450 O 
1 O 
( O 
Cyp1 O 
) O 
by O 
vanadium B-SYSTEMATIC 
in O 
hepatic O 
tissue O 
and O 
isolated O 
hepatocyte O 
of O 
C57BL O 
/ O 
6 O 
mice O 
. O 

objective O 
of O 
the O 
current O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
vanadium B-SYSTEMATIC 
( O 
V(5+) B-FORMULA 
) O 
on O 
Cyp1 O 
expression O 
and O 
activity O 
in O 
C57BL O 
/ O 
6 O 
mice O 
liver O 
and O 
isolated O 
hepatocytes O 
. O 
For O 
this O 
purpose O 
, O 
C57BL6 O 
mice O 
were O 
injected O 
intraperitoneally O 
with O 
V(5+) B-FORMULA 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
in O 
the O 
absence O 
and O 
presence O 
of O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
( O 
15 O 
μg O 
/ O 
kg O 
) O 
for O 
6 O 
and O 
24 O 
h O 
. O 
Furthermore O 
, O 
isolated O 
hepatocytes O 
from O 
C57BL6 O 
mice O 
were O 
treated O 
with O 
V(5+) B-FORMULA 
( O 
5 O 
, O 
10 O 
, O 
and O 
20 O 
μM O 
) O 
in O 
the O 
absence O 
and O 
presence O 
of O 
TCDD B-ABBREVIATION 
( O 
1 O 
nM O 
) O 
for O 
3 O 
, O 
6 O 
, O 
12 O 
, O 
and O 
24 O 
h O 
. O 
In O 
vivo O 
, O 
V(5+) B-FORMULA 
alone O 
did O 
not O 
significantly O 
alter O 
Cyp1a1 O 
, O 
Cyp1a2 O 
, O 
or O 
Cyp1b1 O 
mRNA O 
, O 
protein O 
, O 
or O 
catalytic O 
activity O 
levels O 
. O 
Upon O 
co O 
- O 
exposure O 
to O 
V(5+) B-FORMULA 
and O 
TCDD B-ABBREVIATION 
, O 
V(5+) B-FORMULA 
significantly O 
potentiated O 
the O 
TCDD B-ABBREVIATION 
-mediated O 
induction O 
of O 
the O 
Cyp1a1 O 
, O 
Cyp1a2 O 
, O 
and O 
Cyp1b1 O 
mRNA O 
, O 
protein O 
, O 
and O 
catalytic O 
activity O 
levels O 
at O 
24 O 
h O 
. O 
In O 
vitro O 
, O 
V(5+) B-FORMULA 
decreased O 
the O 
TCDD B-ABBREVIATION 
-mediated O 
induction O 
of O 
Cyp1a1 O 
mRNA O 
, O 
protein O 
, O 
and O 
catalytic O 
activity O 
levels O 
. O 
Furthermore O 
, O 
V(5+) B-FORMULA 
significantly O 
inhibited O 
the O 
TCDD B-ABBREVIATION 
-induced O 
AhR-dependent O 
luciferase O 
activity O 
. O 
V(5+) B-FORMULA 
also O 
increased O 
serum O 
hemoglobin O 
( O 
Hb O 
) O 
levels O 
in O 
animals O 
treated O 
for O 
24 O 
h O 
. O 
Upon O 
treatment O 
of O 
isolated O 
hepatocytes O 
with O 
Hb O 
alone O 
or O 
in O 
the O 
presence O 
of O 
TCDD B-ABBREVIATION 
, O 
there O 
was O 
an O 
increase O 
in O 
the O 
AhR-dependent O 
luciferase O 
activity O 
. O 
When O 
isolated O 
hepatocytes O 
were O 
treated O 
for O 
2 O 
h O 
with O 
V(5+) B-FORMULA 
in O 
the O 
presence O 
of O 
TCDD B-ABBREVIATION 
, O 
followed O 
by O 
replacement O 
of O 
the O 
medium O 
with O 
new O 
medium O 
containing O 
Hb O 
, O 
there O 
was O 
further O 
potentiation O 
to O 
the O 
TCDD B-ABBREVIATION 
-mediated O 
effect O 
. O 
The O 
present O 
study O 
demonstrates O 
that O 
there O 
is O 
a O 
differential O 
modulation O 
of O 
Cyp1a1 O 
by O 
V(5+) B-FORMULA 
in O 
C57BL O 
/ O 
6 O 
mice O 
livers O 
and O 
isolated O 
hepatocytes O 
and O 
demonstrates O 
Hb O 
as O 
an O 
in O 
vivo O 
specific O 
modulator O 
. O 

has O 
greater O 
potency O 
and O 
efficacy O 
than O 
theophylline B-TRIVIAL 
to O 
reverse O 
the O 
motor O 
impairment O 
caused O 
by O 
chronic O 
but O 
not O 
acute O 
interruption O 
of O 
striatal O 
dopaminergic O 
transmission O 
in O 
rats O 
. O 

order O 
to O 
assess O 
whether O 
caffeine B-TRIVIAL 
and O 
theophylline B-TRIVIAL 
have O 
the O 
same O 
potency O 
and O 
efficacy O 
to O 
reverse O 
the O 
impairment O 
of O 
motor O 
function O 
caused O 
by O 
acute O 
or O 
chronic O 
interruption O 
of O 
striatal O 
dopamine B-TRIVIAL 
transmission O 
, O 
a O 
comparison O 
of O 
their O 
dose O 
- O 
response O 
relationship O 
was O 
made O 
in O 
the O 
acute O 
model O 
of O 
haloperidol B-TRIVIAL 
-induced O 
catalepsy O 
, O 
and O 
the O 
chronic O 
model O 
of O 
unilateral O 
lesion O 
of O 
the O 
dopamine B-TRIVIAL 
nigrostriatal O 
pathway O 
with O 
6-hydroxydopamine B-SYSTEMATIC 
. O 
At O 
equimolar O 
doses O 
, O 
both O 
drugs O 
reduced O 
catalepsy O 
intensity O 
and O 
increased O 
its O 
onset O 
latency O 
in O 
a O 
dose O 
- O 
dependent O 
fashion O 
, O 
showing O 
comparable O 
potencies O 
and O 
attaining O 
the O 
maximal O 
effect O 
at O 
similar O 
doses O 
. O 
Catalepsy O 
intensity O 
: O 
caffeine B-TRIVIAL 
ED50 O 
= O 
24.1 O 
μmol O 
/ O 
kg O 
[ O 
95% O 
CI O 
, O 
18.4-31.5 O 
] O 
; O 
theophylline B-TRIVIAL 
ED50 O 
= O 
22 O 
μmol O 
/ O 
kg O 
[ O 
95% O 
CI O 
, O 
17.0-28.4 O 
] O 
. O 
Catalepsy O 
latency O 
: O 
caffeine B-TRIVIAL 
ED50 O 
= O 
27 O 
μmol O 
/ O 
kg O 
[ O 
95% O 
CI O 
, O 
21.1-34.6 O 
] O 
; O 
theophylline B-TRIVIAL 
ED50 O 
= O 
28.8 O 
μmol O 
/ O 
kg O 
[ O 
95% O 
CI O 
, O 
22.5-36.7 O 
] O 
. O 
In O 
one O 
group O 
of O 
hemiparkinsonian O 
rats O 
( O 
n O 
= O 
5 O 
) O 
, O 
caffeine B-TRIVIAL 
caused O 
a O 
dose O 
- O 
dependent O 
recovery O 
of O 
the O 
contralateral O 
forepaw O 
stepping O 
: O 
ED50 O 
= O 
2.4 O 
μmol O 
/ O 
kg O 
/ O 
day O 
[ O 
95% O 
CI O 
, O 
1.9-3.1 O 
] O 
) O 
, O 
reaching O 
its O 
maximum O 
at O 
the O 
dose O 
of O 
5.15 O 
μmol O 
/ O 
kg O 
/ O 
day O 
. O 
When O 
the O 
treatment O 
of O 
these O 
same O 
rats O 
was O 
switched O 
to O 
5.15 O 
μmol O 
/ O 
kg O 
/ O 
day O 
of O 
theophylline B-TRIVIAL 
, O 
the O 
stepping O 
recovery O 
was O 
only O 
51 O 
± O 
12% O 
of O 
that O 
induced O 
by O 
caffeine B-TRIVIAL 
. O 
Assessing O 
the O 
dose O 
- O 
response O 
relationship O 
of O 
theophylline B-TRIVIAL 
in O 
another O 
group O 
of O 
hemiparkinsonian O 
rats O 
( O 
n O 
= O 
7 O 
) O 
revealed O 
that O 
it O 
caused O 
stepping O 
recovery O 
in O 
an O 
all O 
- O 
or O 
- O 
none O 
fashion O 
. O 
Thus O 
, O 
the O 
three O 
lower O 
doses O 
had O 
no O 
effect O 
, O 
but O 
at O 
the O 
dose O 
of O 
5.15 O 
μmol O 
/ O 
kg O 
/ O 
day O 
theophylline B-TRIVIAL 
suddenly O 
increased O 
the O 
stepping O 
to O 
56 O 
± O 
5% O 
of O 
the O 
maximal O 
effect O 
observed O 
when O 
the O 
treatment O 
of O 
these O 
same O 
rats O 
was O 
switched O 
to O 
an O 
equimolar O 
dose O 
of O 
caffeine B-TRIVIAL 
. O 
Increasing O 
the O 
dose O 
of O 
theophylline B-TRIVIAL 
up O 
to O 
15.45 O 
μmol O 
/ O 
kg O 
/ O 
day O 
caused O 
no O 
further O 
stepping O 
improvement O 
since O 
it O 
was O 
only O 
41 O 
± O 
6% O 
of O 
the O 
maximal O 
effect O 
produced O 
by O 
caffeine B-TRIVIAL 
at O 
the O 
dose O 
of O 
5.15 O 
μmol O 
/ O 
kg O 
/ O 
day O 
. O 
Given O 
that O 
theophylline B-TRIVIAL 
showed O 
less O 
potency O 
and O 
efficacy O 
than O 
caffeine B-TRIVIAL 
to O 
reverse O 
the O 
motor O 
impairment O 
caused O 
by O 
chronic O 
, O 
but O 
not O 
acute O 
, O 
interruption O 
of O 
striatal O 
dopaminergic O 
transmission O 
in O 
rats O 
, O 
it O 
is O 
suggested O 
that O 
caffeine B-TRIVIAL 
would O 
provide O 
more O 
benefits O 
than O 
theophylline B-TRIVIAL 
to O 
improve O 
the O 
motor O 
function O 
in O 
patients O 
with O 
Parkinson's O 
disease O 
. O 

investigate O 
changes O 
in O 
body O 
composition O 
after O 
12 O 
months O 
of O 
high O 
- O 
intensity O 
progressive O 
resistance O 
training O 
( O 
PRT O 
) O 
in O 
relation O 
to O 
changes O 
in O 
insulin O 
resistance O 
( O 
IR O 
) O 
or O 
glucose B-TRIVIAL 
homeostasis O 
in O 
older O 
adults O 
with O 
type O 
2 O 
diabetes.RESEARCH O 
DESIGN O 
AND O 
METHODSOne O 
- O 
hundred O 
three O 
participants O 
were O 
randomized O 
to O 
receive O 
either O 
PRT O 
or O 
sham O 
exercise O 
3 O 
days O 
per O 
week O 
for O 
12 O 
months O 
. O 
Homeostatic O 
model O 
of O 
assessment O 
2 O 
( O 
HOMA2-IR O 
) O 
and O 
glycosylated O 
hemoglobin O 
( O 
HbA1c O 
) O 
were O 
used O 
as O 
indices O 
of O 
IR O 
and O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Skeletal O 
muscle O 
mass O 
( O 
SkMM O 
) O 
and O 
total O 
fat O 
mass O 
were O 
assessed O 
using O 
bioelectrical O 
impedance O 
. O 
Visceral O 
adipose O 
tissue O 
, O 
mid O 
- O 
thigh O 
cross O 
- O 
sectional O 
area O 
, O 
and O 
mid O 
- O 
thigh O 
muscle O 
attenuation O 
were O 
quantified O 
using O 
computed O 
tomography.RESULTSWithin O 
the O 
PRT O 
group O 
, O 
changes O 
in O 
HOMA2-IR O 
were O 
associated O 
with O 
changes O 
in O 
SkMM O 
( O 
r O 
= O 
-0.38 O 
; O 
P O 
= O 
0.04 O 
) O 
and O 
fat O 
mass O 
( O 
r O 
= O 
0.42 O 
; O 
P O 
= O 
0.02 O 
) O 
. O 
Changes O 
in O 
visceral O 
adipose O 
tissue O 
tended O 
to O 
be O 
related O 
to O 
changes O 
in O 
HOMA2-IR O 
( O 
r O 
= O 
0.35 O 
; O 
P O 
= O 
0.07 O 
) O 
. O 
Changes O 
in O 
HbA1c O 
were O 
related O 
to O 
changes O 
in O 
mid O 
- O 
thigh O 
muscle O 
attenuation O 
( O 
r O 
= O 
0.52 O 
; O 
P O 
= O 
0.001 O 
) O 
. O 
None O 
of O 
these O 
relationships O 
were O 
present O 
in O 
the O 
sham O 
group O 
( O 
P O 
> O 
0.05 O 
) O 
. O 
Using O 
ANCOVA O 
models O 
, O 
participants O 
in O 
the O 
PRT O 
group O 
who O 
had O 
increased O 
SkMM O 
had O 
decreased O 
HOMA2-IR O 
( O 
P O 
= O 
0.05 O 
) O 
and O 
HbA1c O 
( O 
P O 
= O 
0.09 O 
) O 
compared O 
with O 
those O 
in O 
the O 
PRT O 
group O 
who O 
lost O 
SkMM O 
. O 
Increases O 
in O 
SkMM O 
in O 
the O 
PRT O 
group O 
decreased O 
HOMA2-IR O 
( O 
P O 
= O 
0.07 O 
) O 
and O 
HbA1c O 
( O 
P O 
< O 
0.05 O 
) O 
compared O 
with O 
those O 
who O 
had O 
increased O 
SkMM O 
in O 
the O 
sham O 
group.CONCLUSIONSImprovements O 
in O 
metabolic O 
health O 
in O 
older O 
adults O 
with O 
type O 
2 O 
diabetes O 
were O 
mediated O 
through O 
improvements O 
in O 
body O 
composition O 
only O 
if O 
they O 
were O 
achieved O 
through O 
high O 
- O 
intensity O 
PRT O 
. O 

advances O 
in O 
multimodality O 
therapies O 
for O 
the O 
treatment O 
of O 
squamous O 
cell O 
carcinoma O 
of O 
the O 
head O 
and O 
neck O 
( O 
SCCHN O 
) O 
, O 
survival O 
rates O 
, O 
functional O 
outcomes O 
and O 
toxicities O 
of O 
therapy O 
remain O 
poor O 
. O 
The O 
recognition O 
of O 
the O 
prognostic O 
value O 
of O 
human O 
papillomavirus O 
( O 
HPV O 
) O 
status O 
, O 
and O 
the O 
advent O 
of O 
biologically O 
targeted O 
therapies O 
with O 
potential O 
for O 
decreased O 
toxicities O 
and O 
increased O 
selectivity O 
, O 
represent O 
significant O 
developments O 
in O 
our O 
understanding O 
of O 
SCCHN O 
. O 
Targeted O 
agents O 
currently O 
approved O 
or O 
under O 
investigation O 
for O 
SCCHN O 
include O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
monoclonal O 
antibodies O 
( O 
cetuximab O 
, O 
panitumumab O 
, O 
zalutumumab O 
, O 
nimotuzumab O 
) O 
, O 
EGFR O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
( O 
gefitinib B-TRIVIAL 
, O 
erlotinib B-TRIVIAL 
, O 
lapatinib B-TRIVIAL 
, O 
afatanib B-TRIVIAL 
, O 
dacomitinib B-TRIVIAL 
) O 
, O 
vascular O 
endothelial O 
growth O 
factor O 
receptor O 
( O 
VEGFR O 
) O 
inhibitors O 
( O 
bevacizumab O 
, O 
sorafenib B-TRIVIAL 
, O 
sunitinib B-TRIVIAL 
, O 
vandetanib B-TRIVIAL 
) O 
and O 
various O 
inhibitors O 
of O 
other O 
pathways O 
and O 
targets O 
, O 
including O 
phosphatidylinositol B-TRIVIAL 
3 O 
' O 
kinase O 
( O 
PI3K O 
) O 
/ O 
AKT O 
/ O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
, O 
MET O 
and O 
insulin O 
- O 
like O 
growth O 
factor O 
receptor O 
( O 
IGF-1R O 
) O 
. O 
On-going O 
clinical O 
trials O 
are O 
evaluating O 
these O 
emerging O 
agents O 
and O 
their O 
combinations O 
in O 
the O 
treatment O 
of O 
SCCHN O 
. O 

- O 
activity O 
relationships O 
of O 
hybrid O 
annonaceous B-FAMILY 
acetogenins I-FAMILY 
: O 
Powerful O 
growth O 
inhibitory O 
effects O 
of O 
their O 
connecting O 
groups O 
between O 
heterocycle O 
and O 
hydrophobic O 
carbon B-SYSTEMATIC 
chain O 
bearing O 
THF B-ABBREVIATION 
ring O 
on O 
human O 
cancer O 
cell O 
lines O 
. O 

novel O 
hybrid O 
molecules O 
of O 
annonaceous B-FAMILY 
acetogenins I-FAMILY 
and O 
insecticides O 
targeting O 
mitochondrial O 
complex O 
I O 
were O 
synthesized O 
and O 
their O 
growth O 
inhibitory O 
activities O 
against O 
39 O 
human O 
cancer O 
cell O 
lines O 
were O 
investigated O 
. O 
It O 
was O 
revealed O 
that O 
the O 
connecting O 
group O 
between O 
the O 
N-methylpyrazole B-SYSTEMATIC 
part O 
and O 
the O 
hydrophobic O 
alkyl B-FAMILY 
chain O 
bearing O 
the O 
THF B-ABBREVIATION 
ring O 
influenced O 
their O 
biological O 
activities O 
significantly O 
. O 
Amide B-SYSTEMATIC 
-connected O 
analog O 
2 O 
, O 
in O 
particular O 
, O 
showed O 
selective O 
and O 
very O 
potent O 
activity O 
( O 
< O 
10 O 
nM O 
) O 
against O 
some O 
cancer O 
cell O 
lines O 
. O 

characterization O 
and O 
authentication O 
of O 
beeswax O 
of O 
Apis O 
mellifera O 
was O 
performed O 
by O 
high O 
temperature O 
capillary O 
gas O 
chromatography O 
coupled O 
to O 
electron O 
impact O 
mass O 
spectrometry O 
or O 
to O 
flame O 
ionisation O 
detection O 
and O 
chemometric O 
analysis O 
. O 
Many O 
major O 
components O 
( O 
> O 
50 O 
) O 
of O 
beeswax O 
, O 
odd O 
and O 
even O 
hydrocarbons B-FAMILY 
, O 
oleofin B-FAMILY 
, O 
palmitate B-TRIVIAL 
, O 
oleate B-TRIVIAL 
and O 
hydroxypalmitate B-FAMILY 
monoesters I-FAMILY 
were O 
detected O 
, O 
and O 
for O 
the O 
first O 
time O 
palmitate B-MULTIPLE 
and I-MULTIPLE 
oleate I-MULTIPLE 
monoesters I-MULTIPLE 
esterified O 
with O 
1-octadecanol B-SYSTEMATIC 
and O 
1-eicosanol B-SYSTEMATIC 
are O 
reported O 
to O 
be O 
present O 
in O 
beeswax O 
. O 
Unsupervised O 
pattern O 
recognition O 
procedures O 
, O 
cluster O 
analysis O 
and O 
principal O 
component O 
analysis O 
, O 
were O 
used O 
to O 
find O 
data O 
patterns O 
and O 
successfully O 
differentiate O 
authentic O 
and O 
paraffin B-FAMILY 
adulterated O 
beeswax O 
based O 
on O 
the O 
chemical O 
profile O 
obtained O 
. O 
Independent O 
assessment O 
of O 
beeswax O 
quality O 
and O 
performance O 
of O 
the O 
unsupervised O 
classification O 
methods O 
were O 
performed O 
using O 
classical O 
analytical O 
parameters O 
. O 
The O 
discrimination O 
power O 
of O 
the O 
chemometric O 
unsupervised O 
methods O 
for O 
detection O 
of O 
paraffin B-FAMILY 
adulterated O 
beeswax O 
was O 
superior O 
to O 
the O 
discriminating O 
power O 
of O 
classical O 
analytical O 
parameters O 
. O 
Using O 
linear O 
discriminant O 
analysis O 
, O 
classification O 
rules O 
for O 
authentic O 
and O 
paraffin B-FAMILY 
adulterated O 
beeswax O 
samples O 
were O 
developed O 
. O 
The O 
model O 
was O 
validated O 
by O 
leave O 
- O 
one O 
- O 
out O 
cross O 
validation O 
and O 
showed O 
good O 
recognition O 
and O 
prediction O 
abilities O 
, O 
100% O 
and O 
99% O 
, O 
respectively O 
. O 

of O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
-induced O 
nephrotoxicity O 
in O 
rats O 
by O 
n-hexane B-SYSTEMATIC 
extract O 
of O 
Sonchus O 
asper O 
. O 

asper O 
is O 
traditionally O 
used O 
in O 
the O 
treatment O 
of O 
renal O 
dysfunction O 
. O 
In O 
the O 
present O 
study O 
, O 
protective O 
effects O 
of O 
S O 
. O 
asper O 
against O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl4 B-FORMULA 
)-induced O 
nephrotoxicity O 
of O 
rats O 
were O 
determined O 
. O 
In O 
this O 
study O 
, O 
24 O 
male O 
albino O 
rats O 
( O 
190-200 O 
g O 
) O 
were O 
equally O 
divided O 
into O 
four O 
groups O 
. O 
Group O 
I O 
( O 
control O 
group O 
) O 
was O 
given O 
saline O 
( O 
1 O 
ml O 
/ O 
kg O 
body O 
weight O 
( O 
b.w O 
. O 
) O 
, O 
0.85% O 
NaC B-FORMULA 
l O 
) O 
and O 
dimethyl B-SYSTEMATIC 
sulfoxid I-SYSTEMATIC 
e O 
( O 
1 O 
ml O 
/ O 
kg O 
b.w O 
. O 
) O 
; O 
group O 
II O 
was O 
treated O 
wit O 
h B-FORMULA 
CC I-FORMULA 
l4 O 
( O 
1 O 
ml O 
/ O 
kg O 
b.w O 
. O 
intraperitoneally O 
) O 
; O 
groups O 
III O 
and O 
IV O 
were O 
administered O 
wit O 
h B-FORMULA 
CC I-FORMULA 
l4 O 
and O 
after O 
48 O 
h O 
with O 
S O 
. O 
aspe O 
r B-SYSTEMATIC 
n-hexa I-SYSTEMATIC 
ne O 
extract O 
( O 
SHE O 
; O 
100 O 
and O 
200 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
. O 
All O 
the O 
treatments O 
were O 
given O 
twice O 
a O 
week O 
for O 
4 O 
weeks O 
. O 
The O 
results O 
revealed O 
tha O 
t B-FORMULA 
CC I-FORMULA 
l4-induced O 
oxidative O 
stress O 
as O 
evidenced O 
by O 
the O 
significant O 
depletion O 
of O 
antioxidant O 
enzymes O 
, O 
namely O 
, B-TRIVIAL 
superoxi I-TRIVIAL 
de O 
dismutase O 
, O 
catalase O 
, O 
peroxidase O 
, B-TRIVIAL 
glutathio I-TRIVIAL 
n O 
e B-FORMULA 
-S-transferase O 
, B-TRIVIAL 
glutathio I-TRIVIAL 
ne O 
peroxidase O 
, B-TRIVIAL 
glutathio I-TRIVIAL 
ne O 
reductase O 
, O 
an O 
d B-TRIVIAL 
glutathio I-TRIVIAL 
ne O 
contents O 
, O 
while O 
increased O 
lipid O 
peroxidation O 
( B-SYSTEMATIC 
thiobarbituric I-SYSTEMATIC 
ac I-SYSTEMATIC 
id O 
- O 
reactive O 
substances O 
contents O 
) O 
. O 
Administration O 
of O 
SHE O 
significantly O 
ameliorated O 
( O 
p O 
< O 
0.01 O 
) O 
the O 
activity O 
of O 
antioxidant O 
enzymes O 
and O 
reduced O 
lipid O 
peroxides O 
. O 
Coadministration O 
revealed O 
that O 
S O 
. O 
asper O 
extract O 
can O 
protect O 
the O 
kidney O 
agains O 
t B-FORMULA 
CC I-FORMULA 
l4 O 
- O 
mediated O 
oxidative O 
damage O 
by O 
restoring O 
the O 
activity O 
of O 
antioxidant O 
enzyme O 
, O 
due O 
to O 
the O 
presence O 
of O 
plant O 
bioactive O 
constituents O 
. O 

apoptosis O 
is O 
a O 
critical O 
mechanism O 
for O 
excessive O 
loss O 
of O 
urinary O 
albumin O 
that O 
eventuates O 
in O 
kidney O 
fibrosis O 
. O 
Pharmacological O 
doses O 
of O 
the O 
mTOR O 
inhibitor O 
rapamycin B-TRIVIAL 
reduce O 
albuminura O 
in O 
diabetes O 
. O 
We O 
explored O 
the O 
hypothesis O 
that O 
mTOR O 
mediates O 
podocyte O 
injury O 
in O 
diabetes O 
. O 
High O 
glucose B-TRIVIAL 
( O 
HG O 
) O 
induces O 
apoptosis O 
of O 
podocytes O 
, O 
inhibits O 
AMPK O 
activation O 
, O 
inactivates O 
tuberin O 
and O 
activates O 
mTOR O 
. O 
HG O 
also O 
increases O 
the O 
levels O 
of O 
Nox4 O 
and O 
Nox1 O 
and O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
. O 
Inhibition O 
of O 
mTOR O 
by O 
low O 
dose O 
rapamycin B-TRIVIAL 
decreases O 
HG-induced O 
Nox4 O 
and O 
Nox1 O 
, O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
and O 
podocyte O 
apoptosis O 
. O 
Inhibition O 
of O 
mTOR O 
had O 
no O 
effect O 
on O 
AMPK O 
or O 
tuberin O 
phosphorylation O 
indicating O 
that O 
mTOR O 
is O 
downstream O 
of O 
these O 
signaling O 
molecules O 
. O 
In O 
isolated O 
glomeruli O 
of O 
OVE26 O 
mice O 
, O 
there O 
is O 
similar O 
decrease O 
in O 
the O 
activation O 
of O 
AMPK O 
and O 
tuberin O 
and O 
activation O 
of O 
mTOR O 
with O 
increase O 
in O 
Nox4 O 
and O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
. O 
Inhibition O 
of O 
mTOR O 
by O 
small O 
dose O 
of O 
rapamycin B-TRIVIAL 
reduces O 
podocyte O 
apoptosis O 
, O 
attenuates O 
glomerular O 
injury O 
and O 
albuminuria O 
. O 
Our O 
data O 
provide O 
evidence O 
for O 
a O 
novel O 
function O 
of O 
mTOR O 
in O 
Nox4 O 
- O 
derived O 
ROS O 
generation O 
and O 
podocyte O 
apoptosis O 
that O 
contributes O 
to O 
urinary O 
albumin O 
excretion O 
in O 
type O 
1 O 
diabetes O 
. O 
Thus O 
mTOR O 
and O 
or O 
NADPH B-ABBREVIATION 
oxidase O 
inhibition O 
may O 
represent O 
a O 
therapeutic O 
modality O 
of O 
diabetic O 
kidney O 
disease O 
. O 

vitro O 
toxicity O 
of O 
camalexin B-TRIVIAL 
derivatives O 
in O 
human O 
cancer O 
and O 
non-cancer O 
cells O 
. O 

aim O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
cytotoxic O 
activity O 
of O 
camalexin B-TRIVIAL 
and O 
its O 
five O 
synthetic O 
derivatives O 
in O 
cancer O 
and O 
non-cancer O 
cells O 
. O 
In O 
cancer O 
cells O 
the O 
benzocamalexin B-TRIVIAL 
( O 
BC O 
) O 
displayed O 
the O 
most O 
potent O 
activity O 
with O 
an O 
IC O 
value O 
of O 
23.3-30.1 O 
μmol O 
/ O 
L O 
. O 
On O 
the O 
other O 
hand O 
, O 
minimal O 
toxicity O 
( O 
IC O 
> O 
100 O 
μmol O 
/ O 
L O 
) O 
in O 
non-cancer O 
cells O 
was O 
observed O 
. O 
Based O 
on O 
these O 
results O 
, O 
BC O 
was O 
selected O 
for O 
further O 
studies O 
. O 
Flow O 
cytometric O 
analysis O 
revealed O 
a O 
BC-induced O 
arrest O 
of O 
the O 
cell O 
cycle O 
in O 
the O 
G2 O 
phase O 
associated O 
with O 
downregulation O 
of O 
α-tubulin O 
, O 
α1-tubulin O 
, O 
β5-tubulin O 
expression O 
. O 
These O 
findings O 
suggest O 
that O 
the O 
inhibitory O 
effect O 
of O 
BC O 
is O 
mediated O 
via O 
inhibition O 
of O 
microtubule O 
formation O 
. O 
Moreover O 
, O 
BC O 
downregulated O 
the O 
expression O 
of O 
microtubule O 
- O 
related O 
protein O 
indicating O 
the O 
effect O 
of O 
this O 
compound O 
on O 
microtubule O 
assembly O 
. O 
After O 
treatment O 
with O 
BC O 
increase O 
of O 
the O 
sub-G O 
DNA O 
content O 
fraction O 
was O 
noted O 
which O 
is O 
considered O 
to O 
be O 
a O 
marker O 
of O 
apoptotic O 
cell O 
death O 
. O 
Apoptosis O 
was O 
also O 
confirmed O 
by O 
DNA O 
fragmentation O 
assay O 
. O 
Moreover O 
, O 
quantitative O 
real O 
- O 
time O 
PCR O 
showed O 
that O 
BC O 
downregulated O 
the O 
expression O 
of O 
antiapoptotic O 
genes O 
Bcl-2 O 
and O 
Bcl-xL O 
and O 
upregulated O 
the O 
expression O 
of O 
proapoptotic O 
Bax O 
. O 
Taken O 
together O 
, O 
our O 
study O 
suggests O 
that O 
the O 
blockade O 
of O 
cell O 
cycle O 
progression O 
and O 
initiation O 
of O 
apoptosis O 
may O 
play O 
an O 
important O 
role O 
in O 
the O 
antiproliferative O 
activity O 
of O 
BC O 
in O 
human O 
cancer O 
cells O 
. O 

EFFECTS O 
OF O 
A O 
D-AMINO B-FAMILY 
ACID I-FAMILY 
OXIDASE O 
INHIBITOR O 
INDICATE O 
A O 
SPINAL O 
SITE O 
OF O 
ACTION O 
IN O 
RAT O 
MODELS O 
OF O 
NEUROPATHIC O 
PAIN O 
. O 

of O 
D-amino B-FAMILY 
acid I-FAMILY 
oxidase O 
( O 
DAAO O 
) O 
activity O 
is O 
a O 
potential O 
target O 
for O 
the O 
treatment O 
of O 
chronic O 
pain O 
. O 
Here O 
we O 
characterized O 
the O 
effects O 
of O 
systemic O 
administration O 
of O 
the O 
DAAO O 
inhibitor O 
4H-furo[3,2-b]pyrrole-5-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
SUN B-ABBREVIATION 
) O 
in O 
rat O 
models O 
of O 
neuropathic O 
and O 
inflammatory O 
pain O 
. O 
Oral O 
administration O 
of O 
SUN B-ABBREVIATION 
dose O 
- O 
dependently O 
attenuated O 
tactile O 
allodynia O 
induced O 
by O 
ligation O 
of O 
the O 
L5 O 
spinal O 
nerve O 
( O 
SNL O 
) O 
, O 
and O 
similarly O 
reversed O 
thermal O 
hyperalgesia O 
produced O 
by O 
chronic O 
constriction O 
injury O 
( O 
CCI O 
) O 
. O 
In O 
addition O 
, O 
SUN B-ABBREVIATION 
was O 
efficacious O 
against O 
Complete O 
Freund's O 
Adjuvant O 
(CFA)-induced O 
thermal O 
hyperalgesia O 
. O 
In O 
these O 
models O 
, O 
maximal O 
reversal O 
of O 
pain O 
- O 
related O 
behaviors O 
corresponded O 
with O 
maximum O 
rates O 
- O 
of O 
- O 
increase O 
in O 
brain O 
and O 
plasma O 
D-serine B-TRIVIAL 
concentrations O 
, O 
indicative O 
of O 
full O 
inhibition O 
of O 
DAAO O 
activity O 
. O 
To O 
investigate O 
the O 
possible O 
site(s) O 
of O 
action O 
, O 
we O 
recorded O 
spontaneous O 
nerve O 
activity O 
and O 
mechanically O 
- O 
evoked O 
responses O 
of O 
central O 
spinal O 
cord O 
dorsal O 
horn O 
neurons O 
and O 
compared O 
these O 
to O 
spontaneous O 
activity O 
of O 
peripheral O 
dorsal O 
root O 
filaments O 
in O 
anesthetized O 
SNL O 
model O 
animals O 
. O 
Oral O 
SUN B-ABBREVIATION 
reduced O 
spontaneous O 
activity O 
in O 
both O 
central O 
and O 
peripheral O 
recordings O 
at O 
doses O 
and O 
pretreatment O 
times O 
that O 
corresponded O 
to O 
reduced O 
mechanical O 
allodynia O 
in O 
behavioral O 
experiments O 
. O 
Following O 
i.v O 
. O 
administration O 
of O 
SUN B-ABBREVIATION 
, O 
the O 
onset O 
of O 
action O 
for O 
this O 
central O 
effect O 
was O 
rapid O 
( O 
maximal O 
effects O 
within O 
30 O 
minutes O 
) O 
, O 
but O 
was O 
abolished O 
by O 
severing O 
afferent O 
inputs O 
to O 
the O 
dorsal O 
horn O 
. O 
Overall O 
, O 
these O 
results O 
indicate O 
that O 
inhibition O 
of O 
DAAO O 
in O 
peripheral O 
afferent-spinal O 
circuits O 
reduced O 
spontaneous O 
neuronal O 
activity O 
to O 
attenuate O 
pain O 
- O 
related O 
behaviors O 
in O 
rat O 
models O 
of O 
neuropathic O 
and O 
inflammatory O 
pain O 
. O 

expression O 
of O 
glucosylceramide B-FAMILY 
synthase O 
in O 
central O 
nervous O 
system O 
regulates O 
body O 
weight O 
and O 
energy O 
homeostasis O 
. O 

neurons O 
are O 
main O 
regulators O 
of O 
energy O 
homeostasis O 
. O 
Neuronal O 
function O 
essentially O 
depends O 
on O 
plasma O 
membrane O 
- O 
located O 
gangliosides O 
. O 
The O 
present O 
work O 
demonstrates O 
that O 
hypothalamic O 
integration O 
of O 
metabolic O 
signals O 
requires O 
neuronal O 
expression O 
of O 
glucosylceramide B-FAMILY 
synthase O 
( O 
GCS O 
; O 
UDP B-ABBREVIATION 
- O 
glucose B-TRIVIAL 
: O 
ceramide B-FAMILY 
glucosyltransferase O 
) O 
. O 
As O 
a O 
major O 
mechanism O 
of O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
metabolic O 
control O 
, O 
we O 
demonstrate O 
that O 
GCS O 
- O 
derived O 
gangliosides O 
interacting O 
with O 
leptin O 
receptors O 
( O 
ObR O 
) O 
in O 
the O 
neuronal O 
membrane O 
modulate O 
leptin O 
- O 
stimulated O 
formation O 
of O 
signaling O 
metabolites O 
in O 
hypothalamic O 
neurons O 
. O 
Furthermore O 
, O 
ganglioside-depleted O 
hypothalamic O 
neurons O 
fail O 
to O 
adapt O 
their O 
activity O 
( O 
c-Fos O 
) O 
in O 
response O 
to O 
alterations O 
in O 
peripheral O 
energy O 
signals O 
. O 
Consequently O 
, O 
mice O 
with O 
inducible O 
forebrain O 
neuron O 
- O 
specific O 
deletion O 
of O 
the O 
UDP B-ABBREVIATION 
- O 
glucose B-TRIVIAL 
: O 
ceramide B-FAMILY 
glucosyltransferase O 
gene O 
( O 
Ugcg O 
) O 
display O 
obesity O 
, O 
hypothermia O 
, O 
and O 
lower O 
sympathetic O 
activity O 
. O 
Recombinant O 
adeno O 
- O 
associated O 
virus O 
( O 
rAAV O 
) O 
- O 
mediated O 
Ugcg O 
delivery O 
to O 
the O 
arcuate O 
nucleus O 
( O 
Arc O 
) O 
significantly O 
ameliorated O 
obesity O 
, O 
specifying O 
gangliosides O 
as O 
seminal O 
components O 
for O 
hypothalamic O 
regulation O 
of O 
body O 
energy O 
homeostasis O 
. O 

nanocargo O 
based O 
on O 
smart O 
polymer O 
functionalized O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
for O 
site O 
- O 
specific O 
drug O 
delivery O 
. O 

oxide I-SYSTEMATIC 
( O 
GO O 
) O 
was O 
functionalized O 
covalently O 
with O 
pH-sensitive O 
poly(2-(diethylamino) B-FAMILY 
ethyl I-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
( O 
PDEA B-ABBREVIATION 
) O 
by O 
surface O 
- O 
initiated O 
in O 
situ O 
atom O 
transfer O 
radical O 
polymerization O 
. O 
The O 
structure O 
of O 
the O 
PDEA-grafted B-ABBREVIATION 
GO I-ABBREVIATION 
( O 
GO-PDEA B-ABBREVIATION 
) O 
were O 
examined O 
by O 
Fourier O 
- O 
transform O 
infrared O 
spectroscopy O 
, O 
proton O 
nuclear O 
magnetic O 
resonance O 
spectroscopy O 
, O 
X-ray O 
photoelectron O 
spectroscopy O 
, O 
thermogravimetric O 
analysis O 
and O 
atomic O 
force O 
microscopy O 
. O 
The O 
grafted O 
PDEA B-ABBREVIATION 
endowed O 
the O 
GO O 
sheets O 
with O 
good O 
solubility O 
and O 
stability O 
in O 
physiological O 
solutions O 
. O 
Simple O 
physisorption O 
by O 
π-π O 
stacking O 
and O 
hydrophobic O 
interactions O 
on O 
GO-PDEA B-ABBREVIATION 
can O 
be O 
used O 
to O 
load O 
camptothecin B-TRIVIAL 
( O 
CPT B-ABBREVIATION 
) O 
, O 
a O 
widely O 
used O 
water O 
- O 
insoluble O 
cancer O 
drug O 
. O 
The O 
loaded O 
CPT B-ABBREVIATION 
was O 
released O 
only O 
at O 
the O 
lower O 
( O 
acidic O 
) O 
pH O 
normally O 
found O 
in O 
a O 
tumor O 
environment O 
but O 
not O 
in O 
basic O 
and O 
neutral O 
pH O 
. O 
GO-PDEA B-ABBREVIATION 
did O 
not O 
show O 
practical O 
toxicity O 
to O 
N2a O 
cancer O 
cells O 
but O 
the O 
GO-PDEA-CPT B-ABBREVIATION 
complex O 
exhibited O 
high O 
potency O 
in O 
killing O 
N2a O 
cancer O 
cells O 
in O 
vitro O 
. O 
These O 
results O 
suggest O 
that O 
the O 
GO-PDEA B-ABBREVIATION 
nanocargo O 
carrier O 
might O 
be O 
a O 
promising O 
material O 
for O 
site O 
- O 
specific O 
anticancer O 
drug O 
delivery O 
and O 
controlled O 
release O 
. O 

of O 
fibrinogen O 
was O 
theoretically O 
studied O 
using O 
the O 
three O 
dimensional O 
( O 
3D O 
) O 
random O 
sequential O 
adsorption O 
( O 
RSA O 
) O 
model O 
. O 
Fibrinogen O 
molecule O 
shape O 
was O 
approximated O 
by O 
the O 
bead O 
model O 
considering O 
the O 
presence O 
of O 
flexible O 
side O 
arms O 
. O 
Various O 
cases O 
were O 
considered O 
inter O 
alia O 
, O 
the O 
side-on O 
adsorption O 
mechanisms O 
and O 
the O 
3D O 
side-on O 
/ O 
end O 
- O 
on O 
simultaneous O 
adsorption O 
mechanism O 
. O 
The O 
latter O 
mechanisms O 
is O 
pertinent O 
to O 
fibrinogen O 
adsorption O 
at O 
lower O 
pH O 
where O 
the O 
entire O 
molecule O 
is O 
positively O 
charged O 
. O 
Extensive O 
calculations O 
enabled O 
one O 
to O 
determine O 
the O 
jamming O 
surface O 
concentration O 
( O 
coverage O 
) O 
of O 
molecules O 
adsorbed O 
under O 
the O 
side-on O 
and O 
end O 
- O 
on O 
orientations O 
as O 
well O 
as O 
the O 
total O 
coverage O 
. O 
For O 
the O 
3D O 
model O 
the O 
maximum O 
surface O 
concentration O 
was O 
7.29x103 O 
μm-2 O 
corresponding O 
to O 
the O 
protein O 
coverage O 
of O 
4.12 O 
mg O 
m-2 O 
( O 
without O 
considering O 
hydration O 
) O 
. O 
Additionally O 
, O 
the O 
surface O 
blocking O 
functions O 
for O 
the O 
side-on O 
and O 
the O 
3D O 
adsorption O 
regimes O 
were O 
determined O 
and O 
analytically O 
approximated O 
for O 
the O 
entire O 
range O 
of O 
coverage O 
by O 
the O 
interpolating O 
polynomials O 
. O 
Using O 
these O 
blocking O 
functions O 
, O 
fibrinogen O 
adsorption O 
kinetics O 
for O 
diffusion O 
controlled O 
transport O 
conditions O 
was O 
evaluated O 
. O 
Comparison O 
of O 
these O 
theoretical O 
results O 
with O 
experimental O 
data O 
was O 
made O 
. O 
It O 
was O 
demonstrated O 
that O 
the O 
3D O 
model O 
properly O 
reflects O 
the O 
maximum O 
coverage O 
of O 
fibrinogen O 
adsorbed O 
on O 
latex O 
particles O 
determined O 
via O 
the O 
electrokinetic O 
( O 
electrophoretic O 
mobility O 
) O 
and O 
AFM O 
measurements O 
. O 
Also O 
, O 
streaming O 
potential O 
measurements O 
of O 
fibrinogen O 
adsorption O 
kinetics O 
on O 
mica B-TRIVIAL 
were O 
successfully O 
interpreted O 
in O 
terms O 
of O 
the O 
3D O 
adsorption O 
model O 
. O 
The O 
theoretical O 
results O 
derived O 
in O 
this O 
work O 
have O 
implications O 
for O 
basic O 
science O 
providing O 
information O 
on O 
mechanisms O 
of O 
anisotropic O 
protein O 
adsorption O 
. O 
Key O 
words O 
: O 
adsorption O 
of O 
fibrinogen O 
, O 
fibrinogen O 
adsorption O 
at O 
lower O 
pH O 
, O 
irreversible O 
adsorption O 
of O 
fibrinogen O 
, O 
jamming O 
coverage O 
of O 
fibrinogen O 
, O 
kinetics O 
of O 
fibrinogen O 
adsorption O 
, O 
random O 
sequential O 
adsorption O 
modeling O 
of O 
fibrinogen O 
adsorption O 
. O 

-induced O 
apoptosis O 
of O 
melanoma O 
cells O 
is O 
mediated O 
by O 
Ras O 
homologous O 
A O 
protein O 
( O 
Rho O 
A O 
) O 
via O 
mitochondrial O 
and O 
non-mitochondrial O 
- O 
dependent O 
mechanisms O 
. O 

the O 
availability O 
of O 
melanoma O 
treatment O 
at O 
the O 
primary O 
site O 
, O 
the O 
recurrence O 
of O 
local O 
melanoma O 
can O 
metastasize O 
to O 
any O 
distant O 
organ O 
. O 
Currently O 
, O 
the O 
available O 
therapies O 
for O 
the O 
treatment O 
of O 
metastatic O 
melanoma O 
are O 
of O 
limited O 
benefit O 
. O 
Thus O 
, O 
the O 
functional O 
analysis O 
of O 
conventional O 
therapies O 
may O 
help O 
to O 
improve O 
their O 
efficiency O 
in O 
the O 
treatment O 
of O 
metastatic O 
melanoma O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
exposure O 
of O 
melanoma O 
cells O 
to O 
vinblastine B-TRIVIAL 
was O 
found O 
to O 
trigger O 
apoptosis O 
as O 
evidenced O 
by O 
the O 
loss O 
of O 
mitochondrial O 
membrane O 
potential O 
, O 
the O 
release O 
of O 
both O 
cytochrome O 
c O 
and O 
apoptosis O 
inducing O 
factor O 
, O 
activation O 
of O 
caspase-9 O 
and O 
3 O 
, O 
and O 
cleavage O 
of O 
Poly B-FAMILY 
( I-FAMILY 
ADP-ribose I-FAMILY 
) I-FAMILY 
-Polymerase O 
. O 
Also O 
, O 
vinblastine B-TRIVIAL 
enhances O 
the O 
phosphorylation O 
of O 
Ras O 
homologous O 
protein O 
A O 
, O 
the O 
accumulation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
the O 
release O 
of O 
intracellular O 
Ca(2+) B-FORMULA 
, O 
as O 
well O 
as O 
the O 
activation O 
of O 
apoptosis O 
signal O 
- O 
regulating O 
kinase O 
1 O 
, O 
c-jun- O 
N B-FORMULA 
-terminal O 
kinase O 
, O 
p38 O 
, O 
inhibitor O 
of O 
kappaBα O 
( O 
IκBα O 
) O 
kinase O 
, O 
and O 
inositol B-TRIVIAL 
requiring O 
enzyme O 
1α O 
. O 
In O 
addition O 
, O 
vinblastine B-TRIVIAL 
induces O 
the O 
DNA O 
- O 
binding O 
activities O 
of O 
the O 
transcription O 
factor O 
NF-κB O 
, O 
HSF1 O 
, O 
AP-1 O 
, O 
and O 
ATF-2 O 
, O 
together O 
with O 
the O 
expression O 
of O 
HSP70 O 
and O 
Bax O 
proteins O 
. O 
Moreover O 
, O 
inhibitory O 
experiments O 
addressed O 
a O 
central O 
role O 
for O 
Rho O 
A O 
in O 
the O 
regulation O 
of O 
vinblastine B-TRIVIAL 
-induced O 
apoptosis O 
of O 
melanoma O 
cells O 
via O 
mitochondrial O 
and O 
non-mitochondrial O 
- O 
dependent O 
mechanisms O 
. O 
In O 
conclusion O 
, O 
the O 
present O 
study O 
addresses O 
for O 
the O 
first O 
time O 
a O 
central O 
role O 
for O 
Rho O 
A O 
in O 
the O 
modulation O 
of O 
vinblastine B-TRIVIAL 
-induced O 
apoptosis O 
of O 
melanoma O 
cells O 
and O 
thereby O 
provides O 
an O 
insight O 
into O 
the O 
molecular O 
action O 
of O 
vinblastine B-TRIVIAL 
in O 
melanoma O 
treatment O 
. O 

content O 
and O 
antioxidant O 
properties O 
of O 
Undaria O 
pinnatifida O 
. O 

study O 
investigated O 
the O 
fucoxanthin B-TRIVIAL 
content O 
of O 
New O 
Zealand O 
( O 
NZ O 
) O 
Undaria O 
pinnatifida O 
harvested O 
from O 
two O 
locations O 
in O 
the O 
Marlborough O 
Sounds O 
, O 
New O 
Zealand O 
across O 
its O 
growing O 
season O 
. O 
Fucoxanthin B-TRIVIAL 
content O 
and O 
antioxidant O 
properties O 
of O 
processed O 
New O 
Zealand O 
U O 
. O 
pinnatifida O 
and O 
commercial O 
wakame O 
from O 
Japan O 
and O 
Korea O 
were O 
further O 
compared O 
. O 
Results O 
showed O 
that O 
U O 
. O 
pinnatifida O 
harvested O 
from O 
Port O 
Underwood O 
had O 
higher O 
fucoxanthin B-TRIVIAL 
content O 
in O 
the O 
blade O 
compared O 
to O 
Pelorus O 
Sound O 
. O 
The O 
sporophyll O 
also O 
contained O 
a O 
significant O 
amount O 
of O 
fucoxanthin B-TRIVIAL 
throughout O 
the O 
harvest O 
season O 
, O 
although O 
lower O 
than O 
in O 
the O 
blade O 
. O 
Two O 
antioxidant O 
measurement O 
methods O 
, O 
DPPH B-ABBREVIATION 
and O 
CUPRAC O 
, O 
were O 
utilised O 
to O 
measure O 
antioxidant O 
activities O 
. O 
Processed O 
NZ O 
U O 
. O 
pinnatifida O 
had O 
a O 
lower O 
fucoxanthin B-TRIVIAL 
content O 
and O 
antioxidant O 
activity O 
than O 
freeze O 
- O 
dried O 
Undaria O 
. O 
Fucoxanthin B-TRIVIAL 
content O 
and O 
antioxidant O 
activities O 
of O 
NZ O 
processed O 
U O 
. O 
pinnatifida O 
were O 
not O 
significantly O 
different O 
from O 
other O 
commercial O 
samples O 
from O 
Japan O 
and O 
Korea O 
. O 
In O 
conclusion O 
, O 
U O 
. O 
pinnatifida O 
in O 
New O 
Zealand O 
has O 
a O 
great O 
potential O 
to O 
be O 
a O 
food O 
and O 
nutraceutical O 
resource O 
. O 

of O 
Glucose B-TRIVIAL 
Lowering O 
of O 
Dipeptidyl O 
Peptidase-4 O 
Inhibitor O 
Sitagliptin B-TRIVIAL 
When O 
Used O 
Alone O 
or O 
With O 
Metformin B-TRIVIAL 
in O 
Type O 
2 O 
Diabetes O 
: O 
A O 
double O 
- O 
tracer O 
study O 
. O 

assess O 
glucose B-TRIVIAL 
-lowering O 
mechanisms O 
of O 
sitagliptin B-TRIVIAL 
( O 
S O 
) O 
, O 
metformin B-TRIVIAL 
( O 
M O 
) O 
, O 
and O 
the O 
two O 
combined O 
(M+S).RESEARCH O 
DESIGN O 
AND O 
METHODSWe O 
randomized O 
16 O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
to O 
four O 
6-week O 
treatments O 
with O 
placebo O 
( O 
P O 
) O 
, O 
M O 
, O 
S O 
, O 
and O 
M O 
+ O 
S O 
. O 
After O 
each O 
period O 
, O 
subjects O 
received O 
a O 
6-h O 
meal O 
tolerance O 
test O 
( O 
MTT B-ABBREVIATION 
) O 
with O 
[(14)C]glucose B-SYSTEMATIC 
to O 
calculate O 
glucose B-TRIVIAL 
kinetics O 
. O 
Fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
, O 
fasting O 
plasma O 
insulin O 
, O 
C B-FORMULA 
-peptide O 
( O 
insulin O 
secretory O 
rate O 
[ O 
ISR O 
] O 
) O 
, O 
fasting O 
plasma O 
glucagon O 
, O 
and O 
bioactive O 
glucagon O 
- O 
like O 
peptide O 
( O 
GLP-1 O 
) O 
and O 
gastrointestinal O 
insulinotropic O 
peptide O 
( O 
GIP O 
) O 
was O 
measured.RESULTSFPG O 
decreased O 
from O 
P O 
, O 
160 O 
± O 
4 O 
to O 
M O 
, O 
150 O 
± O 
4 O 
; O 
S O 
, O 
154 O 
± O 
4 O 
; O 
and O 
M O 
+ O 
S O 
, O 
125 O 
± O 
3 O 
mg O 
/ O 
dL O 
. O 
Mean O 
post- O 
MTT B-ABBREVIATION 
PG O 
decreased O 
from O 
P O 
, O 
207 O 
± O 
5 O 
to O 
M O 
, O 
191 O 
± O 
4 O 
; O 
S O 
, O 
195 O 
± O 
4 O 
; O 
and O 
M O 
+ O 
S O 
, O 
161 O 
± O 
3 O 
mg O 
/ O 
dL O 
( O 
P O 
< O 
0.01 O 
] O 
. O 
The O 
increase O 
in O 
mean O 
post- O 
MTT B-ABBREVIATION 
plasma O 
insulin O 
and O 
in O 
ISR O 
was O 
similar O 
in O 
P O 
, O 
M O 
, O 
and O 
S O 
and O 
slightly O 
greater O 
in O 
M O 
+ O 
S O 
. O 
Fasting O 
plasma O 
glucagon O 
was O 
equal O 
( O 
∼65-75 O 
pg O 
/ O 
mL O 
) O 
with O 
all O 
treatments O 
, O 
but O 
there O 
was O 
a O 
significant O 
drop O 
during O 
the O 
initial O 
120 O 
min O 
with O 
S O 
24% O 
and O 
M O 
+ O 
S O 
34% O 
( O 
both O 
P O 
< O 
0.05 O 
) O 
vs O 
. O 
P O 
17% O 
and O 
M O 
16% O 
. O 
Fasting O 
and O 
mean O 
post- O 
MTT B-ABBREVIATION 
plasma O 
bioactive O 
GLP-1 O 
were O 
higher O 
( O 
P O 
< O 
0.01 O 
) O 
after O 
S O 
and O 
M O 
+ O 
S O 
vs O 
. O 
M O 
and O 
P O 
. O 
Basal O 
endogenous O 
glucose B-TRIVIAL 
production O 
( O 
EGP O 
) O 
fell O 
from O 
P O 
2 O 
± O 
0.1 O 
to O 
S O 
1.8 O 
± O 
0.1 O 
mg O 
/ O 
kg O 
⋅ O 
min O 
, O 
M O 
1.8 O 
± O 
0.2 O 
mg O 
/ O 
kg O 
⋅ O 
min O 
[ O 
both O 
P O 
< O 
0.05 O 
vs O 
. O 
P O 
) O 
, O 
and O 
M O 
+ O 
S O 
1.5 O 
± O 
0.1 O 
mg O 
/ O 
kg O 
⋅ O 
min O 
( O 
P O 
< O 
0.01 O 
vs O 
. O 
P O 
) O 
. O 
Although O 
the O 
EGP O 
slope O 
of O 
decline O 
was O 
faster O 
in O 
M O 
and O 
M O 
+ O 
S O 
vs O 
. O 
S O 
, O 
all O 
had O 
comparable O 
greater O 
post-MTT O 
EGP O 
inhibition O 
vs O 
. O 
P O 
( O 
P O 
< O 
0.05).CONCLUSIONSM+S O 
combined O 
produce O 
additive O 
effects O 
to O 
1 O 
) O 
reduce O 
FPG O 
and O 
postmeal O 
PG O 
, O 
2 O 
) O 
augment O 
GLP-1 O 
secretion O 
and O 
β-cell O 
function O 
, O 
3 O 
) O 
decrease O 
plasma O 
glucagon O 
, O 
and O 
4 O 
) O 
inhibit O 
fasting O 
and O 
postmeal O 
EGP O 
compared O 
with O 
M O 
or O 
S O 
monotherapy O 
. O 

interactions O 
between O 
lecithin O 
and O 
bile B-MULTIPLE 
salts I-MULTIPLE 
/ I-MULTIPLE 
acids I-MULTIPLE 
in O 
oils O 
and O 
their O 
effects O 
on O 
reverse O 
micellization O 
. O 

has O 
been O 
known O 
that O 
the O 
addition O 
of O 
bile B-FAMILY 
salts I-FAMILY 
to O 
lecithin O 
organosols O 
induces O 
the O 
formation O 
of O 
reverse O 
wormlike O 
micelles O 
and O 
that O 
the O 
worms O 
are O 
similar O 
to O 
long O 
polymer O 
chains O 
that O 
entangle O 
each O 
other O 
to O 
form O 
viscoelastic O 
solutions O 
. O 
In O 
this O 
study O 
, O 
we O 
further O 
investigated O 
the O 
effects O 
of O 
different O 
bile B-FAMILY 
salts I-FAMILY 
and O 
bile B-FAMILY 
acids I-FAMILY 
on O 
the O 
growth O 
of O 
lecithin O 
reverse O 
worms O 
in O 
cyclohexane B-SYSTEMATIC 
and O 
n-decane B-SYSTEMATIC 
. O 
We O 
utilized O 
rheological O 
and O 
small O 
- O 
angle O 
scattering O 
techniques O 
to O 
analyze O 
the O 
properties O 
and O 
structures O 
of O 
the O 
reverse O 
micelles O 
. O 
All O 
of O 
the O 
bile B-FAMILY 
salts I-FAMILY 
can O 
transform O 
the O 
originally O 
spherical O 
lecithin O 
reverse O 
micelles O 
into O 
wormlike O 
micelles O 
and O 
their O 
rheological O 
behaviors O 
can O 
be O 
described O 
by O 
the O 
single O 
- O 
relaxation O 
- O 
time O 
Maxwell O 
model O 
. O 
However O 
, O 
their O 
efficiencies O 
to O 
induce O 
the O 
worms O 
are O 
different O 
. O 
In O 
contrast O 
, O 
before O 
phase O 
separation O 
, O 
bile B-FAMILY 
acids I-FAMILY 
can O 
induce O 
only O 
short O 
cylindrical O 
micelles O 
that O 
are O 
not O 
long O 
enough O 
to O 
impart O 
viscoelasticity O 
. O 
We O 
used O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
to O 
investigate O 
the O 
interactions O 
between O 
lecithin O 
and O 
bile B-MULTIPLE 
salts I-MULTIPLE 
/ I-MULTIPLE 
acids I-MULTIPLE 
and O 
found O 
that O 
different O 
bile B-MULTIPLE 
salts I-MULTIPLE 
/ I-MULTIPLE 
acids I-MULTIPLE 
employ O 
different O 
functional O 
groups O 
to O 
form O 
hydrogen B-SYSTEMATIC 
bonds O 
with O 
lecithin O 
. O 
Such O 
effects O 
determine O 
the O 
relative O 
positions O 
of O 
the O 
bile B-MULTIPLE 
salts I-MULTIPLE 
/ I-MULTIPLE 
acids I-MULTIPLE 
in O 
the O 
headgroups O 
of O 
lecithin O 
, O 
thus O 
resulting O 
in O 
varying O 
efficiencies O 
to O 
alter O 
the O 
effective O 
critical O 
packing O 
parameter O 
for O 
the O 
formation O 
of O 
wormlike O 
micelles O 
. O 
This O 
work O 
highlights O 
the O 
importance O 
of O 
intermolecular O 
interactions O 
in O 
molecular O 
self O 
- O 
assembly O 
. O 

9G O 
DNAChip O 
obtained O 
by O 
allowing O 
the O 
formation O 
of O 
a O 
self O 
- O 
assembled O 
monolayer O 
( O 
SAM O 
) O 
of O 
oligonucleotides O 
appended O 
with O 
nine O 
consecutive O 
guanines B-FAMILY 
on O 
the O 
chip O 
surface O 
has O 
been O 
applied O 
in O 
the O 
detection O 
of O 
biomarkers O 
. O 
Using O 
a O 
9G O 
DNAChip O 
, O 
biomarker O 
in O 
the O 
concentration O 
range O 
of O 
4 O 
pg O 
/ O 
mL O 
to O 
40 O 
fg O 
/ O 
mL O 
can O 
be O 
easily O 
differentiated O 
in O 
the O 
buffer O 
matrix O 
. O 
Moreover O 
, O 
it O 
is O 
the O 
first O 
time O 
that O 
a O 
biomarker O 
with O 
a O 
concentration O 
of O 
40 O 
fg O 
/ O 
mL O 
has O 
been O 
detected O 
in O 
a O 
mixture O 
of O 
proteins O 
without O 
use O 
of O 
any O 
signal O 
amplification O 
technique O 
. O 

, O 
properties O 
and O 
cDNA O 
cloning O 
of O 
glutamate B-TRIVIAL 
decarboxylase O 
in O 
germinated O 
faba O 
bean O 
( O 
Vicia O 
faba O 
L O 
. O 
) O 
. O 

acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
is O 
a O 
non O 
- O 
protein O 
amino B-FAMILY 
acid I-FAMILY 
with O 
bioactive O 
functions O 
in O 
humans O 
. O 
In O 
this O 
work O 
, O 
glutamate B-TRIVIAL 
decarboxylase O 
( O 
EC O 
4.1.1.15 O 
, O 
GAD O 
) O 
which O 
is O 
key O 
in O 
the O 
GABA B-ABBREVIATION 
bioformation O 
was O 
purified O 
from O 
5-day O 
germinated O 
faba O 
beans O 
and O 
characterized O 
. O 
A O 
single O 
band O 
was O 
observed O 
at O 
58 O 
kDa O 
using O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
gel O 
electrophoresis O 
. O 
GAD O 
optimal O 
activity O 
was O 
at O 
pH O 
6 O 
at O 
40°C O 
with O 
a O 
K(m) O 
value O 
for O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
( O 
Glu B-FORMULA 
) O 
of O 
2.63 O 
mM O 
. O 
The O 
enzyme O 
was O 
inhibited O 
significantly O 
by O 
Cu(2+) B-FORMULA 
, O 
Fe(3+) B-FORMULA 
, O 
Mg(2+) B-FORMULA 
, O 
Ba(2+) B-FORMULA 
, O 
aminoxyacetate B-SYSTEMATIC 
, O 
EGTA B-ABBREVIATION 
, O 
Na(2)EDTA B-FORMULA 
, O 
l-cysteine B-TRIVIAL 
and O 
beta-mercaptoethanol B-SYSTEMATIC 
; O 
and O 
activated O 
at O 
low O 
Ca(2+) B-FORMULA 
0.2mM O 
. O 
Using O 
RT-PCR O 
, O 
the O 
GAD O 
cDNA O 
was O 
sequenced O 
which O 
indicated O 
1787 O 
bp O 
long O 
, O 
containing O 
a O 
1527 O 
bp O 
open O 
reading O 
frame O 
( O 
ORF O 
) O 
that O 
encoded O 
509 O 
amino-acid B-FAMILY 
peptides O 
with O 
a O 
calculated O 
molecular O 
weight O 
of O 
57.74 O 
kDa O 
and O 
a O 
pI O 
of O 
5.41 O 
( O 
GenBank O 
accession O 
number O 
: O 
JX444699 O 
) O 
. O 

polycystic O 
ovary O 
syndrome O 
, O 
a O 
state O 
of O 
relative O 
estrogen B-FAMILY 
excess O 
, O 
a O 
real O 
risk O 
factor O 
for O 
estrogen B-FAMILY 
-dependant O 
malignancies O 
? O 

ovary O 
syndrome O 
( O 
PCOS O 
) O 
is O 
a O 
common O 
endocrinopathy O 
affecting O 
women O 
of O 
fertile O 
age O 
. O 
It O 
is O 
associated O 
with O 
several O 
risk O 
factors O 
and O 
long O 
- O 
term O 
health O 
consequences O 
. O 
Chronic O 
anovulation O 
combined O 
with O 
relative O 
estrogen B-FAMILY 
excess O 
and O 
consequent O 
prolonged O 
stimulatory O 
effect O 
on O 
the O 
endometrium O 
can O 
lead O 
to O 
the O 
pathogenesis O 
of O 
hormonal O 
dependant O 
carcinoma O 
. O 
PCOS O 
is O 
thus O 
traditionally O 
reported O 
to O 
be O 
associated O 
with O 
increased O 
risk O 
of O 
endometrial O 
, O 
as O 
well O 
as O 
breast O 
and O 
ovarian O 
cancers O 
. O 
This O 
article O 
provides O 
a O 
critical O 
literature O 
review O 
of O 
the O 
relationship O 
between O 
PCOS O 
and O 
the O 
incidence O 
of O 
estrogen B-FAMILY 
-dependant O 
gynecological O 
tumours O 
, O 
and O 
it O 
then O 
discusses O 
whether O 
the O 
commonly O 
cited O 
risk O 
factor O 
association O 
can O 
be O 
substantiated O 
by O 
high O 
quality O 
studies O 
which O 
comply O 
with O 
the O 
requirements O 
of O 
" O 
evidence O 
- O 
based O 
medicine O 
. O 
" O 

vivo O 
and O 
in O 
vitro O 
antioxidant O 
activity O 
and O 
α-glucosidase O 
, O 
α-amylase O 
inhibitory O 
effects O 
of O 
flavonoids B-FAMILY 
from O 
Cichorium O 
glandulosum O 
seeds O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
antioxidant O 
, O 
anti-glucosidase O 
and O 
anti-amylase O 
activities O 
of O 
total O 
flavonoids B-FAMILY 
( O 
TFs O 
) O 
from O 
Cichorium O 
glandulosum O 
seeds O 
, O 
and O 
to O 
analyse O 
its O 
chemical O 
composition O 
by O 
HPLC-ESI O 
/ O 
MS O 
. O 
In O 
vitro O 
study O 
, O 
radical O 
scavenging O 
IC50 O 
values O 
of O 
TFs O 
were O 
7.33±0.093 O 
, O 
9.24±0.100 O 
, O 
154.33±11.38 O 
and O 
256.7±4.86μg O 
/ O 
ml O 
for O 
DPPH B-ABBREVIATION 
, O 
ABTS B-ABBREVIATION 
, O 
hydroxyl B-SYSTEMATIC 
radicals O 
, O 
and O 
superoxide B-TRIVIAL 
anion O 
, O 
respectively O 
. O 
In O 
the O 
8-64mg O 
/ O 
ml O 
range O 
, O 
α-glucosidase O 
and O 
α-amylase O 
were O 
inhibited O 
by O 
TFs O 
to O 
a O 
certain O 
extent O 
. O 
In O 
vivo O 
, O 
the O 
treatment O 
groups O 
with O 
TFs O 
( O 
100 O 
, O 
200 O 
, O 
400mg O 
/ O 
kg O 
) O 
showed O 
a O 
significant O 
decrease O 
in O 
the O 
malondialdehyde B-TRIVIAL 
level O 
, O 
the O 
superoxide B-TRIVIAL 
dismutase O 
and O 
glutathione B-TRIVIAL 
levels O 
were O 
restored O 
to O 
almost O 
normal O 
levels O 
, O 
and O 
the O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
levels O 
significantly O 
increased O 
compared O 
to O 
the O 
CCl4 B-FORMULA 
-intoxicated O 
group O 
in O 
rats O 
. O 
The O 
present O 
study O 
suggests O 
that O 
C O 
. O 
glandulosum O 
seeds O 
should O 
be O 
given O 
special O 
attention O 
because O 
of O 
their O 
antioxidant O 
and O 
anti-glucosidase O 
, O 
anti-amylase O 
activity O 
. O 

Objective O 
: O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
develop O 
a O 
nanoemulsion O 
formulation O 
for O 
its O 
use O 
as O 
a O 
transcutaneous O 
vaccine O 
delivery O 
system O 
. O 
Materials O 
and O 
methods O 
: O 
With O 
bovine O 
albumin- O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
conjugate O 
( O 
FITC B-ABBREVIATION 
-BSA O 
) O 
as O 
a O 
vaccine O 
model O 
, O 
formulations O 
were O 
selected O 
with O 
the O 
construction O 
of O 
pseudo O 
- O 
ternary O 
phase O 
diagrams O 
and O 
a O 
short O 
- O 
term O 
stability O 
study O 
. O 
The O 
size O 
of O 
the O 
emulsion O 
droplets O 
was O 
furthered O 
optimized O 
with O 
high O 
- O 
pressure O 
homogenization O 
. O 
The O 
optimized O 
formulation O 
was O 
evaluated O 
for O 
its O 
skin O 
permeation O 
efficiency O 
. O 
In O 
vitro O 
skin O 
permeation O 
studies O 
were O 
conducted O 
with O 
shaved O 
BALB O 
/ O 
c O 
mice O 
skin O 
samples O 
with O 
a O 
Franz O 
diffusion O 
cell O 
system O 
. O 
Different O 
drug O 
concentrations O 
were O 
compared O 
, O 
and O 
the O 
effect O 
of O 
the O 
nanoemulsion O 
excipients O 
on O 
the O 
permeation O 
of O 
the O 
FITC B-ABBREVIATION 
-BSA O 
was O 
also O 
studied O 
. O 
Results O 
: O 
The O 
optimum O 
homogenization O 
regime O 
was O 
determined O 
to O 
be O 
five O 
passes O 
at O 
20 O 
0 O 
psi O 
, O 
with O 
no O 
evidence O 
of O 
protein O 
degradation O 
during O 
processing O 
. O 
With O 
these O 
conditions O 
, O 
the O 
particle O 
diameter O 
was O 
85.2 O 
nm O 
± O 
15.5 O 
nm O 
with O 
a O 
polydispersity O 
index O 
of O 
0.186 O 
± O 
0.026 O 
and O 
viscosity O 
of O 
14.6 O 
cP O 
± O 
1.2 O 
cP O 
. O 
The O 
optimized O 
formulation O 
proved O 
stable O 
for O 
1 O 
year O 
at O 
4 O 
°C O 
. O 
In O 
vitro O 
skin O 
diffusion O 
studies O 
show O 
that O 
the O 
optimized O 
formulation O 
improves O 
the O 
permeation O 
of O 
FITC B-ABBREVIATION 
-BSA O 
through O 
skin O 
with O 
an O 
enhancement O 
ratio O 
of O 
4.2 O 
compared O 
to O 
a O 
neat O 
control O 
solution O 
. O 
Finally O 
, O 
a O 
comparison O 
of O 
the O 
skin O 
permeation O 
of O 
the O 
nanoemulsion O 
versus O 
only O 
the O 
surfactant O 
excipients O 
resulted O 
in O 
a O 
steady O 
state O 
flux O 
of O 
23.44 O 
μg O 
/ O 
cm(2) O 
/ O 
h O 
for O 
the O 
nanoemulsion O 
as O 
opposed O 
to O 
6.1 O 
μg O 
/ O 
cm(2) O 
/ O 
h O 
for O 
the O 
emulsifiers O 
. O 
Conclusion O 
: O 
A O 
novel O 
nanoemulsion O 
with O 
optimized O 
physical O 
characteristics O 
and O 
superior O 
skin O 
permeation O 
compared O 
to O 
control O 
solution O 
was O 
manufactured O 
. O 
The O 
formulation O 
proposed O 
in O 
this O 
study O 
has O 
the O 
flexibility O 
for O 
the O 
incorporation O 
of O 
a O 
variety O 
of O 
active O 
ingredients O 
and O 
warrants O 
further O 
development O 
as O 
a O 
transcutaneous O 
vaccine O 
delivery O 
vehicle O 
. O 

incidence O 
of O 
thyroid O 
carcinoma O 
has O 
increased O 
steadily O 
over O 
the O 
last O 
few O 
decades O 
. O 
Most O 
differentiated O 
thyroid O 
carcinomas O 
( O 
DTC O 
) O 
are O 
cured O 
thanks O 
to O 
the O 
initial O 
treatment O 
with O 
surgery O 
and O 
radioiodine B-SYSTEMATIC 
therapy O 
. O 
Nevertheless O 
, O 
neck O 
lymph O 
node O 
metastases O 
are O 
found O 
in O 
a O 
few O 
of O 
these O 
patients O 
during O 
their O 
long O 
- O 
term O 
clinical O 
and O 
ultrasound O 
follow O 
- O 
up O 
. O 
In O 
some O 
of O 
these O 
cases O 
radioiodine B-SYSTEMATIC 
treatment O 
may O 
not O 
be O 
effective O 
in O 
eradicating O 
nodal O 
metastases O 
due O 
to O 
scant O 
131-I B-FORMULA 
uptake O 
. O 
Additionally O 
, O 
a O 
few O 
of O 
these O 
patients O 
undergo O 
repeated O 
neck O 
explorations O 
and O 
/ O 
or O 
resections O 
. O 
Based O 
on O 
these O 
considerations O 
and O 
on O 
the O 
frequently O 
indolent O 
course O 
of O 
DTC O 
neck O 
metastases O 
, O 
a O 
non-surgical O 
therapeutic O 
approach O 
should O 
be O 
considered O 
to O 
control O 
small O 
local O 
foci O 
of O 
DTC O 
. O 
There O 
is O 
increasing O 
interest O 
in O 
mini O 
- O 
invasive O 
image O 
- O 
guided O 
procedures O 
that O 
can O 
be O 
performed O 
under O 
local O 
anesthesia O 
which O 
do O 
not O 
affect O 
the O 
performance O 
status O 
of O 
the O 
patient O 
. O 
Image O 
- O 
guided O 
minimally O 
invasive O 
ablative O 
therapies O 
delivered O 
by O 
using O 
needle O 
- O 
like O 
applicators O 
include O 
both O 
thermal O 
and O 
non O 
- O 
thermal O 
source O 
techniques O 
. O 
Over O 
the O 
past O 
25 O 
years O 
, O 
these O 
therapies O 
have O 
gained O 
widespread O 
attention O 
and O 
, O 
in O 
many O 
cases O 
, O 
broad O 
clinical O 
acceptance O 
as O 
methods O 
for O 
treating O 
focal O 
malignancies O 
. O 
In O 
an O 
attempt O 
to O 
overcome O 
the O 
limitations O 
of O 
treating O 
certain O 
unresectable O 
tumor O 
types O 
not O 
amenable O 
to O 
a O 
further O 
surgical O 
treatment O 
, O 
a O 
few O 
investigators O 
have O 
reported O 
successfully O 
combining O 
percutaneous O 
therapies O 
with O 
other O 
oncologic O 
treatment O 
strategies O 
( O 
combined O 
treatments O 
) O 
. O 
In O 
this O 
review O 
, O 
we O 
reported O 
mini O 
- O 
invasive O 
techniques O 
more O 
commonly O 
employed O 
in O 
selected O 
cases O 
to O 
ameliorate O 
local O 
compressive O 
symptoms O 
, O 
control O 
hormonal O 
production O 
, O 
and O 
reduce O 
the O 
volume O 
of O 
neoplastic O 
tissue O 
prior O 
to O 
traditional O 
palliative O 
treatment O 
. O 

mesoporous O 
SiO2 B-FORMULA 
nanoparticles O 
for O 
the O 
DNAzyme O 
- O 
induced O 
multiplexed O 
release O 
of O 
substrates O 
. O 

fluorescent O 
dyes O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
, O 
MB(+) O 
, O 
and O 
thionine B-TRIVIAL 
, O 
Th(+) O 
, O 
can O 
be O 
trapped O 
in O 
the O 
pores O 
of O 
mesoporous O 
silica B-TRIVIAL 
, O 
MP- O 
SiO(2) B-FORMULA 
, O 
by O 
means O 
of O 
functional O 
nanostructures O 
consisting O 
of O 
the O 
Mg(2+) B-FORMULA 
- O 
or O 
Zn(2+) B-FORMULA 
-dependent O 
DNAzyme O 
sequences O 
. O 
In O 
the O 
presence O 
of O 
Mg(2+) B-FORMULA 
or O 
Zn(2+) B-FORMULA 
ions O 
the O 
respective O 
DNAzymes O 
are O 
activated O 
, O 
leading O 
to O 
the O 
specific O 
cleavage O 
of O 
the O 
respective O 
caps O 
, O 
and O 
the O 
selective O 
release O 
of O 
MB(+) O 
or O 
Th(+) O 
. O 
The O 
enlargement O 
of O 
the O 
conserved O 
loop O 
domains O 
of O 
the O 
Mg(2+) B-FORMULA 
- O 
or O 
Zn(2+) B-FORMULA 
-dependent O 
DNAzyme O 
sequences O 
with O 
foreign O 
nucleotides B-FAMILY 
prohibits O 
the O 
formation O 
of O 
active O 
DNAzymes O 
and O 
eliminates O 
the O 
release O 
of O 
the O 
respective O 
dyes O 
. O 
This O 
is O 
due O 
to O 
the O 
flexibility O 
of O 
the O 
loops O 
that O 
lacks O 
affinity O 
for O 
the O 
association O 
of O 
the O 
ions O 
. O 
The O 
insertion O 
of O 
aptamer O 
sequences O 
( O 
e.g O 
. O 
, O 
the O 
adenosine-5'-triphosphate B-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
aptamer O 
) O 
or O 
ion O 
- O 
binding O 
sequences O 
( O 
e.g O 
. O 
, O 
T-rich O 
Hg(2+) B-FORMULA 
ion O 
- O 
binding O 
domains O 
) O 
as O 
foreign O 
components O 
to O 
the O 
loop O 
regions O 
allows O 
the O 
formation O 
of O 
active O 
Mg(2+) B-FORMULA 
- O 
or O 
Zn(2+) B-FORMULA 
-dependent O 
DNAzyme O 
structures O 
through O 
the O 
cooperative O 
formation O 
of O 
aptamer- O 
ATP B-ABBREVIATION 
complexes O 
or O 
T- O 
Hg(2+) B-FORMULA 
-T O 
bridges O 
. O 
These O 
aptamer O 
- O 
substrate O 
complexes O 
or O 
T- O 
Hg(2+) B-FORMULA 
-T O 
bridges O 
allosterically O 
stabilize O 
and O 
activate O 
the O 
DNAzymes O 
, O 
thus O 
allowing O 
the O 
selective O 
release O 
of O 
the O 
fluorescent O 
substrates O 
MB(+) O 
or O 
Th(+) O 
. O 
The O 
metal O 
ion O 
- O 
driven O 
DNAzyme O 
release O 
of O 
substrates O 
from O 
the O 
pores O 
of O 
MP- O 
SiO(2) B-FORMULA 
, O 
and O 
particularly O 
the O 
allosteric O 
activation O 
of O 
the O 
DNAzymes O 
through O 
cooperative O 
aptamer O 
- O 
substrate O 
complexes O 
or O 
metal O 
- O 
ion O 
bridges O 
, O 
has O 
important O 
future O 
nanomedical O 
implications O 
for O 
targeted O 
release O 
of O 
drugs O 
. O 
This O 
is O 
demonstrated O 
with O 
the O 
triggered O 
release O 
of O 
the O 
anticancer O 
drug O 
, O 
doxorubicin B-TRIVIAL 
, O 
by O 
the O 
Mg(2+) B-FORMULA 
-DNAzyme O 
- O 
locked O 
pores O 
or O 
by O 
the O 
aptamer- O 
ATP B-ABBREVIATION 
complex O 
- O 
triggered O 
activation O 
of O 
the O 
Mg(2+) B-FORMULA 
-dependent O 
DNAzyme O 
. O 

NAD+ B-ABBREVIATION 
-dependent O 
deacetylases O 
Sirt1 O 
and O 
Sirt2 O 
mediate O 
cellular O 
stress O 
responses O 
and O 
are O 
highly O 
expressed O 
in O 
vascular O 
endothelial O 
cells O 
. O 
In O 
contrast O 
to O 
the O 
well O 
- O 
documented O 
protective O 
actions O 
of O 
Sirt1 O 
, O 
the O 
role O 
of O 
endothelial O 
Sirt2 O 
remains O 
unknown O 
. O 
Using O 
cDNA O 
microarray O 
and O 
PCR O 
validation O 
, O 
we O 
examined O 
global O 
gene O 
expression O 
changes O 
in O 
response O 
to O 
Sirt2 O 
knock O 
down O 
in O 
primary O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
under O 
oxidative O 
stress O 
. O 
We O 
found O 
that O 
Sirt2 O 
knock O 
down O 
changed O 
expression O 
of O 
340 O 
genes O 
, O 
which O 
are O 
mainly O 
involved O 
in O 
cellular O 
processes O 
including O 
actin O 
binding O 
, O 
cellular O 
amino B-FAMILY 
acid I-FAMILY 
metabolic O 
process O 
, O 
transmembrane O 
receptor O 
protein O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
signaling O 
, O 
ferrous B-SYSTEMATIC 
iron I-SYSTEMATIC 
transport O 
, O 
protein O 
transport O 
and O 
localization O 
, O 
cell O 
morphogenesis O 
, O 
and O 
functions O 
associated O 
with O 
endosome O 
membrane O 
and O 
the O 
trans-Golgi O 
network O 
. O 
These O 
genes O 
and O 
associated O 
functions O 
were O 
largely O 
non-overlapping O 
with O 
those O 
altered O 
by O 
Sirt1 O 
knock O 
down O 
. O 
Moreover O 
, O 
we O 
showed O 
that O 
pharmacological O 
inhibition O 
of O 
Sirt2 O 
attenuated O 
oxidant O 
- O 
induced O 
cell O 
toxicity O 
in O 
endothelial O 
cells O 
. O 
These O 
suggest O 
that O 
Sirt2 O 
is O 
functionally O 
important O 
in O 
endothelial O 
cells O 
under O 
oxidative O 
stress O 
, O 
and O 
may O 
have O 
a O 
primarily O 
distinct O 
role O 
as O 
compared O 
to O 
Sirt1 O 
. O 
Our O 
results O 
may O 
provide O 
a O 
basis O 
for O 
future O 
studies O 
aiming O 
to O 
dissect O 
the O 
specific O 
signaling O 
pathway(s) O 
that O 
mediates O 
specific O 
Sirt2 O 
functions O 
in O 
endothelial O 
cells O 
. O 

is O 
increasing O 
awareness O 
that O 
the O 
negative O 
effects O 
of O 
anthropogenic O 
stressors O 
may O 
be O 
magnified O 
in O 
the O 
presence O 
of O 
natural O 
stressors O 
. O 
Very O 
few O 
of O 
these O 
studies O 
have O 
included O 
physiology O 
, O 
yet O 
including O 
physiological O 
studies O 
may O 
help O 
learning O 
about O 
the O 
mechanistic O 
base O 
of O 
such O 
synergisms O 
at O 
the O 
life O 
history O 
level O 
and O 
identify O 
synergistic O 
interactions O 
not O 
translated O 
in O 
life O 
history O 
traits O 
. O 
We O 
studied O 
in O 
Enallagma O 
cyathigerum O 
damselfly O 
larvae O 
potential O 
synergistic O 
effects O 
between O 
exposure O 
to O 
the O 
pesticide O 
glyphosate B-TRIVIAL 
and O 
predator O 
cues O 
on O 
a O 
key O 
life O 
history O 
trait O 
, O 
growth O 
rate O 
, O 
its O 
associated O 
behavioural O 
trait O 
, O 
food O 
intake O 
, O 
and O 
three O 
types O 
of O 
physiological O 
traits O 
known O 
to O 
be O 
affected O 
by O 
both O 
stressors O 
in O 
isolation O 
: O 
the O 
stress O 
protein O 
Hsp70 O 
, O 
energy O 
storage O 
and O 
variables O 
related O 
to O 
oxidative O 
stress O 
and O 
damage O 
. O 
The O 
pesticide O 
and O 
predator O 
cues O 
reduced O 
growth O 
rate O 
in O 
an O 
additive O 
way O 
. O 
Food O 
intake O 
increased O 
under O 
pesticide O 
exposure O 
and O 
was O 
not O 
affected O 
by O 
the O 
predator O 
cues O 
, O 
indicating O 
physiological O 
mediation O 
of O 
the O 
growth O 
reduction O 
. O 
One O 
potential O 
physiological O 
mechanism O 
was O 
that O 
both O 
stressors O 
additively O 
increased O 
Hsp70 O 
levels O 
, O 
this O 
may O 
also O 
have O 
contributed O 
to O 
the O 
reduced O 
levels O 
of O 
total O 
carbohydrates B-FAMILY 
when O 
exposed O 
to O 
predator O 
cues O 
. O 
Chronic O 
exposure O 
to O 
predator O 
cues O 
reduced O 
oxygen B-SYSTEMATIC 
consumption O 
, O 
possibly O 
to O 
avoid O 
too O 
high O 
costs O 
of O 
an O 
increased O 
metabolic O 
rate O 
. O 
This O 
reduction O 
did O 
not O 
occur O 
in O 
the O 
presence O 
of O 
the O 
pesticide O 
, O 
reflecting O 
the O 
need O 
for O 
energetically O 
expensive O 
defence O 
mechanisms O 
( O 
such O 
as O 
Hsp70 O 
upregulation O 
) O 
. O 
When O 
both O 
stressors O 
were O 
combined O 
, O 
there O 
was O 
a O 
reduction O 
of O 
the O 
antioxidant O 
enzyme O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
( O 
SOD O 
) O 
and O 
an O 
associated O 
increase O 
of O 
oxidative O 
damage O 
in O 
lipids O 
. O 
While O 
synergistic O 
interactions O 
were O 
not O 
present O 
for O 
growth O 
rate O 
and O 
food O 
intake O 
, O 
they O 
were O 
identified O 
for O 
antioxidant O 
defence O 
and O 
oxidative O 
damage O 
. O 
This O 
novel O 
type O 
of O 
" O 
hidden O 
" O 
synergistic O 
interaction O 
may O 
have O 
profound O 
fitness O 
implications O 
, O 
and O 
when O 
ignored O 
will O 
lead O 
to O 
underestimations O 
of O 
the O 
impact O 
of O 
pollutants O 
in O 
natural O 
populations O 
where O 
predators O 
are O 
omnipresent O 
. O 

antagonizes O 
the O 
in O 
vivo O 
myotoxic O 
and O 
inflammatory O 
effects O 
of O 
Bothrops O 
venoms O 
. O 

the O 
present O 
work O 
we O 
investigated O 
the O 
toxic O 
activities O 
of O 
two O 
Bothrops O 
snake O 
venoms O 
using O 
in O 
vivo O 
and O 
in O 
vitro O 
experimental O 
protocols O 
in O 
mice O 
and O 
tested O 
the O 
protective O 
effect O 
of O 
dexamethasone B-TRIVIAL 
( O 
DEXA B-ABBREVIATION 
) O 
in O 
different O 
conditions O 
, O 
comparing O 
it O 
with O 
the O 
polyvalent O 
antivenom O 
. O 
We O 
also O 
expanded O 
the O 
investigations O 
on O 
the O 
antiophidic O 
effect O 
of O 
the O 
Eclipta O 
prostrata O 
( O 
EP O 
) O 
crude O 
extract O 
. O 
The O 
administration O 
of O 
Bothrops O 
jararaca O 
and O 
Bothrops O 
jararacussu O 
snake O 
venoms O 
induced O 
muscle O 
damage O 
demonstrated O 
in O 
vivo O 
by O 
the O 
elevation O 
on O 
plasma O 
creatine B-TRIVIAL 
kinase O 
( O 
CK O 
) O 
activity O 
in O 
mice O 
and O 
by O 
the O 
decrease O 
in O 
CK O 
content O 
in O 
the O 
extensor O 
digitorum O 
longus O 
( O 
EDL O 
) O 
muscle O 
of O 
these O 
animals O 
, O 
and O 
in O 
vitro O 
by O 
the O 
increase O 
in O 
the O 
rate O 
of O 
CK O 
release O 
from O 
the O 
isolated O 
EDL O 
muscle O 
. O 
We O 
also O 
observed O 
inflammatory O 
response O 
following O 
perimuscular O 
injection O 
of O 
B O 
. O 
jararacussu O 
venom O 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
. O 
Treatment O 
with O 
DEXA B-ABBREVIATION 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
preserved O 
over O 
50% O 
of O 
the O 
EDL O 
muscle O 
CK O 
content O 
in O 
vivo O 
when O 
evaluated O 
24 O 
and O 
72 O 
h O 
after O 
the O 
injection O 
of O 
B O 
. O 
jararacussu O 
venom O 
in O 
mice O 
, O 
and O 
likewise O 
reduced O 
about O 
20% O 
of O 
the O 
edema O 
induced O 
by O 
this O 
venom O 
. O 
DEXA B-ABBREVIATION 
reduced O 
in O 
50% O 
the O 
presence O 
of O 
inflammatory O 
cells O 
and O 
their O 
activity O 
in O 
EDL O 
muscle O 
. O 
The O 
EP O 
extract O 
( O 
50 O 
mg O 
/ O 
kg O 
) O 
showed O 
similar O 
ability O 
in O 
preventing O 
the O 
induction O 
of O 
edema O 
and O 
the O 
decrease O 
in O 
muscle O 
CK O 
content O 
, O 
and O 
its O 
association O 
with O 
DEXA B-ABBREVIATION 
showed O 
additive O 
effect O 
. O 
EP O 
reduced O 
over O 
77% O 
of O 
the O 
plasma O 
CK O 
activity O 
induced O 
by O 
the O 
B O 
. O 
jararacussu O 
venom O 
. O 
In O 
the O 
in O 
vitro O 
experiments O 
, O 
DEXA B-ABBREVIATION 
was O 
not O 
able O 
to O 
change O 
the O 
rate O 
of O 
CK O 
release O 
from O 
EDL O 
muscles O 
exposed O 
to O 
25 O 
μg O 
/ O 
mL O 
of O 
B O 
. O 
jararacussu O 
venom O 
, O 
neither O 
to O 
prevent O 
the O 
fall O 
in O 
the O 
amplitude O 
of O 
the O 
indirectly O 
evoked O 
twitch O 
at O 
the O 
phrenic O 
- O 
diaphragm O 
preparation O 
. O 
EP O 
extract O 
showed O 
otherwise O 
a O 
protective O 
effect O 
on O 
these O 
protocols O 
, O 
reaching O 
up O 
to O 
100% O 
of O 
protection O 
when O 
concentrations O 
of O 
50 O 
and O 
100 O 
μg O 
/ O 
mL O 
were O 
used O 
. O 
Altogether O 
our O 
results O 
show O 
that O 
inflammation O 
is O 
at O 
least O 
in O 
part O 
responsible O 
for O 
the O 
tissue O 
damage O 
induced O 
by O 
Bothrops O 
snake O 
venoms O 
, O 
once O 
the O 
steroidal O 
anti-inflammatory O 
drug O 
dexamethasone B-TRIVIAL 
was O 
able O 
to O 
decrease O 
the O 
myotoxic O 
effects O 
of O 
these O 
venoms O 
, O 
by O 
reducing O 
the O 
inflammatory O 
response O 
to O 
the O 
venom O 
injection O 
. O 

( O 
5-IAI B-SYSTEMATIC 
) O 
: O 
chemistry O 
, O 
pharmacology O 
, O 
and O 
toxicology O 
of O 
a O 
research O 
chemical O 
producing O 
MDMA B-ABBREVIATION 
-like O 
effects O 
. O 

2010 O 
, O 
an O 
internet O 
snapshot O 
of O 
EMCDDA O 
anticipated O 
the O 
presence O 
of O 
5-iodo-2-aminoindan B-SYSTEMATIC 
( O 
5-IAI B-SYSTEMATIC 
) O 
within O 
the O 
recreational O 
drug O 
market O 
. O 
In O 
2011 O 
, O 
this O 
compound O 
, O 
a O 
psychoactive O 
derivative O 
of O 
2-aminoindane B-SYSTEMATIC 
, O 
was O 
identified O 
in O 
recreational O 
products O 
sold O 
in O 
the O 
United O 
Kingdom O 
. O 
5-IAI B-SYSTEMATIC 
is O 
a O 
rigid O 
analogue O 
of O 
p-iodoamphetamine B-SYSTEMATIC 
producing O 
MDMA B-ABBREVIATION 
-like O 
effects O 
. O 
The O 
aim O 
of O 
this O 
paper O 
is O 
to O 
summarize O 
the O 
clinical O 
, O 
pharmacological O 
, O 
and O 
toxicological O 
information O 
about O 
this O 
new O 
potential O 
drug O 
of O 
abuse O 
. O 

dimethylarginine I-SYSTEMATIC 
predicts O 
decline O 
of O 
glucose B-TRIVIAL 
tolerance O 
in O 
men O 
with O 
stable O 
coronary O 
artery O 
disease O 
: O 
a O 
4.5-year O 
follow O 
- O 
up O 
study O 
. O 

: O 
Endothelial O 
dysfunction O 
, O 
largely O 
dependent O 
on O 
impaired O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
bioavailability O 
, O 
has O 
been O 
reportedly O 
associated O 
with O 
incident O 
type O 
2 O 
diabetes O 
. O 
Our O 
aim O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
asymmetric B-SYSTEMATIC 
dimethylarginine I-SYSTEMATIC 
( O 
ADMA B-ABBREVIATION 
) O 
, O 
an O 
endogenous O 
inhibitor O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
formation O 
, O 
might O 
be O 
linked O 
to O 
future O 
deterioration O 
in O 
glucose B-TRIVIAL 
tolerance O 
in O 
stable O 
coronary O 
artery O 
disease O 
( O 
CAD O 
) O 
. O 
METHODS O 
: O 
We O 
studied O 
80 O 
non-diabetic O 
men O 
( O 
mean O 
age O 
55 O 
+ O 
/ O 
- O 
11 O 
years O 
) O 
with O 
stable O 
angina O 
who O 
underwent O 
successful O 
elective O 
complex O 
coronary O 
angioplasty O 
and O 
were O 
receiving O 
a O 
standard O 
medical O 
according O 
to O 
practice O 
guidelines O 
. O 
Plasma O 
ADMA B-ABBREVIATION 
and O 
its O 
structural O 
isomer O 
symmetric B-SYSTEMATIC 
dimethylarginine I-SYSTEMATIC 
( O 
SDMA B-ABBREVIATION 
) O 
were O 
measured O 
prior O 
to O 
coronary O 
angiography O 
. O 
An O 
estimate O 
of O 
insulin O 
resistance O 
by O 
homeostasis O 
model O 
assessment O 
( O 
HOMA-IR O 
index O 
) O 
was O 
calculated O 
from O 
fasting O 
insulin O 
and O 
glucose B-TRIVIAL 
. O 
Deterioration O 
in O 
glucose B-TRIVIAL 
tolerance O 
was O 
defined O 
as O 
development O 
of O 
type O 
2 O 
diabetes O 
or O 
progression O 
from O 
a O 
normal O 
glucose B-TRIVIAL 
tolerance O 
to O 
impaired O 
fasting O 
glucose B-TRIVIAL 
. O 
RESULTS O 
: O 
Over O 
a O 
median O 
follow O 
- O 
up O 
of O 
55 O 
months O 
11 O 
subjects O 
developed O 
type O 
2 O 
diabetes O 
and O 
13 O 
progressed O 
to O 
impaired O 
fasting O 
glucose B-TRIVIAL 
. O 
Incident O 
deterioration O 
of O 
glucose B-TRIVIAL 
tolerance O 
was O 
associated O 
with O 
ADMA B-ABBREVIATION 
( O 
hazard O 
ratio O 
[ O 
HR O 
] O 
per O 
1-SD O 
increment O 
1.64 O 
[ O 
95% O 
CI O 
: O 
1.14 O 
-- O 
2.35 O 
] O 
; O 
P O 
= O 
0.007 O 
) O 
, O 
log O 
( O 
HOMA-IR O 
index O 
) O 
( O 
HR O 
= O 
1.6 O 
[ O 
1.16 O 
-- O 
2.2 O 
] O 
; O 
P O 
= O 
0.004 O 
) O 
and O 
body O 
- O 
mass O 
index O 
( O 
HR O 
= O 
1.44 O 
[ O 
0.95 O 
-- O 
2.17 O 
] O 
; O 
P O 
= O 
0.08 O 
) O 
by O 
univariate O 
Cox O 
regression O 
. O 
ADMA B-ABBREVIATION 
( O 
HR O 
= O 
1.65 O 
[ O 
1.14 O 
-- O 
2.38 O 
] O 
; O 
p O 
= O 
0.008 O 
) O 
and O 
log O 
( O 
HOMA-IR O 
index O 
) O 
( O 
HR O 
= O 
1.55 O 
[ O 
1.1 O 
-- O 
2.17 O 
] O 
; O 
P O 
= O 
0.01 O 
) O 
were O 
multivariate O 
predictors O 
of O 
a O 
decline O 
in O 
glucose B-TRIVIAL 
tolerance O 
. O 
ADMA B-ABBREVIATION 
and O 
SDMA B-ABBREVIATION 
were O 
unrelated O 
to O 
body O 
- O 
mass O 
index O 
, O 
HOMA-IR O 
index O 
, O 
insulin O 
or O 
glucose B-TRIVIAL 
. O 
CONCLUSIONS O 
: O 
ADMA B-ABBREVIATION 
predicts O 
future O 
deterioration O 
of O 
glucose B-TRIVIAL 
tolerance O 
independently O 
of O 
baseline O 
insulin O 
resistance O 
in O 
men O 
with O 
stable O 
CAD O 
. O 
Whether O 
this O 
association O 
reflects O 
a O 
contribution O 
of O 
endothelial O 
dysfunction O 
to O 
accelerated O 
decline O 
of O 
insulin O 
sensitivity O 
, O 
or O 
represents O 
only O 
an O 
epiphenomenon O 
accompanying O 
pre O 
- O 
diabetes O 
, O 
remains O 
to O 
be O 
elucidated O 
. O 
The O 
observed O 
relationship O 
might O 
contribute O 
to O 
the O 
well O 
- O 
recognized O 
ability O 
of O 
ADMA B-ABBREVIATION 
to O 
predict O 
cardiovascular O 
outcome O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
relationship O 
between O 
oxidative O 
stress O 
and O 
chronic O 
daily O 
headache O 
( O 
CDH O 
) O 
in O 
children O 
. O 
Although O 
there O 
are O 
reports O 
that O 
oxidative O 
injury O 
may O 
play O 
a O 
role O 
in O 
the O 
pathophysiology O 
of O 
some O 
neurologic O 
disorders O 
, O 
such O 
as O 
migraine O 
and O 
epilepsy O 
, O 
by O 
disrupting O 
or O 
destroying O 
cell O 
membranes O 
through O 
the O 
formation O 
of O 
free O 
radical O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
the O 
pathophysiology O 
of O 
headache O 
is O 
not O 
clearly O 
established O 
. O 
A O 
total O 
of O 
38 O 
children O 
( O 
16 O 
boys O 
and O 
22 O 
girls O 
) O 
with O 
CDH O 
, O 
aged O 
between O 
7 O 
and O 
15 O 
years O 
, O 
were O 
enrolled O 
in O 
the O 
study O 
. O 
The O 
control O 
group O 
consisted O 
of O 
39 O 
healthy O 
children O 
( O 
17 O 
boys O 
and O 
22 O 
girls O 
) O 
, O 
aged O 
between O 
7 O 
and O 
14 O 
years O 
. O 
The O 
mean O 
age O 
was O 
10.9 O 
± O 
2.2 O 
years O 
for O 
both O 
the O 
groups O 
. O 
Activities O 
of O 
erythrocyte O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
as O 
well O 
as O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
in O 
all O 
the O 
children O 
of O 
both O 
the O 
groups O 
were O 
measured O 
. O 
Mean O 
activities O 
of O 
erythrocyte O 
SOD O 
, O 
CAT O 
, O 
and O 
GPx O 
as O 
well O 
as O 
MDA B-ABBREVIATION 
levels O 
were O 
significantly O 
higher O 
in O 
the O 
study O 
group O 
than O 
in O 
the O 
control O 
group O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
The O 
findings O 
of O 
this O 
study O 
suggest O 
that O 
oxidative O 
stress O 
may O 
play O 
a O 
causal O 
or O 
consequential O 
role O 
in O 
children O 
with O 
CDH O 
. O 

-conjugated O 
and O 
hyperbranched O 
polyglycerol B-FAMILY 
-grafted O 
Fe₃O₄ B-FORMULA 
magnetic O 
nanoparticles O 
for O 
targeted O 
anticancer O 
effects O 
. O 

nanoparticles O 
grafted O 
with O 
hyperbranched O 
polyglycerol B-FAMILY 
( O 
HPG O 
) O 
and O 
conjugated O 
with O 
methotrexate B-TRIVIAL 
( O 
MTX B-ABBREVIATION 
) O 
( O 
MNP-g-HPG- O 
MTX B-ABBREVIATION 
) O 
were O 
synthesized O 
via O 
a O 
sol O 
- O 
gel O 
reaction O 
followed O 
by O 
thiol B-FAMILY 
- I-FAMILY 
ene I-FAMILY 
click O 
chemistry O 
and O 
esterification O 
reaction O 
. O 
The O 
successful O 
grafting O 
of O 
MTX B-ABBREVIATION 
and O 
HPG O 
onto O 
the O 
nanoparticles O 
was O 
confirmed O 
by O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
, O 
Fourier O 
transform O 
infrared O 
( O 
FT-IR O 
) O 
spectroscopy O 
, O 
and O 
UV-visible O 
spectroscopy O 
. O 
The O 
HPG-graft O 
layer O 
confers O 
the O 
magnetic O 
nanoparticles O 
with O 
good O 
dispersibility O 
and O 
stability O 
in O 
aqueous O 
medium O 
and O 
macrophage O 
- O 
evasive O 
property O 
while O 
the O 
MTX B-ABBREVIATION 
acts O 
as O 
a O 
chemotherapeutic O 
drug O 
as O 
well O 
as O 
a O 
tumor O 
targeting O 
ligand O 
. O 
The O 
dose O 
- O 
dependent O 
targeting O 
and O 
anticancer O 
effect O 
of O 
the O 
MNP-g-HPG- O 
MTX B-ABBREVIATION 
nanoparticles O 
were O 
evaluated O 
, O 
and O 
the O 
results O 
showed O 
that O 
depending O 
on O 
the O 
amount O 
of O 
conjugated O 
MTX B-ABBREVIATION 
and O 
the O 
concentration O 
of O 
the O 
incubated O 
nanoparticles O 
, O 
the O 
uptake O 
of O 
MNP-g-HPG- O 
MTX B-ABBREVIATION 
nanoparticles O 
by O 
human O 
head O 
and O 
neck O 
cancer O 
( O 
KB O 
) O 
cells O 
can O 
be O 
eight O 
times O 
or O 
more O 
higher O 
than O 
those O 
by O 
3T3 O 
fibroblasts O 
and O 
RAW O 
macrophages O 
. O 
As O 
a O 
result O 
, O 
the O 
MNP-g-HPG- O 
MTX B-ABBREVIATION 
nanoparticles O 
are O 
capable O 
of O 
killing O 
∼50% O 
of O 
the O 
KB O 
cells O 
while O 
at O 
the O 
same O 
time O 
exhibiting O 
low O 
cytotoxicity O 
towards O 
3T3 O 
fibroblasts O 
and O 
RAW O 
macrophages O 
. O 
Thus O 
, O 
such O 
nanoparticles O 
can O 
potentially O 
be O 
used O 
as O 
active O 
targeting O 
anticancer O 
agents O 
. O 

must O 
react O 
with O 
cellular O 
proteins O 
to O 
be O 
recognized O 
by O 
antigen O 
presenting O 
cells O 
. O 
Therefore O 
, O 
monitoring O 
reactivity O 
of O 
chemicals O 
with O 
peptide O 
/ O 
protein O 
has O 
been O 
considered O 
an O 
in O 
vitro O 
skin O 
sensitization O 
testing O 
method O 
. O 
The O 
reactivity O 
of O 
peptides O 
with O 
chemicals O 
( O 
peptide O 
reactivity O 
) O 
has O 
usually O 
been O 
monitored O 
by O 
chromatographic O 
methods O 
like O 
HPLC O 
or O 
LC O 
/ O 
MS O 
, O 
which O 
are O 
robust O 
tools O 
for O 
monitoring O 
common O 
chemical O 
reactions O 
but O 
are O 
rather O 
expensive O 
and O 
time O 
consuming O 
. O 
Here O 
, O 
we O 
examined O 
the O 
possibility O 
of O 
using O 
spectrophotometric O 
methods O 
to O 
monitor O 
peptide O 
reactivity O 
. O 
Two O 
synthetic O 
peptides O 
, O 
Ac-RWAACAA O 
and O 
Ac-RWAAKAA O 
, O 
were O 
reacted O 
with O 
48 O 
chemicals O 
( O 
34 O 
sensitizers O 
and O 
14 O 
non-sensitizers O 
) O 
. O 
Peptide O 
reactivity O 
was O 
measured O 
by O 
monitoring O 
unreacted O 
peptides O 
with O 
UV-Vis O 
spectrophotometer O 
using O 
5,5'-dithiobis-2-nitrobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
a O 
detection O 
reagent O 
for O 
the O 
free O 
thiol B-FAMILY 
group O 
of O 
cysteine B-TRIVIAL 
-containing O 
peptide O 
or O 
fluorometer O 
using O 
fluorescamine B-TRIVIAL 
™ O 
as O 
a O 
detection O 
reagent O 
for O 
the O 
free O 
amine O 
group O 
of O 
lysine B-TRIVIAL 
-containing O 
peptide O 
. O 
Chemicals O 
were O 
categorized O 
as O 
sensitizers O 
when O 
they O 
induced O 
more O 
than O 
10% O 
depletion O 
of O 
cysteine B-TRIVIAL 
-containing O 
peptide O 
or O 
20% O 
depletion O 
of O 
lysine B-TRIVIAL 
-containing O 
peptide O 
. O 
The O 
sensitivity O 
, O 
specificity O 
, O 
and O 
accuracy O 
of O 
this O 
method O 
were O 
82.4% O 
, O 
85.7% O 
, O 
and O 
83.3% O 
, O 
respectively O 
. O 
These O 
results O 
demonstrate O 
that O 
spectrophotometric O 
methods O 
can O 
be O 
easy O 
, O 
fast O 
, O 
and O 
high O 
- O 
throughput O 
screening O 
tools O 
for O 
the O 
prediction O 
of O 
the O 
skin O 
sensitization O 
potential O 
of O 
chemical O 
haptens O 
. O 

of O 
ozone B-TRIVIAL 
and O 
fine O 
particulate O 
matter O 
(PM(2.5)) O 
on O 
rat O 
system O 
inflammation O 
and O 
cardiac O 
function O 
. O 

order O 
to O 
understand O 
the O 
toxic O 
mechanisms O 
of O 
cardiovascular O 
system O 
injuries O 
induced O 
by O 
ambient O 
PM(2.5) O 
and O 
/ O 
or O 
ozone B-TRIVIAL 
, O 
a O 
subacute O 
toxicological O 
animal O 
experiment O 
was O 
designed O 
with O 
exposure O 
twice O 
a O 
week O 
for O 
3 O 
continuous O 
weeks O 
. O 
Wistar O 
rats O 
were O 
randomly O 
categorized O 
into O 
8 O 
groups O 
( O 
n=6 O 
) O 
: O 
1 O 
control O 
group O 
, O 
3 O 
groups O 
exposed O 
to O 
fine O 
particulate O 
matters O 
(PM(2.5)) O 
alone O 
at O 
3 O 
doses O 
( O 
0.2 O 
, O 
0.8 O 
, O 
or O 
3.2 O 
mg O 
/ O 
rat O 
) O 
, O 
1 O 
group O 
to O 
ozone B-TRIVIAL 
( O 
0.81 O 
ppm O 
) O 
alone O 
and O 
3 O 
groups O 
to O 
ozone B-TRIVIAL 
plus O 
PM(2.5) O 
at O 
3 O 
doses O 
( O 
0.2 O 
, O 
0.8 O 
, O 
or O 
3.2 O 
mg O 
/ O 
rat O 
) O 
. O 
Heart O 
rate O 
( O 
HR O 
) O 
and O 
electrocardiogram O 
( O 
ECG O 
) O 
was O 
monitored O 
at O 
approximately O 
24-h O 
both O 
after O 
the O 
3rd O 
exposure O 
and O 
the O 
last O 
( O 
6th O 
) O 
exposure O 
, O 
and O 
systolic O 
blood O 
pressure O 
( O 
SBP O 
) O 
was O 
monitored O 
at O 
approximately O 
24-h O 
after O 
the O 
6th O 
exposure O 
. O 
Biomarkers O 
of O 
systemic O 
inflammation O 
and O 
injuries O 
( O 
CRP O 
, O 
IL-6 O 
, O 
LDH O 
, O 
CK O 
) O 
, O 
heart O 
oxidative O 
stress O 
( O 
MDA B-ABBREVIATION 
, O 
SOD O 
) O 
and O 
endothelial O 
function O 
( O 
ET-1 O 
, O 
VEGF O 
) O 
were O 
analyzed O 
after O 
the O 
6th O 
exposure O 
. O 
Additionally O 
, O 
myocardial O 
ultrastructural O 
alterations O 
were O 
observed O 
under O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
for O 
histopathological O 
analyses O 
. O 
Results O 
showed O 
that O 
PM(2.5) O 
alone O 
exposure O 
could O 
trigger O 
the O 
significant O 
increase O 
of O 
CRP O 
, O 
MDA B-ABBREVIATION 
, O 
CK O 
, O 
ET-1 O 
and O 
SBP O 
and O 
decrease O 
of O 
heart O 
rate O 
variability O 
( O 
HRV O 
) O 
, O 
a O 
marker O 
of O 
cardiac O 
autonomic O 
nervous O 
system O 
( O 
ANS O 
) O 
function O 
. O 
Ozone B-TRIVIAL 
alone O 
exposure O 
in O 
rats O 
did O 
not O 
show O 
significant O 
alterations O 
in O 
any O 
indicators O 
. O 
Ozone B-TRIVIAL 
plus O 
PM(2.5) O 
exposure O 
, O 
however O 
, O 
induced O 
CRP O 
, O 
IL-6 O 
, O 
CK O 
, O 
LDH O 
and O 
MDA B-ABBREVIATION 
increase O 
, O 
SOD O 
and O 
HRV O 
decrease O 
significantly O 
in O 
a O 
dose O 
- O 
response O 
way O 
. O 
Meanwhile O 
, O 
abnormal O 
ECG O 
types O 
were O 
monitored O 
in O 
rats O 
exposed O 
to O 
PM(2.5) O 
with O 
and O 
without O 
ozone B-TRIVIAL 
and O 
obvious O 
myocardial O 
ultrastructural O 
changes O 
were O 
observed O 
by O 
TEM O 
. O 
In O 
conclusion O 
, O 
PM(2.5) O 
alone O 
exposure O 
could O 
cause O 
inflammation O 
, O 
endothelial O 
function O 
and O 
ANS O 
injuries O 
, O 
and O 
ozone B-TRIVIAL 
potentiated O 
these O 
effects O 
induced O 
by O 
PM(2.5) O 
. O 

ways O 
of O 
fagopyrin B-TRIVIAL 
biosynthesis O 
and O 
production O 
in O 
buckwheat O 
plants O 
. O 

present O 
work O 
extends O 
knowledge O 
about O 
possible O 
biosynthesis O 
of O 
fagopyrin B-TRIVIAL 
in O 
buckwheat O 
plants O 
by O 
providing O 
possible O 
candidate O 
genes O 
for O 
its O 
biosynthesis O 
and O 
the O 
role O 
of O 
type O 
III O 
polyketide O 
synthases O 
( O 
PKSs O 
) O 
. O 
Moreover O 
, O 
new O 
information O 
is O 
presented O 
about O 
the O 
possible O 
connection O 
between O 
naphthodianthrones B-FAMILY 
and O 
phenolic B-FAMILY 
biosynthesis O 
. O 
Possible O 
regulation O 
of O 
fagopyrin B-TRIVIAL 
biosynthesis O 
and O 
production O 
under O 
different O 
growth O 
conditions O 
is O 
also O 
discussed O 
. O 

of O 
the O 
α-glycosidase O 
inhibitor O 
1-deoxynojirimycin B-SYSTEMATIC 
from O 
Bacillus O 
species O 
. O 

( O 
DNJ B-ABBREVIATION 
) O 
, O 
a O 
potent O 
α-glycosidase O 
inhibitor O 
, O 
has O 
therapeutic O 
applications O 
in O 
treatments O 
of O 
HIV O 
, O 
Gaucher's O 
disease O 
, O 
and O 
diabetes O 
. O 
DNJ B-ABBREVIATION 
has O 
been O 
extracted O 
from O 
natural O 
sources O 
( O 
mulberry O 
leaves O 
) O 
for O 
therapeutic O 
purposes O 
; O 
however O 
, O 
DNJ B-ABBREVIATION 
ingredients O 
are O 
in O 
limited O 
supply O 
and O 
are O 
costly O 
to O 
obtain O 
on O 
a O 
large O 
scale O 
. O 
Since O 
certain O 
strains O 
of O 
Bacillus O 
and O 
Streptomyces O 
species O 
reportedly O 
produce O 
DNJ B-ABBREVIATION 
, O 
they O 
may O 
serve O 
as O 
potential O 
sources O 
for O 
high O 
- O 
yield O 
DNJ B-ABBREVIATION 
production O 
. O 
In O 
this O 
study O 
, O 
we O 
obtained O 
evidence O 
for O 
a O 
DNJ B-ABBREVIATION 
production O 
in O 
Bacillus O 
subtilis O 
DSM704 O 
by O 
hydrophilic O 
interaction O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 
In O 
addition O 
, O 
from O 
a O 
screen O 
of O 
750 O 
microorganisms O 
, O 
we O 
identified O 
additional O 
Bacillus O 
strains O 
( O 
Bacillus O 
amyloliquefaciens O 
AS385 O 
and O 
Bacillus O 
subtilis O 
B4 O 
) O 
that O 
produce O 
DNJ B-ABBREVIATION 
in O 
large O 
quantities O 
. O 
Investigation O 
of O 
the O 
effect O 
of O 
various O 
culture O 
conditions O 
, O 
using O 
Bacillus O 
subtilis O 
DSM704 O 
and O 
the O 
DNJ B-ABBREVIATION 
high O 
- O 
production O 
Bacillus O 
strains O 
, O 
provided O 
evidence O 
for O 
the O 
importance O 
of O 
sorbitol B-TRIVIAL 
supplementation O 
on O 
the O 
yield O 
of O 
the O 
DNJ B-ABBREVIATION 
precursor O 
, O 
2-amino-2-deoxy-D-mannitol B-SYSTEMATIC 
, O 
thereby O 
increasing O 
DNJ B-ABBREVIATION 
production O 
. O 
The O 
role O 
of O 
sorbitol B-TRIVIAL 
in O 
increased O 
DNJ B-ABBREVIATION 
production O 
was O 
supported O 
by O 
an O 
observed O 
increase O 
in O 
mRNA O 
expression O 
of O 
the O 
biosynthetic O 
gene O 
, O 
gabT1 O 
. O 
When O 
Bacillus O 
amyloliquefaciens O 
AS385 O 
was O 
cultured O 
in O 
medium O 
supplemented O 
with O 
sorbitol B-TRIVIAL 
, O 
extracellular O 
DNJ B-ABBREVIATION 
concentration O 
reached O 
a O 
maximum O 
of O 
460 O 
mg O 
/ O 
l O 
of O 
medium O 
( O 
equivalent O 
to O 
9.20mg O 
/ O 
g O 
of O 
freeze O 
- O 
dried O 
medium O 
) O 
, O 
indicating O 
that O 
this O 
strain O 
can O 
serve O 
as O 
a O 
source O 
for O 
food- O 
and O 
drug O 
- O 
grade O 
products O 
. O 
These O 
findings O 
not O 
only O 
lead O 
to O 
a O 
further O 
understanding O 
of O 
the O 
DNJ B-ABBREVIATION 
biosynthetic O 
pathway O 
, O 
but O 
also O 
suggest O 
a O 
method O 
for O 
microbial O 
mass O 
production O 
of O 
DNJ B-ABBREVIATION 
for O 
therapeutic O 
applications O 
. O 

alters O 
epithelium O 
proliferation O 
and O 
survival O 
and O 
suppresses O 
Wnt O 
/ O 
β-catenin O 
signaling O 
in O 
developing O 
cleft O 
palate O 
. O 

( O 
Dex B-ABBREVIATION 
) O 
contributes O 
to O 
a O 
cleft O 
palate O 
, O 
but O 
the O 
cellular O 
and O 
molecular O 
mechanisms O 
responsible O 
for O 
the O 
deleterious O 
effect O 
on O 
the O 
developing O 
palate O 
are O 
unclear O 
. O 
Wnt O 
signaling O 
is O 
a O 
causal O 
mechanism O 
of O 
Dex B-ABBREVIATION 
-induced O 
osteoporosis O 
, O 
so O 
this O 
study O 
was O 
conducted O 
to O 
determine O 
whether O 
Dex B-ABBREVIATION 
-induced O 
cleft O 
palate O 
may O 
result O 
from O 
altered O 
Wnt O 
signaling O 
. O 
Administration O 
of O 
Dex B-ABBREVIATION 
to O 
mice O 
completely O 
inhibited O 
canonical O 
Wnt O 
/ O 
β-catenin O 
signaling O 
and O 
altered O 
cell O 
proliferation O 
and O 
apoptosis O 
of O 
the O 
craniofacial O 
epithelium O 
in O 
developing O 
embryos O 
. O 
Thus O 
, O 
downregulated O 
Wnt O 
/ O 
β-catenin O 
signaling O 
was O 
associated O 
with O 
Dex B-ABBREVIATION 
-induced O 
cleft O 
palate O 
. O 
Moreover O 
, O 
altered O 
cell O 
fate O 
by O 
Dex B-ABBREVIATION 
responsible O 
for O 
small O 
palates O 
, O 
delaying O 
shelf O 
elevation O 
and O 
unfused O 
palates O 
was O 
a O 
crucial O 
mechanism O 
in O 
cleft O 
palate O 
. O 
Our O 
findings O 
help O 
in O 
elucidating O 
the O 
mechanisms O 
of O 
Dex B-ABBREVIATION 
-induced O 
cleft O 
palate O 
. O 

from O 
repeated O 
amphetamine B-TRIVIAL 
treatment O 
induces O 
depressive O 
- O 
like O 
behaviors O 
and O 
oxidative O 
damage O 
in O 
rat O 
brain O 
. O 

: O 
Amphetamine B-TRIVIAL 
has O 
a O 
significant O 
potential O 
for O 
abuse O 
and O 
addiction O 
. O 
Among O 
prolonged O 
abusers O 
, O 
amphetamine B-TRIVIAL 
withdrawal O 
- O 
induced O 
depressive O 
symptoms O 
are O 
common O 
; O 
however O 
, O 
their O 
pathophysiological O 
mechanism O 
is O 
not O 
fully O 
understood O 
. O 
Previously O 
, O 
we O 
found O 
that O 
repeated O 
treatment O 
with O 
amphetamine B-TRIVIAL 
for O 
2 O 
weeks O 
induced O 
oxidative O 
stress O 
in O 
rat O 
brain O 
. O 
OBJECTIVES O 
: O 
The O 
purpose O 
of O 
the O 
current O 
study O 
is O 
to O 
analyze O 
whether O 
abstinence O 
from O 
repeated O 
amphetamine B-TRIVIAL 
treatment O 
in O 
rats O 
induces O 
depressive O 
- O 
like O 
behaviors O 
and O 
if O 
oxidative O 
damage O 
in O 
the O 
brain O 
continues O 
during O 
abstinence O 
. O 
METHODS O 
: O 
Rats O 
were O 
given O 
repeated O 
treatment O 
with O 
amphetamine B-TRIVIAL 
once O 
daily O 
at O 
1 O 
, O 
2 O 
, O 
or O 
4 O 
mg O 
/ O 
kg O 
for O 
14 O 
days O 
. O 
From O 
10 O 
to O 
14 O 
days O 
after O 
final O 
amphetamine B-TRIVIAL 
treatment O 
, O 
behavioral O 
changes O 
were O 
monitored O 
using O 
open O 
field O 
test O 
, O 
novel O 
object O 
recognition O 
test O 
, O 
and O 
forced O 
swim O 
test O 
. O 
Oxidative O 
damage O 
in O 
the O 
medial O 
frontal O 
cortex O 
and O 
hippocampus O 
was O 
analyzed O 
by O 
immunohistochemistry O 
. O 
RESULTS O 
: O 
We O 
found O 
that O 
drug O 
abstinence O 
after O 
repeated O 
amphetamine B-TRIVIAL 
stimulation O 
decreased O 
locomotor O 
activity O 
and O 
exploratory O 
behavior O 
in O 
the O 
open O 
field O 
test O 
, O 
increased O 
immobility O 
in O 
the O 
forced O 
swim O 
test O 
, O 
and O 
had O 
no O 
significant O 
effect O 
on O 
the O 
recognition O 
index O 
in O 
the O 
novel O 
object O 
recognition O 
test O 
. O 
We O 
also O 
found O 
that O 
amphetamine B-TRIVIAL 
abstinence O 
increased O 
levels O 
of O 
4-hydroxynonenal B-SYSTEMATIC 
-protein O 
adducts O 
and O 
8-hydroxyguanosine B-SYSTEMATIC 
in O 
rat O 
medial O 
frontal O 
cortex O 
and O 
in O 
CA3 O 
and O 
dentate O 
gyrus O 
regions O 
of O 
the O 
hippocampus O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
suggest O 
that O 
amphetamine B-TRIVIAL 
abstinence O 
displays O 
depressive O 
- O 
like O 
behaviors O 
in O 
rats O 
and O 
induces O 
oxidative O 
damage O 
to O 
lipids O 
and O 
RNA O 
in O 
rat O 
brain O 
. O 
Our O 
findings O 
indicate O 
that O 
the O 
process O 
of O 
oxidative O 
stress O 
may O 
play O 
a O 
role O 
in O 
pathophysiological O 
changes O 
during O 
drug O 
abstinence O 
from O 
repeated O 
amphetamine B-TRIVIAL 
stimulation O 
. O 

characterization O 
of O 
CK2 O 
inhibitor O 
CX-4945 B-IDENTIFIER 
. O 

- O 
expression O 
of O 
protein O 
kinase O 
CK2 O 
is O 
highly O 
linked O 
to O 
the O 
survival O 
of O 
cancer O 
cells O 
and O 
the O 
poor O 
prognosis O 
of O 
patients O 
with O 
cancers O 
. O 
CX-4945 B-IDENTIFIER 
, O 
a O 
potent O 
and O 
selective O 
orally O 
bioavailable O 
ATP B-ABBREVIATION 
-competitive O 
inhibitor O 
of O 
CK2 O 
, O 
inhibits O 
the O 
oncogenic O 
cellular O 
events O 
such O 
as O 
proliferation O 
and O 
angiogenesis O 
, O 
and O 
the O 
increase O 
of O 
tumor O 
growth O 
in O 
mouse O 
xenograft O 
model O 
. O 
In O 
this O 
study O 
, O 
the O 
pharmacokinetic O 
information O 
about O 
CX-4945 B-IDENTIFIER 
was O 
provided O 
; O 
at O 
10 O 
μM O 
, O 
CX-4945 B-IDENTIFIER 
with O 
high O 
stability O 
in O 
human O 
and O 
rat O 
liver O 
microsome O 
exhibited O 
low O 
percentage O 
of O 
inhibition O 
( O 
< O 
10 O 
% O 
) O 
in O 
CYP450 O 
isoforms O 
( O 
1A2 O 
, O 
2C19 O 
, O 
3A4 O 
) O 
, O 
but O 
considerable O 
inhibition O 
( O 
~70 O 
% O 
) O 
in O 
CYP450 O 
2C9 O 
and O 
2D6 O 
. O 
In O 
hERG O 
potassium B-SYSTEMATIC 
channel O 
inhibition O 
assay O 
, O 
CX-4945 B-IDENTIFIER 
exhibited O 
relatively O 
low O 
inhibition O 
rate O 
. O 
Additionally O 
, O 
CX-4945 B-IDENTIFIER 
showed O 
high O 
MDCK O 
cell O 
permeability O 
( O 
> O 
10 O 
× O 
10(-6) O 
cm O 
/ O 
s O 
) O 
and O 
above O 
98 O 
% O 
of O 
plasma O 
protein O 
binding O 
in O 
the O 
rat O 
. O 
After O 
intravenous O 
administration O 
, O 
Vss O 
( O 
1.39 O 
l O 
/ O 
kg O 
) O 
and O 
extremely O 
low O 
CL O 
( O 
0.08 O 
l O 
/ O 
kg O 
/ O 
h O 
) O 
were O 
observed O 
. O 
Moreover O 
, O 
orally O 
administrated O 
CX-4945 B-IDENTIFIER 
showed O 
high O 
bioavailability O 
( O 
> O 
70 O 
% O 
) O 
and O 
these O 
data O 
might O 
be O 
related O 
to O 
the O 
MDCK O 
cell O 
permeability O 
results O 
. O 

the O 
quantum O 
efficiency O 
of O 
a O 
highly O 
emissive O 
binuclear O 
copper B-SYSTEMATIC 
complex O 
is O 
enhanced O 
by O 
changing O 
the O 
processing O 
solvent O 
. O 

is O 
often O 
linked O 
to O 
the O 
choice O 
of O 
processing O 
solvents O 
. O 
Packing O 
effects O 
or O 
the O 
preference O 
of O 
one O 
certain O 
conformer O 
as O 
possible O 
causes O 
of O 
this O 
phenomenon O 
are O 
strongly O 
dependent O 
on O 
solvents O 
and O 
especially O 
on O 
their O 
polarity O 
. O 
Even O 
in O 
amorphous O 
solids O 
, O 
the O 
microstructure O 
can O 
be O 
controlled O 
by O 
the O 
choice O 
of O 
solvents O 
. O 
Polymorphs O 
or O 
amorphous O 
solids O 
featuring O 
different O 
packing O 
densities O 
can O 
exhibit O 
different O 
properties O 
in O 
terms O 
of O 
stability O 
or O 
optical O 
effects O 
. O 
The O 
influence O 
of O 
these O 
effects O 
on O 
a O 
binuclear O 
, O 
strongly O 
luminescent O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
complex O 
was O 
investigated O 
. O 
Many O 
possible O 
applications O 
for O 
luminescent O 
, O 
amorphous O 
coordination O 
compounds O 
, O 
such O 
as O 
organic O 
light O 
- O 
emitting O 
diodes O 
, O 
sensors O 
, O 
and O 
organic O 
lasers O 
, O 
rely O 
on O 
photophysical O 
properties O 
like O 
quantum O 
efficiency O 
to O 
be O 
repeatable O 
. O 
The O 
effect O 
of O 
processing O 
solvents O 
in O 
this O 
context O 
is O 
often O 
underestimated O 
, O 
but O 
very O 
relevant O 
for O 
utilization O 
in O 
device O 
manufacturing O 
and O 
should O 
therefore O 
be O 
understood O 
more O 
deeply O 
. O 
In O 
this O 
work O 
, O 
theoretical O 
derivations O 
, O 
DFT O 
calculations O 
, O 
X-ray O 
- O 
diffraction O 
, O 
photoluminescence O 
spectroscopy O 
, O 
and O 
the O 
time O 
- O 
dependent O 
single O 
- O 
photon O 
- O 
counting O 
- O 
technique O 
( O 
TDSPC O 
) O 
were O 
used O 
to O 
understand O 
this O 
phenomenon O 
more O 
deeply O 
. O 
The O 
influence O 
of O 
five O 
different O 
solvents O 
on O 
Cu2I2(MePyrPHOS)3 B-FORMULA 
was O 
probed O 
. O 
This O 
resulted O 
in O 
a O 
modulation O 
of O 
the O 
photoluminescence O 
quantum O 
yield O 
ϕ O 
between O 
0.5 O 
and O 
0.9 O 
in O 
amorphous O 
solid O 
state O 
. O 
A O 
new O 
polymorph O 
of O 
the O 
material O 
with O 
slightly O 
reduced O 
values O 
for O 
ϕ O 
has O 
been O 
identified O 
. O 
The O 
reduced O 
efficiency O 
could O 
be O 
correlated O 
with O 
a O 
higher O 
porosity O 
and O 
a O 
reduced O 
packing O 
density O 
. O 
Dense O 
packing O 
reduces O 
nonradiative O 
decay O 
by O 
geometrical O 
fixation O 
and O 
thus O 
increases O 
the O 
quantum O 
efficiency O 
. O 
The O 
existence O 
of O 
similar O 
effects O 
on O 
aluminum B-SYSTEMATIC 
and O 
iridium B-SYSTEMATIC 
compounds O 
has O 
been O 
confirmed O 
by O 
application O 
of O 
different O 
processing O 
solvents O 
on O 
Alq3 B-FORMULA 
and O 
Ir(ppy)3 B-FORMULA 
. O 
These O 
results O 
show O 
that O 
a O 
tuning O 
of O 
the O 
efficiency O 
of O 
a O 
emissive O 
metal O 
complexes O 
by O 
choosing O 
a O 
proper O 
processing O 
solvent O 
is O 
possible O 
. O 
If O 
highly O 
efficient O 
materials O 
for O 
practical O 
applications O 
are O 
desired O 
, O 
an O 
evaluation O 
of O 
multiple O 
solvents O 
has O 
to O 
be O 
considered O 
. O 

stress O 
test O 
reveals O 
exaggerated O 
cardiovascular O 
effects O 
in O 
hypertensive O 
rats O 
after O 
exposure O 
to O 
the O 
air O 
pollutant O 
acrolein B-TRIVIAL 
. O 

to O 
air O 
pollution O 
increases O 
the O 
risk O 
of O 
cardiovascular O 
morbidity O 
and O 
mortality O 
, O 
especially O 
in O 
susceptible O 
populations O 
. O 
Despite O 
increased O 
risk O 
, O 
adverse O 
responses O 
are O 
often O 
delayed O 
and O 
require O 
additional O 
stress O 
tests O 
to O 
reveal O 
latent O 
effects O 
of O 
exposure O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
use O 
an O 
episode O 
of O 
" O 
transient O 
hypoxia O 
" O 
as O 
an O 
extrinsic O 
stressor O 
to O 
uncover O 
latent O 
susceptibility O 
to O 
environmental O 
pollutants O 
in O 
a O 
rodent O 
model O 
of O 
hypertension O 
. O 
We O 
hypothesized O 
that O 
exposure O 
to O 
acrolein B-TRIVIAL 
, O 
an O 
unsaturated O 
aldehyde B-SYSTEMATIC 
and O 
mucosal O 
irritant O 
found O 
in O 
cigarette O 
smoke O 
, O 
diesel O 
exhaust O 
, O 
and O 
power O 
plant O 
emissions O 
, O 
would O 
increase O 
cardiopulmonary O 
sensitivity O 
to O 
hypoxia O 
, O 
particularly O 
in O 
hypertensive O 
rats O 
. O 
Spontaneously O 
hypertensive O 
and O 
Wistar O 
Kyoto O 
( O 
normotensive O 
) O 
rats O 
, O 
implanted O 
with O 
radiotelemeters O 
, O 
were O 
exposed O 
once O 
for O 
3h O 
to O 
3 O 
ppm O 
acrolein B-TRIVIAL 
gas O 
or O 
filtered O 
air O 
in O 
whole O 
- O 
body O 
plethysmograph O 
chambers O 
and O 
challenged O 
with O 
a O 
10% O 
oxygen B-SYSTEMATIC 
atmosphere O 
( O 
10min O 
) O 
24h O 
later O 
. O 
Acrolein B-TRIVIAL 
exposure O 
increased O 
heart O 
rate O 
, O 
blood O 
pressure O 
, O 
breathing O 
frequency O 
, O 
and O 
minute O 
volume O 
in O 
hypertensive O 
rats O 
and O 
also O 
increased O 
the O 
heart O 
rate O 
variability O 
parameter O 
LF O 
, O 
suggesting O 
a O 
potential O 
role O 
for O 
increased O 
sympathetic O 
tone O 
. O 
Normotensive O 
rats O 
only O 
had O 
increased O 
blood O 
pressure O 
during O 
acrolein B-TRIVIAL 
exposure O 
. O 
The O 
hypoxia O 
stress O 
test O 
after O 
acrolein B-TRIVIAL 
exposure O 
revealed O 
increased O 
diastolic O 
blood O 
pressure O 
only O 
in O 
hypertensive O 
rats O 
and O 
increased O 
minute O 
volume O 
and O 
expiratory O 
time O 
only O 
in O 
normotensive O 
rats O 
. O 
These O 
results O 
suggest O 
that O 
hypertension O 
confers O 
exaggerated O 
sensitivity O 
to O 
air O 
pollution O 
and O 
that O 
the O 
hypoxia O 
stress O 
test O 
is O 
a O 
novel O 
tool O 
to O 
reveal O 
the O 
potential O 
latent O 
effects O 
of O 
air O 
pollution O 
exposure O 
. O 

oxazolidinone B-SYSTEMATIC 
analogues O 
having O 
a O 
N-hydroxyacetyl B-SYSTEMATIC 
-substituted O 
seven O 
- O 
membered O 
[1,2,5]triazepane B-SYSTEMATIC 
or O 
[1,2,5]oxadiazepane B-SYSTEMATIC 
C B-FORMULA 
-ring O 
unit O 
. O 

synthesized O 
a O 
series O 
of O 
oxazolidinone B-SYSTEMATIC 
analogues O 
bearing O 
a O 
N-hydroxyacetyl- B-MULTIPLE 
substituted I-MULTIPLE 
[1,2,5]triazepane I-MULTIPLE 
or I-MULTIPLE 
[1,2,5]oxadiazepane I-MULTIPLE 
C B-FORMULA 
-ring O 
unit O 
as O 
homologues O 
of O 
an O 
earlier O 
drug O 
candidate O 
, O 
eperezolid B-TRIVIAL 
. O 
Several O 
of O 
these O 
compounds O 
exhibited O 
potent O 
in O 
vitro O 
antibacterial O 
activities O 
towards O 
not O 
only O 
Gram O 
- O 
positive O 
, O 
but O 
also O 
Gram O 
- O 
negative O 
and O 
linezolid B-TRIVIAL 
-resistant O 
pathogens O 
. O 
Compounds O 
21a O 
and O 
21b O 
, O 
bearing O 
a O 
thiocarbamate B-SYSTEMATIC 
side O 
chain O 
, O 
showed O 
high O 
in O 
vivo O 
activity O 
against O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
SR3637 O 
, O 
together O 
with O 
a O 
promising O 
safety O 
profile O 
in O 
terms O 
of O 
weak O 
inhibition O 
of O 
monoamine B-FAMILY 
oxidase O 
and O 
cytochrome O 
P450 O 
isozymes O 
. O 

- O 
soluble O 
protein O 
, O 
surface O 
reactive O 
sulfhydryl B-FAMILY 
content O 
, O 
and O 
surface O 
hydrophobicity O 
of O 
Alaska O 
pollock O 
, O 
Pacific O 
whiting O 
, O 
and O 
threadfin O 
bream O 
surimi O 
were O 
characterised O 
, O 
as O 
affected O 
by O 
various O 
comminution O 
conditions O 
. O 
Chopping O 
time O 
/ O 
temperatures O 
were O 
explored O 
in O 
consideration O 
of O 
their O 
habitat O 
temperatures O 
. O 
Salt O 
- O 
soluble O 
protein O 
( O 
SSP O 
) O 
significantly O 
decreased O 
when O 
chopping O 
time O 
was O 
extended O 
. O 
Corresponding O 
to O 
our O 
follow O 
- O 
up O 
study O 
, O 
no O 
relationship O 
between O 
SSP O 
and O 
gel O 
texture O 
was O 
found O 
. O 
Surface O 
hydrophobicity O 
was O 
inversely O 
proportional O 
to O 
SSP O 
concentration O 
, O 
indicating O 
the O 
unfolding O 
of O 
protein O 
upon O 
comminution O 
. O 
Alaska O 
pollock O 
surimi O 
demonstrated O 
aggregation O 
during O 
chopping O 
at O 
10 O 
and O 
20 O 
°C O 
, O 
based O 
on O 
the O 
surface O 
hydrophobicity O 
. O 
Surface O 
reactive O 
sulfhydryl B-FAMILY 
( O 
SRSH O 
) O 
contents O 
of O 
the O 
three O 
fish O 
species O 
behaved O 
differently O 
. O 
The O 
SH B-FORMULA 
groups O 
were O 
oxidized O 
to O 
disulphide B-SYSTEMATIC 
bonds O 
when O 
higher O 
chopping O 
temperature O 
was O 
applied O 
. O 
As O 
a O 
result O 
, O 
increased O 
SRSH O 
content O 
was O 
not O 
observed O 
in O 
Alaska O 
pollock O 
( O 
10 O 
and O 
20 O 
°C O 
chopping O 
) O 
and O 
threadfin O 
bream O 
paste O 
( O 
25 O 
and O 
30 O 
°C O 
chopping O 
) O 
. O 

study O 
presents O 
new O 
important O 
aspects O 
in O 
the O 
design O 
of O 
contrast O 
agents O 
for O 
X-ray O 
preclinical O 
imaging O 
. O 
The O 
first O 
one O 
is O 
a O 
new O 
simple O 
formulation O 
of O 
long O 
circulating O 
contrast O 
agents O 
, O 
formulated O 
from O 
a O 
commercial O 
iodinated O 
oil O 
, O 
and O 
resulting O 
in O 
CT O 
contrast O 
agents O 
containing O 
more O 
than O 
twice O 
the O 
iodine B-SYSTEMATIC 
concentration O 
commercial O 
contrast O 
agents O 
. O 
The O 
second O 
point O 
is O 
a O 
methodological O 
aspect O 
, O 
utilizing O 
tangential O 
filtration O 
for O 
reducing O 
the O 
residual O 
surfactants O 
in O 
the O 
bulk O 
phase O 
and O 
serving O 
as O 
well O 
for O 
concentrating O 
droplets O 
( O 
and O 
iodine B-SYSTEMATIC 
) O 
in O 
the O 
suspension O 
. O 
The O 
last O 
point O 
is O 
a O 
more O 
general O 
aspect O 
regarding O 
the O 
influence O 
of O 
the O 
free O 
surfactant O 
on O 
the O 
pharmacokinetics O 
and O 
biodistribution O 
of O 
the O 
nano O 
- O 
emulsion O 
droplets O 
on O 
mice O 
. O 
We O 
showed O 
that O 
cross O 
- O 
flow O 
filtration O 
is O 
efficient O 
for O 
concentrating O 
the O 
droplets O 
and O 
reducing O 
the O 
concentration O 
of O 
free O 
surfactant O 
from O 
10wt.% O 
to O 
1wt.% O 
, O 
without O 
any O 
changes O 
in O 
the O 
nano O 
- O 
emulsion O 
droplet O 
morphologies O 
or O 
surface O 
properties O 
. O 
We O 
also O 
showed O 
that O 
the O 
presence O 
of O 
free O 
surfactant O 
has O 
a O 
significant O 
impact O 
on O 
the O 
elimination O 
way O 
of O 
the O 
nano O 
- O 
emulsion O 
droplets O 
, O 
shared O 
between O 
liver O 
and O 
kidneys O 
. O 
The O 
purified O 
nano O 
- O 
emulsions O 
are O 
preferentially O 
eliminated O 
by O 
the O 
kidneys O 
in O 
contrast O 
to O 
raw O 
nano O 
- O 
emulsions O 
, O 
predominantly O 
eliminated O 
by O 
the O 
liver O 
. O 
In O 
practice O 
, O 
for O 
two O 
similar O 
suspensions O 
, O 
half O 
- O 
life O 
decreases O 
from O 
4.1±1.10h O 
to O 
2.5±0.77h O 
before O 
and O 
after O 
purification O 
. O 
Since O 
the O 
design O 
and O 
development O 
of O 
long O 
circulating O 
systems O 
are O 
critical O 
in O 
numerous O 
domains O 
, O 
and O 
not O 
for O 
preclinical O 
CT O 
imaging O 
, O 
this O 
study O 
presents O 
important O 
results O 
in O 
that O 
field O 
, O 
taken O 
under O 
a O 
formulation O 
and O 
technical O 
point O 
of O 
view O 
. O 

dosimetry O 
of O 
inspired O 
naphthalene B-SYSTEMATIC 
vapor O 
in O 
the O 
male O 
and O 
female O 
B6C3F1 O 
mouse O 
. O 

vapor O 
is O 
a O 
nasal O 
cytotoxicant O 
in O 
the O 
rat O 
and O 
mouse O 
but O 
is O 
a O 
nasal O 
carcinogen O 
in O 
only O 
the O 
rat O 
. O 
Inhalation O 
dosimetry O 
is O 
a O 
critical O 
aspect O 
of O 
the O 
inhalation O 
toxicology O 
of O 
inspired O 
vapors O 
and O 
may O 
contribute O 
to O 
the O 
species O 
differences O 
in O 
the O 
nasal O 
response O 
. O 
To O 
define O 
the O 
nasal O 
dosimetry O 
of O 
naphthalene B-SYSTEMATIC 
in O 
the O 
B6C3F1 O 
male O 
and O 
female O 
mouse O 
, O 
uptake O 
of O 
naphthalene B-SYSTEMATIC 
vapor O 
was O 
measured O 
in O 
the O 
surgically O 
isolated O 
upper O 
respiratory O 
tract O 
( O 
URT O 
) O 
at O 
inspiratory O 
flow O 
rates O 
of O 
25 O 
or O 
50ml O 
/ O 
min O 
. O 
Uptake O 
was O 
measured O 
at O 
multiple O 
concentrations O 
( O 
0.5 O 
, O 
3 O 
, O 
10 O 
, O 
30ppm O 
) O 
in O 
controls O 
and O 
mice O 
treated O 
with O 
the O 
cytochrome O 
P450 O 
inhibitor O 
5-phenyl-1-pentyne B-SYSTEMATIC 
. O 
In O 
both O 
sexes O 
, O 
URT O 
uptake O 
efficiency O 
was O 
strongly O 
concentration O 
dependent O 
averaging O 
90% O 
at O 
0.5ppm O 
compared O 
to O 
50% O 
at O 
30ppm O 
( O 
25ml O 
/ O 
min O 
flow O 
rate O 
) O 
, O 
indicating O 
saturable O 
processes O 
were O 
involved O 
. O 
Both O 
uptake O 
efficiency O 
and O 
the O 
concentration O 
dependence O 
of O 
uptake O 
were O 
significantly O 
diminished O 
by O 
5-phenyl-1-pentyne B-SYSTEMATIC 
indicating O 
inspired O 
naphthalene B-SYSTEMATIC 
vapor O 
is O 
extensively O 
metabolized O 
in O 
the O 
mouse O 
nose O 
with O 
saturation O 
of O 
metabolism O 
occurring O 
at O 
the O 
higher O 
concentrations O 
. O 
A O 
hybrid O 
computational O 
fluid O 
dynamic O 
physiologically O 
based O 
pharmacokinetic O 
model O 
was O 
developed O 
for O 
nasal O 
dosimetry O 
. O 
This O 
model O 
accurately O 
predicted O 
the O 
observed O 
URT O 
uptake O 
efficiencies O 
. O 
Overall O 
, O 
the O 
high O 
URT O 
uptake O 
efficiency O 
of O 
naphthalene B-SYSTEMATIC 
in O 
the O 
mouse O 
nose O 
indicates O 
the O 
absence O 
of O 
a O 
tumorigenic O 
response O 
is O 
not O 
attributable O 
to O 
low O 
delivered O 
dose O 
rates O 
in O 
this O 
species O 
. O 

botulinum O 
neurotoxin O 
( O 
BoNT O 
) O 
is O 
a O 
multi O 
- O 
domain O 
protein O 
made O 
up O 
of O 
the O 
approximately O 
100 O 
kDa O 
heavy O 
chain O 
( O 
HC O 
) O 
and O 
the O 
approximately O 
50 O 
kDa O 
light O 
chain O 
( O 
LC O 
) O 
. O 
The O 
HC O 
can O 
be O 
further O 
subdivided O 
into O 
two O 
halves O 
: O 
the O 
N B-FORMULA 
-terminal O 
translocation O 
domain O 
( O 
TD O 
) O 
and O 
the O 
C B-FORMULA 
-terminal O 
Receptor O 
Binding O 
Domain O 
( O 
RBD O 
) O 
. O 
We O 
have O 
investigated O 
the O 
minimal O 
requirements O 
for O 
channel O 
activity O 
and O 
LC O 
translocation O 
. O 
We O 
utilize O 
a O 
cellular O 
protection O 
assay O 
and O 
a O 
single O 
channel O 
/ O 
single O 
molecule O 
LC O 
translocation O 
assay O 
to O 
characterize O 
in O 
real O 
time O 
the O 
channel O 
and O 
chaperone O 
activities O 
of O 
BoNT O 
/ O 
A O 
truncation O 
constructs O 
in O 
Neuro O 
2A O 
cells O 
. O 
The O 
unstructured O 
, O 
elongated O 
belt O 
region O 
of O 
the O 
TD O 
is O 
demonstrated O 
to O 
be O 
dispensable O 
for O 
channel O 
activity O 
, O 
although O 
may O 
be O 
required O 
for O 
productive O 
LC O 
translocation O 
. O 
We O 
show O 
that O 
the O 
RBD O 
is O 
not O 
necessary O 
for O 
channel O 
activity O 
or O 
LC O 
translocation O 
, O 
however O 
it O 
dictates O 
the O 
pH O 
threshold O 
of O 
channel O 
insertion O 
into O 
the O 
membrane O 
. O 
These O 
findings O 
indicate O 
that O 
each O 
domain O 
functions O 
as O 
a O 
chaperone O 
for O 
the O 
others O 
in O 
addition O 
to O 
their O 
individual O 
functions O 
, O 
working O 
in O 
concert O 
to O 
achieve O 
productive O 
intoxication O 
. O 

of O 
lurasidone B-TRIVIAL 
in O 
behavioral O 
models O 
of O 
depression O 
. O 
Role O 
of O 
the O 
5-HT7 O 
receptor O 
subtype O 
. O 

depression O 
is O 
a O 
common O 
psychiatric O 
disorder O 
associated O 
with O 
high O 
symptomatic O 
and O 
functional O 
burdens O 
. O 
Pharmacological O 
treatment O 
is O 
often O 
effective O 
, O 
but O 
there O 
remain O 
substantial O 
unmet O 
needs O 
in O 
the O 
form O 
of O 
non-responders O 
, O 
delayed O 
onset O 
of O 
clinical O 
effect O 
, O 
and O 
side O 
effects O 
. O 
Recent O 
studies O 
have O 
positioned O 
the O 
serotonin B-TRIVIAL 
5-HT7 O 
receptor O 
as O 
a O 
new O 
target O 
for O 
the O 
treatment O 
of O 
depression O 
. O 
Preclinical O 
studies O 
have O 
shown O 
that O 
antagonists O 
induce O 
an O 
antidepressant O 
- O 
like O 
response O 
, O 
a O 
phenotype O 
that O 
can O 
also O 
be O 
observed O 
in O 
mice O 
lacking O 
the O 
receptor O 
. O 
Lurasidone B-TRIVIAL 
is O 
a O 
new O 
atypical O 
antipsychotic O 
agent O 
with O 
very O 
high O 
affinity O 
for O 
the O 
5-HT7 O 
receptor O 
. O 
Patients O 
in O 
clinical O 
trials O 
have O 
reported O 
improved O 
scores O 
in O 
depression O 
ratings O 
. O 
We O 
have O 
tested O 
lurasidone B-TRIVIAL 
in O 
both O 
acute O 
and O 
chronic O 
mouse O 
models O 
of O 
depression O 
. O 
In O 
the O 
tail O 
suspension O 
and O 
forced O 
swim O 
tests O 
lurasidone B-TRIVIAL 
decreased O 
immobility O 
, O 
an O 
antidepressant O 
- O 
like O 
response O 
. O 
The O 
effect O 
required O 
functional O 
5-HT7 O 
receptors O 
as O 
it O 
was O 
absent O 
in O 
mice O 
lacking O 
the O 
receptor O 
. O 
In O 
the O 
repeated O 
open O 
- O 
space O 
swim O 
test O 
lurasidone B-TRIVIAL 
was O 
able O 
to O 
reverse O 
the O 
despair O 
induced O 
by O 
repeated O 
swims O 
in O 
a O 
manner O 
similar O 
to O 
the O 
commonly O 
used O 
antidepressant O 
citalopram B-TRIVIAL 
. O 
The O 
results O 
provide O 
evidence O 
that O 
lurasidone B-TRIVIAL 
can O 
act O 
as O 
a O 
5-HT7 O 
receptor O 
antagonist O 
and O 
provide O 
a O 
possible O 
explanation O 
for O 
the O 
antidepressant O 
effect O 
data O 
currently O 
emerging O 
from O 
lurasidone B-TRIVIAL 
clinical O 
trials O 
. O 
Additionally O 
, O 
the O 
results O 
give O 
further O 
support O 
for O 
targeting O 
the O 
5-HT7 O 
receptor O 
in O 
the O 
treatment O 
of O 
depression O 
. O 
It O 
will O 
be O 
of O 
interest O 
to O 
clinically O 
evaluate O 
lurasidone B-TRIVIAL 
as O 
an O 
antidepressant O 
either O 
as O 
monotherapy O 
or O 
as O 
an O 
adjunctive O 
therapy O 
to O 
available O 
drugs O 
. O 

report O 
an O 
approach O 
to O 
deliver O 
DNA O 
to O 
vascular O 
tissue O 
in O 
vivo O 
using O 
intravascular O 
stents O 
coated O 
with O 
degradable O 
, O 
DNA O 
- O 
containing O 
polyelectrolyte O 
multilayers O 
( O 
PEMs O 
) O 
. O 
Ionically O 
cross O 
- O 
linked O 
multilayers O 
∼120 O 
nm O 
thick O 
were O 
fabricated O 
layer O 
- O 
by O 
- O 
layer O 
on O 
the O 
surfaces O 
of O 
balloon O 
- O 
mounted O 
stainless O 
steel O 
stents O 
using O 
plasmid O 
DNA O 
and O 
a O 
hydrolytically O 
degradable O 
poly(β-amino B-FAMILY 
ester I-FAMILY 
) I-FAMILY 
( O 
polymer O 
1 O 
) O 
. O 
Characterization O 
of O 
stents O 
coated O 
using O 
a O 
fluorescently O 
end O 
- O 
labeled O 
analog O 
of O 
polymer O 
1 O 
revealed O 
film O 
erosion O 
to O 
be O 
uniform O 
across O 
the O 
surfaces O 
of O 
the O 
stents O 
; O 
differential O 
stresses O 
experienced O 
upon O 
balloon O 
expansion O 
did O 
not O 
lead O 
to O 
faster O 
film O 
erosion O 
or O 
dose O 
dumping O 
of O 
DNA O 
in O 
areas O 
near O 
stent O 
joints O 
when O 
stents O 
were O 
incubated O 
in O 
physiologically O 
relevant O 
media O 
. O 
The O 
ability O 
of O 
film O 
- O 
coated O 
stents O 
to O 
transfer O 
DNA O 
and O 
transfect O 
arterial O 
tissue O 
in O 
vivo O 
was O 
then O 
investigated O 
in O 
pigs O 
and O 
rabbits O 
. O 
Stents O 
coated O 
with O 
films O 
fabricated O 
using O 
fluorescently O 
labeled O 
DNA O 
resulted O 
in O 
uniform O 
transfer O 
of O 
DNA O 
to O 
sub O 
- O 
endothelial O 
tissue O 
in O 
the O 
arteries O 
of O 
pigs O 
in O 
patterns O 
corresponding O 
to O 
the O 
locations O 
and O 
geometries O 
of O 
stent O 
struts O 
. O 
Stents O 
coated O 
with O 
films O 
fabricated O 
using O 
polymer O 
1 O 
and O 
plasmid O 
DNA O 
encoding O 
EGFP O 
resulted O 
in O 
expression O 
of O 
EGFP O 
in O 
the O 
medial O 
layers O 
of O 
stented O 
tissue O 
in O 
both O 
pigs O 
and O 
rabbits O 
two O 
days O 
after O 
implantation O 
. O 
The O 
results O 
of O 
this O 
study O 
, O 
combined O 
with O 
the O 
modular O 
and O 
versatile O 
nature O 
of O 
layer O 
- O 
by O 
- O 
layer O 
assembly O 
, O 
provide O 
a O 
polymer O 
- O 
based O 
platform O 
that O 
is O 
well O 
suited O 
for O 
fundamental O 
studies O 
of O 
stent O 
- O 
mediated O 
gene O 
transfer O 
. O 
With O 
further O 
development O 
, O 
this O 
approach O 
could O 
also O 
prove O 
useful O 
for O 
the O 
design O 
of O 
nonviral O 
, O 
gene O 
- O 
based O 
approaches O 
for O 
prevention O 
of O 
complications O 
that O 
arise O 
from O 
the O 
implantation O 
of O 
stents O 
and O 
other O 
implantable O 
interventional O 
devices O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
use O 
a O 
polyphasic O 
approach O 
to O 
identify O 
Aspergillus O 
section O 
Flavi O 
isolated O 
from O 
Brazil O 
nuts O 
collected O 
in O 
the O 
Amazon O 
forest O 
: O 
investigation O 
of O 
macro- O 
and O 
microscopic O 
morphology O 
, O 
production O 
of O 
extrolites O 
, O 
heat O 
- O 
resistance O 
fungi O 
, O 
and O 
sequencing O 
of O 
DNA O 
regions O 
. O 
The O 
following O 
Aspergillus O 
section O 
Flavi O 
species O 
were O 
identified O 
: O 
Aspergillus O 
flavus O 
( O 
75.5% O 
) O 
, O 
Aspergillus O 
nomius O 
( O 
22.3% O 
) O 
, O 
and O 
Aspergillus O 
parasiticus O 
( O 
2.2% O 
) O 
. O 
All O 
A O 
. O 
nomius O 
and O 
A O 
. O 
parasiticus O 
isolates O 
produced O 
aflatoxins B-MULTIPLE 
B I-MULTIPLE 
and I-MULTIPLE 
G I-MULTIPLE 
, O 
but O 
not O 
cyclopiazonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CPA B-ABBREVIATION 
) O 
. O 
A O 
. O 
flavus O 
isolates O 
were O 
more O 
diversified O 
and O 
a O 
high O 
frequency O 
of O 
mycotoxigenic O 
strains O 
was O 
observed O 
. O 
The O 
polyphasic O 
approach O 
permitted O 
the O 
reliable O 
identification O 
of O 
section O 
Flavi O 
species O 
. O 
The O 
rate O 
of O 
mycotoxigenic O 
strains O 
was O 
high O 
( O 
92.7% O 
) O 
and O 
mainly O 
included O 
A O 
. O 
flavus O 
strains O 
producing O 
elevated O 
levels O 
of O 
aflatoxins B-FAMILY 
and O 
CPA B-ABBREVIATION 
. O 
These O 
results O 
highlight O 
the O 
possibility O 
of O 
co O 
- O 
occurrence O 
of O 
both O 
toxins O 
, O 
increasing O 
their O 
potential O 
toxic O 
effect O 
in O 
this O 
commodity O 
. O 

hormone O 
( O 
PTH O 
) O 
and O 
parathyroid O 
hormone O 
related O 
peptide O 
( O 
PTHrP O 
) O 
, O 
acting O 
through O 
the O 
osteoblast O 
PTH1R O 
, O 
play O 
important O 
roles O 
in O 
bone O 
remodeling O 
. O 
Intermittent O 
administration O 
of O 
PTH(1-34) O 
( O 
teriparatide O 
) O 
leads O 
to O 
bone O 
formation O 
while O 
continuous O 
administration O 
paradoxically O 
leads O 
to O 
bone O 
resorption O 
. O 
Activation O 
of O 
PTH1R O 
promotes O 
regulation O 
of O 
multiple O 
signaling O 
pathways O 
, O 
including O 
Gs/ O 
cAMP B-ABBREVIATION 
/ O 
PKA O 
, O 
Gq/ O 
calcium B-SYSTEMATIC 
/ O 
PKC O 
, O 
β-arrestin O 
recruitment O 
and O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
as O 
well O 
as O 
receptor O 
internalization O 
but O 
their O 
role O 
in O 
promoting O 
anabolic O 
and O 
catabolic O 
actions O 
of O 
PTH(1-34) O 
are O 
unclear O 
. O 
In O 
the O 
present O 
investigation O 
, O 
a O 
collection O 
of O 
PTH(1-34) O 
and O 
PTHrP(1-34) O 
peptide O 
analogs O 
were O 
evaluated O 
in O 
orthogonal O 
hPTH1R O 
functional O 
assays O 
capturing O 
Gs- O 
and O 
Gq-signaling O 
, O 
β-arrestin O 
recruitment O 
, O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
and O 
receptor O 
internalization O 
to O 
further O 
define O 
patterns O 
of O 
of O 
PTH1R O 
signaling O 
they O 
stimulate O 
and O 
to O 
further O 
establish O 
peptide O 
domains O 
contributing O 
to O 
agonist O 
activity O 
. O 
Results O 
indicate O 
that O 
both O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
domains O 
are O 
critical O 
for O 
activation O 
of O 
signaling O 
pathways O 
. O 
However O 
, O 
modifications O 
of O 
both O 
regions O 
leads O 
to O 
more O 
substantial O 
decreases O 
in O 
agonist O 
potency O 
and O 
efficacy O 
to O 
stimulate O 
Gq-signaling O 
, O 
β-arrestin O 
recruitment O 
, O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
and O 
receptor O 
internalization O 
than O 
to O 
stimulate O 
Gs O 
. O 
The O 
substantial O 
contribution O 
of O 
the O 
peptide O 
C B-FORMULA 
-terminal O 
domain O 
in O 
activation O 
of O 
hPTH1R-signaling O 
suggests O 
a O 
role O 
in O 
positioning O 
of O 
the O 
peptide O 
N B-FORMULA 
-terminal O 
region O 
into O 
the O 
receptor O 
J-domain O 
. O 
Several O 
PTH O 
and O 
PTHrP O 
peptide O 
analogs O 
evaluated O 
in O 
this O 
study O 
promote O 
different O 
patterns O 
of O 
biased O 
agonist O 
signaling O 
and O 
may O 
serve O 
as O 
useful O 
tools O 
to O 
further O 
elucidate O 
therapeutically O 
relevant O 
PTH1R O 
signaling O 
in O 
osteoblasts O 
. O 
With O 
a O 
better O 
understanding O 
of O 
therapeutically O 
relevant O 
signaling O 
, O 
novel O 
biased O 
peptides O 
with O 
desired O 
signaling O 
could O 
be O 
designed O 
for O 
safer O 
and O 
more O 
effective O 
treatment O 
of O 
osteoporosis O 
. O 

inverse O 
- O 
electron O 
- O 
demand O 
hetero- O 
/ O 
retro-Diels-Alder O 
reactions O 
for O 
aromatic O 
nitrogen B-SYSTEMATIC 
heterocycle O 
synthesis O 
. O 

merged O 
inverse O 
- O 
electron O 
- O 
demand O 
hetero-Diels-Alder O 
( O 
ihDA O 
) O 
/ O 
retro-Diels-Alder O 
( O 
rDA O 
) O 
reaction O 
sequence O 
can O 
be O 
used O 
to O 
rapidly O 
synthesise O 
highly O 
functionalised O 
nitrogen B-SYSTEMATIC 
heteroaromatics O 
. O 
The O 
reaction O 
offers O 
many O 
advantages O 
: O 
high O 
atom O 
economy O 
, O 
high O 
levels O 
of O 
regioselectivity O 
, O 
it O 
rarely O 
requires O 
a O 
catalyst O 
and O 
, O 
in O 
some O 
cases O 
, O 
can O 
be O 
performed O 
in O 
the O 
absence O 
of O 
solvent O 
. O 
In O 
this O 
tutorial O 
review O 
we O 
discuss O 
the O 
range O 
of O 
commonly O 
used O 
dienophiles O 
and O 
aza B-FAMILY 
- I-FAMILY 
dienes I-FAMILY 
for O 
this O 
process O 
whilst O 
highlighting O 
the O 
reactivity O 
trends O 
, O 
and O 
illustrating O 
their O 
applications O 
. O 

initiation O 
of O 
β-ionone B-TRIVIAL 
in O 
SGC-7901 O 
gastric O 
carcinoma O 
cancer O 
cells O 
via O 
a O 
PI3K-AKT O 
pathway O 
. O 

has O 
been O 
shown O 
to O 
hold O 
potent O 
anti-proliferative O 
and O 
apoptosis O 
induction O 
properties O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
To O 
investigate O 
the O 
effects O 
of O 
β-ionone B-TRIVIAL 
on O 
apoptosis O 
initiation O 
and O 
its O 
possible O 
mechanisms O 
of O 
action O 
, O 
we O 
qualified O 
cell O 
apoptosis O 
, O 
proteins O 
related O 
to O 
apoptosis O 
and O 
a O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
(PI3K)-AKT O 
pathway O 
in O 
human O 
gastric O 
adenocarcinoma O 
cancer O 
SGC-7901 O 
cells O 
. O 
The O 
results O 
demonstrated O 
that O 
β-ionone B-TRIVIAL 
-induced O 
apoptosis O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
in O 
SGC-7901 O 
cells O 
treated O 
with O 
β-ionone B-TRIVIAL 
( O 
25 O 
, O 
50 O 
, O 
100 O 
and O 
200 O 
μmol O 
/ O 
L O 
) O 
for O 
24 O 
h O 
. O 
β-ionone B-TRIVIAL 
was O 
also O 
shown O 
to O 
induce O 
the O 
expression O 
of O 
cleaved-caspase-3 O 
and O 
inhibit O 
bcl-2 O 
expression O 
in O 
SGC-7901 O 
cells O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
significantly O 
decreased O 
levels O 
of O 
p-PI3K O 
and O 
p-AKT O 
expression O 
were O 
observed O 
in O 
SGC-7901 O 
cells O 
after O 
β-ionone B-TRIVIAL 
treatments O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Thus O 
, O 
the O 
apoptosis O 
induction O 
in O 
SGC-7901 O 
cells O 
by O 
β-ionone B-TRIVIAL 
may O 
be O 
regulated O 
through O 
a O 
PI3K-AKT O 
pathway O 
. O 
These O 
results O 
demonstrate O 
a O 
potential O 
mechanism O 
by O 
which O 
β-ionone B-TRIVIAL 
to O 
induce O 
apoptosis O 
initiation O 
in O 
SGC-7901 O 
cells O 
. O 

trypsin O 
- O 
like O 
serine B-TRIVIAL 
protease O 
plasmin O 
is O 
a O 
target O 
for O 
the O 
development O 
of O 
antifibrinolytic O 
drugs O 
for O 
use O 
in O 
cardiac O 
surgery O 
with O 
cardiopulmonary O 
bypass O 
or O 
organ O 
transplantations O 
to O 
reduce O 
excessive O 
blood O 
loss O 
. O 
The O 
optimization O 
of O 
our O 
recently O 
described O 
substrate O 
- O 
analogue O 
plasmin O 
inhibitors O 
, O 
which O 
were O 
cyclized O 
between O 
their O 
P3 O 
and O 
P2 O 
side O 
chains O 
, O 
provided O 
a O 
new O 
series O 
with O 
improved O 
efficacy O 
and O 
excellent O 
selectivity O 
. O 
The O 
most O 
potent O 
inhibitor O 
8 O 
binds O 
to O 
plasmin O 
with O 
an O 
inhibition O 
constant O 
of O 
0.2 O 
nM O 
, O 
whereas O 
K O 
(i) O 
values O 
> O 
1 O 
μM O 
were O 
determined O 
for O 
nearly O 
all O 
other O 
tested O 
trypsin O 
- O 
like O 
serine B-TRIVIAL 
proteases O 
, O 
with O 
the O 
exception O 
of O 
trypsin O 
, O 
which O 
is O 
also O 
inhibited O 
in O 
the O 
nanomolar O 
range O 
. O 
Docking O 
studies O 
revealed O 
a O 
potential O 
binding O 
mode O 
in O 
the O 
widely O 
open O 
active O 
site O 
of O 
plasmin O 
that O 
explains O 
the O 
strong O 
potency O 
and O 
selectivity O 
profile O 
of O 
these O 
inhibitors O 
. O 
The O 
dialkylated O 
piperazine B-SYSTEMATIC 
-linker O 
segment O 
contributes O 
to O 
an O 
excellent O 
solubility O 
of O 
all O 
analogues O 
. O 
Based O 
on O 
their O 
overall O 
profile O 
the O 
presented O 
inhibitors O 
are O 
well O 
suited O 
for O 
further O 
development O 
as O 
injectable O 
antifibrinolytic O 
drugs O 
. O 

regulation O 
of O 
nicotine B-TRIVIAL 
and O 
polyamines B-FAMILY 
biosynthesis O 
in O 
tobacco O 
cells O 
by O 
enantiomers O 
of O 
ornithine B-TRIVIAL 
. O 

and I-MULTIPLE 
D-amino I-MULTIPLE 
acids I-MULTIPLE 
have O 
diverse O 
functions O 
and O 
effects O 
on O 
the O 
metabolism O 
, O 
growth O 
, O 
and O 
development O 
of O 
plants O 
. O 
Ornithine B-TRIVIAL 
( O 
Orn B-ABBREVIATION 
) O 
plays O 
a O 
main O 
role O 
in O 
the O 
biosynthesis O 
of O 
many O 
amino B-FAMILY 
acids I-FAMILY 
, O 
nicotinic B-FAMILY 
alkaloids I-FAMILY 
, O 
and O 
polyamines B-FAMILY 
in O 
tobacco O 
. O 
This O 
investigation O 
describes O 
the O 
impact O 
of O 
Orn B-ABBREVIATION 
enantiomers O 
on O 
the O 
production O 
and O 
distribution O 
of O 
free O 
, O 
conjugated O 
, O 
and O 
bound O 
polyamines B-FAMILY 
, O 
as O 
well O 
as O 
nicotine B-TRIVIAL 
in O 
tobacco O 
cells O 
. O 
It O 
was O 
recognized O 
that O 
the O 
biosynthesis O 
of O 
metabolites O 
was O 
differently O 
upregulated O 
by O 
each O 
enantiomer O 
. O 
Putrescine B-TRIVIAL 
was O 
abundantly O 
produced O 
by O 
exogenous O 
L-ornithine B-TRIVIAL 
( O 
L-Orn B-ABBREVIATION 
) O 
, O 
and O 
both O 
spermidine B-TRIVIAL 
and O 
spermine B-TRIVIAL 
were O 
significantly O 
accumulated O 
in O 
D-ornithine B-TRIVIAL 
( O 
D-Orn B-ABBREVIATION 
)-supplied O 
tobacco O 
cells O 
. O 
Furthermore O 
, O 
nicotine B-TRIVIAL 
production O 
was O 
highly O 
upregulated O 
by O 
L-Orn B-ABBREVIATION 
, O 
while O 
the O 
addition O 
of O 
D-Orn B-ABBREVIATION 
had O 
no O 
effect O 
on O 
the O 
nicotine B-TRIVIAL 
content O 
of O 
tobacco O 
cells O 
. O 
It O 
was O 
observed O 
that O 
transcript O 
expression O 
of O 
S-adenosylmethionine B-TRIVIAL 
decarboxylase O 
, O 
as O 
the O 
key O 
enzyme O 
of O 
spermidine B-TRIVIAL 
/ O 
spermine B-TRIVIAL 
biosynthesis O 
, O 
is O 
coincident O 
with O 
their O 
metabolic O 
levels O 
and O 
is O 
highly O 
upregulated O 
by O 
D-Orn B-ABBREVIATION 
, O 
as O 
opposed O 
to O 
L-Orn B-ABBREVIATION 
. O 
These O 
results O 
indicate O 
that O 
both O 
enantiomers O 
of O 
Orn B-ABBREVIATION 
can O 
trigger O 
selected O 
biosynthetic O 
pathways O 
in O 
the O 
cells O 
, O 
at O 
the O 
transcript O 
level O 
. O 
Regarding O 
these O 
observations O 
, O 
it O 
is O 
proposed O 
that O 
L- B-MULTIPLE 
and I-MULTIPLE 
D-Orn I-MULTIPLE 
function O 
differently O 
in O 
the O 
same O 
biological O 
pathways O 
in O 
which O 
the O 
latter O 
, O 
D-Orn B-ABBREVIATION 
specifically O 
regulates O 
important O 
polyamines B-FAMILY 
in O 
the O 
plant O 
cells O 
. O 

nanoparticle O 
- O 
enhanced O 
luminescence O 
of O 
silicon B-SYSTEMATIC 
quantum O 
dots O 
co O 
- O 
encapsulated O 
in O 
polymer O 
nanoparticles O 
. O 

preparation O 
of O 
two O 
- O 
component O 
polymer O 
composite O 
nanoparticles O 
encapsulating O 
both O 
Si B-FORMULA 
quantum O 
dots O 
( O 
SiQDs O 
) O 
and O 
Au B-FORMULA 
nanoparticles O 
( O 
AuNPs O 
) O 
by O 
a O 
single O 
step O 
miniemulsion O 
polymerization O 
of O 
divinylbenzene B-SYSTEMATIC 
is O 
described O 
. O 
This O 
simple O 
and O 
robust O 
method O 
affords O 
well O 
- O 
defined O 
polymer O 
composite O 
nanoparticles O 
with O 
mean O 
diameters O 
in O 
a O 
range O 
of O 
100-200 O 
nm O 
and O 
with O 
narrow O 
polydispersity O 
indices O 
as O 
determined O 
by O 
dynamic O 
light O 
scattering O 
and O 
transmission O 
electron O 
microscopy O 
. O 
The O 
successful O 
encapsulation O 
of O 
AuNPs O 
within O 
poly(divinylbenzene) B-FAMILY 
was O 
confirmed O 
by O 
UV-visible O 
spectroscopy O 
and O 
from O 
TEM O 
images O 
. O 
Plasmon O 
- O 
enhanced O 
fluorescence O 
of O 
the O 
luminescence O 
of O 
the O 
SiQDs O 
by O 
AuNPs O 
encapsulated O 
within O 
the O 
polymer O 
composite O 
nanoparticles O 
was O 
evaluated O 
by O 
confocal O 
microspectroscopy O 
, O 
and O 
luminescence O 
enhancements O 
of O 
up O 
to O 
15 O 
times O 
were O 
observed O 
. O 
These O 
observations O 
indicate O 
that O 
the O 
luminescence O 
of O 
the O 
SiQDs O 
is O 
enhanced O 
by O 
the O 
proximity O 
of O 
the O 
AuNPs O 
. O 
The O 
polymer O 
composite O 
nanoparticles O 
were O 
successfully O 
ink O 
- O 
jet O 
printed O 
onto O 
a O 
glass O 
substrate O 
, O 
which O 
demonstrates O 
that O 
these O 
composites O 
are O 
processable O 
in O 
printing O 
applications O 
. O 

, O 
fate O 
and O 
histopathological O 
effects O 
of O 
ethion B-TRIVIAL 
insecticide O 
on O 
selected O 
organs O 
of O 
the O 
crayfish O 
, O 
Procambarus O 
clarkii O 
. O 

study O 
aims O 
to O 
investigate O 
the O 
fate O 
and O 
histopathological O 
effects O 
of O 
ethion B-TRIVIAL 
on O 
selected O 
organs O 
of O 
the O 
crayfish O 
, O 
Procamabrus O 
clarkii O 
. O 
Crayfish O 
were O 
exposed O 
to O 
1 O 
mg O 
l(-1) O 
(14)C-ethion B-SYSTEMATIC 
and O 
the O 
concentrations O 
of O 
ethion B-TRIVIAL 
and O 
its O 
possible O 
degradation O 
products O 
were O 
measured O 
in O 
water O 
and O 
different O 
organs O 
of O 
the O 
crayfish O 
over O 
both O 
the O 
exposure O 
and O 
recovery O 
periods O 
. O 
Chromatographic O 
analysis O 
revealed O 
that O 
ethion B-TRIVIAL 
was O 
degraded O 
into O 
ethion B-SYSTEMATIC 
monooxon I-SYSTEMATIC 
, O 
ethion B-SYSTEMATIC 
dioxon I-SYSTEMATIC 
, O 
O,O-diethyl B-SYSTEMATIC 
phosphorothioate I-SYSTEMATIC 
, O 
O-ethyl B-SYSTEMATIC 
phosphorothioate I-SYSTEMATIC 
and O 
one O 
unknown O 
compound O 
. O 
At O 
the O 
end O 
of O 
exposure O 
period O 
, O 
ethion B-TRIVIAL 
was O 
accumulated O 
in O 
different O 
organs O 
of O 
the O 
crayfish O 
especially O 
in O 
the O 
hepatopancreas O 
and O 
gills O 
. O 
Following O 
the O 
transfer O 
of O 
crayfish O 
to O 
clean O 
water O 
for O 
seven O 
days O 
, O 
the O 
concentration O 
of O 
insecticide O 
residues O 
were O 
decreased O 
in O 
both O 
the O 
hepatopancreas O 
and O 
gills O 
suggesting O 
that O 
these O 
organs O 
play O 
an O 
important O 
role O 
in O 
elimination O 
of O 
ethion B-TRIVIAL 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
exposure O 
of O 
the O 
crayfish O 
to O 
¼ O 
96 O 
h-LC(50) O 
( O 
0.36 O 
mg O 
l(-1) O 
) O 
of O 
ethion B-TRIVIAL 
caused O 
extensive O 
ultrastructural O 
alterations O 
to O 
both O 
hepatopancreas O 
and O 
gill O 
epithelial O 
cells O 
. O 
In O 
the O 
hepatopancreas O 
, O 
the O 
most O 
notable O 
pathological O 
features O 
included O 
vacuolation O 
, O 
degradation O 
and O 
distinct O 
cell O 
lysis O 
. O 
In O 
the O 
gill O 
epithelium O 
, O 
the O 
histopathological O 
alterations O 
included O 
infiltration O 
of O 
hemocytes O 
, O 
cytoplasmic O 
vacuolation O 
and O 
a O 
decrease O 
in O 
the O 
number O 
of O 
basal O 
plasma O 
membrane O 
infoldings O 
. O 

new O 
phenylethanoid B-FAMILY 
glucoside I-FAMILY 
from O 
Plantago O 
depressa O 
Willd O 
. O 

research O 
of O 
Plantago O 
depressa O 
Willd O 
. O 
led O 
to O 
one O 
new O 
phenylethanoid B-FAMILY 
glucoside I-FAMILY 
with O 
α-L-rhamnosyl B-SYSTEMATIC 
(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-β-D-glucose I-SYSTEMATIC 
structure O 
, O 
together O 
with O 
four O 
known O 
compounds O 
. O 
These O 
five O 
compounds O 
( O 
1-5 O 
) O 
were O 
isolated O 
from O 
the O 
family O 
Plantaginaceae O 
for O 
the O 
first O 
time O 
; O 
the O 
chemotaxonomic O 
significance O 
of O 
cerebrosides B-FAMILY 
was O 
also O 
discussed O 
. O 

- O 
species O 
transcriptomic O 
analysis O 
of O 
mouse O 
and O 
rat O 
lung O 
exposed O 
to O 
chloroprene B-TRIVIAL 
. O 

( O 
2-chloro-1,3-butadiene B-SYSTEMATIC 
) O 
, O 
a O 
monomer O 
used O 
in O 
the O 
production O 
of O 
neoprene B-FAMILY 
elastomers O 
, O 
is O 
of O 
regulatory O 
interest O 
due O 
to O 
the O 
production O 
of O 
multiorgan O 
tumors O 
in O 
mouse O 
and O 
rat O 
cancer O 
bioassays O 
. O 
A O 
significant O 
increase O 
in O 
female O 
mouse O 
lung O 
tumors O 
was O 
observed O 
at O 
the O 
lowest O 
exposure O 
concentration O 
of O 
12.8 O 
ppm O 
, O 
whereas O 
a O 
small O 
, O 
but O 
not O 
statistically O 
significant O 
increase O 
was O 
observed O 
in O 
female O 
rats O 
only O 
at O 
the O 
highest O 
exposure O 
concentration O 
of O 
80 O 
ppm O 
. O 
The O 
metabolism O 
of O 
chloroprene B-TRIVIAL 
results O 
in O 
the O 
generation O 
of O 
reactive O 
epoxides B-FAMILY 
, O 
and O 
the O 
rate O 
of O 
overall O 
chloroprene B-TRIVIAL 
metabolism O 
is O 
highly O 
species O 
dependent O 
. O 
To O 
identify O 
potential O 
key O 
events O 
in O 
the O 
mode O 
of O 
action O 
of O 
chloroprene B-TRIVIAL 
lung O 
tumorigenesis O 
, O 
dose O 
- O 
response O 
and O 
time O 
- O 
course O 
gene O 
expression O 
microarray O 
measurements O 
were O 
made O 
in O 
the O 
lungs O 
of O 
female O 
mice O 
and O 
female O 
rats O 
. O 
The O 
gene O 
expression O 
changes O 
were O 
analyzed O 
using O 
both O 
a O 
traditional O 
ANOVA O 
approach O 
followed O 
by O 
pathway O 
enrichment O 
analysis O 
and O 
a O 
pathway O 
- O 
based O 
benchmark O 
dose O 
( O 
BMD O 
) O 
analysis O 
approach O 
. O 
Pathways O 
related O 
to O 
glutathione B-TRIVIAL 
biosynthesis O 
and O 
metabolism O 
were O 
the O 
primary O 
pathways O 
consistent O 
with O 
cross O 
- O 
species O 
differences O 
in O 
tumor O 
incidence O 
. O 
Transcriptional O 
BMD O 
values O 
for O 
the O 
pathway O 
were O 
more O 
similar O 
to O 
differences O 
in O 
tumor O 
response O 
than O 
were O 
estimated O 
target O 
tissue O 
dose O 
surrogates O 
based O 
on O 
the O 
total O 
amount O 
of O 
chloroprene B-TRIVIAL 
metabolized O 
per O 
unit O 
mass O 
of O 
lung O 
tissue O 
per O 
day O 
. O 
The O 
closer O 
correspondence O 
of O 
the O 
transcriptional O 
changes O 
with O 
the O 
tumor O 
response O 
is O 
likely O 
due O 
to O 
their O 
reflection O 
of O 
the O 
overall O 
balance O 
between O 
metabolic O 
activation O 
and O 
detoxication O 
reactions O 
, O 
whereas O 
the O 
current O 
tissue O 
dose O 
surrogate O 
reflects O 
only O 
oxidative O 
metabolism O 
. O 

generation O 
sequencing O 
in O 
predicting O 
gene O 
function O 
in O 
podophyllotoxin B-TRIVIAL 
biosynthesis O 
. O 

species O 
are O 
sources O 
of O 
(-)-podophyllotoxin B-TRIVIAL 
, O 
an O 
aryltetralin B-FAMILY 
lignan I-FAMILY 
used O 
for O 
semi-synthesis O 
of O 
various O 
powerful O 
and O 
extensively O 
employed O 
cancer O 
- O 
treating O 
drugs O 
. O 
Its O 
biosynthetic O 
pathway O 
, O 
however O 
, O 
remains O 
largely O 
unknown O 
, O 
with O 
the O 
last O 
unequivocally O 
demonstrated O 
intermediate O 
being O 
(-)-matairesinol B-TRIVIAL 
. O 
Herein O 
, O 
massively O 
parallel O 
sequencing O 
of O 
Podophyllum O 
hexandrum O 
and O 
Podophyllum O 
peltatum O 
transcriptomes O 
and O 
subsequent O 
bioinformatics O 
analyses O 
of O 
the O 
corresponding O 
assemblies O 
were O 
carried O 
out O 
. O 
Validation O 
of O 
the O 
assembly O 
process O 
was O 
first O 
achieved O 
through O 
confirmation O 
of O 
assembled O 
sequences O 
with O 
those O 
of O 
various O 
genes O 
previously O 
established O 
as O 
involved O 
in O 
podophyllotoxin B-TRIVIAL 
biosynthesis O 
as O 
well O 
as O 
other O 
candidate O 
biosynthetic O 
pathway O 
genes O 
. O 
This O 
contribution O 
describes O 
characterization O 
of O 
two O 
of O 
the O 
latter O 
, O 
namely O 
the O 
cytochrome O 
P450s O 
, O 
CYP719A23 O 
from O 
P O 
. O 
hexandrum O 
and O 
CYP719A24 O 
from O 
P O 
. O 
peltatum O 
. O 
Both O 
enzymes O 
were O 
capable O 
of O 
converting O 
(-)-matairesinol B-TRIVIAL 
into O 
(-)-pluviatolide B-TRIVIAL 
by O 
catalyzing O 
methylenedioxy B-SYSTEMATIC 
bridge O 
formation O 
and O 
did O 
not O 
act O 
on O 
other O 
possible O 
substrates O 
tested O 
. O 
Interestingly O 
, O 
the O 
enzymes O 
described O 
herein O 
were O 
highly O 
similar O 
to O 
methylenedioxy B-SYSTEMATIC 
bridge O 
- O 
forming O 
enzymes O 
from O 
alkaloid O 
biosynthesis O 
, O 
whereas O 
candidates O 
more O 
similar O 
to O 
lignan B-FAMILY 
biosynthetic O 
enzymes O 
were O 
catalytically O 
inactive O 
with O 
the O 
substrates O 
employed O 
. O 
This O 
overall O 
strategy O 
has O 
thus O 
enabled O 
facile O 
further O 
identification O 
of O 
enzymes O 
putatively O 
involved O 
in O 
(-)-podophyllotoxin B-TRIVIAL 
biosynthesis O 
and O 
underscores O 
the O 
deductive O 
power O 
of O 
next O 
generation O 
sequencing O 
and O 
bioinformatics O 
to O 
probe O 
and O 
deduce O 
medicinal O 
plant O 
biosynthetic O 
pathways O 
. O 

randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
crossover O 
study O 
of O 
α4β O 
2* O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
agonist O 
AZD1446 B-IDENTIFIER 
( O 
TC-6683 B-IDENTIFIER 
) O 
in O 
adults O 
with O 
attention O 
- O 
deficit O 
/ O 
hyperactivity O 
disorder O 
. O 

: O 
Stimulation O 
of O 
nicotinic O 
cholinergic O 
systems O 
has O 
been O 
shown O 
to O 
alleviate O 
ADHD O 
symptoms O 
and O 
to O 
improve O 
cognitive O 
performance O 
. O 
AZD1446 B-IDENTIFIER 
is O 
a O 
selective O 
α4β2* O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
agonist O 
with O 
potential O 
effect O 
on O 
the O 
symptoms O 
of O 
ADHD O 
. O 
OBJECTIVES O 
: O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
evaluate O 
the O 
efficacy O 
, O 
safety O 
, O 
and O 
pharmacokinetics O 
of O 
AZD1446 B-IDENTIFIER 
in O 
adults O 
with O 
ADHD O 
treated O 
for O 
2 O 
weeks O 
. O 
METHOD O 
: O 
This O 
was O 
a O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
crossover O 
trial O 
. O 
Participants O 
were O 
79 O 
adults O 
with O 
ADHD O 
, O 
grouped O 
according O 
to O 
their O 
use O 
of O 
nicotine B-TRIVIAL 
-containing O 
products O 
. O 
Nicotine B-TRIVIAL 
non-users O 
received O 
placebo O 
and O 
two O 
of O 
three O 
AZD1446 B-IDENTIFIER 
treatment O 
regimens O 
( O 
80 O 
mg O 
tid O 
, O 
80 O 
mg O 
qd O 
, O 
10 O 
mg O 
tid O 
) O 
. O 
Nicotine B-TRIVIAL 
users O 
received O 
placebo O 
, O 
AZD1446 B-IDENTIFIER 
80 O 
mg O 
tid O 
and O 
80 O 
mg O 
qd O 
. O 
Efficacy O 
measures O 
included O 
the O 
Conners' O 
Adult O 
ADHD O 
Rating O 
Scale O 
and O 
cognitive O 
measures O 
of O 
immediate O 
and O 
delayed O 
verbal O 
episodic O 
memory O 
, O 
learning O 
, O 
attention O 
, O 
working O 
memory O 
, O 
executive O 
functioning O 
, O 
and O 
spatial O 
problem O 
solving O 
( O 
CogState O 
computerized O 
test O 
battery O 
) O 
. O 
RESULTS O 
: O 
There O 
was O 
no O 
significant O 
effect O 
of O 
AZD1446 B-IDENTIFIER 
on O 
any O 
of O 
the O 
clinical O 
scores O 
irrespective O 
of O 
dose O 
, O 
schedule O 
, O 
or O 
concomitant O 
use O 
of O 
nicotine B-TRIVIAL 
products O 
. O 
A O 
statistically O 
significant O 
improvement O 
was O 
seen O 
on O 
the O 
Groton O 
Maze O 
Learning O 
Task O 
, O 
a O 
measure O 
of O 
executive O 
functioning O 
, O 
in O 
nicotine B-TRIVIAL 
non-users O 
after O 
treatment O 
with O 
AZD1446 B-IDENTIFIER 
80 O 
mg O 
qd O 
. O 
CONCLUSIONS O 
: O 
AZD1446 B-IDENTIFIER 
was O 
well O 
tolerated O 
, O 
but O 
did O 
not O 
significantly O 
improve O 
ADHD O 
symptoms O 
after O 
2 O 
weeks O 
of O 
treatment O 
compared O 
to O 
placebo O 
. O 
While O 
the O 
present O 
study O 
does O 
not O 
support O 
the O 
therapeutic O 
utility O 
of O 
AZD1446 B-IDENTIFIER 
in O 
ADHD O 
, O 
its O 
potential O 
pro O 
- O 
cognitive O 
effects O 
remain O 
to O 
be O 
explored O 
in O 
other O 
neuropsychiatric O 
disorders O 
. O 

provenance O 
of O 
palm O 
oil O 
by O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
volatile O 
compound O 
fingerprinting O 
techniques O 
. O 

methods O 
are O 
required O 
in O 
addition O 
to O 
administrative O 
controls O 
to O 
verify O 
the O 
geographical O 
origin O 
of O 
vegetable O 
oils O 
such O 
as O 
palm O 
oil O 
in O 
an O 
objective O 
manner O 
. O 
In O 
this O 
study O 
the O 
application O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
volatile O 
organic O 
compound O 
fingerprinting O 
in O 
combination O 
with O 
chemometrics O 
have O 
been O 
applied O 
to O 
verify O 
the O 
geographical O 
origin O 
of O 
crude O 
palm O 
oil O 
( O 
continental O 
scale O 
) O 
. O 
For O 
this O 
purpose O 
94 O 
crude O 
palm O 
oil O 
samples O 
were O 
collected O 
from O 
South O 
East O 
Asia O 
( O 
55 O 
) O 
, O 
South O 
America O 
( O 
11 O 
) O 
and O 
Africa O 
( O 
28 O 
) O 
. O 
Partial O 
least O 
squares O 
discriminant O 
analysis O 
( O 
PLS-DA O 
) O 
was O 
used O 
to O 
develop O 
a O 
hierarchical O 
classification O 
model O 
by O 
combining O 
two O 
consecutive O 
binary O 
PLS-DA O 
models O 
. O 
First O 
, O 
a O 
PLS-DA O 
model O 
was O 
built O 
to O 
distinguish O 
South O 
East O 
Asian O 
from O 
non-South O 
East O 
Asian O 
palm O 
oil O 
samples O 
. O 
Then O 
a O 
second O 
model O 
was O 
developed O 
, O 
only O 
for O 
the O 
non-Asian O 
samples O 
, O 
to O 
discriminate O 
African O 
from O 
South O 
American O 
crude O 
palm O 
oil O 
. O 
Models O 
were O 
externally O 
validated O 
by O 
using O 
them O 
to O 
predict O 
the O 
identity O 
of O 
new O 
authentic O 
samples O 
. O 
The O 
fatty B-FAMILY 
acid I-FAMILY 
fingerprinting O 
model O 
revealed O 
three O 
misclassified O 
samples O 
. O 
The O 
volatile O 
compound O 
fingerprinting O 
models O 
showed O 
an O 
88% O 
, O 
100% O 
and O 
100% O 
accuracy O 
for O 
the O 
South O 
East O 
Asian O 
, O 
African O 
and O 
American O 
class O 
, O 
respectively O 
. O 
The O 
verification O 
of O 
the O 
geographical O 
origin O 
of O 
crude O 
palm O 
oil O 
is O 
feasible O 
by O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
volatile O 
compound O 
fingerprinting O 
. O 
Further O 
research O 
is O 
required O 
to O 
further O 
validate O 
the O 
approach O 
and O 
to O 
increase O 
its O 
spatial O 
specificity O 
to O 
country O 
/ O 
province O 
scale O 
. O 

deletion O 
of O 
the O 
adenosine B-TRIVIAL 
A2A O 
receptor O 
prevents O 
nicotine B-TRIVIAL 
-induced O 
upregulation O 
of O 
α7 O 
, O 
but O 
not O 
α4β2* O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
binding O 
in O 
the O 
brain O 
. O 

evidence O 
indicates O 
that O 
adenosine B-TRIVIAL 
A2A O 
receptors O 
( O 
A2ARs O 
) O 
modulate O 
cholinergic O 
neurotransmission O 
, O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
function O 
, O 
and O 
nicotine B-TRIVIAL 
-induced O 
behavioural O 
effects O 
. O 
To O 
explore O 
the O 
interaction O 
between O 
A2A O 
and O 
nAChRs O 
, O 
we O 
examined O 
if O 
the O 
complete O 
genetic O 
deletion O 
of O 
adenosine B-TRIVIAL 
A2ARs O 
in O 
mice O 
induces O 
compensatory O 
alterations O 
in O 
the O 
binding O 
of O 
different O 
nAChR O 
subtypes O 
, O 
and O 
whether O 
the O 
long O 
- O 
term O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
nAChR O 
regulation O 
are O 
altered O 
in O 
the O 
absence O 
of O 
the O 
A2AR O 
gene O 
. O 
Quantitative O 
autoradiography O 
was O 
used O 
to O 
measure O 
cytisine B-TRIVIAL 
-sensitive O 
[(125)I]epibatidine B-SYSTEMATIC 
and O 
[ O 
(125)I B-FORMULA 
]α-bungarotoxin O 
binding O 
to O 
α4β2* O 
and O 
α7 O 
nAChRs O 
, O 
respectively O 
, O 
in O 
brain O 
sections O 
of O 
drug-naïve O 
( O 
n O 
= O 
6 O 
) O 
or O 
nicotine B-TRIVIAL 
treated O 
( O 
n O 
= O 
5-7 O 
) O 
, O 
wild O 
- O 
type O 
and O 
adenosine B-TRIVIAL 
A2AR O 
knockout O 
mice O 
. O 
Saline O 
or O 
nicotine B-TRIVIAL 
( O 
7.8 O 
mg O 
/ O 
kg O 
/ O 
day O 
; O 
free O 
- O 
base O 
weight O 
) O 
were O 
administered O 
to O 
male O 
CD1 O 
mice O 
via O 
subcutaneous O 
osmotic O 
minipumps O 
for O 
a O 
period O 
of O 
14 O 
days O 
. O 
Blood O 
plasma O 
levels O 
of O 
nicotine B-TRIVIAL 
and O 
cotinine B-TRIVIAL 
were O 
measured O 
at O 
the O 
end O 
of O 
treatment O 
. O 
There O 
were O 
no O 
compensatory O 
developmental O 
alterations O 
in O 
nAChR O 
subtype O 
distribution O 
or O 
density O 
in O 
drug-naïve O 
A2AR O 
knockout O 
mice O 
. O 
In O 
nicotine B-TRIVIAL 
treated O 
wild O 
- O 
type O 
mice O 
, O 
both O 
α4β2* O 
and O 
α7 O 
nAChR O 
binding O 
sites O 
were O 
increased O 
compared O 
with O 
saline O 
treated O 
controls O 
. O 
The O 
genetic O 
ablation O 
of O 
adenosine B-TRIVIAL 
A2ARs O 
prevented O 
nicotine B-TRIVIAL 
-induced O 
upregulation O 
of O 
α7 O 
nAChRs O 
, O 
without O 
affecting O 
α4β2* O 
receptor O 
upregulation O 
. O 
This O 
selective O 
effect O 
was O 
observed O 
at O 
plasma O 
levels O 
of O 
nicotine B-TRIVIAL 
that O 
were O 
within O 
the O 
range O 
reported O 
for O 
smokers O 
(10-50 O 
ng O 
ml(-1)) O 
. O 
Our O 
data O 
highlight O 
the O 
involvement O 
of O 
adenosine B-TRIVIAL 
A2ARs O 
in O 
the O 
mechanisms O 
of O 
nicotine B-TRIVIAL 
-induced O 
α7 O 
nAChR O 
upregulation O 
, O 
and O 
identify O 
A2ARs O 
as O 
novel O 
pharmacological O 
targets O 
for O 
modulating O 
the O 
long O 
- O 
term O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
α7 O 
receptors O 
. O 

, O 
Synthesis O 
and O 
biological O 
evaluation O 
of O 
catecholamine B-TRIVIAL 
vehicle O 
for O 
studying O 
dopaminergic O 
system O 
. O 

mimetic O 
EDTA-bis(tyramide) B-SYSTEMATIC 
was O 
synthesized O 
and O 
characterized O 
by O 
various O 
spectroscopic O 
techniques O 
( O 
NMR O 
, O 
Mass O 
spectroscopy O 
) O 
and O 
λem O 
310 O 
nm O 
for O 
the O 
excitation O 
at O 
270 O 
nm O 
. O 
Molecular O 
docking O 
studies O 
were O 
performed O 
with O 
Human O 
Serum O 
Albumin O 
( O 
HSA O 
: O 
PDB O 
1E+078 O 
) O 
, O 
showing O 
binding O 
pattern O 
with O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
Arg B-FORMULA 
218 O 
, O 
Arg B-FORMULA 
222 O 
and O 
Lys B-FORMULA 
444 O 
, O 
identifies O 
the O 
ligand-HSA O 
interaction O 
for O 
the O 
transportation O 
affinity O 
of O 
the O 
ligand O 
at O 
the O 
specific O 
site O 
of O 
the O 
target O 
. O 
Subsequently O 
binding O 
study O 
with O 
HSA O 
at O 
λex O 
= O 
350 O 
nm O 
found O 
to O 
be O 
5.847x10(4) O 
M(-1) O 
shows O 
effective O 
quenching O 
effect O 
. O 
Additionally O 
to O 
go O 
more O 
insight O 
AChE O 
binding O 
affinity O 
was O 
investigated O 
, O 
which O 
shows O 
90% O 
binding O 
affinity O 
for O 
the O 
10 O 
mM O 
concentration O 
. O 
IC50 O 
value O 
was O 
was O 
found O 
18.6 O 
μM O 
for O 
MAO-B O 
inhibition O 
. O 
Finally O 
, O 
EDTA-bis(tyramide) B-SYSTEMATIC 
labeled O 
with O 
( B-FORMULA 
99m I-FORMULA 
) I-FORMULA 
Tc I-FORMULA 
to O 
investigate O 
its O 
in O 
- O 
vivo O 
radiopharmaceutical O 
efficiency O 
, O 
having O 
97% O 
binding O 
affinity O 
with O 
98% O 
radiochemical O 
purity O 
. O 
In-vivo O 
studies O 
were O 
carried O 
out O 
for O 
( B-SYSTEMATIC 
99m I-SYSTEMATIC 
) I-SYSTEMATIC 
Tc- I-SYSTEMATIC 
EDTA-bis(tyramide) I-SYSTEMATIC 
included O 
blood O 
kinetics O 
showed O 
a O 
quick O 
wash O 
out O 
from O 
the O 
circulation O 
via O 
renal O 
route O 
and O 
biodistribution O 
revealed O 
that O 
maximum%ID O 
/ O 
g O 
was O 
found O 
in O 
kidney O 
at O 
1h O 
and O 
its O 
scintigraphy O 
image O 
shows O 
3.96% O 
brain O 
uptake O 
with O 
respect O 
to O 
whole O 
body O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

: O 
To O 
investigate O 
the O 
antioxidant O 
role O 
in O 
reversing O 
cytogenetic O 
changes O 
caused O 
by O 
solvent O 
exposure O 
in O 
paint O 
industry.Subjects O 
and O 
METHODS O 
: O 
A O 
prospective O 
controlled O 
clinical O 
trial O 
was O 
performed O 
on O 
39 O 
workers O 
exposed O 
to O 
solvents O 
and O 
39 O 
workers O 
not O 
exposed O 
to O 
solvents O 
by O 
supplying O 
a O 
mixture O 
of O 
antioxidant O 
vitamins B-MULTIPLE 
( I-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
C I-MULTIPLE 
, I-MULTIPLE 
E I-MULTIPLE 
and O 
selenium B-SYSTEMATIC 
) O 
and O 
the O 
after O 
effects O 
of O 
such O 
regimen O 
were O 
analyzed O 
. O 
Environmental O 
monitoring O 
was O 
carried O 
out O 
for O 
air O 
concentrations O 
of O 
different O 
solvents O 
at O 
workplace O 
. O 
Exposed O 
group O 
was O 
cytogenetically O 
tested O 
before O 
and O 
after O 
giving O 
the O 
mixture O 
of O 
antioxidant O 
vitamins O 
for O 
1 O 
month O 
duration O 
. O 
RESULTS O 
: O 
Frequency O 
of O 
chromosomal O 
aberrations O 
( O 
CAs O 
) O 
and O 
the O 
mean O 
of O 
sister O 
chromatid O 
exchanges O 
( O 
SCEs O 
) O 
were O 
statistically O 
significantly O 
higher O 
among O 
exposed O 
workers O 
than O 
among O 
controls O 
. O 
After O 
the O 
supplementation O 
of O 
antioxidants O 
, O 
there O 
was O 
a O 
statistically O 
significant O 
decrease O 
in O 
the O 
frequency O 
of O 
CAs O 
, O 
and O 
88% O 
abnormal O 
levels O 
of O 
SCEs O 
were O 
back O 
to O 
normal O 
levels O 
. O 
CONCLUSION O 
: O 
Antioxidant O 
supplementation O 
decreases O 
the O 
frequency O 
of O 
CAs O 
and O 
SCEs O 
among O 
exposed O 
workers O 
. O 

elucidation O 
of O 
possible O 
lutein B-TRIVIAL 
oxidation O 
products O 
mediated O 
through O 
peroxyl B-SYSTEMATIC 
radical O 
inducer O 
2,2'-Azobis B-SYSTEMATIC 
( I-SYSTEMATIC 
2-methylpropionamidine I-SYSTEMATIC 
) I-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
: O 
Antioxidant O 
and O 
cytotoxic O 
influence O 
of O 
oxidized O 
lutein B-TRIVIAL 
in O 
HeLa O 
cells O 
. O 

of O 
this O 
study O 
was O 
to O 
elucidate O 
lutein B-TRIVIAL 
oxidation O 
products O 
mediated O 
through O 
peroxyl B-SYSTEMATIC 
radical O 
inducer O 
2,2'-Azobis B-SYSTEMATIC 
( I-SYSTEMATIC 
2-methylpropionamidine I-SYSTEMATIC 
) I-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
( O 
AAPH B-ABBREVIATION 
) O 
and O 
to O 
study O 
antioxidant O 
and O 
cytotoxic O 
effects O 
of O 
oxidized B-TRIVIAL 
lutein I-TRIVIAL 
using O 
liposome O 
and O 
HeLa O 
cells O 
. O 
Lutein B-TRIVIAL 
( O 
20μmol O 
) O 
with O 
AAPH B-ABBREVIATION 
( O 
5mM O 
) O 
in O 
liposome's O 
was O 
incubated O 
at O 
37°C O 
in O 
dark O 
for O 
3h O 
, O 
oxidized B-TRIVIAL 
lutein I-TRIVIAL 
products O 
were O 
characterized O 
by O 
LC-MS O 
(APCI(+)) O 
and O 
studied O 
for O 
their O 
free O 
radical O 
scavenging O 
activity O 
and O 
cytotoxic O 
effects O 
in O 
terms O 
of O 
cell O 
viability O 
, O 
cellular O 
glutathione B-TRIVIAL 
, O 
and O 
malondialdehyde B-TRIVIAL 
levels O 
. O 
AAPH B-ABBREVIATION 
mediated O 
lutein B-TRIVIAL 
fragmented O 
ions O 
were O 
identified O 
as O 
551 O 
( O 
M(+)+ O 
H(+) B-FORMULA 
- O 
H2O B-FORMULA 
) O 
, O 
391 O 
( O 
M(+)+ O 
H(+) B-FORMULA 
+ O 
O2-C22H32O B-FORMULA 
) O 
and O 
276 O 
( O 
M(+)+ O 
H(+) B-FORMULA 
+ O 
O2-C12H20O B-FORMULA 
) O 
and O 
its O 
isomers O 
as O 
13-Z B-SYSTEMATIC 
lutein I-SYSTEMATIC 
, O 
13-Z B-SYSTEMATIC 
zeaxanthin I-SYSTEMATIC 
, O 
13'-Z B-SYSTEMATIC 
zeaxanthin I-SYSTEMATIC 
and O 
all-E B-TRIVIAL 
zeaxanthin I-TRIVIAL 
. O 
Free O 
radical O 
scavenging O 
activity O 
of O 
oxidized B-TRIVIAL 
lutein I-TRIVIAL 
was O 
higher O 
by O 
32.7% O 
( O 
IC50 O 
, O 
2.64μg O 
) O 
than O 
lutein B-TRIVIAL 
( O 
IC50 O 
, O 
5.28μg O 
) O 
. O 
Oxidized B-TRIVIAL 
lutein I-TRIVIAL 
lowered O 
the O 
lipid O 
peroxidation O 
( O 
21% O 
) O 
, O 
HeLa O 
cells O 
viability O 
( O 
22% O 
) O 
and O 
glutathione B-TRIVIAL 
levels O 
( O 
32% O 
) O 
than O 
lutein B-TRIVIAL 
. O 
To O 
conclude O 
, O 
the O 
oxidized B-TRIVIAL 
lutein I-TRIVIAL 
may O 
be O 
highly O 
reactive O 
, O 
since O 
oxidation O 
by O 
AAPH B-ABBREVIATION 
results O 
in O 
peroxyl B-SYSTEMATIC 
radical O 
ions O 
, O 
which O 
can O 
react O 
with O 
conjugated O 
polyene B-SYSTEMATIC 
chain O 
of O 
lutein B-TRIVIAL 
that O 
could O 
lead O 
to O 
higher O 
antioxidant O 
and O 
cytotoxic O 
effects O 
on O 
HeLa O 
cells O 
. O 

effects O 
of O 
mercaptoethylleonurine B-SYSTEMATIC 
and O 
mercaptoethylguanidine B-SYSTEMATIC 
analogs O 
on O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
-induced O 
apoptosis O 
in O 
human O 
neuronal O 
SH-SY5Y O 
cells O 
. O 

series O 
of O 
mercaptoethylleonurine B-SYSTEMATIC 
and O 
mercaptoethylguanidine B-SYSTEMATIC 
derivatives O 
were O 
designed O 
and O 
synthesized O 
. O 
Their O 
neuroprotective O 
effects O 
toward O 
H2O2 B-FORMULA 
-induced O 
apoptosis O 
were O 
investigated O 
in O 
human O 
SH-SY5Y O 
cells O 
. O 
The O 
results O 
from O 
these O 
studies O 
identified O 
several O 
potent O 
compounds O 
, O 
with O 
compound O 
8k O 
emerging O 
as O 
the O 
most O 
effective O 
. O 
Further O 
investigation O 
demonstrated O 
that O 
8k O 
reduced O 
H2O2 B-FORMULA 
-induced O 
activation O 
of O 
mitochondrial O 
apoptosis O 
by O 
inhibiting O 
the O 
expression O 
of O 
Bax O 
and O 
elevating O 
the O 
expression O 
of O 
Bcl-2 O 
. O 
Moreover O 
, O 
the O 
molecular O 
mechanism O 
underlying O 
the O 
observed O 
neuroprotective O 
effects O 
of O 
8k O 
was O 
exerted O 
via O 
the O 
Akt O 
and O 
JNK O 
pathways O 
. O 
Compound O 
8k O 
can O 
be O 
a O 
lead O 
compound O 
for O 
further O 
discovery O 
of O 
neuroprotective O 
medicine O 
. O 

is O 
evidence O 
that O 
high O 
- O 
density O 
lipoproteins O 
( O 
HDLs O 
) O 
may O 
regulate O 
platelet O 
function O 
, O 
but O 
disparate O 
results O 
exist O 
regarding O 
the O 
effects O 
of O 
oxidized O 
HDLs O 
on O 
platelets O 
. O 
The O 
objective O 
of O 
our O 
study O 
was O 
to O 
determine O 
the O 
role O 
of O 
in O 
vivo O 
oxidized O 
HDLs O 
on O 
platelet O 
aggregation O 
. O 
Platelet O 
aggregation O 
and O 
redox O 
status O 
were O 
investigated O 
in O 
5 O 
patients O 
with O 
abetalipoproteinemia O 
( O 
ABLP O 
) O 
or O 
homozygous O 
hypobetalipoproteinemia O 
, O 
two O 
rare O 
metabolic O 
diseases O 
characterized O 
by O 
the O 
absence O 
of O 
apolipoprotein O 
B O 
- O 
containing O 
lipoproteins O 
, O 
compared O 
to O 
5 O 
control O 
subjects O 
. O 
Platelets O 
isolated O 
from O 
plasma O 
of O 
patients O 
with O 
ABLP O 
aggregated O 
4 O 
to O 
10 O 
times O 
more O 
than O 
control O 
platelets O 
, O 
depending O 
on O 
the O 
agonist O 
. O 
By O 
contrast O 
, O 
no O 
differences O 
in O 
the O 
extent O 
of O 
platelet O 
aggregation O 
were O 
observed O 
between O 
ABLP O 
platelet O 
- O 
rich O 
plasma O 
( O 
PRP O 
) O 
and O 
control O 
PRP O 
, O 
suggesting O 
the O 
presence O 
of O 
a O 
protective O 
factor O 
in O 
ABLP O 
plasma O 
. O 
ABLP O 
HDLs O 
inhibited O 
agonist O 
- O 
induced O 
platelet O 
aggregation O 
by O 
binding O 
to O 
SR-BI O 
, O 
while O 
control O 
HDLs O 
had O 
no O 
effect O 
. O 
On O 
the O 
other O 
hand O 
, O 
lipoprotein O 
- O 
deficient O 
plasma O 
from O 
patients O 
with O 
ABLP O 
did O 
not O 
inhibit O 
platelet O 
aggregation O 
. O 
Severe O 
oxidative O 
stress O 
was O 
evidenced O 
in O 
patients O 
with O 
ABLP O 
. O 
Compared O 
to O 
control O 
HDLs O 
, O 
ABLP O 
HDLs O 
showed O 
a O 
40% O 
decrease O 
of O 
α-tocopherol B-TRIVIAL 
and O 
an O 
11-fold O 
increased O 
malondialdehyde B-TRIVIAL 
concentration O 
. O 
These O 
results O 
demonstrate O 
that O 
in O 
vivo O 
oxidized O 
HDLs O 
do O 
not O 
lose O 
their O 
antiaggregatory O 
properties O 
despite O 
oxidation.-Calzada O 
, O 
C O 
. O 
, O 
Véricel O 
, O 
E O 
. O 
, O 
Colas O 
, O 
R O 
. O 
, O 
Guillot O 
, O 
N O 
. O 
, O 
El O 
Khoury O 
, O 
G O 
. O 
, O 
Drai O 
, O 
J O 
. O 
, O 
Sassolas O 
, O 
A O 
. O 
, O 
Peretti O 
, O 
N O 
. O 
, O 
Ponsin O 
, O 
G O 
. O 
, O 
Lagarde O 
, O 
M O 
. O 
, O 
Moulin O 
, O 
P O 
. O 
Inhibitory O 
effects O 
of O 
in O 
vivo O 
oxidized O 
high O 
- O 
density O 
lipoproteins O 
on O 
platelet O 
aggregation O 
: O 
evidence O 
from O 
patients O 
with O 
abetalipoproteinemia O 
. O 

exposure O 
to O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
impacts O 
midbrain O 
dopamine B-TRIVIAL 
neurons O 
and O 
hippocampal O 
spine O 
synapses O 
in O 
non-human O 
primates O 
. O 

use O 
of O 
bisphenol-A B-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
in O 
the O 
manufacture O 
of O 
resins O 
, O 
plastics O 
and O 
paper O 
products O 
has O 
led O 
to O 
frequent O 
exposure O 
of O 
most O 
people O 
to O 
this O 
endocrine O 
disruptor O 
. O 
Some O 
rodent O 
studies O 
have O 
suggested O 
that O 
BPA B-ABBREVIATION 
can O 
exert O 
detrimental O 
effects O 
on O 
brain O 
development O 
. O 
However O 
as O 
rodent O 
models O 
cannot O 
be O 
relied O 
on O 
to O 
predict O 
consequences O 
of O 
human O 
exposure O 
to O 
BPA B-ABBREVIATION 
during O 
development O 
, O 
it O 
is O 
important O 
to O 
investigate O 
the O 
effects O 
of O 
BPA B-ABBREVIATION 
on O 
non-human O 
primate O 
brain O 
development O 
. O 
Previous O 
research O 
suggests O 
that O 
BPA B-ABBREVIATION 
preferentially O 
targets O 
dopamine B-TRIVIAL 
neurons O 
in O 
ventral O 
mesencephalon O 
and O 
glutamatergic O 
neurons O 
in O 
hippocampus O 
, O 
so O 
the O 
present O 
work O 
examined O 
the O 
susceptibility O 
of O 
these O 
systems O 
to O 
low O 
dose O 
BPA B-ABBREVIATION 
exposure O 
at O 
the O 
fetal O 
and O 
juvenile O 
stages O 
of O 
development O 
in O 
non-human O 
primates O 
. O 
Exposure O 
of O 
pregnant O 
rhesus O 
monkeys O 
to O 
relatively O 
low O 
levels O 
of O 
BPA B-ABBREVIATION 
during O 
the O 
final O 
2 O 
months O 
of O 
gestation O 
, O 
induced O 
abnormalities O 
in O 
fetal O 
ventral O 
mesencephalon O 
and O 
hippocampus O 
. O 
Specifically O 
, O 
light O 
microscopy O 
revealed O 
a O 
decrease O 
in O 
tyrosine B-TRIVIAL 
hydroxylase O 
- O 
expressing O 
( O 
dopamine B-TRIVIAL 
) O 
neurons O 
in O 
the O 
midbrain O 
of O 
BPA B-ABBREVIATION 
-exposed O 
fetuses O 
and O 
electron O 
microscopy O 
identified O 
a O 
reduction O 
in O 
spine O 
synapses O 
in O 
the O 
CA1 O 
region O 
of O 
hippocampus O 
. O 
In O 
contrast O 
, O 
administration O 
of O 
BPA B-ABBREVIATION 
to O 
juvenile O 
vervet O 
monkeys O 
( O 
14-18 O 
months O 
of O 
age O 
) O 
was O 
without O 
effect O 
on O 
these O 
indices O 
, O 
or O 
on O 
dopamine B-TRIVIAL 
and O 
serotonin B-TRIVIAL 
concentrations O 
in O 
striatum O 
and O 
prefrontal O 
cortex O 
, O 
or O 
on O 
performance O 
of O 
a O 
cognitive O 
task O 
that O 
tests O 
working O 
memory O 
capacity O 
. O 
These O 
data O 
indicate O 
that O 
BPA B-ABBREVIATION 
exerts O 
an O 
age O 
- O 
dependent O 
detrimental O 
impact O 
on O 
primate O 
brain O 
development O 
, O 
at O 
blood O 
levels O 
within O 
the O 
range O 
measured O 
in O 
humans O 
having O 
only O 
environmental O 
contact O 
with O 
BPA B-ABBREVIATION 
. O 

European O 
Union's O 
directive O 
for O 
sustainable O 
use O 
of O 
pesticides O 
requires O 
implementing O 
risk O 
mitigation O 
measures O 
at O 
streams O 
threatened O 
by O 
pesticide O 
entries O 
. O 
The O 
need O 
for O 
mitigation O 
measures O 
was O 
investigated O 
at O 
10 O 
stream O 
sites O 
within O 
an O 
intensively O 
used O 
arable O 
region O 
in O 
central O 
Germany O 
by O 
characterizing O 
pesticide O 
exposure O 
following O 
edge O 
- O 
of O 
- O 
field O 
runoff O 
and O 
effects O 
on O 
the O 
aquatic O 
macroinvertebrates O 
. O 
Moreover O 
, O 
the O 
influence O 
of O 
riparian O 
buffer O 
strip O 
width O 
( O 
as O 
a O 
mitigation O 
measure O 
) O 
at O 
the O 
sampling O 
sites O 
was O 
considered O 
. O 
Generally O 
, O 
invertebrate O 
fauna O 
was O 
dominated O 
by O 
pesticide-tolerant O 
species O 
, O 
suggesting O 
a O 
high O 
pesticide O 
exposure O 
at O 
almost O 
all O 
sites O 
. O 
This O 
result O 
is O 
also O 
reflected O 
by O 
the O 
elevated O 
levels O 
of O 
suspended O 
particle O 
contamination O 
in O 
terms O 
of O 
toxic O 
units O 
( O 
logTUMax O 
> O 
-2 O 
) O 
, O 
corresponding O 
to O 
one O 
- O 
hundredth O 
of O 
the O 
median O 
lethal O 
concentration O 
( O 
LC50 O 
) O 
to O 
Daphnia O 
magna O 
. O 
At O 
two O 
sites O 
that O 
received O 
high O 
aqueous O 
- O 
phase O 
entries O 
of O 
the O 
pyrethroid O 
lambda-cyhalothrin B-TRIVIAL 
( O 
logTUMax O 
> O 
-0.6 O 
) O 
, O 
the O 
abundance O 
and O 
number O 
of O 
sensitive O 
species O 
in O 
terms O 
of O 
the O 
species O 
at O 
risk O 
index O 
decreased O 
during O 
the O 
pesticide O 
application O 
period O 
. O 
In O 
contrast O 
, O 
no O 
acute O 
significant O 
negative O 
effects O 
on O 
macroinvertebrates O 
were O 
observed O 
at O 
sites O 
characterised O 
by O 
low O 
water O 
- O 
phase O 
toxicity O 
( O 
logTUMax O 
< O 
-3.5 O 
) O 
. O 
An O 
influence O 
of O 
riparian O 
buffer O 
strip O 
width O 
on O 
pesticide O 
exposure O 
was O 
not O 
observed O 
, O 
supposedly O 
because O 
of O 
the O 
presence O 
of O 
erosion O 
rills O 
and O 
ephemeral O 
ditches O 
. O 
In O 
conclusion O 
, O 
results O 
show O 
that O 
mitigation O 
measures O 
( O 
such O 
as O 
the O 
improvement O 
of O 
currently O 
present O 
riparian O 
buffer O 
strips O 
) O 
are O 
needed O 
in O 
the O 
study O 
area O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1254-1263 O 
. O 
© O 
2013 O 
SETAC O 
. O 

study O 
of O 
the O 
pH-dependent O 
antioxidant O 
properties O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
. O 

acting O 
as O 
antioxidants O 
capable O 
of O 
scavenging O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
are O 
of O 
utmost O 
importance O 
in O 
the O 
living O 
cell O 
. O 
Vitamin B-TRIVIAL 
C I-TRIVIAL 
is O 
known O 
to O 
be O 
one O 
of O 
these O 
molecules O 
. O 
In O 
this O 
study O 
we O 
have O 
analyzed O 
the O 
reactivity O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
toward O 
the O 
[ O 
Formula O 
: O 
see O 
text O 
] O 
and O 
[ O 
Formula O 
: O 
see O 
text O 
] O 
ROS O 
species O 
, O 
in O 
all O 
acidic O 
, O 
neutral O 
and O 
basic O 
media O 
. O 
In O 
order O 
to O 
do O 
so O 
, O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
have O 
been O 
used O 
. O 
More O 
concretely O 
, O 
the O 
meta-GGA O 
functional O 
MPW1B95 O 
have O 
been O 
used O 
. O 
Two O 
reaction O 
types O 
have O 
been O 
studied O 
in O 
each O 
case O 
: O 
addition O 
to O 
the O 
ring O 
atoms O 
, O 
and O 
hydrogen B-SYSTEMATIC 
/ O 
proton O 
abstraction O 
. O 
Our O 
results O 
show O 
that O 
[ O 
Formula O 
: O 
see O 
text O 
] O 
is O 
the O 
most O 
reactive O 
species O 
, O 
while O 
[ O 
Formula O 
: O 
see O 
text O 
] O 
displays O 
low O 
reactivity O 
. O 
In O 
all O 
three O 
media O 
, O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
reactions O 
with O 
two O 
hydroxyl B-SYSTEMATIC 
radicals O 
show O 
a O 
wide O 
variety O 
of O 
possible O 
products O 
. O 

self O 
- O 
healing O 
of O 
polyethylene B-SYSTEMATIC 
/ O 
carbon B-TRIVIAL 
black I-TRIVIAL 
nanocomposites O 
by O 
their O 
shape O 
memory O 
effect O 
. O 

this O 
work O 
, O 
the O 
improved O 
self O 
- O 
healing O 
of O 
cross O 
- O 
linked O 
polyethylene B-SYSTEMATIC 
( O 
PE O 
) O 
(cPE)/ O 
carbon B-TRIVIAL 
black I-TRIVIAL 
( O 
CB O 
) O 
nanocomposites O 
by O 
their O 
shape O 
memory O 
effect O 
( O 
SME O 
) O 
is O 
investigated O 
. O 
CB O 
nanoparticles O 
are O 
found O 
to O 
be O 
homogeneously O 
dispersed O 
in O 
the O 
PE O 
matrix O 
and O 
significantly O 
increase O 
the O 
strength O 
of O 
the O 
materials O 
. O 
Compared O 
with O 
the O 
breaking O 
of O 
linear O 
PE O 
( O 
lPE O 
) O 
at O 
the O 
melting O 
temperature O 
(T(m)) O 
, O 
the O 
cPE O 
and O 
cPE O 
/ O 
CB O 
nanocomposites O 
still O 
have O 
high O 
strength O 
above O 
T(m) O 
due O 
to O 
the O 
formation O 
of O 
networks O 
. O 
The O 
cPE O 
and O 
cPE O 
/ O 
CB O 
nanocomposites O 
show O 
both O 
high O 
strain O 
fixity O 
ratio O 
(R(f)) O 
and O 
high O 
strain O 
recovery O 
ratio O 
(R(r)) O 
. O 
Crystallization O 
- O 
induced O 
elongation O 
is O 
observed O 
for O 
all O 
the O 
prepared O 
shape O 
memory O 
polymer O 
( O 
SMP O 
) O 
materials O 
and O 
the O 
effect O 
becomes O 
less O 
remarkable O 
with O 
increasing O 
volume O 
fraction O 
of O 
CB O 
nanoparticles O 
(v(CB)) O 
. O 
The O 
scratch O 
self O 
- O 
healing O 
tests O 
show O 
that O 
the O 
cross O 
- O 
linking O 
of O 
PE O 
matrix O 
, O 
the O 
addition O 
of O 
CB O 
nanoparticles O 
, O 
and O 
the O 
previous O 
stretching O 
in O 
the O 
direction O 
perpendicular O 
to O 
the O 
scratch O 
favor O 
the O 
closure O 
of O 
the O 
scratch O 
and O 
its O 
complete O 
healing O 
. O 
This O 
SME-aided O 
self O 
- O 
healing O 
could O 
have O 
potential O 
applications O 
in O 
diverse O 
fields O 
such O 
as O 
coating O 
and O 
structure O 
materials O 
. O 

OUR O 
KNOWLEDGE O 
: O 
Natural O 
lipocyclocarbamate O 
natural O 
products O 
have O 
provided O 
the O 
inspiration O 
for O 
the O 
first O 
- O 
in O 
- O 
class O 
synthetic O 
phospholipase O 
inhibitor O 
darapladib B-TRIVIAL 
, O 
currently O 
in O 
phase O 
III O 
clinical O 
trials O 
for O 
the O 
treatment O 
of O 
atherosclerosis O 
. O 
Here O 
, O 
we O 
discuss O 
their O 
biosynthesis O 
by O 
a O 
nonribosomal O 
peptide O 
synthetase O 
. O 

stimulates O 
glucose B-TRIVIAL 
transport O 
in O 
C2C12 O 
myotubes O 
via O 
an O 
IRS-1 O 
and O 
calcium B-SYSTEMATIC 
-dependent O 
mechanism O 
. O 

, O 
a O 
compound O 
derived O 
from O 
Gardenia O 
jasminoides O 
Ellis O 
fruits O 
, O 
has O 
been O 
used O 
over O 
the O 
years O 
in O 
traditional O 
Chinese O 
medicine O 
to O 
treat O 
symptoms O 
of O 
type O 
2 O 
diabetes O 
. O 
However O 
, O 
the O 
molecular O 
basis O 
for O 
its O 
antidiabetic O 
effect O 
has O 
not O 
been O 
fully O 
revealed O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
genipin B-TRIVIAL 
on O 
glucose B-TRIVIAL 
uptake O 
and O 
signaling O 
pathways O 
in O 
C(2)C(12) O 
myotubes O 
. O 
Our O 
study O 
demonstrates O 
that O 
genipin B-TRIVIAL 
stimulated O 
glucose B-TRIVIAL 
uptake O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
maximal O 
effect O 
was O 
achieved O 
at O 
2 O 
h O 
with O 
a O 
concentration O 
of O 
10 O 
μM O 
. O 
In O 
myotubes O 
, O 
genipin B-TRIVIAL 
promoted O 
glucose B-TRIVIAL 
transporter O 
4 O 
( O 
GLUT4 O 
) O 
translocation O 
to O 
the O 
cell O 
surface O 
, O 
which O 
was O 
observed O 
by O 
analyzing O 
their O 
distribution O 
in O 
subcellular O 
membrane O 
fraction O 
, O 
and O 
increased O 
the O 
phosphorylation O 
of O 
insulin O 
receptor O 
substrate-1 O 
( O 
IRS-1 O 
) O 
, O 
AKT O 
, O 
and O 
GSK3β O 
. O 
Meanwhile O 
, O 
genipin B-TRIVIAL 
increased O 
ATP B-ABBREVIATION 
levels O 
, O 
closed O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
, O 
and O 
then O 
increased O 
the O 
concentration O 
of O 
calcium B-SYSTEMATIC 
in O 
the O 
cytoplasm O 
in O 
C(2)C(12) O 
myotubes O 
. O 
Genipin B-TRIVIAL 
-stimulated O 
glucose B-TRIVIAL 
uptake O 
could O 
be O 
blocked O 
by O 
both O 
the O 
PI3-K O 
inhibitor O 
wortmannin B-TRIVIAL 
and O 
calcium B-SYSTEMATIC 
chelator O 
EGTA B-ABBREVIATION 
. O 
Moreover O 
, O 
genipin B-TRIVIAL 
increases O 
the O 
level O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
ATP B-ABBREVIATION 
in O 
C(2)C(12) O 
myotubes O 
. O 
These O 
results O 
suggest O 
that O 
genipin B-TRIVIAL 
activates O 
IRS-1 O 
, O 
PI3-K O 
, O 
and O 
downstream O 
signaling O 
pathway O 
and O 
increases O 
concentrations O 
of O 
calcium B-SYSTEMATIC 
, O 
resulting O 
in O 
GLUT4 O 
translocation O 
and O 
glucose B-TRIVIAL 
uptake O 
increase O 
in O 
C(2)C(12) O 
myotubes O 
. O 

, O 
little O 
is O 
known O 
about O 
the O 
environmental O 
fate O 
and O 
persistence O 
of O 
novel O 
brominated O 
flame O 
retardants O 
( O 
NBFRs O 
) O 
. O 
The O 
recent O 
detection O 
of O 
NBFRs O 
in O 
sediment O 
cores O 
and O 
air O 
samples O 
provides O 
insight O 
into O 
their O 
persistence O 
and O 
potential O 
for O 
transport O 
. O 
Limited O 
numbers O 
of O 
laboratory O 
studies O 
have O 
examined O 
the O 
fate O 
and O 
behavior O 
of O 
these O 
compounds O 
, O 
but O 
field O 
- O 
based O 
fate O 
studies O 
have O 
been O 
especially O 
lacking O 
. O 
The O 
authors O 
conducted O 
an O 
aquatic O 
mesocosm O 
experiment O 
to O 
assess O 
the O 
behavior O 
of O 
three O 
NBFRs O 
: O 
bis(tribromophenoxy)ethane B-SYSTEMATIC 
( O 
BTBPE B-ABBREVIATION 
) O 
, O 
tetrabromobisphenol B-SYSTEMATIC 
A I-SYSTEMATIC 
bis(2,3-dibromopropyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
; O 
TBBPA B-ABBREVIATION 
- O 
DBPE B-ABBREVIATION 
) O 
, O 
and O 
Firemaster B-TRIVIAL 
BZ-54 I-TRIVIAL 
, O 
a O 
commercial O 
mixture O 
containing O 
bis(2-ethylhexyl)tetrabromophthalate B-SYSTEMATIC 
( O 
BEHTBP B-ABBREVIATION 
) O 
and O 
2-ethylhexyl-2,3,4,5-tetrabromobenzoate B-SYSTEMATIC 
( O 
EHTeBB B-ABBREVIATION 
) O 
in O 
a O 
ratio O 
of O 
1 O 
: O 
4 O 
. O 
Analysis O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
, O 
operated O 
in O 
the O 
electron O 
capture O 
negative O 
ionization O 
mode O 
, O 
revealed O 
partitioning O 
between O 
the O 
particulate O 
and O 
sediment O 
phases O 
, O 
with O 
BTBPE B-ABBREVIATION 
, O 
TBBPA B-ABBREVIATION 
- O 
DBPE B-ABBREVIATION 
, O 
and O 
BEHTBP B-ABBREVIATION 
identified O 
as O 
being O 
environmentally O 
persistent O 
in O 
both O 
the O 
particulate O 
and O 
the O 
sediment O 
compartments O 
. O 
The O 
median O 
dissipation O 
times O 
( O 
DT50 O 
) O 
differed O 
in O 
each O 
compartment O 
, O 
with O 
more O 
rapid O 
disappearance O 
in O 
the O 
particulate O 
( O 
9-30 O 
d O 
) O 
compared O 
with O 
the O 
sediment O 
compartment O 
( O 
> O 
100 O 
d O 
) O 
for O 
each O 
compound O 
. O 
The O 
degradation O 
products O 
were O 
more O 
concentrated O 
in O 
the O 
particulate O 
compartment O 
and O 
corresponded O 
to O 
known O 
photodegradation O 
products O 
. O 
The O 
ratio O 
of O 
EHTeBB B-ABBREVIATION 
to O 
BEHTBP B-ABBREVIATION 
differed O 
in O 
the O 
mesocosm O 
compartments O 
compared O 
with O 
the O 
technical O 
product O 
used O 
for O 
treatment O 
, O 
indicating O 
increased O 
degradation O 
of O 
EHTeBB B-ABBREVIATION 
relative O 
to O 
BETHBP B-ABBREVIATION 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1060-1068 O 
. O 
© O 
2013 O 
SETAC O 
. O 

mycotoxins O 
including O 
six O 
aspergillic B-TRIVIAL 
acid I-TRIVIAL 
group O 
toxins O 
, O 
aluminiumneoaspergillin B-TRIVIAL 
( O 
1 O 
) O 
, O 
zirconiumneoaspergillin B-TRIVIAL 
( O 
2 O 
) O 
, O 
aspergilliamide B-TRIVIAL 
( O 
3 O 
) O 
, O 
ferrineoaspergillin B-TRIVIAL 
( O 
5 O 
) O 
, O 
flavacol B-TRIVIAL 
( O 
6 O 
) O 
, O 
neoaspergillic B-TRIVIAL 
acid I-TRIVIAL 
( O 
7 O 
) O 
, O 
and O 
three O 
ochratoxins B-FAMILY 
, O 
ochratoxin B-SYSTEMATIC 
A I-SYSTEMATIC 
n-butyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
( O 
8 O 
) O 
, O 
ochratoxin B-SYSTEMATIC 
A I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
9 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
fermentation O 
broth O 
of O 
marine O 
gorgonian O 
derived O 
fungus O 
Aspergillus O 
sp O 
. O 
SCSGAF0093 O 
. O 
Four O 
of O 
them O 
( O 
1-4 O 
) O 
were O 
new O 
mycotoxins O 
, O 
and O 
their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
analysis O 
and O 
chemical O 
evidence O 
. O 
The O 
bio O 
- O 
toxicity O 
of O 
compounds O 
1-9 O 
were O 
determined O 
by O 
brine O 
shrimp O 
lethality O 
bioassay O 
with O 
median O 
lethal O 
concentration O 
(LC(50)) O 
values O 
of O 
2.59-205.67 O 
μM O 
. O 
This O 
was O 
the O 
first O 
report O 
about O 
zirconium B-FAMILY 
complex O 
obtained O 
from O 
nature O 
and O 
ochratoxins B-FAMILY 
isolated O 
from O 
marine O 
environment O 
. O 

objective O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
the O 
plasma O 
total O 
oxidative O 
status O 
( O 
TOS O 
) O 
and O 
total O 
antioxidant O 
capacity O 
( O 
TAC O 
) O 
in O 
patients O 
with O 
endemic O 
fluorosis O 
. O 
A O 
total O 
of O 
79 O 
( O 
35 O 
males O 
and O 
44 O 
females O 
; O 
mean O 
age O 
44 O 
± O 
11.9 O 
years O 
) O 
patients O 
with O 
endemic O 
fluorosis O 
and O 
55 O 
( O 
23 O 
males O 
and O 
32 O 
females O 
; O 
mean O 
age O 
48.3 O 
± O 
8.5 O 
years O 
) O 
age- O 
, O 
sex- O 
and O 
body O 
mass O 
index O 
- O 
matched O 
healthy O 
controls O 
were O 
included O 
in O 
this O 
study O 
. O 
The O 
urine O 
fluoride B-SYSTEMATIC 
levels O 
and O 
plasma O 
TOS O 
and O 
TAC O 
levels O 
were O 
measured O 
. O 
The O 
urine O 
fluoride B-SYSTEMATIC 
levels O 
of O 
fluorosis O 
patients O 
were O 
significantly O 
higher O 
than O 
control O 
subjects O 
as O 
expected O 
( O 
1.91 O 
± O 
0.15 O 
vs O 
. O 
0.49 O 
± O 
0.13 O 
mg O 
/ O 
L O 
, O 
respectively O 
; O 
p O 
< O 
0.001 O 
) O 
. O 
TOS O 
was O 
significantly O 
higher O 
in O 
fluorosis O 
group O 
than O 
in O 
control O 
group O 
( O 
17.55 O 
± O 
3.82 O 
vs O 
. O 
15.06 O 
± O 
4.31 O 
μmol O 
H(2)O(2) O 
Eq O 
/ O 
L O 
, O 
respectively O 
; O 
p O 
= O 
0.001 O 
) O 
. O 
TAC O 
was O 
significantly O 
lower O 
in O 
fluorosis O 
group O 
than O 
in O 
control O 
group O 
( O 
1.6 O 
± O 
0.36 O 
vs O 
. O 
1.82 O 
± O 
0.51 O 
mmol O 
Trolox B-TRIVIAL 
Eq O 
/ O 
L O 
, O 
respectively O 
; O 
p O 
= O 
0.004 O 
) O 
. O 
Oxidative O 
stress O 
index O 
( O 
OSI O 
) O 
was O 
significantly O 
higher O 
in O 
fluorosis O 
group O 
than O 
in O 
control O 
group O 
( O 
11.5 O 
± O 
3.8 O 
vs O 
. O 
8.8 O 
± O 
3.7 O 
, O 
respectively O 
; O 
p O 
< O 
0.001 O 
) O 
. O 
Correlation O 
analysis O 
in O 
all O 
the O 
groups O 
indicated O 
that O 
TAC O 
was O 
negatively O 
correlated O 
with O 
urine O 
fluoride B-SYSTEMATIC 
( O 
r O 
= O 
-0.25 O 
, O 
p O 
= O 
0.003 O 
) O 
, O 
TOS O 
was O 
positively O 
correlated O 
with O 
urine O 
fluoride B-SYSTEMATIC 
( O 
r O 
= O 
0.34 O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
OSI O 
was O 
positively O 
correlated O 
with O 
urine O 
fluoride B-SYSTEMATIC 
( O 
r O 
= O 
0.36 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
The O 
results O 
of O 
our O 
study O 
demonstrate O 
that O 
oxidative O 
stress O 
plays O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
the O 
endemic O 
fluorosis O 
. O 

effect O 
of O 
ganodermanondiol B-TRIVIAL 
isolated O 
from O 
the O 
Lingzhi O 
mushroom O 
against O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
-induced O 
hepatotoxicity O 
through O 
Nrf2 O 
- O 
mediated O 
antioxidant O 
enzymes O 
. O 

, O 
a O 
biologically O 
active O 
compound O 
, O 
was O 
isolated O 
from O 
the O 
Lingzhi O 
mushroom O 
( O 
Ganoderma O 
lucidum O 
) O 
. O 
The O 
present O 
study O 
examined O 
the O 
protective O 
effects O 
of O 
ganodermanondiol B-TRIVIAL 
against O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
( O 
t-BHP B-ABBREVIATION 
)-induced O 
hepatotoxicity O 
. O 
Ganodermanondiol B-TRIVIAL 
protected O 
human O 
liver O 
- O 
derived O 
HepG2 O 
cells O 
through O 
nuclear O 
factor-E2 O 
- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
pathway O 
- O 
dependent O 
heme B-FAMILY 
oxygenase-1 O 
expressions O 
. O 
Moreover O 
, O 
ganodermanondiol B-TRIVIAL 
increased O 
cellular O 
glutathione B-TRIVIAL 
levels O 
and O 
the O 
expression O 
of O 
the O 
glutamine B-TRIVIAL 
- O 
cysteine B-TRIVIAL 
ligase O 
gene O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Furthermore O 
, O 
ganodermanondiol B-TRIVIAL 
exposure O 
enhanced O 
the O 
phosphorylation O 
of O 
adenosine B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
and O 
its O 
upstream O 
kinase O 
activators O 
, O 
LKB1 O 
and O 
Ca(2+) B-FORMULA 
/ O 
calmodulin O 
- O 
dependent O 
protein O 
kinase-II O 
( O 
CaMKII O 
) O 
. O 
This O 
study O 
indicates O 
that O 
ganodermanondiol B-TRIVIAL 
exhibits O 
potent O 
cytoprotective O 
effects O 
on O 
t-BHP B-ABBREVIATION 
-induced O 
hepatotoxicity O 
in O 
human O 
liver O 
- O 
derived O 
HepG2 O 
cells O 
, O 
presumably O 
through O 
Nrf2 O 
- O 
mediated O 
antioxidant O 
enzymes O 
and O 
AMPK O 
. O 

' O 
/ O 
C4'-Stereochemical O 
Effects O 
of O 
Digitoxigenin B-TRIVIAL 
α-L- B-MULTIPLE 
/ I-MULTIPLE 
α-D-Glycoside I-MULTIPLE 
in O 
Cancer O 
Cytotoxicity O 
. O 

low O 
in O 
stereo O 
: O 
A O 
Wharton O 
reaction O 
was O 
employed O 
along O 
with O 
a O 
diastereoselective O 
palladium B-SYSTEMATIC 
-catalyzed O 
glycosylation O 
and O 
other O 
post O 
- O 
glycosylation O 
transformations O 
to O 
synthesize O 
digitoxin B-TRIVIAL 
analogues O 
. O 
Cytotoxic O 
evaluation O 
against O 
a O 
panel O 
of O 
cancer O 
cell O 
lines O 
uncovered O 
the O 
stereochemical O 
and O 
substitutional O 
limits O 
of O 
the O 
C3 B-SYSTEMATIC 
' I-SYSTEMATIC 
/ I-SYSTEMATIC 
C4'-hydroxy I-SYSTEMATIC 
functionality O 
in O 
digitoxin B-TRIVIAL 
monosaccharide B-FAMILY 
. O 

, O 
estrogens B-FAMILY 
and O 
frailty O 
. O 

The O 
controversy O 
surrounding O 
the O 
results O 
from O 
the O 
Women's O 
Health O 
Initiative O 
( O 
WHI O 
) O 
trials O 
published O 
a O 
decade O 
ago O 
caused O 
a O 
significant O 
decline O 
in O 
the O 
use O 
of O 
menopausal O 
hormone O 
replacement O 
therapy O 
. O 
However O 
, O 
these O 
results O 
have O 
been O 
vehemently O 
contested O 
and O 
several O 
lines O 
of O 
evidence O 
suggest O 
that O 
in O 
perimenopausal O 
and O 
non-obese O 
women O 
, O 
estrogen B-FAMILY 
therapy O 
may O 
indeed O 
be O 
of O 
benefit O 
. O 
There O 
is O 
ample O 
proof O 
that O 
menopause O 
causes O 
a O 
loss O 
of O 
musculoskeletal O 
tissue O 
mass O 
and O 
quality O 
, O 
thereby O 
causing O 
a O 
loss O 
of O 
health O 
and O 
quality O 
of O 
life O 
. O 
There O 
is O 
also O 
solid O 
evidence O 
that O 
hormone O 
replacement O 
therapy O 
in O 
itself O 
prevents O 
most O 
of O 
these O 
effects O 
in O 
connective O 
tissue O 
in O 
it O 
self O 
. O 
Besides O 
the O 
independent O 
, O 
direct O 
effects O 
on O 
the O 
musculoskeletal O 
tissues O 
, O 
estrogen B-FAMILY 
deficiency O 
also O 
reduces O 
the O 
ability O 
to O 
adequately O 
respond O 
and O 
adapt O 
to O 
external O 
mechanical O 
and O 
metabolic O 
stressors O 
, O 
e.g O 
. O 
exercise O 
, O 
which O 
are O 
otherwise O 
the O 
main O 
stimuli O 
that O 
should O 
maintain O 
musculoskeletal O 
integrity O 
and O 
metabolic O 
function O 
. O 
Thus O 
, O 
normophysiological O 
estrogen B-FAMILY 
levels O 
appear O 
to O 
exert O 
a O 
permissive O 
effect O 
on O 
musculoskeletal O 
adaptations O 
to O 
loading O 
, O 
thereby O 
likely O 
improving O 
the O 
outcome O 
of O 
rehabilitation O 
following O 
critical O 
illness O 
, O 
musculoskeletal O 
trauma O 
or O 
orthopedic O 
surgical O 
therapy O 
. O 
These O 
effects O 
add O 
to O 
the O 
evidence O 
supporting O 
the O 
use O 
of O 
estrogen B-FAMILY 
therapy O 
, O 
particularly O 
accelerated O 
gain O 
of O 
functional O 
capacity O 
and O 
independence O 
following O 
musculoskeletal O 
disuse O 
. O 

of O 
oxysterol B-FAMILY 
-derived O 
pharmacological O 
chaperones O 
for O 
NPC1 O 
: O 
implication O 
for O 
the O 
existence O 
of O 
second O 
sterol B-FAMILY 
-binding O 
site O 
. O 

type O 
C1 O 
( O 
NPC1 O 
) O 
is O 
a O 
polytopic O 
endosomal O 
membrane O 
protein O 
required O 
for O 
efflux O 
of O 
LDL O 
- O 
derived O 
cholesterol B-TRIVIAL 
from O 
endosomes O 
, O 
and O 
mutations O 
of O 
this O 
protein O 
are O 
associated O 
with O 
Niemann-Pick O 
disease O 
type O 
C O 
, O 
a O 
fatal O 
neurodegenerative O 
disease O 
. O 
At O 
least O 
one O 
prevalent O 
mutation O 
( O 
I1061T O 
) O 
has O 
been O 
shown O 
to O 
cause O 
a O 
folding O 
defect O 
, O 
which O 
results O 
in O 
failure O 
of O 
endosomal O 
localization O 
, O 
leading O 
to O 
a O 
loss O 
- O 
of O 
- O 
function O 
phenotype O 
. O 
Here O 
, O 
we O 
show O 
that O 
several O 
oxysterols B-FAMILY 
and O 
their O 
derivatives O 
act O 
as O 
pharmacological O 
chaperones O 
; O 
binding O 
of O 
these O 
compounds O 
to O 
I1061T O 
NPC1 O 
corrects O 
the O 
localization O 
/ O 
maturation O 
defect O 
of O 
the O 
mutant O 
protein O 
. O 
Further O 
, O 
these O 
compounds O 
alleviate O 
intracellular O 
cholesterol B-TRIVIAL 
accumulation O 
in O 
patient O 
- O 
derived O 
fibroblasts O 
, O 
suggesting O 
that O 
they O 
may O 
have O 
therapeutic O 
potential O 
. O 
These O 
oxysterol B-FAMILY 
derivatives O 
bind O 
to O 
a O 
domain O 
of O 
NPC1 O 
that O 
is O 
different O 
from O 
the O 
known O 
N B-FORMULA 
-terminal O 
sterol B-FAMILY 
-binding O 
domain O 
; O 
i.e O 
. O 
, O 
there O 
is O 
an O 
additional O 
sterol B-FAMILY 
-binding O 
site O 
on O 
NPC1 O 
. O 

of O 
Chloronitrobenzamides B-FAMILY 
( O 
CNBs B-FAMILY 
) O 
as O 
Therapeutic O 
Leads O 
for O 
Human O 
African O 
Trypanosomiasis O 
( O 
HAT O 
) O 
. O 

previously O 
reported O 
the O 
discovery O 
of O 
the O 
activity O 
of O 
chloronitrobenzamides B-FAMILY 
( O 
CNBs B-FAMILY 
) O 
against O 
bloodstream O 
forms O 
of O 
Trypanosoma O 
brucei O 
. O 
Herein O 
we O 
disclose O 
extensive O 
structure O 
- O 
activity O 
relationship O 
and O 
structure O 
- O 
property O 
relationship O 
studies O 
aimed O 
at O 
identification O 
of O 
tractable O 
early O 
leads O 
for O 
clinical O 
development O 
. O 
These O 
studies O 
revealed O 
a O 
promising O 
lead O 
compound O 
, O 
17b O 
, O 
that O 
exhibited O 
nanomolar O 
potency O 
against O 
T O 
. O 
brucei O 
( O 
EC50 O 
= O 
27 O 
nM O 
for O 
T O 
. O 
b O 
. O 
brucei O 
, O 
7 O 
nM O 
for O 
T O 
. O 
b O 
. O 
rhodesiense O 
, O 
and O 
2 O 
nM O 
for O 
T O 
. O 
b O 
. O 
gambiense O 
) O 
with O 
excellent O 
selectivity O 
for O 
parasite O 
cells O 
relative O 
to O 
mammalian O 
cell O 
lines O 
( O 
EC50 O 
> O 
25 O 
μM O 
) O 
. O 
In O 
addition O 
compound O 
17b O 
displayed O 
suitable O 
physiochemical O 
characteristics O 
and O 
microsomal O 
stability O 
( O 
t1 O 
/ O 
2 O 
> O 
4 O 
h O 
for O 
human O 
and O 
mouse O 
) O 
to O 
justify O 
pursuing O 
in O 
vivo O 
studies O 
. O 

colon O 
carcinogen O 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
is O 
actively O 
secreted O 
in O 
the O 
distal O 
colon O 
of O 
the O 
rat O 
: O 
an O 
integrated O 
view O 
on O 
the O 
role O 
of O 
PhIP B-ABBREVIATION 
transport O 
and O 
metabolism O 
in O 
PhIP B-ABBREVIATION 
-induced O 
colon O 
carcinogenesis O 
. O 

studies O 
show O 
that O 
a O 
positive O 
correlation O 
exists O 
between O 
the O 
consumption O 
of O 
strongly O 
heated O 
meat O 
and O 
fish O 
and O 
the O 
development O 
of O 
colorectal O 
tumours O 
. O 
In O 
this O 
context O 
, O 
it O 
has O 
been O 
postulated O 
that O 
the O 
uptake O 
of O 
toxic O 
substances O 
formed O 
during O 
meat O 
and O 
fish O 
processing O 
such O 
as O 
heterocyclic B-FAMILY 
aromatic I-FAMILY 
amines I-FAMILY 
( O 
HCAs B-ABBREVIATION 
) O 
may O 
be O 
causally O 
related O 
to O 
colon O 
carcinogenesis O 
. O 
In O 
a O 
previous O 
study O 
, O 
we O 
have O 
shown O 
that O 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
, O 
the O 
most O 
abundantly O 
formed O 
HCA B-ABBREVIATION 
in O 
the O 
above O 
- O 
mentioned O 
food O 
items O 
, O 
is O 
mainly O 
absorbed O 
in O 
the O 
small O 
intestine O 
( O 
i.e O 
. O 
proximal O 
jejunum O 
) O 
of O 
the O 
rat O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
analysed O 
whether O 
PhIP B-ABBREVIATION 
can O 
actively O 
be O 
secreted O 
by O 
enterocytes O 
in O 
the O 
rat O 
proximal O 
jejunum O 
and O 
distal O 
colon O 
. O 
Unidirectional O 
PhIP B-ABBREVIATION 
flux O 
rates O 
from O 
the O 
mucosal O 
- O 
to O 
- O 
the O 
serosal O 
compartment O 
( O 
J O 
ms O 
) O 
and O 
in O 
the O 
opposite O 
direction O 
( O 
J O 
sm O 
) O 
were O 
examined O 
in O 
Ussing O 
chambers O 
with O 
(14)C-PhIP B-FORMULA 
as O 
radiotracer O 
and O 
in O 
the O 
absence O 
of O 
electrochemical O 
gradients O 
. O 
Under O 
these O 
experimental O 
conditions O 
, O 
significant O 
negative O 
net O 
flux O 
rates O 
( O 
J O 
net O 
= O 
J O 
ms O 
- O 
J O 
sm O 
) O 
can O 
only O 
be O 
explained O 
by O 
an O 
active O 
secretion O 
of O 
PhIP B-ABBREVIATION 
into O 
the O 
luminal O 
compartment O 
, O 
and O 
such O 
an O 
effect O 
was O 
observed O 
in O 
the O 
rat O 
distal O 
colon O 
, O 
but O 
not O 
in O 
the O 
proximal O 
jejunum O 
. O 
Moreover O 
, O 
the O 
data O 
obtained O 
suggest O 
that O 
the O 
breast O 
cancer O 
resistance O 
protein O 
, O 
the O 
multidrug O 
resistance O 
protein O 
4 O 
and O 
P-glycoprotein O 
are O 
not O 
involved O 
in O 
the O 
active O 
secretion O 
of O 
PhIP B-ABBREVIATION 
in O 
the O 
rat O 
distal O 
colon O 
. O 
The O 
potential O 
role O 
of O 
PhIP B-ABBREVIATION 
transport O 
in O 
colon O 
carcinogenesis O 
is O 
discussed O 
. O 

the O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
activates O 
is O 
incompletely O 
understood O 
. O 
The O 
intracellular O 
portion O 
of O 
the O 
receptor O 
is O 
intrinsically O 
active O 
in O 
solution O 
, O 
and O 
to O 
study O 
its O 
regulation O 
, O 
we O 
measured O 
autophosphorylation O 
as O 
a O 
function O 
of O 
EGFR O 
surface O 
density O 
in O 
cells O 
. O 
Without O 
EGF O 
, O 
intact O 
EGFR O 
escapes O 
inhibition O 
only O 
at O 
high O 
surface O 
densities O 
. O 
Although O 
the O 
transmembrane O 
helix O 
and O 
the O 
intracellular O 
module O 
together O 
suffice O 
for O 
constitutive O 
activity O 
even O 
at O 
low O 
densities O 
, O 
the O 
intracellular O 
module O 
is O 
inactivated O 
when O 
tethered O 
on O 
its O 
own O 
to O 
the O 
plasma O 
membrane O 
, O 
and O 
fluorescence O 
cross O 
- O 
correlation O 
shows O 
that O 
it O 
fails O 
to O 
dimerize O 
. O 
NMR O 
and O 
functional O 
data O 
indicate O 
that O 
activation O 
requires O 
an O 
N B-FORMULA 
-terminal O 
interaction O 
between O 
the O 
transmembrane O 
helices O 
, O 
which O 
promotes O 
an O 
antiparallel O 
interaction O 
between O 
juxtamembrane O 
segments O 
and O 
release O 
of O 
inhibition O 
by O 
the O 
membrane O 
. O 
We O 
conclude O 
that O 
EGF O 
binding O 
removes O 
steric O 
constraints O 
in O 
the O 
extracellular O 
module O 
, O 
promoting O 
activation O 
through O 
N B-FORMULA 
-terminal O 
association O 
of O 
the O 
transmembrane O 
helices O 
. O 

protects O 
human O 
EA.hy926 O 
endothelial O 
cells O 
against O 
gamma-radiation O 
induced O 
oxidative O 
injury O 
by O 
activating O 
the O 
NF-E2 O 
- O 
related O 
factor O 
2/ O 
heme B-FAMILY 
oxygenase-1 O 
pathway O 
. O 

endothelial O 
cells O 
have O 
been O 
demonstrated O 
to O 
have O 
a O 
critical O 
role O 
in O 
the O 
pathogenesis O 
of O 
radiation O 
- O 
induced O 
lung O 
injury O 
. O 
Our O 
preliminary O 
experiments O 
indicated O 
that O 
Paeoniflorin B-TRIVIAL 
protected O 
human O 
EA.hy926 O 
endothelial O 
cells O 
from O 
radiation O 
- O 
induced O 
oxidative O 
injury O 
. O 
This O 
study O 
was O 
designed O 
to O 
confirm O 
the O 
protective O 
effect O 
of O 
Paeoniflorin B-TRIVIAL 
against O 
radiation O 
- O 
induced O 
endothelial O 
cellular O 
damage O 
and O 
to O 
elucidate O 
the O 
underlying O 
mechanisms O 
. O 
Preincubation O 
of O 
EA.hy926 O 
cells O 
with O 
Paeoniflorin B-TRIVIAL 
before O 
γ-radiation O 
resulted O 
in O 
significant O 
inhibition O 
of O 
apoptosis O 
, O 
a O 
decrease O 
in O 
mitochondrial O 
membrane O 
potential O 
and O 
enhanced O 
cell O 
viability O 
. O 
In O 
particular O 
, O 
we O 
showed O 
that O 
Paeoniflorin B-TRIVIAL 
significantly O 
reduced O 
the O 
formation O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
the O 
level O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
and O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
leakage O 
, O 
and O 
enhanced O 
production O 
of O 
the O 
endogenous O 
antioxidants O 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
in O 
EA.hy926 O 
cells O 
. O 
Treatment O 
of O 
these O 
cells O 
with O 
Paeoniflorin B-TRIVIAL 
significantly O 
induced O 
HO-1 O 
expression O 
. O 
Moreover O 
, O 
Paeoniflorin B-TRIVIAL 
promoted O 
the O 
nuclear O 
translocation O 
of O 
nuclear O 
factor O 
erythroid O 
2 O 
related O 
factor-2 O 
( O 
Nrf-2 O 
) O 
. O 
The O 
Paeoniflorin B-TRIVIAL 
-induced O 
HO-1 O 
expression O 
was O 
abrogated O 
by O 
Nrf2 O 
siRNA O 
. O 
Furthermore O 
, O 
inhibition O 
of O 
HO-1 O 
with O 
zinc B-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
IX I-SYSTEMATIC 
( O 
ZNPP B-ABBREVIATION 
) O 
significantly O 
reversed O 
the O 
protective O 
effect O 
of O 
Paeoniflorin B-TRIVIAL 
against O 
radiation O 
- O 
induced O 
damage O 
in O 
EA.hy926 O 
cells O 
. O 
Our O 
findings O 
confirmed O 
that O 
Paeoniflorin B-TRIVIAL 
protected O 
EA.hy926 O 
cells O 
against O 
radiation O 
- O 
induced O 
injury O 
through O 
the O 
Nrf2 O 
/ O 
HO-1 O 
pathway O 
. O 

present O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
role O 
of O 
TNF-α O 
in O 
renal O 
damage O 
observed O 
in O 
mice O 
with O 
hepatic O 
steatosis O 
. O 
We O 
induced O 
hepatic O 
steatosis O 
in O 
mice O 
using O 
high O 
fat O 
diet O 
and O 
treated O 
mice O 
with O 
ectanercept O 
at O 
the O 
dose O 
sufficient O 
to O 
block O 
TNF-α O 
receptors O 
or O 
vehicle O 
for O 
1 O 
month O 
. O 
Plasma O 
TNF-α O 
, O 
total O 
cholesterol B-TRIVIAL 
( O 
TC O 
) O 
, O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
, O 
LDL- O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
, O 
and O 
HDL- O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
were O 
determined O 
at O 
the O 
end O 
of O 
this O 
treatment O 
. O 
Renal O 
damage O 
was O 
identified O 
by O 
histologic O 
observation O 
and O 
the O 
higher O 
of O 
serum O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
and O 
creatinine B-TRIVIAL 
. O 
Also O 
, O 
changes O 
of O 
PPAR-δ O 
in O 
kidney O 
and O 
renal O 
mesangial O 
cell O 
( O 
RMC O 
) O 
were O 
analyzed O 
using O 
Western O 
blot O 
. O 
Plasma O 
TNF-α O 
was O 
markedly O 
raised O 
in O 
mice O 
showing O 
hepatic O 
steatosis O 
. O 
However O 
, O 
the O 
levels O 
of O 
blood O 
lipids O 
( O 
TC O 
, O 
TG O 
, O 
HDL-C O 
, O 
and O 
LDL-C O 
) O 
and O 
TNF-α O 
were O 
not O 
modified O 
by O 
the O 
treatment O 
of O 
etanercept O 
although O 
the O 
hepatic O 
steatosis O 
has O 
been O 
improved O 
. O 
Etanercept O 
shows O 
renal O 
protection O 
from O 
histological O 
identification O 
and O 
recovery O 
of O 
serum O 
BUN O 
and O 
creatinine B-TRIVIAL 
levels O 
. O 
Moreover O 
, O 
restoration O 
of O 
PPAR-δ O 
expression O 
by O 
etanercept O 
was O 
observed O 
in O 
mice O 
kidney O 
. O 
Direct O 
effect O 
of O 
TNF-α O 
on O 
PPAR-δ O 
expression O 
was O 
also O 
characterized O 
in O 
RMC O 
cell O 
. O 
We O 
suggest O 
that O 
renal O 
damage O 
in O 
mice O 
with O 
hepatic O 
steatosis O 
is O 
mainly O 
induced O 
by O 
increase O 
of O 
TNF-α O 
through O 
the O 
decrease O 
of O 
renal O 
PPAR-δ O 
. O 
Etanercept O 
could O 
block O 
TNF-α O 
receptors O 
to O 
restore O 
PPAR-δ O 
and O 
improve O 
renal O 
function O 
in O 
mice O 
with O 
hepatic O 
steatosis O 
. O 

of O 
serotonin B-TRIVIAL 
derivatives O 
by O 
the O 
larvae O 
of O 
common O 
cutworm O 
( O 
Spodoptera O 
litura O 
) O 
. O 

serotonin B-TRIVIAL 
derivatives O 
( O 
1-7 O 
) O 
were O 
biotransformed O 
using O 
larvae O 
of O 
Spodoptera O 
litura O 
. O 
N-p-methoxy B-SYSTEMATIC 
cinnamoyl I-SYSTEMATIC 
serotonin I-SYSTEMATIC 
( O 
3 O 
) O 
was O 
converted O 
into O 
its O 
O B-FORMULA 
-demethylated O 
compound O 
, O 
N-p-coumaroyl B-SYSTEMATIC 
serotonin I-SYSTEMATIC 
( O 
2 O 
) O 
. O 
Furthermore O 
, O 
N-feruloyl B-SYSTEMATIC 
serotonin I-SYSTEMATIC 
( O 
5 O 
) O 
and O 
N-isoferuloyl B-SYSTEMATIC 
serotonin I-SYSTEMATIC 
( O 
6 O 
) O 
were O 
converted O 
into O 
, O 
two O 
new O 
compounds O 
, O 
N-feruloyl B-SYSTEMATIC 
serotonin-4'-O-β-D-glucopyranoside I-SYSTEMATIC 
( O 
8 O 
) O 
and O 
N-isoferuloyl B-SYSTEMATIC 
serotonin-3'-O-β-D-glucopyranoside I-SYSTEMATIC 
( O 
9 O 
) O 
, O 
respectively O 
. O 
These O 
structures O 
were O 
established O 
by O 
IR O 
, O 
1D-NMR O 
and O 
2D-NMR O 
spectral O 
studies O 
. O 

investigated O 
whether O 
television O 
( O 
TV O 
) O 
viewing O 
and O 
low O 
leisure O 
- O 
time O 
physical O 
activity O 
in O 
adolescence O 
predict O 
the O 
metabolic O 
syndrome O 
in O 
mid-adulthood.RESEARCH O 
DESIGN O 
AND O 
METHODSTV O 
viewing O 
habits O 
and O 
participation O 
in O 
leisure O 
- O 
time O 
physical O 
activity O 
at O 
age O 
16 O 
years O 
were O 
assessed O 
by O 
self O 
- O 
administered O 
questionnaires O 
in O 
a O 
population O 
- O 
based O 
cohort O 
in O 
Northern O 
Sweden O 
. O 
The O 
presence O 
of O 
the O 
metabolic O 
syndrome O 
at O 
age O 
43 O 
years O 
was O 
ascertained O 
in O 
888 O 
participants O 
( O 
82% O 
of O 
the O 
baseline O 
sample O 
) O 
using O 
the O 
International O 
Diabetes O 
Federation O 
criteria O 
. O 
Odds O 
ratios O 
( O 
ORs O 
) O 
and O 
CIs O 
were O 
calculated O 
using O 
logistic O 
regression.RESULTSThe O 
overall O 
prevalence O 
of O 
the O 
metabolic O 
syndrome O 
at O 
age O 
43 O 
years O 
was O 
26.9% O 
. O 
Adjusted O 
OR O 
for O 
the O 
metabolic O 
syndrome O 
at O 
age O 
43 O 
years O 
was O 
2.14 O 
( O 
95% O 
CI O 
1.24-3.71 O 
) O 
for O 
those O 
who O 
reported O 
" O 
watching O 
several O 
shows O 
a O 
day O 
" O 
versus O 
" O 
one O 
show O 
/ O 
week O 
" O 
or O 
less O 
and O 
2.31 O 
( O 
1.13-4.69 O 
) O 
for O 
leisure O 
- O 
time O 
physical O 
activity O 
" O 
several O 
times O 
/ O 
month O 
" O 
or O 
less O 
compared O 
with O 
" O 
daily O 
" O 
leisure O 
- O 
time O 
physical O 
activity O 
at O 
age O 
16 O 
years O 
. O 
TV O 
viewing O 
at O 
age O 
16 O 
years O 
was O 
associated O 
with O 
central O 
obesity O 
, O 
low O 
HDL O 
cholesterol B-TRIVIAL 
, O 
and O 
hypertension O 
at O 
age O 
43 O 
years O 
, O 
whereas O 
low O 
leisure O 
- O 
time O 
physical O 
activity O 
at O 
age O 
16 O 
years O 
was O 
associated O 
with O 
central O 
obesity O 
and O 
triglycerides B-FAMILY 
at O 
age O 
43 O 
years.CONCLUSIONSBoth O 
TV O 
viewing O 
and O 
low O 
leisure O 
- O 
time O 
physical O 
activity O 
in O 
adolescence O 
independently O 
predicted O 
the O 
metabolic O 
syndrome O 
and O 
several O 
of O 
the O 
metabolic O 
syndrome O 
components O 
in O 
mid O 
- O 
adulthood O 
. O 
These O 
findings O 
suggest O 
that O 
reduced O 
TV O 
viewing O 
in O 
adolescence O 
, O 
in O 
addition O 
to O 
regular O 
physical O 
activity O 
, O 
may O 
contribute O 
to O 
cardiometabolic O 
health O 
later O 
in O 
life O 
. O 

effect O 
and O 
gastroprotective O 
mechanisms O 
of O 
3,5-diprenyl-4-hydroxyacetophenone B-SYSTEMATIC 
from O 
Ageratina O 
pichinchensis O 
. O 

present O 
study O 
aimed O 
to O 
evaluate O 
the O 
antinociceptive O 
activity O 
( O 
in O 
inflammatory O 
and O 
neuropathic O 
pain O 
models O 
) O 
and O 
gastroprotective O 
effect O 
of O 
the O 
3,5-diprenyl-4-hydroxyacetophenone B-SYSTEMATIC 
( O 
HYDP B-ABBREVIATION 
) O 
, O 
isolated O 
from O 
Ageratina O 
pichinchensis O 
. O 
The O 
gastroprotective O 
activity O 
of O 
this O 
plant O 
was O 
previously O 
reported O 
by O 
our O 
workgroup O 
, O 
finding O 
encesanescin B-TRIVIAL 
to O 
be O 
one O 
active O 
compound O 
. O 
The O 
present O 
results O 
show O 
that O 
HYDP B-ABBREVIATION 
reduced O 
nociception O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
in O 
carrageenan O 
and O 
L5 O 
/ O 
L6 O 
spinal O 
nerve O 
ligation O 
, O 
with O 
efficacies O 
of O 
72.6 O 
and O 
57.1% O 
, O 
respectively O 
, O 
at O 
doses O 
of O 
100 O 
and O 
562mg O 
/ O 
kg O 
. O 
HYDP B-ABBREVIATION 
also O 
showed O 
gastroprotective O 
activity O 
in O 
the O 
model O 
of O 
ethanol B-SYSTEMATIC 
-induced O 
gastric O 
lesion O 
, O 
with O 
a O 
75.59% O 
maximum O 
inhibition O 
of O 
ulcers O 
at O 
a O 
dose O 
of O 
100mg O 
/ O 
kg O 
. O 
This O 
gastroprotective O 
effect O 
was O 
attenuated O 
by O 
N(G)-nitro-l-arginine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
, O 
indomethacin B-TRIVIAL 
and O 
N-ethylmaleimide B-SYSTEMATIC 
, O 
indicating O 
that O 
NO B-FORMULA 
, O 
prostaglandins B-FAMILY 
and O 
sulfhydryl B-FAMILY 
groups O 
are O 
involved O 
in O 
the O 
mechanisms O 
of O 
action O 
. O 
This O 
is O 
the O 
first O 
evidence O 
, O 
to O 
our O 
knowledge O 
, O 
of O 
the O 
antinociceptive O 
and O 
gastroprotective O 
activities O 
of O 
HYDP B-ABBREVIATION 
. O 

rates O 
and O 
mercury B-SYSTEMATIC 
concentrations O 
in O 
St O 
. O 
Lawrence O 
river O 
sediments O 
and O 
a O 
benthic O 
invertebrate O 
. O 

, O 
the O 
release O 
of O 
gas O 
from O 
anaerobic O 
decomposition O 
in O 
sediments O 
, O 
was O 
recorded O 
in O 
a O 
mercury B-SYSTEMATIC 
-contaminated O 
depositional O 
zone O 
( O 
Zone O 
1 O 
) O 
of O 
the O 
St O 
. O 
Lawrence O 
River O 
Area O 
of O 
Concern O 
in O 
Cornwall O 
, O 
Ontario O 
, O 
Canada O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
test O 
if O 
this O 
disturbance O 
affected O 
the O 
bioavailability O 
of O 
total O 
mercury B-SYSTEMATIC 
( O 
THg O 
) O 
and O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
in O 
surficial O 
sediments O 
to O 
a O 
benthic O 
invertebrate O 
( O 
Echinogammarus O 
ischnus O 
) O 
. O 
Ebullition O 
rates O 
ranged O 
from O 
< O 
1 O 
to O 
2800 O 
ml O 
/ O 
m(2) O 
daily O 
, O 
with O 
methane B-SYSTEMATIC 
gas O 
comprising O 
29 O 
to O 
84% O 
of O 
the O 
total O 
. O 
No O 
direct O 
effects O 
of O 
ebullition O 
were O 
found O 
on O 
either O 
abiotic O 
( O 
sediment O 
or O 
pore O 
water O 
THg O 
or O 
MeHg B-FORMULA 
concentrations O 
) O 
or O 
biotic O 
( O 
amphipod O 
THg O 
or O 
MeHg B-FORMULA 
concentrations O 
) O 
variables O 
measured O 
. O 
Instead O 
, O 
amphipod O 
MeHg B-FORMULA 
concentrations O 
were O 
best O 
predicted O 
by O 
pore O 
water O 
THg O 
and O 
MeHg B-FORMULA 
concentrations O 
, O 
organic O 
matter O 
of O 
surficial O 
sediments O 
, O 
and O 
water O 
depth O 
and O 
location O 
. O 
Trend O 
surface O 
analyses O 
demonstrated O 
that O 
a O 
shallow O 
, O 
southwestern O 
part O 
of O 
Zone O 
1 O 
was O 
most O 
contaminated O 
with O 
pore O 
water O 
mercury B-SYSTEMATIC 
, O 
which O 
decreased O 
in O 
a O 
gradient O 
toward O 
the O 
northeast O 
. O 
Further O 
study O 
is O 
needed O 
to O 
determine O 
if O 
the O 
amount O 
of O 
sediment O 
resuspended O 
by O 
ebullition O 
affects O 
the O 
spatial O 
distribution O 
of O 
mercury B-SYSTEMATIC 
. O 

MAPK-activated O 
protein O 
kinases O 
2 O 
and O 
3 O 
( O 
MAPKAPK2 O 
/ O 
3 O 
, O 
MK2 O 
/ O 
3 O 
) O 
represent O 
protein O 
kinases O 
downstream O 
of O 
the O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
. O 
Using O 
MK2 O 
/ O 
3 O 
double O 
knockout O 
mice O 
( O 
MK2 O 
/ O 
3(- O 
/ O 
- O 
) O 
) O 
, O 
we O 
analyzed O 
the O 
role O 
of O 
MK2 O 
/ O 
3 O 
in O 
cross O 
- O 
striated O 
muscle O 
by O 
transcriptome O 
and O 
proteome O 
analyses O 
, O 
and O 
by O 
histology O 
. O 
We O 
demonstrated O 
enhanced O 
expression O 
of O 
the O 
slow O 
oxidative O 
skeletal O 
muscle O 
myofiber O 
gene O 
program O 
, O 
including O 
the O 
PPARγ O 
coactivator O 
1α O 
( O 
PGC-1α O 
) O 
. O 
Using O 
reporter O 
gene O 
and O 
electrophoretic O 
gel O 
mobility O 
shift O 
assays O 
we O 
demonstrated O 
that O 
MK2 O 
catalytic O 
activity O 
directly O 
regulated O 
the O 
promoters O 
of O 
the O 
fast O 
fiber O 
- O 
specific O 
myosin O 
heavy O 
chain O 
IId O 
/ O 
x O 
and O 
the O 
slow O 
fiber O 
- O 
specific O 
sarco O 
/ O 
endoplasmic O 
reticulum O 
Ca(2+) B-FORMULA 
-ATPase O 
( O 
SERCA O 
) O 
2 O 
gene O 
. O 
Elevated O 
SERCA2a O 
gene O 
expression O 
caused O 
by O 
a O 
decreased O 
transcription O 
factor O 
Egr-1 O 
to O 
Sp1 O 
ratio O 
was O 
associated O 
with O 
accelerated O 
relaxation O 
and O 
enhanced O 
contractility O 
in O 
MK2 O 
/ O 
3(- O 
/ O 
- O 
) O 
cardiomyocytes O 
, O 
concomitant O 
with O 
improved O 
force O 
parameters O 
in O 
MK2 O 
/ O 
3(- O 
/ O 
- O 
) O 
soleus O 
muscle O 
. O 
These O 
results O 
link O 
MK2 O 
/ O 
3 O 
to O 
the O 
regulation O 
of O 
calcium B-SYSTEMATIC 
dynamics O 
and O 
identify O 
enzymatic O 
activity O 
of O 
MK2 O 
/ O 
3 O 
as O 
a O 
critical O 
factor O 
for O 
modulating O 
cross O 
- O 
striated O 
muscle O 
function O 
by O 
generating O 
a O 
unique O 
muscle O 
phenotype O 
exhibiting O 
both O 
, O 
reduced O 
fatigability O 
and O 
enhanced O 
force O 
in O 
MK2 O 
/ O 
3(- O 
/ O 
- O 
) O 
mice O 
. O 
Hence O 
, O 
the O 
p38-MK2 O 
/ O 
3 O 
axis O 
may O 
represent O 
a O 
novel O 
target O 
for O 
the O 
design O 
of O 
therapeutic O 
strategies O 
for O 
diseases O 
related O 
to O 
fiber O 
type O 
changes O 
or O 
impaired O 
SERCA2 O 
function O 
. O 

glycine I-SYSTEMATIC 
does O 
not O 
activate O 
G O 
protein O 
- O 
coupled O 
receptor O 
18 O 
signaling O 
via O 
canonical O 
pathways O 
. O 

studies O 
propose O 
that O 
N-arachidonyl B-SYSTEMATIC 
glycine I-SYSTEMATIC 
( O 
NAGly B-FORMULA 
) O 
, O 
a O 
carboxylic B-SYSTEMATIC 
analogue O 
of O 
anandamide B-TRIVIAL 
, O 
is O 
an O 
endogenous O 
ligand O 
of O 
the O 
Gα(i O 
/ O 
o O 
) O 
protein O 
- O 
coupled O 
receptor O 
18 O 
( O 
GPR18 O 
) O 
. O 
However O 
, O 
a O 
high O 
- O 
throughput O 
β-arrestin- O 
based O 
screen O 
failed O 
to O 
detect O 
activation O 
of O 
GPR18 O 
by O 
NAGly B-FORMULA 
( O 
Yin O 
et O 
al O 
. O 
, O 
2009 O 
; O 
JBC O 
, O 
18 O 
: O 
12328 O 
) O 
. O 
To O 
address O 
this O 
inconsistency O 
, O 
this O 
study O 
investigated O 
GPR18 O 
coupling O 
in O 
a O 
native O 
neuronal O 
system O 
with O 
endogenous O 
signaling O 
pathways O 
and O 
effectors O 
. O 
GPR18 O 
was O 
heterologously O 
expressed O 
in O 
rat O 
sympathetic O 
neurons O 
, O 
and O 
the O 
modulation O 
of O 
N B-FORMULA 
-type O 
( O 
Ca B-FORMULA 
(v)2.2 O 
) O 
calcium B-SYSTEMATIC 
channels O 
was O 
examined O 
. O 
Proper O 
expression O 
and O 
trafficking O 
of O 
receptor O 
were O 
confirmed O 
by O 
the O 
" O 
rim O 
- O 
like O 
" O 
fluorescence O 
of O 
fluorescently O 
tagged O 
receptor O 
and O 
the O 
positive O 
staining O 
of O 
external O 
hemagglutinin O 
- O 
tagged O 
GPR18-expressing O 
cells O 
. O 
Application O 
of O 
NAGly B-FORMULA 
on O 
GPR18-expressing O 
neurons O 
did O 
not O 
inhibit O 
calcium B-SYSTEMATIC 
currents O 
but O 
instead O 
potentiated O 
currents O 
in O 
a O 
voltage O 
- O 
dependent O 
manner O 
, O 
similar O 
to O 
what O 
has O 
previously O 
been O 
reported O 
( O 
Guo O 
et O 
al O 
. O 
, O 
2008 O 
; O 
J O 
Neurophysiol O 
, O 
100 O 
: O 
1147 O 
) O 
. O 
Other O 
proposed O 
agonists O 
of O 
GPR18 O 
, O 
including O 
anandamide B-TRIVIAL 
and O 
abnormal O 
cannabidiol B-TRIVIAL 
, O 
also O 
failed O 
to O 
induce O 
inhibition O 
of O 
calcium B-SYSTEMATIC 
currents O 
. O 
Mutants O 
of O 
GPR18 O 
, O 
designed O 
to O 
constitutively O 
activate O 
receptors O 
, O 
did O 
not O 
tonically O 
inhibit O 
calcium B-SYSTEMATIC 
currents O 
, O 
indicating O 
a O 
lack O 
of O 
GPR18 O 
activation O 
or O 
coupling O 
to O 
endogenous O 
G O 
proteins O 
. O 
Other O 
downstream O 
effectors O 
of O 
Gα(i O 
/ O 
o)-coupled O 
receptors O 
, O 
G O 
protein O 
- O 
coupled O 
inwardly O 
rectifying O 
potassium B-SYSTEMATIC 
channels O 
and O 
adenylate B-TRIVIAL 
cyclase O 
, O 
were O 
not O 
modulated O 
by O 
GPR18 O 
signaling O 
. O 
Furthermore O 
, O 
GPR18 O 
did O 
not O 
couple O 
to O 
other O 
G O 
proteins O 
tested O 
: O 
Gα(s) O 
, O 
Gα(z) O 
, O 
and O 
Gα(15) O 
. O 
These O 
results O 
suggest O 
NAGly B-FORMULA 
is O 
not O 
an O 
agonist O 
for O 
GPR18 O 
or O 
that O 
GPR18 O 
signaling O 
involves O 
noncanonical O 
pathways O 
not O 
examined O 
in O 
these O 
studies O 
. O 

separation O 
and O 
purification O 
of O 
total O 
polyphenols B-FAMILY 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
phlorizin B-TRIVIAL 
from O 
thinned O 
young O 
apples O 
. O 

efficient O 
preparative O 
separation O 
of O 
polyphenols B-FAMILY 
from O 
thinned O 
young O 
apples O 
( O 
TYA O 
) O 
has O 
been O 
developed O 
in O 
the O 
present O 
study O 
. O 
X-5 O 
resin O 
was O 
verified O 
to O 
offer O 
the O 
best O 
adsorption O 
capacity O 
and O 
desorption O 
ratio O 
for O 
total O 
polyphenols B-FAMILY 
among O 
the O 
eight O 
macroporous O 
resins O 
investigated O 
. O 
Influential O 
factors O 
, O 
such O 
as O 
pH O 
value O 
and O 
concentration O 
of O 
feeding O 
solution O 
, O 
strippant O 
, O 
and O 
adsorption O 
isotherm O 
to O 
the O 
separation O 
of O 
total O 
polyphenols B-FAMILY 
, O 
were O 
successively O 
investigated O 
on O 
X-5 O 
resin O 
. O 
After O 
one O 
run O 
treatment O 
, O 
the O 
phenolic B-FAMILY 
content O 
was O 
increased O 
2.12-fold O 
from O 
35.17% O 
to O 
74.64% O 
, O 
with O 
a O 
recovery O 
yield O 
of O 
89.35% O 
. O 
Chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
phlorizin B-TRIVIAL 
were O 
selectively O 
purified O 
using O 
X-5 O 
and O 
polyamide B-FAMILY 
resins O 
. O 
The O 
contents O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
phlorizin B-TRIVIAL 
were O 
15.20% O 
and O 
97.52% O 
with O 
recovery O 
yields O 
of O 
89.16% O 
and O 
64.95% O 
, O 
respectively O 
. O 
The O 
method O 
developed O 
will O 
provide O 
a O 
potential O 
approach O 
for O 
its O 
wide O 
industrial O 
and O 
pharmaceutical O 
use O 
. O 

identification O 
of O 
sibutramine B-TRIVIAL 
in O 
dietary O 
supplements O 
using O 
a O 
stepwise O 
approach O 
. O 

of O 
botanical O 
food O 
supplements O 
with O 
undeclared O 
synthetic O 
drugs O 
is O 
a O 
common O 
problem O 
. O 
One O 
of O 
the O 
most O 
affected O 
product O 
groups O 
are O 
the O 
slimming O 
agents O 
. O 
There O 
are O 
no O 
analytical O 
protocols O 
for O 
the O 
detection O 
of O 
synthetic O 
adulterants O 
from O 
these O 
products O 
. O 
The O 
present O 
study O 
aimed O 
at O 
the O 
development O 
of O 
a O 
multistep O 
analytical O 
method O 
for O 
the O 
quick O 
and O 
reliable O 
determination O 
of O 
sibutramine B-TRIVIAL 
, O 
one O 
of O 
the O 
most O 
common O 
adulterants O 
among O 
botanical O 
food O 
supplements O 
. O 
The O 
extract O 
of O 
a O 
sibutramine B-TRIVIAL 
-containing O 
slimming O 
formula O 
was O 
analysed O 
by O 
colour O 
tests O 
, O 
TLC O 
, O 
HPLC-DAD O 
, O 
MS O 
and O 
NMR O 
. O 
The O 
multistep O 
method O 
proposed O 
by O 
the O 
authors O 
allows O 
the O 
quick O 
identification O 
of O 
sibutramine B-TRIVIAL 
in O 
counterfeit O 
samples O 
in O 
laboratories O 
with O 
different O 
instrumentation O 
. O 

cells O 
( O 
DCs O 
) O 
play O 
crucial O 
roles O 
in O 
initiating O 
and O 
promoting O 
immune O 
defences O 
, O 
providing O 
a O 
pivotal O 
target O 
for O 
vaccines O 
. O 
Although O 
nanoparticle O 
/ O 
nanogel O 
- O 
based O 
delivery O 
vehicles O 
are O 
showing O 
potential O 
for O 
delivering O 
vaccines O 
to O 
the O 
immune O 
system O 
, O 
there O 
is O 
little O 
information O 
on O 
their O 
characteristics O 
of O 
interaction O 
with O 
DCs O 
. O 
While O 
particle O 
uptake O 
by O 
DCs O 
has O 
been O 
shown O 
, O 
the O 
mechanism O 
of O 
cell O 
targeting O 
has O 
not O 
been O 
studied O 
. O 
Moreover O 
, O 
it O 
is O 
still O 
unclear O 
how O 
particle O 
surface O 
decoration O 
influences O 
the O 
handling O 
of O 
such O 
vaccines O 
by O 
DCs O 
. O 
Accordingly O 
, O 
chitosan O 
nanogels O 
carrying O 
a O 
model O 
antigen O 
, O 
ovalbumin O 
( O 
ova O 
) O 
, O 
were O 
analysed O 
for O 
interaction O 
with O 
and O 
processing O 
by O 
DCs O 
. O 
Nanogel O 
surfaces O 
decorated O 
with O 
alginate O 
( O 
alg O 
) O 
or O 
mannosylated O 
alginate O 
( O 
alg- O 
man B-ABBREVIATION 
) O 
, O 
were O 
used O 
for O 
targeting O 
particular O 
DC O 
receptors O 
. O 
DC O 
uptake O 
of O 
particles O 
was O 
observed O 
, O 
being O 
dependent O 
on O 
endosomal O 
- O 
based O 
processes O 
. O 
Inhibiting O 
PI3-kinase O 
or O 
lipid O 
raft O 
activities O 
impaired O 
the O 
uptake O 
, O 
which O 
was O 
only O 
reduced O 
, O 
indicating O 
the O 
involvement O 
of O 
more O 
than O 
one O 
endocytic O 
pathway O 
; O 
notably O 
, O 
this O 
was O 
observed O 
with O 
both O 
nanogel O 
- O 
delivered O 
or O 
free O 
ova O 
. O 
Importantly O 
, O 
surface O 
decoration O 
of O 
particles O 
was O 
less O 
influential O 
on O 
particle O 
uptake O 
, O 
contrasting O 
with O 
the O 
ova O 
cargo O 
which O 
played O 
the O 
major O 
role O 
. O 
Such O 
influence O 
of O 
the O 
vaccine O 
cargo O 
has O 
to O 
date O 
been O 
largely O 
ignored O 
. O 
When O 
receptors O 
interacting O 
directly O 
with O 
ova O 
were O 
blocked O 
, O 
this O 
altered O 
the O 
uptake O 
of O 
alg O 
- O 
nanogels O 
and O 
alg- O 
man B-ABBREVIATION 
-nanogels O 
carrying O 
ova O 
. O 
The O 
nanogels O 
did O 
have O 
an O 
influential O 
role O 
, O 
in O 
that O 
modulation O 
of O 
DC O 
functional O 
activity O 
owed O 
more O 
to O 
the O 
nanogel O 
structure O 
. O 
Using O 
an O 
in O 
vitro O 
restimulation O 
assay O 
with O 
ova O 
- O 
specific O 
lymphocytes O 
, O 
nanogel O 
- O 
delivered O 
and O 
free O 
ova O 
were O 
similarly O 
effective O 
at O 
inducing O 
specific O 
antibody O 
. O 
Nanogel O 
- O 
delivered O 
ova O 
with O 
mannose B-TRIVIAL 
surface O 
decoration O 
was O 
superior O 
to O 
free O 
ova O 
for O 
inducing O 
interferon-γ O 
production O 
by O 
T-lymphocytes O 
. O 
Together O 
, O 
the O 
data O 
demonstrates O 
that O 
particle O 
- O 
based O 
vaccine O 
delivery O 
should O 
consider O 
the O 
influences O 
of O 
both O 
the O 
surface O 
decoration O 
and O 
the O 
vaccine O 
cargo O 
; O 
each O 
can O 
influence O 
different O 
aspects O 
of O 
the O 
interaction O 
with O 
DCs O 
. O 
Such O 
combined O 
influences O 
are O 
likely O 
to O 
impinge O 
on O 
the O 
characteristics O 
of O 
the O 
immune O 
response O 
induced O 
. O 

risky O 
cocktail O 
: O 
what O 
combination O 
effects O 
can O 
we O 
expect O 
between O 
ecstasy B-TRIVIAL 
and O 
other O 
amphetamines B-FAMILY 
? O 

recreational O 
and O 
illicit O 
use O 
of O 
amphetaminic O 
designer O 
compounds O 
, O 
specially O 
3,4-methylenedioxymethamphetamine B-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
; O 
Ecstasy B-TRIVIAL 
) O 
, O 
is O 
of O 
concern O 
worldwide O 
. O 
Such O 
psychostimulating O 
drugs O 
are O 
frequently O 
present O 
as O 
complex O 
mixtures O 
in O 
' O 
rave O 
' O 
pills O 
, O 
making O 
concomitant O 
polysubstance O 
use O 
a O 
common O 
trend O 
. O 
However O 
, O 
the O 
understanding O 
of O 
possible O 
combination O 
effects O 
with O 
these O 
substances O 
is O 
still O 
scarce O 
. O 
The O 
present O 
study O 
was O 
aimed O 
at O 
predicting O 
the O 
cytotoxic O 
effects O 
of O 
mixtures O 
of O 
four O 
amphetaminic O 
derivatives O 
: O 
MDMA B-ABBREVIATION 
, O 
methamphetamine B-TRIVIAL 
, O 
4-methylthioamphetamine B-SYSTEMATIC 
and O 
d-amphetamine B-TRIVIAL 
in O 
a O 
human O 
hepatoma O 
cell O 
line O 
. O 
Concentration O 
- O 
response O 
curves O 
for O 
all O 
single O 
- O 
mixture O 
components O 
were O 
recorded O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
. O 
Data O 
obtained O 
for O 
individual O 
agents O 
were O 
then O 
used O 
to O 
compute O 
the O 
additivity O 
expectations O 
for O 
mixtures O 
of O 
definite O 
composition O 
, O 
using O 
the O 
pharmacological O 
models O 
of O 
concentration O 
addition O 
( O 
CA O 
) O 
and O 
independent O 
action O 
. O 
By O 
comparing O 
the O 
predicted O 
calculations O 
with O 
the O 
experimentally O 
observed O 
effects O 
, O 
we O 
concluded O 
that O 
CA O 
accurately O 
predicts O 
the O 
combination O 
of O 
amphetamines B-FAMILY 
, O 
which O 
act O 
together O 
to O 
generate O 
additive O 
effects O 
over O 
a O 
large O 
range O 
of O 
concentrations O 
. O 
Notably O 
, O 
we O 
observed O 
substantial O 
mixture O 
effects O 
even O 
when O 
each O 
drug O 
was O 
present O 
at O 
low O 
concentrations O 
, O 
which O 
individually O 
produced O 
unnoticeable O 
effects O 
. O 
Nonetheless O 
, O 
for O 
all O 
tested O 
mixtures O 
, O 
a O 
small O 
deviation O 
from O 
additivity O 
was O 
observed O 
towards O 
higher O 
concentrations O 
, O 
particularly O 
at O 
high O 
effect O 
levels O 
. O 
A O 
possible O 
metabolic O 
interaction O 
, O 
which O 
could O 
explain O 
such O 
deviation O 
, O 
was O 
investigated O 
, O 
and O 
it O 
was O 
observed O 
that O 
at O 
higher O 
mixture O 
concentrations O 
increased O 
MDMA B-ABBREVIATION 
metabolism O 
could O 
be O 
contributing O 
to O 
divergences O 
from O 
additivity O 
. O 
In O 
conclusion O 
, O 
the O 
present O 
work O 
clearly O 
demonstrates O 
that O 
potentially O 
harmful O 
interactions O 
among O 
amphetaminic O 
drugs O 
are O 
expected O 
when O 
these O 
drugs O 
are O 
taken O 
concomitantly O 
. O 

the O 
molecular O 
evolution O 
of O 
genes O 
that O 
underlie O 
intraspecific O 
polymorphisms O 
can O 
provide O 
insights O 
into O 
the O 
process O 
of O 
adaptive O 
evolution O 
. O 
For O 
adaptive O 
polymorphisms O 
characterized O 
by O 
gene O 
presence O 
/ O 
absence O 
( O 
P O 
/ O 
A O 
) O 
variation O 
, O 
underlying O 
loci O 
commonly O 
show O 
signatures O 
of O 
long O 
- O 
term O 
balancing O 
selection O 
, O 
with O 
gene O 
- O 
presence O 
and O 
gene O 
- O 
absence O 
alleles O 
maintained O 
as O 
two O 
divergent O 
lineages O 
. O 
We O 
examined O 
the O 
molecular O 
evolution O 
of O 
two O 
unlinked O 
P O 
/ O 
A O 
polymorphisms O 
that O 
underlie O 
a O 
well O 
- O 
documented O 
adaptive O 
polymorphism O 
for O 
cyanogenesis O 
( O 
hydrogen B-SYSTEMATIC 
cyanide I-SYSTEMATIC 
release O 
with O 
tissue O 
damage O 
) O 
in O 
white O 
clover O 
. O 
Both O 
cyanogenic O 
and O 
acyanogenic O 
plants O 
occur O 
in O 
this O 
species O 
, O 
and O 
the O 
ecological O 
forces O 
that O 
maintain O 
this O 
chemical O 
defence O 
polymorphism O 
have O 
been O 
studied O 
for O 
several O 
decades O 
. O 
Using O 
a O 
sample O 
of O 
65 O 
plants O 
, O 
we O 
investigated O 
the O 
molecular O 
evolution O 
of O 
sequences O 
flanking O 
the O 
two O 
underlying O 
cyanogenesis O 
genes O 
: O 
Ac O 
/ O 
ac O 
( O 
controlling O 
the O 
presence O 
/ O 
absence O 
of O 
cyanogenic B-FAMILY 
glucosides I-FAMILY 
) O 
and O 
Li O 
/ O 
li O 
( O 
controlling O 
the O 
presence O 
/ O 
absence O 
of O 
their O 
hydrolysing O 
enzyme O 
, O 
linamarase O 
) O 
. O 
A O 
combination O 
of O 
genome O 
walking O 
, O 
PCR O 
assays O 
, O 
DNA O 
sequence O 
analysis O 
and O 
Southern O 
blotting O 
was O 
used O 
to O 
test O 
whether O 
these O 
adaptive O 
P O 
/ O 
A O 
polymorphisms O 
show O 
evidence O 
of O 
long O 
- O 
term O 
balancing O 
selection O 
, O 
or O 
whether O 
gene O 
- O 
absence O 
alleles O 
have O 
evolved O 
repeatedly O 
through O 
independent O 
deletion O 
events O 
. O 
For O 
both O 
loci O 
, O 
we O 
detect O 
no O 
signatures O 
of O 
balancing O 
selection O 
in O 
the O 
closest O 
flanking O 
genomic O 
sequences O 
. O 
Instead O 
, O 
we O 
find O 
evidence O 
for O 
variation O 
in O 
the O 
size O 
of O 
the O 
deletions O 
characterizing O 
gene O 
- O 
absence O 
alleles O 
. O 
These O 
observations O 
strongly O 
suggest O 
that O 
both O 
of O 
these O 
polymorphisms O 
have O 
been O 
evolving O 
through O 
recurrent O 
gene O 
deletions O 
over O 
time O 
. O 
We O 
discuss O 
the O 
genetic O 
mechanisms O 
that O 
could O 
account O 
for O 
this O 
surprising O 
pattern O 
and O 
the O 
implications O 
of O 
these O 
findings O 
for O 
mechanisms O 
of O 
rapid O 
adaptive O 
evolution O 
in O 
white O 
clover O 
. O 

of O 
heme B-FAMILY 
oxygenase-1 O 
protects O 
mouse O 
liver O 
from O 
apoptotic O 
ischemia O 
/ O 
reperfusion O 
injury O 
. O 

/ O 
reperfusion O 
( O 
I O 
/ O 
R O 
) O 
injury O 
is O 
the O 
main O 
cause O 
of O 
primary O 
graft O 
dysfunction O 
of O 
liver O 
allografts O 
. O 
Cobalt B-SYSTEMATIC 
- I-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
( O 
CoPP B-FORMULA 
)-dependent O 
induction O 
of O 
heme B-FAMILY 
oxygenase O 
(HO)-1 O 
has O 
been O 
shown O 
to O 
protect O 
the O 
liver O 
from O 
I O 
/ O 
R O 
injury O 
. O 
This O 
study O 
analyzes O 
the O 
apoptotic O 
mechanisms O 
of O 
HO-1 O 
- O 
mediated O 
cytoprotection O 
in O 
mouse O 
liver O 
exposed O 
to O 
I O 
/ O 
R O 
injury O 
. O 
HO-1 O 
induction O 
was O 
achieved O 
by O 
the O 
administration O 
of O 
CoPP B-FORMULA 
( O 
1.5 O 
mg O 
/ O 
kg O 
body O 
weight O 
i.p O 
. O 
) O 
. O 
Mice O 
were O 
studied O 
in O 
in O 
vivo O 
model O 
of O 
hepatic O 
segmental O 
( O 
70 O 
% O 
) O 
ischemia O 
for O 
60 O 
min O 
and O 
reperfusion O 
injury O 
. O 
Mice O 
were O 
randomly O 
allocated O 
to O 
four O 
main O 
experimental O 
groups O 
( O 
n O 
= O 
10 O 
each O 
) O 
: O 
( O 
1 O 
) O 
A O 
control O 
group O 
undergoing O 
sham O 
operation O 
. O 
( O 
2 O 
) O 
Similar O 
to O 
group O 
1 O 
but O 
with O 
the O 
administration O 
of O 
CoPP B-FORMULA 
72 O 
h O 
before O 
the O 
operation O 
. O 
( O 
3 O 
) O 
Mice O 
undergoing O 
in O 
vivo O 
hepatic O 
I O 
/ O 
R O 
. O 
( O 
4 O 
) O 
Similar O 
to O 
group O 
3 O 
but O 
with O 
the O 
administration O 
of O 
CoPP B-FORMULA 
72 O 
h O 
before O 
ischemia O 
induction O 
. O 
When O 
compared O 
with O 
the O 
I O 
/ O 
R O 
mice O 
group O 
, O 
in O 
the O 
I O 
/ O 
R+ O 
CoPP B-FORMULA 
mice O 
group O 
, O 
the O 
increased O 
hepatic O 
expression O 
of O 
HO-1 O 
was O 
associated O 
with O 
a O 
significant O 
reduction O 
in O 
liver O 
enzyme O 
levels O 
, O 
fewer O 
apoptotic O 
hepatocytes O 
cells O 
were O 
identified O 
by O 
morphological O 
criteria O 
and O 
by O 
immunohistochemistry O 
for O 
caspase-3 O 
, O 
there O 
was O 
a O 
decreased O 
mean O 
number O 
of O 
proliferating O 
cells O 
( O 
positively O 
stained O 
for O 
Ki67 O 
) O 
, O 
and O 
a O 
reduced O 
hepatic O 
expression O 
of O 
: O 
C O 
/ O 
EBP O 
homologous O 
protein O 
( O 
an O 
index O 
of O 
endoplasmic O 
reticulum O 
stress O 
) O 
, O 
the O 
NF-κB's O 
regulated O 
genes O 
( O 
CIAP2 O 
, O 
MCP-1 O 
and O 
IL-6 O 
) O 
, O 
and O 
increased O 
hepatic O 
expression O 
of O 
IκBa O 
( O 
the O 
inhibitory O 
protein O 
of O 
NF-κB O 
) O 
. O 
HO-1 O 
over O 
- O 
expression O 
plays O 
a O 
pivotal O 
role O 
in O 
reducing O 
the O 
hepatic O 
apoptotic O 
IR O 
injury O 
. O 
HO-1 O 
may O 
serve O 
as O 
a O 
potential O 
target O 
for O 
therapeutic O 
intervention O 
in O 
hepatic O 
I O 
/ O 
R O 
injury O 
during O 
liver O 
transplantation O 
. O 

nanoparticles O 
supported O 
on O 
nitrogen B-SYSTEMATIC 
-doped O 
HOPG O 
: O 
a O 
surface O 
science O 
and O 
electrochemical O 
study O 
. O 

have O 
investigated O 
by O 
photoemission O 
spectroscopy O 
and O 
scanning O 
tunnelling O 
microscopy O 
what O 
are O 
the O 
chemical O 
and O 
structural O 
changes O 
induced O 
by O 
nitrogen B-SYSTEMATIC 
ion O 
implantation O 
( O 
500 O 
eV O 
) O 
on O 
highly O 
oriented O 
pyrolytic O 
graphite B-TRIVIAL 
and O 
how O 
the O 
defects O 
induced O 
by O 
this O 
process O 
modify O 
the O 
growth O 
and O 
thermal O 
stability O 
of O 
palladium B-SYSTEMATIC 
nanoparticles O 
, O 
deposited O 
in O 
situ O 
by O 
physical O 
vapour O 
deposition O 
. O 
Since O 
nitrogen B-SYSTEMATIC 
derived O 
defects O 
are O 
mostly O 
buried O 
below O 
the O 
surface O 
, O 
they O 
are O 
not O 
accessible O 
for O 
a O 
chemical O 
interaction O 
with O 
metal O 
nanoparticles O 
; O 
however O 
, O 
the O 
amorphization O 
induced O 
by O 
the O 
ion O 
beam O 
in O 
the O 
outermost O 
layers O 
of O 
the O 
substrate O 
beneficially O 
affects O 
the O 
metal O 
morphology O 
, O 
limiting O 
the O 
size O 
of O 
the O 
nanoparticles O 
and O 
improving O 
their O 
thermal O 
stability O 
. O 
The O 
supported O 
nanoparticles O 
have O 
been O 
tested O 
towards O 
the O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
indicating O 
that O 
the O 
electrochemical O 
activity O 
does O 
not O 
depend O 
significantly O 
on O 
the O 
ion O 
implantation O 
, O 
but O 
mostly O 
on O 
the O 
amount O 
of O 
palladium B-SYSTEMATIC 
. O 

and O 
antiviral O 
effect O 
of O 
efavirenz B-TRIVIAL 
metabolites O 
in O 
blood O 
plasma O 
, O 
seminal O 
plasma O 
, O 
and O 
cerebrospinal O 
fluid O 
. O 

( O 
EFV B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
most O 
commonly O 
prescribed O 
antiretrovirals O 
for O 
use O 
in O 
the O 
treatment O 
of O 
human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
infection O 
. O 
EFV B-ABBREVIATION 
is O 
extensively O 
metabolized O 
by O 
cytochrome O 
P450 O 
to O 
a O 
number O 
of O 
oxygenated O 
products O 
; O 
however O 
, O 
the O 
pharmacologic O 
activity O 
and O 
distribution O 
of O 
these O 
metabolites O 
in O 
anatomic O 
compartments O 
have O 
yet O 
to O 
be O 
explored O 
. O 
The O 
systemic O 
distribution O 
of O 
EFV B-ABBREVIATION 
oxidative O 
metabolites O 
was O 
examined O 
in O 
blood O 
plasma O 
, O 
seminal O 
plasma O 
, O 
and O 
cerebrospinal O 
fluid O 
from O 
subjects O 
on O 
an O 
EFV B-ABBREVIATION 
-based O 
regimen O 
. O 
The O 
8-hydroxy B-SYSTEMATIC 
EFV I-SYSTEMATIC 
metabolite O 
was O 
detected O 
in O 
blood O 
plasma O 
, O 
seminal O 
plasma O 
, O 
and O 
cerebrospinal O 
fluid O 
, O 
with O 
median O 
concentrations O 
of O 
314.5 O 
ng O 
/ O 
ml O 
, O 
358.5 O 
ng O 
/ O 
ml O 
, O 
and O 
3.37 O 
ng O 
/ O 
ml O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
7-hydroxy B-MULTIPLE 
and I-MULTIPLE 
8,14-hydroxy I-MULTIPLE 
EFV I-MULTIPLE 
were O 
only O 
detected O 
in O 
blood O 
plasma O 
and O 
seminal O 
plasma O 
with O 
median O 
concentrations O 
of O 
8.84 O 
ng O 
/ O 
ml O 
and O 
10.23 O 
ng O 
/ O 
ml O 
, O 
and O 
5.63 O 
ng O 
/ O 
ml O 
and O 
5.43 O 
ng O 
/ O 
ml O 
, O 
respectively O 
. O 
Interestingly O 
, O 
protein O 
- O 
free O 
concentrations O 
of O 
metabolites O 
were O 
only O 
detectable O 
in O 
seminal O 
plasma O 
, O 
where O 
a O 
novel O 
dihdyroxylated O 
metabolite O 
of O 
EFV B-ABBREVIATION 
was O 
also O 
detected O 
. O 
This O 
accumulation O 
of O 
protein O 
- O 
free O 
EFV B-ABBREVIATION 
metabolites O 
was O 
demonstrated O 
to O 
be O 
the O 
result O 
of O 
differential O 
protein O 
binding O 
in O 
seminal O 
plasma O 
compared O 
with O 
that O 
of O 
blood O 
plasma O 
. O 
In O 
addition O 
, O 
the O 
oxidative O 
metabolites O 
of O 
EFV B-ABBREVIATION 
did O 
not O 
present O 
with O 
any O 
significant O 
pharmacologic O 
activity O 
toward O 
HIV-1 O 
as O 
measured O 
using O 
an O 
HIV O 
green O 
fluorescent O 
protein O 
single O 
- O 
round O 
infectivity O 
assay O 
. O 
This O 
study O 
is O 
the O 
first O 
to O 
report O 
the O 
physiologic O 
distribution O 
of O 
metabolites O 
of O 
an O 
antiretroviral O 
into O 
biologic O 
compartments O 
that O 
the O 
virus O 
is O 
known O 
to O 
distribute O 
and O 
to O 
examine O 
their O 
anti-HIV O 
activity O 
. O 
These O 
data O 
suggest O 
that O 
the O 
male O 
genital O 
tract O 
may O 
be O 
a O 
novel O 
compartment O 
that O 
should O 
be O 
considered O 
in O 
the O 
evaluation O 
of O 
drug O 
metabolite O 
exposure O 
. O 

stress O 
and O 
alteration O 
of O 
biochemical O 
markers O 
in O 
liver O 
and O 
kidney O 
by O 
malathion B-TRIVIAL 
in O 
rat O 
pups O 
. O 

present O 
study O 
was O 
undertaken O 
to O 
determine O 
the O 
effects O 
of O 
malathion B-TRIVIAL 
exposure O 
through O 
maternal O 
milk O 
on O 
oxidative O 
stress O 
, O 
functional O 
an O 
metabolic O 
parameters O 
in O 
kidney O 
and O 
liver O 
of O 
rat O 
pups O 
. O 
We O 
found O 
that O 
lactational O 
exposure O 
to O 
malation B-TRIVIAL 
( O 
200 O 
mg O 
/ O 
kg O 
, O 
body O 
weight O 
( O 
bw O 
) O 
) O 
induced O 
an O 
oxidative O 
stress O 
status O 
assessed O 
by O 
an O 
increase O 
in O 
malondialdhyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
content O 
, O 
reflecting O 
lipoperoxidation O 
, O 
a O 
decrease O 
in O 
thiol B-FAMILY 
groups O 
' O 
content O 
as O 
well O 
as O 
depletion O 
of O 
enzyme O 
activities O 
as O 
a O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
on O 
postnatal O 
days O 
( O 
Pnds O 
) O 
21 O 
and O 
51 O 
. O 
Moreover O 
, O 
the O 
current O 
study O 
showed O 
that O 
malathion B-TRIVIAL 
induced O 
liver O 
and O 
kidney O 
dysfunctions O 
demonstrated O 
by O 
considerable O 
increase O 
in O 
phosphatase O 
alkaline O 
( O 
PAL O 
) O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
and O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
activities O 
as O 
well O 
as O 
total O 
and O 
direct O 
bilirubin B-TRIVIAL 
, O 
creatinine B-TRIVIAL 
urea B-TRIVIAL 
and O 
acid B-TRIVIAL 
uric I-TRIVIAL 
contents O 
. O 
We O 
also O 
observed O 
an O 
increase O 
in O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
, O 
total O 
cholesterol B-TRIVIAL 
( O 
TC O 
) O 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
and O 
a O 
decrease O 
in O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
in O 
the O 
plasma O 
of O 
treated O 
rat O 
pups O 
. O 
These O 
findings O 
evidenced O 
that O 
malathion B-TRIVIAL 
exposure O 
during O 
lactation O 
through O 
maternal O 
milk O 
of O 
rats O 
pups O 
induced O 
kidney O 
and O 
liver O 
oxidative O 
stress O 
as O 
well O 
as O 
functional O 
and O 
metabolic O 
disorders O 
that O 
play O 
a O 
role O 
in O 
the O 
development O 
of O 
others O 
pathologies O 
as O 
cardiovascular O 
diseases O 
and O 
cancers O 
. O 

: O 
Ectopic O 
thyroid O 
tissue O 
is O 
usually O 
found O 
anywhere O 
along O 
the O 
embryonic O 
descent O 
pathway O 
of O 
the O 
medial O 
thyroid O 
anlage O 
from O 
the O 
tongue O 
to O 
the O 
trachea O 
( O 
Wölfler O 
area O 
) O 
. O 
However O 
, O 
ectopic O 
thyroid O 
tissue O 
in O 
the O 
adrenal O 
gland O 
( O 
ETTAG O 
) O 
is O 
not O 
easy O 
to O 
understand O 
on O 
the O 
basis O 
of O 
thyroid O 
embryology O 
; O 
because O 
it O 
is O 
so O 
rare O 
, O 
the O 
possibility O 
of O 
metastasis O 
should O 
first O 
be O 
considered O 
. O 
Here O 
, O 
we O 
describe O 
2 O 
cases O 
of O 
ETTAG O 
with O 
pathogenetic O 
implications O 
and O 
review O 
the O 
literature O 
. O 
Patient O 
findings O 
: O 
Two O 
cases O 
of O 
ETTAG O 
presented O 
as O 
incidental O 
cystic O 
adrenal O 
masses O 
in O 
adult O 
females O 
, O 
one O 
having O 
a O 
congenital O 
hernia O 
of O 
Morgagni O 
. O 
The O 
ETTAG O 
was O 
histologically O 
indistinguishable O 
from O 
normal O 
orthotopic O 
thyroid O 
tissue O 
, O 
and O 
its O 
follicular O 
nature O 
was O 
confirmed O 
by O 
immunohistochemical O 
positivity O 
for O 
thyroglobulin O 
, O 
thyroperoxidase O 
, O 
thyroid O 
transcription O 
factor-1 O 
( O 
TTF-1 O 
/ O 
Titf-1 O 
/ O 
Nkx2.1 O 
) O 
, O 
cytokeratin O 
( O 
CK O 
) O 
AE1 O 
/ O 
AE3 O 
, O 
CK O 
7 O 
, O 
pendrin O 
, O 
human O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
( O 
hNIS O 
) O 
, O 
paired O 
box O 
gene O 
8 O 
( O 
PAX8 O 
) O 
and O 
FOXE1 O 
( O 
TTF-2 O 
) O 
, O 
as O 
well O 
as O 
positivity O 
for O 
the O 
messenger O 
RNA O 
of O 
the O 
thyroglobulin O 
gene O 
by O 
in O 
situ O 
hybridization O 
analysis O 
. O 
No O 
C O 
cells O 
( O 
negativity O 
for O 
calcitonin O 
, O 
cromogranin O 
and O 
synaptophysin O 
) O 
were O 
present O 
. O 
Neither O 
BRAF O 
nor O 
KRAS O 
mutations O 
were O 
detected O 
with O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
analysis O 
. O 
Further O 
work O 
- O 
up O 
did O 
not O 
show O 
evidence O 
of O 
thyroid O 
malignancy O 
. O 
Summary O 
: O 
ETTAG O 
is O 
a O 
rare O 
finding O 
, O 
with O 
only O 
7 O 
cases O 
reported O 
; O 
women O 
are O 
much O 
more O 
frequently O 
affected O 
than O 
men O 
( O 
8 O 
: O 
1 O 
) O 
and O 
it O 
usually O 
clinically O 
presents O 
in O 
the O 
fifth O 
decade O 
( O 
mean O 
age O 
: O 
54 O 
, O 
range O 
: O 
38-67 O 
) O 
as O 
a O 
cystic O 
adrenal O 
mass O 
incidentally O 
discovered O 
on O 
abdominal O 
ultrasonography O 
and O 
/ O 
or O 
in O 
computed O 
tomography O 
images O 
. O 
ETTAG O 
is O 
composed O 
of O 
normal O 
follicular O 
cells O 
without O 
C O 
cells O 
. O 
The O 
expression O 
of O 
some O 
transcription O 
factors O 
( O 
TTF-1 O 
, O 
PAX8 O 
and O 
FOXE1 O 
) O 
involved O 
in O 
development O 
and O 
/ O 
or O 
migration O 
of O 
the O 
medial O 
thyroid O 
anlage O 
is O 
preserved O 
. O 
Coexistence O 
of O 
a O 
congenital O 
hernia O 
of O 
Morgagni O 
in O 
one O 
patient O 
suggests O 
an O 
over O 
- O 
descent O 
of O 
medial O 
thyroid O 
anlage O 
derived O 
cells O 
in O 
its O 
pathogenesis O 
. O 
Conclusion O 
: O 
Although O 
ETTAG O 
pathogenesis O 
remains O 
unknown O 
, O 
the O 
lack O 
of O 
C O 
cells O 
together O 
with O 
the O 
coexistence O 
of O 
a O 
congenital O 
defect O 
of O 
the O 
anterior O 
diaphragm O 
( O 
hernia O 
of O 
Morgagni O 
) O 
in O 
one O 
of O 
our O 
patients O 
could O 
suggest O 
an O 
over O 
- O 
descent O 
of O 
medial O 
thyroid O 
anlagen O 
derived O 
cells O 
in O 
the O 
origin O 
of O 
this O 
heterotopia O 
. O 

( O 
P-gp O 
) O 
is O 
an O 
active O 
efflux O 
pump O 
affecting O 
the O 
pharmacokinetic O 
( O 
PK O 
) O 
profiles O 
of O 
drugs O 
that O 
are O 
P-gp O 
substrates O 
. O 
The O 
Caco-2 O 
bi O 
- O 
directional O 
assay O 
is O 
widely O 
used O 
to O 
identify O 
drug-P-gp O 
interactions O 
in O 
vitro O 
. O 
For O 
molecules O 
exhibiting O 
non-classical O 
drug O 
properties O 
however O 
, O 
ambiguous O 
results O 
limit O 
its O 
use O 
in O 
lead O 
optimization O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
develop O 
a O 
robust O 
cell O 
- O 
based O 
assay O 
system O 
to O 
directly O 
measure O 
the O 
role O 
of O 
P-gp O 
- O 
driven O 
efflux O 
in O 
reducing O 
the O 
potency O 
of O 
hepatitis O 
C O 
virus O 
( O 
HCV O 
) O 
replication O 
inhibitors O 
. O 
Vinblastine B-TRIVIAL 
( O 
Vin B-ABBREVIATION 
) O 
was O 
employed O 
to O 
select O 
for O 
a O 
Vin B-ABBREVIATION 
-resistant O 
HCV O 
replicon O 
( O 
313-11 O 
) O 
from O 
the O 
parental O 
cell O 
line O 
( O 
377-2 O 
) O 
. O 
The O 
313-11 O 
cell O 
line O 
was O 
> O 
50-fold O 
resistant O 
to O 
Vin B-ABBREVIATION 
and O 
over O 
- O 
expressed O 
P-gp O 
, O 
as O 
determined O 
by O 
Western O 
immunoblots O 
. O 
Increased O 
expression O 
of O 
P-gp O 
was O 
mediated O 
by O 
up O 
- O 
regulation O 
of O 
the O 
MDR1 O 
transcript O 
. O 
The O 
reduced O 
potency O 
of O 
different O 
classes O 
of O 
HCV O 
replication O 
inhibitors O 
in O 
the O 
313-11 O 
P-gp O 
cell O 
line O 
was O 
restored O 
in O 
the O 
presence O 
of O 
known O 
P-gp O 
inhibitors O 
. O 
Addition O 
of O 
the O 
P-gp O 
inhibitor O 
, O 
tariquidar B-TRIVIAL 
, O 
increased O 
the O 
uptake O 
of O 
a O 
radiolabeled O 
HCV O 
replication O 
inhibitor O 
by O 
14-fold O 
in O 
the O 
313-11 O 
replicon O 
cell O 
line O 
. O 
Finally O 
, O 
a O 
positive O 
correlation O 
was O 
demonstrated O 
between O 
potency O 
in O 
the O 
313-11 O 
replicon O 
and O 
the O 
bi O 
- O 
directional O 
Caco-2 O 
efflux O 
ratio O 
for O 
a O 
panel O 
of O 
HCV O 
protease O 
inhibitors O 
. O 
In O 
conclusion O 
, O 
a O 
robust O 
P-gp O 
HCV O 
replicon O 
cell O 
- O 
based O 
assay O 
has O 
been O 
developed O 
to O 
measure O 
the O 
effect O 
of O 
the O 
P-gp O 
efflux O 
pump O 
on O 
the O 
potency O 
of O 
different O 
classes O 
of O 
HCV O 
replication O 
inhibitors O 
. O 
This O 
system O 
establishes O 
a O 
direct O 
correlation O 
between O 
antiviral O 
activity O 
and O 
the O 
effect O 
of O 
P-gp O 
efflux O 
in O 
a O 
single O 
cell O 
line O 
. O 

of O 
human O 
alcohol B-FAMILY 
and O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
by O 
cimetidine B-TRIVIAL 
and O 
assessment O 
of O 
its O 
effects O 
on O 
ethanol B-SYSTEMATIC 
metabolism O 
. O 

studies O 
have O 
reported O 
that O 
cimetidine B-TRIVIAL 
, O 
an O 
H2-receptor O 
antagonist O 
used O 
to O 
treat O 
gastric O 
and O 
duodenal O 
ulcers O 
, O 
can O 
inhibit O 
alcohol B-FAMILY 
dehydrogenases O 
( O 
ADHs O 
) O 
and O 
ethanol B-SYSTEMATIC 
metabolism O 
. O 
Human O 
alcohol B-FAMILY 
dehydrogenases O 
and O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
( O 
ALDHs O 
) O 
, O 
the O 
principal O 
enzymes O 
responsible O 
for O 
metabolism O 
of O 
ethanol B-SYSTEMATIC 
, O 
are O 
complex O 
enzyme O 
families O 
that O 
exhibit O 
functional O 
polymorphisms O 
among O 
ethnic O 
groups O 
and O 
distinct O 
tissue O 
distributions O 
. O 
We O 
investigated O 
the O 
inhibition O 
by O 
cimetidine B-TRIVIAL 
of O 
alcohol B-FAMILY 
oxidation O 
by O 
recombinant O 
human O 
ADH1A O 
, O 
ADH1B1 O 
, O 
ADH1B2 O 
, O 
ADH1B3 O 
, O 
ADH1C1 O 
, O 
ADH1C2 O 
, O 
ADH2 O 
, O 
and O 
ADH4 O 
, O 
and O 
aldehyde B-SYSTEMATIC 
oxidation O 
by O 
ALDH1A1 O 
and O 
ALDH2 O 
at O 
pH O 
7.5 O 
and O 
a O 
cytosolic O 
NAD(+) B-ABBREVIATION 
concentration O 
. O 
Cimetidine B-TRIVIAL 
acted O 
as O 
competitive O 
or O 
noncompetitive O 
inhibitors O 
for O 
the O 
ADH O 
and O 
ALDH O 
isozymes O 
/ O 
allozymes O 
with O 
near O 
mM O 
inhibition O 
constants O 
. O 
The O 
metabolic O 
interactions O 
between O 
cimetidine B-TRIVIAL 
and O 
ethanol B-SYSTEMATIC 
/ O 
acetaldehyde B-SYSTEMATIC 
were O 
assessed O 
by O 
computer O 
simulation O 
using O 
the O 
inhibition O 
equations O 
and O 
the O 
determined O 
kinetic O 
constants O 
. O 
At O 
therapeutic O 
drug O 
levels O 
( O 
0.015 O 
mM O 
) O 
and O 
physiologically O 
relevant O 
concentrations O 
of O 
ethanol B-SYSTEMATIC 
( O 
10 O 
mM O 
) O 
and O 
acetaldehyde B-SYSTEMATIC 
( O 
10 O 
μM O 
) O 
in O 
target O 
tissues O 
, O 
cimetidine B-TRIVIAL 
could O 
weakly O 
inhibit O 
( O 
< O 
5% O 
) O 
the O 
activities O 
of O 
ADH1B2 O 
and O 
ADH1B3 O 
in O 
liver O 
, O 
ADH2 O 
in O 
liver O 
and O 
small O 
intestine O 
, O 
ADH4 O 
in O 
stomach O 
, O 
and O 
ALDH1A1 O 
in O 
the O 
three O 
tissues O 
, O 
but O 
not O 
significantly O 
affect O 
ADH1A O 
, O 
ADH1B1 O 
, O 
ADH1C1 O 
/ O 
2 O 
, O 
or O 
ALDH2 O 
. O 
At O 
higher O 
drug O 
levels O 
, O 
which O 
may O 
accumulate O 
in O 
cells O 
( O 
0.2 O 
mM O 
) O 
, O 
the O 
activities O 
of O 
the O 
weakly O 
- O 
inhibited O 
enzymes O 
may O 
be O 
decreased O 
more O 
significantly O 
. O 
The O 
quantitative O 
effects O 
of O 
cimetidine B-TRIVIAL 
on O 
metabolism O 
of O 
ethanol B-SYSTEMATIC 
and O 
other O 
physiological O 
substrates O 
of O 
ADHs O 
need O 
further O 
investigation O 
. O 

chemical O 
universe O 
database O 
GDB-17 O 
contains O 
166.4 O 
billion O 
molecules O 
of O 
up O 
to O 
17 O 
atoms O 
of O 
C B-FORMULA 
, O 
N B-FORMULA 
, O 
O B-FORMULA 
, O 
S B-FORMULA 
, O 
and O 
halogens B-FAMILY 
obeying O 
rules O 
for O 
chemical O 
stability O 
, O 
synthetic O 
feasibility O 
, O 
and O 
medicinal O 
chemistry O 
. O 
GDB-17 O 
was O 
analyzed O 
using O 
42 O 
integer O 
value O 
descriptors O 
of O 
molecular O 
structure O 
which O 
we O 
term O 
" O 
Molecular O 
Quantum O 
Numbers O 
" O 
( O 
MQN O 
) O 
. O 
Principal O 
component O 
analysis O 
and O 
representation O 
of O 
the O 
( O 
PC1 O 
, O 
PC2)-plane O 
provided O 
a O 
graphical O 
overview O 
of O 
the O 
GDB-17 O 
chemical O 
space O 
. O 
Rapid O 
ligand O 
- O 
based O 
virtual O 
screening O 
( O 
LBVS O 
) O 
of O 
GDB-17 O 
using O 
the O 
city O 
- O 
block O 
distance O 
CBD(MQN) O 
as O 
a O 
similarity O 
search O 
measure O 
was O 
enabled O 
by O 
a O 
hashed O 
MQN-fingerprint O 
. O 
LBVS O 
of O 
the O 
entire O 
GDB-17 O 
and O 
of O 
selected O 
subsets O 
identified O 
shape O 
similar O 
, O 
scaffold O 
hopping O 
analogs O 
( O 
ROCS O 
> O 
1.6 O 
and O 
T(SF) O 
< O 
0.5 O 
) O 
of O 
15 O 
drugs O 
. O 
Over O 
97% O 
of O 
these O 
analogs O 
occurred O 
within O 
CBD(MQN) O 
≤ O 
12 O 
from O 
each O 
drug O 
, O 
a O 
constraint O 
which O 
might O 
help O 
focus O 
advanced O 
virtual O 
screening O 
. O 
An O 
MQN-searchable O 
50 O 
million O 
subset O 
of O 
GDB-17 O 
is O 
publicly O 
available O 
at O 
www.gdb.unibe.ch O 
. O 

poikilotherms O 
and O 
homeotherms O 
live O 
longer O 
at O 
lower O 
body O 
temperatures O 
, O 
highlighting O 
a O 
general O 
role O 
of O 
temperature O 
reduction O 
in O 
lifespan O 
extension O 
. O 
However O 
, O 
the O 
underlying O 
mechanisms O 
remain O 
unclear O 
. O 
One O 
prominent O 
model O 
is O 
that O 
cold O 
temperatures O 
reduce O 
the O 
rate O 
of O 
chemical O 
reactions O 
, O 
thereby O 
slowing O 
the O 
rate O 
of O 
aging O 
. O 
This O 
view O 
suggests O 
that O 
cold O 
- O 
dependent O 
lifespan O 
extension O 
is O 
simply O 
a O 
passive O 
thermodynamic O 
process O 
. O 
Here O 
, O 
we O 
challenge O 
this O 
view O 
in O 
C O 
. O 
elegans O 
by O 
showing O 
that O 
genetic O 
programs O 
actively O 
promote O 
longevity O 
at O 
cold O 
temperatures O 
. O 
We O 
find O 
that O 
TRPA-1 O 
, O 
a O 
cold O 
- O 
sensitive O 
TRP O 
channel O 
, O 
detects O 
temperature O 
drop O 
in O 
the O 
environment O 
to O 
extend O 
lifespan O 
. O 
This O 
effect O 
requires O 
cold O 
- O 
induced O 
, O 
TRPA-1 O 
- O 
mediated O 
calcium B-SYSTEMATIC 
influx O 
and O 
a O 
calcium B-SYSTEMATIC 
-sensitive O 
PKC O 
that O 
signals O 
to O 
the O 
transcription O 
factor O 
DAF-16 O 
/ O 
FOXO O 
. O 
Human O 
TRPA1 O 
can O 
functionally O 
substitute O 
for O 
worm O 
TRPA-1 O 
in O 
promoting O 
longevity O 
. O 
Our O 
results O 
reveal O 
a O 
previously O 
unrecognized O 
function O 
for O 
TRP O 
channels O 
, O 
link O 
calcium B-SYSTEMATIC 
signaling O 
to O 
longevity O 
, O 
and O 
, O 
importantly O 
, O 
demonstrate O 
that O 
genetic O 
programs O 
contribute O 
to O 
lifespan O 
extension O 
at O 
cold O 
temperatures O 
. O 

of O 
oxygen B-SYSTEMATIC 
and O 
glucose B-TRIVIAL 
deprivation O 
on O 
synaptic O 
transmission O 
in O 
rat O 
dentate O 
gyrus O 
: O 
role O 
of O 
A(2A) O 
adenosine B-TRIVIAL 
receptors O 
. O 

hippocampus O 
is O 
comprised O 
of O 
two O 
distinct O 
subfields O 
that O 
show O 
different O 
responses O 
to O 
hypoxic O 
- O 
ischemic O 
brain O 
injury O 
: O 
the O 
CA1 O 
region O 
is O 
particularly O 
susceptible O 
whereas O 
the O 
dentate O 
gyrus O 
( O 
DG O 
) O 
is O 
quite O 
resistant O 
. O 
Our O 
aim O 
was O 
to O 
determine O 
the O 
synaptic O 
and O 
proliferative O 
response O 
of O 
the O 
DG O 
to O 
severe O 
oxygen B-SYSTEMATIC 
and O 
glucose B-TRIVIAL 
deprivation O 
( O 
OGD O 
) O 
in O 
acute O 
rat O 
hippocampal O 
slices O 
and O 
to O 
investigate O 
the O 
contribution O 
of O 
A(2A) O 
adenosine B-TRIVIAL 
receptor O 
antagonism O 
to O 
recovery O 
of O 
synaptic O 
activity O 
after O 
OGD O 
. O 
Extracellular O 
recordings O 
of O 
field O 
excitatory O 
post O 
- O 
synaptic O 
potentials O 
( O 
fEPSPs O 
) O 
in O 
granule O 
cells O 
of O 
the O 
DG O 
in O 
brain O 
slices O 
prepared O 
from O 
male O 
Wistar O 
rats O 
were O 
used O 
. O 
A O 
9-min O 
OGD O 
is O 
needed O 
in O 
the O 
DG O 
to O 
always O 
induce O 
the O 
appearance O 
of O 
anoxic O 
depolarization O 
( O 
AD O 
) O 
and O 
the O 
irreversible O 
block O 
of O 
synaptic O 
activity O 
, O 
as O 
recorded O 
up O 
to O 
24 O 
h O 
from O 
the O 
end O 
of O 
the O 
insult O 
, O 
whereas O 
only O 
7-min O 
OGD O 
is O 
required O 
in O 
the O 
CA1 O 
region O 
. O 
Selective O 
antagonism O 
of O 
A(2A) O 
adenosine B-TRIVIAL 
receptors O 
by O 
ZM241385 B-IDENTIFIER 
significantly O 
prevents O 
or O 
delays O 
the O 
appearance O 
of O 
AD O 
and O 
protects O 
from O 
the O 
irreversible O 
block O 
of O 
neurotransmission O 
induced O 
by O 
9-min O 
OGD O 
in O 
the O 
DG O 
. O 
The O 
effects O 
of O 
9-min O 
OGD O 
on O 
proliferation O 
and O 
maturation O 
of O 
cells O 
localized O 
in O 
the O 
subgranular O 
zone O 
of O 
DG O 
in O 
slices O 
prepared O 
from O 
5-bromo-2'-deoxyuridine B-SYSTEMATIC 
( O 
BrdU B-ABBREVIATION 
) O 
treated O 
rats O 
was O 
investigated O 
. O 
Slices O 
were O 
further O 
incubated O 
with O 
an O 
immature O 
neuronal O 
marker O 
, O 
doublecortin O 
( O 
DCX O 
) O 
. O 
The O 
number O 
of O 
BrdU(+) B-FORMULA 
cells O 
was O 
significantly O 
decreased O 
6 O 
h O 
after O 
9-min O 
OGD O 
and O 
this O 
effect O 
was O 
antagonized O 
by O 
ZM241385 B-IDENTIFIER 
. O 
After O 
24 O 
h O 
from O 
the O 
end O 
of O 
9-min O 
OGD O 
, O 
the O 
number O 
of O 
BrdU(+) B-FORMULA 
cells O 
returned O 
to O 
that O 
found O 
before O 
OGD O 
and O 
increased O 
arborization O 
of O 
tertiary O 
dendrites O 
of O 
DCX(+) O 
cells O 
was O 
observed O 
. O 
The O 
adenosine B-TRIVIAL 
A(2A) O 
antagonist O 
ZM241385 B-IDENTIFIER 
protects O 
from O 
synaptic O 
failure O 
and O 
from O 
decreased O 
proliferation O 
of O 
immature O 
neuronal O 
cells O 
at O 
a O 
precocious O 
time O 
after O 
OGD O 
. O 

it O 
has O 
been O 
suggested O 
that O 
high O 
- O 
resolution O 
computed O 
tomography O 
( O 
HRCT O 
) O 
scans O 
can O 
be O 
obtained O 
when O 
plain O 
radiographs O 
are O 
equivocal O 
for O 
the O 
presence O 
of O 
interstitial O 
lung O 
fibrosis O 
( O 
ILF O 
) O 
caused O 
by O 
inhalation O 
of O 
dust O 
, O 
such O 
as O 
silica B-TRIVIAL 
, O 
asbestos B-FAMILY 
fibres O 
, O 
etc O 
. O 
, O 
the O 
specificity O 
of O 
the O 
findings O 
remains O 
in O 
question O 
. O 
The O 
present O 
study O 
was O 
carried O 
out O 
to O 
compare O 
the O 
relative O 
efficacy O 
of O 
chest O 
radiography O 
by O 
conventional O 
method O 
and O 
HRCT O 
in O 
evaluating O 
ILF O 
which O 
included O 
22 O 
workers O 
exposed O 
to O 
fibrogenic O 
dust O 
, O 
who O 
were O 
subjected O 
to O 
clinical O 
examination O 
, O 
pulmonary O 
function O 
testing O 
, O 
posteroanterior O 
chest O 
radiography O 
and O 
HRCT O 
. O 
In O 
the O 
six O 
subjects O 
who O 
had O 
findings O 
suggestive O 
of O 
ILF O 
on O 
HRCT O 
, O 
four O 
had O 
normal O 
chest O 
x-ray O 
( O 
CXR O 
) O 
while O 
one O 
each O 
has O 
been O 
diagnosed O 
as O 
having O 
tuberculosis O 
and O 
ILF O 
on O 
CXR O 
. O 
The O 
agreement O 
analysis O 
between O 
HRCT O 
and O 
CXR O 
suggests O 
that O 
there O 
was O 
a O 
poor O 
agreement O 
between O 
HRCT O 
and O 
CXR O 
( O 
kappa O 
= O 
0.34 O 
) O 
. O 

RELEVANCE O 
: O 
In O 
the O 
genus O 
Curculigo O 
, O 
Curculigo O 
orchioides O 
Gaertn O 
, O 
Curculigo O 
capitulata O 
( O 
Lour O 
) O 
O O 
. O 
Ktze O 
and O 
Curculigo O 
pilosa O 
( O 
Schumach O 
. O 
& O 
Thonn O 
. O 
) O 
Engl O 
are O 
often O 
used O 
in O 
traditional O 
medicine O 
. O 
Curculigo O 
orchioides O 
is O 
used O 
for O 
the O 
treatment O 
of O 
impotence O 
, O 
limb O 
limpness O 
, O 
arthritis O 
of O 
the O 
lumbar O 
and O 
knee O 
joints O 
, O 
and O 
watery O 
diarrhea O 
in O 
traditional O 
Chinese O 
medicine O 
, O 
and O 
also O 
used O 
as O 
a O 
potent O 
immunomodulator O 
and O 
aphrodisiac O 
in O 
the O 
Ayurvedic O 
medical O 
system O 
. O 
Curculigo O 
capitulata O 
is O 
used O 
for O 
the O 
treatment O 
of O 
consumptive O 
cough O 
, O 
kidney O 
asthenia O 
, O 
impotence O 
and O 
spermatorrhea O 
, O 
hemorrhoids O 
, O 
asthma O 
, O 
jaundice O 
, O 
diarrhea O 
, O 
colic O 
and O 
gonorrhea O 
in O 
traditional O 
Chinese O 
and O 
India O 
medicine O 
, O 
and O 
to O 
treat O 
urinary O 
tract O 
infection O 
, O 
acute O 
renal O 
pelvis O 
and O 
nephritis O 
, O 
nephritis O 
- O 
edema O 
, O 
cystitis O 
, O 
nephrolithiasis O 
, O 
hypertension O 
and O 
rheumatic O 
arthritis O 
in O 
traditional O 
Dai O 
medicine O 
. O 
Curculigo O 
pilosa O 
are O 
applied O 
to O 
treat O 
gastrointestinal O 
and O 
heart O 
diseases O 
in O 
Africa O 
. O 
AIM O 
OF O 
THE O 
REVIEW O 
: O 
This O 
review O 
aims O 
to O 
exhibit O 
up O 
- O 
to O 
- O 
date O 
and O 
comprehensive O 
information O 
about O 
traditional O 
uses O 
, O 
phytochemistry O 
, O 
pharmacology O 
and O 
toxicology O 
of O 
medicinal O 
plants O 
in O 
the O 
genus O 
Curculigo O 
, O 
and O 
has O 
an O 
insight O 
into O 
the O 
opportunities O 
for O 
the O 
future O 
research O 
and O 
development O 
of O 
Curculigo O 
plant O 
. O 
METHODS O 
: O 
A O 
bibliographic O 
investigation O 
was O 
performed O 
by O 
analyzing O 
the O 
information O 
available O 
on O 
Curculigo O 
plant O 
from O 
worldwide O 
accepted O 
scientific O 
databases O 
( O 
Pubmed O 
, O 
Scopus O 
and O 
Web O 
of O 
Science O 
, O 
SciFinder O 
, O 
Google O 
Scholar O 
, O 
Yahoo O 
) O 
. O 
Furthermore O 
, O 
information O 
also O 
was O 
obtained O 
from O 
some O 
local O 
and O 
foreign O 
books O 
on O 
ethnobotany O 
and O 
ethnomedicines O 
. O 
RESULTS O 
: O 
Curculigo O 
orchioides O 
, O 
Curculigo O 
capitulata O 
and O 
Curculigo O 
pilosa O 
have O 
been O 
used O 
as O 
traditional O 
medicine O 
to O 
treat O 
kinds O 
of O 
diseases O 
such O 
as O 
impotence O 
, O 
limb O 
limpness O 
, O 
gastrointestinal O 
and O 
heart O 
diseases O 
, O 
etc O 
. O 
Phytochemical O 
investigation O 
of O 
eight O 
species O 
of O 
the O 
genus O 
Curculigo O 
has O 
resulted O 
in O 
identification O 
of O 
more O 
than O 
110 O 
compounds O 
. O 
The O 
content O 
of O 
curculigoside B-FAMILY 
is O 
used O 
as O 
an O 
indicator O 
to O 
evaluate O 
the O 
quality O 
of O 
rhizome O 
of O 
Curculigo O 
orchioides O 
. O 
The O 
medicinal O 
plants O 
have O 
showed O 
a O 
wide O 
spectrum O 
pharmacological O 
activities O 
, O 
including O 
adaptive O 
, O 
immunostimulatory O 
, O 
taste O 
- O 
modifying O 
and O 
sweet O 
- O 
tasting O 
, O 
antioxidant O 
, O 
mast O 
cell O 
stabilization O 
, O 
antihistaminic O 
and O 
antiasthmatic O 
, O 
hepatoprotective O 
and O 
neuroprotective O 
activity O 
. O 
Toxicological O 
test O 
indicated O 
that O 
Curculigo O 
orchioides O 
at O 
the O 
dose O 
of O 
120g O 
/ O 
kg O 
after O 
administrating O 
rats O 
for O 
180 O 
days O 
may O 
cause O 
injury O 
of O 
liver O 
and O 
kidney O 
. O 
CONCLUSION O 
: O 
The O 
medicinal O 
plants O 
of O 
genus O 
Curculigo O 
have O 
emerged O 
as O 
a O 
good O 
source O 
of O 
the O 
traditional O 
medicines O 
. O 
Some O 
uses O 
of O 
these O 
plants O 
in O 
the O 
traditional O 
medicines O 
have O 
been O 
validated O 
by O 
pharmacological O 
investigation O 
. O 
However O 
, O 
the O 
mechanism O 
of O 
their O 
actions O 
should O 
be O 
further O 
elucidated O 
; O 
the O 
particular O 
constituent O 
responsible O 
for O 
toxicity O 
should O 
be O 
isolated O 
and O 
identified O 
, O 
and O 
the O 
target O 
tissue O 
and O 
mechanism O 
of O 
toxic O 
ingredients O 
also O 
deserve O 
to O 
be O 
further O 
investigated O 
; O 
more O 
reference O 
substances O 
should O 
be O 
prepared O 
, O 
and O 
sophisticated O 
analytical O 
technologies O 
should O 
be O 
developed O 
to O 
comprehensively O 
assess O 
the O 
quality O 
of O 
Curculigo O 
herbs O 
. O 
These O 
investigations O 
will O 
be O 
helpful O 
for O 
further O 
utilization O 
of O 
the O 
plants O 
of O 
genus O 
Curculigo O 
. O 

, O 
just O 
- O 
percolated O 
gold O 
films O 
were O 
prepared O 
by O 
evaporation O 
on O 
bare O 
glass O 
. O 
Annealing O 
of O 
the O 
films O 
at O 
temperatures O 
close O 
to O 
or O 
higher O 
than O 
the O 
softening O 
temperature O 
of O 
the O 
glass O 
substrate O 
induces O 
morphological O 
transformation O 
to O 
discrete O 
Au B-FORMULA 
islands O 
and O 
gradual O 
embedding O 
of O 
the O 
formed O 
islands O 
in O 
the O 
glass O 
. O 
The O 
mechanism O 
and O 
kinetics O 
of O 
these O 
processes O 
are O 
studied O 
here O 
using O 
a O 
combination O 
of O 
in O 
situ O 
high O 
- O 
temperature O 
optical O 
spectroscopy O 
; O 
ex O 
situ O 
characterization O 
of O 
the O 
island O 
shape O 
by O 
high O 
- O 
resolution O 
scanning O 
electron O 
microscopy O 
( O 
HRSEM O 
) O 
, O 
atomic O 
force O 
microcopy O 
( O 
AFM O 
) O 
and O 
cross O 
- O 
sectional O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
; O 
and O 
numerical O 
simulations O 
of O 
transmission O 
spectra O 
using O 
the O 
Multiple O 
Multipole O 
Program O 
( O 
MMP O 
) O 
approach O 
. O 
It O 
is O 
shown O 
that O 
the O 
morphological O 
transformation O 
of O 
just O 
- O 
percolated O 
, O 
10 O 
nm O 
( O 
nominal O 
thickness O 
) O 
Au B-FORMULA 
films O 
evaporated O 
on O 
glass O 
and O 
annealed O 
at O 
600 O 
°C O 
, O 
i.e O 
. O 
, O 
in O 
the O 
vicinity O 
of O 
the O 
substrate O 
glass O 
transition O 
temperature O 
( O 
Tg O 
= O 
557 O 
°C O 
) O 
, O 
proceeds O 
via O 
three O 
processes O 
exhibiting O 
different O 
time O 
scales O 
: O 
(i) O 
fast O 
recrystallization O 
and O 
dewetting O 
, O 
leading O 
to O 
formation O 
of O 
single O 
- O 
crystalline O 
islands O 
( O 
minutes O 
) O 
; O 
the O 
initial O 
spectrum O 
characteristic O 
of O 
a O 
continuous O 
Au B-FORMULA 
film O 
is O 
transformed O 
to O 
that O 
of O 
an O 
island O 
film O 
, O 
displaying O 
a O 
surface O 
plasmon O 
( O 
SP O 
) O 
absorption O 
band O 
. O 
(ii) O 
Reshaping O 
and O 
faceting O 
of O 
the O 
single O 
- O 
crystalline O 
islands O 
accompanied O 
by O 
formation O 
of O 
circumferential O 
glass O 
rims O 
around O 
them O 
( O 
first O 
few O 
hours O 
) O 
; O 
the O 
overall O 
optical O 
response O 
shows O 
a O 
blue O 
shift O 
of O 
the O 
SP O 
band O 
. O 
(iii) O 
Gradual O 
island O 
embedding O 
in O 
the O 
glass O 
substrate O 
( O 
tens O 
of O 
hours O 
) O 
, O 
seen O 
as O 
a O 
characteristic O 
red O 
shift O 
of O 
the O 
SP O 
band O 
. O 
The O 
influence O 
of O 
the O 
annealing O 
atmosphere O 
( O 
air O 
, O 
vacuum O 
) O 
on O 
the O 
embedding O 
process O 
is O 
found O 
to O 
be O 
minor O 
. O 
Numerical O 
modeling O 
of O 
the O 
extinction O 
cross O 
- O 
section O 
corresponding O 
to O 
the O 
morphological O 
transformations O 
during O 
island O 
recrystallization O 
and O 
embedding O 
is O 
in O 
qualitative O 
agreement O 
with O 
the O 
experimental O 
data O 
. O 

of O 
novel O 
object O 
recognition O 
in O 
adulthood O 
after O 
neonatal O 
exposure O 
to O 
diazinon B-TRIVIAL 
. O 

is O 
an O 
organophosphate B-FAMILY 
pesticide O 
that O 
is O 
still O 
heavily O 
used O 
in O 
agriculture O 
, O 
home O 
gardening O 
, O 
and O 
indoor O 
pest O 
control O 
in O 
Japan O 
. O 
The O 
present O 
study O 
investigated O 
the O 
effect O 
of O 
neonatal O 
exposure O 
to O 
diazinon B-TRIVIAL 
on O 
hippocampus O 
- O 
dependent O 
novel O 
object O 
recognition O 
test O 
performance O 
and O 
the O 
expression O 
of O 
the O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptor O 
and O 
its O 
signal O 
transduction O 
pathway O 
- O 
related O 
genes O 
in O 
the O 
hippocampi O 
of O 
young O 
adult O 
and O 
adult O 
mice O 
. O 
Male O 
offspring O 
of O 
C3H O 
/ O 
HeN O 
mice O 
were O 
subcutaneously O 
treated O 
with O 
0 O 
, O 
0.5 O 
, O 
or O 
5 O 
mg O 
/ O 
kg O 
of O 
diazinon B-TRIVIAL 
for O 
4 O 
consecutive O 
days O 
beginning O 
on O 
postnatal O 
day O 
( O 
PND O 
) O 
8 O 
. O 
Beginning O 
on O 
PND O 
46 O 
or O 
PND O 
81 O 
, O 
a O 
novel O 
object O 
recognition O 
test O 
was O 
performed O 
on O 
4 O 
consecutive O 
days O 
. O 
The O 
hippocampi O 
were O 
collected O 
on O 
PND O 
50 O 
or O 
PND O 
85 O 
after O 
the O 
completion O 
of O 
the O 
novel O 
object O 
recognition O 
test O 
, O 
and O 
the O 
expression O 
levels O 
of O 
neurotrophins O 
and O 
the O 
NMDA B-ABBREVIATION 
receptor O 
and O 
its O 
signal O 
transduction O 
pathway O 
- O 
related O 
genes O 
were O 
examined O 
using O 
real O 
- O 
time O 
RT-PCR O 
. O 
Diazinon B-TRIVIAL 
-injected O 
mice O 
exhibited O 
a O 
poor O 
ability O 
to O 
discriminate O 
between O 
novel O 
and O 
familiar O 
objects O 
during O 
both O 
the O 
PND O 
49 O 
and O 
the O 
PND O 
84 O 
tests O 
. O 
The O 
NMDA B-ABBREVIATION 
receptor O 
subunits O 
NR1 O 
and O 
NR2B O 
and O 
the O 
related O 
protein O 
kinase O 
calcium B-SYSTEMATIC 
/ O 
calmodulin O 
- O 
dependent O 
protein O 
kinase O 
(CaMK)-IV O 
and O 
the O 
transcription O 
factor O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
responsive O 
element O 
binding O 
protein O 
(CREB)-1 O 
mRNA O 
levels O 
were O 
reduced O 
in O 
the O 
PND O 
50 O 
mice O 
. O 
However O 
, O 
no O 
significant O 
changes O 
in O 
the O 
expressions O 
of O 
the O 
NMDA B-ABBREVIATION 
subunits O 
and O 
their O 
signal O 
transduction O 
molecules O 
were O 
observed O 
in O 
the O 
hippocampi O 
of O 
the O 
PND O 
85 O 
mice O 
. O 
The O 
expression O 
level O 
of O 
nerve O 
growth O 
factor O 
mRNA O 
was O 
significantly O 
reduced O 
in O 
the O 
PND O 
50 O 
or O 
85 O 
mice O 
. O 
These O 
results O 
indicate O 
that O 
neonatal O 
diazinon B-TRIVIAL 
exposure O 
impaired O 
the O 
hippocampus O 
- O 
dependent O 
novel O 
object O 
recognition O 
ability O 
, O 
accompanied O 
by O 
a O 
modulation O 
in O 
the O 
expressions O 
of O 
the O 
NMDA B-ABBREVIATION 
receptor O 
and O 
neurotrophin O 
in O 
young O 
adult O 
and O 
adult O 
mice O 
. O 

receptors O 
and O 
memory O 
encoding O 
. O 

is O 
humbling O 
to O 
think O 
that O 
30 O 
years O 
have O 
passed O 
since O 
the O 
paper O 
by O 
Collingridge O 
, O 
Kehl O 
and O 
McLennan O 
showing O 
that O 
one O 
of O 
Jeff O 
Watkins O 
most O 
interesting O 
compounds O 
, O 
R-2-amino-5-phosphonopentanoate B-SYSTEMATIC 
( O 
d-AP5 B-IDENTIFIER 
) O 
, O 
blocked O 
the O 
induction O 
of O 
long O 
- O 
term O 
potentiation O 
in O 
vitro O 
at O 
synapses O 
from O 
area O 
CA3 O 
of O 
the O 
hippocampus O 
to O 
CA1 O 
without O 
apparent O 
effect O 
on O 
baseline O 
synaptic O 
transmission O 
( O 
Collingridge O 
et O 
al O 
. O 
, O 
1983 O 
) O 
. O 
This O 
dissociation O 
was O 
one O 
of O 
the O 
key O 
triggers O 
for O 
an O 
explosion O 
of O 
interest O 
in O 
glutamate B-TRIVIAL 
receptors O 
, O 
and O 
much O 
has O 
been O 
discovered O 
since O 
that O 
collectively O 
contributes O 
to O 
our O 
contemporary O 
understanding O 
of O 
glutamatergic O 
synapses O 
- O 
their O 
biophysics O 
and O 
subunit O 
composition O 
, O 
of O 
the O 
agonists O 
and O 
antagonists O 
acting O 
on O 
them O 
, O 
and O 
their O 
diverse O 
functions O 
in O 
different O 
networks O 
of O 
the O 
brain O 
and O 
spinal O 
cord O 
. O 
It O 
can O 
be O 
fairly O 
said O 
that O 
Collingridge O 
et O 
al O 
. O 
' O 
s O 
( O 
1983 O 
) O 
observation O 
was O 
the O 
stimulus O 
that O 
has O 
led O 
, O 
on O 
the O 
one O 
hand O 
, O 
to O 
structural O 
biological O 
work O 
at O 
the O 
atomic O 
scale O 
describing O 
the O 
key O 
features O 
of O 
NMD B-ABBREVIATION 
A O 
receptors O 
that O 
enables O 
their O 
coincidence O 
function O 
to O 
happen O 
; O 
and O 
, O 
on O 
the O 
other O 
, O 
to O 
work O 
with O 
whole O 
animals O 
investigating O 
the O 
contributions O 
that O 
calciu B-SYSTEMATIC 
m O 
signalling O 
via O 
this O 
receptor O 
can O 
have O 
on O 
rhythmical O 
activities O 
controlled O 
by O 
spinal O 
circuits O 
, O 
memory O 
encoding O 
in O 
the O 
hippocampus O 
( O 
the O 
topic O 
of O 
this O 
article O 
) O 
, O 
visual O 
cortical O 
plasticity O 
, O 
sensitization O 
in O 
pain O 
, O 
and O 
other O 
functions O 
. O 
In O 
this O 
article O 
, O 
I O 
lay O 
out O 
how O 
my O 
then O 
interest O 
in O 
long-term O 
potentiation O 
( O 
LTP O 
) O 
as O 
a O 
model O 
of O 
memory O 
enabled O 
me O 
to O 
recognise O 
the O 
importance O 
of O 
Collingridge O 
et O 
al O 
. O 
' O 
s O 
discovery O 
- O 
and O 
how O 
I O 
and O 
my O 
colleagues O 
endeavoured O 
to O 
take O 
things O 
forward O 
in O 
the O 
area O 
of O 
learning O 
and O 
memory O 
. O 
This O 
is O 
in O 
some O 
respects O 
a O 
personal O 
story O 
, O 
and O 
I O 
tell O 
it O 
as O 
such O 
. O 
The O 
idea O 
tha O 
t B-ABBREVIATION 
NM I-ABBREVIATION 
DA O 
receptor O 
activation O 
is O 
essential O 
for O 
memory O 
encoding O 
, O 
though O 
not O 
for O 
storage O 
, O 
took O 
time O 
to O 
develop O 
and O 
to O 
be O 
accepted O 
. O 
Along O 
the O 
way O 
, O 
there O 
have O 
been O 
confusions O 
, O 
challenges O 
, O 
and O 
surprises O 
surrounding O 
the O 
idea O 
that O 
activation O 
o O 
f B-ABBREVIATION 
NM I-ABBREVIATION 
DA O 
receptors O 
can O 
trigger O 
memory O 
. O 
Some O 
of O 
these O 
are O 
described O 
and O 
how O 
they O 
have O 
been O 
addressed O 
and O 
resolved O 
. O 
Last O 
, O 
I O 
touch O 
on O 
some O 
new O 
directions O 
of O 
interest O 
with O 
respect O 
to O 
the O 
functional O 
role O 
of O 
th O 
e B-ABBREVIATION 
NM I-ABBREVIATION 
DA O 
receptor O 
in O 
cognition O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
GluR-dep O 
synaptic O 
plasticity O 
' O 
. O 

of O 
molecular O 
adsorbates O 
on O 
gold O 
nanoparticles O 
using O 
sodium B-SYSTEMATIC 
borohydride I-SYSTEMATIC 
in O 
water O 
. O 

mechanism O 
of O 
sodium B-SYSTEMATIC 
borohydride I-SYSTEMATIC 
removal O 
of O 
organothiols B-FAMILY 
from O 
gold O 
nanoparticles O 
( O 
AuNPs O 
) O 
was O 
studied O 
using O 
an O 
experimental O 
investigation O 
and O 
computational O 
modeling O 
. O 
Organothiols B-FAMILY 
and O 
other O 
AuNP O 
surface O 
adsorbates O 
such O 
as O 
thiophene B-SYSTEMATIC 
, O 
adenine B-TRIVIAL 
, O 
rhodamine B-TRIVIAL 
, O 
small O 
anions O 
( O 
Br(-) B-FORMULA 
and O 
I(-) B-FORMULA 
) O 
, O 
and O 
a O 
polymer O 
( O 
PVP B-ABBREVIATION 
, O 
poly(N-vinylpyrrolidone) B-FAMILY 
) O 
can O 
all O 
be O 
rapidly O 
and O 
completely O 
removed O 
from O 
the O 
AuNP O 
surfaces O 
. O 
A O 
computational O 
study O 
showed O 
that O 
hydride B-SYSTEMATIC 
derived O 
from O 
sodium B-SYSTEMATIC 
borohydride I-SYSTEMATIC 
has O 
a O 
higher O 
binding O 
affinity O 
to O 
AuNPs O 
than O 
organothiols B-FAMILY 
. O 
Thus O 
, O 
it O 
can O 
displace O 
organothiols B-FAMILY 
and O 
all O 
the O 
other O 
adsorbates O 
tested O 
from O 
AuNPs O 
. O 
Sodium B-SYSTEMATIC 
borohydride I-SYSTEMATIC 
may O 
be O 
used O 
as O 
a O 
hazard O 
- O 
free O 
, O 
general O 
- O 
purpose O 
detergent O 
that O 
should O 
find O 
utility O 
in O 
a O 
variety O 
of O 
AuNP O 
applications O 
including O 
catalysis O 
, O 
biosensing O 
, O 
surface O 
enhanced O 
Raman O 
spectroscopy O 
, O 
and O 
AuNP O 
recycle O 
and O 
reuse O 
. O 

disruption O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
protects O 
against O 
aging O 
, O 
S B-FORMULA 
-nitrosation O 
, O 
and O 
insulin O 
resistance O 
in O 
muscle O 
of O 
male O 
mice O 
. O 

evidence O 
has O 
demonstrated O 
that O 
S B-FORMULA 
-nitrosation O 
of O 
proteins O 
plays O 
a O 
critical O 
role O 
in O 
several O 
human O 
diseases O 
. O 
Here O 
, O 
we O 
explored O 
the O 
role O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
in O 
the O 
S B-FORMULA 
-nitrosation O 
of O 
proteins O 
involved O 
in O 
the O 
early O 
steps O 
of O 
the O 
insulin O 
- O 
signaling O 
pathway O 
and O 
insulin O 
resistance O 
in O 
the O 
skeletal O 
muscle O 
of O 
aged O 
mice O 
. O 
Aging O 
increased O 
iNOS O 
expression O 
and O 
S B-FORMULA 
-nitrosation O 
of O 
major O 
proteins O 
involved O 
in O 
insulin O 
signaling O 
, O 
thereby O 
reducing O 
insulin O 
sensitivity O 
in O 
skeletal O 
muscle O 
. O 
Conversely O 
, O 
aged O 
iNOS-null O 
mice O 
were O 
protected O 
from O 
S B-FORMULA 
-nitrosation O 
- O 
induced O 
insulin O 
resistance O 
. O 
Moreover O 
, O 
pharmacological O 
treatment O 
with O 
an O 
iNOS O 
inhibitor O 
and O 
acute O 
exercise O 
reduced O 
iNOS-induced O 
S B-FORMULA 
-nitrosation O 
and O 
increased O 
insulin O 
sensitivity O 
in O 
the O 
muscle O 
of O 
aged O 
animals O 
. O 
These O 
findings O 
indicate O 
that O 
the O 
insulin O 
resistance O 
observed O 
in O 
aged O 
mice O 
is O 
mainly O 
mediated O 
through O 
the O 
S B-FORMULA 
-nitrosation O 
of O 
the O 
insulin O 
- O 
signaling O 
pathway O 
. O 

investigation O 
into O 
optical O 
and O 
electronic O 
properties O 
of O 
1,8-naphthalimide B-SYSTEMATIC 
derivatives O 
. O 

series O 
of O 
1,8-naphthalimide B-SYSTEMATIC 
derivatives O 
has O 
been O 
designed O 
to O 
explore O 
their O 
optical O 
, O 
electronic O 
, O 
and O 
charge O 
transport O 
properties O 
as O 
charge O 
transport O 
and O 
/ O 
or O 
luminescent O 
materials O 
for O 
organic O 
light O 
- O 
emitting O 
diodes O 
( O 
OLEDs O 
) O 
. O 
The O 
frontier O 
molecular O 
orbitals O 
( O 
FMOs O 
) O 
analysis O 
have O 
shown O 
that O 
the O 
vertical O 
electronic O 
transitions O 
of O 
absorption O 
and O 
emission O 
are O 
characterized O 
as O 
intramolecular O 
charge O 
transfer O 
( O 
ICT O 
) O 
for O 
electron O 
- O 
donating O 
and O 
aromatic O 
groups O 
substituted O 
derivatives O 
. O 
However O 
, O 
the O 
ICT O 
character O 
of O 
the O 
electron O 
- O 
withdrawing O 
substituted O 
derivatives O 
is O 
not O 
significant O 
. O 
The O 
calculated O 
results O 
show O 
that O 
their O 
optical O 
and O 
electronic O 
properties O 
are O 
affected O 
by O 
the O 
substituent O 
groups O 
in O 
4- O 
position O 
of O 
1,8-naphthalimide B-SYSTEMATIC 
. O 
Our O 
results O 
suggest O 
that O 
1,8-naphthalimide B-SYSTEMATIC 
derivatives O 
with O 
electron O 
- O 
donating O 
-OCH3 B-FORMULA 
and O 
-N(CH3)2 B-FORMULA 
( O 
1 O 
and O 
2 O 
) O 
, O 
electron O 
- O 
withdrawing O 
-CN B-FORMULA 
and O 
-COCH3 B-FORMULA 
( O 
3 O 
and O 
4 O 
) O 
, O 
2-(thiophen-2-yl)thiophene B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
2,3-dihydrothieno[3,4-b][1 B-SYSTEMATIC 
, I-SYSTEMATIC 
4]dioxine I-SYSTEMATIC 
( O 
6 O 
) O 
, O 
2-phenyl-1,3,4-oxadiazole B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
and O 
benzo[c][1,2,5]thiadiazole B-SYSTEMATIC 
( O 
8 O 
) O 
fragments O 
are O 
expected O 
to O 
be O 
promising O 
candidates O 
for O 
luminescent O 
materials O 
for O 
OLEDs O 
, O 
particularly O 
for O 
5 O 
and O 
7 O 
. O 
In O 
addition O 
, O 
3 O 
and O 
7 O 
can O 
be O 
used O 
as O 
promising O 
hole O 
transport O 
materials O 
for O 
OLEDs O 
. O 
This O 
study O 
should O 
be O 
helpful O 
in O 
further O 
theoretical O 
investigations O 
on O 
such O 
kind O 
of O 
systems O 
and O 
also O 
to O 
the O 
experimental O 
study O 
for O 
charge O 
transport O 
and O 
/ O 
or O 
luminescent O 
materials O 
for O 
OLEDs O 
. O 

hydrazones I-FAMILY 
are O 
better O 
amoebicides O 
than O 
their O 
cyclized O 
1,3,4-oxadiazoline B-SYSTEMATIC 
analogues O 
: O 
In O 
vitro O 
studies O 
and O 
Lipophilic O 
efficiency O 
analysis O 
. O 

series O 
of O 
compounds O 
with O 
hydrazone B-FAMILY 
derivatives O 
( O 
HZ1-HZl2 O 
, O 
series O 
1 O 
) O 
and O 
oxadiazoline B-SYSTEMATIC 
derivatives O 
( O 
OZ1-OZ12 O 
, O 
series O 
2 O 
) O 
of O 
the O 
2-methyl-5-nitro-1H-imidazole B-SYSTEMATIC 
scaffold O 
were O 
designed O 
and O 
synthesized O 
. O 
Physicochemical O 
properties O 
and O 
Lipophilic O 
efficiency O 
( O 
LipE O 
) O 
analysis O 
predicted O 
higher O 
intrinsic O 
quality O 
of O 
the O 
acylhydrazone B-SYSTEMATIC 
derivatives O 
( O 
series O 
1 O 
) O 
than O 
their O 
corresponding O 
oxadiazoline B-SYSTEMATIC 
analogues O 
( O 
series O 
2 O 
) O 
. O 
In O 
vitro O 
antiamoebic O 
results O 
supported O 
the O 
above O 
findings O 
and O 
validated O 
that O 
the O 
acylhydrazone B-SYSTEMATIC 
derivatives O 
( O 
HZ1-HZl2 O 
) O 
show O 
better O 
activity O 
than O 
the O 
oxadiazoline B-SYSTEMATIC 
derivatives O 
( O 
OZ1-OZ12 O 
) O 
. O 
MTT B-ABBREVIATION 
assay O 
, O 
using O 
HepG2 O 
cell O 
line O 
, O 
revealed O 
noncytotoxic O 
nature O 
of O 
the O 
compounds O 
. O 
The O 
most O 
promising O 
results O 
were O 
observed O 
for O 
compounds O 
HZ5 O 
( O 
IC50 O 
= O 
0.96 O 
μM O 
) O 
and O 
HZ9 O 
( O 
IC50 O 
= O 
0.81 O 
μM O 
) O 
both O 
in O 
silico O 
and O 
in O 
vitro O 
. O 
Analysis O 
of O 
the O 
Lipophilic O 
efficiency O 
( O 
LipE O 
) O 
of O 
the O 
compounds O 
provided O 
new O 
insight O 
for O 
the O 
design O 
of O 
potent O 
and O 
selective O 
amoebicides O 
. O 

networks O 
of O 
vertical O 
multi O 
- O 
layer O 
graphenes B-FAMILY 
with O 
morphology O 
- O 
tunable O 
magnetoresistance O 
. O 

report O 
on O 
the O 
comparative O 
study O 
of O 
magnetotransport O 
properties O 
of O 
large O 
- O 
area O 
vertical O 
few O 
- O 
layer O 
graphene B-TRIVIAL 
networks O 
with O 
different O 
morphologies O 
, O 
measured O 
in O 
a O 
strong O 
( O 
up O 
to O 
10 O 
T O 
) O 
magnetic O 
field O 
over O 
a O 
wide O 
temperature O 
range O 
. O 
The O 
petal O 
- O 
like O 
and O 
tree O 
- O 
like O 
graphene B-TRIVIAL 
networks O 
grown O 
by O 
a O 
plasma O 
enhanced O 
CVD O 
process O 
on O 
a O 
thin O 
( O 
500 O 
nm O 
) O 
silicon B-SYSTEMATIC 
oxide I-SYSTEMATIC 
layer O 
supported O 
by O 
a O 
silicon B-SYSTEMATIC 
wafer O 
demonstrate O 
a O 
significant O 
difference O 
in O 
the O 
resistance O 
- O 
magnetic O 
field O 
dependencies O 
at O 
temperatures O 
ranging O 
from O 
2 O 
to O 
200 O 
K O 
. O 
This O 
behaviour O 
is O 
explained O 
in O 
terms O 
of O 
the O 
effect O 
of O 
electron O 
scattering O 
at O 
ultra O 
- O 
long O 
reactive O 
edges O 
and O 
ultra O 
- O 
dense O 
boundaries O 
of O 
the O 
graphene B-TRIVIAL 
nanowalls O 
. O 
Our O 
results O 
pave O 
a O 
way O 
towards O 
three O 
- O 
dimensional O 
vertical O 
graphene B-TRIVIAL 
-based O 
magnetoelectronic O 
nanodevices O 
with O 
morphology O 
- O 
tuneable O 
anisotropic O 
magnetic O 
properties O 
. O 

displays O 
anti-inflammatory O 
effects O 
through O 
modulating O 
inflammatory O 
mediator O 
expression O 
using O 
RAW264.7 O 
cells O 
. O 

RELEVANCE O 
: O 
The O 
root O 
of O 
Scutellaria O 
baicalensis O 
Georgi O 
, O 
also O 
called O 
Huangqin O 
in O 
China O 
, O 
is O 
an O 
herbal O 
- O 
based O 
nutraceutical O 
which O 
is O 
usually O 
used O 
in O 
Chinese O 
medicated O 
diet O 
( O 
CMD O 
) O 
. O 
As O 
an O 
abundant O 
ingredient O 
in O 
Huangqin O 
, O 
wogonoside B-TRIVIAL 
is O 
a O 
flavonoid B-FAMILY 
glycoside I-FAMILY 
. O 
The O 
present O 
work O 
investigated O 
the O 
anti-inflammatory O 
activities O 
of O 
wogonoside B-TRIVIAL 
in O 
lipopolysaccharides O 
(LPS)-induced O 
RAW264.7 O 
cells O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
RAW264.7 O 
cells O 
were O 
used O 
. O 
The O 
inhibition O 
of O 
wogonoside B-TRIVIAL 
against O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
and O 
interleukin-6 O 
( O 
IL-6 O 
) O 
in O 
LPS-induced O 
RAW264.7 O 
cells O 
were O 
measured O 
. O 
Additionally O 
, O 
the O 
effects O 
of O 
wogonoside B-TRIVIAL 
on O 
mRNA O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
cyclooxygenase O 
2 O 
( O 
COX2 O 
) O 
, O 
TNF-α O 
and O 
IL-6 O 
were O 
also O 
investigated O 
. O 
RESULTS O 
AND O 
DISCUSSION O 
: O 
Wogonoside B-TRIVIAL 
not O 
only O 
dose O 
- O 
dependently O 
decreased O 
the O 
production O 
of O 
inflammatory O 
mediators O 
including O 
NO B-FORMULA 
and O 
PGE2 B-ABBREVIATION 
but O 
also O 
inhibited O 
the O 
release O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
including O 
TNF-α O 
and O 
IL-6 O 
in O 
LPS-induced O 
RAW264.7 O 
cells O 
. O 
Furthermore O 
, O 
wogonoside B-TRIVIAL 
possessed O 
significantly O 
in O 
vitro O 
inhibitory O 
effects O 
on O 
the O 
gene O 
expression O 
of O 
iNOS O 
, O 
COX2 O 
, O 
TNF-α O 
and O 
IL-6 O 
. O 
CONCLUSION O 
: O 
These O 
results O 
suggest O 
that O 
wogonoside B-TRIVIAL 
may O 
be O 
used O 
as O 
a O 
functional O 
food O 
component O 
for O 
prevention O 
and O 
treatment O 
of O 
inflammation O 
. O 

effects O 
of O 
puerarin B-TRIVIAL 
on O 
CCl4 B-FORMULA 
-induced O 
hepatic O 
fibrosis O 
in O 
rats O 
possibly O 
through O 
the O 
regulation O 
of O 
PPAR-γ O 
expression O 
and O 
inhibition O 
of O 
PI3K O 
/ O 
Akt O 
pathway O 
. O 

fibrosis O 
( O 
HF O 
) O 
is O 
a O 
chronic O 
disease O 
, O 
which O 
primarily O 
leads O 
to O 
liver O 
unregulated O 
metabolism O 
. O 
In O 
this O 
study O 
, O 
we O 
aimed O 
to O 
investigate O 
the O 
therapeutic O 
effects O 
of O 
puerarin B-TRIVIAL 
( O 
PR O 
) O 
, O 
an O 
active O 
ingredient O 
from O 
kudzu O 
root O 
, O 
on O 
CCl4 B-FORMULA 
-induced O 
HF O 
rats O 
. O 
PR O 
effectively O 
ameliorated O 
the O 
liver O 
metabolic O 
function O 
, O 
resulting O 
in O 
reduced O 
serum O 
enzymatic O 
activities O 
of O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
, O 
total- O 
bilirubin B-TRIVIAL 
( O 
T- O 
bilirubin B-TRIVIAL 
) O 
, O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
contents O 
and O 
increased O 
levels O 
of O 
albumin O 
, O 
total O 
- O 
protein O 
( O 
T O 
- O 
protein O 
) O 
in O 
HF O 
rats O 
. O 
Similarly O 
, O 
pathological O 
examination O 
showed O 
that O 
the O 
CCl4 B-FORMULA 
-lesioned O 
liver O 
was O 
mitigated O 
by O 
PR O 
treatments O 
. O 
Meanwhile O 
, O 
we O 
also O 
detected O 
significantly O 
reduced O 
levels O 
of O 
hydroxyproline B-SYSTEMATIC 
( O 
Hyp B-ABBREVIATION 
) O 
, O 
type O 
III O 
precollagen O 
( O 
PCIII O 
) O 
and O 
collagen O 
I O 
( O 
Col O 
I O 
) O 
in O 
the O 
liver O 
tissue O 
of O 
HF O 
rats O 
, O 
whereas O 
the O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
- O 
gamma O 
( O 
PPAR-γ O 
) O 
expression O 
was O 
effectively O 
increased O 
. O 
Moreover O 
, O 
the O 
expression O 
of O 
tissue O 
inhibitor O 
of O 
metal O 
protease-1 O 
( O 
TIMP-1 O 
) O 
was O 
decreased O 
, O 
while O 
the O 
expression O 
of O 
matrix O 
metalloproteinase-2 O 
( O 
MMP-2 O 
) O 
was O 
increased O 
. O 
In O 
addition O 
, O 
the O 
expression O 
of O 
p-PI3K O 
and O 
p-Akt O 
was O 
significantly O 
down O 
- O 
regulated O 
by O 
PR O 
treatments O 
. O 
Taken O 
together O 
, O 
PR O 
could O 
attenuate O 
the O 
CCl4 B-FORMULA 
-induced O 
toxicity O 
in O 
the O 
hepatocytes O 
of O 
HF O 
rats O 
. O 
It O 
played O 
a O 
protective O 
role O 
in O 
the O 
liver O 
tissue O 
probably O 
through O 
regulating O 
the O 
PPAR-γ O 
expression O 
and O 
blocking O 
the O 
PI3K O 
/ O 
Akt O 
pathway O 
to O 
inhibit O 
the O 
excessive O 
deposition O 
of O 
collagen O 
. O 

role O 
of O 
DNA O 
methylation O 
and O 
histone O 
acetylation O 
in O 
the O 
regulation O 
of O 
progesterone B-TRIVIAL 
receptor O 
isoforms O 
expression O 
in O 
human O 
astrocytoma O 
cell O 
lines O 
. O 

progesterone B-TRIVIAL 
( O 
P4 O 
) O 
effects O 
are O 
mediated O 
by O 
its O 
intracellular O 
receptor O 
( O 
PR O 
) O 
, O 
which O 
has O 
two O 
isoforms O 
, O 
PR-A O 
and O 
PR-B O 
, O 
each O 
of O 
them O 
with O 
different O 
function O 
and O 
regulation O 
. O 
Differential O 
PR O 
expression O 
in O 
cancer O 
cells O 
has O 
been O 
associated O 
to O 
a O 
PR O 
isoform O 
- O 
specific O 
promoter O 
methylation O 
. O 
In O 
astrocytomas O 
, O 
the O 
most O 
frequent O 
and O 
aggressive O 
brain O 
tumors O 
, O 
PR O 
isoforms O 
expression O 
is O 
directly O 
correlated O 
to O 
the O 
tumor's O 
evolution O 
grade O 
. O 
However O 
, O 
there O 
is O 
no O 
evidence O 
of O 
the O 
role O 
of O 
epigenetic O 
regulation O 
of O 
PR O 
expression O 
in O 
astrocytomas O 
. O 
We O 
evaluated O 
the O 
effect O 
of O 
the O 
demethylating O 
agent O 
5-aza-2'-deoxycytidine B-SYSTEMATIC 
( O 
5AzadC B-SYSTEMATIC 
) O 
and O 
the O 
histone O 
deacetylase O 
inhibitor O 
trichostatin B-TRIVIAL 
A I-TRIVIAL 
( O 
TSA B-ABBREVIATION 
) O 
on O 
PR O 
expression O 
in O 
human O 
astrocytoma O 
cell O 
lines O 
U373 O 
( O 
grade O 
III O 
) O 
and O 
D54 O 
( O 
grade O 
IV O 
) O 
by O 
RT-PCR O 
and O 
Western O 
blot O 
. O 
Total O 
PR O 
expression O 
increased O 
with O 
5μM O 
5AzadC B-SYSTEMATIC 
treatment O 
, O 
whereas O 
PR-B O 
expression O 
increased O 
with O 
5 O 
and O 
10μM O 
5AzadC B-SYSTEMATIC 
treatment O 
in O 
U373 O 
cells O 
, O 
but O 
not O 
in O 
D54 O 
cells O 
. O 
In O 
U373 O 
cells O 
, O 
PR-A O 
protein O 
content O 
augmented O 
with O 
10μM O 
5AzadC B-SYSTEMATIC 
treatment O 
, O 
while O 
PR-B O 
content O 
increased O 
with O 
5 O 
and O 
10μM O 
5AzadC B-SYSTEMATIC 
. O 
PR-B O 
expression O 
was O 
not O 
modified O 
by O 
the O 
TSA B-ABBREVIATION 
concentrations O 
that O 
were O 
used O 
, O 
and O 
the O 
combination O 
with O 
5AzadC B-SYSTEMATIC 
did O 
not O 
change O 
the O 
effects O 
of O 
the O 
latter O 
. O 
The O 
study O 
of O 
5AzadC B-SYSTEMATIC 
effects O 
on O 
the O 
number O 
of O 
astrocytoma O 
cells O 
showed O 
that O 
P4 O 
treatment O 
increased O 
the O 
number O 
of O 
U373 O 
cells O 
, O 
whereas O 
5AzadC B-SYSTEMATIC 
and O 
the O 
combined O 
treatment O 
with O 
P4 O 
reduced O 
it O 
. O 
Our O 
results O 
suggest O 
that O 
PR-B O 
expression O 
is O 
regulated O 
by O 
methylation O 
and O 
not O 
by O 
histone O 
acetylation O 
in O 
U373 O 
cells O 
, O 
and O 
that O 
DNA O 
demethylation O 
reduced O 
the O 
number O 
of O 
U373 O 
cells O 
. O 

of O 
3,3'-diindolylmethanes B-FAMILY 
as O 
potent O 
antileishmanial O 
agents O 
. O 

efficient O 
protocol O 
for O 
synthesis O 
of O 
3,3'-diindolylmethanes B-FAMILY 
using O 
recyclable O 
Fe B-FORMULA 
-pillared O 
interlayered O 
clay O 
( O 
Fe B-FORMULA 
-PILC O 
) O 
catalyst O 
under O 
aqueous O 
medium O 
has O 
been O 
developed O 
. O 
All O 
synthesized O 
3,3'-diindolylmethanes B-FAMILY 
showed O 
promising O 
antileishmanial O 
activity O 
against O 
Leishmania O 
donovani O 
promastigotes O 
as O 
well O 
as O 
axenic O 
amastigotes O 
. O 
Structure O 
- O 
activity O 
relationship O 
analysis O 
revealed O 
that O 
nitroaryl B-FAMILY 
substituted I-FAMILY 
diindolylmethanes I-FAMILY 
showed O 
potent O 
antileishmanial O 
activity O 
. O 
The O 
4-nitrophenyl B-SYSTEMATIC 
linked I-SYSTEMATIC 
3,3'-diindolylmethane I-SYSTEMATIC 
8g O 
was O 
found O 
to O 
be O 
the O 
most O 
potent O 
antileishmanial O 
analog O 
showing O 
IC50 O 
values O 
of O 
7.88 O 
and O 
8.37 O 
μM O 
against O 
both O 
L. O 
donovani O 
promastigotes O 
and O 
amastigotes O 
, O 
respectively O 
. O 
Further O 
, O 
a O 
pharmacophore O 
based O 
QSAR O 
model O 
was O 
established O 
to O 
understand O 
the O 
crucial O 
molecular O 
features O 
of O 
3,3'-diindolylmethanes B-FAMILY 
essential O 
for O 
potent O 
antileishmanial O 
activity O 
. O 
These O 
compounds O 
also O 
exhibited O 
promising O 
antifungal O 
activity O 
against O 
Cryptococcus O 
neoformans O 
, O 
wherein O 
fluorophenyl B-FAMILY 
substituted I-FAMILY 
3,3'-diindolylmethanes I-FAMILY 
were O 
found O 
to O 
be O 
most O 
potent O 
antifungal O 
agents O 
. O 
Developed O 
synthetic O 
protocol O 
will O 
be O 
useful O 
for O 
economical O 
and O 
eco O 
- O 
friendly O 
synthesis O 
of O 
potent O 
antileishmanial O 
and O 
antifungal O 
3,3'-diindolylmethane B-SYSTEMATIC 
class O 
of O 
compounds O 
. O 

oncogenic O 
kinase O 
PAK4 O 
was O 
recently O 
found O 
to O 
be O 
involved O 
in O 
the O 
regulation O 
of O 
the O 
G1 O 
phase O 
and O 
the O 
G2 O 
/ O 
M O 
transition O 
of O 
the O 
cell O 
cycle O 
. O 
We O 
have O 
also O 
identified O 
that O 
PAK4 O 
regulates O 
Ran O 
GTPase O 
activity O 
during O 
mitosis O 
. O 
Here O 
, O 
we O 
show O 
that O 
after O 
entering O 
mitosis O 
, O 
PAK4-depleted O 
cells O 
maintain O 
a O 
prolonged O 
metaphase O 
- O 
like O 
state O 
. O 
In O 
these O 
cells O 
, O 
chromosome O 
congression O 
to O 
the O 
metaphase O 
plate O 
occurs O 
with O 
normal O 
kinetics O 
but O 
is O 
followed O 
by O 
an O 
extended O 
period O 
during O 
which O 
membrane O 
blebbing O 
and O 
spindle O 
rotation O 
are O 
observed O 
. O 
These O 
bipolar O 
PAK4-depleted O 
metaphase O 
- O 
like O 
spindles O 
have O 
a O 
defective O 
astral O 
microtubule O 
( O 
MT O 
) O 
network O 
and O 
are O 
not O 
centered O 
in O 
the O 
cell O 
but O 
are O 
in O 
close O 
contact O 
with O 
the O 
cell O 
cortex O 
. O 
As O 
the O 
metaphase O 
- O 
like O 
state O 
persists O 
, O 
centrosome O 
fragmentation O 
occurs O 
, O 
chromosomes O 
scatter O 
from O 
the O 
metaphase O 
plate O 
and O 
move O 
toward O 
the O 
spindle O 
poles O 
with O 
an O 
active O 
spindle O 
assembly O 
checkpoint O 
, O 
a O 
phenotype O 
that O 
is O 
reminiscent O 
of O 
cohesion O 
fatigue O 
. O 
PAK4 O 
also O 
regulates O 
the O 
acto O 
- O 
myosin O 
cytoskeleton O 
and O 
we O 
report O 
that O 
PAK4 O 
depletion O 
results O 
in O 
the O 
induction O 
of O 
cortical O 
membrane O 
blebbing O 
during O 
prometaphase O 
arrest O 
. O 
However O 
, O 
we O 
show O 
that O 
membrane O 
blebs O 
, O 
which O 
are O 
strongly O 
enriched O 
in O 
phospho B-SYSTEMATIC 
-cofilin O 
, O 
are O 
not O 
responsible O 
for O 
the O 
poor O 
anchoring O 
of O 
the O 
spindle O 
. O 
As O 
PAK4 O 
depletion O 
interferes O 
with O 
the O 
localization O 
of O 
components O 
of O 
the O 
dynein O 
/ O 
dynactin O 
complexes O 
at O 
the O 
kinetochores O 
and O 
on O 
the O 
astral O 
MTs O 
, O 
we O 
propose O 
that O 
loss O 
of O 
PAK4 O 
could O 
induce O 
a O 
change O 
in O 
the O 
activities O 
of O 
motor O 
proteins O 
. O 

The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effects O 
of O 
the O 
Zhizhu O 
decoction O 
on O 
gastric O 
emptying O 
and O 
gastric O 
mucosal O 
protection O 
. O 
The O 
Zhizhu O 
decoction O 
is O 
composed O 
of O 
Aurantii O 
fructus O 
and O 
Atractylodes O 
macrocephala O 
Rhizoma O 
. O 
Results O 
showed O 
that O 
oral O 
administration O 
of O 
the O 
Zhizhu O 
decoction O 
accelerated O 
gastric O 
emptying O 
in O 
mouse O 
and O 
protected O 
gastric O 
mucosa O 
from O 
ethanol B-SYSTEMATIC 
-induced O 
ulcers O 
in O 
rat O 
. O 
Our O 
investigations O 
demonstrated O 
that O 
the O 
Zhizhu O 
decoction O 
accelerated O 
gastric O 
emptying O 
, O 
at O 
least O 
in O 
part O 
, O 
by O 
activating O 
the O 
muscarinic O 
and O 
5-HT3 O 
receptors O 
. O 
The O 
gastroprotective O 
effect O 
is O 
involved O 
in O 
its O 
antioxidant O 
effects O 
and O 
increased O 
vascular O 
endothelial O 
growth O 
factor O 
expression O 
. O 

breathing O 
and O 
shear O 
modes O 
in O 
few O 
- O 
trilayer O 
MoS2 B-FORMULA 
and O 
WSe2 B-FORMULA 
. O 

- O 
dimensional O 
( O 
2D O 
) O 
layered O 
transition B-FAMILY 
metal I-FAMILY 
dichalcogenides I-FAMILY 
( O 
TMDs B-FAMILY 
) O 
have O 
recently O 
attracted O 
tremendous O 
interest O 
as O 
potential O 
valleytronic O 
and O 
nanoelectronic O 
materials O 
, O 
in O 
addition O 
to O 
being O 
well O 
- O 
known O 
as O 
excellent O 
lubricants O 
in O 
the O 
bulk O 
. O 
The O 
interlayer O 
van O 
der O 
Waals O 
( O 
vdW O 
) O 
coupling O 
and O 
low O 
- O 
frequency O 
phonon O 
modes O 
and O 
how O 
they O 
evolve O 
with O 
the O 
number O 
of O 
layers O 
are O 
important O 
for O 
both O 
the O 
mechanical O 
and O 
the O 
electrical O 
properties O 
of O 
2D O 
TMDs B-FAMILY 
. O 
Here O 
we O 
uncover O 
the O 
ultralow O 
frequency O 
interlayer O 
breathing O 
and O 
shear O 
modes O 
in O 
few O 
- O 
layer O 
MoS2 B-FORMULA 
and O 
WSe2 B-FORMULA 
, O 
prototypical O 
layered O 
TMDs B-FAMILY 
, O 
using O 
both O 
Raman O 
spectroscopy O 
and O 
first O 
principles O 
calculations O 
. O 
Remarkably O 
, O 
the O 
frequencies O 
of O 
these O 
modes O 
can O 
be O 
perfectly O 
described O 
using O 
a O 
simple O 
linear O 
chain O 
model O 
with O 
only O 
nearest O 
- O 
neighbor O 
interactions O 
. O 
We O 
show O 
that O 
the O 
derived O 
in O 
- O 
plane O 
( O 
shear O 
) O 
and O 
out O 
- O 
of O 
- O 
plane O 
( O 
breathing O 
) O 
force O 
constants O 
from O 
experiment O 
remain O 
the O 
same O 
from O 
two O 
- O 
layer O 
2D O 
crystals O 
to O 
the O 
bulk O 
materials O 
, O 
suggesting O 
that O 
the O 
nanoscale O 
interlayer O 
frictional O 
characteristics O 
of O 
these O 
excellent O 
lubricants O 
should O 
be O 
independent O 
of O 
the O 
number O 
of O 
layers O 
. O 

gastrointestinal O 
epithelium O 
functions O 
as O 
an O 
important O 
barrier O 
that O 
separates O 
luminal B-TRIVIAL 
contents O 
from O 
the O 
underlying O 
tissue O 
compartment O 
and O 
is O 
vital O 
in O 
maintaining O 
mucosal O 
homeostasis O 
. O 
Mucosal O 
wounds O 
in O 
inflammatory O 
disorders O 
compromise O 
the O 
critical O 
epithelial O 
barrier O 
. O 
In O 
response O 
to O 
injury O 
, O 
intestinal O 
epithelial O 
cells O 
( O 
IECs O 
) O 
rapidly O 
migrate O 
to O 
reseal O 
wounds O 
. O 
We O 
have O 
previously O 
observed O 
that O 
a O 
membrane O 
associated O 
, O 
Actin O 
binding O 
protein O 
, O 
Annexin O 
A2 O 
( O 
AnxA2 O 
) O 
, O 
is O 
up O 
- O 
regulated O 
in O 
migrating O 
IECs O 
and O 
plays O 
an O 
important O 
role O 
in O 
promoting O 
wound O 
closure O 
. O 
To O 
identify O 
the O 
mechanisms O 
by O 
which O 
AnxA2 O 
promotes O 
IEC O 
movement O 
and O 
wound O 
closure O 
we O 
used O 
a O 
loss O 
of O 
function O 
approach O 
. O 
AnxA2 O 
specific O 
shRNA O 
was O 
utilized O 
to O 
generate O 
IECs O 
with O 
stable O 
down O 
- O 
regulation O 
of O 
AnxA2 O 
. O 
Loss O 
of O 
AnxA2 O 
inhibited O 
IEC O 
migration O 
while O 
promoting O 
enhanced O 
cell O 
- O 
matrix O 
adhesion O 
. O 
These O 
functional O 
effects O 
were O 
associated O 
with O 
increased O 
levels O 
of O 
β1 O 
integrin O 
protein O 
, O 
which O 
is O 
reported O 
to O 
play O 
an O 
important O 
role O 
in O 
mediating O 
the O 
cell O 
- O 
matrix O 
adhesive O 
properties O 
of O 
epithelial O 
cells O 
. O 
Since O 
cell O 
migration O 
requires O 
dynamic O 
turnover O 
of O 
integrin O 
based O 
adhesions O 
, O 
we O 
tested O 
if O 
AnxA2 O 
modulates O 
internalization O 
of O 
cell O 
surface O 
β1 O 
integrin O 
required O 
for O 
forward O 
cell O 
movement O 
. O 
Indeed O 
, O 
pulse O 
- O 
chase O 
biotinylation O 
experiments O 
in O 
IECs O 
lacking O 
AnxA2 O 
demonstrated O 
a O 
significant O 
increase O 
in O 
cell O 
surface O 
β1 O 
integrin O 
that O 
was O 
accompanied O 
by O 
decreased O 
β1 O 
integrin O 
internalization O 
and O 
degradation O 
. O 
These O 
findings O 
support O 
an O 
important O 
role O 
of O 
AnxA2 O 
in O 
controlling O 
dynamics O 
of O 
β1 O 
integrin O 
at O 
the O 
cell O 
surface O 
that O 
in O 
turn O 
is O 
required O 
for O 
the O 
active O 
turnover O 
of O 
cell O 
- O 
matrix O 
associations O 
, O 
cell O 
migration O 
and O 
wound O 
closure O 
. O 

levothyroxine B-TRIVIAL 
replacement O 
for O 
primary O 
hypothyroidism O 
is O 
associated O 
with O 
poor O 
health O 
- O 
related O 
quality O 
of O 
life-a O 
Brazilian O 
multicentre O 
study O 
. O 

study O 
aimed O 
to O 
verify O 
the O 
impact O 
of O 
levothyroxine B-TRIVIAL 
replacement O 
on O 
health O 
- O 
related O 
quality O 
of O 
life O 
( O 
HRQoL O 
) O 
in O 
a O 
Brazilian O 
sample O 
of O 
primary O 
hypothyroidism O 
patients O 
. O 
A O 
cross O 
- O 
sectional O 
study O 
was O 
performed O 
with O 
2057 O 
consecutive O 
primary O 
hypothyroidism O 
patients O 
on O 
levothyroxine B-TRIVIAL 
( O 
LT4 B-ABBREVIATION 
) O 
replacement O 
at O 
four O 
referral O 
centers O 
in O 
Brazil O 
( O 
median O 
age O 
= O 
53 O 
; O 
25th O 
percentile O 
= O 
43 O 
; O 
75th O 
percentile O 
= O 
61 O 
years O 
) O 
. O 
Patient O 
biochemical O 
data O 
were O 
acquired O 
from O 
medical O 
records O 
, O 
and O 
patients O 
completed O 
a O 
questionnaire O 
on O 
socioeconomic O 
issues O 
and O 
clinical O 
signs O 
and O 
symptoms O 
of O 
hypothyroidism O 
. O 
HRQoL O 
was O 
assessed O 
using O 
the O 
SF-36v2 O 
. O 
Patients O 
were O 
divided O 
into O 
three O 
groups O 
according O 
to O 
TSH O 
levels O 
: O 
overtreated O 
( O 
OvT O 
; O 
TSH O 
< O 
0.4 O 
mU O 
/ O 
L O 
) O 
, O 
appropriately O 
treated O 
( O 
AT O 
; O 
TSH O 
between O 
0.4 O 
and O 
4 O 
mU O 
/ O 
L O 
) O 
, O 
and O 
undertreated O 
( O 
UnT O 
; O 
TSH O 
> O 
4 O 
mU O 
/ O 
L O 
) O 
. O 
Patients O 
were O 
also O 
analyzed O 
by O 
TSH O 
and O 
FT4 O 
serum O 
levels O 
: O 
overt O 
hyperthyroidism O 
( O 
OHyper O 
; O 
TSH O 
< O 
0.4 O 
mU O 
/ O 
L O 
and O 
FT4 O 
> O 
1.9 O 
ng O 
/ O 
dL O 
) O 
, O 
subclinical O 
hyperthyroidism O 
( O 
SHyper O 
; O 
TSH O 
< O 
0.4 O 
mU O 
/ O 
L O 
and O 
FT4 O 
0.8-1.9 O 
ng O 
/ O 
dL O 
) O 
, O 
subclinical O 
hypothyroidism O 
( O 
SHypo O 
; O 
TSH O 
> O 
4 O 
mU O 
/ O 
L O 
and O 
FT4 O 
0.8-1.9 O 
ng O 
/ O 
dL O 
) O 
, O 
and O 
overt O 
hypothyroidism O 
( O 
OHypo O 
; O 
TSH O 
> O 
4 O 
mU O 
/ O 
L O 
and O 
FT4 O 
< O 
0.8 O 
ng O 
/ O 
dL O 
) O 
. O 
A O 
total O 
of O 
14.4 O 
% O 
of O 
patients O 
were O 
OvT O 
, O 
with O 
13 O 
% O 
SHyper O 
and O 
1.4 O 
% O 
OHyper O 
. O 
The O 
prevalence O 
of O 
UnT O 
was O 
25.9 O 
% O 
, O 
with O 
21.5 O 
% O 
SHypo O 
and O 
4.4 O 
% O 
OHypo O 
. O 
Overtreatment O 
was O 
not O 
associated O 
with O 
HRQoL O 
impairment O 
. O 
UnT O 
patients O 
had O 
worse O 
HRQoL O 
than O 
AT O 
patients O 
, O 
especially O 
for O 
physical O 
and O 
emotional O 
aspects O 
, O 
independent O 
of O 
SHypo O 
or O 
OHypo O 
status O 
. O 
Hypothyroidism O 
undertreatment O 
is O 
associated O 
with O 
poor O 
patient O 
HRQoL O 
. O 
Therefore O 
, O 
adequate O 
LT4 B-ABBREVIATION 
therapy O 
should O 
be O 
given O 
to O 
maintain O 
serum O 
TSH O 
within O 
the O 
reference O 
range O 
. O 

Domains O 
in O 
Polymersomes O 
: O 
Mixtures O 
of O 
Polyanionic O 
and O 
Neutral O 
Diblocks O 
Respond O 
More O 
Rapidly O 
to O 
Changes O 
in O 
Calcium B-SYSTEMATIC 
than O 
to O 
pH O 
. O 

triggering O 
of O 
membrane O 
domain O 
dynamics O 
is O 
of O 
broad O 
relevance O 
to O 
cell O 
signaling O 
through O 
lipid O 
bilayers O 
and O 
might O 
also O 
be O 
exploited O 
in O 
application O 
of O 
phase O 
- O 
separated O 
vesicles O 
. O 
Here O 
we O 
describe O 
the O 
morphodynamics O 
and O 
remixing O 
kinetics O 
of O 
spotted O 
polymersomes O 
made O 
with O 
mixtures O 
of O 
polyanionic O 
and O 
neutral O 
amphiphiles O 
plus O 
calcium B-SYSTEMATIC 
. O 
Addition O 
of O 
the O 
calcium B-SYSTEMATIC 
chelator O 
EDTA B-ABBREVIATION 
to O 
vesicle O 
dispersions O 
produced O 
a O 
decrease O 
in O 
domain O 
size O 
within O 
minutes O 
, O 
whereas O 
increasing O 
the O 
pH O 
with O 
NaOH B-FORMULA 
led O 
to O 
the O 
viscous O 
fingering O 
of O 
domains O 
and O 
decreased O 
domain O 
size O 
over O 
hours O 
. O 
Although O 
the O 
latter O 
suggests O 
that O 
the O 
charge O 
of O 
the O 
polyanion O 
contributes O 
to O 
domain O 
formation O 
, O 
the O 
remixing O 
of O 
more O 
negative O 
chains O 
at O 
high O 
pH O 
is O 
surprising O 
. O 
Domain O 
roughening O 
at O 
high O 
pH O 
is O 
also O 
accelerated O 
by O 
EDTA B-ABBREVIATION 
, O 
which O 
highlights O 
the O 
dominance O 
of O 
cross O 
- O 
bridging O 
. O 
Importantly O 
, O 
even O 
though O 
vesicles O 
were O 
perturbed O 
only O 
externally O 
, O 
the O 
inner O 
and O 
outer O 
leaflets O 
remain O 
coupled O 
throughout O 
, O 
consistent O 
with O 
molecular O 
dynamics O 
simulations O 
and O 
suggestive O 
of O 
an O 
order O 
- O 
disorder O 
transition O 
that O 
underlies O 
the O 
remixing O 
kinetics O 
. O 

from O 
medicinal O 
plants O 
, O 
many O 
of O 
which O 
have O 
been O 
used O 
for O 
centuries O 
, O 
are O 
increasingly O 
tested O 
in O 
models O 
of O 
hepatotoxicity O 
. O 
One O 
of O 
the O 
most O 
popular O 
models O 
to O 
evaluate O 
the O 
hepatoprotective O 
potential O 
of O 
natural O 
products O 
is O 
acetaminophen B-TRIVIAL 
( O 
APAP B-ABBREVIATION 
)-induced O 
liver O 
injury O 
, O 
although O 
other O 
hepatotoxicity O 
models O 
such O 
as O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
, O 
thioacetamide B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
and O 
endotoxin O 
are O 
occasionally O 
used O 
. O 
APAP B-ABBREVIATION 
overdose O 
is O 
a O 
clinically O 
relevant O 
model O 
of O 
drug O 
- O 
induced O 
liver O 
injury O 
. O 
Critical O 
mechanisms O 
and O 
signaling O 
pathways O 
, O 
which O 
trigger O 
necrotic O 
cell O 
death O 
and O 
sterile O 
inflammation O 
, O 
are O 
discussed O 
. O 
Although O 
there O 
is O 
increasing O 
understanding O 
of O 
the O 
pathophysiology O 
of O 
APAP B-ABBREVIATION 
-induced O 
liver O 
injury O 
, O 
the O 
mechanism O 
is O 
complex O 
and O 
prone O 
to O 
misinterpretation O 
, O 
especially O 
when O 
unknown O 
chemicals O 
such O 
as O 
plant O 
extracts O 
are O 
tested O 
. O 
This O 
review O 
discusses O 
the O 
fundamental O 
aspects O 
that O 
need O 
to O 
be O 
considered O 
when O 
using O 
this O 
model O 
, O 
such O 
as O 
selection O 
of O 
the O 
animal O 
species O 
or O 
in O 
vitro O 
system O 
, O 
timing O 
and O 
dose O 
- O 
responses O 
of O 
signaling O 
events O 
, O 
metabolic O 
activation O 
and O 
protein O 
adduct O 
formation O 
, O 
the O 
role O 
of O 
lipid O 
peroxidation O 
and O 
apoptotic O 
versus O 
necrotic O 
cell O 
death O 
, O 
and O 
the O 
impact O 
of O 
the O 
ensuing O 
sterile O 
inflammatory O 
response O 
. O 
The O 
goal O 
is O 
to O 
enable O 
researchers O 
to O 
select O 
the O 
appropriate O 
model O 
and O 
experimental O 
conditions O 
for O 
testing O 
of O 
natural O 
products O 
that O 
will O 
yield O 
clinically O 
relevant O 
results O 
and O 
allow O 
valid O 
interpretations O 
of O 
the O 
pharmacological O 
mechanisms O 
. O 

potential O 
and O 
cellular O 
uptake O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
in O 
human O 
astrocytes O 
in O 
primary O 
culture O 
. O 

trichothecene B-FAMILY 
mycotoxin O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
, O 
which O 
is O 
produced O 
by O 
fungi O 
of O 
the O 
Fusarium O 
species O 
, O 
is O 
a O 
worldwide O 
occurring O 
contaminant O 
of O 
cereal O 
based O 
food O 
and O 
feed O 
. O 
The O 
cytotoxic O 
properties O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
are O 
already O 
well O 
described O 
with O 
apoptosis O 
being O 
a O 
major O 
mechanism O 
of O 
action O 
in O 
various O 
cell O 
lines O 
as O 
well O 
as O 
in O 
primary O 
cells O 
of O 
different O 
origin O 
. O 
However O 
, O 
only O 
few O 
data O 
on O 
neurotoxic O 
properties O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
are O 
reported O 
so O 
far O 
, O 
but O 
in O 
vivo O 
studies O 
showed O 
different O 
effects O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
on O 
behavior O 
as O 
well O 
as O 
on O 
levels O 
of O 
brain O 
amines B-FAMILY 
in O 
animals O 
. O 
To O 
further O 
investigate O 
the O 
cytotoxic O 
properties O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
on O 
cells O 
derived O 
from O 
brain O 
tissue O 
, O 
normal O 
human O 
astrocytes O 
in O 
primary O 
culture O 
( O 
NHA O 
) O 
were O 
used O 
in O 
this O 
study O 
. O 
Besides O 
studies O 
of O 
cytotoxicity O 
, O 
apoptosis O 
( O 
caspase-3-activation O 
, O 
Annexin O 
V O 
) O 
and O 
necrosis O 
( O 
LDH-release O 
) O 
, O 
the O 
cellular O 
uptake O 
and O 
metabolism O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
in O 
NHA O 
was O 
analyzed O 
and O 
compared O 
to O 
the O 
uptake O 
in O 
an O 
established O 
human O 
cell O 
line O 
( O 
HT-29 O 
) O 
. O 
The O 
results O 
show O 
that O 
human O 
astrocytes O 
were O 
highly O 
sensitive O 
to O 
the O 
cytotoxic O 
properties O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
, O 
and O 
apoptosis O 
, O 
induced O 
at O 
low O 
concentrations O 
, O 
was O 
identified O 
for O 
the O 
first O 
time O 
as O 
the O 
mechanism O 
of O 
toxic O 
action O 
in O 
NHA O 
. O 
Furthermore O 
, O 
a O 
strong O 
accumulation O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
in O 
NHA O 
and O 
HT-29 O 
cells O 
was O 
detected O 
, O 
and O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
was O 
subjected O 
to O 
metabolism O 
leading O 
to O 
HT-2 B-TRIVIAL 
toxin I-TRIVIAL 
, O 
a O 
commonly O 
found O 
metabolite O 
after O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
incubation O 
in O 
both O 
cell O 
types O 
. O 
This O 
formation O 
seems O 
to O 
occur O 
within O 
the O 
cells O 
since O 
incubations O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
with O 
cell O 
depleted O 
culture O 
medium O 
did O 
not O 
lead O 
to O 
any O 
degradation O 
of O 
the O 
parent O 
toxin O 
. O 
The O 
results O 
of O 
this O 
study O 
emphasize O 
the O 
neurotoxic O 
potential O 
of O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
in O 
human O 
astrocytes O 
at O 
low O 
concentrations O 
after O 
short O 
incubation O 
times O 
. O 

exposure O 
to O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
and O 
dioxins B-FAMILY 
from O 
the O 
maternal O 
diet O 
may O 
be O 
associated O 
with O 
immunosuppressive O 
effects O 
that O 
persist O 
into O 
early O 
childhood O 
. O 

investigated O 
whether O 
prenatal O 
exposure O 
from O 
the O 
maternal O 
diet O 
to O 
the O 
toxicants O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
and O 
dioxins B-FAMILY 
is O 
associated O 
with O 
the O 
development O 
of O 
immune O 
- O 
related O 
diseases O 
in O 
childhood O 
. O 
Children O 
participating O 
in O 
BraMat O 
, O 
a O 
sub O 
- O 
cohort O 
of O 
the O 
Norwegian O 
Mother O 
and O 
Child O 
Cohort O 
Study O 
( O 
MoBa O 
) O 
, O 
were O 
followed O 
in O 
the O 
three O 
first O 
years O 
of O 
life O 
using O 
annual O 
questionnaires O 
( O 
0-3years O 
; O 
n=162 O 
, O 
2-3years O 
; O 
n=180 O 
) O 
, O 
and O 
blood O 
parameters O 
were O 
examined O 
at O 
three O 
years O 
of O 
age O 
( O 
n=114 O 
) O 
. O 
The O 
maternal O 
intake O 
of O 
the O 
toxicants O 
was O 
calculated O 
using O 
a O 
validated O 
food O 
frequency O 
questionnaire O 
from O 
MoBa O 
. O 
Maternal O 
exposure O 
to O 
PCBs B-ABBREVIATION 
and O 
dioxins B-FAMILY 
was O 
found O 
to O 
be O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
wheeze O 
and O 
more O 
frequent O 
upper O 
respiratory O 
tract O 
infections O 
. O 
Furthermore O 
, O 
maternal O 
exposure O 
to O 
PCBs B-ABBREVIATION 
and O 
dioxins B-FAMILY 
was O 
found O 
to O 
be O 
associated O 
with O 
reduced O 
antibody O 
response O 
to O 
a O 
measles O 
vaccine O 
. O 
No O 
associations O 
were O 
found O 
between O 
prenatal O 
exposure O 
and O 
immunophenotype O 
data O 
, O 
allergic O 
sensitization O 
and O 
vaccine O 
- O 
induced O 
antibody O 
responses O 
other O 
than O 
measles O 
. O 
Our O 
results O 
suggest O 
that O 
prenatal O 
dietary O 
exposure O 
to O 
PCBs B-ABBREVIATION 
and O 
dioxins B-FAMILY 
may O 
increase O 
the O 
risk O 
of O 
wheeze O 
and O 
the O 
susceptibility O 
to O 
infectious O 
diseases O 
in O 
early O 
childhood O 
. O 

control O 
of O 
group O 
IVA O 
cytosolic O 
phospholipase O 
A2 O 
( O 
cPLA2α O 
or O 
PLA2G4A O 
) O 
expression O 
modulates O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
production O 
, O 
thus O 
tightly O 
regulating O 
the O 
downstream O 
effects O 
of O 
pro- O 
and O 
anti-inflammatory O 
eicosanoids B-FAMILY 
. O 
The O 
significance O 
of O 
this O 
pathway O 
in O 
human O 
disease O 
is O 
apparent O 
in O 
a O 
range O 
of O 
pathologies O 
from O 
inflammation O 
to O 
tumorigenesis O 
. O 
While O 
much O 
of O 
the O 
regulation O 
of O 
cPLA2α O 
has O 
focused O 
on O 
post O 
- O 
translational O 
phosphorylation O 
of O 
the O 
protein O 
, O 
studies O 
on O 
transcriptional O 
regulation O 
of O 
this O 
gene O 
have O 
focused O 
only O 
on O 
proximal O 
promoter O 
regions O 
. O 
We O 
have O 
identified O 
a O 
DNase O 
I O 
hypersensitive O 
site O 
encompassing O 
a O 
5 O 
' O 
distal O 
enhancer O 
element O 
containing O 
a O 
highly O 
conserved O 
consensus O 
AP-1 O 
site O 
involved O 
in O 
transcriptional O 
activation O 
of O 
cPLA2α O 
by O 
IL-1β O 
. O 
ChIP O 
, O 
knockdown O 
, O 
knockout O 
and O 
overexpression O 
analyses O 
have O 
shown O 
that O 
c-Jun O 
acts O 
both O 
in O 
a O 
negative O 
and O 
positive O 
regulatory O 
role O 
. O 
Transcriptional O 
activation O 
of O 
cPLA2α O 
occurs O 
through O 
the O 
phosphorylation O 
of O 
c-Jun O 
in O 
conjunction O 
with O 
increased O 
association O 
of O 
C O 
/ O 
EBPβ O 
with O 
the O 
distal O 
novel O 
enhancer O 
. O 
The O 
association O 
of O 
C O 
/ O 
EBPβ O 
with O 
the O 
transcriptional O 
activation O 
complex O 
does O 
not O 
require O 
an O 
obvious O 
DNA O 
binding O 
site O 
. O 
These O 
data O 
provide O 
new O 
and O 
important O 
contributions O 
to O 
the O 
understanding O 
of O 
cPLA2α O 
regulation O 
at O 
the O 
transcriptional O 
level O 
with O 
implications O 
to O 
eicosanoid B-FAMILY 
metabolism O 
, O 
cellular O 
signaling O 
and O 
disease O 
pathogenesis O 
. O 

metals O 
pollution O 
in O 
the O 
Sarno O 
River O 
and O 
its O 
environmental O 
impact O 
on O 
the O 
Gulf O 
of O 
Naples O 
( O 
Tyrrhenian O 
Sea O 
, O 
Central O 
Mediterranean O 
Sea O 
) O 
were O 
estimated O 
. O 
Eight O 
selected O 
metals O 
( O 
As B-FORMULA 
, O 
Hg B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Pb B-FORMULA 
and O 
Zn B-FORMULA 
) O 
were O 
determined O 
in O 
the O 
water O 
dissolved O 
phase O 
( O 
DP O 
) O 
, O 
suspended O 
particulate O 
matter O 
( O 
SPM O 
) O 
and O 
sediment O 
samples O 
. O 
Selected O 
metals O 
concentrations O 
ranged O 
from O 
0.32 O 
to O 
1680.39 O 
μg O 
l(-1) O 
in O 
water O 
DP O 
, O 
from O 
103.6 O 
to O 
7734.6 O 
μg O 
l(-1) O 
in O 
SPM O 
and O 
from O 
90.7 O 
to O 
2470.3 O 
mg O 
kg(-1) O 
in O 
sediment O 
samples O 
. O 
Contaminant O 
discharges O 
of O 
selected O 
metals O 
into O 
the O 
sea O 
were O 
calculated O 
in O 
about O 
13977.6 O 
kg O 
year(-1) O 
showing O 
that O 
this O 
river O 
should O 
account O 
as O 
one O 
of O 
the O 
main O 
contribution O 
sources O 
of O 
metals O 
to O 
the O 
Tyrrhenian O 
Sea O 
. O 

surface O 
area O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
) O 
particles O 
influences O 
cyto- O 
and O 
photo O 
- O 
toxicity O 
. O 

aim O 
of O 
this O 
study O 
is O 
to O 
examine O 
how O 
different O 
specific O 
surface O 
areas O 
of O 
similar O 
- O 
sized O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO(2) B-FORMULA 
) O 
particles O 
could O 
influence O 
both O 
cytotoxicity O 
and O 
phototoxicity O 
. O 
TiO(2) B-FORMULA 
particles O 
of O 
different O 
specific O 
surface O 
areas O 
were O 
compared O 
for O 
their O 
toxic O 
effects O 
on O 
RAW264.7 O 
cells O 
in O 
the O 
absence O 
and O 
presence O 
of O 
UV O 
light O 
. O 
From O 
the O 
results O 
, O 
TiO(2) B-FORMULA 
particles O 
with O 
larger O 
specific O 
surface O 
area O 
were O 
found O 
to O 
induce O 
higher O 
cyto- O 
( O 
UV O 
absent O 
) O 
and O 
photo O 
- O 
toxicity O 
( O 
UV O 
activated O 
) O 
to O 
cells O 
after O 
24h O 
incubation O 
. O 
The O 
observed O 
cytotoxicity O 
from O 
TiO(2) B-FORMULA 
particles O 
with O 
larger O 
surface O 
area O 
could O 
be O 
explained O 
from O 
their O 
interactions O 
with O 
biomolecules O 
. O 
Upon O 
photoactivation O 
, O 
a O 
larger O 
number O 
of O 
hydroxyl B-SYSTEMATIC 
radicals O 
were O 
detected O 
from O 
TiO(2) B-FORMULA 
particles O 
with O 
larger O 
surface O 
area O 
, O 
again O 
suggesting O 
a O 
surface O 
area O 
dependent O 
phototoxic O 
effect O 
. O 
On O 
the O 
other O 
hand O 
, O 
pre O 
- O 
adsorbing O 
TiO(2) B-FORMULA 
particles O 
with O 
extracellular O 
proteins O 
were O 
found O 
to O 
decrease O 
toxicity O 
effects O 
. O 

new O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
from O 
the O 
root O 
of O 
Platycodon O 
grandiflorum O 
. O 

new O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
, O 
named O 
platycodon B-TRIVIAL 
A I-TRIVIAL 
( O 
3-O-β-D-glucopyranosyl-16-O-β-D-glucopyranosyl-2β,3β,16β,21β-tetrahydroxyolean-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
and O 
platycodon B-TRIVIAL 
B I-TRIVIAL 
( O 
3-O-β-D-glucopyranosyl-16-O-β-D-xylopyranosyl-2β,3β,16β,21β-tetrahydroxyolean-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Platycodon O 
grandiflorum O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
elucidated O 
by O 
means O 
of O 
various O 
spectroscopic O 
analyses O 
. O 
Compounds O 
1 O 
and O 
2 O 
were O 
tested O 
in O 
HepG-2 O 
, O 
A549 O 
and O 
DU145 O 
human O 
cancer O 
cell O 
lines O 
and O 
showed O 
remarkable O 
cytotoxic O 
activities O 
against O 
HepG-2 O 
and O 
A549 O 
cancer O 
cell O 
lines O 
with O 
IC(50) O 
values O 
ranging O 
from O 
4.9 O 
to O 
9.4 O 
µM O 
, O 
but O 
they O 
displayed O 
weak O 
cytotoxic O 
activities O 
against O 
DU145 O 
cancer O 
cell O 
line O 
with O 
IC(50) O 
values O 
greater O 
than O 
10 O 
µM O 
. O 

study O 
of O 
mutarotation O 
of O 
fructose B-TRIVIAL 
in O 
anhydrous O 
state O 
. O 

measurement O 
was O 
employed O 
to O 
study O 
the O 
mutarotation O 
of O 
D-fructose B-TRIVIAL 
in O 
anhydrous O 
state O 
. O 
By O 
monitoring O 
the O 
evolution O 
of O 
shear O 
viscosity O 
with O 
time O 
, O 
rate O 
constants O 
for O 
mutarotation O 
were O 
estimated O 
, O 
and O 
two O 
different O 
stages O 
of O 
this O 
reaction O 
were O 
identified O 
. O 
One O 
of O 
the O 
mutarotation O 
stages O 
is O 
rapid O 
and O 
has O 
a O 
low O 
activation O 
energy O 
, O 
whereas O 
the O 
other O 
is O 
much O 
slower O 
and O 
has O 
a O 
much O 
higher O 
activation O 
energy O 
. O 
Possible O 
conversions O 
corresponding O 
to O 
these O 
two O 
phases O 
are O 
discussed O 
. O 
This O 
work O 
demonstrates O 
that O 
, O 
in O 
addition O 
to O 
the O 
routine O 
techniques O 
such O 
polarimetry O 
and O 
gas-liquid O 
chromatography O 
, O 
rheological O 
measurement O 
can O 
be O 
used O 
as O 
an O 
alternative O 
method O 
to O 
continuously O 
monitor O 
the O 
mutarotation O 
of O 
sugars B-FAMILY 
. O 

is O 
associated O 
with O 
increased O 
systemic O 
and O 
airway O 
oxidative O 
stress O 
, O 
which O 
may O 
result O 
from O 
a O 
combination O 
of O 
adipokine O 
imbalance O 
and O 
antioxidant O 
defenses O 
reduction O 
. O 
Obesity O 
- O 
mediated O 
oxidative O 
stress O 
plays O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
dyslipidemia O 
, O 
vascular O 
disease O 
, O 
and O 
nonalcoholic O 
hepatic O 
steatosis O 
. O 
The O 
antidyslipidemic O 
activity O 
of O 
pigeon O 
pea O 
were O 
evaluated O 
by O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
hamsters O 
model O 
, O 
in O 
which O 
the O 
level O 
of O 
high O 
- O 
density O 
lipoprotein- O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
, O 
low O 
- O 
density O 
lipoprotein- O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
, O 
total O 
cholesterol B-TRIVIAL 
( O 
TC O 
) O 
, O 
and O 
total O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
were O 
examined O 
. O 
We O 
found O 
that O 
pigeon O 
pea O 
administration O 
promoted O 
cholesterol B-TRIVIAL 
converting O 
to O 
bile B-FAMILY 
acid I-FAMILY 
in O 
HFD-induced O 
hamsters O 
, O 
thereby O 
exerting O 
hypolipidemic O 
activity O 
. O 
In O 
the O 
statistical O 
results O 
, O 
pigeon O 
pea O 
significantly O 
increased O 
hepatic O 
carnitine B-TRIVIAL 
palmitoyltransferase-1 O 
( O 
CPT-1 O 
) O 
, O 
LDL O 
receptor O 
, O 
and O 
cholesterol B-TRIVIAL 
7α-hydroxylase O 
( O 
also O 
known O 
as O 
cytochrome O 
P450 O 
7A1 O 
, O 
CYP7A1 O 
) O 
expression O 
to O 
attenuate O 
dyslipidemia O 
in O 
HFD-fed O 
hamsters O 
; O 
and O 
markedly O 
elevated O 
antioxidant O 
enzymes O 
in O 
the O 
liver O 
of O 
HFD-induced O 
hamsters O 
, O 
further O 
alleviating O 
lipid O 
peroxidation O 
. O 
These O 
effects O 
may O 
attribute O 
to O 
pigeon O 
pea O 
contained O 
large O 
of O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
UFA B-ABBREVIATION 
; O 
C18 O 
: O 
2 O 
) O 
and O 
phytosterol B-FAMILY 
( O 
β-sitosterol B-TRIVIAL 
, O 
campesterol B-TRIVIAL 
, O 
and O 
stigmasterol B-TRIVIAL 
) O 
. O 
Moreover O 
, O 
the O 
effects O 
of O 
pigeon O 
pea O 
on O 
dyslipidemia O 
were O 
greater O 
than O 
β-sitosterol B-TRIVIAL 
administration O 
( O 
4% O 
) O 
, O 
suggesting O 
that O 
phytosterone B-FAMILY 
in O 
pigeon O 
pea O 
could O 
prevent O 
metabolic O 
syndrome O 
. O 

studies O 
on O 
the O 
structural O 
functionality O 
of O 
whey O 
protein O 
isolate O 
in O 
the O 
presence O 
of O 
small O 
polyhydroxyl B-SYSTEMATIC 
compounds O 
as O 
co O 
- O 
solute O 
. O 

present O 
work O 
deals O 
with O 
the O 
changing O 
network O 
morphology O 
of O 
whey O 
protein O 
isolate O 
( O 
15% O 
, O 
w O 
/ O 
w O 
) O 
in O 
the O 
presence O 
of O 
glucose B-TRIVIAL 
syrup O 
( O 
co O 
- O 
solute O 
) O 
with O 
concentrations O 
ranging O 
from O 
0% O 
to O 
65%(w O 
/ O 
w O 
) O 
in O 
10mM O 
CaCl2 B-FORMULA 
solution O 
, O 
thus O 
producing O 
formulations O 
with O 
a O 
total O 
level O 
of O 
solids O 
of O 
up O 
to O 
80%(w O 
/ O 
w O 
) O 
. O 
Denaturation O 
behaviour O 
and O 
aggregation O 
of O 
whey O 
protein O 
systems O 
were O 
investigated O 
using O 
small O 
deformation O 
dynamic O 
oscillation O 
on O 
shear O 
, O 
micro O 
and O 
modulated O 
differential O 
scanning O 
calorimetry O 
, O 
and O 
confocal O 
laser O 
scanning O 
microscopy O 
. O 
A O 
progression O 
in O 
the O 
mechanical O 
strength O 
of O 
protein O 
aggregates O 
was O 
observed O 
resulting O 
from O 
enhanced O 
protein O 
- O 
protein O 
interactions O 
in O 
the O 
presence O 
of O 
glucose B-TRIVIAL 
syrup O 
. O 
Addition O 
of O 
the O 
co O 
- O 
solute O 
resulted O 
in O 
better O 
thermal O 
stability O 
of O 
protein O 
molecules O 
by O 
shifting O 
the O 
process O 
of O 
denaturation O 
to O 
higher O 
temperature O 
, O 
as O 
observed O 
by O 
calorimetry O 
. O 
Observations O 
are O 
supported O 
by O 
micrographs O 
showing O 
coherent O 
networks O 
with O 
reduced O 
size O 
of O 
whey O 
protein O 
aggregates O 
in O 
the O 
presence O 
of O 
high O 
levels O 
of O 
glucose B-TRIVIAL 
syrup O 
, O 
as O 
opposed O 
to O 
thick O 
and O 
random O 
clusters O 
for O 
systems O 
of O 
whey O 
protein O 
by O 
itself O 
. O 
Glass O 
transition O 
phenomenon O 
was O 
observed O 
for O 
condensed O 
protein O 
/ O 
co O 
- O 
solute O 
systems O 
, O 
which O 
were O 
treated O 
with O 
theoretical O 
concepts O 
adapted O 
from O 
synthetic O 
polymer O 
research O 
to O 
pinpoint O 
the O 
mechanical O 
glass O 
transition O 
temperature O 
. O 

new O 
sesquiterpene B-FAMILY 
lactone I-FAMILY 
from O 
Salvia O 
plebeia O 
. O 

new O 
eudesmanolide B-TRIVIAL 
, O 
1α-acetoxy-8α,9β-dihydroxy-2-oxo-eudesman-3,7(11)-dien-8,12-olide B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
together O 
with O 
a O 
known O 
eudesmanolide B-TRIVIAL 
, O 
1α-acetoxy-8α-hydroxy-2-oxo-eudesman-3,7(11)-dien-8,12-olide B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
and O 
a O 
known O 
flavone B-TRIVIAL 
, O 
4',5,7-trihydroxy-6-methoxyflavone B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
plant O 
of O 
Salvia O 
plebeia O 
. O 
Three O 
compounds O 
were O 
structurally O 
elucidated O 
by O 
spectroscopic O 
and O 
chemical O 
methods O 
. O 

of O 
cAMP B-ABBREVIATION 
-responsive O 
element O 
binding O 
proteins O 
( O 
CREBs O 
) O 
in O 
fast- O 
and O 
slow O 
- O 
twitch O 
muscles O 
: O 
A O 
signaling O 
pathway O 
to O 
account O 
for O 
the O 
synaptic O 
expression O 
of O 
collagen O 
- O 
tailed O 
subunit O 
( O 
ColQ O 
) O 
of O 
acetylcholinesterase O 
at O 
the O 
rat O 
neuromuscular O 
junction O 
. O 

gene O 
encoding O 
the O 
collagen O 
- O 
tailed O 
subunit O 
( O 
ColQ O 
) O 
of O 
acetylcholinesterase O 
( O 
AChE O 
) O 
contains O 
two O 
distinct O 
promoters O 
that O 
drive O 
the O 
production O 
of O 
two O 
ColQ O 
mRNAs O 
, O 
ColQ-1 O 
and O 
ColQ-1a O 
, O 
in O 
slow- O 
and O 
fast O 
- O 
twitch O 
muscles O 
, O 
respectively O 
. O 
ColQ-1a O 
is O 
expressed O 
at O 
the O 
neuromuscular O 
junction O 
( O 
NMJ O 
) O 
in O 
fast O 
- O 
twitch O 
muscle O 
, O 
and O 
this O 
expression O 
depends O 
on O 
trophic O 
factors O 
supplied O 
by O 
motor O 
neurons O 
signaling O 
via O 
a O 
cAMP B-ABBREVIATION 
-dependent O 
pathway O 
in O 
muscle O 
. O 
To O 
further O 
elucidate O 
the O 
molecular O 
basis O 
of O 
ColQ-1a's O 
synaptic O 
expression O 
, O 
here O 
we O 
investigated O 
the O 
expression O 
and O 
localization O 
of O 
cAMP B-ABBREVIATION 
-responsive O 
element O 
binding O 
protein O 
( O 
CREB O 
) O 
at O 
the O 
synaptic O 
and O 
extra O 
- O 
synaptic O 
regions O 
of O 
fast- O 
and O 
slow O 
- O 
twitch O 
muscles O 
from O 
adult O 
rats O 
. O 
The O 
total O 
amount O 
of O 
active O 
, O 
phosphorylated O 
CREB O 
( O 
P-CREB O 
) O 
present O 
in O 
slow O 
- O 
twitch O 
soleus O 
muscle O 
was O 
higher O 
than O 
that O 
in O 
fast O 
- O 
twitch O 
tibialis O 
muscle O 
, O 
but O 
P-CREB O 
was O 
predominantly O 
expressed O 
in O 
the O 
fast O 
- O 
twitch O 
muscle O 
at O 
NMJs O 
. O 
In O 
contrast O 
, O 
P-CREB O 
was O 
detected O 
in O 
both O 
synaptic O 
and O 
extra O 
- O 
synaptic O 
regions O 
of O 
slow O 
- O 
twitch O 
muscle O 
. O 
These O 
results O 
reveal O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
differential O 
distribution O 
of O 
P-CREB O 
in O 
fast- O 
and O 
slow O 
- O 
twitch O 
muscles O 
, O 
which O 
might O 
support O 
the O 
crucial O 
role O 
of O 
cAMP B-ABBREVIATION 
-dependent O 
signaling O 
in O 
controlling O 
the O 
synapse O 
- O 
specific O 
expression O 
of O 
ColQ-1a O 
in O 
fast O 
- O 
twitch O 
muscles O 
. O 

dimorphic O 
behavior O 
after O 
developmental O 
exposure O 
to O 
characterize O 
endocrine O 
- O 
mediated O 
effects O 
of O 
different O 
non- O 
dioxin B-FAMILY 
-like O 
PCBs B-ABBREVIATION 
in O 
rats O 
. O 

chemicals O 
are O 
known O 
to O 
exhibit O 
endocrine O 
activity O 
and O 
affect O 
reproductive O 
functions O 
in O 
vertebrates O 
and O 
invertebrates O 
. O 
Endocrine O 
effects O 
include O 
influences O 
on O 
sexual O 
differentiation O 
of O 
the O 
brain O 
during O 
development O 
and O 
reproductive O 
and O 
non-reproductive O 
behavior O 
in O 
adult O 
offspring O 
. O 
We O 
previously O 
demonstrated O 
that O 
developmental O 
exposure O 
to O 
a O 
mixture O 
of O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
which O 
was O 
reconstituted O 
according O 
to O 
the O 
congener O 
pattern O 
found O 
in O 
human O 
breast O 
milk O 
caused O 
feminization O 
of O 
sweet O 
preference O 
as O 
a O 
sexually O 
dimorphic O 
behavior O 
in O 
adult O 
male O 
rats O 
, O 
following O 
decreases O 
in O 
aromatase O 
activity O 
in O 
the O 
brain O 
of O 
newborn O 
male O 
pups O 
. O 
This O 
result O 
may O 
be O 
due O 
to O 
dioxin B-FAMILY 
-like O 
or O 
non- O 
dioxin B-FAMILY 
-like O 
( O 
NDL O 
) O 
PCBs B-ABBREVIATION 
and O 
their O 
respective O 
effects O 
on O 
steroid B-FAMILY 
hormones O 
. O 
The O 
aim O 
of O 
the O 
present O 
experiments O 
was O 
to O 
determine O 
if O 
exposure O 
to O 
highly O 
purified O 
NDL- O 
PCBs B-ABBREVIATION 
( O 
to O 
remove O 
Ah O 
receptor O 
active O 
contaminants O 
) O 
also O 
results O 
in O 
alteration O 
of O 
sweet O 
preference O 
. O 
Pregnant O 
rats O 
were O 
orally O 
exposed O 
to O 
PCB52 B-ABBREVIATION 
( O 
6 O 
dose O 
groups O 
, O 
total O 
dose O 
of O 
0-3000mg O 
/ O 
kg O 
body O 
weight O 
) O 
or O 
PCB180 B-ABBREVIATION 
( O 
6 O 
dose O 
groups O 
, O 
total O 
dose O 
of O 
0-1000mg O 
/ O 
kg O 
body O 
weight O 
) O 
. O 
In O 
a O 
further O 
experiment O 
rat O 
dams O 
were O 
treated O 
with O 
equimolar O 
doses O 
of O 
PCB74 B-ABBREVIATION 
or O 
PCB95 B-ABBREVIATION 
( O 
total O 
dose O 
, O 
760μmol O 
/ O 
kg O 
body O 
weight O 
, O 
corresponding O 
to O 
229mg O 
/ O 
kg O 
or O 
248mg O 
/ O 
kg O 
body O 
weight O 
of O 
PCB74 B-ABBREVIATION 
and O 
PCB95 B-ABBREVIATION 
, O 
respectively O 
) O 
. O 
Adult O 
male O 
and O 
female O 
offspring O 
were O 
given O 
a O 
choice O 
between O 
a O 
bottle O 
of O 
saccharin B-TRIVIAL 
solution O 
( O 
0.25% O 
) O 
and O 
a O 
bottle O 
of O 
tap O 
water O 
on O 
five O 
consecutive O 
days O 
. O 
Control O 
females O 
consumed O 
approximately O 
twice O 
as O 
much O 
sweetened O 
solution O 
compared O 
with O 
control O 
males O 
, O 
thus O 
, O 
demonstrating O 
sexual O 
dimorphism O 
of O 
this O 
behavior O 
. O 
Only O 
non-significant O 
reduction O 
of O 
sweet O 
preference O 
was O 
found O 
at O 
the O 
top O 
dose O 
level O 
in O 
female O 
offspring O 
after O 
exposure O 
to O 
PCB52 B-ABBREVIATION 
. O 
Female O 
offspring O 
exposed O 
to O 
PCB180 B-ABBREVIATION 
exhibited O 
signs O 
of O 
supernormal O 
behavior O 
as O 
illustrated O 
by O 
increased O 
saccharin B-TRIVIAL 
consumption O 
at O 
intermediate O 
dose O 
levels O 
. O 
Decreased O 
sweet O 
preference O 
was O 
observed O 
in O 
females O 
after O 
developmental O 
PCB74 B-ABBREVIATION 
, O 
whereas O 
males O 
were O 
unaffected O 
. O 
Only O 
PCB95 B-ABBREVIATION 
increased O 
saccharin B-TRIVIAL 
consumption O 
in O 
exposed O 
males O 
, O 
leading O 
to O 
decreased O 
sexual O 
dimorphism O 
of O 
this O 
behavior O 
and O 
behavioral O 
feminization O 
. O 
The O 
results O 
demonstrate O 
that O 
different O 
NDL- O 
PCBs B-ABBREVIATION 
exhibit O 
differential O 
effects O 
on O 
sexually O 
dimorphic O 
behavior O 
and O 
that O 
feminization O 
occurs O 
after O 
removal O 
of O 
Ah O 
receptor O 
active O 
contaminants O 
. O 
Comparison O 
with O 
data O 
from O 
the O 
literature O 
reveals O 
little O 
evidence O 
for O 
a O 
relation O 
to O 
anti-androgenic O 
activity O 
of O 
the O 
studied O 
NDL- O 
PCBs B-ABBREVIATION 
. O 

investigation O 
of O 
extracts O 
from O 
the O 
stems O 
and O 
leaves O 
of O 
Alchorneopsis O 
floribunda O 
Müll O 
. O 
Arg O 
. O 
, O 
collected O 
in O 
the O 
Amazon O 
region O 
, O 
was O 
performed O 
. O 
The O 
main O 
isolated O 
compounds O 
were O 
triterpenes B-FAMILY 
( O 
α-amyrin B-TRIVIAL 
, O 
β-amyrin B-TRIVIAL 
, O 
lupeol B-TRIVIAL 
, O 
betulin B-TRIVIAL 
, O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
uvaol B-TRIVIAL 
, O 
erythrodiol B-TRIVIAL 
and O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
) O 
and O 
phenolic B-FAMILY 
acid I-FAMILY 
derivatives O 
from O 
4-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
gallic B-MULTIPLE 
and I-MULTIPLE 
protocatechuic I-MULTIPLE 
acids I-MULTIPLE 
and O 
isocorilagin B-TRIVIAL 
) O 
. O 
In O 
the O 
germination O 
assays O 
, O 
high O 
inhibitory O 
allelopathic O 
effects O 
of O 
the O 
extracts O 
and O 
isocorilagin B-TRIVIAL 
were O 
observed O 
and O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
radical O 
scavenging O 
activity O 
of O 
isocorilagin B-TRIVIAL 
was O 
higher O 
than O 
those O 
of O 
the O 
standards O 
used O 
( O 
Trolox B-TRIVIAL 
and O 
butylated B-SYSTEMATIC 
hydroxyanisole I-SYSTEMATIC 
) O 
. O 
This O 
is O 
the O 
first O 
chemical O 
study O 
of O 
the O 
genus O 
Alchorneopsis O 
( O 
Euphorbiaceae O 
) O 
. O 

earth's O 
crust O 
and O 
outer O 
space O 
are O 
rich O 
sources O 
of O 
technologically O 
relevant O 
materials O 
which O 
have O 
found O 
application O 
in O 
a O 
wide O 
range O 
of O 
fields O 
. O 
Well O 
- O 
established O 
examples O 
are O 
diamond B-TRIVIAL 
, O 
one O 
of O 
the O 
hardest O 
known O 
materials O 
, O 
or O 
graphite B-TRIVIAL 
as O 
a O 
suitable O 
precursor O 
of O 
graphene B-TRIVIAL 
. O 
The O 
ongoing O 
drive O 
to O 
discover O 
novel O 
materials O 
useful O 
for O 
(opto)electronic O 
applications O 
has O 
recently O 
drawn O 
strong O 
attention O 
to O 
topological O 
insulators O 
. O 
Here O 
, O 
we O 
report O 
that O 
Kawazulite B-TRIVIAL 
, O 
a O 
mineral O 
with O 
the O 
approximate O 
composition O 
Bi2(Te,Se)2(Se,S) B-FORMULA 
, O 
represents O 
a O 
naturally O 
occurring O 
topological O 
insulator O 
whose O 
electronic O 
properties O 
compete O 
well O 
with O 
those O 
of O 
its O 
synthetic O 
counterparts O 
. O 
Kawazulite O 
flakes O 
with O 
a O 
thickness O 
of O 
a O 
few O 
tens O 
of O 
nanometers O 
were O 
prepared O 
by O 
mechanical O 
exfoliation O 
. O 
They O 
exhibit O 
a O 
low O 
intrinsic O 
bulk O 
doping O 
level O 
and O 
correspondingly O 
a O 
sizable O 
mobility O 
of O 
surface O 
state O 
carriers O 
of O 
more O 
than O 
1000 O 
cm(2) O 
/ O 
( O 
V O 
s O 
) O 
at O 
low O 
temperature O 
. O 
Based O 
on O 
these O 
findings O 
, O 
further O 
minerals O 
which O 
due O 
to O 
their O 
minimized O 
defect O 
densities O 
display O 
even O 
better O 
electronic O 
characteristics O 
may O 
be O 
identified O 
in O 
the O 
future O 
. O 

supplementation O 
: O 
current O 
implications O 
in O 
pregnancy O 
and O 
childhood O 
. O 

supplementation O 
with O 
ω-3 B-FAMILY 
long I-FAMILY 
chain I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
including O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
has O 
increased O 
in O 
popularity O 
in O 
recent O 
years O 
and O 
adequate O 
DHA B-ABBREVIATION 
supplementation O 
during O 
pregnancy O 
and O 
early O 
childhood O 
is O 
of O 
clinical O 
importance O 
. O 
Some O 
evidence O 
has O 
been O 
built O 
for O 
the O 
neuro O 
- O 
cognitive O 
benefits O 
of O 
supplementation O 
with O 
long B-FAMILY 
chain I-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
LCPUFA B-ABBREVIATION 
) O 
such O 
as O 
DHA B-ABBREVIATION 
during O 
pregnancy O 
; O 
however O 
, O 
recent O 
data O 
indicate O 
that O 
the O 
anti-inflammatory O 
properties O 
may O 
be O 
of O 
at O 
least O 
equal O 
significance O 
. O 
Adequate O 
DHA B-ABBREVIATION 
availability O 
in O 
the O 
fetus O 
/ O 
infant O 
optimizes O 
brain O 
and O 
retinal O 
maturation O 
in O 
part O 
by O 
influencing O 
neurotransmitter O 
pathways O 
. O 
The O 
anti-inflammatory O 
properties O 
of O 
LCPUFA B-ABBREVIATION 
are O 
largely O 
mediated O 
through O 
modulation O 
of O 
signaling O 
either O 
directly O 
through O 
binding O 
to O 
receptors O 
or O 
through O 
changes O 
in O 
lipid O 
raft O 
formation O 
and O 
receptor O 
presentation O 
. O 
Our O 
goal O 
is O 
to O 
review O 
the O 
current O 
findings O 
on O 
DHA B-ABBREVIATION 
supplementation O 
, O 
specifically O 
in O 
pregnancy O 
and O 
infant O 
neurodevelopment O 
, O 
as O 
a O 
pharmacologic O 
agent O 
with O 
both O 
preventative O 
and O 
therapeutic O 
value O 
. O 
Given O 
the O 
overall O 
benefits O 
of O 
DHA B-ABBREVIATION 
, O 
maternal O 
and O 
infant O 
supplementation O 
may O 
improve O 
neurological O 
outcomes O 
especially O 
in O 
vulernable O 
populations O 
. O 
However O 
, O 
optimal O 
composition O 
of O 
the O 
supplement O 
and O 
dosing O 
and O 
treatment O 
strategies O 
still O 
need O 
to O 
be O 
determined O 
to O 
lend O 
support O 
for O 
routine O 
supplementation O 
. O 

to O 
distribution O 
and O 
accumulation O 
of O 
dibutyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
in O 
rats O 
by O 
immunoassay O 
. O 

phthalate I-SYSTEMATIC 
( O 
DBP B-ABBREVIATION 
) O 
is O 
mainly O 
taken O 
up O 
by O 
the O 
general O 
population O 
from O 
food O 
intake O 
. O 
To O 
estimate O 
intake O 
of O 
phthalates B-FAMILY 
, O 
determining O 
distribution O 
and O 
accumulation O 
of O 
DBP B-ABBREVIATION 
in O 
biological O 
materials O 
was O 
a O 
critical O 
need O 
. O 
In O 
this O 
work O 
, O 
we O 
set O 
up O 
two O 
novel O 
approaches O 
with O 
a O 
monoclonal O 
antibody O 
specific O 
to O 
DBP B-ABBREVIATION 
to O 
determine O 
the O 
distribution O 
and O 
accumulation O 
of O 
DBP B-ABBREVIATION 
in O 
vivo O 
. O 
The O 
contents O 
of O 
DBP B-ABBREVIATION 
in O 
liver O 
, O 
kidney O 
, O 
stomach O 
and O 
testes O 
were O 
detected O 
by O 
immunofluorescence O 
assays O 
and O 
indirect O 
competitive O 
ELISA O 
. O 
This O 
data O 
give O 
directly O 
evidence O 
that O 
indicates O 
the O 
distribution O 
and O 
accumulation O 
of O 
DBP B-ABBREVIATION 
in O 
vivo O 
. O 
Double O 
- O 
label O 
immunofluorescence O 
assay O 
provides O 
with O 
a O 
visual O 
approach O 
to O 
determination O 
of O 
the O 
distribution O 
and O 
accumulation O 
of O 
DBP B-ABBREVIATION 
. O 
It O 
indicated O 
that O 
DBP B-ABBREVIATION 
accumulated O 
in O 
subcutaneous O 
tissue O 
such O 
as O 
sweat O 
gland O 
, O 
hair O 
follicle O 
. O 
Both O 
of O 
immunofluorescence O 
assay O 
and O 
ELISA O 
can O 
be O 
used O 
to O 
detect O 
the O 
content O 
of O 
DBP B-ABBREVIATION 
in O 
biological O 
materials O 
. O 
Our O 
assays O 
showed O 
that O 
DBP B-ABBREVIATION 
accumulated O 
in O 
viscera O 
being O 
rich O 
in O 
fat O 
, O 
such O 
as O 
liver O 
, O 
kidney O 
and O 
could O 
overcome O 
physiological O 
barriers O 
to O 
penetrate O 
testes O 
. O 
The O 
date O 
suggested O 
that O 
the O 
accumulations O 
of O 
DBP B-ABBREVIATION 
exposed O 
through O 
dermal O 
route O 
were O 
less O 
than O 
that O 
of O 
oral O 
route O 
and O 
most O 
of O 
DBP B-ABBREVIATION 
was O 
metabolized O 
in O 
2 O 
or O 
3days O 
. O 

-exposed O 
developing O 
rats O 
display O 
motor O 
deficits O 
and O 
striatal O 
oxidative O 
stress O 
that O 
are O 
reversed O 
by O 
Trolox B-TRIVIAL 
. O 

manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
is O 
essential O 
for O 
proper O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
development O 
, O 
excessive O 
Mn B-FORMULA 
exposure O 
may O 
lead O 
to O 
neurotoxicity O 
. O 
Mn B-FORMULA 
preferentially O 
accumulates O 
in O 
the O 
basal O 
ganglia O 
, O 
and O 
in O 
adults O 
it O 
may O 
cause O 
Parkinson's O 
disease O 
- O 
like O 
disorder O 
. O 
Compared O 
to O 
adults O 
, O 
younger O 
individuals O 
accumulate O 
greater O 
Mn B-FORMULA 
levels O 
in O 
the O 
CNS O 
and O 
are O 
more O 
vulnerable O 
to O 
its O 
toxicity O 
. O 
Moreover O 
, O 
the O 
mechanisms O 
mediating O 
developmental O 
Mn B-FORMULA 
-induced O 
neurotoxicity O 
are O 
not O 
completely O 
understood O 
. O 
The O 
present O 
study O 
investigated O 
the O 
developmental O 
neurotoxicity O 
elicited O 
by O 
Mn B-FORMULA 
exposure O 
( O 
5 O 
, O 
10 O 
and O 
20 O 
mg O 
/ O 
kg O 
; O 
i.p O 
. O 
) O 
from O 
postnatal O 
day O 
8 O 
to O 
PN27 O 
in O 
rats O 
. O 
Neurochemical O 
analyses O 
were O 
carried O 
out O 
on O 
PN29 O 
, O 
with O 
a O 
particular O 
focus O 
on O 
striatal O 
alterations O 
in O 
intracellular O 
signaling O 
pathways O 
( O 
MAPKs O 
, O 
Akt O 
and O 
DARPP-32 O 
) O 
, O 
oxidative O 
stress O 
generation O 
and O 
cell O 
death O 
. O 
Motor O 
alterations O 
were O 
evaluated O 
later O 
in O 
life O 
at O 
3 O 
, O 
4 O 
or O 
5 O 
weeks O 
of O 
age O 
. O 
Mn B-FORMULA 
exposure O 
( O 
20 O 
mg O 
/ O 
kg O 
) O 
increased O 
p38(MAPK) O 
and O 
Akt O 
phosphorylation O 
, O 
but O 
decreased O 
DARPP-32-Thr-34 O 
phosphorylation O 
. O 
Mn B-FORMULA 
( O 
10 O 
and O 
20 O 
mg O 
/ O 
kg O 
) O 
increased O 
caspase O 
activity O 
and O 
F(2)-isoprostane B-FAMILY 
production O 
( O 
a O 
biological O 
marker O 
of O 
lipid O 
peroxidation O 
) O 
. O 
Paralleling O 
the O 
changes O 
in O 
striatal O 
biochemical O 
parameters O 
, O 
Mn B-FORMULA 
( O 
20 O 
mg O 
/ O 
kg O 
) O 
also O 
caused O 
motor O 
impairment O 
, O 
evidenced O 
by O 
increased O 
falling O 
latency O 
in O 
the O 
rotarod O 
test O 
, O 
decreased O 
distance O 
traveled O 
and O 
motor O 
speed O 
in O 
the O 
open O 
- O 
field O 
test O 
. O 
Notably O 
, O 
the O 
antioxidant O 
Trolox B-TRIVIAL 
™ O 
reversed O 
the O 
Mn B-FORMULA 
( O 
20 O 
mg O 
/ O 
kg)-dependent O 
augmentation O 
in O 
p38(MAPK) O 
phosphorylation O 
and O 
reduced O 
the O 
Mn B-FORMULA 
( O 
20 O 
mg O 
/ O 
kg)-induced O 
caspase O 
activity O 
and O 
F(2)-isoprostane B-FAMILY 
production O 
. O 
Trolox B-TRIVIAL 
™ O 
also O 
reversed O 
the O 
Mn B-FORMULA 
-induced O 
motor O 
coordination O 
deficits O 
. O 
These O 
findings O 
are O 
the O 
first O 
to O 
show O 
that O 
long O 
- O 
term O 
exposure O 
to O 
Mn B-FORMULA 
during O 
a O 
critical O 
period O 
of O 
neurodevelopment O 
causes O 
motor O 
coordination O 
dysfunction O 
with O 
parallel O 
increment O 
in O 
oxidative O 
stress O 
markers O 
, O 
p38(MAPK) O 
phosphorylation O 
and O 
caspase O 
activity O 
in O 
the O 
striatum O 
. O 
Moreover O 
, O 
we O 
establish O 
Trolox B-TRIVIAL 
™ O 
as O 
a O 
potential O 
neuroprotective O 
agent O 
given O 
its O 
efficacy O 
in O 
reversing O 
the O 
Mn B-FORMULA 
-induced O 
neurodevelopmental O 
effects O 
. O 

critical O 
effect O 
of O 
polarization O 
on O 
the O 
dynamical O 
structure O 
of O 
guanine B-TRIVIAL 
quadruplex O 
DNA O 
. O 

quadruplex O 
DNA O 
( O 
G-DNA O 
) O 
, O 
found O 
in O 
eukaryotic O 
telomeres O 
and O 
recently O 
in O 
non-telomeric O 
genomic O 
DNA O 
, O 
plays O 
important O 
biological O 
roles O 
and O 
their O 
structures O 
are O 
being O 
explored O 
as O 
potential O 
targets O 
for O 
therapeutic O 
intervention O 
. O 
Since O 
the O 
quadruplex O 
structure O 
of O 
G-DNA O 
is O 
stabilized O 
by O 
cations O 
, O 
electrostatic O 
interaction O 
is O 
expected O 
to O 
play O 
important O 
roles O 
in O 
the O 
dynamical O 
structure O 
of O 
G-DNA O 
. O 
In O 
current O 
work O 
, O 
MD O 
simulation O 
was O 
carried O 
out O 
to O 
study O 
the O 
dynamical O 
structure O 
of O 
a O 
special O 
G-DNA O 
( O 
with O 
sequence O 
d(G(4)T(4)G(4)) O 
) O 
complexed O 
with O 
five O 
K(+) B-FORMULA 
ions O 
. O 
In O 
order O 
to O 
properly O 
include O 
polarization O 
in O 
MD O 
simulation O 
, O 
a O 
new O 
set O 
of O 
polarized O 
nucleic O 
acid O 
specific O 
charge O 
based O 
on O 
fragment O 
quantum O 
chemistry O 
calculation O 
was O 
developed O 
for O 
G-DNA O 
. O 
Our O 
study O 
showed O 
that O 
polarization O 
of O 
the O 
nucleobases B-FAMILY 
by O 
K(+) B-FORMULA 
enhanced O 
electrostatic O 
attraction O 
between O 
the O 
base O 
and O 
ions O 
. O 
This O 
increased O 
attractive O 
interaction O 
is O 
critical O 
to O 
stabilizing O 
the O 
stem O 
- O 
loop O 
junction O 
ions O 
in O 
G-DNA O 
. O 
Without O 
this O 
polarization O 
effect O 
, O 
as O 
in O 
MD O 
simulation O 
using O 
a O 
standard O 
( O 
nonpolarizable O 
) O 
force O 
field O 
, O 
the O 
top O 
and O 
bottom O 
cations O 
escaped O 
into O 
the O 
solvent O 
within O 
just O 
a O 
few O 
nanoseconds O 
. O 
Furthermore O 
, O 
an O 
incorrect O 
bifurcated O 
bonding O 
geometry O 
of O 
G-DNA O 
, O 
found O 
in O 
previous O 
MD O 
simulation O 
study O 
under O 
a O 
standard O 
force O 
field O 
but O 
not O 
observed O 
in O 
experiments O 
, O 
disappeared O 
in O 
the O 
present O 
stimulation O 
using O 
the O 
new O 
polarized O 
force O 
field O 
. O 
The O 
current O 
study O 
bridged O 
an O 
important O 
gap O 
between O 
the O 
simulation O 
study O 
and O 
experimental O 
observation O 
on O 
the O 
dynamical O 
structure O 
of O 
G-DNA O 
. O 

broaden O 
our O 
knowledge O 
about O 
the O 
toxicity O 
of O 
metals O 
in O 
marine O 
elasmobranchs O 
, O 
cannulated O 
spiny O 
dogfish O 
( O 
Squalus O 
acanthias O 
) O 
were O 
exposed O 
to O 
20 O 
μM O 
and O 
100 O 
μM O 
lead O 
( O 
Pb B-FORMULA 
) O 
. O 
Since O 
we O 
wanted O 
to O 
focus O 
on O 
sub O 
lethal O 
ion O 
- O 
osmoregulatory O 
and O 
respiratory O 
disturbances O 
, O 
arterial O 
blood O 
samples O 
were O 
analysed O 
for O 
pH(a) O 
, O 
PaO(2) O 
, O 
haematocrit O 
and O 
total O 
CO(2) B-FORMULA 
values O 
at O 
several O 
time O 
points O 
. O 
Plasma O 
was O 
used O 
to O 
determine O 
urea B-TRIVIAL 
, O 
TMAO B-ABBREVIATION 
, O 
lactate B-FAMILY 
and O 
ion O 
concentrations O 
. O 
After O 
96 O 
h O 
, O 
Pb B-FORMULA 
concentrations O 
were O 
determined O 
in O 
a O 
number O 
of O 
tissues O 
, O 
such O 
as O 
gill O 
, O 
rectal O 
gland O 
, O 
skin O 
and O 
liver O 
. O 
To O 
further O 
investigate O 
ion O 
and O 
osmoregulation O 
, O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
activities O 
in O 
gill O 
and O 
rectal O 
gland O 
were O 
analysed O 
as O 
well O 
as O 
rates O 
of O 
ammonia B-SYSTEMATIC 
and O 
urea B-TRIVIAL 
excretion O 
. O 
Additionally O 
, O 
we O 
studied O 
the O 
energy O 
reserves O 
in O 
muscle O 
and O 
liver O 
. O 
Pb B-FORMULA 
strongly O 
accumulated O 
in O 
gills O 
and O 
especially O 
in O 
skin O 
. O 
Lower O 
accumulation O 
rates O 
occurred O 
in O 
gut O 
, O 
kidney O 
and O 
rectal O 
gland O 
. O 
A O 
clear O 
disturbance O 
in O 
acid O 
- O 
base O 
status O 
was O 
observed O 
after O 
one O 
day O 
of O 
exposure O 
indicating O 
a O 
transient O 
period O 
of O 
hyperventilation O 
. O 
The O 
increase O 
in O 
pH(a) O 
was O 
temporary O 
at O 
20 O 
μM O 
, O 
but O 
persisted O 
at O 
100 O 
μM O 
. O 
After O 
2 O 
days O 
, O 
plasma O 
Na B-FORMULA 
and O 
Cl B-FORMULA 
concentrations O 
were O 
reduced O 
compared O 
to O 
controls O 
at O 
100 O 
μM O 
Pb B-FORMULA 
and O 
urea B-TRIVIAL 
excretion O 
rates O 
were O 
elevated O 
. O 
Pb B-FORMULA 
caused O 
impaired O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
activity O 
in O 
gills O 
, O 
but O 
not O 
in O 
rectal O 
gland O 
. O 
We O 
conclude O 
that O 
spiny O 
dogfish O 
experienced O 
relatively O 
low O 
ion O 
- O 
osmoregulatory O 
and O 
respiratory O 
distress O 
when O 
exposed O 
to O 
lead O 
, O 
particularly O 
when O 
compared O 
to O 
effects O 
of O 
other O 
metals O 
such O 
as O 
silver B-SYSTEMATIC 
. O 
These O 
elasmobranchs O 
appear O 
to O 
be O 
able O 
to O 
minimize O 
the O 
disturbance O 
and O 
maintain O 
physiological O 
homeostasis O 
during O 
an O 
acute O 
Pb B-FORMULA 
exposure O 
. O 

- O 
induced O 
nausea O 
and O 
vomiting O 
( O 
CINV O 
) O 
is O 
associated O 
with O 
a O 
significant O 
deterioration O 
in O 
quality O 
of O 
life O 
. O 
The O 
emetogenicity O 
of O 
the O 
chemotherapeutic O 
agents O 
, O 
repeated O 
chemotherapy O 
cycles O 
, O 
and O 
patient O 
risk O 
factors O 
significantly O 
influence O 
CINV O 
. O 
The O 
use O 
of O 
a O 
combination O 
of O 
a O 
serotonin B-TRIVIAL 
5-HT3 O 
receptor O 
antagonist O 
, O 
dexamethasone B-TRIVIAL 
and O 
a O 
neurokinin O 
1 O 
( O 
NK1 O 
) O 
receptor O 
antagonist O 
has O 
significantly O 
improved O 
the O 
control O 
of O 
acute O 
and O 
delayed O 
emesis O 
in O 
single O 
- O 
day O 
chemotherapy O 
. O 
Palonosetron B-TRIVIAL 
, O 
a O 
second O 
- O 
generation O 
5-HT3 O 
receptor O 
antagonist O 
with O 
a O 
different O 
half O 
- O 
life O 
, O 
a O 
different O 
binding O 
capacity O 
and O 
a O 
different O 
mechanism O 
of O 
action O 
than O 
the O 
first O 
- O 
generation O 
5-HT3 O 
receptor O 
antagonists O 
appears O 
to O 
be O 
the O 
most O 
effective O 
agent O 
in O 
its O 
class O 
. O 
Aprepitant B-TRIVIAL 
, O 
the O 
first O 
and O 
only O 
agent O 
clinically O 
available O 
in O 
the O 
NK1 O 
receptor O 
antagonist O 
drug O 
class O 
has O 
been O 
used O 
effectively O 
as O 
an O 
additive O 
agent O 
to O 
the O 
5-HT3 O 
receptor O 
antagonists O 
and O 
dexamethasone B-TRIVIAL 
to O 
control O 
CINV O 
. O 
Rolapitant B-TRIVIAL 
and O 
netupitant B-TRIVIAL 
are O 
other O 
NK1 O 
receptor O 
antagonists O 
that O 
are O 
currently O 
in O 
phase O 
III O 
clinical O 
trials O 
. O 
Despite O 
the O 
control O 
of O 
emesis O 
, O 
nausea O 
has O 
not O 
been O 
well O 
controlled O 
by O 
current O 
agents O 
. O 
Olanzapine B-TRIVIAL 
, O 
a O 
US-FDA O 
approved O 
antipsychotic O 
, O 
has O 
emerged O 
in O 
recent O 
trials O 
as O 
an O 
effective O 
preventative O 
agent O 
for O 
CINV O 
, O 
as O 
well O 
as O 
a O 
very O 
effective O 
agent O 
for O 
the O 
treatment O 
of O 
breakthrough O 
emesis O 
and O 
nausea O 
. O 
Clinical O 
trials O 
using O 
gabapentin B-TRIVIAL 
, O 
cannabinoids O 
and O 
ginger O 
have O 
not O 
been O 
definitive O 
regarding O 
their O 
efficacy O 
in O 
the O 
prevention O 
of O 
CINV O 
. O 
Additional O 
studies O 
are O 
necessary O 
for O 
the O 
control O 
of O 
nausea O 
and O 
for O 
the O 
control O 
of O 
CINV O 
in O 
the O 
clinical O 
settings O 
of O 
multiple O 
- O 
day O 
chemotherapy O 
and O 
bone O 
marrow O 
transplantation O 
. O 

an O 
effort O 
to O 
identify O 
novel O 
active O 
constituents O 
on O 
the O 
cardiovascular O 
system O 
, O 
a O 
systematic O 
study O 
on O 
macroporous O 
resin O 
adsorption O 
of O 
extracts O 
from O 
the O 
fibrous O 
root O 
of O 
Ophiopogon O 
japonicus O 
was O 
performed O 
in O 
a O 
human O 
myocardial O 
microvascular O 
endothelial O 
cell O 
line O 
( O 
HMMEC O 
) O 
based O 
assay O 
. O 
One O 
novel O 
spirostan B-TRIVIAL 
, O 
named O 
ophiogenin B-TRIVIAL 
( O 
1 O 
) O 
, O 
together O 
with O 
six O 
known O 
spirostans B-FAMILY 
( O 
4-8 O 
, O 
10 O 
) O 
, O 
and O 
one O 
new O 
sesquiterpene B-FAMILY 
glycoside I-FAMILY 
, O 
named O 
ophioside B-TRIVIAL 
A I-TRIVIAL 
( O 
2 O 
) O 
, O 
together O 
with O 
one O 
known O 
monoterpene B-FAMILY 
glycoside I-FAMILY 
( O 
9 O 
) O 
were O 
isolated O 
from O 
the O 
active O 
fractions O 
, O 
and O 
the O 
aglycone O 
of O 
compound O 
2 O 
that O 
was O 
a O 
new O 
natural O 
compound O 
was O 
obtained O 
from O 
the O 
acid O 
hydrolysis O 
of O 
2 O 
, O 
named O 
ophiopogonol B-TRIVIAL 
( O 
3 O 
) O 
. O 
Their O 
structures O 
were O 
determined O 
by O 
spectral O 
and O 
chemical O 
analyses O 
. O 
Furthermore O 
, O 
their O 
effect O 
on O 
HMMEC O 
tube O 
formation O 
was O 
also O 
determined O 
. O 
Our O 
results O 
indicated O 
that O 
compounds O 
4 O 
and O 
8 O 
could O 
significantly O 
improve O 
the O 
tube O 
formation O 
and O 
2 O 
showed O 
moderate O 
increasing O 
effect O 
, O 
while O 
compound O 
5 O 
exhibited O 
potent O 
inhibitory O 
effect O 
. O 

as O 
Selective O 
Spleen O 
Tyrosine B-TRIVIAL 
Kinase O 
Inhibitors O 
. O 

describe O 
the O 
discovery O 
of O 
several O 
pyrrolopyrazines B-FAMILY 
as O 
potent O 
and O 
selective O 
Syk O 
inhibitors O 
and O 
the O 
efforts O 
that O 
eventually O 
led O 
to O 
the O 
desired O 
improvements O 
in O 
physicochemical O 
properties O 
and O 
human O 
whole O 
blood O 
potencies O 
. O 
Ultimately O 
, O 
our O 
mouse O 
model O 
revealed O 
unexpected O 
toxicity O 
that O 
precluded O 
us O 
from O 
further O 
advancing O 
this O 
series O 
. O 

physico O 
- O 
chemical O 
" O 
anatomy O 
" O 
of O 
the O 
tautomerization O 
through O 
the O 
DPT O 
of O 
the O 
biologically O 
important O 
pairs O 
of O 
hypoxanthine B-TRIVIAL 
with O 
DNA O 
bases O 
: O 
QM O 
and O 
QTAIM O 
perspectives O 
. O 

biologically O 
important O 
tautomerization O 
of O 
the O 
Hyp B-ABBREVIATION 
· O 
Cyt B-FORMULA 
, O 
Hyp B-ABBREVIATION 
*· O 
Thy B-FORMULA 
and O 
Hyp B-ABBREVIATION 
· O 
Hyp B-ABBREVIATION 
base O 
pairs O 
to O 
the O 
Hyp B-ABBREVIATION 
*· O 
Cyt B-FORMULA 
* O 
, O 
Hyp B-ABBREVIATION 
· O 
Thy B-FORMULA 
* O 
and O 
Hyp B-ABBREVIATION 
*· O 
Hyp B-ABBREVIATION 
* O 
base O 
pairs O 
, O 
respectively O 
, O 
by O 
the O 
double O 
proton O 
transfer O 
( O 
DPT O 
) O 
was O 
comprehensively O 
studied O 
in O 
vacuo O 
and O 
in O 
the O 
continuum O 
with O 
a O 
low O 
dielectric O 
constant O 
( O 
ε O 
= O 
4 O 
) O 
corresponding O 
to O 
hydrophobic O 
interfaces O 
of O 
protein O 
- O 
nucleic O 
acid O 
interactions O 
by O 
combining O 
theoretical O 
investigations O 
at O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
+ O 
G(d,p) O 
level O 
of O 
QM O 
theory O 
with O 
QTAIM O 
topological O 
analysis O 
. O 
Based O 
on O 
the O 
sweeps O 
of O 
the O 
energetic O 
, O 
electron O 
- O 
topological O 
, O 
geometric O 
and O 
polar O 
parameters O 
, O 
which O 
describe O 
the O 
course O 
of O 
the O 
tautomerization O 
along O 
the O 
intrinsic O 
reaction O 
coordinate O 
( O 
IRC O 
) O 
, O 
it O 
was O 
proved O 
that O 
the O 
tautomerization O 
through O 
the O 
DPT O 
is O 
concerted O 
and O 
asynchronous O 
process O 
for O 
the O 
Hyp B-ABBREVIATION 
· O 
Cyt B-FORMULA 
and O 
Hyp B-ABBREVIATION 
*· O 
Thy B-FORMULA 
base O 
pairs O 
, O 
while O 
concerted O 
and O 
synchronous O 
for O 
the O 
Hyp B-ABBREVIATION 
· O 
Hyp B-ABBREVIATION 
homodimer O 
. O 
The O 
continuum O 
with O 
ε O 
= O 
4 O 
does O 
not O 
affect O 
qualitatively O 
the O 
course O 
of O 
the O 
tautomerization O 
reaction O 
for O 
all O 
studied O 
complexes O 
. O 
The O 
nine O 
key O 
points O 
along O 
the O 
IRC O 
of O 
the O 
Hyp B-ABBREVIATION 
· O 
Cyt B-FORMULA 
↔ O 
Hyp B-ABBREVIATION 
*· O 
Cyt B-FORMULA 
* O 
and O 
Hyp B-ABBREVIATION 
*· O 
Thy B-FORMULA 
↔ O 
Hyp B-ABBREVIATION 
· O 
Thy B-FORMULA 
* O 
tautomerizations O 
and O 
the O 
six O 
key O 
points O 
of O 
the O 
Hyp B-ABBREVIATION 
· O 
Hyp B-ABBREVIATION 
↔ O 
Hyp B-ABBREVIATION 
*· O 
Hyp B-ABBREVIATION 
* O 
tautomerization O 
have O 
been O 
identified O 
and O 
fully O 
characterized O 
. O 
These O 
key O 
points O 
could O 
be O 
considered O 
as O 
electron O 
- O 
topological O 
" O 
fingerprints O 
" O 
of O 
concerted O 
asynchronous O 
( O 
for O 
Hyp B-ABBREVIATION 
· O 
Cyt B-FORMULA 
and O 
Hyp B-ABBREVIATION 
*· O 
Thy B-FORMULA 
) O 
or O 
synchronous O 
( O 
for O 
Hyp B-ABBREVIATION 
· O 
Hyp B-ABBREVIATION 
) O 
tautomerization O 
process O 
via O 
the O 
DPT O 
. O 
It O 
was O 
found O 
, O 
that O 
in O 
the O 
Hyp B-ABBREVIATION 
*· O 
Cyt B-FORMULA 
* O 
, O 
Hyp B-ABBREVIATION 
· O 
Thy B-FORMULA 
* O 
, O 
Hyp B-ABBREVIATION 
· O 
Hyp B-ABBREVIATION 
and O 
Hyp B-ABBREVIATION 
*· O 
Hyp B-ABBREVIATION 
* O 
base O 
pairs O 
all O 
H B-FORMULA 
-bonds O 
are O 
significantly O 
cooperative O 
and O 
mutually O 
reinforce O 
each O 
other O 
, O 
while O 
the O 
C2H B-FORMULA 
… O 
O2 B-FORMULA 
H I-FORMULA 
-bond O 
in O 
the O 
Hyp B-ABBREVIATION 
· O 
Cyt B-FORMULA 
base O 
pair O 
and O 
the O 
O6 B-FORMULA 
H B-FORMULA 
… O 
O4 B-FORMULA 
H B-FORMULA 
-bond O 
in O 
the O 
Hyp B-ABBREVIATION 
*· O 
Thy B-FORMULA 
base O 
pair O 
behave O 
anti-cooperatively O 
, O 
i.e O 
. O 
, O 
they O 
become O 
weakened O 
, O 
while O 
two O 
others O 
become O 
strengthened O 
. O 

evidence O 
suggests O 
executive O 
dysfunction O 
in O 
ecstasy B-TRIVIAL 
polydrug O 
users O 
. O 

: O 
Deficits O 
in O 
executive O 
functions O 
such O 
as O 
access O 
to O 
semantic O 
/ O 
long O 
- O 
term O 
memory O 
have O 
been O 
shown O 
in O 
ecstasy B-TRIVIAL 
users O 
in O 
previous O 
research O 
. O 
Equally O 
, O 
there O 
have O 
been O 
many O 
reports O 
of O 
equivocal O 
findings O 
in O 
this O 
area O 
. O 
The O 
current O 
study O 
sought O 
to O 
further O 
investigate O 
behavioural O 
and O 
electro O 
- O 
physiological O 
measures O 
of O 
this O 
executive O 
function O 
in O 
ecstasy B-TRIVIAL 
users O 
. O 
METHOD O 
: O 
Twenty O 
ecstasy B-TRIVIAL 
-polydrug O 
users O 
, O 
20 O 
non- O 
ecstasy B-TRIVIAL 
-polydrug O 
users O 
and O 
20 O 
drug-naïve O 
controls O 
were O 
recruited O 
. O 
Participants O 
completed O 
background O 
questionnaires O 
about O 
their O 
drug O 
use O 
, O 
sleep O 
quality O 
, O 
fluid O 
intelligence O 
and O 
mood O 
state O 
. O 
Each O 
individual O 
also O 
completed O 
a O 
semantic O 
retrieval O 
task O 
whilst O 
64 O 
channel O 
Electroencephalography O 
( O 
EEG O 
) O 
measures O 
were O 
recorded O 
. O 
RESULTS O 
: O 
Analysis O 
of O 
Variance O 
( O 
ANOVA O 
) O 
revealed O 
no O 
between O 
- O 
group O 
differences O 
in O 
behavioural O 
performance O 
on O 
the O 
task O 
. O 
Mixed O 
ANOVA O 
on O 
event O 
- O 
related O 
potential O 
( O 
ERP O 
) O 
components O 
P2 O 
, O 
N2 O 
and O 
P3 O 
revealed O 
significant O 
between O 
- O 
group O 
differences O 
in O 
the O 
N2 O 
component O 
. O 
Subsequent O 
exploratory O 
univariate O 
ANOVAs O 
on O 
the O 
N2 O 
component O 
revealed O 
marginally O 
significant O 
between O 
- O 
group O 
differences O 
, O 
generally O 
showing O 
greater O 
negativity O 
at O 
occipito O 
- O 
parietal O 
electrodes O 
in O 
ecstasy B-TRIVIAL 
users O 
compared O 
to O 
drug-naïve O 
controls O 
. O 
Despite O 
absence O 
of O 
behavioural O 
differences O 
, O 
differences O 
in O 
N2 O 
magnitude O 
are O 
evidence O 
of O 
abnormal O 
executive O 
functioning O 
in O 
ecstasy B-TRIVIAL 
-polydrug O 
users O 
. O 

ordered O 
cobalt B-SYSTEMATIC 
- O 
phthalocyanine B-TRIVIAL 
chains O 
on O 
fractional O 
atomic O 
steps O 
: O 
one O 
- O 
dimensionality O 
and O 
electron O 
hybridization O 
. O 

controlled O 
fabrication O 
of O 
low O 
- O 
dimensional O 
molecular O 
structures O 
with O 
tailored O 
morphologies O 
and O 
electronic O 
properties O 
is O 
at O 
the O 
heart O 
of O 
the O 
nanotechnology O 
research O 
. O 
Especially O 
, O 
the O 
formation O 
of O 
one O 
- O 
dimensional O 
( O 
1D O 
) O 
structures O 
has O 
been O 
strongly O 
desired O 
due O 
to O 
their O 
expected O 
high O 
performance O 
for O 
information O 
processing O 
in O 
electronic O 
/ O 
magnetic O 
devices O 
. O 
So O 
far O 
, O 
however O 
, O 
they O 
have O 
been O 
obtained O 
by O 
tough O 
and O 
slow O 
methods O 
such O 
as O 
manipulation O 
of O 
individual O 
molecules O 
, O 
which O 
are O 
totally O 
unsuited O 
for O 
mass O 
production O 
. O 
Here O 
we O 
show O 
that O 
highly O 
ordered O 
cobalt B-SYSTEMATIC 
- O 
phthalocyanine B-TRIVIAL 
chains O 
can O 
be O 
self O 
- O 
assembled O 
on O 
a O 
metal O 
surface O 
using O 
fractional O 
atomic O 
steps O 
as O 
a O 
template O 
. O 
We O 
also O 
demonstrate O 
that O 
the O 
substrate O 
surface O 
electrons O 
, O 
which O 
can O 
be O 
confined O 
by O 
cobalt B-SYSTEMATIC 
- O 
phthalocyanine B-TRIVIAL 
molecules O 
, O 
can O 
propagate O 
along O 
the O 
step O 
arrays O 
and O 
can O 
hybridize O 
with O 
the O 
molecular O 
orbitals O 
. O 
These O 
findings O 
provide O 
a O 
significant O 
step O 
toward O 
readily O 
realization O 
of O 
1D O 
charge O 
/ O 
spin O 
transport O 
, O 
which O 
can O 
be O 
mediated O 
either O 
directly O 
by O 
the O 
molecules O 
or O 
by O 
the O 
surface O 
electrons O 
. O 

content O 
of O 
elements O 
( O 
Cd B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Pb B-FORMULA 
and O 
Zn B-FORMULA 
) O 
in O 
edible O 
oils O 
( O 
sunflower O 
, O 
hazelnut O 
, O 
canola O 
, O 
corn O 
and O 
olive O 
oils O 
) O 
from O 
Turkey O 
was O 
determined O 
using O 
inductively O 
coupled O 
plasma O 
optical O 
emission O 
spectrometry O 
( O 
ICP-OES O 
) O 
after O 
ultrasonic O 
extraction O 
, O 
wet O 
digestion O 
, O 
and O 
extraction O 
induced O 
by O 
emulsion O 
breaking O 
procedures O 
( O 
EIEB O 
) O 
. O 
In O 
order O 
to O 
evaluate O 
the O 
best O 
sample O 
preparation O 
procedure O 
, O 
EIEB O 
procedure O 
was O 
compared O 
by O 
ultrasonic O 
extraction O 
and O 
wet O 
digestion O 
procedures O 
. O 
The O 
results O 
in O 
the O 
samples O 
( O 
minimum O 
- O 
maximum O 
in O 
mgkg(-1) O 
) O 
were O 
: O 
0.022-0.058 O 
, O 
Cr B-FORMULA 
0.126-7.106 O 
, O 
Cu B-FORMULA 
0.570-4.504 O 
, O 
Fe B-FORMULA 
8.004-12.588 O 
, O 
Mn B-FORMULA 
0.035-0.054 O 
, O 
Ni B-FORMULA 
0.908-2.182 O 
, O 
Pb B-FORMULA 
0.099-0.134 O 
and O 
Zn B-FORMULA 
2.206-8.982 O 
. O 
The O 
EIEB O 
procedure O 
was O 
found O 
to O 
be O 
fast O 
, O 
reliable O 
, O 
simple O 
, O 
and O 
excellent O 
in O 
comparison O 
with O 
the O 
other O 
studied O 
procedures O 
. O 
The O 
recovery O 
test O 
was O 
performed O 
by O 
spiking O 
the O 
samples O 
with O 
known O 
amounts O 
of O 
the O 
metals O 
in O 
the O 
form O 
of O 
organometallic O 
standards O 
and O 
applying O 
the O 
EIEB O 
procedure O 
. O 
The O 
recoveries O 
were O 
in O 
the O 
range O 
of O 
96-109% O 
. O 

: O 
SiCN B-FORMULA 
Nanofibers O 
with O 
a O 
Diameter O 
Below O 
100 O 
nm O 
Synthesized O 
via O 
Concerted O 
Block O 
Copolymer O 
Formation O 
, O 
Microphase O 
Separation O 
, O 
and O 
Crosslinking O 
( O 
Small O 
7 O 
/ O 
2013 O 
) O 
. O 

fibers O 
with O 
a O 
mean O 
diameter O 
of O 
50 O 
nm O 
and O 
an O 
aspect O 
ratio O 
of O 
up O 
to O 
100 O 
are O 
produced O 
in O 
a O 
two O 
- O 
step O 
process O 
by O 
R O 
. O 
Kempe O 
and O 
co O 
- O 
workers O 
. O 
The O 
key O 
step O 
to O 
fabricate O 
the O 
longitudinal O 
and O 
crosssectional O 
views O 
of O 
the O 
mesofibers O 
shown O 
here O 
is O 
a O 
concerted O 
block O 
- O 
copolymer O 
synthesis O 
, O 
microphase O 
separation O 
, O 
and O 
cross O 
linking O 
at O 
140 O 
°C O 
followed O 
by O 
pyrolysis O 
at O 
1100 O 
°C O 
. O 
Inexpensive O 
components O 
like O 
a O 
commercially O 
available O 
silazane B-TRIVIAL 
and O 
polyethylene B-SYSTEMATIC 
are O 
linked O 
. O 
The O 
fibers O 
may O 
find O 
application O 
in O 
electronic O 
devices O 
, O 
as O 
components O 
of O 
ceramic O 
matrix O 
composites O 
, O 
as O 
fiber O 
beds O 
in O 
hightemperature O 
nano O 
- O 
filtering O 
like O 
diesel O 
fine O 
dust O 
removal O 
, O 
or O 
as O 
thermally O 
robust O 
and O 
chemically O 
inert O 
catalyst O 
supports O 
. O 
Furthermore O 
, O 
the O 
SiCN B-FORMULA 
nanofibers O 
introduced O 
on O 
page O 
984 O 
are O 
a O 
promising O 
alternative O 
to O 
ultrathin O 
carbon B-SYSTEMATIC 
fibers O 
, O 
due O 
to O 
their O 
oxidation O 
resistance O 
. O 

of O 
a O 
tyrosine B-TRIVIAL 
adduct O 
involved O 
in O 
lignin O 
degradation O 
by O 
Trametopsis O 
cervina O 
lignin O 
peroxidase O 
: O 
A O 
novel O 
peroxidase O 
activation O 
mechanism O 
. O 

peroxidase O 
( O 
LiP O 
) O 
from O 
Trametopsis O 
cervina O 
has O 
an O 
exposed O 
catalytic O 
tyrosine B-TRIVIAL 
( O 
Tyr B-FORMULA 
-181 O 
) O 
instead O 
of O 
the O 
conserved O 
tryptophan B-TRIVIAL 
of O 
other O 
lignin O 
- O 
degrading O 
peroxidases O 
. O 
Pristine O 
LiP O 
showed O 
a O 
lag O 
period O 
in O 
veratryl B-TRIVIAL 
alcohol I-TRIVIAL 
( O 
VA O 
) O 
oxidation O 
. O 
However O 
, O 
LiP O 
after O 
turnover O 
with O 
H2O2 B-FORMULA 
/ O 
VA O 
( O 
VA-LiP O 
) O 
lacked O 
this O 
lag O 
, O 
and O 
H2O2 B-FORMULA 
-pretreated O 
LiP O 
( O 
H2O2 B-FORMULA 
-LiP O 
) O 
was O 
inactive O 
. O 
MS O 
analyses O 
revealed O 
that O 
VA-LiP O 
includes O 
one O 
VA O 
molecule O 
covalently O 
bound O 
to O 
the O 
side-chain O 
of O 
Tyr B-FORMULA 
-181 O 
, O 
whereas O 
H2O2 B-FORMULA 
-LiP O 
contains O 
hydroxylated O 
Tyr B-FORMULA 
-181 O 
. O 
No O 
adduct O 
is O 
formed O 
by O 
the O 
Y171N O 
variant O 
. O 
Molecular O 
docking O 
showed O 
that O 
VA O 
binding O 
is O 
favored O 
by O 
sandwich O 
π O 
stacking O 
with O 
Tyr B-FORMULA 
-181 O 
and O 
Phe B-FORMULA 
-89 O 
. O 
EPR O 
spectroscopy O 
after O 
peroxide B-SYSTEMATIC 
activation O 
of O 
the O 
pretreated O 
LiPs O 
showed O 
other O 
protein O 
radicals O 
than O 
the O 
tyrosine B-TRIVIAL 
radical O 
found O 
in O 
pristine O 
LiP O 
, O 
which O 
were O 
assigned O 
to O 
a O 
tyrosine B-TRIVIAL 
/ O 
VA O 
adduct O 
radical O 
in O 
VA-LiP O 
and O 
a O 
dihydroxyphenyalanine B-SYSTEMATIC 
radical O 
in O 
H2O2 B-FORMULA 
-LiP O 
. O 
Both O 
radicals O 
are O 
able O 
to O 
oxidize O 
large O 
low O 
redox O 
- O 
potential O 
substrates O 
, O 
but O 
H2O2 B-FORMULA 
-LiP O 
is O 
unable O 
to O 
oxidize O 
high O 
redox O 
- O 
potential O 
substrates O 
. O 
Transient-state O 
kinetics O 
showed O 
that O 
the O 
tyrosine B-TRIVIAL 
/ O 
VA O 
adduct O 
strongly O 
promotes O 
( O 
> O 
100-fold O 
) O 
substrate O 
oxidation O 
by O 
compound O 
II O 
, O 
the O 
rate O 
- O 
limiting O 
step O 
in O 
catalysis O 
. O 
The O 
novel O 
activation O 
mechanism O 
is O 
involved O 
in O 
ligninolysis O 
, O 
as O 
demonstrated O 
using O 
lignin O 
model O 
substrates O 
. O 
This O 
is O 
the O 
first O 
report O 
on O 
autocatalytic O 
modification O 
, O 
resulting O 
in O 
functional O 
alteration O 
, O 
among O 
class-II O 
peroxidases O 
. O 

vitro O 
binding O 
affinities O 
of O 
a O 
series O 
of O 
flavonoids B-FAMILY 
for O 
μ-opioid O 
receptors O 
. O 
Antinociceptive O 
effect O 
of O 
the O 
synthetic O 
flavonoid B-FAMILY 
3,3-dibromoflavanone B-SYSTEMATIC 
in O 
mice O 
. O 

pharmacotherapy O 
for O 
the O 
treatment O 
of O 
pain O 
is O 
an O 
active O 
area O 
of O 
investigation O 
. O 
There O 
are O 
effective O 
drugs O 
to O 
treat O 
this O 
problem O 
, O 
but O 
there O 
is O 
also O 
a O 
need O 
to O 
find O 
alternative O 
treatments O 
free O 
of O 
undesirable O 
side O 
effects O 
. O 
In O 
the O 
present O 
work O 
the O 
capacity O 
of O 
a O 
series O 
of O 
flavonoids B-FAMILY 
to O 
bind O 
to O 
the O 
μ O 
opioid O 
receptor O 
was O 
evaluated O 
. O 
The O 
most O 
active O 
compound O 
, O 
3,3-dibromoflavanone B-SYSTEMATIC 
( O 
31 O 
) O 
, O 
a O 
synthetic O 
flavonoid B-FAMILY 
, O 
presented O 
a O 
significant O 
inhibition O 
of O 
the O 
binding O 
of O 
the O 
selective O 
μ O 
opioid O 
ligand O 
[(3)H]DAMGO B-SYSTEMATIC 
, O 
with O 
a O 
Ki O 
of O 
0.846 O 
± O 
0.263 O 
μM O 
. O 
Flavanone B-TRIVIAL 
31 O 
was O 
further O 
synthesized O 
using O 
a O 
simple O 
and O 
cheap O 
procedure O 
with O 
good O 
yield O 
. O 
Its O 
in O 
vivo O 
effects O 
in O 
mice O 
, O 
after O 
acute O 
treatments O 
, O 
were O 
studied O 
using O 
antinociceptive O 
and O 
behavioral O 
assays O 
. O 
It O 
showed O 
no O 
sedative O 
, O 
anxiolytic O 
, O 
motor O 
incoordination O 
effects O 
or O 
inhibition O 
of O 
the O 
gastrointestinal O 
transit O 
in O 
mice O 
at O 
the O 
doses O 
tested O 
. O 
It O 
evidenced O 
antinociceptive O 
activity O 
on O 
the O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
nociception O 
, O 
hot O 
plate O 
and O 
formalin B-TRIVIAL 
tests O 
( O 
at O 
10 O 
mg O 
/ O 
kg O 
and O 
30 O 
mg O 
/ O 
kg O 
) O 
. O 
The O 
results O 
showed O 
that O 
the O 
5-HT2 O 
receptor O 
and O 
the O 
adrenoceptors O 
seem O 
unlikely O 
to O 
be O 
involved O 
in O 
its O 
antinociceptive O 
effects O 
. O 
Naltrexone B-TRIVIAL 
, O 
a O 
nonselective O 
opioid O 
receptors O 
antagonist O 
, O 
totally O 
blocked O 
compound O 
31 O 
antinociceptive O 
effects O 
on O 
the O 
hot O 
plate O 
test O 
, O 
but O 
naltrindole B-TRIVIAL 
( O 
δ O 
opioid O 
antagonist O 
) O 
and O 
nor-binaltorphimine B-TRIVIAL 
( O 
κ O 
opioid O 
antagonist O 
) O 
did O 
not O 
. O 
These O 
findings O 
demonstrated O 
that O 
3,3-dibromoflavanone B-SYSTEMATIC 
( O 
31 O 
) O 
, O 
at O 
doses O 
that O 
did O 
not O 
interfere O 
with O 
the O 
motor O 
performance O 
, O 
exerted O 
clear O 
dose O 
dependent O 
antinociception O 
when O 
assessed O 
in O 
the O 
chemical O 
and O 
thermal O 
models O 
of O 
nociception O 
in O 
mice O 
and O 
it O 
seems O 
that O 
its O 
action O 
is O 
related O 
to O 
the O 
activation O 
of O 
the O 
μ O 
opioid O 
receptor O 
. O 

(Glyco)protein O 
Mimetic O 
Behavior O 
of O 
Poly(vinyl B-FAMILY 
alcohol I-FAMILY 
) I-FAMILY 
: O 
Detailed O 
Structure O 
Ice O 
Recrystallization O 
Inhibition O 
Activity O 
Study O 
. O 

manuscript O 
reports O 
a O 
detailed O 
study O 
on O 
the O 
ability O 
of O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
to O 
act O 
as O 
a O 
biomimetic O 
surrogate O 
for O 
antifreeze(glyco)proteins O 
, O 
with O 
a O 
focus O 
on O 
the O 
specific O 
property O 
of O 
ice O 
- O 
recrystallization O 
inhibition O 
( O 
IRI O 
) O 
. O 
Despite O 
over O 
40 O 
years O 
of O 
study O 
, O 
the O 
underlying O 
mechanisms O 
that O 
govern O 
the O 
action O 
of O 
biological O 
antifreezes O 
are O 
still O 
poorly O 
understood O 
, O 
which O 
is O 
in O 
part O 
due O 
to O 
their O 
limited O 
availability O 
and O 
challenging O 
synthesis O 
. O 
Poly(vinyl B-FAMILY 
alcohol I-FAMILY 
) I-FAMILY 
( O 
PVA B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
display O 
remarkable O 
ice O 
recrystallization O 
inhibition O 
activity O 
despite O 
its O 
major O 
structural O 
differences O 
to O 
native O 
antifreeze O 
proteins O 
. O 
Here O 
, O 
controlled O 
radical O 
polymerization O 
is O 
used O 
to O 
synthesize O 
well O 
- O 
defined O 
PVA B-ABBREVIATION 
, O 
which O 
has O 
enabled O 
us O 
to O 
obtain O 
the O 
first O 
quantitative O 
structure O 
- O 
activity O 
relationships O 
, O 
to O 
probe O 
the O 
role O 
of O 
molecular O 
weight O 
and O 
comonomers O 
on O 
IRI O 
activity O 
. O 
Crucially O 
, O 
it O 
was O 
found O 
that O 
IRI O 
activity O 
is O 
" O 
switched O 
on O 
" O 
when O 
the O 
polymer O 
chain O 
length O 
increases O 
from O 
10 O 
and O 
20 O 
repeat O 
units O 
. O 
Substitution O 
of O 
the O 
polymer O 
side O 
chains O 
with O 
hydrophilic O 
or O 
hydrophobic O 
units O 
was O 
found O 
to O 
diminish O 
activity O 
. O 
Hydrophobic O 
modifications O 
to O 
the O 
backbone O 
were O 
slightly O 
more O 
tolerated O 
than O 
side O 
chain O 
modifications O 
, O 
which O 
implies O 
an O 
unbroken O 
sequence O 
of O 
hydroxyl B-SYSTEMATIC 
units O 
is O 
necessary O 
for O 
activity O 
. O 
These O 
results O 
highlight O 
that O 
, O 
although O 
hydrophobic O 
domains O 
are O 
key O 
components O 
of O 
IRI O 
activity O 
, O 
the O 
random O 
inclusion O 
of O 
addition O 
hydrophobic O 
units O 
does O 
not O 
guarantee O 
an O 
increase O 
in O 
activity O 
and O 
that O 
the O 
actual O 
polymer O 
conformation O 
is O 
important O 
. O 

of O 
new O 
cathepsin O 
B O 
inhibitors O 
: O 
combining O 
bioisosteric O 
replacements O 
and O 
structure O 
- O 
based O 
design O 
to O 
explore O 
the O 
structure O 
- O 
activity O 
relationships O 
of O 
nitroxoline B-TRIVIAL 
derivatives O 
. O 

cathepsin O 
B O 
has O 
many O 
house O 
- O 
keeping O 
functions O 
, O 
such O 
as O 
protein O 
turnover O 
in O 
lysosomes O 
. O 
However O 
, O 
dysregulation O 
of O 
its O 
activity O 
is O 
associated O 
with O 
numerous O 
diseases O 
, O 
including O 
cancers O 
. O 
We O 
present O 
here O 
the O 
structure O 
- O 
based O 
design O 
and O 
synthesis O 
of O 
new O 
cathepsin O 
B O 
inhibitors O 
using O 
the O 
cocrystal O 
structure O 
of O 
5-nitro-8-hydroxyquinoline B-SYSTEMATIC 
in O 
the O 
cathepsin O 
B O 
active O 
site O 
. O 
A O 
focused O 
library O 
of O 
over O 
50 O 
compounds O 
was O 
prepared O 
by O 
modifying O 
positions O 
5 O 
, O 
7 O 
, O 
and O 
8 O 
of O 
the O 
parent O 
compound O 
nitroxoline B-TRIVIAL 
. O 
The O 
kinetic O 
parameters O 
and O 
modes O 
of O 
inhibition O 
were O 
characterized O 
, O 
and O 
the O 
selectivities O 
of O 
the O 
most O 
promising O 
inhibitors O 
were O 
determined O 
. O 
The O 
best O 
performing O 
inhibitor O 
17 O 
was O 
effective O 
in O 
cell O 
- O 
based O 
in O 
vitro O 
models O 
of O 
tumor O 
invasion O 
, O 
where O 
it O 
significantly O 
abrogated O 
invasion O 
of O 
MCF-10A O 
neoT O 
cells O 
. O 
These O 
data O 
show O 
that O 
we O 
have O 
successfully O 
explored O 
the O 
structure O 
- O 
activity O 
relationships O 
of O 
nitroxoline B-TRIVIAL 
derivatives O 
to O 
provide O 
new O 
inhibitors O 
that O 
could O 
eventually O 
lead O 
to O 
compounds O 
with O 
clinical O 
usefulness O 
against O 
the O 
deleterious O 
effects O 
of O 
cathepsin O 
B O 
in O 
cancer O 
progression O 
. O 

as O 
potential O 
antitumor O 
agents O 
for O 
human O 
prostate O 
cancer O 
cells O 
. O 

are O 
currently O 
being O 
studied O 
and O 
used O 
in O 
a O 
variety O 
of O 
applications O 
beyond O 
their O 
traditional O 
place O 
in O 
supramolecular O 
and O 
co O 
- O 
ordination O 
chemistry O 
. O 
This O 
study O 
suggests O 
additional O 
applications O 
of O 
these O 
compounds O 
with O 
particular O 
emphasis O 
on O 
their O 
use O 
as O 
antiproliferative O 
agents O 
that O 
could O 
be O 
potentially O 
used O 
to O 
treat O 
cancer O 
. O 
Four O 
polyazamacrocycles B-FAMILY 
were O 
tested O 
in O 
human O 
prostate O 
cancer O 
LNCaP O 
and O 
prostate O 
epithelial O 
PNTA1 O 
cells O 
to O 
analyze O 
changes O 
in O 
cell O 
proliferation O 
and O 
cell O 
death O 
capabilities O 
. O 
Their O 
intracellular O 
localization O 
was O 
also O 
evaluated O 
by O 
confocal O 
microscopy O 
. O 
The O 
results O 
show O 
a O 
decrease O 
in O 
proliferation O 
rate O 
and O 
cell O 
viability O 
of O 
LNCaP O 
and O 
PNTA1 O 
, O 
after O 
treatment O 
with O 
these O 
compounds O 
. O 
The O 
decrease O 
in O 
the O 
number O 
of O 
viable O 
cells O 
is O 
similar O 
for O 
the O 
majority O 
of O 
the O 
compounds O 
studied O 
, O 
and O 
at O 
higher O 
concentration O 
, O 
the O 
proliferation O 
efficiency O 
decreased O 
significantly O 
in O 
the O 
cell O 
lines O 
studied O 
. O 
Also O 
, O 
our O 
results O 
suggest O 
that O 
L O 
and O 
L2 O 
induce O 
early O 
apoptosis O 
in O 
PNTA1 O 
cells O 
and O 
late O 
apoptosis O 
/ O 
necrosis O 
in O 
LNCaP O 
cells O 
. O 
The O 
compounds O 
did O 
not O 
induce O 
a O 
significant O 
increase O 
in O 
necrosis O 
of O 
both O 
cell O 
types O 
. O 
Although O 
the O 
compounds O 
did O 
not O 
localize O 
in O 
a O 
unique O 
organelle O 
, O 
all O 
of O 
them O 
have O 
as O 
main O 
target O 
the O 
Golgi O 
apparatus O 
and O 
other O 
localization O 
profiles O 
differed O 
depending O 
on O 
the O 
cell O 
line O 
. O 

, O 
interest O 
in O 
small O 
peptide O 
molecules O 
as O 
potential O 
drug O 
candidates O 
has O 
revived O 
. O 
In O 
this O 
review O 
, O 
two O 
series O 
of O 
synthetic O 
peptides O 
and O 
their O 
selective O 
effects O 
on O 
the O 
inflammatory O 
response O 
have O 
been O 
described O 
, O 
focusing O 
on O 
the O 
intracellular O 
pathways O 
involved O 
and O 
on O 
their O 
therapeutic O 
potential O 
. O 
A O 
series O 
of O 
F(D)LF(D)LF O 
analogs O 
has O 
been O 
synthesized O 
, O 
including O 
either O 
N- B-FORMULA 
t-Boc I-FORMULA 
or O 
different O 
N-ureido B-TRIVIAL 
substituents O 
. O 
The O 
free O 
acid O 
derivatives O 
as O 
they O 
are O 
good O 
candidates O 
as O 
antiinflammatory O 
drugs O 
are O 
able O 
to O 
antagonize O 
the O 
multiple O 
neutrophil O 
functions O 
evoked O 
by O 
N- B-SYSTEMATIC 
formyl-L-methionyl-L-leucyl-Lphenylalanine I-SYSTEMATIC 
( O 
fMLF B-ABBREVIATION 
) O 
, O 
i.e O 
. O 
chemotaxis O 
, O 
superoxide B-TRIVIAL 
anion O 
production O 
and O 
lysozyme O 
release O 
. O 
Their O 
methyl-ester B-SYSTEMATIC 
derivatives O 
are O 
ineffective O 
. O 
The O 
second O 
series O 
of O 
peptides O 
derives O 
from O 
the O 
endogenous O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
inhibitor O 
PKI55 O 
, O 
a O 
55- O 
amino B-FAMILY 
acid I-FAMILY 
protein O 
, O 
whose O 
synthesis O 
is O 
induced O 
by O 
PKC O 
activation O 
, O 
so O 
that O 
a O 
feedback O 
loop O 
of O 
inhibition O 
is O 
established O 
. O 
In O 
vitro O 
experiments O 
showed O 
that O 
PKI55 O 
inhibits O 
recombinant O 
PKC O 
isoforms O 
α O 
, O 
β1 O 
, O 
β2 O 
, O 
γ O 
, O 
δ O 
, O 
ζ O 
, O 
; O 
to O 
identify O 
the O 
minimal O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
PKI55 O 
protein O 
maintaining O 
the O 
inhibitory O 
effects O 
on O 
PKC O 
, O 
peptides O 
derived O 
from O 
both O 
C B-FORMULA 
- O 
and O 
N B-FORMULA 
-terminal O 
sequences O 
have O 
been O 
synthesized O 
. O 
The O 
N B-FORMULA 
-terminal O 
peptides O 
5 O 
( O 
MLYKLHDVCRQLWFSC O 
) O 
, O 
8 O 
( O 
CRQLWFSC O 
) O 
and O 
9 O 
( O 
CRQLW O 
) O 
, O 
that O 
in O 
human O 
neutrophils O 
retain O 
the O 
inhibitory O 
activity O 
on O 
PKC O 
, O 
decrease O 
the O 
chemotaxis O 
, O 
and O 
, O 
in O 
mice O 
, O 
display O 
anti-inflammatory O 
and O 
analgesic O 
action O 
, O 
after O 
both O 
central O 
and O 
peripheral O 
administration O 
of O 
very O 
low O 
doses O 
. O 
Furthermore O 
, O 
the O 
peptide O 
5 O 
shows O 
neuroprotective O 
activity O 
in O 
a O 
model O 
of O 
cerebral O 
ischemia O 
in O 
vitro O 
, O 
favouring O 
the O 
recovery O 
of O 
synaptic O 
function O 
. O 
These O 
findings O 
suggest O 
interesting O 
possible O 
therapeutic O 
applications O 
for O 
these O 
peptides O 
. O 

protects O 
cells O 
against O 
oxidative O 
damage O 
by O 
reducing O 
disulfide B-SYSTEMATIC 
bonds O 
in O 
improperly O 
oxidized O 
proteins O 
. O 
Previously O 
, O 
we O 
found O 
that O 
the O 
baker's O 
yeast O 
cytosolic O 
thioredoxin O 
Trx2 O 
undergoes O 
cross O 
- O 
linking O 
to O 
form O 
several O 
protein O 
- O 
protein O 
complexes O 
in O 
cells O 
treated O 
with O 
the O 
bifunctional O 
electrophile O 
divinyl B-SYSTEMATIC 
sulfone I-SYSTEMATIC 
( O 
DVSF B-ABBREVIATION 
) O 
. O 
Here O 
, O 
we O 
report O 
that O 
the O 
peroxiredoxin O 
Tsa1 O 
and O 
the O 
thioredoxin O 
reductase O 
Trr1 O 
, O 
both O 
of O 
which O 
function O 
in O 
a O 
redox O 
relay O 
network O 
with O 
thioredoxin O 
, O 
become O 
cross O 
- O 
linked O 
in O 
complexes O 
with O 
Trx2 O 
upon O 
DVSF B-ABBREVIATION 
treatment O 
. O 
Treatment O 
of O 
yeast O 
with O 
other O 
bifunctional O 
electrophiles O 
, O 
including O 
diethyl B-SYSTEMATIC 
acetylenedicarboxylate I-SYSTEMATIC 
( O 
DAD B-ABBREVIATION 
) O 
, O 
mechlorethamine B-TRIVIAL 
( O 
HN2 B-FORMULA 
) O 
, O 
and O 
1,2,3,4-diepoxybutane B-SYSTEMATIC 
( O 
DEB B-ABBREVIATION 
) O 
, O 
resulted O 
in O 
the O 
formation O 
of O 
similar O 
cross O 
- O 
linked O 
complexes O 
. O 
Cross O 
- O 
linking O 
of O 
Trx2 O 
and O 
Tsa1 O 
to O 
other O 
proteins O 
by O 
DVSF B-ABBREVIATION 
and O 
DAD B-ABBREVIATION 
is O 
dependent O 
on O 
modification O 
of O 
the O 
active O 
site O 
Cys B-FORMULA 
residues O 
within O 
these O 
proteins O 
. O 
In O 
addition O 
, O 
the O 
human O 
cytosolic O 
thioredoxin O 
, O 
cytosolic O 
thioredoxin O 
reductase O 
, O 
and O 
peroxiredoxin O 
2 O 
form O 
cross O 
- O 
linked O 
complexes O 
to O 
other O 
proteins O 
in O 
the O 
presence O 
of O 
DVSF B-ABBREVIATION 
, O 
although O 
each O 
protein O 
shows O 
different O 
susceptibilities O 
to O 
modification O 
by O 
DAD B-ABBREVIATION 
, O 
HN2 B-FORMULA 
, O 
and O 
DEB B-ABBREVIATION 
. O 
Taken O 
together O 
, O 
our O 
results O 
indicate O 
that O 
bifunctional O 
electrophiles O 
potentially O 
disrupt O 
redox O 
homeostasis O 
in O 
yeast O 
and O 
human O 
cells O 
by O 
forming O 
cross O 
- O 
linked O 
complexes O 
between O 
thioredoxins O 
and O 
their O 
redox O 
partners O 
. O 

oligo(poly(ethylene B-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
fumarate I-FAMILY 
) I-FAMILY 
( O 
OPF B-ABBREVIATION 
) O 
composite O 
hydrogels O 
have O 
been O 
investigated O 
for O 
the O 
delivery O 
of O 
growth O 
factors O 
( O 
GFs O 
) O 
with O 
the O 
aid O 
of O 
gelatin O 
microparticles O 
( O 
GMPs O 
) O 
and O 
stem O 
cell O 
populations O 
for O 
osteochondral O 
tissue O 
regeneration O 
. O 
In O 
this O 
study O 
, O 
a O 
bilayered O 
OPF B-ABBREVIATION 
composite O 
hydrogel O 
that O 
mimics O 
the O 
distinctive O 
hierarchical O 
structure O 
of O 
native O 
osteochondral O 
tissue O 
was O 
utilized O 
to O 
investigate O 
the O 
effect O 
of O 
transforming O 
growth O 
factor-β3 O 
( O 
TGF-β3 O 
) O 
with O 
varying O 
release O 
kinetics O 
and O 
/ O 
or O 
insulin O 
- O 
like O 
growth O 
factor-1 O 
( O 
IGF-1 O 
) O 
on O 
osteochondral O 
tissue O 
regeneration O 
in O 
a O 
rabbit O 
full O 
- O 
thickness O 
osteochondral O 
defect O 
model O 
. O 
The O 
four O 
groups O 
investigated O 
included O 
(i) O 
a O 
blank O 
control O 
( O 
no O 
GFs O 
) O 
, O 
(ii) O 
GMP-loaded O 
IGF-1 O 
alone O 
, O 
(iii) O 
GMP-loaded O 
IGF-1 O 
and O 
gel O 
- O 
loaded O 
TGF-β3 O 
, O 
and O 
(iv) O 
GMP-loaded O 
IGF-1 O 
and O 
GMP-loaded O 
TGF-β3 O 
in O 
OPF B-ABBREVIATION 
composite O 
hydrogels O 
. O 
The O 
results O 
of O 
an O 
in O 
vitro O 
release O 
study O 
demonstrated O 
that O 
TGF-β3 O 
release O 
kinetics O 
could O 
be O 
modulated O 
by O 
the O 
GF O 
incorporation O 
method O 
. O 
At O 
12weeks O 
post O 
- O 
implantation O 
, O 
the O 
quality O 
of O 
tissue O 
repair O 
in O 
both O 
chondral O 
and O 
subchondral O 
layers O 
was O 
analyzed O 
based O 
on O 
quantitative O 
histological O 
scoring O 
. O 
All O 
groups O 
incorporating O 
GFs O 
resulted O 
in O 
a O 
significant O 
improvement O 
in O 
cartilage O 
morphology O 
compared O 
to O 
the O 
control O 
. O 
Single O 
delivery O 
of O 
IGF-1 O 
showed O 
higher O 
scores O 
in O 
subchondral O 
bone O 
morphology O 
as O 
well O 
as O 
chondrocyte O 
and O 
glycosaminoglycan O 
amount O 
in O 
adjacent O 
cartilage O 
tissue O 
when O 
compared O 
to O 
a O 
dual O 
delivery O 
of O 
IGF-1 O 
and O 
TGF-β3 O 
, O 
independent O 
of O 
the O 
TGF-β3 O 
release O 
kinetics O 
. O 
The O 
results O 
suggest O 
that O 
although O 
the O 
dual O 
delivery O 
of O 
TGF-β3 O 
and O 
IGF-1 O 
may O 
not O 
synergistically O 
enhance O 
the O 
quality O 
of O 
engineered O 
tissue O 
, O 
the O 
delivery O 
of O 
IGF-1 O 
alone O 
from O 
bilayered O 
composite O 
hydrogels O 
positively O 
affects O 
osteochondral O 
tissue O 
repair O 
and O 
holds O 
promise O 
for O 
osteochondral O 
tissue O 
engineering O 
applications O 
. O 

is O 
a O 
project O 
within O 
the O 
6th O 
European O 
Framework O 
Programme O 
which O 
had O 
as O 
one O 
of O 
its O 
goals O 
to O 
develop O 
, O 
optimise O 
and O 
prevalidate O 
a O 
non-animal O 
testing O 
strategy O 
for O 
predicting O 
human O 
acute O 
oral O 
toxicity O 
. O 
In O 
its O 
last O 
6months O 
, O 
a O 
challenging O 
exercise O 
was O 
conducted O 
to O 
assess O 
the O 
predictive O 
capacity O 
of O 
the O 
developed O 
testing O 
strategies O 
and O 
final O 
identification O 
of O 
the O 
most O 
promising O 
ones O 
. O 
Thirty O 
- O 
two O 
chemicals O 
were O 
tested O 
blind O 
in O 
the O 
battery O 
of O 
in O 
vitro O 
and O 
in O 
silico O 
methods O 
selected O 
during O 
the O 
first O 
phase O 
of O 
the O 
project O 
. O 
This O 
paper O 
describes O 
the O 
classification O 
approaches O 
studied O 
: O 
single O 
step O 
procedures O 
and O 
two O 
step O 
tiered O 
testing O 
strategies O 
. O 
In O 
summary O 
, O 
four O 
in O 
vitro O 
testing O 
strategies O 
were O 
proposed O 
as O 
best O 
performing O 
in O 
terms O 
of O 
predictive O 
capacity O 
with O 
respect O 
to O 
the O 
European O 
acute O 
oral O 
toxicity O 
classification O 
. O 
In O 
addition O 
, O 
a O 
heuristic O 
testing O 
strategy O 
is O 
suggested O 
that O 
combines O 
the O 
prediction O 
results O 
gained O 
from O 
the O 
neutral O 
red O 
uptake O 
assay O 
performed O 
in O 
3T3 O 
cells O 
, O 
with O 
information O 
on O 
neurotoxicity O 
alerts O 
identified O 
by O 
the O 
primary O 
rat O 
brain O 
aggregates O 
test O 
method O 
. O 
Octanol B-SYSTEMATIC 
-water O 
partition O 
coefficients O 
and O 
in O 
silico O 
prediction O 
of O 
intestinal O 
absorption O 
and O 
blood O 
- O 
brain O 
barrier O 
passage O 
are O 
also O 
considered O 
. O 
This O 
approach O 
allows O 
to O 
reduce O 
the O 
number O 
of O 
chemicals O 
wrongly O 
predicted O 
as O 
not O 
classified O 
( O 
LD50 O 
> O 
2000mg O 
/ O 
kg O 
b.w O 
. O 
) O 
. O 

biological O 
properties O 
of O 
macelignan B-TRIVIAL 
and O 
its O 
pharmacological O 
implications O 
. O 

found O 
in O 
the O 
nutmeg O 
mace O 
of O 
Myristica O 
fragrans O 
obtains O 
increasing O 
attention O 
as O 
a O 
new O 
avenue O 
in O 
treating O 
various O 
diseases O 
. O 
Macelignan B-TRIVIAL 
has O 
been O 
shown O 
to O 
possess O 
a O 
spectrum O 
of O 
pharmacological O 
activities O 
, O 
including O 
anti-bacterial O 
, O 
anti-inflammatory O 
, O 
anti-cancer O 
, O 
anti-diabetes O 
, O 
and O 
hepatoprotective O 
activities O 
; O 
recently O 
, O 
it O 
has O 
also O 
been O 
shown O 
to O 
have O 
neuroprotective O 
activities O 
. O 
This O 
review O 
summarizes O 
the O 
current O 
research O 
on O 
the O 
biological O 
effects O 
of O 
macelignan B-TRIVIAL 
derived O 
from O 
M O 
. O 
fragrans O 
, O 
with O 
emphasis O 
on O 
the O 
importance O 
in O 
understanding O 
and O 
treating O 
complex O 
diseases O 
such O 
as O 
cancer O 
and O 
Alzheimer's O 
disease O 
. O 

is O 
a O 
cellular O 
energy O 
sensor O 
conserved O 
across O 
eukaryotes O 
that O 
in O 
C O 
. O 
elegans O 
prolongs O 
life O 
span O 
and O 
mimics O 
dietary O 
restriction O 
. O 
Stenesen O 
and O 
colleagues O 
( O 
2012 O 
) O 
activate O 
AMPK O 
both O 
directly O 
and O 
indirectly O 
by O 
altering O 
AMP B-ABBREVIATION 
biosynthesis O 
to O 
slow O 
aging O 
in O 
Drosophila O 
, O 
highlighting O 
AMPK O 
as O 
a O 
conserved O 
life O 
span O 
modulator O 
that O 
links O 
energy O 
sensing O 
to O 
longevity O 
. O 

90-day O 
oral O 
( O 
dietary O 
) O 
toxicity O 
study O 
of O 
arruva B-FAMILY 
, O 
an O 
R B-TRIVIAL 
, I-TRIVIAL 
R-monatin I-TRIVIAL 
salt O 
isomer O 
, O 
in O 
Crl O 
: O 
CD-1(ICR) O 
mice O 
. O 

[ O 
2R,4R- B-SYSTEMATIC 
isomer I-SYSTEMATIC 
of I-SYSTEMATIC 
2-hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric I-SYSTEMATIC 
acid I-SYSTEMATIC 
] O 
is O 
one O 
of O 
four O 
natural O 
constituent O 
isomers O 
in O 
the O 
root O 
bark O 
of O 
Sclerochitin O 
ilicifolius O 
; O 
and O 
" O 
arruva B-FAMILY 
" O 
is O 
the O 
common O 
/ O 
usual O 
name O 
that O 
is O 
proposed O 
to O 
represent O 
R,R-monatin B-TRIVIAL 
salt O 
forms O 
, O 
which O 
have O 
potential O 
use O 
as O 
high O 
potency O 
sweetener O 
food O 
ingredients O 
. O 
In O 
the O 
present O 
study O 
, O 
groups O 
of O 
male O 
and O 
female O 
Crl O 
: O 
CD-1(ICR) O 
mice O 
were O 
exposed O 
to O 
0 O 
( O 
control O 
) O 
, O 
5000 O 
, O 
10000 O 
, O 
20000 O 
, O 
or O 
35,000ppm O 
of O 
arruva B-FAMILY 
in O 
the O 
diet O 
for O 
90days O 
. O 
There O 
were O 
no O 
toxicologically O 
relevant O 
clinical O 
or O 
histopathological O 
findings O 
in O 
any O 
of O 
the O 
test O 
article O 
- O 
treated O 
groups O 
. O 
Significantly O 
lower O 
mean O 
body O 
weights O 
and O 
cumulative O 
body O 
weight O 
gains O 
were O 
noted O 
in O 
the O 
35,000ppm O 
group O 
when O 
compared O 
to O 
the O 
control O 
group O 
. O 
Mean O 
body O 
weights O 
in O 
the O 
35,000ppm O 
group O 
males O 
and O 
females O 
were O 
9% O 
and O 
7% O 
less O 
than O 
the O 
control O 
group O 
, O 
respectively O 
, O 
at O 
week O 
13 O 
. O 
In O 
the O 
absence O 
of O 
observations O 
associated O 
with O 
systemic O 
toxicity O 
and O 
in O 
consideration O 
of O 
the O 
magnitude O 
of O 
body O 
weight O 
difference O 
, O 
these O 
effects O 
were O 
not O 
considered O 
toxicologically O 
significant O 
. O 
Based O 
on O 
the O 
results O 
of O 
this O 
study O 
, O 
the O 
dietary O 
no O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
level O 
( O 
NOAEL O 
) O 
of O 
arruva B-FAMILY 
for O 
90days O 
in O 
male O 
and O 
female O 
mice O 
was O 
35,000ppm O 
( O 
equivalent O 
to O 
an O 
exposure O 
level O 
of O 
5764 O 
and O 
8013mg O 
/ O 
kg O 
bw O 
/ O 
day O 
, O 
respectively O 
) O 
. O 

of O 
xyloglucan O 
endotransglucosylase O 
/ O 
hydrolase O 
genes O 
( O 
XTHs O 
) O 
and O 
their O 
expression O 
in O 
persimmon O 
fruit O 
as O 
influenced O 
by O 
1-methylcyclopropene B-SYSTEMATIC 
and O 
gibberellic B-TRIVIAL 
acid I-TRIVIAL 
during O 
storage O 
at O 
ambient O 
temperature O 
. O 

endotransglucosylase O 
/ O 
hydrolase O 
( O 
XTH O 
) O 
is O 
thought O 
to O 
contribute O 
to O 
fruit O 
softening O 
by O 
degrading O 
xyloglucan O 
that O 
is O 
a O 
predominant O 
hemicellulose O 
in O 
the O 
cell O 
wall O 
. O 
In O 
this O 
study O 
, O 
two O 
full O 
- O 
length O 
XTH O 
genes O 
( O 
DKXTH1 O 
and O 
DKXTH2 O 
) O 
were O 
identified O 
from O 
' O 
Fupingjianshi O 
' O 
persimmon O 
fruit O 
, O 
and O 
the O 
expression O 
level O 
of O 
both O 
XTH O 
genes O 
was O 
investigated O 
during O 
softening O 
for O 
18-24 O 
d O 
using O 
RT-qPCR O 
. O 
Sequence O 
analysis O 
showed O 
that O 
DKXTH1 O 
and O 
DKXTH2 O 
contained O 
a O 
putative O 
open O 
reading O 
frame O 
of O 
861 O 
and O 
876 O 
bp O 
encoding O 
polypeptides O 
of O 
287 O 
and O 
292 O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
, O 
respectively O 
, O 
which O 
contained O 
the O 
conserved O 
DEIDFEFLG O 
motif O 
of O 
XTH O 
, O 
a O 
potential O 
N- O 
linked O 
glycosylation O 
signal O 
site O 
. O 
RT-qPCR O 
analysis O 
showed O 
that O 
DKXTH1 O 
and O 
DKXTH2 O 
in O 
untreated O 
fruit O 
had O 
different O 
expression O 
patterns O 
during O 
fruit O 
softening O 
, O 
in O 
which O 
maximum O 
expression O 
occurred O 
on O 
days O 
3 O 
and O 
12 O 
of O 
ripening O 
, O 
respectively O 
. O 
1-Methylcyclopropene B-SYSTEMATIC 
( O 
1-MCP B-SYSTEMATIC 
) O 
and O 
gibberellic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA(3) B-ABBREVIATION 
) O 
treatments O 
delayed O 
the O 
softening O 
and O 
ethylene B-SYSTEMATIC 
peak O 
of O 
persimmon O 
fruit O 
, O 
as O 
well O 
as O 
suppressed O 
the O 
expression O 
of O 
both O 
XTH O 
genes O 
, O 
especially O 
DKXTH1 O 
. O 
These O 
results O 
indicated O 
that O 
the O 
expression O 
of O 
both O 
XTH O 
genes O 
might O 
be O 
ethylene B-SYSTEMATIC 
dependent O 
action O 
, O 
and O 
closely O 
related O 
to O 
softening O 
of O 
persimmon O 
in O 
the O 
early O 
( O 
DKXTH1 O 
) O 
and O 
later O 
( O 
DKXTH2 O 
) O 
ripening O 
stages O 
. O 

analysis O 
of O 
sugars B-FAMILY 
in O 
honey O 
by O 
processing O 
Raman O 
spectrum O 
using O 
chemometric O 
methods O 
and O 
artificial O 
neural O 
networks O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
quantify O 
glucose B-TRIVIAL 
, O 
fructose B-TRIVIAL 
, O 
sucrose B-TRIVIAL 
and O 
maltose B-TRIVIAL 
contents O 
of O 
honey O 
samples O 
using O 
Raman O 
spectroscopy O 
as O 
a O 
rapid O 
method O 
. O 
By O 
performing O 
a O 
single O 
measurement O 
, O 
quantifications O 
of O 
sugar B-FAMILY 
contents O 
have O 
been O 
said O 
to O 
be O 
unaffordable O 
according O 
to O 
the O 
molecular O 
similarities O 
between O 
sugar B-FAMILY 
molecules O 
in O 
honey O 
matrix O 
. O 
This O 
bottleneck O 
was O 
overcome O 
by O 
coupling O 
Raman O 
spectroscopy O 
with O 
chemometric O 
methods O 
( O 
principal O 
component O 
analysis O 
( O 
PCA O 
) O 
and O 
partial O 
least O 
squares O 
( O 
PLS O 
) O 
) O 
and O 
an O 
artificial O 
neural O 
network O 
( O 
ANN O 
) O 
. O 
Model O 
solutions O 
of O 
four O 
sugars B-FAMILY 
were O 
processed O 
with O 
PCA O 
and O 
significant O 
separation O 
was O 
observed O 
. O 
This O 
operation O 
, O 
done O 
with O 
the O 
spectral O 
features O 
by O 
using O 
PLS O 
and O 
ANN O 
methods O 
, O 
led O 
to O 
the O 
discriminant O 
analysis O 
of O 
sugar B-FAMILY 
contents O 
. O 
Models O 
/ O 
trained O 
networks O 
were O 
created O 
using O 
a O 
calibration O 
data O 
set O 
and O 
evaluated O 
using O 
a O 
validation O 
data O 
set O 
. O 
The O 
correlation O 
coefficient O 
values O 
between O 
actual O 
and O 
predicted O 
values O 
of O 
glucose B-TRIVIAL 
, O 
fructose B-TRIVIAL 
, O 
sucrose B-TRIVIAL 
and O 
maltose B-TRIVIAL 
were O 
determined O 
as O 
0.964 O 
, O 
0.965 O 
, O 
0.968 O 
and O 
0.949 O 
for O 
PLS O 
and O 
0.965 O 
, O 
0.965 O 
, O 
0.978 O 
and O 
0.956 O 
for O 
ANN O 
, O 
respectively O 
. O 
The O 
requirement O 
of O 
rapid O 
analysis O 
of O 
sugar B-FAMILY 
contents O 
of O 
commercial O 
honeys O 
has O 
been O 
met O 
by O 
the O 
data O 
processed O 
within O 
this O 
article O 
. O 

and O 
biological O 
evaluation O 
of O 
novel O 
aliphatic B-FAMILY 
amido I-FAMILY 
- I-FAMILY 
quaternary I-FAMILY 
ammonium I-FAMILY 
salts I-FAMILY 
for O 
anticancer O 
chemotherapy O 
: O 
Part O 
II O 
. O 

series O 
of O 
novel O 
aliphatic B-FAMILY 
amido I-FAMILY 
- I-FAMILY 
quaternary I-FAMILY 
ammonium I-FAMILY 
salts I-FAMILY 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
anticancer O 
effects O 
involving O 
induction O 
of O 
RhoB O 
. O 
Most O 
of O 
these O 
compounds O 
, O 
featuring O 
open O 
- O 
ring O 
forms O 
of O 
aliphatic B-FAMILY 
amido I-FAMILY 
- I-FAMILY 
quaternary I-FAMILY 
ammonium I-FAMILY 
salts I-FAMILY 
, O 
exhibited O 
potent O 
anti-proliferative O 
activities O 
in O 
human O 
cancer O 
cell O 
lines O 
, O 
including O 
PC-3 O 
, O 
NUGC-3 O 
, O 
MDA-MB-231 O 
, O 
ACHN O 
, O 
HCT O 
- O 
15 O 
, O 
and O 
NCI-H23 O 
. O 
In O 
further O 
evaluation O 
, O 
the O 
representative O 
compound O 
N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
3b O 
) O 
exhibited O 
potent O 
pro O 
- O 
apoptotic O 
activity O 
, O 
through O 
RhoB O 
activation O 
, O 
in O 
HeLa O 
cells O 
. O 

clearance O 
, O 
distribution O 
, O 
metabolism O 
, O 
and O 
excretion O 
in O 
monkeys O 
following O 
intravenous O 
administration O 
. O 

, O 
a O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
)ylated O 
peptide O 
- O 
based O 
erythropoiesis O 
- O 
stimulating O 
agent O 
, O 
stimulates O 
the O 
erythropoietin O 
receptor O 
dimer O 
that O 
governs O 
erythropoiesis O 
. O 
Studies O 
were O 
designed O 
to O 
determine O 
the O 
erythropoietic O 
response O 
, O 
pharmacokinetics O 
( O 
PK O 
) O 
, O 
tissue O 
distribution O 
, O 
metabolism O 
, O 
and O 
excretion O 
of O 
peginesatide B-TRIVIAL 
in O 
nonhuman O 
primates O 
following O 
a O 
single O 
i.v O 
. O 
dose O 
. O 
The O 
PK O 
profile O 
of O 
peginesatide B-TRIVIAL 
( O 
0.1-5 O 
mg O 
/ O 
kg O 
) O 
is O 
characterized O 
by O 
low O 
, O 
dose O 
- O 
dependent O 
plasma O 
clearance O 
; O 
small O 
volume O 
of O 
distribution O 
; O 
and O 
long O 
half O 
- O 
life O 
. O 
The O 
peginesatide B-TRIVIAL 
PK O 
profile O 
following O 
a O 
single O 
i.v O 
. O 
dose O 
is O 
consistent O 
with O 
the O 
sustained O 
erythropoiesis O 
. O 
Biodistribution O 
quantitative O 
whole O 
- O 
body O 
autoradiography O 
demonstrated O 
high O 
peginesatide B-TRIVIAL 
levels O 
in O 
bone O 
marrow O 
( O 
i.e O 
. O 
, O 
primary O 
hematopoietic O 
site O 
) O 
as O 
well O 
as O 
other O 
known O 
hematopoietic O 
sites O 
persisting O 
through O 
at O 
least O 
3 O 
weeks O 
at O 
2.1 O 
mg O 
/ O 
kg O 
. O 
Microautoradiography O 
analysis O 
at O 
48 O 
hours O 
postdose O 
revealed O 
uniform O 
and O 
high O 
distribution O 
of O 
radioactivity O 
in O 
the O 
bone O 
marrow O 
and O 
splenic O 
red O 
pulp O 
with O 
less O 
extensive O 
distribution O 
in O 
the O 
renal O 
cortex O 
( O 
glomeruli O 
, O 
associated O 
ducts O 
, O 
interstitial O 
cells O 
) O 
. O 
Radioactivity O 
in O 
the O 
kidney O 
was O 
most O 
prominent O 
in O 
the O 
outer O 
medullary O 
and O 
papillary O 
interstitium O 
. O 
At O 
2 O 
weeks O 
after O 
dosing O 
, O 
cumulative O 
radioactivity O 
recovery O 
in O 
the O 
urine O 
and O 
feces O 
was O 
60 O 
and O 
7% O 
of O 
the O 
administered O 
dose O 
, O 
respectively O 
, O 
with O 
most O 
of O 
the O 
radioactivity O 
associated O 
with O 
the O 
parent O 
molecule O 
. O 
In O 
conclusion O 
, O 
the O 
PK O 
characteristics O 
are O 
consistent O 
with O 
a O 
PEGylated O 
peptide O 
of O 
a O 
45-kDa O 
molecular O 
mass O 
, O 
specifically O 
low O 
volume O 
of O 
distribution O 
and O 
long O 
half O 
- O 
life O 
. O 
Drug O 
was O 
localized O 
principally O 
to O 
hematopoietic O 
sites O 
, O 
and O 
nonspecific O 
tissue O 
retention O 
was O 
not O 
observed O 
. O 
The O 
nonhuman O 
primate O 
data O 
indicate O 
that O 
peginesatide B-TRIVIAL 
is O 
metabolically O 
stable O 
and O 
primarily O 
excreted O 
in O 
the O 
urine O 
. O 

of O 
Ciliatamide B-TRIVIAL 
D I-TRIVIAL 
from O 
a O 
Marine O 
Sponge O 
Stelletta O 
sp O 
. O 
and O 
a O 
Reinvestigation O 
of O 
the O 
Configuration O 
of O 
Ciliatamide B-TRIVIAL 
A I-TRIVIAL 
. O 

new O 
lipopeptide O 
, O 
ciliatamide B-TRIVIAL 
D I-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
a O 
marine O 
sponge O 
Stelletta O 
sp O 
. O 
, O 
collected O 
at O 
Oshimashinsone O 
, O 
together O 
with O 
the O 
known O 
compound O 
ciliatamide B-TRIVIAL 
A I-TRIVIAL 
( O 
2 O 
) O 
. O 
Ciliatamide B-TRIVIAL 
D I-TRIVIAL 
( O 
1 O 
) O 
is O 
a O 
congener O 
of O 
2 O 
, O 
in O 
which O 
N-Me-Phe B-FORMULA 
is O 
replaced O 
by O 
N-Me-Met B-FORMULA 
(O) I-FORMULA 
. O 
Marfey's O 
analysis O 
of O 
the O 
acid O 
hydrolysate O 
of O 
1 O 
demonstrated O 
that O 
the O 
two O 
constituent O 
amino B-FAMILY 
acids I-FAMILY 
were O 
both O 
in O 
the O 
l O 
- O 
form O 
. O 
This O 
result O 
prompted O 
us O 
to O 
carefully O 
investigate O 
the O 
configuration O 
of O 
2 O 
, O 
resulting O 
in O 
the O 
assignment O 
of O 
the O 
l O 
- O 
form O 
for O 
both O 
residues O 
. O 

bladder O 
distension O 
causes O 
various O 
morphological O 
and O 
functional O 
changes O 
, O 
in O 
part O 
through O 
altered O 
gene O 
expression O 
. O 
We O 
aimed O 
to O 
investigate O 
the O 
physiological O 
role O 
of O 
PTHrP O 
, O 
which O 
is O 
upregulated O 
in O 
an O 
acute O 
bladder O 
distension O 
model O 
in O 
female O 
rats O 
. O 
In O 
the O 
control O 
Empty O 
group O 
, O 
bladders O 
were O 
kept O 
empty O 
for O 
6 O 
h O 
, O 
and O 
in O 
the O 
Distension O 
group O 
, O 
bladders O 
were O 
kept O 
distended O 
for O 
3 O 
h O 
after O 
an O 
artificial O 
storing O 
- O 
voiding O 
cycle O 
for O 
3 O 
h O 
. O 
In O 
the O 
Distention O 
group O 
bladder O 
, O 
upregulation O 
of O 
transcripts O 
was O 
noted O 
for O 
three O 
genes O 
reported O 
to O 
be O 
upregulated O 
by O 
stretch O 
in O 
the O 
cultured O 
bladder O 
smooth O 
muscle O 
cells O 
( O 
BSMC O 
) O 
in O 
vitro O 
. O 
Further O 
transcriptome O 
analysis O 
by O 
microarray O 
identified O 
PTHrP O 
as O 
the O 
2second O 
highest O 
gene O 
upregulated O 
in O 
Distension O 
group O 
bladder O 
, O 
among O 
more O 
than O 
27000 O 
genes O 
. O 
Localization O 
of O 
PTHrP O 
and O 
its O 
functional O 
receptor O 
, O 
PTH O 
/ O 
PTHrP O 
receptor O 
1(PTH1R) O 
, O 
were O 
analyzed O 
in O 
the O 
untreated O 
rat O 
bladders O 
and O 
cultured O 
bladder O 
cells O 
using O 
real O 
- O 
time O 
RT-PCR O 
and O 
immunoblotting O 
, O 
which O 
revealed O 
that O 
PTH1R O 
and O 
PTHrP O 
were O 
more O 
predominantly O 
expressed O 
in O 
smooth O 
muscle O 
than O 
in O 
urothelium O 
. O 
Exogenous O 
PTHrP O 
peptide O 
( O 
1-34 O 
) O 
increased O 
intracellular O 
cAMP B-ABBREVIATION 
level O 
in O 
cultured O 
BSMC O 
. O 
In O 
organ O 
bath O 
study O 
using O 
bladder O 
strips O 
, O 
the O 
PTHrP O 
peptide O 
caused O 
a O 
marked O 
reduction O 
in O 
the O 
amplitude O 
of O 
spontaneous O 
contraction O 
, O 
but O 
caused O 
only O 
modest O 
suppression O 
for O 
carbachol B-TRIVIAL 
-induced O 
contraction O 
. O 
In O 
in O 
vivo O 
functional O 
study O 
by O 
cystometrogram O 
, O 
the O 
PTHrP O 
peptide O 
decreased O 
voiding O 
pressure O 
and O 
increased O 
bladder O 
compliance O 
. O 
Thus O 
, O 
PTHrP O 
is O 
a O 
potent O 
endogenous O 
relaxant O 
of O 
bladder O 
contraction O 
, O 
and O 
autocrine O 
or O 
paracrine O 
mechanism O 
of O 
PTHrP-PTH1R O 
axis O 
is O 
a O 
physiologically O 
relevant O 
pathway O 
functioning O 
in O 
the O 
bladder O 
. O 

and O 
bond O 
activation O 
in O 
complexes O 
of O 
regioisomeric O 
phenylpyridines B-FAMILY 
with O 
the O 
nickel B-SYSTEMATIC 
(II) I-SYSTEMATIC 
chloride I-SYSTEMATIC 
cation O 
in O 
the O 
gas O 
phase O 
. O 

ionization O 
of O 
dilute O 
solutions O 
of O 
phenylpyridines B-FAMILY 
( O 
phpy B-ABBREVIATION 
) O 
in O 
the O 
presence O 
of O 
nickel B-SYSTEMATIC 
(II) I-SYSTEMATIC 
chloride I-SYSTEMATIC 
leads O 
to O 
gaseous O 
ions O 
of O 
the O 
type O 
[Ni(phpy)(m)](2+) B-FAMILY 
with O 
m O 
= O 
3-5 O 
and O 
[NiCl(phpy)(n)](+) B-FAMILY 
with O 
n O 
= O 
1-3 O 
, O 
which O 
are O 
characterized O 
by O 
various O 
gas-phase O 
experiments O 
in O 
combination O 
with O 
calculations O 
using O 
density O 
functional O 
theory O 
. O 
Of O 
the O 
regioisomeric O 
phpy B-ABBREVIATION 
' O 
s O 
, O 
2-phpy B-SYSTEMATIC 
behaves O 
drastically O 
different O 
compared O 
to O 
3- B-MULTIPLE 
and I-MULTIPLE 
4-phpy I-MULTIPLE 
. O 
Ion O 
mobility O 
mass O 
spectrometry O 
allows O 
a O 
differentiation O 
of O 
the O 
gaseous O 
ions O 
and O 
an O 
elucidation O 
of O 
characteristic O 
properties O 
of O 
the O 
metal O 
complexes O 
. O 
For O 
2-phpy B-SYSTEMATIC 
, O 
C-H B-FORMULA 
bond O 
activation O 
in O 
the O 
[NiCl(phpy)(2)](+) B-FORMULA 
complex O 
is O 
significant O 
, O 
whereas O 
this O 
route O 
is O 
almost O 
suppressed O 
for O 
the O 
corresponding O 
complexes O 
of O 
3- B-MULTIPLE 
and I-MULTIPLE 
4-phpy I-MULTIPLE 
and O 
only O 
occurs O 
at O 
elevated O 
energies O 
. O 

of O 
TiO(2) B-FORMULA 
nanoparticles O 
influences O 
their O 
phototoxicity O 
: O 
an O 
in O 
vitro O 
investigation O 
. O 

uncover O 
the O 
size O 
influence O 
of O 
TiO(2) B-FORMULA 
nanoparticles O 
on O 
their O 
potential O 
toxicity O 
, O 
the O 
cytotoxicity O 
of O 
different-sized O 
TiO(2) B-FORMULA 
nanoparticles O 
with O 
and O 
without O 
photoactivation O 
was O 
tested O 
. O 
It O 
was O 
demonstrated O 
that O 
without O 
photoactivation O 
, O 
TiO(2) B-FORMULA 
nanoparticles O 
were O 
inert O 
up O 
to O 
100 O 
μg O 
/ O 
ml O 
. O 
On O 
the O 
contrary O 
, O 
with O 
photoactivation O 
, O 
the O 
toxicity O 
of O 
TiO(2) B-FORMULA 
nanoparticles O 
significantly O 
increased O 
, O 
which O 
correlated O 
well O 
with O 
the O 
specific O 
surface O 
area O 
of O 
the O 
particles O 
. O 
Our O 
results O 
also O 
suggest O 
that O 
the O 
generation O 
of O 
hydroxyl B-SYSTEMATIC 
radicals O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
- O 
mediated O 
damage O 
to O 
the O 
surface O 
- O 
adsorbed O 
biomolecules O 
could O 
be O 
the O 
two O 
major O 
reasons O 
for O 
the O 
cytotoxicity O 
of O 
TiO(2) B-FORMULA 
nanoparticles O 
after O 
photoactivation O 
. O 
Higher O 
ROS O 
generation O 
from O 
smaller O 
particles O 
was O 
detected O 
under O 
both O 
biotic O 
and O 
abiotic O 
conditions O 
. O 
Smaller O 
particles O 
could O 
adsorb O 
more O 
proteins O 
, O 
which O 
was O 
confirmed O 
by O 
thermogravimetric O 
analysis O 
. O 
To O 
further O 
investigate O 
the O 
influence O 
of O 
the O 
generation O 
of O 
hydroxyl B-SYSTEMATIC 
radicals O 
and O 
adsorption O 
of O 
protein O 
, O 
poly B-FAMILY 
( I-FAMILY 
ethylene I-FAMILY 
- I-FAMILY 
alt I-FAMILY 
- I-FAMILY 
maleic I-FAMILY 
anhydride I-FAMILY 
) I-FAMILY 
( O 
PEMA B-ABBREVIATION 
) O 
and O 
chitosan O 
were O 
used O 
to O 
coat O 
TiO(2) B-FORMULA 
nanoparticles O 
. O 
The O 
results O 
confirmed O 
that O 
surface O 
coating O 
of O 
TiO(2) B-FORMULA 
nanoparticles O 
could O 
reduce O 
such O 
toxicity O 
after O 
photoactivation O 
, O 
by O 
hindering O 
adsorption O 
of O 
biomolecules O 
and O 
generation O 
of O 
hydroxyl B-SYSTEMATIC 
radical O 
( O 
·OH B-FORMULA 
) O 
during O 
photoactivation O 
. O 

sulfonamide B-SYSTEMATIC 
compounds O 
for O 
inhibition O 
of O 
metastatic O 
tumor O 
growth O 
( O 
WO2012021963 O 
) O 
. O 

series O 
of O 
novel O 
ureido B-FAMILY 
- I-FAMILY 
sulfonamides I-FAMILY 
was O 
prepared O 
by O 
reaction O 
of O 
aminobenzenesulfonamide B-SYSTEMATIC 
with O 
alkyl B-MULTIPLE 
/ I-MULTIPLE 
aryl I-MULTIPLE 
isocyanate I-MULTIPLE 
. O 
These O 
compounds O 
are O 
claimed O 
for O 
use O 
as O 
therapeutic O 
agents O 
of O 
metastatic O 
tumors O 
, O 
which O 
are O 
poorly O 
responsive O 
to O 
classical O 
chemotherapies O 
and O 
constitute O 
a O 
conceptually O 
novel O 
approach O 
for O 
cancer O 
treatment O 
. O 

effects O 
of O 
magnesium B-SYSTEMATIC 
on O 
copper B-SYSTEMATIC 
toxicity O 
and O 
accumulation O 
in O 
grapevine O 
roots O 
evaluated O 
with O 
biotic O 
ligand O 
models O 
. O 

toxicity O 
and O 
accumulation O 
in O 
plants O 
are O 
affected O 
by O 
physicochemical O 
characteristics O 
of O 
soil O 
solutions O 
such O 
as O 
the O 
concentrations O 
of O 
coexistent O 
cations O 
( O 
e.g O 
. O 
, O 
Ca(2+) B-FORMULA 
, O 
Mg(2+) B-FORMULA 
, O 
K(+) B-FORMULA 
, O 
Na(+) B-FORMULA 
, O 
and O 
H(+) B-FORMULA 
) O 
. O 
The O 
biotic O 
ligand O 
model O 
( O 
BLM O 
) O 
approach O 
has O 
been O 
proposed O 
to O 
predict O 
metal O 
phyto O 
- O 
toxicity O 
and O 
-accumulation O 
by O 
taking O 
into O 
account O 
the O 
effects O 
of O 
coexistent O 
cations O 
, O 
given O 
the O 
assumption O 
of O 
the O 
partition O 
equilibrium O 
of O 
metal O 
ions O 
between O 
soil O 
solution O 
and O 
solid O 
phase O 
. O 
The O 
alleviation O 
effects O 
of O 
Mg B-FORMULA 
on O 
Cu B-FORMULA 
toxicity O 
and O 
accumulation O 
in O 
grapevine O 
roots O 
were O 
the O 
main O 
concerns O 
in O 
this O 
study O 
and O 
were O 
investigated O 
by O 
using O 
a O 
hydroponic O 
experiment O 
of O 
grapevine O 
cuttings O 
. O 
The O 
BLM O 
approach O 
, O 
which O 
incorporated O 
competition O 
of O 
Mg(2+) B-FORMULA 
with O 
Cu(2+) B-FORMULA 
to O 
occupy O 
the O 
biotic O 
ligands O 
on O 
root O 
surfaces O 
, O 
was O 
developed O 
to O 
predict O 
Cu B-FORMULA 
rhizotoxicity O 
and O 
accumulation O 
by O 
grapevine O 
roots O 
. O 
In O 
the O 
results O 
, O 
the O 
effective O 
activity O 
of O 
Cu B-FORMULA 
, O 
{ O 
Cu B-FORMULA 
( I-FORMULA 
2+ I-FORMULA 
) I-FORMULA 
} O 
, O 
resulting O 
in O 
a O 
50 O 
% O 
reduction O 
of O 
root O 
elongation O 
( O 
EA O 
( O 
50 O 
) O 
) O 
, O 
linearly O 
increased O 
with O 
increments O 
of O 
Mg B-FORMULA 
activity O 
, O 
{ O 
Mg B-FORMULA 
( I-FORMULA 
2+ I-FORMULA 
) I-FORMULA 
} O 
. O 
In O 
addition O 
, O 
the O 
Cu B-FORMULA 
concentration O 
in O 
root O 
, O 
Cu B-FORMULA 
( O 
root O 
) O 
, O 
was O 
retarded O 
by O 
an O 
increase O 
of O 
{ O 
Mg B-FORMULA 
( I-FORMULA 
2+ I-FORMULA 
) I-FORMULA 
} O 
. O 
The O 
linear O 
model O 
was O 
significantly O 
fitted O 
to O 
the O 
relationship O 
between O 
{ O 
Cu B-FORMULA 
( I-FORMULA 
2+ I-FORMULA 
) I-FORMULA 
}/ O 
Cu B-FORMULA 
( O 
root O 
) O 
and O 
{ O 
Mg B-FORMULA 
( I-FORMULA 
2+ I-FORMULA 
) I-FORMULA 
} O 
. O 
According O 
to O 
the O 
concept O 
of O 
BLM O 
, O 
the O 
present O 
results O 
revealed O 
that O 
the O 
amelioration O 
effects O 
of O 
Mg B-FORMULA 
on O 
Cu B-FORMULA 
toxicity O 
and O 
accumulation O 
in O 
roots O 
could O 
arise O 
from O 
competition O 
between O 
Mg(2+) B-FORMULA 
and O 
Cu(2+) B-FORMULA 
on O 
the O 
binding O 
sites O 
( O 
i.e O 
. O 
, O 
the O 
biotic O 
ligands O 
) O 
. O 
Then O 
, O 
the O 
developed O 
Cu B-FORMULA 
-BLMs O 
incorporating O 
the O 
Mg(2+) B-FORMULA 
competition O 
effectiveness O 
were O 
validated O 
provide O 
accurate O 
predictions O 
of O 
Cu B-FORMULA 
toxicity O 
and O 
accumulation O 
in O 
grapevine O 
roots O 
. O 
To O 
our O 
knowledge O 
this O 
is O 
the O 
first O 
report O 
of O 
the O 
successful O 
development O 
of O 
BLMs O 
for O 
a O 
woody O 
plant O 
. O 
This O 
BLM O 
approach O 
shows O 
promise O 
of O 
being O 
widely O 
applicable O 
for O 
various O 
terrestrial O 
plants O 
. O 

of O 
enzymatic O 
and O 
non-enzymatic O 
juice O 
pressing O 
on O 
key O 
orosensory O 
and O 
chemical O 
quality O 
factors O 
of O 
blackcurrant O 
juices O 
were O 
studied O 
in O 
laboratory O 
scale O 
using O 
berries O 
of O 
five O 
different O 
cultivars O 
( O 
Mortti O 
, O 
Mikael O 
, O 
Marski O 
, O 
Ola O 
and O 
Breed15 O 
) O 
. O 
Enzymatic O 
processing O 
increased O 
the O 
juice O 
yield O 
by O 
10-22% O 
and O 
the O 
content O 
of O 
various O 
phenolic B-FAMILY 
compounds O 
in O 
juice O 
by O 
4-10-fold O 
as O 
compared O 
to O 
the O 
non-enzymatic O 
process O 
. O 
Higher O 
intensity O 
of O 
the O 
mouth O 
- O 
drying O 
astringency O 
of O 
the O 
enzyme O 
- O 
aided O 
juice O 
was O 
the O 
most O 
significant O 
orosensory O 
difference O 
between O 
the O 
processes O 
. O 
Juices O 
of O 
different O 
blackcurrant O 
cultivars O 
varied O 
in O 
sweetness O 
, O 
sourness O 
and O 
bitterness O 
. O 
The O 
most O 
intensive O 
sensory O 
attributes O 
of O 
the O 
juices O 
were O 
sourness O 
and O 
puckering O 
astringency O 
regardless O 
of O 
processing O 
method O 
. O 
They O 
correlated O 
positively O 
with O 
each O 
other O 
and O 
were O 
contributed O 
by O 
acid O 
content O 
and O 
pH O 
. O 
In O 
enzyme O 
- O 
aided O 
juices O 
, O 
the O 
contents O 
of O 
flavonol B-FAMILY 
glycosides I-FAMILY 
and O 
hydroxycinnamic B-FAMILY 
acids I-FAMILY 
were O 
associated O 
with O 
mouth O 
- O 
drying O 
astringency O 
, O 
and O 
sugar B-FAMILY 
/ O 
acid O 
ratio O 
correlated O 
with O 
sweetness O 
. O 
These O 
correlations O 
were O 
less O 
clear O 
in O 
non O 
- O 
enzyme O 
juices O 
possibly O 
due O 
to O 
lower O 
content O 
of O 
phenolic B-FAMILY 
compounds O 
and O 
the O 
high O 
content O 
of O 
pectin O 
. O 

Chinese O 
medicine O 
( O 
TCM O 
) O 
and O 
Ayurveda O 
have O 
been O 
used O 
in O 
humans O 
for O 
thousands O 
of O 
years O 
. O 
While O 
the O 
link O 
to O 
a O 
particular O 
indication O 
has O 
been O 
established O 
in O 
man O 
, O 
the O 
mode-of O 
- O 
action O 
( O 
MOA O 
) O 
of O 
the O 
formulations O 
often O 
remains O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
aim O 
to O 
understand O 
the O 
MOA O 
of O 
formulations O 
used O 
in O 
traditional O 
medicine O 
using O 
an O 
in O 
silico O 
target O 
prediction O 
algorithm O 
, O 
which O 
aims O 
to O 
predict O 
protein O 
targets O 
( O 
and O 
hence O 
MOAs O 
) O 
, O 
given O 
the O 
chemical O 
structure O 
of O 
a O 
compound O 
. O 
Following O 
this O 
approach O 
we O 
were O 
able O 
to O 
establish O 
several O 
links O 
between O 
suggested O 
MOAs O 
and O 
experimental O 
evidence O 
. O 
In O 
particular O 
, O 
compounds O 
from O 
the O 
' O 
tonifying O 
and O 
replenishing O 
medicinal O 
' O 
class O 
from O 
TCM O 
exhibit O 
a O 
hypoglycemic O 
effect O 
which O 
can O 
be O 
related O 
to O 
activity O 
of O 
the O 
ingredients O 
against O 
the O 
Sodium B-SYSTEMATIC 
- O 
Glucose B-TRIVIAL 
Transporters O 
( O 
SGLT O 
) O 
1 O 
and O 
2 O 
as O 
well O 
as O 
Protein O 
Tyrosine B-TRIVIAL 
Phosphatase O 
( O 
PTP O 
) O 
. O 
Similar O 
results O 
were O 
obtained O 
for O 
Ayurvedic O 
anticancer O 
drugs O 
. O 
Here O 
, O 
both O 
primary O 
anticancer O 
targets O 
( O 
those O 
directly O 
involved O 
in O 
cancer O 
pathogenesis O 
) O 
such O 
as O 
steroid B-FAMILY 
-5-alpha-reductase O 
1 O 
and O 
2 O 
were O 
predicted O 
as O 
well O 
as O 
targets O 
which O 
act O 
synergistically O 
with O 
the O 
primary O 
target O 
, O 
such O 
as O 
the O 
efflux O 
pump O 
P-glycoprotein O 
( O 
P-gp O 
) O 
. O 
In O 
addition O 
, O 
we O 
were O 
able O 
to O 
elucidate O 
some O 
targets O 
which O 
may O 
point O 
us O 
to O 
novel O 
MOAs O 
as O 
well O 
as O 
explain O 
side O 
effects O 
. O 
Most O 
notably O 
, O 
GPBAR1 O 
, O 
which O 
was O 
predicted O 
as O 
a O 
target O 
for O 
both O 
' O 
tonifying O 
and O 
replenishing O 
medicinal O 
' O 
and O 
anticancer O 
classes O 
, O 
suggests O 
an O 
influence O 
of O 
the O 
compounds O 
on O 
metabolism O 
. O 
Understanding O 
the O 
MOA O 
of O 
these O 
compounds O 
is O 
beneficial O 
as O 
it O 
provides O 
a O 
resource O 
for O 
NMEs O 
with O 
possibly O 
higher O 
efficacy O 
in O 
the O 
clinic O 
than O 
those O 
identified O 
by O 
single O 
- O 
target O 
biochemical O 
assays O 
. O 

of O 
phagocyte O 
- O 
like O 
NADPH B-ABBREVIATION 
oxidase O 
by O 
cytokines O 
in O 
pancreatic O 
beta-cells O 
: O 
attenuation O 
of O 
oxidative O 
and O 
nitrosative O 
stress O 
by O 
2-bromopalmitate B-SYSTEMATIC 
. O 

- O 
like O 
NADPH B-ABBREVIATION 
oxidase O 
( O 
Nox2 O 
) O 
has O 
been O 
shown O 
to O 
play O 
regulatory O 
roles O 
in O 
the O 
metabolic O 
dysfunction O 
of O 
the O 
islet O 
β-cell O 
under O 
the O 
duress O 
of O 
glucolipotoxic O 
conditions O 
and O 
exposure O 
to O 
proinflammatory O 
cytokines O 
. O 
However O 
, O 
the O 
precise O 
mechanisms O 
underlying O 
Nox2 O 
activation O 
by O 
these O 
stimuli O 
remain O 
less O 
understood O 
. O 
To O 
this O 
end O 
, O 
we O 
report O 
a O 
time O 
- O 
dependent O 
phosphorylation O 
of O 
p47phox O 
, O 
a O 
cytosolic O 
subunit O 
of O 
Nox2 O 
, O 
by O 
cytomix O 
( O 
IL-1β O 
+ O 
TNFα O 
+ O 
IFNγ O 
) O 
in O 
insulin O 
- O 
secreting O 
INS-1 O 
832 O 
/ O 
13 O 
cells O 
. O 
Furthermore O 
, O 
cytomix O 
induced O 
the O 
expression O 
of O 
gp91phox O 
, O 
a O 
membrane O 
component O 
of O 
Nox2 O 
. O 
2-Bromopalmitate B-SYSTEMATIC 
( O 
2-BP B-SYSTEMATIC 
) O 
, O 
a O 
known O 
inhibitor O 
of O 
protein O 
palmitoylation O 
, O 
markedly O 
attenuated O 
cytokine O 
- O 
induced O 
, O 
Nox2 O 
- O 
mediated O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
and O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
- O 
mediated O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
generation O 
. O 
However O 
, O 
2-BP B-SYSTEMATIC 
failed O 
to O 
exert O 
any O 
significant O 
effects O 
on O 
cytomix O 
- O 
induced O 
CHOP O 
expression O 
, O 
a O 
marker O 
for O 
endoplasmic O 
reticulum O 
stress O 
. O 
Together O 
, O 
our O 
findings O 
identify O 
palmitoyltransferase O 
as O 
a O 
target O 
for O 
inhibition O 
of O 
cytomix O 
- O 
induced O 
oxidative O 
( O 
ROS O 
generation O 
) O 
and O 
nitrosative O 
( O 
NO B-FORMULA 
generation O 
) O 
stress O 
in O 
the O 
pancreatic O 
β-cell O 
. O 

cation-π O 
box O 
is O 
a O 
specific O 
phosphatidylcholine B-FAMILY 
membrane O 
targeting O 
motif O 
. O 

membrane O 
proteins O 
can O 
be O 
targeted O 
to O 
specific O 
organelles O 
or O 
the O 
plasma O 
membrane O 
by O 
differential O 
recognition O 
of O 
phospholipid O 
headgroups O 
. O 
While O 
molecular O 
determinants O 
of O 
specificity O 
for O 
several O 
headgroups O 
, O 
including O 
phosphatidylserine B-FAMILY 
and O 
phosphoinositides B-FAMILY 
are O 
well O 
defined O 
, O 
specific O 
recognition O 
of O 
the O 
headgroup O 
of O 
the O 
zwitterionic O 
phosphatidylcholine B-FAMILY 
( O 
PC O 
) O 
is O 
less O 
well O 
understood O 
. O 
In O 
cytosolic O 
proteins O 
the O 
cation-π O 
box O 
provides O 
a O 
suitable O 
receptor O 
for O 
choline B-FAMILY 
recognition O 
and O 
binding O 
through O 
the O 
trimethylammonium B-SYSTEMATIC 
moiety O 
. O 
In O 
PC O 
, O 
this O 
moiety O 
might O 
provide O 
a O 
sufficient O 
handle O 
to O 
bind O 
to O 
peripheral O 
proteins O 
via O 
a O 
cation-π O 
cage O 
, O 
where O 
the O 
π O 
systems O 
of O 
two O 
or O 
more O 
aromatic O 
residues O 
are O 
within O 
4-5 O 
Å O 
of O 
the O 
quaternary B-FAMILY 
amine I-FAMILY 
. O 
We O 
prove O 
this O 
hypothesis O 
by O 
engineering O 
the O 
cation-π O 
box O 
into O 
secreted O 
phosphatidylinositol B-TRIVIAL 
-specific O 
phospholipase O 
C O 
from O 
Staphylococcus O 
aureus O 
, O 
which O 
lacks O 
specific O 
PC O 
recognition O 
. O 
The O 
N254Y O 
/ O 
H258Y O 
variant O 
selectively O 
binds O 
PC O 
- O 
enriched O 
vesicles O 
, O 
and O 
X-ray O 
crystallography O 
reveals O 
N254Y O 
/ O 
H258Y O 
binds O 
choline B-FAMILY 
and O 
dibutyroylphosphatidylcholine B-SYSTEMATIC 
within O 
the O 
cation-π O 
motif O 
. O 
Such O 
simple O 
PC O 
recognition O 
motifs O 
could O 
be O 
engineered O 
into O 
a O 
wide O 
variety O 
of O 
secondary O 
structures O 
providing O 
a O 
generally O 
applicable O 
method O 
for O 
specific O 
recognition O 
of O 
PC O 
. O 

of O 
tertiary B-SYSTEMATIC 
amine I-SYSTEMATIC 
-derivatized O 
surfaces O 
to O 
control O 
protein O 
adhesion O 
. O 

oxidation O 
of O 
ω-tertiary B-SYSTEMATIC 
amine I-SYSTEMATIC 
self O 
- O 
assembled O 
thiol B-FAMILY 
monolayers O 
to O 
tertiary B-FAMILY 
amine I-FAMILY 
N-oxides I-FAMILY 
is O 
shown O 
to O 
transform O 
the O 
adhesion O 
of O 
model O 
proteins O 
lysozyme O 
and O 
fibrinogen O 
upon O 
them O 
. O 
Efficient O 
preparation O 
of O 
both O 
secondary B-MULTIPLE 
and I-MULTIPLE 
tertiary I-MULTIPLE 
linker I-MULTIPLE 
amides I-MULTIPLE 
as O 
judged O 
by O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
and O 
water O 
droplet O 
contact O 
angle O 
was O 
achieved O 
with O 
an O 
improved O 
amide B-FAMILY 
bond O 
formation O 
on O 
gold O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
( O 
QCM O 
) O 
sensors O 
using O 
2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl B-SYSTEMATIC 
hexafluorophosphate I-SYSTEMATIC 
methanaminium I-SYSTEMATIC 
uronium I-SYSTEMATIC 
( O 
HATU B-ABBREVIATION 
) O 
. O 
Oxidation O 
with O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
was O 
similarly O 
assessed O 
, O 
and O 
adhesion O 
of O 
lysozyme O 
and O 
fibrinogen O 
from O 
phosphate B-SYSTEMATIC 
buffered O 
saline O 
was O 
then O 
assayed O 
by O 
QCM O 
and O 
imaged O 
by O 
AFM O 
. O 
Tertiary B-FAMILY 
amine I-FAMILY 
-functionalized O 
sensors O 
adsorbed O 
multilayers O 
of O 
aggregated O 
lysozyme O 
, O 
whereas O 
tertiary B-FAMILY 
amine I-FAMILY 
N-oxides I-FAMILY 
and O 
triethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
-terminated O 
monolayers O 
are O 
consistent O 
with O 
small O 
protein O 
aggregates O 
. O 
The O 
surface O 
containing O 
a O 
dimethylamine B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
headgroup O 
and O 
ethyl B-SYSTEMATIC 
secondary I-SYSTEMATIC 
amide I-SYSTEMATIC 
linker O 
showed O 
the O 
largest O 
difference O 
in O 
adsorption O 
of O 
both O 
proteins O 
. O 
Oxidation O 
of O 
tertiary B-SYSTEMATIC 
amine I-SYSTEMATIC 
decorated O 
surfaces O 
therefore O 
holds O 
the O 
potential O 
for O 
selective O 
deposition O 
of O 
proteins O 
and O 
cells O 
through O 
masking O 
and O 
other O 
patterning O 
techniques O 
. O 

. O 
The O 
performance O 
of O 
low O 
background O 
( O 
BG O 
) O 
liquid O 
scintillation O 
counter O 
( O 
LSC O 
) O 
was O 
evaluated O 
for O 
practical O 
purposes O 
of O 
non-clinical O 
drug O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
and O 
excretion O 
( O 
ADME O 
) O 
studies O 
. O 
The O 
measurement O 
conditions O 
for O 
the O 
radioactivity O 
for O 
low O 
BG O 
LSC O 
were O 
investigated O 
and O 
metabolite O 
profiling O 
in O 
rat O 
plasma O 
after O 
single O 
oral O 
administration O 
of O 
(14)C B-FORMULA 
-labeled O 
compounds O 
was O 
performed O 
. O 
Metabolite O 
profiling O 
was O 
also O 
conducted O 
using O 
conventional O 
LSC O 
and O 
accelerator O 
mass O 
spectrometer O 
( O 
AMS O 
) O 
, O 
and O 
the O 
performances O 
of O 
these O 
measuring O 
instruments O 
were O 
compared O 
. O 
2 O 
. O 
The O 
established O 
measurement O 
conditions O 
showed O 
good O 
linearity O 
of O 
the O 
calibration O 
curve O 
over O 
the O 
concentration O 
range O 
from O 
3 O 
to O 
300 O 
dpm O 
/ O 
vial O 
. O 
Metabolite O 
profiling O 
using O 
low O 
BG O 
LSC O 
for O 
the O 
plasma O 
samples O 
diluted O 
to O 
5-55 O 
times O 
was O 
comparable O 
to O 
that O 
using O 
conventional O 
LSC O 
for O 
the O 
undiluted O 
plasma O 
samples O 
. O 
Meanwhile O 
, O 
metabolite O 
profiling O 
using O 
AMS O 
for O 
the O 
plasma O 
samples O 
diluted O 
to O 
250-2000 O 
times O 
was O 
comparable O 
to O 
that O 
using O 
conventional O 
LSC O 
. O 
3 O 
. O 
These O 
results O 
suggest O 
that O 
the O 
application O 
of O 
low O 
BG O 
LSC O 
is O 
one O 
of O 
the O 
useful O 
tools O 
for O 
non-clinical O 
ADME O 
studies O 
and O 
that O 
it O 
is O 
possible O 
to O 
select O 
conventional O 
LSC O 
, O 
low O 
BG O 
LSC O 
or O 
AMS O 
for O 
radioactivity O 
measurement O 
by O 
considering O 
the O 
specific O 
radioactivity O 
of O 
the O 
compounds O 
and O 
the O 
predicted O 
concentrations O 
of O 
radioactivity O 
in O 
biological O 
samples O 
in O 
ADME O 
studies O 
. O 

of O 
a O 
paraffin B-FAMILY 
phase O 
change O 
material O 
microencapsulated O 
in O 
a O 
siloxane B-SYSTEMATIC 
polymer O 
. O 

coemulsification O 
method O 
suitable O 
for O 
the O 
formulation O 
of O 
microcapsules O 
of O 
n-eicosane B-SYSTEMATIC 
coated O 
with O 
a O 
polysiloxane B-FAMILY 
is O 
developed O 
. O 
This O 
method O 
allows O 
to O 
synthesize O 
core O 
- O 
shell O 
microcapsules O 
of O 
paraffin B-FAMILY 
which O 
have O 
the O 
shape O 
of O 
spheres O 
or O 
distorted O 
spheres O 
and O 
are O 
designed O 
for O 
the O 
use O 
as O 
phase O 
change O 
materials O 
. O 
The O 
microcapsules O 
are O 
formed O 
in O 
aqueous O 
phase O 
by O 
the O 
precipitation O 
of O 
n-eicosane B-SYSTEMATIC 
together O 
with O 
modified O 
polyhydromethylsiloxane B-FAMILY 
from O 
a O 
common O 
solvent O 
which O 
is O 
miscible O 
with O 
aqueous O 
media O 
. O 
The O 
polysiloxane B-FAMILY 
is O 
modified O 
by O 
the O 
attachment O 
of O 
silylvinyl B-SYSTEMATIC 
and O 
alkoxy B-FAMILY 
functions O 
before O 
coemulsification O 
with O 
the O 
paraffin B-FAMILY 
. O 
It O 
also O 
contains O 
the O 
Pt(0) B-TRIVIAL 
Karstedt I-TRIVIAL 
catalyst I-TRIVIAL 
. O 
The O 
microcapsules O 
formed O 
by O 
coemulsification O 
are O 
stabilized O 
by O 
the O 
in O 
situ O 
cross O 
- O 
linking O 
of O 
the O 
polysiloxane B-FAMILY 
shell O 
. O 
The O 
shell O 
is O 
additionally O 
modified O 
by O 
the O 
in O 
situ O 
generation O 
of O 
silanol B-SYSTEMATIC 
groups O 
which O 
provide O 
colloidal O 
stabilization O 
of O 
microspheres O 
in O 
aqueous O 
phase O 
. O 
Microcapsules O 
were O 
studied O 
by O 
DSC O 
, O 
SEM O 
, O 
optical O 
polarized O 
microscope O 
, O 
and O 
by O 
thermooptical O 
analysis O 
( O 
TOA O 
) O 
. O 

manufacturing O 
methods O 
offer O 
economic O 
and O 
quality O 
advantages O 
when O 
compared O 
with O 
batch O 
manufacturing O 
methods O 
. O 
In O 
continuous O 
manufacturing O 
, O 
one O 
requires O 
real O 
time O 
assurance O 
of O 
quality O 
of O 
product O 
via O 
the O 
implementation O 
of O 
PAT O 
tools O 
. O 
This O 
study O 
focuses O 
on O 
an O 
in O 
- O 
line O 
near O 
- O 
infrared O 
( O 
NIR O 
) O 
spectroscopic O 
method O 
for O 
determining O 
the O 
drug O 
content O 
of O 
powder O 
mixtures O 
and O 
tablets O 
during O 
a O 
continuous O 
tableting O 
process O 
. O 
Tablets O 
consisting O 
of O 
acetaminophen B-TRIVIAL 
( O 
20-30% O 
) O 
, O 
lactose B-TRIVIAL 
( O 
69.07-78.93% O 
) O 
and O 
magnesium B-SYSTEMATIC 
stearate I-SYSTEMATIC 
( O 
0.93-1.07% O 
) O 
were O 
prepared O 
in O 
a O 
continuous O 
direct O 
compression O 
line O 
that O 
consisted O 
of O 
two O 
loss O 
- O 
in O 
- O 
weight O 
feeders O 
, O 
one O 
for O 
acetaminophen B-TRIVIAL 
and O 
one O 
for O 
premixed O 
lactose B-TRIVIAL 
and O 
magnesium B-SYSTEMATIC 
stearate I-SYSTEMATIC 
, O 
and O 
a O 
continuous O 
mixer O 
followed O 
by O 
a O 
rotary O 
tablet O 
press O 
. O 
NIR O 
spectroscopy O 
was O 
applied O 
to O 
the O 
continuous O 
mixer O 
and O 
tablet O 
press O 
to O 
perform O 
a O 
100% O 
product O 
check O 
at O 
full O 
tableting O 
speed O 
. O 
The O 
UV-spectrophotometric O 
method O 
was O 
used O 
as O 
an O 
off O 
- O 
line O 
reference O 
method O 
to O 
determine O 
the O 
acetaminophen B-TRIVIAL 
content O 
in O 
the O 
samples O 
. O 
The O 
powder O 
mixture O 
and O 
tablet O 
samples O 
were O 
taken O 
during O 
the O 
process O 
for O 
the O 
calibration O 
of O 
continuous O 
mixer O 
and O 
tablet O 
press O 
, O 
respectively O 
. O 
For O 
the O 
continuous O 
mixer O 
, O 
model O 
creation O 
with O 
the O 
PLS O 
method O 
yielded O 
R-Square O 
and O 
RMSEC O 
( O 
root O 
mean O 
square O 
error O 
of O 
calibration O 
) O 
values O 
of O 
0.975% O 
and O 
0.56% O 
, O 
respectively O 
. O 
For O 
the O 
tablet O 
press O 
, O 
the O 
corresponding O 
R-Square O 
and O 
RMSEC O 
values O 
were O 
0.943% O 
and O 
0.75% O 
, O 
respectively O 
. O 
A O 
test O 
run O 
demonstrated O 
good O 
predictability O 
in O 
the O 
estimation O 
of O 
the O 
API O 
content O 
in O 
the O 
powder O 
mixtures O 
and O 
tablets O 
during O 
the O 
continuous O 
tableting O 
process O 
. O 
For O 
the O 
continuous O 
mixer O 
and O 
tablet O 
press O 
, O 
the O 
RMSEP O 
( O 
root O 
mean O 
square O 
error O 
of O 
prediction O 
) O 
values O 
were O 
0.96% O 
and O 
1.37% O 
, O 
respectively O 
. O 
This O 
study O 
demonstrates O 
that O 
an O 
NIR O 
instrument O 
capable O 
of O 
fast O 
spectra O 
acquisition O 
can O 
be O 
a O 
valuable O 
tool O 
for O 
the O 
in O 
- O 
line O 
monitoring O 
of O 
the O 
continuous O 
mixing O 
and O 
tableting O 
processes O 
. O 

activity O 
of O 
various O 
4- B-MULTIPLE 
and I-MULTIPLE 
5- I-MULTIPLE 
substituted I-MULTIPLE 
1-phenylnaphthalenes I-MULTIPLE 
. O 

cell O 
division O 
occurs O 
in O 
conjunction O 
with O 
the O 
formation O 
of O 
a O 
cytokinetic O 
Z-ring O 
structure O 
comprised O 
of O 
FtsZ O 
subunits O 
. O 
Agents O 
that O 
can O 
disrupt O 
Z-ring O 
formation O 
have O 
the O 
potential O 
, O 
through O 
this O 
unique O 
mechanism O 
, O 
to O 
be O 
effective O 
against O 
several O 
of O 
the O 
newly O 
emerging O 
multi O 
- O 
drug O 
resistant O 
strains O 
of O 
infectious O 
bacteria O 
. O 
1- B-MULTIPLE 
and I-MULTIPLE 
12-Aryl I-MULTIPLE 
substituted I-MULTIPLE 
benzo[c]phenanthridines I-MULTIPLE 
have O 
been O 
identified O 
as O 
antibacterial O 
agents O 
that O 
could O 
exert O 
their O 
activity O 
by O 
disruption O 
of O 
Z-ring O 
formation O 
. O 
Substituted O 
4- B-MULTIPLE 
and I-MULTIPLE 
5-amino-1-phenylnaphthalenes I-MULTIPLE 
represent O 
substructures O 
within O 
the O 
pharmacophore O 
of O 
these O 
benzo[c]phenanthridines B-FAMILY 
. O 
Several O 
4- B-MULTIPLE 
and I-MULTIPLE 
5- I-MULTIPLE 
substituted I-MULTIPLE 
1-phenylnaphthalenes I-MULTIPLE 
were O 
synthesized O 
and O 
evaluated O 
for O 
antibacterial O 
activity O 
against O 
Staphylococcus O 
aureus O 
and O 
Enterococcus O 
faecalis O 
. O 
The O 
impact O 
of O 
select O 
compounds O 
on O 
the O 
polymerization O 
dynamics O 
of O 
S. O 
aureus O 
FtsZ O 
was O 
also O 
assessed O 
. O 

this O 
study O 
, O 
the O 
ethanolic O 
extract O 
obtained O 
from O 
piquiá O 
pulp O 
was O 
assessed O 
for O 
genotoxicity O 
and O 
oxidative O 
stress O 
by O 
employing O 
the O 
micronucleus O 
test O 
in O 
bone O 
marrow O 
and O 
peripheral O 
blood O 
cells O 
in O 
addition O 
to O 
comet O 
, O 
thiobarbituric B-SYSTEMATIC 
- I-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substances O 
( O 
TBARS O 
) O 
, O 
and O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
assays O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
heart O 
. O 
Additionally O 
, O 
phytochemical O 
analyses O 
were O 
performed O 
to O 
identify O 
and O 
quantify O 
the O 
chemical O 
constituents O 
of O 
the O 
piquiá O 
extract O 
. O 
Wistar O 
rats O 
were O 
treated O 
by O 
gavage O 
with O 
an O 
ethanolic O 
extract O 
from O 
piquiá O 
pulp O 
( O 
75 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
for O 
14 O 
days O 
, O 
and O 
24 O 
h O 
prior O 
to O 
euthanasia O 
, O 
they O 
received O 
an O 
injection O 
of O 
saline O 
or O 
doxorubicin B-TRIVIAL 
( O 
15 O 
mg O 
/ O 
kg O 
body O 
weight O 
, O 
intraperoneally O 
) O 
. O 
The O 
results O 
demonstrated O 
that O 
piquiá O 
extract O 
at O 
the O 
tested O 
dose O 
was O 
genotoxic O 
but O 
not O 
mutagenic O 
, O 
and O 
it O 
increased O 
the O 
TBARS O 
levels O 
in O 
the O 
heart O 
. O 
Further O 
studies O 
are O 
required O 
to O 
fully O 
elucidate O 
how O 
the O 
properties O 
of O 
ethanolic O 
extract O 
of O 
piquiá O 
pulp O 
can O 
affect O 
human O 
health O 
. O 

α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
subtype O 
is O 
abundantly O 
expressed O 
in O 
the O 
central O 
nervous O 
system O 
and O 
in O 
the O 
periphery O 
. O 
Recent O 
evidence O 
suggests O 
that O 
α7 O 
nAChR O 
subtypes O 
, O 
which O 
can O 
be O 
activated O 
by O 
an O 
endogenous O 
cholinergic O 
tone O 
, O 
comprising O 
acetylcholine B-SYSTEMATIC 
and O 
the O 
α7 O 
nAChR O 
agonist O 
choline B-FAMILY 
, O 
play O 
an O 
important O 
role O 
in O 
subchronic O 
pain O 
and O 
inflammation O 
. O 
This O 
study's O 
objective O 
was O 
to O 
test O 
whether O 
α7 O 
nAChR O 
positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
produce O 
antinociception O 
in O 
in O 
vivo O 
mouse O 
models O 
of O 
acute O 
and O 
persistent O 
pain O 
. O 
Testing O 
type O 
I O 
[ O 
N-(5-chloro-2-hydroxyphenyl)-N'-[2-chloro-5-(trifluoromethyl)phenyl B-SYSTEMATIC 
] O 
( O 
NS1738 B-IDENTIFIER 
) O 
] O 
and O 
type O 
II O 
[ O 
1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl) B-SYSTEMATIC 
( O 
PNU-120596 B-IDENTIFIER 
) O 
] O 
α7 O 
nAChR O 
PAMs O 
in O 
acute O 
and O 
persistent O 
pain O 
, O 
we O 
found O 
that O 
, O 
although O 
neither O 
reduced O 
acute O 
thermal O 
pain O 
, O 
only O 
PNU-120596 B-IDENTIFIER 
dose O 
- O 
dependently O 
attenuated O 
paw O 
- O 
licking O 
behavior O 
in O 
the O 
formalin B-TRIVIAL 
test O 
. O 
The O 
long O 
- O 
acting O 
effect O 
of O 
PNU-120596 B-IDENTIFIER 
in O 
this O 
test O 
was O 
in O 
discordance O 
with O 
its O 
pharmacokinetic O 
profile O 
in O 
mice O 
, O 
which O 
suggests O 
the O 
involvement O 
of O 
postreceptor O 
signaling O 
mechanisms O 
. O 
Our O 
results O 
with O 
selective O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
kinase O 
inhibitor O 
1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene B-SYSTEMATIC 
monoethanolate I-SYSTEMATIC 
( O 
U0126 B-IDENTIFIER 
) O 
argues O 
for O 
an O 
important O 
role O 
of O 
extracellular O 
signal O 
- O 
regulated O 
kinase-1 O 
/ O 
2 O 
pathways O 
activation O 
in O 
PNU-120596 B-IDENTIFIER 
' O 
s O 
antinociceptive O 
effects O 
. O 
The O 
α7 O 
antagonist O 
MLA B-ABBREVIATION 
, O 
administered O 
intrathecally O 
, O 
reversed O 
PNU-120596 B-IDENTIFIER 
' O 
s O 
effects O 
, O 
confirming O 
PNU-120596 B-IDENTIFIER 
' O 
s O 
action O 
, O 
in O 
part O 
, O 
through O 
central O 
α7 O 
nAChRs O 
. O 
Importantly O 
, O 
tolerance O 
to O 
PNU-120596 B-IDENTIFIER 
was O 
not O 
developed O 
after O 
subchronic O 
treatment O 
of O 
the O 
drug O 
. O 
Surprisingly O 
, O 
PNU-120596 B-IDENTIFIER 
' O 
s O 
antinociceptive O 
effects O 
were O 
blocked O 
by O 
NS1738 B-IDENTIFIER 
. O 
Our O 
results O 
indicate O 
that O 
type O 
II O 
α7 O 
nAChR O 
PAM O 
PNU-120596 B-IDENTIFIER 
, O 
but O 
not O 
type O 
I O 
α7 O 
nAChR O 
PAM O 
NS1738 B-IDENTIFIER 
, O 
shows O 
significant O 
antinociception O 
effects O 
in O 
persistent O 
pain O 
models O 
in O 
mice O 
. O 

effect O 
of O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
on O 
lead O 
induced O 
cognitive O 
dysfunction O 
. O 

effect O 
of O 
lead O 
( O 
Pb B-FORMULA 
) O 
on O 
spatial O 
memory O 
and O 
hippocampal O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
as O 
a O 
key O 
risk O 
factor O 
has O 
been O 
widely O 
recognized O 
and O 
the O 
oxidative O 
damage O 
has O 
been O 
proposed O 
as O 
a O 
possible O 
mechanism O 
of O 
lead O 
neurotoxicity O 
. O 
Selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
is O 
a O 
nutritionally O 
essential O 
trace O 
element O 
with O 
known O 
antioxidant O 
potential O 
. O 
In O 
this O 
study O 
we O 
investigated O 
the O 
effect O 
and O 
the O 
underlying O 
mechanisms O 
of O 
Se B-FORMULA 
supplementary O 
on O 
Pb B-FORMULA 
induced O 
cognition O 
and O 
synaptic O 
plasticity O 
impairment O 
. O 
Lactating O 
Sprague-Dawley O 
rats O 
( O 
SD O 
rats O 
) O 
were O 
randomly O 
divided O 
to O 
four O 
groups O 
: O 
0ppm O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
Pb B-FORMULA 
) O 
; O 
0ppm O 
Pb B-FORMULA 
and O 
0.2ppm O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
; O 
100ppm O 
Pb B-FORMULA 
; O 
100ppm O 
Pb B-FORMULA 
and O 
0.2ppm O 
Se B-FORMULA 
. O 
Lactating O 
rats O 
were O 
treated O 
with O 
or O 
without O 
Pb B-FORMULA 
and O 
/ O 
or O 
Se B-FORMULA 
throughout O 
lactation O 
until O 
weaning O 
. O 
The O 
levels O 
of O 
hippocampal O 
LTP O 
, O 
the O 
spatial O 
memory O 
, O 
the O 
apoptosis O 
of O 
hippocampal O 
neurons O 
, O 
the O 
levels O 
of O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
release O 
, O 
and O 
the O 
serum O 
level O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
were O 
assayed O 
. O 
It O 
had O 
been O 
observed O 
that O 
in O 
Pb B-FORMULA 
group O 
the O 
spatial O 
memory O 
, O 
the O 
induce O 
level O 
of O 
LTP O 
, O 
the O 
serum O 
SOD O 
level O 
decreased O 
, O 
the O 
LDH O 
release O 
level O 
, O 
the O 
neurons O 
apoptosis O 
level O 
, O 
the O 
serum O 
MDA B-ABBREVIATION 
level O 
increased O 
, O 
while O 
in O 
the O 
Se B-FORMULA 
supplements O 
groups O 
, O 
the O 
spatial O 
memory O 
, O 
the O 
induce O 
level O 
of O 
LTP O 
increased O 
significantly O 
. O 
Compared O 
with O 
the O 
Pb B-FORMULA 
group O 
, O 
Se B-FORMULA 
supplements O 
shown O 
down O 
regulated O 
the O 
level O 
of O 
LDH O 
, O 
the O 
neurons O 
apoptosis O 
and O 
the O 
serum O 
MDA B-ABBREVIATION 
, O 
and O 
up O 
regulated O 
the O 
level O 
of O 
serum O 
SOD O 
. O 
We O 
could O 
draw O 
the O 
conclusion O 
that O 
Se B-FORMULA 
supplements O 
could O 
alleviate O 
toxic O 
effect O 
of O 
lead O 
on O 
hippocampal O 
LTP O 
and O 
spatial O 
memory O 
. O 
The O 
treated O 
with O 
selenium B-SYSTEMATIC 
around O 
0.2ppm O 
may O 
protect O 
against O 
spatial O 
memory O 
dysfunction O 
induced O 
by O 
lead O 
exposure O 
. O 

ubiquitous O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
protein O 
phosphatase O 
1 O 
( O 
PP1 O 
) O 
regulates O 
diverse O 
, O 
essential O 
cellular O 
processes O 
such O 
as O 
cell O 
cycle O 
progression O 
, O 
protein O 
synthesis O 
, O 
muscle O 
contraction O 
, O 
carbohydrate B-FAMILY 
metabolism O 
, O 
transcription O 
and O 
neuronal O 
signaling O 
. O 
However O 
, O 
the O 
free O 
catalytic O 
subunit O 
of O 
PP1 O 
, O 
while O 
an O 
effective O 
enzyme O 
, O 
lacks O 
substrate O 
specificity O 
. O 
Instead O 
, O 
it O 
depends O 
on O 
a O 
diverse O 
set O 
of O 
regulatory O 
proteins O 
( O 
≥ O 
200 O 
) O 
to O 
confer O 
specificity O 
towards O 
distinct O 
substrates O 
. O 
Here O 
, O 
we O 
discuss O 
recent O 
advances O 
in O 
structural O 
studies O 
of O 
PP1 O 
holoenzyme O 
complexes O 
and O 
summarize O 
the O 
new O 
insights O 
these O 
studies O 
have O 
provided O 
into O 
the O 
molecular O 
basis O 
of O 
PP1 O 
regulation O 
and O 
specificity O 
. O 

LC O 
separation O 
techniques O 
for O 
quantitative O 
analysis O 
of O 
free O 
amino B-FAMILY 
acids I-FAMILY 
in O 
human O 
plasma O 
. O 

quantitative O 
analysis O 
of O 
free O 
amino B-FAMILY 
acids I-FAMILY 
in O 
human O 
plasma O 
has O 
become O 
an O 
important O 
and O 
essential O 
analysis O 
parameter O 
in O 
different O 
areas O 
of O 
life O 
sciences O 
. O 
Free O 
amino B-FAMILY 
acid I-FAMILY 
concentrations O 
in O 
human O 
plasma O 
samples O 
are O 
generally O 
determined O 
by O 
means O 
of O 
GC O 
or O 
LC O 
after O 
chemical O 
derivatization O 
followed O 
by O 
UV O 
, O 
fluorescent O 
or O 
MS O 
detection O 
of O 
the O 
amino B-FAMILY 
acid I-FAMILY 
derivatives O 
. O 
Derivatization O 
of O 
free O 
amino B-FAMILY 
acids I-FAMILY 
is O 
done O 
either O 
pre- O 
or O 
post O 
- O 
column O 
, O 
and O 
the O 
amino B-FAMILY 
acid I-FAMILY 
derivatives O 
obtained O 
posess O 
improved O 
chromatographic O 
behavior O 
, O 
increased O 
detection O 
sensitivity O 
and O 
selectivity O 
compared O 
with O 
non-derivatized O 
free O 
amino B-FAMILY 
acids I-FAMILY 
. O 
This O 
work O 
gives O 
an O 
overview O 
of O 
different O 
chemical O 
derivatization O 
methods O 
applied O 
and O 
their O 
liquid O 
separation O 
techniques O 
in O 
bioanalytical O 
assays O 
for O 
quantitative O 
free O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
in O 
human O 
plasma O 
samples O 
. O 
Important O 
plasma O 
preparation O 
procedures O 
, O 
pre- O 
and O 
post O 
- O 
column O 
derivatization O 
, O 
and O 
different O 
LC O 
separation O 
techniques O 
are O 
presented O 
. O 

between O 
CYP2E1 O 
and O 
CYP2B4 O 
: O 
effects O 
on O 
affinity O 
for O 
NADPH B-ABBREVIATION 
-cytochrome O 
P450 O 
reductase O 
and O 
substrate O 
metabolism O 
. O 

in O 
microsomal O 
and O 
reconstituted O 
systems O 
have O 
shown O 
that O 
the O 
presence O 
of O 
one O 
cytochrome O 
P450 O 
isoform O 
can O 
significantly O 
influence O 
the O 
catalytic O 
activity O 
of O 
another O 
isoform O 
. O 
In O 
this O 
study O 
, O 
we O 
assessed O 
whether O 
CYP2E1 O 
could O 
influence O 
the O 
catalytic O 
activity O 
of O 
CYP2B4 O 
under O 
steady O 
- O 
state O 
turnover O 
conditions O 
. O 
The O 
results O 
show O 
that O 
CYP2E1 O 
inhibits O 
CYP2B4 O 
- O 
mediated O 
metabolism O 
of O 
benzphetamine B-TRIVIAL 
( O 
BNZ B-ABBREVIATION 
) O 
with O 
a O 
K O 
(i) O 
of O 
0.04 O 
µM O 
. O 
However O 
, O 
CYP2B4 O 
is O 
not O 
an O 
inhibitor O 
of O 
CYP2E1 O 
- O 
mediated O 
p-nitrophenol B-SYSTEMATIC 
hydroxylation O 
. O 
When O 
these O 
inhibition O 
studies O 
were O 
performed O 
with O 
the O 
artificial O 
oxidant O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
, O 
CYP2E1 O 
did O 
not O 
significantly O 
inhibit O 
CYP2B4 O 
activity O 
. O 
Determinations O 
of O 
the O 
apparent O 
K(M) O 
and O 
k(cat) O 
of O 
CYP2B4 O 
for O 
CPR O 
in O 
the O 
presence O 
of O 
increasing O 
concentrations O 
of O 
CYP2E1 O 
revealed O 
a O 
mixed O 
inhibition O 
of O 
CYP2B4 O 
by O 
CYP2E1 O 
. O 
At O 
low O 
concentrations O 
of O 
CYP2E1 O 
, O 
the O 
apparent O 
K(M) O 
of O 
CYP2B4 O 
for O 
CPR O 
increased O 
up O 
to O 
23-fold O 
with O 
virtually O 
no O 
change O 
in O 
the O 
k(cat) O 
for O 
the O 
reaction O 
, O 
however O 
, O 
at O 
higher O 
concentrations O 
of O 
CYP2E1 O 
, O 
the O 
apparent O 
K(M) O 
of O 
CYP2B4 O 
for O 
CPR O 
decreased O 
to O 
levels O 
similar O 
to O 
those O 
observed O 
in O 
the O 
absence O 
of O 
CYP2E1 O 
and O 
the O 
k(cat) O 
also O 
decreased O 
by O 
11-fold O 
. O 
Additionally O 
, O 
CYP2E1 O 
increased O 
the O 
apparent O 
K(M) O 
of O 
CYP2B4 O 
for O 
BNZ B-ABBREVIATION 
by O 
8-fold O 
and O 
the O 
apparent O 
K(M) O 
did O 
not O 
decrease O 
to O 
its O 
original O 
value O 
when O 
saturating O 
concentrations O 
of O 
CPR O 
were O 
used O 
. O 
While O 
the O 
individual O 
apparent O 
K(M) O 
values O 
of O 
CYP2B4 O 
and O 
CYP2E1 O 
for O 
CPR O 
are O 
similar O 
, O 
the O 
apparent O 
K(M) O 
of O 
CYP2E1 O 
for O 
CPR O 
in O 
the O 
presence O 
of O 
CYP2B4 O 
decreased O 
significantly O 
, O 
thus O 
suggesting O 
that O 
CYP2B4 O 
enhances O 
the O 
affinity O 
of O 
CYP2E1 O 
for O 
CPR O 
and O 
this O 
may O 
allow O 
CYP2E1 O 
to O 
out O 
- O 
compete O 
CYP2B4 O 
for O 
CPR O 
. O 

, O 
stability O 
and O 
function O 
of O 
5-chlorouracil B-SYSTEMATIC 
modified O 
A O 
: O 
U O 
and O 
G O 
: O 
U O 
base O 
pairs O 
. O 

thymine B-TRIVIAL 
analog O 
5-chlorouridine B-SYSTEMATIC 
, O 
first O 
reported O 
in O 
the O 
1950s O 
as O 
anti-tumor O 
agent O 
, O 
is O 
known O 
as O 
an O 
effective O 
mutagen O 
, O 
clastogen O 
and O 
toxicant O 
as O 
well O 
as O 
an O 
effective O 
inducer O 
of O 
sister O 
- O 
chromatid O 
exchange O 
. O 
Recently O 
, O 
the O 
first O 
microorganism O 
with O 
a O 
chemically O 
different O 
genome O 
was O 
reported O 
; O 
the O 
selected O 
Escherichia O 
coli O 
strain O 
relies O 
on O 
the O 
four O 
building O 
blocks O 
5-chloro-2'-deoxyuridine B-SYSTEMATIC 
( O 
ClU B-ABBREVIATION 
) O 
, O 
A O 
, O 
C O 
and O 
G O 
instead O 
of O 
the O 
standard O 
T O 
, O 
A O 
, O 
C O 
, O 
G O 
alphabet O 
[ O 
Marlière,P O 
. O 
, O 
Patrouix,J O 
. O 
, O 
Döring,V O 
. O 
, O 
Herdewijn,P O 
. O 
, O 
Tricot,S O 
. O 
, O 
Cruveiller,S O 
. O 
, O 
Bouzon,M O 
. O 
and O 
Mutzel,R O 
. O 
( O 
2011 O 
) O 
Chemical O 
evolution O 
of O 
a O 
bacterium's O 
genome O 
. O 
Angew O 
. O 
Chem O 
. O 
Int O 
. O 
Ed O 
. O 
, O 
50 O 
, O 
7109-7114 O 
] O 
. O 
The O 
residual O 
fraction O 
of O 
T O 
in O 
the O 
DNA O 
of O 
adapted O 
bacteria O 
was O 
< O 
2% O 
and O 
the O 
switch O 
from O 
T O 
to O 
ClU B-ABBREVIATION 
was O 
accompanied O 
by O 
a O 
massive O 
number O 
of O 
mutations O 
, O 
including O 
> O 
1500 O 
A O 
to O 
G O 
or O 
G O 
to O 
A O 
transitions O 
in O 
a O 
culture O 
. O 
The O 
former O 
is O 
most O 
likely O 
due O 
to O 
wobble O 
base O 
pairing O 
between O 
ClU B-ABBREVIATION 
and O 
G O 
, O 
which O 
may O 
be O 
more O 
common O 
for O 
ClU B-ABBREVIATION 
than O 
T O 
. O 
To O 
identify O 
potential O 
changes O 
in O 
the O 
geometries O 
of O 
base O 
pairs O 
and O 
duplexes O 
as O 
a O 
result O 
of O 
replacement O 
of O 
T O 
by O 
ClU B-ABBREVIATION 
, O 
we O 
determined O 
four O 
crystal O 
structures O 
of O 
a O 
B O 
- O 
form O 
DNA O 
dodecamer O 
duplex O 
containing O 
ClU B-ABBREVIATION 
:A O 
or O 
ClU B-ABBREVIATION 
:G O 
base O 
pairs O 
. O 
The O 
structures O 
reveal O 
nearly O 
identical O 
geometries O 
of O 
these O 
pairs O 
compared O 
with O 
T O 
: O 
A O 
or O 
T O 
: O 
G O 
, O 
respectively O 
, O 
and O 
no O 
consequences O 
for O 
stability O 
and O 
cleavage O 
by O 
an O 
endonuclease O 
( O 
EcoRI O 
) O 
. O 
The O 
lack O 
of O 
significant O 
changes O 
in O 
the O 
geometry O 
of O 
ClU B-ABBREVIATION 
:A O 
and O 
ClU B-ABBREVIATION 
:G O 
base O 
pairs O 
relative O 
to O 
the O 
corresponding O 
native O 
pairs O 
is O 
consistent O 
with O 
the O 
sustained O 
unlimited O 
self O 
- O 
reproduction O 
of O 
E O 
. O 
coli O 
strains O 
with O 
virtually O 
complete O 
T→ O 
ClU B-ABBREVIATION 
genome O 
substitution O 
. O 

nanoparticle O 
aggregate O 
carbon B-SYSTEMATIC 
nanotube O 
functionalized O 
colloidal O 
particles O 
serve O 
as O 
an O 
efficient O 
platform O 
for O 
probing O 
the O 
intracellular O 
environment O 
. O 
The O 
probes O 
provide O 
the O 
means O 
of O 
effective O 
localization O 
of O 
signal O 
and O 
detection O 
of O 
molecular O 
fingerprints O 
of O 
biomolecules O 
in O 
living O 
cells O 
. O 
The O 
approach O 
demonstrated O 
in O 
this O 
work O 
opens O 
significant O 
opportunities O 
in O 
molecular O 
imaging O 
as O 
well O 
as O 
intracellular O 
sensing O 
and O 
trafficking O 
. O 

of O 
the O 
translational O 
machinery O 
in O 
digestive O 
glands O 
of O 
mussels O 
exposed O 
to O 
mercury B-SYSTEMATIC 
ions O 
. O 

is O 
an O 
element O 
naturally O 
occurring O 
in O 
the O 
biosphere O 
, O 
but O 
is O 
also O 
released O 
into O 
the O 
environment O 
by O 
human O 
activities O 
, O 
such O 
as O 
mining O 
, O 
smelting O 
, O 
and O 
industrial O 
discharge O 
. O 
Mercury B-SYSTEMATIC 
is O 
a O 
biologically O 
harmful O 
element O 
and O 
any O 
exposure O 
of O 
living O 
organisms O 
mainly O 
due O 
to O 
contamination O 
, O 
can O 
cause O 
severe O 
or O 
even O 
lethal O 
side O 
effects O 
. O 
In O 
every O 
form O 
detected O 
, O 
elemental O 
, O 
inorganic O 
, O 
or O 
organic O 
, O 
mercury B-SYSTEMATIC 
exhibits O 
toxicity O 
associated O 
with O 
induced O 
oxidative O 
stress O 
. O 
Although O 
the O 
genotoxicity O 
of O 
mercury B-SYSTEMATIC 
has O 
been O 
well O 
demonstrated O 
in O 
mussels O 
, O 
little O 
is O 
known O 
about O 
its O 
toxic O 
effects O 
on O 
the O 
translational O 
machinery O 
at O 
the O 
molecular O 
level O 
. O 
To O 
investigate O 
possible O 
effects O 
, O 
we O 
exposed O 
the O 
common O 
mussel O 
Mytilus O 
galloprovincialis O 
in O 
seawater O 
supplemented O 
by O 
30μg O 
/ O 
L O 
Hg(2+) B-FORMULA 
for O 
15 O 
days O 
. O 
We O 
observed O 
that O 
Hg(2+) B-FORMULA 
was O 
significantly O 
accumulated O 
in O 
the O 
digestive O 
glands O 
of O 
mussels O 
, O 
reaching O 
a O 
level O 
around O 
80μg O 
/ O 
g O 
tissue O 
( O 
dry O 
weight O 
) O 
at O 
the O 
15th O 
day O 
of O 
exposure O 
. O 
Exposure O 
of O 
mussels O 
to O 
Hg(2+) B-FORMULA 
resulted O 
in O 
failure O 
of O 
redox O 
homeostasis O 
, O 
as O 
reflected O 
on O 
lipid O 
peroxidation O 
levels O 
and O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
in O 
glands O 
, O 
and O 
micronucleus O 
frequency O 
in O 
gills O 
. O 
Extracts O 
from O 
digestive O 
glands O 
after O 
15-day O 
exposure O 
to O 
Hg(2+) B-FORMULA 
exhibited O 
decreased O 
tRNA O 
aminoacylation O 
ability O 
and O 
, O 
moreover O 
, O 
a O 
70% O 
reduction O 
in O 
the O 
ability O 
of O 
40S O 
ribosomal O 
subunits O 
to O 
form O 
the O 
48S O 
initiation O 
ribosomal O 
complex O 
. O 
A O 
similar O 
reduction O 
was O 
detected O 
in O 
the O 
ability O 
of O 
ribosomes O 
to O 
translocate O 
peptidyl-tRNA O 
from O 
the O 
A-site O 
to O 
the O 
P-site O 
, O 
an O 
observation O 
coinciding O 
with O 
the O 
notion O 
that O 
regulation O 
of O 
protein O 
synthesis O 
by O 
Hg(2+) B-FORMULA 
mainly O 
occurs O 
at O 
the O 
initiation O 
and O 
elongation O 
stages O 
of O 
translation O 
. O 
A-site O 
binding O 
, O 
peptidyl O 
transferase O 
activity O 
, O 
and O 
termination O 
of O 
peptide O 
chain O 
synthesis O 
underwent O 
less O 
pronounced O 
but O 
measurable O 
reductions O 
, O 
a O 
finding O 
which O 
explains O 
why O 
poly(Phe) B-FAMILY 
-synthesis O 
in O 
ribosomes O 
isolated O 
from O 
exposed O 
mussels O 
is O 
reduced O 
by O 
70% O 
. O 
In O 
conclusion O 
, O 
Hg(2+) B-FORMULA 
apart O 
from O 
being O 
a O 
genotoxic O 
ion O 
acts O 
as O 
a O 
modulator O 
of O 
protein O 
synthesis O 
in O 
mussels O 
, O 
an O 
observation O 
probably O 
related O 
with O 
its O 
ability O 
to O 
induce O 
oxidative O 
stress O 
. O 

kernel O 
cake O 
( O 
PKC O 
) O 
, O 
the O 
most O 
useful O 
by O 
- O 
product O 
resulted O 
from O 
palm O 
kernel O 
oil O 
production O 
. O 
In O 
this O 
study O 
, O 
PKC O 
- O 
derived O 
protein O 
product O 
was O 
found O 
suitable O 
for O 
use O 
as O 
an O 
antimicrobial O 
agent O 
with O 
potent O 
antibacterial O 
activity O 
, O 
particularly O 
against O 
Bacillus O 
species O 
, O 
after O 
enzymatic O 
hydrolysis O 
with O 
alcalase O 
. O 
The O 
hydrolysate O 
was O 
further O 
purified O 
by O 
gel O 
filtration O 
chromatography O 
. O 
The O 
purified O 
fraction O 
was O 
found O 
to O 
have O 
14.63±0.70% O 
( O 
w O 
/ O 
w O 
) O 
protein O 
, O 
a O 
molecular O 
mass O 
of O 
2.4kDa O 
and O 
low O 
hemolytic O 
activity O 
( O 
< O 
50% O 
hemolysis O 
of O 
human O 
erythrocytes O 
at O 
concentration O 
of O 
1000μg O 
/ O 
ml O 
) O 
. O 
The O 
presence O 
of O 
lysine B-TRIVIAL 
and O 
the O 
major O 
component O 
lauric B-TRIVIAL 
acid I-TRIVIAL 
derivative O 
, O 
as O 
indicated O 
by O 
electrospray O 
ionisation O 
- O 
mass O 
spectrometry O 
( O 
ESI-MS O 
) O 
direct O 
infusion O 
and O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
spectroscopy O 
, O 
may O 
have O 
contributed O 
to O 
the O 
antibacterial O 
effect O 
of O 
purified O 
PKC O 
fraction O 
. O 
This O 
study O 
suggests O 
that O 
the O 
antibacterial O 
PKC O 
compound O 
may O 
be O 
not O 
a O 
pure O 
peptide O 
but O 
instead O 
a O 
peptide O 
- O 
containing O 
compound O 
high O 
in O 
lauric B-TRIVIAL 
acid I-TRIVIAL 
derivative O 
. O 

synergistic O 
apoptotic O 
interaction O 
of O 
panaxadiol B-TRIVIAL 
and O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
in O 
human O 
colorectal O 
cancer O 
cells O 
. O 

( O 
PD O 
) O 
is O 
a O 
purified O 
sapogenin B-FAMILY 
of O 
ginseng O 
saponins B-FAMILY 
, O 
which O 
exhibits O 
anticancer O 
activity O 
. O 
Epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
, O 
a O 
major O 
catechin B-TRIVIAL 
in O 
green O 
tea O 
, O 
is O 
a O 
strong O 
botanical O 
antioxidant O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
possible O 
synergistic O 
anticancer O 
effects O 
of O 
PD O 
and O 
EGCG B-ABBREVIATION 
on O 
human O 
colorectal O 
cancer O 
cells O 
and O 
explored O 
the O 
potential O 
role O 
of O 
apoptosis O 
in O 
the O 
synergistic O 
activities O 
. O 
Effects O 
of O 
selected O 
compounds O 
on O 
HCT-116 O 
and O 
SW-480 O 
human O 
colorectal O 
cancer O 
cells O 
were O 
evaluated O 
by O 
a O 
modified O 
trichrome O 
stain O 
cell O 
proliferation O 
analysis O 
. O 
Cell O 
cycle O 
distribution O 
and O 
apoptotic O 
effects O 
were O 
analyzed O 
by O 
flow O 
cytometry O 
after O 
staining O 
with O 
PI O 
/ O 
RNase O 
or O 
annexin O 
V O 
/ O 
PI O 
. O 
Cell O 
growth O 
was O 
suppressed O 
after O 
treatment O 
with O 
PD O 
( O 
10 O 
and O 
20 O 
µm O 
) O 
for O 
48 O 
h O 
. O 
When O 
PD O 
( O 
10 O 
and O 
20 O 
µm O 
) O 
was O 
combined O 
with O 
EGCG B-ABBREVIATION 
( O 
10 O 
, O 
20 O 
, O 
and O 
30 O 
µm O 
) O 
, O 
significantly O 
enhanced O 
antiproliferative O 
effects O 
were O 
observed O 
in O 
both O 
cell O 
lines O 
. O 
Combining O 
20 O 
µm O 
of O 
PD O 
with O 
20 O 
and O 
30 O 
µm O 
of O 
EGCG B-ABBREVIATION 
significantly O 
decreased O 
S-phase O 
fractions O 
of O 
cells O 
. O 
In O 
the O 
apoptotic O 
assay O 
, O 
the O 
combination O 
of O 
PD O 
and O 
EGCG B-ABBREVIATION 
significantly O 
increased O 
the O 
percentage O 
of O 
apoptotic O 
cells O 
compared O 
with O 
PD O 
alone O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
synergistic O 
apoptotic O 
effects O 
were O 
also O 
supported O 
by O 
docking O 
analysis O 
, O 
which O 
demonstrated O 
that O 
PD O 
and O 
EGCG B-ABBREVIATION 
bound O 
in O 
two O 
different O 
sites O 
of O 
the O 
annexin O 
V O 
protein O 
. O 
Data O 
from O 
this O 
study O 
suggested O 
that O 
apoptosis O 
might O 
play O 
an O 
important O 
role O 
in O 
the O 
EGCG B-ABBREVIATION 
-enhanced O 
antiproliferative O 
effects O 
of O 
PD O 
on O 
human O 
colorectal O 
cancer O 
cells O 
. O 

receptor O 
induces O 
bcl-x O 
expression O 
through O 
intragenic O 
binding O 
sites O 
favoring O 
RNA O 
polymerase O 
II O 
elongation O 
. O 

receptors O 
were O 
classically O 
described O 
for O 
regulating O 
transcription O 
by O 
binding O 
to O 
target O 
gene O 
promoters O 
. O 
However O 
, O 
genome O 
- O 
wide O 
studies O 
reveal O 
that O 
steroid B-FAMILY 
receptors O 
- O 
binding O 
sites O 
are O 
mainly O 
located O 
at O 
intragenic O 
regions O 
. O 
To O 
determine O 
the O 
role O 
of O 
these O 
sites O 
, O 
we O 
examined O 
the O 
effect O 
of O 
progestins O 
on O 
the O 
transcription O 
of O 
the O 
bcl-x O 
gene O 
, O 
where O 
only O 
intragenic O 
progesterone B-TRIVIAL 
receptor O 
- O 
binding O 
sites O 
( O 
PRbs O 
) O 
were O 
identified O 
. O 
We O 
found O 
that O 
in O 
response O 
to O 
hormone O 
treatment O 
, O 
the O 
PR O 
is O 
recruited O 
to O 
these O 
sites O 
along O 
with O 
two O 
histone O 
acetyltransferases O 
CREB O 
- O 
binding O 
protein O 
( O 
CBP O 
) O 
and O 
GCN5 O 
, O 
leading O 
to O 
an O 
increase O 
in O 
histone O 
H3 O 
and O 
H4 O 
acetylation O 
and O 
to O 
the O 
binding O 
of O 
the O 
SWI O 
/ O 
SNF O 
complex O 
. O 
Concomitant O 
, O 
a O 
more O 
relaxed O 
chromatin O 
was O 
detected O 
along O 
bcl-x O 
gene O 
mainly O 
in O 
the O 
regions O 
surrounding O 
the O 
intragenic O 
PRbs O 
. O 
PR O 
also O 
mediated O 
the O 
recruitment O 
of O 
the O 
positive O 
elongation O 
factor O 
pTEFb O 
, O 
favoring O 
RNA O 
polymerase O 
II O 
( O 
Pol O 
II O 
) O 
elongation O 
activity O 
. O 
Together O 
these O 
events O 
promoted O 
the O 
re O 
- O 
distribution O 
of O 
the O 
active O 
Pol O 
II O 
toward O 
the O 
3'-end O 
of O 
the O 
gene O 
and O 
a O 
decrease O 
in O 
the O 
ratio O 
between O 
proximal O 
and O 
distal O 
transcription O 
. O 
These O 
results O 
suggest O 
a O 
novel O 
mechanism O 
by O 
which O 
PR O 
regulates O 
gene O 
expression O 
by O 
facilitating O 
the O 
proper O 
passage O 
of O 
the O 
polymerase O 
along O 
hormone O 
- O 
dependent O 
genes O 
. O 

-dependent O 
lysosomal O 
enlargement O 
in O 
TRPML1-deficient O 
cells O 
involves O 
MTF-1 O 
transcription O 
factor O 
and O 
ZnT4 O 
( O 
Slc30a4 O 
) O 
transporter O 
. O 

is O 
critical O 
for O 
a O 
multitude O 
of O 
cellular O 
processes O 
, O 
including O 
gene O 
expression O 
, O 
secretion O 
and O 
enzymatic O 
activities O 
. O 
Cellular O 
zinc B-SYSTEMATIC 
is O 
controlled O 
by O 
zinc B-SYSTEMATIC 
-chelating O 
proteins O 
and O 
by O 
zinc B-SYSTEMATIC 
transporters O 
. O 
The O 
recent O 
identification O 
of O 
zinc B-SYSTEMATIC 
permeability O 
of O 
the O 
lysosomal O 
ion O 
channel O 
TRPML1 O 
( O 
transient O 
receptor O 
potential O 
mucolipin O 
1 O 
) O 
, O 
and O 
the O 
evidence O 
of O 
abnormal O 
zinc B-SYSTEMATIC 
levels O 
in O 
cells O 
deficient O 
in O 
TRPML1 O 
, O 
suggested O 
a O 
role O 
for O 
TRPML1 O 
in O 
zinc B-SYSTEMATIC 
transport O 
. O 
In O 
the O 
present O 
study O 
we O 
provide O 
new O 
evidence O 
for O 
such O 
a O 
role O 
and O 
identify O 
additional O 
cellular O 
components O 
responsible O 
for O 
it O 
. O 
In O 
agreement O 
with O 
the O 
previously O 
published O 
data O 
, O 
an O 
acute O 
siRNA O 
( O 
small O 
interfering O 
RNA)-driven O 
TRPML1 O 
KD O 
( O 
knockdown O 
) O 
leads O 
to O 
the O 
build O 
- O 
up O 
of O 
large O 
cytoplasmic O 
vesicles O 
positive O 
for O 
LysoTracker O 
™ O 
and O 
zinc B-SYSTEMATIC 
staining O 
, O 
when O 
cells O 
are O 
exposed O 
to O 
high O 
concentrations O 
of O 
zinc B-SYSTEMATIC 
. O 
We O 
now O 
show O 
that O 
lysosomal O 
enlargement O 
and O 
zinc B-SYSTEMATIC 
build O 
- O 
up O 
in O 
TRPML1-KD O 
cells O 
exposed O 
to O 
zinc B-SYSTEMATIC 
are O 
ameliorated O 
by O 
KD O 
of O 
the O 
zinc B-SYSTEMATIC 
-sensitive O 
transcription O 
factor O 
MTF-1 O 
( O 
metal O 
- O 
regulatory O 
- O 
element O 
- O 
binding O 
transcription O 
factor-1 O 
) O 
or O 
the O 
zinc B-SYSTEMATIC 
transporter O 
ZnT4 O 
. O 
TRPML1 O 
KD O 
is O 
associated O 
with O 
a O 
build O 
- O 
up O 
of O 
cytoplasmic O 
zinc B-SYSTEMATIC 
and O 
with O 
enhanced O 
transcriptional O 
response O 
of O 
mRNA O 
for O 
MT2a O 
( O 
metallothionein O 
2a O 
) O 
. O 
TRPML1 O 
KD O 
did O 
not O 
suppress O 
lysosomal O 
secretion O 
, O 
but O 
it O 
did O 
delay O 
zinc B-SYSTEMATIC 
leak O 
from O 
the O 
lysosomes O 
into O 
the O 
cytoplasm O 
. O 
These O 
results O 
underscore O 
a O 
role O 
for O 
TRPML1 O 
in O 
zinc B-SYSTEMATIC 
metabolism O 
. O 
Furthermore O 
, O 
they O 
suggest O 
that O 
TRPML1 O 
works O 
in O 
concert O 
with O 
ZnT4 O 
to O 
regulate O 
zinc B-SYSTEMATIC 
translocation O 
between O 
the O 
cytoplasm O 
and O 
lysosomes O 
. O 

Raman O 
spectral O 
imaging O 
of O 
intracellular O 
uptake O 
of O 
β-carotene B-TRIVIAL 
loaded O 
poly(D,L-lactide-co-glycolide) B-FAMILY 
nanoparticles O 
. O 

use O 
of O 
nanoparticles O 
for O 
drug O 
delivery O 
has O 
been O 
drawing O 
considerable O 
attention O 
in O 
pharmaceutical O 
research O 
. O 
With O 
increasing O 
diversity O 
and O 
potential O 
of O 
various O 
carrier O 
systems O 
, O 
it O 
is O 
important O 
to O 
study O 
the O 
impact O 
of O 
nanocarriers O 
on O 
sub O 
- O 
cellular O 
metabolic O 
processes O 
and O 
organelles O 
, O 
since O 
the O 
delivery O 
of O 
a O 
drug O 
usually O 
involves O 
intra O 
- O 
cellular O 
internalization O 
. O 
Herein O 
, O 
we O 
employ O 
Raman O 
microscopy O 
as O 
a O 
non-invasive O 
method O 
for O 
cellular O 
and O 
sub O 
- O 
cellular O 
imaging O 
, O 
to O 
monitor O 
the O 
uptake O 
and O 
translocation O 
patterns O 
of O 
particles O 
based O 
on O 
poly(D,L-lactide-co-glycolide) B-FAMILY 
over O 
time O 
. O 
As O 
the O 
technique O 
detects O 
inherent O 
signals O 
from O 
the O 
molecules O 
of O 
interest O 
, O 
it O 
does O 
not O 
rely O 
on O 
external O 
labels O 
or O 
dyes O 
, O 
which O 
is O 
an O 
advantage O 
over O 
fluorescence O 
labeling O 
. O 
For O 
this O 
purpose O 
, O 
the O 
particles O 
were O 
loaded O 
with O 
β-carotene B-TRIVIAL 
. O 
The O 
conjugated O 
π-system O 
of O 
the O 
molecule O 
has O 
a O 
large O 
Raman O 
scattering O 
cross O 
- O 
section O 
and O 
gives O 
rise O 
to O 
resonance O 
Raman O 
effects O 
, O 
which O 
can O 
enhance O 
the O 
sensitivity O 
by O 
orders O 
of O 
magnitude O 
. O 
β-Carotene B-TRIVIAL 
as O 
a O 
provitamin O 
is O 
not O 
soluble O 
in O 
water O 
and O 
is O 
thus O 
usually O 
of O 
low O 
bioavailability O 
, O 
which O 
is O 
enhanced O 
by O 
encapsulation O 
into O 
the O 
nanoparticles O 
. O 

the O 
advent O 
of O 
many O 
new O 
devices O 
for O 
glaucoma O 
surgery O 
, O 
scarring O 
is O 
the O 
main O 
cause O 
of O 
suboptimal O 
pressure O 
control O 
and O 
surgical O 
failure O 
in O 
all O 
forms O 
of O 
surgery O 
. O 
The O 
cytotoxic O 
antimetabolites O 
, O 
5-flurouracil B-SYSTEMATIC 
and O 
mitomycin B-TRIVIAL 
C I-TRIVIAL 
both O 
prolong O 
success O 
but O 
with O 
the O 
increased O 
risk O 
of O 
blinding O 
complications O 
. O 
A O 
greater O 
understanding O 
of O 
the O 
cellular O 
mechanisms O 
of O 
the O 
wound O 
healing O 
response O 
has O 
led O 
to O 
the O 
identification O 
and O 
modulation O 
of O 
potential O 
therapeutic O 
targets O 
. O 
These O 
include O 
transforming O 
factor O 
β O 
, O 
inflammatory O 
mediators O 
, O 
the O 
acute O 
phase O 
protein O 
serum O 
amyloid O 
P O 
, O 
vascular O 
endothelial O 
growth O 
factor O 
and O 
the O 
matrix O 
metallaproteinases O 
. O 
While O 
optimal O 
drug O 
delivery O 
is O 
still O 
a O 
major O 
challenge O 
, O 
modulating O 
these O 
effects O 
either O 
directly O 
or O 
through O 
downstream O 
signalling O 
promises O 
to O 
yield O 
anti-scarring O 
efficacy O 
, O 
while O 
minimising O 
side O 
effects O 
. O 

is O 
an O 
important O 
cellular O 
process O 
that O 
mediates O 
lysosomal O 
degradation O 
of O 
damaged O 
organelles O 
, O 
which O 
is O 
activated O 
in O 
response O 
to O 
a O 
variety O 
of O 
stress O 
- O 
related O 
diseases O 
, O 
including O 
hypertension O 
. O 
The O 
basal O 
level O 
of O 
autophagy O 
plays O 
an O 
important O 
role O 
in O 
the O 
maintenance O 
of O 
cellular O 
homeostasis O 
, O 
whereas O 
excessive O 
autophagic O 
activity O 
leads O 
to O 
cell O 
death O 
and O 
is O 
considered O 
as O 
a O 
contributing O 
factor O 
to O 
several O 
disorders O 
. O 
Recent O 
works O 
have O 
demonstrated O 
that O 
Angiotensin-(1-7) O 
[Ang-(1-7)] O 
exerted O 
its O 
neuroprotective O 
effects O 
by O 
modulating O 
classic O 
components O 
of O 
renin O 
- O 
angiotensin O 
system O 
associated O 
with O 
reducing O 
oxidative O 
stress O 
and O 
apoptosis O 
in O 
brains O 
of O 
spontaneously O 
hypertensive O 
rats O 
( O 
SHRs O 
) O 
. O 
However O 
, O 
the O 
effect O 
of O 
Ang-(1-7) O 
on O 
autophagic O 
activity O 
in O 
brain O 
of O 
hypertensive O 
individual O 
remains O 
unclear O 
. O 
In O 
this O 
study O 
, O 
Wistar-Kyoto O 
rats O 
received O 
intracerebroventricular O 
( O 
I.C.V O 
. O 
) O 
infusion O 
of O 
artificial O 
cerebrospinal O 
fluid O 
( O 
aCSF O 
) O 
while O 
SHRs O 
received O 
I.C.V O 
. O 
infusion O 
of O 
aCSF O 
, O 
Ang-(1-7) O 
, O 
Mas O 
receptor O 
antagonist O 
A-779 B-IDENTIFIER 
, O 
or O 
angiotensin O 
II O 
type O 
2 O 
receptor O 
antagonist O 
PD123319 B-IDENTIFIER 
for O 
4 O 
weeks O 
. O 
Brain O 
tissues O 
were O 
collected O 
and O 
analyzed O 
by O 
western O 
blotting O 
analysis O 
, O 
immunofluorescence O 
assay O 
, O 
and O 
transmission O 
electron O 
microscopic O 
examination O 
. O 
Our O 
study O 
showed O 
that O 
infusion O 
of O 
Ang-(1-7) O 
for O 
4 O 
weeks O 
inhibited O 
the O 
increase O 
of O 
microtubule O 
- O 
associated O 
protein O 
1 O 
light O 
chain O 
3 O 
(LC3)-II O 
and O 
Beclin-1 O 
levels O 
, O 
as O 
well O 
as O 
the O 
autophagosome O 
formation O 
in O 
SHR O 
brain O 
. O 
Meanwhile O 
, O 
the O 
reduction O 
of O 
p62 O 
expression O 
in O 
SHR O 
brain O 
was O 
also O 
reversed O 
by O 
Ang-(1-7) O 
. O 
Of O 
note O 
, O 
the O 
anti-autophagic O 
effects O 
of O 
Ang-(1-7) O 
were O 
independent O 
of O 
blood O 
pressure O 
reduction O 
and O 
can O 
be O 
inhibited O 
by O 
A-779 B-IDENTIFIER 
and O 
PD123319 B-IDENTIFIER 
. O 
These O 
findings O 
suggest O 
that O 
treatment O 
with O 
Ang-(1-7) O 
may O 
be O 
useful O 
to O 
prevent O 
hypertension O 
- O 
induced O 
excessive O 
autophagic O 
activation O 
in O 
brain O 
. O 

separation O 
and O 
purification O 
of O 
sulforaphene B-TRIVIAL 
from O 
radish O 
seeds O 
by O 
high O 
- O 
speed O 
countercurrent O 
chromatography O 
. O 

, O 
a O 
kind O 
of O 
isothiocyanates B-FAMILY 
, O 
derived O 
from O 
glucoraphenin B-TRIVIAL 
which O 
is O 
the O 
important O 
ingredient O 
of O 
radish O 
( O 
Raphanus O 
sativus O 
L O 
. O 
) O 
seeds O 
, O 
has O 
shown O 
significant O 
pharmacological O 
activities O 
. O 
In O 
this O 
paper O 
, O 
the O 
separation O 
and O 
purification O 
of O 
sulforaphene B-TRIVIAL 
from O 
radish O 
seeds O 
, O 
was O 
achieved O 
by O 
high O 
- O 
speed O 
countercurrent O 
chromatography O 
( O 
HSCCC O 
) O 
. O 
A O 
two O 
- O 
phase O 
solvent O 
system O 
consisted O 
of O 
n-hexane B-SYSTEMATIC 
- O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
- O 
methanol B-SYSTEMATIC 
-water O 
( O 
35 O 
: O 
100 O 
: O 
35 O 
: O 
100 O 
, O 
v O 
/ O 
v O 
/ O 
v O 
/ O 
v O 
) O 
was O 
applied O 
. O 
The O 
revolution O 
speed O 
of O 
the O 
separation O 
column O 
, O 
flow O 
rate O 
of O 
the O 
mobile O 
phase O 
and O 
separation O 
temperature O 
were O 
800 O 
rpm O 
, O 
2 O 
ml O 
/ O 
min O 
and O 
30°C O 
, O 
respectively O 
. O 
From O 
about O 
1000 O 
mg O 
amount O 
of O 
the O 
crude O 
plant O 
extract O 
, O 
249.4 O 
mg O 
of O 
pure O 
sulforaphene B-TRIVIAL 
was O 
obtained O 
by O 
one O 
- O 
step O 
separation O 
on O 
a O 
280 O 
ml O 
HSCCC O 
column O 
. O 
The O 
purified O 
sulforaphene B-TRIVIAL 
was O 
at O 
a O 
high O 
purity O 
of O 
96.9% O 
and O 
the O 
mass O 
recovery O 
was O 
more O 
than O 
95% O 
. O 
The O 
purity O 
of O 
sulforaphene B-TRIVIAL 
was O 
determined O 
by O 
HPLC O 
analysis O 
and O 
its O 
chemical O 
structure O 
was O 
assessed O 
by O 
MS O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
and O 
DEPT-135 O 
NMR O 
. O 

nanoribbons O 
as O 
an O 
advanced O 
precursor O 
for O 
making O 
carbon B-SYSTEMATIC 
fiber O 
. O 

oxide I-SYSTEMATIC 
nanoribbons O 
( O 
GONRs O 
) O 
and O 
chemically O 
reduced B-TRIVIAL 
graphene I-TRIVIAL 
nanoribbons O 
( O 
crGNRs O 
) O 
were O 
dispersed O 
at O 
high O 
concentrations O 
in O 
chlorosulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
to O 
form O 
anisotropic O 
liquid O 
crystal O 
phases O 
. O 
The O 
liquid O 
crystal O 
solutions O 
were O 
spun O 
directly O 
into O 
hundreds O 
of O 
meters O 
of O 
continuous O 
macroscopic O 
fibers O 
. O 
The O 
relationship O 
of O 
fiber O 
morphology O 
to O 
coagulation O 
bath O 
conditions O 
was O 
studied O 
. O 
The O 
effects O 
of O 
colloid O 
concentration O 
, O 
annealing O 
temperature O 
, O 
spinning O 
air O 
gap O 
, O 
and O 
pretension O 
during O 
annealing O 
on O 
the O 
fibers O 
' O 
performance O 
were O 
also O 
investigated O 
. O 
Heat O 
treatment O 
of O 
the O 
as-spun O 
GONR O 
fibers O 
at O 
1500 O 
°C O 
produced O 
thermally O 
reduced B-TRIVIAL 
graphene I-TRIVIAL 
nanoribbon O 
( O 
trGNR O 
) O 
fibers O 
with O 
a O 
tensile O 
strength O 
of O 
378 O 
MPa O 
, O 
Young's O 
modulus O 
of O 
36.2 O 
GPa O 
, O 
and O 
electrical O 
conductivity O 
of O 
285 O 
S O 
/ O 
cm O 
, O 
which O 
is O 
considerably O 
higher O 
than O 
that O 
in O 
other O 
reported O 
graphene B-TRIVIAL 
-derived O 
fibers O 
. O 
This O 
better O 
trGNR O 
fiber O 
performance O 
was O 
due O 
to O 
the O 
air O 
gap O 
spinning O 
and O 
annealing O 
with O 
pretension O 
that O 
produced O 
higher O 
molecular O 
alignment O 
within O 
the O 
fibers O 
, O 
as O 
determined O 
by O 
X-ray O 
diffraction O 
and O 
scanning O 
electron O 
microscopy O 
. O 
The O 
specific O 
modulus O 
of O 
trGNR O 
fibers O 
is O 
higher O 
than O 
that O 
of O 
the O 
commercial O 
general O 
purpose O 
carbon B-SYSTEMATIC 
fibers O 
and O 
commonly O 
used O 
metals O 
such O 
as O 
Al B-FORMULA 
, O 
Cu B-FORMULA 
, O 
and O 
steel B-TRIVIAL 
. O 
The O 
properties O 
of O 
trGNR O 
fibers O 
can O 
be O 
further O 
improved O 
by O 
optimizing O 
the O 
spinning O 
conditions O 
with O 
higher O 
draw O 
ratio O 
, O 
annealing O 
conditions O 
with O 
higher O 
pretensions O 
, O 
and O 
using O 
longer O 
flake O 
GONRs O 
. O 
This O 
technique O 
is O 
a O 
new O 
high- O 
carbon B-SYSTEMATIC 
-yield O 
approach O 
to O 
make O 
the O 
next O 
generation O 
carbon B-SYSTEMATIC 
fibers O 
based O 
on O 
solution O 
- O 
based O 
liquid O 
crystal O 
phase O 
spinning O 
. O 

of O 
surface O 
charge O 
density O 
on O 
the O 
affinity O 
of O 
oxide B-SYSTEMATIC 
nanoparticles O 
for O 
the O 
vapor O 
- O 
water O 
interface O 
. O 

in O 
- O 
situ O 
X-ray O 
photoelectron O 
spectroscopy O 
at O 
the O 
vapor O 
- O 
water O 
interface O 
, O 
the O 
affinity O 
of O 
nanometer O 
- O 
sized O 
silica B-TRIVIAL 
colloids O 
to O 
adsorb O 
at O 
the O 
interface O 
is O 
shown O 
to O 
depend O 
on O 
colloid O 
surface O 
charge O 
density O 
. O 
In O 
aqueous O 
suspensions O 
at O 
pH O 
10 O 
corrected O 
Debye-Hückel O 
theory O 
for O 
surface O 
complexation O 
calculations O 
predict O 
that O 
smaller O 
silica B-TRIVIAL 
colloids O 
have O 
increased O 
negative O 
surface O 
charge O 
density O 
that O 
originates O 
from O 
enhanced O 
screening O 
of O 
deprotonated O 
silanol B-SYSTEMATIC 
groups O 
( O 
≡ B-FORMULA 
Si-O(-) I-FORMULA 
) O 
by O 
counterions O 
in O 
the O 
condensed O 
ion O 
layer O 
. O 
The O 
increased O 
negative O 
surface O 
charge O 
density O 
results O 
in O 
an O 
electrostatic O 
repulsion O 
from O 
the O 
vapor O 
- O 
water O 
interface O 
that O 
is O 
seen O 
to O 
a O 
lesser O 
extent O 
for O 
larger O 
particles O 
that O 
have O 
a O 
reduced O 
charge O 
density O 
in O 
the O 
XPS O 
measurements O 
. O 
We O 
compare O 
the O 
results O 
and O 
interpretation O 
of O 
the O 
in O 
- O 
situ O 
XPS O 
and O 
corrected O 
Debye-Hückel O 
theory O 
for O 
surface O 
complexation O 
calculations O 
with O 
traditional O 
surface O 
tension O 
measurements O 
. O 
Our O 
results O 
show O 
that O 
controlling O 
the O 
surface O 
charge O 
density O 
of O 
colloid O 
particles O 
can O 
regulate O 
their O 
adsorption O 
to O 
the O 
interface O 
between O 
two O 
dielectrics O 
. O 

two O 
decades O 
of O 
research O 
and O 
development O 
activity O 
focussed O 
on O 
orally O 
active O 
kinase O 
inhibitors O 
, O 
the O 
first O 
such O 
drug O 
( O 
the O 
JAK O 
inhibitor O 
Xeljanz B-TRIVIAL 
, O 
tofacitinib B-TRIVIAL 
) O 
was O 
approved O 
by O 
the O 
FDA O 
in O 
November O 
2012 O 
for O 
the O 
treatment O 
of O 
rheumatoid O 
arthritis O 
( O 
RA O 
) O 
. O 
There O 
is O 
an O 
intense O 
activity O 
in O 
many O 
companies O 
both O 
on O 
expanding O 
the O 
utility O 
of O 
JAK O 
inhibitors O 
in O 
other O 
auto O 
- O 
immune O 
indications O 
and O 
in O 
discovering O 
inhibitors O 
of O 
the O 
JAK O 
family O 
with O 
different O 
and O 
more O 
selective O 
profiles O 
. O 
Progress O 
is O 
also O 
being O 
made O 
with O 
orally O 
active O 
Syk O 
inhibitors O 
. O 
One O 
such O 
inhibitor O 
( O 
fostamatinib B-TRIVIAL 
) O 
is O 
currently O 
in O 
large O 
- O 
scale O 
phase O 
3 O 
trials O 
, O 
and O 
there O 
are O 
others O 
in O 
clinical O 
development O 
. O 
The O 
last O 
two O 
to O 
three O 
years O 
have O 
been O 
transformative O 
for O 
kinase O 
inhibitors O 
in O 
auto O 
- O 
immune O 
diseases O 
, O 
as O 
several O 
inhibitors O 
have O 
finally O 
progressed O 
beyond O 
phase O 
2 O 
trials O 
after O 
so O 
many O 
failures O 
on O 
other O 
targets O 
. O 
Thus O 
, O 
there O 
are O 
new O 
treatment O 
options O 
for O 
RA O 
patients O 
beyond O 
existing O 
oral O 
DMARDs O 
and O 
parenteral O 
biologics O 
. O 

reward O 
- O 
sensitive O 
interaction O 
of O 
ghrelin O 
and O 
opioid O 
receptor O 
pathways O 
in O 
mesolimbic O 
dopamine B-TRIVIAL 
system O 
. O 

is O 
a O 
stomach O 
- O 
derived O 
orexigenic O 
peptide O 
. O 
The O 
goal O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
roles O 
of O 
mu O 
and O 
kappa O 
opioid O 
receptors O 
in O 
systemic O 
ghrelin O 
- O 
mediated O 
regulation O 
of O 
the O 
mesolimbic O 
dopamine B-TRIVIAL 
system O 
. O 
To O 
evaluate O 
the O 
interaction O 
of O 
systemic O 
ghrelin O 
with O 
values O 
of O 
food O 
reward O 
, O 
rats O 
were O 
exposed O 
to O 
food O 
removal O 
, O 
regular O 
food O 
or O 
palatable O 
food O 
after O 
systemic O 
ghrelin O 
administration O 
. O 
Extracellular O 
dopamine B-TRIVIAL 
levels O 
were O 
quantified O 
in O 
the O 
nucleus O 
accumbens O 
( O 
NAc O 
) O 
and O 
receptor O 
- O 
specific O 
compounds O 
were O 
infused O 
into O 
the O 
ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
using O 
dual O 
- O 
probe O 
microdialysis O 
. O 
Consumption O 
of O 
regular O 
or O 
palatable O 
food O 
without O 
systemic O 
ghrelin O 
administration O 
induced O 
an O 
increase O 
in O 
dopamine B-TRIVIAL 
levels O 
in O 
the O 
NAc O 
via O 
activation O 
of O 
mu O 
opioid O 
receptors O 
in O 
the O 
VTA O 
. O 
Systemic O 
ghrelin O 
administration O 
( O 
3 O 
nmol O 
, O 
i.v O 
. O 
) O 
followed O 
by O 
no O 
food O 
induced O 
a O 
decrease O 
in O 
dopamine B-TRIVIAL 
levels O 
via O 
activation O 
of O 
kappa O 
opioid O 
receptors O 
in O 
the O 
VTA O 
. O 
Systemic O 
ghrelin O 
administration O 
followed O 
by O 
consumption O 
of O 
regular O 
food O 
induced O 
an O 
increase O 
in O 
dopamine B-TRIVIAL 
levels O 
via O 
preferential O 
activation O 
of O 
mu O 
opioid O 
receptors O 
, O 
whereas O 
systemic O 
ghrelin O 
administration O 
followed O 
by O 
consumption O 
of O 
palatable O 
food O 
suppressed O 
the O 
increase O 
in O 
dopamine B-TRIVIAL 
levels O 
via O 
preferential O 
activation O 
of O 
kappa O 
opioid O 
receptors O 
. O 
Thus O 
, O 
natural O 
food O 
reward O 
and O 
systemic O 
ghrelin O 
activate O 
mu O 
and O 
kappa O 
opioid O 
receptor O 
pathways O 
in O 
the O 
VTA O 
, O 
respectively O 
, O 
resulting O 
in O 
opposite O 
influences O 
on O 
dopamine B-TRIVIAL 
release O 
in O 
the O 
NAc O 
. O 
Furthermore O 
, O 
systemic O 
ghrelin O 
induces O 
switching O 
of O 
the O 
dominant O 
opioid O 
receptor O 
pathway O 
for O 
highly O 
rewarding O 
food O 
from O 
mu O 
to O 
kappa O 
, O 
resulting O 
in O 
suppression O 
of O 
the O 
mesolimbic O 
dopamine B-TRIVIAL 
system O 
. O 
These O 
novel O 
findings O 
might O 
provide O 
insights O 
into O 
the O 
neural O 
pathways O 
involved O 
in O 
eating O 
disorders O 
. O 

and O 
Electronic O 
Transport O 
Properties O 
of O 
DNA O 
Translocation O 
through O 
Graphene B-TRIVIAL 
Nanopores O 
. O 

layers O 
have O 
been O 
targeted O 
in O 
the O 
last O 
years O 
as O 
excellent O 
host O 
materials O 
for O 
sensing O 
a O 
remarkable O 
variety O 
of O 
gases O 
and O 
molecules O 
. O 
Such O 
sensing O 
abilities O 
can O 
also O 
benefit O 
other O 
important O 
scientific O 
fields O 
such O 
as O 
medicine O 
and O 
biology O 
. O 
This O 
has O 
automatically O 
led O 
scientists O 
to O 
probe O 
graphene B-TRIVIAL 
as O 
a O 
potential O 
platform O 
for O 
sequencing O 
DNA O 
strands O 
. O 
In O 
this O 
work O 
, O 
we O 
use O 
robust O 
numerical O 
tools O 
to O 
model O 
the O 
dynamic O 
and O 
electronic O 
properties O 
of O 
molecular O 
sensor O 
devices O 
composed O 
of O 
a O 
graphene B-TRIVIAL 
nanopore O 
through O 
which O 
DNA O 
molecules O 
are O 
driven O 
by O 
external O 
electric O 
fields O 
. O 
We O 
performed O 
molecular O 
dynamic O 
simulations O 
to O 
determine O 
the O 
relation O 
between O 
the O 
intensity O 
of O 
the O 
electric O 
field O 
and O 
the O 
translocation O 
time O 
spent O 
by O 
the O 
DNA O 
to O 
pass O 
through O 
the O 
pore O 
. O 
Our O 
results O 
reveal O 
that O 
one O 
can O 
have O 
extra O 
control O 
on O 
the O 
DNA O 
passage O 
when O 
four O 
additional O 
graphene B-TRIVIAL 
layers O 
are O 
deposited O 
on O 
the O 
top O 
of O 
the O 
main O 
graphene B-TRIVIAL 
platform O 
containing O 
the O 
pore O 
in O 
a O 
2 O 
× O 
2 O 
grid O 
arrangement O 
. O 
In O 
addition O 
to O 
the O 
dynamic O 
analysis O 
, O 
we O 
carried O 
electronic O 
transport O 
calculations O 
on O 
realistic O 
pore O 
structures O 
with O 
diameters O 
reaching O 
nanometer O 
scales O 
. O 
The O 
transmission O 
obtained O 
along O 
the O 
graphene B-TRIVIAL 
sensor O 
at O 
the O 
Fermi O 
level O 
is O 
affected O 
by O 
the O 
presence O 
of O 
the O 
DNA O 
. O 
However O 
, O 
it O 
is O 
rather O 
hard O 
to O 
distinguish O 
the O 
respective O 
nucleobases B-FAMILY 
. O 
This O 
scenario O 
can O 
be O 
significantly O 
altered O 
when O 
the O 
transport O 
is O 
conducted O 
away O 
from O 
the O 
Fermi O 
level O 
of O 
the O 
graphene B-TRIVIAL 
platform O 
. O 
Under O 
an O 
energy O 
shift O 
, O 
we O 
observed O 
that O 
the O 
graphene B-TRIVIAL 
pore O 
manifests O 
selectiveness O 
toward O 
DNA O 
nucleobases B-FAMILY 
. O 

of O 
the O 
First O 
C-Nucleoside B-FAMILY 
HCV O 
Polymerase O 
Inhibitor O 
( O 
GS-6620 B-IDENTIFIER 
) O 
with O 
Demonstrated O 
Antiviral O 
Response O 
in O 
HCV O 
Infected O 
Patients O 
. O 

C O 
virus O 
( O 
HCV O 
) O 
infection O 
presents O 
an O 
unmet O 
medical O 
need O 
requiring O 
more O 
effective O 
treatment O 
options O 
. O 
Nucleoside B-FAMILY 
inhibitors O 
( O 
NI O 
) O 
of O 
HCV O 
polymerase O 
( O 
NS5B O 
) O 
have O 
demonstrated O 
pan O 
- O 
genotypic O 
activity O 
and O 
durable O 
antiviral O 
response O 
in O 
the O 
clinic O 
, O 
and O 
they O 
are O 
likely O 
to O 
become O 
a O 
key O 
component O 
of O 
future O 
treatment O 
regimens O 
. O 
NI O 
candidates O 
that O 
have O 
entered O 
clinical O 
development O 
thus O 
far O 
have O 
all O 
been O 
N-nucleoside B-FAMILY 
derivatives O 
. O 
Herein O 
, O 
we O 
report O 
the O 
discovery O 
of O 
a O 
C-nucleoside B-FAMILY 
class O 
of O 
NS5B O 
inhibitors O 
. O 
Exploration O 
of O 
adenosine B-TRIVIAL 
analogs O 
in O 
this O 
class O 
identified O 
1'-cyano-2'-C-methyl B-SYSTEMATIC 
4-aza-7,9-dideaza I-SYSTEMATIC 
adenosine I-SYSTEMATIC 
as O 
a O 
potent O 
and O 
selective O 
inhibitor O 
of O 
NS5B O 
. O 
A O 
monophosphate B-SYSTEMATIC 
prodrug O 
approach O 
afforded O 
a O 
series O 
of O 
compounds O 
showing O 
submicromolar O 
activity O 
in O 
HCV O 
replicon O 
assays O 
. O 
Further O 
pharmacokinetic O 
optimization O 
for O 
sufficient O 
oral O 
absorption O 
and O 
liver O 
triphosphate B-SYSTEMATIC 
loading O 
led O 
to O 
identification O 
of O 
a O 
clinical O 
development O 
candidate O 
GS-6620 B-IDENTIFIER 
. O 
In O 
a O 
phase O 
I O 
clinical O 
study O 
, O 
the O 
potential O 
for O 
potent O 
activity O 
was O 
demonstrated O 
but O 
with O 
high O 
intra- O 
and O 
interpatient O 
pharmacokinetic O 
and O 
pharmacodynamic O 
variability O 
. O 

of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
ameliorates O 
metabolism O 
- O 
secretion O 
coupling O 
in O 
islets O 
of O 
diabetic O 
GK O 
rats O 
by O 
suppressing O 
lactate B-FAMILY 
overproduction O 
. O 

previously O 
demonstrated O 
that O 
impaired O 
glucose B-TRIVIAL 
-induced O 
insulin O 
secretion O 
( O 
IS O 
) O 
and O 
ATP B-ABBREVIATION 
elevation O 
in O 
islets O 
of O 
Goto-Kakizaki O 
( O 
GK O 
) O 
rats O 
, O 
a O 
non-obese O 
model O 
of O 
diabetes O 
, O 
were O 
significantly O 
restored O 
by O 
30∼60 O 
min O 
suppression O 
of O 
endogenous O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
overproduction O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
longer O 
( O 
12 O 
h O 
) O 
suppression O 
of O 
ROS O 
on O 
metabolism O 
- O 
secretion O 
coupling O 
in O 
β-cells O 
by O 
exposure O 
to O 
tempol B-TRIVIAL 
, O 
a O 
superoxide B-TRIVIAL 
dismutase O 
mimic O 
, O 
plus O 
ebselen B-TRIVIAL 
, O 
a O 
glutathione B-TRIVIAL 
peroxidase O 
mimic O 
( O 
TE O 
- O 
treatment O 
) O 
. O 
In O 
GK O 
islets O 
, O 
both O 
H(2)O(2) B-FORMULA 
and O 
superoxide B-TRIVIAL 
were O 
sufficiently O 
reduced O 
and O 
glucose B-TRIVIAL 
-induced O 
IS O 
and O 
ATP B-ABBREVIATION 
elevation O 
were O 
improved O 
by O 
TE O 
- O 
treatment O 
. O 
Glucose B-TRIVIAL 
oxidation O 
, O 
an O 
indicator O 
of O 
Krebs O 
cycle O 
velocity O 
, O 
also O 
was O 
improved O 
by O 
TE O 
- O 
treatment O 
at O 
high O 
glucose B-TRIVIAL 
, O 
whereas O 
glucokinase O 
activity O 
, O 
which O 
determines O 
glycolytic O 
velocity O 
, O 
was O 
not O 
affected O 
. O 
Lactate B-TRIVIAL 
production O 
was O 
markedly O 
increased O 
in O 
GK O 
islets O 
and O 
TE O 
- O 
treatment O 
reduced O 
lactate B-FAMILY 
production O 
and O 
protein O 
expression O 
of O 
lactate B-FAMILY 
dehydrogenase O 
and O 
hypoxia O 
- O 
inducible O 
factor O 
1α O 
( O 
HIF1α O 
) O 
. O 
These O 
results O 
indicate O 
that O 
the O 
Warburg O 
- O 
like O 
effect O 
, O 
which O 
is O 
characteristic O 
of O 
aerobic O 
metabolism O 
in O 
cancer O 
cells O 
by O 
which O 
lactate B-FAMILY 
is O 
overproduced O 
with O 
reduced O 
linking O 
to O 
mitochondria O 
metabolism O 
, O 
plays O 
an O 
important O 
role O 
in O 
impaired O 
metabolism O 
- O 
secretion O 
coupling O 
in O 
diabetic O 
β-cells O 
and O 
suggest O 
that O 
ROS O 
reduction O 
can O 
improve O 
mitochondrial O 
metabolism O 
by O 
suppressing O 
lactate B-FAMILY 
overproduction O 
through O 
inhibition O 
of O 
HIF1α O 
stabilization O 
. O 

has O 
been O 
enzymatically O 
oligomerized O 
by O 
laccase O 
from O 
Trametes O 
versicolor O 
. O 
Five O 
fractions O 
of O 
oligomers O 
were O 
obtained O 
from O 
the O 
monomers O 
having O 
high O 
solubility O 
in O 
water O 
, O 
which O 
can O 
reach O 
351-times O 
that O 
of O 
rutin B-TRIVIAL 
. O 
Cytotoxicity O 
of O 
rutin B-TRIVIAL 
and O 
oligorutin O 
fractions O 
was O 
evaluated O 
towards O 
K562 O 
cells O 
. O 
Oligorutin O 
fractions O 
showed O 
a O 
lower O 
antiproliferative O 
effect O 
compared O 
with O 
its O 
monomer O 
. O 
The O 
genotoxic O 
potential O 
of O 
rutin B-TRIVIAL 
and O 
oligorutin O 
fractions O 
was O 
assessed O 
, O 
at O 
the O 
limit O 
of O 
the O 
solubility O 
of O 
each O 
molecule O 
, O 
using O 
the O 
comet O 
test O 
. O 
None O 
of O 
the O 
tested O 
concentrations O 
of O 
either O 
rutin B-TRIVIAL 
or O 
oligorutin O 
fractions O 
has O 
showed O 
a O 
genotoxic O 
effect O 
. O 
Similarly O 
, O 
the O 
antigenotoxic O 
effect O 
of O 
these O 
flavonoids B-FAMILY 
was O 
tested O 
using O 
the O 
same O 
assay O 
. O 
The O 
obtained O 
results O 
showed O 
a O 
higher O 
ability O 
of O 
oligorutin O 
fractions O 
to O 
reduce O 
the O 
genotoxicity O 
induced O 
by O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
compared O 
with O 
monomeric O 
rutin B-TRIVIAL 
. O 

capsules O 
featuring O 
(i) O 
an O 
external O 
shell O 
by O 
layer O 
- O 
by O 
- O 
layer O 
assembly O 
of O 
poly(l-lysine) B-SYSTEMATIC 
, O 
alginate O 
, O 
and O 
chitosan O 
, O 
and O 
encapsulating O 
(ii) O 
surface O 
functionalized O 
poly(l-lactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PLLA B-ABBREVIATION 
) O 
microparticles O 
were O 
developed O 
. O 
We O 
hypothesize O 
that O 
, O 
while O 
the O 
liquified O 
environment O 
enhances O 
the O 
diffusion O 
of O 
essential O 
molecules O 
for O 
cell O 
survival O 
, O 
microparticles O 
dispersed O 
in O 
the O 
liquified O 
core O 
of O 
capsules O 
provide O 
the O 
physical O 
support O 
required O 
for O 
cellular O 
functions O 
of O 
anchorage O 
- O 
dependent O 
cells O 
. O 
The O 
influence O 
of O 
the O 
incorporation O 
of O 
PLL B-ABBREVIATION 
on O 
the O 
regime O 
growth O 
, O 
thickness O 
, O 
and O 
stability O 
was O 
analyzed O 
. O 
Results O 
show O 
a O 
more O 
resistant O 
and O 
thicker O 
film O 
with O 
an O 
exponential O 
build O 
- O 
up O 
growth O 
regime O 
. O 
Moreover O 
, O 
capsules O 
ability O 
to O 
support O 
cell O 
survival O 
was O 
assessed O 
. O 
Capsules O 
containing O 
microparticles O 
revealed O 
an O 
enhanced O 
biological O 
outcome O 
in O 
cell O 
metabolic O 
activity O 
and O 
proliferation O 
, O 
suggesting O 
their O 
potential O 
to O 
boost O 
the O 
development O 
of O 
innovative O 
biomaterial O 
designs O 
for O 
bioencapsulation O 
systems O 
and O 
tissue O 
engineering O 
products O 
. O 

- O 
induced O 
visible O 
supramolecular O 
chiral O 
recognition O 
by O 
fluorescent O 
metal O 
complexes O 
of O 
quinolinol B-TRIVIAL 
- O 
glutamide B-TRIVIAL 
. O 

metal O 
complexes O 
consisting O 
of O 
Li(+) B-FORMULA 
, O 
Zn(2+) B-FORMULA 
, O 
and O 
Al(3+) B-FORMULA 
and O 
quinolinol B-FAMILY 
- I-FAMILY 
functionalized I-FAMILY 
l-glutamides I-FAMILY 
( O 
HQLG B-FAMILY 
) O 
, O 
( O 
abbreviated O 
as O 
LiHQLG B-FORMULA 
, O 
Zn(HQLG)2 B-FORMULA 
, O 
and O 
Al(HQLG)3 B-FORMULA 
) O 
were O 
found O 
to O 
form O 
fluorescent O 
metallogels O 
in O 
several O 
organic O 
solvents O 
. O 
In O 
solution O 
, O 
these O 
chiral O 
complexes O 
showed O 
neither O 
any O 
CD O 
signal O 
in O 
the O 
chromophore O 
region O 
nor O 
chiral O 
recognition O 
of O 
the O 
chiral O 
species O 
. O 
However O 
, O 
upon O 
gel O 
formation O 
, O 
the O 
supramolecular O 
chirality O 
emerged O 
because O 
of O 
the O 
self O 
- O 
assembled O 
nanostructures O 
, O 
which O 
provided O 
an O 
opportunity O 
for O 
the O 
chiral O 
recognition O 
of O 
enantiomeric O 
ligands O 
. O 
The O 
metallogels O 
showed O 
different O 
fluorescence O 
changes O 
when O 
they O 
met O 
with O 
enantiomeric O 
(R,R)- B-MULTIPLE 
or I-MULTIPLE 
(S,S)-1,2-diaminocyclohexane I-MULTIPLE 
. O 
Among O 
them O 
, O 
the O 
Al(HQLG)3 B-FORMULA 
metallogels O 
did O 
not O 
show O 
any O 
change O 
whereas O 
the O 
LiHQLG B-FORMULA 
gels O 
exhibited O 
the O 
same O 
decrease O 
in O 
fluorescence O 
. O 
Interestingly O 
, O 
the O 
Zn(HQLG)2 B-FORMULA 
gels O 
showed O 
obviously O 
different O 
fluorescent O 
color O 
with O 
respect O 
to O 
(R,R)- B-MULTIPLE 
and I-MULTIPLE 
(S,S)-1,2-diaminocyclohexane I-MULTIPLE 
, O 
thus O 
providing O 
visible O 
chiral O 
recognition O 
via O 
the O 
naked O 
eye O 
. O 
Such O 
different O 
recognition O 
ability O 
was O 
discussed O 
on O 
the O 
basis O 
of O 
the O 
assembled O 
chiral O 
nanostructures O 
and O 
the O 
primary O 
molecular O 
structures O 
of O 
the O 
metal O 
complexes O 
. O 
It O 
was O 
shown O 
that O 
both O 
of O 
them O 
played O 
important O 
roles O 
in O 
chiral O 
recognition O 
. O 

VUV O 
photoionization O 
study O 
of O 
the O 
multichannel O 
reaction O 
of O 
phenyl B-SYSTEMATIC 
radicals O 
with O 
1,3-butadiene B-SYSTEMATIC 
under O 
combustion O 
relevant O 
conditions O 
. O 

studied O 
the O 
reaction O 
of O 
phenyl B-SYSTEMATIC 
radicals O 
( O 
C(6)H(5) B-FORMULA 
) O 
with O 
1,3-butadiene B-SYSTEMATIC 
( O 
H(2)CCHCHCH(2) B-FORMULA 
) O 
exploiting O 
a O 
high O 
temperature O 
chemical O 
reactor O 
under O 
combustion O 
- O 
like O 
conditions O 
( O 
300 O 
Torr O 
, O 
873 O 
K O 
) O 
. O 
The O 
reaction O 
products O 
were O 
probed O 
in O 
a O 
supersonic O 
beam O 
by O 
utilizing O 
VUV O 
radiation O 
from O 
the O 
Advanced O 
Light O 
Source O 
and O 
by O 
recording O 
the O 
experimental O 
PIE O 
curves O 
at O 
mass O 
- O 
to O 
- O 
charge O 
ratios O 
of O 
m O 
/ O 
z O 
= O 
130 O 
( O 
C(10)H(10)(+) B-FORMULA 
) O 
, O 
116 O 
( O 
C(9)H(8)(+) B-FORMULA 
) O 
, O 
and O 
104 O 
( O 
C(8)H(8)(+) B-FORMULA 
) O 
. O 
Our O 
data O 
suggest O 
that O 
the O 
atomic O 
hydrogen B-SYSTEMATIC 
( O 
H B-FORMULA 
) O 
, O 
methyl B-SYSTEMATIC 
( O 
CH(3) B-FORMULA 
) O 
, O 
and O 
vinyl B-FAMILY 
( O 
C(2)H(3) B-FORMULA 
) O 
losses O 
are O 
open O 
with O 
estimated O 
branching O 
ratios O 
of O 
about O 
86 O 
± O 
4% O 
, O 
8 O 
± O 
2% O 
, O 
and O 
6 O 
± O 
2% O 
, O 
respectively O 
. O 
The O 
isomer O 
distributions O 
were O 
probed O 
further O 
by O 
fitting O 
the O 
experimentally O 
recorded O 
PIE O 
curves O 
with O 
a O 
linear O 
combination O 
of O 
the O 
PIE O 
curves O 
of O 
individual O 
C(10)H(10) B-FORMULA 
, O 
C(9)H(8) B-FORMULA 
, O 
and O 
C(8)H(8) B-FORMULA 
isomers O 
. O 
These O 
fits O 
indicate O 
the O 
formation O 
of O 
three O 
C(10)H(10) B-FORMULA 
isomers O 
( O 
trans-1,3-butadienylbenzene B-SYSTEMATIC 
, O 
1,4-dihydronaphthalene B-SYSTEMATIC 
, O 
1-methylindene B-SYSTEMATIC 
) O 
, O 
three O 
C(9)H(8) B-FORMULA 
isomers O 
( O 
indene B-TRIVIAL 
, O 
phenylallene B-SYSTEMATIC 
, O 
1-phenyl-1-methylacetylene B-SYSTEMATIC 
) O 
, O 
and O 
a O 
C(8)H(8) B-FORMULA 
isomer O 
( O 
styrene B-TRIVIAL 
) O 
. O 
A O 
comparison O 
with O 
results O 
from O 
recent O 
crossed O 
molecular O 
beam O 
studies O 
of O 
the O 
1,3-butadiene- B-SYSTEMATIC 
phenyl I-SYSTEMATIC 
radical O 
reaction O 
and O 
electronic O 
structure O 
calculations O 
suggests O 
that O 
trans-1,3-butadienylbenzene B-SYSTEMATIC 
( O 
130 O 
amu O 
) O 
, O 
1,4-dihydronaphthalene B-SYSTEMATIC 
( O 
130 O 
amu O 
) O 
, O 
and O 
styrene B-TRIVIAL 
( O 
104 O 
amu O 
) O 
are O 
reaction O 
products O 
formed O 
as O 
a O 
consequence O 
of O 
a O 
bimolecular O 
reaction O 
between O 
the O 
phenyl B-SYSTEMATIC 
radical O 
and O 
1,3-butadiene B-SYSTEMATIC 
. O 
1-Methylindene B-SYSTEMATIC 
( O 
130 O 
amu O 
) O 
, O 
indene B-TRIVIAL 
( O 
116 O 
amu O 
) O 
, O 
phenylallene B-SYSTEMATIC 
( O 
116 O 
amu O 
) O 
, O 
and O 
1-phenyl-1-methylacetylene B-SYSTEMATIC 
( O 
116 O 
amu O 
) O 
are O 
synthesized O 
upon O 
reaction O 
of O 
the O 
phenyl B-SYSTEMATIC 
radical O 
with O 
three O 
C(4)H(6) B-FORMULA 
isomers O 
: O 
1,2-butadiene B-SYSTEMATIC 
( O 
H(2)CCCH(CH(3)) B-FORMULA 
) O 
, O 
1-butyne B-SYSTEMATIC 
( O 
HCCC(2)H(5) B-FORMULA 
) O 
, O 
and O 
2-butyne B-SYSTEMATIC 
( O 
CH(3)CCCH(3) B-FORMULA 
) O 
; O 
these O 
C(4)H(6) B-FORMULA 
isomers O 
can O 
be O 
formed O 
from O 
1,3-butadiene B-SYSTEMATIC 
via O 
hydrogen B-SYSTEMATIC 
atom O 
assisted O 
isomerization O 
reactions O 
or O 
via O 
thermal O 
rearrangements O 
of O 
1,3-butadiene B-SYSTEMATIC 
involving O 
hydrogen B-SYSTEMATIC 
shifts O 
in O 
the O 
high O 
temperature O 
chemical O 
reactor O 
. O 

cytoplasmic O 
receptor O 
NOD2 O 
( O 
nucleotide B-FAMILY 
-binding O 
oligomerization O 
domain O 
2 O 
) O 
senses O 
peptidoglycan O 
fragments O 
and O 
triggers O 
host O 
defense O 
pathways O 
, O 
including O 
activation O 
of O 
nuclear O 
factor O 
κB O 
( O 
NF-κB O 
) O 
signaling O 
, O 
which O 
lead O 
to O 
inflammatory O 
immune O 
responses O 
. O 
Dysregulation O 
of O 
NOD2 O 
signaling O 
is O 
associated O 
with O 
inflammatory O 
diseases O 
, O 
such O 
as O 
Crohn's O 
disease O 
and O 
Blau O 
syndrome O 
. O 
We O 
used O 
a O 
genome O 
- O 
wide O 
small O 
interfering O 
RNA O 
screen O 
to O 
identify O 
regulators O 
of O 
the O 
NOD2 O 
signaling O 
pathway O 
. O 
Several O 
genes O 
associated O 
with O 
Crohn's O 
disease O 
risk O 
were O 
identified O 
in O 
the O 
screen O 
. O 
A O 
comparison O 
of O 
candidates O 
from O 
this O 
screen O 
with O 
other O 
" O 
omics O 
" O 
data O 
sets O 
revealed O 
interconnected O 
networks O 
of O 
genes O 
implicated O 
in O 
NF-κB O 
signaling O 
, O 
thus O 
supporting O 
a O 
role O 
for O 
NOD2 O 
and O 
NF-κB O 
pathways O 
in O 
the O 
pathogenesis O 
of O 
Crohn's O 
disease O 
. O 
Many O 
of O 
these O 
regulators O 
were O 
validated O 
in O 
secondary O 
assays O 
, O 
such O 
as O 
measurement O 
of O 
interleukin-8 O 
secretion O 
, O 
which O 
is O 
partially O 
dependent O 
on O 
NF-κB O 
. O 
Knockdown O 
of O 
putative O 
regulators O 
in O 
human O 
embryonic O 
kidney O 
293 O 
cells O 
followed O 
by O 
stimulation O 
with O 
tumor O 
necrosis O 
factor-α O 
revealed O 
that O 
most O 
of O 
the O 
genes O 
identified O 
were O 
general O 
regulators O 
of O 
NF-κB O 
signaling O 
. O 
Overall O 
, O 
the O 
genes O 
identified O 
here O 
provide O 
a O 
resource O 
to O 
facilitate O 
the O 
elucidation O 
of O 
the O 
molecular O 
mechanisms O 
that O 
regulate O 
NOD2- O 
and O 
NF-κB O 
- O 
mediated O 
inflammation O 
. O 

traceability O 
/ O 
authenticity O 
is O 
a O 
worldwide O 
concern O 
. O 
Stable O 
isotope O 
techniques O 
have O 
been O 
suggested O 
as O 
a O 
tool O 
to O 
address O 
this O 
issue O 
. O 
To O 
further O 
validate O 
the O 
use O 
of O 
these O 
techniques O 
, O 
a O 
research O 
project O 
was O 
undertaken O 
to O 
evaluate O 
what O 
effect O 
sample O 
collection O 
and O 
preparation O 
have O 
on O 
the O 
measured O 
isotopic O 
composition O 
of O 
egg O 
components O 
. O 
The O 
timing O 
of O 
egg O 
collection O 
, O 
the O 
timing O 
of O 
egg O 
preparation O 
after O 
collection O 
, O 
and O 
the O 
use O 
of O 
pasteurisation O 
were O 
investigated O 
. O 
The O 
C B-FORMULA 
, O 
N B-FORMULA 
, O 
O B-FORMULA 
, O 
and O 
S B-FORMULA 
isotopic O 
compositions O 
of O 
egg O 
components O 
from O 
7 O 
different O 
production O 
systems O 
were O 
measured O 
. O 
Two O 
sets O 
of O 
eggs O 
were O 
collected O 
( O 
4 O 
months O 
apart O 
) O 
. O 
It O 
was O 
found O 
that O 
the O 
' O 
isotopic O 
fingerprint O 
' O 
of O 
a O 
particular O 
production O 
system O 
was O 
maintained O 
over O 
time O 
, O 
and O 
that O 
it O 
may O 
be O 
possible O 
to O 
trace O 
liquid O 
egg O 
products O 
based O 
on O 
isotopic O 
data O 
from O 
fresh O 
eggs O 
. O 
The O 
findings O 
from O 
this O 
study O 
support O 
the O 
integration O 
of O 
stable O 
isotope O 
techniques O 
in O 
egg O 
traceability O 
/ O 
authenticity O 
systems O 
. O 

activities O 
of O 
thiosemicarbazones B-FAMILY 
from O 
substituted O 
benzaldehydes B-FAMILY 
and O 
N-(tetra-O-acetyl-β-D-galactopyranosyl)thiosemicarbazide B-SYSTEMATIC 
. O 

of O 
N-(2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl)thiosemicarbazide B-SYSTEMATIC 
and O 
different O 
substituted O 
benzaldehydes B-FAMILY 
gave O 
some O 
new O 
substituted O 
benzaldehyde B-FAMILY 
N-(2,3,4,6-tetra-O-acetyl-β-d-galactopyranosyl)thiosemicarbazones I-FAMILY 
. O 
The O 
reaction O 
was O 
performed O 
using O 
conventional O 
and O 
microwave O 
- O 
assisted O 
heating O 
methods O 
. O 
The O 
structures O 
of O 
thiosemicarbazones B-FAMILY 
were O 
confirmed O 
by O 
spectroscopic O 
( O 
IR O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
and O 
ESI-MS O 
) O 
method O 
. O 
The O 
antioxidant O 
activity O 
of O 
these O 
thiosemicarbazones B-FAMILY 
was O 
evaluated O 
in O 
vitro O 
and O 
in O 
vivo O 
, O 
and O 
it's O 
shown O 
that O 
some O 
of O 
these O 
compounds O 
had O 
significant O 
antioxidant O 
activity O 
. O 
Amongst O 
the O 
compounds O 
screened O 
for O 
antioxidant O 
activity O 
, O 
thiosemicarbazones B-FAMILY 
4a O 
, O 
4b O 
and O 
4c O 
showed O 
good O 
antioxidant O 
activity O 
on O 
DPPH B-ABBREVIATION 
. O 
The O 
compounds O 
4g O 
, O 
4i O 
, O 
4l O 
caused O 
significant O 
elevation O 
of O 
SOD O 
activity O 
and O 
4e O 
, O 
4g O 
, O 
4i O 
, O 
4l O 
had O 
higher O 
catalase O 
activity O 
, O 
and O 
only O 
compounds O 
4c O 
and O 
4f O 
expressed O 
the O 
GSH B-ABBREVIATION 
-Px O 
activity O 
. O 

Activity O 
of O 
Simvastatin B-TRIVIAL 
Induces O 
Cell O 
Cycle O 
Arrest O 
in O 
G1 O 
via O 
Blockade O 
of O 
Cyclin O 
D-Cdk4 O 
Expression O 
in O 
Non-Small O 
Cell O 
Lung O 
Cancer O 
( O 
NSCLC O 
) O 
. O 

cancer O 
is O 
the O 
most O 
common O 
cause O 
of O 
cancer O 
- O 
related O 
death O 
. O 
Nonetheless O 
, O 
a O 
decrease O 
in O 
overall O 
incidence O 
and O 
mortality O 
has O 
been O 
observed O 
in O 
the O 
last O 
30 O 
years O 
due O 
to O 
prevention O 
strategies O 
and O 
improvements O 
in O 
the O 
use O 
of O 
chemotherapeutic O 
agents O 
. O 
In O 
recent O 
studies O 
, O 
Simvastatin B-TRIVIAL 
( O 
SIM B-ABBREVIATION 
) O 
has O 
demonstrated O 
anti-tumor O 
activity O 
, O 
as O 
well O 
as O 
potent O 
chemopreventive O 
action O 
. O 
As O 
an O 
inhibitor O 
of O 
3-hydroxy-3-methylglutaryl-coenzyme B-SYSTEMATIC 
A I-SYSTEMATIC 
reductase O 
( O 
HMG B-ABBREVIATION 
- O 
CoA B-ABBREVIATION 
) O 
, O 
SIM B-ABBREVIATION 
has O 
been O 
shown O 
to O 
stimulate O 
apoptotic O 
cell O 
death O 
. O 
In O 
this O 
study O 
, O 
an O 
MTT B-ABBREVIATION 
assay O 
revealed O 
the O 
cytotoxic O 
activity O 
of O 
SIM B-ABBREVIATION 
against O 
human O 
large O 
cell O 
lung O 
cancer O 
( O 
Non-small O 
cell O 
lung O 
cancer O 
; O 
NSCLC O 
) O 
cells O 
( O 
NCI-H460 O 
) O 
; O 
however O 
, O 
induced O 
apoptosis O 
was O 
not O 
observed O 
in O 
NCI-H460 O 
cells O 
. O 
Protein O 
expression O 
levels O 
of O 
cell O 
cycle O 
regulating O 
proteins O 
Cdk4 O 
, O 
Cyclin O 
D1 O 
, O 
p16 O 
and O 
p27 O 
were O 
markedly O 
altered O 
by O 
SIM B-ABBREVIATION 
. O 
Collectively O 
, O 
our O 
results O 
indicate O 
that O 
SIM B-ABBREVIATION 
inhibits O 
cell O 
proliferation O 
and O 
arrests O 
NCI-H460 O 
cell O 
cycle O 
progression O 
via O 
inhibition O 
of O 
cyclin O 
- O 
dependent O 
kinases O 
and O 
cyclins O 
and O 
the O 
enhancement O 
of O 
CDK O 
inhibitors O 
p16 O 
and O 
p27 O 
. O 
Our O 
findings O 
suggest O 
that O 
, O 
in O 
addition O 
to O 
the O 
known O 
effects O 
on O 
hypercholesterolemia O 
therapy O 
, O 
SIM B-ABBREVIATION 
may O 
also O 
provide O 
antitumor O 
activity O 
in O 
established O 
NSCLC O 
. O 

fracture O 
( O 
PF O 
) O 
is O 
known O 
as O 
a O 
traumatic O 
rupture O 
of O 
the O 
tunica O 
albuginea O 
of O 
corpus O 
cavernosum O 
. O 
In O 
this O 
study O 
, O 
we O 
aimed O 
to O 
investigate O 
the O 
healing O 
influence O 
of O 
topical O 
extra O 
virgin O 
olive O 
oil O 
( O 
EVOO O 
) O 
on O 
PF O 
through O 
evaluating O 
levels O 
of O 
some O 
oxidative O 
stress O 
biomarkers O 
for O 
the O 
first O 
time O 
. O 
Histopathological O 
evaluation O 
was O 
also O 
realized O 
. O 
A O 
total O 
of O 
18 O 
male O 
Sprague-Dawley O 
albino O 
rats O 
were O 
divided O 
into O 
three O 
groups O 
of O 
six O 
rats O 
each O 
as O 
control O 
group O 
, O 
in O 
PF O 
( O 
alone O 
) O 
group O 
, O 
and O 
PF O 
+ O 
EVOO O 
group O 
. O 
Experimental O 
PF O 
was O 
formed O 
via O 
incising O 
from O 
the O 
proximal O 
dorsal O 
side O 
of O 
the O 
penis O 
in O 
the O 
rats O 
of O 
all O 
groups O 
except O 
control O 
. O 
While O 
in O 
PF O 
( O 
alone O 
) O 
group O 
, O 
fracture O 
was O 
formed O 
and O 
the O 
incision O 
was O 
primarily O 
closed O 
, O 
in O 
PF O 
+ O 
EVOO O 
group O 
in O 
addition O 
to O 
foregoing O 
processes O 
, O 
EVOO O 
was O 
also O 
administrated O 
topically O 
twice O 
a O 
day O 
for O 
3 O 
weeks O 
. O 
At O 
the O 
end O 
of O 
the O 
experiment O 
, O 
all O 
rats O 
were O 
killed O 
and O 
penectomy O 
was O 
carried O 
out O 
. O 
While O 
malondialdehyde B-TRIVIAL 
, O 
myeloperoxidase O 
, O 
lipid O 
hyroperoxide B-SYSTEMATIC 
, O 
and O 
total O 
oxidant O 
status O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
increased O 
, O 
reduced O 
glutathione B-TRIVIAL 
and O 
total O 
free O 
sulfhydryl B-FAMILY 
groups O 
markedly O 
( O 
p O 
< O 
0.05 O 
) O 
decreased O 
in O 
PF O 
( O 
alone O 
) O 
group O 
when O 
compared O 
with O 
PF O 
+ O 
EVOO O 
group O 
. O 
Levels O 
of O 
these O 
parameters O 
were O 
reversed O 
to O 
nearly O 
normal O 
values O 
by O 
topical O 
EVOO O 
application O 
. O 
Protection O 
by O 
EVOO O 
is O 
further O 
substantiated O 
via O 
the O 
improved O 
histological O 
findings O 
in O 
PF O 
+ O 
EVOO O 
group O 
as O 
against O 
degenerative O 
changes O 
in O 
the O 
rats O 
of O 
PF O 
( O 
alone O 
) O 
group O 
. O 
Our O 
data O 
revealed O 
that O 
EVOO O 
has O 
protective O 
effect O 
in O 
penile O 
cavernosal O 
tissue O 
through O 
probably O 
its O 
antioxidant O 
, O 
free O 
radical O 
defusing O 
, O 
anti-inflammatory O 
, O 
and O 
antimicrobial O 
effects O 
. O 

Lake O 
is O 
the O 
largest O 
shallow O 
freshwater O 
lake O 
in O 
eastern O 
China O 
and O 
is O 
suffering O 
not O 
only O 
from O 
an O 
increasingly O 
serious O 
threat O 
of O 
eutrophication O 
but O 
also O 
potential O 
ecological O 
risk O 
due O 
to O 
the O 
input O 
of O 
emerging O 
contaminants O 
. O 
Active O 
biomonitoring O 
was O 
conducted O 
in O 
Taihu O 
Lake O 
using O 
transplanted O 
goldfish O 
( O 
Carassius O 
auratus O 
) O 
to O 
determine O 
the O 
contamination O 
by O 
pharmaceuticals O 
and O 
metals O 
and O 
to O 
assess O 
the O 
potential O 
ecological O 
risk O 
. O 
A O 
suite O 
of O 
biomarkers O 
including O 
acetylcholinesterase O 
, O 
ethoxyresorufin B-SYSTEMATIC 
O B-FORMULA 
-deethylase O 
, O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
superoxide B-TRIVIAL 
dismutase O 
activities O 
in O 
fish O 
after O 
7 O 
, O 
14 O 
, O 
21 O 
and O 
28 O 
days O 
of O 
exposure O 
in O 
situ O 
, O 
as O 
well O 
as O 
pharmaceuticals O 
and O 
metals O 
in O 
water O 
, O 
were O 
determined O 
during O 
the O 
field O 
exposure O 
period O 
. O 
The O 
results O 
indicate O 
that O 
pharmaceuticals O 
exist O 
mainly O 
in O 
Zhushan O 
Bay O 
and O 
Meiliang O 
Bay O 
, O 
while O 
metals O 
are O 
present O 
mainly O 
in O 
Gong O 
Bay O 
. O 
An O 
integrated O 
biomarker O 
response O 
( O 
IBR O 
) O 
was O 
calculated O 
and O 
used O 
to O 
evaluate O 
the O 
ecological O 
risk O 
of O 
the O 
polluted O 
area O 
of O 
Taihu O 
Lake O 
. O 
It O 
was O 
found O 
that O 
Zhushan O 
Bay O 
might O 
present O 
higher O 
risk O 
to O 
fish O 
, O 
followed O 
by O 
Meiliang O 
Bay O 
. O 
IBR O 
values O 
were O 
in O 
good O 
agreement O 
with O 
copper B-SYSTEMATIC 
and O 
caffeine B-TRIVIAL 
concentrations O 
. O 

report O 
describes O 
an O 
improved O 
protocol O 
to O 
generate O 
stranded O 
, O 
barcoded O 
RNA-seq O 
libraries O 
to O 
capture O 
the O 
whole O 
transcriptome O 
. O 
By O 
optimizing O 
the O 
use O 
of O 
duplex O 
specific O 
nuclease O 
( O 
DSN O 
) O 
to O 
remove O 
ribosomal O 
RNA O 
reads O 
from O 
stranded O 
barcoded O 
libraries O 
, O 
we O 
demonstrate O 
improved O 
efficiency O 
of O 
multiplexed O 
next O 
generation O 
sequencing O 
( O 
NGS O 
) O 
. O 
This O 
approach O 
detects O 
expression O 
profiles O 
of O 
all O 
RNA O 
types O 
, O 
including O 
miRNA O 
( O 
microRNA O 
) O 
, O 
piRNA O 
( O 
Piwi O 
- O 
interacting O 
RNA O 
) O 
, O 
snoRNA O 
( O 
small O 
nucleolar O 
RNA O 
) O 
, O 
lincRNA O 
( O 
long O 
non-coding O 
RNA O 
) O 
, O 
mtRNA O 
( O 
mitochondrial O 
RNA O 
) O 
and O 
mRNA O 
( O 
messenger O 
RNA O 
) O 
without O 
the O 
use O 
of O 
gel O 
electrophoresis O 
. O 
The O 
improved O 
protocol O 
generates O 
high O 
quality O 
data O 
that O 
can O 
be O 
used O 
to O 
identify O 
differential O 
expression O 
in O 
known O 
and O 
novel O 
coding O 
and O 
non-coding O 
transcripts O 
, O 
splice O 
variants O 
, O 
mitochondrial O 
genes O 
and O 
SNPs O 
( O 
single O 
nucleotide B-FAMILY 
polymorphisms O 
) O 
. O 

effect O 
of O 
5-fluorouracil B-SYSTEMATIC 
is O 
enhanced O 
by O 
rosemary O 
extract O 
in O 
both O 
drug O 
sensitive O 
and O 
resistant O 
colon O 
cancer O 
cells O 
. O 

( O 
5-FU B-SYSTEMATIC 
) O 
is O 
the O 
most O 
used O 
chemotherapeutic O 
agent O 
in O 
colorectal O 
cancer O 
. O 
However O 
, O 
resistance O 
to O 
this O 
drug O 
is O 
relatively O 
frequent O 
, O 
and O 
new O 
strategies O 
to O 
overcome O 
it O 
are O 
urgently O 
needed O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
determine O 
the O 
antitumor O 
properties O 
of O 
a O 
supercritical O 
fluid O 
rosemary O 
extract O 
( O 
SFRE O 
) O 
, O 
alone O 
and O 
in O 
combination O 
with O 
5-FU B-SYSTEMATIC 
, O 
as O 
a O 
potential O 
adjuvant O 
therapy O 
useful O 
for O 
colon O 
cancer O 
patients O 
. O 
This O 
extract O 
has O 
been O 
recognized O 
as O 
a O 
healthy O 
component O 
by O 
the O 
European O 
Food O 
Safety O 
Authority O 
( O 
EFSA O 
) O 
. O 
The O 
effects O 
of O 
SFRE O 
both O 
alone O 
and O 
in O 
combination O 
with O 
5-FU B-SYSTEMATIC 
were O 
evaluated O 
in O 
different O 
human O 
colon O 
cancer O 
cells O 
in O 
terms O 
of O 
cell O 
viability O 
, O 
cytotoxicity O 
, O 
and O 
cell O 
transformation O 
. O 
Additionally O 
, O 
colon O 
cancer O 
cells O 
resistant O 
to O 
5-FU B-SYSTEMATIC 
were O 
used O 
to O 
assay O 
the O 
effects O 
of O 
SFRE O 
on O 
drug O 
resistance O 
. O 
Finally O 
, O 
qRT-PCR O 
was O 
performed O 
to O 
ascertain O 
the O 
mechanism O 
by O 
which O 
SFRE O 
potentiates O 
the O 
effect O 
of O 
5-FU B-SYSTEMATIC 
. O 
Our O 
results O 
show O 
that O 
SFRE O 
displays O 
dose O 
- O 
dependent O 
antitumor O 
activities O 
and O 
exerts O 
a O 
synergistic O 
effect O 
in O 
combination O 
with O 
5-FU B-SYSTEMATIC 
on O 
colon O 
cancer O 
cells O 
. O 
Furthermore O 
, O 
SFRE O 
sensitizes O 
5-FU B-SYSTEMATIC 
-resistant O 
cells O 
to O 
the O 
therapeutic O 
activity O 
of O 
this O 
drug O 
, O 
constituting O 
a O 
beneficial O 
agent O 
against O 
both O 
5-FU B-SYSTEMATIC 
sensitive O 
and O 
resistant O 
tumor O 
cells O 
. O 
Gene O 
expression O 
analysis O 
indicates O 
that O 
the O 
enhancement O 
of O 
the O 
effect O 
of O 
5-FU B-SYSTEMATIC 
by O 
SFRE O 
might O 
be O 
explained O 
by O 
the O 
downregulation O 
of O 
TYMS O 
and O 
TK1 O 
, O 
enzymes O 
related O 
to O 
5-FU B-SYSTEMATIC 
resistance O 
. O 

analyses O 
of O 
protein O 
sequence O 
alignments O 
identify O 
structures O 
and O 
mechanisms O 
in O 
signal O 
activation O 
of O 
sensor O 
histidine B-TRIVIAL 
kinases O 
. O 

analyses O 
of O 
genome O 
sequence O 
- O 
derived O 
protein O 
sequence O 
data O 
can O 
identify O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
that O 
interact O 
between O 
proteins O 
or O 
between O 
domains O 
of O 
a O 
protein O 
. O 
These O 
statistical O 
methods O 
are O 
based O 
on O 
evolution O 
- O 
directed O 
amino B-FAMILY 
acid I-FAMILY 
variation O 
responding O 
to O 
structural O 
and O 
functional O 
constraints O 
in O 
proteins O 
. O 
The O 
identified O 
residues O 
form O 
a O 
basis O 
for O 
determining O 
structure O 
and O 
folding O 
of O 
proteins O 
as O 
well O 
as O 
inferring O 
mechanisms O 
of O 
protein O 
function O 
. O 
When O 
applied O 
to O 
two O 
- O 
component O 
systems O 
, O 
several O 
research O 
groups O 
have O 
shown O 
they O 
can O 
be O 
used O 
to O 
identify O 
the O 
amino B-FAMILY 
acid I-FAMILY 
interactions O 
between O 
response O 
regulators O 
and O 
histidine B-TRIVIAL 
kinases O 
and O 
the O 
specificity O 
therein O 
. O 
Recently O 
, O 
statistical O 
studies O 
between O 
the O 
HisKA O 
and O 
HATPase- O 
ATP B-ABBREVIATION 
-binding O 
domains O 
of O 
histidine B-TRIVIAL 
kinases O 
identified O 
amino B-FAMILY 
acid I-FAMILY 
interactions O 
for O 
both O 
the O 
inactive O 
and O 
the O 
active O 
catalytic O 
states O 
of O 
such O 
kinases O 
. O 
The O 
identified O 
interactions O 
generated O 
a O 
model O 
structure O 
for O 
the O 
domain O 
conformation O 
of O 
the O 
active O 
state O 
. O 
This O 
conformation O 
requires O 
an O 
unwinding O 
of O 
a O 
portion O 
of O 
the O 
C B-FORMULA 
-terminal O 
helix O 
of O 
the O 
HisKA O 
domain O 
that O 
destroys O 
the O 
inactive O 
state O 
residue O 
contacts O 
and O 
suggests O 
how O 
signal O 
- O 
binding O 
determines O 
the O 
equilibrium O 
between O 
the O 
inactive O 
and O 
active O 
states O 
of O 
histidine B-TRIVIAL 
kinases O 
. O 
The O 
rapidly O 
accumulating O 
protein O 
sequence O 
databases O 
from O 
genome O 
, O 
metagenome O 
and O 
microbiome O 
studies O 
are O 
an O 
important O 
resource O 
for O 
functional O 
and O 
structural O 
understanding O 
of O 
proteins O 
and O 
protein O 
complexes O 
in O 
microbes O 
. O 

of O 
nuclear O 
vibrations O 
, O 
temperature O 
, O 
co O 
- O 
adsorbed O 
water O 
, O 
and O 
dye O 
orientation O 
on O 
light O 
absorption O 
, O 
charge O 
injection O 
and O 
recombination O 
conditions O 
in O 
organic O 
dyes O 
on O 
TiO2 B-FORMULA 
. O 

study O 
the O 
effect O 
of O 
nuclear O 
motions O 
at O 
different O 
temperatures O 
, O 
including O 
the O 
effect O 
of O 
a O 
dye O 
molecule's O 
orientation O 
with O 
respect O 
to O 
the O 
oxide B-SYSTEMATIC 
surface O 
, O 
on O 
factors O 
determining O 
the O 
performance O 
of O 
dye O 
sensitized O 
solar O 
cells O 
: O 
light O 
absorption O 
, O 
electron O 
injection O 
, O 
and O 
back O 
- O 
donation O 
. O 
We O 
perform O 
ab O 
initio O 
molecular O 
dynamics O 
simulations O 
of O 
aminophenyl B-SYSTEMATIC 
acid I-SYSTEMATIC 
dyes O 
NK1 B-TRIVIAL 
and O 
NK7 B-TRIVIAL 
, O 
differing O 
by O 
the O 
electron O 
donating O 
group O 
, O 
in O 
a O 
vacuum O 
and O 
adsorbed O 
in O 
mono- O 
and O 
bi O 
- O 
dentate O 
modes O 
on O 
a O 
dry O 
and O 
a O 
water O 
- O 
covered O 
anatase B-TRIVIAL 
( I-TRIVIAL 
101 I-TRIVIAL 
) I-TRIVIAL 
surface O 
of O 
TiO(2) B-FORMULA 
, O 
at O 
300 O 
and O 
350 O 
K O 
. O 
Nuclear O 
vibrations O 
and O 
an O 
increase O 
of O 
temperature O 
cause O 
a O 
red O 
shift O 
in O 
the O 
absorption O 
spectra O 
of O 
free O 
dyes O 
. O 
This O 
effect O 
is O 
preserved O 
in O 
dyes O 
on O 
dry O 
TiO(2) B-FORMULA 
but O 
largely O 
disappears O 
in O 
the O 
presence O 
of O 
water O 
. O 
Averaged O 
over O 
nuclear O 
vibrations O 
, O 
the O 
driving O 
force O 
to O 
injection O 
, O 
ΔG O 
, O 
differs O 
from O 
the O 
static O 
estimate O 
. O 
It O 
depends O 
on O 
the O 
adsorption O 
mode O 
and O 
the O 
presence O 
of O 
H(2)O B-FORMULA 
but O 
is O 
almost O 
the O 
same O 
for O 
300 O 
and O 
350 O 
K O 
. O 
Recombination O 
to O 
the O 
dye O 
cation O 
is O 
expected O 
to O 
be O 
much O 
enhanced O 
by O 
the O 
approach O 
of O 
the O 
dye O 
oxidation O 
equivalent O 
hole O 
to O 
the O 
surface O 
during O 
dye O 
wagging O 
around O 
TiO(2) B-FORMULA 
. O 
This O 
effect O 
is O 
somewhat O 
mitigated O 
by O 
the O 
co O 
- O 
adsorbed O 
water O 
. O 
The O 
dynamics O 
of O 
ΔG(t) O 
are O 
explained O 
by O 
uncorrelated O 
evolution O 
of O 
the O 
energies O 
of O 
the O 
dye O 
excited O 
state O 
and O 
the O 
conduction O 
band O 
minimum O 
of O 
the O 
oxide B-SYSTEMATIC 
due O 
to O 
their O 
respective O 
vibrations O 
, O 
and O 
are O 
almost O 
independent O 
of O 
dye O 
orientation O 
. O 
It O 
may O 
therefore O 
be O 
possible O 
to O 
independently O 
control O 
the O 
conditions O 
of O 
recombination O 
and O 
of O 
injection O 
. O 

: O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
association O 
of O 
PON1 O 
genetic O 
variants O 
with O 
the O 
susceptibility O 
to O 
coronary O 
artery O 
disease O 
( O 
CAD O 
) O 
and O 
with O 
the O 
clinical O 
endpoints O 
in O 
aspirin B-TRIVIAL 
and O 
clopidogrel B-TRIVIAL 
( O 
dual O 
antiplatelet O 
therapy O 
) O 
- O 
treated O 
Han O 
Chinese O 
patients O 
with O 
CAD O 
after O 
percutaneous O 
coronary O 
intervention O 
( O 
PCI O 
) O 
. O 
METHODS O 
: O 
A O 
total O 
of O 
538 O 
Han O 
Chinese O 
patients O 
undergoing O 
PCI O 
and O 
receiving O 
dual O 
- O 
antiplatelet O 
therapy O 
were O 
sequentially O 
recruited O 
to O 
the O 
study O 
and O 
followed O 
for O 
up O 
to O 
1 O 
year O 
. O 
Healthy O 
controls O 
( O 
n O 
= O 
539 O 
) O 
were O 
enrolled O 
during O 
the O 
same O 
period O 
. O 
All O 
study O 
participants O 
were O 
genotyped O 
for O 
five O 
genetic O 
variants O 
in O 
PON1 O 
and O 
the O 
cytochrome O 
P450 O 
2C19*2 O 
mutation O 
( O 
CYP2C19*2 O 
) O 
. O 
The O 
effect O 
of O 
genetic O 
variants O 
on O 
disease O 
risk O 
and O 
clinical O 
outcome O 
of O 
major O 
adverse O 
cardiac O 
events O 
( O 
MACE O 
) O 
within O 
1 O 
year O 
or O 
bleeding O 
within O 
6 O 
months O 
was O 
assessed O 
. O 
RESULTS O 
: O 
CYP2C19*2 O 
was O 
associated O 
with O 
a O 
higher O 
risk O 
of O 
MACE O 
( O 
adjusted O 
P O 
= O 
0.0098 O 
) O 
, O 
but O 
a O 
lower O 
risk O 
of O 
bleeding O 
events O 
( O 
adjusted O 
P O 
= O 
0.0016 O 
) O 
. O 
The O 
PON1 O 
Q192R O 
polymorphism O 
was O 
significantly O 
associated O 
with O 
a O 
lower O 
risk O 
of O 
bleeding O 
events O 
[ O 
odds O 
ratio O 
( O 
OR O 
) O 
0.61 O 
, O 
95% O 
confidence O 
interval O 
( O 
CI O 
) O 
0.43-0.87 O 
, O 
adjusted O 
P O 
= O 
0.0066 O 
) O 
. O 
The O 
haplotype O 
bearing O 
the O 
PON1 O 
-126C O 
allele O 
was O 
associated O 
with O 
a O 
higher O 
risk O 
to O 
CAD O 
( O 
OR O 
1.48 O 
, O 
95% O 
CI O 
1.04-2.09 O 
, O 
P O 
= O 
0.029 O 
) O 
and O 
a O 
higher O 
risk O 
of O 
bleeding O 
events O 
( O 
OR O 
1.68 O 
, O 
95% O 
CI O 
1.10-2.56 O 
, O 
P O 
= O 
0.017 O 
) O 
compared O 
to O 
the O 
most O 
frequent O 
haplotype O 
. O 
The O 
transcription O 
activity O 
of O 
haplotype O 
p-162A-126C-108C O 
in O 
the O 
PON1 O 
promoter O 
was O 
2.6-fold O 
higher O 
than O 
that O 
of O 
the O 
most O 
frequent O 
haplotype O 
( O 
p-162G-126G-108T O 
) O 
. O 
CONCLUSIONS O 
: O 
Based O 
on O 
these O 
results O 
, O 
we O 
suggest O 
that O 
the O 
haplotype O 
- O 
bearing O 
PON1 O 
-126C O 
allele O 
contributes O 
to O 
the O 
disease O 
risk O 
and O 
the O 
risk O 
of O 
bleeding O 
events O 
in O 
dual O 
antiplatelet O 
- O 
treated O 
CAD O 
patients O 
after O 
PCI O 
. O 

humans O 
, O 
the O 
double O 
- O 
stranded O 
RNA O 
(dsRNA)-activated O 
protein O 
kinase O 
( O 
PKR O 
) O 
is O 
expressed O 
in O 
late O 
stages O 
of O 
the O 
innate O 
immune O 
response O 
to O 
viral O 
infection O 
by O 
the O 
interferon O 
pathway O 
. O 
PKR O 
consists O 
of O 
tandem O 
dsRNA O 
binding O 
motifs O 
( O 
dsRBMs O 
) O 
connected O 
via O 
a O 
flexible O 
linker O 
to O 
a O 
Ser B-FORMULA 
/ O 
Thr B-FORMULA 
kinase O 
domain O 
. O 
Upon O 
interaction O 
with O 
viral O 
dsRNA O 
, O 
PKR O 
is O 
converted O 
into O 
a O 
catalytically O 
active O 
enzyme O 
capable O 
of O 
phosphorylating O 
a O 
number O 
of O 
target O 
proteins O 
that O 
often O 
results O 
in O 
host O 
cell O 
translational O 
repression O 
. O 
A O 
number O 
of O 
high O 
- O 
resolution O 
structural O 
studies O 
involving O 
individual O 
dsRBMs O 
from O 
proteins O 
other O 
than O 
PKR O 
have O 
highlighted O 
the O 
key O 
features O 
required O 
for O 
interaction O 
with O 
perfectly O 
duplexed O 
RNA O 
substrates O 
. O 
However O 
, O 
viral O 
dsRNA O 
molecules O 
are O 
highly O 
structured O 
and O 
often O 
contain O 
deviations O 
from O 
perfect O 
A O 
- O 
form O 
RNA O 
helices O 
. O 
By O 
use O 
of O 
small O 
- O 
angle O 
X-ray O 
scattering O 
( O 
SAXS O 
) O 
, O 
we O 
present O 
solution O 
conformations O 
of O 
the O 
tandem O 
dsRBMs O 
of O 
PKR O 
in O 
complex O 
with O 
two O 
imperfectly O 
base O 
- O 
paired O 
viral O 
dsRNA O 
stem O 
- O 
loops O 
; O 
HIV-1 O 
TAR O 
and O 
adenovirus O 
VA(I)-AS O 
. O 
Both O 
individual O 
components O 
and O 
complexes O 
were O 
purified O 
by O 
size O 
exclusion O 
chromatography O 
and O 
characterized O 
by O 
dynamic O 
light O 
scattering O 
at O 
multiple O 
concentrations O 
to O 
ensure O 
monodispersity O 
. O 
SAXS O 
ab O 
initio O 
solution O 
conformations O 
of O 
the O 
individual O 
components O 
and O 
RNA O 
- O 
protein O 
complexes O 
were O 
determined O 
and O 
highlight O 
the O 
potential O 
of O 
PKR O 
to O 
interact O 
with O 
both O 
stem O 
and O 
loop O 
regions O 
of O 
the O 
RNA O 
. O 
Excellent O 
agreement O 
between O 
experimental O 
and O 
model O 
- O 
based O 
hydrodynamic O 
parameter O 
determination O 
heightens O 
our O 
confidence O 
in O 
the O 
obtained O 
models O 
. O 
Taken O 
together O 
, O 
these O 
data O 
support O 
and O 
provide O 
a O 
framework O 
for O 
the O 
existing O 
biochemical O 
data O 
regarding O 
the O 
tolerance O 
of O 
imperfectly O 
base O 
- O 
paired O 
viral O 
dsRNA O 
by O 
PKR O 
. O 

Status O 
in O 
Pregnant O 
Women O 
in O 
the O 
United O 
States O 
: O 
National O 
Children's O 
Study O 
and O 
National O 
Health O 
and O 
Nutrition O 
Examination O 
Survey O 
. O 

: O 
This O 
report O 
presents O 
iodine B-SYSTEMATIC 
data O 
from O 
NHANES O 
and O 
from O 
a O 
sample O 
of O 
pregnant O 
women O 
in O 
the O 
National O 
Children's O 
Study O 
( O 
NCS O 
) O 
Vanguard O 
Study O 
. O 
Methods O 
: O 
UI O 
was O 
measured O 
in O 
a O 
one O 
third O 
subsample O 
of O 
NHANES O 
2005-2006 O 
, O 
and O 
2009-2010 O 
participants O 
and O 
in O 
all O 
2007-2008 O 
participants O 
age O 
six O 
years O 
and O 
older O 
. O 
These O 
measurements O 
are O 
representative O 
of O 
the O 
general O 
U.S O 
. O 
population O 
. O 
UI O 
was O 
also O 
measured O 
in O 
a O 
convenience O 
sample O 
of O 
501 O 
pregnant O 
women O 
enrolled O 
in O 
the O 
NCS O 
initial O 
Vanguard O 
Study O 
from O 
seven O 
study O 
sites O 
across O 
the O 
U.S O 
. O 
Results O 
: O 
NHANES O 
median O 
UI O 
concentration O 
in O 
2009-2010 O 
( O 
144 O 
µg O 
/ O 
L O 
) O 
was O 
significantly O 
lower O 
than O 
in O 
2007-2008 O 
( O 
164 O 
µg O 
/ O 
L O 
) O 
. O 
Non-Hispanic O 
blacks O 
had O 
the O 
lowest O 
UI O 
concentrations O 
( O 
131µg O 
/ O 
L O 
) O 
compared O 
to O 
non-Hispanic O 
whites O 
or O 
Hispanics O 
( O 
147 O 
and O 
148 O 
µg O 
/ O 
L O 
, O 
respectively O 
) O 
. O 
The O 
median O 
for O 
all O 
pregnant O 
women O 
in O 
NHANES O 
2005-2010 O 
was O 
less O 
than O 
adequate O 
( O 
129 O 
µg O 
/ O 
L O 
) O 
, O 
the O 
third O 
trimester O 
women O 
had O 
UI O 
concentrations O 
that O 
were O 
adequate O 
( O 
median O 
UI O 
172 O 
µg O 
/ O 
L O 
) O 
. O 
Third O 
trimester O 
women O 
participating O 
in O 
the O 
NCS O 
study O 
similarly O 
had O 
an O 
adequate O 
level O 
of O 
iodine B-SYSTEMATIC 
intake O 
, O 
with O 
a O 
median O 
UI O 
concentration O 
of O 
167µg O 
/ O 
L O 
. O 
Furthermore O 
, O 
NCS O 
median O 
UI O 
concentrations O 
varied O 
by O 
geographic O 
location O 
. O 
Conclusions O 
: O 
Dairy O 
, O 
but O 
not O 
salt O 
, O 
seafood O 
or O 
grain O 
consumption O 
, O 
was O 
significantly O 
positively O 
associated O 
with O 
median O 
UI O 
concentration O 
in O 
women O 
of O 
childbearing O 
age O 
. O 
Pregnant O 
women O 
in O 
their O 
third O 
trimester O 
in O 
the O 
NHANES O 
2005-2010 O 
had O 
adequate O 
median O 
UI O 
concentrations O 
, O 
but O 
pregnant O 
women O 
in O 
NHANES O 
who O 
were O 
in O 
their O 
first O 
or O 
second O 
trimesters O 
had O 
median O 
UI O 
concentrations O 
that O 
were O 
less O 
than O 
adequate O 
. O 
Non-Hispanic O 
black O 
pregnant O 
women O 
from O 
both O 
the O 
NHANES O 
2005-20010 O 
and O 
the O 
NCS O 
consistently O 
had O 
lower O 
UI O 
median O 
concentrations O 
than O 
non-Hispanic O 
whites O 
or O 
Hispanics O 
. O 

A O 
, O 
the O 
hydrophobic O 
anchor O 
of O 
lipopolysaccharide O 
, O 
is O 
an O 
essential O 
component O 
in O 
the O 
outer O 
membrane O 
of O 
most O 
Gram O 
- O 
negative O 
bacteria O 
. O 
Food O 
- O 
borne O 
pathogen O 
Cronobacter O 
sakazakii O 
synthesizes O 
two O 
lipid O 
A O 
species O 
, O 
differing O 
by O 
the O 
length O 
of O 
the O 
secondary O 
acyl B-FAMILY 
chain O 
. O 
In O 
this O 
work O 
, O 
we O 
identified O 
three O 
genes O 
ESA02293 O 
, O 
ESA02951 O 
and O 
ESA01386 O 
encoding O 
for O 
the O 
late O 
acyltransferases O 
of O 
lipid O 
A O 
biosynthesis O 
pathway O 
in O 
C O 
. O 
sakazakii O 
. O 
Based O 
on O 
the O 
sequence O 
alignment O 
, O 
proteins O 
YP_001438378.1 O 
encoded O 
by O 
ESA02293 O 
, O 
YP_001439016.1 O 
encoded O 
by O 
ESA02951 O 
, O 
and O 
YP_001437482.1 O 
encoded O 
by O 
ESA01386 O 
are O 
homologous O 
to O 
E O 
. O 
coli O 
LpxL O 
, O 
LpxP O 
and O 
LpxM O 
, O 
respectively O 
. O 
Functions O 
of O 
the O 
three O 
acyltransferases O 
were O 
confirmed O 
by O 
overexpressing O 
the O 
genes O 
in O 
E O 
. O 
coli O 
, O 
isolating O 
lipid O 
As O 
and O 
analyzing O 
their O 
structures O 
using O 
an O 
ESI O 
/ O 
MS O 
. O 
C O 
. O 
sakazakii O 
LpxL O 
and O 
LpxM O 
transfer O 
a O 
C14 O 
: O 
0 O 
secondary O 
acyl B-FAMILY 
chain O 
to O 
the O 
2'- O 
and O 
3'- O 
position O 
of O 
lipid O 
A O 
, O 
respectively O 
. O 
C O 
. O 
sakazakii O 
LpxP O 
can O 
transfer O 
either O 
a O 
C16 O 
: O 
1 O 
or O 
a O 
C14 O 
: O 
0 O 
secondary O 
acyl B-FAMILY 
chains O 
to O 
the O 
2'- O 
position O 
of O 
lipid O 
A O 
. O 

a O 
previous O 
paper O 
we O 
demonstrated O 
the O 
results O 
of O 
biological O 
screening O 
of O 
Yemeni O 
basidiomycetes O 
. O 
The O 
present O 
study O 
was O 
aimed O 
to O 
investigate O 
the O 
antimicrobial O 
and O 
the O 
antioxidant O 
activity O 
of O 
further O 
basidiomycetes O 
collected O 
in O 
Yemen O 
. O 
Dichloromethane B-SYSTEMATIC 
, O 
methanol B-SYSTEMATIC 
and O 
aqueous O 
extracts O 
of O 
the O 
fruiting O 
bodies O 
of O 
25 O 
species O 
were O 
screened O 
in O 
vitro O 
for O 
their O 
antibacterial O 
activities O 
against O 
three O 
Gram O 
- O 
positive O 
bacteria O 
( O 
Staphyloccocus O 
aureus O 
, O 
Bacillus O 
subtilis O 
, O 
Micrococcus O 
flavus O 
) O 
and O 
two O 
Gram O 
- O 
negative O 
bacteria O 
( O 
Escherichia O 
coli O 
, O 
Pseudomonas O 
aeruginosa O 
) O 
, O 
against O 
six O 
human O 
fungal O 
pathogens O 
( O 
Candida O 
albicans O 
, O 
Candida O 
krusei O 
, O 
Aspergillus O 
fumigatus O 
, O 
Mucor O 
sp O 
. O 
, O 
Microsporum O 
gypseum O 
, O 
Trichophyton O 
mentagrophytes O 
) O 
and O 
against O 
one O 
non O 
human O 
pathogenic O 
fungus O 
( O 
Candida O 
maltosa O 
) O 
. O 
The O 
results O 
indicated O 
that O 
75 O 
extracts O 
exhibited O 
activity O 
against O 
one O 
or O 
more O 
of O 
the O 
bacteria O 
. O 
The O 
methanol B-SYSTEMATIC 
extracts O 
of O 
Agaricus O 
cf O 
. O 
bernardii O 
, O 
Agrocybe O 
pediades O 
, O 
Chlorophyllum O 
molybdites O 
, O 
Coriolopsis O 
polyzona O 
, O 
Ganoderma O 
xylonoides O 
, O 
Pycnoporus O 
sanguineus O 
, O 
Trametes O 
lactinea O 
and O 
Trametes O 
cingulata O 
showed O 
activity O 
against O 
all O 
tested O 
bacteria O 
. O 
The O 
highest O 
antibacterial O 
activity O 
was O 
exhibited O 
by O 
methanol B-SYSTEMATIC 
extracts O 
from O 
Chlorophyllum O 
molybdites O 
, O 
Ganoderma O 
xylonoides O 
and O 
Trametes O 
cingulata O 
and O 
Agaricus O 
cf O 
. O 
bernardii O 
, O 
Agrocybe O 
pediades O 
, O 
Coriolopsis O 
polyzona O 
, O 
Pycnoporus O 
sanguineus O 
and O 
Trametes O 
lactinea O 
. O 
The O 
methanol B-SYSTEMATIC 
extracts O 
of O 
Chlorophyllum O 
molybdites O 
, O 
Ganoderma O 
xylonoides O 
and O 
Pycnoporus O 
sanguineus O 
showed O 
considerable O 
antifungal O 
activities O 
against O 
the O 
tested O 
fungal O 
strains O 
. O 
Strong O 
antioxidative O 
effects O 
employing O 
the O 
DPPH B-ABBREVIATION 
assay O 
were O 
exhibited O 
by O 
methanol B-SYSTEMATIC 
extracts O 
from O 
Chlorophyllum O 
molybdites O 
, O 
Ganoderma O 
xylonoides O 
, O 
Hexagonia O 
velutina O 
, O 
Pycnoporus O 
sanguineus O 
, O 
Trametes O 
lactinea O 
and O 
Trametes O 
cingulata O 
. O 
Our O 
previous O 
and O 
presented O 
studies O 
about O 
48 O 
basidiomycetes O 
collected O 
in O 
Yemen O 
provide O 
evidence O 
that O 
basidiomycetes O 
from O 
the O 
Arabic O 
region O 
so O 
far O 
should O 
attract O 
more O 
attention O 
as O 
potential O 
source O 
for O 
new O 
biologically O 
active O 
agents O 
. O 

inhibition O 
of O 
extracellular O 
thioredoxin O 
by O 
asymmetric O 
disulfides B-FAMILY 
. O 

the O 
role O 
of O 
mammalian O 
thioredoxin O 
( O 
Trx O 
) O 
as O 
an O 
intracellular O 
protein O 
cofactor O 
is O 
widely O 
appreciated O 
, O 
its O 
function O 
in O 
the O 
extracellular O 
environment O 
is O 
not O 
well O 
- O 
understood O 
. O 
Only O 
few O 
extracellular O 
targets O 
of O 
Trx O 
- O 
mediated O 
thiol B-SYSTEMATIC 
- I-SYSTEMATIC 
disulfide I-SYSTEMATIC 
exchange O 
are O 
known O 
. O 
For O 
example O 
, O 
Trx O 
activates O 
extracellular O 
transglutaminase O 
2 O 
( O 
TG2 O 
) O 
via O 
reduction O 
of O 
an O 
intramolecular O 
disulfide B-SYSTEMATIC 
bond O 
. O 
Because O 
hyperactive O 
TG2 O 
is O 
thought O 
to O 
play O 
a O 
role O 
in O 
various O 
diseases O 
, O 
understanding O 
the O 
biological O 
role O 
of O 
extracellular O 
Trx O 
may O 
provide O 
critical O 
insight O 
into O 
the O 
pathogenesis O 
of O 
these O 
disorders O 
. O 
Starting O 
from O 
a O 
clinical O 
- O 
stage O 
asymmetric O 
disulfide B-SYSTEMATIC 
lead O 
, O 
we O 
have O 
identified O 
analogs O 
with O 
> O 
100-fold O 
specificity O 
for O 
Trx O 
. O 
Structure O 
- O 
activity O 
relationship O 
and O 
computational O 
docking O 
model O 
analyses O 
have O 
provided O 
insights O 
into O 
the O 
features O 
important O 
for O 
enhancing O 
potency O 
and O 
specificity O 
. O 
The O 
most O 
active O 
compound O 
identified O 
had O 
an O 
IC(50) O 
below O 
0.1 O 
μM O 
in O 
cell O 
culture O 
and O 
may O 
be O 
appropriate O 
for O 
in O 
vivo O 
use O 
to O 
interrogate O 
the O 
role O 
of O 
extracellular O 
Trx O 
in O 
health O 
and O 
disease O 
. O 

Sensitization O 
of O 
Epoxyaldehydes B-FAMILY 
: O 
Importance O 
of O 
Conjugation O 
. O 

- O 
activity O 
relationship O 
( O 
SAR O 
) O 
models O 
are O 
important O 
tools O 
for O 
predicting O 
the O 
skin O 
sensitization O 
potential O 
of O 
new O 
compounds O 
without O 
animal O 
testing O 
. O 
In O 
compounds O 
possessing O 
a O 
structural O 
alert O 
( O 
aldehyde B-SYSTEMATIC 
) O 
and O 
an O 
activation O 
alert O 
( O 
double O 
bond O 
) O 
, O 
it O 
is O 
important O 
to O 
consider O 
bioactivation O 
/ O 
autoxidation O 
( O 
e.g O 
. O 
, O 
epoxidation O 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
have O 
explored O 
a O 
series O 
of O 
aldehydes B-FAMILY 
with O 
regard O 
to O 
contact O 
allergy O 
. O 
The O 
chemical O 
reactivity O 
of O 
these O 
6 O 
aldehydes B-FAMILY 
toward O 
a O 
model O 
hexapeptide O 
was O 
investigated O 
, O 
and O 
their O 
skin O 
sensitization O 
potencies O 
were O 
evaluated O 
using O 
the O 
local O 
lymph O 
node O 
assay O 
( O 
LLNA O 
) O 
. O 
Overall O 
, O 
we O 
observed O 
a O 
similar O 
trend O 
for O 
the O 
in O 
vitro O 
reactivity O 
and O 
the O 
in O 
vivo O 
sensitization O 
potency O 
for O 
the O 
structural O 
analogues O 
in O 
this O 
study O 
. O 
The O 
highly O 
reactive O 
conjugated O 
aldehydes B-FAMILY 
( O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
aldehydes I-FAMILY 
and O 
2,3-epoxyaldehydes B-FAMILY 
) O 
are O 
sensitizing O 
moieties O 
, O 
while O 
nonconjugated O 
aldehydes B-FAMILY 
and O 
nonterminal O 
aliphatic O 
epoxides B-FAMILY 
show O 
low O 
reactivity O 
and O 
low O 
sensitization O 
potency O 
. O 
Our O 
data O 
show O 
the O 
importance O 
of O 
not O 
only O 
double O 
bond O 
conjugation O 
to O 
aldehyde B-SYSTEMATIC 
but O 
also O 
epoxide B-SYSTEMATIC 
- O 
aldehyde B-SYSTEMATIC 
conjugation O 
. O 
The O 
observations O 
indicate O 
that O 
the O 
formation O 
of O 
nonconjugated O 
epoxides B-FAMILY 
by O 
bioactivation O 
or O 
autoxidation O 
is O 
not O 
sufficient O 
to O 
significantly O 
increase O 
the O 
sensitization O 
potency O 
of O 
weakly O 
sensitizing O 
parent O 
compounds O 
. O 

-bond O 
reinforced O 
vanadia B-TRIVIAL 
nanofiber O 
paper O 
of O 
high O 
stiffness O 
. O 

- O 
temperature O 
, O 
solution O 
- O 
based O 
self O 
- O 
assembly O 
of O 
vanadia B-TRIVIAL 
nanofibers O 
yields O 
a O 
free O 
- O 
standing O 
, O 
ceramic O 
paper O 
with O 
an O 
outstanding O 
combination O 
of O 
high O 
strength O 
, O 
stiffness O 
, O 
and O 
macroscopic O 
flexibility O 
. O 
Its O 
excellent O 
mechanical O 
performance O 
results O 
from O 
a O 
brick O 
- O 
and O 
- O 
mortar O 
like O 
architecture O 
, O 
which O 
combines O 
strong O 
covalent O 
bonding O 
within O 
the O 
single O 
- O 
crystalline O 
nanofibers O 
with O 
an O 
intricate O 
hydrogen B-SYSTEMATIC 
bonding O 
network O 
between O 
them O 
. O 

effects O 
of O 
polyphenols B-FAMILY 
on O 
cardiovascular O 
disease O 
. O 

recent O 
years O 
, O 
numerous O 
studies O 
have O 
demonstrated O 
the O 
health O 
benefits O 
of O 
polyphenols B-FAMILY 
, O 
and O 
special O 
attention O 
has O 
been O 
paid O 
to O 
their O 
beneficial O 
effects O 
against O 
cardiovascular O 
disease O 
, O 
the O 
leading O 
cause O 
of O 
death O 
in O 
the O 
world O 
today O 
. O 
Polyphenols B-FAMILY 
present O 
vasodilator O 
effects O 
and O 
are O 
able O 
to O 
improve O 
lipid O 
profiles O 
and O 
attenuate O 
the O 
oxidation O 
of O 
low O 
density O 
lipoproteins O 
. O 
In O 
addition O 
, O 
they O 
present O 
clear O 
anti-inflammatory O 
effects O 
and O 
can O 
modulate O 
apoptotic O 
processes O 
in O 
the O 
vascular O 
endothelium O 
. O 
It O 
has O 
been O 
suggested O 
that O 
most O 
of O 
these O 
effects O 
are O 
a O 
consequence O 
of O 
the O 
antioxidant O 
properties O 
of O 
polyphenols B-FAMILY 
, O 
but O 
this O 
idea O 
is O 
not O 
completely O 
accepted O 
, O 
and O 
many O 
other O 
mechanisms O 
have O 
been O 
proposed O 
recently O 
to O 
explain O 
the O 
health O 
effects O 
of O 
these O 
compounds O 
. O 
In O 
fact O 
, O 
different O 
signaling O 
pathways O 
have O 
been O 
linked O 
to O 
polyphenols B-FAMILY 
. O 
This O 
review O 
brings O 
together O 
some O 
recent O 
studies O 
which O 
establish O 
the O 
beneficial O 
properties O 
of O 
polyphenols B-FAMILY 
for O 
cardiovascular O 
disease O 
and O 
analyzes O 
the O 
mechanisms O 
involved O 
in O 
these O 
properties O 
. O 

suggests O 
that O 
prenatal O 
exposure O 
to O 
air O 
pollution O 
affects O 
the O 
ontogeny O 
and O 
development O 
of O 
the O 
fetal O 
immune O 
system O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
maternal O 
exposure O 
to O 
airborne O 
particulate O 
matter O 
( O 
PM O 
) O 
on O 
immune O 
function O 
in O 
postnatal O 
offspring O 
. O 
Pregnant O 
female O 
ICR O 
mice O 
were O 
intralaryngopharyngeally O 
administered O 
with O 
30μl O 
of O 
phosphate B-SYSTEMATIC 
buffered O 
solution O 
( O 
the O 
control O 
group O 
) O 
or O 
resuspended O 
PM O 
of O 
Standard O 
Reference O 
Material O 
1649a O 
at O 
0.09 O 
( O 
low O 
) O 
, O 
0.28 O 
( O 
medium O 
) O 
, O 
1.85 O 
( O 
high O 
) O 
or O 
6.92 O 
( O 
overdose O 
) O 
μg O 
/ O 
μl O 
once O 
every O 
three O 
days O 
from O 
day O 
0 O 
to O 
18 O 
of O 
pregnancy O 
( O 
n=8-10 O 
) O 
. O 
Offspring O 
were O 
sacrificed O 
on O 
postnatal O 
day O 
30 O 
. O 
Interleukin-4 O 
and O 
interferon-γ O 
levels O 
in O 
plasma O 
and O 
splenocytes O 
, O 
splenic O 
lymphocyte O 
proliferation O 
, O 
and O 
expressions O 
of O 
GATA-3 O 
and O 
T-bet O 
mRNA O 
in O 
the O 
spleen O 
were O 
tested O 
. O 
The O 
spleen O 
and O 
thymus O 
were O 
histopathologically O 
examined O 
. O 
The O 
offspring O 
of O 
the O 
medium O 
, O 
high O 
and O 
overdose O 
PM-exposed O 
dams O 
showed O 
significantly O 
suppressed O 
splenocyte O 
proliferation O 
. O 
Decreased O 
interferon-γ O 
and O 
increased O 
interleukin-4 O 
levels O 
in O 
the O 
blood O 
and O 
splenocytes O 
, O 
and O 
lowered O 
T-bet O 
and O 
elevated O 
GATA-3 O 
mRNA O 
expressions O 
were O 
found O 
in O 
the O 
spleen O 
in O 
the O 
medium O 
, O 
high O 
and O 
overdose O 
groups O 
when O 
compared O 
with O 
the O 
control O 
or O 
low O 
dose O 
group O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Histopathology O 
revealed O 
prominent O 
tissue O 
damage O 
in O 
the O 
spleen O 
and O 
thymus O 
in O 
the O 
overdose O 
group O 
. O 
These O 
results O 
suggest O 
that O 
exposure O 
of O 
pregnant O 
mice O 
to O 
PM O 
modulates O 
the O 
fetal O 
immune O 
system O 
, O 
resulting O 
in O 
postnatal O 
immune O 
dysfunction O 
by O 
exacerbation O 
of O 
Thl O 
/ O 
Th2 O 
deviation O 
. O 
This O 
deviation O 
is O 
associated O 
with O 
altered O 
T-bet O 
and O 
GATA-3 O 
gene O 
expressions O 
. O 

-Induced O 
Structural O 
Plasticity O 
in O 
Mesencephalic O 
Dopaminergic O 
Neurons O 
Is O 
Mediated O 
by O 
Dopamine B-TRIVIAL 
D3 O 
Receptors O 
and O 
Akt-mTORC1 O 
Signalling O 
. O 

long O 
- O 
term O 
exposure O 
to O 
nicotine B-TRIVIAL 
is O 
highly O 
addictive O 
, O 
one O 
" O 
beneficial O 
" O 
consequence O 
of O 
chronic O 
tobacco O 
use O 
is O 
a O 
reduced O 
risk O 
for O 
Parkinson's O 
disease O 
. O 
Interestingly O 
, O 
these O 
effects O 
both O 
reflect O 
structural O 
and O 
functional O 
plasticity O 
of O 
brain O 
circuits O 
controlling O 
reward O 
and O 
motor O 
behavior O 
, O 
and O 
specifically O 
recruitment O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChR O 
) O 
in O 
mesencephalic O 
dopaminergic O 
neurons O 
. O 
Since O 
the O 
underlying O 
cellular O 
mechanisms O 
are O 
poorly O 
understood O 
, O 
we O 
addressed O 
this O 
issue O 
employing O 
primary O 
cultures O 
of O 
mouse O 
mesencephalic O 
dopaminergic O 
neurons O 
. O 
Exposure O 
to O 
nicotine B-TRIVIAL 
( O 
1-10 O 
μM O 
) O 
for O 
72 O 
hr O 
in O 
vitro O 
increased O 
dendritic O 
arborization O 
and O 
soma O 
size O 
in O 
primary O 
cultures O 
. O 
These O 
effects O 
were O 
blocked O 
by O 
mecamylamine B-TRIVIAL 
and O 
dihydro-β-erythroidine B-SYSTEMATIC 
, O 
but O 
not O 
methyllycaconitine B-TRIVIAL 
. O 
The O 
involvement O 
of O 
α4β2 O 
nAChR O 
was O 
supported O 
by O 
the O 
lack O 
of O 
nicotine B-TRIVIAL 
-induced O 
structural O 
remodeling O 
in O 
neurons O 
from O 
α4 O 
nan O 
mutant O 
mice O 
( O 
KO O 
) O 
. O 
Challenge O 
with O 
nicotine B-TRIVIAL 
triggered O 
phosphorylation O 
of O 
the O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
and O 
the O 
thymoma O 
viral O 
proto O 
- O 
oncogene O 
( O 
Akt O 
) O 
followed O 
by O 
activation O 
of O 
the O 
mTORC1-dependent O 
p70 O 
ribosomal O 
S6 O 
protein O 
kinase O 
. O 
Upstream O 
pathway O 
blockade O 
using O 
the O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
inhibitor O 
LY294002 B-IDENTIFIER 
resulted O 
in O 
suppression O 
of O 
nicotine B-TRIVIAL 
-induced O 
phosphorylations O 
and O 
structural O 
plasticity O 
. O 
These O 
effects O 
were O 
dependent O 
upon O 
functional O 
DA O 
D3 O 
receptor O 
( O 
D3R O 
) O 
since O 
nicotine B-TRIVIAL 
was O 
inactive O 
both O 
in O 
cultures O 
from O 
D3R O 
KO O 
mice O 
and O 
following O 
pharmacologic O 
blockade O 
with O 
D3R O 
antagonist O 
SB-277011-A B-IDENTIFIER 
( O 
50 O 
nM O 
) O 
. O 
Finally O 
, O 
exposure O 
to O 
nicotine B-TRIVIAL 
in O 
utero O 
( O 
5 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
5 O 
days O 
) O 
resulted O 
in O 
increased O 
soma O 
area O 
of O 
DAergic O 
neurons O 
of O 
newborn O 
mice O 
, O 
effects O 
not O 
observed O 
in O 
D3KO O 
mice O 
. O 
These O 
findings O 
indicate O 
that O 
nicotine B-TRIVIAL 
-induced O 
structural O 
plasticity O 
in O 
mesencephalic O 
dopaminergic O 
neurons O 
involves O 
α4β2 O 
nAChRs O 
together O 
with O 
dopamine B-TRIVIAL 
D3R O 
- O 
mediated O 
recruitment O 
of O 
ERK O 
/ O 
Akt-mTORC1 O 
signaling O 
. O 

causes O 
similar O 
electroretinogram O 
modifications O 
, O 
neuronal O 
phospholipidosis O 
and O 
marked O 
impairment O 
of O 
synaptic O 
vesicle O 
transport O 
in O 
Albino O 
and O 
Pigmented O 
Rats O 
. O 

toxicity O 
of O 
chloroquine B-TRIVIAL 
has O 
been O 
known O 
for O 
several O 
years O 
, O 
but O 
the O 
mechanism(s) O 
of O 
toxicity O 
remain O 
controversial O 
; O 
some O 
author O 
support O 
the O 
idea O 
that O 
the O 
binding O 
of O 
chloroquine B-TRIVIAL 
to O 
melanin O 
pigments O 
in O 
the O 
retinal O 
pigmented O 
epithelium O 
( O 
RPE O 
) O 
play O 
a O 
major O 
toxic O 
role O 
by O 
concentrating O 
the O 
drug O 
in O 
the O 
eye O 
. O 
In O 
our O 
study O 
, O 
12 O 
albinos O 
Sprague-Dawley O 
( O 
SD O 
) O 
and O 
12 O 
pigmented O 
Brown O 
Norway O 
( O 
BN O 
) O 
rats O 
were O 
treated O 
orally O 
for O 
3 O 
months O 
with O 
chloroquine B-TRIVIAL 
to O 
compare O 
functional O 
and O 
pathological O 
findings O 
. O 
On O 
Flash O 
electroretinograms O 
( O 
ERG O 
) O 
performed O 
in O 
scotopic O 
conditions O 
, O 
similar O 
and O 
progressive O 
( O 
time O 
- O 
dependent O 
) O 
delayed O 
onset O 
and O 
decreased O 
amplitudes O 
of O 
oscillatory O 
potentials O 
( O 
from O 
Day O 
71 O 
) O 
and O 
b-waves O 
( O 
on O 
Day O 
92 O 
) O 
were O 
identified O 
in O 
both O 
BN O 
and O 
SD O 
rats O 
. O 
In O 
both O 
strains O 
, O 
identical O 
morphological O 
changes O 
consisted O 
of O 
neuronal O 
phospholipidosis O 
associated O 
with O 
UV O 
auto O 
- O 
fluorescence O 
without O 
evidence O 
of O 
retinal O 
degeneration O 
and O 
gliosis O 
; O 
the O 
RPE O 
did O 
not O 
show O 
any O 
morphological O 
lesions O 
or O 
autofluorescence O 
. O 
IHC O 
analyses O 
demonstrated O 
a O 
decrease O 
in O 
GABA B-ABBREVIATION 
expression O 
in O 
the O 
inner O 
nuclear O 
layer O 
. O 
In O 
addition O 
, O 
a O 
marked O 
accumulation O 
of O 
synaptic O 
vesicles O 
coupled O 
with O 
a O 
marked O 
disruption O 
of O 
neurofilaments O 
in O 
the O 
optic O 
nerve O 
fibers O 
was O 
identified O 
. O 
In O 
conclusion O 
, O 
ERG O 
observations O 
were O 
very O 
similar O 
to O 
those O 
described O 
in O 
humans O 
. O 
Comparable O 
ERG O 
modifications O 
, O 
histopathology O 
and O 
immunohistochemistry O 
findings O 
were O 
observed O 
in O 
the O 
retina O 
of O 
both O 
rat O 
strains O 
suggesting O 
that O 
melanin O 
pigment O 
is O 
unlikely O 
involved O 
. O 
chloroquine B-TRIVIAL 
-induced O 
impairment O 
of O 
synaptic O 
vesicle O 
transport O 
, O 
likely O 
related O 
to O 
disruption O 
of O 
neurofilaments O 
was O 
identified O 
and O 
non-previously O 
reported O 
. O 
This O 
new O 
mechanism O 
of O 
toxicity O 
may O 
also O 
be O 
responsible O 
for O 
the O 
burry O 
vision O 
described O 
in O 
humans O 
chronically O 
treated O 
with O 
chloroquine B-TRIVIAL 
. O 

- O 
enzyme O 
kinetic O 
isotope O 
effects O 
on O 
proton O 
transfer O 
in O 
alanine B-TRIVIAL 
racemase O 
. O 

catalytic O 
effects O 
of O 
perdeuterating O 
the O 
pyridoxal B-TRIVIAL 
phosphate I-TRIVIAL 
-dependent O 
enzyme O 
alanine B-TRIVIAL 
racemase O 
from O 
Geobacillus O 
stearothermophilus O 
are O 
reported O 
. O 
The O 
mass O 
of O 
the O 
heavy O 
perdeuterated O 
form O 
is O 
~5.5% O 
greater O 
than O 
that O 
of O 
the O 
protiated O 
form O 
, O 
causing O 
kinetic O 
isotope O 
effects O 
( O 
KIEs O 
) O 
of O 
~1.3 O 
on O 
k(cat) O 
and O 
k(cat) O 
/ O 
K(M) O 
for O 
both O 
L- B-MULTIPLE 
and I-MULTIPLE 
D-alanine I-MULTIPLE 
. O 
These O 
values O 
increase O 
when O 
Cα-deuterated B-TRIVIAL 
alanine I-TRIVIAL 
is O 
used O 
as O 
the O 
substrate O 
. O 
The O 
heavy O 
- O 
enzyme O 
KIEs O 
of O 
~3 O 
on O 
k(cat) O 
/ O 
K(M) O 
with O 
deuterated O 
substrates O 
are O 
greater O 
than O 
the O 
product O 
of O 
the O 
individual O 
heavy O 
- O 
enzyme O 
and O 
primary O 
substrate O 
KIEs O 
. O 
This O 
breakdown O 
of O 
the O 
rule O 
of O 
the O 
geometric O 
mean O 
is O 
likely O 
due O 
to O 
coupled O 
motion O 
between O 
the O 
protein O 
and O 
the O 
proton O 
- O 
transfer O 
reaction O 
coordinate O 
in O 
the O 
rate O 
- O 
limiting O 
step O 
. O 
These O 
data O 
implicate O 
a O 
direct O 
role O 
for O 
protein O 
vibrational O 
motions O 
in O 
barrier O 
crossing O 
for O 
proton O 
- O 
transfer O 
steps O 
in O 
alanine B-TRIVIAL 
racemase O 
. O 

analysis O 
of O 
four O 
oxidized O 
guanine B-TRIVIAL 
lesions O 
from O 
reactions O 
of O 
DNA O 
with O 
peroxynitrite B-SYSTEMATIC 
, O 
singlet O 
oxygen B-SYSTEMATIC 
, O 
and O 
γ-radiation O 
. O 

damage O 
to O 
DNA O 
has O 
many O 
origins O 
, O 
including O 
irradiation O 
, O 
inflammation O 
, O 
and O 
oxidative O 
stress O 
, O 
but O 
the O 
chemistries O 
are O 
not O 
the O 
same O 
. O 
The O 
most O 
oxidizable O 
base O 
in O 
DNA O 
is O 
2-deoxyguanosine B-SYSTEMATIC 
( O 
dG O 
) O 
, O 
and O 
the O 
primary O 
oxidation O 
products O 
are O 
8-oxodG B-SYSTEMATIC 
and O 
2-amino-imidazolone B-SYSTEMATIC 
. O 
The O 
latter O 
rapidly O 
converts O 
to O 
2,2-diamino-oxazolone B-SYSTEMATIC 
( O 
Ox O 
) O 
, O 
and O 
8-oxodG B-SYSTEMATIC 
is O 
further O 
oxidized O 
to O 
spiroiminodihydantoin B-SYSTEMATIC 
( O 
Sp O 
) O 
and O 
guanidinohydantoin B-SYSTEMATIC 
( O 
Gh O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
examined O 
the O 
dose O 
- O 
response O 
relationship O 
for O 
the O 
formation O 
of O 
the O 
above O 
four O 
products O 
arising O 
in O 
calf O 
thymus O 
DNA O 
exposed O 
to O 
gamma O 
irradiation O 
, O 
photoactivated O 
rose B-TRIVIAL 
bengal I-TRIVIAL 
, O 
and O 
two O 
sources O 
of O 
peroxynitrite B-SYSTEMATIC 
. O 
In O 
order O 
to O 
carry O 
out O 
these O 
experiments O 
, O 
we O 
developed O 
a O 
chromatographic O 
system O 
and O 
synthesized O 
isotopomeric O 
internal O 
standards O 
to O 
enable O 
accurate O 
and O 
precise O 
analysis O 
based O 
upon O 
selected O 
reaction O 
monitoring O 
mass O 
spectrometry O 
. O 
8-OxodG B-SYSTEMATIC 
was O 
the O 
most O 
abundant O 
products O 
in O 
all O 
cases O 
, O 
but O 
its O 
accumulation O 
was O 
highly O 
dependent O 
on O 
the O 
nature O 
of O 
the O 
oxidizing O 
agent O 
and O 
the O 
subsequent O 
conversion O 
to O 
Sp O 
and O 
Gh O 
. O 
Among O 
the O 
other O 
oxidation O 
products O 
, O 
Ox O 
was O 
the O 
most O 
abundant O 
, O 
and O 
Sp O 
was O 
formed O 
in O 
significantly O 
greater O 
yield O 
than O 
Gh O 
. O 

effects O 
of O 
prenatal O 
di-n-hexyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
and O 
dicyclohexyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
exposure O 
on O 
reproductive O 
tract O 
of O 
male O 
rats O 
: O 
Postnatal O 
outcomes O 
. O 

present O 
study O 
is O 
to O 
investigate O 
the O 
effects O 
of O 
in O 
utero O 
di-n-hexyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DHP B-ABBREVIATION 
) O 
and O 
dicyclohexyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
exposure O 
( O 
DCHP B-ABBREVIATION 
) O 
on O 
the O 
development O 
of O 
male O 
reproductive O 
tract O 
at O 
prepubertal O 
, O 
pubertal O 
and O 
adult O 
stages O 
. O 
Pregnant O 
rats O 
were O 
exposed O 
to O 
DHP B-ABBREVIATION 
and O 
DCHP B-ABBREVIATION 
at O 
doses O 
of O 
0 O 
, O 
20 O 
, O 
100 O 
and O 
500mg O 
/ O 
kg O 
/ O 
day O 
, O 
by O 
gavage O 
, O 
on O 
gestational O 
days O 
( O 
GD O 
) O 
6-19 O 
. O 
Testosterone B-TRIVIAL 
( O 
T O 
) O 
levels O 
of O 
prepubertal O 
rats O 
diminished O 
at O 
high O 
dose O 
DHP B-ABBREVIATION 
and O 
middle O 
dose O 
DCHP B-ABBREVIATION 
groups O 
. O 
MIS O 
/ O 
AMH O 
levels O 
elevated O 
in O 
DHP B-ABBREVIATION 
and O 
DCHP B-ABBREVIATION 
groups O 
. O 
T O 
levels O 
of O 
pubertal O 
rats O 
decreased O 
in O 
low O 
and O 
high O 
dose O 
DHP B-ABBREVIATION 
and O 
DCHP B-ABBREVIATION 
groups O 
. O 
Inhibin O 
B O 
levels O 
of O 
adult O 
rats O 
diminished O 
in O 
DCHP B-ABBREVIATION 
groups O 
. O 
Atrophic O 
and O 
amorphous O 
tubules O 
, O 
spermatogenic O 
cell O 
debris O 
, O 
apoptotic O 
cells O 
, O 
adherent O 
tubules O 
, O 
Sertoli O 
cell O 
vacuolisation O 
, O 
prostatic O 
atrophic O 
tubules O 
and O 
prostatic O 
intraepithelial O 
neoplasia O 
( O 
PIN O 
) O 
were O 
observed O 
in O 
the O 
reproductive O 
organs O 
of O 
treated O 
animals O 
at O 
all O 
developmental O 
stages O 
. O 
There O 
was O 
an O 
increase O 
in O 
immunoexpression O 
of O 
MIS O 
/ O 
AMH O 
in O 
testes O 
of O 
treated O 
rats O 
. O 
There O 
were O 
no O 
changes O 
in O 
sperm O 
head O 
count O 
but O 
percentages O 
of O 
abnormal O 
sperms O 
increased O 
. O 
The O 
diameters O 
of O 
seminiferous O 
and O 
epididymal O 
tubules O 
in O 
treatment O 
groups O 
were O 
significantly O 
lower O 
. O 
This O 
study O 
shows O 
that O 
DHP B-ABBREVIATION 
and O 
DCHP B-ABBREVIATION 
may O 
have O 
antiandrogenic O 
effects O 
on O 
male O 
reproductive O 
development O 
before O 
and O 
after O 
birth O 
. O 

Inhibition O 
of O 
CYP3A4 O 
by O 
Lapatinib B-TRIVIAL 
: O 
Evidence O 
for O 
Formation O 
of O 
a O 
Metabolic O 
Intermediate O 
Complex O 
with O 
a O 
Nitroso B-SYSTEMATIC 
/ O 
Oxime B-SYSTEMATIC 
Metabolite O 
Formed O 
via O 
a O 
Nitrone B-SYSTEMATIC 
Intermediate O 
. O 

- O 
dependent O 
inhibition O 
( O 
MDI O 
) O 
of O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
enzymes O 
has O 
the O 
potential O 
to O 
cause O 
clinically O 
relevant O 
drug O 
- O 
drug O 
interactions O 
. O 
In O 
the O 
case O 
of O 
several O 
alkylamine B-FAMILY 
drugs O 
, O 
MDI O 
of O 
P450 O 
involves O 
formation O 
of O 
a O 
metabolite O 
that O 
binds O 
quasi O 
- O 
irreversibly O 
to O 
the O 
ferrous B-SYSTEMATIC 
heme B-FAMILY 
iron B-SYSTEMATIC 
to O 
form O 
a O 
metabolic O 
intermediate O 
( O 
MI O 
) O 
complex O 
. O 
The O 
specific O 
metabolites O 
coordinately O 
bound O 
to O 
ferrous B-SYSTEMATIC 
iron B-SYSTEMATIC 
and O 
the O 
pathways O 
leading O 
to O 
MI O 
complex O 
formation O 
are O 
the O 
subject O 
of O 
debate O 
. O 
We O 
describe O 
an O 
approach O 
combining O 
heme B-FAMILY 
iron B-SYSTEMATIC 
oxidation O 
with O 
potassium B-SYSTEMATIC 
ferricyanide I-SYSTEMATIC 
and O 
metabolite O 
profiling O 
to O 
probe O 
the O 
mechanism O 
of O 
MI O 
complex O 
- O 
based O 
CYP3A4 O 
inactivation O 
by O 
the O 
secondary B-FAMILY 
alkylamine I-FAMILY 
drug O 
lapatinib B-TRIVIAL 
. O 
Ten O 
metabolites O 
formed O 
from O 
lapatinib B-TRIVIAL 
by O 
CYP3A4 O 
- O 
mediated O 
heteroatom O 
dealkylation O 
, O 
C B-FORMULA 
-hydroxylation O 
, O 
N B-FORMULA 
-oxygenation O 
with O 
or O 
without O 
further O 
oxidation O 
, O 
or O 
a O 
combination O 
thereof O 
, O 
were O 
detected O 
by O 
accurate O 
mass O 
spectrometry O 
. O 
The O 
abundance O 
of O 
one O 
metabolite O 
, O 
the O 
N B-FORMULA 
-dealkylated O 
nitroso B-SYSTEMATIC 
/ O 
oxime B-SYSTEMATIC 
lapatinib B-TRIVIAL 
metabolite O 
( O 
M9 O 
) O 
, O 
correlated O 
directly O 
with O 
the O 
prevalence O 
or O 
the O 
disruption O 
of O 
the O 
MI O 
complex O 
with O 
CYP3A4 O 
. O 
Nitroso B-SYSTEMATIC 
/ O 
oxime B-SYSTEMATIC 
metabolite O 
formation O 
from O 
secondary O 
alkylamines B-FAMILY 
has O 
been O 
proposed O 
to O 
occur O 
through O 
two O 
possible O 
pathways O 
: O 
( O 
1 O 
) O 
sequential O 
N B-FORMULA 
-dealkylation O 
, O 
N B-FORMULA 
-hydroxylation O 
, O 
and O 
dehydrogenation O 
( O 
primary B-SYSTEMATIC 
hydroxylamine I-SYSTEMATIC 
pathway O 
) O 
or O 
( O 
2 O 
) O 
N B-FORMULA 
-hydroxylation O 
with O 
dehydrogenation O 
to O 
yield O 
a O 
nitrone B-SYSTEMATIC 
followed O 
by O 
N B-FORMULA 
-dealkylation O 
( O 
secondary B-SYSTEMATIC 
hydroxylamine I-SYSTEMATIC 
pathway O 
) O 
. O 
All O 
intermediates O 
for O 
the O 
secondary B-SYSTEMATIC 
hydroxylamine I-SYSTEMATIC 
pathway O 
were O 
detected O 
but O 
the O 
primary O 
N B-FORMULA 
- O 
hydroxylamine B-SYSTEMATIC 
intermediate O 
of O 
the O 
primary B-SYSTEMATIC 
hydroxylamine I-SYSTEMATIC 
pathway O 
was O 
not O 
. O 
Our O 
findings O 
support O 
the O 
mechanism O 
of O 
lapatinib B-TRIVIAL 
CYP3A4 O 
inactivation O 
as O 
MI O 
complex O 
formation O 
with O 
the O 
nitroso B-SYSTEMATIC 
metabolite O 
formed O 
through O 
the O 
secondary B-SYSTEMATIC 
hydroxylamine I-SYSTEMATIC 
and O 
nitrone B-SYSTEMATIC 
pathway O 
, O 
rather O 
than O 
by O 
N B-FORMULA 
-dealkylation O 
to O 
the O 
primary B-FAMILY 
amine I-FAMILY 
followed O 
by O 
N B-FORMULA 
-hydroxylation O 
and O 
dehydrogenation O 
as O 
is O 
usually O 
assumed O 
. O 

effects O 
of O 
trans-1,3-diphenyl-2,3-epoxypropane-1-one B-SYSTEMATIC 
mediated O 
by O 
suppression O 
of O 
inflammatory O 
mediators O 
in O 
LPS-stimulated O 
RAW O 
264.7 O 
macrophages O 
. O 

assess O 
the O 
potential O 
therapeutic O 
properties O 
of O 
trans-1,3-diphenyl-2,3-epoxypropane-1-one B-SYSTEMATIC 
( O 
DPEP B-ABBREVIATION 
) O 
, O 
its O 
anti-inflammatory O 
effects O 
were O 
investigated O 
in O 
lipopolysaccharide O 
(LPS)-stimulated O 
mouse O 
macrophage O 
( O 
RAW O 
264.7 O 
) O 
cells O 
. O 
DPEP B-ABBREVIATION 
induced O 
dose O 
- O 
dependent O 
reduction O 
of O 
the O 
protein O 
levels O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
and O 
concomitant O 
reduction O 
in O 
the O 
production O 
of O 
NO B-FORMULA 
and O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
. O 
Additionally O 
, O 
DPEP B-ABBREVIATION 
suppressed O 
the O 
production O 
of O 
inflammatory O 
cytokines O 
, O 
including O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
interleukin O 
(IL)-1β O 
, O 
and O 
IL-6 O 
. O 
We O 
investigated O 
the O 
mechanism O 
by O 
which O 
DPEP B-ABBREVIATION 
inhibits O 
NO B-FORMULA 
and O 
PGE(2) B-ABBREVIATION 
by O 
examining O 
the O 
level O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
activation O 
within O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
pathway O 
, O 
which O 
is O 
an O 
inflammation O 
- O 
induced O 
signaling O 
pathway O 
in O 
RAW O 
264.7 O 
cells O 
. O 
DPEP B-ABBREVIATION 
inhibited O 
LPS-induced O 
phosphorylation O 
of O 
ERK O 
, O 
JNK O 
, O 
and O 
p38 O 
. O 
Furthermore O 
, O 
DPEP B-ABBREVIATION 
inhibited O 
the O 
LPS-induced O 
phosphorylation O 
of O 
inhibitor O 
κB O 
(IκB)-α O 
and O 
NF-κB O 
p50 O 
. O 
Taken O 
together O 
, O 
the O 
results O 
of O 
this O 
study O 
demonstrate O 
that O 
DPEP B-ABBREVIATION 
inhibits O 
LPS-stimulated O 
inflammation O 
by O 
blocking O 
the O 
NF-κB O 
and O 
MAPK O 
pathways O 
in O 
macrophages O 
. O 

and O 
poly(ethylene B-FAMILY 
imine I-FAMILY 
) I-FAMILY 
are O 
employed O 
in O 
a O 
layer O 
- O 
by O 
- O 
layer O 
deposition O 
process O 
to O 
form O 
covalently O 
connected O 
, O 
redox O 
- O 
active O 
multilayer O 
thin O 
films O 
by O 
means O 
of O 
an O 
amine B-SYSTEMATIC 
alkylation O 
reaction O 
. O 
The O 
stepwise O 
buildup O 
of O 
these O 
multilayers O 
on O 
silicon B-SYSTEMATIC 
, O 
ITO B-ABBREVIATION 
, O 
and O 
quartz B-TRIVIAL 
substrates O 
was O 
monitored O 
by O 
UV-vis O 
absorption O 
spectroscopy O 
, O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FTIR O 
) O 
, O 
static O 
contact O 
angle O 
measurements O 
, O 
surface O 
plasmon O 
resonance O 
( O 
SPR O 
) O 
, O 
atomic O 
force O 
microscopy O 
, O 
ellipsometry O 
, O 
and O 
cyclic O 
voltammetry O 
, O 
which O 
provide O 
evidence O 
for O 
a O 
linear O 
increase O 
in O 
multilayer O 
thickness O 
with O 
the O 
number O 
of O 
deposited O 
bilayers O 
. O 
Upon O 
oxidation O 
and O 
reduction O 
, O 
these O 
covalently O 
interconnected O 
layers O 
do O 
not O 
disassemble O 
, O 
in O 
contrast O 
to O 
poly(ferrocenylsilane) B-FAMILY 
( O 
PFS B-ABBREVIATION 
) O 
layers O 
featuring O 
similar O 
backbone O 
structures O 
that O 
are O 
held O 
together O 
by O 
electrostatic O 
forces O 
. O 
The O 
PFS B-ABBREVIATION 
/ O 
PEI B-ABBREVIATION 
multilayers O 
are O 
effective O 
for O 
the O 
electrochemical O 
sensing O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
and O 
show O 
improved O 
sensing O 
performance O 
at O 
higher O 
bilayer O 
numbers O 
. O 
These O 
covalently O 
linked O 
layers O 
are O 
readily O 
derivatized O 
further O 
and O 
can O 
therefore O 
be O 
regarded O 
as O 
a O 
versatile O 
platform O 
for O 
creating O 
robust O 
, O 
tailorable O 
, O 
redox O 
- O 
active O 
interfaces O 
with O 
applications O 
in O 
sensing O 
and O 
biofuel O 
cells O 
. O 

and O 
high O 
oxidation O 
state O 
metal B-MULTIPLE 
/ I-MULTIPLE 
non-metal I-MULTIPLE 
fluoride I-MULTIPLE 
and O 
oxide B-SYSTEMATIC 
- O 
fluoride B-SYSTEMATIC 
complexes O 
with O 
neutral O 
donor O 
ligands O 
. O 

most O 
high O 
and O 
medium O 
oxidation O 
state O 
( O 
O.S O 
. O 
≥ O 
3 O 
) O 
metal B-MULTIPLE 
and I-MULTIPLE 
non-metal I-MULTIPLE 
fluorides I-MULTIPLE 
and O 
oxide B-SYSTEMATIC 
fluorides B-FAMILY 
are O 
strong O 
Lewis B-FAMILY 
acids I-FAMILY 
, O 
exploration O 
of O 
their O 
coordination O 
chemistry O 
with O 
neutral O 
ligands O 
has O 
been O 
limited O 
and O 
mostly O 
non-systematic O 
. O 
This O 
is O 
despite O 
the O 
very O 
different O 
properties O 
conferred O 
on O 
the O 
acceptor O 
centre O 
by O 
the O 
small O 
electronegative O 
fluoride B-SYSTEMATIC 
ligands O 
compared O 
to O 
the O 
heavier O 
halides B-FAMILY 
. O 
This O 
article O 
sets O 
out O 
these O 
key O 
differences O 
, O 
discusses O 
possible O 
synthetic O 
routes O 
, O 
the O 
key O 
characterisation O 
techniques O 
, O 
and O 
appropriate O 
bonding O 
models O 
. O 
Current O 
knowledge O 
of O 
the O 
coordination O 
chemistry O 
of O 
d O 
, O 
f O 
and O 
p-block O 
fluorides B-FAMILY 
and O 
oxide B-SYSTEMATIC 
fluorides B-FAMILY 
with O 
neutral O 
ligands O 
( O 
with O 
donor O 
atoms O 
drawn O 
from O 
Groups O 
15 O 
and O 
16 O 
and O 
including O 
N-heterocyclic B-FAMILY 
carbenes I-FAMILY 
) O 
is O 
then O 
presented O 
and O 
discussed O 
, O 
and O 
the O 
differences O 
in O 
properties O 
compared O 
to O 
complexes O 
containing O 
the O 
heavier O 
halides B-FAMILY 
are O 
illustrated O 
. O 
The O 
emphasis O 
is O 
on O 
work O 
published O 
post O 
1990 O 
, O 
but O 
earlier O 
work O 
is O 
also O 
included O 
as O 
essential O 
background O 
and O 
where O 
no O 
more O 
recent O 
information O 
exists O 
. O 
Attention O 
is O 
drawn O 
to O 
unexplored O 
areas O 
meriting O 
investigation O 
and O 
to O 
possible O 
applications O 
of O 
these O 
complexes O 
. O 

the O 
protein O 
native O 
state O 
is O 
a O 
Boltzmann O 
conformational O 
ensemble O 
, O 
practical O 
applications O 
often O 
require O 
a O 
representative O 
model O 
from O 
the O 
most O 
populated O 
region O 
of O 
that O 
distribution O 
. O 
The O 
acidity O 
of O 
the O 
backbone O 
amides B-FAMILY 
, O 
as O 
reflected O 
in O 
hydrogen B-SYSTEMATIC 
exchange O 
rates O 
, O 
is O 
exquisitely O 
sensitive O 
to O 
the O 
surrounding O 
charge O 
and O 
dielectric O 
volume O 
distribution O 
. O 
For O 
each O 
of O 
four O 
proteins O 
, O 
three O 
independently O 
determined O 
X-ray O 
structures O 
of O 
differing O 
crystallographic O 
resolution O 
were O 
used O 
to O 
predict O 
exchange O 
for O 
the O 
static O 
solvent-exposed O 
amide B-FAMILY 
hydrogens I-FAMILY 
. O 
The O 
average O 
correlation O 
coefficients O 
range O 
from O 
0.74 O 
for O 
ubiquitin O 
to O 
0.93 O 
for O 
Pyrococcus O 
furiosus O 
rubredoxin O 
, O 
reflecting O 
the O 
larger O 
range O 
of O 
experimental O 
exchange O 
rates O 
exhibited O 
by O 
the O 
latter O 
protein O 
. O 
The O 
exchange O 
prediction O 
errors O 
modestly O 
correlate O 
with O 
the O 
crystallographic O 
resolution O 
. O 
MODELLER O 
9v6 O 
- O 
derived O 
homology O 
models O 
at O 
~60% O 
sequence O 
identity O 
( O 
36% O 
identity O 
for O 
chymotrypsin O 
inhibitor O 
CI2 O 
) O 
yielded O 
correlation O 
coefficients O 
that O 
are O 
~0.1 O 
smaller O 
than O 
for O 
the O 
cognate O 
X-ray O 
structures O 
. O 
The O 
most O 
recently O 
deposited O 
NOE O 
- O 
based O 
ubiquitin O 
structure O 
and O 
the O 
original O 
NMR O 
structure O 
of O 
CI2 O 
fail O 
to O 
provide O 
statistically O 
significant O 
predictions O 
of O 
hydrogen B-SYSTEMATIC 
exchange O 
. O 
However O 
, O 
the O 
more O 
recent O 
RECOORD O 
refinement O 
study O 
of O 
CI2 O 
yielded O 
predictions O 
comparable O 
to O 
the O 
X-ray O 
and O 
homology O 
model O 
- O 
based O 
analyses O 
. O 

of O 
flavonoids B-FAMILY 
in O 
Mouratón O 
berries O 
taken O 
from O 
both O 
bunch O 
halves O 
. O 

( O 
N.W O 
. O 
Spain O 
) O 
is O 
a O 
Spanish O 
region O 
with O 
several O 
old O 
- O 
traditional O 
winegrowing O 
areas O 
. O 
There O 
are O 
autochthonous O 
grapevine O 
varieties O 
, O 
such O 
as O 
Vitis O 
vinifera O 
L O 
. O 
cv O 
. O 
Mouratón O 
, O 
considered O 
a O 
biodiversity O 
resource O 
in O 
viticulture O 
and O 
an O 
opportunity O 
for O 
Galician O 
sustainable O 
wine O 
production O 
. O 
Therefore O 
, O 
it O 
is O 
necessary O 
to O 
assess O 
the O 
potential O 
of O 
traditional O 
cultivars O 
to O 
produce O 
quality O 
red O 
wines O 
. O 
In O 
this O 
work O 
, O 
anthocyanin B-FAMILY 
and O 
flavonol B-TRIVIAL 
evolution O 
was O 
followed O 
in O 
red O 
berries O 
from O 
V O 
. O 
vinifera O 
L O 
. O 
cv O 
. O 
Mouratón O 
. O 
The O 
novelty O 
of O 
this O 
study O 
is O 
that O 
grapes O 
were O 
separately O 
collected O 
from O 
two O 
different O 
positions O 
( O 
tips O 
and O 
shoulders O 
) O 
within O 
the O 
cluster O 
, O 
over O 
ripening O 
to O 
examine O 
the O 
effects O 
of O 
berry O 
position O 
within O 
the O 
fruit O 
cluster O 
on O 
the O 
flavonoid B-FAMILY 
compounds O 
. O 
Derivatives O 
of O 
five O 
anthocyanins B-FAMILY 
( O 
malvidin B-TRIVIAL 
, O 
peonidin B-TRIVIAL 
, O 
petunidin B-TRIVIAL 
, O 
delphinidin B-TRIVIAL 
and O 
cyanidin B-TRIVIAL 
) O 
and O 
derivatives O 
of O 
six O 
flavonols B-FAMILY 
( O 
quercetin B-TRIVIAL 
, O 
myricetin B-TRIVIAL 
, O 
kaempherol B-TRIVIAL 
, O 
laricitrin B-TRIVIAL 
isorhamnetin B-TRIVIAL 
and O 
syringetin B-TRIVIAL 
) O 
were O 
detected O 
in O 
both O 
positions O 
within O 
the O 
cluster O 
. O 
Dynamic O 
of O 
anthocyanins B-FAMILY 
( O 
from O 
819 O 
mg O 
/ O 
kg O 
to O 
1206 O 
mg O 
/ O 
kg O 
in O 
tips O 
; O 
and O 
from O 
786 O 
mg O 
/ O 
kg O 
to O 
1077 O 
mg O 
/ O 
kg O 
in O 
shoulders O 
) O 
and O 
dynamic O 
of O 
flavonols B-FAMILY 
( O 
from O 
25mg O 
/ O 
kg O 
to O 
41 O 
mg O 
/ O 
kg O 
in O 
tips O 
; O 
and O 
from O 
18 O 
mg O 
/ O 
kg O 
to O 
21 O 
mg O 
/ O 
kg O 
in O 
shoulders O 
) O 
confirmed O 
their O 
upward O 
trends O 
over O 
ripening O 
. O 
Grapes O 
located O 
inside O 
the O 
shoulder O 
bunch O 
receive O 
less O 
sunlight O 
radiation O 
than O 
those O 
located O 
inside O 
the O 
tip O 
bunch O 
and O 
this O 
fact O 
could O 
explain O 
the O 
different O 
accumulation O 
observed O 
for O 
both O 
positions O 
. O 
These O 
results O 
can O 
be O 
useful O 
for O 
winemakers O 
in O 
order O 
to O 
obtain O 
different O 
final O 
red O 
wine O 
quality O 
. O 

neuromuscular O 
activity O 
of O 
Bbil-TX O 
, O 
a O 
PLA2 O 
with O 
catalytic O 
activity O 
isolated O 
from O 
Bothriopsis O 
bilineata O 
smargadina O 
venom O 
, O 
was O 
examined O 
in O 
chick O 
biventer O 
cervicis O 
( O 
BC O 
) O 
and O 
mouse O 
phrenic O 
nerve O 
- O 
diaphragm O 
( O 
PND O 
) O 
preparations O 
. O 
In O 
BC O 
preparations O 
, O 
Bbil-TX O 
( O 
0.5-10 O 
μg O 
/ O 
ml O 
) O 
caused O 
time- O 
and O 
concentration O 
- O 
dependent O 
blockade O 
that O 
was O 
not O 
reversed O 
by O 
washing O 
; O 
the O 
times O 
for O 
50% O 
blockade O 
were O 
87 O 
± O 
7 O 
, O 
41 O 
± O 
7 O 
and O 
19 O 
± O 
2 O 
min O 
( O 
mean O 
± O 
SEM O 
; O 
n O 
= O 
4-6 O 
) O 
for O 
1 O 
, O 
5 O 
and O 
10 O 
μg O 
/ O 
ml O 
, O 
respectively O 
. O 
Muscle O 
contractures O 
to O 
exogenous O 
ACh B-ABBREVIATION 
and O 
KCl B-FORMULA 
were O 
unaffected O 
. O 
The O 
toxin O 
( O 
10 O 
μg O 
/ O 
ml O 
) O 
also O 
did O 
not O 
affect O 
the O 
twitch O 
- O 
tension O 
of O 
directly O 
- O 
stimulated O 
, O 
curarized O 
( O 
10 O 
μg O 
/ O 
ml O 
) O 
BC O 
preparations O 
. O 
However O 
, O 
Bbil-TX O 
( O 
10 O 
μg O 
/ O 
ml O 
) O 
produced O 
mild O 
morphological O 
alterations O 
( O 
edematous O 
and O 
/ O 
or O 
hyperchromic O 
fibers O 
) O 
in O 
BC O 
; O 
there O 
was O 
also O 
a O 
progressive O 
release O 
of O 
CK O 
( O 
from O 
116 O 
± O 
17 O 
IU O 
/ O 
ml O 
( O 
basal O 
) O 
to O 
710 O 
± O 
91 O 
IU O 
/ O 
ml O 
after O 
45 O 
min O 
) O 
. O 
Bbil-TX O 
( O 
5 O 
μg O 
/ O 
ml)-induced O 
blockade O 
was O 
markedly O 
inhibited O 
at O 
22-24 O 
°C O 
and O 
pretreatment O 
with O 
p-bromophenacyl B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
p-BPB B-ABBREVIATION 
) O 
abolished O 
the O 
neuromuscular O 
blockade O 
. O 
Bbil-TX O 
( O 
3-30 O 
μg O 
/ O 
ml O 
, O 
n O 
= O 
4-6 O 
) O 
caused O 
partial O 
time- O 
and O 
concentration O 
- O 
dependent O 
blockade O 
in O 
PND O 
preparations O 
( O 
52 O 
± O 
2% O 
at O 
the O 
highest O 
concentration O 
) O 
. O 
Bbil-TX O 
( O 
30 O 
μg O 
/ O 
ml O 
) O 
also O 
markedly O 
reduced O 
the O 
MEPPs O 
frequency O 
[ O 
from O 
26 O 
± O 
2.5 O 
( O 
basal O 
) O 
to O 
10 O 
± O 
1 O 
after O 
60 O 
min O 
; O 
n O 
= O 
5 O 
; O 
p O 
< O 
0.05 O 
] O 
and O 
the O 
quantal O 
content O 
[ O 
from O 
94 O 
± O 
14 O 
( O 
basal O 
) O 
to O 
24 O 
± O 
3 O 
after O 
60 O 
min O 
; O 
n O 
= O 
5 O 
; O 
p O 
< O 
0.05 O 
] O 
of O 
PND O 
preparations O 
, O 
but O 
caused O 
only O 
minor O 
depolarization O 
of O 
the O 
membrane O 
resting O 
potential O 
[ O 
from O 
-80 O 
± O 
1 O 
mV O 
( O 
basal O 
) O 
to O 
-66 O 
± O 
2 O 
mV O 
after O 
120 O 
min O 
; O 
n O 
= O 
5 O 
; O 
p O 
< O 
0.05 O 
] O 
, O 
with O 
no O 
significant O 
change O 
in O 
the O 
depolarizing O 
response O 
to O 
exogenous O 
carbachol B-TRIVIAL 
. O 
These O 
results O 
show O 
that O 
Bbil-TX O 
is O 
a O 
presynaptic O 
PLA2 O 
that O 
contributes O 
to O 
the O 
neuromuscular O 
blockade O 
caused O 
by O 
B O 
. O 
b O 
. O 
smargadina O 
venom O 
. O 

and O 
metals O 
induce O 
changes O 
in O 
the O 
mitochondria O 
- O 
rich O 
cells O 
of O 
fish O 
gills O 
: O 
an O 
integrative O 
field O 
study O 
involving O 
chemical O 
, O 
biochemical O 
and O 
morphological O 
analyses O 
. O 

integrating O 
chemical O 
, O 
biochemical O 
and O 
morphological O 
analyses O 
, O 
this O 
study O 
investigated O 
the O 
effects O 
of O 
multiple O 
pollutants O 
on O 
the O 
gill O 
mitochondria O 
- O 
rich O 
cells O 
( O 
MRCs O 
) O 
in O 
two O 
fish O 
species O 
, O 
Astyanax O 
fasciatus O 
and O 
Pimelodus O 
maculatus O 
, O 
collected O 
from O 
five O 
sites O 
( O 
FU10 O 
, O 
FU20 O 
, O 
FU30 O 
, O 
FU40 O 
and O 
FU50 O 
) O 
in O 
the O 
Furnas O 
Hydroelectric O 
Power O 
Station O 
reservoir O 
. O 
Water O 
analyses O 
revealed O 
aluminum B-SYSTEMATIC 
, O 
iron B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
as O 
well O 
as O 
organochlorine B-FAMILY 
( O 
aldrin B-TRIVIAL 
/ O 
dieldrin B-TRIVIAL 
, O 
endosulfan B-TRIVIAL 
, O 
heptachlor B-TRIVIAL 
/ O 
heptachlor B-TRIVIAL 
epoxide I-TRIVIAL 
and O 
metolachlor B-TRIVIAL 
) O 
contamination O 
at O 
all O 
of O 
the O 
sites O 
, O 
with O 
the O 
exception O 
of O 
FU10 O 
. O 
Copper B-SYSTEMATIC 
, O 
chrome B-TRIVIAL 
, O 
iron B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
were O 
detected O 
in O 
the O 
gills O 
of O 
both O 
species O 
, O 
and O 
aldrin B-TRIVIAL 
/ O 
dieldrin B-TRIVIAL 
, O 
endosulfan B-TRIVIAL 
and O 
heptachlor B-TRIVIAL 
/ O 
heptachlor B-TRIVIAL 
epoxide I-TRIVIAL 
were O 
detected O 
in O 
the O 
gills O 
of O 
fish O 
from O 
all O 
of O 
the O 
sites O 
, O 
with O 
the O 
exception O 
of O 
FU10 O 
. O 
Fish O 
collected O 
at O 
FU20 O 
, O 
FU30 O 
and O 
FU50 O 
exhibited O 
numerous O 
alterations O 
in O 
the O 
surface O 
architecture O 
of O 
their O 
pavement O 
cells O 
and O 
MRCs O 
. O 
The O 
surface O 
MRC O 
density O 
and O 
MRC O 
fractional O 
area O 
were O 
lower O 
in O 
fish O 
from O 
FU20 O 
, O 
FU30 O 
, O 
FU40 O 
and O 
FU50 O 
than O 
in O 
those O 
from O 
the O 
reference O 
site O 
( O 
FU10 O 
) O 
in O 
the O 
winter O 
, O 
and O 
some O 
variability O 
between O 
the O 
sites O 
was O 
observed O 
in O 
the O 
summer O 
. O 
The O 
organochlorine B-FAMILY 
contamination O 
at O 
FU20 O 
and O 
FU50 O 
was O 
associated O 
with O 
variable O 
changes O 
in O 
the O 
MRCs O 
and O 
inhibition O 
of O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
( O 
NKA O 
) O 
activity O 
, O 
especially O 
in O 
P O 
. O 
maculatus O 
. O 
At O 
FU30 O 
, O 
the O 
alterations O 
in O 
the O 
MRCs O 
were O 
associated O 
with O 
the O 
contaminants O 
present O 
, O 
especially O 
metals O 
. O 
A O 
multivariate O 
analysis O 
demonstrated O 
a O 
positive O 
association O 
between O 
the O 
biological O 
responses O 
of O 
both O 
species O 
and O 
environmental O 
contamination O 
, O 
indicating O 
that O 
under O 
realistic O 
conditions O 
, O 
a O 
mixture O 
of O 
organochlorines B-FAMILY 
and O 
metals O 
affected O 
the O 
MRCs O 
by O 
inhibiting O 
NKA O 
activity O 
and O 
inducing O 
morphological O 
changes O 
, O 
which O 
may O 
cause O 
an O 
ionic O 
imbalance O 
. O 

comparison O 
between O 
the O 
temperatures O 
within O 
imploding O 
acoustic O 
cavitation O 
bubbles O 
and O 
the O 
extent O 
of O 
sonoluminescence O 
( O 
SL O 
) O 
quenching O 
by O 
C(1)-C(5) O 
aliphatic B-FAMILY 
alcohols I-FAMILY 
in O 
1-ethyl-3-methylimidazolium B-SYSTEMATIC 
ethylsulfate I-SYSTEMATIC 
( O 
[EMIM][EtSO(4)] B-FORMULA 
, O 
a O 
well O 
known O 
imidazolium B-SYSTEMATIC 
based O 
room O 
temperature O 
ionic O 
liquid O 
( O 
RTIL O 
) O 
) O 
, O 
has O 
been O 
made O 
at O 
an O 
ultrasound O 
frequency O 
of O 
213 O 
kHz O 
. O 
The O 
temperatures O 
obtained O 
ranged O 
from O 
3500 O 
± O 
200K O 
, O 
in O 
neat O 
[EMIM][EtSO(4)] B-FORMULA 
, O 
to O 
about O 
3200 O 
± O 
200K O 
in O 
RTIL- O 
alcohol B-FAMILY 
containing O 
solutions O 
. O 
It O 
was O 
also O 
found O 
that O 
the O 
SL O 
intensity O 
decreased O 
with O 
increasing O 
concentration O 
( O 
up O 
to O 
1M O 
) O 
of O 
the O 
alcohols B-FAMILY 
to O 
a O 
greater O 
extent O 
compared O 
with O 
the O 
relative O 
changes O 
to O 
the O 
bubble O 
temperatures O 
. O 
Both O 
the O 
extent O 
of O 
the O 
reduction O 
in O 
the O 
bubble O 
temperatures O 
and O 
the O 
SL O 
quenching O 
were O 
much O 
smaller O 
than O 
those O 
obtained O 
in O 
comparable O 
aqueous O 
solutions O 
containing O 
aliphatic B-FAMILY 
alcohols I-FAMILY 
. O 
Possible O 
reasons O 
for O 
the O 
differences O 
in O 
the O 
observed O 
trends O 
between O 
water/ O 
alcohol B-FAMILY 
and O 
[EMIM][EtSO(4)] B-FORMULA 
/ O 
alcohol B-FAMILY 
systems O 
under O 
sonication O 
at O 
213 O 
kHz O 
are O 
discussed O 
. O 

and O 
dilational O 
rheology O 
of O 
mixed O 
β-casein/ O 
DoTAB B-ABBREVIATION 
layers O 
formed O 
by O 
sequential O 
and O 
simultaneous O 
adsorption O 
at O 
the O 
water/ O 
hexane B-SYSTEMATIC 
interface O 
. O 

interfacial O 
behavior O 
of O 
β-casein O 
( O 
βCS O 
) O 
has O 
been O 
investigated O 
in O 
presence O 
of O 
the O 
cationic O 
surfactant O 
dodecyl B-SYSTEMATIC 
trimethyl I-SYSTEMATIC 
ammonium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
DoTAB B-ABBREVIATION 
) O 
at O 
the O 
water/ O 
hexane B-SYSTEMATIC 
interface O 
and O 
compared O 
to O 
that O 
obtained O 
for O 
the O 
water O 
/ O 
air O 
interface O 
. O 
The O 
used O 
experimental O 
technique O 
is O 
a O 
drop O 
profile O 
analysis O 
tensiometer O 
specially O 
equipped O 
with O 
a O 
coaxial O 
double O 
capillary O 
, O 
which O 
allows O 
investigation O 
of O 
sequential O 
adsorption O 
of O 
individual O 
components O 
besides O 
the O 
traditional O 
simultaneous O 
adsorption O 
of O 
two O 
species O 
. O 
This O 
method O 
also O 
provides O 
the O 
dilational O 
rheological O 
measurements O 
based O 
on O 
low O 
frequency O 
harmonic O 
drop O 
oscillations O 
. O 
The O 
tensiometric O 
results O 
show O 
that O 
the O 
equilibrium O 
states O 
of O 
the O 
mixed O 
βCS/ O 
DoTAB B-ABBREVIATION 
layers O 
built O 
up O 
on O 
the O 
two O 
different O 
routes O 
do O 
not O 
differ O 
significantly O 
, O 
that O 
is O 
, O 
the O 
general O 
compositions O 
of O 
the O 
mixed O 
layers O 
are O 
similar O 
. O 
However O 
, O 
the O 
results O 
of O 
dilational O 
rheology O 
for O 
the O 
two O 
adsorption O 
strategies O 
are O 
remarkably O 
different O 
indicating O 
different O 
dynamic O 
characteristics O 
of O 
the O 
adsorbed O 
layers O 
. O 
These O 
findings O 
suggest O 
that O 
the O 
respective O 
mixed O 
layers O 
are O 
more O 
proteinlike O 
if O 
they O 
are O 
formed O 
via O 
sequential O 
adsorption O 
and O 
more O 
surfactant O 
- O 
like O 
after O 
simultaneous O 
adsorption O 
. O 
In O 
contrast O 
to O 
the O 
W O 
/ O 
A O 
interface O 
, O 
at O 
the O 
W O 
/ O 
H O 
interface O 
proteins O 
remain O 
at O 
the O 
interface O 
once O 
adsorbed O 
and O 
cannot O 
be O 
displaced O 
just O 
by O 
competitive O 
adsorption O 
of O 
surfactants O 
. O 

effects O 
induced O 
by O 
BSA-stabilized O 
silica B-TRIVIAL 
nanoparticles O 
in O 
mammalian O 
cell O 
lines O 
. O 

of O 
the O 
concerns O 
regarding O 
engineered O 
nanoparticle O 
( O 
NP O 
) O 
toxicity O 
are O 
based O 
on O 
knowledge O 
from O 
previous O 
studies O 
on O 
particles O 
in O 
ambient O 
air O 
or O 
occupational O 
situations O 
. O 
E.g O 
. O 
, O 
the O 
effects O 
of O 
exposure O 
to O 
silica B-TRIVIAL 
dust O 
particles O 
have O 
been O 
studied O 
intensely O 
due O 
to O 
the O 
carcinogenicity O 
of O 
crystalline O 
silica B-TRIVIAL 
. O 
However O 
, O 
the O 
increasing O 
usage O 
of O 
engineered O 
amorphous O 
silica B-TRIVIAL 
NPs O 
has O 
emphasized O 
the O 
need O 
for O 
further O 
mechanistic O 
insight O 
to O 
predict O 
the O 
consequences O 
of O 
exposure O 
to O 
the O 
amorphous O 
type O 
of O 
silica B-TRIVIAL 
NPs O 
. O 
The O 
present O 
study O 
focused O 
on O 
the O 
in O 
vitro O 
biological O 
effects O 
following O 
exposure O 
to O 
well O 
- O 
dispersed O 
, O 
BSA-stabilized O 
, O 
amorphous O 
silica B-TRIVIAL 
NPs O 
whereas O 
unmodified O 
silica B-TRIVIAL 
NPs O 
where O 
included O 
for O 
reasons O 
of O 
comparison O 
. O 
The O 
cytotoxicity O 
of O 
the O 
silica B-TRIVIAL 
NPs O 
was O 
investigated O 
in O 
six O 
different O 
cell O 
lines O 
( O 
A549 O 
, O 
THP-1 O 
, O 
CaCo-2 O 
, O 
ASB-XIV O 
, O 
J-774A.1 O 
, O 
and O 
Colon-26 O 
) O 
selected O 
to O 
explore O 
the O 
significance O 
of O 
organ O 
and O 
species O 
sensitivity O 
in O 
vitro O 
. O 
Viability O 
data O 
demonstrated O 
that O 
macrophages O 
were O 
most O 
sensitive O 
to O 
silica B-TRIVIAL 
NP O 
and O 
interestingly O 
, O 
murine O 
cell O 
lines O 
were O 
generally O 
found O 
to O 
be O 
more O 
sensitive O 
than O 
comparable O 
human O 
cell O 
lines O 
. O 
Further O 
studies O 
were O 
conducted O 
in O 
the O 
human O 
epithelial O 
lung O 
cell O 
line O 
, O 
A549 O 
, O 
to O 
explore O 
the O 
molecular O 
mechanism O 
of O 
silica B-TRIVIAL 
toxicity O 
. O 
Generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
one O 
of O 
the O 
proposed O 
toxicological O 
mechanisms O 
of O 
NPs O 
, O 
was O 
investigated O 
in O 
A549 O 
cells O 
by O 
the O 
dichlorofluorescin B-SYSTEMATIC 
( O 
DCF B-ABBREVIATION 
) O 
assay O 
to O 
be O 
significantly O 
induced O 
at O 
NP O 
concentrations O 
above O 
113μg O 
/ O 
mL O 
. O 
However O 
, O 
induction O 
of O 
oxidative O 
stress O 
related O 
pathways O 
was O 
not O 
found O 
after O 
silica B-TRIVIAL 
NP O 
exposure O 
for O 
24h O 
in O 
gene O 
array O 
studies O 
conducted O 
in O 
A549 O 
cells O 
at O 
a O 
relatively O 
low O 
NP O 
concentration O 
( O 
EC20 O 
) O 
. O 
Up-regulated O 
genes O 
( O 
more O 
than O 
2-fold O 
) O 
were O 
primarily O 
related O 
to O 
lipid O 
metabolism O 
and O 
biosynthesis O 
whereas O 
down O 
- O 
regulated O 
genes O 
included O 
several O 
processes O 
such O 
as O 
transcription O 
, O 
cell O 
junction O 
, O 
extra O 
cellular O 
matrix O 
(ECM)-receptor O 
interaction O 
and O 
others O 
. O 
Thus O 
, O 
gene O 
expression O 
data O 
proposes O 
that O 
several O 
cellular O 
processes O 
other O 
than O 
oxidative O 
stress O 
could O 
be O 
affected O 
by O 
exposure O 
to O 
silica B-TRIVIAL 
NPs O 
. O 

of O 
10 O 
nm O 
scale O 
cylinder O 
orientation O 
in O 
self O 
- O 
organized O 
sugar B-FAMILY 
-based O 
block O 
copolymer O 
thin O 
films O 
. O 

present O 
paper O 
describes O 
the O 
orientational O 
control O 
of O 
10 O 
nm O 
scale O 
cylinders O 
in O 
sugar B-FAMILY 
-based O 
block O 
copolymer O 
thin O 
films O 
by O 
simply O 
varying O 
the O 
composition O 
of O 
the O 
annealing O 
co O 
- O 
solvent O 
. O 
The O 
affinity O 
of O 
the O 
block O 
copolymer O 
to O 
the O 
solvent O 
vapor O 
could O 
be O 
systematically O 
adjusted O 
in O 
this O 
way O 
. O 

seed O 
procyanidin B-FAMILY 
extract O 
modulates O 
proliferation O 
and O 
apoptosis O 
of O 
pancreatic O 
beta-cells O 
. O 

seed O 
procyanidin B-FAMILY 
extract O 
( O 
GSPE O 
) O 
modulates O 
glucose B-TRIVIAL 
homeostasis O 
and O 
insulinemia O 
in O 
several O 
animal O 
models O 
. O 
Under O 
pathological O 
conditions O 
, O 
insulin O 
levels O 
are O 
dependent O 
on O 
pancreatic O 
beta-cell O 
functionality O 
, O 
as O 
well O 
as O 
on O 
the O 
beta-cell O 
mass O 
expansion O 
or O 
apoptosis O 
in O 
the O 
pancreas O 
. O 
In O 
this O 
study O 
, O 
we O 
analysed O 
the O 
effects O 
of O 
GSPE O 
on O 
modulating O 
apoptosis O 
and O 
proliferation O 
in O 
beta-cells O 
. O 
We O 
tested O 
the O 
effects O 
of O 
GSPE O 
in O 
the O 
INS-1E O 
pancreatic O 
beta-cell O 
line O 
, O 
either O 
under O 
basal O 
or O 
altered O 
conditions O 
with O 
high O 
glucose B-TRIVIAL 
, O 
insulin O 
or O 
palmitate B-TRIVIAL 
levels O 
. O 
GSPE O 
enhanced O 
the O 
pro O 
- O 
apoptotic O 
effect O 
of O 
high O 
glucose B-TRIVIAL 
and O 
showed O 
clear O 
antiproliferative O 
effects O 
under O 
high O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
palmitate B-TRIVIAL 
conditions O 
. O 
These O 
antiproliferative O 
effects O 
are O 
likely O 
due O 
to O 
high O 
molecular O 
weight O 
compounds O 
contained O 
in O 
the O 
extract O 
. O 
GSPE O 
also O 
modulated O 
pro- O 
and O 
anti-apoptotic O 
markers O 
in O 
the O 
pancreas O 
of O 
rats O 
fed O 
a O 
cafeteria O 
diet O 
, O 
with O 
the O 
effect O 
depending O 
on O 
the O 
dose O 
of O 
GSPE O 
and O 
duration O 
of O 
treatment O 
. O 
Thus O 
, O 
GSPE O 
is O 
able O 
to O 
modulate O 
apoptosis O 
and O 
proliferation O 
of O 
beta-cells O 
under O 
altered O 
, O 
but O 
not O 
basal O 
, O 
conditions O 
. O 

and O 
3-Arylcoumarin B-FAMILY 
from O 
Pterocarpus O 
soyauxii O 
. O 

study O 
on O 
the O 
constituents O 
of O 
the O 
heartwood O 
of O 
Pterocarpus O 
soyauxii O 
led O 
to O 
the O 
isolation O 
of O 
five O 
new O 
isoflavonoids B-FAMILY 
and O 
one O 
new O 
3-arylcoumarin B-FAMILY 
, O 
pterosonins B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
together O 
with O 
17 O 
known O 
analogues O 
, O 
among O 
which O 
8 O 
, O 
9 O 
, O 
and O 
18 O 
were O 
reported O 
as O 
natural O 
products O 
for O 
the O 
first O 
time O 
. O 
Structure O 
elucidation O 
was O 
achieved O 
by O 
way O 
of O 
spectroscopic O 
measurements O 
as O 
well O 
as O 
by O 
comparison O 
with O 
literature O 
data O 
. O 
Only O 
Compound O 
6 O 
showed O 
potent O 
cytotoxicity O 
against O 
human O 
non-small O 
cell O 
lung O 
cancer O 
( O 
A549 O 
) O 
, O 
pancreatic O 
cancer O 
( O 
Panc-28 O 
) O 
, O 
and O 
colon O 
carcinoma O 
( O 
HCT-116 O 
) O 
cells O 
with O 
GI50 O 
values O 
at O 
7.39 O 
, O 
25 O 
, O 
and O 
19.17 O 
µM O 
, O 
respectively O 
; O 
the O 
other O 
isolates O 
showed O 
no O 
cytotoxicity O 
against O 
the O 
above O 
tested O 
cell O 
lines O 
with O 
GI50 O 
values O 
> O 
50 O 
µM O 
. O 

oral O 
bioavailability O 
of O 
3-MCPD B-SYSTEMATIC 
from O 
3-MCPD B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
esters I-FAMILY 
in O 
rats O 
. O 

order O 
to O 
quantify O 
the O 
relative O 
oral O 
bioavailability O 
of O 
3-chloropropane-1,2-diol B-SYSTEMATIC 
( O 
3-MCPD B-SYSTEMATIC 
) O 
from O 
3-MCPD B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
diesters I-FAMILY 
in O 
vivo O 
, O 
1,2-dipalmitoyl-3-chloropropane-1,2-diol B-SYSTEMATIC 
( O 
3-MCPD B-SYSTEMATIC 
diester I-SYSTEMATIC 
) O 
and O 
3-MCPD B-SYSTEMATIC 
were O 
orally O 
applied O 
to O 
rats O 
in O 
equimolar O 
doses O 
. O 
In O 
both O 
cases O 
, O 
the O 
time O 
courses O 
of O 
3-MCPD B-SYSTEMATIC 
concentrations O 
were O 
measured O 
in O 
blood O 
, O 
various O 
organs O 
, O 
tissues O 
and O 
intestinal O 
luminal O 
contents O 
. O 
The O 
results O 
show O 
that O 
3-MCPD B-SYSTEMATIC 
is O 
released O 
by O 
enzymatic O 
hydrolysis O 
from O 
the O 
3-MCPD B-SYSTEMATIC 
diester I-SYSTEMATIC 
in O 
the O 
gastrointestinal O 
tract O 
and O 
distributed O 
to O 
blood O 
, O 
organs O 
and O 
tissues O 
. O 
Based O 
on O 
the O 
measurements O 
in O 
blood O 
, O 
the O 
areas O 
under O 
the O 
curve O 
( O 
AUC O 
) O 
for O 
3-MCPD B-SYSTEMATIC 
were O 
calculated O 
. O 
By O 
comparing O 
both O 
AUC O 
, O 
the O 
relative O 
amount O 
of O 
3-MCPD B-SYSTEMATIC 
bioavailable O 
from O 
the O 
3-MCPD B-SYSTEMATIC 
diester I-SYSTEMATIC 
was O 
calculated O 
to O 
be O 
86 O 
% O 
on O 
average O 
of O 
the O 
amount O 
bioavailable O 
following O 
administration O 
of O 
3-MCPD B-SYSTEMATIC 
. O 
In O 
view O 
of O 
limited O 
experimental O 
data O 
, O 
it O 
is O 
justified O 
for O 
the O 
purpose O 
of O 
risk O 
assessment O 
to O 
assume O 
complete O 
hydrolysis O 
of O 
the O 
diesters O 
in O 
the O 
gastro O 
- O 
intestinal O 
tract O 
. O 
Therefore O 
, O 
assessment O 
of O 
the O 
extent O 
of O 
exposure O 
to O 
3-MCPD B-SYSTEMATIC 
released O 
from O 
its O 
fatty B-FAMILY 
acid I-FAMILY 
esters I-FAMILY 
should O 
be O 
performed O 
in O 
the O 
same O 
way O 
as O 
exposure O 
to O 
the O 
same O 
molar O 
quantity O 
of O 
3-MCPD B-SYSTEMATIC 
. O 

iridoid B-FAMILY 
glycoside I-FAMILY 
and O 
triterpenoid B-FAMILY 
glycoside I-FAMILY 
from O 
Premna O 
fulva O 
. O 

chromatography O 
- O 
photodiode O 
array O 
detector O 
- O 
mass O 
spectrometry O 
- O 
based O 
chemical O 
investigation O 
of O 
the O 
leaves O 
and O 
stems O 
of O 
Premna O 
fulva O 
yielded O 
one O 
new O 
iridoid B-FAMILY 
glycoside I-FAMILY 
( O 
1 O 
) O 
, O 
one O 
new O 
triterpenoid B-FAMILY 
glycoside I-FAMILY 
( O 
2 O 
) O 
along O 
with O 
six O 
known O 
compounds O 
isolated O 
for O 
the O 
first O 
time O 
from O 
the O 
genus O 
. O 
Their O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
data O 
analyses O 
and O 
chemical O 
methods O 
. O 

in O 
P-Glycoprotein O 
Inhibitory O 
Potency O 
( O 
IC50 O 
) O 
Using O 
Various O 
In O 
Vitro O 
Experimental O 
Systems O 
: O 
Implications O 
for O 
Universal O 
Digoxin B-TRIVIAL 
DDI O 
Risk O 
Assessment O 
Decision O 
Criteria O 
. O 

P-glycoprotein O 
( O 
P-gp O 
) O 
IC50 O 
working O 
group O 
was O 
established O 
with O 
twenty O 
- O 
three O 
participating O 
pharmaceutical O 
and O 
contract O 
research O 
laboratories O 
and O 
one O 
academic O 
institution O 
to O 
assess O 
inter O 
- O 
laboratory O 
variability O 
in O 
P-gp O 
IC50 O 
determinations O 
. O 
Each O 
lab O 
followed O 
their O 
in O 
- O 
house O 
protocol O 
to O 
determine O 
in O 
vitro O 
IC50 O 
values O 
for O 
sixteen O 
inhibitors O 
using O 
four O 
different O 
test O 
systems O 
: O 
Caco-2 O 
( O 
11 O 
labs O 
) O 
, O 
MDCKII-MDR1 O 
( O 
6 O 
labs O 
) O 
and O 
LLC-PK1-MDR1 O 
( O 
4 O 
labs O 
) O 
cells O 
, O 
and O 
membrane O 
vesicles O 
containing O 
human O 
P-gp O 
( O 
5 O 
labs O 
) O 
. O 
For O 
cell O 
models O 
, O 
various O 
equations O 
to O 
calculate O 
remaining O 
transport O 
activity O 
( O 
e.g O 
. O 
efflux O 
ratio O 
, O 
unidirectional O 
flux O 
, O 
net O 
secretory O 
flux O 
) O 
were O 
also O 
evaluated O 
. O 
The O 
difference O 
in O 
IC50 O 
values O 
for O 
each O 
of O 
the O 
inhibitors O 
across O 
all O 
test O 
systems O 
and O 
equations O 
ranged O 
from O 
a O 
minimum O 
of O 
20- O 
and O 
24-fold O 
between O 
lowest O 
and O 
highest O 
IC50 O 
values O 
for O 
sertraline B-TRIVIAL 
and O 
isradipine B-TRIVIAL 
, O 
to O 
a O 
maximum O 
of O 
407- O 
and O 
796-fold O 
for O 
telmisartan B-TRIVIAL 
and O 
verapamil B-TRIVIAL 
, O 
respectively O 
. O 
For O 
telmisartan B-TRIVIAL 
and O 
verapamil B-TRIVIAL 
, O 
variability O 
was O 
greatly O 
influenced O 
by O 
data O 
from O 
one O 
laboratory O 
in O 
each O 
case O 
. O 
Excluding O 
these O 
two O 
data O 
sets O 
brings O 
the O 
range O 
in O 
IC50 O 
values O 
for O 
telmisartan B-TRIVIAL 
and O 
verapamil B-TRIVIAL 
down O 
to O 
69- O 
and O 
159-fold O 
. O 
The O 
efflux O 
ratio O 
based O 
- O 
equation O 
generally O 
resulted O 
in O 
several O 
fold O 
lower O 
IC50 O 
values O 
compared O 
to O 
unidirectional O 
or O 
net O 
- O 
secretory O 
flux O 
equations O 
. O 
Statistical O 
analysis O 
indicated O 
that O 
variability O 
in O 
IC50 O 
values O 
was O 
mainly O 
due O 
to O 
inter O 
- O 
laboratory O 
variability O 
, O 
rather O 
than O 
an O 
implicit O 
systematic O 
difference O 
between O 
test O 
systems O 
. O 
Potential O 
reasons O 
for O 
variability O 
are O 
discussed O 
and O 
the O 
simplest O 
, O 
most O 
robust O 
experimental O 
design O 
for O 
P-gp O 
IC50 O 
determination O 
proposed O 
. O 
The O 
impact O 
of O 
these O 
findings O 
on O 
drug O 
- O 
drug O 
interaction O 
risk O 
assessment O 
is O 
discussed O 
in O 
the O 
companion O 
paper O 
and O 
recommendations O 
are O 
provided O 
. O 

between O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
and O 
abnormal O 
free O 
thyroxine B-TRIVIAL 
level O 
in O 
men O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
a O 
chemical O 
that O 
is O 
used O 
in O 
a O 
variety O 
of O 
consumer O 
products O 
, O 
and O 
exposure O 
to O 
BPA B-ABBREVIATION 
is O 
widespread O 
among O 
the O 
general O 
population O 
. O 
Recent O 
studies O 
have O 
suggested O 
that O 
BPA B-ABBREVIATION 
may O 
affect O 
the O 
thyroid O 
and O 
related O 
pathways O 
. O 
However O 
, O 
human O 
studies O 
are O 
still O 
limited O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
relationship O 
between O 
BPA B-ABBREVIATION 
exposure O 
and O 
thyroid O 
function O 
. O 
We O 
obtained O 
survey O 
data O 
and O 
blood O 
samples O 
from O 
The O 
Thai O 
National O 
Health O 
Examination O 
Survey O 
IV O 
2009 O 
, O 
a O 
nationally O 
representative O 
cross O 
- O 
sectional O 
survey O 
using O 
a O 
multistage O 
, O 
stratified O 
sampling O 
of O 
the O 
Thai O 
population O 
. O 
A O 
total O 
of O 
2340 O 
subjects O 
aged O 
18-94 O 
years O 
were O 
sampled O 
for O 
the O 
present O 
study O 
. O 
Serum O 
BPA B-ABBREVIATION 
, O 
TSH O 
, O 
FT(4) O 
, O 
and O 
related O 
covariates O 
were O 
measured O 
. O 
BPA B-ABBREVIATION 
was O 
log O 
- O 
transformed O 
prior O 
to O 
analysis O 
. O 
BPA B-ABBREVIATION 
was O 
detected O 
in O 
52.8 O 
% O 
of O 
serum O 
samples O 
with O 
a O 
median O 
concentration O 
of O 
0.33 O 
( O 
range O 
0-66.91) O 
ng O 
/ O 
mL O 
. O 
We O 
excluded O 
subjects O 
who O 
tested O 
positive O 
for O 
thyroid O 
autoantibody O 
and O 
then O 
stratified O 
the O 
remaining O 
subjects O 
by O 
gender O 
; O 
the O 
analysis O 
showed O 
a O 
significantly O 
negative O 
correlation O 
between O 
serum O 
BPA B-ABBREVIATION 
and O 
FT(4) O 
levels O 
in O 
males O 
( O 
r O 
= O 
-0.14 O 
, O 
P O 
< O 
0.001 O 
) O 
. O 
In O 
contrast O 
, O 
no O 
association O 
was O 
observed O 
in O 
females O 
. O 
BPA B-ABBREVIATION 
was O 
not O 
associated O 
with O 
TSH O 
in O 
either O 
gender O 
. O 
This O 
gender O 
- O 
related O 
discrepancy O 
is O 
possibly O 
related O 
to O 
androgen B-FAMILY 
-related O 
differences O 
in O 
the O 
metabolism O 
of O 
BPA B-ABBREVIATION 
. O 
Our O 
preliminary O 
results O 
provide O 
evidence O 
of O 
a O 
negative O 
association O 
between O 
BPA B-ABBREVIATION 
and O 
FT(4) O 
levels O 
. O 
Additional O 
detailed O 
studies O 
are O 
needed O 
to O 
investigate O 
the O 
temporal O 
relationship O 
and O 
potential O 
public O 
health O 
implications O 
of O 
such O 
an O 
association O 
. O 

power O 
conversion O 
efficiency O 
of O 
the O 
most O 
efficient O 
organic O 
photovoltaic O 
( O 
OPV O 
) O 
cells O 
has O 
recently O 
increased O 
to O 
over O 
10% O 
. O 
To O 
enable O 
further O 
increases O 
, O 
the O 
factors O 
limiting O 
the O 
device O 
efficiency O 
in O 
OPV O 
must O 
be O 
identified O 
. O 
In O 
this O 
review O 
, O 
the O 
operational O 
mechanism O 
of O 
OPV O 
cells O 
is O 
explained O 
and O 
the O 
detailed O 
balance O 
limit O 
to O 
photovoltaic O 
energy O 
conversion O 
, O 
as O 
developed O 
by O 
Shockley O 
and O 
Queisser O 
, O 
is O 
outlined O 
. O 
The O 
various O 
approaches O 
that O 
have O 
been O 
developed O 
to O 
estimate O 
the O 
maximum O 
practically O 
achievable O 
efficiency O 
in O 
OPV O 
are O 
then O 
discussed O 
, O 
based O 
on O 
empirical O 
knowledge O 
of O 
organic O 
semiconductor O 
materials O 
. O 
Subsequently O 
, O 
approaches O 
made O 
to O 
adapt O 
the O 
detailed O 
balance O 
theory O 
to O 
incorporate O 
some O 
of O 
the O 
fundamentally O 
different O 
processes O 
in O 
organic O 
solar O 
cells O 
that O 
originate O 
from O 
using O 
a O 
combination O 
of O 
two O 
complementary O 
, O 
donor O 
and O 
acceptor O 
, O 
organic O 
semiconductors O 
using O 
thermodynamic O 
and O 
kinetic O 
approaches O 
are O 
described O 
. O 
The O 
more O 
empirical O 
formulations O 
to O 
the O 
efficiency O 
limits O 
provide O 
estimates O 
of O 
10-12% O 
, O 
but O 
the O 
more O 
fundamental O 
descriptions O 
suggest O 
limits O 
of O 
20-24% O 
to O 
be O 
reachable O 
in O 
single O 
junctions O 
, O 
similar O 
to O 
the O 
highest O 
efficiencies O 
obtained O 
for O 
crystalline O 
silicon B-SYSTEMATIC 
p-n O 
junction O 
solar O 
cells O 
. O 
Closing O 
this O 
gap O 
sets O 
the O 
stage O 
for O 
future O 
materials O 
research O 
and O 
development O 
of O 
OPV O 
. O 

semiexperimental O 
structure O 
of O 
1,3,4-oxadiazole B-SYSTEMATIC 
by O 
the O 
mixed O 
estimation O 
method O 
. O 

order O 
to O 
determine O 
an O 
accurate O 
equilibrium O 
structure O 
for O 
1,3,4-oxadiazole B-SYSTEMATIC 
, O 
microwave O 
transitions O 
and O 
ground O 
- O 
state O 
rotational O 
constants O 
are O 
reported O 
for O 
the O 
parent O 
species O 
and O 
for O 
the O 
(18)O B-FORMULA 
isotopologue O 
measured O 
in O 
natural O 
abundance O 
. O 
These O 
rotational O 
constants O 
along O 
with O 
those O 
of O 
the O 
(13)C B-FORMULA 
, O 
(15)N B-FORMULA 
, O 
and O 
D1 O 
species O 
were O 
used O 
together O 
with O 
vibration O 
- O 
rotation O 
constants O 
calculated O 
from O 
a O 
cubic O 
force O 
field O 
calculated O 
at O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
G(3df,2pd) O 
level O 
of O 
theory O 
to O 
derive O 
a O 
semiexperimental O 
equilibrium O 
structure O 
. O 
However O 
, O 
the O 
results O 
of O 
this O 
fit O 
were O 
not O 
satisfactory O 
; O 
therefore O 
, O 
the O 
structure O 
was O 
later O 
significantly O 
improved O 
by O 
the O 
mixed O 
estimation O 
method O 
. O 
In O 
this O 
method O 
, O 
internal O 
coordinates O 
from O 
good O 
- O 
quality O 
quantum O 
chemical O 
calculations O 
( O 
with O 
appropriate O 
uncertainties O 
) O 
are O 
fitted O 
simultaneously O 
with O 
moments O 
of O 
inertia O 
of O 
the O 
full O 
set O 
of O 
isotopologues O 
. O 
The O 
accuracy O 
of O 
this O 
structure O 
has O 
been O 
confirmed O 
by O 
using O 
an O 
extrapolation O 
technique O 
. O 
All O 
elements O 
of O 
the O 
(14)N B-FORMULA 
nuclear O 
quadrupole O 
coupling O 
tensor O 
have O 
been O 
determined O 
. O 

Treatment O 
of O 
Tart O 
Cherry O 
Extract O 
and O 
Essential O 
Fatty B-FAMILY 
Acids I-FAMILY 
Reduces O 
Cognitive O 
Impairments O 
and O 
Inflammation O 
in O 
the O 
mu-p75 O 
Saporin-Induced O 
Mouse O 
Model O 
of O 
Alzheimer's O 
Disease O 
. O 

Alzheimer's O 
disease O 
( O 
AD O 
) O 
is O 
a O 
progressive O 
neurodegenerative O 
disorder O 
that O 
affects O 
more O 
than O 
five O 
million O 
Americans O 
and O 
is O 
characterized O 
by O 
a O 
progressive O 
loss O 
of O 
memory O 
, O 
loss O 
of O 
cholinergic O 
neurons O 
in O 
the O 
basal O 
forebrain O 
, O 
formation O 
of O 
amyloid O 
plaques O 
and O 
neurofibrillary O 
tangles O 
, O 
and O 
an O 
increase O 
in O 
oxidative O 
stress O 
. O 
Recent O 
studies O 
indicate O 
that O 
dietary O 
supplements O 
of O 
antioxidants O 
and O 
omega-3 B-MULTIPLE 
and I-MULTIPLE 
omega-6 I-MULTIPLE 
fatty I-MULTIPLE 
acids I-MULTIPLE 
may O 
reduce O 
the O 
cognitive O 
deficits O 
in O 
AD O 
patients O 
. O 
The O 
current O 
study O 
tested O 
a O 
combinatorial O 
treatment O 
of O 
antioxidants O 
from O 
tart O 
cherry O 
extract O 
and O 
essential O 
fatty B-FAMILY 
acids I-FAMILY 
from O 
Nordic O 
fish O 
and O 
emu O 
oils O 
for O 
reducing O 
cognitive O 
deficits O 
in O 
the O 
mu-p75 O 
saporin O 
(SAP)-induced O 
mouse O 
model O 
of O 
AD O 
. O 
Mice O 
were O 
given O 
daily O 
gavage O 
treatments O 
of O 
Cerise(®) O 
Total-Body-Rhythm O 
™ O 
( O 
TBR O 
; O 
containing O 
tart O 
cherry O 
extract O 
, O 
Nordic O 
fish O 
oil O 
, O 
and O 
refined O 
emu O 
oil O 
) O 
or O 
vehicle O 
( O 
methylcellulose O 
) O 
for O 
2 O 
weeks O 
before O 
intracerebroventricular O 
injections O 
of O 
the O 
cholinergic O 
toxin O 
, O 
mu-p75 O 
SAP O 
, O 
or O 
phosphate B-SYSTEMATIC 
-buffered O 
saline O 
. O 
The O 
TBR O 
treatments O 
continued O 
for O 
an O 
additional O 
17 O 
days O 
, O 
when O 
the O 
mice O 
were O 
tested O 
on O 
a O 
battery O 
of O 
cognitive O 
and O 
motor O 
tasks O 
. O 
Results O 
indicate O 
that O 
TBR O 
decreased O 
the O 
SAP-induced O 
cognitive O 
deficits O 
assessed O 
by O 
the O 
object O 
- O 
recognition O 
, O 
place O 
- O 
recognition O 
, O 
and O 
Morris O 
- O 
water O 
- O 
maze O 
tasks O 
. O 
Histological O 
examination O 
of O 
the O 
brain O 
tissue O 
indicated O 
that O 
TBR O 
protected O 
against O 
SAP-induced O 
inflammatory O 
response O 
and O 
loss O 
of O 
cholinergic O 
neurons O 
in O 
the O 
area O 
around O 
the O 
medial O 
septum O 
. O 
These O 
findings O 
indicate O 
that O 
TBR O 
has O 
the O 
potential O 
to O 
serve O 
as O 
an O 
adjunctive O 
treatment O 
which O 
may O 
help O 
reduce O 
the O 
severity O 
of O 
cognitive O 
deficits O 
in O 
disorders O 
involving O 
cholinergic O 
deficits O 
, O 
such O 
as O 
AD O 
. O 

II O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
type O 
2 O 
allosteric O 
potentiators O 
prevent O 
sodium B-SYSTEMATIC 
lactate I-SYSTEMATIC 
-induced O 
panic O 
- O 
like O 
response O 
in O 
panic O 
- O 
vulnerable O 
rats O 
. O 

with O 
chronic O 
inhibition O 
of O 
GABA B-ABBREVIATION 
synthesis O 
by O 
infusion O 
of O 
l-allyglycine B-SYSTEMATIC 
, O 
a O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
decarboxylase O 
inhibitor O 
, O 
into O 
their O 
dorsomedial O 
/ O 
perifornical O 
hypothalamus O 
are O 
anxious O 
and O 
exhibit O 
panic O 
- O 
like O 
cardio O 
- O 
respiratory O 
responses O 
to O 
treatment O 
with O 
intravenous O 
( O 
i.v O 
. O 
) O 
sodium B-SYSTEMATIC 
lactate I-SYSTEMATIC 
( O 
NaLac B-FORMULA 
) O 
infusions O 
, O 
in O 
a O 
manner O 
similar O 
to O 
what O 
occurs O 
in O 
patients O 
with O 
panic O 
disorder O 
. O 
We O 
previously O 
showed O 
that O 
either O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
or O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
type O 
2 O 
/ O 
3 O 
receptor O 
agonists O 
can O 
block O 
such O 
a O 
NaLac B-FORMULA 
response O 
, O 
suggesting O 
that O 
a O 
glutamate B-TRIVIAL 
mechanism O 
is O 
contributing O 
to O 
this O 
panic O 
- O 
like O 
state O 
. O 
Using O 
this O 
animal O 
model O 
of O 
panic O 
, O 
we O 
tested O 
the O 
efficacy O 
of O 
CBiPES B-ABBREVIATION 
and O 
THIIC B-ABBREVIATION 
, O 
which O 
are O 
selective O 
group O 
II O 
metabotropic O 
glutamate B-TRIVIAL 
type O 
2 O 
receptor O 
allosteric O 
potentiators O 
( O 
at O 
10-30 O 
mg O 
/ O 
kg O 
i.p O 
. O 
) O 
, O 
in O 
preventing O 
NaLa B-FORMULA 
c-induced O 
panic O 
- O 
like O 
behavioral O 
and O 
cardiovascular O 
responses O 
. O 
The O 
positive O 
control O 
was O 
alprazola B-TRIVIAL 
m O 
( O 
3mg O 
/ O 
kg O 
i.p O 
. O 
) O 
, O 
a O 
clinically O 
effective O 
anti-pani O 
c B-FAMILY 
benzodiazepi I-FAMILY 
ne O 
. O 
As O 
predicted O 
, O 
panic O 
- O 
prone O 
rats O 
given O 
a B-FORMULA 
NaL I-FORMULA 
ac O 
challenge O 
displaye O 
d B-FORMULA 
NaL I-FORMULA 
ac O 
- O 
induced O 
panic O 
- O 
like O 
cardiovascular O 
( O 
i.e O 
. O 
tachycardia O 
and O 
hypertensive O 
) O 
responses O 
and O 
" O 
anxiety O 
" O 
( O 
i.e O 
. O 
decreased O 
social O 
interaction O 
time O 
) O 
and O 
" O 
flight O 
" O 
( O 
i.e O 
. O 
increased O 
locomotion O 
) O 
-associated O 
behaviors O 
; O 
however O 
, O 
systemic O 
injection O 
of O 
the O 
panic O 
- O 
prone O 
rats O 
wit O 
h B-ABBREVIATION 
CBiP I-ABBREVIATION 
ES O 
, B-ABBREVIATION 
THI I-ABBREVIATION 
IC O 
o O 
r B-TRIVIAL 
alprazol I-TRIVIAL 
am O 
prior O 
to O 
th O 
e B-FORMULA 
NaL I-FORMULA 
ac O 
dose O 
blocked O 
al O 
l B-FORMULA 
NaL I-FORMULA 
ac O 
- O 
induced O 
panic O 
- O 
like O 
behaviors O 
and O 
cardiovascular O 
responses O 
. O 
These O 
data O 
suggested O 
that O 
in O 
a O 
rat O 
animal O 
model O 
, O 
selective O 
group O 
II O 
metabotropi O 
c B-TRIVIAL 
glutama I-TRIVIAL 
te O 
type O 
2 O 
receptor O 
allosteric O 
potentiators O 
show O 
an O 
anti-panic O 
efficacy O 
similar O 
t O 
o B-TRIVIAL 
alprazol I-TRIVIAL 
am O 
. O 

studies O 
have O 
revealed O 
a O 
close O 
relationship O 
between O 
transcription O 
, O 
histone O 
modification O 
, O 
and O 
RNA O 
processing O 
. O 
In O 
fact O 
, O 
genome O 
- O 
wide O 
analyses O 
that O 
correlate O 
histone O 
marks O 
with O 
RNA O 
processing O 
signals O 
raise O 
the O 
possibility O 
that O 
specific O 
RNA O 
processing O 
factors O 
may O 
modulate O 
transcription O 
and O 
help O 
to O 
" O 
write O 
" O 
chromatin O 
marks O 
. O 
Here O 
we O 
show O 
that O 
the O 
nuclear O 
cap O 
binding O 
complex O 
( O 
CBC O 
) O 
directs O 
recruitment O 
of O 
transcription O 
elongation O 
factors O 
and O 
establishes O 
proper O 
histone O 
marks O 
during O 
active O 
transcription O 
. O 
A O 
directed O 
genetic O 
screen O 
revealed O 
that O 
deletion O 
of O 
either O 
subunit O 
of O 
the O 
CBC O 
confers O 
a O 
synthetic O 
growth O 
defect O 
when O 
combined O 
with O 
deletion O 
of O 
genes O 
encoding O 
either O 
Ctk2 O 
or O 
Bur2 O 
, O 
a O 
component O 
of O 
the O 
Saccharomyces O 
cerevisiae O 
ortholog O 
of O 
P-TEFb O 
. O 
The O 
CBC O 
physically O 
associates O 
with O 
these O 
complexes O 
to O 
recruit O 
them O 
during O 
transcription O 
and O 
mediates O 
phosphorylation O 
at O 
Ser B-FORMULA 
-2 O 
of O 
the O 
C B-FORMULA 
-terminal O 
domain O 
( O 
CTD O 
) O 
of O 
RNA O 
polymerase O 
II O 
. O 
To O 
understand O 
how O 
these O 
interactions O 
influence O 
downstream O 
events O 
, O 
histone O 
H3K36me3 O 
was O 
examined O 
, O 
and O 
we O 
demonstrate O 
that O 
CBCΔ O 
affects O 
proper O 
Set2-dependent O 
H3K36me3 O 
. O 
Consistent O 
with O 
this O 
, O 
the O 
CBC O 
and O 
Set2 O 
have O 
similar O 
effects O 
on O 
the O 
ability O 
to O 
rapidly O 
induce O 
and O 
sustain O 
activated O 
gene O 
expression O 
, O 
and O 
these O 
effects O 
are O 
distinct O 
from O 
other O 
histone O 
methyltransferases O 
. O 
This O 
work O 
provides O 
evidence O 
for O 
an O 
emerging O 
model O 
that O 
RNA O 
processing O 
factors O 
can O 
modulate O 
the O 
recruitment O 
of O 
transcription O 
factors O 
and O 
influence O 
histone O 
modification O 
during O 
elongation O 
. O 

Dibenzo-p-dioxins I-FAMILY 
( O 
PBDDs B-FAMILY 
) O 
, O 
Dibenzofurans B-FAMILY 
( O 
PBDFs B-FAMILY 
) O 
and O 
Biphenyls B-FAMILY 
( O 
PBBs B-FAMILY 
) O 
- O 
Inclusion O 
in O 
the O 
Toxicity O 
Equivalency O 
Factor O 
Concept O 
for O 
Dioxin B-FAMILY 
-like O 
Compounds O 
- O 

2011 O 
a O 
joint O 
World O 
Health O 
Organization O 
( O 
WHO O 
) O 
and O 
United O 
Nations O 
Environment O 
Programme O 
( O 
UNEP O 
) O 
expert O 
consultation O 
took O 
place O 
, O 
during O 
which O 
the O 
possible O 
inclusion O 
of O 
brominated O 
analogues O 
of O 
the O 
dioxin B-FAMILY 
-like O 
compounds O 
in O 
the O 
WHO O 
Toxicity O 
Equivalency O 
Factor O 
( O 
TEF O 
) O 
scheme O 
were O 
evaluated O 
. O 
The O 
expert O 
panel O 
concluded O 
that O 
polybrominated B-FAMILY 
dibenzo-p-dioxins I-FAMILY 
( O 
PBDDs B-FAMILY 
) O 
, O 
dibenzofurans B-FAMILY 
( O 
PBDFs B-FAMILY 
) O 
, O 
and O 
some O 
dioxin B-FAMILY 
-like O 
biphenyls B-FAMILY 
( O 
dl- O 
PBBs B-FAMILY 
) O 
may O 
contribute O 
significantly O 
in O 
daily O 
human O 
background O 
exposure O 
to O 
the O 
total O 
dioxin B-FAMILY 
toxic O 
equivalencies O 
( O 
TEQs O 
) O 
. O 
These O 
compounds O 
are O 
also O 
commonly O 
found O 
in O 
the O 
aquatic O 
environment O 
. O 
Available O 
data O 
for O 
fish O 
toxicity O 
were O 
evaluated O 
for O 
possible O 
inclusion O 
in O 
the O 
WHO-UNEP O 
TEF O 
scheme O 
( O 
Van O 
den O 
Berg O 
et O 
al O 
. O 
, O 
1998 O 
) O 
. O 
Because O 
of O 
the O 
limited O 
database O 
it O 
was O 
decided O 
not O 
to O 
derive O 
specific O 
WHO-UNEP O 
TEFs O 
for O 
fish O 
, O 
but O 
for O 
ecotoxicological O 
risk O 
assessment O 
the O 
use O 
of O 
specific O 
relative O 
effect O 
potencies O 
( O 
REPs O 
) O 
from O 
fish O 
embryo O 
assays O 
is O 
recommended O 
. O 
Based O 
on O 
the O 
limited O 
mammalian O 
REP O 
database O 
for O 
these O 
brominated O 
compounds O 
, O 
it O 
was O 
concluded O 
that O 
sufficient O 
differentiation O 
from O 
the O 
present O 
TEF O 
values O 
of O 
the O 
chlorinated O 
analogues O 
( O 
Van O 
den O 
Berg O 
et O 
al O 
. O 
, O 
2005 O 
) O 
was O 
not O 
possible O 
. O 
However O 
, O 
the O 
REPs O 
for O 
PBDDs B-FAMILY 
, O 
PBDFs B-FAMILY 
, O 
and O 
non-ortho O 
dl- O 
PBBs B-FAMILY 
in O 
mammals O 
closely O 
follow O 
those O 
of O 
the O 
chlorinated O 
analogues O 
, O 
at O 
least O 
within O 
one O 
order O 
of O 
magnitude O 
. O 
Therefore O 
, O 
the O 
use O 
of O 
similar O 
interim O 
TEF O 
values O 
for O 
brominated O 
and O 
chlorinated O 
congeners O 
for O 
human O 
risk O 
assessment O 
is O 
recommended O 
, O 
pending O 
more O 
detailed O 
information O 
in O 
the O 
future O 
. O 

alterations O 
following O 
developmental O 
atrazine B-TRIVIAL 
exposure O 
in O 
zebrafish O 
are O 
associated O 
with O 
disruption O 
of O 
neuroendocrine O 
and O 
reproductive O 
system O 
function O 
, O 
cell O 
cycle O 
, O 
and O 
carcinogenesis O 
. O 

, O 
a O 
herbicide O 
commonly O 
applied O 
to O 
agricultural O 
areas O 
and O 
a O 
common O 
contaminant O 
of O 
potable O 
water O 
supplies O 
, O 
is O 
implicated O 
as O 
an O 
endocrine O 
- O 
disrupting O 
chemical O 
( O 
EDC O 
) O 
and O 
potential O 
carcinogen O 
. O 
Studies O 
show O 
that O 
EDCs O 
can O 
cause O 
irreversible O 
changes O 
in O 
tissue O 
formation O 
, O 
decreased O 
reproductive O 
potential O 
, O 
obesity O 
, O 
and O 
cancer O 
. O 
The O 
U.S O 
. O 
Environmental O 
Protection O 
Agency O 
considers O 
an O 
atrazine B-TRIVIAL 
concentration O 
of O 
≤ O 
3 O 
ppb O 
in O 
drinking O 
water O 
safe O 
for O 
consumption O 
. O 
The O 
specific O 
adverse O 
human O 
health O 
effects O 
associated O 
with O 
a O 
developmental O 
atrazine B-TRIVIAL 
exposure O 
and O 
the O 
underlying O 
genetic O 
mechanisms O 
of O 
these O 
effects O 
are O 
not O 
well O 
defined O 
. O 
In O 
this O 
study O 
, O 
zebrafish O 
embryos O 
were O 
exposed O 
to O 
a O 
range O 
of O 
atrazine B-TRIVIAL 
concentrations O 
to O 
establish O 
toxicity O 
. O 
Morphological O 
, O 
transcriptomic O 
, O 
and O 
protein O 
alterations O 
were O 
then O 
assessed O 
at O 
72h O 
postfertilization O 
following O 
developmental O 
atrazine B-TRIVIAL 
exposure O 
at O 
0 O 
, O 
0.3 O 
, O 
3 O 
, O 
or O 
30 O 
ppb O 
. O 
A O 
significant O 
increase O 
in O 
head O 
length O 
was O 
observed O 
in O 
all O 
three O 
atrazine B-TRIVIAL 
treatments O 
. O 
Transcriptomic O 
profiles O 
revealed O 
21 O 
, O 
62 O 
, O 
and O 
64 O 
genes O 
with O 
altered O 
expression O 
in O 
the O 
0.3 O 
, O 
3 O 
, O 
and O 
30 O 
ppb O 
atrazine B-TRIVIAL 
treatments O 
, O 
respectively O 
. O 
Altered O 
genes O 
were O 
associated O 
with O 
neuroendocrine O 
and O 
reproductive O 
system O 
development O 
, O 
function O 
, O 
and O 
disease O 
; O 
cell O 
cycle O 
control O 
; O 
and O 
carcinogenesis O 
. O 
There O 
was O 
a O 
significant O 
overlap O 
( O 
42 O 
genes O 
) O 
between O 
the O 
3 O 
and O 
30 O 
ppb O 
differentially O 
expressed O 
gene O 
lists O 
, O 
with O 
two O 
of O 
these O 
genes O 
( O 
CYP17A1 O 
and O 
SAMHD1 O 
) O 
present O 
in O 
all O 
three O 
atrazine B-TRIVIAL 
treatments O 
. O 
Increased O 
transcript O 
levels O 
were O 
translated O 
to O 
significant O 
upregulation O 
in O 
protein O 
expression O 
. O 
Overall O 
, O 
this O 
study O 
identifies O 
genetic O 
and O 
molecular O 
targets O 
altered O 
in O 
response O 
to O 
a O 
developmental O 
atrazine B-TRIVIAL 
exposure O 
to O 
further O 
define O 
the O 
biological O 
pathways O 
and O 
mechanisms O 
of O 
toxicity O 
. O 

effect O 
of O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
on O 
ferric B-SYSTEMATIC 
nitrilotriacetate I-SYSTEMATIC 
induced O 
hepatotoxicity O 
and O 
oxidative O 
stress O 
in O 
mice O 
. O 

present O 
study O 
was O 
undertaken O 
to O 
evaluate O 
the O 
possible O 
ameliorating O 
effect O 
of O 
butylated B-SYSTEMATIC 
hydroxyl I-SYSTEMATIC 
toluene I-SYSTEMATIC 
( O 
BHT B-ABBREVIATION 
) O 
, O 
associated O 
with O 
ferric B-SYSTEMATIC 
nitrilotriacetate I-SYSTEMATIC 
( O 
Fe-NTA B-FORMULA 
)-induced O 
oxidative O 
stress O 
and O 
liver O 
injury O 
in O 
mice O 
. O 
The O 
treatment O 
of O 
mice O 
with O 
Fe-NTA B-FORMULA 
alone O 
enhances O 
ornithine B-TRIVIAL 
decarboxylase O 
activity O 
to O 
4.6 O 
folds O 
, O 
protein O 
carbonyl B-FAMILY 
formation O 
increased O 
up O 
to O 
2.9 O 
folds O 
and O 
DNA O 
synthesis O 
expressed O 
in O 
terms O 
of O 
[ B-SYSTEMATIC 
(3)H I-SYSTEMATIC 
] I-SYSTEMATIC 
thymidine I-SYSTEMATIC 
incorporation O 
increased O 
to O 
3.2 O 
folds O 
, O 
and O 
antioxidants O 
and O 
antioxidant O 
enzymes O 
decreased O 
to O 
1.8-2.5 O 
folds O 
, O 
compared O 
with O 
the O 
corresponding O 
saline O 
- O 
treated O 
controls O 
. O 
These O 
changes O 
were O 
reversed O 
significantly O 
( O 
p O 
< O 
0.001 O 
) O 
in O 
animals O 
receiving O 
a O 
pretreatment O 
of O 
BHT B-ABBREVIATION 
. O 
Our O 
data O 
show O 
that O 
BHT B-ABBREVIATION 
can O 
reciprocate O 
the O 
toxic O 
effects O 
of O 
Fe-NTA B-FORMULA 
and O 
can O 
serve O 
as O 
a O 
potent O 
chemopreventive O 
agent O 
. O 

expression O 
profiling O 
and O 
pathway O 
analysis O 
of O 
hepatotoxicity O 
induced O 
by O 
triptolide B-TRIVIAL 
in O 
Wistar O 
rats O 
. O 

( O 
TP O 
) O 
, O 
a O 
major O 
component O 
of O 
TWHF O 
, O 
is O 
widely O 
used O 
to O 
treat O 
rheumatoid O 
arthritis O 
, O 
systemic O 
lupus O 
erythematosus O 
, O 
nephritis O 
and O 
leprosy O 
. O 
However O 
, O 
its O 
clinical O 
use O 
is O 
limited O 
by O 
hepatotoxicity O 
. O 
To O 
further O 
elucidate O 
the O 
underlying O 
mechanism O 
of O 
its O 
hepatotoxic O 
effects O 
, O 
hepatic O 
gene O 
expression O 
profiles O 
were O 
analyzed O 
. O 
TP O 
( O 
1000 O 
and O 
300μg O 
/ O 
kg O 
) O 
was O 
orally O 
administered O 
to O 
Wistar O 
rats O 
for O 
14days O 
. O 
Current O 
study O 
indicated O 
that O 
female O 
rats O 
were O 
more O 
sensitive O 
to O 
TP-induced O 
hepatotoxicity O 
than O 
males O 
. O 
Genome O 
- O 
wide O 
microarray O 
analyses O 
identified O 
3329 O 
differentially O 
expressed O 
genes O 
in O 
liver O 
of O 
female O 
rats O 
. O 
Analyses O 
of O 
these O 
genes O 
identified O 
over O 
- O 
represented O 
functions O 
associated O 
with O 
insulin O 
signaling O 
pathway O 
, O 
glucose B-TRIVIAL 
metabolism O 
, O 
cell O 
cycle O 
, O 
oxidative O 
stress O 
and O 
apoptosis O 
, O 
which O 
were O 
consistent O 
with O 
the O 
results O 
of O 
significant O 
increase O 
of O 
Caspase-3 O 
activity O 
and O 
reduction O 
of O 
serum O 
glucose B-TRIVIAL 
, O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
ratio O 
, O 
glucose B-TRIVIAL 
-6-phosphatase O 
and O 
phosphoenolpyruvate B-SYSTEMATIC 
carboxykinase O 
activities O 
, O 
liver O 
glycogen O 
. O 
In O 
addition O 
, O 
it O 
was O 
observed O 
for O 
the O 
first O 
time O 
that O 
glucocorticoids O 
and O 
IGF1 O 
might O 
get O 
involved O 
in O 
TP-induced O 
hepatotoxicity O 
. O 
These O 
data O 
suggest O 
that O 
TP O 
treatment O 
could O 
alter O 
the O 
hepatic O 
redox O 
status O 
, O 
reduce O 
serum O 
glucose B-TRIVIAL 
and O 
induce O 
hepatocyte O 
apoptosis O 
, O 
consistent O 
with O 
the O 
differential O 
expression O 
of O 
genes O 
involved O 
in O 
insulin O 
signaling O 
pathway O 
, O 
glucose B-TRIVIAL 
metabolism O 
pathway O 
and O 
cell O 
stress O 
pathway O 
, O 
all O 
of O 
which O 
might O 
contribute O 
to O 
the O 
overall O 
TP-induced O 
hepatotoxicity O 
. O 

active O 
and O 
low O 
toxic O 
N-phenyl- B-FAMILY 
substituted I-FAMILY 
β-amidoamidines I-FAMILY 
structurally O 
related O 
to O 
natural O 
antibiotic O 
amidinomycin B-TRIVIAL 
. O 

set O 
of O 
racemic B-FAMILY 
N-phenyl- I-FAMILY 
substituted I-FAMILY 
β-amidoamidines I-FAMILY 
hydrochlorides I-FAMILY 
4 O 
, O 
which O 
are O 
structurally O 
related O 
to O 
natural O 
antiviral O 
agent O 
amidinomycin B-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
synthesized O 
in O 
four O 
steps O 
starting O 
from O 
methacryloyl B-SYSTEMATIC 
anilide I-SYSTEMATIC 
( O 
5 O 
) O 
. O 
In O 
the O 
final O 
step O 
of O 
the O 
synthetic O 
route O 
, O 
an O 
uncommon O 
monoacylation O 
of O 
β-aminoamidine B-SYSTEMATIC 
8 O 
at O 
the O 
less O 
reactive O 
β-phenylamino B-SYSTEMATIC 
-group O 
took O 
place O 
. O 
To O 
rationalize O 
this O 
result O 
, O 
a O 
mechanism O 
which O 
involves O 
initial O 
acylation O 
at O 
the O 
more O 
active O 
amidine B-SYSTEMATIC 
-function O 
followed O 
by O 
intramolecular O 
acyl B-FAMILY 
-group O 
transfer O 
to O 
β-phenylamino B-SYSTEMATIC 
-group O 
was O 
suggested O 
. O 
All O 
three O 
β-amidoamidines B-FAMILY 
4d-f O 
bearing O 
long O 
linear O 
aliphatic O 
chain O 
( O 
from O 
n-C8H17 B-FORMULA 
to O 
n-C12H25 B-FORMULA 
) O 
revealed O 
significant O 
in O 
vitro O 
activity O 
against O 
influenza O 
A O 
virus O 
( O 
H3N2 O 
) O 
and O 
modest O 
cytotoxicity O 
. O 
The O 
in O 
vitro O 
antiviral O 
potency O 
of O 
4d,e O 
is O 
6-20 O 
times O 
greater O 
than O 
that O 
of O 
commercial O 
rimantadine B-TRIVIAL 
with O 
lower O 
EC50 O 
values O 
and O 
higher O 
therapeutic O 
index O 
. O 
The O 
non-toxic O 
in O 
vivo O 
compounds O 
4d-f O 
showed O 
a O 
beneficial O 
protective O 
effect O 
in O 
influenza O 
A O 
( O 
H3N2 O 
) O 
infected O 
mice O 
. O 

amino I-FAMILY 
acids I-FAMILY 
are O 
known O 
for O 
their O 
hydrophobicity O 
and O 
the O 
active O 
role O 
they O 
play O 
in O 
protein O 
folding O 
. O 
Here O 
, O 
we O 
investigate O 
the O 
intrinsic O 
propensity O 
of O 
small O 
peptides O 
to O 
form O 
hydrophobic O 
domains O 
in O 
the O 
absence O 
of O 
solvent O 
water O 
molecules O 
. O 
The O 
structures O 
of O 
three O 
aromatic O 
- O 
rich O 
isolated O 
peptides O 
, O 
Ac-Phe-Phe-NH2 B-FORMULA 
( O 
FF O 
) O 
, O 
Ac-Trp-Tyr-NH2 B-FORMULA 
( O 
WY O 
) O 
, O 
and O 
Ac-Phe-Phe-Phe-NH2 B-FORMULA 
( O 
FFF O 
) O 
, O 
all O 
in O 
the O 
gas O 
phase O 
, O 
have O 
been O 
studied O 
by O 
infrared O 
- O 
ultraviolet O 
( O 
IR O 
/ O 
UV O 
) O 
double O 
resonance O 
laser O 
spectroscopy O 
, O 
aided O 
by O 
dispersion O 
- O 
corrected O 
density O 
functional O 
theory O 
( O 
DFT-D O 
) O 
calculations O 
. O 
Spontaneous O 
formation O 
of O 
hydrophobic O 
domains O 
is O 
systematically O 
observed O 
, O 
whatever O 
the O 
secondary O 
structure O 
adopted O 
by O 
the O 
backbone O 
. O 
Various O 
types O 
of O 
aromatic O 
- O 
aromatic O 
arrangements O 
have O 
been O 
identified O 
and O 
associated O 
to O 
specific O 
secondary O 
structures O 
, O 
illustrating O 
the O 
interplay O 
between O 
the O 
hydrophobic O 
clusters O 
and O 
the O 
backbone O 
. O 
Backbone O 
NH B-FORMULA 
amide B-FAMILY 
groups O 
surrounded O 
by O 
aromatic O 
rings O 
have O 
also O 
been O 
evidenced O 
and O 
are O 
found O 
to O 
contribute O 
significantly O 
to O 
the O 
stabilization O 
of O 
aromatic O 
pairs O 
. O 
These O 
results O 
suggest O 
that O 
the O 
formation O 
of O 
aromatic O 
clusters O 
involving O 
contiguous O 
residues O 
might O 
be O 
a O 
very O 
efficient O 
process O 
leading O 
to O 
the O 
formation O 
of O 
hydrophobic O 
domains O 
in O 
the O 
early O 
stages O 
of O 
protein O 
folding O 
, O 
well O 
before O 
a O 
hydrophobic O 
collapse O 
into O 
the O 
tertiary O 
structure O 
. O 

receptors O 
of O 
type O 
6 O 
( O 
5-HT6 O 
) O 
: O 
from O 
neuroscience O 
to O 
clinical O 
pharmacology O 
. O 

serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
receptors O 
of O 
type O 
6 O 
( O 
5-HT6 O 
) O 
are O 
quite O 
different O 
from O 
all O 
other O 
5-HT B-SYSTEMATIC 
receptors O 
, O 
as O 
they O 
include O 
a O 
short O 
third O 
cytoplasmatic O 
loop O 
and O 
a O 
long O 
C B-FORMULA 
-terminal O 
tail O 
, O 
and O 
one O 
intron O 
located O 
in O 
the O 
middle O 
of O 
the O 
third O 
cytoplasmatic O 
loop O 
. O 
A O 
lot O 
of O 
controversies O 
still O 
exist O 
regarding O 
their O 
binding O 
affinity O 
, O 
effects O 
of O 
5-HT6 O 
ligands O 
on O 
brain O 
catecholamines B-FAMILY 
, O 
behavioral O 
syndromes O 
regulated O 
by O 
them O 
, O 
and O 
brain O 
distribution O 
. O 
In O 
spite O 
of O 
the O 
lack O 
of O 
information O 
on O 
metabolic O 
pattern O 
of O 
the O 
various O 
compounds O 
, O 
some O 
of O 
5-HT6 O 
receptor O 
ligands O 
entered O 
the O 
clinical O 
development O 
as O 
potential O 
anti-dementia O 
, O 
antipsychotic O 
, O 
antidepressant O 
and O 
anti-obese O 
drugs O 
. O 
The O 
present O 
paper O 
is O 
a O 
comprehensive O 
review O 
on O 
the O 
state O 
of O 
art O 
of O 
the O 
5-HT6 O 
receptors O 
, O 
while O 
highlighting O 
the O 
potential O 
clinical O 
applications O 
of O 
5-HT6 O 
receptor O 
agonists O 
/ O 
antagonists O 
. O 

, O 
past O 
and O 
present O 
- O 
a O 
pharmacological O 
and O 
clinical O 
perspective O 
. O 

was O 
discovered O 
over O 
100 O 
years O 
ago O 
. O 
Since O 
then O 
, O 
it O 
has O 
transformed O 
from O 
a O 
drug O 
that O 
was O 
freely O 
available O 
without O 
prescription O 
as O 
a O 
panacea O 
for O 
a O 
broad O 
range O 
of O 
disorders O 
into O 
a O 
highly O 
restricted O 
Controlled O 
Drug O 
with O 
therapeutic O 
applications O 
restricted O 
to O 
attention O 
deficit O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
and O 
narcolepsy O 
. O 
This O 
review O 
describes O 
the O 
relationship O 
between O 
chemical O 
structure O 
and O 
pharmacology O 
of O 
amphetamine B-TRIVIAL 
and O 
its O 
congeners O 
. O 
Amphetamine B-TRIVIAL 
' O 
s O 
diverse O 
pharmacological O 
actions O 
translate O 
not O 
only O 
into O 
therapeutic O 
efficacy O 
, O 
but O 
also O 
into O 
the O 
production O 
of O 
adverse O 
events O 
and O 
liability O 
for O 
recreational O 
abuse O 
. O 
Accordingly O 
, O 
the O 
balance O 
of O 
benefit O 
/ O 
risk O 
is O 
the O 
key O 
challenge O 
for O 
its O 
clinical O 
use O 
. O 
The O 
review O 
charts O 
advances O 
in O 
pharmaceutical O 
development O 
from O 
the O 
introduction O 
of O 
once O 
- O 
daily O 
formulations O 
of O 
amphetamine B-TRIVIAL 
through O 
to O 
lisdexamfetamine B-TRIVIAL 
, O 
which O 
is O 
the O 
first O 
d-amphetamine B-TRIVIAL 
prodrug O 
approved O 
for O 
the O 
management O 
of O 
ADHD O 
in O 
children O 
, O 
adolescents O 
and O 
adults O 
. O 
The O 
unusual O 
metabolic O 
route O 
for O 
lisdexamfetamine B-TRIVIAL 
to O 
deliver O 
d-amphetamine B-TRIVIAL 
makes O 
an O 
important O 
contribution O 
to O 
its O 
pharmacology O 
. O 
How O 
lisdexamfetamine B-TRIVIAL 
' O 
s O 
distinctive O 
pharmacokinetic O 
/ O 
pharmacodynamic O 
profile O 
translates O 
into O 
sustained O 
efficacy O 
as O 
a O 
treatment O 
for O 
ADHD O 
and O 
its O 
reduced O 
potential O 
for O 
recreational O 
abuse O 
is O 
also O 
discussed O 
. O 

of O 
A2E O 
may O 
be O 
involved O 
in O 
diseases O 
of O 
the O 
macula O 
, O 
and O 
antioxidants O 
could O 
serve O 
as O 
therapeutic O 
agents O 
for O 
these O 
diseases O 
. O 
Inhibitors O 
of O 
A2E O 
photooxidation O 
were O 
prepared O 
by O 
Mannich O 
reaction O 
of O 
the O 
antioxidant O 
quercetin B-TRIVIAL 
. O 
These O 
compounds O 
contain O 
water O 
- O 
solubilizing O 
amine B-SYSTEMATIC 
groups O 
, O 
and O 
several O 
were O 
more O 
potent O 
inhibitors O 
of O 
A2E O 
photooxidation O 
than O 
quercetin B-TRIVIAL 
. O 

to O 
DEHP B-ABBREVIATION 
decreased O 
four O 
fatty B-FAMILY 
acid I-FAMILY 
levels O 
in O 
plasma O 
of O 
prepartum O 
mice O 
. O 

exposure O 
to O 
di(2-ethylhexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
decreased O 
the O 
plasma O 
triglyceride B-FAMILY 
in O 
prepartum O 
mice O 
. O 
To O 
identify O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
( O 
FA O 
) O 
species O 
involved O 
and O 
to O 
understand O 
the O 
underlying O 
mechanisms O 
, O 
pregnant O 
Sv O 
/ O 
129 O 
wild O 
- O 
type O 
( O 
mPPARα O 
) O 
, O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α-null O 
( O 
Pparα-null O 
) O 
and O 
humanized O 
PPARα O 
( O 
hPPARα O 
) O 
mice O 
were O 
treated O 
with O 
diets O 
containing O 
0% O 
, O 
0.01% O 
, O 
0.05% O 
or O 
0.1% O 
DEHP B-ABBREVIATION 
. O 
Dams O 
were O 
dissected O 
on O 
gestational O 
day O 
18 O 
together O 
with O 
fetuses O 
, O 
and O 
on O 
postnatal O 
day O 
2 O 
together O 
with O 
newborns O 
. O 
n-3 B-MULTIPLE 
/ I-MULTIPLE 
n-6 I-MULTIPLE 
polyunsaturated I-MULTIPLE 
, I-MULTIPLE 
saturated I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
monounsaturated I-MULTIPLE 
FAs I-MULTIPLE 
in O 
maternal O 
plasma O 
and O 
in O 
liver O 
of O 
wild O 
- O 
type O 
offspring O 
, O 
and O 
representative O 
enzymes O 
for O 
FA O 
desaturation O 
and O 
elongation O 
in O 
maternal O 
liver O 
, O 
were O 
measured O 
. O 
The O 
plasma O 
levels O 
of O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
α-linolenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
and O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
were O 
higher O 
in O 
the O 
pregnant O 
control O 
mPPARa O 
mice O 
than O 
in O 
Ppara-null O 
and O 
hPPARa O 
mice O 
. O 
DEHP B-ABBREVIATION 
exposure O 
significantly O 
decreased O 
the O 
levels O 
of O 
these O 
four O 
FAs O 
only O 
in O 
pregnant O 
mPPARα O 
mice O 
. O 
Plasma O 
levels O 
of O 
many O 
FAs O 
were O 
higher O 
in O 
pregnant O 
mice O 
than O 
in O 
postpartum O 
ones O 
in O 
a O 
genotype O 
- O 
independent O 
manner O 
, O 
while O 
it O 
was O 
lower O 
in O 
the O 
livers O 
of O 
fetuses O 
than O 
pups O 
. O 
DEHP B-ABBREVIATION 
exposure O 
slightly O 
increased O 
hepatic O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
, O 
α-linolenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
palmitoleic B-TRIVIAL 
acid I-TRIVIAL 
and O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
in O 
fetuses O 
, O 
but O 
not O 
in O 
pups O 
. O 
However O 
, O 
DEHP B-ABBREVIATION 
exposure O 
did O 
not O 
clearly O 
influence O 
FA O 
desaturase O 
1 O 
and O 
2 O 
nor O 
elongase O 
2 O 
and O 
5 O 
expressions O 
in O 
the O 
liver O 
of O 
all O 
maternal O 
mice O 
. O 
Taken O 
together O 
, O 
the O 
levels O 
of O 
plasma O 
four O 
FAs O 
with O 
shorter O 
carbon B-SYSTEMATIC 
chains O 
were O 
higher O 
in O 
pregnant O 
mPPARα O 
mice O 
than O 
in O 
other O 
genotypes O 
, O 
and O 
DEHP B-ABBREVIATION 
exposure O 
decreased O 
these O 
specific O 
FA O 
concentrations O 
only O 
in O 
mPPARα O 
mice O 
, O 
similarly O 
to O 
triglyceride B-FAMILY 
levels O 
. O 

are O 
brown O 
, O 
nitrogen B-SYSTEMATIC 
containing O 
, O 
high O 
molecular O 
weight O 
end O 
products O 
of O 
Maillard O 
reaction O 
with O 
poorly O 
established O 
activity O 
towards O 
tumor O 
cells O 
. O 
The O 
goal O 
of O 
present O 
study O 
was O 
to O 
verify O 
whether O 
both O 
heated O 
potato O 
fiber O 
Potex O 
extract O 
( O 
180°C O 
for O 
2h O 
) O 
and O 
melanoidins O 
isolated O 
from O 
the O 
extract O 
exerts O 
growth O 
- O 
inhibiting O 
activity O 
in O 
human O 
colon O 
cancer O 
cells O 
in O 
vitro O 
. O 
The O 
cells O 
of O 
LS180 O 
colon O 
cancer O 
cell O 
line O 
were O 
tested O 
upon O 
treatment O 
with O 
roasted O 
potato O 
fiber O 
extract O 
( O 
AM4 O 
) O 
as O 
well O 
as O 
with O 
high O 
( O 
HMW O 
) O 
and O 
low O 
( O 
LMW O 
) O 
molecular O 
weight O 
fractions O 
isolated O 
from O 
the O 
extract O 
, O 
since O 
both O 
may O 
be O 
regarded O 
as O 
/ O 
or O 
contain O 
melanoidins O 
. O 
The O 
tested O 
compounds O 
at O 
concentration O 
of O 
1000μg O 
/ O 
ml O 
reduced O 
cell O 
growth O 
down O 
to O 
45% O 
, O 
69% O 
and O 
54% O 
, O 
respectively O 
. O 
Furthermore O 
, O 
deregulated O 
ERK1 O 
/ O 
2 O 
signaling O 
was O 
revealed O 
upon O 
treatment O 
. O 
Moreover O 
, O 
multiple O 
alternations O 
in O 
cell O 
cycle O 
regulators O 
activity O 
were O 
found O 
( O 
i.e O 
. O 
cyclinD1 O 
, O 
cyclin O 
- O 
dependent O 
kinase O 
4 O 
and O 
6 O 
, O 
p21 O 
, O 
p27 O 
, O 
p53 O 
, O 
pRb O 
) O 
leading O 
to O 
cell O 
cycle O 
cessation O 
in O 
G0 O 
phase O 
. O 
Importantly O 
, O 
LMW O 
compounds O 
revealed O 
markedly O 
stronger O 
potential O 
to O 
alter O 
specific O 
molecular O 
targets O 
comparing O 
to O 
HMW O 
compounds O 
. O 
Summarizing O 
, O 
the O 
results O 
emphasize O 
that O 
both O 
high O 
and O 
low O 
molecular O 
weight O 
melanoidins O 
contribute O 
to O 
antiproliferative O 
activity O 
of O 
heated O 
potato O 
fiber O 
in O 
LS180 O 
colon O 
cancer O 
cells O 
in O 
vitro O 
. O 

self O 
- O 
healable O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
hydrogels O 
formed O 
by O 
selective O 
metal- O 
phosphate B-SYSTEMATIC 
interactions O 
. O 

self O 
- O 
healable O 
and O 
biocompatible O 
hydrogels O 
were O 
prepared O 
using O 
the O 
selective O 
formation O 
of O 
metal O 
- O 
ligand O 
interactions O 
between O 
selected O 
metal O 
ions O 
and O 
phosphate B-SYSTEMATIC 
end O 
groups O 
of O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
. O 
The O 
phosphate B-SYSTEMATIC 
-terminated O 
branch O 
of O 
PEG B-ABBREVIATION 
was O 
synthesized O 
via O 
a O 
substitution O 
reaction O 
of O 
the O 
hydroxyl B-SYSTEMATIC 
end O 
groups O 
using O 
phosphoryl B-SYSTEMATIC 
chloride I-SYSTEMATIC 
. O 
The O 
gelation O 
and O 
gel O 
properties O 
including O 
rheological O 
properties O 
can O 
be O 
tuned O 
by O 
the O 
careful O 
selection O 
of O 
metal O 
ions O 
, O 
branch O 
numbers O 
, O 
and O 
temperature O 
. O 
Especially O 
, O 
the O 
gels O 
rapidly O 
formed O 
by O 
trivalent O 
metal O 
ions O 
such O 
as O 
Fe(3+) B-FORMULA 
, O 
V(3+) B-FORMULA 
, O 
Al(3+) B-FORMULA 
, O 
Ti(3+) B-FORMULA 
, O 
and O 
Ga(3+) B-FORMULA 
have O 
relatively O 
small O 
ionic O 
radii O 
. O 
The O 
ligand O 
substitution O 
rates O 
also O 
affected O 
the O 
repeatable O 
autonomic O 
healing O 
ability O 
. O 
We O 
have O 
also O 
demonstrated O 
a O 
gel O 
- O 
sol O 
/ O 
sol O 
- O 
gel O 
transition O 
by O 
switching O 
the O 
redox O 
states O 
of O 
Fe(3+) B-FORMULA 
/ O 
Fe(2+) B-FORMULA 
ions O 
. O 
Learning O 
from O 
biological O 
systems O 
, O 
the O 
proposed O 
phosphate B-SYSTEMATIC 
-metal O 
ion O 
based O 
self O 
- O 
healable O 
hydrogels O 
could O 
become O 
an O 
attractive O 
candidate O 
for O 
various O 
biomedical O 
and O 
environmental O 
applications O 
. O 

of O 
the O 
main O 
sources O 
of O 
emerging O 
Fusarium O 
mycotoxins O 
in O 
human O 
nutrition O 
is O 
the O 
cereals O 
and O 
cereal O 
products O 
. O 
In O 
this O 
study O 
, O 
an O 
analytical O 
method O 
to O 
determine O 
enniatins B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
A1 I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
and I-MULTIPLE 
B1 I-MULTIPLE 
( O 
ENs O 
) O 
, O 
beauvericin B-TRIVIAL 
( O 
BEA B-ABBREVIATION 
) O 
and O 
fusaproliferin B-TRIVIAL 
( O 
FUS B-ABBREVIATION 
) O 
based O 
on O 
Ultra-Turrax O 
extraction O 
followed O 
by O 
liquid O 
chromatography O 
coupled O 
to O 
triple O 
quadrupole O 
mass O 
spectrometer O 
detector O 
( O 
MS O 
/ O 
MS O 
QqQ O 
) O 
, O 
was O 
applied O 
for O 
the O 
analysis O 
of O 
pasta O 
. O 
For O 
this O 
purpose O 
, O 
114 O 
commercial O 
samples O 
of O 
pasta O 
were O 
acquired O 
from O 
supermarkets O 
located O 
in O 
Valencia O 
. O 
The O 
results O 
showed O 
higher O 
frequencies O 
of O 
contamination O 
in O 
organic O 
pasta O 
than O 
in O 
conventional O 
pasta O 
, O 
while O 
the O 
concentration O 
levels O 
were O 
variable O 
for O 
both O 
types O 
of O 
pasta O 
. O 
In O 
positive O 
samples O 
, O 
BEA B-ABBREVIATION 
levels O 
varied O 
from O 
0.1 O 
to O 
20.96μg O 
/ O 
kg O 
and O 
FUS B-ABBREVIATION 
levels O 
varied O 
from O 
0.05 O 
to O 
8.02μg O 
/ O 
kg O 
. O 
ENs O 
levels O 
ranged O 
from O 
0.25 O 
to O 
979.56μg O 
/ O 
kg O 
, O 
though O 
the O 
majority O 
of O 
the O 
values O 
were O 
below O 
25μg O 
/ O 
kg O 
. O 
Besides O 
, O 
it O 
was O 
observed O 
the O 
simultaneous O 
presence O 
of O 
two O 
or O 
more O 
mycotoxins O 
in O 
a O 
high O 
percentage O 
of O 
the O 
samples O 
. O 
Finally O 
, O 
an O 
evaluation O 
of O 
the O 
dietary O 
exposure O 
of O 
the O 
emerging O 
Fusarium O 
mycotoxins O 
was O 
performed O 
in O 
the O 
Spanish O 
population O 
. O 
The O 
prevalence O 
of O 
ENs O 
, O 
BEA B-ABBREVIATION 
and O 
FUS B-ABBREVIATION 
in O 
cereal O 
products O 
suggests O 
that O 
the O 
toxins O 
may O 
pose O 
a O 
health O 
risk O 
to O 
Spanish O 
population O 
. O 

and O 
characterization O 
of O 
novel O 
quick O 
- O 
release O 
propofol B-TRIVIAL 
prodrug O 
via O 
lactonization O 
. O 

water O 
- O 
soluble O 
derivatives O 
of O 
propofol B-TRIVIAL 
have O 
gained O 
attention O 
as O 
a O 
method O 
to O 
increase O 
solubility O 
of O 
propofol B-TRIVIAL 
. O 
According O 
to O 
the O 
principle O 
of O 
lactonization O 
, O 
the O 
lead O 
compound O 
HX0969 B-IDENTIFIER 
was O 
synthesized O 
first O 
and O 
then O 
the O 
pharmacological O 
features O 
of O 
HX0969 B-IDENTIFIER 
were O 
evaluated O 
in O 
a O 
comparison O 
with O 
those O 
of O 
propofol B-TRIVIAL 
in O 
the O 
SD O 
rats O 
. O 
Then O 
, O 
HX0969 B-SYSTEMATIC 
disodium I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
monoester I-SYSTEMATIC 
( O 
HX0969W B-IDENTIFIER 
) O 
and O 
glycine B-SYSTEMATIC 
ester I-SYSTEMATIC 
trifluoroacetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
salt I-SYSTEMATIC 
( O 
HX101230 B-IDENTIFIER 
) O 
were O 
synthesized O 
, O 
and O 
their O 
pharmacological O 
features O 
were O 
compared O 
with O 
those O 
of O 
Lusedra B-TRIVIAL 
® O 
, O 
which O 
has O 
been O 
recognized O 
and O 
marketed O 
as O 
a O 
water O 
- O 
soluble O 
prodrug O 
of O 
propofol B-TRIVIAL 
since O 
2008 O 
. O 
The O 
results O 
showed O 
that O 
HX0969 B-IDENTIFIER 
could O 
produce O 
an O 
anesthetic O 
effect O 
within O 
a O 
few O 
seconds O 
( O 
3.6±3.0s O 
) O 
and O 
its O 
therapeutic O 
index O 
was O 
4.66 O 
in O 
the O 
SD O 
rat O 
. O 
The O 
pharmacodynamic O 
characteristics O 
of O 
HX0969W B-IDENTIFIER 
were O 
similar O 
to O 
those O 
of O 
the O 
Lusedra B-TRIVIAL 
® O 
. O 
HX101230 B-IDENTIFIER 
could O 
still O 
produce O 
an O 
anesthetic O 
effect O 
within O 
60s O 
in O 
the O 
rats O 
though O 
its O 
therapeutic O 
index O 
was O 
not O 
so O 
high O 
( O 
TI=2.96 O 
) O 
. O 
Therefore O 
, O 
our O 
study O 
has O 
indicated O 
that O 
HX0969 B-IDENTIFIER 
is O 
a O 
potentially O 
useful O 
lead O 
compound O 
of O 
propofol B-TRIVIAL 
derivative O 
. O 
Its O 
rapid O 
anesthetic O 
effect O 
is O 
probably O 
associated O 
with O 
lactonization O 
. O 

of O 
2-methylene-1,3-dioxepane B-SYSTEMATIC 
and O 
glycidyl B-TRIVIAL 
methacrylate I-TRIVIAL 
, O 
a O 
well O 
- O 
defined O 
and O 
efficient O 
process O 
for O 
achieving O 
functionalized O 
polyesters B-FAMILY 
for O 
covalent O 
binding O 
of O 
bioactive O 
molecules O 
. O 

understanding O 
of O 
cell O 
- O 
material O 
interactions O 
is O 
important O 
for O 
creating O 
personalized O 
implants O 
for O 
tissue O 
engineering O 
. O 
This O 
has O 
resulted O 
in O 
an O 
interest O 
in O 
developing O 
polymers O 
with O 
functional O 
groups O 
with O 
the O 
possibility O 
of O 
controlling O 
the O 
macromolecular O 
surface O 
. O 
We O 
have O 
in O 
a O 
one O 
- O 
pot O 
reaction O 
synthesized O 
a O 
series O 
of O 
amorphous O 
and O 
degradable O 
polyester B-FAMILY 
-based O 
copolymers O 
with O 
active O 
functional O 
groups O 
by O 
copolymerization O 
of O 
2-methylene-1,3-dioxepane B-SYSTEMATIC 
and O 
glycidyl B-TRIVIAL 
methacrylate I-TRIVIAL 
. O 
The O 
properties O 
of O 
the O 
final O 
polymers O 
were O 
varied O 
by O 
varying O 
the O 
feed O 
ratios O 
of O 
the O 
monomers O 
and O 
it O 
was O 
seen O 
that O 
it O 
was O 
possible O 
to O 
control O 
the O 
amount O 
of O 
active O 
functional O 
groups O 
. O 
The O 
resulting O 
epoxy-functionalized B-FAMILY 
polyester I-FAMILY 
was O 
further O 
modified O 
by O 
covalent O 
immobilization O 
of O 
heparin O 
. O 
The O 
heparinization O 
was O 
done O 
in O 
order O 
, O 
in O 
a O 
future O 
aspect O 
, O 
to O 
enhance O 
the O 
osteogenic O 
differentiation O 
of O 
mesenchymal O 
stem O 
cells O 
. O 
Heparin O 
binds O 
directly O 
with O 
the O 
growth O 
factor O 
bone O 
morphogenetic O 
protein-2 O 
and O 
helps O 
to O 
retain O 
its O 
activity O 
. O 
The O 
molecular O 
structure O 
of O 
the O 
copolymers O 
was O 
characterized O 
by O 
nuclear O 
magnetic O 
resonance O 
, O 
size O 
exclusion O 
chromatography O 
, O 
and O 
fourier O 
transform O 
infrared O 
spectroscopy O 
. O 
Differential O 
scanning O 
calorimetry O 
and O 
tensile O 
testing O 
showed O 
that O 
the O 
monomer O 
feed O 
ratio O 
had O 
a O 
great O 
influence O 
on O 
the O 
properties O 
of O 
the O 
final O 
polymer O 
and O 
that O 
it O 
thus O 
was O 
possible O 
to O 
control O 
the O 
mechanical O 
properties O 
to O 
suit O 
an O 
intended O 
application O 
. O 
The O 
presence O 
of O 
heparin O 
was O 
verified O 
by O 
toluidine B-TRIVIAL 
blue I-TRIVIAL 
staining O 
and O 
all O 
the O 
films O 
tested O 
showed O 
positive O 
signals O 
for O 
heparin O 
. O 

against O 
neuroblastoma O 
cell O 
death O 
induced O 
by O 
depletion O 
of O 
mitochondrial O 
glutathione B-TRIVIAL 
. O 

glutathione B-TRIVIAL 
pool O 
is O 
vital O 
in O 
protecting O 
cells O 
against O 
oxidative O 
stress O 
as O 
the O 
majority O 
of O 
the O 
cellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
are O 
generated O 
in O 
mitochondria O 
. O 
Oxidative O 
stress O 
is O 
implicated O 
as O 
a O 
causative O 
factor O 
in O 
neuronal O 
death O 
in O 
neurodegenerative O 
disorders O 
. O 
We O 
hypothesized O 
that O 
depletion O 
of O 
mitochondrial O 
glutathione B-TRIVIAL 
leads O 
to O 
mitochondrial O 
dysfunction O 
and O 
apoptotic O 
death O 
of O 
SK-N-SH O 
( O 
human O 
neuroblastoma O 
) O 
cells O 
and O 
investigated O 
the O 
neuroprotective O 
strategies O 
against O 
GSH B-ABBREVIATION 
depletion O 
. O 
SK-N-SH O 
cells O 
were O 
treated O 
with O 
two O 
distinct O 
inhibitors O 
of O 
glutathione B-TRIVIAL 
metabolism O 
: O 
L-buthionine-(S B-SYSTEMATIC 
, I-SYSTEMATIC 
R)-sulfoximine I-SYSTEMATIC 
( O 
BSO B-ABBREVIATION 
) O 
and O 
ethacrynic B-TRIVIAL 
acid I-TRIVIAL 
( O 
EA O 
) O 
. O 
EA O 
treatment O 
caused O 
depletion O 
of O 
both O 
the O 
total O 
and O 
mitochondrial O 
glutathione B-TRIVIAL 
( O 
while O 
BSO B-ABBREVIATION 
had O 
no O 
effect O 
on O 
mitochondrial O 
glutathione B-TRIVIAL 
) O 
, O 
enhanced O 
rotenone B-TRIVIAL 
-induced O 
ROS O 
production O 
, O 
and O 
reduced O 
the O 
viability O 
of O 
SK-N-SH O 
cells O 
. O 
Glutathione B-TRIVIAL 
depletion O 
by O 
BSO B-ABBREVIATION 
or O 
EA O 
demonstrated O 
positive O 
features O 
of O 
mitochondria O 
- O 
mediated O 
apoptosis O 
in O 
neuroblastoma O 
cell O 
death O 
. O 
Prevention O 
of O 
apoptosis O 
by O 
Bcl2 O 
overexpression O 
or O 
use O 
of O 
antioxidant O 
ebselen B-TRIVIAL 
did O 
not O 
confer O 
neuroprotection O 
. O 
Co-culture O 
with O 
U-87 O 
( O 
human O 
glioblastoma O 
) O 
cells O 
protected O 
SK-N-SH O 
cells O 
from O 
the O 
cell O 
death O 
. O 
Our O 
data O 
suggest O 
that O 
depletion O 
of O 
mitochondrial O 
glutathione B-TRIVIAL 
leads O 
to O 
mitochondrial O 
dysfunction O 
and O 
apoptosis O 
. O 
The O 
study O 
indicates O 
that O 
preventing O 
mitochondrial O 
glutathione B-TRIVIAL 
depletion O 
could O 
become O 
a O 
novel O 
strategy O 
for O 
the O 
development O 
of O 
neuroprotective O 
therapeutics O 
in O 
neurodegenerative O 
disorders O 
. O 

, O 
a O 
new O 
anti-inflammatory O 
phloroglucinol B-TRIVIAL 
derivative O 
from O 
Hypericum O 
nakamurai O 
. O 

investigation O 
of O 
Hypericum O 
nakamurai O 
( O 
Masamune O 
) O 
Robson O 
has O 
led O 
to O 
the O 
isolation O 
of O 
three O 
phloroglucinol B-TRIVIAL 
derivatives O 
1-3 O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
determined O 
by O 
the O 
analysis O 
of O 
their O 
spectroscopic O 
data O 
( O 
IR O 
, O 
mass O 
and O 
UV O 
) O 
, O 
and O 
by O 
the O 
application O 
of O 
1-D O 
and O 
2-D-NMR O 
techniques O 
. O 
Hyperinakin B-TRIVIAL 
( O 
1 O 
) O 
is O 
a O 
new O 
compound O 
. O 
The O 
anti-inflammatory O 
activities O 
of O 
compounds O 
1-3 O 
were O 
also O 
tested O 
and O 
evaluated O 
. O 
A O 
biogenetic O 
pathway O 
for O 
compounds O 
1-3 O 
was O 
also O 
proposed O 
. O 

rotunda O 
( O 
Menispermaceae O 
) O 
, O 
a O 
creeper O 
commonly O 
found O 
in O 
the O 
mountainous O 
areas O 
of O 
Cambodia O 
, O 
has O 
been O 
mainly O 
used O 
for O 
the O 
treatment O 
of O 
fever O 
and O 
malaria O 
. O 
Thus O 
, O 
the O 
aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
chemical O 
composition O 
and O 
antiplasmodial O 
activity O 
of O 
different O 
samples O 
of O 
S O 
. O 
rotunda O 
and O 
compare O 
their O 
antiplasmodial O 
activity O 
with O 
their O 
alkaloid O 
content O 
. O 
Sixteen O 
samples O 
from O 
different O 
parts O 
( O 
roots O 
, O 
stem O 
, O 
and O 
tuber O 
) O 
of O 
S O 
. O 
rotunda O 
were O 
collected O 
from O 
four O 
regions O 
of O 
Cambodia O 
( O 
Battambang O 
, O 
Pailin O 
, O 
Siem O 
Reap O 
, O 
and O 
Kampot O 
) O 
. O 
Reversed O 
- O 
phase O 
HPLC O 
was O 
used O 
to O 
determine O 
the O 
content O 
of O 
three O 
bioactive O 
alkaloids O 
( O 
cepharanthine B-TRIVIAL 
, O 
tetrahydropalmatine B-SYSTEMATIC 
, O 
and O 
xylopinine B-TRIVIAL 
) O 
. O 
These O 
three O 
alkaloids O 
have O 
been O 
found O 
in O 
all O 
samples O 
from O 
Battambang O 
and O 
Pailin O 
( O 
samples O 
I-IX O 
) O 
, O 
whereas O 
only O 
tetrahydropalmatine B-SYSTEMATIC 
was O 
present O 
in O 
samples O 
from O 
Siem O 
Reap O 
and O 
Kampot O 
( O 
samples O 
X-XVI O 
) O 
. O 
The O 
analyzed O 
extracts O 
were O 
evaluated O 
for O 
their O 
antiplasmodial O 
activity O 
on O 
W2 O 
strain O 
of O 
Plasmodium O 
falciparum O 
. O 
Among O 
them O 
, O 
13 O 
extracts O 
were O 
significantly O 
active O 
with O 
inhibitory O 
concentration O 
50 O 
( O 
IC(50) O 
) O 
from O 
1.2 O 
to O 
3.7 O 
µg O 
/ O 
mL O 
and O 
2 O 
extracts O 
were O 
moderately O 
active O 
( O 
IC(50) O 
= O 
6.1 O 
and O 
10 O 
µg O 
/ O 
mL O 
, O 
respectively O 
) O 
, O 
whereas O 
sample O 
XI O 
was O 
not O 
active O 
( O 
IC(50) O 
= O 
19.6 O 
µg O 
/ O 
mL O 
) O 
. O 
A O 
comparison O 
between O 
antiplasmodial O 
activity O 
and O 
concentration O 
of O 
the O 
three O 
bioactive O 
alkaloids O 
in O 
S O 
. O 
rotunda O 
extracts O 
has O 
been O 
realized O 
. O 

are O 
disc O 
- O 
like O 
self O 
- O 
assembled O 
structures O 
formed O 
by O 
phospholipids O 
and O 
amphipatic O 
proteins O 
. O 
The O 
proteins O 
wrap O 
like O 
a O 
belt O 
around O 
the O 
hydrophobic O 
part O 
of O 
the O 
lipids O 
, O 
basically O 
producing O 
nanometer O 
- O 
sized O 
patches O 
of O 
lipid O 
bilayers O 
. O 
The O 
bilayer O 
in O 
the O 
nanodisc O 
constitutes O 
a O 
native O 
- O 
like O 
model O 
of O 
the O 
cell O 
membrane O 
and O 
can O 
act O 
as O 
a O 
nanometer O 
- O 
sized O 
container O 
for O 
functional O 
single O 
membrane O 
proteins O 
. O 
In O 
this O 
study O 
, O 
we O 
present O 
a O 
general O 
nanodisc O 
- O 
based O 
system O 
, O 
intended O 
for O 
structural O 
and O 
functional O 
studies O 
of O 
membrane O 
proteins O 
. O 
In O 
this O 
method O 
, O 
the O 
nanodiscs O 
are O 
aligned O 
at O 
a O 
solid O 
surface O 
, O 
providing O 
the O 
ability O 
to O 
determine O 
the O 
average O 
structure O 
of O 
the O 
film O 
along O 
an O 
axis O 
perpendicular O 
to O 
the O 
interface O 
as O 
measured O 
by O 
neutron O 
reflectivity O 
. O 
The O 
nanodisc O 
film O 
was O 
optimized O 
in O 
terms O 
of O 
nanodisc O 
coverage O 
, O 
reduced O 
film O 
roughness O 
, O 
and O 
stability O 
for O 
time O 
- O 
consuming O 
studies O 
. O 
This O 
was O 
achieved O 
by O 
a O 
systematic O 
variation O 
of O 
the O 
lipid O 
phase O 
, O 
charge O 
, O 
and O 
length O 
of O 
lipid O 
tails O 
. O 
Herein O 
, O 
we O 
show O 
that O 
, O 
although O 
all O 
studied O 
nanodiscs O 
align O 
with O 
their O 
lipid O 
bilayer O 
parallel O 
to O 
the O 
interface O 
, O 
gel O 
- O 
phase O 
DMPC B-ABBREVIATION 
nanodiscs O 
form O 
the O 
most O 
suitable O 
film O 
for O 
future O 
membrane O 
protein O 
studies O 
since O 
they O 
yield O 
a O 
dense O 
irreversibly O 
adsorbed O 
film O 
with O 
low O 
roughness O 
and O 
high O 
stability O 
over O 
time O 
. O 
This O 
may O 
be O 
explained O 
by O 
the O 
appropriate O 
matching O 
between O 
the O 
thickness O 
of O 
the O 
hydrophobic O 
lipid O 
core O 
of O 
gel O 
phase O 
DMPC B-ABBREVIATION 
and O 
the O 
height O 
of O 
the O 
belt O 
protein O 
. O 
Moreover O 
, O 
once O 
formed O 
the O 
gel O 
- O 
phase O 
DMPC B-ABBREVIATION 
nanodiscs O 
film O 
can O 
be O 
heated O 
up O 
to O 
melt O 
the O 
lipid O 
bilayer O 
, O 
thus O 
providing O 
a O 
more O 
biologically O 
friendly O 
environment O 
for O 
membrane O 
proteins O 
. O 

Platform O 
for O 
Large-Scale O 
Graphene B-TRIVIAL 
Electronics O 
- O 
CVD O 
Growth O 
of O 
Single O 
- O 
Layer O 
Graphene B-TRIVIAL 
on O 
CVD-Grown O 
Hexagonal O 
Boron B-SYSTEMATIC 
Nitride I-SYSTEMATIC 
. O 

chemical O 
vapor O 
deposition O 
( O 
CVD O 
) O 
growth O 
of O 
single O 
- O 
layer O 
graphene B-TRIVIAL 
on O 
CVD-grown O 
hexagonal O 
boron B-SYSTEMATIC 
nitride I-SYSTEMATIC 
( O 
h- O 
BN B-FORMULA 
) O 
film O 
can O 
suggest O 
a O 
large O 
- O 
scale O 
and O 
high O 
- O 
quality O 
graphene B-TRIVIAL 
/ O 
h- O 
BN B-FORMULA 
film O 
hybrid O 
structure O 
with O 
a O 
defect O 
- O 
free O 
interface O 
. O 
This O 
sequentially O 
grown O 
graphene B-TRIVIAL 
/ O 
h- O 
BN B-FORMULA 
film O 
shows O 
better O 
electronic O 
properties O 
than O 
that O 
of O 
graphene B-TRIVIAL 
/ O 
SiO2 B-FORMULA 
or O 
graphene B-TRIVIAL 
transferred O 
on O 
h- O 
BN B-FORMULA 
film O 
, O 
and O 
suggests O 
a O 
new O 
promising O 
template O 
for O 
graphene B-TRIVIAL 
device O 
fabrication O 
. O 

Stress O 
and O 
DNA O 
Damage O 
in O 
Human O 
Gastric O 
Carcinoma O 
: O 
8-Oxo-7'8-dihydro-2'-deoxyguanosine B-SYSTEMATIC 
( O 
8-oxo-dG B-SYSTEMATIC 
) O 
as O 
a O 
Possible O 
Tumor O 
Marker O 
. O 

characterized O 
the O 
oxidative O 
stress O 
( O 
OS O 
) O 
status O 
by O 
the O 
levels O 
of O 
reduced B-MULTIPLE 
/ I-MULTIPLE 
oxidized I-MULTIPLE 
glutathione I-MULTIPLE 
( O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
) O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
and O 
the O 
mutagenic O 
base O 
8-oxo-7'8-dihydro-2'-deoxyguanosine B-SYSTEMATIC 
( O 
8-oxo-dG B-SYSTEMATIC 
) O 
in O 
human O 
gastric O 
carcinoma O 
( O 
HGC O 
) O 
samples O 
and O 
compared O 
the O 
results O 
with O 
normal O 
tissue O 
from O 
the O 
same O 
patients O 
. O 
We O 
also O 
analyzed O 
8-oxo-dG B-SYSTEMATIC 
in O 
peripheral O 
mononuclear O 
cells O 
( O 
PMNC O 
) O 
and O 
urine O 
from O 
healthy O 
control O 
subjects O 
and O 
in O 
affected O 
patients O 
in O 
the O 
basal O 
state O 
and O 
one O 
, O 
three O 
, O 
six O 
, O 
nine O 
and O 
twelve O 
months O 
after O 
tumor O 
resection O 
. O 
The O 
levels O 
of O 
DNA O 
repair O 
enzyme O 
mRNA O 
expression O 
( O 
hOGG1 O 
, O 
RAD51 O 
, O 
MUYTH O 
and O 
MTH1 O 
) O 
were O 
determined O 
in O 
tumor O 
specimens O 
and O 
compared O 
with O 
normal O 
mucosa O 
. O 
Tumor O 
specimens O 
exhibited O 
increased O 
levels O 
of O 
MDA B-ABBREVIATION 
and O 
8-oxo-dG B-SYSTEMATIC 
compared O 
with O 
normal O 
gastric O 
tissue O 
. O 
GSH B-ABBREVIATION 
levels O 
were O 
also O 
increased O 
, O 
while O 
GSSG B-ABBREVIATION 
levels O 
remained O 
stable O 
. O 
DNA O 
repair O 
enzyme O 
mRNA O 
expression O 
was O 
induced O 
in O 
the O 
tumor O 
tissues O 
. O 
Levels O 
of O 
8-oxo-dG B-SYSTEMATIC 
were O 
significantly O 
elevated O 
in O 
both O 
urine O 
and O 
PMNC O 
of O 
gastric O 
cancer O 
patients O 
compared O 
with O 
healthy O 
controls O 
. O 
After O 
gastrectomy O 
, O 
the O 
levels O 
of O 
the O 
damaged O 
base O 
in O 
urine O 
and O 
PMNC O 
decreased O 
progressively O 
to O 
values O 
close O 
to O 
those O 
found O 
in O 
the O 
healthy O 
population O 
. O 
The O 
high O 
levels O 
of O 
8-oxo-dG B-SYSTEMATIC 
in O 
urine O 
may O 
be O 
related O 
to O 
the O 
increased O 
induction O 
of O 
DNA O 
repair O 
activity O 
in O 
tumor O 
tissue O 
, O 
and O 
the O 
changes O 
observed O 
after O 
tumor O 
resection O 
support O 
its O 
potential O 
use O 
as O 
a O 
tumor O 
marker O 
. O 

transformation O 
of O 
alcohols B-FAMILY 
to O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
salts O 
and O 
H2 B-FORMULA 
using O 
water O 
as O 
the O 
oxygen B-SYSTEMATIC 
atom O 
source O 
. O 

oxidation O 
of O 
alcohols B-FAMILY 
to O 
carboxylic B-FAMILY 
acids I-FAMILY 
is O 
an O 
important O 
industrial O 
reaction O 
used O 
in O 
the O 
synthesis O 
of O 
bulk O 
and O 
fine O 
chemicals O 
. O 
Most O 
current O 
processes O 
are O 
performed O 
by O 
making O 
use O 
of O 
either O 
stoichiometric O 
amounts O 
of O 
toxic O 
oxidizing O 
agents O 
or O 
the O 
use O 
of O 
pressurized O 
dioxygen B-SYSTEMATIC 
. O 
Here O 
, O 
we O 
describe O 
an O 
alternative O 
dehydrogenative O 
pathway O 
effected O 
by O 
water O 
and O 
base O 
with O 
the O 
concomitant O 
generation O 
of O 
hydrogen B-SYSTEMATIC 
gas O 
. O 
A O 
homogeneous O 
ruthenium B-SYSTEMATIC 
complex O 
catalyses O 
the O 
transformation O 
of O 
primary O 
alcohols B-FAMILY 
to O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
salts O 
at O 
low O 
catalyst O 
loadings O 
( O 
0.2 O 
mol% O 
) O 
in O 
basic O 
aqueous O 
solution O 
. O 
A O 
consequence O 
of O 
this O 
finding O 
could O 
be O 
a O 
safer O 
and O 
cleaner O 
process O 
for O 
the O 
synthesis O 
of O 
carboxylic B-FAMILY 
acids I-FAMILY 
and O 
their O 
derivatives O 
at O 
both O 
laboratory O 
and O 
industrial O 
scales O 
. O 

- O 
based O 
adhesions O 
promote O 
cell O 
survival O 
as O 
well O 
as O 
cell O 
motility O 
and O 
invasion O 
. O 
We O 
show O 
here O 
that O 
the O 
adhesion O 
regulatory O 
protein O 
supervillin O 
increases O 
cell O 
survival O 
by O 
decreasing O 
levels O 
of O 
the O 
tumor O 
suppressor O 
protein O 
p53 O 
and O 
downstream O 
target O 
genes O 
. O 
RNAi O 
- O 
mediated O 
knockdown O 
of O 
a O 
new O 
splice O 
form O 
of O 
supervillin O 
( O 
isoform O 
4 O 
) O 
or O 
both O 
isoforms O 
1 O 
and O 
4 O 
increases O 
the O 
amount O 
of O 
p53 O 
and O 
cell O 
death O 
, O 
whereas O 
p53 O 
levels O 
decrease O 
after O 
overexpression O 
of O 
either O 
supervillin O 
isoform O 
. O 
Cellular O 
responses O 
to O 
DNA O 
damage O 
induced O 
by O 
etoposide B-TRIVIAL 
or O 
doxorubicin B-TRIVIAL 
include O 
down O 
- O 
regulation O 
of O 
endogenous O 
supervillin O 
coincident O 
with O 
increases O 
in O 
p53 O 
. O 
In O 
DNA-damaged O 
supervillin O 
knockdown O 
cells O 
, O 
p53 O 
knockdown O 
or O 
inhibition O 
partially O 
rescues O 
the O 
loss O 
of O 
cell O 
metabolic O 
activity O 
, O 
a O 
measure O 
of O 
cell O 
proliferation O 
. O 
Knockdown O 
of O 
the O 
p53 O 
deubiquitinating O 
enzyme O 
USP7 O 
/ O 
HAUSP O 
also O 
reverses O 
the O 
supervillin O 
phenotype O 
, O 
blocking O 
the O 
increase O 
in O 
p53 O 
levels O 
seen O 
after O 
supervillin O 
knockdown O 
and O 
accentuating O 
the O 
decrease O 
in O 
p53 O 
levels O 
triggered O 
by O 
supervillin O 
overexpression O 
. O 
Conversely O 
, O 
supervillin O 
overexpression O 
decreases O 
the O 
association O 
of O 
USP7 O 
and O 
p53 O 
and O 
attenuates O 
USP7 O 
- O 
mediated O 
p53 O 
deubiquitination O 
. O 
USP7 O 
binds O 
directly O 
to O 
the O 
supervillin O 
N B-FORMULA 
terminus O 
and O 
can O 
deubiquitinate O 
and O 
stabilize O 
supervillin O 
. O 
Supervillin O 
also O 
is O 
stabilized O 
by O 
derivatization O 
with O 
the O 
ubiquitin O 
- O 
like O 
protein O 
SUMO1 O 
. O 
These O 
results O 
show O 
that O 
supervillin O 
regulates O 
cell O 
survival O 
through O 
control O 
of O 
p53 O 
levels O 
and O 
suggest O 
that O 
supervillin O 
and O 
its O 
interaction O 
partners O 
at O 
sites O 
of O 
cell O 
- O 
substrate O 
adhesion O 
constitute O 
a O 
locus O 
for O 
cross O 
- O 
talk O 
between O 
survival O 
signaling O 
and O 
cell O 
motility O 
pathways O 
. O 

International O 
Transporter O 
Consortium O 
( O 
ITC O 
) O 
has O 
described O 
recently O 
seven O 
transporters O 
of O 
particular O 
relevance O 
for O 
drug O 
development O 
( O 
Giacomini O 
et O 
al O 
. O 
, O 
Nat O 
. O 
Rev O 
. O 
Drug O 
Discov O 
. O 
9 O 
: O 
215-236 O 
, O 
2010 O 
) O 
. O 
Based O 
on O 
the O 
second O 
ITC O 
transporter O 
workshop O 
in O 
2012 O 
, O 
we O 
have O 
identified O 
additional O 
transporters O 
of O 
emerging O 
importance O 
in O 
pharmacokinetics O 
, O 
interference O 
of O 
drugs O 
with O 
transport O 
of O 
endogenous O 
compounds O 
and O 
drug O 
- O 
drug O 
interactions O 
in O 
humans O 
. O 
The O 
multidrug O 
and O 
toxin O 
extrusion O 
proteins O 
( O 
MATEs O 
, O 
gene O 
symbol O 
SLC47A O 
) O 
mediate O 
excretion O 
of O 
organic O 
cations O 
into O 
bile O 
and O 
urine O 
. O 
MATEs O 
are O 
important O 
in O 
renal O 
drug O 
- O 
drug O 
interactions O 
. O 
Multidrug O 
resistance O 
proteins O 
( O 
MRPs O 
or O 
ABCCs O 
) O 
are O 
drug O 
and O 
conjugate O 
efflux O 
pumps O 
, O 
and O 
impaired O 
activity O 
of O 
MRP2 O 
results O 
in O 
conjugated O 
hyperbilirubinemia O 
. O 
The O 
bile B-FAMILY 
salt I-FAMILY 
export O 
pump O 
( O 
BSEP O 
or O 
ABCB11 O 
) O 
prevents O 
accumulation O 
of O 
toxic O 
bile B-FAMILY 
salt I-FAMILY 
concentrations O 
in O 
hepatocytes O 
, O 
and O 
BSEP O 
inhibition O 
or O 
deficiency O 
may O 
cause O 
cholestasis O 
and O 
liver O 
injury O 
. O 
Additionally O 
, O 
examples O 
are O 
presented O 
on O 
the O 
roles O 
of O 
nucleoside B-FAMILY 
and O 
peptide O 
transporters O 
in O 
drug O 
targeting O 
and O 
disposition.Clinical O 
Pharmacology O 
& O 
Therapeutics O 
( O 
2013 O 
) O 
; O 
accepted O 
article O 
preview O 
online O 
8 O 
April O 
2013 O 
doi O 
: O 
10.1038 O 
/ O 
clpt.2013.74 O 
. O 

Mechanism O 
of O 
the O 
Inhibition O 
of O 
EGCG B-ABBREVIATION 
on O 
the O 
Alzheimer O 
Aβ1-42 O 
Dimer O 
. O 

evidence O 
supports O 
that O 
amyloid O 
β O 
( O 
Aβ O 
) O 
oligomers O 
are O 
the O 
major O 
causative O 
agents O 
leading O 
to O 
neural O 
cell O 
death O 
in O 
Alzheimer's O 
disease O 
. O 
The O 
polyphenol B-FAMILY 
(-)-epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
was O 
recently O 
reported O 
to O 
inhibit O 
Aβ O 
fibrillization O 
and O 
redirect O 
Aβ O 
aggregation O 
into O 
unstructured O 
, O 
off O 
- O 
pathway O 
oligomers O 
. O 
Given O 
the O 
experimental O 
challenge O 
to O 
characterize O 
the O 
structures O 
of O 
Aβ/ O 
EGCG B-ABBREVIATION 
complexes O 
, O 
we O 
performed O 
extensive O 
atomistic O 
replica O 
exchange O 
molecular O 
dynamics O 
simulations O 
of O 
Aβ1-42 O 
dimer O 
in O 
the O 
present O 
and O 
absence O 
of O 
EGCG B-ABBREVIATION 
in O 
explicit O 
solvent O 
. O 
Our O 
equilibrium O 
Aβ O 
dimeric O 
structures O 
free O 
of O 
EGCG B-ABBREVIATION 
are O 
consistent O 
with O 
the O 
collision O 
cross O 
section O 
from O 
ion O 
- O 
mobility O 
mass O 
spectrometry O 
and O 
the O 
secondary O 
structure O 
composition O 
from O 
circular O 
dichroism O 
experiment O 
. O 
In O 
the O 
presence O 
of O 
EGCG B-ABBREVIATION 
, O 
the O 
Aβ O 
structures O 
are O 
characterized O 
by O 
increased O 
inter O 
- O 
center O 
- O 
of O 
- O 
mass O 
distances O 
, O 
reduced O 
interchain O 
and O 
intrachain O 
contacts O 
, O 
reduced O 
β-sheet O 
content O 
, O 
and O 
increased O 
coil O 
and O 
α-helix O 
contents O 
. O 
Analysis O 
of O 
the O 
free O 
energy O 
surfaces O 
reveals O 
that O 
the O 
Aβ O 
dimer O 
with O 
EGCG B-ABBREVIATION 
adopts O 
new O 
conformations O 
, O 
affecting O 
therefore O 
its O 
propensity O 
to O 
adopt O 
fibril O 
- O 
prone O 
states O 
. O 
Overall O 
, O 
this O 
study O 
provides O 
, O 
for O 
the O 
first O 
time O 
, O 
insights O 
on O 
the O 
equilibrium O 
structures O 
of O 
Aβ1-42 O 
dimer O 
in O 
explicit O 
aqueous O 
solution O 
and O 
an O 
atomic O 
picture O 
of O 
the O 
EGCG B-ABBREVIATION 
-mediated O 
conformational O 
change O 
on O 
Aβ O 
dimer O 
. O 

induced O 
neurotoxicity O 
of O 
Di-n-butyl-di-(4-chlorobenzohydroxamato) B-SYSTEMATIC 
Tin I-SYSTEMATIC 
(IV) I-SYSTEMATIC 
via O 
mitochondria O 
- O 
mediated O 
pathway O 
in O 
PC12 O 
cells O 
. O 

severe O 
toxicity O 
of O 
antitumor O 
organotin B-FAMILY 
(IV) I-FAMILY 
compounds O 
limits O 
their O 
application O 
in O 
clinic O 
, O 
however O 
, O 
the O 
toxic O 
mechanism O 
is O 
still O 
unclear O 
. O 
Di-n-butyl-di-(4-chlorobenzohydroxamato) B-SYSTEMATIC 
Tin I-SYSTEMATIC 
(IV) I-SYSTEMATIC 
( O 
DBDCT B-ABBREVIATION 
) O 
, O 
an O 
antitumor O 
agent O 
with O 
high O 
activity O 
and O 
obvious O 
neurotoxicity O 
was O 
chosen O 
as O 
a O 
typical O 
diorganotin B-FAMILY 
(IV) I-FAMILY 
compound O 
to O 
investigate O 
its O 
neurotoxic O 
mechanism O 
using O 
PC12 O 
cells O 
and O 
comprehensive O 
methods O 
. O 
Treatment O 
with O 
DBDCT B-ABBREVIATION 
resulted O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
growth O 
inhibition O 
of O 
PC12 O 
cells O 
. O 
The O 
changes O 
in O 
cell O 
morphology O 
were O 
observed O 
using O 
light O 
microscopy O 
, O 
fluorescence O 
microscopy O 
and O 
transmission O 
electron O 
microscopy O 
. O 
PC12 O 
cell O 
apoptosis O 
induced O 
by O 
DBDCT B-ABBREVIATION 
was O 
confirmed O 
by O 
annexin O 
V/ O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
staining O 
, O 
and O 
characterized O 
by O 
cleavage O 
of O 
caspase-9 O 
and O 
caspase-3 O 
proteins O 
. O 
DBDCT B-ABBREVIATION 
induced O 
the O 
release O 
of O 
cytochrome O 
c O 
from O 
the O 
mitochondria O 
to O 
the O 
cytosol O 
and O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
DBDCT B-ABBREVIATION 
up O 
- O 
regulated O 
the O 
expression O 
of O 
Bax O 
, O 
down O 
- O 
regulated O 
the O 
expression O 
of O 
Bcl-2 O 
, O 
and O 
significantly O 
increased O 
the O 
ratio O 
of O 
Bax O 
/ O 
Bcl-2 O 
. O 
DBDCT B-ABBREVIATION 
also O 
caused O 
the O 
phosphorylation O 
of O 
JNK O 
and O 
p38(MAPK) O 
. O 
In O 
rats O 
exposed O 
to O 
DBDCT B-ABBREVIATION 
, O 
apoptosis O 
was O 
also O 
observed O 
in O 
brain O 
, O 
as O 
shown O 
by O 
the O 
detection O 
of O 
cleaved O 
caspase-9 O 
and O 
caspase-3 O 
proteins O 
and O 
increased O 
TUNEL O 
positive O 
staining O 
. O 
In O 
conclusion O 
, O 
the O 
results O 
demonstrated O 
that O 
DBDCT B-ABBREVIATION 
caused O 
the O 
neurotoxicity O 
by O 
inducing O 
apoptosis O 
via O 
mitochondria O 
- O 
mediated O 
pathway O 
. O 

composition O 
, O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
sterols B-FAMILY 
, O 
total O 
phenolic O 
content O 
( O 
TPC O 
) O 
, O 
individual O 
polyphenols B-FAMILY 
and O 
terpenic B-FAMILY 
acids I-FAMILY 
were O 
determined O 
in O 
five O 
wild O 
edible O 
mushrooms O 
species O 
( O 
Lactarius O 
deliciosus O 
, O 
Lactarius O 
sanguifluus O 
, O 
Lactarius O 
semisanguifluus O 
, O 
Russula O 
delica O 
, O 
Suillus O 
bellinii O 
) O 
from O 
Lesvos O 
Island O 
, O 
Greece O 
. O 
In O 
addition O 
, O 
the O 
DPPH B-ABBREVIATION 
scavenging O 
capacity O 
, O 
the O 
ferric B-SYSTEMATIC 
ion O 
reducing O 
power O 
( O 
FRAP O 
) O 
and O 
the O 
ferrous B-SYSTEMATIC 
ion O 
chelating O 
activity O 
of O 
mushroom O 
methanolic O 
extracts O 
were O 
assessed O 
. O 
Among O 
sterols B-FAMILY 
, O 
ergosterol B-TRIVIAL 
predominated O 
at O 
concentrations O 
9.2-18.0mg O 
/ O 
100g O 
fw O 
. O 
Total O 
phenolic O 
content O 
of O 
mushroom O 
extracts O 
ranged O 
from O 
6 O 
to O 
20.8mg O 
GAE O 
/ O 
100g O 
fw O 
. O 
Up O 
to O 
19 O 
simple O 
polyphenols B-FAMILY 
were O 
determined O 
in O 
mushrooms O 
extracts O 
, O 
the O 
more O 
abundant O 
being O 
p-OH-benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
p-OH-phenylacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
o-coumaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
and O 
chrysin B-TRIVIAL 
. O 
In O 
addition O 
, O 
the O 
triterpenic B-FAMILY 
acids I-FAMILY 
oleanolic B-TRIVIAL 
and O 
ursolic B-TRIVIAL 
were O 
detected O 
for O 
the O 
first O 
time O 
in O 
mushrooms O 
. O 
All O 
species O 
exerted O 
antioxidant O 
activity O 
and O 
ferrous B-SYSTEMATIC 
ion O 
chelating O 
capacity O 
. O 
Principal O 
component O 
analysis O 
revealed O 
good O 
correlations O 
between O 
TPC O 
, O 
DPPH B-ABBREVIATION 
and O 
FRAP O 
but O 
not O 
with O 
metal O 
chelating O 
activity O 
. O 
It O 
seems O 
that O 
mushrooms O 
polyphenols B-FAMILY 
exert O 
antiradical O 
and O 
reducing O 
activities O 
, O 
but O 
they O 
are O 
not O 
strong O 
metal O 
chelators O 
, O 
the O 
observed O 
chelating O 
ability O 
being O 
probably O 
due O 
to O 
other O 
classes O 
of O 
compounds O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
on O 
the O 
bioactive O 
microconstituents O 
and O 
antioxidant O 
activity O 
of O 
wild O 
Greek O 
edible O 
mushrooms O 
. O 

- O 
ligand O 
coordination O 
and O 
hydrophobic O 
interaction O 
are O 
two O 
significant O 
driving O 
forces O 
in O 
the O 
aggregation O 
of O 
mixtures O 
of O 
M(n+) O 
surfactants O 
and O 
alkyldimethylamine B-FAMILY 
oxide I-FAMILY 
( O 
CnDMAO B-FAMILY 
) O 
in O 
aqueous O 
solutions O 
. O 
The O 
coordinated O 
systems O 
exhibit O 
rich O 
aggregation O 
behavior O 
. O 
This O 
study O 
investigated O 
the O 
effect O 
of O 
M(n+) O 
ions O 
( O 
Zn(2+) B-FORMULA 
, O 
Ca(2+) B-FORMULA 
, O 
Ba(2+) B-FORMULA 
, O 
Al(3+) B-FORMULA 
, O 
Fe(3+) B-FORMULA 
, O 
La(3+) B-FORMULA 
, O 
Eu(3+) B-FORMULA 
, O 
and O 
Tb(3+) B-FORMULA 
) O 
and O 
hydrophobic O 
chains O 
( O 
hydrocarbon B-FAMILY 
and O 
fluorocarbon B-FAMILY 
) O 
on O 
the O 
formation O 
of O 
metal O 
- O 
coordinated O 
bilayers O 
. O 
We O 
found O 
that O 
fluorocarbon B-FAMILY 
chains O 
and O 
branched O 
hydrocarbon B-FAMILY 
chains O 
are O 
preferable O 
to O 
the O 
corresponding O 
linear O 
hydrocarbon B-FAMILY 
chains O 
for O 
the O 
formation O 
of O 
an O 
Lα O 
phase O 
. O 
Moreover O 
, O 
Lα O 
phases O 
formed O 
by O 
fluorocarbon B-FAMILY 
chains O 
exhibited O 
higher O 
viscoelasticity O 
than O 
ones O 
formed O 
by O 
the O 
hydrocarbons B-FAMILY 
, O 
and O 
the O 
bilayers O 
formed O 
by O 
branched O 
chains O 
were O 
rather O 
flexible O 
, O 
revealing O 
obvious O 
undulation O 
. O 
The O 
construction O 
of O 
bilayers O 
was O 
also O 
strongly O 
affected O 
by O 
metal O 
ions O 
due O 
to O 
their O 
variable O 
coordination O 
ability O 
with O 
CnDMAO B-FAMILY 
. O 
Our O 
results O 
contribute O 
to O 
the O 
understanding O 
of O 
the O 
formation O 
of O 
metal O 
- O 
coordinated O 
bilayers O 
, O 
which O 
is O 
driven O 
by O 
the O 
interplay O 
of O 
noncovalent O 
forces O 
. O 

molecular O 
and O 
cellular O 
targets O 
for O 
chemoprevention O 
and O 
treatment O 
of O 
skin O 
tumors O 
by O 
plant O 
polyphenols B-FAMILY 
: O 
a O 
critical O 
review O 
. O 

the O 
incidence O 
of O 
skin O 
tumors O 
has O 
been O 
steadily O 
growing O 
, O 
there O 
is O 
an O 
urgent O 
need O 
for O 
the O 
preventive O 
measures O 
as O 
well O 
as O 
the O 
improved O 
therapeutic O 
approaches O 
. O 
In O 
the O 
last O 
two O 
decades O 
, O 
natural O 
plant O 
derived O 
polyphenols B-FAMILY 
( O 
PPs O 
, O 
resveratrol B-TRIVIAL 
, O 
silibinin B-TRIVIAL 
, O 
green O 
tea O 
polyphenols B-FAMILY 
, O 
flavonoids B-FAMILY 
, O 
anthocyanins B-FAMILY 
, O 
etc O 
. O 
) O 
have O 
been O 
drawing O 
particular O 
interest O 
as O 
emerging O 
active O 
substances O 
in O 
dermatological O 
/ O 
cosmeceutical O 
compositions O 
for O 
the O 
prevention O 
, O 
slowing O 
, O 
or O 
reversion O 
of O 
skin O 
tumorigenesis O 
( O 
chemoprevention O 
) O 
. O 
When O 
chronically O 
applied O 
to O 
the O 
skin O 
, O 
they O 
supposedly O 
would O 
not O 
damage O 
normal O 
skin O 
cells O 
or O 
negatively O 
affect O 
their O 
functions O 
while O 
they O 
would O 
suppress O 
tumorigenic O 
cell O 
transformation O 
, O 
inhibit O 
tumor O 
cell O 
proliferation O 
, O 
and O 
activate O 
tumor O 
cell O 
apoptosis O 
. O 
PPs O 
are O 
also O 
reported O 
to O 
synergize O 
with O 
conventional O 
anti-cancer O 
therapies O 
. O 
The O 
major O 
aim O 
of O 
this O 
critical O 
review O 
is O 
to O 
provide O 
recent O 
updates O 
on O 
the O 
molecular O 
and O 
cellular O 
targets O 
for O 
the O 
prevention O 
and O 
therapy O 
of O 
skin O 
tumors O 
with O 
a O 
special O 
focus O 
on O 
the O 
crossroad O 
between O 
inflammation O 
and O 
carcinogenesis O 
as O 
the O 
most O 
promising O 
approach O 
to O 
chemoprevention O 
. O 
Novel O 
therapeutic O 
targets O 
as O 
different O 
as O 
epidermal O 
stem O 
cells O 
, O 
cellular O 
senescence O 
, O 
epigenetic O 
enzymes O 
involved O 
in O 
carcinogenesis O 
, O 
epidermal O 
growth O 
factor O 
and O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptors O 
, O 
and O 
metabolic O 
CYP1 O 
subfamily O 
enzymes O 
are O 
highlighted O 
. O 
The O 
mechanisms O 
of O 
PPs O 
interaction O 
with O 
these O 
molecular O 
and O 
cellular O 
targets O 
are O 
reviewed O 
. O 
The O 
feasibility O 
of O 
PPs O 
to O 
prevent/ O 
cure O 
specific O 
cutaneous O 
toxicity O 
connected O 
to O 
anti-EGFR O 
therapy O 
and O 
to O 
reduce O 
multidrug O 
resistance O 
of O 
skin O 
tumors O 
is O 
also O 
discussed O 
. O 

regulation O 
of O 
airway O 
smooth O 
muscle O 
function O 
. O 

activating O 
β(2)-adrenoceptors O 
( O 
β(2)ARs O 
) O 
on O 
airway O 
smooth O 
muscle O 
( O 
ASM O 
) O 
are O 
the O 
drug O 
of O 
choice O 
for O 
rescue O 
from O 
acute O 
bronchoconstriction O 
in O 
patients O 
with O 
both O 
asthma O 
and O 
chronic O 
obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
. O 
Moreover O 
, O 
the O 
use O 
of O 
long O 
- O 
acting O 
β-agonists O 
combined O 
with O 
inhaled O 
corticosteroids B-FAMILY 
constitutes O 
an O 
important O 
maintenance O 
therapy O 
for O 
these O 
diseases O 
. O 
β-Agonists O 
are O 
effective O 
bronchodilators O 
due O 
primarily O 
to O 
their O 
ability O 
to O 
antagonize O 
ASM O 
contraction O 
. O 
The O 
presumed O 
cellular O 
mechanism O 
of O 
action O 
involves O 
the O 
generation O 
of O 
intracellular O 
cAMP B-ABBREVIATION 
, O 
which O 
in O 
turn O 
can O 
activate O 
the O 
effector O 
molecules O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
PKA O 
) O 
and O 
Epac O 
. O 
Other O 
agents O 
such O 
as O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
and O 
phosphodiesterase O 
inhibitors O 
that O 
also O 
increase O 
intracellular O 
cAMP B-ABBREVIATION 
levels O 
in O 
ASM O 
, O 
can O 
also O 
antagonize O 
ASM O 
contraction O 
, O 
and O 
inhibit O 
other O 
ASM O 
functions O 
including O 
proliferation O 
and O 
migration O 
. O 
Therefore O 
, O 
β(2)ARs O 
and O 
cAMP B-ABBREVIATION 
are O 
key O 
players O 
in O 
combating O 
the O 
pathophysiology O 
of O 
airway O 
narrowing O 
and O 
remodeling O 
. O 
However O 
, O 
limitations O 
of O 
β-agonist O 
therapy O 
due O 
to O 
drug O 
tachyphylaxis O 
related O 
to O 
β(2)AR O 
desensitization O 
, O 
and O 
recent O 
findings O 
regarding O 
the O 
manner O 
in O 
which O 
β(2)ARs O 
and O 
cAMP B-ABBREVIATION 
signal O 
, O 
have O 
raised O 
new O 
and O 
interesting O 
questions O 
about O 
these O 
well O 
- O 
studied O 
molecules O 
. O 
In O 
this O 
review O 
we O 
discuss O 
current O 
concepts O 
regarding O 
β(2)ARs O 
and O 
cAMP B-ABBREVIATION 
in O 
the O 
regulation O 
of O 
ASM O 
cell O 
functions O 
and O 
their O 
therapeutic O 
roles O 
in O 
asthma O 
and O 
COPD O 
. O 

and O 
activity O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
isoforms O 
in O 
methamphetamine B-TRIVIAL 
-induced O 
striatal O 
dopamine B-TRIVIAL 
toxicity O 
. O 

oxide I-SYSTEMATIC 
is O 
implicated O 
in O 
methamphetamine B-TRIVIAL 
( O 
METH B-ABBREVIATION 
)-induced O 
neurotoxicity O 
; O 
however O 
, O 
the O 
source O 
of O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
has O 
not O 
been O 
identified O 
. O 
Previous O 
work O 
has O 
also O 
revealed O 
that O 
animals O 
with O 
partial O 
dopamine B-TRIVIAL 
loss O 
induced O 
by O 
a O 
neurotoxic O 
regimen O 
of O 
methamphetamine B-TRIVIAL 
fail O 
to O 
exhibit O 
further O 
decreases O 
in O 
striatal O 
dopamine B-TRIVIAL 
when O 
re O 
- O 
exposed O 
to O 
methamphetamine B-TRIVIAL 
7-30 O 
days O 
later O 
. O 
The O 
current O 
study O 
examined O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
expression O 
and O 
activity O 
and O 
protein O 
nitration O 
in O 
striata O 
of O 
animals O 
administered O 
saline O 
or O 
neurotoxic O 
regimens O 
of O 
methamphetamine B-TRIVIAL 
at O 
postnatal O 
days O 
60 O 
and O 
/ O 
or O 
90 O 
, O 
resulting O 
in O 
four O 
treatment O 
groups O 
: O 
Saline O 
: O 
Saline O 
, O 
METH B-ABBREVIATION 
: O 
Saline O 
, O 
Saline O 
: O 
METH B-ABBREVIATION 
, O 
and O 
METH B-ABBREVIATION 
: O 
METH B-ABBREVIATION 
. O 
Acute O 
administration O 
of O 
methamphetamine B-TRIVIAL 
on O 
postnatal O 
day O 
90 O 
( O 
Saline O 
: O 
METH B-ABBREVIATION 
and O 
METH B-ABBREVIATION 
: O 
METH B-ABBREVIATION 
) O 
increased O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
, O 
as O 
evidenced O 
by O 
increased O 
protein O 
nitration O 
. O 
Methamphetamine B-TRIVIAL 
did O 
not O 
, O 
however O 
, O 
change O 
the O 
expression O 
of O 
endothelial O 
or O 
inducible O 
isoforms O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
, O 
nor O 
did O 
it O 
change O 
the O 
number O 
of O 
cells O 
positive O 
for O 
neuronal O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
mRNA O 
expression O 
or O 
the O 
amount O 
of O 
neuronal O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
mRNA O 
per O 
cell O 
. O 
However O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
activity O 
in O 
striatal O 
interneurons O 
was O 
increased O 
in O 
the O 
Saline O 
: O 
METH B-ABBREVIATION 
and O 
METH B-ABBREVIATION 
: O 
METH B-ABBREVIATION 
animals O 
. O 
These O 
data O 
suggest O 
that O 
increased O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
after O 
a O 
neurotoxic O 
regimen O 
of O 
methamphetamine B-TRIVIAL 
results O 
from O 
increased O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
activity O 
, O 
rather O 
than O 
an O 
induction O 
of O 
mRNA O 
, O 
and O 
that O 
constitutively O 
expressed O 
neuronal O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
is O 
the O 
most O 
likely O 
source O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
after O 
methamphetamine B-TRIVIAL 
administration O 
. O 
Of O 
interest O 
, O 
animals O 
rendered O 
resistant O 
to O 
further O 
methamphetamine B-TRIVIAL 
-induced O 
dopamine B-TRIVIAL 
depletions O 
still O 
show O 
equivalent O 
degrees O 
of O 
methamphetamine B-TRIVIAL 
-induced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
, O 
suggesting O 
that O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
alone O 
in O 
response O 
to O 
methamphetamine B-TRIVIAL 
is O 
not O 
sufficient O 
to O 
induce O 
acute O 
neurotoxic O 
injury O 
. O 

" O 
pinking O 
" O 
of O 
onion O 
, O 
E-(+)-S-(1-propenyl)-l-cysteine B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
is O 
first O 
cleaved O 
by O 
alliinase O 
to O 
yield O 
colour O 
developers O 
( O 
CDs O 
) O 
, O 
which O 
react O 
with O 
amino B-FAMILY 
acids I-FAMILY 
, O 
such O 
as O 
valine B-TRIVIAL 
, O 
to O 
form O 
pigment O 
precursors O 
( O 
PPs O 
) O 
. O 
The O 
PPs O 
react O 
with O 
naturally O 
occurring O 
carbonyls B-FAMILY 
( O 
NOCs O 
) O 
to O 
form O 
pigments O 
. O 
By O 
inducing O 
a O 
PP O 
from O 
previously O 
isolated O 
cepathiolanes B-NO_CLASS 
and O 
l-valine B-TRIVIAL 
, O 
it O 
was O 
confirmed O 
that O 
cepathiolanes B-NO_CLASS 
constitute O 
at O 
least O 
a O 
part O 
of O 
the O 
CDs O 
. O 
From O 
the O 
PP O 
and O 
formaldehyde B-SYSTEMATIC 
as O 
a O 
NOC O 
, O 
two O 
colourless O 
and O 
two O 
pink O 
compounds O 
were O 
derived O 
. O 
The O 
structure O 
of O 
one O 
of O 
the O 
colourless O 
compounds O 
was O 
established O 
as O 
2-(2-(1-(1-carboxy-2-methylpropyl)-3,4-dimethyl-1H-pyrrol-2-yl)methyl-3,4-dimethyl-1H-pyrrol-1-yl)-3-methylbutanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
The O 
structures O 
of O 
the O 
other O 
colourless O 
compound O 
and O 
the O 
pink O 
pigments O 
were O 
predicted O 
based O 
on O 
their O 
molecular O 
formula O 
and O 
the O 
MS(n) O 
spectral O 
data O 
. O 
A O 
trimeric O 
pigment O 
structure O 
was O 
predicted O 
for O 
one O 
of O 
the O 
pink O 
pigments O 
, O 
which O 
was O 
believed O 
to O 
be O 
the O 
first O 
to O 
be O 
reported O 
in O 
the O 
literature O 
. O 
With O 
these O 
, O 
a O 
new O 
reaction O 
scheme O 
for O 
" O 
pinking O 
" O 
of O 
onion O 
is O 
proposed O 
. O 

released O 
by O 
HIV(+) O 
cells O 
, O 
p17 O 
binds O 
heparan O 
sulfate B-SYSTEMATIC 
proteoglycans O 
( O 
HSPGs O 
) O 
and O 
CXCR1 O 
on O 
leukocytes O 
causing O 
their O 
dysfunction O 
. O 
By O 
exploiting O 
an O 
approach O 
integrating O 
computational O 
modeling O 
, O 
site O 
- O 
directed O 
mutagenesis O 
of O 
p17 O 
, O 
chemical O 
desulfation O 
of O 
heparin O 
, O 
and O 
surface O 
plasmon O 
resonance O 
, O 
we O 
characterized O 
the O 
interaction O 
of O 
p17 O 
with O 
heparin O 
, O 
a O 
HSPG O 
structural O 
analog O 
, O 
and O 
CXCR1 O 
. O 
p17 O 
binds O 
to O 
heparin O 
with O 
an O 
affinity O 
( O 
K(d) O 
= O 
190 O 
nm O 
) O 
that O 
is O 
similar O 
to O 
those O 
of O 
other O 
heparin O 
- O 
binding O 
viral O 
proteins O 
. O 
Two O 
stretches O 
of O 
basic O 
amino B-FAMILY 
acids I-FAMILY 
( O 
basic O 
motifs O 
) O 
are O 
present O 
in O 
p17 O 
N B-FORMULA 
and O 
C B-FORMULA 
termini O 
. O 
Neutralization O 
( O 
Arg B-FORMULA 
→ O 
Ala B-FORMULA 
substitution O 
) O 
of O 
the O 
N B-FORMULA 
-terminal O 
, O 
but O 
not O 
of O 
the O 
C B-FORMULA 
-terminal O 
basic O 
motif O 
, O 
causes O 
the O 
loss O 
of O 
p17 O 
heparin O 
- O 
binding O 
capacity O 
. O 
The O 
N B-FORMULA 
-terminal O 
heparin O 
- O 
binding O 
motif O 
of O 
p17 O 
partially O 
overlaps O 
the O 
CXCR1 O 
- O 
binding O 
domain O 
. O 
Accordingly O 
, O 
its O 
neutralization O 
prevents O 
also O 
p17 O 
binding O 
to O 
the O 
chemochine O 
receptor O 
. O 
Competition O 
experiments O 
demonstrated O 
that O 
free O 
heparin O 
and O 
heparan O 
sulfate B-SYSTEMATIC 
( O 
HS O 
) O 
, O 
but O 
not O 
selectively O 
2- O 
O B-FORMULA 
- O 
, O 
6- O 
O B-FORMULA 
- O 
, O 
and O 
N-O B-FORMULA 
desulfated O 
heparins O 
, O 
prevent O 
p17 O 
binding O 
to O 
substrate O 
- O 
immobilized O 
heparin O 
, O 
indicating O 
that O 
the O 
sulfate B-SYSTEMATIC 
groups O 
of O 
the O 
glycosaminoglycan O 
mediate O 
p17 O 
interaction O 
. O 
Evaluation O 
of O 
the O 
p17 O 
antagonist O 
activity O 
of O 
a O 
panel O 
of O 
biotechnological O 
heparins O 
derived O 
by O 
chemical O 
sulfation O 
of O 
the O 
Escherichia O 
coli O 
K5 O 
polysaccharide O 
revealed O 
that O 
the O 
highly O 
N B-FORMULA 
, O 
O B-FORMULA 
-sulfated O 
derivative O 
prevents O 
the O 
binding O 
of O 
p17 O 
to O 
both O 
heparin O 
and O 
CXCR1 O 
, O 
thus O 
inhibiting O 
p17-driven O 
chemotactic O 
migration O 
of O 
human O 
monocytes O 
with O 
an O 
efficiency O 
that O 
is O 
higher O 
than O 
those O 
of O 
heparin O 
and O 
HS O 
. O 
Here O 
, O 
we O 
characterized O 
at O 
a O 
molecular O 
level O 
the O 
interaction O 
of O 
p17 O 
with O 
its O 
cellular O 
receptors O 
, O 
laying O 
the O 
basis O 
for O 
the O 
development O 
of O 
heparin O 
- O 
mimicking O 
p17 O 
antagonists O 
. O 

, O 
an O 
essential O 
oil O 
from O 
flowers O 
of O 
Lavandula O 
angustifolia O 
, O 
is O 
not O 
recognized O 
as O 
benzodiazepine B-FAMILY 
-like O 
in O 
rats O 
trained O 
to O 
discriminate O 
a O 
diazepam B-TRIVIAL 
cue O 
. O 

, O 
an O 
essential O 
oil O 
of O 
selected O 
quality O 
produced O 
from O 
the O 
flowering O 
tops O 
of O 
Lavandula O 
angustifolia O 
Mill O 
. O 
by O 
steam O 
distillation O 
( O 
Silexan O 
) O 
has O 
been O 
approved O 
in O 
Germany O 
for O 
the O 
treatment O 
of O 
restlessness O 
in O 
case O 
of O 
anxious O 
mood O 
. O 
Based O 
on O 
the O 
observed O 
clinical O 
effects O 
, O 
it O 
has O 
been O 
speculated O 
that O 
lavender O 
oil O 
may O 
exert O 
benzodiazepine B-FAMILY 
-like O 
action O 
including O 
the O 
known O 
dependence O 
and O 
abuse O 
potential O 
of O 
this O 
class O 
of O 
drugs O 
. O 
Although O 
no O 
evidence O 
for O 
such O 
an O 
activity O 
was O 
generated O 
during O 
the O 
long O 
- O 
standing O 
medicinal O 
use O 
of O 
lavender O 
oil O 
, O 
further O 
preclinical O 
investigations O 
were O 
now O 
conducted O 
to O 
evaluate O 
this O 
potential O 
side O 
effect O 
in O 
more O 
detail O 
. O 
Twelve O 
adult O 
, O 
male O 
, O 
Sprague-Dawley O 
rats O 
were O 
trained O 
to O 
discriminate O 
the O 
benzodiazepine B-FAMILY 
drug O 
diazepam B-TRIVIAL 
( O 
2 O 
mg O 
/ O 
kg O 
i.p O 
. O 
) O 
from O 
saline O 
using O 
a O 
two O 
- O 
lever O 
operant O 
procedure O 
. O 
After O 
approximately O 
40 O 
training O 
sessions O 
the O 
majority O 
of O 
rats O 
learned O 
the O 
discrimination O 
and O 
pre O 
- O 
treatment O 
with O 
ascending O 
doses O 
of O 
diazepam B-TRIVIAL 
( O 
0.3-2 O 
mg O 
/ O 
kg O 
i.p O 
. O 
) O 
produced O 
a O 
dose O 
related O 
generalization O 
to O 
the O 
diazepam B-TRIVIAL 
cue O 
. O 
In O 
these O 
same O 
animals O 
Silexan O 
was O 
administered O 
to O 
see O 
if O 
animals O 
recognized O 
the O 
drug O 
as O 
" O 
diazepam B-TRIVIAL 
-like O 
" O 
i.e O 
. O 
generalized O 
to O 
diazepam B-TRIVIAL 
or O 
" O 
saline O 
- O 
like O 
" O 
. O 
Silexan O 
tested O 
at O 
doses O 
3-30 O 
mg O 
/ O 
kg O 
i.p O 
. O 
produced O 
almost O 
exclusively O 
( O 
> O 
90% O 
) O 
saline O 
- O 
like O 
responding O 
. O 
Also O 
there O 
was O 
no O 
effect O 
of O 
Silexan O 
on O 
response O 
rate O 
, O 
i.e O 
. O 
rate O 
of O 
lever O 
pressing O 
, O 
at O 
any O 
dose O 
suggesting O 
that O 
the O 
test O 
article O 
is O 
well O 
tolerated O 
and O 
does O 
not O 
exert O 
a O 
sedating O 
effect O 
. O 
In O 
sum O 
, O 
Silexan O 
has O 
no O 
diazepam B-TRIVIAL 
-like O 
interoceptive O 
property O 
in O 
adult O 
, O 
male O 
rats O 
. O 
This O 
suggests O 
that O 
Silexan O 
does O 
not O 
share O 
the O 
potential O 
of O 
benzodiazepines B-FAMILY 
to O 
induce O 
the O 
development O 
of O 
tolerance O 
, O 
dependence O 
and O 
addiction O 
. O 

of O 
H2O2 B-FORMULA 
stress O 
- O 
responsive O 
genes O 
through O 
a O 
novel O 
transcription O 
factor O 
in O 
the O 
protozoan O 
pathogen O 
Entamoeba O 
histolytica O 
. O 

of O 
infection O 
depends O 
upon O 
complex O 
interactions O 
between O 
the O 
invading O 
pathogen O 
and O 
the O 
host O 
. O 
As O 
part O 
of O 
the O 
host's O 
innate O 
immune O 
response O 
, O 
the O 
release O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
by O 
phagocytes O 
represents O 
a O 
major O 
obstacle O 
to O 
the O 
establishment O 
of O 
infection O 
. O 
The O 
ability O 
of O 
the O 
human O 
parasite O 
Entamoeba O 
histolytica O 
to O 
survive O 
reactive O 
oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
is O 
central O 
to O 
its O 
pathogenic O 
potential O 
and O 
contributes O 
to O 
disease O 
outcome O 
. O 
In O 
order O 
to O 
define O 
the O 
transcriptional O 
network O 
associated O 
with O 
oxidative O 
stress O 
, O 
we O 
utilized O 
the O 
MEME O 
and O 
MAST O 
programs O 
to O 
analyze O 
the O 
promoter O 
regions O 
of O 
57 O 
amoebic O 
genes O 
that O 
had O 
increased O 
expression O 
specifically O 
in O 
response O 
to O 
H(2)O(2) B-FORMULA 
exposure O 
. O 
We O 
functionally O 
characterized O 
an O 
H(2)O(2) B-FORMULA 
-regulatory O 
motif O 
( O 
HRM O 
) O 
((1)AAACCTCAATGAAGA(15)) O 
, O 
which O 
was O 
enriched O 
in O 
these O 
promoters O 
and O 
specifically O 
bound O 
amoebic O 
nuclear O 
protein(s) O 
. O 
Assays O 
with O 
promoter O 
- O 
luciferase O 
fusions O 
established O 
the O 
importance O 
of O 
key O 
residues O 
and O 
that O 
the O 
HRM O 
motif O 
directly O 
impacted O 
the O 
ability O 
of O 
H(2)O(2) B-FORMULA 
-responsive O 
promoters O 
to O 
drive O 
gene O 
expression O 
. O 
DNA O 
affinity O 
chromatography O 
and O 
mass O 
spectrometry O 
identified O 
EHI_108720 O 
as O 
an O 
HRM O 
DNA O 
- O 
binding O 
protein O 
. O 
Overexpression O 
and O 
down O 
- O 
regulation O 
of O 
EHI_108720 O 
demonstrated O 
the O 
specificity O 
of O 
EHI_108720 O 
protein O 
binding O 
to O 
the O 
HRM O 
, O 
and O 
overexpression O 
increased O 
basal O 
expression O 
from O 
an O 
H(2)O(2) B-FORMULA 
-responsive O 
wild O 
- O 
type O 
promoter O 
but O 
not O 
from O 
its O 
mutant O 
counterpart O 
. O 
Thus O 
, O 
EHI_108720 O 
, O 
or O 
HRM O 
- O 
binding O 
protein O 
, O 
represents O 
a O 
new O 
stress O 
- O 
responsive O 
transcription O 
factor O 
in O 
E O 
. O 
histolytica O 
that O 
controls O 
a O 
transcriptional O 
regulatory O 
network O 
associated O 
with O 
oxidative O 
stress O 
. O 
Overexpression O 
of O 
EHI_108720 O 
increased O 
parasite O 
virulence O 
. O 
Insight O 
into O 
how O 
E O 
. O 
histolytica O 
responds O 
to O 
oxidative O 
stress O 
increases O 
our O 
understanding O 
of O 
how O 
this O 
important O 
human O 
pathogen O 
establishes O 
invasive O 
disease O 
. O 

have O 
a O 
storied O 
history O 
in O 
medicinal O 
chemistry O 
as O 
pain O 
management O 
drugs O 
but O 
have O 
received O 
attention O 
as O 
modulators O 
of O 
cholinergic O 
signaling O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
Disease O 
( O 
AD O 
) O 
. O 
Galantamine B-TRIVIAL 
is O 
a O 
reversible O 
, O 
competitive O 
acetylcholinesterase O 
( O 
AChE O 
) O 
inhibitor O 
and O 
allosteric O 
potentiating O 
ligand O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChR-APL O 
) O 
that O 
shares O 
many O 
common O 
structural O 
elements O 
with O 
morphinan B-TRIVIAL 
-based O 
opioids O 
. O 
The O 
structurally O 
diverse O 
opioids O 
codeine B-TRIVIAL 
and O 
eseroline B-TRIVIAL 
, O 
like O 
galantamine B-TRIVIAL 
, O 
are O 
also O 
nAChR-APL O 
that O 
have O 
greatly O 
diminished O 
affinity O 
for O 
AChE O 
, O 
representing O 
potential O 
lead O 
compounds O 
for O 
selective O 
nAChR-APL O 
development O 
. O 
In O 
accordance O 
with O 
the O 
emerging O 
repurposing O 
trend O 
of O 
evaluating O 
known O 
compounds O 
for O 
novel O 
pharmacological O 
activity O 
, O 
ongoing O 
research O 
on O 
augmentation O 
of O 
cholinergic O 
signaling O 
that O 
has O 
been O 
aided O 
by O 
the O 
use O 
of O 
opioids O 
will O 
be O 
reviewed O 
. O 

improve O 
future O 
drug O 
development O 
efficiency O 
in O 
renal O 
cell O 
carcinoma O 
( O 
RCC O 
) O 
, O 
a O 
disease O 
- O 
progression O 
model O 
was O 
developed O 
with O 
longitudinal O 
tumor O 
size O 
data O 
from O 
a O 
phase O 
III O 
trial O 
of O 
sorafenib B-TRIVIAL 
in O 
RCC O 
. O 
The O 
best O 
- O 
fit O 
model O 
was O 
externally O 
evaluated O 
on O 
145 O 
placebo O 
- O 
treated O 
patients O 
in O 
a O 
phase O 
III O 
trial O 
of O 
pazopanib B-TRIVIAL 
; O 
the O 
model O 
incorporated O 
baseline O 
tumor O 
size O 
, O 
a O 
linear O 
disease O 
- O 
progression O 
component O 
, O 
and O 
an O 
exponential O 
drug O 
effect O 
( O 
DE O 
) O 
parameter O 
. O 
With O 
the O 
model O 
- O 
estimated O 
effect O 
of O 
sorafenib B-TRIVIAL 
on O 
RCC O 
growth O 
, O 
we O 
calculated O 
the O 
power O 
of O 
randomized O 
phase O 
II O 
trials O 
between O 
sorafenib B-TRIVIAL 
and O 
hypothetical O 
comparators O 
over O 
a O 
range O 
of O 
effects O 
. O 
A O 
hypothetical O 
comparator O 
with O 
80% O 
greater O 
DE O 
than O 
sorafenib B-TRIVIAL 
would O 
have O 
82% O 
power O 
( O 
one O 
- O 
sided O 
α O 
= O 
0.1 O 
) O 
with O 
50 O 
patients O 
per O 
arm O 
. O 
Model O 
- O 
based O 
quantitation O 
of O 
treatment O 
effect O 
with O 
computed O 
tomography O 
( O 
CT O 
) O 
imaging O 
offers O 
a O 
scaffold O 
on O 
which O 
to O 
develop O 
new O 
, O 
more O 
efficient O 
, O 
phase O 
II O 
trial O 
end O 
points O 
and O 
analytic O 
strategies O 
for O 
RCC O 
. O 

multi O 
- O 
locus O 
heterozygosity O 
is O 
associated O 
with O 
lower O 
morning O 
plasma O 
cortisol B-TRIVIAL 
concentration O 
. O 

. O 
STRESS O 
IS O 
IMPLICATED O 
AS O 
A O 
RISK O 
FACTOR O 
FOR O 
NUMEROUS O 
ILLNESSES O 
IN O 
HUMANS O 
, O 
PUTATIVELY O 
IN O 
PART O 
MEDIATED O 
BY O 
BIOLOGICAL O 
RESPONSES O 
TO O 
STRESS O 
, O 
SUCH O 
AS O 
ELEVATED O 
CORTISOL B-TRIVIAL 
. O 
THE O 
THEORY O 
OF O 
GENETIC O 
HOMEOSTASIS O 
SUGGESTS O 
THAT O 
INDIVIDUAL O 
HETEROZYGOSITY O 
FACILITATES O 
COMPENSATION O 
FOR O 
ENVIRONMENTAL O 
STRESSES O 
. O 
WE O 
HYPOTHESIZED O 
THAT O 
HETEROZYGOSITY O 
AMELIORATES O 
THE O 
BIOLOGICAL O 
RESPONSE O 
TO O 
A O 
GIVEN O 
LEVEL O 
OF O 
PERCEIVED O 
STRESS O 
, O 
REFLECTED O 
IN O 
LOWER O 
PLASMA O 
CORTISOL B-TRIVIAL 
CONCENTRATIONS.DESIGN O 
. O 
WE O 
EXAMINE O 
THE O 
ROLE O 
OF O 
HETEROZYGOSITY O 
ON O 
THE O 
ASSOCIATION O 
BETWEEN O 
PERCEIVED O 
PSYCHOLOGICAL O 
STRESS O 
AND O 
MORNING O 
CORTISOL B-TRIVIAL 
CONCENTRATIONS O 
IN O 
854 O 
INDIVIDUALS O 
FROM O 
THE O 
ISOLATED O 
ISLAND O 
OF O 
VIS O 
, O 
CROATIA.METHODS O 
. O 
CORTISOL B-TRIVIAL 
WAS O 
MEASURED O 
IN O 
MORNING O 
PLASMA O 
SAMPLES O 
. O 
1184 O 
AUTOSOMAL O 
MICROSATELLITE O 
MARKERS O 
WERE O 
GENOTYPED O 
AND O 
INDIVIDUAL O 
MULTI-LOCUS O 
HETEROZYGOSITY O 
WAS O 
CALCULATED O 
AS O 
THE O 
PROPORTION O 
OF O 
HETEROZYGOUS O 
MARKERS O 
. O 
GENERAL O 
HEALTH O 
QUESTIONNAIRE O 
( O 
GHQ-30 O 
) O 
WAS O 
USED O 
TO O 
ASSESS O 
THE O 
DEGREE O 
OF O 
PSYCHOLOGICAL O 
DISTRESS.RESULTS O 
. O 
MEAN O 
MULTI-LOCUS O 
HETEROZYGOSITY O 
WAS O 
34.850.45% O 
( O 
RANGE O 
: O 
31.97-36.22% O 
) O 
. O 
Psychological O 
distress O 
( O 
GHQ O 
Likert O 
score O 
> O 
31 O 
) O 
was O 
more O 
prevalent O 
in O 
women O 
( O 
37% O 
versus O 
18% O 
in O 
men O 
, O 
p O 
< O 
0.0001 O 
) O 
, O 
in O 
less O 
educated O 
people O 
( O 
β=-0.35 O 
per O 
year O 
in O 
school O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
in O 
lower O 
socio O 
- O 
economic O 
classes O 
( O 
β=-3.59 O 
, O 
p O 
< O 
0.0001 O 
) O 
. O 
Cortisol B-TRIVIAL 
was O 
positively O 
associated O 
with O 
psychological O 
distress O 
( O 
β=2.20 O 
, O 
p=0.01 O 
) O 
. O 
In O 
a O 
regression O 
model O 
adjusting O 
for O 
age O 
, O 
BMI O 
, O 
education O 
and O 
GHQ-30 O 
score O 
, O 
multi O 
- O 
locus O 
heterozygosity O 
was O 
independently O 
and O 
inversely O 
associated O 
with O 
morning O 
plasma O 
cortisol B-TRIVIAL 
(p=0.005).Conclusion O 
. O 
More O 
heterozygous O 
individuals O 
, O 
as O 
measured O 
by O 
microsatellite O 
markers O 
, O 
had O 
lower O 
morning O 
plasma O 
cortisol B-TRIVIAL 
concentrations O 
for O 
a O 
given O 
level O 
of O 
perceived O 
psychological O 
stress O 
. O 
This O 
may O 
be O 
important O 
, O 
as O 
higher O 
cortisol B-TRIVIAL 
concentrations O 
may O 
increase O 
allostatic O 
load O 
and O 
be O 
associated O 
with O 
higher O 
risk O 
of O 
stress O 
- O 
related O 
illness O 
. O 

and O 
zinc B-SYSTEMATIC 
bioavailability O 
in O 
Caco-2 O 
cells O 
: O 
influence O 
of O 
caseinophosphopeptides O 
. O 

study O 
has O 
been O 
made O 
of O 
the O 
influence O 
of O 
two O 
pools O 
of O 
caseinophosphopeptides O 
( O 
CPPs O 
) O 
obtained O 
from O 
α(s)- O 
and O 
β-casein O 
( O 
CN O 
) O 
fractions O 
, O 
and O 
of O 
three O 
specific O 
CPPs O 
( O 
β-CN(1-25)4P O 
, O 
α(s1)-CN(64-74)4P O 
and O 
α(s2)-CN(1-19)4P O 
) O 
, O 
on O 
iron B-SYSTEMATIC 
bioavailability O 
( O 
ferritin O 
synthesis O 
) O 
and O 
zinc B-SYSTEMATIC 
bioavailability O 
( O 
retention O 
, O 
transport O 
and O 
uptake O 
of O 
zinc B-SYSTEMATIC 
) O 
in O 
Caco-2 O 
cells O 
. O 
α-CPP O 
and O 
β-CPP O 
pools O 
did O 
not O 
improve O 
ferritin O 
synthesis O 
, O 
but O 
the O 
three O 
specific O 
CPPs O 
showed O 
an O 
increase O 
in O 
ferritin O 
synthesis O 
in O 
Caco-2 O 
cells O 
versus O 
iron B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
, O 
β-CN(1-25)4P O 
being O 
the O 
most O 
effective O 
. O 
In O 
relation O 
to O 
zinc B-SYSTEMATIC 
bioavailability O 
, O 
α-CPPs O 
, O 
β-CPPs O 
, O 
α(s1)-CN(64-74)4P O 
and O 
β-CN(1-25)4P O 
increased O 
zinc B-SYSTEMATIC 
uptake O 
. O 
However O 
, O 
this O 
increase O 
was O 
of O 
the O 
same O 
order O 
as O 
the O 
increase O 
due O 
to O 
the O 
presence O 
of O 
zinc B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
. O 

associated O 
with O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
. O 

experiencing O 
atrial O 
fibrillation O 
are O 
at O 
an O 
increased O 
risk O 
for O 
thromboembolic O 
events O 
. O 
Therefore O 
, O 
anticoagulation O 
therapy O 
is O 
imperative O 
to O 
prevent O 
thrombus O 
formation O 
and O 
stroke O 
. O 
Dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
was O 
approved O 
by O 
the O 
Food O 
and O 
Drug O 
Administration O 
in O 
2010 O 
as O 
anticoagulant O 
prophylaxis O 
for O 
patients O 
with O 
nonvalvular O 
atrial O 
fibrillation O 
. O 
The O 
frequency O 
of O 
dermatologic O 
reactions O 
to O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
is O 
estimated O 
in O 
the O 
product O 
labeling O 
to O 
be O 
less O 
than O 
0.1% O 
. O 
To O 
date O 
, O 
five O 
cases O 
of O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
-associated O 
rash O 
have O 
reported O 
, O 
including O 
three O 
published O 
cases O 
. O 
We O 
describe O 
the O 
sixth O 
reported O 
case O 
of O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
-associated O 
rash O 
, O 
in O 
a O 
59-year- O 
old O 
man O 
with O 
a O 
history O 
of O 
atrial O 
fibrillation O 
who O 
received O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
150 O 
mg O 
twice O 
/ O 
day O 
for O 
atrial O 
flutter O 
before O 
cardioversion O 
. O 
The O 
patient O 
had O 
taken O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
for O 
5 O 
days O 
before O 
the O 
rash O 
was O 
noted O 
on O 
hospital O 
admission O 
. O 
He O 
had O 
no O 
known O 
previous O 
drug O 
allergies O 
, O 
and O 
his O 
platelet O 
count O 
, O 
serum O 
creatinine B-TRIVIAL 
concentration O 
, O 
and O 
hepatic O 
function O 
were O 
normal O 
. O 
The O 
rash O 
resolved O 
7 O 
days O 
after O 
the O 
discontinuation O 
of O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
, O 
and O 
the O 
patient O 
was O 
stabilized O 
on O 
warfarin B-TRIVIAL 
therapy O 
. O 
Use O 
of O 
the O 
Naranjo O 
Adverse O 
Drug O 
Reaction O 
Probability O 
Scale O 
indicated O 
a O 
probable O 
relationship O 
( O 
score O 
of O 
5 O 
) O 
between O 
the O 
patient's O 
development O 
of O 
the O 
rash O 
and O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
therapy O 
. O 
Clinicians O 
should O 
be O 
aware O 
of O 
this O 
adverse O 
effect O 
of O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
and O 
monitor O 
for O 
dermatologic O 
reactions O 
during O 
follow O 
- O 
up O 
visits O 
. O 

salt O 
is O 
a O 
traditional O 
food O 
widely O 
used O 
in O 
Korea O 
. O 
The O 
in O 
vitro O 
anticancer O 
effects O 
of O 
this O 
salt O 
were O 
evaluated O 
in O 
HCT-116 O 
human O 
colon O 
cancer O 
cells O 
using O 
a O 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
. O 
A O 
1% O 
salt O 
concentration O 
of O 
bamboo O 
salt O 
baked O 
nine O 
times O 
( O 
9× O 
) O 
inhibited O 
the O 
growth O 
of O 
HCT-116 O 
cells O 
by O 
53% O 
, O 
which O 
was O 
higher O 
than O 
salt O 
baked O 
three O 
times O 
( O 
3× O 
) O 
or O 
once O 
( O 
1× O 
; O 
44% O 
and O 
41% O 
, O 
respectively O 
) O 
and O 
much O 
higher O 
than O 
solar O 
sea O 
salt O 
( O 
Korean O 
sea O 
salt O 
) O 
and O 
purified O 
salt O 
( O 
22% O 
and O 
18% O 
, O 
respectively O 
) O 
. O 
To O 
elucidate O 
the O 
inhibitory O 
mechanisms O 
underlying O 
the O 
anticancer O 
effect O 
of O 
the O 
salt O 
samples O 
in O 
cancer O 
cells O 
, O 
expression O 
of O 
genes O 
associated O 
with O 
apoptosis O 
, O 
inflammation O 
, O 
and O 
metastasis O 
was O 
measured O 
with O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
and O 
Western O 
blotting O 
. O 
Bamboo O 
salt O 
( O 
9× O 
) O 
significantly O 
induced O 
apoptosis O 
in O 
cancer O 
cells O 
( O 
P O 
< O 
0.05 O 
) O 
by O 
upregulating O 
Bax O 
, O 
caspase-9 O 
, O 
and O 
caspase-3 O 
, O 
and O 
downregulating O 
Bcl-2 O 
. O 
The O 
expression O 
of O 
genes O 
associated O 
with O 
inflammation O 
( O 
NF-κB O 
, O 
iNOS O 
, O 
and O 
COX-2 O 
) O 
was O 
significantly O 
downregulated O 
( O 
P O 
< O 
0.05 O 
) O 
by O 
9× O 
bamboo O 
salt O 
, O 
demonstrating O 
its O 
anti-inflammatory O 
properties O 
. O 
The O 
9× O 
bamboo O 
salt O 
also O 
exerted O 
a O 
greater O 
anti-metastatic O 
effect O 
on O 
cancer O 
cells O 
than O 
the O 
other O 
salts O 
as O 
demonstrated O 
by O 
decreased O 
mRNA O 
expression O 
of O 
MMP O 
genes O 
and O 
increased O 
expression O 
of O 
tissue O 
inhibitors O 
of O 
metalloproteinases O 
, O 
which O 
was O 
confirmed O 
by O 
the O 
inhibition O 
of O 
tumor O 
metastasis O 
induced O 
in O 
colon O 
26-M3.1 O 
cells O 
in O 
BALB O 
/ O 
c O 
mice O 
. O 
In O 
contrast O 
, O 
purified O 
and O 
solar B-FAMILY 
salts I-FAMILY 
increased O 
metastasis O 
in O 
the O 
mice O 
. O 
Our O 
results O 
demonstrated O 
that O 
9× O 
bamboo O 
salt O 
had O 
the O 
most O 
potent O 
in O 
vitro O 
anticancer O 
effect O 
, O 
induced O 
apoptosis O 
, O 
had O 
anti-inflammatory O 
activities O 
, O 
and O 
exerted O 
in O 
vivo O 
anti-metastatic O 
effects O 
. O 
Additionally O 
, O 
the O 
anticancer O 
, O 
anti-inflammatory O 
, O 
and O 
anti-metastatic O 
effects O 
of O 
the O 
1× O 
and O 
3× O 
bamboo O 
salts O 
were O 
stronger O 
than O 
those O 
of O 
the O 
purified O 
and O 
solar B-FAMILY 
salts I-FAMILY 
. O 

methyltransferases O 
( O 
PMTs O 
) O 
have O 
emerged O 
as O 
important O 
epigenetic O 
regulators O 
in O 
myriad O 
biological O 
processes O 
in O 
both O 
normal O 
physiology O 
and O 
disease O 
conditions O 
. O 
However O 
, O 
elucidating O 
PMT-regulated O 
epigenetic O 
processes O 
has O 
been O 
hampered O 
by O 
ambiguous O 
knowledge O 
about O 
in O 
vivo O 
activities O 
of O 
individual O 
PMTs O 
particularly O 
because O 
of O 
their O 
overlapping O 
but O 
nonredundant O 
functions O 
. O 
To O 
address O 
limitations O 
of O 
conventional O 
approaches O 
in O 
mapping O 
chromatin O 
modification O 
of O 
specific O 
PMTs O 
, O 
we O 
have O 
engineered O 
the O 
chromatin O 
- O 
modifying O 
apparatus O 
and O 
formulated O 
a O 
novel O 
technology O 
, O 
termed O 
clickable O 
chromatin O 
enrichment O 
with O 
parallel O 
DNA O 
sequencing O 
( O 
CliEn-seq O 
) O 
, O 
to O 
probe O 
genome O 
- O 
wide O 
chromatin O 
modification O 
within O 
living O 
cells O 
. O 
The O 
three O 
- O 
step O 
approach O 
of O 
CliEn-seq O 
involves O 
in O 
vivo O 
synthesis O 
of O 
S-adenosyl-L-methionine B-TRIVIAL 
( O 
SAM B-ABBREVIATION 
) O 
analogues O 
from O 
cell O 
- O 
permeable O 
methionine B-TRIVIAL 
analogues O 
by O 
engineered O 
SAM B-ABBREVIATION 
synthetase O 
( O 
methionine B-TRIVIAL 
adenosyltransferase O 
or O 
MAT O 
) O 
, O 
in O 
situ O 
chromatin O 
modification O 
by O 
engineered O 
PMTs O 
, O 
subsequent O 
enrichment O 
and O 
sequencing O 
of O 
the O 
uniquely O 
modified O 
chromatins O 
. O 
Given O 
critical O 
roles O 
of O 
the O 
chromatin O 
- O 
modifying O 
enzymes O 
in O 
epigenetics O 
and O 
structural O 
similarity O 
among O 
many O 
PMTs O 
, O 
we O 
envision O 
that O 
the O 
CliEn-seq O 
technology O 
is O 
generally O 
applicable O 
in O 
deciphering O 
chromatin O 
methylation O 
events O 
of O 
individual O 
PMTs O 
in O 
diverse O 
biological O 
settings O 
. O 

of O 
an O 
apoptotic O 
signal O 
transduction O 
pathway O 
involved O 
in O 
the O 
upregulation O 
of O 
calpain O 
and O 
apoptosis O 
- O 
inducing O 
factor O 
in O 
aldosterone B-TRIVIAL 
-induced O 
primary O 
cultured O 
cardiomyocytes O 
. O 

this O 
study O 
, O 
aldosterone B-TRIVIAL 
( O 
ALD B-ABBREVIATION 
)-induced O 
apoptosis O 
of O 
cardiomyocyte O 
was O 
evaluated O 
based O 
on O 
the O 
previous O 
studies O 
, O 
and O 
the O 
roles O 
of O 
calpain O 
signaling O 
were O 
clarified O 
. O 
Primary O 
cultured O 
rat O 
cardiomyocytes O 
were O 
injured O 
by O 
ALD B-ABBREVIATION 
( O 
0.01-10 O 
μM O 
) O 
for O 
varying O 
time O 
periods O 
. O 
Then O 
, O 
the O 
effects O 
of O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
tetraacetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EGTA B-ABBREVIATION 
) O 
( O 
0.5 O 
mM O 
) O 
, O 
calpeptin B-TRIVIAL 
( O 
2.5 O 
μM O 
) O 
, O 
and O 
spironoclactone B-TRIVIAL 
( O 
10 O 
μM O 
) O 
were O 
evaluated O 
on O 
cardiomyocytes O 
activated O 
by O 
ALD B-ABBREVIATION 
. O 
Cardiomyocytes O 
that O 
were O 
injured O 
by O 
ALD B-ABBREVIATION 
were O 
assayed O 
by O 
the O 
MTT B-ABBREVIATION 
and O 
LDH O 
leakage O 
ratio O 
. O 
Apoptosis O 
was O 
evaluated O 
by O 
a O 
TUNEL O 
assay O 
, O 
annexin O 
V O 
/ O 
PI O 
staining O 
, O 
and O 
caspase-3 O 
activity O 
. O 
The O 
expression O 
of O 
cleavage O 
of O 
Bid O 
( O 
tBid O 
) O 
, O 
calpain O 
and O 
apoptosis O 
- O 
inducing O 
factor O 
( O 
AIF O 
) O 
was O 
evaluated O 
by O 
western O 
blot O 
analysis O 
. O 
ALD B-ABBREVIATION 
increased O 
calpain O 
expression O 
and O 
caspase-3 O 
activity O 
and O 
promoted O 
Bid O 
cleavage O 
. O 
It O 
also O 
induced O 
the O 
release O 
of O 
AIF O 
from O 
mitochondria O 
into O 
the O 
cytosol O 
. O 
The O 
upregulation O 
of O 
calpain O 
, O 
tBid O 
and O 
caspase-3 O 
activity O 
were O 
further O 
inhibited O 
by O 
treatment O 
with O 
EGTA B-ABBREVIATION 
in O 
the O 
presence O 
of O 
ALD B-ABBREVIATION 
. O 
Additionally O 
, O 
AIF O 
levels O 
in O 
the O 
cytosol O 
decreased O 
due O 
to O 
EGTA B-ABBREVIATION 
but O 
not O 
due O 
to O 
calpeptin B-TRIVIAL 
. O 
This O 
was O 
also O 
accompanied O 
by O 
a O 
significant O 
decrease O 
in O 
apoptosis O 
. O 
Furthermore O 
, O 
treatment O 
with O 
spironoclactone B-TRIVIAL 
not O 
only O 
attenuated O 
the O 
pro O 
- O 
apoptotic O 
effect O 
of O 
ALD B-ABBREVIATION 
but O 
reversed O 
the O 
ALD B-ABBREVIATION 
-induced O 
increase O 
of O 
calpain O 
and O 
AIF O 
levels O 
. O 

homeodomain O 
transcription O 
factor O 
Pitx3 O 
is O 
critical O 
for O 
the O 
survival O 
of O 
midbrain O 
dopaminergic O 
( O 
mDA O 
) O 
neurons O 
. O 
Pitx3-deficient O 
mice O 
exhibit O 
severe O 
but O 
selective O 
developmental O 
loss O 
of O 
mDA O 
neurons O 
, O 
with O 
accompanying O 
locomotor O 
deficits O 
resembling O 
those O 
seen O 
in O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
models O 
. O 
Here O 
, O 
we O 
identify O 
specific O 
mDA O 
cell O 
subpopulations O 
that O 
are O 
consistently O 
spared O 
in O 
adult O 
Pitx3-hypomorphic O 
( O 
aphakia O 
) O 
mice O 
, O 
demonstrating O 
that O 
Pitx3 O 
is O 
not O 
indiscriminately O 
required O 
by O 
all O 
mDA O 
neurons O 
for O 
their O 
survival O 
. O 
In O 
aphakia O 
mice O 
, O 
virtually O 
all O 
surviving O 
mDA O 
neurons O 
in O 
the O 
substantia O 
nigra O 
( O 
SN O 
) O 
and O 
the O 
majority O 
of O 
neurons O 
in O 
the O 
adjacent O 
ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
also O 
express O 
calbindin-D28k O 
, O 
a O 
calcium B-SYSTEMATIC 
-binding O 
protein O 
previously O 
associated O 
with O 
resistance O 
to O 
injury O 
in O 
PD O 
and O 
in O 
animal O 
models O 
. O 
Cell O 
- O 
mapping O 
studies O 
in O 
wild O 
- O 
type O 
mice O 
revealed O 
that O 
Pitx3 O 
is O 
primarily O 
expressed O 
in O 
the O 
ventral O 
SN O 
, O 
a O 
region O 
particularly O 
susceptible O 
to O 
MPTP B-ABBREVIATION 
and O 
other O 
dopaminergic O 
neurotoxins O 
. O 
Furthermore O 
, O 
Pitx3-expressing O 
SN O 
cells O 
are O 
preferentially O 
lost O 
following O 
MPTP B-ABBREVIATION 
treatment O 
. O 
Finally O 
, O 
SN O 
mDA O 
neurons O 
in O 
Pitx3 O 
hemizygous O 
mice O 
show O 
increased O 
sensitivity O 
when O 
exposed O 
to O 
MPTP B-ABBREVIATION 
. O 
Thus O 
, O 
SN O 
mDA O 
neurons O 
are O 
represented O 
by O 
at O 
least O 
two O 
distinct O 
subpopulations O 
including O 
MPTP B-ABBREVIATION 
-resistant O 
Pitx3-autonomous O 
, O 
calbindin O 
- O 
positive O 
neurons O 
, O 
and O 
calbindin O 
- O 
negative O 
Pitx-3-dependent O 
cells O 
that O 
display O 
elevated O 
vulnerability O 
to O 
toxic O 
injury O 
, O 
and O 
probably O 
correspond O 
to O 
the O 
subpopulation O 
that O 
degenerates O 
in O 
PD O 
. O 
Impairment O 
of O 
Pitx3-dependent O 
pathways O 
therefore O 
increases O 
vulnerability O 
of O 
mDA O 
neurons O 
to O 
toxic O 
injury O 
. O 
Together O 
, O 
these O 
data O 
suggest O 
a O 
novel O 
link O 
between O 
Pitx3 O 
function O 
and O 
the O 
selective O 
pattern O 
of O 
mDA O 
cell O 
loss O 
observed O 
in O 
PD O 
. O 

D I-FAMILY 
metabolism O 
in O 
human O 
bone O 
marrow O 
stromal O 
( O 
mesenchymal O 
stem O 
) O 
cells O 
. O 

are O 
many O 
human O 
extra O 
- O 
renal O 
tissues O 
and O 
cells O 
that O 
biosynthesize O 
1α,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
1α,25(OH)(2)D B-SYSTEMATIC 
) O 
by O 
the O 
action O 
of O 
CYP27B1 O 
/ O 
1α-hydroxylase O 
. O 
Human O 
marrow O 
stromal O 
cells O 
( O 
hMSCs O 
) O 
, O 
also O 
known O 
as O 
mesenchymal O 
stem O 
cells O 
, O 
were O 
isolated O 
from O 
marrow O 
discarded O 
from O 
well O 
- O 
characterized O 
, O 
consented O 
subjects O 
during O 
common O 
orthopedic O 
procedures O 
. O 
Human O 
MSCs O 
can O 
give O 
rise O 
to O 
osteoblasts O 
, O 
chondrocytes O 
, O 
adipocytes O 
, O 
and O 
other O 
lineages O 
. O 
Their O 
in O 
vitro O 
differentiation O 
to O 
osteoblasts O 
is O 
stimulated O 
by O 
1α,25(OH)(2)D B-SYSTEMATIC 
, O 
and O 
recent O 
evidence O 
indicates O 
that O 
they O 
have O 
the O 
capacity O 
to O 
metabolize O 
vitamin B-FAMILY 
D I-FAMILY 
in O 
a O 
regulated O 
manner O 
. O 
Human O 
MSCs O 
express O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
, O 
25-hydroxylases O 
, O 
1α-hydroxylase O 
, O 
and O 
24-hydroxylase O 
; O 
stimulation O 
of O 
in O 
vitro O 
osteoblastogenesis O 
by O 
25(OH)D B-SYSTEMATIC 
depends O 
on O 
the O 
activity O 
of O 
CYP27B1 O 
/ O 
1α-hydroxylase O 
. O 
The O 
finding O 
that O 
hMSCs O 
are O 
a O 
both O 
a O 
producer O 
and O 
target O 
of O 
1α,25(OH)(2)D B-SYSTEMATIC 
suggests O 
a O 
potential O 
autocrine O 
/ O 
paracrine O 
role O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
metabolism O 
in O 
osteoblast O 
differentiation O 
. O 
Expression O 
and O 
enzyme O 
activity O 
of O 
CYP27B1 O 
/ O 
1α-hydroxylase O 
are O 
upregulated O 
by O 
substrate O 
25(OH)D B-SYSTEMATIC 
and O 
Parathyroid O 
Hormone O 
( O 
PTH O 
) O 
and O 
are O 
downregulated O 
by O 
1α,25(OH)(2)D B-SYSTEMATIC 
. O 
With O 
subject O 
age O 
, O 
there O 
are O 
decreases O 
in O 
basal O 
osteoblast O 
potential O 
and O 
in O 
stimulation O 
of O 
osteoblastogenesis O 
by O 
1α,25(OH)(2)D B-SYSTEMATIC 
, O 
25(OH)D B-SYSTEMATIC 
, O 
and O 
PTH O 
. O 
In O 
vitro O 
treatment O 
with O 
a O 
combination O 
of O 
25(OH)D B-SYSTEMATIC 
and O 
PTH O 
rejuvenated O 
osteoblastogenesis O 
with O 
hMSCs O 
from O 
elders O 
; O 
this O 
was O 
attributable O 
to O 
increases O 
in O 
CYP27B1 O 
/ O 
1α-hydroxylase O 
and O 
in O 
receptor O 
for O 
each O 
hormone O 
by O 
the O 
reciprocal O 
factor O 
. O 
Other O 
clinical O 
variables O 
beside O 
age O 
, O 
i.e O 
. O 
low O 
serum O 
25(OH)D B-SYSTEMATIC 
or O 
low O 
estimated O 
glomerular O 
filtration O 
rate O 
, O 
are O 
correlated O 
with O 
reduced O 
osteoblastogenesis O 
. O 
These O 
studies O 
suggest O 
that O 
osteoblastogenesis O 
may O 
not O 
be O 
optimal O 
unless O 
there O 
is O 
sufficient O 
serum O 
25(OH)D B-SYSTEMATIC 
substrate O 
for O 
hMSCs O 
to O 
synthesize O 
and O 
respond O 
to O 
local O 
1α,25(OH)(2)D B-SYSTEMATIC 
. O 

pharmacokinetic O 
/ O 
pharmacodynamic O 
modeling O 
to O 
assist O 
dosing O 
schedule O 
selection O 
for O 
dovitinib B-TRIVIAL 
. O 

is O 
an O 
oral O 
multitargeted O 
kinase O 
inhibitor O 
with O 
potent O 
activity O 
against O 
receptors O 
for O 
vascular O 
endothelial O 
growth O 
factor O 
, O 
platelet O 
- O 
derived O 
growth O 
factor O 
, O 
and O 
basic O 
fibroblast O 
growth O 
factor O 
. O 
Initial O 
phase O 
1 O 
to O 
2 O 
studies O 
of O 
dovitinib B-TRIVIAL 
using O 
a O 
continuous O 
daily O 
dosing O 
schedule O 
has O 
shown O 
that O 
dovitinib B-TRIVIAL 
exhibits O 
a O 
prolonged O 
and O 
overproportional O 
increase O 
in O 
dose O 
and O 
exposure O 
relationship O 
above O 
400 O 
mg O 
/ O 
d O 
. O 
To O 
address O 
this O 
, O 
intermittent O 
dosing O 
schedules O 
were O 
explored O 
using O 
a O 
model O 
- O 
based O 
approach O 
. O 
A O 
semi-mechanistic O 
population O 
pharmcokinetic O 
/ O 
pharmacodynamic O 
( O 
PD O 
) O 
model O 
was O 
developed O 
from O 
4 O 
dovitinib B-TRIVIAL 
phase O 
1 O 
studies O 
with O 
daily O 
dosing O 
schedules O 
. O 
Autoinduction O 
of O 
cytochrome O 
P450 O 
1A O 
( O 
CYP1A O 
) O 
responsible O 
for O 
dovitinib B-TRIVIAL 
metabolism O 
was O 
described O 
using O 
an O 
indirect O 
response O 
model O 
. O 
Simulation O 
of O 
dovitinib B-TRIVIAL 
plasma O 
concentration O 
profiles O 
following O 
4 O 
intermittent O 
dosing O 
schedules O 
suggested O 
that O 
intermittent O 
dosing O 
could O 
prevent O 
prolonged O 
drug O 
accumulation O 
. O 
Based O 
on O 
the O 
simulated O 
plasma O 
profiles O 
, O 
PD O 
response O 
, O 
and O 
patient O 
compliance O 
, O 
a O 
5-days- O 
on O 
/ O 
2-days- O 
off O 
intermittent O 
dosing O 
schedule O 
was O 
selected O 
for O 
a O 
phase O 
1 O 
to O 
2 O 
clinical O 
study O 
. O 
The O 
observed O 
dovitinib B-TRIVIAL 
plasma O 
concentrations O 
in O 
this O 
study O 
confirmed O 
the O 
model O 
predictions O 
. O 
Furthermore O 
, O 
dovitinib B-TRIVIAL 
was O 
well O 
tolerated O 
, O 
and O 
antitumor O 
activity O 
was O 
observed O 
as O 
well O 
in O 
this O 
new O 
study O 
. O 
The O 
5-days- O 
on O 
/ O 
2-days- O 
off O 
dosing O 
schedule O 
is O 
currently O 
used O 
in O 
a O 
dovitinib B-TRIVIAL 
registration O 
trial O 
and O 
other O 
clinical O 
trials O 
. O 

improves O 
cardiomyopathy O 
in O 
dystrophin O 
- O 
deficient O 
mice O 
through O 
SIRT1 O 
protein O 
- O 
mediated O 
modulation O 
of O 
p300 O 
protein O 
. O 

is O 
the O 
main O 
cause O 
of O 
death O 
in O 
Duchenne O 
muscular O 
dystrophy O 
. O 
Here O 
, O 
we O 
show O 
that O 
oral O 
administration O 
of O 
resveratrol B-TRIVIAL 
, O 
which O 
leads O 
to O 
activation O 
of O 
an O 
NAD(+) B-ABBREVIATION 
-dependent O 
protein O 
deacetylase O 
SIRT1 O 
, O 
suppresses O 
cardiac O 
hypertrophy O 
and O 
fibrosis O 
and O 
restores O 
cardiac O 
diastolic O 
function O 
in O 
dystrophin O 
- O 
deficient O 
mdx O 
mice O 
. O 
The O 
pro O 
- O 
hypertrophic O 
co O 
- O 
activator O 
p300 O 
protein O 
but O 
not O 
p300 O 
mRNA O 
was O 
up O 
- O 
regulated O 
in O 
the O 
mdx O 
heart O 
, O 
and O 
resveratrol B-TRIVIAL 
administration O 
down O 
- O 
regulated O 
the O 
p300 O 
protein O 
level O 
. O 
In O 
cultured O 
cardiomyocytes O 
, O 
cardiomyocyte O 
hypertrophy O 
induced O 
by O 
the O 
α(1)-agonist O 
phenylephrine B-TRIVIAL 
was O 
inhibited O 
by O 
the O 
overexpression O 
of O 
SIRT1 O 
as O 
well O 
as O 
resveratrol B-TRIVIAL 
, O 
both O 
of O 
which O 
down O 
- O 
regulated O 
p300 O 
protein O 
levels O 
but O 
not O 
p300 O 
mRNA O 
levels O 
. O 
In O 
addition O 
, O 
activation O 
of O 
atrial O 
natriuretic O 
peptide O 
promoter O 
by O 
p300 O 
was O 
inhibited O 
by O 
SIRT1 O 
. O 
We O 
found O 
that O 
SIRT1 O 
induced O 
p300 O 
down O 
- O 
regulation O 
via O 
the O 
ubiquitin O 
- O 
proteasome O 
pathway O 
by O 
deacetylation O 
of O 
lysine B-TRIVIAL 
residues O 
for O 
ubiquitination O 
. O 
These O 
findings O 
indicate O 
the O 
pathological O 
significance O 
of O 
p300 O 
up O 
- O 
regulation O 
in O 
the O 
dystrophic O 
heart O 
and O 
indicate O 
that O 
SIRT1 O 
activation O 
has O 
therapeutic O 
potential O 
for O 
dystrophic O 
cardiomyopathy O 
. O 

, O 
CYP2C19 O 
, O 
and O 
a O 
Black O 
Box O 
. O 

has O 
been O 
presumed O 
that O 
CYP2C19 O 
has O 
a O 
major O 
role O 
in O 
the O 
metabolism O 
of O 
clopidogrel B-TRIVIAL 
. O 
This O 
presumption O 
has O 
been O 
based O 
on O 
in O 
vitro O 
drug O 
metabolism O 
studies O 
using O 
microsomes O 
from O 
baculovirus O 
infected O 
insect O 
cells O 
( O 
BD-Supersomes O 
™ O 
) O 
. O 
If O 
clopidogrel B-TRIVIAL 
were O 
primarily O 
a O 
CYP2C19 O 
substrate O 
, O 
a O 
drug O 
/ O 
drug O 
interaction O 
with O 
CYP2C19 O 
inhibitors O 
, O 
such O 
as O 
proton O 
pump O 
inhibitors O 
( O 
PPIs O 
) O 
, O 
for O 
example O 
, O 
omeprazole B-TRIVIAL 
and O 
lansoprazole B-TRIVIAL 
would O 
be O 
anticipated O 
. O 
Several O 
ex O 
vivo O 
studies O 
, O 
using O 
ADP B-ABBREVIATION 
stimulated O 
platelet O 
aggregation O 
, O 
suggested O 
that O 
there O 
was O 
such O 
an O 
interaction O 
. O 
The O 
data O 
from O 
these O 
studies O 
served O 
as O 
a O 
basis O 
for O 
FDA O 
to O 
provide O 
a O 
" O 
Black O 
Box O 
" O 
warning O 
for O 
the O 
clopidogrel B-TRIVIAL 
label O 
in O 
March O 
of O 
2010 O 
. O 
However O 
, O 
a O 
prospective O 
clinical O 
study O 
, O 
COGENT O 
, O 
and O 
several O 
large O 
meta-analyses O 
have O 
failed O 
to O 
demonstrate O 
a O 
negative O 
effect O 
on O 
major O 
adverse O 
cardiovascular O 
events O 
( O 
MACE O 
) O 
, O 
with O 
concomitant O 
administration O 
of O 
clopidogrel B-TRIVIAL 
and O 
PPIs O 
. O 
The O 
in O 
vitro O 
work O 
using O 
" O 
Supersomes O 
" O 
was O 
revisited O 
. O 
In O 
vitro O 
metabolism O 
using O 
hepatosomes O 
, O 
which O 
resemble O 
the O 
native O 
cytochrome O 
P-450 O 
enzyme O 
expression O 
, O 
has O 
confirmed O 
the O 
earlier O 
work O 
that O 
clopidogrel B-TRIVIAL 
is O 
primarily O 
a O 
CYP3A O 
substrate O 
. O 
This O 
result O 
correlates O 
better O 
with O 
clinical O 
findings O 
. O 
The O 
absence O 
of O 
an O 
increase O 
in O 
MACE O 
by O 
concomitant O 
administration O 
of O 
PPIs O 
, O 
which O 
are O 
CYP2C19 O 
inhibitors O 
, O 
to O 
a O 
regimen O 
including O 
clopidogrel B-TRIVIAL 
, O 
is O 
therefore O 
not O 
surprising O 
. O 
A O 
hypothesis O 
is O 
offered O 
to O 
explain O 
why O 
subjects O 
, O 
who O 
carry O 
two O 
reduced O 
function O 
alleles O 
of O 
CYP2C19 O 
, O 
may O 
have O 
more O 
reactive O 
platelets O 
. O 

analysis O 
of O 
the O 
interaction O 
of O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
with O 
chemicals O 
and O 
steroid B-FAMILY 
receptor O 
coactivator O 
1 O 
using O 
surface O 
plasmon O 
resonance O 
biosensor O 
systems O 
: O 
a O 
case O 
study O 
of O 
the O 
Baikal O 
seal O 
( O 
Pusa O 
sibirica O 
) O 
and O 
the O 
mouse O 
. O 

constitutive O 
androstane B-TRIVIAL 
receptor O 
( O 
CAR O 
) O 
not O 
only O 
displays O 
a O 
high O 
basal O 
transcriptional O 
activity O 
but O 
also O 
acts O 
as O 
a O 
ligand O 
- O 
dependent O 
transcriptional O 
factor O 
. O 
It O 
is O 
known O 
that O 
CAR O 
exhibits O 
different O 
ligand O 
profiles O 
across O 
species O 
. O 
However O 
, O 
the O 
mechanisms O 
underlying O 
CAR O 
activation O 
by O 
chemicals O 
and O 
the O 
species O 
- O 
specific O 
responses O 
are O 
not O 
fully O 
understood O 
. O 
The O 
objectives O 
of O 
this O 
study O 
are O 
to O 
establish O 
a O 
high O 
- O 
throughput O 
tool O 
to O 
screen O 
CAR O 
ligands O 
and O 
to O 
clarify O 
how O 
CAR O 
proteins O 
from O 
the O 
Baikal O 
seal O 
( O 
bsCAR O 
) O 
and O 
the O 
mouse O 
( O 
mCAR O 
) O 
interact O 
with O 
chemicals O 
and O 
steroid B-FAMILY 
receptor O 
coactivator O 
1 O 
( O 
SRC1 O 
) O 
. O 
We O 
developed O 
the O 
surface O 
plasmon O 
resonance O 
( O 
SPR O 
) O 
system O 
to O 
assess O 
quantitatively O 
the O 
interaction O 
of O 
CAR O 
with O 
potential O 
ligands O 
and O 
SRC1 O 
. O 
The O 
ligand O 
- O 
binding O 
domain O 
( O 
LBD O 
) O 
of O 
bsCAR O 
and O 
mCAR O 
was O 
synthesized O 
in O 
a O 
wheat O 
germ O 
cell O 
- O 
free O 
system O 
. O 
The O 
purified O 
CAR O 
LBD O 
was O 
then O 
immobilized O 
on O 
the O 
sensor O 
chip O 
for O 
the O 
SPR O 
assay O 
, O 
and O 
the O 
kinetics O 
of O 
direct O 
interaction O 
of O 
CARs O 
with O 
ligand O 
candidates O 
was O 
measured O 
. O 
Androstanol B-TRIVIAL 
and O 
androstenol B-TRIVIAL 
, O 
estrone B-TRIVIAL 
, O 
17β-estradiol B-SYSTEMATIC 
, O 
TCPOBOP B-TRIVIAL 
, O 
and O 
CITCO B-ABBREVIATION 
showed O 
compound O 
- O 
specific O 
but O 
similar O 
affinities O 
for O 
both O 
CARs O 
. O 
The O 
CAR-SRC1 O 
interaction O 
was O 
ligand O 
dependent O 
but O 
exhibited O 
a O 
different O 
ligand O 
profile O 
between O 
the O 
seal O 
and O 
the O 
mouse O 
. O 
The O 
results O 
of O 
SRC1 O 
interaction O 
assay O 
accounted O 
for O 
those O 
of O 
our O 
previous O 
in O 
vitro O 
CAR O 
- O 
mediated O 
transactivation O 
assay O 
. O 
In O 
silico O 
analyses O 
also O 
supported O 
the O 
results O 
of O 
CAR-SRC1 O 
interaction O 
; O 
there O 
is O 
little O 
structural O 
difference O 
in O 
the O 
ligand O 
- O 
binding O 
pocket O 
of O 
bsCAR O 
and O 
mCAR O 
, O 
but O 
there O 
is O 
a O 
distinct O 
discrimination O 
in O 
the O 
helix O 
11 O 
and O 
12 O 
of O 
these O 
receptors O 
, O 
suggesting O 
that O 
the O 
interaction O 
of O 
ligand O 
- O 
bound O 
CAR O 
and O 
SRC1 O 
is O 
critical O 
for O 
determining O 
species O 
- O 
specific O 
and O 
ligand O 
- O 
dependent O 
transactivation O 
over O 
the O 
basal O 
activity O 
. O 
The O 
SPR O 
assays O 
demonstrated O 
a O 
potential O 
as O 
a O 
high O 
- O 
throughput O 
screening O 
tool O 
of O 
CAR O 
ligands O 
. O 

work O 
elucidates O 
the O 
possible O 
reasons O 
for O 
the O 
outstanding O 
, O 
but O 
never O 
reproduced O 
thermoelectric O 
properties O 
of O 
the O 
doped O 
Ti(0.5)Zr(0.25)Hf(0.25)NiSn B-FORMULA 
Heusler O 
compounds O 
. O 
The O 
structural O 
investigations O 
done O 
via O 
synchrotron O 
X-ray O 
diffraction O 
measurements O 
and O 
scanning O 
electron O 
microscope O 
measurements O 
, O 
which O 
clearly O 
show O 
that O 
the O 
microstructure O 
consists O 
of O 
three O 
temperature O 
stable O 
C1(b) O 
phases O 
with O 
possible O 
semi-coherent O 
interfaces O 
, O 
are O 
presented O 
. O 
The O 
exceptional O 
thermoelectric O 
properties O 
are O 
due O 
to O 
this O 
intrinsic O 
phase O 
separation O 
. O 
It O 
is O 
possible O 
to O 
reproduce O 
the O 
high O 
Figure O 
of O 
Merit O 
values O 
with O 
ZT O 
= O 
1.2 O 
at O 
830 O 
K O 
. O 
Furthermore O 
, O 
the O 
influence O 
of O 
doping O 
different O 
elements O 
on O 
the O 
Sn B-FORMULA 
position O 
in O 
this O 
Heusler O 
material O 
system O 
is O 
investigated O 
. O 

- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
increases O 
the O 
excitability O 
of O 
hippocampal O 
CA1 O 
neurons O 
through O 
inhibition O 
of O 
potassium B-SYSTEMATIC 
channels O 
in O 
rat's O 
brain O 
slices O 
. O 

study O 
was O 
to O 
investigate O 
the O 
neurotoxicity O 
of O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
MWCNT O 
) O 
by O 
measuring O 
neuronal O 
excitability O 
in O 
rat O 
hippocampal O 
neurons O 
and O 
exploring O 
the O 
underlying O 
mechanism O 
. O 
Whole O 
cell O 
patch O 
- O 
clamp O 
technique O 
was O 
used O 
. O 
Action O 
potential O 
properties O 
and O 
the O 
pattern O 
of O 
repetitive O 
firing O 
rate O 
were O 
assessed O 
. O 
Our O 
data O 
showed O 
that O 
spike O 
half O 
- O 
width O 
and O 
repetitive O 
firing O 
rate O 
were O 
significantly O 
increased O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Furthermore O 
, O 
voltage O 
- O 
activated O 
potassium B-SYSTEMATIC 
currents O 
were O 
recorded O 
. O 
It O 
was O 
found O 
that O 
MWCNT O 
produced O 
a O 
concentration O 
- O 
dependent O 
inhibition O 
in O 
amplitudes O 
of O 
I(A) O 
and O 
I( O 
K B-FORMULA 
) O 
. O 
In O 
addition O 
, O 
MWCNT O 
had O 
effect O 
on O 
the O 
activation O 
kinetics O 
of O 
I(A) O 
and O 
I( O 
K B-FORMULA 
) O 
with O 
V(h) O 
being O 
shifted O 
to O 
the O 
negative O 
potential O 
at O 
high O 
concentration O 
, O 
while O 
I(A) O 
inactivation O 
curve O 
was O 
considerably O 
shifted O 
to O 
the O 
hyperpolarize O 
potential O 
with O 
V(h) O 
being O 
increased O 
. O 
However O 
, O 
no O 
effect O 
was O 
found O 
on O 
the O 
recovery O 
from O 
inactivation O 
of O 
I(A) O 
. O 
The O 
results O 
suggest O 
that O 
MWCNT O 
increases O 
the O 
excitability O 
of O 
hippocampal O 
CA1 O 
neurons O 
by O 
inhibiting O 
voltage O 
- O 
gated O 
potassium B-SYSTEMATIC 
current O 
. O 

derivatives O 
with O 
cytotoxicity O 
from O 
the O 
fungus O 
Penicillium O 
commune O 
. O 

new O 
cyclohexanone B-SYSTEMATIC 
derivatives O 
( O 
2-5 O 
) O 
and O 
one O 
known O 
analog O 
, O 
(-)-Palitantin B-TRIVIAL 
( O 
1 O 
) O 
were O 
isolated O 
from O 
the O 
EtOAc B-FORMULA 
extract O 
of O 
Penicillium O 
commune O 
, O 
a O 
fungal O 
strain O 
of O 
low O 
- O 
temperature O 
habitats O 
. O 
The O 
structures O 
of O 
2-5 O 
were O 
determined O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
. O 
Furthermore O 
, O 
the O 
absolute O 
configuration O 
of O 
2 O 
was O 
assigned O 
by O 
electronic O 
circular O 
dichroism O 
( O 
ECD O 
) O 
calculations O 
, O 
whereas O 
that O 
3-5 O 
were O 
deduced O 
via O 
the O 
CD O 
data O 
. O 
Cytotoxicities O 
of O 
2-5 O 
against O 
five O 
human O 
carcinoma O 
cell O 
lines O 
( O 
Hela O 
, O 
A549 O 
, O 
MCF7 O 
, O 
HCT116 O 
, O 
T24 O 
) O 
were O 
evaluated O 
. O 

of O 
10-Hydroxycamptothecin B-SYSTEMATIC 
with O 
Doxorubicin B-TRIVIAL 
Conjugated O 
Prodrugs O 
for O 
Enhanced O 
Anticancer O 
Efficacy O 
. O 

- O 
defined O 
amphiphilic O 
linear O 
- O 
dendritic O 
prodrugs O 
( O 
MPEG-b-PAMAM-DOX B-ABBREVIATION 
) O 
are O 
synthesized O 
by O 
conjugating O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
, O 
to O 
MPEG-b-PAMAM B-ABBREVIATION 
through O 
the O 
acid O 
- O 
labile O 
hydrazone B-FAMILY 
bond O 
. O 
The O 
amphiphilic O 
prodrugs O 
form O 
self O 
- O 
assembled O 
nanoparticles O 
in O 
deionized O 
water O 
and O 
encapsulate O 
the O 
hydrophobic O 
anticancer O 
drug O 
10-hydroxycamptothecin B-SYSTEMATIC 
( O 
HCPT B-ABBREVIATION 
) O 
with O 
a O 
high O 
drug O 
loading O 
efficiency O 
. O 
Studies O 
on O 
drug O 
release O 
and O 
cellular O 
uptake O 
of O 
the O 
co O 
- O 
delivery O 
system O 
reveal O 
that O 
both O 
drugs O 
are O 
released O 
in O 
a O 
pH-dependent O 
manner O 
and O 
effectively O 
taken O 
up O 
by O 
MCF-7 O 
cells O 
. O 
In O 
vitro O 
methyl B-SYSTEMATIC 
thiazolyl I-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assays O 
and O 
drug O 
- O 
induced O 
apoptosis O 
tests O 
demonstrate O 
the O 
HCPT B-ABBREVIATION 
-loaded O 
nanoparticles O 
suppress O 
cancer O 
cell O 
growth O 
more O 
efficiently O 
than O 
the O 
MPEG-b-PAMAM-DOX B-ABBREVIATION 
prodrugs O 
, O 
free O 
HCPT B-ABBREVIATION 
, O 
and O 
physical O 
mixtures O 
of O 
MPEG-b-PAMAM-DOX B-ABBREVIATION 
and O 
HCPT B-ABBREVIATION 
at O 
equivalent O 
DOX B-ABBREVIATION 
or O 
HCPT B-ABBREVIATION 
doses O 
. O 

sequence O 
- O 
specific O 
transcription O 
factor O 
NF-Y O 
binds O 
the O 
CCAAT O 
box O 
, O 
one O 
of O 
the O 
sequence O 
elements O 
most O 
frequently O 
found O 
in O 
eukaryotic O 
promoters O 
. O 
NF-Y O 
is O 
composed O 
of O 
the O 
NF-YA O 
and O 
NF-YB O 
/ O 
NF-YC O 
subunits O 
, O 
the O 
latter O 
two O 
hosting O 
histone O 
- O 
fold O 
domains O 
( O 
HFDs O 
) O 
. O 
The O 
crystal O 
structure O 
of O 
NF-Y O 
bound O 
to O 
a O 
25 O 
bp O 
CCAAT O 
oligonucleotide O 
shows O 
that O 
the O 
HFD O 
dimer O 
binds O 
to O 
the O 
DNA O 
sugar B-FAMILY 
- O 
phosphate B-SYSTEMATIC 
backbone O 
, O 
mimicking O 
the O 
nucleosome O 
H2A O 
/ O 
H2B-DNA O 
assembly O 
. O 
NF-YA O 
both O 
binds O 
to O 
NF-YB O 
/ O 
NF-YC O 
and O 
inserts O 
an O 
α O 
helix O 
deeply O 
into O 
the O 
DNA O 
minor O 
groove O 
, O 
providing O 
sequence O 
- O 
specific O 
contacts O 
to O 
the O 
CCAAT O 
box O 
. O 
Structural O 
considerations O 
and O 
mutational O 
data O 
indicate O 
that O 
NF-YB O 
ubiquitination O 
at O 
Lys B-FORMULA 
138 O 
precedes O 
and O 
is O 
equivalent O 
to O 
H2B O 
Lys B-FORMULA 
120 O 
monoubiquitination O 
, O 
important O 
in O 
transcriptional O 
activation O 
. O 
Thus O 
, O 
NF-Y O 
is O 
a O 
sequence O 
- O 
specific O 
transcription O 
factor O 
with O 
nucleosome O 
- O 
like O 
properties O 
of O 
nonspecific O 
DNA O 
binding O 
and O 
helps O 
establish O 
permissive O 
chromatin O 
modifications O 
at O 
CCAAT O 
promoters O 
. O 
Our O 
findings O 
suggest O 
that O 
other O 
HFD O 
- O 
containing O 
proteins O 
may O 
function O 
in O 
similar O 
ways O 
. O 

of O 
the O 
circulating O 
metabolites O 
for O 
a O 
new O 
chemical O 
entity O 
in O 
humans O 
is O 
essential O 
for O 
safety O 
assessment O 
, O 
an O 
understanding O 
of O 
their O 
contributions O 
to O 
pharmacologic O 
activities O 
, O 
and O 
their O 
potential O 
involvement O 
in O 
drug O 
- O 
drug O 
interactions O 
. O 
This O 
review O 
examines O 
the O 
abundance O 
of O 
metabolites O 
relative O 
to O 
the O 
total O 
parent O 
drug O 
[ O 
metabolite O 
- O 
to O 
- O 
parent O 
( O 
M O 
/ O 
P O 
) O 
ratio O 
] O 
from O 
125 O 
drugs O 
in O 
relation O 
to O 
their O 
structural O 
and O 
physicochemical O 
characteristics O 
, O 
lipoidal O 
permeability O 
, O 
protein O 
binding O 
, O 
and O 
fractional O 
formation O 
from O 
parent O 
( O 
fm O 
) O 
. O 
Our O 
analysis O 
suggests O 
that O 
fm O 
is O 
the O 
major O 
determinant O 
of O 
total O 
drug O 
M O 
/ O 
P O 
ratio O 
for O 
amine B-SYSTEMATIC 
, O 
alcohol B-FAMILY 
, O 
N- B-MULTIPLE 
and I-MULTIPLE 
S-oxide I-MULTIPLE 
, O 
and O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
metabolites O 
. O 
Passage O 
from O 
the O 
hepatocyte O 
to O 
systemic O 
circulation O 
does O 
not O 
appear O 
to O 
be O 
limiting O 
owing O 
to O 
the O 
vast O 
majority O 
of O 
metabolites O 
formed O 
being O 
relatively O 
lipid O 
permeable O 
. O 
In O 
some O 
cases O 
, O 
active O 
transport O 
plays O 
an O 
important O 
role O 
in O 
this O 
process O 
( O 
e.g O 
. O 
, O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
metabolites O 
) O 
. O 
Differences O 
in O 
total O 
parent O 
drug O 
clearance O 
and O 
metabolite O 
clearance O 
are O 
attenuated O 
by O 
the O 
reduction O 
in O 
lipophilicity O 
introduced O 
by O 
the O 
metabolic O 
step O 
and O 
resultant O 
compensatory O 
changes O 
in O 
unbound O 
clearance O 
and O 
protein O 
binding O 
. O 
A O 
small O 
subclass O 
of O 
these O 
drugs O 
( O 
e.g O 
. O 
, O 
terfenadine B-TRIVIAL 
) O 
is O 
unintentional O 
prodrugs O 
with O 
very O 
high O 
parent O 
drug O 
clearance O 
, O 
resulting O 
in O 
very O 
high O 
M O 
/ O 
P O 
ratios O 
. O 
In O 
contrast O 
, O 
arenol B-TRIVIAL 
metabolites O 
show O 
a O 
more O 
complex O 
relationship O 
with O 
fm O 
due O 
largely O 
to O 
the O 
new O 
metabolic O 
routes O 
( O 
conjugation O 
) O 
available O 
to O 
the O 
metabolite O 
compared O 
with O 
the O 
parent O 
drug O 
molecule O 
. O 
For O 
these O 
metabolites O 
, O 
a O 
more O 
thorough O 
understanding O 
of O 
the O 
elimination O 
clearance O 
of O 
the O 
metabolite O 
is O 
critical O 
to O 
discern O 
the O 
likelihood O 
of O 
whether O 
the O 
phenol B-SYSTEMATIC 
will O 
constitute O 
a O 
major O 
circulating O 
metabolite O 
. O 

dislocations O 
and O 
grain O 
boundaries O 
in O 
two O 
- O 
dimensional O 
metal B-FAMILY 
- I-FAMILY 
disulfides I-FAMILY 
from O 
the O 
first O 
principles O 
. O 

by O 
the O 
principles O 
of O 
dislocation O 
theory O 
, O 
we O 
use O 
the O 
first O 
- O 
principles O 
calculations O 
to O 
determine O 
the O 
structure O 
and O 
properties O 
of O 
dislocations O 
and O 
grain O 
boundaries O 
( O 
GB O 
) O 
in O 
single O 
- O 
layer O 
transition B-FAMILY 
metal I-FAMILY 
disulfides I-FAMILY 
MS(2) B-FAMILY 
( O 
M O 
= O 
Mo B-FORMULA 
or O 
W B-FORMULA 
) O 
. O 
In O 
sharp O 
contrast O 
to O 
other O 
two O 
- O 
dimensional O 
materials O 
( O 
truly O 
planar O 
graphene B-TRIVIAL 
and O 
h-BN B-ABBREVIATION 
) O 
, O 
here O 
the O 
edge O 
dislocations O 
extend O 
in O 
third O 
dimension O 
, O 
forming O 
concave O 
dreidel O 
- O 
shaped O 
polyhedra O 
. O 
They O 
include O 
different O 
number O 
of O 
homoelemental O 
bonds O 
and O 
, O 
by O 
reacting O 
with O 
vacancies O 
, O 
interstitials O 
, O 
and O 
atom O 
substitutions O 
, O 
yield O 
families O 
of O 
the O 
derivative O 
cores O 
for O 
each O 
Burgers O 
vector O 
. O 
The O 
overall O 
structures O 
of O 
GB O 
are O 
controlled O 
by O 
both O 
local O 
- O 
chemical O 
and O 
far O 
- O 
field O 
mechanical O 
energies O 
and O 
display O 
different O 
combinations O 
of O 
dislocation O 
cores O 
. O 
Further O 
, O 
we O 
find O 
two O 
distinct O 
electronic O 
behaviors O 
of O 
GB O 
. O 
Typically O 
, O 
their O 
localized O 
deep O 
- O 
level O 
states O 
act O 
as O 
sinks O 
for O 
carriers O 
but O 
at O 
large O 
60°-tilt O 
the O 
GB O 
become O 
metallic O 
. O 
The O 
analysis O 
shows O 
how O 
the O 
versatile O 
GB O 
in O 
MS(2) B-FAMILY 
( O 
if O 
carefully O 
engineered O 
) O 
should O 
enable O 
new O 
developments O 
for O 
electronic O 
and O 
opto O 
- O 
electronic O 
applications O 
. O 

of O 
5-benzyl-3-phenyl-4,5-dihydroisoxazoles B-FAMILY 
and O 
5-benzyl-3-phenyl-1,4,2-dioxazoles B-FAMILY 
as O 
potent O 
firefly O 
luciferase O 
inhibitors O 
. O 

reporter O 
assays O 
are O 
commonly O 
used O 
in O 
high O 
- O 
throughput O 
screening O 
methods O 
. O 
Here O 
, O 
we O 
report O 
new O 
firefly O 
luciferase O 
( O 
FLuc O 
) O 
inhibitors O 
based O 
on O 
5-benzyl-3-phenyl-4,5-dihydroisoxazoles B-FAMILY 
and O 
5-benzyl-3-phenyl-1,4,2-dioxazoles B-FAMILY 
, O 
which O 
showed O 
up O 
as O 
" O 
false O 
positives O 
" O 
in O 
a O 
luciferase O 
reporter O 
gene O 
- O 
based O 
assay O 
for O 
nuclear O 
receptor O 
antagonists O 
. O 
The O 
inhibition O 
was O 
shown O 
to O 
be O 
noncompetitive O 
for O 
both O 
natural O 
enzyme O 
substrates O 
( O 
d-luciferin B-TRIVIAL 
and O 
ATP B-ABBREVIATION 
) O 
and O 
selective O 
to O 
FLuc O 
and O 
proven O 
to O 
arise O 
from O 
a O 
direct O 
interaction O 
between O 
the O 
enzyme O 
and O 
the O 
inhibitor O 
. O 
Of O 
the O 
63 O 
evaluated O 
compounds O 
, O 
28 O 
showed O 
significantly O 
better O 
inhibition O 
potency O 
than O 
the O 
well O 
- O 
known O 
inhibitor O 
resveratrol B-TRIVIAL 
( O 
IC(50) O 
= O 
59 O 
nM O 
) O 
, O 
with O 
five O 
compounds O 
having O 
distinctly O 
subnanomolar O 
IC(50) O 
values O 
. O 
The O 
most O 
efficient O 
compounds O 
inhibited O 
the O 
luminescence O 
at O 
concentrations O 
lower O 
than O 
( O 
1 O 
) O 
/ O 
( O 
100 O 
) O 
in O 
comparison O 
to O 
resveratrol B-TRIVIAL 
( O 
lowest O 
IC(50) O 
= O 
0.26 O 
nM O 
) O 
and O 
can O 
thus O 
be O 
considered O 
to O 
belong O 
to O 
the O 
most O 
potent O 
FLuc O 
inhibitors O 
reported O 
thus O 
far O 
. O 
Overall O 
, O 
the O 
novel O 
inhibitors O 
form O 
a O 
unique O 
molecular O 
library O 
for O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
analyses O 
. O 

is O 
an O 
important O 
and O 
well O 
- O 
established O 
pharmaceutical O 
drying O 
process O 
. O 
Product O 
temperature O 
is O 
the O 
most O 
critical O 
process O 
parameter O 
during O 
lyophilization O 
as O 
it O 
impacts O 
both O 
product O 
quality O 
and O 
process O 
efficiency O 
. O 
Traditionally O 
, O 
thermocouples O 
( O 
TCs O 
) O 
or O 
resistance O 
temperature O 
detectors O 
( O 
RTDs O 
) O 
and O 
recently O 
, O 
manometric O 
temperatures O 
measurements O 
( O 
MTMs O 
) O 
have O 
been O 
used O 
to O 
monitor O 
the O 
product O 
temperature O 
. O 
But O 
, O 
all O 
of O 
these O 
techniques O 
have O 
several O 
drawbacks O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
the O 
implementation O 
and O 
evaluation O 
of O 
an O 
optical O 
fiber O 
system O 
as O 
novel O 
process O 
monitoring O 
tool O 
during O 
lyophilization O 
. O 
Therefore O 
, O 
temperature O 
profiles O 
of O 
mannitol B-TRIVIAL 
, O 
sucrose B-TRIVIAL 
, O 
or O 
trehalose B-TRIVIAL 
were O 
recorded O 
with O 
various O 
prototypes O 
of O 
the O 
optical O 
fiber O 
sensors O 
( O 
OFSs O 
) O 
and O 
compared O 
to O 
data O 
obtained O 
with O 
conventional O 
TCs O 
or O 
Pirani O 
/ O 
capacitance O 
manometry O 
with O 
respect O 
to O 
the O 
endpoint O 
of O 
primary O 
drying O 
. O 
The O 
OFS O 
allowed O 
easy O 
handling O 
and O 
easy O 
center O 
bottom O 
positioning O 
. O 
Data O 
obtained O 
with O 
the O 
OFS O 
in O 
contact O 
with O 
product O 
were O 
in O 
good O 
agreement O 
with O 
data O 
obtained O 
via O 
TCs O 
or O 
Pirani O 
/ O 
capacitance O 
manometry O 
. O 
The O 
OFSs O 
showed O 
significantly O 
higher O 
sensitivity O 
, O 
faster O 
response O 
, O 
and O 
better O 
resolution O 
compared O 
to O 
TCs O 
. O 
This O 
allowed O 
for O 
the O 
detection O 
of O 
additional O 
excipient O 
crystallization O 
events O 
. O 
It O 
was O 
found O 
that O 
force O 
effects O 
on O 
unshielded O 
sensors O 
enabled O 
to O 
detect O 
glass O 
transitions O 
. O 
Three O 
- O 
dimensional O 
temperature O 
profiles O 
were O 
obtained O 
with O 
an O 
OFS O 
helix O 
configuration O 
. O 
The O 
possible O 
integration O 
of O 
a O 
glass O 
fiber O 
with O 
several O 
OFSs O 
in O 
series O 
into O 
the O 
shelf O 
surface O 
enables O 
non-invasive O 
, O 
automatic O 
loading O 
compatible O 
monitoring O 
of O 
the O 
drying O 
process O 
. O 
In O 
conclusion O 
, O 
these O 
advantages O 
turn O 
the O 
novel O 
optical O 
fiber O 
systems O 
into O 
a O 
highly O 
attractive O 
process O 
monitoring O 
tool O 
during O 
lyophilization O 
. O 

new O 
iridoid B-FAMILY 
glycoside I-FAMILY 
and O 
potential O 
MRB O 
inhibitory O 
activity O 
of O 
isolated O 
compounds O 
from O 
the O 
rhizomes O 
of O 
Cyperus O 
rotundus O 
L O 
. O 

new O 
iridoid B-FAMILY 
glycoside I-FAMILY 
, O 
rotunduside B-TRIVIAL 
( O 
1 O 
) O 
, O 
along O 
with O 
four O 
known O 
iridoid B-FAMILY 
glycosides I-FAMILY 
, O 
10-O-p-hydroxybenzoyltheviridoside B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
10-O-vanilloyltheviridoside B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
6″-O-(trans-p-coumaroyl)-procumbide B-SYSTEMATIC 
( O 
4 O 
) O 
and O 
loganic B-TRIVIAL 
acid I-TRIVIAL 
( O 
5 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
rhizomes O 
of O 
Cyperus O 
rotundus O 
L O 
. O 
Their O 
chemical O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
UV O 
, O 
IR O 
, O 
MS O 
and O 
NMR O 
spectroscopic O 
analyses O 
. O 
In O 
addition O 
, O 
the O 
macrophages O 
respiratory O 
burst O 
( O 
MRB O 
) O 
inhibitory O 
activity O 
of O 
the O 
isolated O 
compounds O 
was O 
reported O 
. O 
Compound O 
2 O 
exhibited O 
considerable O 
MRB O 
inhibitory O 
activity O 
in O 
the O 
test O 
with O 
IC(50) O 
value O 
of O 
∼37 O 
μM O 
. O 

of O 
social O 
novelty O 
discrimination O 
by O 
positive O 
allosteric O 
modulators O 
at O 
metabotropic O 
glutamate B-TRIVIAL 
5 O 
receptors O 
: O 
adolescent O 
administration O 
prevents O 
adult O 
- O 
onset O 
deficits O 
induced O 
by O 
neonatal O 
treatment O 
with O 
phencyclidine B-TRIVIAL 
. O 

glutamate B-TRIVIAL 
-5 O 
receptors O 
( O 
mGluR5 O 
) O 
, O 
which O 
physically O 
and O 
functionally O 
interact O 
with O 
N-methyl-D-Aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptors O 
, O 
likewise O 
control O 
cognitive O 
processes O 
and O 
have O 
been O 
proposed O 
as O 
targets O 
for O 
novel O 
classes O 
of O 
antipsychotic O 
agent O 
. O 
Since O 
social O 
cognition O 
is O 
impaired O 
in O 
schizophrenia O 
and O 
disrupted O 
by O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
like O 
dizocilpine B-TRIVIAL 
, O 
we O 
evaluated O 
its O 
potential O 
modulation O 
by O 
mGluR5 O 
. O 
Acute O 
administration O 
( O 
0.63-40 O 
mg O 
/ O 
kg O 
) O 
of O 
the O 
mGluR5 O 
positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
, O 
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide B-SYSTEMATIC 
( O 
CDPPB B-ABBREVIATION 
) O 
and O 
ADX47273 B-IDENTIFIER 
, O 
reversed O 
a O 
delay O 
- O 
induced O 
impairment O 
in O 
social O 
novelty O 
discrimination O 
( O 
SND O 
) O 
in O 
adult O 
rats O 
. O 
The O 
action O 
of O 
CDPPB B-ABBREVIATION 
was O 
blocked O 
by O 
the O 
mGluR5 O 
antagonist O 
, O 
2-methyl-6-(phenylethynyl)-pyridine B-SYSTEMATIC 
( O 
2.5-10 O 
mg O 
/ O 
kg O 
) O 
, O 
and O 
was O 
also O 
expressed O 
upon O 
microinjection O 
into O 
frontal O 
cortex O 
( O 
0.63-10 O 
μg O 
/ O 
side O 
) O 
, O 
but O 
not O 
striatum O 
. O 
Supporting O 
an O 
interrelationship O 
between O 
mGluR5 O 
and O 
NMDA B-ABBREVIATION 
receptors O 
, O 
enhancement O 
of O 
SND O 
by O 
CDPPB B-ABBREVIATION 
was O 
blocked O 
by O 
dizocilpine B-TRIVIAL 
( O 
0.08 O 
mg O 
/ O 
kg O 
) O 
while O 
, O 
reciprocally O 
, O 
dizocilpine B-TRIVIAL 
-induced O 
impairment O 
in O 
SND O 
was O 
attenuated O 
by O 
CDPPB B-ABBREVIATION 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
. O 
The O 
SND O 
deficit O 
elicited O 
by O 
post O 
- O 
natal O 
administration O 
of O 
phencyclidine B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
days O 
7-11 O 
) O 
was O 
reversed O 
by O 
CDPPB B-ABBREVIATION 
or O 
ADX47273 B-IDENTIFIER 
in O 
adults O 
at O 
week O 
8 O 
. O 
This O 
phencyclidine B-TRIVIAL 
-induced O 
impairment O 
in O 
cognition O 
emerged O 
in O 
adult O 
rats O 
from O 
week O 
7 O 
on O 
, O 
and O 
chronic O 
, O 
pre O 
- O 
symptomatic O 
treatment O 
of O 
adolescent O 
rats O 
with O 
CDPPB B-ABBREVIATION 
over O 
weeks O 
5-6 O 
( O 
10 O 
mg O 
/ O 
kg O 
per O 
day O 
) O 
prevented O 
the O 
appearance O 
of O 
SND O 
deficits O 
in O 
adults O 
until O 
at O 
least O 
week O 
13 O 
. O 
In O 
conclusion O 
, O 
as O 
evaluated O 
by O 
a O 
SND O 
procedure O 
, O 
mGluR5 O 
PAMs O 
promote O 
social O 
cognition O 
via O 
actions O 
expressed O 
in O 
interaction O 
with O 
NMDA B-ABBREVIATION 
receptors O 
and O 
exerted O 
in O 
frontal O 
cortex O 
. O 
MGluR5 O 
PAMs O 
not O 
only O 
reverse O 
but O 
also O 
( O 
when O 
given O 
during O 
adolescence O 
) O 
prevent O 
the O 
emergence O 
of O 
cognitive O 
impairment O 
associated O 
with O 
a O 
developmental O 
model O 
of O 
schizophrenia O 
. O 

and O 
glucooligosaccharides O 
( O 
GLOS O 
) O 
are O 
produced O 
by O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
bacteria O 
( O 
LAB O 
) O 
during O 
sourdough O 
fermentation O 
. O 
The O 
dextrans O 
can O 
act O 
as O 
hydrocolloids O 
in O 
sourdough O 
bread O 
, O 
while O 
the O 
GLOS O 
may O 
have O 
antistaling O 
and O 
prebiotic O 
properties O 
, O 
depending O 
on O 
their O 
structure O 
. O 
Development O 
of O 
high O 
- O 
throughput O 
methods O 
for O 
screening O 
the O 
structural O 
properties O 
of O 
dextrans O 
and O 
GLOS O 
produced O 
by O 
different O 
LAB O 
in O 
varying O 
fermentation O 
conditions O 
is O 
therefore O 
of O 
interest O 
. O 
In O 
this O 
study O 
we O 
explored O 
the O 
possibility O 
of O 
using O 
electrospray O 
ionisation O 
tandem O 
mass O 
spectroscopy O 
( O 
ESI-MS O 
/ O 
MS O 
) O 
to O 
unequivocally O 
determine O 
the O 
structures O 
of O 
underivatised O 
GLOS O 
. O 
The O 
emphasis O 
was O 
on O 
linear O 
mixed O 
linked O 
model O 
GLOS O 
, O 
especially O 
those O 
containing O 
( O 
1→3 O 
) O 
linkages O 
that O 
are O 
common O 
in O 
dextrans O 
. O 
After O 
evaluation O 
of O 
the O 
model O 
GLOS O 
, O 
the O 
ESI-MS O 
/ O 
MS O 
method O 
was O 
used O 
to O 
determine O 
the O 
linkage O 
positions O 
of O 
two O 
mixed O 
- O 
linked O 
tetrasaccharides B-FAMILY 
obtained O 
by O 
hydrolysis O 
of O 
Weissella O 
confusa O 
and O 
Leuconostoc O 
citreum O 
dextrans O 
. O 
In O 
positive O 
mode O 
, O 
only O 
the O 
reducing O 
end O 
linkage O 
could O 
be O 
determined O 
because O 
isomeric O 
fragment O 
ions O 
, O 
present O 
in O 
subsequent O 
MS(n) O 
cycles O 
, O 
hindered O 
assignment O 
of O 
the O 
remaining O 
linkages O 
. O 
By O 
contrast O 
, O 
it O 
was O 
possible O 
to O 
unambiguously O 
assign O 
all O 
the O 
linkages O 
in O 
each O 
GLOS O 
using O 
the O 
negative O 
mode O 
spectra O 
. O 
The O 
present O 
study O 
thus O 
shows O 
that O 
negative O 
mode O 
is O 
the O 
preferred O 
method O 
for O 
ESI-MS O 
/ O 
MS O 
structural O 
analysis O 
of O 
underivatised O 
GLOS O 
. O 
In O 
combination O 
with O 
liquid O 
chromatography O 
this O 
method O 
will O 
enable O 
rapid O 
profiling O 
of O 
the O 
structural O 
variation O 
of O 
dextrans O 
and O 
prebiotic O 
GLOS O 
. O 

establish O 
stable O 
communities O 
, O 
known O 
as O 
biofilms O 
, O 
that O 
are O 
resistant O 
to O 
antimicrobials O 
. O 
Biofilm O 
robustness O 
is O 
due O 
to O 
the O 
presence O 
of O 
an O 
extracellular O 
matrix O 
, O 
which O 
for O 
several O 
species O 
- O 
among O 
them O 
Bacillus O 
subtilis O 
- O 
includes O 
amyloid O 
- O 
like O 
protein O 
fibers O 
. O 
In O 
this O 
work O 
, O 
we O 
show O 
that O 
B O 
. O 
subtilis O 
biofilms O 
can O 
be O 
a O 
simple O 
and O 
reliable O 
tool O 
for O 
screening O 
of O 
molecules O 
with O 
antiamyloid O 
activity O 
. O 
We O 
identified O 
two O 
molecules O 
, O 
AA-861 B-TRIVIAL 
and O 
parthenolide B-TRIVIAL 
, O 
which O 
efficiently O 
inhibited O 
biofilms O 
by O 
preventing O 
the O 
formation O 
of O 
amyloid O 
- O 
like O 
fibers O 
. O 
Parthenolide B-TRIVIAL 
also O 
disrupted O 
pre O 
- O 
established O 
biofilms O 
. O 
These O 
molecules O 
also O 
impeded O 
the O 
formation O 
of O 
biofilms O 
of O 
other O 
bacterial O 
species O 
that O 
secrete O 
amyloid O 
proteins O 
, O 
such O 
as O 
Bacillus O 
cereus O 
and O 
Escherichia O 
coli O 
. O 
Furthermore O 
, O 
the O 
identified O 
molecules O 
decreased O 
the O 
conversion O 
of O 
the O 
yeast O 
protein O 
New1 O 
to O 
the O 
prion O 
state O 
in O 
a O 
heterologous O 
host O 
, O 
indicating O 
the O 
broad O 
range O 
of O 
activity O 
of O 
the O 
molecules O 
. O 

is O 
considered O 
as O 
a O 
main O 
factor O 
restricting O 
efficacy O 
of O 
radiotherapy O 
. O 
However O 
, O 
the O 
exact O 
molecular O 
mechanism O 
of O 
radioresistance O 
has O 
not O 
been O 
explained O 
yet O 
. O 
In O 
this O 
study O 
, O 
to O 
elucidate O 
radioresistance O 
mechanism O 
in O 
lung O 
cancer O 
, O 
we O 
compared O 
radiation O 
responses O 
in O 
two O 
types O 
of O 
non-small O 
cell O 
lung O 
cancer O 
( O 
NSCLC O 
) O 
cells O 
with O 
different O 
radiosensitivity O 
and O 
identified O 
key O 
molecules O 
conferring O 
radioresistance O 
. O 
In O 
radioresistant O 
NSCLC O 
cells O 
, O 
ionizing O 
radiation O 
( O 
IR O 
) O 
led O 
to O 
casein O 
kinase O 
2α O 
(CK2α)- O 
and O 
PKC O 
- O 
mediated O 
phosphorylation O 
of O 
rpS3 O 
and O 
TRAF2 O 
, O 
respectively O 
, O 
which O 
induced O 
dissociation O 
of O 
rpS3-TRAF2 O 
complex O 
and O 
NF-κB O 
activation O 
, O 
resulting O 
in O 
significant O 
up O 
- O 
regulation O 
of O 
prosurvival O 
genes O 
( O 
cIAP1 O 
, O 
cIAP2 O 
, O 
and O 
survivin O 
) O 
. O 
Also O 
, O 
dissociated O 
phospho B-SYSTEMATIC 
-rpS3 O 
translocated O 
into O 
nucleus O 
and O 
bound O 
with O 
NF-κB O 
complex O 
( O 
p65 O 
and O 
p50 O 
) O 
, O 
contributing O 
to O 
p65 O 
DNA O 
binding O 
property O 
and O 
specificity O 
. O 
However O 
, O 
in O 
radiosensitive O 
NSCLC O 
cells O 
, O 
IR O 
- O 
mediated O 
rpS3 O 
phosphorylation O 
was O 
not O 
detected O 
due O 
to O 
the O 
absence O 
of O 
CK2α O 
overexpression O 
. O 
Consequently O 
, O 
IR-induced O 
rpS3-TRAF2 O 
complex O 
dissociation O 
, O 
NF-κB O 
activation O 
, O 
and O 
prosurvival O 
gene O 
expression O 
were O 
not O 
presented O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
revealed O 
a O 
novel O 
radioresistance O 
mechanism O 
through O 
functional O 
orchestration O 
of O 
rpS3 O 
, O 
TRAF2 O 
, O 
and O 
NF-κB O 
in O 
NSCLC O 
cells O 
. O 
Moreover O 
, O 
we O 
provided O 
the O 
first O 
evidence O 
for O 
the O 
function O 
of O 
rpS3 O 
as O 
a O 
new O 
TRAF2 O 
- O 
binding O 
protein O 
and O 
demonstrated O 
that O 
phosphorylation O 
of O 
both O 
rpS3 O 
and O 
TRAF2 O 
is O 
a O 
key O 
control O 
point O 
of O 
radioresistance O 
in O 
NSCLC O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
regulation O 
of O 
rpS3 O 
and O 
TRAF2 O 
in O 
combination O 
with O 
radiotherapy O 
could O 
have O 
high O 
pharmacological O 
therapeutic O 
potency O 
for O 
radioresistance O 
of O 
NSCLC O 
. O 

of O 
indolyl-3-acetonitrile B-SYSTEMATIC 
derivatives O 
and O 
their O 
inhibitory O 
effects O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
PGE2 B-ABBREVIATION 
productions O 
in O 
LPS-induced O 
RAW O 
264.7 O 
cells O 
. O 

is O 
one O 
of O 
major O 
constituents O 
of O 
Brassica O 
rapa O 
that O 
exerts O 
anti-inflammatory O 
activities O 
. O 
Several O 
indolyl-3-acetonitrile B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
as O 
arvelexin B-TRIVIAL 
analogs O 
and O 
evaluated O 
for O 
their O 
abilities O 
to O 
inhibit O 
NO B-FORMULA 
and O 
PGE2 B-ABBREVIATION 
productions O 
in O 
LPS-induced O 
RAW O 
264.7 O 
cells O 
. O 
Of O 
the O 
indolyl-3-acetonitriles B-FAMILY 
synthesized O 
, O 
compound O 
2k O 
, O 
which O 
possesses O 
a O 
hydroxyl B-SYSTEMATIC 
group O 
at O 
C-7 O 
position O 
of O 
the O 
indole B-SYSTEMATIC 
ring O 
and O 
an O 
N-methyl B-SYSTEMATIC 
substituent O 
, O 
more O 
potently O 
inhibited O 
NO B-FORMULA 
and O 
PGE2 B-ABBREVIATION 
productions O 
and O 
was O 
less O 
cytotoxic O 
than O 
arvelexin B-TRIVIAL 
on O 
macrophage O 
cells O 
. O 

of O 
transient O 
receptor O 
potential O 
melastatin O 
8 O 
activation O 
by O 
phthalate B-FAMILY 
esters I-FAMILY 
that O 
enhance O 
contact O 
hypersensitivity O 
in O 
mice O 
. O 

studied O 
the O 
involvement O 
of O 
sensory O 
neurons O 
in O 
skin O 
sensitization O 
to O 
allergens O 
using O 
a O 
mouse O 
model O 
in O 
which O 
the O 
T-helper O 
type O 
2 O 
response O 
is O 
essential O 
. O 
Skin O 
sensitization O 
to O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
( O 
FITC B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
be O 
enhanced O 
by O 
several O 
phthalate B-FAMILY 
esters I-FAMILY 
, O 
including O 
dibutyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DBP B-ABBREVIATION 
) O 
. O 
For O 
different O 
types O 
of O 
phthalate B-FAMILY 
esters I-FAMILY 
, O 
we O 
found O 
a O 
correlation O 
between O 
the O 
ability O 
of O 
transient O 
receptor O 
potential O 
( O 
TRP O 
) O 
A1 O 
activation O 
and O 
that O 
of O 
enhancing O 
skin O 
sensitization O 
. O 
A O 
TRPA1-specific O 
antagonist O 
, O 
HC-030031 B-IDENTIFIER 
, O 
was O 
shown O 
to O 
suppress O 
skin O 
sensitization O 
in O 
the O 
presence O 
of O 
DBP B-ABBREVIATION 
. O 
However O 
, O 
since O 
phthalate B-FAMILY 
esters I-FAMILY 
also O 
activate O 
TRPV1 O 
, O 
phthalate B-FAMILY 
esters I-FAMILY 
could O 
activate O 
other O 
types O 
of O 
TRP O 
channels O 
non-selectively O 
. O 
Furthermore O 
, O 
sensitization O 
to O 
FITC B-ABBREVIATION 
is O 
also O 
enhanced O 
by O 
menthol B-TRIVIAL 
, O 
which O 
activates O 
TRPA1 O 
and O 
TRPM8 O 
. O 
Here O 
we O 
established O 
an O 
in O 
vitro O 
system O 
for O 
measuring O 
TRPM8 O 
activation O 
. O 
The O 
selectivity O 
for O 
TRPM8 O 
was O 
established O 
by O 
the O 
fact O 
that O 
two O 
TRPM8 O 
agonists O 
( O 
menthol B-TRIVIAL 
and O 
icilin B-TRIVIAL 
) O 
induced O 
calcium B-SYSTEMATIC 
mobilization O 
, O 
whereas O 
agonists O 
of O 
TRPA1 O 
and O 
TRPV1 O 
did O 
not O 
. O 
We O 
demonstrated O 
that O 
phthalate B-FAMILY 
esters I-FAMILY 
do O 
not O 
activate O 
TRPM8 O 
. O 
TRPA1-antagonist O 
HC-030031 B-IDENTIFIER 
did O 
not O 
inhibit O 
TRPM8 O 
activation O 
induced O 
by O 
menthol B-TRIVIAL 
or O 
icilin B-TRIVIAL 
. O 
These O 
results O 
show O 
that O 
phthalate B-FAMILY 
esters I-FAMILY 
activate O 
TRPA1 O 
and O 
TRPV1 O 
with O 
selectivity O 
. O 
TRPM8 O 
activation O 
is O 
not O 
likely O 
to O 
be O 
involved O 
in O 
the O 
sensitization O 
to O 
FITC B-ABBREVIATION 
. O 

wide O 
association O 
studies O 
have O 
identified O 
several O 
type O 
2 O 
diabetes O 
( O 
T2D O 
) O 
risk O 
loci O 
linked O 
to O 
impaired O 
β-cell O 
function O 
. O 
The O 
identity O 
and O 
function O 
of O 
the O 
causal O 
genes O 
in O 
these O 
susceptibility O 
loci O 
remain O 
, O 
however O 
, O 
elusive O 
. O 
The O 
HHEX O 
/ O 
IDE O 
T2D O 
locus O 
is O 
associated O 
with O 
decreased O 
insulin O 
secretion O 
in O 
response O 
to O 
oral O 
glucose B-TRIVIAL 
stimulation O 
in O 
humans O 
. O 
Here O 
we O 
have O 
assessed O 
β-cell O 
function O 
in O 
Ide O 
knock O 
- O 
out O 
( O 
KO O 
) O 
mice O 
. O 
We O 
find O 
that O 
glucose B-TRIVIAL 
stimulated O 
insulin O 
secretion O 
( O 
GSIS O 
) O 
is O 
decreased O 
in O 
Ide O 
KO O 
mice O 
due O 
to O 
impaired O 
replenishment O 
of O 
the O 
releasable O 
pool O 
of O 
granules O 
and O 
that O 
the O 
Ide O 
gene O 
is O 
haploinsufficient O 
. O 
We O 
also O 
show O 
that O 
autophagic O 
flux O 
and O 
microtubule O 
content O 
is O 
reduced O 
in O 
β-cells O 
of O 
Ide O 
KO O 
mice O 
. O 
One O 
important O 
cellular O 
role O 
for O 
IDE O 
involves O 
the O 
neutralization O 
of O 
amyloidogenic O 
proteins O 
and O 
we O 
find O 
that O 
α-synuclein O 
and O 
IDE O 
levels O 
are O 
inversely O 
correlated O 
in O 
β-cells O 
of O 
Ide O 
KO O 
mice O 
and O 
T2D O 
patients O 
. O 
Moreover O 
, O 
we O 
provide O 
evidence O 
that O 
both O 
gain- O 
and O 
loss O 
- O 
of O 
- O 
function O 
of O 
α-synuclein O 
in O 
β-cells O 
in O 
vivo O 
not O 
only O 
impair O 
GSIS O 
but O 
also O 
autophagy O 
. O 
Together O 
, O 
these O 
data O 
identify O 
the O 
Ide O 
gene O 
as O 
a O 
regulator O 
of O 
GSIS O 
, O 
suggest O 
a O 
molecular O 
mechanism O 
for O 
β-cell O 
degeneration O 
as O 
a O 
consequence O 
of O 
Ide O 
deficiency O 
, O 
and O 
additionally O 
corroborates O 
and O 
extends O 
a O 
previously O 
established O 
important O 
role O 
for O 
α-synuclein O 
in O 
β-cell O 
function O 
. O 

of O 
proteins O 
by O 
skin O 
sensitizers O 
is O 
a O 
pivotal O 
step O 
in O 
T O 
cell O 
mediated O 
allergic O 
contact O 
dermatitis O 
( O 
ACD O 
) O 
. O 
In O 
this O 
process O 
small O 
reactive O 
chemicals O 
interact O 
covalently O 
or O 
non-covalently O 
with O 
cellular O 
or O 
extracellular O 
skin O 
self O 
- O 
proteins O 
or O 
self O 
- O 
peptides O 
to O 
become O 
recognized O 
by O 
the O 
human O 
immune O 
system O 
. O 
Aiming O 
to O 
develop O 
a O 
novel O 
non-animal O 
in O 
vitro O 
test O 
system O 
for O 
predicting O 
sensitization O 
potential O 
of O 
small O 
reactive O 
chemicals O 
in O 
human O 
skin O 
the O 
allergen O 
- O 
peptide O 
/ O 
protein O 
interaction O 
assay O 
( O 
APIA O 
) O 
has O 
been O 
developed O 
. O 
By O 
applying O 
modern O 
proteomic O 
technologies O 
together O 
with O 
a O 
target O 
peptide O 
containing O 
all O 
amino B-FAMILY 
acids I-FAMILY 
, O 
the O 
assay O 
permits O 
the O 
profiling O 
of O 
all O 
amino B-FAMILY 
acid I-FAMILY 
specific O 
allergen O 
- O 
peptide O 
interactions O 
. O 
Moreover O 
, O 
potentially O 
crucial O 
allergen O 
- O 
specific O 
Cys B-FORMULA 
-modifications O 
are O 
qualitatively O 
monitored O 
by O 
mass O 
spectrometry O 
and O 
confirmed O 
by O 
a O 
dual O 
peptide O 
approach O 
. O 
Assay O 
conditions O 
chosen O 
mimic O 
the O 
distinct O 
human O 
epidermal O 
reactivity O 
compartments O 
of O 
the O 
skin O 
surface O 
( O 
pH O 
5.5 O 
) O 
, O 
stratum O 
basale O 
( O 
pH O 
6.8 O 
) O 
, O 
and O 
typical O 
physiological O 
conditions O 
( O 
pH O 
7.4 O 
) O 
. O 
An O 
extreme O 
as O 
well O 
as O 
a O 
moderate O 
human O 
contact O 
sensitizer O 
produced O 
Cys B-FORMULA 
-specific O 
mass O 
shifts O 
, O 
whereas O 
a O 
skin O 
irritant O 
did O 
not O 
. O 
Our O 
data O 
indicate O 
that O 
MALDI-MS O 
based O 
and O 
skin O 
- O 
related O 
in O 
vitro O 
technology O 
platforms O 
- O 
like O 
the O 
APIA O 
- O 
are O 
promising O 
tools O 
in O 
developing O 
alternative O 
non-animal O 
allergen O 
assays O 
. O 
This O 
will O 
assist O 
in O 
chemical O 
classification O 
and O 
next O 
generation O 
risk O 
assessment O 
strategies O 
, O 
including O 
REACH O 
and O 
experimental O 
immunotoxicology O 
. O 

for O 
the O 
Prevention O 
of O 
Stroke O 
and O 
Systemic O 
Embolism O 
in O 
Atrial O 
Fibrillation O 
: O 
A O 
NICE O 
Single O 
Technology O 
Appraisal O 
. O 

National O 
Institute O 
for O 
Health O 
and O 
Clinical O 
Excellence O 
( O 
NICE O 
) O 
invited O 
the O 
manufacturer O 
of O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
( O 
Boehringer O 
Ingelheim O 
Ltd O 
, O 
UK O 
) O 
to O 
submit O 
evidence O 
for O 
the O 
clinical O 
and O 
cost O 
- O 
effectiveness O 
of O 
this O 
drug O 
for O 
the O 
prevention O 
of O 
stroke O 
and O 
systemic O 
embolism O 
in O 
patients O 
with O 
non-valvular O 
atrial O 
fibrillation O 
( O 
AF O 
) O 
as O 
part O 
of O 
the O 
NICE O 
single O 
technology O 
appraisal O 
process O 
. O 
The O 
Centre O 
for O 
Reviews O 
and O 
Dissemination O 
and O 
the O 
Centre O 
for O 
Health O 
Economics O 
at O 
the O 
University O 
of O 
York O 
were O 
commissioned O 
to O 
act O 
as O 
the O 
evidence O 
review O 
group O 
( O 
ERG O 
) O 
. O 
This O 
article O 
presents O 
a O 
summary O 
of O 
the O 
manufacturer's O 
submission O 
, O 
the O 
ERG O 
report O 
and O 
the O 
subsequent O 
development O 
of O 
NICE O 
guidance O 
for O 
the O 
use O 
of O 
dabigatran B-TRIVIAL 
within O 
the O 
UK O 
National O 
Health O 
Service O 
. O 
Dabigatran B-TRIVIAL 
was O 
granted O 
marketing O 
authorisation O 
by O 
the O 
European O 
Medicines O 
Agency O 
for O 
a O 
sequential O 
dosing O 
regimen O 
( O 
DBG O 
sequential O 
) O 
, O 
in O 
which O 
patients O 
under O 
80 O 
years O 
are O 
treated O 
with O 
dabigatran B-TRIVIAL 
150 O 
mg O 
twice O 
daily O 
( O 
DBG150 O 
) O 
and O 
patients O 
80 O 
years O 
and O 
over O 
are O 
given O 
dabigatran B-TRIVIAL 
110 O 
mg O 
twice O 
daily O 
( O 
DBG110 O 
) O 
. O 
NICE O 
decisions O 
are O 
bound O 
by O 
the O 
marketing O 
authorisation O 
; O 
therefore O 
, O 
the O 
decision O 
problem O 
faced O 
by O 
the O 
committee O 
was O 
whether O 
the O 
DBG O 
sequential O 
regimen O 
was O 
effective O 
and O 
cost O 
- O 
effective O 
compared O 
with O 
warfarin B-TRIVIAL 
or O 
aspirin B-TRIVIAL 
for O 
patients O 
with O 
non-valvular O 
AF O 
and O 
one O 
or O 
more O 
risk O 
factors O 
. O 
The O 
RE-LY O 
trial O 
, O 
a O 
large O 
multi O 
- O 
centre O 
non-inferiority O 
randomised O 
clinical O 
trial O 
, O 
was O 
the O 
primary O 
source O 
of O 
clinical O 
evidence O 
. O 
DBG150 O 
was O 
shown O 
to O 
be O 
non-inferior O 
, O 
and O 
subsequently O 
superior O 
to O 
warfarin B-TRIVIAL 
, O 
for O 
the O 
primary O 
outcome O 
of O 
all O 
stroke O 
/ O 
systemic O 
embolism O 
. O 
DBG110 O 
was O 
found O 
to O 
be O 
non-inferior O 
to O 
warfarin B-TRIVIAL 
. O 
Results O 
were O 
presented O 
for O 
a O 
post O 
hoc O 
subgroup O 
analysis O 
for O 
patients O 
under O 
and O 
over O 
80 O 
years O 
of O 
age O 
, O 
where O 
DBG110 O 
showed O 
a O 
statistically O 
significant O 
reduction O 
of O 
haemorrhagic O 
stroke O 
and O 
intracranial O 
haemorrhage O 
in O 
comparison O 
to O 
warfarin B-TRIVIAL 
in O 
patients O 
over O 
80 O 
years O 
of O 
age O 
. O 
This O 
post O 
hoc O 
subgroup O 
analysis O 
by O 
age O 
was O 
the O 
basis O 
for O 
the O 
licensed O 
DBG O 
sequential O 
regimen O 
. O 
The O 
economic O 
evaluation O 
compared O 
the O 
costs O 
and O 
outcomes O 
of O 
DBG110 O 
, O 
DBG150 O 
and O 
DBG O 
sequential O 
against O 
warfarin B-TRIVIAL 
, O 
aspirin B-TRIVIAL 
, O 
and O 
aspirin B-TRIVIAL 
plus O 
clopidogrel B-TRIVIAL 
. O 
Across O 
the O 
three O 
dosing O 
regimens O 
, O 
dabigatran B-TRIVIAL 
was O 
associated O 
with O 
greater O 
costs O 
and O 
better O 
health O 
outcomes O 
than O 
warfarin B-TRIVIAL 
; O 
however O 
, O 
DBG150 O 
offered O 
the O 
most O 
benefits O 
and O 
dominated O 
DBG110 O 
and O 
DBG O 
sequential O 
( O 
i.e O 
. O 
less O 
costly O 
and O 
more O 
effective O 
) O 
. O 
The O 
cost O 
- O 
effectiveness O 
of O 
DBG150 O 
was O 
less O 
favourable O 
for O 
patients O 
well O 
controlled O 
on O 
warfarin B-TRIVIAL 
. O 
In O 
the O 
first O 
appraisal O 
meeting O 
, O 
the O 
committee O 
issued O 
a O 
' O 
minded O 
no O 
' O 
decision O 
until O 
additional O 
analyses O 
on O 
the O 
licensed O 
DBG O 
sequential O 
regimen O 
were O 
presented O 
by O 
the O 
manufacturer O 
. O 
These O 
additional O 
analyses O 
indicated O 
that O 
the O 
incremental O 
cost O 
- O 
effectiveness O 
ratio O 
( O 
ICER O 
) O 
of O 
the O 
DBG O 
sequential O 
regimen O 
compared O 
with O 
warfarin B-TRIVIAL 
ranged O 
from O 
£8,388 O 
to O 
£18,987 O 
per O 
quality O 
- O 
adjusted O 
life O 
year O 
( O 
QALY O 
) O 
gained O 
depending O 
on O 
the O 
level O 
of O 
monitoring O 
costs O 
assumed O 
for O 
warfarin B-TRIVIAL 
. O 
Patients O 
on O 
warfarin B-TRIVIAL 
would O 
need O 
to O 
be O 
within O 
therapeutic O 
range O 
83-85 O 
% O 
of O 
the O 
time O 
for O 
the O 
ICER O 
to O 
exceed O 
£30,000 O 
per O 
additional O 
QALY O 
. O 
Following O 
consideration O 
of O 
the O 
additional O 
evidence O 
and O 
the O 
responses O 
from O 
a O 
large O 
number O 
of O 
consultees O 
and O 
commentators O 
, O 
the O 
committee O 
recommended O 
dabigatran B-TRIVIAL 
as O 
DBG O 
sequential O 
as O 
an O 
option O 
for O 
the O 
prevention O 
of O 
stroke O 
and O 
systemic O 
embolism O 
in O 
people O 
with O 
non-valvular O 
AF O 
with O 
one O 
or O 
more O 
risk O 
factors O 
for O 
ischaemic O 
stroke O 
. O 

-- O 
synthesis O 
via O 
McMurry O 
reaction O 
and O 
cyclooxygenase O 
( O 
COX O 
) O 
inhibition O 
activity O 
. O 

( O 
COX-2 O 
) O 
inhibitors O 
have O 
been O 
the O 
focus O 
of O 
medicinal O 
chemistry O 
efforts O 
for O 
years O 
, O 
and O 
many O 
compounds O 
that O 
exhibit O 
high O 
selectivity O 
and O 
affinity O 
have O 
been O 
developed O 
. O 
As O 
carbaboranes B-FAMILY 
represent O 
interesting O 
pharmacophores O 
as O 
phenyl B-SYSTEMATIC 
mimetics O 
in O 
drug O 
development O 
, O 
this O 
paper O 
presents O 
the O 
synthesis O 
of O 
carbaboranyl B-FAMILY 
derivatives O 
of O 
COX-2-selective O 
2,3- B-FAMILY 
disubstituted I-FAMILY 
indoles I-FAMILY 
. O 
Despite O 
the O 
lability O 
of O 
carbaboranes B-FAMILY 
under O 
reducing O 
conditions O 
, O 
2-carbaborane-3-phenyl-1H-indoles B-FAMILY 
could O 
be O 
synthesized O 
by O 
McMurry O 
cyclization O 
of O 
the O 
corresponding O 
amides B-FAMILY 
. O 
Whereas O 
the O 
meta-carbaboranyl B-TRIVIAL 
-substituted O 
derivatives O 
lacked O 
COX O 
inhibitory O 
activity O 
, O 
an O 
ortho-carbaboranyl B-TRIVIAL 
analogue O 
was O 
active O 
, O 
but O 
showed O 
a O 
selectivity O 
shift O 
toward O 
COX-1 O 
. O 

stabilized O 
by O 
multilamellar O 
polyglycerol B-FAMILY 
ester I-FAMILY 
self O 
- O 
assemblies O 
. O 

importance O 
of O 
surfactant O 
self O 
- O 
assemblies O 
in O 
foam O 
stabilization O 
is O 
well O 
- O 
known O 
. O 
The O 
aim O 
of O 
the O 
current O 
study O 
was O 
to O 
investigate O 
the O 
self O 
- O 
assemblies O 
of O 
the O 
nonionic O 
surfactant O 
polyglycerol B-FAMILY 
ester I-FAMILY 
( O 
PGE B-ABBREVIATION 
) O 
in O 
bulk O 
solutions O 
, O 
at O 
the O 
interface O 
and O 
within O 
foams O 
, O 
using O 
a O 
combined O 
approach O 
of O 
small O 
- O 
angle O 
neutron O 
scattering O 
, O 
neutron O 
reflectivity O 
, O 
and O 
electron O 
microscopy O 
. O 
PGE B-ABBREVIATION 
bulk O 
solutions O 
contain O 
vesicles O 
as O 
well O 
as O 
open O 
lamellar O 
structures O 
. O 
Upon O 
heating O 
of O 
the O 
solutions O 
the O 
lamellar O 
spacing O 
increases O 
, O 
with O 
significant O 
differences O 
in O 
the O 
presence O 
of O 
NaCl B-FORMULA 
or O 
CaCl(2) B-FORMULA 
as O 
compared O 
to O 
the O 
standard O 
solution O 
. O 
The O 
adsorption O 
of O 
the O 
multilamellar O 
structures O 
present O 
in O 
the O 
bulk O 
solutions O 
lead O 
to O 
a O 
multilayered O 
film O 
at O 
the O 
air O 
- O 
water O 
interface O 
. O 
The O 
ordering O 
within O 
this O 
film O 
was O 
increased O 
as O 
a O 
result O 
of O 
a O 
20% O 
area O 
compression O 
mimicking O 
a O 
coalescence O 
event O 
. O 
Finally O 
, O 
PGE B-ABBREVIATION 
foams O 
were O 
shown O 
to O 
be O 
stabilized O 
not O 
only O 
by O 
strong O 
interfacial O 
films O 
but O 
also O 
by O 
agglomerated O 
self O 
- O 
assemblies O 
within O 
the O 
interstitial O 
areas O 
of O 
the O 
foams O 
. O 

allopurinol B-TRIVIAL 
doses O 
are O 
sufficient O 
to O 
optimize O 
azathioprine B-TRIVIAL 
therapy O 
in O 
inflammatory O 
bowel O 
disease O 
patients O 
with O 
inadequate O 
thiopurine B-TRIVIAL 
metabolite O 
concentrations O 
. O 

: O 
Recent O 
studies O 
in O 
patients O 
with O 
inflammatory O 
bowel O 
diseases O 
( O 
IBD O 
) O 
on O 
thiopurine B-TRIVIAL 
therapy O 
suggest O 
that O 
too O 
low O 
6-thioguanine B-SYSTEMATIC 
nucleotide I-SYSTEMATIC 
concentrations O 
( O 
6-TGN B-SYSTEMATIC 
) O 
and O 
too O 
high O 
methylmercaptopurine B-SYSTEMATIC 
nucleotide I-SYSTEMATIC 
concentrations O 
( O 
MMPN B-ABBREVIATION 
) O 
can O 
be O 
reversed O 
by O 
a O 
combination O 
therapy O 
of O 
allopurinol B-TRIVIAL 
and O 
low O 
- O 
dose O 
thiopurines B-FAMILY 
. O 
To O 
date O 
, O 
however O 
, O 
optimal O 
dosing O 
has O 
not O 
been O 
established O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
minimal O 
allopurinol B-TRIVIAL 
doses O 
necessary O 
to O 
achieve O 
adequate O 
6-TGN B-SYSTEMATIC 
concentrations O 
in O 
combination O 
with O 
low O 
- O 
dose O 
azathioprine B-TRIVIAL 
. O 
METHODS O 
: O 
A O 
stepwise O 
dose O 
- O 
escalation O 
of O 
allopurinol B-TRIVIAL 
was O 
performed O 
in O 
11 O 
azathioprine B-TRIVIAL 
-pretreated O 
IBD O 
patients O 
with O 
inadequately O 
low O 
6-TGN B-SYSTEMATIC 
concentrations O 
( O 
< O 
235 O 
pmol O 
/ O 
8 O 
× O 
10(8) O 
erythrocytes O 
) O 
and O 
/ O 
or O 
elevated O 
MMPN B-ABBREVIATION 
concentrations O 
( O 
> O 
5000 O 
pmol O 
/ O 
8 O 
× O 
10(8) O 
erythrocytes O 
) O 
and O 
/ O 
or O 
elevated O 
liver O 
enzymes O 
( O 
alanine B-TRIVIAL 
aminotransferase O 
and O 
/ O 
or O 
aspartate B-TRIVIAL 
aminotransferase O 
levels O 
one- O 
to O 
threefold O 
the O 
upper O 
limit O 
of O 
normal O 
) O 
. O 
Six O 
patients O 
were O 
recruited O 
into O 
an O 
open O 
study O 
, O 
and O 
five O 
were O 
treated O 
in O 
the O 
context O 
of O 
an O 
individualized O 
therapeutic O 
approach O 
. O 
Adverse O 
effects O 
, O 
azathioprine B-TRIVIAL 
metabolites O 
, O 
liver O 
enzymes O 
and O 
whole O 
blood O 
counts O 
were O 
monitored O 
two O 
to O 
three O 
times O 
per O 
month O 
. O 
RESULTS O 
: O 
Adequate O 
6-TGN B-SYSTEMATIC 
concentrations O 
were O 
achieved O 
with O 
a O 
combination O 
of O 
25 O 
mg O 
allopurinol B-TRIVIAL 
and O 
50 O 
mg O 
azathioprine B-TRIVIAL 
in O 
one O 
patient O 
and O 
with O 
50 O 
mg O 
allopurinol B-TRIVIAL 
and O 
50 O 
mg O 
azathioprine B-TRIVIAL 
in O 
nine O 
patients O 
. O 
Median O 
6-TGN B-SYSTEMATIC 
concentrations O 
( O 
range O 
) O 
were O 
336 O 
( O 
290-488 O 
) O 
pmol O 
/ O 
8 O 
× O 
10(8) O 
erythrocytes O 
after O 
an O 
8-week- O 
long O 
intake O 
of O 
the O 
final O 
dose O 
combination O 
. O 
One O 
patient O 
dropped O 
out O 
due O 
to O 
nausea O 
after O 
the O 
first O 
intake O 
. O 
MMPN B-ABBREVIATION 
concentrations O 
and O 
liver O 
enzymes O 
normalized O 
immediately O 
in O 
all O 
affected O 
patients O 
. O 
All O 
patients O 
finishing O 
the O 
dose O 
- O 
escalation O 
regimen O 
tolerated O 
the O 
treatment O 
without O 
toxicity O 
. O 
CONCLUSIONS O 
: O 
Combination O 
therapy O 
with O 
only O 
50 O 
mg O 
allopurinol B-TRIVIAL 
and O 
50 O 
mg O 
azathioprine B-TRIVIAL 
daily O 
is O 
sufficient O 
, O 
efficacious O 
and O 
safe O 
in O 
most O 
IBD O 
patients O 
with O 
inadequate O 
thiopurine B-TRIVIAL 
metabolite O 
concentrations O 
to O 
optimize O 
azathioprine B-TRIVIAL 
-based O 
IBD O 
therapy O 
. O 

carcinogenicity O 
by O 
coexposure O 
to O 
arsenic B-SYSTEMATIC 
and O 
iron B-SYSTEMATIC 
and O 
a O 
novel O 
remediation O 
system O 
for O 
the O 
elements O 
in O 
well O 
drinking O 
water O 
. O 

carcinomas O 
including O 
skin O 
cancer O 
are O 
explosively O 
increasing O 
in O 
arsenicosis O 
patients O 
who O 
drink O 
arsenic B-SYSTEMATIC 
-polluted O 
well O 
water O 
, O 
especially O 
in O 
Bangladesh O 
. O 
Although O 
well O 
drinking O 
water O 
in O 
the O 
cancer O 
- O 
prone O 
areas O 
contains O 
various O 
elements O 
, O 
very O 
little O 
is O 
known O 
about O 
the O 
effects O 
of O 
elements O 
except O 
arsenic B-SYSTEMATIC 
on O 
carcinogenicity O 
. O 
In O 
order O 
to O 
clarify O 
the O 
carcinogenic O 
effects O 
of O 
coexposure O 
to O 
arsenic B-SYSTEMATIC 
and O 
iron B-SYSTEMATIC 
, O 
anchorage O 
- O 
independent O 
growth O 
and O 
invasion O 
in O 
human O 
untransformed O 
HaCaT O 
and O 
transformed O 
A431 O 
keratinocytes O 
were O 
examined O 
. O 
Since O 
the O 
mean O 
ratio O 
of O 
arsenic B-SYSTEMATIC 
and O 
iron B-SYSTEMATIC 
in O 
well O 
water O 
was O 
1 O 
: O 
10 O 
in O 
cancer O 
- O 
prone O 
areas O 
of O 
Bangladesh O 
, O 
effects O 
of O 
1 O 
μM O 
arsenic B-SYSTEMATIC 
and O 
10 O 
μM O 
iron B-SYSTEMATIC 
were O 
investigated O 
. O 
Iron B-SYSTEMATIC 
synergistically O 
promoted O 
arsenic B-SYSTEMATIC 
-mediated O 
anchorage O 
- O 
independent O 
growth O 
in O 
untransformed O 
and O 
transformed O 
keratinocytes O 
. O 
Iron B-SYSTEMATIC 
additionally O 
increased O 
invasion O 
in O 
both O 
types O 
of O 
keratinocytes O 
. O 
Activities O 
of O 
c-SRC O 
and O 
ERK O 
that O 
regulate O 
anchorage O 
- O 
independent O 
growth O 
and O 
invasion O 
were O 
synergistically O 
enhanced O 
in O 
both O 
types O 
of O 
keratinocytes O 
. O 
Our O 
results O 
suggest O 
that O 
iron B-SYSTEMATIC 
promotes O 
arsenic B-SYSTEMATIC 
-mediated O 
transformation O 
of O 
untransformed O 
keratinocytes O 
and O 
progression O 
of O 
transformed O 
keratinocytes O 
. O 
We O 
then O 
developed O 
a O 
low O 
- O 
cost O 
and O 
high O 
- O 
performance O 
adsorbent O 
composed O 
of O 
a O 
hydrotalcite B-TRIVIAL 
-like O 
compound O 
for O 
arsenic B-SYSTEMATIC 
and O 
iron B-SYSTEMATIC 
. O 
The O 
adsorbent O 
rapidly O 
reduced O 
concentrations O 
of O 
both O 
elements O 
from O 
well O 
drinking O 
water O 
in O 
cancer O 
- O 
prone O 
areas O 
of O 
Bangladesh O 
to O 
levels O 
less O 
than O 
those O 
in O 
WHO O 
health O 
- O 
based O 
guidelines O 
for O 
drinking O 
water O 
. O 
Thus O 
, O 
we O 
not O 
only O 
demonstrated O 
for O 
the O 
first O 
time O 
increased O 
carcinogenicity O 
by O 
coexposure O 
to O 
arsenic B-SYSTEMATIC 
and O 
iron B-SYSTEMATIC 
but O 
also O 
proposed O 
a O 
novel O 
remediation O 
system O 
for O 
well O 
drinking O 
water O 
. O 

edema O 
constitutes O 
a O 
serious O 
pathologic O 
entity O 
of O 
ophthalmology O 
resulting O 
in O 
vision O 
loss O 
with O 
a O 
remarkable O 
impact O 
on O 
the O 
quality O 
of O 
life O 
of O 
patients O 
. O 
It O 
is O 
the O 
final O 
common O 
pathway O 
of O 
various O 
systemic O 
diseases O 
and O 
underlying O 
intraocular O 
conditions O 
, O 
with O 
diabetes O 
mellitus O 
being O 
the O 
most O 
frequent O 
cause O 
. O 
Other O 
causes O 
include O 
venous O 
occlusive O 
disease O 
, O 
intraocular O 
surgery O 
, O 
and O 
inflammatory O 
conditions O 
of O 
the O 
posterior O 
segment O 
of O 
the O 
eye O 
. O 
Macular O 
edema O 
is O 
a O 
recognized O 
side O 
effect O 
of O 
various O 
systemic O 
and O 
local O 
medications O 
and O 
requires O 
special O 
consideration O 
among O 
ophthalmologists O 
and O 
other O 
clinicians O 
. O 
Recently O 
, O 
antidiabetic O 
thiazolidinediones B-FAMILY 
have O 
been O 
implicated O 
in O 
the O 
development O 
of O 
macular O 
edema O 
, O 
and O 
a O 
review O 
of O 
the O 
English O 
literature O 
revealed O 
that O 
other O 
systemically O 
administered O 
drugs O 
like O 
fingolimod B-TRIVIAL 
, O 
recently O 
approved O 
for O 
relapsing O 
forms O 
of O 
multiple O 
sclerosis O 
, O 
the O 
anticancer O 
agents O 
tamoxifen B-TRIVIAL 
and O 
the O 
taxanes B-FAMILY 
, O 
as O 
well O 
as O 
niacin B-TRIVIAL 
and O 
interferons O 
have O 
been O 
reported O 
to O 
cause O 
macular O 
edema O 
. O 
Ophthalmologic O 
pharmaceutical O 
agents O 
, O 
like O 
prostaglandin B-FAMILY 
analogs O 
, O 
epinephrine B-TRIVIAL 
, O 
timolol B-TRIVIAL 
, O 
and O 
ophthalmic O 
preparation O 
preservatives O 
have O 
also O 
been O 
reported O 
to O 
cause O 
macular O 
edema O 
as O 
an O 
adverse O 
event O 
. O 
The O 
purpose O 
of O 
this O 
article O 
is O 
to O 
provide O 
a O 
short O 
, O 
balanced O 
overview O 
of O 
the O 
available O 
evidence O 
in O 
this O 
regard O 
. O 
The O 
available O 
data O 
and O 
the O 
possible O 
pathophysiologic O 
mechanisms O 
leading O 
to O 
the O 
development O 
of O 
macular O 
edema O 
are O 
discussed O 
. O 
Possible O 
therapeutic O 
strategies O 
for O 
drug O 
- O 
induced O 
macular O 
edema O 
are O 
also O 
proposed O 
. O 

of O 
photophysics O 
and O 
pKa O 
shift O 
of O 
the O 
anti-cancer O 
drug O 
camptothecin B-TRIVIAL 
in O 
the O 
nanocavities O 
of O 
supramolecular O 
hosts O 
. O 

article O 
reports O 
the O 
pK(a) O 
shift O 
of O 
an O 
anti-cancer O 
drug O 
, O 
20(S)-camptothecin B-SYSTEMATIC 
( O 
CPT B-ABBREVIATION 
) O 
, O 
upon O 
encapsulation O 
into O 
the O 
nanocavity O 
of O 
a O 
cucurbit[7]uril B-TRIVIAL 
( O 
CB7 B-ABBREVIATION 
) O 
macrocycle O 
. O 
Steady O 
- O 
state O 
, O 
time O 
- O 
resolved O 
fluorescence O 
and O 
electrospray O 
ionisation O 
mass O 
spectrometry O 
( O 
ESI-MS O 
) O 
studies O 
provide O 
evidence O 
for O 
the O 
formation O 
of O 
both O 
1 O 
: O 
1 O 
and O 
2 O 
: O 
1 O 
( O 
CB7 B-ABBREVIATION 
⋅ O 
CPT B-ABBREVIATION 
) O 
stoichiometries O 
. O 
Astonishingly O 
, O 
we O 
have O 
found O 
that O 
protonation O 
of O 
CPT B-ABBREVIATION 
takes O 
place O 
at O 
a O 
higher O 
concentration O 
of O 
macrocycle O 
( O 
≥ O 
50 O 
μM O 
) O 
when O 
the O 
2 O 
: O 
1 O 
stoichiometric O 
complex O 
develops O 
. O 
However O 
, O 
we O 
did O 
not O 
find O 
any O 
proof O 
for O 
protonation O 
of O 
CPT B-ABBREVIATION 
when O 
it O 
is O 
encased O 
by O 
a O 
β-cyclodextrin B-TRIVIAL 
cavity O 
, O 
which O 
has O 
a O 
cavity O 
size O 
almost O 
the O 
same O 
as O 
that O 
of O 
CB7 B-ABBREVIATION 
. O 
Hence O 
, O 
we O 
conclude O 
that O 
electron O 
- O 
rich O 
carbonyl B-FAMILY 
portals O 
of O 
CB7 B-ABBREVIATION 
have O 
an O 
important O 
role O 
in O 
protonation O 
of O 
the O 
drug O 
in O 
the O 
2 O 
: O 
1 O 
inclusion O 
complex O 
. O 
Docking O 
and O 
semi-empirical O 
quantum O 
chemical O 
calculations O 
have O 
been O 
employed O 
to O 
gain O 
an O 
insight O 
into O 
the O 
molecular O 
picture O 
of O 
orientation O 
of O 
CPT B-ABBREVIATION 
in O 
the O 
inclusion O 
complexes O 
. O 
It O 
is O 
clearly O 
seen O 
from O 
the O 
optimised O 
structure O 
of O 
the O 
2 O 
: O 
1 O 
( O 
CB7 B-ABBREVIATION 
⋅ O 
CPT B-ABBREVIATION 
) O 
inclusion O 
complex O 
that O 
the O 
quinoline B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
of O 
CPT B-ABBREVIATION 
does O 
not O 
reside O 
within O 
either O 
of O 
the O 
CB7 B-ABBREVIATION 
cavities O 
, O 
rather O 
it O 
is O 
almost O 
sandwiched O 
between O 
two O 
CB7 B-ABBREVIATION 
rings O 
, O 
and O 
therefore O 
, O 
it O 
experiences O 
huge O 
electron O 
density O 
exerted O 
by O 
both O 
carbonyl B-FAMILY 
portals O 
of O 
the O 
macrocycles O 
. O 
As O 
a O 
result O 
, O 
the O 
pK(a) O 
of O 
CPT B-ABBREVIATION 
shifts O 
from O 
1.2 O 
to O 
6.2 O 
. O 
Finally O 
, O 
controlled O 
release O 
of O 
the O 
drug O 
has O 
been O 
achieved O 
through O 
the O 
introduction O 
of O 
NaCl B-FORMULA 
, O 
which O 
is O 
rich O 
in O 
cells O 
, O 
as O 
an O 
external O 
stimulus O 
. O 
We O 
hope O 
this O 
recognition O 
- O 
mediated O 
binding O 
and O 
release O 
mechanism O 
can O 
be O 
useful O 
for O 
activation O 
of O 
the O 
drug O 
and O 
controlled O 
release O 
of O 
the O 
drug O 
in O 
therapeutic O 
uses O 
. O 

novel O 
antioxidant O 
regenerating O 
system O 
consisting O 
of O 
cellobiose B-TRIVIAL 
dehydrogenase O 
( O 
CDH O 
) O 
, O 
cellobiose B-TRIVIAL 
, O 
and O 
phenolic B-FAMILY 
antioxidants O 
with O 
potential O 
application O 
for O 
continuous O 
quenching O 
of O 
free O 
radical O 
species O 
in O 
chronic O 
wounds O 
was O 
developed O 
. O 
This O 
antioxidant O 
regenerating O 
system O 
, O 
continuously O 
quenched O 
in O 
situ O 
produced O 
·NO B-FORMULA 
, O 
O(2)(·-) B-FORMULA 
and O 
OH· B-FORMULA 
radicals O 
and O 
the O 
produced O 
oxidized O 
phenolic B-FAMILY 
antioxidants O 
were O 
regenerated O 
back O 
to O 
their O 
original O 
parent O 
compounds O 
by O 
CDH O 
using O 
cellobiose B-TRIVIAL 
as O 
electron O 
donor O 
. O 
This O 
system O 
therefore O 
prevented O 
the O 
accumulation O 
of O 
oxidized O 
phenolic B-FAMILY 
antioxidants O 
. O 
Interestingly O 
, O 
this O 
study O 
also O 
challenges O 
the O 
relevance O 
of O 
using O 
total O 
antioxidant O 
capacities O 
values O 
of O 
plant O 
crude O 
extracts O 
obtained O 
using O 
biologically O 
none O 
relevant O 
radical O 
species O 
like O 
( O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
) O 
, O 
Trolox B-TRIVIAL 
Equivalent O 
Antioxidant O 
Capacity O 
( O 
TEAC O 
) O 
, O 
etc O 
. O 
when O 
applied O 
as O 
medicinal O 
remedies O 
. O 
This O 
is O 
because O 
methoxylated B-FAMILY 
phenolic I-FAMILY 
antioxidants O 
like O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
, O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
; O 
2,6-dimethoxyphenol B-SYSTEMATIC 
readily O 
donate O 
their O 
electrons O 
to O 
these O 
radicals O 
( O 
DPPH B-ABBREVIATION 
, O 
TEAC O 
, O 
etc O 
. O 
) O 
, O 
thereby O 
greatly O 
influencing O 
the O 
total O 
antioxidant O 
values O 
although O 
this O 
study O 
showed O 
that O 
they O 
are O 
not O 
at O 
all O 
effective O 
in O 
quenching O 
O(2)(·- B-FORMULA 
) O 
radicals O 
and O 
again O 
are O 
not O 
the O 
most O 
effective O 
quenchers O 
of O 
N B-FORMULA 
O O 
and O 
O B-FORMULA 
H O 
radicals O 
as O 
demonstrated O 
during O 
this O 
study O 
. O 

glutamate B-TRIVIAL 
7 O 
( O 
mGlu7 O 
) O 
receptor O 
: O 
a O 
target O 
for O 
medication O 
development O 
for O 
the O 
treatment O 
of O 
cocaine B-TRIVIAL 
dependence O 
. O 

glutamate B-TRIVIAL 
has O 
been O 
shown O 
to O 
play O 
an O 
important O 
role O 
in O 
reinstatement O 
to O 
drug O 
seeking O 
, O 
a O 
behavior O 
considered O 
to O 
be O 
of O 
relevance O 
to O 
relapse O 
to O 
drug O 
taking O 
in O 
humans O 
. O 
Therefore O 
, O 
glutamate B-TRIVIAL 
receptors O 
, O 
in O 
particular O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
, O 
have O 
become O 
important O 
targets O 
for O 
medication O 
development O 
for O 
the O 
treatment O 
of O 
drug O 
dependence O 
. O 
In O 
this O 
review O 
article O 
, O 
we O 
focus O 
on O 
the O 
mGlu7 O 
receptor O 
subtype O 
, O 
and O 
discuss O 
recent O 
findings O 
with O 
AMN082 B-IDENTIFIER 
, O 
a O 
selective O 
mGlu7 O 
receptor O 
allosteric O 
agonist O 
, O 
in O 
animal O 
models O 
with O 
relevance O 
to O 
drug O 
dependence O 
. O 
Systemic O 
or O 
local O 
administration O 
of O 
AMN082 B-IDENTIFIER 
into O 
the O 
nucleus O 
accumbens O 
( O 
NAc O 
) O 
, O 
a O 
critical O 
brain O 
region O 
involved O 
in O 
reward O 
and O 
drug O 
dependence O 
processes O 
, O 
inhibited O 
the O 
reinforcing O 
and O 
motivational O 
effects O 
of O 
cocaine B-TRIVIAL 
, O 
heroin B-TRIVIAL 
and O 
ethanol B-SYSTEMATIC 
, O 
as O 
assessed O 
by O 
the O 
intravenous O 
drug O 
self O 
- O 
administration O 
procedure O 
. O 
In O 
addition O 
, O 
AMN082 B-IDENTIFIER 
inhibited O 
the O 
reward O 
- O 
enhancing O 
effects O 
induced O 
by O 
cocaine B-TRIVIAL 
, O 
as O 
assessed O 
in O 
the O 
intracranial O 
self O 
- O 
stimulation O 
procedure O 
, O 
and O 
cocaine B-TRIVIAL 
- O 
or O 
cue O 
- O 
induced O 
reinstatement O 
of O 
drug O 
- O 
seeking O 
behavior O 
. O 
In O 
vivo O 
microdialysis O 
studies O 
indicated O 
that O 
systemic O 
or O 
intra-NAc O 
administration O 
of O 
AMN082 B-IDENTIFIER 
significantly O 
decreased O 
extracellular O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
and O 
elevated O 
extracellular O 
glutamate B-TRIVIAL 
, O 
but O 
had O 
no O 
effect O 
on O 
extracellular O 
dopamine B-TRIVIAL 
in O 
the O 
NAc O 
, O 
suggesting O 
that O 
a O 
non-dopaminergic O 
mechanism O 
underlies O 
the O 
effects O 
of O 
AMN082 B-IDENTIFIER 
on O 
the O 
actions O 
of O 
cocaine B-TRIVIAL 
. O 
Further O 
, O 
data O 
indicated O 
that O 
AMN082 B-IDENTIFIER 
-induced O 
changes O 
in O 
glutamate B-TRIVIAL 
were O 
the O 
net O 
effect O 
of O 
two O 
actions O 
: O 
one O 
is O 
the O 
direct O 
inhibition O 
of O 
glutamate B-TRIVIAL 
release O 
by O 
activation O 
of O 
mGlu7 O 
receptors O 
on O 
glutamatergic O 
neurons O 
; O 
another O 
is O 
the O 
indirect O 
increases O 
of O 
glutamate B-TRIVIAL 
release O 
mediated O 
by O 
decreases O 
in O 
GABA B-ABBREVIATION 
transmission O 
. O 
These O 
increases O 
in O 
extracellular O 
glutamate B-TRIVIAL 
functionally O 
antagonized O 
cocaine B-TRIVIAL 
-induced O 
inhibition O 
of O 
NAc-ventral O 
pallidum B-SYSTEMATIC 
GABAergic O 
neurotransmission O 
, O 
and O 
therefore O 
, O 
the O 
rewarding O 
effects O 
of O 
cocaine B-TRIVIAL 
. O 
In O 
addition O 
, O 
elevated O 
extracellular O 
glutamate B-TRIVIAL 
activated O 
presynaptic O 
mGlu2 O 
/ O 
3 O 
autoreceptors O 
which O 
in O 
turn O 
inhibited O 
cocaine B-TRIVIAL 
priming- O 
or O 
cue O 
- O 
induced O 
enhancement O 
of O 
glutamate B-TRIVIAL 
release O 
and O 
reinstatement O 
of O 
drug O 
- O 
seeking O 
behavior O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
suggest O 
that O 
the O 
mGlu7 O 
receptor O 
is O 
an O 
important O 
target O 
for O 
medication O 
development O 
for O 
the O 
treatment O 
of O 
drug O 
dependence O 
. O 
AMN082 B-IDENTIFIER 
or O 
other O 
mGlu7 O 
receptor O 
allosteric O 
agonists O 
may O 
have O 
potential O 
as O 
novel O 
pharmacotherapies O 
for O 
cocaine B-TRIVIAL 
addiction O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

work O 
demonstrates O 
that O 
metal O 
nanowires O 
in O 
a O 
percolating O 
network O 
can O 
reversibly O 
slide O 
across O 
one O 
another O 
. O 
Reversible O 
sliding O 
allows O 
networks O 
of O 
metal O 
nanowires O 
to O 
maintain O 
electrical O 
contact O 
while O 
being O 
stretched O 
to O 
strains O 
greater O 
than O 
the O 
fracture O 
strain O 
for O 
individual O 
nanowires O 
. O 
This O 
phenomenon O 
was O 
demonstrated O 
by O 
using O 
networks O 
of O 
nanowires O 
as O 
compliant O 
electrodes O 
for O 
a O 
dielectric O 
elastomer O 
actuator O 
. O 
Reversible O 
nanowire O 
sliding O 
enabled O 
actuation O 
to O 
a O 
maximum O 
area O 
strain O 
of O 
200% O 
, O 
and O 
repetitive O 
cycling O 
of O 
the O 
actuator O 
to O 
an O 
area O 
strain O 
of O 
25% O 
over O 
150 O 
times O 
. O 
During O 
actuation O 
, O 
the O 
transmittance O 
of O 
the O 
network O 
increased O 
4.5 O 
times O 
, O 
from O 
13% O 
to O 
58% O 
. O 
Compared O 
to O 
carbon B-SYSTEMATIC 
-based O 
compliant O 
electrodes O 
, O 
networks O 
of O 
metal O 
nanowires O 
can O 
actuate O 
across O 
a O 
broader O 
range O 
of O 
optical O 
transmittance O 
. O 
The O 
widely O 
tunable O 
transmittance O 
of O 
nanowire O 
- O 
based O 
actuators O 
allows O 
for O 
their O 
use O 
as O 
a O 
light O 
valve O 
. O 

femoral O 
fractures O 
( O 
AFF O 
) O 
associated O 
with O 
long O 
- O 
term O 
bisphosphonates B-FAMILY 
( O 
LTB O 
) O 
are O 
a O 
growing O 
concern O 
. O 
Their O 
etiology O 
is O 
unknown O 
, O 
but O 
bone O 
material O 
properties O 
might O 
be O 
deteriorated O 
. O 
In O 
an O 
AFF O 
series O 
, O 
we O 
analyzed O 
the O 
bone O 
material O 
properties O 
by O 
microindentation O 
. O 
Four O 
groups O 
of O 
patients O 
were O 
included O 
: O 
6 O 
AFF O 
, O 
38 O 
typical O 
osteoporotic O 
fractures O 
, O 
6 O 
LTB O 
, O 
and O 
20 O 
controls O 
without O 
fracture O 
. O 
Neither O 
typical O 
osteoporotic O 
fractures O 
nor O 
controls O 
have O 
received O 
any O 
antiosteoporotic O 
medication O 
. O 
A O 
general O 
laboratory O 
workup O 
, O 
bone O 
densitometry O 
by O 
dual O 
- O 
energy O 
X-ray O 
absorptiometry O 
( O 
DXA O 
) O 
, O 
and O 
microindentation O 
testing O 
at O 
the O 
tibia O 
were O 
done O 
in O 
all O 
patients O 
. O 
Total O 
indentation O 
distance O 
( O 
Total O 
ID O 
) O 
, O 
indentation O 
distance O 
increase O 
( O 
IDI O 
) O 
, O 
and O 
creep O 
indentation O 
distance O 
( O 
Creep O 
ID O 
) O 
were O 
measured O 
( O 
microns O 
) O 
. O 
Age O 
- O 
adjusted O 
analysis O 
of O 
covariance O 
( O 
ANCOVA O 
) O 
was O 
used O 
for O 
comparisons O 
. O 
Controls O 
were O 
significantly O 
younger O 
than O 
fracture O 
groups O 
. O 
Bisphosphonate B-SYSTEMATIC 
exposure O 
was O 
on O 
average O 
5.5 O 
years O 
( O 
range O 
5 O 
to O 
12 O 
years O 
) O 
for O 
the O 
AFF O 
and O 
5.4 O 
years O 
( O 
range O 
5 O 
to O 
8 O 
years O 
) O 
for O 
the O 
LTB O 
groups O 
. O 
Total O 
ID O 
( O 
microns O 
) O 
showed O 
better O 
material O 
properties O 
( O 
lower O 
Total O 
ID O 
) O 
for O 
controls O 
36 O 
( O 
± O 
6 O 
; O 
mean O 
± O 
SD O 
) O 
than O 
for O 
AFF O 
46 O 
( O 
± O 
4 O 
) O 
and O 
for O 
typical O 
femoral O 
fractures O 
47 O 
( O 
± O 
13 O 
) O 
, O 
respectively O 
. O 
Patients O 
on O 
LTB O 
showed O 
values O 
between O 
controls O 
and O 
fractures O 
, O 
38 O 
( O 
± O 
4 O 
) O 
, O 
although O 
not O 
significantly O 
different O 
from O 
any O 
of O 
the O 
other O 
three O 
groups O 
. O 
IDI O 
values O 
showed O 
a O 
similar O 
pattern O 
13 O 
( O 
± O 
2 O 
) O 
, O 
16 O 
( O 
± O 
6 O 
) O 
, O 
19 O 
( O 
± O 
3 O 
) O 
, O 
and O 
18 O 
( O 
± O 
5 O 
) O 
. O 
After O 
adjusting O 
by O 
age O 
, O 
significant O 
differences O 
were O 
seen O 
between O 
controls O 
and O 
typical O 
( O 
p O 
< O 
0.001 O 
) O 
and O 
atypical O 
fractures O 
( O 
p O 
= O 
0.03 O 
) O 
for O 
Total O 
ID O 
and O 
for O 
IDI O 
( O 
p O 
< O 
0.001 O 
and O 
p O 
< O 
0.05 O 
, O 
respectively O 
) O 
. O 
There O 
were O 
no O 
differences O 
in O 
Creep O 
ID O 
between O 
groups O 
. O 
Our O 
data O 
suggest O 
that O 
patients O 
with O 
AFF O 
have O 
a O 
deep O 
deterioration O 
in O 
bone O 
material O 
properties O 
at O 
a O 
tissue O 
level O 
similar O 
to O 
that O 
for O 
the O 
osteoporotic O 
fracture O 
group O 
. O 
The O 
LTB O 
group O 
shows O 
levels O 
that O 
are O 
in O 
between O 
controls O 
and O 
both O 
type O 
of O 
fractures O 
, O 
although O 
not O 
statistically O 
different O 
. O 
These O 
results O 
suggest O 
that O 
bisphosphonate B-SYSTEMATIC 
therapy O 
probably O 
does O 
not O 
put O 
the O 
majority O 
of O 
patients O 
at O 
risk O 
for O 
AFF O 
. O 

: O 
The O 
mTOR O 
( O 
mechanistic O 
target O 
of O 
rapamycin B-TRIVIAL 
, O 
formerly O 
known O 
as O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
) O 
kinase O 
is O 
centrally O 
involved O 
in O 
the O 
regulation O 
of O 
cell O 
growth O 
and O 
metabolism O 
in O 
response O 
to O 
intra- O 
and O 
extracellular O 
energetic O 
stimuli O 
and O 
growth O 
factors O 
. O 
The O 
importance O 
of O 
mTOR O 
in O 
health O 
and O 
diseases O 
has O 
fueled O 
the O 
development O 
of O 
molecules O 
that O 
inhibit O 
mTOR O 
signaling O 
, O 
including O 
rapalogs O 
( O 
sirolimus B-TRIVIAL 
, O 
temsirolimus B-TRIVIAL 
, O 
everolimus B-TRIVIAL 
and O 
deforolimus B-TRIVIAL 
) O 
, O 
which O 
complex O 
with O 
FK506 O 
- O 
binding O 
protein O 
12 O 
( O 
FK-BP12 O 
) O 
to O 
inhibit O 
mTOR O 
complex O 
1 O 
( O 
MTORC1 O 
) O 
activity O 
in O 
an O 
allosteric O 
manner O 
, O 
or O 
the O 
more O 
recent O 
ATP B-ABBREVIATION 
-competitive O 
mTOR O 
inhibitors O 
( O 
mTORi O 
) O 
, O 
which O 
target O 
the O 
catalytic O 
site O 
of O 
the O 
enzyme O 
. O 
However O 
, O 
clinical O 
development O 
of O 
these O 
mTORi O 
has O 
revealed O 
that O 
these O 
drugs O 
produced O 
numerous O 
side O 
effects O 
that O 
could O 
be O 
serious O 
and O 
/ O 
or O 
debilitating O 
. O 
Despite O 
pharmacological O 
efforts O 
to O 
develop O 
drugs O 
with O 
an O 
improved O 
safety O 
profile O 
, O 
these O 
side O 
effects O 
are O 
often O 
unpredictable O 
and O 
may O 
frequently O 
preclude O 
the O 
efficiency O 
of O 
mTORi O 
. O 
AREAS O 
COVERED O 
: O 
The O 
objective O 
of O 
this O 
review O 
is O 
to O 
perform O 
a O 
comprehensive O 
survey O 
of O 
the O 
safety O 
profiles O 
of O 
various O 
rapalog O 
- O 
based O 
therapies O 
from O 
the O 
available O 
clinical O 
literature O 
. O 
The O 
authors O 
will O 
discuss O 
the O 
potential O 
mechanisms O 
of O 
these O 
therapies O 
, O 
taking O 
into O 
account O 
the O 
knowledge O 
of O 
the O 
biological O 
pathways O 
regulated O 
by O 
mTOR O 
. O 
EXPERT O 
OPINION O 
: O 
A O 
better O 
prevention O 
and O 
management O 
of O 
mTORi O 
- O 
related O 
side O 
effects O 
requires O 
the O 
identification O 
of O 
alterations O 
in O 
related O 
biological O 
pathways O 
that O 
will O 
help O 
to O 
delineate O 
therapeutic O 
targets O 
. O 

potential O 
of O 
synthesizing O 
new O 
nanocomposites O 
from O 
nanocrystalline O 
cellulose O 
( O 
NCC O 
) O 
and O 
fibrin O 
for O 
small O 
- O 
diameter O 
replacement O 
vascular O 
graft O 
( O 
SDRVG O 
) O 
application O 
was O 
demonstrated O 
. O 
Periodate O 
oxidation O 
of O 
NCC O 
can O 
augment O 
reactive O 
carbonyl B-FAMILY 
groups O 
on O 
NCC O 
and O 
facilitate O 
its O 
cross O 
- O 
linking O 
with O 
fibrin O 
. O 
NCC-fibrin O 
nanocomposites O 
were O 
synthesized O 
, O 
composed O 
of O 
homogeneously O 
dispersed O 
oxidized O 
NCC O 
( O 
ONCC O 
) O 
in O 
a O 
fibrin O 
matrix O 
, O 
with O 
fibrin O 
providing O 
elasticity O 
and O 
ONCC O 
providing O 
strength O 
. O 
The O 
maximum O 
strength O 
and O 
elongation O 
of O 
the O 
nanocomposites O 
were O 
determined O 
by O 
Atomic O 
Force O 
Microscopy O 
( O 
AFM O 
) O 
and O 
compared O 
with O 
a O 
native O 
blood O 
vessel O 
. O 
The O 
manipulation O 
of O 
degree O 
of O 
oxidation O 
of O 
NCC O 
and O 
the O 
NCC-to O 
- O 
fibrin O 
ratio O 
resulted O 
in O 
the O 
variation O 
of O 
strength O 
and O 
elongation O 
of O 
the O 
nanocomposites O 
, O 
indicating O 
that O 
the O 
nanocomposites O 
can O 
be O 
tailored O 
to O 
conform O 
to O 
the O 
diverse O 
mechanical O 
properties O 
of O 
native O 
blood O 
vessels O 
. O 
A O 
mechanistic O 
understanding O 
of O 
the O 
molecular O 
interactions O 
of O 
ONCC O 
and O 
fibrin O 
was O 
illustrated O 
. O 
This O 
study O 
established O 
fundamental O 
information O 
to O 
utilizing O 
NCC O 
for O 
SDRVG O 
applications O 
. O 

present O 
in O 
the O 
soil O 
- O 
vine O 
- O 
wine O 
chain O 
in O 
vineyards O 
situated O 
in O 
an O 
old O 
mining O 
area O 
in O 
Trentino O 
, O 
Italy O 
. O 

present O 
study O 
follows O 
arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
) O 
transfer O 
through O 
the O 
chain O 
of O 
soil O 
- O 
vine O 
- O 
leaves O 
- O 
grapes O 
- O 
wine O 
to O 
assess O 
the O 
possible O 
risk O 
of O 
arsenic B-SYSTEMATIC 
intake O 
related O 
to O 
consuming O 
grapes O 
and O 
wines O 
produced O 
in O 
10 O 
vineyards O 
located O 
in O 
a O 
mining O 
area O 
rich O 
in O 
this O 
element O 
. O 
The O 
results O 
are O 
compared O 
with O 
date O 
from O 
18 O 
uncontaminated O 
areas O 
. O 
In O 
the O 
soil O 
, O 
the O 
content O 
of O 
As B-FORMULA 
extracted O 
with O 
acqua O 
regia O 
and O 
that O 
extracted O 
with O 
ammonium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
were O 
analyzed O 
. O 
Leaves O 
and O 
berries O 
were O 
analyzed O 
after O 
washing O 
with O 
acidified O 
aqueous O 
solution O 
and O 
acid O 
mineralization O 
in O 
a O 
closed O 
vessel O 
, O 
whereas O 
wines O 
were O 
simply O 
diluted O 
before O 
analysis O 
. O 
All O 
analyses O 
were O 
performed O 
using O 
an O 
inductively O 
coupled O 
plasma O 
mass O 
- O 
spectrometer O 
. O 
The O 
aqua O 
regia O 
extractable O 
As B-FORMULA 
concentration O 
in O 
soil O 
ranged O 
from O 
3.7 O 
to O 
283 O 
mg O 
/ O 
kg O 
, O 
whereas O 
available O 
As B-FORMULA 
varied O 
from O 
18 O 
to O 
639 O 
µg O 
/ O 
kg O 
, O 
and O 
As B-FORMULA 
total O 
concentration O 
ranged O 
from O 
16.3 O 
to O 
579 O 
µg O 
/ O 
kg O 
dry O 
weight O 
in O 
leaves O 
and O 
from O 
< O 
0.1 O 
to O 
36.8 O 
µg O 
/ O 
kg O 
dry O 
weight O 
in O 
grapes O 
. O 
Arsenic B-SYSTEMATIC 
levels O 
in O 
wines O 
were O 
always O 
below O 
1.62 O 
µg O 
/ O 
L O 
, O 
with O 
higher O 
concentration O 
in O 
red O 
wines O 
than O 
in O 
white O 
wines O 
. O 
Significant O 
and O 
positive O 
correlations O 
between O 
the O 
As B-FORMULA 
concentrations O 
in O 
soils O 
, O 
leaves O 
, O 
and O 
berries O 
are O 
highlighted O 
, O 
with O 
the O 
samples O 
collected O 
near O 
the O 
mining O 
area O 
having O 
significantly O 
higher O 
values O 
. O 
Nevertheless O 
, O 
As B-FORMULA 
levels O 
in O 
wines O 
were O 
always O 
well O 
below O 
the O 
limit O 
( O 
200 O 
µg O 
/ O 
L O 
) O 
suggested O 
by O 
the O 
International O 
Organization O 
of O 
Vine O 
and O 
Wine O 
. O 

, O 
antimicrobial O 
evaluation O 
and O 
molecular O 
modelling O 
of O 
novel O 
sulfonamides B-FAMILY 
carrying O 
a O 
biologically O 
active O 
quinazoline B-SYSTEMATIC 
nucleus O 
. O 

novel O 
series O 
of O 
quinazolines B-FAMILY 
5-10 O 
, O 
triazoloquinazolines B-FAMILY 
11-17 O 
and O 
triazinoquinazoline B-FAMILY 
19 O 
bearing O 
a O 
biologically O 
active O 
sulfonamide B-SYSTEMATIC 
moiety O 
were O 
synthesized O 
, O 
utilizing O 
methyl B-SYSTEMATIC 
2-isothiocyanato I-SYSTEMATIC 
benzoate I-SYSTEMATIC 
2 O 
. O 
Some O 
of O 
the O 
newly O 
synthesized O 
compounds O 
revealed O 
promising O 
bacterial O 
growth O 
inhibition O 
, O 
compared O 
with O 
the O 
ampicillin B-TRIVIAL 
, O 
as O 
the O 
reference O 
drug O 
. O 
A O 
LigandScout O 
approach O 
- O 
generated O 
pharmacophore O 
model O 
for O 
the O 
Staph O 
aureus O 
bacteria O 
growth O 
inhibition O 
was O 
done O 
. O 
The O 
degree O 
of O 
fitting O 
of O 
the O 
test O 
set O 
compounds O 
( O 
3 O 
, O 
4 O 
, O 
6 O 
, O 
8 O 
, O 
11 O 
, O 
17 O 
) O 
to O 
the O 
generated O 
hypothetical O 
model O 
revealed O 
a O 
qualitative O 
measure O 
of O 
the O 
more O 
or O 
less O 
microbial O 
inhibition O 
of O 
Staphylococcus O 
aureus O 
. O 
Compounds O 
( O 
7 O 
, O 
8 O 
, O 
10 O 
, O 
12 O 
, O 
15 O 
, O 
17 O 
and O 
22 O 
) O 
, O 
which O 
revealed O 
significant O 
activity O 
, O 
are O 
able O 
to O 
effectively O 
satisfy O 
the O 
proposed O 
pharmacophore O 
geometry O 
, O 
using O 
the O 
energy O 
accessible O 
conformers O 
( O 
E O 
conf O 
< O 
20 O 
kcal O 
/ O 
mol O 
) O 
. O 

freshwater O 
fish O 
, O 
Rasbora O 
sumatrana O 
( O 
Cyprinidae O 
) O 
and O 
Poecilia O 
reticulata O 
( O 
guppy O 
; O 
Poeciliidae O 
) O 
, O 
were O 
exposed O 
to O 
a O 
range O 
of O 
eight O 
heavy O 
metals O 
( O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
, O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
, O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
, O 
lead O 
( O 
Pb B-FORMULA 
) O 
, O 
nickel B-SYSTEMATIC 
( O 
Ni B-FORMULA 
) O 
, O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
, O 
aluminium B-SYSTEMATIC 
( O 
Al B-FORMULA 
) O 
, O 
and O 
manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
) O 
at O 
varied O 
concentrations O 
for O 
96 O 
h O 
in O 
the O 
laboratory O 
. O 
Mortality O 
was O 
assessed O 
and O 
median O 
lethal O 
concentrations O 
(LC(50)) O 
were O 
calculated O 
. O 
It O 
was O 
observed O 
that O 
the O 
LC(50) O 
values O 
increased O 
with O 
a O 
decrease O 
in O 
mean O 
exposure O 
times O 
, O 
for O 
all O 
metals O 
and O 
for O 
both O 
fish O 
types O 
. O 
The O 
96-h O 
LC(50) O 
values O 
for O 
Cu B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Pb B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Al B-FORMULA 
, O 
and O 
Mn B-FORMULA 
were O 
0.006 O 
, O 
0.1 O 
, O 
0.46 O 
, O 
0.63 O 
, O 
0.83 O 
, O 
1.71 O 
, O 
1.53 O 
, O 
and O 
5.71 O 
mg O 
/ O 
L O 
for O 
R O 
. O 
sumatrana O 
and O 
0.038 O 
, O 
0.17 O 
, O 
1.06 O 
, O 
1.99 O 
, O 
15.62 O 
, O 
1.46 O 
, O 
6.76 O 
, O 
and O 
23.91 O 
mg O 
/ O 
L O 
for O 
P O 
. O 
reticulata O 
, O 
respectively O 
. O 
The O 
metal O 
toxicity O 
trend O 
for O 
R O 
. O 
sumatrana O 
and O 
P O 
. O 
reticulata O 
from O 
most O 
to O 
least O 
toxic O 
was O 
Cu B-FORMULA 
> O 
Cd B-FORMULA 
> O 
Zn B-FORMULA 
> O 
Pb B-FORMULA 
> O 
Ni B-FORMULA 
> O 
Al B-FORMULA 
> O 
Fe B-FORMULA 
> O 
Mn B-FORMULA 
and O 
Cu B-FORMULA 
> O 
Cd B-FORMULA 
> O 
Zn B-FORMULA 
> O 
Fe B-FORMULA 
> O 
Pb B-FORMULA 
> O 
Al B-FORMULA 
> O 
Ni B-FORMULA 
> O 
Mn B-FORMULA 
, O 
respectively O 
. O 
Results O 
indicated O 
that O 
Cu B-FORMULA 
was O 
the O 
most O 
toxic O 
metal O 
on O 
both O 
fish O 
, O 
and O 
R O 
. O 
sumatrana O 
was O 
more O 
sensitive O 
than O 
P O 
. O 
reticulata O 
to O 
all O 
the O 
eight O 
metals O 
. O 

type O 
voltage O 
- O 
dependent O 
calcium B-SYSTEMATIC 
channel O 
is O 
involved O 
in O 
the O 
snake O 
venom O 
group O 
IA O 
secretory O 
phospholipase O 
A2-induced O 
neuronal O 
apoptosis O 
. O 

venom O 
group O 
IA O 
secretory O 
phospholipase O 
A2 O 
( O 
sPLA2-IA O 
) O 
is O 
known O 
as O 
a O 
neurotoxin O 
. O 
Snake O 
venom O 
sPLA2s O 
are O 
neurotoxic O 
in O 
vivo O 
and O 
in O 
vitro O 
, O 
causing O 
synergistic O 
neurotoxicity O 
to O 
cortical O 
cultures O 
when O 
applied O 
with O 
toxic O 
concentrations O 
of O 
glutamate B-TRIVIAL 
. O 
However O 
, O 
it O 
has O 
not O 
yet O 
been O 
cleared O 
sufficiently O 
how O 
sPLA2-IA O 
exerts O 
neurotoxicity O 
. O 
Here O 
, O 
we O 
found O 
sPLA2-IA O 
induced O 
neuronal O 
cell O 
death O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
This O 
death O 
was O 
a O 
delayed O 
response O 
requiring O 
a O 
latent O 
time O 
for O 
6h O 
. O 
sPLA2-IA-induced O 
neuronal O 
cell O 
death O 
was O 
accompanied O 
with O 
apoptotic O 
blebbing O 
, O 
condensed O 
chromatin O 
, O 
and O 
fragmented O 
DNA O 
, O 
exhibiting O 
apoptotic O 
features O 
. O 
NMDA B-ABBREVIATION 
receptor O 
blockers O 
suppressed O 
the O 
neurotoxicity O 
of O 
sPLA2-IA O 
, O 
but O 
an O 
AMPA B-ABBREVIATION 
receptor O 
blocker O 
did O 
not O 
. O 
Interestingly O 
, O 
L- O 
type O 
voltage O 
- O 
dependent O 
Ca(2+) B-FORMULA 
channel O 
( O 
L-VDCC O 
) O 
blocker O 
significantly O 
protected O 
neurons O 
from O 
the O 
sPLA2-IA-induced O 
apoptosis O 
. O 
On O 
the O 
other O 
hand O 
, O 
neither O 
N-VDCC O 
blockers O 
nor O 
P O 
/ O 
Q-VDCC O 
blocker O 
did O 
. O 
In O 
conclusion O 
, O 
we O 
demonstrated O 
that O 
sPLA2-IA O 
induced O 
neuronal O 
cell O 
death O 
via O 
apoptosis O 
. O 
Furthermore O 
, O 
the O 
present O 
study O 
suggests O 
that O 
not O 
only O 
NMDA B-ABBREVIATION 
receptor O 
but O 
also O 
L-VDCC O 
contributed O 
to O 
the O 
neurotoxicity O 
of O 
snake O 
venom O 
sPLA2-IA O 
. O 

25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
, O 
parathyroid O 
hormone O 
, O 
and O 
their O 
association O 
with O 
metabolic O 
syndrome O 
in O 
Chinese O 
. O 

evidence O 
suggests O 
that O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
[ O 
25(OH)D B-SYSTEMATIC 
] O 
and O 
parathyroid O 
hormone O 
( O 
PTH O 
) O 
levels O 
are O 
associated O 
with O 
metabolic O 
syndrome O 
( O 
MetS O 
) O 
. O 
In O 
2010 O 
, O 
we O 
explored O 
the O 
association O 
of O 
serum O 
25(OH)D B-SYSTEMATIC 
and O 
PTH O 
levels O 
with O 
MetS O 
in O 
1390 O 
Chinese O 
participants O 
, O 
aged O 
20-83 O 
years O 
. O 
Anthropometric O 
phenotypes O 
, O 
blood O 
pressure O 
, O 
and O 
the O 
incidence O 
of O 
MetS O 
were O 
evaluated O 
. O 
In O 
addition O 
, O 
serum O 
lipids O 
, O 
25(OH)D B-SYSTEMATIC 
, O 
and O 
PTH O 
were O 
measured O 
. O 
The O 
median O 
concentration O 
of O 
25(OH)D B-SYSTEMATIC 
and O 
PTH O 
were O 
55.3 O 
nmol O 
/ O 
l O 
and O 
2.8 O 
pmol O 
/ O 
l O 
, O 
respectively O 
. O 
The O 
prevalence O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
( O 
< O 
50 O 
nmol O 
/ O 
l O 
) O 
was O 
39.9 O 
% O 
, O 
with O 
34.5 O 
% O 
in O 
men O 
and O 
47.8 O 
% O 
in O 
women O 
. O 
After O 
accounting O 
for O 
confounding O 
factors O 
and O 
serum O 
PTH O 
, O 
a O 
10 O 
nmol O 
/ O 
l O 
higher O 
serum O 
25(OH)D B-SYSTEMATIC 
level O 
was O 
associated O 
with O 
a O 
10 O 
% O 
lower O 
risk O 
of O 
MetS O 
( O 
OR O 
= O 
0.9 O 
, O 
95 O 
% O 
CI O 
0.84-0.96 O 
, O 
P O 
= O 
0.0007 O 
) O 
. O 
Furthermore O 
, O 
participants O 
with O 
vitamin B-FAMILY 
D I-FAMILY 
sufficiency O 
had O 
a O 
35 O 
% O 
lower O 
risk O 
of O 
MetS O 
than O 
those O 
with O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
( O 
OR O 
= O 
0.65 O 
, O 
95 O 
% O 
CI O 
0.51-0.84 O 
, O 
P O 
= O 
0.0009 O 
) O 
. O 
PTH O 
was O 
not O 
associated O 
with O 
the O 
risk O 
of O 
MetS O 
after O 
adjustment O 
for O 
confounding O 
factors O 
. O 
These O 
results O 
were O 
confirmed O 
in O 
both O 
men O 
and O 
women O 
. O 
Thus O 
in O 
this O 
cohort O 
of O 
Chinese O 
individuals O 
, O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
is O 
common O 
and O 
optimal O 
vitamin B-FAMILY 
D I-FAMILY 
level O 
is O 
inversely O 
associated O 
with O 
MetS O 
, O 
independent O 
of O 
several O 
confounders O 
and O 
PTH O 
level O 
. O 
The O 
clinical O 
significance O 
of O 
these O 
findings O 
warrants O 
further O 
study O 
. O 

of O 
the O 
5-hydroxymethylcytosine B-SYSTEMATIC 
-specific O 
DNA O 
restriction O 
endonucleases O 
. O 

T4 O 
bacteriophage O 
, O 
5-hydroxymethylcytosine B-SYSTEMATIC 
( O 
5hmC B-SYSTEMATIC 
) O 
is O 
incorporated O 
into O 
DNA O 
during O 
replication O 
. O 
In O 
response O 
, O 
bacteria O 
may O 
have O 
developed O 
modification O 
- O 
dependent O 
type O 
IV O 
restriction O 
enzymes O 
to O 
defend O 
the O 
cell O 
from O 
T4 O 
- O 
like O 
infection O 
. O 
PvuRts1I O 
was O 
the O 
first O 
identified O 
restriction O 
enzyme O 
to O 
exhibit O 
specificity O 
toward O 
hmC B-ABBREVIATION 
over O 
5-methylcytosine B-SYSTEMATIC 
( O 
5mC B-SYSTEMATIC 
) O 
and O 
cytosine B-TRIVIAL 
. O 
By O 
using O 
PvuRts1I O 
as O 
the O 
original O 
member O 
, O 
we O 
identified O 
and O 
characterized O 
a O 
number O 
of O 
homologous O 
proteins O 
. O 
Most O 
enzymes O 
exhibited O 
similar O 
cutting O 
properties O 
to O 
PvuRts1I O 
, O 
creating O 
a O 
double O 
- O 
stranded O 
cleavage O 
on O 
the O 
3 O 
' O 
side O 
of O 
the O 
modified O 
cytosine B-TRIVIAL 
. O 
In O 
addition O 
, O 
for O 
efficient O 
cutting O 
, O 
the O 
enzymes O 
require O 
two O 
cytosines B-FAMILY 
21-22-nt O 
apart O 
and O 
on O 
opposite O 
strands O 
where O 
one O 
cytosine B-TRIVIAL 
must O 
be O 
modified O 
. O 
Interestingly O 
, O 
the O 
specificity O 
determination O 
unveiled O 
a O 
new O 
layer O 
of O 
complexity O 
where O 
the O 
enzymes O 
not O 
only O 
have O 
specificity O 
for O 
5-β-glucosylated B-SYSTEMATIC 
hmC I-SYSTEMATIC 
( O 
5βghmC B-SYSTEMATIC 
) O 
but O 
also O 
5-α-glucosylated B-SYSTEMATIC 
hmC I-SYSTEMATIC 
( O 
5αghmC B-SYSTEMATIC 
) O 
. O 
In O 
some O 
cases O 
, O 
the O 
enzymes O 
are O 
inhibited O 
by O 
5βghmC B-SYSTEMATIC 
, O 
whereas O 
in O 
others O 
they O 
are O 
inhibited O 
by O 
5αghmC B-SYSTEMATIC 
. O 
These O 
observations O 
indicate O 
that O 
the O 
position O 
of O 
the O 
sugar B-FAMILY 
ring O 
relative O 
to O 
the O 
base O 
is O 
a O 
determining O 
factor O 
in O 
the O 
substrate O 
specificity O 
of O 
the O 
PvuRts1I O 
homologues O 
. O 
Lastly O 
, O 
we O 
envision O 
that O 
the O 
unique O 
properties O 
of O 
select O 
PvuRts1I O 
homologues O 
will O 
permit O 
their O 
use O 
as O 
an O 
additive O 
or O 
alternative O 
tool O 
to O 
map O 
the O 
hydroxymethylome O 
. O 

new O 
triterpene B-FAMILY 
glycosides I-FAMILY 
from O 
Ilex O 
asprella O 
. O 

new O 
sulfated B-FAMILY 
triterpene I-FAMILY 
glycosides I-FAMILY 
, O 
asprellanosides B-MULTIPLE 
C-E I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Ilex O 
asprella O 
. O 
Their O 
structures O 
were O 
elucidated O 
as O 
3β-[(2-O-sulfo-β-d-xylopyranosyl)oxy]urs-12,19(29)-diene-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
28-β-d-glucopyranoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
3β-[(2-O-sulfo-β-d-xylopyranosyl)oxy]urs-12,19-diene-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
28-β-d-glucopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
3β-[(2-O-sulfo-β-d-xylopyranosyl)oxy]urs-12,19-diene-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3 O 
) O 
on O 
the O 
basis O 
of O 
the O 
spectral O 
and O 
chemical O 
methods O 
. O 

fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
is O 
considered O 
the O 
most O 
common O 
liver O 
disorder O 
in O 
the O 
Western O 
world O 
. O 
It O 
is O 
commonly O 
associated O 
with O 
insulin O 
resistance O 
, O 
obesity O 
, O 
dyslipidaemia O 
, O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
and O 
cardiovascular O 
disease O 
. O 
Nonalcoholic O 
steatohepatitis O 
( O 
NASH O 
) O 
is O 
characterized O 
by O 
steatosis O 
with O 
necroinflammation O 
and O 
eventual O 
fibrosis O 
, O 
which O 
can O 
lead O 
to O 
end O 
- O 
stage O 
liver O 
disease O 
and O 
hepatocellular O 
carcinoma O 
. O 
Its O 
pathogenesis O 
is O 
complex O 
, O 
and O 
involves O 
a O 
state O 
of O 
' O 
lipotoxicity O 
' O 
in O 
which O 
insulin O 
resistance O 
, O 
with O 
increased O 
free B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
release O 
from O 
adipose O 
tissue O 
to O 
the O 
liver O 
, O 
play O 
a O 
key O 
role O 
in O 
the O 
onset O 
of O 
a O 
' O 
lipotoxic O 
liver O 
disease O 
' O 
and O 
its O 
progression O 
to O 
NASH O 
. O 
The O 
diagnosis O 
of O 
NASH O 
is O 
challenging O 
, O 
as O 
most O 
affected O 
patients O 
are O 
symptom O 
free O 
and O 
the O 
role O 
of O 
routine O 
screening O 
is O 
not O 
clearly O 
established O 
. O 
A O 
complete O 
medical O 
history O 
is O 
important O 
to O 
rule O 
out O 
other O 
causes O 
of O 
fatty O 
liver O 
disease O 
( O 
alcohol B-FAMILY 
abuse O 
, O 
medications O 
, O 
other O 
) O 
. O 
Plasma O 
aminotransferase O 
levels O 
and O 
liver O 
ultrasound O 
are O 
helpful O 
in O 
the O 
diagnosis O 
of O 
NAFLD O 
/ O 
NASH O 
, O 
but O 
a O 
liver O 
biopsy O 
is O 
often O 
required O 
for O 
a O 
definitive O 
diagnosis O 
. O 
However O 
, O 
there O 
is O 
an O 
active O 
search O 
for O 
plasma O 
biomarkers O 
and O 
imaging O 
techniques O 
that O 
may O 
non-invasively O 
aid O 
in O 
the O 
diagnosis O 
. O 
The O 
treatment O 
of O 
NASH O 
requires O 
a O 
multifaceted O 
approach O 
. O 
The O 
goal O 
is O 
to O 
reverse O 
obesity O 
- O 
associated O 
lipotoxicity O 
and O 
insulin O 
resistance O 
via O 
lifestyle O 
intervention O 
. O 
Although O 
there O 
is O 
no O 
pharmacological O 
agent O 
approved O 
for O 
the O 
treatment O 
of O 
NAFLD O 
, O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
in O 
patients O 
without O 
T2DM O 
) O 
and O 
the O 
thiazolidinedione O 
pioglitazone B-TRIVIAL 
( O 
in O 
patients O 
with O 
and O 
without O 
T2DM O 
) O 
have O 
shown O 
the O 
most O 
consistent O 
results O 
in O 
randomized O 
controlled O 
trials O 
. O 
This O 
review O 
concentrates O 
on O 
our O 
current O 
understanding O 
of O 
the O 
disease O 
, O 
with O 
a O 
focus O 
on O 
the O 
existing O 
therapeutic O 
approaches O 
and O 
potential O 
future O 
pharmacological O 
developments O 
for O 
NAFLD O 
and O 
NASH O 
. O 

training O 
of O 
monosodium B-SYSTEMATIC 
L-glutamate I-SYSTEMATIC 
-obese O 
mice O 
improves O 
the O 
impaired O 
insulin O 
receptor O 
tyrosine B-TRIVIAL 
phosphorylation O 
in O 
pancreatic O 
islets O 
. O 

goal O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
changes O 
on O 
glucose B-TRIVIAL 
homoeostasis O 
and O 
of O 
the O 
insulin O 
receptor O 
( O 
IR O 
) O 
and O 
insulin O 
receptor O 
substrate-1 O 
( O 
IRS-1 O 
) O 
signalling O 
in O 
pancreatic O 
islets O 
from O 
MSG B-ABBREVIATION 
-obese O 
mice O 
submitted O 
to O 
or O 
not O 
submitted O 
to O 
swim O 
training O 
. O 
Swim O 
training O 
of O 
90-day- O 
old O 
MSG B-ABBREVIATION 
mice O 
was O 
used O 
to O 
evaluate O 
whether O 
signalling O 
pathways O 
of O 
the O 
IR O 
and O 
IRS-1 O 
in O 
islets O 
are O 
involved O 
with O 
the O 
insulin O 
resistance O 
and O 
glucose B-TRIVIAL 
intolerance O 
observed O 
in O 
this O 
obese O 
animal O 
model O 
. O 
The O 
results O 
showed O 
that O 
IR O 
tyrosine B-TRIVIAL 
phosphorylation O 
( O 
pIR O 
) O 
was O 
reduced O 
by O 
42 O 
% O 
in O 
MSG B-ABBREVIATION 
-obese O 
mice O 
( O 
MSG B-ABBREVIATION 
, O 
6.7 O 
± O 
0.2 O 
arbitrary O 
units O 
( O 
a.u O 
. O 
) O 
; O 
control O 
, O 
11.5 O 
± O 
0.4 O 
a.u O 
. O 
) O 
; O 
on O 
the O 
other O 
hand O 
, O 
exercise O 
training O 
increased O 
pIR O 
by O 
76 O 
% O 
i O 
n B-ABBREVIATION 
M I-ABBREVIATION 
SG O 
mice O 
without O 
affecting O 
control O 
mice O 
( B-ABBREVIATION 
M I-ABBREVIATION 
SG O 
, O 
11.8 O 
± O 
0.3 O 
; O 
control O 
, O 
12.8 O 
± O 
0.2 O 
a.u O 
. O 
) O 
. O 
Although O 
the O 
treatment O 
wit O 
h B-ABBREVIATION 
M I-ABBREVIATION 
SG O 
increased O 
IRS- O 
1 B-TRIVIAL 
tyrosi I-TRIVIAL 
ne O 
phosphorylation O 
( O 
pIRS-1 O 
) O 
by O 
96 O 
% O 
( B-ABBREVIATION 
M I-ABBREVIATION 
SG O 
, O 
17.02 O 
± O 
0.6 O 
; O 
control O 
, O 
8.7 O 
± O 
0.2 O 
a.u O 
. O 
) O 
, O 
exercise O 
training O 
also O 
increased O 
it O 
in O 
both O 
groups O 
( O 
control O 
, O 
13.6 O 
± O 
0 O 
. O 
1 B-ABBREVIATION 
; I-ABBREVIATION 
MSG O 
, O 
22.2 O 
± O 
1.1 O 
a.u O 
. O 
) O 
. O 
Current O 
research O 
shows O 
that O 
the O 
practice O 
of O 
swim O 
training O 
increases O 
t O 
he B-TRIVIAL 
tyros I-TRIVIAL 
ine O 
phosphorylation O 
of O 
IRS-1 O 
which O 
can O 
modulate O 
the O 
effect O 
caused O 
by O 
obesity O 
in O 
insulin O 
receptors O 
. O 

PB I-TRIVIAL 
, O 
a O 
phloroglucinol B-TRIVIAL 
derivative O 
, O 
induces O 
apoptosis O 
in O 
human O 
hepatocarcinoma O 
HepG2 O 
cells O 
by O 
modulating O 
PI3K O 
/ O 
Akt O 
/ O 
GSK3β O 
pathway O 
. O 

PB I-TRIVIAL 
, O 
a O 
phloroglucinol B-TRIVIAL 
derivative O 
isolated O 
from O 
Dryopteris O 
fragrans O 
( O 
L O 
. O 
) O 
Schott O 
, O 
has O 
been O 
previously O 
reported O 
to O 
exert O 
high O 
biological O 
activities O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
analyzed O 
the O 
apoptotic O 
mechanisms O 
of O 
aspidin B-TRIVIAL 
PB I-TRIVIAL 
on O 
human O 
hepatoma O 
cell O 
line O 
, O 
HepG2 O 
. O 
Initially O 
, O 
aspidin B-TRIVIAL 
PB I-TRIVIAL 
was O 
shown O 
to O 
inhibit O 
the O 
growth O 
of O 
HepG2 O 
cells O 
in O 
a O 
time O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
After O 
treatment O 
with O 
aspidin B-TRIVIAL 
PB I-TRIVIAL 
for O 
72 O 
h O 
, O 
48 O 
h O 
and O 
24 O 
h O 
using O 
MTT B-ABBREVIATION 
assay O 
, O 
the O 
IC(50) O 
values O 
were O 
10.59 O 
μM O 
, O 
20.86 O 
μM O 
and O 
46.59 O 
μM O 
, O 
respectively O 
. O 
Aspidin B-TRIVIAL 
PB I-TRIVIAL 
was O 
capable O 
to O 
induce O 
apoptosis O 
, O 
as O 
measured O 
by O 
mitochondrial O 
membrane O 
potential O 
( O 
ΔΨm O 
) O 
, O 
acridine B-TRIVIAL 
orange I-TRIVIAL 
( O 
AO O 
) O 
staining O 
and O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
( O 
PI O 
) O 
/ O 
annexin O 
V- O 
FITC B-ABBREVIATION 
double O 
staining O 
. O 
To O 
further O 
explore O 
the O 
signaling O 
pathway O 
of O 
aspidin B-TRIVIAL 
PB I-TRIVIAL 
-mediated O 
apoptosis O 
, O 
we O 
examined O 
PI3K O 
/ O 
Akt O 
related O 
proteins O 
. O 
Western O 
blot O 
analysis O 
revealed O 
that O 
aspidin B-TRIVIAL 
PB I-TRIVIAL 
inhibited O 
PI3K O 
expression O 
, O 
phosphorylation O 
of O 
Ser B-FORMULA 
473 O 
Akt O 
and O 
Ser B-FORMULA 
9 O 
GSK3β O 
followed O 
by O 
up O 
- O 
regulation O 
of O 
nonsteroidal O 
anti-inflammatory O 
drugs O 
activated O 
gene-1 O 
( O 
NAG-1 O 
) O 
expression O 
. O 
Similarly O 
, O 
the O 
effects O 
of O 
aspidin B-TRIVIAL 
PB I-TRIVIAL 
on O 
PI3K O 
, O 
Akt O 
, O 
GSK3β O 
, O 
NAG-1 O 
expression O 
were O 
abolished O 
by O 
treatment O 
with O 
the O 
PI3K O 
inhibitor O 
, O 
wortmannin B-TRIVIAL 
. O 
Taken O 
together O 
, O 
our O 
data O 
suggested O 
that O 
the O 
PI3K O 
/ O 
Akt O 
/ O 
GSK3β O 
signal O 
pathway O 
may O 
represent O 
one O 
of O 
the O 
major O 
mechanisms O 
of O 
the O 
effects O 
of O 
aspidin B-TRIVIAL 
PB I-TRIVIAL 
on O 
human O 
hepatocarcinoma O 
cells O 
. O 

the O 
azo B-SYSTEMATIC 
/ O 
hydrazo B-SYSTEMATIC 
equilibrium O 
in O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
azo B-SYSTEMATIC 
dye O 
derivatives O 
. O 

this O 
study O 
, O 
Raman O 
, O 
infrared O 
, O 
UV O 
/ O 
vis O 
, O 
NMR O 
, O 
and O 
single O 
crystal O 
X-ray O 
diffraction O 
spectroscopies O 
are O 
used O 
to O 
elucidate O 
the O 
tautomeric O 
equilibrium O 
of O 
azo B-SYSTEMATIC 
dyes O 
derived O 
from O 
1-phenyl-azo-2-naphthol B-SYSTEMATIC 
( O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
) O 
. O 
A O 
new O 
crystallographic O 
structure O 
is O 
described O 
for O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
, O 
revealing O 
the O 
presence O 
of O 
intramolecular O 
hydrogen B-SYSTEMATIC 
bonds O 
and O 
supramolecular O 
interactions O 
, O 
such O 
as O 
the O 
unconventional O 
C-H B-FORMULA 
··· O 
O B-FORMULA 
hydrogen B-SYSTEMATIC 
bond O 
type O 
, O 
π-stacking O 
, O 
and O 
charge O 
- O 
dipole O 
interactions O 
. O 
All O 
of O 
these O 
weak O 
intermolecular O 
interactions O 
play O 
a O 
role O 
in O 
the O 
stability O 
of O 
the O 
crystalline O 
structure O 
. O 
Theoretical O 
calculations O 
are O 
also O 
reported O 
for O 
geometries O 
, O 
energy O 
, O 
and O 
spectroscopic O 
properties O 
. O 
The O 
predicted O 
spectra O 
are O 
in O 
accordance O 
with O 
the O 
experiments O 
carried O 
out O 
in O 
the O 
solid O 
state O 
and O 
in O 
solution O 
of O 
dichloromethane B-SYSTEMATIC 
, O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
, O 
and O 
chloroform B-TRIVIAL 
, O 
suggesting O 
the O 
hydrazo B-SYSTEMATIC 
form O 
as O 
the O 
preferable O 
tautomer O 
in O 
gas O 
and O 
condensate O 
phases O 
for O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
and O 
its O 
derivatives O 
. O 

and O 
thiazinan-4-one B-SYSTEMATIC 
derivatives O 
analogous O 
to O 
rosiglitazone B-TRIVIAL 
as O 
potential O 
antihyperglycemic O 
and O 
antidyslipidemic O 
agents O 
. O 

number O 
of O 
thiazolidin-4-one B-SYSTEMATIC 
and O 
thiazinan-4-one B-SYSTEMATIC 
derivatives O 
were O 
prepared O 
by O 
three O 
component O 
condensation O 
in O 
one O 
pot O 
reaction O 
method O 
. O 
These O 
compounds O 
were O 
evaluated O 
for O 
anti-hyperglycemic O 
activity O 
by O 
in O 
vitro O 
and O 
in O 
vivo O 
assay O 
systems O 
. O 
The O 
compounds O 
with O 
thiazolidin-4-one B-SYSTEMATIC 
and O 
thiazinan-4-one B-SYSTEMATIC 
moieties O 
exhibited O 
significant O 
anti-hyperglycemic O 
activity O 
. O 
A O 
few O 
compounds O 
( O 
3a O 
, O 
3b O 
, O 
4a O 
and O 
4b O 
) O 
have O 
exhibited O 
both O 
anti-hyperglycemic O 
and O 
anti-dyslipidemic O 
activities O 
. O 
Among O 
them O 
the O 
thiazinan-4-one B-SYSTEMATIC 
derivative O 
4a O 
showed O 
maximal O 
( O 
45% O 
) O 
improvement O 
in O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
in O 
db O 
/ O 
db O 
mice O 
at O 
30 O 
mg O 
/ O 
kg O 
oral O 
dose O 
. O 

, O 
purification O 
and O 
proteomic O 
analysis O 
of O 
recombinant O 
histone O 
H4 O 
acetylated O 
at O 
lysine B-TRIVIAL 
16 O 
. O 

histone O 
covalent O 
modifications O 
have O 
been O 
identified O 
and O 
shown O 
to O 
play O 
key O 
regulatory O 
roles O 
in O 
eukaryotic O 
transcription O 
, O 
DNA O 
damage O 
repair O 
, O 
and O 
replication O 
. O 
In O 
vitro O 
experiments O 
designed O 
to O 
understand O 
the O 
mechanistic O 
role O 
of O 
individual O 
modifications O 
require O 
the O 
availability O 
of O 
substantial O 
quantities O 
of O 
pure O 
histones O 
, O 
homogeneously O 
modified O 
at O 
specific O 
residues O 
. O 
We O 
have O 
applied O 
the O 
amber O 
stop O 
codon O 
/ O 
suppressor O 
tRNA O 
strategy O 
to O 
the O 
production O 
of O 
histone O 
H4 O 
acetylated O 
at O 
lysine B-TRIVIAL 
16 O 
, O 
a O 
particularly O 
important O 
isoform O 
of O 
this O 
histone O 
. O 
Our O 
success O 
relies O 
on O 
adapting O 
the O 
H4 O 
DNA O 
sequence O 
to O 
the O 
codon O 
preference O 
of O 
E O 
. O 
coli O 
and O 
on O 
preventing O 
the O 
premature O 
decay O 
of O 
the O 
H4 O 
mRNA O 
. O 
These O 
modifications O 
to O 
the O 
original O 
procedure O 
render O 
it O 
easily O 
applicable O 
to O 
the O 
generation O 
of O 
any O 
covalently O 
modified O 
histone O 
H4 O 
isoform O 
. O 

and O 
antiprogestational O 
properties O 
of O 
novel O 
17-fluorinated B-FAMILY 
steroids I-FAMILY 
. O 

receptor O 
( O 
PR O 
) O 
plays O 
a O 
key O 
role O 
in O 
reproductive O 
functions O 
, O 
and O 
compounds O 
that O 
inhibit O 
progesterone B-TRIVIAL 
action O 
( O 
antiprogestins B-FAMILY 
) O 
have O 
potential O 
use O 
in O 
the O 
treatment O 
of O 
estrogen B-FAMILY 
- O 
and O 
progesterone B-TRIVIAL 
-dependent O 
diseases O 
, O 
including O 
uterine O 
leiomyomas O 
and O 
breast O 
cancer O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
chemically O 
synthesized O 
novel O 
17-fluorinated B-FAMILY 
steroids I-FAMILY 
and O 
evaluated O 
the O 
cytotoxicity O 
profiles O 
of O 
these O 
compounds O 
in O 
T47D O 
breast O 
cancer O 
cells O 
compared O 
to O 
the O 
activity O 
of O 
known O 
antiprogestins B-FAMILY 
, O 
including O 
ZK230 B-IDENTIFIER 
211 I-IDENTIFIER 
, O 
RU-486 B-IDENTIFIER 
, O 
CDB2914 B-IDENTIFIER 
, O 
CDB4124 B-IDENTIFIER 
and O 
ORG33628 B-IDENTIFIER 
. O 
We O 
analyzed O 
in O 
vitro O 
receptor O 
- O 
binding O 
assays O 
and O 
PR-transactivation O 
assays O 
to O 
establish O 
the O 
antiprogestational O 
activity O 
of O 
these O 
molecules O 
. O 
The O 
representative O 
antiprogestin O 
EC304 B-IDENTIFIER 
was O 
found O 
to O 
inhibit O 
in O 
vitro O 
tumorigenicity O 
in O 
a O 
dose O 
- O 
dependent O 
fashion O 
in O 
T47D O 
cells O 
by O 
a O 
colony O 
formation O 
assay O 
at O 
1 O 
and O 
10nM O 
concentrations O 
. O 
The O 
potent O 
in O 
vivo O 
antiprogestational O 
activity O 
of O 
EC304 B-IDENTIFIER 
was O 
also O 
demonstrated O 
in O 
an O 
antinidation O 
assay O 
for O 
the O 
interruption O 
of O 
early O 
pregnancy O 
in O 
rats O 
. O 
The O 
strong O 
antiprogestational O 
activity O 
and O 
absence O 
of O 
antiglucocorticoid O 
activity O 
in O 
EC O 
compounds O 
may O 
demonstrate O 
their O 
utility O 
in O 
the O 
treatment O 
of O 
leiomyoma O 
, O 
endometriosis O 
and O 
breast O 
cancer O 
. O 

vitro O 
intestinal O 
and O 
hepatic O 
metabolism O 
of O 
Di(2-ethylhexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
in O 
human O 
and O 
rat O 
. O 

and O 
organ O 
differences O 
in O 
the O 
intrinsic O 
clearance O 
and O 
the O 
enzymes O 
involved O 
in O 
the O 
metabolism O 
of O 
DEHP B-ABBREVIATION 
were O 
examined O 
in O 
subcellular O 
fractions O 
of O 
the O 
intestine O 
and O 
liver O 
as O 
well O 
as O 
by O 
recombinant O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
isoforms O 
of O 
human O 
and O 
rat O 
. O 
Estimated O 
clearance O 
( O 
CLint O 
) O 
of O 
DEHP B-ABBREVIATION 
via O 
esterase O 
- O 
mediated O 
pathway O 
in O 
human O 
intestine O 
was O 
2.4-fold O 
greater O 
than O 
that O 
in O 
human O 
liver O 
while O 
its O 
value O 
in O 
rat O 
intestine O 
was O 
1.7-fold O 
less O 
than O 
that O 
in O 
rat O 
liver O 
. O 
Ranks O 
of O 
CLint O 
for O 
CYP O 
- O 
mediated O 
oxidation O 
/ O 
dealkylation O 
of O 
MEHP B-ABBREVIATION 
were O 
human O 
liver O 
> O 
rat O 
liver O 
> O 
human O 
intestine O 
> O 
rat O 
intestine O 
. O 
Estimates O 
of O 
CLint O 
for O 
the O 
production O 
of O 
mono(2-ethyl-5-hydroxyhexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
and O 
mono(2-ethyl-5-oxohexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
by O 
human O 
CYP2C9(*)1 O 
were O 
4.2- O 
and O 
2.6-fold O 
greater O 
than O 
those O 
by O 
rat O 
CYP2C6 O 
, O 
respectively O 
. O 
Total O 
CLint O 
via O 
hCYP2C9(*)3 O 
- O 
mediated O 
oxidation O 
was O 
1.9- O 
and O 
2.6-fold O 
less O 
than O 
those O 
by O 
hCYP2C9(*)2 O 
and O 
2C9(*)1 O 
, O 
respectively O 
. O 
Estimated O 
CLint O 
for O 
phthalic B-TRIVIAL 
acid I-TRIVIAL 
production O 
by O 
hCYP3A4 O 
was O 
24.5μLnmolCYP(-1)min(-1) O 
while O 
it O 
was O 
continuously O 
produced O 
by O 
rCYP2C6 O 
and O 
3A2 O 
via O 
passive O 
mechanism O 
. O 
These O 
species O 
/ O 
organ O 
differences O 
in O 
major O 
metabolic O 
pathway O 
and O 
CYP O 
isoforms O 
should O 
be O 
considered O 
for O 
appraisal O 
of O 
the O 
potential O 
adverse O 
health O 
effects O 
of O 
DEHP B-ABBREVIATION 
. O 

non-trivial O 
behaviour O 
of O 
phase O 
is O 
crucial O 
for O 
many O 
important O 
physical O 
phenomena O 
, O 
such O 
as O 
, O 
for O 
example O 
, O 
the O 
Aharonov-Bohm O 
effect O 
and O 
the O 
Berry O 
phase O 
. O 
By O 
manipulating O 
the O 
phase O 
of O 
light O 
one O 
can O 
create O 
' O 
twisted O 
' O 
photons O 
, O 
vortex O 
knots O 
and O 
dislocations O 
which O 
has O 
led O 
to O 
the O 
emergence O 
of O 
the O 
field O 
of O 
singular O 
optics O 
relying O 
on O 
abrupt O 
phase O 
changes O 
. O 
Here O 
we O 
demonstrate O 
the O 
feasibility O 
of O 
singular O 
visible O 
- O 
light O 
nano O 
- O 
optics O 
which O 
exploits O 
the O 
benefits O 
of O 
both O 
plasmonic O 
field O 
enhancement O 
and O 
the O 
peculiarities O 
of O 
the O 
phase O 
of O 
light O 
. O 
We O 
show O 
that O 
properly O 
designed O 
plasmonic O 
metamaterials O 
exhibit O 
topologically O 
protected O 
zero O 
reflection O 
yielding O 
to O 
sharp O 
phase O 
changes O 
nearby O 
, O 
which O 
can O 
be O 
employed O 
to O 
radically O 
improve O 
the O 
sensitivity O 
of O 
detectors O 
based O 
on O 
plasmon O 
resonances O 
. O 
By O 
using O 
reversible O 
hydrogenation O 
of O 
graphene B-TRIVIAL 
and O 
binding O 
of O 
streptavidin- O 
biotin B-TRIVIAL 
, O 
we O 
demonstrate O 
an O 
areal O 
mass O 
sensitivity O 
at O 
a O 
level O 
of O 
fg O 
mm(-2) O 
and O 
detection O 
of O 
individual O 
biomolecules O 
, O 
respectively O 
. O 
Our O 
proof O 
- O 
of O 
- O 
concept O 
results O 
offer O 
a O 
route O 
towards O 
simple O 
and O 
scalable O 
single O 
- O 
molecule O 
label O 
- O 
free O 
biosensing O 
technologies O 
. O 

Properties O 
and O 
Erosion O 
Behavior O 
of O 
Poly(trimethylene B-FAMILY 
carbonate-co-ε-caprolactone I-FAMILY 
) I-FAMILY 
Networks O 
. O 

- O 
stable O 
resorbable O 
networks O 
are O 
prepared O 
by O 
gamma O 
irradiating O 
trimethylene B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
( O 
TMC B-ABBREVIATION 
)- O 
and O 
ε-caprolactone B-SYSTEMATIC 
( O 
CL O 
) O 
- O 
based O 
(co)polymer O 
films O 
. O 
To O 
evaluate O 
their O 
suitability O 
for O 
biomedical O 
applications O 
, O 
their O 
physical O 
properties O 
and O 
erosion O 
behavior O 
are O 
investigated O 
. O 
Homopolymer O 
and O 
copolymer O 
networks O 
that O 
are O 
amorphous O 
at O 
room O 
temperature O 
are O 
flexible O 
and O 
rubbery O 
with O 
elastic O 
moduli O 
ranging O 
from O 
1.8 O 
± O 
0.3 O 
to O 
5.2 O 
± O 
0.4 O 
MPa O 
and O 
permanent O 
set O 
values O 
as O 
low O 
as O 
0.9% O 
strain O 
. O 
The O 
elastic O 
moduli O 
of O 
the O 
semicrystalline O 
networks O 
are O 
higher O 
and O 
range O 
from O 
61 O 
± O 
3 O 
to O 
484 O 
± O 
34 O 
MPa O 
. O 
The O 
erosion O 
behavior O 
of O 
(co)polymer O 
networks O 
is O 
investigated O 
in O 
vitro O 
using O 
macrophage O 
cultures O 
, O 
and O 
in O 
vivo O 
by O 
subcutaneous O 
implantation O 
in O 
rats O 
. O 
In O 
macrophage O 
cultures O 
, O 
as O 
well O 
as O 
upon O 
implantation O 
, O 
a O 
surface O 
erosion O 
process O 
is O 
observed O 
for O 
the O 
amorphous O 
(co)polymer O 
networks O 
, O 
while O 
an O 
abrupt O 
decrease O 
in O 
the O 
rate O 
and O 
a O 
change O 
in O 
the O 
nature O 
of O 
the O 
erosion O 
process O 
are O 
observed O 
with O 
increasing O 
crystallinity O 
. O 
These O 
resorbable O 
and O 
form O 
- O 
stable O 
networks O 
with O 
tuneable O 
properties O 
may O 
find O 
application O 
in O 
a O 
broad O 
range O 
of O 
biomedical O 
applications O 
. O 

A I-TRIVIAL 
improves O 
attention O 
deficit O 
hyperactivity O 
disorder O 
- O 
like O 
behaviors O 
in O 
the O 
spontaneously O 
hypertensive O 
rat O 
and O 
inhibits O 
reuptake O 
of O 
dopamine B-TRIVIAL 
in O 
vitro O 
. O 

previous O 
studies O 
we O 
have O 
demonstrated O 
that O 
the O 
γ-aminobutryic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-A O 
( O 
GABA B-ABBREVIATION 
-A O 
) O 
receptor O 
antagonist O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
has O 
an O 
awakening O 
effect O 
and O 
it O 
also O 
represses O 
ADHD O 
- O 
like O 
behaviors O 
( O 
hyperactivity O 
, O 
impulsivity O 
and O 
inattention O 
) O 
in O 
the O 
spontaneously O 
hypertensive O 
rat O 
( O 
SHR O 
) O 
model O 
of O 
attention O 
- O 
deficit O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
. O 
We O 
hypothesized O 
that O 
the O 
effects O 
of O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
were O 
exerted O 
via O 
the O 
GABA B-ABBREVIATION 
-A O 
receptor O 
given O 
the O 
important O 
role O 
of O 
the O 
GABAergic O 
system O 
in O 
ADHD O 
. O 
However O 
, O 
it O 
is O 
possible O 
that O 
aside O 
from O 
the O 
GABAergic O 
system O 
, O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
may O 
influence O 
other O 
systems O 
especially O 
those O 
implicated O 
in O 
ADHD O 
( O 
e.g O 
. O 
DAergic O 
, O 
etc O 
. O 
) O 
. O 
To O 
test O 
this O 
hypothesis O 
, O 
we O 
evaluated O 
the O 
effects O 
of O 
GABA B-ABBREVIATION 
agonist O 
, O 
or O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
antagonist O 
in O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
-induced O 
alleviation O 
of O 
ADHD O 
- O 
like O 
behaviors O 
in O 
SHR O 
. O 
SHR O 
showed O 
inattention O 
and O 
impulsivity O 
as O 
measured O 
by O 
the O 
Y-maze O 
and O 
the O 
electro O 
- O 
foot O 
shock O 
aversive O 
water O 
drinking O 
tests O 
, O 
respectively O 
. O 
Oroxylin B-TRIVIAL 
A I-TRIVIAL 
significantly O 
improved O 
these O 
behaviors O 
, O 
furthermore O 
, O 
its O 
effect O 
on O 
SHR O 
impulsivity O 
was O 
attenuated O 
by O 
haloperidol B-TRIVIAL 
, O 
a O 
DA O 
antagonist O 
, O 
but O 
not O 
by O 
baicalein B-TRIVIAL 
, O 
an O 
agonist O 
of O 
the O 
GABA B-ABBREVIATION 
-A O 
receptor O 
. O 
In O 
vitro O 
studies O 
showed O 
that O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
inhibited O 
DA O 
uptake O 
similar O 
to O 
methylphenidate B-SYSTEMATIC 
, O 
a O 
dopamine B-TRIVIAL 
transporter O 
blocker O 
, O 
but O 
did O 
not O 
influence O 
norepinephrine B-TRIVIAL 
uptake O 
unlike O 
atomoxetine B-TRIVIAL 
, O 
a O 
selective O 
NE O 
reuptake O 
inhibitor O 
. O 
Collectively O 
, O 
the O 
present O 
findings O 
suggest O 
that O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
improves O 
ADHD O 
- O 
like O 
behaviors O 
in O 
SHR O 
via O 
enhancement O 
of O 
DA O 
neurotransmission O 
and O 
not O 
modulation O 
of O 
GABA B-ABBREVIATION 
pathway O 
as O 
previously O 
reported O 
. O 
Importantly O 
, O 
the O 
present O 
study O 
indicates O 
the O 
potential O 
therapeutic O 
value O 
of O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
in O 
the O 
treatment O 
of O 
ADHD O 
. O 

pyruvate B-TRIVIAL 
kinase O 
isoenzyme O 
type O 
M2 O 
( O 
M2-PK O 
) O 
plays O 
a O 
key O 
role O 
in O 
tumor O 
metabolism O 
and O 
energy O 
production O 
. O 
Vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
is O 
critical O 
in O 
regulating O 
angiogenesis O 
which O 
is O 
an O 
essential O 
process O 
required O 
for O 
tumor O 
growth O 
and O 
metastasis O 
. O 
These O 
two O 
genes O 
may O 
function O 
in O 
accordance O 
with O 
tumor O 
development O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
relationship O 
between O 
the O 
expression O 
of O 
M2-PK O 
and O 
VEGF O 
, O 
and O 
their O 
association O 
with O 
clinicopathological O 
features O 
in O 
patients O 
with O 
advanced O 
gastric O 
cancer O 
. O 
Expression O 
of O 
M2-PK O 
and O 
VEGF O 
were O 
examined O 
in O 
142 O 
cases O 
of O 
paraffin O 
- O 
embedded O 
tissue O 
blocks O 
from O 
patients O 
with O 
advanced O 
gastric O 
cancer O 
. O 
M2-PK O 
expression O 
was O 
found O 
to O 
strongly O 
correlate O 
with O 
that O 
of O 
VEGF O 
( O 
r O 
= O 
0.718 O 
) O 
. O 
In O 
addition O 
, O 
expression O 
of O 
M2-PK O 
and O 
VEGF O 
correlates O 
with O 
tumor O 
size O 
( O 
p O 
= O 
0.0001 O 
, O 
and O 
p O 
= O 
0.0017 O 
, O 
respectively O 
) O 
, O 
depth O 
of O 
invasion O 
( O 
p O 
= O 
0.0024 O 
, O 
and O 
p O 
= O 
0.0261 O 
, O 
respectively O 
) O 
, O 
and O 
lymph O 
node O 
metastasis O 
( O 
p O 
= O 
0.036 O 
, O 
and O 
p O 
= O 
0.028 O 
, O 
respectively O 
) O 
. O 
The O 
high O 
expression O 
levels O 
of O 
M2-PK O 
and O 
VEGF O 
may O 
indicate O 
poor O 
prognosis O 
in O 
patients O 
with O 
advanced O 
gastric O 
cancer O 
. O 

: O 
Low O 
thyroid O 
function O 
may O 
be O 
associated O 
with O 
a O 
reduced O 
glomerular O 
filtration O 
rate O 
( O 
GFR O 
) O 
calculated O 
on O 
the O 
basis O 
of O 
creatinine B-TRIVIAL 
metabolism O 
. O 
Thyroid B-FAMILY 
hormone I-FAMILY 
directly O 
affects O 
serum O 
creatinine B-TRIVIAL 
in O 
muscle O 
and O 
low O 
thyroid O 
function O 
might O 
exert O 
a O 
similar O 
direct O 
effect O 
in O 
the O 
kidney O 
. O 
The O 
goal O 
of O 
the O 
study O 
was O 
to O 
evaluate O 
this O 
possibility O 
by O 
assessment O 
of O 
the O 
inulin O 
- O 
based O 
GFR O 
and O 
to O 
examine O 
the O 
mechanism O 
underlying O 
the O 
reduction O 
of O 
GFR O 
. O 
PATIENTS O 
AND O 
METHODS O 
: O 
Renal O 
and O 
glomerular O 
hemodynamics O 
were O 
assessed O 
by O 
simultaneous O 
measurements O 
of O 
plasma O 
clearance O 
of O 
para-aminohippurate B-SYSTEMATIC 
( O 
CPAH O 
) O 
and O 
inulin O 
( O 
Cin O 
) O 
in O 
26 O 
patients O 
with O 
serum O 
creatinine B-TRIVIAL 
< O 
1 O 
mg O 
/ O 
dl O 
and O 
without O 
thyroid O 
disease O 
. O 
All O 
subjects O 
were O 
normotensive O 
with O 
or O 
without O 
antihypertensive O 
treatment O 
and O 
were O 
kept O 
in O 
a O 
sodium B-SYSTEMATIC 
-replete O 
state O 
. O 
Renal O 
and O 
glomerular O 
hemodynamics O 
were O 
calculated O 
using O 
Gomez`s O 
formulae O 
. O 
RESULTS O 
: O 
Serum O 
thyroid O 
stimulating O 
hormone O 
( O 
TSH O 
) O 
, O 
including O 
within O 
the O 
normal O 
range O 
( O 
0.69-4.30 O 
μIU O 
/ O 
ml O 
) O 
, O 
was O 
positively O 
correlated O 
with O 
vascular O 
resistance O 
at O 
the O 
afferent O 
arteriole O 
( O 
Ra O 
) O 
( O 
r O 
= O 
0.609 O 
, O 
p O 
= O 
0.001 O 
) O 
, O 
but O 
not O 
at O 
the O 
efferent O 
arteriole O 
( O 
Re O 
) O 
. O 
Serum O 
TSH O 
was O 
significantly O 
and O 
negatively O 
correlated O 
with O 
renal O 
plasma O 
flow O 
( O 
RPF O 
) O 
, O 
renal O 
blood O 
flow O 
( O 
RBF O 
) O 
, O 
and O 
glomerular O 
filtration O 
rate O 
( O 
GFR O 
) O 
( O 
r O 
= O 
-0.456 O 
, O 
p O 
= O 
0.0192 O 
; O 
r O 
= O 
-0.438 O 
, O 
p O 
= O 
0.0252 O 
; O 
r O 
= O 
-0.505 O 
, O 
p O 
= O 
0.0086 O 
, O 
respectively O 
) O 
. O 
In O 
multiple O 
regression O 
analysis O 
, O 
serum O 
TSH O 
was O 
significantly O 
positively O 
associated O 
with O 
Ra O 
after O 
adjustment O 
for O 
age O 
and O 
mean O 
blood O 
pressure O 
. O 
CONCLUSIONS O 
: O 
These O 
findings O 
suggest O 
that O 
low O 
thyroid O 
function O 
, O 
even O 
within O 
the O 
normal O 
range O 
, O 
is O 
associated O 
with O 
reduced O 
RPF O 
, O 
RBF O 
and O 
GFR O 
, O 
which O 
might O 
be O 
caused O 
by O 
a O 
preferential O 
increase O 
of O 
Ra O 
. O 

acid I-TRIVIAL 
and O 
rifampicin B-TRIVIAL 
co O 
- O 
loaded O 
PLGA B-ABBREVIATION 
nanofibers O 
for O 
the O 
prevention O 
of O 
orthopedic O 
implant O 
associated O 
infections O 
. O 

- O 
associated O 
infections O 
following O 
invasive O 
orthopedic O 
surgery O 
are O 
a O 
major O 
clinical O 
problem O 
, O 
and O 
are O 
one O 
of O 
the O 
primary O 
causes O 
of O 
joint O 
failure O 
following O 
total O 
joint O 
arthroplasty O 
. O 
Current O 
strategies O 
using O 
perioperative O 
antibiotics O 
have O 
been O 
met O 
with O 
little O 
clinical O 
success O 
and O 
have O 
resulted O 
in O 
various O 
systemic O 
toxicities O 
and O 
the O 
promotion O 
of O 
antibiotic O 
resistant O 
microorganisms O 
. O 
Here O 
we O 
report O 
the O 
development O 
of O 
a O 
biodegradable O 
localized O 
delivery O 
system O 
using O 
poly(D,L-lactic B-FAMILY 
acid I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
for O 
the O 
combinatorial O 
release O 
of O 
fusidic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
( O 
or O 
its O 
sodium B-SYSTEMATIC 
salt O 
; O 
SF O 
) O 
and O 
rifampicin B-TRIVIAL 
( O 
RIF B-ABBREVIATION 
) O 
using O 
electrospinning O 
. O 
The O 
drug O 
- O 
loaded O 
formulations O 
showed O 
good O 
antibiotic O 
encapsulation O 
( O 
~75%-100% O 
) O 
, O 
and O 
a O 
biphasic O 
drug O 
release O 
profile O 
. O 
All O 
dual O 
- O 
loaded O 
formulations O 
showed O 
direct O 
antimicrobial O 
activity O 
in O 
vitro O 
against O 
Staphylococcus O 
epidermidis O 
, O 
and O 
two O 
strains O 
of O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
. O 
Furthermore O 
, O 
lead O 
formulations O 
containing O 
10% O 
( O 
w O 
/ O 
w O 
) O 
FA O 
/ O 
SF O 
and O 
5% O 
( O 
w O 
/ O 
w O 
) O 
RIF B-ABBREVIATION 
were O 
able O 
to O 
prevent O 
the O 
adherence O 
of O 
MRSA O 
to O 
a O 
titanium B-SYSTEMATIC 
implant O 
in O 
an O 
in O 
vivo O 
rodent O 
model O 
of O 
subcutaneous O 
implant O 
- O 
associated O 
infection O 
. O 

review O 
on O 
the O 
development O 
in O 
the O 
field O 
of O 
NIDDM O 
based O 
thiazolidinedione B-FAMILY 
PPARγ O 
agonists O 
. O 

Proliferator O 
Activated O 
Receptors O 
gamma O 
( O 
PPARγ O 
) O 
are O 
a O 
class O 
of O 
ligand O 
activated O 
transcription O 
factors O 
with O 
a O 
prominent O 
role O 
in O 
the O 
regulation O 
of O 
metabolic O 
processes O 
. O 
The O 
present O 
work O 
aims O 
towards O 
examining O 
the O 
functional O 
and O 
structural O 
features O 
that O 
facilitate O 
the O 
binding O 
of O 
small O 
molecules O 
based O 
on O 
Thiazolidinedione B-SYSTEMATIC 
pharmacophore O 
to O 
PPARs O 
. O 
The O 
intent O 
of O 
this O 
article O 
is O 
to O 
review O 
all O 
the O 
reported O 
thiazolidinediones B-FAMILY 
and O 
associated O 
groups O 
of O 
PPARγ O 
ligands O 
. O 

PEGylated O 
hyaluronic O 
acid O 
nanoparticles O 
as O 
the O 
carrier O 
of O 
doxorubicin B-TRIVIAL 
: O 
Mineralization O 
and O 
its O 
effect O 
on O 
tumor O 
targetability O 
in O 
vivo O 
. O 

in O 
vivo O 
stability O 
and O 
tumor O 
targetability O 
of O 
self O 
- O 
assembled O 
polymeric O 
nanoparticles O 
are O 
crucial O 
for O 
effective O 
drug O 
delivery O 
. O 
In O 
this O 
study O 
, O 
to O 
develop O 
biostable O 
nanoparticles O 
with O 
high O 
tumor O 
targetability O 
, O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
-conjugated O 
hyaluronic O 
acid O 
nanoparticles O 
( O 
PEG B-ABBREVIATION 
-HANPs O 
) O 
were O 
mineralized O 
through O 
controlled O 
deposition O 
of O 
inorganic O 
calcium B-SYSTEMATIC 
and O 
phosphate B-SYSTEMATIC 
ions O 
on O 
the O 
nanoparticular O 
shell O 
via O 
a O 
sequential O 
addition O 
method O 
. O 
The O 
resulting O 
nanoparticles O 
( O 
M- O 
PEG B-ABBREVIATION 
-HANPs O 
) O 
had O 
a O 
smaller O 
size O 
( O 
153.7±4.5nm O 
) O 
than O 
bare O 
PEG B-ABBREVIATION 
-HANPs O 
( O 
265.1±9.5nm O 
) O 
, O 
implying O 
that O 
mineralization O 
allows O 
the O 
formation O 
of O 
compact O 
nanoparticles O 
. O 
Interestingly O 
, O 
when O 
the O 
mineralized O 
nanoparticles O 
were O 
exposed O 
to O 
acidic O 
buffer O 
conditions O 
( O 
< O 
pH6.5 O 
) O 
, O 
their O 
sizes O 
increased O 
rapidly O 
due O 
to O 
dissolution O 
of O 
the O 
inorganic O 
minerals O 
. O 
Doxorubicin O 
( O 
DOX O 
) O 
, O 
chosen O 
as O 
the O 
model O 
anticancer O 
drug O 
, O 
was O 
effectively O 
encapsulated O 
into O 
the O 
bare O 
and O 
mineralized O 
nanoparticles O 
. O 
For O 
bare O 
PEG-HANPs O 
, O 
DOX O 
was O 
released O 
in O 
a O 
sustained O 
manner O 
and O 
its O 
release O 
rate O 
was O 
not O 
dependent O 
on O 
the O 
pH O 
of O 
the O 
solution O 
. O 
On O 
the O 
other O 
hand O 
, O 
DOX O 
release O 
from O 
M-PEG-HANPs O 
was O 
pH-dependent O 
: O 
i.e O 
. O 
DOX O 
was O 
slowly O 
released O 
from O 
nanoparticles O 
under O 
physiological O 
condition O 
( O 
pH7.4 O 
) O 
, O 
whereas O 
its O 
release O 
rates O 
were O 
much O 
higher O 
at O 
mildly O 
acidic O 
environments O 
( O 
< O 
pH6.5 O 
) O 
. O 
From O 
in O 
vivo O 
biodistribution O 
study O 
, O 
it O 
was O 
found O 
that O 
M-PEG-HANPs O 
could O 
reach O 
the O 
tumor O 
site O 
more O 
effectively O 
than O 
bare O 
PEG-HANPs O 
. O 
The O 
antitumor O 
efficacy O 
of O 
DOX-loaded O 
nanoparticles O 
was O 
evaluated O 
after O 
systemic O 
administration O 
into O 
the O 
tumor O 
- O 
bearing O 
mice O 
. O 
Of O 
the O 
samples O 
tested O 
, O 
the O 
most O 
effective O 
antitumor O 
efficacy O 
was O 
observed O 
for O 
DOX-loaded O 
M-PEG-HANPs O 
. O 
Overall O 
, O 
these O 
results O 
suggest O 
that O 
M-PEG-HANPs O 
could O 
be O 
a O 
promising O 
carrier O 
for O 
an O 
anticancer O 
drug O 
. O 

, O 
characterization O 
, O 
screening O 
and O 
docking O 
analysis O 
of O 
4-anilinoquinazoline B-SYSTEMATIC 
derivatives O 
as O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
. O 

report O 
here O 
the O 
design O 
and O 
synthesis O 
of O 
a O 
series O 
of O 
4-anilinoquinazoline B-SYSTEMATIC 
derivatives O 
, O 
of O 
which O 
7 O 
compounds O 
were O 
crystallographically O 
characterized O 
, O 
as O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
inhibitors O 
by O 
modifications O 
on O 
the O 
aniline B-SYSTEMATIC 
ring O 
or O 
at O 
the O 
6-alkoxy B-FAMILY 
site O 
of O 
the O 
6,7-dimethoxy-4-anilinoquinazoline B-SYSTEMATIC 
pharmacophore O 
. O 
The O 
relative O 
inhibition O 
efficiency O 
on O 
EGFR O 
of O 
all O 
as-prepared O 
compounds O 
were O 
measured O 
and O 
ordered O 
, O 
and O 
the O 
IC50 O 
values O 
of O 
nine O 
highly O 
active O 
compounds O 
were O 
determined O 
by O 
ELISA O 
. O 
Docking O 
studies O 
indicated O 
that O 
all O 
4-anilinoquinazoline B-SYSTEMATIC 
derivatives O 
could O 
be O 
inserted O 
into O 
the O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
of O 
the O 
EGFR O 
via O 
indirect O 
docking O 
, O 
and O 
that O 
the O 
modifications O 
at O 
the O 
3'- O 
position O 
of O 
the O 
anilino B-TRIVIAL 
group O 
and O 
6-alkoxy B-FAMILY 
site O 
of O 
the O 
quinazoline B-SYSTEMATIC 
ring O 
have O 
little O 
interference O 
with O 
the O 
formation O 
of O 
the O 
two O 
essential O 
H B-FORMULA 
-bonds O 
between O 
the O 
N3 O 
of O 
the O 
quinazoline B-SYSTEMATIC 
ring O 
and O 
Thr B-FORMULA 
766 O 
through O 
a O 
water O 
molecule O 
, O 
and O 
the O 
N1 O 
of O 
the O 
quinazoline B-SYSTEMATIC 
ring O 
and O 
N-H B-FORMULA 
of O 
Met B-FORMULA 
769 O 
. O 
The O 
displacing O 
of O 
the O 
phenyl B-SYSTEMATIC 
at O 
4- O 
position O 
with O 
pyridinyl B-SYSTEMATIC 
dramatically O 
reduces O 
the O 
activity O 
of O 
the O 
quinazoline B-SYSTEMATIC 
pharmacophore O 
, O 
the O 
resulting O 
derivative O 
( O 
10 O 
) O 
being O 
the O 
least O 
active O 
compound O 
. O 
The O 
docking O 
results O 
also O 
showed O 
that O 
the O 
formation O 
of O 
new O 
H B-FORMULA 
-bonds O 
between O 
the O 
N-H B-FORMULA 
of O 
the O 
ethylenediamine B-SYSTEMATIC 
group O 
linked O 
to O 
the O 
6-alkoxy B-FAMILY 
site O 
and O 
Asp B-FORMULA 
776/ O 
Cys B-FORMULA 
773 O 
in O 
the O 
binding O 
pocket O 
of O 
EGFR O 
makes O 
compounds O 
19 O 
( O 
IC50=12.1±1.6 O 
nM O 
) O 
and O 
20 O 
( O 
IC50=13.6±0.8 O 
nM O 
) O 
the O 
most O 
potent O 
EGFR O 
inhibitors O 
in O 
this O 
class O 
and O 
worthy O 
of O 
further O 
modification O 
to O 
obtain O 
more O 
potent O 
anticancer O 
compounds O 
. O 

Optical O 
Stark O 
and O 
Zeeman O 
Study O 
of O 
the O 
[17.8]0(+)-X(1)Σ(+) O 
( O 
0,0 O 
) O 
Band O 
System O 
of O 
AuF B-ABBREVIATION 
. O 

[17.8]0(+)-X(1)Σ(+) O 
( O 
0,0 O 
) O 
band O 
of O 
gold B-SYSTEMATIC 
monofluoride I-SYSTEMATIC 
, O 
AuF B-ABBREVIATION 
, O 
has O 
been O 
recorded O 
at O 
a O 
resolution O 
of O 
40 O 
MHz O 
both O 
field O 
free O 
and O 
in O 
the O 
presence O 
of O 
a O 
static O 
electric O 
and O 
magnetic O 
field O 
. O 
The O 
observed O 
Stark O 
shifts O 
were O 
analyzed O 
to O 
determine O 
the O 
permanent O 
electric O 
dipole O 
moment O 
, O 
μel O 
, O 
of O 
2.03 O 
± O 
0.05 O 
D O 
and O 
4.13 O 
± O 
0.02 O 
D O 
, O 
for O 
the O 
[ O 
17.8]0(+)(v O 
= O 
0 O 
) O 
and O 
X(1)Σ(+)(v O 
= O 
0 O 
) O 
states O 
, O 
respectively O 
. O 
The O 
small O 
magnetic O 
tuning O 
observed O 
for O 
the O 
[ O 
17.8]0(+)(v O 
= O 
0 O 
) O 
state O 
is O 
attributed O 
to O 
rotational O 
and O 
magnetic O 
field O 
mixing O 
with O 
the O 
[17.7]1 O 
state O 
and O 
has O 
been O 
successfully O 
modeled O 
using O 
an O 
effective O 
Hamiltonian O 
for O 
the O 
(3)Π O 
state O 
. O 
A O 
comparison O 
with O 
the O 
numerous O 
published O 
theoretical O 
predictions O 
is O 
made O 
. O 

configuration O 
and O 
conformational O 
analysis O 
of O 
brevipolides B-FAMILY 
, O 
bioactive O 
5,6-dihydro-α-pyrones B-FAMILY 
from O 
Hyptis O 
brevipes O 
. O 

( O 
6'S O 
) O 
- O 
configuration O 
of O 
brevipolides B-FAMILY 
A-J I-FAMILY 
( O 
1-10 O 
) O 
, O 
isolated O 
from O 
Hyptis O 
brevipes O 
, O 
was O 
established O 
by O 
X-ray O 
diffraction O 
analysis O 
of O 
9 O 
in O 
conjunction O 
with O 
Mosher's B-TRIVIAL 
ester I-TRIVIAL 
analysis O 
of O 
the O 
tetrahydro O 
derivative O 
11 O 
obtained O 
from O 
both O 
geometric O 
isomers O 
8 O 
and O 
9 O 
as O 
well O 
as O 
by O 
chemical O 
correlations O 
. O 
The O 
structure O 
of O 
the O 
new O 
brevipolide B-TRIVIAL 
J I-TRIVIAL 
( O 
10 O 
) O 
was O 
characterized O 
through O 
NMR O 
and O 
MS O 
data O 
as O 
having O 
the O 
same O 
6-heptyl-5,6-dihydro-2H-pyran-2-one B-SYSTEMATIC 
framework O 
possessing O 
the O 
cyclopropane B-SYSTEMATIC 
moiety O 
of O 
all O 
brevipolides B-FAMILY 
but O 
substituted O 
by O 
an O 
isoferuloyl B-TRIVIAL 
group O 
instead O 
of O 
the O 
p-methoxycinnamoyl B-SYSTEMATIC 
moiety O 
found O 
in O 
8 O 
and O 
9 O 
. O 
Conformational O 
analysis O 
of O 
these O 
cytotoxic O 
6-heptyl-5,6-dihydro-α-pyrones B-FAMILY 
was O 
carried O 
out O 
on O 
compound O 
9 O 
by O 
application O 
of O 
a O 
protocol O 
based O 
on O 
comparison O 
between O 
experimental O 
and O 
DFT-calculated O 
vicinal O 
(1)H-(1)H B-FORMULA 
NMR O 
coupling O 
constants O 
. O 
Molecular O 
modeling O 
was O 
used O 
to O 
correlate O 
minimum O 
energy O 
conformers O 
and O 
observed O 
electronic O 
circular O 
dichroism O 
transitions O 
for O 
the O 
isomeric O 
series O 
of O 
brevipolides B-FAMILY 
. O 
Compounds O 
7-10 O 
exhibited O 
moderate O 
activity O 
( O 
ED(50) O 
0.3-8.0 O 
μg O 
/ O 
mL O 
) O 
against O 
a O 
variety O 
of O 
tumor O 
cell O 
lines O 
. O 

-enhanced O 
magnetic O 
resonance O 
imaging O 
detects O 
declining O 
pancreatic O 
β-cell O 
mass O 
in O 
a O 
cyclophosphamide B-TRIVIAL 
-accelerated O 
mouse O 
model O 
of O 
type O 
1 O 
diabetes O 
. O 

, O 
there O 
is O 
no O 
ideal O 
noninvasive O 
method O 
to O 
quantify O 
the O 
progressive O 
loss O 
of O 
pancreatic O 
β-cell O 
mass O 
( O 
BCM O 
) O 
that O 
occurs O 
in O 
type O 
1 O 
diabetes O 
. O 
Magnetic O 
resonance O 
imaging O 
has O 
detected O 
gross O 
differences O 
in O 
BCM O 
between O 
healthy O 
and O 
diabetic O 
mice O 
using O 
the O 
contrast O 
agent O 
manganese B-SYSTEMATIC 
, O 
which O 
labels O 
functional O 
β-cells O 
and O 
increases O 
the O 
water O 
proton O 
relaxation O 
rate O 
( O 
R1 O 
) O 
, O 
but O 
its O 
ability O 
to O 
measure O 
gradations O 
in O 
BCM O 
during O 
disease O 
progression O 
is O 
unknown O 
. O 
Our O 
objective O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
measurements O 
of O 
the O 
manganese B-SYSTEMATIC 
-enhanced O 
pancreatic O 
R1 O 
could O 
detect O 
decreasing O 
BCM O 
in O 
a O 
mouse O 
model O 
of O 
type O 
1 O 
diabetes O 
. O 
We O 
used O 
cyclophosphamide B-TRIVIAL 
-accelerated O 
BDC2.5 O 
T-cell O 
receptor O 
transgenic O 
nonobese O 
diabetic O 
mice O 
, O 
which O 
experience O 
development O 
of O 
type O 
1 O 
diabetes O 
during O 
a O 
7-day O 
time O 
period O 
after O 
cyclophosphamide B-TRIVIAL 
injection O 
, O 
whereas O 
transgene O 
- O 
negative O 
mice O 
do O 
not O 
. O 
We O 
measured O 
the O 
manganese B-SYSTEMATIC 
-enhanced O 
pancreatic O 
R1 O 
before O 
cyclophosphamide B-TRIVIAL 
injection O 
( O 
day O 
0 O 
) O 
and O 
on O 
days O 
3 O 
, O 
4 O 
, O 
5 O 
, O 
and O 
7 O 
afterward O 
. O 
Pancreatic O 
R1 O 
remained O 
constant O 
in O 
transgene O 
- O 
negative O 
mice O 
and O 
decreased O 
stepwise O 
day O 
- O 
to O 
- O 
day O 
in O 
transgene O 
- O 
positive O 
mice O 
, O 
mirroring O 
their O 
loss O 
of O 
BCM O 
, O 
confirmed O 
by O 
pancreatic O 
insulin O 
measurements O 
and O 
histology O 
. O 
Changes O 
in O 
R1 O 
in O 
transgene O 
- O 
positive O 
mice O 
occurred O 
before O 
elevations O 
in O 
blood O 
glucose B-TRIVIAL 
, O 
a O 
clinical O 
indicator O 
of O 
diabetes O 
, O 
suggesting O 
potential O 
for O 
early O 
noninvasive O 
detection O 
of O 
changes O 
in O 
functional O 
BCM O 
. O 

vascular O 
protective O 
properties O 
of O 
kinsenoside B-TRIVIAL 
isolated O 
from O 
Anoectochilus O 
roxburghii O 
under O 
high O 
glucose B-TRIVIAL 
condition O 
. O 

roxburghii O 
is O 
a O 
traditional O 
Chinese O 
herb O 
used O 
for O 
the O 
treatment O 
of O 
diabetes O 
and O 
some O 
other O 
diseases O 
. O 
The O 
vascular O 
protective O 
effect O 
of O 
its O 
major O 
active O 
ingredient O 
, O 
kinsenoside B-TRIVIAL 
, O 
in O 
high O 
glucose B-TRIVIAL 
conditions O 
was O 
investigated O 
in O 
in O 
vivo O 
and O 
in O 
vitro O 
experiments O 
. O 
In O 
in O 
vivo O 
tests O 
, O 
kinsenoside B-TRIVIAL 
( O 
50 O 
and O 
100mg O 
/ O 
kg O 
) O 
efficiently O 
lowered O 
blood O 
glucose B-TRIVIAL 
and O 
cholesterol B-TRIVIAL 
levels O 
and O 
it O 
enhanced O 
the O 
oxidation O 
resistance O 
of O 
diabetic O 
mice O 
induced O 
by O 
streptozotocin B-TRIVIAL 
. O 
In O 
the O 
in O 
vitro O 
assay O 
, O 
kinsenoside B-TRIVIAL 
( O 
20 O 
and O 
50μg O 
/ O 
mL O 
) O 
markedly O 
inhibited O 
changes O 
in O 
various O 
biochemical O 
substances O 
( O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
lactic B-TRIVIAL 
dehydrogenase O 
( O 
LDH O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
and O 
catalase O 
( O 
CAT O 
) O 
) O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
damaged O 
by O 
high O 
glucose B-TRIVIAL 
( O 
35mM O 
) O 
and O 
restored O 
vascular O 
endothelial O 
structure O 
by O 
balancing O 
the O 
matrix O 
metalloproteinases O 
- O 
the O 
tissue O 
inhibitors O 
of O 
matrix O 
metalloproteinases O 
( O 
MMP-TIMP O 
) O 
system O 
. O 
The O 
vascular O 
protective O 
effects O 
of O 
kinsenoside B-TRIVIAL 
were O 
speculated O 
to O 
be O 
attributed O 
to O 
oxidative O 
stress O 
inhibition O 
and O 
the O 
reduction O 
of O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
mRNA O 
expression O 
levels O 
in O 
high O 
glucose B-TRIVIAL 
conditions O 
. O 
Moreover O 
, O 
histological O 
examination O 
, O 
including O 
hematoxylin B-TRIVIAL 
- O 
eosin B-FAMILY 
( O 
H&E O 
) O 
staining O 
, O 
masson O 
trichrome O 
( O 
Masson O 
) O 
staining O 
, O 
and O 
periodic O 
Schiff- O 
methenamine B-TRIVIAL 
( O 
PASM O 
) O 
staining O 
, O 
greatly O 
supported O 
the O 
morphological O 
and O 
functional O 
amelioration O 
of O 
diabetes O 
- O 
related O 
changes O 
in O 
mice O 
aortas O 
after O 
kinsenoside B-TRIVIAL 
( O 
20 O 
and O 
50μg O 
/ O 
mL O 
) O 
treatment O 
. O 
These O 
results O 
indicated O 
that O 
kinsenoside B-TRIVIAL 
might O 
be O 
a O 
promising O 
agent O 
for O 
the O 
treatment O 
of O 
diabetic O 
vascular O 
disease O 
. O 

have O 
successfully O 
designed O 
and O 
expressed O 
a O 
new O 
fluorescent O 
protein O 
with O 
improved O 
second O 
- O 
order O 
nonlinear O 
optical O 
properties O 
. O 
It O 
is O 
the O 
first O 
time O 
that O 
a O 
fluorescent O 
protein O 
has O 
been O 
rationally O 
altered O 
for O 
this O 
particular O 
characteristic O 
. O 
On O 
the O 
basis O 
of O 
the O 
specific O 
noncentrosymmetry O 
requirements O 
for O 
second O 
- O 
order O 
nonlinear O 
optical O 
effects O 
, O 
we O 
had O 
hypothesized O 
that O 
the O 
surprisingly O 
low O 
first O 
hyperpolarizability O 
( O 
β O 
) O 
of O 
the O 
enhanced O 
yellow O 
fluorescent O 
protein O 
( O 
eYFP O 
) O 
could O 
be O 
explained O 
by O 
centrosymmetric O 
stacking O 
of O 
the O 
chromophoric O 
Tyr B-FORMULA 
66 O 
and O 
the O 
neighboring O 
Tyr B-FORMULA 
203 O 
residue O 
. O 
The O 
inversion O 
center O 
was O 
removed O 
by O 
mutating O 
Tyr B-FORMULA 
203 O 
into O 
Phe B-FORMULA 
203 O 
, O 
with O 
minor O 
changes O 
in O 
the O 
linear O 
optical O 
properties O 
and O 
even O 
an O 
improved O 
fluorescence O 
quantum O 
yield O 
. O 
Structure O 
determination O 
by O 
X-ray O 
crystallography O 
as O 
well O 
as O 
linear O 
optical O 
characterization O 
corroborate O 
a O 
correct O 
folding O 
and O 
maturation O 
. O 
Measurement O 
of O 
β O 
by O 
means O 
of O 
hyper-Rayleigh O 
scattering O 
( O 
HRS O 
) O 
as O 
well O 
as O 
their O 
analysis O 
using O 
quantum O 
chemistry O 
calculations O 
validate O 
our O 
hypothesis O 
. O 
This O 
observation O 
can O 
eventually O 
lead O 
to O 
improved O 
red O 
fluorescent O 
proteins O 
for O 
even O 
better O 
performance O 
. O 
On O 
the O 
basis O 
of O 
the O 
specific O 
function O 
( O 
second O 
- O 
harmonic O 
generation O 
) O 
, O 
the O 
color O 
of O 
its O 
emission O 
, O 
and O 
in O 
analogy O 
with O 
the O 
" O 
fruit O 
" O 
names O 
, O 
we O 
propose O 
SHardonnay O 
as O 
the O 
name O 
for O 
this O 
Tyr203Phe O 
mutant O 
of O 
eYFP O 
. O 

- O 
dose O 
resveratrol B-TRIVIAL 
supplementation O 
in O 
obese O 
men O 
: O 
an O 
investigator O 
- O 
initiated O 
, O 
randomized O 
, O 
placebo O 
- O 
controlled O 
clinical O 
trial O 
of O 
substrate O 
metabolism O 
, O 
insulin O 
sensitivity O 
, O 
and O 
body O 
composition O 
. O 

, O 
diabetes O 
, O 
hypertension O 
, O 
and O 
hyperlipidemia O 
constitute O 
risk O 
factors O 
for O 
morbidity O 
and O 
premature O 
mortality O 
. O 
Based O 
on O 
animal O 
and O 
in O 
vitro O 
studies O 
, O 
resveratrol B-TRIVIAL 
reverts O 
these O 
risk O 
factors O 
via O 
stimulation O 
of O 
silent O 
mating O 
type O 
information O 
regulation O 
2 O 
homolog O 
1 O 
( O 
SIRT1 O 
) O 
, O 
but O 
data O 
in O 
human O 
subjects O 
are O 
scarce O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
metabolic O 
effects O 
of O 
high O 
- O 
dose O 
resveratrol B-TRIVIAL 
in O 
obese O 
human O 
subjects O 
. O 
In O 
a O 
randomized O 
, O 
placebo O 
- O 
controlled O 
, O 
double O 
- O 
blinded O 
, O 
and O 
parallel O 
- O 
group O 
design O 
, O 
24 O 
obese O 
but O 
otherwise O 
healthy O 
men O 
were O 
randomly O 
assigned O 
to O 
4 O 
weeks O 
of O 
resveratrol B-TRIVIAL 
or O 
placebo O 
treatment O 
. O 
Extensive O 
metabolic O 
examinations O 
including O 
assessment O 
of O 
glucose B-TRIVIAL 
turnover O 
and O 
insulin O 
sensitivity O 
( O 
hyperinsulinemic O 
euglycemic O 
clamp O 
) O 
were O 
performed O 
before O 
and O 
after O 
the O 
treatment O 
. O 
Insulin O 
sensitivity O 
, O 
the O 
primary O 
outcome O 
measure O 
, O 
deteriorated O 
insignificantly O 
in O 
both O 
groups O 
. O 
Endogenous O 
glucose B-TRIVIAL 
production O 
and O 
the O 
turnover O 
and O 
oxidation O 
rates O 
of O 
glucose B-TRIVIAL 
remained O 
unchanged O 
. O 
Resveratrol B-TRIVIAL 
supplementation O 
also O 
had O 
no O 
effect O 
on O 
blood O 
pressure O 
; O 
resting O 
energy O 
expenditure O 
; O 
oxidation O 
rates O 
of O 
lipid O 
; O 
ectopic O 
or O 
visceral O 
fat O 
content O 
; O 
or O 
inflammatory O 
and O 
metabolic O 
biomarkers O 
. O 
The O 
lack O 
of O 
effect O 
disagrees O 
with O 
persuasive O 
data O 
obtained O 
from O 
rodent O 
models O 
and O 
raises O 
doubt O 
about O 
the O 
justification O 
of O 
resveratrol B-TRIVIAL 
as O 
a O 
human O 
nutritional O 
supplement O 
in O 
metabolic O 
disorders O 
. O 

of O 
ropivacaine B-TRIVIAL 
into O 
the O 
subarachnoid O 
changes O 
the O 
ultrastructure O 
and O 
proteome O 
of O 
the O 
rat O 
spinal O 
cord O 
. O 

1 O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
impact O 
of O 
1.0% O 
ropivacaine B-TRIVIAL 
on O 
the O 
ultrastructure O 
and O 
proteome O 
of O 
the O 
rat O 
spinal O 
cord O 
. O 
2 O 
. O 
Rats O 
received O 
three O 
injections O 
( O 
90-min O 
intervals O 
, O 
0.2 O 
mL O 
/ O 
kg O 
) O 
of O 
0.9% O 
NaCl B-FORMULA 
, O 
0.5% O 
ropivacaine B-TRIVIAL 
or O 
1.0% O 
ropivacaine B-TRIVIAL 
via O 
an O 
implanted O 
intrathecal O 
catheter O 
. O 
Transmission O 
electron O 
microscopy O 
was O 
performed O 
to O 
exam O 
the O 
ultrastructure O 
of O 
the O 
spinal O 
cord O 
. O 
Two O 
- O 
dimensional O 
electrophoresis O 
followed O 
by O 
mass O 
spectrometry O 
identification O 
were O 
carried O 
out O 
to O 
investigate O 
the O 
proteome O 
. O 
3 O 
. O 
In O 
the O 
rats O 
administered O 
1.0% O 
ropivacaine B-TRIVIAL 
, O 
deformed O 
organelles O 
, O 
detached O 
myelinated O 
nerve O 
fiber O 
layer O 
, O 
and O 
incomplete O 
inner O 
and O 
outer O 
shaft O 
membranes O 
were O 
observed O 
in O 
the O 
spinal O 
cord O 
and O 
posterior O 
root O 
shrunken O 
nuclei O 
. O 
Furthermore O 
, O 
in O 
the O 
rat O 
spinal O 
cord O 
1.0% O 
ropivacaine B-TRIVIAL 
induced O 
the O 
down O 
- O 
regulation O 
of O 
voltage O 
- O 
dependent O 
anion O 
channel O 
2 O 
( O 
VDAC2 O 
) O 
and O 
mitochondrial O 
pyruvate B-TRIVIAL 
dehydrogenase O 
subunit O 
alpha O 
( O 
ODPA O 
) O 
, O 
the O 
upregulation O 
of O 
myelin O 
basic O 
protein O 
( O 
MBP O 
) O 
, O 
the O 
disappearance O 
of O 
myelin O 
transcription O 
factor O 
1 O 
( O 
MYT1 O 
) O 
and O 
the O 
appearance O 
of O 
heat O 
shock O 
protein O 
25 O 
( O 
HSP25 O 
) O 
. O 
Little O 
change O 
was O 
observed O 
in O 
the O 
0.5% O 
ropivacaine B-TRIVIAL 
or O 
control O 
groups O 
. O 
4 O 
. O 
Our O 
results O 
suggest O 
that O 
1.0% O 
ropivacaine B-TRIVIAL 
treatment O 
led O 
to O 
neurotoxicity O 
, O 
as O 
shown O 
by O 
ultrastructural O 
and O 
proteomic O 
changes O 
in O 
the O 
rat O 
spinal O 
cord O 
. O 
Specific O 
proteins O 
were O 
identified O 
that O 
are O 
implicated O 
in O 
1.0% O 
ropivacaine B-TRIVIAL 
-induced O 
neurotoxicity O 
. O 

of O 
MCD O 
spectroscopy O 
and O 
TD-DFT O 
to O 
endohedral O 
metallofullerenes B-FAMILY 
for O 
characterization O 
of O 
their O 
electronic O 
transitions O 
. O 

describe O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
application O 
of O 
magnetic O 
circular O 
dichroism O 
( O 
MCD O 
) O 
spectroscopy O 
and O 
time O 
- O 
dependent O 
density O 
functional O 
theory O 
( O 
TD-DFT O 
) O 
calculations O 
using O 
B3LYP O 
and O 
M06-2X O 
functionals O 
to O 
characterize O 
the O 
electronic O 
transitions O 
of O 
endohedral O 
metallofullerenes O 
( O 
EMFs O 
) O 
. O 
Results O 
revealed O 
that O 
the O 
electronic O 
transitions O 
of O 
La B-FORMULA 
@C(2v)- O 
C(82) B-TRIVIAL 
, O 
La(2) B-FORMULA 
@I(h)- O 
C(80) B-TRIVIAL 
, O 
and O 
Sc(3)N B-FORMULA 
@I(h)- O 
C(80) B-TRIVIAL 
can O 
be O 
assigned O 
using O 
these O 
techniques O 
. O 
Particularly O 
, O 
a O 
difference O 
in O 
the O 
electronic O 
transitions O 
between O 
La(2) B-FORMULA 
@I(h)- O 
C(80) B-TRIVIAL 
and O 
Sc(3)N B-FORMULA 
@I(h)- O 
C(80) B-TRIVIAL 
, O 
which O 
is O 
invisible O 
in O 
absorption O 
spectra O 
, O 
was O 
observed O 
clearly O 
in O 
MCD O 
spectra O 
. O 
The O 
observed O 
MCD O 
bands O 
agree O 
well O 
with O 
the O 
oscillator O 
strengths O 
calculated O 
using O 
the O 
B3LYP O 
functional O 
. O 
In O 
addition O 
, O 
the O 
MCD O 
bands O 
of O 
La(2) B-FORMULA 
@I(h)- O 
C(80) B-TRIVIAL 
were O 
altered O 
upon O 
[5,6]-addition O 
, O 
demonstrating O 
that O 
the O 
MCD O 
spectroscopy O 
is O 
sensitive O 
to O 
chemical O 
functionalization O 
of O 
EMFs O 
, O 
and O 
that O 
it O 
is O 
therefore O 
powerful O 
to O 
distinguish O 
[5,6]-adducts O 
from O 
pristine O 
La(2) B-FORMULA 
@I(h)- O 
C(80) B-TRIVIAL 
, O 
although O 
no O 
marked O 
difference O 
exists O 
in O 
their O 
absorption O 
spectra O 
. O 

effectors O 
of O 
white O 
adipocyte O 
- O 
selective O 
gene O 
expression O 
have O 
not O 
been O 
described O 
. O 
Here O 
we O 
show O 
that O 
TLE3 O 
is O 
a O 
white O 
- O 
selective O 
cofactor O 
that O 
acts O 
reciprocally O 
with O 
the O 
brown O 
- O 
selective O 
cofactor O 
Prdm16 O 
to O 
specify O 
lipid O 
storage O 
and O 
thermogenic O 
gene O 
programs O 
. O 
Occupancy O 
of O 
TLE3 O 
and O 
Prdm16 O 
on O 
certain O 
promoters O 
is O 
mutually O 
exclusive O 
, O 
due O 
to O 
the O 
ability O 
of O 
TLE3 O 
to O 
disrupt O 
the O 
physical O 
interaction O 
between O 
Prdm16 O 
and O 
PPARγ O 
. O 
When O 
expressed O 
at O 
elevated O 
levels O 
in O 
brown O 
fat O 
, O 
TLE3 O 
counters O 
Prdm16 O 
, O 
suppressing O 
brown O 
- O 
selective O 
genes O 
and O 
inducing O 
white O 
- O 
selective O 
genes O 
, O 
resulting O 
in O 
impaired O 
fatty B-FAMILY 
acid I-FAMILY 
oxidation O 
and O 
thermogenesis O 
. O 
Conversely O 
, O 
mice O 
lacking O 
TLE3 O 
in O 
adipose O 
tissue O 
show O 
enhanced O 
thermogenesis O 
in O 
inguinal O 
white O 
adipose O 
depots O 
and O 
are O 
protected O 
from O 
age O 
- O 
dependent O 
deterioration O 
of O 
brown O 
adipose O 
tissue O 
function O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
establishment O 
of O 
distinct O 
adipocyte O 
phenotypes O 
with O 
different O 
capacities O 
for O 
thermogenesis O 
and O 
lipid O 
storage O 
is O 
accomplished O 
in O 
part O 
through O 
the O 
cell O 
- O 
type O 
- O 
selective O 
recruitment O 
of O 
TLE3 O 
or O 
Prdm16 O 
to O 
key O 
adipocyte O 
target O 
genes O 
. O 

of O 
enterovirus O 
71 O 
infections O 
and O 
viral O 
IRES O 
activity O 
by O 
Fructus O 
gardeniae O 
and O 
geniposide B-TRIVIAL 
. O 

gardeniae O 
has O 
long O 
been O 
used O 
by O 
traditional O 
Chinese O 
medical O 
practitioners O 
for O 
its O 
anti-inflammatory O 
, O 
anti-oxidant O 
, O 
anti-tumor O 
and O 
anti-hyperlipidemic O 
characteristics O 
. O 
Here O 
we O 
describe O 
our O 
finding O 
that O 
F. O 
gardeniae O 
greatly O 
reduces O 
anti-enterovirus O 
71 O 
( O 
EV71 O 
) O 
activity O 
, O 
resulting O 
in O 
significant O 
decreases O 
in O 
EV71 O 
virus O 
yields O 
, O 
EV71 O 
infections O 
, O 
and O 
internal O 
ribosome O 
entry O 
site O 
activity O 
. O 
We O 
also O 
found O 
that O 
geniposide B-TRIVIAL 
, O 
a O 
primary O 
F. O 
gardeniae O 
component O 
, O 
inhibited O 
both O 
EV71 O 
replication O 
and O 
viral O 
IRES O 
activity O 
. O 
Our O 
data O 
suggest O 
the O 
presence O 
of O 
a O 
mechanism O 
that O 
blocks O 
viral O 
protein O 
translation O 
. O 
According O 
to O 
our O 
findings O 
, O 
F. O 
gardeniae O 
and O 
geniposide B-TRIVIAL 
deserve O 
a O 
closer O 
look O 
as O 
potential O 
chemopreventive O 
agents O 
against O 
EV71 O 
infections O 
. O 

stabilization O 
of O 
new O 
phases O 
in O 
the O 
PbTe B-FORMULA 
- O 
Sb2Te3 B-FORMULA 
system O 
: O 
Pb(m)Sb(2n)Te(m+3n) B-FAMILY 
nanocrystals O 
. O 

series O 
of O 
novel O 
rock O 
- O 
salt O 
- O 
type O 
Pb(m)Sb(2n)Te(m+3n) B-FAMILY 
nanocrystals O 
( O 
m O 
= O 
2 O 
, O 
3 O 
, O 
4 O 
, O 
6 O 
, O 
8 O 
, O 
and O 
10 O 
; O 
n O 
= O 
1 O 
and O 
2 O 
) O 
were O 
successfully O 
prepared O 
using O 
a O 
colloidal O 
synthesis O 
route O 
. O 
These O 
materials O 
are O 
stable O 
only O 
on O 
the O 
nanoscale O 
and O 
have O 
no O 
bulk O 
analogues O 
. O 
Elemental O 
compositions O 
were O 
determined O 
using O 
scanning O 
transmission O 
electron O 
microscopy O 
/ O 
energy O 
- O 
dispersive O 
X-ray O 
spectroscopy O 
( O 
STEM O 
/ O 
EDS O 
) O 
and O 
inductively O 
coupled O 
plasma O 
atomic O 
emission O 
spectroscopy O 
( O 
ICP-AES O 
) O 
. O 
The O 
nanocrystals O 
exhibit O 
well O 
- O 
defined O 
band O 
energies O 
in O 
the O 
mid-IR O 
region O 
that O 
are O 
nearly O 
independent O 
of O 
their O 
atomic O 
compositions O 
. O 
Pb(m)Sb(2n)Te(m+3n) B-FAMILY 
nanocrystals O 
behave O 
as O 
metastable O 
homogeneous O 
solid O 
solutions O 
at O 
room O 
temperature O 
and O 
tend O 
to O 
phase O 
separate O 
into O 
the O 
respective O 
binary O 
PbTe B-FORMULA 
+ O 
Sb(2)Te(3) B-FORMULA 
at O 
300 O 
°C O 
. O 
Furthermore O 
, O 
pair O 
distribution O 
function O 
( O 
PDF O 
) O 
analysis O 
suggests O 
that O 
the O 
local O 
structure O 
of O 
these O 
Pb(m)Sb(2n)Te(m+3n) B-FAMILY 
nanocrystals O 
is O 
distorted O 
with O 
respect O 
to O 
the O 
rock O 
- O 
salt O 
structure O 
. O 

self O 
- O 
assembled O 
nanocarrier O 
loading O 
teniposide B-TRIVIAL 
improves O 
the O 
oral O 
delivery O 
and O 
drug O 
concentration O 
in O 
tumor O 
. O 

attempted O 
to O 
improve O 
the O 
oral O 
delivery O 
of O 
lipophilic O 
teniposide B-TRIVIAL 
to O 
achieve O 
higher O 
drug O 
concentration O 
in O 
tumor O 
by O 
self O 
- O 
assembled O 
nanocarrier O 
for O 
further O 
oral O 
chemotherapy O 
. O 
The O 
teniposide B-TRIVIAL 
loaded O 
self O 
- O 
assembled O 
nanocarrier O 
( O 
TSN O 
) O 
was O 
spherical O 
nanometric O 
particles O 
with O 
narrow O 
size O 
distribution O 
. O 
The O 
intestinal O 
absorption O 
of O 
teniposide B-TRIVIAL 
from O 
TSN O 
was O 
obviously O 
improved O 
4.09- O 
and O 
6.35-fold O 
in O 
duodenum O 
and O 
jejunum O 
at O 
0.5h O 
after O 
oral O 
administration O 
, O 
then O 
significantly O 
decreased O 
with O 
the O 
prolongation O 
of O 
time O 
. O 
The O 
cellular O 
uptake O 
of O 
TSN O 
in O 
Caco-2 O 
cell O 
monolayer O 
was O 
significantly O 
enhanced O 
over O 
3 O 
folds O 
and O 
increased O 
with O 
incubation O 
time O 
. O 
Moreover O 
, O 
TSN O 
could O 
be O 
internalized O 
into O 
Caco-2 O 
cell O 
monolayer O 
through O 
clathrin O 
- O 
mediated O 
endocytosis O 
pathway O 
, O 
and O 
then O 
mainly O 
transported O 
into O 
the O 
systemic O 
circulation O 
via O 
portal O 
vein O 
and O 
intestinal O 
lymphatic O 
pathway O 
. O 
The O 
pharmacokinetic O 
results O 
indicated O 
that O 
the O 
AUC(0-t) O 
value O 
of O 
TSN O 
in O 
rats O 
was O 
significantly O 
improved O 
5.41-fold O 
than O 
that O 
of O 
teniposide B-TRIVIAL 
solution O 
, O 
moreover O 
, O 
the O 
teniposide B-TRIVIAL 
concentration O 
in O 
tumor O 
from O 
TSN O 
was O 
obviously O 
improved O 
over O 
7-fold O 
in O 
tumor O 
bearing O 
mice O 
. O 
The O 
captured O 
image O 
indicated O 
that O 
the O 
oral O 
administered O 
TSN O 
could O 
specifically O 
accumulate O 
in O 
tumor O 
in O 
the O 
xenograft O 
model O 
. O 
Therefore O 
, O 
the O 
self O 
- O 
assembled O 
nanocarrier O 
was O 
promising O 
to O 
enhance O 
the O 
oral O 
delivery O 
of O 
lipophilic O 
teniposide B-TRIVIAL 
and O 
its O 
concentration O 
in O 
tumor O 
for O 
oral O 
chemotherapy O 
. O 

interrupt O 
! O 
Protein O 
serotonylation O 
has O 
been O 
implicated O 
in O 
living O 
cells O 
, O 
yet O 
its O 
role O 
remains O 
poorly O 
defined O 
because O 
of O 
the O 
lack O 
of O 
characterization O 
tools O 
. O 
We O 
synthesized O 
a O 
serotonin B-TRIVIAL 
derivative O 
to O 
enable O 
selective O 
tagging O 
of O 
serotonylation O 
and O 
to O 
investigate O 
its O 
effect O 
on O 
Ras O 
; O 
the O 
latter O 
displayed O 
undisrupted O 
interaction O 
with O 
Raf-1 O 
at O 
the O 
Ras O 
binding O 
domain O 
. O 

type O 
dual O 
inhibitors O 
of O 
aromatase/ O 
aldosterone B-TRIVIAL 
synthase O 
as O 
a O 
novel O 
strategy O 
for O 
breast O 
cancer O 
patients O 
with O 
elevated O 
cardiovascular O 
risks O 
. O 

application O 
of O 
aromatase O 
inhibitors O 
to O 
postmenopausal O 
breast O 
cancer O 
patients O 
increases O 
the O 
risk O 
of O 
cardiovascular O 
diseases O 
( O 
CVD O 
) O 
, O 
which O 
is O 
believed O 
to O 
be O 
caused O 
by O 
the O 
abnormally O 
high O 
concentrations O 
of O 
aldosterone B-TRIVIAL 
as O 
a O 
consequence O 
of O 
the O 
estrogen B-FAMILY 
deficiency O 
. O 
Dual O 
inhibitors O 
of O 
aromatase O 
( O 
CYP19 O 
) O 
and O 
aldosterone B-TRIVIAL 
synthase O 
( O 
CYP11B2 O 
) O 
are O 
therefore O 
proposed O 
as O 
a O 
novel O 
strategy O 
for O 
the O 
adjuvant O 
therapy O 
to O 
reduce O 
the O 
CVD O 
risk O 
for O 
these O 
patients O 
. O 
By O 
combining O 
decisive O 
structural O 
features O 
of O 
CYP11B2 O 
and O 
CYP19 O 
inhibitors O 
into O 
a O 
common O 
template O 
, O 
a O 
series O 
of O 
pyridinylmethyl B-FAMILY 
substituted I-FAMILY 
1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones I-FAMILY 
were O 
designed O 
and O 
synthesized O 
. O 
Interestingly O 
, O 
the O 
substituents O 
on O 
the O 
methylene B-SYSTEMATIC 
bridge O 
showed O 
strong O 
influences O 
on O 
the O 
inhibitory O 
activities O 
leading O 
to O 
opposite O 
effects O 
, O 
that O 
is O 
, O 
a O 
given O 
substituent O 
showed O 
an O 
increase O 
in O 
inhibition O 
of O 
one O 
enzyme O 
, O 
while O 
it O 
led O 
to O 
a O 
decrease O 
for O 
the O 
other O 
enzyme O 
. O 
The O 
compromise O 
of O 
this O 
conflict O 
led O 
to O 
compounds O 
3j O 
, O 
3k O 
, O 
3n O 
, O 
and O 
3p O 
as O 
potent O 
and O 
selective O 
dual O 
inhibitors O 
of O 
CYP19 O 
and O 
CYP11B2 O 
, O 
especially O 
compound O 
3p O 
, O 
which O 
exhibited O 
IC(50) O 
values O 
of O 
32 O 
and O 
41 O 
nM O 
for O 
CYP19 O 
and O 
CYP11B2 O 
, O 
respectively O 
, O 
and O 
a O 
high O 
selectivity O 
toward O 
CYP17 O 
and O 
CYP11B1 O 
. O 
This O 
compound O 
is O 
considered O 
as O 
a O 
candidate O 
for O 
further O 
evaluation O 
in O 
vivo O 
. O 

of O 
perinatal O 
exposure O 
to O 
waterborne O 
fluoxetine B-TRIVIAL 
on O 
memory O 
processing O 
in O 
the O 
cuttlefish O 
Sepia O 
officinalis O 
. O 

ecotoxicological O 
studies O 
highlight O 
the O 
increasing O 
presence O 
of O 
pharmaceuticals O 
discharged O 
in O 
the O 
aquatic O 
environment O 
. O 
Amongst O 
them O 
is O 
the O 
antidepressant O 
fluoxetine B-TRIVIAL 
( O 
FLX B-ABBREVIATION 
) O 
, O 
a O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitor O 
, O 
primarily O 
indicated O 
for O 
treatment O 
of O 
depression O 
. O 
The O 
effect O 
of O 
chronic O 
exposure O 
to O 
FLX B-ABBREVIATION 
on O 
memory O 
processing O 
in O 
1-month- O 
old O 
cuttlefish O 
Sepia O 
officinalis O 
was O 
evaluated O 
. O 
Three O 
groups O 
of O 
new O 
- O 
borns O 
were O 
reared O 
in O 
different O 
conditions O 
: O 
one O 
control O 
group O 
( O 
no O 
FLX B-ABBREVIATION 
) O 
and O 
two O 
groups O 
exposed O 
to O 
environmental O 
concentrations O 
of O 
FLX B-ABBREVIATION 
( O 
1 O 
and O 
100ng O 
/ O 
L O 
) O 
from O 
15 O 
days O 
pre O 
- O 
hatching O 
to O 
1 O 
month O 
post O 
- O 
hatching O 
. O 
Acquisition O 
and O 
retention O 
performances O 
were O 
assessed O 
using O 
the O 
' O 
prawn O 
- O 
in O 
- O 
the O 
- O 
tube O 
' O 
procedure O 
. O 
Perinatal O 
exposure O 
to O 
fluoxetine B-TRIVIAL 
led O 
to O 
significant O 
changes O 
in O 
memory O 
processing O 
of O 
the O 
animals O 
. O 
The O 
lowest O 
observed O 
effect O 
concentration O 
of O 
this O 
antidepressant O 
on O 
learning O 
and O 
retention O 
was O 
1ng O 
/ O 
L O 
which O 
is O 
under O 
the O 
range O 
of O 
environmental O 
contamination O 
. O 
Cuttlefish O 
exposed O 
at O 
low O 
FLX B-ABBREVIATION 
concentration O 
had O 
impaired O 
acquisition O 
capabilities O 
and O 
animals O 
exposed O 
at O 
high O 
FLX B-ABBREVIATION 
concentration O 
displayed O 
a O 
deficit O 
of O 
memory O 
retention O 
compared O 
to O 
the O 
control O 
group O 
that O 
had O 
nonimpaired O 
initial O 
acquisition O 
and O 
retention O 
performances O 
. O 
The O 
results O 
subsequently O 
suggested O 
that O 
FLX B-ABBREVIATION 
-induced O 
changes O 
in O 
cognitive O 
capacities O 
could O 
potentially O 
lead O 
to O 
inappropriate O 
predatory O 
behaviors O 
in O 
the O 
natural O 
environment O 
. O 
The O 
study O 
provides O 
the O 
basis O 
for O 
future O 
studies O 
on O 
how O 
pharmaceutical O 
contaminants O 
disrupt O 
cognition O 
in O 
ecologically O 
and O 
economically O 
relevant O 
marine O 
invertebrates O 
. O 

- O 
based O 
metabonomic O 
in O 
hippocampus O 
, O 
nucleus O 
accumbens O 
and O 
prefrontal O 
cortex O 
of O 
methamphetamine B-TRIVIAL 
-sensitized O 
rats O 
. O 

NMR O 
spectroscopy O 
was O 
applied O 
to O 
investigate O 
the O 
changes O 
of O 
cerebral O 
metabolites O 
in O 
brain O 
hippocampus O 
, O 
nucleus O 
accumbens O 
( O 
NAC O 
) O 
and O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
of O 
the O 
rats O 
subjected O 
to O 
subcutaneous O 
twice O 
- O 
daily O 
injections O 
of O 
2.5mg O 
/ O 
kg O 
methamphetamine B-TRIVIAL 
( O 
MAP B-ABBREVIATION 
) O 
for O 
7 O 
days O 
. O 
The O 
results O 
indicated O 
that O 
MAP B-ABBREVIATION 
exposure O 
induced O 
significant O 
behavioral O 
sensitization O 
and O 
altered O 
cerebral O 
metabolites O 
in O 
rats O 
. O 
The O 
neurotransmitters O 
glutamate B-TRIVIAL 
, O 
glutamine B-TRIVIAL 
and O 
GABA B-ABBREVIATION 
significantly O 
decreased O 
in O 
hippocampus O 
, O 
NAC O 
and O 
PFC O 
. O 
Specifically O 
, O 
increased O 
succinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
semialdehyde I-SYSTEMATIC 
, O 
a O 
metabolism O 
product O 
of O 
GABA B-ABBREVIATION 
, O 
was O 
observed O 
in O 
hippocampus O 
. O 
Additionally O 
, O 
decreased O 
serotonin B-TRIVIAL 
was O 
observed O 
in O 
both O 
NAC O 
and O 
PFC O 
, O 
whereas O 
decreased O 
dopamine B-TRIVIAL 
was O 
only O 
observed O 
in O 
NAC O 
after O 
repeated O 
MAP B-ABBREVIATION 
treatment O 
. O 
Glutathione B-TRIVIAL 
obviously O 
decreased O 
in O 
above O 
brain O 
regions O 
, O 
whereas O 
acetylcysteine B-SYSTEMATIC 
declined O 
in O 
hippocampus O 
and O 
NAC O 
, O 
and O 
taurine B-TRIVIAL 
declined O 
in O 
NAC O 
and O 
PFC O 
. O 
Homocysteic B-TRIVIAL 
acid I-TRIVIAL 
was O 
elevated O 
in O 
hippocampus O 
and O 
NAC O 
by O 
repeated O 
MAP B-ABBREVIATION 
administration O 
. O 
Membrane O 
ingredients O 
like O 
phosphocholine B-SYSTEMATIC 
elevated O 
in O 
response O 
to O 
MAP B-ABBREVIATION 
administration O 
in O 
NAC O 
and O 
PFC O 
. O 
N-Acetyl-aspartate B-SYSTEMATIC 
, O 
a O 
marker O 
of O 
neuronal O 
viability O 
, O 
decreased O 
in O 
the O 
three O 
regions O 
; O 
however O 
, O 
myo-inositol B-TRIVIAL 
, O 
a O 
glial O 
cell O 
marker O 
, O 
increased O 
in O 
hippocampus O 
and O 
PFC O 
. O 
Tricarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
cycle O 
intermediate O 
products O 
, O 
such O 
as O 
α-ketoglutarate B-TRIVIAL 
, O 
succinate B-TRIVIAL 
, O 
citrate B-FAMILY 
and O 
the O 
methionine B-TRIVIAL 
significantly O 
decreased O 
in O 
above O 
three O 
brain O 
regions O 
after O 
MAP B-ABBREVIATION 
administration O 
; O 
however O 
, O 
ADP B-ABBREVIATION 
decreased O 
in O 
hippocampus O 
. O 
These O 
results O 
indicate O 
that O 
repeated O 
MAP B-ABBREVIATION 
treatment O 
causes O 
neurotransmitters O 
disturbance O 
, O 
imbalance O 
between O 
oxidative O 
stress O 
and O 
antioxidants O 
, O 
and O 
gliosis O 
in O 
hippocampus O 
, O 
NAC O 
and O 
PFC O 
. O 
Profound O 
metabolic O 
changes O 
detected O 
across O 
brain O 
regions O 
provide O 
the O 
first O 
evidence O 
of O 
metabonomic O 
changes O 
in O 
MAP B-ABBREVIATION 
-induced O 
sensitized O 
rats O 
. O 

and O 
Optoelectronic O 
Characterization O 
of O 
RF O 
Sputtered O 
ZnSnN2 B-FORMULA 
. O 

, O 
a O 
new O 
earth O 
- O 
abundant O 
semiconductor O 
, O 
is O 
synthesized O 
and O 
characterized O 
for O 
use O 
as O 
a O 
photovoltaic O 
absorber O 
material O 
. O 
Results O 
confirm O 
the O 
predicted O 
orthorhombic O 
Pna21 O 
crystal O 
structure O 
in O 
RF O 
sputtered O 
thin O 
films O 
. O 
Additionally O 
, O 
optical O 
measurements O 
reveal O 
a O 
direct O 
bandgap O 
of O 
about O 
2 O 
eV O 
, O 
which O 
is O 
larger O 
than O 
our O 
calculated O 
bandgap O 
of O 
1.42 O 
eV O 
due O 
to O 
the O 
Burstein-Moss O 
effect O 
. O 

racemic O 
tetrahydrocurcuminoid B-SYSTEMATIC 
dihydropyrimidinone I-SYSTEMATIC 
analogues O 
as O 
potent O 
acetylcholinesterase O 
inhibitors O 
. O 

synthesis O 
of O 
racemic O 
tetrahydrocurcumin B-SYSTEMATIC 
- O 
( O 
THC B-ABBREVIATION 
- O 
) O 
, O 
tetrahydrodemethoxycurcumin B-SYSTEMATIC 
- O 
( O 
THDC B-ABBREVIATION 
- O 
) O 
and O 
tetrahydrobisdemethoxycurcumin B-SYSTEMATIC 
- O 
( O 
THBDC B-ABBREVIATION 
- O 
) O 
dihydropyrimidinone B-SYSTEMATIC 
( O 
DHPM B-ABBREVIATION 
) O 
analogues O 
was O 
achieved O 
by O 
utilizing O 
the O 
multi O 
- O 
component O 
Biginelli O 
reaction O 
in O 
the O 
presence O 
of O 
copper B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
as O 
a O 
catalyst O 
. O 
The O 
evaluation O 
of O 
acetylcholinesterase O 
inhibitors O 
for O 
Alzheimer's O 
disease O 
of O 
these O 
compounds O 
showed O 
that O 
they O 
exhibited O 
higher O 
inhibitory O 
activity O 
than O 
their O 
parent O 
analogues O 
. O 
THBDC-DHPM B-ABBREVIATION 
demonstrated O 
the O 
most O 
potent O 
inhibitory O 
activity O 
with O 
an O 
IC50 O 
value O 
of O 
1.34±0.03μM O 
which O 
was O 
more O 
active O 
than O 
the O 
approved O 
drug O 
galanthamine B-TRIVIAL 
( O 
IC50=1.45±0.04μM O 
) O 
. O 

effects O 
of O 
caffeic B-SYSTEMATIC 
acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
on O 
dose O 
- O 
dependent O 
intoxication O 
of O 
rats O 
with O 
paraquat B-TRIVIAL 
. O 

: O 
Paraquat B-TRIVIAL 
( O 
PQ O 
; O 
1,1'dimethyl-bipyridilium B-SYSTEMATIC 
4,4'-dichloride I-SYSTEMATIC 
) O 
, O 
which O 
is O 
used O 
extensively O 
throughout O 
the O 
world O 
, O 
is O 
highly O 
toxic O 
to O 
humans O 
. O 
We O 
aimed O 
to O 
investigate O 
the O 
protective O 
effects O 
of O 
different O 
doses O 
of O 
caffeic B-SYSTEMATIC 
acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
CAPE B-ABBREVIATION 
) O 
on O 
PQ-intoxicated O 
rats.Materials O 
and O 
methods O 
: O 
A O 
total O 
of O 
80 O 
rats O 
were O 
divided O 
into O 
the O 
following O 
eight O 
groups O 
, O 
comprising O 
10 O 
rats O 
in O 
each O 
group O 
: O 
group O 
1 O 
: O 
control O 
; O 
group O 
2 O 
: O 
administered O 
with O 
CAPE B-ABBREVIATION 
( O 
10 O 
µmol O 
/ O 
kg O 
) O 
; O 
group O 
3 O 
: O 
administered O 
with O 
15 O 
mg O 
/ O 
kg O 
PQ O 
( O 
PQ15 O 
group O 
) O 
; O 
group O 
4 O 
: O 
administered O 
with O 
30 O 
mg O 
/ O 
kg O 
PQ O 
( O 
PQ30 O 
group O 
) O 
; O 
group O 
5 O 
: O 
administered O 
with O 
45 O 
mg O 
/ O 
kg O 
PQ O 
( O 
PQ45 O 
group O 
) O 
; O 
group O 
6 O 
: O 
administered O 
with O 
15 O 
mg O 
/ O 
kg O 
PQ O 
+ O 
CAPE B-ABBREVIATION 
; O 
group O 
7 O 
: O 
administered O 
with O 
30 O 
mg O 
/ O 
kg O 
PQ O 
+ O 
CAPE B-ABBREVIATION 
and O 
group O 
8 O 
: O 
administered O 
with O 
45 O 
mg O 
/ O 
kg O 
PQ O 
+ O 
CAPE B-ABBREVIATION 
. O 
Both O 
PQ O 
and O 
CAPE B-ABBREVIATION 
were O 
injected O 
intraperitoneally O 
. O 
Pancreatic O 
tissue O 
was O 
examined O 
with O 
both O 
haematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
and O 
immunochemical O 
staining O 
. O 
RESULTS O 
: O 
The O 
ratio O 
of O 
the O 
immunohistochemical O 
staining O 
area O 
to O 
the O 
total O 
pancreatic O 
area O 
of O 
the O 
β O 
cells O 
revealed O 
that O 
statistically O 
significant O 
differences O 
were O 
observed O 
only O 
between O 
the O 
PQ O 
and O 
PQ O 
+ O 
CAPE B-ABBREVIATION 
groups O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Discussion O 
: O 
The O 
evaluation O 
of O 
the O 
data O 
suggests O 
that O 
CAPE B-ABBREVIATION 
can O 
be O 
used O 
to O 
prevent O 
acute O 
effects O 
of O 
PQ O 
intoxication O 
. O 

the O 
Electrical O 
and O 
Optical O 
Properties O 
of O 
Graphene B-TRIVIAL 
by O 
Ozone B-TRIVIAL 
Treatment O 
for O 
Patterning O 
Monolithic O 
Transparent O 
Electrodes O 
. O 

electrical O 
and O 
optical O 
properties O 
of O 
graphene B-TRIVIAL 
are O 
vital O 
to O 
promote O 
its O 
use O 
as O 
film O 
electrodes O 
in O 
a O 
variety O 
of O 
devices O 
. O 
We O 
developed O 
an O 
etching O 
- O 
free O 
ozone B-TRIVIAL 
treatment O 
method O 
to O 
continuously O 
tune O 
the O 
electrical O 
resistance O 
and O 
optical O 
transmittance O 
of O 
graphene B-TRIVIAL 
films O 
by O 
simply O 
varying O 
the O 
time O 
and O 
temperature O 
of O 
graphene B-TRIVIAL 
exposure O 
to O 
ozone B-TRIVIAL 
. O 
Initially O 
, O 
ozone B-TRIVIAL 
exposure O 
dramatically O 
decreases O 
the O 
electrical O 
resistance O 
of O 
graphene B-TRIVIAL 
films O 
by O 
p-doping O 
, O 
but O 
this O 
is O 
followed O 
by O 
increases O 
in O 
the O 
resistance O 
and O 
optical O 
transmittance O 
as O 
a O 
result O 
of O 
surface O 
oxidation O 
. O 
The O 
rate O 
of O 
resistance O 
increase O 
can O 
be O 
significantly O 
increased O 
by O 
raising O 
the O 
treatment O 
temperature O 
. O 
The O 
ozone B-TRIVIAL 
- O 
oxidized B-TRIVIAL 
graphene I-TRIVIAL 
is O 
not O 
removed O 
but O 
is O 
gradually O 
transformed O 
to O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
. O 
On O 
the O 
basis O 
of O 
such O 
effects O 
of O 
ozone B-TRIVIAL 
treatment O 
, O 
we O 
demonstrate O 
a O 
well O 
- O 
defined O 
graphene B-TRIVIAL 
pattern O 
by O 
using O 
ozone B-TRIVIAL 
photolithography O 
, O 
in O 
which O 
the O 
ozone B-TRIVIAL 
-treated O 
graphene B-TRIVIAL 
electrodes O 
are O 
monolithic O 
but O 
separated O 
by O 
insulating O 
GO O 
regions O 
. O 
Such O 
a O 
monolithic O 
graphene B-TRIVIAL 
pattern O 
shows O 
low O 
optical O 
contrast O 
, O 
a O 
clean O 
and O 
more O 
hydrophilic O 
surface O 
, O 
indicating O 
the O 
promising O 
use O 
of O 
ozone B-TRIVIAL 
treatment O 
to O 
achieve O 
high O 
- O 
performance O 
graphene B-TRIVIAL 
-based O 
optoelectronic O 
devices O 
. O 

and O 
evaluation O 
of O 
colloidal O 
modified O 
nanolipid O 
carrier O 
: O 
Application O 
to O 
topical O 
delivery O 
of O 
tacrolimus B-TRIVIAL 
, O 
Part O 
II O 
-In O 
vivo O 
assessment O 
, O 
drug O 
targeting O 
, O 
efficacy O 
, O 
and O 
safety O 
in O 
treatment O 
for O 
atopic O 
dermatitis O 
. O 

atopic O 
dermatitis O 
( O 
AD O 
) O 
, O 
topical O 
anti-inflammatory O 
therapy O 
with O 
skin O 
barrier O 
restoration O 
to O 
prevent O 
repeated O 
inflammatory O 
episodes O 
leads O 
to O 
long O 
- O 
term O 
therapeutic O 
success O 
. O 
Tacrolimus B-TRIVIAL 
, O 
although O 
effective O 
against O 
AD O 
, O 
is O 
a O 
challenging O 
molecule O 
due O 
to O 
low O 
solubility O 
, O 
low O 
- O 
penetration O 
, O 
poor O 
- O 
bioavailability O 
, O 
and O 
toxicity O 
. O 
Part O 
I O 
of O 
this O 
paper O 
, O 
reported O 
novel O 
modified O 
nanolipid O 
carrier O 
system O 
for O 
topical O 
delivery O 
of O 
tacrolimus B-TRIVIAL 
( O 
T-MNLC O 
) O 
, O 
offering O 
great O 
opportunity O 
to O 
load O 
low O 
- O 
solubility O 
drug O 
with O 
improved O 
entrapment O 
efficiency O 
, O 
enhanced O 
stability O 
and O 
improved O 
skin O 
deposition O 
. O 
Present O 
investigation O 
focused O 
on O 
restoration O 
of O 
skin O 
barrier O 
, O 
site O 
- O 
specific O 
delivery O 
, O 
therapeutic O 
effectiveness O 
, O 
and O 
safety O 
of O 
novel O 
T-MNLC O 
. O 
T-MNLC O 
greatly O 
enhanced O 
occlusive O 
properties O 
, O 
skin O 
hydration O 
potential O 
and O 
reduced O 
transepidermal O 
water O 
loss O 
. O 
This O 
might O 
help O 
to O 
reduce O 
the O 
number O 
of O 
flares O 
and O 
better O 
control O 
the O 
disease O 
. O 
Cutaneous O 
uptake O 
and O 
drug O 
deposition O 
in O 
albino O 
rats O 
by O 
HPLC O 
and O 
confocal O 
laser O 
scanning O 
microscopy O 
revealed O 
prominently O 
elevated O 
drug O 
levels O 
in O 
all O 
skin O 
strata O 
with O 
T-MNLC O 
as O 
compared O 
to O 
reference O 
. O 
T-MNLC O 
demonstrated O 
efficient O 
suppression O 
of O 
inflammatory O 
responses O 
in O 
BALB O 
/ O 
c O 
mice O 
model O 
of O 
AD O 
. O 
Safety O 
assessment O 
by O 
acute O 
and O 
repeated O 
- O 
dose O 
dermal O 
toxicity O 
demonstrated O 
mild O 
keratosis O 
and O 
collagenous O 
mass O 
infiltration O 
at O 
the O 
treatment O 
area O 
with O 
repeated O 
application O 
of O 
reference O 
. O 
Interestingly O 
, O 
T-MNLC O 
showed O 
no O 
evident O 
toxicity O 
exhibiting O 
safe O 
drug O 
delivery O 
. O 
Thus O 
, O 
novel O 
T-MNLC O 
would O 
be O 
a O 
safe O 
, O 
effective O 
, O 
and O 
esthetically O 
appealing O 
alternative O 
to O 
conventional O 
vehicles O 
for O 
treatment O 
for O 
AD O 
. O 

- O 
resolution O 
mapping O 
of O 
reactive O 
sites O 
on O 
titania B-TRIVIAL 
-based O 
nanoparticles O 
with O 
water O 
- O 
soluble O 
fluorogenic O 
probes O 
. O 

charge O 
transfer O 
at O 
the O 
heterogeneous O 
surface O 
of O 
semiconductor O 
nanoparticles O 
is O 
a O 
fundamental O 
process O 
that O 
is O 
relevant O 
to O 
many O 
important O 
applications O 
, O 
such O 
as O 
photocatalysis O 
, O 
solar O 
cells O 
, O 
and O 
sensors O 
. O 
In O 
this O 
study O 
, O 
we O 
developed O 
new O 
water O 
- O 
soluble O 
fluorogenic O 
probes O 
for O 
interfacial O 
electron O 
transfer O 
reactions O 
on O 
semiconductor O 
nanoparticles O 
. O 
The O 
synthesized O 
boron B-TRIVIAL 
- I-TRIVIAL 
dipyrromethene I-TRIVIAL 
-based O 
fluorescence O 
dyes O 
have O 
one O 
or O 
two O 
sulfonate B-SYSTEMATIC 
groups O 
, O 
which O 
confer O 
solubility O 
in O 
aqueous O 
media O 
, O 
and O 
a O 
dinitrophenyl B-SYSTEMATIC 
group O 
as O 
a O 
redox O 
reaction O 
site O 
. O 
These O 
probes O 
produce O 
the O 
corresponding O 
fluorescent O 
products O 
via O 
multiple O 
interfacial O 
electron O 
transfer O 
processes O 
, O 
allowing O 
us O 
to O 
investigate O 
the O 
photoinduced O 
redox O 
reactions O 
over O 
individual O 
pristine O 
and O 
Au B-FORMULA 
-nanoparticle O 
- O 
deposited O 
TiO(2) B-FORMULA 
nanoparticles O 
at O 
the O 
single O 
- O 
particle O 
, O 
single O 
- O 
molecule O 
levels O 
. O 
The O 
minimum O 
probe O 
concentration O 
to O 
detect O 
single O 
- O 
product O 
molecules O 
on O 
a O 
single O 
TiO(2) B-FORMULA 
nanoparticle O 
was O 
found O 
to O 
be O 
in O 
the O 
nanomolar O 
range O 
( O 
< O 
10 O 
nM O 
) O 
in O 
acidic O 
solution O 
. O 
Furthermore O 
, O 
super O 
- O 
resolution O 
mapping O 
of O 
the O 
reaction O 
sites O 
revealed O 
that O 
visible O 
- O 
light O 
- O 
induced O 
reduction O 
reactions O 
preferentially O 
occurred O 
on O 
the O 
TiO(2) B-FORMULA 
surface O 
within O 
a O 
distance O 
of O 
a O 
few O 
tens O 
of O 
nanometers O 
around O 
the O 
deposited O 
Au B-FORMULA 
nanoparticles O 
. O 
This O 
result O 
was O 
qualitatively O 
interpreted O 
on O 
the O 
basis O 
of O 
plasmon O 
- O 
induced O 
electron O 
and O 
/ O 
or O 
energy O 
transfer O 
mechanisms O 
. O 
Overall O 
, O 
this O 
study O 
provides O 
a O 
great O 
deal O 
of O 
valuable O 
information O 
related O 
to O 
solar O 
- O 
energy O 
- O 
conversion O 
processes O 
that O 
is O 
impossible O 
or O 
difficult O 
to O 
obtain O 
from O 
ensemble O 
- O 
averaged O 
experiments O 
. O 

of O 
4-hydroxynonenal B-SYSTEMATIC 
and O 
malondialdehyde B-TRIVIAL 
modified O 
protein O 
levels O 
in O 
cerebral O 
cortex O 
with O 
cognitive O 
dysfunction O 
in O 
rats O 
exposed O 
to O 
1-bromopropane B-SYSTEMATIC 
. O 

( O 
1-BP B-SYSTEMATIC 
) O 
, O 
an O 
alternative O 
to O 
ozone B-TRIVIAL 
-depleting O 
solvents O 
( O 
ODS O 
) O 
, O 
exhibits O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
toxicity O 
in O 
animals O 
and O 
humans O 
. O 
This O 
study O 
was O 
designed O 
to O 
relate O 
CNS O 
damage O 
by O 
Morris O 
water O 
maze O 
( O 
MWM O 
) O 
test O 
and O 
oxidative O 
stress O 
to O 
1-BP B-SYSTEMATIC 
exposure O 
in O 
the O 
rat O 
. O 
Male O 
Wistar O 
rats O 
were O 
randomly O 
divided O 
into O 
4 O 
groups O 
( O 
n=10 O 
) O 
, O 
and O 
treated O 
with O 
0 O 
, O 
200 O 
, O 
400 O 
and O 
800mg O 
/ O 
kgbw O 
1-BP B-SYSTEMATIC 
for O 
consecutive O 
12 O 
days O 
, O 
respectively O 
. O 
From O 
day O 
8 O 
to O 
day O 
12 O 
of O 
the O 
experiment O 
, O 
MWM O 
test O 
was O 
employed O 
to O 
assess O 
the O 
cognitive O 
function O 
of O 
rats O 
. O 
The O 
cerebral O 
cortex O 
of O 
rats O 
was O 
obtained O 
immediately O 
following O 
the O 
24h O 
after O 
MWM O 
test O 
conclusion O 
. O 
Glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
oxidized B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSSG B-ABBREVIATION 
) O 
and O 
total O 
thiol B-FAMILY 
( O 
total- O 
SH B-FORMULA 
) O 
content O 
, O 
GSH B-ABBREVIATION 
reductase O 
( O 
GR O 
) O 
and O 
GSH B-ABBREVIATION 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
activities O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
level O 
, O 
as O 
well O 
as O 
4-hydroxynonenal B-SYSTEMATIC 
( O 
4-HNE B-SYSTEMATIC 
) O 
and O 
MDA B-ABBREVIATION 
modified O 
proteins O 
in O 
homogenates O 
of O 
cerebral O 
cortex O 
were O 
measured O 
. O 
The O 
obtained O 
results O 
showed O 
that O 
1-BP B-SYSTEMATIC 
led O 
to O 
cognitive O 
dysfunction O 
of O 
rats O 
, O 
which O 
was O 
evidenced O 
by O 
delayed O 
escape O 
latency O 
time O 
and O 
swimming O 
distances O 
in O 
MWM O 
performance O 
. O 
GSH B-ABBREVIATION 
and O 
total- O 
SH B-FORMULA 
content O 
, O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
ratio O 
, O 
GR O 
activity O 
significantly O 
decreased O 
in O 
cerebral O 
cortex O 
of O 
rats O 
, O 
coupling O 
with O 
the O 
increase O 
of O 
MDA B-ABBREVIATION 
level O 
. O 
4-HNE B-SYSTEMATIC 
and O 
MDA B-ABBREVIATION 
modified O 
protein O 
levels O 
obviously O 
elevated O 
after O 
1-BP B-SYSTEMATIC 
exposure O 
. O 
GSH B-ABBREVIATION 
-Px O 
activities O 
in O 
cerebral O 
cortex O 
of O 
rats O 
also O 
increased O 
. O 
These O 
data O 
suggested O 
that O 
1-BP B-SYSTEMATIC 
resulted O 
in O 
enhanced O 
lipid O 
peroxidation O 
of O 
brain O 
, O 
which O 
might O 
play O 
an O 
important O 
role O 
in O 
CNS O 
damage O 
induced O 
by O 
1-BP B-SYSTEMATIC 
. O 

have O 
revisited O 
the O 
RC-LH1 O 
complex O 
from O 
Rhodopseudomonas O 
( O 
Rps O 
. O 
) O 
acidophila O 
for O 
single O 
- O 
molecule O 
spectroscopy O 
. O 
For O 
the O 
current O 
study O 
the O 
pigment O 
- O 
protein O 
complexes O 
were O 
stabilized O 
in O 
the O 
detergent O 
buffer O 
solution O 
using O 
a O 
relatively O 
mild O 
detergent O 
( O 
dodecyl-β-D-maltoside B-SYSTEMATIC 
( O 
DDM B-ABBREVIATION 
) O 
instead O 
of O 
lauryldimethylamine B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
( O 
LDAO B-ABBREVIATION 
) O 
) O 
. O 
This O 
leads O 
to O 
a O 
significant O 
reduction O 
of O 
the O 
fraction O 
of O 
broken O 
/ O 
dissociated O 
RC-LH1 O 
complexes O 
with O 
respect O 
to O 
previous O 
studies O 
and O 
has O 
allowed O 
us O 
to O 
investigate O 
a O 
sufficiently O 
large O 
sample O 
of O 
individual O 
RC-LH1 O 
complexes O 
. O 
For O 
most O 
of O 
the O 
complexes O 
the O 
fluorescence O 
- O 
excitation O 
spectra O 
exhibit O 
a O 
narrow O 
spectral O 
feature O 
at O 
the O 
red O 
end O 
of O 
the O 
spectrum O 
. O 
Analysis O 
of O 
the O 
statistics O 
of O 
the O 
spectral O 
properties O 
yields O 
a O 
close O 
resemblance O 
with O 
the O 
results O 
obtained O 
on O 
RC-LH1 O 
complexes O 
from O 
Rps O 
. O 
palustris O 
for O 
which O 
a O 
low O 
- O 
resolution O 
X-ray O 
structure O 
is O 
available O 
. O 
Based O 
on O 
this O 
comparison O 
we O 
come O 
to O 
the O 
conclusion O 
that O 
for O 
both O 
species O 
the O 
RC-LH1 O 
complex O 
can O 
be O 
described O 
by O 
the O 
same O 
structural O 
model O 
, O 
that O 
is O 
, O 
an O 
overall O 
elliptical O 
assembly O 
of O 
pigments O 
that O 
features O 
a O 
gap O 
. O 

Suppresses O 
MPP+ B-ABBREVIATION 
-Induced O 
Oxidative O 
Damage O 
in O 
PC12 O 
Cells O 
through O 
a O 
Sp1 O 
/ O 
NR1 O 
Signaling O 
Pathway O 
. O 

: O 
To O 
investigate O 
astaxanthin B-TRIVIAL 
( O 
ATX B-ABBREVIATION 
) O 
neuroprotection O 
, O 
and O 
its O 
mechanism O 
, O 
on O 
a O 
1-methyl-4-phenyl-pyridine B-SYSTEMATIC 
ion O 
( O 
MPP+ B-ABBREVIATION 
)-induced O 
cell O 
model O 
of O 
Parkinson's O 
disease O 
. O 
Methods O 
: O 
Mature O 
, O 
differentiated O 
PC12 O 
cells O 
treated O 
with O 
MPP+ B-ABBREVIATION 
were O 
used O 
as O 
an O 
in O 
vitro O 
cell O 
model O 
. O 
The O 
MTT B-ABBREVIATION 
assay O 
was O 
used O 
to O 
investigate O 
cell O 
viability O 
after O 
ATX B-ABBREVIATION 
treatment O 
, O 
and O 
western O 
blot O 
analysis O 
was O 
used O 
to O 
observe O 
Sp1 O 
( O 
activated O 
transcription O 
factor O 
1 O 
) O 
and O 
NR1 O 
( O 
NMDA B-ABBREVIATION 
receptor O 
subunit O 
1 O 
) O 
protein O 
expression O 
, O 
real O 
- O 
time O 
PCR O 
was O 
used O 
to O 
monitor O 
Sp1 O 
and O 
NR1 O 
mRNA O 
, O 
and O 
cell O 
immunofluorescence O 
was O 
used O 
to O 
determine O 
the O 
location O 
of O 
Sp1 O 
and O 
NR1 O 
protein O 
and O 
the O 
nuclear O 
translocation O 
of O 
Sp1 O 
. O 
Results O 
: O 
PC12 O 
cell O 
viability O 
was O 
significantly O 
reduced O 
by O 
MPP+ B-ABBREVIATION 
treatment O 
. O 
The O 
expression O 
of O 
Sp1 O 
and O 
NR1 O 
mRNA O 
and O 
protein O 
were O 
increased O 
compared O 
with O 
the O 
control O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Following O 
co O 
- O 
treatment O 
with O 
ATX B-ABBREVIATION 
and O 
MPP+ B-ABBREVIATION 
, O 
cell O 
viability O 
was O 
significantly O 
increased O 
, O 
and O 
Sp1 O 
and O 
NR1 O 
mRNA O 
and O 
protein O 
were O 
decreased O 
, O 
compared O 
with O 
the O 
MPP+ B-ABBREVIATION 
groups O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
In O 
addition O 
, O 
mithracycin B-TRIVIAL 
A I-TRIVIAL 
protected O 
PC12 O 
cells O 
from O 
oxidative O 
stress O 
caused O 
by O 
MPP+ B-ABBREVIATION 
by O 
specifically O 
inhibiting O 
the O 
expression O 
of O 
Sp1 O 
. O 
Moreover O 
, O 
cell O 
immunofluorescence O 
revealed O 
that O 
ATX B-ABBREVIATION 
could O 
suppress O 
Sp1 O 
nuclear O 
transfer O 
. O 
Conclusion O 
: O 
ATX B-ABBREVIATION 
inhibited O 
oxidative O 
stress O 
induced O 
by O 
MPP+ B-ABBREVIATION 
in O 
PC12 O 
cells O 
, O 
via O 
the O 
SP1 O 
/ O 
NR1 O 
signaling O 
pathway O 
. O 

-type O 
diterpenoid B-FAMILY 
analogs O 
from O 
natural O 
kaurene B-TRIVIAL 
-type O 
oridonin B-TRIVIAL 
: O 
Synthesis O 
and O 
their O 
antitumor O 
biological O 
evaluation O 
. O 

series O 
of O 
enmein B-TRIVIAL 
-type O 
diterpenoid B-FAMILY 
analogs O 
( O 
11-20 O 
) O 
derived O 
from O 
natural O 
kaurene B-TRIVIAL 
-type O 
diterpenoid O 
oridonin B-TRIVIAL 
were O 
synthesized O 
and O 
biologically O 
evaluated O 
. O 
All O 
target O 
compounds O 
showed O 
improved O 
anti-proliferative O 
activities O 
against O 
four O 
human O 
cancer O 
cell O 
lines O 
compared O 
with O 
natural O 
oridonin B-TRIVIAL 
and O 
parent O 
compound O 
10 O 
. O 
Some O 
compounds O 
were O 
more O 
potent O 
than O 
positive O 
control O 
Taxol B-TRIVIAL 
. O 
Furthermore O 
, O 
mechanistic O 
investigation O 
showed O 
that O 
the O 
representative O 
compound O 
17 O 
affected O 
cell O 
cycle O 
and O 
induced O 
apoptosis O 
at O 
low O 
micro O 
- O 
molar O 
level O 
in O 
human O 
hepatoma O 
Bel-7402 O 
cells O 
, O 
via O 
an O 
oxidative O 
stress O 
triggered O 
mitochondria O 
- O 
related O 
caspase O 
- O 
dependent O 
pathway O 
. O 

, O 
a O 
cholestatic O 
liver O 
injury O 
- O 
inducible O 
drug O 
, O 
causes O 
dysfunction O 
of O 
bile O 
formation O 
via O 
diminished O 
biliary O 
secretion O 
of O 
phospholipids O 
: O 
involvement O 
of O 
biliary O 
- O 
excreted O 
glutathione B-TRIVIAL 
-conjugated O 
ticlopidine B-TRIVIAL 
metabolites O 
. O 

antiplatelet O 
drug O 
, O 
ticlopidine B-TRIVIAL 
( O 
TIC B-ABBREVIATION 
) O 
, O 
reportedly O 
causes O 
cholestatic O 
liver O 
injuries O 
. O 
The O 
present O 
study O 
analyzed O 
the O 
effect O 
of O 
TIC B-ABBREVIATION 
on O 
bile O 
formation O 
, O 
revealing O 
that O 
the O 
biliary O 
secretion O 
of O 
phospholipids O 
was O 
significantly O 
decreased O 
in O 
TIC B-ABBREVIATION 
-administered O 
Sprague O 
Dawley O 
( O 
SD O 
) O 
rats O 
. O 
However O 
, O 
the O 
effect O 
of O 
TIC B-ABBREVIATION 
on O 
biliary O 
phospholipids O 
was O 
not O 
observed O 
in O 
SD O 
rats O 
pretreated O 
with O 
diethylaminoethyl B-SYSTEMATIC 
diphenylpropylacetate I-SYSTEMATIC 
that O 
inhibits O 
cytochrome O 
P450s O 
( O 
P450 O 
) O 
, O 
or O 
in O 
Eisai O 
hyperbilirubinemic O 
rats O 
( O 
EHBR O 
) O 
lacking O 
functional O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2 O 
( O 
MRP2 O 
/ O 
ABCC2 O 
) O 
. O 
These O 
results O 
suggest O 
that O 
glutathione B-TRIVIAL 
-conjugated O 
TIC B-ABBREVIATION 
metabolites O 
( O 
TIC B-ABBREVIATION 
-SGs O 
) O 
, O 
which O 
were O 
formed O 
in O 
the O 
liver O 
after O 
P450s O 
- O 
mediated O 
metabolism O 
and O 
were O 
excreted O 
extensively O 
into O 
bile O 
by O 
MRP2 O 
, O 
mediated O 
the O 
observed O 
alterations O 
of O 
the O 
bile O 
composition O 
. O 
Administration O 
of O 
TIC B-ABBREVIATION 
caused O 
significant O 
liver O 
injuries O 
in O 
SD O 
rats O 
, O 
with O 
decreased O 
biliary O 
phospholipids O 
, O 
but O 
not O 
in O 
EHBR O 
, O 
consistent O 
with O 
the O 
in O 
vitro O 
observation O 
that O 
phospholipid- O 
bile B-FAMILY 
acid I-FAMILY 
-mixed O 
micelles O 
moderated O 
the O 
cytotoxic O 
effects O 
of O 
bile B-FAMILY 
acids I-FAMILY 
. O 
Further O 
analyses O 
revealed O 
that O 
TIC B-ABBREVIATION 
-SGs O 
did O 
not O 
directly O 
inhibit O 
multidrug O 
resistance O 
3 O 
P-glycoprotein O 
( O 
MDR3 O 
/ O 
ABCB4 O 
) O 
- O 
mediated O 
phosphatidylcholine B-FAMILY 
efflux O 
in O 
vitro O 
. O 
Because O 
the O 
diminished O 
biliary O 
secretion O 
of O 
phospholipids O 
with O 
TIC B-ABBREVIATION 
administration O 
was O 
restored O 
by O 
taurocholate B-TRIVIAL 
infusion O 
in O 
SD O 
rats O 
, O 
the O 
decreased O 
biliary O 
concentration O 
of O 
bile B-FAMILY 
acids I-FAMILY 
, O 
due O 
to O 
the O 
stimulation O 
of O 
bile B-FAMILY 
acid I-FAMILY 
-independent O 
bile O 
flow O 
driven O 
by O 
TIC B-ABBREVIATION 
-SGs O 
, O 
might O 
have O 
indirectly O 
attenuated O 
phospholipid O 
secretion O 
. O 
In O 
conclusion O 
, O 
extensive O 
biliary O 
excretion O 
of O 
TIC B-ABBREVIATION 
-SGs O 
decreased O 
the O 
biliary O 
secretion O 
of O 
phospholipids O 
, O 
which O 
might O 
have O 
increased O 
the O 
risk O 
of O 
TIC B-ABBREVIATION 
-induced O 
cholestatic O 
liver O 
injury O 
. O 

and O 
antimalarial O 
activity O 
of O 
semisynthetic O 
lycorenine B-TRIVIAL 
derivatives O 
. O 

set O 
of O 
twenty O 
one O 
lycorenine B-TRIVIAL 
derivatives O 
has O 
been O 
prepared O 
from O 
the O 
alkaloid O 
hippeastrine B-TRIVIAL 
( O 
1 O 
) O 
. O 
The O 
modifications O 
performed O 
on O 
hippeastrine B-TRIVIAL 
included O 
some O 
functional O 
group O 
transformations O 
, O 
structural O 
simplification O 
and O 
preparation O 
of O 
dimers O 
. O 
All O 
alkaloids O 
were O 
tested O 
as O 
potential O 
antimalarial O 
agents O 
, O 
being O 
the O 
hippeastrine B-TRIVIAL 
dimers O 
the O 
most O 
active O 
compounds O 
. O 

quercetin B-TRIVIAL 
ameliorates O 
nonalcoholic O 
steatohepatitis O 
induced O 
by O 
a O 
high O 
- O 
fat O 
diet O 
in O 
gerbils O 
. O 

quercetin B-TRIVIAL 
is O 
highly O 
abundant O 
in O 
edible O 
plants O 
, O 
which O 
possesses O 
a O 
wide O 
range O 
of O 
pharmacological O 
properties O 
. O 
This O 
study O 
was O 
to O 
investigate O 
hepatoprotective O 
effects O 
of O 
quercetin B-TRIVIAL 
in O 
the O 
nonalcoholic O 
steatohepatitis O 
( O 
NASH O 
) O 
gerbils O 
induced O 
by O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
, O 
and O 
to O 
evaluate O 
its O 
regulatory O 
mechanism O 
on O 
hepatic O 
inflammatory O 
response O 
. O 
The O 
gerbils O 
were O 
fed O 
with O 
HFD O 
for O 
28 O 
days O 
to O 
induce O 
NASH O 
. O 
From O 
15th O 
day O 
to O 
28th O 
day O 
, O 
the O 
treated O 
drugs O 
were O 
given O 
daily O 
to O 
each O 
animal O 
, O 
respectively O 
. O 
The O 
lipid O 
profiles O 
and O 
biochemical O 
markers O 
were O 
determined O 
at O 
the O 
end O 
of O 
the O 
experiment O 
. O 
The O 
expressions O 
of O 
Sirt1 O 
, O 
NF-κB O 
p65 O 
and O 
iNOS O 
were O 
detected O 
by O 
immunohistochemistry O 
and O 
Western O 
blot O 
analysis O 
. O 
The O 
results O 
showed O 
that O 
oral O 
administration O 
of O 
quercetin B-TRIVIAL 
at O 
doses O 
of O 
30-60 O 
mg O 
/ O 
kg O 
to O 
hyperlipidemia O 
rats O 
for O 
14 O 
days O 
were O 
highly O 
effective O 
in O 
decreasing O 
the O 
levels O 
of O 
serum O 
total O 
cholesterol B-TRIVIAL 
( O 
TC O 
) O 
, O 
triglycerides B-FAMILY 
( O 
TG O 
) O 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
. O 
It O 
could O 
decrease O 
lipid O 
accumulation O 
in O 
the O 
hepatocytes O 
, O 
and O 
reduce O 
serum O 
levels O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
TNF-α O 
and O 
IL-6 O 
via O 
regulating O 
the O 
expressions O 
of O 
Sirt1 O 
, O 
NF-κB O 
p65 O 
and O 
iNOS O 
. O 
Thus O 
, O 
dietary O 
quercetin B-TRIVIAL 
had O 
significant O 
therapeutic O 
benefits O 
and O 
could O 
be O 
explored O 
as O 
a O 
potential O 
promising O 
candidate O 
for O 
the O 
prevention O 
of O 
NASH O 
. O 

induces O 
abnormal O 
nuclear O 
morphology O 
and O 
cell O 
cycle O 
arrest O 
in O 
murine O 
RAW O 
264.7 O 
macrophages O 
. O 

mycotoxin O 
alternariol B-TRIVIAL 
( O 
AOH B-FORMULA 
) O 
, O 
a O 
frequent O 
contaminant O 
in O 
fruit O 
and O 
cereal O 
products O 
, O 
is O 
known O 
to O 
induce O 
DNA O 
damage O 
with O 
subsequent O 
cell O 
cycle O 
arrest O 
. O 
Here O 
we O 
elucidated O 
the O 
effects O 
of O 
AOH B-FORMULA 
on O 
stages O 
of O 
cell O 
cycle O 
progression O 
using O 
the O 
RAW O 
264.7 O 
macrophage O 
model O 
. O 
AOH B-FORMULA 
resulted O 
in O 
an O 
accumulation O 
of O 
cells O 
in O 
the O 
G2 O 
/ O 
M-phase O 
( O 
4N O 
) O 
. O 
Most O 
cells O 
exhibited O 
a O 
large O 
G2 O 
nucleus O 
whereas O 
numbers O 
of O 
true O 
mitotic O 
cells O 
were O 
reduced O 
relative O 
to O 
control O 
. O 
Both O 
cyclin O 
B1 O 
and O 
p-cdc2 O 
levels O 
increased O 
, O 
while O 
cyclin O 
B1 O 
remained O 
in O 
the O 
cytoplasm O 
; O 
suggesting O 
arrest O 
in O 
the O 
G2 O 
/ O 
M O 
transition O 
point O 
. O 
Remarkably O 
, O 
after O 
exposure O 
to O 
AOH B-FORMULA 
for O 
24h O 
, O 
most O 
of O 
the O 
cells O 
exhibited O 
abnormally O 
shaped O 
nuclei O 
, O 
as O 
evidenced O 
by O 
partly O 
divided O 
nuclei O 
, O 
nuclear O 
blebs O 
, O 
polyploidy O 
and O 
micronuclei O 
( O 
MN O 
) O 
. O 
AOH B-FORMULA 
treatment O 
also O 
induced O 
abnormal O 
Aurora O 
B O 
bridges O 
, O 
suggesting O 
that O 
cytokinesis O 
was O 
interfered O 
within O 
cells O 
undergoing O 
karyokinesis O 
. O 
A O 
minor O 
part O 
of O 
the O 
resultant O 
G1 O 
tetraploid O 
( O 
4N O 
) O 
cells O 
re O 
- O 
entered O 
the O 
S-phase O 
and O 
progressed O 
to O 
8N O 
cells O 
. O 

characterisation O 
has O 
been O 
carried O 
out O 
on O 
45 O 
honey O 
samples O 
collected O 
from O 
Hatay O 
region O 
of O 
Turkey O 
. O 
The O 
concentrations O 
of O 
17 O 
elements O 
were O 
determined O 
by O 
inductively O 
coupled O 
plasma O 
optical O 
emission O 
spectrometry O 
( O 
ICP-OES O 
) O 
. O 
Ca B-FORMULA 
, O 
K B-FORMULA 
, O 
Mg B-FORMULA 
and O 
Na B-FORMULA 
were O 
the O 
most O 
abundant O 
elements O 
, O 
with O 
mean O 
contents O 
of O 
219.38 O 
, O 
446.93 O 
, O 
49.06 O 
and O 
95.91mgkg(-1) O 
respectively O 
. O 
The O 
trace O 
element O 
mean O 
contents O 
ranged O 
between O 
0.03 O 
and O 
15.07mgkg(-1) O 
. O 
Chemometric O 
methods O 
such O 
as O 
principal O 
component O 
analysis O 
( O 
PCA O 
) O 
and O 
cluster O 
analysis O 
( O 
CA O 
) O 
techniques O 
were O 
applied O 
to O 
classify O 
honey O 
according O 
to O 
mineral O 
content O 
. O 
The O 
first O 
most O 
important O 
principal O 
component O 
( O 
PC O 
) O 
was O 
strongly O 
associated O 
with O 
the O 
value O 
of O 
Al B-FORMULA 
, O 
B B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Co B-FORMULA 
. O 
CA O 
showed O 
eight O 
clusters O 
corresponding O 
to O 
the O 
eight O 
botanical O 
origins O 
of O 
honey O 
. O 
PCA O 
explained O 
75.69% O 
of O 
the O 
variance O 
with O 
the O 
first O 
six O 
PC O 
variables O 
. O 
Chemometric O 
analysis O 
of O 
the O 
analytical O 
data O 
allowed O 
the O 
accurate O 
classification O 
of O 
the O 
honey O 
samples O 
according O 
to O 
origin O 
. O 

artificial O 
saliva O 
( O 
CAS O 
) O 
is O 
a O 
saliva O 
substitute O 
often O 
used O 
as O 
a O 
vehicle O 
for O 
test O 
articles O 
, O 
including O 
smokeless O 
tobacco O 
products O 
. O 
In O 
the O 
course O 
of O 
a O 
study O 
employing O 
normal O 
adult O 
human O 
dermal O 
fibroblasts O 
( O 
HDFa O 
) O 
as O 
a O 
model O 
in O 
vitro O 
, O 
we O 
discovered O 
that O 
CAS O 
as O 
a O 
vehicle O 
introduced O 
a O 
significant O 
change O 
in O 
the O 
expression O 
of O 
proinflammatory O 
cytokines O 
. O 
To O 
determine O 
the O 
effects O 
of O 
CAS O 
on O 
gene O 
expression O 
, O 
real O 
- O 
time O 
quantitative O 
reverse O 
- O 
transcriptase O 
polymerase O 
chain O 
reaction O 
( O 
qRT-PCR O 
) O 
gene O 
array O 
analysis O 
was O 
used O 
. O 
Results O 
indicate O 
that O 
robust O 
changes O 
in O 
the O 
expression O 
of O 
the O 
proinflammatory O 
cytokine O 
interleukin O 
8 O 
( O 
IL8 O 
) O 
and O 
the O 
vascular O 
cell O 
adhesion O 
molecule O 
1 O 
( O 
VCAM1 O 
) O 
occur O 
within O 
5 O 
hours O 
of O 
exposure O 
to O 
CAS O 
. O 
To O 
determine O 
whether O 
CAS O 
also O 
alters O 
cytokine O 
release O 
into O 
the O 
culture O 
media O 
, O 
cytometric O 
bead O 
array O 
( O 
CBA O 
) O 
assays O 
for O 
human O 
inflammatory O 
cytokines O 
were O 
performed O 
. O 
Analysis O 
shows O 
that O 
CAS O 
induced O 
the O 
release O 
of O 
IL8 O 
and O 
interleukin O 
6 O 
( O 
IL6 O 
) O 
. O 
This O 
study O 
focused O 
on O 
determining O 
which O 
components O 
in O 
CAS O 
were O 
responsible O 
for O 
the O 
proinflammatory O 
response O 
in O 
HDFa O 
. O 
The O 
following O 
components O 
were O 
investigated O 
: O 
α-amylase O 
, O 
lysozyme O 
, O 
acid O 
phosphatase O 
, O 
and O 
urea B-TRIVIAL 
. O 
Results O 
demonstrated O 
that O 
enzymatically O 
active O 
α-amylase O 
induced O 
gene O 
expression O 
for O 
proinflammatory O 
cytokines O 
IL8 O 
, O 
IL6 O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNFα O 
) O 
, O 
and O 
interleukin O 
1α O 
( O 
IL1α O 
) O 
, O 
and O 
for O 
VCAM1 O 
. O 
Therefore O 
, O 
it O 
is O 
important O 
to O 
carefully O 
evaluate O 
the O 
" O 
vehicle O 
effects O 
" O 
of O 
CAS O 
and O 
its O 
components O 
in O 
in O 
vitro O 
toxicology O 
research O 
. O 

hydrolysis O 
by O 
a O 
histidine B-TRIVIAL 
-containing O 
cavitein O 
. O 

have O 
used O 
a O 
template O 
- O 
assembled O 
synthetic O 
protein O 
( O 
TASP O 
) O 
to O 
investigate O 
catalytic O 
function O 
in O 
ester B-FAMILY 
hydrolysis O 
. O 
A O 
histidine B-TRIVIAL 
-containing O 
cavitein O 
has O 
been O 
found O 
to O 
catalyze O 
ester B-FAMILY 
hydrolysis O 
with O 
a O 
rate O 
increase O 
of O 
18 O 
times O 
that O 
of O 
background O 
. O 

toxicological O 
study O 
of O 
the O 
novel O 
protein O 
phosphatase O 
inhibitor O 
19-Epi-okadaic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
primary O 
cultures O 
of O 
rat O 
cerebellar O 
cells O 
. O 

acid I-TRIVIAL 
( O 
OKA B-ABBREVIATION 
) O 
and O 
analogues O 
are O 
frequent O 
contaminants O 
of O 
coastal O 
waters O 
and O 
seafood O 
. O 
Structure O 
analysis O 
of O 
the O 
isolated O 
OKA B-ABBREVIATION 
analogue O 
19-epi-OKA B-SYSTEMATIC 
showed O 
important O 
conformation O 
differences O 
expected O 
to O 
result O 
in O 
lower O 
protein O 
phosphatase O 
( O 
PP O 
) O 
inhibitory O 
potencies O 
than O 
OKA B-ABBREVIATION 
. O 
However O 
, O 
19-epi-OKA B-SYSTEMATIC 
and O 
OKA B-ABBREVIATION 
inhibitory O 
activities O 
versus O 
PP2A O 
were O 
unexpectedly O 
found O 
to O 
be O 
virtually O 
equipotent O 
. O 
To O 
investigate O 
the O 
toxicological O 
relevance O 
of O 
these O 
findings O 
, O 
we O 
tested O 
the O 
effects O 
of O 
19-epi-OKA B-SYSTEMATIC 
on O 
cultured O 
cerebellar O 
cells O 
and O 
compared O 
them O 
with O 
those O 
of O 
OKA B-ABBREVIATION 
and O 
its O 
isomer O 
dinophysistoxin-2 B-TRIVIAL 
. O 
19-epi-OKA B-SYSTEMATIC 
caused O 
degeneration O 
of O 
neurites O 
and O 
neuronal O 
death O 
with O 
much O 
lower O 
potency O 
than O 
its O 
congeners O 
. O 
The O 
concentration O 
of O 
19-epi-OKA B-SYSTEMATIC 
that O 
reduced O 
after O 
24h O 
the O 
maximum O 
neuronal O 
survival O 
( O 
EC5024 O 
) O 
by O 
50% O 
was O 
~300nM O 
compared O 
with O 
~2nM O 
and O 
~8nM O 
for O 
OKA B-ABBREVIATION 
and O 
dinophysistoxin-2 B-TRIVIAL 
, O 
respectively O 
. O 
Exposure O 
to O 
19-epi-OKA B-SYSTEMATIC 
resulted O 
also O 
in O 
less O 
toxicity O 
for O 
cultured O 
glial O 
cells O 
( O 
EC5024 O 
, O 
19-epi-OKA B-SYSTEMATIC 
~ O 
600nM O 
; O 
EC5024 O 
, O 
OKA B-ABBREVIATION 
~ O 
20nM O 
) O 
. O 
19-epi-OKA B-SYSTEMATIC 
induced O 
apoptotic O 
condensation O 
and O 
fragmentation O 
of O 
chromatin O 
, O 
activation O 
of O 
caspases O 
, O 
and O 
activation O 
of O 
ERK1 O 
/ O 
2 O 
MAP O 
kinases O 
, O 
features O 
previously O 
reported O 
for O 
OKA B-ABBREVIATION 
and O 
dinophysistoxin-2 B-TRIVIAL 
. O 
Also O 
, O 
differential O 
sensitivity O 
to O 
19-epi-OKA B-SYSTEMATIC 
was O 
observed O 
between O 
neuronal O 
and O 
glial O 
cells O 
, O 
a O 
specific O 
characteristic O 
shared O 
by O 
OKA B-ABBREVIATION 
and O 
dinophysistoxin-2 B-TRIVIAL 
but O 
not O 
by O 
other O 
toxins O 
. O 
Our O 
results O 
are O 
consistent O 
with O 
19-epi-OKA B-SYSTEMATIC 
being O 
included O 
among O 
the O 
group O 
of O 
toxins O 
of O 
OKA B-ABBREVIATION 
and O 
derivatives O 
and O 
support O 
the O 
suitability O 
of O 
cellular O 
bioassays O 
for O 
the O 
detection O 
of O 
these O 
compounds O 
. O 

semisynthetics O 
: O 
chemotherapeutics O 
for O 
cancer O 
? O 

-containing O 
bioactive O 
alkaloids O 
of O 
plant O 
origin O 
play O 
a O 
significant O 
role O 
in O 
human O 
health O 
and O 
medicine O 
. O 
Several O 
semisynthetic O 
antimitotic O 
alkaloids O 
are O 
successful O 
in O 
anticancer O 
drug O 
development O 
. O 
Gloriosa O 
superba O 
biosynthesizes O 
substantial O 
quantities O 
of O 
colchicine B-TRIVIAL 
, O 
a O 
bioactive O 
molecule O 
for O 
gout O 
treatment O 
. O 
Colchicine B-TRIVIAL 
also O 
has O 
antimitotic O 
activity O 
, O 
preventing O 
growth O 
of O 
cancer O 
cells O 
by O 
interacting O 
with O 
microtubules O 
, O 
which O 
could O 
lead O 
to O 
the O 
design O 
of O 
better O 
cancer O 
therapeutics O 
. O 
Further O 
, O 
several O 
colchicine B-TRIVIAL 
semisynthetics O 
are O 
less O 
toxic O 
than O 
colchicine B-TRIVIAL 
. O 
Research O 
is O 
being O 
conducted O 
on O 
effective O 
, O 
less O 
toxic O 
colchicine B-TRIVIAL 
semisynthetic O 
formulations O 
with O 
potential O 
drug O 
delivery O 
strategies O 
directly O 
targeting O 
multiple O 
solid O 
cancers O 
. O 
This O 
article O 
reviews O 
the O 
dynamic O 
state O 
of O 
anticancer O 
drug O 
development O 
from O 
colchicine B-TRIVIAL 
semisynthetics O 
and O 
natural O 
colchicine B-TRIVIAL 
production O 
and O 
briefly O 
discusses O 
colchicine B-TRIVIAL 
biosynthesis O 
. O 

of O 
individuals O 
worldwide O 
suffer O 
from O 
acute O 
and O 
, O 
more O 
severely O 
, O 
chronic O 
pain O 
conditions O 
( O 
e.g O 
. O 
, O 
neuropathic O 
pain O 
, O 
and O 
migraine O 
) O 
. O 
The O 
latter O 
bear O 
tremendous O 
personal O 
, O 
familial O 
, O 
and O 
social O 
costs O 
, O 
since O 
sufferers O 
and O 
their O 
relatives O 
undergo O 
a O 
complete O 
turnaround O 
of O 
their O 
lives O 
with O 
the O 
search O 
of O 
relief O 
from O 
pain O 
becoming O 
their O 
pivotal O 
thought O 
. O 
Sadly O 
, O 
to O 
date O 
no O 
effective O 
pharmacological O 
approaches O 
are O 
available O 
which O 
can O 
alleviate O 
chronic O 
pain O 
significantly O 
or O 
in O 
the O 
long O 
run O 
in O 
all O 
patients O 
. O 
The O 
current O 
central O 
strategy O 
for O 
the O 
development O 
of O 
new O 
and O 
effective O 
painkillers O 
lies O 
in O 
the O 
hypothesis O 
that O 
cellular O 
and O 
/ O 
or O 
molecular O 
players O 
in O 
nociception O 
must O 
exists O 
that O 
are O 
not O 
targeted O 
by O 
" O 
classical O 
" O 
analgesics O 
, O 
and O 
therefore O 
researchers O 
have O 
put O 
tremendous O 
efforts O 
into O 
the O 
in O 
- O 
depth O 
analysis O 
of O 
the O 
pathways O 
leading O 
to O 
pain O 
development O 
and O 
maintenance O 
over O 
time O 
. O 
In O 
this O 
complex O 
scenario O 
, O 
two O 
outsiders O 
are O 
now O 
taking O 
the O 
center O 
stage O 
: O 
glial O 
cells O 
in O 
sensory O 
ganglia O 
and O 
in O 
the O 
central O 
nervous O 
system O 
, O 
thanks O 
to O 
their O 
ability O 
to O 
communicate O 
with O 
neurons O 
and O 
to O 
modulate O 
their O 
firing O 
, O 
and O 
the O 
purinergic O 
system O 
. O 
Extracellular O 
purine B-MULTIPLE 
and I-MULTIPLE 
pyrimidine I-MULTIPLE 
nucleotides I-MULTIPLE 
are O 
involved O 
in O 
the O 
physiology O 
of O 
virtually O 
every O 
body O 
district O 
, O 
and O 
their O 
extracellular O 
concentrations O 
massively O 
increase O 
under O 
pathological O 
situations O 
, O 
suggesting O 
that O 
they O 
might O 
represent O 
potential O 
targets O 
for O 
the O 
modulation O 
of O 
disease O 
- O 
associated O 
symptoms O 
, O 
like O 
pain O 
. O 
Here O 
, O 
we O 
provide O 
an O 
overview O 
of O 
the O 
present O 
knowledge O 
of O 
the O 
role O 
of O 
nucleotides B-FAMILY 
in O 
nociception O 
, O 
with O 
a O 
particular O 
emphasis O 
on O 
G O 
protein O 
- O 
coupled O 
P2Y O 
receptors O 
and O 
their O 
involvement O 
in O 
the O 
communication O 
between O 
first- O 
and O 
second O 
- O 
order O 
neurons O 
in O 
sensory O 
nerve O 
pathways O 
and O 
surrounding O 
glial O 
cells O 
. O 

some O 
novel O 
7-chloroquinolines B-FAMILY 
carrying O 
a O 
biologically O 
active O 
benzenesulfonamide B-SYSTEMATIC 
moiety O 
as O 
a O 
new O 
class O 
of O 
anticancer O 
agents O 
. O 

on O 
the O 
reported O 
anticancer O 
activity O 
of O 
quinolines B-FAMILY 
, O 
a O 
new O 
series O 
of O 
7-chloroquinoline B-SYSTEMATIC 
derivatives O 
bearing O 
the O 
biologically O 
active O 
benzenesulfonamide B-SYSTEMATIC 
moiety O 
2-17 O 
and O 
19-25 O 
were O 
synthesized O 
starting O 
with O 
4,7-dichloroquinolne B-SYSTEMATIC 
1 O 
. O 
Compound O 
17 O 
was O 
the O 
most O 
active O 
compound O 
with O 
IC(50) O 
value O 
64.41 O 
, O 
75.05 O 
and O 
30.71 O 
µM O 
compared O 
with O 
Doxorubicin B-TRIVIAL 
as O 
reference O 
drug O 
with O 
IC(50) O 
values O 
82.53 O 
, O 
88.32 O 
and O 
73.72 O 
µM O 
on O 
breast O 
cancer O 
cells O 
, O 
skin O 
cancer O 
cells O 
and O 
neuroblastoma O 
, O 
respectively O 
. O 
All O 
the O 
synthesized O 
compounds O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
anticancer O 
activity O 
on O 
breast O 
cancer O 
cells O 
, O 
skin O 
cancer O 
cells O 
and O 
neuroblastoma O 
cells O 
. O 
Most O 
of O 
the O 
synthesized O 
compounds O 
showed O 
moderate O 
activity O 
. O 
In O 
order O 
to O 
suggest O 
the O 
mechanism O 
of O 
action O 
for O 
their O 
cytotoxic O 
activity O 
, O 
molecular O 
docking O 
for O 
all O 
synthesized O 
compounds O 
was O 
done O 
on O 
the O 
active O 
site O 
of O 
phosphoinositide B-FAMILY 
kinase O 
( O 
PI3K O 
) O 
and O 
good O 
results O 
were O 
obtained O 
. O 

geochemical O 
markers O 
, O 
including O 
aliphatic B-FAMILY 
hydrocarbons I-FAMILY 
( O 
n-alkanes B-FAMILY 
) O 
, O 
linear B-FAMILY 
alkylbenzenes I-FAMILY 
( O 
LABs B-FAMILY 
) O 
, O 
and O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
, O 
were O 
employed O 
to O 
relate O 
sediment O 
organic O 
chemical O 
pollution O 
in O 
the O 
coastal O 
zone O 
off O 
South O 
China O 
to O 
socioeconomic O 
development O 
there O 
. O 
Concentrations O 
of O 
Σ O 
n-C(15-35) B-MULTIPLE 
( O 
n-alkanes B-FAMILY 
with O 
15-35 O 
carbon B-SYSTEMATIC 
atoms O 
) O 
, O 
Σ O 
LAB B-ABBREVIATION 
( O 
sum O 
of O 
C(10) B-MULTIPLE 
to I-MULTIPLE 
C(13) I-MULTIPLE 
LABs I-MULTIPLE 
) O 
, O 
and O 
Σ(26) O 
PAH B-ABBREVIATION 
( O 
sum O 
of O 
26 O 
PAH B-ABBREVIATION 
compounds O 
) O 
ranged O 
from O 
110 O 
to O 
3160 O 
, O 
11 O 
to O 
160 O 
, O 
and O 
26 O 
to O 
600 O 
ng O 
/ O 
g O 
, O 
with O 
medians O 
of O 
730 O 
, O 
40 O 
, O 
and O 
230 O 
ng O 
/ O 
g O 
, O 
respectively O 
. O 
Natural O 
hydrocarbons B-FAMILY 
were O 
mainly O 
derived O 
from O 
terrestrial O 
higher O 
plant O 
waxes O 
, O 
and O 
in O 
minor O 
amounts O 
from O 
aquatic O 
plankton O 
and O 
bacteria O 
. O 
Compositions O 
of O 
LABs B-FAMILY 
indicated O 
that O 
considerable O 
amounts O 
of O 
poorly O 
treated O 
wastewater O 
had O 
been O 
directly O 
discharged O 
or O 
transported O 
to O 
the O 
eastern O 
and O 
western O 
coastal O 
areas O 
of O 
Guangdong O 
Province O 
. O 
In O 
addition O 
, O 
anthropogenic O 
hydrocarbons B-FAMILY 
were O 
derived O 
largely O 
from O 
vehicular O 
emissions O 
and O 
combustion O 
of O 
domestic O 
coal O 
and O 
biomass O 
and O 
to O 
a O 
lesser O 
extent O 
from O 
oil O 
spills O 
. O 
Eastern O 
and O 
western O 
coastal O 
sediments O 
contained O 
higher O 
levels O 
of O 
LABs B-FAMILY 
but O 
lower O 
levels O 
of O 
PAHs B-ABBREVIATION 
than O 
those O 
of O 
the O 
Pearl O 
River O 
Estuary O 
, O 
a O 
coastal O 
area O 
of O 
the O 
Pearl O 
River O 
Delta O 
. O 
This O 
spatial O 
pattern O 
of O 
organic O 
pollution O 
was O 
consistent O 
with O 
chemical O 
use O 
patterns O 
. O 
The O 
eastern O 
and O 
western O 
regions O 
of O 
Guangdong O 
Province O 
are O 
economically O 
less O 
developed O 
than O 
the O 
Pearl O 
River O 
Delta O 
region O 
, O 
where O 
more O 
domestic O 
wastewater O 
treatment O 
plants O 
have O 
been O 
built O 
. O 
However O 
, O 
greater O 
amounts O 
of O 
energy O 
are O 
consumed O 
in O 
the O 
latter O 
region O 
to O 
produce O 
more O 
combustion O 
- O 
derived O 
PAH B-ABBREVIATION 
contamination O 
. O 

cirrhosis O 
alters O 
nuclear O 
receptor O 
and O 
drug O 
transporter O 
expression O 
in O 
human O 
liver O 
. O 

use O 
of O 
alcohol B-FAMILY 
results O 
in O 
approximately O 
2.5 O 
million O 
deaths O 
worldwide O 
, O 
with O 
cirrhosis O 
contributing O 
to O 
16.6% O 
of O 
reported O 
deaths O 
. O 
Serum O 
insulin O 
levels O 
are O 
often O 
elevated O 
in O 
alcoholism O 
and O 
may O 
result O 
in O 
diabetes O 
, O 
which O 
is O 
why O 
alcoholic O 
liver O 
disease O 
and O 
diabetes O 
often O 
are O 
present O 
together O 
. O 
Because O 
there O 
is O 
a O 
sizable O 
population O 
with O 
these O 
diseases O 
alone O 
or O 
in O 
combination O 
, O 
the O 
purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
transporter O 
expression O 
in O 
human O 
liver O 
is O 
affected O 
by O 
alcoholic O 
cirrhosis O 
, O 
diabetes O 
, O 
and O 
alcoholic O 
cirrhosis O 
coexisting O 
with O 
diabetes O 
. O 
Transporters O 
aid O 
in O 
hepatobiliary O 
excretion O 
of O 
many O 
drugs O 
and O 
toxic O 
chemicals O 
and O 
can O 
be O 
determinants O 
of O 
drug O 
- O 
induced O 
liver O 
injury O 
. O 
Drug O 
transporter O 
expression O 
and O 
transcription O 
factor O 
- O 
relative O 
mRNA O 
and O 
protein O 
expression O 
in O 
normal O 
, O 
diabetic O 
, O 
cirrhotic O 
, O 
and O 
cirrhosis O 
with O 
diabetes O 
human O 
livers O 
were O 
quantified O 
. O 
Cirrhosis O 
significantly O 
increased O 
ABCC4 O 
, O 
5 O 
, O 
ABCG2 O 
, O 
and O 
solute O 
carrier O 
organic O 
anion O 
( O 
SLCO O 
) O 
2B1 O 
mRNA O 
expression O 
and O 
decreased O 
SLCO1B3 O 
mRNA O 
expression O 
in O 
the O 
liver O 
. O 
ABCC1 O 
, O 
3-5 O 
, O 
and O 
ABCG2 O 
protein O 
expression O 
was O 
also O 
upregulated O 
by O 
alcoholic O 
cirrhosis O 
. O 
ABCC3-5 O 
and O 
ABCG2 O 
protein O 
expression O 
was O 
also O 
upregulated O 
in O 
diabetic O 
cirrhosis O 
. O 
Cirrhosis O 
increased O 
nuclear O 
factor O 
E2 O 
- O 
related O 
factor O 
2 O 
mRNA O 
expression O 
, O 
whereas O 
it O 
decreased O 
pregnane B-TRIVIAL 
-X-receptor O 
and O 
farnesoid-X-receptor O 
mRNA O 
expression O 
in O 
comparison O 
with O 
normal O 
livers O 
. O 
Hierarchical O 
cluster O 
analysis O 
indicated O 
that O 
expressions O 
of O 
ABCC2 O 
, O 
3 O 
, O 
and O 
6 O 
; O 
SLCO1B1 O 
and O 
1B3 O 
; O 
and O 
ABCC4 O 
and O 
5 O 
were O 
more O 
closely O 
related O 
in O 
the O 
livers O 
from O 
this O 
cohort O 
. O 
Overall O 
, O 
alcoholic O 
cirrhosis O 
altered O 
transporter O 
expression O 
in O 
human O 
liver O 
. O 

performance O 
of O 
gold O 
nanotubes O 
obtained O 
by O 
sputtering O 
onto O 
polycarbonate B-FAMILY 
track O 
- O 
etched O 
membranes O 
. O 

- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
is O 
a O 
powerful O 
and O 
versatile O 
tool O 
for O 
studying O 
molecules O 
on O 
metallic O 
surfaces O 
with O 
great O 
impact O 
on O 
areas O 
such O 
as O 
electrochemistry O 
, O 
catalysis O 
and O 
related O 
subjects O 
. O 
The O 
search O 
for O 
new O 
SERS-active O 
substrates O 
with O 
high O 
performance O 
, O 
namely O 
high O 
enhancement O 
factors O 
and O 
reproducibility O 
, O 
is O 
currently O 
the O 
main O 
focus O 
of O 
several O 
research O 
groups O 
. O 
Here O 
is O 
shown O 
an O 
alternative O 
easy O 
and O 
inexpensive O 
synthetic O 
approach O 
to O 
a O 
SERS-substrate O 
comprised O 
of O 
gold O 
nanotubes O 
obtained O 
by O 
the O 
sputtering O 
onto O 
polycarbonate B-FAMILY 
track O 
- O 
etched O 
membranes O 
used O 
as O 
template O 
. O 
Its O 
SERS O 
performance O 
was O 
evaluated O 
by O 
mapping O 
( O 
10 O 
× O 
10 O 
) O 
μm(2) O 
areas O 
and O 
resulted O 
in O 
average O 
enhancement O 
factors O 
that O 
span O 
from O 
2.3 O 
× O 
10(3) O 
to O 
1.2 O 
× O 
10(5) O 
with O 
a O 
maximum O 
enhancement O 
factor O 
of O 
2.5 O 
× O 
10(5) O 
. O 
The O 
enhancement O 
depended O 
strongly O 
on O 
the O 
template O 
pore O 
diameter O 
, O 
with O 
the O 
best O 
performance O 
obtained O 
when O 
membranes O 
with O 
pore O 
diameters O 
of O 
400 O 
nm O 
were O 
used O 
as O 
template O 
. O 
Further O 
analysis O 
showed O 
that O 
the O 
larger O 
enhancements O 
came O 
from O 
coalesced O 
gold O 
nanotubes O 
and O 
detection O 
of O 
the O 
dye O 
rhodamine B-TRIVIAL 
6G I-TRIVIAL 
at O 
concentrations O 
as O 
low O 
as O 
0.1 O 
nM O 
was O 
possible O 
. O 
These O 
results O 
put O 
this O 
substrate O 
as O 
a O 
valuable O 
and O 
easy O 
- O 
to O 
- O 
fabricate O 
tool O 
for O 
studying O 
and O 
detecting O 
molecules O 
on O 
surfaces O 
. O 
The O 
proposed O 
methodology O 
could O 
be O 
easily O 
adapted O 
to O 
other O 
metals O 
, O 
such O 
as O 
silver B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
. O 

suppresses O 
advanced O 
glycation O 
end O 
- O 
products O 
- O 
induced O 
inflammatory O 
responses O 
through O 
inhibition O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
human O 
monocytic O 
THP-1 O 
cells O 
. O 

glycation O 
end O 
- O 
products O 
( O 
AGEs O 
) O 
play O 
a O 
pivotal O 
role O 
in O 
the O 
development O 
of O 
diabetic O 
complications O 
by O 
inducing O 
inflammation O 
. O 
We O 
previously O 
reported O 
that O 
the O 
fresh O 
roots O 
of O 
Rehmannia O 
glutinosa O 
Libosch O 
. O 
, O 
which O 
have O 
been O 
used O 
for O 
the O 
treatment O 
of O 
diabetes O 
in O 
traditional O 
Korean O 
medicine O 
, O 
also O 
have O 
the O 
potential O 
to O 
suppress O 
AGE O 
- O 
mediated O 
inflammatory O 
response O 
in O 
THP-1 O 
cells O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
isolated O 
catalpol B-TRIVIAL 
from O 
R O 
. O 
glutinosa O 
, O 
and O 
examined O 
whether O 
it O 
has O 
anti-inflammatory O 
effects O 
on O 
AGE-stimulated O 
THP-1 O 
cells O 
. O 
Catalpol B-TRIVIAL 
reduced O 
the O 
expression O 
of O 
pro O 
- O 
inflammatory O 
mediates O 
, O 
such O 
as O 
monocyte O 
chemotactic O 
protein-1 O 
( O 
MCP-1 O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
inducible O 
NO B-FORMULA 
synthase O 
( O 
iNOS O 
) O 
, O 
and O 
receptor O 
for O 
AGE O 
( O 
RAGE O 
) O 
. O 
Promoter O 
and O 
electromobility O 
shift O 
assays O 
showed O 
that O 
transcriptional O 
activation O 
of O 
NF-κB O 
was O 
significantly O 
reduced O 
by O 
catalpol B-TRIVIAL 
treatment O 
, O 
while O 
AP-1 O 
was O 
not O 
. O 
Catalpol B-TRIVIAL 
also O 
suppressed O 
AGE-induced O 
phosphorylation O 
of O 
mitogen O 
activated O 
protein O 
( O 
MAP O 
) O 
kinases O 
, O 
degradation O 
of O 
IκBα O 
and O 
the O 
nuclear O 
localization O 
of O 
NF-κB O 
. O 
Moreover O 
, O 
the O 
production O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
elicited O 
by O 
AGE O 
was O 
also O 
suppressed O 
by O 
catalpol B-TRIVIAL 
treatment O 
, O 
through O 
dual O 
action O 
of O 
reducing O 
ROS O 
itself O 
and O 
inhibiting O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
. O 
Our O 
findings O 
indicate O 
that O 
catalpol B-TRIVIAL 
suppresses O 
AGE O 
- O 
mediated O 
inflammation O 
by O 
inhibiting O 
ROS O 
production O 
and O 
NF-κB O 
activity O 
. O 
We O 
suggest O 
that O 
catalpol B-TRIVIAL 
, O 
a O 
major O 
constituent O 
of O 
the O 
fresh O 
roots O 
of O 
R O 
. O 
glutinosa O 
, O 
contributes O 
to O 
the O 
prevention O 
of O 
AGE O 
- O 
mediated O 
diabetic O 
complications O 
. O 

involvement O 
of O 
heme B-FAMILY 
oxygenase O 
1 O 
but O 
not O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
2 O 
in O 
a O 
hepatoprotective O 
action O 
of O 
quercetin B-TRIVIAL 
in O 
lipopolysaccharide-induced O 
hepatotoxicity O 
of O 
d-galactosamine B-TRIVIAL 
sensitized O 
rats O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
potential O 
hepatoprotective O 
capabilities O 
of O 
quercetin B-TRIVIAL 
in O 
relation O 
to O 
its O 
modulation O 
of O 
the O 
HO-1 O 
and O 
NOS-2 O 
activities O 
in O 
an O 
experimental O 
model O 
of O 
fulminant O 
liver O 
failure O 
. O 
Liver O 
insult O 
was O 
induced O 
by O 
in O 
vivo O 
administration O 
of O 
d-galactosamine B-TRIVIAL 
( O 
d-GalN B-ABBREVIATION 
, O 
400mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
and O 
lipopolysaccharide O 
( O 
LPS O 
, O 
10μg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
. O 
The O 
effects O 
of O 
quercetin B-TRIVIAL 
( O 
50mg O 
/ O 
kg O 
, O 
i.p O 
) O 
on O 
d-GalN B-ABBREVIATION 
toxicity O 
was O 
evaluated O 
by O 
standard O 
biochemical O 
, O 
RT-PCR O 
and O 
Western O 
blot O 
methods O 
. O 
Administration O 
of O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
combination O 
resulted O 
in O 
significantly O 
higher O 
plasma O 
levels O 
of O 
aminotransferases O 
, O 
as O 
well O 
as O 
increased O 
mRNA O 
and O 
protein O 
expressions O 
of O 
both O 
HO-1 O 
and O 
NOS-2 O 
enzymes O 
. O 
Quercetin B-TRIVIAL 
exhibited O 
cytoprotective O 
effects O 
on O 
the O 
liver O 
, O 
as O 
evidenced O 
by O 
decreased O 
aminotransferase O 
plasma O 
levels O 
. O 
Additionally O 
, O 
quercetin B-TRIVIAL 
treatment O 
in O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
treated O 
rats O 
significantly O 
increased O 
HO-1 O 
mRNA O 
and O 
its O 
protein O 
expressions O 
. O 
On O 
the O 
contrary O 
, O 
quercetin B-TRIVIAL 
did O 
not O 
exhibit O 
any O 
significant O 
effects O 
on O 
the O 
levels O 
of O 
nitrites B-FAMILY 
, O 
and O 
NOS-2 O 
mRNA O 
and O 
protein O 
expressions O 
in O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
treated O 
rats O 
. O 
Quercetin B-TRIVIAL 
when O 
given O 
alone O 
did O 
not O 
have O 
any O 
significant O 
changes O 
on O 
liver O 
enzymes O 
nor O 
HO-1 O 
and O 
NOS-2 O 
mRNA O 
and O 
protein O 
expressions O 
. O 
It O 
can O 
be O 
concluded O 
that O 
the O 
quercetin B-TRIVIAL 
' O 
s O 
induction O 
of O 
HO-1 O 
and O 
its O 
byproducts O 
, O 
without O 
concomitant O 
NOS-2 O 
activity O 
reduction O 
, O 
is O 
among O 
mechanisms O 
contributing O 
to O 
the O 
hepatoprotective O 
effect O 
in O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
hepatotoxicity O 
. O 

vasorelaxant O 
effects O 
of O 
1-nitro-2-phenylethane B-SYSTEMATIC 
involve O 
stimulation O 
of O 
the O 
soluble O 
guanylate B-TRIVIAL 
cyclase- O 
cGMP B-ABBREVIATION 
pathway O 
. O 

is O 
the O 
first O 
organic O 
NO₂ B-FORMULA 
-containing O 
molecule O 
isolated O 
from O 
plants O 
. O 
It O 
possesses O 
interesting O 
hypotensive O 
, O 
bradycardic O 
, O 
and O 
vasodilator O 
properties O 
, O 
but O 
the O 
mode O 
by O 
which O 
it O 
induces O 
vasorelaxation O 
is O 
still O 
unknown O 
. O 
The O 
underlying O 
mechanism O 
involved O 
in O 
the O 
vasodilator O 
effect O 
of O 
1-nitro-2-phenylethane B-SYSTEMATIC 
was O 
investigated O 
in O 
rat O 
aorta O 
. O 
The O 
vasorelaxant O 
effects O 
of O 
1-nitro-2-phenylethane B-SYSTEMATIC 
did O 
not O 
depend O 
on O 
endothelial O 
layer O 
integrity O 
, O 
and O 
the O 
effects O 
were O 
refractory O 
to O 
L-N(G)-nitroarginine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
L-NAME B-ABBREVIATION 
)-induced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibition O 
. O 
Vasorelaxation O 
was O 
similarly O 
resistant O 
to O 
treatment O 
with O 
indomethacin B-TRIVIAL 
, O 
cis-N-(2-phenylcyclopentyl)-azacyclotridec-1-en-2-amine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
MDL-12330A B-IDENTIFIER 
) O 
, O 
and O 
KT5720 B-IDENTIFIER 
, O 
indicating O 
that O 
neither O 
prostaglandin B-FAMILY 
release O 
nor O 
adenylyl B-TRIVIAL 
cyclase O 
activation O 
is O 
involved O 
. O 
Conversely O 
, O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
- O 
and O 
ODQ B-ABBREVIATION 
-induced O 
guanylate B-TRIVIAL 
cyclase O 
inhibition O 
reduced O 
the O 
vasorelaxation O 
induced O 
by O 
1-nitro-2-phenylethane B-SYSTEMATIC 
. O 
The O 
pharmacological O 
blockade O 
of O 
K(+) B-FORMULA 
channels O 
with O 
tetraethylammonium B-SYSTEMATIC 
, O 
glybenclamide B-TRIVIAL 
, O 
and O 
4-aminopyridine B-SYSTEMATIC 
also O 
blunted O 
vasorelaxation O 
induced O 
by O 
1-nitro-2-phenylethane B-SYSTEMATIC 
. O 
The O 
effects O 
of O 
1-nitro-2-phenylethane B-SYSTEMATIC 
were O 
reversed O 
by O 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one B-SYSTEMATIC 
( O 
ODQ B-ABBREVIATION 
) O 
and O 
comparable O 
to O 
the O 
effects O 
induced O 
by O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
. O 
In O 
silico O 
analysis O 
using O 
an O 
Ns O 
H-NOX O 
subunit O 
of O 
guanylate B-TRIVIAL 
cyclase O 
revealed O 
a O 
pocket O 
on O 
the O 
macromolecule O 
surface O 
where O 
1-nitro-2-phenylethane B-SYSTEMATIC 
preferentially O 
docked O 
. O 
In O 
vitro O 
, O 
1-nitro-2-phenylethane B-SYSTEMATIC 
increased O 
cyclic B-SYSTEMATIC 
guanosine I-SYSTEMATIC 
3',5'-monophosphate I-SYSTEMATIC 
( O 
cGMP B-ABBREVIATION 
) O 
levels O 
in O 
rat O 
aortic O 
rings O 
, O 
an O 
effect O 
also O 
reversed O 
by O 
ODQ B-ABBREVIATION 
. O 
In O 
conclusion O 
, O 
1-nitro-2-phenylethane B-SYSTEMATIC 
produces O 
vasodilator O 
effects O 
by O 
stimulating O 
the O 
soluble O 
guanylate B-TRIVIAL 
cyclase- O 
cGMP B-ABBREVIATION 
pathway O 
. O 

new O 
flavonoid B-FAMILY 
and O 
other O 
polar O 
compounds O 
from O 
Galeopsis O 
angustifolia O 
Ehrh O 
. O 
ex O 
Hoffm O 
. O 

analysis O 
of O 
the O 
polar O 
fraction O 
of O 
Galeopsis O 
angustifolia O 
Ehrh O 
. O 
ex O 
Hoffm O 
. O 
indicates O 
that O 
the O 
main O 
components O 
are O 
iridoids B-FAMILY 
and O 
flavonoids B-FAMILY 
. O 
Six O 
compounds O 
were O 
identified O 
: O 
a O 
new O 
flavonoid B-FAMILY 
, O 
3'-hydroxy-isoscutellarein B-SYSTEMATIC 
7-O-[6'″acetyl-β-D-glucopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-β-D-glucopyranoside] I-SYSTEMATIC 
; O 
three O 
iridoid B-FAMILY 
glucosides I-FAMILY 
: O 
harpagide B-TRIVIAL 
, O 
acetyl B-SYSTEMATIC 
harpagide I-SYSTEMATIC 
and O 
for O 
the O 
first O 
time O 
in O 
this O 
species O 
, O 
8-epi-loganin B-SYSTEMATIC 
; O 
two O 
known O 
acetylated B-FAMILY 
flavonoid I-FAMILY 
glycosides I-FAMILY 
: O 
3'-hydroxy-4'-O-methylisoscutellarein B-SYSTEMATIC 
7-O-[6'″acetyl-β-D-allopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-6″-acetyl-β-D-glucopyranoside] I-SYSTEMATIC 
, O 
3'-hydroxy-4'-O-methylisoscutellarein B-SYSTEMATIC 
7-O-[6'″acetyl-β-D-allopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-β-D-glucopyranoside] I-SYSTEMATIC 
. O 
Both O 
flavonoids B-FAMILY 
and O 
iridoids B-FAMILY 
are O 
present O 
in O 
high O 
amount O 
; O 
respectively O 
, O 
16.7% O 
and O 
4.5% O 
of O 
the O 
crude O 
extract O 
. O 

A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
: O 
Mixed O 
- O 
Ligand O 
Siderophores O 
Discovered O 
Using O 
Proteomics O 
. O 

Omic O 
" O 
strategies O 
have O 
been O 
increasingly O 
applied O 
to O 
natural O 
product O 
discovery O 
processes O 
, O 
with O 
(meta-)genome O 
sequencing O 
and O 
mining O 
implemented O 
in O 
many O 
laboratories O 
to O 
date O 
. O 
Using O 
the O 
proteomics O 
- O 
based O 
discovery O 
platform O 
called O 
PrISM O 
( O 
Proteomic O 
Investigation O 
of O 
Secondary O 
Metabolism O 
) O 
, O 
we O 
discovered O 
two O 
new O 
siderophores O 
gobichelin B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
from O 
Streptomyces O 
sp O 
. O 
NRRL O 
F-4415 O 
, O 
a O 
strain O 
without O 
a O 
sequenced O 
genome O 
. O 
Using O 
the O 
proteomics O 
information O 
as O 
a O 
guide O 
, O 
the O 
37 O 
kb O 
gene O 
cluster O 
responsible O 
for O 
production O 
of O 
gobichelins B-FAMILY 
was O 
sequenced O 
and O 
its O 
20 O 
open O 
reading O 
frames O 
interpreted O 
into O 
a O 
biosynthetic O 
scheme O 
. O 
This O 
led O 
to O 
the O 
targeted O 
detection O 
and O 
structure O 
elucidation O 
of O 
the O 
new O 
compounds O 
produced O 
by O 
nonribosomal O 
peptide O 
( O 
NRP O 
) O 
synthesis O 
. O 

acid I-TRIVIAL 
( O 
CSA B-ABBREVIATION 
) O 
exerts O 
cytoprotective O 
effects O 
against O 
oxidative O 
stress O 
through O 
the O 
Nrf2-dependent O 
antioxidant O 
pathway O 
. O 

acid I-TRIVIAL 
( O 
CSA B-ABBREVIATION 
) O 
, O 
an O 
active O 
compound O 
separated O 
from O 
pigeon O 
pea O 
leaves O 
, O 
possesses O 
the O 
highly O 
efficient O 
antioxidant O 
activities O 
. O 
Transcription O 
factor O 
nuclear O 
factor O 
- O 
erythroid O 
2- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
is O 
an O 
important O 
regulator O 
of O 
cellular O 
oxidative O 
stress O 
. O 
This O 
study O 
examined O 
the O 
role O 
of O 
Nrf2 O 
in O 
CSA B-ABBREVIATION 
-mediated O 
antioxidant O 
effects O 
on O 
human O 
hepatocarcinoma O 
( O 
HepG2 O 
) O 
cell O 
line O 
. O 
The O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
upon O 
H2O2 B-FORMULA 
and O 
CSA B-ABBREVIATION 
treatment O 
was O 
lower O 
than O 
that O 
of O 
H2O2 B-FORMULA 
alone O 
. O 
CSA B-ABBREVIATION 
activated O 
Nrf2 O 
as O 
evaluated O 
by O 
Western O 
blotting O 
. O 
A O 
luciferase O 
reporter O 
assay O 
also O 
demonstrated O 
that O 
CSA B-ABBREVIATION 
-activated O 
signaling O 
resulted O 
in O 
the O 
increased O 
transcriptional O 
activity O 
of O 
Nrf2 O 
through O 
binding O 
to O 
the O 
antioxidant O 
response O 
element O 
( O 
ARE O 
) O 
enhancer O 
sequence O 
. O 
Our O 
study O 
indicated O 
that O 
treatment O 
of O 
HepG2 O 
cells O 
with O 
CSA B-ABBREVIATION 
induces O 
Nrf2-dependent O 
ARE O 
activity O 
and O 
gene O 
expression O 
of O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
, O 
NAD(P)H B-ABBREVIATION 
quinone B-FAMILY 
oxidoreductase O 
1 O 
( O 
NQO1 O 
) O 
, O 
and O 
glutamate B-TRIVIAL 
- O 
cysteine B-TRIVIAL 
ligase O 
modifier O 
subunits O 
by O 
activation O 
of O 
PI3K O 
/ O 
AKT O 
, O 
ERK O 
and O 
JNK O 
signaling O 
pathways O 
. O 
Inhibition O 
of O 
Nrf2 O 
by O 
siRNA O 
reduced O 
CSA B-ABBREVIATION 
-induced O 
upregulation O 
of O 
these O 
Nrf2 O 
- O 
related O 
enzymes O 
. O 
These O 
results O 
suggest O 
that O 
the O 
Nrf2 O 
/ O 
ARE O 
pathway O 
plays O 
an O 
important O 
role O 
in O 
the O 
regulation O 
of O 
CSA B-ABBREVIATION 
-mediated O 
antioxidant O 
effects O 
in O 
HepG2 O 
cells O 
. O 

-- O 
no O 
transgenerational O 
inheritance O 
of O 
anti-androgenic O 
effects O 
after O 
maternal O 
exposure O 
during O 
organogenesis O 
via O 
the O 
intraperitoneal O 
route O 
. O 

goal O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
potential O 
transgenerational O 
inheritance O 
of O 
anti-androgenic O 
effects O 
induced O 
by O 
Vinclozolin B-TRIVIAL 
administered O 
intraperitoneally O 
to O 
pregnant O 
Wistar O 
rats O 
(Crl:WI[Han]) O 
. O 
Dams O 
were O 
dosed O 
with O 
Vinclozolin B-TRIVIAL 
at O 
0 O 
, O 
4 O 
or O 
100mg O 
/ O 
kg O 
bw O 
/ O 
d O 
on O 
gestation O 
days O 
6- O 
15 O 
. O 
Male O 
offspring O 
of O 
F1-F3 O 
generations O 
were O 
bred O 
with O 
untreated O 
females O 
to O 
yield O 
F2-F4 O 
offspring O 
. O 
No O 
evident O 
anti-androgenic O 
effects O 
were O 
observed O 
at O 
4mg O 
/ O 
kg O 
bw O 
/ O 
d O 
, O 
but O 
a O 
case O 
of O 
hypospadias O 
as O 
well O 
as O 
delayed O 
sexual O 
maturation O 
in O 
F1 O 
male O 
offspring O 
was O 
observed O 
as O 
a O 
sign O 
of O 
anti-androgenicity O 
at O 
100mg O 
/ O 
kg O 
bw O 
/ O 
d O 
. O 
However O 
, O 
F1-F3 O 
males O 
developed O 
normally O 
to O 
sexual O 
maturity O 
and O 
were O 
able O 
to O 
mate O 
and O 
to O 
generate O 
healthy O 
progeny O 
. O 
Sperm O 
count O 
, O 
morphology O 
and O 
motility O 
were O 
not O 
affected O 
in O 
F1-F4 O 
generation O 
male O 
offspring O 
. O 
In O 
conclusion O 
, O 
transgenerational O 
inheritance O 
of O 
Vinclozolin B-TRIVIAL 
' O 
s O 
anti-androgenic O 
effects O 
was O 
not O 
evident O 
in O 
outbred O 
Wistar O 
rats O 
. O 

influence O 
of O 
pectolytic O 
enzyme O 
addition O 
and O 
prefermentative O 
mash O 
heating O 
during O 
the O 
winemaking O 
process O 
on O 
the O 
phenolic B-FAMILY 
composition O 
of O 
Okuzgozu O 
red O 
wine O 
. O 

effects O 
of O 
pectolytic O 
enzyme O 
addition O 
and O 
mash O 
heating O 
prior O 
to O 
fermentation O 
on O 
the O 
phenolic B-FAMILY 
component O 
of O 
Okuzgozu O 
red O 
wine O 
during O 
the O 
winemaking O 
and O 
ageing O 
processes O 
were O 
investigated O 
. O 
In O 
general O 
, O 
the O 
highest O 
concentration O 
of O 
total O 
phenolics B-FAMILY 
was O 
found O 
in O 
the O 
mash O 
- O 
heated O 
wines O 
, O 
whereas O 
the O 
total O 
flavan-3-ol B-FAMILY 
and O 
total O 
anthocyanin B-FAMILY 
contents O 
in O 
all O 
of O 
the O 
wines O 
, O 
decreased O 
notably O 
during O 
the O 
winemaking O 
and O 
ageing O 
processes O 
. O 
As O 
determined O 
by O 
HPLC O 
, O 
hydroxycinnamic B-FAMILY 
acids I-FAMILY 
were O 
the O 
major O 
phenolic B-FAMILY 
acids I-FAMILY 
in O 
the O 
red O 
wines O 
. O 
After O 
6 O 
months O 
in O 
the O 
bottle O 
, O 
the O 
enzyme O 
- O 
treated O 
wines O 
had O 
lower O 
phenolic B-FAMILY 
acid I-FAMILY 
concentrations O 
than O 
had O 
the O 
control O 
and O 
mash O 
- O 
heated O 
wines O 
, O 
but O 
no O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
differences O 
were O 
found O 
in O 
the O 
concentration O 
of O 
total O 
phenolic B-FAMILY 
acids I-FAMILY 
between O 
the O 
control O 
and O 
mash O 
- O 
heated O 
wines O 
. O 
All O 
of O 
the O 
phenolic B-FAMILY 
acid I-FAMILY 
levels O 
decreased O 
with O 
the O 
winemaking O 
and O 
ageing O 
processes O 
whereas O 
only O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
increased O 
. O 
The O 
wines O 
treated O 
by O 
the O 
pectolytic O 
enzyme O 
addition O 
had O 
a O 
lower O 
monomeric O 
flavan-3-ol B-FAMILY 
content O 
than O 
had O 
the O 
other O 
wines O 
, O 
and O 
the O 
amount O 
of O 
monomeric O 
anthocyanins B-FAMILY 
extracted O 
did O 
not O 
increase O 
with O 
the O 
addition O 
of O 
enzymes O 
. O 

Dielectric O 
Transistor O 
of O 
CuPc B-FORMULA 
Single O 
Crystalline O 
Nanowire O 
for O 
SO2 B-FORMULA 
Detection O 
Down O 
to O 
Sub O 
- O 
ppm O 
Levels O 
at O 
Room O 
Temperature O 
. O 

room O 
- O 
temperature O 
highly O 
- O 
sensitive O 
SO2 B-FORMULA 
sensor O 
with O 
fast O 
response O 
and O 
complete O 
recovery O 
is O 
constructed O 
based O 
on O 
gas O 
dielectric O 
field O 
- O 
effect O 
transistor O 
( O 
FET O 
) O 
of O 
CuPc B-FORMULA 
single O 
crystalline O 
nanowire O 
. O 
The O 
exposed O 
conductive O 
channel O 
by O 
gas O 
dielectric O 
is O 
responsible O 
for O 
the O 
high O 
sensitivity O 
to O 
SO2 B-FORMULA 
and O 
the O 
adsorption O 
of O 
the O 
SO2 B-FORMULA 
molecules O 
dramatically O 
enhances O 
the O 
field O 
- O 
effect O 
mobility O 
. O 
These O 
results O 
not O 
only O 
open O 
up O 
new O 
opportunities O 
to O 
develop O 
new O 
SO2 B-FORMULA 
sensors O 
, O 
but O 
also O 
provide O 
an O 
efficient O 
way O 
to O 
improve O 
the O 
performance O 
of O 
organic O 
FETs O 
. O 

in O 
Vitis O 
berry O 
skins O 
and O 
leaves O 
: O 
their O 
extraction O 
and O 
analysis O 
by O 
HPLC O 
. O 

orthogonal O 
L(36) O 
(6)(5) O 
test O 
design O 
was O 
applied O 
to O 
select O 
the O 
optimum O 
conditions O 
for O 
extracting O 
resveratrols B-FAMILY 
from O 
grape O 
berry O 
skins O 
and O 
leaves O 
. O 
Solvent O 
choice O 
was O 
the O 
most O 
important O 
factor O 
in O 
the O 
extraction O 
of O 
resveratrols B-FAMILY 
, O 
and O 
mixed O 
methanol B-SYSTEMATIC 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
[ O 
50 O 
: O 
50 O 
( O 
v O 
/ O 
v O 
) O 
] O 
had O 
much O 
higher O 
extraction O 
efficiency O 
than O 
the O 
other O 
five O 
solvents O 
tested O 
. O 
For O 
extracting O 
resveratrols B-FAMILY 
, O 
1g O 
of O 
berry O 
skins O 
or O 
leaf O 
tissue O 
extracted O 
in O 
10 O 
mL O 
methanol B-SYSTEMATIC 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
[ O 
50 O 
: O 
50 O 
( O 
v O 
/ O 
v O 
) O 
] O 
for O 
24h O 
at O 
25°C O 
in O 
darkness O 
was O 
the O 
optimized O 
extraction O 
condition O 
. O 
The O 
optimized O 
analytical O 
method O 
for O 
HPLC O 
was O 
a O 
multi O 
- O 
step O 
gradient O 
elution O 
using O 
acetonitrile B-SYSTEMATIC 
and O 
water O 
. O 
The O 
optimized O 
method O 
was O 
used O 
to O 
determine O 
resveratrols B-FAMILY 
among O 
three O 
different O 
cultivars O 
. O 
The O 
cultivar O 
' O 
Zhi O 
168 O 
' O 
had O 
the O 
highest O 
total O 
resveratrols B-FAMILY 
in O 
berry O 
skins O 
while O 
' O 
Saint-Emilion O 
' O 
had O 
the O 
lowest O 
resveratrols B-FAMILY 
. O 
The O 
resveratrol B-TRIVIAL 
content O 
of O 
' O 
Beta O 
' O 
was O 
between O 
that O 
of O 
' O 
Zhi O 
168 O 
' O 
and O 
' O 
Saint-Emilion O 
' O 
. O 

is O 
a O 
hypoxia O 
- O 
activated O 
prodrug O 
that O 
sensitizes O 
cells O 
to O 
hypoxia O 
/ O 
reoxygenation O 
through O 
inhibition O 
of O 
Chk1 O 
and O 
Aurora O 
A O 
. O 

increased O 
resistance O 
of O 
hypoxic O 
cells O 
to O 
all O 
forms O 
of O 
cancer O 
therapy O 
presents O 
a O 
major O 
barrier O 
to O 
the O 
successful O 
treatment O 
of O 
most O 
solid O 
tumors O 
. O 
Inhibition O 
of O 
the O 
essential O 
kinase O 
, O 
Checkpoint O 
kinase O 
1 O 
( O 
Chk1 O 
) O 
has O 
been O 
described O 
as O 
a O 
promising O 
cancer O 
therapy O 
for O 
tumors O 
with O 
high O 
levels O 
of O 
hypoxia O 
- O 
induced O 
replication O 
stress O 
. O 
However O 
, O 
as O 
inhibition O 
of O 
Chk1 O 
affects O 
normal O 
replication O 
and O 
induces O 
DNA O 
damage O 
, O 
these O 
agents O 
also O 
have O 
the O 
potential O 
to O 
induce O 
genomic O 
instability O 
and O 
contribute O 
to O 
tumorigenesis O 
. O 
To O 
overcome O 
this O 
problem O 
, O 
we O 
have O 
developed O 
a O 
bioreductive O 
prodrug O 
, O 
which O 
functions O 
as O 
a O 
Chk1 O 
/ O 
Aurora O 
A O 
inhibitor O 
specifically O 
in O 
hypoxic O 
conditions O 
. O 
To O 
achieve O 
this O 
activity O 
, O 
a O 
key O 
functionality O 
on O 
the O 
Chk1 O 
inhibitor O 
( O 
CH-01 B-IDENTIFIER 
) O 
is O 
masked O 
by O 
a O 
bioreductive O 
group O 
, O 
rendering O 
the O 
compound O 
inactive O 
as O 
a O 
Chk1 O 
/ O 
Aurora O 
A O 
inhibitor O 
. O 
Reduction O 
of O 
the O 
bioreductive O 
group O 
nitro B-SYSTEMATIC 
moiety O 
, O 
under O 
hypoxic O 
conditions O 
, O 
reveals O 
an O 
electron O 
- O 
donating O 
substituent O 
that O 
leads O 
to O 
fragmentation O 
of O 
the O 
molecule O 
, O 
affording O 
the O 
active O 
inhibitor O 
. O 
Most O 
importantly O 
, O 
we O 
show O 
a O 
significant O 
loss O 
of O 
viability O 
in O 
cancer O 
cell O 
lines O 
exposed O 
to O 
hypoxia O 
in O 
the O 
presence O 
of O 
CH-01 B-IDENTIFIER 
. O 
This O 
novel O 
approach O 
targets O 
the O 
most O 
aggressive O 
and O 
therapy O 
- O 
resistant O 
tumor O 
fraction O 
while O 
protecting O 
normal O 
tissue O 
from O 
therapy O 
- O 
induced O 
genomic O 
instability O 
. O 

of O 
bidentate O 
coordination O 
on O 
the O 
molecular O 
properties O 
rapta-C B-ABBREVIATION 
based O 
complex O 
using O 
theoretical O 
approach O 
. O 

this O 
work O 
several O 
quantum O 
properties O 
including O 
the O 
NEDA O 
and O 
QTAIM O 
are O 
computed O 
on O 
three O 
models O 
of O 
rapta-C B-ABBREVIATION 
complexes O 
using O 
DFT O 
with O 
hybrid O 
functional O 
and O 
basis O 
set O 
with O 
ECP O 
and O 
without O 
ECP O 
. O 
Several O 
interesting O 
correlations O 
within O 
the O 
observed O 
properties O 
and O 
also O 
with O 
the O 
reported O 
experimental O 
behaviors O 
of O 
these O 
complexes O 
including O 
their O 
biological O 
activities O 
are O 
presented O 
. O 
The O 
study O 
shows O 
that O 
the O 
stability O 
of O 
the O 
two O 
complexes O 
with O 
bidentate O 
ligands O 
is O 
associated O 
with O 
their O 
high O 
hydrogen B-SYSTEMATIC 
bonding O 
stability O 
and O 
existence O 
of O 
stronger O 
non-covalent O 
metal O 
- O 
ligand O 
bonds O 
. O 
The O 
energy O 
decomposition O 
analysis O 
indicated O 
that O 
inter O 
- O 
atomic O 
interactions O 
in O 
the O 
three O 
forms O 
of O 
rapta-C B-ABBREVIATION 
complexes O 
and O 
their O 
stability O 
are O 
governed O 
by O 
the O 
charge O 
transfer O 
term O 
with O 
significant O 
contributions O 
from O 
polarization O 
and O 
electrostatic O 
terms O 
. O 
The O 
higher O 
stability O 
of O 
complex O 
1 O 
and O 
2 O 
over O 
3 O 
comes O 
from O 
the O 
lower O 
exchange O 
repulsion O 
and O 
higher O 
polarization O 
contributions O 
to O 
their O 
stability O 
which O 
agrees O 
perfectly O 
with O 
the O 
experimental O 
observation O 
. O 
Our O 
results O 
provide O 
insight O 
into O 
the O 
nature O 
of O 
intramolecular O 
forces O 
that O 
influence O 
the O 
structural O 
stability O 
of O 
the O 
three O 
complexes O 
. O 

of O 
methamphetamine B-TRIVIAL 
seeking O 
by O 
the O 
mGluR2 O 
/ O 
3 O 
agonist O 
LY379268 B-IDENTIFIER 
in O 
rats O 
with O 
histories O 
of O 
restricted O 
and O 
escalated O 
self O 
- O 
administration O 
. O 

findings O 
implicate O 
group O 
II O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGluR(2 O 
/ O 
3 O 
) O 
) O 
in O 
the O 
reinforcing O 
effects O 
of O 
psychostimulants O 
and O 
have O 
identified O 
these O 
receptors O 
as O 
potential O 
treatment O 
targets O 
for O 
drug O 
addiction O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
mGluR(2 O 
/ O 
3 O 
) O 
stimulation O 
on O 
cue- O 
and O 
drug O 
- O 
primed O 
reinstatement O 
in O 
rats O 
with O 
different O 
histories O 
of O 
methamphetamine B-TRIVIAL 
( O 
METH B-ABBREVIATION 
) O 
self O 
- O 
administration O 
training O 
, O 
under O 
two O 
conditions O 
: O 
16 O 
daily O 
sessions O 
of O 
short O 
access O 
( O 
90 O 
min O 
/ O 
day O 
, O 
ShA O 
) O 
, O 
or O 
8 O 
daily O 
sessions O 
of O 
short O 
access O 
followed O 
by O 
8 O 
sessions O 
of O 
long O 
access O 
( O 
6 O 
h O 
/ O 
day O 
, O 
LgA O 
) O 
. O 
Following O 
self O 
- O 
administration O 
and O 
subsequent O 
extinction O 
training O 
, O 
rats O 
were O 
pretreated O 
with O 
the O 
selective O 
mGluR(2 O 
/ O 
3 O 
) O 
agonist O 
LY379268 B-IDENTIFIER 
( O 
variable O 
dose O 
, O 
0-3 O 
mg O 
/ O 
kg O 
) O 
, O 
exposed O 
to O 
METH B-ABBREVIATION 
-paired O 
cues O 
or O 
a O 
priming O 
injection O 
of O 
METH B-ABBREVIATION 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
, O 
and O 
tested O 
for O 
reinstatement O 
of O 
METH B-ABBREVIATION 
-seeking O 
behavior O 
. O 
LgA O 
rats O 
self O 
- O 
administered O 
greater O 
amounts O 
of O 
METH B-ABBREVIATION 
during O 
the O 
second O 
half O 
of O 
training O 
, O 
but O 
when O 
pretreated O 
with O 
vehicle O 
, O 
ShA O 
and O 
LgA O 
rats O 
showed O 
cue- O 
and O 
drug O 
- O 
primed O 
reinstatement O 
at O 
equivalent O 
response O 
rates O 
. O 
However O 
, O 
LgA O 
rats O 
demonstrated O 
greater O 
sensitivity O 
to O 
mGluR(2 O 
/ O 
3 O 
) O 
stimulation O 
with O 
attenuated O 
responding O 
during O 
cue O 
- O 
induced O 
reinstatement O 
after O 
0.3 O 
mg O 
/ O 
kg O 
and O 
higher O 
doses O 
of O 
LY379268 B-IDENTIFIER 
, O 
whereas O 
ShA O 
rats O 
decreased O 
cue O 
- O 
induced O 
reinstatement O 
behavior O 
following O 
1 O 
mg O 
/ O 
kg O 
and O 
3 O 
mg O 
/ O 
kg O 
LY379268 B-IDENTIFIER 
. O 
Additionally O 
, O 
both O 
LgA O 
and O 
ShA O 
rats O 
exhibited O 
decreased O 
METH B-ABBREVIATION 
-primed O 
reinstatement O 
behavior O 
following O 
0.3 O 
mg O 
/ O 
kg O 
and O 
higher O 
doses O 
of O 
LY379268 B-IDENTIFIER 
. O 
A O 
separate O 
group O 
of O 
control O 
rats O 
was O 
trained O 
to O 
self O 
- O 
administer O 
sucrose O 
pellets O 
, O 
and O 
demonstrated O 
attenuated O 
cue O 
- O 
induced O 
sucrose O 
- O 
seeking O 
behavior O 
following O 
1 O 
and O 
3 O 
mg O 
/ O 
kg O 
LY379268 B-IDENTIFIER 
. O 
Together O 
, O 
the O 
results O 
indicate O 
that O 
LY379268 B-IDENTIFIER 
has O 
differential O 
attenuating O 
effects O 
on O 
cue O 
- O 
induced O 
reinstatement O 
behavior O 
in O 
rats O 
with O 
different O 
histories O 
of O 
METH B-ABBREVIATION 
intake O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

structure O 
and O 
dynamics O 
of O 
benzene B-SYSTEMATIC 
confined O 
in O 
the O 
IRMOF-1 B-ABBREVIATION 
nanocavity O 
as O 
studied O 
by O 
molecular O 
dynamics O 
simulation O 
. O 

local O 
structure O 
and O 
dynamic O 
behaviour O 
of O 
a O 
benzene B-SYSTEMATIC 
molecular O 
assembly O 
confined O 
within O 
the O 
nano O 
- O 
cavities O 
of O 
a O 
zinc B-SYSTEMATIC 
-based O 
metal O 
- O 
organic O 
framework O 
, O 
[Zn(4)O(CO(2)C(6)H(4)CO(2))(3)](n) B-FAMILY 
( O 
IRMOF-1 B-ABBREVIATION 
) O 
, O 
were O 
investigated O 
by O 
means O 
of O 
molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
. O 
The O 
local O 
structure O 
of O 
the O 
confined O 
benzene B-SYSTEMATIC 
molecules O 
was O 
evaluated O 
using O 
radial O 
distribution O 
functions O 
. O 
The O 
sites O 
for O 
adsorption O 
of O 
benzene B-SYSTEMATIC 
in O 
IRMOF-1 B-ABBREVIATION 
were O 
well O 
defined O 
by O 
the O 
simulation O 
. O 
The O 
diffusion O 
coefficients O 
at O 
ambient O 
temperature O 
suggested O 
that O 
the O 
mobility O 
of O 
the O 
confined O 
benzene B-SYSTEMATIC 
was O 
high O 
, O 
comparable O 
to O 
the O 
bulk O 
fluid O 
. O 
Decreasing O 
the O 
temperature O 
gave O 
rise O 
to O 
the O 
aggregation O 
of O 
benzene B-SYSTEMATIC 
in O 
the O 
IRMOF-1 B-ABBREVIATION 
frameworks O 
. O 
Molecular O 
aggregation O 
was O 
attributed O 
to O 
the O 
localization O 
of O 
benzene B-SYSTEMATIC 
in O 
the O 
large O 
and O 
the O 
small O 
cavities O 
of O 
IRMOF-1 B-ABBREVIATION 
, O 
respectively O 
. O 
Both O 
the O 
translational O 
diffusion O 
coefficient O 
and O 
the O 
trajectory O 
of O 
benzene B-SYSTEMATIC 
provided O 
evidence O 
that O 
the O 
localization O 
of O 
benzene B-SYSTEMATIC 
in O 
the O 
large O 
and O 
the O 
small O 
cavities O 
takes O 
place O 
at O 
ca O 
. O 
200 O 
K O 
. O 
Furthermore O 
, O 
at O 
high O 
benzene B-SYSTEMATIC 
loading O 
, O 
the O 
migration O 
of O 
benzene B-SYSTEMATIC 
in O 
the O 
small O 
cavities O 
was O 
prevented O 
( O 
frozen O 
) O 
below O 
135 O 
K O 
. O 
Thus O 
, O 
the O 
translational O 
degree O 
of O 
freedom O 
of O 
the O 
benzene B-SYSTEMATIC 
molecules O 
changed O 
drastically O 
, O 
depending O 
on O 
the O 
temperature O 
. O 

role O 
of O 
individual O 
gastric O 
emptying O 
of O 
pellets O 
in O 
the O 
prediction O 
of O 
diclofenac B-TRIVIAL 
in O 
vivo O 
dissolution O 
. O 

objective O 
of O 
the O 
present O 
study O 
was O 
to O 
check O 
for O 
the O 
possibility O 
to O 
successfully O 
predict O 
individual O 
in O 
vivo O 
dissolution O 
/ O 
absorption O 
profiles O 
resulting O 
from O 
fasted O 
administration O 
of O 
a O 
diclofenac B-TRIVIAL 
extended O 
release O 
pellet O 
formulation O 
. O 
For O 
this O 
purpose O 
dissolution O 
profiles O 
were O 
generated O 
with O 
different O 
dissolution O 
setups O 
using O 
a O 
set O 
of O 
media O 
reflecting O 
pH-conditions O 
in O 
the O 
different O 
segments O 
of O 
the O 
gastrointestinal O 
tract O 
. O 
Since O 
gastric O 
emptying O 
of O 
pellets O 
seemed O 
to O 
be O 
a O 
critical O 
factor O 
for O 
in O 
vivo O 
drug O 
release O 
, O 
a O 
set O 
of O 
different O 
gastric O 
residence O 
times O 
was O 
screened O 
in O 
in O 
vitro O 
studies O 
. O 
Subsequently O 
, O 
in O 
vitro O 
release O 
profiles O 
were O 
first O 
directly O 
compared O 
with O 
the O 
individual O 
in O 
vivo O 
absorption O 
profiles O 
and O 
in O 
a O 
second O 
step O 
a O 
mathematical O 
model O 
, O 
which O 
had O 
been O 
developed O 
in O 
a O 
previous O 
study O 
, O 
was O 
applied O 
to O 
calculate O 
predicted O 
individual O 
in O 
vivo O 
release O 
profiles O 
based O 
on O 
in O 
vitro O 
release O 
profiles O 
and O 
individual O 
gastric O 
emptying O 
. O 
The O 
comparison O 
of O 
predicted O 
individual O 
in O 
vivo O 
release O 
profiles O 
and O 
individual O 
in O 
vivo O 
absorption O 
profiles O 
showed O 
a O 
high O 
degree O 
of O 
similarity O 
, O 
thus O 
confirming O 
the O 
suitability O 
of O 
a O 
set O 
of O 
different O 
gastric O 
residence O 
times O 
used O 
in O 
in O 
vitro O 
drug O 
release O 
testing O 
. O 
Additionally O 
, O 
obtained O 
results O 
indicated O 
that O 
a O 
substantial O 
part O 
of O 
variability O 
of O 
diclofenac B-TRIVIAL 
absorption O 
profiles O 
can O 
be O 
explained O 
by O 
the O 
variability O 
of O 
pellet O 
gastric O 
emptying O 
kinetics O 
. O 

oxidation O 
of O 
a O 
phosphocholine B-SYSTEMATIC 
on O 
synthetic O 
sea O 
salt O 
by O 
ozone B-TRIVIAL 
at O 
room O 
temperature O 
. O 

ozonolysis O 
of O 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
POPC B-ABBREVIATION 
) O 
adsorbed O 
on O 
salt O 
mixtures O 
as O 
models O 
for O 
sea O 
- O 
salt O 
particles O 
was O 
studied O 
in O 
real O 
time O 
using O 
diffuse O 
reflection O 
infrared O 
Fourier O 
transform O 
spectrometry O 
( O 
DRIFTS O 
) O 
at O 
room O 
temperature O 
with O 
and O 
without O 
added O 
water O 
vapor O 
. O 
The O 
salt O 
substrates O 
were O 
a O 
mixture O 
of O 
MgCl(2)·6H(2)O B-FORMULA 
with O 
NaCl B-FORMULA 
or O 
a O 
commercially O 
available O 
synthetic O 
sea O 
salt O 
. O 
Ozone B-TRIVIAL 
concentrations O 
ranged O 
from O 
( O 
0.25 O 
to O 
3.9 O 
) O 
× O 
10(13) O 
molecules O 
cm(-3) O 
( O 
0.1-1.6 O 
ppm O 
) O 
. O 
The O 
major O 
products O 
identified O 
by O 
FTIR O 
and O 
confirmed O 
using O 
matrix O 
- O 
assisted O 
laser O 
desorption O 
/ O 
ionization O 
( O 
MALDI O 
) O 
mass O 
spectrometry O 
were O 
the O 
secondary B-FAMILY 
ozonide I-FAMILY 
( O 
SOZ B-ABBREVIATION 
) O 
and O 
a O 
phospholipid O 
aldehyde B-SYSTEMATIC 
and O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
formed O 
by O 
scission O 
of O 
the O 
double O 
bond O 
. O 
The O 
reaction O 
probabilities O 
for O 
the O 
two O 
substrates O 
were O 
similar O 
, O 
γ O 
= O 
( O 
6-7 O 
) O 
× O 
10(-7) O 
, O 
with O 
an O 
estimated O 
overall O 
uncertainty O 
of O 
a O 
factor O 
of O 
two O 
. O 
The O 
presence O 
of O 
water O 
vapor O 
decreased O 
the O 
yield O 
of O 
SOZ B-ABBREVIATION 
relative O 
to O 
the O 
products O 
formed O 
by O 
C B-FORMULA 
[ O 
double O 
bond O 
, O 
length O 
as O 
m-dash O 
] O 
C B-FORMULA 
scission O 
, O 
but O 
also O 
increased O 
the O 
availability O 
of O 
the O 
double O 
bond O 
for O 
reaction O 
, O 
particularly O 
on O 
the O 
less O 
hygroscopic O 
commercial O 
sea O 
- O 
salt O 
substrate O 
. O 
Thus O 
, O 
water O 
not O 
only O 
affects O 
the O 
mechanisms O 
and O 
products O 
, O 
but O 
also O 
the O 
structure O 
of O 
the O 
phospholipid O 
on O 
the O 
salt O 
in O 
a O 
manner O 
that O 
affects O 
its O 
reactivity O 
. O 
The O 
results O 
of O 
these O 
studies O 
suggest O 
that O 
the O 
reactivity O 
and O 
products O 
of O 
oxidation O 
of O 
unsaturated O 
phospholipids O 
on O 
sea O 
- O 
salt O 
particles O 
in O 
air O 
will O 
be O 
very O 
sensitive O 
to O 
the O 
nature O 
and O 
phase O 
of O 
the O 
substrate O 
, O 
the O 
amount O 
of O 
water O 
present O 
, O 
and O 
whether O 
there O 
is O 
phase O 
separation O 
between O 
the O 
organics O 
and O 
the O 
inorganic O 
salt O 
mixture O 
. O 

report O 
the O 
mechanical O 
strength O 
of O 
native O 
cellulose O 
nanofibrils O 
. O 
Native O 
cellulose O 
nanofibrils O 
, O 
purified O 
from O 
wood O 
and O 
sea O 
tunicate O 
, O 
were O 
fully O 
dispersed O 
in O 
water O 
via O 
a O 
topochemical O 
modification O 
of O 
cellulose O 
nanofibrils O 
using O 
2,2,6,6-tetramethylpiperidinyl-1-oxyl B-SYSTEMATIC 
( O 
TEMPO B-ABBREVIATION 
) O 
as O 
a O 
catalyst O 
. O 
The O 
strength O 
of O 
individual O 
nanofibrils O 
was O 
estimated O 
based O 
on O 
a O 
model O 
for O 
the O 
sonication O 
- O 
induced O 
fragmentation O 
of O 
filamentous O 
nanostructures O 
. O 
The O 
resulting O 
strength O 
parameters O 
were O 
then O 
analyzed O 
based O 
on O 
fracture O 
statistics O 
. O 
The O 
mean O 
strength O 
of O 
the O 
wood O 
cellulose O 
nanofibrils O 
ranged O 
from O 
1.6 O 
to O 
3 O 
GPa O 
, O 
depending O 
on O 
the O 
method O 
used O 
to O 
measure O 
the O 
nanofibril O 
width O 
. O 
The O 
highly O 
crystalline O 
, O 
thick O 
tunicate O 
cellulose O 
nanofibrils O 
exhibited O 
higher O 
mean O 
strength O 
of O 
3-6 O 
GPa O 
. O 
The O 
strength O 
values O 
estimated O 
for O 
the O 
cellulose O 
nanofibrils O 
in O 
the O 
present O 
study O 
are O 
comparable O 
with O 
those O 
of O 
commercially O 
available O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

loop O 
II O 
modulates O 
GTP B-ABBREVIATION 
sensitivity O 
of O 
the O 
prostaglandin B-FAMILY 
EP3 O 
receptor O 
. O 

the O 
majority O 
of O 
G O 
protein O 
- O 
coupled O 
receptors O 
, O 
the O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
E-prostanoid B-FAMILY 
3 O 
( O 
EP3 O 
) O 
receptor O 
binds O 
agonist O 
with O 
high O 
affinity O 
that O 
is O 
insensitive O 
to O 
the O 
presence O 
of O 
guanosine B-SYSTEMATIC 
5[prime]-O-(3-thio)triphosphate I-SYSTEMATIC 
( O 
GTPγS B-ABBREVIATION 
) O 
. O 
We O 
report O 
the O 
identification O 
of O 
mutations O 
that O 
confer O 
GTPγS B-ABBREVIATION 
sensitivity O 
to O 
agonist O 
binding O 
. O 
Seven O 
point O 
mutations O 
were O 
introduced O 
into O 
the O 
conserved O 
motif O 
in O 
the O 
second O 
extracellular O 
loop O 
( O 
ECII O 
) O 
of O 
EP3 O 
, O 
resulting O 
in O 
acquisition O 
of O 
GTP B-ABBREVIATION 
-sensitive O 
agonist O 
binding O 
. O 
One O 
receptor O 
mutation O 
W203A O 
was O 
studied O 
in O 
detail O 
. O 
Loss O 
of O 
agonist O 
binding O 
was O 
observed O 
on O 
intact O 
human O 
embryonic O 
kidney O 
293 O 
cells O 
expressing O 
the O 
W203A O 
receptor O 
, O 
conditions O 
where O 
high O 
GTP B-ABBREVIATION 
levels O 
are O 
present O 
; O 
however O 
, O 
high O 
affinity O 
binding O 
[(3)H]PGE(2) B-SYSTEMATIC 
was O 
observed O 
in O 
broken O 
cell O 
preparations O 
washed O 
free O 
of O 
GTP B-ABBREVIATION 
. O 
The O 
[(3)H]PGE(2) B-SYSTEMATIC 
binding O 
of O 
W203A O 
in O 
broken O 
cell O 
membrane O 
fractions O 
was O 
inhibited O 
by O 
addition O 
of O 
GTPγS B-ABBREVIATION 
( O 
IC(50) O 
21 O 
± O 
1.8 O 
nM O 
) O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
the O 
wild O 
- O 
type O 
EP3 O 
receptor O 
displays O 
unusual O 
characteristics O 
of O 
the O 
complex O 
coupled O 
equilibria O 
between O 
agonist O 
- O 
receptor O 
and O 
receptor-G O 
protein O 
interaction O 
. O 
Moreover O 
, O 
mutation O 
of O 
ECII O 
can O 
alter O 
this O 
coupled O 
equilibrium O 
from O 
GTP B-ABBREVIATION 
-insensitive O 
agonist O 
binding O 
to O 
more O 
conventional O 
GTP B-ABBREVIATION 
-sensitive O 
binding O 
. O 
This O 
suggests O 
that O 
for O 
the O 
mutant O 
receptors O 
, O 
ECII O 
plays O 
a O 
critical O 
role O 
in O 
linking O 
the O 
agonist O 
bound O 
receptor O 
conformation O 
to O 
the O 
G O 
protein O 
nucleotide B-FAMILY 
bound O 
state O 
. O 

B I-TRIVIAL 
suppresses O 
lipopolysaccharide-induced O 
inflammation O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
. O 

B I-TRIVIAL 
( O 
SsnB B-ABBREVIATION 
) O 
is O 
an O 
isocoumarin B-TRIVIAL 
compound O 
isolated O 
from O 
the O 
tubers O 
of O 
both O 
Sparganium O 
stoloniferum O 
and O 
Scirpus O 
yagara O 
. O 
We O 
previously O 
demonstrated O 
that O 
SsnB B-ABBREVIATION 
blocked O 
the O 
Toll O 
- O 
like O 
receptor O 
( O 
TLR O 
) O 
2- O 
and O 
TLR4-triggered O 
inflammatory O 
signaling O 
in O 
macrophages O 
by O 
inhibiting O 
the O 
recruitment O 
of O 
MyD88 O 
to O 
the O 
TIR O 
domains O 
of O 
TLR2 O 
and O 
TLR4 O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
examine O 
the O 
effects O 
of O 
SsnB B-ABBREVIATION 
on O 
vascular O 
inflammatory O 
responses O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
challenged O 
by O 
lipopolysaccharide O 
( O 
LPS O 
, O 
a O 
TLR4 O 
ligand O 
) O 
. O 
We O 
found O 
that O 
SsnB B-ABBREVIATION 
dose O 
- O 
dependently O 
attenuated O 
the O 
LPS-induced O 
expression O 
of O 
interleukin O 
(IL)-1β O 
and O 
monocyte O 
chemoattractant O 
protein O 
1 O 
both O 
at O 
the O 
transcription O 
and O 
translation O 
levels O 
in O 
HUVEC O 
. O 
LPS-induced O 
endothelial O 
cell O 
adhesion O 
molecules O 
, O 
intercellular O 
adhesion O 
molecular-1 O 
and O 
vascular O 
cell O 
adhesion O 
molecule-1 O 
expressions O 
were O 
also O 
reduced O 
by O 
treatment O 
with O 
SsnB B-ABBREVIATION 
. O 
In O 
addition O 
, O 
co O 
- O 
incubation O 
with O 
SsnB B-ABBREVIATION 
attenuated O 
THP-1 O 
monocyte O 
adhesion O 
to O 
LPS-activated O 
HUVECs O 
. O 
Furthermore O 
, O 
SsnB B-ABBREVIATION 
efficiently O 
suppressed O 
LPS-induced O 
phosphorylation O 
of O 
extracellular O 
-signal O 
- O 
regulated O 
kinase O 
( O 
Erk1 O 
/ O 
2 O 
) O 
and O 
Akt O 
in O 
HUVECs O 
. O 
These O 
findings O 
show O 
that O 
SsnB B-ABBREVIATION 
can O 
suppress O 
endothelial O 
cell O 
inflammation O 
, O 
suggesting O 
that O 
SsnB B-ABBREVIATION 
might O 
be O 
suitable O 
for O 
development O 
as O 
a O 
therapeutic O 
agent O 
for O 
inflammatory O 
cardiovascular O 
disease O 
. O 

confirmatory O 
method O 
development O 
for O 
the O 
determination O 
of O 
seven O 
quinolones B-FAMILY 
in O 
salmon O 
tissue O 
( O 
Salmo O 
salar O 
L O 
. O 
) O 
validated O 
according O 
to O 
the O 
European O 
Union O 
Decision O 
2002 O 
/ O 
657 O 
/ O 
EC O 
. O 

confirmatory O 
high O 
pressure O 
liquid O 
chromatographic O 
method O 
for O 
the O 
determination O 
of O 
seven O 
quinolone B-FAMILY 
antibiotics O 
in O 
tissue O 
of O 
Atlantic O 
salmon O 
( O 
Salmo O 
salar O 
L O 
. O 
) O 
was O 
developed O 
. O 
Ciprofloxacin B-TRIVIAL 
( O 
CIP B-ABBREVIATION 
) O 
, O 
danofloxacin B-TRIVIAL 
( O 
DAN B-ABBREVIATION 
) O 
, O 
enrofloxacin B-TRIVIAL 
( O 
ENR B-ABBREVIATION 
) O 
, O 
sarafloxacin B-TRIVIAL 
( O 
SAR B-ABBREVIATION 
) O 
, O 
oxolinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
OXO B-ABBREVIATION 
) O 
, O 
nalidixic B-TRIVIAL 
acid I-TRIVIAL 
( O 
NAL B-ABBREVIATION 
) O 
and O 
flumequine B-TRIVIAL 
( O 
FLU B-ABBREVIATION 
) O 
were O 
separated O 
on O 
a O 
Perfectsil O 
ODS-2 O 
120 O 
( O 
250 O 
mm O 
× O 
4 O 
mm O 
, O 
5 O 
μm O 
) O 
column O 
by O 
gradient O 
elution O 
with O 
a O 
mobile O 
phase O 
consisting O 
of O 
0.1% O 
trifluoroacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
pH=1 O 
) O 
, O 
acetonitrile B-SYSTEMATIC 
and O 
methanol B-SYSTEMATIC 
at O 
25°C O 
within O 
22 O 
min O 
. O 
Analytes O 
were O 
monitored O 
at O 
255 O 
nm O 
( O 
for O 
the O 
determination O 
of O 
OXO B-ABBREVIATION 
, O 
NAL B-ABBREVIATION 
and O 
FLU B-ABBREVIATION 
) O 
and O 
275 O 
nm O 
( O 
for O 
CIP B-ABBREVIATION 
, O 
DAN B-ABBREVIATION 
, O 
ENR B-ABBREVIATION 
and O 
SAR B-ABBREVIATION 
) O 
by O 
means O 
of O 
photodiode O 
array O 
detector O 
. O 
Examined O 
quinolones B-FAMILY 
were O 
isolated O 
from O 
salmon O 
tissue O 
by O 
extraction O 
with O 
citrate B-FAMILY 
buffer O 
solution O 
( O 
pH=4.7 O 
) O 
and O 
purified O 
by O 
solid O 
phase O 
extraction O 
using O 
Oasis O 
HLB O 
( O 
200mg O 
/ O 
6 O 
mL O 
) O 
cartridges O 
. O 
The O 
developed O 
method O 
was O 
fully O 
validated O 
in O 
terms O 
of O 
selectivity O 
, O 
linearity O 
, O 
accuracy O 
, O 
precision O 
, O 
stability O 
and O 
sensitivity O 
according O 
to O 
the O 
European O 
Union O 
Decision O 
2002 O 
/ O 
657 O 
/ O 
EC O 
. O 
The O 
accuracy O 
of O 
the O 
method O 
was O 
additionally O 
proved O 
by O 
its O 
application O 
to O 
certified O 
reference O 
material O 
of O 
salmon O 
tissue O 
( O 
BCR O 
® O 
725 O 
) O 
. O 

A I-TRIVIAL 
inhibits O 
voltage O 
- O 
activated O 
Ca(2+) B-FORMULA 
channels O 
in O 
vitro O 
: O 
mechanisms O 
and O 
structural O 
requirements O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
, O 
a O 
high O 
volume O 
production O 
chemical O 
compound O 
attracts O 
growing O 
attention O 
as O 
a O 
health O 
- O 
relevant O 
xenobiotic O 
in O 
humans O 
. O 
It O 
can O 
directly O 
bind O 
to O 
hormone O 
receptors O 
, O 
enzymes O 
, O 
and O 
ion O 
channels O 
to O 
become O 
biologically O 
active O 
. O 
In O 
this O 
study O 
we O 
show O 
that O 
BPA B-ABBREVIATION 
acts O 
as O 
a O 
potent O 
blocker O 
of O 
voltage O 
- O 
activated O 
Ca(2+) B-FORMULA 
channels O 
. O 
We O 
determined O 
the O 
mechanisms O 
of O 
block O 
and O 
the O 
structural O 
elements O 
of O 
BPA B-ABBREVIATION 
essential O 
for O 
its O 
action O 
. O 
Macroscopic O 
Ba(2+) B-FORMULA 
/ O 
Ca(2+) B-FORMULA 
currents O 
through O 
native O 
L- O 
, O 
N- O 
, O 
P O 
/ O 
Q- O 
, O 
T O 
- O 
type O 
Ca(2+) B-FORMULA 
channels O 
in O 
rat O 
endocrine O 
GH(3) O 
cells O 
, O 
mouse O 
dorsal O 
root O 
ganglion O 
neurons O 
or O 
cardiac O 
myocytes O 
, O 
and O 
recombinant O 
human O 
R- O 
type O 
Ca(2+) B-FORMULA 
channels O 
expressed O 
in O 
human O 
embryonic O 
kidney O 
( O 
HEK O 
) O 
293 O 
cells O 
were O 
rapidly O 
and O 
reversibly O 
inhibited O 
by O 
BPA B-ABBREVIATION 
with O 
similar O 
potency O 
( O 
EC(50) O 
values O 
: O 
26-35 O 
μM O 
) O 
. O 
Pharmacological O 
and O 
biophysical O 
analysis O 
of O 
R- O 
type O 
Ca(2+) B-FORMULA 
channels O 
revealed O 
that O 
BPA B-ABBREVIATION 
interacts O 
with O 
the O 
extracellular O 
part O 
of O 
the O 
channel O 
protein O 
. O 
Its O 
action O 
does O 
not O 
require O 
intracellular O 
signaling O 
pathways O 
, O 
is O 
neither O 
voltage- O 
nor O 
use O 
- O 
dependent O 
, O 
and O 
does O 
not O 
affect O 
channel O 
gating O 
. O 
This O 
indicates O 
that O 
BPA B-ABBREVIATION 
interacts O 
with O 
the O 
channel O 
in O 
its O 
resting O 
state O 
by O 
directly O 
binding O 
to O 
an O 
external O 
site O 
outside O 
the O 
pore O 
- O 
forming O 
region O 
. O 
Structure O 
- O 
effect O 
analyses O 
of O 
various O 
phenolic B-FAMILY 
and O 
bisphenolic B-FAMILY 
compounds O 
revealed O 
that O 
1 O 
) O 
a O 
double O 
- O 
alkylated O 
( O 
R-C(CH(3))(2)-R B-FAMILY 
, O 
R-C(CH(3))(CH(2)CH(3))-R B-FAMILY 
) O 
, O 
or O 
double O 
- O 
trifluoromethylated O 
sp(3)-hybridized O 
carbon B-SYSTEMATIC 
atom O 
between O 
the O 
two O 
aromatic O 
rings O 
and O 
2 O 
) O 
the O 
two O 
aromatic O 
moieties O 
in O 
angulated O 
orientation O 
are O 
optimal O 
for O 
BPA B-ABBREVIATION 
' O 
s O 
effectiveness O 
. O 
Since O 
BPA B-ABBREVIATION 
highly O 
pollutes O 
the O 
environment O 
and O 
is O 
incorporated O 
into O 
the O 
human O 
organism O 
, O 
our O 
data O 
may O 
provide O 
a O 
basis O 
for O 
future O 
studies O 
relevant O 
for O 
human O 
health O 
and O 
development O 
. O 

but O 
not O 
antidepressant O 
- O 
like O 
activity O 
of O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
, O 
a O 
novel O 
, O 
selective O 
positive O 
allosteric O 
modulator O 
of O 
the O 
mGlu₄ O 
receptor O 
. O 

studies O 
demonstrated O 
that O 
the O 
Group O 
III O 
mGlu O 
receptor O 
- O 
selective O 
orthosteric O 
agonist O 
, O 
LSP1-2111 B-IDENTIFIER 
produced O 
anxiolytic- O 
but O 
not O 
antidepressant O 
- O 
like O 
effects O 
upon O 
peripheral O 
administration O 
. O 
Herein O 
, O 
we O 
report O 
the O 
pharmacological O 
actions O 
of O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
, O 
a O 
novel O 
, O 
selective O 
, O 
and O 
brain O 
- O 
penetrant O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
of O 
the O 
mGlu(4) O 
receptor O 
in O 
the O 
stress O 
- O 
induced O 
hyperthermia O 
( O 
SIH O 
) O 
, O 
four O 
- O 
plate O 
, O 
marble O 
- O 
burying O 
and O 
Vogel's O 
conflict O 
tests O 
. O 
In O 
all O 
models O 
, O 
except O 
Vogel's O 
conflict O 
test O 
, O 
a O 
dose O 
- O 
dependent O 
anxiolytic O 
- O 
like O 
effect O 
was O 
seen O 
. O 
The O 
anti-hyperthermic O 
effect O 
of O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
in O 
the O 
SIH O 
test O 
was O 
inhibited O 
by O 
the O 
benzodiazepine B-FAMILY 
receptor O 
antagonist O 
flumazenil B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
and O 
was O 
not O 
serotonin B-TRIVIAL 
-dependent O 
, O 
as O 
it O 
persisted O 
in O 
serotonin B-TRIVIAL 
-deficient O 
mice O 
and O 
upon O 
blockade O 
of O 
either O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
receptors O 
by O 
WAY100635 B-IDENTIFIER 
, O 
or O 
5-HT B-SYSTEMATIC 
( O 
2A O 
/ O 
2C O 
) O 
receptors O 
by O 
ritanserin B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
the O 
GABAergic O 
system O 
, O 
but O 
not O 
the O 
serotonergic O 
system O 
, O 
is O 
involved O 
in O 
the O 
mechanism O 
of O 
the O 
anxiolytic O 
- O 
like O 
phenotype O 
of O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
in O 
rodents O 
. O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
did O 
not O 
produce O 
antidepressant O 
- O 
like O 
effects O 
in O 
the O 
tail O 
suspension O 
test O 
( O 
TST O 
) O 
in O 
mice O 
; O 
however O 
, O 
it O 
decreased O 
the O 
basal O 
locomotor O 
activity O 
of O 
mice O 
that O 
were O 
not O 
habituated O 
to O 
activity O 
cages O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

Volatile O 
organic O 
compounds O 
( O 
VOCs O 
) O 
are O 
widely O 
used O 
as O 
constituents O 
of O 
household O 
chemicals O 
. O 
Although O 
adverse O 
health O 
effects O 
have O 
been O 
reported O 
, O 
long O 
- O 
term O 
exposure O 
to O 
low O 
- O 
level O 
VOCs O 
mixture O 
has O 
not O 
been O 
studied O 
. O 
Especially O 
, O 
there O 
is O 
a O 
lack O 
of O 
substantial O 
information O 
on O 
the O 
sensitive O 
biomarkers O 
and O 
carcinogenic O 
markers O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
oxidative O 
stress O 
and O 
genotoxic O 
effects O 
of O 
sub O 
- O 
chronic O 
low O 
- O 
dose O 
VOCs O 
mixture O 
( O 
formaldehyde B-SYSTEMATIC 
, O 
benzene B-SYSTEMATIC 
, O 
toluene B-TRIVIAL 
and O 
xylene B-FAMILY 
) O 
. O 
Male O 
Kunming O 
mice O 
were O 
exposed O 
to O 
0 O 
( O 
control O 
) O 
and O 
three O 
different O 
doses O 
of O 
VOCs O 
mixture O 
( O 
group O 
1S O 
, O 
5S O 
and O 
10S O 
) O 
for O 
90 O 
d O 
( O 
2 O 
h O 
/ O 
d O 
) O 
. O 
Group O 
1S O 
is O 
0.1 O 
, O 
0.11 O 
, O 
0.2 O 
and O 
0.2 O 
mg O 
/ O 
m(3) O 
, O 
group O 
5S O 
is O 
0.5 O 
, O 
0.55 O 
, O 
1 O 
and O 
1 O 
mg O 
/ O 
m(3) O 
, O 
group O 
10S O 
is O 
1 O 
, O 
1.1 O 
, O 
2 O 
and O 
2 O 
mg O 
/ O 
m(3) O 
, O 
which O 
, O 
respectively O 
, O 
corresponded O 
to O 
1 O 
, O 
5 O 
and O 
10 O 
times O 
of O 
indoor O 
air O 
quality O 
standard O 
( O 
IAQS O 
) O 
in O 
China O 
. O 
One O 
day O 
following O 
VOCs O 
exposure O 
, O 
oxidative O 
stress O 
markers O 
in O 
lung O 
, O 
8-hydroxy-2'-deoxyguanosine B-SYSTEMATIC 
in O 
bronchoalveolar O 
lavage O 
fluid O 
and O 
genotoxicity O 
( O 
DNA O 
damage O 
) O 
in O 
liver O 
were O 
examined O 
. O 
Results O 
showed O 
that O 
exposure O 
to O 
VOCs O 
( O 
IAQS O 
dose O 
) O 
resulted O 
in O 
oxidative O 
damages O 
of O 
lung O 
, O 
which O 
were O 
supported O 
by O 
the O 
significant O 
changes O 
on O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
GSH B-ABBREVIATION 
S B-FORMULA 
-transferase O 
, O 
total O 
antioxidative O 
capacity O 
, O 
malondialdehyde B-TRIVIAL 
, O 
protein O 
carbonyl B-FAMILY 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
. O 
Moreover O 
, O 
oxidative O 
stress O 
markers O 
in O 
group O 
5S O 
and O 
10S O 
( O 
except O 
NO B-FORMULA 
) O 
in O 
lung O 
were O 
affected O 
significantly O 
. O 
In O 
addition O 
, O 
VOCs O 
exposure O 
also O 
induced O 
significantly O 
DNA O 
damage O 
in O 
liver O 
. O 
Our O 
study O 
suggested O 
long O 
- O 
term O 
VOCs O 
inhalation O 
at O 
low O 
levels O 
caused O 
oxidative O 
stress O 
and O 
genotoxicity O 
response O 
in O 
mice O 
. O 
Since O 
effects O 
were O 
seen O 
at O 
the O 
current O 
IAQS O 
level O 
, O 
further O 
studies O 
below O 
this O 
level O 
are O 
necessary O 
. O 

simulations O 
of O 
the O 
formation O 
of O 
stable O 
clusters O 
in O 
mixtures O 
of O 
alkaline B-FAMILY 
salts I-FAMILY 
and O 
imidazolium B-SYSTEMATIC 
-based O 
ionic O 
liquids O 
. O 

and O 
dynamical O 
properties O 
of O 
room O 
- O 
temperature O 
ionic O 
liquids O 
containing O 
the O 
cation O 
1-butyl-3-methylimidazolium B-SYSTEMATIC 
( O 
[BMIM](+) B-ABBREVIATION 
) O 
and O 
three O 
different O 
anions O 
( O 
hexafluorophosphate B-SYSTEMATIC 
, O 
[PF6](-) B-FORMULA 
, O 
tetrafluoroborate B-SYSTEMATIC 
, O 
[BF4](-) B-FORMULA 
, O 
and O 
bis(trifluoromethylsulfonyl)imide B-SYSTEMATIC 
, O 
[NTf2](-) B-FORMULA 
) O 
doped O 
with O 
several O 
molar O 
fractions O 
of O 
lithium B-SYSTEMATIC 
salts O 
with O 
a O 
common O 
anion O 
at O 
298.15 O 
K O 
and O 
1 O 
atm O 
were O 
investigated O 
by O 
means O 
of O 
molecular O 
dynamics O 
simulations O 
. O 
The O 
effect O 
of O 
the O 
size O 
of O 
the O 
salt O 
cation O 
was O 
also O 
analyzed O 
by O 
comparing O 
these O 
results O 
with O 
those O 
for O 
mixtures O 
of O 
[BMIM][PF6] B-FORMULA 
with O 
NaPF6 B-FORMULA 
. O 
Lithium B-SYSTEMATIC 
/ O 
sodium B-SYSTEMATIC 
solvation O 
and O 
ionic O 
mobilities O 
were O 
analyzed O 
via O 
the O 
study O 
of O 
radial O 
distribution O 
functions O 
, O 
coordination O 
numbers O 
, O 
cage O 
autocorrelation O 
functions O 
, O 
mean O 
- O 
square O 
displacements O 
( O 
including O 
the O 
analysis O 
of O 
both O 
ballistic O 
and O 
diffusive O 
regimes O 
) O 
, O 
self O 
- O 
diffusion O 
coefficients O 
of O 
all O 
the O 
ionic O 
species O 
, O 
velocity O 
and O 
current O 
autocorrelation O 
functions O 
, O 
and O 
ionic O 
conductivity O 
in O 
all O 
the O 
ionic O 
liquid O 
/ O 
salt O 
systems O 
. O 
We O 
found O 
that O 
lithium B-SYSTEMATIC 
and O 
sodium B-SYSTEMATIC 
cations O 
are O 
strongly O 
coordinated O 
in O 
two O 
different O 
positions O 
with O 
the O 
anion O 
present O 
in O 
the O 
mixture O 
. O 
Moreover O 
, O 
[Li](+) B-FORMULA 
and O 
[Na](+) B-FORMULA 
cations O 
were O 
found O 
to O 
form O 
bonded O 
- O 
like O 
, O 
long O 
- O 
lived O 
aggregates O 
with O 
the O 
anions O 
in O 
their O 
first O 
solvation O 
shell O 
, O 
which O 
act O 
as O 
very O 
stable O 
kinetic O 
entities O 
within O 
which O 
a O 
marked O 
rattling O 
motion O 
of O 
salt O 
ions O 
takes O 
place O 
. O 
With O 
very O 
long O 
MD O 
simulation O 
runs O 
, O 
this O 
phenomenon O 
is O 
proved O 
to O 
be O 
on O 
the O 
basis O 
of O 
the O 
decrease O 
of O 
self O 
- O 
diffusion O 
coefficients O 
and O 
ionic O 
conductivities O 
previously O 
reported O 
in O 
experimental O 
and O 
computational O 
results O 
. O 

/ O 
β-Hydrolase O 
domain O 
- O 
containing O 
6 O 
( O 
ABHD6 O 
) O 
represents O 
a O 
potentially O 
attractive O 
therapeutic O 
target O 
for O 
indirectly O 
potentiating O 
2-arachidonoylglycerol B-SYSTEMATIC 
signaling O 
; O 
however O 
, O 
the O 
enzyme O 
is O 
currently O 
largely O 
uncharacterized O 
. O 
Here O 
, O 
we O 
describe O 
a O 
five O 
element O 
, O 
ligand O 
- O 
based O 
pharmacophore O 
model O 
along O 
with O 
a O 
refined O 
homology O 
model O 
of O 
ABHD6 O 
. O 
Following O 
a O 
virtual O 
screen O 
of O 
a O 
modest O 
database O 
, O 
both O 
the O 
pharmacophore O 
and O 
homology O 
models O 
were O 
found O 
to O 
be O 
highly O 
predictive O 
, O 
preferentially O 
identifying O 
ABHD6 O 
inhibitors O 
over O 
drug O 
- O 
like O 
non-inhibitors O 
. O 
The O 
models O 
yield O 
insight O 
into O 
the O 
features O 
required O 
for O 
optimal O 
ligand O 
binding O 
to O 
ABHD6 O 
and O 
the O 
atomic O 
structure O 
of O 
the O 
binding O 
site O 
. O 
In O 
combination O 
, O 
the O 
two O 
models O 
should O 
be O 
very O 
helpful O 
not O 
only O 
in O 
high O 
- O 
throughput O 
virtual O 
screening O 
, O 
but O 
also O 
in O 
lead O 
optimization O 
, O 
and O 
will O 
facilitate O 
the O 
development O 
of O 
novel O 
, O 
selective O 
ABHD6 O 
inhibitors O 
as O 
potential O 
drugs O 
. O 

by O 
the O 
water O 
- O 
enhanced O 
mechanical O 
gradient O 
character O 
of O 
the O 
squid O 
beak O 
, O 
we O 
herein O 
report O 
a O 
nanocomposite O 
that O 
mimics O 
both O 
the O 
architecture O 
and O 
properties O 
of O 
this O 
interesting O 
natural O 
material O 
. O 
Similar O 
to O 
the O 
squid O 
beak O 
, O 
we O 
have O 
developed O 
nanocomposites O 
where O 
the O 
degree O 
of O 
cross O 
- O 
linking O 
is O 
controlled O 
along O 
the O 
length O 
of O 
the O 
film O 
. O 
In O 
this O 
study O 
, O 
we O 
utilized O 
tunicate O 
cellulose O 
nanocrystals O 
as O 
the O 
nanofiller O 
that O 
are O 
functionalized O 
with O 
allyl B-SYSTEMATIC 
moieties O 
. O 
Using O 
photoinduced O 
thiol B-FAMILY 
-ene O 
chemistry O 
, O 
we O 
have O 
been O 
able O 
to O 
cross O 
- O 
link O 
the O 
CNC O 
nanofiller O 
. O 
In O 
the O 
dry O 
state O 
where O 
strong O 
CNC O 
interactions O 
can O 
occur O 
, O 
only O 
a O 
small O 
mechanical O 
contrast O 
is O 
observed O 
between O 
the O 
cross O 
- O 
linked O 
and O 
uncross O 
- O 
linked O 
samples O 
. O 
However O 
, O 
when O 
the O 
films O 
are O 
exposed O 
to O 
water O 
, O 
which O 
" O 
switches O 
off O 
" O 
the O 
noncovalent O 
CNC O 
interactions O 
, O 
a O 
significant O 
mechanical O 
contrast O 
is O 
observed O 
between O 
the O 
same O 
films O 
. O 
For O 
example O 
, O 
at O 
20 O 
wt O 
% O 
CNC O 
( O 
in O 
the O 
dry O 
film O 
) O 
, O 
an O 
increase O 
in O 
wet O 
modulus O 
from O 
60 O 
to O 
300 O 
MPa O 
( O 
∼500% O 
increase O 
) O 
is O 
observed O 
after O 
photoirradiation O 
. O 
Furthermore O 
, O 
we O 
show O 
that O 
the O 
wet O 
modulus O 
can O 
be O 
controlled O 
by O 
altering O 
the O 
UV O 
exposure O 
time O 
which O 
allows O 
access O 
to O 
mechanical O 
gradient O 
films O 
. O 

acid I-FAMILY 
profiling O 
of O 
the O 
seed O 
oils O 
of O 
some O 
varieties O 
of O 
field O 
peas O 
( O 
Pisum O 
sativum O 
) O 
by O 
RP-LC O 
/ O 
ESI-MS O 
/ O 
MS O 
: O 
Towards O 
the O 
development O 
of O 
an O 
oilseed O 
pea O 
. O 

- O 
phase O 
liquid O 
chromatography O 
coupled O 
to O 
negative O 
- O 
ion O 
electrospray O 
tandem O 
mass O 
spectrometry O 
( O 
RP-LC O 
/ O 
ESI-MS O 
/ O 
MS O 
) O 
was O 
used O 
to O 
study O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
profile O 
from O 
the O 
oil O 
of O 
harvested O 
field O 
pea O 
( O 
Pisum O 
sativum O 
) O 
varieties O 
as O 
part O 
of O 
a O 
research O 
project O 
to O 
develop O 
this O 
legume O 
as O 
a O 
commercial O 
oilseed O 
for O 
Canada O 
. O 
The O 
seed O 
oils O 
from O 
pea O 
samples O 
contained O 
palmitic B-MULTIPLE 
and I-MULTIPLE 
stearic I-MULTIPLE 
acids I-MULTIPLE 
as O 
major O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
. O 
Oleic B-MULTIPLE 
, I-MULTIPLE 
linoleic I-MULTIPLE 
and I-MULTIPLE 
linolenic I-MULTIPLE 
acids I-MULTIPLE 
were O 
the O 
major O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
found O 
. O 
Small O 
percentages O 
of O 
other O 
long O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
were O 
also O 
detected O 
. O 
This O 
profile O 
suggests O 
that O 
the O 
species O 
of O 
field O 
pea O 
investigated O 
might O 
have O 
the O 
potential O 
to O 
be O 
used O 
as O 
raw O 
materials O 
to O 
develop O 
a O 
future O 
new O 
oilseed O 
crop O 
for O 
the O 
food O 
industry O 
. O 
Fatty B-FAMILY 
acid I-FAMILY 
extracts O 
did O 
not O 
require O 
further O 
manipulation O 
before O 
final O 
analysis O 
by O 
RP-LC O 
/ O 
ESI-MS O 
/ O 
MS O 
, O 
indicating O 
the O 
utility O 
and O 
relative O 
simplicity O 
of O 
this O 
technique O 
for O 
future O 
screening O 
studies O 
. O 

and O 
epigallocatechin-3-gallate B-SYSTEMATIC 
effect O 
on O 
the O 
anisotropy O 
of O 
model O 
membranes O 
with O 
cholesterol B-TRIVIAL 
. O 

membrane O 
fluidity O 
, O 
which O 
can O 
be O 
altered O 
by O 
oxidative O 
stress O 
, O 
plays O 
an O 
important O 
role O 
in O 
the O 
cell O 
physiology O 
. O 
Flavonoids B-FAMILY 
are O 
among O 
the O 
most O 
studied O 
food O 
substances O 
that O 
prevent O 
and O 
/ O 
or O 
reduce O 
oxidative O 
stress O 
, O 
but O 
their O 
action O 
mechanisms O 
are O 
far O 
from O 
being O 
understood O 
. O 
We O 
performed O 
a O 
study O 
on O 
the O 
effect O 
of O 
quercetin B-TRIVIAL 
and O 
epigallocatechin-3-gallate B-SYSTEMATIC 
on O 
2-Dimyristoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
small O 
unilamellar O 
vesicles O 
( O 
SUVs O 
) O 
with O 
different O 
amounts O 
of O 
cholesterol B-TRIVIAL 
, O 
using O 
Laurdan B-ABBREVIATION 
as O 
a O 
fluorescent O 
probe O 
, O 
to O 
put O 
into O 
evidence O 
the O 
perturbations O 
of O 
the O 
phospholipid O 
membrane O 
fluidity O 
and O 
local O 
lipid O 
order O 
in O 
an O 
attempt O 
to O 
decipher O 
the O 
action O 
mechanism O 
of O 
the O 
flavonoids B-FAMILY 
at O 
the O 
cell O 
membrane O 
level O 
. O 
Results O 
indicate O 
that O 
polyphenols B-FAMILY 
modulate O 
the O 
transition O 
from O 
the O 
gel O 
phase O 
to O 
the O 
liquid O 
crystalline O 
phase O 
of O 
SUVs O 
in O 
all O 
studied O 
membranes O 
. O 
SUVs O 
with O 
cholesterol B-TRIVIAL 
have O 
by O 
themselves O 
higher O 
phase O 
transition O 
temperature O 
and O 
the O 
presence O 
of O 
polyphenols B-FAMILY 
stabilizes O 
further O 
the O 
membrane O 
. O 
Quercetin B-TRIVIAL 
has O 
a O 
dose O 
- O 
dependent O 
effect O 
on O 
the O 
fluidity O 
and O 
local O 
order O 
of O 
the O 
lipid O 
membranes O 
, O 
whilst O 
epigallocatechin-3-gallate B-SYSTEMATIC 
action O 
is O 
not O 
dose O 
- O 
dependent O 
, O 
the O 
differences O 
being O 
attributable O 
to O 
the O 
hydrophobic O 
/ O 
hydrophilic O 
character O 
of O 
the O 
substances O 
. O 
The O 
findings O 
are O 
discussed O 
within O 
the O 
frame O 
of O 
earlier O 
reports O 
on O 
the O 
effect O 
of O 
polyphenols B-FAMILY 
on O 
artificial O 
membranes O 
. O 

: O 
An O 
epileptic O 
seizure O 
is O 
a O 
transient O 
occurrence O 
of O 
signs O 
and O 
/ O 
or O 
symptoms O 
due O 
to O 
abnormal O 
excessive O 
or O 
synchronous O 
neuronal O 
activity O 
in O 
the O 
brain O 
. O 
The O 
International O 
League O 
Against O 
Epilepsy O 
classifies O 
seizures O 
in O 
two O 
broad O 
categories O 
: O 
partial O 
( O 
localized O 
to O 
one O 
cerebral O 
hemisphere O 
) O 
and O 
generalized O 
( O 
localized O 
to O 
both O 
cerebral O 
hemispheres O 
) O 
. O 
One O 
indirect O 
pathway O 
for O 
the O 
treatment O 
of O 
epilepsy O 
includes O 
the O 
inhibition O 
of O 
carbonic O 
anhydrase O 
( O 
CA O 
) O 
, O 
thereby O 
increasing O 
CO2 B-FORMULA 
levels O 
in O 
the O 
brain O 
. O 
Areas O 
covered O 
: O 
Carbonic O 
anhydrases O 
( O 
EC O 
4.2.1.1 O 
) O 
are O 
ubiquitous O 
metalloenzymes O 
that O 
catalyze O 
the O 
reversible O 
hydration O 
/ O 
dehydration O 
of O 
CO2 B-FORMULA 
/ O 
HCO3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
, O 
respectively O 
. O 
CA O 
inhibitors O 
( O 
CAIs O 
) O 
such O 
as O 
acetazolamide B-TRIVIAL 
, O 
methazolamide B-TRIVIAL 
, O 
topiramate B-TRIVIAL 
, O 
zonisamide B-TRIVIAL 
, O 
and O 
sulthiame B-TRIVIAL 
can O 
reduce O 
seizures O 
through O 
perturbation O 
of O 
the O 
CO2 B-FORMULA 
equilibrium O 
and O 
/ O 
or O 
the O 
inhibition O 
of O 
ion O 
channels O 
. O 
This O 
review O 
focuses O 
on O 
the O 
mechanism O 
of O 
epilepsy O 
, O 
CA O 
catalysis O 
, O 
and O 
recent O 
developments O 
in O 
the O 
treatment O 
of O 
epilepsy O 
using O 
CAIs O 
. O 
Expert O 
opinion O 
: O 
Based O 
on O 
the O 
observed O 
active O 
- O 
site O 
binding O 
interactions O 
of O 
CAIs O 
in O 
crystal O 
structures O 
and O 
their O 
respective O 
inhibition O 
constants O 
, O 
structure O 
- O 
activity O 
relationships O 
can O 
be O 
mapped O 
. O 
Various O 
CAIs O 
along O 
with O 
novel O 
techniques O 
to O 
administer O 
them O 
have O 
been O 
patented O 
in O 
the O 
last O 
four O 
years O 
. O 
However O 
, O 
epilepsy O 
continues O 
to O 
be O 
a O 
path O 
less O 
traveled O 
when O 
it O 
comes O 
to O 
CAIs O 
. O 
A O 
major O 
area O 
of O 
research O 
must O 
focus O 
toward O 
the O 
design O 
of O 
isoform O 
- O 
specific O 
inhibitors O 
using O 
analogs O 
of O 
existing O 
CAIs O 
. O 

clinical O 
pharmacology O 
concepts O 
in O 
individualized O 
therapy O 
with O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
. O 

kinases O 
have O 
emerged O 
as O 
important O 
tumor O 
targets O 
for O 
the O 
design O 
of O 
potent O 
and O 
selective O 
inhibitors O 
. O 
Eighteen O 
of O 
these O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
( O 
TKIs O 
) O 
have O 
already O 
been O 
approved O 
for O 
the O 
treatment O 
of O 
diseases O 
that O 
were O 
previously O 
essentially O 
resistant O 
to O 
standard O 
chemotherapy O 
. O 
Major O 
efforts O 
are O 
ongoing O 
that O 
focus O 
on O 
the O 
development O 
of O 
companion O 
diagnostics O 
for O 
investigational O 
and O 
approved O 
TKIs O 
, O 
as O 
well O 
as O 
on O 
integrating O 
clinical O 
pharmacology O 
principles O 
in O 
clinical O 
practice O 
to O 
decrease O 
toxicity O 
and O 
improve O 
efficacy O 
. O 

disruptors O 
fludioxonil B-TRIVIAL 
and O 
fenhexamid B-TRIVIAL 
stimulate O 
miR-21 O 
expression O 
in O 
breast O 
cancer O 
cells O 
. O 

and O 
fludioxonil B-TRIVIAL 
are O 
antifungal O 
agents O 
used O 
in O 
agricultural O 
applications O 
, O 
which O 
are O 
present O 
at O 
measurable O 
amounts O 
in O 
fruits O 
and O 
vegetables O 
. O 
Fenhexamid B-TRIVIAL 
and O 
fludioxonil B-TRIVIAL 
showed O 
endocrine O 
disruptor O 
activity O 
as O 
antiandrogens O 
in O 
an O 
androgen B-FAMILY 
receptor O 
reporter O 
assay O 
in O 
engineered O 
human O 
breast O 
cancer O 
cells O 
. O 
Little O 
is O 
known O 
about O 
how O 
environmental O 
chemicals O 
regulate O 
microRNA O 
( O 
miRNA O 
) O 
expression O 
. O 
This O 
study O 
examined O 
the O 
effect O 
of O 
fenhexamid B-TRIVIAL 
and O 
fludioxonil B-TRIVIAL 
on O 
the O 
expression O 
of O 
the O 
oncomiR O 
miR-21 O 
in O 
MCF-7 O 
, O 
T47D O 
, O 
and O 
MDA-MB-231 O 
human O 
breast O 
cancer O 
cells O 
and O 
downstream O 
targets O 
of O 
miR-21 O 
in O 
MCF-7 O 
cells O 
. O 
Fenhexamid B-TRIVIAL 
and O 
fludioxonil B-TRIVIAL 
stimulated O 
miR-21 O 
expression O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
and O 
reduced O 
the O 
expression O 
of O 
miR-21 O 
target O 
Pdcd4 O 
protein O 
. O 
Antisense O 
to O 
miR-21 O 
blocked O 
the O 
increase O 
in O 
Pdcd4 O 
protein O 
by O 
fenhexamid B-TRIVIAL 
and O 
fludioxonil B-TRIVIAL 
. O 
Fenhexamid B-TRIVIAL 
and O 
fludioxonil B-TRIVIAL 
reduced O 
miR-125b O 
and O 
miR-181a O 
, O 
demonstrating O 
specificity O 
of O 
miRNA O 
regulation O 
. O 
Induction O 
of O 
miR-21 O 
was O 
inhibited O 
by O 
the O 
estrogen B-FAMILY 
receptor O 
antagonist O 
fulvestrant B-TRIVIAL 
, O 
by O 
androgen B-FAMILY 
receptor O 
antagonist O 
bicalutamide B-TRIVIAL 
, O 
by O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
and O 
cycloheximide B-TRIVIAL 
, O 
and O 
by O 
inhibitors O 
of O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
and O 
phosphoinositide B-FAMILY 
3-kinase O 
pathways O 
. O 
Fenhexamid B-TRIVIAL 
activation O 
was O 
inhibited O 
by O 
the O 
arylhydrocarbon B-FAMILY 
receptor O 
antagonist O 
α-napthoflavone B-TRIVIAL 
. O 
Fenhexamid B-TRIVIAL 
and O 
fludioxonil B-TRIVIAL 
did O 
not O 
affect O 
dihydrotestosterone B-SYSTEMATIC 
-induced O 
miR-21 O 
expression O 
. O 
Fludioxonil B-TRIVIAL 
, O 
but O 
not O 
fenhexamid B-TRIVIAL 
, O 
inhibited O 
MCF-7 O 
cell O 
viability O 
, O 
and O 
both O 
inhibited O 
estradiol B-TRIVIAL 
-induced O 
cell O 
proliferation O 
and O 
reduced O 
cell O 
motility O 
. O 
Together O 
these O 
data O 
indicate O 
that O 
fenhexamid B-TRIVIAL 
and O 
fludioxonil B-TRIVIAL 
use O 
similar O 
and O 
distinct O 
mechanisms O 
to O 
increase O 
miR-21 O 
expression O 
with O 
downstream O 
antiestrogenic O 
activity O 
. O 

assembly O 
of O 
ultrathin O 
hexagonal O 
SnS2 B-FORMULA 
nanosheets O 
onto O 
electrospun O 
TiO2 B-FORMULA 
nanofibers O 
: O 
enhanced O 
photocatalytic O 
activity O 
based O 
on O 
photoinduced O 
interfacial O 
charge O 
transfer O 
. O 

- O 
designed O 
hierarchical O 
nanostructures O 
with O 
one O 
dimensional O 
( O 
1D O 
) O 
TiO(2) B-FORMULA 
nanofibers O 
( O 
120-350 O 
nm O 
in O 
diameter O 
and O 
several O 
micrometers O 
in O 
length O 
) O 
and O 
ultrathin O 
hexagonal O 
SnS(2) B-FORMULA 
nanosheets O 
( O 
40-70 O 
nm O 
in O 
lateral O 
size O 
and O 
4-8 O 
nm O 
in O 
thickness O 
) O 
were O 
successfully O 
synthesized O 
by O 
combining O 
the O 
electrospinning O 
technique O 
( O 
for O 
TiO(2) B-FORMULA 
nanofibers O 
) O 
and O 
a O 
hydrothermal O 
growth O 
method O 
( O 
for O 
SnS(2) B-FORMULA 
nanosheets O 
) O 
. O 
The O 
single O 
- O 
crystalline O 
SnS(2) B-FORMULA 
nanosheets O 
with O 
a O 
2D O 
layered O 
structure O 
were O 
uniformly O 
grown O 
onto O 
the O 
electrospun O 
TiO(2) B-FORMULA 
nanofibers O 
consisted O 
of O 
either O 
anatase B-TRIVIAL 
( O 
A O 
) O 
phase O 
or O 
anatase B-TRIVIAL 
- O 
rutile B-TRIVIAL 
( O 
AR O 
) O 
mixed O 
phase O 
TiO(2) B-FORMULA 
nanoparticles O 
. O 
The O 
definite O 
heterojunction O 
interface O 
between O 
SnS(2) B-FORMULA 
nanosheets O 
and O 
TiO(2) B-MULTIPLE 
( I-MULTIPLE 
A I-MULTIPLE 
or I-MULTIPLE 
R I-MULTIPLE 
) I-MULTIPLE 
nanoparticles O 
were O 
investigated O 
by O 
high O 
resolution O 
transmission O 
electron O 
microscopy O 
( O 
HRTEM O 
) O 
and O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
. O 
Moreover O 
, O 
the O 
as-prepared O 
SnS(2) B-FORMULA 
/ O 
TiO(2) B-FORMULA 
hierarchical O 
nanostructures O 
as O 
nanoheterojunction O 
photocatalysts O 
exhibited O 
excellent O 
UV O 
and O 
visible O 
light O 
photocatalytic O 
activities O 
for O 
the O 
degradation O 
of O 
organic O 
dyes O 
( O 
rhodamine B-TRIVIAL 
B I-TRIVIAL 
and O 
methyl B-TRIVIAL 
orange I-TRIVIAL 
) O 
and O 
phenols B-FAMILY 
( O 
4-nitrophenol B-SYSTEMATIC 
) O 
, O 
remarkably O 
superior O 
to O 
the O 
TiO(2) B-FORMULA 
nanofibers O 
and O 
the O 
SnS(2) B-FORMULA 
nanosheets O 
, O 
mainly O 
owing O 
to O 
the O 
photoinduced O 
interfacial O 
charge O 
transfer O 
based O 
on O 
the O 
photosynergistic O 
effect O 
of O 
the O 
SnS(2) B-FORMULA 
/ O 
TiO(2) B-FORMULA 
heterojunction O 
. O 
Significantly O 
, O 
the O 
SnS(2) B-FORMULA 
/ O 
TiO(2) B-MULTIPLE 
( I-MULTIPLE 
AR I-MULTIPLE 
) I-MULTIPLE 
hierarchical O 
nanostructures O 
as O 
the O 
tricomponent O 
heterojunction O 
system O 
possessed O 
stronger O 
photocatalytic O 
activity O 
than O 
the O 
bicomponent O 
heterojunction O 
system O 
of O 
SnS(2) B-FORMULA 
/ O 
TiO(2) B-FORMULA 
( I-FORMULA 
A I-FORMULA 
) I-FORMULA 
hierarchical O 
nanostructures O 
or O 
TiO(2) B-MULTIPLE 
( I-MULTIPLE 
AR I-MULTIPLE 
) I-MULTIPLE 
nanofibers O 
, O 
which O 
was O 
discussed O 
in O 
terms O 
of O 
the O 
three O 
- O 
way O 
photosynergistic O 
effect O 
between O 
SnS(2) B-FORMULA 
, O 
TiO(2) B-FORMULA 
( I-FORMULA 
A I-FORMULA 
) I-FORMULA 
and O 
TiO(2) B-FORMULA 
( I-FORMULA 
R I-FORMULA 
) I-FORMULA 
component O 
in O 
the O 
SnS(2) B-FORMULA 
/ O 
TiO(2) B-MULTIPLE 
( I-MULTIPLE 
AR I-MULTIPLE 
) I-MULTIPLE 
heterojunction O 
resulting O 
in O 
the O 
high O 
separation O 
efficiency O 
of O 
photoinduced O 
electron O 
- O 
hole O 
pairs O 
, O 
as O 
evidenced O 
by O 
photoluminescence O 
( O 
PL O 
) O 
and O 
surface O 
photovoltage O 
spectra O 
( O 
SPS O 
) O 
. O 

of O 
sodium B-SYSTEMATIC 
caseinate O 
concentration O 
and O 
storage O 
conditions O 
on O 
the O 
oxidative O 
stability O 
of O 
oil O 
- O 
in O 
- O 
water O 
emulsions O 
. O 

oxidative O 
stability O 
of O 
various O 
oils O 
( O 
sunflower O 
, O 
camelina O 
and O 
fish O 
) O 
and O 
20% O 
oil O 
- O 
in O 
- O 
water O 
( O 
O O 
/ O 
W O 
) O 
emulsions O 
, O 
were O 
examined O 
. O 
The O 
mean O 
particle O 
size O 
decreased O 
from O 
1179 O 
to O 
325 O 
nm O 
as O 
sodium B-SYSTEMATIC 
caseinate O 
( O 
emulsifier O 
) O 
concentration O 
was O 
increased O 
from O 
0.25% O 
to O 
3% O 
in O 
O O 
/ O 
W O 
emulsions O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Increasing O 
the O 
microfluidisation O 
pressure O 
from O 
21 O 
to O 
138 O 
MPa O 
, O 
resulted O 
in O 
a O 
particle O 
size O 
decrease O 
from O 
289 O 
to O 
194 O 
nm O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Emulsified O 
oils O 
had O 
lower O 
detectable O 
lipid O 
hydroperoxide B-FAMILY 
and O 
p-Anisidine B-TRIVIAL 
values O 
than O 
their O 
corresponding O 
bulk O 
oils O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
lipid O 
hydroperoxide B-FAMILY 
and O 
p-Anisidine B-TRIVIAL 
values O 
of O 
emulsions O 
generally O 
decreased O 
as O 
sodium B-SYSTEMATIC 
caseinate O 
concentration O 
increased O 
, O 
and O 
similarly O 
decreased O 
as O 
microfluidisation O 
pressure O 
increased O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Increasing O 
storage O 
temperature O 
of O 
the O 
emulsions O 
from O 
5 O 
to O 
60°C O 
, O 
resulted O 
in O 
lower O 
detectable O 
lipid O 
oxidation O 
products O 
during O 
storage O 
( O 
P O 
< O 
0.05 O 
) O 
. O 

expression O 
of O 
cholesterol B-TRIVIAL 
transport O 
- O 
related O 
proteins O 
and O 
inflammation O 
markers O 
through O 
the O 
induction O 
of O 
7-ketosterol B-FAMILY 
-mediated O 
stress O 
in O 
Caco-2 O 
cells O 
. O 

diets O 
contain O 
sterol B-FAMILY 
oxidation O 
products O 
that O 
can O 
induce O 
cytotoxic O 
effects O 
, O 
mainly O 
caused O 
by O 
cholesterol B-FAMILY 
oxides I-FAMILY 
. O 
However O 
, O 
phytosterol B-FAMILY 
oxides I-FAMILY 
effects O 
have O 
been O 
less O 
extensively O 
investigated O 
. O 
This O 
study O 
evaluates O 
the O 
production O 
of O 
inflammatory O 
biomarkers O 
( O 
IL-1β O 
, O 
IL-8 O 
, O 
IL-10 O 
, O 
TNFα O 
) O 
and O 
the O 
influence O 
of O 
gene O 
expression O 
transporters O 
and O 
enzymes O 
related O 
to O 
cholesterol B-TRIVIAL 
absorption O 
and O 
metabolism O 
( O 
NPC1L1 O 
, O 
ABCG5 O 
/ O 
8 O 
, O 
HMGCoA B-TRIVIAL 
, O 
ACAT O 
) O 
produced O 
by O 
7-ketosterols B-FAMILY 
( O 
stigmasterol B-TRIVIAL 
/ O 
cholesterol B-TRIVIAL 
) O 
in O 
Caco-2 O 
cells O 
. O 
These O 
effects O 
were O 
linked O 
to O 
intracellular O 
signaling O 
pathways O 
by O 
using O 
several O 
inhibitors O 
. O 
Results O 
showed O 
7-ketostigmasterol B-SYSTEMATIC 
to O 
have O 
a O 
greater O 
proinflammatory O 
potential O 
than O 
7-ketocholesterol B-SYSTEMATIC 
. O 
In O 
non-pre O 
- O 
treated O 
cells O 
, O 
only O 
efflux O 
transporters O 
were O 
down O 
- O 
regulated O 
by O 
7-ketosterols B-FAMILY 
, O 
showing O 
a O 
greater O 
influence O 
upon O 
ABCG5 O 
expression O 
. O 
Cell O 
- O 
pre O 
- O 
incubation O 
with O 
bradykinin B-TRIVIAL 
induced O 
changes O 
in O 
ABCG O 
expression O 
levels O 
after O 
7-ketostigmasterol B-SYSTEMATIC 
-incubation O 
; O 
however O 
, O 
the O 
energetic O 
metabolism O 
inhibition O 
reduced O 
NPC1L1 O 
expression O 
only O 
in O 
7-ketocholesterol B-SYSTEMATIC 
-incubated O 
cells O 
. O 
In O 
non-pre O 
- O 
treated O 
cells O 
, O 
HMG-CoA B-ABBREVIATION 
was O 
up O 
- O 
regulated O 
by O 
both O 
7-ketosterols B-FAMILY 
. O 
However O 
, O 
exposure O 
to O 
inhibitors O 
down O 
- O 
regulated O 
the O 
expression O 
levels O 
, O 
mainly O 
in O 
7-ketocholesterol B-SYSTEMATIC 
-incubated O 
cells O 
. O 
While O 
ACAT O 
expression O 
values O 
in O 
non-pre O 
- O 
treated O 
cells O 
were O 
unchanged O 
, O 
exposure O 
to O 
inhibitors O 
caused O 
down O 
- O 
regulation O 
of O 
mRNA O 
levels O 
. O 
These O 
results O 
suggest O 
that O 
internalization O 
and O 
excretion O 
of O 
7-ketostigmasterol B-SYSTEMATIC 
is O 
probably O 
influenced O 
by O 
[ O 
Ca B-FORMULA 
]i O 
, O 
which O 
also O 
could O 
mediate O 
HMGCoA B-TRIVIAL 
activity O 
in O 
POPs O 
metabolism O 
. O 
However O 
, O 
energetic O 
metabolism O 
and O 
reducing O 
equivalents O 
exert O 
different O 
influences O 
upon O 
the O 
7-ketosterol B-FAMILY 
internalization O 
. O 

Val158Met O 
modulates O 
subjective O 
responses O 
to O 
intravenous O 
nicotine B-TRIVIAL 
and O 
cognitive O 
performance O 
in O 
abstinent O 
smokers O 
. O 

catechol B-TRIVIAL 
- O 
O B-FORMULA 
-methyltransferase O 
( O 
COMT O 
) O 
Val158Met O 
polymorphism O 
may O 
be O 
a O 
risk O 
factor O 
for O 
nicotine B-TRIVIAL 
addiction O 
. O 
This O 
study O 
examined O 
the O 
influence O 
of O 
the O 
COMT O 
Val158Met O 
polymorphism O 
on O 
subjective O 
, O 
physiological O 
and O 
cognitive O 
effects O 
of O 
intravenous O 
(IV) O 
nicotine B-TRIVIAL 
use O 
in O 
African O 
Americans O 
( O 
AAs O 
; O 
n=56 O 
) O 
and O 
European O 
Americans O 
( O 
EAs O 
; O 
n=68 O 
) O 
smokers O 
. O 
Overnight O 
abstinent O 
smokers O 
received O 
saline O 
followed O 
by O 
0.5 O 
and O 
1 O 
mg O 
per O 
70 O 
kg O 
doses O 
of O 
nicotine B-TRIVIAL 
, O 
administered O 
30 O 
min O 
apart O 
. O 
Smokers O 
with O 
valine B-TRIVIAL 
( O 
Val B-ABBREVIATION 
)/ O 
Val B-ABBREVIATION 
genotype O 
, O 
compared O 
with O 
methionine B-TRIVIAL 
( O 
Met B-FORMULA 
) O 
carriers O 
, O 
had O 
greater O 
negative O 
subjective O 
effects O 
from O 
IV O 
nicotine B-TRIVIAL 
and O 
had O 
more O 
severe O 
withdrawal O 
severity O 
following O 
overnight O 
abstinence O 
from O 
smoking O 
. O 
Women O 
with O 
Val B-ABBREVIATION 
/ O 
Val B-ABBREVIATION 
genotype O 
reported O 
greater O 
difficulty O 
concentrating O 
and O 
irritability O 
than O 
men O 
with O 
Val B-ABBREVIATION 
/ O 
Val B-ABBREVIATION 
or O 
Met B-FORMULA 
carrier O 
genotypes O 
. O 
The O 
Val B-ABBREVIATION 
/ O 
Val B-ABBREVIATION 
genotype O 
was O 
associated O 
with O 
better O 
performance O 
on O 
the O 
math O 
task O 
and O 
in O 
AA O 
smokers O 
it O 
was O 
associated O 
with O 
greater O 
systolic O 
blood O 
pressure O 
. O 
These O 
results O 
support O 
the O 
rationale O 
of O 
pharmacologically O 
inhibiting O 
COMT O 
to O 
aid O 
with O 
smoking O 
cessation O 
among O 
Val B-ABBREVIATION 
/ O 
Val B-ABBREVIATION 
genotype O 
smokers.The O 
Pharmacogenomics O 
Journal O 
advance O 
online O 
publication O 
, O 
5 O 
March O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
tpj.2013.1 O 
. O 

-type O 
depsides O 
from O 
the O 
lichen O 
Thamnolia O 
vermicularis O 
. O 

phytochemical O 
investigation O 
of O 
a O 
herb O 
tea O 
made O 
from O 
Thamnolia O 
vermicularis O 
led O 
to O 
the O 
isolation O 
of O 
three O 
new O 
β-orcinol B-TRIVIAL 
-type O 
depsides B-FAMILY 
( O 
1 O 
, O 
2 O 
and O 
3 O 
) O 
, O 
along O 
with O 
seven O 
known O 
compounds O 
hypothamnolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
4 O 
) O 
, O 
3'-methylevenic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
baeomycesic B-TRIVIAL 
acid I-TRIVIAL 
( O 
6 O 
) O 
, O 
squamatic B-TRIVIAL 
acid I-TRIVIAL 
( O 
7 O 
) O 
, O 
methyl B-SYSTEMATIC 
3'-methyllecanorate I-SYSTEMATIC 
( O 
8 O 
) O 
, O 
barbatinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
9 O 
) O 
and O 
atranorin B-TRIVIAL 
( O 
10 O 
) O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
determined O 
on O 
the O 
basis O 
of O 
spectroscopic O 
evidence O 
, O 
including O 
1-D O 
and O 
2-D O 
NMR O 
and O 
ESI-MS O 
techniques O 
. O 

acid I-TRIVIAL 
, O 
a O 
new O 
cytotoxic O 
and O 
antifungal O 
hopene B-TRIVIAL 
- O 
triterpenoid B-FAMILY 
from O 
Zehneria O 
scabra O 
camerunensis O 
. O 

new O 
hopene B-TRIVIAL 
-type O 
triterpenoid B-FAMILY 
, O 
namely O 
sonhafouonic B-TRIVIAL 
acid I-TRIVIAL 
1a O 
was O 
isolated O 
from O 
Zehneria O 
scabra O 
camerunensis O 
, O 
together O 
with O 
eight O 
known O 
compounds O 
. O 
The O 
structure O 
of O 
1a O 
was O 
established O 
by O 
extensive O 
NMR O 
and O 
high O 
resolution O 
MS O 
techniques O 
and O 
confirmed O 
by O 
single O 
- O 
crystal O 
X-ray O 
crystallographic O 
analysis O 
. O 
Compound O 
1a O 
exhibited O 
inhibitory O 
activity O 
against O 
mycelial O 
growth O 
of O 
two O 
peronosporomycete O 
phytopathogens O 
Pythium O 
ultimum O 
and O 
Aphanomyces O 
cochliodes O 
and O 
cytotoxicity O 
towards O 
brine O 
shrimp O 
larvae O 
( O 
Artemia O 
salina O 
) O 
at O 
10 O 
μg O 
/ O 
mL O 
. O 

50% O 
of O 
melanomas O 
depend O 
on O 
mutant O 
B-RAF O 
for O 
proliferation O 
, O 
metastasis O 
and O 
survival O 
. O 
The O 
inhibition O 
of O 
oncogenic O 
B-RAF O 
with O 
highly O 
targeted O 
compounds O 
has O 
produced O 
remarkable O 
albeit O 
short O 
- O 
lived O 
clinical O 
responses O 
in O 
B-RAF O 
mutant O 
melanoma O 
patients O 
. O 
Reactivation O 
of O 
signaling O 
downstream O 
of O 
B-RAF O 
is O 
frequently O 
associated O 
with O 
acquired O 
resistance O 
to O 
B-RAF O 
inhibitors O 
, O 
and O 
the O 
identification O 
of O 
B-RAF O 
targets O 
may O 
provide O 
new O 
strategies O 
for O 
managing O 
melanoma O 
. O 
Oncogenic O 
B-RAF(V600E) O 
is O 
known O 
to O 
promote O 
the O 
stabilizing O 
phosphorylation O 
of O 
the O 
anti-apoptotic O 
protein O 
Mcl-1 O 
, O 
implicated O 
in O 
melanoma O 
survival O 
and O 
chemoresistance O 
. O 
We O 
now O 
show O 
that O 
B-RAF(V600E) O 
signaling O 
also O 
induces O 
the O 
transcription O 
of O 
Mcl-1 O 
in O 
melanocytes O 
and O 
melanoma O 
. O 
We O 
demonstrate O 
that O 
activation O 
of O 
STAT3 O 
serine B-TRIVIAL 
-727 O 
and O 
tyrosine B-TRIVIAL 
-705 O 
phosphorylations O 
is O 
promoted O 
by O 
B-RAF(V600E) O 
activity O 
and O 
that O 
the O 
Mcl-1 O 
promoter O 
is O 
dependent O 
on O 
a O 
STAT O 
consensus O 
- O 
site O 
for O 
B-RAF O 
- O 
mediated O 
activation O 
. O 
Consequently O 
, O 
suppression O 
of O 
STAT3 O 
activity O 
disrupted O 
B-RAF(V600E) O 
- O 
mediated O 
induction O 
of O 
Mcl-1 O 
and O 
reduced O 
melanoma O 
cell O 
survival O 
. O 
We O 
propose O 
that O 
STAT3 O 
has O 
a O 
central O 
role O 
in O 
the O 
survival O 
and O 
contributes O 
to O 
chemoresistance O 
of O 
B-RAF(V600E) O 
melanoma.Oncogene O 
advance O 
online O 
publication O 
, O 
4 O 
March O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
onc.2013.45 O 
. O 

( O 
Citrus O 
grandis O 
L O 
. O 
Osbeck O 
) O 
is O 
a O 
native O 
fruit O 
of O 
great O 
economic O 
importance O 
in O 
Southeast O 
Asia O 
. O 
To O 
provide O 
experimental O 
evidence O 
for O 
the O 
antioxidant O 
and O 
antihyperlipidemic O 
properties O 
of O 
pomelo O 
, O 
6 O 
cultivars O 
, O 
including O 
Kao-Yai O 
( O 
KY O 
) O 
, O 
Thong O 
- O 
dee O 
( O 
TD O 
) O 
, O 
Kao-Tangkwa O 
( O 
KT O 
) O 
, O 
Kao-Numpueng O 
( O 
KN O 
) O 
, O 
Ta-Koi O 
( O 
TK O 
) O 
, O 
and O 
Tubtim O 
Siam O 
( O 
TS O 
) O 
were O 
evaluated O 
. O 
KY O 
had O 
the O 
highest O 
phenolic B-FAMILY 
content O 
, O 
and O 
the O 
strongest O 
1,1-diphenyl-2-pireyhydrazyl B-SYSTEMATIC 
radical O 
scavenging O 
capacity O 
and O 
hydroxyl B-SYSTEMATIC 
radical O 
scavenging O 
activity O 
. O 
From O 
the O 
high O 
- O 
performance O 
liquid O 
chromatography O 
analysis O 
, O 
naringin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
were O 
the O 
major O 
flavonoids B-FAMILY 
in O 
the O 
KT O 
and O 
TK O 
cultivars O 
. O 
Six O 
pomelo O 
cultivars O 
had O 
antihyperlipidemic O 
activities O 
including O 
the O 
inhibition O 
of O 
pancreatic O 
lipase O 
and O 
cholesterol B-TRIVIAL 
esterase O 
, O 
as O 
well O 
as O 
cholesterol B-TRIVIAL 
micelle O 
formation O 
and O 
bile B-FAMILY 
acid I-FAMILY 
binding O 
. O 
Hierarchical O 
clustering O 
analysis O 
showed O 
that O 
the O 
6 O 
cultivars O 
were O 
separated O 
into O 
2 O 
classifications O 
. O 
In O 
addition O 
, O 
the O 
total O 
phenolics B-FAMILY 
of O 
the O 
pomelo O 
cultivars O 
were O 
significantly O 
correlated O 
with O 
ferric B-SYSTEMATIC 
reducing O 
antioxidant O 
power O 
and O 
Trolox B-TRIVIAL 
equivalent O 
antioxidant O 
capacity O 
. O 
The O 
results O 
suggest O 
that O 
pomelo O 
provides O 
significant O 
health O 
benefits O 
and O 
may O 
be O 
used O 
for O 
developing O 
functional O 
foods O 
. O 

structural O 
and O 
functional O 
studies O 
of O 
4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile B-SYSTEMATIC 
CDK9 O 
inhibitors O 
suggest O 
the O 
basis O 
for O 
isotype O 
selectivity O 
. O 

- O 
dependent O 
kinase O 
9 O 
/ O 
cyclin O 
T O 
, O 
the O 
protein O 
kinase O 
heterodimer O 
that O 
constitutes O 
positive O 
transcription O 
elongation O 
factor O 
b O 
, O 
is O 
a O 
well O 
- O 
validated O 
target O 
for O 
treatment O 
of O 
several O 
diseases O 
, O 
including O 
cancer O 
and O 
cardiac O 
hypertrophy O 
. O 
In O 
order O 
to O 
aid O 
inhibitor O 
design O 
and O 
rationalize O 
the O 
basis O 
for O 
CDK9 O 
selectivity O 
, O 
we O 
have O 
studied O 
the O 
CDK O 
- O 
binding O 
properties O 
of O 
six O 
different O 
members O 
of O 
a O 
4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile B-SYSTEMATIC 
series O 
that O 
bind O 
to O 
both O 
CDK9 O 
/ O 
cyclin O 
T O 
and O 
CDK2 O 
/ O 
cyclin O 
A O 
. O 
We O 
find O 
that O 
for O 
a O 
given O 
CDK O 
, O 
the O 
melting O 
temperature O 
of O 
a O 
CDK O 
/ O 
cyclin O 
/ O 
inhibitor O 
complex O 
correlates O 
well O 
with O 
inhibitor O 
potency O 
, O 
suggesting O 
that O 
differential O 
scanning O 
fluorimetry O 
( O 
DSF O 
) O 
is O 
a O 
useful O 
orthogonal O 
measure O 
of O 
inhibitory O 
activity O 
for O 
this O 
series O 
. O 
We O 
have O 
used O 
DSF O 
to O 
demonstrate O 
that O 
the O 
binding O 
of O 
these O 
compounds O 
is O 
independent O 
of O 
the O 
presence O 
or O 
absence O 
of O 
the O 
C B-FORMULA 
-terminal O 
tail O 
region O 
of O 
CDK9 O 
, O 
unlike O 
the O 
binding O 
of O 
the O 
CDK9-selective O 
inhibitor O 
5,6-dichlorobenzimidazone-1-β-d-ribofuranoside B-SYSTEMATIC 
( O 
DRB B-ABBREVIATION 
) O 
. O 
Finally O 
, O 
on O 
the O 
basis O 
of O 
11 O 
cocrystal O 
structures O 
bound O 
to O 
CDK9 O 
/ O 
cyclin O 
T O 
or O 
CDK2 O 
/ O 
cyclin O 
A O 
, O 
we O 
conclude O 
that O 
selective O 
inhibition O 
of O 
CDK9 O 
/ O 
cyclin O 
T O 
by O 
members O 
of O 
the O 
4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile B-SYSTEMATIC 
series O 
results O 
from O 
the O 
relative O 
malleability O 
of O 
the O 
CDK9 O 
active O 
site O 
rather O 
than O 
from O 
the O 
formation O 
of O 
specific O 
polar O 
contacts O 
. O 

induces O 
fatty O 
liver O 
in O 
mice O 
mediated O 
by O 
the O 
AMP B-ABBREVIATION 
-activated O 
kinase O 
and O 
sterol B-FAMILY 
response O 
element O 
binding O 
protein O 
pathway O 
. O 

use O 
of O 
herbal O 
medicines O 
in O 
disease O 
prevention O 
and O 
treatment O 
is O 
growing O 
rapidly O 
worldwide O 
, O 
without O 
careful O 
consideration O 
of O 
safety O 
issues O 
. O 
α-Terpineol B-TRIVIAL 
is O 
a O 
monoterpene B-FAMILY 
alcoholic B-FAMILY 
component O 
of O 
Melaleuca O 
alternifolia O 
, O 
Salvia O 
officinalis O 
and O 
Carthamus O 
tinctorius O 
that O 
is O 
used O 
widely O 
as O 
a O 
flavor O 
and O 
essential O 
oil O 
in O 
food O 
. O 
The O 
present O 
study O 
showed O 
that O 
α-terpineol B-TRIVIAL 
induces O 
fatty O 
liver O 
via O 
the O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
(AMPK)-mTOR- O 
sterol B-FAMILY 
regulatory O 
element O 
- O 
binding O 
protein-1 O 
( O 
SREBP-1 O 
) O 
pathway O 
. O 
α-Terpineol B-TRIVIAL 
-treated O 
hepatocytes O 
had O 
significantly O 
increased O 
neutral O 
lipid O 
accumulation O 
. O 
α-Terpineol B-TRIVIAL 
suppressed O 
AMPK O 
phosphorylation O 
, O 
and O 
increased O 
p70S6 O 
kinase O 
( O 
p70S6K O 
) O 
phosphorylation O 
and O 
SREBP-1 O 
activation O 
. O 
It O 
also O 
increased O 
luciferase O 
activity O 
in O 
cells O 
transfected O 
with O 
LXRE-tk-Luc O 
and O 
SRE-tk-Luc O 
. O 
Inhibition O 
of O 
mTOR O 
signaling O 
by O 
co O 
- O 
treatment O 
with O 
rapamycin B-TRIVIAL 
or O 
co O 
- O 
transfection O 
with O 
dominant O 
negative O 
p70S6K O 
blocked O 
completely O 
the O 
effects O 
of O 
α-terpineol B-TRIVIAL 
. O 
α-Terpineol B-TRIVIAL 
oral O 
administration O 
to O 
mice O 
for O 
2weeks O 
led O 
to O 
decreased O 
AMPK O 
phosphorylation O 
and O 
increased O 
SREBP-1 O 
activation O 
in O 
the O 
liver O 
, O 
followed O 
by O 
hepatic O 
lipid O 
accumulation O 
. O 
Conversely O 
, O 
rapamycin B-TRIVIAL 
co O 
- O 
treatment O 
reversed O 
α-terpineol B-TRIVIAL 
-induced O 
SREBP-1 O 
activation O 
and O 
fatty O 
liver O 
in O 
mice O 
. O 
These O 
data O 
provide O 
evidence O 
that O 
α-terpineol B-TRIVIAL 
causes O 
fatty O 
liver O 
, O 
an O 
effect O 
mediated O 
by O 
the O 
AMPK O 
/ O 
mTOR O 
/ O 
SREBP-1 O 
pathway O 
. O 

Spectroscopy O 
of O 
Quantum O 
Confined O 
States O 
in O 
a O 
Single O 
CdSe B-FORMULA 
Nanowire O 
. O 

measure O 
for O 
the O 
first O 
time O 
transient O 
absorption O 
spectra O 
of O 
individual O 
CdSe B-FORMULA 
nanowires O 
with O 
about O 
10 O 
nm O 
diameter O 
. O 
Confinement O 
of O 
the O 
carrier O 
wave O 
functions O 
leads O 
to O 
discrete O 
states O 
which O 
can O 
be O 
described O 
by O 
a O 
six O 
- O 
band O 
effective O 
mass O 
model O 
. O 
Combining O 
transient O 
absorption O 
and O 
luminescence O 
spectroscopy O 
allows O 
us O 
to O 
track O 
the O 
excitation O 
dynamics O 
in O 
the O 
visible O 
and O 
near O 
- O 
infrared O 
spectral O 
range O 
. O 
About O 
10% O 
of O 
all O 
absorbed O 
photons O 
lead O 
to O 
an O 
excitation O 
of O 
the O 
lowest O 
energy O 
state O 
. O 
Of O 
these O 
excitations O 
, O 
less O 
than O 
1% O 
lead O 
to O 
a O 
photon O 
in O 
the O 
optical O 
far O 
- O 
field O 
. O 
Almost O 
all O 
emission O 
is O 
reabsorbed O 
by O 
other O 
parts O 
of O 
the O 
nanowire O 
. O 
These O 
findings O 
might O 
explain O 
the O 
low O 
overall O 
quantum O 
efficiency O 
of O 
CdSe B-FORMULA 
nanowires O 
. O 

glycosides I-FAMILY 
from O 
the O 
bulbs O 
of O 
Fritillaria O 
meleagris O 
and O 
their O 
cytotoxic O 
activities O 
. O 

glycosides I-FAMILY 
( O 
1-18 O 
) O 
, O 
including O 
10 O 
new O 
compounds O 
( O 
1-10 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
bulbs O 
of O 
Fritillaria O 
meleagris O 
( O 
Liliaceae O 
) O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
determined O 
by O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
NMR O 
analysis O 
, O 
and O 
by O 
hydrolytic O 
cleavage O 
followed O 
by O 
spectroscopic O 
and O 
chromatographic O 
analysis O 
. O 
The O 
isolated O 
compounds O 
and O 
their O 
aglycones O 
were O 
evaluated O 
for O 
cytotoxic O 
activity O 
against O 
HL-60 O 
human O 
promyelocytic O 
leukemia O 
cells O 
and O 
A549 O 
human O 
lung O 
adenocarcinoma O 
cells O 
. O 
Morphological O 
observation O 
and O 
flow O 
cytometry O 
analysis O 
showed O 
that O 
5β-spirostanol B-FAMILY 
glycoside I-FAMILY 
( O 
2 O 
) O 
and O 
a O 
cholestane B-TRIVIAL 
derivative O 
( O 
17a O 
) O 
induced O 
apoptotic O 
cell O 
death O 
in O 
HL-60 O 
cells O 
through O 
different O 
mechanisms O 
of O 
action O 
. O 
Furthermore O 
, O 
the O 
(22R)-spirosolanol B-FAMILY 
glycoside I-FAMILY 
( O 
11 O 
) O 
selectively O 
induced O 
apoptosis O 
in O 
A549 O 
cells O 
without O 
affecting O 
the O 
caspase-3 O 
activity O 
level O 
. O 

C-M I-MULTIPLE 
, O 
eleven O 
new O 
triterpene B-FAMILY 
saponins I-FAMILY 
from O 
the O 
roots O 
of O 
Ilex O 
pubescens O 
. O 

new O 
triterpene B-FAMILY 
saponins I-FAMILY 
, O 
ilexpublesnins B-MULTIPLE 
C-M I-MULTIPLE 
( O 
1-11 O 
) O 
, O 
along O 
with O 
ten O 
known O 
analogues O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Ilex O 
pubescens O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
experiments O 
. O 
Compounds O 
1 O 
, O 
2 O 
, O 
10 O 
, O 
and O 
11 O 
contain O 
a O 
24- O 
aldehyde B-SYSTEMATIC 
, O 
which O 
is O 
rare O 
for O 
triterpene B-FAMILY 
saponins I-FAMILY 
from O 
Ilex O 
. O 
These O 
compounds O 
were O 
evaluated O 
in O 
vitro O 
for O 
their O 
cytotoxic O 
effects O 
on O 
human O 
cancer O 
cell O 
lines O 
HepG2 O 
, O 
HLE O 
, O 
BEL7402 O 
, O 
BEL7403 O 
, O 
BEL7405 O 
, O 
MCF-7 O 
, O 
and O 
HeLa O 
. O 
Among O 
them O 
, O 
only O 
compounds O 
6 O 
and O 
19 O 
showed O 
cytotoxicity O 
against O 
the O 
MCF-7 O 
cell O 
line O 
[ O 
inhibition O 
( O 
% O 
) O 
: O 
33.14 O 
and O 
34.03 O 
, O 
respectively O 
] O 
. O 

insulin O 
/ O 
IGF-1 O 
pathway O 
controls O 
a O 
number O 
of O 
physiological O 
processes O 
in O 
the O 
nematode O 
worm O 
Caenorhabditis O 
elegans O 
, O 
including O 
development O 
, O 
aging O 
and O 
stress O 
response O 
. O 
We O 
previously O 
found O 
that O 
the O 
Akt O 
/ O 
PKB O 
ortholog O 
AKT-1 O 
dampens O 
the O 
apoptotic O 
response O 
to O 
genotoxic O 
stress O 
in O 
the O 
germline O 
by O 
negatively O 
regulating O 
the O 
p53 O 
- O 
like O 
transcription O 
factor O 
CEP-1 O 
. O 
Here O 
, O 
we O 
report O 
unexpected O 
rearrangements O 
to O 
the O 
insulin O 
/ O 
IGF-1 O 
pathway O 
, O 
whereby O 
the O 
insulin O 
- O 
like O 
receptor O 
DAF-2 O 
and O 
3- O 
phosphoinositide B-FAMILY 
-dependent O 
protein O 
kinase O 
PDK-1 O 
oppose O 
AKT-1 O 
to O 
promote O 
DNA O 
damage O 
- O 
induced O 
apoptosis O 
. O 
While O 
DNA O 
damage O 
does O 
not O 
affect O 
phosphorylation O 
at O 
the O 
PDK-1 O 
site O 
Thr350 O 
/ O 
Thr308 O 
of O 
AKT-1 O 
, O 
it O 
increased O 
phosphorylation O 
at O 
Ser B-FORMULA 
517/ O 
Ser B-FORMULA 
473 O 
. O 
Although O 
ablation O 
of O 
daf-2 O 
or O 
pdk-1 O 
completely O 
suppressed O 
akt-1-dependent O 
apoptosis O 
, O 
the O 
transcriptional O 
activation O 
of O 
CEP-1 O 
was O 
unaffected O 
, O 
suggesting O 
that O 
daf-2 O 
and O 
pdk-1 O 
act O 
independently O 
or O 
downstream O 
of O 
cep-1 O 
and O 
akt-1 O 
. O 
Ablation O 
of O 
the O 
akt-1 O 
paralog O 
akt-2 O 
or O 
the O 
downstream O 
target O 
of O 
the O 
insulin O 
/ O 
IGF-1 O 
pathway O 
daf-16 O 
( O 
a O 
FOXO O 
transcription O 
factor O 
) O 
restored O 
sensitivity O 
to O 
damage O 
- O 
induced O 
apoptosis O 
in O 
daf-2 O 
and O 
pdk-1 O 
mutants O 
. O 
In O 
addition O 
, O 
daf-2 O 
and O 
pdk-1 O 
mutants O 
have O 
reduced O 
levels O 
of O 
phospho B-SYSTEMATIC 
-MPK-1 O 
/ O 
ERK O 
in O 
their O 
germ O 
cells O 
, O 
indicating O 
that O 
the O 
insulin O 
/ O 
IGF-1 O 
pathway O 
promotes O 
Ras O 
signaling O 
in O 
the O 
germline O 
. O 
Ablation O 
of O 
the O 
Ras O 
effector O 
gla-3 O 
, O 
a O 
negative O 
regulator O 
of O 
mpk-1 O 
, O 
restored O 
sensitivity O 
to O 
apoptosis O 
in O 
daf-2 O 
mutants O 
, O 
suggesting O 
that O 
gla-3 O 
acts O 
downstream O 
of O 
daf-2 O 
. O 
In O 
addition O 
, O 
the O 
hypersensitivity O 
of O 
let-60 O 
/ O 
Ras O 
gain O 
- O 
of O 
- O 
function O 
mutants O 
to O 
damage O 
- O 
induced O 
apoptosis O 
was O 
suppressed O 
to O 
wild O 
- O 
type O 
levels O 
by O 
ablation O 
of O 
daf-2 O 
. O 
Thus O 
, O 
insulin O 
/ O 
IGF-1 O 
signaling O 
selectively O 
engages O 
AKT-2 O 
/ O 
DAF-16 O 
to O 
promote O 
DNA O 
damage O 
- O 
induced O 
germ O 
cell O 
apoptosis O 
downstream O 
of O 
CEP-1 O 
through O 
the O 
Ras O 
pathway O 
. O 

Synthesis O 
of O 
Gold O 
Cubic O 
Nanoframes O 
through O 
a O 
Combination O 
of O 
Galvanic O 
Replacement O 
, O 
Gold O 
Deposition O 
, O 
and O 
Silver B-SYSTEMATIC 
Dealloying O 
. O 

facile O 
, O 
robust O 
approach O 
to O 
the O 
synthesis O 
of O 
Au B-FORMULA 
cubic O 
nanoframes O 
is O 
described O 
. O 
The O 
synthesis O 
involves O 
three O 
major O 
steps O 
: O 
1 O 
) O 
preparation O 
of O 
Au-Ag B-FORMULA 
alloyed O 
nanocages O 
using O 
a O 
galvanic O 
replacement O 
reaction O 
between O 
Ag B-FORMULA 
nanocubes O 
and O 
HAuCl4 B-FORMULA 
; O 
2 O 
) O 
deposition O 
of O 
thin O 
layers O 
of O 
pure O 
Au B-FORMULA 
onto O 
the O 
surfaces O 
of O 
the O 
nanocages O 
by O 
reducing O 
HAuCl4 B-FORMULA 
with O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
; O 
3 O 
) O 
formation O 
of O 
Au B-FORMULA 
cubic O 
nanoframes O 
through O 
a O 
dealloying O 
process O 
with O 
HAuCl4 B-FORMULA 
. O 
The O 
key O 
to O 
the O 
formation O 
of O 
Au B-FORMULA 
cubic O 
nanoframes O 
is O 
to O 
coat O 
the O 
surfaces O 
of O 
the O 
Au-Ag B-FORMULA 
nanocages O 
with O 
sufficiently O 
thick O 
layers O 
of O 
Au B-FORMULA 
before O 
they O 
are O 
dealloyed O 
. O 
The O 
Au B-FORMULA 
layer O 
could O 
prevent O 
the O 
skeleton O 
of O 
a O 
nanocage O 
from O 
being O 
fragmented O 
during O 
the O 
dealloying O 
step O 
. O 
The O 
as-prepared O 
Au B-FORMULA 
cubic O 
nanoframes O 
exhibit O 
tunable O 
localized O 
surface O 
plasmon O 
resonance O 
peaks O 
in O 
the O 
near O 
- O 
infrared O 
region O 
, O 
but O 
with O 
much O 
lower O 
Ag B-FORMULA 
content O 
as O 
compared O 
with O 
the O 
initial O 
Au-Ag B-FORMULA 
nanocages O 
. O 

EU O 
project O 
BRAFO O 
proposed O 
a O 
framework O 
for O 
risk O 
- O 
benefit O 
assessment O 
of O 
foods O 
, O 
or O 
changes O 
in O 
diet O 
, O 
that O 
present O 
both O 
potential O 
risks O 
and O 
potential O 
benefits O 
to O 
consumers O 
( O 
Hoekstra O 
et O 
al O 
. O 
, O 
2012a O 
) O 
. O 
In O 
higher O 
tiers O 
of O 
the O 
BRAFO O 
framework O 
, O 
risks O 
and O 
benefits O 
are O 
integrated O 
quantitatively O 
to O 
estimate O 
net O 
health O 
impact O 
measured O 
in O 
DALYs O 
or O 
QALYs O 
( O 
disability- O 
or O 
quality O 
- O 
adjusted O 
life O 
years O 
) O 
. O 
This O 
paper O 
describes O 
a O 
general O 
model O 
that O 
was O 
developed O 
by O 
a O 
second O 
EU O 
project O 
, O 
Qalibra O 
, O 
to O 
assist O 
users O 
in O 
conducting O 
these O 
assessments O 
. O 
Its O 
flexible O 
design O 
makes O 
it O 
applicable O 
to O 
a O 
wide O 
range O 
of O 
dietary O 
questions O 
involving O 
different O 
nutrients O 
, O 
contaminants O 
and O 
health O 
effects O 
. O 
Account O 
can O 
be O 
taken O 
of O 
variation O 
between O 
consumers O 
in O 
their O 
diets O 
and O 
also O 
other O 
characteristics O 
relevant O 
to O 
the O 
estimation O 
of O 
risk O 
and O 
benefit O 
, O 
such O 
as O 
body O 
weight O 
, O 
gender O 
and O 
age O 
. O 
Uncertainty O 
in O 
any O 
input O 
parameter O 
may O 
be O 
quantified O 
probabilistically O 
, O 
using O 
probability O 
distributions O 
, O 
or O 
deterministically O 
by O 
repeating O 
the O 
assessment O 
with O 
alternative O 
assumptions O 
. O 
Uncertainties O 
that O 
are O 
not O 
quantified O 
should O 
be O 
evaluated O 
qualitatively O 
. O 
Outputs O 
produced O 
by O 
the O 
model O 
are O 
illustrated O 
using O 
results O 
from O 
a O 
simple O 
assessment O 
of O 
fish O 
consumption O 
. O 
More O 
detailed O 
case O 
studies O 
on O 
oily O 
fish O 
and O 
phytosterols B-FAMILY 
are O 
presented O 
in O 
companion O 
papers O 
. O 
The O 
model O 
can O 
be O 
accessed O 
as O 
web O 
- O 
based O 
software O 
at O 
www.qalibra.eu O 
. O 

fibrils O 
implicated O 
in O 
numerous O 
human O 
diseases O 
are O 
thermodynamically O 
very O 
stable O 
. O 
Stringent O 
conditions O 
that O 
would O 
not O 
be O 
possible O 
in O 
a O 
physiological O 
environment O 
are O 
often O 
required O 
to O 
disrupt O 
the O 
stable O 
fibrils O 
. O 
Recently O 
, O 
there O 
is O 
increasing O 
evidence O 
that O 
small O 
molecules O 
can O 
remodel O 
amyloid O 
fibrils O 
in O 
a O 
physiologically O 
relevant O 
manner O 
. O 
In O 
order O 
to O 
investigate O 
possible O 
fibril O 
remodeling O 
mechanisms O 
using O 
this O 
approach O 
, O 
we O 
performed O 
comparative O 
studies O 
on O 
the O 
structural O 
features O 
of O 
the O 
different O 
amyloid-β O 
( O 
Aβ O 
) O 
aggregates O 
remodeled O 
from O 
Aβ O 
fibrils O 
by O 
three O 
biocompatible O 
small O 
molecules O 
: O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
; O 
brilliant B-TRIVIAL 
blue I-TRIVIAL 
G I-TRIVIAL 
; O 
and O 
erythrosine B-TRIVIAL 
B I-TRIVIAL 
. O 
Combined O 
with O 
circular O 
dichroism O 
( O 
CD O 
) O 
, O 
immuno O 
- O 
blotting O 
, O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
, O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
results O 
, O 
it O 
was O 
found O 
that O 
brilliant B-TRIVIAL 
blue I-TRIVIAL 
G I-TRIVIAL 
- O 
and O 
erythrosine B-TRIVIAL 
B I-TRIVIAL 
-treatment O 
generate O 
fragmented O 
Aβ O 
fibrils O 
and O 
protofibrils O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
incubation O 
of O 
the O 
Aβ O 
fibrils O 
with O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
perturbs O 
fibrillar O 
structure O 
, O 
leading O 
to O 
amorphous O 
Aβ O 
aggregates O 
. O 
Our O 
findings O 
provide O 
insights O 
on O 
the O 
molecular O 
mechanism O 
of O 
amyloid O 
fibril O 
formation O 
and O 
remodeling O 
and O 
also O 
illustrate O 
the O 
possibility O 
of O 
controlled O 
changes O 
in O 
biomolecule O 
nanostructures O 
. O 

of O 
the O 
cytoprotective O 
functions O 
of O 
autophagy O 
that O 
occur O 
in O 
tumor O 
cells O 
exposed O 
to O 
various O 
forms O 
of O 
chemotherapy O 
or O 
radiation O 
has O 
generated O 
intense O 
interest O 
in O 
the O 
possibility O 
that O 
pharmacological O 
interference O 
with O 
autophagy O 
could O 
provide O 
a O 
clinical O 
strategy O 
for O 
overcoming O 
therapeutic O 
resistance O 
. O 
Multiple O 
clinical O 
trials O 
are O 
currently O 
in O 
progress O 
to O 
evaluate O 
the O 
antimalarial O 
agent O 
chloroquine B-TRIVIAL 
( O 
generally O 
in O 
its O 
clinical O 
formulation O 
as O 
hydroxychloroquine B-SYSTEMATIC 
) O 
and O 
its O 
impact O 
on O 
various O 
forms O 
of O 
cancer O 
therapy O 
. O 
In O 
this O 
commentary O 
/ O 
review O 
, O 
we O 
focus O 
on O 
the O 
relatively O 
limited O 
number O 
of O 
studies O 
in O 
the O 
literature O 
where O 
chloroquine B-TRIVIAL 
has O 
been O 
tested O 
in O 
combination O 
with O 
chemotherapy O 
or O 
radiation O 
in O 
experimental O 
tumor O 
- O 
bearing O 
animal O 
models O 
. O 
We O 
also O 
present O 
recent O 
data O 
from O 
our O 
own O 
laboratories O 
, O 
in O 
cell O 
culture O 
experiments O 
as O 
well O 
as O 
in O 
vivo O 
studies O 
, O 
which O 
demonstrate O 
that O 
neither O 
chloroquine B-TRIVIAL 
nor O 
silencing O 
of O 
an O 
autophagy O 
regulatory O 
gene O 
was O 
effective O 
in O 
conferring O 
radiation O 
sensitivity O 
in O 
an O 
experimental O 
model O 
of O 
breast O 
cancer O 
. O 
The O 
capacity O 
for O 
sensitization O 
by O 
chloroquine B-TRIVIAL 
appears O 
to O 
be O 
quite O 
wide-ranging O 
, O 
with O 
dramatic O 
effects O 
for O 
some O 
drugs O 
/ O 
tumor O 
models O 
and O 
modest O 
or O 
minimal O 
effects O 
in O 
others O 
. O 
One O 
possible O 
caveat O 
is O 
that O 
, O 
with O 
only O 
a O 
few O 
exceptions O 
, O 
experiments O 
have O 
generally O 
been O 
performed O 
in O 
xenograft O 
models O 
, O 
thereby O 
eliminating O 
the O 
involvement O 
of O 
the O 
immune O 
system O 
, O 
which O 
might O 
ultimately O 
be O 
proven O 
to O 
play O 
a O 
central O 
role O 
in O 
determining O 
the O 
effectiveness O 
of O 
autophagy O 
inhibition O 
in O 
chemosensitization O 
or O 
radiosensitization O 
. O 
Nevertheless O 
, O 
a O 
careful O 
review O 
of O 
the O 
current O 
literature O 
suggests O 
that O 
caution O 
is O 
likely O 
to O 
be O 
warranted O 
in O 
translating O 
preclinical O 
findings O 
relating O 
to O 
autophagy O 
inhibition O 
as O 
an O 
adjunctive O 
therapeutic O 
strategy O 
. O 

analogues O 
with O 
second O 
- O 
generation O 
noviose B-TRIVIAL 
surrogates O 
. O 

is O 
a O 
promising O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 
Novobiocin B-TRIVIAL 
is O 
the O 
first O 
Hsp90 O 
C- O 
terminal O 
inhibitor O 
ever O 
identified O 
and O 
recent O 
structure O 
- O 
activity O 
relationship O 
studies O 
on O 
the O 
noviose B-TRIVIAL 
sugar B-FAMILY 
identified O 
several O 
commercially O 
available O 
amines B-FAMILY 
as O 
suitable O 
surrogates O 
. O 
In O 
an O 
effort O 
to O 
further O 
understand O 
this O 
region O 
of O 
the O 
molecule O 
, O 
analogues O 
containing O 
various O 
N'-amino B-SYSTEMATIC 
substituents O 
were O 
prepared O 
and O 
evaluated O 
against O 
two O 
breast O 
cancer O 
cell O 
lines O 
for O 
determination O 
of O 
their O 
efficacy O 
. O 
Compound O 
37j O 
manifested O 
the O 
most O 
potent O 
anti-proliferative O 
activity O 
from O 
these O 
studies O 
and O 
induced O 
Hsp90-dependent O 
client O 
protein O 
degradation O 
at O 
mid O 
nano O 
- O 
molar O 
concentrations O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
examine O 
the O 
relationship O 
of O 
skeletal O 
muscle O 
apoptosis O 
and O 
postmortem O 
development O 
of O 
meat O 
quality O 
. O 
Colour O 
, O 
cooking O 
loss O 
, O 
myofibril O 
fragmentation O 
index O 
( O 
MFI O 
) O 
and O 
shear O 
force O 
of O 
duck O 
breast O 
and O 
thigh O 
meat O 
postmortem O 
were O 
measured O 
, O 
and O 
changes O 
of O 
positive O 
nuclei O 
were O 
assessed O 
with O 
Terminal O 
deoxynucleotidyl B-FAMILY 
transferase O 
- O 
mediated O 
deoxyuridine B-SYSTEMATIC 
triphosphophate I-SYSTEMATIC 
nick O 
end O 
- O 
labelling O 
method O 
( O 
TUNEL O 
) O 
. O 
Correlation O 
analysis O 
revealed O 
that O 
apoptosis O 
were O 
positively O 
correlated O 
with O 
colour O 
( O 
L(*) O 
, O 
a(*) O 
and O 
b(*) O 
) O 
, O 
cooking O 
loss O 
and O 
MFI O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
while O 
it O 
is O 
negatively O 
correlated O 
with O 
shear O 
force O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Our O 
results O 
indicate O 
the O 
growing O 
level O 
of O 
duck O 
skeletal O 
muscle O 
cell O 
apoptosis O 
was O 
associated O 
with O 
the O 
postmortem O 
development O 
of O 
meat O 
quality O 
traits O 
such O 
as O 
meat O 
colour O 
, O 
water O 
holding O 
capacity O 
and O 
tenderness O 
. O 

acid I-FAMILY 
composition O 
, O 
antinutrients O 
and O 
allergens O 
in O 
the O 
peanut O 
protein O 
fraction O 
obtained O 
by O 
an O 
aqueous O 
enzymatic O 
process O 
. O 

- O 
assisted O 
aqueous O 
extraction O 
( O 
EAE O 
) O 
of O 
peanut O 
kernel O 
was O 
used O 
to O 
extract O 
oil O 
and O 
protein O 
. O 
The O 
aqueous O 
fraction O 
( O 
AF O 
) O 
obtained O 
by O 
EAE O 
had O 
a O 
better O 
essential O 
amino B-FAMILY 
acid I-FAMILY 
profile O 
than O 
the O 
residues O 
obtained O 
by O 
solvent O 
extraction O 
( O 
Rs O 
) O 
and O 
cold O 
pressing O 
( O 
Rc O 
) O 
. O 
No O 
major O 
difference O 
in O 
the O 
trypsin O 
inhibitor O 
activity O 
among O 
AF O 
, O 
Rs O 
and O 
Rc O 
was O 
observed O 
; O 
however O 
, O 
the O 
trypsin O 
inhibitor O 
activity O 
was O 
drastically O 
reduced O 
in O 
the O 
residue O 
obtained O 
after O 
EAE O 
. O 
AF O 
was O 
subjected O 
to O 
MALDI-TOF O 
/ O 
MS O 
, O 
revealing O 
it O 
to O 
be O 
rich O 
in O 
peptides O 
( O 
107 O 
) O 
with O 
molecular O 
masses O 
from O 
m O 
/ O 
z O 
700 O 
to O 
2369Da O 
. O 
AF O 
had O 
an O 
extremely O 
low O 
phytate B-TRIVIAL 
content O 
and O 
was O 
rich O 
in O 
peptides O 
, O 
which O 
could O 
be O 
used O 
as O 
a O 
food O 
supplement O 
. O 
ESI-MS O 
/ O 
MS O 
data O 
were O 
used O 
for O 
the O 
identification O 
of O 
major O 
peanut O 
allergens O 
, O 
viz O 
. O 
, O 
Ara O 
h1 O 
, O 
h3 O 
, O 
h6-8 O 
. O 
Their O 
allergenic O 
potential O 
needs O 
to O 
be O 
established O 
. O 

and O 
Modulation O 
of O 
Cancer O 
- O 
Related O 
Signaling O 
by O 
(Z)- B-MULTIPLE 
and I-MULTIPLE 
(E)-3,4,3',5'-Tetramethoxystilbene I-MULTIPLE 
Isolated O 
from O 
Eugenia O 
rigida O 
. O 

- O 
guided O 
fractionation O 
of O 
the O 
leaves O 
of O 
Eugenia O 
rigida O 
yielded O 
three O 
stilbenes B-FAMILY 
, O 
(Z)-3,4,3',5'-tetramethoxystilbene B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(E)-3,4,3',5'-tetramethoxystilbene B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
(E)-3,5,4'-trimethoxystilbene B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
Their O 
structures O 
were O 
determined O 
using O 
1D- O 
and O 
2D-NMR O 
spectroscopy O 
and O 
HRESIMS O 
. O 
The O 
sterically O 
hindered O 
Z-stereoisomer O 
1 O 
, O 
a O 
new O 
natural O 
product O 
, O 
was O 
prepared O 
by O 
time O 
- O 
dependent O 
photoisomerization O 
of O 
the O 
E- O 
isomer O 
( O 
2 O 
) O 
under O 
UV O 
irradiation O 
at O 
λ254 O 
nm O 
, O 
while O 
2,3,5,7-tetramethoxyphenanthrene B-SYSTEMATIC 
( O 
5 O 
) O 
was O 
identified O 
at O 
λ365 O 
nm O 
by O 
UHPLC O 
/ O 
APCI-MS O 
and O 
NMR O 
spectroscopy O 
. O 
Compounds O 
1-3 O 
were O 
tested O 
against O 
a O 
panel O 
of O 
luciferase O 
reporter O 
gene O 
assays O 
that O 
assess O 
the O 
activity O 
of O 
many O 
cancer O 
- O 
related O 
signaling O 
pathways O 
, O 
and O 
the O 
Z- O 
isomer O 
( O 
1 O 
) O 
was O 
found O 
to O 
be O 
more O 
potent O 
than O 
the O 
E- O 
isomer O 
( O 
2 O 
) O 
in O 
inhibiting O 
the O 
activation O 
of O 
Stat3 O 
, O 
Smad3 O 
/ O 
4 O 
, O 
myc O 
, O 
Ets O 
, O 
Notch O 
, O 
and O 
Wnt O 
signaling O 
, O 
with O 
IC50 O 
values O 
between O 
40 O 
and O 
80 O 
μM O 
. O 
However O 
, O 
both O 
compounds O 
showed O 
similar O 
inhibition O 
against O 
Ap-1 O 
and O 
NF-κB O 
signaling O 
. O 
In O 
addition O 
, O 
1 O 
demonstrated O 
cytotoxic O 
activity O 
toward O 
human O 
leukemia O 
cells O 
, O 
solid O 
tumor O 
cells O 
of O 
epidermal O 
, O 
breast O 
, O 
and O 
cervical O 
carcinomas O 
, O 
and O 
skin O 
melanoma O 
, O 
with O 
IC50 O 
values O 
between O 
3.6 O 
and O 
4.3 O 
μM O 
, O 
while O 
2 O 
was O 
weakly O 
active O 
against O 
leukemia O 
, O 
cervical O 
carcinoma O 
, O 
and O 
skin O 
melanoma O 
cells O 
. O 
Interestingly O 
, O 
2 O 
showed O 
antioxidant O 
activity O 
by O 
inhibition O 
of O 
ROS O 
generation O 
to O 
50% O 
at O 
33.3 O 
μM O 
in O 
PMA B-ABBREVIATION 
-induced O 
HL-60 O 
cells O 
, O 
while O 
1 O 
was O 
inactive O 
at O 
100 O 
μM O 
( O 
vs O 
Trolox B-TRIVIAL 
1.4 O 
μM O 
) O 
. O 

free O 
radical O 
scavenging O 
, O 
bactericidal O 
, O 
fungicidal O 
and O 
leishmanicidal O 
properties O 
of O 
Teucrium O 
stocksianum O 
. O 

the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
pharmacological O 
and O 
toxicological O 
effects O 
of O 
Teucrium O 
stocksianum O 
. O 
The O 
crude O 
extract O 
of O 
T O 
. O 
stocksianum O 
( O 
Ts.Cr O 
) O 
and O 
its O 
subsequent O 
organic O 
fractions O 
: O 
n-hexane B-SYSTEMATIC 
( O 
Ts O 
. O 
Hex B-ABBREVIATION 
) O 
, O 
chloroform B-TRIVIAL 
( O 
Ts O 
. O 
CHCl3 B-FORMULA 
) O 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
Ts O 
. O 
EtAc B-FORMULA 
) O 
exhibited O 
1,1-diphenyl,2-picrylhydrazyl B-SYSTEMATIC 
free O 
radical O 
scavenging O 
activity O 
with O 
different O 
potencies O 
. O 
Ts O 
. O 
EtAc B-FORMULA 
was O 
found O 
to O 
be O 
most O 
potent O 
. O 
Ts.Cr O 
, O 
Ts O 
. O 
Hex B-ABBREVIATION 
, O 
Ts O 
. O 
CHCl3 B-FORMULA 
and O 
Ts O 
. O 
EtAc B-FORMULA 
showed O 
significant O 
bactericidal O 
activity O 
against O 
Escherichia O 
coli O 
, O 
Staphylococcus O 
aureus O 
, O 
Salmonella O 
typhi O 
, O 
Shigella O 
flexneri O 
and O 
Bacillus O 
subtilis O 
at O 
their O 
extent O 
. O 
Ts.Cr O 
, O 
Ts O 
. O 
Hex B-ABBREVIATION 
, O 
Ts O 
. O 
CHCl3 B-FORMULA 
and O 
Ts O 
. O 
EtAc B-FORMULA 
displayed O 
fungicidal O 
action O 
against O 
Aspergillus O 
niger O 
, O 
Aspergillus O 
flavus O 
, O 
Aspergillus O 
fumigatus O 
and O 
Fusarium O 
solani O 
at O 
various O 
minimum O 
inhibitory O 
concentrations O 
. O 
Ts.Cr O 
and O 
Ts O 
. O 
EtAc B-FORMULA 
exhibited O 
marked O 
inhibition O 
of O 
Leishmania O 
tropica O 
growth O 
, O 
observed O 
after O 
48 O 
and O 
96 O 
hrs O 
of O 
treatment O 
. O 
These O 
data O 
indicate O 
that O 
the O 
T O 
. O 
stocksianum O 
methanolic O 
extract O 
and O 
its O 
resultant O 
fractions O 
possess O 
antioxidant O 
, O 
antibacterial O 
, O 
antifungal O 
and O 
antileishmanial O 
activities O 
. O 
Thus O 
, O 
the O 
present O 
research O 
unearths O 
the O 
scientific O 
base O 
for O 
T O 
. O 
stocksianum O 
medicinal O 
application O 
as O 
antioxidant O 
and O 
antimicrobial O 
agents O 
. O 

and O 
pharmacodynamic O 
modeling O 
of O 
hedgehog O 
inhibitor O 
TAK-441 B-IDENTIFIER 
for O 
the O 
inhibition O 
of O 
Gli1 O 
messenger O 
RNA O 
expression O 
and O 
antitumor O 
efficacy O 
in O 
xenografted O 
tumor O 
model O 
mice O 
. O 

( O 
TAK-441 B-IDENTIFIER 
) O 
is O 
a O 
potent O 
, O 
selective O 
hedgehog O 
signaling O 
pathway O 
inhibitor O 
that O 
binds O 
to O 
Smo O 
and O 
is O 
being O 
developed O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 
The O 
objectives O 
of O 
these O 
studies O 
were O 
to O 
explore O 
the O 
possibility O 
of O 
establishing O 
of O 
a O 
link O 
between O 
the O 
pharmacokinetics O 
of O 
TAK-441 B-IDENTIFIER 
and O 
the O 
responses O 
of O 
Gli1 O 
mRNA O 
in O 
tumor O 
- O 
associated O 
stromal O 
or O 
skin O 
cells O 
and O 
the O 
antitumor O 
effect O 
of O 
hedgehog O 
inhibition O 
. O 
To O 
this O 
end O 
, O 
we O 
built O 
pharmacokinetic O 
and O 
pharmacodynamic O 
models O 
that O 
describe O 
the O 
relationship O 
of O 
the O 
concentrations O 
of O 
TAK-441 B-IDENTIFIER 
plasma O 
to O 
the O 
responses O 
of O 
Gli1 O 
mRNA O 
in O 
the O 
tumor O 
( O 
target O 
) O 
and O 
skin O 
( O 
surrogate O 
) O 
and O 
to O 
tumor O 
growth O 
inhibition O 
in O 
mice O 
bearing O 
xenografts O 
of O 
human O 
pancreatic O 
tumors O 
( O 
PAN-04 O 
) O 
. O 
The O 
responses O 
of O 
Gli1 O 
mRNA O 
and O 
tumor O 
growth O 
were O 
described O 
by O 
an O 
indirect O 
response O 
model O 
and O 
an O 
exponential O 
tumor O 
growth O 
model O 
, O 
respectively O 
. O 
The O 
IC50 O 
values O 
for O 
Gli1 O 
mRNA O 
inhibition O 
in O 
the O 
tumor O 
and O 
skin O 
by O 
TAK-441 B-IDENTIFIER 
were O 
estimated O 
to O 
be O 
0.0457 O 
and O 
0.113 O 
μg O 
/ O 
ml O 
, O 
respectively O 
. O 
The O 
IC90 O 
value O 
for O 
tumor O 
growth O 
inhibition O 
was O 
estimated O 
to O 
be O 
0.68 O 
μg O 
/ O 
ml O 
. O 
These O 
results O 
suggest O 
that O 
a O 
> O 
83% O 
inhibition O 
of O 
Gli1 O 
mRNA O 
expression O 
in O 
the O 
skin O 
or O 
a O 
> O 
94% O 
inhibition O 
of O 
Gli1 O 
mRNA O 
expression O 
in O 
the O 
tumor O 
would O 
be O 
required O 
to O 
sufficiently O 
inhibit O 
( O 
> O 
90% O 
) O 
hedgehog O 
- O 
related O 
tumor O 
growth O 
in O 
the O 
xenografted O 
model O 
mice O 
. O 
We O 
conclude O 
that O 
Gli1 O 
mRNA O 
expression O 
in O 
the O 
tumor O 
and O 
skin O 
could O 
be O 
a O 
useful O 
biomarker O 
for O 
predicting O 
the O 
antitumor O 
effect O 
of O 
hedgehog O 
inhibitors O 
. O 

3 O 
genotype O 
and O 
emotional O 
adverse O 
effects O 
of O 
osmotic O 
- O 
release O 
oral O 
system O 
methylphenidate B-SYSTEMATIC 
( O 
OROS- O 
MPH B-ABBREVIATION 
) O 
in O 
children O 
with O 
attention-deficit/ O 
hyperactivity O 
disorder O 
. O 

3 O 
( O 
NTF3 O 
) O 
has O 
been O 
studied O 
in O 
relation O 
to O 
the O 
pathophysiology O 
of O 
attention O 
- O 
deficit O 
/ O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
and O 
mood O 
disorders O 
as O 
well O 
as O 
psychostimulant O 
action O 
. O 
We O 
hypothesized O 
that O 
the O 
risk O 
of O 
an O 
emotional O 
side O 
effect O 
to O 
methylphenidate B-SYSTEMATIC 
( O 
MPH B-ABBREVIATION 
) O 
treatment O 
may O 
be O 
associated O 
with O 
NTF3 O 
genotypes O 
. O 
Ninety O 
- O 
six O 
medication-naïve O 
children O 
with O 
ADHD O 
( O 
mean O 
age O 
8.7 O 
, O 
standard O 
deviation O 
1.41 O 
years O 
, O 
79 O 
males O 
) O 
were O 
genotyped O 
and O 
treated O 
with O 
MPH B-ABBREVIATION 
. O 
At O 
baseline O 
, O 
which O 
was O 
prior O 
to O 
MPH B-ABBREVIATION 
treatment O 
, O 
and O 
after O 
two O 
weeks O 
of O 
medication O 
, O 
investigators O 
asked O 
children O 
and O 
their O 
parents O 
or O 
caregivers O 
about O 
adverse O 
events O 
using O 
a O 
symptom O 
rating O 
scale O 
. O 
ADHD O 
subjects O 
with O 
the O 
A O 
/ O 
A O 
genotype O 
at O 
the O 
NTF3 O 
rs6332 O 
polymorphism O 
showed O 
the O 
highest O 
' O 
Emotionality O 
' O 
and O 
' O 
Over O 
- O 
focus O 
/ O 
euphoria O 
' O 
factor O 
scores O 
, O 
followed O 
by O 
those O 
with O 
the O 
G O 
/ O 
A O 
genotype O 
and O 
those O 
with O 
the O 
G O 
/ O 
G O 
genotype O 
( O 
p=0.042 O 
and O 
p=0.045 O 
, O 
respectively O 
) O 
. O 
ADHD O 
subjects O 
with O 
the O 
A O 
/ O 
A O 
genotype O 
at O 
the O 
NTF3 O 
rs6332 O 
polymorphism O 
showed O 
the O 
highest O 
' O 
Proneness O 
to O 
crying O 
' O 
and O 
' O 
Nail O 
biting O 
' O 
item O 
scores O 
, O 
followed O 
by O 
those O 
with O 
the O 
G O 
/ O 
A O 
genotype O 
and O 
those O 
with O 
the O 
G O 
/ O 
G O 
genotype O 
( O 
p=0.047 O 
and O 
p=0.017 O 
, O 
respectively O 
) O 
. O 
These O 
data O 
provide O 
preliminary O 
evidence O 
that O 
genetic O 
variation O 
in O 
the O 
NTF3 O 
gene O 
is O 
related O 
to O 
susceptibility O 
to O 
emotional O 
side O 
effects O 
in O 
response O 
to O 
MPH B-ABBREVIATION 
treatment O 
in O 
Korean O 
children O 
with O 
ADHD O 
. O 

WHO O 
TobReg O 
proposed O 
mandating O 
ceilings O 
on O 
selected O 
smoke O 
constituents O 
determined O 
from O 
the O 
market O 
- O 
specific O 
median O 
of O 
nicotine B-TRIVIAL 
-normalized O 
yield O 
distributions O 
. O 
Data O 
validating O 
this O 
regulatory O 
concept O 
were O 
obtained O 
from O 
essentially O 
single O 
- O 
blend O 
surveys O 
. O 
This O 
process O 
is O 
strongly O 
impacted O 
by O 
inverse O 
correlations O 
among O 
yields O 
. O 
In O 
the O 
present O 
study O 
, O 
18 O 
priority O 
WHO O 
smoke O 
constituent O 
yields O 
( O 
nicotine B-TRIVIAL 
-normalized O 
) O 
were O 
determined O 
( O 
using O 
two O 
smoking O 
regimens O 
) O 
from O 
262 O 
commercial O 
brands O 
including O 
American O 
, O 
Virginia O 
and O 
local O 
blends O 
from O 
13 O 
countries O 
. O 
Principal O 
Component O 
Analysis O 
was O 
used O 
to O 
identify O 
yields O 
patterns O 
, O 
clustering O 
of O 
blend O 
types O 
and O 
the O 
inverse O 
correlations O 
causing O 
these O 
clusters O 
. O 
Three O 
principal O 
components O 
explain O 
about O 
75% O 
of O 
total O 
data O 
variability O 
. O 
PC1 O 
was O 
sensitive O 
to O 
the O 
relative O 
levels O 
of O 
gas- O 
and O 
particle O 
- O 
phase O 
compounds O 
. O 
PC2 O 
and O 
PC3 O 
cluster O 
American- O 
and O 
Virginia O 
- O 
blends O 
, O 
revealing O 
inverse O 
correlations O 
: O 
Nitrogen B-FAMILY 
oxides I-FAMILY 
and O 
amino B-FAMILY 
- O 
or O 
nitroso B-SYSTEMATIC 
-aromatic O 
compounds O 
inversely O 
correlate O 
to O 
either O 
formaldehyde B-SYSTEMATIC 
and O 
acrolein B-TRIVIAL 
, O 
or O 
benzo(a)pyrene B-SYSTEMATIC 
and O 
di B-FAMILY 
- I-FAMILY 
hydroxybenzenes I-FAMILY 
. O 
These O 
results O 
can O 
be O 
explained O 
by O 
reviewing O 
the O 
processes O 
determining O 
each O 
components O 
smoke O 
delivery O 
. O 
Regulatory O 
initiatives O 
simultaneously O 
targeting O 
selected O 
smoke O 
constituents O 
in O 
markets O 
with O 
mixed O 
blend O 
styles O 
will O 
be O 
strongly O 
impacted O 
by O 
the O 
inverse O 
correlations O 
described O 
. O 
It O 
is O 
difficult O 
to O 
predict O 
the O 
ultimate O 
impact O 
of O 
such O 
regulations O 
on O 
public O 
health O 
, O 
considering O 
the O 
complex O 
chemistry O 
of O 
cigarette O 
smoke O 
formation O 
. O 

phosphoproteome O 
of O 
the O 
striatum O 
from O 
pleiotrophin O 
knockout O 
and O 
midkine O 
knockout O 
mice O 
treated O 
with O 
amphetamine B-TRIVIAL 
: O 
Correlations O 
with O 
amphetamine B-TRIVIAL 
-induced O 
neurotoxicity O 
. O 

neurotrophic O 
factors O 
pleiotrophin O 
( O 
PTN O 
) O 
and O 
midkine O 
( O 
MK O 
) O 
have O 
been O 
shown O 
to O 
modulate O 
amphetamine B-TRIVIAL 
-induced O 
neurotoxicity O 
. O 
Accordingly O 
, O 
PTN- O 
/ O 
- O 
and O 
MK- O 
/ O 
- O 
mice O 
show O 
an O 
increased O 
vulnerability O 
to O 
amphetamine B-TRIVIAL 
-induced O 
neurotoxic O 
effects O 
. O 
In O 
an O 
effort O 
to O 
uncover O 
new O 
pharmacological O 
targets O 
to O 
prevent O 
amphetamine B-TRIVIAL 
neurotoxic O 
effects O 
, O 
we O 
have O 
now O 
used O 
a O 
proteomic O 
approach O 
to O 
study O 
protein O 
phosphorylation O 
, O 
in O 
which O 
we O 
combined O 
phosphoprotein O 
enrichment O 
, O 
by O 
immobilized O 
metal O 
affinity O 
chromatography O 
( O 
IMAC O 
) O 
, O 
with O 
two O 
- O 
dimensional O 
gel O 
electrophoresis O 
and O 
mass O 
spectrometry O 
, O 
in O 
order O 
to O 
identify O 
the O 
phosphoproteins O 
regulated O 
in O 
the O 
striatum O 
of O 
PTN- O 
/ O 
- O 
, O 
MK- O 
/ O 
- O 
and O 
wild O 
type O 
( O 
WT O 
) O 
mice O 
treated O 
with O 
amphetamine B-TRIVIAL 
. O 
We O 
identified O 
13 O 
differentially O 
expressed O 
phosphoproteins O 
that O 
are O 
judged O 
to O 
be O 
relevant O 
in O 
the O 
neuroprotective O 
roles O 
of O 
PTN O 
and O 
MK O 
against O 
amphetamine B-TRIVIAL 
-induced O 
neurotoxicity O 
. O 
It O 
is O 
very O 
interesting O 
to O 
note O 
that O 
4 O 
of O 
these O 
phosphoproteins O 
, O 
annexin O 
A7 O 
( O 
ANXA7 O 
) O 
, O 
COP9 O 
signalosome O 
subunit O 
5 O 
( O 
COPS5 O 
) O 
, O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
family O 
1 O 
member O 
A1 O 
( O 
ALDH1A1 O 
) O 
and O 
creatine B-TRIVIAL 
kinase O 
U O 
- O 
type O 
( O 
CKMT1 O 
) O 
, O 
are O 
known O 
to O 
be O 
involved O 
in O 
Parkinson's O 
disease O 
, O 
a O 
result O 
of O 
significant O 
importance O 
since O 
PTN O 
and O 
MK O 
have O 
been O 
also O 
demonstrated O 
to O 
limit O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
progress O 
and O 
have O 
been O 
suggested O 
to O 
be O 
among O 
the O 
important O 
genetic O 
factors O 
possibly O 
preventing O 
the O 
development O 
of O 
PD O 
in O 
methamphetamine B-TRIVIAL 
abusers O 
. O 
The O 
data O 
identify O 
phosphoproteins O 
differentially O 
regulated O 
by O 
amphetamine B-TRIVIAL 
treatment O 
and O 
/ O 
or O 
the O 
presence O 
of O 
endogenous O 
PTN O 
/ O 
MK O 
which O 
may O 
be O 
relevant O 
mediators O 
of O 
PTN O 
/ O 
MK O 
neuroprotective O 
effects O 
against O 
amphetamine B-TRIVIAL 
-induced O 
neurotoxicity O 
. O 
The O 
data O 
support O 
further O 
studies O 
to O 
validate O 
the O 
phosphoproteins O 
here O 
identified O 
as O 
possible O 
new O 
pharmacological O 
targets O 
to O 
prevent O 
amphetamine B-TRIVIAL 
neurotoxic O 
effects O 
. O 

Thyroxine B-TRIVIAL 
Absorption O 
Test O 
Followed O 
by O 
Weekly O 
Thyroxine B-TRIVIAL 
Administration O 
: O 
A O 
Method O 
to O 
Assess O 
Non-Adherence O 
to O 
Treatment O 
. O 

: O 
For O 
patients O 
, O 
who O 
remain O 
hypothyroid O 
despite O 
the O 
administration O 
of O 
what O 
would O 
seem O 
adequate O 
doses O 
of O 
levothyroxine B-TRIVIAL 
, O 
the O 
underlying O 
cause O 
can O 
be O 
difficult O 
to O 
determine O 
. O 
The O 
possibility O 
of O 
a O 
biological O 
cause O 
should O 
first O 
be O 
explored O 
; O 
however O 
, O 
in O 
the O 
majority O 
of O 
cases O 
poor O 
adherence O 
to O 
medication O 
is O 
likely O 
to O 
be O 
the O 
main O 
cause O 
of O 
treatment O 
failure O 
. O 
When O 
non-adherence O 
is O 
suspected O 
but O 
not O 
volunteered O 
, O 
options O 
to O 
confirm O 
the O 
suspicion O 
are O 
limited O 
. O 
In O 
this O 
study O 
we O 
identified O 
patients O 
for O 
whom O 
known O 
drug O 
and O 
pathological O 
causes O 
of O 
levothyroxine B-TRIVIAL 
malabsorption O 
were O 
excluded O 
and O 
despite O 
often O 
high O 
doses O 
of O 
levothyroxine B-TRIVIAL 
, O 
the O 
patients O 
remained O 
hypothyroid O 
. O 
DESIGN O 
: O 
Using O 
a O 
weight O 
- O 
determined O 
oral O 
levothyroxine B-TRIVIAL 
bolus O 
administration O 
, O 
absorption O 
was O 
initially O 
assessed O 
in O 
twenty O 
- O 
three O 
patients O 
. O 
In O 
nearly O 
all O 
patients O 
this O 
was O 
shown O 
to O 
be O 
maximal O 
at O 
120mins O 
post O 
ingestion O 
. O 
This O 
was O 
then O 
followed O 
by O 
the O 
continued O 
administration O 
of O 
a O 
weekly O 
thyroxine B-TRIVIAL 
bolus O 
for O 
a O 
four O 
- O 
week O 
period O 
after O 
which O 
TSH O 
and O 
free O 
T4 O 
levels O 
were O 
recorded O 
. O 
RESULTS O 
: O 
All O 
patients O 
showed O 
a O 
rise O 
in O 
free O 
T4 O 
at O 
120mins O 
following O 
the O 
administration O 
of O 
the O 
levothyroxine B-TRIVIAL 
bolus O 
, O 
with O 
a O 
mean O 
increase O 
of O 
54± O 
3% O 
from O 
baseline O 
. O 
Following O 
the O 
treatment O 
period O 
, O 
using O 
an O 
equivalent O 
weekly O 
levothyroxine B-TRIVIAL 
dose O 
which O 
was O 
significantly O 
less O 
than O 
that O 
of O 
the O 
daily O 
dose O 
taken O 
by O 
the O 
patients O 
before O 
the O 
test O 
, O 
the O 
TSH O 
reduced O 
from O 
baseline O 
in O 
~75% O 
of O 
cases O 
. O 
CONCLUSION O 
: O 
Using O 
this O 
combination O 
of O 
tests O 
allows O 
significant O 
malabsorptive O 
problems O 
to O 
be O 
first O 
identified O 
, O 
then O 
potential O 
non-adherence O 
to O 
be O 
demonstrated O 
. O 
A O 
management O 
plan O 
can O 
then O 
be O 
implemented O 
to O 
increase O 
adherence O 
, O 
aiming O 
to O 
improve O 
treatment O 
outcomes O 
. O 

induced O 
neuronal O 
apoptosis O 
in O 
guinea O 
pigs O 
is O 
Ca2+ B-FORMULA 
dependent O 
and O 
abrogated O 
by O 
chelation O 
therapy O 
: O 
role O 
of O 
voltage O 
gated O 
calcium B-SYSTEMATIC 
channels O 
. O 

contaminated O 
drinking O 
water O 
has O 
affected O 
more O 
than O 
200 O 
million O 
people O 
globally O 
. O 
Chronic O 
arsenicism O 
has O 
also O 
been O 
associated O 
with O 
numerous O 
neurological O 
diseases O 
. O 
One O 
of O 
the O 
prime O 
mechanisms O 
postulated O 
for O 
arsenic B-SYSTEMATIC 
toxicity O 
is O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
mediated O 
oxidative O 
stress O 
. O 
In O 
this O 
study O 
, O 
we O 
explored O 
the O 
kinetic O 
relationship O 
of O 
ROS O 
with O 
calcium B-SYSTEMATIC 
and O 
attempted O 
to O 
dissect O 
the O 
calcium B-SYSTEMATIC 
ion O 
channels O 
responsible O 
for O 
calcium B-SYSTEMATIC 
imbalance O 
after O 
arsenic B-SYSTEMATIC 
exposure O 
. O 
We O 
also O 
explored O 
if O 
mono- O 
or O 
combinational O 
chelation O 
therapy O 
prevents O 
arsenic B-SYSTEMATIC 
-induced O 
( O 
25ppm O 
in O 
drinking O 
water O 
for O 
4 O 
months O 
) O 
neuronal O 
apoptosis O 
in O 
a O 
guinea O 
pig O 
animal O 
model O 
. O 
Results O 
indicate O 
that O 
chronic O 
arsenic B-SYSTEMATIC 
exposure O 
caused O 
a O 
significant O 
increase O 
in O 
ROS O 
followed O 
by O 
NO B-FORMULA 
and O 
calcium B-SYSTEMATIC 
influx O 
. O 
This O 
calcium B-SYSTEMATIC 
influx O 
is O 
mainly O 
dependent O 
on O 
L- O 
type O 
voltage O 
gated O 
channels O 
that O 
disrupt O 
mitochondrial O 
membrane O 
potential O 
, O 
increase O 
bax O 
/ O 
bcl2 O 
levels O 
and O 
caspase O 
3 O 
activity O 
leading O 
to O 
apoptosis O 
. O 
Interestingly O 
, O 
blocking O 
of O 
ROS O 
could O 
completely O 
reduce O 
calcium B-SYSTEMATIC 
influx O 
whereas O 
calcium B-SYSTEMATIC 
blockage O 
partially O 
reduced O 
ROS O 
increase O 
. O 
While O 
in O 
general O 
mono- O 
and O 
combinational O 
chelation O 
therapies O 
were O 
effective O 
in O 
reversing O 
arsenic B-SYSTEMATIC 
induced O 
alteration O 
, O 
combinational O 
therapy O 
of O 
DMSA B-ABBREVIATION 
and O 
MiADMSA B-ABBREVIATION 
was O 
most O 
effective O 
. O 
Our O 
results O 
provide O 
evidence O 
for O 
the O 
role O 
of O 
L- O 
type O 
calcium B-SYSTEMATIC 
channels O 
in O 
regulating O 
arsenic B-SYSTEMATIC 
-induced O 
calcium B-SYSTEMATIC 
influx O 
and O 
DMSA B-ABBREVIATION 
+ O 
MiADMSA B-ABBREVIATION 
combinational O 
therapy O 
may O 
be O 
a O 
better O 
protocol O 
than O 
monotherapy O 
in O 
mitigating O 
chronic O 
arsenicosis O 
. O 

cell O 
culture O 
platforms O 
from O 
enzymatically O 
cross O 
- O 
linked O 
multifunctional O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
-based O 
hydrogels O 
. O 

stem O 
- O 
cell O 
- O 
based O 
therapies O 
rapidly O 
advance O 
toward O 
clinical O 
applications O 
, O 
there O 
is O 
a O 
need O 
for O 
cheap O 
, O 
easily O 
manufactured O 
, O 
injectable O 
gels O 
that O 
can O 
be O 
tailored O 
to O 
carry O 
stem O 
cells O 
and O 
impart O 
function O 
to O 
such O 
cells O 
. O 
Herein O 
we O 
describe O 
a O 
process O 
for O 
making O 
hydrogels O 
composed O 
of O 
hydroxyphenyl B-SYSTEMATIC 
propionic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HPA B-ABBREVIATION 
) O 
conjugated O 
, O 
branched O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
via O 
an O 
enzyme O 
mediated O 
, O 
oxidative O 
cross O 
- O 
linking O 
method O 
. O 
Functionalization O 
of O 
the O 
branched O 
PEG B-ABBREVIATION 
with O 
HPA B-ABBREVIATION 
at O 
varying O 
degrees O 
of O 
substitution O 
was O 
confirmed O 
via O 
attenuated O 
total O 
reflectance O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
ATR-FTIR O 
) O 
and O 
(1)H B-FORMULA 
NMR O 
. O 
The O 
versatility O 
of O 
this O 
hydrogel O 
system O 
was O 
exemplified O 
through O 
variations O 
in O 
the O 
degree O 
of O 
HPA B-ABBREVIATION 
substitution O 
, O 
polymer O 
concentration O 
, O 
and O 
the O 
concentration O 
of O 
cross O 
- O 
linking O 
reagents O 
( O 
horseradish O 
peroxidase O 
and O 
H(2)O(2) B-FORMULA 
) O 
, O 
which O 
resulted O 
in O 
a O 
range O 
of O 
mechanical O 
properties O 
and O 
gelation O 
kinetics O 
for O 
these O 
gels O 
. O 
Cross O 
- O 
linking O 
of O 
the O 
PEG-HPA B-ABBREVIATION 
conjugate O 
with O 
a O 
recombinantly O 
produced O 
Fibronectin O 
fragment O 
( O 
Type O 
III O 
domains O 
7-10 O 
) O 
encouraged O 
attachment O 
and O 
spreading O 
of O 
human O 
mesenchymal O 
stem O 
cells O 
( O 
hMSCs O 
) O 
when O 
assessed O 
in O 
both O 
two O 
- O 
dimensional O 
and O 
three O 
- O 
dimensional O 
formats O 
. O 
Interestingly O 
, O 
when O 
encapsulated O 
in O 
both O 
nonfunctionalized O 
and O 
functionalized O 
cross O 
- O 
linked O 
PEG-HPA B-ABBREVIATION 
gels O 
, O 
MSCs O 
showed O 
good O 
viability O 
over O 
all O 
time O 
periods O 
assessed O 
. O 
With O 
tunable O 
gelation O 
kinetics O 
and O 
mechanical O 
properties O 
, O 
these O 
hydrogels O 
provide O 
a O 
flexible O 
in O 
vitro O 
cell O 
culture O 
platform O 
that O 
will O 
likely O 
have O 
significant O 
utility O 
in O 
tissue O 
engineering O 
as O 
an O 
injectable O 
delivery O 
platform O 
for O 
cells O 
to O 
sites O 
of O 
tissue O 
damage O 
. O 

of O 
glyphosate B-TRIVIAL 
-based O 
herbicides O 
on O 
embryo O 
- O 
larval O 
development O 
and O 
metamorphosis O 
in O 
the O 
Pacific O 
oyster O 
, O 
Crassostrea O 
gigas O 
. O 

may O 
be O 
involved O 
in O 
oyster O 
summer O 
mortality O 
events O 
, O 
not O 
necessarily O 
as O 
a O 
single O 
causative O 
agent O 
but O 
as O 
an O 
additional O 
stressor O 
. O 
In O 
this O 
context O 
, O 
the O 
present O 
study O 
aimed O 
to O 
assess O 
the O 
toxicity O 
of O 
glyphosate B-TRIVIAL 
, O 
its O 
by O 
- O 
product O 
, O 
aminomethylphosphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AMPA B-ABBREVIATION 
) O 
and O 
two O 
commercial O 
formulations O 
, O 
Roundup O 
Express(®) O 
(R(EX)) O 
and O 
Roundup O 
Allées O 
et O 
Terrasses(®) O 
(R(AT)) O 
, O 
containing O 
glyphosate B-TRIVIAL 
as O 
the O 
active O 
ingredient O 
, O 
on O 
the O 
early O 
life O 
stages O 
of O 
the O 
Pacific O 
oyster O 
, O 
Crassostrea O 
gigas O 
. O 
The O 
embryotoxicity O 
of O 
these O 
chemicals O 
were O 
quantified O 
by O 
considering O 
both O 
the O 
rates O 
of O 
abnormalities O 
and O 
the O 
arrested O 
development O 
or O 
types O 
of O 
abnormalities O 
in O 
D- O 
shaped O 
larvae O 
after O 
48 O 
h O 
exposure O 
. O 
The O 
success O 
of O 
metamorphosis O 
was O 
examined O 
in O 
pediveliger O 
larvae O 
exposed O 
for O 
24 O 
h O 
. O 
Experiments O 
involving O 
both O 
endpoints O 
included O 
range O 
finding O 
experiments O 
for O 
herbicide O 
concentrations O 
ranging O 
from O 
0.1 O 
to O 
100000 O 
μg O 
L(-1) O 
. O 
This O 
range O 
was O 
then O 
narrowed O 
down O 
in O 
order O 
to O 
determine O 
precise O 
EC(50) O 
values O 
. O 
Actual O 
concentrations O 
of O 
the O 
herbicide O 
were O 
determined O 
at O 
the O 
beginning O 
and O 
after O 
48 O 
h O 
( O 
embryotoxicity O 
) O 
and O 
24 O 
h O 
( O 
metamorphosis O 
) O 
to O 
evaluate O 
the O 
potential O 
temporal O 
variation O 
in O 
the O 
concentrations O 
. O 
During O 
embryo O 
- O 
larval O 
development O 
, O 
no O 
mortalities O 
were O 
recorded O 
at O 
any O 
of O 
the O 
concentrations O 
of O 
glyphosate B-TRIVIAL 
and O 
AMPA B-ABBREVIATION 
, O 
whereas O 
no O 
embryos O 
or O 
D- O 
shaped O 
larvae O 
could O 
be O 
observed O 
after O 
exposure O 
to O 
10000 O 
μg O 
L(-1) O 
of O 
R(EX) O 
or O 
R(AT) O 
. O 
Compared O 
with O 
the O 
controls O 
, O 
no O 
effects O 
on O 
embryo O 
- O 
larval O 
development O 
were O 
recorded O 
between O 
0.1 O 
and O 
1000 O 
μg O 
L(-1) O 
, O 
regardless O 
of O 
the O 
chemical O 
tested O 
. O 
Above O 
a O 
threshold O 
, O 
which O 
varied O 
according O 
to O 
the O 
chemical O 
used O 
, O 
the O 
gradient O 
of O 
herbicide O 
concentrations O 
correlated O 
with O 
a O 
gradient O 
of O 
severity O 
of O 
abnormality O 
ranging O 
from O 
normal O 
larvae O 
to O 
arrested O 
development O 
( O 
an O 
" O 
old O 
embryo O 
" O 
stage O 
) O 
. O 
The O 
EC(50) O 
values O 
were O 
28315 O 
and O 
40617 O 
μg O 
L(-1) O 
for O 
glyphosate B-TRIVIAL 
and O 
its O 
metabolite O 
, O 
respectively O 
, O 
but O 
much O 
lowered O 
values O 
of O 
1133 O 
and O 
1675 O 
μg O 
L(-1) O 
for O 
R(EX) O 
and O 
R(AT) O 
, O 
respectively O 
. O 
Metamorphosis O 
tests O 
also O 
revealed O 
a O 
significant O 
difference O 
between O 
molecules O 
, O 
as O 
the O 
EC(50) O 
values O 
exceeded O 
100000 O 
μg O 
L(-1) O 
for O 
glyphosate B-TRIVIAL 
and O 
AMPA B-ABBREVIATION 
but O 
were O 
as O 
low O 
as O 
6366 O 
and O 
6060 O 
μg O 
L(-1) O 
for O 
the O 
commercial O 
formulations O 
, O 
which O 
appeared O 
relatively O 
more O 
toxic O 
. O 
Overall O 
, O 
the O 
embryo O 
- O 
larval O 
development O 
of O 
C O 
. O 
gigas O 
was O 
more O 
sensitive O 
to O 
glyphosate B-TRIVIAL 
-based O 
herbicides O 
compared O 
to O 
various O 
endpoints O 
studied O 
in O 
regulatory O 
model O 
organisms O 
, O 
and O 
embryos O 
and O 
D- O 
shaped O 
larvae O 
were O 
more O 
sensitive O 
compared O 
to O 
pediveliger O 
larvae O 
. O 

pyridyl B-SYSTEMATIC 
group O 
in O 
ligand O 
design O 
for O 
selective O 
metal O 
ion O 
complexation O 
and O 
sensing O 
. O 

in O 
polypyridyl B-FAMILY 
ligands O 
that O 
control O 
their O 
thermodynamic O 
metal O 
ion O 
selectivity O 
in O 
aqueous O 
solution O 
, O 
and O 
their O 
use O 
in O 
selective O 
fluorescent O 
sensing O 
, O 
are O 
examined O 
. O 
Preorganization O 
of O 
polypyridyl B-FAMILY 
ligands O 
ranging O 
from O 
bidentate O 
to O 
tetradentate O 
by O 
bridging O 
benzo B-SYSTEMATIC 
groups O 
, O 
as O 
are O 
present O 
in O 
1,10-phenanthroline B-SYSTEMATIC 
( O 
phen B-ABBREVIATION 
) O 
compared O 
to O 
2,2'-bipyridyl B-SYSTEMATIC 
( O 
bpy B-ABBREVIATION 
) O 
, O 
is O 
discussed O 
. O 
The O 
role O 
of O 
solvation O 
is O 
considered O 
in O 
relation O 
to O 
the O 
relative O 
affinity O 
of O 
ligands O 
containing O 
pyridyl B-SYSTEMATIC 
groups O 
for O 
divalent O 
and O 
trivalent O 
metal O 
ions O 
in O 
aqueous O 
solution O 
. O 
The O 
effects O 
of O 
steric O 
clashes O 
between O 
H B-FORMULA 
atoms O 
on O 
polypyridyl B-FAMILY 
ligands O 
in O 
decreasing O 
complex O 
stability O 
are O 
evaluated O 
, O 
as O 
well O 
as O 
the O 
effect O 
of O 
chelate O 
ring O 
size O 
on O 
metal O 
ion O 
selectivity O 
. O 
Phen B-ABBREVIATION 
ligands O 
with O 
other O 
donor O 
groups O 
present O 
at O 
the O 
2 O 
and O 
9 O 
positions O 
, O 
such O 
as O 
alcohols B-FAMILY 
, O 
amides B-FAMILY 
, O 
carboxylates B-FAMILY 
, O 
and O 
oximes B-FAMILY 
are O 
discussed O 
. O 
The O 
design O 
of O 
pyridyl B-SYSTEMATIC 
-based O 
ligands O 
for O 
the O 
separation O 
of O 
Am B-FORMULA 
(III) I-FORMULA 
from O 
lanthanide B-SYSTEMATIC 
(III) I-SYSTEMATIC 
ions O 
is O 
considered O 
, O 
as O 
well O 
as O 
ligands O 
for O 
the O 
removal O 
of O 
metal O 
ions O 
such O 
as O 
Cu B-FORMULA 
(II) I-FORMULA 
or O 
Zn B-FORMULA 
(II) I-FORMULA 
in O 
neurological O 
diseases O 
such O 
as O 
Alzheimer's O 
. O 
The O 
design O 
of O 
pyridyl B-SYSTEMATIC 
-based O 
fluorescent O 
sensors O 
for O 
selective O 
sensing O 
of O 
metal O 
ions O 
is O 
examined O 
in O 
terms O 
of O 
the O 
role O 
of O 
spin O 
- O 
orbit O 
coupling O 
constants O 
( O 
ζ O 
) O 
, O 
paramagnetism O 
, O 
and O 
steric O 
effects O 
in O 
the O 
development O 
of O 
selective O 
fluorescent O 
sensors O 
that O 
operate O 
via O 
chelation O 
enhanced O 
fluorescence O 
( O 
CHEF O 
) O 
. O 
It O 
is O 
concluded O 
that O 
for O 
lighter O 
metal O 
ions O 
with O 
smaller O 
ζ O 
values O 
such O 
as O 
Zn B-FORMULA 
(II) I-FORMULA 
and O 
Ca B-FORMULA 
(II) I-FORMULA 
, O 
and O 
to O 
a O 
lesser O 
extent O 
Cd B-FORMULA 
(II) I-FORMULA 
, O 
that O 
the O 
CHEF O 
effect O 
can O 
be O 
achieved O 
with O 
pyridyl B-SYSTEMATIC 
-containing O 
fluorophores O 
that O 
coordinate O 
directly O 
to O 
the O 
metal O 
ion O 
. O 
The O 
way O 
in O 
which O 
steric O 
effects O 
can O 
be O 
used O 
to O 
decrease O 
the O 
CHEF O 
effect O 
in O 
Zn B-FORMULA 
(II) I-FORMULA 
relative O 
to O 
Cd B-FORMULA 
(II) I-FORMULA 
to O 
enable O 
selective O 
sensing O 
of O 
the O 
latter O 
is O 
analyzed O 
. O 
For O 
heavier O 
metal O 
ions O 
such O 
as O 
Hg B-FORMULA 
(II) I-FORMULA 
and O 
Pb B-FORMULA 
(II) I-FORMULA 
, O 
because O 
of O 
their O 
large O 
ζ O 
values O 
which O 
quench O 
fluorescence O 
, O 
it O 
is O 
concluded O 
that O 
the O 
fluorophore O 
should O 
be O 
tethered O 
to O 
the O 
metal O 
- O 
binding O 
part O 
of O 
the O 
sensor O 
, O 
and O 
prevented O 
from O 
binding O 
to O 
the O 
metal O 
ion O 
by O 
steric O 
and O 
electronic O 
factors O 
. O 
How O 
Hg B-FORMULA 
(II) I-FORMULA 
can O 
quench O 
the O 
CHEF O 
effect O 
by O 
π-contact O 
with O 
fluorophores O 
such O 
as O 
the O 
anthracenyl B-SYSTEMATIC 
group O 
, O 
which O 
at O 
first O 
sight O 
might O 
not O 
seem O 
able O 
to O 
bond O 
with O 
metal O 
ions O 
, O 
is O 
examined O 
. O 

experience O 
( O 
BE O 
) O 
can O 
critically O 
influence O 
later O 
behavior O 
and O 
brain O 
function O 
, O 
but O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
consequences O 
of O 
most O 
developmental O 
neurotoxicants O 
are O 
examined O 
in O 
the O 
absence O 
of O 
any O 
such O 
context O 
. O 
We O 
previously O 
demonstrated O 
marked O 
differences O 
in O 
neurotransmitter O 
changes O 
produced O 
by O 
developmental O 
lead O 
( O 
Pb B-FORMULA 
) O 
exposure O 
± O 
prenatal O 
stress O 
( O 
PS O 
) O 
depending O 
upon O 
whether O 
or O 
not O 
rats O 
had O 
been O 
given O 
BE O 
( O 
Cory-Slechta O 
, O 
D O 
. O 
A O 
. O 
, O 
Virgolini O 
, O 
M O 
. O 
B O 
. O 
, O 
Rossi-George O 
, O 
A O 
. O 
, O 
Weston O 
, O 
D O 
. O 
, O 
and O 
Thiruchelvam O 
, O 
M O 
. O 
( O 
2009 O 
) O 
. O 
The O 
current O 
study O 
examined O 
the O 
hypothesis O 
that O 
the O 
nature O 
of O 
the O 
BE O 
itself O 
would O 
be O 
a O 
critical O 
determinant O 
of O 
outcome O 
in O 
mice O 
that O 
had O 
been O 
continually O 
exposed O 
to O 
0 O 
or O 
100 O 
ppm O 
Pb B-SYSTEMATIC 
acetate I-SYSTEMATIC 
in O 
drinking O 
water O 
alone O 
or O 
in O 
combination O 
with O 
prenatal O 
restraint O 
stress O 
. O 
Half O 
of O 
the O 
offspring O 
in O 
each O 
of O 
the O 
four O 
resulting O 
groups O 
/ O 
gender O 
were O 
exposed O 
to O 
positively O 
reinforced O 
( O 
food O 
- O 
rewarded O 
Fixed O 
Interval O 
schedule O 
- O 
controlled O 
behavior O 
) O 
or O 
negatively O 
reinforced O 
( O 
inescapable O 
forced O 
swim O 
) O 
BE O 
. O 
Brain O 
monoamines B-FAMILY 
and O 
amino B-FAMILY 
acids I-FAMILY 
differed O 
significantly O 
in O 
relation O 
to O 
BE O 
, O 
even O 
in O 
control O 
animals O 
, O 
as O 
did O 
the O 
trajectory O 
of O 
effects O 
of O 
Pb B-FORMULA 
± O 
PS O 
, O 
particularly O 
in O 
frontal O 
cortex O 
, O 
hippocampus O 
( O 
both O 
genders O 
) O 
, O 
and O 
midbrain O 
( O 
males O 
) O 
. O 
In O 
males O 
, O 
Pb B-FORMULA 
± O 
PS O 
- O 
related O 
changes O 
in O 
neurotransmitters O 
correlated O 
with O 
behavioral O 
performance O 
. O 
These O 
findings O 
suggest O 
that O 
CNS O 
consequences O 
of O 
developmental O 
toxicants O 
studied O 
in O 
the O 
absence O 
of O 
a O 
broader O 
spectrum O 
of O 
BEs O 
may O 
not O 
necessarily O 
be O 
predictive O 
of O 
human O 
outcomes O 
. O 
Evaluating O 
the O 
role O 
of O 
specific O 
BEs O 
as O 
a O 
modulator O 
of O 
neurodevelopmental O 
insults O 
offers O 
the O 
opportunity O 
to O 
determine O 
what O 
specific O 
BEs O 
may O 
ameliorate O 
the O 
associated O 
impacts O 
and O 
can O 
assist O 
in O 
establishing O 
underlying O 
neurobiological O 
mechanisms O 
. O 

impairs O 
fear O 
memory O 
consolidation O 
in O 
rodents O 
. O 

( O 
AZ O 
) O 
is O 
an O 
carbonic O 
anhydrase O 
inhibitor O 
, O 
which O 
has O 
been O 
used O 
in O 
the O 
treatment O 
of O 
seizures O 
, O 
mountain O 
sickness O 
and O 
glaucoma O 
. O 
Memory O 
impairment O 
by O 
AZ O 
has O 
been O 
reported O 
in O 
patient O 
interviews O 
; O 
however O 
, O 
the O 
related O 
mechanism O 
is O 
unclear O 
. O 
We O 
applied O 
two O 
fear O 
conditioning O 
paradigms O 
, O 
shuttle O 
avoidance O 
and O 
passive O 
avoidance O 
, O 
in O 
both O 
rats O 
and O 
mice O 
to O 
investigate O 
this O 
clinical O 
anecdote O 
. O 
Adult O 
Wistar O 
rats O 
receiving O 
AZ O 
1 O 
h O 
before O 
the O 
shuttle O 
avoidance O 
test O 
showed O 
decreased O 
avoidance O 
rates O 
, O 
especially O 
at O 
high O 
dosage O 
. O 
Adult O 
ICR O 
mice O 
receiving O 
AZ O 
both O 
before O 
and O 
after O 
acquisition O 
trials O 
showed O 
the O 
decreased O 
step O 
- O 
through O 
latencies O 
during O 
the O 
passive O 
avoidance O 
test O 
. O 
This O 
impairment O 
of O 
fear O 
memory O 
was O 
corroborated O 
with O 
decreased O 
LTP O 
by O 
AZ O 
in O 
the O 
amygdala O 
. O 
AZ O 
only O 
inhibited O 
fear O 
conditioning O 
- O 
induced O 
ERK O 
phosphorylation O 
and O 
had O 
no O 
effect O 
on O 
Akt O 
phosphorylation O 
. O 
In O 
conclusion O 
, O 
our O 
study O 
confirmed O 
the O 
adverse O 
cognitive O 
effect O 
of O 
AZ O 
in O 
animal O 
and O 
electrophysiological O 
studies O 
. O 
In O 
clinical O 
practice O 
, O 
clinicians O 
should O 
be O 
aware O 
of O 
this O 
side O 
effect O 
in O 
patients O 
taking O 
AZ O 
. O 
In O 
addition O 
, O 
this O 
inhibition O 
of O 
fear O 
memory O 
by O 
AZ O 
could O 
potentially O 
be O 
applied O 
to O 
patients O 
with O 
posttraumatic O 
stress O 
disorder O 
. O 

leaf O 
structures O 
as O 
a O 
UV O 
detector O 
formed O 
by O 
the O 
self O 
- O 
assembly O 
of O 
ZnO B-FORMULA 
nanoparticles O 
. O 

leaf O 
structures O 
have O 
been O 
fabricated O 
by O 
the O 
self O 
- O 
assembly O 
of O 
ZnO B-FORMULA 
nanoparticles O 
. O 
A O 
hydrothermal O 
method O 
was O 
used O 
to O 
synthesize O 
the O 
nanoparticles O 
. O 
The O 
self O 
- O 
assembly O 
patterns O 
showed O 
asymmetric O 
dendritic O 
morphologies O 
, O 
larger O 
surface O 
- O 
to O 
- O 
volume O 
ratios O 
, O 
a O 
broad O 
absorption O 
band O 
and O 
high O 
resistance O 
. O 
A O 
non-equilibrium O 
two O 
- O 
stage O 
- O 
formation O 
process O 
included O 
diffusion O 
limited O 
aggregation O 
, O 
and O 
the O 
phase O 
- O 
field O 
model O 
was O 
introduced O 
to O 
explain O 
the O 
formation O 
mechanism O 
of O 
the O 
pattern O 
. O 
A O 
high O 
- O 
performance O 
ultraviolet O 
detector O 
was O 
fabricated O 
on O 
the O 
artificial O 
leaf O 
structures O 
, O 
which O 
showed O 
that O 
the O 
current O 
under O 
the O 
irradiation O 
of O 
a O 
UV O 
lamp O 
( O 
1.21 O 
mW O 
cm(-2) O 
) O 
was O 
about O 
10(4) O 
times O 
greater O 
than O 
in O 
the O 
dark O 
. O 
The O 
various O 
and O 
functional O 
properties O 
of O 
the O 
pattern O 
show O 
us O 
the O 
vast O 
prospects O 
of O 
potential O 
applications O 
for O 
light O 
harvesting O 
systems O 
and O 
other O 
optical O 
- O 
electric O 
devices O 
. O 

is O 
the O 
second O 
major O 
cause O 
of O 
mortality O 
worldwide O 
, O 
losing O 
only O 
to O 
cardiovascular O 
disease O 
. O 
Nowadays O 
, O 
around O 
50% O 
of O 
antineoplastic O 
drugs O 
were O 
discovered O 
and O 
isolated O 
by O 
indications O 
of O 
plants O 
in O 
folk O 
medicine O 
. O 
In O 
Brazilian O 
flora O 
there O 
are O 
many O 
species O 
of O 
plants O 
which O 
have O 
great O 
therapeutic O 
importance O 
, O 
highlighting O 
the O 
Mikania O 
laevigata O 
( O 
Asteraceae O 
) O 
that O 
has O 
been O 
used O 
for O 
their O 
valuable O 
properties O 
, O 
especially O 
in O 
the O 
respiratory O 
tract O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
compounds O 
of O 
M O 
. O 
laevigata O 
extracts O 
were O 
characterized O 
by O 
High O 
Resolution O 
Mass O 
Spectrometry O 
( O 
HRMS O 
) O 
and O 
Gas O 
Chromatography O 
with O 
Mass O 
analysis O 
( O 
GC O 
/ O 
MS-EI O 
) O 
. O 
Therefore O 
, O 
the O 
presence O 
of O 
some O 
compounds O 
with O 
promising O 
biological O 
properties O 
as O 
antitumor O 
activity O 
was O 
detected O 
. O 
Coumarin B-TRIVIAL 
( O 
1,2-benzopyrone B-SYSTEMATIC 
) O 
was O 
previously O 
reported O 
as O 
responsible O 
for O 
some O 
biological O 
activities O 
of O 
this O 
plant O 
species O 
. O 
Here O 
, O 
the O 
extracts O 
were O 
evaluated O 
by O 
their O 
cytotoxic O 
activity O 
against O 
tumor O 
( O 
Hep-2 O 
, O 
HeLa O 
) O 
and O 
non O 
tumor O 
( O 
MRC-5 O 
) O 
cell O 
lines O 
, O 
presenting O 
significant O 
inhibitory O 
activity O 
of O 
cell O 
growth O 
in O 
all O 
extracts O 
analyzed O 
, O 
chloroform B-TRIVIAL 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
hexane B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
, O 
which O 
is O 
related O 
to O 
its O 
chemical O 
composition O 
. O 
From O 
the O 
four O 
different O 
extracts O 
here O 
tested O 
, O 
two O 
of O 
them O 
, O 
hexane B-SYSTEMATIC 
and O 
ethanol B-SYSTEMATIC 
, O 
presented O 
a O 
clear O 
selectivity O 
against O 
both O 
tumor O 
cells O 
lines O 
investigated O 
. O 
This O 
can O 
be O 
explained O 
by O 
variances O 
and O 
increase O 
of O 
phenolic B-FAMILY 
compounds O 
in O 
the O 
ethanol B-SYSTEMATIC 
fraction O 
and O 
an O 
association O 
of O 
molecules O 
with O 
coumarin B-TRIVIAL 
found O 
in O 
the O 
hexane B-SYSTEMATIC 
fraction O 
. O 

its O 
identification O 
in O 
1988 O 
and O 
the O 
recognition O 
of O 
its O 
primary O 
role O 
as O 
a O 
potent O 
vasoconstrictor O 
, O 
endothelin O 
has O 
been O 
extensively O 
studied O 
and O 
is O 
now O 
considered O 
as O 
a O 
ubiquitous O 
protein O 
, O 
involved O 
in O 
important O 
aspects O 
of O 
human O 
homeostasis O 
as O 
well O 
as O 
in O 
several O 
pathophysiological O 
pathways O 
, O 
mostly O 
associated O 
with O 
cardiovascular O 
disease O 
. O 
From O 
an O 
evolutionary O 
point O 
of O 
view O 
, O 
endothelin O 
consists O 
a O 
primitive O 
molecule O 
with O 
the O 
rare O 
characteristic O 
of O 
being O 
exactly O 
the O 
same O 
in O 
all O 
mammals O 
, O 
thus O 
permitting O 
scientists O 
to O 
perform O 
experiments O 
in O 
animals O 
and O 
doing O 
predictions O 
for O 
humans O 
. O 
The O 
understanding O 
of O 
its O 
contribution O 
to O 
the O 
genesis O 
, O 
evolution O 
and O 
maintenance O 
of O 
disease O 
through O 
activation O 
of O 
special O 
receptor O 
subtypes O 
has O 
led O 
to O 
the O 
development O 
of O 
both O 
selective O 
and O 
unselective O 
receptor O 
antagonists O 
. O 
Despite O 
the O 
disappointing O 
results O 
of O 
these O 
antagonists O 
in O 
the O 
field O 
of O 
heart O 
failure O 
, O 
almost O 
from O 
the O 
initial O 
animal O 
trials O 
of O 
bosentan B-TRIVIAL 
, O 
a O 
dual O 
endothelin O 
receptor O 
antagonist O 
, O 
in O 
pulmonary O 
arterial O 
hypertension O 
, O 
it O 
has O 
been O 
demonstrated O 
that O 
the O 
drug O 
leads O 
at O 
least O 
to O 
hemodynamic O 
and O 
clinical O 
improvement O 
of O 
the O 
patients O 
, O 
thus O 
receiving O 
official O 
approval O 
for O 
the O 
management O 
of O 
this O 
rare O 
but O 
eventually O 
lethal O 
disease O 
. O 
Resistant O 
hypertension O 
is O 
another O 
area O 
where O 
endothelin O 
receptor O 
blockers O 
might O 
potentially O 
play O 
a O 
role O 
, O 
while O 
the O 
pathophysiological O 
role O 
of O 
endothelin O 
in O 
atherosclerotic O 
coronary O 
artery O 
disease O 
is O 
well O 
- O 
established O 
and O 
the O 
relative O 
research O 
goes O 
on O 
. O 
The O 
main O 
goal O 
of O 
this O 
review O 
is O 
to O 
describe O 
the O 
endothelin O 
system O 
and O 
mostly O 
to O 
enlighten O 
its O 
role O 
in O 
pathophysiologic O 
pathways O 
, O 
as O 
well O 
to O 
state O 
the O 
relative O 
research O 
in O 
the O 
various O 
fields O 
of O 
cardiovascular O 
disease O 
and O 
also O 
highlight O 
its O 
prognostic O 
significance O 
wherever O 
there O 
exists O 
one O 
. O 

effect O 
of O 
ketoconazole B-TRIVIAL 
on O 
the O 
pharmacokinetics O 
of O 
a O 
multireceptor O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
BMS-690514 B-IDENTIFIER 
in O 
healthy O 
participants O 
: O 
assessing O 
the O 
mechanism O 
of O 
the O 
interaction O 
with O 
physiologically O 
- O 
based O 
pharmacokinetic O 
simulations O 
. O 

, O 
a O 
selective O 
inhibitor O 
of O 
the O 
ErbB O 
and O 
vascular O 
endothelial O 
growth O 
factor O 
receptors O 
, O 
has O 
shown O 
antitumor O 
activity O 
in O 
early O 
clinical O 
development O 
. O 
The O 
compound O 
is O 
metabolized O 
by O 
multiple O 
enzymes O 
, O 
with O 
CYP3A4 O 
responsible O 
for O 
the O 
largest O 
fraction O 
( O 
34% O 
) O 
of O 
metabolism O 
. O 
It O 
is O 
also O 
a O 
substrate O 
of O 
P-glycoprotein O 
( O 
P-gp O 
) O 
in O 
vitro O 
. O 
To O 
assess O 
the O 
effect O 
of O 
ketoconazole B-TRIVIAL 
on O 
BMS-690514 B-IDENTIFIER 
pharmacokinetics O 
, O 
17 O 
healthy O 
volunteers O 
received O 
200 O 
mg O 
BMS-690514 B-IDENTIFIER 
alone O 
followed O 
by O 
100 O 
mg O 
BMS-690514 B-IDENTIFIER 
with O 
ketoconazole B-TRIVIAL 
( O 
400 O 
mg O 
once O 
daily O 
for O 
4 O 
days O 
) O 
. O 
The O 
AUC(∞) O 
of O 
100 O 
mg O 
BMS-690514 B-IDENTIFIER 
concomitantly O 
administered O 
with O 
ketoconazole B-TRIVIAL 
was O 
similar O 
to O 
that O 
of O 
200 O 
mg O 
BMS-690514 B-IDENTIFIER 
alone O 
. O 
The O 
dose O 
- O 
normalized O 
C(max) O 
and O 
AUC(∞) O 
of O 
BMS-690514 B-IDENTIFIER 
from O 
the O 
100-mg O 
BMS-690514 B-IDENTIFIER 
/ O 
400-mg O 
ketoconazole B-TRIVIAL 
treatment O 
increased O 
by O 
55% O 
and O 
127% O 
, O 
respectively O 
, O 
relative O 
to O 
those O 
from O 
200 O 
mg O 
BMS-690514 B-IDENTIFIER 
alone O 
. O 
Prediction O 
of O 
the O 
drug O 
- O 
drug O 
interaction O 
( O 
DDI O 
) O 
using O 
a O 
population O 
- O 
based O 
simulator O 
( O 
Simcyp O 
) O 
indicated O 
that O 
, O 
in O 
addition O 
to O 
CYP3A4 O 
inhibition O 
, O 
the O 
inhibition O 
of O 
P-gp O 
by O 
ketoconazole B-TRIVIAL 
in O 
the O 
intestine O 
, O 
liver O 
, O 
and O 
kidneys O 
must O 
be O 
invoked O 
to O 
fully O 
account O 
for O 
the O 
DDI O 
observed O 
. O 
This O 
finding O 
suggests O 
that O 
the O 
inhibition O 
of O 
P-gp O 
by O 
ketoconazole B-TRIVIAL 
, O 
along O 
with O 
its O 
effect O 
on O 
CYP3A4 O 
, O 
needs O 
to O 
be O 
considered O 
when O 
designing O 
a O 
DDI O 
study O 
of O 
ketoconazole B-TRIVIAL 
with O 
a O 
victim O 
drug O 
that O 
is O 
a O 
dual O 
substrate O 
. O 

of O 
copper B-SYSTEMATIC 
overload O 
on O 
the O 
survival O 
of O 
HepG2 O 
and O 
A-549 O 
human O 
- O 
derived O 
cells O 
. O 

investigated O 
the O 
effect O 
of O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
overload O 
( O 
20-160 O 
µM O 
/ O 
24 O 
h O 
) O 
in O 
two O 
cell O 
lines O 
of O 
human O 
hepatic O 
( O 
HepG2 O 
) O 
and O 
pulmonary O 
( O 
A-549 O 
) O 
origin O 
by O 
determining O 
lipid O 
and O 
protein O 
damage O 
and O 
the O 
response O 
of O 
the O 
antioxidant O 
defence O 
system O 
. O 
A-549 O 
cells O 
were O 
more O 
sensitive O 
to O 
Cu B-FORMULA 
overload O 
than O 
HepG2 O 
cells O 
. O 
A O 
marked O 
increase O 
was O 
observed O 
in O 
both O 
the O 
cell O 
lines O 
in O 
the O 
nitrate B-SYSTEMATIC 
plus O 
nitrite B-SYSTEMATIC 
concentration O 
, O 
protein O 
carbonyls B-FAMILY 
and O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
( O 
TBARS O 
) O 
. O 
The O 
TBARS O 
increase O 
was O 
consistent O 
with O 
an O 
increment O 
in O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
at O 
the O 
expense O 
of O 
polyunsaturated O 
acids O 
in O 
a O 
Cu B-FORMULA 
concentration O 
- O 
dependent O 
fashion O 
. O 
Antioxidant O 
enzymes O 
were O 
stimulated O 
by O 
Cu B-FORMULA 
overload O 
. O 
Superoxide B-TRIVIAL 
dismutase O 
activity O 
increased O 
significantly O 
in O 
both O 
the O 
cell O 
lines O 
, O 
with O 
greater O 
increases O 
in O 
HepG2 O 
than O 
in O 
A-549 O 
cells O 
. O 
A O 
marked O 
increase O 
in O 
ceruloplasmin O 
and O 
metallothionein O 
content O 
in O 
both O 
the O 
cell O 
types O 
was O 
also O 
observed O 
. O 
Dose O 
- O 
dependent O 
decreases O 
in O 
α-tocopherol B-TRIVIAL 
and O 
ferric B-SYSTEMATIC 
reducing O 
ability O 
were O 
observed O 
. O 
Total O 
glutathione B-TRIVIAL 
content O 
was O 
lower O 
in O 
A-549 O 
cells O 
and O 
higher O 
in O 
HepG2 O 
. O 
Calpain O 
and O 
caspase-3 O 
were O 
differentially O 
activated O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
under O 
copper B-SYSTEMATIC 
-induced O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
. O 
We O 
conclude O 
that O 
Cu B-FORMULA 
exposure O 
of O 
human O 
lung- O 
and O 
liver O 
- O 
derived O 
cells O 
should O 
be O 
considered O 
a O 
reliable O 
experimental O 
system O 
for O 
detailed O 
study O 
of O 
mechanism O 
/ O 
mechanisms O 
by O 
which O 
Cu B-FORMULA 
overload O 
exerts O 
its O 
deleterious O 
effects O 
. O 

fabrication O 
method O 
is O 
developed O 
for O 
superhydrophilic O 
surfaces O 
with O 
high O 
capillary O 
pressure O 
and O 
fast O 
spreading O 
speed O 
. O 
The O 
fabrication O 
method O 
consists O 
of O 
electrophoretic O 
deposition O 
( O 
EPD O 
) O 
and O 
breakdown O 
anodization O 
( O 
BDA O 
) O 
. O 
Nanopores O 
and O 
micropores O 
were O 
produced O 
on O 
titanium B-SYSTEMATIC 
plates O 
by O 
EPD O 
and O 
BDA O 
, O 
respectively O 
. O 
In O 
EPD O 
, O 
TiO(2) B-FORMULA 
nanoparticles O 
were O 
used O 
to O 
enhance O 
the O 
surface O 
energy O 
and O 
create O 
nanoporous O 
structures O 
, O 
while O 
BDA O 
was O 
employed O 
to O 
produce O 
microporous O 
structures O 
. O 
Capillary O 
rise O 
measurements O 
( O 
CRM O 
) O 
were O 
utilized O 
to O 
characterize O 
superhydrophilic O 
surfaces O 
in O 
terms O 
of O 
capillary O 
pressure O 
and O 
spreading O 
speed O 
. O 
From O 
CRM O 
, O 
it O 
was O 
revealed O 
that O 
microporous O 
structures O 
play O 
a O 
dominant O 
role O 
in O 
determining O 
transport O 
properties O 
, O 
and O 
nanoporous O 
structures O 
affect O 
local O 
wettability O 
without O 
significantly O 
reducing O 
spreading O 
speed O 
. O 
By O 
combining O 
BDA O 
and O 
EPD O 
into O 
a O 
hybrid O 
method O 
, O 
dual O 
- O 
scale O 
( O 
nano O 
and O 
micro O 
) O 
porous O 
structures O 
were O 
produced O 
on O 
titanium B-SYSTEMATIC 
plates O 
. O 
The O 
methods O 
presented O 
offer O 
the O 
potential O 
to O 
vary O 
the O 
transport O 
characteristics O 
of O 
superhydrophilic O 
surfaces O 
by O 
altering O 
the O 
nanoscale O 
and O 
microscale O 
features O 
independently O 
. O 
As O 
an O 
example O 
, O 
surfaces O 
with O 
unconventional O 
capillary O 
flows O 
were O 
produced O 
by O 
the O 
hybrid O 
method O 
. O 
This O 
method O 
provides O 
additional O 
opportunities O 
to O 
investigate O 
wetting O 
phenomena O 
while O 
offering O 
a O 
potentially O 
low O 
cost O 
process O 
for O 
industrial O 
applications O 
. O 

effects O 
of O 
treatment O 
with O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
selenium B-SYSTEMATIC 
on O 
the O 
skin O 
of O 
diabetic O 
rats O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
on O 
the O 
skin O 
tissue O 
of O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
. O 
Swiss O 
albino O 
rats O 
were O 
divided O 
into O 
four O 
groups O 
: O 
control O 
, O 
control O 
+ O 
antioxidants O 
, O 
diabetic O 
, O 
diabetic O 
+ O 
antioxidants O 
groups O 
. O 
Diabetes O 
was O 
induced O 
by O 
intraperitoneal O 
injection O 
of O 
65 O 
mg O 
/ O 
kg O 
streptozotocin B-TRIVIAL 
. O 
Vitamin B-TRIVIAL 
C I-TRIVIAL 
( O 
250 O 
mg O 
/ O 
kg O 
) O 
, O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
250 O 
mg O 
/ O 
kg O 
) O 
and O 
Se B-FORMULA 
( O 
0.2 O 
mg O 
/ O 
kg O 
) O 
were O 
given O 
by O 
gavage O 
technique O 
to O 
rats O 
of O 
one O 
diabetic O 
and O 
one O 
control O 
group O 
for O 
30 O 
days O 
. O 
In O 
the O 
diabetic O 
group O 
, O 
the O 
levels O 
of O 
serum O 
urea B-TRIVIAL 
and O 
creatinine B-TRIVIAL 
, O 
skin O 
lipid O 
peroxidation O 
and O 
nonenzymatic O 
glycosylation O 
levels O 
increased O 
, O 
but O 
skin O 
glutathione B-TRIVIAL 
levels O 
decreased O 
. O 
Treatment O 
with O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
Se B-FORMULA 
reversed O 
these O 
effects O 
. O 
The O 
present O 
study O 
showed O 
that O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
Se B-FORMULA 
exerted O 
antioxidant O 
effects O 
and O 
consequently O 
may O 
prevent O 
skin O 
damage O 
caused O 
by O 
streptozotocin B-TRIVIAL 
-induced O 
diabetes O 
. O 

hormone I-FAMILY 
levels O 
reflect O 
social O 
opportunities O 
in O 
the O 
facultatively O 
eusocial O 
sweat O 
bee O 
Megalopta O 
genalis O 
( O 
Hymenoptera O 
: O 
Halictidae O 
) O 
. O 

evolution O 
of O 
eusociality O 
is O 
hypothesized O 
to O 
have O 
involved O 
de-coupling O 
parental O 
care O 
from O 
reproduction O 
mediated O 
by O 
changes O 
in O 
endocrine O 
regulation O 
. O 
While O 
data O 
for O 
obligately O 
eusocial O 
insects O 
are O 
consistent O 
with O 
this O 
hypothesis O 
, O 
we O 
lack O 
information O 
from O 
species O 
representative O 
of O 
the O 
transition O 
from O 
solitary O 
reproduction O 
to O 
eusociality O 
. O 
Here O 
we O 
report O 
the O 
first O 
evidence O 
for O 
a O 
link O 
between O 
endocrine O 
processes O 
and O 
social O 
behavior O 
in O 
a O 
facultatively O 
eusocial O 
bee O 
, O 
Megalopta O 
genalis O 
( O 
Halictidae O 
) O 
. O 
Using O 
females O 
that O 
varied O 
in O 
social O 
, O 
reproductive O 
, O 
and O 
ecological O 
context O 
, O 
we O 
measured O 
juvenile B-FAMILY 
hormone I-FAMILY 
( O 
JH O 
) O 
, O 
a O 
major O 
regulator O 
of O 
colony O 
caste O 
dynamics O 
in O 
other O 
eusocial O 
species O 
. O 
JH O 
was O 
low O 
at O 
adult O 
emergence O 
, O 
but O 
elevated O 
after O 
10 O 
days O 
in O 
all O 
nesting O 
females O 
. O 
Females O 
reared O 
in O 
cages O 
with O 
ad O 
lib O 
nutrition O 
, O 
however O 
, O 
did O 
not O 
elevate O 
JH O 
levels O 
after O 
10 O 
days O 
. O 
All O 
reproductive O 
females O 
had O 
significantly O 
more O 
JH O 
than O 
all O 
age O 
- O 
matched O 
non-reproductive O 
females O 
, O 
suggesting O 
a O 
gonadotropic O 
function O 
. O 
Among O 
females O 
in O 
established O 
nests O 
, O 
JH O 
was O 
higher O 
in O 
queens O 
than O 
workers O 
and O 
solitary O 
reproductives O 
, O 
suggesting O 
a O 
role O 
for O 
JH O 
in O 
social O 
dominance O 
. O 
A O 
lack O 
of O 
significant O 
differences O 
in O 
JH O 
between O 
solitary O 
reproductives O 
and O 
non-reproductive O 
workers O 
suggests O 
that O 
JH O 
content O 
reflects O 
more O 
than O 
reproductive O 
status O 
. O 
Our O 
data O 
support O 
the O 
hypothesis O 
that O 
endocrine O 
modifications O 
are O 
involved O 
in O 
the O 
evolutionary O 
decoupling O 
of O 
reproductive O 
and O 
somatic O 
effort O 
in O 
social O 
insects O 
. O 
These O 
are O 
the O 
first O 
measurements O 
of O 
JH O 
in O 
a O 
solitary O 
- O 
nesting O 
hymenopteran O 
, O 
and O 
the O 
first O 
to O 
compare O 
eusocial O 
and O 
solitary O 
nesting O 
individuals O 
of O 
the O 
same O 
species O 
. O 

of O 
the O 
synthetic O 
polymeric O 
3-alkylpyridinium B-FAMILY 
salt I-FAMILY 
( O 
APS3 B-ABBREVIATION 
) O 
is O 
due O 
to O 
specific O 
block O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
. O 

in O 
vivo O 
and O 
in O 
vitro O 
toxic O 
effects O 
of O 
the O 
synthetic O 
polymeric O 
3-alkylpyridinium B-FAMILY 
salt I-FAMILY 
( O 
APS3 B-ABBREVIATION 
) O 
, O 
from O 
the O 
Mediterranean O 
marine O 
sponge O 
Reniera O 
sarai O 
, O 
were O 
evaluated O 
on O 
mammals O 
, O 
with O 
emphasis O 
to O 
determine O 
its O 
mode O 
of O 
action O 
. O 
The O 
median O 
lethal O 
doses O 
of O 
APS3 B-ABBREVIATION 
were O 
7.25 O 
and O 
higher O 
that O 
20mg O 
/ O 
kg O 
in O 
mouse O 
and O 
rat O 
, O 
respectively O 
. O 
Intravenous O 
administration O 
of O 
7.25 O 
and O 
20mg O 
/ O 
kg O 
APS3 B-ABBREVIATION 
to O 
rat O 
caused O 
a O 
significant O 
fall O 
followed O 
by O 
an O 
increase O 
in O 
mean O 
arterial O 
blood O 
pressure O 
accompanied O 
by O 
tachycardia O 
. O 
In O 
addition O 
, O 
cumulative O 
doses O 
of O 
APS3 B-ABBREVIATION 
( O 
up O 
to O 
60 O 
mg O 
/ O 
kg O 
) O 
inhibited O 
rat O 
nerve O 
- O 
evoked O 
skeletal O 
muscle O 
contraction O 
in O 
vivo O 
, O 
with O 
a O 
median O 
inhibitory O 
dose O 
(ID(50)) O 
of O 
37.25mg O 
/ O 
kg O 
. O 
When O 
administrated O 
locally O 
by O 
intramuscular O 
injection O 
to O 
mouse O 
, O 
APS3 B-ABBREVIATION 
decreased O 
the O 
compound O 
muscle O 
action O 
potential O 
recorded O 
in O 
response O 
to O 
in O 
vivo O 
nerve O 
stimulation O 
, O 
with O 
an O 
ID(50) O 
of O 
0.5mg O 
/ O 
kg O 
. O 
In O 
vitro O 
experiments O 
confirmed O 
the O 
inhibitory O 
effect O 
of O 
APS3 B-ABBREVIATION 
on O 
mouse O 
hemidiaphragm O 
nerve O 
- O 
evoked O 
muscle O 
contraction O 
with O 
a O 
median O 
inhibitory O 
concentration O 
(IC(50)) O 
of O 
20.3 O 
μM O 
, O 
without O 
affecting O 
directly O 
elicited O 
muscle O 
contraction O 
. O 
The O 
compound O 
inhibited O 
also O 
miniature O 
endplate O 
potentials O 
and O 
nerve O 
- O 
evoked O 
endplate O 
potentials O 
with O 
an O 
IC(50) O 
of O 
7.28 O 
μM O 
in O 
mouse O 
hemidiaphragm O 
. O 
Finally O 
, O 
APS3 B-ABBREVIATION 
efficiently O 
blocked O 
acetylcholine B-SYSTEMATIC 
-activated O 
membrane O 
inward O 
currents O 
flowing O 
through O 
Torpedo O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
incorporated O 
to O 
Xenopus O 
oocytes O 
, O 
with O 
an O 
IC(50) O 
of O 
0.19 O 
μM O 
. O 
In O 
conclusion O 
, O 
our O 
results O 
strongly O 
suggest O 
that O 
APS3 B-ABBREVIATION 
blocks O 
muscle O 
- O 
type O 
nAChRs O 
, O 
and O 
show O 
for O 
the O 
first O 
time O 
that O 
in O 
vivo O 
toxicity O 
of O 
APS3 B-ABBREVIATION 
is O 
likely O 
to O 
occur O 
through O 
an O 
antagonist O 
action O 
of O 
the O 
compound O 
on O 
these O 
receptors O 
. O 

vitro O 
polyphenolics B-FAMILY 
erythrocyte O 
model O 
and O 
in O 
vivo O 
chicken O 
embryo O 
model O 
revealed O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
to O 
be O 
a O 
potential O 
hemorrhage O 
inducer O 
: O 
physicochemical O 
action O 
mechanisms O 
. O 

in O 
vivo O 
chicken O 
embryo O 
model O 
( O 
CEM O 
) O 
demonstrated O 
that O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
induced O 
dysvascularization O 
and O 
hypoxia O 
. O 
Inflammatory O 
edema O 
, O 
Zenker's O 
necrosis O 
, O 
hemolysis O 
, O 
and O 
liposis O 
of O 
cervical O 
muscles O 
were O 
the O 
common O 
symptoms O 
. O 
Levels O 
of O 
the O 
gene O 
hif-1α O 
, O 
HIF-1α O 
, O 
TNF-α O 
, O 
IL-6 O 
, O 
and O 
NFκB O 
in O 
cervical O 
muscles O 
were O 
all O 
significantly O 
upregulated O 
, O 
while O 
the O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
was O 
downregulated O 
in O 
a O 
dose O 
- O 
responsive O 
manner O 
. O 
Consequently O 
, O 
the O 
cervical O 
muscle O 
inflammation O 
and O 
hemolysis O 
could O 
have O 
been O 
stimulated O 
en O 
route O 
to O 
the O 
tissue O 
TNF-α-canonical O 
and O 
the O 
atypical O 
pathways O 
. O 
We O 
hypothesized O 
that O 
GA O 
could O 
deplete O 
the O 
dissolved O 
oxygen B-SYSTEMATIC 
( O 
DO O 
) O 
at O 
the O 
expense O 
of O 
semiquinone B-FAMILY 
and O 
quinone B-FAMILY 
formation O 
, O 
favoring O 
the O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
to O 
induce O 
RBC O 
disruption O 
and O 
Fe(2+) B-FORMULA 
ion O 
release O 
. O 
To O 
explore O 
this O 
, O 
the O 
in O 
vitro O 
polyphenolics B-FAMILY 
-erythrocyte O 
model O 
( O 
PEM O 
) O 
was O 
established O 
. O 
PEM O 
revealed O 
that O 
the O 
DO O 
was O 
rapidly O 
depleted O 
, O 
leading O 
to O 
the O 
release O 
of O 
a O 
huge O 
amount O 
of O 
Fe B-FORMULA 
(II) I-FORMULA 
ions O 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
HPO B-ABBREVIATION 
) O 
in O 
a O 
two O 
- O 
phase O 
kinetic O 
pattern O 
. O 
The O 
kinetic O 
coefficients O 
for O 
Fe B-FORMULA 
(II) I-FORMULA 
ion O 
release O 
ranged O 
from O 
0.347 O 
h(-1) O 
to O 
0.774 O 
h(-1) O 
; O 
and O 
those O 
for O 
Fe B-FORMULA 
(III) I-FORMULA 
ion O 
production O 
were O 
from O 
6.66 O 
× O 
10(-3) O 
h(-1) O 
to O 
8.93 O 
× O 
10(-3) O 
h(-1) O 
. O 
For O 
phase O 
I O 
HPO B-ABBREVIATION 
production O 
, O 
they O 
ranged O 
from O 
0.236 O 
h(-1) O 
to O 
0.774 O 
h(-1) O 
and O 
for O 
phase O 
II O 
HPO B-ABBREVIATION 
production O 
from O 
0.764 O 
h(-1) O 
to O 
2.56 O 
h(-1) O 
at O 
GA O 
within O 
6 O 
μM O 
to O 
14 O 
μM O 
. O 
Thus O 
, O 
evidence O 
obtained O 
from O 
PEM O 
could O 
strongly O 
support O 
the O 
phenomena O 
of O 
CEM O 
. O 
To O 
conclude O 
, O 
GA O 
tends O 
to O 
elicit O 
hypoxia O 
- O 
related O 
inflammation O 
and O 
hemolysis O 
in O 
chicken O 
cervical O 
muscles O 
through O 
its O 
extremely O 
high O 
prooxidant O 
activity O 
. O 

effects O 
on O 
free O 
phenolic B-FAMILY 
acids I-FAMILY 
under O 
ultrasound O 
treatment O 
in O 
a O 
model O 
system O 
. O 

effects O 
on O 
seven O 
free O 
phenolic B-FAMILY 
acids I-FAMILY 
under O 
ultrasound O 
treatment O 
in O 
a O 
model O 
system O 
have O 
been O 
investigated O 
. O 
The O 
degradation O 
products O 
have O 
also O 
been O 
tentatively O 
identified O 
by O 
FTIR O 
and O 
HPLC-UV-ESIMS O 
. O 
Five O 
phenolic B-FAMILY 
acids I-FAMILY 
( O 
protocatechuic B-TRIVIAL 
acid I-TRIVIAL 
, O 
p-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
vanillic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
) O 
proved O 
to O 
be O 
stable O 
, O 
while O 
two O 
others O 
( O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
and O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
) O 
were O 
degraded O 
under O 
ultrasound O 
treatment O 
. O 
The O 
nature O 
of O 
the O 
solvent O 
and O 
the O 
temperature O 
has O 
been O 
identified O 
as O 
important O 
factors O 
in O 
determining O 
the O 
degradation O 
reaction O 
. O 
Liquid O 
height O 
, O 
ultrasonic O 
intensity O 
, O 
and O 
duty O 
cycle O 
of O 
the O 
ultrasound O 
exposure O 
affected O 
only O 
the O 
degradation O 
rate O 
and O 
did O 
not O 
change O 
the O 
nature O 
of O 
the O 
degradation O 
. O 
The O 
degradation O 
rates O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
and O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
decreased O 
with O 
increasing O 
temperature O 
. O 
The O 
degradation O 
kinetics O 
of O 
these O 
two O 
acids O 
under O 
ultrasound O 
conformed O 
to O 
zeroth O 
- O 
order O 
reactions O 
at O 
-5 O 
to O 
25 O 
°C O 
. O 
Both O 
decomposition O 
and O 
polymerization O 
reactions O 
occurred O 
when O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
and O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
were O 
subjected O 
to O 
ultrasound O 
. O 
Degradation O 
products O 
, O 
such O 
as O 
the O 
corresponding O 
decarboxylation O 
products O 
and O 
their O 
dimers O 
, O 
have O 
been O 
tentatively O 
identified O 
. O 

treatment O 
of O 
food O 
is O 
a O 
promising O 
non O 
- O 
thermal O 
processing O 
technology O 
to O 
improve O 
food O 
safety O 
and O 
preservation O 
. O 
Most O 
of O 
the O 
chemical O 
constituents O 
of O 
food O 
absorb O 
UV-C O 
light O 
that O 
can O 
lead O 
to O 
chemical O 
modifications O 
and O 
quality O 
changes O 
. O 
This O 
work O 
investigated O 
the O 
effects O 
of O 
UV-C O 
treatment O 
of O 
liquid O 
egg O 
products O 
on O 
lipid O 
, O 
protein O 
oxidations O 
and O 
potential O 
cyto- O 
and O 
genotoxic O 
effects O 
on O 
intestinal O 
epithelial O 
cells O 
in O 
vitro O 
. O 
Egg O 
preparations O 
( O 
egg O 
white O 
, O 
yolk O 
, O 
liquid O 
whole O 
egg O 
) O 
were O 
treated O 
with O 
UV-C O 
( O 
254 O 
nm O 
, O 
volumetric O 
doses O 
between O 
0 O 
and O 
115619 O 
J O 
L(-1) O 
) O 
using O 
a O 
commercial O 
UV-C O 
processing O 
unit O 
equipped O 
with O 
a O 
Dean O 
Flow O 
reactor O 
. O 
UV-C O 
treatment O 
at O 
high O 
doses O 
( O 
from O 
32181 O 
J O 
L(-1) O 
, O 
about O 
2 O 
times O 
higher O 
than O 
that O 
needed O 
to O 
inactivate O 
5 O 
log O 
of O 
relevant O 
microorganisms O 
) O 
showed O 
an O 
increased O 
lipid O 
oxidation O 
in O 
egg O 
yolk O 
and O 
slight O 
effects O 
in O 
liquid O 
whole O 
eggs O 
; O 
this O 
was O 
confirmed O 
by O 
slightly O 
but O 
not O 
statistically O 
significant O 
increased O 
peroxide B-SYSTEMATIC 
values O 
. O 
UV-C O 
induced O 
also O 
slight O 
protein O 
damage O 
, O 
characterised O 
by O 
the O 
total O 
sulfhydryl B-FAMILY 
group O 
reduction O 
. O 
These O 
UV-C-induced O 
oxidative O 
modifications O 
in O 
egg O 
preparations O 
however O 
did O 
not O 
cause O 
any O 
increase O 
in O 
the O 
cyto- O 
or O 
genotoxic O 
( O 
DNA O 
strand O 
breaks O 
) O 
effects O 
in O 
intestinal O 
Caco-2 O 
cells O 
. O 

study O 
of O 
the O 
thermodynamic O 
and O 
burning O 
properties O 
of O 
oxygen B-SYSTEMATIC 
-rich O 
hydrazine B-SYSTEMATIC 
derivatives O 
- O 
green O 
and O 
powerful O 
oxidants O 
for O 
energetic O 
materials O 
. O 

series O 
of O 
no- O 
chlorine B-SYSTEMATIC 
and O 
oxygen B-SYSTEMATIC 
-rich O 
hydrazine B-SYSTEMATIC 
derivatives O 
( O 
hydrazine B-SYSTEMATIC 
modified O 
with O 
- O 
NO2 B-FORMULA 
and O 
NO3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
groups O 
) O 
was O 
designed O 
and O 
optimized O 
to O 
obtain O 
molecular O 
geometries O 
and O 
electronic O 
structures O 
at O 
density O 
functional O 
theory-B3PW91 O 
/ O 
6-311 O 
+ O 
+ O 
G(3df,3pd) O 
level O 
. O 
Some O 
important O 
properties O 
such O 
as O 
bond O 
dissociation O 
enthalpy O 
, O 
density O 
, O 
natural O 
bond O 
orbitals O 
, O 
thermodynamic O 
parameters O 
, O 
molecular O 
orbital O 
energy O 
and O 
burning O 
rate O 
were O 
then O 
calculated O 
. O 
The O 
simulation O 
results O 
revealed O 
that O 
these O 
compounds O 
exhibit O 
excellent O 
performance O 
, O 
with O 
significant O 
superiority O 
over O 
traditional O 
oxidants O 
found O 
in O 
propellants O 
. O 

1 I-FORMULA 
) I-FORMULA 
H I-FORMULA 
and O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
NMR O 
analysis O 
of O 
2-acetamido-3-mercapto-3-methyl-N-aryl-butanamides B-FAMILY 
and O 
2-acetamido-3-methyl-3-nitrososulfanyl-N-aryl-butanamide B-SYSTEMATIC 
derivatives O 
. O 

complete O 
assignment O 
of O 
the O 
( B-FORMULA 
1 I-FORMULA 
) I-FORMULA 
H I-FORMULA 
and O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
NMR O 
spectra O 
of O 
various O 
2-acetamido-3-mercapto-3-methyl-N-aryl-butanamides B-FAMILY 
and O 
2-acetamide-3-methyl-3-nitrososulfanyl-N-aryl-butanamides B-FAMILY 
with O 
p-methoxy B-SYSTEMATIC 
, O 
o-chloro B-SYSTEMATIC 
and O 
m-chloro B-SYSTEMATIC 
substituents O 
is O 
reported O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
different O 
maize O 
meal O 
diets O 
on O 
growth O 
and O 
vitamin B-FAMILY 
A I-FAMILY 
: O 
Case O 
- O 
study O 
on O 
chickens O 
. O 

Africa O 
embarked O 
on O 
mandatory O 
vitamin O 
and O 
mineral O 
fortification O 
of O 
wheat O 
flour O 
and O 
maize O 
meal O 
in O 
2003 O 
as O 
part O 
of O 
a O 
multi O 
- O 
faceted O 
approach O 
to O 
alleviate O 
malnutrition O 
. O 
However O 
, O 
it O 
was O 
reported O 
, O 
in O 
2008 O 
, O 
that O 
vitamin B-FAMILY 
A I-FAMILY 
deficiency O 
increased O 
despite O 
the O 
mandatory O 
fortification O 
programme O 
. O 
This O 
motivates O 
an O 
investigation O 
into O 
the O 
absorption O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
as O 
fortificant O 
in O 
the O 
maize O 
meal O 
. O 
Relative O 
absorption O 
, O 
in O 
chickens O 
as O 
the O 
biological O 
model O 
, O 
was O 
determined O 
by O 
evaluating O 
growth O 
and O 
vitamin B-FAMILY 
A I-FAMILY 
status O 
. O 
The O 
weight O 
, O 
cumulative O 
feed O 
intake O 
and O 
liver O 
retinol B-TRIVIAL 
stores O 
of O 
chickens O 
on O 
different O 
diets O 
were O 
measured O 
over O 
a O 
6week O 
period O 
. O 
The O 
fortified O 
white O 
maize O 
meal O 
diet O 
was O 
able O 
to O 
maintain O 
the O 
vitamin B-FAMILY 
A I-FAMILY 
status O 
of O 
the O 
chickens O 
. O 
Poor O 
absorption O 
of O 
the O 
fortificant O 
vitamin B-FAMILY 
A I-FAMILY 
is O 
therefore O 
not O 
a O 
constraint O 
in O 
combating O 
vitamin B-FAMILY 
A I-FAMILY 
deficiency O 
. O 
It O 
is O 
in O 
therefore O 
also O 
important O 
to O 
focus O 
on O 
the O 
level O 
of O 
fortification O 
delivered O 
when O 
consumed O 
as O 
a O 
traditional O 
prepared O 
dish O 
. O 
In O 
the O 
traditional O 
diet O 
, O 
maize O 
porridge O 
is O 
often O 
consumed O 
with O 
only O 
a O 
relish O 
. O 
The O 
total O 
fat O 
content O 
of O 
the O 
traditional O 
meal O 
is O 
very O 
low O 
, O 
lacking O 
absorption O 
enhancers O 
. O 

with O 
primary O 
ovarian O 
insufficiency O 
( O 
POI O 
) O 
/ O 
premature O 
ovarian O 
failure O 
exhibit O 
hypergonadotropic O 
hypogonadism O 
due O 
to O 
follicle O 
dysfunction O 
and O 
depletion O 
before O 
the O 
age O 
of O 
40 O 
years O 
. O 
Because O 
ovulation O 
is O 
extremely O 
rare O 
and O 
thought O 
to O 
be O 
unpredictable O 
in O 
women O 
with O 
POI O 
and O 
because O 
no O 
ovulation O 
induction O 
regimens O 
have O 
been O 
shown O 
to O 
be O 
efficacious O 
, O 
oocyte O 
donation O 
is O 
the O 
only O 
evidence O 
- O 
based O 
treatment O 
for O 
women O 
with O 
POI O 
with O 
desired O 
fertility O 
. O 
Oocyte O 
donation O 
is O 
, O 
however O 
, O 
extremely O 
limited O 
in O 
several O 
countries O 
including O 
Japan O 
. O 
Here O 
, O 
we O 
report O 
four O 
women O 
with O 
POI O 
who O 
achieved O 
pregnancies O 
resulting O 
from O 
timed O 
intercourse O 
or O 
intrauterine O 
insemination O 
in O 
combination O 
with O 
cyclic O 
estrogen B-FAMILY 
/ O 
progesterone B-TRIVIAL 
therapy O 
and O 
close O 
monitoring O 
of O 
follicle O 
development O 
. O 
These O 
four O 
patients O 
were O 
diagnosed O 
with O 
POI O 
at O 
the O 
mean O 
age O 
of O 
27.5 O 
± O 
8.5 O 
( O 
mean O 
± O 
SD O 
; O 
range O 
, O 
19-35 O 
) O 
, O 
subjected O 
to O 
follicle O 
monitoring O 
at O 
the O 
mean O 
age O 
of O 
29.8 O 
± O 
5.7 O 
( O 
23-35 O 
) O 
, O 
and O 
conceived O 
at O 
the O 
mean O 
age O 
of O 
34.5 O 
± O 
3.9 O 
( O 
29-38 O 
) O 
. O 
The O 
interval O 
between O 
the O 
initiation O 
of O 
follicle O 
monitoring O 
and O 
pregnancy O 
was O 
4.8 O 
± O 
2.8 O 
( O 
2-8 O 
) O 
years O 
. O 
In O 
one O 
of O 
the O 
patients O 
, O 
her O 
most O 
recent O 
ovulation O 
occurred O 
after O 
a O 
three O 
- O 
year O 
interval O 
. O 
All O 
four O 
patients O 
had O 
uncomplicated O 
pregnancies O 
with O 
term O 
deliveries O 
. O 
In O 
the O 
event O 
that O 
oocyte O 
donation O 
and O 
adoption O 
are O 
not O 
available O 
and O 
/ O 
or O 
various O 
treatments O 
with O 
intensive O 
ovulation O 
induction O 
have O 
been O 
unsuccessful O 
, O 
close O 
and O 
continuous O 
monitoring O 
of O 
follicle O 
growth O 
to O 
identify O 
very O 
rare O 
ovulatory O 
events O 
might O 
be O 
considered O 
for O 
patients O 
with O 
POI O 
and O 
desired O 
fertility O 
. O 

2 O 
diabetes O 
( O 
T2D O 
) O 
is O 
associated O 
with O 
vascular O 
dysfunction O 
. O 
We O 
hypothesized O 
that O 
increased O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NFκB O 
) O 
signaling O 
contributes O 
to O 
vascular O 
dysfunction O 
in O 
T2D O 
. O 
We O 
have O 
treated O 
type O 
2 O 
diabetic O 
( O 
db(-) O 
/ O 
db(-) O 
) O 
and O 
control O 
( O 
db(-) O 
/ O 
db(+) O 
) O 
mice O 
with O 
two O 
NFκB O 
inhibitors O 
( O 
DHMEQ B-ABBREVIATION 
, O 
6mg O 
/ O 
kg O 
, O 
twice O 
a O 
week O 
and O 
IKK-NBD O 
peptide O 
, O 
500 O 
μg O 
/ O 
kg O 
/ O 
day O 
) O 
for O 
four O 
weeks O 
. O 
Pressure O 
- O 
induced O 
myogenic O 
tone O 
( O 
MT O 
) O 
was O 
significantly O 
potentiated O 
, O 
while O 
endothelium O 
dependent O 
relaxation O 
( O 
EDR O 
) O 
was O 
impaired O 
in O 
small O 
coronary O 
arterioles O 
( O 
CA O 
) O 
and O 
mesenteric O 
resistance O 
artery O 
( O 
MRA O 
) O 
from O 
diabetic O 
mice O 
compared O 
to O 
control O 
. O 
Interestingly O 
, O 
diabetic O 
mice O 
treated O 
with O 
NFκB O 
inhibitors O 
significantly O 
reduced O 
MT O 
potentiation O 
and O 
improved O 
EDR O 
. O 
Importantly O 
, O 
vascular O 
function O 
was O 
also O 
rescued O 
in O 
db(-) O 
/ O 
db(-p50NFκB- O 
/ O 
- O 
) O 
and O 
db(-) O 
/ O 
db(-PARP-1- O 
/ O 
- O 
) O 
double O 
knockout O 
mice O 
compared O 
to O 
db(-) O 
/ O 
db(-) O 
mice O 
. O 
Additionally O 
, O 
the O 
acute O 
in O 
vitro O 
down O 
regulation O 
of O 
NFκB-p65 O 
using O 
p65NFκB O 
shRNA O 
lentivirus O 
in O 
arteries O 
from O 
db(-) O 
/ O 
db(-) O 
mice O 
also O 
improved O 
vascular O 
function O 
. O 
The O 
NFκB O 
inhibition O 
did O 
not O 
affect O 
blood O 
glucose B-TRIVIAL 
level O 
and O 
body O 
weight O 
. O 
The O 
RNA O 
levels O 
for O 
Sp-1 O 
and O 
eNOS O 
phosphorylation O 
were O 
decreased O 
, O 
while O 
p65NFκB O 
phosphorylation O 
, O 
cleaved O 
PARP-1 O 
and O 
COX-2 O 
expression O 
were O 
increased O 
in O 
arteries O 
from O 
diabetic O 
mice O 
, O 
which O 
were O 
restored O 
after O 
NFκB O 
inhibition O 
and O 
in O 
db(-) O 
/ O 
db(-p50NFκB- O 
/ O 
- O 
) O 
and O 
db(-) O 
/ O 
db(-PARP-1- O 
/ O 
- O 
) O 
mice.In O 
the O 
present O 
study O 
, O 
we O 
provided O 
evidence O 
that O 
enhanced O 
NFκB O 
activity O 
impairs O 
vascular O 
function O 
by O 
PARP-1 O 
, O 
Sp-1 O 
and O 
COX-2-dependent O 
mechanisms O 
in O 
male O 
type O 
2 O 
diabetic O 
mice O 
. O 
Therefore O 
, O 
NFκB O 
could O 
be O 
a O 
potential O 
target O 
to O 
overcome O 
diabetes O 
- O 
induced O 
vascular O 
dysfunction O 
. O 

inhibits O 
the O 
growth O 
of O 
adrenocortical O 
cancer O 
cells O 
in O 
vitro O 
. O 

centrosomes O 
and O 
aneuploidy O 
are O 
associated O 
with O 
a O 
malignant O 
phenotype O 
of O 
tumor O 
cells O 
. O 
Centrosomal O 
clustering O 
is O 
a O 
mechanism O 
used O 
by O 
cancer O 
cells O 
with O 
supernumerary O 
centrosomes O 
to O 
solve O 
the O 
threatening O 
problem O 
of O 
multipolar O 
spindles O 
. O 
Griseofulvin B-TRIVIAL 
is O 
an O 
antifungal O 
substance O 
that O 
interferes O 
with O 
the O 
microtubule O 
apparatus O 
and O 
inhibits O 
centrosomal O 
clustering O 
. O 
It O 
has O 
also O 
been O 
demonstrated O 
that O 
griseofulvin B-TRIVIAL 
inhibits O 
the O 
growth O 
of O 
tumor O 
cells O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
However O 
, O 
it O 
is O 
not O 
yet O 
known O 
whether O 
treatment O 
with O 
griseofulvin B-TRIVIAL 
inhibits O 
growth O 
of O 
adrenocortical O 
tumor O 
cells O 
. O 
We O 
studied O 
the O 
viability O 
and O 
antiproliferative O 
effects O 
of O 
griseofulvin B-TRIVIAL 
on O 
cultured O 
NCI-H295R O 
adrenocortical O 
carcinoma O 
cells O 
using O 
Wst-1 B-TRIVIAL 
- O 
, O 
BrdUrd B-FORMULA 
- O 
, O 
and O 
[3H]-thymidine B-SYSTEMATIC 
assays O 
. O 
For O 
the O 
detection O 
of O 
apoptosis O 
we O 
used O 
a O 
caspase O 
3 O 
/ O 
7 O 
cleavage O 
assay O 
and O 
light O 
microscopy O 
techniques O 
. O 
We O 
observed O 
that O 
incubation O 
with O 
griseofulvin B-TRIVIAL 
for O 
24-48 O 
h O 
leads O 
to O 
a O 
decrease O 
in O 
the O 
viability O 
and O 
proliferation O 
of O 
NCI-H295R O 
cells O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Significant O 
effects O 
could O 
be O 
observed O 
after O 
incubation O 
with O 
griseofulvin B-TRIVIAL 
as O 
measured O 
by O 
Wst-1 B-TRIVIAL 
- O 
, O 
BrdUrd B-FORMULA 
- O 
, O 
and O 
[3H]dT B-SYSTEMATIC 
- O 
uptake O 
assays O 
. O 
Apoptosis O 
of O 
NCI-H295R O 
cells O 
was O 
increased O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
up O 
to O 
4.5-fold O 
after O 
incubation O 
with O 
griseofulvin B-TRIVIAL 
40 O 
μM O 
for O 
24 O 
h O 
as O 
shown O 
by O 
caspase O 
3 O 
/ O 
7 O 
cleavage O 
assay O 
and O 
light O 
microscopy O 
. O 
With O 
regard O 
to O 
new O 
treatment O 
strategies O 
for O 
adrenocortical O 
cancer O 
, O 
griseofulvin B-TRIVIAL 
, O 
and O 
possibly O 
other O 
agents O 
, O 
which O 
interfere O 
with O 
the O 
microtubule O 
apparatus O 
and O 
inhibit O 
centrosomal O 
clustering O 
, O 
may O 
turn O 
out O 
to O 
be O 
interesting O 
targets O 
for O 
further O 
research O 
. O 

gastric O 
TFF2 O 
peptide O 
contains O 
an O 
N- B-SYSTEMATIC 
linked I-SYSTEMATIC 
fucosylated I-SYSTEMATIC 
N,N'-diacetyllactosediamine I-SYSTEMATIC 
( O 
LacdiNAc B-FORMULA 
) O 
oligosaccharide O 
. O 

the O 
human O 
stomach O 
, O 
the O 
peptide O 
trefoil O 
factor O 
family O 
2 O 
( O 
TFF2 O 
) O 
is O 
secreted O 
together O 
with O 
the O 
mucin O 
MUC6 O 
by O 
mucous O 
neck O 
cells O 
( O 
MNCs O 
) O 
and O 
antral O 
gland O 
cells O 
. O 
TFF2 O 
is O 
strongly O 
associated O 
with O 
the O 
gastric O 
mucus O 
and O 
promotes O 
gastric O 
restitution O 
. O 
Here O 
, O 
TFF2 O 
was O 
purified O 
from O 
the O 
human O 
corpus O 
and O 
antrum O 
, O 
respectively O 
, O 
by O 
size O 
- O 
exclusion O 
chromatography O 
, O 
and O 
the O 
N B-FORMULA 
-linked O 
glycan O 
structure O 
at O 
N- O 
15 O 
of O 
the O 
mature O 
peptide O 
was O 
determined O 
. O 
As O 
a O 
hallmark O 
, O 
the O 
unusual O 
monofucosylated B-SYSTEMATIC 
N,N'-diacetylhexosediamine I-SYSTEMATIC 
( O 
tentatively O 
assigned O 
as O 
GalNAcβ1 B-FORMULA 
→ I-FORMULA 
4GlcNAc I-FORMULA 
, O 
LacdiNAc B-FORMULA 
) O 
modification O 
was O 
detected O 
as O 
the O 
terminal O 
structure O 
of O 
a O 
bi O 
- O 
antennary O 
complex O 
type O 
N B-FORMULA 
-glycan O 
exhibiting O 
also O 
core O 
fucosylation O 
. O 
Replicate O 
analyses O 
did O 
not O 
show O 
microheterogeneities O 
in O 
the O 
fraction O 
of O 
peptide- O 
N B-FORMULA 
-glycosidase O 
F O 
cleaved O 
and O 
permethylated O 
N B-FORMULA 
-glycans O 
when O 
analyzed O 
by O 
matrix O 
- O 
assisted O 
laser O 
desorption O 
ionization O 
( O 
MALDI O 
) O 
mass O 
spectrometry O 
( O 
MS O 
) O 
. O 
On O 
the O 
glycopeptide O 
level O 
, O 
a O 
minor O 
glycan O 
microheterogeneity O 
was O 
evident O 
in O 
liquid O 
chromatography O 
- O 
electrospray O 
ionization O 
(ESI)-MS O 
, O 
demonstrating O 
the O 
presence O 
of O 
underfucosylated O 
species O 
. O 
The O 
tryptic O 
TFF2 O 
N B-FORMULA 
-glycopeptide O 
p34-39 O 
( O 
LSPHNR O 
N B-FORMULA 
-glycosylated O 
with O 
Fuc3Hex3HexNAc6 B-FORMULA 
) O 
was O 
identified O 
by O 
both O 
ESI-tandem O 
mass O 
spectrometry O 
and O 
MALDI-post O 
- O 
source O 
decay O 
analysis O 
. O 
Lectin O 
analyses O 
with O 
the O 
Wisteria O 
floribunda O 
agglutinin O 
indicated O 
the O 
potential O 
presence O 
of O 
LacdiNAc B-FORMULA 
terminating O 
glycans O 
and O 
revealed O 
minor O 
differences O 
between O 
TFF2 O 
from O 
fundic O 
units O 
, O 
i.e O 
. O 
MNCs O 
, O 
and O 
antral O 
units O 
, O 
i.e O 
. O 
antral O 
gland O 
cells O 
. O 
Strikingly O 
, O 
on O 
the O 
level O 
of O 
the O 
primary O 
structure O 
, O 
there O 
was O 
no O 
indication O 
that O 
the O 
formation O 
of O 
the O 
proposed O 
LacdiNAc B-FORMULA 
structure O 
is O 
cis-controlled O 
by O 
a O 
peptidic O 
determinant O 
related O 
to O 
the O 
published O 
sequences O 
. O 

of O 
pipecolic B-TRIVIAL 
acid I-TRIVIAL 
with O 
stochastic O 
and O 
potentiometric O 
microsensors O 
. O 

and O 
potentiometric O 
microsensors O 
based O 
on O 
porphyrins B-FAMILY 
and O 
polymeric O 
surfactants O 
such O 
as O 
polysodium B-FAMILY 
N-undecanoyl-L-leucylvanilate I-FAMILY 
and O 
polysodium B-FAMILY 
N-undecanoyl-L-vanilate I-FAMILY 
were O 
developed O 
for O 
enantioselective O 
assay O 
of O 
pipecolic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
matrices O 
used O 
for O 
the O 
design O 
of O 
the O 
stochastic O 
sensors O 
were O 
diamond B-TRIVIAL 
paste O 
and O 
graphite B-TRIVIAL 
paste O 
, O 
while O 
the O 
matrix O 
used O 
for O 
the O 
design O 
of O 
potentiometric O 
sensors O 
was O 
carbon B-SYSTEMATIC 
paste O 
. O 
The O 
response O 
characteristics O 
of O 
the O 
microsensors O 
were O 
determined O 
for O 
the O 
enantiomers O 
of O 
pipecolic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
response O 
characteristics O 
, O 
selectivity O 
, O 
and O 
enantioselectivity O 
studies O 
proved O 
that O 
the O 
proposed O 
microsensors O 
can O 
be O 
used O 
for O 
clinical O 
enantioanalysis O 
of O 
pipecolic B-TRIVIAL 
acid I-TRIVIAL 
in O 
biological O 
fluids O 
, O 
e.g O 
. O 
, O 
urine O 
and O 
whole O 
blood O 
. O 

of O 
suppressive O 
and O 
pro O 
- O 
resolving O 
effects O 
of O 
EPA B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
in O 
human O 
primary O 
monocytes O 
and O 
T-helper O 
cells O 
. O 

their O 
beneficial O 
anti-inflammatory O 
properties O 
, O 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
and O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
may O 
increase O 
the O 
infection O 
risk O 
at O 
high O 
doses O 
, O 
likely O 
by O 
generating O 
an O 
immune O 
- O 
depressed O 
state O 
. O 
To O 
assess O 
the O 
contribution O 
of O 
different O 
immune O 
cell O 
populations O 
to O 
the O 
immunomodulatory O 
fatty B-FAMILY 
acid I-FAMILY 
effect O 
, O 
we O 
comparatively O 
investigated O 
several O 
aspects O 
of O 
inflammation O 
in O 
human O 
T-helper O 
( O 
Th O 
) O 
cells O 
and O 
monocytes O 
. O 
Both O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
but O 
DHA B-ABBREVIATION 
to O 
a O 
lesser O 
extent O 
compared O 
with O 
EPA B-ABBREVIATION 
, O 
selectively O 
and O 
dose O 
- O 
dependently O 
reduced O 
the O 
percentage O 
of O 
cytokine O 
- O 
expressing O 
Th O 
cells O 
in O 
a O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
(PPAR)γ-dependent O 
fashion O 
, O 
whereas O 
the O 
expression O 
of O 
the O 
cell O 
surface O 
marker O 
CD69 O 
was O 
unaltered O 
on O 
activated O 
T O 
cells O 
. O 
In O 
monocytes O 
, O 
both O 
EPA B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
increased O 
interleukin O 
(IL)-10 O 
without O 
affecting O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
and O 
IL-6 O 
. O 
Cellular O 
incorporation O 
of O 
EPA B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
occurred O 
mainly O 
at O 
the O 
expense O 
of O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Concomitantly O 
, O 
thromboxane B-NO_CLASS 
B I-NO_CLASS 
(TXB)2 B-ABBREVIATION 
and O 
leukotriene B-NO_CLASS 
B I-NO_CLASS 
(LTB)4 B-ABBREVIATION 
in O 
supernatants O 
decreased O 
, O 
while O 
levels O 
of O 
TXB3 B-ABBREVIATION 
and O 
LTB5 B-ABBREVIATION 
increased O 
. O 
This O 
increase O 
was O 
independent O 
of O 
activation O 
and O 
in O 
accordance O 
with O 
cyclooxygenase O 
expression O 
patterns O 
in O 
monocytes O 
. O 
Moreover O 
, O 
EPA B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
gave O 
rise O 
to O 
a O 
variety O 
of O 
mono- B-MULTIPLE 
and I-MULTIPLE 
trihydroxy I-MULTIPLE 
derivatives O 
of O 
highly O 
anti-inflammatory O 
potential O 
, O 
such O 
as O 
resolvins B-FAMILY 
and O 
their O 
precursors O 
. O 
Our O 
results O 
suggest O 
that O 
EPA B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
do O 
not O 
generally O 
affect O 
immune O 
cell O 
functions O 
in O 
an O 
inhibitory O 
manner O 
but O 
rather O 
promote O 
pro O 
- O 
resolving O 
responses O 
. O 

- O 
assembly O 
of O 
double O 
helical O 
nanostructures O 
inside O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

use O 
molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
to O 
show O 
that O 
a O 
DNA O 
- O 
like O 
double O 
helix O 
of O 
two O 
poly(acetylene) B-FAMILY 
( O 
PA O 
) O 
chains O 
can O 
form O 
inside O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
. O 
The O 
computational O 
results O 
indicate O 
that O 
SWNTs O 
can O 
activate O 
and O 
guide O 
the O 
self O 
- O 
assembly O 
of O 
polymer O 
chains O 
, O 
allowing O 
them O 
to O 
adopt O 
a O 
helical O 
configuration O 
in O 
a O 
SWNT O 
through O 
the O 
combined O 
action O 
of O 
the O 
van O 
der O 
Waals O 
potential O 
well O 
and O 
the O 
π-π O 
stacking O 
interaction O 
between O 
the O 
polymer O 
and O 
the O 
inner O 
surface O 
of O 
SWNTs O 
. O 
Meanwhile O 
both O 
the O 
SWNT O 
size O 
and O 
polymer O 
chain O 
stiffness O 
determine O 
the O 
outcome O 
of O 
the O 
nanostructure O 
. O 
Furthermore O 
, O 
we O 
also O 
found O 
that O 
water O 
clusters O 
encourage O 
the O 
self O 
- O 
assembly O 
of O 
PA O 
helical O 
structures O 
in O 
the O 
tube O 
. O 
This O 
molecular O 
model O 
may O 
lead O 
to O 
a O 
better O 
understanding O 
of O 
the O 
formation O 
of O 
a O 
double O 
helix O 
biological O 
molecule O 
inside O 
SWNTs O 
. O 
Alternatively O 
, O 
it O 
could O 
form O 
the O 
basis O 
of O 
a O 
novel O 
nanoscale O 
material O 
by O 
utilizing O 
the O 
' O 
empty O 
' O 
spaces O 
of O 
SWNTs O 
. O 

- O 
induced O 
Dirac O 
cone O 
- O 
like O 
electronic O 
structures O 
and O 
semiconductor O 
- O 
semimetal O 
transition O 
in O 
graphdiyne B-TRIVIAL 
. O 

means O 
of O 
first O 
- O 
principles O 
calculations O 
combined O 
with O 
the O 
tight O 
- O 
binding O 
approximation O 
, O 
the O 
strain O 
- O 
induced O 
semiconductor O 
- O 
semimetal O 
transition O 
in O 
graphdiyne B-TRIVIAL 
is O 
discovered O 
. O 
It O 
is O 
shown O 
that O 
the O 
band O 
gap O 
of O 
graphdiyne B-TRIVIAL 
increases O 
from O 
0.47 O 
eV O 
to O 
1.39 O 
eV O 
with O 
increasing O 
the O 
biaxial O 
tensile O 
strain O 
, O 
while O 
the O 
band O 
gap O 
decreases O 
from O 
0.47 O 
eV O 
to O 
nearly O 
zero O 
with O 
increasing O 
the O 
uniaxial O 
tensile O 
strain O 
, O 
and O 
Dirac O 
cone O 
- O 
like O 
electronic O 
structures O 
are O 
observed O 
. O 
The O 
uniaxial O 
strain O 
- O 
induced O 
changes O 
of O 
the O 
electronic O 
structures O 
of O 
graphdiyne B-TRIVIAL 
come O 
from O 
the O 
breaking O 
of O 
geometrical O 
symmetry O 
that O 
lifts O 
the O 
degeneracy O 
of O 
energy O 
bands O 
. O 
The O 
properties O 
of O 
graphdiyne B-TRIVIAL 
under O 
strains O 
are O 
found O 
to O 
differ O 
remarkably O 
from O 
that O 
of O 
graphene B-TRIVIAL 
. O 

/ O 
sulfur B-SYSTEMATIC 
batteries O 
with O 
high O 
specific O 
energy O 
: O 
old O 
challenges O 
and O 
new O 
opportunities O 
. O 

this O 
review O 
, O 
we O 
begin O 
with O 
a O 
brief O 
discussion O 
of O 
the O 
operating O 
principles O 
and O 
scientific O 
/ O 
technical O 
challenges O 
faced O 
by O 
the O 
development O 
of O 
lithium B-SYSTEMATIC 
/ O 
sulfur B-SYSTEMATIC 
cells O 
. O 
We O 
then O 
introduce O 
some O 
recent O 
progress O 
in O 
exploring O 
cathodes O 
, O 
anodes O 
, O 
and O 
electrolytes O 
for O 
lithium B-SYSTEMATIC 
/ O 
sulfur B-SYSTEMATIC 
cells O 
. O 
In O 
particular O 
, O 
several O 
effective O 
strategies O 
used O 
to O 
enhance O 
energy O 
/ O 
power O 
density O 
, O 
obtain O 
good O 
efficiencies O 
, O 
and O 
prolong O 
cycle O 
life O 
will O 
be O 
highlighted O 
. O 
We O 
also O 
discuss O 
recent O 
advancements O 
in O 
techniques O 
for O 
investigating O 
electrode O 
reactions O 
in O 
real O 
time O 
and O 
monitoring O 
structural O 
/ O 
morphological O 
changes O 
of O 
electrode O 
materials O 
under O 
cell O 
operating O 
conditions O 
to O 
gain O 
a O 
better O 
understanding O 
of O 
the O 
mechanistic O 
details O 
of O 
electrode O 
processes O 
. O 
Finally O 
, O 
the O 
opportunities O 
and O 
perspective O 
for O 
future O 
research O 
directions O 
will O 
be O 
discussed O 
. O 

pair O 
dynamics O 
: O 
solvolyses O 
of O 
chiral B-FAMILY 
1,3-diarylallyl I-FAMILY 
carboxylates I-FAMILY 
as O 
a O 
case O 
study O 
. O 

ion O 
pairs O 
play O 
a O 
key O 
role O 
in O 
modern O 
enantioselective O 
synthesis O 
, O 
though O 
little O 
is O 
known O 
about O 
their O 
properties O 
. O 
We O 
have O 
now O 
used O 
the O 
special O 
features O 
of O 
unsymmetrically O 
substituted O 
allyl B-SYSTEMATIC 
derivatives O 
to O 
obtain O 
unprecedented O 
insight O 
into O 
ion O 
pair O 
dynamics O 
. O 
By O 
employing O 
chiral O 
high O 
- O 
performance O 
liquid O 
chromatography O 
, O 
it O 
was O 
possible O 
to O 
follow O 
the O 
time O 
- O 
dependent O 
concentrations O 
of O 
all O 
four O 
isomeric O 
esters B-FAMILY 
( O 
two O 
regioisomeric O 
pairs O 
of O 
enantiomers O 
) O 
and O 
all O 
four O 
isomeric O 
alcohols B-FAMILY 
generated O 
during O 
the O 
hydrolysis O 
of O 
enantiopure O 
1-(4-chlorophenyl)-3-phenylallyl B-MULTIPLE 
and I-MULTIPLE 
3-(4-chlorophenyl)-1-phenylallyl I-MULTIPLE 
4-nitrobenzoates I-MULTIPLE 
. O 
Combination O 
of O 
these O 
results O 
with O 
the O 
directly O 
measured O 
rate O 
constant O 
for O 
the O 
reaction O 
of O 
the O 
laser O 
- O 
flash O 
photolytically O 
generated O 
1-(4-chlorophenyl)-3-phenylallyl B-SYSTEMATIC 
cation O 
with O 
water O 
provided O 
a O 
complete O 
mechanistic O 
scheme O 
for O 
allyl B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
solvolysis O 
. O 
It O 
is O 
demonstrated O 
that O 
solvolysis O 
and O 
internal O 
return O 
can O 
be O 
explained O 
by O 
the O 
same O 
intermediates O 
. O 
The O 
correlation O 
equation O 
log O 
k O 
= O 
s(N)(N O 
+ O 
E O 
) O 
was O 
used O 
to O 
elucidate O 
the O 
variable O 
importance O 
of O 
external O 
and O 
internal O 
return O 
in O 
the O 
solvolysis O 
reactions O 
. O 
This O 
information O 
will O 
be O 
crucial O 
for O 
the O 
interpretation O 
of O 
the O 
ultrafast O 
dynamics O 
of O 
ion O 
pairs O 
generated O 
by O 
femtosecond O 
laser O 
pulses O 
. O 

effects O 
of O 
acute O 
and O 
chronic O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
exposure O 
on O 
hepatic O 
lipid O 
deposition O 
and O 
metabolism O 
in O 
yellow O 
catfish O 
Pelteobagrus O 
fulvidraco O 
. O 

present O 
study O 
is O 
conducted O 
to O 
determine O 
the O 
potential O 
mechanisms O 
of O 
Zn B-FORMULA 
on O 
hepatic O 
lipid O 
deposition O 
and O 
metabolism O 
for O 
yellow O 
catfish O 
Pelteobagrus O 
fulvidraco O 
with O 
8-week O 
chronic O 
exposure O 
to O 
low O 
Zn B-FORMULA 
levels O 
( O 
Zn B-FORMULA 
levels O 
: O 
0.05 O 
, O 
0.35 O 
and O 
0.86mg O 
/ O 
l O 
Zn B-FORMULA 
, O 
respectively O 
) O 
and O 
96-h O 
acute O 
exposure O 
to O 
a O 
high O 
Zn B-FORMULA 
level O 
( O 
Zn B-FORMULA 
level O 
: O 
4.71mg O 
/ O 
l O 
Zn B-FORMULA 
, O 
respectively O 
) O 
. O 
For O 
that O 
purpose O 
, O 
hepatic O 
lipid O 
deposition O 
and O 
Zn B-FORMULA 
accumulation O 
, O 
hepatic O 
carnitine B-TRIVIAL 
palmitoyltransferase O 
I O 
( O 
CPT O 
I O 
) O 
and O 
lipoprotein O 
lipase O 
( O 
LPL O 
) O 
activities O 
, O 
and O 
the O 
hepatic O 
mRNA O 
expression O 
of O 
ten O 
genes O 
involved O 
in O 
lipid O 
metabolism O 
are O 
determined O 
. O 
Chronic O 
( O 
8 O 
weeks O 
) O 
exposure O 
to O 
low O 
Zn B-FORMULA 
levels O 
apparently O 
increases O 
hepatic O 
lipid O 
content O 
, O 
hepatosomatic O 
index O 
( O 
HSI O 
) O 
( O 
P O 
< O 
0.05 O 
) O 
and O 
LPL O 
activity O 
, O 
and O 
reduces O 
hepatic O 
CPT O 
I O 
activity O 
. O 
In O 
contrast O 
, O 
the O 
acute O 
( O 
96h O 
) O 
exposure O 
to O 
high O 
Zn B-FORMULA 
level O 
reduces O 
hepatic O 
lipid O 
content O 
, O 
HSI O 
and O 
LPL O 
activity O 
, O 
and O 
increases O 
CPT O 
I O 
activity O 
. O 
The O 
change O 
of O 
mRNA O 
levels O 
of O 
genes O 
related O 
to O 
lipid O 
metabolism O 
is O 
Zn B-FORMULA 
concentration O 
- O 
dependent O 
. O 
Pearson O 
correlations O 
among O 
mRNA O 
expression O 
levels O 
, O 
lipid O 
content O 
, O 
CPT O 
I O 
and O 
LPL O 
activities O 
in O 
liver O 
are O 
also O 
observed O 
in O 
yellow O 
catfish O 
with O 
the O 
8-week O 
chronic O 
Zn B-FORMULA 
exposure O 
. O 
For O 
the O 
first O 
time O 
, O 
our O 
study O 
demonstrates O 
the O 
effect O 
of O 
waterborne O 
Zn B-FORMULA 
exposure O 
on O 
lipid O 
metabolism O 
at O 
the O 
molecular O 
levels O 
in O 
fish O 
, O 
which O 
may O 
contribute O 
to O 
understanding O 
the O 
mechanism O 
of O 
Zn B-FORMULA 
-induced O 
hepatic O 
toxicity O 
in O 
fish O 
. O 

RELEVANCE O 
: O 
Arisaema O 
franchetianum O 
and O 
Arisaema O 
lobatum O 
are O 
two O 
perennial O 
plants O 
native O 
to O 
China O 
. O 
Arisaema O 
franchetianum O 
is O 
universally O 
used O 
to O 
promote O 
the O 
subsidence O 
of O 
induration O 
and O 
swelling O 
, O 
quicken O 
blood O 
and O 
relieve O 
pains O 
, O 
and O 
kill O 
intestinal O 
parasites O 
in O 
humans O 
and O 
animals O 
. O 
Arisaema O 
lobatum O 
is O 
used O 
to O 
treat O 
malaria O 
, O 
intestinal O 
parasites O 
, O 
and O 
snake O 
and O 
insect O 
bites O 
in O 
humans O 
and O 
animals O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
composition O 
of O 
the O 
essential O 
oils O 
from O 
Arisaema O 
franchetianum O 
and O 
Arisaema O 
lobatum O 
and O 
evaluate O 
the O 
anthelmintic O 
effect O 
against O 
Haemonchus O 
contortus O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Two O 
oils O 
were O 
investigated O 
by O 
GC O 
and O 
GC-MS O 
. O 
The O 
anthelmintic O 
bioassay O 
tests O 
of O 
Arisaema O 
franchetianum O 
and O 
Arisaema O 
lobatum O 
essential O 
oil O 
, O 
linalool B-TRIVIAL 
and O 
carvacrol B-TRIVIAL 
were O 
performed O 
using O 
egg O 
hatch O 
assay O 
( O 
EHA O 
) O 
, O 
larval O 
development O 
assay O 
( O 
LDA O 
) O 
and O 
larval O 
migration O 
inhibition O 
assay O 
( O 
LMIA O 
) O 
. O 
RESULTS O 
: O 
Fifty O 
six O 
components O 
representing O 
96.88% O 
of O 
the O 
Arisaema O 
franchetianum O 
oil O 
and O 
64 O 
components O 
representing O 
96.88% O 
of O 
the O 
Arisaema O 
lobatum O 
oil O 
were O 
identified O 
. O 
Carvacrol B-TRIVIAL 
and O 
linalool B-TRIVIAL 
were O 
found O 
to O 
be O 
the O 
major O 
constituents O 
of O 
two O 
oils O 
. O 
In O 
the O 
EHA O 
, O 
greater O 
than O 
99% O 
inhibition O 
were O 
observed O 
with O 
Arisaema O 
franchetianum O 
oil O 
at O 
10mg O 
/ O 
mL O 
( O 
CE50 O 
1.63mg O 
/ O 
mL O 
) O 
and O 
Arisaema O 
lobatum O 
oil O 
at O 
5 O 
and O 
10mg O 
/ O 
mL O 
( O 
CE50 O 
0.48mg O 
/ O 
mL O 
) O 
. O 
In O 
the O 
LDA O 
, O 
both O 
oils O 
induced O 
complete O 
inhibition O 
at O 
10mg O 
/ O 
mL O 
, O 
with O 
the O 
CE50 O 
being O 
1.10mg O 
/ O 
mL O 
for O 
Arisaema O 
franchetianum O 
oil O 
and O 
0.73mg O 
/ O 
mL O 
for O 
Arisaema O 
lobatum O 
oil O 
. O 
In O 
the O 
LMIA O 
, O 
the O 
Arisaema O 
franchetianum O 
oil O 
and O 
Arisaema O 
lobatum O 
oil O 
at O 
best O 
inhibited O 
74.1% O 
and O 
95.6% O 
of O 
larval O 
migration O 
at O 
10mg O 
/ O 
mL O 
, O 
respectively O 
. O 
Carvacrol B-TRIVIAL 
exhibited O 
similar O 
activity O 
to O 
Arisaema O 
lobatum O 
essential O 
oil O 
and O 
linalool B-TRIVIAL 
did O 
not O 
show O 
high O 
activity O 
in O 
every O 
assay O 
. O 
CONCLUSIONS O 
: O 
These O 
data O 
show O 
for O 
the O 
first O 
time O 
that O 
the O 
essential O 
oils O 
obtained O 
from O 
Arisaema O 
franchetianum O 
or O 
Arisaema O 
lobatum O 
had O 
promising O 
anthelmintic O 
activity O 
against O 
Haemonchus O 
contortus O 
. O 
Arisaema O 
plant O 
may O 
offer O 
an O 
alternative O 
source O 
for O 
the O 
control O 
of O 
gastrointestinal O 
nematodes O 
of O 
sheep O 
and O 
goats O 
. O 

nitration O 
promotes O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
transcription O 
mediated O 
by O 
NF-κB O 
in O 
high O 
glucose B-TRIVIAL 
-stimulated O 
human O 
lens O 
epithelial O 
cells O 
. O 

an O 
important O 
event O 
in O 
hyperglycaemia O 
- O 
induced O 
oxidative O 
stress O 
is O 
the O 
nuclear O 
factor O 
- O 
kappa O 
b O 
(NF-κB)-activated O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
expression O 
, O 
the O 
underlying O 
mechanism O 
is O 
not O 
fully O 
characterized O 
. O 
Peroxynitrite B-SYSTEMATIC 
, O 
formed O 
from O 
NO B-FORMULA 
and O 
superoxide B-TRIVIAL 
, O 
can O 
induce O 
multiple O 
proteins O 
nitration O 
, O 
even O 
including O 
NF-κB O 
and O 
iNOS O 
, O 
to O 
alter O 
their O 
functions O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
high O 
glucose B-TRIVIAL 
caused O 
conspicuous O 
nitration O 
of O 
nuclear O 
NF-κB O 
p65 O 
and O 
its O 
co O 
- O 
activator O 
p300 O 
in O 
human O 
lens O 
epithelial O 
cells O 
. O 
The O 
nitration O 
of O 
NF-κB O 
and O 
p300 O 
promoted O 
their O 
co O 
- O 
localization O 
and O 
binding O 
to O 
ensure O 
the O 
activation O 
of O 
the O 
iNOS O 
gene O 
transcription O 
. O 
Moreover O 
, O 
nearly O 
all O 
predicted O 
NF-κB O 
binding O 
sites O 
in O 
the O 
human O 
iNOS O 
gene O 
promoter O 
were O 
responsive O 
to O 
high O 
glucose B-TRIVIAL 
stimulation O 
, O 
might O 
for O 
a O 
synergistic O 
role O 
. O 
While O 
, O 
only O 
the O 
NF-κB O 
binding O 
site O 
-5212 O 
showed O 
significant O 
alterations O 
by O 
high O 
glucose B-TRIVIAL 
and O 
peroxynitrite B-SYSTEMATIC 
stimulations O 
, O 
indicating O 
it O 
a O 
more O 
important O 
role O 
in O 
the O 
protein O 
nitration O 
promoted O 
iNOS O 
gene O 
transcription O 
. O 
Our O 
results O 
demonstrated O 
that O 
protein O 
nitration O 
can O 
promote O 
the O 
NF-κB-activated O 
iNOS O 
gene O 
transcription O 
in O 
human O 
lens O 
epithelial O 
cells O 
by O 
high O 
glucose B-TRIVIAL 
stimulation O 
. O 

in O 
pinnipeds O 
represents O 
the O 
most O 
significant O 
cost O 
to O 
mothers O 
during O 
the O 
reproductive O 
cycle O 
. O 
Dynamics O 
of O 
trace O 
elements O 
and O 
their O 
mobilization O 
associated O 
with O 
energy O 
reserves O 
during O 
such O 
an O 
intense O 
physiological O 
process O 
remains O 
poorly O 
understood O 
in O 
marine O 
mammals O 
. O 
The O 
changes O 
in O 
tissue O 
concentrations O 
of O 
11 O 
elements O 
( O 
Ca B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Hg B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Pb B-FORMULA 
, O 
Se B-FORMULA 
, O 
V B-FORMULA 
, O 
and O 
Zn B-FORMULA 
) O 
were O 
investigated O 
in O 
a O 
longitudinal O 
study O 
during O 
the O 
lactation O 
period O 
and O 
during O 
the O 
post O 
- O 
weaning O 
fast O 
period O 
. O 
Blood O 
, O 
milk O 
, O 
blubber O 
, O 
and O 
hair O 
samples O 
were O 
collected O 
sequentially O 
from O 
21 O 
mother O 
- O 
pup O 
pairs O 
of O 
grey O 
seals O 
( O 
Halichoerus O 
grypus O 
) O 
from O 
the O 
Isle O 
of O 
May O 
in O 
Scotland O 
. O 
Maternal O 
transfer O 
through O 
the O 
milk O 
was O 
observed O 
for O 
all O 
trace O 
elements O 
, O 
except O 
for O 
Cd B-FORMULA 
. O 
As O 
an O 
indicator O 
of O 
the O 
placental O 
transfer O 
, O 
levels O 
in O 
pup O 
lanugo O 
( O 
natal O 
coat O 
) O 
revealed O 
also O 
the O 
existence O 
of O 
maternal O 
transfer O 
and O 
accumulation O 
of O 
all O 
assayed O 
trace O 
elements O 
during O 
the O 
foetal O 
development O 
. O 
The O 
placental O 
and O 
mammary O 
barriers O 
against O 
non-essential O 
metal O 
transfer O 
to O 
offspring O 
appear O 
to O 
be O 
absent O 
or O 
weak O 
in O 
grey O 
seals O 
. O 
Examining O 
the O 
contamination O 
levels O 
showed O 
that O 
this O 
grey O 
seal O 
population O 
seems O 
more O 
highly O 
exposed O 
to O 
Pb B-FORMULA 
than O 
other O 
phocid O 
populations O 
( O 
2.2 O 
mg O 
/ O 
kg O 
dw O 
of O 
grey O 
seal O 
hair O 
) O 
. O 
In O 
contrast O 
, O 
blood O 
and O 
hair O 
levels O 
reflected O 
a O 
lower O 
Hg B-FORMULA 
exposure O 
in O 
grey O 
seals O 
from O 
the O 
Isle O 
of O 
May O 
than O 
in O 
harbour O 
seals O 
from O 
the O 
southeastern O 
North O 
Sea O 
. O 
This O 
study O 
also O 
showed O 
that O 
trace O 
element O 
concentrations O 
in O 
blood O 
and O 
blubber O 
could O 
change O 
rapidly O 
over O 
the O 
lactation O 
period O 
. O 
Such O 
physiological O 
processes O 
must O 
be O 
considered O 
carefully O 
during O 
biomonitoring O 
of O 
trace O 
elements O 
, O 
and O 
potential O 
impacts O 
that O 
rapid O 
fluctuations O 
in O 
concentrations O 
can O 
exert O 
on O 
seal O 
health O 
should O 
be O 
further O 
investigated O 
. O 

of O 
bottom O 
- O 
up O 
fabricated O 
graphene B-TRIVIAL 
nanoribbons O 
. O 

precise O 
graphene B-TRIVIAL 
nanoribbons O 
( O 
GNRs O 
) O 
can O 
be O 
obtained O 
via O 
thermally O 
induced O 
polymerization O 
of O 
suitable O 
precursor O 
molecules O 
on O 
a O 
metal O 
surface O 
. O 
This O 
communication O 
discusses O 
the O 
atomic O 
structure O 
found O 
at O 
the O 
termini O 
of O 
armchair O 
GNRs O 
obtained O 
via O 
this O 
bottom O 
- O 
up O 
approach O 
. O 
The O 
short O 
zigzag O 
edge O 
at O 
the O 
termini O 
of O 
the O 
GNRs O 
under O 
study O 
gives O 
rise O 
to O 
a O 
localized O 
midgap O 
state O 
with O 
a O 
characteristic O 
signature O 
in O 
scanning O 
tunneling O 
microscopy O 
( O 
STM O 
) O 
. O 
By O 
combining O 
STM O 
experiments O 
with O 
large O 
- O 
scale O 
density O 
functional O 
theory O 
calculations O 
, O 
we O 
demonstrate O 
that O 
the O 
termini O 
are O 
passivated O 
by O 
hydrogen B-SYSTEMATIC 
. O 
Our O 
results O 
suggest O 
that O 
the O 
length O 
of O 
nanoribbons O 
grown O 
by O 
this O 
protocol O 
may O 
be O 
limited O 
by O 
hydrogen B-SYSTEMATIC 
passivation O 
during O 
the O 
polymerization O 
step O 
. O 

: O 
a O 
review O 
of O 
its O 
use O 
as O 
add O 
- O 
on O 
therapy O 
in O 
patients O 
with O 
chronic O 
stable O 
angina O 
pectoris O 
. O 

- I-TRIVIAL 
release I-TRIVIAL 
ranolazine I-TRIVIAL 
( O 
ranolazine B-TRIVIAL 
ER I-TRIVIAL 
) O 
[ O 
Ranexa B-TRIVIAL 
( O 
® O 
) O 
] O 
is O 
an O 
antianginal O 
agent O 
that O 
achieves O 
its O 
effects O 
via O 
a O 
novel O 
mechanism O 
of O 
action O 
( O 
inhibition O 
of O 
the O 
late O 
phase O 
of O 
the O 
inward O 
sodium B-SYSTEMATIC 
current O 
) O 
, O 
without O 
affecting O 
heart O 
rate O 
or O 
blood O 
pressure O 
( O 
BP O 
) O 
. O 
This O 
article O 
reviews O 
the O 
efficacy O 
, O 
safety O 
and O 
tolerability O 
of O 
ranolazine B-TRIVIAL 
ER I-TRIVIAL 
as O 
add O 
- O 
on O 
therapy O 
in O 
patients O 
with O 
chronic O 
stable O 
angina O 
pectoris O 
, O 
as O 
well O 
as O 
summarizing O 
its O 
pharmacological O 
properties O 
and O 
its O 
use O 
in O 
non-ST-elevation O 
acute O 
coronary O 
syndromes O 
. O 
In O 
the O 
CARISA O 
and O 
ERICA O 
trials O 
, O 
add O 
- O 
on O 
therapy O 
with O 
ranolazine B-TRIVIAL 
ER I-TRIVIAL 
improved O 
exercise O 
tolerance O 
and O 
/ O 
or O 
reduced O 
angina O 
frequency O 
and O 
nitroglycerin B-SYSTEMATIC 
use O 
in O 
patients O 
with O 
chronic O 
stable O 
angina O 
; O 
benefits O 
were O 
seen O 
across O 
a O 
variety O 
of O 
patient O 
subgroups O 
. O 
Although O 
results O 
of O 
the O 
MERLIN-TIMI O 
36 O 
trial O 
do O 
not O 
support O 
the O 
use O 
of O 
ranolazine B-TRIVIAL 
ER I-TRIVIAL 
in O 
the O 
acute O 
management O 
of O 
non-ST-elevation O 
acute O 
coronary O 
syndromes O 
, O 
they O 
do O 
support O 
its O 
use O 
as O 
an O 
antianginal O 
therapy O 
. O 
Ranolazine B-TRIVIAL 
ER I-TRIVIAL 
was O 
generally O 
well O 
tolerated O 
, O 
with O 
the O 
most O 
commonly O 
reported O 
adverse O 
events O 
including O 
dizziness O 
, O 
nausea O 
, O 
asthenia O 
and O 
constipation O 
. O 
Despite O 
being O 
associated O 
with O 
modest O 
increases O 
in O 
the O 
corrected O 
QT O 
interval O 
, O 
ranolazine B-TRIVIAL 
ER I-TRIVIAL 
demonstrated O 
antiarrhythmic O 
effects O 
in O 
the O 
MERLIN-TIMI O 
36 O 
trial O 
. O 
In O 
conclusion O 
, O 
ranolazine B-TRIVIAL 
ER I-TRIVIAL 
provides O 
an O 
important O 
option O 
for O 
use O 
as O 
add O 
- O 
on O 
therapy O 
to O 
reduce O 
symptoms O 
in O 
patients O 
with O 
chronic O 
stable O 
angina O 
. O 

Processes O 
in O 
Squaraine B-TRIVIAL 
Dye I-TRIVIAL 
-Doped O 
OLEDs O 
for O 
Emission O 
in O 
the O 
Near-Infrared O 
. O 

proliferator O 
- O 
activated O 
receptor O 
γ O 
( O 
PPARγ O 
) O 
is O 
a O 
nuclear O 
receptor O 
and O 
plays O 
important O 
roles O 
in O 
breast O 
cancer O 
cell O 
proliferation O 
. O 
The O 
complexity O 
of O 
the O 
underlying O 
biochemical O 
and O 
molecular O 
mechanisms O 
of O 
breast O 
cancer O 
and O 
the O 
involvement O 
of O 
PPARγ O 
in O 
breast O 
cancer O 
pathophysiology O 
are O 
unclear O 
. O 
In O 
this O 
study O 
, O 
we O 
carried O 
out O 
prediction O 
of O 
the O 
peroxisome O 
proliferator O 
response O 
element O 
( O 
PPRE O 
) O 
motifs O 
in O 
2332 O 
genes O 
reported O 
to O 
be O 
involved O 
in O 
breast O 
cancer O 
in O 
literature O 
. O 
A O 
total O 
of O 
178 O 
genes O 
were O 
found O 
to O 
have O 
PPRE O 
( O 
DR1 O 
/ O 
DR2 O 
) O 
and O 
/ O 
or O 
PPAR-associated O 
conserved O 
motif O 
( O 
PACM O 
) O 
motifs O 
. O 
We O 
further O 
constructed O 
protein O 
- O 
protein O 
interaction O 
network O 
, O 
disease O 
gene O 
network O 
and O 
gene O 
ontology O 
( O 
GO O 
) O 
analyses O 
to O 
identify O 
novel O 
key O 
genes O 
for O 
experimental O 
validation O 
. O 
We O 
identified O 
two O 
genes O 
in O 
the O 
glycolytic O 
pathway O 
( O 
phosphoglycerate B-SYSTEMATIC 
kinase O 
1 O 
( O 
PGK1 O 
) O 
and O 
pyruvate B-TRIVIAL 
kinase O 
M2 O 
( O 
PKM2 O 
) O 
) O 
at O 
the O 
ATP B-ABBREVIATION 
production O 
steps O 
and O 
experimentally O 
validated O 
their O 
repression O 
by O 
PPARγ O 
in O 
two O 
breast O 
cancer O 
cell O 
lines O 
MDA-MB-231 O 
and O 
MCF-7 O 
. O 
Further O 
analysis O 
suggested O 
that O 
this O 
repression O 
leads O 
to O 
decrease O 
in O 
ATP B-ABBREVIATION 
levels O 
and O 
apoptosis O 
. O 
These O 
investigations O 
will O 
help O 
us O 
in O 
understanding O 
the O 
molecular O 
mechanisms O 
by O 
which O 
PPARγ O 
regulates O 
the O 
cellular O 
energy O 
pathway O 
and O 
the O 
use O 
of O 
its O 
ligands O 
in O 
human O 
breast O 
cancer O 
therapeutics O 
. O 

this O 
study O 
, O 
biological O 
activities O 
of O 
methanolic O 
extracts O 
from O 
Artemisia O 
herba O 
- O 
alba O 
, O 
Ruta O 
chalpensis O 
L O 
. O 
and O 
Peganum O 
harmala O 
L O 
. O 
plants O 
, O 
collected O 
in O 
Centre O 
of O 
Tunisia O 
, O 
were O 
investigated O 
. O 
Results O 
showed O 
an O 
important O 
phenolic O 
composition O 
of O 
Artemisia O 
herba O 
- O 
alba O 
( O 
123.95±4.3g O 
GAE O 
/ O 
kg O 
of O 
dry O 
mass O 
) O 
. O 
The O 
extract O 
of O 
this O 
plant O 
showed O 
, O 
using O 
different O 
antioxidant O 
assays O 
( O 
DPPH B-ABBREVIATION 
, O 
ABTS B-ABBREVIATION 
and O 
AAPH B-ABBREVIATION 
/ O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
methods O 
) O 
and O 
an O 
IFN-γ O 
/ O 
LPS O 
induced O 
RAW O 
264.7 O 
murine O 
macrophages O 
' O 
assay O 
, O 
the O 
highest O 
antioxidant O 
( O 
IC50 O 
( O 
DPPH B-ABBREVIATION 
assay O 
) O 
20.64±0.84mg O 
/ O 
L O 
) O 
and O 
anti-inflammatory O 
( O 
72% O 
inhibition O 
at O 
150mg O 
/ O 
L O 
) O 
activities O 
, O 
respectively O 
. O 
Excepting O 
Peganum O 
harmala O 
L O 
. O 
extract O 
, O 
the O 
two O 
other O 
extracts O 
showed O 
a O 
high O 
anticancer O 
activity O 
against O 
several O 
cell O 
lines O 
( O 
human O 
bladder O 
carcinoma O 
RT112 O 
, O 
human O 
laryngeal O 
carcinoma O 
Hep2 O 
and O 
human O 
myelogenous O 
leukemia O 
K562 O 
) O 
, O 
for O 
A O 
. O 
herba O 
- O 
laba O 
IC50=81.59±4.4 O 
, O 
59.05±3.66 O 
and O 
90.96mg O 
/ O 
L O 
respectively O 
, O 
but O 
not O 
on O 
normal O 
peripheral O 
blood O 
mononuclear O 
cells O 
. O 
All O 
these O 
biological O 
activities O 
are O 
well O 
correlated O 
with O 
the O 
phenolic O 
contents O 
of O 
these O 
extracts O 
. O 
These O 
findings O 
demonstrate O 
the O 
remarkable O 
potential O 
of O 
these O 
plants O 
as O 
valuable O 
source O 
of O 
antioxidants O 
with O 
exhibit O 
original O 
and O 
interesting O 
anti-inflammatory O 
and O 
anticancer O 
capacities O 
. O 

( O 
AChE O 
) O 
is O 
a O 
most O 
remarkable O 
protein O 
, O 
not O 
only O 
because O 
it O 
is O 
one O 
of O 
the O 
fastest O 
enzymes O 
in O 
nature O 
, O 
but O 
also O 
since O 
it O 
appears O 
in O 
many O 
molecular O 
forms O 
and O 
is O 
regulated O 
by O 
elaborate O 
genetic O 
networks O 
. O 
AChE O 
is O 
expressed O 
in O 
many O 
tissues O 
during O 
development O 
and O 
in O 
mature O 
organisms O 
, O 
as O 
well O 
as O 
in O 
healthy O 
and O 
diseased O 
states O 
. O 
In O 
search O 
for O 
alternative O 
, O 
" O 
non-classical O 
" O 
functions O 
of O 
cholinesterases O 
( O 
ChEs O 
) O 
, O 
AChE O 
could O 
either O 
work O 
within O 
the O 
frame O 
of O 
classic O 
cholinergic O 
systems O 
, O 
but O 
in O 
non-neural O 
tissues O 
( O 
" O 
non-synaptic O 
function O 
" O 
) O 
, O 
or O 
act O 
non-enzymatically O 
. O 
Here O 
, O 
we O 
review O 
briefly O 
some O 
of O 
the O 
major O 
ideas O 
and O 
advances O 
of O 
this O 
field O 
, O 
and O 
report O 
on O 
some O 
recent O 
progress O 
from O 
our O 
own O 
experimental O 
work O 
, O 
e.g O 
. O 
that O 
(i) O 
non-neural O 
ChEs O 
have O 
pronounced O 
, O 
predominantly O 
enzymatic O 
effects O 
on O 
early O 
embryonic O 
( O 
limb O 
) O 
development O 
in O 
chick O 
and O 
mouse O 
, O 
that O 
(ii) O 
retinal O 
R28 O 
cells O 
of O 
the O 
rat O 
overexpressing O 
synaptic O 
AChE O 
present O 
a O 
significantly O 
decreased O 
cell O 
proliferation O 
, O 
and O 
that O 
(iii) O 
in O 
developing O 
chick O 
retina O 
ACh B-ABBREVIATION 
-synthesizing O 
and O 
ACh B-ABBREVIATION 
-degrading O 
cells O 
originate O 
from O 
the O 
same O 
postmitotic O 
precursor O 
cells O 
, O 
which O 
later O 
form O 
two O 
locally O 
opposing O 
cell O 
populations O 
. O 
We O 
suggest O 
that O 
such O 
distinct O 
distributions O 
of O 
ChAT(+) O 
vs O 
. O 
AChE(+) O 
cells O 
in O 
the O 
inner O 
half O 
retina O 
provide O 
graded O 
distributions O 
of O 
ACh B-ABBREVIATION 
, O 
which O 
can O 
direct O 
cell O 
differentiation O 
and O 
network O 
formation O 
. O 
Thus O 
, O 
as O 
corroborated O 
by O 
works O 
from O 
many O 
labs O 
, O 
AChE O 
can O 
be O 
considered O 
a O 
highly O 
co O 
- O 
opting O 
protein O 
, O 
which O 
can O 
combine O 
enzymatic O 
and O 
non-enzymatic O 
functions O 
within O 
one O 
molecule O 
. O 

partition O 
of O 
carbon B-SYSTEMATIC 
nanotubes O 
in O 
polymer O 
- O 
modified O 
aqueous O 
phases O 
. O 

distribution O 
of O 
nanoparticles O 
in O 
different O 
aqueous O 
environments O 
is O 
a O 
fundamental O 
problem O 
underlying O 
a O 
number O 
of O 
processes O 
, O 
ranging O 
from O 
biomedical O 
applications O 
of O 
nanoparticles O 
to O 
their O 
effects O 
on O 
the O 
environment O 
, O 
health O 
, O 
and O 
safety O 
. O 
Here O 
, O 
we O 
study O 
distribution O 
of O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
in O 
two O 
immiscible O 
aqueous O 
phases O 
formed O 
by O 
the O 
addition O 
of O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
and O 
dextran O 
. O 
This O 
well O 
- O 
defined O 
model O 
system O 
exhibits O 
a O 
strikingly O 
robust O 
phenomenon O 
: O 
CNTs O 
spontaneously O 
partition O 
between O 
the O 
PEG B-ABBREVIATION 
- O 
and O 
the O 
dextran O 
- O 
rich O 
phases O 
according O 
to O 
nanotube's O 
diameter O 
and O 
metallicity O 
. O 
Thermodynamic O 
analysis O 
suggests O 
that O 
this O 
chirality O 
- O 
dependent O 
partition O 
is O 
determined O 
by O 
nanotube's O 
intrinsic O 
hydrophobicity O 
and O 
reveals O 
two O 
distinct O 
regimes O 
in O 
hydrophobicity O 
- O 
chirality O 
relation O 
: O 
a O 
small O 
diameter O 
( O 
< O 
1 O 
nm O 
) O 
regime O 
, O 
where O 
curvature O 
effect O 
makes O 
larger O 
diameter O 
tubes O 
more O 
hydrophobic O 
than O 
small O 
diameter O 
ones O 
, O 
and O 
a O 
large O 
diameter O 
( O 
> O 
1.2 O 
nm O 
) O 
regime O 
, O 
where O 
nanotube's O 
polarizability O 
renders O 
semiconducting O 
tubes O 
more O 
hydrophobic O 
than O 
metallic O 
ones O 
. O 
These O 
findings O 
reveal O 
a O 
general O 
rule O 
governing O 
CNT O 
behaviors O 
in O 
aqueous O 
phase O 
and O 
provide O 
an O 
extremely O 
simple O 
way O 
to O 
achieve O 
spatial O 
separation O 
of O 
CNTs O 
by O 
their O 
electronic O 
structures O 
. O 

determination O 
of O 
evodiamine B-TRIVIAL 
and O 
evodine B-TRIVIAL 
in O 
Beagle O 
dog O 
plasma O 
using O 
liquid O 
chromatography O 
tandem O 
mass O 
spectrometry O 
. O 

sensitive O 
, O 
rapid O 
, O 
and O 
specific O 
liquid O 
chromatography O 
/ O 
tandem O 
mass O 
spectrometry O 
assay O 
has O 
been O 
established O 
and O 
validated O 
for O 
the O 
quantitation O 
of O 
evodiamine B-TRIVIAL 
and O 
evodine B-TRIVIAL 
in O 
Beagle O 
dog O 
plasma O 
. O 
Plasma O 
samples O 
of O 
0.2 O 
ml O 
were O 
processed O 
by O 
liquid O 
- O 
liquid O 
extraction O 
with O 
n-hexane B-SYSTEMATIC 
/ O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
2 O 
: O 
1 O 
, O 
v O 
/ O 
v O 
) O 
. O 
Chromatographic O 
separations O 
were O 
done O 
on O 
a O 
Symmetry O 
C(18) O 
column O 
( O 
100 O 
mm O 
× O 
4.6 O 
mm O 
, O 
ID O 
, O 
5 O 
μm O 
) O 
at O 
35°C O 
with O 
a O 
linear O 
gradient O 
of O 
methanol B-SYSTEMATIC 
and O 
20 O 
mM O 
ammonium B-SYSTEMATIC 
formate I-SYSTEMATIC 
containing O 
0.2% O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Evodiamine B-TRIVIAL 
, O 
evodine B-TRIVIAL 
, O 
and O 
glibenclamide B-TRIVIAL 
[ O 
internal O 
standard O 
( O 
IS O 
) O 
] O 
were O 
ionized O 
with O 
an O 
electrospray O 
ionization O 
source O 
operated O 
in O 
positive O 
ion O 
mode O 
. O 
The O 
MS O 
/ O 
MS O 
transitions O 
were O 
m O 
/ O 
z O 
304.1 O 
→ O 
161.1 O 
for O 
evodiamine B-TRIVIAL 
, O 
m O 
/ O 
z O 
471.2 O 
→ O 
425.1 O 
for O 
evodine B-TRIVIAL 
, O 
and O 
m O 
/ O 
z O 
494.1 O 
→ O 
369.1 O 
for O 
IS O 
. O 
Calibration O 
curves O 
were O 
linear O 
over O 
the O 
concentration O 
range O 
of O 
0.1-100 O 
ng O 
/ O 
ml O 
for O 
evodiamine B-TRIVIAL 
and O 
0.5-500 O 
ng O 
/ O 
ml O 
for O 
evodine B-TRIVIAL 
. O 
The O 
mean O 
extraction O 
recoveries O 
were O 
88.1 O 
± O 
3.21% O 
for O 
evodiamine B-TRIVIAL 
and O 
81.24 O 
± O 
4.07% O 
for O 
evodine B-TRIVIAL 
. O 
The O 
intra- O 
and O 
inter O 
- O 
day O 
precisions O 
were O 
less O 
than O 
11.10% O 
and O 
12.81% O 
, O 
and O 
the O 
accuracy O 
was O 
within O 
± O 
11.76% O 
for O 
both O 
analytes O 
. O 
Evodiamine B-TRIVIAL 
and O 
evodine B-TRIVIAL 
were O 
stable O 
during O 
storage O 
and O 
analytical O 
periods O 
. O 
The O 
validated O 
method O 
has O 
been O 
successfully O 
applied O 
to O 
a O 
pharmacokinetic O 
study O 
of O 
evodiamine B-TRIVIAL 
and O 
evodine B-TRIVIAL 
in O 
beagle O 
dogs O 
after O 
oral O 
administration O 
. O 

- O 
component O 
signal O 
transduction O 
systems O 
( O 
TCSs O 
) O 
are O 
commonly O 
used O 
by O 
bacteria O 
to O 
couple O 
environmental O 
stimuli O 
to O 
adaptive O 
responses O 
. O 
Targeting O 
the O 
highly O 
conserved O 
kinase O 
domain O 
in O 
these O 
systems O 
represents O 
a O 
promising O 
strategy O 
for O 
the O 
design O 
of O 
a O 
broad O 
- O 
spectrum O 
antibiotic O 
; O 
however O 
, O 
development O 
of O 
such O 
compounds O 
has O 
been O 
marred O 
by O 
an O 
incomplete O 
understanding O 
of O 
the O 
conserved O 
binding O 
features O 
within O 
the O 
active O 
site O 
that O 
could O 
be O 
exploited O 
in O 
molecule O 
design O 
. O 
Consequently O 
, O 
a O 
large O 
percentage O 
of O 
the O 
available O 
TCS O 
inhibitors O 
demonstrate O 
poor O 
target O 
specificity O 
and O 
act O 
via O 
multiple O 
mechanisms O 
, O 
with O 
aggregation O 
of O 
the O 
kinase O 
being O 
the O 
most O 
notable O 
. O 
In O 
order O 
to O 
elucidate O 
the O 
mode O 
of O 
action O 
of O 
some O 
of O 
these O 
compounds O 
, O 
molecular O 
modeling O 
was O 
employed O 
to O 
dock O 
a O 
suite O 
of O 
molecules O 
into O 
the O 
ATP B-ABBREVIATION 
-binding O 
domain O 
of O 
several O 
histidine B-TRIVIAL 
kinases O 
. O 
This O 
effort O 
revealed O 
a O 
key O 
structural O 
feature O 
of O 
the O 
domain O 
that O 
is O 
likely O 
interacting O 
with O 
several O 
known O 
inhibitors O 
and O 
is O 
also O 
highly O 
conserved O 
. O 
Furthermore O 
, O 
generation O 
of O 
several O 
simplified O 
scaffolds O 
derived O 
from O 
a O 
reported O 
inhibitor O 
and O 
characterization O 
of O 
these O 
compounds O 
using O 
activity O 
assays O 
, O 
protein O 
aggregation O 
studies O 
and O 
saturation O 
transfer O 
differential O 
( O 
STD O 
) O 
NMR O 
suggests O 
that O 
targeting O 
of O 
this O 
protein O 
feature O 
may O 
provide O 
a O 
basis O 
for O 
the O 
design O 
of O 
ATP B-ABBREVIATION 
-competitive O 
compounds O 
. O 

- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
signaling O 
via O 
TrkB O 
crucially O 
regulates O 
synaptic O 
plasticity O 
in O 
the O 
brain O 
. O 
Although O 
BDNF O 
is O 
abundant O 
at O 
hippocampal O 
mossy O 
fiber O 
( O 
MF O 
) O 
synapses O 
, O 
which O 
critically O 
contribute O 
to O 
hippocampus O 
dependent O 
memory O 
, O 
its O 
role O 
in O 
MF O 
synaptic O 
plasticity O 
( O 
long O 
- O 
term O 
potentiation O 
, O 
LTP O 
) O 
remained O 
largely O 
unclear O 
. O 
Using O 
field O 
potential O 
recordings O 
in O 
CA3 O 
of O 
adult O 
heterozygous O 
BDNF O 
knockout O 
( O 
ko O 
, O 
BDNF+ O 
/ O 
- O 
) O 
mice O 
we O 
observed O 
impaired O 
( O 
∼50% O 
) O 
NMDAR O 
- O 
independent O 
MF-LTP O 
. O 
In O 
contrast O 
to O 
MF O 
synapses O 
, O 
LTP O 
at O 
neighboring O 
associative O 
/ O 
commissural O 
( O 
A O 
/ O 
C O 
) O 
fiber O 
synapses O 
remained O 
unaffected O 
. O 
To O 
exclude O 
that O 
impaired O 
MF-LTP O 
in O 
BDNF+ O 
/ O 
- O 
mice O 
was O 
due O 
to O 
developmental O 
changes O 
in O 
response O 
to O 
chronically O 
reduced O 
BDNF O 
levels O 
, O 
and O 
to O 
prove O 
the O 
importance O 
of O 
acute O 
availability O 
of O 
BDNF O 
in O 
MF-LTP O 
, O 
we O 
also O 
tested O 
effects O 
of O 
acute O 
interference O 
with O 
BDNF O 
/ O 
TrkB O 
signaling O 
. O 
Inhibition O 
of O 
TrkB O 
tyrosine B-TRIVIAL 
kinase O 
signaling O 
with O 
k252a O 
, O 
or O 
with O 
the O 
selective O 
BDNF O 
scavenger O 
TrkB-Fc O 
, O 
both O 
inhibited O 
MF-LTP O 
to O 
the O 
same O 
extent O 
as O 
observed O 
in O 
BDNF+ O 
/ O 
- O 
mice O 
. O 
Basal O 
synaptic O 
transmission O 
, O 
short O 
- O 
term O 
plasticity O 
, O 
and O 
synaptic O 
fatigue O 
during O 
LTP O 
induction O 
were O 
not O 
significantly O 
altered O 
by O 
treatment O 
with O 
k252a O 
or O 
TrkB-Fc O 
, O 
or O 
by O 
chronic O 
BDNF O 
reduction O 
in O 
BDNF+ O 
/ O 
- O 
mice O 
. O 
Since O 
the O 
acute O 
interference O 
with O 
BDNF-signaling O 
did O 
not O 
completely O 
block O 
MF-LTP O 
, O 
our O 
results O 
provide O 
evidence O 
that O 
an O 
additional O 
mechanism O 
besides O 
BDNF O 
induced O 
TrkB O 
signaling O 
contributes O 
to O 
this O 
type O 
of O 
LTP O 
. O 
Our O 
results O 
prove O 
for O 
the O 
first O 
time O 
a O 
mechanistic O 
action O 
of O 
acute O 
BDNF O 
/ O 
TrkB O 
signaling O 
in O 
presynaptic O 
expression O 
of O 
MF-LTP O 
in O 
adult O 
hippocampus O 
. O 

as O 
an O 
antioxidant O 
in O 
frying O 
oils O 
. O 

antioxidative O 
effect O 
of O 
sitosterol B-TRIVIAL 
at O 
1 O 
, O 
2 O 
and O 
5% O 
levels O 
, O 
in O 
triolein B-TRIVIAL 
, O 
refined O 
canola O 
, O 
high O 
oleic O 
sunflower O 
and O 
flaxseed O 
oils O 
, O 
continuously O 
heated O 
for O 
a O 
period O 
of O 
up O 
to O 
72 O 
h O 
at O 
frying O 
temperature O 
of O 
180 O 
°C O 
, O 
was O 
studied O 
. O 
High O 
Pressure O 
Size O 
Exclusion O 
Chromatography O 
( O 
HPSEC O 
) O 
was O 
used O 
to O 
monitor O 
changes O 
in O 
peak O 
areas O 
of O 
triacylglycerol B-FAMILY 
( O 
TG O 
) O 
polymer O 
, O 
monomer O 
and O 
ester B-FAMILY 
hydrolysis O 
products O 
. O 
The O 
presence O 
of O 
enhanced O 
levels O 
of O 
sitosterol B-TRIVIAL 
was O 
found O 
to O 
significantly O 
decrease O 
TG O 
polymer O 
formation O 
in O 
triolein B-TRIVIAL 
and O 
the O 
vegetable O 
oil O 
samples O 
after O 
heating O 
at O 
180 O 
°C O 
for O 
a O 
period O 
of O 
72 O 
h O 
. O 
A O 
corresponding O 
increase O 
in O 
the O 
level O 
of O 
intact O 
TG O 
monomer O 
and O 
the O 
extent O 
of O 
TG B-FAMILY 
ester I-FAMILY 
hydrolysis O 
was O 
observed O 
in O 
all O 
samples O 
with O 
enhanced O 
levels O 
of O 
sitosterol B-TRIVIAL 
. O 
Conversion O 
of O 
sterol B-FAMILY 
to O 
steradiene B-FAMILY 
, O 
by O 
the O 
1 O 
, O 
2 O 
elimination O 
of O 
water O 
, O 
may O 
be O 
responsible O 
for O 
the O 
antioxidative O 
effect O 
of O 
sitosterol B-TRIVIAL 
at O 
frying O 
temperatures O 
. O 

essential O 
oil O 
of O 
roots O 
, O 
branches O 
, O 
leaves O 
, O 
flowers O 
and O 
fruits O 
of O 
Periploca O 
laevigata O 
Aiton O 
subsp O 
. O 
angustifolia O 
( O 
Apocynaceae O 
) O 
from O 
Lampedusa O 
Island O 
has O 
been O 
obtained O 
by O 
hydrodistillation O 
and O 
its O 
composition O 
analysed O 
. O 
The O 
analyses O 
allowed O 
the O 
identification O 
and O 
quantification O 
of O 
86 O 
volatile O 
compounds O 
. O 
Branches O 
showed O 
the O 
higher O 
diversity O 
with O 
57 O 
compounds O 
followed O 
by O 
fruits O 
with O 
33 O 
, O 
roots O 
with O 
23 O 
, O 
flowers O 
with O 
16 O 
and O 
leaves O 
with O 
six O 
compounds O 
, O 
respectively O 
. O 
In O 
the O 
matrices O 
examined O 
three O 
constituents O 
, O 
heneicosane B-SYSTEMATIC 
, O 
docosane B-SYSTEMATIC 
and O 
tricosane B-SYSTEMATIC 
are O 
in O 
common O 
, O 
although O 
with O 
different O 
percentages O 
. O 
At O 
least O 
the O 
most O 
abundant O 
compounds O 
found O 
in O 
the O 
matrices O 
have O 
been O 
reported O 
to O 
have O 
several O 
biological O 
activities O 
. O 
2-Hydroxy-4-methoxybenzaldehyde B-SYSTEMATIC 
identified O 
in O 
the O 
roots O 
as O 
the O 
most O 
abundant O 
component O 
( O 
70.7% O 
) O 
and O 
present O 
with O 
8.3% O 
in O 
the O 
branches O 
is O 
a O 
potent O 
tyrosinase O 
inhibitor O 
present O 
in O 
several O 
African O 
medicinal O 
plants O 
, O 
and O 
thus O 
being O 
used O 
as O 
an O 
ingredient O 
in O 
cosmetic O 
and O 
other O 
medicinal O 
products O 
, O 
primarily O 
in O 
relation O 
to O 
hyperpigmentation O 
. O 
Among O 
the O 
compounds O 
identified O 
, O 
several O 
play O 
a O 
role O 
as O 
semiochemicals O 
for O 
many O 
animals O 
, O 
and O 
28 O 
allomones O 
, O 
43 O 
pheromones O 
, O 
21 O 
kairomones O 
have O 
been O 
identified O 
. O 
P O 
. O 
laevigata O 
subsp O 
. O 
angustifolia O 
in O 
Lampedusa O 
Island O 
is O 
host O 
to O 
a O 
community O 
of O 
visitors O 
, O 
and O 
the O 
possible O 
ecological O 
role O 
of O 
the O 
volatiles O 
found O 
is O 
briefly O 
discussed O 
. O 

D4 I-TRIVIAL 
induces O 
cognitive O 
impairment O 
through O 
enhancement O 
of O 
CysLT₁ O 
R- O 
mediated O 
amyloid-β O 
generation O 
in O 
mice O 
. O 

plaques O 
in O 
the O 
extracellular O 
parenchyma O 
mainly O 
consist O 
of O 
amyloid-β O 
peptides O 
( O 
Aβ O 
) O 
, O 
one O 
of O 
the O 
pathological O 
hallmarks O 
in O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
neuroinflammation O 
, O 
amyloidogenesis O 
, O 
and O 
memory O 
performance O 
following O 
intracerebral O 
infusions O 
of O 
leukotriene B-TRIVIAL 
D4 I-TRIVIAL 
( O 
LTD4 B-ABBREVIATION 
) O 
in O 
mice O 
. O 
The O 
results O 
demonstrated O 
that O 
intracerebral O 
infusions O 
of O 
LTD4 B-ABBREVIATION 
( O 
1 O 
ng O 
/ O 
mouse O 
) O 
produced O 
memory O 
impairment O 
as O 
determined O 
by O 
Morris O 
water O 
maze O 
test O 
and O 
Y-maze O 
test O 
in O 
mice O 
, O 
and O 
caused O 
the O 
accumulation O 
of O 
Aβ1-40 O 
and O 
Aβ1-42 O 
in O 
the O 
hippocampus O 
and O 
cortex O 
through O 
increased O 
activity O 
of O 
β- O 
and O 
γ-secretases O 
accompanied O 
with O 
increased O 
expression O 
of O 
amyloid O 
precursor O 
protein O 
( O 
APP O 
) O 
. O 
LTD4 B-ABBREVIATION 
also O 
induced O 
expression O 
of O 
cysteinyl B-TRIVIAL 
leukotriene I-TRIVIAL 
receptor O 
1 O 
( O 
CysLT(1)R O 
) O 
and O 
NF-κB O 
p65 O 
in O 
the O 
hippocampus O 
and O 
cortex O 
. O 
Pretreatment O 
with O 
pranlukast B-TRIVIAL 
( O 
1.5 O 
ng O 
/ O 
mouse O 
, O 
intracerebroventricularly O 
) O 
, O 
a O 
CysLT(1)R O 
antagonist O 
, O 
blocked O 
LTD4 B-ABBREVIATION 
-induced O 
amyloidogenesis O 
, O 
memory O 
deficits O 
. O 
Pranlukast B-TRIVIAL 
( O 
0.6 O 
μM O 
) O 
also O 
prevented O 
LTD4 B-ABBREVIATION 
( O 
20 O 
nM)-induced O 
amyloidogenesis O 
in O 
the O 
cultured O 
neurons O 
in O 
vitro O 
. O 
Moreover O 
, O 
LTD4 B-ABBREVIATION 
-induced O 
increases O 
in O 
CysLT(1)R O 
and O 
NF-κB O 
p65 O 
in O 
the O 
brain O 
were O 
also O 
attenuated O 
by O 
pranlukast B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
LTD4 B-ABBREVIATION 
increases O 
Aβ O 
peptide O 
burden O 
via O 
activation O 
of O 
CysLT(1)R O 
, O 
which O 
further O 
affects O 
APP O 
levels O 
and O 
activity O 
of O 
β- O 
and O 
γ-secretases O 
via O 
the O 
NF-κB O 
pathway O 
. O 
Our O 
findings O 
identify O 
CysLT(1)R O 
signaling O 
as O 
a O 
novel O 
proinflammatory O 
and O 
proamyloidogenic O 
pathway O 
, O 
and O 
suggest O 
a O 
rationale O 
for O 
development O 
of O 
therapeutics O 
targeting O 
the O 
CysLT(1)R O 
in O 
neuroinflammatory O 
diseases O 
such O 
as O 
AD O 
. O 

officinalis O 
L O 
. O 
can O 
be O 
found O 
worldwide O 
and O 
its O 
leaves O 
are O 
commonly O 
used O 
as O 
ingredient O 
in O 
food O 
industry O 
. O 
Sage O 
essential O 
oil O 
is O 
applied O 
in O 
the O 
treatment O 
of O 
a O 
range O 
of O 
diseases O 
and O 
has O 
been O 
shown O 
to O 
possess O 
different O 
biological O 
activities O 
. O 
The O 
objectives O 
of O 
our O 
research O 
were O 
to O 
study O 
the O 
effects O 
of O 
environment O 
on O 
crop O 
, O 
chemical O 
composition O 
and O 
anticancer O 
activity O 
on O 
S O 
. O 
officinalis O 
essential O 
oil O 
. O 
Sage O 
was O 
cultivated O 
at O 
eighteen O 
experimental O 
sites O 
in O 
south O 
- O 
central O 
Italy O 
( O 
Molise O 
) O 
in O 
different O 
growing O 
environments O 
. O 
The O 
essential O 
oils O 
( O 
S1-S18 O 
) O 
, O 
extracted O 
by O 
hydrodistillation O 
, O 
were O 
analyzed O 
by O 
GC O 
and O 
CG O 
/ O 
MS O 
. O 
Results O 
show O 
that O 
the O 
main O 
components O 
were O 
α-thujone B-TRIVIAL 
, O 
camphor B-TRIVIAL 
, O 
borneol B-TRIVIAL 
, O 
γ-muurolene B-TRIVIAL 
and O 
sclareol B-TRIVIAL 
for O 
all O 
the O 
samples O 
, O 
but O 
the O 
percentages O 
of O 
these O 
compounds O 
varied O 
depending O 
on O 
environmental O 
factors O 
such O 
as O 
altitude O 
, O 
water O 
availability O 
and O 
pedo O 
- O 
climatic O 
conditions O 
. O 
The O 
growth O 
- O 
inhibitory O 
and O 
proapoptotic O 
effects O 
of O 
the O 
eighteen O 
sage O 
essential O 
oils O 
were O 
evaluated O 
in O 
three O 
human O 
melanoma O 
cell O 
lines O 
, O 
A375 O 
, O 
M14 O 
, O 
and O 
A2058 O 
. O 

and O 
ASIC O 
channels O 
mediate O 
the O 
antinociceptive O 
effect O 
of O 
citronellyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 

Citronellyl B-TRIVIAL 
acetate I-TRIVIAL 
( O 
CAT B-ABBREVIATION 
) O 
, O 
a O 
monoterpene B-FAMILY 
product O 
of O 
the O 
secondary O 
metabolism O 
of O 
plants O 
, O 
has O 
been O 
shown O 
in O 
the O 
literature O 
to O 
possess O 
several O 
different O 
biological O 
activities O 
. O 
However O 
, O 
no O 
antinociceptive O 
abilities O 
have O 
yet O 
been O 
discussed O 
. O 
Here O 
, O 
we O 
used O 
acute O 
pain O 
animal O 
models O 
to O 
describe O 
the O 
antinociceptive O 
action O 
of O 
CAT B-ABBREVIATION 
. O 
Methods O 
The O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
writhing O 
test O 
and O 
the O 
paw O 
- O 
licking O 
test O 
, O 
in O 
which O 
paw O 
licking O 
was O 
induced O 
by O 
glutamate B-TRIVIAL 
and O 
formalin B-TRIVIAL 
, O 
were O 
performed O 
to O 
evaluate O 
the O 
antinociceptive O 
action O 
of O 
CAT B-ABBREVIATION 
and O 
to O 
determine O 
the O 
involvement O 
of O 
PKC O 
, O 
PKA O 
, O 
TRPV1 O 
, O 
TRPA1 O 
, O 
TRPM8 O 
and O 
ASIC O 
in O 
its O 
antinociceptive O 
mechanism O 
. O 
To O 
do O 
so O 
, O 
we O 
induced O 
paw O 
- O 
linking O 
using O 
agonists O 
. O 
Results O 
CAT B-ABBREVIATION 
was O 
administered O 
intragastrically O 
( O 
25 O 
, O 
50 O 
, O 
75 O 
, O 
100 O 
and O 
200mg O 
/ O 
kg O 
) O 
, O 
and O 
the O 
two O 
higher O 
doses O 
caused O 
antinociceptive O 
effects O 
in O 
the O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
model O 
; O 
the O 
highest O 
dose O 
reduced O 
pain O 
for O 
4h O 
after O 
it O 
was O 
administered O 
( O 
200mg O 
/ O 
kg O 
) O 
. O 
In O 
the O 
formalin B-TRIVIAL 
test O 
, O 
two O 
doses O 
of O 
CAT B-ABBREVIATION 
promoted O 
antinociception O 
in O 
both O 
the O 
early O 
and O 
later O 
phases O 
of O 
the O 
test O 
. O 
The O 
glutamate B-TRIVIAL 
test O 
showed O 
that O 
its O 
receptors O 
are O 
involved O 
in O 
the O 
antinociceptive O 
mechanism O 
of O 
CAT B-ABBREVIATION 
. O 
Pretreatment O 
with O 
CAT B-ABBREVIATION 
did O 
not O 
alter O 
locomotor O 
activity O 
or O 
motor O 
coordination O 
. O 
In O 
an O 
investigation O 
into O 
the O 
participation O 
of O 
TRP O 
channels O 
and O 
ASICs O 
in O 
CAT B-ABBREVIATION 
' O 
s O 
antinociceptive O 
mechanism O 
, O 
we O 
used O 
capsaicin B-TRIVIAL 
( O 
2.2μg O 
/ O 
paw O 
) O 
, O 
cinnamaldehyde B-TRIVIAL 
( O 
10mmol O 
/ O 
paw O 
) O 
, O 
menthol B-TRIVIAL 
( O 
1.2mmol O 
/ O 
paw O 
) O 
and O 
acidified O 
saline O 
( O 
2% O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
pH O 
1.98 O 
) O 
. O 
The O 
results O 
showed O 
that O 
TRPV1 O 
, O 
TRPM8 O 
and O 
ASIC O 
, O 
but O 
not O 
TRPA1 O 
, O 
are O 
involved O 
in O 
the O 
antinociceptive O 
mechanism O 
. O 
Finally O 
, O 
the O 
involvement O 
of O 
PKC O 
and O 
PKA O 
was O 
also O 
studied O 
, O 
and O 
we O 
showed O 
that O 
both O 
play O 
a O 
role O 
in O 
the O 
antinociceptive O 
mechanism O 
of O 
CAT B-ABBREVIATION 
. O 
Conclusion O 
The O 
results O 
of O 
this O 
work O 
contribute O 
information O 
regarding O 
the O 
antinociceptive O 
properties O 
of O 
CAT B-ABBREVIATION 
on O 
acute O 
pain O 
and O 
show O 
that O 
, O 
at O 
least O 
in O 
part O 
, O 
TRPV1 O 
, O 
TRPM8 O 
, O 
ASIC O 
, O 
glutamate B-TRIVIAL 
receptors O 
, O 
PKC O 
and O 
PKA O 
participate O 
in O 
CAT B-ABBREVIATION 
' O 
s O 
antinociceptive O 
mechanism O 
. O 

hybrid O 
hydrogels O 
have O 
generated O 
broad O 
interest O 
in O 
tissue O 
engineering O 
and O 
regenerative O 
medicine O 
. O 
Hyaluronic O 
acid O 
( O 
HA O 
) O 
and O 
gelatin O 
( O 
hydrolyzed O 
collagen O 
) O 
are O 
naturally O 
derived O 
polymers O 
and O 
biodegradable O 
under O 
physiological O 
conditions O 
. O 
Moreover O 
, O 
collagen O 
and O 
HA O 
are O 
major O 
components O 
of O 
the O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
in O 
most O 
of O 
the O 
tissues O 
( O 
e.g O 
. O 
, O 
cardiovascular O 
, O 
cartilage O 
, O 
neural O 
) O 
. O 
When O 
used O 
as O 
a O 
hybrid O 
material O 
, O 
HA-gelatin O 
hydrogels O 
may O 
enable O 
mimicking O 
the O 
ECM O 
of O 
native O 
tissues O 
. O 
Although O 
HA-gelatin O 
hybrid O 
hydrogels O 
are O 
promising O 
biomimetic O 
substrates O 
, O 
their O 
material O 
properties O 
have O 
not O 
been O 
thoroughly O 
characterized O 
in O 
the O 
literature O 
. O 
Herein O 
, O 
we O 
generated O 
hybrid O 
hydrogels O 
with O 
tunable O 
physical O 
and O 
biological O 
properties O 
by O 
using O 
different O 
concentrations O 
of O 
HA O 
and O 
gelatin O 
. O 
The O 
physical O 
properties O 
of O 
the O 
fabricated O 
hydrogels O 
including O 
swelling O 
ratio O 
, O 
degradation O 
, O 
and O 
mechanical O 
properties O 
were O 
investigated O 
. O 
In O 
addition O 
, O 
in O 
vitro O 
cellular O 
responses O 
in O 
both O 
two O 
and O 
three O 
- O 
dimensional O 
culture O 
conditions O 
were O 
assessed O 
. O 
It O 
was O 
found O 
that O 
the O 
addition O 
of O 
gelatin O 
methacrylate B-TRIVIAL 
( O 
GelMA O 
) O 
into O 
HA O 
methacrylate B-TRIVIAL 
( O 
HAMA O 
) O 
promoted O 
cell O 
spreading O 
in O 
the O 
hybrid O 
hydogels O 
. O 
Moreover O 
, O 
the O 
hybrid O 
hydrogels O 
showed O 
significantly O 
improved O 
mechanical O 
properties O 
compared O 
to O 
their O 
single O 
component O 
analogs O 
. O 
The O 
HAMA-GelMA O 
hydrogels O 
exhibited O 
remarkable O 
tunability O 
behavior O 
and O 
may O 
be O 
useful O 
for O 
cardiovascular O 
tissue O 
engineering O 
applications O 
. O 

inhibits O 
invasion O 
and O 
metastasis O 
in O 
K1 O 
papillary O 
thyroid O 
cancer O 
cells O 
. O 

, O 
the O 
active O 
constituent O 
of O 
dietary O 
spice O 
turmeric O 
, O 
possesses O 
a O 
strong O 
potential O 
for O 
cancer O 
prevention O 
and O 
treatment O 
. O 
However O 
, O 
there O 
is O 
no O 
study O 
to O 
address O 
the O 
effects O 
of O 
curcumin B-TRIVIAL 
on O 
invasion O 
and O 
metastasis O 
of O 
thyroid O 
cancers O 
. O 
Thyroid O 
cancer O 
is O 
the O 
most O 
common O 
malignancy O 
of O 
endocrine O 
organs O 
, O 
and O 
its O 
incidence O 
rates O 
have O 
steadily O 
increased O 
over O 
recent O 
decades O 
. O 
Although O 
most O 
indolent O 
tumours O 
can O 
be O 
effectively O 
managed O 
, O 
metastatic O 
tumours O 
at O 
distant O 
secondary O 
sites O 
behave O 
aggressively O 
and O 
currently O 
there O 
is O 
no O 
effective O 
form O 
of O 
treatment O 
. O 
Here O 
, O 
for O 
the O 
first O 
time O 
it O 
has O 
been O 
reported O 
that O 
curcumin B-TRIVIAL 
inhibit O 
multiple O 
metastasis O 
steps O 
of O 
K1 O 
papillary O 
thyroid O 
cancer O 
cells O 
. O 
Curcumin B-TRIVIAL 
dose O 
- O 
dependently O 
suppressed O 
viability O 
of O 
K1 O 
cells O 
as O 
well O 
as O 
its O 
cell O 
attachment O 
, O 
spreading O 
, O 
migration O 
and O 
invasion O 
abilities O 
. O 
Moreover O 
, O 
curcumin B-TRIVIAL 
could O 
also O 
down O 
- O 
regulate O 
the O 
expression O 
and O 
activity O 
of O 
matrix O 
metalloproteinase-9 O 
( O 
MMP-9 O 
) O 
. O 
The O 
findings O 
showed O 
that O 
curcumin B-TRIVIAL 
might O 
be O 
an O 
effective O 
tumouristatic O 
agent O 
for O 
the O 
treatment O 
of O 
aggressive O 
papillary O 
thyroid O 
carcinomas O 
. O 

new O 
2,5-diketopiperazine B-SYSTEMATIC 
, O 
(R)-2-(2-(furan-2-yl)-oxoethyl)-octahydropyrrolo[1,2-a]pyrazine-1,4-dione B-SYSTEMATIC 
, O 
and O 
seven O 
known O 
compounds O 
were O 
isolated O 
from O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
liquid O 
fermentation O 
broth O 
of O 
Armillaria O 
mellea O 
. O 
The O 
structures O 
of O 
the O 
isolated O 
compounds O 
were O 
established O 
from O 
NMR O 
and O 
HR-MS O 
data O 
. O 
The O 
absolute O 
configuration O 
of O 
the O 
new O 
compound O 
was O 
established O 
by O 
comparing O 
the O 
experimental O 
electronic O 
circular O 
dichroism O 
( O 
ECD O 
) O 
spectrum O 
with O 
the O 
calculated O 
ECD O 
data O 
. O 

Changes O 
and O 
Oxidative O 
Stress O 
Response O 
to O 
Magnetite B-TRIVIAL 
in O 
A549 O 
Human O 
Lung O 
Cells O 
. O 

a O 
recent O 
study O 
, O 
magnetite B-TRIVIAL 
was O 
investigated O 
for O 
its O 
potential O 
to O 
induce O 
toxic O 
effects O 
and O 
influence O 
signaling O 
pathways O 
. O 
It O 
was O 
clearly O 
demonstrated O 
that O 
ROS O 
formation O 
leads O 
to O 
mitochondrial O 
damage O 
and O 
genotoxic O 
effects O 
in O 
A549 O 
cells O 
. O 
On O 
the O 
basis O 
of O 
these O 
findings O 
, O 
we O 
wanted O 
to O 
elucidate O 
the O 
origin O 
of O 
magnetite B-TRIVIAL 
-mediated O 
ROS O 
formation O 
and O 
its O 
influence O 
on O 
the O 
cell O 
cycle O 
of O 
A549 O 
and O 
H1299 O 
human O 
lung O 
epithelial O 
cells O 
. O 
Concentration- O 
and O 
size O 
- O 
dependent O 
superoxide B-TRIVIAL 
formation O 
, O 
measured O 
by O 
electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
, O 
was O 
observed O 
. O 
Furthermore O 
, O 
we O 
could O 
show O 
that O 
the O 
GSH B-ABBREVIATION 
level O 
decreased O 
significantly O 
after O 
exposure O 
to O 
magnetite B-TRIVIAL 
particles O 
, O 
while O 
catalase O 
( O 
CAT O 
) O 
activity O 
was O 
increased O 
. O 
These O 
effects O 
were O 
also O 
dependent O 
on O 
particle O 
size O 
, O 
albeit O 
less O 
pronounced O 
than O 
those O 
observed O 
with O 
EPR O 
. O 
We O 
were O 
able O 
to O 
show O 
that O 
incubation O 
of O 
A549 O 
cells O 
prior O 
to O 
particle O 
treatment O 
with O 
diphenyleneiodonium B-TRIVIAL 
( O 
DPI B-ABBREVIATION 
) O 
, O 
a O 
NADPH B-ABBREVIATION 
-oxidase O 
( O 
NOX O 
) O 
inhibitor O 
, O 
leads O 
to O 
decreased O 
ROS O 
formation O 
, O 
but O 
this O 
effect O 
was O 
not O 
observed O 
for O 
the O 
NOX O 
inhibitor O 
apocynin B-TRIVIAL 
. O 
Soluble O 
iron B-SYSTEMATIC 
does O 
not O 
contribute O 
considerably O 
to O 
ROS O 
production O 
. O 
Analysis O 
of O 
cell O 
- O 
cycle O 
distribution O 
revealed O 
a O 
pronounced O 
sub-G1 O 
peak O 
, O 
which O 
cannot O 
be O 
linked O 
to O 
increased O 
cell O 
death O 
. O 
Western O 
blot O 
analysis O 
did O 
not O 
show O 
activation O 
of O 
p53 O 
but O 
upregulation O 
of O 
p21 O 
in O 
A549 O 
. O 
Here O 
, O 
we O 
were O 
unexpectedly O 
able O 
to O 
demonstrate O 
that O 
exposure O 
to O 
magnetite B-TRIVIAL 
leads O 
to O 
p21 O 
- O 
mediated O 
G1 O 
- O 
like O 
arrest O 
. O 
This O 
has O 
been O 
reported O 
previously O 
only O 
for O 
low O 
concentrations O 
of O 
microtubule O 
stabilization O 
drugs O 
. O 
Importantly O 
, O 
the O 
arrested O 
sub-G1 O 
cells O 
were O 
viable O 
and O 
showed O 
no O 
caspase O 
3 O 
/ O 
7 O 
activation O 
. O 

oxygen B-SYSTEMATIC 
tension O 
maintains O 
multipotency O 
, O 
whereas O 
normoxia O 
increases O 
differentiation O 
of O 
mouse O 
bone O 
marrow O 
stromal O 
cells O 
. O 

of O 
mesenchymal O 
stem O 
cells O 
( O 
MSC O 
) O 
culture O 
conditions O 
is O 
of O 
great O 
importance O 
for O 
their O 
more O 
successful O 
application O 
in O 
regenerative O 
medicine O 
. O 
O(2) B-FORMULA 
regulates O 
various O 
aspects O 
of O 
cellular O 
biology O 
and O 
, O 
in O 
vivo O 
, O 
MSC O 
are O 
exposed O 
to O 
different O 
O(2) B-FORMULA 
concentrations O 
spanning O 
from O 
very O 
low O 
tension O 
in O 
the O 
bone O 
marrow O 
niche O 
, O 
to O 
higher O 
amounts O 
in O 
wounds O 
. O 
In O 
our O 
present O 
work O 
, O 
we O 
isolated O 
mouse O 
bone O 
marrow O 
stromal O 
cells O 
( O 
BMSC O 
) O 
and O 
showed O 
that O 
they O 
contained O 
a O 
population O 
meeting O 
requirements O 
for O 
MSC O 
definition O 
. O 
In O 
order O 
to O 
establish O 
the O 
effect O 
of O 
low O 
O(2) B-FORMULA 
on O 
cellular O 
properties O 
, O 
we O 
examined O 
BSMC O 
cultured O 
under O 
hypoxic O 
( O 
3% O 
O(2) B-FORMULA 
) O 
conditions O 
. O 
Our O 
results O 
demonstrate O 
that O 
3% O 
O(2) B-FORMULA 
augmented O 
proliferation O 
of O 
BMSC O 
, O 
as O 
well O 
as O 
the O 
formation O 
of O 
colonies O 
in O 
the O 
colony O 
- O 
forming O 
unit O 
assay O 
( O 
CFU-A O 
) O 
, O 
the O 
percentage O 
of O 
quiescent O 
cells O 
, O 
and O 
the O 
expression O 
of O 
stemness O 
markers O 
Rex-1 O 
and O 
Oct-4 O 
, O 
thereby O 
suggesting O 
an O 
increase O 
in O 
the O 
stemness O 
of O 
culture O 
when O 
exposed O 
to O 
hypoxia O 
. O 
In O 
contrast O 
, O 
intrinsic O 
differentiation O 
processes O 
were O 
inhibited O 
by O 
3% O 
O(2) B-FORMULA 
. O 
Overall O 
yield O 
of O 
differentiation O 
was O 
dependent O 
on O 
the O 
adjustment O 
of O 
O(2) B-FORMULA 
tension O 
to O 
the O 
specific O 
stage O 
of O 
BMSC O 
culture O 
. O 
Thus O 
, O 
we O 
established O 
a O 
strategy O 
for O 
efficient O 
BMSC O 
in O 
vitro O 
differentiation O 
using O 
an O 
initial O 
phase O 
of O 
cell O 
propagation O 
at O 
3% O 
O(2) B-FORMULA 
, O 
followed O 
by O 
differentiation O 
stage O 
at O 
21% O 
O(2) B-FORMULA 
. O 
We O 
also O 
demonstrated O 
that O 
3% O 
O(2) B-FORMULA 
affected O 
BMSC O 
differentiation O 
in O 
p53 O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
independent O 
pathways O 
. O 
Our O 
findings O 
can O 
significantly O 
contribute O 
to O 
the O 
obtaining O 
of O 
high O 
- O 
quality O 
MSC O 
for O 
effective O 
cell O 
therapy O 
. O 

ameliorates O 
stress O 
- O 
induced O 
cognitive O 
inflexibility O 
in O 
rats O 
. O 

antidepressant O 
action O 
of O 
quetiapine B-TRIVIAL 
has O 
been O 
demonstrated O 
in O 
clinical O 
and O 
preclinical O 
studies O 
. O 
Nevertheless O 
, O 
little O 
is O 
known O 
about O 
its O 
effectiveness O 
in O 
the O 
treatment O 
of O 
frontal O 
- O 
like O 
cognitive O 
disturbances O 
that O 
may O 
be O 
associated O 
with O 
stress O 
- O 
related O 
disorder O 
. O 
Therefore O 
, O 
the O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
whether O 
quetiapine B-TRIVIAL 
would O 
prevent O 
and O 
/ O 
or O 
reverse O 
stress O 
- O 
induced O 
cognitive O 
impairments O 
in O 
a O 
rat O 
model O 
of O 
prefrontal O 
cortex O 
(PFC)-dependent O 
attentional O 
set O 
- O 
shifting O 
task O 
( O 
ASST O 
) O 
. O 
Because O 
quetiapine B-TRIVIAL 
augmentation O 
to O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
( O 
SSRIs O 
) O 
has O 
recently O 
been O 
proven O 
to O 
be O 
beneficial O 
in O 
neuropsychiatric O 
disorders O 
, O 
a O 
separate O 
experiment O 
was O 
designed O 
to O 
assess O 
the O 
impact O 
of O 
combined O 
administration O 
of O 
inactive O 
doses O 
of O 
quetiapine B-TRIVIAL 
and O 
escitalopram B-TRIVIAL 
on O 
ASST O 
performance O 
in O 
rats O 
. O 
According O 
to O 
our O 
previous O 
studies O 
, O 
1 O 
h O 
daily O 
exposure O 
to O 
restraint O 
stress O 
for O 
7 O 
days O 
significantly O 
and O 
specifically O 
impaired O 
extra O 
- O 
dimensional O 
( O 
ED O 
) O 
set O 
- O 
shifting O 
ability O 
of O 
rats O 
. O 
Quetiapine B-TRIVIAL 
( O 
2.5 O 
mg O 
/ O 
kg O 
, O 
PO O 
) O 
given O 
to O 
rats O 
prior O 
to O 
the O 
restraint O 
sessions O 
completely O 
prevented O 
this O 
stress O 
- O 
induced O 
cognitive O 
inflexibility O 
. O 
Similar O 
effect O 
was O 
demonstrated O 
after O 
pretreatment O 
with O 
the O 
α1-adrenoceptor O 
antagonist O 
, O 
prazosin B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
kg O 
, O 
IP O 
) O 
. O 
Moreover O 
, O 
acute O 
administration O 
of O 
quetiapine B-TRIVIAL 
before O 
the O 
test O 
reversed O 
set O 
- O 
shifting O 
deficits O 
in O 
stressed O 
rats O 
( O 
0.63 O 
, O 
1.25 O 
and O 
2.5 O 
mg O 
/ O 
kg O 
, O 
PO O 
) O 
and O 
improved O 
ED O 
performance O 
of O 
cognitively O 
unimpaired O 
control O 
animals O 
( O 
1.25 O 
and O 
2.5 O 
mg O 
/ O 
kg O 
, O 
PO O 
) O 
. O 
Finally O 
, O 
the O 
combined O 
administration O 
of O 
inactive O 
doses O 
of O 
quetiapine B-TRIVIAL 
( O 
0.63 O 
and O 
0.3 O 
mg O 
/ O 
kg O 
in O 
control O 
and O 
stressed O 
rats O 
, O 
respectively O 
) O 
and O 
escitalopram B-TRIVIAL 
( O 
0.3 O 
mg O 
/ O 
kg O 
, O 
IP O 
) O 
facilitated O 
set O 
- O 
shifting O 
performance O 
in O 
either O 
control O 
or O 
stressed O 
rats O 
. O 
In O 
conclusion O 
, O 
quetiapine B-TRIVIAL 
administration O 
either O 
prevented O 
or O 
reversed O 
stress O 
- O 
induced O 
cognitive O 
inflexibility O 
in O 
rats O 
. O 
In O 
addition O 
to O 
promoting O 
of O 
set O 
- O 
shifting O 
by O 
itself O 
, O 
quetiapine B-TRIVIAL 
also O 
enhanced O 
the O 
procognitive O 
efficacy O 
of O 
escitalopram B-TRIVIAL 
. O 
The O 
potential O 
contribution O 
of O 
the O 
antagonism O 
at O 
α1-adrenoceptors O 
to O 
the O 
mechanisms O 
underlying O 
the O 
protective O 
action O 
of O 
quetiapine B-TRIVIAL 
requires O 
further O 
evaluation O 
. O 
These O 
findings O 
may O 
have O 
therapeutic O 
implications O 
for O 
the O 
treatment O 
of O 
frontal O 
- O 
like O 
disturbances O 
, O 
particularly O 
cognitive O 
inflexibility O 
, O 
in O 
stress O 
- O 
related O 
psychiatric O 
disorders O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

effect O 
of O 
dihydroartemisinin B-SYSTEMATIC 
against O 
phorbol B-FAMILY 
ester I-FAMILY 
-induced O 
cyclooxygenase-2 O 
expression O 
in O 
macrophages O 
. O 

( O 
DHA B-ABBREVIATION 
) O 
, O 
a O 
semi-synthetic O 
derivative O 
of O 
artemisinin B-TRIVIAL 
isolated O 
from O 
the O 
traditional O 
Chinese O 
herb O 
Artemisia O 
annua O 
L O 
. O 
, O 
has O 
recently O 
been O 
shown O 
to O 
possess O 
antitumor O 
activity O 
in O 
various O 
cancer O 
cells O 
. O 
However O 
, O 
the O 
effect O 
of O 
anti-inflammatory O 
potentials O 
of O 
DHA B-ABBREVIATION 
in O 
murine O 
macrophage O 
RAW O 
264.7 O 
cells O 
has O 
not O 
been O 
studied O 
. O 
The O 
present O 
study O 
investigated O 
the O 
effect O 
of O 
COX-2 O 
and O 
molecular O 
mechanisms O 
by O 
DHA B-ABBREVIATION 
in O 
PMA B-ABBREVIATION 
stimulated O 
RAW O 
264.7 O 
cells O 
. O 
DHA B-ABBREVIATION 
dose O 
- O 
dependently O 
decreased O 
PMA B-ABBREVIATION 
-induced O 
COX-2 O 
expression O 
and O 
PGE2 B-ABBREVIATION 
production O 
, O 
as O 
well O 
as O 
COX-2 O 
promoter O 
- O 
driven O 
luciferase O 
activity O 
. O 
Additionally O 
, O 
DHA B-ABBREVIATION 
decreased O 
luciferase O 
activity O 
of O 
COX-2 O 
regulation O 
- O 
related O 
transcription O 
factors O 
including O 
NF-κB O 
, O 
AP-1 O 
, O 
C O 
/ O 
EBP O 
and O 
CREB O 
. O 
DHA B-ABBREVIATION 
also O 
remarkably O 
reduced O 
PMA B-ABBREVIATION 
-induced O 
p65 O 
, O 
C O 
/ O 
EBPβ O 
, O 
c-jun O 
and O 
CREB O 
nuclear O 
translocation O 
. O 
Furthermore O 
, O 
DHA B-ABBREVIATION 
evidently O 
inhibited O 
PMA B-ABBREVIATION 
-induced O 
phosphorylation O 
of O 
AKT O 
and O 
the O 
MAP O 
Kinases O 
, O 
such O 
as O 
ERK O 
, O 
JNK O 
and O 
p38 O 
. O 
Taken O 
together O 
, O 
our O 
data O 
indicated O 
that O 
DHA B-ABBREVIATION 
effectively O 
attenuates O 
COX-2 O 
production O 
via O 
down O 
- O 
regulation O 
of O 
AKT O 
and O 
MAPK O 
pathway O 
, O 
revealing O 
partial O 
molecular O 
basis O 
for O 
the O 
anti-inflammatory O 
properties O 
of O 
DHA B-ABBREVIATION 
. O 

-rich O 
Ecklonia O 
cava O 
reduces O 
the O 
production O 
of O 
beta-amyloid O 
by O 
modulating O 
alpha- O 
and O 
gamma-secretase O 
expression O 
and O 
activity O 
. O 

( O 
Aβ O 
) O 
is O 
a O 
major O 
pathogenic O 
peptide O 
in O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
and O 
is O 
generated O 
by O 
the O 
processing O 
of O 
amyloid O 
precursor O 
protein O 
( O 
APP O 
) O 
. O 
We O 
have O 
previously O 
reported O 
that O 
the O 
brown O 
algae O 
Ecklonia O 
cava O 
, O 
which O 
has O 
anti-oxidant O 
and O 
anti-inflammatory O 
functions O 
, O 
decreased O 
Aβ O 
production O 
and O 
further O 
aggregation O 
in O 
HEK293 O 
cells O 
expressing O 
the O 
APP O 
Swedish O 
mutation O 
. O 
Here O 
, O 
we O 
show O 
the O 
reduction O 
mechanism O 
of O 
Aβ O 
production O 
using O 
the O 
butanol B-SYSTEMATIC 
extract O 
of O 
Ecklonia O 
cava O 
through O 
the O 
examination O 
of O 
expression O 
and O 
activity O 
of O 
alpha- O 
, O 
beta- O 
, O 
and O 
gamma-secretase O 
. O 
Treatment O 
with O 
the O 
extract O 
resulted O 
in O 
the O 
activation O 
of O 
alpha-secretase O 
with O 
a O 
contrasting O 
decrease O 
in O 
its O 
mRNA O 
and O 
protein O 
expression O 
. O 
This O 
activation O 
was O 
consistent O 
with O 
the O 
translocation O 
of O 
the O 
extract O 
into O 
the O 
plasma O 
membrane O 
of O 
the O 
secretase O 
. O 
Gamma-secretase O 
activity O 
was O 
lowered O 
by O 
E O 
. O 
cava O 
, O 
and O 
this O 
effect O 
may O 
be O 
due O 
to O 
the O 
decreased O 
expression O 
of O 
PSEN1 O 
mRNA O 
and O 
protein O 
. O 
In O 
addition O 
, O 
the O 
basal O 
nuclear O 
location O 
of O 
PSEN1 O 
, O 
which O 
may O 
affect O 
chromosome O 
missegregation O 
in O 
neurodegenerative O 
disease O 
, O 
was O 
reduced O 
by O 
the O 
extract O 
, O 
despite O 
the O 
significance O 
of O 
this O 
finding O 
remains O 
unclear O 
. O 
Taken O 
together O 
, O 
these O 
results O 
led O 
us O 
to O 
conclude O 
that O 
E O 
. O 
cava O 
regulated O 
the O 
expression O 
and O 
activity O 
of O 
gamma-secretase O 
and O 
alpha-secretase O 
, O 
leading O 
to O 
a O 
reduction O 
in O 
Aβ O 
production O 
by O 
the O 
stable O 
cells O 
. O 
Our O 
data O 
indicate O 
that O 
E O 
. O 
cava O 
is O 
a O 
novel O 
natural O 
- O 
product O 
candidate O 
for O 
AD O 
treatment O 
, O 
although O 
further O 
in O 
vivo O 
studies O 
are O 
needed O 
. O 

spectrometry O 
method O 
to O 
identify O 
aging O 
pathways O 
of O 
Sp- B-MULTIPLE 
and I-MULTIPLE 
Rp-tabun I-MULTIPLE 
adducts O 
on O 
human O 
butyrylcholinesterase O 
based O 
on O 
the O 
acid O 
labile O 
P-N B-FORMULA 
bond O 
. O 

phosphoramidate B-SYSTEMATIC 
nerve O 
agent O 
tabun B-TRIVIAL 
inhibits O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
and O 
acetylcholinesterase O 
by O 
making O 
a O 
covalent O 
bond O 
on O 
the O 
active O 
site O 
serine B-TRIVIAL 
. O 
The O 
adduct O 
loses O 
an O 
alkyl B-FAMILY 
group O 
in O 
a O 
process O 
called O 
aging O 
. O 
The O 
mechanism O 
of O 
aging O 
of O 
the O 
tabun B-TRIVIAL 
adduct O 
is O 
controversial O 
. O 
Some O 
studies O 
claim O 
that O 
aging O 
proceeds O 
through O 
deamination O 
, O 
whereas O 
crystal O 
structure O 
studies O 
show O 
aging O 
by O 
O B-FORMULA 
-dealkylation O 
. O 
Our O 
goal O 
was O 
to O 
develop O 
a O 
method O 
that O 
clearly O 
distinguishes O 
between O 
deamination O 
and O 
O B-FORMULA 
-dealkylation O 
. O 
We O 
began O 
by O 
studying O 
the O 
tetraisopropyl B-SYSTEMATIC 
pyrophosphoramide I-SYSTEMATIC 
adduct O 
of O 
BChE O 
because O 
this O 
adduct O 
has O 
two O 
P-N B-FORMULA 
bonds O 
. O 
Mass O 
spectra O 
showed O 
that O 
the O 
P-N B-FORMULA 
bonds O 
were O 
stable O 
during O 
trypsin O 
digestion O 
at O 
pH O 
8 O 
but O 
were O 
cleaved O 
during O 
pepsin O 
digestion O 
at O 
pH O 
2 O 
. O 
The O 
P-N B-FORMULA 
bond O 
in O 
tabun B-TRIVIAL 
was O 
also O 
acid O 
labile O 
, O 
whereas O 
the O 
P-O B-FORMULA 
bond O 
was O 
stable O 
. O 
A O 
scheme O 
to O 
distinguish O 
aging O 
by O 
deamination O 
from O 
aging O 
by O 
O B-FORMULA 
-dealkylation O 
was O 
based O 
on O 
the O 
acid O 
labile O 
P-N B-FORMULA 
bond O 
. O 
BChE O 
was O 
inhibited O 
with O 
Sp- B-MULTIPLE 
and I-MULTIPLE 
Rp-tabun I-MULTIPLE 
thiocholine I-MULTIPLE 
nerve O 
agent O 
model O 
compounds O 
to O 
make O 
adducts O 
identical O 
to O 
those O 
of O 
tabun B-TRIVIAL 
with O 
known O 
stereochemistry O 
. O 
After O 
aging O 
and O 
digestion O 
with O 
pepsin O 
at O 
pH O 
2 O 
, O 
peptide O 
FGES198AGAAS O 
from O 
Sp-tabun B-TRIVIAL 
thiocholine I-TRIVIAL 
had O 
a O 
mass O 
of O 
902.2 O 
m O 
/ O 
z O 
in O 
negative O 
mode O 
, O 
indicating O 
that O 
it O 
had O 
aged O 
by O 
deamination O 
, O 
whereas O 
peptide O 
FGES198AGAAS O 
from O 
Rp-tabun B-TRIVIAL 
thiocholine I-TRIVIAL 
had O 
a O 
mass O 
of O 
874.2 O 
m O 
/ O 
z O 
in O 
negative O 
mode O 
, O 
indicating O 
that O 
it O 
had O 
aged O 
by O 
O B-FORMULA 
-dealkylation O 
. O 
BChE O 
inhibited O 
by O 
authentic O 
, O 
racemic B-TRIVIAL 
tabun I-TRIVIAL 
yielded O 
both O 
902.2 O 
and O 
874.2 O 
m O 
/ O 
z O 
peptides O 
, O 
indicating O 
that O 
both O 
stereoisomers O 
reacted O 
with O 
BChE O 
and O 
aged O 
either O 
by O 
deamination O 
or O 
dealkylation O 
. O 

new O 
ganoderic B-TRIVIAL 
acid I-TRIVIAL 
from O 
Ganoderma O 
lucidum O 
mycelia O 
and O 
its O 
stability O 
. O 

new O 
ganoderic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
, O 
3α,22β-diacetoxy-7α-hydroxyl-5α-lanost-8,24E-dien-26-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
together O 
with O 
four O 
known O 
compounds O 
GA-Mk B-ABBREVIATION 
( O 
2 O 
) O 
, O 
-Mc O 
( O 
3 O 
) O 
, O 
-S O 
( O 
4 O 
) O 
and O 
-Mf O 
( O 
5 O 
) O 
, O 
was O 
isolated O 
and O 
characterized O 
from O 
Ganoderma O 
lucidum O 
mycelia O 
. O 
The O 
structure O 
of O 
compound O 
1 O 
was O 
elucidated O 
on O 
the O 
basis O 
of O 
interpretation O 
of O 
extensive O 
spectroscopic O 
data O 
( O 
HRMS O 
, O 
IR O 
, O 
UV O 
, O 
1D O 
and O 
2D O 
NMR O 
) O 
. O 
Due O 
to O 
its O 
apparent O 
degradation O 
during O 
preparation O 
procedures O 
, O 
the O 
stability O 
of O 
compound O 
1 O 
was O 
assessed O 
in O 
several O 
solvents O 
in O 
a O 
short O 
- O 
term O 
study O 
that O 
demonstrated O 
the O 
optimal O 
stability O 
in O 
aproptic O 
environment O 
. O 
A O 
possible O 
mechanism O 
of O 
acid O 
- O 
catalyzed O 
degradation O 
of O 
compound O 
1 O 
in O 
methanol B-SYSTEMATIC 
was O 
proposed O 
, O 
consisting O 
of O 
a O 
fast O 
protonation O 
, O 
followed O 
by O 
a O 
committed O 
step O 
of O 
hydroxyl B-SYSTEMATIC 
group O 
removal O 
. O 
In O 
addition O 
, O 
all O 
isolated O 
compounds O 
were O 
tested O 
in O 
vitro O 
for O 
their O 
cytotoxic O 
activities O 
against O 
95D O 
and O 
HeLa O 
tumor O 
cell O 
lines O 
, O 
with O 
IC(50) O 
values O 
ranging O 
from14.7 O 
to O 
38.5μM O 
. O 
The O 
results O 
may O 
improve O 
the O 
understanding O 
of O 
chemical O 
stability O 
of O 
GAs O 
and O 
provide O 
valuable O 
information O 
on O 
their O 
separation O 
, O 
analysis O 
and O 
application O 
. O 

detection O 
of O 
spin O 
precession O 
in O 
freely O 
suspended O 
graphene B-TRIVIAL 
spin O 
valves O 
on O 
cross O 
- O 
linked O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
. O 

injection O 
and O 
detection O 
is O 
achieved O 
in O 
freely O 
suspended O 
graphene B-TRIVIAL 
using O 
cobalt B-SYSTEMATIC 
electrodes O 
and O 
a O 
nonlocal O 
spin O 
- O 
valve O 
geometry O 
. O 
The O 
devices O 
are O 
fabricated O 
with O 
a O 
single O 
electron O 
- O 
beam O 
- O 
resist O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
process O 
that O 
minimizes O 
both O 
the O 
fabrication O 
steps O 
and O 
the O 
number O 
of O 
( O 
aggressive O 
) O 
chemicals O 
used O 
, O 
greatly O 
reducing O 
contamination O 
and O 
increasing O 
the O 
yield O 
of O 
high O 
- O 
quality O 
, O 
mechanically O 
stable O 
devices O 
. O 
As-grown O 
devices O 
can O 
present O 
mobilities O 
exceeding O 
10(4) O 
cm(2) O 
V(-1) O 
s(-1) O 
at O 
room O 
temperature O 
and O 
, O 
because O 
the O 
contacts O 
deposited O 
on O 
graphene B-TRIVIAL 
are O 
only O 
exposed O 
to O 
acetone B-SYSTEMATIC 
and O 
isopropanol B-SYSTEMATIC 
, O 
the O 
method O 
is O 
compatible O 
with O 
almost O 
any O 
contacting O 
material O 
. O 
Spin O 
accumulation O 
and O 
spin O 
precession O 
are O 
studied O 
in O 
these O 
nonlocal O 
spin O 
valves O 
. O 
Fitting O 
of O 
Hanle O 
spin O 
precession O 
data O 
in O 
bilayer O 
and O 
multilayer O 
graphene B-TRIVIAL 
yields O 
a O 
spin O 
relaxation O 
time O 
of O 
∼125-250 O 
ps O 
and O 
a O 
spin O 
diffusion O 
length O 
of O 
1.7-1.9 O 
μm O 
at O 
room O 
temperature O 
. O 

caffeine B-TRIVIAL 
intake O 
in O 
the O 
United O 
Kingdom O 
diet O 
. O 

occurs O 
naturally O 
in O 
the O 
leaves O 
and O 
seeds O 
of O 
many O 
plants O 
and O 
is O 
artificially O 
added O 
to O 
some O 
beverages O 
. O 
Consumption O 
of O 
caffeine B-TRIVIAL 
has O 
been O 
linked O 
to O 
both O 
positive O 
and O 
adverse O 
health O 
outcomes O 
. O 
We O 
incorporated O 
estimates O 
of O 
caffeine B-TRIVIAL 
content O 
( O 
mg O 
/ O 
100g O 
or O 
ml O 
) O 
of O 
foods O 
and O 
drinks O 
, O 
taken O 
from O 
the O 
published O 
literature O 
, O 
to O 
provide O 
a O 
preliminary O 
estimate O 
of O 
caffeine B-TRIVIAL 
intake O 
for O 
the O 
UK O 
population O 
, O 
based O 
on O 
data O 
collected O 
in O 
the O 
National O 
Diet O 
and O 
Nutrition O 
Survey O 
2008-10 O 
. O 
Among O 
consumers O 
mean O 
total O 
caffeine B-TRIVIAL 
intakes O 
of O 
adult O 
men O 
19+ O 
y O 
were O 
significantly O 
greater O 
than O 
intakes O 
by O 
boys O 
4-10y O 
and O 
11-18y O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
with O 
the O 
same O 
age O 
- O 
related O 
differences O 
seen O 
for O 
females O 
. O 
4.1% O 
of O 
men O 
19+ O 
y O 
and O 
3.8% O 
of O 
women O 
19+ O 
y O 
had O 
caffeine B-TRIVIAL 
intakes O 
in O 
excess O 
of O 
300mg O 
/ O 
d O 
. O 
The O 
addition O 
of O 
caffeine B-TRIVIAL 
to O 
UK O 
food O 
composition O 
databases O 
will O 
allow O 
more O 
detailed O 
study O 
of O 
the O 
health O 
effects O 
of O 
caffeine B-TRIVIAL 
consumption O 
. O 

inhibits O 
STAT3 O 
tyrosine B-TRIVIAL 
705 O 
phosphorylation O 
in O 
tumor O 
cells O 
through O 
activation O 
of O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
SHP1 O 
. O 

major O 
goal O 
of O 
cancer O 
drug O 
discovery O 
is O 
to O 
find O 
an O 
agent O 
that O 
is O 
safe O 
and O 
affordable O 
, O 
yet O 
effective O 
against O 
cancer O 
. O 
Here O 
we O 
show O 
that O 
morin B-TRIVIAL 
( O 
3,5,7,2',4'-pentahydroxyflavone B-SYSTEMATIC 
) O 
has O 
potential O 
against O 
cancer O 
cells O 
through O 
suppression O 
of O 
the O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
3 O 
( O 
STAT3 O 
) O 
pathway O 
, O 
which O 
is O 
closely O 
linked O 
to O 
the O 
transformation O 
, O 
survival O 
, O 
proliferation O 
, O 
and O 
metastasis O 
of O 
cancer O 
. O 
We O 
found O 
that O 
morin B-TRIVIAL 
completely O 
suppressed O 
inducible O 
and O 
constitutively O 
activated O 
STAT3 O 
and O 
blocked O 
the O 
nuclear O 
translocation O 
of O 
STAT3 O 
and O 
its O 
DNA O 
binding O 
in O 
multiple O 
myeloma O 
and O 
head O 
and O 
neck O 
squamous O 
carcinoma O 
cells O 
. O 
Morin B-TRIVIAL 
inhibited O 
activated O 
Src O 
, O 
JAK-1 O 
, O 
and O 
JAK-2 O 
, O 
all O 
of O 
which O 
are O 
linked O 
to O 
STAT3 O 
activation O 
, O 
while O 
up O 
- O 
regulating O 
a O 
protein O 
inhibitor O 
of O 
activated O 
STAT3 O 
, O 
PIAS3 O 
. O 
Pervanadate O 
reversed O 
the O 
effects O 
of O 
morin B-TRIVIAL 
on O 
STAT3 O 
phosphorylation O 
, O 
indicating O 
the O 
role O 
of O 
a O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
. O 
Furthermore O 
, O 
morin B-TRIVIAL 
induced O 
SHP1 O 
expression O 
at O 
both O 
the O 
mRNA O 
and O 
protein O 
levels O 
, O 
and O 
silencing O 
of O 
SHP1 O 
abrogated O 
the O 
effect O 
of O 
morin B-TRIVIAL 
on O 
STAT3 O 
phosphorylation O 
, O 
indicating O 
that O 
morin B-TRIVIAL 
mediates O 
its O 
effects O 
on O 
STAT3 O 
through O 
SHP1 O 
. O 
Suppression O 
of O 
STAT3 O 
correlated O 
with O 
the O 
down O 
- O 
regulation O 
of O 
various O 
gene O 
products O 
linked O 
to O 
tumor O 
survival O 
, O 
proliferation O 
, O 
and O 
angiogenesis O 
and O 
led O 
to O 
sensitization O 
of O 
tumor O 
cells O 
to O 
thalidomide B-TRIVIAL 
and O 
bortezomib B-TRIVIAL 
. O 
Comparing O 
the O 
activities O 
of O 
morin B-TRIVIAL 
with O 
those O 
of O 
four O 
structurally O 
related O 
flavonols B-FAMILY 
demonstrated O 
the O 
importance O 
of O 
hydroxyl B-SYSTEMATIC 
groups O 
in O 
the O 
B O 
ring O 
in O 
inhibiting O 
STAT3 O 
activation O 
. O 
These O 
findings O 
suggest O 
that O 
morin B-TRIVIAL 
suppresses O 
the O 
STAT3 O 
pathway O 
, O 
leading O 
to O 
the O 
down O 
- O 
regulation O 
of O 
STAT3-dependent O 
gene O 
expression O 
and O 
chemosensitization O 
of O 
tumor O 
cells O 
. O 

demonstrated O 
radiolytic O 
ligation O 
of O 
oligodeoxynucleotides O 
( O 
ODNs O 
) O 
possessing O 
disulfide B-SYSTEMATIC 
bond O 
and O 
its O 
application O 
to O 
regulation O 
of O 
DNA O 
quadruplex O 
formation O 
. O 
G-rich O 
hexamer O 
ODNs O 
had O 
poor O 
ability O 
to O 
form O 
quadruplex O 
, O 
while O 
X-irradiation O 
of O 
the O 
ODNs O 
induced O 
interstrand O 
exchange O 
reaction O 
at O 
disulfide B-SYSTEMATIC 
bond O 
to O 
form O 
ligated O 
12 O 
mer O 
ODNs O 
, O 
leading O 
to O 
the O 
ready O 
formation O 
of O 
quadruplex O 
due O 
to O 
the O 
entropic O 
effect O 
. O 
Since O 
complexation O 
of O 
the O 
ligated O 
ODNs O 
with O 
hemin B-TRIVIAL 
in O 
the O 
presence O 
of O 
K(+) B-FORMULA 
showed O 
strong O 
soret O 
band O 
absorption O 
and O 
also O 
catalyzed O 
the O 
H(2)O(2) B-FORMULA 
-mediated O 
oxidation O 
of O 
luminol B-TRIVIAL 
, O 
it O 
appears O 
that O 
the O 
quadruplex O 
formed O 
from O 
ligated O 
ODNs O 
showed O 
a O 
function O 
similar O 
to O 
native O 
DNA O 
quadruplex O 
. O 

taxa O 
, O 
cooperative O 
breeding O 
has O 
been O 
associated O 
with O 
high O 
reproductive O 
skew O 
. O 
Cooperatively O 
breeding O 
golden O 
lion O 
tamarins O 
( O 
Leontopithecus O 
rosalia O 
) O 
were O 
long O 
thought O 
to O 
have O 
a O 
monogynous O 
mating O 
system O 
in O 
which O 
reproduction O 
was O 
limited O 
to O 
a O 
single O 
dominant O 
female O 
. O 
Subordinates O 
with O 
few O 
reproductive O 
opportunities O 
delayed O 
dispersal O 
and O 
remained O 
in O 
the O 
natal O 
group O 
to O 
provide O 
alloparental O 
care O 
to O 
siblings O 
, O 
thus O 
allowing O 
dominant O 
reproductive O 
females O 
to O 
meet O 
the O 
energetic O 
needs O 
associated O 
with O 
high O 
rates O 
of O 
reproduction O 
and O 
successful O 
infant O 
rearing O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
re O 
- O 
assess O 
monogyny O 
in O 
wild O 
golden O 
lion O 
tamarin O 
groups O 
based O 
upon O 
pregnancy O 
diagnoses O 
that O 
used O 
non-invasive O 
enzyme O 
immunoassay O 
for O 
progesterone B-TRIVIAL 
and O 
cortisol B-TRIVIAL 
, O 
combined O 
with O 
weekly O 
data O 
on O 
individual O 
weight O 
gain O 
, O 
bi O 
- O 
annual O 
physical O 
examinations O 
noting O 
pregnancy O 
and O 
lactation O 
status O 
and O 
daily O 
behavioral O 
observations O 
. O 
We O 
established O 
quantitative O 
and O 
qualitative O 
criteria O 
to O 
detect O 
and O 
determine O 
the O 
timing O 
of O 
pregnancies O 
that O 
did O 
not O 
result O 
in O 
the O 
birth O 
of O 
infants O 
. O 
Pregnancy O 
polygyny O 
occurred O 
in O 
83% O 
of O 
golden O 
lion O 
tamarin O 
groups O 
studied O 
. O 
The O 
loss O 
of O 
64% O 
of O 
subordinate O 
pregnancies O 
compared O 
to O 
only O 
15% O 
by O 
dominant O 
females O 
limited O 
reproductive O 
success O 
mainly O 
to O 
dominant O 
females O 
, O 
thus O 
maintaining O 
high O 
reproductive O 
skew O 
in O 
female O 
golden O 
lion O 
tamarins O 
. O 
Pregnancy O 
loss O 
by O 
subordinate O 
adults O 
did O 
not O 
appear O 
to O 
result O 
from O 
dominant O 
interference O 
in O 
subordinate O 
hormonal O 
mechanisms O 
, O 
but O 
more O 
likely O 
resulted O 
from O 
subordinate O 
abandonment O 
of O 
newborn O 
infants O 
to O 
mitigate O 
dominant O 
aggression O 
. O 

and O 
prevention O 
of O 
various O 
therapeutic O 
conditions O 
using O 
OX O 
receptor O 
antagonistic O 
activity O 
( O 
WO2012081692 B-IDENTIFIER 
) O 
. O 

WO2012081692 B-IDENTIFIER 
from O 
Taisho O 
Pharmaceutical O 
Co O 
. O 
Ltd O 
. O 
claims O 
pyrazole B-SYSTEMATIC 
-based O 
antagonists O 
of O 
the O 
orexin-1 O 
and O 
orexin-2 O 
receptors O 
. O 
Utility O 
in O 
a O 
number O 
of O 
therapeutic O 
areas O 
is O 
claimed O 
, O 
including O 
the O 
treatment O 
of O 
sleep O 
disorders O 
; O 
the O 
most O 
likely O 
use O 
of O 
the O 
claimed O 
compounds O 
. O 
Data O 
from O 
in O 
vitro O 
functional O 
assays O 
are O 
presented O 
, O 
with O 
the O 
claimed O 
compounds O 
typically O 
being O 
dual O 
orexin O 
receptor O 
antagonists O 
( O 
DORAs O 
) O 
or O 
having O 
moderate O 
selectivity O 
for O 
orexin-1 O 
. O 
Structurally O 
, O 
the O 
claimed O 
compounds O 
represent O 
a O 
variation O 
on O 
established O 
DORA O 
SAR O 
themes O 
and O 
translate O 
features O 
of O 
clinical O 
compounds O 
into O 
a O 
pyrazole B-SYSTEMATIC 
-based O 
scaffold O 
. O 
Example O 
52 O 
, O 
the O 
most O 
potent O 
molecule O 
in O 
the O 
application O 
, O 
has O 
similar O 
molecular O 
weight O 
and O 
lipophilicity O 
to O 
suvorexant B-TRIVIAL 
, O 
the O 
most O 
advanced O 
DORA O 
, O 
with O 
broadly O 
comparable O 
potency O 
in O 
functional O 
assays O 
. O 

and O 
OAT3 O 
: O 
targets O 
of O 
drug O 
- O 
drug O 
interaction O 
between O 
entecavir B-TRIVIAL 
and O 
JBP485 B-IDENTIFIER 
. O 

and O 
JBP485 B-IDENTIFIER 
( O 
a O 
dipeptide B-FAMILY 
) O 
exhibit O 
the O 
antihepatitis O 
activities O 
and O 
it O 
is O 
possible O 
for O 
the O 
two O 
drugs O 
to O 
be O 
coadministered O 
in O 
the O 
treatment O 
of O 
hepatitis O 
. O 
We O 
aimed O 
to O 
elucidate O 
whether O 
entecavir B-TRIVIAL 
was O 
a O 
substrate O 
of O 
OAT1 O 
, O 
OAT3 O 
, O 
OCT O 
, O 
and O 
PEPT1 O 
and O 
to O 
investigate O 
the O 
targets O 
of O 
drug O 
- O 
drug O 
interactions O 
between O 
entecavir B-TRIVIAL 
and O 
JBP485 B-IDENTIFIER 
. O 
Plasma O 
and O 
urine O 
concentrations O 
of O 
entecavir B-TRIVIAL 
following O 
intravenous O 
and O 
oral O 
administration O 
in O 
vivo O 
, O 
uptake O 
of O 
entecavir B-TRIVIAL 
in O 
kidney O 
slices O 
and O 
transfected O 
cells O 
in O 
vitro O 
, O 
were O 
determined O 
by O 
LC-MS O 
/ O 
MS O 
. O 
Following O 
intravenous O 
co O 
- O 
administration O 
of O 
entecavir B-TRIVIAL 
and O 
JBP485 B-IDENTIFIER 
in O 
rats O 
, O 
entecavir B-TRIVIAL 
AUC O 
increased O 
1.93-fold O 
, O 
t1 O 
/ O 
2β O 
was O 
prolonged O 
2.08-fold O 
, O 
CLP O 
decreased O 
49% O 
, O 
CLR O 
decreased O 
73% O 
, O 
and O 
accumulated O 
urinary O 
excretion O 
decreased O 
54% O 
. O 
However O 
, O 
following O 
oral O 
co O 
- O 
administration O 
, O 
the O 
entecavir B-TRIVIAL 
Tmax O 
and O 
Cmax O 
were O 
not O 
affected O 
; O 
the O 
degree O 
of O 
change O 
in O 
other O 
pharmacokinetic O 
parameters O 
( O 
AUC O 
, O 
t1 O 
/ O 
2β O 
, O 
CLP O 
, O 
and O 
accumulated O 
urinary O 
excretion O 
) O 
was O 
similar O 
to O 
that O 
of O 
intravenous O 
administration O 
. O 
The O 
uptake O 
of O 
entecavir B-TRIVIAL 
was O 
nearly O 
identical O 
in O 
hPEPT1- O 
as O 
in O 
vector-HELA O 
cells O 
. O 
In O 
rat O 
kidney O 
slices O 
, O 
uptake O 
of O 
entecavir B-TRIVIAL 
was O 
markedly O 
inhibited O 
by O 
p-aminohippurate B-TRIVIAL 
, O 
benzylpenicillin B-SYSTEMATIC 
, O 
JBP485 B-IDENTIFIER 
, O 
and O 
tetraethyl B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
. O 
In O 
hOAT1- O 
and O 
hOAT3-HEK293 O 
cells O 
, O 
uptake O 
of O 
entecavir B-TRIVIAL 
was O 
significantly O 
higher O 
compared O 
to O 
vector-HEK293 O 
cells O 
and O 
was O 
markedly O 
inhibited O 
by O 
p-aminohippurate B-TRIVIAL 
, O 
benzylpenicillin B-SYSTEMATIC 
, O 
and O 
JBP485 B-IDENTIFIER 
. O 
Km O 
and O 
Vmax O 
values O 
of O 
entecavir B-TRIVIAL 
were O 
250 O 
μM O 
and O 
0.83 O 
nmol O 
/ O 
mg O 
protein O 
/ O 
30s O 
( O 
OAT1 O 
) O 
and O 
23 O 
μM O 
and O 
1.1 O 
nmol O 
/ O 
mg O 
protein O 
/ O 
30 O 
s O 
( O 
OAT3 O 
) O 
, O 
respectively O 
. O 
Entecavir B-TRIVIAL 
is O 
the O 
substrate O 
of O 
OAT1 O 
, O 
OAT3 O 
, O 
and O 
OCT O 
. O 
Moreover O 
, O 
OAT1 O 
and O 
OAT3 O 
are O 
the O 
targets O 
of O 
DDI O 
between O 
entecavir B-TRIVIAL 
and O 
JBP485 B-IDENTIFIER 
. O 

- O 
pot O 
synthesis O 
of O 
tin B-SYSTEMATIC 
-embedded O 
carbon B-SYSTEMATIC 
/ O 
silica B-TRIVIAL 
nanocomposites O 
for O 
anode O 
materials O 
in O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 

report O 
a O 
facile O 
" O 
one O 
- O 
pot O 
" O 
method O 
for O 
the O 
synthesis O 
of O 
Sn B-FORMULA 
-embedded O 
carbon B-SYSTEMATIC 
- O 
silica B-TRIVIAL 
( O 
CS O 
) O 
mesostructured O 
( O 
nanostructured O 
) O 
composites O 
through O 
the O 
selective O 
interaction O 
of O 
resol O 
( O 
carbon B-SYSTEMATIC 
precursor O 
) O 
, O 
tetraethylorthosilicate B-SYSTEMATIC 
( O 
TEOS B-ABBREVIATION 
) O 
, O 
and O 
tributylphenyltin B-SYSTEMATIC 
( O 
Sn B-FORMULA 
precursor O 
) O 
with O 
an O 
amphiphilic O 
diblock O 
copolymer O 
, O 
poly(ethylene B-FAMILY 
oxide-b-styrene I-FAMILY 
) I-FAMILY 
, O 
PEO-b-PS B-ABBREVIATION 
. O 
A O 
unique O 
morphology O 
transition O 
from O 
Sn B-FORMULA 
nanowires O 
to O 
spherical O 
Sn B-FORMULA 
nanoparticles O 
embedded O 
in O 
CS O 
framework O 
has O 
been O 
obtained O 
. O 
Metallic O 
Sn B-FORMULA 
species O 
are O 
homogeneously O 
embedded O 
in O 
a O 
rigid O 
CS O 
framework O 
and O 
are O 
effectively O 
confined O 
within O 
the O 
nanostructures O 
. O 
The O 
resulting O 
composites O 
are O 
used O 
as O 
anode O 
materials O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
and O 
exhibit O 
high O 
specific O 
capacities O 
( O 
600 O 
mA O 
h O 
g⁻¹ O 
at O 
a O 
current O 
density O 
of O 
45 O 
mA O 
g⁻¹ O 
, O 
and O 
440 O 
mA O 
h O 
g⁻¹ O 
at O 
a O 
current O 
density O 
of O 
300 O 
mA O 
g⁻¹ O 
) O 
and O 
an O 
excellent O 
cyclability O 
of O 
over O 
100 O 
cycles O 
with O 
high O 
Coulombic O 
efficiency O 
. O 
Most O 
of O 
all O 
, O 
the O 
novel O 
method O 
developed O 
in O 
this O 
work O 
for O 
synthesizing O 
functional O 
hybrid O 
materials O 
can O 
be O 
extended O 
to O 
the O 
preparation O 
of O 
various O 
functional O 
nanocomposites O 
owing O 
to O 
its O 
versatility O 
and O 
facileness O 
. O 

and O 
immunomodulatory O 
activity O 
of O 
selenium B-SYSTEMATIC 
exopolysaccharide O 
produced O 
by O 
Lactococcus O 
lactis O 
subsp O 
. O 
lactis O 
. O 

( O 
EPS O 
) O 
was O 
isolated O 
and O 
purified O 
from O 
Lactococcus O 
lactis O 
subsp O 
. O 
Lactis O 
culture O 
broth O 
. O 
Selenium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
SeCl(2)O B-FORMULA 
) O 
was O 
added O 
to O 
the O 
EPS O 
to O 
synthesize O 
selenium B-SYSTEMATIC 
-exopolysaccharide O 
( O 
Se B-FORMULA 
-EPS O 
) O 
. O 
The O 
in O 
vitro O 
and O 
in O 
vivo O 
antioxidant O 
and O 
in O 
vivo O 
immunomodulatory O 
activity O 
of O 
EPS O 
and O 
Se B-FORMULA 
-EPS O 
were O 
compared O 
. O 
EPS O 
and O 
Se B-FORMULA 
-EPS O 
scavenged O 
superoxide B-TRIVIAL 
anions O 
and O 
hydroxyl B-SYSTEMATIC 
radicals O 
. O 
They O 
also O 
increased O 
catalase O 
( O 
CAT O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
activity O 
, O 
while O 
decreasing O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
in O 
serum O 
and O 
in O 
the O 
livers O 
of O 
mice O 
. O 
Se B-FORMULA 
-EPS O 
showed O 
stronger O 
in O 
vitro O 
and O 
in O 
vivo O 
antioxidant O 
activity O 
than O 
were O 
shown O 
by O 
EPS O 
. O 
The O 
in O 
vivo O 
immunoenhancement O 
activity O 
of O 
EPS O 
and O 
Se B-FORMULA 
-EPS O 
induced O 
by O 
cyclophosphamide B-TRIVIAL 
( O 
CY O 
) O 
treatment O 
in O 
immunosuppressed O 
mice O 
was O 
researched O 
. O 
EPS O 
and O 
Se B-FORMULA 
-EPS O 
treatments O 
increased O 
macrophage O 
phagocytosis O 
, O 
spleen O 
and O 
thymus O 
indices O 
and O 
haemolytic O 
complement O 
activity O 
(HC(50)) O 
. O 
Se B-FORMULA 
-EPS O 
showed O 
stronger O 
immunomodulatory O 
activity O 
than O 
did O 
EPS O 
. O 

are O 
single O 
- O 
domain O 
antibodies O 
found O 
in O 
camelids O 
. O 
These O 
are O 
the O 
smallest O 
naturally O 
occurring O 
binding O 
domains O 
and O 
derive O 
functionality O 
via O 
three O 
hypervariable O 
loops O 
( O 
H1-H3 O 
) O 
that O 
form O 
the O 
binding O 
surface O 
. O 
They O 
are O 
excellent O 
candidates O 
for O 
antibody O 
engineering O 
because O 
of O 
their O 
favorable O 
characteristics O 
like O 
small O 
size O 
, O 
high O 
solubility O 
, O 
and O 
stability O 
. O 
To O 
rationally O 
engineer O 
antibodies O 
with O 
affinity O 
for O 
a O 
specific O 
target O 
, O 
the O 
hypervariable O 
loops O 
can O 
be O 
tailored O 
to O 
obtain O 
the O 
desired O 
binding O 
surface O 
. O 
As O 
a O 
first O 
step O 
toward O 
such O 
a O 
goal O 
, O 
we O 
consider O 
the O 
design O 
of O 
loops O 
with O 
a O 
desired O 
conformation O 
. O 
In O 
this O 
study O 
, O 
we O 
focus O 
on O 
the O 
H1 O 
loop O 
of O 
the O 
anti-hCG O 
llama O 
nanobody O 
that O 
exhibits O 
a O 
noncanonical O 
conformation O 
. O 
We O 
aim O 
to O 
" O 
tilt O 
" O 
the O 
stability O 
of O 
the O 
H1 O 
loop O 
structure O 
from O 
a O 
noncanonical O 
conformation O 
to O 
a O 
( O 
humanized O 
) O 
type O 
1 O 
canonical O 
conformation O 
by O 
studying O 
the O 
effect O 
of O 
selected O 
mutations O 
to O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
the O 
H1 O 
, O 
H2 O 
, O 
and O 
proximal O 
residues O 
. O 
We O 
use O 
all O 
- O 
atomistic O 
, O 
explicit O 
- O 
solvent O 
, O 
biased O 
molecular O 
dynamic O 
simulations O 
to O 
simulate O 
the O 
wild O 
- O 
type O 
and O 
mutant O 
loops O 
in O 
a O 
prefolded O 
framework O 
. O 
We O 
thus O 
find O 
mutants O 
with O 
increasing O 
propensity O 
to O 
form O 
a O 
stable O 
type O 
1 O 
canonical O 
conformation O 
of O 
the O 
H1 O 
loop O 
. O 
Free O 
energy O 
landscapes O 
reveal O 
the O 
existence O 
of O 
conformational O 
isomers O 
of O 
the O 
canonical O 
conformation O 
that O 
may O 
play O 
a O 
role O 
in O 
binding O 
different O 
antigenic O 
surfaces O 
. O 
We O 
also O 
elucidate O 
the O 
approximate O 
mechanism O 
and O 
kinetics O 
of O 
transitions O 
between O 
such O 
conformational O 
isomers O 
by O 
using O 
a O 
Markovian O 
model O 
. O 
We O 
find O 
that O 
a O 
particular O 
three O 
- O 
point O 
mutant O 
has O 
the O 
strongest O 
thermodynamic O 
propensity O 
to O 
form O 
the O 
H1 O 
type O 
1 O 
canonical O 
structure O 
but O 
also O 
to O 
exhibit O 
transitions O 
between O 
conformational O 
isomers O 
, O 
while O 
a O 
different O 
, O 
more O 
rigid O 
three O 
- O 
point O 
mutant O 
has O 
the O 
strongest O 
propensity O 
to O 
be O 
kinetically O 
trapped O 
in O 
such O 
a O 
canonical O 
structure O 
. O 

directly O 
inhibits O 
ghrelin O 
secretion O 
through O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
in O 
rat O 
primary O 
gastric O 
cells O 
. O 

antidiabetic O 
drug O 
Metformin B-TRIVIAL 
causes O 
weight O 
loss O 
in O 
both O 
diabetic O 
and O 
non-diabetic O 
individuals O 
. O 
Metformin B-TRIVIAL 
treatment O 
is O 
also O 
associated O 
with O 
lower O 
circulating O 
levels O 
of O 
the O 
orexigenic O 
hormone O 
ghrelin O 
. O 
To O 
test O 
whether O 
Metformin B-TRIVIAL 
directly O 
affects O 
ghrelin O 
cells O 
, O 
rat O 
primary O 
stomach O 
cells O 
were O 
treated O 
with O 
Metformin B-TRIVIAL 
and O 
the O 
levels O 
of O 
ghrelin O 
secretion O 
, O 
proghrelin O 
gene O 
expression O 
and O 
activation O 
of O 
adenosine B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
were O 
examined O 
. O 
Metformin B-TRIVIAL 
significantly O 
reduced O 
ghrelin O 
secretion O 
and O 
proghrelin O 
mRNA O 
production O 
and O 
both O 
these O 
effects O 
were O 
blocked O 
by O 
co O 
- O 
incubation O 
with O 
the O 
AMPK O 
inhibitor O 
compound B-TRIVIAL 
C I-TRIVIAL 
. O 
Furthermore O 
, O 
the O 
AMPK O 
activator O 
5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide B-SYSTEMATIC 
( O 
AICAR B-ABBREVIATION 
) O 
significantly O 
inhibited O 
ghrelin O 
secretion O 
. O 
Additionally O 
, O 
ghrelin O 
cells O 
were O 
shown O 
to O 
express O 
AMPK O 
. O 
Finally O 
, O 
Metformin B-TRIVIAL 
treatment O 
caused O 
a O 
significant O 
increase O 
in O 
the O 
level O 
of O 
phosphorylated O 
( O 
active O 
) O 
AMPK O 
. O 
Our O 
results O 
show O 
that O 
Metformin B-TRIVIAL 
directly O 
inhibits O 
stomach O 
ghrelin O 
production O 
and O 
secretion O 
through O 
AMPK O 
. O 
This O 
reduction O 
in O 
ghrelin O 
secretion O 
may O 
be O 
one O 
of O 
the O 
key O 
components O 
in O 
Metformin B-TRIVIAL 
' O 
s O 
mechanism O 
of O 
weight O 
loss O 
. O 

Flaxseed O 
Oil O 
Supplementation O 
Mitigates O 
the O 
Effect O 
of O 
Lead O 
on O 
the O 
Enzymes O 
of O 
Carbohydrate B-FAMILY 
Metabolism O 
, O 
Brush O 
Border O 
Membrane O 
, O 
and O 
Oxidative O 
Stress O 
in O 
Rat O 
Kidney O 
Tissues O 
. O 

is O 
a O 
heavy O 
metal O 
widely O 
distributed O 
in O 
the O 
environment O 
. O 
Lead O 
is O 
a O 
ubiquitous O 
environmental O 
toxin O 
that O 
is O 
capable O 
of O 
causing O 
numerous O 
acute O 
and O 
chronic O 
illnesses O 
. O 
Human O 
and O 
animal O 
exposure O 
demonstrates O 
that O 
lead O 
is O 
nephrotoxic O 
. O 
However O 
, O 
attempts O 
to O 
reduce O 
lead O 
- O 
induced O 
nephrotoxicity O 
were O 
not O 
found O 
suitable O 
for O 
clinical O 
use O 
. O 
Recently O 
, O 
flaxseed O 
oil O 
( O 
FXO O 
) O 
, O 
a O 
rich O 
source O 
of O 
ω-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
and O 
lignans B-FAMILY 
, O 
has O 
been O 
shown O 
to O 
prevent O 
/ O 
reduce O 
the O 
progression O 
of O 
certain O 
types O 
of O 
cardiovascular O 
and O 
renal O 
disorders O 
. O 
In O 
view O 
of O 
this O 
, O 
the O 
present O 
study O 
investigates O 
the O 
protective O 
effect O 
of O 
FXO O 
on O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
PbAc B-FORMULA 
)-induced O 
renal O 
damage O 
. O 
Rats O 
were O 
pre O 
- O 
fed O 
normal O 
diet O 
and O 
the O 
diet O 
rich O 
in O 
FXO O 
for O 
14 O 
days O 
, O 
and O 
then O 
, O 
four O 
doses O 
of O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
25 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
were O 
administered O 
intraperitoneally O 
while O 
still O 
on O 
diet O 
. O 
Various O 
serum O 
parameters O 
, O 
enzymes O 
of O 
carbohydrate B-FAMILY 
metabolism O 
, O 
brush O 
border O 
membrane O 
( O 
BBM O 
) O 
, O 
and O 
oxidative O 
stress O 
were O 
analyzed O 
in O 
rat O 
kidney O 
. O 
PbAc B-FORMULA 
nephrotoxicity O 
was O 
characterized O 
by O 
increased O 
serum O 
creatinine B-TRIVIAL 
and O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
. O 
PbAc B-FORMULA 
increased O 
the O 
activities O 
of O 
lactate B-FAMILY 
dehydrogenase O 
and O 
NADP B-ABBREVIATION 
-malic O 
enzyme O 
, O 
whereas O 
it O 
decreased O 
malate B-TRIVIAL 
and O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
, O 
glucose B-TRIVIAL 
-6-phosphatase O 
, O 
fructose B-TRIVIAL 
-1 O 
, O 
6-bisphosphatase O 
, O 
and O 
BBM O 
enzyme O 
activities O 
. O 
PbAc B-FORMULA 
caused O 
oxidant O 
/ O 
antioxidant O 
imbalances O 
as O 
reflected O 
by O 
increased O 
lipid O 
peroxidation O 
and O 
decreased O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
and O 
catalase O 
. O 
In O 
contrast O 
, O 
FXO O 
alone O 
enhanced O 
the O 
enzyme O 
activities O 
of O 
carbohydrate B-FAMILY 
metabolism O 
, O 
BBM O 
, O 
and O 
antioxidant O 
defense O 
system O 
. O 
FXO O 
feeding O 
to O 
PbAc B-FORMULA 
-treated O 
rats O 
markedly O 
enhanced O 
resistance O 
to O 
PbAc B-FORMULA 
-elicited O 
deleterious O 
effects O 
. O 
In O 
conclusion O 
, O 
dietary O 
FXO O 
supplementation O 
ameliorated O 
PbAc B-FORMULA 
-induced O 
specific O 
metabolic O 
alterations O 
and O 
oxidative O 
damage O 
by O 
empowering O 
antioxidant O 
defense O 
mechanism O 
and O 
improving O 
BBM O 
integrity O 
and O 
energy O 
metabolism O 
. O 

is O 
a O 
54- O 
amino B-FAMILY 
acid I-FAMILY 
peptide O 
which O 
is O 
encoded O 
by O 
the O 
KiSS-1 O 
gene O 
and O 
activates O 
the O 
G O 
protein O 
- O 
coupled O 
receptor O 
GPR54 O 
. O 
Evidence O 
suggests O 
that O 
this O 
system O 
is O 
a O 
key O 
regulator O 
of O 
mammalian O 
and O 
human O 
reproduction O 
. O 
Animal O 
studies O 
have O 
shown O 
that O 
GPR54-deficient O 
mice O 
have O 
abnormal O 
sexual O 
development O 
. O 
Central O 
and O 
peripheral O 
administration O 
of O 
kisspeptin O 
stimulates O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
gonadal O 
( O 
HPG O 
) O 
axis O 
whilst O 
pre O 
- O 
administration O 
of O 
a O 
gonadotrophin B-TRIVIAL 
releasing I-TRIVIAL 
hormone I-TRIVIAL 
( O 
GnRH B-ABBREVIATION 
) O 
antagonist O 
abolishes O 
this O 
effect O 
. O 
In O 
humans O 
, O 
inactivating O 
GPR54 O 
mutations O 
cause O 
normosmic O 
hypogonadotrophic O 
hypogonadism O 
whilst O 
activation O 
of O 
GPR54 O 
signalling O 
is O 
associated O 
with O 
premature O 
puberty O 
. O 
In O 
healthy O 
human O 
volunteers O 
, O 
the O 
acute O 
intravenous O 
administration O 
of O 
kisspeptin O 
potently O 
increases O 
plasma O 
luteinising O 
hormone O 
( O 
LH O 
) O 
levels O 
and O 
significantly O 
increases O 
plasma O 
follicle O 
stimulating O 
hormone O 
( O 
FSH O 
) O 
and O 
testosterone B-TRIVIAL 
without O 
side O 
effects O 
in O 
both O 
males O 
and O 
in O 
females O 
particularly O 
in O 
the O 
preovulatatory O 
phase O 
of O 
the O 
menstrual O 
cycle O 
. O 
In O 
infertility O 
due O 
to O 
hypothalamic O 
amenorrhoea O 
acute O 
administration O 
of O 
kisspeptin O 
results O 
in O 
stimulation O 
of O 
reproductive O 
hormones O 
. O 
The O 
kisspeptin O 
/ O 
GPR54 O 
system O 
therefore O 
appears O 
to O 
play O 
an O 
important O 
role O 
in O 
the O 
regulation O 
of O 
reproduction O 
in O 
humans O 
. O 
Hence O 
kisspeptin O 
has O 
potential O 
as O 
a O 
novel O 
tool O 
for O 
the O 
manipulation O 
of O 
the O 
HPG O 
axis O 
and O 
treatment O 
of O 
infertility O 
in O 
humans O 
. O 
This O 
review O 
discusses O 
the O 
evidence O 
highlighting O 
kisspeptin's O 
key O 
role O 
in O 
human O 
reproduction O 
. O 

dephenylation O 
of O 
the O 
rubber O 
antioxidant O 
N-phenyl-2-naphthylamine B-SYSTEMATIC 
to O 
carcinogenic O 
2-naphthylamine B-SYSTEMATIC 
in O 
rats O 
. O 

( O 
P2NA B-SYSTEMATIC 
) O 
was O 
widely O 
used O 
as O 
oxidation O 
inhibitor O 
, O 
particularly O 
in O 
rubber O 
manufacturing O 
. O 
Technical O 
- O 
grade O 
P2NA B-SYSTEMATIC 
was O 
contaminated O 
with O 
carcinogenic O 
2-naphthylamine B-SYSTEMATIC 
( O 
2NA B-SYSTEMATIC 
) O 
, O 
and O 
bladder O 
cancer O 
risk O 
in O 
exposed O 
workers O 
was O 
attributed O 
to O 
this O 
impurity O 
. O 
Investigations O 
in O 
humans O 
and O 
mammalian O 
species O 
revealed O 
that O 
small O 
amounts O 
of O 
2NA B-SYSTEMATIC 
are O 
excreted O 
into O 
urine O 
after O 
exposure O 
to O 
P2NA B-SYSTEMATIC 
. O 
However O 
, O 
since O 
2NA B-SYSTEMATIC 
per O 
se O 
is O 
not O 
carcinogenic O 
and O 
main O 
downstream O 
metabolites O 
of O 
2NA B-SYSTEMATIC 
have O 
not O 
been O 
found O 
in O 
urine O 
so O 
far O 
, O 
it O 
remained O 
uncertain O 
if O 
2NA B-SYSTEMATIC 
derived O 
from O 
P2NA B-SYSTEMATIC 
dephenylation O 
is O 
further O 
activated O 
to O 
carcinogenic O 
downstream O 
metabolites O 
. O 
An O 
experimental O 
animal O 
study O 
was O 
therefore O 
designed O 
to O 
indicate O 
if O 
, O 
and O 
if O 
yes O 
to O 
which O 
extent O 
, O 
2NA B-SYSTEMATIC 
from O 
P2NA B-SYSTEMATIC 
dephenylation O 
is O 
accessible O 
to O 
the O 
metabolic O 
pathway O 
that O 
is O 
held O 
responsible O 
for O 
the O 
carcinogenicity O 
of O 
2NA B-SYSTEMATIC 
. O 
Groups O 
of O 
5 O 
male O 
and O 
female O 
CD O 
rats O 
were O 
dosed O 
with O 
P2NA B-SYSTEMATIC 
( O 
2-550 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
and O 
2NA B-SYSTEMATIC 
( O 
0.075-75 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
; O 
2N B-SYSTEMATIC 
A-haemoglobin O 
adducts O 
and O 
urinary O 
2N B-SYSTEMATIC 
A O 
excretion O 
were O 
determined O 
applying O 
GC-MS O 
/ O 
MS O 
. O 
2NA O 
haemoglobin O 
adducts O 
originated O 
dose O 
- O 
dependently O 
after O 
2N B-SYSTEMATIC 
A O 
and O 
P2N B-SYSTEMATIC 
A O 
dosing O 
. O 
To O 
induce O 
identical O 
adduct O 
concentrations O 
, O 
an O 
approximately O 
100-200-fold O 
higher O 
dose O 
of O 
P2N B-SYSTEMATIC 
A O 
was O 
necessary O 
compared O 
to O 
2N B-SYSTEMATIC 
A O 
. O 
Since O 
haemoglobin O 
adducts O 
are O 
formed O 
by O 
the O 
same O 
pathway O 
( B-FORMULA 
N-hydroxylation O 
) O 
as O 
the O 
ultimate O 
carcinogens O 
from O 
2N B-SYSTEMATIC 
A O 
, O 
the O 
comparison O 
of O 
adduct O 
concentrations O 
after O 
2N B-SYSTEMATIC 
A O 
and O 
P2N B-SYSTEMATIC 
A O 
dosage O 
permits O 
a O 
quantitative O 
estimate O 
of O 
the O 
carcinogenicity O 
of O 
P2N B-SYSTEMATIC 
A O 
. O 
The O 
results O 
show O 
that O 
2N B-SYSTEMATIC 
A O 
derived O 
from O 
dephenylation O 
of O 
P2N B-SYSTEMATIC 
A O 
enters O 
the O 
carcinogenic O 
downstream O 
pathway O 
of O 
2N B-SYSTEMATIC 
A O 
in O 
rats O 
. O 
Hence O 
, O 
the O 
bladder O 
cancer O 
risk O 
after O 
human O 
exposures O 
to O 
P2N B-SYSTEMATIC 
A O 
must O 
be O 
re O 
- O 
evaluated O 
. O 

-bonding O 
- O 
triggered O 
supramolecular O 
gel O 
formation O 
. O 

gels O 
are O 
topical O 
soft O 
materials O 
involving O 
the O 
reversible O 
formation O 
of O 
fibrous O 
aggregates O 
using O 
non-covalent O 
interactions O 
. O 
There O 
is O 
significant O 
interest O 
in O 
controlling O 
the O 
properties O 
of O 
such O 
materials O 
by O 
the O 
formation O 
of O 
multicomponent O 
systems O 
, O 
which O 
exhibit O 
non-additive O 
properties O 
emerging O 
from O 
interaction O 
of O 
the O 
components O 
. O 
The O 
use O 
of O 
hydrogen B-SYSTEMATIC 
bonding O 
to O 
assemble O 
supramolecular O 
gels O 
in O 
organic O 
solvents O 
is O 
well O 
established O 
. O 
In O 
contrast O 
, O 
the O 
use O 
of O 
halogen B-FAMILY 
bonding O 
to O 
trigger O 
supramolecular O 
gel O 
formation O 
in O 
a O 
two O 
- O 
component O 
gel O 
( O 
' O 
co O 
- O 
gel O 
' O 
) O 
is O 
essentially O 
unexplored O 
, O 
and O 
forms O 
the O 
basis O 
for O 
this O 
study O 
. O 
Here O 
, O 
we O 
show O 
that O 
halogen B-FAMILY 
bonding O 
between O 
a O 
pyridyl B-SYSTEMATIC 
substituent O 
in O 
a O 
bis(pyridyl B-SYSTEMATIC 
urea I-SYSTEMATIC 
) I-SYSTEMATIC 
and O 
1,4-diiodotetrafluorobenzene B-SYSTEMATIC 
brings O 
about O 
gelation O 
, O 
even O 
in O 
polar O 
media O 
such O 
as O 
aqueous O 
methanol B-SYSTEMATIC 
and O 
aqueous O 
dimethylsulfoxide B-SYSTEMATIC 
. O 
This O 
demonstrates O 
that O 
halogen B-FAMILY 
bonding O 
is O 
sufficiently O 
strong O 
to O 
interfere O 
with O 
competing O 
gel O 
- O 
inhibitory O 
interactions O 
and O 
create O 
a O 
' O 
tipping O 
point O 
' O 
in O 
gel O 
assembly O 
. O 
Using O 
this O 
concept O 
, O 
we O 
have O 
prepared O 
a O 
halogen B-FAMILY 
bond O 
donor O 
bis(urea) B-SYSTEMATIC 
gelator O 
that O 
forms O 
co O 
- O 
gels O 
with O 
halogen B-FAMILY 
bond O 
acceptors O 
. O 

( O 
miRs O 
) O 
play O 
important O 
roles O 
in O 
initiation O 
and O 
progression O 
of O 
many O 
pathologic O 
processes O 
. O 
However O 
, O 
the O 
roles O 
of O 
miRs O 
in O 
diabetic O 
nephropathy O 
remain O 
unclear O 
. O 
This O 
study O 
was O 
to O 
determine O 
whether O 
miR-21 O 
was O 
involved O 
in O 
diabetic O 
nephropathy O 
and O 
to O 
explore O 
the O 
relationship O 
between O 
miR-21 O 
and O 
MMP9 O 
/ O 
TIMP1 O 
expression O 
in O 
diabetic O 
nephropathy O 
. O 
In O 
situ O 
hybridization O 
studies O 
showed O 
that O 
miR-21 O 
was O 
primarily O 
localized O 
and O 
distributed O 
in O 
cortical O 
glomerular O 
and O 
renal O 
tubular O 
cells O 
in O 
diabetic O 
kk O 
- O 
ay O 
kidney O 
. O 
Real O 
- O 
time O 
quantitative O 
RT-PCR O 
demonstrated O 
that O 
the O 
expression O 
of O 
miR-21 O 
was O 
significantly O 
increased O 
in O 
kk O 
- O 
ay O 
mice O 
, O 
compared O 
with O 
control O 
C57BL O 
mice O 
. O 
Interestingly O 
, O 
miR-21 O 
expression O 
positively O 
correlated O 
with O 
urine O 
albumin O 
creatine B-TRIVIAL 
ratio O 
( O 
ACR O 
) O 
, O 
TIMP1 O 
, O 
collagen O 
IV O 
( O 
ColIV O 
) O 
, O 
and O 
fibronectin O 
( O 
FN O 
) O 
; O 
while O 
negatively O 
correlated O 
with O 
creatine B-TRIVIAL 
clearance O 
ratio O 
( O 
Ccr O 
) O 
and O 
MMP-9 O 
protein O 
. O 
Importantly O 
, O 
antagomir-21 O 
not O 
only O 
ameliorated O 
Ccr O 
and O 
ACR O 
but O 
also O 
decreased O 
TIMP1 O 
, O 
ColIV O 
, O 
and O 
FN O 
proteins O 
. O 
In O 
conclusion O 
, O 
our O 
data O 
demonstrate O 
that O 
miR-21 O 
contributes O 
to O 
renal O 
fibrosis O 
by O 
mediating O 
MMP9 O 
/ O 
TIMP1 O 
and O 
that O 
inhibition O 
of O 
miR-21 O 
may O 
be O 
a O 
novel O 
target O 
for O 
diabetic O 
nephropathy O 
. O 

of O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
in O 
Camellia O 
oleifera O 
oil O 
by O 
near O 
infrared O 
transmittance O 
spectroscopy O 
( O 
NITS O 
) O 
. O 

the O 
serious O 
circumstances O 
of O 
Camellia O 
oleifera O 
adulteration O 
, O 
the O 
accurate O 
examination O 
for O 
quality O 
trait O 
of O 
C O 
. O 
oleifera O 
oil O 
is O 
extremely O 
urgent O 
. O 
For O 
rapid O 
determination O 
of O 
FA O 
composition O 
in O 
C O 
. O 
oleifera O 
oil O 
, O 
the O 
feasibility O 
of O 
NITS O 
was O 
first O 
studied O 
. O 
The O 
quantitative O 
models O 
for O 
FA O 
were O 
built O 
based O 
on O 
PLS O 
regression O 
. O 
NITS O 
spectra O 
is O 
able O 
to O 
accurately O 
predict O 
for O 
oleic B-MULTIPLE 
, I-MULTIPLE 
linoleic I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
palmitic I-MULTIPLE 
acids I-MULTIPLE 
( O 
R(cv) O 
> O 
0.844 O 
, O 
R(2) O 
> O 
0.886 O 
) O 
. O 
R(cv) O 
are O 
0.91987 O 
, O 
0.95755 O 
, O 
and O 
0.84447 O 
, O 
and O 
R(2) O 
are O 
0.9424 O 
, O 
0.9682 O 
, O 
0.8862 O 
for O 
NITS O 
models O 
of O 
oleic B-MULTIPLE 
, I-MULTIPLE 
linoleic I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
palmitic I-MULTIPLE 
acids I-MULTIPLE 
, O 
respectively O 
. O 
But O 
models O 
for O 
stearic B-MULTIPLE 
and I-MULTIPLE 
unsaturated I-MULTIPLE 
acids I-MULTIPLE 
are O 
less O 
accurate O 
, O 
with O 
values O 
of O 
R(cv) O 
from O 
0.6744 O 
to O 
0.69114 O 
, O 
and O 
R(2) O 
from O 
0.6834 O 
to O 
0.7587 O 
. O 
These O 
results O 
indicate O 
that O 
NITS O 
will O 
have O 
potential O 
to O 
be O 
used O 
in O 
predicting O 
FA O 
composition O 
of O 
C O 
. O 
oleifera O 
oil O 
. O 

role O 
of O 
residues O 
T248 O 
, O 
Y249 O 
and O 
T422 O 
in O 
the O 
function O 
of O 
human O 
pregnane B-TRIVIAL 
X O 
receptor O 
. O 

pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
is O 
a O 
key O 
xenobiotic O 
receptor O 
that O 
regulates O 
the O 
expression O 
of O 
numerous O 
drug O 
- O 
metabolizing O 
enzymes O 
. O 
Some O 
posttranslational O 
mechanisms O 
modulate O 
its O 
transcriptional O 
activity O 
. O 
Although O 
several O 
kinases O 
have O 
been O 
shown O 
to O 
directly O 
phosphorylate O 
this O 
receptor O 
, O 
little O 
is O 
known O 
about O 
phosphorylation O 
sites O 
of O 
PXR O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
examined O 
T248 O 
, O 
Y249 O 
and O 
T422 O 
putative O 
phosphorylation O 
sites O 
determined O 
based O 
on O 
in O 
silico O 
consensus O 
kinase O 
site O 
prediction O 
analysis O 
. O 
T248 O 
and O 
T422 O 
residues O 
are O 
critical O 
for O 
the O 
interaction O 
of O 
the O 
PXR O 
ligand O 
- O 
binding O 
domain O 
and O 
the O 
activation O 
function-2 O 
( O 
AF2 O 
) O 
domain O 
. O 
Site O 
- O 
directed O 
mutagenesis O 
analysis O 
was O 
performed O 
to O 
generate O 
phospho B-SYSTEMATIC 
-deficient O 
and O 
phospho B-SYSTEMATIC 
-mimetic O 
mutants O 
. O 
We O 
examined O 
transactivation O 
activity O 
of O 
the O 
PXR O 
mutants O 
in O 
gene O 
reporter O 
assays O 
, O 
formation O 
of O 
PXRmutant O 
/ O 
RXRα O 
heterodimer O 
, O 
binding O 
of O 
PXR O 
mutants O 
to O 
the O 
CYP3A4 O 
gene O 
response O 
element O 
DR3 O 
and O 
CYP3A4 O 
expression O 
in O 
HepG2 O 
cells O 
after O 
expression O 
of O 
the O 
mutants O 
. O 
We O 
found O 
that O 
T248D O 
mutant O 
activated O 
CYP3A4 O 
transactivation O 
constitutively O 
regardless O 
of O 
the O 
presence O 
or O 
absence O 
of O 
a O 
ligand O 
. O 
Contrary O 
, O 
T248V O 
mutant O 
exhibited O 
low O 
basal O 
and O 
ligand O 
- O 
inducible O 
transactivation O 
capacity O 
as O 
compared O 
to O 
wild O 
- O 
type O 
PXR O 
. O 
Dose O 
- O 
response O 
analysis O 
revealed O 
reduced O 
ligand O 
- O 
dependent O 
transactivation O 
potency O 
of O 
PXR O 
Y249D O 
mutant O 
. O 
Transactivation O 
of O 
the O 
CYP3A4 O 
promoter O 
was O 
abolished O 
with O 
T422A O 
/ O 
D O 
mutants O 
. O 
All O 
PXR O 
mutants O 
formed O 
heterodimer O 
with O 
RXRα O 
at O 
a O 
similar O 
level O 
to O 
that O 
observed O 
with O 
wild O 
- O 
type O 
PXR O 
. O 
The O 
ability O 
to O 
bind O 
to O 
DNA O 
in O 
vitro O 
was O 
substantially O 
decreased O 
in O 
case O 
of O 
T248D O 
, O 
T422D O 
and O 
T248V O 
mutants O 
. O 
Our O 
data O 
thus O 
indicate O 
that O 
phosphorylation O 
of O 
T248 O 
, O 
Y249 O 
and O 
T422 O 
residues O 
may O 
be O 
critical O 
for O 
the O 
both O 
basal O 
and O 
ligand O 
- O 
activated O 
function O 
of O 
PXR O 
. O 

need O 
to O 
overcome O 
several O 
biological O 
barriers O 
such O 
as O 
the O 
endothelium O 
and O 
cellular O 
membranes O 
in O 
order O 
to O 
reach O 
their O 
target O 
. O 
Promising O 
new O 
therapeutics O 
, O 
many O 
of O 
which O 
are O 
charged O 
and O 
macromolecular O 
, O 
are O 
not O 
able O 
to O 
passively O 
extravasate O 
, O 
let O 
alone O 
cross O 
cell O 
membranes O 
, O 
and O 
stay O 
mainly O 
in O 
the O 
blood O 
pool O 
upon O 
intravenous O 
injection O 
until O 
clearance O 
. O 
Using O 
focused O 
ultrasound O 
( O 
fUS O 
) O 
in O 
combination O 
with O 
circulating O 
microbubbles O 
( O 
MBs O 
) O 
leads O 
to O 
temporary O 
localized O 
tissue O 
permeabilization O 
allowing O 
extravasation O 
of O 
( O 
macro O 
) O 
molecules O 
from O 
the O 
vascular O 
system O 
. O 
Thus O 
, O 
fUS O 
is O 
a O 
promising O 
approach O 
for O 
localized O 
drug O 
delivery O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
permeabilization O 
kinetics O 
in O 
skeletal O 
muscle O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
single O 
photon O 
emission O 
computed O 
tomography O 
( O 
SPECT O 
) O 
to O 
characterize O 
the O 
kinetics O 
of O 
extravasation O 
of O 
(111)In B-FORMULA 
-labeled O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
, O 
a O 
model O 
macromolecular O 
drug O 
, O 
in O 
muscle O 
treated O 
with O 
fUS O 
and O 
MBs O 
. O 
The O 
same O 
fUS O 
protocol O 
was O 
applied O 
to O 
6 O 
groups O 
of O 
mice O 
with O 
different O 
times O 
, O 
∆t O 
, O 
between O 
fUS O 
application O 
and O 
BSA O 
injection O 
( O 
∆t=-10 O 
, O 
2.5 O 
, O 
10 O 
, O 
30 O 
, O 
60 O 
, O 
90min O 
) O 
followed O 
by O 
SPECT O 
imaging O 
. O 
For O 
∆t≤30min O 
we O 
observed O 
an O 
exponential O 
accumulation O 
of O 
activity O 
in O 
an O 
area O 
of O 
the O 
treated O 
muscle O 
which O 
extended O 
to O 
a O 
volume O 
larger O 
than O 
the O 
fUS O 
pattern O 
with O 
highest O 
accumulation O 
for O 
short O 
waiting O 
times O 
∆t O 
. O 
The O 
extent O 
of O 
extravasation O 
decreased O 
exponentially O 
with O 
increasing O 
∆t O 
, O 
with O 
a O 
calculated O 
half O 
- O 
life O 
of O 
ca O 
. O 
21min O 
, O 
defining O 
the O 
time O 
window O 
of O 
extravasation O 
. O 
The O 
same O 
treatment O 
without O 
MBs O 
did O 
not O 
induce O 
extravasation O 
of O 
BSA O 
thus O 
supporting O 
MBs O 
and O 
drug O 
co O 
- O 
injection O 
strategies O 
. O 
These O 
results O 
provide O 
essential O 
information O 
for O 
the O 
development O 
of O 
fUS O 
based O 
strategies O 
for O 
localized O 
drug O 
delivery O 
. O 

prevents O 
LPS-induced O 
release O 
of O 
pro O 
- O 
inflammatory O 
and O 
apoptotic O 
mediators O 
in O 
neuronal O 
cells O 
. O 

- O 
inflammatory O 
and O 
pro O 
- O 
apoptotic O 
mediators O 
have O 
been O 
involved O 
in O 
the O 
pathogenesis O 
of O 
neurodegenerative O 
diseases O 
. O 
Tigecycline B-TRIVIAL 
( O 
Tig B-ABBREVIATION 
) O 
, O 
a O 
glycylcycline B-FAMILY 
antibiotic O 
and O 
an O 
analog O 
of O 
Minocycline B-TRIVIAL 
, O 
is O 
shown O 
to O 
exert O 
anti-inflammatory O 
effects O 
that O 
are O 
distinct O 
from O 
its O 
anti-microbial O 
activity O 
. O 
Its O 
neuroprotective O 
mechanism O 
is O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
direct O 
protective O 
mechanisms O 
of O 
tigecycline B-TRIVIAL 
against O 
lipopolysaccharide O 
(LPS)-induced O 
Rat O 
pheochromocytoma O 
( O 
PC12 O 
) O 
cells O 
. O 
The O 
results O 
showed O 
that O 
tigecycline B-TRIVIAL 
significantly O 
attenuated O 
the O 
expression O 
and O 
the O 
release O 
of O 
nuclear O 
factor O 
- O 
kappa O 
beta O 
( O 
NF-κB O 
) O 
, O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
and O 
interleukin-1beta O 
( O 
IL-1β O 
) O 
, O 
as O 
well O 
as O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
levels O 
in O 
LPS-induced O 
PC12 O 
cells O 
. O 
In O 
addition O 
, O 
tigecycline B-TRIVIAL 
dose O 
- O 
dependently O 
decreased O 
cytochrome O 
c O 
release O 
and O 
caspase-3 O 
activity O 
. O 
This O 
later O 
finding O 
corroborated O 
the O 
results O 
of O 
decreased O 
pro O 
- O 
apoptotic O 
Bad O 
, O 
and O 
increased O 
anti-apoptotic O 
Bcl-2 O 
protein O 
expression O 
thus O 
, O 
confirming O 
a O 
neuroprotective O 
effect O 
of O 
the O 
drug O 
in O 
differentiated O 
PC12 O 
cells O 
induced O 
with O 
LPS O 
. O 
The O 
findings O 
of O 
our O 
study O 
suggest O 
new O 
targets O 
for O 
tigecycline B-TRIVIAL 
and O 
support O 
the O 
potential O 
for O 
tigecycline B-TRIVIAL 
to O 
be O 
investigated O 
as O 
a O 
therapeutic O 
agent O 
for O 
neurodegenerative O 
disorders O 
. O 

DNAs O 
that O 
harness O 
violet O 
light O 
to O 
repair O 
thymine B-TRIVIAL 
dimers O 
in O 
a O 
DNA O 
substrate O 
. O 

is O 
an O 
in O 
vitro O 
selected O 
catalytic O 
DNA O 
that O 
shows O 
efficient O 
photolyase O 
activity O 
, O 
using O 
light O 
of O 
< O 
310 O 
nm O 
wavelength O 
to O 
photo O 
- O 
reactivate O 
CPD O 
thymine B-TRIVIAL 
dimers O 
within O 
a O 
substrate O 
DNA O 
. O 
We O 
show O 
here O 
that O 
a O 
minimal O 
mutational O 
strategy O 
of O 
substituting O 
a O 
guanine B-TRIVIAL 
analogue O 
, O 
6MI O 
, O 
for O 
single O 
guanine B-TRIVIAL 
residues O 
within O 
UV1C O 
extends O 
the O 
DNAzyme's O 
activity O 
into O 
the O 
violet O 
region O 
of O 
the O 
spectrum O 
. O 
These O 
6MI O 
point O 
mutant O 
DNAzymes O 
fall O 
into O 
three O 
distinct O 
functional O 
classes O 
, O 
which O 
photo O 
- O 
reactivate O 
the O 
thymine B-TRIVIAL 
dimer O 
along O 
different O 
pathways O 
. O 
Cumulatively O 
, O 
they O 
reveal O 
the O 
modus O 
operandi O 
of O 
the O 
original O 
UV1C O 
DNAzyme O 
to O 
be O 
a O 
surprisingly O 
versatile O 
one O 
. O 
The O 
interchangeable O 
properties O 
of O 
no O 
less O 
than O 
six O 
of O 
the O 
G→6MI O 
point O 
mutants O 
highlight O 
UV1C's O 
built O 
- O 
in O 
functional O 
flexibility O 
, O 
which O 
may O 
serve O 
as O 
a O 
starting O 
point O 
for O 
the O 
creation O 
of O 
efficient O 
, O 
visible O 
light O 
- O 
harnessing O 
, O 
photolyase O 
DNAzymes O 
for O 
either O 
the O 
prophylaxis O 
or O 
therapy O 
of O 
UV O 
damage O 
to O 
human O 
skin O 
. O 

chemically O 
induce O 
redox O 
activation O 
of O 
BTZ043 B-IDENTIFIER 
and O 
related O 
potent O 
nitroaromatic B-FAMILY 
anti-tuberculosis O 
agents O 
. O 

development O 
of O 
multidrug O 
resistant O 
( O 
MDR O 
) O 
and O 
extensively O 
drug O 
resistant O 
( O 
XDR O 
) O 
forms O 
of O 
tuberculosis O 
( O 
TB O 
) O 
has O 
stimulated O 
research O 
efforts O 
globally O 
to O 
expand O 
the O 
new O 
drug O 
pipeline O 
. O 
Nitroaromatic B-FAMILY 
compounds O 
, O 
including O 
1,3-benzothiazin-4-ones B-SYSTEMATIC 
( O 
BTZs B-ABBREVIATION 
) O 
and O 
related O 
agents O 
, O 
are O 
a O 
promising O 
new O 
class O 
for O 
the O 
treatment O 
of O 
TB O 
. O 
Research O 
has O 
shown O 
that O 
the O 
nitroso B-SYSTEMATIC 
intermediates O 
of O 
BTZs B-ABBREVIATION 
that O 
are O 
generated O 
in O 
vivo O 
cause O 
suicide O 
inhibition O 
of O 
decaprenylphosphoryl-β-D-ribose B-SYSTEMATIC 
2 O 
' O 
oxidase O 
( O 
DprE1 O 
) O 
, O 
which O 
is O 
responsible O 
for O 
cell O 
wall O 
arabinogalactan O 
biosynthesis O 
. O 
We O 
have O 
designed O 
and O 
synthesized O 
novel O 
anti-TB O 
agents O 
inspired O 
from O 
BTZs B-ABBREVIATION 
and O 
other O 
nitroaromatic B-FAMILY 
compounds O 
. O 
Computational O 
studies O 
indicated O 
that O 
the O 
unsubstituted O 
aromatic O 
carbons B-FAMILY 
of O 
BTZ043 B-IDENTIFIER 
and O 
related O 
nitroaromatic B-FAMILY 
compounds O 
are O 
the O 
most O 
electron O 
- O 
deficient O 
and O 
might O 
be O 
prone O 
to O 
nucleophilic O 
attack O 
. O 
Our O 
chemical O 
studies O 
on O 
BTZ043 B-IDENTIFIER 
and O 
the O 
additional O 
nitroaromatic B-FAMILY 
compounds O 
synthesized O 
by O 
us O 
and O 
others O 
confirmed O 
the O 
postulated O 
reactivity O 
. O 
The O 
results O 
indicate O 
that O 
nucleophiles O 
such O 
as O 
thiolates B-FAMILY 
, O 
cyanide B-SYSTEMATIC 
, O 
and O 
hydride B-SYSTEMATIC 
induce O 
nonenzymatic O 
reduction O 
of O 
the O 
nitro B-SYSTEMATIC 
groups O 
present O 
in O 
these O 
compounds O 
to O 
the O 
corresponding O 
nitroso B-SYSTEMATIC 
intermediates O 
by O 
addition O 
at O 
the O 
unsubstituted O 
electron O 
- O 
deficient O 
aromatic O 
carbon B-SYSTEMATIC 
present O 
in O 
these O 
compounds O 
. O 
Furthermore O 
, O 
we O 
demonstrate O 
here O 
that O 
these O 
compounds O 
are O 
good O 
candidates O 
for O 
the O 
classical O 
von O 
Richter O 
reaction O 
. O 
These O 
chemical O 
studies O 
offer O 
an O 
alternate O 
hypothesis O 
for O 
the O 
mechanism O 
of O 
action O 
of O 
nitroaromatic B-FAMILY 
anti-TB O 
agents O 
, O 
in O 
that O 
the O 
cysteine B-SYSTEMATIC 
thiol(ate) I-SYSTEMATIC 
or O 
a O 
hydride B-SYSTEMATIC 
source O 
at O 
the O 
active O 
site O 
of O 
DprE1 O 
may O 
trigger O 
the O 
reduction O 
of O 
the O 
nitro B-SYSTEMATIC 
groups O 
in O 
a O 
manner O 
similar O 
to O 
the O 
von O 
Richter O 
reaction O 
to O 
the O 
nitroso B-SYSTEMATIC 
intermediates O 
, O 
to O 
initiate O 
the O 
inhibition O 
of O 
DprE1 O 
. O 

of O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
with O 
acetaminophen B-TRIVIAL 
- O 
A O 
study O 
on O 
solubility O 
, O 
spherulitic O 
growth O 
, O 
and O 
morphology O 
. O 

simple O 
, O 
sensitive O 
, O 
efficient O 
, O 
and O 
novel O 
method O 
analyzing O 
the O 
number O 
of O 
spherulitic O 
nuclei O 
was O 
proposed O 
to O 
estimate O 
the O 
solubility O 
of O 
a O 
model O 
drug O 
acetaminophen B-TRIVIAL 
( O 
APAP B-ABBREVIATION 
) O 
in O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEO B-ABBREVIATION 
) O 
. O 
At O 
high O 
crystallization O 
temperature O 
( O 
323K O 
) O 
, O 
10% O 
APAP B-ABBREVIATION 
- O 
PEO B-ABBREVIATION 
had O 
the O 
same O 
low O 
number O 
of O 
spherulitic O 
nuclei O 
as O 
pure O 
PEO B-ABBREVIATION 
, O 
indicating O 
that O 
APAP B-ABBREVIATION 
and O 
PEO B-ABBREVIATION 
were O 
fully O 
miscible O 
. O 
At O 
low O 
crystallization O 
temperature O 
( O 
303K O 
) O 
, O 
the O 
number O 
of O 
nuclei O 
for O 
10% O 
APAP B-ABBREVIATION 
- O 
PEO B-ABBREVIATION 
was O 
significantly O 
higher O 
, O 
suggesting O 
that O 
APAP B-ABBREVIATION 
was O 
oversaturated O 
and O 
therefore O 
recrystallized O 
and O 
acted O 
as O 
a O 
nucleating O 
agent O 
. O 
Based O 
on O 
the O 
results O 
obtained O 
, O 
the O 
solubility O 
of O 
APAP B-ABBREVIATION 
in O 
PEO B-ABBREVIATION 
is O 
possibly O 
between O 
the O 
concentration O 
of O 
0.1% O 
and O 
1% O 
at O 
303K O 
. O 
The O 
spherulitic O 
growth O 
rate O 
G O 
of O 
PEO B-ABBREVIATION 
was O 
found O 
to O 
decrease O 
with O 
increasing O 
APAP B-ABBREVIATION 
concentration O 
, O 
suggesting O 
that O 
APAP B-ABBREVIATION 
is O 
most O 
likely O 
functioning O 
as O 
a O 
chemical O 
defect O 
and O 
is O 
either O 
rejected O 
from O 
or O 
included O 
in O 
the O 
PEO B-ABBREVIATION 
crystals O 
during O 
chain O 
folding O 
. O 
APAP B-ABBREVIATION 
could O 
possibly O 
locate O 
in O 
the O 
inter O 
- O 
spherulitic O 
, O 
inter O 
- O 
fibrillar O 
, O 
inter O 
- O 
lamellar O 
, O 
or O 
intra O 
- O 
lamellar O 
regions O 
of O 
PEO B-ABBREVIATION 
. O 
At O 
323K O 
, O 
the O 
morphology O 
of O 
10% O 
APAP B-ABBREVIATION 
- O 
PEO B-ABBREVIATION 
is O 
more O 
dendritic O 
than O 
spherulitic O 
with O 
large O 
unfilled O 
space O 
in O 
between O 
dendrites O 
and O 
spherulites O 
, O 
which O 
is O 
a O 
sign O 
of O 
one O 
or O 
the O 
combination O 
of O 
the O 
four O 
modes O 
of O 
segregation O 
. O 
An O 
extensive O 
spherulitic O 
nucleation O 
and O 
growth O 
kinetics O 
study O 
using O 
the O 
classical O 
theoretical O 
relationships O 
, O 
for O 
example O 
, O 
the O 
Hoffman-Lauritzen O 
( O 
HL O 
) O 
and O 
Avrami O 
theories O 
, O 
was O 
conducted O 
. O 
Both O 
microscopic O 
and O 
differential O 
scanning O 
calorimetric O 
( O 
DSC O 
) O 
analysis O 
yielded O 
similar O 
values O 
for O 
the O 
nucleation O 
constant O 
Kg O 
as O 
well O 
as O 
the O 
fold O 
surface O 
free O 
energy O 
σe O 
and O 
work O 
of O 
chain O 
folding O 
q O 
. O 
The O 
values O 
of O 
σe O 
and O 
q O 
increased O 
with O 
APAP B-ABBREVIATION 
concentration O 
, O 
indicating O 
that O 
the O 
chain O 
folding O 
of O 
PEO B-ABBREVIATION 
was O 
hindered O 
by O 
APAP B-ABBREVIATION 
. O 

relevance O 
of O 
potentially O 
reversible O 
post O 
- O 
translational O 
modifications O 
required O 
for O 
controlling O 
cellular O 
processes O 
in O 
cancer O 
is O 
one O 
of O 
the O 
most O 
thriving O 
arenas O 
of O 
cellular O 
and O 
molecular O 
biology O 
. O 
Any O 
alteration O 
in O 
the O 
balanced O 
equilibrium O 
between O 
kinases O 
and O 
phosphatases O 
may O 
result O 
in O 
development O 
and O 
progression O 
of O 
various O 
diseases O 
, O 
including O 
different O 
types O 
of O 
cancer O 
, O 
though O 
phosphatases O 
are O 
relatively O 
under O 
- O 
studied O 
. O 
Loss O 
of O 
phosphatases O 
such O 
as O 
PTEN O 
( O 
phosphatase O 
and O 
tensin O 
homologue O 
deleted O 
on O 
chromosome O 
10 O 
) O 
, O 
a O 
known O 
tumour O 
suppressor O 
, O 
across O 
tumour O 
types O 
lends O 
credence O 
to O 
the O 
development O 
of O 
phosphatidylinositol B-TRIVIAL 
3 O 
-- O 
kinase O 
inhibitors O 
alongside O 
the O 
use O 
of O 
phosphatase O 
expression O 
as O 
a O 
biomarker O 
, O 
though O 
phase O 
3 O 
trial O 
data O 
are O 
lacking O 
. O 
In O 
this O 
review O 
, O 
we O 
give O 
an O 
updated O 
report O 
on O 
phosphatase O 
dysregulation O 
linked O 
to O 
organ O 
- O 
specific O 
malignancies.Oncogene O 
advance O 
online O 
publication O 
, O 
18 O 
March O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
onc.2013.80 O 
. O 

of O 
phenolic B-FAMILY 
compounds O 
in O 
in O 
vitro O 
cultures O 
and O 
wild O 
plants O 
of O 
Lavandula O 
viridis O 
L'Hér O 
and O 
their O 
antioxidant O 
and O 
anti-cholinesterase O 
potential O 
. O 

this O 
study O 
, O 
we O 
evaluated O 
the O 
phenolic O 
profile O 
, O 
antioxidant O 
and O 
anti-cholinesterase O 
potential O 
of O 
different O 
extracts O 
from O 
wild O 
plants O 
and O 
in O 
vitro O 
cultures O 
of O 
Lavandula O 
viridis O 
L'Hér O 
. O 
The O 
HPLC-DAD O 
analysis O 
allowed O 
the O 
identification O 
and O 
quantification O 
of O 
3-O-caffeoylquinic B-MULTIPLE 
, I-MULTIPLE 
4-O-caffeoylquinic I-MULTIPLE 
, I-MULTIPLE 
5-O-caffeoylquinic I-MULTIPLE 
and I-MULTIPLE 
rosmarinic I-MULTIPLE 
acids I-MULTIPLE 
, O 
and O 
luteolin B-TRIVIAL 
and O 
pinocembrin B-TRIVIAL 
. O 
Water/ O 
ethanol B-SYSTEMATIC 
extract O 
from O 
in O 
vitro O 
cultures O 
contained O 
the O 
highest O 
amount O 
of O 
the O 
identified O 
phenolic B-FAMILY 
compounds O 
( O 
51652.92mg O 
/ O 
kg O 
) O 
. O 
To O 
investigate O 
the O 
antioxidant O 
activity O 
we O 
used O 
Trolox B-TRIVIAL 
equivalent O 
antioxidant O 
capacity O 
, O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
, O 
Fe(2+) B-FORMULA 
chelation O 
activity O 
and O 
the O 
inhibition O 
of O 
Fe(2+) B-FORMULA 
-induced O 
lipid O 
peroxidation O 
in O 
mouse O 
brain O 
homogenates O 
( O 
in O 
vitro O 
) O 
. O 
Overall O 
, O 
all O 
the O 
extracts O 
from O 
both O 
wild O 
plants O 
and O 
in O 
vitro O 
cultures O 
exhibited O 
ability O 
to O 
scavenge O 
free O 
radicals O 
, O 
to O 
chelate O 
Fe(2+) B-FORMULA 
and O 
to O 
protect O 
against O 
lipid O 
peroxidation O 
. O 
In O 
addition O 
, O 
the O 
extracts O 
from O 
L O 
. O 
viridis O 
were O 
active O 
in O 
inhibiting O 
both O 
acetylcholinesterase O 
and O 
butyrylcholinesterase O 
( O 
Ellman's O 
method O 
) O 
. O 
Our O 
findings O 
suggest O 
that O 
L O 
. O 
viridis O 
in O 
vitro O 
cultures O 
represent O 
a O 
promising O 
alternative O 
for O 
the O 
production O 
of O 
active O 
metabolites O 
with O 
antioxidant O 
and O 
anti-cholinesterase O 
activity O 
. O 

reflection O 
from O 
a- O 
Si B-FORMULA 
nanograss/ O 
Si B-FORMULA 
nanofrustum O 
double O 
layers O 
. O 

double O 
- O 
layer O 
nanostructure O 
comprising O 
amorphous O 
Si B-FORMULA 
nanograss O 
on O 
top O 
of O 
Si B-FORMULA 
nanofrustums O 
( O 
NFs O 
) O 
with O 
a O 
total O 
height O 
of O 
680 O 
nm O 
exhibits O 
ultralow O 
reflection O 
. O 
Almost O 
near O 
- O 
unity O 
absorption O 
and O 
near O 
- O 
zero O 
reflectance O 
result O 
in O 
this O 
layered O 
nanostructure O 
, O 
over O 
a O 
broad O 
range O 
of O 
wavelengths O 
and O 
a O 
wide O 
range O 
of O 
angles O 
of O 
incidence O 
, O 
due O 
to O 
the O 
low O 
packing O 
density O 
of O 
a- O 
Si B-FORMULA 
and O 
the O 
smooth O 
transition O 
of O 
the O 
refractive O 
index O 
from O 
the O 
air O 
to O 
the O 
Si B-FORMULA 
substrate O 
across O 
both O 
the O 
nanograss O 
and O 
NF O 
layers O 
. O 

and O 
characterization O 
of O 
bacterial O 
diterpene B-FAMILY 
cyclases O 
that O 
synthesize O 
the O 
cembrane O 
skeleton O 
. O 

up O 
skeletons O 
: O 
We O 
report O 
the O 
identification O 
and O 
the O 
functional O 
characterization O 
of O 
two O 
terpene B-FAMILY 
cyclases O 
( O 
DtcycA O 
and O 
DtcycB O 
) O 
that O 
were O 
mined O 
from O 
the O 
genome O 
of O 
Streptomyces O 
sp O 
. O 
SANK O 
60404 O 
. O 
DtcycA O 
and O 
DtcycB O 
are O 
novel O 
bacterial O 
diterpene B-FAMILY 
cyclases O 
for O 
the O 
synthesis O 
of O 
the O 
cembrane O 
skeleton O 
. O 

attenuates O 
allergic O 
airway O 
inflammation O 
by O 
regulation O 
of O 
CD4(+)CD25(+) O 
regulatory O 
T O 
cells O 
( O 
Tregs O 
) O 
/ O 
Th17 O 
balance O 
in O 
ovalbumin O 
- O 
sensitized O 
mice O 
. O 

present O 
study O 
aimed O 
to O 
determine O 
the O 
protective O 
effects O 
and O 
the O 
underlying O 
mechanisms O 
of O 
curcumin B-TRIVIAL 
on O 
ovalbumin O 
(OVA)-induced O 
allergic O 
inflammation O 
in O 
a O 
mouse O 
model O 
of O 
allergic O 
asthma O 
. O 
Asthma O 
mice O 
model O 
was O 
established O 
by O 
ovalbumin O 
. O 
A O 
total O 
of O 
60 O 
mice O 
were O 
randomly O 
assigned O 
to O 
six O 
experimental O 
groups O 
: O 
control O 
, O 
model O 
, O 
dexamethasone B-TRIVIAL 
( O 
2mg O 
/ O 
kg O 
) O 
, O 
and O 
curcumin B-TRIVIAL 
( O 
50mg O 
/ O 
kg O 
, O 
100mg O 
/ O 
kg O 
, O 
200mg O 
/ O 
kg O 
) O 
. O 
Airway O 
resistance O 
( O 
Raw O 
) O 
was O 
measured O 
by O 
the O 
forced O 
oscillation O 
technique O 
, O 
differential O 
cell O 
count O 
in O 
BAL O 
fluid O 
( O 
BALF O 
) O 
was O 
measured O 
by O 
Wright-Giemsa O 
staining O 
, O 
histological O 
assessment O 
was O 
measured O 
by O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
( O 
HE O 
) O 
staining O 
, O 
BALF O 
levels O 
of O 
Treg O 
/ O 
Th17 O 
cytokines O 
were O 
measured O 
by O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
, O 
Treg O 
cells O 
and O 
Th17 O 
cells O 
were O 
evaluated O 
by O 
flow O 
cytometry O 
( O 
FCM O 
) O 
. O 
Our O 
study O 
demonstrated O 
that O 
curcumin B-TRIVIAL 
inhibited O 
OVA-induced O 
increases O 
in O 
eosinophil O 
count O 
; O 
interleukin O 
(IL)-17A O 
level O 
were O 
recovered O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
increased O 
IL-10 O 
level O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
. O 
Histological O 
studies O 
demonstrated O 
that O 
curcumin B-TRIVIAL 
substantially O 
inhibited O 
OVA-induced O 
eosinophilia O 
in O 
lung O 
tissue O 
. O 
Flow O 
cytometry O 
( O 
FCM O 
) O 
studies O 
demonstrated O 
that O 
curcumin B-TRIVIAL 
remarkably O 
inhibited O 
Th17 O 
cells O 
and O 
significantly O 
increased O 
Treg O 
cells O 
. O 
The O 
results O 
in O 
vivo O 
show O 
ovalbumin O 
- O 
induced O 
significantly O 
broke O 
Treg O 
/ O 
Th17 O 
balance O 
; O 
curcumin B-TRIVIAL 
treatments O 
markedly O 
attenuated O 
the O 
inflammatory O 
in O 
asthma O 
model O 
by O 
regulating O 
Treg O 
/ O 
Th17 O 
balance O 
. O 
Our O 
findings O 
support O 
the O 
possible O 
use O 
of O 
curcumin B-TRIVIAL 
as O 
a O 
therapeutic O 
drug O 
for O 
patients O 
with O 
allergic O 
asthma O 
. O 

calponin O 
( O 
CNN1 O 
) O 
is O 
known O 
as O 
a O 
smooth O 
muscle O 
- O 
specific O 
, O 
actin O 
- O 
binding O 
protein O 
which O 
regulates O 
smooth O 
muscle O 
contractive O 
activity O 
. O 
Although O 
previous O 
studies O 
have O 
shown O 
that O 
CNN1 O 
has O 
effect O 
on O 
bone O 
, O 
the O 
mechanism O 
is O 
not O 
well O 
defined O 
. O 
To O 
investigate O 
the O 
role O 
of O 
CNN1 O 
in O 
maintaining O 
bone O 
homeostasis O 
, O 
we O 
generated O 
transgenic O 
mice O 
overexpressing O 
Cnn1 O 
under O 
the O 
control O 
of O 
the O 
osteoblast O 
- O 
specific O 
3.6-kb O 
Col1a1 O 
promoter O 
. O 
Col1a1-Cnn1 O 
transgenic O 
mice O 
showed O 
delayed O 
bone O 
formation O 
at O 
embryonic O 
stage O 
and O 
decreased O 
bone O 
mass O 
at O 
adult O 
stage O 
. O 
Morphology O 
analyses O 
showed O 
reduced O 
trabecular O 
number O 
, O 
thickness O 
and O 
defects O 
in O 
bone O 
formation O 
. O 
The O 
proliferation O 
and O 
migration O 
of O 
osteoblasts O 
were O 
decreased O 
in O 
Col1a1-Cnn1 O 
mice O 
due O 
to O 
alterations O 
in O 
cytoskeleton O 
. O 
The O 
early O 
osteoblast O 
differentiation O 
of O 
Col1a1-Cnn1 O 
mice O 
was O 
increased O 
, O 
but O 
the O 
late O 
stage O 
differentiation O 
and O 
mineralization O 
of O 
osteoblasts O 
derived O 
from O 
Col1a1-Cnn1 O 
mice O 
were O 
significantly O 
decreased O 
. O 
In O 
addition O 
to O 
impaired O 
bone O 
formation O 
, O 
the O 
decreased O 
bone O 
mass O 
was O 
also O 
associated O 
with O 
enhanced O 
osteoclastogenesis O 
. O 
Tartrate B-TRIVIAL 
-resistant O 
acid O 
phosphatase O 
( O 
TRAP O 
) O 
staining O 
revealed O 
increased O 
osteoclast O 
numbers O 
in O 
tibias O 
of O 
2-month- O 
old O 
Col1a1-Cnn1 O 
mice O 
, O 
and O 
increased O 
numbers O 
of O 
osteoclasts O 
co O 
- O 
cultured O 
with O 
Col1a1-Cnn1 O 
osteoblasts O 
. O 
The O 
ratio O 
of O 
RANKL O 
to O 
OPG O 
was O 
significantly O 
increased O 
in O 
Col1a1-Cnn1 O 
osteoblasts O 
. O 
These O 
findings O 
reveal O 
a O 
novel O 
function O 
of O 
CNN1 O 
in O 
maintaining O 
bone O 
homeostasis O 
by O 
coupling O 
bone O 
formation O 
to O 
bone O 
resorption O 
. O 

Subtoxic O 
levels O 
of O 
chlorate B-SYSTEMATIC 
influence O 
the O 
desiccation O 
tolerance O 
of O 
Egeria O 
densa O 
? O 

the O 
different O 
factors O 
hypothesized O 
to O 
be O 
responsible O 
for O 
the O 
virtual O 
disappearance O 
of O 
Egeria O 
densa O 
, O 
once O 
a O 
dominant O 
aquatic O 
macrophyte O 
in O 
a O 
southern O 
Chile O 
wetland O 
ecosystem O 
, O 
are O 
the O 
negative O 
effects O 
of O 
certain O 
chemical O 
compounds O 
( O 
mainly O 
chlorate B-SYSTEMATIC 
) O 
and O 
harsh O 
environmental O 
conditions O 
( O 
desiccation O 
caused O 
by O 
prolonged O 
atmospheric O 
exposure O 
) O 
. O 
The O 
authors O 
performed O 
an O 
integrated O 
experiment O 
in O 
which O 
E O 
. O 
densa O 
plants O 
were O 
first O 
exposed O 
for O 
four O 
weeks O 
inside O 
a O 
mesocosm O 
system O 
to O 
levels O 
of O 
chlorate B-SYSTEMATIC 
that O 
existed O 
in O 
the O 
wetland O 
at O 
the O 
time O 
of O 
the O 
plant's O 
demise O 
and O 
then O 
exposed O 
to O 
desiccation O 
conditions O 
that O 
also O 
resembled O 
those O 
that O 
the O 
system O 
had O 
experienced O 
. O 
Hence O 
, O 
the O 
authors O 
tested O 
the O 
hypothesis O 
that O 
E O 
. O 
densa O 
plants O 
exposed O 
to O 
sublethal O 
levels O 
of O 
chlorate B-SYSTEMATIC 
are O 
more O 
susceptible O 
to O 
the O 
deleterious O 
effect O 
of O 
desiccation O 
compared O 
with O 
plants O 
that O 
had O 
not O 
been O 
exposed O 
to O 
chlorate B-SYSTEMATIC 
. O 
This O 
hypothesis O 
was O 
tested O 
by O 
means O 
of O 
quantifying O 
physiologically O 
related O 
parameters O 
in O 
plants O 
right O 
after O 
the O 
four O 
weeks O 
under O 
water O 
and O 
then O 
after O 
the O 
desiccation O 
period O 
of O 
6 O 
h O 
. O 
Their O 
results O 
rejected O 
this O 
hypothesis O 
, O 
because O 
all O 
plants O 
, O 
regardless O 
of O 
their O 
history O 
, O 
are O 
equally O 
affected O 
by O 
desiccation O 
. O 

seemingly O 
disparate O 
areas O 
of O 
oxygen B-SYSTEMATIC 
toxicity O 
, O 
radiation O 
exposure O 
, O 
and O 
aging O 
are O 
now O 
recognized O 
to O 
share O 
a O 
common O 
feature O 
- O 
the O 
aberrant O 
production O 
and O 
/ O 
or O 
removal O 
of O 
biologically O 
derived O 
free O 
radicals O 
and O 
other O 
reactive O 
oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
( O 
ROS O 
/ O 
RNS O 
) O 
. O 
Advances O 
in O 
our O 
understanding O 
of O 
the O 
effects O 
of O 
free O 
radicals O 
in O 
biology O 
and O 
medicine O 
have O 
been O 
, O 
and O 
continue O 
to O 
be O 
, O 
actively O 
translated O 
into O 
clinically O 
tractable O 
diagnostic O 
and O 
therapeutic O 
applications O 
. O 
This O 
issue O 
is O 
dedicated O 
to O 
recent O 
advances O 
, O 
both O 
basic O 
discoveries O 
and O 
clinical O 
applications O 
, O 
in O 
the O 
field O 
of O 
free O 
radicals O 
in O 
biology O 
and O 
medicine O 
. O 
As O 
more O 
is O 
understood O 
about O 
the O 
proximal O 
biological O 
targets O 
of O 
aberrantly O 
produced O 
or O 
removed O 
reactive O 
species O 
, O 
their O 
sensors O 
, O 
and O 
effectors O 
of O 
compensatory O 
response O 
, O 
a O 
great O 
deal O 
more O 
will O 
be O 
learned O 
about O 
the O 
commonalities O 
in O 
mechanisms O 
underlying O 
seemingly O 
disparate O 
disease O 
states O 
. O 
Together O 
with O 
this O 
deeper O 
understanding O 
, O 
opportunities O 
will O 
arise O 
to O 
devise O 
rational O 
therapeutic O 
interventions O 
to O 
decrease O 
the O 
incidence O 
and O 
severity O 
of O 
these O 
diseases O 
and O 
positively O 
impact O 
the O 
human O 
healthspan O 
. O 

low O 
- O 
overpotential O 
potassium B-SYSTEMATIC 
- O 
oxygen B-SYSTEMATIC 
battery O 
based O 
on O 
potassium B-SYSTEMATIC 
superoxide I-SYSTEMATIC 
. O 

battery O 
is O 
regarded O 
as O 
one O 
of O 
the O 
most O 
promising O 
energy O 
storage O 
systems O 
for O 
future O 
applications O 
. O 
However O 
, O 
its O 
energy O 
efficiency O 
is O 
greatly O 
undermined O 
by O 
the O 
large O 
overpotentials O 
of O 
the O 
discharge O 
( O 
formation O 
of O 
Li(2)O(2) B-FORMULA 
) O 
and O 
charge O 
( O 
oxidation O 
of O 
Li(2)O(2) B-FORMULA 
) O 
reactions O 
. O 
The O 
parasitic O 
reactions O 
of O 
electrolyte O 
and O 
carbon B-SYSTEMATIC 
electrode O 
induced O 
by O 
the O 
high O 
charging O 
potential O 
cause O 
the O 
decay O 
of O 
capacity O 
and O 
limit O 
the O 
battery O 
life O 
. O 
Here O 
, O 
a O 
K-O(2) B-FORMULA 
battery O 
is O 
report O 
that O 
uses O 
K(+) B-FORMULA 
ions O 
to O 
capture O 
O(2)(-) B-FORMULA 
to O 
form O 
the O 
thermodynamically O 
stable O 
KO(2) B-FORMULA 
product O 
. O 
This O 
allows O 
for O 
the O 
battery O 
to O 
operate O 
through O 
the O 
one O 
- O 
electron O 
redox O 
process O 
of O 
O(2) B-FORMULA 
/ O 
O(2)(-) B-FORMULA 
. O 
Our O 
studies O 
confirm O 
the O 
formation O 
and O 
removal O 
of O 
KO(2) B-FORMULA 
in O 
the O 
battery O 
cycle O 
test O 
. O 
Furthermore O 
, O 
without O 
the O 
use O 
of O 
catalysts O 
, O 
the O 
battery O 
shows O 
a O 
low O 
discharge O 
/ O 
charge O 
potential O 
gap O 
of O 
less O 
than O 
50 O 
mV O 
at O 
a O 
modest O 
current O 
density O 
, O 
which O 
is O 
the O 
lowest O 
one O 
that O 
has O 
ever O 
been O 
reported O 
in O 
metal B-FAMILY 
- I-FAMILY 
oxygen I-FAMILY 
batteries O 
. O 

of O 
osteoblasts O 
to O 
a O 
vertically O 
aligned O 
TiO2 B-FORMULA 
nanotube O 
surface O 
. O 

adhesion O 
of O 
cells O 
to O 
vertically O 
aligned O 
TiO2 B-FORMULA 
nanotubes O 
is O 
reviewed O 
. O 
The O 
attraction O 
between O 
a O 
negatively O 
charged O 
nanotube O 
surface O 
and O 
a O 
negatively O 
charged O 
osteoblast O 
is O 
facilitated O 
by O 
charged O 
protein O 
- O 
mediators O 
like O 
proteins O 
with O 
a O 
quadrupolar O 
internal O 
charge O 
distribution O 
, O 
fibronectin O 
and O 
vitronectin O 
. O 
It O 
is O 
shown O 
that O 
adhesion O 
and O 
spreading O 
of O 
osteoblasts O 
on O 
vertically O 
aligned O 
TiO2 B-FORMULA 
nanotube O 
surfaces O 
depend O 
on O 
the O 
diameter O 
of O 
the O 
nanotubes O 
. O 
Apparently O 
, O 
a O 
small O 
diameter O 
nanotube O 
surface O 
has O 
on O 
average O 
more O 
sharp O 
convex O 
edges O 
per O 
unit O 
area O 
than O 
a O 
large O 
one O 
, O 
leading O 
to O 
stronger O 
binding O 
affinity O 
on O 
its O 
surface O 
. O 

ameliorates O 
renal O 
injury O 
by O 
attenuating O 
oxidative O 
stress O 
- O 
related O 
inflammatory O 
responses O 
in O 
fructose B-TRIVIAL 
-induced O 
urate B-SYSTEMATIC 
nephropathic O 
mice O 
. O 

series O 
of O 
studies O 
have O 
recently O 
demonstrated O 
that O 
the O 
oxidative O 
stress O 
, O 
nuclear O 
factor O 
- O 
kappa O 
B O 
( O 
NF-κB O 
) O 
activation O 
and O 
the O 
subsequent O 
coordinated O 
inflammatory O 
responses O 
played O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
urate B-SYSTEMATIC 
nephropathy O 
( O 
UN O 
) O 
. O 
Polydatin B-TRIVIAL 
has O 
been O 
suggested O 
to O 
have O 
the O 
properties O 
of O 
anti-oxidative O 
, O 
anti-inflammatory O 
and O 
nephroprotective O 
effects O 
. O 
However O 
, O 
the O 
possible O 
protective O 
and O 
beneficial O 
effects O 
of O 
polydatin B-TRIVIAL 
on O 
UN O 
are O 
not O 
fully O 
elucidated O 
. O 
Therefore O 
, O 
we O 
investigated O 
the O 
potential O 
beneficial O 
effects O 
and O 
possible O 
mechanisms O 
of O 
polydatin B-TRIVIAL 
on O 
UN O 
. O 
In O 
this O 
study O 
, O 
polydatin B-TRIVIAL 
showed O 
inhibitory O 
activities O 
on O 
xanthine B-TRIVIAL 
oxidase O 
to O 
repress O 
the O 
level O 
of O 
serum O 
uric B-TRIVIAL 
acid I-TRIVIAL 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
Further O 
investigations O 
revealed O 
that O 
polydatin B-TRIVIAL 
displayed O 
little O 
toxic O 
effects O 
and O 
significantly O 
ameliorated O 
the O 
renal O 
function O 
in O 
fructose B-TRIVIAL 
-induced O 
UN O 
mice O 
. O 
The O 
nephroprotective O 
activities O 
of O 
polydatin B-TRIVIAL 
was O 
not O 
only O 
due O 
to O 
the O 
effects O 
on O 
remarkably O 
attenuating O 
the O 
oxidative O 
stress O 
induced O 
by O 
uric B-TRIVIAL 
acid I-TRIVIAL 
, O 
but O 
also O 
on O 
markedly O 
suppressing O 
the O 
oxidative O 
stress O 
- O 
related O 
inflammatory O 
cascade O 
, O 
including O 
decreasing O 
the O 
expressions O 
of O 
NF-κB O 
p65 O 
, O 
COX-2 O 
and O 
iNOS O 
proteins O 
and O 
inhibiting O 
the O 
productions O 
of O 
TNF-α O 
, O 
PGE(2) O 
and O 
IL-1β O 
. O 
These O 
findings O 
elucidated O 
that O 
polydatin B-TRIVIAL 
exhibited O 
prominent O 
nephroprotective O 
activities O 
and O 
low O 
toxic O 
effects O 
. O 

raft O 
modulation O 
by O 
Rp1 B-TRIVIAL 
reverses O 
multidrug O 
resistance O 
via O 
inactivating O 
MDR-1 O 
and O 
Src O 
inhibition O 
. O 

resistance O 
( O 
MDR O 
) O 
is O 
a O 
major O 
obstacle O 
to O 
effective O 
cancer O 
therapy O 
. O 
The O 
membrane O 
transporter O 
MDR-1 O 
( O 
P-gp O 
, O 
ABCB1 O 
) O 
, O 
a O 
member O 
of O 
the O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
( O 
ABC O 
) O 
transporter O 
family O 
, O 
effluxes O 
anti-cancer O 
drugs O 
from O 
cancer O 
cells O 
. O 
Increased O 
activity O 
of O 
MDR-1 O 
is O 
known O 
to O 
be O 
the O 
main O 
mechanism O 
for O 
multidrug O 
resistance O 
. O 
MDR-1 O 
is O 
known O 
to O 
be O 
localized O 
in O 
the O 
cholesterol B-TRIVIAL 
- O 
and O 
sphingolipid B-FAMILY 
-enriched O 
plasma O 
membrane O 
microdomains O 
, O 
known O 
as O 
lipid O 
rafts O 
. O 
Disruption O 
of O 
lipid O 
rafts O 
by O 
cholesterol B-TRIVIAL 
depletion O 
alters O 
lipid O 
raft O 
functions O 
, O 
indicating O 
that O 
cholesterol B-TRIVIAL 
is O 
critical O 
for O 
raft O 
function O 
. O 
Because O 
ginsenosides B-FAMILY 
are O 
structurally O 
similar O 
to O 
cholesterol B-TRIVIAL 
, O 
in O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
Rp1 B-TRIVIAL 
, O 
a O 
novel O 
ginsenoside B-FAMILY 
derivative O 
, O 
on O 
drug O 
resistance O 
using O 
drug O 
- O 
sensitive O 
OVCAR-8 O 
and O 
drug O 
- O 
resistant O 
NCI O 
/ O 
ADR-RES O 
and O 
DXR O 
cells O 
. O 
Rp1 B-TRIVIAL 
treatment O 
resulted O 
in O 
an O 
accumulation O 
of O 
doxorubicin B-TRIVIAL 
or O 
rhodamine B-TRIVIAL 
123 I-TRIVIAL 
by O 
decreasing O 
MDR-1 O 
activity O 
in O 
doxorubicin B-TRIVIAL 
-resistant O 
cells O 
. O 
Rp1 B-TRIVIAL 
synergistically O 
induced O 
cell O 
death O 
with O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
in O 
DXR O 
cells O 
. O 
Rp1 B-TRIVIAL 
appeared O 
to O 
redistribute O 
lipid O 
rafts O 
and O 
MDR-1 O 
protein O 
. O 
Moreover O 
, O 
Rp1 B-TRIVIAL 
reversed O 
resistance O 
to O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
by O 
decreasing O 
MDR-1 O 
protein O 
levels O 
and O 
Src O 
phosphorylation O 
with O 
modulation O 
of O 
lipid O 
rafts O 
. O 
Addition O 
of O 
cholesterol B-TRIVIAL 
attenuated O 
Rp1 B-TRIVIAL 
-induced O 
raft O 
aggregation O 
and O 
MDR-1 O 
redistribution O 
. O 
Rp1 B-TRIVIAL 
and O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
reduced O 
Src O 
activity O 
, O 
and O 
overexpression O 
of O 
active O 
Src O 
decreased O 
the O 
synergistic O 
effect O 
of O 
Rp1 B-TRIVIAL 
with O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
. O 
Rp1 B-TRIVIAL 
-induced O 
drug O 
sensitization O 
was O 
also O 
observed O 
with O 
several O 
anti-cancer O 
drugs O 
, O 
including O 
doxorubicin B-TRIVIAL 
. O 
These O 
data O 
suggest O 
that O 
lipid O 
raft O 
- O 
modulating O 
agents O 
can O 
be O 
used O 
to O 
inhibit O 
MDR-1 O 
activity O 
and O 
thus O 
overcome O 
drug O 
resistance O 
. O 

chemico O 
evaluation O 
of O 
prohapten O 
skin O 
sensitizers O 
: O 
behavior O 
of O 
2-methoxy-4-(¹³C)methylphenol B-SYSTEMATIC 
in O 
the O 
peroxidase O 
peptide O 
reactivity O 
assay O 
( O 
PPRA O 
) O 
as O 
an O 
alternative O 
to O 
animal O 
testing O 
. O 

chemico O 
methods O 
, O 
based O 
on O 
the O 
assessment O 
of O 
a O 
hapten's O 
reactivity O 
toward O 
peptides O 
, O 
have O 
been O 
proposed O 
as O 
alternative O 
methods O 
for O 
the O 
assessment O 
of O 
the O 
skin O 
sensitizing O 
potential O 
of O 
chemicals O 
. O 
However O 
, O 
even O 
with O 
these O 
approaches O 
showing O 
promise O 
, O 
a O 
major O 
drawback O 
is O 
the O 
activation O 
of O 
prohaptens O 
, O 
i.e O 
. O 
molecules O 
needing O 
a O 
metabolic O 
activation O 
to O 
become O 
reactive O 
and O 
therefore O 
sensitizing O 
. O 
Recently O 
, O 
it O 
has O 
been O 
proposed O 
to O 
couple O 
an O 
enzymatic O 
activation O 
step O 
based O 
on O 
horseradish O 
peroxidase O 
(HRP)/ O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
to O 
such O 
peptide O 
reactivity O 
assays O 
. O 
To O 
evaluate O 
this O 
approach O 
, O 
the O 
behavior O 
of O 
2-methoxy-4-methylphenol B-SYSTEMATIC 
( O 
2M4MP B-SYSTEMATIC 
) O 
, O 
reported O 
as O 
a O 
moderate O 
sensitizer O 
according O 
to O 
the O 
Local O 
Lymph O 
Node O 
Assay O 
( O 
LLNA O 
) O 
, O 
has O 
been O 
investigated O 
in O 
this O 
assay O 
. O 
To O 
follow O 
the O 
reaction O 
with O 
the O 
peptides O 
and O 
characterize O 
more O 
easily O 
intermediates O 
and O 
adducts O 
, O 
the O 
molecule O 
was O 
first O 
(13)C B-FORMULA 
isotopically O 
substituted O 
at O 
the O 
most O 
probable O 
reactive O 
position O 
. O 
When O 
2M4MP B-SYSTEMATIC 
was O 
incubated O 
with O 
HRP/ O 
H2O2 B-FORMULA 
in O 
a O 
mixture O 
PBS O 
( O 
pH O 
7.4 O 
, O 
0.1M)/ O 
acetonitrile B-SYSTEMATIC 
2 O 
: O 
1 O 
, O 
two O 
main O 
products O 
were O 
formed O 
deriving O 
from O 
the O 
formation O 
of O 
a O 
quinone O 
methide O 
2M4MQ B-SYSTEMATIC 
subsequently O 
trapped O 
by O 
either O 
H2O2 B-FORMULA 
or O 
H2O B-FORMULA 
to O 
form O 
a O 
benzylic B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
or O 
alcohol B-FAMILY 
, O 
respectively O 
. O 
When O 
nucleophiles O 
such O 
as O 
GSH B-ABBREVIATION 
or O 
a O 
peptide O 
containing O 
a O 
cysteine B-TRIVIAL 
residue O 
( O 
Pep- O 
Cys B-FORMULA 
) O 
were O 
present O 
in O 
the O 
reaction O 
medium O 
, O 
the O 
quinone O 
methide O 
2M4MQ B-SYSTEMATIC 
was O 
trapped O 
by O 
the O 
more O 
nucleophilic O 
thiol B-FAMILY 
function O 
to O 
form O 
thio B-SYSTEMATIC 
-adducts O 
. O 
No O 
modifications O 
of O 
2M4MP B-SYSTEMATIC 
were O 
observed O 
when O 
the O 
same O 
reactions O 
were O 
carried O 
out O 
without O 
HRP O 
confirming O 
that O 
the O 
activation O 
of O 
the O 
molecule O 
was O 
enzyme O 
related O 
. O 
Amino B-SYSTEMATIC 
nucleophiles O 
were O 
shown O 
to O 
be O 
far O 
less O 
reactive O 
towards O 
the O 
quinone O 
methide O 
2M4MQ B-SYSTEMATIC 
with O 
only O 
tiny O 
formation O 
of O 
adducts O 
with O 
lysine B-TRIVIAL 
or O 
arginine B-TRIVIAL 
side O 
chains O 
. O 
In O 
addition O 
we O 
demonstrated O 
that O 
the O 
same O 
enzymatic O 
activation O 
could O 
also O 
take O 
place O 
in O 
a O 
microemulsion O 
based O 
on O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
/ O 
tert-butanol B-SYSTEMATIC 
/ O 
chloroform B-TRIVIAL 
/ O 
buffer O 
. O 

prolyl B-TRIVIAL 
cis O 
/ O 
trans- O 
isomerase O 
A1 O 
( O 
Pin1 O 
) O 
is O 
a O 
target O 
for O 
modification O 
by O 
lipid O 
electrophiles O 
. O 

of O 
membrane O 
phospholipids O 
is O 
associated O 
with O 
inflammation O 
, O 
neurodegenerative O 
disease O 
, O 
and O 
cancer O 
. O 
Oxyradical O 
damage O 
to O 
phospholipids O 
results O 
in O 
the O 
production O 
of O 
reactive O 
aldehydes B-FAMILY 
that O 
adduct O 
proteins O 
and O 
modulate O 
their O 
function O 
. O 
4-Hydroxynonenal B-SYSTEMATIC 
( O 
HNE B-ABBREVIATION 
) O 
, O 
a O 
common O 
product O 
of O 
oxidative O 
damage O 
to O 
lipids O 
, O 
adducts O 
proteins O 
at O 
exposed O 
Cys B-FORMULA 
, O 
His B-FORMULA 
, O 
or O 
Lys B-FORMULA 
residues O 
. O 
Here O 
, O 
we O 
demonstrate O 
that O 
peptidyl- O 
prolyl B-TRIVIAL 
cis O 
/ O 
trans- O 
isomerase O 
A1 O 
( O 
Pin1 O 
) O 
, O 
an O 
enzyme O 
that O 
catalyzes O 
the O 
conversion O 
of O 
the O 
peptide O 
bond O 
of O 
pSer B-FORMULA 
/ O 
pThr B-FORMULA 
- O 
Pro B-FORMULA 
moieties O 
in O 
signaling O 
proteins O 
from O 
cis O 
to O 
trans O 
, O 
is O 
highly O 
susceptible O 
to O 
HNE B-ABBREVIATION 
modification O 
. O 
Incubation O 
of O 
purified O 
Pin1 O 
with O 
HNE B-ABBREVIATION 
followed O 
by O 
MALDI-TOF O 
/ O 
TOF O 
mass O 
spectrometry O 
resulted O 
in O 
detection O 
of O 
Michael O 
adducts O 
at O 
the O 
active O 
site O 
residues O 
His B-FORMULA 
-157 O 
and O 
Cys B-FORMULA 
-113 O 
. O 
Time O 
and O 
concentration O 
dependencies O 
indicate O 
that O 
Cys B-FORMULA 
-113 O 
is O 
the O 
primary O 
site O 
of O 
HNE B-ABBREVIATION 
modification O 
. O 
Pin1 O 
was O 
adducted O 
in O 
MDA-MB-231 O 
breast O 
cancer O 
cells O 
treated O 
with O 
8-alkynyl-HNE B-FAMILY 
as O 
judged O 
by O 
click O 
chemistry O 
conjugation O 
with O 
biotin B-TRIVIAL 
followed O 
by O 
streptavidin O 
- O 
based O 
pulldown O 
and O 
Western O 
blotting O 
with O 
anti-Pin1 O 
antibody O 
. O 
Furthermore O 
, O 
orbitrap O 
MS O 
data O 
support O 
the O 
adduction O 
of O 
Cys B-FORMULA 
-113 O 
in O 
the O 
Pin1 O 
active O 
site O 
upon O 
HNE B-ABBREVIATION 
treatment O 
of O 
MDA-MB-231 O 
cells O 
. O 
siRNA O 
knockdown O 
of O 
Pin1 O 
in O 
MDA-MB-231 O 
cells O 
partially O 
protected O 
the O 
cells O 
from O 
HNE B-ABBREVIATION 
-induced O 
toxicity O 
. O 
Recent O 
studies O 
indicate O 
that O 
Pin1 O 
is O 
an O 
important O 
molecular O 
target O 
for O 
the O 
chemopreventive O 
effects O 
of O 
green O 
tea O 
polyphenols B-FAMILY 
. O 
The O 
present O 
study O 
establishes O 
that O 
it O 
is O 
also O 
a O 
target O 
for O 
electrophilic O 
modification O 
by O 
products O 
of O 
lipid O 
peroxidation O 
. O 

effects O 
of O 
organochlorine B-FAMILY 
pesticides O 
heptachlor B-TRIVIAL 
and O 
hexachlorobenzene B-SYSTEMATIC 
on O 
the O 
promotion O 
stage O 
of O 
hepatocarcinogenesis O 
in O 
rats O 
. O 

aimed O 
to O 
investigate O 
the O 
combined O 
effect O 
of O 
organochlorine B-FAMILY 
pesticides O 
heptachlor B-TRIVIAL 
( O 
HEP B-ABBREVIATION 
) O 
and O 
hexachlorobenzene B-SYSTEMATIC 
( O 
HCB B-ABBREVIATION 
) O 
by O 
using O 
a O 
medium O 
- O 
term O 
rat O 
liver O 
bioassay O 
. O 
Male O 
F344 O 
rats O 
were O 
initially O 
administered O 
diethylnitrosamine B-SYSTEMATIC 
( O 
DEN B-ABBREVIATION 
, O 
200mg O 
/ O 
kgi.p O 
. O 
) O 
; O 
after O 
a O 
2-week O 
non-dosing O 
period O 
, O 
they O 
were O 
given O 
diets O 
containing O 
HE B-ABBREVIATION 
P O 
( O 
5 O 
or O 
25ppm O 
) O 
, O 
HC B-ABBREVIATION 
B O 
( O 
70 O 
or O 
350ppm O 
) O 
, O 
or O 
their O 
mixtures O 
( O 
5 O 
and O 
70ppm O 
or O 
25 O 
and O 
350ppm O 
) O 
for O 
6weeks O 
. O 
All O 
rats O 
were O 
subjected O 
to O 
partial O 
hepatectomy O 
at O 
week O 
3 O 
and O 
killed O 
at O 
week O 
8 O 
. O 
We O 
observed O 
additive O 
or O 
synergistic O 
effects O 
of O 
HE B-ABBREVIATION 
P O 
and O 
HC B-ABBREVIATION 
B O 
in O 
groups O 
treated O 
with O 
mixtures O 
of O 
these O 
pesticides O 
. O 
Number O 
and O 
area O 
of O 
preneoplastic O 
foci O 
positive O 
for O 
glutathion B-TRIVIAL 
e O 
S-transferase O 
placental O 
form O 
( O 
GST-P O 
) O 
were O 
consistently O 
higher O 
in O 
these O 
groups O 
than O 
the O 
sum O 
of O 
individual O 
values O 
in O 
the O 
groups O 
treated O 
with O 
HE B-ABBREVIATION 
P O 
or O 
HC B-ABBREVIATION 
B O 
alone O 
. O 
Consistent O 
with O 
these O 
findings O 
, O 
HE B-ABBREVIATION 
P O 
and O 
HC B-ABBREVIATION 
B O 
had O 
additive O 
or O 
synergistic O 
effects O 
on O 
cell O 
proliferation O 
induction O 
within O 
the O 
preneoplastic O 
foci O 
and O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
2B1 O 
and O 
3A1 O 
induction O 
, O 
which O 
may O 
lead O 
to O 
more O 
efficient O 
metabolic O 
activation O 
of O 
HE B-ABBREVIATION 
P O 
and O 
HC B-ABBREVIATION 
B O 
. O 
On O 
the O 
basis O 
of O 
these O 
findings O 
, O 
we O 
conclude O 
that O 
HE B-ABBREVIATION 
P O 
and O 
HC B-ABBREVIATION 
B O 
have O 
additive O 
and O 
synergistic O 
effects O 
on O 
the O 
development O 
of O 
GST-P-positive O 
foci O 
and O 
that O 
higher O 
risks O 
are O 
associated O 
with O 
a O 
combination O 
of O 
residual O 
organochlorin B-FAMILY 
e O 
pesticides O 
in O 
foods O 
than O 
with O 
individual O 
residual O 
organochlorin B-FAMILY 
e O 
pesticides O 
. O 

successive O 
events O 
of O 
shedding O 
and O 
regulated O 
intramembrane O 
proteolysis O 
are O 
known O 
to O 
comprise O 
a O 
fundamental O 
biological O 
process O 
of O 
type O 
I O 
and O 
II O 
membrane O 
proteins O 
( O 
e.g O 
. O 
amyloid O 
precursor O 
protein O 
, O 
Notch O 
receptor O 
and O 
pro O 
- O 
tumor O 
necrosis O 
factor-α O 
) O 
. O 
Some O 
of O 
the O 
resulting O 
fragments O 
were O 
shown O 
to O 
be O 
involved O 
in O 
important O 
intra- O 
and O 
extracellular O 
signalling O 
events O 
. O 
Although O 
shedding O 
of O 
the O 
human O 
transferrin O 
receptor-1 O 
( O 
TfR1 O 
) O 
has O 
been O 
known O 
for O 
> O 
30 O 
years O 
and O 
soluble O 
TfR1 O 
is O 
an O 
accepted O 
diagnostic O 
marker O 
, O 
the O 
fate O 
of O 
the O 
remaining O 
N B-FORMULA 
-terminal O 
fragment O 
( O 
NTF O 
) O 
remains O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
TfR1-NTF O 
is O 
subject O 
to O 
regulated O 
intramembrane O 
proteolysis O 
and O 
, O 
using O 
MALDI-TOF-TOF-MS O 
, O 
we O 
have O 
identified O 
the O 
cleavage O 
site O 
as O 
being O 
located O 
C B-FORMULA 
-terminal O 
from O 
Gly B-FORMULA 
-84 O 
. O 
We O 
showed O 
that O 
the O 
resulting O 
C B-FORMULA 
-terminal O 
peptide O 
is O 
extracellularly O 
released O 
after O 
regulated O 
intramembrane O 
proteolysis O 
and O 
it O 
was O 
detected O 
as O 
a O 
monomer O 
with O 
an O 
internal O 
disulfide B-SYSTEMATIC 
bridge O 
. O 
We O 
further O 
identified O 
signal O 
peptide O 
peptidase O 
- O 
like O 
2a O 
and O 
mainly O 
signal O 
peptide O 
peptidase O 
- O 
like O 
2b O 
as O 
being O 
responsible O 
for O 
the O 
intramembrane O 
proteolysis O 
of O 
TfR1-NTF O 
. O 

cytotoxicity O 
of O 
wool O 
polypeptide O 
has O 
been O 
evaluated O 
by O 
both O 
cell O 
and O 
animal O 
models O 
. O 
Wool O 
was O 
dissolved O 
in O 
sodium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
solution O 
, O 
the O 
pH O 
value O 
of O 
the O 
solution O 
was O 
adjusted O 
to O 
5.55 O 
and O 
the O 
precipitate O 
was O 
harvested O 
as O 
wool O 
polypeptide O 
. O 
The O 
spray O 
- O 
dried O 
polypeptide O 
was O 
collected O 
as O 
powders O 
and O 
characterized O 
by O 
SEM O 
, O 
FTIR O 
and O 
TG-DSC O 
. O 
The O 
cell O 
culturing O 
results O 
showed O 
that O 
wool O 
polypeptide O 
had O 
no O 
obvious O 
negative O 
effect O 
on O 
cell O 
viability O 
in O 
vitro O 
. O 
Both O 
acute O 
oral O 
toxicity O 
and O 
subacute O 
30-day O 
oral O 
toxicology O 
studies O 
showed O 
that O 
wool O 
polypeptide O 
had O 
no O 
influence O 
on O 
body O 
weight O 
, O 
feed O 
consumption O 
, O 
blood O 
chemistry O 
, O 
and O 
hematology O 
at O 
any O 
dose O 
levels O 
. O 
There O 
were O 
no O 
treatment O 
related O 
findings O 
on O 
gross O 
or O 
detailed O 
necroscopy O 
, O 
organ O 
weights O 
, O 
organ O 
/ O 
body O 
weight O 
ratios O 
and O 
histology O 
. O 
Our O 
study O 
indicated O 
the O 
absence O 
of O 
toxicity O 
in O 
wool O 
polypeptide O 
and O 
supported O 
its O 
safe O 
use O 
as O 
a O 
food O 
ingredient O 
or O 
drug O 
carrier O 
. O 

present O 
a O 
novel O 
method O 
for O 
full O 
- O 
field O 
scalar O 
visualization O 
and O 
quantification O 
of O 
species O 
concentration O 
fields O 
. O 
We O 
term O 
this O 
method O 
species O 
- O 
altered O 
fluorescence O 
imaging O 
( O 
SAFI O 
) O 
. O 
The O 
method O 
employs O 
electrically O 
neutral O 
fluorescent O 
dyes O 
whose O 
quantum O 
yields O 
are O 
selectively O 
quenched O 
or O 
enhanced O 
by O 
species O 
of O 
interest O 
. O 
SAFI O 
enables O 
simultaneous O 
imaging O 
of O 
material O 
interfaces O 
and O 
provides O 
non-invasive O 
, O 
scalar O 
- O 
field O 
quantitation O 
of O 
two O 
- O 
dimensional O 
species O 
concentration O 
fields O 
. O 
We O 
describe O 
criteria O 
for O 
choosing O 
SAFI O 
dyes O 
and O 
tabulate O 
35 O 
promising O 
SAFI O 
dyes O 
and O 
their O 
relevant O 
properties O 
. O 
Next O 
, O 
we O 
describe O 
species O 
concentration O 
quantification O 
with O 
SAFI O 
via O 
Stern-Volmer O 
quenching O 
and O 
discuss O 
the O 
sensitivity O 
and O 
resolution O 
of O 
our O 
method O 
. O 
We O 
demonstrate O 
this O 
method O 
with O 
two O 
dyes O 
, O 
6-methoxy-N-(3-sulfopropyl)quinolinium B-SYSTEMATIC 
( O 
SPQ B-ABBREVIATION 
) O 
and O 
10-(3-sulfopropyl)acridinium B-SYSTEMATIC 
betaine I-SYSTEMATIC 
( O 
SAB B-ABBREVIATION 
) O 
. O 
We O 
demonstrate O 
our O 
method O 
in O 
full O 
- O 
field O 
visualization O 
of O 
several O 
challenging O 
electrokinetic O 
flows O 
: O 
isotachophoresis O 
( O 
ITP O 
) O 
in O 
both O 
cationic O 
and O 
anionic O 
modes O 
, O 
and O 
in O 
a O 
convective O 
electrokinetic O 
instability O 
( O 
EKI O 
) O 
flow O 
. O 
Through O 
these O 
experiments O 
we O 
collectively O 
quantify O 
ion O 
concentration O 
shock O 
velocities O 
, O 
simultaneously O 
measure O 
concentrations O 
of O 
five O 
species O 
, O 
and O 
quantify O 
the O 
development O 
of O 
an O 
unsteady O 
, O 
chaotic O 
, O 
2D O 
flow O 
. O 

biarylpyrazole B-FAMILY 
compound O 
AM251 B-IDENTIFIER 
alters O 
mitochondrial O 
physiology O 
via O 
proteolytic O 
degradation O 
of O 
ERRα O 
. O 

orphan O 
nuclear O 
receptor O 
estrogen B-FAMILY 
-related O 
receptor O 
alpha O 
( O 
ERRα O 
) O 
directs O 
the O 
transcription O 
of O 
nuclear O 
genes O 
involved O 
in O 
energy O 
homeostasis O 
control O 
and O 
the O 
regulation O 
of O 
mitochondrial O 
mass O 
and O 
function O 
. O 
A O 
crucial O 
role O 
for O 
controlling O 
ERRα O 
- O 
mediated O 
target O 
gene O 
expression O 
has O 
been O 
ascribed O 
to O 
the O 
biarylpyrazole B-FAMILY 
compound O 
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide B-SYSTEMATIC 
( O 
AM251 B-IDENTIFIER 
) O 
through O 
direct O 
binding O 
to O 
and O 
destabilization O 
of O 
ERRα O 
protein O 
. O 
Here O 
, O 
we O 
provide O 
evidence O 
that O 
structurally O 
related O 
AM251 B-IDENTIFIER 
analogs O 
also O 
have O 
negative O 
impacts O 
on O 
ERRα O 
protein O 
levels O 
in O 
a O 
cell O 
- O 
type O 
- O 
dependent O 
manner O 
while O 
having O 
no O 
deleterious O 
actions O 
on O 
ERRγ O 
. O 
We O 
show O 
that O 
these O 
off O 
- O 
target O 
cellular O 
effects O 
of O 
AM251 B-IDENTIFIER 
are O 
mediated O 
by O 
proteasomal O 
degradation O 
of O 
nuclear O 
ERRα O 
. O 
Cell O 
treatment O 
with O 
the O 
nuclear O 
export O 
inhibitor O 
leptomycin B-TRIVIAL 
B I-TRIVIAL 
did O 
not O 
prevent O 
AM251 B-IDENTIFIER 
-induced O 
destabilization O 
of O 
ERRα O 
protein O 
, O 
whereas O 
proteasome O 
inhibition O 
with O 
MG132 B-IDENTIFIER 
stabilized O 
and O 
maintained O 
its O 
DNA O 
- O 
binding O 
function O 
, O 
indicative O 
of O 
ERRα O 
being O 
a O 
target O 
of O 
nuclear O 
proteasomal O 
complexes O 
. O 
NativePAGE O 
analysis O 
revealed O 
that O 
ERRα O 
formed O 
a O 
∼220-kDa O 
multiprotein O 
nuclear O 
complex O 
that O 
was O 
devoid O 
of O 
ERRγ O 
and O 
the O 
coregulator O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
γ O 
coactivator-1 O 
. O 
AM251 B-IDENTIFIER 
induced O 
SUMO-2,3 O 
incorporation O 
in O 
ERRα O 
in O 
conjunction O 
with O 
increased O 
protein O 
kinase O 
C O 
activity O 
, O 
whose O 
activation O 
by O 
phorbol B-FAMILY 
ester I-FAMILY 
also O 
promoted O 
ERRα O 
protein O 
loss O 
. O 
Down O 
- O 
regulation O 
of O 
ERRα O 
by O 
AM251 B-IDENTIFIER 
or O 
small O 
interfering O 
RNA O 
led O 
to O 
increased O 
mitochondria O 
biogenesis O 
while O 
negatively O 
impacting O 
mitochondrial O 
membrane O 
potential O 
. O 
These O 
results O 
reveal O 
a O 
novel O 
molecular O 
mechanism O 
by O 
which O 
AM251 B-IDENTIFIER 
and O 
related O 
compounds O 
alter O 
mitochondrial O 
physiology O 
through O 
destabilization O 
of O 
ERRα O 
. O 

performance O 
of O 
(99m)Tc-MIBI B-FORMULA 
scan O 
in O 
predicting O 
the O 
malignancy O 
of O 
thyroid O 
nodules O 
: O 
a O 
meta-analysis O 
. O 

studies O 
have O 
investigated O 
the O 
diagnostic O 
performance O 
of O 
(99m)Tc-MIBI B-FORMULA 
scan O 
in O 
the O 
evaluation O 
of O 
thyroid O 
nodules O 
suspicious O 
for O 
malignancy O 
with O 
conflicting O 
results O 
. O 
The O 
aim O 
of O 
our O 
study O 
is O 
to O 
meta-analyze O 
published O 
data O 
on O 
this O 
topic O 
. O 
A O 
comprehensive O 
literature O 
search O 
of O 
studies O 
published O 
through O 
December O 
2012 O 
regarding O 
the O 
diagnostic O 
performance O 
of O 
(99m)Tc-MIBI B-FORMULA 
scan O 
in O 
the O 
evaluation O 
of O 
thyroid O 
nodules O 
suspicious O 
for O 
malignancy O 
was O 
carried O 
out O 
. O 
Pooled O 
sensitivity O 
and O 
specificity O 
of O 
(99m)Tc-MIBI B-FORMULA 
scan O 
on O 
a O 
per O 
lesion O 
- O 
based O 
analysis O 
and O 
the O 
area O 
under O 
the O 
ROC O 
curve O 
were O 
calculated O 
. O 
Pathological O 
reports O 
of O 
thyroid O 
nodules O 
were O 
considered O 
as O 
reference O 
standard O 
. O 
Twenty O 
- O 
one O 
studies O 
were O 
included O 
in O 
the O 
meta-analysis O 
. O 
Pooled O 
sensitivity O 
and O 
specificity O 
of O 
(99m)Tc-MIBI B-FORMULA 
scan O 
in O 
detecting O 
malignant O 
thyroid O 
nodules O 
were O 
85.1 O 
% O 
[ O 
95 O 
% O 
confidence O 
interval O 
( O 
95 O 
% O 
CI O 
) O 
: O 
81.1-88.5 O 
% O 
] O 
and O 
45.7 O 
% O 
( O 
95 O 
% O 
CI O 
: O 
42.7-48.7 O 
% O 
) O 
, O 
respectively O 
, O 
on O 
a O 
per O 
lesion O 
- O 
based O 
analysis O 
, O 
irrespective O 
of O 
eventual O 
results O 
of O 
previous O 
technetium B-SYSTEMATIC 
pertechnetate I-SYSTEMATIC 
( O 
(99m)TcO4 B-FORMULA 
) O 
or O 
iodine-123 B-SYSTEMATIC 
( O 
(123)I B-FORMULA 
) O 
scan O 
. O 
The O 
area O 
under O 
the O 
ROC O 
curve O 
was O 
0.78 O 
. O 
A O 
sub O 
- O 
analysis O 
restricted O 
to O 
data O 
on O 
hypofunctioning O 
nodules O 
on O 
(99m)TcO4 B-FORMULA 
or O 
(123)I B-FORMULA 
scans O 
was O 
performed O 
: O 
pooled O 
sensitivity O 
and O 
specificity O 
of O 
(99m)Tc-MIBI B-FORMULA 
scan O 
in O 
these O 
nodules O 
were O 
82.1 O 
% O 
( O 
95 O 
% O 
CI O 
: O 
77.2-86.3 O 
% O 
) O 
and O 
62.8 O 
% O 
( O 
95 O 
% O 
CI O 
: O 
58.9-66.7 O 
% O 
) O 
, O 
respectively O 
, O 
on O 
a O 
per O 
lesion O 
- O 
based O 
analysis O 
. O 
The O 
area O 
under O 
the O 
ROC O 
curve O 
was O 
0.81 O 
. O 
(99m)Tc-MIBI B-FORMULA 
scan O 
is O 
a O 
sensitive O 
diagnostic O 
tool O 
in O 
predicting O 
the O 
malignancy O 
of O 
thyroid O 
nodules O 
. O 
Therefore O 
, O 
this O 
imaging O 
method O 
could O 
be O 
helpful O 
in O 
patients O 
with O 
thyroid O 
nodules O 
in O 
which O 
malignancy O 
is O 
suspected O 
on O 
the O 
basis O 
of O 
conventional O 
diagnostic O 
techniques O 
. O 
Higher O 
specificity O 
can O 
be O 
reached O 
when O 
hypofunctioning O 
thyroid O 
nodules O 
are O 
considered O 
. O 

total O 
of O 
68 O 
chemicals O 
including O 
derivatives O 
of O 
naphthalene B-SYSTEMATIC 
, O 
phenanthrene B-SYSTEMATIC 
, O 
fluoranthene B-SYSTEMATIC 
, O 
pyrene B-SYSTEMATIC 
, O 
biphenyl B-SYSTEMATIC 
, O 
and O 
flavone B-TRIVIAL 
were O 
examined O 
for O 
their O 
abilities O 
to O 
interact O 
with O 
human O 
P450s O 
2A13 O 
and O 
2A6 O 
. O 
Fifty O 
- O 
one O 
of O 
these O 
68 O 
chemicals O 
induced O 
stronger O 
Type O 
I O 
binding O 
spectra O 
( O 
iron B-SYSTEMATIC 
low- O 
to O 
high O 
- O 
spin O 
state O 
shift O 
) O 
with O 
P450 O 
2A13 O 
than O 
those O 
seen O 
with O 
P450 O 
2A6 O 
, O 
i.e O 
. O 
, O 
the O 
spectral O 
binding O 
intensities O 
( O 
ΔAmax O 
/ O 
Ks O 
ratio O 
) O 
determined O 
with O 
these O 
chemicals O 
were O 
always O 
higher O 
for O 
P450 O 
2A13 O 
. O 
In O 
addition O 
, O 
benzo[c]phenanthrene B-SYSTEMATIC 
, O 
fluoranthene B-SYSTEMATIC 
, O 
2,3-dihydroxy-2,3-dihydrofluoranthene B-SYSTEMATIC 
, O 
pyrene B-SYSTEMATIC 
, O 
1-hydroxypyrene B-SYSTEMATIC 
, O 
1-nitropyrene B-SYSTEMATIC 
, O 
1-acetylpyrene B-SYSTEMATIC 
, O 
2-acetylpyrene B-SYSTEMATIC 
, O 
2,5,2',5'-tetrachlorobiphenyl B-SYSTEMATIC 
, O 
7-hydroxyflavone B-SYSTEMATIC 
, O 
chrysin B-TRIVIAL 
, O 
and O 
galangin B-TRIVIAL 
were O 
found O 
to O 
induce O 
a O 
Type O 
I O 
spectral O 
change O 
only O 
with O 
P450 O 
2A13 O 
. O 
Coumarin B-TRIVIAL 
7-hydroxylation O 
, O 
catalyzed O 
by O 
P450 O 
2A13 O 
, O 
was O 
strongly O 
inhibited O 
by O 
2'-methoxy-5,7-dihydroxyflavone B-SYSTEMATIC 
, O 
2-ethynylnaphthalene B-SYSTEMATIC 
, O 
2'-methoxyflavone B-SYSTEMATIC 
, O 
2-naphththalene B-SYSTEMATIC 
propargyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
, O 
acenaphthene B-TRIVIAL 
, O 
acenaphthylene B-TRIVIAL 
, O 
naphthalene B-SYSTEMATIC 
, O 
1-acetylpyrene B-SYSTEMATIC 
, O 
flavanone B-TRIVIAL 
, O 
chrysin B-TRIVIAL 
, O 
3-ethynylphenanthrene B-SYSTEMATIC 
, O 
flavone B-TRIVIAL 
, O 
and O 
7-hydroxyflavone B-SYSTEMATIC 
; O 
these O 
chemicals O 
induced O 
Type O 
I O 
spectral O 
changes O 
with O 
low O 
Ks O 
values O 
. O 
On O 
the O 
basis O 
of O 
the O 
intensities O 
of O 
the O 
spectral O 
changes O 
and O 
inhibition O 
of O 
P450 O 
2A13 O 
, O 
we O 
classified O 
the O 
68 O 
chemicals O 
into O 
eight O 
groups O 
based O 
on O 
the O 
order O 
of O 
affinities O 
for O 
these O 
chemicals O 
and O 
inhibition O 
of O 
P450 O 
2A13 O 
. O 
The O 
metabolism O 
of O 
chemicals O 
by O 
P450 O 
2A13 O 
during O 
the O 
assays O 
explained O 
why O 
some O 
of O 
the O 
chemicals O 
that O 
bound O 
well O 
were O 
poor O 
inhibitors O 
of O 
P450 O 
2A13 O 
. O 
Finally O 
, O 
we O 
compared O 
the O 
68 O 
chemicals O 
for O 
their O 
abilities O 
to O 
induce O 
Type O 
I O 
spectral O 
changes O 
of O 
P450 O 
2A13 O 
with O 
the O 
Reverse O 
Type O 
I O 
binding O 
spectra O 
observed O 
with O 
P450 O 
1B1 O 
: O 
45 O 
chemicals O 
interacted O 
with O 
both O 
P450s O 
2A13 O 
and O 
1B1 O 
, O 
indicating O 
that O 
the O 
two O 
enzymes O 
have O 
some O 
similarty O 
of O 
structural O 
features O 
regarding O 
these O 
chemicals O 
. O 
Molecular O 
docking O 
analyses O 
suggest O 
similarities O 
at O 
the O 
active O 
sites O 
of O 
these O 
P450 O 
enzymes O 
. O 
These O 
results O 
indicate O 
that O 
P450 O 
2A13 O 
, O 
as O 
well O 
as O 
Family O 
1 O 
P450 O 
enzymes O 
, O 
is O 
able O 
to O 
catalyze O 
many O 
detoxication O 
and O 
activation O 
reactions O 
with O 
chemicals O 
of O 
environmental O 
interest O 
. O 

phenomenon O 
of O 
hyperpigmentation O 
( O 
melanosis O 
) O 
in O 
shellfish O 
has O 
long O 
been O 
attributed O 
to O 
phenoloxidase O 
enzymes O 
. O 
Over O 
the O 
last O 
number O 
of O 
years O 
, O 
the O 
oxygen B-SYSTEMATIC 
carrier O 
hemocyanin O 
, O 
has O 
demonstrated O 
several O 
immune- O 
and O 
physiological O 
functionalities O 
, O 
most O 
notably O 
, O 
inducible O 
phenoloxidase O 
activity O 
. O 
In O 
this O 
study O 
, O 
hemocyanin O 
purified O 
from O 
the O 
hemolymph O 
of O 
Nephrops O 
norvegicus O 
displays O 
diphenoloxidase O 
activity O 
in O 
the O 
presence O 
of O 
a O 
number O 
of O 
elicitors O 
and O 
retains O 
structural O 
and O 
functional O 
integrity O 
throughout O 
the O 
process O 
of O 
freeze O 
- O 
thawing O 
( O 
at O 
-25°C O 
) O 
. O 
Conversely O 
, O 
cellular O 
phenoloxidase O 
activity O 
( O 
present O 
in O 
cell O 
- O 
lysates O 
) O 
, O 
demonstrates O 
> O 
98% O 
reduction O 
in O 
activity O 
after O 
freeze O 
- O 
thawing O 
. O 
We O 
present O 
evidence O 
that O 
hemocyanin O 
may O 
act O 
as O 
a O 
causative O 
agent O 
of O 
hyperpigmentation O 
in O 
N O 
. O 
norvegicus O 
. O 
The O 
inhibition O 
of O 
hemocyanin O 
- O 
derived O 
phenoloxidase O 
activity O 
is O 
discussed O 
, O 
and O 
for O 
the O 
first O 
time O 
, O 
the O 
biophysical O 
interactions O 
of O 
shellfish O 
hemocyanin O 
with O 
known O 
phenoloxidase O 
inhibitors O 
are O 
presented O 
. O 

angiogenesis O 
and O 
osteogenesis O 
are O 
critically O 
linked O 
, O 
the O 
importance O 
of O 
angiogenesis O 
for O 
stress O 
fracture O 
healing O 
is O 
unknown O 
. O 
In O 
this O 
study O 
, O 
mechanical O 
loading O 
was O 
used O 
to O 
create O 
a O 
non-displaced O 
stress O 
fracture O 
in O 
the O 
adult O 
rat O 
forelimb O 
. O 
Fumagillin B-TRIVIAL 
, O 
an O 
anti-angiogenic O 
agent O 
, O 
was O 
used O 
as O 
the O 
water O 
soluble O 
analogue O 
TNP-470 B-IDENTIFIER 
( O 
25mg O 
/ O 
kg O 
) O 
as O 
well O 
as O 
incorporated O 
into O 
lipid O 
- O 
encapsulated O 
α(v)β(3) O 
integrin O 
targeted O 
nanoparticles O 
( O 
0.25mg O 
/ O 
kg O 
) O 
. O 
In O 
the O 
first O 
experiment O 
, O 
TNP-470 B-IDENTIFIER 
was O 
administered O 
daily O 
for O 
5 O 
days O 
following O 
mechanical O 
loading O 
, O 
and O 
changes O 
in O 
gene O 
expression O 
, O 
vascularity O 
, O 
and O 
woven O 
bone O 
formation O 
were O 
quantified O 
. O 
Although O 
no O 
changes O 
in O 
vascularity O 
were O 
detected O 
3 O 
days O 
after O 
loading O 
, O 
treatment O 
- O 
related O 
downregulation O 
of O 
angiogenic O 
( O 
Pecam1 O 
) O 
and O 
osteogenic O 
( O 
Bsp O 
, O 
Osx O 
) O 
genes O 
was O 
observed O 
at O 
this O 
early O 
time O 
point O 
. O 
On O 
day O 
7 O 
, O 
microCT O 
imaging O 
of O 
loaded O 
limbs O 
revealed O 
diminished O 
woven O 
bone O 
formation O 
in O 
treated O 
limbs O 
compared O 
to O 
vehicle O 
treated O 
limbs O 
. O 
In O 
the O 
second O 
experiment O 
, O 
α(v)β(3) O 
integrin O 
targeted O 
fumagillin B-TRIVIAL 
nanoparticles O 
were O 
administered O 
as O 
before O 
, O 
albeit O 
with O 
a O 
100-fold O 
lower O 
dose O 
, O 
and O 
changes O 
in O 
vascularity O 
and O 
woven O 
bone O 
formation O 
were O 
determined O 
. O 
There O 
were O 
no O 
treatment O 
- O 
related O 
changes O 
in O 
vessel O 
count O 
or O 
volume O 
3 O 
days O 
after O 
loading O 
, O 
although O 
fewer O 
angiogenic O 
( O 
CD105 O 
positive O 
) O 
blood O 
vessels O 
were O 
present O 
in O 
treated O 
limbs O 
compared O 
to O 
vehicle O 
treated O 
limbs O 
. O 
This O 
result O 
manifested O 
on O 
day O 
7 O 
as O 
a O 
reduction O 
in O 
total O 
vascularity O 
, O 
as O 
measured O 
by O 
histology O 
( O 
vessel O 
count O 
) O 
and O 
microCT O 
( O 
vessel O 
volume O 
) O 
. O 
Similar O 
to O 
the O 
first O 
experiment O 
, O 
treated O 
limbs O 
had O 
diminished O 
woven O 
bone O 
formation O 
on O 
day O 
7 O 
compared O 
to O 
vehicle O 
treated O 
limbs O 
. O 
These O 
results O 
indicate O 
that O 
angiogenesis O 
is O 
required O 
for O 
stress O 
fracture O 
healing O 
, O 
and O 
may O 
have O 
implications O 
for O 
inducing O 
rapid O 
repair O 
of O 
stress O 
fractures O 
. O 

modifies O 
the O 
antidepressant O 
- O 
like O 
effects O 
of O 
reboxetine B-TRIVIAL 
and O 
fluoxetine B-TRIVIAL 
in O 
rats O 
. O 

the O 
most O 
widely O 
used O 
antidepressants O 
are O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
( O 
SSRI O 
) O 
or O 
noradrenaline B-TRIVIAL 
reuptake O 
inhibitors O 
( O 
NRI O 
) O 
, O 
however O 
, O 
these O 
take O 
four O 
to O 
eight O 
weeks O 
to O 
exert O 
their O 
effects O 
and O 
each O 
drug O 
is O 
efficacious O 
only O 
in O 
60-70% O 
of O 
patients O 
. O 
In O 
an O 
attempt O 
to O 
improve O 
the O 
efficacy O 
of O 
antidepressants O 
, O 
new O 
drugs O 
that O 
also O 
modify O 
dopamine B-TRIVIAL 
levels O 
are O 
being O 
developed O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
impact O 
of O 
l-DOPA B-ABBREVIATION 
administration O 
on O 
the O 
effect O 
elicited O 
by O 
antidepressants O 
on O 
serotonergic O 
and O 
noradrenergic O 
neurotransmission O 
. O 
To O 
this O 
end O 
, O 
single O 
- O 
unit O 
extracellular O 
recordings O 
of O 
the O 
noradrenergic O 
nucleus O 
, O 
locus O 
coeruleus O 
( O 
LC O 
) O 
, O 
and O 
the O 
serotonergic O 
nucleus O 
, O 
dorsal O 
raphe O 
( O 
DRN O 
) O 
combined O 
with O 
behavioural O 
approaches O 
were O 
performed O 
. O 
l-DOPA B-ABBREVIATION 
did O 
not O 
modify O 
the O 
basal O 
neuronal O 
activity O 
in O 
either O 
the O 
LC O 
or O 
the O 
DRN O 
or O 
induce O 
any O 
change O 
in O 
the O 
modified O 
forced O 
swimming O 
test O 
. O 
However O 
, O 
l-DOPA B-ABBREVIATION 
enhanced O 
the O 
neuronal O 
response O 
to O 
reboxetine B-TRIVIAL 
in O 
the O 
LC O 
and O 
increased O 
its O 
antidepressant O 
- O 
like O 
effects O 
but O 
counteracted O 
the O 
effect O 
of O 
fluoxetine B-TRIVIAL 
on O 
neurons O 
in O 
the O 
LC O 
and O 
decreased O 
its O 
antidepressant O 
- O 
like O 
effect O 
. O 
The O 
sensitivity O 
of O 
neurons O 
in O 
the O 
DRN O 
to O 
reboxetine B-TRIVIAL 
and O 
fluoxetine B-TRIVIAL 
was O 
not O 
altered O 
by O 
the O 
administration O 
of O 
l-DOPA B-ABBREVIATION 
. O 
Taken O 
together O 
, O 
these O 
results O 
indicate O 
that O 
l-DOPA B-ABBREVIATION 
modifies O 
the O 
effect O 
of O 
SSRI O 
and O 
NRI O 
antidepressants O 
in O 
opposing O 
ways O 
. O 

regulates O 
GnRH B-ABBREVIATION 
-induced O 
FSHβ O 
gene O 
expression O 
. O 

regulation O 
of O 
gonadotropin O 
synthesis O 
by O 
GnRH B-ABBREVIATION 
plays O 
an O 
essential O 
role O 
in O 
the O 
neuroendocrine O 
control O 
of O 
reproduction O 
. O 
The O 
known O 
signaling O 
mechanisms O 
involved O 
in O 
gonadotropin O 
synthesis O 
have O 
been O 
expanding O 
. O 
For O 
example O 
, O 
involvement O 
of O 
β-catenin O 
in O 
LHβ O 
induction O 
by O 
GnRH B-ABBREVIATION 
has O 
been O 
discovered O 
. O 
We O 
examined O 
the O 
role O 
of O 
β-catenin O 
in O 
FSHβ O 
gene O 
expression O 
in O 
LβT2 O 
gonadotrope O 
cells O 
. O 
GnRH B-ABBREVIATION 
caused O 
a O 
sustained O 
increase O 
in O 
nuclear O 
β-catenin O 
levels O 
, O 
which O 
was O 
significantly O 
reduced O 
by O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
inhibition O 
. O 
Small O 
interfering O 
RNA O 
- O 
mediated O 
knockdown O 
of O 
β-catenin O 
mRNA O 
demonstrated O 
that O 
induction O 
of O 
FSHβ O 
mRNA O 
by O 
GnRH B-ABBREVIATION 
depended O 
on O 
β-catenin O 
and O 
that O 
regulation O 
of O 
FSHβ O 
by O 
β-catenin O 
occurred O 
independently O 
of O 
the O 
JNK-c-jun O 
pathway O 
. O 
β-Catenin O 
depletion O 
had O 
no O 
impact O 
on O 
FSHβ O 
mRNA O 
stability O 
. O 
In O 
LβT2 O 
cells O 
transfected O 
with O 
FSHβ O 
promoter O 
luciferase O 
fusion O 
constructs O 
, O 
GnRH B-ABBREVIATION 
responsiveness O 
was O 
conferred O 
by O 
the O 
proximal O 
promoter O 
( O 
-944 O 
/ O 
-1 O 
) O 
and O 
was O 
markedly O 
decreased O 
by O 
β-catenin O 
knockdown O 
. O 
However O 
, O 
none O 
of O 
the O 
T-cell O 
factor O 
/ O 
lymphoid O 
enhancer O 
factor O 
binding O 
sites O 
in O 
that O 
region O 
were O 
required O 
for O 
promoter O 
activation O 
by O 
GnRH B-ABBREVIATION 
. O 
Chromatin O 
immunoprecipitation O 
further O 
corroborated O 
the O 
absence O 
of O 
direct O 
interaction O 
between O 
β-catenin O 
and O 
the O 
1.8-kb O 
FSHβ O 
promoter O 
. O 
To O 
elucidate O 
the O 
mechanism O 
for O 
the O 
β-catenin O 
effect O 
, O 
we O 
analyzed O 
approximately O 
1 O 
billion O 
reads O 
of O 
next O 
- O 
generation O 
RNA O 
sequencing O 
β-catenin O 
knockdown O 
assays O 
and O 
selected O 
the O 
nuclear O 
cofactor O 
breast O 
cancer O 
metastasis O 
- O 
suppressor O 
1- O 
like O 
( O 
Brms1L O 
) O 
as O 
one O 
candidate O 
for O 
further O 
study O 
. O 
Subsequent O 
experiments O 
confirmed O 
that O 
Brms1L O 
mRNA O 
expression O 
was O 
decreased O 
by O 
β-catenin O 
knockdown O 
as O 
well O 
as O 
by O 
JNK O 
inhibition O 
. O 
Furthermore O 
, O 
knockdown O 
of O 
Brms1L O 
significantly O 
attenuated O 
GnRH B-ABBREVIATION 
-induced O 
FSHβ O 
expression O 
. O 
Thus O 
, O 
our O 
findings O 
indicate O 
that O 
the O 
expression O 
of O 
Brms1L O 
depends O 
on O 
β-catenin O 
activity O 
and O 
contributes O 
to O 
FSHβ O 
induction O 
by O 
GnRH B-ABBREVIATION 
. O 

role O 
of O 
a O 
methyl B-SYSTEMATIC 
group O 
on O 
the O 
γ-lactone B-SYSTEMATIC 
ring O 
of O 
annonaceous O 
acetogenins B-FAMILY 
in O 
the O 
potent O 
inhibition O 
of O 
mitochondrial O 
complex O 
I O 
. O 

and O 
C34-epi-C35-trifluoro B-SYSTEMATIC 
analogues O 
of O 
solamin B-TRIVIAL 
, O 
a O 
mono-THF B-FAMILY 
annonaceous O 
acetogenin B-FAMILY 
, O 
were O 
synthesized O 
. O 
Their O 
inhibitory O 
activity O 
, O 
along O 
with O 
previously O 
synthesized O 
analogues O 
( O 
C35-fluoro B-MULTIPLE 
, I-MULTIPLE 
C35-difluoro I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
C35-trifluorosolamins I-MULTIPLE 
) O 
, O 
against O 
bovine O 
mitochondrial O 
NADH B-ABBREVIATION 
- O 
ubiquinone B-FAMILY 
oxidoreductase O 
( O 
complex O 
I O 
) O 
was O 
determined O 
. O 
The O 
present O 
study O 
revealed O 
that O 
the O 
methyl B-SYSTEMATIC 
group O 
on O 
the O 
γ-lactone B-SYSTEMATIC 
moiety O 
is O 
critical O 
to O 
the O 
potent O 
inhibition O 
of O 
complex O 
I O 
by O 
natural O 
acetogenins B-FAMILY 
. O 

effect O 
in O 
2-benzoylmethylenequinoline B-FAMILY 
difluoroborates I-FAMILY 
exhibiting O 
through O 
- O 
space O 
couplings O 
. O 
Multinuclear O 
magnetic O 
resonance O 
, O 
X-ray O 
diffraction O 
, O 
and O 
computational O 
study O 
. O 

series O 
of O 
nine O 
2-benzoylmethylenequinoline B-FAMILY 
difluoroborates I-FAMILY 
have O 
been O 
synthesized O 
and O 
characterized O 
by O 
multinuclear O 
magnetic O 
resonance O 
, O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
and O 
computational O 
methods O 
. O 
The O 
through O 
- O 
space O 
spin O 
- O 
spin O 
couplings O 
between O 
(19)F B-FORMULA 
and O 
(1)H B-FORMULA 
/ O 
(13)C B-FORMULA 
nuclei O 
have O 
been O 
observed O 
in O 
solution O 
. O 
The O 
NMR O 
chemical O 
shifts O 
have O 
been O 
correlated O 
to O 
the O 
Hammett O 
substituent O 
constants O 
. O 
The O 
crystal O 
structures O 
of O 
six O 
compounds O 
have O 
been O 
solved O 
by O 
XRD O 
. O 
For O 
two O 
derivatives O 
the O 
X-ray O 
wave O 
function O 
refinement O 
was O 
performed O 
to O 
evaluate O 
the O 
character O 
of O 
bonds O 
in O 
the O 
NBF(2)O B-FORMULA 
moiety O 
by O 
topological O 
and O 
integrated O 
bond O 
descriptors O 
. O 

Emerging O 
Use O 
of O 
Ketamine B-TRIVIAL 
for O 
Anesthesia O 
and O 
Sedation O 
in O 
Traumatic O 
Brain O 
Injuries O 
. O 

: O 
Traditionally O 
, O 
the O 
use O 
of O 
ketamine B-TRIVIAL 
for O 
patients O 
with O 
traumatic O 
brain O 
injuries O 
is O 
contraindicated O 
due O 
to O 
the O 
concern O 
of O 
increasing O 
intracranial O 
pressure O 
( O 
ICP O 
) O 
. O 
These O 
concerns O 
, O 
however O 
, O 
originated O 
from O 
early O 
studies O 
and O 
case O 
reports O 
that O 
were O 
inadequately O 
controlled O 
and O 
designed O 
. O 
Recently O 
, O 
the O 
concern O 
of O 
using O 
ketamine B-TRIVIAL 
in O 
these O 
patients O 
has O 
been O 
challenged O 
by O 
a O 
number O 
of O 
published O 
studies O 
demonstrating O 
that O 
the O 
use O 
of O 
ketamine B-TRIVIAL 
was O 
safe O 
in O 
these O 
patients O 
. O 
AIMS O 
: O 
The O 
purpose O 
of O 
this O 
article O 
was O 
to O 
review O 
the O 
current O 
literature O 
in O 
regards O 
to O 
using O 
ketamine B-TRIVIAL 
in O 
patients O 
with O 
traumatic O 
brain O 
injuries O 
in O 
different O 
clinical O 
settings O 
associated O 
with O 
anesthesia O 
, O 
as O 
well O 
as O 
review O 
the O 
potential O 
mechanisms O 
underlying O 
the O 
neuroprotective O 
effects O 
of O 
ketamine B-TRIVIAL 
. O 
RESULTS O 
: O 
Studies O 
examining O 
the O 
use O 
of O 
ketamine B-TRIVIAL 
for O 
induction O 
, O 
maintenance O 
, O 
and O 
sedation O 
in O 
patients O 
with O 
TBI O 
have O 
had O 
promising O 
results O 
. O 
The O 
use O 
of O 
ketamine B-TRIVIAL 
in O 
a O 
controlled O 
ventilation O 
setting O 
and O 
in O 
combination O 
with O 
other O 
sedative O 
agents O 
has O 
demonstrated O 
no O 
increase O 
in O 
ICP O 
. O 
CONCLUSIONS O 
: O 
The O 
role O 
of O 
ketamine B-TRIVIAL 
as O 
a O 
neuroprotective O 
agent O 
in O 
humans O 
remains O 
inconclusive O 
and O 
adequately O 
powered O 
; O 
randomized O 
controlled O 
trials O 
performed O 
in O 
patients O 
undergoing O 
surgery O 
for O 
traumatic O 
brain O 
injury O 
are O 
necessary O 
. O 

of O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporter O 
ABCG2 O 
as O 
a O 
potential O 
mechanism O 
of O 
acquired O 
resistance O 
to O 
vemurafenib B-TRIVIAL 
in O 
BRAF(V600E) O 
mutant O 
cancer O 
cells O 
. O 

is O 
the O 
most O 
serious O 
type O 
of O 
skin O 
cancer O 
with O 
a O 
high O 
potential O 
for O 
metastasis O 
and O 
very O 
low O 
survival O 
rates O 
. O 
The O 
discovery O 
of O 
constitutive O 
activation O 
of O 
the O 
BRAF O 
kinase O 
caused O 
by O 
activating O 
BRAF(V600E) O 
kinase O 
mutation O 
in O 
most O 
melanoma O 
patients O 
led O 
to O 
the O 
discovery O 
of O 
the O 
first O 
potent O 
BRAF(V600E) O 
signaling O 
inhibitor O 
, O 
vemurafenib B-TRIVIAL 
. O 
Vemurafenib B-TRIVIAL 
was O 
effective O 
in O 
treating O 
advanced O 
melanoma O 
patients O 
and O 
was O 
proposed O 
for O 
the O 
treatment O 
of O 
other O 
BRAF(V600E) O 
mutant O 
cancers O 
as O 
well O 
. O 
Unfortunately O 
, O 
the O 
success O 
of O 
vemurafenib B-TRIVIAL 
was O 
hampered O 
by O 
the O 
rapid O 
development O 
of O 
acquired O 
resistance O 
in O 
different O 
types O 
of O 
BRAF(V600E) O 
mutant O 
cancer O 
cells O 
. O 
It O 
becomes O 
important O 
to O 
identify O 
and O 
evaluate O 
all O 
of O 
the O 
potential O 
mechanisms O 
of O 
cellular O 
resistance O 
to O 
vemurafenib B-TRIVIAL 
. O 
In O 
this O 
study O 
, O 
we O 
characterized O 
the O 
interactions O 
of O 
vemurafenib B-TRIVIAL 
with O 
three O 
major O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
( O 
ABC O 
) O 
transporters O 
, O 
ABCB1 O 
, O 
ABCC1 O 
and O 
ABCG2 O 
. O 
We O 
found O 
that O 
vemurafenib B-TRIVIAL 
stimulated O 
the O 
ATPase O 
activity O 
and O 
potently O 
inhibited O 
drug O 
efflux O 
mediated O 
by O 
ABCB1 O 
and O 
ABCG2 O 
. O 
Vemurafenib B-TRIVIAL 
also O 
restored O 
drug O 
sensitivity O 
in O 
ABCG2-overexpressing O 
cells O 
. O 
Moreover O 
, O 
we O 
revealed O 
that O 
in O 
the O 
presence O 
of O 
functional O 
ABCG2 O 
, O 
BRAF O 
kinase O 
inhibition O 
by O 
vemurafenib B-TRIVIAL 
is O 
reduced O 
in O 
BRAF(V600E) O 
mutant O 
A375 O 
cells O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
indicate O 
that O 
ABCG2 O 
confers O 
resistance O 
to O 
vemurafenib B-TRIVIAL 
in O 
A375 O 
cells O 
, O 
suggesting O 
involvement O 
of O 
this O 
transporter O 
in O 
acquired O 
resistance O 
to O 
vemurafenib B-TRIVIAL 
. O 
Thus O 
, O 
combination O 
chemotherapy O 
targeting O 
multiple O 
pathways O 
could O 
be O 
an O 
effective O 
therapeutic O 
strategy O 
to O 
overcome O 
acquired O 
resistance O 
to O 
vemurafenib B-TRIVIAL 
for O 
cancers O 
harboring O 
the O 
BRAF(V600E) O 
mutation O 
. O 

: O 
The O 
nucleus O 
accumbens O 
( O 
NAc O 
) O 
is O 
a O 
site O 
critical O 
for O 
the O 
actions O 
of O 
many O 
drugs O 
of O 
abuse O 
. O 
Psychoactive O 
compounds O 
, O 
such O 
as O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptor O 
( O 
NMDAR O 
) O 
antagonists O 
, O 
modify O 
gamma O 
( O 
40-90 O 
) O 
and O 
high O 
frequency O 
oscillations O 
( O 
HFO O 
, O 
130-180 O 
Hz O 
) O 
in O 
local O 
field O 
potentials O 
( O 
LFPs O 
) O 
recorded O 
in O 
the O 
NAc O 
. O 
Lysergic B-SYSTEMATIC 
acid I-SYSTEMATIC 
diethylamide I-SYSTEMATIC 
( O 
LSD B-ABBREVIATION 
) O 
and O 
2,5-dimethoxy-4-iodoamphetamine B-SYSTEMATIC 
( O 
DOI B-ABBREVIATION 
) O 
are O 
serotonergic O 
hallucinogens O 
and O 
activation O 
of O 
5HT2A O 
receptors O 
likely O 
underlies O 
their O 
hallucinogenic O 
effects O 
. O 
Whether O 
these O 
compounds O 
can O 
also O 
modulate O 
LFP O 
oscillations O 
in O 
the O 
NAc O 
is O 
unclear O 
. O 
OBJECTIVE O 
: O 
This O 
study O 
aims O 
to O 
examine O 
the O 
effect O 
of O 
serotonergic O 
hallucinogens O 
on O 
gamma O 
and O 
HFO O 
recorded O 
in O 
the O 
NAc O 
and O 
to O 
test O 
whether O 
5HT2A O 
receptors O 
mediate O 
the O 
effects O 
observed O 
. O 
METHODS O 
: O 
LFPs O 
were O 
recorded O 
from O 
the O 
NAc O 
of O 
freely O 
moving O 
rats O 
. O 
Drugs O 
were O 
administered O 
intraperitoneally O 
. O 
RESULTS O 
: O 
LSD B-ABBREVIATION 
( O 
0.03-0.3 O 
mg O 
/ O 
kg O 
) O 
and O 
DOI B-ABBREVIATION 
( O 
0.5-2.0 O 
mg O 
/ O 
kg O 
) O 
increased O 
the O 
power O 
and O 
reduced O 
the O 
frequency O 
of O 
HFO O 
. O 
In O 
contrast O 
, O 
the O 
hallucinogens O 
produced O 
a O 
robust O 
reduction O 
in O 
the O 
power O 
of O 
low O 
( O 
40-60 O 
Hz O 
) O 
, O 
but O 
not O 
high O 
gamma O 
oscillations O 
( O 
70-90 O 
Hz O 
) O 
. O 
MDL B-IDENTIFIER 
11939 I-IDENTIFIER 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
, O 
a O 
5HT2A O 
receptor O 
antagonist O 
, O 
fully O 
reversed O 
the O 
changes O 
induced O 
by O 
DOI B-ABBREVIATION 
on O 
HFO O 
but O 
only O 
partially O 
for O 
the O 
low O 
gamma O 
band O 
. O 
Equivalent O 
increases O 
in O 
HFO O 
power O 
were O 
observed O 
after O 
TCB-2 B-IDENTIFIER 
( O 
5HT2A O 
receptor O 
agonist O 
, O 
0.1-1.5 O 
mg O 
/ O 
kg O 
) O 
, O 
but O 
not O 
CP B-IDENTIFIER 
809101 I-IDENTIFIER 
( O 
5H2C O 
receptor O 
agonist O 
, O 
0.1-3 O 
mg O 
/ O 
kg O 
) O 
. O 
Notably O 
, O 
hallucinogen O 
- O 
induced O 
increases O 
in O 
HFO O 
power O 
were O 
smaller O 
than O 
those O 
produced O 
by O 
ketamine B-TRIVIAL 
( O 
25 O 
mg O 
/ O 
kg O 
) O 
. O 
CONCLUSIONS O 
: O 
Serotonergic O 
hallucinogen O 
- O 
induced O 
changes O 
in O 
HFO O 
and O 
gamma O 
are O 
mediated O 
, O 
at O 
least O 
in O 
part O 
, O 
by O 
stimulation O 
of O 
5HT2A O 
receptors O 
. O 
Comparison O 
of O 
the O 
oscillatory O 
changes O 
produced O 
by O 
serotonergic O 
hallucinogens O 
and O 
NMDAR O 
antagonists O 
are O 
also O 
discussed O 
. O 

of O 
Octahedral O 
Tilts O 
and O 
Polar O 
Order O 
in O 
BiFeO3 B-FORMULA 
Films O 
. O 

stabilization O 
of O 
a O 
distinct O 
nonpolar O 
BiFeO3 B-FORMULA 
phase O 
occurs O 
simultaneously O 
with O 
changes O 
in O 
octahedral O 
tilts O 
. O 
The O 
resulting O 
phase O 
arises O 
via O 
suppression O 
of O 
polarization O 
by O 
a O 
structural O 
order O 
parameter O 
and O 
can O 
thus O 
be O 
identified O 
as O 
anti-ferroelectric O 
( O 
Fe B-FORMULA 
displacements O 
- O 
bottom O 
panel O 
) O 
. O 
The O 
phase O 
is O 
metastable O 
and O 
can O 
be O 
switched O 
into O 
a O 
polar O 
ferroelectric O 
state O 
( O 
top O 
panel O 
) O 
under O 
an O 
applied O 
electric O 
bias O 
. O 

trypanosomiasis O 
is O 
still O 
a O 
major O 
health O 
problem O 
in O 
many O 
sub-Saharan O 
countries O 
in O 
Africa O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
three O 
preparations O 
of O 
Panax O 
ginseng O 
, O 
Panax O 
notoginseng O 
, O 
isolated O 
ginsenosides B-FAMILY 
, O 
and O 
the O 
polyacetylene B-SYSTEMATIC 
panaxynol B-TRIVIAL 
on O 
Trypanosoma O 
brucei O 
brucei O 
and O 
the O 
human O 
cancer O 
cell O 
line O 
HeLa O 
. O 
Hexane B-SYSTEMATIC 
extracts O 
and O 
the O 
pure O 
panaxynol B-TRIVIAL 
were O 
toxic O 
and O 
at O 
the O 
same O 
time O 
highly O 
selective O 
against O 
T O 
. O 
b O 
. O 
brucei O 
, O 
whereas O 
methanol B-SYSTEMATIC 
extracts O 
and O 
12 O 
isolated O 
ginsenosides B-FAMILY 
were O 
significantly O 
less O 
toxic O 
and O 
showed O 
only O 
weak O 
selectivity O 
. O 
Panaxynol B-TRIVIAL 
was O 
cytotoxic O 
against O 
T O 
. O 
b O 
. O 
brucei O 
at O 
the O 
concentration O 
of O 
0.01 O 
µg O 
/ O 
mL O 
with O 
a O 
selectivity O 
index O 
of O 
858 O 
, O 
superior O 
even O 
to O 
established O 
antitrypanosomal O 
drugs O 
. O 
We O 
suggest O 
that O 
the O 
inhibition O 
of O 
trypanothione B-TRIVIAL 
reductase O 
, O 
which O 
is O 
only O 
found O 
in O 
trypanosomes O 
, O 
might O 
explain O 
the O 
observed O 
selectivity O 
. O 
The O 
high O 
selectivity O 
together O 
with O 
a O 
cytotoxic O 
concentration O 
in O 
the O 
range O 
of O 
the O 
bioavailability O 
makes O 
panaxynol B-TRIVIAL 
and O 
other O 
polyacetylenes B-FAMILY 
in O 
general O 
very O 
promising O 
lead O 
compounds O 
for O 
the O 
treatment O 
of O 
African O 
trypanosomiasis O 
. O 

and O 
structural O 
properties O 
of O 
a O 
highly O 
engineered O 
halohydrin B-FAMILY 
dehalogenase O 
. O 

highly O 
engineered O 
halohydrin B-FAMILY 
dehalogenase O 
variants O 
were O 
characterized O 
in O 
terms O 
of O 
their O 
performance O 
in O 
dehalogenation O 
and O 
epoxide B-SYSTEMATIC 
cyanolysis O 
reactions O 
. O 
Both O 
enzyme O 
variants O 
outperformed O 
the O 
wild O 
- O 
type O 
enzyme O 
in O 
the O 
cyanolysis O 
of O 
ethyl B-SYSTEMATIC 
(S)-3,4-epoxybutyrate I-SYSTEMATIC 
, O 
a O 
conversion O 
yielding O 
ethyl B-SYSTEMATIC 
(R)-4-cyano-3-hydroxybutyrate I-SYSTEMATIC 
, O 
an O 
important O 
chiral O 
building O 
block O 
for O 
statin O 
synthesis O 
. O 
One O 
of O 
the O 
enzyme O 
variants O 
, O 
HheC2360 O 
, O 
displayed O 
catalytic O 
rates O 
for O 
this O 
cyanolysis O 
reaction O 
enhanced O 
up O 
to O 
tenfold O 
. O 
Furthermore O 
, O 
the O 
enantioselectivity O 
of O 
this O 
variant O 
was O 
the O 
opposite O 
of O 
that O 
of O 
the O 
wild O 
- O 
type O 
enzyme O 
, O 
both O 
for O 
dehalogenation O 
and O 
for O 
cyanolysis O 
reactions O 
. O 
The O 
37-fold O 
mutant O 
HheC2360 O 
showed O 
an O 
increase O 
in O 
thermal O 
stability O 
of O 
8 O 
°C O 
relative O 
to O 
the O 
wild O 
- O 
type O 
enzyme O 
. O 
Crystal O 
structures O 
of O 
this O 
enzyme O 
were O 
elucidated O 
with O 
chloride B-SYSTEMATIC 
and O 
ethyl B-SYSTEMATIC 
(S)-3,4-epoxybutyrate I-SYSTEMATIC 
or O 
with O 
ethyl B-SYSTEMATIC 
(R)-4-cyano-3-hydroxybutyrate I-SYSTEMATIC 
bound O 
in O 
the O 
active O 
site O 
. O 
The O 
observed O 
increase O 
in O 
temperature O 
stability O 
was O 
explained O 
in O 
terms O 
of O 
a O 
substantial O 
increase O 
in O 
buried O 
surface O 
area O 
relative O 
to O 
the O 
wild O 
- O 
type O 
HheC O 
, O 
together O 
with O 
enhanced O 
interfacial O 
interactions O 
between O 
the O 
subunits O 
that O 
form O 
the O 
tetramer O 
. O 
The O 
structures O 
also O 
revealed O 
that O 
the O 
substrate O 
binding O 
pocket O 
was O 
modified O 
both O 
by O 
substitutions O 
and O 
by O 
backbone O 
movements O 
in O 
loops O 
surrounding O 
the O 
active O 
site O 
. O 
The O 
observed O 
changes O 
in O 
the O 
mutant O 
structures O 
are O 
partly O 
governed O 
by O 
coupled O 
mutations O 
, O 
some O 
of O 
which O 
are O 
necessary O 
to O 
remove O 
steric O 
clashes O 
or O 
to O 
allow O 
backbone O 
movements O 
to O 
occur O 
. O 
The O 
importance O 
of O 
interactions O 
between O 
substitutions O 
suggests O 
that O 
efficient O 
directed O 
evolution O 
strategies O 
should O 
allow O 
for O 
compensating O 
and O 
synergistic O 
mutations O 
during O 
library O 
design O 
. O 

of O 
genotoxicity O 
of O 
nitrile B-SYSTEMATIC 
fragrance O 
ingredients O 
using O 
in O 
vitro O 
and O 
in O 
vivo O 
assays O 
. O 

studies O 
were O 
conducted O 
on O 
a O 
group O 
of O 
8 O 
fragrance O 
ingredients O 
that O 
belong O 
to O 
the O 
nitrile B-SYSTEMATIC 
family O 
. O 
These O 
nitriles B-FAMILY 
are O 
widely O 
used O 
in O 
consumer O 
products O 
however O 
there O 
is O 
very O 
limited O 
data O 
in O 
the O 
literature O 
regarding O 
the O 
genotoxicity O 
of O 
these O 
nitriles B-FAMILY 
. O 
The O 
8 O 
nitriles B-FAMILY 
were O 
assessed O 
for O 
genotoxicity O 
using O 
an O 
Ames O 
test O 
, O 
in O 
- O 
vitro O 
chromosome O 
aberration O 
test O 
or O 
in O 
- O 
vitro O 
micronucleus O 
test O 
. O 
The O 
positive O 
results O 
observed O 
in O 
the O 
in O 
- O 
vitro O 
tests O 
were O 
further O 
investigated O 
using O 
an O 
in O 
- O 
vivo O 
micronucleus O 
test O 
. O 
The O 
results O 
from O 
these O 
different O 
tests O 
were O 
compared O 
and O 
these O 
8 O 
nitriles B-FAMILY 
are O 
not O 
considered O 
to O 
be O 
genotoxic O 
. O 
Dodecanitrile B-SYSTEMATIC 
and O 
2,2,3-trimethylcyclopent-3-enylacetonitrile B-SYSTEMATIC 
were O 
negative O 
in O 
the O 
in O 
- O 
vitro O 
chromosome O 
aberration O 
test O 
and O 
in O 
- O 
vitro O 
micronucleus O 
test O 
, O 
respectively O 
. O 
While O 
citronellyl B-SYSTEMATIC 
nitrile I-SYSTEMATIC 
, O 
3-methyl-5-phenylpentanenitrile B-SYSTEMATIC 
, O 
cinnamyl B-SYSTEMATIC 
nitrile I-SYSTEMATIC 
, O 
and O 
3-methyl-5-phenylpent-2-enenitrile B-SYSTEMATIC 
revealed O 
positive O 
results O 
in O 
the O 
in O 
- O 
vitro O 
tests O 
, O 
but O 
confirmatory O 
in O 
- O 
vivo O 
tests O 
determined O 
these O 
nitriles B-FAMILY 
to O 
be O 
negative O 
in O 
the O 
in O 
- O 
vivo O 
micronucleus O 
assay O 
. O 
The O 
remaining O 
two O 
nitriles B-FAMILY 
( O 
benzonitrile B-SYSTEMATIC 
and O 
α-cyclohexylidene B-SYSTEMATIC 
benzeneacetonitrile I-SYSTEMATIC 
) O 
were O 
negative O 
in O 
the O 
in O 
- O 
vivo O 
micronucleus O 
test O 
. O 
This O 
study O 
aims O 
to O 
evaluate O 
the O 
genotoxicity O 
potential O 
of O 
these O 
nitriles B-FAMILY 
as O 
well O 
as O 
enrich O 
the O 
literature O 
with O 
genotoxicity O 
data O 
on O 
fragrance O 
ingredients O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
use O 
of O 
sonicated O 
pineapple O 
juice O 
as O 
substrate O 
for O 
producing O 
a O 
probiotic O 
beverage O 
by O 
Lactobacillus O 
casei O 
NRRL O 
B442 O 
. O 
Maximal O 
microbial O 
viability O 
was O 
found O 
by O 
cultivating O 
L O 
. O 
casei O 
at O 
31°C O 
and O 
pH O 
5.8 O 
( O 
optimised O 
conditions O 
) O 
. O 
After O 
fermentation O 
, O 
samples O 
of O 
sweetened O 
and O 
non-sweetened O 
juice O 
were O 
stored O 
. O 
After O 
42days O 
of O 
storage O 
under O 
refrigeration O 
( O 
4°C O 
) O 
, O 
the O 
microbial O 
viability O 
was O 
6.03LogCFU O 
/ O 
mL O 
in O 
the O 
non-sweetened O 
sample O 
and O 
4.77LogCFU O 
/ O 
mL O 
in O 
the O 
sweetened O 
sample O 
. O 
The O 
pH O 
of O 
both O 
samples O 
decreased O 
during O 
storage O 
due O 
to O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
production O 
( O 
post O 
acidification O 
) O 
. O 
The O 
characteristic O 
colour O 
of O 
the O 
juice O 
was O 
maintained O 
throughout O 
the O 
shelf O 
life O 
and O 
no O 
browning O 
was O 
observed O 
. O 
Sonicated O 
pineapple O 
juice O 
was O 
shown O 
to O 
be O 
a O 
suitable O 
substrate O 
for O 
L O 
. O 
casei O 
cultivation O 
and O 
for O 
the O 
development O 
of O 
an O 
alternative O 
non-dairy O 
probiotic O 
beverage O 
. O 

- O 
, O 
tobacco O 
particulate O 
matter- O 
and O 
methamphetamine B-TRIVIAL 
-produced O 
locomotor O 
sensitisation O 
in O 
rats O 
. O 

: O 
Repeated O 
nicotine B-TRIVIAL 
exposure O 
produces O 
a O 
weak O 
and O 
transient O 
sensitised O 
locomotor O 
response O 
in O 
rats O 
. O 
Since O 
tobacco O 
smoke O 
contains O 
thousands O 
of O 
non- O 
nicotine B-TRIVIAL 
chemical O 
constituents O 
, O 
these O 
could O 
alter O 
the O 
sensitised O 
response O 
. O 
OBJECTIVES O 
: O 
This O 
study O 
aims O 
to O 
compare O 
the O 
magnitude O 
, O 
persistence O 
and O 
spatial O 
distribution O 
of O 
locomotor O 
sensitisation O 
produced O 
by O 
repeated O 
doses O 
of O 
nicotine B-TRIVIAL 
, O 
aqueous O 
tobacco O 
particulate O 
matter O 
( O 
TPM O 
) O 
and O 
a O 
positive O 
methamphetamine B-TRIVIAL 
control O 
. O 
METHODS O 
: O 
Male O 
Sprague-Dawley O 
rats O 
received O 
five O 
nicotine B-TRIVIAL 
( O 
0 O 
, O 
0.2 O 
or O 
0.4 O 
mg O 
/ O 
kg O 
) O 
, O 
TPM O 
( O 
containing O 
0.2 O 
or O 
0.4 O 
mg O 
/ O 
kg O 
nicotine B-TRIVIAL 
) O 
or O 
methamphetamine B-TRIVIAL 
( O 
0.5 O 
mg O 
/ O 
kg O 
) O 
injections O 
every O 
second O 
day O 
, O 
followed O 
by O 
a O 
4-day O 
withdrawal O 
before O 
the O 
first O 
challenge O 
( O 
Challenge O 
1 O 
, O 
C1 O 
) O 
. O 
The O 
animals O 
were O 
re O 
- O 
challenged O 
again O 
at O 
15 O 
days O 
post O 
C1 O 
to O 
test O 
for O 
the O 
persistence O 
of O 
sensitisation O 
( O 
Challenge O 
2 O 
, O 
C2 O 
) O 
. O 
RESULTS O 
: O 
There O 
were O 
no O 
major O 
differences O 
in O 
sensitisation O 
profile O 
between O 
nicotine B-TRIVIAL 
and O 
TPM O 
. O 
At O 
the O 
lowest O 
0.2 O 
mg O 
/ O 
kg O 
nicotine B-TRIVIAL 
/ O 
TPM O 
dose O 
, O 
however O 
, O 
small O 
differences O 
emerged O 
on O 
select O 
test O 
days O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
indicated O 
that O 
the O 
non-nicotinic O 
agents O 
in O 
TPM O 
did O 
not O 
greatly O 
impact O 
the O 
nicotine B-TRIVIAL 
-produced O 
locomotor O 
- O 
sensitised O 
response O 
. O 
These O 
findings O 
might O 
suggest O 
that O 
the O 
differential O 
pharmacological O 
properties O 
of O 
TPM O 
do O 
not O 
have O 
major O 
clinical O 
significance O 
. O 
Alternatively O 
, O 
the O 
locomotor O 
model O 
might O 
not O 
expose O 
effects O 
of O 
non-nicotinic O 
constituents O 
, O 
and O 
furthermore O 
, O 
might O 
not O 
closely O 
relate O 
to O 
human O 
tobacco O 
dependence O 
. O 
Different O 
reward O 
- O 
related O 
behavioural O 
models O 
should O 
also O 
be O 
utilised O 
to O 
assess O 
potential O 
effects O 
of O 
non-nicotinic O 
constituents O 
before O 
a O 
role O 
in O 
dependence O 
is O 
discounted O 
. O 

and O 
pH-Responsive O 
Cysteamine B-TRIVIAL 
-Modified O 
Poly(aspartic B-FAMILY 
acid I-FAMILY 
) I-FAMILY 
Showing O 
a O 
Reversible O 
Sol-Gel O 
Transition O 
. O 

and O 
characterization O 
of O 
a O 
pH- O 
and O 
redox O 
- O 
sensitive O 
hydrogel O 
of O 
poly(aspartic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
are O 
reported O 
. O 
Reversible O 
gelation O 
and O 
dissolution O 
are O 
achieved O 
both O 
in O 
dimethylformamide B-SYSTEMATIC 
and O 
in O 
aqueous O 
medium O 
via O 
a O 
thiol B-SYSTEMATIC 
- I-SYSTEMATIC 
disulphide I-SYSTEMATIC 
interconversion O 
in O 
the O 
side O 
chain O 
of O 
the O 
polymers O 
. O 
Structural O 
changes O 
are O 
confirmed O 
by O 
Raman O 
microscopy O 
and O 
rheological O 
measurements O 
. O 
Injectable O 
aqueous O 
solutions O 
of O 
thiolated B-FAMILY 
poly(aspartic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
can O 
be O 
converted O 
into O 
mechanically O 
stable O 
gels O 
by O 
oxidation O 
, O 
which O 
can O 
be O 
useful O 
for O 
drug O 
encapsulation O 
and O 
targeted O 
delivery O 
. O 
Reduction O 
- O 
facilitated O 
release O 
of O 
an O 
entrapped O 
drug O 
from O 
disulphide B-SYSTEMATIC 
cross O 
- O 
linked O 
hydrogels O 
is O 
studied O 
. O 

B I-TRIVIAL 
from O 
Machilus O 
Thunbergii O 
targets O 
barrier O 
- O 
to O 
- O 
autointegration O 
factor O 
to O 
treat O 
cancer O 
. O 

specific O 
molecules O 
is O 
a O 
promising O 
cancer O 
treatment O 
because O 
certain O 
types O 
of O 
cancer O 
cells O 
are O 
dependent O 
on O 
specific O 
oncogenes O 
. O 
This O 
strategy O 
led O 
to O 
the O 
development O 
of O 
therapeutics O 
that O 
use O 
monoclonal O 
antibodies O 
or O 
small O 
- O 
molecule O 
inhibitors O 
. O 
However O 
, O 
the O 
continued O 
development O 
of O 
novel O 
molecular O 
targeting O 
inhibitors O 
is O 
required O 
to O 
target O 
the O 
various O 
oncogenes O 
associated O 
with O 
the O 
diverse O 
types O 
and O 
stages O 
of O 
cancer O 
. O 
Obtusilactone B-TRIVIAL 
B I-TRIVIAL 
is O 
a O 
butanolide B-SYSTEMATIC 
derivative O 
purified O 
from O 
Machilus O 
thunbergii O 
. O 
In O 
this O 
study O 
, O 
we O 
show O 
that O 
obtusilactone B-TRIVIAL 
B I-TRIVIAL 
functions O 
as O 
a O 
small O 
- O 
molecule O 
inhibitor O 
that O 
causes O 
abnormal O 
nuclear O 
envelope O 
dynamics O 
and O 
inhibits O 
growth O 
by O 
suppressing O 
vaccinia O 
- O 
related O 
kinase O 
1 O 
( O 
VRK1 O 
) O 
- O 
mediated O 
phosphorylation O 
of O 
barrier O 
- O 
to O 
- O 
autointegration O 
factor O 
( O 
BAF O 
) O 
. O 
BAF O 
is O 
important O 
in O 
maintaining O 
lamin O 
integrity O 
, O 
which O 
is O 
closely O 
associated O 
with O 
diseases O 
that O 
include O 
cancer O 
. O 
Specific O 
binding O 
of O 
obtusilactone B-TRIVIAL 
B I-TRIVIAL 
to O 
BAF O 
suppressed O 
VRK1 O 
- O 
mediated O 
BAF O 
phosphorylation O 
and O 
the O 
subsequent O 
dissociation O 
of O 
the O 
nuclear O 
envelope O 
from O 
DNA O 
that O 
allows O 
cells O 
to O 
progress O 
through O 
the O 
cell O 
cycle O 
. O 
Obtusilactone B-TRIVIAL 
B I-TRIVIAL 
potently O 
induced O 
tumor O 
cell O 
death O 
in O 
vitro O 
, O 
indicating O 
that O 
specific O 
targeting O 
of O 
BAF O 
to O 
block O 
cell O 
cycle O 
progression O 
can O 
be O 
an O 
effective O 
anticancer O 
strategy O 
. O 
Our O 
results O 
demonstrate O 
that O 
targeting O 
a O 
major O 
constituent O 
of O 
the O 
nuclear O 
envelope O 
may O 
be O 
a O 
novel O 
and O 
promising O 
alternative O 
approach O 
to O 
cancer O 
treatment O 
. O 

-induced O 
behavioral O 
deficits O 
precede O 
structural O 
neural O 
degeneration O 
. O 

-containing O 
fungicides O 
like O 
Mancozeb B-FAMILY 
have O 
been O 
associated O 
with O 
neurodegenerative O 
conditions O 
like O 
Parkinson's O 
disease O 
. O 
We O 
examined O 
the O 
behavioral O 
damage O 
and O 
differential O 
neuronal O 
vulnerability O 
resulting O 
from O 
Mancozeb B-FAMILY 
exposure O 
using O 
Caenorhabditis O 
elegans O 
, O 
an O 
important O 
mid O 
- O 
trophic O 
level O 
soil O 
organism O 
that O 
is O 
also O 
a O 
powerful O 
model O 
for O 
studying O 
mechanisms O 
of O 
environmental O 
pollutant O 
- O 
induced O 
neurodegenerative O 
disease O 
. O 
The O 
dopamine B-TRIVIAL 
-mediated O 
swim O 
to O 
crawl O 
locomotory O 
transition O 
behavior O 
is O 
exquisitely O 
vulnerable O 
to O 
Mancozeb B-FAMILY 
, O 
with O 
functional O 
impairment O 
preceding O 
markers O 
of O 
neuronal O 
structural O 
damage O 
. O 
The O 
damage O 
is O 
partially O 
rescued O 
in O 
mutants O 
lacking O 
the O 
divalent O 
metal O 
transporter O 
, O 
SMF-1 O 
, O 
demonstrating O 
that O 
some O 
, O 
but O 
not O 
all O 
, O 
of O 
the O 
damage O 
is O 
mediated O 
by O 
manganese B-SYSTEMATIC 
. O 
Increasing O 
concentrations O 
of O 
Mancozeb B-FAMILY 
recruit O 
additional O 
behavioral O 
dysfunction O 
, O 
notably O 
serotonin B-TRIVIAL 
-mediated O 
egg O 
- O 
laying O 
behavior O 
, O 
but O 
without O 
evident O 
serotonergic O 
neuronal O 
structural O 
damage O 
. O 
Thus O 
, O 
measurements O 
of O 
behavioral O 
dysfunction O 
are O 
a O 
sensitive O 
early O 
marker O 
of O 
fungicide O 
toxicity O 
that O 
could O 
be O 
exploited O 
to O 
examine O 
further O 
mechanisms O 
of O 
neuron O 
damage O 
and O 
possible O 
therapeutic O 
interventions O 
. O 
These O 
results O 
also O 
provide O 
important O 
insight O 
into O 
the O 
consequences O 
of O 
fungicide O 
use O 
on O 
the O 
ecological O 
behavior O 
of O 
nematodes O 
. O 

nitrogen B-SYSTEMATIC 
vs O 
. O 
amino-acid B-FAMILY 
profile O 
as O 
indicator O 
of O 
protein O 
content O 
of O 
beef O 
. O 

most O 
cited O 
food O 
composition O 
studies O 
and O 
tables O 
, O 
the O 
proximate O 
system O 
measures O 
protein O 
as O 
total O 
nitrogen B-SYSTEMATIC 
( O 
N B-FORMULA 
) O 
( O 
determined O 
by O 
Kjeldahl O 
or O 
Dumas O 
method O 
) O 
multiplied O 
by O 
a O 
specific O 
factor O 
. O 
A O 
factor O 
of O 
6.25 O 
is O 
used O 
for O 
determining O 
total O 
protein O 
from O 
total O 
N B-FORMULA 
( O 
Jones O 
, O 
Munsey O 
, O 
& O 
Walker O 
, O 
1942 O 
) O 
. O 
Although O 
more O 
expensive O 
, O 
it O 
is O 
considered O 
more O 
accurate O 
to O 
base O 
protein O 
content O 
of O 
foods O 
on O 
amino B-FAMILY 
acid I-FAMILY 
data O 
( O 
Greenfield O 
& O 
Southgate O 
, O 
2003 O 
) O 
. O 
A O 
study O 
on O 
the O 
nutrient O 
composition O 
of O 
beef O 
analysed O 
the O 
full O 
amino-acid B-FAMILY 
profile O 
of O 
fifteen O 
retail O 
cuts O 
from O 
three O 
age O 
groups O 
and O 
six O 
fat O 
codes O 
, O 
as O 
well O 
as O 
determined O 
total O 
nitrogen B-SYSTEMATIC 
content O 
to O 
determine O 
proximate O 
protein O 
composition O 
. O 
For O 
all O 
cuts O 
, O 
the O 
correlation O 
coefficient O 
of O 
total O 
amino B-FAMILY 
acids I-FAMILY 
to O 
protein O 
( O 
N×6.25 O 
) O 
was O 
0.635 O 
. O 
This O 
indicates O 
a O 
poor O 
correlation O 
for O 
predicting O 
actual O 
protein O 
content O 
( O 
as O 
determined O 
by O 
total O 
amino B-FAMILY 
acid I-FAMILY 
count O 
) O 
, O 
based O 
on O 
the O 
nitrogen B-SYSTEMATIC 
factor O 
of O 
6.25 O 
. O 
On O 
average O 
, O 
the O 
sum O 
of O 
amino B-FAMILY 
acids I-FAMILY 
per O 
cut O 
amounted O 
to O 
91% O 
of O 
total O 
determined O 
protein O 
( O 
N×6.25 O 
) O 
for O 
the O 
same O 
cut O 
. O 

studies O 
of O 
electrochemically O 
controlled O 
surface O 
oxidation O 
and O 
hydrophobicity O 
of O 
natural O 
enargite B-TRIVIAL 
. O 

surface O 
oxidation O 
and O 
hydrophobicity O 
of O 
natural O 
enargite B-TRIVIAL 
( O 
Cu(3)AsS(4) B-FORMULA 
) O 
and O 
the O 
formation O 
of O 
oxidation O 
species O 
at O 
the O 
mineral O 
surface O 
have O 
been O 
examined O 
by O 
a O 
novel O 
experimental O 
approach O 
that O 
combines O 
electrochemical O 
techniques O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
. O 
This O 
approach O 
allows O 
for O 
in O 
- O 
situ O 
, O 
synchronized O 
electrochemical O 
control O 
and O 
examination O 
of O 
the O 
oxidative O 
surface O 
morphology O 
of O 
enargite B-TRIVIAL 
. O 
Combined O 
with O 
ex O 
- O 
situ O 
cryo O 
X-ray O 
photoelectron O 
spectroscopy O 
surface O 
analysis O 
, O 
the O 
surface O 
speciation O 
of O 
enargite B-TRIVIAL 
surface O 
oxidation O 
has O 
been O 
obtained O 
, O 
comparing O 
the O 
newly O 
fractured O 
natural O 
enargite B-TRIVIAL 
surface O 
with O 
those O 
that O 
have O 
been O 
electrochemically O 
oxidized O 
at O 
pHs O 
4 O 
and O 
10 O 
. O 
At O 
pH O 
4 O 
, O 
surface O 
layer O 
formations O 
consisting O 
of O 
metal O 
- O 
deficient O 
sulfide B-SYSTEMATIC 
and O 
elemental O 
sulfur B-SYSTEMATIC 
were O 
identified O 
, O 
associated O 
with O 
a O 
limited O 
increase O 
in O 
root O 
- O 
mean O 
- O 
square O 
( O 
rms O 
) O 
roughness O 
( O 
1.228 O 
to O 
3.143 O 
nm O 
) O 
and O 
apparent O 
heterogeneous O 
distribution O 
of O 
surface O 
products O 
as O 
demonstrated O 
by O 
AFM O 
imaging O 
. O 
A O 
mechanism O 
of O 
initial O 
rapid O 
dissolution O 
of O 
Cu B-FORMULA 
followed O 
by O 
diffusion O 
- O 
limited O 
surface O 
layer O 
deposition O 
was O 
identified O 
. O 
At O 
pH O 
10 O 
, O 
a O 
similar O 
mechanism O 
was O 
identified O 
although O 
the O 
differences O 
between O 
the O 
initial O 
and O 
diffusion O 
- O 
limited O 
phases O 
were O 
less O 
definitive O 
. O 
Surface O 
species O 
were O 
identified O 
as O 
copper B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
. O 
A O 
significant O 
increase O 
in O 
surface O 
roughness O 
was O 
found O 
as O 
rms O 
roughness O 
increased O 
from O 
0.795 O 
to O 
9.723 O 
nm O 
. O 
Dynamic O 
( O 
receding O 
) O 
contact O 
angle O 
measurements O 
were O 
obtained O 
by O 
a O 
droplet O 
evaporation O 
method O 
. O 
No O 
significant O 
difference O 
in O 
the O 
contact O 
angle O 
on O 
a O 
surface O 
oxidized O 
at O 
pH O 
10 O 
and O 
the O 
freshly O 
polished O 
surface O 
was O 
found O 
. O 
A O 
significant O 
difference O 
was O 
found O 
between O 
the O 
polished O 
surface O 
and O 
that O 
oxidized O 
at O 
pH O 
4 O 
, O 
with O 
an O 
increase O 
in O 
contact O 
angle O 
of O 
about O 
13° O 
( O 
46° O 
to O 
59° O 
) O 
after O 
oxidation O 
. O 
Competing O 
effects O 
of O 
hydrophilic O 
( O 
copper B-MULTIPLE 
oxides I-MULTIPLE 
and I-MULTIPLE 
hydroxides I-MULTIPLE 
) O 
and O 
hydrophobic O 
( O 
elemental O 
sulfur B-SYSTEMATIC 
) O 
species O 
on O 
the O 
mineral O 
surface O 
under O 
oxidizing O 
conditions O 
at O 
pH O 
4 O 
and O 
the O 
change O 
in O 
surface O 
roughness O 
at O 
pH O 
10 O 
may O 
contribute O 
to O 
the O 
observed O 
effects O 
of O 
electrochemically O 
controlled O 
oxidation O 
on O 
enargite B-TRIVIAL 
hydrophobicity O 
. O 

positively O 
associated O 
with O 
both O 
male O 
mating O 
effort O 
and O 
paternal O 
behavior O 
in O 
savanna O 
baboons O 
( O 
Papio O 
cynocephalus O 
) O 
. O 

( O 
T O 
) O 
is O 
often O 
positively O 
associated O 
with O 
male O 
sexual O 
behavior O 
and O 
negatively O 
associated O 
with O 
paternal O 
care O 
. O 
These O 
associations O 
have O 
primarily O 
been O 
demonstrated O 
in O 
species O 
where O 
investment O 
in O 
paternal O 
care O 
begins O 
well O 
after O 
mating O 
activity O 
is O 
complete O 
, O 
when O 
offspring O 
are O 
hatched O 
or O 
born O 
. O 
Different O 
patterns O 
may O 
emerge O 
in O 
studies O 
of O 
species O 
where O 
investment O 
in O 
mating O 
and O 
paternal O 
care O 
overlap O 
temporally O 
, O 
for O 
instance O 
in O 
non-seasonal O 
breeders O 
in O 
which O 
males O 
mate O 
with O 
multiple O 
females O 
sequentially O 
and O 
may O 
simultaneously O 
have O 
multiple O 
offspring O 
of O 
different O 
ages O 
. O 
In O 
a O 
9-year O 
data O 
set O 
on O 
levels O 
of O 
T O 
in O 
male O 
baboons O 
, O 
fecal O 
concentrations O 
of O 
T O 
( O 
fT O 
) O 
were O 
positively O 
associated O 
with O 
both O 
mate O 
guarding O 
( O 
" O 
consortship O 
" O 
) O 
- O 
a O 
measure O 
of O 
current O 
reproductive O 
activity O 
- O 
and O 
with O 
the O 
number O 
of O 
immature O 
offspring O 
a O 
male O 
had O 
in O 
his O 
social O 
group O 
- O 
a O 
measure O 
of O 
past O 
reproductive O 
activity O 
and O 
an O 
indicator O 
of O 
likely O 
paternal O 
behavior O 
. O 
To O 
further O 
examine O 
the O 
relationship O 
between O 
T O 
and O 
potential O 
paternal O 
behavior O 
, O 
we O 
next O 
drew O 
on O 
an O 
intensive O 
8-month O 
study O 
of O 
male O 
behavior O 
, O 
and O 
found O 
that O 
fathers O 
were O 
more O 
likely O 
to O 
be O 
in O 
close O 
proximity O 
to O 
their O 
offspring O 
than O 
expected O 
by O 
chance O 
. O 
Because O 
male O 
baboons O 
are O 
known O 
to O 
provide O 
paternal O 
care O 
, O 
and O 
because O 
time O 
in O 
proximity O 
to O 
offspring O 
would O 
facilitate O 
such O 
care O 
, O 
this O 
suggests O 
that O 
T O 
concentrations O 
in O 
wild O 
male O 
baboons O 
may O 
be O 
associated O 
with O 
both O 
current O 
reproductive O 
activity O 
and O 
with O 
current O 
paternal O 
behavior O 
. O 
These O 
results O 
are O 
consistent O 
with O 
the O 
predicted O 
positive O 
association O 
between O 
T O 
and O 
mating O 
effort O 
but O 
not O 
with O 
a O 
negative O 
association O 
between O 
T O 
and O 
paternal O 
care O 
; O 
in O 
male O 
baboons O 
, O 
high O 
levels O 
of O 
T O 
occur O 
in O 
males O 
that O 
are O 
differentially O 
associating O 
with O 
their O 
offspring O 
. O 

in O 
prescribing O 
patterns O 
and O 
therapeutic O 
drug O 
monitoring O 
of O 
intravenous O 
busulfan B-TRIVIAL 
in O 
pediatric O 
hematopoietic O 
cell O 
transplant O 
recipients O 
. O 

intravenous O 
(IV) O 
busulfan B-TRIVIAL 
doses O 
in O 
children O 
using O 
therapeutic O 
drug O 
monitoring O 
( O 
TDM O 
) O 
is O 
an O 
integral O 
component O 
of O 
hematopoietic O 
cell O 
transplant O 
. O 
The O 
authors O 
sought O 
to O 
characterize O 
initial O 
dosing O 
and O 
TDM O 
of O 
IV O 
busulfan B-TRIVIAL 
, O 
along O 
with O 
factors O 
associated O 
with O 
busulfan B-TRIVIAL 
clearance O 
, O 
in O 
729 O 
children O 
who O 
underwent O 
busulfan B-TRIVIAL 
TDM O 
from O 
December O 
2005 O 
to O 
December O 
2008 O 
. O 
The O 
initial O 
IV O 
busulfan B-TRIVIAL 
dose O 
in O 
children O 
weighing O 
≤ O 
12 O 
kg O 
ranged O 
4.8-fold O 
, O 
with O 
only O 
19% O 
prescribed O 
the O 
package O 
insert O 
dose O 
of O 
1.1 O 
mg O 
/ O 
kg O 
. O 
In O 
those O 
children O 
weighing O 
> O 
12 O 
kg O 
, O 
the O 
initial O 
dose O 
ranged O 
5.4-fold O 
, O 
and O 
79% O 
were O 
prescribed O 
the O 
package O 
insert O 
dose O 
. O 
The O 
initial O 
busulfan B-TRIVIAL 
dose O 
achieved O 
the O 
target O 
exposure O 
in O 
only O 
24.3% O 
of O 
children O 
. O 
A O 
wide O 
range O 
of O 
busulfan B-TRIVIAL 
exposures O 
were O 
targeted O 
for O 
children O 
with O 
the O 
same O 
disease O 
( O 
eg O 
, O 
39 O 
target O 
busulfan B-TRIVIAL 
exposures O 
for O 
the O 
264 O 
children O 
diagnosed O 
with O 
acute O 
myeloid O 
leukemia O 
) O 
. O 
Considerable O 
heterogeneity O 
exists O 
regarding O 
when O 
TDM O 
is O 
conducted O 
and O 
the O 
number O 
of O 
pharmacokinetic O 
samples O 
obtained O 
. O 
Busulfan B-TRIVIAL 
clearance O 
varied O 
by O 
age O 
and O 
dosing O 
frequency O 
but O 
not O 
by O 
underlying O 
disease O 
. O 
The O 
authors- O 
group O 
is O 
currently O 
evaluating O 
how O 
using O 
population O 
pharmacokinetics O 
to O 
optimize O 
initial O 
busulfan B-TRIVIAL 
dose O 
and O 
TDM O 
( O 
eg O 
, O 
limited O 
sampling O 
schedule O 
in O 
conjunction O 
with O 
maximum O 
a O 
posteriori O 
Bayesian O 
estimation O 
) O 
may O 
affect O 
clinical O 
outcomes O 
in O 
children O 
. O 

in O 
vitro O 
model O 
of O 
human O 
acute O 
ethanol B-SYSTEMATIC 
exposure O 
that O 
incorporates O 
CXCR3- O 
and O 
CXCR4-dependent O 
recruitment O 
of O 
immune O 
cells O 
. O 

liver O 
disease O 
( O 
ALD O 
) O 
is O 
one O 
of O 
the O 
commonest O 
causes O 
of O 
cirrhosis O 
and O 
liver O 
failure O 
in O 
the O 
developed O 
world O 
. O 
Hepatic O 
inflammation O 
is O 
the O 
critical O 
stage O 
in O 
progression O 
of O 
both O 
ALD O 
and O 
non-ALD O 
, O 
but O 
it O 
remains O 
difficult O 
to O 
study O 
the O 
underlying O 
mechanisms O 
in O 
a O 
human O 
system O 
, O 
and O 
current O 
animal O 
models O 
do O 
not O 
fully O 
recapitulate O 
human O 
liver O 
disease O 
. O 
We O 
developed O 
a O 
human O 
tissue O 
- O 
based O 
system O 
to O 
study O 
lymphocyte O 
recruitment O 
in O 
response O 
to O 
ethanol B-SYSTEMATIC 
challenge O 
. O 
Precision O 
- O 
cut O 
liver O 
slices O 
( O 
PCLS O 
) O 
from O 
human O 
livers O 
were O 
incubated O 
in O 
culture O 
, O 
and O 
hepatic O 
function O 
was O 
determined O 
by O 
albumin O 
production O 
, O 
3-(4,5-dimethylthiazol)-2,5-diphenyl B-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
assay O 
, O 
glucose B-TRIVIAL 
uptake O 
responses O 
, O 
and O 
morphometric O 
assessment O 
. O 
Responses O 
of O 
tissue O 
and O 
lymphocytes O 
to O 
ethanol B-SYSTEMATIC 
exposure O 
were O 
determined O 
by O 
PCR O 
, O 
flow O 
cytometry O 
, O 
histology O 
, O 
and O 
lymphocyte O 
infiltration O 
assays O 
. O 
Human O 
PCLS O 
demonstrated O 
appropriate O 
upregulation O 
of O 
CYP2E1 O 
, O 
ADH1α O 
, O 
and O 
ADH3 O 
in O 
response O 
to O 
ethanol B-SYSTEMATIC 
treatment O 
. O 
Ethanol B-SYSTEMATIC 
also O 
induced O 
expression O 
of O 
endothelial O 
VCAM-1 O 
and O 
ICAM-1 O 
, O 
production O 
of O 
sICAM-1 O 
and O 
CXCL8 O 
, O 
and O 
the O 
chemokine O 
receptors O 
CXCR3 O 
and O 
CXCR4 O 
on O 
CD4 O 
and O 
CD8 O 
lymphocytes O 
. O 
CXCR3- O 
and O 
CXCR4-dependent O 
migration O 
of O 
lymphocytes O 
into O 
the O 
tissue O 
increased O 
significantly O 
in O 
response O 
to O 
treatment O 
with O 
ethanol B-SYSTEMATIC 
. O 
We O 
have O 
demonstrated O 
that O 
ethanol B-SYSTEMATIC 
increases O 
chemokine O 
receptor O 
expression O 
and O 
lymphocyte O 
recruitment O 
into O 
human O 
liver O 
tissue O 
, O 
suggesting O 
that O 
it O 
may O 
operate O 
directly O 
to O 
promote O 
hepatitis O 
in O 
ALD O 
. O 
The O 
physiological O 
and O 
pathophysiological O 
responses O 
of O 
the O 
PCLS O 
to O 
ethanol B-SYSTEMATIC 
in O 
vitro O 
highlight O 
the O 
potential O 
of O 
this O 
assay O 
for O 
dissecting O 
the O 
molecular O 
mechanisms O 
underlying O 
human O 
liver O 
inflammation O 
and O 
as O 
a O 
screening O 
tool O 
for O 
novel O 
therapeutics O 
. O 

assisted O 
nano O 
( O 
ZnO B-FORMULA 
- O 
TiO2 B-FORMULA 
) O 
catalyzed O 
synthesis O 
of O 
some O 
new O 
4,5,6,7-tetrahydro-6-((5-substituted-1,3,4-oxadiazol-2-yl)methyl)thieno[2,3-c]pyridine B-FAMILY 
as O 
antimicrobial O 
agents O 
. O 

nano O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
[ O 
nano O 
( O 
ZnO B-FORMULA 
- O 
TiO(2) B-FORMULA 
) O 
] O 
has O 
been O 
reported O 
first O 
time O 
for O 
the O 
synthesis O 
of O 
novel O 
series O 
of O 
4,5,6,7-tetrahydro-6-((5-substituted-1,3,4-oxadiazol-2-yl)methyl)thieno[2,3-c]pyridine B-FAMILY 
. O 
All O 
the O 
synthesized O 
compounds O 
( O 
7a-7m O 
) O 
are O 
novel O 
and O 
were O 
screened O 
for O 
their O 
antimicrobial O 
activity O 
against O 
four O 
different O 
strains O 
like O 
Escherichia O 
coli O 
, O 
Pseudomonas O 
aeruginosa O 
, O 
Staphylococcus O 
aureus O 
and O 
Bacillus O 
subtilis O 
and O 
antifungal O 
activity O 
was O 
determined O 
against O 
two O 
strains O 
Candida O 
albicans O 
and O 
Aspergillus O 
niger O 
. O 
SAR O 
for O 
the O 
newly O 
synthesised O 
derivatives O 
has O 
been O 
developed O 
by O 
comparing O 
their O 
MIC O 
values O 
with O 
ampicillin B-TRIVIAL 
, O 
ciprofloxacin B-TRIVIAL 
and O 
miconazole B-TRIVIAL 
for O 
antibacterial O 
and O 
antifungal O 
activities O 
, O 
respectively O 
. O 
Among O 
the O 
synthesized O 
compounds O 
, O 
2,6 B-SYSTEMATIC 
dichlorophenyl I-SYSTEMATIC 
analogue O 
( O 
7f O 
) O 
, O 
4 B-SYSTEMATIC 
fluorophenyl I-SYSTEMATIC 
analogue O 
( O 
7k O 
) O 
and O 
2,6 B-SYSTEMATIC 
dichlorophenyl I-SYSTEMATIC 
analogue O 
( O 
7l O 
) O 
shows O 
promising O 
antibacterial O 
as O 
well O 
as O 
antifungal O 
activity O 
whereas O 
thiophene B-SYSTEMATIC 
substituted O 
compound O 
( O 
7j O 
) O 
shows O 
promising O 
antibacterial O 
activity O 
. O 

Hedgehog O 
( O 
Hh O 
) O 
pathway O 
is O 
a O 
developmental O 
signaling O 
pathway O 
involved O 
in O 
numerous O 
developmental O 
processes O 
, O 
including O 
determination O 
of O 
cell O 
fate O 
, O 
patterning O 
, O 
proliferation O 
, O 
survival O 
, O 
and O 
differentiation O 
. O 
While O 
this O 
pathway O 
is O 
silenced O 
in O 
most O 
adult O 
tissues O 
, O 
aberrant O 
activation O 
of O 
it O 
has O 
been O 
documented O 
in O 
a O 
variety O 
of O 
malignancies O 
. O 
In O 
cancers O 
such O 
as O 
basal O 
cell O 
carcinoma O 
( O 
BCC O 
) O 
, O 
ligand O 
- O 
independent O 
mechanisms O 
lead O 
to O 
constitutive O 
Hh O 
pathway O 
activation O 
through O 
mutations O 
in O 
components O 
of O 
the O 
pathway O 
, O 
including O 
patched-1 O 
( O 
PTCH1 O 
) O 
or O 
smoothened O 
( O 
SMO O 
) O 
. O 
On O 
the O 
contrary O 
, O 
numerous O 
other O 
solid O 
and O 
hematologic O 
tumors O 
have O 
been O 
shown O 
to O 
harbor O 
ligand O 
- O 
dependent O 
activation O 
of O 
the O 
Hh O 
pathway O 
by O 
autocrine O 
or O 
paracrine O 
mechanisms O 
. O 
Given O 
that O 
aberrant O 
Hh O 
pathway O 
signaling O 
has O 
been O 
seen O 
in O 
a O 
number O 
of O 
malignancies O 
, O 
this O 
pathway O 
has O 
been O 
an O 
attractive O 
target O 
for O 
drug O 
development O 
. O 
While O 
the O 
best O 
- O 
characterized O 
approach O 
is O 
to O 
target O 
the O 
SMO O 
receptor O 
, O 
other O 
rational O 
approaches O 
for O 
inhibiting O 
the O 
Hh O 
pathway O 
include O 
inhibiting O 
downstream O 
components O 
or O 
directly O 
binding O 
Hh O 
ligands O 
. O 
In O 
January O 
of O 
2012 O 
, O 
vismodegib B-TRIVIAL 
, O 
a O 
SMO O 
antagonist O 
, O 
became O 
the O 
first O 
agent O 
to O 
target O 
the O 
Hh O 
pathway O 
to O 
receive O 
approval O 
by O 
the O 
United O 
States O 
Food O 
and O 
Drug O 
Administration O 
( O 
FDA O 
) O 
after O 
this O 
agent O 
showed O 
remarkable O 
activity O 
in O 
phase O 
I O 
and O 
II O 
trials O 
for O 
the O 
treatment O 
of O 
BCC O 
. O 
Despite O 
promising O 
preclinical O 
studies O 
with O 
Hh O 
pathway O 
inhibitors O 
in O 
other O 
malignancies O 
that O 
have O 
suggested O 
a O 
potential O 
role O 
for O 
these O 
agents O 
, O 
attempts O 
to O 
translate O 
this O 
potential O 
to O 
clinical O 
benefit O 
has O 
been O 
disappointing O 
. O 
Future O 
efforts O 
will O 
require O 
further O 
careful O 
interpretation O 
and O 
analysis O 
to O 
determine O 
the O 
potential O 
determinants O 
and O 
predictors O 
of O 
efficacy O 
. O 
Currently O 
, O 
several O 
phase O 
I O 
and O 
II O 
trials O 
evaluating O 
Hh O 
inhibitors O 
in O 
a O 
variety O 
of O 
tumor O 
settings O 
are O 
underway O 
. O 

: O 
efficacy O 
against O 
oral O 
squamous O 
cell O 
carcinoma O 
. O 

medicinal O 
chemistry O 
, O 
one O 
of O 
the O 
most O 
studied O 
molecules O 
in O 
recent O 
history O 
is O 
taxol B-TRIVIAL 
. O 
Taxol B-TRIVIAL 
is O 
a O 
versatile O 
natural O 
product O 
that O 
is O 
used O 
in O 
various O 
cancer O 
treatment O 
regimens O 
. O 
It O 
is O 
administered O 
to O 
patients O 
with O 
breast O 
, O 
lung O 
, O 
and O 
ovarian O 
cancers O 
, O 
and O 
is O 
currently O 
being O 
studied O 
for O 
the O 
treatment O 
of O 
squamous O 
cell O 
carcinoma O 
of O 
the O 
oral O 
cavity O 
and O 
tongue O 
. O 
Taxol B-TRIVIAL 
has O 
been O 
tested O 
in O 
a O 
number O 
of O 
research O 
and O 
clinical O 
phase O 
trials O 
to O 
determine O 
feasibility O 
, O 
toxicity O 
, O 
and O 
cytotoxicity O 
against O 
oral O 
squamous O 
cell O 
carcinoma O 
as O 
a O 
single O 
drug O 
regimen O 
and O 
as O 
a O 
contributing O 
drug O 
component O 
in O 
treatment O 
plans O 
. O 
This O 
paper O 
reviews O 
over O 
forty O 
articles O 
that O 
examine O 
cell O 
lines O 
, O 
murine O 
models O 
, O 
and O 
human O 
results O 
for O 
the O 
response O 
of O 
taxol B-TRIVIAL 
against O 
squamous O 
cell O 
carcinoma O 
( O 
SCC O 
) O 
of O 
the O 
oral O 
cavity O 
and O 
the O 
tongue O 
. O 

belonging O 
to O 
the O 
DinB O 
class O 
of O 
the O 
Y-family O 
translesion O 
synthesis O 
DNA O 
polymerases O 
have O 
a O 
preference O 
for O 
accurately O 
and O 
efficiently O 
bypassing O 
damaged O 
guanosines B-FAMILY 
. O 
These O 
DinB O 
polymerases O 
also O 
generate O 
single O 
- O 
base O 
( O 
-1 O 
) O 
deletions O 
at O 
high O 
frequencies O 
with O 
most O 
occurring O 
on O 
repetitive O 
' O 
deletion O 
hotspot O 
' O 
sequences O 
. O 
Human O 
DNA O 
polymerase O 
kappa O 
( O 
hPolκ O 
) O 
, O 
the O 
eukaryotic O 
DinB O 
homologue O 
, O 
displays O 
an O 
unusual O 
efficiency O 
for O 
to O 
extend O 
from O 
mispaired O 
primer O 
termini O 
, O 
either O 
by O 
extending O 
directly O 
from O 
the O 
mispair O 
or O 
by O 
primer O 
- O 
template O 
misalignment O 
. O 
This O 
latter O 
property O 
explains O 
how O 
hPolκ O 
creates O 
single O 
- O 
base O 
deletions O 
in O 
non-repetitive O 
sequences O 
, O 
but O 
does O 
not O 
address O 
how O 
deletions O 
occur O 
in O 
repetitive O 
deletion O 
hotspots O 
. O 
Here O 
, O 
we O 
show O 
that O 
hPolκ O 
uses O 
a O 
classical O 
Streisinger O 
template O 
- O 
slippage O 
mechanism O 
to O 
generate O 
-1 O 
deletions O 
in O 
repetitive O 
sequences O 
, O 
as O 
do O 
the O 
bacterial O 
and O 
archaeal O 
homologues O 
. O 
After O 
the O 
first O 
nucleotide B-FAMILY 
is O 
added O 
by O 
template O 
slippage O 
, O 
however O 
, O 
hPolκ O 
can O 
efficiently O 
realign O 
the O 
primer O 
- O 
template O 
duplex O 
before O 
continuing O 
DNA O 
synthesis O 
. O 
Strand O 
realignment O 
results O 
in O 
a O 
base O 
- O 
substitution O 
mutation O 
, O 
minimizing O 
generation O 
of O 
more O 
deleterious O 
frameshift O 
mutations O 
. O 
On O 
non-repetitive O 
sequences O 
, O 
we O 
find O 
that O 
nucleotide B-FAMILY 
misincorporation O 
is O 
slower O 
if O 
the O 
incoming O 
nucleotide B-FAMILY 
can O 
correctly O 
basepair O 
with O 
the O 
nucleotide B-FAMILY 
immediately O 
5 O 
' O 
to O 
the O 
templating O 
base O 
, O 
thereby O 
competing O 
against O 
the O 
mispairing O 
with O 
the O 
templating O 
base O 
. O 

affecting O 
silver B-SYSTEMATIC 
antimicrobial O 
efficacy O 
on O 
Listeria O 
monocytogenes O 
and O 
Salmonella O 
enterica O 
. O 

silver B-SYSTEMATIC 
is O 
being O 
extensively O 
used O 
in O 
food O 
or O 
other O 
applications O 
as O 
the O 
key O 
component O 
to O 
control O 
microbial O 
proliferation O 
, O 
many O 
factors O 
affecting O 
its O 
real O 
potential O 
are O 
still O 
unknown O 
. O 
In O 
the O 
present O 
work O 
, O 
the O 
presence O 
of O 
specific O 
ligands O 
or O 
the O 
contents O 
in O 
organic O 
matter O 
was O 
correlated O 
with O 
silver B-SYSTEMATIC 
speciation O 
and O 
its O 
antibacterial O 
performance O 
. O 
Silver B-SYSTEMATIC 
was O 
found O 
to O 
be O 
only O 
active O 
in O 
form O 
of O 
free O 
silver B-SYSTEMATIC 
ions O 
( O 
FSI O 
) O 
. O 
The O 
presence O 
of O 
chloride B-SYSTEMATIC 
ions O 
produced O 
an O 
equilibrium O 
of O 
stable O 
silver B-SYSTEMATIC 
chloride I-SYSTEMATIC 
complexes O 
which O 
were O 
void O 
of O 
antimicrobial O 
efficacy O 
. O 
However O 
, O 
even O 
at O 
relatively O 
high O 
concentrations O 
of O 
chlorides B-FAMILY 
, O 
a O 
small O 
fraction O 
of O 
FSI O 
may O 
still O 
be O 
present O 
, O 
producing O 
a O 
bactericidal O 
effect O 
with O 
concentrations O 
at O 
the O 
nanomolar O 
level O 
under O 
optimum O 
conditions O 
. O 
Low O 
concentrations O 
of O 
thiol B-FAMILY 
groups O 
completely O 
inactivated O 
silver B-SYSTEMATIC 
, O 
while O 
methylsulphur B-SYSTEMATIC 
groups O 
only O 
affected O 
its O 
efficacy O 
at O 
very O 
high O 
concentrations O 
. O 
Antibacterial O 
performance O 
revealed O 
differences O 
of O 
about O 
1000-fold O 
between O 
results O 
for O 
environments O 
with O 
high O 
organic O 
matter O 
content O 
and O 
results O 
for O 
aqueous O 
salt O 
buffers O 
. O 
Thiol B-SYSTEMATIC 
groups O 
were O 
nonetheless O 
not O 
found O 
directly O 
associated O 
with O 
the O 
decrease O 
in O 
antimicrobial O 
performance O 
in O 
a O 
nutrient O 
rich O 
environment O 
. O 
These O 
results O 
point O 
out O 
the O 
complexity O 
of O 
the O 
antimicrobial O 
systems O 
based O 
on O 
silver B-SYSTEMATIC 
and O 
can O 
have O 
relevance O 
in O 
food O 
or O 
other O 
applications O 
of O 
silver B-SYSTEMATIC 
as O 
an O 
antimicrobial O 
. O 

Action O 
and O 
Glucose B-TRIVIAL 
Tolerance O 
in O 
Subjects O 
With O 
Remission O 
of O 
Type O 
2 O 
Diabetes O 
Mellitus O 
After O 
Gastric O 
Bypass O 
Surgery O 
. O 

like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
has O 
been O 
suggested O 
as O 
a O 
major O 
factor O 
for O 
the O 
improved O 
glucose B-TRIVIAL 
tolerance O 
ensuing O 
after O 
Roux-en-Y O 
Gastric O 
Bypass O 
( O 
RYGBP O 
) O 
surgery O 
. O 
We O 
examined O 
the O 
effect O 
of O 
blocking O 
endogenous O 
GLP-1 O 
action O 
on O 
glucose B-TRIVIAL 
tolerance O 
in O 
subjects O 
with O 
sustained O 
remission O 
of O 
type O 
2 O 
diabetes O 
( O 
T2DM O 
) O 
present O 
before O 
RYGBP.RESEARCH O 
DESIGN O 
AND O 
METHODSBlood O 
glucose B-TRIVIAL 
, O 
insulin O 
, O 
C- O 
peptide O 
, O 
glucagon O 
, O 
GLP-1 O 
, O 
and O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
peptide O 
levels O 
were O 
measured O 
after O 
a O 
meal O 
challenge O 
with O 
either O 
exendin-(9-39) O 
( O 
a O 
GLP-1r O 
antagonist O 
) O 
or O 
saline O 
infusion O 
in O 
eight O 
subjects O 
with O 
sustained O 
remission O 
of O 
T2DM O 
after O 
RYGBP O 
and O 
seven O 
healthy O 
controls.RESULTSInfusion O 
of O 
exendin-(9-39) O 
resulted O 
in O 
marginal O 
deterioration O 
of O 
the O 
2-h O 
plasma O 
glucose B-TRIVIAL 
after O 
meal O 
intake O 
in O 
RYGBP O 
subjects O 
( O 
saline O 
78.4 O 
± O 
15.1 O 
mg O 
/ O 
dL O 
compared O 
with O 
exendin-(9-39) O 
116.5 O 
± O 
22.3 O 
mg O 
/ O 
dL O 
; O 
P O 
< O 
0.001 O 
) O 
. O 
Furthermore O 
, O 
glucose B-TRIVIAL 
response O 
to O 
meal O 
intake O 
was O 
similarly O 
enlarged O 
in O 
the O 
two O 
study O 
groups O 
( O 
percent O 
change O 
in O 
the O 
area O 
under O 
the O 
curve O 
of O 
glucose B-TRIVIAL 
exendin-(9-39)-infusion O 
versus O 
saline O 
- O 
infusion O 
: O 
controls O 
10.84 O 
± O 
8.8% O 
versus O 
RYGBP O 
9.94 O 
± O 
8.4% O 
; O 
P O 
= O 
0.884 O 
) O 
. O 
In O 
the O 
RYGBP O 
group O 
, O 
the O 
blockade O 
of O 
the O 
enlarged O 
GLP-1 O 
response O 
to O 
meal O 
intake O 
resulted O 
in O 
reduced O 
insulin O 
( O 
P O 
= O 
0.001 O 
) O 
and O 
C- O 
peptide O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
but O 
no O 
change O 
in O 
glucagon O 
( O 
P O 
= O 
0.258 O 
) O 
responses.CONCLUSIONThe O 
limited O 
deterioration O 
of O 
glucose B-TRIVIAL 
tolerance O 
on O 
blockade O 
of O 
GLP-1 O 
action O 
in O 
our O 
study O 
suggests O 
the O 
resolution O 
of O 
T2DM O 
after O 
RYGBP O 
may O 
be O 
explained O 
by O 
mechanisms O 
beyond O 
enhancement O 
of O 
GLP-1 O 
action O 
. O 

dioxide I-SYSTEMATIC 
nanoparticles O 
increase O 
inflammatory O 
responses O 
in O 
vascular O 
endothelial O 
cells O 
. O 

is O 
a O 
chronic O 
inflammatory O 
disease O 
that O 
remains O 
the O 
leading O 
cause O 
of O 
death O 
in O 
the O 
United O 
States O 
. O 
Numerous O 
risk O 
factors O 
for O 
endothelial O 
cell O 
inflammation O 
and O 
the O 
development O 
of O 
atherosclerosis O 
have O 
been O 
identified O 
, O 
including O 
inhalation O 
of O 
ultrafine O 
particles O 
. O 
Recently O 
, O 
engineered O 
nanoparticles O 
( O 
NPs O 
) O 
such O 
as O 
titanium B-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
) O 
NPs O 
have O 
attracted O 
much O 
attention O 
due O 
to O 
their O 
wide O 
range O 
of O 
applications O 
. O 
However O 
, O 
there O 
are O 
also O 
great O 
concerns O 
surrounding O 
potential O 
adverse O 
health O 
effects O 
in O 
vascular O 
systems O 
. O 
Although O 
TiO2 B-FORMULA 
NPs O 
are O 
known O 
to O 
induce O 
oxidative O 
stress O 
and O 
inflammation O 
, O 
the O 
associated O 
signaling O 
pathways O 
have O 
not O 
been O 
well O 
studied O 
. O 
The O 
focus O 
of O 
this O 
work O 
, O 
therefore O 
, O 
deals O 
with O 
examination O 
of O 
the O 
cellular O 
signaling O 
pathways O 
responsible O 
for O 
TiO2 B-FORMULA 
NP-induced O 
endothelial O 
oxidative O 
stress O 
and O 
inflammation O 
. O 
In O 
this O 
study O 
, O 
primary O 
vascular O 
endothelial O 
cells O 
were O 
treated O 
with O 
TiO2 B-FORMULA 
NPs O 
for O 
2-16h O 
at O 
concentrations O 
of O 
0-50μg O 
/ O 
mL O 
. O 
TiO2 B-FORMULA 
NP O 
exposure O 
increased O 
cellular O 
oxidative O 
stress O 
and O 
DNA O 
binding O 
of O 
NF-κB O 
. O 
Further O 
, O 
phosphorylation O 
of O 
Akt O 
, O 
ERK O 
, O 
JNK O 
and O 
p38 O 
was O 
increased O 
in O 
cells O 
exposed O 
to O 
TiO2 B-FORMULA 
NPs O 
. O 
TiO2 B-FORMULA 
NPs O 
also O 
significantly O 
increased O 
induction O 
of O 
mRNA O 
and O 
protein O 
levels O 
of O 
vascular O 
cell O 
adhesion O 
molecule-1 O 
( O 
VCAM-1 O 
) O 
and O 
mRNA O 
levels O 
of O 
monocyte O 
chemoattractant O 
protein-1 O 
( O 
MCP-1 O 
) O 
. O 
Pretreatment O 
with O 
inhibitors O 
for O 
NF-κB O 
( O 
pyrrolidine B-SYSTEMATIC 
dithiocarbamate I-SYSTEMATIC 
) O 
, O 
oxidative O 
stress O 
( O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
and O 
apocynin B-TRIVIAL 
) O 
, O 
Akt O 
( O 
LY294002 B-IDENTIFIER 
) O 
, O 
ERK O 
( O 
PD98059 B-IDENTIFIER 
) O 
, O 
JNK O 
( O 
SP600125 B-IDENTIFIER 
) O 
and O 
p38 O 
( O 
SB203580 B-IDENTIFIER 
) O 
significantly O 
attenuated O 
TiO2 B-FORMULA 
NP-induced O 
MCP-1 O 
and O 
VCAM-1 O 
gene O 
expression O 
. O 
These O 
data O 
indicate O 
that O 
TiO2 B-FORMULA 
NPs O 
can O 
induce O 
endothelial O 
inflammatory O 
responses O 
via O 
redox O 
- O 
sensitive O 
cellular O 
signaling O 
pathways O 
. O 

chemopreventive O 
effect O 
of O 
β-cryptoxanthin B-TRIVIAL 
from O 
mandarin O 
on O 
human O 
stomach O 
cells O 
( O 
BGC-823 O 
) O 
. O 

, O 
a O 
provitaminic O 
carotenoid O 
, O 
present O 
in O 
many O 
fruits O 
and O 
vegetables O 
, O 
has O 
been O 
associated O 
with O 
decreased O 
risk O 
of O 
chronic O 
diseases O 
, O 
including O 
cancer O 
. O 
The O 
influence O 
of O 
β-cryptoxanthin B-TRIVIAL 
derived O 
from O 
mandarin O 
on O 
the O 
proliferation O 
of O 
the O 
stomach O 
tumor O 
cell O 
line O 
BGC-823 O 
was O 
tested O 
using O 
MTT B-ABBREVIATION 
and O 
cell O 
count O 
assay O 
at O 
72 O 
h O 
and O 
dose O 
- O 
response O 
( O 
from O 
0.01 O 
to O 
20 O 
μM O 
) O 
. O 
β-Cryptoxanthin B-TRIVIAL 
suppressed O 
the O 
cell O 
migration O 
by O 
the O 
scratch O 
assay O 
. O 
Furthermore O 
, O 
β-cryptoxanthin B-TRIVIAL 
induced O 
an O 
accumulation O 
of O 
cells O 
in O 
the O 
G1 O 
/ O 
G0 O 
phase O 
of O 
the O 
cell O 
cycle O 
( O 
as O 
detected O 
by O 
flow O 
cytometry O 
) O 
, O 
which O 
was O 
in O 
accordance O 
with O 
an O 
increased O 
expression O 
of O 
p21 O 
and O 
down O 
regulations O 
of O 
cyclin O 
D1 O 
and O 
cyclin O 
E O 
, O 
detected O 
by O 
Western O 
blot O 
analysis O 
, O 
and O 
β-cryptoxanthin B-TRIVIAL 
increased O 
the O 
mRNA O 
levels O 
of O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
receptor O 
β O 
( O 
RARβ O 
) O 
with O 
the O 
treatment O 
at O 
10 O 
μM O 
for O 
24 O 
h O 
. O 
Collectively O 
, O 
the O 
above O 
findings O 
suggest O 
that O 
β-cryptoxanthin B-TRIVIAL 
could O 
be O 
therapeutic O 
in O 
the O 
treatment O 
of O 
stomach O 
cancer O 
cell O 
in O 
vitro O 
. O 

the O 
role O 
of O 
the O 
ubiquitin O 
- O 
proteasome O 
system O 
( O 
UPS O 
) O 
in O 
cardiac O 
hypertrophy O 
induced O 
by O 
pressure O 
overload O 
has O 
been O 
consistently O 
studied O 
, O 
the O 
fundamental O 
importance O 
of O 
the O 
UPS O 
in O 
cardiac O 
fibrosis O 
has O 
received O 
much O 
less O 
attention O 
. O 
Our O 
previous O 
study O 
found O 
that O 
proteasome O 
inhibitor O 
( O 
MG132 B-IDENTIFIER 
) O 
treatment O 
attenuated O 
cardiac O 
fibrosis O 
and O 
heart O 
failure O 
during O 
the O 
early O 
and O 
middle O 
stages O 
of O 
pressure O 
overload O 
. O 
However O 
, O 
the O 
effects O 
of O 
this O 
inhibitor O 
on O 
late O 
- O 
stage O 
pressure O 
overload O 
hearts O 
remain O 
unclear O 
and O 
controversial O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
effects O 
and O 
possible O 
mechanisms O 
of O 
MG132 B-IDENTIFIER 
on O 
cardiac O 
fibrosis O 
and O 
dysfunction O 
during O 
the O 
late O 
stages O 
of O 
pressure O 
overload O 
. O 
Male O 
Sprague O 
Dawley O 
rats O 
with O 
abdominal O 
aortic O 
constriction O 
( O 
AAC O 
) O 
or O 
a O 
sham O 
operation O 
received O 
an O 
intraperitoneal O 
injection O 
of O 
MG132 B-IDENTIFIER 
( O 
0.1 O 
mg O 
kg⁻¹ O 
day⁻¹ O 
) O 
or O 
vehicle O 
for O 
16 O 
weeks O 
. O 
Left O 
ventricular O 
( O 
LV O 
) O 
function O 
, O 
collagen O 
deposition O 
and O 
Ang O 
II O 
levels O 
were O 
evaluated O 
at O 
study O 
termination O 
. O 
Ang O 
II-stimulated O 
adult O 
rat O 
cardiac O 
fibroblasts O 
were O 
utilized O 
to O 
examine O 
the O 
effects O 
of O 
MG132 B-IDENTIFIER 
on O 
collagen O 
synthesis O 
and O 
the O 
relationship O 
between O 
the O 
renin-angiotensin- O 
aldosterone B-TRIVIAL 
system O 
( O 
RAAS O 
) O 
and O 
the O 
UPS O 
. O 
MG132 B-IDENTIFIER 
treatment O 
attenuated O 
ventricular O 
dysfunction O 
by O 
suppressing O 
cardiac O 
fibrosis O 
rather O 
than O 
inhibiting O 
cardiac O 
hypertrophy O 
during O 
the O 
late O 
- O 
stages O 
of O 
pressure O 
overload O 
. O 
We O 
also O 
found O 
that O 
Ang O 
II O 
activates O 
UPS O 
in O 
the O 
heart O 
and O 
MG132 B-IDENTIFIER 
attenuates O 
Ang O 
II-induced O 
collagen O 
synthesis O 
via O 
suppression O 
of O 
the O 
NF-κB O 
/ O 
TGF-β O 
/ O 
Smad2 O 
signaling O 
pathways O 
. O 
Proteasome O 
inhibition O 
therefore O 
could O 
provide O 
a O 
new O 
promising O 
therapeutic O 
strategy O 
to O 
prevent O 
cardiac O 
fibrosis O 
and O 
progression O 
of O 
heart O 
failure O 
even O 
during O 
the O 
late O 
- O 
stages O 
of O 
pressure O 
overload O 
. O 

the O 
perturbation O 
of O 
cellular O 
cyclic B-TRIVIAL 
di-GMP I-TRIVIAL 
levels O 
in O 
bacterial O 
cells O 
. O 

di-GMP I-TRIVIAL 
( O 
c-di-GMP B-ABBREVIATION 
) O 
has O 
emerged O 
as O 
a O 
prominent O 
intracellular O 
messenger O 
that O 
coordinates O 
biofilm O 
formation O 
and O 
pathogenicity O 
in O 
many O 
bacterial O 
species O 
. O 
Developing O 
genetically O 
encoded O 
biosensors O 
for O 
c-di-GMP B-ABBREVIATION 
will O 
help O 
us O 
understand O 
how O 
bacterial O 
cells O 
respond O 
to O 
environmental O 
changes O 
via O 
the O 
modulation O 
of O 
cellular O 
c-di-GMP B-ABBREVIATION 
levels O 
. O 
Here O 
we O 
report O 
the O 
design O 
of O 
two O 
genetically O 
encoded O 
c-di-GMP B-ABBREVIATION 
fluorescent O 
biosensors O 
with O 
complementary O 
dynamic O 
ranges O 
. O 
By O 
using O 
the O 
biosensors O 
, O 
we O 
found O 
that O 
several O 
compounds O 
known O 
to O 
promote O 
biofilm O 
dispersal O 
trigger O 
a O 
decline O 
in O 
c-di-GMP B-ABBREVIATION 
levels O 
in O 
Escherichia O 
coli O 
cells O 
. O 
In O 
contrast O 
, O 
cellular O 
c-di-GMP B-ABBREVIATION 
levels O 
were O 
elevated O 
when O 
the O 
bacterial O 
cells O 
were O 
treated O 
with O 
subinhibitory O 
concentrations O 
of O 
biofilm O 
- O 
promoting O 
antibiotics O 
. O 
The O 
biosensors O 
also O 
revealed O 
that O 
E O 
. O 
coli O 
cells O 
engulfed O 
by O 
macrophages O 
exhibit O 
lower O 
c-di-GMP B-ABBREVIATION 
levels O 
, O 
most O 
likely O 
as O 
a O 
response O 
to O 
the O 
enormous O 
pressures O 
of O 
survival O 
during O 
phagocytosis O 
. O 

anhydrase O 
inhibitors O 
. O 
Benzenesulfonamides B-FAMILY 
incorporating O 
cyanoacrylamide B-SYSTEMATIC 
moieties O 
strongly O 
inhibit O 
Saccharomyces O 
cerevisiae O 
β-carbonic O 
anhydrase O 
. O 

series O 
of O 
benzenesulfonamides B-FAMILY 
incorporating O 
cyanoacrylamide B-SYSTEMATIC 
moieties O 
( O 
tyrphostine B-TRIVIAL 
analogs O 
) O 
were O 
assayed O 
as O 
inhibitors O 
of O 
the O 
β-carbonic O 
anhydrase O 
( O 
CA O 
, O 
EC O 
4.2.1.1 O 
) O 
from O 
Saccharomyces O 
cerevisiae O 
, O 
ScCA O 
. O 
Some O 
of O 
these O 
compounds O 
were O 
low O 
nanomolar O 
or O 
subnanomolar O 
ScCA O 
inhibitors O 
and O 
showed O 
selectivity O 
ratios O 
in O 
the O 
range O 
of O 
4.91-69.86 O 
for O 
inhibiting O 
the O 
yeast O 
enzyme O 
over O 
the O 
offtarget O 
human O 
( O 
h O 
) O 
isoforms O 
hCA O 
I O 
and O 
of O 
6.46-13.52 O 
for O 
inhibiting O 
ScCA O 
over O 
hCA O 
II O 
. O 
The O 
model O 
organism O 
S O 
. O 
cerevisiae O 
and O 
this O 
particular O 
enzyme O 
may O 
be O 
useful O 
for O 
detecting O 
antifungals O 
with O 
a O 
novel O 
mechanism O 
of O 
action O 
compared O 
to O 
the O 
classical O 
azole B-FAMILY 
drugs O 
to O 
which O 
significant O 
drug O 
resistance O 
emerged O 
. O 
Indeed O 
, O 
some O 
of O 
these O 
sulfonamides B-FAMILY 
inhibited O 
the O 
growth O 
of O 
the O 
yeast O 
with O 
CC50-s O 
in O 
the O 
range O 
of O 
0.73-6.54μM O 
. O 

antinociception O 
of O 
opioids O 
in O 
rats O 
and O 
mice O 
by O 
vaccination O 
with O 
immunogens O 
containing O 
oxycodone B-TRIVIAL 
and O 
hydrocodone B-TRIVIAL 
haptens O 
. O 

opioids O 
abuse O 
and O 
associated O 
deaths O 
are O 
an O 
emerging O 
concern O 
in O 
the O 
USA O 
. O 
Vaccination O 
against O 
prescription O 
opioids O 
may O 
provide O 
an O 
alternative O 
to O 
pharmacotherapy O 
. O 
An O 
oxycodone B-TRIVIAL 
hapten O 
containing O 
a O 
tetraglycine B-TRIVIAL 
linker O 
at O 
the O 
C6 O 
position O 
( O 
6OXY(Gly)(4)OH B-SYSTEMATIC 
) O 
conjugated O 
to O 
keyhole O 
limpet O 
hemocyanin O 
( O 
KLH O 
) O 
has O 
shown O 
early O 
proof O 
- O 
of O 
- O 
efficacy O 
in O 
rodents O 
as O 
a O 
candidate O 
immunogen O 
( O 
6OXY(Gly)(4) B-SYSTEMATIC 
-KLH O 
) O 
for O 
the O 
treatment O 
of O 
oxycodone B-TRIVIAL 
abuse O 
. O 
In O 
this O 
study O 
, O 
oxycodone B-TRIVIAL 
-based O 
and O 
hydrocodone B-TRIVIAL 
-based O 
haptens O 
were O 
conjugated O 
to O 
KLH O 
to O 
generate O 
immunogens O 
that O 
would O 
recognize O 
both O 
oxycodone B-TRIVIAL 
and O 
hydrocodone B-TRIVIAL 
. O 
Vaccination O 
with O 
6OXY(Gly)(4) B-SYSTEMATIC 
-KLH O 
increased O 
drug O 
binding O 
in O 
serum O 
, O 
reduced O 
drug O 
distribution O 
to O 
brain O 
, O 
and O 
blunted O 
analgesia O 
for O 
both O 
oxycodone B-TRIVIAL 
and O 
hydrocodone B-TRIVIAL 
. O 
An O 
analogous O 
C6- O 
linked O 
hydrocodone B-TRIVIAL 
vaccine O 
blocked O 
hydrocodone B-TRIVIAL 
effects O 
but O 
less O 
so O 
than O 
6OXY(Gly)(4) B-SYSTEMATIC 
-KLH O 
. O 
C8- O 
Linked O 
hydrocodone B-TRIVIAL 
immunogens O 
had O 
only O 
limited O 
efficacy O 
. O 
Amide B-SYSTEMATIC 
conjugation O 
showed O 
higher O 
haptenation O 
ratios O 
and O 
greater O 
efficacy O 
than O 
thioether B-SYSTEMATIC 
conjugation O 
to O 
maleimide B-SYSTEMATIC 
activated O 
KLH O 
( O 
mKLH O 
) O 
. O 
The O 
6OXY(Gly)(4) B-SYSTEMATIC 
-KLH O 
vaccine O 
may O 
be O 
used O 
for O 
treatment O 
of O 
prescription O 
opioid O 
abuse O 
. O 

nanoparticles O 
induce O 
toxicity O 
in O 
A549 O 
cells O 
via O 
ROS-dependent O 
and O 
ROS O 
- O 
independent O 
pathways O 
. O 

nanoparticles O 
( O 
AgNPs O 
) O 
are O 
incorporated O 
into O 
a O 
large O 
number O 
of O 
consumer O 
and O 
medical O 
products O 
. O 
Several O 
experiments O 
have O 
demonstrated O 
that O 
AgNPs O 
can O 
be O 
toxic O 
to O 
the O 
vital O 
organs O 
of O 
humans O 
and O 
especially O 
to O 
the O 
lung O 
. O 
The O 
present O 
study O 
evaluated O 
the O 
in O 
vitro O 
mechanisms O 
of O 
AgNP O 
( O 
< O 
100 O 
nm O 
) O 
toxicity O 
in O 
relationship O 
to O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
in O 
A549 O 
cells O 
. O 
AgNPs O 
caused O 
ROS O 
formation O 
in O 
the O 
cells O 
, O 
a O 
reduction O 
in O 
their O 
cell O 
viability O 
and O 
mitochondrial O 
membrane O 
potential O 
( O 
MMP O 
) O 
, O 
an O 
increase O 
in O 
the O 
proportion O 
of O 
cells O 
in O 
the O 
sub-G1 O 
( O 
apoptosis O 
) O 
population O 
, O 
S O 
phase O 
arrest O 
and O 
down O 
- O 
regulation O 
of O 
the O 
cell O 
cycle O 
associated O 
proliferating O 
cell O 
nuclear O 
antigen O 
( O 
PCNA O 
) O 
protein O 
, O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
Pretreatment O 
of O 
the O 
A549 O 
cells O 
with O 
N-acetyl-cysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
an O 
antioxidant O 
, O 
decreased O 
the O 
effects O 
of O 
AgNPs O 
on O 
the O 
reduced O 
cell O 
viability O 
, O 
change O 
in O 
the O 
MMP O 
and O 
proportion O 
of O 
cells O 
in O 
the O 
sub-G1population O 
, O 
but O 
had O 
no O 
effect O 
on O 
the O 
AgNP O 
- O 
mediated O 
S O 
phase O 
arrest O 
or O 
down O 
- O 
regulation O 
of O 
PCNA O 
. O 
These O 
observations O 
allow O 
us O 
to O 
propose O 
that O 
the O 
in O 
vitro O 
toxic O 
effects O 
of O 
AgNPs O 
on O 
A549 O 
cells O 
are O 
mediated O 
via O 
both O 
ROS-dependent O 
( O 
cytotoxicity O 
) O 
and O 
ROS O 
- O 
independent O 
( O 
cell O 
cycle O 
arrest O 
) O 
pathways O 
. O 

aggregation O 
and O 
interfacial O 
behavior O 
of O 
mixtures O 
of O 
anionic O 
( O 
sodium B-SYSTEMATIC 
dodecylsulfate I-SYSTEMATIC 
, O 
SDS B-ABBREVIATION 
) O 
and O 
cationic O 
( O 
dodecylammonium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
, O 
DTAB B-ABBREVIATION 
) O 
surfactants O 
were O 
investigated O 
. O 
A O 
room O 
- O 
temperature O 
ionic O 
liquid O 
( O 
IL O 
) O 
was O 
explored O 
as O 
a O 
solvent O 
for O 
the O 
SDS B-ABBREVIATION 
/ O 
DTAB B-ABBREVIATION 
system O 
and O 
compared O 
to O 
water O 
. O 
The O 
critical O 
micelle O 
concentration O 
( O 
cmc O 
) O 
and O 
composition O 
in O 
mixed O 
micelles O 
were O 
determined O 
for O 
both O 
solvents O 
. O 
Our O 
experiments O 
showed O 
nearly O 
ideal O 
mixing O 
of O 
SDS B-ABBREVIATION 
/ O 
DTAB B-ABBREVIATION 
over O 
the O 
entire O 
composition O 
range O 
and O 
suggest O 
that O 
charge O 
screening O 
is O 
prominent O 
in O 
ILs O 
. O 
This O 
behavior O 
is O 
in O 
sharp O 
contrast O 
to O 
the O 
strong O 
electrostatic O 
attraction O 
and O 
a O 
multiphase O 
composition O 
gap O 
in O 
water O 
. O 
Two O 
models O 
by O 
Clint O 
and O 
Rubingh O 
, O 
which O 
describe O 
ideal O 
and O 
nonideal O 
micellar O 
behavior O 
, O 
respectively O 
, O 
are O 
discussed O 
on O 
the O 
basis O 
of O 
our O 
results O 
. O 
According O 
to O 
Rubingh's O 
model O 
, O 
the O 
composition O 
of O 
mixed O 
micelles O 
is O 
gradually O 
changing O 
with O 
the O 
bulk O 
composition O 
in O 
ILs O 
but O 
tends O 
to O 
be O 
a O 
1 O 
: O 
1 O 
ratio O 
in O 
water O 
. O 
The O 
results O 
here O 
are O 
further O 
support O 
of O 
the O 
strong O 
charge O 
screening O 
in O 
ionic O 
liquids O 
. O 

, O 
food O 
dyes O 
obtained O 
from O 
herbal O 
, O 
animal O 
, O 
microbial O 
and O 
mineral O 
sources O 
are O 
widely O 
used O 
as O 
food O 
additives O 
. O 
In O 
this O 
study O 
, O 
the O 
toxic O 
effects O 
of O 
three O 
different O 
natural O 
food O 
dyes O 
( O 
carmine B-TRIVIAL 
, O 
turmeric O 
and O 
annatto O 
) O 
on O 
72 O 
± O 
4 O 
h O 
larvae O 
of O 
Oregon-R O 
wild O 
type O 
of O 
Drosophila O 
melanogaster O 
were O 
investigated O 
. O 
For O 
this O 
purpose O 
, O 
four O 
different O 
application O 
doses O 
( O 
50 O 
, O 
75 O 
, O 
100 O 
, O 
125 O 
mg O 
mL(-1) O 
) O 
were O 
chosen O 
by O 
means O 
of O 
preliminary O 
studies O 
. O 
It O 
was O 
determined O 
that O 
larval O 
mortality O 
increased O 
with O 
increasing O 
concentration O 
in O 
the O 
application O 
groups O 
and O 
the O 
toxicity O 
order O 
was O 
carmine B-TRIVIAL 
> O 
turmeric O 
> O 
annatto O 
. O 
It O 
was O 
observed O 
that O 
the O 
survival O 
rate O 
was O 
highest O 
in O 
the O 
control O 
with O 
98% O 
and O 
lowest O 
in O 
125 O 
mg O 
mL(-1) O 
carmine B-TRIVIAL 
with O 
16% O 
. O 
In O 
addition O 
, O 
the O 
average O 
lifespan O 
of O 
the O 
adult O 
individuals O 
obtained O 
from O 
third O 
instar O 
larvae O 
was O 
also O 
studied O 
. O 
While O 
the O 
average O 
lifespan O 
was O 
40.88 O 
± O 
1.44 O 
days O 
in O 
the O 
control O 
group O 
, O 
these O 
values O 
were O 
10.81 O 
± O 
0.55-23.90 O 
± O 
1.27 O 
days O 
in O 
the O 
carmine B-TRIVIAL 
group O 
, O 
15 O 
± O 
0.80-22.42 O 
± O 
1.43 O 
days O 
in O 
the O 
turmeric O 
group O 
and O 
10.33 O 
± O 
1.03-35.68 O 
± O 
1.54 O 
days O 
in O 
the O 
annatto O 
group O 
, O 
respectively O 
. O 
According O 
to O 
the O 
obtained O 
results O 
, O 
when O 
both O 
the O 
developmental O 
period O 
from O 
larvae O 
into O 
adults O 
and O 
the O 
lifespan O 
of O 
the O 
developing O 
adults O 
were O 
compared O 
with O 
the O 
control O 
group O 
, O 
the O 
food O 
dyes O 
were O 
found O 
to O 
be O 
toxic O 
and O 
the O 
toxicity O 
order O 
of O 
carmine B-TRIVIAL 
> O 
turmeric O 
> O 
annatto O 
was O 
identified O 
. O 

MDR1 O 
gene O 
encodes O 
P-glycoprotein O 
, O 
a O 
transmembrane O 
drug O 
efflux O 
transporter O 
that O 
confers O 
multidrug O 
resistance O 
in O 
cancer O 
cells O 
and O 
affects O 
drug O 
pharmacokinetics O 
by O 
virtue O 
of O 
its O 
expression O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
colon O 
. O 
Nuclear O 
receptors O 
SXR O 
and O 
CAR O 
are O 
possible O 
master O 
regulators O 
of O 
xenobiotic O 
- O 
inducible O 
MDR1 O 
expression O 
in O 
drug O 
processing O 
organs O 
, O 
but O 
the O 
mechanism O 
of O 
MDR1 O 
regulation O 
has O 
yet O 
to O 
be O 
directly O 
demonstrated O 
in O 
vivo O 
. O 
Moreover O 
, O 
it O 
has O 
previously O 
been O 
impossible O 
to O 
determine O 
the O 
sustained O 
or O 
cumulative O 
effect O 
of O 
repeated O 
doses O 
of O 
xenobiotics O 
on O 
in O 
vivo O 
MDR1 O 
expression O 
. O 
We O 
previously O 
reported O 
a O 
mouse O 
model O 
containing O 
firefly O 
luciferase O 
( O 
fLUC O 
) O 
knocked O 
into O 
the O 
mdr1a O 
genomic O 
locus O 
, O 
allowing O 
non-invasive O 
bioimaging O 
of O 
intestinal O 
mdr1a O 
gene O 
expression O 
in O 
live O 
animals O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
crossed O 
mdr1a.fLUC O 
mice O 
into O 
the O 
pxr O 
knockout O 
( O 
pxr(- O 
/ O 
- O 
) O 
) O 
genetic O 
background O 
and O 
injected O 
mice O 
with O 
pregnenolone-16α-carbonitrile B-SYSTEMATIC 
( O 
PCN B-ABBREVIATION 
) O 
, O 
a O 
strong O 
PXR O 
ligand O 
, O 
and O 
two O 
therapeutically O 
relevant O 
taxanes B-FAMILY 
, O 
paclitaxel B-TRIVIAL 
and O 
docetaxel B-TRIVIAL 
. O 
All O 
three O 
agents O 
induced O 
mdr1a.fLUC O 
expression O 
( O 
bioluminescence O 
) O 
, O 
but O 
only O 
PCN B-ABBREVIATION 
and O 
docetaxel B-TRIVIAL 
appeared O 
to O 
act O 
primarily O 
via O 
PXR O 
. O 
Luminescence O 
returned O 
to O 
baseline O 
by O 
24-48 O 
hrs O 
after O 
drug O 
injection O 
and O 
was O 
re O 
- O 
inducible O 
over O 
two O 
additional O 
rounds O 
of O 
drug O 
dosing O 
in O 
pxr(+ O 
/ O 
+ O 
) O 
mice O 
. O 
TCPOBOP B-TRIVIAL 
, O 
a O 
CAR O 
ligand O 
, O 
modestly O 
induced O 
mdr1a.fLUC O 
in O 
pxr(+ O 
/ O 
+ O 
) O 
and O 
pxr(- O 
/ O 
- O 
) O 
strains O 
, O 
consistent O 
with O 
CAR's O 
minor O 
role O 
in O 
mdr1a O 
regulation O 
. O 
Collectively O 
, O 
these O 
results O 
demonstrate O 
that O 
the O 
mdr1a.fLUC O 
bioimaging O 
model O 
can O 
capture O 
changes O 
in O 
mdr1 O 
gene O 
expression O 
under O 
conditions O 
of O 
repeated O 
xenobiotic O 
treatment O 
in O 
vivo O 
and O 
that O 
it O 
can O 
be O 
used O 
to O 
probe O 
the O 
mechanism O 
of O 
gene O 
regulation O 
in O 
response O 
to O 
different O 
xenobiotic O 
agents O 
. O 

, O 
raphasatin B-TRIVIAL 
and O 
(-)-epigallocatechin-3-gallate B-TRIVIAL 
synergistically O 
affect O 
cell O 
growth O 
and O 
apoptosis O 
of O 
colon O 
cancer O 
cells O 
. O 

effects O 
of O 
the O 
combination O 
of O 
the O 
food O 
components O 
vitexin-2-O-xyloside B-SYSTEMATIC 
(X) O 
, O 
raphasatin B-TRIVIAL 
( O 
4-methylsulphanyl-3-butenyl B-FAMILY 
isothiocyanates I-FAMILY 
; O 
G O 
) O 
and O 
(-)-epigallocatechin-3-gallate B-TRIVIAL 
( O 
E O 
) O 
were O 
investigated O 
in O 
colon O 
( O 
LoVo O 
and O 
CaCo-2 O 
) O 
and O 
breast O 
( O 
MDA-MB-231 O 
and O 
MCF-7 O 
) O 
cancer O 
cells O 
. O 
Breast O 
cancer O 
cells O 
were O 
more O 
resistant O 
than O 
colon O 
cells O 
to O 
X O 
, O 
G O 
and O 
E O 
inhibition O 
. O 
On O 
the O 
contrary O 
, O 
marked O 
synergistic O 
effects O 
among O 
X O 
, O 
G O 
and O 
E O 
on O 
cell O 
growth O 
were O 
found O 
in O 
both O 
colon O 
cancer O 
cells O 
. O 
Further O 
analysis O 
revealed O 
a O 
G0 O 
/ O 
G1 O 
arrest O 
of O 
the O 
phase O 
cell O 
progression O 
and O 
apoptosis O 
, O 
linked O 
to O 
modulation O 
of O 
Bax O 
, O 
Bcl2 O 
, O 
caspase-9 O 
and O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerase O 
as O 
well O 
as O 
Reactive O 
Oxygen B-SYSTEMATIC 
Species O 
( O 
ROS O 
) O 
generation O 
in O 
both O 
colon O 
cancer O 
cells O 
, O 
whereas O 
apoptosis O 
and O 
ROS O 
were O 
not O 
significantly O 
detected O 
in O 
normal O 
human O 
lymphocytes O 
. O 
We O 
conclude O 
that O 
the O 
X O 
, O 
G O 
and O 
E O 
mixture O 
might O 
act O 
by O 
mitochondrial O 
pathway O 
activation O 
of O 
apoptosis O 
, O 
possibly O 
elicited O 
by O 
ROS O 
and O 
the O 
mixture O 
may O 
be O 
effective O 
in O 
the O 
chemoprevention O 
of O 
colon O 
cancer O 
. O 

we O 
demonstrate O 
electric O 
- O 
field O 
induced O 
magnetic O 
anisotropy O 
in O 
a O 
multiferroic O 
composite O 
containing O 
nickel B-SYSTEMATIC 
nanocrystals O 
strain O 
coupled O 
to O 
a O 
piezoelectric O 
substrate O 
. O 
This O 
system O 
can O 
be O 
switched O 
between O 
a O 
superparamagnetic O 
state O 
and O 
a O 
single O 
- O 
domain O 
ferromagnetic O 
state O 
at O 
room O 
temperature O 
. O 
The O 
nanocrystals O 
show O 
a O 
shift O 
in O 
the O 
blocking O 
temperature O 
of O 
40 O 
K O 
upon O 
electric O 
poling O 
. O 
We O 
believe O 
this O 
is O 
the O 
first O 
example O 
of O 
a O 
system O 
where O 
an O 
electric O 
field O 
can O 
be O 
used O 
to O 
switch O 
on O 
and O 
off O 
a O 
permanent O 
magnetic O 
moment O 
. O 

beta O 
and O 
glatiramer B-TRIVIAL 
acetate I-TRIVIAL 
therapy O 
. O 

beta O 
and O 
glatiramer B-TRIVIAL 
acetate I-TRIVIAL 
have O 
been O 
mainstays O 
of O 
treatment O 
in O 
relapsingremitting O 
multiple O 
sclerosis O 
for O 
two O 
decades O 
. O 
Remarkable O 
advances O 
in O 
our O 
understanding O 
of O 
immune O 
function O 
and O 
dysfunction O 
as O 
well O 
as O 
increasingly O 
sophisticated O 
clinical O 
trial O 
design O 
have O 
stemmed O 
from O 
efforts O 
to O 
better O 
understand O 
these O 
drugs O 
. O 
In O 
this O 
chapter O 
, O 
we O 
review O 
the O 
history O 
of O 
their O 
development O 
and O 
elaborate O 
on O 
known O 
and O 
theorized O 
mechanisms O 
of O 
action O 
. O 
We O 
describe O 
the O 
pivotal O 
clinical O 
trials O 
that O 
have O 
led O 
to O 
their O 
widespread O 
use O 
. O 
We O 
evaluate O 
the O 
clinical O 
use O 
of O 
the O 
drugs O 
including O 
tolerability O 
, O 
side O 
effects O 
, O 
and O 
efficacy O 
measures O 
. O 
Finally O 
, O 
we O 
look O 
to O 
the O 
future O 
of O 
interferon O 
beta O 
and O 
glatiramer B-TRIVIAL 
acetate I-TRIVIAL 
in O 
the O 
context O 
of O 
an O 
ever O 
growing O 
armamentarium O 
of O 
treatments O 
for O 
relapsing O 
remitting O 
multiple O 
sclerosis O 
. O 

Strange O 
Kinetics O 
" O 
in O 
the O 
Temperature O 
Dependence O 
of O 
Methionine B-TRIVIAL 
Ligand O 
Rebinding O 
Dynamics O 
in O 
Cytochrome O 
c O 
. O 

dependence O 
of O 
methionine B-TRIVIAL 
ligand O 
dissociation O 
and O 
rebinding O 
dynamics O 
in O 
cytochrome O 
c O 
in O 
aqueous O 
solution O 
has O 
been O 
studied O 
using O 
classical O 
molecular O 
dynamics O 
simulation O 
. O 
Results O 
are O 
compared O 
with O 
previous O 
study O 
of O 
rebinding O 
dynamics O 
at O 
300K O 
in O 
water O 
in O 
order O 
to O 
understand O 
how O 
the O 
change O 
of O 
protein O 
environment O 
and O 
the O 
underlying O 
protein O 
energy O 
landscape O 
influence O 
the O 
dynamics O 
. O 
Rebinding O 
dynamics O 
at O 
77K O 
, O 
180K O 
, O 
and O 
300K O 
exhibits O 
changes O 
in O 
both O 
timescale O 
and O 
mechanism O 
as O 
the O 
protein O 
and O 
solvent O 
undergo O 
a O 
dynamic O 
" O 
glass O 
transition O 
. O 
" O 
At O 
each O 
temperature O 
, O 
the O 
rebinding O 
dynamics O 
yields O 
a O 
subset O 
of O 
trajectories O 
that O 
undergo O 
fast O 
rebinding O 
as O 
well O 
as O 
a O 
subset O 
of O 
trajectories O 
that O 
undergo O 
slower O 
rebinding O 
. O 
At O 
300K O 
in O 
water O 
, O 
both O 
a O 
fast O 
( O 
4 O 
ps O 
) O 
and O 
slow O 
( O 
14.6 O 
ps O 
) O 
rebinding O 
is O 
observed O 
. O 
While O 
fast O 
rebinding O 
occurs O 
from O 
a O 
" O 
downward O 
" O 
( O 
heme B-FAMILY 
pointing O 
) O 
substate O 
of O 
the O 
methionine B-TRIVIAL 
, O 
the O 
slow O 
rebinding O 
involves O 
interconversion O 
between O 
an O 
" O 
upward O 
" O 
substate O 
, O 
from O 
which O 
rebinding O 
cannot O 
occur O 
, O 
and O 
the O 
downward O 
substate O 
. O 
At O 
lower O 
temperatures O 
( O 
77K O 
and O 
180K O 
) O 
the O 
upward O 
dissociated O 
substate O 
was O 
not O 
observed O 
due O 
to O 
the O 
high O 
barrier O 
imposed O 
by O 
the O 
" O 
frozen O 
" O 
protein O 
structure O 
. O 
However O 
, O 
a O 
slow O 
rebinding O 
phase O 
is O 
observed O 
at O 
both O 
77K O 
and O 
180K O 
and O 
is O 
associated O 
with O 
a O 
process O 
of O 
trapping O 
in O 
downward O 
but O 
" O 
binding O 
forbidden O 
" O 
substates O 
with O 
subsequent O 
slow O 
dynamical O 
conversion O 
to O 
" O 
binding O 
competent O 
" O 
substates O 
from O 
which O 
rebinding O 
is O 
relatively O 
rapid O 
. O 
Distinctive O 
rebinding O 
dynamics O 
at O 
77K O 
and O 
180K O 
suggest O 
that O 
different O 
rebinding O 
time O 
scales O 
are O 
predetermined O 
by O 
the O 
protein O 
and O 
solvent O 
structural O 
arrangement O 
prior O 
to O 
photodissociation O 
, O 
which O 
causes O 
either O 
fast O 
rebinding O 
( O 
about O 
2ps O 
) O 
or O 
slow O 
( O 
> O 
50ps O 
) O 
rebinding O 
. O 
Suggestions O 
for O 
future O 
experiments O 
to O 
further O 
probe O 
the O 
role O 
of O 
dynamic O 
heterogeneity O 
in O 
the O 
kinetics O 
of O 
methionine B-TRIVIAL 
ligand O 
binding O 
in O 
cytochrome O 
c O 
protein O 
are O 
proposed O 
. O 

nanoparticles O 
( O 
AuNPs O 
) O 
are O 
currently O 
used O 
in O 
several O 
fields O 
including O 
biomedical O 
applications O 
, O 
although O 
no O 
conclusive O 
information O 
on O 
their O 
cytotoxicity O 
is O 
available O 
. O 
For O 
this O 
reason O 
this O 
work O 
has O 
investigated O 
the O 
effects O 
of O 
AuNPs O 
in O 
vitro O 
on O 
Balb O 
/ O 
3T3 O 
mouse O 
fibroblasts O 
. O 
Results O 
obtained O 
exposing O 
cells O 
for O 
72 O 
h O 
to O 
AuNPs O 
5 O 
and O 
15 O 
nm O 
citrate B-FAMILY 
stabilized O 
, O 
revealed O 
cytotoxic O 
effects O 
only O 
for O 
AuNPs O 
5 O 
nm O 
at O 
concentration O 
≥ O 
50 O 
μM O 
if O 
measured O 
by O 
colony O 
forming O 
efficiency O 
( O 
CFE O 
) O 
. O 
To O 
understand O 
the O 
differences O 
in O 
cytotoxicity O 
observed O 
for O 
the O 
two O 
AuNPs O 
sizes O 
, O 
we O 
investigated O 
the O 
uptake O 
and O 
the O 
intracellular O 
distribution O 
of O 
the O 
nanoparticles O 
. O 
By O 
TEM O 
it O 
was O 
observed O 
that O 
5 O 
and O 
15 O 
nm O 
AuNPs O 
are O 
internalized O 
by O 
Balb O 
/ O 
3T3 O 
cells O 
and O 
located O 
within O 
intracellular O 
endosomal O 
compartments O 
. O 
Quantification O 
of O 
the O 
uptake O 
by O 
ICP-MS O 
showed O 
that O 
AuNPs O 
internalization O 
enhanced O 
even O 
up O 
to O 
72 O 
h O 
. O 
Disruption O 
of O 
the O 
actin O 
cytoskeleton O 
was O 
evident O 
, O 
with O 
cell O 
footprints O 
narrow O 
and O 
contracted O 
; O 
effects O 
more O 
remarkable O 
in O 
cells O 
exposed O 
to O 
5 O 
nm O 
AuNP O 
. O 
The O 
mechanism O 
of O 
NPs O 
cell O 
internalization O 
was O 
investigated O 
using O 
immunocytochemistry O 
and O 
western O 
blot O 
. O 
No O 
significant O 
effect O 
was O 
observed O 
in O 
the O 
expression O 
level O 
of O 
caveolin O 
, O 
while O 
reduction O 
of O 
the O 
expression O 
and O 
degradation O 
of O 
the O 
clathrin O 
heavy O 
chain O 
was O 
observed O 
in O 
cells O 
exposed O 
for O 
72 O 
h O 
to O 
AuNPs O 
. O 

- O 
scale O 
synthesis O 
and O 
in O 
situ O 
functionalization O 
of O 
Zn3P2 B-FORMULA 
and O 
Zn4Sb3 B-FORMULA 
nanowire O 
powders O 
. O 

simple O 
method O 
for O 
the O 
large O 
- O 
scale O 
synthesis O 
of O 
gram O 
quantities O 
of O 
compound O 
semiconductor O 
nanowires O 
without O 
the O 
need O 
for O 
any O 
external O 
catalysts O 
or O 
templates O 
is O 
presented O 
. O 
This O 
method O 
is O 
demonstrated O 
using O 
zinc B-SYSTEMATIC 
phosphide I-SYSTEMATIC 
( O 
Zn3P2 B-FORMULA 
) O 
and O 
zinc B-SYSTEMATIC 
antimonide I-SYSTEMATIC 
( O 
β- O 
Zn4Sb3 B-FORMULA 
) O 
nanowires O 
as O 
example O 
systems O 
. O 
Large O 
- O 
scale O 
synthesis O 
of O 
Zn3P2 B-FORMULA 
and O 
Zn4Sb3 B-FORMULA 
nanowire O 
powders O 
was O 
accomplished O 
using O 
a O 
hot O 
- O 
walled O 
chemical O 
vapor O 
deposition O 
chamber O 
by O 
transporting O 
phosphorus B-SYSTEMATIC 
and O 
antimony B-SYSTEMATIC 
, O 
respectively O 
, O 
via O 
the O 
vapor O 
phase O 
onto O 
heated O 
zinc B-SYSTEMATIC 
foils O 
. O 
The O 
zinc B-SYSTEMATIC 
foils O 
were O 
rolled O 
concentrically O 
into O 
coils O 
to O 
maximize O 
the O 
substrate O 
surface O 
area O 
, O 
and O 
consequently O 
, O 
the O 
nanowire O 
yield O 
. O 
Using O 
this O 
method O 
, O 
250 O 
mg O 
of O 
Zn3P2 B-FORMULA 
nanowires O 
were O 
obtained O 
on O 
480 O 
cm(2) O 
of O 
zinc B-SYSTEMATIC 
foil O 
in O 
a O 
span O 
of O 
45 O 
minutes O 
. O 
Furthermore O 
, O 
a O 
process O 
of O 
exposing O 
the O 
synthesized O 
nanowires O 
to O 
a O 
vapor O 
of O 
organic O 
functional O 
molecules O 
immediately O 
after O 
their O 
synthesis O 
and O 
before O 
their O 
removal O 
from O 
the O 
vacuum O 
chamber O 
was O 
developed O 
to O 
obtain O 
large O 
quantities O 
of O 
surface O 
functionalized O 
nanowire O 
powders O 
. O 
This O 
in O 
situ O 
vapor O 
- O 
phase O 
functionalization O 
procedure O 
passivated O 
the O 
nanowire O 
surfaces O 
without O 
adversely O 
affecting O 
their O 
morphology O 
or O 
dimensions O 
. O 
Our O 
studies O 
revealed O 
that O 
both O 
4-aminothiophenol B-SYSTEMATIC 
and O 
3-propanedithiol B-SYSTEMATIC 
functionalized O 
Zn3P2 B-FORMULA 
nanowires O 
were O 
stable O 
over O 
a O 
120 O 
day O 
duration O 
without O 
any O 
agglomeration O 
or O 
degradation O 
. O 
This O 
method O 
of O 
mass O 
producing O 
nanowires O 
can O 
also O 
be O 
extended O 
to O 
other O 
binary O 
semiconductors O 
. O 

of O 
ginkgolic B-TRIVIAL 
acid I-TRIVIAL 
( I-TRIVIAL 
15 I-TRIVIAL 
: I-TRIVIAL 
1 I-TRIVIAL 
) I-TRIVIAL 
metabolites O 
in O 
rats O 
following O 
oral O 
administration O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
coupled O 
to O 
tandem O 
mass O 
spectrometry O 
. O 

. O 
In O 
this O 
article O 
, O 
metabolites O 
of O 
ginkgolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
( O 
15 O 
: O 
1 O 
) O 
in O 
rats O 
plasma O 
, O 
bile O 
, O 
urine O 
and O 
faeces O 
after O 
oral O 
administration O 
have O 
been O 
investigated O 
for O 
the O 
first O 
time O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
coupled O 
to O 
tandem O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
/ O 
MS O 
) O 
with O 
the O 
aid O 
of O 
on O 
- O 
line O 
hydrogen B-SYSTEMATIC 
/ O 
deuterium B-SYSTEMATIC 
( O 
H B-FORMULA 
/ O 
D B-FORMULA 
) O 
exchange O 
technique O 
and O 
β-glucuronidase O 
hydrolysis O 
experiments O 
. O 
2 O 
. O 
After O 
oral O 
administration O 
of O 
GA O 
( O 
15 O 
: O 
1 O 
, O 
M0 O 
) O 
to O 
rats O 
at O 
a O 
dose O 
of O 
10 O 
mg O 
/ O 
kg O 
, O 
it O 
was O 
found O 
that O 
metabolites O 
M1-M5 O 
together O 
with O 
parent O 
compound O 
( O 
M0 O 
) O 
existed O 
in O 
rat O 
plasma O 
; O 
parent O 
compound O 
( O 
M0 O 
) O 
and O 
metabolites O 
M2-M5 O 
were O 
observed O 
in O 
rat O 
bile O 
, O 
and O 
parent O 
compound O 
( O 
M0 O 
) O 
with O 
metabolites O 
M1 O 
and O 
M2 O 
were O 
discovered O 
in O 
rat O 
faeces O 
, O 
and O 
there O 
was O 
no O 
parent O 
compound O 
and O 
metabolite O 
detectable O 
in O 
rat O 
urine O 
. O 
3 O 
. O 
Two O 
oxidative O 
metabolites O 
of O 
GA O 
( O 
15 O 
: O 
1 O 
, O 
M0 O 
) O 
were O 
identified O 
as O 
2-hydroxy-6-(pentadec-8-enyl-10-hydroxy) B-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
M1 O 
) O 
and O 
2-hydroxy-6-(pentadec-8-enyl-11-hydroxy-13-carbonyl) B-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
M2 O 
) O 
, O 
respectively O 
. O 
Metabolites O 
M3 O 
, O 
M4 O 
and O 
M5 O 
were O 
identified O 
as O 
the O 
mono-glucuronic B-TRIVIAL 
acid I-TRIVIAL 
conjugates O 
of O 
parent O 
compound O 
( O 
M0 O 
) O 
, O 
M1 O 
and O 
M2 O 
, O 
respectively O 
. O 
4 O 
. O 
The O 
results O 
indicated O 
that O 
M1 O 
and O 
M2 O 
with O 
parent O 
compound O 
( O 
M0 O 
) O 
were O 
mainly O 
eliminated O 
in O 
faeces O 
and O 
three O 
glucuronide B-TRIVIAL 
metabolites O 
( O 
M3 O 
, O 
M4 O 
and O 
M5 O 
) O 
excreted O 
in O 
bile O 
as O 
the O 
predominant O 
forms O 
after O 
oral O 
administration O 
of O 
GA B-ABBREVIATION 
( I-ABBREVIATION 
15 I-ABBREVIATION 
: I-ABBREVIATION 
1 I-ABBREVIATION 
) I-ABBREVIATION 
to O 
rats O 
. O 

arsenic B-SYSTEMATIC 
exposure O 
in O 
nanomolar O 
concentrations O 
compromises O 
wound O 
response O 
and O 
intercellular O 
signaling O 
in O 
airway O 
epithelial O 
cells O 
. O 

ATP B-ABBREVIATION 
signaling O 
in O 
the O 
lung O 
epithelium O 
participates O 
in O 
a O 
variety O 
of O 
innate O 
immune O 
functions O 
, O 
including O 
mucociliary O 
clearance O 
, O 
bactericide O 
production O 
, O 
and O 
as O 
an O 
initiating O 
signal O 
in O 
wound O 
repair O 
. O 
We O 
evaluated O 
the O 
effects O 
of O 
chronic O 
low O 
- O 
dose O 
arsenic B-SYSTEMATIC 
relevant O 
to O 
U.S O 
. O 
drinking O 
water O 
standards O 
( O 
i.e O 
. O 
, O 
10 O 
ppb O 
[ O 
130nM O 
] O 
) O 
on O 
airway O 
epithelial O 
cells O 
. O 
Immortalized O 
human O 
bronchial O 
epithelial O 
cells O 
( O 
16HBE14o- O 
) O 
were O 
exposed O 
to O 
0 O 
, O 
130 O 
, O 
or O 
330nM O 
arsenic B-SYSTEMATIC 
( O 
as O 
Na-arsenite B-SYSTEMATIC 
) O 
for O 
4-5 O 
weeks O 
and O 
examined O 
for O 
wound O 
repair O 
efficiency O 
and O 
ATP B-ABBREVIATION 
-mediated O 
Ca(2+) B-FORMULA 
signaling O 
. O 
We O 
found O 
that O 
chronic O 
arsenic B-SYSTEMATIC 
exposure O 
at O 
these O 
low O 
doses O 
slows O 
wound O 
repair O 
and O 
reduces O 
ATP B-ABBREVIATION 
-mediated O 
Ca(2+) B-FORMULA 
signaling O 
. O 
We O 
further O 
show O 
that O 
arsenic B-SYSTEMATIC 
compromises O 
ATP B-ABBREVIATION 
-mediated O 
Ca(2+) B-FORMULA 
signaling O 
by O 
altering O 
both O 
Ca(2+) B-FORMULA 
release O 
from O 
intracellular O 
stores O 
( O 
via O 
metabotropic O 
P2Y O 
receptors O 
) O 
and O 
Ca(2+) B-FORMULA 
influx O 
mechanisms O 
( O 
via O 
ionotropic O 
P2X O 
receptors O 
) O 
. O 
To O 
better O 
model O 
the O 
effects O 
of O 
arsenic B-SYSTEMATIC 
on O 
ATP B-ABBREVIATION 
-mediated O 
Ca(2+) B-FORMULA 
signaling O 
under O 
conditions O 
of O 
natural O 
exposure O 
, O 
we O 
cultured O 
tracheal O 
epithelial O 
cells O 
obtained O 
from O 
mice O 
exposed O 
to O 
control O 
or O 
50 O 
ppb O 
Na-arsenite B-SYSTEMATIC 
supplemented O 
drinking O 
water O 
for O 
4 O 
weeks O 
. O 
Tracheal O 
epithelial O 
cells O 
from O 
arsenic B-SYSTEMATIC 
-exposed O 
mice O 
displayed O 
reduced O 
ATP B-ABBREVIATION 
-mediated O 
Ca(2+) B-FORMULA 
signaling O 
dynamics O 
similar O 
to O 
our O 
in O 
vitro O 
chronic O 
exposure O 
. O 
Our O 
findings O 
demonstrate O 
that O 
chronic O 
arsenic B-SYSTEMATIC 
exposure O 
at O 
levels O 
that O 
are O 
commonly O 
found O 
in O 
drinking O 
water O 
( O 
i.e O 
. O 
, O 
10-50 O 
ppb O 
) O 
alters O 
cellular O 
mechanisms O 
critical O 
to O 
airway O 
innate O 
immunity O 
. O 

the O 
continuing O 
study O 
of O 
antifeedant O 
compounds O 
in O 
Protium O 
javanicum O 
Burm O 
. O 
f O 
. O 
against O 
Coptotermes O 
formosanus O 
Shiraki O 
, O 
6-desacetylnimbin B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
quercitrin B-TRIVIAL 
( O 
2 O 
) O 
and O 
myricitrin B-TRIVIAL 
( O 
3 O 
) O 
were O 
isolated O 
from O 
P O 
. O 
javanicum O 
extract O 
. O 
All O 
compounds O 
were O 
characterised O 
by O 
NMR O 
and O 
MS O 
. O 
Furthermore O 
, O 
the O 
structure O 
of O 
6-desacetylnimbin B-SYSTEMATIC 
was O 
confirmed O 
by O 
X-ray O 
crystallography O 
. O 
The O 
antifeedant O 
activity O 
was O 
evaluated O 
with O 
no O 
- O 
choice O 
feeding O 
tests O 
. O 
At O 
a O 
dose O 
of O 
0.5 O 
mg O 
, O 
6-desacetylnimbin B-SYSTEMATIC 
exhibited O 
the O 
highest O 
antifeedant O 
activity O 
among O 
the O 
isolates O 
. O 

of O 
fluorine B-SYSTEMATIC 
in O 
milk O 
samples O 
via O 
calcium B-SYSTEMATIC 
- I-SYSTEMATIC 
monofluoride I-SYSTEMATIC 
by O 
electrothermal O 
molecular O 
absorption O 
spectrometry O 
. O 

determination O 
of O 
fluorine B-SYSTEMATIC 
in O 
milk O 
samples O 
via O 
the O 
molecular O 
absorption O 
of O 
calcium B-SYSTEMATIC 
mono-fluoride I-SYSTEMATIC 
( O 
CaF B-FORMULA 
) O 
was O 
performed O 
using O 
a O 
HR-CS-ETAAS O 
. O 
For O 
this O 
purpose O 
, O 
calcium B-SYSTEMATIC 
was O 
pipetted O 
to O 
graphite B-TRIVIAL 
furnace O 
together O 
with O 
samples O 
. O 
The O 
amount O 
of O 
Ca B-FORMULA 
and O 
the O 
graphite B-TRIVIAL 
furnace O 
program O 
were O 
optimised O 
. O 
Fluorine B-SYSTEMATIC 
was O 
determined O 
in O 
pyrolytically O 
coated O 
platforms O 
at O 
606.44 O 
nm O 
applying O 
a O 
pyrolysis O 
temperature O 
of O 
700 O 
°C O 
and O 
a O 
molecule O 
forming O 
temperature O 
of O 
2250 O 
°C O 
. O 
Finally O 
, O 
applying O 
standard O 
addition O 
technique O 
, O 
F B-FORMULA 
contents O 
of O 
several O 
milk O 
samples O 
were O 
determined O 
. O 
The O 
results O 
obtained O 
by O 
linear O 
calibration O 
and O 
standard O 
addition O 
techniques O 
were O 
significantly O 
different O 
which O 
can O 
be O 
attributed O 
to O 
non-spectral O 
interferences O 
in O 
milk O 
due O 
to O 
matrix O 
concomitants O 
. O 
Therefore O 
, O 
in O 
order O 
to O 
tolerate O 
the O 
errors O 
, O 
the O 
F B-FORMULA 
contents O 
of O 
several O 
milk O 
samples O 
were O 
determined O 
applying O 
standard O 
addition O 
technique O 
. O 
However O 
, O 
since O 
the O 
ingredients O 
of O 
milk O 
samples O 
change O 
for O 
different O 
kinds O 
, O 
the O 
F B-FORMULA 
in O 
each O 
sample O 
was O 
determined O 
from O 
its O 
own O 
standard O 
addition O 
curve O 
. O 
The O 
range O 
of O 
F B-FORMULA 
content O 
for O 
the O 
milk O 
samples O 
were O 
0.027-0.543 O 
μg O 
mL(-1) O 
. O 
The O 
limit O 
of O 
detection O 
and O 
characteristic O 
mass O 
of O 
the O 
method O 
were O 
0.26 O 
and O 
0.13 O 
ng O 
of O 
F B-FORMULA 
, O 
respectively O 
. O 

measurement O 
of O 
specific O 
protein O 
phosphorylation O 
sites O 
is O 
a O 
primary O 
interest O 
of O 
biologists O 
, O 
as O 
site O 
- O 
specific O 
phosphorylation O 
information O 
provides O 
insights O 
into O 
cell O 
signaling O 
networks O 
and O 
cellular O 
dynamics O 
at O 
a O 
system O 
level O 
. O 
Over O 
the O 
last O 
decade O 
, O 
selective O 
phosphopeptide O 
enrichment O 
methods O 
including O 
IMAC O 
and O 
metal B-FAMILY 
oxides I-FAMILY 
( O 
TiO2 B-FORMULA 
and O 
ZrO2 B-FORMULA 
) O 
have O 
been O 
developed O 
and O 
greatly O 
facilitate O 
large O 
scale O 
phosphoproteome O 
analysis O 
of O 
various O 
cells O 
, O 
tissues O 
and O 
living O 
organisms O 
, O 
in O 
combination O 
with O 
modern O 
mass O 
spectrometers O 
featuring O 
high O 
mass O 
accuracy O 
and O 
high O 
mass O 
resolution O 
. O 
Various O 
quantification O 
strategies O 
have O 
been O 
applied O 
to O 
detecting O 
relative O 
changes O 
in O 
expression O 
of O 
proteins O 
, O 
peptides O 
, O 
and O 
specific O 
modifications O 
between O 
samples O 
. O 
The O 
combination O 
of O 
mass O 
spectrometry O 
- O 
based O 
phosphoproteome O 
analysis O 
with O 
quantification O 
strategies O 
provides O 
a O 
straightforward O 
and O 
unbiased O 
method O 
to O 
identify O 
and O 
quantify O 
site O 
- O 
specific O 
phosphorylation O 
. O 
We O 
describe O 
common O 
strategies O 
for O 
mass O 
spectrometric O 
analysis O 
of O 
stable O 
isotope O 
labeled O 
samples O 
, O 
as O 
well O 
as O 
two O 
widely O 
applied O 
phosphopeptide O 
enrichment O 
methods O 
based O 
on O 
IMAC( O 
NTA-Fe(3+) B-FORMULA 
) O 
and O 
metal B-FAMILY 
oxide I-FAMILY 
( O 
ZrO2 B-FORMULA 
) O 
. O 
Instrumental O 
configurations O 
for O 
on O 
- O 
line O 
LC-tandem O 
mass O 
spectrometric O 
analysis O 
and O 
parameters O 
of O 
conventional O 
bioinformatic O 
analysis O 
of O 
large O 
data O 
sets O 
are O 
also O 
considered O 
for O 
confident O 
identification O 
, O 
localization O 
, O 
and O 
reliable O 
quantification O 
of O 
site O 
- O 
specific O 
phosphorylation O 
. O 

pharmacokinetic O 
profiles O 
of O 
picrosides B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
from O 
kutkin O 
, O 
Picrorhiza O 
kurroa O 
extract O 
and O 
its O 
formulation O 
in O 
rats O 
. O 

I I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
are O 
the O 
active O 
chemical O 
constituents O 
, O 
present O 
in O 
the O 
roots O 
and O 
rhizomes O 
of O 
Picrorhiza O 
kurroa O 
Royle O 
( O 
family O 
: O 
Scrophulariaceae O 
) O 
. O 
The O 
plant O 
is O 
ethnomedically O 
claimed O 
for O 
the O 
treatment O 
of O 
liver O 
and O 
upper O 
respiratory O 
tract O 
infection O 
, O 
fever O 
, O 
dyspepsia O 
and O 
scorpion O 
sting O 
. O 
This O 
study O 
attempts O 
to O 
determine O 
the O 
in O 
vivo O 
pharmacokinetic O 
profile O 
of O 
picrosides B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
in O 
rats O 
after O 
oral O 
administration O 
of O 
three O 
different O 
preparations O 
namely O 
, O 
kutkin B-TRIVIAL 
( O 
a O 
mixture O 
of O 
picrosides B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
) O 
, O 
P O 
. O 
kurroa O 
extract O 
and O 
Picrolax O 
® O 
capsule O 
( O 
marketed O 
formulation O 
) O 
. O 
A O 
simple O 
, O 
precise O 
, O 
specific O 
and O 
sensitive O 
method O 
was O 
developed O 
for O 
simultaneous O 
quantification O 
of O 
picrosides B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
in O 
rat O 
plasma O 
and O 
was O 
applied O 
for O 
the O 
pharmacokinetic O 
study O 
. O 
Pharmacokinetic O 
parameters O 
were O 
calculated O 
from O 
the O 
observed O 
plasma O 
concentration O 
of O 
picrosides B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
. O 
The O 
results O 
showed O 
a O 
significant O 
difference O 
( O 
p≤0.05 O 
) O 
in O 
oral O 
bioavailability O 
of O 
picrosides B-MULTIPLE 
I I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
from O 
different O 
preparations O 
. O 
Both O 
the O 
compounds O 
were O 
found O 
to O 
be O 
more O 
bioavailable O 
from O 
P O 
. O 
kurroa O 
extract O 
followed O 
by O 
Picrolax O 
® O 
capsule O 
and O 
kutkin B-TRIVIAL 
. O 
Moreover O 
, O 
we O 
also O 
developed O 
a O 
novel O 
method O 
for O 
isolation O 
of O 
kutkin B-TRIVIAL 
from O 
roots O 
of O 
P O 
. O 
kurroa O 
with O 
a O 
high O 
yield O 
of O 
2.4% O 
w O 
/ O 
w O 
. O 
The O 
information O 
gained O 
from O 
this O 
study O 
provides O 
a O 
meaningful O 
basis O 
for O 
clinical O 
application O 
and O 
mechanistic O 
study O 
of O 
such O 
phytochemicals O 
. O 

ABC O 
Transporter-Associated O 
Activity O 
of O 
Isoflavonoids B-FAMILY 
from O 
the O 
Root O 
Extract O 
of O 
Dalea O 
formosa O 
. O 

potential O 
treatments O 
for O 
disseminated O 
fungal O 
infections O 
are O 
needed O 
, O 
especially O 
for O 
infections O 
caused O 
by O 
the O 
commonly O 
drug O 
- O 
resistant O 
pathogens O 
Candida O 
albicans O 
and O 
C O 
. O 
glabrata O 
. O 
These O 
pathogens O 
cause O 
systemic O 
candidiasis O 
, O 
a O 
significant O 
cause O 
of O 
mortality O 
in O 
immune O 
- O 
compromised O 
patients O 
. O 
ABC O 
transporters O 
of O 
the O 
pleiotropic O 
drug O 
resistance O 
subfamily O 
, O 
such O 
as O 
Cdr1p O 
of O 
C O 
. O 
albicans O 
, O 
play O 
an O 
important O 
role O 
in O 
antifungal O 
resistance O 
and O 
are O 
potential O 
bioassay O 
targets O 
for O 
antifungal O 
therapies O 
against O 
drug O 
- O 
resistant O 
pathogens O 
. O 
We O 
observed O 
strong O 
antifungal O 
growth O 
inhibitory O 
activity O 
in O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
Dalea O 
formosa O 
roots O 
. O 
This O 
extract O 
afforded O 
six O 
new O 
isoflavonoids B-FAMILY 
, O 
sedonans B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
a O 
new O 
but-2-enolide B-SYSTEMATIC 
, O 
4'-O-methylpuerol B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
7 O 
) O 
, O 
and O 
the O 
new O 
pterocarpan O 
ent-sandwicensin B-TRIVIAL 
( O 
8 O 
) O 
. O 
The O 
structures O 
and O 
absolute O 
configurations O 
of O 
these O 
compounds O 
were O 
assigned O 
using O 
spectroscopic O 
and O 
chiroptical O 
techniques O 
. O 
The O 
direct O 
antifungal O 
activity O 
of O 
1 O 
against O 
C O 
. O 
glabrata O 
( O 
MIC O 
= O 
20 O 
μM O 
) O 
was O 
higher O 
than O 
that O 
of O 
fluconazole B-TRIVIAL 
. O 
Sedonans B-MULTIPLE 
A-F I-MULTIPLE 
and O 
ent-sandwicensin B-TRIVIAL 
were O 
also O 
active O 
against O 
Saccharomyces O 
cerevisiae O 
strains O 
that O 
express O 
differing O 
ABC O 
transporter O 
- O 
associated O 
resistance O 
mechanisms O 
but O 
differed O 
in O 
their O 
susceptibility O 
to O 
Cdr1p O 
- O 
mediated O 
detoxification O 
. O 
A O 
sedonan B-TRIVIAL 
A I-TRIVIAL 
(1)/ O 
ent-sandwicensin B-TRIVIAL 
( O 
8 O 
) O 
combination O 
exhibited O 
synergistic O 
growth O 
inhibition O 
. O 
The O 
results O 
demonstrate O 
that O 
multiple O 
crude O 
extract O 
compounds O 
are O 
differentially O 
affected O 
by O 
efflux O 
- O 
mediated O 
resistance O 
and O 
are O 
collectively O 
responsible O 
for O 
the O 
observed O 
bioactivity O 
. O 

Diterpenes B-FAMILY 
from O 
a O 
Godavari O 
Mangrove O 
, O 
Ceriops O 
decandra O 
. O 

new O 
diterpenes B-FAMILY 
, O 
named O 
decandrins B-MULTIPLE 
A-K I-MULTIPLE 
( O 
1-11 O 
) O 
, O 
including O 
nine O 
abietanes B-FAMILY 
( O 
1-9 O 
) O 
and O 
two O 
podocarpanes B-FAMILY 
( O 
10-11 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
barks O 
of O 
an O 
Indian O 
mangrove O 
, O 
Ceriops O 
decandra O 
, O 
collected O 
in O 
the O 
mangrove O 
swamp O 
of O 
Godavari O 
estuary O 
, O 
Andhra O 
Pradesh O 
, O 
together O 
with O 
four O 
known O 
abietanes B-FAMILY 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
established O 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
( O 
new O 
compounds O 
) O 
or O 
comparison O 
with O 
data O 
in O 
the O 
literature O 
( O 
known O 
compounds O 
) O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
abietane B-TRIVIAL 
and O 
podocarpane B-TRIVIAL 
diterpenoids B-FAMILY 
from O 
C O 
. O 
decandra O 
. O 

cancer O 
tumors O 
, O 
growth O 
, O 
invasion O 
, O 
and O 
formation O 
of O 
metastasis O 
at O 
a O 
secondary O 
site O 
play O 
a O 
pivotal O 
role O 
, O 
participating O 
in O 
diverse O 
processes O 
in O 
the O 
development O 
of O 
the O 
pathology O 
, O 
such O 
as O 
degradation O 
of O 
extracellular O 
matrix O 
. O 
Bauhinia O 
seeds O 
contain O 
relatively O 
large O 
quantities O 
of O 
peptidase O 
inhibitors O 
, O 
and O 
two O 
Bauhinia O 
inhibitors O 
were O 
obtained O 
in O 
a O 
recombinant O 
form O 
from O 
the O 
Bauhinia O 
bauhinioides O 
species O 
, O 
B O 
. O 
bauhinoides O 
cruzipain O 
inhibitor O 
, O 
which O 
is O 
a O 
cysteine B-TRIVIAL 
and O 
serine B-TRIVIAL 
peptidase O 
inhibitor O 
, O 
and O 
B O 
. O 
bauhinioides O 
kallikrein O 
inhibitor O 
, O 
which O 
is O 
a O 
serine B-TRIVIAL 
peptidase O 
inhibitor O 
. O 
While O 
recombinant O 
B O 
. O 
bauhinoides O 
cruzipain O 
inhibitor O 
inhibits O 
human O 
neutrophil O 
elastase O 
cathepsin O 
G O 
and O 
the O 
cysteine B-TRIVIAL 
proteinase O 
cathepsin O 
L O 
, O 
recombinant O 
B O 
. O 
bauhinioides O 
kallikrein O 
inhibitor O 
inhibits O 
plasma O 
kallikrein O 
and O 
plasmin O 
. O 
The O 
effects O 
of O 
recombinant O 
B O 
. O 
bauhinoides O 
cruzipain O 
inhibitor O 
and O 
recombinant O 
B O 
. O 
bauhinioides O 
kallikrein O 
inhibitor O 
on O 
the O 
viability O 
of O 
tumor O 
cell O 
lines O 
with O 
a O 
distinct O 
potential O 
of O 
growth O 
from O 
the O 
same O 
tissue O 
were O 
compared O 
to O 
those O 
of O 
the O 
clinical O 
cytotoxic O 
drug O 
5-fluorouracil B-SYSTEMATIC 
. O 
At O 
12.5 O 
µM O 
concentration O 
, O 
recombinant O 
B O 
. O 
bauhinoides O 
cruzipain O 
inhibitor O 
and O 
recombinant O 
B O 
. O 
bauhinioides O 
kallikrein O 
inhibitor O 
were O 
more O 
efficient O 
than O 
5-fluorouracil B-SYSTEMATIC 
in O 
inhibiting O 
MKN-28 O 
and O 
Hs746T O 
( O 
gastric O 
) O 
, O 
HCT116 O 
and O 
HT29 O 
( O 
colorectal O 
) O 
, O 
SkBr-3 O 
and O 
MCF-7 O 
( O 
breast O 
) O 
, O 
and O 
THP-1 O 
and O 
K562 O 
( O 
leukemia O 
) O 
cell O 
lines O 
. O 
Additionally O 
, O 
recombinant O 
B O 
. O 
bauhinoides O 
cruzipain O 
inhibitor O 
inhibited O 
40 O 
% O 
of O 
the O 
migration O 
of O 
Hs746T O 
, O 
the O 
most O 
invasive O 
gastric O 
cell O 
line O 
, O 
while O 
recombinant O 
B O 
. O 
bauhinioides O 
kallikrein O 
inhibitor O 
did O 
not O 
affect O 
cell O 
migration O 
. O 
Recombinant O 
B O 
. O 
bauhinioides O 
kallikrein O 
inhibitor O 
and O 
recombinant O 
B O 
. O 
bauhinoides O 
cruzipain O 
inhibitor O 
, O 
even O 
at O 
high O 
doses O 
, O 
did O 
not O 
affect O 
hMSC O 
proliferation O 
while O 
5-fluorouracil B-SYSTEMATIC 
greatly O 
reduced O 
the O 
proliferation O 
rates O 
of O 
hMSCs O 
. O 
Therefore O 
, O 
both O 
recombinant O 
B O 
. O 
bauhinoides O 
cruzipain O 
inhibitor O 
and O 
recombinant O 
B O 
. O 
bauhinioides O 
kallikrein O 
inhibitor O 
might O 
be O 
considered O 
for O 
further O 
studies O 
to O 
block O 
peptidase O 
activities O 
in O 
order O 
to O 
target O 
specific O 
peptidase O 
- O 
mediated O 
growth O 
and O 
invasion O 
characteristics O 
of O 
individual O 
tumors O 
, O 
mainly O 
in O 
patients O 
resistant O 
to O 
5-fluorouracil B-SYSTEMATIC 
chemotherapy O 
. O 

neuronal O 
coenzyme B-TRIVIAL 
Q10 I-TRIVIAL 
deficiency O 
results O 
in O 
global O 
loss O 
of O 
mitochondrial O 
respiratory O 
chain O 
activity O 
, O 
increased O 
mitochondrial O 
oxidative O 
stress O 
and O 
reversal O 
of O 
ATP B-ABBREVIATION 
synthase O 
activity O 
: O 
implications O 
for O 
pathogenesis O 
and O 
treatment O 
. O 

of O 
coenzyme B-TRIVIAL 
Q(10) I-TRIVIAL 
( O 
CoQ(10) B-ABBREVIATION 
) O 
biosynthesis O 
represent O 
the O 
most O 
treatable O 
subgroup O 
of O 
mitochondrial O 
diseases O 
. O 
Neurological O 
involvement O 
is O 
frequently O 
observed O 
in O 
CoQ(10) B-ABBREVIATION 
deficiency O 
, O 
typically O 
presenting O 
as O 
cerebellar O 
ataxia O 
and O 
/ O 
or O 
seizures O 
. O 
The O 
aetiology O 
of O 
the O 
neurological O 
presentation O 
of O 
CoQ(10) B-ABBREVIATION 
deficiency O 
has O 
yet O 
to O 
be O 
fully O 
elucidated O 
and O 
therefore O 
in O 
order O 
to O 
investigate O 
these O 
phenomena O 
we O 
have O 
established O 
a O 
neuronal O 
cell O 
model O 
of O 
CoQ(10) B-ABBREVIATION 
deficiency O 
by O 
treatment O 
of O 
neuronal O 
SH-SY5Y O 
cell O 
line O 
with O 
para-aminobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PABA B-ABBREVIATION 
) O 
. O 
PABA B-ABBREVIATION 
is O 
a O 
competitive O 
inhibitor O 
of O 
the O 
CoQ(10) B-ABBREVIATION 
biosynthetic O 
pathway O 
enzyme O 
, O 
COQ2 O 
. O 
PABA B-ABBREVIATION 
treatment O 
( O 
1 O 
mM O 
) O 
resulted O 
in O 
a O 
54 O 
% O 
decrease O 
( O 
46 O 
% O 
residual O 
CoQ(10) B-ABBREVIATION 
) O 
decrease O 
in O 
neuronal O 
CoQ(10) B-ABBREVIATION 
status O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Reduction O 
of O 
neuronal O 
CoQ(10) B-ABBREVIATION 
status O 
was O 
accompanied O 
by O 
a O 
progressive O 
decrease O 
in O 
mitochondrial O 
respiratory O 
chain O 
enzyme O 
activities O 
, O 
with O 
a O 
67.5 O 
% O 
decrease O 
in O 
cellular O 
ATP B-ABBREVIATION 
production O 
at O 
46 O 
% O 
residual O 
CoQ(10) B-ABBREVIATION 
. O 
Mitochondrial O 
oxidative O 
stress O 
increased O 
four O 
- O 
fold O 
at O 
77 O 
% O 
and O 
46 O 
% O 
residual O 
CoQ(10) B-ABBREVIATION 
. O 
A O 
40 O 
% O 
increase O 
in O 
mitochondrial O 
membrane O 
potential O 
was O 
detected O 
at O 
46 O 
% O 
residual O 
CoQ(10) B-ABBREVIATION 
with O 
depolarisation O 
following O 
oligomycin O 
treatment O 
suggesting O 
a O 
reversal O 
of O 
complex O 
V O 
activity O 
. O 
This O 
neuronal O 
cell O 
model O 
provides O 
insights O 
into O 
the O 
effects O 
of O 
CoQ(10) B-ABBREVIATION 
deficiency O 
on O 
neuronal O 
mitochondrial O 
function O 
and O 
oxidative O 
stress O 
, O 
and O 
will O 
be O 
an O 
important O 
tool O 
to O 
evaluate O 
candidate O 
therapies O 
for O 
neurological O 
conditions O 
associated O 
with O 
CoQ(10) B-ABBREVIATION 
deficiency O 
. O 

leptin O 
increases O 
the O 
electrical O 
activity O 
of O 
supraoptic O 
nucleus O 
oxytocin B-TRIVIAL 
neurones O 
in O 
virgin O 
and O 
late O 
pregnant O 
rats O 
. O 

the O 
rat O 
hypothalamus O 
, O 
fasting O 
attenuates O 
the O 
expression O 
of O 
oxytocin B-TRIVIAL 
and O 
this O 
can O 
be O 
reversed O 
by O 
exogenous O 
leptin O 
administration O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
systemically O 
administered O 
leptin O 
on O 
the O 
electrical O 
activity O 
of O 
magnocellular O 
neurones O 
in O 
the O 
supraoptic O 
nucleus O 
of O 
urethane B-TRIVIAL 
-anaesthetised O 
rats O 
. O 
In O 
virgin O 
female O 
rats O 
, O 
systemic O 
leptin O 
significantly O 
excited O 
identified O 
oxytocin B-TRIVIAL 
neurones O 
with O 
no O 
detected O 
effects O 
on O 
the O 
patterning O 
of O 
activity O 
, O 
as O 
reflected O 
by O 
hazard O 
function O 
analyses O 
. O 
The O 
lowest O 
dose O 
that O 
was O 
consistently O 
effective O 
was O 
100 O 
μg O 
/ O 
i.v O 
. O 
, O 
and O 
this O 
dose O 
had O 
no O 
significant O 
effect O 
on O 
vasopressin B-FAMILY 
neurones O 
. O 
In O 
virgin O 
rats O 
fasted O 
overnight O 
, O 
the O 
spontaneous O 
firing O 
rate O 
of O 
oxytocin B-TRIVIAL 
neurones O 
was O 
significantly O 
lower O 
than O 
in O 
unfasted O 
rats O 
, O 
although O 
leptin O 
had O 
a O 
similar O 
excitatory O 
effect O 
as O 
in O 
unfasted O 
rats O 
. O 
In O 
late O 
pregnant O 
rats O 
( O 
days O 
19-21 O 
of O 
pregnancy O 
) O 
, O 
spontaneous O 
firing O 
rates O 
of O 
oxytocin B-TRIVIAL 
neurones O 
were O 
higher O 
than O 
in O 
virgins O 
, O 
and O 
the O 
initial O 
response O 
to O 
leptin O 
was O 
similar O 
to O 
that O 
in O 
virgin O 
rats O 
, O 
although O 
the O 
increase O 
in O 
activity O 
was O 
more O 
persistent O 
. O 
In O 
fasted O 
pregnant O 
rats O 
, O 
the O 
mean O 
spontaneous O 
firing O 
rate O 
of O 
oxytocin B-TRIVIAL 
neurones O 
was O 
again O 
lower O 
than O 
in O 
unfasted O 
rats O 
, O 
although O 
leptin O 
had O 
no O 
significant O 
effect O 
even O 
at O 
the O 
higher O 
dose O 
of O 
1 O 
mg O 
/ O 
rat O 
. O 
Thus O 
, O 
fasting O 
reduced O 
the O 
spontaneous O 
firing O 
rates O 
of O 
oxytocin B-TRIVIAL 
neurones O 
in O 
nonpregnant O 
rats O 
, O 
and O 
this O 
effect O 
could O 
be O 
reversed O 
by O 
the O 
excitatory O 
effects O 
of O 
leptin O 
. O 
Pregnant O 
rats O 
showed O 
some O 
evidence O 
of O 
leptin O 
resistance O 
but O 
only O 
after O 
an O 
overnight O 
fast O 
. O 

, O 
tissue O 
distribution O 
and O 
excretion O 
study O 
of O 
resveratrol B-TRIVIAL 
and O 
its O 
prodrug O 
3,5,4'-tri-O-acetylresveratrol B-SYSTEMATIC 
in O 
rats O 
. O 

( O 
TARES B-ABBREVIATION 
) O 
synthesized O 
by O 
acetylating O 
three O 
hydroxyl B-SYSTEMATIC 
groups O 
of O 
resveratrol B-TRIVIAL 
( O 
RES B-ABBREVIATION 
) O 
is O 
a O 
prodrug O 
of O 
RES B-ABBREVIATION 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
and O 
compare O 
the O 
pharmacokinetics O 
, O 
tissue O 
distribution O 
and O 
excretion O 
of O 
TARES B-ABBREVIATION 
and O 
RES B-ABBREVIATION 
in O 
rats O 
following O 
a O 
single O 
intragastric O 
gavage O 
( O 
i.g O 
. O 
) O 
administration O 
. O 
After O 
RES B-ABBREVIATION 
is O 
transformed O 
into O 
TARES B-ABBREVIATION 
, O 
its O 
pharmacokinetic O 
properties O 
are O 
improved O 
, O 
such O 
as O 
the O 
t1 O 
/ O 
2 O 
has O 
been O 
prolonged O 
and O 
the O 
AUC O 
has O 
been O 
enhanced O 
. O 
And O 
TARES B-ABBREVIATION 
follows O 
linear O 
plasma O 
pharmacokinetics O 
across O 
the O 
investigated O 
dosage O 
range O 
in O 
rats O 
( O 
77.5-310mg O 
/ O 
kg O 
) O 
. O 
The O 
major O 
distribution O 
tissues O 
of O 
TARES B-ABBREVIATION 
or O 
RES B-ABBREVIATION 
in O 
rats O 
were O 
liver O 
, O 
spleen O 
, O 
heart O 
and O 
lung O 
. O 
TARES B-ABBREVIATION 
can O 
increase O 
the O 
content O 
of O 
RES B-ABBREVIATION 
in O 
lung O 
significantly O 
. O 
There O 
was O 
no O 
long O 
- O 
term O 
accumulation O 
of O 
RES B-ABBREVIATION 
in O 
rat O 
tissues O 
. O 
Whether O 
we O 
administrated O 
to O 
rats O 
of O 
equimolar O 
TARES B-ABBREVIATION 
or O 
RES B-ABBREVIATION 
, O 
total O 
recoveries O 
of O 
RES B-ABBREVIATION 
in O 
urine O 
and O 
feces O 
within O 
36h O 
were O 
low O 
( O 
0.99% O 
or O 
0.07% O 
in O 
urine O 
and O 
1.69% O 
or O 
0.15% O 
in O 
feces O 
) O 
. O 

carotenoids O 
are O 
absorbed O 
in O 
the O 
intestine O 
and O 
delivered O 
to O 
various O 
tissues O 
by O 
circulating O 
lipoproteins O 
; O 
however O 
, O 
the O 
mechanism O 
underlying O 
selective O 
delivery O 
of O 
different O 
carotenoid O 
species O 
to O 
individual O 
tissues O 
remains O 
elusive O 
. O 
The O 
products O 
of O 
the O 
Yellow O 
cocoon O 
( O 
C O 
) O 
gene O 
and O 
the O 
Flesh O 
( O 
F O 
) O 
gene O 
of O 
the O 
silkworm O 
Bombyx O 
mori O 
determine O 
the O 
selectivity O 
for O 
transport O 
of O 
lutein B-TRIVIAL 
and O 
β-carotene B-TRIVIAL 
, O 
respectively O 
, O 
to O 
the O 
silk O 
gland O 
. O 
We O 
previously O 
showed O 
that O 
the O 
C O 
gene O 
encodes O 
Cameo2 O 
, O 
a O 
CD36 O 
family O 
member O 
, O 
which O 
is O 
thought O 
to O 
function O 
as O 
a O 
transmembrane O 
lipoprotein O 
receptor O 
. O 
Here O 
, O 
we O 
elucidated O 
the O 
molecular O 
identity O 
of O 
the O 
F O 
gene O 
product O 
by O 
positional O 
cloning O 
, O 
as O 
SCRB15 O 
, O 
a O 
paralog O 
of O 
Cameo2 O 
with O 
26% O 
amino B-FAMILY 
acid I-FAMILY 
identity O 
. O 
In O 
the O 
F O 
mutant O 
, O 
SCRB15 O 
mRNA O 
structure O 
was O 
severely O 
disrupted O 
, O 
due O 
to O 
a O 
1.4 O 
kb O 
genomic O 
insertion O 
in O 
a O 
coding O 
exon O 
. O 
Transgenic O 
expression O 
of O 
SCRB15 O 
in O 
the O 
middle O 
silk O 
gland O 
using O 
the O 
binary O 
GAL4-UAS O 
expression O 
system O 
enhanced O 
selective O 
β-carotene B-TRIVIAL 
uptake O 
by O 
the O 
middle O 
silk O 
gland O 
, O 
while O 
transgenic O 
expression O 
of O 
Cameo2 O 
enhanced O 
selective O 
lutein B-TRIVIAL 
uptake O 
under O 
the O 
same O 
GAL4 O 
driver O 
. O 
Our O 
findings O 
indicate O 
that O 
divergence O 
of O 
genes O 
in O 
the O 
CD36 O 
family O 
determines O 
the O 
selectivity O 
of O 
carotenoid O 
species O 
uptake O 
by O 
silk O 
gland O 
tissue O 
and O 
that O 
CD36-homologous O 
proteins O 
can O 
discriminate O 
among O 
carotenoid O 
species O 
. O 

work O 
reports O 
on O 
the O 
composition O 
and O 
bionutritional O 
value O 
of O 
organic O 
virgin O 
olive O 
oil O 
from O 
the O 
Nocellara O 
del O 
Belice O 
variety O 
, O 
one O 
cultivated O 
in O 
the O 
olive O 
areas O 
of O 
the O 
Sicily O 
region O 
, O 
Italy O 
. O 
Destoned O 
oils O 
obtained O 
by O 
processing O 
olives O 
with O 
a O 
destoning O 
- O 
based O 
procedure O 
were O 
compared O 
with O 
conventional O 
oils O 
. O 
This O 
innovative O 
technique O 
, O 
consisting O 
in O 
removing O 
the O 
stone O 
from O 
fruits O 
prior O 
to O 
processing O 
, O 
strongly O 
enhanced O 
the O 
already O 
high O 
- O 
quality O 
level O 
of O 
the O 
conventional O 
product O 
. O 
An O 
in O 
- O 
depth O 
analytical O 
investigation O 
from O 
2008 O 
to O 
2010 O 
showed O 
how O 
this O 
innovative O 
olive O 
extraction O 
process O 
led O 
to O 
an O 
excellent O 
peculiar O 
final O 
product O 
, O 
mainly O 
attributable O 
to O 
the O 
improved O 
biophenol O 
and O 
volatile O 
composition O 
, O 
as O 
well O 
as O 
higher O 
concentrations O 
of O 
the O 
lipophilic O 
and O 
vitamin O 
antioxidants O 
( O 
tocopherols B-FAMILY 
and O 
tocotrienols B-FAMILY 
) O 
. O 
It O 
had O 
higher O 
levels O 
of O 
oleocanthal B-TRIVIAL 
( O 
p-HPEA-EDA B-ABBREVIATION 
) O 
, O 
a O 
nutraceutical O 
compound O 
exerting O 
actions O 
against O 
COX1 O 
and O 
COX2 O 
( O 
cycloxygenases O 
) O 
. O 
Its O 
head O 
- O 
space O 
aroma O 
displayed O 
new O 
volatile O 
phytomolecules O 
and O 
also O 
had O 
higher O 
levels O 
of O 
green O 
volatiles O 
from O 
the O 
lipoxygenase O 
(LOX)-pathway O 
( O 
one O 
having O 
as O 
precursors O 
the O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
containing O 
a O 
cis-cis-1,4-pentadiene B-SYSTEMATIC 
system O 
) O 
. O 
Among O 
the O 
other O 
bioactives O 
, O 
we O 
highlight O 
its O 
significant O 
levels O 
of O 
trans-β-carotene B-TRIVIAL 
and O 
xanthophylls B-FAMILY 
( O 
lutein B-TRIVIAL 
, O 
violaxanthin B-TRIVIAL 
, O 
neoxanthin B-TRIVIAL 
and O 
other O 
carotenoids O 
) O 
. O 
Its O 
enhanced O 
nutritional O 
value O 
was O 
also O 
attributable O 
to O 
the O 
increased O 
intensity O 
of O 
valuable O 
tasting O 
notes O 
. O 

proof O 
- O 
of O 
- O 
concept O 
study O 
with O 
MSDC-0160 B-NO_CLASS 
, O 
a O 
prototype O 
mTOT-modulating O 
insulin O 
sensitizer O 
. O 

may O 
be O 
possible O 
to O 
achieve O 
insulin O 
sensitivity O 
through O 
the O 
recently O 
identified O 
mitochondrial O 
target O 
of O 
thiazolidinediones B-FAMILY 
( O 
mTOT O 
) O 
, O 
thereby O 
avoiding O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor-γ O 
(PPAR-γ)-dependent O 
side O 
effects O 
. O 
In O 
this O 
phase O 
IIb O 
clinical O 
trial O 
, O 
258 O 
patients O 
with O 
type O 
2 O 
diabetes O 
completed O 
a O 
12-week O 
protocol O 
with O 
50 O 
, O 
100 O 
, O 
or O 
150 O 
mg O 
of O 
MSDC-0160 B-NO_CLASS 
( O 
an O 
mTOT O 
modulator O 
) O 
, O 
45 O 
mg O 
pioglitazone B-FORMULA 
HCl I-FORMULA 
( O 
a O 
PPAR-γ O 
agonist O 
) O 
, O 
or O 
a O 
placebo O 
. O 
The O 
two O 
active O 
treatments O 
lowered O 
fasting O 
glucose B-TRIVIAL 
levels O 
to O 
the O 
same O 
extent O 
. O 
The O 
decreases O 
in O 
glycated O 
hemoglobin O 
( O 
HbA1c O 
) O 
observed O 
with O 
the O 
two O 
higher O 
doses O 
of O 
MSDC-0160 B-NO_CLASS 
were O 
not O 
different O 
from O 
those O 
associated O 
with O 
pioglitazone B-TRIVIAL 
. O 
By O 
contrast O 
, O 
fluid O 
retention O 
as O 
evidenced O 
by O 
reduction O 
in O 
hematocrit O 
, O 
red O 
blood O 
cells O 
, O 
and O 
total O 
hemoglobin O 
was O 
50% O 
less O 
in O 
the O 
MSDC-0160 B-NO_CLASS 
-treated O 
groups O 
. O 
There O 
was O 
also O 
a O 
smaller O 
increase O 
in O 
high O 
- O 
molecular O 
- O 
weight O 
( O 
HMW O 
) O 
adiponectin O 
with O 
MSDC-0160 B-NO_CLASS 
than O 
with O 
pioglitazone B-TRIVIAL 
( O 
P O 
< O 
0.0001 O 
) O 
, O 
suggesting O 
that O 
MSDC-0160 B-NO_CLASS 
produces O 
less O 
expansion O 
of O 
white O 
adipose O 
tissue O 
. O 
Thus O 
, O 
mTOT O 
modulators O 
may O 
have O 
glucose B-TRIVIAL 
-lowering O 
effects O 
similar O 
to O 
those O 
of O 
pioglitazone B-TRIVIAL 
but O 
without O 
the O 
adverse O 
effects O 
associated O 
with O 
PPAR-γ O 
agonists O 
. O 

studies O 
should O 
be O 
taken O 
into O 
account O 
when O 
evaluating O 
the O 
physiological O 
effects O 
of O 
ingested O 
compounds O 
at O 
the O 
intestine O 
level O 
. O 
Several O 
in O 
vitro O 
digestion O 
protocols O 
have O 
been O 
described O 
, O 
with O 
a O 
wide O 
range O 
of O 
experimental O 
conditions O 
but O 
no O 
optimised O 
protocol O 
exists O 
. O 
In O 
order O 
to O 
fill O 
in O 
this O 
gap O 
, O 
we O 
evaluated O 
the O 
influence O 
of O 
three O 
continuous O 
factors O 
( O 
pH O 
, O 
incubation O 
time O 
, O 
and O 
enzyme O 
concentrations O 
) O 
, O 
in O 
the O 
range O 
of O 
values O 
found O 
in O 
literature O 
, O 
on O 
the O 
digestion O 
of O 
standard O 
macronutrients O 
( O 
starch O 
, O 
albumin O 
, O 
triolein B-TRIVIAL 
) O 
alone O 
or O 
in O 
mixture O 
. O 
Three O 
central O 
composite O 
designs O 
, O 
using O 
response O 
surface O 
methodology O 
, O 
were O 
employed O 
to O 
model O 
the O 
three O 
abiotic O 
steps O 
of O 
pre O 
- O 
colonic O 
digestion O 
. O 
A O 
validated O 
in O 
vitro O 
digestion O 
was O 
eventually O 
set O 
up O 
for O 
the O 
salivary O 
step O 
( O 
pH O 
6.9 O 
, O 
5 O 
min O 
, O 
3.9 O 
units O 
α-amylase O 
/ O 
ml O 
) O 
, O 
the O 
gastric O 
step O 
( O 
pH O 
2 O 
, O 
90 O 
min O 
, O 
71.2 O 
units O 
pepsin O 
/ O 
ml O 
) O 
, O 
and O 
the O 
abiotic O 
duodenal O 
step O 
( O 
pH O 
7 O 
, O 
150 O 
min O 
, O 
9.2mg O 
pancreatin O 
and O 
55.2mg O 
bile O 
extract O 
/ O 
ml O 
) O 
. O 

- O 
based O 
therapeutics O 
have O 
grown O 
in O 
importance O 
over O 
the O 
last O 
few O 
decades O 
. O 
Furthermore O 
, O 
peptides O 
have O 
been O 
extensively O 
used O 
as O 
lead O 
compounds O 
in O 
the O 
drug O 
discovery O 
process O 
to O 
investigate O 
the O 
nature O 
of O 
chemical O 
space O 
required O 
for O 
molecular O 
recognition O 
and O 
activity O 
at O 
a O 
variety O 
of O 
targets O 
. O 
This O 
critical O 
commentary O 
reviews O 
scanning O 
techniques O 
, O 
which O 
employ O 
natural O 
and O 
non O 
- O 
proteinogenic O 
amino B-FAMILY 
acids I-FAMILY 
to O 
facilitate O 
understanding O 
of O 
structural O 
requirements O 
for O 
peptide O 
biological O 
activity O 
. O 
The O 
value O 
of O 
sequence O 
analysis O 
by O 
such O 
methods O 
is O 
highlighted O 
by O 
examples O 
, O 
in O 
which O 
the O 
elements O 
for O 
peptide O 
affinity O 
and O 
activity O 
have O 
been O 
elucidated O 
and O 
employed O 
to O 
prepare O 
peptidomimetic O 
leads O 
for O 
drug O 
development O 
. O 

this O 
paper O 
, O 
we O 
present O 
a O 
rapid O 
, O 
high O 
- O 
yield O 
, O 
low O 
- O 
end O 
and O 
low O 
- O 
cost O 
fabrication O 
of O 
nanojet O 
motors O 
using O 
a O 
template O 
directed O 
electrochemical O 
deposition O 
method O 
. O 
Using O 
an O 
electrochemical O 
deposition O 
method O 
, O 
the O 
bubble O 
- O 
ejecting O 
nanojets O 
were O 
grown O 
within O 
the O 
alumina B-TRIVIAL 
template O 
, O 
which O 
is O 
commercially O 
available O 
. O 
These O 
fabricated O 
nanosized O 
devices O 
have O 
typical O 
dimensions O 
of O 
300 O 
nm O 
( O 
diameter O 
) O 
by O 
4.5 O 
μm O 
( O 
length O 
) O 
, O 
and O 
they O 
are O 
able O 
to O 
move O 
in O 
a O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
fuel O 
solution O 
with O 
velocities O 
up O 
to O 
approximately O 
40 O 
body O 
lengths O 
per O 
second O 
. O 
They O 
are O 
also O 
capable O 
of O 
exhibiting O 
various O 
modes O 
of O 
movement O 
such O 
as O 
straight O 
, O 
screw O 
- O 
like O 
and O 
circular O 
motions O 
, O 
in O 
a O 
similar O 
manner O 
comparable O 
to O 
larger O 
micro O 
- O 
sized O 
jets O 
. O 
In O 
addition O 
, O 
due O 
to O 
their O 
small O 
dimensions O 
, O 
the O 
movements O 
of O 
these O 
nanojets O 
can O 
be O 
strongly O 
influenced O 
by O 
colliding O 
them O 
with O 
microbubbles O 
. O 
This O 
highly O 
parallel O 
method O 
which O 
is O 
of O 
low O 
- O 
cost O 
and O 
requires O 
the O 
usage O 
of O 
low O 
- O 
end O 
equipment O 
that O 
can O 
be O 
easily O 
located O 
in O 
any O 
laboratory O 
opens O 
up O 
the O 
doors O 
for O 
world O 
- O 
wide O 
nanojet O 
fabrication O 
in O 
the O 
near O 
future O 
. O 

formation O 
mechanism O 
of O 
the O 
thymine B-TRIVIAL 
- I-TRIVIAL 
thymine I-TRIVIAL 
( I-TRIVIAL 
6-4 I-TRIVIAL 
) I-TRIVIAL 
adduct O 
. O 

photoinduced O 
mechanism O 
leading O 
to O 
the O 
formation O 
of O 
the O 
thymine B-TRIVIAL 
- I-TRIVIAL 
thymine I-TRIVIAL 
( I-TRIVIAL 
6-4 I-TRIVIAL 
) I-TRIVIAL 
photolesion O 
has O 
been O 
studied O 
by O 
using O 
the O 
CASPT2 O 
/ O 
/ O 
CASSCF O 
approach O 
over O 
a O 
dinucleotide B-FAMILY 
model O 
in O 
vacuo O 
. O 
Following O 
light O 
absorption O 
, O 
localization O 
of O 
the O 
excitation O 
on O 
a O 
single O 
thymine B-TRIVIAL 
leads O 
to O 
fast O 
singlet O 
- O 
triplet O 
crossing O 
that O 
populates O 
the O 
triplet O 
(3)(nπ*) O 
state O 
of O 
thymine B-TRIVIAL 
. O 
This O 
state O 
, O 
displaying O 
an O 
elongated O 
C(4)═O O 
bond O 
, O 
triggers O 
( O 
6-4 O 
) O 
dimer O 
formation O 
by O 
reaction O 
with O 
the O 
C(5)═C(6) O 
double O 
bond O 
of O 
the O 
adjacent O 
thymine B-TRIVIAL 
, O 
followed O 
by O 
a O 
second O 
intersystem O 
crossing O 
, O 
which O 
acts O 
as O 
a O 
gate O 
between O 
the O 
excited O 
state O 
of O 
the O 
reactant O 
and O 
the O 
ground O 
state O 
of O 
the O 
photoproduct O 
. O 
The O 
requirement O 
of O 
localized O 
excitation O 
on O 
just O 
one O 
thymine B-TRIVIAL 
, O 
whose O 
main O 
decay O 
channel O 
( O 
by O 
radiationless O 
repopulation O 
of O 
its O 
ground O 
state O 
) O 
is O 
nonphotochemical O 
, O 
can O 
rationalize O 
the O 
experimentally O 
observed O 
low O 
quantum O 
yield O 
of O 
formation O 
for O 
the O 
thymine B-TRIVIAL 
- I-TRIVIAL 
thymine I-TRIVIAL 
( I-TRIVIAL 
6-4 I-TRIVIAL 
) I-TRIVIAL 
adduct O 
. O 

activity O 
of O 
hydroxytyrosol B-SYSTEMATIC 
and O 
hydroxytyrosyl B-TRIVIAL 
laurate I-TRIVIAL 
. O 

( O 
HyT B-ABBREVIATION 
) O 
is O 
a O 
polyphenol B-FAMILY 
primarily O 
released O 
in O 
olive O 
mill O 
wastewater O 
and O 
in O 
olive O 
oil O 
. O 
In O 
animal O 
and O 
cell O 
model O 
studies O 
, O 
HyT B-ABBREVIATION 
and O 
its O 
metabolites O 
have O 
strong O 
antioxidant O 
and O 
antimicrobial O 
activities O 
, O 
as O 
well O 
as O 
beneficial O 
effects O 
on O 
the O 
cardiovascular O 
system O 
and O 
in O 
several O 
human O 
diseases O 
. O 
Differently O 
, O 
many O 
researchers O 
reported O 
that O 
HyT B-ABBREVIATION 
down O 
- O 
regulates O 
tumor O 
cell O 
viability O 
and O 
cell O 
cycle O 
progression O 
, O 
and O 
induces O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
and O 
apoptosis O 
. O 
In O 
this O 
study O 
we O 
have O 
investigated O 
the O 
effects O 
of O 
HyT B-ABBREVIATION 
and O 
the O 
corresponding O 
ester O 
hydroxytyrosyl B-TRIVIAL 
laurate I-TRIVIAL 
in O 
U937 O 
cells O 
, O 
a O 
human O 
monocytoid O 
cell O 
line O 
, O 
and O 
in O 
C2C12 O 
myoblasts O 
, O 
a O 
murine O 
proliferating O 
muscle O 
cell O 
model O 
, O 
after O 
apoptotic O 
death O 
induction O 
. O 
Inverted O 
, O 
light O 
and O 
transmission O 
electron O 
microscopy O 
have O 
been O 
utilized O 
to O 
characterize O 
cell O 
death O 
patterns O 
. O 
H2O2 B-FORMULA 
, O 
at O 
the O 
concentrations O 
known O 
to O 
induce O 
apoptosis O 
, O 
was O 
utilized O 
as O 
cell O 
death O 
trigger O 
. O 
The O 
results O 
obtained O 
show O 
that O 
laur-HyT B-ABBREVIATION 
has O 
a O 
protective O 
antioxidant O 
effect O 
against O 
H2O2 B-FORMULA 
treatment O 
, O 
greater O 
than O 
HyT B-ABBREVIATION 
, O 
so O 
having O 
a O 
role O 
in O 
the O 
prevention O 
of O 
apoptotic O 
death O 
in O 
normal O 
and O 
tumor O 
cells O 
. O 
These O 
data O 
suggest O 
these O 
compounds O 
as O 
good O 
candidate O 
for O 
novel O 
therapeutic O 
strategies O 
. O 

of O 
eukaryotic O 
initiation O 
factor O 
4E O 
( O 
eIF4E O 
) O 
are O 
frequently O 
elevated O 
in O 
human O 
cancers O 
and O 
in O 
some O 
instances O 
have O 
been O 
associated O 
with O 
poor O 
prognosis O 
and O 
outcome O 
. O 
Here O 
we O 
utilize O 
transgenic O 
and O 
allograft O 
breast O 
cancer O 
models O 
to O 
demonstrate O 
that O 
increased O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
signalling O 
can O 
be O 
a O 
significant O 
contributor O 
to O 
breast O 
cancer O 
progression O 
in O 
vivo O 
. O 
Suppressing O 
mTOR O 
activity O 
, O 
as O 
well O 
as O 
levels O 
and O 
activity O 
of O 
the O 
downstream O 
translation O 
regulators O 
, O 
eIF4E O 
and O 
eIF4A O 
, O 
delayed O 
breast O 
cancer O 
progression O 
, O 
onset O 
of O 
associated O 
pulmonary O 
metastasis O 
in O 
vivo O 
and O 
breast O 
cancer O 
cell O 
invasion O 
and O 
migration O 
in O 
vitro O 
. O 
Translation O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
, O 
matrix O 
metallopeptidase O 
9 O 
( O 
MMP9 O 
) O 
and O 
cyclin O 
D1 O 
mRNAs O 
, O 
which O 
encode O 
products O 
associated O 
with O 
the O 
metastatic O 
phenotype O 
, O 
is O 
inhibited O 
upon O 
eIF4E O 
suppression O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
mTOR O 
/ O 
eIF4F O 
axis O 
is O 
an O 
important O 
contributor O 
to O 
tumor O 
maintenance O 
and O 
progression O 
programs O 
in O 
breast O 
cancer O 
. O 
Targeting O 
this O 
pathway O 
may O 
be O 
of O 
therapeutic O 
benefit O 
. O 

between O 
stimulation O 
of O 
mesolimbic O 
dopamine B-TRIVIAL 
and O 
place O 
conditioning O 
in O 
rats O 
produced O 
by O 
cocaine B-TRIVIAL 
or O 
drugs O 
that O 
are O 
tolerant O 
to O 
dopamine B-TRIVIAL 
transporter O 
conformational O 
change O 
. O 

: O 
Dopamine B-TRIVIAL 
transporter O 
( O 
DAT O 
) O 
conformation O 
plays O 
a O 
role O 
in O 
the O 
effectiveness O 
of O 
cocaine B-TRIVIAL 
-like O 
and O 
other O 
DAT O 
inhibitors O 
. O 
Cocaine B-TRIVIAL 
-like O 
stimulants O 
are O 
intolerant O 
to O 
DAT O 
conformation O 
changes O 
having O 
decreased O 
potency O 
in O 
cells O 
transfected O 
with O 
DAT O 
constructs O 
that O 
face O 
the O 
cytosol O 
compared O 
to O 
wild O 
- O 
type O 
DAT O 
. O 
In O 
contrast O 
, O 
analogs O 
of O 
benztropine B-TRIVIAL 
( O 
BZT B-ABBREVIATION 
) O 
are O 
among O 
compounds O 
that O 
are O 
less O 
affected O 
by O 
DAT O 
conformational O 
change O 
. O 
METHODS O 
: O 
We O 
compared O 
the O 
displacement O 
of O 
radioligand O 
binding O 
to O 
various O 
mammalian O 
CNS O 
sites O 
, O 
acute O 
stimulation O 
of O 
accumbens O 
shell O 
dopamine B-TRIVIAL 
levels O 
, O 
and O 
place O 
conditioning O 
in O 
rats O 
among O 
cocaine B-TRIVIAL 
and O 
four O 
BZT B-ABBREVIATION 
analogs O 
with O 
Cl B-FORMULA 
substitutions O 
on O 
the O 
diphenyl-ether B-SYSTEMATIC 
system O 
including O 
two O 
with O 
carboalkoxy B-FAMILY 
substitutions O 
at O 
the O 
2- O 
position O 
of O 
the O 
tropane B-TRIVIAL 
ring O 
. O 
RESULTS O 
: O 
Binding O 
assays O 
confirmed O 
high O 
- O 
affinity O 
and O 
selectivity O 
for O 
the O 
DAT O 
with O 
the O 
BZT B-ABBREVIATION 
analogs O 
which O 
also O 
produced O 
significant O 
stimulation O 
of O 
mesolimbic O 
dopamine B-TRIVIAL 
efflux O 
. O 
Because O 
BZT B-ABBREVIATION 
analogs O 
produced O 
temporal O 
patterns O 
of O 
extracellular O 
dopamine B-TRIVIAL 
levels O 
different O 
from O 
those O 
by O 
cocaine B-TRIVIAL 
( O 
3-10 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
, O 
the O 
place O 
conditioning O 
produced O 
by O 
BZ B-ABBREVIATION 
T O 
analogs O 
and O 
cocain B-TRIVIAL 
e O 
was O 
compared O 
at O 
doses O 
and O 
times O 
at O 
which O 
both O 
the O 
increase O 
in O 
dopamin B-TRIVIAL 
e O 
levels O 
and O 
rates O 
of O 
increase O 
were O 
similar O 
to O 
those O 
produced O 
by O 
an O 
effective O 
dose O 
of O 
cocain B-TRIVIAL 
e O 
. O 
Despite O 
this O 
equilibration O 
, O 
none O 
of O 
the O 
BZ B-ABBREVIATION 
T O 
analogs O 
tested O 
produced O 
significant O 
place O 
conditioning O 
. O 
CONCLUSIONS O 
: O 
The O 
present O 
results O 
extend O 
previous O 
findings O 
suggesting O 
that O 
cocain B-TRIVIAL 
e O 
- O 
like O 
actions O 
are O 
dependent O 
on O 
a O 
binding O 
equilibrium O 
that O 
favors O 
the O 
outward O 
conformational O 
state O 
of O 
the O 
DAT O 
. O 
In O 
contrast O 
, O 
BZ B-ABBREVIATION 
T O 
analogs O 
with O 
reduced O 
dependence O 
on O 
DAT O 
conformation O 
have O 
reduced O 
cocain B-TRIVIAL 
e O 
- O 
like O 
behavioral O 
effects O 
and O 
may O 
prove O 
useful O 
in O 
development O 
of O 
medications O 
for O 
stimulant O 
abuse O 
. O 

of O 
structural O 
materials O 
and O 
fibers O 
is O 
usually O 
increased O 
at O 
the O 
expense O 
of O 
strain O 
at O 
failure O 
and O 
toughness O 
. O 
Recent O 
experimental O 
studies O 
have O 
demonstrated O 
improvements O 
in O 
modulus O 
and O 
strength O 
of O 
electrospun O 
polymer O 
nanofibers O 
with O 
reduction O 
of O 
their O 
diameter O 
. O 
Nanofiber O 
toughness O 
has O 
not O 
been O 
analyzed O 
; O 
however O 
, O 
from O 
the O 
classical O 
materials O 
property O 
trade-off O 
, O 
one O 
can O 
expect O 
it O 
to O 
decrease O 
. O 
Here O 
, O 
on O 
the O 
basis O 
of O 
a O 
comprehensive O 
analysis O 
of O 
long O 
( O 
5-10 O 
mm O 
) O 
individual O 
polyacrylonitrile B-FAMILY 
nanofibers O 
, O 
we O 
show O 
that O 
nanofiber O 
toughness O 
also O 
dramatically O 
improves O 
. O 
Reduction O 
of O 
fiber O 
diameter O 
from O 
2.8 O 
μm O 
to O 
∼100 O 
nm O 
resulted O 
in O 
simultaneous O 
increases O 
in O 
elastic O 
modulus O 
from O 
0.36 O 
to O 
48 O 
GPa O 
, O 
true O 
strength O 
from O 
15 O 
to O 
1750 O 
MPa O 
, O 
and O 
toughness O 
from O 
0.25 O 
to O 
605 O 
MPa O 
with O 
the O 
largest O 
increases O 
recorded O 
for O 
the O 
ultrafine O 
nanofibers O 
smaller O 
than O 
250 O 
nm O 
. O 
The O 
observed O 
size O 
effects O 
showed O 
no O 
sign O 
of O 
saturation O 
. O 
Structural O 
investigations O 
and O 
comparisons O 
with O 
mechanical O 
behavior O 
of O 
annealed O 
nanofibers O 
allowed O 
us O 
to O 
attribute O 
ultrahigh O 
ductility O 
( O 
average O 
failure O 
strain O 
stayed O 
over O 
50% O 
) O 
and O 
toughness O 
to O 
low O 
nanofiber O 
crystallinity O 
resulting O 
from O 
rapid O 
solidification O 
of O 
ultrafine O 
electrospun O 
jets O 
. O 
Demonstrated O 
superior O 
mechanical O 
performance O 
coupled O 
with O 
the O 
unique O 
macro O 
- O 
nano O 
nature O 
of O 
continuous O 
nanofibers O 
makes O 
them O 
readily O 
available O 
for O 
macroscopic O 
materials O 
and O 
composites O 
that O 
can O 
be O 
used O 
in O 
safety O 
- O 
critical O 
applications O 
. O 
The O 
proposed O 
mechanism O 
of O 
simultaneously O 
high O 
strength O 
, O 
modulus O 
, O 
and O 
toughness O 
challenges O 
the O 
prevailing O 
50 O 
year O 
old O 
paradigm O 
of O 
high O 
- O 
performance O 
polymer O 
fiber O 
development O 
calling O 
for O 
high O 
polymer O 
crystallinity O 
and O 
may O 
have O 
broad O 
implications O 
in O 
fiber O 
science O 
and O 
technology O 
. O 

interacts O 
with O 
a O 
common O 
binding O 
site O 
to O 
elicit O 
opposite O 
effects O 
on O 
inactivation O 
gating O 
of O 
EAG O 
and O 
ERG O 
potassium B-SYSTEMATIC 
channels O 
. O 

and O 
voltage O 
- O 
dependent O 
inactivation O 
greatly O 
attenuates O 
outward O 
currents O 
in O 
ether B-SYSTEMATIC 
-a-go O 
- O 
go O 
- O 
related O 
gene O 
( O 
ERG O 
) O 
K(+) B-FORMULA 
channels O 
. O 
In O 
contrast O 
, O 
inactivation O 
of O 
related O 
ether B-SYSTEMATIC 
-a-go O 
- O 
go O 
( O 
EAG O 
) O 
K(+) B-FORMULA 
channels O 
is O 
very O 
slow O 
and O 
minimally O 
reduces O 
outward O 
currents O 
. O 
ICA-105574 B-IDENTIFIER 
( O 
ICA B-ABBREVIATION 
, O 
or O 
3-nitro-N-[4-phenoxyphenyl]-benzamide B-SYSTEMATIC 
) O 
has O 
opposite O 
effects O 
on O 
inactivation O 
of O 
these O 
two O 
channel O 
types O 
. O 
Although O 
ICA B-ABBREVIATION 
greatly O 
attenuates O 
ERG O 
inactivation O 
by O 
shifting O 
its O 
voltage O 
dependence O 
to O 
more O 
positive O 
potentials O 
, O 
it O 
enhances O 
the O 
rate O 
and O 
extent O 
of O 
EAG O 
inactivation O 
without O 
altering O 
its O 
voltage O 
dependence O 
. O 
Here O 
, O 
we O 
investigate O 
whether O 
the O 
inverse O 
functional O 
response O 
to O 
ICA B-ABBREVIATION 
in O 
EAG O 
and O 
ERG O 
channels O 
is O 
related O 
to O 
differences O 
in O 
ICA B-ABBREVIATION 
binding O 
site O 
or O 
to O 
intrinsic O 
mechanisms O 
of O 
inactivation O 
. O 
Molecular O 
modeling O 
coupled O 
with O 
site O 
- O 
directed O 
mutagenesis O 
suggests O 
that O 
ICA B-ABBREVIATION 
binds O 
in O 
a O 
channel O 
- O 
specific O 
orientation O 
to O 
a O 
hydrophobic O 
pocket O 
bounded O 
by O 
the O 
S5 O 
/ O 
pore O 
helix O 
/ O 
S6 O 
of O 
one O 
subunit O 
and O 
S6 O 
of O 
an O 
adjacent O 
subunit O 
. O 
ICA B-ABBREVIATION 
is O 
a O 
mixed O 
agonist O 
of O 
mutant O 
EAG O 
and O 
EAG O 
/ O 
ERG O 
chimera O 
channels O 
that O 
inactivate O 
by O 
a O 
combination O 
of O 
slow O 
and O 
fast O 
mechanisms O 
. O 
With O 
the O 
exception O 
of O 
three O 
residues O 
, O 
the O 
specific O 
amino B-FAMILY 
acids I-FAMILY 
that O 
form O 
the O 
putative O 
binding O 
pocket O 
for O 
ICA B-ABBREVIATION 
in O 
ERG O 
are O 
conserved O 
in O 
EAG O 
. O 
Mutations O 
introduced O 
into O 
EAG O 
to O 
replicate O 
the O 
ICA B-ABBREVIATION 
binding O 
site O 
in O 
ERG O 
did O 
not O 
alter O 
the O 
functional O 
response O 
to O 
ICA B-ABBREVIATION 
. O 
Together O 
these O 
findings O 
suggest O 
that O 
ICA B-ABBREVIATION 
binds O 
to O 
the O 
same O 
site O 
in O 
EAG O 
and O 
ERG O 
channels O 
to O 
elicit O 
opposite O 
functional O 
effects O 
. O 
The O 
resultant O 
agonist O 
or O 
antagonist O 
activity O 
is O 
determined O 
solely O 
by O 
channel O 
- O 
specific O 
differences O 
in O 
the O 
mechanisms O 
of O 
inactivation O 
gating O 
. O 

present O 
study O 
was O 
conducted O 
on O 
80 O 
pesticide O 
male O 
sprayers O 
( O 
42 O 
nonsmokers O 
and O 
38 O 
smokers O 
) O 
. O 
Our O 
aim O 
was O 
to O 
estimate O 
the O 
smoking O 
effects O 
on O 
blood O 
lipids O 
and O 
oxidant O 
/ O 
antioxidant O 
status O 
in O 
pesticide O 
sprayers O 
. O 
Results O 
revealed O 
that O 
cholesterol B-TRIVIAL 
, O 
low O 
- O 
density O 
lipoprotein O 
( O 
LDL O 
) O 
and O 
glutathion B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
enzyme O 
were O 
significantly O 
higher O 
in O 
the O 
38 O 
smoker O 
sprayers O 
than O 
in O 
the O 
42 O 
nonsmoker O 
sprayers O 
. O 
Cholesterol B-TRIVIAL 
and O 
LDL O 
were O 
correlated O 
with O 
smoking O 
index O 
and O 
high O 
- O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
enzyme O 
and O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
were O 
inversely O 
correlated O 
with O 
duration O 
of O 
pesticides O 
' O 
exposure O 
. O 
In O 
nonsmokers O 
, O 
LDL O 
and O 
cholesterol B-TRIVIAL 
were O 
negatively O 
correlated O 
with O 
SOD O 
and O 
correlated O 
with O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
and O 
cholesterol B-TRIVIAL 
was O 
negatively O 
correlated O 
with O 
Zn B-FORMULA 
. O 
HDL O 
was O 
negatively O 
correlated O 
with O 
MDA B-ABBREVIATION 
in O 
all O 
the O 
sprayers O 
, O 
but O 
was O 
correlated O 
with O 
GPx O 
in O 
smokers O 
and O 
with O 
Zn B-FORMULA 
in O 
nonsmokers O 
. O 
In O 
smokers O 
, O 
LDL O 
was O 
negatively O 
correlated O 
with O 
GPx O 
, O 
HDL O 
was O 
negatively O 
correlated O 
with O 
MDA B-ABBREVIATION 
and O 
triglycerides B-FAMILY 
and O 
very O 
- O 
low O 
- O 
density O 
lipoprotein O 
were O 
negatively O 
correlated O 
with O 
Zn B-FORMULA 
. O 
MDA B-ABBREVIATION 
was O 
negatively O 
correlated O 
with O 
SOD O 
, O 
GPx O 
and O 
Zn B-FORMULA 
. O 
Smoking O 
and O 
pesticide O 
exposure O 
could O 
be O 
responsible O 
for O 
hyperlipidemia O 
and O 
oxidative O 
stress O 
. O 
Therefore O 
, O 
improvement O 
in O 
the O 
antioxidant O 
status O 
is O 
mandatory O 
for O 
pesticide O 
sprayers O 
especially O 
the O 
ones O 
who O 
smoke O 
. O 

capable O 
of O 
dynamically O 
controlling O 
surface O 
chemistry O 
and O 
topography O 
are O 
highly O 
desirable O 
. O 
We O 
have O 
designed O 
a O 
system O 
that O 
is O 
uniquely O 
able O 
to O 
remotely O 
control O 
the O 
presented O 
functionality O 
and O 
geometry O 
at O 
a O 
given O 
time O 
by O 
using O 
a O 
functionalizable O 
shape O 
memory O 
material O 
. O 
This O 
was O 
accomplished O 
by O 
incorporating O 
controlled O 
amounts O 
of O 
an O 
azide B-SYSTEMATIC 
-containing O 
monomer O 
into O 
a O 
shape O 
memory O 
polymeric O 
material O 
. O 
These O 
materials O 
are O 
capable O 
of O 
physically O 
changing O 
surface O 
geometry O 
over O 
a O 
broad O 
range O 
of O 
length O 
scales O 
from O 
> O 
1 O 
mm O 
to O 
100 O 
nm O 
. O 
Using O 
copper B-SYSTEMATIC 
-assisted O 
click O 
chemistry O 
, O 
they O 
can O 
be O 
functionalized O 
with O 
a O 
variety O 
of O 
molecules O 
to O 
yield O 
different O 
surfaces O 
. O 
Combining O 
these O 
features O 
gave O 
materials O 
that O 
can O 
change O 
both O 
the O 
presented O 
geometry O 
and O 
functionality O 
at O 
tunable O 
transition O 
temperatures O 
. O 

Vegetable O 
- O 
based O 
diets O 
have O 
generally O 
focused O 
on O 
their O 
health O 
benefits O 
including O 
negative O 
associations O 
with O 
the O 
serum O 
cholesterol B-TRIVIAL 
concentrations O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
serum O 
lipid O 
concentrations O 
are O 
influenced O 
by O 
the O 
amount O 
of O 
kimchi O 
intake O 
. O 
For O 
the O 
study O 
, O 
100 O 
volunteers O 
were O 
assigned O 
to O 
2 O 
dietary O 
groups O 
, O 
low O 
( O 
15 O 
g O 
/ O 
day O 
, O 
n=50 O 
) O 
and O 
high O 
( O 
210 O 
g O 
/ O 
day O 
, O 
n=50 O 
) O 
kimchi O 
intake O 
, O 
and O 
were O 
housed O 
together O 
in O 
a O 
dormitory O 
for O 
7 O 
days O 
. O 
Identical O 
meals O 
except O 
with O 
different O 
amount O 
of O 
kimchi O 
were O 
provided O 
and O 
subjects O 
were O 
instructed O 
to O 
maintain O 
their O 
normal O 
physical O 
activity O 
. O 
Concentrations O 
of O 
fasting O 
blood O 
glucose B-TRIVIAL 
( O 
FBG O 
) O 
, O 
total O 
glucose B-TRIVIAL 
, O 
total O 
cholesterol B-TRIVIAL 
and O 
low O 
density O 
lipoprotein O 
(LDL)-C O 
significantly O 
decreased O 
in O 
both O 
groups O 
after O 
7 O 
days O 
of O 
kimchi O 
intake O 
, O 
but O 
the O 
effects O 
were O 
dose O 
dependent O 
. O 
Lipid O 
lowering O 
effects O 
of O 
kimchi O 
were O 
more O 
profound O 
in O 
the O 
subjects O 
with O 
total O 
cholesterol B-TRIVIAL 
and O 
LDL-C O 
level O 
over O 
190 O 
and O 
130 O 
mg O 
/ O 
dL O 
, O 
respectively O 
, O 
in O 
both O 
groups O 
. O 
FBG O 
was O 
significantly O 
decreased O 
in O 
the O 
high O 
kimchi O 
intake O 
as O 
compared O 
to O 
the O 
low O 
intake O 
group O 
( O 
P=.003 O 
) O 
. O 
In O 
conclusion O 
, O 
greater O 
consumption O 
of O 
kimchi O 
improved O 
FBG O 
and O 
serum O 
total O 
cholesterol B-TRIVIAL 
in O 
young O 
healthy O 
adults O 
. O 

c I-TRIVIAL 
( O 
LSTc B-ABBREVIATION 
)-bearing O 
liposomal O 
decoys O 
capture O 
influenza O 
A O 
virus O 
. O 

is O 
a O 
severe O 
disease O 
in O 
humans O 
and O 
animals O 
with O 
few O 
effective O 
therapies O 
available O 
. O 
All O 
strains O 
of O 
influenza O 
virus O 
are O 
prone O 
to O 
developing O 
drug O 
resistance O 
due O 
to O 
the O 
high O 
mutation O 
rate O 
in O 
the O 
viral O 
genome O 
. O 
A O 
therapeutic O 
agent O 
that O 
targets O 
a O 
highly O 
conserved O 
region O 
of O 
the O 
virus O 
could O 
bypass O 
resistance O 
and O 
also O 
be O 
effective O 
against O 
multiple O 
strains O 
of O 
influenza O 
. O 
Influenza O 
uses O 
many O 
individually O 
weak O 
ligand O 
binding O 
interactions O 
for O 
a O 
high O 
avidity O 
multivalent O 
attachment O 
to O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
-bearing O 
cells O 
. O 
Polymerized O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
analogs O 
can O 
form O 
multivalent O 
interactions O 
with O 
influenza O 
but O 
are O 
not O 
ideal O 
therapeutics O 
due O 
to O 
solubility O 
and O 
toxicity O 
issues O 
. O 
We O 
used O 
liposomes O 
as O 
a O 
novel O 
means O 
for O 
delivery O 
of O 
the O 
glycan O 
sialylneolacto-N-tetraose B-TRIVIAL 
c I-TRIVIAL 
( O 
LSTc B-ABBREVIATION 
) O 
. O 
LSTc B-ABBREVIATION 
-bearing O 
decoy O 
liposomes O 
form O 
multivalent O 
, O 
polymer O 
- O 
like O 
interactions O 
with O 
influenza O 
virus O 
. O 
Decoy O 
liposomes O 
competitively O 
bind O 
influenza O 
virus O 
in O 
hemagglutination O 
inhibition O 
assays O 
and O 
inhibit O 
infection O 
of O 
target O 
cells O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Inhibition O 
is O 
specific O 
for O 
influenza O 
virus O 
, O 
as O 
inhibition O 
of O 
Sendai O 
virus O 
and O 
respiratory O 
syncytial O 
virus O 
is O 
not O 
observed O 
. O 
In O 
contrast O 
, O 
monovalent O 
LSTc B-ABBREVIATION 
does O 
not O 
bind O 
influenza O 
virus O 
or O 
inhibit O 
infectivity O 
. O 
LSTc B-ABBREVIATION 
decoy O 
liposomes O 
prevent O 
the O 
spread O 
of O 
influenza O 
virus O 
during O 
multiple O 
rounds O 
of O 
replication O 
in O 
vitro O 
and O 
extend O 
survival O 
of O 
mice O 
challenged O 
with O 
a O 
lethal O 
dose O 
of O 
virus O 
. O 
LSTc B-ABBREVIATION 
decoy O 
liposomes O 
co O 
- O 
localize O 
with O 
fluorescently O 
tagged O 
influenza O 
virus O 
, O 
whereas O 
control O 
liposomes O 
do O 
not O 
. O 
Considering O 
the O 
conservation O 
of O 
the O 
hemagglutinin O 
binding O 
pocket O 
and O 
the O 
ability O 
of O 
decoy O 
liposomes O 
to O 
form O 
high O 
avidity O 
interactions O 
with O 
influenza O 
hemagglutinin O 
, O 
our O 
decoy O 
liposomes O 
have O 
potential O 
as O 
a O 
new O 
therapeutic O 
agent O 
against O 
emerging O 
influenza O 
strains O 
. O 

new O 
program O 
, O 
PHI O 
, O 
with O 
the O 
ability O 
to O 
calculate O 
the O 
magnetic O 
properties O 
of O 
large O 
spin O 
systems O 
and O 
complex O 
orbitally O 
degenerate O 
systems O 
, O 
such O 
as O 
clusters O 
of O 
d-block B-FAMILY 
and O 
f-block B-FAMILY 
ions O 
, O 
is O 
presented O 
. O 
The O 
program O 
can O 
intuitively O 
fit O 
experimental O 
data O 
from O 
multiple O 
sources O 
, O 
such O 
as O 
magnetic O 
and O 
spectroscopic O 
data O 
, O 
simultaneously O 
. O 
PHI O 
is O 
extensively O 
parallelized O 
and O 
can O 
operate O 
under O 
the O 
symmetric O 
multiprocessing O 
, O 
single O 
process O 
multiple O 
data O 
, O 
or O 
GPU O 
paradigms O 
using O 
a O 
threaded O 
, O 
MPI O 
or O 
GPU O 
model O 
, O 
respectively O 
. O 
For O 
a O 
given O 
problem O 
PHI O 
is O 
been O 
shown O 
to O 
be O 
almost O 
12 O 
times O 
faster O 
than O 
the O 
well O 
- O 
known O 
program O 
MAGPACK O 
, O 
limited O 
only O 
by O 
available O 
hardware O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

in O 
the O 
synthesis O 
of O 
canthine B-FAMILY 
alkaloids I-FAMILY 
and O 
ring O 
- O 
truncated O 
congeners O 
. O 

canthines B-FAMILY 
represent O 
a O 
fairly O 
large O 
subclass O 
of O 
β-carboline B-FAMILY 
alkaloids I-FAMILY 
, O 
with O 
the O 
first O 
members O 
described O 
75 O 
years O 
ago O 
. O 
Over O 
the O 
last O 
60 O 
years O 
, O 
many O 
members O 
of O 
the O 
parent O 
compound O 
, O 
canthin-6-one B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
have O 
been O 
isolated O 
from O 
various O 
plant O 
sources O 
, O 
principally O 
the O 
Rutaceae O 
and O 
Simaroubaceae O 
families O 
, O 
and O 
recently O 
from O 
fungi O 
. O 
Structures O 
isolated O 
from O 
these O 
sources O 
have O 
been O 
the O 
subject O 
of O 
total O 
synthesis O 
, O 
which O 
continues O 
to O 
the O 
present O 
day O 
. O 
This O 
review O 
gives O 
a O 
broad O 
overview O 
of O 
synthetic O 
approaches O 
to O 
canthines B-FAMILY 
over O 
a O 
30-year O 
period O 
from O 
1982 O 
to O 
2012 O 
and O 
summarizes O 
recent O 
reports O 
on O 
the O 
synthesis O 
of O 
less O 
well O 
known O 
ring O 
- O 
truncated O 
congeners O 
. O 
These O 
include O 
C-ring- O 
truncated O 
( O 
" O 
ABD O 
" O 
, O 
2 O 
) O 
and O 
A-ring O 
- O 
truncated O 
( O 
" O 
BCD O 
" O 
, O 
3 O 
) O 
ring O 
systems O 
, O 
which O 
are O 
providing O 
new O 
scaffolds O 
for O 
potentially O 
useful O 
therapeutic O 
applications O 
. O 

androgen B-FAMILY 
receptor O 
regulates O 
insulin O 
sensitivity O 
via O 
suppression O 
of O 
hypothalamic O 
NF-κB O 
- O 
mediated O 
PTP1B O 
expression O 
. O 

investigations O 
highlight O 
the O 
increased O 
incidence O 
of O 
metabolic O 
syndrome O 
in O 
prostate O 
cancer O 
( O 
PCa O 
) O 
patients O 
receiving O 
androgen B-FAMILY 
deprivation O 
therapy O 
( O 
ADT O 
) O 
. O 
Studies O 
using O 
global O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
knockout O 
mice O 
demonstrate O 
that O 
AR O 
deficiency O 
results O 
in O 
the O 
development O 
of O 
insulin O 
resistance O 
in O 
males O 
. O 
However O 
, O 
mechanisms O 
by O 
which O 
AR O 
in O 
individual O 
organs O 
coordinately O 
regulates O 
insulin O 
sensitivity O 
remain O 
unexplored O 
. O 
Here O 
we O 
tested O 
the O 
hypothesis O 
that O 
functional O 
AR O 
in O 
the O 
brain O 
contributes O 
to O 
whole O 
- O 
body O 
insulin O 
sensitivity O 
regulation O 
and O 
to O 
the O 
metabolic O 
abnormalities O 
developed O 
in O 
AR-deficient O 
male O 
mice O 
. O 
The O 
mouse O 
model O 
selectively O 
lacking O 
AR O 
in O 
the O 
central O 
nervous O 
system O 
and O 
AR-expressing O 
GT1-7 O 
neuronal O 
cells O 
were O 
established O 
and O 
used O 
to O 
delineate O 
molecular O 
mechanisms O 
in O 
insulin O 
signaling O 
modulated O 
by O 
AR O 
. O 
Neuronal O 
AR O 
deficiency O 
leads O 
to O 
reduced O 
insulin O 
sensitivity O 
in O 
middle O 
- O 
aged O 
mice O 
. O 
Neuronal O 
AR O 
regulates O 
hypothalamic O 
insulin O 
signaling O 
by O 
repressing O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
- O 
mediated O 
induction O 
of O 
protein- O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
( O 
PTP1B O 
) O 
. O 
Hypothalamic O 
insulin O 
resistance O 
leads O 
to O 
hepatic O 
insulin O 
resistance O 
, O 
lipid O 
accumulation O 
, O 
and O 
visceral O 
obesity O 
. O 
The O 
functional O 
deficiency O 
of O 
AR O 
in O 
the O 
hypothalamus O 
leads O 
to O 
male O 
mice O 
being O 
more O 
susceptible O 
to O 
the O 
effects O 
of O 
high O 
- O 
fat O 
diet O 
consumption O 
on O 
PTP1B O 
expression O 
and O 
NF-κB O 
activation O 
. O 
These O 
findings O 
suggest O 
that O 
in O 
men O 
with O 
PCa O 
undergoing O 
ADT O 
, O 
reduction O 
of O 
AR O 
function O 
in O 
the O 
brain O 
may O 
contribute O 
to O 
insulin O 
resistance O 
and O 
visceral O 
obesity O 
. O 
Pharmacotherapies O 
targeting O 
neuronal O 
AR O 
and O 
NF-κB O 
may O 
be O 
developed O 
to O 
combat O 
the O 
metabolic O 
syndrome O 
in O 
men O 
receiving O 
ADT O 
and O 
in O 
elderly O 
men O 
with O 
age O 
- O 
associated O 
hypogonadism O 
. O 

Organic O 
Anion O 
Transporting O 
Polypeptide O 
2B1 O 
( O 
OATP2B1 O 
) O 
is O 
a O 
membrane O 
transporter O 
that O 
facilitates O 
the O 
cellular O 
uptake O 
of O 
a O 
number O 
of O 
endogenous O 
compounds O 
and O 
drugs O 
. O 
OATP2B1 O 
is O 
widely O 
expressed O 
in O 
tissues O 
including O 
the O 
small O 
intestine O 
, O 
liver O 
, O 
kidney O 
, O 
placenta O 
, O 
heart O 
, O 
skeletal O 
muscle O 
and O 
platelets O 
. O 
Recently O 
, O 
it O 
has O 
been O 
shown O 
that O 
differential O 
promoter O 
usage O 
in O 
tissues O 
results O 
in O 
expression O 
of O 
five O 
OATP2B1 O 
transcriptional O 
start O 
site O 
variants O 
which O 
utilize O 
distinct O 
first O 
exons O 
but O 
share O 
common O 
subsequent O 
exons O 
. O 
These O 
variants O 
are O 
expected O 
to O 
encode O 
either O 
a O 
full O 
length O 
( O 
OATP2B1-FL O 
) O 
or O 
shortened O 
protein O 
lacking O 
22 O 
N B-FORMULA 
-terminus O 
amino B-FAMILY 
acids I-FAMILY 
( O 
OATP2B-Short O 
) O 
. O 
Little O 
is O 
known O 
regarding O 
the O 
transport O 
activity O 
and O 
regulation O 
of O 
OATP2B1 O 
variants O 
with O 
N B-FORMULA 
-terminus O 
truncation O 
. O 
Here O 
, O 
using O 
absolute O 
quantitative O 
polymerase O 
chain O 
reaction O 
we O 
find O 
the O 
full O 
length O 
variant O 
is O 
the O 
major O 
form O 
expressed O 
in O 
duodenum O 
but O 
the O 
short O 
variant O 
predominates O 
in O 
liver O 
. O 
Using O 
a O 
transient O 
heterologous O 
cell O 
expression O 
system O 
, O 
we O 
find O 
that O 
the O 
transport O 
activities O 
of O 
the O 
short O 
OATP2B1 O 
variant O 
towards O 
substrates O 
estrone B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
and O 
rosuvastatin B-TRIVIAL 
are O 
similar O 
to O 
the O 
well O 
- O 
characterized O 
full O 
length O 
variant O 
. O 
Transcriptional O 
activity O 
screening O 
of O 
the O 
liver O 
enriched O 
OATP2B1 O 
variant O 
promoter O 
identified O 
hepatocyte O 
nuclear O 
factor O 
4 O 
alpha O 
( O 
HNF4α O 
) O 
as O 
a O 
novel O 
transacting O 
factor O 
. O 
With O 
a O 
combination O 
of O 
in O 
silico O 
screening O 
, O 
promoter O 
mutation O 
in O 
cell O 
- O 
based O 
reporter O 
assays O 
, O 
siRNA O 
knockdown O 
and O 
chromatin O 
immunoprecipitation O 
studies O 
, O 
we O 
identified O 
a O 
functional O 
HNF4α O 
binding O 
site O 
close O 
to O 
the O 
transcription O 
start O 
site O 
( O 
-17 O 
to O 
-4 O 
bp O 
) O 
. O 
We O 
conclude O 
that O 
the O 
major O 
OATP2B1 O 
protein O 
form O 
in O 
liver O 
is O 
transport O 
competent O 
and O 
its O 
hepatic O 
expression O 
is O 
regulated O 
by O 
HNF4α O 
. O 

amino B-FAMILY 
acid I-FAMILY 
bioisosteres O 
and O 
mass O 
spectrometry O 
: O 
snapshots O 
of O 
in O 
vivo O 
3D O 
protein O 
structures O 
. O 

folded O 
to O 
crosslinked O 
proteins O 
. O 
A O 
new O 
promising O 
photo O 
- O 
crosslinking O 
/ O 
mass O 
spectrometry O 
method O 
for O 
the O 
structural O 
characterisation O 
of O 
folded O 
proteins O 
is O 
highlighted O 
. O 
A O 
reactive O 
photo- O 
leucine B-TRIVIAL 
can O 
clamp O 
the O 
front O 
residues O 
in O 
β-turn O 
and O 
β-hairpin O 
domains O 
, O 
thus O 
allowing O 
us O 
to O 
look O 
into O 
the O 
specific O 
native O 
3D O 
structure O 
of O 
proteins O 
. O 

derivatives O 
as O 
inhibitors O 
of O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
-induced O 
platelet O 
aggregation O 
. O 

drugs O 
are O 
promising O 
therapeutics O 
to O 
intervene O 
with O 
platelet O 
aggregation O 
in O 
arterial O 
thrombosis O 
, O 
most O 
prominently O 
in O 
myocardial O 
infarction O 
and O 
ischemic O 
stroke O 
. O 
Here O 
, O 
we O 
describe O 
the O 
synthesis O 
and O 
structure O 
- O 
activity O 
relationships O 
of O 
potent O 
inhibitors O 
of O 
platelet O 
aggregation O 
based O 
on O 
the O 
1,5-diarylpyrazol-3-carboxamide B-FAMILY 
scaffold O 
. O 
Analogs O 
from O 
this O 
series O 
demonstrated O 
potent O 
anti-aggregatory O 
activities O 
against O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
-induced O 
platelet O 
aggregation O 
, O 
as O 
measured O 
by O 
turbidimetric O 
method O 
of O 
Born O 
. O 
1,5-Diarylpyrazole-3-carboxamides B-FAMILY 
obtained O 
with O 
small O 
- O 
basic O 
amines B-FAMILY 
( O 
7 O 
, O 
8 O 
, O 
50 O 
, O 
51 O 
, O 
61 O 
, O 
62 O 
) O 
displayed O 
the O 
strongest O 
activity O 
with O 
IC50 O 
values O 
in O 
low O 
nanomolar O 
range O 
( O 
5.7-83 O 
nM O 
) O 
. O 
On O 
the O 
basis O 
of O 
their O 
high O 
potency O 
in O 
cellular O 
environment O 
, O 
these O 
straightforward O 
pyrazole B-SYSTEMATIC 
derivatives O 
may O 
possess O 
potential O 
in O 
the O 
design O 
of O 
more O 
potent O 
compounds O 
for O 
intervention O 
with O 
cardiovascular O 
diseases O 
. O 

of O 
Dehydroepiandrosterone B-SYSTEMATIC 
Sulfate I-SYSTEMATIC 
with O 
Overweight O 
and O 
Insulin O 
Sensitivity O 
in O 
12-16-Year- O 
old O 
Spanish O 
Children O 
. O 

is O 
the O 
most O 
abundant O 
steroid B-FAMILY 
hormone O 
in O 
human O 
circulation O 
. O 
Although O 
a O 
relationship O 
of O 
DHEA-S B-ABBREVIATION 
with O 
obesity O 
- O 
related O 
diseases O 
has O 
been O 
reported O 
, O 
the O 
metabolic O 
role O 
of O 
this O 
hormone O 
remains O 
unclear O 
, O 
particularly O 
in O 
children O 
. O 
In O 
our O 
study O 
, O 
we O 
have O 
investigated O 
the O 
relationship O 
of O 
DHEA-S B-ABBREVIATION 
levels O 
with O 
anthropometric O 
variables O 
, O 
insulin O 
, O 
HOMA O 
, O 
and O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
in O 
adolescents O 
. O 
The O 
study O 
sample O 
included O 
812 O 
healthy O 
12-16-year- O 
old O 
children O 
( O 
383 O 
boys O 
and O 
429 O 
girls O 
) O 
. O 
Plasma O 
DHEA-S B-ABBREVIATION 
was O 
determined O 
by O 
RIA O 
, O 
insulin O 
concentrations O 
by O 
IRMA O 
, O 
and O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
by O 
using O 
a O 
commercial O 
kit O 
. O 
Insulin O 
resistance O 
was O 
estimated O 
using O 
the O 
HOMA O 
index O 
. O 
No O 
significant O 
differences O 
in O 
plasma O 
DHEA-S B-ABBREVIATION 
levels O 
were O 
found O 
between O 
sexes O 
. O 
DHEA-S B-ABBREVIATION 
levels O 
in O 
overweight O 
children O 
were O 
significantly O 
higher O 
than O 
in O 
normal O 
- O 
weight O 
children O 
. O 
DHEA-S B-ABBREVIATION 
levels O 
were O 
significantly O 
correlated O 
with O 
weight O 
and O 
BMI O 
after O 
adjusting O 
for O 
age O 
. O 
Significant O 
positive O 
correlations O 
between O 
DHEA-S B-ABBREVIATION 
and O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
levels O 
were O 
found O 
after O 
adjusting O 
for O 
age O 
and O 
BMI O 
, O 
particularly O 
in O 
boys O 
, O 
but O 
not O 
between O 
DHEA-S B-ABBREVIATION 
levels O 
and O 
insulin O 
or O 
HOMA O 
in O 
either O 
gender O 
. O 
DHEA-S B-ABBREVIATION 
levels O 
in O 
12-16-year- O 
old O 
children O 
are O 
correlated O 
with O 
weight O 
and O 
BMI O 
independently O 
of O 
age O 
. O 
We O 
failed O 
to O 
find O 
any O 
association O 
between O 
DHEA-S B-ABBREVIATION 
and O 
insulin O 
levels O 
, O 
but O 
we O 
did O 
find O 
a O 
-significant O 
correlation O 
between O 
DHEA-S B-ABBREVIATION 
and O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
levels O 
, O 
suggesting O 
that O 
its O 
association O 
with O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
may O 
be O 
related O 
to O 
the O 
onset O 
of O 
the O 
association O 
of O 
DHEA-S B-ABBREVIATION 
with O 
insulin O 
resi O 
- O 
stance O 
. O 

protects O 
H9c2 O 
cardiac O 
cells O 
from O 
oxidative O 
stress O 
and O 
inhibits O 
phenylephrine B-TRIVIAL 
-induced O 
hypertrophy O 
: O 
potential O 
mechanisms O 
. O 

hypertrophy O 
is O 
the O 
main O 
response O 
of O 
the O 
heart O 
to O 
various O 
extrinsic O 
and O 
intrinsic O 
stimuli O 
, O 
and O 
it O 
is O 
characterized O 
by O 
specific O 
molecular O 
and O 
phenotypic O 
changes O 
. O 
Recent O 
in O 
vitro O 
and O 
in O 
vivo O 
studies O 
indicate O 
the O 
involvement O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
the O 
hypertrophic O 
response O 
. O 
In O 
this O 
study O 
, O 
silibinin B-TRIVIAL 
, O 
a O 
plant O 
flavonolignan B-FAMILY 
extracted O 
from O 
milk O 
thistle O 
with O 
potent O 
antioxidant O 
activity O 
, O 
was O 
evaluated O 
for O 
its O 
effects O 
in O 
( O 
a O 
) O 
preventing O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
)-induced O 
cellular O 
damage O 
and O 
( O 
b O 
) O 
blocking O 
the O 
phenylephrine B-TRIVIAL 
-induced O 
hypertrophic O 
response O 
. O 
Using O 
the O 
in O 
vitro O 
model O 
of O 
embryonic O 
rat O 
heart O 
- O 
derived O 
H9c2 O 
cells O 
, O 
we O 
showed O 
that O 
silibinin B-TRIVIAL 
has O 
a O 
rather O 
safe O 
profile O 
as O 
concentrations O 
up O 
to O 
200μM O 
did O 
not O 
affect O 
cell O 
viability O 
. O 
Pretreatment O 
of O 
H9c2 O 
cells O 
with O 
silibinin B-TRIVIAL 
resulted O 
in O 
better O 
protection O 
of O 
H9c2 O 
cells O 
under O 
conditions O 
of O 
H2O2 B-FORMULA 
-induced O 
cellular O 
stress O 
compared O 
to O 
untreated O 
cells O 
as O 
indicated O 
by O 
cell O 
viability O 
and O 
DNA O 
fragmentation O 
assays O 
. O 
Furthermore O 
, O 
silibinin B-TRIVIAL 
attenuated O 
the O 
phenylephrine B-TRIVIAL 
-induced O 
hypertrophic O 
response O 
as O 
evidenced O 
by O 
the O 
measurement O 
of O 
cell O 
surface O 
, O 
up O 
- O 
regulation O 
of O 
atrial O 
natriuretic O 
peptide O 
and O 
increase O 
of O 
cellular O 
protein O 
levels O 
. O 
Moreover O 
, O 
silibinin B-TRIVIAL 
repressed O 
the O 
phenylephrine B-TRIVIAL 
-induced O 
phosphorylation O 
of O 
ERK1 O 
/ O 
2 O 
kinases O 
, O 
while O 
it O 
appeared O 
to O 
inhibit O 
the O 
weakly O 
activated O 
by O 
phenylephrine B-TRIVIAL 
phosphorylation O 
of O 
Akt O 
. O 
Based O 
on O 
our O 
results O 
, O 
silibinin B-TRIVIAL 
may O 
attenuate O 
the O 
phenylephrine B-TRIVIAL 
-induced O 
hypertrophic O 
response O 
of O 
H9c2 O 
cells O 
via O 
antioxidant O 
mechanisms O 
involving O 
mainly O 
the O 
inhibition O 
of O 
the O 
intracellular O 
signaling O 
pathways O 
mediated O 
by O 
ERK1 O 
/ O 
2 O 
MAPKs O 
and O 
Akt O 
. O 

for O 
the O 
higher O 
reactivity O 
of O 
interfacial O 
sites O 
in O 
methanol B-SYSTEMATIC 
decomposition O 
on O 
Au13 B-FORMULA 
/ I-FORMULA 
TiO2(110) I-FORMULA 
. O 

and O 
perimeter O 
sites O 
have O 
been O 
known O 
for O 
their O 
high O 
activity O 
in O 
various O 
reactions O 
on O 
supported O 
gold O 
nanoparticles O 
. O 
We O 
find O 
that O 
the O 
higher O 
activity O 
of O 
interfacial O 
sites O 
in O 
Au13 B-FORMULA 
/ I-FORMULA 
TiO2(110) I-FORMULA 
towards O 
methanol B-SYSTEMATIC 
decomposition O 
originates O 
from O 
charge O 
- O 
transfer O 
- O 
induced O 
Coulomb O 
interaction O 
among O 
the O 
gold O 
, O 
reactant O 
, O 
and O 
reducible O 
TiO2 B-FORMULA 
support O 
, O 
brought O 
about O 
through O 
the O 
formation O 
of O 
an O 
ionic O 
O-Au B-FORMULA 
bond O 
between O 
gold O 
and O 
methoxy B-SYSTEMATIC 
in O 
such O 
sites O 
, O 
which O 
turns O 
the O 
participating O 
perimeter O 
gold O 
atom O 
cationic O 
. O 
A O 
direct O 
result O 
of O 
such O 
charge O 
- O 
transfer O 
- O 
induced O 
repulsive O 
interaction O 
between O 
cationic O 
gold O 
and O 
positively O 
charged O 
C B-FORMULA 
moiety O 
of O 
methoxy B-SYSTEMATIC 
is O 
activation O 
of O 
the O 
positively O 
charged O 
C B-FORMULA 
moiety O 
of O 
methoxy B-SYSTEMATIC 
, O 
as O 
manifested O 
by O 
the O 
pronounced O 
elongation O 
of O 
O-C B-FORMULA 
bond O 
length O 
and O 
the O 
tilting O 
of O 
the O 
methoxy B-SYSTEMATIC 
axis O 
, O 
which O 
facilitate O 
reaction O 
of O 
methoxy B-SYSTEMATIC 
through O 
C-H B-FORMULA 
scission O 
with O 
the O 
bridge O 
oxygen B-SYSTEMATIC 
atoms O 
that O 
are O 
readily O 
available O 
from O 
the O 
reducible O 
support O 
. O 
More O 
generally O 
, O 
our O 
proposed O 
mechanism O 
for O 
the O 
reactivity O 
of O 
the O 
gold/ O 
TiO2 B-FORMULA 
interface O 
should O 
hold O 
for O 
oxidation O 
of O 
organic O 
molecules O 
with O 
the O 
structure O 
of O 
R-O-R B-FAMILY 
' I-FAMILY 
, O 
where O 
R O 
and O 
R O 
' O 
are O 
( B-FAMILY 
saturated I-FAMILY 
) I-FAMILY 
hydrocarbons I-FAMILY 
. O 

activity O 
of O 
patchouli B-TRIVIAL 
alcohol I-TRIVIAL 
in O 
RAW264.7 O 
and O 
HT-29 O 
cells O 
. O 

alcohol I-TRIVIAL 
( O 
PA O 
) O 
is O 
a O 
chemical O 
compound O 
extracted O 
from O 
patchouli O 
which O 
belongs O 
to O 
the O 
genus O 
Pogostemon O 
, O 
herb O 
of O 
mint O 
family O 
. O 
Recently O 
, O 
it O 
has O 
been O 
reported O 
that O 
PA O 
inhibits O 
the O 
production O 
of O 
inflammatory O 
mediators O 
. O 
However O 
, O 
the O 
biological O 
mechanisms O 
of O 
PA O 
for O 
anti-inflammatory O 
activities O 
have O 
not O 
been O 
studied O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
whether O 
PA O 
decreases O 
the O 
production O 
of O 
inflammatory O 
mediators O 
through O 
downregulation O 
of O 
the O 
NF-κB O 
and O 
ERK O 
pathway O 
. O 
Our O 
data O 
indicated O 
that O 
PA O 
inhibits O 
the O 
over O 
- O 
expression O 
of O 
iNOS O 
and O 
IL-6 O 
in O 
protein O 
and O 
mRNA O 
levels O 
in O 
LPS-stimulated O 
RAW264.7 O 
and O 
TNF-α O 
stimulated O 
HT-29 O 
cells O 
. O 
PA O 
inhibited O 
IκB-α O 
degradation O 
and O 
p65 O 
nuclear O 
translocation O 
, O 
and O 
subsequently O 
suppressed O 
transcriptional O 
activity O 
of O 
NF-κB O 
in O 
LPS-stimulated O 
RAW264.7 O 
and O 
TNF-α-stimulated O 
HT-29 O 
cells O 
. O 
In O 
addition O 
, O 
PA O 
inhibited O 
LPS- O 
or O 
TNF-α-stimulated O 
ERK1 O 
/ O 
2 O 
activation O 
by O 
decreasing O 
phosphorylation O 
of O 
ERK1 O 
/ O 
2 O 
. O 
These O 
findings O 
suggest O 
that O 
PA O 
shows O 
anti-inflammatory O 
activities O 
through O 
suppressing O 
ERK O 
- O 
mediated O 
NF-κB O 
pathway O 
in O 
mouse O 
macrophage O 
and O 
human O 
colorectal O 
cancer O 
cells O 
. O 

mating O 
behavior O 
in O 
rats O 
is O 
associated O 
with O 
hormone O 
- O 
induced O 
changes O 
in O 
the O 
dendritic O 
arbor O 
of O 
neurons O 
in O 
the O 
ventromedial O 
nucleus O 
of O 
the O 
hypothalamus O 
( O 
VMH O 
) O 
, O 
particularly O 
the O 
ventrolateral O 
portion O 
. O 
Regulation O 
of O 
mating O 
behavior O 
in O 
female O 
prairie O 
voles O 
differs O 
substantially O 
from O 
that O 
in O 
rats O 
; O 
therefore O 
, O 
we O 
examined O 
the O 
dendritic O 
morphology O 
of O 
VMH O 
neurons O 
in O 
this O 
species O 
. O 
Sexually O 
naïve O 
adult O 
female O 
prairie O 
voles O 
were O 
housed O 
with O 
a O 
male O 
to O 
activate O 
the O 
females O 
' O 
reproductive O 
endocrine O 
system O 
. O 
Following O 
48 O 
h O 
of O 
cohabitation O 
, O 
females O 
were O 
tested O 
for O 
evidence O 
of O 
reproductive O 
activation O 
by O 
assessing O 
the O 
level O 
of O 
male O 
sexual O 
interest O 
, O 
after O 
which O 
their O 
brains O 
were O 
processed O 
using O 
Golgi O 
impregnation O 
, O 
which O 
allowed O 
ventrolateral O 
VMH O 
neurons O 
to O 
be O 
visualized O 
and O 
analyzed O 
. O 
Dendritic O 
arborization O 
in O 
the O 
female O 
prairie O 
vole O 
VMH O 
neurons O 
was O 
strikingly O 
similar O 
to O 
that O 
of O 
female O 
rats O 
. O 
The O 
key O 
difference O 
was O 
that O 
in O 
the O 
prairie O 
voles O 
the O 
long O 
primary O 
dendrites O 
extended O 
considerably O 
further O 
than O 
those O 
observed O 
in O 
rats O 
. O 
Although O 
most O 
female O 
voles O 
paired O 
with O 
males O 
exhibited O 
sexual O 
activation O 
, O 
some O 
females O 
did O 
not O 
. O 
These O 
two O 
groups O 
displayed O 
specific O 
differences O 
in O 
their O 
VMH O 
dendrites O 
. O 
In O 
particular O 
, O 
the O 
long O 
primary O 
dendrites O 
were O 
longer O 
in O 
the O 
reproductively O 
active O 
females O 
compared O 
with O 
those O 
in O 
the O 
non-activated O 
females O 
. O 
Overall O 
, O 
dendrite O 
lengths O 
were O 
positively O 
correlated O 
with O 
plasma O 
estradiol B-TRIVIAL 
levels O 
in O 
females O 
exposed O 
to O 
males O 
, O 
but O 
not O 
in O 
unpaired O 
females O 
. O 
Although O 
causal O 
relationships O 
between O 
the O 
neuroendocrine O 
events O 
, O 
dendrite O 
length O 
, O 
and O 
the O 
outward O 
, O 
behavioral O 
manifestation O 
of O 
reproductive O 
activation O 
cannot O 
be O 
determined O 
from O 
this O 
study O 
, O 
these O 
results O 
suggest O 
an O 
association O 
between O 
ventrolateral O 
VMH O 
dendrite O 
morphology O 
and O 
female O 
mating O 
behavior O 
in O 
prairie O 
voles O 
, O 
akin O 
to O 
what O 
has O 
been O 
observed O 
in O 
female O 
rats O 
. O 

β-casein O 
was O 
purified O 
from O 
phosphocasein O 
by O 
rennet O 
coagulation O 
and O 
cold O 
solubilisation O 
from O 
the O 
resultant O 
curd O 
. O 
β-Casein O 
was O 
then O 
dephosphorylated O 
using O 
potato O 
acid O 
phosphatase O 
. O 
Urea B-TRIVIAL 
- O 
polyacrylamide B-SYSTEMATIC 
gel O 
electrophoresis O 
( O 
PAGE O 
) O 
of O 
partially O 
dephosphorylated O 
β-casein O 
showed O 
a O 
number O 
of O 
bands O 
, O 
depending O 
on O 
the O 
final O 
level O 
of O 
phosphorylation O 
. O 
Dephosphorylating O 
β-casein O 
increased O 
its O 
pH O 
of O 
minimum O 
solubility O 
from O 
∼pH O 
5 O 
to O 
5.5 O 
and O 
reduced O 
its O 
net O 
negative O 
charge O 
from O 
-30.8 O 
to O 
-27 O 
mV O 
. O 
During O 
the O 
acidification O 
of O 
β-casein O 
solutions O 
, O 
partially O 
dephosphorylated O 
β-casein O 
failed O 
to O 
form O 
a O 
gel O 
, O 
unlike O 
the O 
phosphorylated O 
( O 
i.e O 
. O 
, O 
control O 
) O 
β-casein O 
. O 
Use O 
of O 
partially O 
dephosphorylated O 
β-casein O 
to O 
stabilise O 
oil O 
- O 
in O 
- O 
water O 
emulsions O 
resulted O 
in O 
larger O 
fat O 
globules O 
compared O 
to O 
control O 
β-casein O 
, O 
but O 
such O 
globules O 
were O 
less O 
susceptible O 
to O 
aggregation O 
in O 
the O 
presence O 
of O 
15 O 
or O 
30 O 
mM O 
CaCl(2) B-FORMULA 
. O 
Overall O 
, O 
the O 
dephosphorylation O 
of O 
β-casein O 
resulted O 
in O 
a O 
protein O 
similar O 
to O 
human O 
β-casein O 
in O 
terms O 
of O 
physicochemical O 
functionality O 
, O 
with O 
increased O 
stability O 
against O 
calcium B-SYSTEMATIC 
-induced O 
aggregation O 
. O 

broadband O 
and O 
omnidirectional O 
performance O 
of O 
Cu(In,Ga)Se2 B-FORMULA 
solar O 
cells O 
with O 
ZnO B-FORMULA 
functional O 
nanotree O 
arrays O 
. O 

effective O 
approach O 
is O 
demonstrated O 
for O 
enhancing O 
photoelectric O 
conversion O 
of O 
Cu(In,Ga)Se2 B-FORMULA 
( O 
CIGS B-ABBREVIATION 
) O 
solar O 
cells O 
with O 
three O 
- O 
dimensional O 
ZnO B-FORMULA 
nanotree O 
arrays O 
. O 
Under O 
a O 
simulated O 
one O 
- O 
sun O 
condition O 
, O 
cells O 
with O 
ZnO B-FORMULA 
nanotree O 
arrays O 
enhance O 
the O 
short O 
- O 
circuit O 
current O 
density O 
by O 
10.62% O 
. O 
The O 
omnidirectional O 
anti-reflection O 
of O 
CIGS B-ABBREVIATION 
solar O 
cells O 
with O 
various O 
ZnO B-FORMULA 
nanostructures O 
is O 
also O 
investigated O 
. O 
The O 
solar O 
- O 
spectrum O 
weighted O 
reflectance O 
is O 
approximately O 
less O 
than O 
5% O 
for O 
incident O 
angles O 
of O 
up O 
to O 
60° O 
and O 
for O 
the O 
wavelengths O 
primarily O 
from O 
400 O 
nm O 
to O 
1000 O 
nm O 
. O 
This O 
enhancement O 
in O 
light O 
harvesting O 
is O 
attributable O 
to O 
the O 
gradual O 
refractive O 
index O 
profile O 
between O 
the O 
ZnO B-FORMULA 
nanostructures O 
and O 
air O 
. O 

of O 
morphine B-TRIVIAL 
-induced O 
mechanical O 
antinociception O 
by O 
σ1 O 
receptor O 
inhibition O 
: O 
Role O 
of O 
peripheral O 
σ1 O 
receptors O 
. O 

studied O 
the O 
modulation O 
of O 
morphine B-TRIVIAL 
-induced O 
mechanical O 
antinociception O 
and O 
side O 
effects O 
by O 
σ1 O 
receptor O 
inhibition O 
. O 
Both O 
wild O 
- O 
type O 
( O 
WT O 
) O 
and O 
σ1 O 
receptor O 
knockout O 
( O 
σ1-KO O 
) O 
mice O 
showed O 
similar O 
responses O 
to O 
paw O 
pressure O 
( O 
100-600 O 
g O 
) O 
. O 
The O 
systemic O 
( O 
subcutaneous O 
) O 
or O 
local O 
( O 
intraplantar O 
) O 
administration O 
of O 
σ1 O 
antagonists O 
( O 
BD-1063 B-IDENTIFIER 
, O 
BD-1047 B-IDENTIFIER 
, O 
NE-100 B-IDENTIFIER 
and O 
S1RA B-TRIVIAL 
) O 
was O 
devoid O 
of O 
antinociceptive O 
effects O 
in O 
WT O 
mice O 
. O 
However O 
, O 
σ1-KO O 
mice O 
exhibited O 
an O 
enhanced O 
mechanical O 
antinociception O 
in O 
response O 
to O 
systemic O 
morphine B-TRIVIAL 
( O 
1-16 O 
mg O 
/ O 
kg O 
) O 
. O 
Similarly O 
, O 
systemic O 
treatment O 
of O 
WT O 
mice O 
with O 
σ1 O 
antagonists O 
markedly O 
potentiated O 
morphine B-TRIVIAL 
-induced O 
antinociception O 
, O 
and O 
its O 
effects O 
were O 
reversed O 
by O 
the O 
selective O 
σ1 O 
agonist O 
PRE-084 B-IDENTIFIER 
. O 
Although O 
the O 
local O 
administration O 
of O 
morphine B-TRIVIAL 
( O 
50-200 O 
μg O 
) O 
was O 
devoid O 
of O 
antinociceptive O 
effects O 
in O 
WT O 
mice O 
, O 
it O 
induced O 
dose O 
- O 
dependent O 
antinociception O 
in O 
σ1-KO O 
mice O 
. O 
This O 
effect O 
was O 
limited O 
to O 
the O 
injected O 
paw O 
. O 
Enhancement O 
of O 
peripheral O 
morphine B-TRIVIAL 
antinociception O 
was O 
replicated O 
in O 
WT O 
mice O 
locally O 
co O 
- O 
administered O 
with O 
σ1 O 
antagonists O 
and O 
the O 
opioid O 
. O 
None O 
of O 
the O 
σ1 O 
antagonists O 
tested O 
enhanced O 
morphine B-TRIVIAL 
-antinociception O 
in O 
σ1-KO O 
mice O 
, O 
confirming O 
a O 
σ1 O 
- O 
mediated O 
action O 
. O 
Morphine B-TRIVIAL 
-induced O 
side-effects O 
( O 
hyperlocomotion O 
and O 
inhibition O 
of O 
gastrointestinal O 
transit O 
) O 
were O 
unaltered O 
in O 
σ1-KO O 
mice O 
. O 
These O 
results O 
cannot O 
be O 
explained O 
by O 
a O 
direct O 
interaction O 
of O 
σ1 O 
ligands O 
with O 
μ-opioid O 
receptors O 
or O 
adaptive O 
changes O 
of O 
μ-receptors O 
in O 
σ1-KO O 
mice O 
, O 
given O 
that O 
[(3)H]DAMGO B-SYSTEMATIC 
binding O 
in O 
forebrain O 
, O 
spinal O 
cord O 
, O 
and O 
hind O 
- O 
paw O 
skin O 
membranes O 
was O 
unaltered O 
in O 
mutant O 
mice O 
, O 
and O 
none O 
of O 
the O 
σ1 O 
drugs O 
tested O 
bound O 
to O 
μ-opioid O 
receptors O 
. O 
These O 
results O 
show O 
that O 
σ1 O 
receptor O 
inhibition O 
potentiates O 
morphine B-TRIVIAL 
-induced O 
mechanical O 
analgesia O 
but O 
not O 
its O 
acute O 
side O 
effects O 
, O 
and O 
that O 
this O 
enhanced O 
analgesia O 
can O 
be O 
induced O 
at O 
peripheral O 
level O 
. O 

of O 
alkenylboronic B-FAMILY 
acids I-FAMILY 
as O 
neuroprotective O 
agents O 
affecting O 
multiple O 
biological O 
targets O 
involved O 
in O 
Alzheimer's O 
disease O 
. O 

acids I-FAMILY 
have O 
shown O 
important O 
biological O 
activities O 
that O 
contribute O 
to O 
neuroprotection O 
. O 
We O 
have O 
determined O 
their O 
influence O 
on O 
the O 
β-amyloid O 
( O 
βA O 
) O 
aggregation O 
process O 
, O 
β-secretase O 
and O 
acethylcholinesterase O 
activities O 
on O 
cell O 
- O 
free O 
systems O 
, O 
on O 
the O 
redox O 
and O 
lipid O 
peroxidation O 
status O 
, O 
and O 
on O 
the O 
vulnerability O 
to O 
apoptotic O 
death O 
in O 
an O 
APPswe O 
neuroblastoma O 
cell O 
line O 
, O 
before O 
and O 
after O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
treatment O 
. O 
We O 
have O 
discovered O 
that O 
2-arylvinylboronic B-FAMILY 
acids I-FAMILY 
and O 
some O 
of O 
their O 
esters B-FAMILY 
possess O 
a O 
set O 
of O 
properties O 
which O 
makes O 
them O 
highly O 
useful O 
as O 
neuroprotective O 
agents O 
affecting O 
multiple O 
biological O 
targets O 
involved O 
in O 
AD O 
. O 
These O 
properties O 
are O 
not O 
paralleled O 
by O 
the O 
related O 
2-arylboronic B-FAMILY 
acids I-FAMILY 
. O 

mechanisms O 
modulating O 
the O 
expression O 
of O 
the O 
cytochrome O 
P450 O 
1A1 O 
gene O 
by O 
methylmercury B-SYSTEMATIC 
in O 
HepG2 O 
cells O 
: O 
A O 
role O 
of O 
heme B-FAMILY 
oxygenase-1 O 
. O 

we O 
demonstrated O 
the O 
ability O 
of O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
Hg(2+) B-FORMULA 
) O 
in O 
human O 
hepatoma O 
HepG2 O 
cells O 
to O 
significantly O 
decrease O 
the O 
TCDD B-ABBREVIATION 
-mediated O 
induction O 
of O 
Cytochrome O 
P450 O 
1A1 O 
( O 
CYP1A1 O 
) O 
mRNA O 
, O 
protein O 
, O 
and O 
catalytic O 
activity O 
levels O 
. O 
In O 
this O 
study O 
we O 
investigated O 
the O 
effect O 
of O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
on O 
CYP1A1 O 
in O 
HepG2 O 
cells O 
. O 
For O 
this O 
purpose O 
, O 
cells O 
were O 
co O 
- O 
exposed O 
to O 
MeHg B-FORMULA 
and O 
TCDD B-ABBREVIATION 
and O 
the O 
expression O 
of O 
CYP1A1 O 
mRNA O 
, O 
protein O 
, O 
and O 
catalytic O 
activity O 
levels O 
were O 
determined O 
. O 
Our O 
results O 
showed O 
that O 
MeHg B-FORMULA 
did O 
not O 
alter O 
the O 
TCDD B-ABBREVIATION 
-mediated O 
induction O 
of O 
CYP1A1 O 
mRNA O 
, O 
or O 
protein O 
levels O 
; O 
however O 
it O 
was O 
able O 
to O 
significantly O 
decrease O 
CYP1A1 O 
catalytic O 
activity O 
levels O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Importantly O 
, O 
this O 
inhibition O 
was O 
specific O 
to O 
CYP1A1and O 
was O 
not O 
radiated O 
to O 
other O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
(AhR)-regulated O 
genes O 
, O 
as O 
MeHg B-FORMULA 
induced O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
1 O 
mRNA O 
and O 
protein O 
levels O 
. O 
Mechanistically O 
, O 
the O 
inhibitory O 
effect O 
of O 
MeHg B-FORMULA 
on O 
the O 
induction O 
of O 
CYP1A1 O 
coincided O 
with O 
an O 
increase O 
in O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
mRNA O 
levels O 
. O 
Furthermore O 
, O 
the O 
inhibition O 
of O 
HO-1 O 
activity O 
, O 
by O 
tin B-SYSTEMATIC 
mesoporphyrin I-SYSTEMATIC 
, O 
caused O 
a O 
complete O 
restoration O 
of O 
MeHg B-FORMULA 
-mediated O 
inhibition O 
of O 
CYP1A1 O 
activity O 
, O 
induced O 
by O 
TCDD B-ABBREVIATION 
. O 
In O 
addition O 
, O 
transfection O 
of O 
HepG2 O 
cells O 
with O 
siRNA O 
targeting O 
the O 
human O 
HO-1 O 
gene O 
reversed O 
the O 
MeHg B-FORMULA 
-mediated O 
inhibition O 
of O 
TCDD B-ABBREVIATION 
-induced O 
CYP1A1 O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
demonstrated O 
that O 
MeHg B-FORMULA 
inhibited O 
the O 
TCDD B-ABBREVIATION 
-mediated O 
induction O 
of O 
CYP1A1 O 
through O 
a O 
posttranslational O 
mechanism O 
and O 
confirms O 
the O 
role O 
of O 
HO-1 O 
in O 
a O 
MeHg B-FORMULA 
-mediated O 
effect O 
. O 

valency O 
in O 
hydrogen B-SYSTEMATIC 
bonded O 
' O 
dimers O 
of O 
dimers O 
' O 
. O 

quadruply O 
bonded O 
compounds O 
containing O 
a O 
pendant O 
lactam B-SYSTEMATIC 
functional O 
group O 
form O 
self O 
- O 
complementary O 
hydrogen B-SYSTEMATIC 
bonded O 
' O 
dimers O 
of O 
dimers O 
' O 
in O 
the O 
solid O 
- O 
state O 
and O 
CH(2)Cl(2) B-FORMULA 
solutions O 
. O 
Electrochemical O 
studies O 
in O 
CH(2)Cl(2) B-FORMULA 
show O 
two O 
consecutive O 
one O 
- O 
electron O 
redox O 
processes O 
corresponding O 
to O 
oxidation O 
of O 
the O 
Mo(2)(4+) B-FORMULA 
cores O 
. O 
Spectroelectrochemical O 
studies O 
on O 
the O 
' O 
dimers O 
of O 
dimers O 
' O 
show O 
no O 
evidence O 
of O 
intervalence O 
charge O 
transfer O 
bands O 
in O 
the O 
mixed O 
valence O 
radical O 
cations O 
formed O 
by O 
one O 
- O 
electron O 
oxidation O 
, O 
indicating O 
that O 
they O 
are O 
examples O 
of O 
proton O 
- O 
coupled O 
mixed O 
valency O 
. O 

mGlu₅ O 
positive O 
allosteric O 
modulator O 
LSN2463359 B-IDENTIFIER 
differentially O 
modulates O 
motor O 
, O 
instrumental O 
and O 
cognitive O 
effects O 
of O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
in O 
the O 
rat O 
. O 

glutamate B-TRIVIAL 
5 O 
( O 
mGlu₅ O 
) O 
receptors O 
are O 
known O 
to O 
functionally O 
interact O 
with O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptors O 
at O 
both O 
neuronal O 
and O 
behavioural O 
levels O 
, O 
in O 
a O 
manner O 
that O 
may O 
be O 
of O 
relevance O 
to O 
the O 
treatment O 
of O 
schizophrenia O 
. O 
We O 
have O 
previously O 
described O 
a O 
novel O 
mGlu₅ O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
, O 
LSN2463359 B-IDENTIFIER 
and O 
provided O 
evidence O 
of O 
its O 
ability O 
to O 
attenuate O 
aspects O 
of O 
the O 
behavioural O 
response O 
to O 
administration O 
of O 
the O 
competitive O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
, O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
. O 
In O 
addition O 
, O 
LSN2463359 B-IDENTIFIER 
was O 
found O 
to O 
selectively O 
attenuate O 
reversal O 
learning O 
deficits O 
observed O 
in O 
the O 
neurodevelopmental O 
MAM O 
E17 O 
model O 
but O 
not O 
in O 
the O 
acute O 
phencyclidine B-TRIVIAL 
( O 
PCP B-ABBREVIATION 
) O 
model O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
interactions O 
between O 
this O 
mGlu₅ O 
PAM O 
and O 
the O 
NMDA B-ABBREVIATION 
receptor O 
were O 
explored O 
further O 
by O 
assessing O 
the O 
effects O 
of O 
LSN2463359 B-IDENTIFIER 
against O 
some O 
of O 
the O 
motor O 
, O 
instrumental O 
and O 
cognitive O 
effects O 
induced O 
by O 
the O 
non-competitive O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
PCP B-ABBREVIATION 
and O 
MK-801 B-IDENTIFIER 
, O 
the O 
competitive O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
and O 
the O 
GluN2B O 
selective O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
, O 
Ro B-IDENTIFIER 
63-1908 I-IDENTIFIER 
. O 
LSN2463359 B-IDENTIFIER 
had O 
either O 
no O 
or O 
minor O 
impact O 
on O 
locomotor O 
hyperactivity O 
induced O 
by O 
either O 
PCP B-ABBREVIATION 
or O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
. O 
However O 
, O 
in O 
rats O 
lever O 
pressing O 
for O 
food O 
rewards O 
under O 
a O 
variable O 
interval O 
30s O 
schedule O 
of O 
instrumental O 
responding O 
, O 
the O 
drug O 
clearly O 
attenuated O 
not O 
only O 
the O 
suppression O 
of O 
response O 
rate O 
induced O 
by O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
but O 
also O 
the O 
stimulation O 
of O 
response O 
rate O 
induced O 
by O 
Ro B-IDENTIFIER 
63-1908 I-IDENTIFIER 
. O 
In O 
contrast O 
, O 
LSN2463359 B-IDENTIFIER 
failed O 
to O 
alter O 
both O 
of O 
the O 
instrumental O 
effects O 
induced O 
by O 
the O 
open O 
channel O 
blockers O 
PCP B-ABBREVIATION 
and O 
MK-801 B-IDENTIFIER 
. O 
In O 
addition O 
, O 
although O 
PCP B-ABBREVIATION 
and O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
induced O 
similar O 
deficits O 
in O 
a O 
discrimination O 
and O 
reversal O 
learning O 
task O 
, O 
LSN2463359 B-IDENTIFIER 
was O 
again O 
only O 
able O 
to O 
reverse O 
the O 
deficit O 
induced O 
by O 
SDZ B-IDENTIFIER 
220581 I-IDENTIFIER 
. O 
The O 
results O 
indicate O 
that O 
the O 
interactions O 
between O 
mGlu₅ O 
and O 
NMDA B-ABBREVIATION 
receptors O 
are O 
dependent O 
on O 
both O 
the O 
mechanism O 
of O 
the O 
blockade O 
of O 
the O 
receptor O 
and O 
the O 
behavioural O 
domain O 
under O 
investigation O 
. O 
Our O 
work O 
has O 
implications O 
for O 
the O 
preclinical O 
use O 
of O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
in O 
the O 
prediction O 
of O 
potential O 
therapeutic O 
efficacy O 
in O 
the O 
search O 
for O 
novel O 
treatments O 
for O 
schizophrenia O 
. O 
Positive O 
allosteric O 
modulators O 
of O 
the O 
mGlu₅ O 
receptor O 
certainly O 
question O 
the O 
predictive O 
validity O 
of O 
such O 
approaches O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

efficacy O 
of O 
silymarin O 
from O 
milk O 
thistle O 
in O 
reducing O 
manganese B-SYSTEMATIC 
-induced O 
hepatic O 
damage O 
and O 
apoptosis O 
in O 
rats O 
. O 

stress O 
has O 
been O 
proposed O 
as O 
a O 
possible O 
mechanism O 
involved O 
in O 
manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
toxicity O 
. O 
Using O 
natural O 
antioxidants O 
against O 
metal O 
- O 
induced O 
hepatotoxicity O 
is O 
a O 
modern O 
approach O 
. O 
The O 
present O 
study O 
investigated O 
the O 
beneficial O 
role O 
of O 
silymarin O 
, O 
a O 
natural O 
flavonoid B-FAMILY 
, O 
in O 
Mn B-FORMULA 
-induced O 
hepatotoxicity O 
focusing O 
on O 
histopathology O 
and O 
biochemical O 
approaches O 
. O 
Male O 
Wistar O 
rats O 
were O 
exposed O 
orally O 
to O 
manganese B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
20 O 
mg O 
/ O 
mL O 
) O 
for O 
30 O 
days O 
followed O 
by O 
intraperitoneal O 
cotreatment O 
with O 
silymarin O 
( O 
100 O 
mg O 
/ O 
kg O 
) O 
. O 
Exposure O 
to O 
Mn B-FORMULA 
resulted O 
in O 
a O 
significant O 
elevation O 
of O 
the O 
plasma O 
marker O 
enzyme O 
activities O 
and O 
bilirubin B-TRIVIAL 
level O 
related O 
to O 
liver O 
dysfunction O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
and O 
hepatic O 
oxidative O 
stress O 
indices O 
. O 
This O 
metal O 
reduced O 
the O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
nonenzymatic O 
antioxidant O 
levels O 
such O 
as O 
reduced O 
glutathione B-TRIVIAL 
, O 
total O 
sulfhydryl B-FAMILY 
groups O 
and O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
. O 
In O 
addition O 
, O 
it O 
caused O 
hepatic O 
hemorrhage O 
, O 
cellular O 
degeneration O 
and O 
necrosis O 
of O 
hepatocytes O 
as O 
indicated O 
by O 
liver O 
histopathology O 
and O 
DNA O 
fragmentation O 
studies O 
. O 
Coadministration O 
of O 
silymarin O 
alleviated O 
Mn B-FORMULA 
oxidative O 
damage O 
effects O 
by O 
inhibiting O 
ROS O 
generation O 
. O 
Histological O 
studies O 
also O 
supported O 
the O 
beneficial O 
role O 
of O 
silymarin O 
against O 
Mn B-FORMULA 
-induced O 
hepatic O 
damages O 
. O 
Combining O 
all O 
, O 
results O 
suggested O 
that O 
silymarin O 
could O 
protect O 
hepatic O 
tissues O 
against O 
Mn B-FORMULA 
-induced O 
oxidative O 
stress O 
probably O 
through O 
its O 
antioxidant O 
activity O 
. O 
Therefore O 
, O 
its O 
supplementation O 
could O 
provide O 
a O 
new O 
approach O 
for O 
the O 
reduction O 
in O 
hepatic O 
complication O 
due O 
to O 
Mn B-FORMULA 
poisoning O 
. O 

pharmacokinetics O 
and O 
conversion O 
of O 
the O 
lactone B-FAMILY 
to O 
the O 
carboxylate B-SYSTEMATIC 
forms O 
of O 
ginkgolide B-TRIVIAL 
B I-TRIVIAL 
in O 
rat O 
plasma O 
. O 

B I-TRIVIAL 
consists O 
of O 
three O 
lactone B-FAMILY 
groups O 
, O 
which O 
may O 
undergo O 
hydrolysis O 
, O 
and O 
lead O 
to O 
the O 
rings O 
opening O 
in O 
aqueous O 
solution O 
with O 
different O 
pHs O 
. O 
From O 
mechanisms O 
of O 
pharmacological O 
activity O 
in O 
vivo O 
, O 
the O 
lactone B-FAMILY 
appears O 
to O 
be O 
the O 
active O 
form O 
of O 
the O 
drug O 
. O 
Pharmacokinetics O 
of O 
lactone B-FAMILY 
form O 
( O 
GB-lac B-ABBREVIATION 
) O 
and O 
the O 
total O 
of O 
the O 
lactone B-FAMILY 
and O 
carboxylate B-SYSTEMATIC 
form O 
( O 
GB-tot O 
) O 
of O 
ginkgolide B-TRIVIAL 
B I-TRIVIAL 
were O 
investigated O 
after O 
intravenous O 
administration O 
of O 
a O 
dose O 
of O 
4 O 
mg O 
/ O 
kg O 
ginkgolide B-TRIVIAL 
B I-TRIVIAL 
. O 
The O 
rate O 
of O 
lactone B-FAMILY 
hydrolysis O 
was O 
also O 
studied O 
in O 
plasma O 
in O 
vitro O 
. O 
After O 
intravenous O 
administration O 
, O 
ginkgolide B-TRIVIAL 
B I-TRIVIAL 
in O 
the O 
original O 
form O 
was O 
converted O 
to O 
its O 
carboxylate B-SYSTEMATIC 
form O 
under O 
simulated O 
physiological O 
conditions O 
. O 
The O 
AUC0 O 
- O 
∞ O 
of O 
GB-lac B-ABBREVIATION 
constituted O 
63.5 O 
± O 
17.4% O 
of O 
the O 
AUC0 O 
- O 
∞ O 
of O 
GB-tot O 
. O 
The O 
ratio O 
of O 
average O 
cumulation O 
of O 
excretion O 
of O 
lactone B-FAMILY 
to O 
carboxylate B-SYSTEMATIC 
reached O 
approximately O 
1 O 
to O 
1 O 
in O 
urine O 
. O 
From O 
the O 
equilibrium O 
of O 
lactone B-FAMILY 
hydrolysis O 
in O 
rat O 
plasma O 
in O 
vitro O 
, O 
the O 
k O 
obs O 
was O 
- O 
0.0176 O 
min(- O 
1) O 
and O 
t O 
1 O 
/ O 
2 O 
was O 
39.38 O 
min O 
. O 
In O 
conclusion O 
, O 
the O 
equilibrium O 
existed O 
between O 
lactone B-FAMILY 
of O 
ginkgolide B-TRIVIAL 
B I-TRIVIAL 
and O 
its O 
carboxylate B-SYSTEMATIC 
form O 
in O 
vivo O 
at O 
physiological O 
pH O 
, O 
which O 
suggested O 
that O 
more O 
attention O 
should O 
be O 
focused O 
on O 
the O 
original O 
and O 
the O 
ionization O 
forms O 
of O 
ginkgolide B-TRIVIAL 
B I-TRIVIAL 
and O 
the O 
conversion O 
of O 
the O 
lactone B-FAMILY 
into O 
carboxylate B-SYSTEMATIC 
in O 
vivo O 
. O 

effects O 
of O 
ectoine B-TRIVIAL 
, O 
a O 
bacteria O 
- O 
derived O 
natural O 
tetrahydropyrimidine B-SYSTEMATIC 
, O 
in O 
experimental O 
colitis O 
. O 

suggests O 
an O 
important O 
role O 
of O 
intestinal O 
barrier O 
dysfunction O 
in O 
the O 
etiology O 
of O 
inflammatory O 
bowel O 
disease O 
( O 
IBD O 
) O 
. O 
Therefore O 
stabilizing O 
mucosal O 
barrier O 
function O 
constitutes O 
a O 
new O 
therapeutic O 
approach O 
in O 
its O 
management O 
. O 
Ectoine B-TRIVIAL 
is O 
a O 
compatible O 
solute O 
produced O 
by O 
aerobic O 
chemoheterotrophic O 
and O 
halophilic O 
/ O 
halotolerant O 
bacteria O 
, O 
where O 
it O 
acts O 
as O 
osmoprotectant O 
and O 
effective O 
biomembrane O 
stabilizer O 
, O 
protecting O 
the O 
producing O 
cells O 
from O 
extreme O 
environmental O 
stress O 
. O 
Since O 
this O 
natural O 
compound O 
was O 
also O 
shown O 
to O 
prevent O 
inflammatory O 
responses O 
associated O 
with O 
IBD O 
, O 
its O 
potential O 
usefulness O 
was O 
studied O 
in O 
a O 
model O 
of O 
colitis O 
. O 
Groups O 
of O 
rats O 
were O 
treated O 
orally O 
with O 
different O 
doses O 
of O 
ectoine B-TRIVIAL 
( O 
30-300mg O 
/ O 
kg O 
) O 
or O 
sulfasalazine B-TRIVIAL 
( O 
reference O 
drug O 
) O 
daily O 
for O 
11 O 
days O 
. O 
On O 
day O 
8 O 
colitis O 
was O 
induced O 
by O 
intracolonic O 
instillation O 
of O 
2,4,6-trinitrobenzenesulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
when O 
overt O 
signs O 
of O 
lesions O 
develop O 
within O 
the O 
next O 
3 O 
days O 
. O 
On O 
day O 
12 O 
, O 
blood O 
was O 
withdrawn O 
from O 
the O 
retro O 
- O 
orbital O 
plexus O 
of O 
the O 
rats O 
and O 
the O 
animals O 
were O 
sacrificed O 
. O 
The O 
colon O 
was O 
excised O 
and O 
examined O 
macroscopically O 
and O 
microscopically O 
. O 
Relevant O 
parameters O 
of O 
oxidative O 
stress O 
and O 
inflammation O 
were O 
measured O 
in O 
serum O 
and O 
colon O 
homogenates O 
. O 
Induction O 
of O 
colitis O 
led O 
to O 
marked O 
weight O 
loss O 
, O 
significant O 
histopathological O 
changes O 
of O 
the O 
colon O 
, O 
and O 
variable O 
changes O 
in O 
levels O 
of O 
myeloperoxidase O 
, O 
reduced O 
glutathione B-TRIVIAL 
, O 
malondialdehyde B-TRIVIAL 
, O 
and O 
all O 
inflammatory O 
markers O 
tested O 
. O 
Treatment O 
with O 
ectoine B-TRIVIAL 
ameliorated O 
the O 
inflammatory O 
changes O 
in O 
TNBS-induced O 
colitis O 
. O 
This O 
effect O 
was O 
associated O 
with O 
reduction O 
in O 
the O 
levels O 
of O 
TNF-α O 
, O 
IL-1β O 
, O 
ICAM-1 O 
, O 
PGE2 O 
and O 
LTB4 O 
. O 
The O 
findings O 
suggest O 
that O 
intestinal O 
barrier O 
stabilizers O 
from O 
natural O 
sources O 
could O 
offer O 
new O 
therapeutic O 
measures O 
for O 
the O 
management O 
of O 
IBD O 
. O 

administered O 
antipsychotic O 
drugs O 
are O 
highly O 
selective O 
for O 
dopamine B-TRIVIAL 
D2 O 
over O 
D3 O 
receptors O 
. O 

showed O 
previously O 
, O 
using O 
[(3)H]-(+)-4-propyl-9-hydroxynaphthoxazine B-SYSTEMATIC 
( O 
[(3)H]-(+)-PHNO B-SYSTEMATIC 
) O 
autoradiography O 
, O 
that O 
several O 
antipsychotic O 
drugs O 
do O 
not O 
occupy O 
dopamine B-TRIVIAL 
D3 O 
receptors O 
at O 
clinically O 
- O 
relevant O 
doses O 
in O 
rat O 
. O 
This O 
is O 
an O 
unexpected O 
finding O 
considering O 
the O 
near O 
- O 
equivalent O 
in O 
vitro O 
affinity O 
of O 
these O 
drugs O 
for O 
D2 O 
and O 
D3 O 
receptors O 
. O 
The O 
purpose O 
of O 
the O 
current O 
study O 
was O 
to O 
address O 
two O 
possible O 
methodological O 
limitations O 
of O 
our O 
previous O 
report O 
, O 
namely O 
that O 
( O 
1 O 
) O 
[(3)H]-(+)-PHNO B-SYSTEMATIC 
may O 
have O 
been O 
administered O 
at O 
non-tracer O 
dose O 
, O 
potentially O 
causing O 
underestimate O 
of O 
D3 O 
receptor O 
occupancy O 
, O 
and O 
( O 
2 O 
) O 
antipsychotic O 
drugs O 
were O 
administered O 
chronically O 
, O 
potentially O 
causing O 
increased O 
D3 O 
receptor O 
expression O 
not O 
accounted O 
for O 
in O 
the O 
vehicle O 
- O 
treated O 
control O 
group O 
. O 
We O 
found O 
that O 
decreasing O 
[(3)H]-(+)-PHNO B-SYSTEMATIC 
dose O 
from O 
5.6nmol O 
/ O 
kg O 
( O 
our O 
previous O 
dose O 
) O 
to O 
0.6nmol O 
/ O 
kg O 
caused O 
a O 
> O 
60% O 
increase O 
in O 
[(3)H]-(+)-PHNO B-SYSTEMATIC 
binding O 
to O 
D3 O 
receptors O 
in O 
cerebellar O 
lobes O 
9 O 
and O 
10 O 
, O 
indicating O 
that O 
our O 
previous O 
study O 
was O 
indeed O 
conducted O 
under O 
non-tracer O 
dose O 
conditions O 
. O 
However O 
, O 
neither O 
reducing O 
[(3)H]-(+)-PHNO B-SYSTEMATIC 
dose O 
further O 
to O 
0.3nmol O 
/ O 
kg O 
( O 
a O 
tracer O 
dose O 
) O 
, O 
nor O 
administering O 
antipsychotics O 
acutely O 
affected O 
antipsychotic O 
receptor O 
occupancy O 
. O 
At O 
clinically O 
- O 
relevant O 
levels O 
of O 
D2 O 
occupancy O 
( O 
57-82% O 
inhibition O 
of O 
striatal O 
binding O 
) O 
, O 
neither O 
olanzapine B-TRIVIAL 
nor O 
haloperidol B-TRIVIAL 
occupied O 
D3 O 
receptors O 
, O 
while O 
clozapine B-TRIVIAL 
occupied O 
D3 O 
receptors O 
at O 
levels O 
similar O 
to O 
our O 
previous O 
report O 
( O 
33% O 
) O 
. O 
Risperidone B-TRIVIAL 
moderately O 
occupied O 
D3 O 
receptors O 
( O 
40% O 
) O 
, O 
but O 
at O 
a O 
dose O 
occupying O 
> O 
90% O 
of O 
D2 O 
receptors O 
and O 
therefore O 
of O 
questionable O 
clinical O 
relevance O 
. O 
These O 
findings O 
demonstrate O 
that O 
the O 
lack O 
of O 
antipsychotic O 
occupancy O 
of O 
D3 O 
receptors O 
is O 
not O 
attributable O 
to O 
limitations O 
of O 
our O 
previous O 
study O 
. O 
These O 
results O 
suggest O 
that O 
D3 O 
receptor O 
blockade O 
is O 
not O 
necessary O 
for O 
the O 
therapeutic O 
effects O 
of O 
the O 
antipsychotic O 
drugs O 
examined O 
. O 

structure O 
of O 
the O 
V301L O 
aldo O 
- O 
keto O 
reductase O 
1B10 O 
complexed O 
with O 
NADP(+) B-ABBREVIATION 
and O 
the O 
potent O 
aldose B-FAMILY 
reductase O 
inhibitor O 
fidarestat B-TRIVIAL 
: O 
implications O 
for O 
inhibitor O 
binding O 
and O 
selectivity O 
. O 

one O 
crystal O 
structure O 
is O 
currently O 
available O 
for O 
tumor O 
marker O 
AKR1B10 O 
, O 
complexed O 
with O 
NADP(+) B-ABBREVIATION 
and O 
tolrestat B-TRIVIAL 
, O 
which O 
is O 
an O 
aldose B-FAMILY 
reductase O 
inhibitor O 
( O 
ARI O 
) O 
of O 
the O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
type O 
. O 
Here O 
, O 
the O 
X-ray O 
structure O 
of O 
the O 
complex O 
of O 
the O 
V301L O 
substituted O 
AKR1B10 O 
holoenzyme O 
with O 
fidarestat B-TRIVIAL 
, O 
an O 
ARI O 
of O 
the O 
cyclic B-SYSTEMATIC 
imide I-SYSTEMATIC 
type O 
, O 
was O 
obtained O 
at O 
1.60Å O 
resolution O 
by O 
replacement O 
soaking O 
of O 
crystals O 
containing O 
tolrestat B-TRIVIAL 
. O 
Previously O 
, O 
fidarestat B-TRIVIAL 
was O 
found O 
to O 
be O 
safe O 
in O 
phase O 
III O 
trials O 
for O 
diabetic O 
neuropathy O 
and O 
, O 
consistent O 
with O 
its O 
low O 
in O 
vivo O 
side O 
effects O 
, O 
was O 
highly O 
selective O 
for O 
aldose B-FAMILY 
reductase O 
( O 
AR O 
or O 
AKR1B1 O 
) O 
versus O 
aldehyde B-SYSTEMATIC 
reductase O 
( O 
AKR1A1 O 
) O 
. O 
Now O 
, O 
inhibition O 
studies O 
showed O 
that O 
fidarestat B-TRIVIAL 
was O 
indeed O 
1300-fold O 
more O 
selective O 
for O 
AR O 
as O 
compared O 
to O 
AKR1B10 O 
, O 
while O 
the O 
change O 
of O 
Val B-ABBREVIATION 
to O 
Leu B-FORMULA 
( O 
found O 
in O 
AR O 
) O 
caused O 
a O 
20-fold O 
decrease O 
in O 
the O 
IC50 O 
value O 
with O 
fidarestat B-TRIVIAL 
. O 
Structural O 
analysis O 
of O 
the O 
V301L O 
AKR1B10- O 
fidarestat B-TRIVIAL 
complex O 
displayed O 
enzyme O 
- O 
inhibitor O 
interactions O 
similar O 
to O 
those O 
of O 
the O 
AR- O 
fidarestat B-TRIVIAL 
complex O 
. O 
However O 
, O 
a O 
close O 
inspection O 
of O 
both O 
the O 
new O 
crystal O 
structure O 
and O 
a O 
computer O 
model O 
of O 
the O 
wild O 
- O 
type O 
AKR1B10 O 
complex O 
with O 
fidarestat B-TRIVIAL 
revealed O 
subtle O 
changes O 
that O 
could O 
affect O 
fidarestat B-TRIVIAL 
binding O 
. O 
In O 
the O 
crystal O 
structure O 
, O 
a O 
significant O 
motion O 
of O 
loop O 
A O 
was O 
observed O 
between O 
AR O 
and O 
V301L O 
AKR1B10 O 
, O 
linked O 
to O 
a O 
Phe B-FORMULA 
-122/ O 
Phe B-FORMULA 
-123 O 
side O 
chain O 
displacement O 
. O 
This O 
was O 
due O 
to O 
the O 
presence O 
of O 
the O 
more O 
voluminous O 
Gln B-FORMULA 
-303 O 
side O 
chain O 
( O 
Ser B-FORMULA 
-302 O 
in O 
AR O 
) O 
and O 
of O 
a O 
water O 
molecule O 
buried O 
in O 
a O 
subpocket O 
located O 
at O 
the O 
base O 
of O 
flexible O 
loop O 
A O 
. O 
In O 
the O 
wild O 
- O 
type O 
AKR1B10 O 
model O 
, O 
a O 
short O 
contact O 
was O 
predicted O 
between O 
the O 
Val B-ABBREVIATION 
-301 O 
side O 
chain O 
and O 
fidarestat B-TRIVIAL 
, O 
but O 
would O 
not O 
be O 
present O 
in O 
AR O 
or O 
in O 
V301L O 
AKR1B10 O 
. O 
Overall O 
, O 
these O 
changes O 
could O 
contribute O 
to O 
the O 
difference O 
in O 
inhibitory O 
potency O 
of O 
fidarestat B-TRIVIAL 
between O 
AR O 
and O 
AKR1B10 O 
. O 

efficacy O 
and O 
pharmacokinetic O 
behavior O 
of O 
novel O 
anti-inflammatory O 
para-phenyl B-FAMILY 
substituted I-FAMILY 
diindolylmethanes I-FAMILY 
in O 
a O 
mouse O 
model O 
of O 
Parkinson's O 
disease O 
. O 

are O 
currently O 
no O 
registered O 
drugs O 
that O 
slow O 
the O 
progression O 
of O 
neurodegenerative O 
diseases O 
, O 
in O 
part O 
because O 
translation O 
from O 
animal O 
models O 
to O 
the O 
clinic O 
has O 
been O 
hampered O 
by O 
poor O 
distribution O 
to O 
the O 
brain O 
. O 
The O 
present O 
studies O 
examined O 
a O 
selected O 
series O 
of O 
para-phenyl- B-FAMILY 
substituted I-FAMILY 
diindolylmethane I-FAMILY 
( O 
C-DIM O 
) O 
compounds O 
that O 
display O 
anti-inflammatory O 
and O 
neuroprotective O 
efficacy O 
in O 
vitro O 
. O 
We O 
postulated O 
that O 
the O 
pharmacokinetic O 
behavior O 
of O 
C-DIM O 
compounds O 
after O 
oral O 
administration O 
would O 
correlate O 
with O 
neuroprotective O 
efficacy O 
in O 
vivo O 
in O 
a O 
mouse O 
model O 
of O 
Parkinson's O 
disease O 
. O 
Pharmacokinetics O 
and O 
metabolism O 
of O 
1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane B-SYSTEMATIC 
( O 
C-DIM5 O 
) O 
, O 
1,1-bis(3'-indolyl)-1-(phenyl)methane B-SYSTEMATIC 
, O 
1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane B-SYSTEMATIC 
( O 
C-DIM8 O 
) O 
, O 
and O 
1,1-bis(3'-indolyl)-1-(p-chlorophenyl)methane B-SYSTEMATIC 
( O 
C-DIM12 O 
) O 
were O 
determined O 
in O 
plasma O 
and O 
brain O 
of O 
C57Bl O 
/ O 
6 O 
mice O 
after O 
oral O 
and O 
intravenous O 
administration O 
at O 
10 O 
and O 
1 O 
mg O 
/ O 
Kg O 
, O 
respectively O 
. O 
Putative O 
metabolites O 
were O 
measured O 
in O 
plasma O 
, O 
liver O 
, O 
and O 
urine O 
. O 
C-DIM O 
compounds O 
given O 
orally O 
displayed O 
the O 
highest O 
area O 
under O 
the O 
curve O 
, O 
Cmax O 
, O 
and O 
Tmax O 
levels O 
, O 
and O 
C-DIM12 O 
exhibited O 
the O 
most O 
favorable O 
pharmacokinetics O 
of O 
the O 
compounds O 
tested O 
. O 
Oral O 
bioavailability O 
of O 
each O 
compound O 
ranged O 
from O 
6% O 
( O 
C-DIM8 O 
) O 
to O 
42% O 
( O 
C-DIM12 O 
) O 
. O 
After O 
pharmacokinetic O 
studies O 
, O 
the O 
neuroprotective O 
efficacy O 
of O 
C-DIM5 O 
, O 
C-DIM8 O 
, O 
and O 
C-DIM12 O 
( O 
50 O 
mg O 
/ O 
Kg O 
per O 
oral O 
) O 
was O 
examined O 
in O 
mice O 
exposed O 
to O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
( O 
MPTP B-ABBREVIATION 
) O 
and O 
probenecid B-TRIVIAL 
for O 
14 O 
days O 
, O 
a O 
model O 
of O 
progressive O 
neurodegeneration O 
with O 
a O 
strong O 
neuroinflammatory O 
component O 
. O 
C-DIM5 O 
and O 
C-DIM12 O 
given O 
orally O 
once O 
daily O 
after O 
one O 
week O 
of O 
exposure O 
to O 
MPTP B-ABBREVIATION 
and O 
probenecid B-TRIVIAL 
prevented O 
further O 
loss O 
of O 
dopaminergic O 
neurons O 
in O 
the O 
substantia O 
nigra O 
pars O 
compacta O 
and O 
striatal O 
dopamine B-TRIVIAL 
terminals O 
, O 
indicating O 
that O 
these O 
compounds O 
could O 
be O 
effective O 
therapeutic O 
agents O 
to O 
prevent O 
neurodegeneration O 
. O 

Methyl I-SYSTEMATIC 
Ester I-SYSTEMATIC 
from O 
Pulsatilla O 
nigricans O 
Induces O 
Apoptosis O 
in O 
HeLa O 
Cells O 
: O 
Its O 
Cytoxicity O 
and O 
Interaction O 
with O 
Calf O 
Thymus O 
DNA O 
. O 

methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
DIME B-ABBREVIATION 
) O 
, O 
the O 
principal O 
biological O 
compound O 
isolated O 
from O 
the O 
medicinal O 
plant O 
Pulsatilla O 
nigricans O 
( O 
Fam O 
: O 
Ranunculaceae O 
) O 
having O 
the O 
molecular O 
formula O 
of O 
C21 B-FORMULA 
H34 I-FORMULA 
O3 I-FORMULA 
( O 
molecular O 
weight O 
334.25 O 
) O 
, O 
was O 
administered O 
to O 
cervical O 
cancer O 
cells O 
( O 
HeLa O 
) O 
in O 
vitro O 
to O 
evaluate O 
its O 
possible O 
apoptotic O 
( O 
anti-cancer O 
) O 
potentials O 
. O 
We O 
analyzed O 
the O 
expression O 
of O 
p53 O 
, O 
Bax O 
, O 
Bcl2 O 
, O 
Apaf O 
and O 
caspase O 
3 O 
signal O 
proteins O 
and O 
analyzed O 
the O 
early O 
apoptotic O 
events O 
in O 
HeLa O 
cells O 
induced O 
by O 
DIME B-ABBREVIATION 
using O 
protocols O 
like O 
Annexin O 
V-FITC O 
and O 
PI O 
staining O 
. O 
DIME B-ABBREVIATION 
caused O 
a O 
significant O 
decrease O 
in O 
cell O 
viability O 
, O 
induced O 
nuclear O 
condensation O 
and O 
inter O 
- O 
nucleosomal O 
DNA O 
fragmentation O 
. O 
We O 
further O 
studied O 
the O 
interaction O 
of O 
DIME B-ABBREVIATION 
with O 
calf O 
thymus O 
DNA O 
as O 
target O 
through O 
circular O 
- O 
dichroism O 
spectra O 
. O 
Results O 
showed O 
that O 
DIME B-ABBREVIATION 
interacted O 
with O 
DNA O 
, O 
bringing O 
indiscernible O 
changes O 
in O 
structure O 
and O 
conformation O 
. O 
Thus O 
, O 
DIME B-ABBREVIATION 
showed O 
its O 
capability O 
to O 
induce O 
apoptosis O 
in O 
cancer O 
cells O 
, O 
signifying O 
its O 
utility O 
in O 
drug O 
design O 
as O 
a O 
possible O 
candidate O 
for O 
chemoprevention O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
the O 
antineoplastic O 
potential O 
of O 
chalcones B-FAMILY 
in O 
animal O 
models O 
. O 

part O 
of O 
chemical O 
space O 
that O 
is O 
endowed O 
with O 
interesting O 
biological O 
properties O 
is O 
the O 
area O 
of O 
the O 
chalcones B-FAMILY 
. O 
With O 
this O 
review O 
, O 
we O 
provide O 
a O 
comprehensive O 
overview O 
of O 
the O 
numerous O 
in O 
vivo O 
animal O 
studies O 
on O 
the O 
antineoplastic O 
potential O 
of O 
both O 
natural O 
and O 
synthetic O 
members O 
of O 
this O 
flavonoid B-FAMILY 
subclass O 
( O 
covering O 
: O 
up O 
to O 
mid-2011 O 
) O 
. O 
The O 
thus O 
far O 
identified O 
modes O 
of O 
action O 
of O 
these O 
compounds O 
are O 
also O 
discussed O 
. O 
We O 
hope O 
that O 
this O 
overview O 
may O 
stimulate O 
deeper O 
investigations O 
into O 
the O 
biochemical O 
mechanisms O 
by O 
which O 
chalcones B-FAMILY 
exert O 
their O 
antineoplastic O 
action O 
. O 
As O 
a O 
result O 
, O 
in O 
the O 
foreseeable O 
future O 
, O 
chalcones B-FAMILY 
may O 
prove O 
suitable O 
lead O 
molecules O 
or O 
early O 
drug O 
candidates O 
for O 
the O 
prevention O 
or O 
treatment O 
of O 
various O 
neoplastic O 
diseases O 
. O 

present O 
review O 
gives O 
an O 
overview O 
of O 
current O 
pharmacological O 
treatment O 
options O 
of O 
tic O 
disorders O 
and O 
Tourette O 
Syndrome O 
( O 
TS O 
) O 
. O 
After O 
a O 
short O 
summary O 
on O 
phenomenology O 
, O 
clinical O 
course O 
and O 
comorbid O 
conditions O 
we O 
review O 
indications O 
for O 
pharmacological O 
treatment O 
in O 
detail O 
. O 
Unfortunately O 
, O 
standardized O 
and O 
large O 
enough O 
drug O 
trials O 
in O 
TS O 
patients O 
fulfilling O 
evidence O 
based O 
medicine O 
standards O 
are O 
still O 
scarce O 
. O 
Treatment O 
decisions O 
are O 
often O 
guided O 
by O 
individual O 
needs O 
and O 
personal O 
experience O 
of O 
treating O 
clinicians O 
. O 
The O 
present O 
recommendations O 
for O 
pharmacological O 
tic O 
treatment O 
are O 
therefore O 
based O 
on O 
both O 
scientific O 
evidence O 
and O 
expert O 
opinion O 
. O 
As O 
first O 
- O 
line O 
treatment O 
of O 
tics O 
risperidone B-TRIVIAL 
( O 
best O 
evidence O 
level O 
for O 
atypical O 
antipsychotics O 
) O 
or O 
tiapride B-TRIVIAL 
( O 
largest O 
clinical O 
experience O 
in O 
Europe O 
and O 
low O 
rate O 
of O 
adverse O 
reactions O 
) O 
are O 
recommended O 
. O 
Aripiprazole B-TRIVIAL 
( O 
still O 
limited O 
but O 
promising O 
data O 
with O 
low O 
risk O 
for O 
adverse O 
reactions O 
) O 
and O 
pimozide B-TRIVIAL 
( O 
best O 
evidence O 
of O 
the O 
typical O 
antipsychotics O 
) O 
are O 
agents O 
of O 
second O 
choice O 
. O 
In O 
TS O 
patients O 
with O 
comorbid O 
attention O 
deficit O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
atomoxetine B-TRIVIAL 
, O 
stimulants O 
or O 
clonidine B-TRIVIAL 
should O 
be O 
considered O 
, O 
or O 
, O 
if O 
tics O 
are O 
severe O 
, O 
a O 
combination O 
of O 
stimulants O 
and O 
risperidone B-TRIVIAL 
. O 
When O 
mild O 
to O 
moderate O 
tics O 
are O 
associated O 
with O 
obsessive O 
- O 
compulsive O 
symptoms O 
, O 
depression O 
or O 
anxiety O 
sulpiride B-TRIVIAL 
monotherapy O 
can O 
be O 
helpful O 
. O 
In O 
more O 
severe O 
cases O 
the O 
combination O 
of O 
risperidone B-TRIVIAL 
and O 
a O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitor O 
should O 
be O 
given O 
. O 
In O 
summary O 
, O 
further O 
studies O 
, O 
particularly O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
trials O 
including O 
larger O 
and O 
/ O 
or O 
more O 
homogenous O 
patient O 
groups O 
over O 
longer O 
periods O 
are O 
urgently O 
needed O 
to O 
enhance O 
the O 
scientific O 
basis O 
for O 
drug O 
treatment O 
in O 
tic O 
disorders O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

vitro O 
evaluation O 
of O 
cytochrome O 
P450 O 
induction O 
and O 
the O 
inhibition O 
potential O 
of O 
mitragynine B-TRIVIAL 
, O 
a O 
stimulant O 
alkaloid O 
. O 

enzymes O 
are O 
key O 
determinants O 
in O 
drug O 
toxicities O 
, O 
reduced O 
pharmacological O 
effect O 
and O 
adverse O 
drug O 
reactions O 
. O 
Mitragynine B-TRIVIAL 
, O 
an O 
euphoric O 
compound O 
was O 
evaluated O 
for O 
its O 
effects O 
on O 
the O 
expression O 
of O 
mRNAs O 
encoding O 
CYP1A2 O 
, O 
CYP2D6 O 
and O 
CYP3A4 O 
and O 
protein O 
expression O 
and O 
resultant O 
enzymatic O 
activity O 
. O 
The O 
mRNA O 
and O 
protein O 
expression O 
of O 
CYP450 O 
isoforms O 
were O 
carried O 
out O 
using O 
an O 
optimized O 
multiplex O 
qRT-PCR O 
assay O 
and O 
Western O 
blot O 
analysis O 
. O 
CYP1A2 O 
and O 
CYP3A4 O 
enzyme O 
activities O 
were O 
evaluated O 
using O 
P450-Glo O 
™ O 
assays O 
. O 
The O 
effects O 
of O 
mitragynine B-TRIVIAL 
on O 
human O 
CYP3A4 O 
protein O 
expression O 
were O 
determined O 
using O 
an O 
optimized O 
hCYP3A4-HepG2 O 
cell O 
- O 
based O 
assay O 
. O 
An O 
in O 
silico O 
computational O 
method O 
to O 
predict O 
the O 
binding O 
conformation O 
of O 
mitragynine B-TRIVIAL 
to O 
the O 
active O 
site O 
of O 
the O 
CYP3A4 O 
enzyme O 
was O 
performed O 
and O 
further O 
validated O 
using O 
in O 
vitro O 
CYP3A4 O 
inhibition O 
assays O 
. O 
Mitragynine B-TRIVIAL 
was O 
found O 
to O 
induce O 
mRNA O 
and O 
protein O 
expression O 
of O 
CYP1A2 O 
. O 
For O 
the O 
highest O 
concentration O 
of O 
25 O 
μM O 
, O 
induction O 
of O 
mRNA O 
was O 
approximately O 
70% O 
that O 
of O 
the O 
positive O 
control O 
and O 
was O 
consistent O 
with O 
the O 
increased O 
CYP1A2 O 
enzymatic O 
activity O 
. O 
Thus O 
, O 
mitragynine B-TRIVIAL 
is O 
a O 
significant O 
in O 
vitro O 
CYP1A2 O 
inducer O 
. O 
However O 
, O 
it O 
appeared O 
to O 
be O 
a O 
weak O 
CYP3A4 O 
inducer O 
at O 
the O 
transcriptional O 
level O 
and O 
a O 
weak O 
CYP3A4 O 
enzyme O 
inhibitor O 
. O 
It O 
is O 
therefore O 
, O 
unlikely O 
to O 
have O 
any O 
significant O 
clinical O 
effects O 
on O 
CYP3A4 O 
activity O 
. O 

of O 
the O 
pharmacodynamics O 
and O 
pharmacokinetics O 
of O 
brucine B-TRIVIAL 
following O 
transdermal O 
administration O 
. O 

the O 
design O 
of O 
brucine B-TRIVIAL 
-containing O 
transdermal O 
formulations O 
, O 
the O 
pharmacodynamics O 
and O 
pharmacokinetics O 
of O 
brucine B-TRIVIAL 
following O 
transdermal O 
administration O 
should O 
be O 
evaluated O 
. O 
In O 
this O 
study O 
, O 
the O 
effect O 
of O 
addition O 
of O 
ethanol B-SYSTEMATIC 
on O 
solubility O 
of O 
bruicne B-TRIVIAL 
was O 
investigated O 
and O 
20% O 
ethanol B-SYSTEMATIC 
was O 
added O 
into O 
PBS O 
to O 
obtain O 
10mg O 
/ O 
mL O 
brucine B-TRIVIAL 
solution O 
. O 
Then O 
three O 
transdermal O 
doses O 
( O 
10 O 
, O 
20 O 
and O 
40mg O 
/ O 
kg O 
) O 
were O 
administered O 
to O 
mice O 
to O 
evaluate O 
pharmacological O 
activity O 
. O 
It O 
had O 
been O 
demonstrated O 
that O 
brucine B-TRIVIAL 
possessed O 
analgesic O 
and O 
anti-inflammatory O 
activity O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Cytotoxicities O 
of O 
brucine B-TRIVIAL 
against O 
various O 
tumor O 
cells O 
including O 
skin O 
tumor O 
cell O 
were O 
also O 
compared O 
in O 
vitro O 
. O 
Brucine B-TRIVIAL 
was O 
found O 
to O 
possess O 
antitumor O 
activity O 
in O 
a O 
concentration O 
and O 
time O 
- O 
dependent O 
manner O 
and O 
gastrointestinal O 
tumor O 
cells O 
seemed O 
to O 
be O 
more O 
sensitive O 
to O 
brucine B-TRIVIAL 
. O 
Then O 
in O 
vitro O 
skin O 
permeation O 
behavior O 
and O 
in O 
vivo O 
pharmacokinetics O 
following O 
transdermal O 
administration O 
were O 
further O 
investigated O 
. O 
The O 
cumulative O 
amounts O 
of O 
brucine B-TRIVIAL 
across O 
mouse O 
skin O 
in O 
vitro O 
were O 
found O 
to O 
be O 
higher O 
than O 
90% O 
. O 
The O 
absolute O 
bioavailability O 
of O 
brucine B-TRIVIAL 
was O 
determined O 
to O 
be O 
40.83% O 
. O 
And O 
compared O 
with O 
intravenous O 
administration O 
, O 
MRT O 
and O 
T1 O 
/ O 
2 O 
values O 
were O 
increased O 
about O 
8~12-fold O 
by O 
transdermal O 
route O 
. O 
Moreover O 
, O 
fluctuations O 
of O 
drug O 
levels O 
were O 
found O 
to O 
be O 
significantly O 
decreased O 
in O 
tissues O 
, O 
especially O 
in O 
brain O 
. O 
Finally O 
, O 
no O 
dermal O 
toxicity O 
of O 
brucine B-TRIVIAL 
was O 
observed O 
. O 
The O 
results O 
of O 
this O 
study O 
indicated O 
that O 
transdermal O 
administration O 
might O 
be O 
beneficial O 
for O 
the O 
sustained O 
efficacy O 
and O 
reduced O 
toxicity O 
of O 
brucine B-TRIVIAL 
. O 

new O 
sesquiterpene B-FAMILY 
from O 
the O 
mangrove O 
endophytic O 
fungus O 
Aspergillus O 
terreus O 
( O 
No O 
. O 
GX7-3B O 
) O 
. O 

new O 
compound O 
1 O 
( O 
named O 
botryosphaerin B-TRIVIAL 
F I-TRIVIAL 
) O 
, O 
along O 
with O 
other O 
three O 
known O 
compounds O 
2 O 
( O 
13,14,15,16-tetranorlabd-7-ene-19,6b B-SYSTEMATIC 
: I-SYSTEMATIC 
12,17-diolide I-SYSTEMATIC 
) O 
, O 
3 O 
( O 
botryosphaerin B-TRIVIAL 
B I-TRIVIAL 
) O 
and O 
4 O 
( O 
LL-Z1271β B-IDENTIFIER 
) O 
, O 
has O 
been O 
isolated O 
from O 
the O 
mangrove O 
fungus O 
Aspergillus O 
terreus O 
( O 
No O 
. O 
GX7-3B O 
) O 
. O 
The O 
structure O 
of O 
the O 
new O 
compound O 
was O 
established O 
by O 
analysis O 
of O 
spectroscopic O 
data O 
. O 
The O 
hypothetical O 
biogenic O 
relationship O 
of O 
four O 
sesquiterpene B-FAMILY 
analogues O 
was O 
also O 
described O 
in O 
this O 
paper O 
. O 
Furthermore O 
, O 
in O 
the O 
cytotoxicity O 
assays O 
, O 
compound O 
1 O 
showed O 
potent O 
inhibiting O 
activity O 
towards O 
MCF-7 O 
and O 
HL-60 O 
cancer O 
cell O 
lines O 
with O 
50% O 
inhibition O 
of O 
cell O 
growth O 
( O 
IC50 O 
) O 
values O 
of O 
4.49 O 
and O 
3.43 O 
μM O 
, O 
respectively O 
, O 
and O 
compound O 
4 O 
exhibited O 
promising O 
activity O 
against O 
HL-60 O 
cell O 
line O 
with O 
an O 
IC50 O 
value O 
of O 
0.6 O 
μM O 
. O 

Dangling O 
Bonds O 
with O 
Large O 
Spin O 
Splitting O 
and O 
Enhanced O 
Spin O 
Polarization O 
on O 
the O 
Surfaces O 
of O 
Bi2Se3 B-FORMULA 
. O 

investigate O 
the O 
topological O 
surface O 
state O 
properties O 
at O 
various O 
surface O 
cleaves O 
in O 
the O 
topological O 
insulator O 
Bi2Se3 B-FORMULA 
, O 
via O 
first O 
principles O 
calculations O 
and O 
scanning O 
tunneling O 
microscopy O 
/ O 
spectroscopy O 
( O 
STM O 
/ O 
STS O 
) O 
. O 
While O 
the O 
typical O 
surface O 
termination O 
occurs O 
between O 
two O 
quintuple O 
layers O 
, O 
we O 
report O 
the O 
existence O 
of O 
a O 
surface O 
termination O 
within O 
a O 
single O 
quintuple O 
layer O 
where O 
dangling O 
bonds O 
form O 
with O 
giant O 
spin O 
splitting O 
owing O 
to O 
strong O 
spin O 
- O 
orbit O 
coupling O 
. O 
Unlike O 
Rashba O 
split O 
states O 
in O 
a O 
2D O 
electron O 
gas O 
, O 
these O 
states O 
are O 
constrained O 
by O 
the O 
band O 
topology O 
of O 
the O 
host O 
insulator O 
with O 
topological O 
properties O 
similar O 
to O 
the O 
typical O 
topological O 
surface O 
state O 
, O 
and O 
thereby O 
offer O 
an O 
alternative O 
candidate O 
for O 
spintronics O 
usage O 
. O 
We O 
name O 
these O 
new O 
states O 
" O 
topological O 
dangling O 
- O 
bond O 
states O 
" O 
. O 
The O 
degree O 
of O 
the O 
spin O 
polarization O 
of O 
these O 
states O 
is O 
greatly O 
enhanced O 
. O 
Since O 
dangling O 
bonds O 
are O 
more O 
chemically O 
reactive O 
, O 
the O 
observed O 
topological O 
dangling O 
- O 
bond O 
states O 
provide O 
a O 
new O 
avenue O 
for O 
manipulating O 
band O 
dispersions O 
and O 
spin O 
- O 
textures O 
by O 
adsorbed O 
atoms O 
or O 
molecules O 
. O 

of O 
a O 
molecular O 
dynamics O 
force O 
field O 
is O 
essential O 
in O 
realistically O 
modeling O 
the O 
physicochemical O 
processes O 
involved O 
in O 
a O 
molecular O 
system O 
. O 
This O 
step O 
is O 
often O 
challenging O 
when O 
the O 
equations O 
involved O 
in O 
describing O 
the O 
force O 
field O 
are O 
complicated O 
as O 
well O 
as O 
when O 
the O 
parameters O 
are O 
mostly O 
empirical O 
. O 
ReaxFF O 
is O 
one O 
such O 
reactive O 
force O 
field O 
which O 
uses O 
hundreds O 
of O 
parameters O 
to O 
describe O 
the O 
interactions O 
between O 
atoms O 
. O 
The O 
optimization O 
of O 
the O 
parameters O 
in O 
ReaxFF O 
is O 
done O 
such O 
that O 
the O 
properties O 
predicted O 
by O 
ReaxFF O 
matches O 
with O 
a O 
set O 
of O 
quantum O 
chemical O 
or O 
experimental O 
data O 
. O 
Usually O 
, O 
the O 
optimization O 
of O 
the O 
parameters O 
is O 
done O 
by O 
an O 
inefficient O 
single O 
- O 
parameter O 
parabolic O 
- O 
search O 
algorithm O 
. O 
In O 
this O 
study O 
, O 
we O 
use O 
a O 
robust O 
metropolis O 
Monte-Carlo O 
algorithm O 
with O 
simulated O 
annealing O 
to O 
search O 
for O 
the O 
optimum O 
parameters O 
for O 
the O 
ReaxFF O 
force O 
field O 
in O 
a O 
high O 
- O 
dimensional O 
parameter O 
space O 
. O 
The O 
optimization O 
is O 
done O 
against O 
a O 
set O 
of O 
quantum O 
chemical O 
data O 
for O 
MgSO4 B-FAMILY 
hydrates I-FAMILY 
. O 
The O 
optimized O 
force O 
field O 
reproduced O 
the O 
chemical O 
structures O 
, O 
the O 
equations O 
of O 
state O 
, O 
and O 
the O 
water O 
binding O 
curves O 
of O 
MgSO4 B-FAMILY 
hydrates I-FAMILY 
. O 
The O 
transferability O 
test O 
of O 
the O 
ReaxFF O 
force O 
field O 
shows O 
the O 
extend O 
of O 
transferability O 
for O 
a O 
particular O 
molecular O 
system O 
. O 
This O 
study O 
points O 
out O 
that O 
the O 
ReaxFF O 
force O 
field O 
is O 
not O 
indefinitely O 
transferable O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

of O 
TAK-491 B-IDENTIFIER 
, O 
a O 
new O 
angiotensin B-TRIVIAL 
II I-TRIVIAL 
receptor O 
antagonist O 
, O 
in O 
animals O 
. O 

absorption O 
process O 
in O 
animals O 
of O 
TAK-491 B-IDENTIFIER 
, O 
designed O 
as O 
ester B-FAMILY 
-based O 
prodrug O 
with O 
medoxomil B-TRIVIAL 
moiety O 
, O 
was O 
evaluated O 
. O 
In O 
the O 
plasma O 
of O 
rats O 
and O 
dogs O 
, O 
TAK-536 B-IDENTIFIER 
, O 
the O 
pharmacologically O 
active O 
metabolite O 
, O 
was O 
present O 
as O 
the O 
main O 
component O 
with O 
hardly O 
detectable O 
concentrations O 
of O 
TAK-491 B-IDENTIFIER 
after O 
oral O 
administration O 
of O 
TAK-491 B-IDENTIFIER 
. O 
In O 
the O 
rat O 
portal O 
plasma O 
, O 
TAK-536 B-IDENTIFIER 
was O 
also O 
present O 
as O 
the O 
main O 
component O 
with O 
hardly O 
detectable O 
concentrations O 
of O 
TAK-491 B-IDENTIFIER 
after O 
jejunal O 
loop O 
injection O 
of O 
TAK-491 B-IDENTIFIER 
, O 
suggesting O 
TAK-491 B-IDENTIFIER 
was O 
absorbed O 
from O 
small O 
intestine O 
and O 
hydrolyzed O 
almost O 
completely O 
during O 
absorption O 
. O 
Caco-2 O 
study O 
indicated O 
the O 
permeability O 
of O 
TAK-491 B-IDENTIFIER 
was O 
improved O 
by O 
prodrug O 
modification O 
and O 
the O 
compound O 
could O 
be O 
mainly O 
transferred O 
as O 
TAK-491 B-IDENTIFIER 
. O 
This O 
is O 
well O 
consistent O 
with O 
the O 
facts O 
that O 
the O 
AUC O 
and O 
T(max) O 
of O 
TAK-536 B-IDENTIFIER 
after O 
oral O 
administration O 
of O 
TAK-491 B-IDENTIFIER 
were O 
higher O 
and O 
shorter O 
than O 
those O 
after O 
oral O 
administration O 
of O 
TAK-536 B-IDENTIFIER 
in O 
dogs O 
Hydrolysis O 
of O 
TAK-491 B-IDENTIFIER 
is O 
observed O 
not O 
only O 
by O 
the O 
intestinal O 
and O 
hepatic O 
S9 O 
fraction O 
, O 
but O 
also O 
by O 
plasma O 
and O 
human O 
serum O 
albumin O 
. O 
However O 
, O 
medoxomil B-TRIVIAL 
alcohol I-TRIVIAL 
wasn't O 
detected O 
during O 
the O 
hydrolysis O 
of O 
TAK-491 B-IDENTIFIER 
. O 
These O 
metabolic O 
features O 
of O 
TAK-491 B-IDENTIFIER 
were O 
similar O 
to O 
olmesartan B-TRIVIAL 
medoxomil I-TRIVIAL 
, O 
suggesting O 
the O 
hydrolytic O 
pathway O 
and O 
enzymes O 
for O 
TAK-491 B-IDENTIFIER 
when O 
catalyzing O 
to O 
TAK-536 B-IDENTIFIER 
would O 
be O 
the O 
same O 
as O 
olmesartan B-TRIVIAL 
medoxomil I-TRIVIAL 
. O 

and O 
Filtration O 
of O 
Carbon B-SYSTEMATIC 
Nanotubes O 
( O 
CNTs O 
) O 
and O 
Measurement O 
of O 
Nanoparticle O 
Agglomerates O 
in O 
Diesel O 
Exhaust O 
. O 

nanotubes O 
( O 
CNTs O 
) O 
tend O 
to O 
form O 
bundles O 
due O 
to O 
their O 
geometry O 
and O 
van O 
der O 
Walls O 
forces O 
, O 
which O 
usually O 
complicates O 
studies O 
of O 
the O 
CNT O 
properties O 
. O 
Dispersion O 
plays O 
a O 
significant O 
role O 
in O 
CNT O 
studies O 
and O 
we O 
summarize O 
dispersion O 
techniques O 
to O 
generate O 
airborne O 
CNTs O 
from O 
suspensions O 
or O 
powders O 
. O 
We O 
describe O 
in O 
detail O 
our O 
technique O 
of O 
CNT O 
aerosolization O 
with O 
controlled O 
degree O 
of O 
agglomeration O 
using O 
an O 
electrospray O 
system O 
. O 
The O 
results O 
of O 
animal O 
inhalation O 
studies O 
using O 
the O 
electrosprayed O 
CNTs O 
are O 
presented O 
. O 
We O 
have O 
performed O 
filtration O 
experiments O 
for O 
CNTs O 
through O 
a O 
screen O 
filter O 
. O 
A O 
numerical O 
model O 
has O 
been O 
established O 
to O 
simulate O 
the O 
CNT O 
filtration O 
experiments O 
. O 
Both O 
the O 
modeling O 
and O 
experimental O 
results O 
show O 
that O 
the O 
CNT O 
penetration O 
is O 
less O 
than O 
the O 
penetration O 
for O 
a O 
sphere O 
with O 
the O 
same O 
mobility O 
diameter O 
, O 
which O 
is O 
mainly O 
due O 
to O 
the O 
larger O 
interception O 
length O 
of O 
the O 
CNTs O 
. O 
There O 
is O 
a O 
need O 
for O 
instruments O 
capable O 
of O 
fast O 
and O 
online O 
measurement O 
of O 
gas-borne O 
nanoparticle O 
agglomerates O 
. O 
We O 
developed O 
an O 
instrument O 
Universal O 
NanoParticle O 
Analyzer O 
( O 
UNPA O 
) O 
and O 
the O 
measurement O 
results O 
for O 
diesel O 
exhaust O 
particulates O 
are O 
presented O 
. O 
The O 
results O 
presented O 
here O 
are O 
pertinent O 
to O 
non-spherical O 
aerosol O 
particles O 
, O 
and O 
illustrate O 
the O 
effects O 
of O 
particle O 
morphology O 
on O 
aerosol O 
behaviors O 
. O 

xenobiotics O 
released O 
in O 
the O 
aquatic O 
environment O 
exhibit O 
a O 
genotoxic O 
potential O 
toward O 
organisms O 
. O 
Long O 
term O 
exposure O 
to O 
such O 
compounds O 
is O 
expected O 
to O 
lead O 
to O 
multigenerational O 
reproductive O 
defects O 
, O 
further O 
influencing O 
the O 
recruitment O 
rate O 
and O 
hence O 
, O 
the O 
population O 
dynamics O 
. O 
Paternal O 
exposure O 
to O 
genotoxicants O 
was O 
previously O 
shown O 
to O 
increase O 
abnormal O 
development O 
in O 
the O 
progeny O 
of O 
mammalian O 
or O 
aquatic O 
species O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
relationship O 
between O 
DNA O 
damage O 
in O 
sperm O 
of O 
the O 
fish O 
three O 
- O 
spined O 
stickleback O 
and O 
progeny O 
developmental O 
defects O 
. O 
Spermatozoa O 
were O 
exposed O 
ex O 
vivo O 
to O 
an O 
alkylating O 
agent O 
( O 
methyl B-SYSTEMATIC 
methanesulfonate I-SYSTEMATIC 
) O 
before O 
in O 
vitro O 
fertilization O 
and O 
DNA O 
damage O 
was O 
assessed O 
by O 
the O 
alkaline O 
comet O 
assay O 
. O 
A O 
significant O 
relationship O 
between O 
abnormal O 
development O 
and O 
sperm O 
DNA O 
damage O 
was O 
underlined O 
. O 
This O 
study O 
illustrates O 
the O 
interest O 
to O 
use O 
germ O 
cell O 
DNA O 
damage O 
after O 
ex O 
vivo O 
exposure O 
to O 
evaluate O 
the O 
impact O 
of O 
genotoxic O 
compounds O 
on O 
progeny O 
fitness O 
in O 
aquatic O 
organisms O 
. O 

properties O 
of O 
nanomultiple O 
CaFe2O4 B-FORMULA 
/ O 
ZnFe2O4 B-FORMULA 
pn O 
junction O 
photoelectrodes O 
. O 

CaFe2O4 B-FORMULA 
/ O 
ZnFe2O4 B-FORMULA 
pn O 
junctions O 
are O 
prepared O 
by O 
a O 
pulsed O 
laser O 
deposition O 
method O 
to O 
explore O 
their O 
photoelectrochemical O 
properties O 
as O 
the O 
photoelectrodes O 
. O 
It O 
is O 
demonstrated O 
that O 
the O 
multiple O 
- O 
pn O 
- O 
junction O 
structure O 
is O 
favorable O 
to O 
enhancing O 
the O 
photocurrent O 
density O 
and O 
the O 
onset O 
potential O 
of O 
the O 
photoelectrode O 
. O 
Furthermore O 
, O 
the O 
20-junction O 
photoelectrode O 
- O 
based O 
PEC O 
cell O 
yields O 
a O 
high O 
open O 
circuit O 
photovoltage O 
of O 
up O 
to O 
0.97 O 
V O 
, O 
which O 
is O 
much O 
higher O 
than O 
that O 
for O 
a O 
single O 
pn O 
junction O 
photoelectrode O 
PEC O 
cell O 
that O 
yields O 
an O 
open O 
circuit O 
photovoltage O 
of O 
0.13 O 
V O 
. O 
A O 
multiple O 
- O 
junction O 
band O 
structure O 
model O 
is O 
assumed O 
to O 
describe O 
the O 
behavior O 
of O 
the O 
CaFe2O4 B-FORMULA 
/ O 
ZnFe2O4 B-FORMULA 
multiple O 
- O 
junction O 
photoelectrodes O 
. O 
It O 
is O 
suggested O 
that O 
the O 
open O 
circuit O 
photovoltage O 
is O 
dominated O 
by O 
the O 
number O 
of O 
pn O 
junctions O 
in O 
a O 
multiple O 
- O 
junction O 
photoelectrode O 
and O 
the O 
carrier O 
transfer O 
inside O 
the O 
photoelectrode O 
is O 
improved O 
by O 
narrowing O 
the O 
single O 
- O 
layer O 
thickness O 
. O 
These O 
findings O 
provide O 
a O 
new O 
approach O 
to O 
designing O 
the O 
multiple O 
- O 
junction O 
structure O 
to O 
improve O 
the O 
PEC O 
properties O 
of O 
the O 
photoelectrodes O 
. O 

effects O 
of O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
via O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
- O 
cGMP B-ABBREVIATION 
-PKG O 
pathway O 
in O 
rat O 
thoracic O 
aorta O 
. O 

acid I-TRIVIAL 
( O 
CA O 
) O 
and O 
its O 
derivatives O 
have O 
a O 
broad O 
therapeutic O 
spectrum O 
that O 
includes O 
antimicrobial O 
, O 
antifungal O 
, O 
and O 
antitumoral O 
activities O 
. O 
However O 
, O 
the O 
vasodilative O 
effect O 
of O 
CA O 
has O 
not O 
been O 
demonstrated O 
. O 
The O 
present O 
study O 
characterizes O 
the O 
vasodilative O 
activity O 
and O 
the O 
mechanism O 
of O 
CA O 
in O 
rat O 
thoracic O 
aorta O 
. O 
The O 
vasomotion O 
of O 
aortic O 
strips O 
following O 
CA O 
treatment O 
was O 
measured O 
in O 
an O 
organ O 
bath O 
system O 
. O 
In O 
addition O 
, O 
vascular O 
strips O 
and O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
were O 
used O 
in O 
organ O 
bath O 
, O 
Western O 
blot O 
, O 
nitrite B-SYSTEMATIC 
, O 
and O 
cyclic B-SYSTEMATIC 
guanosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
( O 
cGMP B-ABBREVIATION 
) O 
measurements O 
. O 
CA O 
relaxed O 
phenylephrine B-TRIVIAL 
-precontracted O 
aortic O 
strips O 
in O 
an O 
endothelium O 
- O 
dependent O 
manner O 
. O 
Pretreatment O 
of O 
the O 
endothelium O 
- O 
intact O 
aortic O 
strips O 
with O 
N(G) B-SYSTEMATIC 
-nitro-l-arginine I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
10(-4) O 
M O 
) O 
, O 
1 B-SYSTEMATIC 
H-[1,2,4]-oxadiazolole-[4,3-a] I-SYSTEMATIC 
quinoxalin-10-one I-SYSTEMATIC 
, O 
( O 
10(-6) O 
M O 
) O 
and O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
( O 
10(-5) O 
M O 
) O 
inhibited O 
CA-induced O 
vasorelaxation O 
. O 
CA O 
also O 
increased O 
the O 
phosphorylation O 
of O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
generation O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
in O 
HUVECs O 
. O 
In O 
addition O 
, O 
cGMP B-ABBREVIATION 
generation O 
and O 
cGMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
G O 
( O 
PKG O 
) O 
expression O 
in O 
aortic O 
strips O 
were O 
increased O 
by O 
CA O 
treatment O 
. O 
Furthermore O 
, O 
CA-induced O 
vasorelaxation O 
was O 
inhibited O 
by O 
the O 
PKG O 
inhibitor O 
KT5823 B-IDENTIFIER 
( O 
0.3 O 
μM O 
) O 
and O 
the O 
Ca(2+) B-FORMULA 
-activated O 
K(+) B-FORMULA 
channel O 
inhibitor O 
tetraethylammonium B-SYSTEMATIC 
( O 
10(-3) O 
M O 
) O 
. O 
These O 
findings O 
suggest O 
that O 
CA O 
exerts O 
an O 
endothelium O 
- O 
dependent O 
vasodilation O 
effect O 
via O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
- O 
cGMP B-ABBREVIATION 
-PKG O 
- O 
mediated O 
pathway O 
in O 
rat O 
thoracic O 
aorta O 
. O 

sesterterpenoids B-FAMILY 
from O 
a O 
Korean O 
sponge O 
Monanchora O 
sp O 
. O 

investigation O 
of O 
a O 
Korean O 
marine O 
sponge O 
, O 
Monanchora O 
sp O 
. O 
, O 
yielded O 
nine O 
new O 
sesterterpenoids B-FAMILY 
( O 
1-9 O 
) O 
along O 
with O 
phorbaketals B-MULTIPLE 
A-C I-MULTIPLE 
( O 
10-12 O 
) O 
. O 
The O 
planar O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
NMR O 
and O 
MS O 
analysis O 
, O 
and O 
the O 
absolute O 
configurations O 
of O 
1-9 O 
were O 
defined O 
using O 
the O 
modified O 
Mosher's O 
method O 
and O 
CD O 
spectroscopic O 
data O 
analysis O 
. O 
Compounds O 
1-8 O 
, O 
designated O 
as O 
phorbaketals B-MULTIPLE 
D-K I-MULTIPLE 
, O 
possess O 
a O 
spiroketal B-FAMILY 
-modified O 
benzopyran B-SYSTEMATIC 
moiety O 
such O 
as O 
phorbaketal B-TRIVIAL 
A I-TRIVIAL 
, O 
and O 
their O 
structural O 
variations O 
are O 
due O 
to O 
oxidation O 
and O 
/ O 
or O 
reduction O 
of O 
the O 
tricyclic O 
core O 
or O 
the O 
side O 
chain O 
. O 
Compound O 
9 O 
, O 
designated O 
as O 
phorbin B-TRIVIAL 
A I-TRIVIAL 
, O 
has O 
a O 
monocyclic O 
structure O 
and O 
is O 
proposed O 
to O 
be O 
a O 
possible O 
biogenetic O 
precursor O 
of O 
the O 
phorbaketals B-FAMILY 
. O 
Compounds O 
1-9 O 
were O 
evaluated O 
for O 
cytotoxicity O 
against O 
four O 
human O 
cancer O 
cell O 
lines O 
( O 
A498 O 
, O 
ACHN O 
, O 
MIA-paca O 
, O 
and O 
PANC-1 O 
) O 
, O 
and O 
a O 
few O 
of O 
them O 
were O 
found O 
to O 
exhibit O 
cytotoxic O 
activity O 
. O 

derived O 
from O 
blue O 
mussel O 
( O 
Mytilus O 
edulis O 
) O 
was O 
hydrolysed O 
using O 
four O 
kinds O 
of O 
proteases O 
( O 
pepsin O 
, O 
papain O 
, O 
neutrase O 
and O 
alcalase O 
) O 
, O 
and O 
the O 
neutrase O 
hydrolysate O 
( O 
BNH O 
) O 
obtained O 
by O 
3-h O 
hydrolysis O 
exhibited O 
the O 
highest O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
radical O 
scavenging O 
activity O 
compared O 
to O 
other O 
hydrolysates O 
. O 
By O 
using O 
ultrafiltration O 
, O 
gel O 
filtration O 
chromatography O 
and O 
reversed O 
phase O 
high O 
performance O 
liquid O 
chromatography O 
( O 
RP-HPLC O 
) O 
, O 
a O 
novel O 
antioxidant O 
peptide O 
( O 
BNH-P7 O 
) O 
was O 
isolated O 
from O 
BNH O 
, O 
and O 
its O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
was O 
identified O 
as O 
YPPAK O 
( O 
Tyr-Pro-Pro-Ala-Lys B-FORMULA 
) O 
with O 
molecular O 
weight O 
of O 
574 O 
Da O 
. O 
BNH-P7 O 
exhibited O 
good O 
scavenging O 
activity O 
on O 
DPPH B-ABBREVIATION 
radical O 
, O 
hydroxyl B-SYSTEMATIC 
radical O 
, O 
and O 
superoxide B-TRIVIAL 
anion O 
radical O 
with O 
EC(50) O 
of O 
2.62 O 
, O 
0.228 O 
, O 
and O 
0.072 O 
mg O 
/ O 
ml O 
, O 
respectively O 
. O 
BNH-P7 O 
was O 
also O 
effectively O 
against O 
lipid O 
peroxidation O 
in O 
a O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
model O 
system O 
. O 
The O 
high O 
activity O 
of O 
BNH-P7 O 
was O 
due O 
to O 
the O 
small O 
size O 
and O 
the O 
presence O 
of O 
antioxidant O 
and O 
hydrophobic O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
( O 
Tyr B-FORMULA 
and O 
Pro B-FORMULA 
) O 
within O 
its O 
sequence O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
the O 
toxicity O 
of O 
a O 
mixture O 
containing O 
the O 
biocides O 
picoxystrobin B-TRIVIAL 
, O 
esfenvalerate B-TRIVIAL 
, O 
and O 
triclosan B-TRIVIAL 
to O 
the O 
reproduction O 
and O 
adult O 
survival O 
of O 
two O 
consecutive O 
generations O 
of O 
Eisenia O 
fetida O 
( O 
Savigny O 
, O 
1826 O 
) O 
. O 
Concentration O 
addition O 
and O 
independent O 
action O 
were O 
used O 
to O 
predict O 
mixture O 
toxicity O 
. O 
Due O 
to O 
degradation O 
of O 
mixture O 
components O 
during O 
the O 
course O 
of O 
the O 
experiment O 
, O 
predictions O 
were O 
based O 
both O 
on O 
the O 
mixture O 
composition O 
at O 
the O 
beginning O 
and O 
the O 
end O 
of O 
the O 
exposure O 
period O 
. O 
As O 
degradations O 
were O 
dose O 
- O 
dependent O 
, O 
none O 
of O 
the O 
calculated O 
predictions O 
were O 
precise O 
for O 
the O 
entire O 
concentration O 
range O 
, O 
although O 
combining O 
both O 
predictions O 
led O 
us O 
to O 
conclude O 
that O 
lethal O 
toxicity O 
was O 
well O 
predicted O 
by O 
concentration O 
addition O 
and O 
sublethal O 
toxicity O 
by O 
independent O 
action O 
. O 
Reproduction O 
of O 
the O 
F1 O 
generation O 
was O 
inhibited O 
more O 
( O 
p O 
< O 
0.0001 O 
) O 
than O 
reproduction O 
of O 
the O 
F0 O 
generation O 
. O 
Adult O 
survival O 
did O 
not O 
differ O 
between O 
generations O 
. O 
The O 
accuracy O 
of O 
the O 
mixture O 
toxicity O 
predictions O 
thus O 
depended O 
on O 
both O 
the O 
time O 
- O 
dependent O 
mixture O 
composition O 
and O 
the O 
earthworm O 
generation O 
. O 
The O 
results O 
of O 
this O 
study O 
underline O 
the O 
need O 
for O 
more O 
advanced O 
mixture O 
toxicity O 
prediction O 
models O 
that O 
consider O 
degradation O 
kinetics O 
and O 
changes O 
in O 
toxic O 
effects O 
over O 
time O 
. O 

Attenuates O 
Adriamycin B-TRIVIAL 
-Induced O 
Cardiac O 
Dysfunction O 
via O 
Restoring O 
Expression O 
of O 
ATP B-ABBREVIATION 
-Sensitive O 
Potassium B-SYSTEMATIC 
Channels O 
in O 
Rats O 
. O 

possible O 
mechanism O 
of O 
adriamycin B-TRIVIAL 
( O 
ADR B-ABBREVIATION 
) O 
and O 
/ O 
or O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
deficiency O 
- O 
induced O 
cardiac O 
dysfunction O 
, O 
and O 
cardioprotective O 
effects O 
of O 
Se B-FORMULA 
against O 
ADR B-ABBREVIATION 
-induced O 
cardiac O 
toxicity O 
were O 
investigated O 
in O 
this O 
study O 
. O 
Cardiac O 
function O 
was O 
evaluated O 
by O 
plasma O 
brain O 
natriuretic O 
peptide O 
level O 
and O 
echocardiographic O 
and O 
hemodynamic O 
parameters O 
. O 
Cardiac O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
activity O 
was O 
assessed O 
spectrophotometrically O 
. O 
Expression O 
of O 
ATP B-ABBREVIATION 
-sensitive O 
potassium B-SYSTEMATIC 
channels O 
( O 
KATP O 
) O 
subunits-SUR2A O 
and O 
Kir6.2-were O 
examined O 
by O 
real O 
- O 
time O 
PCR O 
and O 
Western O 
blotting O 
. O 
The O 
results O 
showed O 
that O 
cardiac O 
function O 
and O 
cardiac O 
GPx O 
activity O 
decreased O 
remarkably O 
after O 
administration O 
of O 
ADR B-ABBREVIATION 
or O 
Se B-FORMULA 
deficiency O 
; O 
more O 
dramatic O 
impairment O 
of O 
cardiac O 
function O 
and O 
cardiac O 
GPx O 
activity O 
were O 
observed O 
after O 
co O 
- O 
administration O 
of O 
ADR B-ABBREVIATION 
and O 
Se B-FORMULA 
deficiency O 
. O 
Mechanically O 
, O 
it O 
is O 
novel O 
for O 
us O 
to O 
find O 
down O 
- O 
regulation O 
of O 
KATP O 
subunits O 
gene O 
expression O 
in O 
cardiac O 
tissue O 
after O 
administration O 
of O 
ADR B-ABBREVIATION 
or O 
Se B-FORMULA 
deficiency O 
, O 
and O 
more O 
significant O 
inhibition O 
of O 
cardiac O 
KATP O 
gene O 
expression O 
was O 
identified O 
after O 
co O 
- O 
administration O 
of O 
ADR B-ABBREVIATION 
and O 
Se B-FORMULA 
deficiency O 
. O 
Furthermore O 
, O 
cardiac O 
toxicity O 
of O 
ADR B-ABBREVIATION 
was O 
found O 
alleviated O 
by O 
Se B-FORMULA 
supplementation O 
, O 
accompanied O 
by O 
restoring O 
of O 
cardiac O 
GPx O 
activity O 
and O 
cardiac O 
KATP O 
gene O 
expression O 
. O 
These O 
results O 
indicate O 
that O 
decreased O 
expression O 
of O 
cardiac O 
KATP O 
is O 
involved O 
in O 
adriamycin B-TRIVIAL 
and O 
/ O 
or O 
Se B-FORMULA 
deficiency O 
- O 
induced O 
cardiac O 
dysfunction O 
; O 
Se B-FORMULA 
deficiency O 
exacerbates O 
adriamycin B-TRIVIAL 
-induced O 
cardiac O 
dysfunction O 
by O 
future O 
inhibition O 
of O 
KATP O 
expression O 
; O 
Se B-FORMULA 
supplementation O 
seems O 
to O 
protect O 
against O 
adriamycin B-TRIVIAL 
-induced O 
cardiac O 
dysfunction O 
via O 
restoring O 
KATP O 
expression O 
, O 
showing O 
potential O 
clinical O 
application O 
in O 
cancer O 
chemotherapy O 
. O 

of O 
CO B-FORMULA 
by O 
Nickel B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Clusters O 
Revealed O 
by O 
Post O 
Heating O 
. O 

of O 
nickel B-SYSTEMATIC 
oxide I-SYSTEMATIC 
cluster O 
ions O 
, O 
NinOn B-FAMILY 
+ I-FAMILY 
x(+) I-FAMILY 
( O 
n O 
= O 
4-10 O 
, O 
x O 
= O 
-1∼ O 
+ O 
3 O 
) O 
, O 
with O 
CO B-FORMULA 
in O 
a O 
He B-FORMULA 
buffer O 
gas O 
were O 
investigated O 
using O 
mass O 
spectrometry O 
. O 
When O 
the O 
cluster O 
ions O 
react O 
at O 
room O 
temperature O 
, O 
a O 
CO B-FORMULA 
molecule O 
tends O 
to O 
attach O 
readily O 
to O 
NinOn B-FAMILY 
+ I-FAMILY 
x(+) I-FAMILY 
for O 
all O 
of O 
the O 
cluster O 
ions O 
with O 
different O 
stoichiometry O 
, O 
although O 
rate O 
constants O 
of O 
the O 
CO B-FORMULA 
attachment O 
reaction O 
are O 
more O 
or O 
less O 
stoichiometry O 
- O 
dependent O 
. O 
However O 
, O 
CO B-FORMULA 
was O 
found O 
to O 
be O 
released O 
from O 
the O 
cluster O 
ions O 
when O 
the O 
cluster O 
ions O 
were O 
heated O 
up O 
to O 
523 O 
K O 
after O 
the O 
reaction O 
. O 
This O 
finding O 
is O 
interpreted O 
such O 
that O 
the O 
CO B-FORMULA 
molecule O 
that O 
physisorbs O 
weakly O 
to O 
NinOn B-FAMILY 
+ I-FAMILY 
x(+) I-FAMILY 
at O 
room O 
temperature O 
desorbs O 
into O 
the O 
gas O 
phase O 
by O 
the O 
post O 
heating O 
. O 
In O 
addition O 
, O 
we O 
found O 
that O 
an O 
oxygen B-SYSTEMATIC 
extraction O 
reaction O 
by O 
a O 
CO B-FORMULA 
molecule O 
actually O 
occurs O 
for O 
oxygen B-SYSTEMATIC 
-rich O 
clusters O 
such O 
as O 
Ni6O7(+) B-FORMULA 
and O 
Ni8O9(+) B-FORMULA 
. O 
As O 
the O 
oxygen B-SYSTEMATIC 
extraction O 
reaction O 
is O 
one O 
order O 
of O 
magnitude O 
slower O 
than O 
physisorption O 
, O 
it O 
lies O 
hidden O 
underneath O 
of O 
the O 
faster O 
physisorption O 
processes O 
in O 
the O 
mass O 
spectrum O 
but O 
is O 
revealed O 
by O 
the O 
elimination O 
of O 
physisorption O 
through O 
the O 
post O 
heating O 
. O 

- O 
synthesis O 
, O 
characterization O 
and O 
catalytic O 
properties O 
of O 
fluorine B-SYSTEMATIC 
-planted O 
MWW O 
- O 
type O 
titanosilicate B-SYSTEMATIC 
. O 

-MWW O 
was O 
post O 
- O 
synthesized O 
by O 
implanting O 
fluorine B-SYSTEMATIC 
species O 
into O 
a O 
Ti B-FORMULA 
-MWW O 
framework O 
through O 
an O 
acid O 
treatment O 
process O 
in O 
the O 
presence O 
of O 
ammonium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
. O 
The O 
effects O 
of O 
NH4F B-FORMULA 
addition O 
amount O 
, O 
acid O 
treatment O 
temperature O 
and O 
precursor O 
Ti B-FORMULA 
content O 
were O 
investigated O 
on O 
the O 
incorporation O 
of O 
F B-FORMULA 
species O 
, O 
the O 
zeolite B-TRIVIAL 
structure O 
and O 
the O 
coordination O 
sites O 
of O 
Ti B-FORMULA 
. O 
Fluorine B-SYSTEMATIC 
-implanting O 
improved O 
the O 
surface O 
hydrophobicity O 
of O 
the O 
zeolite B-TRIVIAL 
and O 
altered O 
the O 
electropositivity O 
nearby O 
the O 
tetrahedral O 
Ti B-FORMULA 
sites O 
through O 
forming O 
the O 
SiO3 B-FORMULA 
/ O 
2F B-FORMULA 
and O 
SiO4 B-FORMULA 
/ O 
2F(-) B-FORMULA 
units O 
. O 
The O 
negative O 
effect O 
of O 
SiO4 B-FORMULA 
/ O 
2F(-) B-FORMULA 
units O 
in O 
F-Ti B-FORMULA 
-MWW O 
was O 
eliminated O 
selectively O 
by O 
convenient O 
anion O 
- O 
exchange O 
with O 
various O 
alkali B-FAMILY 
chlorides I-FAMILY 
. O 
F-Ti B-FORMULA 
-MWW O 
containing O 
the O 
SiO3 B-FORMULA 
/ O 
2F B-FORMULA 
units O 
possessed O 
better O 
catalytic O 
activity O 
and O 
reusability O 
, O 
and O 
a O 
longer O 
catalyst O 
lifetime O 
than O 
conventional O 
Ti B-FORMULA 
-MWW O 
. O 

ATP B-ABBREVIATION 
required O 
for O 
potentiation O 
of O 
skeletal O 
muscle O 
contraction O 
is O 
released O 
via O 
pannexin O 
hemichannels O 
. O 

repetitive O 
stimulation O 
of O 
skeletal O 
muscle O 
, O 
extracellular O 
ATP B-ABBREVIATION 
levels O 
raise O 
, O 
activating O 
purinergic O 
receptors O 
, O 
increasing O 
Ca(2+) B-FORMULA 
influx O 
, O 
and O 
enhancing O 
contractile O 
force O 
, O 
a O 
response O 
called O 
potentiation O 
. O 
We O 
found O 
that O 
ATP B-ABBREVIATION 
appears O 
to O 
be O 
released O 
through O 
pannexin1 O 
hemichannels O 
( O 
Panx1 O 
HCs O 
) O 
. O 
Immunocytochemical O 
analyses O 
and O 
function O 
were O 
consistent O 
with O 
pannexin1 O 
localization O 
to O 
T-tubules O 
intercalated O 
with O 
dihydropyridine B-SYSTEMATIC 
and O 
ryanodine B-TRIVIAL 
receptors O 
in O 
slow O 
( O 
soleus O 
) O 
and O 
fast O 
( O 
extensor O 
digitorum O 
longus O 
, O 
EDL O 
) O 
muscles O 
. O 
Isolated O 
myofibers O 
took O 
up O 
ethidium B-TRIVIAL 
( O 
Etd(+) B-ABBREVIATION 
) O 
and O 
released O 
small O 
molecules O 
( O 
as O 
ATP B-ABBREVIATION 
) O 
during O 
electrical O 
stimulation O 
. O 
Consistent O 
with O 
two O 
glucose B-TRIVIAL 
uptake O 
pathways O 
, O 
induced O 
uptake O 
of O 
2-NBDG B-SYSTEMATIC 
, O 
a O 
fluorescent O 
glucose B-TRIVIAL 
derivative O 
, O 
was O 
decreased O 
by O 
inhibition O 
of O 
HCs O 
or O 
glucose B-TRIVIAL 
transporter O 
( O 
GLUT4 O 
) O 
, O 
and O 
blocked O 
by O 
dual O 
blockade O 
. O 
Adult O 
skeletal O 
muscles O 
apparently O 
do O 
not O 
express O 
connexins O 
, O 
making O 
it O 
unlikely O 
that O 
connexin O 
hemichannels O 
contribute O 
to O 
the O 
uptake O 
and O 
release O 
of O 
small O 
molecules O 
. O 
ATP B-ABBREVIATION 
release O 
, O 
Etd(+) B-ABBREVIATION 
uptake O 
, O 
and O 
potentiation O 
induced O 
by O 
repetitive O 
electrical O 
stimulation O 
were O 
blocked O 
by O 
HC O 
blockers O 
and O 
did O 
not O 
occur O 
in O 
muscles O 
of O 
pannexin1 O 
knockout O 
mice O 
. O 
MRS2179 O 
, O 
a O 
P2Y1R O 
blocker O 
, O 
prevented O 
potentiation O 
in O 
EDL O 
, O 
but O 
not O 
soleus O 
muscles O 
, O 
suggesting O 
that O 
in O 
fast O 
muscles O 
ATP B-ABBREVIATION 
activates O 
P2Y1 O 
but O 
not O 
P2X O 
receptors O 
. O 
Phosphorylation O 
on O 
Ser B-FORMULA 
and O 
Thr B-FORMULA 
residues O 
of O 
pannexin1 O 
was O 
increased O 
during O 
potentiation O 
, O 
possibly O 
mediating O 
HC O 
opening O 
. O 
Opening O 
of O 
Panx1 O 
HCs O 
during O 
repetitive O 
activation O 
allows O 
efflux O 
of O 
ATP B-ABBREVIATION 
, O 
influx O 
of O 
glucose B-TRIVIAL 
and O 
possibly O 
Ca(2+) B-FORMULA 
too O 
, O 
which O 
are O 
required O 
for O 
potentiation O 
of O 
contraction O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Connexin O 
based O 
channels O 
' O 
. O 

molecular O 
mystique O 
of O 
tetrodotoxin B-TRIVIAL 
. O 

many O 
respects O 
tetrodotoxin B-TRIVIAL 
( O 
TTX B-ABBREVIATION 
) O 
is O 
the O 
quintessential O 
natural O 
toxin O 
. O 
It O 
is O 
unequivocally O 
toxic O 
to O 
mammals O 
with O 
LD(50) O 
values O 
for O 
mice O 
in O 
the O 
range O 
of O 
10 O 
μg O 
/ O 
kg O 
( O 
intraperitoneal O 
) O 
, O 
16 O 
μg O 
/ O 
kg O 
( O 
subcutaneous O 
) O 
, O 
and O 
332 O 
μg O 
/ O 
kg O 
( O 
oral O 
) O 
( O 
Kao O 
, O 
1966 O 
) O 
. O 
Its O 
biothreat O 
status O 
is O 
recognized O 
by O 
its O 
listing O 
as O 
a O 
" O 
Select O 
Agent O 
" O 
by O 
the O 
US O 
Department O 
of O 
Health O 
and O 
Human O 
Services O 
which O 
includes O 
regulated O 
agents O 
" O 
determined O 
to O 
have O 
the O 
potential O 
to O 
pose O 
a O 
severe O 
threat O 
to O 
both O 
human O 
and O 
animal O 
health O 
" O 
( O 
http O 
: O 
/ O 
/ O 
www.selectagents.gov/ O 
) O 
. O 
It O 
has O 
a O 
well O 
- O 
defined O 
cellular O 
target O 
( O 
i.e O 
. O 
, O 
NaV O 
channels O 
) O 
and O 
pharmacological O 
mode O 
of O 
action O 
( O 
i.e O 
. O 
, O 
block O 
of O 
nerve O 
and O 
muscle O 
action O 
potentials O 
) O 
, O 
and O 
it O 
is O 
an O 
indispensable O 
chemical O 
tool O 
in O 
neuroscience O 
. O 
It O 
is O 
widely O 
distributed O 
in O 
marine O 
and O 
terrestrial O 
ecosystems O 
where O 
it O 
plays O 
a O 
role O 
in O 
the O 
chemical O 
ecology O 
of O 
predator O 
- O 
prey O 
relationships O 
and O 
drives O 
evolutionary O 
selection O 
of O 
TTX B-ABBREVIATION 
-resistance O 
( O 
Hanifin O 
, O 
2010 O 
; O 
Williams O 
, O 
2010 O 
; O 
Zimmer O 
and O 
Ferrer O 
, O 
2007 O 
) O 
. O 
Lastly O 
, O 
TTX B-ABBREVIATION 
has O 
acquired O 
a O 
certain O 
mystique O 
in O 
scientific O 
lore O 
attributable O 
to O 
many O 
fascinating O 
aspects O 
of O 
its O 
natural O 
history O 
and O 
molecular O 
interactions O 
as O 
presented O 
in O 
selected O 
summary O 
below O 
. O 
Additional O 
information O 
may O 
be O 
found O 
in O 
other O 
excellent O 
reviews O 
( O 
Fozzard O 
and O 
Lipkind O 
, O 
2010 O 
; O 
Kao O 
, O 
1966 O 
; O 
Lee O 
and O 
Ruben O 
, O 
2008 O 
; O 
Narahashi O 
, O 
2001 O 
, O 
2008 O 
) O 
. O 

- O 
dependent O 
pharmacokinetics O 
of O 
bulleyaconitine B-TRIVIAL 
A I-TRIVIAL 
in O 
rats O 
. O 

study O 
was O 
conducted O 
to O 
determine O 
the O 
pharmacokinetic O 
characteristics O 
of O 
bulleyaconitine B-TRIVIAL 
A I-TRIVIAL 
( O 
BLA B-ABBREVIATION 
) O 
after O 
oral O 
gavage O 
and O 
intravenous O 
administration O 
of O 
BLA B-ABBREVIATION 
at O 
a O 
single O 
dose O 
of O 
0.04 O 
, O 
0.12 O 
, O 
0.36 O 
mg O 
/ O 
kg O 
( O 
oral O 
) O 
or O 
0.02 O 
mg O 
/ O 
kg O 
( O 
i.v O 
. O 
) O 
in O 
male O 
Sprague-Dawley O 
rats O 
. O 
Plasma O 
concentration O 
profiles O 
were O 
analysed O 
using O 
a O 
non-compartmental O 
pharmacokinetic O 
method O 
. O 
Following O 
i.v O 
. O 
0.02 O 
mg O 
/ O 
kg O 
and O 
oral O 
administration O 
0.04 O 
, O 
0.12 O 
or O 
0.36 O 
mg O 
/ O 
kg O 
, O 
the O 
geometric O 
mean O 
Cmax O 
values O 
were O 
19.97 O 
, O 
2.11 O 
, O 
5.11 O 
and O 
11.47 O 
ng O 
/ O 
ml O 
, O 
respectively O 
; O 
the O 
corresponding O 
geometric O 
mean O 
AUC(0-t) O 
values O 
were O 
10.5 O 
, O 
3.19 O 
, O 
9.59 O 
and O 
18.1 O 
ng O 
x O 
h O 
/ O 
ml O 
, O 
respectively O 
. O 
The O 
median O 
Tmax O 
values O 
were O 
0.033 O 
, O 
0.167 O 
, O 
0.167 O 
and O 
0.167 O 
h O 
, O 
respectively O 
. O 
The O 
terminal O 
elimination O 
half O 
- O 
lives O 
( O 
t1 O 
/ O 
2 O 
) O 
were O 
1.23 O 
, O 
2.48 O 
, O 
1.93 O 
and O 
2.17h O 
, O 
respectively O 
. O 
The O 
results O 
showed O 
that O 
Cmax O 
and O 
AUC(0-t) O 
increased O 
with O 
increasing O 
doses O 
of O 
BLA B-ABBREVIATION 
. O 
The O 
increase O 
in O 
exposure O 
with O 
increasing O 
dose O 
was O 
lower O 
than O 
expected O 
under O 
conditions O 
of O 
strict O 
proportionality O 
. O 

- O 
induced O 
crystal O 
polymorphism O 
in O 
a O 
room O 
- O 
temperature O 
ionic O 
liquid O 
, O 
N,N-diethyl-N-methyl-N-(2-methoxyethyl) B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
tetrafluoroborate I-SYSTEMATIC 
. O 

explore O 
the O 
phase O 
behavior O 
of O 
room O 
- O 
temperature O 
ionic O 
liquids O 
( O 
RTILs O 
) O 
compressed O 
under O 
high O 
pressure O 
to O 
determine O 
whether O 
they O 
crystallize O 
or O 
hold O 
a O 
liquid O 
state O 
. O 
RTILs O 
have O 
attractive O 
supercooling O 
properties O 
compared O 
with O 
ordinary O 
molecular O 
liquids O 
, O 
which O 
easily O 
become O 
a O 
glassy O 
state O 
without O 
crystallizing O 
at O 
ambient O 
pressure O 
. O 
Thus O 
, O 
phase O 
behavior O 
under O 
extreme O 
stress O 
, O 
such O 
as O 
pressure O 
, O 
might O 
yield O 
interesting O 
results O 
. O 
Here O 
, O 
we O 
show O 
that O 
N,N-diethyl-N-methyl-N-(2-methoxyethyl) B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
tetrafluoroborate I-SYSTEMATIC 
( O 
[DEME][BF4] B-FORMULA 
) O 
could O 
be O 
crystallized O 
upon O 
compression O 
, O 
but O 
it O 
usually O 
formed O 
a O 
superpressed O 
liquid O 
. O 
Alternatively O 
, O 
unusual O 
crystallization O 
could O 
be O 
induced O 
by O 
releasing O 
the O 
pressure O 
on O 
the O 
superpressed O 
liquid O 
. O 
Notably O 
, O 
crystal O 
polymorphism O 
was O 
observed O 
in O 
the O 
decompression O 
process O 
. O 
These O 
facts O 
along O 
with O 
visual O 
observations O 
indicate O 
the O 
possibility O 
of O 
[DEME][BF4] B-FORMULA 
serving O 
as O 
a O 
superpressurized O 
glass O 
. O 
Our O 
findings O 
may O 
facilitate O 
the O 
development O 
of O 
a O 
new O 
range O 
of O 
applications O 
for O 
RTILs O 
that O 
have O 
undergone O 
high O 
- O 
pressure O 
recrystallization O 
. O 

by O 
two O 
phenolic B-FAMILY 
compounds O 
: O 
chlorogenic B-MULTIPLE 
and I-MULTIPLE 
quinic I-MULTIPLE 
acid I-MULTIPLE 
, O 
on O 
X-ray O 
induced O 
DNA O 
damage O 
in O 
human O 
blood O 
lymphocytes O 
in O 
vitro O 
. O 

present O 
study O 
was O 
designed O 
to O 
determine O 
the O 
radioprotective O 
effect O 
of O 
two O 
phytochemicals O 
, O 
namely O 
, O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
against O 
X-ray O 
irradiation O 
- O 
induced O 
genomic O 
instability O 
in O 
non-tumorigenic O 
human O 
blood O 
lymphocytes O 
. O 
The O 
protective O 
ability O 
of O 
two O 
phenolic B-FAMILY 
acids I-FAMILY 
against O 
radiation O 
- O 
induced O 
DNA O 
damage O 
was O 
assessed O 
using O 
the O 
alkaline O 
comet O 
assay O 
in O 
human O 
blood O 
lymphocytes O 
isolated O 
from O 
two O 
healthy O 
human O 
donors O 
. O 
A O 
Siemens O 
Mevatron O 
MD2 O 
( O 
Siemens O 
AG O 
, O 
USA O 
, O 
1994 O 
) O 
linear O 
accelerator O 
was O 
used O 
for O 
irradiation O 
. O 
The O 
results O 
of O 
the O 
alkaline O 
comet O 
assay O 
revealed O 
that O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
decreased O 
the O 
DNA O 
damage O 
induced O 
by O 
X-ray O 
irradiation O 
and O 
provided O 
a O 
significant O 
radioprotective O 
effect O 
. O 
Quinic B-TRIVIAL 
acid I-TRIVIAL 
decreased O 
the O 
presence O 
of O 
irradiation O 
- O 
induced O 
DNA O 
damage O 
by O 
5.99-53.57% O 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
by O 
4.49-48.15% O 
, O 
as O 
determined O 
by O 
the O 
alkaline O 
comet O 
assay O 
. O 
The O 
results O 
show O 
that O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
may O 
act O 
as O 
radioprotective O 
compounds O 
. O 
Future O 
studies O 
should O 
focus O 
on O 
determining O 
the O 
mechanism O 
by O 
which O 
these O 
phenolic B-FAMILY 
acids I-FAMILY 
provide O 
radioprotection O 
. O 

poisoning O 
of O 
Ctnnb1-mutated O 
hepatoma O 
cells O 
in O 
mouse O 
liver O 
tumors O 
by O 
a O 
single O 
application O 
of O 
acetaminophen B-TRIVIAL 
. O 

liver O 
tumors O 
that O 
harbor O 
activating O 
mutations O 
in O 
Ctnnb1 O 
, O 
encoding O 
β-catenin O 
, O 
express O 
high O 
levels O 
of O 
various O 
cytochromes O 
P450 O 
( O 
CYP O 
) O 
, O 
including O 
CYP2E1 O 
and O 
CYP1A2 O 
. O 
Acetaminophen B-TRIVIAL 
( O 
AAP B-ABBREVIATION 
) O 
is O 
metabolized O 
in O 
hepatocytes O 
by O 
these O 
CYPs O 
to O 
the O 
reactive O 
intermediate O 
N-acetyl-p-benzoquinone- B-SYSTEMATIC 
imine I-SYSTEMATIC 
, O 
which O 
is O 
toxic O 
to O 
hepatocytes O 
at O 
high O 
doses O 
where O 
depletion O 
of O 
glutathione B-TRIVIAL 
occurs O 
. O 
We O 
have O 
induced O 
liver O 
tumors O 
in O 
mice O 
by O 
treatment O 
with O 
the O 
liver O 
carcinogen O 
N-nitrosodiethylamine B-SYSTEMATIC 
followed O 
by O 
chronic O 
treatment O 
with O 
the O 
tumor O 
promoter O 
phenobarbital B-TRIVIAL 
. O 
Under O 
this O 
protocol O 
, O 
~80 O 
% O 
of O 
tumors O 
display O 
Ctnnb1 O 
mutations O 
and O 
express O 
high O 
levels O 
of O 
various O 
CYP O 
isoforms O 
. O 
Tumor O 
- O 
bearing O 
animals O 
were O 
given O 
a O 
single O 
intraperitoneal O 
injection O 
of O 
300 O 
mg O 
/ O 
kg O 
body O 
weight O 
AAP B-ABBREVIATION 
, O 
which O 
was O 
well O 
tolerated O 
by O 
the O 
animals O 
. O 
This O 
dose O 
, O 
however O 
, O 
eradicated O 
essentially O 
all O 
larger O 
Ctnnb1-mutated O 
, O 
CYP-positive O 
liver O 
tumors O 
, O 
killing O 
> O 
90 O 
% O 
of O 
hepatoma O 
cells O 
: O 
at O 
2 O 
days O 
after O 
AAP B-ABBREVIATION 
, O 
large O 
necrotic O 
areas O 
filled O 
with O 
cell O 
debris O 
were O 
observed O 
in O 
tumors O 
. O 
These O 
were O 
infiltrated O 
in O 
the O 
following O 
days O 
by O 
immune O 
cells O 
starting O 
from O 
the O 
outer O 
parts O 
of O 
the O 
damaged O 
areas O 
slowly O 
closing O 
the O 
" O 
wounds O 
" O 
left O 
from O 
the O 
poisoned O 
tumor O 
cells O 
. O 
During O 
this O 
period O 
, O 
there O 
was O 
increased O 
proliferation O 
of O 
normal O 
hepatocytes O 
, O 
but O 
some O 
residual O 
tumor O 
cells O 
were O 
also O 
proliferating O 
. O 
Our O 
results O 
show O 
that O 
a O 
selective O 
poisoning O 
of O 
Ctnnb1-mutated O 
liver O 
tumors O 
by O 
administration O 
of O 
AAP B-ABBREVIATION 
is O 
possible O 
in O 
this O 
experimental O 
system O 
. O 
Application O 
of O 
an O 
adapted O 
protocol O 
could O 
be O 
envisaged O 
for O 
neo-adjuvant O 
treatment O 
of O 
human O 
hepatoblastoma O 
which O 
are O 
frequently O 
mutated O 
in O 
CTNNB1 O 
and O 
often O 
show O 
high O 
expression O 
of O 
CYP2E1 O 
. O 

efficiency O 
and O 
safety O 
evaluation O 
of O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
in O 
peanuts O 
. O 

efficiency O 
of O 
aflatoxin B-FAMILY 
-contaminated O 
peanuts O 
( O 
ACPs O 
) O 
was O 
investigated O 
, O 
and O 
the O 
safety O 
of O 
ACPs O 
untreated O 
/ O 
treated O 
by O 
ozone B-TRIVIAL 
was O 
evaluated O 
after O 
28-day O 
intragastrically O 
administration O 
in O 
male O 
and O 
female O 
Wistar O 
rats O 
. O 
89.40% O 
of O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
( O 
AFB1 B-ABBREVIATION 
) O 
in O 
peanuts O 
was O 
decomposed O 
by O 
ozone B-TRIVIAL 
with O 
a O 
concentration O 
of O 
50mg O 
/ O 
L O 
, O 
flow O 
rate O 
of O 
5L O 
/ O 
min O 
for O 
60h O 
. O 
After O 
60h O 
, O 
the O 
ozonolysis O 
efficiency O 
of O 
AFB1 B-ABBREVIATION 
was O 
not O 
further O 
improved O 
. O 
In O 
the O 
subchronic O 
toxicity O 
experiment O 
, O 
all O 
rats O 
did O 
not O 
have O 
unusual O 
changes O 
in O 
behavior O 
, O 
and O 
no O 
signs O 
of O 
intoxication O 
were O 
observed O 
except O 
for O 
several O 
dead O 
rats O 
due O 
to O 
inappropriate O 
gavage O 
or O 
anesthesia O 
. O 
The O 
results O 
of O 
subchronic O 
toxicity O 
indicated O 
that O 
rats O 
fed O 
on O 
ACPs O 
alone O 
had O 
significantly O 
decreased O 
in O 
body O 
weight O 
gain O 
and O 
feed O 
conversion O 
efficiency O 
. O 
Most O 
serum O 
biochemical O 
indexes O 
of O 
rats O 
had O 
apparently O 
changed O 
compared O 
with O 
those O 
in O 
the O 
negative O 
control O 
, O 
and O 
gender O 
difference O 
significantly O 
affected O 
most O 
indexes O 
of O 
subchronic O 
toxicity O 
except O 
for O 
the O 
ratios O 
of O 
organ O 
to O 
body O 
weight O 
and O 
histopathological O 
observation O 
. O 
Rats O 
fed O 
on O 
ACPs O 
treated O 
by O 
ozone B-TRIVIAL 
showed O 
significant O 
beneficial O 
health O 
effects O 
. O 
All O 
the O 
results O 
suggested O 
that O 
the O 
deleterious O 
effects O 
of O 
AFB1 B-ABBREVIATION 
could O 
be O 
highly O 
reduced O 
by O 
ozone B-TRIVIAL 
, O 
and O 
ozone B-TRIVIAL 
itself O 
did O 
not O 
show O 
any O 
toxic O 
effects O 
on O 
animals O 
in O 
this O 
processing O 
. O 

vivo O 
and O 
in O 
vitro O 
anti-inflammatory O 
potential O 
of O 
pentahydroxy-pregn-14-ol B-SYSTEMATIC 
, I-SYSTEMATIC 
20-one-β-d- I-SYSTEMATIC 
thevetopyranoside I-SYSTEMATIC 
in O 
rats O 
. O 

pregnane I-FAMILY 
glycoside I-FAMILY 
( O 
PPG B-ABBREVIATION 
) O 
, O 
a O 
steroidal B-FAMILY 
glycoside I-FAMILY 
was O 
isolated O 
from O 
Wattakaka O 
volubilis O 
Linn O 
. O 
( O 
Stap.f O 
. O 
) O 
. O 
PPG B-ABBREVIATION 
was O 
evaluated O 
for O 
in O 
vivo O 
and O 
in O 
vitro O 
anti-inflammatory O 
activity O 
using O 
acute O 
inflammation O 
and O 
chronic O 
model O 
of O 
inflammation O 
in O 
rats O 
and O 
LPS-induced O 
RAW O 
264.7 O 
macrophage O 
cells O 
. O 
PPG B-ABBREVIATION 
seemed O 
to O 
be O 
responsible O 
for O 
the O 
anti-inflammatory O 
activity O 
in O 
the O 
studied O 
models O 
. O 
PPG B-ABBREVIATION 
at O 
dose O 
level O 
of O 
both O 
5 O 
and O 
10mg O 
/ O 
kg O 
significantly O 
reduced O 
the O 
edema O 
induced O 
by O 
the O 
carrageenan O 
in O 
acute O 
model O 
of O 
inflammation O 
. O 
It O 
also O 
showed O 
significant O 
anti-proliferative O 
effect O 
( O 
dry O 
pellet O 
weight O 
basis O 
) O 
in O 
chronic O 
model O 
of O 
inflammation O 
. O 
Cellular O 
content O 
of O 
granuloma O 
was O 
measured O 
by O 
assaying O 
activity O 
of O 
N-acetyl B-SYSTEMATIC 
glucosaminidase O 
( O 
NAG O 
) O 
and O 
total O 
nucleic O 
acid O 
content O 
. O 
PPG B-ABBREVIATION 
at O 
5 O 
and O 
10mg O 
/ O 
kg O 
significantly O 
suppressed O 
the O 
cellular O 
infiltration O 
measured O 
by O 
total O 
nucleic O 
acid O 
content O 
. O 
In O 
contrast O 
, O 
NAG O 
activity O 
decreased O 
over O 
a O 
period O 
of O 
10 O 
days O 
resulting O 
in O 
inhibition O 
of O 
granuloma O 
weight O 
gain O 
. O 
PPG B-ABBREVIATION 
had O 
a O 
more O 
effective O 
response O 
than O 
the O 
reference O 
drug O 
diclofenac B-SYSTEMATIC 
sodium I-SYSTEMATIC 
in O 
both O 
the O 
models O 
of O 
inflammation O 
. O 
Wattakaka O 
volubilis O 
steroidal B-FAMILY 
glycoside I-FAMILY 
mixture O 
( O 
WVSM O 
) O 
and O 
PPG B-ABBREVIATION 
( O 
1-50μM O 
) O 
significantly O 
inhibited O 
the O 
COX-2 O 
and O 
iNOS O 
enzymes O 
resulting O 
in O 
low O 
levels O 
of O 
PGE2 O 
and O 
NO O 
in O 
LPS-induced O 
RAW O 
264.7 O 
macrophage O 
cells O 
. O 
Hence O 
the O 
study O 
supports O 
the O 
traditional O 
use O 
of O 
Wattakaka O 
volubilis O 
and O 
its O 
constituent O 
PPG B-ABBREVIATION 
in O 
treatment O 
of O 
inflammatory O 
disorders O 
. O 

recognition O 
of O 
molecular O 
imprinting O 
electrochemical O 
sensor O 
based O 
on O 
core O 
- O 
shell O 
nanoparticles O 
. O 

novel O 
electrochemistry O 
- O 
molecular O 
imprinting O 
sensor O 
for O 
determining O 
tert-butylhydroquinone B-SYSTEMATIC 
( O 
TBHQ B-ABBREVIATION 
) O 
in O 
foodstuff O 
was O 
developed O 
. O 
TBHQ B-ABBREVIATION 
-imprinted O 
core O 
- O 
shell O 
nanoparticles O 
( O 
TICSNs O 
) O 
were O 
fabricated O 
using O 
silica B-TRIVIAL 
nanoparticles O 
as O 
core O 
material O 
. O 
The O 
silica B-TRIVIAL 
nanoparticles O 
were O 
modified O 
with O 
( B-SYSTEMATIC 
3-chloropropyl I-SYSTEMATIC 
) I-SYSTEMATIC 
trimethoxysilan I-SYSTEMATIC 
and O 
polyethylenimine B-SYSTEMATIC 
, O 
respectively O 
, O 
and O 
polymerised O 
to O 
form O 
the O 
TICSNs O 
with O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
dimethacrylate I-SYSTEMATIC 
as O 
cross O 
- O 
linker O 
. O 
The O 
specific O 
core O 
- O 
shell O 
structure O 
demonstrates O 
extremely O 
high O 
specific O 
surface O 
area O 
which O 
greatly O 
increases O 
the O 
effective O 
binding O 
sites O 
and O 
improves O 
the O 
recognition O 
capability O 
for O 
model O 
molecules O 
. O 
Under O 
the O 
optimal O 
conditions O 
, O 
the O 
linear O 
range O 
of O 
the O 
calibration O 
curve O 
was O 
0.1-50.0mgkg(-1) O 
with O 
the O 
detection O 
limit O 
of O 
0.27mgkg(-1) O 
. O 
The O 
sensor O 
has O 
been O 
successfully O 
applied O 
to O 
the O 
determination O 
of O 
TBHQ B-ABBREVIATION 
in O 
food O 
samples O 
and O 
achieved O 
high O 
sensitivity O 
and O 
selectivity O 
. O 

Dimethylarginine I-TRIVIAL 
( O 
ADMA B-ABBREVIATION 
) O 
: O 
A O 
Promising O 
Biomarker O 
for O 
Cardiovascular O 
Disease O 
? O 

Dimethylarginine I-TRIVIAL 
( O 
ADMA B-ABBREVIATION 
) O 
is O 
an O 
endogenous O 
inhibitor O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
production O 
. O 
ADMA B-ABBREVIATION 
is O 
generated O 
from O 
methylation O 
of O 
arginine B-TRIVIAL 
residues O 
by O 
protein O 
arginine B-TRIVIAL 
methyltransferases O 
( O 
PRMTs O 
) O 
and O 
subsequent O 
proteolysis O 
, O 
while O 
its O 
elimination O 
is O 
achieved O 
mainly O 
by O 
degradation O 
with O 
dimethylarginine B-SYSTEMATIC 
dimethylaminohydrolase O 
( O 
DDAH O 
) O 
. O 
Oxidative O 
stress O 
, O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
eNOS O 
) O 
inhibition O 
, O 
eNOS O 
uncoupling O 
, O 
inflammation O 
and O 
shear O 
stress O 
play O 
a O 
pivotal O 
role O 
in O 
ADMA B-ABBREVIATION 
pathophysiology O 
by O 
managing O 
PRMT O 
/ O 
DDAH O 
expression O 
and O 
NO B-FORMULA 
synthesis O 
and O 
leading O 
to O 
a O 
common O 
result O 
- O 
endothelial O 
dysfunction O 
. O 
Endothelial O 
dysfunction O 
seems O 
to O 
be O 
the O 
common O 
finding O 
in O 
studies O 
investigating O 
the O 
role O 
of O 
ADMA B-ABBREVIATION 
in O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
. O 
High O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
, O 
mass O 
spectrometry O 
( O 
MS O 
) O 
and O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
ELISA O 
) O 
are O 
the O 
existing O 
methods O 
for O 
ADMA B-ABBREVIATION 
quantification O 
. O 
However O 
, O 
none O 
of O 
them O 
fulfils O 
all O 
the O 
criteria O 
to O 
be O 
characterized O 
as O 
" O 
gold O 
standard O 
" O 
. O 
ADMA B-ABBREVIATION 
is O 
significantly O 
associated O 
with O 
risk O 
factors O 
for O 
CVD O 
and O 
almost O 
with O 
every O 
disease O 
of O 
the O 
cardiovascular O 
system O 
; O 
showing O 
an O 
independent O 
, O 
strong O 
prognostic O 
value O 
for O 
mortality O 
and O 
future O 
cardiovascular O 
events O 
. O 
This O 
article O 
aims O 
to O 
review O 
the O 
current O 
knowledge O 
about O 
ADMA B-ABBREVIATION 
biology O 
and O 
metabolism O 
, O 
pathophysiological O 
mechanisms O 
implicating O 
ADMA B-ABBREVIATION 
in O 
CVD O 
, O 
methods O 
for O 
the O 
determination O 
of O 
ADMA B-ABBREVIATION 
and O 
its O 
association O 
with O 
CVD O 
risk O 
factors O 
and O 
established O 
CVDs O 
. O 

- O 
mode O 
direct O 
analysis O 
in O 
real O 
time O 
ionization O 
coupled O 
with O 
high O 
resolution O 
mass O 
spectrometry O 
( O 
TM-DART-HRMS O 
) O 
was O 
used O 
to O 
monitor O 
chemical O 
changes O 
in O 
various O 
vegetable O 
oils O 
( O 
olive O 
, O 
rapeseed O 
, O 
soybean O 
and O 
sunflower O 
oil O 
) O 
during O 
their O 
thermally O 
- O 
induced O 
oxidation O 
. O 
This O 
novel O 
instrumental O 
approach O 
enabled O 
rapid O 
fingerprinting O 
of O 
examined O 
samples O 
and O 
detection O 
of O 
numerous O 
sample O 
components O 
, O 
such O 
as O 
triacylglycerols B-FAMILY 
( O 
TAGs B-ABBREVIATION 
) O 
, O 
phytosterols O 
, O 
free B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
FFA B-ABBREVIATION 
) O 
, O 
and O 
their O 
respective O 
oxidation O 
products O 
. O 
Mass O 
spectra O 
obtained O 
from O 
DART O 
were O 
processed O 
with O 
the O 
use O 
of O 
principal O 
component O 
analysis O 
( O 
PCA O 
) O 
in O 
order O 
to O 
assess O 
the O 
compositional O 
differences O 
between O 
heated O 
and O 
non-heated O 
samples O 
. O 
Good O 
correlation O 
was O 
observed O 
between O 
the O 
normalized O 
intensities O 
of O 
the O 
pre O 
- O 
selected O 
ion O 
corresponding O 
to O 
mono-oxidized O 
TAG B-ABBREVIATION 
and O 
' O 
classic O 
' O 
criterion O 
represented O 
by O 
the O 
levels O 
of O 
TAG B-ABBREVIATION 
polymers O 
determined O 
by O 
high O 
performance O 
- O 
size O 
exclusion O 
chromatography O 
with O 
refractometric O 
detection O 
( O 
HP-SEC-RID O 
) O 
. O 

2 O 
diabetes O 
mellitus O 
( O 
T2D O 
) O 
patients O 
often O 
exhibit O 
hyperglucagonemia O 
despite O 
hyperglycemia O 
suggesting O 
defective O 
α-cell O 
function O 
. O 
While O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
has O 
been O 
suggested O 
to O 
underlie O 
β-cell O 
dysfunction O 
in O 
T2D O 
, O 
its O 
role O 
in O 
α-cell O 
biology O 
remains O 
unclear O 
. O 
X-box O 
binding O 
protein O 
1 O 
( O 
XBP1 O 
) O 
is O 
a O 
transcription O 
factor O 
that O 
plays O 
a O 
crucial O 
role O 
in O 
the O 
unfolded O 
protein O 
response O 
( O 
UPR O 
) O 
and O 
its O 
deficiency O 
in O 
β-cells O 
has O 
been O 
reported O 
to O 
impair O 
insulin O 
secretion O 
leading O 
to O 
glucose B-TRIVIAL 
intolerance O 
. O 
To O 
evaluate O 
the O 
role O 
of O 
XBP1 O 
in O 
α-cells O 
, O 
we O 
created O 
complementary O 
in O 
vivo O 
( O 
α-cell O 
specific O 
XBP1 O 
knockout O 
( O 
αXBPKO O 
) O 
mice O 
) O 
and O 
in O 
vitro O 
( O 
stable O 
XBP1 O 
knock O 
down O 
α-cell O 
line O 
, O 
αXBPKD O 
) O 
models O 
. O 
αXBPKO O 
mice O 
exhibited O 
glucose B-TRIVIAL 
intolerance O 
, O 
mild O 
insulin O 
resistance O 
and O 
an O 
inability O 
to O 
suppress O 
glucagon O 
secretion O 
following O 
glucose B-TRIVIAL 
stimulation O 
. O 
αXBPKD O 
cells O 
exhibited O 
activation O 
of O 
IRE1 O 
, O 
an O 
upstream O 
activator O 
of O 
XBP1 O 
, O 
leading O 
to O 
phosphorylation O 
of O 
JNK O 
. O 
Interestingly O 
, O 
insulin O 
treatment O 
of O 
αXBPKD O 
cells O 
reduced O 
tyrosine B-TRIVIAL 
phosphorylation O 
of O 
IRS-1 O 
(pY(896)) O 
, O 
and O 
phosphorylation O 
of O 
Akt O 
, O 
while O 
enhancing O 
serine B-TRIVIAL 
phosphorylation O 
(pS(307)) O 
of O 
IRS-1 O 
. O 
Consequently O 
the O 
αXBPKD O 
cells O 
exhibited O 
blunted O 
suppression O 
of O 
glucagon O 
secretion O 
following O 
insulin O 
treatment O 
in O 
the O 
presence O 
of O 
high O 
glucose B-TRIVIAL 
. O 
Together O 
, O 
these O 
data O 
indicate O 
that O 
XBP1 O 
deficiency O 
in O 
pancreatic O 
α-cells O 
induces O 
altered O 
insulin O 
signaling O 
and O 
dysfunctional O 
glucagon O 
secretion O 
. O 

- O 
state O 
NMR O 
study O 
reveals O 
collagen O 
I O 
structural O 
modifications O 
of O 
amino B-FAMILY 
acid I-FAMILY 
side O 
chains O 
upon O 
fibrillogenesis O 
. O 

vivo O 
, O 
collagen O 
I O 
, O 
the O 
major O 
structural O 
protein O 
in O 
human O 
body O 
, O 
is O 
found O 
assembled O 
into O 
fibrils O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
study O 
a O 
high O 
concentrated O 
collagen O 
sample O 
in O 
its O 
soluble O 
, O 
fibrillar O 
, O 
and O 
denatured O 
states O 
using O 
one O 
and O 
two O 
dimensional O 
{ O 
(1)H B-FORMULA 
}- O 
(13)C B-FORMULA 
solid O 
- O 
state O 
NMR O 
spectroscopy O 
. O 
We O 
interpret O 
(13)C B-FORMULA 
chemical O 
shift O 
variations O 
in O 
terms O 
of O 
dihedral O 
angle O 
conformation O 
changes O 
. O 
Our O 
data O 
show O 
that O 
fibrillogenesis O 
increases O 
the O 
side O 
chain O 
and O 
backbone O 
structural O 
complexity O 
. O 
Nevertheless O 
, O 
only O 
three O 
to O 
five O 
rotameric O 
equilibria O 
are O 
found O 
for O 
each O 
amino B-FAMILY 
acid I-FAMILY 
residue O 
, O 
indicating O 
a O 
relatively O 
low O 
structural O 
heterogeneity O 
of O 
collagen O 
upon O 
fibrillogenesis O 
. O 
Using O 
side O 
chain O 
statistical O 
data O 
, O 
we O 
calculate O 
equilibrium O 
constants O 
for O 
a O 
great O 
number O 
of O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
. O 
Moreover O 
, O 
based O 
on O 
a O 
(13)C B-FORMULA 
quantitative O 
spectrum O 
, O 
we O 
estimate O 
the O 
percentage O 
of O 
residues O 
implicated O 
in O 
each O 
equilibrium O 
. O 
Our O 
data O 
indicate O 
that O 
fibril O 
formation O 
greatly O 
affects O 
hydroxyproline B-SYSTEMATIC 
and O 
proline B-TRIVIAL 
prolyl I-TRIVIAL 
pucker O 
ring O 
conformation O 
. O 
Finally O 
, O 
we O 
discuss O 
the O 
implication O 
of O 
these O 
structural O 
data O 
and O 
propose O 
a O 
model O 
in O 
which O 
the O 
attractive O 
force O 
of O 
fibrillogenesis O 
comes O 
from O 
a O 
structural O 
reorganization O 
of O 
10 O 
to O 
15% O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
. O 
These O 
results O 
allow O 
us O 
to O 
further O 
understand O 
the O 
self O 
- O 
assembling O 
process O 
and O 
fibrillar O 
structure O 
of O 
collagen O 
. O 

discovery O 
of O 
novel O 
human O 
androgen B-FAMILY 
receptor O 
antagonist O 
chemotypes O 
using O 
a O 
combined O 
pharmacophore O 
screening O 
procedure O 
. O 

the O 
mechanisms O 
involved O 
in O 
castration- O 
and O 
therapy O 
- O 
resistant O 
prostate O 
cancer O 
has O 
led O 
to O 
a O 
renewed O 
interest O 
in O 
androgen B-FAMILY 
receptor O 
(AR)-targeted O 
therapeutics O 
. O 
Anti- O 
androgens B-FAMILY 
that O 
block O 
the O 
activity O 
of O 
the O 
AR O 
therefore O 
remain O 
a O 
valid O 
therapeutic O 
option O 
. O 
However O 
, O 
they O 
must O 
be O 
more O 
effective O 
than O 
, O 
or O 
display O 
a O 
distinct O 
mechanism O 
of O 
action O 
or O 
binding O 
mode O 
from O 
those O 
of O 
bicalutamide B-TRIVIAL 
and O 
hydroxyflutamide B-TRIVIAL 
, O 
which O 
are O 
currently O 
in O 
clinical O 
use O 
. O 
For O 
that O 
reason O 
, O 
the O 
second O 
- O 
generation O 
anti- O 
androgen B-FAMILY 
MDV3100 B-IDENTIFIER 
was O 
developed O 
. O 
MDV3100 B-IDENTIFIER 
, O 
however O 
, O 
shares O 
its O 
4-cyano-3-(trifluoromethyl)phenyl B-SYSTEMATIC 
group O 
with O 
bicalutamide B-TRIVIAL 
and O 
hydroxyflutamide B-TRIVIAL 
required O 
for O 
binding O 
to O 
the O 
AR O 
. O 
In O 
this O 
work O 
, O 
we O 
used O 
a O 
combined O 
strategy O 
to O 
find O 
new O 
antagonist O 
structures O 
distinct O 
from O 
the O 
4-cyano-3-(trifluoromethyl)phenyl B-SYSTEMATIC 
group O 
to O 
avoid O 
cross O 
- O 
resistance O 
for O 
these O 
compounds O 
and O 
to O 
find O 
structures O 
without O 
agonist O 
activity O 
on O 
mutant O 
ARs O 
( O 
AR O 
W741C O 
and O 
AR O 
T877A O 
) O 
. O 
We O 
found O 
two O 
novel O 
chemotypes O 
with O 
AR-antagonistic O 
activity O 
( O 
IC(50) O 
: O 
3-6 O 
μM O 
) O 
by O 
virtual O 
screening O 
and O 
confirmed O 
their O 
biological O 
activity O 
in O 
an O 
androgen B-FAMILY 
-responsive O 
reporter O 
assay O 
. O 
The O 
design O 
of O 
our O 
computational O 
approach O 
was O 
validated O 
by O 
the O 
observation O 
of O 
strongly O 
decreased O 
or O 
absence O 
of O 
agonistic O 
activity O 
on O 
the O 
two O 
mutant O 
ARs O 
. O 
Further O 
structural O 
derivatization O 
to O 
optimize O 
the O 
potency O 
of O 
these O 
compounds O 
can O 
render O 
these O 
chemotypes O 
into O 
very O 
promising O 
, O 
alternative O 
AR O 
antagonists O 
for O 
prostate O 
cancer O 
therapy O 
. O 

of O 
mixed O 
ceramic O 
Mg(x)Zn(1-x)O B-FAMILY 
nanofibers O 
via O 
Mg2+ B-FORMULA 
doping O 
using O 
sol O 
- O 
gel O 
electrospinning O 
. O 

report O 
on O 
the O 
synthesis O 
of O 
tuned O 
energy O 
band O 
gap O 
Mg(x)Zn(1-x)O B-FAMILY 
nanofibers O 
( O 
NFs O 
) O 
with O 
different O 
Mg(2+) B-FORMULA 
content O 
via O 
the O 
sol O 
- O 
gel O 
electrospinning O 
( O 
ES O 
) O 
technique O 
wherein O 
the O 
addition O 
of O 
the O 
doping O 
material O 
affects O 
not O 
only O 
the O 
morphologies O 
of O 
as-spun O 
ZnAc B-FORMULA 
/ O 
PVA B-ABBREVIATION 
and O 
MgAc B-FORMULA 
/ O 
ZnAc B-FORMULA 
/ O 
PVA B-ABBREVIATION 
nanofibers O 
but O 
also O 
the O 
crystal O 
microstructure O 
and O 
optical O 
properties O 
of O 
calcined O 
ZnO B-FORMULA 
and O 
Mg(x)Zn(1-x)O B-FAMILY 
nanofibers O 
. O 
Following O 
an O 
appropriate O 
aqueous O 
solution O 
preparation O 
of O 
magnesium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
MgAc B-FORMULA 
) O 
and O 
zinc B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
ZnAc B-FORMULA 
) O 
with O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
, O 
electrospinning O 
is O 
performed O 
and O 
then O 
as-spun O 
nanofibers O 
are O 
calcined O 
in O 
an O 
air O 
atmosphere O 
at O 
600 O 
°C O 
for O 
3 O 
h O 
. O 
As-spun O 
and O 
calcined O 
nanofiber O 
diameters O 
and O 
morphologies O 
are O 
evaluated O 
with O 
scanning O 
( O 
SEM O 
) O 
and O 
transmission O 
( O 
TEM O 
) O 
electron O 
microscopies O 
, O 
whereas O 
crystalline O 
microstructural O 
interpretations O 
of O 
ZnO B-FORMULA 
and O 
Mg(x)Zn(1-x)O B-FAMILY 
are O 
conducted O 
with O 
wide-angle O 
X-ray O 
diffraction O 
spectra O 
( O 
XRD O 
) O 
. O 
Surface O 
chemical O 
composition O 
and O 
elemental O 
evaluation O 
of O 
calcined O 
nanofibers O 
are O 
examined O 
with O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
, O 
and O 
optical O 
properties O 
and O 
crystal O 
defect O 
analyses O 
of O 
the O 
calcined O 
nanofibers O 
are O 
conducted O 
with O 
photoluminescence O 
spectra O 
( O 
PL O 
) O 
. O 
We O 
observe O 
a O 
sharp O 
reduction O 
in O 
fiber O 
diameter O 
upon O 
calcination O 
as O 
a O 
result O 
of O 
the O 
removal O 
of O 
organic O 
species O 
from O 
the O 
fibers O 
and O 
conversion O 
of O 
ceramic O 
precursors O 
into O 
ceramic O 
nanofibers O 
, O 
and O 
the O 
appearance O 
of O 
a O 
range O 
of O 
fiber O 
morphologies O 
from O 
" O 
bead O 
in O 
a O 
string O 
" O 
to O 
" O 
sesame O 
seed O 
" O 
coverage O 
depending O 
on O 
fiber O 
composition O 
. O 
Because O 
Zn(2+) B-FORMULA 
and O 
Mg(2+) B-FORMULA 
have O 
similar O 
ionicity O 
and O 
atomic O 
radii O 
, O 
some O 
Zn(2+) B-FORMULA 
atoms O 
are O 
replaced O 
by O 
Mg(2+) B-FORMULA 
atoms O 
in O 
the O 
crystals O 
, O 
leading O 
to O 
a O 
change O 
in O 
the O 
properties O 
of O 
crystal O 
lattices O 
. O 
The O 
band O 
gap O 
energy O 
of O 
the O 
calcined O 
fibers O 
increases O 
significantly O 
with O 
addition O 
of O 
Mg(2+) B-FORMULA 
along O 
with O 
an O 
increase O 
in O 
the O 
ultraviolet O 
( O 
UV O 
) O 
photoluminescence O 
emission O 
of O 
the O 
fibers O 
. O 

- O 
effectiveness O 
of O 
alendronate B-TRIVIAL 
for O 
the O 
treatment O 
of O 
osteopenic O 
postmenopausal O 
women O 
in O 
Japan O 
. O 

postmenopausal O 
women O 
have O 
osteopenia O 
, O 
a O 
condition O 
characterized O 
by O 
loss O 
of O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
that O 
is O 
not O 
as O 
severe O 
as O 
in O 
osteoporosis O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
estimate O 
the O 
cost O 
- O 
effectiveness O 
of O 
alendronate B-TRIVIAL 
to O 
prevent O 
fractures O 
in O 
osteopenic O 
postmenopausal O 
women O 
without O 
a O 
history O 
of O 
fracture O 
in O 
Japan O 
. O 
An O 
individual O 
simulation O 
model O 
was O 
developed O 
to O 
predict O 
lifetime O 
costs O 
and O 
quality O 
- O 
adjusted O 
life O 
years O 
( O 
QALYs O 
) O 
of O 
5 O 
years O 
of O 
preventive O 
alendronate B-TRIVIAL 
therapy O 
versus O 
no O 
preventive O 
therapy O 
. O 
The O 
risk O 
of O 
hip O 
and O 
vertebral O 
fracture O 
associated O 
with O 
age O 
and O 
BMD O 
was O 
derived O 
from O 
epidemiologic O 
studies O 
in O 
Japan O 
. O 
We O 
ran O 
the O 
model O 
with O 
different O 
combinations O 
of O 
age O 
( O 
65 O 
, O 
70 O 
, O 
and O 
75 O 
years O 
) O 
, O 
BMD O 
( O 
70% O 
, O 
75% O 
, O 
and O 
80% O 
of O 
young O 
adult O 
mean O 
[ O 
YAM O 
] O 
) O 
, O 
and O 
additional O 
clinical O 
risk O 
factors O 
. O 
For O 
70-year- O 
old O 
women O 
with O 
a O 
BMD O 
of O 
70% O 
of O 
the O 
YAM O 
having O 
one O 
of O 
the O 
following O 
risk O 
factors O 
: O 
a O 
family O 
history O 
of O 
hip O 
fracture O 
, O 
high O 
alcohol B-FAMILY 
intake O 
, O 
or O 
current O 
smoking O 
, O 
the O 
incremental O 
cost O 
- O 
effectiveness O 
ratio O 
( O 
ICER O 
) O 
of O 
alendronate B-TRIVIAL 
was O 
$92,937, O 
$126,251, O 
and O 
$129,067 O 
per O 
QALY O 
, O 
respectively O 
. O 
These O 
results O 
were O 
sensitive O 
to O 
age O 
, O 
BMD O 
, O 
and O 
number O 
of O 
clinical O 
risk O 
factors O 
. O 
Probabilistic O 
sensitivity O 
analysis O 
for O 
the O 
base O 
case O 
showed O 
that O 
in O 
the O 
presence O 
of O 
one O 
, O 
two O 
, O 
and O 
three O 
risk O 
factors O 
, O 
alendronate B-TRIVIAL 
was O 
cost O 
- O 
effective O 
in O 
0.2% O 
to O 
2.6% O 
, O 
13.1% O 
to O 
56.1% O 
, O 
and O 
99.1% O 
of O 
the O 
simulations O 
, O 
respectively O 
, O 
if O 
society O 
is O 
willing O 
to O 
pay O 
$50,000 O 
per O 
QALY O 
. O 
Additional O 
analysis O 
indicated O 
that O 
alendronate B-TRIVIAL 
can O 
be O 
a O 
good O 
value O 
in O 
osteopenic O 
women O 
if O 
the O 
10-year O 
probability O 
for O 
a O 
osteoporotic O 
hip O 
or O 
vertebral O 
fracture O 
is O 
more O 
than O 
26.2% O 
. O 
Our O 
results O 
indicate O 
that O 
whether O 
to O 
treat O 
osteopenia O 
with O 
alendronate B-TRIVIAL 
should O 
be O 
determined O 
on O 
the O 
basis O 
of O 
age O 
, O 
BMD O 
, O 
and O 
number O 
of O 
clinical O 
risk O 
factors O 
in O 
terms O 
of O 
cost O 
- O 
effectiveness O 
. O 

concepts O 
in O 
ecotoxicology O 
: O 
tracing O 
the O 
genetic O 
background O 
of O 
differential O 
cadmium B-SYSTEMATIC 
sensitivities O 
in O 
invertebrate O 
lineages O 
. O 

many O 
toxicological O 
and O 
ecotoxicological O 
studies O 
and O 
experimental O 
setups O 
, O 
the O 
investigator O 
is O 
mainly O 
interested O 
in O 
traditional O 
parameters O 
such O 
as O 
toxicity O 
data O 
and O 
effects O 
of O 
toxicants O 
on O 
molecular O 
, O 
cellular O 
or O 
physiological O 
functions O 
of O 
individuals O 
, O 
species O 
or O 
statistical O 
populations O 
. O 
It O 
is O 
clear O 
, O 
however O 
, O 
that O 
such O 
approaches O 
focus O 
on O 
the O 
phenotype O 
level O 
of O 
animal O 
species O 
, O 
whilst O 
the O 
genetic O 
and O 
evolutionary O 
background O 
of O 
reactions O 
to O 
environmental O 
toxicants O 
may O 
remain O 
untold O 
. O 
In O 
ecotoxicological O 
risk O 
assessment O 
, O 
moreover O 
, O 
species O 
sensitivities O 
towards O 
pollutants O 
are O 
often O 
regarded O 
as O 
random O 
variables O 
in O 
a O 
statistical O 
approach O 
. O 
Beyond O 
statistics O 
, O 
however O 
, O 
toxicant O 
sensitivity O 
of O 
every O 
species O 
assumes O 
a O 
biological O 
significance O 
, O 
especially O 
if O 
we O 
consider O 
that O 
sensitivity O 
traits O 
have O 
developed O 
in O 
lineages O 
of O 
species O 
with O 
common O 
evolutionary O 
roots O 
. O 
In O 
this O 
article O 
, O 
the O 
genetic O 
and O 
evolutionary O 
background O 
of O 
differential O 
Cd B-FORMULA 
sensitivities O 
among O 
invertebrate O 
populations O 
and O 
species O 
and O 
their O 
potential O 
of O 
adaptation O 
to O 
environmental O 
Cd B-FORMULA 
exposure O 
will O 
be O 
highlighted O 
. O 
Important O 
evolutionary O 
and O 
population O 
genetic O 
concepts O 
such O 
as O 
genome O 
structure O 
and O 
their O 
importance O 
for O 
evolutionary O 
adaptation O 
, O 
population O 
structure O 
of O 
affected O 
individuals O 
, O 
as O 
well O 
as O 
micro O 
and O 
macroevolutionary O 
mechanisms O 
of O 
Cd B-FORMULA 
resistance O 
in O 
invertebrate O 
lineages O 
will O 
be O 
stressed O 
by O 
discussing O 
examples O 
of O 
work O 
from O 
our O 
own O 
laboratory O 
along O 
with O 
a O 
review O 
of O 
relevant O 
literature O 
data O 
and O 
a O 
brief O 
discussion O 
of O 
open O 
questions O 
along O 
with O 
some O 
perspectives O 
for O 
further O 
research O 
. O 
Both O 
, O 
differences O 
and O 
similarities O 
in O 
Cd B-FORMULA 
sensitivity O 
traits O 
of O 
related O 
invertebrate O 
species O 
can O 
only O 
be O 
understood O 
if O 
we O 
consider O 
the O 
underlying O 
evolutionary O 
processes O 
and O 
genetic O 
( O 
or O 
epigenetic O 
) O 
mechanisms O 
. O 
Keeping O 
in O 
mind O 
this O 
perception O 
can O 
help O 
us O 
to O 
better O 
understand O 
and O 
interpret O 
more O 
precisely O 
why O 
the O 
sensitivity O 
of O 
some O 
species O 
or O 
species O 
groups O 
towards O 
a O 
certain O 
toxicant O 
( O 
or O 
metal O 
) O 
may O 
be O 
ranked O 
in O 
the O 
lower O 
or O 
higher O 
range O 
of O 
species O 
sensitivity O 
distributions O 
. O 
Hence O 
, O 
such O 
a O 
perspective O 
will O 
transcend O 
a O 
purely O 
statistical O 
view O 
of O 
the O 
sensitivity O 
distributions O 
concept O 
, O 
and O 
will O 
enhance O 
ecotoxicology O 
in O 
many O 
respects O 
. O 

role O 
of O 
molybdenum B-SYSTEMATIC 
in O 
the O 
electrochemical O 
deposition O 
of O 
biological O 
macromolecules O 
on O 
metallic O 
surfaces O 
. O 

corrosion O 
of O 
CoCrMo B-FORMULA 
, O 
an O 
alloy O 
frequently O 
used O 
in O 
orthopedic O 
implants O 
, O 
was O 
studied O 
with O 
an O 
electrochemical O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
( O 
QCM O 
) O 
in O 
three O 
physiologically O 
relevant O 
solutions O 
. O 
Mass O 
changes O 
were O 
measured O 
during O 
potentiodynamic O 
tests O 
, O 
showing O 
material O 
deposition O 
in O 
protein O 
solutions O 
at O 
potential O 
levels O 
that O 
caused O 
mass O 
loss O 
when O 
the O 
proteins O 
were O 
not O 
present O 
. O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
data O 
indicated O 
that O 
the O 
deposited O 
material O 
was O 
primarily O 
organic O 
and O 
therefore O 
was O 
most O 
likely O 
derived O 
from O 
proteins O 
in O 
the O 
electrolyte O 
. O 
Material O 
deposition O 
consistently O 
occurred O 
at O 
a O 
critical O 
potential O 
and O 
was O 
not O 
dependent O 
on O 
the O 
current O 
density O 
or O 
total O 
charge O 
released O 
into O 
solution O 
. O 
Corrosion O 
studies O 
on O 
pure O 
Co B-FORMULA 
, O 
Cr B-FORMULA 
, O 
and O 
Mo B-FORMULA 
in O 
protein O 
solutions O 
found O 
material O 
deposition O 
only O 
on O 
Mo B-FORMULA 
. O 
We O 
hypothesize O 
that O 
organic O 
deposition O 
results O 
from O 
the O 
interaction O 
of O 
Mo B-FORMULA 
(VI) I-FORMULA 
with O 
proteins O 
in O 
the O 
surrounding O 
solution O 
. O 
The O 
organic O 
layer O 
is O 
reminiscent O 
of O 
tribochemical O 
reaction O 
layers O 
that O 
form O 
on O 
the O 
surface O 
of O 
CoCrMo B-FORMULA 
hip O 
bearings O 
, O 
suggesting O 
that O 
these O 
types O 
of O 
layers O 
can O 
be O 
formed O 
by O 
purely O 
electrochemical O 
means O 
. O 

- O 
guided O 
isolation O 
of O 
proanthocyanidins B-FAMILY 
with O 
antiangiogenic O 
activities O 
. O 

proangiogenic O 
members O 
of O 
the O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
family O 
and O 
related O 
receptors O 
play O 
a O 
central O 
role O 
in O 
the O 
modulation O 
of O 
pathological O 
angiogenesis O 
. O 
In O 
order O 
to O 
identify O 
plant O 
compounds O 
able O 
to O 
interfere O 
in O 
the O 
VEGFs O 
/ O 
VEGFR-1 O 
( O 
Flt-1 O 
) O 
recognition O 
by O 
VEGF O 
family O 
members O 
, O 
the O 
extracts O 
of O 
the O 
aerial O 
parts O 
of O 
Campsiandra O 
guayanensis O 
and O 
Feretia O 
apodanthera O 
were O 
screened O 
by O 
a O 
competitive O 
ELISA O 
- O 
based O 
assay O 
. O 
By O 
using O 
this O 
bioassay O 
- O 
oriented O 
approach O 
five O 
proanthocyanindins B-FAMILY 
, O 
including O 
the O 
new O 
natural O 
compounds O 
(2S)-4',5,7-trihydroxyflavan-(4β→8)-afzelechin B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
(2S)-4',5,7-trihydroxyflavan-(4β→8)-epiafzelechin B-SYSTEMATIC 
( O 
2 O 
) O 
and O 
the O 
known O 
geranin B-TRIVIAL 
B I-TRIVIAL 
( O 
3 O 
) O 
, O 
proanthocyanidin B-TRIVIAL 
A2 I-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
proanthocyanidin B-TRIVIAL 
A1 I-TRIVIAL 
( O 
5 O 
) O 
, O 
were O 
isolated O 
. O 
The O 
study O 
of O 
the O 
antiangiogenic O 
activities O 
of O 
compounds O 
1-5 O 
using O 
ELISA O 
and O 
SPR O 
assays O 
showed O 
compound O 
1 O 
as O 
being O 
the O 
most O 
active O 
. O 
The O 
antiangiogenic O 
activity O 
of O 
1 O 
was O 
also O 
confirmed O 
in O 
vivo O 
by O 
the O 
chicken O 
chorioallantoic O 
membrane O 
assay O 
. O 
Our O 
results O 
indicated O 
1 O 
as O 
a O 
new O 
antiangiogenic O 
compound O 
inhibiting O 
the O 
interaction O 
between O 
VEGF-A O 
or O 
PlGF O 
and O 
their O 
receptor O 
VEGRF-1 O 
. O 

vitro O 
metabolism O 
, O 
permeation O 
, O 
and O 
brain O 
availability O 
of O 
six O 
major O 
boswellic B-FAMILY 
acids I-FAMILY 
from O 
Boswellia O 
serrata O 
gum O 
resins O 
. O 

serrata O 
gum O 
resin O 
extracts O 
( O 
BSE O 
) O 
revealed O 
potent O 
anti-inflammatory O 
actions O 
in O 
preclinical O 
and O 
clinical O 
studies O 
. O 
In O 
2002 O 
BSE O 
was O 
assigned O 
an O 
orphan O 
drug O 
status O 
by O 
the O 
European O 
Medicines O 
Agency O 
( O 
EMA O 
) O 
for O 
the O 
treatment O 
of O 
peritumoral O 
edema O 
. O 
In O 
the O 
past O 
pharmacological O 
effects O 
of O 
BSE O 
were O 
mainly O 
attributed O 
to O 
11-keto-β-boswellic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
KBA B-ABBREVIATION 
) O 
and O 
3-acetyl-11-keto-β-boswellic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AKBA B-ABBREVIATION 
) O 
. O 
Therefore O 
pharmacokinetic O 
and O 
pharmacodynamic O 
studies O 
focused O 
mainly O 
on O 
these O 
two O 
boswellic B-FAMILY 
acids I-FAMILY 
( O 
BAs O 
) O 
. O 
However O 
, O 
other O 
BAs O 
, O 
like O 
β-boswellic B-TRIVIAL 
acid I-TRIVIAL 
( O 
βBA B-ABBREVIATION 
) O 
, O 
might O 
also O 
contribute O 
to O 
the O 
anti-inflammatory O 
actions O 
of O 
BSE O 
. O 
Here O 
, O 
we O 
determined O 
the O 
metabolic O 
stability O 
, O 
permeability O 
and O 
brain O 
availability O 
of O 
six O 
major O 
BAs O 
, O 
that O 
is O 
, O 
KBA B-ABBREVIATION 
, O 
AKBA B-ABBREVIATION 
, O 
βBA B-ABBREVIATION 
, O 
3-acetyl-β-boswellic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AβBA B-ABBREVIATION 
) O 
, O 
α-boswellic B-TRIVIAL 
acid I-TRIVIAL 
( O 
αBA B-ABBREVIATION 
) O 
, O 
and O 
3-acetyl-α-boswellic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AαBA B-ABBREVIATION 
) O 
. O 
For O 
permeability O 
studies O 
, O 
the O 
Caco-2 O 
model O 
was O 
adapted O 
to O 
physiological O 
conditions O 
by O 
the O 
addition O 
of O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
to O 
the O 
basolateral O 
side O 
and O 
the O 
use O 
of O 
modified O 
fasted O 
state O 
simulated O 
intestinal O 
fluid O 
( O 
FaSSIF O 
) O 
on O 
the O 
apical O 
side O 
. O 
Under O 
these O 
conditions O 
the O 
four O 
BAs O 
lacking O 
the O 
11-keto B-SYSTEMATIC 
moiety O 
revealed O 
moderate O 
permeability O 
. O 
Furthermore O 
the O 
permeability O 
of O 
AKBA B-ABBREVIATION 
and O 
KBA B-ABBREVIATION 
was O 
improved O 
compared O 
to O 
earlier O 
studies O 
. O 
In O 
contrast O 
to O 
Aα- B-MULTIPLE 
and I-MULTIPLE 
AβBA I-MULTIPLE 
, O 
βBA B-ABBREVIATION 
and O 
αBA B-ABBREVIATION 
were O 
intensively O 
metabolized O 
after O 
incubation O 
with O 
human O 
and O 
rat O 
liver O 
microsomes O 
. O 
Finally O 
, O 
the O 
availability O 
of O 
all O 
six O 
major O 
BAs O 
could O 
be O 
confirmed O 
in O 
rat O 
brain O 
8h O 
after O 
oral O 
administration O 
of O 
240mg O 
/ O 
kg O 
BSE O 
to O 
rats O 
showing O 
mean O 
concentrations O 
of O 
11.6ng O 
/ O 
g O 
for O 
KBA B-ABBREVIATION 
, O 
37.5ng O 
/ O 
g O 
for O 
AKBA B-ABBREVIATION 
, O 
485.1ng O 
/ O 
g O 
for O 
αBA B-ABBREVIATION 
, O 
1066.6ng O 
/ O 
g O 
for O 
βBA B-ABBREVIATION 
, O 
43.0ng O 
/ O 
g O 
for O 
AαBA B-ABBREVIATION 
and O 
163.7ng O 
/ O 
g O 
for O 
AβBA B-ABBREVIATION 
. O 

Surgical O 
Model O 
in O 
Male O 
Obese O 
Rats O 
Uncovers O 
Protective O 
Effects O 
of O 
Bile B-FAMILY 
Acids I-FAMILY 
Post-Bariatric O 
Surgery O 
. O 

surgery O 
elevates O 
serum O 
bile B-FAMILY 
acids I-FAMILY 
. O 
Conjugated O 
bile B-FAMILY 
acid I-FAMILY 
administration O 
, O 
such O 
as O 
tauroursodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
( O 
TUDCA B-ABBREVIATION 
) O 
, O 
improves O 
insulin O 
sensitivity O 
, O 
while O 
short O 
- O 
circuiting O 
bile B-FAMILY 
acid I-FAMILY 
circulation O 
through O 
ileal O 
interposition O 
surgery O 
in O 
rats O 
raises O 
TUDCA B-ABBREVIATION 
levels O 
. O 
We O 
hypothesized O 
that O 
bariatric O 
surgery O 
outcomes O 
could O 
be O 
recapitulated O 
by O 
short O 
- O 
circuiting O 
the O 
normal O 
entero O 
- O 
hepatic O 
bile O 
circulation O 
. O 
We O 
established O 
a O 
model O 
wherein O 
male O 
obese O 
rats O 
underwent O 
either O 
bile O 
diversion O 
( O 
BD O 
) O 
or O 
Sham O 
( O 
SH O 
) O 
surgery O 
. O 
The O 
BD O 
group O 
had O 
a O 
catheter O 
inserted O 
into O 
the O 
common O 
bile O 
duct O 
and O 
its O 
distal O 
end O 
anchored O 
into O 
the O 
mid O 
- O 
distal O 
jejunum O 
for O 
4-5 O 
weeks O 
. O 
Glucose B-TRIVIAL 
tolerance O 
, O 
insulin O 
and O 
glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
response O 
, O 
hepatic O 
steatosis O 
and O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
were O 
measured O 
. O 
Rats' O 
post-BD O 
lost O 
significantly O 
more O 
weight O 
than O 
the O 
SH-rats O 
. O 
BD O 
rats O 
gained O 
less O 
fat O 
mass O 
post O 
- O 
surgery O 
. O 
BD O 
rats O 
had O 
improved O 
glucose B-TRIVIAL 
tolerance O 
, O 
increased O 
higher O 
post O 
- O 
prandial O 
GLP-1 O 
response O 
and O 
serum O 
bile B-FAMILY 
acids I-FAMILY 
but O 
less O 
liver O 
steatosis O 
. O 
Serum O 
bile B-FAMILY 
acid I-FAMILY 
levels O 
including O 
TUDCA B-ABBREVIATION 
concentrations O 
were O 
higher O 
in O 
BD O 
compared O 
to O 
SH O 
pair O 
- O 
fed O 
rats O 
. O 
Fecal O 
bile B-FAMILY 
acid I-FAMILY 
levels O 
were O 
not O 
different O 
. O 
Liver O 
ER O 
stress O 
( O 
CHOP O 
mRNA O 
and O 
pJNK O 
protein O 
) O 
was O 
decreased O 
in O 
BD O 
rats O 
. O 
Bile B-FAMILY 
acid I-FAMILY 
gavage O 
( O 
TUDCA B-ABBREVIATION 
/ O 
UDCA B-ABBREVIATION 
) O 
in O 
diet O 
- O 
induced O 
obese O 
rats O 
, O 
elevated O 
serum O 
TUDCA B-ABBREVIATION 
and O 
concomitantly O 
reduced O 
hepatic O 
steatosis O 
and O 
ER O 
stress O 
( O 
CHOP O 
mRNA O 
) O 
. O 
These O 
data O 
demonstrate O 
the O 
ability O 
of O 
alterations O 
in O 
bile B-FAMILY 
acids I-FAMILY 
to O 
recapitulate O 
important O 
metabolic O 
improvements O 
seen O 
after O 
bariatric O 
surgery O 
. O 
Further O 
, O 
our O 
work O 
establishes O 
a O 
model O 
for O 
focused O 
study O 
of O 
bile B-FAMILY 
acids I-FAMILY 
in O 
the O 
context O 
of O 
bariatric O 
surgery O 
that O 
may O 
lead O 
to O 
the O 
identification O 
of O 
therapeutics O 
for O 
metabolic O 
disease O 
. O 

D₂-agonist O 
rotigotine B-TRIVIAL 
effects O 
on O 
cortical O 
excitability O 
and O 
central O 
cholinergic O 
transmission O 
in O 
Alzheimer's O 
disease O 
patients O 
. O 

is O 
a O 
neurotransmitter O 
involved O 
in O 
several O 
brain O 
functions O 
ranging O 
from O 
emotions O 
control O 
, O 
movement O 
organization O 
to O 
memory O 
formation O 
. O 
It O 
is O 
also O 
involved O 
in O 
the O 
regulation O 
of O 
mechanisms O 
of O 
synaptic O 
plasticity O 
. O 
However O 
, O 
its O 
role O 
in O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
pathogenesis O 
is O 
still O 
puzzling O 
. O 
Several O 
recent O 
line O 
of O 
research O 
instead O 
indicates O 
a O 
clear O 
role O 
for O 
dopamine B-TRIVIAL 
in O 
both O 
amyloid O 
β O 
formation O 
as O 
well O 
as O 
in O 
cognitive O 
decline O 
progression O 
. O 
In O 
particular O 
it O 
has O 
been O 
shown O 
that O 
dopamine B-TRIVIAL 
D₂ O 
- O 
like O 
receptors O 
( O 
namely O 
D₃ O 
and O 
D₂ O 
) O 
could O 
be O 
mostly O 
responsible O 
for O 
dopamine B-TRIVIAL 
dysfunction O 
in O 
AD O 
. O 
Here O 
we O 
aimed O 
to O 
study O 
the O 
effects O 
of O 
the O 
dopamine B-TRIVIAL 
agonist O 
Rotigotine B-TRIVIAL 
on O 
cortical O 
excitability O 
and O 
on O 
central O 
cholinergic O 
transmission O 
in O 
cases O 
of O 
AD O 
. O 
Rotigotine B-TRIVIAL 
is O 
a O 
dopamine B-TRIVIAL 
agonist O 
with O 
a O 
pharmacological O 
profile O 
with O 
high O 
affinity O 
for O 
D₃ O 
and O 
D₂ O 
receptors O 
. O 
We O 
used O 
paired O 
pulse O 
protocols O 
assessing O 
short O 
intracortical O 
inhibition O 
( O 
SICI O 
) O 
and O 
intracortical O 
facilitation O 
( O 
ICF O 
) O 
to O 
asses O 
cortical O 
excitability O 
over O 
the O 
primary O 
motor O 
cortex O 
and O 
Short O 
Latency O 
Afferent O 
Inhibition O 
( O 
SLAI O 
) O 
protocols O 
, O 
to O 
verify O 
the O 
effects O 
of O 
the O 
drug O 
on O 
central O 
cholinergic O 
transmission O 
in O 
a O 
group O 
of O 
AD O 
patients O 
compared O 
to O 
age O 
- O 
matched O 
controls O 
. O 
We O 
observed O 
that O 
rotigotine B-TRIVIAL 
induces O 
unexpected O 
changes O 
in O 
both O 
cortical O 
excitability O 
( O 
increased O 
) O 
and O 
central O 
cholinergic O 
transmission O 
( O 
restored O 
) O 
of O 
AD O 
patients O 
. O 
These O 
unexpected O 
effects O 
might O 
depend O 
on O 
the O 
dopamine B-TRIVIAL 
D₂ O 
- O 
like O 
receptors O 
dysfunction O 
previously O 
described O 
in O 
AD O 
brains O 
. O 
The O 
current O 
findings O 
could O 
indicate O 
that O 
future O 
strategies O 
aimed O 
to O 
ameliorate O 
symptoms O 
of O 
the O 
related O 
AD O 
cognitive O 
decline O 
could O 
also O 
involve O 
some O 
dopaminergic O 
drugs O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

examine O 
factors O 
associated O 
with O 
clinical O 
microalbuminuria O 
( O 
MA O 
) O 
diagnosis O 
in O 
children O 
and O 
adolescents O 
in O 
the O 
T1D O 
Exchange O 
clinic O 
registry.RESEARCH O 
DESIGN O 
AND O 
METHODST1D O 
Exchange O 
participants O 
< O 
20 O 
years O 
of O 
age O 
with O 
type O 
1 O 
diabetes O 
≥ O 
1 O 
year O 
and O 
urinary O 
albumin-to- O 
creatinine B-TRIVIAL 
ratio O 
( O 
ACR O 
) O 
measured O 
within O 
the O 
prior O 
2 O 
years O 
were O 
included O 
in O 
the O 
analysis O 
. O 
MA O 
diagnosis O 
required O 
all O 
of O 
the O 
following O 
: O 
1 O 
) O 
a O 
clinical O 
diagnosis O 
of O 
sustained O 
MA O 
or O 
macroalbuminuria O 
, O 
2 O 
) O 
confirmation O 
of O 
MA O 
diagnosis O 
by O 
either O 
the O 
most O 
recent O 
ACR O 
being O 
≥ O 
30 O 
mg O 
/ O 
g O 
or O 
current O 
treatment O 
with O 
an O 
ACE O 
inhibitor O 
( O 
ACEI O 
) O 
or O 
angiotensin O 
receptor O 
blocker O 
( O 
ARB O 
) O 
, O 
and O 
3 O 
) O 
no O 
known O 
cause O 
for O 
nephropathy O 
other O 
than O 
diabetes O 
. O 
Logistic O 
regression O 
was O 
used O 
to O 
assess O 
factors O 
associated O 
with O 
MA.RESULTSMA O 
was O 
present O 
in O 
329 O 
of O 
7549 O 
( O 
4.4% O 
) O 
participants O 
, O 
with O 
a O 
higher O 
frequency O 
associated O 
with O 
longer O 
diabetes O 
duration O 
, O 
higher O 
mean O 
glycosylated O 
hemoglobin O 
( O 
HbA1c O 
) O 
level O 
, O 
older O 
age O 
, O 
female O 
sex O 
, O 
higher O 
diastolic O 
blood O 
pressure O 
( O 
BP O 
) O 
, O 
and O 
lower O 
BMI O 
( O 
P O 
≤ O 
0.01 O 
for O 
each O 
in O 
multivariate O 
analysis O 
) O 
. O 
Older O 
age O 
was O 
most O 
strongly O 
associated O 
with O 
MA O 
among O 
participants O 
with O 
HbA1c O 
≥ O 
9.5% O 
( O 
≥ O 
80 O 
mmol O 
/ O 
mol O 
) O 
. O 
MA O 
was O 
uncommon O 
( O 
< O 
2% O 
) O 
among O 
participants O 
with O 
HbA1c O 
< O 
7.5% O 
( O 
< O 
58 O 
mmol O 
/ O 
mol O 
) O 
. O 
Of O 
those O 
with O 
MA O 
, O 
only O 
36% O 
were O 
receiving O 
ACEI O 
/ O 
ARB O 
treatment.CONCLUSIONSOur O 
results O 
emphasize O 
the O 
importance O 
of O 
good O 
glycemic O 
and O 
BP O 
control O 
, O 
particularly O 
as O 
diabetes O 
duration O 
increases O 
, O 
in O 
order O 
to O 
reduce O 
the O 
risk O 
of O 
nephropathy O 
. O 
Since O 
age O 
and O 
diabetes O 
duration O 
are O 
important O 
nonmodifiable O 
factors O 
associated O 
with O 
MA O 
, O 
the O 
importance O 
of O 
routine O 
screening O 
is O 
underscored O 
to O 
ensure O 
early O 
diagnosis O 
and O 
timely O 
treatment O 
of O 
MA O 
. O 

planning O 
remains O 
a O 
high O 
priority O 
area O 
for O 
the O 
United O 
States O 
, O 
with O 
goals O 
to O 
increase O 
the O 
proportion O 
of O 
pregnancies O 
that O 
are O 
intended O 
, O 
reduce O 
pregnancy O 
rates O 
among O 
adolescents O 
, O 
and O 
increase O 
contraceptive O 
use O 
prioritized O 
in O 
the O 
Healthy O 
People O 
2020 O 
objectives O 
. O 
Contraception O 
intended O 
for O 
use O 
after O 
unprotected O 
intercourse O 
, O 
known O 
as O 
emergency O 
contraception O 
, O 
remains O 
underutilized O 
. O 
Levonorgestrel B-TRIVIAL 
is O 
one O 
method O 
of O 
oral O 
emergency O 
contraception O 
, O 
which O 
prevents O 
fertilization O 
and O 
does O 
not O 
disrupt O 
an O 
already O 
established O 
pregnancy O 
; O 
thus O 
, O 
timing O 
of O 
administration O 
is O 
critical O 
. O 
Despite O 
data O 
demonstrating O 
safety O 
and O 
efficacy O 
, O 
evidence O 
- O 
based O 
decision O 
making O 
has O 
been O 
overshadowed O 
by O 
politically O 
charged O 
actions O 
involving O 
levonorgestrel B-TRIVIAL 
emergency O 
contraception O 
for O 
over O 
a O 
decade O 
. O 
The O 
Women's O 
Health O 
Practice O 
and O 
Research O 
Network O 
of O 
the O 
American O 
College O 
of O 
Clinical O 
Pharmacy O 
supports O 
expanded O 
access O 
to O 
levonorgestrel B-TRIVIAL 
emergency O 
contraception O 
and O 
removal O 
of O 
barriers O 
such O 
as O 
age O 
restrictions O 
on O 
the O 
nonprescription O 
drug O 
product O 
. O 
Pharmacists O 
remain O 
a O 
key O 
provider O 
of O 
emergency O 
contraceptive O 
services O 
and O 
can O 
help O 
ensure O 
timely O 
access O 
. O 
In O 
states O 
where O 
direct O 
pharmacy O 
access O 
to O 
emergency O 
contraception O 
is O 
available O 
, O 
pharmacists O 
are O 
encouraged O 
to O 
participate O 
. O 
Education O 
, O 
research O 
, O 
and O 
advocacy O 
are O 
other O 
important O 
responsibilities O 
for O 
pharmacists O 
in O 
this O 
arena O 
. O 

sensitive O 
detection O 
of O 
cancer O 
biomarkers O 
in O 
urine O 
could O 
revolutionize O 
cancer O 
diagnosis O 
and O 
treatment O 
. O 
Such O 
detectors O 
must O 
be O 
inexpensive O 
, O 
easy O 
to O 
interpret O 
, O 
and O 
sensitive O 
. O 
This O 
report O 
describes O 
a O 
bioaffinity O 
matrix O 
of O 
viruses O 
integrated O 
into O 
PEDOT B-ABBREVIATION 
films O 
for O 
electrochemical O 
sensing O 
of O 
prostate O 
specific O 
membrane O 
antigen O 
( O 
PSMA O 
) O 
, O 
a O 
prostate O 
cancer O 
biomarker O 
. O 
High O 
sensitivity O 
to O 
PSMA O 
resulted O 
from O 
synergistic O 
action O 
by O 
two O 
different O 
ligands O 
to O 
PSMA O 
on O 
the O 
same O 
phage O 
particle O 
. O 
One O 
ligand O 
was O 
chemically O 
synthesized O 
and O 
wrapped O 
around O 
the O 
phage O 
, O 
and O 
the O 
second O 
was O 
genetically O 
encoded O 
. O 
The O 
dual O 
ligands O 
result O 
in O 
a O 
bidentate O 
binder O 
with O 
high O 
copy O 
, O 
dense O 
ligand O 
display O 
for O 
enhanced O 
PSMA O 
detection O 
through O 
a O 
chelate O 
- O 
based O 
, O 
avidity O 
effect O 
. O 
Biosensing O 
with O 
virus- O 
PEDOT B-ABBREVIATION 
films O 
provides O 
a O 
100 O 
pM O 
limit O 
of O 
detection O 
for O 
PSMA O 
in O 
synthetic O 
urine O 
without O 
requiring O 
enzymatic O 
or O 
other O 
amplification O 
. O 

temperature O 
dependence O 
of O 
viscosity O 
( O 
the O 
reciprocal O 
of O 
fluidity O 
) O 
in O 
polar O 
liquids O 
has O 
been O 
studied O 
for O 
over O 
a O 
century O 
, O 
but O 
the O 
available O 
theoretical O 
models O 
have O 
serious O 
limitations O 
. O 
Consequently O 
, O 
the O 
viscosity O 
is O 
often O 
described O 
with O 
empirical O 
equations O 
using O 
adjustable O 
fitting O 
parameters O 
that O 
offer O 
no O 
insight O 
into O 
the O 
molecular O 
mechanism O 
of O 
transport O 
. O 
We O 
have O 
previously O 
reported O 
a O 
novel O 
approach O 
called O 
the O 
compensated O 
Arrhenius O 
formalism O 
( O 
CAF O 
) O 
to O 
describe O 
ionic O 
conductivity O 
, O 
self O 
- O 
diffusion O 
, O 
and O 
dielectric O 
relaxation O 
in O 
terms O 
of O 
molecular O 
and O 
system O 
properties O 
. O 
Here O 
the O 
CAF O 
is O 
applied O 
to O 
fluidity O 
data O 
of O 
pure O 
n-acetates B-FAMILY 
, O 
2-ketones B-FAMILY 
, O 
n-nitriles B-FAMILY 
, O 
and O 
n-alcohols B-FAMILY 
over O 
the O 
temperature O 
range O 
5-85 O 
°C O 
. O 
The O 
fluidity O 
is O 
represented O 
as O 
an O 
Arrhenius O 
- O 
like O 
expression O 
that O 
includes O 
a O 
static O 
dielectric O 
constant O 
dependence O 
in O 
the O 
exponential O 
prefactor O 
. O 
The O 
dielectric O 
constant O 
dependence O 
results O 
from O 
the O 
dependence O 
of O 
mass O 
and O 
charge O 
transport O 
on O 
the O 
molecular O 
dipole O 
moment O 
and O 
the O 
solvent O 
dipole O 
density O 
. O 
The O 
CAF O 
is O 
the O 
only O 
self O 
- O 
consistent O 
description O 
of O 
fluid O 
transport O 
in O 
polar O 
liquids O 
written O 
solely O 
in O 
terms O 
of O 
molecular O 
and O 
system O 
parameters O 
. O 
A O 
scaling O 
procedure O 
is O 
used O 
to O 
calculate O 
the O 
activation O 
energy O 
for O 
transport O 
. O 
We O 
find O 
that O 
the O 
activation O 
energies O 
for O 
fluidity O 
of O 
the O 
aprotic O 
liquids O 
are O 
comparable O 
in O 
value O 
, O 
whereas O 
a O 
higher O 
average O 
E(a) O 
value O 
is O 
observed O 
for O 
the O 
n-alcohol B-FAMILY 
data O 
. O 
Finally O 
, O 
we O 
contrast O 
the O 
molecular O 
description O 
of O 
transport O 
presented O 
here O 
with O 
the O 
conventional O 
hydrodynamic O 
model O 
. O 

nonfermentable O 
dietary O 
fiber O 
hydroxypropyl B-SYSTEMATIC 
methylcellulose O 
modulates O 
intestinal O 
microbiota O 
. O 

influences O 
host O 
metabolism O 
and O 
intestinal O 
microbiota O 
; O 
however O 
, O 
detailed O 
understanding O 
of O 
this O 
tripartite O 
interaction O 
is O 
limited O 
. O 
To O 
determine O 
whether O 
the O 
nonfermentable O 
fiber O 
hydroxypropyl B-SYSTEMATIC 
methylcellulose O 
( O 
HPMC O 
) O 
could O 
alter O 
the O 
intestinal O 
microbiota O 
and O 
whether O 
such O 
changes O 
correlated O 
with O 
metabolic O 
improvements O 
, O 
C57B O 
/ O 
L6 O 
mice O 
were O 
normalized O 
to O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
, O 
then O 
either O 
maintained O 
on O 
HFD O 
( O 
control O 
) O 
, O 
or O 
switched O 
to O 
HFD O 
supplemented O 
with O 
10% O 
HPMC O 
, O 
or O 
a O 
low O 
- O 
fat O 
diet O 
( O 
LFD O 
) O 
. O 
Compared O 
to O 
control O 
treatment O 
, O 
both O 
LFD O 
and O 
HPMC O 
reduced O 
weight O 
gain O 
( O 
11.8 O 
and O 
5.7 O 
g O 
, O 
respectively O 
) O 
, O 
plasma O 
cholesterol B-TRIVIAL 
( O 
23.1 O 
and O 
19.6% O 
) O 
, O 
and O 
liver O 
triglycerides B-FAMILY 
( O 
73.1 O 
and O 
44.6% O 
) O 
, O 
and O 
, O 
as O 
revealed O 
by O 
454-pyrosequencing O 
of O 
the O 
microbial O 
16S O 
rRNA O 
gene O 
, O 
decreased O 
microbial O 
α-diversity O 
and O 
differentially O 
altered O 
intestinal O 
microbiota O 
. O 
Both O 
LFD O 
and O 
HPMC O 
increased O 
intestinal O 
Erysipelotrichaceae O 
( O 
7.3- O 
and O 
12.4-fold O 
) O 
and O 
decreased O 
Lachnospiraceae O 
( O 
2.0- O 
and O 
2.7-fold O 
) O 
, O 
while O 
only O 
HPMC O 
increased O 
Peptostreptococcaceae O 
( O 
3.4-fold O 
) O 
and O 
decreased O 
Ruminococcaceae O 
( O 
2.7-fold O 
) O 
. O 
Specific O 
microorganisms O 
were O 
directly O 
linked O 
with O 
weight O 
change O 
and O 
metabolic O 
parameters O 
in O 
HPMC O 
and O 
HFD O 
mice O 
, O 
but O 
not O 
in O 
LFD O 
mice O 
, O 
indicating O 
that O 
the O 
intestinal O 
microbiota O 
may O 
play O 
differing O 
roles O 
during O 
the O 
two O 
dietary O 
modulations O 
. O 
This O 
work O 
indicates O 
that O 
HPMC O 
is O 
a O 
potential O 
prebiotic O 
fiber O 
that O 
influences O 
intestinal O 
microbiota O 
and O 
improves O 
host O 
metabolism O 
. O 

serum O 
is O 
a O 
rich O 
source O 
of O 
cytokines O 
and O 
growth O 
factors O 
supporting O 
in O 
vitro O 
cell O 
culture O 
. O 
Here O 
, O 
a O 
novel O 
bovine O 
monocyte O 
chemotactic O 
factor O 
( O 
boMCF-1 O 
) O 
was O 
isolated O 
from O 
commercial O 
bovine O 
serum O 
by O 
a O 
four O 
step O 
purification O 
procedure O 
including O 
adsorption O 
to O 
silicic B-TRIVIAL 
acid I-TRIVIAL 
, O 
heparin O 
affinity O 
and O 
cation O 
- O 
exchange O 
chromatography O 
and O 
reversed O 
phase O 
HPLC O 
. O 
Homogeneous O 
boMCF-1 O 
was O 
characterized O 
as O 
a O 
7717Da O 
protein O 
by O 
mass O 
spectrometry O 
and O 
identified O 
by O 
Edman O 
degradation O 
as O 
the O 
predicted O 
product O 
of O 
bovine O 
macrophage O 
inflammatory O 
protein-1α O 
gene O 
( O 
boMIP-1α O 
/ O 
CCL3 O 
) O 
isoform O 
2 O 
( O 
lacking O 
three O 
NH₂ B-FORMULA 
-terminal O 
amino B-FAMILY 
acids I-FAMILY 
) O 
, O 
belonging O 
to O 
the O 
MIP O 
subfamily O 
of O 
CC O 
chemokines O 
. O 
Monocyte O 
chemotactic O 
activity O 
of O 
boCCL3 O 
isoform O 
2 O 
was O 
completely O 
desensitized O 
by O 
human O 
CCL3 O 
and O 
CCL5 O 
, O 
partially O 
by O 
CCL7 O 
and O 
not O 
by O 
CCL2 O 
. O 
Its O 
activity O 
was O 
better O 
inhibited O 
by O 
CCR1 O 
than O 
by O 
CCR5 O 
blockade O 
. O 
BoCCL3 O 
isoform O 
2 O 
, O 
present O 
in O 
bovine O 
serum O 
at O 
about O 
10 O 
ng O 
/ O 
ml O 
, O 
functioned O 
as O 
a O 
most O 
potent O 
chemoattractant O 
for O 
immature O 
( O 
but O 
not O 
mature O 
) O 
dendritic O 
cells O 
with O 
a O 
minimal O 
effective O 
concentration O 
of O 
0.03 O 
ng O 
/ O 
ml O 
and O 
a O 
maximal O 
chemotactic O 
index O 
of O 
30 O 
at O 
0.3 O 
ng O 
/ O 
ml O 
. O 
Its O 
chemotactic O 
activity O 
on O 
immature O 
dendritic O 
cells O 
was O 
significantly O 
desensitized O 
by O 
human O 
CCL3 O 
, O 
CCL5 O 
and O 
CCL7 O 
. O 
Blockade O 
of O 
CCR5 O 
rather O 
than O 
CCR1 O 
partially O 
prevented O 
chemotactic O 
activity O 
, O 
whereas O 
blockade O 
of O 
both O 
further O 
enhanced O 
this O 
inhibition O 
. O 
BoCCL3 O 
isoform O 
2 O 
was O 
not O 
chemokinetic O 
but O 
, O 
like O 
human O 
CCL3 O 
, O 
synergized O 
with O 
CXCL12 O 
in O 
monocytic O 
cell O 
chemotaxis O 
. O 
Since O 
it O 
cannot O 
be O 
deduced O 
which O 
is O 
the O 
exact O 
human O 
homolog O 
of O 
boCCL3 O 
isoform O 
2 O 
, O 
further O 
research O 
is O 
required O 
to O 
study O 
the O 
biology O 
of O 
other O 
boCCL3 O 
family O 
members O 
. O 

study O 
of O 
the O 
coordination O 
of O 
methane B-SYSTEMATIC 
to O 
first O 
row O 
transition B-FAMILY 
metal I-FAMILY 
dication I-FAMILY 
complexes I-FAMILY 
. O 

coordination O 
of O 
methane B-SYSTEMATIC 
, O 
the O 
first O 
step O 
in O 
methane B-SYSTEMATIC 
activation O 
, O 
to O 
coordinately O 
unsaturated O 
first O 
row O 
transition B-FAMILY 
metal I-FAMILY 
dication I-FAMILY 
complexes I-FAMILY 
has O 
been O 
studied O 
computationally O 
to O 
determine O 
the O 
most O 
stable O 
metal- O 
methane B-SYSTEMATIC 
interaction O 
. O 
The O 
geometries O 
and O 
the O 
vibrational O 
frequencies O 
of O 
the O 
encounter O 
complexes O 
[M(pyridine)2(CH4)](2+) B-FAMILY 
have O 
been O 
determined O 
using O 
density O 
functional O 
theory O 
with O 
the O 
ωB97XD O 
hybrid O 
functional O 
and O 
triple-ζ O 
basis O 
sets O 
. O 
The O 
structure O 
is O 
dependent O 
on O 
the O 
metal O 
center O 
; O 
for O 
the O 
early O 
transition B-FAMILY 
metals I-FAMILY 
η(3) O 
coordination O 
is O 
favored O 
, O 
whereas O 
η(2) O 
is O 
more O 
favorable O 
for O 
the O 
later O 
transition B-FAMILY 
metals I-FAMILY 
. O 
The O 
periodic O 
trend O 
in O 
methane B-SYSTEMATIC 
binding O 
energies O 
in O 
the O 
[M(pyridine)2(CH4)](2+) B-FAMILY 
complexes O 
follows O 
the O 
trend O 
in O 
electron O 
affinity O 
until O 
the O 
Mn B-FORMULA 
complex O 
but O 
then O 
exhibits O 
decreasing O 
energies O 
from O 
Fe B-FORMULA 
to O 
Zn B-FORMULA 
. O 
This O 
is O 
attributed O 
to O 
increasing O 
Pauli O 
repulsion O 
and O 
ligand O 
- O 
ligand O 
repulsion O 
. O 
For O 
the O 
most O 
stable O 
complex O 
, O 
[Cr(pyridine)2(CH4)](2+) B-FORMULA 
, O 
the O 
structures O 
, O 
energies O 
, O 
and O 
spin O 
states O 
of O 
the O 
key O 
intermediates O 
and O 
products O 
in O 
the O 
oxidative O 
addition O 
/ O 
reductive O 
elimination O 
pathway O 
have O 
been O 
investigated O 
. O 
It O 
is O 
found O 
that O 
the O 
reaction O 
is O 
thermodynamically O 
favorable O 
and O 
indicates O 
that O 
two O 
- O 
state O 
reactivity O 
may O 
play O 
an O 
important O 
role O 
in O 
lowering O 
the O 
energy O 
of O 
the O 
hydridomethyl B-SYSTEMATIC 
intermediate O 
. O 

of O 
2-deoxy-2,3-didehydro-N-acetylneuraminic B-SYSTEMATIC 
acid I-SYSTEMATIC 
analogues O 
modified O 
by O 
α-acylaminoamido B-FAMILY 
groups O 
at O 
the O 
C-4 O 
position O 
using O 
isocyanide B-SYSTEMATIC 
-based O 
four O 
- O 
component O 
coupling O 
and O 
biological O 
evaluation O 
as O 
inhibitors O 
of O 
human O 
parainfluenza O 
virus O 
type O 
1 O 
. O 

sialidase O 
inhibitors O 
11 O 
having O 
an O 
α-acylaminoamido B-FAMILY 
group O 
at O 
the O 
C-4 O 
position O 
of O 
Neu5Ac2en O 
1 O 
against O 
human O 
parainfluenza O 
virus O 
type O 
1 O 
( O 
hPIV-1 O 
) O 
were O 
synthesized O 
using O 
one O 
- O 
pot O 
isocyanide B-SYSTEMATIC 
-based O 
four O 
- O 
component O 
condensation O 
, O 
and O 
their O 
inhibitory O 
activities O 
against O 
hPIV-1 O 
sialidase O 
were O 
studied O 
. O 
Compound O 
11b O 
showed O 
inhibitory O 
activity O 
( O 
IC(50)=5.1 O 
mM O 
) O 
against O 
hPIV-1 O 
sialidase O 
. O 
The O 
degree O 
of O 
inhibition O 
of O 
11b O 
was O 
much O 
weaker O 
than O 
that O 
of O 
1 O 
( O 
IC(50)=0.3 O 
mM O 
) O 
. O 

of O 
arsenic B-SYSTEMATIC 
levels O 
in O 
some O 
ready O 
- O 
to O 
- O 
use O 
anti-malaria O 
herbal O 
products O 
from O 
drug O 
sales O 
outlets O 
in O 
the O 
Madina O 
area O 
of O 
Accra O 
, O 
Ghana O 
. O 

Ghana O 
anti-malaria O 
herbal O 
medicines O 
or O 
products O 
are O 
used O 
to O 
compliment O 
commercial O 
drugs O 
in O 
treatment O 
and O 
prevention O 
of O 
Plasmodium O 
falciparum O 
infections O 
. O 
In O 
this O 
study O 
, O 
four O 
common O 
aqueous O 
based O 
anti-malaria O 
herbal O 
products O 
( O 
coded O 
HEB O 
, O 
KFE O 
, O 
MDM O 
and O 
NIB O 
) O 
which O 
are O 
used O 
by O 
Ghanaian O 
population O 
from O 
pharmacy O 
/ O 
herbal O 
stores O 
in O 
the O 
Madina O 
area O 
, O 
Accra O 
were O 
blindly O 
and O 
randomly O 
sampled O 
for O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
, O 
arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
) O 
and O 
Lead O 
( O 
Pb B-FORMULA 
) O 
analysis O 
using O 
Atomic O 
Absorption O 
Spectrophotometry O 
technique O 
. O 
Arsenic B-SYSTEMATIC 
concentrations O 
were O 
1.087μg O 
/ O 
mL O 
( O 
108.7% O 
) O 
, O 
1.027μg O 
/ O 
mL O 
( O 
102.7% O 
) O 
, O 
0.330μg O 
/ O 
mL O 
( O 
33.0% O 
) O 
and O 
0.274μg O 
/ O 
mL O 
( O 
27.4% O 
) O 
in O 
MDM O 
, O 
KFE O 
, O 
NIB O 
and O 
HEB O 
respectively O 
. O 
Arsenic B-SYSTEMATIC 
concentration O 
determined O 
in O 
MDM O 
and O 
KFE O 
were O 
above O 
the O 
maximum O 
permissible O 
limit O 
of O 
1.0ppm O 
determined O 
by O 
WHO O 
/ O 
FAO O 
. O 
Cadmium B-SYSTEMATIC 
concentration O 
in O 
each O 
of O 
the O 
four O 
products O 
as O 
well O 
as O 
lead O 
concentration O 
in O 
KFE O 
, O 
NIB O 
and O 
HEB O 
were O 
below O 
the O 
detection O 
limit O 
of O 
< O 
0.002mg O 
/ O 
mL O 
( O 
Cd B-FORMULA 
) O 
and O 
< O 
0.005mg O 
/ O 
mL O 
( O 
Pb B-FORMULA 
) O 
respectively O 
. O 
The O 
maximum O 
permissible O 
limits O 
for O 
Pb B-FORMULA 
and O 
Cd B-FORMULA 
determined O 
by O 
WHO O 
/ O 
FAO O 
are O 
10.0ppm O 
and O 
0.3ppm O 
respectively O 
. O 
Thus O 
, O 
random O 
assessment O 
on O 
the O 
safety O 
of O 
some O 
ready O 
- O 
to O 
- O 
use O 
aqueous O 
based O 
anti-malaria O 
herbal O 
products O 
on O 
the O 
market O 
is O 
necessary O 
to O 
prevent O 
public O 
health O 
hazards O 
associated O 
with O 
consuming O 
these O 
plant O 
extracts O 
. O 
Although O 
lead O 
and O 
cadmium B-SYSTEMATIC 
concentration O 
in O 
the O 
anti-malaria O 
herbal O 
products O 
were O 
below O 
the O 
maximum O 
permissible O 
limits O 
, O 
their O 
cumulative O 
effect O 
on O 
the O 
health O 
of O 
an O 
individual O 
which O 
consume O 
recommended O 
volume O 
of O 
not O 
less O 
than O 
1000 O 
mL O 
for O 
effective O 
malaria O 
parasite O 
clearance O 
cannot O 
be O 
ignored O 
. O 

of O 
vitamin B-FAMILY 
D I-FAMILY 
on O 
antigen O 
- O 
specific O 
and O 
non-antigen O 
- O 
specific O 
immune O 
modulation O 
: O 
relevance O 
for O 
type O 
1 O 
diabetes O 
. O 

D I-FAMILY 
is O 
a O 
fat O 
- O 
soluble O 
precursor O 
of O 
the O 
circulating O 
25-hydroxyvitamin B-SYSTEMATIC 
D₃ I-SYSTEMATIC 
( O 
25(OH)D₃ B-SYSTEMATIC 
)which O 
can O 
be O 
converted O 
by O 
the O 
1α-hydroxylase O 
( O 
1α(OH)ase O 
) O 
enzyme O 
into O 
the O 
bioactive O 
hormonal O 
metabolite O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D₃ I-SYSTEMATIC 
( O 
1,25(OH)₂D₃ B-SYSTEMATIC 
) O 
, O 
generally O 
known O 
to O 
promote O 
bone O 
mineralization O 
through O 
its O 
ability O 
to O 
enhance O 
calcium B-SYSTEMATIC 
absorption O 
from O 
the O 
gut O 
. O 
Importantly O 
, O 
in O 
humans O 
, O 
vitamin B-FAMILY 
D I-FAMILY 
is O 
mainly O 
derived O 
from O 
endogenous O 
production O 
of O 
vitamin B-TRIVIAL 
D₃ I-TRIVIAL 
from O 
ultraviolet O 
( O 
UV O 
) O 
radiation O 
exposure O 
to O 
the O 
skin O 
while O 
a O 
small O 
part O 
( O 
< O 
10% O 
) O 
is O 
obtained O 
via O 
dietary O 
intake O 
of O 
dairy O 
products O 
and O 
fatty O 
fish O 
( O 
1 O 
) O 
. O 
Taking O 
these O 
factors O 
into O 
account O 
, O 
geographic O 
distribution O 
and O 
seasonality O 
, O 
skin O 
pigmentation O 
, O 
age O 
, O 
and O 
lifestyle O 
may O 
predispose O 
certain O 
populations O 
to O 
be O 
at O 
a O 
higher O 
risk O 
of O 
developing O 
vitamin B-FAMILY 
D I-FAMILY 
insufficiency O 
or O 
deficiency O 
( O 
2 O 
) O 
. O 
The O 
first O 
valid O 
reports O 
correlating O 
the O 
importance O 
of O 
an O 
adequate O 
vitamin B-FAMILY 
D I-FAMILY 
status O 
to O 
optimal O 
human O 
health O 
originate O 
from O 
the O 
early O 
part O 
of O 
the O 
20th O 
century O 
, O 
when O 
vitamin B-FAMILY 
D I-FAMILY 
was O 
described O 
to O 
prevent O 
and O 
treat O 
the O 
bone O 
disease O 
rickets O 
. O 
Since O 
then O 
, O 
the O 
findings O 
that O 
vitamin B-FAMILY 
D I-FAMILY 
receptors O 
( O 
VDR O 
) O 
are O 
present O 
in O 
many O 
body O 
tissues O 
and O 
that O 
vitamin B-FAMILY 
D I-FAMILY 
metabolizing O 
enzymes O 
can O 
be O 
found O 
in O 
various O 
cells O 
outside O 
the O 
kidney O 
, O 
including O 
the O 
intestine O 
, O 
prostate O 
, O 
immune O 
cells O 
, O 
and O 
within O 
the O 
skin O 
itself O 
( O 
reviewed O 
in O 
reference O 
3 O 
) O 
, O 
have O 
revolutionized O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
business O 
. O 
In O 
this O 
review O 
, O 
we O 
will O 
mainly O 
focus O 
on O 
vitamin B-FAMILY 
D I-FAMILY 
as O 
a O 
component O 
of O 
immune O 
regulation O 
and O 
on O 
the O 
role O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
in O 
antigen O 
- O 
specific O 
and O 
non-specific O 
therapies O 
with O 
potential O 
relevance O 
for O 
type O 
1 O 
diabetes O 
( O 
T1D O 
) O 
. O 

diltiazem B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
-containing O 
pellets O 
were O 
prepared O 
using O 
the O 
solution O 
layering O 
technique O 
. O 
Unusual O 
thermal O 
behavior O 
was O 
detected O 
with O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
and O 
its O 
source O 
was O 
determined O 
using O 
thermogravimetry O 
( O 
TG O 
) O 
, O 
X-ray O 
powder O 
diffraction O 
( O 
XRPD O 
) O 
and O 
hot O 
- O 
stage O 
microscopy O 
. O 
The O 
coated O 
pellets O 
contained O 
diltiazem B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
both O 
in O 
crystalline O 
and O 
amorphous O 
form O 
. O 
Crystallization O 
occurs O 
on O 
heat O 
treatment O 
causing O 
an O 
exothermic O 
peak O 
on O 
the O 
DSC O 
curves O 
that O 
only O 
appears O 
in O 
pellets O 
containing O 
both O 
diltiazem B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
and O 
the O 
coating O 
. O 
Results O 
indicate O 
that O 
the O 
amorphous O 
fraction O 
is O 
situated O 
in O 
the O 
coating O 
layer O 
. O 
The O 
migration O 
of O 
drugs O 
into O 
the O 
coating O 
layer O 
can O 
cause O 
changes O 
in O 
its O 
degree O 
of O 
crystallinity O 
. O 
Polymeric O 
coating O 
materials O 
should O 
therefore O 
be O 
investigated O 
as O 
possible O 
crystallization O 
inhibitors O 
. O 

of O 
dipeptides B-FAMILY 
having O 
N B-FORMULA 
-terminal O 
selenocysteine B-TRIVIAL 
residues O 
: O 
a O 
DFT O 
study O 
in O 
gas O 
and O 
aqueous O 
phase O 
. O 

the O 
last O 
few O 
decades O 
, O 
dipeptides B-FAMILY 
as O 
well O 
as O 
their O 
analogues O 
have O 
served O 
as O 
important O 
model O 
systems O 
for O 
the O 
computational O 
studies O 
concerning O 
the O 
structure O 
of O 
protein O 
and O 
energetics O 
of O 
protein O 
folding O 
. O 
Here O 
, O 
we O 
present O 
a O 
density O 
functional O 
structural O 
study O 
on O 
a O 
set O 
of O 
seven O 
dipeptides B-FAMILY 
having O 
N B-FORMULA 
-terminal O 
selenocysteine B-TRIVIAL 
residues O 
( O 
the O 
component O 
in O 
the O 
C B-FORMULA 
-terminus O 
is O 
varied O 
with O 
seven O 
different O 
combinations O 
viz O 
. O 
Ala B-FORMULA 
, O 
Phe B-FORMULA 
, O 
Glu B-FORMULA 
, O 
Thr B-FORMULA 
, O 
Asn B-FORMULA 
, O 
Arg B-FORMULA 
and O 
Sec B-FORMULA 
) O 
in O 
gas O 
and O 
simulated O 
aqueous O 
phase O 
using O 
a O 
polarizable O 
continuum O 
model O 
( O 
PCM O 
) O 
. O 
The O 
molecular O 
geometries O 
of O 
the O 
dipeptides B-FAMILY 
are O 
fully O 
optimized O 
at O 
B3LYP O 
/ O 
6-311 O 
+ O 
+ O 
G(d,p) O 
level O 
and O 
subsequent O 
frequency O 
calculations O 
confirm O 
them O 
as O 
true O 
minima O 
. O 
The O 
effects O 
of O 
solvation O 
and O 
identity O 
of O 
the O 
varying O 
C B-FORMULA 
-terminal O 
residue O 
on O 
the O 
energetics O 
, O 
structural O 
features O 
of O 
the O 
peptide O 
planes O 
, O 
values O 
of O 
the O 
ψ O 
and O 
ф O 
dihedrals O 
, O 
geometry O 
around O 
the O 
α-carbon B-SYSTEMATIC 
atoms O 
and O 
theoretically O 
predicted O 
vibrational O 
spectra O 
of O 
the O 
dipeptides B-FAMILY 
are O 
investigated O 
. O 
Two O 
types O 
of O 
intramolecular O 
H B-FORMULA 
-bonds O 
, O 
namely O 
N B-FORMULA 
… O 
H-N B-FORMULA 
and O 
O B-FORMULA 
… O 
H-C B-FORMULA 
, O 
are O 
found O 
to O 
play O 
important O 
roles O 
in O 
influencing O 
the O 
planarity O 
of O 
the O 
peptide O 
planes O 
and O 
geometry O 
around O 
the O 
α-carbon B-SYSTEMATIC 
atoms O 
of O 
the O 
dipeptides B-FAMILY 
. O 
The O 
identity O 
of O 
the O 
varying O 
C B-FORMULA 
-terminal O 
residue O 
influences O 
the O 
values O 
of O 
ф O 
, O 
planarity O 
of O 
the O 
peptide O 
planes O 
and O 
geometry O 
around O 
the O 
C7 O 
α-carbon B-SYSTEMATIC 
atoms O 
while O 
the O 
solvation O 
effects O 
are O 
evident O 
on O 
the O 
values O 
of O 
bond O 
lengths O 
and O 
bond O 
angles O 
of O 
the O 
amide B-FAMILY 
planes O 
. O 

and O 
application O 
of O 
FePt B-FORMULA 
/ O 
CNTs O 
nanocomposite O 
as O 
a O 
sensor O 
and O 
novel O 
amide B-FAMILY 
ligand O 
as O 
a O 
mediator O 
for O 
simultaneous O 
determination O 
of O 
glutathione B-TRIVIAL 
, O 
nicotinamide B-TRIVIAL 
adenine I-TRIVIAL 
dinucleotide I-TRIVIAL 
and O 
tryptophan B-TRIVIAL 
. O 

this O 
study O 
, O 
we O 
report O 
the O 
synthesis O 
and O 
application O 
of O 
a O 
FePt B-FORMULA 
/ O 
CNTs O 
nanocomposite O 
as O 
a O 
highly O 
sensitive O 
sensor O 
and O 
novel O 
amide B-FAMILY 
ligand O 
(9,10-dihydro-9,10-ethanoanthracene-11,12-dicarboximido)-4-ethylbenzene-1,2-diol B-SYSTEMATIC 
as O 
a O 
mediator O 
for O 
the O 
determination O 
of O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
nicotinamide B-TRIVIAL 
adenine I-TRIVIAL 
dinucleotide I-TRIVIAL 
( O 
NADH B-ABBREVIATION 
) O 
and O 
tryptophan B-TRIVIAL 
( O 
Trp B-FORMULA 
) O 
. O 
The O 
synthesized O 
materials O 
were O 
characterized O 
with O 
different O 
methods O 
such O 
as O 
NMR O 
, O 
IR O 
spectroscopy O 
, O 
TEM O 
, O 
XRD O 
, O 
FESEM O 
, O 
cyclic O 
voltammetry O 
, O 
electrochemical O 
impedance O 
spectroscopy O 
and O 
square O 
wave O 
voltammetry O 
( O 
SWV O 
) O 
. O 
The O 
modified O 
electrode O 
exhibited O 
a O 
potent O 
and O 
persistent O 
electron O 
mediating O 
behavior O 
followed O 
by O 
well O 
- O 
separated O 
oxidation O 
peaks O 
of O 
GSH B-ABBREVIATION 
, O 
NADH B-ABBREVIATION 
and O 
Trp B-FORMULA 
. O 
The O 
peak O 
currents O 
were O 
linearly O 
dependent O 
on O 
GSH B-ABBREVIATION 
, O 
NADH B-ABBREVIATION 
and O 
Trp B-FORMULA 
concentrations O 
in O 
the O 
range O 
of O 
0.08-220 O 
, O 
1.0-400 O 
and O 
5.0-500 O 
μmol O 
L(-1) O 
, O 
with O 
detection O 
limits O 
of O 
0.05 O 
, O 
0.8 O 
and O 
1 O 
μmol O 
L(-1) O 
, O 
respectively O 
. O 
The O 
modified O 
electrode O 
was O 
used O 
for O 
the O 
determination O 
of O 
these O 
compounds O 
in O 
real O 
samples O 
. O 

of O 
human O 
pregnane B-TRIVIAL 
X O 
receptor O 
by O 
rilpivirine B-TRIVIAL 
and O 
etravirine B-TRIVIAL 
: O 
Comparison O 
with O 
first O 
generation O 
non- O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitors O 
. O 

and O 
etravirine B-TRIVIAL 
are O 
second O 
generation O 
non- O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitors O 
approved O 
recently O 
by O 
the O 
United O 
States O 
Food O 
and O 
Drug O 
Administration O 
for O 
the O 
treatment O 
of O 
human O 
immunodeficiency O 
virus-1 O 
infection O 
. O 
Pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
is O 
a O 
member O 
of O 
the O 
superfamily O 
of O 
nuclear O 
receptors O 
that O 
regulate O 
the O 
expression O 
of O 
various O 
genes O 
controlling O 
diverse O 
biological O 
functions O 
. O 
The O 
present O 
study O 
investigated O 
the O 
effects O 
of O 
rilpivirine B-TRIVIAL 
and O 
etravirine B-TRIVIAL 
on O 
the O 
activity O 
of O 
human O 
PXR O 
( O 
hPXR O 
) O 
, O 
including O 
the O 
mode O 
of O 
activation O 
, O 
and O 
compared O 
them O 
to O 
those O 
of O 
efavirenz B-TRIVIAL 
, O 
nevirapine B-TRIVIAL 
, O 
and O 
delavirdine B-TRIVIAL 
, O 
which O 
are O 
first O 
generation O 
non- O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitors O 
. O 
In O 
transiently O 
transfected O 
HepG2 O 
cells O 
, O 
rilpivirine B-TRIVIAL 
, O 
etravirine B-TRIVIAL 
, O 
and O 
efavirenz B-TRIVIAL 
, O 
but O 
not O 
nevirapine B-TRIVIAL 
or O 
delavirdine B-TRIVIAL 
, O 
activated O 
human O 
, O 
mouse O 
, O 
and O 
rat O 
PXR O 
. O 
Results O 
from O 
mechanistic O 
studies O 
indicated O 
that O 
rilpivirine B-TRIVIAL 
, O 
etravirine B-TRIVIAL 
, O 
and O 
efavirenz B-TRIVIAL 
, O 
but O 
not O 
nevirapine B-TRIVIAL 
or O 
delavirdine B-TRIVIAL 
, O 
bound O 
to O 
the O 
ligand O 
- O 
binding O 
domain O 
of O 
hPXR O 
, O 
as O 
assessed O 
by O 
a O 
transactivation O 
assay O 
and O 
by O 
a O 
competitive O 
ligand O 
- O 
binding O 
assay O 
using O 
time O 
- O 
resolved O 
fluorescence O 
resonance O 
energy O 
transfer O 
; O 
triggered O 
nuclear O 
translocation O 
of O 
a O 
green O 
fluorescence O 
protein O 
- O 
tagged O 
hPXR O 
, O 
as O 
visualized O 
by O 
confocal O 
imaging O 
; O 
and O 
recruited O 
steroid B-FAMILY 
receptor O 
coactivator-1 O 
( O 
SRC-1 O 
) O 
, O 
SRC-2 O 
, O 
and O 
SRC-3 O 
to O 
hPXR O 
, O 
as O 
demonstrated O 
by O 
mammalian O 
two O 
- O 
hybrid O 
assays O 
. O 
Rilpivirine B-TRIVIAL 
, O 
etravirine B-TRIVIAL 
, O 
and O 
efavirenz B-TRIVIAL 
, O 
but O 
not O 
nevirapine B-TRIVIAL 
or O 
delavirdine B-TRIVIAL 
, O 
increased O 
hPXR O 
target O 
gene O 
( O 
CYP3A4 O 
) O 
expression O 
in O 
primary O 
cultures O 
of O 
human O 
hepatocytes O 
. O 
In O 
summary O 
, O 
select O 
non- O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitors O 
activated O 
human O 
and O 
rodent O 
PXR O 
. O 
Rilpivirine B-TRIVIAL 
, O 
etravirine B-TRIVIAL 
, O 
and O 
efavirenz B-TRIVIAL 
, O 
but O 
not O 
nevirapine B-TRIVIAL 
or O 
delavirdine B-TRIVIAL 
, O 
were O 
identified O 
as O 
agonists O 
of O 
hPXR O 
, O 
as O 
assessed O 
in O 
mechanistic O 
experiments O 
, O 
and O 
inducers O 
of O 
CYP3A4 O 
, O 
as O 
determined O 
in O 
primary O 
cultures O 
of O 
human O 
hepatocytes O 
. O 

development O 
of O 
insulin O 
resistance O 
is O 
tightly O 
linked O 
to O 
fatty O 
liver O 
disease O 
and O 
is O 
considered O 
a O 
major O 
health O 
concern O 
worldwide O 
, O 
although O 
their O 
mechanistic O 
relationship O 
remains O 
controversial O 
. O 
Activin O 
has O 
emerging O 
roles O 
in O 
nutrient O 
homeostasis O 
but O 
its O 
metabolic O 
effects O 
on O 
hepatocytes O 
remain O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
increased O 
endogenous O 
activin O 
bioactivity O 
on O 
hepatic O 
nutrient O 
homeostasis O 
by O 
creating O 
mice O 
with O 
inactivating O 
mutations O 
that O 
deplete O 
the O 
circulating O 
activin O 
antagonists O 
, O 
follistatin O 
like-3 O 
( O 
FSTL3 O 
) O 
or O 
the O 
follistatin O 
315 O 
isoform O 
( O 
FST315 O 
; O 
FST288 O 
- O 
only O 
mice O 
) O 
. O 
We O 
investigated O 
liver O 
histology O 
and O 
lipid O 
content O 
, O 
hepatic O 
insulin O 
sensitivity O 
, O 
and O 
metabolic O 
gene O 
expression O 
including O 
the O 
HepG2 O 
cell O 
and O 
primary O 
hepatocyte O 
response O 
to O 
activin O 
treatment O 
. O 
Both O 
FSTL3KO O 
and O 
FST288 O 
- O 
only O 
mice O 
had O 
extensive O 
hepatic O 
steatosis O 
and O 
elevated O 
hepatic O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
content O 
. O 
Unexpectedly O 
, O 
insulin O 
signaling O 
, O 
as O 
assessed O 
by O 
phospho-AKT O 
, O 
was O 
enhanced O 
in O 
both O 
mouse O 
models O 
. O 
Pretreatment O 
of O 
HepG2 O 
cells O 
with O 
activin O 
A O 
increased O 
their O 
response O 
to O 
subsequent O 
insulin O 
challenge O 
. O 
Gene O 
expression O 
analysis O 
suggests O 
that O 
increased O 
lipid O 
uptake O 
, O 
enhanced O 
de O 
novo O 
lipid O 
synthesis O 
, O 
decreased O 
lipolysis O 
and O 
/ O 
or O 
enhanced O 
glucose B-TRIVIAL 
uptake O 
contribute O 
to O 
increased O 
hepatic O 
TG O 
content O 
in O 
these O 
models O 
. O 
However O 
, O 
activin O 
treatment O 
recapitulated O 
only O 
some O 
of O 
these O 
gene O 
changes O 
suggesting O 
that O 
increased O 
activin O 
bioactivity O 
may O 
be O 
only O 
partially O 
responsible O 
for O 
this O 
phenotype O 
. O 
Nevertheless O 
, O 
our O 
results O 
indicate O 
that O 
activin O 
enhances O 
hepatocyte O 
insulin O 
response O 
which O 
ultimately O 
leads O 
to O 
hepatic O 
steatosis O 
despite O 
the O 
increased O 
insulin O 
sensitivity O 
. O 
Thus O 
, O 
regulation O 
of O 
activin O 
bioactivity O 
is O 
critical O 
for O 
maintaining O 
normal O 
liver O 
lipid O 
homeostasis O 
and O 
response O 
to O 
insulin O 
while O 
activin O 
agonists O 
may O 
be O 
useful O 
for O 
increasing O 
liver O 
insulin O 
sensitivity O 
. O 

bioactivation O 
and O 
covalent O 
binding O 
in O 
the O 
skin O 
. O 

( O 
NVP B-ABBREVIATION 
) O 
treatment O 
is O 
associated O 
with O 
serious O 
skin O 
rashes O 
that O 
appear O 
to O 
be O 
immune O 
- O 
mediated O 
. O 
We O 
previously O 
developed O 
a O 
rat O 
model O 
of O 
this O 
skin O 
rash O 
that O 
is O 
immune O 
- O 
mediated O 
and O 
is O 
very O 
similar O 
to O 
the O 
rash O 
in O 
humans O 
. O 
Treatment O 
of O 
rats O 
with O 
the O 
major O 
NVP B-ABBREVIATION 
metabolite O 
, O 
12-OH-NVP B-SYSTEMATIC 
, O 
also O 
caused O 
the O 
rash O 
. O 
Most O 
idiosyncratic O 
drug O 
reactions O 
are O 
caused O 
by O 
reactive O 
metabolites O 
; O 
12-OH-NVP B-SYSTEMATIC 
forms O 
a O 
benzylic B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
which O 
was O 
detected O 
in O 
the O 
blood O 
of O 
animals O 
treated O 
with O 
NVP B-ABBREVIATION 
or O 
12-OH-NVP B-SYSTEMATIC 
. O 
This O 
sulfate B-SYSTEMATIC 
is O 
presumably O 
formed O 
in O 
the O 
liver O 
; O 
however O 
, O 
the O 
skin O 
also O 
has O 
significant O 
sulfotransferase O 
activity O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
a O 
serum O 
against O 
NVP B-ABBREVIATION 
to O 
detect O 
covalent O 
binding O 
in O 
the O 
skin O 
of O 
rats O 
. O 
There O 
was O 
a O 
large O 
artifact O 
band O 
in O 
immunoblots O 
of O 
whole O 
skin O 
homogenates O 
that O 
interfered O 
with O 
detection O 
of O 
covalent O 
binding O 
; O 
however O 
, O 
when O 
the O 
skin O 
was O 
separated O 
into O 
dermal O 
and O 
epidermal O 
fractions O 
, O 
covalent O 
binding O 
was O 
clearly O 
present O 
in O 
the O 
epidermis O 
, O 
which O 
is O 
also O 
the O 
location O 
of O 
sulfotransferases O 
. O 
In O 
contrast O 
to O 
rats O 
, O 
treatment O 
of O 
mice O 
with O 
NVP B-ABBREVIATION 
did O 
not O 
result O 
in O 
covalent O 
binding O 
in O 
the O 
skin O 
or O 
skin O 
rash O 
. O 
Although O 
the O 
reaction O 
of O 
12-OH-NVP B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
with O 
nucleophiles O 
such O 
as O 
glutathione B-TRIVIAL 
is O 
slow O 
, O 
incubation O 
of O 
this O 
sulfate B-SYSTEMATIC 
with O 
homogenized O 
human O 
and O 
rat O 
skin O 
led O 
to O 
extensive O 
covalent O 
binding O 
. O 
Incubations O 
of O 
12-OH-NVP B-SYSTEMATIC 
with O 
the O 
soluble O 
fraction O 
from O 
a O 
9,000g O 
centrifugation O 
( O 
S9 O 
) O 
of O 
rat O 
or O 
human O 
skin O 
homogenate O 
in O 
the O 
presence O 
of O 
3'-phosphoadenosine-5'-phosphosulfate B-SYSTEMATIC 
( O 
PAPS B-ABBREVIATION 
) O 
produced O 
extensive O 
covalent O 
binding O 
, O 
but O 
no O 
covalent O 
binding O 
was O 
detected O 
with O 
mouse O 
skin O 
S9 O 
, O 
which O 
suggests O 
that O 
the O 
reason O 
mice O 
do O 
not O 
develop O 
a O 
rash O 
is O 
that O 
they O 
lack O 
the O 
required O 
sulfotransferase O 
. O 
This O 
is O 
the O 
first O 
study O 
to O 
report O 
covalent O 
binding O 
of O 
NVP B-ABBREVIATION 
to O 
rat O 
and O 
human O 
skin O 
. O 
These O 
data O 
provide O 
strong O 
evidence O 
that O 
covalent O 
binding O 
of O 
NVP B-ABBREVIATION 
in O 
the O 
skin O 
is O 
due O 
to O 
12-OH-NVP B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
which O 
is O 
likely O 
responsible O 
for O 
NVP B-ABBREVIATION 
-induced O 
skin O 
rash O 
. O 
Sulfation O 
may O 
represent O 
a O 
bioactivation O 
pathway O 
for O 
other O 
drugs O 
that O 
cause O 
a O 
skin O 
rash O 
. O 

human O 
telomeric O 
protein O 
TRF2 O 
is O 
required O 
to O 
protect O 
chromosome O 
ends O 
by O 
facilitating O 
their O 
organization O 
into O 
the O 
protective O 
capping O 
structure O 
. O 
Post O 
- O 
translational O 
modifications O 
of O 
TRF2 O 
such O 
as O 
phosphorylation O 
, O 
ubiquitination O 
, O 
SUMOylation O 
, O 
methylation O 
and O 
poly( O 
ADP B-ABBREVIATION 
-ribosyl)ation O 
have O 
been O 
shown O 
to O 
play O 
important O 
roles O 
in O 
telomere O 
function O 
. O 
Here O 
we O 
show O 
that O 
TRF2 O 
specifically O 
interacts O 
with O 
the O 
histone O 
acetyltransferase O 
p300 O 
, O 
and O 
that O 
p300 O 
acetylates O 
the O 
lysine B-TRIVIAL 
residue O 
at O 
position O 
293 O 
of O 
TRF2 O 
. O 
We O 
also O 
report O 
that O 
p300 O 
- O 
mediated O 
acetylation O 
stabilizes O 
the O 
TRF2 O 
protein O 
by O 
inhibiting O 
its O 
ubiquitin O 
- O 
dependent O 
proteolysis O 
and O 
is O 
required O 
for O 
efficient O 
telomere O 
binding O 
of O 
TRF2 O 
. O 
Furthermore O 
, O 
overexpression O 
of O 
the O 
acetylation O 
- O 
deficient O 
mutant O 
, O 
K293R O 
, O 
induces O 
DNA-damage O 
response O 
foci O 
at O 
telomeres O 
, O 
thereby O 
leading O 
to O 
induction O 
of O 
impaired O 
cell O 
growth O 
, O 
cellular O 
senescence O 
and O 
altered O 
cell O 
cycle O 
distribution O 
. O 
A O 
small O 
but O 
significant O 
number O 
of O 
metaphase O 
chromosomes O 
show O 
no O 
telomeric O 
signals O 
at O 
chromatid O 
ends O 
, O 
suggesting O 
an O 
aberrant O 
telomere O 
structure O 
. O 
These O 
findings O 
demonstrate O 
that O 
acetylation O 
of O 
TRF2 O 
by O 
p300 O 
plays O 
a O 
crucial O 
role O 
in O 
the O 
maintenance O 
of O 
functional O 
telomeres O 
as O 
well O 
as O 
in O 
the O 
regulation O 
of O 
the O 
telomere O 
- O 
associated O 
DNA-damage O 
response O 
, O 
thus O 
providing O 
a O 
new O 
route O 
for O 
modulating O 
telomere O 
protection O 
function O 
. O 

A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
, O 
Cytotoxic O 
Alkaloids O 
from O 
the O 
Endophytic O 
Fungus O 
Mycoleptodiscus O 
sp O 
. O 
F0194 O 
. O 

novel O 
reddish O 
- O 
orange O 
alkaloids O 
, O 
mycoleptodiscin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
and O 
mycoleptodiscin B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
liquid O 
cultures O 
of O 
the O 
endophytic O 
fungus O 
Mycoleptodiscus O 
sp O 
. O 
that O 
had O 
been O 
isolated O 
from O 
Desmotes O 
incomparabilis O 
in O 
Panama O 
. O 
Elucidation O 
of O 
their O 
structures O 
was O 
accomplished O 
using O 
1D O 
and O 
2D O 
NMR O 
spectroscopy O 
in O 
combination O 
with O 
IR O 
spectroscopic O 
and O 
MS O 
data O 
. O 
These O 
compounds O 
are O 
indole B-SYSTEMATIC 
- O 
terpenes B-FAMILY 
with O 
a O 
new O 
skeleton O 
uncommon O 
in O 
nature O 
. O 
Mycoleptodiscin B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
was O 
active O 
in O 
inhibiting O 
the O 
growth O 
of O 
cancer O 
cell O 
lines O 
with O 
IC50 O 
values O 
in O 
the O 
range O 
0.60-0.78 O 
μM O 
. O 

the O 
polyamine B-FAMILY 
regulatory O 
site O 
of O 
the O 
NMDA B-ABBREVIATION 
receptor O 
: O 
a O 
parallel O 
synthesis O 
approach O 
. O 

elongated O 
structures O 
of O 
polyamine B-FAMILY 
inverse O 
agonists O 
such O 
as O 
1,12-diaminododecane B-SYSTEMATIC 
( O 
N12N B-SYSTEMATIC 
) O 
and O 
5-(4-aminobutyl)-2-thiopheneoctanamine B-SYSTEMATIC 
( O 
N4T8N B-SYSTEMATIC 
) O 
lend O 
themselves O 
to O 
a O 
combinatorial O 
chemistry O 
approach O 
to O 
explore O 
a O 
potential O 
polyamine B-FAMILY 
pharmacophore O 
at O 
the O 
NMDA B-ABBREVIATION 
receptor O 
. O 
Herein O 
we O 
describe O 
more O 
than O 
100 O 
new O 
analogues O 
of O 
N4T8N B-SYSTEMATIC 
obtained O 
by O 
breaking O 
up O 
the O 
long O 
octanamine B-SYSTEMATIC 
arm O 
into O 
a O 
dipeptide O 
chain O 
of O 
equivalent O 
length O 
. O 
Solid O 
- O 
phase O 
parallel O 
synthesis O 
based O 
on O 
cross O 
- O 
linked O 
polystyrene B-SYSTEMATIC 
and O 
a O 
Wang O 
anchor O 
allowed O 
the O 
low O 
- O 
scale O 
preparation O 
of O 
four O 
small O 
libraries O 
based O 
on O 
the O 
combination O 
of O 
two O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
( O 
out O 
of O 
Gly B-FORMULA 
, O 
Leu B-FORMULA 
, O 
Phe B-FORMULA 
, O 
Lys B-FORMULA 
, O 
phenylglycine B-SYSTEMATIC 
, O 
Tyr B-FORMULA 
, O 
Trp B-FORMULA 
, O 
His B-FORMULA 
, O 
and O 
Arg B-FORMULA 
) O 
. O 
The O 
obtained O 
compounds O 
were O 
tested O 
as O 
modulators O 
of O 
[ B-SYSTEMATIC 
( I-SYSTEMATIC 
3 I-SYSTEMATIC 
) I-SYSTEMATIC 
H]MK-801 I-SYSTEMATIC 
binding O 
to O 
rat O 
brain O 
membranes O 
and O 
of O 
NMDA B-ABBREVIATION 
-induced O 
currents O 
in O 
cultured O 
rat O 
hippocampal O 
neurons O 
. O 
Compounds O 
with O 
two O 
aromatic O 
residues O 
acted O 
as O 
binding O 
inhibitors O 
( O 
inverse O 
agonists O 
) O 
. O 
Compounds O 
with O 
two O 
Lys B-FORMULA 
residues O 
acted O 
as O 
binding O 
stimulators O 
( O 
agonists O 
) O 
and O 
had O 
stimulatory O 
and O 
inhibitory O 
effects O 
on O 
NMDA B-ABBREVIATION 
-induced O 
currents O 
, O 
depending O 
on O 
the O 
holding O 
potential O 
. O 
High O 
sensitivity O 
of O 
binding O 
inhibition O 
to O 
spermine B-TRIVIAL 
was O 
conferred O 
by O 
a O 
Tyr B-FORMULA 
residue O 
, O 
whereas O 
a O 
His B-FORMULA 
residue O 
favored O 
high O 
potency O 
at O 
acidic O 
pH O 
. O 

is O 
an O 
antibacterial O 
agent O 
capable O 
of O 
killing O 
methicillin B-TRIVIAL 
-resistant O 
vancomycin B-TRIVIAL 
-intermediate O 
Staphylococcus O 
aureus O 
in O 
the O 
nanomolar O 
range O 
. O 

, O 
there O 
is O 
a O 
pressing O 
need O 
for O 
novel O 
antibacterial O 
agents O 
against O 
drug O 
- O 
resistant O 
bacteria O 
, O 
especially O 
those O 
which O 
have O 
been O 
common O 
in O 
our O 
communities O 
and O 
hospitals O 
, O 
such O 
as O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
. O 
The O 
South O 
American O 
plant O 
Achyrocline O 
satureioides O 
( O 
" O 
Marcela O 
" O 
) O 
has O 
been O 
widely O 
used O 
in O 
traditional O 
medicine O 
for O 
a O 
number O 
of O 
diseases O 
, O 
including O 
infections O 
. O 
Several O 
crude O 
extracts O 
from O 
this O 
plant O 
have O 
shown O 
good O 
antimicrobial O 
activities O 
in O 
vitro O 
. O 
In O 
the O 
search O 
for O 
the O 
active O 
principle(s) O 
that O 
confers O 
these O 
antimicrobial O 
activities O 
, O 
we O 
have O 
processed O 
the O 
dichloromethane B-SYSTEMATIC 
extract O 
from O 
the O 
aerial O 
parts O 
of O 
the O 
plant O 
. O 
One O 
of O 
the O 
isolated O 
compounds O 
showed O 
extraordinary O 
antibacterial O 
activities O 
against O 
a O 
set O 
of O 
clinically O 
relevant O 
Gram O 
- O 
positive O 
strains O 
that O 
widely O 
differ O 
in O 
their O 
antibiogram O 
profiles O 
. O 
This O 
compound O 
was O 
identified O 
as O 
achyrofuran B-TRIVIAL 
on O 
the O 
basis O 
of O 
its O 
spectroscopic O 
and O 
physical O 
data O 
. O 
We O 
determined O 
the O 
MIC O 
to O 
be O 
around O 
0.1 O 
μM O 
( O 
0.07 O 
μg O 
/ O 
ml O 
) O 
for O 
the O 
reference O 
methicillin B-TRIVIAL 
-resistant O 
and O 
vancomycin B-TRIVIAL 
-intermediate O 
S O 
. O 
aureus O 
strain O 
NRS402 O 
. O 
Moreover O 
, O 
nanomolar O 
concentrations O 
of O 
achyrofuran B-TRIVIAL 
killed O 
10(6) O 
bacteria O 
within O 
12 O 
h O 
. O 
Based O 
on O 
the O 
presence O 
of O 
the O 
2,2'-biphenol B-SYSTEMATIC 
core O 
, O 
we O 
further O 
studied O 
whether O 
achyrofuran B-TRIVIAL 
killed O 
bacteria O 
through O 
a O 
mechanism O 
of O 
action O 
similar O 
to O 
that O 
reported O 
for O 
the O 
naturally O 
occurring O 
antibiotic O 
MC21-A B-IDENTIFIER 
. O 
Indeed O 
, O 
we O 
found O 
that O 
achyrofuran B-TRIVIAL 
was O 
not O 
bacteriolytic O 
by O 
itself O 
although O 
it O 
greatly O 
compromised O 
membrane O 
impermeability O 
as O 
determined O 
by O 
increased O 
SYTOX B-NO_CLASS 
Green I-NO_CLASS 
uptake O 
. O 

Filtration O 
Rate O 
Equations O 
Overestimate O 
Creatinine B-TRIVIAL 
Clearance O 
in O 
Older O 
Individuals O 
Enrolled O 
in O 
the O 
Baltimore O 
Longitudinal O 
Study O 
on O 
Aging O 
: O 
Impact O 
on O 
Renal O 
Drug O 
Dosing O 
. O 

: O 
To O 
evaluate O 
the O 
performance O 
of O 
kidney O 
function O 
estimation O 
equations O 
and O 
to O 
determine O 
the O 
frequency O 
of O 
drug O 
dose O 
discordance O 
in O 
an O 
older O 
population O 
. O 
DESIGN O 
: O 
Cross O 
- O 
sectional O 
analysis O 
of O 
data O 
from O 
community O 
- O 
dwelling O 
volunteers O 
randomly O 
selected O 
from O 
the O 
Baltimore O 
Longitudinal O 
Study O 
of O 
Aging O 
from O 
January O 
1 O 
, O 
2005 O 
, O 
to O 
December O 
31 O 
, O 
2010 O 
. O 
SUBJECTS O 
: O 
A O 
total O 
of O 
269 O 
men O 
and O 
women O 
with O 
a O 
mean O 
± O 
SD O 
age O 
of O 
81 O 
± O 
6 O 
years O 
, O 
mean O 
serum O 
creatinine B-TRIVIAL 
concentration O 
( O 
Scr O 
) O 
of O 
1.1 O 
± O 
0.4 O 
mg O 
/ O 
dl O 
, O 
and O 
mean O 
24-hour O 
measured O 
creatinine B-TRIVIAL 
clearance O 
( O 
mClcr O 
) O 
of O 
53 O 
± O 
13 O 
ml O 
/ O 
minute O 
. O 
MEASUREMENTS O 
AND O 
MAIN O 
RESULTS O 
: O 
Kidney O 
function O 
was O 
estimated O 
by O 
using O 
the O 
following O 
equations O 
: O 
Cockcroft-Gault O 
( O 
CG O 
) O 
, O 
Modification O 
of O 
Diet O 
in O 
Renal O 
Disease O 
( O 
MDRD O 
) O 
, O 
and O 
Chronic O 
Kidney O 
Disease O 
Epidemiology O 
Collaboration O 
( O 
CKD-EPI O 
) O 
. O 
The O 
performance O 
of O 
each O 
equation O 
was O 
assessed O 
by O 
measuring O 
bias O 
and O 
precision O 
relative O 
to O 
mClcr O 
. O 
Dose O 
calculation O 
errors O 
( O 
discordance O 
) O 
were O 
determined O 
for O 
10 O 
drugs O 
requiring O 
renal O 
dosage O 
adjustments O 
to O 
avoid O 
toxicity O 
when O 
compared O 
with O 
the O 
dosages O 
approved O 
by O 
the O 
Food O 
and O 
Drug O 
Administration O 
. O 
The O 
CG O 
equation O 
was O 
the O 
least O 
biased O 
estimate O 
of O 
mClcr O 
. O 
The O 
MDRD O 
and O 
CKD-EPI O 
equations O 
were O 
significantly O 
positively O 
biased O 
compared O 
with O 
CG O 
( O 
mean O 
± O 
SD O 
34 O 
± O 
20% O 
and O 
22 O 
± O 
15% O 
, O 
respectively O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
mClcr O 
( O 
29 O 
± O 
47% O 
and O 
18 O 
± O 
40% O 
, O 
respectively O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Rounding O 
low O 
Scr O 
values O 
( O 
less O 
than O 
1 O 
mg O 
/ O 
dl O 
) O 
up O 
to O 
an O 
arbitrary O 
value O 
of O 
1 O 
mg O 
/ O 
dl O 
resulted O 
in O 
CG O 
values O 
( O 
44 O 
± O 
10 O 
ml O 
/ O 
minute O 
) O 
that O 
were O 
significantly O 
lower O 
than O 
mClcr O 
( O 
56 O 
± O 
12 O 
ml O 
/ O 
minute O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
CG O 
( O 
56 O 
± O 
15 O 
ml O 
/ O 
minute O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
The O 
MDRD O 
and O 
CKD-EPI O 
equations O 
had O 
median O 
dose O 
discordance O 
rates O 
of O 
28.6% O 
and O 
22.9% O 
, O 
respectively O 
. O 
CONCLUSION O 
: O 
The O 
MDRD O 
and O 
CKD-EPI O 
equations O 
significantly O 
overestimated O 
creatinine B-TRIVIAL 
clearance O 
( O 
mClcr O 
and O 
CG O 
) O 
in O 
elderly O 
individuals O 
. O 
This O 
leads O 
to O 
dose O 
calculation O 
errors O 
for O 
many O 
drugs O 
, O 
particularly O 
in O 
individuals O 
with O 
severe O 
renal O 
impairment O 
. O 
Thus O 
equations O 
estimating O 
glomerular O 
filtration O 
rate O 
should O 
not O 
be O 
substituted O 
in O 
place O 
of O 
the O 
CG O 
equation O 
in O 
older O 
adults O 
for O 
the O 
purpose O 
of O 
renal O 
dosage O 
adjustments O 
. O 
In O 
addition O 
, O 
the O 
common O 
practice O 
of O 
rounding O 
or O 
replacing O 
low O 
Scr O 
values O 
with O 
an O 
arbitrary O 
value O 
of O 
1 O 
mg O 
/ O 
dl O 
for O 
use O 
in O 
the O 
CG O 
equation O 
should O 
be O 
avoided O 
. O 
Additional O 
studies O 
that O 
evaluate O 
alternative O 
eGFR O 
equations O 
in O 
the O 
older O 
populations O 
that O 
incorporate O 
pharmacokinetic O 
and O 
pharmacodynamic O 
outcomes O 
measures O 
are O 
needed O 
. O 

Dynamics O 
and O 
Protein O 
Adhesivity O 
of O 
Alkylamine B-FAMILY 
Self-Assembled O 
Monolayers O 
on O 
Graphene B-TRIVIAL 
. O 

- O 
scale O 
molecular O 
dynamics O 
computer O 
simulations O 
are O 
used O 
to O 
probe O 
the O 
structure O 
, O 
dynamics O 
, O 
and O 
energetics O 
of O 
alkylamine B-FAMILY 
self O 
- O 
assembled O 
monolayer O 
( O 
SAM O 
) O 
films O 
on O 
graphene B-TRIVIAL 
and O 
to O 
model O 
the O 
formation O 
of O 
molecular O 
bilayers O 
and O 
protein O 
complexes O 
on O 
the O 
films O 
. O 
Routes O 
toward O 
the O 
development O 
and O 
exploitation O 
of O 
functionalized O 
graphene B-TRIVIAL 
structures O 
are O 
detailed O 
here O 
, O 
and O 
we O 
show O 
that O 
the O 
SAM O 
architecture O 
can O 
be O 
tailored O 
for O 
use O 
in O 
emerging O 
applications O 
( O 
e.g O 
. O 
, O 
electrically O 
stimulated O 
nerve O 
fiber O 
growth O 
via O 
the O 
targeted O 
binding O 
of O 
specific O 
cell O 
surface O 
peptide O 
sequences O 
on O 
the O 
functionalized O 
graphene B-TRIVIAL 
scaffold O 
) O 
. O 
The O 
simulations O 
quantify O 
the O 
changes O 
in O 
film O 
physisorption O 
on O 
graphene B-TRIVIAL 
and O 
the O 
alkyl B-FAMILY 
chain O 
packing O 
efficiency O 
as O 
the O 
film O 
surface O 
is O 
made O 
more O 
polar O 
by O 
changing O 
the O 
terminal O 
groups O 
from O 
methyl B-SYSTEMATIC 
( O 
- O 
CH(3) B-FORMULA 
) O 
to O 
amine B-SYSTEMATIC 
( O 
- O 
NH(2) B-FORMULA 
) O 
to O 
hydroxyl B-SYSTEMATIC 
( O 
- O 
OH B-FORMULA 
) O 
. O 
The O 
mode O 
of O 
molecule O 
packing O 
dictates O 
the O 
orientation O 
and O 
spacing O 
between O 
terminal O 
groups O 
on O 
the O 
surface O 
of O 
the O 
SAM O 
, O 
which O 
determines O 
the O 
way O 
in O 
which O 
successive O 
layers O 
build O 
up O 
on O 
the O 
surface O 
, O 
whether O 
via O 
the O 
formation O 
of O 
bilayers O 
of O 
the O 
molecule O 
or O 
the O 
immobilization O 
of O 
other O 
(macro)molecules O 
( O 
e.g O 
. O 
, O 
proteins O 
) O 
on O 
the O 
SAM O 
. O 
The O 
simulations O 
show O 
the O 
formation O 
of O 
ordered O 
, O 
stable O 
assemblies O 
of O 
monolayers O 
and O 
bilayers O 
of O 
decylamine B-SYSTEMATIC 
-based O 
molecules O 
on O 
graphene B-TRIVIAL 
. O 
These O 
films O 
can O 
serve O 
as O 
protein O 
adsorption O 
platforms O 
, O 
with O 
a O 
hydrophobin O 
protein O 
showing O 
strong O 
and O 
selective O 
adsorption O 
by O 
binding O 
via O 
its O 
hydrophobic O 
patch O 
to O 
methyl B-SYSTEMATIC 
-terminated O 
films O 
and O 
binding O 
to O 
amine B-SYSTEMATIC 
-terminated O 
films O 
using O 
its O 
more O 
hydrophilic O 
surface O 
regions O 
. O 
Design O 
rules O 
obtained O 
from O 
modeling O 
the O 
atomic O 
- O 
scale O 
structure O 
of O 
the O 
films O 
and O 
interfaces O 
may O 
provide O 
input O 
into O 
experiments O 
for O 
the O 
rational O 
design O 
of O 
assemblies O 
in O 
which O 
the O 
electronic O 
, O 
physicochemical O 
, O 
and O 
mechanical O 
properties O 
of O 
the O 
substrate O 
, O 
film O 
, O 
and O 
protein O 
layer O 
can O 
be O 
tuned O 
to O 
provide O 
the O 
desired O 
functionality O 
. O 

microwave O 
assisted O 
chemical O 
synthesis O 
of O 
Nd₂Fe₁₄B B-FORMULA 
hard O 
magnetic O 
nanoparticles O 
. O 

high O 
coercivity O 
and O 
excellent O 
energy O 
product O 
of O 
Nd2Fe14B B-FORMULA 
hard O 
magnets O 
have O 
led O 
to O 
a O 
large O 
number O 
of O 
high O 
value O 
added O 
industrial O 
applications O 
. O 
Chemical O 
synthesis O 
of O 
Nd2Fe14B B-FORMULA 
nanoparticles O 
is O 
challenging O 
due O 
to O 
the O 
large O 
reduction O 
potential O 
of O 
Nd(3+) B-FORMULA 
and O 
the O 
high O 
tendency O 
for O 
Nd2Fe14B B-FORMULA 
oxidation O 
. O 
We O 
report O 
the O 
novel O 
synthesis O 
of O 
Nd2Fe14B B-FORMULA 
nanoparticles O 
by O 
a O 
microwave O 
assisted O 
combustion O 
process O 
. O 
The O 
process O 
consisted O 
of O 
Nd-Fe-B B-FORMULA 
mixed O 
oxide B-SYSTEMATIC 
preparation O 
by O 
microwave O 
assisted O 
combustion O 
, O 
followed O 
by O 
the O 
reduction O 
of O 
the O 
mixed O 
oxide B-SYSTEMATIC 
by O 
CaH2 B-FORMULA 
. O 
This O 
combustion O 
process O 
is O 
fast O 
, O 
energy O 
efficient O 
and O 
offers O 
facile O 
elemental O 
substitution O 
. O 
The O 
coercivity O 
of O 
the O 
resulting O 
powders O 
was O 
∼8.0 O 
kOe O 
and O 
the O 
saturation O 
magnetization O 
was O 
∼40 O 
emu O 
g(-1) O 
. O 
After O 
removal O 
of O 
CaO B-FORMULA 
by O 
washing O 
, O 
saturation O 
magnetization O 
increased O 
and O 
an O 
energy O 
product O 
of O 
3.57 O 
MGOe O 
was O 
obtained O 
. O 
A O 
range O 
of O 
magnetic O 
properties O 
was O 
obtained O 
by O 
varying O 
the O 
microwave O 
power O 
, O 
reduction O 
temperature O 
and O 
Nd B-FORMULA 
to O 
Fe B-FORMULA 
ratio O 
. O 
A O 
transition O 
from O 
soft O 
to O 
exchange O 
coupled O 
to O 
hard O 
magnetic O 
properties O 
was O 
obtained O 
by O 
varying O 
the O 
composition O 
of O 
NdxFe1-xB8 B-FAMILY 
( O 
x O 
varies O 
from O 
7% O 
to O 
40% O 
) O 
. O 
This O 
synthesis O 
procedure O 
offers O 
an O 
inexpensive O 
and O 
facile O 
platform O 
to O 
produce O 
exchange O 
coupled O 
hard O 
magnets O 
. O 

and O 
Scopolin B-TRIVIAL 
Isolated O 
from O 
Artemisia O 
iwayomogi O 
Suppress O 
Differentiation O 
of O 
Osteoclastic O 
Macrophage O 
RAW O 
264.7 O 
Cells O 
by O 
Scavenging O 
Reactive O 
Oxygen B-SYSTEMATIC 
Species O 
. O 

iwayomogi O 
has O 
been O 
used O 
as O 
a O 
folk O 
medicine O 
for O 
treating O 
various O 
diseases O 
including O 
inflammatory O 
and O 
immune O 
- O 
related O 
diseases O 
. O 
Scopoletin B-TRIVIAL 
( O 
1 O 
) O 
and O 
scopolin B-TRIVIAL 
( O 
2 O 
) O 
were O 
isolated O 
from O 
this O 
species O 
. O 
Scopoletin B-TRIVIAL 
( O 
1 O 
) O 
showed O 
more O 
potent O 
peroxyl B-SYSTEMATIC 
radical O 
- O 
scavenging O 
capacity O 
, O 
reducing O 
capacity O 
, O 
and O 
cellular O 
antioxidant O 
capacity O 
compared O 
to O 
scopolin B-TRIVIAL 
( O 
2 O 
) O 
. O 
The O 
inhibitory O 
effect O 
of O 
1 O 
on O 
the O 
receptor O 
activator O 
of O 
nuclear O 
factor O 
κB O 
ligand O 
- O 
induced O 
osteoclastic O 
differentiation O 
of O 
RAW O 
264.7 O 
macrophage O 
cells O 
was O 
also O 
more O 
potent O 
than O 
that O 
of O 
2 O 
. O 
The O 
production O 
of O 
general O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
superoxide B-TRIVIAL 
anions O 
during O 
differentiation O 
of O 
preosteoclastic O 
RAW O 
264.7 O 
cells O 
into O 
osteoclasts O 
was O 
attenuated O 
by O 
compounds O 
1 O 
and O 
2 O 
. O 
These O 
findings O 
indicate O 
that O 
the O 
suppressive O 
effects O 
of O 
1 O 
and O 
2 O 
on O 
the O 
differentiation O 
of O 
preosteoclastic O 
RAW O 
264.7 O 
cells O 
is O 
partially O 
due O 
to O 
their O 
intracellular O 
antioxidant O 
capacity O 
, O 
as O 
they O 
can O 
scavenge O 
ROS O 
and O 
play O 
an O 
important O 
signaling O 
role O 
in O 
the O 
differentiation O 
process O 
. O 

Carbohydrate B-FAMILY 
Complex O 
Reveals O 
Circulating O 
Metastatic O 
Cells O 
in O 
a O 
Microfluidic O 
Assay O 
. O 

in O 
carbohydrate B-FAMILY 
sequencing O 
technologies O 
reveal O 
the O 
tremendous O 
complexity O 
of O 
the O 
glycome O 
and O 
the O 
role O 
that O 
glycomics O 
might O 
have O 
to O 
bring O 
insight O 
into O 
the O 
biological O 
functions O 
. O 
Carbohydrate B-FAMILY 
-protein O 
interactions O 
, O 
in O 
particular O 
, O 
are O 
known O 
to O 
be O 
crucial O 
to O 
most O 
mammalian O 
physiological O 
processes O 
as O 
mediators O 
of O 
cell O 
adhesion O 
and O 
metastasis O 
, O 
signal O 
transducers O 
, O 
and O 
organizers O 
of O 
protein O 
interactions O 
. O 
An O 
assay O 
is O 
developed O 
here O 
to O 
mimic O 
the O 
multivalency O 
of O 
biological O 
complexes O 
that O 
selectively O 
and O 
sensitively O 
detect O 
carbohydrate B-FAMILY 
-protein O 
interactions O 
. O 
The O 
binding O 
of O 
β-galactosides B-FAMILY 
and O 
galectin-3-a O 
protein O 
that O 
is O 
correlated O 
to O 
the O 
progress O 
of O 
tumor O 
and O 
metastasis O 
- O 
is O 
examined O 
. O 
The O 
efficiency O 
of O 
the O 
assay O 
is O 
related O 
to O 
the O 
expression O 
of O 
the O 
receptor O 
while O 
anchoring O 
to O 
the O 
interaction's O 
strength O 
. O 
Comparative O 
binding O 
experiments O 
reveal O 
molecular O 
binding O 
preferences O 
. O 
This O 
study O 
establishes O 
that O 
the O 
assay O 
is O 
robust O 
to O 
isolate O 
metastatic O 
cells O 
from O 
colon O 
affected O 
patients O 
and O 
paves O 
the O 
way O 
to O 
personalized O 
medicine O 
. O 

polyphenols B-FAMILY 
suppress O 
antigen O 
presentation O 
of O 
ovalbumin O 
by O 
THP-1 O 
- O 
derived O 
dendritic O 
cells O 
. O 

polyphenol B-FAMILY 
extract O 
( O 
AP O 
) O 
and O 
procyanidin B-FAMILY 
contained O 
in O 
AP O 
were O 
investigated O 
for O 
their O 
immunomodulatory O 
effects O 
using O 
THP-1 O 
- O 
derived O 
human O 
dendritic O 
cells O 
( O 
TDDCs O 
) O 
. O 
The O 
expression O 
levels O 
of O 
HLA-DR O 
( O 
MHC O 
class O 
II O 
) O 
and O 
CD86 O 
( O 
costimulatory O 
molecule O 
) O 
were O 
measured O 
as O 
an O 
indicator O 
of O 
antigen O 
presentation O 
in O 
TDDCs O 
. O 
A O 
significant O 
decrease O 
in O 
HLA-DR O 
expression O 
was O 
observed O 
in O 
the O 
AP O 
and O 
fractionated O 
procyanidin B-FAMILY 
-treated O 
cells O 
in O 
the O 
presence O 
of O 
ovalbumin O 
( O 
OVA O 
) O 
, O 
but O 
no O 
effect O 
on O 
CD86 O 
expression O 
was O 
observed O 
. O 
The O 
uptake O 
of O 
OVA O 
was O 
not O 
inhibited O 
by O 
AP O 
treatment O 
, O 
and O 
the O 
gene O 
expression O 
of O 
membrane O 
- O 
associated O 
RING-CH O 
ubiquitin O 
E3 O 
ligase O 
, O 
MARCH1 O 
, O 
was O 
up O 
- O 
regulated O 
by O 
AP O 
treatment O 
. O 
It O 
can O 
therefore O 
be O 
presumed O 
that O 
AP O 
suppresses O 
HLA-DR O 
expression O 
via O 
the O 
ubiquitin O 
- O 
proteasome O 
pathway O 
. O 
Furthermore O 
, O 
the O 
up O 
- O 
regulation O 
of O 
IL-12 O 
and O 
TNF-α O 
was O 
found O 
in O 
the O 
procyanidin B-FAMILY 
trimers O 
- O 
treated O 
cells O 
in O 
the O 
presence O 
of O 
OVA O 
. O 
These O 
results O 
suggest O 
that O 
apple O 
polyphenols B-FAMILY 
would O 
be O 
an O 
effective O 
factor O 
for O 
the O 
development O 
of O 
immunomodulatory O 
agents O 
with O 
suppressive O 
effects O 
of O 
antigen O 
presentation O 
. O 

5-HT2A O 
and O 
metabotropic O 
glutamate B-TRIVIAL 
2 O 
( O 
mGlu2 O 
) O 
are O 
G O 
protein O 
- O 
coupled O 
receptors O 
suspected O 
in O 
the O 
pathophysiology O 
of O 
psychiatric O 
disorders O 
such O 
as O 
schizophrenia O 
, O 
depression O 
and O 
suicide O 
. O 
Previous O 
findings O 
demonstrate O 
that O 
mGlu2 O 
mRNA O 
expression O 
is O 
down O 
- O 
regulated O 
in O 
brain O 
cortical O 
regions O 
of O 
5-HT2A O 
knockout O 
( O 
KO O 
) O 
mice O 
. O 
However O 
, O 
the O 
molecular O 
mechanism O 
responsible O 
for O 
this O 
alteration O 
remains O 
unknown O 
. O 
We O 
show O 
here O 
repressive O 
epigenetic O 
changes O 
at O 
the O 
promoter O 
region O 
of O 
the O 
mGlu2 O 
gene O 
in O 
frontal O 
cortex O 
of O 
5-HT2A-KO O 
mice O 
. O 
Disruption O 
of O 
5-HT2A O 
receptor O 
- O 
dependent O 
signaling O 
in O 
mice O 
was O 
associated O 
with O 
decreased O 
acetylation O 
of O 
histone O 
H3 O 
( O 
H3ac O 
) O 
and O 
H4 O 
( O 
H4ac O 
) O 
, O 
and O 
increased O 
tri O 
- O 
methylation O 
of O 
histone O 
H3 O 
at O 
lysine B-TRIVIAL 
27 O 
( O 
H3K27me3 O 
) O 
at O 
the O 
mGlu2 O 
promoter O 
- O 
epigenetic O 
changes O 
that O 
correlate O 
with O 
transcriptional O 
repression O 
. O 
Neither O 
methylation O 
of O 
histone O 
H3 O 
at O 
lysine B-TRIVIAL 
4 O 
( O 
H3K4me1 O 
/ O 
2 O 
/ O 
3 O 
) O 
nor O 
tri O 
- O 
methylation O 
of O 
histone O 
H3 O 
at O 
lysine B-TRIVIAL 
9 O 
( O 
H3K9me3 O 
) O 
was O 
affected O 
. O 
We O 
found O 
that O 
Egr1 O 
, O 
a O 
transcription O 
factor O 
whose O 
promoter O 
activity O 
was O 
positively O 
regulated O 
by O 
the O 
5-HT2A O 
receptor O 
agonist O 
TCB-2 B-IDENTIFIER 
, O 
binds O 
less O 
to O 
the O 
mGlu2 O 
promoter O 
in O 
frontal O 
cortex O 
of O 
5-HT2A-KO O 
as O 
compared O 
to O 
wild O 
- O 
type O 
mice O 
. O 
Furthermore O 
, O 
expression O 
of O 
mGlu2 O 
was O 
increased O 
by O 
viral O 
- O 
mediated O 
gene O 
transfer O 
of O 
Flag O 
- O 
tagged O 
Egr1 O 
in O 
mouse O 
frontal O 
cortex O 
. O 
Together O 
, O 
these O 
observations O 
suggest O 
that O 
5-HT2A O 
receptor O 
- O 
dependent O 
signaling O 
epigenetically O 
affects O 
mGlu2 O 
transcription O 
in O 
mouse O 
frontal O 
cortex O 
. O 

IIβ O 
deficiency O 
enhances O 
camptothecin B-TRIVIAL 
-induced O 
apoptosis O 
. O 

( O 
CPT B-ABBREVIATION 
) O 
, O 
a O 
topoisomerase O 
( O 
Top O 
) O 
I-targeting O 
drug O 
that O 
stabilizes O 
Top1-DNA O 
covalent O 
adducts O 
, O 
can O 
induce O 
S-phase- O 
specific O 
cytotoxicity O 
due O 
to O 
the O 
arrest O 
of O 
progressing O 
replication O 
forks O 
. O 
However O 
, O 
CPT B-ABBREVIATION 
-induced O 
non-S-phase O 
cytotoxicity O 
is O 
less O 
well O 
characterized O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
identified O 
topoisomerase O 
IIβ O 
( O 
Top2β O 
) O 
as O 
a O 
specific O 
determinant O 
for O 
CPT B-ABBREVIATION 
sensitivity O 
, O 
but O 
not O 
for O 
many O 
other O 
cytotoxic O 
agents O 
, O 
in O 
non-S-phase O 
cells O 
. O 
First O 
, O 
quiescent O 
mouse O 
embryonic O 
fibroblasts O 
( O 
MEFs O 
) O 
lacking O 
Top2β O 
were O 
shown O 
to O 
be O 
hypersensitive O 
to O 
CPT B-ABBREVIATION 
with O 
prominent O 
induction O 
of O 
apoptosis O 
. O 
Second O 
, O 
ICRF-187 B-IDENTIFIER 
, O 
a O 
Top2 O 
catalytic O 
inhibitor O 
known O 
to O 
deplete O 
Top2β O 
, O 
specifically O 
sensitized O 
MEFs O 
to O 
CPT B-ABBREVIATION 
. O 
To O 
explore O 
the O 
molecular O 
basis O 
for O 
CPT B-ABBREVIATION 
hypersensitivity O 
in O 
Top2β-deficient O 
cells O 
, O 
we O 
found O 
that O 
upon O 
CPT B-ABBREVIATION 
exposure O 
, O 
the O 
RNA O 
polymerase O 
II O 
large O 
subunit O 
( O 
RNAP O 
LS O 
) O 
became O 
progressively O 
depleted O 
, O 
followed O 
by O 
recovery O 
to O 
nearly O 
the O 
original O 
level O 
in O 
wild O 
- O 
type O 
MEFs O 
, O 
whereas O 
RNAP O 
LS O 
remained O 
depleted O 
without O 
recovery O 
in O 
Top2β-deficient O 
cells O 
. O 
Concomitant O 
with O 
the O 
reduction O 
of O 
the O 
RNAP O 
LS O 
level O 
, O 
the O 
p53 O 
protein O 
level O 
was O 
greatly O 
induced O 
. O 
Interestingly O 
, O 
RNAP O 
LS O 
depletion O 
has O 
been O 
well O 
documented O 
to O 
lead O 
to O 
p53-dependent O 
apoptosis O 
. O 
Altogether O 
, O 
our O 
findings O 
support O 
a O 
model O 
in O 
which O 
Top2β O 
deficiency O 
promotes O 
CPT B-ABBREVIATION 
-induced O 
apoptosis O 
in O 
quiescent O 
non-S-phase O 
cells O 
, O 
possibly O 
due O 
to O 
RNAP O 
LS O 
depletion O 
and O 
p53 O 
accumulation O 
. O 

papillary O 
injury O 
is O 
a O 
common O 
side O 
effect O 
observed O 
during O 
nonclinical O 
and O 
clinical O 
investigations O 
in O 
drug O 
development O 
. O 
The O 
present O 
study O 
aimed O 
to O 
identify O 
genomic O 
biomarkers O 
for O 
early O 
and O 
sensitive O 
detection O 
of O 
renal O 
papillary O 
injury O 
in O 
rats O 
. O 
We O 
hypothesized O 
that O 
previously O 
identified O 
genomic O 
biomarkers O 
for O 
tubular O 
injury O 
might O 
be O 
applicable O 
for O 
the O 
sensitive O 
detection O 
of O 
papillary O 
injury O 
in O 
rats O 
. O 
We O 
selected O 
18 O 
genes O 
as O 
candidate O 
biomarkers O 
for O 
papillary O 
injury O 
based O 
on O 
previously O 
published O 
studies O 
and O 
analyzed O 
their O 
expression O 
profiles O 
by O 
RT-PCR O 
in O 
each O 
kidney O 
region O 
, O 
namely O 
the O 
cortex O 
, O 
cortico O 
- O 
medullary O 
junction O 
, O 
and O 
papilla O 
in O 
various O 
nephrotoxicity O 
models O 
. O 
Comparative O 
analysis O 
of O 
gene O 
expression O 
profiles O 
revealed O 
that O 
some O 
genes O 
were O 
commonly O 
upregulated O 
or O 
downregulated O 
in O 
the O 
renal O 
papilla O 
, O 
reflecting O 
papillary O 
injuries O 
induced O 
by O 
2-bromoethylamine B-SYSTEMATIC 
hydrobromide I-SYSTEMATIC 
, O 
phenylbutazone B-TRIVIAL 
, O 
or O 
n-phenylanthranilic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
By O 
applying O 
receiver O 
operator O 
characteristics O 
analysis O 
, O 
six O 
candidate O 
biomarkers O 
were O 
identified O 
and O 
their O 
usefulness O 
was O 
confirmed O 
by O 
using O 
an O 
independent O 
data O 
set O 
. O 
The O 
three O 
top O 
- O 
ranked O 
genes O 
, O 
Timp1 O 
, O 
Igf1 O 
, O 
and O 
Lamc2 O 
, O 
exhibited O 
the O 
best O 
prediction O 
performance O 
in O 
an O 
external O 
data O 
set O 
with O 
area O 
under O 
the O 
curve O 
( O 
AUC O 
) O 
values O 
of O 
greater O 
than O 
0.91 O 
. O 
An O 
optimized O 
support O 
vector O 
machine O 
model O 
consisting O 
of O 
three O 
genes O 
achieved O 
the O 
highest O 
AUC O 
value O 
of O 
0.99 O 
. O 
In O 
conclusion O 
, O 
even O 
though O 
definitive O 
validation O 
studies O 
are O 
required O 
for O 
the O 
establishment O 
of O 
their O 
usefulness O 
and O 
reliability O 
, O 
these O 
identified O 
genes O 
may O 
prove O 
to O 
be O 
the O 
most O 
promising O 
candidate O 
genomic O 
biomarkers O 
of O 
renal O 
papillary O 
injury O 
in O 
rats O 
. O 

and O 
cytotoxic O 
evaluation O 
of O 
novel O 
pyrimidine B-FAMILY 
deoxyapiothionucleosides I-FAMILY 
. O 

synthesis O 
of O 
novel O 
pyrimidine B-FAMILY 
deoxyapiothionucleosides I-FAMILY 
of O 
d- O 
and O 
l-series O 
was O 
realized O 
following O 
application O 
of O 
a O 
versatile O 
and O 
high O 
- O 
yielding O 
scheme O 
, O 
which O 
utilized O 
inexpensive O 
l- B-MULTIPLE 
and I-MULTIPLE 
d-arabinose I-MULTIPLE 
as O 
starting O 
materials O 
, O 
respectively O 
, O 
and O 
which O 
makes O 
use O 
of O 
a O 
regio- O 
and O 
stereo O 
- O 
selective O 
Pummerer O 
rearrangement O 
reaction O 
for O 
the O 
coupling O 
of O 
the O 
nucleobase B-FAMILY 
with O 
the O 
thiosugar B-FAMILY 
moiety O 
. O 
Some O 
of O 
the O 
targeted O 
compounds O 
have O 
shown O 
selective O 
cytotoxic O 
effects O 
( O 
with O 
IC50 O 
< O 
10μM O 
) O 
against O 
specific O 
cancer O 
cell O 
lines O 
. O 
All O 
of O 
the O 
tested O 
compounds O 
had O 
no O 
cytotoxic O 
effect O 
on O 
the O 
normal O 
cell O 
line O 
tested O 
. O 

progression O 
and O 
exacerbations O 
of O 
chronic O 
obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
are O 
intimately O 
associated O 
with O 
tobacco O 
smoke O 
/ O 
biomass O 
fuel O 
- O 
induced O 
oxidative O 
and O 
aldehyde B-SYSTEMATIC 
/ O 
carbonyl B-FAMILY 
stress O 
. O 
Alterations O 
in O 
redox O 
signaling O 
proinflammatory O 
kinases O 
and O 
transcription O 
factors O 
, O 
steroid B-FAMILY 
resistance O 
, O 
unfolded O 
protein O 
response O 
, O 
mucus O 
hypersecretion O 
, O 
extracellular O 
matrix O 
remodeling O 
, O 
autophagy O 
/ O 
apoptosis O 
, O 
epigenetic O 
changes O 
, O 
cellular O 
senescence O 
/ O 
aging O 
, O 
endothelial O 
dysfunction O 
, O 
autoimmunity O 
, O 
and O 
skeletal O 
muscle O 
dysfunction O 
are O 
some O 
of O 
the O 
pathological O 
hallmarks O 
of O 
COPD O 
. O 
In O 
light O 
of O 
the O 
above O 
it O 
would O 
be O 
prudent O 
to O 
target O 
systemic O 
and O 
local O 
oxidative O 
stress O 
with O 
agents O 
that O 
can O 
modulate O 
the O 
antioxidants/ O 
redox O 
system O 
or O 
by O 
boosting O 
the O 
endogenous O 
levels O 
of O 
antioxidants O 
for O 
the O 
treatment O 
and O 
management O 
of O 
COPD O 
. O 
Identification O 
of O 
various O 
antioxidant O 
agents O 
, O 
such O 
as O 
thiol B-FAMILY 
molecules O 
( O 
glutathione B-TRIVIAL 
and O 
mucolytic O 
drugs O 
, O 
such O 
as O 
N-acetyl-Lcysteine B-SYSTEMATIC 
, O 
N-acystelyn B-TRIVIAL 
, O 
erdosteine B-TRIVIAL 
, O 
fudosteine B-TRIVIAL 
, O 
ergothioneine B-TRIVIAL 
, O 
and O 
carbocysteine B-TRIVIAL 
lysine I-TRIVIAL 
salt O 
) O 
, O 
dietary O 
natural O 
productderived O 
polyphenols B-FAMILY 
and O 
other O 
compounds O 
( O 
curcumin B-TRIVIAL 
, O 
resveratrol B-TRIVIAL 
, O 
green O 
tea O 
catechins B-FAMILY 
, O 
quercetin B-TRIVIAL 
sulforaphane I-TRIVIAL 
, O 
lycopene B-TRIVIAL 
, O 
acai O 
, O 
alpha-lipoic B-TRIVIAL 
acid I-TRIVIAL 
, O 
tocotrienols B-FAMILY 
, O 
and O 
apocynin B-TRIVIAL 
) O 
have O 
made O 
it O 
possible O 
to O 
modulate O 
various O 
biochemical O 
aspects O 
of O 
COPD O 
. O 
Various O 
researches O 
and O 
clinical O 
trials O 
have O 
revealed O 
that O 
these O 
antioxidants O 
can O 
detoxify O 
free O 
radicals O 
and O 
oxidants O 
, O 
control O 
expression O 
of O 
redox O 
and O 
glutathione B-TRIVIAL 
biosynthesis O 
genes O 
, O 
chromatin O 
remodeling O 
, O 
and O 
ultimately O 
inflammatory O 
gene O 
expression O 
. O 
In O 
addition O 
, O 
modulation O 
of O 
cigarette O 
smoke O 
- O 
induced O 
oxidative O 
stress O 
and O 
related O 
cellular O 
changes O 
have O 
also O 
been O 
reported O 
to O 
be O 
effected O 
by O 
synthetic O 
molecules O 
. O 
This O 
includes O 
specific O 
spin O 
traps O 
like O 
α-phenyl-N-tert-butyl B-SYSTEMATIC 
nitrone I-SYSTEMATIC 
, O 
a O 
catalytic O 
antioxidant O 
( O 
ECSOD O 
mimetic O 
) O 
, O 
porphyrins B-FAMILY 
( O 
AEOL B-IDENTIFIER 
10150 I-IDENTIFIER 
and O 
AEOL B-IDENTIFIER 
10113 I-IDENTIFIER 
) O 
, O 
and O 
a O 
superoxide B-TRIVIAL 
dismutase O 
mimetic O 
M40419 B-IDENTIFIER 
, O 
lipid O 
peroxidation O 
and O 
protein O 
carbonylation O 
blockers O 
/ O 
inhibitors O 
, O 
such O 
as O 
edaravone B-TRIVIAL 
and O 
lazaroids B-FAMILY 
/ O 
tirilazad B-TRIVIAL 
, O 
myeloperoxidase O 
inhibitors O 
, O 
as O 
well O 
as O 
specialized O 
pro O 
- O 
resolving O 
mediators O 
/ O 
inflammatory O 
resolving O 
lipid O 
mediators O 
, O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
vitamin B-FAMILY 
D I-FAMILY 
, O 
and O 
hydrogen B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
. O 
According O 
to O 
various O 
studies O 
it O 
appears O 
that O 
the O 
administration O 
of O 
multiple O 
antioxidants O 
could O 
be O 
a O 
more O 
effective O 
mode O 
used O 
in O 
the O 
treatment O 
of O 
COPD O 
. O 
In O 
this O 
review O 
, O 
various O 
pharmacological O 
and O 
dietary O 
approaches O 
to O 
enhance O 
lung O 
antioxidant O 
levels O 
and O 
beneficial O 
effects O 
of O 
antioxidant O 
therapeutics O 
in O 
treating O 
or O 
intervening O 
the O 
progression O 
of O 
COPD O 
have O 
been O 
discussed O 
. O 

Immunity O 
to O 
Small O 
Tumor-Associated O 
Carbohydrates B-FAMILY 
with O 
Bacteriophage O 
Qβ O 
Capsids O 
. O 

development O 
of O 
an O 
effective O 
immunotherapy O 
is O 
an O 
attractive O 
strategy O 
toward O 
cancer O 
treatment O 
. O 
Tumor O 
associated O 
carbohydrate B-FAMILY 
antigens O 
( O 
TACAs O 
) O 
are O 
overexpressed O 
on O 
a O 
variety O 
of O 
cancer O 
cell O 
surfaces O 
, O 
which O 
present O 
tempting O 
targets O 
for O 
anticancer O 
vaccine O 
development O 
. O 
However O 
, O 
such O 
carbohydrates B-FAMILY 
are O 
often O 
poorly O 
immunogenic O 
. O 
To O 
overcome O 
this O 
challenge O 
, O 
we O 
show O 
here O 
that O 
the O 
display O 
of O 
a O 
very O 
weak O 
TACA O 
, O 
the O 
monomeric O 
Tn O 
antigen O 
, O 
on O 
bacteriophage O 
Qβ O 
virus O 
- O 
like O 
particles O 
elicits O 
powerful O 
humoral O 
responses O 
to O 
the O 
carbohydrate B-FAMILY 
. O 
The O 
effects O 
of O 
adjuvants O 
, O 
antigen O 
display O 
pattern O 
, O 
and O 
vaccine O 
dose O 
on O 
the O 
strength O 
and O 
subclasses O 
of O 
antibody O 
responses O 
were O 
established O 
. O 
The O 
local O 
density O 
of O 
antigen O 
rather O 
than O 
the O 
total O 
amount O 
of O 
antigen O 
administered O 
was O 
found O 
to O 
be O 
crucial O 
for O 
induction O 
of O 
high O 
Tn-specific O 
IgG O 
titers O 
. O 
The O 
ability O 
to O 
display O 
antigens O 
in O 
an O 
organized O 
and O 
high O 
density O 
manner O 
is O 
a O 
key O 
advantage O 
of O 
virus O 
- O 
like O 
particles O 
such O 
as O 
Qβ O 
as O 
vaccine O 
carriers O 
. O 
Glycan O 
microarray O 
analysis O 
showed O 
that O 
the O 
antibodies O 
generated O 
were O 
highly O 
selective O 
toward O 
Tn O 
antigens O 
. O 
Furthermore O 
, O 
Qβ O 
elicited O 
much O 
higher O 
levels O 
of O 
IgG O 
antibodies O 
than O 
other O 
types O 
of O 
virus O 
- O 
like O 
particles O 
, O 
and O 
the O 
IgG O 
antibodies O 
produced O 
reacted O 
strongly O 
with O 
the O 
native O 
Tn O 
antigens O 
on O 
human O 
leukemia O 
cells O 
. O 
Thus O 
, O 
Qβ O 
presents O 
a O 
highly O 
attractive O 
platform O 
for O 
the O 
development O 
of O 
carbohydrate B-FAMILY 
-based O 
anticancer O 
vaccines O 
. O 

multivalent O 
approach O 
towards O 
linked O 
dual O 
- O 
pharmacology O 
prostaglandin B-FAMILY 
F I-FAMILY 
receptor O 
agonist O 
/ O 
carbonic O 
anhydrase-II O 
inhibitors O 
for O 
the O 
treatment O 
of O 
glaucoma O 
. O 

of O 
intra O 
- O 
ocular O 
pressure O 
is O 
the O 
primary O 
pharmacologic O 
approach O 
for O 
the O 
treatment O 
of O 
glaucoma O 
and O 
a O 
number O 
of O 
distinct O 
mechanisms O 
of O 
action O 
have O 
been O 
clinically O 
validated O 
. O 
Targeting O 
of O 
multiple O 
mechanisms O 
in O 
combination O 
therapies O 
has O 
proven O 
effective O 
both O 
clinically O 
and O 
commercially O 
although O 
potential O 
improvements O 
with O 
regards O 
to O 
efficacy O 
, O 
tolerability O 
and O 
dosing O 
frequency O 
remain O 
. O 
Application O 
of O 
Theravance's O 
multivalent O 
approach O 
to O 
drug O 
discovery O 
towards O 
linked O 
dual O 
- O 
pharmacology O 
prostaglandin B-FAMILY 
F I-FAMILY 
receptor O 
( O 
FP O 
) O 
agonist O 
/ O 
carbonic O 
anhydrase O 
(CA)-II O 
inhibitor O 
compounds O 
is O 
described O 
. O 
Compound O 
29 O 
exhibits O 
weak O 
potency O 
( O 
pEC(50)=5.7 O 
, O 
IA O 
> O 
1 O 
) O 
as O 
an O 
FP O 
agonist O 
with O 
high O 
binding O 
affinity O 
( O 
pK(i)=8.1 O 
) O 
to O 
the O 
CA-II O 
enzyme O 
, O 
and O 
has O 
comparable O 
corneal O 
permeability O 
to O 
the O 
CA-II O 
inhibitor O 
dorzolamide B-TRIVIAL 
. O 

Glucuronidation O 
of O 
Ornidazole B-TRIVIAL 
in O 
Humans O 
: O 
Predominant O 
Contribution O 
of O 
UDP B-ABBREVIATION 
-Glucuronosyltransferases O 
1A9 O 
and O 
2B7 O 
. O 

[ O 
R,S-1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol B-SYSTEMATIC 
] O 
is O 
a O 
chiral O 
5-nitroimidazole B-SYSTEMATIC 
class O 
antimicrobial O 
agent O 
. O 
This O 
study O 
aimed O 
to O 
investigate O 
the O 
principal O 
metabolic O 
pathway O 
of O 
ornidazole B-TRIVIAL 
in O 
humans O 
and O 
identify O 
the O 
major O 
enzymes O 
involved O 
. O 
A O 
total O 
of O 
19 O 
metabolites O 
were O 
identified O 
in O 
human O 
urine O 
collected O 
from O 
patients O 
with O 
hepatobiliary O 
diseases O 
after O 
an O 
intravenous O 
drip O 
infusion O 
of O 
500 O 
mg O 
of O 
racemic B-TRIVIAL 
ornidazole I-TRIVIAL 
. O 
Stereoselective O 
glucuronidation O 
, O 
followed O 
by O 
renal O 
excretion O 
, O 
was O 
the O 
principal O 
metabolic O 
pathway O 
of O 
ornidazole B-TRIVIAL 
in O 
humans O 
, O 
accounting O 
for O 
37.3% O 
of O 
the O 
administered O 
dose O 
. O 
Screening O 
assays O 
with O 
12 O 
available O 
human O 
recombinant O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGTs O 
) O 
demonstrated O 
that O 
UGT1A9 O 
was O 
the O 
predominant O 
UGT O 
isoform O 
involved O 
in O 
R-ornidazole B-TRIVIAL 
glucuronidation O 
, O 
whereas O 
S-ornidazole B-TRIVIAL 
glucuronidation O 
was O 
almost O 
exclusively O 
catalyzed O 
by O 
UGT2B7 O 
. O 
Chemical O 
inhibition O 
study O 
with O 
niflumic B-TRIVIAL 
acid I-TRIVIAL 
and O 
flurbiprofen B-TRIVIAL 
supported O 
these O 
findings O 
. O 
Enzyme O 
kinetic O 
parameters O 
were O 
then O 
determined O 
in O 
human O 
liver O 
microsomes O 
( O 
HLMs O 
) O 
, O 
human O 
kidney O 
microsomes O 
( O 
HKMs O 
) O 
, O 
UGT1A9 O 
and O 
2B7 O 
. O 
The O 
Km O 
values O 
for O 
UGT1A9 O 
( O 
15.6 O 
± O 
1.6 O 
mM O 
for O 
R-ornidazole B-TRIVIAL 
) O 
and O 
2B7 O 
( O 
3.8 O 
± O 
0.9 O 
mM O 
for O 
S-ornidazole B-TRIVIAL 
) O 
were O 
quite O 
similar O 
to O 
those O 
determined O 
in O 
HLMs O 
and O 
HKMs O 
( O 
20.1 O 
± O 
1.4 O 
and O 
17.7 O 
± O 
4 O 
mM O 
for O 
R-ornidazole B-TRIVIAL 
; O 
6.6 O 
± O 
1.3 O 
and O 
3.2 O 
± O 
0.4 O 
mM O 
for O 
S-ornidazole B-TRIVIAL 
) O 
. O 
The O 
in O 
vitro O 
intrinsic O 
clearance O 
( O 
CLint O 
) O 
ratios O 
of O 
S- B-MULTIPLE 
and I-MULTIPLE 
R-ornidazole I-MULTIPLE 
were O 
approximately O 
4.3 O 
in O 
HLMs O 
and O 
6.5 O 
in O 
HKMs O 
, O 
respectively O 
. O 
The O 
hepatic O 
and O 
renal O 
clearances O 
were O 
estimated O 
based O 
on O 
the O 
well O 
- O 
stirred O 
model O 
. O 
Overall O 
, O 
stereoselective O 
glucuronidation O 
was O 
the O 
principal O 
metabolic O 
pathway O 
of O 
ornidazole B-TRIVIAL 
in O 
humans O 
. O 
Furthermore O 
, O 
UGT1A9 O 
and O 
2B7 O 
were O 
the O 
predominant O 
UGT O 
isoforms O 
responsible O 
for O 
R- B-MULTIPLE 
and I-MULTIPLE 
S-ornidazole I-MULTIPLE 
glucuronidation O 
in O 
humans O 
, O 
respectively O 
. O 

, O 
isolation O 
and O 
characterisation O 
of O 
cyclolinopeptides B-MULTIPLE 
J I-MULTIPLE 
and I-MULTIPLE 
K I-MULTIPLE 
in O 
ageing O 
flax O 
. O 

sulfone I-SYSTEMATIC 
containing O 
peptides O 
CLs O 
J O 
( O 
11 O 
) O 
and O 
K O 
( O 
12 O 
) O 
may O 
be O 
produced O 
from O 
their O 
reduced O 
forms O 
by O 
oxidation O 
but O 
it O 
is O 
not O 
known O 
if O 
these O 
compounds O 
occur O 
in O 
foods O 
that O 
contain O 
flax O 
. O 
These O 
compounds O 
have O 
been O 
reported O 
to O 
possess O 
greater O 
immunosuppressive O 
activity O 
than O 
their O 
reduced O 
methionine B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
peptide O 
forms O 
4 O 
and O 
6 O 
, O 
respectively O 
. O 
Since O 
11 O 
and O 
12 O 
have O 
not O 
been O 
detected O 
in O 
commercial O 
flax O 
oil O 
and O 
milled O 
flax O 
seed O 
, O 
we O 
tested O 
for O 
their O 
presence O 
in O 
flax O 
food O 
products O 
. O 
Here O 
we O 
report O 
that O 
11 O 
and O 
12 O 
accumulate O 
in O 
ground O 
flaxseed O 
that O 
is O 
exposed O 
to O 
air O 
and O 
heat O 
( O 
100°C O 
) O 
for O 
more O 
than O 
4h O 
. O 
Standards O 
of O 
11 O 
and O 
12 O 
were O 
prepared O 
, O 
isolated O 
and O 
extensively O 
characterised O 
using O 
HPLC-MS O 
/ O 
MS O 
, O 
1D O 
and O 
2D O 
NMR O 
methods O 
. O 
We O 
also O 
report O 
the O 
excellent O 
thermal O 
and O 
oxidative O 
stability O 
of O 
these O 
peptides O 
. O 
Due O 
to O 
the O 
harsh O 
conditions O 
required O 
to O 
produce O 
11 O 
and O 
12 O 
, O 
it O 
is O 
expected O 
that O 
their O 
levels O 
in O 
flax O 
based O 
foods O 
would O 
be O 
low O 
and O 
therefore O 
their O 
presence O 
could O 
serve O 
as O 
an O 
indicative O 
measure O 
of O 
severe O 
oxidation O 
of O 
a O 
food O 
product O 
. O 

- O 
synthesised O 
, O 
atomically O 
- O 
precise O 
gold O 
clusters O 
deposited O 
and O 
activated O 
on O 
titania B-TRIVIAL 
. O 

XPS O 
was O 
used O 
to O 
investigate O 
a O 
series O 
of O 
chemically O 
- O 
synthesised O 
, O 
atomically O 
- O 
precise O 
gold O 
clusters O 
Au(n)(PPh(3))(y) B-FAMILY 
( O 
n O 
= O 
8 O 
, O 
9 O 
, O 
11 O 
and O 
101 O 
, O 
with O 
y O 
depending O 
on O 
cluster O 
size O 
) O 
immobilized O 
on O 
titania B-TRIVIAL 
nanoparticles O 
. O 
The O 
gold O 
clusters O 
were O 
washed O 
with O 
toluene B-TRIVIAL 
at O 
100 O 
°C O 
or O 
calcined O 
at O 
200 O 
°C O 
to O 
remove O 
the O 
organic O 
ligand O 
. O 
From O 
the O 
position O 
of O 
the O 
Au B-FORMULA 
4f(7 O 
/ O 
2 O 
) O 
peak O 
it O 
is O 
concluded O 
that O 
cluster O 
size O 
is O 
not O 
altered O 
through O 
the O 
deposition O 
. O 
From O 
the O 
analysis O 
of O 
the O 
phosphorous B-SYSTEMATIC 
spectra O 
, O 
it O 
can O 
be O 
concluded O 
that O 
the O 
applied O 
heat O 
treatment O 
removes O 
the O 
organic O 
ligands O 
. O 
Washing O 
and O 
calcination O 
leads O 
to O 
partial O 
oxidation O 
and O 
partial O 
agglomeration O 
of O 
the O 
clusters O 
. O 
Oxidation O 
of O 
the O 
clusters O 
is O 
most O 
likely O 
due O 
to O 
the O 
interaction O 
of O 
the O 
cluster O 
core O 
with O 
the O 
oxygen B-SYSTEMATIC 
of O 
the O 
titania B-TRIVIAL 
surface O 
after O 
removal O 
of O 
ligands O 
. O 
The O 
position O 
of O 
the O 
Au B-FORMULA 
4f(7 O 
/ O 
2 O 
) O 
peak O 
indicates O 
that O 
the O 
size O 
of O 
the O 
agglomerated O 
clusters O 
is O 
still O 
smaller O 
than O 
that O 
of O 
Au(101) B-FORMULA 
. O 

of O 
arsenic B-SYSTEMATIC 
induced O 
cytotoxicity O 
in O 
liver O 
with O 
stress O 
in O 
erythrocytes O 
and O 
its O 
reversibility O 
with O 
Pleurotus O 
florida O 
lectin O 
. O 

is O 
one O 
of O 
the O 
most O 
hazardous O 
substances O 
in O 
the O 
environment O 
known O 
to O 
cause O 
toxicity O 
in O 
multiple O 
organs O 
. O 
Cell O 
adhesion O 
, O 
morphological O 
alterations O 
, O 
cell O 
proliferation O 
, O 
terminal O 
deoxyuridine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
nick O 
- O 
end O 
labeling O 
( O 
TUNEL O 
) O 
and O 
caspase-3 O 
/ O 
CPP32 O 
fluorometric O 
protease O 
assay O 
were O 
important O 
biomarkers O 
to O 
assess O 
apoptosis O 
in O 
cells O 
. O 
This O 
study O 
aimed O 
to O 
evaluate O 
arsenic B-SYSTEMATIC 
-induced O 
apoptosis O 
in O 
the O 
hepatocytes O 
of O 
rat O 
and O 
its O 
protective O 
efficacy O 
with O 
coadministration O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
and O 
Pleurotus O 
florida O 
lectin O 
( O 
PFL O 
) O 
individually O 
. O 
Results O 
of O 
the O 
present O 
study O 
also O 
showed O 
that O 
arsenic B-SYSTEMATIC 
caused O 
cytotoxicity O 
by O 
elevating O 
morphological O 
alterations O 
, O 
TUNEL-positive O 
nuclei O 
, O 
caspase-3 O 
activity O 
and O 
DNA O 
damage O 
and O 
reducing O 
cell O 
adhesion O 
and O 
cell O 
proliferation O 
in O 
a O 
time O 
- O 
dependent O 
manner O 
. O 
The O 
apoptosis O 
in O 
hepatocytes O 
was O 
reverted O 
to O 
normal O 
value O 
after O 
coadministration O 
of O 
mushroom O 
lectin O 
in O 
arsenic B-SYSTEMATIC 
-exposed O 
rat O 
. O 
The O 
study O 
provided O 
significant O 
evidence O 
that O 
PFL O 
has O 
antiapoptotic O 
property O 
against O 
arsenic B-SYSTEMATIC 
-induced O 
toxicity O 
. O 
The O 
beneficial O 
effect O 
of O 
PFL O 
was O 
proportional O 
to O 
its O 
duration O 
of O 
exposure O 
. O 
Retard O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
and O 
catalase O 
, O 
enhanced O 
lipid O 
peroxidation O 
as O 
well O 
as O 
protein O 
carbonyl B-FAMILY 
in O 
erythrocytes O 
caused O 
by O 
arsenic B-SYSTEMATIC 
could O 
also O 
be O 
maintained O 
toward O 
normalcy O 
by O 
supplementation O 
of O 
AA O 
and O 
PFL O 
. O 
These O 
antioxidative O 
effects O 
were O 
exhibited O 
in O 
a O 
time O 
- O 
dependant O 
manner O 
. O 
In O 
rat O 
, O 
treatment O 
with O 
AA O 
and O 
PFL O 
prevented O 
alteration O 
of O 
plasma O 
enzyme O 
activities O 
caused O 
by O 
arsenic B-SYSTEMATIC 
. O 
The O 
results O 
concluded O 
that O 
treatment O 
with O 
PFL O 
has O 
significant O 
role O 
in O 
protecting O 
animals O 
from O 
arsenic B-SYSTEMATIC 
-induced O 
erythrocytic O 
damage O 
. O 
This O 
finding O 
might O 
be O 
of O 
therapeutic O 
benefit O 
in O 
people O 
suffering O 
from O 
chronic O 
exposure O 
to O 
arsenic B-SYSTEMATIC 
from O 
natural O 
sources O 
, O 
a O 
global O 
problem O 
especially O 
relevant O 
to O 
millions O 
of O 
people O 
on O 
the O 
Indian O 
subcontinent O 
. O 

and O 
Kinetic O 
Study O 
of O 
the O 
Reaction O 
of O 
Ethyl B-SYSTEMATIC 
Methyl I-SYSTEMATIC 
Ketone I-SYSTEMATIC 
with O 
HO2 B-FORMULA 
for O 
T O 
= O 
600 O 
- O 
1 O 
, O 
600 O 
K O 
. O 
Part O 
II O 
: O 
Addition O 
Reaction O 
Channels O 
. O 

temperature O 
and O 
pressure O 
dependence O 
of O 
the O 
addition O 
reaction O 
of O 
ethyl B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ketone I-SYSTEMATIC 
( O 
EMK B-ABBREVIATION 
) O 
with O 
HO2 B-FORMULA 
radical O 
has O 
been O 
calculated O 
with O 
the O 
master O 
equation O 
method O 
employing O 
conventional O 
transition O 
state O 
theory O 
estimates O 
for O 
the O 
microcanonical O 
rate O 
coefficients O 
in O 
the O 
temperature O 
range O 
of O 
600-1600 O 
K O 
. O 
Geometries O 
, O 
frequencies O 
, O 
and O 
hindrance O 
potentials O 
were O 
obtained O 
at O 
the O 
B3LYP O 
/ O 
6-311G(d,p) O 
level O 
of O 
theory O 
. O 
A O 
modified O 
G3(MP2,CC) O 
method O 
has O 
been O 
used O 
to O 
calculate O 
accurate O 
electronic O 
energies O 
for O 
all O 
of O 
the O 
species O 
involved O 
in O 
the O 
reactions O 
. O 
The O 
rigid O 
- O 
rotor O 
harmonic O 
oscillator O 
approximation O 
has O 
been O 
used O 
for O 
all O 
of O 
the O 
vibrations O 
except O 
for O 
the O 
torsional O 
degrees O 
of O 
freedom O 
which O 
are O 
being O 
treated O 
as O 
1D O 
hindered O 
rotor O 
. O 
Asymmetric O 
Eckart O 
barriers O 
were O 
used O 
to O 
model O 
tunneling O 
effect O 
in O 
a O 
one O 
- O 
dimensional O 
reaction O 
coordinate O 
through O 
saddle O 
points O 
. O 
Our O 
calculated O 
results O 
show O 
that O 
the O 
four O 
reaction O 
channels O 
forming O 
1-buten-2-ol B-SYSTEMATIC 
+ O 
HÿO2 B-FORMULA 
radical O 
( O 
R5 O 
) O 
, O 
2-buten-2-ol B-SYSTEMATIC 
+ O 
HÿO2 B-FORMULA 
radical O 
( O 
R10 O 
) O 
, O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
+ O 
ethylene B-SYSTEMATIC 
+ O 
ÿ O 
O B-FORMULA 
H I-FORMULA 
radical O 
( O 
R13 O 
) O 
, O 
2-methyl-2-oxetanol B-SYSTEMATIC 
+ O 
ÿ O 
OH B-FORMULA 
radical O 
( O 
R15 O 
) O 
are O 
the O 
dominant O 
channels O 
. O 
When O 
the O 
temperature O 
is O 
below O 
1000 O 
K O 
, O 
the O 
reaction O 
R15 O 
forming O 
the O 
cyclic B-FAMILY 
ether I-FAMILY 
, O 
2-methyl-2-oxetanol B-SYSTEMATIC 
, O 
is O 
dominant O 
; O 
while O 
the O 
reaction O 
R13 O 
forming O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
+ O 
ethylene B-SYSTEMATIC 
+ O 
ÿ O 
OH B-FORMULA 
radical O 
becomes O 
increasingly O 
dominant O 
at O 
temperatures O 
above O 
1000 O 
K O 
. O 
The O 
other O 
two O 
channels O 
forming O 
1-buten-2-ol B-SYSTEMATIC 
, O 
2-buten-2-ol B-SYSTEMATIC 
and O 
HO2 B-FORMULA 
radical O 
are O 
not O 
dominant O 
but O 
are O 
still O 
important O 
product O 
channels O 
over O 
the O 
whole O 
temperature O 
range O 
investigated O 
here O 
. O 
No O 
pressure O 
dependence O 
has O 
been O 
found O 
for O 
the O 
reaction O 
channels O 
forming O 
2-methyl-2-oxetanol B-SYSTEMATIC 
+ O 
OH B-FORMULA 
radical O 
and O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
+ O 
ethylene B-SYSTEMATIC 
+ O 
OH B-FORMULA 
radical O 
. O 
A O 
slightly O 
negative O 
pressure O 
dependence O 
has O 
been O 
found O 
for O 
the O 
reaction O 
channels O 
producing O 
the O 
two O 
butenols B-FAMILY 
. O 
Rate O 
constants O 
for O 
the O 
four O 
important O 
reaction O 
channels O 
at O 
1 O 
atm O 
( O 
in O 
cm3mol-1s-1 O 
) O 
are O 
: O 
kR5 O 
= O 
2.67 O 
× O 
1015 O 
× O 
T-1.32 O 
exp(-16637 O 
/ O 
T O 
) O 
kR10 O 
= O 
1.62 O 
× O 
108 O 
× O 
T O 
0.57 O 
exp(-13142 O 
/ O 
T O 
) O 
kR13 O 
= O 
2.29 O 
× O 
1017 O 
× O 
T-1.66 O 
exp(-18169 O 
/ O 
T O 
) O 
kR15 O 
= O 
6.17 O 
× O 
10-2 O 
× O 
T O 
3.35 O 
exp(-10136 O 
/ O 
T O 
) O 
A O 
comparison O 
of O 
the O 
total O 
rate O 
constants O 
for O 
the O 
addition O 
of O 
HO2 B-FORMULA 
radical O 
to O 
EMK B-ABBREVIATION 
and O 
that O 
for O 
H B-FORMULA 
-atom O 
abstraction O 
by O 
HO2 B-FORMULA 
radical O 
from O 
EMK B-ABBREVIATION 
has O 
also O 
been O 
carried O 
out O 
. O 
We O 
find O 
that O 
the O 
abstraction O 
reaction O 
channels O 
are O 
dominant O 
over O 
the O 
entire O 
temperature O 
range O 
of O 
600-1600 O 
K O 
. O 

analyses O 
and O 
mass O 
spectrometry O 
were O 
used O 
to O 
study O 
the O 
structure O 
of O 
the O 
lipopolysaccharide O 
( O 
LPS O 
) O 
isolated O 
from O 
Aeromonas O 
bestiarum O 
strain O 
K296 O 
, O 
serotype O 
O18 O 
. O 
ESI-MS O 
revealed O 
that O 
the O 
most O 
abundant O 
A O 
. O 
bestiarum O 
LPS O 
glycoforms O 
have O 
a O 
hexa O 
- O 
acylated O 
or O 
tetra O 
- O 
acylated O 
lipid O 
A O 
with O 
conserved O 
architecture O 
of O 
the O 
backbone O 
, O 
consisting O 
of O 
a O 
1,4'-bisphosphorylated B-FAMILY 
β-(1→6)- I-FAMILY 
linked I-FAMILY 
d-GlcN I-FAMILY 
disaccharide I-FAMILY 
with O 
an O 
AraN B-FORMULA 
residue O 
as O 
a O 
non-stoichiometric O 
substituent O 
and O 
a O 
core O 
oligosaccharide O 
composed O 
of O 
Kdo1Hep6Hex1HexN1P1 O 
. O 
1D O 
and O 
2D O 
NMR O 
spectroscopy O 
revealed O 
that O 
the O 
O B-FORMULA 
-specific O 
polysaccharide O 
( O 
OPS O 
) O 
of O 
A O 
. O 
bestiarum O 
K296 O 
consists O 
of O 
a O 
branched O 
tetrasaccharide B-FAMILY 
repeating O 
unit O 
containing O 
two O 
6-deoxy-l-talose B-SYSTEMATIC 
( O 
6dTalp B-SYSTEMATIC 
) O 
, O 
one O 
Manp O 
and O 
one O 
GalpNAc B-FORMULA 
residues O 
; O 
thus O 
, O 
it O 
is O 
similar O 
to O 
that O 
of O 
the O 
OPS O 
of O 
A O 
. O 
hydrophila O 
AH-3 O 
( O 
serotype O 
O34 O 
) O 
in O 
both O 
the O 
sugar B-FAMILY 
composition O 
and O 
the O 
glycosylation O 
pattern O 
. O 
Moreover O 
, O 
3- O 
substituted O 
6dTalp B-SYSTEMATIC 
was O 
2-O-acetylated O 
and O 
additional O 
O-acetyl B-SYSTEMATIC 
groups O 
were O 
identified O 
at O 
O-2 O 
and O 
O-4 O 
( O 
or O 
O-3 O 
) O 
positions O 
of O 
the O 
terminal O 
6dTalp B-SYSTEMATIC 
. O 
Western O 
blots O 
with O 
polyclonal O 
rabbit O 
sera O 
showed O 
that O 
serotypes O 
O18 O 
and O 
O34 O 
share O 
some O 
epitopes O 
in O 
the O 
LPS O 
. O 
The O 
very O 
weak O 
reaction O 
of O 
the O 
anti-O34 O 
serum O 
with O 
the O 
O B-FORMULA 
-deacylated O 
LPS O 
of O 
A O 
. O 
bestiarum O 
K296 O 
might O 
have O 
been O 
due O 
to O 
the O 
different O 
O B-FORMULA 
-acetylation O 
pattern O 
of O 
the O 
terminal O 
6dTalp B-SYSTEMATIC 
. O 
The O 
latter O 
suggestion O 
was O 
further O 
confirmed O 
by O 
NMR O 
. O 

complex O 
I O 
dysfunction O 
induced O 
by O 
cocaine B-TRIVIAL 
and O 
cocaine B-TRIVIAL 
plus O 
morphine B-TRIVIAL 
in O 
brain O 
and O 
liver O 
mitochondria O 
. O 

function O 
and O 
energy O 
metabolism O 
are O 
affected O 
in O 
brains O 
of O 
human O 
cocaine B-TRIVIAL 
abusers O 
. O 
Cocaine B-TRIVIAL 
is O 
known O 
to O 
induce O 
mitochondrial O 
dysfunction O 
in O 
cardiac O 
and O 
hepatic O 
tissues O 
, O 
but O 
its O 
effects O 
on O 
brain O 
bioenergetics O 
are O 
less O 
documented O 
. O 
Furthermore O 
, O 
the O 
combination O 
of O 
cocaine B-TRIVIAL 
and O 
opioids O 
( O 
speedball O 
) O 
was O 
also O 
shown O 
to O 
induce O 
mitochondrial O 
dysfunction O 
. O 
In O 
this O 
work O 
, O 
we O 
compared O 
the O 
effects O 
of O 
cocaine B-TRIVIAL 
and O 
/ O 
or O 
morphine B-TRIVIAL 
on O 
the O 
bioenergetics O 
of O 
isolated O 
brain O 
and O 
liver O 
mitochondria O 
, O 
to O 
understand O 
their O 
specific O 
effects O 
in O 
each O 
tissue O 
. O 
Upon O 
energization O 
with O 
complex O 
I O 
substrates O 
, O 
cocaine B-TRIVIAL 
decreased O 
state-3 O 
respiration O 
in O 
brain O 
( O 
but O 
not O 
in O 
liver O 
) O 
mitochondria O 
and O 
decreased O 
uncoupled O 
respiration O 
and O 
mitochondrial O 
potential O 
in O 
both O 
tissues O 
, O 
through O 
a O 
direct O 
effect O 
on O 
complex O 
I O 
. O 
Morphine B-TRIVIAL 
presented O 
only O 
slight O 
effects O 
on O 
brain O 
and O 
liver O 
mitochondria O 
, O 
and O 
the O 
combination O 
cocaine B-TRIVIAL 
+ O 
morphine B-TRIVIAL 
had O 
similar O 
effects O 
to O 
cocaine B-TRIVIAL 
alone O 
, O 
except O 
for O 
a O 
greater O 
decrease O 
in O 
state-3 O 
respiration O 
. O 
Brain O 
and O 
liver O 
mitochondrial O 
respirations O 
were O 
differentially O 
affected O 
, O 
and O 
liver O 
mitochondria O 
were O 
more O 
prone O 
to O 
proton O 
leak O 
caused O 
by O 
the O 
drugs O 
or O 
their O 
combination O 
. O 
This O 
was O 
possibly O 
related O 
with O 
a O 
different O 
dependence O 
on O 
complex O 
I O 
in O 
mitochondrial O 
populations O 
from O 
these O 
tissues O 
. O 
In O 
summary O 
, O 
cocaine B-TRIVIAL 
and O 
cocaine B-TRIVIAL 
+ O 
morphine B-TRIVIAL 
induce O 
mitochondrial O 
complex O 
I O 
dysfunction O 
in O 
isolated O 
brain O 
and O 
liver O 
mitochondria O 
, O 
with O 
specific O 
effects O 
in O 
each O 
tissue O 
. O 

and O 
lipopolysaccharide O 
trigger O 
synergistic O 
ceramide B-FAMILY 
production O 
in O 
primary O 
macrophages O 
. O 

play O 
a O 
key O 
role O 
in O 
host O 
defense O 
and O 
in O 
tissue O 
repair O 
after O 
injury O 
. O 
Emerging O 
evidence O 
suggests O 
that O 
macrophage O 
dysfunction O 
in O 
states O 
of O 
lipid O 
excess O 
can O 
contribute O 
to O 
the O 
development O 
of O 
insulin O 
resistance O 
and O 
may O 
underlie O 
inflammatory O 
complications O 
of O 
diabetes O 
. O 
Ceramides B-FAMILY 
are O 
sphingolipids B-FAMILY 
that O 
modulate O 
a O 
variety O 
of O 
cellular O 
responses O 
including O 
cell O 
death O 
, O 
autophagy O 
, O 
insulin O 
signaling O 
, O 
and O 
inflammation O 
. O 
In O 
this O 
study O 
we O 
investigated O 
the O 
intersection O 
between O 
TLR4 O 
- O 
mediated O 
inflammatory O 
signaling O 
and O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
with O 
regard O 
to O 
ceramide B-FAMILY 
generation O 
. O 
Primary O 
macrophages O 
treated O 
with O 
lipopolysaccharide O 
( O 
LPS O 
) O 
did O 
not O 
produce O 
C16 B-SYSTEMATIC 
ceramide I-SYSTEMATIC 
, O 
whereas O 
palmitate B-TRIVIAL 
exposure O 
led O 
to O 
a O 
modest O 
increase O 
in O 
this O 
sphingolipid B-FAMILY 
. O 
Strikingly O 
, O 
the O 
combination O 
of O 
LPS O 
and O 
palmitate B-TRIVIAL 
led O 
to O 
a O 
synergistic O 
increase O 
in O 
C16 B-SYSTEMATIC 
ceramide I-SYSTEMATIC 
. O 
This O 
response O 
occurred O 
via O 
cross O 
- O 
talk O 
at O 
the O 
level O 
of O 
de O 
novo O 
ceramide B-FAMILY 
synthesis O 
in O 
the O 
ER O 
. O 
The O 
synergistic O 
response O 
required O 
TLR4 O 
signaling O 
via O 
MyD88 O 
and O 
TIR-domain O 
- O 
containing O 
adaptor O 
- O 
inducing O 
interferon O 
beta O 
( O 
TRIF O 
) O 
, O 
whereas O 
palmitate B-TRIVIAL 
-induced O 
ceramide B-FAMILY 
production O 
occurred O 
independent O 
of O 
these O 
inflammatory O 
molecules O 
. O 
This O 
ceramide B-FAMILY 
response O 
augmented O 
IL-1β O 
and O 
TNFα O 
release O 
, O 
a O 
process O 
that O 
may O 
contribute O 
to O 
the O 
enhanced O 
inflammatory O 
response O 
in O 
metabolic O 
diseases O 
characterized O 
by O 
dyslipidemia O 
. O 

of O 
rare O 
- O 
earth O 
oxide B-SYSTEMATIC 
ceramics O 
. O 

materials O 
that O 
are O 
robust O 
to O 
harsh O 
environments O 
are O 
needed O 
in O 
a O 
broad O 
range O 
of O 
applications O 
. O 
Although O 
durable O 
materials O 
such O 
as O 
metals O 
and O 
ceramics O 
, O 
which O 
are O 
generally O 
hydrophilic O 
, O 
can O 
be O 
rendered O 
hydrophobic O 
by O 
polymeric O 
modifiers O 
, O 
these O 
deteriorate O 
in O 
harsh O 
environments O 
. O 
Here O 
we O 
show O 
that O 
a O 
class O 
of O 
ceramics O 
comprising O 
the O 
entire O 
lanthanide B-FAMILY 
oxide I-FAMILY 
series O 
, O 
ranging O 
from O 
ceria O 
to O 
lutecia O 
, O 
is O 
intrinsically O 
hydrophobic O 
. O 
We O 
attribute O 
their O 
hydrophobicity O 
to O 
their O 
unique O 
electronic O 
structure O 
, O 
which O 
inhibits O 
hydrogen B-SYSTEMATIC 
bonding O 
with O 
interfacial O 
water O 
molecules O 
. O 
We O 
also O 
show O 
with O 
surface O 
- O 
energy O 
measurements O 
that O 
polar O 
interactions O 
are O 
minimized O 
at O 
these O 
surfaces O 
and O 
with O 
Fourier O 
transform O 
infrared O 
/ O 
grazing O 
- O 
angle O 
attenuated O 
total O 
reflection O 
that O 
interfacial O 
water O 
molecules O 
are O 
oriented O 
in O 
the O 
hydrophobic O 
hydration O 
structure O 
. O 
Moreover O 
, O 
we O 
demonstrate O 
that O 
these O 
ceramic O 
materials O 
promote O 
dropwise O 
condensation O 
, O 
repel O 
impinging O 
water O 
droplets O 
, O 
and O 
sustain O 
hydrophobicity O 
even O 
after O 
exposure O 
to O 
harsh O 
environments O 
. O 
Rare O 
- O 
earth O 
oxide B-SYSTEMATIC 
ceramics O 
should O 
find O 
widespread O 
applicability O 
as O 
robust O 
hydrophobic O 
surfaces O 
. O 

sulfide I-SYSTEMATIC 
/ O 
nitrogen B-TRIVIAL 
- I-TRIVIAL 
doped I-TRIVIAL 
graphene I-TRIVIAL 
composites O 
: O 
phase O 
- O 
controlled O 
synthesis O 
and O 
high O 
performance O 
anode O 
materials O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 

- O 
controlled O 
nickel B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
( O 
Ni3 B-FORMULA 
S4 I-FORMULA 
and O 
NiS1.03 B-FORMULA 
) O 
nanoparticle O 
(NP)/ O 
nitrogen B-TRIVIAL 
- I-TRIVIAL 
doped I-TRIVIAL 
graphene I-TRIVIAL 
( O 
NG O 
) O 
composites O 
are O 
prepared O 
through O 
a O 
facile O 
one O 
- O 
pot O 
hydrothermal O 
process O 
. O 
The O 
composites O 
show O 
ultrahigh O 
capacity O 
retentions O 
of O 
98.87% O 
and O 
95.94% O 
for O 
Ni3 B-FORMULA 
S4 I-FORMULA 
/ O 
NG O 
and O 
NiS1.03 B-FORMULA 
/ O 
NG O 
electrodes O 
, O 
respectively O 
, O 
as O 
anode O 
materials O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 

of O 
Mussel O 
Foot O 
Protein-3 O 
to O 
TiO2 B-FORMULA 
Surfaces O 
: O 
the O 
Effect O 
of O 
pH O 
. O 

underwater O 
adhesion O 
of O 
marine O 
mussels O 
relies O 
on O 
mussel O 
foot O 
proteins O 
( O 
mfps O 
) O 
rich O 
in O 
the O 
catecholic O 
amino O 
acid O 
3,4-dihydroxyphenylalanine B-SYSTEMATIC 
( O 
Dopa B-ABBREVIATION 
) O 
. O 
As O 
a O 
side O 
chain O 
, O 
Dopa B-ABBREVIATION 
is O 
capable O 
of O 
strong O 
bidentate O 
interactions O 
with O 
a O 
variety O 
of O 
surfaces O 
, O 
including O 
many O 
minerals O 
and O 
metal B-FAMILY 
oxides I-FAMILY 
. O 
Titanium B-SYSTEMATIC 
is O 
among O 
the O 
most O 
widely O 
used O 
medical O 
implant O 
material O 
and O 
quickly O 
forms O 
a O 
TiO2 B-FORMULA 
passivation O 
layer O 
under O 
physiological O 
conditions O 
. O 
Understanding O 
the O 
binding O 
mechanism O 
of O 
Dopa B-ABBREVIATION 
to O 
TiO2 B-FORMULA 
surfaces O 
is O 
therefore O 
of O 
considerable O 
theoretical O 
and O 
practical O 
interest O 
. O 
Using O 
a O 
surface O 
forces O 
apparatus O 
, O 
we O 
explored O 
the O 
force O 
- O 
distance O 
profiles O 
and O 
adhesion O 
energies O 
of O 
mussel O 
foot O 
protein O 
3 O 
( O 
mfp-3 O 
) O 
to O 
TiO2 B-FORMULA 
surfaces O 
at O 
three O 
different O 
pHs O 
( O 
pH O 
3 O 
, O 
5.5 O 
and O 
7.5 O 
) O 
. O 
At O 
pH O 
3 O 
, O 
mfp-3 O 
showed O 
the O 
strongest O 
adhesion O 
force O 
on O 
TiO2 B-FORMULA 
, O 
with O 
an O 
adhesion O 
energy O 
of O 
∼-7.0 O 
mJ O 
/ O 
m(2) O 
. O 
Increasing O 
the O 
pH O 
gives O 
rise O 
to O 
two O 
opposing O 
effects O 
: O 
( O 
1 O 
) O 
increased O 
oxidation O 
of O 
Dopa B-ABBREVIATION 
, O 
thus O 
, O 
decreasing O 
availability O 
for O 
the O 
Dopa B-ABBREVIATION 
-mediated O 
adhesion O 
, O 
and O 
( O 
2 O 
) O 
increased O 
bidentate O 
Dopa B-ABBREVIATION 
- O 
Ti B-FORMULA 
coordination O 
, O 
leading O 
to O 
the O 
further O 
stabilization O 
of O 
the O 
Dopa B-ABBREVIATION 
group O 
and O 
, O 
thus O 
, O 
an O 
increase O 
in O 
adhesion O 
force O 
. O 
Both O 
effects O 
were O 
reflected O 
in O 
the O 
resonance O 
- O 
enhanced O 
Raman O 
spectra O 
obtained O 
at O 
the O 
three O 
deposition O 
pHs O 
. O 
The O 
two O 
competing O 
effects O 
give O 
rise O 
to O 
a O 
higher O 
adhesion O 
force O 
of O 
mfp-3 O 
on O 
the O 
TiO2 B-FORMULA 
surface O 
at O 
pH O 
7.5 O 
than O 
at O 
pH O 
5.5 O 
. O 
Our O 
results O 
suggest O 
that O 
Dopa B-ABBREVIATION 
-containing O 
proteins O 
and O 
synthetic O 
polymers O 
have O 
great O 
potential O 
as O 
coating O 
materials O 
for O 
medical O 
implant O 
materials O 
, O 
particularly O 
if O 
redox O 
activity O 
can O 
be O 
controlled O 
. O 

nervous O 
system O 
damage O 
due O 
to O 
acute O 
paraquat B-TRIVIAL 
poisoning O 
: O 
an O 
experimental O 
study O 
with O 
rat O 
model O 
. O 

( O 
PQ O 
) O 
is O 
a O 
common O 
herbicide O 
and O 
PQ O 
poisoning O 
is O 
a O 
major O 
medical O 
problem O 
in O 
Asia O 
. O 
However O 
, O 
few O 
studies O 
have O 
focused O 
on O 
the O 
acute O 
neurotoxic O 
changes O 
caused O 
by O 
PQ O 
. O 
Here O 
we O 
report O 
the O 
acute O 
neurotoxicological O 
findings O 
of O 
rats O 
treated O 
with O 
lethal O 
dose O 
of O 
PQ O 
. O 
In O 
substantia O 
nigra O 
( O 
SN O 
) O 
and O 
striatum O 
we O 
found O 
obvious O 
microglia O 
( O 
labeled O 
by O 
Iba-1 O 
) O 
activation O 
within O 
one O 
week O 
. O 
In O 
SN O 
and O 
hippocampus O 
, O 
we O 
detected O 
increased O 
oxidative O 
stress O 
in O 
the O 
neurons O 
based O 
on O 
NeuN/ O 
8-OHdG B-SYSTEMATIC 
immunofluorescence O 
double O 
labeling O 
and O 
laser O 
cofocal O 
microscopy O 
. O 
Moreover O 
, O 
we O 
provided O 
ultrastructural O 
evidences O 
of O 
astrocyte O 
edema O 
and O 
neurons O 
apoptosis O 
in O 
rat O 
brain O 
by O 
electron O 
microscopy O 
. O 
Further O 
studies O 
will O 
be O 
needed O 
with O 
non-lethal O 
dose O 
of O 
PQ O 
to O 
confirm O 
these O 
results O 
and O 
demonstrate O 
the O 
direct O 
CNS O 
toxicity O 
of O 
PQ O 
. O 

over O 
the O 
anisotropic O 
assembly O 
of O 
small O 
building O 
blocks O 
into O 
organized O 
structures O 
is O 
considered O 
an O 
effective O 
way O 
to O 
design O 
organic O 
nanosheets O 
and O 
atomically O 
thick O 
inorganic O 
nanosheets O 
with O 
nonlayered O 
structure O 
. O 
However O 
, O 
there O 
is O 
still O 
no O 
available O 
route O 
so O 
far O 
to O 
control O 
the O 
assembly O 
of O 
inorganic O 
and O 
organic O 
building O 
blocks O 
into O 
a O 
flattened O 
hybrid O 
nanosheet O 
with O 
atomic O 
thickness O 
. O 
Herein O 
, O 
we O 
highlight O 
for O 
the O 
first O 
time O 
a O 
universal O 
in O 
- O 
plane O 
coassembly O 
process O 
for O 
the O 
design O 
and O 
synthesis O 
of O 
transition B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
chalcogenide-alkylamine I-FAMILY 
inorganic O 
- O 
organic O 
hybrid O 
nanosheets O 
with O 
atomic O 
thickness O 
. O 
The O 
structure O 
, O 
formation O 
mechanism O 
, O 
and O 
stability O 
of O 
the O 
hybrid O 
nanosheets O 
were O 
investigated O 
in O 
detail O 
by O 
taking O 
the O 
Co₉S₈ B-FORMULA 
- O 
oleylamine B-SYSTEMATIC 
( O 
Co₉S₈ B-FORMULA 
-OA O 
) O 
hybrid O 
nanosheets O 
as O 
an O 
example O 
. O 
Both O 
experimental O 
data O 
and O 
theoretical O 
simulations O 
demonstrate O 
that O 
the O 
hybrid O 
nanosheets O 
were O 
formed O 
by O 
in O 
- O 
plane O 
connection O 
of O 
small O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
Co₉S₈ B-FORMULA 
nanoplates O 
via O 
oleylamine B-SYSTEMATIC 
molecules O 
adsorbed O 
at O 
the O 
side O 
surface O 
and O 
corner O 
sites O 
of O 
the O 
nanoplates O 
. O 
X-ray O 
absorption O 
fine O 
structure O 
spectroscopy O 
study O 
reveals O 
the O 
structure O 
distortion O 
of O 
the O 
small O 
2D O 
Co₉S₈ B-FORMULA 
nanoplates O 
that O 
endows O 
structural O 
stability O 
of O 
the O 
atomically O 
thick O 
Co₉S₈ B-FORMULA 
-OA O 
hybrid O 
nanosheets O 
. O 
The O 
brand O 
new O 
atomically O 
thick O 
nanosheets O 
with O 
inorganic O 
- O 
organic O 
hybrid O 
network O 
nanostructure O 
will O 
not O 
only O 
enrich O 
the O 
family O 
of O 
atomically O 
thick O 
2D O 
nanosheets O 
but O 
also O 
inspire O 
more O 
interest O 
in O 
their O 
potential O 
applications O 
. O 

present O 
investigation O 
focuses O 
on O 
the O 
methanolic O 
extract O 
obtained O 
from O 
Geranium O 
robertianum O 
L O 
. O 
( O 
Geraniaceae O 
) O 
( O 
Herb O 
Robert O 
) O 
, O 
a O 
herbal O 
plant O 
used O 
in O 
traditional O 
medicine O 
for O 
the O 
treatment O 
of O 
human O 
and O 
animal O 
diseases O 
. O 
The O 
antioxidant O 
capacities O 
of O 
the O 
extract O 
were O 
evaluated O 
using O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
radical O 
, O 
β-carotene B-TRIVIAL 
/ O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
and O 
reducing O 
power O 
and O 
metal O 
chelating O 
activity O 
assays O 
. O 
The O 
amount O 
of O 
total O 
phenolic O 
content O 
, O 
flavonoids B-FAMILY 
and O 
condensed O 
tannins B-FAMILY 
was O 
very O 
high O 
, O 
and O 
the O 
correlation O 
between O 
the O 
antioxidant O 
activity O 
potential O 
and O 
total O 
phenolic O 
level O 
of O 
the O 
extract O 
was O 
pointed O 
out O 
. O 

benefit O 
of O 
cancer O 
chemotherapy O 
based O 
on O 
alkylating O 
agents O 
is O 
limited O 
due O 
to O 
the O 
action O 
of O 
DNA O 
repair O 
enzymes O 
which O 
mitigate O 
the O 
damage O 
induced O 
by O 
these O 
agents O 
. O 
The O 
interaction O 
between O 
the O 
proteins O 
ERCC1 O 
and O 
XPF O 
, O 
involves O 
two O 
major O 
components O 
of O 
the O 
nucleotide B-FAMILY 
excision O 
repair O 
pathway O 
. O 
Here O 
, O 
novel O 
inhibitors O 
of O 
this O 
interaction O 
were O 
identified O 
by O 
virtual O 
screening O 
based O 
on O 
available O 
structures O 
using O 
the O 
National O 
Cancer O 
Institute O 
( O 
NCI O 
) O 
diversity O 
set O 
and O 
a O 
panel O 
of O 
DrugBank O 
- O 
small O 
- O 
molecules O 
. O 
Subsequently O 
, O 
experimental O 
validation O 
of O 
the O 
in O 
silico O 
screening O 
was O 
undertaken O 
. O 
Top O 
hits O 
were O 
evaluated O 
on O 
A549 O 
and O 
HCT116 O 
cancer O 
cells O 
. O 
In O 
particular O 
, O 
the O 
compound O 
labeled O 
NSC130813 B-IDENTIFIER 
was O 
shown O 
to O 
act O 
synergistically O 
with O 
cisplatin B-TRIVIAL 
and O 
mitomycin B-TRIVIAL 
C I-TRIVIAL 
, O 
to O 
increase O 
UVC O 
mediated O 
cytotoxicity O 
, O 
to O 
modify O 
DNA O 
repair O 
as O 
indicated O 
by O 
the O 
staining O 
of O 
phosphorylated O 
H2AX O 
and O 
to O 
disrupt O 
interaction O 
between O 
ERCC1 O 
and O 
XPF O 
in O 
cells O 
. O 
In O 
addition O 
, O 
using O 
the O 
Biacore O 
technique O 
, O 
we O 
showed O 
that O 
this O 
compound O 
interacts O 
with O 
the O 
domain O 
of O 
XPF O 
responsible O 
for O 
interaction O 
with O 
ERCC1 O 
. O 
This O 
study O 
shows O 
that O 
small O 
molecules O 
targeting O 
the O 
protein O 
- O 
protein O 
interaction O 
of O 
ERCC1 O 
and O 
XPF O 
can O 
be O 
developed O 
in O 
order O 
to O 
enhance O 
the O 
effects O 
of O 
alkylating O 
agents O 
on O 
cancer O 
cells O 
. O 

aciduria O 
- O 
lessons O 
from O 
50 O 
genes O 
and O 
977 O 
patients O 
. O 

urinary O 
excretion O 
of O 
3-methylglutaconic B-SYSTEMATIC 
acid I-SYSTEMATIC 
is O 
considered O 
rare O 
in O 
patients O 
suspected O 
of O 
a O 
metabolic O 
disorder O 
. O 
In O 
3-methylglutaconyl-CoA B-SYSTEMATIC 
hydratase O 
deficiency O 
( O 
mutations O 
in O 
AUH O 
) O 
, O 
it O 
derives O 
from O 
leucine B-TRIVIAL 
degradation O 
. O 
In O 
all O 
other O 
disorders O 
with O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
the O 
origin O 
is O 
unknown O 
, O 
yet O 
mitochondrial O 
dysfunction O 
is O 
thought O 
to O 
be O 
the O 
common O 
denominator O 
. O 
We O 
investigate O 
the O 
biochemical O 
, O 
clinical O 
and O 
genetic O 
data O 
of O 
388 O 
patients O 
referred O 
to O 
our O 
centre O 
under O 
suspicion O 
of O 
a O 
metabolic O 
disorder O 
showing O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
in O 
routine O 
metabolic O 
screening O 
. O 
Furthermore O 
, O 
we O 
investigate O 
591 O 
patients O 
with O 
50 O 
different O 
, O 
genetically O 
proven O 
, O 
mitochondrial O 
disorders O 
for O 
the O 
presence O 
of O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
. O 
Three O 
percent O 
of O 
all O 
urine O 
samples O 
of O 
the O 
patients O 
referred O 
showed O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
, O 
often O 
in O 
correlation O 
with O 
disorders O 
not O 
reported O 
earlier O 
in O 
association O 
with O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
( O 
e.g O 
. O 
organic O 
acidurias O 
, O 
urea B-TRIVIAL 
cycle O 
disorders O 
, O 
haematological O 
and O 
neuromuscular O 
disorders O 
) O 
. O 
In O 
the O 
patient O 
cohort O 
with O 
genetically O 
proven O 
mitochondrial O 
disorders O 
11 O 
% O 
presented O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
. O 
It O 
was O 
more O 
frequently O 
seen O 
in O 
ATPase O 
related O 
disorders O 
, O 
with O 
mitochondrial O 
DNA O 
depletion O 
or O 
deletion O 
, O 
but O 
not O 
in O 
patients O 
with O 
single O 
respiratory O 
chain O 
complex O 
deficiencies O 
. O 
Besides O 
, O 
it O 
was O 
a O 
consistent O 
feature O 
of O 
patients O 
with O 
mutations O 
in O 
TAZ O 
, O 
SERAC1 O 
, O 
OPA3 O 
, O 
DNAJC19 O 
and O 
TMEM70 O 
accounting O 
for O 
mitochondrial O 
membrane O 
related O 
pathology O 
. O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
is O 
found O 
quite O 
frequently O 
in O 
patients O 
suspected O 
of O 
a O 
metabolic O 
disorder O 
, O 
and O 
mitochondrial O 
dysfunction O 
is O 
indeed O 
a O 
common O 
denominator O 
. O 
It O 
is O 
only O 
a O 
discriminative O 
feature O 
of O 
patients O 
with O 
mutations O 
in O 
AUH O 
, O 
TAZ O 
, O 
SERAC1 O 
, O 
OPA3 O 
, O 
DNAJC19 O 
TMEM70 O 
. O 
These O 
conditions O 
should O 
therefore O 
be O 
referred O 
to O 
as O 
inborn O 
errors O 
of O 
metabolism O 
with O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
as O 
discriminative O 
feature O 
. O 

native O 
binding O 
of O 
a O 
fluorescent O 
serotonin B-TRIVIAL 
conjugate O 
to O 
serotonin B-TRIVIAL 
type O 
3 O 
receptors O 
. O 

is O 
the O 
synthesis O 
of O 
5-hydroxytryptamine- B-SYSTEMATIC 
tetramethylrhodamine I-SYSTEMATIC 
( O 
5HT B-SYSTEMATIC 
* O 
) O 
; O 
an O 
indole B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
linked O 
fluorescent O 
conjugate O 
of O 
serotonin B-TRIVIAL 
. O 
Through O 
a O 
series O 
fluorescence O 
quenching O 
experiments O 
and O 
experiments O 
in O 
the O 
presence O 
of O 
a O 
known O 
competitive O 
antagonist O 
( O 
Granisetron B-TRIVIAL 
) O 
, O 
it O 
was O 
shown O 
that O 
5HT B-SYSTEMATIC 
* O 
specifically O 
binds O 
to O 
purified O 
homo-pentameric O 
type-3 O 
human O 
serotonin B-TRIVIAL 
receptors O 
( O 
5HT B-SYSTEMATIC 
( O 
3A O 
) O 
) O 
. O 
The O 
measured O 
dissociation O 
constant O 
and O 
Hill O 
coefficient O 
are O 
K(d) O 
= O 
83 O 
± O 
3 O 
nM O 
and O 
n O 
= O 
3.1 O 
± O 
0.3 O 
, O 
respectively O 
which O 
is O 
indicative O 
of O 
multi O 
- O 
ligand O 
binding O 
and O 
cooperativity O 
similar O 
to O 
that O 
of O 
unconjugated O 
serotonin O 
. O 

formation O 
and O 
modification O 
in O 
avermectin B-FAMILY 
biosynthesis O 
involves O 
a O 
dual O 
activity O 
of O 
AveC O 
. O 

( O 
AVEs B-FAMILY 
) O 
, O 
which O 
are O 
widely O 
used O 
for O 
the O 
treatment O 
of O 
agricultural O 
parasitic O 
diseases O 
, O 
belong O 
to O 
a O 
family O 
of O 
6,6-spiroketal O 
moiety O 
- O 
containing O 
, O 
macrolide B-FAMILY 
natural O 
products O 
. O 
AVE B-ABBREVIATION 
biosynthesis O 
is O 
known O 
to O 
employ O 
a O 
type O 
I O 
polyketide B-FAMILY 
synthase O 
( O 
PKS O 
) O 
system O 
to O 
assemble O 
the O 
molecular O 
skeleton O 
for O 
further O 
functionalization O 
. O 
It O 
remains O 
unknown O 
how O 
and O 
when O 
spiroketal O 
formation O 
proceeds O 
, O 
particularly O 
regarding O 
the O 
role O 
of O 
AveC O 
, O 
a O 
unique O 
protein O 
in O 
the O 
pathway O 
that O 
shares O 
no O 
sequence O 
homology O 
to O 
any O 
enzyme O 
of O 
known O 
function O 
. O 
Here O 
, O 
we O 
report O 
the O 
unprecedented O 
, O 
dual O 
function O 
of O 
AveC O 
by O 
correlating O 
its O 
activity O 
with O 
spiroketal O 
formation O 
and O 
modification O 
during O 
the O 
AVE B-ABBREVIATION 
biosynthetic O 
process O 
. O 
The O 
findings O 
in O 
this O 
study O 
were O 
supported O 
by O 
characterizing O 
extremely O 
unstable O 
intermediates O 
, O 
products O 
and O 
their O 
spontaneous O 
derivative O 
products O 
from O 
the O 
simplified O 
chemical O 
profile O 
and O 
by O 
comparative O 
analysis O 
of O 
in O 
vitro O 
biotransformations O 
and O 
in O 
vivo O 
complementations O 
mediated O 
by O 
AveC O 
and O 
MeiC O 
( O 
the O 
counterpart O 
in O 
biosynthesizing O 
the O 
naturally O 
occurring O 
, O 
AVE B-ABBREVIATION 
-like O 
meilingmycins B-FAMILY 
) O 
. O 
AveC O 
catalyzes O 
the O 
stereospecific O 
spiroketalization O 
of O 
a O 
dihydroxy-ketone B-FAMILY 
polyketide I-FAMILY 
intermediate O 
and O 
the O 
optional O 
dehydration O 
to O 
determine O 
the O 
regiospecific O 
saturation O 
characteristics O 
of O 
spiroketal O 
diversity O 
. O 
These O 
reactions O 
take O 
place O 
between O 
the O 
closures O 
of O 
the O 
hexene B-SYSTEMATIC 
ring O 
and O 
16-membered O 
macrolide B-FAMILY 
and O 
the O 
formation O 
of O 
the O 
hexahydrobenzofuran B-SYSTEMATIC 
unit O 
. O 
MeiC O 
can O 
replace O 
the O 
spirocyclase O 
activity O 
of O 
AveC O 
, O 
but O 
it O 
lacks O 
the O 
independent O 
dehydratase O 
activity O 
. O 
Elucidation O 
of O 
the O 
generality O 
and O 
specificity O 
of O 
AveC O 
- O 
type O 
proteins O 
allows O 
for O 
the O 
rationalization O 
of O 
previously O 
published O 
results O 
that O 
were O 
not O 
completely O 
understood O 
, O 
suggesting O 
that O 
enzyme O 
- O 
mediated O 
spiroketal O 
formation O 
was O 
initially O 
underestimated O 
, O 
but O 
is O 
, O 
in O 
fact O 
, O 
widespread O 
in O 
nature O 
for O 
the O 
control O 
of O 
stereoselectivity O 
. O 

in O 
Light O 
: O 
Design O 
, O 
Synthesis O 
and O 
Applications O 
of O 
Photo O 
- O 
active O 
Graphene B-TRIVIAL 
and O 
Graphene B-TRIVIAL 
-Like O 
Materials O 
. O 

functionalized O 
with O 
photo O 
- O 
active O 
units O 
has O 
become O 
one O 
of O 
the O 
most O 
exciting O 
topics O 
of O 
research O 
in O 
the O 
last O 
few O 
years O 
, O 
which O 
remarkably O 
sustains O 
and O 
expands O 
the O 
graphene B-TRIVIAL 
boom O 
. O 
The O 
rise O 
of O 
photo O 
- O 
active O 
graphene B-TRIVIAL 
in O 
photonics O 
and O 
optoelectronics O 
is O 
evidenced O 
by O 
a O 
spate O 
of O 
recent O 
reports O 
on O 
topics O 
ranging O 
from O 
photodetectors O 
, O 
photovoltaics O 
, O 
and O 
optoelectronics O 
to O 
photocatalysis O 
. O 
For O 
these O 
applications O 
, O 
the O 
fabrication O 
of O 
photo O 
- O 
active O 
graphene B-TRIVIAL 
through O 
appropriate O 
chemical O 
functionalization O 
strategies O 
is O 
essential O 
as O 
pristine O 
graphene B-TRIVIAL 
has O 
zero O 
bandgap O 
and O 
only O 
weak O 
absorption O 
of O 
photons O 
. O 
Written O 
from O 
the O 
chemists O 
' O 
point O 
of O 
view O 
, O 
up O 
- O 
to O 
- O 
date O 
chemical O 
functionalization O 
of O 
graphene B-TRIVIAL 
with O 
various O 
small O 
organic O 
molecules O 
, O 
conjugated O 
polymers O 
, O 
rare O 
- O 
earth O 
components O 
, O 
and O 
inorganic O 
semiconductors O 
is O 
reviewed O 
. O 
Particular O 
attention O 
is O 
paid O 
to O 
the O 
development O 
of O 
graphene B-TRIVIAL 
functionalized O 
with O 
light O 
- O 
harvesting O 
moieties O 
, O 
including O 
materials O 
synthesis O 
, O 
characterization O 
, O 
energy O 
/ O 
charge O 
- O 
transfer O 
processes O 
, O 
and O 
applications O 
in O 
photovoltaics O 
. O 
Challenges O 
currently O 
faced O 
by O 
researchers O 
and O 
future O 
perspectives O 
in O 
this O 
field O 
are O 
also O 
discussed O 
. O 

muscle O 
- O 
type O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
activation O 
in O 
TE-671 O 
cells O 
and O 
inhibition O 
of O 
fetal O 
movement O 
in O 
a O 
day O 
40 O 
pregnant O 
goat O 
model O 
by O 
optical O 
isomers O 
of O 
the O 
piperidine B-FAMILY 
alkaloid I-FAMILY 
coniine B-TRIVIAL 
. O 

is O 
an O 
optically O 
active O 
toxic O 
piperidine B-FAMILY 
alkaloid I-FAMILY 
and O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
agonist O 
found O 
in O 
poison O 
hemlock O 
( O 
Conium O 
maculatum O 
L O 
. O 
) O 
. O 
Coniine B-TRIVIAL 
teratogenicity O 
is O 
hypothesized O 
to O 
be O 
attributable O 
to O 
the O 
binding O 
, O 
activation O 
, O 
and O 
prolonged O 
desensitization O 
of O 
fetal O 
muscle O 
- O 
type O 
nAChR O 
, O 
which O 
results O 
in O 
the O 
complete O 
inhibition O 
of O 
fetal O 
movement O 
. O 
However O 
, O 
pharmacological O 
evidence O 
of O 
coniine B-TRIVIAL 
actions O 
at O 
fetal O 
muscle O 
- O 
type O 
nAChR O 
is O 
lacking O 
. O 
The O 
present O 
study O 
compared O 
(-)-coniine B-TRIVIAL 
, O 
(+)-coniine B-TRIVIAL 
, O 
and O 
nicotine B-TRIVIAL 
for O 
the O 
ability O 
to O 
inhibit O 
fetal O 
movement O 
in O 
a O 
day O 
40 O 
pregnant O 
goat O 
model O 
and O 
in O 
TE-671 O 
cells O 
that O 
express O 
fetal O 
muscle O 
- O 
type O 
nAChR O 
. O 
Furthermore O 
, O 
α-conotoxins O 
( O 
CTx O 
) O 
EI O 
and O 
GI O 
were O 
used O 
to O 
antagonize O 
the O 
actions O 
of O 
(+)- B-MULTIPLE 
and I-MULTIPLE 
(-)-coniine I-MULTIPLE 
in O 
TE-671 O 
cells O 
. O 
(-)-Coniine B-TRIVIAL 
was O 
more O 
effective O 
at O 
eliciting O 
electrical O 
changes O 
in O 
TE-671 O 
cells O 
and O 
inhibiting O 
fetal O 
movement O 
than O 
was O 
(+)-coniine B-TRIVIAL 
, O 
suggesting O 
stereoselectivity O 
by O 
the O 
receptor O 
. O 
The O 
pyridine B-FAMILY 
alkaloid I-FAMILY 
nicotine B-TRIVIAL 
did O 
not O 
inhibit O 
fetal O 
movement O 
in O 
a O 
day O 
40 O 
pregnant O 
goat O 
model O 
, O 
suggesting O 
agonist O 
specificity O 
for O 
the O 
inhibition O 
of O 
fetal O 
movement O 
. O 
Low O 
concentrations O 
of O 
both O 
CTxs O 
potentiated O 
the O 
TE-671 O 
cell O 
response O 
and O 
higher O 
concentrations O 
of O 
CTx O 
EI O 
, O 
and O 
GI O 
antagonized O 
the O 
actions O 
of O 
both O 
coniine B-TRIVIAL 
enantiomers O 
demonstrating O 
concentration O 
- O 
dependent O 
coagonism O 
and O 
selective O 
antagonism O 
. O 
These O 
results O 
provide O 
pharmacological O 
evidence O 
that O 
the O 
piperidine B-FAMILY 
alkaloid I-FAMILY 
coniine B-TRIVIAL 
is O 
acting O 
at O 
fetal O 
muscle O 
- O 
type O 
nAChR O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 

, O 
a O 
common O 
pediatric O 
malignancy O 
of O 
neural O 
crest O 
origin O 
, O 
is O 
unique O 
in O 
its O 
wide O 
spectrum O 
of O 
clinical O 
and O 
biological O 
behavior O 
, O 
ranging O 
from O 
spontaneous O 
regression O 
or O 
differentiation O 
to O 
rapid O 
progression O 
and O 
metastasis O 
. O 
Overexpression O 
of O 
neurotrophin O 
receptors O 
of O 
the O 
tyrosine B-TRIVIAL 
kinase O 
( O 
Trk O 
) O 
family O 
has O 
been O 
identified O 
as O 
a O 
major O 
prognostic O 
and O 
biological O 
factor O 
for O 
this O 
disease O 
. O 
Novel O 
molecules O 
were O 
selected O 
using O 
cheminformatics O 
tools O 
( O 
SBVS O 
& O 
LBVS O 
) O 
and O 
screened O 
in O 
cell O 
- O 
based O 
assays O 
to O 
modulate O 
Trk O 
receptor O 
activity O 
. O 
One O 
compound O 
( O 
C390-0031 O 
) O 
had O 
a O 
potent O 
anti-proliferative O 
activity O 
in O 
dose O 
- O 
response O 
studies O 
using O 
neuroblastoma O 
cell O 
lines O 
. O 
The O 
molecular O 
effects O 
of O 
this O 
molecule O 
were O 
further O 
characterized O 
by O 
using O 
cell O 
- O 
cycle O 
and O 
western O 
blot O 
analysis O 
. O 
Interestingly O 
, O 
despite O 
the O 
presence O 
of O 
the O 
anchoring O 
fragment O 
to O 
the O 
Trk O 
kinase O 
domain O 
composing O 
its O 
structure O 
, O 
this O 
molecule O 
does O 
not O 
inhibit O 
TrkA O 
like O 
lestaurtinib B-TRIVIAL 
, O 
constituting O 
a O 
new O 
chemical O 
with O 
a O 
yet O 
unknown O 
mechanism O 
of O 
action O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

to O 
international O 
guidelines O 
skin O 
penetration O 
experiments O 
can O 
be O 
carried O 
out O 
using O 
freshly O 
excised O 
or O 
frozen O 
stored O 
skin O 
. O 
However O 
, O 
this O 
recommendation O 
refers O 
to O 
data O 
obtained O 
in O 
experiments O 
with O 
human O 
cadaver O 
skin O 
. O 
In O 
our O 
study O 
, O 
the O 
percutaneous O 
penetration O 
of O 
the O 
occupationally O 
relevant O 
chemicals O 
anisole B-TRIVIAL 
, O 
cyclohexanone B-SYSTEMATIC 
and O 
1,4-dioxane B-SYSTEMATIC 
was O 
investigated O 
for O 
freshly O 
excised O 
as O 
well O 
as O 
for O 
4 O 
and O 
30 O 
days O 
at O 
-20°C O 
stored O 
human O 
skin O 
using O 
the O 
diffusion O 
cell O 
technique O 
. O 
As O 
indicator O 
for O 
the O 
impairment O 
of O 
skin O 
barrier O 
by O 
freezing O 
cholesterol B-TRIVIAL 
dissolution O 
was O 
determined O 
in O 
the O 
solvents O 
in O 
exposure O 
chambers O 
of O 
diffusion O 
cells O 
. O 
Considering O 
the O 
percutaneously O 
penetrated O 
amounts O 
, O 
the O 
following O 
ranking O 
was O 
determined O 
: O 
1,4-dioxane B-SYSTEMATIC 
> O 
anisole B-TRIVIAL 
> O 
cyclohexanone B-SYSTEMATIC 
( O 
decline O 
to O 
a O 
factor O 
of O 
5.9 O 
) O 
. O 
The O 
differences O 
of O 
fluxes O 
between O 
freshly O 
excised O 
and O 
frozen O 
stored O 
skin O 
( O 
4 O 
and O 
30 O 
days O 
) O 
were O 
not O 
significant O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
Cholesterol B-TRIVIAL 
dissolved O 
from O 
the O 
skin O 
indicates O 
no O 
significant O 
differences O 
between O 
freshly O 
excised O 
and O 
frozen O 
stored O 
skin O 
. O 
This O 
study O 
shows O 
that O 
freezing O 
of O 
human O 
skin O 
for O 
up O 
to O 
30 O 
days O 
does O 
not O 
alter O 
the O 
skin O 
barrier O 
function O 
and O 
the O 
permeability O 
of O 
chemicals O 
. O 

oligonucleotides O 
are O 
typically O 
introduced O 
to O 
bulk O 
solution O 
to O 
promote O 
hybridization O 
activity O 
on O 
DNA-functionalized O 
surfaces O 
. O 
Here O 
, O 
an O 
alternative O 
approach O 
is O 
explored O 
by O 
encapsulating O 
secondary O 
target O 
strands O 
inside O 
semipermeable O 
colloidal O 
satellite O 
assemblies O 
, O 
then O 
triggering O 
their O 
release O 
at O 
37 O 
°C O 
for O 
subsequent O 
surface O 
hybridization O 
activity O 
. O 
To O 
prepare O 
DNA-loaded O 
satellite O 
assemblies O 
, O 
uniform O 
gelatin O 
microspheres O 
are O 
fabricated O 
using O 
microfluidics O 
, O 
loaded O 
with O 
15 O 
base O 
- O 
long O 
secondary O 
DNA O 
targets O 
, O 
capped O 
with O 
a O 
polyelectrolyte O 
bilayer O 
, O 
and O 
finally O 
coated O 
with O 
a O 
monolayer O 
of O 
polystyrene B-SYSTEMATIC 
microspheres O 
functionalized O 
with O 
duplexes O 
comprised O 
of O 
immobilized O 
probes O 
and O 
soluble O 
, O 
13 O 
base O 
- O 
long O 
hybridization O 
partner O 
strands O 
. O 
Once O 
warmed O 
to O 
37 O 
°C O 
, O 
secondary O 
DNA O 
targets O 
are O 
released O 
from O 
the O 
gelatin O 
template O 
and O 
then O 
competitively O 
displace O 
the O 
shorter O 
, O 
original O 
hybridization O 
partners O 
on O 
the O 
polystyrene B-SYSTEMATIC 
microspheres O 
. O 

Merlot O 
wines O 
the O 
evolution O 
of O 
volatile O 
and O 
non-volatile O 
( O 
ellagitannins O 
) O 
compounds O 
extracted O 
from O 
winewoods O 
while O 
being O 
macerated O 
for O 
12months O 
was O 
studied O 
. O 
Seven O 
types O 
of O 
winewoods O 
subjected O 
to O 
different O 
toasting O 
methods O 
were O 
used O 
. O 
Different O 
rates O 
of O 
extraction O 
, O 
depending O 
mainly O 
on O 
wood O 
compounds O 
origin O 
( O 
toasting O 
or O 
naturally O 
present O 
in O 
wood O 
) O 
and O 
on O 
the O 
watering O 
process O 
during O 
toasting O 
, O 
were O 
observed O 
, O 
which O 
were O 
reflected O 
in O 
sensory O 
differences O 
. O 
Globally O 
, O 
volatile O 
phenols B-FAMILY 
together O 
with O 
aldehydes B-FAMILY 
, O 
phenols B-FAMILY 
and O 
lactones B-FAMILY 
showed O 
an O 
increase O 
with O 
increasing O 
maceration O 
time O 
. O 
Ellagitannins O 
were O 
extracted O 
faster O 
during O 
the O 
first O 
3months O 
; O 
after O 
6months O 
an O 
important O 
decrease O 
was O 
observed O 
. O 
Wines O 
with O 
winewoods O 
subjected O 
to O 
watering O 
during O 
toasting O 
were O 
lower O 
in O 
ellagitannins O 
concentrations O 
and O 
demonstrated O 
the O 
greatest O 
decrease O 
of O 
these O 
compounds O 
during O 
maceration O 
. O 
Astringency O 
and O 
bitterness O 
intensified O 
with O 
increasing O 
ellagitannins O 
. O 
Lactones B-FAMILY 
induced O 
positive O 
sweetness O 
sensations O 
, O 
whereas O 
furanic B-FAMILY 
and O 
guaiacol B-TRIVIAL 
compounds O 
influenced O 
bitterness O 
and O 
astringency O 
. O 
Spicy O 
and O 
vanilla O 
descriptors O 
were O 
related O 
to O 
eugenol B-TRIVIAL 
, O 
vanillin B-TRIVIAL 
and O 
other O 
odorous O 
chemicals O 
. O 

precursor O 
of O 
tetraterpenoids B-FAMILY 
from O 
the O 
soft O 
coral O 
Sarcophyton O 
glaucum O 
. O 

new O 
precursor O 
of O 
tetraterpenoids B-FAMILY 
, O 
Sarglaucol B-TRIVIAL 
( O 
1 O 
) O 
, O 
along O 
with O 
eight O 
known O 
compounds O 
have O 
been O 
isolated O 
from O 
the O 
soft O 
coral O 
Sarcophyton O 
glaucum O 
collected O 
from O 
the O 
Sanya O 
Bay O 
, O 
Hainan O 
Island O 
, O 
China O 
. O 
Their O 
structures O 
were O 
elucidated O 
through O 
spectroscopic O 
techniques O 
including O 
1D- O 
and O 
2D-NMR O 
, O 
and O 
their O 
relative O 
configurations O 
were O 
also O 
assigned O 
by O 
NMR O 
and O 
NOESY O 
analysis O 
. O 
Compounds O 
1 O 
showed O 
weak O 
antitumour O 
activities O 
. O 

attachment O 
of O 
inert O 
polymers O 
, O 
such O 
as O 
polyethyleneglycol B-SYSTEMATIC 
, O 
to O 
proteins O 
has O 
driven O 
the O 
emergence O 
of O 
a O 
multibillion O 
dollar O 
biotechnology O 
industry O 
. O 
In O 
all O 
cases O 
, O 
proteins O 
have O 
been O 
stabilized O 
or O 
altered O 
by O 
covalently O 
coupling O 
the O 
pre O 
- O 
existing O 
polymer O 
to O 
the O 
surface O 
of O 
the O 
protein O 
. O 
This O 
approach O 
is O 
inherently O 
limited O 
by O 
a O 
lack O 
of O 
exquisite O 
control O 
of O 
polymer O 
architecture O 
, O 
chain O 
length O 
, O 
site O 
and O 
density O 
of O 
attachment O 
. O 
Using O 
a O 
novel O 
water O 
- O 
soluble O 
atom O 
transfer O 
radical O 
polymerization O 
initiator O 
, O 
we O 
have O 
grown O 
temperature- O 
and O 
pH-responsive O 
polymers O 
from O 
the O 
surface O 
of O 
a O 
model O 
protein O 
, O 
the O 
enzyme O 
chymotrypsin O 
. O 
Poly(2-(dimethylamino)ethyl B-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
changes O 
in O 
conformation O 
with O 
altered O 
temperature O 
and O 
pH O 
. O 
Growing O 
the O 
polymer O 
from O 
the O 
surface O 
of O 
chymotrypsin O 
we O 
were O 
able O 
to O 
demonstrate O 
that O 
changes O 
in O 
temperature O 
or O 
pH O 
can O 
change O 
predictably O 
the O 
conformation O 
of O 
the O 
polymer O 
surrounding O 
the O 
enzyme O 
, O 
which O 
in O 
turn O 
enabled O 
the O 
rational O 
tailoring O 
of O 
enzyme O 
activity O 
and O 
stability O 
. O 
Using O 
what O 
we O 
now O 
term O 
" O 
Polymer O 
- O 
Based O 
Protein O 
Engineering O 
" O 
we O 
have O 
increased O 
the O 
activity O 
and O 
stability O 
of O 
chymotrypsin O 
by O 
an O 
order O 
of O 
magnitude O 
at O 
pH's O 
where O 
the O 
enzyme O 
is O 
usually O 
inactive O 
or O 
unstable O 
. O 

GABA B-ABBREVIATION 
A O 
receptor O 
subunits O 
heterologously O 
expressed O 
in O 
Xenopus O 
oocytes O 
. O 

γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
A O 
receptor O 
is O 
composed O 
of O 
a O 
variety O 
of O 
subunits O 
and O 
combinations O 
and O 
shows O 
a O 
characteristic O 
distribution O 
in O 
the O 
CNS O 
. O 
To O 
date O 
, O 
20 O 
subunits O 
of O 
the O 
GABA B-ABBREVIATION 
A O 
receptor O 
have O 
been O 
cloned O 
: O 
α1-6 O 
, O 
β1-4 O 
, O 
γ1-3 O 
, O 
δ O 
, O 
π O 
, O 
ε O 
, O 
Θ O 
, O 
and O 
ρ1-3 O 
. O 
Oocyte O 
of O 
Xenopus O 
laevis O 
is O 
one O 
of O 
the O 
most O 
frequently O 
used O 
heterologous O 
expression O 
systems O 
, O 
which O 
are O 
used O 
to O 
design O 
and O 
analyze O 
specific O 
combinations O 
of O 
GABA B-ABBREVIATION 
A O 
receptor O 
subunits O 
. O 
In O 
oocytes O 
, O 
a O 
certain O 
GABA B-ABBREVIATION 
A O 
receptor O 
function O 
is O 
studied O 
only O 
by O 
comparing O 
the O 
amplitude O 
of O 
the O 
response O 
to O 
GABA B-ABBREVIATION 
and O 
other O 
drugs O 
by O 
physiological O 
and O 
pharmacological O 
methods O 
. O 
According O 
to O 
the O 
studies O 
on O 
Xenopus O 
laevis O 
oocytes O 
, O 
the O 
α1β2γ2S O 
receptor O 
combination O 
is O 
mostly O 
used O 
. O 
The O 
α1 O 
- O 
containing O 
receptors O 
mediate O 
sedative O 
and O 
anticonvulsant O 
acts O 
. O 
The O 
results O 
of O 
studies O 
on O 
oocytes O 
show O 
that O 
PKA O 
, O 
NKCC1 O 
, O 
P2X3 O 
receptors O 
, O 
and O 
GABA B-ABBREVIATION 
A O 
receptor O 
- O 
associated O 
protein O 
, O 
etc O 
. O 
, O 
are O 
existing O 
systems O 
that O 
show O 
different O 
reactivity O 
to O 
the O 
GABA B-ABBREVIATION 
A O 
receptors O 
. O 
The O 
GABA B-ABBREVIATION 
A O 
receptor O 
subunits O 
contain O 
distinct O 
binding O 
sites O 
for O 
BZDs B-FAMILY 
, O 
neurosteroids B-FAMILY 
, O 
general O 
anesthetics O 
, O 
etc O 
. O 
, O 
which O 
are O 
responsible O 
for O 
the O 
numerous O 
functions O 
of O 
the O 
GABA B-ABBREVIATION 
A O 
receptor O 
. O 
A O 
variety O 
of O 
other O 
drugs O 
, O 
such O 
as O 
topiramate B-TRIVIAL 
, O 
TG41 B-IDENTIFIER 
, O 
(+)- B-MULTIPLE 
and I-MULTIPLE 
(-)-borneol I-MULTIPLE 
, O 
apigenin B-TRIVIAL 
, O 
and O 
6-methylflavone B-SYSTEMATIC 
could O 
also O 
have O 
modulatory O 
effects O 
on O 
the O 
GABA B-ABBREVIATION 
A O 
receptors O 
. O 
Some O 
of O 
the O 
different O 
models O 
and O 
hypotheses O 
on O 
GABA B-ABBREVIATION 
A O 
receptor O 
structure O 
and O 
function O 
have O 
been O 
achieved O 
by O 
using O 
the O 
two O 
- O 
electrode O 
voltage O 
clamp O 
method O 
in O 
oocytes O 
. O 

imbalance O 
in O 
expression O 
of O 
the O 
human O 
aldo O 
- O 
keto O 
reductases O 
AKR1C1-AKR1C3 O 
is O 
related O 
to O 
different O 
hormone O 
dependent O 
and O 
independent O 
cancers O 
and O 
some O 
other O 
diseases O 
. O 
The O 
AKR1C1-3 O 
enzymes O 
thus O 
represent O 
emerging O 
targets O 
for O 
the O 
development O 
of O 
new O 
drugs O 
. O 
Currently O 
, O 
various O 
enzymatic O 
assays O 
are O 
used O 
in O 
the O 
search O 
for O 
AKR1C O 
inhibitors O 
, O 
and O 
consequently O 
the O 
results O 
of O 
different O 
research O 
groups O 
are O 
not O 
necessarily O 
comparable O 
. O 
During O 
our O 
recent O 
search O 
for O 
AKR1C O 
inhibitors O 
, O 
we O 
found O 
a O 
cyclopentanol B-SYSTEMATIC 
derivative O 
( O 
2-(4-chlorobenzylidene)cyclopentanol B-SYSTEMATIC 
, O 
CBCP-ol B-ABBREVIATION 
) O 
and O 
its O 
respective O 
cyclopentanone B-SYSTEMATIC 
counterpart O 
( O 
2-(4-chlorobenzylidene)cyclopentanone B-SYSTEMATIC 
, O 
CBCP-one B-ABBREVIATION 
) O 
that O 
acted O 
as O 
AKR1C O 
substrates O 
. O 
We O 
determined O 
the O 
kinetic O 
parameters O 
KM O 
, O 
kcat O 
and O 
kcat O 
/ O 
KM O 
for O 
oxidation O 
of O 
CBCP-ol B-ABBREVIATION 
and O 
reduction O 
of O 
CBCP-one B-ABBREVIATION 
by O 
AKR1C O 
enzymes O 
in O 
the O 
presence O 
of O 
NAD(+) B-ABBREVIATION 
/ O 
NADP(+) B-ABBREVIATION 
and O 
NADH B-ABBREVIATION 
/ O 
NADPH B-ABBREVIATION 
, O 
respectively O 
. O 
The O 
catalytic O 
efficiencies O 
for O 
the O 
oxidation O 
of O 
CBCP-ol B-ABBREVIATION 
in O 
the O 
presence O 
of O 
NAD(+) B-ABBREVIATION 
or O 
NADP(+) B-ABBREVIATION 
were O 
in O 
general O 
higher O 
when O 
compared O 
to O 
the O 
catalytic O 
efficiencies O 
for O 
reduction O 
of O 
CBCP-one B-ABBREVIATION 
in O 
the O 
presence O 
of O 
NADH B-ABBREVIATION 
or O 
NADPH B-ABBREVIATION 
. O 
When O 
NADPH B-ABBREVIATION 
was O 
used O 
, O 
as O 
compared O 
to O 
NADH B-ABBREVIATION 
, O 
the O 
reductions O 
of O 
CBCP-one B-ABBREVIATION 
by O 
AKR1C1 O 
, O 
AKR1C2 O 
and O 
AKR1C3 O 
were O 
14- O 
, O 
51- O 
and O 
31-fold O 
more O 
efficient O 
, O 
respectively O 
. O 
When O 
comparing O 
to O 
oxidations O 
of O 
the O 
well O 
- O 
known O 
artificial O 
substrates O 
, O 
1-acenaphthenol B-SYSTEMATIC 
and O 
S-tetralol B-TRIVIAL 
, O 
we O 
observed O 
similar O 
catalytic O 
efficiencies O 
as O 
for O 
CBCP-ol B-ABBREVIATION 
oxidation O 
with O 
NAD(+) B-ABBREVIATION 
and O 
NADP(+) B-ABBREVIATION 
. O 
The O 
comparison O 
of O 
CBCP-one B-ABBREVIATION 
reduction O 
with O 
NADPH B-ABBREVIATION 
to O 
reductions O 
of O 
physiological O 
substrates O 
revealed O 
in O 
general O 
higher O 
efficiencies O 
, O 
except O 
for O 
reduction O 
of O 
9-cis-retinaldehyde B-SYSTEMATIC 
by O 
AKR1C3 O 
. O 
This O 
NADPH B-ABBREVIATION 
-dependent O 
reduction O 
of O 
CBCP-one B-ABBREVIATION 
was O 
then O 
used O 
to O 
re O 
- O 
evaluate O 
inhibitory O 
potencies O 
of O 
the O 
known O 
inhibitors O 
of O 
the O 
target O 
AKR1C3 O 
and O 
the O 
anti-target O 
AKR1C2 O 
, O 
medroxyprogesterone B-TRIVIAL 
acetate I-TRIVIAL 
and O 
ursodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
respectively O 
, O 
showing O 
Ki O 
constants O 
similar O 
to O 
the O 
reported O 
values O 
. O 
Our O 
data O 
thus O 
confirm O 
that O 
the O 
new O 
enzymatic O 
assays O 
with O 
two O 
cyclopentane B-SYSTEMATIC 
substrates O 
CBP-ol B-ABBREVIATION 
and O 
CBP-one B-ABBREVIATION 
, O 
and O 
especially O 
reduction O 
of O 
CBCP-one B-ABBREVIATION 
with O 
NADPH B-ABBREVIATION 
, O 
are O 
appropriate O 
for O 
the O 
evaluation O 
of O 
AKR1C O 
inhibitors O 
. O 

paraoxonase O 
double O 
mutants O 
hydrolyze O 
V O 
and O 
G O 
class O 
organophosphorus B-FAMILY 
nerve O 
agents O 
. O 

of O 
human O 
paraoxonase O 
1 O 
( O 
PON1 O 
) O 
are O 
being O 
developed O 
as O 
catalytic O 
bioscavengers O 
for O 
the O 
organophosphorus B-FAMILY 
chemical O 
warfare O 
agents O 
( O 
OP O 
) O 
. O 
It O 
is O 
preferable O 
that O 
the O 
new O 
PON1 O 
variants O 
have O 
broad O 
spectrum O 
hydrolase O 
activities O 
to O 
hydrolyze O 
both O 
G- O 
and O 
V-class O 
OPs O 
. O 
H115W O 
PON1 O 
has O 
shown O 
improvements O 
over O 
wild O 
type O 
PON1 O 
in O 
its O 
capacity O 
to O 
hydrolyze O 
some O 
OP O 
compounds O 
. O 
We O 
improved O 
upon O 
these O 
activities O 
either O 
by O 
substituting O 
a O 
tryptophan B-TRIVIAL 
( O 
F347W O 
) O 
near O 
the O 
putative O 
active O 
site O 
residues O 
for O 
enhanced O 
substrate O 
binding O 
or O 
by O 
reducing O 
a O 
bulky O 
group O 
( O 
Y71A O 
) O 
at O 
the O 
periphery O 
of O 
the O 
putative O 
enzyme O 
active O 
site O 
. O 
When O 
compared O 
to O 
H115W O 
alone O 
, O 
we O 
found O 
that O 
H115W O 
/ O 
Y71A O 
and O 
H115W O 
/ O 
F347W O 
maintained O 
VX O 
catalytic O 
efficiency O 
but O 
showed O 
mixed O 
results O 
for O 
the O 
capacity O 
to O 
hydrolyze O 
paraoxon B-TRIVIAL 
. O 
Testing O 
our O 
double O 
mutants O 
against O 
racemic B-TRIVIAL 
sarin I-TRIVIAL 
, O 
we O 
observed O 
reduced O 
values O 
of O 
KM O 
for O 
H115W O 
/ O 
F347W O 
that O 
modestly O 
improved O 
catalytic O 
efficiency O 
over O 
wild O 
type O 
and O 
H115W O 
. O 
Contrary O 
to O 
previous O 
reports O 
, O 
we O 
show O 
that O 
H115W O 
can O 
hydrolyze O 
soman B-TRIVIAL 
, O 
and O 
the O 
double O 
mutant O 
H115W O 
/ O 
Y71A O 
is O 
nearly O 
4-fold O 
more O 
efficient O 
than O 
H115W O 
for O 
paraoxon B-TRIVIAL 
hydrolysis O 
. O 
We O 
also O 
observed O 
modest O 
stereoselectivity O 
for O 
hydrolysis O 
of O 
the O 
P(-) O 
stereoisomer O 
of O 
tabun B-TRIVIAL 
by O 
H115W O 
/ O 
F347W O 
. O 
These O 
data O 
demonstrate O 
enhancements O 
made O 
in O 
PON1 O 
for O 
the O 
purpose O 
of O 
developing O 
an O 
improved O 
catalytic O 
bioscavenger O 
to O 
protect O 
cholinesterase O 
against O 
chemical O 
warfare O 
agents O 
. O 

Expression O 
of O 
Human O 
Cytochrome O 
P450 O 
Enzymes O 
from O 
the O 
CYP3A O 
Subfamily O 
in O 
the O 
Brains O 
of O 
Alcoholics B-FAMILY 
and O 
Drug O 
Free O 
Controls O 
. O 

P450 O 
( O 
P450 O 
, O 
CYP O 
) O 
enzymes O 
are O 
responsible O 
for O 
the O 
metabolism O 
of O 
most O 
commonly O 
used O 
drugs O 
. O 
Amongst O 
these O 
enzymes O 
, O 
CYP3A O 
forms O 
mediate O 
the O 
clearance O 
of O 
around O 
40-50 O 
% O 
of O 
drugs O 
and O 
may O 
also O 
play O 
roles O 
in O 
the O 
biotransformation O 
of O 
endogenous O 
compounds O 
. O 
CYP3A O 
forms O 
are O 
expressed O 
both O 
in O 
the O 
liver O 
and O 
extrahepatically O 
. O 
However O 
little O 
is O 
known O 
about O 
the O 
expression O 
of O 
CYP3A O 
proteins O 
in O 
specific O 
regions O 
of O 
the O 
human O 
brain O 
. O 
In O 
this O 
study O 
, O 
form O 
- O 
selective O 
antibodies O 
raised O 
to O 
CYP3A4 O 
and O 
CYP3A5 O 
were O 
utilized O 
to O 
characterize O 
the O 
expression O 
of O 
these O 
forms O 
in O 
the O 
human O 
brain O 
. O 
Both O 
CYP3A4 O 
and O 
CYP3A5 O 
immunoreactivity O 
was O 
found O 
to O 
varying O 
extents O 
in O 
the O 
microsomal O 
fractions O 
of O 
cortex O 
, O 
hippocampus O 
, O 
basal O 
ganglia O 
, O 
amygdala O 
and O 
cerebellum O 
. O 
However O 
, O 
only O 
CYP3A4 O 
expression O 
was O 
observed O 
in O 
the O 
mitochondrial O 
fractions O 
of O 
these O 
brain O 
regions O 
. O 
N B-FORMULA 
-terminal O 
sequencing O 
confirmed O 
the O 
principal O 
antigen O 
detected O 
by O 
the O 
anti-CYP3A4 O 
antibody O 
in O 
cortical O 
microsomes O 
to O 
be O 
CYP3A4 O 
. O 
Immunohistochemical O 
analysis O 
revealed O 
that O 
CYP3A4 O 
and O 
CYP3A5 O 
expression O 
was O 
primarily O 
localized O 
in O 
the O 
soma O 
and O 
axonal O 
hillock O 
of O 
neurons O 
and O 
varied O 
according O 
to O 
cell O 
type O 
and O 
cell O 
layer O 
within O 
brain O 
regions O 
. O 
Finally O 
, O 
analysis O 
of O 
the O 
frontal O 
cortex O 
of O 
chronic O 
alcohol B-FAMILY 
abusers O 
revealed O 
elevated O 
expression O 
of O 
CYP3A4 O 
in O 
microsomal O 
but O 
not O 
mitochondrial O 
fractions O 
; O 
CYP3A5 O 
expression O 
was O 
unchanged O 
. O 
The O 
site O 
- O 
specific O 
expression O 
of O 
CYP3A4 O 
and O 
CYP3A5 O 
in O 
the O 
human O 
brain O 
may O 
have O 
implications O 
for O 
the O 
role O 
of O 
these O 
enzymes O 
in O 
both O 
normal O 
brain O 
physiology O 
and O 
the O 
response O 
to O 
drugs O 
. O 

Role O 
for O 
Cargo O 
in O 
the O 
Activation O 
of O 
ADP B-ABBREVIATION 
-Ribosylation O 
Factors O 
( O 
Arf O 
) O 
and O 
Adaptor O 
Recruitment O 
. O 

traffic O 
requires O 
the O 
specific O 
concentration O 
of O 
protein O 
cargos O 
and O 
exclusion O 
of O 
other O 
proteins O 
into O 
nascent O 
carriers O 
. O 
Critical O 
components O 
of O 
this O 
selectivity O 
are O 
the O 
protein O 
adaptors O 
that O 
bind O 
to O 
short O 
, O 
linear O 
motifs O 
in O 
the O 
cytoplasmic O 
tails O 
of O 
transmembrane O 
protein O 
cargos O 
and O 
sequester O 
them O 
into O 
nascent O 
carriers O 
. O 
The O 
recruitment O 
of O 
the O 
adaptors O 
is O 
mediated O 
by O 
activated O 
Arf O 
GTPases O 
and O 
the O 
Arf O 
- O 
adaptor O 
complexes O 
mark O 
sites O 
of O 
carrier O 
formation O 
. O 
However O 
, O 
the O 
nature O 
of O 
the O 
signal(s) O 
that O 
initiate O 
carrier O 
biogenesis O 
remains O 
unknown O 
. O 
We O 
examined O 
the O 
specificity O 
and O 
initial O 
sites O 
of O 
recruitment O 
of O 
Arf O 
- O 
dependent O 
adaptors O 
( O 
AP-1 O 
and O 
GGAs O 
) O 
in O 
response O 
to O 
the O 
Golgi O 
or O 
endosomal O 
localization O 
of O 
specific O 
cargo O 
proteins O 
( O 
furin O 
, O 
mannose-6-phosphate B-SYSTEMATIC 
receptor O 
( O 
M6PR O 
) O 
and O 
M6PR O 
lacking O 
a O 
C B-FORMULA 
-terminal O 
domain O 
M6PRΔC O 
) O 
. O 
We O 
find O 
that O 
cargo O 
promotes O 
the O 
recruitment O 
of O 
specific O 
adaptors O 
, O 
suggesting O 
that O 
it O 
is O 
part O 
of O 
an O 
upstream O 
signaling O 
event O 
. O 
Cargos O 
do O 
not O 
promote O 
adaptor O 
recruitment O 
to O 
all O 
compartments O 
in O 
which O 
they O 
reside O 
and O 
thus O 
additional O 
factors O 
regulate O 
the O 
cargo's O 
ability O 
to O 
promote O 
Arf O 
activation O 
and O 
adaptor O 
recruitment O 
. O 
We O 
document O 
that O 
within O 
a O 
given O 
compartment O 
different O 
cargos O 
recruit O 
different O 
adaptors O 
suggesting O 
that O 
there O 
is O 
little O 
or O 
no O 
free O 
, O 
activated O 
Arf O 
at O 
the O 
membrane O 
and O 
that O 
Arf O 
activation O 
is O 
spatially O 
and O 
temporally O 
coupled O 
to O 
the O 
cargo O 
and O 
the O 
adaptor O 
. O 
Using O 
temperature O 
block O 
, O 
Brefeldin B-TRIVIAL 
A I-TRIVIAL 
, O 
and O 
recovery O 
from O 
each O 
, O 
we O 
found O 
that O 
the O 
cytoplasmic O 
tail O 
of O 
M6PR O 
causes O 
the O 
recruitment O 
of O 
AP-1 O 
and O 
GGAs O 
to O 
recycling O 
endosomes O 
and O 
not O 
at O 
the O 
Golgi O 
, O 
as O 
predicted O 
by O 
steady O 
state O 
staining O 
profiles O 
. O 
These O 
results O 
are O 
discussed O 
with O 
respect O 
to O 
the O 
generation O 
of O 
novel O 
models O 
for O 
cargo O 
- O 
dependent O 
regulation O 
of O 
membrane O 
traffic O 
. O 

sonochemical O 
synthesis O 
of O 
novel O 
pyrazolyne B-TRIVIAL 
derivates O 
at O 
ambient O 
conditions O 
. O 

condensation O 
reaction O 
of O 
4-acetamidoacetophenone B-SYSTEMATIC 
with O 
aromatic B-FAMILY 
aldehydes I-FAMILY 
under O 
ultrasonic O 
irradiation O 
affords O 
acetylaminochalcones B-FAMILY 
( O 
yields O 
: O 
71-90% O 
) O 
which O 
also O 
under O 
ultrasonic O 
irradiation O 
and O 
in O 
the O 
presence O 
of O 
sodium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
aqueous O 
undergo O 
facile O 
and O 
clean O 
cyclocondensation O 
with O 
hydrazine B-SYSTEMATIC 
to O 
afford O 
3-(4-acetamidophenyl)-5-(aryl)-1-H-pyrazolines B-FAMILY 
. O 
The O 
pyrazolines B-FAMILY 
were O 
obtained O 
in O 
good O 
to O 
excellent O 
yields O 
( O 
81-89% O 
) O 
, O 
and O 
were O 
characterized O 
by O 
conventional O 
spectral O 
data O 
. O 
The O 
work O 
- O 
up O 
is O 
simple O 
and O 
the O 
results O 
obtained O 
indicate O 
that O 
, O 
unlike O 
classical O 
heating O 
, O 
ultrasonic O 
irradiation O 
results O 
in O 
higher O 
yields O 
, O 
shorter O 
reaction O 
times O 
( O 
1.5-2.3 O 
h O 
) O 
and O 
milder O 
conditions O 
. O 

series O 
of O 
new O 
substrate O 
analogue O 
inhibitors O 
of O 
the O 
WNV O 
NS2B-NS3 O 
protease O 
containing O 
decarboxylated B-TRIVIAL 
arginine I-TRIVIAL 
mimetics O 
at O 
the O 
P1 O 
position O 
was O 
developed O 
. O 
Among O 
the O 
various O 
analogues O 
, O 
trans-(4-guanidino)cyclohexylmethylamide B-SYSTEMATIC 
( O 
GCMA B-ABBREVIATION 
) O 
was O 
identified O 
as O 
the O 
most O 
suitable O 
P1 O 
residue O 
. O 
In O 
combination O 
with O 
dichloro B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
phenylacetyl I-FAMILY 
groups O 
at O 
the O 
P4 O 
position O 
, O 
three O 
inhibitors O 
with O 
inhibition O 
constants O 
of O 
< O 
0.2 O 
μM O 
were O 
obtained O 
. O 
These O 
GCMA B-ABBREVIATION 
inhibitors O 
have O 
a O 
better O 
selectivity O 
profile O 
than O 
the O 
previously O 
described O 
agmatine B-TRIVIAL 
analogues O 
, O 
and O 
possess O 
negligible O 
affinity O 
for O 
the O 
trypsin O 
- O 
like O 
serine B-TRIVIAL 
proteases O 
thrombin O 
, O 
factor O 
Xa O 
, O 
and O 
matriptase O 
. O 
A O 
crystal O 
structure O 
in O 
complex O 
with O 
the O 
WNV O 
protease O 
was O 
determined O 
for O 
one O 
of O 
the O 
most O 
potent O 
inhibitors O 
, O 
3,4-dichlorophenylacetyl-Lys-Lys-GCMA B-SYSTEMATIC 
( O 
K(i)=0.13 O 
μM O 
) O 
. O 
The O 
inhibitor O 
adopts O 
a O 
horseshoe O 
- O 
like O 
conformation O 
, O 
most O 
likely O 
due O 
to O 
a O 
hydrophobic O 
contact O 
between O 
the O 
P4 O 
phenyl B-SYSTEMATIC 
ring O 
and O 
the O 
P1 O 
cyclohexyl B-SYSTEMATIC 
group O 
, O 
which O 
is O 
further O 
stabilized O 
by O 
an O 
intramolecular O 
hydrogen B-SYSTEMATIC 
bond O 
between O 
the O 
P1 O 
guanidino B-SYSTEMATIC 
group O 
and O 
the O 
P4 O 
carbonyl B-SYSTEMATIC 
oxygen I-SYSTEMATIC 
atom O 
. O 
These O 
inhibitors O 
are O 
stable O 
, O 
readily O 
accessible O 
, O 
and O 
have O 
a O 
noncovalent O 
binding O 
mode O 
. O 
Therefore O 
, O 
they O 
may O 
serve O 
as O 
suitable O 
lead O 
structures O 
for O 
further O 
development O 
. O 

difference O 
in O 
the O 
mechanism O 
of O 
nonlinear O 
pharmacokinetics O 
of O 
e2074 B-IDENTIFIER 
, O 
a O 
novel O 
sodium B-SYSTEMATIC 
channel O 
inhibitor O 
, O 
in O 
rats O 
, O 
dogs O 
, O 
and O 
monkeys O 
. O 

chemical O 
entities O 
often O 
exhibit O 
nonlinear O 
pharmacokinetics O 
( O 
PK O 
) O 
profiles O 
in O 
experimental O 
animals O 
. O 
However O 
, O 
the O 
number O 
of O 
studies O 
that O 
have O 
focused O 
on O 
species O 
differences O 
in O 
nonlinear O 
PK O 
is O 
very O 
limited O 
; O 
thus O 
, O 
the O 
aim O 
of O 
this O 
study O 
was O 
to O 
clarify O 
the O 
mechanism O 
of O 
the O 
nonlinear O 
PK O 
of O 
E2074 B-IDENTIFIER 
( O 
2-[(2R)-2-fluoro-3-{(3r)-[(3-fluorobenzyl)oxy]-8-azabicyclo[3.2.1]oct-8-yl}propyl]-4,5-dimethyl-2,4-dihydro-3H-1,2,4-triazol-3-one B-SYSTEMATIC 
) O 
, O 
a O 
novel O 
sodium B-SYSTEMATIC 
channel O 
inhibitor O 
, O 
in O 
rats O 
, O 
dogs O 
, O 
and O 
monkeys O 
. O 
Nonlinear O 
PK O 
profiles O 
with O 
more O 
than O 
dose O 
- O 
proportional O 
increases O 
of O 
Cmax O 
and O 
area O 
under O 
the O 
plasma O 
concentration O 
curve O 
were O 
observed O 
in O 
all O 
species O 
after O 
oral O 
administration O 
. O 
The O 
Michaelis-Menten O 
constant O 
( O 
Km O 
) O 
values O 
of O 
hepatic O 
microsomal O 
metabolism O 
were O 
7.23 O 
and O 
0.41 O 
μM O 
in O 
rats O 
and O 
dogs O 
in O 
vitro O 
, O 
respectively O 
, O 
which O 
were O 
lower O 
than O 
the O 
unbound O 
maximum O 
plasma O 
concentrations O 
after O 
oral O 
administration O 
in O 
vivo O 
, O 
indicating O 
that O 
the O 
nonlinear O 
PK O 
in O 
rats O 
and O 
dogs O 
was O 
attributable O 
to O 
the O 
saturation O 
of O 
hepatic O 
metabolism O 
. O 
However O 
, O 
we O 
do O 
not O 
believe O 
that O 
the O 
saturation O 
of O 
hepatic O 
metabolism O 
was O 
the O 
mechanism O 
of O 
nonlinearity O 
in O 
monkeys O 
because O 
of O 
the O 
high O 
Km O 
value O 
( O 
42.44 O 
μM O 
) O 
observed O 
in O 
liver O 
microsomes O 
. O 
Intestinal O 
metabolism O 
was O 
observed O 
in O 
monkey O 
intestinal O 
microsomes O 
but O 
not O 
in O 
rats O 
and O 
dogs O 
, O 
and O 
the O 
nonlinear O 
PK O 
in O 
monkeys O 
was O 
diminished O 
by O 
inhibition O 
of O 
intestinal O 
metabolism O 
with O 
a O 
concomitant O 
oral O 
dose O 
of O 
ketoconazole B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
saturation O 
of O 
the O 
intestinal O 
metabolism O 
is O 
the O 
potential O 
mechanism O 
of O 
nonlinearity O 
in O 
monkeys O 
. O 
P-glycoprotein O 
was O 
not O 
involved O 
in O 
the O 
nonlinear O 
PK O 
profiles O 
in O 
any O 
species O 
. O 
In O 
conclusion O 
, O 
the O 
mechanism O 
of O 
the O 
nonlinear O 
PK O 
of O 
E2074 B-IDENTIFIER 
is O 
species O 
dependent O 
, O 
with O 
the O 
saturation O 
of O 
hepatic O 
metabolism O 
in O 
rats O 
and O 
dogs O 
and O 
that O 
of O 
intestinal O 
metabolism O 
in O 
monkeys O 
being O 
the O 
primary O 
cause O 
. O 

neuroprotective O 
activity O 
of O 
diterpenoids B-FAMILY 
isolated O 
from O 
Sideritis O 
spp O 
. O 

RELEVANCE O 
: O 
The O 
species O 
of O 
the O 
genus O 
Sideritis O 
are O 
extensively O 
used O 
in O 
the O 
Mediterranean O 
area O 
in O 
folk O 
medicine O 
for O 
their O 
digestive O 
, O 
antimicrobial O 
, O 
anti-inflammatory O 
and O 
antioxidant O 
properties O 
, O 
among O 
others O 
. O 
Moreover O 
, O 
Sideritis O 
species O 
as O 
tea O 
infusions O 
are O 
popularly O 
known O 
for O 
improving O 
memory O 
function O 
and O 
cognitive O 
ability O 
. O 
Diterpenoids B-FAMILY 
are O 
one O 
of O 
the O 
most O 
abundant O 
and O 
important O 
pharmacological O 
interest O 
of O 
the O 
classes O 
of O 
natural O 
products O 
presented O 
in O 
these O 
medicinal O 
plants O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
determine O 
for O 
the O 
first O 
time O 
the O 
neuroprotective O 
effects O 
, O 
based O 
on O 
their O 
antioxidant O 
properties O 
, O 
of O 
the O 
three O 
isolated O 
major O 
diterpenoids B-FAMILY 
andalusol B-TRIVIAL 
, O 
conchitriol B-TRIVIAL 
and O 
lagascatriol B-TRIVIAL 
in O 
an O 
oxidative O 
stress O 
model O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
H2O2 B-FORMULA 
was O 
used O 
as O 
oxidant O 
inductor O 
and O 
rat O 
adrenal O 
pheochromocytoma O 
PC12 O 
cells O 
as O 
cellular O 
model O 
. O 
Cell O 
viability O 
was O 
measured O 
using O 
MTT B-ABBREVIATION 
and O 
LDH O 
assays O 
, O 
lipid O 
peroxidation O 
was O 
determined O 
by O 
HPLC O 
, O 
GSH B-ABBREVIATION 
and O 
GSSG B-ABBREVIATION 
levels O 
assessed O 
by O 
fluorometric O 
techniques O 
, O 
enzymatic O 
activity O 
and O 
protein O 
expression O 
were O 
determined O 
by O 
spectrofometric O 
techniques O 
and O 
Western O 
blot O 
, O 
respectively O 
. O 
RESULTS O 
: O 
Pretreatments O 
with O 
the O 
three O 
diterpenoids B-FAMILY 
significantly O 
attenuated O 
H2O2 B-FORMULA 
-induced O 
changes O 
in O 
mitochondrial O 
integrity O 
and O 
activity O 
( O 
MTT B-ABBREVIATION 
assay O 
) O 
, O 
in O 
cell O 
membrane O 
integrity O 
( O 
LDH O 
assay O 
) O 
and O 
in O 
cell O 
morphology O 
. O 
Moreover O 
, O 
these O 
diterpenoids B-FAMILY 
inhibited O 
intracellular O 
ROS O 
production O 
H2O2 B-FORMULA 
-induced O 
, O 
reduced O 
lipid O 
peroxidation O 
and O 
counteracted O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
changes O 
. O 
Furthermore O 
, O 
both O 
activities O 
and O 
protein O 
expression O 
of O 
the O 
endogenous O 
antioxidant O 
enzymes O 
( O 
CAT O 
, O 
SOD O 
, O 
GR O 
, O 
GPx O 
and O 
HO-1 O 
) O 
were O 
increased O 
. O 
The O 
Nrf2 O 
pathway O 
was O 
involved O 
, O 
at O 
least O 
in O 
part O 
, O 
in O 
the O 
protective O 
effects O 
of O 
these O 
diterpenoids B-FAMILY 
. O 
CONCLUSION O 
: O 
These O 
findings O 
suggest O 
that O 
these O 
natural O 
compounds O 
provide O 
significant O 
antioxidant O 
effects O 
in O 
PC12 O 
under O 
for O 
counteracting O 
the O 
oxidative O 
damage O 
H2O2 B-FORMULA 
-induced O 
and O 
their O 
potential O 
role O 
as O 
useful O 
agents O 
for O 
the O 
prevention O 
of O 
those O 
oxidative O 
stress O 
- O 
mediated O 
dementia O 
disorders O 
. O 
Andalusol B-TRIVIAL 
was O 
the O 
most O 
active O 
compound O 
among O 
the O 
studied O 
diterpenoids B-FAMILY 
. O 

and O 
gastric O 
antisecretory O 
effects O 
of O 
dichloromethane B-SYSTEMATIC 
fraction O 
and O 
piplartine B-TRIVIAL 
obtained O 
from O 
fruits O 
of O 
Piper O 
tuberculatum O 
Jacq O 
. O 
in O 
rats O 
. O 

RELEVANCE O 
: O 
Piper O 
tuberculatum O 
Jacq O 
. O 
( O 
Piperaceae O 
) O 
is O 
medicinally O 
used O 
as O 
an O 
analgesic O 
and O 
as O 
a O 
treatment O 
for O 
gastric O 
complaints O 
. O 
Thus O 
, O 
the O 
current O 
study O 
aimed O 
to O 
investigate O 
the O 
gastroprotective O 
and O 
antisecretory O 
properties O 
of O 
the O 
dichloromethane B-SYSTEMATIC 
fraction O 
of O 
the O 
fruit O 
of O 
Piper O 
tuberculatum O 
( O 
DFPT O 
) O 
and O 
piplartine B-TRIVIAL 
, O 
a O 
compound O 
isolated O 
from O 
the O 
DFPT O 
, O 
in O 
rats O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Gastric O 
ulcers O 
were O 
induced O 
in O 
fasted O 
rats O 
by O 
oral O 
administration O 
of O 
absolute O 
ethanol B-SYSTEMATIC 
and O 
then O 
mucus O 
content O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
were O 
measured O 
. O 
Mechanisms O 
underlying O 
the O 
antisecretory O 
action O 
were O 
studied O 
through O 
gastric O 
H(+) B-FORMULA 
, O 
K(+) B-FORMULA 
-ATPase O 
activity O 
of O 
highly O 
purified O 
rabbit O 
gastric O 
microsomes O 
and O 
pylorus O 
ligature O 
method O 
in O 
rats O 
. O 
RESULTS O 
: O 
In O 
the O 
acute O 
toxicity O 
test O 
the O 
values O 
of O 
estimated O 
LD50 O 
for O 
oral O 
and O 
intraperitoneal O 
administration O 
of O 
DFPT O 
were O 
1.6266 O 
and O 
0.2684g O 
/ O 
kg O 
, O 
respectively O 
. O 
The O 
DFPT O 
( O 
ED50=29mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
and O 
piplartine B-TRIVIAL 
( O 
4.5mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
promoted O 
gastroprotection O 
against O 
acute O 
lesions O 
induced O 
by O 
ethanol B-SYSTEMATIC 
, O 
effect O 
that O 
could O 
be O 
related O 
with O 
the O 
maintenance O 
of O 
GSH B-ABBREVIATION 
levels O 
in O 
the O 
gastric O 
mucosa O 
. O 
However O 
, O 
only O 
DFPT O 
stimulated O 
gastric O 
mucus O 
secretion O 
. O 
In O 
vitro O 
, O 
the O 
DFPT O 
and O 
piplartine B-TRIVIAL 
inhibited O 
the O 
H(+) B-FORMULA 
, O 
K(+) B-FORMULA 
-ATPase O 
activity O 
and O 
, O 
in O 
vivo O 
DFPT O 
and O 
piplartine B-TRIVIAL 
also O 
reduced O 
basal O 
gastric O 
acid O 
secretion O 
, O 
as O 
well O 
as O 
that O 
stimulated O 
by O 
pentagastrin B-TRIVIAL 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
demonstrate O 
that O 
DFPT O 
and O 
piplatine B-TRIVIAL 
cause O 
marked O 
gastroprotective O 
effects O 
accompanied O 
by O 
the O 
increase O 
and O 
maintenance O 
of O 
gastric O 
mucus O 
and O 
GSH B-ABBREVIATION 
levels O 
, O 
as O 
well O 
as O 
a O 
reduction O 
in O 
gastric O 
acid O 
secretion O 
through O 
the O 
gastrinergic O 
pathway O 
. O 

single O 
nucleotide O 
polymorphisms O 
( O 
SNPs O 
) O 
within O 
a O 
transcript's O 
coding O 
region O 
produce O 
no O 
change O 
in O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
the O 
protein O 
product O 
and O 
are O 
therefore O 
intuitively O 
assumed O 
to O 
have O 
a O 
neutral O 
effect O 
on O 
protein O 
function O 
. O 
We O 
report O 
that O 
two O 
common O 
variants O 
of O 
high O 
- O 
temperature O 
requirement O 
A1 O 
( O 
HTRA1 O 
) O 
that O 
increase O 
the O 
inherited O 
risk O 
of O 
neovascular O 
age O 
- O 
related O 
macular O 
degeneration O 
( O 
NvAMD O 
) O 
harbor O 
synonymous O 
SNPs O 
within O 
exon O 
1 O 
of O 
HTRA1 O 
that O 
convert O 
common O 
codons O 
for O 
Ala B-FORMULA 
34 O 
and O 
Gly B-FORMULA 
36 O 
to O 
less O 
frequently O 
used O 
codons O 
. O 
The O 
frequent-to O 
- O 
rare O 
codon O 
conversion O 
reduced O 
the O 
mRNA O 
translation O 
rate O 
and O 
appeared O 
to O 
compromise O 
HtrA1's O 
conformation O 
and O 
function O 
. O 
The O 
protein O 
product O 
generated O 
from O 
the O 
SNP O 
- O 
containing O 
cDNA O 
displayed O 
enhanced O 
susceptibility O 
to O 
proteolysis O 
and O 
a O 
reduced O 
affinity O 
for O 
an O 
anti-HtrA1 O 
antibody O 
. O 
The O 
NvAMD-associated O 
synonymous O 
polymorphisms O 
lie O 
within O 
HtrA1's O 
putative O 
insulin O 
- O 
like O 
growth O 
factor O 
1 O 
( O 
IGF-1 O 
) O 
binding O 
domain O 
. O 
They O 
reduced O 
HtrA1's O 
abilities O 
to O 
associate O 
with O 
IGF-1 O 
and O 
to O 
ameliorate O 
IGF-1-stimulated O 
signaling O 
events O 
and O 
cellular O 
responses O 
. O 
These O 
observations O 
highlight O 
the O 
relevance O 
of O 
synonymous O 
codon O 
usage O 
to O 
protein O 
function O 
and O 
implicate O 
homeostatic O 
protein O 
quality O 
control O 
mechanisms O 
that O 
may O 
go O 
awry O 
in O 
NvAMD O 
. O 

for O 
the O 
selection O 
of O 
catalytic O 
antibodies O 
against O 
organophosphorus B-FAMILY 
nerve O 
agents O 
. O 

the O 
strategies O 
aimed O 
at O 
biocompatible O 
means O 
for O 
organophosphorus B-FAMILY 
nerve O 
agents O 
neutralization O 
, O 
immunoglobulins O 
have O 
attracted O 
attention O 
in O 
the O 
1990's O 
and O 
2000's O 
both O 
for O 
their O 
ability O 
to O 
immobilize O 
the O 
toxicants O 
, O 
but O 
also O 
for O 
their O 
ability O 
to O 
be O 
turned O 
into O 
enzymatically O 
active O 
antibodies O 
known O 
as O 
catalytic O 
antibodies O 
or O 
abzymes O 
( O 
antibodies O 
- O 
enzymes O 
) O 
. O 
We O 
will O 
present O 
here O 
a O 
critical O 
review O 
of O 
the O 
successive O 
strategies O 
used O 
for O 
the O 
selection O 
of O 
these O 
nerve O 
agent-hydrolyzing O 
abzymes O 
, O 
based O 
on O 
hapten O 
design O 
, O 
namely O 
antibodies O 
raised O 
against O 
a O 
wide O 
variety O 
of O 
transition O 
state O 
analogs O 
, O 
and O 
eventually O 
the O 
strategies O 
based O 
on O 
anti-idiotypic O 
antibodies O 
and O 
reactibodies O 
. O 

, O 
Synthesis O 
and O 
Antiviral O 
Activity O 
of O 
2-(3-Amino-4-piperazinylphenyl)chromone B-SYSTEMATIC 
Derivatives O 
. O 

, O 
we O 
have O 
confirmed O 
that O 
the O 
antiviral O 
activities O 
of O 
the O 
chromone B-TRIVIAL 
derivatives O 
were O 
controlled O 
by O 
the O 
type O 
as O 
well O 
as O 
the O 
position O 
of O 
the O 
substituents O 
attached O 
to O 
the O 
chromone B-TRIVIAL 
core O 
structure O 
. O 
In O 
the O 
course O 
of O 
our O 
ongoing O 
efforts O 
to O 
optimize O 
the O 
antiviral O 
activity O 
of O 
the O 
chromone B-TRIVIAL 
derivatives O 
, O 
we O 
have O 
been O 
attempting O 
to O 
derivatize O 
the O 
chromone B-TRIVIAL 
scaffold O 
via O 
introduction O 
of O 
various O 
substituents O 
. O 
In O 
this O 
proof O 
- O 
of O 
- O 
concept O 
study O 
, O 
we O 
introduced O 
a O 
3-amino-4-piperazinylphenyl B-SYSTEMATIC 
functionality O 
to O 
the O 
chromone B-TRIVIAL 
scaffold O 
and O 
evaluated O 
the O 
antiviral O 
activities O 
of O 
the O 
resulting O 
chromone B-TRIVIAL 
derivatives O 
. O 
The O 
synthesized O 
2-(3-amino-4-piperazinylphenyl)-chromones B-FAMILY 
showed O 
severe O 
acute O 
respiratory O 
syndrome O 
- O 
corona O 
virus O 
(SARS-CoV)-specific O 
antiviral O 
activity O 
. O 
In O 
particular O 
, O 
the O 
2-pyridinylpiperazinylphenyl B-SYSTEMATIC 
substituents O 
provided O 
the O 
resulting O 
chromone B-TRIVIAL 
derivatives O 
with O 
selective O 
antiviral O 
activity O 
. O 
Taken O 
together O 
, O 
this O 
result O 
indicates O 
the O 
possible O 
pharmacophoric O 
role O 
of O 
the O 
2-pyridinylpiperazine B-SYSTEMATIC 
functionality O 
attached O 
to O 
the O 
chromone B-TRIVIAL 
scaffold O 
, O 
which O 
warrants O 
further O 
in O 
- O 
depth O 
structure O 
- O 
activity O 
relationship O 
study O 
. O 

of O 
the O 
metabolites O 
of O 
lesogaberan B-TRIVIAL 
using O 
linear O 
trap O 
quadrupole O 
orbitrap O 
mass O 
spectrometry O 
and O 
hydrophilic O 
interaction O 
liquid O 
chromatography O 
. O 

. O 
In O 
this O 
study O 
, O 
hydrophilic O 
interaction O 
liquid O 
chromatography O 
( O 
HILIC O 
) O 
, O 
radiochemical O 
activity O 
monitoring O 
and O 
linear O 
trap O 
quadrupole O 
orbitrap O 
mass O 
spectrometry O 
( O 
MS O 
) O 
and O 
tandem O 
mass O 
spectrometry O 
( O 
MS O 
/ O 
MS O 
) O 
were O 
used O 
to O 
identify O 
the O 
metabolites O 
of O 
a O 
highly O 
polar O 
novel O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
type-B O 
receptor O 
agonist O 
, O 
lesogaberan B-TRIVIAL 
, O 
in O 
rats O 
. O 
2 O 
. O 
Urine O 
was O 
collected O 
from O 
three O 
male O 
Wistar O 
rats O 
for O 
24 O 
h O 
after O 
dosing O 
with O 
(14)C B-SYSTEMATIC 
- I-SYSTEMATIC 
labelled I-SYSTEMATIC 
lesogaberan I-SYSTEMATIC 
( O 
170 O 
mg O 
/ O 
kg O 
, O 
10 O 
MBq O 
/ O 
kg O 
) O 
; O 
plasma O 
samples O 
were O 
taken O 
2 O 
and O 
24 O 
h O 
after O 
dosing O 
. O 
Pooled O 
samples O 
were O 
separated O 
by O 
HILIC O 
and O 
eluents O 
were O 
analysed O 
by O 
radiochemical O 
activity O 
monitoring O 
, O 
MS O 
and O 
MS O 
/ O 
MS O 
. O 
3 O 
. O 
Only O 
the O 
parent O 
compound O 
was O 
detected O 
in O 
plasma O 
, O 
but O 
six O 
metabolites O 
( O 
M1-M6 O 
) O 
were O 
detected O 
in O 
urine O 
. O 
Analysis O 
of O 
MS O 
and O 
MS O 
/ O 
MS O 
data O 
and O 
comparison O 
with O 
synthetic O 
reference O 
standards O 
enabled O 
the O 
identification O 
of O 
the O 
structure O 
of O 
each O 
metabolite O 
. O 
M1 O 
was O 
identified O 
as O 
the O 
N B-FORMULA 
-acetylated O 
species O 
[(2R)-3-acetamido-2-fluoropropyl]-phosphinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
M6 O 
as O 
[(2R)-3-amino-2-fluoropropyl]-phosphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Metabolites O 
M2 O 
and O 
M5 O 
were O 
the O 
alcohol B-FAMILY 
and O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
species O 
3-hydroxypropyl-phosphinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
3-hydroxyphosphonoyl-propanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
respectively O 
, O 
both O 
of O 
which O 
had O 
lost O 
the O 
fluorine B-SYSTEMATIC 
atom O 
present O 
in O 
the O 
parent O 
compound O 
. O 
M3 O 
was O 
the O 
corresponding O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
species O 
retaining O 
the O 
fluorine B-SYSTEMATIC 
atom O 
, O 
(2R)-2-fluoro-3-hydroxyphosphonoyl-propanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Finally O 
M4 O 
was O 
identified O 
as O 
[(2R)-2-fluoro-3-guanidino-propyl]-phosphinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 

and O 
animal O 
precision O 
- O 
cut O 
organ O 
slices O 
are O 
being O 
widely O 
used O 
to O 
obtain O 
drug O 
metabolism O 
and O 
toxicity O 
profiles O 
in O 
vitro O 
. O 
These O 
data O 
are O 
then O 
used O 
to O 
predict O 
what O 
might O 
be O 
seen O 
in O 
human O 
patients O 
. O 
The O 
accuracy O 
of O 
this O 
prediction O 
and O 
extrapolation O 
of O 
the O 
findings O 
based O 
on O 
human O 
or O 
animal O 
in O 
vitro O 
systems O 
to O 
the O 
findings O 
that O 
occur O 
in O 
vivo O 
is O 
dependent O 
on O 
both O 
the O 
quality O 
of O 
the O 
tissue O 
itself O 
and O 
the O 
quality O 
of O 
the O 
in O 
vitro O 
system O 
. O 
2.The O 
quality O 
of O 
human O 
organs O 
used O 
in O 
research O 
is O 
dependent O 
on O 
procurement O 
methods O 
, O 
warm O 
ischaemia O 
time O 
, O 
preservation O 
solutions O 
, O 
cold O 
ischaemia O 
time O 
, O 
and O 
donor-specific O 
factors O 
. O 
It O 
is O 
important O 
to O 
confirm O 
that O 
the O 
organs O 
being O 
used O 
are O 
highly O 
viable O 
and O 
fully O 
functional O 
before O 
using O 
them O 
in O 
scientific O 
studies O 
. O 
3.The O 
optimal O 
preparation O 
and O 
incubation O 
of O 
organ O 
slices O 
is O 
also O 
essential O 
in O 
maintaining O 
slice O 
viability O 
and O 
function O 
. O 
It O 
is O 
important O 
to O 
prepare O 
the O 
slices O 
in O 
a O 
cold O 
preservation O 
solution O 
, O 
to O 
prepare O 
the O 
slices O 
at O 
a O 
correct O 
thickness O 
, O 
and O 
to O 
incubate O 
the O 
slices O 
in O 
a O 
system O 
where O 
the O 
slice O 
rotates O 
in O 
out O 
of O 
the O 
oxygen B-SYSTEMATIC 
atmosphere O 
and O 
medium O 
. O 
4.Meeting O 
the O 
criteria O 
outlined O 
here O 
will O 
lead O 
to O 
successful O 
organ O 
slice O 
cultures O 
for O 
investigating O 
drug O 
- O 
induced O 
mechanisms O 
and O 
organ O 
- O 
specific O 
toxicity O 
. O 

of O 
pyrrolo[2,3-g]indazoles B-FAMILY 
as O 
new O 
Pim O 
kinase O 
inhibitors O 
. O 

synthesis O 
and O 
Pim O 
kinase O 
inhibition O 
potency O 
of O 
a O 
new O 
series O 
of O 
pyrrolo[2,3-g]indazole B-SYSTEMATIC 
derivatives O 
is O 
described O 
. O 
The O 
results O 
obtained O 
in O 
this O 
preliminary O 
structure O 
- O 
activity O 
relationship O 
study O 
pointed O 
out O 
that O 
sub O 
- O 
micromolar O 
Pim-1 O 
and O 
Pim-3 O 
inhibitory O 
potencies O 
could O 
be O 
obtained O 
in O 
this O 
series O 
, O 
more O 
particularly O 
for O 
compounds O 
10 O 
and O 
20 O 
, O 
showing O 
that O 
pyrrolo[2,3-g]indazole B-SYSTEMATIC 
scaffold O 
could O 
be O 
used O 
for O 
the O 
development O 
of O 
new O 
potent O 
Pim O 
kinase O 
inhibitors O 
. O 
Molecular O 
modeling O 
experiments O 
were O 
also O 
performed O 
to O 
study O 
the O 
binding O 
mode O 
of O 
these O 
compounds O 
in O 
Pim-3 O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
. O 

acute O 
toxicological O 
experiment O 
was O 
designed O 
to O 
characterize O 
the O 
sequence O 
of O 
renal O 
ultrastructural O 
changes O 
with O 
accumulated O 
MCs O 
in O 
crucian O 
carp O 
injected O 
intraperitoneally O 
( O 
i.p O 
. O 
) O 
with O 
extracted O 
microcystins O 
( O 
mainly O 
MC-RR O 
and O 
-LR O 
) O 
at O 
two O 
doses O 
, O 
50 O 
and O 
200 O 
μg O 
MC-LReq O 
. O 
kg(-1) O 
body O 
weight O 
. O 
Quantitative O 
and O 
qualitative O 
determinations O 
of O 
MCs O 
in O 
the O 
kidney O 
were O 
conducted O 
by O 
HPLC O 
and O 
LC-MS O 
, O 
respectively O 
. O 
MC-RR O 
content O 
in O 
kidney O 
of O 
crucian O 
carp O 
showed O 
a O 
time O 
dose O 
- O 
dependent O 
increase O 
within O 
48 O 
h O 
post O 
- O 
injection O 
, O 
followed O 
by O 
a O 
sharp O 
decline O 
afterward O 
, O 
while O 
no O 
MC-LR O 
in O 
kidney O 
was O 
detectable O 
throughout O 
the O 
experiment O 
. O 
Ultrastructural O 
changes O 
in O 
the O 
kidney O 
of O 
crucian O 
carp O 
progressed O 
with O 
increasing O 
accumulated O 
MCs O 
and O 
exposure O 
times O 
within O 
48 O 
h O 
post O 
- O 
injection O 
, O 
whereas O 
renal O 
ultrastructural O 
recovery O 
of O 
crucian O 
carp O 
in O 
the O 
50 O 
μg O 
MC-LReq O 
. O 
kg(-1) O 
dose O 
group O 
was O 
evident O 
at O 
168 O 
h O 
post O 
- O 
injection O 
. O 
Our O 
ultrastructural O 
observation O 
suggests O 
that O 
the O 
membranous O 
structure O 
is O 
the O 
main O 
action O 
site O 
of O 
MCs O 
in O 
the O 
kidney O 
, O 
among O 
which O 
mitochondria O 
damage O 
in O 
the O 
tubules O 
is O 
clearly O 
an O 
early O 
, O 
and O 
presumably O 
a O 
critically O 
important O 
effect O 
of O 
MCs O 
. O 
The O 
increases O 
in O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
and O 
creatinine B-TRIVIAL 
( O 
CR O 
) O 
in O 
both O 
dose O 
groups O 
further O 
revealed O 
severe O 
impairment O 
occurred O 
in O 
the O 
kidney O 
of O 
crucian O 
carp O 
. O 

1,6-diphenylnaphthalenes B-FAMILY 
as O 
FtsZ-targeting O 
antibacterial O 
agents O 
. O 

cell O 
division O 
occurs O 
in O 
conjunction O 
with O 
the O 
formation O 
of O 
a O 
cytokinetic O 
Z-ring O 
structure O 
comprised O 
of O 
FtsZ O 
subunits O 
. O 
Agents O 
that O 
disrupt O 
Z-ring O 
formation O 
have O 
the O 
potential O 
, O 
through O 
this O 
unique O 
mechanism O 
, O 
to O 
be O 
effective O 
against O 
several O 
of O 
the O 
newly O 
emerging O 
multidrug O 
- O 
resistant O 
strains O 
of O 
infectious O 
bacteria O 
. O 
Several O 
1-phenylbenzo[c]phenanthridines B-FAMILY 
exhibit O 
notable O 
antibacterial O 
activity O 
. O 
Based O 
upon O 
their O 
structural O 
similarity O 
to O 
these O 
compounds O 
, O 
a O 
distinct O 
series O 
of O 
substituted O 
1,6-diphenylnaphthalenes B-FAMILY 
were O 
synthesized O 
and O 
evaluated O 
for O 
antibacterial O 
activity O 
against O 
Staphylococcus O 
aureus O 
and O 
Enterococcus O 
faecalis O 
. O 
In O 
addition O 
, O 
the O 
effect O 
of O 
select O 
1,6-diphenylnaphthalenes B-FAMILY 
on O 
the O 
polymerization O 
dynamics O 
of O 
S O 
. O 
aureus O 
FtsZ O 
and O 
mammalian O 
β-tubulin O 
was O 
also O 
assessed O 
. O 
The O 
presence O 
of O 
a O 
basic O 
functional O 
group O 
or O 
a O 
quaternary B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
substituent O 
on O 
the O 
6-phenylnaphthalene B-SYSTEMATIC 
was O 
required O 
for O 
significant O 
antibacterial O 
activity O 
. O 
Diphenylnaphthalene B-FAMILY 
derivatives O 
that O 
were O 
active O 
as O 
antibiotics O 
, O 
did O 
exert O 
a O 
pronounced O 
effect O 
on O 
bacterial O 
FtsZ O 
polymerization O 
and O 
do O 
not O 
appear O 
to O 
cross O 
- O 
react O 
with O 
mammalian O 
tubulin O 
to O 
any O 
significant O 
degree O 
. O 

Photocurrent O 
in O 
InAsSb B-FORMULA 
Nanowire O 
Infrared O 
Photodetectors O 
. O 

using O 
vertical O 
arrays O 
of O 
InAs B-FORMULA 
/ O 
InAs1-xSbx B-FAMILY 
nanowires O 
with O 
varying O 
Sb B-FORMULA 
composition O 
x O 
have O 
been O 
fabricated O 
and O 
characterized O 
. O 
The O 
spectrally O 
resolved O 
photocurrents O 
are O 
strongly O 
diameter O 
dependent O 
with O 
peaks O 
, O 
which O 
are O 
red O 
- O 
shifted O 
with O 
diameter O 
, O 
appearing O 
for O 
thicker O 
wires O 
. O 
Results O 
from O 
numerical O 
simulations O 
are O 
in O 
good O 
agreement O 
with O 
the O 
experimental O 
data O 
and O 
reveal O 
that O 
the O 
peaks O 
are O 
due O 
to O 
resonant O 
modes O 
that O 
enhance O 
the O 
coupling O 
of O 
light O 
into O 
the O 
wires O 
. O 
Through O 
proper O 
selection O 
of O 
wire O 
diameter O 
, O 
the O 
absorptance O 
can O 
be O 
increased O 
by O 
more O 
than O 
1 O 
order O 
of O 
magnitude O 
at O 
a O 
specific O 
wavelength O 
compared O 
to O 
a O 
thin O 
planar O 
film O 
with O 
the O 
same O 
amount O 
of O 
material O 
. O 
A O 
maximum O 
20% O 
cutoff O 
wavelength O 
of O 
5.7 O 
μm O 
is O 
obtained O 
at O 
5 O 
K O 
for O 
a O 
wire O 
diameter O 
of O 
717 O 
nm O 
at O 
a O 
Sb B-FORMULA 
content O 
of O 
x O 
= O 
0.62 O 
, O 
but O 
simulations O 
predict O 
that O 
detection O 
at O 
longer O 
wavelengths O 
can O 
be O 
achieved O 
by O 
increasing O 
the O 
diameter O 
. O 
Furthermore O 
, O 
photodetection O 
in O 
InAsSb B-FORMULA 
nanowire O 
arrays O 
integrated O 
on O 
Si B-FORMULA 
substrates O 
is O 
also O 
demonstrated O 
. O 

novel O 
method O 
for O 
preparing O 
complete O 
antigens O 
of O 
gonyautoxin B-MULTIPLE 
2,3 I-MULTIPLE 
and O 
their O 
feature O 
of O 
immunogenicity O 
. O 

this O 
paper O 
, O 
a O 
novel O 
method O 
was O 
proposed O 
to O 
prepare O 
artificial O 
antigens O 
of O 
gonyaulax O 
parlaytic O 
shellfish O 
toxin O 
2 O 
and O 
3 O 
( O 
GTX2,3 B-MULTIPLE 
) O 
. O 
An O 
intermediate O 
GTX2,3-aldehyde B-MULTIPLE 
was O 
first O 
synthesized O 
by O 
activating O 
the O 
NH2 B-FORMULA 
group O 
of O 
the O 
2nd O 
and O 
8th O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
with O 
three O 
different O 
aldehydes B-FAMILY 
and O 
two O 
artificial O 
complete O 
antigens O 
GTX2,3-aldehyde B-MULTIPLE 
-bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
and O 
GTX2,3-aldehyde B-MULTIPLE 
- O 
keyhole O 
limpet O 
hemocyanin O 
( O 
KLH O 
) O 
were O 
then O 
prepared O 
by O 
cross O 
- O 
linking O 
the O 
intermediate O 
with O 
BSA O 
or O 
KLH O 
. O 
The O 
successful O 
preparation O 
of O 
the O 
two O 
complete O 
antigens O 
was O 
confirmed O 
by O 
UV O 
spectral O 
scanning O 
, O 
HPLC O 
, O 
production O 
of O 
antibodies O 
with O 
titer O 
of O 
1.28 O 
× O 
10(4) O 
from O 
mice O 
immunized O 
with O 
the O 
two O 
complete O 
antigens O 
, O 
indirect O 
ELISA O 
and O 
Western O 
- O 
blot O 
. O 
In O 
conclusion O 
, O 
the O 
synthesized O 
complete O 
antigens O 
have O 
strong O 
immunogenicity O 
, O 
which O 
provides O 
a O 
solid O 
foundation O 
for O 
preparing O 
GTX2,3 B-MULTIPLE 
monoclonal O 
antibody O 
and O 
rapid O 
detection O 
kit O 
. O 

activity O 
comparison O 
between O 
[6S]-5-methyltetrahydrofolic B-SYSTEMATIC 
acid I-SYSTEMATIC 
calcium I-SYSTEMATIC 
salt O 
and O 
the O 
related O 
racemate O 
form O 
. O 

, O 
such O 
as O 
[6S]-5-methyltetrahydrofolic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
have O 
been O 
introduced O 
in O 
the O 
market O 
both O 
in O 
vitamin O 
pills O 
and O 
in O 
fortified O 
foods O 
. O 
Their O 
antioxidant O 
activity O 
has O 
been O 
evaluated O 
, O 
but O 
stereoisomer O 
influence O 
on O 
activity O 
has O 
not O 
been O 
proven O 
. O 
In O 
this O 
study O 
, O 
a O 
comparison O 
between O 
[6S]-5-methyltetrahydrofolic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
5-MTHF B-SYSTEMATIC 
) O 
and O 
its O 
racemate O 
[ O 
6R,S O 
] O 
form O 
was O 
made O 
by O 
TEAC O 
assay O 
at O 
different O 
pHs O 
, O 
FRAP O 
assay O 
, O 
and O 
ORAC O 
assay O 
. O 
The O 
results O 
showed O 
that O 
the O 
[ O 
6S O 
] O 
form O 
had O 
higher O 
antioxidant O 
activity O 
than O 
its O 
racemate O 
form O 
in O 
the O 
TEAC O 
assay O 
at O 
all O 
pHs O 
, O 
with O 
similar O 
values O 
in O 
the O 
FRAP O 
and O 
ORAC O 
assays O 
. O 
Results O 
suggest O 
that O 
stereoisomeric O 
difference O 
could O 
influence O 
the O 
antioxidant O 
activity O 
of O 
5-MTHF B-SYSTEMATIC 
and O 
hence O 
should O 
be O 
taken O 
into O 
account O 
when O 
folates B-FAMILY 
are O 
added O 
to O 
foodstuffs O 
to O 
improve O 
their O 
nutritional O 
value O 
. O 

- O 
free O 
microemulsion O 
composed O 
of O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
n-propanol B-SYSTEMATIC 
, O 
and O 
H2O B-FORMULA 
. O 

, O 
a O 
microemulsion O 
consists O 
of O 
oil O 
, O 
water O 
, O 
surfactant O 
, O 
and O 
sometimes O 
cosurfactant O 
. O 
Herein O 
, O 
we O 
report O 
a O 
surfactant O 
- O 
free O 
microemulsion O 
( O 
denoted O 
as O 
SFME O 
) O 
, O 
consisting O 
of O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
oil O 
phase O 
) O 
, O 
water O 
, O 
and O 
n-propanol B-SYSTEMATIC 
without O 
the O 
amphiphilic O 
molecular O 
structure O 
of O 
a O 
traditional O 
surfactant O 
. O 
The O 
phase O 
behavior O 
of O 
the O 
ternary O 
system O 
was O 
investigated O 
, O 
showing O 
that O 
there O 
were O 
a O 
single O 
- O 
phase O 
microemulsion O 
region O 
and O 
a O 
multiphase O 
region O 
in O 
the O 
ternary O 
phase O 
diagram O 
. O 
The O 
electrical O 
conductivity O 
measurement O 
was O 
employed O 
to O 
investigate O 
the O 
microregions O 
of O 
the O 
single O 
- O 
phase O 
microemulsion O 
region O 
, O 
and O 
three O 
different O 
microregions O 
, O 
that O 
is O 
, O 
water-in- O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
W O 
/ O 
O O 
) O 
, O 
a O 
bicontinuous O 
( O 
B.C O 
. O 
) O 
region O 
, O 
and O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
-in O 
- O 
water O 
( O 
O O 
/ O 
W O 
) O 
, O 
were O 
identified O 
, O 
which O 
were O 
further O 
confirmed O 
by O 
freeze O 
- O 
fracture O 
and O 
cryogenic O 
transmission O 
electron O 
microscopy O 
( O 
FF-TEM O 
and O 
Cryo-TEM O 
) O 
observations O 
. O 
The O 
polarity O 
and O 
the O 
salt O 
solubility O 
of O 
water O 
domains O 
in O 
the O 
W O 
/ O 
O O 
SFME O 
were O 
investigated O 
by O 
UV-visible O 
spectroscopy O 
using O 
methyl B-TRIVIAL 
orange I-TRIVIAL 
and O 
potassium B-SYSTEMATIC 
ferricyanide I-SYSTEMATIC 
as O 
probes O 
, O 
respectively O 
. O 
Experimental O 
results O 
showed O 
that O 
the O 
water O 
domains O 
in O 
the O 
W O 
/ O 
O O 
microemulsion O 
had O 
a O 
lower O 
polarity O 
than O 
bulk O 
water O 
and O 
a O 
normal O 
solubility O 
for O 
salt O 
species O 
, O 
indicating O 
that O 
the O 
SFMEs O 
have O 
much O 
significance O 
in O 
the O 
preparation O 
of O 
various O 
nanomaterials O 
. O 

vitro O 
read O 
- O 
through O 
of O 
phenylalanine B-TRIVIAL 
hydroxylase O 
( O 
PAH O 
) O 
nonsense O 
mutations O 
using O 
aminoglycosides B-FAMILY 
: O 
a O 
potential O 
therapy O 
for O 
phenylketonuria O 
. O 

( O 
PKU O 
, O 
OMIM O 
261600 O 
) O 
is O 
an O 
autosomal O 
recessive O 
inborn O 
error O 
of O 
phenylalanine B-TRIVIAL 
metabolism O 
, O 
predominantly O 
caused O 
by O 
mutations O 
in O 
the O 
phenylalanine B-TRIVIAL 
hydroxylase O 
( O 
PAH O 
) O 
gene O 
. O 
Approximately O 
10 O 
% O 
of O 
patients O 
carry O 
a O 
nonsense O 
mutation O 
, O 
which O 
results O 
in O 
an O 
inactive O 
or O 
unstable O 
truncated O 
protein O 
. O 
In O 
some O 
genetic O 
disorders O 
, O 
including O 
cystic O 
fibrosis O 
and O 
Duchenne O 
muscular O 
dystrophy O 
, O 
restoration O 
of O 
full O 
- O 
length O 
protein O 
has O 
been O 
achieved O 
by O 
aminoglycoside B-FAMILY 
antibiotics O 
, O 
such O 
as O 
gentamicin B-FAMILY 
and O 
G-418 B-IDENTIFIER 
( O 
Geneticin B-TRIVIAL 
) O 
. O 
More O 
recently O 
, O 
nonsense O 
read O 
- O 
through O 
has O 
been O 
induced O 
at O 
greater O 
rates O 
using O 
a O 
non- O 
aminoglycoside B-FAMILY 
drug O 
, O 
PTC124 B-IDENTIFIER 
( O 
Ataluren B-TRIVIAL 
) O 
, O 
which O 
has O 
the O 
advantage O 
of O 
being O 
non-toxic O 
in O 
contrast O 
to O 
the O 
antibiotics O 
. O 
The O 
efficacy O 
of O 
read O 
- O 
through O 
induced O 
by O 
three O 
compounds O 
, O 
aminoglycosides B-FAMILY 
G418 B-IDENTIFIER 
and O 
gentamicin B-FAMILY 
, O 
and O 
PTC124 B-IDENTIFIER 
were O 
evaluated O 
for O 
four O 
nonsense O 
mutations O 
of O 
PAH O 
in O 
an O 
in O 
vitro O 
expression O 
system O 
in O 
two O 
mammalian O 
cell O 
lines O 
( O 
COS-7 O 
and O 
HEK293 O 
) O 
. O 
The O 
production O 
of O 
full O 
- O 
length O 
PAH O 
was O 
investigated O 
using O 
western O 
blotting O 
and O 
the O 
functionality O 
confirmed O 
by O 
enzyme O 
activity O 
. O 
Gentamicin B-FAMILY 
and O 
G-418 B-IDENTIFIER 
induced O 
read O 
- O 
through O 
of O 
nonsense O 
PAH O 
mutations O 
in O 
HEK293 O 
cells O 
. O 
The O 
read O 
- O 
through O 
product O 
partially O 
restored O 
enzymatic O 
activity O 
, O 
which O 
was O 
significantly O 
less O 
than O 
that O 
of O 
wild O 
- O 
type O 
, O 
but O 
comparable O 
to O 
a O 
missense O 
mutation O 
of O 
PAH O 
associated O 
with O 
less O 
severe O 
forms O 
of O 
PKU O 
. O 
Treatment O 
with O 
PTC124 B-IDENTIFIER 
up O 
to O 
100 O 
μM O 
did O 
not O 
result O 
in O 
full O 
- O 
length O 
PAH O 
polypeptide O 
. O 
Nonsense O 
read O 
- O 
through O 
drugs O 
are O 
a O 
potential O 
form O 
of O 
treatment O 
for O 
PKU O 
, O 
although O 
the O 
high O 
dosage O 
of O 
aminoglycosides B-FAMILY 
used O 
is O 
not O 
appropriate O 
in O 
a O 
clinical O 
setting O 
. O 
In O 
vitro O 
studies O 
with O 
new O 
non-toxic O 
read O 
- O 
through O 
agents O 
as O 
well O 
as O 
in O 
vivo O 
studies O 
would O 
also O 
be O 
essential O 
to O 
determine O 
the O 
extent O 
of O 
read O 
- O 
through O 
required O 
to O 
restore O 
normal O 
phenylalanine B-TRIVIAL 
levels O 
. O 

density O 
lipoprotein O 
as O 
a O 
source O 
of O 
cholesterol B-TRIVIAL 
for O 
adrenal O 
steroidogenesis O 
: O 
a O 
study O 
in O 
individuals O 
with O 
low O 
plasma O 
HDL-C O 
. O 

studies O 
have O 
addressed O 
the O 
delivery O 
of O 
lipoprotein O 
- O 
derived O 
cholesterol B-TRIVIAL 
to O 
the O 
adrenals O 
for O 
steroid B-FAMILY 
production O 
in O 
humans O 
. O 
While O 
there O 
is O 
evidence O 
against O 
a O 
role O 
for O 
low O 
- O 
density O 
lipoprotein O 
( O 
LDL O 
) O 
, O 
it O 
is O 
unresolved O 
whether O 
high O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
contributes O 
to O 
adrenal O 
steroidogenesis O 
. O 
To O 
study O 
this O 
, O 
steroid B-FAMILY 
hormone I-FAMILY 
profiles O 
in O 
urine O 
were O 
assessed O 
in O 
male O 
subjects O 
suffering O 
from O 
functional O 
mutations O 
in O 
ATP B-ABBREVIATION 
binding O 
cassette O 
transporter O 
A1 O 
( O 
ABCA1 O 
) O 
( O 
n O 
= O 
24 O 
) O 
, O 
lecithin O 
: O 
cholesterol B-TRIVIAL 
acyltransferase O 
( O 
LCAT O 
) O 
( O 
n O 
= O 
40 O 
) O 
, O 
as O 
well O 
as O 
in O 
11 O 
subjects O 
with O 
low O 
HDL O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
without O 
ABCA1 O 
/ O 
LCAT O 
mutations O 
. O 
HDL-C O 
levels O 
were O 
39% O 
lower O 
in O 
the O 
ABCA1 O 
, O 
LCAT O 
, O 
and O 
low O 
HDL-C O 
groups O 
compared O 
with O 
controls O 
( O 
all O 
P O 
< O 
0.001 O 
) O 
. O 
In O 
all O 
groups O 
with O 
low O 
HDL-C O 
levels O 
, O 
urinary O 
excretion O 
of O 
17-ketogenic B-FAMILY 
steroids I-FAMILY 
was O 
reduced O 
by O 
33% O 
, O 
27% O 
, O 
and O 
32% O 
compared O 
with O 
controls O 
( O 
all O 
P O 
< O 
0.04 O 
) O 
. O 
In O 
seven O 
carriers O 
of O 
either O 
type O 
of O 
mutation O 
, O 
adrenocorticotropic O 
hormone O 
( O 
ACTH O 
) O 
stimulation O 
did O 
not O 
reveal O 
differences O 
from O 
normolipidemic O 
controls O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
shows O 
that O 
basal O 
but O 
not O 
stimulated O 
corticosteroid O 
metabolism O 
is O 
attenuated O 
in O 
subjects O 
with O 
low O 
HDL-C O 
, O 
irrespective O 
of O 
its O 
molecular O 
origin O 
. O 
These O 
findings O 
lend O 
support O 
to O 
a O 
role O 
for O 
HDL O 
as O 
a O 
cholesterol B-TRIVIAL 
donor O 
for O 
basal O 
adrenal O 
steroidogenesis O 
in O 
humans O 
. O 

Molecule O 
from O 
O(2)-(2,4-Dinitrophenyl)diazeniumdiolate B-SYSTEMATIC 
and O 
Oleanolic B-TRIVIAL 
Acid I-TRIVIAL 
: O 
a O 
GSTπ O 
Activated O 
Nitric B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Prodrug O 
with O 
Selective O 
Anti-human O 
Hepatocellular O 
Carcinoma O 
Activity O 
and O 
Improved O 
Stability O 
. O 

series O 
of O 
hybrids O 
from O 
O(2)-(2,4-dinitrophenyl)diazeniumdiolate B-SYSTEMATIC 
and O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
OA O 
) O 
were O 
designed O 
, O 
synthesized O 
, O 
and O 
biologically O 
evaluated O 
as O 
novel O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
releasing O 
prodrugs O 
which O 
could O 
be O 
activated O 
by O 
glutathione B-TRIVIAL 
S-transferase O 
π O 
( O 
GSTπ O 
) O 
overexpressed O 
in O 
a O 
number O 
of O 
cancer O 
cells O 
. O 
It O 
was O 
discovered O 
that O 
the O 
most O 
active O 
compound O 
21 O 
released O 
high O 
levels O 
of O 
NO B-FORMULA 
selectively O 
in O 
HCC O 
cells O 
but O 
not O 
in O 
the O 
normal O 
cells O 
, O 
and O 
exhibited O 
potent O 
antiproliferative O 
activity O 
in O 
vitro O 
as O 
well O 
as O 
remarkable O 
tumor O 
- O 
retarding O 
effects O 
in O 
vivo O 
. O 
Compared O 
with O 
the O 
reported O 
GSTπ-activated O 
prodrugs O 
JS-K O 
and O 
PABA B-ABBREVIATION 
/ O 
NO B-FORMULA 
, O 
21 O 
exhibited O 
remarkably O 
improved O 
stability O 
in O 
the O 
absence O 
of O 
GSTπ O 
. O 
Importantly O 
, O 
the O 
decomposition O 
of O 
21 O 
occurred O 
in O 
the O 
presence O 
of O 
GSTπ O 
, O 
and O 
was O 
much O 
more O 
effective O 
than O 
in O 
GSTα O 
. O 
Additionally O 
, O 
21 O 
induced O 
HepG2 O 
cells O 
apoptosis O 
by O 
arresting O 
cell O 
cycle O 
at O 
G2 O 
/ O 
M O 
phase O 
, O 
activating O 
both O 
the O 
mitochondria O 
- O 
mediated O 
pathway O 
and O 
the O 
MAPKs O 
pathway O 
, O 
as O 
well O 
as O 
enhancing O 
the O 
intracellular O 
production O 
of O 
ROS O 
. O 

the O 
endogenous O 
and O 
exogenous O 
urinary O 
estrogens B-FAMILY 
in O 
human O 
by O 
isotopic O 
ratio O 
mass O 
spectrometry O 
and O 
its O 
potential O 
clinical O 
value O 
. O 

were O 
prohibited O 
in O 
the O 
food O 
producing O 
animals O 
by O 
European O 
Union O 
( O 
96 O 
/ O 
22 O 
/ O 
EC O 
directive O 
) O 
and O 
added O 
to O 
the O 
Report O 
on O 
Carcinogens O 
in O 
United O 
States O 
since O 
2002 O 
. O 
Due O 
to O 
very O 
low O 
concentration O 
in O 
serum O 
or O 
urine O 
( O 
~pg O 
/ O 
mL O 
) O 
, O 
the O 
method O 
of O 
control O 
its O 
abuse O 
had O 
not O 
been O 
fully O 
developed O 
. O 
The O 
endogenous O 
estrogens B-FAMILY 
were O 
separated O 
from O 
urines O 
of O 
18 O 
adult O 
men O 
and O 
women O 
. O 
The O 
exogenous O 
estrogens B-FAMILY 
were O 
chemical O 
reference O 
standards O 
and O 
over O 
the O 
counter O 
preparations O 
. O 
Two O 
patients O 
of O 
dysfunctional O 
uterine O 
bleeding O 
( O 
DUB O 
) O 
administered O 
exogenous O 
estradiol B-TRIVIAL 
and O 
the O 
urines O 
were O 
collected O 
for O 
72 O 
h O 
. O 
The O 
urinary O 
estrogens B-FAMILY 
were O 
separated O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
and O 
confirmed O 
. O 
The O 
exogenous O 
and O 
exogenous O 
estrogens B-FAMILY 
were O 
analyzed O 
by O 
gas O 
chromatography O 
combustion O 
isotope O 
ratio O 
mass O 
spectrometry O 
( O 
GC-C-IRMS O 
) O 
to O 
determine O 
the O 
(13)C B-FORMULA 
/ O 
(12)C B-FORMULA 
ratio O 
( O 
δ O 
(13)C B-FORMULA 
‰ O 
) O 
. O 
The O 
δ O 
(13)C B-FORMULA 
‰ O 
values O 
of O 
reference O 
standard O 
of O 
E1 O 
, O 
E2 O 
, O 
and O 
E3 O 
were O 
-29.36±0.72 O 
, O 
-27.98±0.35 O 
, O 
-27.62±0.51 O 
, O 
respectively O 
. O 
The O 
δ O 
(13)C B-FORMULA 
‰ O 
values O 
of O 
the O 
endogenous O 
E1 O 
, O 
E2 O 
, O 
and O 
E3 O 
were O 
-21.62±1.07 O 
, O 
-22.14±0.98 O 
, O 
and O 
-21.88±1.16 O 
, O 
with O 
P O 
< O 
0.01 O 
( O 
t-test O 
) O 
. O 
Two O 
DUB O 
patients O 
' O 
urinary O 
estradiol B-TRIVIAL 
δ O 
(13)C B-FORMULA 
‰ O 
values O 
was O 
depleted O 
to O 
-28.02±0.33 O 
after O 
the O 
administration O 
. O 
The O 
progesterone B-TRIVIAL 
, O 
17α-hydroxyprogesterone B-SYSTEMATIC 
, O 
pregnanediol B-TRIVIAL 
, O 
as O 
well O 
as O 
desogestrel B-TRIVIAL 
and O 
ethinylestradiol B-SYSTEMATIC 
from O 
contraceptives O 
were O 
also O 
determined O 
. O 
Stable O 
carbon B-SYSTEMATIC 
isotope O 
analysis O 
can O 
distinguish O 
the O 
endogenous O 
and O 
exogenous O 
urinary O 
estrogen B-FAMILY 
in O 
human O 
. O 

of O 
a O 
zinc B-SYSTEMATIC 
-binding O 
residue O 
in O 
the O 
glycine B-TRIVIAL 
receptor O 
α1 O 
subunit O 
changes O 
ethanol B-SYSTEMATIC 
sensitivity O 
in O 
vitro O 
and O 
alcohol B-FAMILY 
consumption O 
in O 
vivo O 
. O 

is O 
a O 
widely O 
used O 
drug O 
, O 
yet O 
an O 
understanding O 
of O 
its O 
sites O 
and O 
mechanisms O 
of O 
action O 
remains O 
incomplete O 
. O 
Among O 
the O 
protein O 
targets O 
of O 
ethanol B-SYSTEMATIC 
are O 
glycine B-TRIVIAL 
receptors O 
( O 
GlyRs O 
) O 
, O 
which O 
are O 
potentiated O 
by O 
millimolar O 
concentrations O 
of O 
ethanol B-SYSTEMATIC 
. O 
In O 
addition O 
, O 
zinc B-SYSTEMATIC 
ions O 
also O 
modulate O 
GlyR O 
function O 
, O 
and O 
recent O 
evidence O 
suggests O 
that O 
physiologic O 
concentrations O 
of O 
zinc B-SYSTEMATIC 
enhance O 
ethanol B-SYSTEMATIC 
potentiation O 
of O 
GlyRs O 
. O 
Here O 
, O 
we O 
first O 
built O 
a O 
homology O 
model O 
of O 
a O 
zinc B-SYSTEMATIC 
-bound O 
GlyR O 
using O 
the O 
D80 O 
position O 
as O 
a O 
coordination O 
site O 
for O 
a O 
zinc B-SYSTEMATIC 
ion O 
. O 
Next O 
, O 
we O 
investigated O 
in O 
vitro O 
the O 
effects O 
of O 
zinc B-SYSTEMATIC 
on O 
ethanol B-SYSTEMATIC 
action O 
at O 
recombinant O 
wild O 
- O 
type O 
( O 
WT O 
) O 
and O 
mutant O 
α1 O 
GlyRs O 
containing O 
the O 
D80A O 
substitution O 
, O 
which O 
eliminates O 
zinc B-SYSTEMATIC 
potentiation O 
. O 
At O 
D80A O 
GlyRs O 
, O 
the O 
effects O 
of O 
50 O 
and O 
200 O 
mM O 
ethanol B-SYSTEMATIC 
were O 
reduced O 
as O 
compared O 
with O 
WT O 
receptors O 
. O 
Also O 
, O 
in O 
contrast O 
to O 
what O 
was O 
seen O 
with O 
WT O 
GlyRs O 
, O 
neither O 
adding O 
nor O 
chelating O 
zinc B-SYSTEMATIC 
changed O 
the O 
magnitude O 
of O 
ethanol B-SYSTEMATIC 
enhancement O 
of O 
mutant O 
D80A O 
receptors O 
. O 
Next O 
, O 
we O 
evaluated O 
the O 
in O 
vivo O 
effects O 
of O 
the O 
D80A O 
substitution O 
by O 
using O 
heterozygous O 
Glra1(D80A) O 
knock O 
- O 
in O 
( O 
KI O 
) O 
mice O 
. O 
The O 
KI O 
mice O 
showed O 
decreased O 
ethanol B-SYSTEMATIC 
consumption O 
and O 
preference O 
, O 
and O 
they O 
displayed O 
increased O 
startle O 
responses O 
compared O 
with O 
their O 
WT O 
littermates O 
. O 
Other O 
behavioral O 
tests O 
, O 
including O 
ethanol B-SYSTEMATIC 
-induced O 
motor O 
incoordination O 
and O 
strychnine B-TRIVIAL 
-induced O 
convulsions O 
, O 
revealed O 
no O 
differences O 
between O 
the O 
KI O 
and O 
WT O 
mice O 
. O 
Together O 
, O 
our O 
findings O 
indicate O 
that O 
zinc B-SYSTEMATIC 
is O 
critical O 
in O 
determining O 
the O 
effects O 
of O 
ethanol B-SYSTEMATIC 
at O 
GlyRs O 
and O 
suggest O 
that O 
zinc B-SYSTEMATIC 
binding O 
at O 
the O 
D80 O 
position O 
may O 
be O 
important O 
for O 
mediating O 
some O 
of O 
the O 
behavioral O 
effects O 
of O 
ethanol B-SYSTEMATIC 
action O 
at O 
GlyRs O 
. O 

cells O 
of O 
Glycyrrhiza O 
( O 
CG O 
) O 
possessed O 
a O 
similar O 
content O 
of O 
flavonoids B-FAMILY 
and O 
a O 
lower O 
content O 
of O 
triterpenes B-FAMILY 
, O 
when O 
compared O 
with O 
its O 
field O 
cultivated O 
equivalent O 
( O 
NG O 
) O 
. O 
Xylene B-FAMILY 
-induced O 
ear O 
oedema O 
and O 
ovalbumin O 
- O 
induced O 
mouse O 
paw O 
oedema O 
were O 
applied O 
, O 
to O 
compare O 
the O 
effects O 
of O 
CG O 
and O 
NG O 
on O 
the O 
acute O 
inflammatory O 
response O 
. O 
Extracts O 
of O 
the O 
cell O 
culture O 
of O 
Glycyrrhiza O 
possessed O 
a O 
similar O 
anti-inflammatory O 
effect O 
to O 
those O 
of O 
NG O 
, O 
through O 
the O 
enhancement O 
of O 
the O 
SOD O 
activity O 
of O 
plasma O 
and O 
liver O 
tissues O 
. O 
The O 
use O 
of O 
a O 
cell O 
culture O 
of O 
liquorice O 
instead O 
of O 
field O 
cultivation O 
would O 
be O 
potentially O 
profitable O 
. O 

hydroxy I-SYSTEMATIC 
palmitate I-SYSTEMATIC 
: O 
possible O 
precursor O 
phase O 
in O 
calcium B-SYSTEMATIC 
precipitation O 
by O 
palmitate B-TRIVIAL 
. O 

(II) I-SYSTEMATIC 
precipitates O 
with O 
palmitate B-TRIVIAL 
( O 
Pal(-) B-ABBREVIATION 
) O 
, O 
a O 
process O 
affecting O 
calcium B-SYSTEMATIC 
absorption O 
in O 
the O 
gut O 
, O 
in O 
a O 
first O 
- O 
order O 
reaction O 
, O 
as O 
followed O 
by O 
a O 
calcium B-SYSTEMATIC 
electrode O 
in O 
neutral O 
aqueous O 
solution O 
for O 
excess O 
of O 
calcium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
, O 
with O 
a O 
rate O 
constant O 
showing O 
a O 
minimum O 
at O 
physiological O 
ionic O 
strength O 
of O 
0.32 O 
± O 
0.09 O 
d(-1) O 
at O 
25°C O 
with O 
a O 
stoichiometry O 
of O 
1.79 O 
± O 
0.03 O 
, O 
lower O 
than O 
the O 
expected O 
1 O 
: O 
2 O 
. O 
During O 
ageing O 
of O 
precipitate O 
, O 
pH O 
increases O 
in O 
the O 
supernatant O 
, O 
while O 
pH O 
decreases O 
for O 
precipitation O 
with O 
excess O 
of O 
palmitate B-TRIVIAL 
. O 
Increasing O 
pH O 
, O 
as O 
in O 
some O 
aged O 
food O 
products O 
, O 
decreases O 
the O 
solubility O 
, O 
and O 
Ksp(')=[ O 
Ca(2+)][Pal(-)][OH(- B-FORMULA 
) I-FORMULA 
] O 
is O 
found O 
constant O 
rather O 
than O 
Ksp= O 
[Ca(2+)][Pal(-)](2) B-FORMULA 
in O 
agreement O 
with O 
an O 
initial O 
precipitation O 
of O 
Ca(OH)(Pal) B-FORMULA 
, O 
which O 
slowly O 
may O 
convert O 
into O 
Ca(Pal)2·Ca(OH)(Pal) B-FORMULA 
has O 
a O 
solubility O 
minimum O 
at O 
physiological O 
ionic O 
strength O 
with O 
Ksp(')=(1.4 O 
± O 
0.4)10(-16)M(3 O 
) O 
. O 
X-ray O 
diffraction O 
showed O 
a O 
d-spacing O 
of O 
44.15Å O 
( O 
different O 
from O 
45.2Å O 
reported O 
for O 
Ca(Pal)2 B-FORMULA 
) O 
, O 
and O 
infrared O 
spectroscopy O 
confirmed O 
the O 
presence O 
of O 
a O 
hydroxy B-SYSTEMATIC 
group O 
. O 

intracellular O 
fate O 
of O 
nanosized O 
drug O 
delivery O 
systems O 
is O 
still O 
not O 
well O 
understood O 
. O 
Various O 
internalization O 
pathways O 
have O 
been O 
discovered O 
, O 
but O 
knowledge O 
of O 
their O 
intracellular O 
trafficking O 
is O 
still O 
incomplete O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
internalization O 
, O 
pathways O 
, O 
and O 
positioning O 
taken O 
by O 
solid O 
lipid O 
nanoparticles O 
( O 
SLNs O 
) O 
in O 
cells O 
. O 
SLNs O 
were O 
fluorescence O 
labeled O 
with O 
a O 
newly O 
synthesized O 
fluorescent O 
probe O 
, O 
14-DACA B-ABBREVIATION 
. O 
The O 
probe O 
was O 
strongly O 
incorporated O 
into O 
the O 
nanoparticle O 
core O 
under O 
the O 
influence O 
of O 
its O 
long O 
lipophilic O 
chain O 
, O 
enabling O 
superior O 
visualization O 
of O 
SLNs O 
under O 
complex O 
and O 
dynamic O 
intracellular O 
conditions O 
. O 
The O 
intracellular O 
distribution O 
of O 
SLNs O 
was O 
studied O 
qualitatively O 
using O 
a O 
co O 
- O 
localization O 
technique O 
and O 
quantitatively O 
using O 
fluorescence O 
intensity O 
profiles O 
. O 
SLNs O 
were O 
seen O 
inside O 
the O 
cells O 
as O 
distinct O 
bright O 
blue O 
dots O 
that O 
underwent O 
dynamic O 
movement O 
and O 
were O 
finally O 
positioned O 
in O 
the O 
proximity O 
of O 
the O 
nucleus O 
. O 
A O 
few O 
SLNs O 
were O 
shown O 
to O 
be O 
present O 
in O 
mitochondria O 
and O 
between O 
actin O 
filaments O 
, O 
but O 
none O 
in O 
the O 
cell O 
nucleus O 
or O 
lysosomes O 
. O 
SLNs O 
are O 
here O 
reported O 
to O 
be O 
present O 
in O 
tunneling O 
nanotubes O 
( O 
TNTs O 
) O 
, O 
which O 
could O 
be O 
a O 
new O 
route O 
of O 
SLN O 
transfer O 
between O 
cells O 
. O 
More O 
TNTs O 
were O 
observed O 
in O 
cells O 
treated O 
with O 
SLNs O 
. O 
The O 
presence O 
of O 
TNTs O 
was O 
additionally O 
confirmed O 
by O 
atomic O 
force O 
microscopy O 
analysis O 
, O 
which O 
indicated O 
that O 
treated O 
cells O 
were O 
more O 
rough O 
than O 
control O 
cells O 
. O 
Detailed O 
investigation O 
of O 
the O 
subcellular O 
localization O 
of O 
SLNs O 
and O 
the O 
evidence O 
for O 
their O 
transfer O 
and O 
distribution O 
via O 
TNTs O 
to O 
the O 
cells O 
, O 
which O 
are O 
not O 
in O 
direct O 
contact O 
with O 
the O 
source O 
of O 
SLNs O 
, O 
are O 
important O 
for O 
understanding O 
the O 
mechanism O 
of O 
targeted O 
drug O 
delivery O 
. O 
Understanding O 
the O 
possible O 
intercellular O 
distribution O 
of O 
SLNs O 
via O 
TNTs O 
can O 
significantly O 
influence O 
approaches O 
to O 
treating O 
organelle O 
- O 
specific O 
diseases O 
. O 

of O 
ozone B-TRIVIAL 
microbubble O 
treatment O 
on O 
removal O 
of O 
residual O 
pesticides O 
and O 
quality O 
of O 
persimmon O 
leaves O 
. O 

study O 
investigated O 
the O 
effects O 
of O 
ozone B-TRIVIAL 
microbubble O 
( O 
OMCB O 
) O 
treatment O 
on O 
the O 
removal O 
of O 
residual O 
fenitrothion B-TRIVIAL 
( O 
FT O 
) O 
and O 
benomyl B-TRIVIAL 
pesticides O 
from O 
red O 
and O 
green O 
persimmon O 
leaves O 
, O 
and O 
also O 
the O 
treatment O 
effect O 
on O 
the O 
leaf O 
colours O 
, O 
physical O 
properties O 
and O 
flavour O 
. O 
The O 
continuous O 
bubbling O 
OMCB O 
treatment O 
was O 
more O 
effective O 
than O 
the O 
non-bubbling O 
OMCB O 
treatments O 
at O 
reducing O 
the O 
FT O 
and O 
benomyl B-TRIVIAL 
agricultural O 
pesticide O 
residues O 
from O 
both O 
the O 
red O 
and O 
green O 
persimmon O 
leaves O 
. O 
Moreover O 
, O 
the O 
bubbling O 
OMCB O 
treatment O 
had O 
no O 
effect O 
on O 
the O 
colour O 
and O 
pulling O 
strength O 
of O 
the O 
leaves O 
. O 
These O 
results O 
indicate O 
that O 
the O 
treatment O 
by O 
bubbling O 
OMCB O 
is O 
an O 
extremely O 
effective O 
method O 
for O 
removing O 
the O 
residues O 
of O 
FT O 
and O 
benomyl B-TRIVIAL 
in O 
persimmon O 
leaves O 
and O 
has O 
relatively O 
little O 
effect O 
on O 
leaf O 
quality O 
characteristics O 
. O 

structure O 
of O 
the O 
biliverdin B-TRIVIAL 
cofactor O 
in O 
the O 
Pfr O 
state O 
of O 
bathy O 
and O 
prototypical O 
phytochromes O 
. O 

structures O 
of O 
the O 
chromophore O 
binding O 
pockets O 
in O 
the O 
Pfr O 
states O 
of O 
various O 
bathy O 
and O 
prototypical O 
biliverdin B-TRIVIAL 
-binding O 
phytochromes O 
were O 
analysed O 
by O 
using O 
a O 
combined O 
spectroscopic O 
- O 
theoretical O 
approach O 
. O 
For O 
the O 
Pfr O 
state O 
of O 
the O 
bathy O 
phytochrome O 
from O 
Pseudomonas O 
aeruginosa O 
( O 
PaBphP O 
) O 
the O 
very O 
good O 
agreement O 
between O 
calculated O 
Raman O 
spectra O 
of O 
the O 
tetrapyrrole B-SYSTEMATIC 
cofactor O 
, O 
obtained O 
by O 
quantum O 
- O 
mechanical O 
/ O 
molecular O 
- O 
mechanical O 
hybrid O 
methods O 
, O 
and O 
the O 
experimental O 
resonance O 
Raman O 
( O 
RR O 
) O 
spectra O 
confirms O 
important O 
conclusions O 
derived O 
from O 
the O 
previous O 
crystallographic O 
analyses O 
, O 
particularly O 
the O 
ZZEssa O 
configuration O 
of O 
the O 
chromophore O 
and O 
its O 
attachment O 
to O 
the O 
thiol B-FAMILY 
side O 
chain O 
of O 
Cys B-FORMULA 
12 O 
via O 
the O 
exocyclic O 
vinyl B-FAMILY 
group O 
of O 
ring O 
A O 
. O 
The O 
match O 
between O 
the O 
RR O 
spectra O 
of O 
the O 
Pfr O 
states O 
of O 
PaBphP O 
and O 
the O 
bathy O 
phytochrome O 
Agp2 O 
from O 
Agrobacterium O 
tumefaciens O 
indicates O 
very O 
similar O 
structures O 
of O 
the O 
chromophore O 
binding O 
pockets O 
. O 
The O 
homogeneous O 
chromophore O 
conformation O 
in O 
bathy O 
phytochromes O 
is O 
in O 
sharp O 
contrast O 
to O 
the O 
Pfr O 
states O 
of O 
prototypical O 
phytochromes O 
as O 
demonstrated O 
by O 
comparative O 
RR O 
spectroscopic O 
analyses O 
. O 
The O 
Pfr O 
states O 
of O 
prototypical O 
phytochromes O 
, O 
thoroughly O 
studied O 
for O 
Agp1 O 
( O 
A O 
. O 
tumefaciens O 
) O 
, O 
display O 
conformational O 
equilibria O 
between O 
two O 
sub O 
- O 
states O 
differing O 
with O 
respect O 
to O 
the O 
CD O 
methine B-SYSTEMATIC 
bridge O 
torsional O 
angle O 
and O 
the O 
AB O 
methine B-SYSTEMATIC 
bridge O 
geometry O 
. O 
These O 
differences O 
may O 
mainly O 
root O 
in O 
the O 
interactions O 
of O 
the O 
cofactor O 
with O 
the O 
highly O 
conserved O 
Asp B-FORMULA 
194 O 
( O 
PaBphP O 
) O 
that O 
occur O 
via O 
its O 
carboxylate B-SYSTEMATIC 
function O 
in O 
bathy O 
phytochromes O 
. O 
The O 
weaker O 
interactions O 
via O 
the O 
carbonyl B-FAMILY 
function O 
in O 
prototypical O 
phytochromes O 
may O 
lead O 
to O 
a O 
higher O 
structural O 
flexibility O 
of O 
the O 
chromophore O 
binding O 
pocket O 
that O 
opens O 
the O 
reaction O 
channel O 
for O 
the O 
thermal O 
( O 
ZZE O 
→ O 
ZZZ O 
) O 
Pfr-to-Pr O 
back O 
- O 
conversion O 
. O 

from O 
Aspergillus O 
sp O 
. O 
is O 
an O 
important O 
factor O 
for O 
aspergillosis O 
. O 
AFUEI O 
is O 
an O 
inhibitor O 
of O 
the O 
elastase O 
derived O 
from O 
Aspergillus O 
fumigatus O 
. O 
AFUEI O 
is O 
a O 
member O 
of O 
the O 
I78 O 
inhibitor O 
family O 
, O 
and O 
has O 
a O 
high O 
inhibitory O 
activity O 
against O 
elastases O 
of O 
Aspergillus O 
fumigatus O 
and O 
Aspergillus O 
flavus O 
, O 
human O 
neutrophil O 
elastase O 
and O 
bovine O 
chymotrypsin O 
, O 
but O 
does O 
not O 
inhibit O 
bovine O 
trypsin O 
. O 
Here O 
we O 
report O 
the O 
crystal O 
structure O 
of O 
AFUEI O 
in O 
two O 
crystal O 
forms O 
. O 
AFUEI O 
is O 
a O 
wedge O 
- O 
shaped O 
protein O 
composed O 
of O 
an O 
extended O 
loop O 
and O 
a O 
scaffold O 
protein O 
core O 
. O 
The O 
structure O 
of O 
AFUEI O 
shows O 
remarkable O 
similarity O 
to O 
serine B-TRIVIAL 
protease O 
inhibitors O 
of O 
the O 
potato O 
inhibitor O 
I O 
family O 
, O 
although O 
they O 
are O 
classified O 
into O 
different O 
inhibitor O 
families O 
. O 
A O 
structural O 
comparison O 
with O 
the O 
potato O 
I O 
family O 
inhibitors O 
suggests O 
that O 
the O 
extended O 
loop O 
of O 
AFUEI O 
corresponds O 
to O 
the O 
binding O 
loop O 
of O 
the O 
potato O 
inhibitor O 
I O 
family O 
and O 
AFUEI O 
inhibits O 
its O 
cognate O 
proteases O 
through O 
the O 
same O 
mechanism O 
as O 
the O 
Potato O 
I O 
family O 
inhibitors O 
. O 

conducting O 
fibres O 
with O 
electrically O 
controlled O 
release O 
of O 
ciprofloxacin B-TRIVIAL 
. O 

hereby O 
present O 
a O 
new O 
method O 
of O 
producing O 
coaxial O 
conducting O 
polymer O 
fibres O 
loaded O 
with O 
an O 
antibiotic O 
drug O 
that O 
can O 
then O 
be O 
subsequently O 
released O 
( O 
or O 
sustained O 
) O 
in O 
response O 
to O 
electrical O 
stimulation O 
. O 
The O 
method O 
involves O 
wet O 
- O 
spinning O 
of O 
poly(3,4-ethylenedioxythiophene) B-SYSTEMATIC 
poly(styrenesulfonate) B-FAMILY 
( O 
PEDOT B-ABBREVIATION 
: O 
PSS B-ABBREVIATION 
) O 
fibre O 
, O 
which O 
served O 
as O 
the O 
inner O 
core O 
to O 
the O 
electropolymerised O 
outer O 
shell O 
layer O 
of O 
polypyrrole B-FAMILY 
( O 
Ppy B-ABBREVIATION 
) O 
. O 
Ciprofloxacin B-TRIVIAL 
hydrochloride B-FAMILY 
( O 
Cipro B-ABBREVIATION 
) O 
was O 
selected O 
as O 
the O 
model O 
drug O 
and O 
as O 
the O 
dopant O 
in O 
the O 
Ppy B-ABBREVIATION 
synthesis O 
. O 
The O 
release O 
of O 
Cipro B-ABBREVIATION 
in O 
phosphate B-SYSTEMATIC 
buffered O 
saline O 
( O 
PBS O 
) O 
from O 
the O 
fibres O 
was O 
controlled O 
by O 
switching O 
the O 
redox O 
state O 
of O 
Ppy B-ABBREVIATION 
. O 
Cipro B-ABBREVIATION 
layer O 
. O 
Released O 
Cipro B-ABBREVIATION 
under O 
passive O 
and O 
stimulated O 
conditions O 
were O 
tested O 
against O 
Gram O 
positive O 
( O 
Streptococcus O 
pyogenes O 
) O 
and O 
Gram O 
negative O 
( O 
Escherichia O 
coli O 
) O 
bacteria O 
. O 
Significant O 
inhibition O 
of O 
bacterial O 
growth O 
was O 
observed O 
against O 
both O 
strains O 
tested O 
. O 
These O 
results O 
confirm O 
that O 
Cipro B-ABBREVIATION 
retains O 
antibacterial O 
properties O 
during O 
fibre O 
fabrication O 
and O 
electrochemically O 
controlled O 
release O 
. O 
In O 
vitro O 
cytotoxicity O 
testing O 
utilising O 
the O 
neural O 
B35 O 
cell O 
line O 
confirmed O 
the O 
cytocompatibility O 
of O 
the O 
drug O 
loaded O 
conducting O 
fibres O 
. O 
Electrical O 
conductivity O 
, O 
cytocompatibility O 
and O 
tuning O 
release O 
profile O 
from O 
this O 
flexible O 
fibre O 
can O 
lead O 
to O 
promising O 
bionic O 
applications O 
such O 
as O 
neuroprosthetics O 
and O 
localised O 
drug O 
delivery O 
. O 

to O 
artificial O 
food O 
colors O 
and O 
additives O 
( O 
AFCAs O 
) O 
has O 
been O 
implicated O 
in O 
the O 
induction O 
and O 
severity O 
of O 
some O 
childhood O 
behavioral O 
and O 
learning O 
disabilities O 
. O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptors O 
( O 
NMDARs O 
) O 
and O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nACHRs O 
) O 
are O 
thought O 
to O 
be O 
effective O 
in O 
the O 
learning O 
and O 
memory O 
- O 
generating O 
process O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
intrauterine O 
exposure O 
to O 
AFCAs O 
on O 
subunit O 
concentrations O 
of O 
NMDARs O 
and O 
nAChRs O 
isoforms O 
in O 
rats O 
. O 
We O 
administered O 
a O 
mixture O 
of O 
AFCAs O 
( O 
Eritrosin B-TRIVIAL 
, O 
Ponceau B-TRIVIAL 
4R I-TRIVIAL 
, O 
Allura B-TRIVIAL 
Red I-TRIVIAL 
AC I-TRIVIAL 
, O 
Sunset B-TRIVIAL 
Yellow I-TRIVIAL 
FCF I-TRIVIAL 
, O 
Tartrazin B-TRIVIAL 
, O 
Amaranth B-TRIVIAL 
, O 
Brilliant B-TRIVIAL 
Blue I-TRIVIAL 
, O 
Azorubin B-TRIVIAL 
and O 
Indigotin B-TRIVIAL 
) O 
to O 
female O 
rats O 
before O 
and O 
during O 
gestation O 
. O 
The O 
concentration O 
of O 
NR2A O 
and O 
NR2B O 
subunits O 
and O 
nAChR O 
α7 O 
, O 
α4β2 O 
isoforms O 
in O 
their O 
offspring's O 
hippocampi O 
were O 
measured O 
by O 
Western O 
Blotting O 
. O 
Expressions O 
of O 
NR2B O 
and O 
nAChR O 
β2 O 
were O 
significantly O 
increased O 
( O 
17% O 
and O 
6.70% O 
, O 
respectively O 
) O 
, O 
whereas O 
expression O 
of O 
nAChR O 
α4 O 
was O 
significantly O 
decreased O 
( O 
5.67% O 
) O 
in O 
male O 
experimental O 
group O 
compared O 
to O 
the O 
male O 
control O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
In O 
the O 
female O 
experimental O 
group O 
, O 
AFCAs O 
caused O 
a O 
14% O 
decrease O 
in O 
NR2B O 
expression O 
when O 
compared O 
to O 
the O 
female O 
control O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Our O 
results O 
indicate O 
that O 
exposure O 
to O 
AFCAs O 
during O 
the O 
fetal O 
period O 
may O 
lead O 
to O 
alterations O 
in O 
expressions O 
of O 
NMDARs O 
and O 
nAChRs O 
in O 
adulthood O 
. O 
These O 
alterations O 
were O 
different O 
between O 
male O 
and O 
female O 
genders O 
. O 

- O 
scale O 
synthesis O 
of O 
graphene B-TRIVIAL 
sheets O 
by O 
a O 
catalytic O 
arc O 
- O 
discharge O 
method O 
. O 

graphite B-TRIVIAL 
is O 
used O 
as O 
carbon B-SYSTEMATIC 
source O 
and O 
ZnO B-FORMULA 
or O 
ZnS B-FORMULA 
as O 
catalyst O 
in O 
the O 
synthesis O 
of O 
high O 
- O 
quality O 
graphene B-TRIVIAL 
sheets O 
. O 
A O 
catalytic O 
growth O 
mechanism O 
for O 
cathode-part O 
graphene B-TRIVIAL 
synthesis O 
in O 
the O 
arc O 
- O 
discharge O 
apparatus O 
and O 
an O 
exfoliation O 
mechanism O 
for O 
wall O 
- O 
part O 
graphene B-TRIVIAL 
synthesis O 
are O 
introduced O 
. O 
N B-FORMULA 
-doped O 
cathode-part O 
graphene B-TRIVIAL 
and O 
undoped O 
wall O 
- O 
part O 
graphene B-TRIVIAL 
are O 
formed O 
simultaneously O 
. O 

: O 
Best O 
dose O 
analysis O 
involves O 
identifying O 
the O 
dose O 
associated O 
with O 
the O 
greatest O 
improvement O 
in O 
performance O 
for O 
each O 
subject O 
and O 
comparing O 
performances O 
associated O 
with O 
these O 
individually O 
determined O 
best O 
doses O 
to O 
control O 
performances O 
. O 
OBJECTIVES O 
: O 
The O 
current O 
experiments O 
were O 
conducted O 
to O 
examine O 
whether O 
significant O 
best O 
dose O 
effects O 
might O 
result O 
from O 
the O 
selective O 
analysis O 
of O 
data O 
rather O 
than O 
an O 
actual O 
drug O 
effect O 
. O 
METHODS O 
: O 
Experiment O 
1 O 
examined O 
the O 
effects O 
of O 
nicotine B-TRIVIAL 
and O 
methylphenidate B-SYSTEMATIC 
on O 
delayed O 
matching O 
- O 
to O 
- O 
sample O 
( O 
DMTS O 
) O 
and O 
self O 
- O 
ordered O 
spatial O 
search O 
( O 
SOSS O 
) O 
performances O 
in O 
rhesus O 
monkeys O 
( O 
DMTS O 
: O 
n O 
= O 
7 O 
; O 
SOSS O 
: O 
n O 
= O 
6 O 
) O 
to O 
determine O 
the O 
validity O 
and O 
reliability O 
of O 
best O 
dose O 
effects O 
. O 
Experiment O 
2 O 
used O 
Monte O 
Carlo O 
computer O 
simulations O 
to O 
estimate O 
the O 
likelihood O 
of O 
obtaining O 
a O 
significant O 
outcome O 
when O 
the O 
best O 
dose O 
method O 
was O 
applied O 
to O 
randomly O 
generated O 
data O 
sets O 
for O 
which O 
no O 
difference O 
existed O 
. O 
RESULTS O 
: O 
Significant O 
effects O 
were O 
obtained O 
when O 
the O 
best O 
dose O 
analysis O 
was O 
applied O 
to O 
performances O 
from O 
nondrug O 
sessions O 
, O 
and O 
best O 
dose O 
performances O 
were O 
not O 
significantly O 
different O 
from O 
the O 
best O 
nondrug O 
performances O 
. O 
The O 
doses O 
identified O 
as O 
best O 
doses O 
from O 
two O 
nicotine B-TRIVIAL 
dose O 
- O 
response O 
curve O 
determinations O 
were O 
unrelated O 
, O 
and O 
the O 
improvement O 
associated O 
with O 
the O 
best O 
dose O 
observed O 
during O 
the O 
first O 
dose O 
- O 
response O 
curve O 
determination O 
was O 
not O 
reliable O 
when O 
the O 
dose O 
was O 
administered O 
repeatedly O 
. O 
Finally O 
, O 
there O 
was O 
a O 
high O 
likelihood O 
of O 
obtaining O 
a O 
statistically O 
significant O 
difference O 
when O 
no O 
real O 
difference O 
existed O 
. O 
CONCLUSIONS O 
: O 
Best O 
dose O 
analysis O 
for O 
the O 
identification O 
of O 
potential O 
therapeutic O 
agents O 
should O 
be O 
replaced O 
by O 
single O 
- O 
subject O 
designs O 
. O 

mutations O 
in O 
the O 
proteolipid O 
protein O 
1 O 
( O 
PLP1 O 
) O 
gene O 
cause O 
a O 
wide O 
spectrum O 
of O 
hypomyelinating O 
disorders O 
, O 
from O 
mild O 
spastic O 
paraplegia O 
type O 
2 O 
to O 
severe O 
Pelizaeus-Merzbacher O 
disease O 
( O 
PMD O 
) O 
. O 
Mutant O 
PLP1 O 
accumulates O 
in O 
the O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
and O 
induces O 
ER O 
stress O 
. O 
However O 
, O 
the O 
link O 
between O 
the O 
clinical O 
severity O 
of O 
PMD O 
and O 
the O 
cellular O 
response O 
induced O 
by O 
mutant O 
PLP1 O 
remains O 
largely O 
unknown O 
. O 
Accumulation O 
of O 
misfolded O 
proteins O 
in O 
the O 
ER O 
generally O 
leads O 
to O 
up O 
- O 
regulation O 
of O 
ER O 
chaperones O 
to O 
alleviate O 
ER O 
stress O 
. O 
Here O 
, O 
we O 
found O 
that O 
expression O 
of O 
the O 
PLP1-A243V O 
mutant O 
, O 
which O 
causes O 
severe O 
disease O 
, O 
depletes O 
some O 
ER O 
chaperones O 
with O 
a O 
KDEL O 
( O 
Lys-Asp-Glu-Leu B-FORMULA 
) O 
motif O 
, O 
in O 
HeLa O 
cells O 
, O 
MO3.13 O 
oligodendrocytic O 
cells O 
, O 
and O 
primary O 
oligodendrocytes O 
. O 
The O 
same O 
PLP1 O 
mutant O 
also O 
induces O 
fragmentation O 
of O 
the O 
Golgi O 
apparatus O 
( O 
GA O 
) O 
. O 
These O 
organelle O 
changes O 
are O 
less O 
prominent O 
in O 
cells O 
with O 
milder O 
disease O 
- O 
associated O 
PLP1 O 
mutants O 
. O 
Similar O 
changes O 
are O 
also O 
observed O 
in O 
cells O 
expressing O 
another O 
disease O 
- O 
causing O 
gene O 
that O 
triggers O 
ER O 
stress O 
, O 
as O 
well O 
as O 
in O 
cells O 
treated O 
with O 
brefeldin B-TRIVIAL 
A I-TRIVIAL 
, O 
which O 
induces O 
ER O 
stress O 
and O 
GA O 
fragmentation O 
by O 
inhibiting O 
GA O 
to O 
ER O 
trafficking O 
. O 
We O 
also O 
found O 
that O 
mutant O 
PLP1 O 
disturbs O 
localization O 
of O 
the O 
KDEL O 
receptor O 
, O 
which O 
transports O 
the O 
chaperones O 
with O 
the O 
KDEL O 
motif O 
from O 
the O 
GA O 
to O 
the O 
ER O 
. O 
These O 
data O 
show O 
that O 
PLP1 O 
mutants O 
inhibit O 
GA O 
to O 
ER O 
trafficking O 
, O 
which O 
reduces O 
the O 
supply O 
of O 
ER O 
chaperones O 
and O 
induces O 
GA O 
fragmentation O 
. O 
We O 
propose O 
that O 
depletion O 
of O 
ER O 
chaperones O 
and O 
GA O 
fragmentation O 
induced O 
by O 
mutant O 
misfolded O 
proteins O 
contribute O 
to O 
the O 
pathogenesis O 
of O 
inherited O 
ER O 
stress O 
- O 
related O 
diseases O 
and O 
affect O 
the O 
disease O 
severity O 
. O 

kinase O 
A O 
( O 
PKA O 
) O 
regulatory O 
subunit O 
type O 
Iα O 
( O 
RIα O 
) O 
is O 
a O 
major O 
regulatory O 
subunit O 
that O 
functions O 
as O 
an O 
inhibitor O 
of O 
PKA O 
kinase O 
activity O 
. O 
We O 
have O 
previously O 
demonstrated O 
that O 
elevated O 
RIα O 
expression O 
is O 
associated O 
with O 
diffuse O 
- O 
to O 
- O 
nodular O 
transformation O 
of O 
hyperplasia O 
in O 
parathyroid O 
glands O 
of O 
renal O 
hyperparathyroidism O 
. O 
The O 
aim O 
of O 
the O 
current O 
study O 
was O 
to O 
determine O 
whether O 
or O 
not O 
RIα O 
expression O 
is O 
increased O 
in O 
adenomas O 
of O 
primary O 
hyperparathyroidism O 
( O 
PHPT O 
) O 
, O 
because O 
monoclonal O 
proliferation O 
has O 
been O 
demonstrated O 
in O 
both O 
adenomas O 
and O 
nodular O 
hyperplasia O 
. O 
Surgical O 
specimens O 
comprising O 
22 O 
adenomas O 
and O 
11 O 
normal O 
glands O 
, O 
obtained O 
from O 
22 O 
patients O 
with O 
PHPT O 
, O 
were O 
analyzed O 
. O 
Western O 
blot O 
and O 
immunohistochemical O 
analyses O 
were O 
employed O 
to O 
evaluate O 
RIα O 
expression O 
. O 
PKA O 
activities O 
were O 
determined O 
in O 
several O 
adenomas O 
highly O 
expressing O 
RIα O 
. O 
RIα O 
expression O 
was O 
also O 
separately O 
evaluated O 
in O 
chief O 
and O 
oxyphilic O 
cells O 
using O 
the O 
" O 
Allred O 
score O 
" O 
system O 
. O 
Expression O 
of O 
proliferating O 
cell O 
nuclear O 
antigen O 
( O 
PCNA O 
) O 
, O 
a O 
proliferation O 
marker O 
, O 
was O 
also O 
immunohistochemically O 
examined O 
. O 
Western O 
blot O 
analysis O 
revealed O 
that O 
5 O 
out O 
of O 
8 O 
adenomas O 
highly O 
expressed O 
RIα O 
, O 
compared O 
with O 
normal O 
glands O 
. O 
PKA O 
activity O 
in O 
adenomas O 
was O 
significantly O 
less O 
than O 
in O 
normal O 
glands O 
. O 
Immunohistochemical O 
analysis O 
further O 
demonstrated O 
high O 
expression O 
of O 
RIα O 
in O 
20 O 
out O 
of O 
22 O 
adenomas O 
. O 
In O 
adenomas O 
, O 
the O 
greater O 
RIα O 
expression O 
and O 
more O 
PCNA O 
positive O 
cells O 
were O 
observed O 
in O 
both O 
chief O 
and O 
oxyphilic O 
cells O 
. O 
The O 
present O 
study O 
suggested O 
that O 
high O 
RIα O 
expression O 
could O 
contribute O 
to O 
monoclonal O 
proliferation O 
of O 
parathyroid O 
cells O 
by O 
impairing O 
the O 
cAMP B-ABBREVIATION 
/ O 
PKA O 
signaling O 
pathway O 
. O 

of O 
definable O 
number O 
of O 
drug O 
or O 
growth O 
factor O 
loaded O 
poly(dl-lactic B-FAMILY 
acid I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
microparticles O 
within O 
human O 
embryonic O 
stem O 
cell O 
derived O 
aggregates O 
. O 

bodies O 
( O 
EBs O 
) O 
generated O 
from O 
embryonic O 
stem O 
cells O 
are O 
used O 
to O 
study O 
processes O 
of O 
differentiation O 
within O 
a O 
three O 
dimensional O 
( O 
3D O 
) O 
cell O 
environment O 
. O 
In O 
many O 
instances O 
however O 
, O 
EBs O 
are O 
dispersed O 
to O 
single O 
cell O 
suspensions O 
with O 
a O 
subsequent O 
monolayer O 
culture O 
. O 
Moreover O 
, O 
where O 
the O 
3D O 
integrity O 
of O 
an O 
EB O 
is O 
maintained O 
, O 
cytokines O 
or O 
drugs O 
of O 
interest O 
to O 
stimulate O 
differentiation O 
are O 
often O 
added O 
directly O 
to O 
the O 
culture O 
medium O 
at O 
fixed O 
concentrations O 
and O 
effects O 
are O 
usually O 
limited O 
to O 
the O 
outer O 
layers O 
of O 
the O 
EB O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
create O 
an O 
EB O 
model O 
with O 
localised O 
drug O 
and O 
or O 
growth O 
factor O 
delivery O 
directly O 
within O 
the O 
EB O 
. O 
Using O 
poly(DL-lactic B-FAMILY 
acid I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
microparticles O 
( O 
MPs O 
) O 
with O 
an O 
average O 
diameter O 
of O 
13μm O 
, O 
we O 
have O 
demonstrated O 
controllable O 
incorporation O 
of O 
defined O 
numbers O 
of O 
MPs O 
within O 
human O 
ES O 
cell O 
derived O 
EBs O 
, O 
down O 
to O 
1 O 
MP O 
per O 
EB O 
. O 
This O 
was O 
achieved O 
by O 
coating O 
MPs O 
with O 
human O 
ES O 
cell O 
lysate O 
and O 
centrifugation O 
of O 
specific O 
ratios O 
of O 
ES O 
cells O 
and O 
MPs O 
to O 
form O 
3D O 
aggregates O 
. O 
Using O 
MPs O 
loaded O 
with O 
simvastatin B-TRIVIAL 
( O 
pro O 
or O 
active O 
drug O 
) O 
or O 
BMP-2 O 
, O 
we O 
have O 
demonstrated O 
osteogenic O 
differentiation O 
within O 
the O 
3D O 
aggregates O 
, O 
maintained O 
in O 
culture O 
for O 
up O 
to O 
21days O 
, O 
and O 
quantified O 
by O 
real O 
time O 
QPCR O 
for O 
osteocalcin O 
. O 
Immunostaining O 
for O 
RUNX2 O 
and O 
osteocalcin O 
, O 
and O 
also O 
histochemical O 
staining O 
with O 
picrosirius O 
red O 
to O 
demonstrate O 
collage O 
type O 
1 O 
and O 
Alizarin B-TRIVIAL 
red I-TRIVIAL 
to O 
demonstrate O 
calcium B-SYSTEMATIC 
/ O 
mineralisation O 
further O 
demonstrated O 
osteogenic O 
differentiation O 
and O 
revealed O 
regional O 
staining O 
associated O 
with O 
the O 
locations O 
of O 
MPs O 
within O 
the O 
aggregates O 
. O 
We O 
also O 
demonstrated O 
endothelial O 
differentiation O 
within O 
human O 
ES O 
cell O 
- O 
derived O 
aggregates O 
using O 
VEGF O 
loaded O 
MPs O 
. O 
In O 
conclusion O 
, O 
we O 
demonstrate O 
an O 
effective O 
and O 
reliable O 
approach O 
for O 
engineering O 
stem O 
aggregates O 
with O 
definable O 
number O 
of O 
MPs O 
within O 
the O 
3D O 
cellular O 
structure O 
. O 
We O 
also O 
achieved O 
localised O 
osteogenic O 
and O 
endothelial O 
differentiation O 
associated O 
with O 
MPs O 
releasing O 
encapsulated O 
drug O 
molecules O 
or O 
cytokines O 
directly O 
within O 
the O 
cell O 
aggregate O 
. O 
This O 
provides O 
a O 
powerful O 
tool O 
for O 
controlling O 
and O 
investigating O 
differentiation O 
within O 
3D O 
cell O 
cultures O 
and O 
has O 
applications O 
to O 
drug O 
delivery O 
, O 
drug O 
discovery O 
, O 
stem O 
cell O 
biology O 
, O 
tissue O 
engineering O 
and O 
regenerative O 
medicine O 
. O 

4-tert-octylphenol B-SYSTEMATIC 
affect O 
estrogen B-FAMILY 
signaling O 
pathways O 
in O 
bank O 
vole O 
Leydig O 
cells O 
and O 
tumor O 
mouse O 
Leydig O 
cells O 
in O 
vitro O 
? O 

Leydig O 
cells O 
obtained O 
from O 
bank O 
vole O 
testes O 
and O 
the O 
established O 
tumor O 
Leydig O 
cell O 
line O 
( O 
MA-10 O 
) O 
have O 
been O 
used O 
to O 
explore O 
the O 
effects O 
of O 
4-tert-octylphenol B-SYSTEMATIC 
( O 
OP O 
) O 
. O 
Leydig O 
cells O 
were O 
treated O 
with O 
two O 
concentrations O 
of O 
OP O 
( O 
10(-4)M O 
, O 
10(-8)M O 
) O 
alone O 
or O 
concomitantly O 
with O 
anti- O 
estrogen B-FAMILY 
ICI B-IDENTIFIER 
182780 I-IDENTIFIER 
( O 
1μM O 
) O 
. O 
In O 
OP O 
- O 
treated O 
bank O 
vole O 
Leydig O 
cells O 
, O 
inhomogeneous O 
staining O 
of O 
estrogen B-FAMILY 
receptor O 
α O 
( O 
ERα O 
) O 
within O 
cell O 
nuclei O 
was O 
found O 
, O 
whereas O 
it O 
was O 
of O 
various O 
intensity O 
among O 
MA-10 O 
Leydig O 
cells O 
. O 
The O 
expression O 
of O 
ERα O 
mRNA O 
and O 
protein O 
decreased O 
in O 
both O 
primary O 
and O 
immortalized O 
Leydig O 
cells O 
independently O 
of O 
OP O 
dose O 
. O 
ICI O 
partially O 
reversed O 
these O 
effects O 
at O 
mRNA O 
level O 
while O 
at O 
protein O 
level O 
abrogation O 
was O 
found O 
only O 
in O 
vole O 
cells O 
. O 
Dissimilar O 
action O 
of O 
OP O 
on O 
cAMP B-ABBREVIATION 
and O 
androgen B-FAMILY 
production O 
was O 
also O 
observed O 
. O 
This O 
study O 
provides O 
further O 
evidence O 
that O 
OP O 
shows O 
estrogenic O 
properties O 
acting O 
on O 
Leydig O 
cells O 
. O 
However O 
, O 
its O 
effect O 
is O 
diverse O 
depending O 
on O 
the O 
cellular O 
origin O 
. O 

Structure O 
of O 
TTBC B-ABBREVIATION 
J-Aggregates O 
in O 
Solution O 
and O 
on O 
Surface O 
. O 

aggregation O 
behavior O 
of O 
cationic O 
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidacarbocyanine B-SYSTEMATIC 
with O 
chloride B-SYSTEMATIC 
( O 
TTBC-Cl B-FORMULA 
) O 
or O 
iodide B-SYSTEMATIC 
counterions O 
( O 
TTBC-I B-FORMULA 
) O 
in O 
aqueous O 
solution O 
is O 
investigated O 
by O 
absorption O 
, O 
linear O 
dichroism O 
, O 
and O 
fluorescence O 
spectroscopies O 
, O 
as O 
well O 
as O 
cryogenic O 
transmission O 
electron O 
microscopy O 
( O 
cryo-TEM O 
) O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
. O 
TTBC-Cl B-FORMULA 
is O 
found O 
to O 
form O 
J-aggregates O 
with O 
a O 
classical O 
Davydov O 
- O 
split O 
absorption O 
band O 
( O 
type O 
I O 
spectrum O 
) O 
even O 
under O 
different O 
preparation O 
conditions O 
. O 
These O 
aggregates O 
remain O 
stable O 
for O 
months O 
. O 
Unlike O 
the O 
chloride B-SYSTEMATIC 
salt O 
, O 
the O 
iodide B-SYSTEMATIC 
salt O 
TTBC-I B-FORMULA 
forms O 
two O 
different O 
types O 
of O 
J-aggregates O 
depending O 
on O 
the O 
pH O 
of O 
the O 
aqueous O 
solution O 
. O 
The O 
TTBC-I B-FORMULA 
aggregates O 
prepared O 
in O 
pure O 
water O 
( O 
pH O 
= O 
6 O 
) O 
are O 
characterized O 
by O 
a O 
single O 
redshifted O 
absorption O 
band O 
( O 
type O 
III O 
spectrum O 
) O 
, O 
whereas O 
those O 
prepared O 
in O 
alkaline O 
solution O 
at O 
pH O 
= O 
13 O 
show O 
a O 
typical O 
Davydov O 
- O 
split O 
( O 
type O 
I O 
) O 
absorption O 
band O 
. O 
Despite O 
differences O 
in O 
counterions O 
, O 
preparation O 
method O 
, O 
stability O 
, O 
and O 
spectroscopic O 
behavior O 
, O 
cryo-TEM O 
reveals O 
an O 
identical O 
tubular O 
architecture O 
for O 
all O 
these O 
J-aggregates O 
. O 
Among O 
the O 
new O 
structure O 
models O 
discussed O 
here O 
is O 
a O 
cylindrical O 
brickwork O 
layer O 
of O 
dye O 
molecules O 
for O 
single O 
- O 
banded O 
J-aggregates O 
( O 
type O 
III O 
) O 
. O 
For O 
Davydov O 
- O 
split O 
aggregates O 
( O 
type O 
I O 
) O 
, O 
a O 
molecular O 
herringbone O 
- O 
like O 
pattern O 
is O 
proposed O 
instead O 
. O 
Moreover O 
, O 
absorption O 
spectra O 
have O 
revealed O 
an O 
additional O 
single O 
redshifted O 
absorption O 
band O 
( O 
type O 
II O 
spectrum O 
) O 
that O 
is O 
assigned O 
to O 
a O 
surface O 
aggregate O 
and O 
is O 
induced O 
by O 
a O 
specific O 
interaction O 
of O 
the O 
dye O 
cation O 
with O 
the O 
negatively O 
charged O 
cuvette O 
wall O 
. O 
AFM O 
measurements O 
of O 
analogous O 
preparations O 
on O 
negatively O 
charged O 
mica O 
surfaces O 
have O 
supported O 
this O 
interpretation O 
and O 
revealed O 
the O 
formation O 
of O 
monolayered O 
sheet O 
structures O 
. O 

and O 
Functional O 
Changes O 
of O 
Salivary O 
Gland O 
Dysfunction O 
after O 
Radioiodine B-SYSTEMATIC 
Ablation O 
in O 
a O 
Murine O 
Model O 
. O 

: O 
Ablation O 
of O 
the O 
thyroid O 
tissue O 
using O 
radioiodine B-SYSTEMATIC 
( O 
RI O 
) O 
after O 
the O 
surgical O 
removal O 
of O 
well O 
- O 
differentiated O 
thyroid O 
cancer O 
( O 
WDTC O 
) O 
can O 
induce O 
radiation O 
- O 
related O 
salivary O 
gland O 
( O 
SG O 
) O 
dysfunction O 
. O 
However O 
, O 
in O 
vivo O 
changes O 
of O 
SGs O 
following O 
RI O 
administration O 
in O 
appropriate O 
animal O 
models O 
are O 
not O 
well O 
described O 
in O 
the O 
literature O 
. O 
This O 
study O 
was O 
undertaken O 
to O 
document O 
morphometric O 
and O 
functional O 
changes O 
during O 
the O 
12 O 
months O 
following O 
RI O 
administration O 
in O 
a O 
murine O 
model O 
of O 
RI-induced O 
SG O 
dysfunction O 
. O 
Methods O 
: O 
Female O 
C57BL O 
/ O 
6 O 
, O 
4-week- O 
old O 
mice O 
( O 
n=60 O 
) O 
were O 
divided O 
into O 
a O 
RI O 
- O 
treated O 
group O 
( O 
n=30 O 
) O 
that O 
received O 
RI O 
orally O 
( O 
0.01 O 
mCi O 
/ O 
g O 
body O 
weight O 
) O 
or O 
an O 
unexposed O 
control O 
group O 
( O 
n=30 O 
) O 
. O 
Mice O 
in O 
both O 
groups O 
were O 
divided O 
into O 
five O 
subgroups O 
( O 
n=6 O 
per O 
subgroup O 
) O 
and O 
sacrificed O 
at O 
1 O 
, O 
2 O 
, O 
3 O 
, O 
6 O 
, O 
and O 
12 O 
months O 
post-RI O 
administration O 
. O 
Salivary O 
flow O 
rates O 
( O 
SFR O 
) O 
and O 
salivary O 
lag O 
times O 
were O 
measured O 
at O 
1 O 
, O 
2 O 
, O 
3 O 
, O 
6 O 
, O 
and O 
12 O 
months O 
after O 
RI O 
administration O 
. O 
Morphological O 
and O 
histological O 
examinations O 
and O 
terminal O 
deoxynucleotidyl B-FAMILY 
transferase O 
dUTP B-ABBREVIATION 
nick O 
end O 
labeling O 
( O 
TUNEL O 
) O 
assays O 
were O 
performed O 
. O 
In O 
addition O 
, O 
changes O 
in O 
salivary O 
99m B-SYSTEMATIC 
Tc I-SYSTEMATIC 
pertechnetate I-SYSTEMATIC 
uptake O 
and O 
excretion O 
were O 
observed O 
by O 
single O 
- O 
photon O 
emission O 
computed O 
tomography O 
( O 
SPECT O 
) O 
. O 
Results O 
: O 
In O 
RI O 
- O 
treated O 
mice O 
, O 
the O 
SGs O 
were O 
significantly O 
lighter O 
compared O 
to O 
unexposed O 
controls O 
at O 
all O 
study O 
time O 
points O 
. O 
Lag O 
times O 
to O 
salivation O 
in O 
the O 
RI O 
- O 
treated O 
group O 
were O 
greater O 
than O 
in O 
the O 
unexposed O 
controls O 
, O 
but O 
mean O 
SFR O 
were O 
lower O 
. O 
Histologic O 
examinations O 
of O 
SGs O 
in O 
the O 
RI O 
- O 
group O 
showed O 
pale O 
cytoplasm O 
, O 
atypical O 
ductal O 
configuration O 
, O 
septal O 
widening O 
, O 
cytoplasmic O 
vacuolization O 
with O 
pleomorphism O 
, O 
lymphocyte O 
infiltration O 
, O 
and O 
increased O 
fibrosis O 
. O 
Furthermore O 
, O 
more O 
apoptotic O 
cells O 
were O 
observed O 
in O 
acini O 
and O 
ducts O 
in O 
the O 
RI O 
group O 
. O 
In O 
addition O 
, O 
patterns O 
of O 
99m B-SYSTEMATIC 
Tc I-SYSTEMATIC 
pertechnetate I-SYSTEMATIC 
uptake O 
and O 
excretion O 
in O 
the O 
RI O 
- O 
group O 
were O 
quite O 
different O 
from O 
those O 
observed O 
in O 
controls O 
at O 
1 O 
and O 
12 O 
months O 
post-RI O 
. O 
Conclusion O 
: O 
Various O 
histological O 
alterations O 
were O 
observed O 
in O 
mice O 
exposed O 
to O 
radioiodine B-SYSTEMATIC 
, O 
that O 
is O 
, O 
an O 
increase O 
in O 
apoptotic O 
acini O 
and O 
ductal O 
cells O 
and O 
functional O 
SG O 
deterioration O 
. O 
The O 
murine O 
model O 
of O 
RI-induced O 
SG O 
dysfunction O 
used O 
in O 
the O 
present O 
study O 
appears O 
to O 
be O 
applicable O 
to O 
preclinical O 
research O 
on O 
RI O 
-induced O 
sialadenitis O 
in O 
patients O 
with O 
WDTC O 
. O 

recent O 
years O 
tartary O 
buckwheat O 
has O 
become O 
popular O 
healthful O 
food O 
due O 
to O 
its O 
antioxidant O 
, O 
antidiabetic O 
and O 
antitumor O 
activities O 
. O 
However O 
, O 
its O 
chemical O 
constituents O 
have O 
not O 
yet O 
been O 
fully O 
characterized O 
and O 
identified O 
. O 
In O 
this O 
paper O 
, O 
a O 
novel O 
high O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
photodiode O 
array O 
detector O 
and O 
linear O 
ion O 
trap O 
FTICR O 
hybrid O 
mass O 
spectrometry O 
( O 
HPLC-PDA O 
/ O 
LTQ-FTICRMS O 
) O 
method O 
was O 
established O 
to O 
characterize O 
and O 
identify O 
a O 
total O 
of O 
36 O 
compounds O 
by O 
a O 
single O 
run O 
. O 
The O 
retention O 
time O 
, O 
maximum O 
UV O 
absorption O 
wavelength O 
, O 
accurate O 
mass O 
weight O 
and O 
characteristic O 
fragment O 
ions O 
were O 
collected O 
on O 
line O 
. O 
To O 
confirm O 
the O 
structures O 
, O 
11 O 
compounds O 
were O 
isolated O 
and O 
identified O 
by O 
MS O 
and O 
NMR O 
experiments O 
. O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
3 I-SYSTEMATIC 
, I-SYSTEMATIC 
6 I-SYSTEMATIC 
, I-SYSTEMATIC 
6'-tetra- I-SYSTEMATIC 
feruloyl I-SYSTEMATIC 
sucrose I-SYSTEMATIC 
named O 
taroside O 
was O 
a O 
new O 
phenlypropanoid B-FAMILY 
glycoside I-FAMILY 
, O 
together O 
with O 
3 B-SYSTEMATIC 
, I-SYSTEMATIC 
6-di-p-coumaroyl-1 I-SYSTEMATIC 
, I-SYSTEMATIC 
6'-di- I-SYSTEMATIC 
feruloyl I-SYSTEMATIC 
sucrose I-SYSTEMATIC 
, O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
6 I-SYSTEMATIC 
, I-SYSTEMATIC 
6'-tri-feruloyl-3-p-coumaroyl I-SYSTEMATIC 
sucrose I-SYSTEMATIC 
, O 
N-trans-feruloyltyramine B-TRIVIAL 
and O 
quercetin-3-O-[β-D-xyloxyl-(1→2)-α-L-rhamnoside] B-SYSTEMATIC 
were O 
isolated O 
for O 
the O 
first O 
time O 
from O 
the O 
Fagopyrum O 
species O 
. O 
The O 
research O 
enriched O 
the O 
chemical O 
information O 
of O 
tartary O 
buckwheat O 
. O 

insight O 
into O 
the O 
discharge O 
mechanism O 
of O 
silicon B-SYSTEMATIC 
-air O 
batteries O 
using O 
electrochemical O 
impedance O 
spectroscopy O 
. O 

mechanism O 
of O 
discharge O 
termination O 
in O 
silicon B-SYSTEMATIC 
-air O 
batteries O 
, O 
employing O 
a O 
silicon B-SYSTEMATIC 
wafer O 
anode O 
, O 
a O 
room O 
- O 
temperature O 
fluorohydrogenate O 
ionic O 
liquid O 
electrolyte O 
and O 
an O 
air O 
cathode O 
membrane O 
, O 
is O 
investigated O 
using O 
a O 
wide O 
range O 
of O 
tools O 
. O 
EIS O 
studies O 
indicate O 
that O 
the O 
interfacial O 
impedance O 
between O 
the O 
electrolyte O 
and O 
the O 
silicon B-SYSTEMATIC 
wafer O 
increases O 
upon O 
continuous O 
discharge O 
. O 
In O 
addition O 
, O 
it O 
is O 
shown O 
that O 
the O 
impedance O 
of O 
the O 
air O 
cathode-electrolyte O 
interface O 
is O 
several O 
orders O 
of O 
magnitude O 
lower O 
than O 
that O 
of O 
the O 
anode O 
. O 
Equivalent O 
circuit O 
fitting O 
parameters O 
indicate O 
the O 
difference O 
in O 
the O 
anode-electrolyte O 
interface O 
characteristics O 
for O 
different O 
types O 
of O 
silicon B-SYSTEMATIC 
wafers O 
. O 
Evolution O 
of O 
porous O 
silicon B-SYSTEMATIC 
surfaces O 
at O 
the O 
anode O 
and O 
their O 
properties O 
, O 
by O 
means O 
of O 
estimated O 
circuit O 
parameters O 
, O 
is O 
also O 
presented O 
. O 
Moreover O 
, O 
it O 
is O 
found O 
that O 
the O 
silicon B-SYSTEMATIC 
anode O 
potential O 
has O 
the O 
highest O 
negative O 
impact O 
on O 
the O 
battery O 
discharge O 
voltage O 
, O 
while O 
the O 
air O 
cathode O 
potential O 
is O 
actually O 
stable O 
and O 
invariable O 
along O 
the O 
whole O 
discharge O 
period O 
. O 
The O 
discharge O 
capacity O 
of O 
the O 
battery O 
can O 
be O 
increased O 
significantly O 
by O 
mechanically O 
replacing O 
the O 
silicon B-SYSTEMATIC 
anode O 
. O 

DNA O 
translocation O 
speed O 
is O 
critically O 
important O 
for O 
nanopore O 
sequencing O 
as O 
free O 
electrophoretic O 
threading O 
is O 
far O 
too O 
rapid O 
to O 
resolve O 
individual O 
bases O 
. O 
A O 
number O 
of O 
promising O 
strategies O 
have O 
been O 
explored O 
in O 
recent O 
years O 
, O 
largely O 
driven O 
by O 
the O 
demands O 
of O 
next O 
- O 
generation O 
sequencing O 
. O 
Engineering O 
DNA-nanopore O 
interactions O 
( O 
known O 
to O 
dominate O 
translocation O 
dynamics O 
) O 
with O 
organic O 
coatings O 
is O 
an O 
attractive O 
method O 
as O 
it O 
does O 
not O 
require O 
sample O 
modification O 
, O 
processive O 
enzymes O 
, O 
or O 
complicated O 
and O 
expensive O 
fabrication O 
steps O 
. O 
In O 
this O 
work O 
, O 
we O 
show O 
for O 
the O 
first O 
time O 
4-fold O 
tuning O 
of O 
unfolded O 
, O 
single O 
- O 
file O 
translocation O 
time O 
through O 
small O 
, O 
amine B-SYSTEMATIC 
-functionalized O 
solid O 
- O 
state O 
nanopores O 
by O 
varying O 
the O 
solution O 
pH O 
in O 
situ O 
. O 
Additionally O 
, O 
we O 
develop O 
a O 
simple O 
analytical O 
model O 
based O 
on O 
electrostatic O 
interactions O 
to O 
explain O 
this O 
effect O 
which O 
will O 
be O 
a O 
useful O 
tool O 
in O 
designing O 
future O 
devices O 
and O 
experiments O 
. O 

effects O 
of O 
extracellular O 
polymeric O 
substances O 
excreted O 
by O 
Thalassiosira O 
pseudonana O 
on O 
algal O 
toxicity O 
of O 
CdSe B-FORMULA 
quantum O 
dots O 
. O 

dots O 
( O 
QDs O 
) O 
are O 
engineered O 
nanoparticles O 
( O 
ENs O 
) O 
that O 
have O 
found O 
increasing O 
applications O 
and O 
shown O 
great O 
potential O 
in O 
drug O 
delivery O 
, O 
biological O 
imaging O 
and O 
industrial O 
products O 
. O 
Knowledge O 
of O 
their O 
stability O 
, O 
fate O 
and O 
transport O 
in O 
the O 
aquatic O 
environment O 
is O 
still O 
lacking O 
, O 
including O 
details O 
of O 
how O 
these O 
nanomaterials O 
interact O 
with O 
marine O 
phytoplankton O 
. O 
Here O 
, O 
we O 
examined O 
the O 
toxicity O 
of O 
functionalized O 
CdSe B-FORMULA 
/ O 
ZnS B-FORMULA 
QDs O 
( O 
amine B-SYSTEMATIC 
- O 
and O 
carboxyl B-SYSTEMATIC 
- O 
) O 
by O 
exposing O 
them O 
for O 
five O 
days O 
to O 
Thalassiosira O 
pseudonana O 
( O 
marine O 
diatom O 
) O 
grown O 
under O 
different O 
nutrient-conditions O 
( O 
enriched O 
versus O 
nitrogen B-SYSTEMATIC 
-limited O 
media O 
) O 
. O 
The O 
released O 
polysaccharides O 
and O 
proteins O 
, O 
the O 
major O 
components O 
of O 
extracellular O 
polymeric O 
substances O 
( O 
EPS O 
) O 
, O 
were O 
measured O 
to O 
assess O 
their O 
potential O 
effects O 
on O 
the O 
interactions O 
between O 
QDs O 
and O 
T O 
. O 
pseudonana O 
. O 
The O 
partitioning O 
of O 
QDs O 
was O 
analyzed O 
by O 
monitoring O 
the O 
concentration O 
of O 
Cd B-FORMULA 
in O 
different O 
size O 
fractions O 
of O 
the O 
cultures O 
( O 
i.e O 
. O 
, O 
filtrate O 
, O 
< O 
0.22 O 
μm O 
and O 
permeate O 
, O 
< O 
3 O 
kDa O 
) O 
. O 
We O 
found O 
that O 
the O 
Cd B-FORMULA 
release O 
of O 
QDs O 
in O 
the O 
T O 
. O 
pseudonana O 
culture O 
was O 
dependent O 
on O 
the O 
nutrient O 
conditions O 
and O 
nature O 
of O 
QDs O 
' O 
surface O 
coating O 
. O 
Both O 
amine B-SYSTEMATIC 
- O 
and O 
carboxyl B-SYSTEMATIC 
-functionalized O 
QDs O 
exhibited O 
higher O 
rates O 
of O 
Cd B-FORMULA 
release O 
in O 
N-limited O 
cultures O 
than O 
in O 
nutrient O 
enriched O 
cultures O 
. O 
The O 
results O 
also O 
showed O 
that O 
amine B-SYSTEMATIC 
-functionalized O 
QDs O 
aggregate O 
with O 
minimal O 
Cd B-FORMULA 
release O 
, O 
independent O 
of O 
nutrient O 
conditions O 
. O 
Laser O 
scanning O 
confocal O 
microscopy O 
images O 
confirmed O 
that O 
aggregates O 
are O 
composed O 
of O 
QDs O 
and O 
the O 
culture O 
matrix O 
( O 
EPS O 
) O 
. O 
In O 
addition O 
, O 
both O 
types O 
of O 
QDs O 
showed O 
limited O 
toxicity O 
to O 
T O 
. O 
pseudonana O 
. O 
The O 
increasing O 
production O 
of O 
proteins O 
induced O 
by O 
QDs O 
suggests O 
that O 
extracellular O 
proteins O 
might O 
be O 
involved O 
in O 
the O 
detoxification O 
of O 
QDs O 
to O 
T O 
. O 
pseudonana O 
via O 
the O 
Cd B-FORMULA 
release O 
of O 
QDs O 
. O 
Our O 
results O 
here O 
demonstrated O 
that O 
EPS O 
can O 
play O 
an O 
ameliorating O 
role O 
in O 
QD O 
toxicity O 
, O 
fate O 
and O 
transport O 
in O 
the O 
aquatic O 
environment O 
. O 

- O 
specific O 
effects O 
of O 
fluoxetine B-TRIVIAL 
on O 
hippocampal O 
glucocorticoid O 
receptor O 
phosphorylation O 
and O 
behavior O 
in O 
chronically O 
stressed O 
rats O 
. O 

psychosocial O 
isolation O 
stress O 
( O 
CPSI O 
) O 
modulates O 
glucocorticoid O 
receptor O 
( O 
GR O 
) O 
functioning O 
in O 
Wistar O 
male O 
rat O 
hippocampus O 
( O 
HIPPO O 
) O 
through O 
alteration O 
of O 
nuclear O 
GR O 
phosphorylation O 
and O 
its O 
upstream O 
kinases O 
signaling O 
, O 
which O 
parallels O 
animal O 
depressive O 
- O 
like O 
behavior O 
. O 
The O 
current O 
study O 
investigated O 
potential O 
gender O 
specificities O 
regarding O 
the O 
effect O 
of O 
chronic O 
therapy O 
by O 
an O 
antidepressant O 
fluoxetine B-TRIVIAL 
( O 
FLU B-ABBREVIATION 
) O 
on O 
GR O 
signaling O 
in O 
HIPPO O 
and O 
depressive O 
- O 
like O 
behavior O 
in O 
CPSI O 
animals O 
. O 
FLU B-ABBREVIATION 
was O 
administrated O 
to O 
female O 
and O 
male O 
naïve O 
or O 
CPSI O 
rats O 
for O 
21 O 
days O 
and O 
GR O 
protein O 
, O 
its O 
phosphorylation O 
status O 
and O 
upstream O 
kinases O 
, O 
as O 
well O 
as O 
GR O 
and O 
BDNF O 
mRNA O 
were O 
followed O 
in O 
HIPPO O 
together O 
with O 
animal O 
serum O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
and O 
depressive O 
- O 
like O 
behavior O 
. O 
The O 
results O 
showed O 
that O 
CPSI O 
increased O 
immobility O 
in O 
males O 
versus O 
hyperactivity O 
in O 
females O 
and O 
disrupted O 
nuclear O 
pGR232-Cdk5 O 
pathway O 
and O 
JNK O 
signaling O 
in O 
a O 
gender O 
- O 
specific O 
way O 
. O 
In O 
contrast O 
, O 
in O 
both O 
genders O 
CPSI O 
increased O 
the O 
nuclear O 
levels O 
of O 
GR O 
and O 
pGR246 O 
but O 
decreased O 
CORT B-ABBREVIATION 
and O 
mRNA O 
levels O 
of O 
GR O 
and O 
BDNF O 
. O 
Concomitant O 
FLU B-ABBREVIATION 
normalized O 
the O 
depressive O 
- O 
like O 
behavior O 
and O 
altered O 
the O 
nuclear O 
pGR232-Cdk5 O 
signaling O 
in O 
a O 
gender O 
- O 
specific O 
manner O 
. O 
In O 
both O 
females O 
and O 
males O 
, O 
FLU B-ABBREVIATION 
reversed O 
the O 
nuclear O 
levels O 
of O 
GR O 
and O 
pGR246 O 
without O 
affecting O 
CORT B-ABBREVIATION 
and O 
GR O 
mRNA O 
levels O 
. O 
In O 
contrast O 
, O 
FLU B-ABBREVIATION 
exhibited O 
gender O 
- O 
specific O 
effect O 
on O 
BDNF O 
mRNA O 
in O 
CPSI O 
animals O 
, O 
by O 
increasing O 
it O 
in O 
females O 
, O 
but O 
not O 
in O 
males O 
. O 
In O 
spite O 
of O 
normalization O 
the O 
total O 
nuclear O 
GR O 
level O 
upon O 
FLU B-ABBREVIATION 
treatment O 
in O 
both O 
gender O 
, O 
down O 
- O 
regulation O 
of O 
GR O 
mRNA O 
is O 
possibly O 
maintained O 
through O 
prevalence O 
of O 
pGR232 O 
isoform O 
only O 
in O 
males O 
. O 
The O 
gender O 
- O 
specific O 
alterations O 
of O 
pGR232-Cdk5 O 
signaling O 
and O 
BDNF O 
gene O 
expression O 
in O 
HIPPO O 
and O 
normalization O 
of O 
depressive O 
- O 
like O 
behavior O 
upon O 
FLU B-ABBREVIATION 
treatment O 
distinguishes O 
this O 
signaling O 
pathway O 
as O 
potential O 
future O 
antidepressant O 
target O 
for O 
gender O 
- O 
specific O 
therapy O 
of O 
stress O 
related O 
mood O 
disorders O 
. O 

of O 
Protein O 
Misfolding O 
/ O 
Aggregation O 
Using O 
Polyglutamine B-FAMILY 
Binding O 
Peptide O 
QBP1 O 
as O 
a O 
Therapy O 
for O 
the O 
Polyglutamine B-FAMILY 
Diseases O 
. O 

misfolding O 
and O 
aggregation O 
in O 
the O 
brain O 
have O 
been O 
recognized O 
to O 
be O 
crucial O 
in O 
the O 
pathogenesis O 
of O 
various O 
neurodegenerative O 
diseases O 
, O 
including O 
Alzheimer's O 
, O 
Parkinson's O 
, O 
and O 
the O 
polyglutamine B-FAMILY 
( O 
polyQ B-ABBREVIATION 
) O 
diseases O 
, O 
which O 
are O 
collectively O 
called O 
the O 
" O 
protein O 
misfolding O 
diseases O 
" O 
. O 
In O 
the O 
polyQ B-ABBREVIATION 
diseases O 
, O 
an O 
abnormally O 
expanded O 
polyQ B-ABBREVIATION 
stretch O 
in O 
the O 
responsible O 
proteins O 
causes O 
the O 
proteins O 
to O 
misfold O 
and O 
aggregate O 
, O 
eventually O 
resulting O 
in O 
neurodegeneration O 
. O 
Hypothesizing O 
that O 
polyQ B-ABBREVIATION 
protein O 
misfolding O 
and O 
aggregation O 
could O 
be O 
inhibited O 
by O 
molecules O 
specifically O 
binding O 
to O 
the O 
expanded O 
polyQ B-ABBREVIATION 
stretch O 
, O 
we O 
identified O 
polyQ B-ABBREVIATION 
binding O 
peptide O 
1 O 
( O 
QBP1 O 
) O 
. O 
We O 
show O 
that O 
QBP1 O 
does O 
, O 
indeed O 
, O 
inhibit O 
misfolding O 
and O 
aggregation O 
of O 
the O 
expanded O 
polyQ B-ABBREVIATION 
protein O 
in O 
vitro O 
. O 
Furthermore O 
overexpression O 
of O 
QBP1 O 
by O 
the O 
crossing O 
of O 
transgenic O 
animals O 
inhibits O 
neurodegeneration O 
in O 
Drosophila O 
models O 
of O 
the O 
polyQ B-ABBREVIATION 
diseases O 
. O 
We O 
also O 
introduce O 
our O 
attempts O 
to O 
deliver O 
QBP1 O 
into O 
the O 
brain O 
by O 
administration O 
using O 
viral O 
vectors O 
and O 
protein O 
transduction O 
domains O 
. O 
Interestingly O 
, O 
recent O 
data O 
suggest O 
that O 
QBP1 O 
can O 
also O 
inhibit O 
the O 
misfolding O 
/ O 
aggregation O 
of O 
proteins O 
responsible O 
for O 
other O 
protein O 
misfolding O 
diseases O 
, O 
highlighting O 
the O 
potential O 
of O 
QBP1 O 
as O 
a O 
general O 
therapeutic O 
molecule O 
for O 
a O 
wide O 
range O 
of O 
neurodegenerative O 
diseases O 
. O 
We O 
hope O 
that O 
in O 
the O 
near O 
future O 
, O 
aggregation O 
inhibitor O 
- O 
based O 
drugs O 
will O 
be O 
developed O 
and O 
bring O 
relief O 
to O 
patients O 
suffering O 
from O 
these O 
currently O 
intractable O 
protein O 
misfolding O 
diseases O 
. O 

( O 
Araliaceae O 
) O 
has O 
multiple O 
pharmacological O 
actions O 
because O 
of O 
its O 
diverse O 
phytochemical O 
constituents O 
. O 
The O 
aims O 
of O 
the O 
present O 
study O 
are O 
to O 
evaluate O 
the O 
preventive O 
effects O 
of O 
North O 
American O 
ginseng O 
on O 
diabetic O 
retinopathy O 
and O 
cardiomyopathy O 
and O 
to O 
delineate O 
the O 
underlying O 
mechanisms O 
of O 
such O 
effects O 
. O 
Models O 
of O 
both O 
type O 
1 O 
( O 
C57BL O 
/ O 
6 O 
mice O 
with O 
streptozotocin B-TRIVIAL 
-induced O 
diabetes O 
) O 
and O 
type O 
2 O 
diabetes O 
( O 
db O 
/ O 
db O 
mice O 
) O 
and O 
age O 
- O 
matched O 
and O 
sex O 
- O 
matched O 
controls O 
were O 
examined O 
. O 
Alcoholic O 
ginseng O 
root O 
( O 
200 O 
mg O 
/ O 
kg O 
body O 
weight O 
, O 
daily O 
oral O 
gavage O 
) O 
extract O 
was O 
administered O 
to O 
groups O 
of O 
both O 
type O 
1 O 
and O 
type O 
2 O 
diabetic O 
mice O 
for O 
2 O 
or O 
4 O 
months O 
. O 
Dysmetabolic O 
state O 
in O 
the O 
diabetic O 
mice O 
was O 
significantly O 
improved O 
by O 
ginseng O 
treatment O 
. O 
In O 
both O 
the O 
heart O 
and O 
retina O 
of O 
diabetic O 
animals O 
, O 
ginseng O 
treatment O 
significantly O 
prevented O 
oxidative O 
stress O 
and O 
diabetes O 
- O 
induced O 
upregulations O 
of O 
extracellular O 
matrix O 
proteins O 
and O 
vasoactive O 
factors O 
. O 
Ginseng O 
treatment O 
in O 
the O 
diabetic O 
animals O 
resulted O 
in O 
enhancement O 
of O 
stroke O 
volume O 
, O 
ejection O 
fraction O 
, O 
cardiac O 
output O 
, O 
and O 
left O 
ventricle O 
pressure O 
during O 
systole O 
and O 
diastole O 
and O 
diminution O 
of O 
stroke O 
work O 
. O 
In O 
addition O 
, O 
mRNA O 
expressions O 
of O 
atrial O 
natriuretic O 
factor O 
and O 
brain O 
natriuretic O 
factor O 
( O 
molecular O 
markers O 
for O 
cardiac O 
hypertrophy O 
) O 
were O 
significantly O 
diminished O 
in O 
ginseng O 
- O 
treated O 
diabetic O 
mice O 
. O 
These O 
data O 
indicate O 
that O 
North O 
American O 
ginseng O 
prevents O 
the O 
diabetes O 
- O 
induced O 
retinal O 
and O 
cardiac O 
biochemical O 
and O 
functional O 
changes O 
probably O 
through O 
inhibition O 
of O 
oxidative O 
stress O 
. O 

of O 
endothelial O 
NO B-FORMULA 
synthase O 
in O 
atherosclerosis O 
and O 
vascular O 
disease O 
. O 

oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
produced O 
by O 
the O 
endothelial O 
NO B-FORMULA 
synthase O 
( O 
eNOS O 
) O 
is O 
an O 
antihypertensive O 
, O 
antithrombotic O 
and O 
anti-atherosclerotic O 
molecule O 
. O 
Hypercholesterolemia O 
leads O 
to O 
a O 
reduction O 
in O 
vascular O 
NO B-FORMULA 
bioavailability O 
. O 
This O 
is O 
attributed O 
to O 
a O 
dysfunction O 
of O 
the O 
eNOS O 
enzyme O 
and O 
a O 
reduced O 
eNOS O 
activity O 
. O 
NADPH B-ABBREVIATION 
oxidase O 
- O 
mediated O 
oxidative O 
stress O 
leads O 
to O 
oxidation O 
of O 
tetrahydrobiopterin B-SYSTEMATIC 
( O 
BH4 B-FORMULA 
) O 
, O 
the O 
essential O 
cofactor O 
of O 
eNOS O 
. O 
In O 
BH4 B-FORMULA 
deficiency O 
, O 
oxygen B-SYSTEMATIC 
reduction O 
uncouples O 
from O 
NO B-FORMULA 
synthesis O 
, O 
thereby O 
converting O 
eNOS O 
to O 
a O 
superoxide B-TRIVIAL 
-producing O 
enzyme O 
. O 
As O 
a O 
consequence O 
of O 
eNOS O 
uncoupling O 
, O 
NO B-FORMULA 
production O 
is O 
reduced O 
and O 
the O 
pre O 
- O 
existing O 
oxidative O 
stress O 
is O 
enhanced O 
, O 
which O 
contribute O 
significantly O 
to O 
atherogenesis O 
. O 
Therefore O 
, O 
pharmacological O 
approaches O 
that O 
prevent O 
eNOS O 
uncoupling O 
and O 
enhance O 
eNOS O 
activity O 
are O 
of O 
therapeutic O 
interest O 
. O 
Angiotensin O 
- O 
converting O 
enzyme O 
inhibitors O 
, O 
AT1 O 
receptor O 
blockers O 
, O 
statins O 
, O 
nebivolol B-TRIVIAL 
and O 
resveratrol B-TRIVIAL 
have O 
been O 
shown O 
to O 
reverse O 
eNOS O 
uncoupling O 
and O 
to O 
stimulate O 
eNOS O 
activity O 
concurrently O 
. O 
Molecular O 
mechanisms O 
of O 
the O 
aforementioned O 
drugs O 
/ O 
compounds O 
on O 
eNOS O 
functionality O 
is O 
summarized O 
and O 
discussed O 
in O 
this O 
review O 
. O 

preventive O 
effect O 
of O 
uncarboxylated O 
osteocalcin O 
against O 
free B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
-induced O 
endothelial O 
apoptosis O 
through O 
the O 
activation O 
of O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
/ O 
Akt O 
signaling O 
pathway O 
: O 
Uncarboxylated O 
osteocalcin O 
and O 
endothelial O 
apoptosis O 
. O 

: O 
Increasing O 
evidence O 
suggests O 
that O 
osteocalcin O 
( O 
OC O 
) O 
, O 
one O 
of O 
the O 
osteoblast O 
- O 
specific O 
proteins O 
, O 
has O 
been O 
associated O 
with O 
atherosclerosis O 
, O 
but O 
results O 
are O 
conflicting O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
elucidate O 
the O 
independent O 
effect O 
of O 
uncarboxylated O 
osteocalcin O 
( O 
ucOC O 
) O 
, O 
an O 
active O 
form O 
of O 
osteocalcin O 
which O 
has O 
been O 
suggested O 
to O 
have O 
an O 
insulin O 
sensitizing O 
effect O 
, O 
on O 
vascular O 
endothelial O 
cells O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
We O 
used O 
human O 
aortic O 
endothelial O 
cells O 
and O 
treated O 
them O 
with O 
ucOC O 
. O 
Linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LA O 
) O 
was O 
used O 
as O 
a O 
representative O 
free B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
. O 
Apoptosis O 
was O 
evaluated O 
using O 
various O 
methods O 
including O 
a O 
terminal O 
deoxyribonucleotide B-FAMILY 
transferase O 
- O 
mediated O 
deoxyuridine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
nick O 
- O 
end O 
labeling O 
analysis O 
kit O 
and O 
Western O 
blotting O 
for O 
cleaved O 
caspase O 
3 O 
, O 
cleaved O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
and O 
Bcl-xL O 
. O 
The O 
phosphorylations O 
of O 
Akt O 
and O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
eNOS O 
) O 
as O 
well O 
as O 
the O 
level O 
of O 
NO B-FORMULA 
were O 
measured O 
to O 
confirm O 
the O 
effect O 
of O 
ucOC O 
on O 
insulin O 
signaling O 
pathway O 
. O 
RESULTS O 
: O 
Pretreatment O 
of O 
ucOC O 
( O 
30ng O 
/ O 
ml O 
) O 
prevented O 
LA-induced O 
apoptosis O 
in O 
insulin O 
- O 
stimulated O 
endothelial O 
cells O 
; O 
effects O 
were O 
abolished O 
by O 
pretreatment O 
with O 
the O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
( O 
PI3-kinase O 
) O 
inhibitor O 
, O 
wortmannin B-TRIVIAL 
. O 
Treatment O 
of O 
ucOC O 
( O 
ranged O 
from O 
0.3 O 
to O 
30ng O 
/ O 
ml O 
) O 
significantly O 
increased O 
the O 
phosphorylation O 
of O 
Akt O 
and O 
eNOS O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
secretion O 
from O 
endothelial O 
cells O 
in O 
a O 
PI3-kinase O 
dependent O 
manner O 
. O 
CONCLUSIONS O 
: O 
Our O 
study O 
is O 
the O 
first O 
to O 
demonstrate O 
the O 
independent O 
effect O 
of O 
ucOC O 
on O 
vascular O 
endothelial O 
cells O 
. O 
Our O 
results O 
further O 
suggest O 
that O 
ucOC O 
could O 
have O 
beneficial O 
effects O 
on O 
atherosclerosis O 
. O 

of O 
acrylamide B-TRIVIAL 
formation O 
by O 
vanadium B-SYSTEMATIC 
salt O 
in O 
potato O 
French O 
fries O 
and O 
chips O 
. O 

effects O 
of O 
vanadyl B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
on O 
the O 
formation O 
of O 
acrylamide B-TRIVIAL 
have O 
been O 
studied O 
in O 
fried O 
potato O 
products O 
, O 
such O 
as O 
French O 
fries O 
and O 
chips O 
. O 
Acrylamide B-TRIVIAL 
formation O 
was O 
inhibited O 
by O 
30.3% O 
, O 
53.3% O 
and O 
89.3% O 
when O 
the O 
sliced O 
potato O 
strips O 
were O 
soaked O 
in O 
0.001 O 
, O 
0.01 O 
and O 
0.1 O 
M O 
vanadyl B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
VOSO(4) B-FORMULA 
) O 
solutions O 
, O 
respectively O 
, O 
for O 
60 O 
min O 
before O 
frying O 
. O 
Moreover O 
, O 
57.7% O 
, O 
71.4% O 
and O 
92.5% O 
inhibition O 
of O 
acrylamide B-TRIVIAL 
formation O 
was O 
observed O 
when O 
chips O 
were O 
soaked O 
in O 
the O 
respective O 
vanadyl B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
solution O 
before O 
frying O 
. O 
In O 
a O 
separate O 
model O 
reaction O 
, O 
a O 
solution O 
containing O 
an O 
equimolar O 
concentration O 
of O 
L-asparagine B-TRIVIAL 
and O 
D-glucose B-SYSTEMATIC 
showed O 
a O 
significant O 
inhibition O 
of O 
acrylamide B-TRIVIAL 
formation O 
when O 
heated O 
at O 
150 O 
°C O 
for O 
30 O 
min O 
in O 
the O 
presence O 
of O 
vanadyl B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
VOSO(4) B-FORMULA 
) O 
. O 
The O 
results O 
indicate O 
that O 
the O 
binding O 
of O 
VO(2+) B-FORMULA 
to O 
asparagine B-TRIVIAL 
and O 
the O 
decrease O 
in O 
the O 
pH O 
of O 
the O 
potato O 
samples O 
resulted O 
in O 
a O 
significant O 
reduction O 
of O 
acrylamide B-TRIVIAL 
formation O 
in O 
fried O 
potato O 
products O 
. O 

address O 
the O 
question O 
about O 
costs O 
of O 
living O 
in O 
polluted O 
areas O 
, O 
biomarkers O 
linked O 
to O 
metabolism O 
were O 
measured O 
in O 
Pterostichus O 
oblongopunctatus O 
( O 
Coleoptera O 
: O 
Carabidae O 
) O 
collected O 
along O 
two O 
metal O 
- O 
pollution O 
gradients O 
in O 
the O 
vicinity O 
of O 
the O 
two O 
largest O 
Polish O 
zinc B-SYSTEMATIC 
smelters O 
: O 
' O 
Bolesław O 
' O 
and O 
' O 
Miasteczko O 
Śląskie O 
' O 
in O 
southern O 
Poland O 
. O 
Both O 
gradients O 
covered O 
a O 
broad O 
range O 
of O 
Zn B-FORMULA 
and O 
Cd B-FORMULA 
concentrations O 
in O 
the O 
humus O 
layer O 
( O 
109-6151 O 
and O 
1.48-71.4 O 
mg O 
kg(-1) O 
, O 
respectively O 
) O 
and O 
body O 
metal O 
concentrations O 
increased O 
with O 
increasing O 
soil O 
metal O 
concentrations O 
. O 
The O 
whole O 
- O 
organism O 
respiration O 
rate O 
was O 
measured O 
as O 
oxygen B-SYSTEMATIC 
consumption O 
with O 
Micro-Oxymax O 
respirometer O 
, O 
and O 
cellular O 
energy O 
consumption O 
- O 
as O 
the O 
activity O 
of O 
electron O 
transport O 
system O 
, O 
which O 
is O 
linked O 
to O 
cellular O 
respiration O 
rate O 
. O 
The O 
significant O 
increase O 
in O 
the O 
whole O 
- O 
organism O 
respiration O 
rate O 
with O 
the O 
body O 
metal O 
concentration O 
was O 
found O 
when O 
taking O 
into O 
account O 
other O 
factors O 
such O 
as O 
body O 
mass O 
, O 
gradient O 
( O 
or O 
year O 
of O 
sampling O 
as O 
the O 
beetles O 
were O 
collected O 
on O 
the O 
gradients O 
in O 
different O 
years O 
) O 
and O 
the O 
interactions O 
: O 
body O 
metal O 
concentrations O 
× O 
collection O 
date O 
, O 
body O 
metal O 
concentrations O 
× O 
body O 
mass O 
, O 
and O 
body O 
mass O 
× O 
gradient O 
/ O 
sampling O 
year O 
. O 
However O 
, O 
no O 
relationships O 
between O 
metal O 
concentrations O 
in O 
soil O 
or O 
body O 
metal O 
concentrations O 
and O 
the O 
whole O 
- O 
organism O 
or O 
cellular O 
respiration O 
rate O 
could O 
be O 
detected O 
when O 
using O 
mean O 
values O 
per O 
site O 
, O 
underlining O 
the O 
crucial O 
importance O 
of O 
incorporating O 
individual O 
variability O 
in O 
such O 
analyses O 
. O 
The O 
observed O 
increase O 
of O 
the O 
whole O 
- O 
organism O 
respiration O 
rate O 
with O 
increasing O 
body O 
contamination O 
with O 
metals O 
suggests O 
that O 
P O 
. O 
oblongopunctatus O 
incurs O 
energetic O 
expenditures O 
resulting O 
from O 
the O 
necessity O 
to O 
facilitate O 
metal O 
elimination O 
or O 
repair O 
of O 
toxicant O 
- O 
induced O 
damage O 
. O 

acids I-FAMILY 
as O 
co O 
- O 
amorphous O 
stabilizers O 
for O 
poorly O 
water O 
soluble O 
drugs O 
- O 
Part O 
1 O 
: O 
Preparation O 
, O 
stability O 
and O 
dissolution O 
enhancement O 
. O 

aqueous O 
solubility O 
of O 
an O 
active O 
pharmaceutical O 
ingredient O 
( O 
API O 
) O 
is O 
one O 
of O 
the O 
most O 
pressing O 
problems O 
in O 
pharmaceutical O 
research O 
and O 
development O 
because O 
up O 
to O 
90% O 
of O 
new O 
API O 
candidates O 
under O 
development O 
are O 
poorly O 
water O 
soluble O 
. O 
These O 
drugs O 
usually O 
have O 
a O 
low O 
and O 
variable O 
oral O 
bioavailability O 
, O 
and O 
therefore O 
an O 
unsatisfactory O 
therapeutic O 
effect O 
. O 
One O 
of O 
the O 
most O 
promising O 
approaches O 
to O 
increase O 
dissolution O 
rate O 
and O 
solubility O 
of O 
these O 
drugs O 
is O 
the O 
conversion O 
of O 
a O 
crystalline O 
form O 
of O 
the O 
drug O 
into O 
its O 
respective O 
amorphous O 
form O 
, O 
usually O 
by O 
incorporation O 
into O 
hydrophilic O 
polymers O 
, O 
forming O 
glass O 
solutions O 
. O 
However O 
, O 
this O 
strategy O 
only O 
led O 
to O 
a O 
small O 
number O 
of O 
marketed O 
products O 
usually O 
because O 
of O 
inadequate O 
physical O 
stability O 
of O 
the O 
drug O 
( O 
crystallization O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
a O 
fundamentally O 
different O 
approach O 
to O 
stabilize O 
the O 
amorphous O 
form O 
of O 
drugs O 
, O 
namely O 
the O 
use O 
of O 
amino B-FAMILY 
acids I-FAMILY 
as O 
small O 
molecular O 
weight O 
excipients O 
that O 
form O 
specific O 
molecular O 
interactions O 
with O 
the O 
drug O 
resulting O 
in O 
co O 
- O 
amorphous O 
forms O 
. O 
The O 
two O 
poorly O 
water O 
soluble O 
drugs O 
carbamazepine B-TRIVIAL 
and O 
indomethacin B-TRIVIAL 
were O 
combined O 
with O 
amino B-FAMILY 
acids I-FAMILY 
from O 
the O 
binding O 
sites O 
of O 
the O 
biological O 
receptors O 
of O 
these O 
drugs O 
. O 
Mixtures O 
of O 
drug O 
and O 
the O 
amino B-FAMILY 
acids I-FAMILY 
arginine B-TRIVIAL 
, O 
phenylalanine B-TRIVIAL 
, O 
tryptophan B-TRIVIAL 
and O 
tyrosine B-TRIVIAL 
were O 
prepared O 
by O 
vibrational O 
ball O 
milling O 
. O 
Solid O 
- O 
state O 
characterization O 
with O 
X-ray O 
powder O 
diffraction O 
( O 
XRPD O 
) O 
and O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
revealed O 
that O 
the O 
various O 
blends O 
could O 
be O 
prepared O 
as O 
homogeneous O 
, O 
single O 
phase O 
co O 
- O 
amorphous O 
formulations O 
indicated O 
by O 
the O 
appearance O 
of O 
an O 
amorphous O 
halo O 
in O 
the O 
XRPD O 
diffractograms O 
and O 
a O 
single O 
glass O 
transition O 
temperature O 
( O 
Tg O 
) O 
in O 
the O 
DSC O 
measurements O 
. O 
In O 
addition O 
, O 
the O 
Tgs O 
of O 
the O 
co O 
- O 
amorphous O 
mixtures O 
were O 
significantly O 
increased O 
over O 
those O 
of O 
the O 
individual O 
drugs O 
. O 
The O 
drugs O 
remained O 
chemically O 
stable O 
during O 
the O 
milling O 
process O 
and O 
the O 
co O 
- O 
amorphous O 
formulations O 
were O 
generally O 
physically O 
stable O 
over O 
at O 
least O 
6months O 
at O 
40°C O 
under O 
dry O 
conditions O 
. O 
The O 
dissolution O 
rate O 
of O 
all O 
co O 
- O 
amorphous O 
drug- O 
amino B-FAMILY 
acid I-FAMILY 
mixtures O 
was O 
significantly O 
increased O 
over O 
that O 
of O 
the O 
respective O 
crystalline O 
and O 
amorphous O 
pure O 
drugs O 
. O 
Amino B-FAMILY 
acids I-FAMILY 
thus O 
appear O 
as O 
promising O 
excipients O 
to O 
solve O 
challenges O 
connected O 
with O 
the O 
stability O 
and O 
dissolution O 
of O 
amorphous O 
drugs O 
. O 

barrigenol B-TRIVIAL 
type O 
triterpenoids B-FAMILY 
from O 
the O 
leaves O 
of O 
Xanthoceras O 
sorbifolia O 
Bunge O 
. O 

order O 
to O 
find O 
out O 
new O 
natural O 
barrigenol B-TRIVIAL 
type O 
triterpenenoids B-FAMILY 
as O 
antitumor O 
agent O 
and O 
reveal O 
the O 
difference O 
on O 
material O 
basis O 
of O 
different O 
parts O 
of O 
Xanthoceras O 
sorbifolia O 
Bunge O 
, O 
the O 
bioassay O 
- O 
directed O 
separation O 
of O 
the O 
saponin B-FAMILY 
fraction O 
from O 
leaves O 
of O 
X O 
. O 
sorbifolia O 
Bunge O 
was O 
carried O 
out O 
to O 
afford O 
5 O 
new O 
barrigenol B-TRIVIAL 
type O 
triterpenoids B-FAMILY 
( O 
1-5 O 
) O 
, O 
together O 
with O 
2 O 
known O 
ones O 
. O 
The O 
antitumor O 
activities O 
were O 
evaluated O 
and O 
compounds O 
2 O 
and O 
7 O 
showed O 
significant O 
cytotoxic O 
activity O 
. O 
Furthermore O 
, O 
the O 
SAR O 
was O 
discussed O 
briefly O 
. O 
On O 
the O 
basis O 
of O 
our O 
research O 
work O 
and O 
related O 
literature O 
, O 
the O 
difference O 
of O 
chemical O 
constituents O 
from O 
different O 
parts O 
of O 
X O 
. O 
sorbifolia O 
was O 
analyzed O 
and O 
concluded O 
. O 
The O 
result O 
can O 
be O 
a O 
useful O 
reference O 
for O 
phytochemistry O 
taxology O 
and O 
safe O 
and O 
rational O 
drug O 
use O 
of O 
X O 
. O 
sorbifolia O 
. O 

of O 
novel O 
phosphorylated B-TRIVIAL 
guanidine I-TRIVIAL 
derivatives O 
from O 
cyanamide B-SYSTEMATIC 
and O 
their O 
anti-inflammatory O 
activity O 
. O 

series O 
of O 
novel O 
guanidine B-TRIVIAL 
derivatives O 
were O 
synthesized O 
in O 
three O 
steps O 
and O 
their O 
anti-inflammatory O 
activities O 
in O 
vitro O 
and O 
in O 
vivo O 
evaluated O 
. O 
2-Aminopyridin-3-ol B-SYSTEMATIC 
( O 
1 O 
) O 
was O 
reacted O 
with O 
thiophosphoryl B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
2 O 
) O 
to O 
give O 
a O 
monochloride B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
It O 
was O 
further O 
reacted O 
with O 
cyanamide B-SYSTEMATIC 
to O 
afford O 
the O 
corresponding O 
cyanamine B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
which O 
was O 
subsequently O 
reacted O 
with O 
different O 
heterocyclic B-FAMILY 
amines I-FAMILY 
to O 
form O 
the O 
title O 
compounds O 
( O 
5a-l O 
) O 
. O 
The O 
substituent O 
in O 
the O 
guanidine B-TRIVIAL 
function O 
affected O 
the O 
potency O 
of O 
anti-inflammatory O 
activity O 
. O 
The O 
compounds O 
having O 
benzothiazole B-SYSTEMATIC 
, O 
fluorophenyl B-SYSTEMATIC 
, O 
and O 
piperazinyl B-SYSTEMATIC 
moieties O 
enhanced O 
the O 
anti-inflammatory O 
activity O 
. O 

of O 
membrane O 
phospholipids O 
, O 
the O 
cytosolic O 
calcium B-SYSTEMATIC 
influx O 
and O 
cell O 
proliferation O 
following O 
treatment O 
of O 
B16-F10 O 
cells O 
with O 
recombinant O 
phospholipase-D O 
from O 
Loxosceles O 
intermedia O 
( O 
brown O 
spider O 
) O 
venom O 
. O 

mechanism O 
through O 
which O 
brown O 
spiders O 
( O 
Loxosceles O 
genus O 
) O 
cause O 
dermonecrosis O 
, O 
dysregulated O 
inflammatory O 
responses O 
, O 
hemolysis O 
and O 
platelet O 
aggregation O 
, O 
which O 
are O 
effects O 
reported O 
following O 
spider O 
bites O 
, O 
is O 
currently O 
attributed O 
to O 
the O 
presence O 
of O 
phospholipase-D O 
in O 
the O 
venom O 
. O 
In O 
the O 
present O 
investigation O 
, O 
through O 
two O 
- O 
dimensional O 
immunoblotting O 
, O 
we O 
observed O 
immunological O 
cross O 
- O 
reactivity O 
for O 
at O 
least O 
25 O 
spots O 
in O 
crude O 
Loxosceles O 
intermedia O 
venom O 
, O 
indicating O 
high O 
expression O 
levels O 
for O 
different O 
isoforms O 
of O 
phospholipase-D O 
. O 
Using O 
a O 
recombinant O 
phospholipase-D O 
from O 
the O 
venom O 
gland O 
of O 
L O 
. O 
intermedia O 
( O 
LiRecDT1 O 
) O 
in O 
phospholipid O 
- O 
degrading O 
kinetic O 
experiments O 
, O 
we O 
determined O 
that O 
this O 
phospholipase-D O 
mainly O 
hydrolyzes O 
synthetic O 
sphingomyelin B-FAMILY 
in O 
a O 
time O 
- O 
dependent O 
manner O 
, O 
generating O 
ceramide B-SYSTEMATIC 
1-phosphate I-SYSTEMATIC 
plus O 
choline B-FAMILY 
, O 
as O 
well O 
as O 
lysophosphatidylcholine B-FAMILY 
, O 
generating O 
lysophosphatidic B-TRIVIAL 
acid I-TRIVIAL 
plus O 
choline B-FAMILY 
, O 
but O 
exhibits O 
little O 
activity O 
against O 
phosphatidylcholine B-FAMILY 
. O 
Through O 
immunofluorescence O 
assays O 
with O 
antibodies O 
against O 
LiRecDT1 O 
and O 
using O 
a O 
recombinant O 
GFP-LiRecDT1 O 
fusion O 
protein O 
, O 
we O 
observed O 
direct O 
binding O 
of O 
LiRecDT1 O 
to O 
the O 
membrane O 
of O 
B16-F10 O 
cells O 
. O 
We O 
determined O 
that O 
LiRecDT1 O 
hydrolyzes O 
phospholipids O 
in O 
detergent O 
extracts O 
and O 
from O 
ghosts O 
of O 
B16-F10 O 
cells O 
, O 
generating O 
choline B-FAMILY 
, O 
indicating O 
that O 
the O 
enzyme O 
can O 
access O 
and O 
modulate O 
and O 
has O 
activity O 
against O 
membrane O 
phospholipids O 
. O 
Additionally O 
, O 
using O 
Fluo-4 B-ABBREVIATION 
, O 
a O 
calcium B-SYSTEMATIC 
-sensitive O 
fluorophore O 
, O 
it O 
was O 
shown O 
that O 
treatment O 
of O 
cells O 
with O 
phospholipase-D O 
induced O 
an O 
increase O 
in O 
the O 
calcium B-SYSTEMATIC 
concentration O 
in O 
the O 
cytoplasm O 
, O 
but O 
without O 
altering O 
viability O 
or O 
causing O 
damage O 
to O 
cells O 
. O 
Finally O 
, O 
based O 
on O 
the O 
known O 
endogenous O 
activity O 
of O 
phospholipase-D O 
as O 
an O 
inducer O 
of O 
cell O 
proliferation O 
and O 
the O 
fact O 
that O 
LiRecDT1 O 
binds O 
to O 
the O 
cell O 
surface O 
, O 
hydrolyzing O 
phospholipids O 
to O 
generate O 
bioactive O 
lipids O 
, O 
we O 
employed O 
LiRecDT1 O 
as O 
an O 
exogenous O 
source O 
of O 
phospholipase-D O 
in O 
B16-F10 O 
cells O 
. O 
Treatment O 
of O 
the O 
cells O 
was O 
effective O 
in O 
increasing O 
their O 
proliferation O 
in O 
a O 
time- O 
and O 
concentration O 
- O 
dependent O 
manner O 
, O 
especially O 
in O 
the O 
presence O 
of O 
synthetic O 
sphingomyelin B-FAMILY 
in O 
the O 
medium O 
. O 
The O 
results O 
described O 
herein O 
indicate O 
the O 
ability O 
of O 
brown O 
spider O 
phospholipase-D O 
to O 
induce O 
the O 
generation O 
of O 
bioactive O 
phospholipids O 
, O 
calcium B-SYSTEMATIC 
influx O 
into O 
the O 
cytoplasm O 
and O 
cell O 
proliferation O 
, O 
suggesting O 
that O 
this O 
molecule O 
can O 
be O 
used O 
as O 
a O 
bioactive O 
tool O 
for O 
experimental O 
protocols O 
in O 
cell O 
biology O 
. O 

vein O 
glucose B-TRIVIAL 
entry O 
triggers O 
a O 
coordinated O 
cellular O 
response O 
that O 
potentiates O 
hepatic O 
glucose B-TRIVIAL 
uptake O 
and O 
storage O 
in O 
normal O 
but O 
not O 
high O 
- O 
fat O 
/ O 
high- O 
fructose B-TRIVIAL 
-fed O 
dogs O 
. O 

cellular O 
events O 
mediating O 
the O 
pleiotropic O 
actions O 
of O 
portal O 
vein O 
glucose B-TRIVIAL 
( O 
PoG O 
) O 
delivery O 
on O 
hepatic O 
glucose B-TRIVIAL 
disposition O 
have O 
not O 
been O 
clearly O 
defined O 
. O 
Likewise O 
, O 
the O 
molecular O 
defects O 
associated O 
with O 
postprandial O 
hyperglycemia O 
and O 
impaired O 
hepatic O 
glucose B-TRIVIAL 
uptake O 
( O 
HGU O 
) O 
following O 
consumption O 
of O 
a O 
high O 
- O 
fat O 
, O 
high- O 
fructose B-TRIVIAL 
diet O 
( O 
HFFD O 
) O 
are O 
unknown O 
. O 
Our O 
goal O 
was O 
to O 
identify O 
hepatocellular O 
changes O 
elicited O 
by O 
hyperinsulinemia O 
, O 
hyperglycemia O 
, O 
and O 
PoG O 
signaling O 
in O 
normal O 
chow O 
- O 
fed O 
( O 
CTR O 
) O 
and O 
HFFD-fed O 
dogs O 
. O 
In O 
CTR O 
dogs O 
, O 
we O 
demonstrated O 
that O 
PoG O 
infusion O 
in O 
the O 
presence O 
of O 
hyperinsulinemia O 
and O 
hyperglycemia O 
triggered O 
an O 
increase O 
in O 
the O 
activity O 
of O 
hepatic O 
glucokinase O 
( O 
GK O 
) O 
and O 
glycogen O 
synthase O 
( O 
GS O 
) O 
, O 
which O 
occurred O 
in O 
association O 
with O 
further O 
augmentation O 
in O 
HGU O 
and O 
glycogen O 
synthesis O 
( O 
GSYN O 
) O 
in O 
vivo O 
. O 
In O 
contrast O 
, O 
4 O 
weeks O 
of O 
HFFD O 
feeding O 
markedly O 
reduced O 
GK O 
protein O 
content O 
and O 
impaired O 
the O 
activation O 
of O 
GS O 
in O 
association O 
with O 
diminished O 
HGU O 
and O 
GSYN O 
in O 
vivo O 
. O 
Furthermore O 
, O 
the O 
enzymatic O 
changes O 
associated O 
with O 
PoG O 
sensing O 
in O 
chow O 
- O 
fed O 
animals O 
were O 
abolished O 
in O 
HFFD-fed O 
animals O 
, O 
consistent O 
with O 
loss O 
of O 
the O 
stimulatory O 
effects O 
of O 
PoG O 
delivery O 
. O 
These O 
data O 
reveal O 
new O 
insight O 
into O 
the O 
molecular O 
physiology O 
of O 
the O 
portal O 
glucose B-TRIVIAL 
signaling O 
mechanism O 
under O 
normal O 
conditions O 
and O 
to O 
the O 
pathophysiology O 
of O 
aberrant O 
postprandial O 
hepatic O 
glucose B-TRIVIAL 
disposition O 
evident O 
under O 
a O 
diet O 
- O 
induced O 
glucose B-TRIVIAL 
-intolerant O 
condition O 
. O 

of O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
methylmercury B-SYSTEMATIC 
on O 
child's O 
brain O 
development O 
due O 
to O 
consumption O 
of O 
fish O 
by O 
Finnish O 
mother O 
during O 
pregnancy O 
: O 
a O 
probabilistic O 
modeling O 
approach O 
. O 

contains O 
both O 
beneficial O 
substances O 
e.g O 
. O 
docosahexaenoic B-FAMILY 
acids I-FAMILY 
but O 
also O 
harmful O 
compounds O 
e.g O 
. O 
methylmercury B-SYSTEMATIC 
. O 
Importantly O 
, O 
the O 
health O 
effects O 
caused O 
by O 
these O 
two O 
substances O 
can O 
be O 
evaluated O 
in O 
one O 
common O 
end O 
point O 
, O 
intelligence O 
quotient O 
( O 
IQ O 
) O 
, O 
providing O 
a O 
more O 
transparent O 
analysis O 
. O 
We O 
estimated O 
health O 
effects O 
of O 
maternal O 
fish O 
consumption O 
on O 
child's O 
central O 
nervous O 
system O 
by O 
creating O 
a O 
model O 
with O 
three O 
alternative O 
maternal O 
fish O 
consumption O 
scenarios O 
( O 
lean O 
fish O 
, O 
fatty O 
fish O 
, O 
and O 
current O 
fish O 
consumption O 
) O 
. O 
Additionally O 
, O 
we O 
analyzed O 
impacts O 
of O 
both O 
regular O 
fish O 
consumption O 
and O 
extreme O 
fish O 
consumption O 
habits O 
. O 
At O 
the O 
individual O 
level O 
, O 
the O 
simulated O 
net O 
effects O 
were O 
small O 
, O 
encompassing O 
a O 
range O 
of O 
one O 
IQ O 
point O 
in O 
all O 
scenarios O 
. O 
Fatty O 
fish O 
consumption O 
, O 
however O 
, O 
clearly O 
generated O 
a O 
beneficial O 
net O 
IQ O 
effect O 
, O 
and O 
lean O 
fish O 
consumption O 
evoked O 
an O 
adverse O 
net O 
IQ O 
effect O 
. O 
In O 
view O 
of O 
the O 
current O 
fish O 
consumption O 
pattern O 
of O 
Finnish O 
mothers O 
the O 
benefits O 
and O 
risks O 
seem O 
to O 
more O 
or O 
less O 
compensate O 
each O 
other O 
. O 
This O 
study O 
clearly O 
shows O 
the O 
significance O 
of O 
which O 
fish O 
species O 
are O 
consumed O 
during O 
pregnancy O 
and O 
lactation O 
, O 
and O 
the O 
results O 
can O 
be O 
generalized O 
to O 
apply O 
to O 
typical O 
western O 
population O 
fish O 
consumption O 
habits O 
. O 

and O 
biological O 
evaluation O 
of O 
guanidino B-SYSTEMATIC 
analogues O 
of O 
roscovitine B-TRIVIAL 
. O 

series O 
of O 
2,9- B-FAMILY 
substituted I-FAMILY 
6-guanidinopurines I-FAMILY 
, O 
structurally O 
related O 
to O 
the O 
cyclin O 
- O 
dependent O 
kinase O 
( O 
CDK O 
) O 
inhibitors O 
olomoucine B-TRIVIAL 
and O 
roscovitine B-TRIVIAL 
, O 
has O 
been O 
synthesized O 
and O 
characterized O 
. O 
A O 
new O 
copper B-SYSTEMATIC 
-catalyzed O 
method O 
for O 
the O 
synthesis O 
of O 
2- B-FAMILY 
substituted I-FAMILY 
6-guanidino-9-isopropylpurines I-FAMILY 
under O 
mild O 
reaction O 
conditions O 
has O 
been O 
developed O 
. O 
All O 
prepared O 
compounds O 
were O 
screened O 
for O 
their O 
CDK1 O 
and O 
CDK2 O 
inhibitory O 
activities O 
, O 
cytotoxicity O 
and O 
antiproliferative O 
effects O 
in O 
the O 
breast O 
cancer O 
- O 
derived O 
cell O 
line O 
MCF7 O 
. O 
The O 
most O 
active O 
derivative O 
16g O 
possessed O 
an O 
identical O 
side O 
chain O 
in O 
the O 
C2 O 
position O 
to O 
roscovitine B-TRIVIAL 
; O 
this O 
compound O 
displayed O 
approximately O 
five O 
fold O 
higher O 
inhibitory O 
activity O 
towards O 
CDK2 O 
/ O 
cyclin O 
E O 
and O 
more O 
than O 
ten O 
fold O 
increase O 
in O 
cytotoxicity O 
in O 
MCF7 O 
cells O 
. O 
Interestingly O 
and O 
in O 
contrast O 
to O 
previously O 
described O 
findings O 
, O 
(S)-6-guanidinopurine B-SYSTEMATIC 
derivatives O 
were O 
generally O 
more O 
active O 
than O 
their O 
(R)-counterparts O 
. O 
Kinase O 
selectivity O 
profiling O 
of O 
(R)- O 
and O 
(S)-enantiomers O 
16e O 
and O 
16g O 
, O 
respectively O 
, O 
revealed O 
that O 
introduction O 
of O 
a O 
guanidino B-SYSTEMATIC 
group O 
at O 
the O 
C6 O 
position O 
of O 
the O 
purine B-TRIVIAL 
moiety O 
decreased O 
selectivity O 
towards O 
protein O 
kinases O 
compared O 
to O 
roscovitine B-TRIVIAL 
. O 
Nevertheless O 
, O 
increased O 
inhibitory O 
activity O 
and O 
decreased O 
selectivity O 
offer O 
a O 
good O 
starting O 
point O 
for O 
further O 
development O 
of O 
new O 
protein O 
kinase O 
inhibitors O 
. O 

Active O 
Role O 
for O 
Steroid B-FAMILY 
-binding O 
Globulins O 
: O 
An O 
Update O 
. O 

has O 
been O 
7 O 
years O 
( O 
can O 
it O 
really O 
be O 
that O 
long O 
? O 
) O 
since O 
we O 
co O 
- O 
edited O 
a O 
volume O 
( O 
#38 O 
) O 
of O 
Hormone O 
and O 
Metabolic O 
Research O 
that O 
focused O 
on O 
evidence O 
that O 
steroid B-FAMILY 
-binding O 
globulins O 
play O 
an O 
active O 
role O 
in O 
the O 
actions O 
of O 
steroids B-FAMILY 
. O 
There O 
has O 
been O 
considerable O 
progress O 
in O 
identifying O 
the O 
location O 
, O 
the O 
physiological O 
actions O 
, O 
and O 
of O 
determining O 
the O 
role O 
of O 
binding O 
globulins O 
in O 
the O 
actions O 
of O 
steroids B-FAMILY 
and O 
identifying O 
a O 
membrane O 
- O 
associated O 
receptor O 
for O 
a O 
binding O 
protein O 
since O 
then O 
and O 
this O 
review O 
will O 
discuss O 
this O 
progress O 
. O 

pharmaceutical O 
stability O 
of O 
a O 
boronphenylalanine B-SYSTEMATIC 
mannitol I-SYSTEMATIC 
formulation O 
for O 
boron B-SYSTEMATIC 
neutron O 
capture O 
therapy O 
. O 

neutron O 
capture O 
therapy O 
( O 
BNCT O 
) O 
is O 
a O 
radiotherapy O 
based O 
cancer O 
treatment O 
requiring O 
the O 
availability O 
of O 
a O 
low O 
energy O 
thermal O 
neutron O 
beam O 
and O 
a O 
boron B-SYSTEMATIC 
containing O 
drug O 
. O 
These O 
requirements O 
limit O 
BNCT O 
availability O 
with O 
the O 
latter O 
pharmaceutical O 
issue O 
related O 
to O 
the O 
extremely O 
short O 
shelf O 
- O 
life O 
and O 
clinical O 
acceptability O 
of O 
the O 
current O 
fructose B-TRIVIAL 
based O 
L-boronphenylalanine B-SYSTEMATIC 
( O 
BPA B-ABBREVIATION 
) O 
formulation O 
. O 
Resolution O 
of O 
the O 
formulation O 
issues O 
would O 
remove O 
this O 
factor O 
and O 
therefore O 
the O 
stability O 
of O 
an O 
alternative O 
mannitol B-TRIVIAL 
BPA I-TRIVIAL 
formulation O 
has O 
been O 
investigated O 
. O 
A O 
mannitol B-TRIVIAL 
BPA I-TRIVIAL 
solution O 
formulation O 
was O 
prepared O 
and O 
either O 
lyophilised O 
or O 
stored O 
as O 
a O 
solution O 
at O 
varying O 
temperatures O 
. O 
After O 
suitable O 
periods O 
the O 
formulation O 
was O 
analysed O 
by O 
HPLC O 
for O 
BPA B-ABBREVIATION 
and O 
degradation O 
products O 
. O 
Lyophilised O 
and O 
solution O 
mannitol B-TRIVIAL 
BPA I-TRIVIAL 
formulations O 
exhibited O 
a O 
temperature O 
and O 
time O 
dependent O 
loss O 
of O 
BPA B-ABBREVIATION 
with O 
concomitant O 
increases O 
in O 
degradation O 
products O 
. O 
Autoclaving O 
the O 
solution O 
induced O 
and O 
accelerated O 
degradation O 
. O 
A O 
solution O 
or O 
lyophilised O 
mannitol B-TRIVIAL 
BPA I-TRIVIAL 
formulation O 
has O 
a O 
shelf O 
- O 
life O 
of O 
between O 
1 O 
and O 
4 O 
years O 
respectively O 
, O 
a O 
marked O 
improvement O 
over O 
the O 
current O 
fructose B-TRIVIAL 
formulation O 
. O 
Due O 
to O 
temperature O 
dependent O 
degradation O 
the O 
formulation O 
cannot O 
be O 
terminally O 
sterilised O 
by O 
autoclaving O 
. O 
The O 
enhanced O 
stability O 
of O 
the O 
mannitol B-TRIVIAL 
formulation O 
removes O 
the O 
requirement O 
for O 
extemporaneous O 
aseptic O 
preparation O 
of O 
BPA B-ABBREVIATION 
just O 
prior O 
to O 
treatment O 
and O 
eliminates O 
one O 
of O 
the O 
issues O 
complicating O 
the O 
delivery O 
of O 
BNCT O 
. O 

contact O 
dermatitis O 
( O 
ACD O 
) O 
is O 
an O 
important O 
occupational O 
and O 
environmental O 
disease O 
caused O 
by O 
topical O 
exposure O 
to O 
chemical O 
allergens O 
. O 
It O 
describes O 
the O 
adverse O 
effects O 
that O 
may O 
results O 
when O 
exposure O 
to O 
a O 
chemical O 
elicits O 
a O 
T O 
cell O 
- O 
mediated O 
inflammatory O 
skin O 
disease O 
. O 
The O 
ability O 
of O 
contact O 
sensitizers O 
to O 
induce O 
the O 
oxidative O 
stress O 
pathway O 
in O 
keratinocytes O 
and O 
dendritic O 
cells O 
has O 
been O 
confirmed O 
by O 
several O 
authors O 
. O 
Reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
can O 
serve O 
as O 
essential O 
second O 
messengers O 
mediating O 
cellular O 
responses O 
resulting O 
in O 
immune O 
cells O 
activation O 
. O 
Oxidative O 
stress O 
may O 
be O 
the O 
starter O 
point O 
, O 
as O 
it O 
leads O 
to O 
the O 
activation O 
of O 
transcription O 
factors O 
and O 
signaling O 
pathways O 
, O 
including O 
NF-kB O 
and O 
p38 O 
MAPK O 
, O 
which O 
leads O 
to O 
the O 
release O 
of O 
cytokines O 
and O 
chemokines O 
. O 
ROS O 
are O 
also O 
involved O 
in O 
the O 
activation O 
of O 
the O 
NLRP3 O 
/ O 
NALP3 O 
inflammasome O 
, O 
which O 
is O 
required O 
to O 
direct O 
the O 
proteolytic O 
maturation O 
of O 
inflammatory O 
cytokines O 
such O 
as O 
IL-1β O 
and O 
IL-18 O 
, O 
which O 
are O 
all O 
integral O 
to O 
the O 
process O 
of O 
dendritic O 
cells O 
mobilization O 
, O 
migration O 
and O 
functional O 
maturation O 
. O 
Moreover O 
, O 
emerging O 
evidence O 
correlates O 
ROS O 
to O 
changes O 
in O 
the O 
constitution O 
of O 
the O 
extracellular O 
microenvironment O 
found O 
to O 
facilitate O 
ACD O 
. O 
The O 
purpose O 
of O 
this O 
review O 
is O 
to O 
provide O 
both O 
conceptual O 
and O 
technical O 
frameworks O 
on O 
the O 
role O 
of O 
oxidative O 
stress O 
in O 
chemical O 
allergy O 
. O 

and O 
arsenic B-SYSTEMATIC 
species O 
in O 
cultured O 
oyster O 
( O 
Crassostrea O 
gigas O 
and O 
C O 
. O 
corteziensis O 
) O 
from O 
coastal O 
lagoons O 
of O 
the O 
SE O 
Gulf O 
of O 
California O 
, O 
Mexico O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
bioavailability O 
of O 
arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
) O 
through O 
cultured O 
oyster O 
Crassostrea O 
gigas O 
and O 
Crassostrea O 
corteziensis O 
from O 
four O 
coastal O 
lagoons O 
( O 
SE O 
Gulf O 
of O 
California O 
) O 
. O 
Organisms O 
were O 
collected O 
in O 
two O 
seasons O 
( O 
rainy O 
and O 
dry O 
season O 
) O 
, O 
and O 
they O 
were O 
analyzed O 
for O 
total O 
arsenic B-SYSTEMATIC 
and O 
chemical O 
speciation O 
of O 
this O 
element O 
. O 
The O 
concentrations O 
of O 
As B-FORMULA 
in O 
oyster O 
soft O 
tissue O 
fluctuated O 
between O 
5.44 O 
and O 
9.56 O 
μg O 
/ O 
g O 
for O 
rainy O 
season O 
and O 
6.46 O 
and O 
8.33 O 
μg O 
/ O 
g O 
for O 
dry O 
season O 
( O 
dry O 
weight O 
) O 
in O 
C O 
. O 
gigas O 
. O 
In O 
C O 
. O 
corteziensis O 
, O 
the O 
As B-FORMULA 
concentrations O 
were O 
< O 
5 O 
μg O 
/ O 
g O 
for O 
both O 
seasons O 
( O 
dry O 
weight O 
) O 
. O 
Arsenic B-SYSTEMATIC 
speciation O 
indicated O 
arsenobetaine B-TRIVIAL 
as O 
the O 
major O 
arseno B-SYSTEMATIC 
-compound O 
accounting O 
for O 
43.2-76.3 O 
% O 
of O 
total O 
content O 
of O 
As B-FORMULA 
. O 
Lower O 
contributions O 
were O 
obtained O 
for O 
non-extractable O 
As B-FORMULA 
( O 
11.3-17.5 O 
% O 
) O 
and O 
other O 
molecules O 
such O 
as O 
arsenocholine B-SYSTEMATIC 
and O 
methyl-arsonate B-SYSTEMATIC 
( O 
< O 
5 O 
% O 
) O 
. O 
Inorganic O 
arsenic B-SYSTEMATIC 
was O 
detectable O 
in O 
only O 
two O 
samples O 
, O 
at O 
concentrations O 
lower O 
than O 
< O 
0.1 O 
μg O 
/ O 
g O 
. O 
These O 
As B-FORMULA 
data O 
are O 
the O 
first O 
generated O 
for O 
these O 
mollusks O 
in O 
NW O 
Mexico O 
and O 
indicate O 
that O 
C O 
. O 
gigas O 
and O 
C O 
. O 
corteziensis O 
farmed O 
in O 
this O 
area O 
are O 
safe O 
for O 
human O 
consumption O 
in O 
terms O 
of O 
arseno B-SYSTEMATIC 
-compounds O 
. O 

access O 
to O 
carba O 
- O 
analogs O 
of O 
C-nucleoside B-FAMILY 
derivatives O 
by O 
recombinant O 
Baeyer-Villiger O 
monooxygenases O 
. O 

novel O 
and O 
stereoselective O 
synthetic O 
route O 
towards O 
carba-C-nucleosides B-FAMILY 
was O 
investigated O 
applying O 
an O 
enantiodivergent O 
biooxidation O 
strategy O 
by O 
two O 
different O 
Baeyer-Villiger O 
monooxygenases O 
. O 
Within O 
only O 
three O 
chemo O 
- O 
enzymatic O 
steps O 
it O 
was O 
possible O 
to O 
introduce O 
four O 
chiral O 
centers O 
starting O 
from O 
commercially O 
available O 
non-chiral O 
starting O 
material O 
. O 

amyloid O 
A O 
upsurge O 
precedes O 
standard O 
biomarkers O 
of O 
hepatotoxicity O 
in O 
ritodrine B-TRIVIAL 
-injected O 
mice O 
. O 

tocolytic O 
agent O 
ritodrine B-TRIVIAL 
acts O 
on O 
the O 
β2-adrenoceptor O 
and O 
is O 
an O 
effective O 
treatment O 
option O 
for O 
preterm O 
labor O 
. O 
However O 
, O 
several O 
adverse O 
effects O 
of O 
ritodrine B-TRIVIAL 
therapy O 
, O 
including O 
liver O 
damage O 
, O 
have O 
been O 
noted O 
. O 
To O 
elucidate O 
the O 
underlying O 
mechanisms O 
of O 
ritodrine B-TRIVIAL 
-induced O 
adverse O 
effects O 
, O 
development O 
of O 
sensitive O 
biomarkers O 
of O 
these O 
adverse O 
events O 
is O 
necessary O 
. O 
Here O 
, O 
we O 
report O 
the O 
development O 
and O 
analysis O 
of O 
an O 
animal O 
model O 
of O 
ritodrine B-TRIVIAL 
-induced O 
liver O 
damage O 
. O 
Female O 
mice O 
received O 
daily O 
ritodrine B-TRIVIAL 
injections O 
for O 
2 O 
weeks O 
; O 
liver O 
samples O 
were O 
then O 
collected O 
and O 
subjected O 
to O 
DNA O 
microarray O 
analysis O 
. O 
Ritodrine B-TRIVIAL 
significantly O 
altered O 
the O 
expression O 
of O 
genes O 
related O 
to O 
steroid B-FAMILY 
and O 
lipid O 
metabolism O 
, O 
as O 
well O 
as O 
the O 
metabolism O 
of O 
ritodrine B-TRIVIAL 
itself O 
. O 
Importantly O 
, O 
expression O 
of O 
the O 
acute O 
- O 
phase O 
reactant O 
serum O 
amyloid O 
A O 
( O 
SAA O 
) O 
significantly O 
increased O 
after O 
ritodrine B-TRIVIAL 
injection O 
, O 
with O 
values O 
indicating O 
the O 
largest O 
fold O 
- O 
change O 
. O 
This O 
large O 
increase O 
in O 
blood O 
SAA O 
levels O 
serves O 
as O 
a O 
more O 
sensitive O 
biomarker O 
than O 
conventional O 
liver O 
enzymes O 
, O 
such O 
as O 
aspartate B-TRIVIAL 
aminotransferase O 
and O 
alanine B-TRIVIAL 
aminotransferase O 
. O 
The O 
increase O 
in O 
SAA O 
expression O 
is O 
specific O 
to O 
ritodrine B-TRIVIAL 
-induced O 
liver O 
damage O 
, O 
because O 
SAA O 
expression O 
was O 
not O 
induced O 
by O 
other O 
hepatotoxic O 
drugs O 
such O 
as O 
acetaminophen B-TRIVIAL 
, O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
, O 
or O 
metformin B-TRIVIAL 
. O 
Our O 
in O 
vitro O 
studies O 
showed O 
that O 
cyclic B-SYSTEMATIC 
adenosine I-SYSTEMATIC 
3',5'-monophosphate I-SYSTEMATIC 
( O 
cAMP B-ABBREVIATION 
) O 
accumulation O 
was O 
not O 
a O 
primary O 
cause O 
of O 
the O 
ritodrine B-TRIVIAL 
-induced O 
SAA O 
increase O 
. O 
Instead O 
, O 
SAA O 
expression O 
was O 
enhanced O 
by O 
indirect O 
phosphorylation O 
of O 
the O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription-3 O 
( O 
STAT3 O 
) O 
mediated O 
by O 
interleukin-6 O 
. O 
Therefore O 
, O 
our O 
study O 
provides O 
a O 
method O 
for O 
sensitive O 
and O 
early O 
detection O 
of O 
hepatic O 
injury O 
, O 
and O 
may O 
thus O 
help O 
preclude O 
serious O 
liver O 
damage O 
due O 
to O 
ritodrine B-TRIVIAL 
use O 
in O 
preterm O 
labor O 
. O 

compounds O 
from O 
Jacaranda O 
caroba O 
( O 
Vell O 
. O 
) O 
A O 
. O 
DC O 
. O 
: O 
Approaches O 
to O 
neurodegenerative O 
disorders O 
. O 

affecting O 
the O 
central O 
nervous O 
system O 
are O 
spread O 
throughout O 
the O 
world O 
. O 
As O 
so O 
, O 
more O 
efficient O 
and O 
safe O 
neuroprotective O 
drugs O 
are O 
required O 
. O 
The O 
present O 
study O 
describes O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
phenolic B-FAMILY 
composition O 
and O 
bioactivity O 
of O 
Jacaranda O 
caroba O 
( O 
Vell O 
. O 
) O 
A O 
. O 
DC O 
, O 
a O 
species O 
whose O 
infusion O 
is O 
consumed O 
as O 
traditional O 
medicine O 
. O 
The O 
HPLC-DAD-ESI O 
/ O 
MS(n) O 
analysis O 
revealed O 
the O 
presence O 
of O 
four O 
dicaffeoyl B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
and O 
nine O 
flavonoids B-FAMILY 
, O 
comprising O 
quercetin B-TRIVIAL 
, O 
kaempferol B-TRIVIAL 
and O 
isorhamnetin B-TRIVIAL 
derivatives O 
. O 
Twelve O 
compounds O 
are O 
described O 
for O 
the O 
first O 
time O 
in O 
Jacaranda O 
genus O 
. O 
Although O 
isorhamnetin-3-O-rhmanoside-7,4'-di-O-glucoside B-SYSTEMATIC 
and O 
quercetin-3-O-(2-pentosyl)hexoside B-SYSTEMATIC 
are O 
the O 
main O 
metabolites O 
in O 
both O 
aqueous O 
and O 
hydromethanolic O 
extracts O 
, O 
qualitative O 
and O 
quantitative O 
differences O 
were O 
found O 
between O 
them O 
. O 
Aqueous O 
extract O 
is O 
richer O 
in O 
dicaffeoyl B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
. O 
Both O 
extracts O 
proved O 
to O 
be O 
strong O 
radicals O 
' O 
scavengers O 
and O 
effective O 
monoamine B-FAMILY 
-oxidase O 
A O 
inhibitors O 
, O 
but O 
showed O 
weak O 
protection O 
against O 
cholinesterases O 
' O 
activity O 
. O 
The O 
results O 
highlight O 
the O 
value O 
of O 
J O 
. O 
caroba O 
as O 
a O 
source O 
of O 
health O 
- O 
promoting O 
antioxidants O 
and O 
antidepressant O 
compounds O 
. O 

for O 
analysis O 
of O 
citrinin B-TRIVIAL 
in O 
human O 
blood O 
and O 
urine O 
. O 

( O 
CIT B-ABBREVIATION 
) O 
, O 
produced O 
by O 
several O 
Penicillium O 
, O 
Aspergillus O 
, O 
and O 
Monascus O 
species O 
, O 
has O 
been O 
detected O 
as O 
contaminant O 
in O 
feeds O 
, O 
grains O 
, O 
and O 
other O 
food O 
commodities O 
. O 
CIT B-ABBREVIATION 
can O 
co O 
- O 
occur O 
with O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
( O 
OTA B-ABBREVIATION 
) O 
, O 
a O 
mycotoxin O 
also O 
known O 
for O 
its O 
nephrotoxicity O 
, O 
and O 
this O 
raises O 
concern O 
regarding O 
possible O 
combined O 
effects O 
. O 
But O 
, O 
in O 
contrast O 
to O 
OTA B-ABBREVIATION 
, O 
data O 
on O 
CIT B-ABBREVIATION 
contamination O 
in O 
foods O 
for O 
human O 
consumption O 
are O 
scarce O 
, O 
and O 
CIT B-ABBREVIATION 
biomonitoring O 
has O 
not O 
been O 
conducted O 
so O 
far O 
due O 
a O 
lack O 
of O 
suitable O 
methods O 
for O 
human O 
specimen O 
. O 
Thus O 
, O 
it O 
was O 
the O 
aim O 
of O 
the O 
present O 
study O 
to O 
develop O 
sensitive O 
methods O 
for O 
the O 
analysis O 
of O 
CIT B-ABBREVIATION 
in O 
human O 
blood O 
and O 
urine O 
to O 
investigate O 
human O 
exposure O 
. O 
To O 
this O 
end O 
, O 
we O 
assessed O 
different O 
methods O 
of O 
sample O 
preparation O 
and O 
instrumental O 
analysis O 
for O 
these O 
matrices O 
. O 
Clean O 
- O 
up O 
of O 
blood O 
plasma O 
by O 
protein O 
precipitation O 
followed O 
by O 
LC-MS O 
/ O 
MS O 
- O 
based O 
analysis O 
allowed O 
robust O 
detection O 
of O 
CIT B-ABBREVIATION 
( O 
LOD O 
0.07 O 
ng O 
/ O 
mL O 
, O 
LOQ O 
0.15 O 
ng O 
/ O 
mL O 
) O 
. O 
For O 
urine O 
, O 
sample O 
clean O 
- O 
up O 
by O 
an O 
immunoaffinity O 
column O 
(CitriTest(®)) O 
proved O 
to O 
be O 
clearly O 
superior O 
to O 
SPE O 
with O 
RP(18) O 
material O 
for O 
subsequent O 
analysis O 
by O 
LC-MS O 
/ O 
MS O 
. O 
For O 
CIT B-ABBREVIATION 
and O 
its O 
metabolite O 
dihydrocitrinone B-SYSTEMATIC 
( O 
HO-CIT B-ABBREVIATION 
) O 
, O 
the O 
LOD O 
and O 
LOQ O 
determined O 
by O 
external O 
calibration O 
curves O 
in O 
matrix O 
were O 
0.02 O 
and O 
0.05 O 
ng O 
/ O 
mL O 
for O 
CIT B-ABBREVIATION 
, O 
and O 
those O 
for O 
HO-CIT B-ABBREVIATION 
were O 
0.05 O 
and O 
0.1 O 
ng O 
/ O 
mL O 
urine O 
. O 
The O 
newly O 
developed O 
method O 
was O 
applied O 
in O 
a O 
small O 
pilot O 
study O 
: O 
CIT B-ABBREVIATION 
was O 
present O 
in O 
all O 
plasma O 
samples O 
from O 
8 O 
German O 
adults O 
, O 
at O 
concentrations O 
ranging O 
from O 
0.11 O 
to O 
0.26 O 
ng O 
/ O 
mL O 
. O 
The O 
molar O 
( O 
nM O 
) O 
concentrations O 
of O 
CIT B-ABBREVIATION 
are O 
similar O 
to O 
those O 
measured O 
for O 
OTA B-ABBREVIATION 
in O 
these O 
samples O 
as O 
a O 
result O 
of O 
dietary O 
mycotoxin O 
intake O 
. O 
CIT B-ABBREVIATION 
was O 
detected O 
in O 
8 O 
/ O 
10 O 
urines O 
( O 
from O 
4 O 
adults O 
and O 
6 O 
infants O 
) O 
in O 
a O 
range O 
of O 
0.16-0.79 O 
ng O 
/ O 
mL O 
, O 
and O 
HO-CIT B-ABBREVIATION 
was O 
present O 
in O 
5 O 
/ O 
10 O 
samples O 
at O 
similar O 
concentrations O 
. O 
Thus O 
, O 
CIT B-ABBREVIATION 
is O 
excreted O 
in O 
urine O 
as O 
parent O 
compound O 
and O 
also O 
as O 
metabolite O 
. O 
These O 
first O 
results O 
in O 
humans O 
point O 
to O 
the O 
need O 
for O 
further O 
studies O 
on O 
CIT B-ABBREVIATION 
exposure O 
. O 

in O 
the O 
gene O 
encoding O 
glucokinase O 
( O 
GCK O 
) O 
cause O 
a O 
mild O 
hereditary O 
form O 
of O 
diabetes O 
termed O 
maturity O 
- O 
onset O 
diabetes O 
of O 
the O 
young O 
(MODY)2 O 
or O 
GCK-MODY O 
. O 
The O 
disease O 
does O 
not O 
progress O 
over O 
time O 
, O 
and O 
diabetes O 
complications O 
rarely O 
develop O 
. O 
It O 
has O 
therefore O 
been O 
suggested O 
that O 
GCK-MODY O 
represents O 
a O 
metabolically O 
compensated O 
condition O 
, O 
but O 
experimental O 
support O 
for O 
this O 
notion O 
is O 
lacking O 
. O 
Here O 
, O 
we O 
profiled O 
metabolites O 
in O 
serum O 
from O 
patients O 
with O 
MODY1 O 
( O 
HNF4A O 
) O 
, O 
MODY2 O 
( O 
GCK O 
) O 
, O 
MODY3 O 
( O 
HNF1A O 
) O 
, O 
and O 
type O 
2 O 
diabetes O 
and O 
from O 
healthy O 
individuals O 
to O 
characterize O 
metabolic O 
perturbations O 
caused O 
by O 
specific O 
mutations O 
. O 
Analysis O 
of O 
four O 
GCK-MODY O 
patients O 
revealed O 
a O 
metabolite O 
pattern O 
similar O 
to O 
that O 
of O 
healthy O 
individuals O 
, O 
while O 
other O 
forms O 
of O 
diabetes O 
differed O 
markedly O 
in O 
their O 
metabolite O 
profiles O 
. O 
Furthermore O 
, O 
despite O 
elevated O 
glucose B-TRIVIAL 
concentrations O 
, O 
carriers O 
of O 
GCK O 
mutations O 
showed O 
lower O 
levels O 
of O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
triglycerides B-FAMILY 
than O 
healthy O 
control O 
subjects O 
. O 
The O 
metabolite O 
profiling O 
was O 
confirmed O 
by O 
enzymatic O 
assays O 
and O 
replicated O 
in O 
a O 
cohort O 
of O 
11 O 
GCK-MODY O 
patients O 
. O 
Elevated O 
levels O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
are O 
known O 
to O 
associate O 
with O 
β-cell O 
dysfunction O 
, O 
insulin O 
resistance O 
, O 
and O 
increased O 
incidence O 
of O 
late O 
complications O 
. O 
Our O 
results O 
show O 
that O 
GCK-MODY O 
represents O 
a O 
metabolically O 
normal O 
condition O 
, O 
which O 
may O 
contribute O 
to O 
the O 
lack O 
of O 
late O 
complications O 
and O 
the O 
nonprogressive O 
nature O 
of O 
the O 
disease O 
. O 

induces O 
the O 
expression O 
of O 
insulin O 
- O 
like O 
growth O 
factor O 
binding O 
protein O 
4 O 
in O 
5L O 
rat O 
hepatoma O 
cells O 
: O 
a O 
cautionary O 
tale O 
of O 
the O 
use O 
of O 
this O 
cell O 
line O 
in O 
studies O 
on O 
dioxin B-FAMILY 
toxicity O 
. O 

quantitative O 
proteomic O 
studies O 
on O 
the O 
actions O 
of O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
in O 
5L O 
rat O 
hepatoma O 
cells O 
, O 
a O 
cell O 
model O 
frequently O 
used O 
for O 
investigating O 
the O 
mechanisms O 
of O 
TCDD B-ABBREVIATION 
toxicity O 
, O 
had O 
indicated O 
that O 
dioxin B-FAMILY 
exposure O 
reduced O 
the O 
abundance O 
of O 
numerous O 
proteins O 
which O 
are O 
regulated O 
at O 
the O 
level O 
of O 
protein O 
synthesis O 
initiation O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
have O 
analysed O 
the O 
mechanism O 
mediating O 
this O 
inhibition O 
. O 
TCDD B-ABBREVIATION 
treatment O 
of O 
the O 
cells O 
largely O 
prevented O 
the O 
activation O 
of O 
eukaryotic O 
translation O 
initiation O 
factor O 
4E- O 
binding O 
protein O 
1 O 
, O 
a O 
regulator O 
of O 
translation O 
initiation O 
and O 
substrate O 
of O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
. O 
By O 
" O 
working O 
upwards O 
" O 
from O 
mTOR O 
, O 
we O 
observed O 
that O 
TCDD B-ABBREVIATION 
inhibited O 
endogenous O 
and O 
IGF-I-induced O 
AKT O 
and O 
ERK O 
activation O 
by O 
interfering O 
with O 
tyrosine B-TRIVIAL 
phosphorylation O 
of O 
insulin O 
receptor O 
substrate O 
1 O 
. O 
This O 
inhibition O 
was O 
mediated O 
by O 
a O 
TCDD B-ABBREVIATION 
-induced O 
secreted O 
factor O 
which O 
was O 
identified O 
as O 
insulin O 
- O 
like O 
growth O 
factor O 
binding O 
protein O 
4 O 
( O 
IGFBP-4 O 
) O 
. O 
The O 
induction O 
of O 
IGFBP-4 O 
protein O 
was O 
dependent O 
on O 
a O 
functional O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
and O 
was O 
preceded O 
by O 
a O 
rapid O 
increase O 
in O 
the O 
level O 
of O 
IGFBP-4 O 
mRNA O 
indicating O 
that O 
IGFBP-4 O 
is O 
a O 
previously O 
unknown O 
transcriptional O 
target O 
of O 
TCDD B-ABBREVIATION 
in O 
5L O 
cells O 
. O 
IGFBP-4 O 
was O 
not O 
induced O 
by O 
TCDD B-ABBREVIATION 
in O 
the O 
parental O 
cell O 
line O 
of O 
5L O 
cells O 
, O 
Fao O 
, O 
and O 
in O 
various O 
closely O 
related O 
rat O 
hepatoma O 
cell O 
lines O 
as O 
well O 
as O 
in O 
other O 
unrelated O 
cell O 
types O 
. O 
Analysis O 
of O 
5L O 
cell O 
chromosomes O 
by O 
multicolour O 
spectral O 
karyotyping O 
( O 
SKY O 
) O 
revealed O 
that O 
the O 
cells O 
carry O 
several O 
hitherto O 
uncharacterised O 
chromosomal O 
translocations O 
. O 
The O 
observations O 
suggest O 
that O 
in O 
5L O 
cells O 
the O 
Igfbp-4 O 
gene O 
may O 
have O 
got O 
under O 
the O 
control O 
of O 
a O 
promoter O 
containing O 
dioxin B-FAMILY 
responsive O 
element(s) O 
leading O 
to O 
the O 
induction O 
of O 
IGFBP-4 O 
by O 
TCDD B-ABBREVIATION 
. O 
These O 
findings O 
emphasise O 
a O 
particular O 
caution O 
when O 
interpreting O 
and O 
extrapolating O 
results O 
on O 
the O 
action O 
mechanisms O 
of O 
TCDD B-ABBREVIATION 
obtained O 
in O 
studies O 
using O 
5L O 
cells O 
as O 
a O 
model O 
system O 
. O 

large O 
and O 
diverse O 
material O 
collection O 
of O 
whole O 
grain O 
wheat O 
samples O 
( O 
n=129 O 
) O 
was O 
analysed O 
for O 
total O 
dietary O 
fibre O 
( O 
TDF O 
) O 
content O 
and O 
composition O 
, O 
including O 
fructan O 
( O 
11.5-15.5% O 
) O 
. O 
Correlations O 
between O 
the O 
dietary O 
fibre O 
components O 
, O 
associated O 
bioactive O 
components O 
( O 
e.g O 
. O 
tocols B-FAMILY 
, O 
sterols B-FAMILY 
, O 
phenolic B-FAMILY 
acids I-FAMILY 
and O 
folates B-FAMILY 
) O 
and O 
agronomic O 
properties O 
previously O 
determined O 
on O 
the O 
same O 
samples O 
were O 
found O 
with O 
multivariate O 
analysis O 
( O 
PCA O 
) O 
. O 
Samples O 
from O 
the O 
same O 
countries O 
had O 
similar O 
characteristics O 
. O 
The O 
first O 
PC O 
described O 
variation O 
in O 
components O 
concentrated O 
in O 
the O 
starchy O 
endosperm O 
( O 
e.g O 
. O 
starch O 
, O 
β-glucan O 
and O 
fructan O 
) O 
and O 
the O 
dietary O 
fibre O 
components O 
concentrated O 
in O 
the O 
bran O 
( O 
e.g O 
. O 
TDF O 
, O 
arabinoxylan O 
and O 
cellulose O 
) O 
. O 
The O 
second O 
PC O 
described O 
the O 
variation O 
in O 
kernel O 
weight O 
and O 
other O 
bran O 
components O 
such O 
as O 
alkylresorcinols B-FAMILY 
, O 
tocols B-FAMILY 
and O 
sterols B-FAMILY 
. O 
Interestingly O 
, O 
there O 
was O 
no O 
correlation O 
among O 
these O 
different O 
groups O 
of O 
bran O 
components O 
, O 
which O 
reflected O 
their O 
concentration O 
in O 
different O 
bran O 
tissues O 
. O 
The O 
results O 
are O 
of O 
importance O 
for O 
plant O 
breeders O 
who O 
wish O 
to O 
develop O 
varieties O 
with O 
health O 
- O 
promoting O 
effects O 
. O 

estradiol I-SYSTEMATIC 
regulation O 
of O 
connexin O 
43- O 
based O 
gap O 
junction O 
and O 
mechanosensitivity O 
through O 
classical O 
estrogen B-FAMILY 
receptor O 
pathway O 
in O 
osteocyte O 
- O 
like O 
MLO-Y4 O 
cells O 
. O 

43 O 
( O 
Cx43 O 
) O 
plays O 
an O 
essential O 
role O 
in O 
osteocyte O 
mechanotransduction O 
. O 
Although O 
estrogen B-FAMILY 
involves O 
in O 
the O 
adaptive O 
responses O 
of O 
bone O 
cells O 
to O 
mechanical O 
loadings O 
, O 
its O 
effects O 
on O 
osteocytic O 
Cx43 O 
- O 
based O 
gap O 
junction O 
intercellular O 
communication O 
( O 
GJIC O 
) O 
remain O 
obscure O 
. O 
We O 
found O 
that O 
17β B-SYSTEMATIC 
estradiol I-SYSTEMATIC 
( O 
E2 O 
) O 
up O 
- O 
regulated O 
Cx43 O 
, O 
and O 
enhanced O 
GJIC O 
in O 
osteocyte O 
- O 
like O 
MLO-Y4 O 
cells O 
in O 
fluorescence O 
recovery O 
after O 
photobleaching O 
( O 
FRAP O 
) O 
assay O 
. O 
Combination O 
of O 
E2 O 
pre O 
- O 
treatment O 
and O 
oscillating O 
fluid O 
flow O 
( O 
OFF O 
) O 
further O 
enhanced O 
Cx43 O 
expression O 
and O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
phosphorylation O 
, O 
comparing O 
to O 
E2 O 
or O 
OFF O 
treatment O 
alone O 
. O 
Both O 
blocking O 
of O 
classical O 
estrogen B-FAMILY 
receptors O 
( O 
ERα O 
/ O 
β O 
) O 
by O 
fulvestrant O 
and O 
ERα O 
knockdown O 
by O 
small O 
interfering O 
RNA O 
inhibited O 
E2 O 
- O 
mediated O 
Cx43 O 
increase O 
, O 
while O 
a O 
GPR30-specific O 
agonist O 
G-1 O 
failed O 
to O 
promote O 
Cx43 O 
expression O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
presence O 
of O 
E2 O 
enhanced O 
Cx43 O 
- O 
based O 
GJIC O 
mainly O 
via O 
ERα O 
/ O 
β O 
pathway O 
, O 
and O 
sensitized O 
osteocytes O 
to O 
mechanical O 
loading O 
. O 

adsorption O 
of O 
the O 
model O 
perfumes O 
phenyl B-SYSTEMATIC 
ethanol I-SYSTEMATIC 
, O 
PE O 
, O 
and O 
linalool B-TRIVIAL 
, O 
LL O 
, O 
at O 
the O 
air O 
- O 
solution O 
interface O 
by O 
coadsorption O 
with O 
the O 
anionic O 
surfactant O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
6-benezene I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
, O 
LAS-6 B-ABBREVIATION 
, O 
has O 
been O 
studied O 
primarily O 
by O 
neutron O 
reflectivity O 
, O 
NR O 
. O 
The O 
variation O 
in O 
the O 
mixed O 
surface O 
adsorption O 
with O 
solution O 
composition O 
is O 
highly O 
nonideal O 
, O 
and O 
the O 
more O 
hydrophobic O 
LL O 
is O 
more O 
surface O 
active O 
. O 
At O 
a O 
LAS-6 B-ABBREVIATION 
concentration O 
of O 
0.5 O 
mM O 
the O 
adsorption O 
of O 
PE O 
and O 
LL O 
is O 
broadly O 
similar O 
but O 
with O 
the O 
LL O 
systematically O 
more O 
surface O 
active O 
, O 
and O 
at O 
2 O 
mM O 
the O 
LL O 
completes O 
more O 
effectively O 
for O 
the O 
surface O 
than O 
the O 
PE O 
. O 
The O 
variation O 
in O 
surface O 
composition O 
with O 
solution O 
composition O 
and O 
concentration O 
reflect O 
the O 
greater O 
hydrophobicity O 
and O 
hence O 
surface O 
activity O 
of O 
LL O 
, O 
and O 
the O 
greater O 
solubility O 
of O 
PE O 
in O 
aqueous O 
solution O 
. O 
Changing O 
the O 
geometry O 
of O 
the O 
LAS B-ABBREVIATION 
isomer O 
, O 
from O 
the O 
symmetrical O 
LAS-6 B-ABBREVIATION 
geometry O 
to O 
the O 
more O 
asymmetrical O 
LAS-4 B-SYSTEMATIC 
, O 
results O 
in O 
the O 
LL O 
competing O 
more O 
effectively O 
for O 
the O 
surface O 
due O 
to O 
changes O 
in O 
the O 
packing O 
constraints O 
associated O 
with O 
the O 
hydrophobic O 
region O 
. O 
The O 
results O 
provide O 
insights O 
into O 
the O 
factors O 
that O 
affect O 
coadsorption O 
that O 
can O 
be O 
more O 
broadly O 
applied O 
to O 
the O 
surface O 
delivery O 
of O 
a O 
wide O 
range O 
of O 
molecules O 
other O 
than O 
perfumes O 
. O 

-lipid O 
hybrid O 
( O 
SLH O 
) O 
formulations O 
enhance O 
the O 
oral O 
bioavailability O 
and O 
efficacy O 
of O 
celecoxib B-TRIVIAL 
: O 
An O 
in O 
vivo O 
evaluation O 
. O 

study O 
is O 
the O 
first O 
to O 
demonstrate O 
in O 
canines O 
the O 
ability O 
of O 
silica B-TRIVIAL 
-lipid O 
hybrid O 
( O 
SLH O 
) O 
microparticles O 
to O 
enhance O 
the O 
bioavailability O 
and O 
efficacy O 
of O 
a O 
poorly O 
water O 
- O 
soluble O 
drug O 
after O 
oral O 
administration O 
. O 
Spray O 
- O 
dried O 
SLH O 
microparticles O 
comprising O 
Capmul B-FAMILY 
MCM I-FAMILY 
( O 
mono-diglycerides B-FAMILY 
of O 
C8 O 
/ O 
C12 O 
fatty B-FAMILY 
acids I-FAMILY 
) O 
and O 
silica B-TRIVIAL 
nanoparticles O 
( O 
Aerosil B-TRIVIAL 
® O 
380 O 
) O 
were O 
shown O 
to O 
significantly O 
enhance O 
the O 
fasted O 
state O 
oral O 
bioavailability O 
of O 
celecoxib B-TRIVIAL 
( O 
CEL B-ABBREVIATION 
) O 
( O 
6.5 O 
fold O 
, O 
relative O 
to O 
an O 
aqueous O 
suspension O 
and O 
more O 
than O 
2-fold O 
higher O 
relative O 
to O 
the O 
fed O 
state O 
) O 
after O 
oral O 
administration O 
to O 
beagle O 
dogs O 
. O 
Comparable O 
bioavailability O 
was O 
observed O 
between O 
the O 
SLH O 
microparticle O 
formulation O 
and O 
a O 
conventional O 
Capmul B-FAMILY 
lipid O 
solution O 
, O 
however O 
, O 
plasma O 
concentrations O 
were O 
observed O 
to O 
be O 
higher O 
( O 
Cmax O 
, O 
1.1±0.06 O 
vs O 
. O 
0.8±0.03μg O 
/ O 
mL O 
) O 
( O 
p≤0.05 O 
) O 
with O 
the O 
SLH O 
microparticle O 
system O 
. O 
The O 
enhanced O 
bioavailability O 
of O 
CEL B-ABBREVIATION 
observed O 
with O 
the O 
SLH O 
microparticles O 
was O 
reflected O 
in O 
a O 
subsequent O 
efficacy O 
study O 
conducted O 
in O 
an O 
adjuvant O 
- O 
induced O 
arthritis O 
model O 
in O 
the O 
rat O 
. O 
Reduced O 
clinical O 
and O 
histological O 
severity O 
was O 
observed O 
at O 
a O 
dose O 
of O 
3mg O 
/ O 
kg O 
/ O 
day O 
, O 
with O 
the O 
progression O 
of O 
arthritic O 
symptoms O 
and O 
tissue O 
damage O 
reduced O 
to O 
a O 
similar O 
degree O 
to O 
that O 
of O 
a O 
higher O 
dose O 
administered O 
at O 
5mg O 
/ O 
kg O 
/ O 
day O 
and O 
prepared O 
in O 
an O 
aqueous O 
suspension O 
. O 
, O 
The O 
enhanced O 
bioavailability O 
and O 
improved O 
efficacy O 
observed O 
with O 
the O 
SLH O 
microparticles O 
were O 
attributed O 
to O 
the O 
maintenance O 
of O 
CEL B-ABBREVIATION 
in O 
a O 
solubilised O 
form O 
during O 
digestion O 
of O 
the O 
lipid O 
vehicle O 
. O 
We O 
hypothesise O 
that O 
the O 
presence O 
of O 
silica B-TRIVIAL 
in O 
the O 
formulation O 
may O 
have O 
contributed O 
to O 
the O 
prevention O 
of O 
drug O 
precipitation O 
in O 
the O 
intestinal O 
lumen O 
by O 
providing O 
an O 
alternative O 
binding O 
site O 
for O 
CEL B-ABBREVIATION 
to O 
adsorb O 
to O 
prior O 
to O 
re O 
- O 
solubilisation O 
and O 
absorption O 
. O 
The O 
study O 
highlights O 
the O 
potential O 
utility O 
of O 
novel O 
SLH O 
microparticle O 
formulations O 
as O 
stable O 
dry O 
powders O 
that O 
possess O 
the O 
properties O 
of O 
a O 
lipid O 
- O 
based O 
formulation O 
for O 
the O 
enhanced O 
delivery O 
and O 
efficacy O 
of O 
poorly O 
water O 
- O 
soluble O 
drugs O 
. O 

are O 
enzymes O 
with O 
pantetheinase O 
activity O 
and O 
are O 
presumed O 
to O 
play O 
a O 
role O 
in O 
the O 
recycling O 
of O 
pantothenic B-TRIVIAL 
acid I-TRIVIAL 
( O 
vitamin B-TRIVIAL 
B5 I-TRIVIAL 
) O 
from O 
pantetheine B-TRIVIAL 
. O 
Pantothenic B-TRIVIAL 
acid I-TRIVIAL 
is O 
an O 
essential O 
nutrient O 
required O 
to O 
synthesize O 
coenzyme B-TRIVIAL 
A I-TRIVIAL 
, O 
a O 
cofactor O 
involved O 
in O 
many O 
biological O 
processes O 
such O 
as O 
fatty B-FAMILY 
acid I-FAMILY 
synthesis O 
and O 
oxidation O 
of O 
pyruvate B-TRIVIAL 
to O 
fuel O 
the O 
citric B-TRIVIAL 
acid I-TRIVIAL 
cycle O 
. O 
Hydrolysis O 
of O 
pantetheine B-TRIVIAL 
also O 
liberates O 
cysteamine B-TRIVIAL 
, O 
a O 
known O 
antioxidant O 
. O 
Vanin-1 O 
is O 
highly O 
expressed O 
in O 
liver O 
and O 
is O 
under O 
transcriptional O 
control O 
of O 
PPAR-α O 
and O 
nutritional O 
status O 
, O 
suggesting O 
a O 
role O 
in O 
energy O 
metabolism O 
. O 
The O 
lack O 
of O 
potent O 
and O 
specific O 
inhibitors O 
of O 
vanins O 
has O 
hampered O 
detailed O 
investigation O 
of O 
their O 
function O 
. O 
We O 
hereby O 
report O 
the O 
design O 
, O 
synthesis O 
, O 
and O 
characterization O 
of O 
a O 
novel O 
pantetheine B-TRIVIAL 
analogue O 
, O 
RR6 B-TRIVIAL 
, O 
that O 
acts O 
as O 
a O 
selective O 
, O 
reversible O 
, O 
and O 
competitive O 
vanin O 
inhibitor O 
at O 
nanomolar O 
concentration O 
. O 
Oral O 
administration O 
of O 
RR6 B-TRIVIAL 
in O 
rats O 
completely O 
inhibited O 
plasma O 
vanin O 
activity O 
and O 
caused O 
alterations O 
of O 
plasma O 
lipid O 
concentrations O 
upon O 
fasting O 
, O 
thereby O 
illustrating O 
its O 
potential O 
use O 
in O 
chemical O 
biology O 
research O 
. O 

of O 
the O 
Mode O 
of O 
Action O 
of O 
the O 
Almiramide B-FAMILY 
Family O 
of O 
Natural O 
Products O 
against O 
the O 
Kinetoplastid O 
Parasite O 
Trypanosoma O 
brucei O 
. O 

C I-TRIVIAL 
is O 
a O 
marine O 
natural O 
product O 
with O 
low O 
micromolar O 
activity O 
against O 
Leishmania O 
donovani O 
, O 
the O 
causative O 
agent O 
of O 
leishmaniasis O 
. O 
We O 
have O 
now O 
shown O 
that O 
almiramide B-TRIVIAL 
C I-TRIVIAL 
is O 
also O 
active O 
against O 
the O 
related O 
parasite O 
Trypanosoma O 
brucei O 
, O 
the O 
causative O 
agent O 
of O 
human O 
African O 
trypanosomiasis O 
. O 
A O 
series O 
of O 
activity O 
- O 
based O 
probes O 
have O 
been O 
synthesized O 
to O 
explore O 
both O 
the O 
molecular O 
target O 
of O 
this O 
compound O 
series O 
in O 
T O 
. O 
brucei O 
lysates O 
and O 
site O 
localization O 
through O 
epifluorescence O 
microscopy O 
. O 
These O 
target O 
identification O 
studies O 
indicate O 
that O 
the O 
almiramides B-FAMILY 
likely O 
perturb O 
glycosomal O 
function O 
through O 
disruption O 
of O 
membrane O 
assembly O 
machinery O 
. O 
Glycosomes O 
, O 
which O 
are O 
organelles O 
specific O 
to O 
kinetoplastid O 
parasites O 
, O 
house O 
the O 
first O 
seven O 
steps O 
of O 
glycolysis O 
and O 
have O 
been O 
shown O 
to O 
be O 
essential O 
for O 
parasite O 
survival O 
in O 
the O 
bloodstream O 
stage O 
. O 
There O 
are O 
currently O 
no O 
reported O 
small O 
- O 
molecule O 
disruptors O 
of O 
glycosome O 
function O 
, O 
making O 
the O 
almiramides B-FAMILY 
unique O 
molecular O 
probes O 
for O 
this O 
understudied O 
parasite O 
- O 
specific O 
organelle O 
. O 
Additionally O 
, O 
examination O 
of O 
toxicity O 
in O 
an O 
in O 
vivo O 
zebrafish O 
model O 
has O 
shown O 
that O 
these O 
compounds O 
have O 
little O 
effect O 
on O 
organism O 
development O 
, O 
even O 
at O 
high O 
concentrations O 
, O 
and O 
has O 
uncovered O 
a O 
potential O 
side O 
effect O 
through O 
localization O 
of O 
fluorescent O 
derivatives O 
to O 
zebrafish O 
neuromast O 
cells O 
. O 
Combined O 
, O 
these O 
results O 
further O 
our O 
understanding O 
of O 
the O 
potential O 
value O 
of O 
this O 
lead O 
series O 
as O 
development O 
candidates O 
against O 
T O 
. O 
brucei O 
. O 

diagnostic O 
applications O 
of O 
side O 
chain O 
oxysterols B-FAMILY 
analysis O 
in O 
plasma O 
and O 
cerebrospinal O 
fluid O 
. O 

neurospecific O 
cholesterol B-TRIVIAL 
24-hydroxylase O 
converts O 
excess O 
brain O 
cholesterol B-TRIVIAL 
into O 
24S-hydroxycholesterol B-SYSTEMATIC 
( O 
24OHC B-SYSTEMATIC 
) O 
which O 
, O 
via O 
the O 
liver O 
X O 
receptor O 
( O 
LXR O 
) O 
, O 
can O 
increase O 
the O 
expression O 
and O 
synthesis O 
of O 
astrocyte O 
ApoE O 
. O 
24OHC B-SYSTEMATIC 
effluxes O 
directly O 
from O 
brain O 
into O 
plasma O 
where O 
it O 
is O 
considered O 
an O 
indicator O 
of O 
brain O 
cholesterol B-TRIVIAL 
turnover O 
. O 
It O 
is O 
reduced O 
in O 
neurodegenerative O 
disease O 
states O 
proportionally O 
to O 
the O 
severity O 
of O 
disease O 
and O 
the O 
degree O 
of O 
brain O 
atrophy O 
. O 
In O 
the O 
early O 
phases O 
of O 
active O 
disease O 
, O 
a O 
higher O 
rate O 
of O 
turnover O 
may O 
result O 
in O 
transitory O 
increases O 
in O 
plasma O 
24OHC B-SYSTEMATIC 
. O 
Less O 
than O 
1% O 
of O 
the O 
total O 
brain O 
excretion O 
of O 
24OHC B-SYSTEMATIC 
occurs O 
via O 
the O 
cerebrospinal O 
fluid O 
( O 
CSF O 
) O 
whereas O 
almost O 
all O 
27-hydroxycholesterol B-SYSTEMATIC 
( O 
27OHC B-SYSTEMATIC 
) O 
excretion O 
is O 
dependent O 
on O 
the O 
function O 
of O 
the O 
blood O 
- O 
cerebrospinal O 
fluid O 
barrier O 
. O 
Iincreased O 
CSF O 
oxysterols B-FAMILY 
were O 
found O 
in O 
patients O 
with O 
neurodegenerative O 
and O 
neuroinflammatory O 
diseases O 
in O 
the O 
presence O 
of O 
barrier O 
dysfunction O 
. O 
In O 
neurodegeneration O 
, O 
free O 
cholesterol B-TRIVIAL 
released O 
from O 
dying O 
cells O 
may O 
engulf O 
neurons O 
. O 
Cholesterol B-TRIVIAL 
also O 
increases O 
Amyloid O 
β O 
( O 
Aβ O 
) O 
deposition O 
and O 
tau O 
pathology O 
. O 
ApoE O 
, O 
24OHC B-SYSTEMATIC 
, O 
tau O 
and O 
soluble O 
APP O 
were O 
correlated O 
in O 
Alzheimer O 
disease O 
( O 
AD O 
) O 
samples O 
. O 
Excess O 
of O 
cholesterol B-TRIVIAL 
converted O 
into O 
24OHC B-SYSTEMATIC 
may O 
up O 
- O 
regulate O 
ApoE O 
synthesis O 
which O 
is O 
a O 
scavenger O 
for O 
Aβ O 
and O 
Tau O 
. O 
In O 
AD O 
this O 
protective O 
mechanism O 
seems O 
to O 
be O 
inefficient O 
, O 
probably O 
due O 
to O 
the O 
presence O 
of O 
high O 
concentrations O 
of O 
27OHC B-SYSTEMATIC 
, O 
microvascular O 
dysfunction O 
and O 
the O 
decreased O 
efficiency O 
of O 
ApoE4 O 
as O 
lipid O 
transporter O 
and O 
Aβ O 
scavenger O 
. O 
24OHC B-SYSTEMATIC 
itself O 
was O 
cytotoxic O 
. O 
Analysis O 
of O 
side O 
chain O 
oxysterols B-FAMILY 
in O 
the O 
CSF O 
is O 
likely O 
to O 
provided O 
useful O 
information O 
about O 
cholesterol B-TRIVIAL 
metabolism O 
and O 
ApoE O 
function O 
in O 
the O 
pathogenesis O 
of O 
AD O 
. O 

of O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
UGT1A9 O 
and O 
UGT2B7 O 
in O 
ethanol B-SYSTEMATIC 
glucuronidation O 
, O 
and O 
interactions O 
with O 
common O 
drugs O 
of O 
abuse O 
. O 

glucuronide I-SYSTEMATIC 
( O 
EtG B-ABBREVIATION 
) O 
determination O 
is O 
increasingly O 
used O 
in O 
clinical O 
and O 
forensic O 
toxicology O 
to O 
document O 
ethanol B-SYSTEMATIC 
consumption O 
. O 
The O 
enzymes O 
involved O 
in O 
EtG B-ABBREVIATION 
production O 
, O 
as O 
well O 
as O 
potential O 
interactions O 
with O 
common O 
drugs O 
of O 
abuse O 
, O 
have O 
not O 
been O 
extensively O 
studied O 
. O 
Activities O 
of O 
human O 
liver O 
( O 
HLM O 
) O 
, O 
kidney O 
( O 
HKM O 
) O 
, O 
and O 
intestinal O 
( O 
HIM O 
) O 
microsomes O 
, O 
as O 
well O 
as O 
of O 
12 O 
major O 
human O 
recombinant O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGTs O 
) O 
, O 
toward O 
ethanol B-SYSTEMATIC 
( O 
50 O 
and O 
500 O 
mM O 
) O 
were O 
evaluated O 
in O 
vitro O 
using O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 
Enzyme O 
kinetic O 
parameters O 
were O 
determined O 
for O 
pooled O 
microsomes O 
and O 
recombinant O 
UGTs O 
with O 
significant O 
activity O 
. O 
Individual O 
contributions O 
of O 
UGTs O 
were O 
estimated O 
using O 
the O 
relative O 
activity O 
factor O 
approach O 
, O 
proposed O 
for O 
scaling O 
activities O 
obtained O 
with O 
cDNA-expressed O 
enzymes O 
to O 
HLM O 
. O 
Interaction O 
of O 
morphine B-TRIVIAL 
, O 
codeine B-TRIVIAL 
, O 
lorazepam B-TRIVIAL 
, O 
oxazepam B-TRIVIAL 
, O 
nicotine B-TRIVIAL 
, O 
cotinine B-TRIVIAL 
, O 
cannabinol B-TRIVIAL 
, O 
and O 
cannabidiol B-TRIVIAL 
( O 
5 O 
, O 
10 O 
, O 
15 O 
mg O 
/ O 
l O 
) O 
with O 
ethanol B-SYSTEMATIC 
( O 
1.15 O 
, O 
4.6 O 
, O 
11.5 O 
g O 
/ O 
l O 
; O 
i.e O 
. O 
, O 
25 O 
, O 
100 O 
, O 
250 O 
mM O 
) O 
glucuronidation O 
was O 
assessed O 
using O 
pooled O 
HLM O 
. O 
Ethanol B-SYSTEMATIC 
glucuronidation O 
intrinsic O 
clearance O 
(Cl(int)) O 
was O 
4 O 
and O 
12.7 O 
times O 
higher O 
for O 
HLM O 
than O 
for O 
HKM O 
and O 
HIM O 
, O 
respectively O 
. O 
All O 
recombinant O 
UGTs O 
, O 
except O 
UGT1A1 O 
, O 
1A6 O 
, O 
and O 
1A10 O 
, O 
produced O 
EtG B-ABBREVIATION 
in O 
detectable O 
amounts O 
. O 
UGT1A9 O 
and O 
2B7 O 
were O 
the O 
most O 
active O 
enzymes O 
, O 
each O 
accounting O 
for O 
17 O 
and O 
33% O 
of O 
HLM O 
Cl(int) O 
, O 
respectively O 
. O 
Only O 
cannabinol B-TRIVIAL 
and O 
cannabidiol B-TRIVIAL 
significantly O 
affected O 
ethanol B-SYSTEMATIC 
glucuronidation O 
. O 
Cannabinol B-TRIVIAL 
increased O 
ethanol B-SYSTEMATIC 
glucuronidation O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
, O 
whereas O 
cannabidiol B-TRIVIAL 
significantly O 
inhibited O 
EtG B-ABBREVIATION 
formation O 
in O 
a O 
noncompetitive O 
manner O 
( O 
IC(50) O 
= O 
1.17 O 
mg O 
/ O 
l O 
; O 
inhibition O 
constant O 
(K(i)) O 
= O 
3.1 O 
mg O 
/ O 
l O 
) O 
. O 
UGT1A9 O 
and O 
2B7 O 
are O 
the O 
main O 
enzymes O 
involved O 
in O 
ethanol B-SYSTEMATIC 
glucuronidation O 
. O 
In O 
addition O 
, O 
our O 
results O 
suggest O 
that O 
cannabinol B-TRIVIAL 
and O 
cannabidiol B-TRIVIAL 
could O 
significantly O 
alter O 
ethanol B-SYSTEMATIC 
glucuronidation O 
. O 

arrays O 
of O 
anisotropic O 
nano- O 
and O 
microparticles O 
, O 
in O 
which O 
the O 
long O 
axes O 
of O 
the O 
particles O 
are O 
oriented O 
perpendicular O 
to O 
the O 
substrate O 
, O 
are O 
of O 
interest O 
for O 
photovoltaics O 
and O 
other O 
applications O 
. O 
Array O 
assembly O 
typically O 
requires O 
applied O 
electric O 
or O 
magnetic O 
fields O 
and O 
/ O 
or O 
controlled O 
drying O 
, O 
which O 
are O 
challenging O 
over O 
large O 
areas O 
. O 
Here O 
, O 
we O 
describe O 
a O 
scalable O 
approach O 
to O 
self O 
- O 
assemble O 
multicomponent O 
nanowires O 
into O 
columnar O 
arrays O 
. O 
Self O 
- O 
assembly O 
of O 
partially O 
etched O 
nanowires O 
( O 
PENs O 
) O 
occurred O 
spontaneously O 
during O 
sedimentation O 
from O 
suspension O 
, O 
without O 
drying O 
or O 
applied O 
fields O 
. O 
PENs O 
, O 
which O 
have O 
segments O 
that O 
are O 
either O 
gold O 
or O 
" O 
empty O 
" O 
( O 
solvent O 
- O 
filled O 
) O 
surrounded O 
by O 
a O 
silica B-TRIVIAL 
shell O 
, O 
were O 
produced O 
from O 
striped O 
metal O 
nanowires O 
by O 
first O 
coating O 
with O 
silica B-TRIVIAL 
and O 
then O 
removing O 
sacrificial O 
segments O 
by O 
acid O 
etching O 
. O 
Electrostatic O 
repulsion O 
between O 
the O 
particles O 
was O 
necessary O 
for O 
array O 
assembly O 
; O 
however O 
, O 
details O 
of O 
PEN O 
surface O 
chemistry O 
were O 
relatively O 
unimportant O 
. O 
The O 
aspect O 
ratio O 
and O 
relative O 
center O 
of O 
mass O 
( O 
COM O 
) O 
of O 
the O 
PENs O 
were O 
important O 
for O 
determining O 
whether O 
the O 
PEN O 
long O 
axes O 
were O 
vertically O 
or O 
horizontally O 
aligned O 
with O 
respect O 
to O 
the O 
underlying O 
substrate O 
. O 
Arrays O 
with O 
predominantly O 
vertically O 
aligned O 
particles O 
were O 
achieved O 
for O 
PENs O 
with O 
a O 
large O 
offset O 
in O 
COM O 
relative O 
to O 
the O 
geometric O 
center O 
, O 
while O 
other O 
types O 
of O 
PENs O 
formed O 
horizontal O 
arrays O 
. O 
Assemblies O 
were O 
formed O 
over O 
> O 
10 O 
cm(2) O 
areas O 
, O 
with O 
over O 
60% O 
of O 
particles O 
standing O 
. O 
We O 
assessed O 
array O 
uniformity O 
and O 
reproducibility O 
by O 
imaging O 
many O 
positions O 
within O 
each O 
sample O 
and O 
performing O 
multiple O 
assemblies O 
of O 
differently O 
segmented O 
PENs O 
. O 
This O 
work O 
demonstrates O 
the O 
versatility O 
of O 
gravity O 
- O 
driven O 
PEN O 
array O 
assembly O 
and O 
provides O 
a O 
framework O 
for O 
designing O 
other O 
anisotropic O 
particle O 
systems O 
that O 
self O 
- O 
assemble O 
into O 
columnar O 
arrays O 
. O 

as O 
fatty B-FAMILY 
- I-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
hydrolase O 
and O 
monoacylglycerol B-SYSTEMATIC 
lipase O 
inhibitors O 
: O 
Synthesis O 
, O 
in O 
vitro O 
evaluation O 
and O 
insight O 
into O 
potency O 
and O 
selectivity O 
determinants O 
by O 
molecular O 
modelling O 
. O 

of O 
the O 
key O 
hydrolytic O 
enzymes O 
of O 
the O 
endocannabinoid O 
system O 
, O 
fatty B-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
hydrolase O 
( O 
FAAH O 
) O 
and O 
monoacylglycerol B-SYSTEMATIC 
lipase O 
( O 
MAGL O 
) O 
, O 
has O 
been O 
proposed O 
as O 
potential O 
mode O 
of O 
action O 
for O 
various O 
therapeutic O 
applications O 
. O 
Continuing O 
our O 
previous O 
work O 
, O 
we O 
take O 
the O 
first O 
steps O 
of O 
structure O 
- O 
activity O 
relationship O 
exploration O 
and O 
show O 
that O 
1,3,4-oxadiazol-2-ones B-FAMILY 
can O 
serve O 
as O 
scaffold O 
for O 
both O 
selective O 
FAAH O 
and O 
MAGL O 
inhibitors O 
, O 
and O 
also O 
function O 
as O 
a O 
dual O 
FAAH O 
/ O 
MAGL O 
inhibitor O 
at O 
sub O 
- O 
micromolar O 
IC50 O 
values O 
. O 
Moreover O 
, O 
10-fold O 
selectivity O 
against O 
MAGL O 
over O 
FAAH O 
was O 
achieved O 
with O 
compound O 
3d O 
( O 
FAAH O 
and O 
MAGL O 
IC50 O 
; O 
2 O 
and O 
0.22μM O 
) O 
. O 
Lastly O 
, O 
enzyme O 
and O 
ligand O 
features O 
contributing O 
to O 
the O 
potency O 
and O 
selectivity O 
differences O 
are O 
analysed O 
by O 
molecular O 
docking O 
. O 

parts O 
of O 
three O 
plants O 
( O 
Primula O 
auriculata O 
, O 
Fumaria O 
vaillantii O 
and O 
Falcaria O 
vulgaris O 
) O 
were O 
extracted O 
with O 
three O 
different O 
solvents O 
to O 
yield O 
72 O 
crude O 
extracts O 
. O 
The O 
phytochemical O 
analysis O 
( O 
chemical O 
screening O 
, O 
GC-MS O 
) O 
of O 
three O 
plants O 
was O 
investigated O 
for O 
their O 
antioxidant O 
and O 
antibacterial O 
activity O 
using O 
nine O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
The O 
principal O 
antioxidant O 
and O 
antimicrobial O 
components O 
were O 
determined O 
using O 
HPLC O 
with O 
UV O 
detection O 
. O 
All O 
extracts O 
possessed O 
antibacterial O 
activity O 
especially O 
methanolic O 
extracts O 
from O 
flowers O 
of O 
P O 
. O 
auriculata O 
. O 
The O 
DPPH B-ABBREVIATION 
-radical O 
scavenging O 
assay O 
exhibited O 
high O 
antioxidant O 
activities O 
in O 
three O 
plants O 
( O 
more O 
than O 
80% O 
at O 
50μg O 
) O 
. O 
The O 
F O 
. O 
vulgaris O 
showed O 
high O 
content O 
of O 
carvacrol B-TRIVIAL 
( O 
29.8% O 
) O 
as O 
main O 
component O 
. O 
The O 
contents O 
of O 
carvacrol B-TRIVIAL 
and O 
fumaric B-TRIVIAL 
acid I-TRIVIAL 
in O 
the O 
methanolic O 
- O 
water O 
extracts O 
were O 
1119 O 
and O 
1966mg O 
/ O 
l O 
respectively O 
. O 
Our O 
results O 
indicate O 
that O 
these O 
plants O 
would O 
be O 
able O 
to O 
promise O 
sources O 
of O 
natural O 
products O 
with O 
potential O 
antibacterial O 
and O 
antioxidant O 
activity O 
. O 

/ O 
HYPOTHESIS O 
: O 
Most O 
genetic O 
variants O 
identified O 
for O 
type O 
2 O 
diabetes O 
have O 
been O 
discovered O 
in O 
European O 
populations O 
. O 
We O 
performed O 
genome O 
- O 
wide O 
association O 
studies O 
( O 
GWAS O 
) O 
in O 
a O 
Chinese O 
population O 
with O 
the O 
aim O 
of O 
identifying O 
novel O 
variants O 
for O 
type O 
2 O 
diabetes O 
in O 
Asians O 
. O 
METHODS O 
: O 
We O 
performed O 
a O 
meta-analysis O 
of O 
three O 
GWAS O 
comprising O 
684 O 
patients O 
with O 
type O 
2 O 
diabetes O 
and O 
955 O 
controls O 
of O 
Southern O 
Han O 
Chinese O 
descent O 
. O 
We O 
followed O 
up O 
the O 
top O 
signals O 
in O 
two O 
independent O 
Southern O 
Han O 
Chinese O 
cohorts O 
( O 
totalling O 
10383 O 
cases O 
and O 
6974 O 
controls O 
) O 
, O 
and O 
performed O 
in O 
silico O 
replication O 
in O 
multiple O 
populations O 
. O 
RESULTS O 
: O 
We O 
identified O 
CDKN2A O 
/ O 
B O 
and O 
four O 
novel O 
type O 
2 O 
diabetes O 
association O 
signals O 
with O 
p O 
< O 
1 O 
× O 
10(-5) O 
from O 
the O 
meta-analysis O 
. O 
Thirteen O 
variants O 
within O 
these O 
four O 
loci O 
were O 
followed O 
up O 
in O 
two O 
independent O 
Chinese O 
cohorts O 
, O 
and O 
rs10229583 O 
at O 
7q32 O 
was O 
found O 
to O 
be O 
associated O 
with O 
type O 
2 O 
diabetes O 
in O 
a O 
combined O 
analysis O 
of O 
11067 O 
cases O 
and O 
7929 O 
controls O 
( O 
p O 
meta O 
= O 
2.6 O 
× O 
10(-8) O 
; O 
OR O 
[ O 
95% O 
CI O 
] O 
1.18 O 
[ O 
1.11 O 
, O 
1.25 O 
] O 
) O 
. O 
In O 
silico O 
replication O 
revealed O 
consistent O 
associations O 
across O 
multiethnic O 
groups O 
, O 
including O 
five O 
East O 
Asian O 
populations O 
( O 
p O 
meta O 
= O 
2.3 O 
× O 
10(-10) O 
) O 
and O 
a O 
population O 
of O 
European O 
descent O 
(p O 
= O 
8.6 O 
× O 
10(-3)) O 
. O 
The O 
rs10229583 O 
risk O 
variant O 
was O 
associated O 
with O 
elevated O 
fasting O 
plasma O 
glucose B-TRIVIAL 
, O 
impaired O 
beta O 
cell O 
function O 
in O 
controls O 
, O 
and O 
an O 
earlier O 
age O 
at O 
diagnosis O 
for O 
the O 
cases O 
. O 
The O 
novel O 
variant O 
lies O 
within O 
an O 
islet O 
- O 
selective O 
cluster O 
of O 
open O 
regulatory O 
elements O 
. O 
There O 
was O 
significant O 
heterogeneity O 
of O 
effect O 
between O 
Han O 
Chinese O 
and O 
individuals O 
of O 
European O 
descent O 
, O 
Malaysians O 
and O 
Indians O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
Our O 
study O 
identifies O 
rs10229583 O 
near O 
PAX4 O 
as O 
a O 
novel O 
locus O 
for O 
type O 
2 O 
diabetes O 
in O 
Chinese O 
and O 
other O 
populations O 
and O 
provides O 
new O 
insights O 
into O 
the O 
pathogenesis O 
of O 
type O 
2 O 
diabetes O 
. O 

DNA O 
glycosylase O 
1 O 
( O 
OGG1 O 
) O 
plays O 
an O 
important O 
role O 
in O 
repairing O 
oxidative O 
DNA O 
damage O 
induced O 
by O 
chemical O 
agents O 
, O 
such O 
as O 
tobacco O 
. O 
This O 
study O 
examined O 
the O 
effects O 
of O 
OGG1 O 
Ser326Cys O 
polymorphism O 
and O 
cigarette O 
smoking O 
, O 
alone O 
or O 
combined O 
, O 
on O 
sperm O 
oxidative O 
DNA O 
damage O 
and O 
the O 
risk O 
of O 
male O 
infertility O 
. O 
A O 
total O 
of O 
620 O 
idiopathic O 
infertile O 
subjects O 
and O 
480 O 
fertile O 
controls O 
were O 
recruited O 
in O 
this O 
study O 
. O 
Sperm O 
8-hydroxydeoxyguanine B-SYSTEMATIC 
( O 
8-OHdG B-SYSTEMATIC 
) O 
was O 
measured O 
by O 
immunofluorescent O 
assay O 
using O 
flow O 
cytometry O 
and O 
genotypes O 
were O 
determined O 
by O 
OpenArray O 
platform O 
with O 
a O 
chip O 
- O 
based O 
Taq-Man O 
genotyping O 
technology O 
. O 
Our O 
results O 
demonstrated O 
that O 
both O 
cigarette O 
smoking O 
and O 
OGG1 O 
polymorphism O 
can O 
affect O 
the O 
sperm O 
8-OHdG B-SYSTEMATIC 
levels O 
. O 
Individuals O 
with O 
variant O 
Cys B-FORMULA 
/ O 
Cys B-FORMULA 
homozygote O 
showed O 
higher O 
levels O 
of O 
sperm O 
8-OHdG B-SYSTEMATIC 
than O 
wide O 
- O 
type O 
homozygote O 
carriers O 
( O 
Ser B-FORMULA 
/ O 
Ser B-FORMULA 
) O 
. O 
Stratified O 
analysis O 
found O 
that O 
the O 
association O 
between O 
OGG1 O 
polymorphism O 
and O 
sperm O 
8-OHdG B-SYSTEMATIC 
levels O 
was O 
only O 
observed O 
among O 
smokers O 
with O 
pack O 
- O 
years O 
≥ O 
5 O 
but O 
not O 
among O 
those O 
subjects O 
with O 
pack O 
- O 
years O 
< O 
5 O 
( O 
pack-years=packs O 
smoked O 
per O 
day×years O 
as O 
a O 
smoker O 
) O 
. O 
Further O 
analysis O 
based O 
on O 
the O 
case O 
- O 
control O 
study O 
revealed O 
that O 
variant O 
allele O 
( O 
Cys B-FORMULA 
) O 
of O 
OGG1 O 
was O 
significantly O 
associated O 
with O 
male O 
infertility O 
risk O 
in O 
a O 
dominant O 
model O 
( O 
OR=1.35 O 
, O 
95% O 
CI O 
: O 
1.01-1.82 O 
; O 
trend O 
P O 
< O 
0.001 O 
) O 
. O 
Furthermore O 
, O 
we O 
found O 
a O 
significant O 
gene O 
- O 
environment O 
interaction O 
between O 
OGG1 O 
Ser326Cys O 
polymorphism O 
and O 
cigarette O 
smoking O 
in O 
relation O 
to O 
male O 
infertility O 
risk O 
( O 
Pinteration=0.0003 O 
) O 
. O 
These O 
findings O 
provided O 
the O 
first O 
evidence O 
about O 
potential O 
interactive O 
effects O 
of O 
OGG1 O 
polymorphism O 
and O 
cigarette O 
smoking O 
on O 
male O 
infertility O 
risk O 
. O 

@ O 
Si14+ B-FORMULA 
: O 
a O 
singlet O 
fullerene- B-TRIVIAL 
like O 
endohedrally O 
doped O 
silicon B-SYSTEMATIC 
cluster O 
. O 

electronic O 
structure O 
of O 
Mn B-FORMULA 
@ O 
Si14(+) B-FORMULA 
is O 
determined O 
using O 
DFT O 
and O 
CASPT2 O 
/ O 
CASSCF(14,15) O 
computations O 
with O 
large O 
basis O 
sets O 
. O 
The O 
endohedrally O 
Mn-doped B-FORMULA 
Si I-FORMULA 
cationic O 
cluster O 
has O 
a O 
D3h O 
fullerene- B-TRIVIAL 
like O 
structure O 
featuring O 
a O 
closed O 
- O 
shell O 
singlet O 
ground O 
state O 
with O 
a O 
singlet O 
- O 
triplet O 
gap O 
of O 
~1 O 
eV O 
. O 
A O 
strong O 
stabilizing O 
interaction O 
occurs O 
between O 
the O 
3d( O 
Mn B-FORMULA 
) O 
and O 
the O 
2D-shell( O 
Si14 B-FORMULA 
) O 
orbitals O 
, O 
and O 
a O 
large O 
amount O 
of O 
charge O 
is O 
transferred O 
from O 
the O 
Si14 B-FORMULA 
cage O 
to O 
the O 
Mn B-FORMULA 
dopant O 
. O 
The O 
3d( O 
Mn B-FORMULA 
) O 
orbitals O 
are O 
filled O 
by O 
encapsulation O 
, O 
and O 
the O 
magnetic O 
moment O 
of O 
Mn B-FORMULA 
is O 
completely O 
quenched O 
. O 
Full O 
occupation O 
of O 
[ O 
2S O 
, O 
2P O 
, O 
2D O 
] O 
shell O 
orbitals O 
by O 
18 O 
delocalized O 
electrons O 
confers O 
the O 
doped O 
Mn B-FORMULA 
@ O 
Si14(+) B-FORMULA 
cluster O 
a O 
spherically O 
aromatic O 
character O 
. O 

Aeropyrum O 
pernix O 
K1 O 
is O 
an O 
obligate O 
aerobic O 
hyperthermophilic O 
organism O 
with O 
C(25,25)-archeol O 
membrane O 
lipids O 
with O 
head O 
groups O 
containing O 
inositol B-TRIVIAL 
. O 
Interactions O 
of O 
archaeosomes O 
, O 
liposomes O 
prepared O 
from O 
lipids O 
of O 
A O 
. O 
pernix O 
, O 
with O 
mammalian O 
cells O 
in O 
vitro O 
were O 
studied O 
. O 
In O 
vitro O 
cytotoxicity O 
was O 
tested O 
on O 
five O 
different O 
cell O 
lines O 
: O 
rodent O 
mouse O 
melanoma O 
cells O 
( O 
B16-F1 O 
) O 
and O 
Chinese O 
hamster O 
ovary O 
( O 
CHO O 
) O 
cells O 
, O 
and O 
three O 
human O 
cell O 
lines O 
- O 
epithelial O 
colorectal O 
adenocarcinoma O 
cells O 
( O 
CACO-2 O 
) O 
, O 
liver O 
hepatocellular O 
carcinoma O 
cell O 
line O 
( O 
Hep O 
G2 O 
) O 
and O 
endothelial O 
umbilical O 
vein O 
cell O 
line O 
( O 
EA.hy926 O 
) O 
. O 
Archaeosomes O 
were O 
nontoxic O 
to O 
human O 
Hep O 
G2 O 
, O 
CACO-2 O 
and O 
mildly O 
toxic O 
to O 
rodent O 
CHO O 
and O 
B16-F1 O 
cells O 
but O 
showed O 
strong O 
cytotoxic O 
effect O 
on O 
EA.hy926 O 
cells O 
. O 
Confocal O 
microscopy O 
revealed O 
that O 
archaeosomes O 
are O 
taken O 
up O 
by O 
endocytosis O 
. O 
The O 
uptake O 
of O 
archaeosomes O 
and O 
the O 
release O 
of O 
loaded O 
calcein B-TRIVIAL 
are O 
more O 
prominent O 
in O 
EA.hy926 O 
cells O 
, O 
which O 
is O 
in O 
line O 
with O 
high O 
toxicity O 
toward O 
these O 
cells O 
. O 
The O 
mechanisms O 
of O 
uptake O 
, O 
release O 
and O 
action O 
in O 
these O 
cells O 
as O 
well O 
as O 
in O 
vivo O 
functioning O 
have O 
to O 
be O 
further O 
studied O 
for O 
possible O 
targeted O 
drug O 
delivery O 
. O 

within O 
a O 
network O 
have O 
the O 
ability O 
to O 
homeostatically O 
scale O 
- O 
down O 
their O 
excitatory O 
synaptic O 
strength O 
under O 
conditions O 
of O 
persistent O 
neuronal O 
activity O 
elevation O 
, O 
a O 
process O 
pivotal O 
to O 
neural O 
circuit O 
stability O 
. O 
How O 
this O 
homeostatic O 
regulation O 
is O 
achieved O 
at O 
the O 
molecular O 
level O 
in O 
developing O 
neural O 
circuits O 
, O 
which O 
face O 
gradually O 
elevated O 
neuronal O 
activity O 
as O 
part O 
of O 
circuit O 
wiring O 
, O 
is O 
not O 
well O 
- O 
understood O 
. O 
Using O 
dissociated O 
hippocampal O 
neuronal O 
cultures O 
, O 
we O 
identified O 
a O 
critical O 
and O 
cell O 
autonomous O 
role O 
for O 
the O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
EphA4 O 
in O 
mediating O 
activity O 
- O 
induced O 
homeostatic O 
down O 
- O 
regulation O 
of O 
excitatory O 
synaptic O 
strength O 
. O 
Reducing O 
the O 
endogenous O 
level O 
of O 
EphA4 O 
in O 
individual O 
neurons O 
by O 
RNAi O 
effectively O 
blocked O 
activity O 
- O 
induced O 
scaling O 
- O 
down O 
of O 
excitatory O 
synaptic O 
strength O 
, O 
while O 
co O 
- O 
transfection O 
of O 
RNAi O 
resistant O 
EphA4 O 
rescued O 
this O 
effect O 
. O 
Furthermore O 
, O 
interfering O 
with O 
EphA4 O 
forward O 
signaling O 
using O 
EphA4-Fc O 
blocked O 
activity O 
- O 
induced O 
homeostatic O 
synaptic O 
scaling O 
- O 
down O 
, O 
while O 
direct O 
activation O 
of O 
EphA4 O 
with O 
its O 
ligand O 
EphrinA1 O 
weakened O 
excitatory O 
synaptic O 
strength O 
. O 
Up- O 
or O 
down O 
- O 
regulating O 
EphA4 O 
function O 
in O 
individual O 
neurons O 
also O 
did O 
not O 
affect O 
the O 
density O 
of O 
excitatory O 
synapses O 
. O 
The O 
kinase O 
activities O 
of O 
EphA4 O 
and O 
its O 
downstream O 
effector O 
Cdk5 O 
were O 
both O 
required O 
for O 
homeostatic O 
synaptic O 
scaling O 
, O 
as O 
overexpression O 
of O 
EphA4 O 
with O 
constitutively O 
active O 
kinase O 
activity O 
reduced O 
excitatory O 
synaptic O 
strength O 
, O 
while O 
interfering O 
with O 
either O 
the O 
kinase O 
activity O 
of O 
EphA4 O 
or O 
Cdk5 O 
blocked O 
activity O 
- O 
induced O 
synaptic O 
scaling O 
. O 
Consistently O 
, O 
the O 
activities O 
of O 
EphA4 O 
and O 
Cdk5 O 
increased O 
significantly O 
during O 
global O 
and O 
persistent O 
activity O 
elevation O 
. O 
Together O 
, O 
our O 
work O 
demonstrated O 
that O 
the O 
kinase O 
activity O 
of O 
EphA4 O 
, O 
via O 
activation O 
of O 
downstream O 
Cdk5 O 
activity O 
, O 
mediates O 
the O 
scaling O 
- O 
down O 
of O 
excitatory O 
synaptic O 
strength O 
under O 
conditions O 
of O 
global O 
activity O 
elevation O 
. O 

determination O 
and O 
characterization O 
of O 
tannins B-FAMILY 
and O 
triterpene B-FAMILY 
saponins I-FAMILY 
from O 
the O 
fruits O 
of O 
various O 
species O 
of O 
Terminalia O 
and O 
Phyllantus O 
emblica O 
using O 
a O 
UHPLC-UV-MS O 
method O 
: O 
application O 
to O 
triphala O 
. O 

species O 
are O 
a O 
rich O 
source O 
of O 
tannins B-FAMILY 
. O 
Many O 
preparations O 
of O 
these O 
species O 
are O 
used O 
in O 
traditional O 
medicine O 
and O 
have O 
many O 
different O 
ethnobotanical O 
applications O 
. O 
A O 
simple O 
UHPLC O 
method O 
was O 
developed O 
for O 
the O 
simultaneous O 
analysis O 
of O 
such O 
hydrolysable O 
tannins B-FAMILY 
and O 
triterpene B-FAMILY 
saponins I-FAMILY 
from O 
the O 
fruit O 
rinds O 
of O 
different O 
species O 
of O 
Terminalia O 
( O 
T O 
. O 
chebula O 
, O 
T O 
. O 
arjuna O 
, O 
T O 
. O 
bellirica O 
) O 
and O 
Phyllantus O 
emblica O 
. O 
A O 
separation O 
by O 
LC O 
was O 
achieved O 
using O 
a O 
reversed O 
- O 
phase O 
column O 
and O 
a O 
water/ O 
acetonitrile B-SYSTEMATIC 
mobile O 
phase O 
, O 
both O 
containing O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
using O 
a O 
gradient O 
system O 
and O 
a O 
temperature O 
of O 
40°C O 
. O 
Eight O 
hydrolysable O 
tannins B-FAMILY 
( O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
gallic B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
, O 
corilagin B-TRIVIAL 
, O 
chebulagic B-TRIVIAL 
acid I-TRIVIAL 
, O 
1,2,3,6-tetra-O-galloyl-β-D-glucose B-SYSTEMATIC 
, O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
, O 
chebulinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
1,2,3,4,6-penta-O-galloyl-β-D-glucose B-SYSTEMATIC 
) O 
and O 
six O 
triterpene B-FAMILY 
saponins I-FAMILY 
( O 
arjunglucoside-I B-TRIVIAL 
, O 
arjunglucoside-III B-TRIVIAL 
, O 
chebuloside B-TRIVIAL 
II I-TRIVIAL 
, O 
bellericoside B-TRIVIAL 
, O 
arjunetin B-TRIVIAL 
, O 
and O 
arjunglucoside-II B-TRIVIAL 
) O 
could O 
be O 
separated O 
within O 
20 O 
minutes O 
. O 
The O 
wavelength O 
used O 
for O 
detection O 
with O 
the O 
diode O 
array O 
detector O 
was O 
254 O 
and O 
275 O 
nm O 
for O 
tannins B-FAMILY 
and O 
205 O 
nm O 
for O 
triterpene B-FAMILY 
saponins I-FAMILY 
. O 
The O 
method O 
was O 
validated O 
for O 
linearity O 
, O 
repeatability O 
, O 
limits O 
of O 
detection O 
, O 
and O 
limits O 
of O 
quantification O 
. O 
The O 
developed O 
method O 
is O 
economical O 
, O 
fast O 
, O 
and O 
especially O 
suitable O 
for O 
quality O 
control O 
analysis O 
of O 
tannins B-FAMILY 
and O 
triterpene B-FAMILY 
saponins I-FAMILY 
in O 
various O 
plant O 
samples O 
and O 
commercial O 
products O 
of O 
Terminalia O 
. O 

ether B-SYSTEMATIC 
-a-go O 
- O 
go O 
- O 
related O 
gene O 
channel O 
blockers O 
and O 
its O 
structural O 
analysis O 
for O 
drug O 
design O 
. O 

human O 
ether B-SYSTEMATIC 
-a-go O 
- O 
go O 
- O 
related O 
gene O 
( O 
hERG O 
) O 
is O 
a O 
K+ B-FORMULA 
channel O 
protein O 
mainly O 
expressed O 
in O 
the O 
heart O 
and O 
the O 
nervous O 
systems O 
and O 
its O 
blockade O 
by O 
non-cardiovascular O 
acting O 
drugs O 
resulted O 
in O 
tachycardia O 
and O 
sudden O 
death O 
. O 
In O 
this O 
present O 
review O 
, O 
we O 
have O 
focused O 
the O 
physicochemical O 
properties O 
responsible O 
for O 
the O 
hERG O 
blocking O 
activity O 
of O 
structurally O 
different O 
compounds O 
. O 
The O 
reported O 
research O 
works O 
showed O 
that O 
the O 
hydrophobicity O 
on O 
the O 
van O 
der O 
Waals O 
( O 
vdW O 
) O 
surface O 
of O 
the O 
molecules O 
( O 
aroused O 
from O 
the O 
aromatic O 
ring O 
) O 
necessary O 
for O 
the O 
hERG O 
blocking O 
activity O 
along O 
with O 
topological O 
and O 
electronic O 
properties O 
. O 
The O 
quinolizidine B-FAMILY 
alkaloids I-FAMILY 
( O 
natural O 
products O 
) O 
such O 
as O 
oxymatrine B-TRIVIAL 
, O 
sophoridine B-TRIVIAL 
, O 
sophocarpine B-TRIVIAL 
and O 
matrine B-TRIVIAL 
carry O 
the O 
common O 
molecular O 
structure O 
of O 
O=C=N-C-C-C-N B-FORMULA 
that O 
possessed O 
positive O 
ionotropic O 
effect O 
and O 
hERG O 
blocking O 
activity O 
. O 
Acehytisine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
previously O 
named O 
Guangfu B-TRIVIAL 
base I-TRIVIAL 
A I-TRIVIAL 
) O 
was O 
isolated O 
from O 
the O 
root O 
of O 
Aconitum O 
coreanum O 
( O 
Levl O 
. O 
) O 
, O 
is O 
an O 
anti-arrhythmic O 
drug O 
in O 
phase O 
IV O 
clinical O 
trial O 
. O 
The O 
isoquinoline B-FAMILY 
alkaloi I-FAMILY 
d O 
, O 
neferin B-TRIVIAL 
e O 
( B-ABBREVIATION 
Ne I-ABBREVIATION 
f O 
) O 
induces O 
a O 
concentration O 
- O 
dependent O 
decrease O 
in O 
current O 
amplitude O 
( O 
IC50 O 
of O 
7.419 O 
MM O 
) O 
. O 
Most O 
of O 
these O 
natural O 
product O 
compounds O 
contain O 
non-flexible O 
aromatic O 
structures O 
but O 
have O 
significant O 
activity O 
due O 
to O 
the O 
presence O 
of O 
optimum O 
hydrophobicity O 
. O 
Recent O 
research O 
works O 
revealed O 
that O 
Eag O 
and O 
hERG O 
channels O 
are O 
expressed O 
by O 
a O 
variety O 
of O 
cancer O 
cell O 
lines O 
and O 
tissues O 
. O 
The O 
Eag O 
channel O 
showed O 
an O 
oncogenic O 
potential O 
while O 
hERG O 
channels O 
are O 
associated O 
with O 
more O 
aggressive O 
tumors O 
and O 
have O 
a O 
role O 
in O 
mediating O 
invasion O 
. O 
This O 
review O 
concluded O 
that O 
the O 
consideration O 
of O 
physicochemical O 
properties O 
necessary O 
for O 
the O 
hERG O 
blocking O 
activity O 
will O 
guide O 
to O 
develop O 
novel O 
drugs O 
with O 
less O 
cardiotoxicity O 
. O 

multiforme O 
( O 
GBM O 
) O 
is O 
the O 
most O 
common O 
and O 
aggressive O 
type O 
of O 
human O 
brain O 
tumor O 
. O 
Although O 
considerable O 
efforts O 
to O 
delineate O 
the O 
underlying O 
pathophysiological O 
pathways O 
have O 
been O 
made O 
during O 
the O 
last O 
decades O 
, O 
only O 
very O 
limited O 
progress O 
on O 
treatment O 
have O 
been O 
achieved O 
because O 
molecular O 
pathways O 
that O 
drive O 
the O 
aggressive O 
nature O 
of O 
GBM O 
are O 
largely O 
unknown O 
. O 
Recent O 
studies O 
have O 
emphasized O 
the O 
importance O 
of O 
environmental O 
factors O 
and O 
the O 
role O 
of O 
gene O 
- O 
environment O 
interactions O 
( O 
GEI O 
) O 
in O 
the O 
development O 
of O 
GBM O 
. O 
Factors O 
such O 
as O 
small O 
sample O 
sizes O 
and O 
study O 
costs O 
have O 
limited O 
the O 
conduct O 
of O 
GEI O 
studies O 
in O 
brain O 
tumors O 
however O 
. O 
Additionally O 
, O 
advances O 
in O 
high O 
- O 
throughput O 
microarrays O 
have O 
produced O 
a O 
wealth O 
of O 
information O 
concerning O 
molecular O 
biology O 
of O 
glioma O 
. O 
In O 
particular O 
, O 
microarrays O 
have O 
been O 
used O 
to O 
obtain O 
genetic O 
and O 
epigenetic O 
changes O 
between O 
normal O 
non-tumor O 
tissue O 
and O 
glioma O 
tissue O 
. O 
Due O 
to O 
the O 
relative O 
rarity O 
of O 
gliomas O 
, O 
microarray O 
data O 
for O 
these O 
tumors O 
is O 
often O 
the O 
product O 
of O 
small O 
studies O 
, O 
and O 
thus O 
pooling O 
this O 
data O 
becomes O 
desirable O 
. O 
To O 
address O 
the O 
challenge O 
of O 
small O 
sample O 
sizes O 
and O 
GEI O 
study O 
difficulties O 
, O 
we O 
introduce O 
a O 
comprehensive O 
bioinformatics O 
method O 
using O 
genetic O 
variations O 
( O 
copy O 
number O 
variations O 
and O 
small O 
- O 
scale O 
variations O 
) O 
and O 
environmental O 
data O 
integration O 
that O 
links O 
with O 
Glioblastoma O 
( O 
GEG O 
) O 
to O 
identify O 
: O 
( O 
1 O 
) O 
genes O 
that O 
interact O 
with O 
chemicals O 
and O 
have O 
genetic O 
variants O 
linked O 
to O 
the O 
development O 
of O 
GBM O 
, O 
( O 
2 O 
) O 
important O 
pathways O 
that O 
may O 
be O 
influenced O 
by O 
environmental O 
exposures O 
( O 
or O 
endogenous O 
chemicals O 
) O 
, O 
and O 
( O 
3 O 
) O 
genes O 
with O 
variants O 
in O 
GBM O 
that O 
have O 
been O 
understudied O 
in O 
relation O 
to O 
GBM O 
development O 
. O 
The O 
first O 
step O 
in O 
our O 
GEG O 
method O 
identified O 
genes O 
responsive O 
to O 
environmental O 
exposures O 
using O 
the O 
Environmental O 
Genome O 
Project O 
, O 
Comparative O 
Toxicology O 
, O 
and O 
Seattle O 
SNPs O 
databases O 
. O 
These O 
environmentally O 
responsive O 
genes O 
were O 
then O 
compared O 
to O 
a O 
curated O 
list O 
of O 
genes O 
containing O 
copy O 
number O 
variation O 
and O 
/ O 
or O 
mutations O 
in O 
GBM O 
. O 
This O 
comparison O 
produced O 
a O 
list O 
of O 
genes O 
responsive O 
to O 
the O 
environment O 
and O 
important O 
to O 
GBM O 
that O 
was O 
then O 
further O 
analyzed O 
using O 
gene O 
networking O 
tools O 
such O 
as O 
RSpider O 
, O 
Cytoscape O 
, O 
and O 
DAVID O 
. O 
Using O 
this O 
GEG O 
bioinformatics O 
method O 
we O 
were O 
able O 
to O 
identify O 
173 O 
genes O 
with O 
the O 
potential O 
to O 
be O 
involved O 
in O 
GEI O 
that O 
may O 
be O 
important O 
to O 
the O 
development O 
of O 
GBM O 
. O 
Sixty O 
five O 
of O 
these O 
environmentally O 
responsive O 
genes O 
have O 
not O 
been O 
reported O 
as O 
important O 
to O 
GBM O 
development O 
, O 
despite O 
several O 
of O 
them O 
having O 
substantial O 
potential O 
for O 
response O 
to O 
chemicals O 
and O 
subsequent O 
disease O 
related O 
actions O 
. O 
The O 
main O 
biological O 
functions O 
of O 
these O 
173 O 
genes O 
include O 
signaling O 
by O 
Nerve O 
Growth O 
Factor O 
, O 
DNA O 
Repair O 
, O 
Integrin O 
Cell O 
Surface O 
Interactions O 
, O 
Biological O 
Oxidations O 
, O 
Apoptosis O 
, O 
Synaptic O 
Transmission O 
, O 
Cell O 
Cycle O 
Checkpoints O 
, O 
and O 
Arachidonic B-TRIVIAL 
Acid I-TRIVIAL 
Metabolism O 
. O 
Importantly O 
, O 
some O 
of O 
these O 
functions O 
have O 
been O 
implicated O 
in O 
the O 
development O 
of O 
several O 
cancers O 
, O 
including O 
glioma O 
. O 
In O 
summary O 
, O 
our O 
GEG O 
bioinformatics O 
approach O 
revealed O 
potential O 
gene O 
- O 
environment O 
interactions O 
, O 
and O 
generated O 
new O 
data O 
for O 
hypothesis O 
generation O 
, O 
in O 
GBM O 
. O 

severe O 
defects O 
in O 
growth O 
plate O 
development O 
caused O 
by O 
chondrocyte O 
extracellular O 
signal O 
- O 
regulated O 
protein O 
kinases O 
1 O 
and O 
2 O 
( O 
ERK1 O 
/ O 
2 O 
) O 
gain O 
or O 
loss O 
- O 
of O 
- O 
function O 
suggest O 
that O 
tight O 
spatial O 
and O 
temporal O 
regulation O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
signaling O 
is O 
necessary O 
to O 
achieve O 
harmonious O 
growth O 
plate O 
elongation O 
and O 
structure O 
. O 
We O 
provide O 
here O 
evidence O 
that O 
neurofibromin O 
, O 
via O 
its O 
Ras O 
guanosine B-TRIVIAL 
triphosphatase O 
-activating O 
activity O 
, O 
controls O 
ERK1 O 
/ O 
2-dependent O 
fibroblast O 
growth O 
factor O 
receptor O 
( O 
FGFR O 
) O 
signaling O 
in O 
chondrocytes O 
. O 
We O 
show O 
first O 
that O 
neurofibromin O 
is O 
expressed O 
in O 
FGFR-positive O 
prehypertrophic O 
and O 
hypertrophic O 
chondrocytes O 
during O 
growth O 
plate O 
endochondral O 
ossification O 
. O 
Using O 
mice O 
lacking O 
neurofibromin O 
1 O 
( O 
Nf1 O 
) O 
in O 
type O 
II O 
collagen O 
- O 
expressing O 
cells O 
, O 
( O 
Nf1col2(- O 
/ O 
- O 
) O 
mutant O 
mice O 
) O 
, O 
we O 
then O 
show O 
that O 
lack O 
of O 
neurofibromin O 
in O 
post O 
- O 
mitotic O 
chondrocytes O 
triggers O 
a O 
number O 
of O 
phenotypes O 
reminiscent O 
of O 
the O 
ones O 
observed O 
in O 
mice O 
characterized O 
by O 
FGFR O 
gain O 
- O 
of O 
- O 
function O 
mutations O 
. O 
Those O 
include O 
dwarfism O 
, O 
constitutive O 
ERK1 O 
/ O 
2 O 
activation O 
, O 
strongly O 
reduced O 
Ihh O 
expression O 
and O 
decreased O 
chondrocyte O 
proliferation O 
and O 
maturation O 
, O 
increased O 
chondrocytic O 
expression O 
of O 
Rankl O 
, O 
matrix O 
metalloproteinase O 
9 O 
( O 
Mmp9 O 
) O 
and O 
Mmp13 O 
and O 
enhanced O 
growth O 
plate O 
osteoclastogenesis O 
, O 
as O 
well O 
as O 
increased O 
sensitivity O 
to O 
caspase-9 O 
mediated O 
apoptosis O 
. O 
Using O 
wildtype O 
( O 
WT O 
) O 
and O 
Nf1(- O 
/ O 
- O 
) O 
chondrocyte O 
cultures O 
in O 
vitro O 
, O 
we O 
show O 
that O 
FGF2 O 
pulse O 
- O 
stimulation O 
triggers O 
rapid O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
in O 
both O 
genotypes O 
, O 
but O 
that O 
return O 
to O 
the O 
basal O 
level O 
is O 
delayed O 
in O 
Nf1(- O 
/ O 
- O 
) O 
chondrocytes O 
. O 
Importantly O 
, O 
in O 
vivo O 
ERK1 O 
/ O 
2 O 
inhibition O 
by O 
daily O 
injection O 
of O 
a O 
recombinant O 
form O 
of O 
C- O 
type O 
natriuretic O 
peptide O 
to O 
post O 
- O 
natal O 
pups O 
for O 
18 O 
days O 
was O 
able O 
to O 
correct O 
the O 
short O 
stature O 
of O 
Nf1col2(- O 
/ O 
- O 
) O 
mice O 
. O 
Together O 
, O 
these O 
results O 
underscore O 
the O 
requirement O 
of O 
neurofibromin O 
and O 
ERK1 O 
/ O 
2 O 
for O 
normal O 
endochondral O 
bone O 
formation O 
and O 
support O 
the O 
notion O 
that O 
neurofibromin O 
, O 
by O 
restraining O 
RAS-ERK1 O 
/ O 
2 O 
signaling O 
, O 
is O 
a O 
negative O 
regulator O 
of O 
FGFR O 
signaling O 
in O 
differentiating O 
chondrocytes O 
. O 

nonribosomal O 
peptide O 
synthetase O 
- O 
derived O 
iron B-SYSTEMATIC 
(III) I-SYSTEMATIC 
complex O 
from O 
the O 
pathogenic O 
fungus O 
Aspergillus O 
fumigatus O 
. O 

molecules O 
( O 
SMs O 
) O 
play O 
central O 
roles O 
as O 
virulence O 
factors O 
of O 
pathogenic O 
fungi O 
and O 
bacteria O 
; O 
however O 
, O 
genomic O 
analyses O 
suggest O 
that O 
the O 
majority O 
of O 
microbial O 
SMs O 
have O 
remained O 
uncharacterized O 
. O 
Based O 
on O 
microarray O 
analysis O 
followed O 
by O 
comparative O 
metabolomics O 
of O 
overexpression O 
/ O 
knockout O 
mutants O 
, O 
we O 
identified O 
a O 
tryptophan B-TRIVIAL 
-derived O 
iron B-SYSTEMATIC 
(III) I-SYSTEMATIC 
-complex O 
, O 
hexadehydro-astechrome B-SYSTEMATIC 
( O 
HAS B-ABBREVIATION 
) O 
, O 
as O 
the O 
major O 
product O 
of O 
the O 
cryptic O 
has O 
nonribosomal O 
peptide O 
synthetase O 
( O 
NRPS O 
) O 
gene O 
cluster O 
in O 
the O 
human O 
pathogen O 
Aspergillus O 
fumigatus O 
. O 
Activation O 
of O 
the O 
has O 
cluster O 
created O 
a O 
highly O 
virulent O 
A O 
. O 
fumigatus O 
strain O 
that O 
increased O 
mortality O 
of O 
infected O 
mice O 
. O 
Comparative O 
metabolomics O 
of O 
different O 
mutant O 
strains O 
allowed O 
to O 
propose O 
a O 
pathway O 
for O 
HAS B-ABBREVIATION 
biosynthesis O 
and O 
further O 
revealed O 
cross O 
- O 
talk O 
with O 
another O 
NRPS O 
pathway O 
producing O 
the O 
anticancer O 
fumitremorgins B-FAMILY 
. O 

effects O 
of O 
temperature O 
and O 
salinity O 
on O 
17-α-ethynylestradiol B-SYSTEMATIC 
uptake O 
and O 
its O 
relationship O 
to O 
oxygen B-SYSTEMATIC 
consumption O 
in O 
the O 
model O 
euryhaline O 
teleost O 
( O 
Fundulus O 
heteroclitus O 
) O 
. O 

synthetic O 
estrogen B-FAMILY 
17-α-ethynylestradiol B-SYSTEMATIC 
( O 
EE2 B-ABBREVIATION 
) O 
, O 
a O 
component O 
of O 
birth O 
control O 
and O 
hormone O 
replacement O 
therapy O 
, O 
is O 
discharged O 
into O 
the O 
environment O 
via O 
wastewater O 
treatment O 
plant O 
( O 
WWTP O 
) O 
effluents O 
. O 
The O 
present O 
study O 
employed O 
radiolabeled O 
EE2 B-ABBREVIATION 
to O 
examine O 
impacts O 
of O 
temperature O 
and O 
salinity O 
on O 
EE2 B-ABBREVIATION 
uptake O 
in O 
male O 
killifish O 
( O 
Fundulus O 
heteroclitus O 
) O 
. O 
Fish O 
were O 
exposed O 
to O 
a O 
nominal O 
concentration O 
of O 
100ng O 
/ O 
L O 
EE2 B-ABBREVIATION 
for O 
2h O 
. O 
The O 
rate O 
of O 
EE2 B-ABBREVIATION 
uptake O 
was O 
constant O 
over O 
the O 
2h O 
period O 
. O 
Oxygen B-SYSTEMATIC 
consumption O 
rates O 
(MO(2)) O 
, O 
whole O 
body O 
uptake O 
rates O 
, O 
and O 
tissue O 
- O 
specific O 
EE2 B-ABBREVIATION 
distribution O 
were O 
determined O 
. O 
In O 
killifish O 
acclimated O 
to O 
18°C O 
at O 
16ppt O 
( O 
50% O 
sea O 
water O 
) O 
, O 
MO(2) O 
and O 
EE2 B-ABBREVIATION 
uptake O 
were O 
both O 
lower O 
after O 
24h O 
exposure O 
to O 
10°C O 
and O 
4°C O 
, O 
and O 
increased O 
after O 
24h O 
exposure O 
to O 
26°C O 
. O 
Transfer O 
to O 
fresh O 
water O 
( O 
FW O 
) O 
for O 
24h O 
lowered O 
EE2 B-ABBREVIATION 
uptake O 
rate O 
, O 
and O 
long O 
- O 
term O 
acclimation O 
to O 
fresh O 
water O 
reduced O 
it O 
by O 
70% O 
. O 
Both O 
long O 
- O 
term O 
acclimation O 
to O 
100% O 
sea O 
water O 
( O 
32ppt O 
) O 
and O 
a O 
24h O 
transfer O 
to O 
100% O 
sea O 
water O 
also O 
reduced O 
EE2 B-ABBREVIATION 
uptake O 
rate O 
by O 
50% O 
relative O 
to O 
16ppt O 
. O 
Tissue O 
- O 
specific O 
accumulation O 
of O 
EE2 B-ABBREVIATION 
was O 
highest O 
( O 
40-60% O 
of O 
the O 
total O 
) O 
in O 
the O 
liver O 
plus O 
gall O 
bladder O 
across O 
all O 
exposures O 
, O 
and O 
the O 
vast O 
majority O 
of O 
this O 
was O 
in O 
the O 
bile O 
at O 
2h O 
, O 
regardless O 
of O 
temperature O 
or O 
salinity O 
. O 
The O 
carcass O 
was O 
the O 
next O 
highest O 
accumulator O 
( O 
30-40% O 
) O 
, O 
followed O 
by O 
the O 
gut O 
( O 
10-20% O 
) O 
with O 
only O 
small O 
amounts O 
in O 
gill O 
and O 
spleen O 
. O 
Killifish O 
chronically O 
exposed O 
( O 
15 O 
days O 
) O 
to O 
100ng O 
/ O 
L O 
EE2 B-ABBREVIATION 
displayed O 
no O 
difference O 
in O 
EE2 B-ABBREVIATION 
uptake O 
rate O 
or O 
tissue O 
- O 
specific O 
distribution O 
. O 
Drinking O 
rate O 
, O 
measured O 
with O 
radiolabeled O 
polyethylene B-TRIVIAL 
glycol-4000 I-TRIVIAL 
, O 
was O 
about O 
25 O 
times O 
greater O 
in O 
16ppt O 
- O 
acclimated O 
killifish O 
relative O 
to O 
FW-acclimated O 
animals O 
. O 
However O 
, O 
drinking O 
accounted O 
for O 
less O 
than O 
30% O 
of O 
gut O 
accumulation O 
, O 
and O 
therefore O 
a O 
negligible O 
percentage O 
of O 
whole O 
body O 
EE2 B-ABBREVIATION 
uptake O 
rates O 
. O 
In O 
general O 
, O 
there O 
were O 
strong O 
positive O 
relationships O 
between O 
EE2 B-ABBREVIATION 
uptake O 
rates O 
and O 
MO(2) O 
, O 
suggesting O 
similar O 
uptake O 
pathways O 
of O 
these O 
lipophilic O 
molecules O 
across O 
the O 
gills O 
. O 
These O 
data O 
will O 
be O 
useful O 
in O 
developing O 
a O 
predictive O 
model O 
of O 
how O 
key O 
environmental O 
parameter O 
variations O 
( O 
salinity O 
, O 
temperature O 
, O 
dissolved O 
oxygen B-SYSTEMATIC 
) O 
affect O 
EE2 B-ABBREVIATION 
uptake O 
in O 
estuarine O 
fish O 
, O 
to O 
determine O 
optimal O 
timing O 
and O 
location O 
of O 
WWTP O 
discharges O 
. O 

acids I-FAMILY 
in O 
the O 
colon O 
, O 
from O 
healthy O 
to O 
cytotoxic O 
molecules O 
. O 

acids I-FAMILY 
are O 
natural O 
detergents O 
mainly O 
involved O 
in O 
facilitating O 
the O 
absorption O 
of O 
dietary O 
fat O 
in O 
the O 
intestine O 
. O 
In O 
addition O 
to O 
this O 
absorptive O 
function O 
, O 
bile B-FAMILY 
acids I-FAMILY 
are O 
also O 
essential O 
in O 
the O 
maintenance O 
of O 
the O 
intestinal O 
epithelium O 
homeostasis O 
. O 
To O 
accomplish O 
this O 
regulatory O 
function O 
, O 
bile B-FAMILY 
acids I-FAMILY 
may O 
induce O 
programmed O 
cell O 
death O 
fostering O 
the O 
renewal O 
of O 
the O 
epithelium O 
. O 
Here O 
we O 
first O 
discuss O 
on O 
the O 
different O 
molecular O 
pathways O 
of O 
cell O 
death O 
focusing O 
on O 
apoptosis O 
in O 
colon O 
epithelial O 
cells O 
. O 
Bile B-FAMILY 
acids I-FAMILY 
may O 
induce O 
apoptosis O 
in O 
colonocytes O 
through O 
different O 
mechanisms O 
. O 
In O 
contrast O 
to O 
hepatocytes O 
, O 
the O 
extrinsic O 
apoptotic O 
pathway O 
seems O 
to O 
have O 
a O 
low O 
relevance O 
regarding O 
bile B-FAMILY 
acid I-FAMILY 
cytotoxicity O 
in O 
the O 
colon O 
. O 
On O 
the O 
contrary O 
, O 
these O 
molecules O 
mainly O 
trigger O 
apoptosis O 
through O 
direct O 
or O 
indirect O 
mitochondrial O 
perturbations O 
, O 
where O 
oxidative O 
stress O 
plays O 
a O 
key O 
role O 
. O 
In O 
addition O 
, O 
bile B-FAMILY 
acids I-FAMILY 
may O 
also O 
act O 
as O 
regulatory O 
molecules O 
involved O 
in O 
different O 
cell O 
signaling O 
pathways O 
in O 
colon O 
cells O 
. O 
On O 
the O 
other O 
hand O 
, O 
there O 
is O 
increasing O 
evidence O 
that O 
the O 
continuous O 
exposure O 
to O 
certain O 
hydrophobic O 
bile B-FAMILY 
acids I-FAMILY 
, O 
due O 
to O 
a O 
fat O 
- O 
rich O 
diet O 
or O 
pathological O 
conditions O 
, O 
may O 
induce O 
oxidative O 
DNA O 
damage O 
that O 
, O 
in O 
turn O 
, O 
may O 
lead O 
to O 
colorectal O 
carcinogenesis O 
as O 
a O 
consequence O 
of O 
the O 
appearance O 
of O 
cell O 
populations O 
resistant O 
to O 
bile B-FAMILY 
acid I-FAMILY 
-induced O 
apoptosis O 
. O 
Finally O 
, O 
some O 
bile B-FAMILY 
acids I-FAMILY 
, O 
such O 
as O 
UDCA B-ABBREVIATION 
, O 
or O 
low O 
concentrations O 
of O 
hydrophobic O 
bile B-FAMILY 
acids I-FAMILY 
, O 
can O 
protect O 
colon O 
cells O 
against O 
apoptosis O 
induced O 
by O 
high O 
concentrations O 
of O 
cytotoxic O 
bile B-FAMILY 
acids I-FAMILY 
, O 
suggesting O 
a O 
dual O 
behavior O 
of O 
these O 
agents O 
as O 
pro O 
- O 
death O 
or O 
pro O 
- O 
survival O 
molecules O 
. O 

relationship O 
between O 
susceptibility O 
of O 
different O 
peach O 
cultivars O 
( O 
cvs O 
) O 
to O 
the O 
Mediterranean O 
fruit O 
fly O 
( O 
medfly O 
) O 
, O 
Ceratitis O 
capitata O 
, O 
and O 
the O 
volatile O 
composition O 
of O 
ripe O 
fruit O 
of O 
each O 
cv O 
has O 
been O 
investigated O 
, O 
since O 
understanding O 
the O 
fruit O 
- O 
insect O 
interaction O 
mechanism O 
is O 
crucial O 
for O 
developing O 
control O 
strategies O 
for O 
such O 
a O 
pest O 
. O 
Volatile O 
compounds O 
were O 
analyzed O 
by O 
SPME-GC-MS O 
in O 
three O 
cvs O 
highly O 
susceptible O 
to O 
medfly O 
attack O 
( O 
Fair O 
Time O 
, O 
Flaminia O 
, O 
Sicilia O 
Piatta O 
) O 
, O 
and O 
in O 
two O 
less O 
susceptible O 
cvs O 
( O 
Percoca O 
Romagnola O 
7 O 
and O 
Doctor O 
Davis O 
) O 
. O 
Among O 
the O 
volatile O 
compounds O 
detected O 
, O 
88 O 
could O 
be O 
identified O 
. O 
The O 
main O 
differences O 
found O 
in O 
the O 
volatile O 
composition O 
of O 
the O 
cvs O 
, O 
concerned O 
the O 
relative O 
abundance O 
of O 
esters B-FAMILY 
. O 
The O 
least O 
susceptible O 
cvs O 
, O 
above O 
all O 
Percoca O 
Romagnola O 
7 O 
, O 
contained O 
the O 
higher O 
amounts O 
of O 
hexenyl B-MULTIPLE 
, I-MULTIPLE 
hexyl I-MULTIPLE 
, I-MULTIPLE 
3-methylbutyl I-MULTIPLE 
, I-MULTIPLE 
butyl I-MULTIPLE 
and I-MULTIPLE 
2-methylpropyl I-MULTIPLE 
esters I-MULTIPLE 
; O 
among O 
these O 
, O 
some O 
C6 O 
derivatives O 
detected O 
, O 
such O 
as O 
(Z)-3-hexenyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
are O 
known O 
to O 
act O 
as O 
priming O 
agents O 
, O 
enhancing O 
plant O 
defence O 
response O 
to O 
insects O 
. O 
Instead O 
, O 
a O 
lower O 
relative O 
content O 
of O 
methyl B-FAMILY 
esters I-FAMILY 
, O 
such O 
as O 
methyl B-SYSTEMATIC 
hexanoate I-SYSTEMATIC 
and O 
methyl B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
, O 
known O 
to O 
act O 
as O 
medfly O 
pheromone O 
and O 
attractant O 
respectively O 
, O 
was O 
found O 
in O 
the O 
least O 
susceptible O 
cvs O 
. O 

antipsoriatic O 
effect O 
of O 
chondroitin O 
sulfate B-SYSTEMATIC 
through O 
inhibition O 
of O 
NF-κB O 
and O 
STAT3 O 
in O 
human O 
keratinocytes O 
. O 

sulfate B-SYSTEMATIC 
( O 
CS O 
) O 
is O 
a O 
natural O 
glycosaminoglycan O 
, O 
formed O 
by O 
the O 
1-3 O 
linkage O 
of O 
d-glucuronic B-TRIVIAL 
acid I-TRIVIAL 
to O 
N-acetylgalactosamine B-SYSTEMATIC 
, O 
present O 
in O 
the O 
extracellular O 
matrix O 
. O 
It O 
is O 
used O 
as O 
a O 
slow O 
acting O 
disease O 
modifying O 
agent O 
in O 
the O 
treatment O 
of O 
osteoarthritis O 
, O 
and O 
part O 
of O 
its O 
beneficial O 
effects O 
are O 
due O 
to O 
its O 
antiinflammatory O 
properties O 
that O 
result O 
from O 
an O 
inhibitory O 
effect O 
on O 
NF-κB O 
signaling O 
pathway O 
. O 
This O 
ability O 
raises O 
the O 
hypothesis O 
that O 
CS O 
might O 
be O 
effective O 
in O 
other O 
chronic O 
inflammatory O 
processes O 
such O 
as O 
psoriasis O 
, O 
in O 
which O 
a O 
deregulation O 
of O 
NF-κB O 
is O 
a O 
key O 
feature O 
. O 
In O 
addition O 
, O 
psoriasis O 
is O 
characterized O 
by O 
an O 
upregulation O 
of O 
STAT3 O 
signaling O 
pathway O 
that O 
is O 
related O 
to O 
the O 
epidermal O 
hyperplasia O 
. O 
In O 
the O 
present O 
study O 
we O 
report O 
the O 
pharmacological O 
modulation O 
of O 
the O 
NF-κB O 
and O 
STAT3 O 
signaling O 
pathways O 
by O 
CS O 
in O 
normal O 
human O 
keratinocytes O 
. O 
CS O 
inhibited O 
NF-κB O 
activation O 
and O 
the O 
release O 
of O 
some O 
of O 
the O 
key O 
psoriatic O 
cytokines O 
such O 
as O 
TNFα O 
, O 
IL-8 O 
, O 
IL-6 O 
and O 
CCL27 O 
. O 
Moreover O 
, O 
it O 
impaired O 
STAT3 O 
translocation O 
to O 
the O 
nucleus O 
and O 
significantly O 
reduced O 
STAT3 O 
transcriptional O 
activity O 
by O 
a O 
mechanism O 
that O 
was O 
independent O 
from O 
STAT3 O 
phosphorylation O 
. O 
Our O 
results O 
confirm O 
the O 
interest O 
of O 
CS O 
as O 
a O 
candidate O 
for O 
future O 
drug O 
research O 
in O 
the O 
therapeutics O 
of O 
psoriasis O 
given O 
the O 
need O 
of O 
more O 
effective O 
and O 
safer O 
oral O 
medications O 
for O 
these O 
patients O 
. O 

derived O 
from O 
montmorillonite B-TRIVIAL 
and O 
metallosupramolecular O 
polyelectrolytes O 
: O 
modular O 
compounds O 
for O 
electrorheological O 
fluids O 
. O 

made O 
from O 
Na B-FORMULA 
- O 
montmorillonite B-TRIVIAL 
and O 
metallo-supramolecular O 
polyelectrolytes O 
( O 
MEPE O 
) O 
based O 
on O 
nickel B-SYSTEMATIC 
and O 
ditopic O 
bis-terpyridine B-TRIVIAL 
ligands O 
are O 
prepared O 
by O 
an O 
aqueous O 
synthesis O 
. O 
Intercalation O 
is O 
confirmed O 
by O 
IR-spectroscopy O 
, O 
thermogravimetric O 
analysis O 
, O 
and O 
X-ray O 
powder O 
diffraction O 
. O 
The O 
rheological O 
response O 
in O 
the O 
presence O 
of O 
an O 
electric O 
field O 
of O 
the O 
dispersed O 
nanocomposites O 
in O 
silicone O 
oil O 
is O 
measured O 
with O 
a O 
rheometer O 
. O 
The O 
nanocomposites O 
show O 
a O 
distinct O 
electrorheological O 
effect O 
depending O 
on O 
the O 
concentration O 
and O 
the O 
kind O 
of O 
intercalated O 
species O 
. O 
The O 
effect O 
occurs O 
with O 
a O 
low O 
content O 
of O 
active O 
material O 
while O 
only O 
very O 
small O 
currents O 
are O 
observed O 
. O 

present O 
a O 
novel O 
microchip O 
- O 
based O 
approach O 
to O 
combine O 
the O 
synthesis O 
, O 
characterization O 
, O 
and O 
utilization O 
of O 
different O 
functional O 
materials O 
on O 
a O 
single O 
platform O 
. O 
A O 
two O 
- O 
layer O 
microfluidic O 
device O 
comprising O 
10 O 
parallel O 
actuated O 
reaction O 
chambers O 
with O 
volumes O 
of O 
a O 
few O 
hundred O 
picoliters O 
is O 
used O 
to O 
localize O 
and O 
confine O 
the O 
synthesis O 
, O 
while O 
the O 
surfaces O 
of O 
the O 
reaction O 
chambers O 
comprise O 
an O 
electrode O 
array O 
for O 
direct O 
integration O 
and O 
further O 
characterization O 
of O 
the O 
created O 
crystalline O 
assemblies O 
without O 
the O 
need O 
for O 
further O 
manipulation O 
or O 
positioning O 
devices O 
. O 
First O 
we O 
visualized O 
and O 
evaluated O 
the O 
dynamics O 
of O 
our O 
method O 
by O 
monitoring O 
the O 
formation O 
of O 
a O 
fluorescent O 
metal O 
- O 
organic O 
complex O 
( O 
Zn(bix) B-FORMULA 
) O 
. O 
Next O 
, O 
we O 
induced O 
the O 
site O 
- O 
specific O 
growth O 
of O 
two O 
types O 
of O 
organic O 
conductive O 
crystals O 
, O 
AuTTF B-FORMULA 
and O 
AgTCNQ B-FORMULA 
, O 
directly O 
onto O 
the O 
electrode O 
arrays O 
in O 
one- O 
and O 
two O 
- O 
step O 
reactions O 
, O 
respectively O 
. O 
The O 
performance O 
of O 
the O 
created O 
AgTCNQ B-FORMULA 
crystals O 
as O 
memory O 
elements O 
was O 
thoroughly O 
examined O 
. O 
Moreover O 
, O 
we O 
proved O 
for O 
first O 
time O 
that O 
AuTTF B-FORMULA 
composites O 
can O 
be O 
used O 
as O 
label O 
- O 
free O 
sensing O 
elements O 
. O 

adaptation O 
of O 
protein O 
synthesis O 
to O 
environmental O 
and O 
physiological O 
challenges O 
is O 
essential O 
for O 
cell O 
viability O 
. O 
Here O 
, O 
we O 
show O 
that O 
translation O 
is O 
tightly O 
linked O 
to O 
the O 
protein O 
- O 
folding O 
environment O 
of O 
the O 
cell O 
through O 
the O 
functional O 
properties O 
of O 
the O 
ribosome O 
bound O 
chaperone O 
NAC O 
( O 
nascent O 
polypeptide-associated O 
complex O 
) O 
. O 
Under O 
non-stress O 
conditions O 
, O 
NAC O 
associates O 
with O 
ribosomes O 
to O 
promote O 
translation O 
and O 
protein O 
folding O 
. O 
When O 
proteostasis O 
is O 
imbalanced O 
, O 
NAC O 
relocalizes O 
from O 
a O 
ribosome O 
- O 
associated O 
state O 
to O 
protein O 
aggregates O 
in O 
its O 
role O 
as O 
a O 
chaperone O 
. O 
This O 
results O 
in O 
a O 
functional O 
depletion O 
of O 
NAC O 
from O 
the O 
ribosome O 
that O 
diminishes O 
translational O 
capacity O 
and O 
the O 
flux O 
of O 
nascent O 
proteins O 
. O 
Depletion O 
of O 
NAC O 
from O 
polysomes O 
and O 
re O 
- O 
localisation O 
to O 
protein O 
aggregates O 
is O 
observed O 
during O 
ageing O 
, O 
in O 
response O 
to O 
heat O 
shock O 
and O 
upon O 
expression O 
of O 
the O 
highly O 
aggregation O 
- O 
prone O 
polyglutamine B-FAMILY 
-expansion O 
proteins O 
and O 
Aβ O 
- O 
peptide O 
. O 
These O 
results O 
demonstrate O 
that O 
NAC O 
has O 
a O 
central O 
role O 
as O 
a O 
proteostasis O 
sensor O 
to O 
provide O 
the O 
cell O 
with O 
a O 
regulatory O 
feedback O 
mechanism O 
in O 
which O 
translational O 
activity O 
is O 
also O 
controlled O 
by O 
the O 
folding O 
state O 
of O 
the O 
cellular O 
proteome O 
and O 
the O 
cellular O 
response O 
to O 
stress O 
. O 

Aim O 
: O 
In O 
order O 
to O 
avoid O 
gastric O 
irritation O 
caused O 
by O 
tolmetin B-SYSTEMATIC 
sodium I-SYSTEMATIC 
( O 
TS O 
) O 
, O 
gastro O 
resistant O 
Eudragit B-TRIVIAL 
® O 
S O 
100 O 
microsphere O 
formulations O 
were O 
prepared O 
with O 
the O 
emulsion O 
/ O 
solvent O 
diffusion O 
method O 
. O 
Materials O 
: O 
Considering O 
the O 
high O 
water O 
solubility O 
of O 
the O 
TS O 
molecule O 
, O 
the O 
effects O 
of O 
the O 
presence O 
of O 
inorganic O 
salt O 
( O 
NaCl B-FORMULA 
, O 
NaBr B-FORMULA 
and O 
KH2PO4 B-FORMULA 
; O 
0.1 O 
M O 
and O 
1 O 
M O 
) O 
in O 
external O 
phase O 
and O 
external O 
phase O 
pH O 
on O 
the O 
encapsulation O 
efficiency O 
were O 
evaluated O 
. O 
Results O 
: O 
Percentage O 
yield O 
value O 
was O 
found O 
to O 
vary O 
between O 
55.8% O 
and O 
72.1% O 
. O 
Improvement O 
in O 
encapsulation O 
efficiency O 
was O 
determined O 
by O 
increasing O 
concentrations O 
of O 
NaCl B-FORMULA 
, O 
NaBr B-FORMULA 
and O 
KH2PO4 B-FORMULA 
. O 
The O 
microspheres O 
were O 
observed O 
to O 
have O 
a O 
spherical O 
shape O 
and O 
the O 
measured O 
particle O 
size O 
values O 
varied O 
between O 
52.1 O 
and O 
81.5 O 
µm O 
. O 
The O 
released O 
amounts O 
of O 
the O 
drug O 
were O 
found O 
to O 
be O 
low O 
as O 
the O 
inorganic O 
salt O 
concentrations O 
increased O 
. O 
Conclusion O 
: O 
Conclusively O 
, O 
drug O 
release O 
in O 
stomach O 
pH O 
was O 
significantly O 
prevented O 
by O 
the O 
microspheres O 
prepared O 
using O 
Eudragit B-TRIVIAL 
® O 
S O 
100 O 
polymer O 
, O 
and O 
these O 
formulations O 
are O 
considered O 
to O 
be O 
a O 
model O 
for O 
other O 
orally O 
administered O 
drugs O 
with O 
similar O 
problems O 
. O 

Multilayer O 
Microcapsules O 
for O 
pH- O 
/ O 
Thermally O 
Responsive O 
Drug O 
Delivery O 
using O 
Aliphatic B-FAMILY 
Poly(urethane-amine) I-FAMILY 
as O 
Smart O 
Component O 
. O 

multilayer O 
microcapsules O 
made O 
of O 
aliphatic B-FAMILY 
poly(urethane-amine) I-FAMILY 
( O 
PUA B-ABBREVIATION 
) O 
and O 
sodium B-FAMILY 
poly(styrene I-FAMILY 
sulfonate I-FAMILY 
) I-FAMILY 
( O 
PSS B-ABBREVIATION 
) O 
, O 
templated O 
on O 
PSS B-ABBREVIATION 
-doped O 
CaCO3 B-FORMULA 
particles O 
, O 
are O 
prepared O 
for O 
pH- O 
/ O 
thermally O 
responsive O 
drug O 
delivery O 
. O 
The O 
electrostatic O 
interaction O 
and O 
hydrogen B-SYSTEMATIC 
bonding O 
under O 
weak O 
- O 
acid O 
conditions O 
between O 
aliphatic O 
PUA B-ABBREVIATION 
and O 
PSS B-ABBREVIATION 
contribute O 
to O 
the O 
formation O 
of O 
multilayer O 
microcapsules O 
. O 
Scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
results O 
demonstrate O 
an O 
obvious O 
variation O 
of O 
the O 
hollow O 
multilayer O 
microcapsules O 
in O 
response O 
to O 
changes O 
in O 
temperature O 
and O 
pH O 
value O 
. O 
Drug O 
- O 
release O 
behaviors O 
using O 
DOX B-ABBREVIATION 
as O 
a O 
model O 
drug O 
demonstrate O 
that O 
the O 
drug O 
release O 
increases O 
on O 
decreasing O 
the O 
pH O 
value O 
because O 
of O 
the O 
interaction O 
weakness O 
between O 
aliphatic O 
PUA B-ABBREVIATION 
and O 
PSS B-ABBREVIATION 
in O 
acidic O 
conditions O 
. O 
Moreover O 
, O 
the O 
drug O 
release O 
is O 
higher O 
at O 
55 O 
°C O 
than O 
that O 
at O 
37 O 
°C O 
for O 
the O 
sake O 
of O 
the O 
shrinkage O 
of O 
aliphatic O 
PUA B-ABBREVIATION 
above O 
its O 
lower O 
critical O 
solution O 
temperature O 
( O 
LCST O 
) O 
. O 

treatment O 
with O 
progesterone B-TRIVIAL 
and O 
vitamin B-FAMILY 
D I-FAMILY 
hormone O 
is O 
more O 
effective O 
than O 
monotherapy O 
in O 
ischemic O 
stroke O 
: O 
The O 
role O 
of O 
BDNF O 
/ O 
TrkB O 
/ O 
Erk1 O 
/ O 
2 O 
signaling O 
in O 
neuroprotection O 
. O 

investigated O 
whether O 
combinatorial O 
post O 
- O 
injury O 
treatment O 
with O 
progesterone B-TRIVIAL 
( O 
P4 O 
) O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
hormone O 
( O 
VDH O 
) O 
would O 
reduce O 
ischemic O 
injury O 
more O 
effectively O 
than O 
P4 O 
alone O 
in O 
an O 
oxygen B-SYSTEMATIC 
glucose B-TRIVIAL 
deprivation O 
( O 
OGD O 
) O 
model O 
in O 
primary O 
cortical O 
neurons O 
and O 
in O 
a O 
transient O 
middle O 
cerebral O 
artery O 
occlusion O 
( O 
tMCAO O 
) O 
model O 
in O 
rats O 
. O 
In O 
the O 
OGD O 
model O 
, O 
P4 O 
and O 
VDH O 
each O 
showed O 
neuroprotection O 
individually O 
, O 
but O 
combination O 
of O 
the O 
" O 
best O 
" O 
doses O 
did O 
not O 
show O 
substantial O 
efficacy O 
; O 
instead O 
, O 
the O 
lower O 
dose O 
of O 
VDH O 
in O 
combination O 
with O 
P4 O 
was O 
the O 
most O 
effective O 
. O 
In O 
the O 
tMCAO O 
model O 
, O 
P4 O 
and O 
VDH O 
were O 
given O 
alone O 
or O 
in O 
combination O 
at O 
different O 
times O 
post O 
- O 
occlusion O 
for O 
7 O 
days O 
. O 
In O 
vivo O 
data O 
confirmed O 
the O 
in O 
vitro O 
findings O 
and O 
showed O 
better O 
infarct O 
reduction O 
at O 
day O 
7 O 
and O 
functional O 
outcomes O 
( O 
at O 
3 O 
, O 
5 O 
and O 
7 O 
days O 
post O 
- O 
occlusion O 
) O 
after O 
combinatorial O 
treatment O 
than O 
when O 
either O 
agent O 
was O 
given O 
alone O 
. O 
VDH O 
, O 
but O 
not O 
P4 O 
, O 
upregulated O 
heme B-FAMILY 
oxygenase-1 O 
, O 
suggesting O 
a O 
pathway O 
for O 
the O 
neuroprotective O 
effects O 
of O 
VDH O 
differing O 
from O 
that O 
of O 
P4 O 
. O 
The O 
combination O 
of O 
P4 O 
and O 
VDH O 
activated O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
and O 
its O 
specific O 
receptor O 
, O 
tyrosine B-TRIVIAL 
kinase O 
receptor-B O 
. O 
Under O 
specific O 
conditions O 
VDH O 
potentiates O 
P4's O 
neuroprotective O 
efficacy O 
and O 
should O 
be O 
considered O 
as O 
a O 
potential O 
partner O 
of O 
P4 O 
in O 
a O 
low O 
- O 
cost O 
, O 
safe O 
and O 
effective O 
combinatorial O 
treatment O 
for O 
stroke O 
. O 

- O 
quality O 
core O 
/ O 
shell O 
CdSe B-FORMULA 
/ O 
CdS B-FORMULA 
colloidal O 
nanocrystals O 
are O 
demonstrated O 
to O 
be O 
efficient O 
sources O 
of O 
non-classical O 
light O 
. O 
As O 
shown O 
by O 
Ferruccio O 
Pisanello O 
and O 
co O 
- O 
workers O 
on O 
page O 
1974 O 
, O 
the O 
intrinsic O 
anisotropy O 
of O 
these O 
nanoparticles O 
allows O 
an O 
independent O 
tuning O 
of O 
shell O 
length O 
and O 
thickness O 
, O 
resulting O 
in O 
a O 
full O 
control O 
of O 
photon O 
statistics O 
. O 
This O 
can O 
be O 
exploited O 
to O 
obtain O 
non-blinking O 
, O 
room O 
- O 
temperature O 
single O 
- O 
photon O 
generation O 
, O 
thus O 
bringing O 
colloidal O 
nanocrystals O 
one O 
step O 
closer O 
to O 
non-classical O 
light O 
sources O 
for O 
quantum O 
applications O 
. O 

is O 
a O 
large O 
family O 
of O 
shrubs O 
commonly O 
distributed O 
in O 
the O 
Mediterranean O 
ecosystem O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
explore O 
the O 
potential O 
antimicrobial O 
properties O 
against O 
Escherichia O 
coli O 
and O 
/ O 
or O 
Staphylococcus O 
aureus O 
of O 
different O 
extracts O 
obtained O 
from O 
four O 
Cistaceae O 
species O 
that O 
are O 
especially O 
abundant O 
in O 
Spanish O 
semi-arid O 
regions O 
. O 
MIC50 O 
values O 
of O 
the O 
extracts O 
of O 
C O 
. O 
salviifolius O 
exhibited O 
potent O 
bacteriostatic O 
effects O 
against O 
S O 
. O 
aureus O 
compared O 
with O 
the O 
other O 
Cistus O 
species O 
tested O 
. O 
Spray O 
- O 
drying O 
had O 
less O 
impact O 
on O 
the O 
antimicrobial O 
activities O 
and O 
polyphenolic B-FAMILY 
contents O 
than O 
did O 
evaporation O 
followed O 
by O 
freeze O 
- O 
drying O 
. O 
When O 
C O 
. O 
salviifolius O 
extract O 
was O 
concentrated O 
and O 
the O 
polar O 
fraction O 
was O 
removed O 
, O 
its O 
bacteriostatic O 
and O 
bactericidal O 
activities O 
against O 
both O 
strains O 
were O 
significantly O 
enhanced O 
. O 
Seasonal O 
influences O 
on O 
the O 
composition O 
have O 
also O 
been O 
found O 
. O 
Up O 
to O 
48 O 
compounds O 
were O 
found O 
in O 
the O 
aqueous O 
extract O 
of O 
C O 
. O 
salviifolius O 
using O 
RRLC-ESI-TOF-MS O 
. O 
The O 
analysis O 
of O 
the O 
composition O 
of O 
the O 
extracts O 
revealed O 
that O 
the O 
inhibitory O 
activity O 
against O 
E O 
. O 
coli O 
may O 
be O 
related O 
to O 
the O 
presence O 
of O 
galloylated B-FAMILY 
flavanols I-FAMILY 
and O 
specific O 
flavonols B-FAMILY 
, O 
whereas O 
the O 
inhibitory O 
capacity O 
against O 
S O 
. O 
aureus O 
may O 
be O 
related O 
primarily O 
to O 
polar O 
compounds O 
and O 
to O 
other O 
flavonols B-FAMILY 
. O 
Potential O 
synergistic O 
effects O 
among O 
polyphenols B-FAMILY 
may O 
deserve O 
further O 
studies O 
. O 
These O 
extracts O 
may O 
serve O 
as O 
an O 
alternative O 
source O 
of O 
antimicrobial O 
ingredients O 
focused O 
on O 
medical O 
devices O 
or O 
cosmetics O 
. O 

compounds O 
modulate O 
extracellular O 
redox O 
by O 
induction O 
of O 
extracellular O 
cysteine B-TRIVIAL 
and O 
cell O 
surface O 
thioredoxin O 
reductase O 
. O 

effect O 
of O 
selenium B-SYSTEMATIC 
compounds O 
on O 
extracellular O 
redox O 
modulating O 
capacity O 
was O 
studied O 
in O 
murine O 
macrophage O 
RAW O 
264.7 O 
cells O 
and O 
differentiated O 
human O 
THP-1 O 
monocytes O 
. O 
The O 
arylselenium B-FAMILY 
compounds O 
benzeneselenol B-SYSTEMATIC 
( O 
PhSeH B-FORMULA 
) O 
, O 
dibenzyl B-SYSTEMATIC 
diselenide I-SYSTEMATIC 
( O 
DBDSe B-FORMULA 
) O 
, O 
diphenyl B-SYSTEMATIC 
diselenide I-SYSTEMATIC 
( O 
DPDSe B-FORMULA 
) O 
, O 
and O 
ebselen B-TRIVIAL 
were O 
capable O 
of O 
inducing O 
extracellular O 
cysteine B-TRIVIAL 
accumulation O 
via O 
a O 
cystine B-TRIVIAL 
- O 
and O 
glucose B-TRIVIAL 
-dependent O 
process O 
. O 
Extracellular O 
cysteine B-TRIVIAL 
production O 
was O 
dose O 
- O 
dependently O 
inhibited O 
by O 
glutamate B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
cystine B-TRIVIAL 
/ O 
glutamate B-TRIVIAL 
antiporter O 
( O 
Xc(-) O 
transporter O 
) O 
, O 
supporting O 
the O 
involvement O 
of O 
Xc(-) O 
transporter O 
for O 
cystine B-TRIVIAL 
uptake O 
in O 
the O 
above O 
process O 
. O 
These O 
arylselenium B-FAMILY 
compounds O 
also O 
induced O 
cellular O 
thioredoxin O 
reductase O 
( O 
TrxR O 
) O 
expression O 
, O 
particularly O 
at O 
the O 
exofacial O 
surface O 
of O 
cells O 
. O 
TrxR1 O 
knockdown O 
using O 
small O 
interfering O 
RNA O 
attenuated O 
TrxR O 
increases O 
and O 
cysteine B-TRIVIAL 
efflux O 
induced O 
in O 
cells O 
by O 
DPDSe B-FORMULA 
. O 
Sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
( O 
Na2SeO3 B-FORMULA 
) O 
, O 
selenomethionine B-SYSTEMATIC 
( O 
SeMet B-FORMULA 
) O 
, O 
seleno-l-cystine B-SYSTEMATIC 
( O 
SeCySS B-FORMULA 
) O 
, O 
and O 
Se-methylselenocysteine B-SYSTEMATIC 
( O 
MeSeCys B-FORMULA 
) O 
did O 
not O 
have O 
these O 
effects O 
on O 
macrophages O 
under O 
the O 
same O 
treatment O 
conditions O 
. O 
The O 
effects O 
of O 
organoselenium B-FAMILY 
compounds O 
on O 
extracellular O 
redox O 
may O 
contribute O 
to O 
the O 
known O 
, O 
but O 
inadequately O 
understood O 
, O 
biological O 
effects O 
of O 
selenium B-SYSTEMATIC 
compounds O 
. O 

benzimidazole B-SYSTEMATIC 
containing O 
inhibitors O 
of O 
respiratory O 
syncytial O 
virus O 
. O 

non- O 
benzimidazole B-SYSTEMATIC 
containing O 
inhibitors O 
of O 
respiratory O 
syncytial O 
virus O 
are O 
described O 
. O 
Core O 
template O 
modification O 
, O 
analysis O 
of O 
antiviral O 
activity O 
, O 
physicochemistry O 
and O 
optimisation O 
of O 
properties O 
led O 
to O 
the O 
thiazole B-SYSTEMATIC 
- O 
imidazole B-SYSTEMATIC 
13 O 
, O 
that O 
showed O 
a O 
good O 
potency O 
and O 
pharmacokinetic O 
profile O 
in O 
the O 
rat O 
. O 

of O 
new O 
N-(arylcyclopropyl)acetamides B-FAMILY 
and O 
N-(arylvinyl)acetamides B-FAMILY 
as O 
conformationally O 
- O 
restricted O 
ligands O 
for O 
melatonin B-TRIVIAL 
receptors O 
. O 

and O 
N-(arylvinyl)acetamides B-FAMILY 
or O 
methyl B-FAMILY 
ureas I-FAMILY 
have O 
been O 
prepared O 
as O 
constrained O 
analogues O 
of O 
melatonin B-TRIVIAL 
. O 
The O 
affinity O 
of O 
these O 
new O 
compounds O 
for O 
chicken O 
brain O 
melatonin B-TRIVIAL 
receptors O 
and O 
recombinant O 
human O 
MT(1) O 
and O 
MT(2) O 
receptors O 
was O 
evaluated O 
using O 
2-[(125)I]-iodomelatonin B-SYSTEMATIC 
as O 
radioligand O 
. O 
Strict O 
ethylenic B-SYSTEMATIC 
or O 
cyclopropyl B-SYSTEMATIC 
analogues O 
of O 
the O 
commercialized O 
agonist O 
agomelatine B-TRIVIAL 
( O 
Valdoxan B-TRIVIAL 
® O 
) O 
were O 
equipotent O 
to O 
agomelatine B-TRIVIAL 
in O 
binding O 
bioassays O 
. O 
However O 
, O 
the O 
ethylenic B-SYSTEMATIC 
analogue O 
was O 
more O 
effective O 
than O 
the O 
cyclopropyl B-SYSTEMATIC 
one O 
in O 
the O 
melanophore O 
aggregation O 
bioassay O 
, O 
but O 
was O 
still O 
less O 
potent O 
than O 
the O 
disubstituted O 
2,7-dimethoxy-naphtalenic B-SYSTEMATIC 
compounds O 
. O 

roseus O 
is O 
an O 
important O 
dicotyledonous O 
medicinal O 
plant O 
that O 
produces O 
anticancer O 
compounds O 
. O 
The O 
active O 
alkaloids O 
vinblastine B-TRIVIAL 
, O 
vindoline B-TRIVIAL 
, O 
ajmalicine B-TRIVIAL 
, O 
catharanthine B-TRIVIAL 
, O 
and O 
vinleurosine B-TRIVIAL 
were O 
identified O 
by O 
direct O 
- O 
injection O 
ion O 
trap O 
- O 
mass O 
spectrometry O 
( O 
IT-MS O 
) O 
for O 
collecting O 
MS(1-2) O 
spectra O 
. O 
The O 
determinations O 
of O 
five O 
alkaloids O 
were O 
accomplished O 
by O 
liquid O 
chromatography O 
( O 
LC O 
) O 
with O 
UV O 
and O 
MS O 
detections O 
. O 
The O 
analytes O 
provided O 
good O 
signals O 
corresponding O 
to O 
the O 
protonated O 
molecular O 
ions O 
[M+H](+) O 
and O 
product O 
ions O 
. O 
The O 
precursor O 
ions O 
and O 
product O 
ions O 
for O 
quantification O 
of O 
vinblastine B-TRIVIAL 
, O 
vindoline B-TRIVIAL 
, O 
ajmalicine B-TRIVIAL 
, O 
catharanthine B-TRIVIAL 
, O 
and O 
vinleurosine B-TRIVIAL 
were O 
m O 
/ O 
z O 
825→807 O 
, O 
457→397 O 
, O 
353→144 O 
, O 
337→144 O 
and O 
809→748 O 
by O 
LC-IT-MS O 
, O 
respectively O 
. O 
Two O 
methods O 
were O 
used O 
to O 
evaluate O 
a O 
number O 
of O 
validation O 
characteristics O 
( O 
repeatability O 
, O 
LOD O 
, O 
calibration O 
range O 
, O 
and O 
recovery O 
) O 
. O 
MS O 
provided O 
a O 
high O 
selectivity O 
and O 
sensitivity O 
for O 
determination O 
of O 
five O 
alkaloids O 
in O 
positive O 
mode O 
. O 
After O 
optimisation O 
of O 
the O 
methods O 
, O 
separation O 
, O 
identification O 
and O 
quantification O 
of O 
the O 
five O 
components O 
in O 
C O 
. O 
roseus O 
were O 
comprehensively O 
accomplished O 
by O 
HPLC O 
with O 
UV O 
and O 
MS O 
detection O 
. O 

RELEVANCE O 
: O 
The O 
bark O 
of O 
Tecomella O 
undulata O 
is O 
traditionally O 
claimed O 
in O 
the O 
treatment O 
of O 
various O 
disease O 
ailments O 
including O 
obesity O 
and O 
cancer O 
. O 
Till O 
now O 
there O 
are O 
no O 
studies O 
about O 
anti O 
obesity O 
activity O 
of O 
Tecomella O 
undulata O 
bark O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
The O 
present O 
study O 
was O 
aimed O 
to O 
establish O 
a O 
scientific O 
evidence O 
for O 
anti O 
obesity O 
efficiency O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
Tecomella O 
undulata O 
bark O 
( O 
EATUB O 
) O 
. O 
Further O 
to O 
standardize O 
the O 
active O 
fractions O 
of O 
EATUB O 
using O 
different O 
biomarkers O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
We O 
investigated O 
activity O 
of O 
EATUB O 
fractions O 
( O 
F1-F7 O 
) O 
using O 
3T3-L1 O 
fibroblasts O 
. O 
Further O 
, O 
F1 O 
- O 
mediated O 
effects O 
were O 
characterized O 
by O 
determining O 
mRNA O 
and O 
protein O 
levels O 
of O 
SIRT1 O 
, O 
one O 
of O 
the O 
key O 
targets O 
for O 
the O 
treatment O 
of O 
obesity O 
, O 
using O 
semi O 
quantitative O 
RT-PCR O 
( O 
sqRT-PCR O 
) O 
and O 
western O 
blot O 
analysis O 
. O 
The O 
consequences O 
of O 
modulation O 
of O 
SIRT1 O 
on O 
mRNA O 
and O 
protein O 
levels O 
of O 
various O 
adipogenesis O 
mediators O 
like O 
PPARγ O 
, O 
C O 
/ O 
EBPα O 
, O 
E2F1 O 
, O 
leptin O 
, O 
adiponectin O 
and O 
LPL O 
were O 
also O 
studied O 
. O 
In-vivo O 
studies O 
were O 
performed O 
using O 
High O 
Fat O 
Diet O 
( O 
HFD O 
) O 
obese O 
mice O 
. O 
RESULTS O 
: O 
Our O 
data O 
showed O 
that O 
compared O 
to O 
controls O 
, O 
preadipocytes O 
and O 
adipocytes O 
incubated O 
with O 
F1 O 
exhibited O 
a O 
significant O 
decrease O 
in O 
adipogenesis O 
and O 
lipogenesis O 
. O 
In O 
addition O 
, O 
sqRT-PCR O 
and O 
western O 
blot O 
analysis O 
showed O 
significant O 
increase O 
in O 
SIRT1 O 
and O 
adiponectin O 
levels O 
and O 
decrease O 
in O 
PPARγ O 
, O 
C O 
/ O 
EBPα O 
, O 
E2F1 O 
, O 
leptin O 
and O 
LPL O 
levels O 
in O 
preadipocytes O 
and O 
adipocytes O 
. O 
In-vivo O 
studies O 
of O 
F1 O 
in O 
HFD O 
induced O 
obese O 
mice O 
showed O 
significant O 
improvement O 
in O 
lipid O 
profile O 
and O 
glucose B-TRIVIAL 
levels O 
. O 
The O 
bioactive O 
fraction O 
( O 
F1 O 
) O 
was O 
determined O 
to O 
possess O 
4.95% O 
of O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
. O 
CONCLUSION O 
: O 
Thus O 
, O 
our O 
findings O 
signified O 
the O 
beneficial O 
effects O 
of O 
Tecomella O 
undulata O 
bark O 
in O 
pharmacologic O 
interventions O 
related O 
to O 
obesity O 
and O 
metabolic O 
disorders O 
. O 
Ferulic B-TRIVIAL 
acid I-TRIVIAL 
and O 
rutin B-TRIVIAL 
are O 
being O 
reported O 
and O 
quantified O 
for O 
the O 
first O 
time O 
from O 
the O 
bark O 
of O 
Tecomella O 
undulata O 
. O 

of O 
Diosmetin B-FAMILY 
Glycosides I-FAMILY 
Isolated O 
from O 
the O 
Epicarp O 
of O 
Date O 
Fruits O 
, O 
Phoenix O 
dactylifera O 
, O 
on O 
the O 
Biochemical O 
Profile O 
of O 
Alloxan B-TRIVIAL 
Diabetic O 
Male O 
Rats O 
. O 

new O 
natural O 
flavonoid B-FAMILY 
compounds O 
- O 
diosmetin B-SYSTEMATIC 
7-O-β-L-arabinofuranosyl I-SYSTEMATIC 
( I-SYSTEMATIC 
1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2 I-SYSTEMATIC 
) I-SYSTEMATIC 
β-D-apiofuranoside I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
diosmetin B-SYSTEMATIC 
7-O-β-D-apiofuranoside I-SYSTEMATIC 
( O 
2 O 
) O 
- O 
were O 
isolated O 
from O 
the O 
acetone B-SYSTEMATIC 
extract O 
of O 
date O 
fruits O 
epicarp O 
belonging O 
to O 
family O 
Arecaceae O 
( O 
Palmae O 
) O 
. O 
Elucidation O 
of O 
their O 
chemical O 
structures O 
was O 
determined O 
by O 
different O 
spectroscopic O 
methods O 
in O 
addition O 
to O 
the O 
chemical O 
and O 
physical O 
methods O 
of O 
analysis O 
. O 
These O 
compounds O 
were O 
assessed O 
for O 
their O 
biological O 
activity O 
on O 
alloxan B-TRIVIAL 
diabetic O 
rats O 
. O 
A O 
dose O 
of O 
1.5 O 
ml O 
of O 
( O 
1 O 
) O 
and O 
( O 
2 O 
) O 
suspensions O 
/ O 
100 O 
gm O 
b O 
. O 
wt O 
were O 
orally O 
administrated O 
to O 
alloxan B-TRIVIAL 
diabetic O 
rats O 
for O 
30 O 
days O 
. O 
The O 
treatment O 
of O 
diabetic O 
rats O 
with O 
these O 
compounds O 
resulted O 
in O 
marked O 
improvement O 
of O 
the O 
different O 
biochemical O 
results O 
, O 
i.e O 
. O 
the O 
serum O 
glucose B-TRIVIAL 
level O 
( O 
highly O 
significant O 
, O 
from O 
330 O 
+ O 
5.5 O 
mg O 
/ O 
dL O 
to O 
140 O 
+ O 
1.2 O 
mg O 
/ O 
dL O 
) O 
treated O 
with O 
( O 
1 O 
) O 
; O 
liver O 
functions O 
markedly O 
developed O 
both O 
by O 
AST O 
and O 
ALT O 
levels O 
, O 
( O 
reduced O 
significantly O 
from O 
68.3 O 
+ O 
4.8 O 
μ O 
/ O 
L O 
to O 
54 O 
+ O 
5.5 O 
μ O 
/ O 
L O 
and O 
from O 
61 O 
+ O 
3.6 O 
μ O 
/ O 
L O 
to O 
40.1 O 
+ O 
3.6 O 
μ O 
/ O 
L O 
, O 
respectively O 
) O 
treated O 
with O 
( O 
2 O 
) O 
, O 
accompanying O 
with O 
mild O 
decrease O 
in O 
both O 
cholesterol B-TRIVIAL 
and O 
triglycerides B-FAMILY 
levels O 
with O 
( O 
1 O 
) O 
or O 
( O 
2 O 
) O 
. O 
Decrease O 
of O 
TBARS O 
level O 
was O 
observed O 
in O 
whole O 
blood O 
when O 
treated O 
with O 
( O 
1 O 
) O 
or O 
( O 
2 O 
) O 
, O 
while O 
levels O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
superoxide B-TRIVIAL 
dismutase O 
were O 
increased O 
in O 
liver O 
. O 
Serum O 
testosterone B-TRIVIAL 
level O 
was O 
highly O 
significantly O 
increased O 
( O 
from O 
705.1 O 
+ O 
3.6 O 
mg O 
/ O 
100 O 
ml O 
to O 
720 O 
+ O 
4.7 O 
mg O 
/ O 
100 O 
ml O 
) O 
, O 
total O 
acid O 
phosphatase O 
and O 
prostate O 
acid O 
phosphatase O 
activities O 
were O 
highly O 
significantly O 
decreased O 
( O 
from O 
16.9 O 
+ O 
0.28 O 
μ O 
/ O 
L O 
to O 
10.7 O 
+ O 
1.2 O 
μ O 
/ O 
L O 
and O 
from O 
9.7 O 
+ O 
0.7 O 
μ O 
/ O 
L O 
to O 
6.5 O 
+ O 
1 O 
μ O 
/ O 
L O 
, O 
respectively O 
) O 
for O 
compound O 
( O 
1 O 
) O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

35kD O 
Phyllanthus O 
niruri O 
protein O 
modulates O 
iron B-SYSTEMATIC 
mediated O 
oxidative O 
impairment O 
to O 
hepatocytes O 
via O 
the O 
inhibition O 
of O 
ERKs O 
, O 
p38 O 
MAPKs O 
and O 
activation O 
of O 
PI3k O 
/ O 
Akt O 
pathway O 
. O 

has O 
been O 
reported O 
that O 
the O 
herb O 
, O 
Phyllanthus O 
niruri O 
, O 
possess O 
antioxidant O 
, O 
anti-infection O 
, O 
anti-asthmatic O 
, O 
anti-diuretic O 
, O 
anti-soresis O 
and O 
many O 
more O 
beneficial O 
activities O 
. O 
The O 
goal O 
of O 
our O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
protective O 
role O 
of O 
a O 
35kD O 
protein O 
( O 
PNP O 
) O 
isolated O 
from O 
this O 
herb O 
against O 
iron B-SYSTEMATIC 
-induced O 
cytotoxicity O 
in O 
murine O 
hepatocytes O 
. O 
Exposure O 
of O 
hepatocytes O 
to O 
iron B-SYSTEMATIC 
( O 
FeSO4 B-FORMULA 
) O 
caused O 
elevation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
, O 
enhanced O 
lipid O 
peroxidation O 
and O 
protein O 
carbonylation O 
, O 
depleted O 
glutathione B-TRIVIAL 
levels O 
, O 
decreased O 
the O 
antioxidant O 
power O 
( O 
FRAP O 
) O 
of O 
the O 
cells O 
and O 
reduced O 
cell O 
viability O 
. O 
Iron B-SYSTEMATIC 
mediated O 
cytotoxicity O 
disrupted O 
mitochondrial O 
membrane O 
potential O 
( O 
Δψm O 
) O 
and O 
thereby O 
caused O 
apoptosis O 
mainly O 
by O 
the O 
intrinsic O 
pathway O 
via O 
the O 
down O 
- O 
regulation O 
of O 
IκBα O 
with O 
a O 
concomitant O 
up O 
- O 
regulation O 
of O 
NF-kB O 
as O 
well O 
as O 
the O 
phosphorylation O 
of O 
ERKs O 
and O 
p38 O 
MAP O 
kinases O 
. O 
In O 
addition O 
, O 
iron B-SYSTEMATIC 
-induced O 
cytotoxicity O 
disrupted O 
the O 
normal O 
balance O 
of O 
Bcl-2 O 
family O 
proteins O 
in O 
hepatocytes O 
. O 
Incubation O 
of O 
hepatocytes O 
with O 
PNP O 
, O 
however O 
, O 
protected O 
the O 
cells O 
from O 
apoptosis O 
by O 
stabilizing O 
the O 
mitochondria O 
and O 
arresting O 
the O 
release O 
of O 
cytochrome O 
c O 
. O 
It O 
also O 
suppressed O 
caspase O 
activation O 
and O 
cleavage O 
of O 
PARP O 
. O 
Moreover O 
, O 
this O 
protein O 
has O 
strong O 
free O 
radical O 
scavenging O 
activity O 
and O 
thereby O 
scavenged O 
ROS O 
extensively O 
. O 
Combining O 
all O 
, O 
results O 
suggest O 
that O 
simultaneous O 
treatment O 
with O 
PNP O 
might O 
suppress O 
the O 
iron B-SYSTEMATIC 
-induced O 
cytotoxicity O 
in O 
hepatocytes O 
. O 

effects O 
of O 
naringin B-TRIVIAL 
against O 
paraquat B-TRIVIAL 
-induced O 
acute O 
lung O 
injury O 
and O 
pulmonary O 
fibrosis O 
in O 
mice O 
. O 

present O 
study O 
evaluates O 
protective O 
effects O 
of O 
naringin B-TRIVIAL 
against O 
paraquat B-TRIVIAL 
(PQ)-induced O 
acute O 
lung O 
injury O 
( O 
ALI O 
) O 
and O 
pulmonary O 
fibrosis O 
in O 
mice O 
. O 
Survival O 
probability O 
against O 
PQ O 
intoxication O 
was O 
tested O 
by O 
a O 
single O 
intraperitoneal O 
injection O 
of O 
PQ O 
. O 
Results O 
showed O 
that O 
survival O 
rates O 
of O 
mice O 
exposed O 
to O 
PQ O 
only O 
( O 
50mg O 
/ O 
kg O 
within O 
7days O 
) O 
were O 
much O 
lower O 
than O 
that O 
in O 
mice O 
daily O 
treatment O 
with O 
NAC B-ABBREVIATION 
or O 
naringin B-TRIVIAL 
. O 
Moreover O 
, O 
protection O 
against O 
PQ-induced O 
ALI O 
was O 
tested O 
by O 
daily O 
pretreatment O 
mice O 
with O 
saline O 
, O 
NAC B-ABBREVIATION 
or O 
naringin B-TRIVIAL 
for O 
3days O 
before O 
PQ O 
( O 
30mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
. O 
Results O 
showed O 
that O 
increase O 
in O 
leukocytes O 
infiltration O 
and O 
overexpressions O 
of O 
TNF-α O 
and O 
TGF-β1 O 
caused O 
by O 
8h O 
of O 
PQ O 
exposure O 
were O 
dose O 
- O 
dependently O 
ameliorated O 
by O 
naringin B-TRIVIAL 
. O 
Furthermore O 
, O 
protection O 
against O 
PQ-induced O 
pulmonary O 
fibrosis O 
was O 
tested O 
by O 
pretreatment O 
mice O 
with O 
PQ O 
( O 
20mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
, O 
and O 
then O 
daily O 
administration O 
with O 
saline O 
, O 
nan B-ABBREVIATION 
C O 
or O 
naringi B-TRIVIAL 
n O 
for O 
prolonged O 
21days O 
. O 
Results O 
showed O 
that O 
naringi B-TRIVIAL 
n O 
of O 
60 O 
and O 
120mg O 
/ O 
kg O 
significantly O 
reduced O 
PQ-induced O 
upregulations O 
of O 
TNF-α O 
, O 
TGF-β1 O 
, O 
MMP-9 O 
and O 
TIMP-1 O 
, O 
levels O 
of O 
pulmonary O 
malonaldehyd B-TRIVIAL 
e O 
and O 
hydroxyprolin B-SYSTEMATIC 
e O 
, O 
as O 
well O 
as O 
pulmonary O 
fibrosis O 
deposition O 
, O 
while O 
increased O 
activities O 
of O 
SOD O 
, O 
GS B-ABBREVIATION 
H-Px O 
and O 
HO-1 O 
. O 
These O 
results O 
indicated O 
that O 
naringi B-TRIVIAL 
n O 
had O 
effective O 
protection O 
against O 
PQ-induced O 
ALI O 
and O 
pulmonary O 
fibrosis O 
. O 

new O 
multifunctional O 
terpolymeric O 
system O 
for O 
simultaneous O 
imaging O 
and O 
drug O 
delivery O 
has O 
been O 
recently O 
developed O 
in O 
our O 
laboratory O 
. O 
Herein O 
we O 
report O 
the O 
investigation O 
of O 
terpolymeric O 
contrast O 
agent O 
for O 
magnetic O 
resonance O 
imaging O 
and O 
doxorubicin B-TRIVIAL 
( O 
Dox B-ABBREVIATION 
) O 
delivery O 
. O 
The O 
polymer O 
was O 
synthesized O 
by O 
graft O 
polymerization O 
of O 
methacrylic B-TRIVIAL 
acid I-TRIVIAL 
( O 
MAA B-ABBREVIATION 
) O 
and O 
polysorbate B-TRIVIAL 
80 I-TRIVIAL 
( O 
PS B-ABBREVIATION 
80 I-ABBREVIATION 
) O 
onto O 
starch O 
with O 
multiple O 
, O 
chemically O 
bound O 
diethylenetriaminepenta B-SYSTEMATIC 
acetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DTPA B-ABBREVIATION 
) O 
groups O 
for O 
gadolinium B-SYSTEMATIC 
chelating O 
. O 
The O 
terpolymer O 
self O 
- O 
assembled O 
to O 
form O 
nanoparticles O 
upon O 
addition O 
of O 
doxorubicin B-TRIVIAL 
which O 
binds O 
with O 
the O 
PMAA B-ABBREVIATION 
chain O 
. O 
The O 
physicochemical O 
, O 
biological O 
and O 
pharmacokinetic O 
properties O 
of O 
the O 
polymeric O 
system O 
were O 
characterized O 
and O 
their O 
contrast O 
enhancement O 
capability O 
was O 
evaluated O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
polymer O 
was O 
able O 
to O 
load O 
gadolinium B-SYSTEMATIC 
with O 
high O 
thermodynamic O 
stability O 
and O 
exhibited O 
low O 
cytotoxicity O 
. O 
The O 
Gd B-FORMULA 
-loaded O 
polymer O 
( O 
PolyGd B-SYSTEMATIC 
) O 
, O 
and O 
Gd B-FORMULA 
- O 
Dox B-ABBREVIATION 
co O 
- O 
loaded O 
nanoparticles O 
( O 
PolyGd-Dox B-SYSTEMATIC 
) O 
significantly O 
enhanced O 
MR O 
signals O 
, O 
with O 
ionic O 
T1 O 
relaxivities O 
3-5 O 
times O 
higher O 
than O 
those O 
from O 
Omniscan B-TRIVIAL 
® O 
, O 
a O 
small O 
molecule O 
contrast O 
agent O 
. O 
In O 
vivo O 
studies O 
showed O 
superior O 
and O 
prolonged O 
contrast O 
enhancement O 
compared O 
to O 
Omniscan B-TRIVIAL 
® O 
at O 
one O 
fourth O 
the O 
equivalent O 
dose O 
, O 
without O 
adverse O 
effects O 
. O 
The O 
PolyGd O 
and O 
PolyGd- O 
Dox B-ABBREVIATION 
accumulated O 
in O 
the O 
tumor O 
and O 
painted O 
the O 
tumor O 
boundaries O 
clearly O 
for O 
at O 
least O 
48h O 
. O 
The O 
PolyGd O 
also O 
enhanced O 
angiogram O 
contrast O 
with O 
contrast O 
to O 
noise O 
ratio O 
values O 
of O 
up O 
to O 
55-fold O 
and O 
a O 
blood O 
half O 
- O 
life O 
time O 
of O 
200min O 
. O 
Seven O 
days O 
after O 
intravenous O 
administration O 
, O 
only O 
relatively O 
small O 
amounts O 
of O 
gadolinium B-SYSTEMATIC 
could O 
be O 
detected O 
in O 
the O 
major O 
organs O 
of O 
the O 
mice O 
( O 
supplementary O 
materials O 
) O 
. O 
These O 
results O 
suggest O 
that O 
the O 
new O 
terpolymeric O 
system O 
is O 
useful O 
as O 
a O 
theranostic O 
platform O 
for O 
contrast O 
enhanced O 
MR O 
imaging O 
of O 
vasculature O 
and O 
tumor O 
as O 
well O 
as O 
Dox B-ABBREVIATION 
delivery O 
. O 

many O 
bacteria O 
, O 
a O 
homodimer O 
of O 
structural O 
- O 
maintenance O 
- O 
of O 
- O 
chromosomes O 
proteins O 
associates O 
with O 
two O 
regulatory O 
subunits O 
( O 
known O 
as O 
ScpA O 
and O 
ScpB O 
) O 
, O 
assembling O 
a O 
protein O 
complex O 
that O 
plays O 
a O 
crucial O 
role O 
in O 
chromosome O 
organization O 
and O 
segregation O 
. O 
It O 
remains O 
poorly O 
understood O 
, O 
however O 
, O 
how O 
this O 
complex O 
might O 
work O 
at O 
the O 
mechanistic O 
level O 
. O 
Here O 
, O 
we O 
report O 
crystal O 
structures O 
of O 
the O 
ScpAB O 
core O 
complex O 
that O 
display O 
a O 
highly O 
unusual O 
structure O 
in O 
which O 
the O 
central O 
segment O 
of O 
ScpA O 
winds O 
around O 
an O 
asymmetrically O 
oriented O 
ScpB O 
dimer O 
. O 
The O 
two O 
C B-FORMULA 
-terminal O 
domains O 
of O 
the O 
ScpB O 
dimer O 
primarily O 
interact O 
with O 
different O 
regions O 
of O 
ScpA O 
with O 
different O 
affinities O 
. O 
Moreover O 
, O 
flexible O 
interdomain O 
regions O 
of O 
ScpB O 
contribute O 
to O 
a O 
dynamic O 
folding O 
process O 
of O 
the O 
ScpAB O 
subcomplex O 
. O 
Together O 
with O 
other O 
genetic O 
and O 
biochemical O 
assays O 
, O 
we O 
provide O 
evidence O 
that O 
internal O 
structural O 
changes O 
of O 
the O 
ScpAB O 
subcomplex O 
are O 
tightly O 
coupled O 
with O 
activation O 
of O 
the O 
structural O 
- O 
maintenance O 
- O 
of O 
- O 
chromosomes O 
ATPase O 
. O 

deficit O 
is O 
a O 
core O 
of O 
schizophrenia O 
and O 
it O 
is O 
not O 
effectively O 
treated O 
by O 
the O 
available O 
antipsychotic O 
drugs O 
, O 
hence O 
new O 
and O 
more O 
effective O 
therapy O 
is O 
needed O 
. O 
Schizophrenia O 
is O 
considered O 
as O 
a O 
pathway O 
disorder O 
where O 
Disrupted-In-Schizophrenia-1 O 
( O 
DISC1 O 
) O 
is O 
important O 
molecular O 
player O 
that O 
regulates O 
multiple O 
cellular O 
cascades O 
. O 
We O 
recently O 
reported O 
synergistic O 
action O 
between O 
phosphodiesterase-4 O 
( O 
PDE4 O 
) O 
and O 
glycogen O 
synthase O 
kinase-3 O 
( O 
GSK-3 O 
) O 
as O 
DISC1 O 
interacting O 
proteins O 
. O 
In O 
the O 
current O 
study O 
we O 
characterized O 
behavioural O 
effects O 
of O 
a O 
newly O 
developed O 
compound O 
, O 
VP1.15 O 
that O 
inhibits O 
both O 
PDE7 O 
and O 
GSK-3 O 
with O 
main O 
focus O 
on O 
its O 
antipsychotic O 
and O 
cognitive O 
capacities O 
. O 
VP1.15 O 
reduced O 
ambulation O 
in O 
C57BL O 
/ O 
6J O 
mice O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
( O 
7.5 O 
mg O 
/ O 
kg O 
and O 
3 O 
mg O 
/ O 
kg O 
, O 
respectively O 
) O 
and O 
, O 
hence O 
, O 
lower O 
dose O 
was O 
chosen O 
for O 
the O 
further O 
analysis O 
. O 
VP1.1.5 O 
facilitated O 
pre O 
- O 
pulse O 
inhibition O 
( O 
PPI O 
) O 
, O 
reversed O 
amphetamine B-TRIVIAL 
- O 
but O 
not O 
MK-801 B-IDENTIFIER 
-induced O 
PPI O 
deficit O 
. O 
The O 
drug O 
was O 
able O 
to O 
ameliorate O 
the O 
disrupted O 
latent O 
inhibition O 
( O 
LI O 
) O 
induced O 
by O 
the O 
increased O 
number O 
of O 
conditioning O 
trials O 
and O 
reversed O 
amphetamine B-TRIVIAL 
-induced O 
LI O 
deficit O 
, O 
supporting O 
further O 
its O 
antipsychotic O 
effects O 
. O 
The O 
drug O 
also O 
significantly O 
improved O 
episodic O 
memory O 
in O 
the O 
spatial O 
object O 
recognition O 
test O 
, O 
facilitated O 
working O 
memory O 
in O 
Y-maze O 
and O 
enhanced O 
cued O 
fear O 
memory O 
, O 
but O 
had O 
no O 
effect O 
on O 
executive O 
function O 
in O 
the O 
Puzzle O 
box O 
and O 
contextual O 
fear O 
conditioning O 
. O 
Taken O 
together O 
, O 
VP1.15 O 
elicited O 
antipsychotic O 
effects O 
and O 
also O 
facilitated O 
cognitive O 
domains O 
in O 
mice O 
, O 
suggesting O 
that O 
multitarget O 
drugs O 
, O 
affecting O 
molecular O 
substrates O 
from O 
the O 
same O 
pathway O 
, O 
perhaps O 
could O 
be O 
antipsychotics O 
of O 
new O 
- O 
generation O 
that O 
open O 
a O 
new O 
possibilities O 
in O 
drug O 
discoveries O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

of O 
a O 
selective O 
M₄ O 
positive O 
allosteric O 
modulator O 
based O 
on O 
the O 
3-amino-thieno[2,3-b]pyridine-2-carboxamide B-SYSTEMATIC 
scaffold O 
: O 
development O 
of O 
ML253 B-IDENTIFIER 
, O 
a O 
potent O 
and O 
brain O 
penetrant O 
compound O 
that O 
is O 
active O 
in O 
a O 
preclinical O 
model O 
of O 
schizophrenia O 
. O 

we O 
report O 
a O 
next O 
generation O 
muscarinic O 
receptor O 
4 O 
(M(4)) O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
, O 
ML253 B-IDENTIFIER 
which O 
exhibits O 
nanomolar O 
activity O 
at O 
both O 
the O 
human O 
( O 
EC(50)=56 O 
nM O 
) O 
and O 
rat O 
( O 
EC(50)=176 O 
nM O 
) O 
receptors O 
and O 
excellent O 
efficacy O 
by O 
the O 
left O 
- O 
ward O 
shift O 
of O 
the O 
ACh B-ABBREVIATION 
concentration O 
response O 
curve O 
( O 
fold O 
shift O 
, O 
human=106 O 
; O 
rat=50 O 
) O 
. O 
In O 
addition O 
, O 
ML253 B-IDENTIFIER 
is O 
selective O 
against O 
the O 
four O 
other O 
muscarinic O 
subtypes O 
, O 
displays O 
excellent O 
CNS O 
exposure O 
and O 
is O 
active O 
in O 
an O 
amphetamine B-TRIVIAL 
-induced O 
hyperlocomotion O 
assay O 
. O 

, O 
exposure O 
to O 
drugs O 
of O 
abuse O 
results O 
in O 
∼1 O 
million O 
emergency O 
department O 
visits O 
in O 
the O 
US O 
. O 
In O 
∼50% O 
of O 
the O 
visits O 
, O 
stimulant O 
drugs O 
like O 
cocaine B-TRIVIAL 
and O 
amphetamine B-TRIVIAL 
-like O 
substances O 
( O 
e.g O 
. O 
3,4-methylenedioxymethamphetamine B-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
, O 
the O 
main O 
active O 
ingredient O 
of O 
ecstasy B-TRIVIAL 
) O 
) O 
are O 
involved O 
, O 
whereas O 
in O 
∼60% O 
multiple O 
drugs O 
are O 
involved O 
. O 
These O 
drugs O 
induce O 
higher O 
dopamine B-TRIVIAL 
and O 
serotonin B-TRIVIAL 
levels O 
resulting O 
in O 
drug O 
- O 
induced O 
toxicity O 
. O 
Since O 
GABA B-ABBREVIATION 
receptors O 
( O 
GABA B-ABBREVIATION 
-R O 
) O 
provide O 
the O 
main O 
inhibitory O 
input O 
on O 
dopaminergic O 
and O 
serotonergic O 
neurons O 
, O 
drug O 
- O 
induced O 
inhibition O 
of O 
GABA B-ABBREVIATION 
-R O 
could O 
contribute O 
to O 
higher O 
neurotransmitter O 
levels O 
and O 
thus O 
toxicity O 
. O 
We O 
therefore O 
investigated O 
the O 
effects O 
of O 
combinations O 
of O 
commonly O 
abused O 
stimulant O 
drugs O 
( O 
cocaine B-TRIVIAL 
, O 
MDMA B-ABBREVIATION 
, O 
3,4-methylenedioxyamphetamine B-SYSTEMATIC 
( O 
MDA B-ABBREVIATION 
) O 
and O 
meta-chlorophenylpiperazine B-SYSTEMATIC 
( O 
mCPP B-ABBREVIATION 
) O 
) O 
on O 
the O 
function O 
of O 
the O 
human O 
α1β2γ2 O 
GABAA O 
receptor O 
( O 
hGABAA-R O 
) O 
, O 
expressed O 
in O 
Xenopus O 
oocytes O 
, O 
using O 
the O 
two O 
- O 
electrode O 
voltage O 
- O 
clamp O 
technique O 
. O 
These O 
drugs O 
concentration O 
- O 
dependently O 
inhibited O 
the O 
GABA B-ABBREVIATION 
-evoked O 
current O 
( O 
mCPP B-ABBREVIATION 
> O 
cocaine B-TRIVIAL 
> O 
MDMA B-ABBREVIATION 
> O 
MDA B-ABBREVIATION 
) O 
. O 
Most O 
drug O 
combinations O 
decreased O 
the O 
GABA B-ABBREVIATION 
-evoked O 
current O 
stronger O 
than O 
the O 
single O 
drug O 
. O 
Additivity O 
was O 
observed O 
during O 
combined O 
exposure O 
to O 
low O 
concentrations O 
of O 
cocaine B-TRIVIAL 
and O 
mCPP B-ABBREVIATION 
as O 
well O 
as O 
during O 
combined O 
exposure O 
to O 
MDA B-ABBREVIATION 
with O 
cocaine B-TRIVIAL 
or O 
mCPP B-ABBREVIATION 
. O 
However O 
, O 
combinations O 
containing O 
MDMA B-ABBREVIATION 
mainly O 
resulted O 
in O 
sub O 
- O 
additivity O 
or O 
no O 
additivity O 
. O 
At O 
drug O 
concentrations O 
relevant O 
for O 
clinical O 
toxicology O 
, O 
co O 
- O 
exposure O 
to O 
≥ O 
2 O 
drugs O 
can O 
decrease O 
the O 
GABA B-ABBREVIATION 
-evoked O 
current O 
in O 
an O 
additive O 
manner O 
. O 
Thus O 
, O 
in O 
patients O 
exposed O 
to O 
multiple O 
drugs O 
, O 
inhibitory O 
GABA B-ABBREVIATION 
-ergic O 
input O 
is O 
reduced O 
more O 
prominently O 
, O 
likely O 
resulting O 
in O 
higher O 
brain O 
dopamine B-TRIVIAL 
levels O 
. O 
As O 
this O 
will O 
increase O 
the O 
risk O 
for O 
drug O 
- O 
induced O 
toxicity O 
, O 
treatment O 
of O 
drug O 
- O 
intoxicated O 
patients O 
with O 
drugs O 
that O 
enhance O 
GABA B-ABBREVIATION 
-ergic O 
input O 
should O 
be O 
further O 
optimized O 
. O 

metabolite O 
profiling O 
approach O 
was O 
used O 
to O 
study O 
the O 
effect O 
of O 
moderate O 
- O 
intensity O 
pulsed O 
electric O 
field O 
( O 
MIPEF O 
) O 
treatments O 
on O 
the O 
individual O 
polyphenol B-FAMILY 
and O 
carotenoid O 
contents O 
of O 
tomato O 
fruit O 
after O 
refrigeration O 
at O 
4°C O 
for O 
24h O 
. O 
The O 
MIPEF O 
processing O 
variables O 
studied O 
were O 
electric O 
field O 
strength O 
( O 
from O 
0.4 O 
to O 
2.0kV O 
/ O 
cm O 
) O 
and O 
number O 
of O 
pulses O 
( O 
from O 
5 O 
to O 
30 O 
) O 
. O 
Twenty O 
four O 
hours O 
after O 
MIPEF O 
treatments O 
, O 
an O 
increase O 
was O 
observed O 
in O 
hydroxycinnamic B-FAMILY 
acids I-FAMILY 
and O 
flavanones B-FAMILY 
, O 
whereas O 
flavonols B-FAMILY 
, O 
coumaric B-MULTIPLE 
and I-MULTIPLE 
ferulic I-MULTIPLE 
acid-O-glucoside I-MULTIPLE 
were O 
not O 
affected O 
. O 
Major O 
changes O 
were O 
also O 
observed O 
for O 
carotenoids O 
, O 
except O 
for O 
the O 
5-cis-lycopene B-SYSTEMATIC 
isomer O 
, O 
which O 
remain O 
unchanged O 
after O 
24h O 
of O 
MIPEF O 
treatments O 
. O 
MIPEF O 
treatments O 
, O 
conducted O 
at O 
1.2kV O 
/ O 
cm O 
and O 
30 O 
pulses O 
, O 
led O 
to O 
the O 
greatest O 
increases O 
in O 
chlorogenic O 
( O 
152% O 
) O 
, O 
caffeic B-SYSTEMATIC 
acid-O-glucoside I-SYSTEMATIC 
( O 
170% O 
) O 
and O 
caffeic B-FAMILY 
( O 
140% O 
) O 
acids O 
. O 
On O 
the O 
other O 
hand O 
, O 
treatments O 
at O 
1.2kV O 
/ O 
cm O 
and O 
5 O 
pulses O 
led O 
to O 
maximum O 
increases O 
of O 
α-carotene B-TRIVIAL 
, O 
9- B-MULTIPLE 
and I-MULTIPLE 
13-cis-lycopene I-MULTIPLE 
, O 
which O 
increased O 
by O 
93% O 
, O 
94% O 
and O 
140% O 
, O 
respectively O 
. O 
Therefore O 
, O 
MIPEF O 
could O 
stimulate O 
synthesis O 
of O 
secondary O 
metabolites O 
and O 
contribute O 
to O 
production O 
of O 
tomatoes O 
with O 
high O 
individual O 
polyphenol B-FAMILY 
and O 
carotenoid O 
contents O 
. O 

- O 
of O 
- O 
function O 
mutations O 
in O 
the O 
canonical O 
transient O 
receptor O 
potential O 
6 O 
( O 
TRPC6 O 
) O 
gene O 
are O 
a O 
cause O 
of O 
autosomal O 
dominant O 
focal O 
segmental O 
glomerulosclerosis O 
( O 
FSGS4 O 
) O 
. O 
The O 
mechanisms O 
whereby O 
abnormal O 
TRPC6 O 
activity O 
results O 
in O 
proteinuria O 
remain O 
unknown O 
. O 
The O 
Erk1 O 
/ O 
2 O 
MAP O 
kinases O 
are O 
activated O 
in O 
glomeruli O 
and O 
podocytes O 
in O 
several O 
proteinuric O 
disease O 
models O 
. O 
We O 
therefore O 
examined O 
whether O 
FSGS-associated O 
mutations O 
in O 
TRPC6 O 
result O 
in O 
activation O 
of O 
these O 
kinases O 
. O 
In O 
293T O 
cells O 
and O 
cultured O 
podocytes O 
, O 
overexpression O 
of O 
gain O 
- O 
of O 
- O 
function O 
TRPC6 O 
mutants O 
resulted O 
in O 
increased O 
Erk1 O 
/ O 
2 O 
phosphorylation O 
, O 
an O 
effect O 
dependent O 
upon O 
channel O 
function O 
. O 
Pharmacologic O 
inhibitor O 
studies O 
implicated O 
several O 
signaling O 
mediators O 
, O 
including O 
calmodulin O 
and O 
calcineurin O 
, O 
supporting O 
the O 
importance O 
of O 
TRPC6 O 
- O 
mediated O 
calcium B-SYSTEMATIC 
influx O 
in O 
this O 
process O 
. O 
Through O 
media O 
transfer O 
experiments O 
, O 
we O 
uncovered O 
two O 
distinct O 
mechanisms O 
for O 
Erk O 
activation O 
by O 
mutant O 
TRPC6 O 
, O 
a O 
cell O 
autonomous O 
, O 
EGFR O 
- O 
independent O 
mechanism O 
and O 
a O 
cell O 
non-autonomous O 
mechanism O 
involving O 
metalloprotease O 
- O 
mediated O 
release O 
of O 
a O 
presumed O 
EGFR O 
ligand O 
. O 
The O 
inhibitors O 
KN-92 B-IDENTIFIER 
and O 
H89 B-IDENTIFIER 
were O 
able O 
to O 
block O 
both O 
pathways O 
in O 
mutant O 
TRPC6 O 
expressing O 
cells O 
, O 
as O 
well O 
as O 
the O 
prolonged O 
elevation O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
levels O 
upon O 
carbachol B-TRIVIAL 
stimulation O 
seen O 
in O 
these O 
cells O 
. O 
However O 
, O 
these O 
effects O 
appear O 
independent O 
of O 
their O 
effects O 
on O 
CaMKII O 
and O 
PKA O 
, O 
respectively O 
. O 
Phosphorylation O 
of O 
T70 O 
, O 
S282 O 
and O 
Y31 O 
/ O 
Y285 O 
were O 
not O 
necessary O 
for O 
Erk O 
activation O 
by O 
mutant O 
TRPC6 O 
, O 
though O 
a O 
phosphomimetic O 
TRPC6 O 
S282E O 
mutant O 
was O 
capable O 
of O 
Erk O 
activation O 
. O 
Taken O 
together O 
, O 
these O 
results O 
identify O 
two O 
pathways O 
downstream O 
of O 
mutant O 
TRPC6 O 
leading O 
to O 
Erk O 
activation O 
that O 
may O 
play O 
a O 
role O 
in O 
the O 
development O 
of O 
FSGS O 
. O 

N-halamine B-FAMILY 
polymers I-FAMILY 
and O 
coatings O 
: O 
a O 
review O 
of O 
their O 
synthesis O 
, O 
characterization O 
, O 
and O 
applications O 
. O 

N-halamine B-FAMILY 
polymers I-FAMILY 
and O 
coatings O 
have O 
been O 
studied O 
extensively O 
over O 
the O 
past O 
decade O 
thanks O 
to O 
their O 
numerous O 
qualities O 
such O 
as O 
effectiveness O 
toward O 
a O 
broad O 
spectrum O 
of O 
microorganisms O 
, O 
long O 
- O 
term O 
stability O 
, O 
regenerability O 
, O 
safety O 
to O 
humans O 
and O 
environment O 
and O 
low O 
cost O 
. O 
In O 
this O 
review O 
, O 
recent O 
developments O 
are O 
described O 
by O 
emphasizing O 
the O 
synthesis O 
of O 
polymers O 
and O 
/ O 
or O 
coatings O 
having O 
N-halamine B-FAMILY 
moieties O 
. O 
Actually O 
, O 
three O 
main O 
approaches O 
of O 
preparation O 
are O 
given O 
in O 
detail O 
: O 
polymerization O 
, O 
generation O 
by O 
electrochemical O 
route O 
with O 
proteins O 
as O 
monomers O 
and O 
grafting O 
with O 
precursor O 
monomers O 
. O 
Identification O 
and O 
characterization O 
of O 
the O 
formation O 
of O 
the O 
N-halamine B-FAMILY 
bonds O 
( O 
> O 
N B-FORMULA 
-X O 
with O 
X O 
= O 
Cl B-FORMULA 
or O 
Br B-FORMULA 
or O 
I B-FORMULA 
) O 
by O 
physical O 
techniques O 
such O 
as O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FTIR O 
) O 
, O 
nuclear O 
magnetic O 
resonance O 
spectroscopy O 
( O 
NMR O 
) O 
, O 
energy O 
- O 
dispersive O 
X-ray O 
spectroscopy O 
( O 
EDX O 
) O 
, O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
, O 
and O 
by O 
chemical O 
reactions O 
are O 
described O 
. O 
In O 
order O 
to O 
check O 
the O 
antimicrobial O 
activity O 
of O 
the O 
N-halamine B-FAMILY 
compounds O 
, O 
bacterial O 
tests O 
are O 
also O 
described O 
. O 
Finally O 
, O 
some O 
examples O 
of O 
application O 
of O 
these O 
N-halamines B-FAMILY 
in O 
the O 
water O 
treatment O 
, O 
paints O 
, O 
healthcare O 
equipment O 
, O 
and O 
textile O 
industries O 
are O 
presented O 
and O 
discussed O 
. O 

( O 
Prunus O 
domestica O 
L O 
. O 
) O 
are O 
a O 
good O 
source O 
of O 
yeasts O 
producing O 
organic O 
acids O 
of O 
industrial O 
interest O 
from O 
glycerol B-TRIVIAL 
. O 

production O 
of O 
organic O 
acids O 
from O 
several O 
yeasts O 
isolated O 
from O 
mature O 
plums O 
on O 
media O 
containing O 
glycerol B-TRIVIAL 
as O 
carbon B-SYSTEMATIC 
source O 
was O 
analysed O 
by O 
HPLC-UV O 
. O 
The O 
yeasts O 
isolated O 
were O 
identified O 
by O 
sequencing O 
the O 
5.8S O 
internal O 
transcribed O 
spacer O 
as O 
Pichia O 
fermentans O 
, O 
Wickerhamomyces O 
anomalus O 
and O 
Candida O 
oleophila O 
. O 
The O 
organic O 
acid O 
profiles O 
of O 
these O 
strains O 
comprise O 
acetic B-MULTIPLE 
, I-MULTIPLE 
citric I-MULTIPLE 
, I-MULTIPLE 
succinic I-MULTIPLE 
and I-MULTIPLE 
malic I-MULTIPLE 
acids I-MULTIPLE 
that O 
qualitatively O 
and O 
quantitatively O 
vary O 
between O 
different O 
species O 
as O 
well O 
as O 
among O 
strains O 
from O 
the O 
same O 
species O 
. O 
The O 
production O 
from O 
glycerol B-TRIVIAL 
of O 
succinic B-MULTIPLE 
, I-MULTIPLE 
acetic I-MULTIPLE 
, I-MULTIPLE 
citric I-MULTIPLE 
, I-MULTIPLE 
malic I-MULTIPLE 
and I-MULTIPLE 
oxalic I-MULTIPLE 
acids I-MULTIPLE 
from O 
C O 
. O 
oleophila O 
and O 
W O 
. O 
anomalus O 
, O 
and O 
that O 
of O 
succinic B-MULTIPLE 
, I-MULTIPLE 
oxalic I-MULTIPLE 
and I-MULTIPLE 
acetic I-MULTIPLE 
acids I-MULTIPLE 
by O 
P O 
. O 
fermentans O 
is O 
reported O 
for O 
the O 
first O 
time O 
in O 
this O 
work O 
, O 
as O 
is O 
the O 
production O 
of O 
oxalic B-TRIVIAL 
acid I-TRIVIAL 
from O 
glycerol B-TRIVIAL 
in O 
yeasts O 
. O 
Our O 
results O 
also O 
showed O 
that O 
mature O 
fruits O 
can O 
be O 
a O 
good O 
source O 
of O 
new O 
yeasts O 
able O 
to O 
metabolise O 
glycerol B-TRIVIAL 
, O 
producing O 
different O 
organic O 
acids O 
with O 
industrial O 
and O 
biotechnological O 
interest O 
. O 

chemistry O 
offers O 
an O 
assortment O 
of O 
synthetic O 
tools O 
for O 
tuning O 
the O 
shape O 
of O 
semiconductor O 
nanocrystals O 
. O 
While O 
many O 
nanocrystal O 
architectures O 
can O 
be O 
obtained O 
directly O 
via O 
colloidal O 
growth O 
, O 
other O 
nanoparticle O 
morphologies O 
require O 
alternative O 
processing O 
strategies O 
. O 
Here O 
, O 
we O 
show O 
that O 
chemical O 
etching O 
of O 
colloidal O 
nanoparticles O 
can O 
facilitate O 
the O 
realization O 
of O 
nanocrystal O 
shapes O 
that O 
are O 
topologically O 
inaccessible O 
by O 
hot O 
- O 
injection O 
techniques O 
alone O 
. O 
The O 
present O 
methodology O 
is O 
demonstrated O 
by O 
synthesizing O 
a O 
two O 
- O 
component O 
CdSe B-FORMULA 
/ O 
CdS B-FORMULA 
nanoparticle O 
dimer O 
, O 
constructed O 
in O 
a O 
way O 
that O 
both O 
CdSe B-FORMULA 
and O 
CdS B-FORMULA 
semiconductor O 
domains O 
are O 
exposed O 
to O 
the O 
external O 
environment O 
. O 
This O 
structural O 
morphology O 
is O 
highly O 
desirable O 
for O 
catalytic O 
applications O 
as O 
it O 
enables O 
both O 
reductive O 
and O 
oxidative O 
reactions O 
to O 
occur O 
simultaneously O 
on O 
dissimilar O 
nanoparticle O 
surfaces O 
. O 
Hydrogen B-SYSTEMATIC 
production O 
tests O 
confirmed O 
the O 
improved O 
catalytic O 
activity O 
of O 
CdSe B-FORMULA 
/ O 
CdS B-FORMULA 
dimers O 
, O 
which O 
was O 
enhanced O 
3-4 O 
times O 
upon O 
etching O 
treatment O 
. O 
We O 
expect O 
that O 
the O 
demonstrated O 
application O 
of O 
etching O 
to O 
shaping O 
of O 
colloidal O 
heteronanocrystals O 
can O 
become O 
a O 
common O 
methodology O 
in O 
the O 
synthesis O 
of O 
charge O 
- O 
separating O 
nanocrystals O 
, O 
leading O 
to O 
advanced O 
nanoparticles O 
architectures O 
for O 
applications O 
in O 
areas O 
of O 
photocatalysis O 
, O 
photovoltaics O 
, O 
and O 
light O 
detection O 
. O 

forms O 
populating O 
the O 
Earth O 
must O 
face O 
environmental O 
challenges O 
to O 
assure O 
individual O 
and O 
species O 
survival O 
. O 
The O 
strategies O 
predisposed O 
to O 
maintain O 
organismal O 
homeostasis O 
and O 
grant O 
selective O 
advantage O 
rely O 
on O 
anticipatory O 
phenomena O 
facing O 
periodic O 
modifications O 
, O 
and O 
compensatory O 
phenomena O 
facing O 
unpredictable O 
changes O 
. O 
Biological O 
processes O 
bringing O 
about O 
these O 
responses O 
are O 
respectively O 
driven O 
by O 
the O 
circadian O 
timing O 
system O 
, O 
a O 
complex O 
of O 
biological O 
oscillators O 
entrained O 
to O 
the O 
environmental O 
light O 
/ O 
dark O 
cycle O 
, O 
and O 
by O 
regulatory O 
and O 
metabolic O 
networks O 
that O 
precisely O 
direct O 
the O 
body's O 
adjustments O 
to O 
variations O 
of O 
external O 
conditions O 
and O 
internal O 
milieu O 
. O 
A O 
critical O 
role O 
in O 
organismal O 
homeostatic O 
functions O 
is O 
played O 
by O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AHR O 
) O 
complex O 
, O 
which O 
senses O 
environmental O 
and O 
endogenous O 
compounds O 
, O 
influences O 
metabolic O 
responses O 
controlling O 
phase O 
I O 
/ O 
II O 
gene O 
expression O 
, O 
and O 
modulates O 
vital O 
phenomena O 
such O 
as O 
development O 
, O 
inflammation O 
and O 
adaptive O 
immunity O 
. O 
A O 
physiological O 
cross O 
- O 
talk O 
between O 
circadian O 
and O 
AHR O 
signaling O 
pathways O 
has O 
been O 
evidenced O 
. O 
The O 
alteration O 
of O 
AHR O 
signaling O 
pathway O 
deriving O 
from O 
genetic O 
damage O 
with O 
polymorphisms O 
or O 
mutations O 
, O 
or O 
produced O 
by O 
exogenous O 
or O 
endogenous O 
AHR O 
activation O 
, O 
and O 
chronodisruption O 
caused O 
by O 
mismatch O 
between O 
the O 
body's O 
internal O 
clock O 
and O 
geophysical O 
time O 
/ O 
social O 
schedules O 
, O 
are O 
capable O 
of O 
triggering O 
pathological O 
mechanisms O 
involved O 
in O 
metabolic O 
, O 
immune O 
- O 
related O 
and O 
neoplastic O 
diseases O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
molecular O 
components O 
of O 
the O 
circadian O 
clock O 
circuitry O 
and O 
AHR O 
signaling O 
pathway O 
may O 
represent O 
useful O 
tools O 
for O 
preventive O 
interventions O 
and O 
valuable O 
targets O 
of O 
therapeutic O 
approaches O 
. O 

atypical O 
antipsychotic O 
risperidone B-TRIVIAL 
reverses O 
the O 
recognition O 
memory O 
deficits O 
induced O 
by O 
post O 
- O 
weaning O 
social O 
isolation O 
in O 
rats O 
. O 

: O 
Rearing O 
rats O 
in O 
isolation O 
from O 
weaning O 
is O 
an O 
established O 
preclinical O 
neurodevelopmental O 
model O 
which O 
induces O 
behavioural O 
deficits O 
with O 
apparent O 
translational O 
relevance O 
to O 
some O 
core O 
symptoms O 
of O 
schizophrenia O 
. O 
OBJECTIVE O 
: O 
This O 
study O 
evaluated O 
the O 
ability O 
of O 
the O 
atypical O 
antipsychotic O 
risperidone B-TRIVIAL 
to O 
reverse O 
behavioural O 
deficits O 
induced O 
by O 
post O 
- O 
weaning O 
social O 
isolation O 
of O 
rat O 
pups O 
and O 
to O 
further O 
characterise O 
the O 
predictive O 
validity O 
of O 
this O 
model O 
. O 
METHOD O 
: O 
Forty O 
- O 
five O 
male O 
Lister O 
hooded O 
rats O 
were O 
housed O 
in O 
groups O 
of O 
3-4 O 
( O 
n O 
= O 
16 O 
) O 
or O 
singly O 
( O 
n O 
= O 
29 O 
) O 
for O 
4 O 
weeks O 
immediately O 
after O 
weaning O 
on O 
postnatal O 
day O 
( O 
PND O 
) O 
22-24 O 
. O 
On O 
PND O 
51 O 
, O 
novel O 
cage O 
- O 
induced O 
locomotor O 
activity O 
( O 
LMA O 
) O 
was O 
assessed O 
to O 
subdivide O 
rats O 
into O 
groups O 
balanced O 
for O 
behavioural O 
response O 
. O 
On O 
PNDs O 
58 O 
, O 
59 O 
, O 
65 O 
and O 
72 O 
, O 
rats O 
received O 
either O 
vehicle O 
( O 
1 O 
ml O 
/ O 
kg O 
; O 
i.p O 
. O 
) O 
or O 
risperidone B-TRIVIAL 
( O 
0.2 O 
or O 
0.5 O 
mg O 
/ O 
kg O 
; O 
i.p O 
. O 
) O 
30 O 
min O 
prior O 
to O 
testing O 
in O 
LMA O 
, O 
novel O 
object O 
discrimination O 
( O 
NOD O 
) O 
, O 
prepulse O 
inhibition O 
( O 
PPI O 
) O 
of O 
acoustic O 
startle O 
and O 
conditioned O 
emotional O 
response O 
( O 
CER O 
) O 
learning O 
paradigms O 
, O 
respectively O 
. O 
RESULTS O 
: O 
Isolation O 
rearing O 
had O 
no O 
effect O 
on O 
PPI O 
, O 
but O 
produced O 
LMA O 
hyperactivity O 
and O 
impaired O 
NOD O 
and O 
CER O 
compared O 
to O 
group O 
- O 
housed O 
controls O 
. O 
Risperidone B-TRIVIAL 
caused O 
a O 
dose O 
- O 
dependent O 
reduction O 
in O 
LMA O 
, O 
irrespective O 
of O 
rearing O 
condition O 
, O 
but O 
selectively O 
reversed O 
the O 
NOD O 
deficit O 
in O 
isolation O 
- O 
reared O 
rats O 
. O 
Risperidone B-TRIVIAL 
did O 
not O 
reverse O 
the O 
isolation O 
rearing O 
- O 
induced O 
CER O 
deficit O 
. O 
CONCLUSIONS O 
: O 
Similar O 
to O 
its O 
clinical O 
profile O 
, O 
risperidone B-TRIVIAL 
only O 
partially O 
reverses O 
the O 
schizophrenic O 
symptomology O 
; O 
since O 
it O 
reversed O 
some O 
, O 
but O 
not O 
all O 
, O 
of O 
the O 
learning O 
and O 
memory O 
deficits O 
induced O 
by O 
post O 
- O 
weaning O 
isolation O 
, O 
the O 
isolation O 
rearing O 
model O 
may O 
be O 
useful O 
to O 
predict O 
antipsychotic O 
activity O 
of O 
novel O 
therapeutic O 
agents O 
. O 

is O 
well O 
established O 
that O 
both O 
estrogen B-FAMILY 
loss O 
and O 
type O 
II O 
diabetes O 
mellitus O 
( O 
DMII O 
) O 
can O 
impair O 
bone O 
metabolism O 
, O 
but O 
whether O 
estrogen B-FAMILY 
loss O 
exacerbates O 
the O 
effects O 
of O 
DMII O 
is O 
unclear O 
. O 
Therefore O 
, O 
we O 
determined O 
if O 
ovariectomy O 
( O 
OVX O 
) O 
of O 
rats O 
on O 
a O 
long O 
- O 
term O 
high-fat/ O 
sugar B-FAMILY 
diet O 
and O 
injection O 
of O 
a O 
low O 
dose O 
of O 
streptozotocin B-TRIVIAL 
( O 
DMII O 
) O 
decreased O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
more O 
than O 
OVX O 
or O 
DMII O 
alone O 
. O 
Bone O 
insulin O 
signaling O 
is O 
known O 
to O 
support O 
bone O 
metabolism O 
; O 
therefore O 
, O 
we O 
also O 
tested O 
the O 
hypothesis O 
that O 
OVX O 
DMII O 
rats O 
( O 
DOVX O 
) O 
would O 
exhibit O 
greater O 
reductions O 
in O 
the O 
expression O 
of O 
proteins O 
important O 
in O 
insulin O 
signaling O 
, O 
including O 
IRS-1 O 
, O 
IRS-2 O 
, O 
and O 
IGF-1 O 
. O 
As O 
hypothesized O 
, O 
BMD O 
and O 
plasma O 
estrogen B-FAMILY 
levels O 
were O 
decreased O 
more O 
in O 
DOVX O 
rats O 
than O 
in O 
rats O 
following O 
OVX O 
( O 
NOVX O 
) O 
or O 
DMII O 
( O 
DS O 
) O 
alone O 
. O 
IGF-1 O 
expression O 
was O 
decreased O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
skeletal O 
muscle O 
, O 
and O 
bone O 
of O 
DOVX O 
, O 
DS O 
, O 
and O 
NOVX O 
rats O 
; O 
however O 
, O 
the O 
decrease O 
was O 
larger O 
and O 
occurred O 
sooner O 
in O 
DOVX O 
rats O 
. O 
While O 
IRS-1 O 
and O 
IRS-2 O 
decreased O 
in O 
most O 
groups O 
in O 
all O 
tissues O 
examined O 
, O 
the O 
expression O 
patterns O 
differed O 
in O 
both O 
a O 
group- O 
and O 
tissue O 
- O 
dependent O 
fashion O 
. O 
In O 
conclusion O 
, O 
these O 
data O 
demonstrate O 
that O 
estrogen B-FAMILY 
loss O 
and O 
DMII O 
induced O 
by O 
a O 
high-fat/ O 
sugar B-FAMILY 
diet O 
interact O 
to O 
produce O 
osteoporosis O 
and O 
support O 
the O 
hypothesis O 
that O 
the O 
bone O 
loss O 
may O 
be O 
mediated O 
at O 
least O 
in O 
part O 
by O 
concurrent O 
decreases O 
in O 
the O 
insulin O 
signaling O 
proteins O 
in O 
bone O 
. O 

of O 
Saccharomyces O 
cerevisiae O 
metabolites O 
in O 
fermenting O 
wheat O 
straight O 
- O 
dough O 
reveals O 
succinic B-TRIVIAL 
acid I-TRIVIAL 
as O 
pH-determining O 
factor O 
. O 

yeast O 
does O 
not O 
merely O 
cause O 
dough O 
leavening O 
, O 
but O 
also O 
contributes O 
to O 
the O 
bread O 
aroma O 
and O 
might O 
alter O 
dough O 
rheology O 
. O 
Here O 
, O 
the O 
yeast O 
carbon B-SYSTEMATIC 
metabolism O 
was O 
mapped O 
during O 
bread O 
straight O 
- O 
dough O 
fermentation O 
. O 
The O 
concentration O 
of O 
most O 
metabolites O 
changed O 
quasi O 
linearly O 
as O 
a O 
function O 
of O 
fermentation O 
time O 
. O 
Ethanol B-SYSTEMATIC 
and O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
concentrations O 
reached O 
up O 
to O 
60 O 
mmol O 
/ O 
100g O 
flour O 
. O 
Interestingly O 
, O 
high O 
levels O 
of O 
glycerol B-TRIVIAL 
( O 
up O 
to O 
10 O 
mmol O 
/ O 
100g O 
flour O 
) O 
and O 
succinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
up O 
to O 
1.6 O 
mmol O 
/ O 
100g O 
flour O 
) O 
were O 
produced O 
during O 
dough O 
fermentation O 
. O 
Further O 
tests O 
showed O 
that O 
, O 
contrary O 
to O 
current O 
belief O 
, O 
the O 
pH O 
decrease O 
in O 
fermenting O 
dough O 
is O 
primarily O 
caused O 
by O 
the O 
production O 
of O 
succinic B-TRIVIAL 
acid I-TRIVIAL 
by O 
the O 
yeast O 
instead O 
of O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
dissolution O 
or O 
bacterial O 
organic O 
acids O 
. O 
Together O 
, O 
our O 
results O 
provide O 
a O 
comprehensive O 
overview O 
of O 
metabolite O 
production O 
during O 
dough O 
fermentation O 
and O 
yield O 
insight O 
into O 
the O 
importance O 
of O 
some O 
of O 
these O 
metabolites O 
for O 
dough O 
properties O 
. O 

donor-acceptor O 
type O 
organic O 
dye O 
connected O 
with O 
a O 
quinoidal B-SYSTEMATIC 
thiophene I-SYSTEMATIC 
for O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

donor-acceptor O 
type O 
organic O 
dye O 
connected O 
with O 
a O 
quinoidal B-SYSTEMATIC 
thiophene I-SYSTEMATIC 
as O 
a O 
π-conjugated O 
chain O 
, O 
cyano-[5'-(4''-(N,N-dimethylamino)benzylidene)-5H-thiophen-2'-ylidene]acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
was O 
synthesized O 
and O 
applied O 
to O 
dye O 
- O 
sensitized O 
solar O 
cells O 
( O 
DSSCs O 
) O 
. O 
The O 
absorption O 
band O 
of O 
this O 
quinoidal B-SYSTEMATIC 
thiophene I-SYSTEMATIC 
dye O 
appeared O 
at O 
longer O 
wavelengths O 
than O 
those O 
of O 
dyes O 
with O 
similar O 
π-conjugation O 
length O 
, O 
indicating O 
the O 
effective O 
π-conjugation O 
through O 
the O 
quinoidal O 
structure O 
. O 
Although O 
the O 
excited O 
state O 
of O 
the O 
quinoidal B-SYSTEMATIC 
thiophene I-SYSTEMATIC 
dye O 
is O 
deactivated O 
within O 
several O 
picoseconds O 
even O 
in O 
solution O 
, O 
the O 
DSSCs O 
using O 
the O 
quinoidal B-SYSTEMATIC 
thiophene I-SYSTEMATIC 
dye O 
showed O 
incident O 
photon O 
to O 
current O 
conversion O 
efficiency O 
( O 
IPCE O 
) O 
values O 
of O 
more O 
than O 
90% O 
, O 
demonstrating O 
the O 
fast O 
and O 
efficient O 
electron O 
injection O 
from O 
the O 
excited O 
dye O 
to O 
TiO(2) B-FORMULA 
. O 
By O 
optimizing O 
the O 
fabrication O 
conditions O 
, O 
the O 
DSSC O 
using O 
this O 
dye O 
afforded O 
a O 
photoelectric O 
conversion O 
efficiency O 
of O 
5.2% O 
, O 
without O 
enlarging O 
the O 
molecular O 
size O 
. O 

of O 
the O 
first O 
synthetic O 
inhibitors O 
of O 
the O 
type O 
II O 
transmembrane O 
serine B-TRIVIAL 
protease O 
TMPRSS2 O 
suitable O 
for O 
inhibition O 
of O 
influenza O 
virus O 
activation O 
. O 

is O 
a O 
multidomain O 
type O 
II O 
transmembrane O 
serine B-TRIVIAL 
protease O 
that O 
cleaves O 
the O 
surface O 
glycoprotein O 
hemagglutinin O 
( O 
HA O 
) O 
of O 
influenza O 
viruses O 
with O 
monobasic O 
cleavage O 
site O 
, O 
which O 
is O 
a O 
prerequisite O 
for O 
virus O 
fusion O 
and O 
propagation O 
. O 
Furthermore O 
, O 
it O 
activates O 
the O 
fusion O 
protein O 
F O 
of O 
the O 
human O 
metapneumovirus O 
and O 
the O 
spike O 
protein O 
S O 
of O 
the O 
SARS O 
coronavirus O 
. O 
Increased O 
TMPRSS2 O 
expression O 
was O 
also O 
described O 
in O 
several O 
tumor O 
entities O 
. O 
Therefore O 
, O 
TMPRSS2 O 
emerged O 
as O 
a O 
potential O 
target O 
for O 
drug O 
design O 
. O 
The O 
catalytic O 
domain O 
of O 
TMPRSS2 O 
was O 
expressed O 
in O 
E O 
. O 
coli O 
and O 
used O 
for O 
an O 
inhibitor O 
screen O 
with O 
previously O 
synthesized O 
inhibitors O 
of O 
various O 
trypsin O 
- O 
like O 
serine B-TRIVIAL 
proteases O 
. O 
Two O 
inhibitor O 
types O 
were O 
identified O 
, O 
which O 
inhibit O 
TMPRSS2 O 
in O 
the O 
nanomolar O 
range O 
. O 
The O 
first O 
series O 
comprises O 
substrate O 
analogue O 
inhibitors O 
containing O 
a O 
4-amidinobenzylamide B-SYSTEMATIC 
moiety O 
in O 
P1 O 
position O 
, O 
whereby O 
some O 
of O 
these O 
analogues O 
possess O 
inhibition O 
constants O 
around O 
20 O 
nM O 
. O 
An O 
improved O 
potency O 
was O 
found O 
for O 
second O 
type O 
derived O 
from O 
sulfonylated B-SYSTEMATIC 
3-amindinophenylalanylamide I-SYSTEMATIC 
derivates O 
. O 
The O 
most O 
potent O 
derivative O 
of O 
this O 
series O 
inhibits O 
TMPRSS2 O 
with O 
a O 
Ki O 
value O 
of O 
0.9 O 
nM O 
and O 
showed O 
an O 
efficient O 
blockage O 
of O 
influenza O 
virus O 
propagation O 
in O 
human O 
airway O 
epithelial O 
cells O 
. O 
Based O 
on O 
the O 
inhibitor O 
studies O 
a O 
series O 
of O 
new O 
fluorogenic O 
substrates O 
containing O 
a O 
d-arginine B-TRIVIAL 
residue O 
in O 
P3 O 
position O 
was O 
synthesized O 
, O 
some O 
of O 
them O 
were O 
efficiently O 
cleaved O 
by O 
TMPRSS2 O 
. O 

of O 
bioactive O 
polyphenols B-FAMILY 
from O 
honey O 
during O 
different O 
extraction O 
methods O 
. O 

LC-MS O 
/ O 
MS O 
technique O 
was O 
applied O 
to O 
the O 
stability O 
study O 
of O 
several O 
flavonoids B-FAMILY 
and O 
phenolic B-FAMILY 
acids I-FAMILY 
in O 
honey O 
samples O 
during O 
the O 
ultrasonic O 
extraction O 
( O 
USE O 
) O 
and O 
microwave O 
- O 
assisted O 
extraction O 
( O 
MAE O 
) O 
. O 
Phenolic B-FAMILY 
compounds O 
from O 
the O 
standard O 
mixture O 
were O 
stable O 
under O 
ultrasounds O 
action O 
with O 
the O 
mean O 
recovery O 
of O 
( O 
90.4%±7.1% O 
) O 
, O 
but O 
during O 
microwave O 
- O 
assisted O 
extraction O 
the O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
and O 
aglycones O 
of O 
flavonoids B-FAMILY 
showed O 
lower O 
recovery O 
( O 
70-80% O 
) O 
. O 
In O 
honey O 
matrix O 
, O 
the O 
phenolic B-FAMILY 
acids I-FAMILY 
and O 
the O 
glycosides O 
exhibited O 
the O 
high O 
stability O 
for O 
MAE O 
and O 
USE O 
treatments O 
. O 
However O 
, O 
the O 
recoveries O 
of O 
tested O 
aglycones O 
were O 
below O 
10% O 
. O 
In O 
the O 
presence O 
of O 
an O 
artificial O 
sugar B-FAMILY 
matrix O 
, O 
flavonols B-FAMILY 
were O 
almost O 
completely O 
degraded O 
after O 
successive O 
treatment O 
under O 
MAE O 
and O 
USE O 
conditions O 
. O 
The O 
obtained O 
results O 
indicated O 
that O 
standard O 
addition O 
method O 
for O 
flavonoids B-FAMILY 
quantification O 
in O 
honey O 
samples O 
should O 
not O 
be O 
recommended O 
. O 
Application O 
of O 
the O 
USE O 
conditions O 
provided O 
higher O 
and O 
/ O 
or O 
similar O 
extraction O 
yields O 
for O 
phenolic B-FAMILY 
acids I-FAMILY 
than O 
usually O 
applied O 
shaking O 
with O 
solvent O 
. O 
It O 
also O 
allowed O 
shortening O 
the O 
time O 
required O 
for O 
the O 
whole O 
sample O 
preparation O 
procedure O 
. O 
Phenolic B-FAMILY 
acids I-FAMILY 
and O 
glycosides O 
such O 
as O 
quercetrin B-TRIVIAL 
, O 
rutin B-TRIVIAL 
and O 
hesperidin B-TRIVIAL 
appeared O 
to O 
be O 
stable O 
under O 
such O 
conditions O 
. O 

mechanism O 
of O 
discrimination O 
between O 
oxidized O 
and O 
reduced O 
coenzyme O 
in O 
the O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
domain O 
of O 
Aldh1l1 O 
. O 

, O 
also O 
known O 
as O 
10- B-SYSTEMATIC 
formyltetrahydrofolate I-SYSTEMATIC 
dehydrogenase O 
( O 
FDH O 
) O 
, O 
contains O 
the O 
carboxy B-SYSTEMATIC 
-terminal O 
domain O 
( O 
Ct-FDH O 
) O 
, O 
which O 
is O 
a O 
structural O 
and O 
functional O 
homolog O 
of O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
( O 
ALDHs O 
) O 
. O 
This O 
domain O 
is O 
capable O 
of O 
catalyzing O 
the O 
NADP(+) B-ABBREVIATION 
-dependent O 
oxidation O 
of O 
short O 
chain O 
aldehydes B-FAMILY 
to O 
their O 
corresponding O 
acids O 
, O 
and O 
similar O 
to O 
most O 
ALDHs O 
it O 
has O 
two O 
conserved O 
catalytic O 
residues O 
, O 
Cys B-FORMULA 
707 O 
and O 
Glu B-FORMULA 
673 O 
. O 
Previously O 
, O 
we O 
demonstrated O 
that O 
in O 
the O 
Ct-FDH O 
mechanism O 
these O 
residues O 
define O 
the O 
conformation O 
of O 
the O 
bound O 
coenzyme O 
and O 
the O 
affinity O 
of O 
its O 
interaction O 
with O 
the O 
protein O 
. O 
Specifically O 
, O 
the O 
replacement O 
of O 
Cys B-FORMULA 
707 O 
with O 
an O 
alanine B-TRIVIAL 
resulted O 
in O 
the O 
enzyme O 
lacking O 
the O 
ability O 
to O 
differentiate O 
between O 
the O 
oxidized O 
and O 
reduced O 
coenzyme O 
. O 
We O 
suggested O 
that O 
this O 
was O 
due O 
to O 
the O 
loss O 
of O 
a O 
covalent O 
bond O 
between O 
the O 
cysteine B-TRIVIAL 
and O 
the O 
C4N O 
atom O 
of O 
nicotinamide B-TRIVIAL 
ring O 
of O 
NADP(+) B-ABBREVIATION 
formed O 
during O 
Ct-FDH O 
catalysis O 
. O 
To O 
obtain O 
further O 
insight O 
into O 
the O 
functional O 
significance O 
of O 
the O 
covalent O 
bond O 
between O 
Cys B-FORMULA 
707 O 
and O 
the O 
coenzyme O 
, O 
and O 
the O 
overall O 
role O 
of O 
the O 
two O 
catalytic O 
residues O 
in O 
the O 
coenzyme O 
binding O 
and O 
positioning O 
, O 
we O 
have O 
now O 
solved O 
crystal O 
structures O 
of O 
Ct-FDH O 
in O 
the O 
complex O 
with O 
thio-NADP(+) B-SYSTEMATIC 
and O 
the O 
complexes O 
of O 
the O 
C707S O 
mutant O 
with O 
NADP(+) B-ABBREVIATION 
and O 
NADPH B-ABBREVIATION 
. O 
This O 
study O 
has O 
allowed O 
us O 
to O 
trap O 
the O 
coenzyme O 
in O 
the O 
contracted O 
conformation O 
, O 
which O 
provided O 
a O 
snapshot O 
of O 
the O 
conformational O 
processing O 
of O 
the O 
coenzyme O 
during O 
the O 
transition O 
from O 
oxidized O 
to O 
reduced O 
form O 
. O 
Overall O 
, O 
the O 
results O 
of O 
this O 
study O 
further O 
support O 
the O 
previously O 
proposed O 
mechanism O 
by O 
which O 
Cys B-FORMULA 
707 O 
helps O 
to O 
differentiate O 
between O 
the O 
oxidized O 
and O 
reduced O 
coenzyme O 
during O 
ALDH O 
catalysis O 
. O 

thermosensitive O 
microspheres O 
: O 
The O 
size O 
of O 
microgels O 
dictates O 
the O 
pulsatile O 
release O 
mechanism O 
. O 

( O 
poly(NIPAAm-co-HEAAm) B-FAMILY 
) O 
was O 
prepared O 
as O 
a O 
new O 
thermosensitive O 
copolymer O 
possessing O 
a O 
sharp O 
phase O 
transition O 
around O 
the O 
human O 
body O 
temperature O 
. O 
The O 
effect O 
of O 
the O 
copolymer O 
concentration O 
on O 
the O 
lower O 
critical O 
solution O 
temperature O 
( O 
LCST O 
) O 
was O 
determined O 
under O 
physiological O 
conditions O 
by O 
cloud O 
point O 
( O 
CP O 
) O 
and O 
differential O 
scanning O 
calorimetric O 
( O 
DSC O 
) O 
methods O 
. O 
Then O 
, O 
thermosensitive O 
microspheres O 
were O 
prepared O 
from O 
preformed O 
copolymers O 
by O 
chemical O 
cross O 
- O 
linking O 
of O 
hydroxyl B-SYSTEMATIC 
groups O 
with O 
glutaraldehyde B-TRIVIAL 
at O 
a O 
temperature O 
situated O 
slightly O 
below O 
LCST O 
of O 
the O 
copolymer O 
solution O 
. O 
The O 
volume O 
phase O 
transition O 
temperature O 
( O 
VPTT O 
) O 
of O 
corresponding O 
cross O 
- O 
linked O 
microspheres O 
was O 
determined O 
from O 
swelling O 
degree O 
- O 
temperature O 
curve O 
. O 
The O 
microspheres O 
were O 
loaded O 
with O 
model O 
drug O 
indomethacin B-TRIVIAL 
by O 
the O 
solvent O 
evaporation O 
method O 
. O 
The O 
DSC O 
analysis O 
proved O 
that O 
the O 
drug O 
is O 
molecularly O 
dispersed O 
in O 
the O 
polymer O 
network O 
. O 
Finally O 
, O 
the O 
influence O 
of O 
the O 
microsphere O 
size O 
on O 
drug O 
release O 
was O 
investigated O 
. O 
It O 
was O 
established O 
that O 
microspheres O 
with O 
the O 
diameter O 
ranging O 
between O 
5 O 
and O 
60μm O 
release O 
the O 
drug O 
with O 
almost O 
the O 
same O 
rate O 
below O 
( O 
in O 
the O 
swollen O 
state O 
) O 
and O 
above O 
the O 
VPTT O 
( O 
in O 
the O 
collapsed O 
state O 
) O 
. O 
On O 
the O 
contrary O 
, O 
microspheres O 
with O 
the O 
diameter O 
ranging O 
between O 
125 O 
and O 
220μm O 
release O 
a O 
significantly O 
higher O 
amount O 
of O 
indomethacin B-TRIVIAL 
below O 
than O 
above O 
the O 
VPTT O 
. O 
This O 
different O 
behavior O 
is O 
enough O 
to O 
assure O 
a O 
pulsatile O 
release O 
mechanism O 
when O 
the O 
temperature O 
changes O 
cyclically O 
below O 
and O 
above O 
the O 
VPTT O 
. O 
However O 
, O 
both O 
small O 
and O 
large O 
microspheres O 
release O 
a O 
large O 
amount O 
of O 
the O 
drug O 
during O 
the O 
collapsing O 
process O 
. O 

of O 
Dietary O 
Factors O 
on O 
the O 
Pharmacokinetics O 
of O 
(58)Fe B-FORMULA 
-labeled O 
Hemin B-TRIVIAL 
After O 
Oral O 
Administration O 
in O 
Normal O 
Rats O 
and O 
the O 
Iron B-SYSTEMATIC 
-deficient O 
Rats O 
. O 

, O 
iron B-SYSTEMATIC 
(III) I-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
chloride I-SYSTEMATIC 
(IX) I-SYSTEMATIC 
, O 
as O 
a O 
stable O 
form O 
of O 
heme B-FAMILY 
iron B-SYSTEMATIC 
, O 
has O 
been O 
used O 
in O 
iron B-SYSTEMATIC 
absorption O 
studies O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
elucidate O 
the O 
influences O 
of O 
body O 
iron B-SYSTEMATIC 
status O 
and O 
three O 
dietary O 
factors O 
( O 
green O 
tea O 
extract O 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
calcium B-SYSTEMATIC 
) O 
on O 
the O 
pharmacokinetics O 
of O 
hemin B-TRIVIAL 
using O 
stable O 
isotope O 
labeling O 
methods O 
followed O 
by O 
ICP-MS O 
measurement O 
. O 
In O 
this O 
study O 
, O 
a O 
rapid O 
, O 
sensitive O 
, O 
and O 
specific O 
ICP-MS O 
method O 
for O 
the O 
determination O 
of O 
(58)Fe B-FORMULA 
originating O 
from O 
hemin B-TRIVIAL 
in O 
rat O 
plasma O 
was O 
developed O 
and O 
a O 
rat O 
model O 
of O 
iron B-SYSTEMATIC 
deficiency O 
anemia O 
was O 
established O 
. O 
It O 
was O 
found O 
that O 
hemin B-TRIVIAL 
iron B-SYSTEMATIC 
absorption O 
increased O 
significantly O 
under O 
iron B-SYSTEMATIC 
deficiency O 
anemia O 
status O 
, O 
with O 
AUC0-t O 
and O 
AUC0-∞ O 
showing O 
significant O 
increase O 
in O 
anemic O 
rats O 
compared O 
to O 
normal O 
ones O 
. O 
Green O 
tea O 
extract O 
strongly O 
inhibited O 
hemin B-TRIVIAL 
iron B-SYSTEMATIC 
absorption O 
in O 
both O 
normal O 
rats O 
and O 
iron B-SYSTEMATIC 
-deficient O 
rats O 
. O 
In O 
normal O 
rats O 
administered O 
with O 
green O 
tea O 
extract O 
, O 
C O 
max O 
resulted O 
significantly O 
reduced O 
, O 
whereas O 
in O 
anemic O 
rats O 
administered O 
with O 
green O 
tea O 
extract O 
both O 
AUC0-t O 
and O 
AUC0-∞ O 
were O 
reduced O 
. O 
On O 
the O 
other O 
hand O 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
significantly O 
affected O 
hemin B-TRIVIAL 
iron B-SYSTEMATIC 
absorption O 
only O 
in O 
iron B-SYSTEMATIC 
-deficient O 
rats O 
, O 
in O 
which O 
C O 
max O 
showed O 
a O 
significant O 
increase O 
. O 
Interestingly O 
, O 
calcium B-SYSTEMATIC 
slowed O 
down O 
the O 
hemin B-TRIVIAL 
iron B-SYSTEMATIC 
absorption O 
rate O 
in O 
normal O 
rats O 
, O 
MRT0-t O 
being O 
significantly O 
different O 
in O 
calcium B-SYSTEMATIC 
-treated O 
animals O 
compared O 
to O 
untreated O 
ones O 
. O 
This O 
trend O 
also O 
appeared O 
in O 
the O 
iron B-SYSTEMATIC 
-deficient O 
group O 
but O 
it O 
did O 
not O 
reach O 
statistical O 
significance O 
. O 
Our O 
data O 
suggest O 
that O 
the O 
mechanism O 
of O 
hemin B-TRIVIAL 
iron B-SYSTEMATIC 
absorption O 
is O 
regulated O 
by O 
body O 
iron B-SYSTEMATIC 
status O 
and O 
dietary O 
factors O 
can O 
influence O 
hemin B-TRIVIAL 
iron B-SYSTEMATIC 
absorption O 
to O 
varying O 
degrees O 
. O 
Moreover O 
, O 
these O 
results O 
may O 
also O 
have O 
general O 
implication O 
in O 
the O 
iron B-SYSTEMATIC 
deficiency O 
treatment O 
with O 
iron B-SYSTEMATIC 
supplements O 
and O 
fortification O 
of O 
foods O 
. O 

of O 
primer O 
- O 
templates O 
by O 
archaeal O 
family-B O 
DNA O 
polymerases O 
in O 
response O 
to O 
template O 
- O 
strand O 
uracil B-TRIVIAL 
. O 

family-B O 
DNA O 
polymerases O 
bind O 
tightly O 
to O 
deaminated O 
bases O 
and O 
stall O 
replication O 
on O 
encountering O 
uracil B-TRIVIAL 
in O 
template O 
strands O 
, O 
four O 
bases O 
ahead O 
of O 
the O 
primer O 
- O 
template O 
junction O 
. O 
Should O 
the O 
polymerase O 
progress O 
further O 
towards O 
the O 
uracil B-TRIVIAL 
, O 
for O 
example O 
, O 
to O 
position O 
uracil B-TRIVIAL 
only O 
two O 
bases O 
in O 
front O 
of O 
the O 
junction O 
, O 
3'-5 O 
' O 
proof O 
- O 
reading O 
exonuclease O 
activity O 
becomes O 
stimulated O 
, O 
trimming O 
the O 
primer O 
and O 
re O 
- O 
setting O 
uracil B-TRIVIAL 
to O 
the O 
4 O 
position O 
. O 
Uracil B-TRIVIAL 
sensing O 
prevents O 
copying O 
of O 
the O 
deaminated O 
base O 
and O 
permanent O 
mutation O 
in O 
50% O 
of O 
the O 
progeny O 
. O 
This O 
publication O 
uses O 
both O 
steady O 
- O 
state O 
and O 
time O 
- O 
resolved O 
2-aminopurine B-SYSTEMATIC 
fluorescence O 
to O 
show O 
pronounced O 
unwinding O 
of O 
primer O 
- O 
templates O 
with O 
Pyrococcus O 
furiosus O 
( O 
Pfu O 
) O 
polymerase-DNA O 
complexes O 
containing O 
uracil B-TRIVIAL 
at O 
2 O 
; O 
much O 
less O 
strand O 
separation O 
is O 
seen O 
with O 
uracil B-TRIVIAL 
at O 
4 O 
. O 
DNA O 
unwinding O 
has O 
long O 
been O 
recognized O 
as O 
necessary O 
for O 
proof O 
- O 
reading O 
exonuclease O 
activity O 
. O 
The O 
roles O 
of O 
M247 O 
and O 
Y261 O 
, O 
amino B-FAMILY 
acids I-FAMILY 
suggested O 
by O 
structural O 
studies O 
to O 
play O 
a O 
role O 
in O 
primer O 
- O 
template O 
unwinding O 
, O 
have O 
been O 
probed O 
. O 
M247 O 
appears O 
to O 
be O 
unimportant O 
, O 
but O 
2-aminopurine B-SYSTEMATIC 
fluorescence O 
measurements O 
show O 
that O 
Y261 O 
plays O 
a O 
role O 
in O 
primer O 
- O 
template O 
strand O 
separation O 
. O 
Y261 O 
is O 
also O 
required O 
for O 
full O 
exonuclease O 
activity O 
and O 
contributes O 
to O 
the O 
fidelity O 
of O 
the O 
polymerase O 
. O 

impairment O 
of O 
postprandial O 
triacylglycerol B-FAMILY 
than O 
glucose B-TRIVIAL 
response O 
in O 
metabolic O 
syndrome O 
subjects O 
with O 
fasting O 
hyperglycaemia O 
. O 

: O 
Studies O 
have O 
started O 
to O 
question O 
whether O 
a O 
specific O 
component O 
or O 
combinations O 
of O 
metabolic O 
syndrome O 
( O 
MetS O 
) O 
components O 
may O 
be O 
more O 
important O 
in O 
relation O 
to O 
cardiovascular O 
disease O 
risk O 
. O 
Our O 
aim O 
was O 
to O 
examine O 
the O 
impact O 
of O 
the O 
presence O 
of O 
raised O 
fasting O 
glucose B-TRIVIAL 
as O 
a O 
MetS O 
component O 
on O 
postprandial O 
lipaemia O 
. O 
METHODS O 
: O 
Men O 
classified O 
with O 
the O 
MetS O 
underwent O 
a O 
sequential O 
test O 
meal O 
investigation O 
, O 
in O 
which O 
blood O 
samples O 
were O 
taken O 
at O 
regular O 
intervals O 
after O 
a O 
test O 
breakfast O 
( O 
t=0 O 
min O 
) O 
and O 
lunch O 
( O 
t=330 O 
min O 
) O 
. O 
Lipids O 
, O 
glucose B-TRIVIAL 
and O 
insulin O 
were O 
measured O 
in O 
the O 
fasting O 
and O 
postprandial O 
samples O 
. O 
RESULTS O 
: O 
MetS O 
subjects O 
with O 
3 O 
or O 
4 O 
components O 
were O 
subdivided O 
into O 
those O 
without O 
( O 
n=34 O 
) O 
and O 
with O 
( O 
n=23 O 
) O 
fasting O 
hyperglycaemia O 
( O 
≥ O 
5.6mmol O 
/ O 
l O 
) O 
, O 
irrespective O 
of O 
the O 
combination O 
of O 
components O 
. O 
Fasting O 
lipids O 
and O 
insulin O 
were O 
similar O 
in O 
the O 
two O 
groups O 
, O 
with O 
glucose B-TRIVIAL 
significantly O 
higher O 
in O 
the O 
men O 
with O 
glucose B-TRIVIAL 
as O 
a O 
MetS O 
component O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
Following O 
the O 
test O 
meals O 
, O 
there O 
were O 
higher O 
maximum O 
concentration O 
( O 
maxC O 
) O 
, O 
area O 
under O 
the O 
curve O 
( O 
AUC O 
) O 
and O 
incremental O 
AUC O 
( O 
P≤0.016 O 
) O 
for O 
the O 
postprandial O 
triacylglycerol B-FAMILY 
( O 
TAG B-ABBREVIATION 
) O 
response O 
in O 
men O 
with O 
fasting O 
hyperglycaemia O 
. O 
Greater O 
glucose B-TRIVIAL 
AUC O 
( O 
P O 
< O 
0.001 O 
) O 
and O 
insulin O 
maxC O 
( O 
P=0.010 O 
) O 
were O 
also O 
observed O 
in O 
these O 
individuals O 
after O 
the O 
test O 
meals O 
. O 
Multiple O 
regression O 
analysis O 
revealed O 
fasting O 
glucose B-TRIVIAL 
to O 
be O 
an O 
important O 
predictor O 
of O 
the O 
postprandial O 
TAG B-ABBREVIATION 
and O 
glucose B-TRIVIAL 
response O 
. O 
CONCLUSION O 
: O 
Our O 
data O 
analysis O 
has O 
revealed O 
a O 
greater O 
impairment O 
of O 
postprandial O 
TAG B-ABBREVIATION 
than O 
glucose B-TRIVIAL 
response O 
in O 
MetS O 
subjects O 
with O 
raised O 
fasting O 
glucose B-TRIVIAL 
. O 
The O 
worsening O 
of O 
postprandial O 
lipaemic O 
control O 
may O 
contribute O 
to O 
the O 
greater O 
CVD O 
risk O 
reported O 
in O 
individuals O 
with O 
MetS O 
component O 
combinations O 
which O 
include O 
hyperglycaemia O 
. O 

Studies O 
of O 
Unformulated O 
Internally O 
[ O 
3H B-FORMULA 
]-labeled O 
siRNAs O 
in O 
Mice O 
. O 

, O 
distribution O 
, O 
metabolism O 
, O 
and O 
excretion O 
properties O 
of O 
two O 
unformulated O 
model O 
siRNAs O 
were O 
determined O 
using O 
a O 
single O 
internal O 
[ O 
(3)H B-FORMULA 
]-radiolabeling O 
procedure O 
, O 
where O 
the O 
full O 
- O 
length O 
oligonucleotides O 
were O 
radiolabeled O 
by O 
Br B-FORMULA 
/ O 
(3)H B-FORMULA 
-exchange O 
. O 
Tissue O 
distribution O 
, O 
excretion O 
, O 
and O 
mass O 
balance O 
of O 
radioactivity O 
were O 
investigated O 
in O 
male O 
CD-1 O 
mice O 
, O 
following O 
a O 
single O 
intravenous O 
administration O 
of O 
the O 
[ O 
(3)H B-FORMULA 
]-siRNAs O 
, O 
at O 
a O 
target O 
dose O 
level O 
of O 
5 O 
mg O 
/ O 
kg O 
. O 
Quantitative O 
whole O 
- O 
body O 
autoradiography O 
( O 
QWBA O 
) O 
and O 
liquid O 
scintillation O 
counting O 
techniques O 
were O 
used O 
to O 
determine O 
tissue O 
distribution O 
. O 
Radiochromatogram O 
profiles O 
were O 
determined O 
in O 
plasma O 
, O 
tissue O 
extracts O 
and O 
urine O 
. O 
Metabolites O 
were O 
separated O 
by O 
liquid O 
chromatography O 
and O 
identified O 
by O 
radiodetection O 
and O 
high O 
- O 
resolution O 
accurate O 
mass O 
spectrometry O 
. O 
In O 
general O 
, O 
there O 
was O 
little O 
difference O 
in O 
the O 
distribution O 
of O 
total O 
radiolabeled O 
components O 
after O 
administration O 
of O 
the O 
two O 
unformulated O 
[ O 
(3)H B-FORMULA 
]-siRNAs O 
. O 
The O 
radioactivity O 
was O 
rapidly O 
and O 
widely O 
distributed O 
throughout O 
the O 
body O 
, O 
and O 
remained O 
detectable O 
in O 
all O 
tissues O 
investigated O 
at O 
later O 
time O 
points O 
( O 
24 O 
and O 
48 O 
hours O 
for O 
[ O 
(3)H B-FORMULA 
]-MRP4 O 
and O 
[ O 
(3)H B-FORMULA 
]-SSB O 
siRNA O 
, O 
respectively O 
) O 
. O 
After O 
an O 
initial O 
rapid O 
decline O 
, O 
concentrations O 
of O 
total O 
radiolabeled O 
components O 
in O 
dried O 
blood O 
declined O 
at O 
a O 
much O 
slower O 
rate O 
. O 
A O 
nearly O 
complete O 
mass O 
balance O 
was O 
obtained O 
for O 
the O 
[ O 
(3)H B-FORMULA 
]-SSB O 
siRNA O 
and O 
renal O 
excretion O 
was O 
the O 
main O 
route O 
of O 
elimination O 
( O 
38% O 
) O 
. O 
The O 
metabolism O 
of O 
the O 
two O 
model O 
siRNAs O 
was O 
rapid O 
and O 
extensive O 
. O 
Five O 
minutes O 
after O 
administration O 
, O 
no O 
parent O 
compound O 
could O 
be O 
detected O 
in O 
plasma O 
. O 
Instead O 
, O 
radiolabeled O 
nucleosides B-FAMILY 
resulting O 
from O 
nuclease O 
hydrolysis O 
were O 
observed O 
. O 
In O 
the O 
metabolism O 
profiles O 
obtained O 
from O 
various O 
tissues O 
only O 
radiolabeled O 
nucleosides B-FAMILY 
were O 
found O 
, O 
suggesting O 
that O 
siRNAs O 
are O 
rapidly O 
metabolized O 
and O 
that O 
the O 
distribution O 
pattern O 
of O 
total O 
radiolabeled O 
components O 
can O 
be O 
ascribed O 
to O 
small O 
molecular O 
weight O 
metabolites O 
. O 

tuning O 
of O 
Fano O 
- O 
resonant O 
metasurfaces O 
using O 
plasmonic O 
response O 
of O 
graphene B-TRIVIAL 
in O 
the O 
mid O 
- O 
infrared O 
. O 

is O 
widely O 
known O 
for O 
its O 
anomalously O 
strong O 
broadband O 
optical O 
absorptivity O 
of O 
2.3% O 
that O 
enables O 
seeing O 
its O 
single O 
- O 
atom O 
layer O 
with O 
the O 
naked O 
eye O 
. O 
However O 
, O 
in O 
the O 
mid O 
- O 
infrared O 
part O 
of O 
the O 
spectrum O 
graphene B-TRIVIAL 
represents O 
a O 
quintessential O 
lossless O 
zero O 
- O 
volume O 
plasmonic O 
material O 
. O 
We O 
experimentally O 
demonstrate O 
that O 
, O 
when O 
integrated O 
with O 
Fano O 
- O 
resonant O 
plasmonic O 
metasurfaces O 
, O 
single O 
- O 
layer O 
graphene B-TRIVIAL 
( O 
SLG O 
) O 
can O 
be O 
used O 
to O 
tune O 
their O 
mid O 
- O 
infrared O 
optical O 
response O 
. O 
SLG's O 
plasmonic O 
response O 
is O 
shown O 
to O 
induce O 
large O 
blue O 
shifts O 
of O 
the O 
metasurface's O 
resonance O 
without O 
reducing O 
its O 
spectral O 
sharpness O 
. O 
This O 
effect O 
is O 
explained O 
by O 
a O 
generalized O 
perturbation O 
theory O 
of O 
SLG-metamaterial O 
interaction O 
that O 
accounts O 
for O 
two O 
unique O 
properties O 
of O 
the O 
SLG O 
that O 
set O 
it O 
apart O 
from O 
all O 
other O 
plasmonic O 
materials O 
: O 
its O 
anisotropic O 
response O 
and O 
zero O 
volume O 
. O 
These O 
results O 
pave O 
the O 
way O 
to O 
using O 
gated O 
SLG O 
as O 
a O 
platform O 
for O 
dynamical O 
spectral O 
tuning O 
of O 
infrared O 
metamaterials O 
and O 
metasurfaces O 
. O 

report O 
is O 
aimed O 
at O 
intra O 
- O 
laboratory O 
and O 
inter O 
- O 
laboratory O 
comparison O 
of O 
the O 
results O 
obtained O 
during O 
spectrophotometric O 
and O 
HPLC O 
analyses O 
of O 
lycopene B-TRIVIAL 
, O 
β-carotene B-TRIVIAL 
and O 
total O 
carotenoids O 
in O 
tomato O 
products O 
and O 
yellow O 
maize O 
flours O 
/ O 
grits O 
. O 
Extensive O 
statistical O 
analyses O 
are O 
performed O 
in O 
order O 
to O 
identify O 
the O 
main O 
sources O 
of O 
uncertainties O 
which O 
may O 
occur O 
when O 
using O 
: O 
(i) O 
different O 
techniques O 
/ O 
methods O 
/ O 
approaches O 
in O 
the O 
same O 
/ O 
different O 
laboratories O 
, O 
in O 
various O 
food O 
samples O 
, O 
and O 
(ii) O 
to O 
indicate O 
the O 
facts O 
/ O 
conditions O 
under O 
which O 
the O 
biases O 
between O 
results O 
may O 
remain O 
unidentified O 
after O 
applying O 
statistical O 
testing O 
. O 
Our O 
data O 
points O 
to O 
the O 
inertness O 
of O 
t-test O 
to O 
detect O 
significance O 
of O 
differences O 
, O 
particularly O 
at O 
low O 
R O 
values O 
: O 
in O 
general O 
, O 
the O 
higher O 
correlation O 
coefficient O 
, O 
the O 
higher O 
is O 
sensitivity O 
of O 
statistical O 
testing O 
, O 
especially O 
of O 
the O 
paired O 
t-test O 
. O 
Therefore O 
, O 
simple O 
deviation O 
of O 
relationship O 
line O 
slope O 
from O 
unity O 
could O 
be O 
used O 
as O 
additional O 
evaluation O 
parameter O 
. O 
This O 
adds O 
to O 
reliable O 
and O 
objective O 
quality O 
assurance O 
of O 
foods O 
in O 
regard O 
to O 
carotenoids O 
. O 

attention O 
has O 
been O 
given O 
to O 
the O 
selection O 
of O 
trial O 
descriptor O 
sets O 
when O 
designing O 
a O 
QSAR O 
analysis O 
even O 
though O 
a O 
great O 
number O 
of O 
descriptor O 
classes O 
, O 
and O 
often O 
a O 
greater O 
number O 
of O 
descriptors O 
within O 
a O 
given O 
class O 
, O 
are O 
now O 
available O 
. O 
This O 
paper O 
reports O 
an O 
effort O 
to O 
explore O 
interrelationships O 
between O 
QSAR O 
models O 
and O 
descriptor O 
sets O 
. O 
Zhou O 
and O 
co O 
- O 
workers O 
( O 
Zhou O 
et O 
al O 
. O 
, O 
Nano O 
Lett O 
. O 
2008 O 
, O 
8 O 
( O 
3 O 
) O 
, O 
859-865 O 
) O 
designed O 
, O 
synthesized O 
, O 
and O 
tested O 
a O 
combinatorial O 
library O 
of O 
80 O 
surface O 
modified O 
, O 
that O 
is O 
decorated O 
, O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
for O 
their O 
composite O 
nanotoxicity O 
using O 
six O 
endpoints O 
all O 
based O 
on O 
a O 
common O 
0 O 
to O 
100 O 
activity O 
scale O 
. O 
Each O 
of O 
the O 
six O 
endpoints O 
for O 
the O 
29 O 
most O 
nanotoxic O 
decorated O 
nanotubes O 
were O 
incorporated O 
as O 
the O 
training O 
set O 
for O 
this O 
study O 
. O 
The O 
study O 
reported O 
here O 
includes O 
trial O 
descriptor O 
sets O 
for O 
all O 
possible O 
combinations O 
of O 
MOE O 
, O 
VolSurf O 
, O 
and O 
4D-fingerprints O 
( O 
FP O 
) O 
descriptor O 
classes O 
, O 
as O 
well O 
as O 
including O 
and O 
excluding O 
explicit O 
spatial O 
contributions O 
from O 
the O 
nanotube O 
. O 
Optimized O 
QSAR O 
models O 
were O 
constructed O 
from O 
these O 
multiple O 
trial O 
descriptor O 
sets O 
. O 
It O 
was O 
found O 
that O 
( O 
a O 
) O 
both O 
the O 
form O 
and O 
quality O 
of O 
the O 
best O 
QSAR O 
models O 
for O 
each O 
of O 
the O 
endpoints O 
are O 
distinct O 
and O 
( O 
b O 
) O 
some O 
endpoints O 
are O 
quite O 
dependent O 
upon O 
4D-FP O 
descriptors O 
of O 
the O 
entire O 
nanotube O 
- O 
decorator O 
complex O 
. O 
However O 
, O 
other O 
endpoints O 
yielded O 
equally O 
good O 
models O 
only O 
using O 
decorator O 
descriptors O 
with O 
and O 
without O 
the O 
decorator O 
- O 
only O 
4D-FP O 
descriptors O 
. O 
Lastly O 
, O 
and O 
most O 
importantly O 
, O 
the O 
quality O 
, O 
significance O 
, O 
and O 
interpretation O 
of O 
a O 
QSAR O 
model O 
were O 
found O 
to O 
be O 
critically O 
dependent O 
on O 
the O 
trial O 
descriptor O 
sets O 
used O 
within O 
a O 
given O 
QSAR O 
endpoint O 
study O 
. O 

. O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGTs O 
) O 
are O 
a O 
group O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
that O 
catalyse O 
the O 
conjugation O 
of O 
endogeonous O 
compounds O 
and O 
xenobiotics O 
to O 
yield O 
hydrophilic O 
glucuronides O 
which O 
subsequently O 
undergo O 
excretion O 
. O 
This O 
report O 
describes O 
an O 
approach O 
for O 
the O 
identification O 
and O 
accurate O 
quantitation O 
of O 
human O 
UGT1A1 O 
in O 
complex O 
biological O 
matrices O 
using O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
/ O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
analysis O 
of O 
protein O 
digests O 
. O 
2 O 
. O 
A O 
stable O 
isotope O 
- O 
labelled O 
( O 
SIL O 
) O 
peptide O 
of O 
a O 
unique O 
peptide O 
spanning O 
residues O 
54-69 O 
in O 
exon O 
1 O 
of O 
the O 
human O 
UGT1A1 O 
protein O 
with O 
the O 
sequence O 
RIYLSADPALVVIEHG O 
was O 
synthesized O 
. O 
The O 
peptide O 
sequence O 
synthesized O 
was O 
in O 
the O 
reverse O 
order O 
of O 
the O 
human O 
peptide O 
with O 
the O 
stable O 
isotope O 
- O 
labels O 
in O 
the O 
amino B-FAMILY 
acid I-FAMILY 
arginine B-TRIVIAL 
( O 
(13)C6(15)N4 B-FORMULA 
) O 
resulting O 
in O 
an O 
increase O 
in O 
the O 
mass O 
of O 
the O 
SIL O 
peptide O 
of O 
10 O 
amu O 
, O 
from O 
1753 O 
to O 
1763 O 
. O 
The O 
SIL O 
peptide O 
was O 
quantitated O 
by O 
injecting O 
increasing O 
concentrations O 
of O 
the O 
peptide O 
into O 
the O 
LC-MS O 
to O 
obtain O 
a O 
standard O 
curve O 
. O 
3 O 
. O 
The O 
labelled O 
peptide O 
along O 
with O 
precursor O 
ion O 
monitoring O 
was O 
used O 
to O 
quantify O 
the O 
levels O 
of O 
UGT1A1 O 
in O 
commercial O 
recombinant O 
preparations O 
( O 
supersomes O 
) O 
and O 
individual O 
human O 
liver O 
microsomal O 
samples O 
and O 
pooled O 
human O 
liver O 
micrsomes O 
obtained O 
from O 
BD O 
Biosciences O 
. O 
4 O 
. O 
Glucuronidation O 
activity O 
studies O 
were O 
performed O 
, O 
which O 
demonstrated O 
a O 
positive O 
correlation O 
between O 
enzyme O 
activity O 
levels O 
and O 
the O 
UGT1A1 O 
content O 
in O 
the O 
liver O 
microsomes O 
obtained O 
from O 
individual O 
human O 
donors O 
. O 

: O 
Evidence O 
suggests O 
that O 
the O 
palatability O 
of O 
food O 
( O 
i.e O 
. O 
, O 
the O 
hedonic O 
impact O 
produced O 
by O 
its O 
sensory O 
features O 
) O 
can O 
promote O 
feeding O 
and O 
may O 
underlie O 
compulsive O 
eating O 
, O 
leading O 
to O 
obesity O 
. O 
Pharmacological O 
studies O 
implicate O 
opioid O 
transmission O 
in O 
the O 
hedonic O 
control O 
of O 
feeding O 
, O 
though O 
these O 
studies O 
often O 
rely O 
on O 
agents O 
lacking O 
specificity O 
for O 
particular O 
opioid O 
receptors O 
. O 
OBJECTIVES O 
: O 
Here O 
, O 
we O 
investigated O 
the O 
role O 
of O 
mu O 
opioid O 
receptors O 
( O 
MORs O 
) O 
specifically O 
in O 
determining O 
hedonic O 
responses O 
to O 
palatable O 
sweet O 
stimuli O 
. O 
METHODS O 
: O 
In O 
Experiment O 
1 O 
, O 
licking O 
microstructure O 
when O 
consuming O 
sucrose B-TRIVIAL 
solution O 
( O 
2 O 
to O 
20 O 
% O 
) O 
was O 
compared O 
in O 
MOR O 
knockout O 
and O 
wildtype O 
mice O 
as O 
a O 
function O 
of O 
sucrose B-TRIVIAL 
concentration O 
and O 
level O 
of O 
food O 
deprivation O 
. O 
In O 
Experiment O 
2 O 
, O 
a O 
similar O 
examination O 
was O 
conducted O 
using O 
the O 
palatable O 
but O 
calorie O 
- O 
free O 
stimulus O 
sucralose B-TRIVIAL 
( O 
0.001 O 
to O 
1 O 
% O 
) O 
, O 
allowing O 
study O 
of O 
licking O 
behavior O 
independent O 
of O 
homeostatic O 
variables O 
. O 
RESULTS O 
: O 
In O 
Experiment O 
1 O 
, O 
MOR O 
knockout O 
mice O 
exhibited O 
several O 
alterations O 
in O 
sucrose B-TRIVIAL 
licking O 
. O 
Although O 
wildtype O 
mice O 
exhibited O 
a O 
twofold O 
increase O 
in O 
the O 
burst O 
length O 
when O 
food O 
deprived O 
, O 
relative O 
to O 
the O 
nondeprived O 
test O 
, O 
this O 
aspect O 
of O 
sucrose B-TRIVIAL 
licking O 
was O 
generally O 
insensitive O 
to O 
manipulations O 
of O 
food O 
deprivation O 
for O 
MOR O 
knockout O 
mice O 
. O 
Furthermore O 
, O 
during O 
concentration O 
testing O 
, O 
their O 
rate O 
of O 
sucrose B-TRIVIAL 
licking O 
was O 
less O 
than O 
half O 
that O 
of O 
wildtype O 
mice O 
. O 
During O 
sucralose B-TRIVIAL 
testing O 
( O 
Experiment O 
2 O 
) O 
, O 
MOR O 
knockout O 
mice O 
licked O 
at O 
approximately O 
half O 
the O 
wildtype O 
rate O 
, O 
providing O 
more O 
direct O 
evidence O 
that O 
MOR O 
knockout O 
mice O 
were O 
impaired O 
in O 
processing O 
stimulus O 
palatability O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
suggest O 
that O 
transmission O 
through O 
MORs O 
mediates O 
hedonic O 
responses O 
to O 
palatable O 
stimuli O 
, O 
and O 
therefore O 
likely O 
contributes O 
to O 
normal O 
and O 
pathological O 
eating O 
. O 

( O 
Tif1α O 
) O 
and O 
Trim33 O 
( O 
Tif1γ O 
) O 
interact O 
to O 
form O 
a O 
co O 
- O 
repressor O 
complex O 
that O 
suppresses O 
murine O 
hepatocellular O 
carcinoma O 
. O 
Here O 
we O 
show O 
that O 
Trim24 O 
and O 
Trim33 O 
cooperatively O 
repress O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
receptor O 
- O 
dependent O 
activity O 
of O 
VL30-class O 
endogenous O 
retroviruses O 
( O 
ERVs O 
) O 
in O 
liver O 
. O 
In O 
Trim24-knockout O 
hepatocytes O 
, O 
VL30 O 
derepression O 
leads O 
to O 
accumulation O 
of O 
reverse O 
- O 
transcribed O 
VL30 O 
cDNA O 
in O 
the O 
cytoplasm O 
that O 
correlates O 
with O 
activation O 
of O 
the O 
viral O 
- O 
defense O 
interferon O 
responses O 
mimicking O 
the O 
preneoplastic O 
inflammatory O 
state O 
seen O 
in O 
human O 
liver O 
following O 
exogenous O 
viral O 
infection O 
. O 
Furthermore O 
, O 
upon O 
derepression O 
, O 
VL30 O 
long O 
terminal O 
repeats O 
( O 
LTRs O 
) O 
act O 
as O 
promoter O 
and O 
enhancer O 
elements O 
deregulating O 
expression O 
of O 
neighboring O 
genes O 
and O 
generating O 
enhancer O 
RNAs O 
that O 
are O 
required O 
for O 
LTR O 
enhancer O 
activity O 
in O 
hepatocytes O 
in O 
vivo O 
. O 
These O 
data O 
reinforce O 
the O 
role O 
of O 
the O 
TRIM O 
family O 
of O 
proteins O 
in O 
retroviral O 
restriction O 
and O 
antiviral O 
defense O 
and O 
provide O 
an O 
example O 
of O 
an O 
ERV O 
- O 
derived O 
oncogenic O 
regulatory O 
network O 
. O 

vegetable O 
crops O 
irrigated O 
with O 
wastewater O 
are O 
highly O 
contaminated O 
with O 
heavy O 
metals O 
and O 
are O 
the O 
main O 
source O 
of O 
human O 
exposure O 
to O 
the O 
contaminants O 
. O 
In O 
this O 
study O 
accumulation O 
of O 
eight O 
heavy O 
metals O 
( O 
Cu B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Co B-FORMULA 
and O 
Pb B-FORMULA 
) O 
in O 
green O 
vegetables O 
like O 
Allium O 
cepa O 
, O 
Allium O 
sativum O 
, O 
Solanum O 
lycopersicum O 
and O 
Solanum O 
melongena O 
, O 
irrigated O 
with O 
wastewater O 
in O 
Mardan O 
are O 
studied O 
using O 
Atomic O 
Absorption O 
spectrophotometer O 
. O 
The O 
studied O 
metals O 
in O 
vegetable O 
grown O 
on O 
wastewater O 
irrigated O 
soil O 
were O 
significantly O 
higher O 
than O 
those O 
of O 
tube O 
well O 
water O 
irrigated O 
soil O 
and O 
WHO O 
/ O 
FAO O 
permissible O 
limits O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
most O 
heavily O 
contaminated O 
vegetable O 
was O 
wastewater O 
irrigated O 
A O 
. O 
cepa O 
, O 
where O 
the O 
accumulation O 
of O 
Mn B-FORMULA 
( O 
28.05 O 
mg O 
kg(-1) O 
) O 
in O 
the O 
edible O 
parts O 
was O 
50-fold O 
greater O 
than O 
A O 
. O 
cepa O 
irrigated O 
with O 
tube O 
well O 
water O 
irrigated O 
soil O 
. O 
It O 
may O 
be O 
concluded O 
that O 
both O 
adults O 
and O 
children O 
consuming O 
these O 
vegetables O 
grown O 
in O 
wastewater O 
irrigated O 
soil O 
ingest O 
significant O 
amount O 
of O 
these O 
metals O 
and O 
thus O 
can O 
cause O 
serious O 
health O 
problems O 
. O 

panel O 
of O 
reporter O 
gene O 
assays O 
( O 
RGAs O 
) O 
coupled O 
with O 
a O 
single O 
solid O 
phase O 
extraction O 
( O 
SPE O 
) O 
step O 
was O 
developed O 
and O 
used O 
to O 
screen O 
bottled O 
mineral O 
water O 
for O 
the O 
presence O 
of O 
four O 
classes O 
of O 
endocrine O 
disruptors O 
( O 
EDs O 
) O 
, O 
oestrogens B-FAMILY 
, O 
androgens B-FAMILY 
, O 
progestagens B-FAMILY 
and O 
glucocorticoids O 
. O 
Fourteen O 
brands O 
of O 
bottled O 
mineral O 
water O 
in O 
triplicate O 
( O 
42 O 
samples O 
) O 
were O 
analysed O 
. O 
Overall O 
, O 
hormonal O 
activity O 
was O 
found O 
in O 
78% O 
of O 
the O 
samples O 
. O 
Oestrogenic O 
, O 
androgenic O 
, O 
progestagenic O 
and O 
glucocorticoid O 
activity O 
was O 
found O 
in O 
38% O 
, O 
38% O 
, O 
36% O 
and O 
55% O 
of O 
the O 
samples O 
, O 
respectively O 
at O 
an O 
average O 
concentration O 
of O 
10 O 
ng O 
/ O 
l O 
17β-estradiol B-SYSTEMATIC 
equivalent O 
( O 
EEQ O 
) O 
, O 
26 O 
ng O 
/ O 
l O 
testosterone B-TRIVIAL 
equivalent O 
( O 
TEQ O 
) O 
, O 
123 O 
ng O 
/ O 
l O 
progesterone B-TRIVIAL 
equivalent O 
( O 
PEQ O 
) O 
and O 
13.5 O 
ng O 
/ O 
l O 
hydrocortisone B-TRIVIAL 
equivalent O 
( O 
HEQ O 
) O 
. O 
The O 
level O 
of O 
oestrogenic O 
, O 
androgenic O 
and O 
progestagenic O 
activity O 
observed O 
is O 
not O 
considered O 
a O 
matter O 
of O 
concern O 
for O 
the O 
consumers O 
' O 
health O 
. O 
It O 
is O 
unknown O 
whether O 
the O 
glucocorticoid O 
levels O 
observed O 
are O 
safe O 
. O 
The O 
ED O 
source O 
, O 
long O 
term O 
exposure O 
and O 
mixture O 
effects O 
remain O 
to O 
be O 
investigated O 
. O 

pathway O 
in O 
many O 
- O 
particle O 
LiFePO4 B-FORMULA 
electrode O 
revealed O 
by O 
nanoscale O 
state O 
- O 
of O 
- O 
charge O 
mapping O 
. O 

intercalation O 
pathway O 
of O 
lithium B-SYSTEMATIC 
iron I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
LFP B-ABBREVIATION 
) O 
in O 
the O 
positive O 
electrode O 
of O 
a O 
lithium B-SYSTEMATIC 
-ion O 
battery O 
was O 
probed O 
at O 
the O 
∼40 O 
nm O 
length O 
scale O 
using O 
oxidation O 
- O 
state O 
- O 
sensitive O 
X-ray O 
microscopy O 
. O 
Combined O 
with O 
morphological O 
observations O 
of O 
the O 
same O 
exact O 
locations O 
using O 
transmission O 
electron O 
microscopy O 
, O 
we O 
quantified O 
the O 
local O 
state O 
- O 
of O 
- O 
charge O 
of O 
approximately O 
450 O 
individual O 
LFP B-ABBREVIATION 
particles O 
over O 
nearly O 
the O 
entire O 
thickness O 
of O 
the O 
porous O 
electrode O 
. O 
With O 
the O 
electrode O 
charged O 
to O 
50% O 
state O 
- O 
of O 
- O 
charge O 
in O 
0.5 O 
h O 
, O 
we O 
observed O 
that O 
the O 
overwhelming O 
majority O 
of O 
particles O 
were O 
either O 
almost O 
completely O 
delithiated O 
or O 
lithiated O 
. O 
Specifically O 
, O 
only O 
∼2% O 
of O 
individual O 
particles O 
were O 
at O 
an O 
intermediate O 
state O 
- O 
of O 
- O 
charge O 
. O 
From O 
this O 
small O 
fraction O 
of O 
particles O 
that O 
were O 
actively O 
undergoing O 
delithiation O 
, O 
we O 
conclude O 
that O 
the O 
time O 
needed O 
to O 
charge O 
a O 
particle O 
is O 
∼1 O 
/ O 
50 O 
the O 
time O 
needed O 
to O 
charge O 
the O 
entire O 
particle O 
ensemble O 
. O 
Surprisingly O 
, O 
we O 
observed O 
a O 
very O 
weak O 
correlation O 
between O 
the O 
sequence O 
of O 
delithiation O 
and O 
the O 
particle O 
size O 
, O 
contrary O 
to O 
the O 
common O 
expectation O 
that O 
smaller O 
particles O 
delithiate O 
before O 
larger O 
ones O 
. O 
Our O 
quantitative O 
results O 
unambiguously O 
confirm O 
the O 
mosaic O 
( O 
particle O 
- O 
by O 
- O 
particle O 
) O 
pathway O 
of O 
intercalation O 
and O 
suggest O 
that O 
the O 
rate O 
- O 
limiting O 
process O 
of O 
charging O 
is O 
initiating O 
the O 
phase O 
transformation O 
by O 
, O 
for O 
example O 
, O 
a O 
nucleation O 
- O 
like O 
event O 
. O 
Therefore O 
, O 
strategies O 
for O 
further O 
enhancing O 
the O 
performance O 
of O 
LFP B-ABBREVIATION 
electrodes O 
should O 
not O 
focus O 
on O 
increasing O 
the O 
phase O 
- O 
boundary O 
velocity O 
but O 
on O 
the O 
rate O 
of O 
phase O 
- O 
transformation O 
initiation O 
. O 

of O 
serotonin B-TRIVIAL 
receptors O 
and O 
depression O 
: O 
state O 
of O 
the O 
art O 
. O 

depression O 
( O 
MD O 
) O 
is O 
a O 
major O 
health O 
problem O 
, O 
partly O 
due O 
to O 
the O 
incomplete O 
understanding O 
of O 
the O 
pathogenic O 
mechanisms O 
of O 
the O 
disease O 
. O 
Research O 
efforts O 
have O 
mainly O 
focused O 
on O 
alterations O 
in O 
monoaminergic O 
neurotransmission O 
, O 
especially O 
in O 
relation O 
to O 
the O 
serotonergic O 
system O 
, O 
due O 
to O 
its O 
key O 
role O 
in O 
the O 
regulation O 
of O 
mood O 
and O 
related O 
biological O 
functions O 
. O 
Given O 
the O 
high O 
heritability O 
of O 
MD O 
( O 
estimated O 
between O 
31% O 
and O 
42% O 
for O 
unipolar O 
depression O 
) O 
, O 
genes O 
coding O 
for O 
key O 
regulators O 
of O 
the O 
serotonergic O 
neurotransmission O 
have O 
been O 
considered O 
as O 
optimal O 
candidates O 
. O 
The O 
present O 
review O 
is O 
focused O 
on O 
the O 
role O 
of O 
genes O 
coding O 
for O 
serotonin B-TRIVIAL 
receptors O 
in O 
MD O 
pathogenesis O 
, O 
since O 
the O 
serotonin B-TRIVIAL 
transporter O 
and O 
enzymes O 
involved O 
in O 
serotonin B-TRIVIAL 
metabolism O 
have O 
been O 
reviewed O 
elsewhere O 
. O 
Despite O 
the O 
large O 
number O 
of O 
candidate O 
gene O 
studies O 
focusing O 
on O 
genes O 
coding O 
for O 
serotonin B-TRIVIAL 
receptors O 
, O 
results O 
have O 
been O 
inconsistent O 
. O 
The O 
most O 
replicated O 
findings O 
are O 
the O 
associations O 
between O 
rs6295 O 
( O 
HTR1A O 
gene O 
) O 
G O 
allele O 
or O 
G O 
/ O 
G O 
genotype O 
and O 
rs6311 O 
( O 
HTR2A O 
gene O 
) O 
A O 
allele O 
or O 
A O 
/ O 
A O 
genotype O 
and O 
MD O 
or O 
depressive O 
symptoms O 
. O 
Preclinical O 
and O 
imaging O 
/ O 
post O 
- O 
mortem O 
studies O 
in O 
humans O 
provide O 
strong O 
support O 
for O 
the O 
involvement O 
of O 
HTR1A O 
and O 
HTR2A O 
genes O 
in O 
MD O 
. O 
Nevertheless O 
, O 
the O 
inconsistency O 
across O 
previous O 
studies O 
clearly O 
suggests O 
that O 
innovative O 
approaches O 
should O 
be O 
designed O 
in O 
order O 
to O 
overcome O 
the O 
limitations O 
of O 
candidate O 
gene O 
studies O 
. O 
To O 
date O 
, O 
the O 
most O 
appealing O 
methodologies O 
seem O 
to O 
be O 
full O 
exome O 
or O 
genome O 
sequencing O 
, O 
genome O 
- O 
wide O 
pathway O 
analyses O 
, O 
endophenotypes O 
, O 
and O 
epigenetic O 
biomarkers O 
. O 
The O 
reported O 
tools O 
may O 
assist O 
in O 
the O 
detection O 
of O 
multiple O 
- O 
loci O 
models O 
, O 
which O 
could O 
potentially O 
explain O 
the O 
high O 
percentage O 
of O 
MD O 
susceptibility O 
ascribed O 
to O 
genetic O 
factors O 
. O 

of O 
density O 
functional O 
methods O 
for O 
reaction O 
energetics O 
: O 
iridium B-SYSTEMATIC 
-catalyzed O 
water O 
oxidation O 
as O 
case O 
study O 
. O 

investigate O 
basis O 
set O 
convergence O 
for O 
a O 
series O 
of O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
functionals O 
( O 
both O 
hybrid O 
and O 
nonhybrid O 
) O 
and O 
compare O 
to O 
coupled O 
- O 
cluster O 
with O 
single O 
and O 
double O 
excitations O 
and O 
perturbative O 
triples O 
[CCSD(T)] O 
benchmark O 
calculations O 
. O 
The O 
case O 
studied O 
is O 
the O 
energetics O 
of O 
the O 
water O 
oxidation O 
reaction O 
by O 
an O 
iridium B-SYSTEMATIC 
- I-SYSTEMATIC 
oxo I-SYSTEMATIC 
complex O 
. O 
Complexation O 
energies O 
for O 
the O 
reactants O 
and O 
products O 
complexes O 
as O 
well O 
as O 
the O 
transition O 
state O 
( O 
TS O 
) O 
energy O 
are O 
considered O 
. O 
Contrary O 
to O 
the O 
expectation O 
of O 
relatively O 
weak O 
basis O 
set O 
dependence O 
for O 
DFT O 
, O 
the O 
basis O 
set O 
effects O 
are O 
large O 
, O 
for O 
example O 
, O 
more O 
than O 
10 O 
kcal O 
mol(-1) O 
difference O 
from O 
converged O 
basis O 
for O 
the O 
activation O 
energy O 
with O 
" O 
small O 
" O 
basis O 
sets O 
( O 
DZ O 
/ O 
6-31G** O 
for O 
Ir B-FORMULA 
/ O 
other O 
atoms O 
, O 
or O 
SVP O 
) O 
and O 
still O 
more O 
than O 
6 O 
kcal O 
mol(-1) O 
for O 
def2-TZVPP O 
/ O 
6-31G** O 
. O 
Inclusion O 
of O 
the O 
dispersion O 
correction O 
in O 
DFT-D3 O 
schemes O 
affects O 
the O 
energies O 
of O 
reactant O 
complex O 
( O 
RC O 
) O 
, O 
TS O 
, O 
and O 
product O 
complex O 
( O 
PC O 
) O 
by O 
almost O 
the O 
same O 
amount O 
; O 
it O 
significantly O 
improves O 
the O 
complexation O 
energy O 
( O 
the O 
formation O 
of O 
RC O 
) O 
, O 
but O 
has O 
little O 
effect O 
on O 
the O 
activation O 
energy O 
with O 
respect O 
to O 
RC O 
. O 
With O 
converged O 
basis O 
, O 
some O 
pure O 
GGAs O 
( O 
PBE-D3 O 
, O 
BP86-D3 O 
) O 
as O 
well O 
as O 
the O 
hybrid O 
functional O 
B3LYP-D3 O 
are O 
very O 
accurate O 
compared O 
to O 
benchmark O 
CCSD(T) O 
calculations O 
. O 

acetylcholinesterase O 
activity O 
be O 
considered O 
as O 
a O 
reliable O 
biomarker O 
for O 
the O 
assessment O 
of O 
cadmium B-SYSTEMATIC 
-induced O 
neurotoxicity O 
? O 

et O 
al O 
. O 
( O 
2012 O 
) O 
recently O 
reported O 
the O 
findings O 
of O 
a O 
long O 
- O 
awaited O 
study O 
on O 
the O 
effects O 
of O 
long O 
- O 
term O 
dietary O 
- O 
induced O 
exposure O 
to O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
on O 
the O 
acetylcholinesterase O 
( O 
AChE O 
) O 
activity O 
of O 
adult O 
rodents O 
' O 
brain O 
regions O 
. O 
Their O 
study O 
can O 
be O 
regarded O 
as O 
a O 
significant O 
contribution O 
to O 
the O 
field O 
, O 
as O 
there O 
is O 
paucity O 
of O 
information O 
on O 
the O 
AChE O 
activity O 
in O 
brain O 
regions O 
following O 
exposure O 
to O 
Cd B-FORMULA 
. O 
However O 
, O 
the O 
Cd B-FORMULA 
-induced O 
modulation O 
of O 
AChE O 
activity O 
is O 
an O 
issue O 
surrounded O 
by O 
controversy O 
. O 
We O 
, O 
herein O 
, O 
discuss O 
and O 
summarize O 
the O 
relative O 
in O 
vivo O 
and O 
in O 
vitro O 
experimental O 
data O 
, O 
and O 
set O 
out O 
to O 
answer O 
the O 
straightforward O 
question O 
: O 
can O 
AChE O 
activity O 
be O 
considered O 
as O 
a O 
reliable O 
biomarker O 
for O 
the O 
assessment O 
of O 
Cd B-FORMULA 
-induced O 
neurotoxicity O 
? O 
At O 
this O 
time O 
, O 
we O 
can O 
not O 
answer O 
in O 
the O 
affirmative O 
because O 
of O 
the O 
variation O 
in O 
techniques O 
used O 
and O 
conclusions O 
reached O 
. O 
We O 
make O 
a O 
plea O 
that O 
authors O 
aiming O 
to O 
explore O 
this O 
potential O 
use O 
of O 
brain O 
AChE O 
activity O 
in O 
the O 
future O 
: O 
( O 
a O 
) O 
are O 
aware O 
of O 
the O 
biases O 
that O 
their O 
experimental O 
approach O 
might O 
exert O 
upon O 
this O 
neurochemical O 
parameter O 
, O 
( O 
b O 
) O 
avoid O 
the O 
use O 
of O 
anaesthesia O 
as O 
a O 
mode O 
of O 
sacrifice O 
and O 
clarify O 
its O 
timing O 
, O 
( O 
c O 
) O 
decide O 
upon O 
the O 
use O 
of O 
previously O 
- O 
studied O 
in O 
vivo O 
experimental O 
schemes O 
( O 
so O 
that O 
they O 
can O 
provide O 
comparable O 
results O 
) O 
, O 
and O 
finally O 
, O 
( O 
d O 
) O 
identify O 
pharmacological O 
, O 
biochemical O 
and O 
molecular O 
approaches O 
that O 
are O 
appropriate O 
to O 
clarify O 
the O 
implicated O 
mechanism(s) O 
through O 
which O 
Cd B-FORMULA 
modifies O 
AChE O 
activity O 
. O 

bilayer O 
graphene B-TRIVIAL 
superlattices O 
. O 

graphene B-TRIVIAL 
is O 
an O 
intriguing O 
material O 
in O 
that O 
its O 
electronic O 
structure O 
can O 
be O 
altered O 
by O 
changing O 
the O 
stacking O 
order O 
or O 
the O 
relative O 
twist O 
angle O 
, O 
yielding O 
a O 
new O 
class O 
of O 
low O 
- O 
dimensional O 
carbon B-SYSTEMATIC 
system O 
. O 
Twisted O 
bilayer O 
graphene B-TRIVIAL 
can O 
be O 
obtained O 
by O 
(i) O 
thermal O 
decomposition O 
of O 
SiC B-FORMULA 
; O 
(ii) O 
chemical O 
vapor O 
deposition O 
( O 
CVD O 
) O 
on O 
metal O 
catalysts O 
; O 
(iii) O 
folding O 
graphene B-TRIVIAL 
; O 
or O 
(iv) O 
stacking O 
graphene B-TRIVIAL 
layers O 
one O 
atop O 
the O 
other O 
, O 
the O 
latter O 
of O 
which O 
suffers O 
from O 
interlayer O 
contamination O 
. O 
Existing O 
synthesis O 
protocols O 
, O 
however O 
, O 
usually O 
result O 
in O 
graphene B-TRIVIAL 
with O 
polycrystalline O 
structures O 
. O 
The O 
present O 
study O 
investigates O 
bilayer O 
graphene B-TRIVIAL 
grown O 
by O 
ambient O 
pressure O 
CVD O 
on O 
polycrystalline O 
Cu B-FORMULA 
. O 
Controlling O 
the O 
nucleation O 
in O 
early O 
stage O 
growth O 
allows O 
the O 
constituent O 
layers O 
to O 
form O 
single O 
hexagonal O 
crystals O 
. O 
New O 
Raman O 
active O 
modes O 
are O 
shown O 
to O 
result O 
from O 
the O 
twist O 
, O 
with O 
the O 
angle O 
determined O 
by O 
transmission O 
electron O 
microscopy O 
. O 
The O 
successful O 
growth O 
of O 
single O 
- O 
crystal O 
bilayer O 
graphene B-TRIVIAL 
provides O 
an O 
attractive O 
jumping O 
- O 
off O 
point O 
for O 
systematic O 
studies O 
of O 
interlayer O 
coupling O 
in O 
misoriented O 
few O 
- O 
layer O 
graphene B-TRIVIAL 
systems O 
with O 
well O 
- O 
defined O 
geometry O 
. O 

, O 
a O 
calcium B-SYSTEMATIC 
-binding O 
protein O 
originally O 
isolated O 
from O 
jellyfish O 
is O 
available O 
commercially O 
as O 
a O 
dietary O 
supplement O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
potential O 
adverse O 
effects O 
, O 
if O 
any O 
, O 
of O 
Apoaequorin O 
, O 
a O 
recombinant O 
protein O 
preparation O 
, O 
in O 
rats O 
following O 
subchronic O 
administration O 
. O 
For O 
this O 
study O 
, O 
Sprague-Dawley O 
( O 
Hsd O 
: O 
SD O 
® O 
) O 
rats O 
( O 
10 O 
/ O 
sex O 
/ O 
group O 
) O 
were O 
administered O 
via O 
oral O 
gavage O 
0 O 
( O 
control O 
) O 
, O 
92.6 O 
, O 
462.9 O 
, O 
and O 
926.0mg O 
/ O 
kg O 
body O 
weight O 
( O 
bw O 
) O 
/ O 
day O 
of O 
Apoaequorin O 
preparation O 
, O 
for O 
90days O 
. O 
The O 
corresponding O 
amount O 
of O 
Apoaequorin O 
protein O 
was O 
0 O 
, O 
66.7 O 
, O 
333.3 O 
and O 
666.7mg O 
/ O 
kg O 
bw O 
/ O 
day O 
, O 
respectively O 
. O 
Administration O 
of O 
the O 
Apoaequorin O 
preparation O 
did O 
not O 
result O 
in O 
any O 
mortality O 
. O 
There O 
were O 
no O 
clinical O 
or O 
ophthalmological O 
signs O 
, O 
body O 
weight O 
, O 
body O 
weight O 
gain O 
, O 
food O 
consumption O 
, O 
food O 
efficiency O 
, O 
clinical O 
pathology O 
or O 
histopathological O 
changes O 
attributable O 
to O 
administration O 
of O 
Apoaequorin O 
. O 
Any O 
changes O 
noted O 
were O 
incidental O 
and O 
in O 
agreement O 
with O 
those O 
historically O 
observed O 
in O 
the O 
age O 
and O 
strain O 
of O 
rats O 
used O 
in O 
this O 
study O 
. O 
Based O 
on O 
the O 
results O 
of O 
this O 
study O 
, O 
the O 
No O 
Observed-Adverse-Effect O 
Level O 
( O 
NOAEL O 
) O 
for O 
Apoaequorin O 
was O 
determined O 
as O 
666.7mg O 
/ O 
kg O 
bw O 
/ O 
day O 
, O 
the O 
highest O 
dose O 
tested O 
. O 

phytochemicals O 
and O 
garlic O 
supplements O 
influence O 
the O 
pharmacokinetic O 
and O 
pharmacodynamic O 
behavior O 
of O 
concomitantly O 
ingested O 
drugs O 
. O 
In O 
this O 
paper O 
we O 
have O 
summarized O 
the O 
mechanisms O 
responsible O 
for O 
first O 
- O 
pass O 
intestinal O 
pharmacokinetic O 
interactions O 
by O 
investigating O 
the O 
intestinal O 
permeability O 
of O 
some O 
cardiovascular O 
, O 
antiviral O 
drugs O 
, O 
their O 
transport O 
with O 
hepatic O 
transporters O 
and O 
CYP3A4 O 
metabolism O 
. O 
Transporter O 
- O 
enzyme O 
interplay O 
was O 
studied O 
with O 
several O 
in O 
vitro O 
models O 
of O 
varying O 
complexity O 
: O 
rat O 
small O 
intestine O 
and O 
Caco-2 O 
cell O 
monolayers O 
were O 
used O 
in O 
studies O 
of O 
intestinal O 
processes O 
, O 
and O 
hepatic O 
pharmacokinetics O 
was O 
monitored O 
in O 
HepG2 O 
cells O 
, O 
isolated O 
rat O 
hepatocytes O 
and O 
rat O 
liver O 
slices O 
. O 
Garlic O 
phytochemicals O 
from O 
aged O 
garlic O 
extract O 
modified O 
the O 
activities O 
of O 
secretory O 
and O 
absorptive O 
transporters O 
in O 
both O 
intestine O 
and O 
liver O 
and O 
competitively O 
inhibited O 
CYP3A4 O 
enzyme O 
. O 
The O 
increased O 
activities O 
of O 
the O 
most O 
important O 
intestinal O 
efflux O 
( O 
P-glycoprotein O 
- O 
Pgp O 
, O 
Multidrug O 
Resistance O 
Associated O 
Protein O 
2 O 
- O 
MRP-2 O 
, O 
Breast O 
Cancer O 
Resistance O 
Protein O 
- O 
BCRP O 
) O 
and O 
uptake O 
( O 
MonoCarboxylate B-SYSTEMATIC 
Transporter O 
1 O 
- O 
MCT1 O 
, O 
Organic O 
Anion O 
Transporting O 
Polypeptide O 
- O 
OATP O 
, O 
Peptide O 
transporter O 
1 O 
- O 
PepT1 O 
) O 
transporters O 
were O 
caused O 
by O 
changes O 
in O 
electrophysiological O 
membrane O 
properties O 
and O 
by O 
allosteric O 
modifications O 
. O 
Because O 
clinical O 
studies O 
investigating O 
interactions O 
between O 
garlic O 
and O 
human O 
immunodeficiency O 
virus O 
protease O 
inhibitors O 
saquinavir B-TRIVIAL 
and O 
ritonavir B-TRIVIAL 
have O 
already O 
been O 
performed O 
, O 
we O 
used O 
these O 
in O 
vivo O 
data O 
to O 
evaluate O 
the O 
in O 
vitro O 
results O 
and O 
the O 
reliability O 
of O 
the O 
models O 
employed O 
as O 
screening O 
tools O 
for O 
forecasting O 
the O 
potential O 
of O 
first O 
- O 
pass O 
intestinal O 
metabolism O 
changes O 
. O 
We O 
also O 
assessed O 
the O 
probability O 
of O 
pharmacokinetic O 
interactions O 
with O 
garlic O 
of O 
the O 
novel O 
drug O 
darunavir B-TRIVIAL 
and O 
other O 
cardiovascular O 
drugs O 
. O 
Finally O 
, O 
selected O 
garlic O 
phytochemicals O 
were O 
tested O 
for O 
their O 
ability O 
to O 
influence O 
P-glycoprotein O 
and O 
CYP3A4 O 
activities O 
. O 

enhancement O 
of O 
social O 
interaction O 
in O 
the O 
BTBR O 
mouse O 
model O 
of O 
autism O 
. O 

is O 
a O 
neurodevelopmental O 
disorder O 
in O 
which O 
the O 
first O 
diagnostic O 
symptom O 
is O 
unusual O 
reciprocal O 
social O 
interactions O 
. O 
Approximately O 
half O 
of O 
the O 
children O 
diagnosed O 
with O 
an O 
autism O 
spectrum O 
disorder O 
also O 
have O 
intellectual O 
impairments O 
. O 
General O 
cognitive O 
abilities O 
may O 
be O 
fundamental O 
to O 
many O 
aspects O 
of O 
social O 
cognition O 
. O 
Cognitive O 
enhancers O 
could O 
conceivably O 
be O 
of O 
significant O 
benefit O 
to O 
children O 
and O 
adults O 
with O 
autism O 
. O 
AMPAKINE B-FAMILY 
compounds O 
are O 
a O 
novel O 
class O 
of O 
pharmacological O 
agents O 
that O 
act O 
as O 
positive O 
modulators O 
of O 
AMPA B-ABBREVIATION 
receptors O 
to O 
enhance O 
excitatory O 
glutamatergic O 
neurotransmission O 
. O 
This O 
class O 
of O 
compounds O 
was O 
reported O 
to O 
improve O 
learning O 
and O 
memory O 
in O 
several O 
rodent O 
and O 
non-human O 
primate O 
tasks O 
, O 
and O 
to O 
normalize O 
respiratory O 
abnormalities O 
in O 
a O 
mouse O 
model O 
of O 
Rett O 
syndrome O 
. O 
Here O 
we O 
evaluate O 
the O 
actions O 
of O 
AMPA B-ABBREVIATION 
compounds O 
in O 
adult O 
male O 
and O 
female O 
BTBR O 
mice O 
, O 
a O 
well O 
characterized O 
mouse O 
model O 
of O 
autism O 
. O 
Acute O 
treatment O 
with O 
CX1837 B-IDENTIFIER 
and O 
CX1739 B-IDENTIFIER 
reversed O 
the O 
deficit O 
in O 
sociability O 
in O 
BTBR O 
mice O 
on O 
the O 
most O 
sensitive O 
parameter O 
, O 
time O 
spent O 
sniffing O 
a O 
novel O 
mouse O 
as O 
compared O 
to O 
time O 
spent O 
sniffing O 
a O 
novel O 
object O 
. O 
The O 
less O 
sensitive O 
parameter O 
, O 
time O 
in O 
the O 
chamber O 
containing O 
the O 
novel O 
mouse O 
versus O 
time O 
in O 
the O 
chamber O 
containing O 
the O 
novel O 
object O 
, O 
was O 
not O 
rescued O 
by O 
CX1837 B-IDENTIFIER 
or O 
CX1739 B-IDENTIFIER 
treatment O 
. O 
Preliminary O 
data O 
with O 
CX546 B-IDENTIFIER 
, O 
in O 
which O 
β-cyclodextrin B-TRIVIAL 
was O 
the O 
vehicle O 
, O 
revealed O 
behavioral O 
effects O 
of O 
the O 
acute O 
intraperitoneal O 
and O 
oral O 
administration O 
of O 
vehicle O 
alone O 
. O 
To O 
circumvent O 
the O 
artifacts O 
introduced O 
by O 
the O 
vehicle O 
administration O 
, O 
we O 
employed O 
a O 
novel O 
treatment O 
regimen O 
using O 
pellets O 
of O 
peanut O 
butter O 
for O 
drug O 
delivery O 
. O 
Absence O 
of O 
vehicle O 
treatment O 
effects O 
when O 
CX1837 B-IDENTIFIER 
and O 
CX1739 B-IDENTIFIER 
were O 
given O 
in O 
the O 
peanut O 
butter O 
pellets O 
, O 
to O 
multiple O 
cohorts O 
of O 
BTBR O 
and O 
B6 O 
control O 
mice O 
, O 
confirmed O 
that O 
the O 
pharmacologically O 
- O 
induced O 
improvements O 
in O 
sociability O 
in O 
BTBR O 
were O 
not O 
confounded O 
by O 
the O 
administration O 
procedures O 
. O 
The O 
highest O 
dose O 
of O 
CX1837 B-IDENTIFIER 
improved O 
the O 
cognitive O 
deficit O 
in O 
novel O 
object O 
recognition O 
in O 
BTBR O 
. O 
No O 
drug O 
effects O 
were O 
detected O 
on O 
the O 
high O 
levels O 
of O 
repetitive O 
self O 
- O 
grooming O 
in O 
BTBR O 
. O 
In O 
open O 
field O 
tests O 
, O 
CX1837 B-IDENTIFIER 
and O 
CX1739 B-IDENTIFIER 
did O 
not O 
induce O 
hyperactivity O 
or O 
sedation O 
in O 
either O 
strain O 
. O 
It O 
is O 
interesting O 
to O 
speculate O 
that O 
the O 
ability O 
of O 
CX1837 B-IDENTIFIER 
and O 
CX1739 B-IDENTIFIER 
to O 
restore O 
aspects O 
of O 
sociability O 
in O 
BTBR O 
mice O 
could O 
utilize O 
synaptic O 
mechanisms O 
regulating O 
social O 
cognition O 
, O 
suggesting O 
a O 
potential O 
pharmacological O 
target O 
for O 
interventions O 
to O 
treat O 
symptoms O 
of O 
autism O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

of O 
the O 
optimized O 
β-Lapachone B-TRIVIAL 
- O 
poloxamer B-FAMILY 
-cyclodextrin O 
ternary O 
system O 
induces O 
apoptosis O 
, O 
DNA O 
damage O 
and O 
reduces O 
tumor O 
growth O 
in O 
a O 
human O 
breast O 
adenocarcinoma O 
xenograft O 
mouse O 
model O 
. O 

( O 
β-Lap B-ABBREVIATION 
) O 
is O 
a O 
1,2-orthonaphthoquinone B-SYSTEMATIC 
that O 
selectively O 
induces O 
cell O 
death O 
in O 
human O 
cancer O 
cells O 
through O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase-1 O 
( O 
NQO1 O 
) O 
. O 
NQO1 O 
is O 
overexpressed O 
in O 
a O 
variety O 
of O 
tumors O 
, O 
as O 
compared O 
to O 
normal O 
adjacent O 
tissue O 
. O 
However O 
, O 
the O 
low O 
solubility O 
and O 
non-specific O 
distribution O 
of O 
β-Lap B-ABBREVIATION 
limit O 
its O 
suitability O 
for O 
clinical O 
assays O 
. O 
We O 
formulated O 
β-Lap B-ABBREVIATION 
in O 
an O 
optimal O 
random O 
methylated-β-cyclodextrin B-TRIVIAL 
/ O 
poloxamer B-TRIVIAL 
407 I-TRIVIAL 
mixture O 
( O 
i.e O 
. O 
, O 
β-Lap B-ABBREVIATION 
ternary O 
system O 
) O 
and O 
, O 
using O 
human O 
breast O 
adenocarcinoma O 
MCF-7 O 
cells O 
and O 
immunodeficient O 
mice O 
, O 
performed O 
in O 
vitro O 
and O 
in O 
vivo O 
evaluation O 
of O 
its O 
anti-tumor O 
effects O 
on O 
proliferation O 
, O 
cell O 
cycle O 
, O 
apoptosis O 
, O 
DNA O 
damage O 
, O 
and O 
tumor O 
growth O 
. O 
This O 
ternary O 
system O 
is O 
fluid O 
at O 
room O 
temperature O 
, O 
gels O 
over O 
29°C O 
, O 
and O 
provides O 
a O 
significant O 
amount O 
of O 
drug O 
, O 
thus O 
facilitating O 
intratumoral O 
delivery O 
, O 
in O 
situ O 
gelation O 
, O 
and O 
the O 
formation O 
of O 
a O 
depot O 
for O 
time O 
- O 
release O 
. O 
Administration O 
of O 
β-Lap B-ABBREVIATION 
ternary O 
system O 
to O 
MCF-7 O 
cells O 
induces O 
an O 
increase O 
in O 
apoptosis O 
and O 
DNA O 
damage O 
, O 
while O 
producing O 
no O 
changes O 
in O 
cell O 
cycle O 
. O 
Moreover O 
, O 
in O 
a O 
mouse O 
xenograft O 
tumor O 
model O 
, O 
intratumoral O 
injection O 
of O 
the O 
system O 
significantly O 
reduces O 
tumor O 
volume O 
, O 
while O 
increasing O 
apoptosis O 
and O 
DNA O 
damage O 
without O 
visible O 
toxicity O 
to O 
liver O 
or O 
kidney O 
. O 
These O 
anti-tumoral O 
effects O 
and O 
lack O 
of O 
visible O 
toxicity O 
make O 
this O 
system O 
a O 
promising O 
new O 
therapeutic O 
agent O 
for O 
breast O 
cancer O 
treatment O 
. O 

is O 
a O 
primary O 
brain O 
disorder O 
resulting O 
from O 
altered O 
modulation O 
of O 
normal O 
sensory O 
stimuli O 
and O 
trigeminal O 
nerve O 
dysfunction O 
. O 
The O 
second O 
edition O 
of O 
the O 
International O 
Classification O 
of O 
Headache O 
Disorders O 
( O 
ICHD-2 O 
) O 
defines O 
seven O 
subtypes O 
of O 
migraine O 
. O 
Migraine O 
treatment O 
can O 
be O 
acute O 
or O 
preventive O 
. O 
New O 
targeted O 
therapies O 
include O 
5-HT B-SYSTEMATIC 
( O 
1F O 
) O 
receptor O 
agonists O 
, O 
calcitonin O 
gene O 
- O 
related O 
peptide O 
( O 
CGRP O 
) O 
antagonists O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthetase O 
inhibitors O 
, O 
and O 
ion O 
channel O 
antagonists O 
. O 
A O 
recent O 
development O 
is O 
the O 
creation O 
of O 
antibodies O 
to O 
CGRP O 
and O 
its O 
receptor O 
for O 
migraine O 
prevention O 
. O 

of O 
p53 O 
knockout O 
on O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
-induced O 
genotoxicity O 
in O 
p53-deficient O 
gpt O 
delta O 
mice O 
. O 

A I-TRIVIAL 
( O 
OTA B-ABBREVIATION 
) O 
is O 
a O 
mycotoxin O 
produced O 
by O 
fungal O 
species O 
and O 
is O 
carcinogenic O 
targeting O 
the O 
S3 O 
segment O 
of O 
the O 
renal O 
proximal O 
tubules O 
in O 
rodents O 
. O 
We O 
previously O 
reported O 
that O 
exposure O 
of O 
gpt O 
delta O 
rats O 
to O 
OTA B-ABBREVIATION 
induced O 
both O 
mutations O 
in O 
the O 
red O 
/ O 
gam O 
gene O 
(Spi(-)) O 
, O 
suggesting O 
large O 
deletion O 
mutations O 
, O 
and O 
fluctuations O 
in O 
genes O 
transcribed O 
by O 
p53 O 
in O 
the O 
kidneys O 
, O 
which O 
were O 
associated O 
with O 
DNA O 
double O 
- O 
strand O 
break O 
( O 
DSB O 
) O 
repair O 
, O 
particularly O 
homologous O 
recombination O 
( O 
HR O 
) O 
repair O 
. O 
In O 
the O 
present O 
study O 
, O 
to O 
investigate O 
the O 
effects O 
of O 
p53 O 
knockout O 
on O 
OTA B-ABBREVIATION 
-induced O 
mutagenicity O 
, O 
apoptosis O 
, O 
and O 
karyomegaly O 
in O 
renal O 
tubular O 
cells O 
, O 
p53-proficient O 
and O 
p53-deficient O 
gpt O 
delta O 
mice O 
were O 
given O 
1 O 
and O 
5mg O 
/ O 
kg O 
of O 
OTA B-ABBREVIATION 
for O 
4 O 
weeks O 
. O 
Significant O 
increases O 
in O 
Spi(-) O 
mutant O 
frequencies O 
( O 
MFs O 
) O 
were O 
observed O 
in O 
the O 
kidneys O 
of O 
p53-deficient O 
gpt O 
delta O 
mice O 
given O 
5 O 
mg O 
/ O 
kg O 
of O 
OTA B-ABBREVIATION 
, O 
but O 
not O 
in O 
the O 
kidneys O 
of O 
p53-proficient O 
gpt O 
delta O 
mice O 
given O 
the O 
same O 
dose O 
. O 
There O 
were O 
no O 
changes O 
in O 
gpt O 
MFs O 
in O 
both O 
genotypes O 
of O 
mice O 
treated O 
with O 
OTA B-ABBREVIATION 
. O 
Western O 
blotting O 
analysis O 
demonstrated O 
that O 
p53 O 
protein O 
levels O 
in O 
the O 
kidneys O 
of O 
p53-proficient O 
mice O 
given O 
OTA B-ABBREVIATION 
were O 
significantly O 
increased O 
compared O 
with O 
the O 
control O 
. O 
Incidences O 
of O 
apoptosis O 
and O 
karyomegaly O 
in O 
not O 
only O 
the O 
outer O 
stripe O 
of O 
outer O 
medulla O 
but O 
also O 
the O 
cortex O 
were O 
significantly O 
higher O 
in O 
p53-deficient O 
at O 
5mg O 
/ O 
kg O 
than O 
in O 
p53-proficient O 
gpt O 
delta O 
mice O 
at O 
same O 
dose O 
, O 
which O 
had O 
no O 
change O 
in O 
the O 
cortex O 
, O 
the O 
inner O 
stripe O 
of O 
outer O 
stripe O 
, O 
and O 
the O 
inner O 
medulla O 
. O 
Given O 
that O 
p53 O 
regulates O 
HR O 
repair O 
in O 
DSBs O 
, O 
these O 
results O 
suggest O 
that O 
OTA B-ABBREVIATION 
may O 
promote O 
large O 
deletion O 
mutations O 
in O 
the O 
process O 
of O 
HR O 
repair O 
for O 
DSBs O 
. O 
Additionally O 
, O 
the O 
lower O 
incidence O 
of O 
karyomegaly O 
and O 
apoptosis O 
found O 
in O 
the O 
p53-proficient O 
gpt O 
delta O 
mice O 
suggests O 
that O 
these O 
phenomena O 
may O 
arise O 
from O 
OTA B-ABBREVIATION 
-induced O 
DNA O 
damage O 
. O 

of O 
lead O 
in O 
milk O 
and O 
yoghurt O 
samples O 
by O 
solid O 
phase O 
extraction O 
using O 
a O 
novel O 
aminothioazole B-SYSTEMATIC 
-polymeric O 
resin O 
. O 

preconcentration O 
method O 
was O 
developed O 
by O 
using O 
a O 
new O 
aminothioazole B-SYSTEMATIC 
-containing O 
sulfonamide B-SYSTEMATIC 
resin O 
in O 
solid O 
phase O 
extraction O 
for O 
the O 
determination O 
of O 
lead O 
and O 
nickel B-SYSTEMATIC 
in O 
milk O 
and O 
yoghurt O 
samples O 
. O 
The O 
optimisation O 
of O 
experimental O 
conditions O 
was O 
performed O 
. O 
The O 
optimum O 
parameters O 
for O 
Pb B-FORMULA 
and O 
Ni B-FORMULA 
were O 
found O 
to O 
be O 
3.5 O 
, O 
30 O 
min O 
and O 
2.5 O 
mL O 
for O 
pH O 
, O 
contact O 
time O 
, O 
eluate O 
volume O 
, O 
respectively O 
. O 
After O 
preconcentration O 
step O 
, O 
atomic O 
absorption O 
spectrometry O 
was O 
used O 
for O 
the O 
determinations O 
. O 
The O 
enhancement O 
of O 
350- O 
and O 
50-fold O 
in O 
the O 
sensitivity O 
of O 
Pb B-FORMULA 
and O 
Ni B-FORMULA 
were O 
achieved O 
by O 
combination O 
of O 
the O 
slotted O 
tube O 
atom O 
trap O 
- O 
atomic O 
absorption O 
spectrometry O 
with O 
the O 
optimised O 
preconcentration O 
method O 
, O 
respectively O 
. O 
Limits O 
of O 
detection O 
were O 
found O 
to O 
be O 
0.15 O 
ng O 
mL⁻¹ O 
for O 
Pb B-FORMULA 
and O 
0.75 O 
ng O 
mL⁻¹ O 
for O 
Ni B-FORMULA 
. O 
The O 
lead O 
concentrations O 
in O 
the O 
studied O 
samples O 
were O 
found O 
to O 
be O 
in O 
the O 
range O 
of O 
15-61 O 
ng O 
Pb B-FORMULA 
mL⁻¹ O 
for O 
milk O 
and O 
21-42 O 
ng O 
Pb B-FORMULA 
g⁻¹ O 
for O 
yoghurt O 
samples O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
purify O 
and O 
identify O 
lipolysis O 
- O 
stimulating O 
peptides O 
derived O 
from O 
Flavourzyme®-soy O 
protein O 
isolate O 
( O 
SPI O 
) O 
hydrolysate O 
( O 
F-SPIH O 
) O 
. O 
Glycerol B-TRIVIAL 
release O 
was O 
employed O 
as O 
a O 
marker O 
for O 
lipolysis O 
in O 
3T3-L1 O 
adipocytes O 
. O 
A O 
higher O 
glycerol B-TRIVIAL 
release O 
represents O 
a O 
better O 
lipolysis O 
- O 
stimulating O 
activity O 
. O 
The O 
peptide O 
fraction O 
with O 
highest O 
glycerol B-TRIVIAL 
release O 
obtained O 
from O 
F-SPIH O 
fractionated O 
by O 
sequential O 
ultrafiltration O 
membranes O 
was O 
further O 
purified O 
using O 
gel O 
filtration O 
chromatography O 
and O 
two O 
steps O 
of O 
reverse O 
- O 
phase O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 
The O 
peptides O 
were O 
identified O 
using O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
LC O 
/ O 
MS O 
/ O 
MS O 
) O 
. O 
Three O 
lipolysis O 
- O 
stimulating O 
peptides O 
were O 
obtained O 
, O 
and O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
were O 
ILL O 
, O 
LLL O 
and O 
VHVV O 
, O 
respectively O 
. O 
The O 
in O 
vitro O 
effect O 
of O 
gastrointestinal O 
proteases O 
on O 
lipolysis O 
- O 
stimulating O 
activity O 
of O 
synthetic O 
ILL O 
, O 
LLL O 
and O 
VHVV O 
, O 
respectively O 
, O 
was O 
also O 
investigated O 
. O 
The O 
result O 
suggested O 
that O 
the O 
gastrointestinal O 
protease O 
did O 
not O 
affect O 
lipolysis O 
- O 
stimulating O 
activity O 
of O 
the O 
three O 
novel O 
peptides O 
, O 
which O 
reveals O 
their O 
potential O 
to O 
act O 
as O 
anti-obesity O 
ingredients O 
. O 

Role O 
of O 
( B-TRIVIAL 
RS I-TRIVIAL 
)-glucoraphanin I-TRIVIAL 
Bioactivated O 
with O 
Myrosinase O 
in O 
an O 
Experimental O 
Model O 
of O 
Multiple O 
Sclerosis O 
. O 

: O 
The O 
discovery O 
of O 
new O 
natural O 
compounds O 
with O 
pharmacological O 
properties O 
is O 
a O 
field O 
of O 
interest O 
widely O 
growing O 
. O 
Recent O 
literature O 
shows O 
that O 
Brassica O 
vegetables O 
( O 
Cruciferae O 
) O 
possess O 
therapeutic O 
effects O 
particularly O 
ascribed O 
due O 
to O 
their O 
content O 
in O 
glucosinolates B-FAMILY 
, O 
which O 
upon O 
myrosinase O 
hydrolysis O 
release O 
the O 
corresponding O 
isothiocyanates B-FAMILY 
. O 
This O 
study O 
examines O 
the O 
potential O 
neuroprotective O 
and O 
immunomodulatory O 
effects O 
of O 
( B-TRIVIAL 
RS I-TRIVIAL 
)-glucoraphanin I-TRIVIAL 
from O 
Tuscan O 
black O 
kale O 
( O 
Brassica O 
oleracea O 
L O 
. O 
var O 
. O 
acephala O 
sabellica O 
) O 
bioactivated O 
with O 
myrosinase O 
( O 
bioactive O 
RS B-ABBREVIATION 
-GRA I-ABBREVIATION 
) O 
( O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
intraperitoneally O 
) O 
, O 
in O 
an O 
experimental O 
autoimmune O 
encephalomyelitis O 
( O 
EAE O 
) O 
, O 
a O 
model O 
of O 
multiple O 
sclerosis O 
. O 
METHODS O 
: O 
EAE O 
was O 
induced O 
by O 
immunization O 
with O 
myelin O 
oligodendroglial O 
glycoprotein O 
peptide O 
( O 
MOG35-55 O 
) O 
in O 
mice O 
. O 
After O 
immunization O 
, O 
mice O 
were O 
observed O 
daily O 
for O 
signs O 
of O 
EAE O 
and O 
weight O 
loss O 
. O 
Clinical O 
score O 
was O 
evaluated O 
using O 
a O 
standardized O 
scoring O 
system O 
. O 
RESULTS O 
: O 
By O 
Western O 
blot O 
analysis O 
of O 
spinal O 
cord O 
tissues O 
, O 
we O 
have O 
demonstrated O 
that O 
treatment O 
with O 
bioactive O 
RS B-ABBREVIATION 
-GRA I-ABBREVIATION 
significantly O 
decreased O 
nuclear O 
factor O 
(NF)-kB O 
translocation O 
, O 
pro O 
- O 
inflammatory O 
cytokine O 
production O 
such O 
as O 
interleukin-1β O 
( O 
IL-1β O 
) O 
, O 
and O 
apoptosis O 
( O 
Bax O 
and O 
caspase O 
3 O 
expression O 
) O 
. O 
CONCLUSION O 
: O 
Our O 
results O 
clearly O 
demonstrate O 
that O 
bioactive O 
RS B-ABBREVIATION 
-GRA I-ABBREVIATION 
treatment O 
may O 
represent O 
a O 
useful O 
therapeutic O 
perspective O 
in O 
the O 
treatment O 
of O 
this O 
disease O 
. O 

surface O 
- O 
adhered O 
enzymatic O 
microreactors O 
based O 
on O 
physical O 
hydrogels O 
of O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
. O 

biomaterials O 
based O 
on O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
PVA B-ABBREVIATION 
, O 
have O 
an O 
extensive O 
history O 
of O 
biomedical O 
applications O 
, O 
yet O 
in O 
their O 
current O 
form O 
suffer O 
from O 
significant O 
shortcomings O 
, O 
such O 
as O 
a O 
lack O 
of O 
mechanism O 
of O 
biodegradation O 
and O 
poor O 
opportunities O 
in O 
controlled O 
drug O 
release O 
. O 
We O 
investigate O 
physical O 
hydrogels O 
of O 
PVA B-ABBREVIATION 
as O 
surface O 
- O 
adhered O 
materials O 
and O 
present O 
biodegradable O 
matrices O 
equipped O 
with O 
innovative O 
tools O 
in O 
substrate O 
- O 
mediated O 
drug O 
release O 
. O 
Toward O 
the O 
final O 
goal O 
, O 
PVA B-ABBREVIATION 
chains O 
with O 
narrow O 
polydispersities O 
( O 
1.1-1.2 O 
) O 
and O 
molecular O 
weights O 
of O 
5 O 
, O 
10 O 
, O 
and O 
28 O 
kDa O 
are O 
synthesized O 
via O 
controlled O 
radical O 
polymerization O 
( O 
RAFT O 
) O 
. O 
These O 
molecular O 
weights O 
are O 
shown O 
to O 
be O 
suitably O 
high O 
to O 
afford O 
robust O 
hydrogel O 
matrices O 
and O 
at O 
the O 
same O 
time O 
suitably O 
low O 
to O 
allow O 
gradual O 
erosion O 
of O 
the O 
hydrogels O 
with O 
kinetics O 
of O 
degradation O 
controlled O 
via O 
polymer O 
macromolecular O 
characteristics O 
. O 
For O 
opportunities O 
in O 
controlled O 
drug O 
release O 
, O 
hydrogels O 
are O 
equipped O 
with O 
enzymatic O 
cargo O 
to O 
achieve O 
an O 
in O 
situ O 
conversion O 
of O 
externally O 
added O 
prodrug O 
into O 
a O 
final O 
product O 
, O 
thus O 
giving O 
rise O 
to O 
surface O 
- O 
adhered O 
enzymatic O 
microreactors O 
. O 
Hydrogel O 
- O 
mediated O 
enzymatic O 
activity O 
was O 
investigated O 
as O 
a O 
function O 
of O 
polymer O 
molecular O 
weight O 
and O 
concentration O 
of O 
solution O 
taken O 
for O 
assembly O 
of O 
hydrogels O 
. O 
Taken O 
together O 
, O 
we O 
present O 
, O 
to O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
the O 
first O 
example O 
of O 
bioresorbable O 
physical O 
hydrogel O 
based O 
on O 
PVA B-ABBREVIATION 
with O 
engineered O 
opportunities O 
in O 
substrate O 
- O 
mediated O 
enzymatic O 
activity O 
and O 
envisioned O 
utility O 
in O 
surface O 
- O 
mediated O 
drug O 
delivery O 
and O 
tissue O 
engineering O 
. O 

of O 
a O 
novel O 
indolylmaleimide B-SYSTEMATIC 
with O 
microtubules O 
induces O 
mitotic O 
arrest O 
and O 
apoptosis O 
in O 
human O 
progenitor O 
and O 
cancer O 
cells O 
. O 

display O 
a O 
broad O 
spectrum O 
of O 
biological O 
activity O 
and O 
offer O 
great O 
opportunity O 
to O 
influence O 
several O 
aspects O 
of O 
cell O 
fate O 
, O 
as O 
proliferation O 
and O 
differentiation O 
. O 
In O 
this O 
study O 
we O 
describe O 
the O 
effect O 
of O 
PDA-66 B-IDENTIFIER 
, O 
a O 
newly O 
synthesised O 
indolylmaleimide B-SYSTEMATIC 
, O 
showing O 
a O 
strong O 
dose O 
dependent O 
anti-proliferative O 
effect O 
on O 
immortalised O 
human O 
progenitor O 
and O 
cancer O 
cells O 
. O 
We O 
demonstrated O 
a O 
highly O 
depolymerizing O 
effect O 
on O 
in O 
vitro O 
tubulin O 
assembly O 
and O 
conclude O 
that O 
PDA-66 B-IDENTIFIER 
acts O 
as O 
microtubule O 
destabilising O 
agent O 
. O 
In O 
addition O 
we O 
found O 
that O 
PDA-66 B-IDENTIFIER 
induces O 
mitotic O 
arrest O 
of O 
cells O 
in O 
the O 
G₂ O 
/ O 
M O 
phase O 
of O 
the O 
cell O 
cycle O 
. O 
Subsequently O 
cells O 
undergo O 
apoptosis O 
, O 
indicating O 
the O 
major O 
mechanism O 
of O 
the O 
anti-proliferative O 
effect O 
. O 
To O 
prove O 
a O 
potential O 
anti-cancer O 
activity O 
of O 
PDA-66 B-IDENTIFIER 
we O 
examined O 
the O 
effect O 
of O 
PDA-66 B-IDENTIFIER 
on O 
human O 
SH-SY5Y O 
neuroblastoma O 
and O 
A-459 O 
lung O 
cancer O 
cells O 
, O 
showing O 
a O 
significant O 
reduction O 
in O 
cancer O 
cell O 
proliferation O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
Thus O 
PDA-66 B-IDENTIFIER 
is O 
a O 
new O 
anti-mitotic O 
compound O 
with O 
an O 
indole B-SYSTEMATIC 
-core O 
with O 
the O 
potential O 
to O 
be O 
used O 
for O 
cancer O 
therapy O 
. O 

evidence O 
suggests O 
that O 
tachykinins O 
are O 
involved O 
in O 
the O 
control O 
of O 
different O 
pathological O 
conditions O 
, O 
including O 
psychiatric O 
disorders O 
. O 
In O 
this O 
study O 
we O 
evaluated O 
the O 
expression O 
of O 
NK(1) O 
and O 
NK(2) O 
receptors O 
( O 
NK-1R O 
and O 
NK-2R O 
) O 
, O 
as O 
well O 
as O 
the O 
effects O 
of O 
substance B-TRIVIAL 
P I-TRIVIAL 
( O 
SP O 
) O 
and O 
neurokinin B-TRIVIAL 
A I-TRIVIAL 
( O 
NKA B-ABBREVIATION 
) O 
, O 
in O 
monocytes O 
isolated O 
from O 
15 O 
healthy O 
subjects O 
and O 
15 O 
patients O 
with O 
recurrent O 
major O 
depressive O 
disorder O 
( O 
RMDD O 
) O 
, O 
under O 
stable O 
antidepressant O 
therapy O 
. O 
NK-1R O 
expression O 
in O 
monocytes O 
from O 
RMDD O 
patients O 
was O 
significantly O 
decreased O 
as O 
compared O 
to O 
healthy O 
subjects O 
, O 
whereas O 
NK-2R O 
expression O 
was O 
markedly O 
increased O 
. O 
Both O 
NK-1R O 
and O 
NK-2R O 
expression O 
correlated O 
with O 
HAM-D O 
, O 
but O 
not O 
HAM-A O 
, O 
score O 
. O 
SP O 
, O 
NKA B-ABBREVIATION 
and O 
selective O 
NK-1R O 
and O 
NK-2R O 
agonists O 
stimulated O 
TNF-α O 
release O 
in O 
monocytes O 
of O 
both O 
groups O 
, O 
with O 
a O 
significant O 
higher O 
effect O 
observed O 
in O 
RMDD O 
. O 
Moreover O 
they O 
induced O 
NF-κB O 
activation O 
, O 
which O 
was O 
reversed O 
by O 
selective O 
NK-1R O 
and O 
NK-2R O 
antagonists O 
, O 
so O 
demonstrating O 
that O 
it O 
was O 
receptor O 
- O 
mediated O 
. O 
The O 
occurrence O 
of O 
a O 
profound O 
alteration O 
in O 
NK O 
receptor O 
expression O 
in O 
RMDD O 
is O 
a O 
novel O 
finding O 
that O 
suggests O 
NK-1R O 
and O 
NK-2R O 
pathways O 
as O 
possible O 
relevant O 
players O 
in O 
major O 
depressive O 
disorder O 
, O 
so O 
improving O 
our O 
understanding O 
of O 
the O 
complex O 
pathogenesis O 
of O 
the O 
disease O 
. O 

I O 
mGluRs O 
evoke O 
K B-FORMULA 
- O 
ATP B-ABBREVIATION 
current O 
by O 
intracellular O 
Ca2+ B-FORMULA 
mobilization O 
in O 
rat O 
subthalamus O 
neurons O 
. O 

reported O 
previously O 
that O 
Ca(2+) B-FORMULA 
influx O 
through O 
N-methly-d-aspartate B-SYSTEMATIC 
-gated O 
channels O 
evokes O 
ATP B-ABBREVIATION 
-sensitive O 
K(+) B-FORMULA 
( O 
K B-FORMULA 
- O 
ATP B-ABBREVIATION 
) O 
currents O 
in O 
rat O 
subthalamic O 
nucleus O 
( O 
STN O 
) O 
neurons O 
. O 
By O 
using O 
whole O 
- O 
cell O 
patch O 
clamp O 
recordings O 
in O 
brain O 
slices O 
, O 
we O 
investigated O 
the O 
ability O 
of O 
(RS)-3,5-dihydroxyphenylglycine B-SYSTEMATIC 
( O 
DHPG B-ABBREVIATION 
) O 
, O 
a O 
group O 
I O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
( O 
mGluR O 
) O 
agonist O 
, O 
to O 
evoke O 
K B-FORMULA 
- O 
ATP B-ABBREVIATION 
currents O 
. O 
DHPG B-ABBREVIATION 
( O 
20 O 
µM O 
) O 
evoked O 
outward O 
current O 
at O 
-70 O 
mV O 
and O 
was O 
associated O 
with O 
a O 
positive O 
slope O 
conductance O 
of O 
2.7 O 
nS O 
. O 
The O 
sulfonylurea B-FAMILY 
agent O 
tolbutamide B-TRIVIAL 
( O 
100 O 
µM O 
) O 
converted O 
the O 
positive O 
slope O 
to O 
negative O 
slope O 
conductance O 
, O 
indicating O 
mediation O 
by O 
K B-FORMULA 
- O 
ATP B-ABBREVIATION 
channels O 
( O 
ATP B-ABBREVIATION 
-sensitive O 
K+ B-FORMULA 
channels O 
) O 
. O 
Currents O 
evoked O 
by O 
DHPG B-ABBREVIATION 
were O 
significantly O 
reduced O 
by O 
a O 
combination O 
of O 
mGluR1 O 
and O 
mGluR5 O 
negative O 
allosteric O 
modulators O 
. O 
DHPG B-ABBREVIATION 
-evoked O 
outward O 
current O 
was O 
blocked O 
by O 
cyclopiazonic B-TRIVIAL 
acid I-TRIVIAL 
and O 
thapsigargin B-TRIVIAL 
and O 
mimicked O 
by O 
caffeine B-TRIVIAL 
, O 
suggesting O 
mediation O 
by O 
release O 
of O 
intracellular O 
Ca(2+) B-FORMULA 
. O 
DHPG B-ABBREVIATION 
outward O 
current O 
was O 
also O 
blocked O 
by O 
ryanodine B-TRIVIAL 
and O 
2-aminoethoxydiphenylborane B-SYSTEMATIC 
, O 
suggesting O 
mediation O 
by O 
ryanodine B-TRIVIAL 
- O 
and O 
inositol B-SYSTEMATIC 
1,4,5-triphosphate I-SYSTEMATIC 
-sensitive O 
Ca(2+) B-FORMULA 
release O 
. O 
The O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibitor O 
N(G)-nitro-l-arginine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
and O 
inhibitors O 
of O 
protein O 
kinase O 
G O 
activity O 
also O 
suppressed O 
DHPG B-ABBREVIATION 
-induced O 
outward O 
current O 
. O 
Voltage O 
recordings O 
showed O 
that O 
tolbutamide B-TRIVIAL 
prolonged O 
depolarizing O 
plateau O 
potentials O 
and O 
increased O 
the O 
spontaneous O 
firing O 
rate O 
of O 
STN O 
neurons O 
recorded O 
in O 
the O 
presence O 
of O 
DHPG B-ABBREVIATION 
. O 
These O 
results O 
show O 
that O 
group O 
I O 
mGluR O 
stimulation O 
generates O 
K B-FORMULA 
- O 
ATP B-ABBREVIATION 
current O 
by O 
a O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
- O 
and O 
protein O 
kinase O 
G-dependent O 
process O 
that O 
is O 
mediated O 
by O 
release O 
of O 
Ca(2+) B-FORMULA 
from O 
intracellular O 
stores O 
. O 
Because O 
burst O 
firing O 
is O 
linked O 
to O 
symptoms O 
of O 
Parkinson's O 
disease O 
, O 
we O 
suggest O 
that O 
K B-FORMULA 
- O 
ATP B-ABBREVIATION 
channels O 
might O 
provide O 
a O 
physiologically O 
important O 
inhibitory O 
influence O 
on O 
STN O 
neuronal O 
activity O 
. O 

studies O 
on O 
muti- O 
hydroxyimides B-FAMILY 
as O 
highly O 
efficient O 
catalysts O 
for O 
aerobic O 
oxidation O 
. O 

( O 
NDHPI B-ABBREVIATION 
) O 
and O 
N,N',N''-trihydroxyisocyanuric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
THICA B-ABBREVIATION 
) O 
have O 
been O 
recently O 
demonstrated O 
to O 
act O 
as O 
better O 
carbon B-SYSTEMATIC 
-radical O 
- O 
producing O 
catalysts O 
than O 
the O 
popular O 
N-hydroxyphthalimide B-SYSTEMATIC 
( O 
NHPI B-ABBREVIATION 
) O 
. O 
To O 
gain O 
a O 
mature O 
understanding O 
of O 
these O 
particular O 
catalysts O 
, O 
herein O 
their O 
geometrical O 
, O 
electronic O 
, O 
and O 
thermochemical O 
properties O 
, O 
as O 
well O 
as O 
their O 
catalytic O 
activities O 
, O 
have O 
been O 
systemically O 
investigated O 
by O 
a O 
theoretical O 
analysis O 
. O 
It O 
appears O 
that O 
THICA B-ABBREVIATION 
, O 
unlike O 
NDHPI B-ABBREVIATION 
and O 
NHPI B-ABBREVIATION 
, O 
is O 
unsuitable O 
for O 
solvent-free O 
catalysis O 
or O 
catalysis O 
in O 
aprotic O 
solvents O 
due O 
to O 
its O 
favorable O 
coexistent O 
planar O 
conformer O 
. O 
Besides O 
, O 
the O 
more O 
remarkable O 
catalytic O 
efficiencies O 
of O 
NDHPI B-ABBREVIATION 
and O 
THICA B-ABBREVIATION 
compared O 
to O 
NHPI B-ABBREVIATION 
can O 
be O 
ascribed O 
to O 
the O 
lower O 
barriers O 
and O 
the O 
endothermicity O 
in O 
the O 
H B-FORMULA 
-abstraction O 
processes O 
by O 
their O 
radicals O 
, O 
especially O 
by O 
their O 
multi O 
- O 
radicals O 
which O 
show O 
stronger O 
electron O 
- O 
withdrawing O 
effects O 
. O 
Furthermore O 
, O 
the O 
generation O 
of O 
THICA B-ABBREVIATION 
radicals O 
would O 
be O 
much O 
feasible O 
at O 
high O 
temperature O 
without O 
co O 
- O 
catalysts O 
. O 
This O 
study O 
provides O 
a O 
new O 
perspective O 
towards O 
the O 
rational O 
design O 
of O 
reactive O 
hydroxyimide B-SYSTEMATIC 
organocatalysts O 
for O 
industrial O 
applications O 
. O 

pharmacological O 
profile O 
of O 
paraxanthine B-TRIVIAL 
, O 
the O 
main O 
metabolite O 
of O 
caffeine B-TRIVIAL 
in O 
humans O 
. O 

induces O 
locomotor O 
activation O 
by O 
its O 
ability O 
to O 
block O 
adenosine B-TRIVIAL 
receptors O 
. O 
Caffeine B-TRIVIAL 
is O 
metabolized O 
to O 
several O 
methylxanthines B-FAMILY 
, O 
with O 
paraxanthine B-TRIVIAL 
being O 
the O 
main O 
metabolite O 
in O 
humans O 
. O 
In O 
this O 
study O 
we O 
show O 
that O 
in O 
rats O 
paraxanthine B-TRIVIAL 
has O 
a O 
stronger O 
locomotor O 
activating O 
effect O 
than O 
caffeine B-TRIVIAL 
or O 
the O 
two O 
other O 
main O 
metabolites O 
of O 
caffeine B-TRIVIAL 
, O 
theophylline B-TRIVIAL 
and O 
theobromine B-TRIVIAL 
. O 
As O 
previously O 
described O 
for O 
caffeine B-TRIVIAL 
, O 
the O 
locomotor O 
activating O 
doses O 
of O 
paraxanthine B-TRIVIAL 
more O 
efficiently O 
counteract O 
the O 
locomotor O 
depressant O 
effects O 
of O 
an O 
adenosine B-TRIVIAL 
A(1) O 
than O 
an O 
adenosine B-TRIVIAL 
A(2A) O 
receptor O 
agonist O 
. O 
In O 
drug O 
discrimination O 
experiments O 
in O 
rats O 
trained O 
to O 
discriminate O 
a O 
maximal O 
locomotor O 
activating O 
dose O 
of O 
caffeine B-TRIVIAL 
, O 
paraxanthine B-TRIVIAL 
, O 
unlike O 
theophylline B-TRIVIAL 
, O 
generalized O 
poorly O 
to O 
caffeine B-TRIVIAL 
suggesting O 
the O 
existence O 
of O 
additional O 
mechanisms O 
other O 
than O 
adenosine B-TRIVIAL 
antagonism O 
in O 
the O 
behavioral O 
effects O 
of O 
paraxanthine B-TRIVIAL 
. O 
Pretreatment O 
with O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
inhibitor O 
N(G)-nitro-l-arginine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
l-NAME B-ABBREVIATION 
) O 
reduced O 
the O 
locomotor O 
activating O 
effects O 
of O 
paraxanthine B-TRIVIAL 
, O 
but O 
not O 
caffeine B-TRIVIAL 
. O 
On O 
the O 
other O 
hand O 
, O 
pretreatment O 
with O 
the O 
selective O 
cGMP B-ABBREVIATION 
-preferring O 
phosphodiesterase O 
PDE9 O 
inhibitor O 
BAY B-IDENTIFIER 
73-6691 I-IDENTIFIER 
, O 
increased O 
locomotor O 
activity O 
induced O 
by O 
caffeine B-TRIVIAL 
, O 
but O 
not O 
paraxanthine B-TRIVIAL 
. O 
Ex O 
vivo O 
experiments O 
demonstrated O 
that O 
paraxanthine B-TRIVIAL 
, O 
but O 
not O 
caffeine B-TRIVIAL 
, O 
can O 
induce O 
cGMP B-ABBREVIATION 
accumulation O 
in O 
the O 
rat O 
striatum O 
. O 
Finally O 
, O 
in O 
vivo O 
microdialysis O 
experiments O 
showed O 
that O 
paraxanthine B-TRIVIAL 
, O 
but O 
not O 
caffeine B-TRIVIAL 
, O 
significantly O 
increases O 
extracellular O 
levels O 
of O 
dopamine B-TRIVIAL 
in O 
the O 
dorsolateral O 
striatum O 
, O 
which O 
was O 
blocked O 
by O 
l-NAME B-ABBREVIATION 
. O 
These O 
findings O 
indicate O 
that O 
inhibition O 
of O 
cGMP B-ABBREVIATION 
-preferring O 
PDE O 
is O 
involved O 
in O 
the O 
locomotor O 
activating O 
effects O 
of O 
the O 
acute O 
administration O 
of O 
paraxanthine B-TRIVIAL 
. O 
The O 
present O 
results O 
demonstrate O 
a O 
unique O 
psychostimulant O 
profile O 
of O 
paraxanthine B-TRIVIAL 
, O 
which O 
might O 
contribute O 
to O 
the O 
reinforcing O 
effects O 
of O 
caffeine B-TRIVIAL 
in O 
humans O 
. O 

Trajectory O 
Study O 
of O 
CH(3)NO(2) B-FORMULA 
Decomposition O 
via O 
Roaming O 
Mediated O 
Isomerization O 
Using O 
a O 
Global O 
Potential O 
Energy O 
Surface O 
. O 

report O 
a O 
global O 
potential O 
energy O 
surface O 
( O 
PES O 
) O 
for O 
CH(3)NO(2) B-FORMULA 
based O 
on O 
fitting O 
roughly O 
114 O 
0 O 
density O 
functional O 
theory O 
( O 
UB3LYP O 
/ O 
6-311 O 
+ O 
g(d,p) O 
) O 
electronic O 
energies O 
. O 
The O 
PES O 
is O 
a O 
precise O 
, O 
permutationally O 
invariant O 
fit O 
to O 
these O 
energies O 
. O 
Properties O 
of O 
the O 
PES O 
are O 
described O 
, O 
as O 
are O 
some O 
preliminary O 
quasiclassical O 
trajectory O 
calculations O 
. O 
An O 
isomerization O 
- O 
roaming O 
pathway O 
to O 
the O 
CH(3)ONO B-FORMULA 
isomer O 
and O 
then O 
to O 
the O 
CH(3)O B-FORMULA 
+ O 
NO B-FORMULA 
products O 
is O 
found O 
. O 
Although O 
the O 
pathway O 
occurs O 
at O 
larger O 
distances O 
than O 
a O 
related O 
loose O 
saddle O 
- O 
point O 
on O 
the O 
PES O 
, O 
the O 
pathway O 
supports O 
the O 
supposition O 
of O 
such O 
a O 
pathway O 
based O 
on O 
locating O 
a O 
loose O 
first O 
- O 
order O 
saddle O 
point O 
and O 
associated O 
IRC O 
, O 
reported O 
previously O 
by O 
Zhu O 
and O 
Lin O 
[ O 
Zhu O 
, O 
R O 
. O 
S O 
. O 
and O 
Lin O 
, O 
M O 
. O 
C O 
. O 
Chem O 
. O 
Phys O 
. O 
Lett O 
. O 
2009 O 
, O 
478 O 
, O 
11 O 
] O 
. O 

knowledge O 
regarding O 
the O 
molecular O 
pathophysiology O 
underlying O 
anxiety O 
disorders O 
remains O 
incomplete O 
. O 
Increasing O 
evidence O 
points O 
to O 
a O 
role O 
of O 
glutamate B-TRIVIAL 
in O 
anxiety O 
. O 
The O 
group O 
III O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGlu4 O 
, O 
mGlu6 O 
, O 
mGlu7 O 
and O 
mGlu8 O 
receptors O 
) O 
remain O 
the O 
least O 
investigated O 
glutamate B-TRIVIAL 
receptor O 
subtypes O 
partially O 
due O 
to O 
a O 
delay O 
in O 
the O 
development O 
of O 
specific O 
pharmacological O 
tools O 
. O 
Early O 
work O 
using O 
knockout O 
animals O 
and O 
pharmacological O 
tools O 
aimed O 
at O 
investigating O 
the O 
role O 
of O 
mGlu7 O 
receptor O 
in O 
the O 
pathophysiology O 
of O 
anxiety O 
disorders O 
has O 
yielded O 
exciting O 
yet O 
not O 
always O 
consistent O 
results O 
. O 
To O 
further O 
investigate O 
the O 
role O 
this O 
receptor O 
plays O 
in O 
anxiety O 
- O 
like O 
behaviour O 
, O 
we O 
knocked O 
down O 
mGlu7 O 
receptor O 
mRNA O 
levels O 
in O 
the O 
adult O 
mouse O 
brain O 
using O 
siRNA O 
delivered O 
via O 
an O 
osmotic O 
minipump O 
. O 
This O 
reduced O 
anxiety O 
- O 
like O 
behaviour O 
in O 
the O 
light O 
- O 
dark O 
box O 
coupled O 
with O 
an O 
attenuation O 
of O 
stress O 
- O 
induced O 
hyperthermia O 
( O 
SIH O 
) O 
and O 
a O 
reduction O 
of O 
the O 
acoustic O 
startle O 
response O 
( O 
ASRs O 
) O 
in O 
the O 
fear O 
- O 
potentiated O 
startle O 
paradigm O 
( O 
FPS O 
) O 
. O 
These O 
effects O 
on O 
anxiety O 
- O 
like O 
behaviour O 
were O 
independent O 
of O 
any O 
impairment O 
of O 
locomotor O 
activity O 
and O 
surprisingly O 
, O 
no O 
behavioural O 
changes O 
were O 
observed O 
in O 
the O 
forced O 
swim O 
test O 
( O 
FST O 
) O 
, O 
which O 
is O 
in O 
contrast O 
to O 
mGlu7 O 
receptor O 
knockout O 
animals O 
. O 
Furthermore O 
, O 
the O 
previously O 
reported O 
epilepsy O 
- O 
prone O 
phenotype O 
seen O 
in O 
mGlu7 O 
receptor O 
knockout O 
animals O 
was O 
not O 
observed O 
following O 
siRNA-induced O 
knockdown O 
of O 
the O 
receptor O 
. O 
These O 
data O 
suggest O 
targeting O 
mGlu7 O 
receptors O 
with O 
selective O 
antagonist O 
drugs O 
may O 
be O 
an O 
effective O 
and O 
safe O 
strategy O 
for O 
the O 
treatment O 
of O 
anxiety O 
disorders O 
. O 

feeding O 
- O 
specific O 
circuits O 
between O 
the O 
nucleus O 
accumbens O 
shell O 
and O 
the O 
lateral O 
hypothalamus O 
: O 
regulation O 
by O 
glutamate B-TRIVIAL 
and O 
GABA B-ABBREVIATION 
receptor O 
subtypes O 
. O 

nucleus O 
accumbens O 
shell O 
( O 
AcbSh O 
) O 
and O 
the O 
lateral O 
hypothalamus O 
( O 
LH O 
) O 
are O 
both O 
involved O 
in O 
the O 
control O 
of O 
food O 
intake O 
. O 
Activation O 
of O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptors O 
or O 
blockade O 
of O 
AMPA B-ABBREVIATION 
and O 
kainate B-TRIVIAL 
receptors O 
within O 
the O 
AcbSh O 
induces O 
feeding O 
, O 
as O 
does O 
blockade O 
of O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptors O 
or O 
activation O 
of O 
NMDA B-ABBREVIATION 
receptors O 
in O 
the O 
LH O 
. O 
Further O 
, O 
evidence O 
suggests O 
that O 
feeding O 
induced O 
via O 
the O 
AcbSh O 
can O 
be O 
suppressed O 
by O 
LH O 
inhibition O 
. O 
However O 
, O 
it O 
is O 
unclear O 
if O 
this O 
suppression O 
is O 
specific O 
to O 
feeding O 
. O 
Adult O 
male O 
Sprague-Dawley O 
rats O 
with O 
3 O 
intracranial O 
guide O 
cannulas O 
, O 
one O 
unilaterally O 
into O 
the O 
AcbSh O 
and O 
two O 
bilaterally O 
into O 
the O 
LH O 
, O 
were O 
used O 
to O 
explore O 
this O 
issue O 
. O 
DNQX B-ABBREVIATION 
( O 
1.25 O 
μg O 
) O 
or O 
muscimol B-TRIVIAL 
( O 
100 O 
ng O 
) O 
infused O 
into O 
the O 
AcbSh O 
unilaterally O 
elicited O 
feeding O 
, O 
and O 
this O 
elicited O 
intake O 
was O 
suppressed O 
by O 
bilateral O 
LH O 
injection O 
of O 
d-AP5 B-IDENTIFIER 
( O 
2 O 
μg O 
) O 
or O 
muscimol B-TRIVIAL 
( O 
25 O 
ng O 
) O 
. O 
The O 
effectiveness O 
of O 
d-AP5 B-IDENTIFIER 
or O 
muscimol B-TRIVIAL 
infusion O 
into O 
either O 
the O 
LH O 
site O 
ipsilateral O 
or O 
contralateral O 
to O 
the O 
AcbSh O 
injection O 
was O 
compared O 
. O 
Ipsilateral O 
LH O 
injection O 
of O 
d-AP5 B-IDENTIFIER 
or O 
muscimol B-TRIVIAL 
was O 
significantly O 
more O 
effective O 
than O 
contralateral O 
injection O 
in O 
suppressing O 
food O 
intake O 
initiated O 
by O 
AcbSh O 
injection O 
of O 
DNQX B-ABBREVIATION 
or O 
muscimol B-TRIVIAL 
. O 
These O 
results O 
add O 
to O 
the O 
prior O 
evidence O 
that O 
inhibition O 
of O 
the O 
LH O 
through O 
pharmacological O 
modulation O 
of O 
NMDA B-ABBREVIATION 
or O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptors O 
specifically O 
suppresses O 
feeding O 
initiated O 
by O 
AcbSh O 
inhibition O 
, O 
and O 
that O 
these O 
two O 
regions O 
communicate O 
via O 
an O 
ipsilateral O 
circuit O 
to O 
specifically O 
regulate O 
feeding O 
. O 

, O 
structural O 
elucidation O 
, O 
comparison O 
of O 
DNA O 
binding O 
, O 
cleavage O 
, O 
radical O 
scavenging O 
activity O 
and O 
anticancer O 
activity O 
of O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
complex O 
with O 
5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)-amino]-1,2-dihydro-pyrazol-3-one B-SYSTEMATIC 
Schiff B-FAMILY 
base I-FAMILY 
ligand O 
. O 

novel O 
copper B-FAMILY 
(I) I-FAMILY 
Schiff I-FAMILY 
base I-FAMILY 
complex O 
has O 
been O 
synthesized O 
and O 
fully O 
characterized O 
by O 
spectral O 
, O 
analytical O 
and O 
structural O 
modes O 
. O 
Single O 
crystal O 
X-ray O 
diffraction O 
studies O 
revealed O 
that O 
the O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
complex O 
[ B-FAMILY 
CuCl(PPh3)L I-FAMILY 
] I-FAMILY 
has O 
a O 
distorted O 
tetrahedral O 
geometry O 
around O 
the O 
central O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
ion O 
. O 
The O 
interaction O 
of O 
the O 
ligand O 
and O 
the O 
complex O 
with O 
CT-DNA O 
has O 
been O 
explored O 
by O 
absorption O 
titration O 
method O 
which O 
revealed O 
that O 
the O 
compounds O 
could O 
interact O 
with O 
CT-DNA O 
through O 
intercalation O 
. O 
A O 
gel O 
electrophoresis O 
assay O 
demonstrated O 
the O 
ability O 
of O 
the O 
complex O 
to O 
cleave O 
the O 
pBR322 O 
DNA O 
. O 
The O 
antioxidative O 
properties O 
showed O 
that O 
the O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
complex O 
has O 
a O 
strong O 
radical O 
- O 
scavenging O 
potency O 
than O 
ligands O 
. O 
Further O 
the O 
cytotoxic O 
effect O 
of O 
the O 
compounds O 
examined O 
on O 
cancerous O 
cell O 
lines O 
showed O 
that O 
the O 
complex O 
exhibited O 
substantial O 
anticancer O 
activity O 
. O 

of O 
quantitative O 
structure O 
- O 
metabolism O 
( O 
QSMR O 
) O 
relationships O 
for O 
substituted O 
anilines B-FAMILY 
based O 
on O 
computational O 
chemistry O 
. O 

1 O 
. O 
A O 
novel O 
stepwise O 
classification O 
approach O 
for O 
predicting O 
the O 
metabolic O 
fate O 
of O 
substituted O 
anilines B-FAMILY 
, O 
based O 
on O 
calculated O 
physicochemical O 
parameters O 
of O 
the O 
parent O 
anilines B-FAMILY 
, O 
was O 
developed O 
. O 
Based O 
on O 
multivariate O 
pattern O 
recognition O 
methods O 
( O 
PLS-DA O 
or O 
soft O 
independent O 
modelling O 
of O 
class O 
analogy O 
[ O 
SIMCA O 
] O 
) O 
, O 
these O 
models O 
allowed O 
prediction O 
of O 
N B-FORMULA 
-acetylation O 
and O 
subsequent O 
N-oxanilic B-TRIVIAL 
acid I-TRIVIAL 
formation O 
. O 
These O 
classification O 
methods O 
provided O 
an O 
improved O 
classification O 
success O 
when O 
compared O 
with O 
existing O 
quantitative O 
structure O 
- O 
metabolism O 
relationship O 
models O 
for O 
substituted O 
anilines B-FAMILY 
. O 
2 O 
. O 
Modelling O 
the O 
physicochemical O 
properties O 
of O 
the O 
N B-FORMULA 
-acetylated O 
compounds O 
was O 
considered O 
as O 
an O 
addition O 
to O 
the O 
stepwise O 
model O 
. O 
Inclusion O 
of O 
parameters O 
describing O 
the O 
N-acetyl B-SYSTEMATIC 
moiety O 
had O 
little O 
effect O 
on O 
the O 
predictive O 
ability O 
of O 
a O 
stepwise O 
parent O 
to O 
N-acetyl B-SYSTEMATIC 
to O 
N-oxanilic B-TRIVIAL 
acid I-TRIVIAL 
PLS-DA O 
model O 
, O 
and O 
had O 
a O 
negative O 
impact O 
on O 
that O 
of O 
SIMCA O 
models O 
. O 
This O 
was O 
attributed O 
to O 
the O 
relatively O 
small O 
contribution O 
to O 
the O 
total O 
parameter O 
variance O 
caused O 
by O 
differences O 
arising O 
as O 
a O 
result O 
of O 
N B-FORMULA 
-acetylation O 
compared O 
to O 
the O 
contribution O 
made O 
by O 
the O 
substituent O 
effects O 
. O 
3 O 
. O 
Calculation O 
of O 
physicochemical O 
properties O 
incorporating O 
the O 
effect O 
of O 
solvation O 
using O 
ab O 
initio O 
methods O 
improved O 
the O 
classification O 
model O 
in O 
terms O 
of O 
both O 
the O 
visual O 
separation O 
in O 
multivariate O 
projections O 
and O 
prediction O 
accuracy O 
. O 

and O 
IGF-I O 
synergistically O 
stimulate O 
gonadal O 
steroid B-FAMILY 
production O 
; O 
conversely O 
, O 
silencing O 
the O 
FSH O 
or O 
the O 
IGF-I O 
genes O 
leads O 
to O 
infertility O 
and O 
hypogonadism O 
. O 
To O 
determine O 
the O 
molecular O 
link O 
between O 
these O 
hormones O 
, O 
we O 
examined O 
the O 
signaling O 
cross O 
talk O 
downstream O 
of O 
their O 
receptors O 
. O 
In O 
human O 
and O 
rodent O 
granulosa O 
cells O 
( O 
GCs O 
) O 
, O 
IGF-I O 
potentiated O 
the O 
stimulatory O 
effects O 
of O 
FSH O 
and O 
cAMP B-ABBREVIATION 
on O 
the O 
expression O 
of O 
steroidogenic O 
genes O 
. O 
In O 
contrast O 
, O 
inhibition O 
of O 
IGF-I O 
receptor O 
( O 
IGF-IR O 
) O 
activity O 
or O 
expression O 
using O 
pharmacological O 
, O 
genetic O 
, O 
or O 
biochemical O 
approaches O 
prevented O 
the O 
FSH- O 
and O 
cAMP B-ABBREVIATION 
-induced O 
expression O 
of O 
steroidogenic O 
genes O 
and O 
estradiol B-TRIVIAL 
production O 
. O 
In O 
vivo O 
experiments O 
demonstrated O 
that O 
IGF-IR O 
inactivation O 
reduces O 
the O 
stimulation O 
of O 
steroidogenic O 
genes O 
and O 
follicle O 
growth O 
by O 
gonadotropins O 
. O 
FSH O 
or O 
IGF-I O 
alone O 
stimulated O 
protein O 
kinase O 
B O 
( O 
PKB O 
) O 
, O 
which O 
is O 
also O 
known O 
as O 
AKT O 
and O 
in O 
combination O 
synergistically O 
increased O 
AKT O 
phosphorylation O 
. O 
Remarkably O 
, O 
blocking O 
IGF-IR O 
expression O 
or O 
activity O 
decreased O 
AKT O 
basal O 
activity O 
and O 
abolished O 
AKT O 
activation O 
by O 
FSH O 
. O 
In O 
GCs O 
lacking O 
IGF-IR O 
activity O 
, O 
FSH O 
stimulation O 
of O 
Cyp19 O 
expression O 
was O 
rescued O 
by O 
overexpression O 
of O 
constitutively O 
active O 
AKT O 
. O 
Our O 
findings O 
demonstrate O 
, O 
for O 
the O 
first O 
time O 
, O 
that O 
in O 
human O 
, O 
mouse O 
, O 
and O 
rat O 
GCs O 
, O 
the O 
well O 
- O 
known O 
stimulatory O 
effect O 
of O 
FSH O 
on O 
Cyp19 O 
and O 
AKT O 
depends O 
on O 
IGF-I O 
and O 
on O 
the O 
expression O 
and O 
activation O 
of O 
the O 
IGF-IR O 
. O 

reduces O 
functional O 
connectivity O 
of O 
nucleus O 
accumbens O 
in O 
brain O 
reward O 
circuit O 
. O 

of O 
dopamine B-TRIVIAL 
in O 
the O 
nucleus O 
accumbens O 
( O 
NAcc O 
) O 
is O 
essential O 
for O 
acute O 
drug O 
reward O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
trace O 
the O 
reinforcing O 
effect O 
of O 
dopamine B-TRIVIAL 
release O 
by O 
measuring O 
the O 
functional O 
connectivity O 
( O 
FC O 
) O 
between O 
the O 
NAcc O 
and O 
brain O 
regions O 
involved O 
in O 
a O 
limbic O 
cortical O 
- O 
subcortical O 
circuit O 
during O 
a O 
dopaminergic O 
challenge O 
. O 
Twenty O 
healthy O 
volunteers O 
received O 
single O 
doses O 
of O 
methylphenidate B-SYSTEMATIC 
( O 
40 O 
mg O 
) O 
and O 
placebo O 
on O 
separate O 
test O 
days O 
according O 
to O 
a O 
double O 
- O 
blind O 
, O 
cross O 
- O 
over O 
study O 
design O 
. O 
Resting O 
state O 
functional O 
magnetic O 
resonance O 
imaging O 
( O 
fMRI O 
) O 
was O 
measured O 
between O 
1.5 O 
and O 
2 O 
h O 
postdosing O 
. O 
FC O 
between O 
regions O 
of O 
interest O 
( O 
ROI O 
) O 
in O 
the O 
NAcc O 
, O 
the O 
medial O 
dorsal O 
nucleus O 
( O 
MDN O 
) O 
of O 
the O 
thalamus O 
and O 
remote O 
areas O 
within O 
the O 
limbic O 
circuit O 
was O 
explored O 
. O 
Methylphenidate B-SYSTEMATIC 
significantly O 
reduced O 
FC O 
between O 
the O 
NAcc O 
and O 
the O 
basal O 
ganglia O 
( O 
i.e O 
. O 
, O 
subthalamic O 
nucleus O 
and O 
ventral O 
pallidum B-SYSTEMATIC 
( O 
VP O 
) O 
) O 
, O 
relative O 
to O 
placebo O 
. O 
Methylphenidate B-SYSTEMATIC 
also O 
decreased O 
FC O 
between O 
the O 
NAcc O 
and O 
the O 
medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
as O 
well O 
as O 
the O 
temporal O 
cortex O 
. O 
Methylphenidate B-SYSTEMATIC 
did O 
not O 
affect O 
FC O 
between O 
MDN O 
and O 
the O 
limbic O 
circuit O 
. O 
It O 
is O 
concluded O 
that O 
methylphenidate B-SYSTEMATIC 
directly O 
affects O 
the O 
limbic O 
reward O 
circuit O 
. O 
Drug O 
- O 
induced O 
changes O 
in O 
FC O 
of O 
the O 
NAcc O 
may O 
serve O 
as O 
a O 
useful O 
marker O 
of O 
drug O 
activity O 
in O 
in O 
the O 
brain O 
reward O 
circuit O 
. O 

effects O 
of O 
alpha B-TRIVIAL 
lipoic I-TRIVIAL 
acid I-TRIVIAL 
versus O 
N-acetylcysteine B-SYSTEMATIC 
on O 
ifosfamide B-TRIVIAL 
-induced O 
nephrotoxicity O 
. O 

( O 
IFO B-ABBREVIATION 
) O 
is O 
a O 
highly O 
effective O 
chemotherapeutic O 
agent O 
for O 
treating O 
a O 
variety O 
of O 
pediatric O 
solid O 
tumors O 
. O 
However O 
, O 
its O 
use O 
is O 
limited O 
due O 
to O 
its O 
serious O 
side O 
effect O 
on O 
kidneys O 
. O 
The O 
side-chain O 
oxidation O 
of O 
IFO B-ABBREVIATION 
in O 
renal O 
tubular O 
cells O 
produces O 
a O 
reactive O 
toxic O 
metabolite O 
that O 
is O 
believed O 
to O 
be O 
responsible O 
for O 
its O 
nephrotoxic O 
effect O 
. O 
Therefore O 
, O 
this O 
study O 
was O 
carried O 
out O 
to O 
investigate O 
the O 
possible O 
underlying O 
mechanisms O 
that O 
may O 
be O 
involved O 
in O 
IFO B-ABBREVIATION 
-induced O 
nephrotoxicity O 
, O 
including O 
free O 
radical O 
generation O 
and O 
the O 
possible O 
role O 
of O 
alpha B-TRIVIAL 
lipoic I-TRIVIAL 
acid I-TRIVIAL 
( O 
ALA B-ABBREVIATION 
) O 
versus O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
in O 
protection O 
against O 
this O 
toxicity O 
. O 
Male O 
albino O 
rats O 
were O 
injected O 
intraperitoneally O 
with O 
saline O 
, O 
IFO B-ABBREVIATION 
( O 
50 O 
mg O 
/ O 
kg O 
daily O 
for O 
5 O 
days O 
) O 
, O 
IFO B-ABBREVIATION 
+ O 
ALA B-ABBREVIATION 
( O 
100 O 
mg O 
/ O 
kg O 
daily O 
for O 
8 O 
days O 
) O 
and O 
IFO B-ABBREVIATION 
+ O 
NAC B-ABBREVIATION 
( O 
200 O 
mg O 
/ O 
kg O 
daily O 
for O 
8 O 
days O 
) O 
. O 
Kidney O 
malondialdehyde B-TRIVIAL 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
glutathione B-TRIVIAL 
contents O 
and O 
serum O 
biochemical O 
parameters O 
and O 
histopathological O 
analysis O 
were O 
determined O 
. O 
Both O 
ALA B-ABBREVIATION 
and O 
NAC B-ABBREVIATION 
markedly O 
reduced O 
the O 
severity O 
of O 
renal O 
dysfunction O 
induced O 
by O 
IFO B-ABBREVIATION 
. O 
NAC B-ABBREVIATION 
was O 
more O 
nephroprotective O 
than O 
ALA B-ABBREVIATION 
. O 
This O 
study O 
suggests O 
that O 
oxidative O 
stress O 
is O 
possibly O 
involved O 
in O 
the O 
IFO B-ABBREVIATION 
-induced O 
nephrotoxicity O 
in O 
rats O 
. O 
The O 
study O 
also O 
suggests O 
the O 
potential O 
therapeutic O 
role O 
for O 
ALA B-ABBREVIATION 
and O 
NAC B-ABBREVIATION 
against O 
IFO B-ABBREVIATION 
-induced O 
nephrotoxicity O 
. O 

Polarized O 
Up-Conversion O 
of O 
Tm(3+)-Yb(3+) B-FORMULA 
Doped I-FORMULA 
β-NaYF4 I-FORMULA 
Single O 
Nanorod O 
. O 

luminescence O 
in O 
rare O 
earth O 
ions O 
( O 
REs O 
) O 
doped O 
nanoparticles O 
has O 
attracted O 
considerable O 
research O 
attention O 
for O 
the O 
promising O 
applications O 
in O 
solid O 
- O 
state O 
lasers O 
, O 
three O 
- O 
dimensional O 
displays O 
, O 
solar O 
cells O 
, O 
biological O 
imaging O 
, O 
and O 
so O 
forth O 
. O 
However O 
, O 
there O 
have O 
been O 
no O 
reports O 
on O 
REs O 
doped O 
nanoparticles O 
to O 
investigate O 
their O 
polarized O 
energy O 
transfer O 
up O 
- O 
conversion O 
, O 
especially O 
for O 
single O 
particle O 
. O 
Herein O 
, O 
the O 
polarized O 
energy O 
transfer O 
up O 
- O 
conversion O 
from O 
REs O 
doped O 
fluoride B-SYSTEMATIC 
nanorods O 
is O 
demonstrated O 
in O 
a O 
single O 
particle O 
spectroscopy O 
mode O 
for O 
the O 
first O 
time O 
. O 
Unique O 
luminescent O 
phenomena O 
, O 
for O 
example O 
, O 
sharp O 
energy O 
level O 
split O 
and O 
singlet O 
- O 
to O 
- O 
triplet O 
transitions O 
at O 
room O 
temperature O 
, O 
multiple O 
discrete O 
luminescence O 
intensity O 
periodic O 
variation O 
with O 
polarization O 
direction O 
, O 
are O 
observed O 
upon O 
excitation O 
with O 
980 O 
nm O 
linearly O 
polarized O 
laser O 
. O 
Furthermore O 
, O 
nanorods O 
with O 
the O 
controllable O 
aspect O 
ratio O 
and O 
symmetry O 
are O 
fabricated O 
for O 
analysis O 
of O 
the O 
mechanism O 
of O 
polarization O 
anisotropy O 
. O 
The O 
comparative O 
experiments O 
suggest O 
that O 
intraions O 
transition O 
properties O 
and O 
crystal O 
local O 
symmetry O 
dominate O 
the O 
polarization O 
anisotropy O 
, O 
which O 
is O 
also O 
confirmed O 
by O 
density O 
functional O 
theory O 
calculations O 
. O 
Taking O 
advantage O 
of O 
the O 
REs O 
based O 
up O 
- O 
conversion O 
, O 
potential O 
application O 
in O 
polarized O 
microscopic O 
multi O 
- O 
information O 
transportation O 
is O 
suggested O 
for O 
the O 
polarization O 
anisotropy O 
from O 
REs O 
doped O 
fluoride B-SYSTEMATIC 
single O 
nanorod O 
or O 
nanorod O 
array O 
. O 

Field-Effect O 
Transistors O 
Having O 
Combined O 
Organic O 
Semiconductor O 
and O 
Metal B-FAMILY 
Oxide I-FAMILY 
Layers O 
. O 

new O 
organic O 
light O 
- O 
emitting O 
field O 
- O 
effect O 
transistor O 
characterized O 
by O 
a O 
metal B-FAMILY 
oxide I-FAMILY 
layer O 
inserted O 
between O 
the O 
organic O 
layer O 
and O 
the O 
gate O 
insulator O 
is O 
proposed O 
. O 
The O 
metal B-FAMILY 
oxide I-FAMILY 
is O 
indirectly O 
connected O 
with O 
source O 
and O 
drain O 
electrodes O 
through O 
the O 
organic O 
layer O 
. O 
Upon O 
increasing O 
the O 
potential O 
difference O 
between O 
the O 
source O 
and O 
drain O 
electrodes O 
, O 
the O 
emission O 
becomes O 
exceedingly O 
strong O 
and O 
the O 
emission O 
region O 
encompasses O 
the O 
whole O 
channel O 
zone O 
. O 

diterpenoids B-FAMILY 
from O 
Vitex O 
trifolia O 
. O 

new O 
halimane B-FAMILY 
diterpenoid I-FAMILY 
, O 
13-hydroxy-5(10),14-halimadien-6-one B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
two O 
new O 
labdane B-FAMILY 
diterpenoids I-FAMILY 
, O 
6α,7α-diacetoxy-13-hydroxy-8(9),14-labdadien B-SYSTEMATIC 
( O 
2 O 
) O 
and O 
9-hydroxy-13(14)-labden-15,16-olide B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
were O 
isolated O 
for O 
the O 
first O 
time O 
, O 
along O 
with O 
fifteen O 
known O 
compounds O 
, O 
from O 
the O 
hexane B-SYSTEMATIC 
soluble O 
fraction O 
of O 
methanolic O 
extract O 
of O 
Vitex O 
trifolia O 
leaves O 
. O 
The O 
structures O 
of O 
these O 
new O 
diterpenoids B-FAMILY 
were O 
elucidated O 
by O 
spectral O 
analysis O 
. O 
Their O 
relative O 
configurations O 
were O 
established O 
using O 
analysis O 
of O 
NOESY O 
correlations O 
and O 
coupling O 
constants O 
observed O 
in O 
(1)H B-FORMULA 
NMR O 
. O 
Compounds O 
2 O 
, O 
3 O 
and O 
another O 
known O 
diterpenoid B-FAMILY 
, O 
isoambreinolide B-TRIVIAL 
( O 
4 O 
) O 
were O 
evaluated O 
for O 
antitubercular O 
activity O 
. O 
3 O 
and O 
4 O 
exhibited O 
antitubercular O 
activity O 
( O 
MIC=100 O 
and O 
25μg O 
/ O 
ml O 
) O 
against O 
Mycobacterium O 
tuberculosis O 
H37Rv O 
in O 
BACTEC-460 O 
assay O 
. O 

is O 
an O 
infectious O 
disease O 
causing O 
almost O 
one O 
million O 
deaths O 
each O 
year O 
. O 
There O 
is O 
an O 
urgent O 
need O 
for O 
discovery O 
of O 
new O 
antimalarial O 
compounds O 
. O 
Natural O 
products O 
have O 
been O 
the O 
single O 
most O 
productive O 
source O 
of O 
leads O 
for O 
the O 
development O 
of O 
drugs O 
, O 
because O 
of O 
their O 
great O 
variety O 
of O 
chemical O 
structures O 
. O 
This O 
review O 
covers O 
studies O 
on O 
antimalarial O 
natural O 
products O 
isolated O 
from O 
plants O 
, O 
published O 
from O 
January O 
2010 O 
until O 
April O 
2012 O 
. O 
A O 
total O 
of O 
171 O 
structures O 
comprising O 
alkaloids O 
, O 
terpenoids B-FAMILY 
, O 
phenolics B-FAMILY 
and O 
other O 
metabolites O 
are O 
listed O 
in O 
this O 
review O 
, O 
including O 
information O 
on O 
their O 
antiplasmodial O 
and O 
cytotoxic O 
activity O 
. O 

the O 
absolute O 
configurations O 
of O 
coatlines B-FAMILY 
via O 
density O 
functional O 
theory O 
calculations O 
of O 
electronic O 
circular O 
dichroism O 
spectra O 
. O 

A I-TRIVIAL 
( O 
1 O 
) O 
and O 
α-epi-coatline B-TRIVIAL 
A I-TRIVIAL 
( O 
4 O 
) O 
co O 
- O 
occur O 
in O 
the O 
trunk O 
extract O 
of O 
Andira O 
coriacea O 
. O 
Inspection O 
of O 
their O 
chiroptical O 
properties O 
led O 
to O 
intriguing O 
results O 
. O 
After O 
a O 
careful O 
examination O 
of O 
the O 
experimental O 
data O 
used O 
for O 
the O 
previously O 
reported O 
absolute O 
configuration O 
of O 
these O 
compounds O 
, O 
some O 
uncertainties O 
were O 
identified O 
. O 
A O 
combined O 
theoretical O 
approach O 
including O 
conformational O 
analyses O 
and O 
calculation O 
of O 
electronic O 
circular O 
dichroism O 
( O 
ECD O 
) O 
spectra O 
, O 
in O 
addition O 
with O 
experimental O 
data O 
obtained O 
for O 
schoepfin B-TRIVIAL 
A I-TRIVIAL 
( O 
5 O 
) O 
and O 
the O 
new O 
schoepfin B-TRIVIAL 
D I-TRIVIAL 
( O 
6 O 
) O 
isolated O 
from O 
Senna O 
quinquangulata O 
, O 
allowed O 
the O 
revision O 
of O 
the O 
absolute O 
configuration O 
of O 
coatlines B-FAMILY 
A O 
( O 
1 O 
) O 
and O 
B O 
( O 
2 O 
) O 
. O 

RELEVANCE O 
: O 
Different O 
parts O 
of O 
Mimosa O 
pigra O 
( O 
MPG O 
) O 
are O 
used O 
in O 
traditional O 
medicine O 
in O 
Madagascar O 
, O 
tropical O 
Africa O 
, O 
South O 
America O 
and O 
Indonesia O 
for O 
various O 
troubles O 
including O 
cardiovascular O 
disorders O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
investigate O 
the O 
mechanisms O 
underlying O 
the O 
vascular O 
effects O 
of O 
MPG O 
by O 
assessing O 
in O 
vitro O 
its O 
antioxidant O 
and O 
anti-inflammatory O 
properties O 
, O 
and O 
its O 
vascular O 
relaxing O 
effects O 
, O 
and O 
in O 
vivo O 
, O 
its O 
action O 
on O 
hypoxic O 
pulmonary O 
hypertension O 
( O 
PAH O 
) O 
in O 
rats O 
. O 
MATERIAL O 
AND O 
METHODS O 
: O 
The O 
antioxidant O 
activity O 
of O 
MPG O 
leaf O 
hydromethanolic O 
extract O 
was O 
determined O 
by O 
using O 
both O 
the O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
radical O 
scavenging O 
and O 
the O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
in O 
vitro O 
assays O 
. O 
Anti-inflammatory O 
properties O 
were O 
assayed O 
on O 
TNFα-induced O 
VCAM-1 O 
expression O 
in O 
endothelial O 
cells O 
. O 
The O 
vasorelaxant O 
effect O 
of O 
MPG O 
extract O 
was O 
studied O 
on O 
rat O 
arterial O 
rings O 
pre O 
- O 
contracted O 
with O 
phenylephrine B-TRIVIAL 
( O 
1μM O 
) O 
in O 
the O 
presence O 
or O 
absence O 
of O 
the O 
endothelium O 
. O 
In O 
vivo O 
MPG O 
extract O 
effects O 
were O 
analyzed O 
in O 
chronic O 
hypoxic O 
PAH O 
, O 
obtained O 
by O 
housing O 
male O 
Wistar O 
rats O 
, O 
orally O 
treated O 
or O 
not O 
with O 
MPG O 
extract O 
( O 
400mg O 
/ O 
kg O 
/ O 
d O 
) O 
, O 
in O 
a O 
hypobaric O 
chamber O 
for O 
21 O 
days O 
. O 
RESULTS O 
: O 
MPG O 
leaf O 
extract O 
had O 
antioxidant O 
and O 
anti-inflammatory O 
properties O 
. O 
It O 
induced O 
endothelium O 
- O 
dependent O 
, O 
NO B-FORMULA 
-mediated O 
relaxation O 
of O 
rat O 
aorta O 
and O 
pulmonary O 
artery O 
. O 
In O 
vivo O 
, O 
chronic O 
MPG O 
treatment O 
reduced O 
hypoxic O 
PAH O 
in O 
rat O 
by O 
decreasing O 
by O 
22.3% O 
the O 
pulmonary O 
arterial O 
pressure O 
and O 
by O 
20.0% O 
and O 
23.9% O 
the O 
pulmonary O 
artery O 
and O 
cardiac O 
remodelling O 
, O 
respectively O 
. O 
This O 
effect O 
was O 
associated O 
with O 
a O 
restoration O 
of O 
endothelium O 
function O 
and O 
a O 
2.3-fold O 
increase O 
in O 
endothelial O 
NO B-FORMULA 
synthase O 
phosphorylation O 
. O 
MPG O 
leaf O 
hydromethanolic O 
extract O 
contained O 
tryptophan B-TRIVIAL 
and O 
flavonoids B-FAMILY 
, O 
including O 
quercetin B-FAMILY 
glycosides I-FAMILY 
. O 
Both O 
compounds O 
also O 
efficiently O 
limit O 
hypoxia O 
- O 
induced O 
PAH O 
. O 
CONCLUSIONS O 
: O 
Our O 
results O 
show O 
endothelial O 
protective O 
action O 
of O 
MPG O 
leaf O 
hydromethanolic O 
extract O 
which O 
is O 
likely O 
to O 
be O 
due O 
to O 
its O 
antioxidant O 
action O 
. O 
MPG O 
successfully O 
attenuated O 
the O 
development O 
of O 
PAH O 
, O 
thus O 
demonstrating O 
the O 
protective O 
effect O 
of O 
MPG O 
on O 
cardiovascular O 
diseases O 
. O 

and O 
microglia O 
respond O 
to O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
injury O 
with O 
changes O 
in O 
morphology O 
, O 
proliferation O 
, O 
migration O 
and O 
expression O 
of O 
inflammatory O 
regulators O 
. O 
This O 
phenomenon O 
is O 
known O 
as O 
reactive O 
gliosis O 
. O 
Activation O 
of O 
astrocytes O 
and O 
microglia O 
after O 
acute O 
neural O 
insults O 
, O 
such O 
as O 
stroke O 
or O 
traumatic O 
CNS O 
injury O 
, O 
is O 
considered O 
to O 
be O 
an O 
adaptive O 
response O 
that O 
contributes O 
to O 
minimize O 
neuronal O 
damage O 
. O 
However O 
, O 
reactive O 
gliosis O 
may O 
amplify O 
CNS O 
damage O 
under O 
chronic O 
neurodegenerative O 
conditions O 
. O 
Progesterone B-TRIVIAL 
, O 
estradiol B-TRIVIAL 
and O 
testosterone B-TRIVIAL 
have O 
been O 
shown O 
to O 
control O 
reactive O 
gliosis O 
in O 
different O 
models O 
of O 
CNS O 
injury O 
, O 
modifying O 
the O 
number O 
of O 
reactive O 
astrocytes O 
and O 
reactive O 
microglia O 
and O 
the O 
expression O 
of O 
anti-inflammatory O 
and O 
proinflammatory O 
mediators O 
. O 
The O 
actions O 
of O 
gonadal O 
hormones O 
on O 
reactive O 
gliosis O 
involve O 
different O 
mechanisms O 
, O 
including O 
the O 
modulation O 
of O 
the O 
activity O 
of O 
steroid B-FAMILY 
receptors O 
, O 
such O 
as O 
estrogen B-FAMILY 
receptors O 
α O 
and O 
β O 
, O 
the O 
regulation O 
of O 
nuclear O 
factor-κB O 
mediated O 
transcription O 
of O 
inflammatory O 
molecules O 
and O 
the O 
recruitment O 
of O 
the O 
transcriptional O 
corepressor O 
c O 
- O 
terminal O 
binding O 
protein O 
to O 
proinflammatory O 
promoters O 
. O 
In O 
addition O 
, O 
the O 
Parkinson's O 
disease O 
related O 
gene O 
parkin O 
and O 
the O 
endocannabinoid O 
system O 
also O 
participate O 
in O 
the O 
regulation O 
of O 
reactive O 
gliosis O 
by O 
estradiol B-TRIVIAL 
. O 
The O 
control O 
exerted O 
by O 
gonadal O 
hormones O 
on O 
reactive O 
gliosis O 
may O 
affect O 
the O 
response O 
of O 
neural O 
tissue O 
to O 
trauma O 
and O 
neurodegeneration O 
and O 
may O 
contribute O 
to O 
sex O 
differences O 
in O 
the O 
manifestation O 
of O 
neurodegenerative O 
diseases O 
. O 
However O 
, O 
the O 
precise O 
functional O 
consequences O 
of O 
the O 
regulation O 
of O 
reactive O 
gliosis O 
by O 
gonadal O 
hormones O 
under O 
acute O 
and O 
chronic O 
neurodegenerative O 
conditions O 
are O 
still O 
not O 
fully O 
clarified O 
. O 

metabolism O 
of O 
ornithine B-SYSTEMATIC 
phenylacetate I-SYSTEMATIC 
( O 
OP O 
) O 
-- O 
a O 
novel O 
strategy O 
for O 
treatment O 
of O 
hyperammonemia O 
. O 

administration O 
of O 
ornithine B-TRIVIAL 
and O 
phenylacetate B-SYSTEMATIC 
( O 
OP O 
) O 
is O 
proposed O 
as O 
a O 
novel O 
treatment O 
of O 
hyperammonemia O 
and O 
hepatic O 
encephalopathy O 
. O 
Ornithine B-TRIVIAL 
is O 
believed O 
to O 
increase O 
ammonia B-SYSTEMATIC 
fixation O 
into O 
glutamine B-TRIVIAL 
in O 
muscle O 
tissue O 
and O 
glutamine B-TRIVIAL 
is O 
subsequently O 
thought O 
to O 
react O 
with O 
phenylacetate B-SYSTEMATIC 
forming O 
phenylacetylglutamine B-SYSTEMATIC 
( O 
PAGN B-ABBREVIATION 
) O 
which O 
is O 
excreted O 
in O 
urine O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
elucidate O 
the O 
interorgan O 
metabolism O 
of O 
ornithine B-TRIVIAL 
and O 
ammonia B-SYSTEMATIC 
in O 
cirrhotic O 
rats O 
treated O 
with O 
OP O 
in O 
order O 
to O 
obtain O 
an O 
understanding O 
of O 
the O 
underlying O 
mechanisms O 
of O 
the O 
beneficial O 
effect O 
of O 
the O 
treatment O 
, O 
which O 
are O 
largely O 
unknown O 
. O 
Bile O 
duct O 
ligated O 
cirrhotic O 
rats O 
and O 
SHAM O 
rats O 
were O 
treated O 
with O 
OP O 
or O 
saline O 
for O 
five O 
days O 
. O 
[2,5-(15)N]Ornithine B-SYSTEMATIC 
or O 
(15)NH(4)(+) B-FORMULA 
were O 
administered O 
intravenously O 
and O 
the O 
incorporation O 
of O 
(15)N B-FORMULA 
in O 
amino B-FAMILY 
acids I-FAMILY 
as O 
well O 
as O 
the O 
content O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
were O 
subsequently O 
determined O 
in O 
plasma O 
, O 
skeletal O 
muscle O 
, O 
liver O 
and O 
kidney O 
. O 
In O 
BDL O 
rats O 
, O 
OP O 
treatment O 
reduced O 
arterial O 
ammonia B-SYSTEMATIC 
concentration O 
and O 
increased O 
that O 
of O 
glutamine B-TRIVIAL 
30 O 
min O 
after O 
the O 
treatment O 
but O 
not O 
after O 
15 O 
h O 
. O 
OP O 
treatment O 
did O 
not O 
increase O 
(15)N B-FORMULA 
labeling O 
in O 
glutamine B-TRIVIAL 
from O 
[2,5-(15)N]ornithine B-SYSTEMATIC 
and O 
(15)NH(4)(+) B-FORMULA 
in O 
skeletal O 
muscle O 
or O 
liver O 
. O 
However O 
, O 
the O 
extent O 
of O 
glutamine B-TRIVIAL 
labeling O 
from O 
[2,5-(15)N]ornithine B-SYSTEMATIC 
or O 
(15)NH(4)(+) B-FORMULA 
was O 
similar O 
in O 
arterial O 
blood O 
and O 
liver O 
and O 
higher O 
than O 
that O 
in O 
skeletal O 
muscle O 
. O 
These O 
findings O 
suggest O 
that O 
the O 
effect O 
of O 
OP O 
was O 
related O 
to O 
hepatic O 
metabolism O 
of O 
ornithine B-TRIVIAL 
. O 
PAGN B-ABBREVIATION 
could O 
not O 
be O 
detected O 
in O 
urine O 
or O 
blood O 
in O 
any O 
of O 
the O 
rats O 
which O 
may O 
explain O 
why O 
OP O 
treatment O 
only O 
reduced O 
arterial O 
ammonia B-SYSTEMATIC 
transiently O 
. O 

K2 I-FAMILY 
covalently O 
binds O 
to O 
Bak O 
and O 
induces O 
Bak O 
- O 
mediated O 
apoptosis O 
. O 

K2 I-FAMILY 
( O 
VK2 B-ABBREVIATION 
, O 
menaquinone B-FAMILY 
) O 
is O 
known O 
to O 
have O 
anticancer O 
activity O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Although O 
its O 
effect O 
is O 
thought O 
to O 
be O 
mediated O 
, O 
at O 
least O 
in O 
part O 
, O 
by O 
the O 
induction O 
of O 
apoptosis O 
, O 
the O 
underlying O 
molecular O 
mechanism O 
remains O 
elusive O 
. O 
Here O 
, O 
we O 
identified O 
Bcl-2 O 
antagonist O 
killer O 
1 O 
( O 
Bak O 
) O 
as O 
a O 
molecular O 
target O 
of O 
VK2 B-ABBREVIATION 
-induced O 
apoptosis O 
. O 
VK2 B-ABBREVIATION 
directly O 
interacts O 
with O 
Bak O 
and O 
induces O 
mitochondrial O 
- O 
mediated O 
apoptosis O 
. O 
Although O 
Bak O 
and O 
Bcl-2-associated O 
X O 
protein O 
( O 
Bax O 
) O 
, O 
another O 
member O 
of O 
the O 
Bcl-2 O 
family O 
, O 
are O 
generally O 
thought O 
to O 
be O 
functionally O 
redundant O 
, O 
only O 
Bak O 
is O 
necessary O 
and O 
sufficient O 
for O 
VK2 B-ABBREVIATION 
-induced O 
cytochrome O 
c O 
( O 
cyt O 
c O 
) O 
release O 
and O 
cell O 
death O 
. O 
Moreover O 
, O 
VK2-2,3 B-SYSTEMATIC 
epoxide I-SYSTEMATIC 
, O 
an O 
intracellular O 
metabolite O 
of O 
VK2 B-ABBREVIATION 
, O 
was O 
shown O 
to O 
covalently O 
bind O 
to O 
the O 
cysteine B-TRIVIAL 
-166 O 
residue O 
of O 
Bak O 
. O 
Several O 
lines O 
of O 
evidence O 
suggested O 
that O 
the O 
covalent O 
attachment O 
of O 
VK2 B-ABBREVIATION 
is O 
critical O 
for O 
apoptosis O 
induction O 
. O 
Thus O 
this O 
study O 
reveals O 
a O 
specific O 
role O 
for O 
Bak O 
in O 
mitochondria O 
- O 
mediated O 
apoptosis O 
. O 
This O 
study O 
also O 
provides O 
insight O 
into O 
the O 
anticancer O 
effects O 
of O 
VK2 B-ABBREVIATION 
and O 
suggests O 
that O 
Bak O 
may O 
be O 
a O 
potential O 
target O 
of O 
cancer O 
therapy O 
. O 

of O 
quinoline B-SYSTEMATIC 
derivatives O 
: O 
discovery O 
of O 
a O 
potent O 
and O 
selective O 
phosphodiesterase O 
5 O 
inhibitor O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 

type O 
5 O 
( O 
PDE5 O 
) O 
mediates O 
the O 
degradation O 
of O 
cGMP B-ABBREVIATION 
in O 
a O 
variety O 
of O 
tissues O 
including O 
brain O 
. O 
Recent O 
studies O 
have O 
demonstrated O 
the O 
importance O 
of O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
/ O 
cGMP B-ABBREVIATION 
/ O 
cAMP B-ABBREVIATION 
-responsive O 
element O 
- O 
binding O 
protein O 
( O 
CREB O 
) O 
pathway O 
to O 
the O 
process O 
of O 
learning O 
and O 
memory O 
. O 
Thus O 
, O 
PDE5 O 
inhibitors O 
( O 
PDE5Is O 
) O 
are O 
thought O 
to O 
be O 
promising O 
new O 
therapeutic O 
agents O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
, O 
a O 
neurodegenerative O 
disorder O 
characterized O 
by O 
memory O 
loss O 
. O 
To O 
explore O 
this O 
possibility O 
, O 
a O 
series O 
of O 
quinoline B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
. O 
We O 
found O 
that O 
compound O 
7a O 
selectively O 
inhibits O 
PDE5 O 
with O 
an O 
IC(50) O 
of O 
0.27 O 
nM O 
and O 
readily O 
crosses O 
the O 
blood O 
brain O 
barrier O 
. O 
In O 
an O 
in O 
vivo O 
mouse O 
model O 
of O 
AD O 
, O 
compound O 
7a O 
rescues O 
synaptic O 
and O 
memory O 
defects O 
. O 
Quinoline B-SYSTEMATIC 
-based O 
, O 
CNS-permeant O 
PDE5Is O 
have O 
potential O 
for O 
AD O 
therapeutic O 
development O 
. O 

novel O 
saponins B-FAMILY 
of O 
20 B-SYSTEMATIC 
, I-SYSTEMATIC 
26-epoxy I-SYSTEMATIC 
derivatives O 
of O 
pseudojujubogenin B-TRIVIAL 
from O 
the O 
seeds O 
of O 
Hovenia O 
trichocarpa O 
. O 

new O 
saponins B-FAMILY 
of O 
20 B-SYSTEMATIC 
, I-SYSTEMATIC 
26-epoxy I-SYSTEMATIC 
derivatives O 
of O 
pseudojujubogenin B-TRIVIAL 
, O 
hoduloside B-TRIVIAL 
XI I-TRIVIAL 
( O 
1 O 
) O 
and O 
hoduloside B-TRIVIAL 
XII I-TRIVIAL 
( O 
2 O 
) O 
were O 
isolated O 
from O 
the O 
seeds O 
of O 
Hovenia O 
trichocarpa O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
established O 
by O 
extensive O 
NMR O 
experiments O 
and O 
chemical O 
methods O 
. O 
Hoduloside B-TRIVIAL 
XI I-TRIVIAL 
was O 
confirmed O 
to O 
be O 
3-O-{β-d-glucopyranosyl(1→3)-[β-d-xylopyranosyl(1→2)]-α-l-arabinopyranosyl}-20 B-SYSTEMATIC 
, I-SYSTEMATIC 
26-epoxypseudojujubogenin I-SYSTEMATIC 
. O 
Hoduloside B-TRIVIAL 
XII I-TRIVIAL 
was O 
identified O 
as O 
3-O-{β-d-xylopyranose(1→2)glucopyranosyl(1→3)[rhamnopyranose(1→2)]β-d-glucopyranosyl}-20 B-SYSTEMATIC 
, I-SYSTEMATIC 
26-epoxypseudojujubogenin I-SYSTEMATIC 
. O 
The O 
in O 
vitro O 
cytotoxic O 
activity O 
of O 
compounds O 
1 O 
and O 
2 O 
was O 
assayed O 
. O 
They O 
displayed O 
inhibitive O 
activities O 
against O 
human O 
cancer O 
cell O 
lines O 
HL60 O 
and O 
K562 O 
. O 

new O 
C-benzylated B-SYSTEMATIC 
dihydrochalcone I-SYSTEMATIC 
derivatives O 
from O 
the O 
leaves O 
of O 
Melodorum O 
siamensis O 
. O 

new O 
C-benzylated B-SYSTEMATIC 
dihydrochalcone I-SYSTEMATIC 
derivatives O 
, O 
4,2',4'-trihydroxy-6'-methoxy-3'(2''-hydroxybenzyl)dihydrochalcone B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
2',4'-dihydroxy-4,6'-dimethoxy-3'(2''-hydroxybenzyl)dihydrochalcone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
along O 
with O 
six O 
known O 
flavonoid B-FAMILY 
derivatives O 
( O 
3-8 O 
) O 
, O 
a O 
known O 
dihydrochalcone B-SYSTEMATIC 
dimer O 
( O 
9 O 
) O 
, O 
three O 
known O 
aromatic B-FAMILY 
esters I-FAMILY 
( O 
10-12 O 
) O 
, O 
and O 
one O 
known O 
aromatic B-FAMILY 
amide I-FAMILY 
( O 
13 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Melodorum O 
siamensis O 
. O 
The O 
structures O 
of O 
the O 
compounds O 
were O 
elucidated O 
by O 
spectroscopic O 
analysis O 
, O 
mainly O 
1D O 
and O 
2D O 
NMR O 
techniques O 
( O 
1H B-FORMULA 
, O 
13C B-FORMULA 
, O 
COSY O 
, O 
HMQC O 
, O 
and O 
HMBC O 
) O 
, O 
as O 
well O 
as O 
by O 
comparison O 
with O 
literature O 
data O 
. O 
The O 
isolated O 
compounds O 
with O 
a O 
sufficient O 
amount O 
for O 
biological O 
assays O 
were O 
evaluated O 
for O 
their O 
antimalarial O 
, O 
antimycobactirial O 
, O 
and O 
cytotoxic O 
activities O 
. O 
Compounds O 
1 O 
, O 
2 O 
, O 
and O 
13 O 
exhibited O 
strong O 
cytotoxicity O 
against O 
human O 
tumor O 
cell O 
lines O 
KB O 
and O 
NCI-H187 O 
, O 
with O 
IC50 O 
values O 
in O 
the O 
range O 
of O 
0.66-7.16 O 
µg O 
/ O 
mL O 
. O 

OBJECTIVES O 
: O 
To O 
measure O 
concordance O 
between O 
different O 
intensive O 
care O 
unit O 
( O 
ICU O 
) O 
clinicians O 
and O 
a O 
consensus O 
group O 
of O 
electrophysiology O 
( O 
EP O 
) O 
cardiologists O 
for O 
use O 
of O 
a O 
common O 
rate O 
- O 
corrected O 
QT O 
interval O 
(QTc)-prolonging O 
medication O 
in O 
cases O 
containing O 
different O 
potential O 
risk O 
factor(s) O 
for O 
torsade O 
de O 
pointes O 
( O 
TdP O 
) O 
. O 
DESIGN O 
: O 
Prospective O 
case O 
- O 
based O 
evaluation O 
. O 
SETTING O 
: O 
Academic O 
medical O 
center O 
with O 
320 O 
beds O 
. O 
SUBJECTS O 
: O 
Medical O 
house O 
staff O 
( O 
MDs O 
) O 
and O 
ICU O 
nurses O 
( O 
RNs O 
) O 
from O 
one O 
center O 
and O 
select O 
critical O 
care O 
pharmacists O 
( O 
PHs O 
) O 
. O 
INTERVENTION O 
: O 
Completion O 
of O 
a O 
survey O 
containing O 
10 O 
hypothetical O 
ICU O 
cases O 
in O 
which O 
patients O 
had O 
agitated O 
delirium O 
for O 
which O 
a O 
psychiatrist O 
recommended O 
intravenous O 
haloperidol B-TRIVIAL 
5 O 
mg O 
every O 
6 O 
hours O 
. O 
Each O 
case O 
contained O 
different O 
potential O 
risk O 
factor(s) O 
for O 
TdP O 
in O 
specific O 
combinations O 
. O 
A O 
group O 
of O 
five O 
EP O 
cardiologists O 
agreed O 
that O 
haloperidol B-TRIVIAL 
use O 
was O 
safe O 
in O 
five O 
cases O 
and O 
not O 
safe O 
in O 
five O 
cases O 
. O 
MEASUREMENTS O 
AND O 
MAIN O 
RESULTS O 
: O 
For O 
each O 
case O 
, O 
participants O 
were O 
asked O 
to O 
document O 
whether O 
they O 
would O 
administer O 
haloperidol B-TRIVIAL 
, O 
to O 
provide O 
a O 
rationale O 
for O 
their O 
decision O 
, O 
and O 
to O 
state O 
their O 
level O 
of O 
confidence O 
in O 
that O 
decision O 
. O 
Most O 
clinicians O 
( O 
92 O 
of O 
115 O 
[ O 
80% O 
] O 
) O 
invited O 
to O 
participate O 
completed O 
the O 
cases O 
. O 
Among O 
the O 
five O 
cases O 
where O 
EP O 
cardiologists O 
agreed O 
that O 
haloperidol B-TRIVIAL 
was O 
not O 
safe O 
, O 
29% O 
of O 
respondents O 
felt O 
that O 
haloperidol B-TRIVIAL 
was O 
safe O 
. O 
Conversely O 
, O 
in O 
the O 
five O 
cases O 
where O 
EP O 
cardiologists O 
felt O 
haloperidol B-TRIVIAL 
was O 
safe O 
, O 
21% O 
of O 
respondents O 
believed O 
that O 
it O 
was O 
not O 
safe O 
. O 
Overall O 
respondent-EP O 
cardiologist O 
agreement O 
for O 
haloperidol B-TRIVIAL 
use O 
across O 
the O 
10 O 
cases O 
was O 
moderate O 
( O 
κ O 
= O 
0.51 O 
) O 
. O 
MDs O 
and O 
PHs O 
were O 
in O 
agreement O 
with O 
the O 
EP O 
cardiologists O 
more O 
than O 
RNs O 
( O 
p=0.03 O 
) O 
. O 
Interprofessional O 
variability O 
existed O 
for O 
the O 
TdP O 
risk O 
factors O 
each O 
best O 
identified O 
. O 
Clinician O 
confidence O 
correlated O 
with O 
EP O 
cardiologist O 
concordance O 
for O 
MDs O 
( O 
p=0.002 O 
) O 
and O 
PHs O 
( O 
p=0.0002 O 
) O 
, O 
but O 
not O 
for O 
RNs O 
( O 
p=0.69 O 
) O 
. O 
CONCLUSION O 
: O 
When O 
evaluating O 
use O 
of O 
a O 
QTc O 
interval O 
- O 
prolonging O 
medication O 
, O 
ICU O 
clinicians O 
often O 
fail O 
to O 
identify O 
the O 
TdP O 
risk O 
factors O 
that O 
EP O 
cardiologists O 
feel O 
should O 
prevent O 
its O 
use O 
. O 
Clinician-EP O 
cardiologist O 
concordance O 
varies O 
by O 
the O 
specific O 
risk O 
factor(s) O 
for O 
TdP O 
and O 
the O 
ICU O 
professional O 
conducting O 
the O 
assessment O 
. O 

abundant O 
research O 
that O 
has O 
been O 
carried O 
out O 
on O 
the O 
potential O 
health O 
benefits O 
of O 
pu O 
- O 
erh O 
tea O 
, O 
no O 
consensus O 
till O 
now O 
, O 
has O 
been O 
reached O 
on O 
which O 
constituent O 
is O 
mainly O 
responsible O 
for O 
its O 
bioactivity O 
. O 
In O 
this O 
work O 
, O 
the O 
aqueous O 
extract O 
( O 
AE O 
) O 
and O 
its O 
fraction O 
enriched O 
with O 
active O 
constituents O 
were O 
prepared O 
from O 
pu O 
- O 
erh O 
tea O 
, O 
and O 
their O 
bioactivities O 
were O 
investigated O 
. O 
It O 
was O 
found O 
that O 
tea O 
polyphenols B-FAMILY 
( O 
TP O 
) O 
, O 
tea O 
polysaccharides O 
( O 
TPS O 
) O 
, O 
caffeine B-TRIVIAL 
( O 
Caf B-ABBREVIATION 
) O 
, O 
protein O 
( O 
Pro O 
) O 
, O 
amino B-FAMILY 
acids I-FAMILY 
( O 
AA O 
) O 
were O 
accumulated O 
in O 
several O 
fractions O 
after O 
solvent O 
extraction O 
despite O 
not O 
being O 
separated O 
completely O 
. O 
Meanwhile O 
, O 
95% O 
ethanol B-SYSTEMATIC 
precipitate O 
( O 
EP O 
) O 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
( O 
EF O 
) O 
possessed O 
remarkable O 
antioxidant O 
activity O 
and O 
potent O 
inhibitory O 
effects O 
against O 
α-glycosidase O 
in O 
vitro O 
. O 
Furthermore O 
, O 
all O 
the O 
extracts O 
( O 
50 O 
mg O 
/ O 
kg O 
BW O 
) O 
showed O 
a O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
effect O 
on O 
postprandial O 
hyperglycemia O 
in O 
diabetic O 
mice O 
as O 
compared O 
with O 
a O 
model O 
group O 
, O 
and O 
the O 
suppression O 
of O 
EP O 
was O 
not O 
significantly O 
( O 
p O 
> O 
0.05 O 
) O 
different O 
from O 
that O 
of O 
acarbose B-TRIVIAL 
at O 
the O 
same O 
dosage O 
( O 
50 O 
mg O 
/ O 
kg O 
BW O 
) O 
, O 
which O 
indicate O 
that O 
these O 
fractions O 
could O 
be O 
developed O 
as O 
potential O 
anti-diabetic O 
agents O 
. O 

of O 
heterocyclic B-FAMILY 
terpenoids I-FAMILY 
by O 
promiscuous O 
squalene B-TRIVIAL 
- O 
hopene B-TRIVIAL 
cyclases O 
. O 

ENZYMES O 
: O 
The O 
substrate O 
promiscuity O 
of O 
squalene B-TRIVIAL 
- O 
hopene B-TRIVIAL 
cyclases O 
has O 
been O 
explored O 
and O 
applied O 
in O 
the O 
enzyme O 
- O 
catalyzed O 
synthesis O 
of O 
heterocyclic B-FAMILY 
terpenoids I-FAMILY 
. O 
Features O 
of O 
this O 
work O 
include O 
cyclization O 
reactions O 
without O 
pyrophosphate B-SYSTEMATIC 
activation O 
, O 
and O 
stereospecific O 
ring O 
closure O 
of O 
substrates O 
of O 
varying O 
chain O 
length O 
and O 
terminal O 
nucleophile O 
. O 
This O 
provides O 
a O 
biocatalytic O 
alternative O 
to O 
traditional O 
chemical O 
catalysts O 
. O 

excreted O 
in O 
urine O 
by O 
neonates O 
with O 
21-hydroxylase O 
deficiency O 
. O 
4 O 
. O 
Characterization O 
, O 
using O 
GC-MS O 
and O 
GC-MS O 
/ O 
MS O 
, O 
of O 
11oxo B-FAMILY 
- I-FAMILY 
pregnanes I-FAMILY 
and O 
11oxo B-FAMILY 
- I-FAMILY 
pregnenes I-FAMILY 
. O 

21-hydroxylase O 
deficiency O 
, O 
urinary O 
metabolites O 
of O 
21-deoxycortisol B-SYSTEMATIC 
, O 
mainly O 
derived O 
from O 
its O 
11oxo B-SYSTEMATIC 
form O 
21-deoxycortisone B-SYSTEMATIC 
, O 
are O 
indicators O 
of O 
intra O 
- O 
adrenal O 
overproduction O 
of O 
17-hydroxyprogesterone B-SYSTEMATIC 
. O 
In O 
affected O 
neonates O 
these O 
metabolites O 
are O 
numerous O 
and O 
most O 
have O 
not O 
been O 
previously O 
described O 
. O 
This O 
work O 
forms O 
the O 
concluding O 
part O 
of O 
a O 
comprehensive O 
study O 
of O 
urinary O 
steroids B-FAMILY 
, O 
aiming O 
to O 
enhance O 
the O 
diagnosis O 
of O 
this O 
disorder O 
and O 
to O 
further O 
elucidate O 
steroid B-FAMILY 
metabolism O 
in O 
neonates O 
. O 
Cortisol B-TRIVIAL 
metabolites O 
found O 
in O 
untreated O 
patients O 
, O 
similarly O 
almost O 
exclusively O 
present O 
in O 
their O 
11oxo B-SYSTEMATIC 
form O 
in O 
neonates O 
, O 
have O 
been O 
included O 
for O 
completeness O 
. O 
Steroids B-FAMILY 
were O 
analyzed O 
, O 
after O 
extraction O 
and O 
enzymatic O 
conjugate O 
hydrolysis O 
, O 
as O 
methyloxime B-SYSTEMATIC 
- I-SYSTEMATIC 
trimethylsilyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
derivatives O 
on O 
gas-chromatographs O 
coupled O 
to O 
quadrupole O 
and O 
ion O 
- O 
trap O 
mass O 
- O 
spectrometers O 
. O 
GC-MS O 
and O 
GC-MS O 
/ O 
MS O 
spectra O 
were O 
used O 
together O 
to O 
determine O 
the O 
structure O 
of O 
hitherto O 
undescribed O 
11oxo-pregnane(enes) B-MULTIPLE 
. O 
Few O 
GC-MS O 
features O 
were O 
associated O 
with O 
the O 
presence O 
of O 
the O 
non-derivatizeable O 
11oxo B-SYSTEMATIC 
group O 
in O 
pregnane(ene)s B-MULTIPLE 
. O 
GC-MS O 
/ O 
MS O 
contributed O 
only O 
to O 
the O 
characterization O 
of O 
structures O 
outside O 
the O 
C B-FORMULA 
-ring O 
, O 
as O 
described O 
in O 
the O 
preceding O 
parts O 
of O 
this O 
study O 
. O 
Parallels O 
were O 
found O 
between O 
the O 
metabolism O 
of O 
21-deoxycortisone B-SYSTEMATIC 
and O 
cortisone B-TRIVIAL 
. O 
The O 
major O 
metabolic O 
pathway O 
was O 
that O 
of O 
classical O 
3α,5β-reduction O 
with O 
a O 
prominent O 
further O 
hydroxylation O 
, O 
predominantly O 
at O 
C6 O 
. O 
Oxidation O 
of O 
the O 
6-hydroxyl B-SYSTEMATIC 
was O 
also O 
common O 
. O 
We O 
conclude O 
that O 
further O 
oxygenated O 
metabolites O 
of O 
21-deoxycortisone B-SYSTEMATIC 
have O 
potential O 
as O 
more O 
reliable O 
markers O 
of O 
21-hydroxylase O 
deficiency O 
in O 
the O 
early O 
neonatal O 
period O 
, O 
because O 
their O 
levels O 
are O 
higher O 
during O 
that O 
period O 
of O 
life O 
than O 
for O 
the O 
classical O 
marker O 
11oxo B-SYSTEMATIC 
- I-SYSTEMATIC 
pregnanetriol I-SYSTEMATIC 
. O 

: O 
Present O 
study O 
was O 
conducted O 
to O 
evaluate O 
the O 
dermatoprotective O 
effects O 
of O 
plant O 
extracts O 
( O 
Ficus O 
religiosa O 
, O 
Ficus O 
benghalensis O 
, O 
and O 
Ficus O 
racemosa O 
) O 
against O 
known O 
irritants O 
such O 
as O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
, O 
atrazine B-TRIVIAL 
, O 
and O 
petrol O 
. O 
METHODS O 
: O 
The O 
study O 
was O 
conducted O 
in O 
adult O 
male O 
rabbits O 
. O 
Ethanol B-SYSTEMATIC 
extracts O 
of O 
plants O 
were O 
obtained O 
through O 
Soxhlet O 
. O 
All O 
irritants O 
and O 
Ficus O 
extracts O 
were O 
topically O 
applied O 
to O 
the O 
backs O 
of O 
rabbits O 
daily O 
for O 
4 O 
days O 
, O 
while O 
pure O 
ethanol B-SYSTEMATIC 
served O 
as O 
control O 
. O 
Skin O 
was O 
examined O 
after O 
24 O 
, O 
48 O 
, O 
and O 
96 O 
h O 
for O 
erythema O 
. O 
Skin O 
biopsies O 
were O 
taken O 
on O 
5th O 
day O 
for O 
microscopic O 
examination O 
. O 
RESULTS O 
: O 
Erythema O 
produced O 
by O 
irritants O 
reduced O 
significantly O 
with O 
the O 
simultaneous O 
application O 
of O 
Ficus O 
extracts O 
. O 
The O 
mean O 
± O 
SEM O 
epidermal O 
thickness O 
( O 
micrometer O 
) O 
with O 
SDS B-ABBREVIATION 
was O 
45.4 O 
± O 
1.89 O 
, O 
F O 
. O 
religiosa O 
+ O 
SDS B-ABBREVIATION 
was O 
18.6 O 
± O 
0.51 O 
, O 
F O 
. O 
benghalensis O 
+ O 
SDS B-ABBREVIATION 
was O 
18.4 O 
± O 
0.25 O 
, O 
F O 
. O 
racemosa O 
+ O 
SDS B-ABBREVIATION 
was O 
18.8 O 
± O 
0.37 O 
, O 
and O 
mixture O 
of O 
three O 
Ficus O 
species O 
+ O 
SDS B-ABBREVIATION 
was O 
16.8 O 
± O 
0.37 O 
. O 
Similar O 
findings O 
were O 
revealed O 
after O 
using O 
plant O 
extracts O 
with O 
atrazine B-TRIVIAL 
and O 
petrol O 
. O 
The O 
mean O 
± O 
SEM O 
epidermal O 
layer O 
count O 
for O 
SDS B-ABBREVIATION 
was O 
3.6 O 
± O 
0.25 O 
, O 
atrazine B-TRIVIAL 
was O 
3.4 O 
± O 
0.25 O 
, O 
petrol O 
was O 
3.4 O 
± O 
0.25 O 
, O 
and O 
ethanol B-SYSTEMATIC 
( O 
control O 
) O 
was O 
1 O 
± O 
0.2 O 
. O 
This O 
count O 
reduced O 
to O 
1.2 O 
± O 
0.2 O 
for O 
three O 
Ficus O 
species O 
+ O 
SDS B-ABBREVIATION 
, O 
1.4 O 
± O 
0.25 O 
for O 
Ficus O 
species O 
+ O 
atrazine B-TRIVIAL 
, O 
and O 
1.4 O 
± O 
0.25 O 
for O 
Ficus O 
species O 
+ O 
petrol O 
. O 
CONCLUSION O 
: O 
Ficus O 
species O 
demonstrated O 
the O 
potential O 
to O 
block O 
the O 
dermatotoxic O 
effects O 
of O 
topical O 
irritants O 
and O 
could O 
be O 
used O 
successfully O 
to O 
prevent O 
skin O 
toxicity O 
. O 

in O 
understanding O 
the O 
mechanisms O 
of O 
skin O 
sensitization O 
, O 
provides O 
us O 
with O 
the O 
opportunity O 
to O 
develop O 
in O 
vitro O 
tests O 
as O 
an O 
alternative O 
to O 
in O 
vivo O 
sensitization O 
testing O 
. O 
Keratinocytes O 
play O 
a O 
key O 
role O 
in O 
all O 
phases O 
of O 
skin O 
sensitization O 
. O 
We O 
have O 
recently O 
identified O 
interleukin-18 O 
( O 
IL-18 O 
) O 
production O 
in O 
keratinocyte O 
as O 
a O 
potentially O 
useful O 
endpoint O 
for O 
determination O 
of O 
contact O 
sensitization O 
potential O 
of O 
low O 
molecular O 
weight O 
chemicals O 
. O 
The O 
aim O 
of O 
the O 
present O 
article O 
is O 
to O 
further O 
exploit O 
the O 
performance O 
of O 
the O 
NCTC O 
2544 O 
assay O 
. O 
NCTC O 
2544 O 
is O 
a O 
commercially O 
available O 
skin O 
epithelial O 
- O 
like O 
cell O 
line O 
originating O 
from O 
normal O 
human O 
skin O 
, O 
which O 
posses O 
a O 
good O 
expression O 
of O 
cytochrome O 
P450-dependent O 
enzymatic O 
activities O 
. O 
Cells O 
were O 
exposed O 
to O 
contact O 
allergens O 
( O 
2-bromo-2-bromomethyl B-SYSTEMATIC 
glutaronitrile I-SYSTEMATIC 
, O 
cinnamaldehyde B-TRIVIAL 
, O 
citral B-TRIVIAL 
, O 
diethylmaleate B-SYSTEMATIC 
, O 
dinitrochlorobenzene B-SYSTEMATIC 
, O 
glyoxal B-TRIVIAL 
, O 
2-mercaptobenzothiazole B-SYSTEMATIC 
, O 
nickel B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
4-nitrobenzylbromide B-SYSTEMATIC 
, O 
oxazolone B-SYSTEMATIC 
, O 
penicillin B-TRIVIAL 
G I-TRIVIAL 
, O 
resorcinol B-TRIVIAL 
, O 
tetramethylthiuram B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
) O 
, O 
to O 
pre- O 
pro O 
- O 
haptens O 
( O 
cinnamyl B-TRIVIAL 
alcohol I-TRIVIAL 
, O 
eugenol B-TRIVIAL 
, O 
isoeugenol B-TRIVIAL 
, O 
p-phenylediamine B-SYSTEMATIC 
) O 
, O 
to O 
respiratory O 
allergens O 
( O 
ammonium B-SYSTEMATIC 
hexachloroplatinate I-SYSTEMATIC 
, O 
diphenylmethane B-SYSTEMATIC 
diisocyanate I-SYSTEMATIC 
, O 
glutaraldehyde B-TRIVIAL 
, O 
hexamethylenediisocyanate B-SYSTEMATIC 
, O 
maleic B-TRIVIAL 
anhydride I-TRIVIAL 
, O 
trimellitic B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
) O 
and O 
to O 
irritants O 
( O 
benzaldehyde B-SYSTEMATIC 
, O 
cholorobenzene B-SYSTEMATIC 
, O 
diethylphtalate B-SYSTEMATIC 
, O 
hydrobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
, O 
octanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
phenol B-SYSTEMATIC 
, O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
, O 
sodium B-SYSTEMATIC 
lauryl I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
, O 
sulfamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
. O 
Cell O 
associated O 
IL-18 O 
was O 
evaluated O 
24 O 
later O 
by O 
ELISA O 
. O 
At O 
not O 
- O 
cytotoxic O 
concentrations O 
( O 
cell O 
viability O 
higher O 
of O 
80% O 
, O 
as O 
assessed O 
by O 
MTT B-ABBREVIATION 
reduction O 
assay O 
) O 
, O 
all O 
contact O 
sensitizers O 
, O 
including O 
pre O 
- O 
pro O 
- O 
haptens O 
, O 
induced O 
a O 
dose O 
- O 
related O 
increase O 
in O 
IL-18 O 
, O 
whereas O 
both O 
irritants O 
, O 
with O 
the O 
exception O 
of O 
sulfamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
respiratory O 
allergens O 
failed O 
. O 
A O 
total O 
of O 
33 O 
chemicals O 
were O 
tested O 
, O 
with O 
an O 
overall O 
accuracy O 
of O 
97% O 
. O 
Overall O 
, O 
results O 
obtained O 
indicated O 
that O 
cell O 
- O 
associated O 
IL-18 O 
might O 
provide O 
an O 
in O 
vitro O 
tool O 
for O 
identification O 
and O 
discrimination O 
of O 
contact O 
vs O 
. O 
respiratory O 
allergens O 
and O 
/ O 
or O 
irritants O 
. O 

of O 
the O 
benzimidazole B-SYSTEMATIC 
anthelmintic O 
drug O 
flubendazole B-TRIVIAL 
on O 
rat O 
embryos O 
in O 
vitro O 
. O 

diseases O 
affect O 
millions O 
of O 
people O 
in O 
poverty O 
- O 
stricken O 
areas O 
. O 
In O 
2011 O 
, O 
an O 
investigation O 
of O 
the O 
potential O 
of O 
flubendazole B-TRIVIAL 
as O 
a O 
safe O 
, O 
highly O 
efficacious O 
, O 
and O 
field O 
- O 
usable O 
macrofilaricidal O 
drug O 
was O 
begun O 
by O 
Drug O 
for O 
Neglected O 
Diseases O 
initiative O 
. O 
As O 
part O 
of O 
the O 
preclinical O 
development O 
program O 
, O 
whole O 
embryo O 
culture O 
was O 
used O 
to O 
investigate O 
the O 
potential O 
embryotoxicity O 
of O 
flubendazole B-TRIVIAL 
and O 
its O 
metabolites O 
, O 
reduced O 
and O 
hydrolyzed O 
flubendazole B-TRIVIAL 
. O 
Albendazole B-TRIVIAL 
was O 
included O 
as O 
a O 
comparator O 
. O 
Flubendazole B-TRIVIAL 
and O 
albendazole B-TRIVIAL 
showed O 
similar O 
potency O 
in O 
affecting O 
rat O 
embryonic O 
development O 
in O 
vitro O 
, O 
inducing O 
retardation O 
of O 
growth O 
and O 
dysmorphogenic O 
effects O 
at O 
concentrations O 
≥ O 
0.5μg O 
/ O 
mL O 
. O 
The O 
head O 
, O 
optic O 
and O 
otic O 
systems O 
, O 
branchial O 
arches O 
and O 
posterior O 
body O 
portion O 
were O 
affected O 
. O 
Diffuse O 
areas O 
of O 
cell O 
death O 
were O 
seen O 
in O 
various O 
embryonic O 
districts O 
. O 
The O 
No O 
Observed O 
Effect O 
Level O 
( O 
NOEL O 
) O 
was O 
0.25μg O 
/ O 
mL O 
for O 
both O 
drugs O 
. O 
Reduced O 
and O 
hydrolyzed O 
flubendazole B-TRIVIAL 
were O 
less O 
embryotoxic O 
than O 
the O 
parent O 
compound O 
, O 
with O 
NOELs O 
4-fold O 
and O 
> O 
40-fold O 
higher O 
than O 
that O 
of O 
flubendazole B-TRIVIAL 
, O 
respectively O 
. O 

have O 
investigated O 
the O 
effects O 
of O 
the O 
intake O 
of O 
oils O 
heated O 
at O 
frying O 
temperature O 
in O 
order O 
to O 
find O 
an O 
oil O 
model O 
for O 
deep O 
- O 
frying O 
that O 
prevents O 
postprandial O 
oxidative O 
stress O 
. O 
Twenty O 
obese O 
people O 
received O 
four O 
breakfasts O 
following O 
a O 
randomised O 
crossover O 
design O 
consisting O 
of O 
different O 
oils O 
( O 
virgin O 
olive O 
oil O 
( O 
VOO O 
) O 
, O 
sunflower O 
oil O 
( O 
SFO O 
) O 
, O 
and O 
a O 
mixed O 
seed O 
oil O 
( O 
SFO O 
/ O 
canola O 
oil O 
) O 
with O 
added O 
dimethylpolysiloxane B-FAMILY 
( O 
SOX B-ABBREVIATION 
) O 
or O 
natural O 
antioxidants O 
from O 
olives O 
( O 
SOP B-ABBREVIATION 
) O 
) O 
, O 
which O 
were O 
subjected O 
to O 
20 O 
heating O 
cycles O 
. O 
The O 
intake O 
of O 
SFO-breakfast O 
reduced O 
plasma O 
GSH B-ABBREVIATION 
levels O 
and O 
the O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
ratio O 
, O 
increased O 
protein O 
carbonyl B-FAMILY 
levels O 
, O 
and O 
induced O 
a O 
higher O 
gene O 
expression O 
of O 
the O 
different O 
NADPH B-ABBREVIATION 
-oxidase O 
subunits O 
, O 
Nrf2-Keap1 O 
activation O 
, O 
gene O 
expression O 
of O 
the O 
antioxidant O 
enzymes O 
in O 
peripheral O 
blood O 
mononuclear O 
cells O 
and O 
antioxidant O 
plasma O 
activities O 
than O 
the O 
intake O 
of O 
the O 
breakfasts O 
prepared O 
with O 
VOO O 
, O 
SOP B-ABBREVIATION 
and O 
SOX B-ABBREVIATION 
. O 
Oils O 
with O 
phenolic B-FAMILY 
compounds O 
, O 
whether O 
natural O 
( O 
VOO O 
) O 
or O 
artificially O 
added O 
( O 
SOP B-ABBREVIATION 
) O 
, O 
or O 
with O 
artificial O 
antioxidant O 
( O 
SOX B-ABBREVIATION 
) O 
, O 
could O 
reduce O 
postprandial O 
oxidative O 
stress O 
compared O 
with O 
sunflower O 
oil O 
. O 

of O 
propofol B-TRIVIAL 
binding O 
sites O 
in O 
a O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
with O 
a O 
photoreactive O 
propofol B-TRIVIAL 
analog O 
. O 

, O 
a O 
widely O 
used O 
intravenous O 
general O 
anesthetic O 
, O 
acts O 
at O 
anesthetic O 
concentrations O 
as O 
a O 
positive O 
allosteric O 
modulator O 
of O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
type O 
A O 
receptors O 
and O 
at O 
higher O 
concentration O 
as O 
an O 
inhibitor O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
. O 
Here O 
, O 
we O 
characterize O 
propofol B-TRIVIAL 
binding O 
sites O 
in O 
a O 
muscle O 
- O 
type O 
nAChR O 
by O 
use O 
of O 
a O 
photoreactive O 
analog O 
of O 
propofol B-TRIVIAL 
, O 
2-isopropyl-5-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenol B-SYSTEMATIC 
( O 
AziPm B-ABBREVIATION 
) O 
. O 
Based O 
upon O 
radioligand O 
binding O 
assays O 
, O 
AziPm B-ABBREVIATION 
stabilized O 
the O 
Torpedo O 
nAChR O 
in O 
the O 
resting O 
state O 
, O 
whereas O 
propofol B-TRIVIAL 
stabilized O 
the O 
desensitized O 
state O 
. O 
nAChR-rich O 
membranes O 
were O 
photolabeled O 
with O 
[(3)H]AziPm B-SYSTEMATIC 
, O 
and O 
labeled O 
amino B-FAMILY 
acids I-FAMILY 
were O 
identified O 
by O 
Edman O 
degradation O 
. O 
[(3)H]AziPm B-SYSTEMATIC 
binds O 
at O 
three O 
sites O 
within O 
the O 
nAChR O 
transmembrane O 
domain O 
: O 
(i) O 
an O 
intrasubunit O 
site O 
in O 
the O 
δ O 
subunit O 
helix O 
bundle O 
, O 
photolabeling O 
in O 
the O 
nAChR O 
desensitized O 
state O 
( O 
+ O 
agonist O 
) O 
δM2-18 O 
' O 
and O 
two O 
residues O 
in O 
δM1 O 
( O 
δPhe B-FORMULA 
-232 O 
and O 
δCys B-FORMULA 
-236 O 
) O 
; O 
(ii) O 
in O 
the O 
ion O 
channel O 
, O 
photolabeling O 
in O 
the O 
nAChR O 
resting O 
, O 
closed O 
channel O 
state O 
( O 
-agonist O 
) O 
amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
M2 O 
helices O 
( O 
αM2-6 O 
' O 
, O 
βM2-6 O 
' O 
and O 
-13 O 
' O 
, O 
and O 
δM2-13 O 
' O 
) O 
that O 
line O 
the O 
channel O 
lumen O 
( O 
with O 
photolabeling O 
reduced O 
by O 
> O 
90% O 
in O 
the O 
desensitized O 
state O 
) O 
; O 
and O 
(iii) O 
at O 
the O 
γ-α O 
interface O 
, O 
photolabeling O 
αM2-10 O 
' O 
. O 
Propofol B-TRIVIAL 
enhanced O 
[(3)H]AziPm B-SYSTEMATIC 
photolabeling O 
at O 
αM2-10 O 
' O 
. O 
Propofol B-TRIVIAL 
inhibited O 
[(3)H]AziPm B-SYSTEMATIC 
photolabeling O 
within O 
the O 
δ O 
subunit O 
helix O 
bundle O 
at O 
lower O 
concentrations O 
( O 
IC50 O 
= O 
40 O 
μm O 
) O 
than O 
it O 
inhibited O 
ion O 
channel O 
photolabeling O 
( O 
IC50 O 
= O 
125 O 
μm O 
) O 
. O 
These O 
results O 
identify O 
for O 
the O 
first O 
time O 
a O 
single O 
intrasubunit O 
propofol B-TRIVIAL 
binding O 
site O 
in O 
the O 
nAChR O 
transmembrane O 
domain O 
and O 
suggest O 
that O 
this O 
is O 
the O 
functionally O 
relevant O 
inhibitory O 
binding O 
site O 
. O 

of O 
the O 
novel O 
histamine B-TRIVIAL 
H3 O 
receptor O 
antagonist O 
ST1283 O 
on O 
voluntary O 
alcohol B-FAMILY 
consumption O 
and O 
ethanol B-SYSTEMATIC 
-induced O 
place O 
preference O 
in O 
mice O 
. O 

: O 
Growing O 
evidence O 
supports O 
a O 
role O 
for O 
the O 
central O 
histaminergic O 
system O 
to O 
have O 
a O 
modulatory O 
influence O 
on O 
drug O 
addiction O 
in O 
general O 
and O 
alcohol B-FAMILY 
-use O 
disorders O 
in O 
particular O 
through O 
histamine B-TRIVIAL 
H3 O 
receptors O 
( O 
H3R O 
) O 
. O 
OBJECTIVE O 
: O 
In O 
the O 
present O 
study O 
, O 
the O 
effects O 
of O 
systemic O 
injection O 
of O 
the O 
newly O 
synthesized O 
H3R O 
antagonist O 
ST1283 O 
on O 
ethanol B-SYSTEMATIC 
( O 
EtOH B-FORMULA 
) O 
voluntary O 
intake O 
and O 
EtOH B-FORMULA 
-conditioned O 
reward O 
in O 
mice O 
have O 
been O 
investigated O 
. O 
METHODS O 
: O 
Oral O 
EtOH B-FORMULA 
, O 
saccharin B-TRIVIAL 
, O 
and O 
quinine B-TRIVIAL 
intake O 
was O 
assessed O 
in O 
a O 
two O 
- O 
bottle O 
choice O 
paradigm O 
using O 
escalating O 
concentrations O 
of O 
alcohol B-FAMILY 
or O 
tastant O 
solutions O 
. O 
EtOH B-FORMULA 
-induced O 
place O 
preference O 
( O 
CPP O 
) O 
, O 
EtOH B-FORMULA 
-induced O 
locomotor O 
activity O 
, O 
and O 
blood O 
ethanol B-SYSTEMATIC 
concentration O 
( O 
BEC O 
) O 
were O 
also O 
measured O 
. O 
RESULTS O 
: O 
Following O 
administration O 
of O 
the O 
H3R O 
antagonist O 
( O 
2.5 O 
, O 
5 O 
, O 
and O 
10 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
, O 
there O 
was O 
a O 
significant O 
dose O 
- O 
dependent O 
decrease O 
in O 
alcoho B-FAMILY 
l O 
consumption O 
and O 
preference O 
. O 
Importantly O 
, O 
vehicle- O 
and O 
ST1283 O 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
- O 
treated O 
mice O 
showed O 
similar O 
consumption O 
and O 
preference O 
to O 
increasing O 
concentration O 
of O 
both O 
sweet O 
and O 
bitter O 
tastes O 
. O 
More O 
interestingly O 
, O 
systemic O 
administration O 
of O 
ST1283 O 
inhibited O 
EtO B-FORMULA 
H-CPP O 
and O 
EtO B-FORMULA 
H-enhanced O 
locomotion O 
. O 
This O 
inhibition O 
was O 
blocked O 
when O 
mice O 
were O 
pretreated O 
with O 
the O 
selective O 
H3R O 
agonist O 
R-(alpha)-methyl-histamin B-SYSTEMATIC 
e O 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
. O 
Finally O 
, O 
vehicle- O 
and O 
ST1283 O 
- O 
treated O 
mice O 
had O 
similar O 
BECs O 
. O 
CONCLUSION O 
: O 
Our O 
results O 
show O 
that O 
ST1283 O 
may O 
decrease O 
voluntary O 
EtO B-FORMULA 
H O 
consumption O 
and O 
EtO B-FORMULA 
H-CPP O 
by O 
altering O 
its O 
reinforcing O 
effects O 
, O 
suggesting O 
a O 
novel O 
role O 
for O 
histamin B-TRIVIAL 
e O 
signaling O 
in O 
regulation O 
of O 
alcoholism O 
. O 
Lastly O 
, O 
the O 
results O 
add O 
to O 
the O 
growing O 
literature O 
on O 
H3R O 
modulation O 
in O 
the O 
pharmacotherapy O 
of O 
EtO B-FORMULA 
H O 
addiction O 
. O 

of O 
NaP B-FORMULA 
zeolite I-FORMULA 
at O 
room O 
temperature O 
and O 
short O 
crystallization O 
time O 
by O 
sonochemical O 
method O 
. O 

zeolite I-FORMULA 
nano O 
crystals O 
were O 
synthesized O 
by O 
sonochemical O 
method O 
at O 
room O 
temperature O 
with O 
crystallization O 
time O 
of O 
3h O 
. O 
For O 
comparison O 
, O 
to O 
insure O 
the O 
effect O 
of O 
sonochemical O 
method O 
, O 
the O 
hydrothermal O 
method O 
at O 
conventional O 
synthesis O 
condition O 
, O 
with O 
same O 
initial O 
sol O 
composition O 
was O 
studied O 
. O 
NaP B-FORMULA 
zeolites I-FORMULA 
are O 
directly O 
formed O 
by O 
ultrasonic O 
treatment O 
without O 
the O 
application O 
of O 
autogenous O 
pressure O 
and O 
also O 
hydrothermal O 
treatment O 
. O 
The O 
effect O 
of O 
ultrasonic O 
energy O 
and O 
irradiation O 
time O 
showed O 
that O 
with O 
increasing O 
sonication O 
energy O 
, O 
the O 
crystallinity O 
of O 
the O 
powders O 
decreased O 
but O 
phase O 
purity O 
remain O 
unchanged O 
. O 
The O 
synthesized O 
powders O 
were O 
characterized O 
by O 
XRD O 
, O 
IR O 
, O 
DTA O 
TGA O 
, O 
FESEM O 
, O 
and O 
TEM O 
analysis O 
. O 
FESEM O 
images O 
revealed O 
that O 
50 O 
nm O 
zeolite O 
crystals O 
were O 
formed O 
at O 
room O 
temperature O 
by O 
using O 
sonochemical O 
method O 
. O 
However O 
, O 
agglomerated O 
particles O 
having O 
cactus O 
/ O 
cabbage O 
like O 
structure O 
was O 
obtained O 
by O 
sonochemical O 
method O 
followed O 
by O 
hydrothermal O 
treatment O 
. O 
In O 
sonochemical O 
process O 
, O 
formation O 
of O 
cavitation O 
and O 
the O 
collapsing O 
of O 
bubbles O 
produced O 
huge O 
energy O 
which O 
is O 
sufficient O 
for O 
crystallization O 
of O 
zeolite O 
compared O 
to O 
that O 
supplied O 
by O 
hydrothermal O 
process O 
for O 
conventional O 
synthesis O 
. O 
With O 
increasing O 
irradiation O 
energy O 
and O 
time O 
, O 
the O 
crystallinity O 
of O 
the O 
synthesized O 
zeolite O 
samples O 
increased O 
slightly O 
. O 

Presents O 
Synergistic O 
Anti-proliferative O 
Activity O 
With O 
Paclitaxel B-TRIVIAL 
Via O 
Altering O 
Cell O 
Cycle O 
and O 
Integrin O 
Signaling O 
in O 
95-D O 
Lung O 
Cancer O 
Cells O 
. O 

( O 
FUR B-ABBREVIATION 
) O 
is O 
a O 
natural O 
terpenoid B-FAMILY 
isolated O 
from O 
Rhizoma O 
Curcumae O 
, O 
a O 
well O 
- O 
known O 
Chinese O 
medicinal O 
herb O 
that O 
presents O 
anti-proliferative O 
activities O 
in O 
several O 
cancer O 
cell O 
lines O 
. O 
Recently O 
, O 
we O 
found O 
that O 
the O 
combined O 
treatment O 
of O 
FUR B-ABBREVIATION 
with O 
paclitaxel B-TRIVIAL 
( O 
TAX B-ABBREVIATION 
) O 
showed O 
synergetic O 
anti-proliferative O 
activities O 
in O 
95-D O 
lung O 
cancer O 
cells O 
. O 
Herein O 
, O 
we O 
showed O 
that O 
FUR B-ABBREVIATION 
reduced O 
the O 
cell O 
numbers O 
distributed O 
in O 
mitosis O 
phase O 
induced O 
by O 
TAX B-ABBREVIATION 
while O 
increased O 
those O 
in O 
G1 O 
phase O 
. O 
The O 
protein O 
levels O 
of O 
cyclin O 
D1 O 
, O 
cyclin O 
B1 O 
, O 
CDK6 O 
and O 
c-Myc O 
were O 
all O 
down O 
- O 
regulated O 
in O 
the O 
group O 
of O 
combined O 
treatment O 
. O 
The O 
dramatically O 
down O 
- O 
regulated O 
expression O 
of O 
integrin O 
β4 O 
, O 
focal O 
adhesion O 
kinase O 
and O 
paxillin O 
might O 
partially O 
contribute O 
to O 
the O 
synergic O 
effect O 
. O 
Though O 
FUR B-ABBREVIATION 
alone O 
obviously O 
induced O 
endoplasmic O 
reticulum O 
stress O 
, O 
this O 
signaling O 
pathway O 
may O 
not O 
contribute O 
to O 
the O 
synergetic O 
anti-proliferative O 
effect O 
as O 
the O 
protein O 
expression O 
of O 
CHOP O 
and O 
BIP O 
was O 
similar O 
in O 
FUR B-ABBREVIATION 
alone O 
and O 
combined O 
treatment O 
group O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Bridging O 
Ligand O 
in O 
a O 
Metal-Organic O 
Framework O 
. O 
Insight O 
into O 
the O 
Aqua-Hydroxo B-SYSTEMATIC 
↔ O 
Hydroxyl B-SYSTEMATIC 
Equilibrium O 
: O 
A O 
Combined O 
Experimental O 
and O 
Theoretical O 
Study O 
. O 

metal O 
- O 
organic O 
framework O 
( O 
MOF O 
) O 
bearing O 
the O 
aqua B-SYSTEMATIC 
- I-SYSTEMATIC 
hydroxo I-SYSTEMATIC 
species O 
(O2H3)(-) B-FORMULA 
in O 
the O 
framework O 
, O 
as O 
well O 
as O 
the O 
processes O 
that O 
govern O 
the O 
equilibrium O 
aqua B-SYSTEMATIC 
- I-SYSTEMATIC 
hydroxo I-SYSTEMATIC 
(O2H3)(-) B-FORMULA 
↔ O 
hydroxyl B-SYSTEMATIC 
( O 
OH B-FORMULA 
) O 
in O 
Sc B-FORMULA 
-MOFs O 
, O 
are O 
studied O 
experimentally O 
and O 
theoretically O 
. O 
Computational O 
studies O 
were O 
employed O 
to O 
determine O 
the O 
relative O 
energies O 
for O 
the O 
two O 
compounds O 
that O 
coexist O 
under O 
certain O 
hydrothermal O 
conditions O 
at O 
pH O 
< O 
2.8 O 
. O 
The O 
thermodynamically O 
more O 
stable O 
[ B-FORMULA 
Sc3(3,5-DSB)2(μ-O2H3)(μ-OH)2(H2O)2 I-FORMULA 
] I-FORMULA 
( O 
from O 
now O 
on O 
, O 
(O2H3)Sc B-FORMULA 
-MOF O 
; O 
3,5-DSB B-SYSTEMATIC 
= O 
3,5-disulfobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
was O 
obtained O 
as O 
a O 
pure O 
and O 
stable O 
phase O 
. O 
It O 
was O 
impossible O 
to O 
isolate O 
[ B-FORMULA 
Sc3(3,5-DSB)2(μ-OH)3(H2O)4 I-FORMULA 
] I-FORMULA 
as O 
a O 
pure O 
phase O 
, O 
as O 
it O 
turned O 
out O 
to O 
be O 
the O 
precursor O 
of O 
(O2H3)Sc B-FORMULA 
-MOF O 
. O 
Additionally O 
, O 
a O 
third O 
compound O 
that O 
appears O 
at O 
pH O 
between O 
3.5 O 
and O 
4 O 
, O 
[Sc3(3,5-DSB)(μ-OH)6(H2O)] B-FORMULA 
and O 
a O 
fourth O 
, O 
[Sc(3,5-DSB)(Phen)(H2O)](H2O) B-FORMULA 
, O 
in O 
whose O 
formula O 
neither O 
OH B-FORMULA 
groups O 
nor O 
H3O2(-) B-FORMULA 
anions O 
appear O 
, O 
are O 
reported O 
for O 
comparative O 
purposes O 
. O 
A O 
study O 
of O 
the O 
(O2H3)Sc B-FORMULA 
-MOF O 
electronic O 
structure O 
, O 
and O 
some O 
heterogeneous O 
catalytic O 
tests O 
in O 
cyanosilylation O 
of O 
aldehydes B-FAMILY 
reactions O 
, O 
are O 
also O 
reported O 
. O 

effect O 
on O 
diazonium B-SYSTEMATIC 
-modified O 
Au(111) B-FORMULA 
: O 
reactions O 
and O 
structures O 
. O 

modifications O 
of O 
a O 
Au(111) B-FORMULA 
electrode O 
with O 
4-bromobenzenediazonium B-SYSTEMATIC 
tetrafluoroborate I-SYSTEMATIC 
( O 
BBD B-ABBREVIATION 
) O 
in O 
acetonitrile B-SYSTEMATIC 
( O 
ACN B-ABBREVIATION 
) O 
and O 
0.1 O 
M O 
HClO4 B-FORMULA 
have O 
been O 
characterized O 
by O 
scanning O 
tunneling O 
microscopy O 
( O 
STM O 
) O 
. O 
In O 
ACN B-ABBREVIATION 
, O 
STM O 
results O 
reveal O 
the O 
formation O 
of O 
disordered O 
thin O 
organic O 
films O 
. O 
The O 
involvement O 
of O 
the O 
radical O 
as O 
an O 
intermediate O 
is O 
evidenced O 
by O 
the O 
negative O 
effect O 
of O 
radical O 
scavengers O 
on O 
organic O 
thin O 
film O 
formation O 
. O 
In O 
contrast O 
, O 
the O 
4,4'-dibromobiphenyl B-SYSTEMATIC 
monolayer O 
is O 
observed O 
when O 
the O 
aqueous O 
solution O 
is O 
used O 
as O 
a O 
medium O 
to O 
carry O 
out O 
the O 
grafting O 
experiment O 
. O 
The O 
biphenyl B-SYSTEMATIC 
compound O 
is O 
considered O 
to O 
be O 
generated O 
by O 
a O 
radical O 
- O 
radical O 
coupling O 
reaction O 
. O 

of O 
indole-3-carbinol B-SYSTEMATIC 
and O 
3,3'-diindolylmethane B-SYSTEMATIC 
in O 
zein/ O 
carboxymethyl B-SYSTEMATIC 
chitosan O 
nanoparticles O 
with O 
controlled O 
release O 
property O 
and O 
improved O 
stability O 
. O 

( O 
I3C B-SYSTEMATIC 
) O 
and O 
3,3'-diindolylmethane B-SYSTEMATIC 
( O 
DIM B-ABBREVIATION 
) O 
are O 
two O 
bioactive O 
compounds O 
from O 
Cruciferous O 
vegetables O 
. O 
The O 
stability O 
of O 
these O 
compounds O 
is O 
a O 
major O 
challenge O 
for O 
their O 
pharmaceutical O 
applications O 
. O 
In O 
this O 
study O 
, O 
zein O 
and O 
zein/ O 
carboxymethyl B-SYSTEMATIC 
chitosan O 
( O 
CMCS O 
) O 
nanoparticles O 
were O 
prepared O 
to O 
encapsulate O 
I3C B-SYSTEMATIC 
and O 
DIM B-ABBREVIATION 
by O 
a O 
combined O 
liquid O 
- O 
liquid O 
phase O 
separation O 
and O 
ionic O 
gelation O 
method O 
. O 
After O 
zein O 
nanoparticles O 
were O 
coated O 
with O 
CMCS O 
, O 
the O 
zeta O 
potential O 
was O 
decreased O 
from O 
around O 
-10 O 
to O 
-20mV O 
, O 
and O 
encapsulation O 
efficiency O 
was O 
greatly O 
improved O 
. O 
Both O 
nanoparticle O 
formulations O 
provided O 
controlled O 
release O 
of O 
I3C B-SYSTEMATIC 
and O 
DIM B-ABBREVIATION 
in O 
PBS O 
medium O 
. O 
Zein O 
and O 
zein O 
/ O 
CMCS O 
nanoparticles O 
demonstrated O 
similar O 
protection O 
for O 
both O 
I3C B-SYSTEMATIC 
and O 
DIM B-ABBREVIATION 
against O 
ultraviolet O 
( O 
UV O 
) O 
light O 
, O 
attributed O 
mainly O 
to O 
the O 
contribution O 
of O 
the O 
zein O 
protein O 
. O 
Compared O 
with O 
zein O 
nanoparticles O 
, O 
zein O 
/ O 
CMCS O 
nanoparticles O 
exhibited O 
better O 
protection O 
of O 
I3C B-SYSTEMATIC 
against O 
degradation O 
and O 
better O 
inhibition O 
against O 
its O 
oligomerization O 
to O 
DIM B-ABBREVIATION 
under O 
thermal O 
condition O 
( O 
37°C O 
) O 
. O 
Based O 
on O 
our O 
results O 
, O 
the O 
encapsulation O 
of O 
hydrophobic O 
bioactives O 
in O 
zein O 
/ O 
CMCS O 
nanoparticles O 
is O 
a O 
promising O 
approach O 
to O 
improve O 
their O 
stability O 
against O 
harsh O 
conditions O 
and O 
provide O 
controlled O 
release O 
for O 
food O 
/ O 
pharmaceutical O 
applications O 
. O 

cytoplasmic O 
Elmo1 O 
: O 
Dock180 O 
complex O 
acts O 
as O 
a O 
guanine B-TRIVIAL 
nucleotide B-FAMILY 
exchange O 
factor O 
( O 
GEF O 
) O 
for O 
the O 
small O 
GTPase O 
Rac O 
and O 
functions O 
downstream O 
of O 
the O 
phagocytic O 
receptor O 
BAI1 O 
during O 
apoptotic O 
cell O 
clearance O 
, O 
and O 
in O 
the O 
entry O 
of O 
Salmonella O 
and O 
Shigella O 
into O 
cells O 
. O 
We O 
discovered O 
an O 
unexpected O 
binding O 
between O 
Elmo1 O 
and O 
the O 
Mediator O 
complex O 
subunit O 
Med31 O 
. O 
The O 
Mediator O 
complex O 
is O 
a O 
regulatory O 
hub O 
for O 
nearly O 
all O 
gene O 
transcription O 
via O 
RNA O 
polymerase O 
II O 
, O 
bridging O 
the O 
general O 
transcription O 
machinery O 
with O 
gene O 
- O 
specific O 
regulatory O 
proteins O 
. O 
Med31 O 
is O 
the O 
smallest O 
and O 
the O 
most O 
evolutionarily O 
conserved O 
Mediator O 
subunit O 
, O 
and O 
knockout O 
of O 
Med31 O 
results O 
in O 
embryonic O 
lethality O 
in O 
mice O 
; O 
however O 
, O 
Med31 O 
function O 
in O 
specific O 
biological O 
contexts O 
is O 
poorly O 
understood O 
. O 
We O 
observed O 
that O 
in O 
primary O 
macrophages O 
, O 
during O 
Salmonella O 
infection O 
, O 
Elmo1 O 
and O 
Med31 O 
specifically O 
affected O 
expression O 
of O 
the O 
cytokine O 
genes O 
Il10 O 
and O 
Il33 O 
among O 
the O 
> O 
25 O 
genes O 
monitored O 
. O 
Although O 
endogenous O 
Med31 O 
is O 
predominantly O 
nuclear O 
localized O 
, O 
Elmo1 O 
increased O 
the O 
cytoplasmic O 
localization O 
of O 
Med31 O 
. O 
We O 
identify O 
ubiquitination O 
as O 
a O 
novel O 
posttranslational O 
modification O 
of O 
Med31 O 
, O 
with O 
the O 
cytoplasmic O 
monoubiquitinated O 
form O 
of O 
Med31 O 
being O 
enhanced O 
by O 
Elmo1 O 
. O 
These O 
data O 
identify O 
Elmo1 O 
as O 
a O 
novel O 
regulator O 
of O 
Med31 O 
, O 
revealing O 
a O 
previously O 
unrecognized O 
link O 
between O 
cytoplasmic O 
signaling O 
proteins O 
and O 
the O 
Mediator O 
complex O 
. O 

new O 
norlignans B-FAMILY 
from O 
Glechoma O 
longituba O 
. O 

new O 
norlignans B-FAMILY 
, O 
glechomols B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
, O 
respectively O 
) O 
, O 
together O 
with O 
a O 
known O 
compound O 
, O 
4-ethylcatechol B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
Glechoma O 
longituba O 
( O 
NaKai O 
) O 
Kupr O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
the O 
detailed O 
analysis O 
of O 
1D O 
and O 
2D O 
NMR O 
and O 
HR-MS O 
data O 
. O 
Glechomols B-MULTIPLE 
A-C I-MULTIPLE 
were O 
the O 
first O 
norlignans B-FAMILY 
reported O 
from O 
genus O 
Glechoma O 
, O 
and O 
compound O 
4 O 
was O 
also O 
isolated O 
from O 
genus O 
Glechoma O 
for O 
the O 
first O 
time O 
. O 
Intracellular O 
antioxidant O 
assays O 
showed O 
that O 
compounds O 
1-4 O 
displayed O 
significant O 
protective O 
effects O 
on O 
H(2)O(2) B-FORMULA 
-induced O 
cardiac O 
cell O 
injury O 
. O 

works O 
have O 
been O 
carried O 
out O 
in O 
developing O 
therapeutics O 
against O 
dengue O 
. O 
However O 
, O 
to O 
date O 
, O 
no O 
effective O 
vaccine O 
or O 
anti-dengue O 
agent O 
has O 
yet O 
been O 
discovered O 
. O 
The O 
development O 
of O 
protease O 
inhibitors O 
is O 
considered O 
as O 
a O 
promising O 
option O 
, O 
but O 
most O 
previous O 
works O 
have O 
involved O 
competitive O 
inhibition O 
. O 
In O 
this O 
study O 
, O 
we O 
focused O 
on O 
rational O 
discovery O 
of O 
potential O 
anti-dengue O 
agents O 
based O 
on O 
non-competitive O 
inhibition O 
of O 
DEN-2 O 
NS2B O 
/ O 
NS3 O 
protease O 
. O 
A O 
homology O 
model O 
of O 
the O 
DEN-2 O 
NS2B O 
/ O 
NS3 O 
protease O 
( O 
using O 
West O 
Nile O 
Virus O 
NS2B O 
/ O 
NS3 O 
protease O 
complex O 
, O 
2FP7 O 
, O 
as O 
the O 
template O 
) O 
was O 
used O 
as O 
the O 
target O 
and O 
pinostrobin B-TRIVIAL 
, O 
a O 
flavanone B-TRIVIAL 
, O 
was O 
used O 
as O 
the O 
standard O 
ligand O 
. O 
Virtual O 
screening O 
was O 
performed O 
involving O 
a O 
total O 
of O 
13341 O 
small O 
compounds O 
, O 
with O 
the O 
backbone O 
structures O 
of O 
chalcone B-FAMILY 
, O 
flavanone B-TRIVIAL 
and O 
flavone B-TRIVIAL 
, O 
available O 
from O 
the O 
ZINC O 
database O 
. O 
Ranking O 
of O 
the O 
resulting O 
compounds O 
yielded O 
compounds O 
with O 
higher O 
binding O 
affinities O 
compared O 
to O 
the O 
standard O 
ligand O 
. O 
Inhibition O 
assay O 
of O 
the O 
selected O 
top O 
ranking O 
compounds O 
against O 
DEN-2 O 
NS2B O 
/ O 
NS3 O 
proteolytic O 
activity O 
resulted O 
in O 
significantly O 
better O 
inhibition O 
compared O 
to O 
the O 
standard O 
and O 
correlated O 
well O 
with O 
in O 
silico O 
results O 
. O 
In O 
conclusion O 
, O 
via O 
this O 
rational O 
discovery O 
technique O 
, O 
better O 
inhibitors O 
were O 
identified O 
. O 
This O 
method O 
can O 
be O 
used O 
in O 
further O 
work O 
to O 
discover O 
lead O 
compounds O 
for O 
anti-dengue O 
agents O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

, O 
we O 
aim O 
to O 
evaluate O 
Gelucire O 
44 O 
/ O 
14 O 
as O 
non-ionic O 
surface O 
- O 
active O 
excipient O 
to O 
produce O 
immediate O 
- O 
release O 
solid O 
dosage O 
forms O 
for O 
poorly O 
water O 
- O 
soluble O 
drugs O 
. O 
Gelucires O 
are O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
glycerides O 
composed O 
of O 
mono- B-MULTIPLE 
, I-MULTIPLE 
di- I-MULTIPLE 
and I-MULTIPLE 
triglycerides I-MULTIPLE 
and O 
mono- O 
and O 
diesters O 
of O 
PEG B-ABBREVIATION 
. O 
They O 
are O 
inert O 
semi-solid O 
waxy O 
amphiphilic O 
excipients O 
with O 
surface O 
- O 
active O 
properties O 
that O 
spontaneously O 
form O 
a O 
fine O 
dispersion O 
or O 
emulsion O 
upon O 
contact O 
with O 
water O 
. O 
Monolithic O 
Gelucire O 
44 O 
/ O 
14 O 
structures O 
are O 
prone O 
to O 
prolonged O 
erosion O 
times O 
, O 
thereby O 
slowing O 
down O 
drug O 
dissolution O 
. O 
To O 
overcome O 
this O 
issue O 
, O 
we O 
combine O 
either O 
granulation O 
or O 
spray O 
- O 
drying O 
, O 
followed O 
by O 
compression O 
into O 
tablets O 
, O 
with O 
an O 
optimized O 
composition O 
of O 
disintegration O 
promoting O 
agents O 
. O 
This O 
formulation O 
strategy O 
allows O 
obtaining O 
nearly O 
100% O 
drug O 
release O 
within O 
10 O 
min O 
dissolution O 
time O 
. O 

and O 
positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
of O 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
are O 
currently O 
being O 
considered O 
as O 
novel O 
therapeutic O 
approaches O 
for O 
managing O 
cognitive O 
deficits O 
in O 
schizophrenia O 
and O 
Alzheimer's O 
disease O 
. O 
Though O 
α7 O 
agonists O 
were O 
recently O 
found O 
to O 
possess O 
antinociceptive O 
and O 
anti-inflammatory O 
properties O 
in O 
rodent O 
models O 
of O 
chronic O 
neuropathic O 
pain O 
and O 
inflammation O 
, O 
the O 
effects O 
of O 
α7 O 
nAChRs O 
PAMs O 
on O 
chronic O 
pain O 
and O 
inflammation O 
remain O 
largely O 
unknown O 
. O 
The O 
present O 
study O 
investigated O 
whether O 
PAMs O 
, O 
by O 
increasing O 
endogenous O 
cholinergic O 
tone O 
, O 
potentiate O 
α7 O 
nAChRs O 
function O 
to O 
attenuate O 
inflammatory O 
and O 
chronic O 
neuropathic O 
pain O 
in O 
mice O 
. O 
We O 
tested O 
two O 
types O 
of O 
PAMS O 
, O 
type O 
I O 
( O 
NS1738 B-IDENTIFIER 
) O 
and O 
type O 
II O 
( O 
PNU-120596 B-IDENTIFIER 
) O 
in O 
carrageenan O 
- O 
induced O 
inflammatory O 
pain O 
and O 
chronic O 
constriction O 
injury O 
( O 
CCI O 
) O 
neuropathic O 
pain O 
models O 
. O 
We O 
found O 
that O 
both O 
NS1738 B-IDENTIFIER 
and O 
PNU-120596 B-IDENTIFIER 
significantly O 
reduced O 
thermal O 
hyperalgesia O 
, O 
while O 
only O 
PNU-120596 B-IDENTIFIER 
significantly O 
reduced O 
edema O 
caused O 
by O 
a O 
hind O 
paw O 
infusion O 
of O 
carrageenan O 
. O 
Importantly O 
, O 
PNU-120596 B-IDENTIFIER 
reversed O 
established O 
thermal O 
hyperalgesia O 
and O 
edema O 
induced O 
by O 
carrageenan O 
. O 
In O 
the O 
CCI O 
model O 
, O 
PNU-120596 B-IDENTIFIER 
had O 
long O 
- O 
lasting O 
( O 
up O 
to O 
6 O 
h O 
) O 
, O 
dose O 
- O 
dependent O 
anti-hyperalgesic O 
and O 
anti-allodynic O 
effects O 
after O 
a O 
single O 
injection O 
, O 
while O 
NS1738 B-IDENTIFIER 
was O 
inactive O 
. O 
Systemic O 
administration O 
of O 
the O 
α7 O 
nAChR O 
antagonist O 
MLA B-ABBREVIATION 
reversed O 
PNU-120596 B-IDENTIFIER 
' O 
s O 
effects O 
, O 
suggesting O 
the O 
involvement O 
of O 
central O 
and O 
peripheral O 
α7 O 
nAChRs O 
. O 
Furthermore O 
, O 
PNU-120596 B-IDENTIFIER 
enhanced O 
an O 
ineffective O 
dose O 
of O 
selective O 
agonist O 
PHA-543613 B-IDENTIFIER 
to O 
produce O 
anti-allodynic O 
effects O 
in O 
the O 
CCI O 
model O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
type O 
II O 
α7 O 
nAChRs O 
PAM O 
PNU-120596 B-IDENTIFIER 
, O 
but O 
not O 
the O 
type O 
I O 
α7 O 
nAChRs O 
PAM O 
NS1738 B-IDENTIFIER 
, O 
shows O 
significant O 
anti-edematous O 
and O 
anti-allodynic O 
effects O 
in O 
inflammatory O 
and O 
CCI O 
pain O 
models O 
in O 
mice O 
. O 

quality O 
CdHgTe B-FORMULA 
nanocrystals O 
with O 
strong O 
near O 
- O 
infrared O 
emission O 
: O 
relationship O 
between O 
composition O 
and O 
cytotoxic O 
effects O 
. O 

quality O 
CdHgTe B-FORMULA 
quasi O 
core O 
/ O 
shell O 
nanocrystals O 
( O 
NCs O 
) O 
were O 
prepared O 
via O 
the O 
one O 
- O 
step O 
method O 
. O 
The O 
relationship O 
between O 
the O 
composition O 
, O 
structure O 
, O 
and O 
property O 
was O 
systematically O 
investigated O 
by O 
the O 
combination O 
of O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
, O 
inductively O 
coupled O 
plasma O 
atomic O 
emission O 
( O 
ICP O 
) O 
, O 
and O 
the O 
photoluminescence O 
( O 
PL O 
) O 
measurements O 
. O 
The O 
quantum O 
yield O 
( O 
QY O 
) O 
was O 
~50% O 
when O 
the O 
feed O 
ratio O 
of O 
Cd(2+) B-FORMULA 
to O 
Hg(2+) B-FORMULA 
was O 
equal O 
to O 
1 O 
. O 
The O 
PL O 
property O 
was O 
further O 
polished O 
, O 
and O 
the O 
QY O 
was O 
improved O 
to O 
~80% O 
through O 
the O 
variance O 
of O 
the O 
prepared O 
conditions O 
such O 
as O 
the O 
ratio O 
of O 
ligand O 
to O 
metal O 
ion O 
and O 
HTe(-) B-FORMULA 
to O 
metal O 
ion O 
, O 
pH O 
value O 
, O 
and O 
temperature O 
. O 
In O 
addition O 
, O 
the O 
cytotoxic O 
effects O 
of O 
CdHgTe B-FORMULA 
NCs O 
were O 
systematically O 
studied O 
. O 
The O 
results O 
showed O 
that O 
, O 
for O 
Cd0.21Hg0.79Te B-FORMULA 
NCs O 
, O 
its O 
quasi O 
core O 
/ O 
shell O 
structure O 
was O 
very O 
stable O 
and O 
little O 
cadmium B-SYSTEMATIC 
ions O 
were O 
released O 
. O 
As O 
a O 
result O 
, O 
such O 
NCs O 
showed O 
little O 
cytotoxicity O 
and O 
would O 
find O 
applications O 
in O 
tissue O 
imaging O 
or O 
detection O 
. O 

cases O 
in O 
which O 
experimental O 
data O 
on O 
chemical O 
- O 
specific O 
input O 
parameters O 
are O 
lacking O 
, O 
chemical O 
regulations O 
allow O 
the O 
use O 
of O 
alternatives O 
to O 
testing O 
, O 
such O 
as O 
in O 
silico O 
predictions O 
based O 
on O 
quantitative O 
structure O 
- O 
property O 
relationships O 
( O 
QSPRs O 
) O 
. O 
Such O 
predictions O 
are O 
often O 
given O 
as O 
point O 
estimates O 
; O 
however O 
, O 
little O 
is O 
known O 
about O 
the O 
extent O 
to O 
which O 
uncertainties O 
associated O 
with O 
QSPR O 
predictions O 
contribute O 
to O 
uncertainty O 
in O 
fate O 
assessments O 
. O 
In O 
the O 
present O 
study O 
, O 
QSPR-induced O 
uncertainty O 
in O 
overall O 
persistence O 
( O 
POV O 
) O 
and O 
long O 
- O 
range O 
transport O 
potential O 
( O 
LRTP O 
) O 
was O 
studied O 
by O 
integrating O 
QSPRs O 
into O 
probabilistic O 
assessments O 
of O 
five O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
, O 
using O 
the O 
multimedia O 
fate O 
model O 
Simplebox O 
. O 
The O 
uncertainty O 
analysis O 
considered O 
QSPR O 
predictions O 
of O 
the O 
fate O 
input O 
parameters O 
' O 
melting O 
point O 
, O 
water O 
solubility O 
, O 
vapor O 
pressure O 
, O 
organic O 
carbon B-SYSTEMATIC 
-water O 
partition O 
coefficient O 
, O 
hydroxyl B-SYSTEMATIC 
radical O 
degradation O 
, O 
biodegradation O 
, O 
and O 
photolytic O 
degradation O 
. O 
Uncertainty O 
in O 
POV O 
and O 
LRTP O 
was O 
dominated O 
by O 
the O 
uncertainty O 
in O 
direct O 
photolysis O 
and O 
the O 
biodegradation O 
half O 
- O 
life O 
in O 
water O 
. O 
However O 
, O 
the O 
QSPRs O 
developed O 
specifically O 
for O 
PBDEs B-ABBREVIATION 
had O 
a O 
relatively O 
low O 
contribution O 
to O 
uncertainty O 
. O 
These O 
findings O 
suggest O 
that O 
the O 
reliability O 
of O 
the O 
ranking O 
of O 
PBDEs B-ABBREVIATION 
on O 
the O 
basis O 
of O 
POV O 
and O 
LRTP O 
can O 
be O 
substantially O 
improved O 
by O 
developing O 
better O 
QSPRs O 
to O 
estimate O 
degradation O 
properties O 
. O 
The O 
present O 
study O 
demonstrates O 
the O 
use O 
of O 
uncertainty O 
and O 
sensitivity O 
analyses O 
in O 
nontesting O 
strategies O 
and O 
highlights O 
the O 
need O 
for O 
guidance O 
when O 
compounds O 
fall O 
outside O 
the O 
applicability O 
domain O 
of O 
a O 
QSPR O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1069-1076 O 
. O 
© O 
2013 O 
SETAC O 
. O 

NMR O 
- O 
based O 
metabonomic O 
analysis O 
of O 
the O 
serum O 
and O 
urine O 
of O 
rats O 
following O 
subchronic O 
exposure O 
to O 
dichlorvos B-TRIVIAL 
, O 
deltamethrin B-TRIVIAL 
, O 
or O 
a O 
combination O 
of O 
these O 
two O 
pesticides O 
. O 

analysis O 
, O 
clinical O 
chemical O 
analysis O 
and O 
histopathology O 
were O 
used O 
to O 
investigate O 
the O 
toxic O 
effects O 
of O 
subchronic O 
exposure O 
to O 
dichlorvos B-TRIVIAL 
, O 
deltamethrin B-TRIVIAL 
, O 
and O 
a O 
combination O 
of O 
these O 
two O 
pesticides O 
, O 
in O 
rats O 
. O 
Weight O 
loss O 
, O 
hind O 
limb O 
weakness O 
and O 
histopathological O 
changes O 
in O 
kidney O 
tissue O 
were O 
only O 
observed O 
in O 
rats O 
exposed O 
to O 
high O 
doses O 
of O 
deltamethrin B-TRIVIAL 
, O 
or O 
a O 
combination O 
of O 
deltamethrin B-TRIVIAL 
and O 
dichlorvos B-TRIVIAL 
. O 
Urinary O 
metabonomic O 
analysis O 
indicated O 
that O 
exposure O 
to O 
a O 
mixture O 
of O 
dichlorvos B-TRIVIAL 
and O 
deltamethrin B-TRIVIAL 
was O 
followed O 
by O 
increases O 
in O 
urinary O 
lactate B-FAMILY 
, O 
dimethylamine B-SYSTEMATIC 
, O 
N B-FORMULA 
-glycoprotein O 
( O 
NAC O 
) O 
and O 
glycine B-TRIVIAL 
similar O 
to O 
those O 
observed O 
in O 
rats O 
treated O 
with O 
either O 
dichlorvos B-TRIVIAL 
or O 
deltamethrin B-TRIVIAL 
alone O 
. O 
Serum O 
metabonomic O 
analysis O 
suggests O 
that O 
dichlorvos B-TRIVIAL 
induced O 
an O 
increase O 
in O 
lactate B-FAMILY 
and O 
alanine B-TRIVIAL 
and O 
a O 
decrease O 
in O 
dimethylglycine B-SYSTEMATIC 
( O 
DMG B-ABBREVIATION 
) O 
, O 
NAC O 
and O 
very O 
low- O 
and O 
low O 
- O 
density O 
lipoprotein O 
( O 
VLDL O 
/ O 
LDL O 
) O 
. O 
High O 
levels O 
of O 
lactate B-FAMILY 
and O 
low O 
levels O 
of O 
NAC O 
and O 
VLDL O 
/ O 
LDL O 
were O 
observed O 
in O 
the O 
deltamethrin B-TRIVIAL 
treatment O 
group O 
. O 
Treating O 
rats O 
with O 
a O 
mixture O 
of O 
dichlorvos B-TRIVIAL 
and O 
deltamethrin B-TRIVIAL 
caused O 
an O 
increase O 
in O 
serum O 
lactate B-FAMILY 
, O 
trimethylamine-N-oxide B-SYSTEMATIC 
( O 
TMAO B-ABBREVIATION 
) O 
, O 
choline B-FAMILY 
and O 
alanine B-TRIVIAL 
, O 
with O 
the O 
highest O 
levels O 
of O 
these O 
metabolites O 
observed O 
in O 
those O 
that O 
received O 
the O 
highest O 
dose O 
. O 
Exposure O 
to O 
a O 
mixture O 
of O 
dichlorvos B-TRIVIAL 
and O 
deltamethrin B-TRIVIAL 
also O 
resulted O 
in O 
a O 
decrease O 
in O 
serum O 
acetone B-SYSTEMATIC 
, O 
DMG B-ABBREVIATION 
, O 
NAC O 
, O 
and O 
VLDL O 
/ O 
LDL O 
. O 
Changes O 
in O 
serum O 
TMAO B-ABBREVIATION 
, O 
alanine B-TRIVIAL 
, O 
choline B-FAMILY 
and O 
acetone B-SYSTEMATIC 
in O 
this O 
treatment O 
group O 
were O 
higher O 
than O 
in O 
rats O 
treated O 
with O 
either O 
dichlorvos B-TRIVIAL 
or O 
deltamethrin B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
exposing O 
rats O 
to O 
subchronic O 
doses O 
of O 
dichlorvos B-TRIVIAL 
, O 
deltamethrin B-TRIVIAL 
, O 
or O 
a O 
combination O 
of O 
these O 
pesticides O 
, O 
disrupted O 
the O 
energy O 
metabolism O 
of O 
the O 
liver O 
and O 
reduced O 
kidney O 
function O 
. O 

new O 
alkaloid O 
was O 
isolated O 
from O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
the O 
culture O 
of O 
a O 
termite O 
- O 
associated O 
Streptomyces O 
koyangensis O 
BY-4 O 
. O 
The O 
structure O 
of O 
1 O 
was O 
elucidated O 
by O 
using O 
MS O 
, O 
NMR O 
, O 
electronic O 
circular O 
dichroism O 
data O 
, O 
and O 
computational O 
approaches O 
. O 
Compound O 
1 O 
showed O 
weak O 
antimicrobial O 
activities O 
against O 
a O 
panel O 
of O 
test O 
microbes O 
. O 

composition O 
of O 
π- O 
donor O 
/ O 
acceptor O 
moieties O 
has O 
been O 
considered O 
as O 
an O 
effective O 
strategy O 
for O 
fine O 
- O 
tuning O 
of O 
the O 
electronic O 
properties O 
of O 
D-A O 
conjugated O 
copolymers O 
. O 
In O 
this O 
study O 
, O 
the O 
change O 
of O 
optoelectronic O 
properties O 
with O 
the O 
change O 
of O 
donor O 
/ O 
acceptor O 
ratios O 
is O 
investigated O 
on O 
the O 
basis O 
of O 
first O 
- O 
principles O 
density O 
functional O 
calculations O 
. O 
Copolymers O 
containing O 
moieties O 
of O 
similar O 
π-electron O 
donating O 
and O 
/ O 
or O 
accepting O 
capabilities O 
, O 
e.g O 
. O 
, O 
thiophene B-SYSTEMATIC 
(T)- O 
methoxythiophene B-SYSTEMATIC 
( O 
OT O 
) O 
, O 
exhibit O 
a O 
linear O 
dependence O 
of O 
electronic O 
properties O 
( O 
especially O 
, O 
HOMO O 
/ O 
LUMO O 
, O 
band O 
gap O 
, O 
and O 
bandwidth O 
) O 
on O 
the O 
D O 
/ O 
A O 
content O 
. O 
In O 
contrast O 
, O 
for O 
strong O 
D O 
/ O 
A O 
contrast O 
systems O 
, O 
e.g O 
. O 
, O 
thiophene B-SYSTEMATIC 
(T)- O 
thienopyrazine B-SYSTEMATIC 
( O 
TP O 
) O 
, O 
the O 
electronic O 
properties O 
vary O 
nonlinearly O 
with O 
D O 
/ O 
A O 
compositions O 
. O 
However O 
, O 
when O 
the O 
block O 
size O 
of O 
one O 
parent O 
monomer O 
in O 
a O 
strong O 
D O 
/ O 
A O 
contrast O 
system O 
is O 
fixed O 
, O 
the O 
variation O 
of O 
electronic O 
properties O 
shows O 
a O 
remarkable O 
linear O 
correlation O 
against O 
D O 
/ O 
A O 
compositions O 
. O 
We O 
found O 
that O 
the O 
deviation O 
of O 
electronic O 
properties O 
from O 
a O 
linear O 
composition O 
dependence O 
is O 
dominated O 
by O 
the O 
strength O 
of O 
orbital O 
interactions O 
between O 
D O 
and O 
A O 
. O 
Weak O 
orbital O 
interactions O 
between O 
D O 
and O 
A O 
moieties O 
tend O 
to O 
lead O 
to O 
a O 
nonlinear O 
composition O 
dependence O 
. O 
Our O 
results O 
provide O 
useful O 
insights O 
for O 
band O 
gap O 
tuning O 
through O 
the O 
adjustment O 
of O 
D O 
/ O 
A O 
compositions O 
in O 
D-A O 
conjugated O 
copolymers O 
. O 

of O 
zinc B-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
conjugated O 
to O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
copolymer O 
for O 
imaging O 
and O 
light O 
- O 
induced O 
antitumor O 
effects O 
in O 
vivo O 
. O 

synthesized O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
polymer O 
conjugated O 
with O 
zinc B-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
- O 
ZnPP B-FORMULA 
) O 
and O 
evaluated O 
its O 
application O 
for O 
tumor O 
detection O 
by O 
imaging O 
and O 
treatment O 
by O 
light O 
exposure O 
using O 
in O 
mouse O 
sarcoma O 
model O 
. O 
To O 
characterize O 
HPMA B-ABBREVIATION 
- O 
ZnPP B-FORMULA 
micelle O 
, O 
we O 
measured O 
its O 
micellar O 
size O 
, O 
surface O 
charge O 
, O 
stability O 
, O 
photochemical O 
, O 
biochemical O 
properties O 
and O 
tissue O 
distribution O 
. O 
In O 
vivo O 
anti-tumor O 
effect O 
and O 
fluorescence O 
imaging O 
were O 
carried O 
out O 
to O 
validate O 
the O 
tumor O 
selective O 
accumulation O 
and O 
therapeutic O 
effect O 
by O 
inducing O 
singlet O 
oxygen B-SYSTEMATIC 
by O 
light O 
exposure O 
. O 
HPMA B-ABBREVIATION 
- O 
ZnPP B-FORMULA 
was O 
highly O 
water O 
soluble O 
and O 
formed O 
micelles O 
spontaneously O 
having O 
hydrophobic O 
clustered O 
head O 
group O 
of O 
ZnPP B-FORMULA 
, O 
in O 
aqueous O 
solution O 
, O 
with O 
a O 
hydrodynamic O 
diameter O 
of O 
82.8±41.8 O 
nm O 
and O 
zeta-potential O 
of O 
+ O 
1.12 O 
mV O 
. O 
HPMA B-ABBREVIATION 
- O 
ZnPP B-FORMULA 
had O 
a O 
long O 
plasma O 
half O 
- O 
life O 
and O 
effectively O 
and O 
selectively O 
accumulated O 
in O 
tumors O 
. O 
Although O 
HPMA B-ABBREVIATION 
- O 
ZnPP B-FORMULA 
alone O 
had O 
no O 
toxicity O 
in O 
S-180 O 
tumor O 
- O 
bearing O 
mice O 
, O 
light O 
- O 
irradiation O 
significantly O 
suppressed O 
tumor O 
growth O 
in O 
vivo O 
, O 
similar O 
to O 
the O 
cytotoxicity O 
to O 
HeLa O 
cells O 
in O 
vitro O 
upon O 
endoscopic O 
light O 
- O 
irradiation O 
. O 
HPMA B-ABBREVIATION 
- O 
ZnPP B-FORMULA 
can O 
visualize O 
tumors O 
by O 
fluorescence O 
after O 
i.v O 
. O 
injection O 
, O 
which O 
suggests O 
that O 
this O 
micelle O 
may O 
be O 
useful O 
for O 
both O 
tumor O 
imaging O 
and O 
therapy O 
. O 
Here O 
we O 
describe O 
preparation O 
of O 
a O 
new O 
fluorescence O 
nanoprobe O 
that O 
is O 
useful O 
for O 
simultaneous O 
tumor O 
imaging O 
and O 
treatment O 
, O 
and O 
application O 
to O 
fluorescence O 
endoscopy O 
is O 
now O 
at O 
visible O 
distance O 
. O 

physiologically O 
based O 
pharmacokinetic O 
model O 
for O 
the O 
oxime B-SYSTEMATIC 
TMB-4 B-IDENTIFIER 
: O 
simulation O 
of O 
rodent O 
and O 
human O 
data O 
. O 

oximes B-FAMILY 
have O 
been O 
synthesized O 
and O 
evaluated O 
for O 
use O 
as O 
countermeasures O 
against O 
chemical O 
warfare O 
nerve O 
agents O 
. O 
The O 
current O 
U.S O 
. O 
military O 
and O 
civilian O 
oxime B-SYSTEMATIC 
countermeasure O 
, O 
2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
2-PAM B-SYSTEMATIC 
) O 
, O 
is O 
under O 
consideration O 
for O 
replacement O 
with O 
a O 
more O 
effective O 
acetylcholinesterase O 
reactivator O 
, O 
1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium B-SYSTEMATIC 
dimethanesulfonate I-SYSTEMATIC 
( O 
MMB-4 B-SYSTEMATIC 
) O 
. O 
Kinetic O 
data O 
in O 
the O 
scientific O 
literature O 
for O 
MMB-4 B-ABBREVIATION 
are O 
limited O 
; O 
therefore O 
, O 
a O 
physiologically O 
based O 
pharmacokinetic O 
( O 
PBPK O 
) O 
model O 
was O 
developed O 
for O 
a O 
structurally O 
related O 
oxime B-SYSTEMATIC 
, O 
1,1'-trimethylenebis{4-hydroximinomethyl}pyridinium B-SYSTEMATIC 
dibromide I-SYSTEMATIC 
. O 
Based O 
on O 
a O 
previous O 
model O 
structure O 
for O 
the O 
organophosphate B-FAMILY 
diisopropylfluorophosphate B-SYSTEMATIC 
, O 
the O 
model O 
includes O 
key O 
sites O 
of O 
acetylcholinesterase O 
inhibition O 
( O 
brain O 
and O 
diaphragm O 
) O 
, O 
as O 
well O 
as O 
fat O 
, O 
kidney O 
, O 
liver O 
, O 
rapidly O 
perfused O 
tissues O 
and O 
slowly O 
perfused O 
tissues O 
. O 
All O 
tissue O 
compartments O 
are O 
diffusion O 
limited O 
. O 
Model O 
parameters O 
were O 
collected O 
from O 
the O 
literature O 
, O 
predicted O 
using O 
quantitative O 
structure O 
- O 
property O 
relationships O 
or O 
, O 
when O 
necessary O 
, O 
fit O 
to O 
available O 
pharmacokinetic O 
data O 
from O 
the O 
literature O 
. O 
The O 
model O 
was O 
parameterized O 
using O 
rat O 
plasma O 
, O 
tissue O 
and O 
urine O 
time O 
course O 
data O 
from O 
intramuscular O 
administration O 
, O 
as O 
well O 
as O 
human O 
blood O 
and O 
urine O 
data O 
from O 
intravenous O 
and O 
intramuscular O 
administration O 
; O 
sensitivity O 
analyses O 
were O 
performed O 
. O 
The O 
PBPK O 
model O 
successfully O 
simulates O 
rat O 
and O 
human O 
data O 
sets O 
and O 
has O 
been O 
evaluated O 
by O 
predicting O 
intravenous O 
mouse O 
and O 
intramuscular O 
human O 
data O 
not O 
used O 
in O 
the O 
development O 
of O 
the O 
model O 
. O 
Monte O 
Carlo O 
analyses O 
were O 
performed O 
to O 
quantify O 
human O 
population O 
kinetic O 
variability O 
in O 
the O 
human O 
evaluation O 
data O 
set O 
. O 
The O 
model O 
identifies O 
potential O 
pharmacokinetic O 
differences O 
between O 
rodents O 
and O 
humans O 
, O 
indicated O 
by O 
differences O 
in O 
model O 
parameters O 
between O 
species O 
. O 
The O 
PBPK O 
model O 
can O 
be O 
used O 
to O 
optimize O 
the O 
dosing O 
regimen O 
to O 
improve O 
oxime B-SYSTEMATIC 
therapeutic O 
efficacy O 
in O 
a O 
human O 
population O 
. O 

and O 
the O 
acute O 
subjective O 
effects O 
of O 
d-amphetamine B-TRIVIAL 
in O 
humans O 
. O 

is O 
evidence O 
that O 
subjective O 
responses O 
to O 
psychoactive O 
drugs O 
are O 
related O 
to O 
personality O 
traits O 
. O 
Here O 
, O 
we O 
extend O 
previous O 
findings O 
by O 
examining O 
personality O 
measures O 
in O 
relation O 
to O 
acute O 
responses O 
to O 
d-amphetamine B-TRIVIAL 
( O 
AMPH B-ABBREVIATION 
) O 
in O 
a O 
large O 
sample O 
of O 
healthy O 
volunteers O 
. O 
Healthy O 
adults O 
( O 
n=286 O 
) O 
completed O 
the O 
Multidimensional O 
Personality O 
Questionnaire O 
Brief O 
Form O 
( O 
MPQ-BF O 
) O 
and O 
participated O 
in O 
four O 
sessions O 
during O 
which O 
they O 
received O 
oral O 
AMPH B-ABBREVIATION 
( O 
0 O 
, O 
5 O 
, O 
10 O 
, O 
20 O 
mg O 
) O 
, O 
under O 
double O 
- O 
blind O 
conditions O 
. O 
Subjective O 
responses O 
to O 
the O 
drug O 
were O 
measured O 
using O 
the O 
Profile O 
of O 
Mood O 
States O 
, O 
Addiction O 
Research O 
Center O 
Inventory O 
, O 
and O 
Drug O 
Effects O 
Questionnaire O 
. O 
Drug O 
responses O 
were O 
reduced O 
via O 
principal O 
components O 
analysis O 
to O 
three O 
higher O 
- O 
order O 
factors O 
( O 
' O 
Euphoria O 
' O 
, O 
' O 
Arousal O 
' O 
, O 
' O 
Dysphoria O 
' O 
) O 
. O 
Participants O 
were O 
rank O 
ordered O 
on O 
selected O 
MPQ-BF O 
scales O 
; O 
the O 
top O 
and O 
bottom O 
third O 
on O 
each O 
trait O 
were O 
compared O 
on O 
the O 
drug O 
response O 
factors O 
. O 
High O 
trait O 
physical O 
fearlessness O 
was O 
significantly O 
associated O 
with O 
greater O 
amphetamine B-TRIVIAL 
-related O 
Arousal O 
, O 
and O 
high O 
trait O 
reward O 
sensitivity O 
was O 
significantly O 
associated O 
with O 
greater O 
Euphoria O 
. O 
In O 
addition O 
, O 
high O 
trait O 
impulsivity O 
was O 
significantly O 
associated O 
with O 
greater O 
Arousal O 
and O 
Euphoria O 
. O 
These O 
results O 
provide O 
further O 
evidence O 
that O 
individual O 
differences O 
in O 
the O 
subjective O 
effects O 
of O 
AMPH B-ABBREVIATION 
are O 
partially O 
explained O 
by O 
differences O 
in O 
personality O 
, O 
and O 
are O 
consistent O 
with O 
the O 
idea O 
that O 
both O 
personality O 
and O 
responses O 
to O 
stimulants O 
depend O 
upon O 
shared O 
neurochemical O 
systems O 
. O 
